Class ID,Preferred Label,Synonyms,Definitions,Obsolete,CUI,Semantic Types,Parents,agent of,alternative term,attribute of,attribute value of,auto-generated-by,bearer of,capable of negatively regulating,capable of positively regulating,capable of regulating,causal relation between processes,causally downstream of or within,causally upstream of or within,channel for,chromosome ID of gene,component of,composed_primarily_of,contains process,context of,curator note,database_cross_reference,date,definition,definition source,development_notes,dysfunctioning of,editor note,editor preferred term,elucidation,example of usage,external definition,family of,finding of,fma_set_term,formula,full name from nomenclature authority,function of,function_notes,gene map location,has agent,has associated axiom(fol),has associated axiom(nl),has attribute,has attribute value,has axiom label,has cause,has component,has context,has core process,has curation status,has dysfunctioning,has family member,has finding,has function,has GO association,has input,has member,has molecular reaction,has occurrent part,has output,has part,has participant,has pathway,has PubMed association,has quality,has related human gene,has related rat gene,has result,has role,has state,has target end location,has target start location,has_alternative_id,has_exact_synonym,has_narrow_synonym,has_related_synonym,homology notes,http://data.bioontology.org/metadata/obo/part_of,http://data.bioontology.org/metadata/prefixIRI,http://data.bioontology.org/metadata/treeView,http://purl.obolibrary.org/obo/OGG_0000000009,http://purl.obolibrary.org/obo/OGG_0000000018,http://purl.org/dc/elements/1.1/contributor,http://purl.org/dc/elements/1.1/creator,http://purl.org/dc/elements/1.1/date,http://purl.org/dc/elements/1.1/description,http://purl.org/dc/elements/1.1/format,http://purl.org/dc/elements/1.1/identifier,http://purl.org/dc/elements/1.1/license,http://purl.org/dc/elements/1.1/member,http://purl.org/dc/elements/1.1/source,http://purl.org/dc/elements/1.1/subject,http://purl.org/dc/elements/1.1/title,http://www.geneontology.org/formats/oboInOwl#default-namespace,http://www.geneontology.org/formats/oboInOwl#hasBroadSynonym,http://www.geneontology.org/formats/oboInOwl#hasOBONamespace,http://www.geneontology.org/formats/oboInOwl#id,http://www.geneontology.org/formats/oboInOwl#saved-by,http://www.w3.org/2000/01/rdf-schema#comment,http://www.w3.org/2000/01/rdf-schema#isDefinedBy,http://www.w3.org/2000/01/rdf-schema#label,http://www.w3.org/2000/01/rdf-schema#seeAlso,http://www.w3.org/2004/02/skos/core#notation,http://www.w3.org/2004/02/skos/core#prefLabel,http://xmlns.com/foaf/0.1/depicted_by,http://xmlns.com/foaf/0.1/homepage,hyperfunction of,imported from,inheres in,inherit,input of,is entity in organism,is gene of organism,is opposite_of,Language,located_in,malfunctioning of,manifested phenotype of,manifests phenotype,member of,metafunctioning type,metafuntioning type of,molecular reaction of,NCBI GeneID,NCBI LocusTag,negatively regulated by,negatively regulates,nomenclature status,observed in,occurent part of,occurs in,organism NCBITaxon ID,output of,part of,participates in,pathway of,positively regulated by,positively regulates,property of,quality of,realizes disease,regulated by,regulates,related assay of,relateds assay,relation between a role and a process,role of,smiles,structure_notes,supplies,symbol from nomenclature authority,taxon notes,term editor
http://purl.obolibrary.org/obo/IMR_0100579,syndecan,transmembrane heparan sulfate proteoglycan,,false,,,http://purl.obolibrary.org/obo/IMR_0001125,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,transmembrane heparan sulfate proteoglycan,,,,,IMR:0100579,,,,,,,,,,,,,,,,,,,,,,syndecan,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0011350,NELF-A protein,P/OKCL.15|mWHSC2|Negative elongation factor A|NELF-A|Wolf-Hirshhorn syndrome candidate 2 protein,,false,,,http://purl.obolibrary.org/obo/IMR_0010013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,P/OKCL.15|mWHSC2|Negative elongation factor A|NELF-A|Wolf-Hirshhorn syndrome candidate 2 protein,,,,,IMR:0011350,,,,,,,,,,,,,,,,,,,,,,NELF-A protein,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000002308,FOXO1,,"Other designations: forkhead box protein O1|forkhead box protein O1A|forkhead, Drosophila, homolog of, in rhabdomyosarcoma",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,FOXO1A|FKH1|FKHR,,,,,,,,,,,,13,,,,,,MIM:136533|HPRD:00645|Vega:OTTHUMG00000016775|Ensembl:ENSG00000150907|HGNC:3819,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,forkhead box O1,,,13q14.1,,,,,,,,,,,,,,,,"GO_0001078 (EC: IEA); GO_0001568 (EC: IBA); GO_0001659 (EC: ISS); GO_0001678 (EC: ISS); GO_0003682 (EC: ISS); GO_0005515 (EC: IPI, PMID: 11237865); GO_0005634 (EC: IDA, PMID: 11311120); GO_0005654 (EC: TAS); GO_0005737 (EC: IDA, PMID: 11237865); GO_0005739 (EC: ISS); GO_0005829 (EC: ISS); GO_0005829 (EC: TAS); GO_0006473 (EC: ISS); GO_0006915 (EC: IEA); GO_0006974 (EC: ISS); GO_0007173 (EC: TAS); GO_0007389 (EC: IBA); GO_0008286 (EC: ISS); GO_0008301 (EC: IBA); GO_0008543 (EC: TAS); GO_0009267 (EC: ISS); GO_0009790 (EC: IBA); GO_0009888 (EC: IBA); GO_0031018 (EC: TAS); GO_0032873 (EC: IDA, PMID: 19696738); GO_0034599 (EC: ISS); GO_0035947 (EC: IEA); GO_0038095 (EC: TAS); GO_0042127 (EC: IEA); GO_0043066 (EC: IDA, PMID: 10871843); GO_0043565 (EC: IDA, PMID: 12228231); GO_0045087 (EC: TAS); GO_0045444 (EC: ISS); GO_0045599 (EC: ISS); GO_0045722 (EC: IEA); GO_0045892 (EC: ISS); GO_0045893 (EC: IDA, PMID: 10871843); GO_0045944 (EC: IDA, PMID: 10871843); GO_0048011 (EC: TAS); GO_0048015 (EC: TAS); GO_0051721 (EC: ISS); GO_0070417 (EC: ISS); GO_0071732 (EC: ISS); GO_2000505 (EC: ISS)",,,,,,,,,PMID: 7630639; 7862145; 8275086; 8634710; 8790412; 9479491; 10358014; 10358075; 10783894; 10871843; 10973497; 11030146; 11237865; 11311120; 11353774; 11435445; 11672436; 11735247; 11893744; 11980723; 12039929; 12150827; 12163409; 12228231; 12242297; 12477932; 12482965; 12493691; 12519792; 12560069; 12606503; 12921955; 12960271; 12966085; 13679577; 14664696; 14726521; 15047604; 15057823; 15084259; 15109499; 15140004; 15184910; 15220471; 15342912; 15489334; 15582274; 15613482; 15632117; 15668399; 15688035; 15688409; 15692560; 15778376; 15890677; 15905404; 15987820; 16076959; 16100571; 16123151; 16133873; 16154098; 16282329; 16485043; 16492665; 16497530; 16571842; 16670089; 16690806; 16709600; 16849544; 16885156; 16916907; 16943287; 16950602; 16952014; 16952980; 16964289; 16973122; 16979636; 17030088; 17038621; 17050673; 17077083; 17202144; 17210752; 17218607; 17258205; 17285543; 17404186; 17442120; 17478621; 17490646; 17491598; 17525748; 17555999; 17556536; 17597184; 17599040; 17609436; 17613043; 17638879; 17873969; 17986608; 17993506; 18006475; 18022385; 18029348; 18096667; 18280254; 18301748; 18303411; 18316359; 18356527; 18408765; 18420577; 18483260; 18497882; 18497885; 18612045; 18660489; 18692812; 18713968; 18718910; 18786403; 18787186; 18788887; 18805788; 18815134; 18844239; 18951090; 18988640; 19049975; 19058789; 19075016; 19086408; 19103600; 19141580; 19150739; 19221179; 19233123; 19244250; 19254690; 19281796; 19293131; 19308286; 19321440; 19442434; 19463968; 19483080; 19503105; 19513505; 19535741; 19549905; 19563779; 19574223; 19584310; 19633686; 19675556; 19686743; 19696738; 19727442; 19740748; 19757185; 19772960; 19787258; 19793722; 19887561; 19893043; 19948975; 19953635; 19956688; 20018872; 20033803; 20061393; 20095040; 20125105; 20151947; 20351326; 20353756; 20357092; 20406953; 20412774; 20485516; 20543840; 20682687; 20719862; 20819778; 20868688; 20874444; 20884733; 20933505; 21069157; 21075101; 21116854; 21177767; 21177856; 21179458; 21185807; 21238503; 21298325; 21320536; 21321994; 21373837; 21388494; 21396404; 21423212; 21440011; 21440577; 21442235; 21505104; 21510935; 21539865; 21541992; 21613825; 21655267; 21666686; 21670150; 21696576; 21697492; 21708191; 21747041; 21775495; 21804543; 21993163; 22013015; 22072736; 22089931; 22159921; 22180177; 22197543; 22213032; 22266855; 22315317; 22343918; 22374423; 22389493; 22400069; 22411791; 22417654; 22454413; 22489460; 22515357; 22538365; 22552808; 22569260; 22622204; 22653055; 22675169; 22761423; 22761592; 22821817; 22865884; 22931788; 22992773; 23002242; 23025577; 23029264; 23035900; 23041154; 23059127; 23077062; 23105097; 23142810; 23160481; 23255113; 23263330; 23277279; 23291589; 23381604; 23389878; 23401241; 23460611; 23469153; 23532851; 23574718; 23603247; 23614736; 23615915; 23640897; 23686362; 23721824; 23733015; 23733882; 23748164; 23778262; 23799156; 23803610; 23814486; 23855308; 23865345; 23874926; 23995837; 24145170; 24268349; 24334454; 24374340,,,,,,,,,,,,,,,OGG:3000002308,,,,,,,forkhead box O1,,,,,,,,,,,,,"Other designations: forkhead box protein O1|forkhead box protein O1A|forkhead, Drosophila, homolog of, in rhabdomyosarcoma",,FOXO1,,,,,,,,,,,,,,,,,,,,,,,2308,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,FOXO1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGMS_0000073,diagnosis,,The representation of a conclusion of a diagnostic process.,false,,,http://purl.obolibrary.org/obo/TXPO_0000614,,,,,,,,,,,,,,,,,,,,,,The representation of a conclusion of a diagnostic process.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,OGMS:0000073,,,,,,,,,,,,,,,,,,,,,,diagnosis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_600520,micafungin,"micafungin|Mycamine|5.1:6-anhydro{(4R,5R)-4,5-dihydroxy-N(2)-(4-{5-[4-(pentyloxy)phenyl]isoxazol-3-yl}benzoyl)-L-ornithyl-L-threonyl-(4R)-4-hydroxy-L-prolyl-(4S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonyl-(3R)-3-hydroxy-L-glutaminyl-(3S,4S)-3-hydroxy-4-methyl-L-proline}|5-[(1S,2S)-2-{(2R,6S,9S,11R,12R,14aS,15S,16S,20S,23S,25aS)-20-[(1R)-3-amino-1-hydroxy-3-oxopropyl]-2,11,12,15-tetrahydroxy-6-[(1R)-1-hydroxyethyl]-16-methyl-5,8,14,19,22,25-hexaoxo-9-[(4-{5-[4-(pentyloxy)phenyl]isoxazol-3-yl}benzoyl)amino]tetracosahydro-1H-dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacyclohenicosin-23-yl}-1,2-dihydroxyethyl]-2-hydroxyphenyl hydrogen sulfate","A cyclic hexapeptide echinocandin antibiotic which exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall. It is used as the sodium salt for the treatment of invasive candidiasis, and of aspergillosis in patients who are intolerant of other therapy.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:17325225|PMID:17420211|CAS:235114-32-6|Beilstein:9610508|PMID:17194830|PMID:17307974|PMID:17325217|PMID:17785512|DrugBank:DB01141,,"A cyclic hexapeptide echinocandin antibiotic which exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall. It is used as the sodium salt for the treatment of invasive candidiasis, and of aspergillosis in patients who are intolerant of other therapy.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35441,,,,,"5.1:6-anhydro{(4R,5R)-4,5-dihydroxy-N(2)-(4-{5-[4-(pentyloxy)phenyl]isoxazol-3-yl}benzoyl)-L-ornithyl-L-threonyl-(4R)-4-hydroxy-L-prolyl-(4S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonyl-(3R)-3-hydroxy-L-glutaminyl-(3S,4S)-3-hydroxy-4-methyl-L-proline}|5-[(1S,2S)-2-{(2R,6S,9S,11R,12R,14aS,15S,16S,20S,23S,25aS)-20-[(1R)-3-amino-1-hydroxy-3-oxopropyl]-2,11,12,15-tetrahydroxy-6-[(1R)-1-hydroxyethyl]-16-methyl-5,8,14,19,22,25-hexaoxo-9-[(4-{5-[4-(pentyloxy)phenyl]isoxazol-3-yl}benzoyl)amino]tetracosahydro-1H-dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacyclohenicosin-23-yl}-1,2-dihydroxyethyl]-2-hydroxyphenyl hydrogen sulfate",,micafungin|Mycamine,,,,,,,,,,,,,,,,,,,,,CHEBI:600520,,,,micafungin,,CHEBI:600520,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000367,cytokeratin 16,,,false,,,http://purl.obolibrary.org/obo/IMR_0000035,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000367,,,,,,,,,,,,,,,,,,,,,,cytokeratin 16,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000063,PERK dimerization [ER stress - translation attenuation],,"PERK dimerization is a subtype of protein dimerization: The formation of a PERK dimer, a macromolecular structure consists of two noncovalently associated identical or nonidentical subunits.
This entity is a specific course-dependent process. This process can constitute the course of ER stress and involves inflammation.",false,,,http://purl.obolibrary.org/obo/TXPO_0000713,,,,,,,,,,,,,,,,,,,,Reactome:R-HSA-381087|http://www.ncbi.nlm.nih.gov/pubmed/11907036,,"PERK dimerization is a subtype of protein dimerization: The formation of a PERK dimer, a macromolecular structure consists of two noncovalently associated identical or nonidentical subunits.
This entity is a specific course-dependent process. This process can constitute the course of ER stress and involves inflammation.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002884,,,,,,http://purl.obolibrary.org/obo/TXPO_0000388,,,,,,,,,,,TXPO:0000063,,,,,,,,,,,,,,,,,,,,,,PERK dimerization [ER stress - translation attenuation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000064,unfolded protein role,,A role played by the protein that has a structure of misfolding,false,,,http://purl.obolibrary.org/obo/CHEBI_52209,,,,,,,,,,,,,,,,,,,,,,A role played by the protein that has a structure of misfolding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000064,,,,,,,,,,,,,,,,,,,,,,unfolded protein role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000061,PERK signaling to eIF2a [ER stress - translation attenuation],,"A process in which a signal to eIF2a is transduced by PERK.
This process is dependent on the translation attenuation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002449|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"A process in which a signal to eIF2a is transduced by PERK.
This process is dependent on the translation attenuation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002514|http://purl.obolibrary.org/obo/TXPO_0002506,http://purl.obolibrary.org/obo/TXPO_0002162,,,,,,http://purl.obolibrary.org/obo/TXPO_0002762,,,,,,,,,,,TXPO:0000061,,,,,,,,,,,,,,,,,,,,,,PERK signaling to eIF2a [ER stress - translation attenuation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000068,negative regulation of formation of cytoplasmic translation initiation complex,negative regulation of formation of translation initiation complex,"Negative regulation of formation of cytoplasmic translation initiation complex is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of formation of cytoplasmic translation initiation complex.",false,,,http://purl.obolibrary.org/obo/TXPO_0000369,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of formation of cytoplasmic translation initiation complex is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of formation of cytoplasmic translation initiation complex.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,negative regulation of formation of translation initiation complex,,,,,TXPO:0000068,,,,,,,,,,,,,,,,,,,,,,negative regulation of formation of cytoplasmic translation initiation complex,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0001732,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000062,PERK signaling to eIF2a [PERK - eIF2A pathway],,"A process in which a signal to eIF2a is transduced by PERK.
This entity is a specific course-dependent process. This process can constitute the course of PERK - eIF2A pathway.",false,,,http://purl.obolibrary.org/obo/TXPO_0000454,,,,,,,,,,,,,,,,,,,,,,"A process in which a signal to eIF2a is transduced by PERK.
This entity is a specific course-dependent process. This process can constitute the course of PERK - eIF2A pathway.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000696,,,,,,,,,,,,,,,,,,TXPO:0000062,,,,,,,,,,,,,,,,,,,,,,PERK signaling to eIF2a [PERK - eIF2A pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000060,ground glass appearance [Liver Pathological Findings],,"Ground glass appearance [Liver PathologicalFindings] is a type of finding observed in hepatocyte cytoplasm. Based on the pathological morphology, lesions are observed as a frosted-like change in whole or most of the hepatocytes.",false,,,http://purl.obolibrary.org/obo/TXPO_0000662,,,,,,,,,,,,,,,,,,,,Open TG-GatesID:FI-L0830,,"Ground glass appearance [Liver PathologicalFindings] is a type of finding observed in hepatocyte cytoplasm. Based on the pathological morphology, lesions are observed as a frosted-like change in whole or most of the hepatocytes.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000060,,,,,,,"Monochromatic eosinophilic change across the whole or most of the hepatocyte.
It is often observed as a changing response to the hepatic metabolism enzyme inducer such as phenobarbital.
In electron microscopy, it is regarded as prominent proliferation of smooth endoplasmic reticulum, dispersion of rough endoplasmic reticulum, with decrease of stored glycogen.",,,,,,,,,,,,,,,ground glass appearance [Liver Pathological Findings],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000067,PERK signaling (integrated pathway),,"PERK signaling (integrated pathway) is a subtype of integrated signaling pathway: Sequence of linked reactions, which has ATF6 signaling and gene regulation pathway.",false,,,http://purl.obolibrary.org/obo/TXPO_0000027,,,,,,,,,,,,,,,,,,,,,,"PERK signaling (integrated pathway) is a subtype of integrated signaling pathway: Sequence of linked reactions, which has ATF6 signaling and gene regulation pathway.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000067,,,,,,,,,,,,,,,,,,,,,,PERK signaling (integrated pathway),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000065,cellular tissue,,Cellular tissue is a subtype of object aggregate that consists of cells or tissues.,false,,,http://purl.obolibrary.org/obo/BFO_0000027,,,,,,,,,,,,,,,,,,,,,,Cellular tissue is a subtype of object aggregate that consists of cells or tissues.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000065,,,,,,,,,,,,,,,,,,,,,,cellular tissue,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000066,changing cytoskeleton [Cholestasis],,"Changing cytoskeleton is a subtype of changing structure: A process that changes the structure of cytoskeleton.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000238|http://purl.obolibrary.org/obo/TXPO_0000034,,,,,,,,,,,,,,,,,,,,,,"Changing cytoskeleton is a subtype of changing structure: A process that changes the structure of cytoskeleton.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000066,,,,,,,,,,,,,,,,,,,,,,changing cytoskeleton [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0014892,skeletal muscle organ,skeletal muscle,"A muscle organ that consists of skeletal muscle tissue ensheathed in epimysium, that develops from myotome and that is innervated by some somatic motor neuron. Skeletal muscles are typically attached (via a tendon) to a bone but there are exceptions (e.g. intrinsic tongue muscles).",false,,,http://purl.obolibrary.org/obo/UBERON_0001630,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0001134,,,,VHOG:0000319|EHDAA:5984|MA:0003148|MAT:0000302|TAO:0005277|MESH:D018482|EHDAA:5978|MIAA:0000302|EMAPA:35988|EHDAA:5043|GAID:141|EFO:0000888|BTO:0001103|OpenCyc:Mx4rv2kf-5wpEbGdrcN5Y29ycA|EHDAA:5035|AAO:0011099|XAO:0000174|CALOHA:TS-0933|EV:0100377|ZFA:0005277,,"A muscle organ that consists of skeletal muscle tissue ensheathed in epimysium, that develops from myotome and that is innervated by some somatic motor neuron. Skeletal muscles are typically attached (via a tendon) to a bone but there are exceptions (e.g. intrinsic tongue muscles).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,UBERON:0014892,,,,,,,,,,,,,,,,skeletal muscle,,,,,,skeletal muscle organ,,,,,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004764,negative regulation of caspase-3 activation [hepatocarcinogenesis],,"Negative regulation of caspase-3 activation is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of caspase-3 activation. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004877,,,,,,,,,,,,,,,,,,,,PMID:29335519|PMID:23284992,,"Negative regulation of caspase-3 activation is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of caspase-3 activation. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004879,,,,,,http://purl.obolibrary.org/obo/TXPO_0004396,,,,,,,,,,,TXPO:0004764,,,,,,,,,,,,,,,,,,,,,,negative regulation of caspase-3 activation [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003098,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004766,PPARA(canonical) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000159|http://purl.obolibrary.org/obo/TXPO_0005063,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:19013|NCBI-Rat-GeneID:25747|NCBI-Human-GeneID:5465|PMID:30008815,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004766,,,,,,,,,,,,,,,,,,,,,,PPARA(canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004760,PKC activation,,PKC activation is a subtype of molecular activation: A process that  changes the activity of the PKC ( protein kinase C) to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000023,,,,,,,,,,,,,,,,,,,,,,PKC activation is a subtype of molecular activation: A process that  changes the activity of the PKC ( protein kinase C) to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004760,,,,,,,,,,,,,,,,,,,,,,PKC activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004767,PPARA(human) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_0000159,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:5465|PMID:25592151,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004767,,,,,,,,,,,,,,,,,,,,,,PPARA(human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004769,PPARGC1A (canonical) [mitochondrial disorder],PGC-1(alpha),,false,,,http://purl.obolibrary.org/obo/TXPO_0005127,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:19017|NCBI-Rat-GeneID:83516|NCBI-Human-GeneID:10891|PMID:31623280|PMID:23299992,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PGC-1(alpha),,,,,TXPO:0004769,,,,,,,,,,,,,,,,,,,,,,PPARGC1A (canonical) [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004761,PKC activation [mitochondrial disorder],,"PKC activation is a subtype of molecular activation: A process that  changes the activity of the PKC ( protein kinase C) to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0004760|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:31649547,,"PKC activation is a subtype of molecular activation: A process that  changes the activity of the PKC ( protein kinase C) to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004416,,,,,,,,,,,TXPO:0004761,,,,,,,,,,,,,,,,,,,,,,PKC activation [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004768,Hypofunction of PPARGC1A gene expression,,"Hypofunction of PPARGC1A gene expression is a subtype of hypofunction of transcription, DNA-templated: A process that performs a decreased or insufficient PPARGC1A gene expression.",false,,,http://purl.obolibrary.org/obo/TXPO_0002356,,,,,,,,,,,,,,,,,,,,,,"Hypofunction of PPARGC1A gene expression is a subtype of hypofunction of transcription, DNA-templated: A process that performs a decreased or insufficient PPARGC1A gene expression.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004768,,,,,,,,,,,,,,,,,,,,,,Hypofunction of PPARGC1A gene expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004765,Increasing PPARA level,,Increasing PPARA level is a subtype of increasing quantity: A process that changes the amount of PPARA level to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing PPARA level is a subtype of increasing quantity: A process that changes the amount of PPARA level to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000159,,,,,,,,,,,,,,,,,,,TXPO:0004765,,,,,,,,,,,,,,,,,,,,,,Increasing PPARA level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004763,PMAIP1 - inactive form (predicted)(human) [hepatocarcinogenesis],NOXA,,false,,,http://purl.obolibrary.org/obo/TXPO_0004200|http://purl.obolibrary.org/obo/TXPO_1000526,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:5366|PMID:25797246|PMID:23284992,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657|http://purl.obolibrary.org/obo/PATO_0002355,http://purl.obolibrary.org/obo/OGG_3000005366,,,,,,,,NOXA,,,,,TXPO:0004763,,,,,,,,,,,,,,,,,,,,,,PMAIP1 - inactive form (predicted)(human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004762,PMAIP1 inactivation,,PMAIP1 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the PMAIP1 (phorbol-12-myristate-13-acetate-induced protein 1) to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000021,,,,,,,,,,,,,,,,,,,,,,PMAIP1 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the PMAIP1 (phorbol-12-myristate-13-acetate-induced protein 1) to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004762,,,,,,,,,,,,,,,,,,,,,,PMAIP1 inactivation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0016051,carbohydrate biosynthetic process,carbohydrate biosynthesis|carbohydrate formation|carbohydrate anabolism|anabolic carbohydrate metabolic process|carbohydrate synthesis|anabolic carbohydrate metabolism,"The chemical reactions and pathways resulting in the formation of carbohydrates, any of a group of organic compounds based of the general formula Cx(H2O)y.",false,,,http://purl.obolibrary.org/obo/GO_0009058,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways resulting in the formation of carbohydrates, any of a group of organic compounds based of the general formula Cx(H2O)y.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_16646,,,,,,,,,,,,,,carbohydrate biosynthesis|carbohydrate formation|carbohydrate anabolism|anabolic carbohydrate metabolic process|carbohydrate synthesis|anabolic carbohydrate metabolism,,,,,GO:0016051,,,,,,,,,,,,,,,,,,,,,,carbohydrate biosynthetic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0016052,carbohydrate catabolic process,catabolic carbohydrate metabolism|catabolic carbohydrate metabolic process|carbohydrate degradation|carbohydrate biosynthesis|carbohydrate catabolism,"The chemical reactions and pathways resulting in the breakdown of carbohydrates, any of a group of organic compounds based of the general formula Cx(H2O)y.",false,,,http://purl.obolibrary.org/obo/GO_0009056,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways resulting in the breakdown of carbohydrates, any of a group of organic compounds based of the general formula Cx(H2O)y.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_16646,,,,,,,,,,,,,,,,,,catabolic carbohydrate metabolism|catabolic carbohydrate metabolic process|carbohydrate degradation|carbohydrate biosynthesis|carbohydrate catabolism,,,,,GO:0016052,,,,,,,,,,,,,,,,,,,,,,carbohydrate catabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000546,fibronectin,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003695,,,,,,,,,,IMR:0000546,,,,,,,,,,,,,,,,,,,,,,fibronectin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000183,regulation of cell cycle related gene expression,,"Regulation of cell cycle related gene expression is a subtype of regulation of gene expression: A process that modulates the frequency, rate or extent of cel cycle related gene expression.",false,,,http://purl.obolibrary.org/obo/GO_0010468,,,,,,,,,,,,,,,,,,,,,,"Regulation of cell cycle related gene expression is a subtype of regulation of gene expression: A process that modulates the frequency, rate or extent of cel cycle related gene expression.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000183,,,,,,,,,,,,,,,,,,,,,,regulation of cell cycle related gene expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000180,increasing demand for peroxisomal fatty acid beta oxidation,,Increasing demand for peroxisomal fatty acid beta oxidation is a subtype of increasing functional demand: A process that changes the functional demand for peroxisomal fatty acid beta oxidation to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000633,,,,,,,,,,,,,,,,,,,,,,Increasing demand for peroxisomal fatty acid beta oxidation is a subtype of increasing functional demand: A process that changes the functional demand for peroxisomal fatty acid beta oxidation to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000180,,,,,,,,,,,,,,,,,,,,,,increasing demand for peroxisomal fatty acid beta oxidation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000187,lipid catabolic process [Eosinophilic granular degeneration],,"The chemical reactions and pathways resulting in the breakdown of lipids, compounds soluble in an organic solvent but not, or sparingly, in an aqueous solvent.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/GO_0016042|http://purl.obolibrary.org/obo/TXPO_0001729,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways resulting in the breakdown of lipids, compounds soluble in an organic solvent but not, or sparingly, in an aqueous solvent.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000187,,,,,,,,,,,,,,,,,,,,,,lipid catabolic process [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000188,SPON2(mouse) - obesity inhibitor[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003278|http://purl.obolibrary.org/obo/TXPO_0003834,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:100689|https://omim.org/entry/605918|PMID:24445216,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000010417,,,http://purl.obolibrary.org/obo/TXPO_0000189|http://purl.obolibrary.org/obo/TXPO_0003351,,,,,,,,,,TXPO:0000188,,,,,,,,,,,,,,,,,,,,,,SPON2(mouse) - obesity inhibitor[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000185,biochemical degradation,,Biochemical degradation is a subtype of decompoing: A process that biochemically decomposes a single chemical entity into multiple element,false,,,http://purl.obolibrary.org/obo/TXPO_0000343,,,,,,,,,,,,,,,,,,,,,,Biochemical degradation is a subtype of decompoing: A process that biochemically decomposes a single chemical entity into multiple element,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000185,,,,,,,,,,,,,,,,,,,,,,biochemical degradation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000186,microtubule cytoskeletal protein,,A role played by the protein related to the microtubules of the cytoskeleton.,false,,,http://purl.obolibrary.org/obo/TXPO_0003689,,,,,,,,,,,,,,,,,,,,IMR:0000196 (obsolete)|related cell structure GO:0015630,,A role played by the protein related to the microtubules of the cytoskeleton.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000186,,,,,,,,,,,,,,,,,,,,,,microtubule cytoskeletal protein,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000181,accumulation of drug in hepatocyte [Ground glass appearance],,"Accumulation of drug in hepatocyte is a subtype of accumulation of xenobiotics: A process that keeps compound in the hepatocyte.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/TXPO_0002325,,,,,,,,,,,,,,,,,,,,,,"Accumulation of drug in hepatocyte is a subtype of accumulation of xenobiotics: A process that keeps compound in the hepatocyte.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000181,,,,,,,,,,,,,,,,,,,,,,accumulation of drug in hepatocyte [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000189,inhibitor of obesity,,A role played by the entity that ihibits the obesity.,false,,,http://purl.obolibrary.org/obo/TXPO_0003230,,,,,,,,,,,,,,,,,,,,,,A role played by the entity that ihibits the obesity.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000189,,,,,,,,,,,,,,,,,,,,,,inhibitor of obesity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000182,negative regulation of lipid biosynthetic process [Eosinophilic granular degeneration],,"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of lipids.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/TXPO_0001729|http://purl.obolibrary.org/obo/GO_0051055,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of lipids.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001328,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000182,,,,,,,,,,,,,,,,,,,,,,negative regulation of lipid biosynthetic process [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000184,regulation of cell cycle related gene expression [Eosinophilic granular degeneration],,"Regulation of cell cycle related gene expression is a subtype of regulation of gene expression: A process that modulates the frequency, rate or extent of cel cycle related gene expression.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/TXPO_0000183|http://purl.obolibrary.org/obo/TXPO_0001729,,,,,,,,,,,,,,,,,,,,PMID:9855014,,"Regulation of cell cycle related gene expression is a subtype of regulation of gene expression: A process that modulates the frequency, rate or extent of cel cycle related gene expression.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003244,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003238|http://purl.obolibrary.org/obo/TXPO_0003242,,,,,,http://purl.obolibrary.org/obo/TXPO_0003231|http://purl.obolibrary.org/obo/TXPO_0002100,,,,,,,,,,,TXPO:0000184,,,,,,,,,,,,,,,,,,,,,,regulation of cell cycle related gene expression [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001148,PKC delta,,,false,,,http://purl.obolibrary.org/obo/IMR_0000246,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001148,,,,,,,,,,,,,,,,,,,,,,PKC delta,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000005166,PDK4,,"Other designations: [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial|[Pyruvate dehydrogenase [lipoamide]] kinase isozyme 4, mitochondrial|pyruvate dehydrogenase kinase, isoenzyme 4|pyruvate dehydrogenase, lipoamide, kinase isozyme 4, mitochondrial",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,7,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"pyruvate dehydrogenase kinase, isozyme 4",,,7q21.3,,,,,,,,,,,,,,,,"GO_0004672 (EC: IDA, PMID: 18658136); GO_0004674 (EC: IEA); GO_0004740 (EC: ISS); GO_0005524 (EC: IDA, PMID: 18658136); GO_0005739 (EC: TAS, PMID: 8798399); GO_0005743 (EC: IEA); GO_0005759 (EC: TAS); GO_0006006 (EC: IEA); GO_0006090 (EC: TAS); GO_0006468 (EC: IDA, PMID: 18658136); GO_0006468 (EC: ISS); GO_0006468 (EC: TAS, PMID: 8798399); GO_0006885 (EC: ISS); GO_0008286 (EC: IMP); GO_0009267 (EC: IDA, PMID: 14966024); GO_0010510 (EC: IMP); GO_0010510 (EC: TAS); GO_0010565 (EC: ISS); GO_0010906 (EC: IMP); GO_0042304 (EC: IMP); GO_0042593 (EC: ISS); GO_0042594 (EC: ISS); GO_0044237 (EC: TAS); GO_0044281 (EC: TAS); GO_0045124 (EC: IEA); GO_0046320 (EC: ISS); GO_0071398 (EC: IMP); GO_0072593 (EC: IMP); GO_2000811 (EC: IMP)",,,,,,,,,PMID: 7499431; 8125298; 8798399; 9787110; 11001762; 11485553; 11486000; 11701428; 11978179; 12145475; 12477932; 12573248; 12582211; 12606505; 12676647; 12690205; 12853948; 14702039; 14966024; 15047604; 15489334; 15516373; 15581486; 15618316; 15721319; 15776585; 15955060; 16344560; 16757381; 17623298; 17652214; 17669420; 18468620; 18519799; 18658136; 18660489; 20715114; 20877624; 21852536; 21883960; 21904029; 21906983; 21963094; 22019269; 23050013,,,,,,,,,,,,,,,OGG:3000005166,,,,,,,"pyruvate dehydrogenase kinase, isozyme 4",,,,,,,,,,,,,"Other designations: [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial|[Pyruvate dehydrogenase [lipoamide]] kinase isozyme 4, mitochondrial|pyruvate dehydrogenase kinase, isoenzyme 4|pyruvate dehydrogenase, lipoamide, kinase isozyme 4, mitochondrial",,PDK4,,,,,,,,,,,,,,,,,,,,,,,5166,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,PDK4,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0002690,IGFBP-2,,,false,,,http://purl.obolibrary.org/obo/IMR_0002688,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0002690,,,,,,,,,,,,,,,,,,,,,,IGFBP-2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100855,IL-1 beta,Interleukin-1 beta,,false,,,http://purl.obolibrary.org/obo/IMR_0000011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Interleukin-1 beta,,,,,IMR:0100855,,,,,,,,,,,,,,,,,,,,,,IL-1 beta,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001692,HSP27,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001692,,,,,,,,,,,,,,,,,,,,,,HSP27,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000284161,GDPD1,,Other designations: glycerophosphodiester phosphodiesterase 4|glycerophosphodiester phosphodiesterase domain-containing protein 1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,GDE4,,,,,,,,,,,,17,,,,,,Ensembl:ENSG00000153982|HGNC:20883|HPRD:08223|Vega:OTTHUMG00000179376,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,glycerophosphodiester phosphodiesterase domain containing 1,,,17q22,,,,,,,,,,,,,,,,GO_0005737 (EC: IEA); GO_0006071 (EC: IEA); GO_0006629 (EC: IEA); GO_0008889 (EC: IEA); GO_0016021 (EC: IEA); GO_0046872 (EC: IEA),,,,,,,,,PMID: 12477932; 14612981; 14702039; 15489334; 17690467; 18991142; 21139048; 21890473; 21906983; 24250222,,,,,,,,,,,,,,,OGG:3000284161,,,,,,,glycerophosphodiester phosphodiesterase domain containing 1,,,,,,,,,,,,,Other designations: glycerophosphodiester phosphodiesterase 4|glycerophosphodiester phosphodiesterase domain-containing protein 1,,GDPD1,,,,,,,,,,,,,,,,,,,,,,,284161,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,GDPD1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0100045,calcitonin,,"A peptide hormone that lowers calcium concentration in the blood. In humans, it is released by thyroid cells and acts to decrease the formation and absorptive activity of osteoclasts. Its role in regulating plasma calcium is much greater in children and in certain diseases than in normal adults.",false,,,http://purl.obolibrary.org/obo/IMR_0000966,,,,,,,,,,,,,,,,,,,,MeSH:D002116,,"A peptide hormone that lowers calcium concentration in the blood. In humans, it is released by thyroid cells and acts to decrease the formation and absorptive activity of osteoclasts. Its role in regulating plasma calcium is much greater in children and in certain diseases than in normal adults.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_24621,,,,,,,,,,IMR:0100045,,,,,,,,,,,,,,,,,,,,,,calcitonin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000010553,HTATIP2,,"Other designations: 30 kDa HIV-1 TAT-interacting protein|HIV-1 TAT-interactive protein 2|Tat-interacting protein (30kD)|oxidoreductase HTATIP2|short chain dehydrogenase/reductase family 44U, member 1",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CC3|TIP30|SDR44U1,,,,,,,,,,,,11,,,,,,HPRD:09288|Vega:OTTHUMG00000166015|MIM:605628|HGNC:16637|Ensembl:ENSG00000109854,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"HIV-1 Tat interactive protein 2, 30kDa",,,11p15.1,,,,,,,,,,,,,,,,"GO_0001525 (EC: IEA); GO_0003713 (EC: TAS, PMID: 9482853); GO_0005515 (EC: IPI, PMID: 15282309); GO_0005634 (EC: TAS, PMID: 9482853); GO_0005635 (EC: IDA, PMID: 15282309); GO_0005737 (EC: IDA); GO_0006357 (EC: TAS, PMID: 9482853); GO_0006915 (EC: IEA); GO_0016032 (EC: IEA); GO_0016491 (EC: IEA); GO_0030154 (EC: IEA); GO_0043066 (EC: TAS, PMID: 10611237); GO_0045765 (EC: IDA, PMID: 11313954); GO_0051170 (EC: IDA, PMID: 15282309)",,,,,,,,,PMID: 8125298; 9174052; 9482853; 10395547; 10611237; 10698937; 10892349; 11313954; 12477932; 14695192; 15073177; 15124103; 15282309; 15342556; 15489334; 15493507; 15633220; 15728189; 16615932; 16799960; 17097132; 17997990; 18029348; 18519672; 18528861; 18537194; 18972434; 19010857; 19027726; 19104151; 19349353; 19798571; 19839715; 20374651; 21139048; 21150275; 21252234; 21543106; 21731680; 21890473; 21906983; 21963094; 21987572; 22490293; 22733137; 23000965; 23178973; 23251661; 23800048; 24037692,,,,,,,,,,,,,,,OGG:3000010553,,,,,,,"HIV-1 Tat interactive protein 2, 30kDa",,,,,,,,,,,,,"Other designations: 30 kDa HIV-1 TAT-interacting protein|HIV-1 TAT-interactive protein 2|Tat-interacting protein (30kD)|oxidoreductase HTATIP2|short chain dehydrogenase/reductase family 44U, member 1",,HTATIP2,,,,,,,,,,,,,,,,,,,,,,,10553,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,HTATIP2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/HINO_0016374,Glutathione synthesis and recycling,,"The combination of glutamate, cysteine and ATP is required to form glutathione. The steps involved in the synthesis and recycling of glutathione are outlined (Meister, 1988).",false,,,http://purl.obolibrary.org/obo/TXPO_0000610,,,,,,,,,,,,,,,,,,,,Reactome: R-HSA-174403.4|PMID:3053703,,"The combination of glutamate, cysteine and ATP is required to form glutathione. The steps involved in the synthesis and recycling of glutathione are outlined (Meister, 1988).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,HINO:0016374,,,,,,,,,,,,,,,,,,,,,,Glutathione synthesis and recycling,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004703,MYC gene promoter demethylation [hepatocarcinogenesis],,"The process of removing one or more methyl groups from MYC gene promoter.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0004702|http://purl.obolibrary.org/obo/TXPO_0002340,,,,,,,,,,,,,,,,,,,,PMID:10774822|PMID:30141584,,"The process of removing one or more methyl groups from MYC gene promoter.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004700|http://purl.obolibrary.org/obo/TXPO_0004699,,,,,,http://purl.obolibrary.org/obo/TXPO_0004675|http://purl.obolibrary.org/obo/TXPO_0004674|http://purl.obolibrary.org/obo/TXPO_0004676|http://purl.obolibrary.org/obo/TXPO_0004448,,,,,,http://purl.obolibrary.org/obo/TXPO_0004698,,,,,,,,,,,TXPO:0004703,,,,,,,,,,,,,,,,,,,,,,MYC gene promoter demethylation [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004708,NDUFB6 inactivation,,NDUFB6 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the NDUFB6 (NADH:ubiquinone oxidoreductase subunit B6) to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000021,,,,,,,,,,,,,,,,,,,,,,NDUFB6 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the NDUFB6 (NADH:ubiquinone oxidoreductase subunit B6) to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004708,,,,,,,,,,,,,,,,,,,,,,NDUFB6 inactivation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004709,NDUFB6 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:4712|NCBI-Mouse-GeneID:230075|NCBI-Rat-GeneID:297990,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004709,,,,,,,,,,,,,,,,,,,,,,NDUFB6 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004701,Myc (canonical) [hepatocarcinogenesis],c-Myc,,false,,,http://purl.obolibrary.org/obo/IMR_0000383|http://purl.obolibrary.org/obo/TXPO_0005063,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:17869|NCBI-Human-GeneID:4609|NCBI-Rat-GeneID:24577,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,c-Myc,,,,,TXPO:0004701,,,,,,,,,,,,,,,,,,,,,,Myc (canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004706,NDUFA12 inactivation,,NDUFA12 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the NDUFA12 (NADH:ubiquinone oxidoreductase subunit A12) to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000021,,,,,,,,,,,,,,,,,,,,,,NDUFA12 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the NDUFA12 (NADH:ubiquinone oxidoreductase subunit A12) to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004706,,,,,,,,,,,,,,,,,,,,,,NDUFA12 inactivation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004707,NDUFA12 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:299739|NCBI-Human-GeneID:55967|NCBI-Mouse-GeneID:66414,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004707,,,,,,,,,,,,,,,,,,,,,,NDUFA12 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004705,N-hydroxy-2-acetamidofluorene [hepatocarcinogenesis],N-(9H-fluoren-2-yl)-N-hydroxyacetamide|N-hydroxy-2-acetylaminofluorene|N-OH-AAF,,false,,,http://purl.obolibrary.org/obo/TXPO_0004455|http://purl.obolibrary.org/obo/CHEBI_17931,,,,,,,,,,,,,,,,,,,,PMID:1596892|CAS:53-95-2,,,,,,,,,,,,,,C15H13NO2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,N-(9H-fluoren-2-yl)-N-hydroxyacetamide|N-hydroxy-2-acetylaminofluorene|N-OH-AAF,,,,,TXPO:0004705,,,,,,,,,,,,,,,,,,,,,,N-hydroxy-2-acetamidofluorene [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CC(=O)N(O)c1ccc-2c(Cc3ccccc-23)c1,,,,,
http://purl.obolibrary.org/obo/TXPO_0004702,MYC gene promoter demethylation,,The process of removing one or more methyl groups from MYC gene promoter.,false,,,http://purl.obolibrary.org/obo/TXPO_0004672,,,,,,,,,,,,,,,,,,,,,,The process of removing one or more methyl groups from MYC gene promoter.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004702,,,,,,,,,,,,,,,,,,,,,,MYC gene promoter demethylation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004704,N-nitrosodiethylamine [hepatocarcinogenesis],DEN|Diethylnitrosamine|N-ethyl-N-nitrosoethanamine,A nitrosamine that is N-ethylethanamine substituted by a nitroso group at the N-atom.,false,,,http://purl.obolibrary.org/obo/TXPO_0004455|http://purl.obolibrary.org/obo/CHEBI_34873,,,,,,,,,,,,,,,,,,,,PMID:1596892|PMID:28932315|CAS:55-18-5,,A nitrosamine that is N-ethylethanamine substituted by a nitroso group at the N-atom.,,,,,,,,,,,,C4H10N2O,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,N-ethyl-N-nitrosoethanamine,,DEN|Diethylnitrosamine,,,TXPO:0004704,,,,,,,,,,,,,,,,,,,,,,N-nitrosodiethylamine [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CCN(CC)N=O,,,,,
http://purl.obolibrary.org/obo/TXPO_0004700,Myc(rat) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/IMR_0000383|http://purl.obolibrary.org/obo/TXPO_0005070,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24577|PMID:30141584,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000383,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004700,,,,,,,,,,,,,,,,,,,,,,Myc(rat) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000008870,IER3,,"Other designations: PACAP-responsive gene 1 protein|anti-death protein|differentiation-dependent gene 2 protein|expressed in pancreatic carcinoma|gly96, mouse, homolog of|immediate early protein GLY96|immediate early response 3 protein|immediately early gene X-1|protein DIF-2|radiation-inducible immediate-early gene IEX-1",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,IEX-1L|DIF2|IEX1|PRG1|DIF-2|GLY96|IEX-1,,,,,,,,,,,,6,,,,,,Vega:OTTHUMG00000031265|Ensembl:ENSG00000137331|MIM:602996|HPRD:04295|HGNC:5392,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,immediate early response 3,,,6p21.3,,,,,,,,,,,,,,,,"GO_0001562 (EC: IEA); GO_0003085 (EC: IEA); GO_0005515 (EC: IPI, PMID: 15451437); GO_0005634 (EC: IDA); GO_0006282 (EC: IEA); GO_0006915 (EC: TAS, PMID: 9196025); GO_0007095 (EC: IEA); GO_0008630 (EC: IEA); GO_0009653 (EC: TAS, PMID: 9196025); GO_0016021 (EC: IEA); GO_0043066 (EC: IEA); GO_0045732 (EC: IEA); GO_0045820 (EC: IEA); GO_0046822 (EC: IEA); GO_0050728 (EC: IEA); GO_1901029 (EC: IEA); GO_2000377 (EC: IEA); GO_2001020 (EC: IMP)",,,,,,,,,PMID: 8125298; 8603392; 8653710; 9196025; 9588170; 9703517; 9781666; 9791001; 9878538; 10448082; 11455449; 11782530; 11844788; 11910304; 12032839; 12356731; 12477932; 12510147; 12682234; 12743274; 12761504; 15120418; 15451437; 15489334; 15767410; 15781630; 15855159; 16344560; 16456541; 16567805; 16702430; 16960879; 16973576; 17704804; 18026799; 18482256; 18564103; 19152102; 19285955; 19690192; 19773435; 19837266; 19851445; 20587610; 20713914; 20848476; 20934684; 21112119; 21250941; 21518511; 21832049; 21906983; 22085302; 23455636; 24311782,,,,,,,,,,,,,,,OGG:3000008870,,,,,,,immediate early response 3,,,,,,,,,,,,,"Other designations: PACAP-responsive gene 1 protein|anti-death protein|differentiation-dependent gene 2 protein|expressed in pancreatic carcinoma|gly96, mouse, homolog of|immediate early protein GLY96|immediate early response 3 protein|immediately early gene X-1|protein DIF-2|radiation-inducible immediate-early gene IEX-1",,IER3,,,,,,,,,,,,,,,,,,,,,,,8870,DADB-118P11.5,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,IER3,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000008876,VNN1,,Other designations: pantetheinase|pantetheine hydrolase|vanin-1|vannin 1|vascular non-inflammatory molecule 1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,HDLCQ8|Tiff66,,,,,,,,,,,,6,,,,,,HPRD:04651|Ensembl:ENSG00000112299|MIM:603570|HGNC:12705|Vega:OTTHUMG00000015587,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,vanin 1,,,6q23-q24,,,,,,,,,,,,,,,,"GO_0002526 (EC: ISS, PMID: 14966568); GO_0002544 (EC: ISS, PMID: 14966568); GO_0005886 (EC: IEA); GO_0006928 (EC: TAS, PMID: 9790769); GO_0006954 (EC: ISS, PMID: 15282320); GO_0006979 (EC: TAS, PMID: 17145956); GO_0015939 (EC: IDA, PMID: 11491533); GO_0016021 (EC: TAS, PMID: 17145956); GO_0016337 (EC: ISS, PMID: 11491533); GO_0017159 (EC: IDA, PMID: 11491533); GO_0031225 (EC: IEA); GO_0033089 (EC: ISS, PMID: 11491533); GO_0034235 (EC: TAS, PMID: 17145956); GO_0045087 (EC: ISS, PMID: 14966568); GO_1902176 (EC: ISS, PMID: 15282320)",,,,,,,,,PMID: 8934567; 9790769; 10567687; 11491533; 12477932; 14574404; 14702039; 14966568; 15084671; 15282320; 15489334; 16335952; 17145956; 17312006; 18043751; 19322213; 20571492; 20641033; 21325602; 21544065; 21550219; 21907259; 23185446; 23978960; 24140347,,,,,,,,,,,,,,,OGG:3000008876,,,,,,,vanin 1,,,,,,,,,,,,,Other designations: pantetheinase|pantetheine hydrolase|vanin-1|vannin 1|vascular non-inflammatory molecule 1,,VNN1,,,,,,,,,,,,,,,,,,,,,,,8876,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,VNN1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000008879,SGPL1,,Other designations: SP-lyase 1|SPL 1|hSPL|sphingosine-1-phosphate aldolase,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,S1PL|SPL,,,,,,,,,,,,10,,,,,,HPRD:07224|Ensembl:ENSG00000166224|HGNC:10817|Vega:OTTHUMG00000018421|MIM:603729,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,sphingosine-1-phosphate lyase 1,,,10q21,,,,,,,,,,,,,,,,"GO_0001553 (EC: IEA); GO_0001570 (EC: IEA); GO_0001822 (EC: IEA); GO_0005515 (EC: IPI); GO_0005783 (EC: IDA, PMID: 14570870); GO_0005789 (EC: TAS); GO_0006665 (EC: TAS); GO_0006672 (EC: IDA, PMID: 14570870); GO_0007283 (EC: IEA); GO_0008117 (EC: IDA, PMID: 14570870); GO_0008117 (EC: NAS, PMID: 11018465); GO_0008209 (EC: IEA); GO_0008210 (EC: IEA); GO_0009791 (EC: IEA); GO_0010761 (EC: IEA); GO_0016831 (EC: IEA); GO_0019752 (EC: IEA); GO_0030097 (EC: IEA); GO_0030148 (EC: TAS); GO_0030149 (EC: NAS, PMID: 11018465); GO_0030170 (EC: IEA); GO_0030176 (EC: NAS, PMID: 11018465); GO_0033327 (EC: IEA); GO_0040014 (EC: IEA); GO_0044281 (EC: TAS); GO_0048008 (EC: IEA); GO_0048705 (EC: IEA); GO_0060021 (EC: IEA); GO_0060325 (EC: IEA); GO_0097194 (EC: IDA, PMID: 14570870)",,,,,,,,,PMID: 2061324; 9464245; 10574462; 11018465; 12477932; 14570870; 14702039; 15342556; 15489334; 16385451; 16777052; 17090686; 17373700; 18029348; 18172856; 19119317; 19322201; 20519401; 21139048; 21184844; 21304987; 21368890; 21565611; 21890473; 21903422; 21906983; 21963094; 22190034; 22784711; 23000965; 23455922; 23956138; 24255178,,,,,,,,,,,,,,,OGG:3000008879,,,,,,,sphingosine-1-phosphate lyase 1,,,,,,,,,,,,,Other designations: SP-lyase 1|SPL 1|hSPL|sphingosine-1-phosphate aldolase,,SGPL1,,,,,,,,,,,,,,,,,,,,,,,8879,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,SGPL1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_9763,trovafloxacin,"trovafloxacinum|trovafloxacin|trovafloxacine|trovafloxacino|7-[(1R,5S,6s)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid","A 1,8-naphthyridine derivative that is 4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid bearing additional 2,4-difluorophenyl, fluoro and  6-amino-3-azabicyclo[3.1.0]hex-3-yl substituents at positions 1, 6 and 7 respectively. A broad-spectrum antibiotic that was withdrawn from the market due to risk of liver failure.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,DrugBank:DB00685|PMID:20655887|PMID:24525298|Drug_Central:2777|PMID:23727874|PMID:20538741|PMID:20022474|PMID:24097668|Reaxys:8172628|PMID:21151465|CAS:147059-72-1|PMID:20462743|PMID:22305082,,"A 1,8-naphthyridine derivative that is 4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid bearing additional 2,4-difluorophenyl, fluoro and  6-amino-3-azabicyclo[3.1.0]hex-3-yl substituents at positions 1, 6 and 7 respectively. A broad-spectrum antibiotic that was withdrawn from the market due to risk of liver failure.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_59517|http://purl.obolibrary.org/obo/CHEBI_33281|http://purl.obolibrary.org/obo/CHEBI_50908|http://purl.obolibrary.org/obo/CHEBI_36047|http://purl.obolibrary.org/obo/CHEBI_53559,,,,,"7-[(1R,5S,6s)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid",,trovafloxacinum|trovafloxacin|trovafloxacine|trovafloxacino,,,,,,,,,,,,,,,,,,,,,CHEBI:9763,,,,trovafloxacin,,CHEBI:9763,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/DOID_9744,type 1 diabetes mellitus,type I diabetes mellitus|IDDM|insulin-dependent diabetes mellitus,A diabetes mellitus that results from the body's failure to produce insulin and has_material_basis_in autoimmune destruction of insulin-producing beta cells of the pancreas.,false,,,http://purl.obolibrary.org/obo/DOID_9351,,,,,,,,,,,,,,,,,,,,MESH:D003922|OMIM:222100,,A diabetes mellitus that results from the body's failure to produce insulin and has_material_basis_in autoimmune destruction of insulin-producing beta cells of the pancreas.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,type I diabetes mellitus|IDDM|insulin-dependent diabetes mellitus,,,,,DOID:9744,,,,,,,,,,,,,,,,,,,,,,type 1 diabetes mellitus,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100380,G-alpha-12,,,false,,,http://purl.obolibrary.org/obo/IMR_0000324,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100380,,,,,,,,,,,,,,,,,,,,,,G-alpha-12,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001620,phosphatidic acid degradation,phosphatidic acid catabolism|phosphatidic acid catabolic process|phosphatic acid breakdown,Phosphatidic acid degradation is a subtype of glycerophospholipid catabolic process: A process of the chemical reactions resulting in the breakdown of  phosphatidic acid.,false,,,http://purl.obolibrary.org/obo/GO_0046475,,,,,,,,,,,,,,,,,,,,,,Phosphatidic acid degradation is a subtype of glycerophospholipid catabolic process: A process of the chemical reactions resulting in the breakdown of  phosphatidic acid.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_16337,,,,,,,,,,,,,,,,,,phosphatidic acid catabolism|phosphatidic acid catabolic process|phosphatic acid breakdown,,,,,TXPO:0001620,,,,,,,,,,,,,,,,,,,,,,phosphatidic acid degradation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001622,hyperfunction of phosphatidic acid biosynthesis,,Hyperfunction of phosphatidic acid biosynthesis is a subtype of hyperfunction of glycerophospholipid biosynthesis: A process that performs an excessive phosphatidic acid biosynthesis.,false,,,http://purl.obolibrary.org/obo/TXPO_0001411,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of phosphatidic acid biosynthesis is a subtype of hyperfunction of glycerophospholipid biosynthesis: A process that performs an excessive phosphatidic acid biosynthesis.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001622,,,,,,,,,,,,,,,,,,,,,,hyperfunction of phosphatidic acid biosynthesis,,,,,,http://purl.obolibrary.org/obo/GO_0006654,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001627,hyperfunction of cytochrome p450 gene expression by phenobarbital (sustained) [Ground glass appearance],,"Hyperfunction of cytochrome p450 gene expression is a subtype of hyperfunction of drug metabolizing enzyme gene expression: A process that performs an excesssive gene expression of cytochrome p450. This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) .",false,,,http://purl.obolibrary.org/obo/TXPO_0003858|http://purl.obolibrary.org/obo/TXPO_0002051,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of cytochrome p450 gene expression is a subtype of hyperfunction of drug metabolizing enzyme gene expression: A process that performs an excesssive gene expression of cytochrome p450. This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000967,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003844,,,,,,,,,,,TXPO:0001627,,,,,,,,,,,,,,,,,,,,,,hyperfunction of cytochrome p450 gene expression by phenobarbital (sustained) [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001629,hyperfunction of drug metabolism phase I by Cytochrome P450 (sustained) [Ground glass appearance],,"Hyperfunction of drug metabolism phase I by Cytochrome P450 is a subtype of hyperfunction of drug metabolism phase I: A process that performs an excesssive drug metabolism phase I by Cytochrome P450. This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) .",false,,,http://purl.obolibrary.org/obo/TXPO_0001621|http://purl.obolibrary.org/obo/TXPO_0001623|http://purl.obolibrary.org/obo/TXPO_0003846,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of drug metabolism phase I by Cytochrome P450 is a subtype of hyperfunction of drug metabolism phase I: A process that performs an excesssive drug metabolism phase I by Cytochrome P450. This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001627,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003850|http://purl.obolibrary.org/obo/TXPO_0001677,,,,,,,,,,,TXPO:0001629,,,,,,,,,,,,,,,,,,,,,,hyperfunction of drug metabolism phase I by Cytochrome P450 (sustained) [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005790,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001626,ER stress response gene expression via PERK,,ER stress response gene expression via PERK is a subtype of gene expression: The process in which a gene sequence is converted into a mature ER stress response gene product or products (proteins or RNA) by PERK.,false,,,http://purl.obolibrary.org/obo/GO_0010467,,,,,,,,,,,,,,,,,,,,,,ER stress response gene expression via PERK is a subtype of gene expression: The process in which a gene sequence is converted into a mature ER stress response gene product or products (proteins or RNA) by PERK.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001626,,,,,,,,,,,,,,,,,,,,,,ER stress response gene expression via PERK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001624,hyperfunction of phosphosphingolipid biosynthesis,,Hyperfunction of phosphosphingolipid biosynthesis is a subtype of hyperfunction of phospholipid biosynthesis: A process that performs an excessive phosphosphingolipid biosynthesis.,false,,,http://purl.obolibrary.org/obo/TXPO_0001410,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of phosphosphingolipid biosynthesis is a subtype of hyperfunction of phospholipid biosynthesis: A process that performs an excessive phosphosphingolipid biosynthesis.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001624,,,,,,,,,,,,,,,,,,,,,,hyperfunction of phosphosphingolipid biosynthesis,,,,,,http://purl.obolibrary.org/obo/TXPO_0001291,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001625,hyperfunction of sphingomyelin biosynthesis,,Hyperfunction of sphingomyelin biosynthesis is a subtype of hyperfunction of phosphosphingolipid biosynthesis: A process that performs an excessive sphingomyelin biosynthesis.,false,,,http://purl.obolibrary.org/obo/TXPO_0001624,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of sphingomyelin biosynthesis is a subtype of hyperfunction of phosphosphingolipid biosynthesis: A process that performs an excessive sphingomyelin biosynthesis.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001625,,,,,,,,,,,,,,,,,,,,,,hyperfunction of sphingomyelin biosynthesis,,,,,,http://purl.obolibrary.org/obo/GO_0006686,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001621,hyperfunction of drug metabolism phase I by Cytochrome P450 [Ground glass appearance],,"Hyperfunction of drug metabolism phase I by Cytochrome P450 is a subtype of hyperfunction of drug metabolism phase I: A process that performs an excesssive drug metabolism phase I by Cytochrome P450.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0000938,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of drug metabolism phase I by Cytochrome P450 is a subtype of hyperfunction of drug metabolism phase I: A process that performs an excesssive drug metabolism phase I by Cytochrome P450.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000937|http://purl.obolibrary.org/obo/TXPO_0003855,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003901|http://purl.obolibrary.org/obo/TXPO_0003902|http://purl.obolibrary.org/obo/TXPO_0000948,,,,,,,,,,,TXPO:0001621,,,,,,,,,,,,,,,,,,,,,,hyperfunction of drug metabolism phase I by Cytochrome P450 [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005790,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001628,increasing phosphatidic acid material,,Increasing phosphatidic acid material is a subtype of increasing glycerophospholipid material: A process that changes the amount of phosphatidic acid material to be larger.,false,,,http://purl.obolibrary.org/obo/TXPO_0001317,,,,,,,,,,,,,,,,,,,,,,Increasing phosphatidic acid material is a subtype of increasing glycerophospholipid material: A process that changes the amount of phosphatidic acid material to be larger.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001628,,,,,,,,,,,,,,,,,,,,,,increasing phosphatidic acid material,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001623,hyperfunction of drug metabolism phase I  by Cytochrome P450,,Hyperfunction of drug metabolism phase I  by Cytochrome P450 is a subtype of hyperfunction of drug metabolism phase I: A process that performs an excesssive drug metabolism phase I by Cytochrome P450.,false,,,http://purl.obolibrary.org/obo/TXPO_0002049,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of drug metabolism phase I  by Cytochrome P450 is a subtype of hyperfunction of drug metabolism phase I: A process that performs an excesssive drug metabolism phase I by Cytochrome P450.,,,http://purl.obolibrary.org/obo/TXPO_0001559,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001623,,,,,,,,,,,,,,,,,,,,,,hyperfunction of drug metabolism phase I  by Cytochrome P450,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0003062,GDF-5,cartilage-derived morphogenetic protein-1|Growth/differentiation factor-5|CDMP-1,,false,,,http://purl.obolibrary.org/obo/IMR_0003085,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,cartilage-derived morphogenetic protein-1|Growth/differentiation factor-5|CDMP-1,,,,,IMR:0003062,,,,,,,,,,,,,,,,,,,,,,GDF-5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_63630,tolcapone,"3,4-dihydroxy-5-nitro-4'-methylbenzophenone|4'-methyl-3,4-dihydroxy-5-nitrobenzophenone|3,4-dihydroxy-4'-methyl-5-nitrobenzophenone|3,4-Dihydroxy-4'-methyl-5-nitrobenzophenone|tolcapone|(3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl)methanone","Benzophenone substituted on one of the phenyl rings at C-3 and C-4 by hydroxy groups and at C-5 by a nitro group, and on the other phenyl ring by a methyl group at C-4. It is an inhibitor of catechol O-methyltransferase.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:20502133|LINCS:LSM-5282|DrugBank:DB00323|PMID:20381177|PMID:21521027|Reaxys:8151577|PMID:22136163|Drug_Central:2697,,"Benzophenone substituted on one of the phenyl rings at C-3 and C-4 by hydroxy groups and at C-5 by a nitro group, and on the other phenyl ring by a methyl group at C-4. It is an inhibitor of catechol O-methyltransferase.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_48406|http://purl.obolibrary.org/obo/CHEBI_48407,,,,,"(3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl)methanone",,"3,4-dihydroxy-5-nitro-4'-methylbenzophenone|4'-methyl-3,4-dihydroxy-5-nitrobenzophenone|3,4-dihydroxy-4'-methyl-5-nitrobenzophenone|3,4-Dihydroxy-4'-methyl-5-nitrobenzophenone|tolcapone",,,,,,,,,,,,,,,,,,,,,CHEBI:63630,,,,tolcapone,,CHEBI:63630,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100084,pituitary hormone,,"Hormones secreted by the PITUITARY GLAND including those from the anterior lobe (adenohypophysis), the posterior lobe (neurohypophysis), and the ill-defined intermediate lobe.",false,,,http://purl.obolibrary.org/obo/IMR_0000966,,,,,,,,,,,,,,,,,,,,MeSH:D010907,,"Hormones secreted by the PITUITARY GLAND including those from the anterior lobe (adenohypophysis), the posterior lobe (neurohypophysis), and the ill-defined intermediate lobe.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_24621,,,,,,,,,,IMR:0100084,,,,,,,,,,,,,,,,,,,,,,pituitary hormone,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0000059,large intestine,,A subdivision of the digestive tract that connects the small intestine to the cloaca or anus. Lacks or has few villi[Kardong].,false,,,http://purl.obolibrary.org/obo/UBERON_0000160,,,,,,,,,,,,,,,,,,,,UMLS:C0021851|FMA:7201|NCIT:C12379,,A subdivision of the digestive tract that connects the small intestine to the cloaca or anus. Lacks or has few villi[Kardong].,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,UBERON:0000059,,,,,,,,,,,,,,,,,,,,,,large intestine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0000058,duct,anatomical duct,A tubular structure that transports secreted or excreted substances.,false,,,http://purl.obolibrary.org/obo/UBERON_0000025,,,,,,,,,,,,,,,,,,,,,,A tubular structure that transports secreted or excreted substances.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,anatomical duct,,,,,UBERON:0000058,,,,,,,,,,,,,,,,,,,,,,duct,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0000056,ureter,metanephric duct,"Muscular duct that propels urine from the kidneys to the urinary bladder, or related organs.|in humans, consists of adventitial, muscular and mucoa layers",false,,,http://purl.obolibrary.org/obo/UBERON_0000025,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0001088,,,,,,,http://en.wikipedia.org/wiki/Ureter|http://linkedlifedata.com/resource/umls/id/C0041951|http://www.snomedbrowser.com/Codes/Details/302511008|http://purl.obolibrary.org/obo/NCIT_C12416|XAO:0000144|EV:0100097|MAT:0000120|OpenCyc:Mx4rvhmm6JwpEbGdrcN5Y29ycA|FMA:9704|MA:0000378|galen:Ureter|EMAPA:17950|BTO:0001409|EHDAA2:0002139|EFO:0000930|EHDAA:9341|CALOHA:TS-1084|MESH:D014513|MIAA:0000120|AAO:0010254|UMLS:C0041951|GAID:438|VHOG:0000605,,"Muscular duct that propels urine from the kidneys to the urinary bladder, or related organs.",,,,,,,,"Anatomical structure consisting of long narrow duct which carries urine from the kidney to the urinary bladder.[AAO]|The duct of amniotes that carries urine from a metanephric kidney to the urinary bladder. [Bemis_WE, Functional_Anatomy_of_the_Vertebrates:_An_Evolutionary_Perspective, Glossary_G-29, Grande_L, Liem_KF, Third_Edition_(2001)_Orlando_Fla.:_Harcourt_College_Publishers, Walker_WF][VHOG]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,metanephric duct,"The first embryonic hint of a metanephros is the formation of the metanephric duct that appears as a ureteric diverticulum arising at the base of preexisting mesonephric duct. The ureteric diverticulum grows dorsally into the posterior region of the nephric ridge. Here it enlarges and stimulates the growth of metanephric tubules that come to make up the metanephric kidney. The metanephros becomes the adult kidney of amniotes, and the metanephric duct is usually called the ureter.[well established][VHOG]",http://purl.obolibrary.org/obo/UBERON_0001008,UBERON:0000056,http://purl.obolibrary.org/obo/UBERON_0001008,,,,,,,,,,,,,,,,,,,"in humans, consists of adventitial, muscular and mucoa layers",,ureter,,,,http://upload.wikimedia.org/wikipedia/commons/3/30/Urinary_system.svg,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000084285,EIF1AD,,Other designations: eukaryotic translation initiation factor 1A domain-containing protein|probable RNA-binding protein EIF1AD,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,haponin,,,,,,,,,,,,11,,,,,,HGNC:28147|HPRD:14411|Vega:OTTHUMG00000166671|Ensembl:ENSG00000175376,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,eukaryotic translation initiation factor 1A domain containing,,,11q13.1,,,,,,,,,,,,,,,,"GO_0003743 (EC: IEA); GO_0005634 (EC: IDA); GO_0005730 (EC: IDA, Qualifier: NOT); GO_0043231 (EC: IDA); GO_0045111 (EC: IDA)",,,,,,,,,PMID:12477932; 14702039; 15342556; 16189514; 16344560; 16751776; 17207965; 18173130; 19322201; 21139048; 21890473; 22095125; 23000965,,,,,,,,,,,,,,,OGG:3000084285,,,,,,,eukaryotic translation initiation factor 1A domain containing,,,,,,,,,,,,,Other designations: eukaryotic translation initiation factor 1A domain-containing protein|probable RNA-binding protein EIF1AD,,EIF1AD,,,,,,,,,,,,,,,,,,,,,,,84285,,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF1AD,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_47868,photosensitizing agent,photosensitising agent,"A chemical compound that can be excited by light of a specific wavelength and subsequently transfer energy to a chosen reactant. This is commonly molecular oxygen within a cancer tissue, which is converted to (highly rective) singlet state oxygen. This rapidly reacts with any nearby biomolecules, ultimately killing the cancer cells.",false,,,http://purl.obolibrary.org/obo/CHEBI_23888,,,,,,,,,,,,,,,,,,,,,,"A chemical compound that can be excited by light of a specific wavelength and subsequently transfer energy to a chosen reactant. This is commonly molecular oxygen within a cancer tissue, which is converted to (highly rective) singlet state oxygen. This rapidly reacts with any nearby biomolecules, ultimately killing the cancer cells.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,photosensitising agent,,,,,,,,,,,,,,,,,,,,,CHEBI:47868,,,,photosensitizing agent,,CHEBI:47868,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_25367,molecule,,Any polyatomic entity that is an electrically neutral entity consisting of more than one atom.,false,,,http://purl.obolibrary.org/obo/CHEBI_23367,,,,,,,,,,,,,,,,,,,,,,Any polyatomic entity that is an electrically neutral entity consisting of more than one atom.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:25367,,,,,,,,,,,,,,,,,,,,,,molecule,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_38497,respiratory-chain inhibitor,,A role played by the entity  that inhibits the  respiratory-chain.,false,,,http://purl.obolibrary.org/obo/CHEBI_38496,,,,,,,,,,,,,,,,,,,,,,A role played by the entity  that inhibits the  respiratory-chain.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:38497,,,,respiratory-chain inhibitor,,CHEBI:38497,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0030101,natural killer cell activation,NK cell activation,"The change in morphology and behavior of a natural killer cell in response to a cytokine, chemokine, cellular ligand, or soluble factor.",false,,,http://purl.obolibrary.org/obo/GO_0046649,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IEV_0003880,,"The change in morphology and behavior of a natural killer cell in response to a cytokine, chemokine, cellular ligand, or soluble factor.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,NK cell activation,,,,,GO:0030101,,,,,,,,,,,,,,,,,,,,,,natural killer cell activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001409,Gab,Grb2-associated binder,"Gab proteins contain a pleckstrin homology (PH) domain and binding sites for SH2 and SH3 domains. Gab family include mammalian Gab1, Gab2, Gab3, Drosophila Dos, and C. elegans Soc1.",false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,"Gab proteins contain a pleckstrin homology (PH) domain and binding sites for SH2 and SH3 domains. Gab family include mammalian Gab1, Gab2, Gab3, Drosophila Dos, and C. elegans Soc1.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003684,,,,,Grb2-associated binder,,,,,IMR:0001409,,,,,,,,,,,,,,,,,,,,,,Gab,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0046618,drug export,,"The directed movement of a drug, a substance used in the diagnosis, treatment or prevention of a disease, out of a cell or organelle.",false,,,http://purl.obolibrary.org/obo/TXPO_0002588,,,,,,,,,,,,,,,,,,,,,,"The directed movement of a drug, a substance used in the diagnosis, treatment or prevention of a disease, out of a cell or organelle.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0046618,,,,,,,,,,,,,,,,,,,,,,drug export,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000304,protease,peptidase,,false,,,http://purl.obolibrary.org/obo/TXPO_0003663,,,,,,,,,,,,,,,,,,,,GO:0008233|EC:3.4.-.-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,peptidase,,,,,IMR:0000304,,,,,,,,,,,,,,,,,,,,,,protease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_1900409,positive regulation of cellular response to oxidative stress,,"Any process that activates or increases the frequency, rate or extent of cellular response to oxidative stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001223,,,,,,,,,,,,,,,,,,,,,,"Any process that activates or increases the frequency, rate or extent of cellular response to oxidative stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:1900409,,,,,,,,,,,,,,,,,,,,,,positive regulation of cellular response to oxidative stress,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000000,,,,,,,http://purl.obolibrary.org/obo/GO_0006979,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001111,importin 8,RanBP8,,false,,,http://purl.obolibrary.org/obo/IMR_0100010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,RanBP8,,,,,IMR:0001111,,,,,,,,,,,,,,,,,,,,,,importin 8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0001906,movement quality,,A physical quality inhering in a bearer by virtue of the bearer's participation in movement.,false,,,http://purl.obolibrary.org/obo/BFO_0000019|http://purl.obolibrary.org/obo/TXPO_0001334,,,,,,,,,,,,,,,,,,,,,,A physical quality inhering in a bearer by virtue of the bearer's participation in movement.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0001906,,,,,,,,,,,,,,,,,,,,,,movement quality,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000000983,CDK1,,"Other designations: cell cycle controller CDC2|cell division control protein 2 homolog|cell division cycle 2, G1 to S and G2 to M|cell division protein kinase 1|p34 protein kinase",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CDC28A|CDC2|P34CDC2,,,,,,,,,,,,10,,,,,,Ensembl:ENSG00000170312|HGNC:1722|HPRD:00302|Vega:OTTHUMG00000018290|MIM:116940,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,cyclin-dependent kinase 1,,,10q21.1,,,,,,,,,,,,,,,,"GO_0000082 (EC: TAS); GO_0000083 (EC: TAS); GO_0000086 (EC: TAS); GO_0000165 (EC: TAS); GO_0000186 (EC: TAS); GO_0000187 (EC: TAS); GO_0000226 (EC: TAS); GO_0000278 (EC: TAS); GO_0002224 (EC: TAS); GO_0002755 (EC: TAS); GO_0002756 (EC: TAS); GO_0004672 (EC: NAS, PMID: 9001210); GO_0004674 (EC: IDA, PMID: 19879842); GO_0004693 (EC: IDA, PMID: 11069302); GO_0004693 (EC: TAS); GO_0005515 (EC: IPI, PMID: 10373560); GO_0005524 (EC: IEA); GO_0005634 (EC: IDA); GO_0005654 (EC: TAS); GO_0005737 (EC: IDA); GO_0005739 (EC: TAS, PMID: 19917720); GO_0005815 (EC: IEA); GO_0005829 (EC: TAS); GO_0005876 (EC: IDA, PMID: 11069302); GO_0006260 (EC: TAS); GO_0006281 (EC: TAS); GO_0006461 (EC: IEA); GO_0006915 (EC: IEA); GO_0007067 (EC: IEA); GO_0007077 (EC: TAS); GO_0007095 (EC: IEA); GO_0007098 (EC: TAS, PMID: 19364923); GO_0007173 (EC: TAS); GO_0007264 (EC: TAS); GO_0007265 (EC: TAS); GO_0007344 (EC: TAS); GO_0007411 (EC: TAS); GO_0007569 (EC: IEA); GO_0008286 (EC: TAS); GO_0008353 (EC: IDA, PMID: 12721286); GO_0008543 (EC: TAS); GO_0009636 (EC: IEA); GO_0010628 (EC: IEA); GO_0014038 (EC: TAS, PMID: 17200138); GO_0014070 (EC: IEA); GO_0014075 (EC: IEA); GO_0014823 (EC: IEA); GO_0016477 (EC: TAS, PMID: 17200138); GO_0018105 (EC: IDA, PMID: 19879842); GO_0030261 (EC: IEA); GO_0030332 (EC: IEA); GO_0030496 (EC: IDA, PMID: 11069302); GO_0030544 (EC: IEA); GO_0030855 (EC: IEP); GO_0031100 (EC: IEA); GO_0031145 (EC: TAS); GO_0033160 (EC: IEA); GO_0034134 (EC: TAS); GO_0034138 (EC: TAS); GO_0034142 (EC: TAS); GO_0034146 (EC: TAS); GO_0034162 (EC: TAS); GO_0034166 (EC: TAS); GO_0034501 (EC: IDA, PMID: 18195732); GO_0035173 (EC: IEA); GO_0035666 (EC: TAS); GO_0038095 (EC: TAS); GO_0038123 (EC: TAS); GO_0038124 (EC: TAS); GO_0042493 (EC: IEA); GO_0043066 (EC: IDA, PMID: 11069302); GO_0045087 (EC: TAS); GO_0045471 (EC: IEA); GO_0045740 (EC: IEA); GO_0045931 (EC: IEA); GO_0045995 (EC: TAS); GO_0046686 (EC: IEA); GO_0046688 (EC: IEA); GO_0048011 (EC: TAS); GO_0048678 (EC: IEA); GO_0051403 (EC: TAS); GO_0051437 (EC: TAS); GO_0051439 (EC: TAS); GO_0055015 (EC: IEA); GO_0060045 (EC: IEA); GO_0070062 (EC: IDA, PMID: 19056867); GO_0070301 (EC: IEA)",,,,,,,,,PMID: 914146; 1310466; 1318195; 1384126; 1388288; 1400350; 1406653; 1425574; 1628647; 1717476; 1748630; 1756735; 1828290; 1916766; 1939057; 2013279; 2183353; 2227411; 2344612; 2473839; 2538242; 2541912; 2570636; 2686978; 3289755; 3553962; 7474080; 7474100; 7494303; 7499230; 7578274; 7590285; 7592773; 7635160; 7666531; 7673335; 7716549; 7724583; 7737117; 7769006; 7790358; 7799941; 7822264; 7876309; 7902715; 7903056; 7925482; 7944411; 7949095; 7969176; 7983050; 8034666; 8051108; 8051175; 8070405; 8084605; 8087847; 8119945; 8125092; 8127873; 8242750; 8325880; 8376365; 8397206; 8397207; 8404858; 8423786; 8428596; 8440392; 8463339; 8475101; 8491187; 8524869; 8548803; 8565853; 8626512; 8626527; 8631817; 8652557; 8662825; 8663071; 8672508; 8806671; 8910336; 9001210; 9053846; 9069267; 9094673; 9109675; 9126608; 9130708; 9141461; 9188632; 9199321; 9235942; 9242535; 9244350; 9247342; 9258347; 9268380; 9271440; 9295339; 9315091; 9315635; 9398320; 9467962; 9515786; 9520381; 9524113; 9525956; 9560267; 9575153; 9585407; 9600099; 9614189; 9668078; 9725910; 9733650; 9753325; 9774639; 9885575; 9891079; 9926943; 9988268; 9990288; 10077596; 10339564; 10359664; 10362260; 10373560; 10383391; 10395539; 10403367; 10497277; 10502411; 10504341; 10524633; 10564259; 10602502; 10636877; 10656688; 10712923; 10716937; 10747892; 10764745; 10766737; 10767298; 10769027; 10793135; 10825186; 10864927; 10884347; 10924145; 10938080; 10958988; 10973963; 11034995; 11069302; 11076863; 11076968; 11113134; 11113184; 11135364; 11136719; 11259605; 11278541; 11278991; 11285280; 11310559; 11326318; 11327730; 11331587; 11395479; 11444800; 11470801; 11504921; 11516829; 11520933; 11531413; 11549262; 11559705; 11574543; 11584018; 11598127; 11683421; 11687586; 11774038; 11779217; 11782384; 11836499; 11861764; 11878934; 11895447; 11901153; 11953320; 11980914; 11986303; 12058066; 12077309; 12107172; 12124778; 12145207; 12151413; 12177195; 12186947; 12190313; 12200623; 12221128; 12361598; 12372621; 12397081; 12407107; 12411508; 12450396; 12468530; 12477932; 12525641; 12551973; 12556484; 12569090; 12569365; 12586835; 12604359; 12612056; 12612082; 12613668; 12648761; 12676926; 12721286; 12742823; 12771130; 12775724; 12791267; 12810701; 12832492; 12839990; 12852856; 12853968; 12881709; 12884029; 12912980; 14499622; 14551205; 14635192; 14645578; 14654553; 14697231; 14993212; 15014043; 15016823; 15024056; 15030318; 15050687; 15070733; 15073847; 15082718; 15125835; 15142377; 15145941; 15147269; 15175024; 15181148; 15215233; 15265780; 15276183; 15311285; 15317660; 15345747; 15367677; 15368451; 15474478; 15489334; 15489336; 15525513; 15525677; 15531913; 15541388; 15578977; 15582998; 15591787; 15592455; 15604258; 15635413; 15662526; 15674323; 15678101; 15725353; 15735702; 15735705; 15767402; 15780175; 15782160; 15790566; 15800651; 15817944; 15888452; 15951569; 15989971; 16009130; 16036217; 16109376; 16118207; 16142332; 16159883; 16192727; 16196087; 16198290; 16205633; 16226712; 16237118; 16247472; 16258277; 16344560; 16354571; 16371510; 16377132; 16381901; 16385451; 16407259; 16427064; 16458891; 16462731; 16465393; 16474839; 16478538; 16519687; 16533053; 16565220; 16629900; 16682949; 16760428; 16784539; 16807237; 16880735; 16880739; 16888198; 16998479; 17011204; 17012222; 17013563; 17043241; 17098733; 17159347; 17171635; 17172867; 17192257; 17200138; 17242184; 17274640; 17327911; 17349584; 17351640; 17359356; 17373700; 17386261; 17419986; 17431037; 17433108; 17466630; 17472438; 17474786; 17488622; 17498878; 17525531; 17540176; 17586317; 17636382; 17679094; 17681274; 17725712; 17906618; 17960875; 18003885; 18025303; 18029348; 18056802; 18069625; 18195732; 18201571; 18230152; 18245089; 18247328; 18271526; 18272572; 18272575; 18329369; 18337751; 18347064; 18356527; 18372919; 18408765; 18434602; 18445273; 18450493; 18457437; 18471975; 18477460; 18480403; 18490441; 18514189; 18550795; 18560763; 18568422; 18593881; 18615582; 18635963; 18655026; 18781797; 18799590; 18950845; 19048596; 19056867; 19061641; 19066288; 19134343; 19158392; 19162005; 19223178; 19275580; 19275583; 19275586; 19275588; 19303298; 19344781; 19364923; 19369249; 19375851; 19454010; 19458171; 19471022; 19473963; 19483727; 19509060; 19615732; 19664338; 19683496; 19687009; 19723060; 19725879; 19737929; 19738201; 19786724; 19789190; 19815027; 19837665; 19879842; 19884882; 19917720; 20062077; 20068230; 20068231; 20126263; 20169205; 20171170; 20181698; 20228808; 20360007; 20360068; 20367638; 20368335; 20368358; 20379221; 20395957; 20404109; 20412769; 20439461; 20444701; 20508983; 20526282; 20581839; 20711190; 20733055; 20739936; 20808790; 20810654; 20890132; 20935635; 20937773; 20956543; 20974803; 20974812; 21041660; 21059642; 21081492; 21081666; 21120602; 21123648; 21131960; 21135039; 21139048; 21148318; 21262764; 21308745; 21319273; 21325631; 21379580; 21406398; 21454540; 21488187; 21489275; 21498573; 21504622; 21522128; 21525341; 21569376; 21659531; 21693764; 21712819; 21743465; 21767532; 21813648; 21840486; 21871177; 21871181; 21875946; 21878504; 21878640; 21887332; 21890473; 21900237; 21900495; 21906983; 21907836; 21918813; 21924351; 21925791; 21951856; 21952639; 21963094; 21987572; 21987589; 21988832; 21998300; 22024133; 22053931; 22071694; 22101338; 22137483; 22158041; 22163316; 22266860; 22268729; 22407595; 22482362; 22496227; 22505724; 22552942; 22580043; 22623428; 22689984; 22718829; 22726437; 22768111; 22784093; 22814604; 22848730; 22863883; 22871736; 22907750; 22939629; 22949227; 22962268; 22965228; 23000965; 23045552; 23264621; 23330000; 23355470; 23383273; 23455152; 23471882; 23518499; 23525902; 23532886; 23543736; 23602568; 23619525; 23667531; 23720738; 23738518; 23775624; 23776131; 23814058; 23824909; 23901111; 23908594; 23921553; 23933584; 23956138; 23958962; 23966160; 23990466; 24101154; 24137814; 24248602; 24250222; 24457600,,,,,,,,,,,,,,,OGG:3000000983,,20140408,protein-coding,,,,cyclin-dependent kinase 1,,,,,,,,,,,,,"Other designations: cell cycle controller CDC2|cell division control protein 2 homolog|cell division cycle 2, G1 to S and G2 to M|cell division protein kinase 1|p34 protein kinase",,CDK1,,,,,,,,,,,,,,,,,,,,,,,983,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,CDK1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0002126,methionyl-lysyl-bradykinin,,,false,,,http://purl.obolibrary.org/obo/IMR_0100165,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0002126,,,,,,,,,,,,,,,,,,,,,,methionyl-lysyl-bradykinin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001424,BMP-2,BMP2|Bone morphogenetic protein 2,,false,,,http://purl.obolibrary.org/obo/IMR_0003083,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BMP2|Bone morphogenetic protein 2,,,,,IMR:0001424,,,,,,,,,,,,,,,,,,,,,,BMP-2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0000122,length,,A 1-D extent quality which is equal to the distance between two points.,false,,,http://purl.obolibrary.org/obo/TXPO_0002415|http://purl.obolibrary.org/obo/PATO_0000117,,,,,,,,,,,,,,,,,,,,,,A 1-D extent quality which is equal to the distance between two points.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0000122,,,,,,,,,,,,,,,,,,,,,,length,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0000125,mass (quality),,A physical quality that inheres in a bearer by virtue of the proportion of the bearer's amount of matter.,false,,,http://purl.obolibrary.org/obo/TXPO_0002414|http://purl.obolibrary.org/obo/BFO_0000019,,,,,,,,,,,,,,,,,,,,,,A physical quality that inheres in a bearer by virtue of the proportion of the bearer's amount of matter.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0000125,,,,,,,,,,,,,,,,,,,,,,mass (quality),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0000128,weight (quality),,A physical attribute entity inhering in a bearer that has mass near a gravitational body.,false,,,http://purl.obolibrary.org/obo/TXPO_0000307|http://purl.obolibrary.org/obo/PATO_0001035,,,,,,,,,,,,,,,,,,,,,,A physical attribute entity inhering in a bearer that has mass near a gravitational body.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0000128,,,,,,,,,,,,,,,,,,,,,,weight (quality),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_119486,efavirenz,"(-)-6-CHLORO-4-CYCLOPROPYLETHYNYL-4-TRIFLUOROMETHYL-1,4-DIHYDRO-2H-3,1-BENZOXAZIN-2-ONE|(S)-6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one|(S)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one|6-chloro-4-(2-cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one|Efavirenz|(4S)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one","1,4-Dihydro-2H-3,1-benzoxazin-2-one substituted at the 4 position by cyclopropylethynyl and trifluoromethyl groups (S configuration) and at the 6 position by chlorine. A non-nucleoside reverse transcriptase inhibitor with activity against HIV, it is used with other antiretrovirals for combination therapy of HIV infection.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:154598-52-4|PMID:10576692|PMID:25017682|DrugBank:DB00625|Reaxys:7387333|Drug_Central:989|LINCS:LSM-5526|PMID:10673109|Beilstein:7387333,,"1,4-Dihydro-2H-3,1-benzoxazin-2-one substituted at the 4 position by cyclopropylethynyl and trifluoromethyl groups (S configuration) and at the 6 position by chlorine. A non-nucleoside reverse transcriptase inhibitor with activity against HIV, it is used with other antiretrovirals for combination therapy of HIV infection.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_53756|http://purl.obolibrary.org/obo/CHEBI_36044,,,,,"Efavirenz|(4S)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one",,"(-)-6-CHLORO-4-CYCLOPROPYLETHYNYL-4-TRIFLUOROMETHYL-1,4-DIHYDRO-2H-3,1-BENZOXAZIN-2-ONE|(S)-6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one|(S)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one|6-chloro-4-(2-cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one",,,,,,,,,,,,,,,,,,,,,CHEBI:119486,,,,efavirenz,,CHEBI:119486,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000090668,LRRC16B,,Other designations: leucine-rich repeat-containing protein 16B,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,C14orf121|crml-1|CARMIL3,,,,,,,,,,,,14,,,,,,Vega:OTTHUMG00000172023|HGNC:20272|HPRD:11278|MIM:614716|Ensembl:ENSG00000186648,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,leucine rich repeat containing 16B,,,14q11.2,,,,,,,,,,,,,,,,GO_0005737 (EC: IEA),,,,,,,,,PMID: 10737800; 12477932; 15028280; 16344560; 19846667; 21102520,,,,,,,,,,,,,,,OGG:3000090668,,,,,,,leucine rich repeat containing 16B,,,,,,,,,,,,,Other designations: leucine-rich repeat-containing protein 16B,,LRRC16B,,,,,,,,,,,,,,,,,,,,,,,90668,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,LRRC16B,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_28874,phosphatidylinositol,PI,Any glycerophosphoinositol having one phosphatidyl group esterified to one of the hydroxy groups of inositol.,false,,,http://purl.obolibrary.org/obo/CHEBI_36315,,,,,,,,,,,,,,,,,,,,IMR:0001651,,Any glycerophosphoinositol having one phosphatidyl group esterified to one of the hydroxy groups of inositol.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PI,,,,,CHEBI:28874,,,,,,,,,,,,,,,,,,,,,,phosphatidylinositol,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0031982,vesicle,membrane-bounded vesicle|membrane-enclosed vesicle,"Any small, fluid-filled, spherical organelle enclosed by membrane.",false,,,http://purl.obolibrary.org/obo/GO_0043227,,,,,,,,,,,,,,,,,,,,,,"Any small, fluid-filled, spherical organelle enclosed by membrane.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,membrane-bounded vesicle|membrane-enclosed vesicle,,http://purl.obolibrary.org/obo/GO_0005737,GO:0031982,http://purl.obolibrary.org/obo/GO_0005737,,,,,,,,,,,,,,,,,,,,,vesicle,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_33697,ribonucleic acid,RNA,"High molecular weight, linear polymers, composed of nucleotides containing ribose and linked by phosphodiester bonds; RNA is central to the synthesis of proteins.",false,,,http://purl.obolibrary.org/obo/CHEBI_33696,,,,,,,,,,,,,,,,,,,,,,"High molecular weight, linear polymers, composed of nucleotides containing ribose and linked by phosphodiester bonds; RNA is central to the synthesis of proteins.",,,,,ribonucleic acid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,RNA,,,,,CHEBI:33697,,,,,,,,,,,,,,,,,,,,,,ribonucleic acid,,,,,,,http://purl.obolibrary.org/obo/chebi.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003490,tumor cell survial [ER stress],,"Tumor cell survial is a subtype of cell survival: A process that keeps the viability of a tumor cell.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/TXPO_0000280,,,,,,,,,,,,,,,,,,,,,,"Tumor cell survial is a subtype of cell survival: A process that keeps the viability of a tumor cell.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003550,,,,,,,,,,,,,,,,,TXPO:0003490,,,,,,,,,,,,,,,,,,,,,,tumor cell survial [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003494,increase in lipid inflow into hepatocyte [Lipidosis],,"Increase in lipid inflow into hepatocyte is a subtype of increasing quantity: A process that changes the lipid inflow into the hepatocyte to be larger.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003493|http://purl.obolibrary.org/obo/TXPO_0001720,,,,,,,,,,,,,,,,,,,,,,"Increase in lipid inflow into hepatocyte is a subtype of increasing quantity: A process that changes the lipid inflow into the hepatocyte to be larger.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000892,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003491,,,,,,,,,,,TXPO:0003494,,,,,,,,,,,,,,,,,,,,,,increase in lipid inflow into hepatocyte [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003493,increase in lipid inflow into hepatocyte,,Increase in lipid inflow into hepatocyte is a subtype of increasing quantity: A process that changes the lipid inflow into the hepatocyte to be larger.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increase in lipid inflow into hepatocyte is a subtype of increasing quantity: A process that changes the lipid inflow into the hepatocyte to be larger.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003493,,,,,,,,,,,,,,,,,,,,,,increase in lipid inflow into hepatocyte,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003492,increaing in fatty acid inflow into hepatocyte,,Increaing in fatty acid inflow into hepatocyte is a subtype of increasing quantity: A process that changes the fatty acid inflow into the hepatocyte to be larger.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increaing in fatty acid inflow into hepatocyte is a subtype of increasing quantity: A process that changes the fatty acid inflow into the hepatocyte to be larger.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003492,,,,,,,,,,,,,,,,,,,,,,increaing in fatty acid inflow into hepatocyte,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003495,necrosis [Lipidosis],,"A type of cell death that is morphologically characterized by an increasingly translucent cytoplasm, swelling of organelles, minor ultrastructural modifications of the nucleus (specifically, dilatation of the nuclear membrane and condensation of chromatin into small, irregular, circumscribed patches) and increased cell volume (oncosis), culminating in the disruption of the plasma membrane and subsequent loss of intracellular contents. Necrotic cells do not fragment into discrete corpses as their apoptotic counterparts do. Moreover, their nuclei remain intact and can aggregate and accumulate in necrotic tissues.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/GO_0070265,,,,,,,,,,,,,,,,,,,,,,"A type of cell death that is morphologically characterized by an increasingly translucent cytoplasm, swelling of organelles, minor ultrastructural modifications of the nucleus (specifically, dilatation of the nuclear membrane and condensation of chromatin into small, irregular, circumscribed patches) and increased cell volume (oncosis), culminating in the disruption of the plasma membrane and subsequent loss of intracellular contents. Necrotic cells do not fragment into discrete corpses as their apoptotic counterparts do. Moreover, their nuclei remain intact and can aggregate and accumulate in necrotic tissues.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000595,,,,,,http://purl.obolibrary.org/obo/TXPO_0000862,,,,,,,,,,,TXPO:0003495,,,,,,,,,,,,,,,,,,,,,,necrosis [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003497,insulin deficiency [Lipidosis],,"Insulin deficiency is a subtype of malfunctioning process: A process that lacks performing the insulin function required.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000072|http://purl.obolibrary.org/obo/TXPO_0001720,,,,,,,,,,,,,,,,,,,,,,"Insulin deficiency is a subtype of malfunctioning process: A process that lacks performing the insulin function required.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000890,,,,,,,,,,,TXPO:0003497,,,,,,,,,,,,,,,,,,,,,,insulin deficiency [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003498,non-alcoholic fatty liver disease,,The totality of all processes through which non-alcoholic fatty liver disease (NAFLD) is realized.,false,,,http://purl.obolibrary.org/obo/TXPO_0000888,,,,,,,,,,,,,,,,,,,,PMID:26962021|PMID:24133660|PMID:30642126,,The totality of all processes through which non-alcoholic fatty liver disease (NAFLD) is realized.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003496|http://purl.obolibrary.org/obo/TXPO_0001115|http://purl.obolibrary.org/obo/TXPO_0001116|http://purl.obolibrary.org/obo/TXPO_0001117|http://purl.obolibrary.org/obo/TXPO_0001113|http://purl.obolibrary.org/obo/TXPO_0000901|http://purl.obolibrary.org/obo/TXPO_0001973|http://purl.obolibrary.org/obo/TXPO_0003264|http://purl.obolibrary.org/obo/TXPO_0003507|http://purl.obolibrary.org/obo/TXPO_0003811|http://purl.obolibrary.org/obo/TXPO_0003810|http://purl.obolibrary.org/obo/TXPO_0003806|http://purl.obolibrary.org/obo/TXPO_0003807|http://purl.obolibrary.org/obo/TXPO_0003809|http://purl.obolibrary.org/obo/TXPO_0003808|http://purl.obolibrary.org/obo/TXPO_0003482|http://purl.obolibrary.org/obo/TXPO_0003484|http://purl.obolibrary.org/obo/TXPO_0001121|http://purl.obolibrary.org/obo/TXPO_0001129|http://purl.obolibrary.org/obo/TXPO_0000893|http://purl.obolibrary.org/obo/TXPO_0000898|http://purl.obolibrary.org/obo/TXPO_0000899|http://purl.obolibrary.org/obo/TXPO_0000891|http://purl.obolibrary.org/obo/TXPO_0000890,,,,,,,,,,,,,,,,,,TXPO:0003498,,,,,,,,,,,,,,,,,,,,,,non-alcoholic fatty liver disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003496,insulin resistance (process) [Lipidosis],,"Insulin resistance (process) is a subtype of decreasing sensitivity: A process that changes the sensitivity to the circulating insulin to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0002189,,,,,,,,,,,,,,,,,,,,PMID:26006114,,"Insulin resistance (process) is a subtype of decreasing sensitivity: A process that changes the sensitivity to the circulating insulin to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001116,,,,,,,,,,,TXPO:0003496,,,,,,,,,,,,,,,,,,,,,,insulin resistance (process) [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003491,lipid homeostasis imbalance [Lipidosis],,"Lipid homeostasis imbalance is a subtype of chemical homeostasis imbalance: A process that becomes lacking a lipid homeostastasis balance.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003488|http://purl.obolibrary.org/obo/TXPO_0001163,,,,,,,,,,,,,,,,,,,,,,"Lipid homeostasis imbalance is a subtype of chemical homeostasis imbalance: A process that becomes lacking a lipid homeostastasis balance.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000893,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001129,,,,,,,,,,,TXPO:0003491,,,,,,,,,,,,,,,,,,,,,,lipid homeostasis imbalance [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003499,vacuolation [Liver Pathological Findings][Lipidosis],,"Fatty change [Liver PathologicalFindings] is a type of finding observed in hepatocytes. Lesions are observed as lipid droplets consisting of neutral fat in the hepatocyte based on pathological morphology.
This finding is observable in the course of lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003524,,,,,,,,,,,,,,,,,,,,,,"Fatty change [Liver PathologicalFindings] is a type of finding observed in hepatocytes. Lesions are observed as lipid droplets consisting of neutral fat in the hepatocyte based on pathological morphology.
This finding is observable in the course of lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003499,,,,,,,"A metabolic disorder of neutral fat causes fatty change.
Lipid droplets consisting of large and small neutral fats (triglycerides) increase in the cytoplasm of hepatocytes.
In the case of large lipid droplets, the uneven distribution of nuclei is observed, but in the case of small loose droplets (microvesicular fatty change), uneven distribution of nuclei is not observed.
According to the distribution, it classifies into centrilobular, periportal, and diffuse type.",,,,,,,,,,,,,,,vacuolation [Liver Pathological Findings][Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005737,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_50510,potassium channel modulator,,,false,,,http://purl.obolibrary.org/obo/CHEBI_38632,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:50510,,,,,,,,,,,,,,,,,,,,,,potassium channel modulator,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0038151,CCL2 signal transduction pathway,CCL2-activated CCR2 signaling pathway,"A series of molecular signals mediated by CCL2 (C-C chemokine CCL2).
A series of molecular signals initiated by the binding of the C-C chemokine CCL2 to a C-C chemokine type 2 receptor (CCR2) on the surface of a cell, and ending with regulation of a downstream cellular process, e.g. transcription.",false,,,http://purl.obolibrary.org/obo/TXPO_0000609,,,,,,,,,,,,,,,,,,,,,,"A series of molecular signals mediated by CCL2 (C-C chemokine CCL2).
A series of molecular signals initiated by the binding of the C-C chemokine CCL2 to a C-C chemokine type 2 receptor (CCR2) on the surface of a cell, and ending with regulation of a downstream cellular process, e.g. transcription.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CCL2-activated CCR2 signaling pathway,,,,,GO:0038151,,,,,,,,,,,,,,,,,,,,,,CCL2 signal transduction pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000679,Plk1,,,false,,,http://purl.obolibrary.org/obo/IMR_0000256,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000679,,,,,,,,,,,,,,,,,,,,,,Plk1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000004023,LPL,,,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24539|NCBI-Mouse-GeneID:16956|NCBI-Human-GeneID:4023|Ensembl:ENSG00000175445|MIM:609708|HGNC:6677,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000004023,,,,,,,,,,,,,OGG:3000004023,,,,,,,"lipoprotein lipase|LPL encodes lipoprotein lipase, which is expressed in heart, muscle, and adipose tissue. LPL functions as a homodimer, and has the dual functions of triglyceride hydrolase and ligand/bridging factor for receptor-mediated lipoprotein uptake. Severe mutations that cause LPL deficiency result in type I hyperlipoproteinemia, while less extreme mutations in LPL are linked to many disorders of lipoprotein metabolism. [provided by RefSeq, Jul 2008]",,,,,,,,,,,,,,,LPL,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000008575,PRKRA,,"Other designations: PKR-associated protein X|PKR-associating protein X|interferon-inducible double stranded RNA-dependent protein kinase activator A|interferon-inducible double-stranded RNA-dependent protein kinase activator A|protein activator of the interferon-induced protein kinase|protein kinase, interferon-inducible double stranded RNA-dependent activator|protein kinase, interferon-inducible double-stranded RNA-dependent activator",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,RAX|DYT16|PACT,,,,,,,,,,,,2,,,,,,HGNC:9438|Ensembl:ENSG00000180228|Vega:OTTHUMG00000132576|HPRD:04573|MIM:603424,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"protein kinase, interferon-inducible double stranded RNA dependent activator",,,2q31.2,,,,,,,,,,,,,,,,"GO_0005515 (EC: IPI, PMID: 16424907); GO_0005737 (EC: IDA); GO_0005829 (EC: TAS); GO_0006468 (EC: IEA); GO_0006955 (EC: TAS, PMID: 9687506); GO_0008047 (EC: TAS, PMID: 9687506); GO_0008285 (EC: TAS, PMID: 9687506); GO_0009615 (EC: TAS, PMID: 9687506); GO_0010467 (EC: TAS); GO_0030422 (EC: IDA, PMID: 17452327); GO_0034599 (EC: IEA); GO_0042473 (EC: IEA); GO_0042474 (EC: IEA); GO_0042803 (EC: IPI, PMID: 17452327); GO_0043085 (EC: TAS, PMID: 9687506); GO_0044822 (EC: IDA); GO_0048471 (EC: IEA); GO_0048705 (EC: IEA); GO_2001244 (EC: IEA)",,,,,,,,,PMID: 8125298; 9010216; 9687506; 10336432; 11230166; 11238927; 11256614; 11526399; 11985496; 12368348; 12477932; 12874289; 14702039; 15299031; 15489334; 15815621; 16169070; 16424907; 16861340; 16982605; 17081983; 17125937; 17353931; 17452327; 18243799; 18420150; 18936160; 19441135; 19580324; 19604093; 19913121; 20379614; 20468071; 20588308; 20628086; 20628624; 21139048; 21145461; 21501829; 21526770; 21595004; 21790829; 21882225; 21900206; 21903422; 21988832; 22025453; 22214662; 22473766; 22505724; 22586326; 22961479; 22990118; 23455922; 23472185; 23550157; 23602568; 23658827; 23661684; 23844083; 23870315; 24067967; 24457600,,,,,,,,,,,,,,,OGG:3000008575,,,,,,,"protein kinase, interferon-inducible double stranded RNA dependent activator",,,,,,,,,,,,,"Other designations: PKR-associated protein X|PKR-associating protein X|interferon-inducible double stranded RNA-dependent protein kinase activator A|interferon-inducible double-stranded RNA-dependent protein kinase activator A|protein activator of the interferon-induced protein kinase|protein kinase, interferon-inducible double stranded RNA-dependent activator|protein kinase, interferon-inducible double-stranded RNA-dependent activator",,PRKRA,,,,,,,,,,,,,,,,,,,,,,,8575,HSD14,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,PRKRA,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/GO_0008643,carbohydrate transport,sugar transport,"The directed movement of carbohydrate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Carbohydrates are any of a group of organic compounds based of the general formula Cx(H2O)y.",false,,,http://purl.obolibrary.org/obo/TXPO_0000111,,,,,,,,,,,,,,,,,,,,GO:0008643,,"The directed movement of carbohydrate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Carbohydrates are any of a group of organic compounds based of the general formula Cx(H2O)y.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sugar transport,,,,GO:0008643,,,,,,,,,,,,,,,,,,,,,,carbohydrate transport,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_25944,pesticide,pesticides|Pestizide|Pestizid|pesticide,"Strictly, a substance intended to kill pests. In common usage, any substance used for controlling, preventing, or destroying animal, microbiological or plant pests.",false,,,http://purl.obolibrary.org/obo/BFO_0000023,,,,,,,,,,,,,,,,,,,,,,"Strictly, a substance intended to kill pests. In common usage, any substance used for controlling, preventing, or destroying animal, microbiological or plant pests.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pesticide,,pesticides|Pestizide|Pestizid,,,,,,,,,,,,,,,,,,,,,CHEBI:25944,,,,pesticide,,CHEBI:25944,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_17268,myo-inositol,,An inositol having myo- configuration.,false,,,http://purl.obolibrary.org/obo/CHEBI_24848,,,,,,,,,,,,,,,,,,,,Wikipedia:Inositol,,An inositol having myo- configuration.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:17268,,,,,,,,,,,,,,,,,,,,,,myo-inositol,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0022411,extracellular matrix disassembly,,A process that results in the breakdown of the extracellular matrix.,false,,,http://purl.obolibrary.org/obo/TXPO_0000343,,,,,,,,,,,,,,,,,,,,,,A process that results in the breakdown of the extracellular matrix.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0031012,,,,,,,,,,,,,,,,,,,,,,,GO:0022411,,,,,,,,,,,,,,,,,,,,,,extracellular matrix disassembly,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CL_0000001,primary cultured cell,,"A cultured cell that is freshly isolated from a organismal source, or derives in culture from such a cell prior to the culture being passaged.",false,,,http://purl.obolibrary.org/obo/CL_0000010,,,,,,,,,,,,,,,,,,,,,,"A cultured cell that is freshly isolated from a organismal source, or derives in culture from such a cell prior to the culture being passaged.",,,,,primary cultured cell,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CL:0000001,,,,,,,,,,,,,,,,,,,,,,primary cultured cell,,,,,,,http://purl.obolibrary.org/obo/cl.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CL_0000000,cell,,"A material entity of anatomical origin (part of or deriving from an organism) that has as its parts a maximally connected cell compartment surrounded by a plasma membrane.|The definition of cell is intended to represent all cells, and thus a cell is defined as a material entity and not an anatomical structure, which implies that it is part of an organism (or the entirety of one).",false,,,http://purl.obolibrary.org/obo/GO_0005575,,,,,,,,,,,,,,,,,,,,http://purl.bioontology.org/ontology/STY/T025,,A material entity of anatomical origin (part of or deriving from an organism) that has as its parts a maximally connected cell compartment surrounded by a plasma membrane.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CL:0000000,,,,,,,,,,,,,,,,,,,,"The definition of cell is intended to represent all cells, and thus a cell is defined as a material entity and not an anatomical structure, which implies that it is part of an organism (or the entirety of one).",,cell,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_18248,iron atom,iron,An iron group element atom that has atomic number 26.,false,,,http://purl.obolibrary.org/obo/CHEBI_33250,,,,,,,,,,,,,,,,,,,,CAS:7439-89-6|DrugBank:DB01592,,An iron group element atom that has atomic number 26.,,,,,,,,,,,,Fe,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,iron,,,,,CHEBI:18248,,,,,,,,,,,,,,,,,,,,,,iron atom,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,[Fe],,,,,
http://purl.obolibrary.org/obo/IMR_0000070,beta PDGF receptor,beta platelet derived growth factor receptor,,false,,,http://purl.obolibrary.org/obo/IMR_0000068,,,,,,,,,,,,,,,,,,,,GO:0005019,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,beta platelet derived growth factor receptor,,,,,IMR:0000070,,,,,,,,,,,,,,,,,,,,,,beta PDGF receptor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_71219,pazopanib,"GW786034|GW 78603|pazopanibum|pazopanib|5-({4-[(2,3-dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl}amino)-2-methylbenzenesulfonamide","A pyrimidine that is 5-(pyrimidin-2-yl}amino-2-methylbenzenesulfonamide substituted at position 4 by a (2,3-dimethylindazol-6-yl)(methyl)amino group. Used as its hydrochloride salt for treatment of kidney cancer.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:22759480|PMID:23088634|PMID:22341567|LINCS:LSM-1114|PMID:23064954|PMID:22190407|PMID:21811833|PMID:23072642|PMID:23135778|PMID:22233389|PMID:22984765|PMID:22733110|Reaxys:11646488|PMID:22917595|Drug_Central:4118|CAS:444731-52-6|PMID:22112314|PMID:22716487|PMID:22766517|PMID:22359392|PMID:22830347|PMID:22595799|PMID:23054212|PMID:21766486|PMID:22733795|PMID:21394443|PMID:22679111|PMID:22688250|PMID:22861374,,"A pyrimidine that is 5-(pyrimidin-2-yl}amino-2-methylbenzenesulfonamide substituted at position 4 by a (2,3-dimethylindazol-6-yl)(methyl)amino group. Used as its hydrochloride salt for treatment of kidney cancer.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35610|http://purl.obolibrary.org/obo/CHEBI_50926|http://purl.obolibrary.org/obo/CHEBI_38637|http://purl.obolibrary.org/obo/CHEBI_65207,,,,,"5-({4-[(2,3-dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl}amino)-2-methylbenzenesulfonamide",,GW786034|GW 78603|pazopanibum|pazopanib,,,,,,,,,,,,,,,,,,,,,CHEBI:71219,,,,pazopanib,,CHEBI:71219,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000010635,RAD51AP1,,Other designations: RAD51-associated protein 1|RAD51-interacting protein,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,PIR51,,,,,,,,,,,,12,,,,,,MIM:603070|Vega:OTTHUMG00000168125|HGNC:16956|Ensembl:ENSG00000111247,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,RAD51 associated protein 1,,,12p13.2-p13.1,,,,,,,,,,,,,,,,"GO_0000724 (EC: NAS, PMID: 9396801); GO_0003690 (EC: IDA, PMID: 9396801); GO_0003697 (EC: IDA, PMID: 9396801); GO_0003723 (EC: IDA, PMID: 9396801); GO_0005515 (EC: IPI); GO_0005634 (EC: IC, PMID: 9396801); GO_0006281 (EC: NAS, PMID: 9396801); GO_0010569 (EC: IDA); GO_0071479 (EC: IDA)",,,,,,,,,PMID: 8889548; 9396801; 12477932; 14702039; 14966907; 15489334; 16920159; 17207965; 17996710; 17996711; 18316552; 19615732; 19953087; 20201926; 20558539; 20871616; 21307306; 21832049; 21903585; 22375013; 22452920; 23263487,,,,,,,,,,,,,,,OGG:3000010635,,20140408,protein-coding,,,,RAD51 associated protein 1,,,,,,,,,,,,,Other designations: RAD51-associated protein 1|RAD51-interacting protein,,RAD51AP1,,,,,,,,,,,,,,,,,,,,,,,10635,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,RAD51AP1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0010475,60S ribosomal protein L26,,,false,,,http://purl.obolibrary.org/obo/IMR_0000897,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0010475,,,,,,,,,,,,,,,,,,,,,,60S ribosomal protein L26,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0051781,positive regulation of cell division,up regulation of cell division,"Any process that activates or increases the frequency, rate or extent of cell division.",false,,,http://purl.obolibrary.org/obo/TXPO_0001223,,,,,,,,,,,,,,,,,,,,,,"Any process that activates or increases the frequency, rate or extent of cell division.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,up regulation of cell division,,,,,GO:0051781,,,,,,,,,,,,,,,,,,,,,,positive regulation of cell division,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0051301,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001552,Cyp1,,Cyp1 is a subtype of cytochrome P450.,false,,,http://purl.obolibrary.org/obo/TXPO_0001558,,,,,,,,,,,,,,,,,,,,,,Cyp1 is a subtype of cytochrome P450.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001552,,,,,,,,,,,,,,,,,,,,,,Cyp1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001551,hyperfunction of drug metabolism phase I [Phospholipidosis],,"Hyperfunction of drug metabolism phase I is a subtype of hyperfunction of drug metabolism: A process that performs an excesssive drug metabolism phase I.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002049|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of drug metabolism phase I is a subtype of hyperfunction of drug metabolism: A process that performs an excesssive drug metabolism phase I.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001568|http://purl.obolibrary.org/obo/TXPO_0001563|http://purl.obolibrary.org/obo/TXPO_0001549|http://purl.obolibrary.org/obo/TXPO_0001173|http://purl.obolibrary.org/obo/TXPO_0001159,,,,,,http://purl.obolibrary.org/obo/TXPO_0004117,,,,,,,,,,,TXPO:0001551,,,,,,,,,,,,,,,,,,,,,,hyperfunction of drug metabolism phase I [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001554,Cyp3,,Cyp3 is a subtype of cytochrome P450.,false,,,http://purl.obolibrary.org/obo/TXPO_0001558,,,,,,,,,,,,,,,,,,,,,,Cyp3 is a subtype of cytochrome P450.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001554,,,,,,,,,,,,,,,,,,,,,,Cyp3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001557,cholesterol transport gene mutation [Niemann Pick Type C],,"Cholesteroltransport gene mutation is a subtype of gene mutation: A process thatchanges the sequence of a cholesterol transport gene.
This process is dependent on the  genetic and can constitute the course of Niemann Pick Type C.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0001167,,,,,,,,,,,,,,,,,,,,,,"Cholesteroltransport gene mutation is a subtype of gene mutation: A process thatchanges the sequence of a cholesterol transport gene.
This process is dependent on the  genetic and can constitute the course of Niemann Pick Type C.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003283,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003285,,,,,,http://purl.obolibrary.org/obo/TXPO_0001556,,,,,,,,,,,TXPO:0001557,,,,,,,,,,,,,,,,,,,,,,cholesterol transport gene mutation [Niemann Pick Type C],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001550,hypofunction of drug metabolism phase I,,Hypofunction of drug metabolism phase I is a subtype of hypofunction of drug metabolism: A process that performs a decreased or insufficient drug metabolism phase I.,false,,,http://purl.obolibrary.org/obo/TXPO_0002190,,,,,,,,,,,,,,,,,,,,,,Hypofunction of drug metabolism phase I is a subtype of hypofunction of drug metabolism: A process that performs a decreased or insufficient drug metabolism phase I.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001550,,,,,,,,,,,,,,,,,,,,,,hypofunction of drug metabolism phase I,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001556,hypofunction of cholesterol transport in lysosome [Niemann-Pick type C] .,,"Hypofunction of cholesterol transport from lysosome is a subtype of hypofunction of transport: A process that performs a decreased or insufficient cholestsrol transport from lysosomes.
This entity is a specific course-dependent process. This process can constitute the course of Niemann-Pick type C.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0000731,,,,,,,,,,,,,,,,,,,,,,"Hypofunction of cholesterol transport from lysosome is a subtype of hypofunction of transport: A process that performs a decreased or insufficient cholestsrol transport from lysosomes.
This entity is a specific course-dependent process. This process can constitute the course of Niemann-Pick type C.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001177,,,,,,,,,,,TXPO:0001556,,,,,,,,,,,,,,,,,,,,,,hypofunction of cholesterol transport in lysosome [Niemann-Pick type C] .,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001555,Cyp4,,Cyp4 is a subtype of cytochrome P450.,false,,,http://purl.obolibrary.org/obo/TXPO_0001558,,,,,,,,,,,,,,,,,,,,,,Cyp4 is a subtype of cytochrome P450.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001555,,,,,,,,,,,,,,,,,,,,,,Cyp4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001558,Cytochrome P450,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,PMID:16584116|IPR:001128|http://purl.obolibrary.org/obo/CHEBI_38559,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000519,,,,,,,,,,TXPO:0001558,,,,,,,,,,,,,,,,,,,,,,Cytochrome P450,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001559,drug metabolism phase I by Cytochrome P450,,Drug metabolism phase I by Cytochrome P450 is a subtype of drug metabolism phase I: A process that is biotransformed by cytochrome P450 (CYP) superfamily .,false,,,http://purl.obolibrary.org/obo/TXPO_0000173,,,,,,,,,,,,,,,,,,,,"https://reactome.org/PathwayBrowser/#/R-HSA-211945&SEL=R-HSA-211981&PATH=R-HSA-1430728,R-HSA-211859|PMID:16584116|NCIT:C91423",,Drug metabolism phase I by Cytochrome P450 is a subtype of drug metabolism phase I: A process that is biotransformed by cytochrome P450 (CYP) superfamily .,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001559,,,,,,,,,,,,,,,,,,,,,,drug metabolism phase I by Cytochrome P450,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001553,Cyp2,,Cyp2 is a subtype of cytochrome P450.,false,,,http://purl.obolibrary.org/obo/TXPO_0001558,,,,,,,,,,,,,,,,,,,,,,Cyp2 is a subtype of cytochrome P450.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001553,,,,,,,,,,,,,,,,,,,,,,Cyp2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000395,p48,IRF9|ISGF3 gamma,,false,,,http://purl.obolibrary.org/obo/IMR_0000386,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IRF9|ISGF3 gamma,,,,,IMR:0000395,,,,,,,,,,,,,,,,,,,,,,p48,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001104,Net,Sap-2|Elk-3,,false,,,http://purl.obolibrary.org/obo/IMR_0000397,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Sap-2|Elk-3,,,,,IMR:0001104,,,,,,,,,,,,,,,,,,,,,,Net,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000814,FOSB,,,false,,,http://purl.obolibrary.org/obo/IMR_0000415,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000814,,,,,,,,,,,,,,,,,,,,,,FOSB,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100549,PDGF A-chain,,,false,,,http://purl.obolibrary.org/obo/IMR_0000032,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100549,,,,,,,,,,,,,,,,,,,,,,PDGF A-chain,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_32957,lysophosphatidic acids,,Any monoacylglycerol phosphate obtained by hydrolytic removal of one of the two acyl groups of any phosphatidic acid or derivatives therein.,false,,,http://purl.obolibrary.org/obo/CHEBI_16961,,,,,,,,,,,,,,,,,,,,,,Any monoacylglycerol phosphate obtained by hydrolytic removal of one of the two acyl groups of any phosphatidic acid or derivatives therein.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:32957,,,,,,,,,,,,,,,,,,,,,,lysophosphatidic acids,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CL_0000842,mononuclear cell,,A leukocyte with a single non-segmented nucleus in the mature form.,false,,,http://purl.obolibrary.org/obo/CL_0000738,,,,,,,,,,,,,,,,,,,,CALOHA:TS-0768|FMA:86713|BTO:0000878,,A leukocyte with a single non-segmented nucleus in the mature form.,,,,,mononuclear cell,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CL:0000842,,,,,,,,,,,,,,,,,,,,,,mononuclear cell,,,,,,,http://purl.obolibrary.org/obo/cl.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000006372,CXCL6,,"Other designations: C-X-C motif chemokine 6|Small inducible cytokine subfamily B (Cys-X-Cys), member b|chemokine (C-X-C motif) ligand 6 (granulocyte chemotactic protein 2)|chemokine alpha 3|granulocyte chemotactic protein 2|small inducible cytokine subfamily B (Cys-X-Cys), member 6 (granulocyte chemotactic protein 2)|small-inducible cytokine B6",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CKA-3|SCYB6|GCP2|GCP-2,,,,,,,,,,,,4,,,,,,MIM:138965|HPRD:00735|Ensembl:ENSG00000124875|HGNC:10643|Vega:OTTHUMG00000130010,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,chemokine (C-X-C motif) ligand 6,,,4q13.3,,,,,,,,,,,,,,,,"GO_0005576 (EC: TAS); GO_0005615 (EC: IEA); GO_0006935 (EC: TAS, PMID: 9164944); GO_0006954 (EC: TAS, PMID: 8399143); GO_0006955 (EC: IEA); GO_0007165 (EC: TAS, PMID: 9164944); GO_0007267 (EC: TAS, PMID: 9164944); GO_0008009 (EC: IEA); GO_0008201 (EC: IEA); GO_0060326 (EC: TAS, PMID: 8399143)",,,,,,,,,PMID: 8399143; 8423327; 9057843; 9164944; 9465307; 9692902; 10343098; 10593335; 12477932; 12524079; 12533683; 12591113; 12628493; 12882792; 12950257; 15214047; 15342556; 15489334; 15652347; 15815621; 17022986; 17703412; 17827342; 18240029; 18443119; 18563170; 18577758; 18782286; 18842116; 19240061; 19258923; 19369450; 20503287; 20507572; 20628624; 21236563; 22886775; 23128233; 23814098,,,,,,,,,,,,,,,OGG:3000006372,,20140408,protein-coding,,,,chemokine (C-X-C motif) ligand 6,,,,,,,,,,,,,"Other designations: C-X-C motif chemokine 6|Small inducible cytokine subfamily B (Cys-X-Cys), member b|chemokine (C-X-C motif) ligand 6 (granulocyte chemotactic protein 2)|chemokine alpha 3|granulocyte chemotactic protein 2|small inducible cytokine subfamily B (Cys-X-Cys), member 6 (granulocyte chemotactic protein 2)|small-inducible cytokine B6",,CXCL6,,,,,,,,,,,,,,,,,,,,,,,6372,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,CXCL6,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000675,B-Raf,,,false,,,http://purl.obolibrary.org/obo/IMR_0000231,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000675,,,,,,,,,,,,,,,,,,,,,,B-Raf,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000464,I-kappaB,IkB|inhibitor of NF-kappaB,,false,,,http://purl.obolibrary.org/obo/IMR_0000463,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IkB|inhibitor of NF-kappaB,,,,,IMR:0000464,,,,,,,,,,,,,,,,,,,,,,I-kappaB,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003546,cell survival-cell death imbalance,,Cell survival-cell death imbalance is a subtype is a subtype of imbalance: A process that lacks a balance between cell death and cell survival within an organ or an organism.,false,,,http://purl.obolibrary.org/obo/TXPO_0000567,,,,,,,,,,,,,,,,,,,,,,Cell survival-cell death imbalance is a subtype is a subtype of imbalance: A process that lacks a balance between cell death and cell survival within an organ or an organism.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003546,,,,,,,,,,,,,,,,,,,,,,cell survival-cell death imbalance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003544,changing cell survival-cell death balance,,Changing cell survival-cell death balance is a subtype of changing balance: A process that changes the steady state of cell number between cell death and cell survival within an organ or an organism.,false,,,http://purl.obolibrary.org/obo/TXPO_0001847,,,,,,,,,,,,,,,,,,,,,,Changing cell survival-cell death balance is a subtype of changing balance: A process that changes the steady state of cell number between cell death and cell survival within an organ or an organism.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003544,,,,,,,,,,,,,,,,,,,,,,changing cell survival-cell death balance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003548,changing cell survival-cell death balance [Phospholipidosis],,"Changing cell survival-cell death balance is a subtype of changing balance: A process that changes the steady state of cell number between cell death and cell survival within an organ or an organism.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003544|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Changing cell survival-cell death balance is a subtype of changing balance: A process that changes the steady state of cell number between cell death and cell survival within an organ or an organism.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003548,,,,,,,,,,,,,,,,,,,,,,changing cell survival-cell death balance [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003542,ground glass appearance [Liver Pathological Findings] [Ground glass appearance (severe)],,"Ground glass appearance [Liver PathologicalFindings] is a type of finding observed in hepatocyte cytoplasm. Based on the pathological morphology, lesions are observed as a frosted-like change in whole or most of the hepatocytes.
This finding is observable in the course of ground glass appearance.
The degree is severe.",false,,,http://purl.obolibrary.org/obo/TXPO_0003522,,,,,,,,,,,,,,,,,,,,,,"Ground glass appearance [Liver PathologicalFindings] is a type of finding observed in hepatocyte cytoplasm. Based on the pathological morphology, lesions are observed as a frosted-like change in whole or most of the hepatocytes.
This finding is observable in the course of ground glass appearance.
The degree is severe.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003542,,,,,,,,,,,,,,,,,,,,,,ground glass appearance [Liver Pathological Findings] [Ground glass appearance (severe)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003540,vacuolation [Liver Pathological Findings][Lipidosis(moderate)],,"Fatty change [Liver PathologicalFindings] is a type of finding observed in hepatocytes. Lesions are observed as lipid droplets consisting of neutral fat in the hepatocyte based on pathological morphology.
This finding is observable in the course of lipidosis. The degree is moderate.",false,,,http://purl.obolibrary.org/obo/TXPO_0003499,,,,,,,,,,,,,,,,,,,,,,"Fatty change [Liver PathologicalFindings] is a type of finding observed in hepatocytes. Lesions are observed as lipid droplets consisting of neutral fat in the hepatocyte based on pathological morphology.
This finding is observable in the course of lipidosis. The degree is moderate.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003540,,,,,,,"A metabolic disorder of neutral fat causes fatty change.
Lipid droplets consisting of large and small neutral fats (triglycerides) increase in the cytoplasm of hepatocytes.
In the case of large lipid droplets, the uneven distribution of nuclei is observed, but in the case of small loose droplets (microvesicular fatty change), uneven distribution of nuclei is not observed.
According to the distribution, it classifies into centrilobular, periportal, and diffuse type.",,,,,,,,,,,,,,,vacuolation [Liver Pathological Findings][Lipidosis(moderate)],,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005737,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003547,cell survival-cell death imbalance [Phospholipidosis (severe)],,"Cell survival-cell death imbalance is a subtype is a subtype of imbalance: A process that lacks a balance between cell death and cell survival within an organ or an organism.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",false,,,http://purl.obolibrary.org/obo/TXPO_0003546|http://purl.obolibrary.org/obo/TXPO_0003548,,,,,,,,,,,,,,,,,,,,,,"Cell survival-cell death imbalance is a subtype is a subtype of imbalance: A process that lacks a balance between cell death and cell survival within an organ or an organism.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003547,,,,,,,,,,,,,,,,,,,,,,cell survival-cell death imbalance [Phospholipidosis (severe)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003549,maintaining cell survival-cell death balance [Phospholipidosis],,"Maintaining cell survival-cell death balance is a subtype of maintaining balance: A process that keeps a balance  between cell death and cell survival within an organ or an organism.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003548|http://purl.obolibrary.org/obo/TXPO_0003545,,,,,,,,,,,,,,,,,,,,,,"Maintaining cell survival-cell death balance is a subtype of maintaining balance: A process that keeps a balance  between cell death and cell survival within an organ or an organism.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003549,,,,,,,,,,,,,,,,,,,,,,maintaining cell survival-cell death balance [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003541,vacuolation [Liver Pathological Findings][Lipidosis(severe)],,"Fatty change [Liver PathologicalFindings] is a type of finding observed in hepatocytes. Lesions are observed as lipid droplets consisting of neutral fat in the hepatocyte based on pathological morphology.
This finding is observable in the course of lipidosis. The degree is severe.",false,,,http://purl.obolibrary.org/obo/TXPO_0003499,,,,,,,,,,,,,,,,,,,,,,"Fatty change [Liver PathologicalFindings] is a type of finding observed in hepatocytes. Lesions are observed as lipid droplets consisting of neutral fat in the hepatocyte based on pathological morphology.
This finding is observable in the course of lipidosis. The degree is severe.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003541,,,,,,,"A metabolic disorder of neutral fat causes fatty change.
Lipid droplets consisting of large and small neutral fats (triglycerides) increase in the cytoplasm of hepatocytes.
In the case of large lipid droplets, the uneven distribution of nuclei is observed, but in the case of small loose droplets (microvesicular fatty change), uneven distribution of nuclei is not observed.
According to the distribution, it classifies into centrilobular, periportal, and diffuse type.",,,,,,,,,,,,,,,vacuolation [Liver Pathological Findings][Lipidosis(severe)],,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005737,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003543,ceramide -apoptosis inducer [Phospholipidosis - positive regulation of apoptosis],,,false,,,http://purl.obolibrary.org/obo/CHEBI_17761|http://purl.obolibrary.org/obo/TXPO_0001849,,,,,,,,,,,,,,,,,,,,PMID:29147025,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_68495,,,,,,,,,,TXPO:0003543,,,,,,,,,,,,,,,,,,,,,,ceramide -apoptosis inducer [Phospholipidosis - positive regulation of apoptosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003545,maintaining cell survival - cell death balance,,Maintaining cell survival-cell death balance is a subtype of maintaining balance: A process that keeps a balance  between cell death and cell survival within an organ or an organism.,false,,,http://purl.obolibrary.org/obo/TXPO_0000682,,,,,,,,,,,,,,,,,,,,,,Maintaining cell survival-cell death balance is a subtype of maintaining balance: A process that keeps a balance  between cell death and cell survival within an organ or an organism.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003545,,,,,,,,,,,,,,,,,,,,,,maintaining cell survival - cell death balance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_25806,oxygen molecular entity,,,false,,,http://purl.obolibrary.org/obo/CHEBI_23367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:25806,,,,,,,,,,,,,,,,,,,,,,oxygen molecular entity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100312,Smad3,,,false,,,http://purl.obolibrary.org/obo/IMR_0100504,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100312,,,,,,,,,,,,,,,,,,,,,,Smad3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100782,Wnt-11,,,false,,,http://purl.obolibrary.org/obo/IMR_0000003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100782,,,,,,,,,,,,,,,,,,,,,,Wnt-11,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002512,ABCC1(canonical)[Glutathione depletion],MRP1 [Glutathione depletion],,false,,,http://purl.obolibrary.org/obo/TXPO_0002045|http://purl.obolibrary.org/obo/TXPO_0002500,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MRP1 [Glutathione depletion],,,,,TXPO:0002512,,,,,,,,,,,,,,,,,,,,,,ABCC1(canonical)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002519,PERK-ATF4-CHOP signaling [ER stress - apoptosis],,"PERK-eIF2a-ATF4-CHOP pathway is a subtype of PERK-eIF2a-ATF4 signaling: Sequence of linked reactions, which has PERK-eIF2a-ATF4 signaling and gene regulation by CHOP.
This pathway is dependent on the apoptosis and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002513,,,,,,,,,,,,,,,,,,,,,,"PERK-eIF2a-ATF4-CHOP pathway is a subtype of PERK-eIF2a-ATF4 signaling: Sequence of linked reactions, which has PERK-eIF2a-ATF4 signaling and gene regulation by CHOP.
This pathway is dependent on the apoptosis and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002440|http://purl.obolibrary.org/obo/TXPO_0002767|http://purl.obolibrary.org/obo/TXPO_0002721|http://purl.obolibrary.org/obo/TXPO_0002722,,http://purl.obolibrary.org/obo/TXPO_0002485|http://purl.obolibrary.org/obo/TXPO_0002483|http://purl.obolibrary.org/obo/TXPO_0000285,,,,,,,,,,,,,,,,TXPO:0002519,,,,,,,,,,,,,,,,,,,,,,PERK-ATF4-CHOP signaling [ER stress - apoptosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002514,PERK activation [ER stress - translation attenuation],,"PERK activation is a subtype of Molecular activation: A process that changes the activity of PERK to be higher.
This process is dependent on the translation attenuation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000402,,,,,,,,,,,,,,,,,,,,,,"PERK activation is a subtype of Molecular activation: A process that changes the activity of PERK to be higher.
This process is dependent on the translation attenuation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000063|http://purl.obolibrary.org/obo/TXPO_0000388,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002506,,,,,,,,,,,TXPO:0002514,,,,,,,,,,,,,,,,,,,,,,PERK activation [ER stress - translation attenuation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002518,changing activity of eIF2a by PERK [ER stress - refolding],,"A process that changes the activity of the eIF2a by PERK.
This process is dependent on the refolding and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002378,,,,,,,,,,,,,,,,,,,,,,"A process that changes the activity of the eIF2a by PERK.
This process is dependent on the refolding and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000700,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000707,,,,,,,,,,,TXPO:0002518,,,,,,,,,,,,,,,,,,,,,,changing activity of eIF2a by PERK [ER stress - refolding],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002511,chaperone gene regulation pathway by ATF6 [ER stress],,Chaperone gene regulation pathway by ATF6 is a subtype of ATF6 gene regulation pathway: Sequence of reactions to regulate genes which have a chaperone role by ATF6. This process can constitute the course of ER stress.,false,,,http://purl.obolibrary.org/obo/TXPO_0002520,,,,,,,,,,,,,,,,,,,,,,Chaperone gene regulation pathway by ATF6 is a subtype of ATF6 gene regulation pathway: Sequence of reactions to regulate genes which have a chaperone role by ATF6. This process can constitute the course of ER stress.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002393,,,,,,,,,,,,,,,,,,TXPO:0002511,,,,,,,,,,,,,,,,,,,,,,chaperone gene regulation pathway by ATF6 [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002517,changing activity of eIF2a by PERK [ER stress - apoptosis],,"A process that changes the activity of the eIF2a by PERK.
This process is dependent on the apoptosis and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002378,,,,,,,,,,,,,,,,,,,,,,"A process that changes the activity of the eIF2a by PERK.
This process is dependent on the apoptosis and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002509,,,,,,,,,,,,,,,,,,,,,TXPO:0002517,,,,,,,,,,,,,,,,,,,,,,changing activity of eIF2a by PERK [ER stress - apoptosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002516,PERK activation [ER stress - refolding],,"PERK activation is a subtype of Molecular activation: A process that changes the activity of PERK to be higher.
This process is dependent on the refolding and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000402,,,,,,,,,,,,,,,,,,,,,,"PERK activation is a subtype of Molecular activation: A process that changes the activity of PERK to be higher.
This process is dependent on the refolding and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002518,,,,,,,,,,,TXPO:0002516,,,,,,,,,,,,,,,,,,,,,,PERK activation [ER stress - refolding],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002513,PERK-eIF2a-ATF4 mediated pathway,,"PERK-eIF2a-ATF4 mediated pathway is a subtype of PERK-eIF2a signaling: Sequence of linked reactions, which has PERK-eIF2a signaling and gene regulation by ATF4.",false,,,http://purl.obolibrary.org/obo/TXPO_0000701,,,,,,,,,,,,,,,,,,,,,,"PERK-eIF2a-ATF4 mediated pathway is a subtype of PERK-eIF2a signaling: Sequence of linked reactions, which has PERK-eIF2a signaling and gene regulation by ATF4.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002433|http://purl.obolibrary.org/obo/TXPO_0000706,,http://purl.obolibrary.org/obo/TXPO_0002483|http://purl.obolibrary.org/obo/TXPO_0000285,,,,,,,,,,,,,,,,TXPO:0002513,,,,,,,,,,,,,,,,,,,,,,PERK-eIF2a-ATF4 mediated pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002515,PERK activation [ER stress - apoptosis (sutained ) ],,"PERK activation is a subtype of Molecular activation: A process that changes the activity of PERK to be higher. This process persists for a certain period or over a long period.
This process is dependent on the apoptosis (sutained) and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000402,,,,,,,,,,,,,,,,,,,,,,"PERK activation is a subtype of Molecular activation: A process that changes the activity of PERK to be higher. This process persists for a certain period or over a long period.
This process is dependent on the apoptosis (sutained) and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0000498,,,http://purl.obolibrary.org/obo/TXPO_0002517,,,,,,,,,,,TXPO:0002515,,,,,,,,,,,,,,,,,,,,,,PERK activation [ER stress - apoptosis (sutained ) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002510,Phosphorylation of eIF2-alpha by PERK [ER stress - inflammation],,"Phosphorylation of eIF2-alpha by PERK is a subtype of eIF2a phosphorylation: A process that The process of introducing a phosphate group into eIF2a by PERK.
This process is dependent on the inflammation and can constitute the course of ER stress.|The C-terminal domain of PERK (EIF2AK3) has kinase activity when PERK homodimerizes. PERK kinase specifically phosphorylates Ser52 of eIF2-alpha, causing an arrest in translation. The result is that translation of ER-targeted proteins is halted on ribosomes in the vicinity of activated PERK. The general arrest of translation results in the loss of short-lived proteins such as Cyclin D1, causing an arrest of the cell cycle in G1.",false,,,http://purl.obolibrary.org/obo/TXPO_0000700,,,,,,,,,,,,,,,,,,,,Reactome:R-HSA-381111|PMID:9930704|PMID:23334697,,"Phosphorylation of eIF2-alpha by PERK is a subtype of eIF2a phosphorylation: A process that The process of introducing a phosphate group into eIF2a by PERK.
This process is dependent on the inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003035,,,,,,,,,,,TXPO:0002510,,,,,,,,,,,,,,,,,,,,"The C-terminal domain of PERK (EIF2AK3) has kinase activity when PERK homodimerizes. PERK kinase specifically phosphorylates Ser52 of eIF2-alpha, causing an arrest in translation. The result is that translation of ER-targeted proteins is halted on ribosomes in the vicinity of activated PERK. The general arrest of translation results in the loss of short-lived proteins such as Cyclin D1, causing an arrest of the cell cycle in G1.",,Phosphorylation of eIF2-alpha by PERK [ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_38632,membrane transport modulator,membrane transport modulators,Any agent that affects the transport of molecular entities across a biological membrane.,false,,,http://purl.obolibrary.org/obo/TXPO_0003230|http://purl.obolibrary.org/obo/CHEBI_52208,,,,,,,,,,,,,,,,,,,,,,Any agent that affects the transport of molecular entities across a biological membrane.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,membrane transport modulators,,,,,,,,,,,,,,,,,,,,,CHEBI:38632,,,,membrane transport modulator,,CHEBI:38632,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001004,MDM2 (canonical)[Ground glass appearance],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000472|http://purl.obolibrary.org/obo/IMR_0100660,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:17246|NCBI-Human-GeneID:4193|NCBI-Rat-GeneID:314856,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_68494,,,,,,,,,,TXPO:0001004,,,,,,,,,,,,,,,,,,,,,,MDM2 (canonical)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001003,Lmnb1 (rat)[Ground glass appearance],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000985|http://purl.obolibrary.org/obo/TXPO_1000230,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:116685,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001003,,,,,,,,,,,,,,,,,,,,,,Lmnb1 (rat)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001002,BIP (mol),GRP78|HSPA5,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:3309|NCBI-Mouse-GeneID:14828|NCBI-Rat-GeneID:25617,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GRP78|HSPA5,,,,,TXPO:0001002,,,,,,,,,,,,,,,,,,,,,,BIP (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001001,Aldh1 (rat)[Ground glass appearance],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000985|http://purl.obolibrary.org/obo/TXPO_1000035,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24188,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001001,,,,,,,,,,,,,,,,,,,,,,Aldh1 (rat)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001000,Vav2 (rat)[Ground glass appearance],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000985|http://purl.obolibrary.org/obo/TXPO_1000401,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:296603|PMID:15866884,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001000,,,,,,,,,,,,,,,,,,,,,,Vav2 (rat)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001007,DDB2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:107986|NCBI-Rat-GeneID:100362121|NCBI-Human-GeneID:1643|OMIM: 600811,,,,,,,,,,,,,,,Damage Specific DNA Binding Protein 2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001007,,,,,,,,,,,,,,,,,,,,,,DDB2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001006,cellular senescence [Ground glass appearance],,"A cell aging process stimulated in response to cellular stress, whereby normal cells lose the ability to divide through irreversible cell cycle arrest.
This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/GO_0090398|http://purl.obolibrary.org/obo/TXPO_0001728,,,,,,,,,,,,,,,,,,,,,,"A cell aging process stimulated in response to cellular stress, whereby normal cells lose the ability to divide through irreversible cell cycle arrest.
This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001006,,,,,,,,,,,,,,,,,,,,,,cellular senescence [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001008,Ankrd37 (rat)[Ground glass appearance],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000985|http://purl.obolibrary.org/obo/TXPO_1000036,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:361149,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001008,,,,,,,,,,,,,,,,,,,,,,Ankrd37 (rat)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001009,ground glass appearance dependent gene (human in vitro),,"Ground glass appearance dependent molecule is a subtype of toxic course dependent chemical entity.
This molecule can participate in the course of ground glass appearance as a gene product.
Gene profile:Human/in vitro/Hepatocyte/",false,,,http://purl.obolibrary.org/obo/TXPO_0000984,,,,,,,,,,,,,,,,,,,,,,"Ground glass appearance dependent molecule is a subtype of toxic course dependent chemical entity.
This molecule can participate in the course of ground glass appearance as a gene product.
Gene profile:Human/in vitro/Hepatocyte/",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001009,,,,,,,,,,,,,,,,,,,,,,ground glass appearance dependent gene (human in vitro),,,,,,,,,,,http://purl.obolibrary.org/obo/NCBITaxon_9606,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001005,PPARalpha activation [Eosinophilic granular degeneration],,"PPARalpha activation is a subtype of activating nuclear receptor: A process that changes the activity of the activating PPAR alpha (Peroxisome Proliferator Activated Receptor Alpha) with a nuclear receptor role to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/TXPO_0000013|http://purl.obolibrary.org/obo/TXPO_0001729,,,,,,,,,,,,,,,,,,,,PMID:20414453|https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2948931/|PMID:20101262,,"PPARalpha activation is a subtype of activating nuclear receptor: A process that changes the activity of the activating PPAR alpha (Peroxisome Proliferator Activated Receptor Alpha) with a nuclear receptor role to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000122|http://purl.obolibrary.org/obo/TXPO_0000121|http://purl.obolibrary.org/obo/TXPO_0001328,,,,,,http://purl.obolibrary.org/obo/TXPO_0000149|http://purl.obolibrary.org/obo/TXPO_0002047|http://purl.obolibrary.org/obo/TXPO_0000105|http://purl.obolibrary.org/obo/TXPO_0000118,,,,,,,,,,,TXPO:0001005,,,,,,,,,,,,,,,,,,,,,,PPARalpha activation [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76133,droxicam,"droxicamum|droxicam|5-methyl-3-(pyridin-2-yl)-2H,5H-[1,3]oxazino[5,6-c][1,2]benzothiazine-2,4(3H)-dione 6,6-dioxide","An organic heterotricyclic compound that is 2H,5H-[1,3]oxazino[5,6-c][1,2]benzothiazine-2,4(3H)-dione 6,6-dioxide substituted at positions 3 and 5 by pyridin-2-yl and methyl groups respectively. A prodrug of piroxicam, it is used for the relief of pain and inflammation in musculoskeletal disorders such as rheumatoid arthritis and osteoarthritis.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:8616003|PMID:3278945|PMID:1365486|Reaxys:6006252|PMID:1365490|PMID:8656732|PMID:1545609|PMID:1365489|PMID:1507923|PMID:23656309|PMID:1487550|PMID:8489815|PMID:2778095|PMID:3762266|PMID:3489870|PMID:1507922|CAS:90101-16-9|PMID:1365491|Drug_Central:970|PMID:12093490|PMID:8983932|PMID:1365484|PMID:8492964|PMID:1365487|PMID:1507924|PMID:3221746|PMID:3110512,,"An organic heterotricyclic compound that is 2H,5H-[1,3]oxazino[5,6-c][1,2]benzothiazine-2,4(3H)-dione 6,6-dioxide substituted at positions 3 and 5 by pyridin-2-yl and methyl groups respectively. A prodrug of piroxicam, it is used for the relief of pain and inflammation in musculoskeletal disorders such as rheumatoid arthritis and osteoarthritis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_50427|http://purl.obolibrary.org/obo/CHEBI_50908|http://purl.obolibrary.org/obo/CHEBI_35475|http://purl.obolibrary.org/obo/CHEBI_50266|http://purl.obolibrary.org/obo/CHEBI_35481|http://purl.obolibrary.org/obo/CHEBI_50630,,,,,"5-methyl-3-(pyridin-2-yl)-2H,5H-[1,3]oxazino[5,6-c][1,2]benzothiazine-2,4(3H)-dione 6,6-dioxide",,droxicamum|droxicam,,,,,,,,,,,,,,,,,,,,,CHEBI:76133,,,,droxicam,,CHEBI:76133,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000301,PERK - stress sensor (canonical)[ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000871|http://purl.obolibrary.org/obo/TXPO_0001841|http://purl.obolibrary.org/obo/TXPO_0001792,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:13666|NCBI-Human-GeneID:9451|NCBI-Rat-GeneID:29702,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000881,,,,,,,,,,TXPO:0000301,,,,,,,,,,,,,,,,,,,,,,PERK - stress sensor (canonical)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000309,meta generic quality,,,false,,,http://purl.obolibrary.org/obo/TXPO_0000300,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000309,,,,,,,,,,,,,,,,,,,,,,meta generic quality,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000307,weight attribute,,A physical attribute entity inhering in a bearer that has mass near a gravitational body.,false,,,http://purl.obolibrary.org/obo/TXPO_0002419,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0000128,,A physical attribute entity inhering in a bearer that has mass near a gravitational body.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000307,,,,,,,,,,,,,,,,,,,,,,weight attribute,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000300,attribute,generic quality,"This is an abstraction of the kinds at the class level. In the use case, it is sometimes referred to with # operator as a class constraint like ""#generic quality"".

In a common term, it would be called ""attribute"".

Its instance is not equal to its value.
The value itself belongs to ""quality value"". Its instance is still an attribute which refers to a specific quantity.

Its instnace plays a quality role like length plays one's height as a quality role.

Quality such as one's height, one's weight, etc. are roles, and hence must be defined in the context of respective contexts(entities). Therefore, they are not defined as basic type like length, weight, etc. See ""physical"" in which a most generic quality is defined.

Quality in DOLCE corresponds to quality role type in YAMATO. This is why ""quality"" is invisible in YAMATO in spite of it knows ""quality"".",false,,,http://purl.obolibrary.org/obo/BFO_0000020,,,,,,,,,,,,,,,,,,,,,,"This is an abstraction of the kinds at the class level. In the use case, it is sometimes referred to with # operator as a class constraint like ""#generic quality"".

In a common term, it would be called ""attribute"".

Its instance is not equal to its value.
The value itself belongs to ""quality value"". Its instance is still an attribute which refers to a specific quantity.

Its instnace plays a quality role like length plays one's height as a quality role.

Quality such as one's height, one's weight, etc. are roles, and hence must be defined in the context of respective contexts(entities). Therefore, they are not defined as basic type like length, weight, etc. See ""physical"" in which a most generic quality is defined.

Quality in DOLCE corresponds to quality role type in YAMATO. This is why ""quality"" is invisible in YAMATO in spite of it knows ""quality"".",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,generic quality,,,,,TXPO:0000300,,,,,,,,,,,,,,,,,,,,,,attribute,,,,,,,YAMATO Ontology,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000305,non-meta generic quality,,,false,,,http://purl.obolibrary.org/obo/TXPO_0000300,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000305,,,,,,,,,,,,,,,,,,,,,,non-meta generic quality,,,,,,,YAMATO ontology,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000306,protein biosynthesis,,Protein biosynthesis is a subtype of biosynthetic process:The chemical reactions resulting in the formation of proteins.,false,,,http://purl.obolibrary.org/obo/GO_0009058,,,,,,,,,,,,,,,,,,,,,,Protein biosynthesis is a subtype of biosynthetic process:The chemical reactions resulting in the formation of proteins.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_36080,,,,,,,,,,,,,,,,,,,TXPO:0000306,,,,,,,,,,,,,,,,,,,,,,protein biosynthesis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000302,counting generic quality,,An attribute that counting numbers of objects and how many times an event happens are essential not to individuals in them but to collectives of objects or events.,false,,,http://purl.obolibrary.org/obo/TXPO_0000309,,,,,,,,,,,,,,,,,,,,,,An attribute that counting numbers of objects and how many times an event happens are essential not to individuals in them but to collectives of objects or events.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000302,,,,,,,,,,,,,,,,,,,,,,counting generic quality,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000303,number of times,,"not clock time but times (how many times). Contrary to the intuition, ""times"" should not be taken as a generic quality. What should be taken as a generic quality is the pai rof ""event"" and times. That is, ""what event happens many times"" corresponds to ""color is red"". For example, ""A month which has many accidents"" corresponds to ""A rose whose color is red"".",false,,,http://purl.obolibrary.org/obo/TXPO_0000302,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000303,,,,,,,,,,,,,,,,,,,,"not clock time but times (how many times). Contrary to the intuition, ""times"" should not be taken as a generic quality. What should be taken as a generic quality is the pai rof ""event"" and times. That is, ""what event happens many times"" corresponds to ""color is red"". For example, ""A month which has many accidents"" corresponds to ""A rose whose color is red"".",,number of times,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000304,number of objects,,"not numerals but ""number"" of somethings(=how many things)",false,,,http://purl.obolibrary.org/obo/TXPO_0000302,,,,,,,,,,,,,,,,,,,,,,"not numerals but ""number"" of somethings(=how many things)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000304,,,,,,,,,,,,,,,,,,,,,,number of objects,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000308,lyase,,"A role played by the entity which catalyses the cleavage of C-C, C-O, C-N and other bonds by other means than by hydrolysis or oxidation, or conversely adding a group to a double bond. They differ from other enzymes in that two substrates are involved in one reaction direction, but only one in the other direction. When acting on the single substrate, a molecule is eliminated and this generates either a new double bond or a new ring.|related molecular function GO:0016829",false,,,http://purl.obolibrary.org/obo/TXPO_0003660,,,,,,,,,,,,,,,,,,,,EC:4.-.-.-,,"A role played by the entity which catalyses the cleavage of C-C, C-O, C-N and other bonds by other means than by hydrolysis or oxidation, or conversely adding a group to a double bond. They differ from other enzymes in that two substrates are involved in one reaction direction, but only one in the other direction. When acting on the single substrate, a molecule is eliminated and this generates either a new double bond or a new ring.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000308,,,,,,,,,,,,,,,,,,,,related molecular function GO:0016829,,lyase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010539,40S ribosomal protein S14,40S small ribosomal protein 14,,false,,,http://purl.obolibrary.org/obo/IMR_0000896,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,40S small ribosomal protein 14,,,,,IMR:0010539,,,,,,,,,,,,,,,,,,,,,,40S ribosomal protein S14,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0002064,Sos2,,,false,,,http://purl.obolibrary.org/obo/IMR_0000435,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0002064,,,,,,,,,,,,,,,,,,,,,,Sos2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002539,protein quality control for unfolded proteins [ER stress (early stage)],,"Protein quality control for misfolded or incompletely synthesized proteins is a subtype of keeping quality: A process that maintains the protein quality in an early stage of toxic course.
This entity is a specific course-dependent process. This process can constitute the course of ER stress (early stage).",false,,,http://purl.obolibrary.org/obo/TXPO_0000213|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"Protein quality control for misfolded or incompletely synthesized proteins is a subtype of keeping quality: A process that maintains the protein quality in an early stage of toxic course.
This entity is a specific course-dependent process. This process can constitute the course of ER stress (early stage).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002207|http://purl.obolibrary.org/obo/TXPO_0000722,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002544,,,,,,,,,,,TXPO:0002539,,,,,,,,,,,,,,,,,,,,,,protein quality control for unfolded proteins [ER stress (early stage)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000000,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002530,aggregated protein production- degradation imbalance,,Aggregated protein production- degradation imbalance is a subtype of imbalance: A process that lacks a balance between aggregated protein production and degradation.,false,,,http://purl.obolibrary.org/obo/TXPO_0000567,,,,,,,,,,,,,,,,,,,,,,Aggregated protein production- degradation imbalance is a subtype of imbalance: A process that lacks a balance between aggregated protein production and degradation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002530,,,,,,,,,,,,,,,,,,,,,,aggregated protein production- degradation imbalance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002536,increasing hepatocellular volume [ER stress],,"Increasing hepatocellular volume is a changing process to change the volume of the hepatocyte to increase.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/TXPO_0000164,,,,,,,,,,,,,,,,,,,,,,"Increasing hepatocellular volume is a changing process to change the volume of the hepatocyte to increase.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002536,,,,,,,,,,,,,,,,,,,,,,increasing hepatocellular volume [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002533,hyperfunction of cell survival[ER stress],,"Hyperfunction of cell survival is a subtype of hyperfunctioning: A process that performs an excesssive cell survival.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002275|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of cell survival is a subtype of hyperfunctioning: A process that performs an excesssive cell survival.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000758|http://purl.obolibrary.org/obo/TXPO_0000831|http://purl.obolibrary.org/obo/TXPO_0003598,,,,,,,,,,,TXPO:0002533,,,,,,,,,,,,,,,,,,,,,,hyperfunction of cell survival[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002531,increasing number of abnormal cells in liver,,Increasing number of abnormal cells in liver is a subtype of cell proliferation: A process that becomes larger in the number of autodigestion of abnormal cells in the liver.,false,,,http://purl.obolibrary.org/obo/TXPO_0000093,,,,,,,,,,,,,,,,,,,,,,Increasing number of abnormal cells in liver is a subtype of cell proliferation: A process that becomes larger in the number of autodigestion of abnormal cells in the liver.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002531,,,,,,,,,,,,,,,,,,,,,,increasing number of abnormal cells in liver,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002538,increasing volume of liver [ER stress],,"Increasing volume of liver is a subtype of increasing volume: A process that changes the volume of the liver to be higher.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000616|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"Increasing volume of liver is a subtype of increasing volume: A process that changes the volume of the liver to be higher.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002538,,,,,,,,,,,,,,,,,,,,,,increasing volume of liver [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002532,increasing number of abnormal cells in liver [ER stress],,"Increasing number of abnormal cells in liver is a subtype of cell proliferation: A process that becomes larger in the number of autodigestion of abnormal cells in the liver.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002531|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"Increasing number of abnormal cells in liver is a subtype of cell proliferation: A process that becomes larger in the number of autodigestion of abnormal cells in the liver.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002114,,,,,,,,,,,TXPO:0002532,,,,,,,,,,,,,,,,,,,,,,increasing number of abnormal cells in liver [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002534,carcinogenesis [ER stress],,"A pathologic process that involves the transformation of normal cells to a neoplastic state.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/NCIT_C18078|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"A pathologic process that involves the transformation of normal cells to a neoplastic state.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002535|http://purl.obolibrary.org/obo/TXPO_0000758|http://purl.obolibrary.org/obo/TXPO_0000767,,,,,,,,,,,TXPO:0002534,,,,,,,,,,,,,,,,,,,,,,carcinogenesis [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002535,tumor cell proliferation [ER stress],,"Tumor cell proliferation is a subtype of cell proliferation: A process of the multiplication or reproduction of tumor cells, resulting in the rapid expansion of a tumor cell population.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/TXPO_0000339,,,,,,,,,,,,,,,,,,,,,,"Tumor cell proliferation is a subtype of cell proliferation: A process of the multiplication or reproduction of tumor cells, resulting in the rapid expansion of a tumor cell population.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002535,,,,,,,,,,,,,,,,,,,,,,tumor cell proliferation [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002537,negative regulation of increasing insulin resistance,,"Negative regulation of increasing insulin resistance is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of insulin resistance.",false,,,http://purl.obolibrary.org/obo/TXPO_0000369,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of increasing insulin resistance is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of insulin resistance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002537,,,,,,,,,,,,,,,,,,,,,,negative regulation of increasing insulin resistance,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002189,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0097193,intrinsic apoptotic signaling pathway,,"A series of molecular signals in which an intracellular signal is conveyed to trigger the apoptotic death of a cell. The pathway starts with reception of an intracellular signal (e.g. DNA damage, endoplasmic reticulum stress, oxidative stress etc.), and ends when the execution phase of apoptosis is triggered. The intrinsic apoptotic signaling pathway is crucially regulated by permeabilization of the mitochondrial outer membrane (MOMP).",false,,,http://purl.obolibrary.org/obo/TXPO_0000609,,,,,,,,,,,,,,,,,,,,,,"A series of molecular signals in which an intracellular signal is conveyed to trigger the apoptotic death of a cell. The pathway starts with reception of an intracellular signal (e.g. DNA damage, endoplasmic reticulum stress, oxidative stress etc.), and ends when the execution phase of apoptosis is triggered. The intrinsic apoptotic signaling pathway is crucially regulated by permeabilization of the mitochondrial outer membrane (MOMP).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0097193,,,,,,,,,,,,,,,,,,,,,,intrinsic apoptotic signaling pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000000960,CD44,,Other designations: CD44 antigen|GP90 lymphocyte homing/adhesion receptor|Hermes antigen|cell surface glycoprotein CD44|chondroitin sulfate proteoglycan 8|epican|extracellular matrix receptor III|hematopoietic cell E- and L-selectin ligand|heparan sulfate proteoglycan|homing function and Indian blood group system|hyaluronate receptor|phagocytic glycoprotein 1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CSPG8|IN|CDW44|MDU2|HCELL|Pgp1|MIC4|ECMR-III|LHR|MDU3|HUTCH-I|MC56,,,,,,,,,,,,11,,,,,,MIM:107269|Ensembl:ENSG00000026508|HPRD:00115|HGNC:1681|Vega:OTTHUMG00000044388,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,CD44 molecule (Indian blood group),,,11p13,,,,,,,,,,,,,,,,"GO_0001658 (EC: IEA); GO_0002246 (EC: IEA); GO_0004415 (EC: IDA, PMID: 17170110); GO_0004888 (EC: IDA, Qualifier: contributes_to, PMID: 17045821); GO_0005515 (EC: IPI, PMID: 11207560); GO_0005518 (EC: NAS, PMID: 2471973); GO_0005540 (EC: IDA, PMID: 17170110); GO_0005540 (EC: NAS, PMID: 1991450); GO_0005737 (EC: IDA); GO_0005794 (EC: IDA); GO_0005886 (EC: IDA); GO_0005886 (EC: TAS); GO_0005887 (EC: NAS, PMID: 1991450); GO_0005975 (EC: TAS); GO_0007160 (EC: NAS, PMID: 1922057); GO_0007596 (EC: TAS); GO_0009897 (EC: IEA); GO_0009986 (EC: IDA, PMID: 16809613); GO_0010628 (EC: IEA); GO_0016055 (EC: IEA); GO_0016323 (EC: IEA); GO_0016337 (EC: NAS, PMID: 1922057); GO_0019221 (EC: TAS); GO_0022617 (EC: TAS); GO_0030198 (EC: TAS); GO_0030203 (EC: TAS); GO_0030212 (EC: TAS); GO_0030214 (EC: IDA, PMID: 17170110); GO_0030214 (EC: TAS); GO_0033138 (EC: IDA, PMID: 17045821); GO_0034116 (EC: IMP, PMID: 15100360); GO_0043066 (EC: IMP, PMID: 19047049); GO_0043154 (EC: IMP, PMID: 19047049); GO_0043518 (EC: IDA, PMID: 17045821); GO_0044281 (EC: TAS); GO_0044344 (EC: IDA, PMID: 19577615); GO_0050731 (EC: IDA, PMID: 17045821); GO_0050900 (EC: TAS); GO_0051216 (EC: IEP, PMID: 11944887); GO_0060333 (EC: TAS); GO_0060442 (EC: IEA); GO_0070062 (EC: IDA, PMID: 19199708); GO_0070374 (EC: IDA, PMID: 17045821); GO_0070487 (EC: IMP, PMID: 15100360); GO_1900625 (EC: IMP); GO_1902166 (EC: IDA, PMID: 17045821)",,,,,,,,,PMID: 1281868; 1465456; 1496383; 1537855; 1694723; 1717145; 1730778; 1734871; 1840487; 1922057; 1991450; 2007624; 2056274; 2454887; 2466575; 2466576; 2471973; 2474557; 7499241; 7505012; 7508842; 7516819; 7529574; 7532176; 7539755; 7542116; 7557500; 7591309; 7699015; 7821789; 7908632; 8148709; 8343954; 8352881; 8576267; 8599448; 8636151; 8640758; 8649806; 8858161; 8871928; 8986622; 9058761; 9334256; 9472040; 9519902; 9573028; 9580567; 9794764; 10636882; 10652271; 10657301; 10737800; 10933060; 10950950; 11084024; 11095749; 11129651; 11207560; 11381077; 11402070; 11463356; 11466334; 11606575; 11716065; 11727257; 11740562; 11759056; 11792412; 11825873; 11825898; 11839564; 11840273; 11935029; 11944887; 12032545; 12090473; 12093135; 12127836; 12145196; 12145287; 12168806; 12183053; 12198147; 12223485; 12226094; 12235127; 12297287; 12356905; 12370738; 12371152; 12377945; 12392323; 12393872; 12407110; 12411303; 12421945; 12439723; 12444143; 12452061; 12477932; 12479099; 12485845; 12506143; 12508241; 12511569; 12511867; 12574156; 12629514; 12635659; 12650924; 12702150; 12711360; 12714503; 12727228; 12730955; 12748184; 12767055; 12779084; 12801931; 12820426; 12826680; 12842543; 12883358; 12893366; 12901833; 12908752; 12909589; 12911725; 12928429; 12939665; 12949055; 14504094; 14525786; 14534711; 14534719; 14614016; 14623895; 14644158; 14669354; 14702039; 14981907; 14992719; 15009704; 15013310; 15017146; 15023889; 15040016; 15048167; 15051494; 15060082; 15070674; 15100360; 15123640; 15239258; 15292257; 15313120; 15361838; 15452148; 15489334; 15509527; 15516973; 15531362; 15558018; 15578568; 15638368; 15638386; 15641486; 15645378; 15652352; 15655247; 15688033; 15728517; 15736104; 15783086; 15809746; 15816636; 15851553; 15867228; 15923644; 15943035; 15962382; 15990174; 16002044; 16085055; 16166750; 16177123; 16208414; 16219515; 16229685; 16234326; 16248506; 16311123; 16325770; 16335952; 16352650; 16354706; 16390331; 16407205; 16415175; 16419149; 16478744; 16494036; 16504370; 16530165; 16533775; 16554035; 16565089; 16565092; 16620830; 16636662; 16652145; 16702221; 16713680; 16809345; 16809613; 16848180; 16868940; 16969488; 16998483; 16998484; 17045821; 17081983; 17085435; 17092940; 17135256; 17136494; 17170110; 17237445; 17265493; 17324121; 17332338; 17343740; 17381240; 17383158; 17392272; 17464868; 17479111; 17482182; 17516109; 17540049; 17579117; 17581168; 17589956; 17599831; 17611661; 17611662; 17627000; 17638891; 17657222; 17679465; 17702746; 17708612; 17726647; 17846873; 17849363; 17891137; 17911438; 17914409; 17919613; 17940137; 17945212; 17945213; 17975002; 17987038; 18005092; 18029348; 18048043; 18077444; 18092951; 18094716; 18155656; 18160820; 18162778; 18193058; 18199543; 18214619; 18227732; 18234849; 18246799; 18265895; 18276068; 18279620; 18326820; 18350162; 18372518; 18375392; 18387829; 18396641; 18414895; 18415803; 18438684; 18441325; 18450428; 18450824; 18476625; 18476632; 18495204; 18502033; 18502153; 18513329; 18516325; 18559090; 18577517; 18608209; 18612220; 18614011; 18632604; 18644869; 18651220; 18654930; 18662989; 18753140; 18757307; 18787423; 18804101; 18804988; 18835619; 18852874; 18952835; 18971959; 18980968; 18981124; 18997126; 19004834; 19009655; 19010227; 19017033; 19017937; 19023892; 19047049; 19073595; 19077409; 19088176; 19097357; 19100415; 19141242; 19148550; 19167378; 19176383; 19199708; 19200980; 19243022; 19254252; 19275586; 19277703; 19322201; 19331807; 19350388; 19351367; 19360323; 19385591; 19396460; 19415765; 19416960; 19432801; 19434087; 19488035; 19506034; 19563418; 19577615; 19580891; 19582779; 19598259; 19621595; 19626493; 19633292; 19635906; 19638429; 19698232; 19703720; 19724852; 19764564; 19773544; 19787202; 19787231; 19794081; 19794958; 19794964; 19799609; 19816074; 19826051; 19857547; 19906290; 19912362; 19913121; 19914206; 19937401; 19952968; 19955840; 19965872; 19996285; 20019840; 20042890; 20083228; 20093404; 20093489; 20098615; 20121756; 20127679; 20142144; 20157733; 20178130; 20193563; 20199686; 20200161; 20211062; 20212041; 20228222; 20237496; 20306693; 20357818; 20361869; 20374021; 20382854; 20403620; 20405247; 20416163; 20454640; 20491779; 20525896; 20526812; 20530438; 20552237; 20562647; 20588206; 20605145; 20606680; 20606732; 20628086; 20628624; 20663864; 20663884; 20670691; 20696077; 20698358; 20799279; 20806065; 20809185; 20819778; 20837694; 20843027; 20851866; 20856229; 20920234; 20956971; 20962267; 20969572; 20971508; 20974992; 21055388; 21078678; 21087933; 21098716; 21105049; 21124918; 21136024; 21139048; 21151997; 21179550; 21194677; 21215700; 21254647; 21257828; 21257905; 21258793; 21278261; 21279958; 21294926; 21299347; 21331451; 21356346; 21374592; 21376257; 21393860; 21397861; 21411116; 21424816; 21454519; 21471214; 21471434; 21473743; 21482826; 21489997; 21493336; 21546273; 21570715; 21617876; 21618131; 21618132; 21630198; 21632186; 21633165; 21645921; 21649540; 21668410; 21678082; 21680714; 21685938; 21694464; 21701559; 21708929; 21718681; 21731740; 21743962; 21749678; 21764578; 21768115; 21768350; 21802218; 21804359; 21813394; 21819617; 21824412; 21827751; 21829201; 21830016; 21833756; 21835433; 21849440; 21895545; 21898409; 21906983; 21912471; 21933023; 21935375; 21935404; 21953074; 21957977; 21963094; 21987572; 21993315; 22014860; 22021370; 22024057; 22048598; 22068886; 22069487; 22072421; 22076958; 22119814; 22119938; 22125838; 22130902; 22135720; 22152097; 22205660; 22213301; 22216242; 22218639; 22234250; 22237177; 22242150; 22266115; 22270319; 22271686; 22272243; 22278305; 22293754; 22304920; 22307465; 22321833; 22322379; 22335271; 22363471; 22386367; 22389315; 22429811; 22433859; 22437554; 22449225; 22456539; 22473523; 22491449; 22493711; 22499789; 22514625; 22525501; 22552294; 22552741; 22559040; 22561518; 22610405; 22610780; 22621373; 22637644; 22654106; 22673507; 22673910; 22706704; 22711991; 22726066; 22733437; 22740085; 22740326; 22753277; 22770970; 22784357; 22804494; 22807608; 22836803; 22839505; 22842095; 22843930; 22847005; 22855175; 22863883; 22865879; 22870202; 22895075; 22901285; 22922740; 22923071; 22923171; 22932199; 22939629; 22947857; 22966907; 22967445; 22969228; 22972620; 23000965; 23002207; 23028444; 23031255; 23039365; 23049743; 23056168; 23071680; 23089492; 23098472; 23112116; 23118219; 23138176; 23143465; 23151220; 23160198; 23170789; 23171677; 23182705; 23220849; 23221384; 23226410; 23238743; 23251004; 23252868; 23263849; 23265944; 23273568; 23326564; 23334333; 23342032; 23373240; 23400010; 23404221; 23419168; 23422486; 23426175; 23435135; 23444222; 23445749; 23449937; 23457460; 23476138; 23547049; 23549458; 23565227; 23589287; 23589310; 23600676; 23603511; 23609373; 23633482; 23645762; 23664487; 23667174; 23679813; 23685894; 23736812; 23744486; 23764310; 23768762; 23778530; 23797812; 23800986; 23848514; 23856463; 23883608; 23884413; 23888049; 23940692; 24005673; 24064218; 24084461; 24091662; 24099991; 24194636; 24333422; 24434386,,,,,,,,,,,,,,,OGG:3000000960,,,,,,,CD44 molecule (Indian blood group),,,,,,,,,,,,,Other designations: CD44 antigen|GP90 lymphocyte homing/adhesion receptor|Hermes antigen|cell surface glycoprotein CD44|chondroitin sulfate proteoglycan 8|epican|extracellular matrix receptor III|hematopoietic cell E- and L-selectin ligand|heparan sulfate proteoglycan|homing function and Indian blood group system|hyaluronate receptor|phagocytic glycoprotein 1,,CD44,,,,,,,,,,,,,,,,,,,,,,,960,AL133330.1,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,CD44,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000716,PLCbeta3,phospholipase C beta 3,,false,,,http://purl.obolibrary.org/obo/IMR_0000286,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,phospholipase C beta 3,,,,,IMR:0000716,,,,,,,,,,,,,,,,,,,,,,PLCbeta3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000295,Rho family,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,IPR:003578,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003669,,,,,,,,,,IMR:0000295,,,,,,,,,,,,,,,,,,,,,,Rho family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001423,GAF,IFNgamma-activated factor|gamma-activated factor,STAT1 dimers form the IFNgamma-activated factor (GAF).,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,STAT1 dimers form the IFNgamma-activated factor (GAF).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,IFNgamma-activated factor|gamma-activated factor,,,,,IMR:0001423,,,,,,,,,,,,,,,,,,,,,,GAF,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76740,EC 1.13.* [oxidoreductase acting on single donors with incorporation of molecular oxygen (oxygenases)] inhibitor,EC 1.13.* [oxidoreductase acting on single donors with incorporation of molecular oxygen (oxygenases)] inhibitors|oxidoreductase acting on single donors with incorporation of molecular oxygen (oxygenases) (EC 1.13.*) inhibitor|oxidoreductase acting on single donors with incorporation of molecular oxygen (oxygenases) (EC 1.13.*) inhibitors|EC 1.13.* inhibitor|EC 1.13.* inhibitors|oxidoreductase acting on single donors with incorporation of molecular oxygen (oxygenases) inhibitor|oxidoreductase acting on single donors with incorporation of molecular oxygen (oxygenases) inhibitors,"An oxidoreductase inhibitor which interferes with the action of an oxidoreductase acting on single donors with incorporation of molecular oxygen (oxygenases), EC 1.13.*.*.",false,,,http://purl.obolibrary.org/obo/CHEBI_76725,,,,,,,,,,,,,,,,,,,,,,"An oxidoreductase inhibitor which interferes with the action of an oxidoreductase acting on single donors with incorporation of molecular oxygen (oxygenases), EC 1.13.*.*.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,EC 1.13.* [oxidoreductase acting on single donors with incorporation of molecular oxygen (oxygenases)] inhibitors|oxidoreductase acting on single donors with incorporation of molecular oxygen (oxygenases) (EC 1.13.*) inhibitor|oxidoreductase acting on single donors with incorporation of molecular oxygen (oxygenases) (EC 1.13.*) inhibitors|EC 1.13.* inhibitor|EC 1.13.* inhibitors|oxidoreductase acting on single donors with incorporation of molecular oxygen (oxygenases) inhibitor|oxidoreductase acting on single donors with incorporation of molecular oxygen (oxygenases) inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:76740,,,,EC 1.13.* [oxidoreductase acting on single donors with incorporation of molecular oxygen (oxygenases)] inhibitor,,CHEBI:76740,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_35705,immunosuppressive agent,immunosuppressant|immunosuppressive agents|inmunosupresor,"An agent that suppresses immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-cells or by inhibiting the activation of helper cells. In addition, an immunosuppressive agent is a role played by a compound which is exhibited by a capability to diminish the extent and/or voracity of an immune response.",false,,,http://purl.obolibrary.org/obo/CHEBI_50846,,,,,,,,,,,,,,,,,,,,,,"An agent that suppresses immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-cells or by inhibiting the activation of helper cells. In addition, an immunosuppressive agent is a role played by a compound which is exhibited by a capability to diminish the extent and/or voracity of an immune response.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,immunosuppressant|immunosuppressive agents|inmunosupresor,,,,,,,,,,,,,,,,,,,,,CHEBI:35705,,,,immunosuppressive agent,,CHEBI:35705,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0015908,fatty acid transport,,"The directed movement of fatty acids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Fatty acids are aliphatic monocarboxylic acids liberated from naturally occurring fats and oils by hydrolysis",false,,,http://purl.obolibrary.org/obo/GO_0006869,,,,,,,,,,,,,,,,,,,,,,"The directed movement of fatty acids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Fatty acids are aliphatic monocarboxylic acids liberated from naturally occurring fats and oils by hydrolysis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0015908,,,,,,,,,,,,,,,,,,,,,,fatty acid transport,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0015909,long-chain fatty acid transport,,"The directed movement of long-chain fatty acids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. A long-chain fatty acid is a fatty acid with a chain length between C13 and C22.",false,,,http://purl.obolibrary.org/obo/GO_0015908,,,,,,,,,,,,,,,,,,,,,,"The directed movement of long-chain fatty acids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. A long-chain fatty acid is a fatty acid with a chain length between C13 and C22.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0015909,,,,,,,,,,,,,,,,,,,,,,long-chain fatty acid transport,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000003956,LGALS1,,Other designations: 14 kDa laminin-binding protein|14 kDa lectin|HBL|HLBP14|HPL|S-Lac lectin 1|beta-galactoside-binding lectin L-14-I|beta-galactoside-binding protein 14kDa|gal-1|galaptin|galectin 1|galectin-1|lactose-binding lectin 1|putative MAPK-activating protein PM12,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,GBP|GAL1,,,,,,,,,,,,22,,,,,,Ensembl:ENSG00000100097|Vega:OTTHUMG00000150661|HGNC:6561|MIM:150570|HPRD:01040,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"lectin, galactoside-binding, soluble, 1",,,22q13.1,,,,,,,,,,,,,,,,"GO_0001948 (EC: IEA); GO_0002317 (EC: IEA); GO_0004871 (EC: IMP, PMID: 12761501); GO_0005515 (EC: IPI, PMID: 10369126); GO_0005578 (EC: IEA); GO_0005615 (EC: IDA); GO_0005622 (EC: IDA); GO_0005634 (EC: IEA); GO_0005737 (EC: TAS, PMID: 16130169); GO_0006915 (EC: IEA); GO_0007165 (EC: IMP, PMID: 12761501); GO_0009986 (EC: IEA); GO_0010812 (EC: IEA); GO_0010977 (EC: IEA); GO_0016936 (EC: IEA); GO_0030395 (EC: IEA); GO_0031012 (EC: IDA, Qualifier: colocalizes_with); GO_0031012 (EC: ISS, Qualifier: colocalizes_with); GO_0031295 (EC: IEA); GO_0033555 (EC: IEA); GO_0034120 (EC: IEA); GO_0042493 (EC: IEA); GO_0042803 (EC: IEA); GO_0042981 (EC: TAS, PMID: 16130169); GO_0043123 (EC: IMP, PMID: 12761501); GO_0043236 (EC: IEA); GO_0044822 (EC: IDA); GO_0045445 (EC: IEA); GO_0048678 (EC: IEA); GO_0071333 (EC: IEA); GO_0071407 (EC: IEA)",,,,,,,,,PMID: 1602151; 1713454; 1988031; 1996404; 2383549; 2719646; 2719964; 2910856; 3020551; 3065332; 3611046; 7501023; 7750127; 7795414; 7821789; 7869048; 8063692; 8432540; 8449510; 8872948; 9264263; 9572443; 9683529; 10369126; 10425546; 10490978; 10591208; 10642604; 10764829; 10950114; 11076863; 11146440; 11256614; 11522829; 11709720; 11846886; 11850528; 11937561; 12008046; 12125737; 12271131; 12477932; 12527107; 12615972; 12665801; 12761501; 12810474; 12823983; 12853445; 14507657; 14550305; 14612929; 14617626; 14693917; 14769876; 15050916; 15297883; 15461802; 15489334; 15489336; 15556936; 15556941; 15663199; 15690107; 15778371; 15862866; 15910247; 15929990; 15972675; 16033063; 16051185; 16130169; 16247730; 16381901; 16388708; 16530434; 16636291; 16751364; 16785517; 16818733; 16940423; 17043243; 17110462; 17177840; 17182582; 17269744; 17304502; 17353931; 17390012; 17438085; 17523619; 17535296; 17537433; 17603562; 17616672; 17649808; 17880528; 17884770; 17984174; 18007053; 18028978; 18223683; 18258591; 18292532; 18315601; 18431251; 18519761; 18570123; 18581052; 18624398; 18630998; 18633135; 18662664; 18671640; 18691335; 18791848; 18796645; 18802059; 18824694; 18838383; 18947333; 18991278; 19011096; 19032754; 19064001; 19103599; 19116313; 19125585; 19128029; 19148478; 19155496; 19171142; 19225046; 19287070; 19287997; 19363525; 19412433; 19454697; 19471022; 19492862; 19506091; 19520156; 19550395; 19561030; 19635795; 19688976; 19730683; 19738201; 19860718; 19886821; 19898636; 19900702; 19913121; 20006954; 20053628; 20157731; 20177845; 20200618; 20332322; 20360068; 20363255; 20399482; 20525878; 20549082; 20570633; 20592339; 20596638; 20628086; 20644118; 20657665; 20728947; 20816214; 20828557; 20873803; 21113146; 21122983; 21139048; 21147166; 21150319; 21191065; 21292557; 21372130; 21378323; 21385934; 21391228; 21397408; 21505194; 21514365; 21614093; 21632118; 21689853; 21724180; 21747316; 21779348; 21780106; 21807362; 21880716; 21880749; 21890473; 21897333; 21906983; 21963094; 21986812; 21998324; 22022970; 22028908; 22081313; 22155450; 22156919; 22167721; 22174828; 22267483; 22271227; 22285770; 22291012; 22353504; 22373585; 22383798; 22386573; 22432916; 22447203; 22456341; 22524424; 22546645; 22561438; 22583806; 22609846; 22623428; 22689223; 22692729; 22696230; 22716213; 22777171; 22785208; 22844466; 22863883; 22884463; 22936677; 22939629; 22939954; 22942212; 23000965; 23002109; 23022198; 23027923; 23113677; 23121677; 23124203; 23142379; 23223580; 23359172; 23389289; 23402259; 23431236; 23444403; 23510298; 23599627; 23681112; 23862649; 23929302; 23956138; 24211210,,,,,,,,,,,,,,,OGG:3000003956,,,,,,,"lectin, galactoside-binding, soluble, 1",,,,,,,,,,,,,Other designations: 14 kDa laminin-binding protein|14 kDa lectin|HBL|HLBP14|HPL|S-Lac lectin 1|beta-galactoside-binding lectin L-14-I|beta-galactoside-binding protein 14kDa|gal-1|galaptin|galectin 1|galectin-1|lactose-binding lectin 1|putative MAPK-activating protein PM12,,LGALS1,,,,,,,,,,,,,,,,,,,,,,,3956,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,LGALS1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000337,Crk-L,Crk-like protein,,false,,,http://purl.obolibrary.org/obo/IMR_0000745,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Crk-like protein,,,,,IMR:0000337,,,,,,,,,,,,,,,,,,,,,,Crk-L,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000085406,DNAJC14,,Other designations: LYST-interacting protein LIP6|dnaJ homolog subfamily C member 14|dnaJ protein homolog 3|dopamine receptor interacting protein|dopamine receptor-interacting protein of 78 kDa|hDj-3|human DnaJ protein 3,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,HDJ3|LIP6|DRIP78|DNAJ,,,,,,,,,,,,12,,,,,,Vega:OTTHUMG00000170427|Ensembl:ENSG00000135392|HPRD:12082|HGNC:24581|MIM:606092,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"DnaJ (Hsp40) homolog, subfamily C, member 14",,,12q13.2,,,,,,,,,,,,,,,,GO_0005789 (EC: IEA); GO_0015031 (EC: IEA); GO_0016021 (EC: IEA),,,,,,,,,PMID:11181995; 11331877; 11984006; 12446598; 12477932; 12768437; 14702039; 14993367; 15489334; 16344560; 18029348; 19322201; 21249176; 22815758; 22915803,,,,,,,,,,,,,,,OGG:3000085406,,,,,,,"DnaJ (Hsp40) homolog, subfamily C, member 14",,,,,,,,,,,,,Other designations: LYST-interacting protein LIP6|dnaJ homolog subfamily C member 14|dnaJ protein homolog 3|dopamine receptor interacting protein|dopamine receptor-interacting protein of 78 kDa|hDj-3|human DnaJ protein 3,,DNAJC14,,,,,,,,,,,,,,,,,,,,,,,85406,hCG_2016179,,,,,,,9606,,,,,,,,,,,,,,,,,,,DNAJC14,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0011138,eIF2B-delta,"Translation initiation factor eIF-2B delta subunit|eIF-2B GDP-GTP exchange factor, delta subunit|translation initiation factor 2B delta subunit|eIF-2B GDP-GTP exchange factor",,false,,,http://purl.obolibrary.org/obo/IMR_0000915,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Translation initiation factor eIF-2B delta subunit|eIF-2B GDP-GTP exchange factor, delta subunit|translation initiation factor 2B delta subunit|eIF-2B GDP-GTP exchange factor",,,,,IMR:0011138,,,,,,,,,,,,,,,,,,,,,,eIF2B-delta,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0001088,urine,,Excretion that is the output of a kidney|kidney excreta from some taxa (e.g. in aves) may not be liquid,false,,,http://purl.obolibrary.org/obo/UBERON_0000463,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C13283|http://en.wikipedia.org/wiki/Urine|http://linkedlifedata.com/resource/umls/id/C0042036|ENVO:00002047|EFO:0001939|CALOHA:TS-1092|EMAPA:36554|galen:Urine|MESH:D014556|GAID:1189|BTO:0001419|UMLS:C0042036|MAT:0000058|MIAA:0000058|FMA:12274|OpenCyc:Mx4rvVjGppwpEbGdrcN5Y29ycA|MA:0002545,,Excretion that is the output of a kidney,,,,,urine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,UBERON:0001088,,,,,,,,,,,,,,,,,,,,kidney excreta from some taxa (e.g. in aves) may not be liquid,,urine,,,,,,,http://purl.obolibrary.org/obo/oae.owl|http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_27226,uric acid,,An oxopurine that is the final oxidation product of purine metabolism.,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,,,An oxopurine that is the final oxidation product of purine metabolism.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:27226,,,,,,,,,,,,,,,,,,,,,,uric acid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000634,signal transduction system,,"Signal transduction system is a subtype of pathway system.
This entity has sub-parts and has a goal of transmitting signals as a systemic context.",false,,,http://purl.obolibrary.org/obo/TXPO_0000603,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,,"Signal transduction system is a subtype of pathway system.
This entity has sub-parts and has a goal of transmitting signals as a systemic context.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000490|http://purl.obolibrary.org/obo/TXPO_0001828|http://purl.obolibrary.org/obo/TXPO_0001833,,,,,,,,,,,,,,,,,,,,,,TXPO:0000634,,,,,,,,,,,,,,,,,,,,,,signal transduction system,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000639,inflammatory cytokine gene expression [Cholestasis],,"Inflammatory cytokine gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature inflammatory cytokine gene product or products (proteins or RNA).
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002266|http://purl.obolibrary.org/obo/TXPO_0000034,,,,,,,,,,,,,,,,,,,,PMID:20303879,,"Inflammatory cytokine gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature inflammatory cytokine gene product or products (proteins or RNA).
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000639,,,,,,,,,,,,,,,,,,,,,,inflammatory cytokine gene expression [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000638,role related to decreasing amount,,,false,,,http://purl.obolibrary.org/obo/TXPO_0003712,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000638,,,,,,,,,,,,,,,,,,,,,,role related to decreasing amount,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000632,increasinging length of time,,Increasinging length of time is a subtype of changing length of time: A process that changes the length of time to be longer.,false,,,http://purl.obolibrary.org/obo/TXPO_0001505,,,,,,,,,,,,,,,,,,,,,,Increasinging length of time is a subtype of changing length of time: A process that changes the length of time to be longer.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000632,,,,,,,,,,,,,,,,,,,,,,increasinging length of time,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000635,Phospholipase family,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000635,,,,,,,,,,,,,,,,,,,,,,Phospholipase family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000630,negative regulation of phospholipase C mediated phosphatidylinositol degradation [Phospholipidosis],,"Negative regulation of phospholipase C mediated phosphatidylinositol is a subtype of negative regulation of phospholipase C mediated phospholipid degradation: A process that stops, prevents, or reduces the frequency, rate or extent of phospholipase C mediated phosphatidylinositol degradation.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000647|http://purl.obolibrary.org/obo/TXPO_0000440,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of phospholipase C mediated phosphatidylinositol is a subtype of negative regulation of phospholipase C mediated phospholipid degradation: A process that stops, prevents, or reduces the frequency, rate or extent of phospholipase C mediated phosphatidylinositol degradation.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000630,,,,,,,,,,,,,,,,,,,,,,negative regulation of phospholipase C mediated phosphatidylinositol degradation [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000636,hyperfunction of Kupffer cell differentiation [Phospholipidosis],,"Hyperfunction of Kupffer cell differentiation is a subtype of hyperfunction of cell differentiation: A process that performs an excesssive kupffer cell differentiation.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0003434,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of Kupffer cell differentiation is a subtype of hyperfunction of cell differentiation: A process that performs an excesssive kupffer cell differentiation.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000636,,,,,,,,,,,,,,,,,,,,,,hyperfunction of Kupffer cell differentiation [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000637,negative regulation of phopholipase C mediated phosphatidyliserine degradation [Phospholipidosis],,"Negative regulation of phopholipase C mediated phosphatidyliserine degradation is a subtype of negative regulation of phosphatidylserine degradation: A process that stops, prevents, or reduces the frequency, rate or extent of phopholipase C mediated phosphatidyliserine degradation.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000647|http://purl.obolibrary.org/obo/TXPO_0000628,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of phopholipase C mediated phosphatidyliserine degradation is a subtype of negative regulation of phosphatidylserine degradation: A process that stops, prevents, or reduces the frequency, rate or extent of phopholipase C mediated phosphatidyliserine degradation.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000637,,,,,,,,,,,,,,,,,,,,,,negative regulation of phopholipase C mediated phosphatidyliserine degradation [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000631,xenobiotics excretion,,"Removing xenobiotics is a subtype of taking process: A process that removes xenobiotics from an organ, tissue,  cell, organelle, or makes a clearance of it from the body.",false,,,http://purl.obolibrary.org/obo/TXPO_0000458,,,,,,,,,,,,,,,,,,,,,,"Removing xenobiotics is a subtype of taking process: A process that removes xenobiotics from an organ, tissue,  cell, organelle, or makes a clearance of it from the body.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000631,,,,,,,,,,,,,,,,,,,,,,xenobiotics excretion,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000633,increasing functional demand,,Increasing functional demand is a subtype of increasing quantity: A process changes the functional demand to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,Rubin　Pathology,,Increasing functional demand is a subtype of increasing quantity: A process changes the functional demand to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000633,,,,,,,,,,,,,,,,,,,,,,increasing functional demand,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100846,Akt3,RAC-gamma serine/threonine protein kinase|PKB gamma|RAC-PK-gamma|STK-2|protein kinase B gamma,,false,,,http://purl.obolibrary.org/obo/IMR_0000250,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,RAC-gamma serine/threonine protein kinase|PKB gamma|RAC-PK-gamma|STK-2|protein kinase B gamma,,,,,IMR:0100846,,,,,,,,,,,,,,,,,,,,,,Akt3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0003677,DNA binding,,Process of any molecular function by which a gene product interacts selectively and non-covalently with DNA (deoxyribonucleic acid).,false,,,http://purl.obolibrary.org/obo/GO_0005488,,,,,,,,,,,,,,,,,,,,GO:0003677,,Process of any molecular function by which a gene product interacts selectively and non-covalently with DNA (deoxyribonucleic acid).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0003677,,,,,,,,,,,,,,,,,,,,,,DNA binding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000870,NF1-B,Nuclear factor 1 B-type|TGGCA-binding protein|NF-I/B|CTF|NF1-B|Nuclear factor 1/B|CCAAT-box binding transcription factor|NFI-B,,false,,,http://purl.obolibrary.org/obo/IMR_0000409,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0010366,Nuclear factor 1 B-type|TGGCA-binding protein|NF-I/B|CTF|NF1-B|Nuclear factor 1/B|CCAAT-box binding transcription factor|NFI-B,,,,,IMR:0000870,,,,,,,,,,,,,,,,,,,,,,NF1-B,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004685,LDLRAD4 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:679578|NCBI-Mouse-GeneID:52662|NCBI-Human-GeneID:753,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004685,,,,,,,,,,,,,,,,,,,,,,LDLRAD4 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004680,Increasing KIAA0101 level,,Increasing KIAA0101 level is a subtype of increasing quantity: A process that changes the amount of KIAA0101 level to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing KIAA0101 level is a subtype of increasing quantity: A process that changes the amount of KIAA0101 level to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_1000520,,,,,,,,,,,,,,,,,,,TXPO:0004680,,,,,,,,,,,,,,,,,,,,,,Increasing KIAA0101 level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004688,LDLRAD4 gene promoter methylation,,The covalent transfer of a methyl group to LDLRAD4 gene promoter.,false,,,http://purl.obolibrary.org/obo/GO_0006306,,,,,,,,,,,,,,,,,,,,,,The covalent transfer of a methyl group to LDLRAD4 gene promoter.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004688,,,,,,,,,,,,,,,,,,,,,,LDLRAD4 gene promoter methylation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004682,KIAA0101 tv1 (predicted)(human) [hepatocarcinogenesis],KIAA0101 transcript variant 1,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_0004193,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:9768|PMID:28410205|PMID:22576474,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000009768,,,,,,,,KIAA0101 transcript variant 1,,,,,TXPO:0004682,,,,,,,,,,,,,,,,,,,,,,KIAA0101 tv1 (predicted)(human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004689,LDLRAD4 gene promoter methylation [hepatocarcinogenesis],,"The covalent transfer of a methyl group to LDLRAD4 gene promoter.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0004688|http://purl.obolibrary.org/obo/TXPO_0002340,,,,,,,,,,,,,,,,,,,,PMID:30690589,,"The covalent transfer of a methyl group to LDLRAD4 gene promoter.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004687,,,,,,http://purl.obolibrary.org/obo/TXPO_0004454,,,,,,http://purl.obolibrary.org/obo/TXPO_0004686,,,,,,,,,,,TXPO:0004689,,,,,,,,,,,,,,,,,,,,,,LDLRAD4 gene promoter methylation [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004684,Decreasing LDLRAD4 level,,Decreasing LDLRAD4 level is a subtype of decreasing quantity: A process that changes the amount of LDLRAD4 level to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000396,,,,,,,,,,,,,,,,,,,,,,Decreasing LDLRAD4 level is a subtype of decreasing quantity: A process that changes the amount of LDLRAD4 level to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004685,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004684,,,,,,,,,,,,,,,,,,,,,,Decreasing LDLRAD4 level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004683,negative regulation of signal transduction by p53 class mediator [hepatocarcinogenesis],,"Any process that stops, prevents or reduces the frequency, rate or extent of signal transduction by p53 class mediator.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/GO_1901797,,,,,,,,,,,,,,,,,,,,PMID:22576474,,"Any process that stops, prevents or reduces the frequency, rate or extent of signal transduction by p53 class mediator.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004800,http://purl.obolibrary.org/obo/TXPO_0004889,,,,,,http://purl.obolibrary.org/obo/TXPO_0004396,,,,,,,,,,,TXPO:0004683,,,,,,,,,,,,,,,,,,,,,,negative regulation of signal transduction by p53 class mediator [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004681,Increasing KIAA0101 tv1 level [hepatocarcinogenesis],,"Increasing KIAA0101 tv1 level is a subtype of increasing quantity: A process that changes the amount of KIAA0101 tv1 level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0004680|http://purl.obolibrary.org/obo/TXPO_0002340,,,,,,,,,,,,,,,,,,,,PMID:28410205|PMID:22576474,,"Increasing KIAA0101 tv1 level is a subtype of increasing quantity: A process that changes the amount of KIAA0101 tv1 level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004682,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004683|http://purl.obolibrary.org/obo/TXPO_0004404|http://purl.obolibrary.org/obo/TXPO_0004479|http://purl.obolibrary.org/obo/TXPO_0004518|http://purl.obolibrary.org/obo/TXPO_0004633,,,,,,,,,,,TXPO:0004681,,,,,,,,,,,,,,,,,,,,,,Increasing KIAA0101 tv1 level [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004686,Decreasing LDLRAD4 level [hepatocarcinogenesis],,"Decreasing LDLRAD4 level is a subtype of decreasing quantity: A process that changes the amount of LDLRAD4 level to be lower.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0004684|http://purl.obolibrary.org/obo/TXPO_0002340,,,,,,,,,,,,,,,,,,,,PMID:30690589,,"Decreasing LDLRAD4 level is a subtype of decreasing quantity: A process that changes the amount of LDLRAD4 level to be lower.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004687,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004588,,,,,,,,,,,TXPO:0004686,,,,,,,,,,,,,,,,,,,,,,Decreasing LDLRAD4 level [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004687,LDLRAD4 (rat) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004685|http://purl.obolibrary.org/obo/TXPO_0005070,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:679578|PMID:30690589,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004687,,,,,,,,,,,,,,,,,,,,,,LDLRAD4 (rat) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001603,Rab19,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001603,,,,,,,,,,,,,,,,,,,,,,Rab19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001304,negative regulation of glycerophospholipid degradation,,"Negative regulation of glycerophospholipid degradation is a subtype of negative regulation of phospholipid degradation: A process that stops, prevents, or reduces the frequency, rate or extent of glycerophospholipid degradation.",false,,,http://purl.obolibrary.org/obo/TXPO_0001256,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of glycerophospholipid degradation is a subtype of negative regulation of phospholipid degradation: A process that stops, prevents, or reduces the frequency, rate or extent of glycerophospholipid degradation.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001304,,,,,,,,,,,,,,,,,,,,,,negative regulation of glycerophospholipid degradation,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0046475,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001309,CD 36 activation,,CD36 activation is a subtype of molecular activation: A process that changes the activity of the CD36 to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000023,,,,,,,,,,,,,,,,,,,,PMID:17728375|PMID:27974793,,CD36 activation is a subtype of molecular activation: A process that changes the activity of the CD36 to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000899,,,,,,,,,,,TXPO:0001309,,,,,,,,,,,,,,,,,,,,,,CD 36 activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001306,ATF6 (ATF6-alpha) activates chaperone genes [ER stress - refolding],,"ATF6 (ATF6-alpha) activates chaperone genes is a subtype of molecular activation: A process that changes the activity of the molecule with chaperone role to be higher by ATF6.
This process is dependent on the refolding and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0003736|http://purl.obolibrary.org/obo/TXPO_0000583,,,,,,,,,,,,,,,,,,,,,,"ATF6 (ATF6-alpha) activates chaperone genes is a subtype of molecular activation: A process that changes the activity of the molecule with chaperone role to be higher by ATF6.
This process is dependent on the refolding and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002899,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001306,,,,,,,,,,,,,,,,,,,,,,ATF6 (ATF6-alpha) activates chaperone genes [ER stress - refolding],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001302,hyperfunction of reduction of NAD(+) to NADH,,Hyperfunction of reduction of NAD(+) to NADH is a subtype of hyperfunction of reduction: A process that performs an excesssive reduction of NAD(+) to NADH.,false,,,http://purl.obolibrary.org/obo/TXPO_0002058,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of reduction of NAD(+) to NADH is a subtype of hyperfunction of reduction: A process that performs an excesssive reduction of NAD(+) to NADH.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001302,,,,,,,,,,,,,,,,,,,,,,hyperfunction of reduction of NAD(+) to NADH,,,,,,http://purl.obolibrary.org/obo/GO_0006735,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001303,PLB,,,false,,,http://purl.obolibrary.org/obo/TXPO_0000635,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003671,,,,,,,,,,TXPO:0001303,,,,,,,,,,,,,,,,,,,,,,PLB,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001301,SCD (canonical)[lipidosis],Stearoyl-CoA Desaturase [lipidosis],,false,,,http://purl.obolibrary.org/obo/TXPO_0003516|http://purl.obolibrary.org/obo/TXPO_0000587,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:6319|PMID:4382040|PMID:21045174|PMID:26519296|PMID:19850634,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000006319,,,http://purl.obolibrary.org/obo/TXPO_0003329,,,,,Stearoyl-CoA Desaturase [lipidosis],,,,,TXPO:0001301,,,,,,,,,,,,,,,,,,,,,,SCD (canonical)[lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001300,refolding promoting gene expression,,Refolding promoting gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature refolding inducing gene product or products (proteins or RNA) .,false,,,http://purl.obolibrary.org/obo/GO_0010467,,,,,,,,,,,,,,,,,,,,,,Refolding promoting gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature refolding inducing gene product or products (proteins or RNA) .,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001300,,,,,,,,,,,,,,,,,,,,,,refolding promoting gene expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001305,acetyl CoA increase [Fibrosis],,"Increasing acetyl CoA is a subtype of increasing quantity: A process that changes the amount of acetyl CoA to be larger.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003742|http://purl.obolibrary.org/obo/TXPO_0000088,,,,,,,,,,,,,,,,,,,,,,"Increasing acetyl CoA is a subtype of increasing quantity: A process that changes the amount of acetyl CoA to be larger.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001310,,,,,,,,,,,TXPO:0001305,,,,,,,,,,,,,,,,,,,,,,acetyl CoA increase [Fibrosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001307,choline transmembrane transporter,,A role played by the entity which enables the transfer of choline from one side of a membrane to the other. Choline (2-hydroxyethyltrimethylammonium) is an amino alcohol that occurs widely in living organisms as a constituent of certain types of phospholipids and in the neurotransmitter acetylcholine.|related molecular function GO:0015220,false,,,http://purl.obolibrary.org/obo/TXPO_0003698,,,,,,,,,,,,,,,,,,,,,,A role played by the entity which enables the transfer of choline from one side of a membrane to the other. Choline (2-hydroxyethyltrimethylammonium) is an amino alcohol that occurs widely in living organisms as a constituent of certain types of phospholipids and in the neurotransmitter acetylcholine.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001307,,,,,,,,,,,,,,,,,,,,related molecular function GO:0015220,,choline transmembrane transporter,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001308,Lgpat1,,,false,,,http://purl.obolibrary.org/obo/TXPO_0000740,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001308,,,,,,,,,,,,,,,,,,,,,,Lgpat1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_16337,phosphatidic acid,,"A derivative of glycerol in which one hydroxy group, commonly but not necessarily primary, is esterified with phosphoric acid and the other two are esterified with fatty acids.",false,,,http://purl.obolibrary.org/obo/CHEBI_37739,,,,,,,,,,,,,,,,,,,,,,"A derivative of glycerol in which one hydroxy group, commonly but not necessarily primary, is esterified with phosphoric acid and the other two are esterified with fatty acids.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:16337,,,,,,,,,,,,,,,,,,,,,,phosphatidic acid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_63951,estrogen receptor agonist,,An agonist at the estrogen receptor.,false,,,http://purl.obolibrary.org/obo/CHEBI_48705,,,,,,,,,,,,,,,,,,,,,,An agonist at the estrogen receptor.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:63951,,,,,,,,,,,,,,,,,,,,,,estrogen receptor agonist,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100304,caspase-4,,,false,,,http://purl.obolibrary.org/obo/IMR_0000305,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100304,,,,,,,,,,,,,,,,,,,,,,caspase-4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010462,60S ribosomal protein L11,,,false,,,http://purl.obolibrary.org/obo/IMR_0000897,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0010462,,,,,,,,,,,,,,,,,,,,,,60S ribosomal protein L11,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000257,GSK3,glycogen synthase kinase 3,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,GO:0004696,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001966,,,,,glycogen synthase kinase 3,,,,,IMR:0000257,,,,,,,,,,,,,,,,,,,,,,GSK3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100456,MKK3,MAPKK 3|MAPK/ERK kinase 3|MAP kinase kinase 3,,false,,,http://purl.obolibrary.org/obo/IMR_0000263,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MAPKK 3|MAPK/ERK kinase 3|MAP kinase kinase 3,,,,,IMR:0100456,,,,,,,,,,,,,,,,,,,,,,MKK3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0002530,gland,glandular organ,An organ that functions as a secretory or excretory organ,false,,,http://purl.obolibrary.org/obo/UBERON_0000062,,,,,,,,,,,,,,,,,,,,UMLS:C1285092|NCIT:C13319|FMA:7146,,An organ that functions as a secretory or excretory organ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,glandular organ,,,,,UBERON:0002530,,,,,,,,,,,,,,,,,,,,,,gland,,,,http://upload.wikimedia.org/wikipedia/commons/a/a1/Gray1026.png,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000050,type II cytokeratin,neutral to basic cytokeratin,,false,,,http://purl.obolibrary.org/obo/IMR_0000202,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,neutral to basic cytokeratin,,,,,IMR:0000050,,,,,,,,,,,,,,,,,,,,,,type II cytokeratin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001411,Gab2,Grb2-associated binder 2,,false,,,http://purl.obolibrary.org/obo/IMR_0001409,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Grb2-associated binder 2,,,,,IMR:0001411,,,,,,,,,,,,,,,,,,,,,,Gab2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0043473,accumulation of pigments,,"The aggregation of coloring matter in a particular location in an organism, tissue or cell, occurring in response to some external stimulus.",false,,,http://purl.obolibrary.org/obo/TXPO_0000247,,,,,,,,,,,,,,,,,,,,,,"The aggregation of coloring matter in a particular location in an organism, tissue or cell, occurring in response to some external stimulus.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0048770,,,,,,,,,,,,,,,,,,,,,,,GO:0043473,,,,,,,,,,,,,,,,,,,,,,accumulation of pigments,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010453,NELF-E,RD protein|Negative elongation factor E,,false,,,http://purl.obolibrary.org/obo/IMR_0010013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,RD protein|Negative elongation factor E,,,,,IMR:0010453,,,,,,,,,,,,,,,,,,,,,,NELF-E,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/NCBITaxon_2759,Eukaryota,eucaryotes|eukaryotes,,false,,,http://purl.obolibrary.org/obo/OBI_0100026,,,,,,,,,,,,,,,,,,,,PMID:23020233,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,eucaryotes|eukaryotes,,,,,NCBITaxon:2759,,,,,,,,,,,,,,,,,,,,,,Eukaryota,,,,,,,http://purl.obolibrary.org/obo/ncbitaxon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004535,ERK signaling (primitive),,ERK signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by ERK.,false,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,,,ERK signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by ERK.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004534,,,,,,,,,,,,,,,,TXPO:0004535,,,,,,,,,,,,,,,,,,,,,,ERK signaling (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004532,negative regulation of EPCR signaling,,"Any process that stops, prevents, or reduces the frequency, rate or extent of EPCR signaling, a series of reactions mediated by EPCR.",false,,,http://purl.obolibrary.org/obo/GO_0023057,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents, or reduces the frequency, rate or extent of EPCR signaling, a series of reactions mediated by EPCR.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004532,,,,,,,,,,,,,,,,,,,,,,negative regulation of EPCR signaling,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004531|http://purl.obolibrary.org/obo/TXPO_0004530,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004531,EPCR signaling (primitive),,EPCR signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by EPCR.,false,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,,,EPCR signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by EPCR.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004530,,,,,,,,,,,,,,,,TXPO:0004531,,,,,,,,,,,,,,,,,,,,,,EPCR signaling (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004537,pentadecafluorooctanoic acid,perfluorooctanoate|Perfluorooctanoic acid|PFOA,A fluoroalkanoic acid that is perfluorinated octanoic acid.,false,,,http://purl.obolibrary.org/obo/TXPO_0004455|http://purl.obolibrary.org/obo/CHEBI_35549,,,,,,,,,,,,,,,,,,,,Wikipedia:Perfluorooctanoic_acid|CAS:335-67-1,,A fluoroalkanoic acid that is perfluorinated octanoic acid.,,,,,,,,,,,,C8HF15O2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,perfluorooctanoate|Perfluorooctanoic acid|PFOA,,,,,TXPO:0004537,,,,,,,,,,,,,,,,,,,,,,pentadecafluorooctanoic acid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,OC(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F,,,,,
http://purl.obolibrary.org/obo/TXPO_0004536,ERK signaling (primitive) [hepatocarcinogenesis],,"ERK signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by ERK.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0004535|http://purl.obolibrary.org/obo/TXPO_0002340,,,,,,,,,,,,,,,,,,,,PMID:19440492,,"ERK signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by ERK.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004537,http://purl.obolibrary.org/obo/TXPO_0004534,,,,,http://purl.obolibrary.org/obo/TXPO_0004538,,,,,,,,,,,TXPO:0004536,,,,,,,,,,,,,,,,,,,,,,ERK signaling (primitive) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004533,PROCR (rat) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0005128|http://purl.obolibrary.org/obo/TXPO_0005070,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:362248|PMID:30690589,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004533,,,,,,,,,,,,,,,,,,,,,,PROCR (rat) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004534,ERK signal transduction pathway,,A series of molecular signals mediated by ERK (extracellular receptor kinase).,false,,,http://purl.obolibrary.org/obo/TXPO_0000609,,,,,,,,,,,,,,,,,,,,,,A series of molecular signals mediated by ERK (extracellular receptor kinase).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004534,,,,,,,,,,,,,,,,,,,,,,ERK signal transduction pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004539,Grp78 signal (primitive),,Grp78 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by Grp78.,false,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,,,Grp78 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by Grp78.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001002,http://purl.obolibrary.org/obo/TXPO_0004540,,,,,,,,,,,,,,,,TXPO:0004539,,,,,,,,,,,,,,,,,,,,,,Grp78 signal (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004538,negative regulation of gap-junctional intercellular communication [hepatocarcinogenesis],PMID:19440492|negative regulation of GJIC,"Negative regulation of gap-junctional intercellular communication is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of gap-junctional intercellular communication.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004572,,,,,,,,,,,,,,,,,,,,PMID:12717835,,"Negative regulation of gap-junctional intercellular communication is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of gap-junctional intercellular communication.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004392,,,,,,PMID:19440492|negative regulation of GJIC,,,,,TXPO:0004538,,,,,,,,,,,,,,,,,,,,,,negative regulation of gap-junctional intercellular communication [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004530,EPCR signal transduction pathway,,A series of molecular signals mediated by EPCR (Endothelial protein C receptor).,false,,,http://purl.obolibrary.org/obo/TXPO_0000609,,,,,,,,,,,,,,,,,,,,,,A series of molecular signals mediated by EPCR (Endothelial protein C receptor).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004530,,,,,,,,,,,,,,,,,,,,,,EPCR signal transduction pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000643,Integrin beta-3,,,false,,,http://purl.obolibrary.org/obo/IMR_0000174,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000643,,,,,,,,,,,,,,,,,,,,,,Integrin beta-3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010481,60S ribosomal protein L30,,,false,,,http://purl.obolibrary.org/obo/IMR_0000897,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0010481,,,,,,,,,,,,,,,,,,,,,,60S ribosomal protein L30,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001034,group IID secretory phospholipase A2,,,false,,,http://purl.obolibrary.org/obo/IMR_0000283,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001034,,,,,,,,,,,,,,,,,,,,,,group IID secretory phospholipase A2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001114,exportin 5,,,false,,,http://purl.obolibrary.org/obo/IMR_0100015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001114,,,,,,,,,,,,,,,,,,,,,,exportin 5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0055037,recycling endosome,endosome recycling compartment|ERC|endosomal recycling compartment,"An organelle consisting of a network of tubules that functions in targeting molecules, such as receptors transporters and lipids, to the plasma membrane.",false,,,http://purl.obolibrary.org/obo/GO_0005768,,,,,,,,,,,,,,,,,,,,,,"An organelle consisting of a network of tubules that functions in targeting molecules, such as receptors transporters and lipids, to the plasma membrane.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,endosomal recycling compartment,,endosome recycling compartment|ERC,,,GO:0055037,,,,,,,,,,,,,,,,,,,,,,recycling endosome,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0002576,"inositol 1,4,5-trisphosphate 3-kinase","IP(3)K|IP3K|IP3-3K|IP(3) 3-kinase|Ins(1,4,5)P3 3-kinase|IP3 3-kinase","Ins(1,4,5)P3 3-kinases (IP3-3K) are the enzymes responsible for the ATP-dependent conversion of Ins(1,4,5)P3 to Ins(1,3,4,5)P4. Three mammalian isoforms of this enzyme have so far been isolated and designated the A, B and C isoforms.",false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,GO:0008440,,"Ins(1,4,5)P3 3-kinases (IP3-3K) are the enzymes responsible for the ATP-dependent conversion of Ins(1,4,5)P3 to Ins(1,3,4,5)P4. Three mammalian isoforms of this enzyme have so far been isolated and designated the A, B and C isoforms.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"IP(3)K|IP3K|IP3-3K|IP(3) 3-kinase|Ins(1,4,5)P3 3-kinase|IP3 3-kinase",,,,,IMR:0002576,,,,,,,,,,,,,,,,,,,,,,"inositol 1,4,5-trisphosphate 3-kinase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_50249,anticoagulant,anticoagulante|anticoagulants,An agent that prevents blood clotting.,false,,,http://purl.obolibrary.org/obo/CHEBI_50248,,,,,,,,,,,,,,,,,,,,,,An agent that prevents blood clotting.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,anticoagulante|anticoagulants,,,,,,,,,,,,,,,,,,,,,CHEBI:50249,,,,anticoagulant,,CHEBI:50249,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_50183,P450 inhibitor,CYP2D6 inhbitor|P450 inhibitors|CYP2D6 inhbitors|cytochrome P450 inhibitor|cytochrome P450 inhibitors,An enzyme inhibitor that interferes with the activity of cytochrome P450 involved in catalysis of organic substances.,false,,,http://purl.obolibrary.org/obo/CHEBI_76898|http://purl.obolibrary.org/obo/CHEBI_76725,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001758,,,,,,,,,,,,,,,An enzyme inhibitor that interferes with the activity of cytochrome P450 involved in catalysis of organic substances.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CYP2D6 inhbitor|P450 inhibitors|CYP2D6 inhbitors|cytochrome P450 inhibitor|cytochrome P450 inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:50183,,,,P450 inhibitor,,CHEBI:50183,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001446,sphingomyelinase gene mutation [Niemann Pick Disease Type A/ B],,"Sphingomyelinase gene mutation is a subtype of phopholipase gene mutation: A process that changes the sequence of a sphingomyelinase gene.
This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type A/ B.",false,,,http://purl.obolibrary.org/obo/TXPO_0003635|http://purl.obolibrary.org/obo/TXPO_0001688,,,,,,,,,,,,,,,,,,,,,,"Sphingomyelinase gene mutation is a subtype of phopholipase gene mutation: A process that changes the sequence of a sphingomyelinase gene.
This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type A/ B.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003469,,,,,,http://purl.obolibrary.org/obo/TXPO_0001475|http://purl.obolibrary.org/obo/TXPO_0004141,,,,,,,,,,,TXPO:0001446,,,,,,,,,,,,,,,,,,,,,,sphingomyelinase gene mutation [Niemann Pick Disease Type A/ B],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001448,dysfunction of phospholipid degradation [Phospholipidosis],,"Dysfunction of phospholipid degradation is a subtype of dysfunctioning: A process that performs an abnormal and incomplete phospholipid degradation.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001447|http://purl.obolibrary.org/obo/TXPO_0000925,,,,,,,,,,,,,,,,,,,,,,"Dysfunction of phospholipid degradation is a subtype of dysfunctioning: A process that performs an abnormal and incomplete phospholipid degradation.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000775|http://purl.obolibrary.org/obo/TXPO_0001804,,,,,,http://purl.obolibrary.org/obo/TXPO_0001778,,,,,,,,,,,TXPO:0001448,,,,,,,,,,,,,,,,,,,,,,dysfunction of phospholipid degradation [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001442,in vitro (human) 24hr,,,false,,,http://purl.obolibrary.org/obo/TXPO_0000795,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001442,,,,,,,,,,,,,,,,,,,,,,in vitro (human) 24hr,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001441,genetic defect,,Genetic defect is a subtype of structural defect: A process  in which a part of a chromosome or a sequence of DNA is lost during DNA replication.,false,,,http://purl.obolibrary.org/obo/TXPO_0001440,,,,,,,,,,,,,,,,,,,,wikipedia: Deletion_(genetics),,Genetic defect is a subtype of structural defect: A process  in which a part of a chromosome or a sequence of DNA is lost during DNA replication.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001441,,,,,,,,,,,,,,,,,,,,,,genetic defect,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001443,ABCA1 (mol),ATP Binding Cassette Subfamily A Member 1,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:19|OMIM:600046,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ATP Binding Cassette Subfamily A Member 1,,,,,TXPO:0001443,,,,,,,,,,,,,,,,,,,,,,ABCA1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001444,phopholipase gene mutation,,Phopholipase gene mutation is a subtype of gene mutation: A process thatchanges the sequence of a phospholipase gene.,false,,,http://purl.obolibrary.org/obo/TXPO_0001985,,,,,,,,,,,,,,,,,,,,,,Phopholipase gene mutation is a subtype of gene mutation: A process thatchanges the sequence of a phospholipase gene.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001444,,,,,,,,,,,,,,,,,,,,,,phopholipase gene mutation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001447,dysfunction of phospholipid degradation,,Dysfunction of phospholipid degradation is a subtype of dysfunctioning: A process that performs an abnormal and incomplete phospholipid degradation.,false,,,http://purl.obolibrary.org/obo/TXPO_0001741,,,,,,,,,,,,,,,,,,,,,,Dysfunction of phospholipid degradation is a subtype of dysfunctioning: A process that performs an abnormal and incomplete phospholipid degradation.,,,http://purl.obolibrary.org/obo/GO_0009395,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_16247,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001447,,,,,,,,,,,,,,,,,,,,,,dysfunction of phospholipid degradation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001449,cell rupture [Cell death],,"Cell rupture is the tearing apart of a cell.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0001727|http://purl.obolibrary.org/obo/TXPO_0001651,,,,,,,,,,,,,,,,,,,,,,"Cell rupture is the tearing apart of a cell.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000527,,,,,,,,,,,TXPO:0001449,,,,,,,,,,,,,,,,,,,,,,cell rupture [Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001440,loss of structure,,Loss of structure is a subtype of changing structure: A process that lacks the structure or decreases structural parts.,false,,,http://purl.obolibrary.org/obo/TXPO_0002566,,,,,,,,,,,,,,,,,,,,,,Loss of structure is a subtype of changing structure: A process that lacks the structure or decreases structural parts.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001440,,,,,,,,,,,,,,,,,,,,,,loss of structure,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001445,sphingomyelinase gene mutation,,Sphingomyelinase gene mutation is a subtype of phopholipase gene mutation: A process that changes the sequence of a sphingomyelinase gene.,false,,,http://purl.obolibrary.org/obo/TXPO_0001444,,,,,,,,,,,,,,,,,,,,,,Sphingomyelinase gene mutation is a subtype of phopholipase gene mutation: A process that changes the sequence of a sphingomyelinase gene.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001445,,,,,,,,,,,,,,,,,,,,,,sphingomyelinase gene mutation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/NCIT_C16702,hydrolysis,,A chemical reaction that uses water to break down a compound.,false,,,http://purl.obolibrary.org/obo/TXPO_0000185,,,,,,,,,,,,,,,,,,,,,,A chemical reaction that uses water to break down a compound.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,NCIT:C16702,,,,,,,,,,,,,,,,,,,,,,hydrolysis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0011352,NELF-C/D protein,Negative elongation factor C/D|HSPC130|TH1-like protein|NELF-C/D,,false,,,http://purl.obolibrary.org/obo/IMR_0010013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Negative elongation factor C/D|HSPC130|TH1-like protein|NELF-C/D,,,,,IMR:0011352,,,,,,,,,,,,,,,,,,,,,,NELF-C/D protein,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010486,60S ribosomal protein L36,Q9Y3U8,,false,,,http://purl.obolibrary.org/obo/IMR_0000897,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Q9Y3U8,,,,,IMR:0010486,,,,,,,,,,,,,,,,,,,,,,60S ribosomal protein L36,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000107,IL-4 receptor,interleukin-4 receptor,,false,,,http://purl.obolibrary.org/obo/IMR_0000096,,,,,,,,,,,,,,,,,,,,GO:0004913,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,interleukin-4 receptor,,,,,IMR:0000107,,,,,,,,,,,,,,,,,,,,,,IL-4 receptor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_36314,glycerophosphoethanolamine,,,false,,,http://purl.obolibrary.org/obo/CHEBI_37739|http://purl.obolibrary.org/obo/CHEBI_36711,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:36314,,,,,,,,,,,,,,,,,,,,,,glycerophosphoethanolamine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003979,AMPK activation (sustained) [Ground glass appearance],,"AMPK activation is a subtype of molecular activation: A process that changes the activity of the AMPK (AMP-activated protein kinase) to be higher. This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) .",false,,,http://purl.obolibrary.org/obo/TXPO_0000405|http://purl.obolibrary.org/obo/TXPO_0003921,,,,,,,,,,,,,,,,,,,,PMID:25500869|PMID:25956158,,"AMPK activation is a subtype of molecular activation: A process that changes the activity of the AMPK (AMP-activated protein kinase) to be higher. This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) .",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003922,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000944,,,,http://purl.obolibrary.org/obo/TXPO_0003948,,http://purl.obolibrary.org/obo/TXPO_0003980,,,,,,http://purl.obolibrary.org/obo/TXPO_0001028,,,,,,,,,,,TXPO:0003979,,,,,,,"AMPK is sensitive to energy charge, which is activated by an increase in the ratio of AMP/ATP.",,,,,,,,,,,,,,,AMPK activation (sustained) [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003971,ACC1 (canonical)[Ground glass appearance],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003970|http://purl.obolibrary.org/obo/TXPO_0000472,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:31|NCBI-Mouse-GeneID:107476|NCBI-Rat-GeneID:60581|MeSH:C000588423,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003973,,,,,,,,,,TXPO:0003971,,,,,,,,,,,,,,,,,,,,,,ACC1 (canonical)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003977,CAR - gluconeogenic inhibitor (canonical)[Ground glass appearance],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003791,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003929,,,,,,,,,,TXPO:0003977,,,,,,,,,,,,,,,,,,,,,,CAR - gluconeogenic inhibitor (canonical)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003973,fatty acid synthesis positive regulator role,,A role played by the entity which positively regulates the formation of fatty acid.,false,,,http://purl.obolibrary.org/obo/TXPO_0003967,,,,,,,,,,,,,,,,,,,,,,A role played by the entity which positively regulates the formation of fatty acid.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003973,,,,,,,,,,,,,,,,,,,,,,fatty acid synthesis positive regulator role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003975,ACC2 (canonical)[Ground glass appearance],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003974|http://purl.obolibrary.org/obo/TXPO_0000472,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:116719|NCBI-Human-GeneID:32|NCBI-Mouse-GeneID:100705,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003973,,,,,,,,,,TXPO:0003975,,,,,,,,,,,,,,,,,,,,,,ACC2 (canonical)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003970,ACC (mol),,"Acetyl-CoA carboxylase (ACC) is a complex multifunctional enzyme system. ACC is a biotin-containing enzyme which catalyzes the carboxylation of acetyl-CoA to malonyl-CoA, the rate-limiting step in fatty acid synthesis. There are two ACC forms, alpha and beta, encoded by two different genes. ACC-alpha is highly enriched in lipogenic tissues. The enzyme is under long term control at the transcriptional and translational levels and under short term regulation by the phosphorylation/dephosphorylation of targeted serine residues and by allosteric transformation by citrate or palmitoyl-CoA. Multiple alternatively spliced transcript variants divergent in the 5' sequence and encoding distinct isoforms have been found for this gene. [provided by RefSeq, Jul 2008]",false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:107476|NCBI-Rat-GeneID:60581|NCBI-Human-GeneID:31,,"Acetyl-CoA carboxylase (ACC) is a complex multifunctional enzyme system. ACC is a biotin-containing enzyme which catalyzes the carboxylation of acetyl-CoA to malonyl-CoA, the rate-limiting step in fatty acid synthesis. There are two ACC forms, alpha and beta, encoded by two different genes. ACC-alpha is highly enriched in lipogenic tissues. The enzyme is under long term control at the transcriptional and translational levels and under short term regulation by the phosphorylation/dephosphorylation of targeted serine residues and by allosteric transformation by citrate or palmitoyl-CoA. Multiple alternatively spliced transcript variants divergent in the 5' sequence and encoding distinct isoforms have been found for this gene. [provided by RefSeq, Jul 2008]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003970,,,,,,,,,,,,,,,,,,,,,,ACC (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003978,negative regulation of ATP consuming,,"Negative regulation of ATP consuming is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of ATP consuming.",false,,,http://purl.obolibrary.org/obo/TXPO_0000369,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of ATP consuming is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of ATP consuming.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003978,,,,,,,,,,,,,,,,,,,,,,negative regulation of ATP consuming,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001165,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003976,ACC2 - inactive form (canonical)[Ground glass appearance],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003975,,,,,,,,,,,,,,,,,,,,ISBN:0071769234,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0002355,,,,,,,,,,,,,,TXPO:0003976,,,,,,,,,,,,,,,,,,,,,,ACC2 - inactive form (canonical)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003974,ACACB (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003974,,,,,,,,,,,,,,,,,,,,,,ACACB (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003972,ACC1 - inactive form (canonical)[Ground glass appearance],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003971,,,,,,,,,,,,,,,,,,,,ISBN:0071769234,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0002355,,,,,,,,,,,,,,TXPO:0003972,,,,,,,,,,,,,,,,,,,,,,ACC1 - inactive form (canonical)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0001429,acidic,,An medium acidity quality inhering in a solution by virtue of the bearer's a high concentration of H+ ions.,false,,,http://purl.obolibrary.org/obo/PATO_0001842,,,,,,,,,,,,,,,,,,,,,,An medium acidity quality inhering in a solution by virtue of the bearer's a high concentration of H+ ions.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0001429,,,,,,,,,,,,,,,,,,,,,,acidic,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0001421,alive,,,false,,,http://purl.obolibrary.org/obo/PATO_0000169,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0001421,,,,,,,,,,,,,,,,,,,,,,alive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0001422,dead,,A viability quality inhering in a bearer by virtue of the cessation of the bearer's life.,false,,,http://purl.obolibrary.org/obo/PATO_0000169,,,,,,,,,,,,,,,,,,,,,,A viability quality inhering in a bearer by virtue of the cessation of the bearer's life.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0001422,,,,,,,,,,,,,,,,,,,,,,dead,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_5001,fenofibrate,propan-2-yl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate,A chlorobenzophenone that is (4-chlorophenyl)(phenyl)methanone substituted by a [2-methyl-1-oxo-1-(propan-2-yloxy)propan-2-yl]oxy group at position 1 on the phenyl ring.,false,,,http://purl.obolibrary.org/obo/TXPO_1000442,,,,,,,,,,,,,,,,,,,,LINCS:LSM-3107,,A chlorobenzophenone that is (4-chlorophenyl)(phenyl)methanone substituted by a [2-methyl-1-oxo-1-(propan-2-yloxy)propan-2-yl]oxy group at position 1 on the phenyl ring.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,propan-2-yl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate,,,,,CHEBI:5001,,,,,,,,,,,,,,,,,,,,,,fenofibrate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1,,,,,
http://purl.obolibrary.org/obo/CHEBI_5004,fenoprofen,(+-)-2-(3-phenoxyphenyl)propionic acid|fenoprofen|2-(m-phenoxyphenyl)propionic acid|fenoprofene|fenoprofeno|2-(3-phenoxyphenyl)propionic acid|alpha-(m-phenoxyphenyl)propionic acid|fenoprofenum|(+-)-m-phenoxyhydratropic acid|alpha-methyl-3-phenoxybenzeneacetic acid|Fenoprofen|FENOPROFEN|2-(3-phenoxyphenyl)propanoic acid,"A monocarboxylic acid that is propanoic acid in which one of the hydrogens at position 2 is substituted by a 3-phenoxyphenyl group. A non-steroidal anti-inflammatory drug, the dihydrate form of the calcium salt is used for the management of mild to moderate pain and for the relief of pain and inflammation associated with  disorders such as arthritis. It is pharmacologically similar to aspirin, but causes less gastrointestinal bleeding.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:21328296|PMID:25554116|PMID:21342694|PMID:28166217|PMID:30168706|CAS:31879-05-7|Drug_Central:1154|PMID:4616811|DrugBank:DB00573|Reaxys:2118687,,"A monocarboxylic acid that is propanoic acid in which one of the hydrogens at position 2 is substituted by a 3-phenoxyphenyl group. A non-steroidal anti-inflammatory drug, the dihydrate form of the calcium salt is used for the management of mild to moderate pain and for the relief of pain and inflammation associated with  disorders such as arthritis. It is pharmacologically similar to aspirin, but causes less gastrointestinal bleeding.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35493|http://purl.obolibrary.org/obo/CHEBI_50629|http://purl.obolibrary.org/obo/CHEBI_35475|http://purl.obolibrary.org/obo/CHEBI_88188|http://purl.obolibrary.org/obo/CHEBI_35481|http://purl.obolibrary.org/obo/CHEBI_50630,,,,,Fenoprofen|FENOPROFEN|2-(3-phenoxyphenyl)propanoic acid,,(+-)-2-(3-phenoxyphenyl)propionic acid|fenoprofen|2-(m-phenoxyphenyl)propionic acid|fenoprofene|fenoprofeno|2-(3-phenoxyphenyl)propionic acid|alpha-(m-phenoxyphenyl)propionic acid|fenoprofenum|(+-)-m-phenoxyhydratropic acid|alpha-methyl-3-phenoxybenzeneacetic acid,,,,,,,,,,,,,,,,,,,,,CHEBI:5004,,,,fenoprofen,,CHEBI:5004,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000801,DNAJB9 - chaperone -vitro (human)[ER stress],ERDJ4,,false,,,http://purl.obolibrary.org/obo/TXPO_0002165,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:4189|https://omim.org/entry/602634,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ERDJ4,,,,,TXPO:0000801,,,,,,,,,,,,,,,,,,,,,,DNAJB9 - chaperone -vitro (human)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000795,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000809,insulin resistance [NASH],,"Insulin resistance (process) is a subtype of decreasing sensitivity: A process that changes the sensitivity to the circulating insulin to be lower.
This entity is a specific course-dependent process. This process can constitute the course of NASH.",false,,,http://purl.obolibrary.org/obo/TXPO_0003496,,,,,,,,,,,,,,,,,,,,PMID:26006114,,"Insulin resistance (process) is a subtype of decreasing sensitivity: A process that changes the sensitivity to the circulating insulin to be lower.
This entity is a specific course-dependent process. This process can constitute the course of NASH.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001095,,,,,,,,,,,TXPO:0000809,,,,,,,,,,,,,,,,,,,,,,insulin resistance [NASH],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000806,GFPT1 (human)[ER stress],,IRE1->Xbp1->GFPT1 reactome,false,,,http://purl.obolibrary.org/obo/TXPO_0000793|http://purl.obolibrary.org/obo/TXPO_1000166,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:2673|PMID:27255611,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000002673,,,,,,,,,,,,,TXPO:0000806,,,,,,,,,,,,,,,,,,,,IRE1->Xbp1->GFPT1 reactome,,GFPT1 (human)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000795,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000804,aldehyde-lyase,aldolase,"A role played by molecules that catalysis of the cleavage of a C-C bond in a molecule containing a hydroxyl group and a carbonyl group to form two smaller molecules, each being an aldehyde or a ketone.",false,,,http://purl.obolibrary.org/obo/TXPO_0000308,,,,,,,,,,,,,,,,,,,,,,"A role played by molecules that catalysis of the cleavage of a C-C bond in a molecule containing a hydroxyl group and a carbonyl group to form two smaller molecules, each being an aldehyde or a ketone.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000804,,,,,,,,,,,,,,,,aldolase,,,,,,aldehyde-lyase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000803,increasing demand for drug metabolism [Ground glass appearance],,"Increasing demand for drug metabolism is a subtype of increasing functional demand: A process changes the functional demand for the for drug metabolism to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/TXPO_0000789,,,,,,,,,,,,,,,,,,,,,,"Increasing demand for drug metabolism is a subtype of increasing functional demand: A process changes the functional demand for the for drug metabolism to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000803,,,,,,,,,,,,,,,,,,,,,,increasing demand for drug metabolism [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000807,CHAC1 (human)[ER stress],,"This gene encodes a member of the gamma-glutamylcyclotransferase family of proteins. The encoded protein has been shown to promote neuronal differentiation by deglycination of the Notch receptor, which prevents receptor maturation and inhibits Notch signaling. This protein may also play a role in the unfolded protein response, and in regulation of glutathione levels and oxidative balance in the cell. Elevated expression of this gene may indicate increased risk of cancer recurrence among breast and ovarian cancer patients. [provided by RefSeq, Sep 2016]",false,,,http://purl.obolibrary.org/obo/TXPO_0000793|http://purl.obolibrary.org/obo/TXPO_1000066,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCBIGene_79094|NCBI-Human-GeneID:79094|PMID:19109178|PMID:23070364|PMID:25931127,,"This gene encodes a member of the gamma-glutamylcyclotransferase family of proteins. The encoded protein has been shown to promote neuronal differentiation by deglycination of the Notch receptor, which prevents receptor maturation and inhibits Notch signaling. This protein may also play a role in the unfolded protein response, and in regulation of glutathione levels and oxidative balance in the cell. Elevated expression of this gene may indicate increased risk of cancer recurrence among breast and ovarian cancer patients. [provided by RefSeq, Sep 2016]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000079094,,,http://purl.obolibrary.org/obo/CHEBI_68495,,,,,,,,,,TXPO:0000807,,,,,,,,,,,,,,,,,,,,,,CHAC1 (human)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000805,ERO1LB (human)[ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000793|http://purl.obolibrary.org/obo/TXPO_1000126,,,,,,,,,,,,,,,,,,,,https://omim.org/entry/615437|http://www.uniprot.org/uniprot/Q86YB8#function|PMID:10818100|PMID:23334697|PMID:21091435|PMID:24469402,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000805,,,,,,,,,,,,,,,,,,,,,,ERO1LB (human)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000795,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000802,HSP90B1 (human)[ER stress],GRP94 [ER stress],,false,,,http://purl.obolibrary.org/obo/TXPO_0000793|http://purl.obolibrary.org/obo/TXPO_1000171,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:7184|PMID:23334697,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000007184,,,http://purl.obolibrary.org/obo/TXPO_0003997,,,,,GRP94 [ER stress],,,,,TXPO:0000802,,,,,,,,,,,,,,,,,,,,,,HSP90B1 (human)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000800,HYOU1 (human)[ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000793|http://purl.obolibrary.org/obo/TXPO_1000191,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:10525|R-HSA-1791066.1|https://omim.org/entry/601746,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000010525,,,http://purl.obolibrary.org/obo/TXPO_0003997,,,,,,,,,,TXPO:0000800,,,,,,,,,,,,,,,,,,,,,,HYOU1 (human)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000808,disease course dependent process,,Toxic course dependent process is a subtype of primitive  process: A process that can constitute the disease course.,false,,,http://purl.obolibrary.org/obo/TXPO_0000271,,,,,,,,,,,,,,,,,,,,,,Toxic course dependent process is a subtype of primitive  process: A process that can constitute the disease course.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000808,,,,,,,,,,,,,,,,,,,,,,disease course dependent process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_37153,EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor,protein phosphatase-2C inhibitors|3-hydroxy 3-methylglutaryl coenzymeA reductase phosphatase inhibitor|HMG-CoA reductase phosphatase inhibitors|serine/threonine specific protein phosphatase inhibitor|protein serine/threonine phosphatase (EC 3.1.3.16) inhibitors|calcineurin inhibitor|casein phosphatase inhibitor|phosphatase IV inhibitor|phosphatase C-II inhibitors|phosphatase III inhibitors|serine/threonine specific protein phosphatase inhibitors|protein phosphatase-2A inhibitors|protein phosphatase-2C inhibitor|protein phosphatase-2B inhibitor|phosphatase II inhibitor|phosphoprotein phosphatase (EC 3.1.3.16) inhibitors|Aspergillus awamori acid protein phosphatase inhibitors|branched-chain alpha-keto acid dehydrogenase phosphatase inhibitors|phosphatase C-II inhibitor|protein D phosphatase inhibitors|protein serine/threonine phosphatase inhibitor|protein phosphatase-1 inhibitors|phosphatase III inhibitor|casein phosphatase inhibitors|phosphoprotein phosphohydrolase inhibitors|phosphatase I inhibitors|phosphatase IB inhibitor|3-hydroxy 3-methylglutaryl coenzymeA reductase phosphatase inhibitors|BCKDH phosphatase inhibitors|phosphatase I inhibitor|protein phosphatase-1 inhibitor|protein phosphatase inhibitors|phosphatase H-II inhibitor|phosphopyruvate dehydrogenase phosphatase inhibitor|protein serine/threonine phosphatase inhibitors|phosphatase H-II inhibitors|protein phosphatase-2B inhibitors|phosphatase 2B inhibitors|phosphopyruvate dehydrogenase phosphatase inhibitors|polycation modulated (PCM-) phosphatase inhibitor|phosphatase 2A inhibitors|EC 3.1.3.16 inhibitors|phosphatase IB inhibitors|polycation modulated (PCM-) phosphatase inhibitors|protein phosphatase inhibitor|phosphatase IV inhibitors|BCKDH phosphatase inhibitor|Aspergillus awamori acid protein phosphatase inhibitor|HMG-CoA reductase phosphatase inhibitor|protein phosphatase-2A inhibitor|phosphoprotein phosphatase (EC 3.1.3.16) inhibitor|branched-chain alpha-keto acid dehydrogenase phosphatase inhibitor|phosphatase 2B inhibitor|calcineurin inhibitors|phosphatase SP inhibitor|EC 3.1.3.16 (protein serine/threonine phosphatase) inhibitors|phosphatase 2A inhibitor|phosphospectrin phosphatase inhibitor|phosphatase II inhibitors|phosphospectrin phosphatase inhibitors|phosphatase SP inhibitors|phosphoprotein phosphohydrolase inhibitor|phosphoprotein phosphatase inhibitor|phosphoprotein phosphatase inhibitors|protein D phosphatase inhibitor|EC 3.1.3.16 inhibitor,Any EC 3.1.3.* (phosphoric monoester hydrolase) inhibitor that interferes with the action of phosphoprotein phosphatase (EC 3.1.3.16).,false,,,http://purl.obolibrary.org/obo/CHEBI_76775,,,,,,,,,,,,,,,,,,,,,,Any EC 3.1.3.* (phosphoric monoester hydrolase) inhibitor that interferes with the action of phosphoprotein phosphatase (EC 3.1.3.16).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,protein phosphatase-2C inhibitors|3-hydroxy 3-methylglutaryl coenzymeA reductase phosphatase inhibitor|HMG-CoA reductase phosphatase inhibitors|serine/threonine specific protein phosphatase inhibitor|protein serine/threonine phosphatase (EC 3.1.3.16) inhibitors|calcineurin inhibitor|casein phosphatase inhibitor|phosphatase IV inhibitor|phosphatase C-II inhibitors|phosphatase III inhibitors|serine/threonine specific protein phosphatase inhibitors|protein phosphatase-2A inhibitors|protein phosphatase-2C inhibitor|protein phosphatase-2B inhibitor|phosphatase II inhibitor|phosphoprotein phosphatase (EC 3.1.3.16) inhibitors|Aspergillus awamori acid protein phosphatase inhibitors|branched-chain alpha-keto acid dehydrogenase phosphatase inhibitors|phosphatase C-II inhibitor|protein D phosphatase inhibitors|protein serine/threonine phosphatase inhibitor|protein phosphatase-1 inhibitors|phosphatase III inhibitor|casein phosphatase inhibitors|phosphoprotein phosphohydrolase inhibitors|phosphatase I inhibitors|phosphatase IB inhibitor|3-hydroxy 3-methylglutaryl coenzymeA reductase phosphatase inhibitors|BCKDH phosphatase inhibitors|phosphatase I inhibitor|protein phosphatase-1 inhibitor|protein phosphatase inhibitors|phosphatase H-II inhibitor|phosphopyruvate dehydrogenase phosphatase inhibitor|protein serine/threonine phosphatase inhibitors|phosphatase H-II inhibitors|protein phosphatase-2B inhibitors|phosphatase 2B inhibitors|phosphopyruvate dehydrogenase phosphatase inhibitors|polycation modulated (PCM-) phosphatase inhibitor|phosphatase 2A inhibitors|EC 3.1.3.16 inhibitors|phosphatase IB inhibitors|polycation modulated (PCM-) phosphatase inhibitors|protein phosphatase inhibitor|phosphatase IV inhibitors|BCKDH phosphatase inhibitor|Aspergillus awamori acid protein phosphatase inhibitor|HMG-CoA reductase phosphatase inhibitor|protein phosphatase-2A inhibitor|phosphoprotein phosphatase (EC 3.1.3.16) inhibitor|branched-chain alpha-keto acid dehydrogenase phosphatase inhibitor|phosphatase 2B inhibitor|calcineurin inhibitors|phosphatase SP inhibitor|EC 3.1.3.16 (protein serine/threonine phosphatase) inhibitors|phosphatase 2A inhibitor|phosphospectrin phosphatase inhibitor|phosphatase II inhibitors|phosphospectrin phosphatase inhibitors|phosphatase SP inhibitors|phosphoprotein phosphohydrolase inhibitor|phosphoprotein phosphatase inhibitor|phosphoprotein phosphatase inhibitors|protein D phosphatase inhibitor|EC 3.1.3.16 inhibitor,,,,,,,,,,,,,,,,,,,,,CHEBI:37153,,,,EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor,,CHEBI:37153,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100278,TGF-alpha,transforming growth factor alpha,,false,,,http://purl.obolibrary.org/obo/IMR_0000047,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,transforming growth factor alpha,,,,,IMR:0100278,,,,,,,,,,,,,,,,,,,,,,TGF-alpha,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003631,in vitro (human) 2hr,,,false,,,http://purl.obolibrary.org/obo/TXPO_0000795,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003631,,,,,,,,,,,,,,,,,,,,,,in vitro (human) 2hr,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003634,fluid flow rate,,A physical quality inhering in a fluid (liquid or gas) by virtue of the amount of fluid which passes through a given surface per unit time.,false,,,http://purl.obolibrary.org/obo/TXPO_0003747|http://purl.obolibrary.org/obo/PATO_0001574,,,,,,,,,,,,,,,,,,,,,,A physical quality inhering in a fluid (liquid or gas) by virtue of the amount of fluid which passes through a given surface per unit time.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003634,,,,,,,,,,,,,,,,,,,,,,fluid flow rate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003638,transporter,,"A role which enables the directed movement of substances (such as macromolecules, small molecules, ions) into, out of or within a cell, or between cells.|related molecular function GO:0005215",false,,,http://purl.obolibrary.org/obo/TXPO_0001393,,,,,,,,,,,,,,,,,,,,,,"A role which enables the directed movement of substances (such as macromolecules, small molecules, ions) into, out of or within a cell, or between cells.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003638,,,,,,,,,,,,,,,,,,,,related molecular function GO:0005215,,transporter,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003635,mutation [Niemann Pick Disease],,"Mutation is a subtype of changing an operand: A process that changes the nucleotide sequence of DNA randomly and permanently.
This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease.",false,,,http://purl.obolibrary.org/obo/TXPO_0001985|http://purl.obolibrary.org/obo/TXPO_0003642,,,,,,,,,,,,,,,,,,,,,,"Mutation is a subtype of changing an operand: A process that changes the nucleotide sequence of DNA randomly and permanently.
This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003635,,,,,,,,,,,,,,,,,,,,,,mutation [Niemann Pick Disease],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003632,toxic course based on fatty change,,"This course is categorized from the viewpoint of the findings of fatty change.
This entity is inferred from Description Logic.",false,,,http://purl.obolibrary.org/obo/TXPO_0000608|http://purl.obolibrary.org/obo/TXPO_0003763,,,,,,,,,,,,,,,,,,,,,,"This course is categorized from the viewpoint of the findings of fatty change.
This entity is inferred from Description Logic.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003632,,,,,,,,,,,,,,,,,,,,,,toxic course based on fatty change,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003637,regulation of bile acid and bile salt transport,,"Regulation of bile acid and bile salt transport is a subtype of regulation of transport (biology): Any process that modulates the frequency, rate or extent of the directed movement of bile acid and bile salts .",false,,,http://purl.obolibrary.org/obo/GO_0051049,,,,,,,,,,,,,,,,,,,,,,"Regulation of bile acid and bile salt transport is a subtype of regulation of transport (biology): Any process that modulates the frequency, rate or extent of the directed movement of bile acid and bile salts .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003637,,,,,,,,,,,,,,,,,,,,,,regulation of bile acid and bile salt transport,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0015721,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003639,channel,,"A role enables the energy-independent facilitated diffusion, mediated by passage of a solute through a transmembrane aqueous pore or channel. Stereospecificity is not exhibited but this transport may be specific for a particular molecular species or class of molecules.|related molecular function GO:0015267",false,,,http://purl.obolibrary.org/obo/TXPO_0003638,,,,,,,,,,,,,,,,,,,,,,"A role enables the energy-independent facilitated diffusion, mediated by passage of a solute through a transmembrane aqueous pore or channel. Stereospecificity is not exhibited but this transport may be specific for a particular molecular species or class of molecules.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003639,,,,,,,,,,,,,,,,,,,,related molecular function GO:0015267,,channel,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003633,Cyp1A2 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0001552,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24297|NCBI-Human-GeneID:1544|NCBI-Mouse-GeneID:13077,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001543,,,,,,,,,,,,,TXPO:0003633,,,,,,,,,,,,,,,,,,,,,,Cyp1A2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003636,regulation of transmitting,,"Regulation of transmitting is a subtype of controlling: A process that modulates the frequency, rate or extent of transmitting.",false,,,http://purl.obolibrary.org/obo/TXPO_0000113,,,,,,,,,,,,,,,,,,,,,,"Regulation of transmitting is a subtype of controlling: A process that modulates the frequency, rate or extent of transmitting.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003636,,,,,,,,,,,,,,,,,,,,,,regulation of transmitting,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000442,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003630,trichloromethyl(.) [NASH],CCL3 [lipidosis],,false,,,http://purl.obolibrary.org/obo/TXPO_0003508|http://purl.obolibrary.org/obo/CHEBI_30737,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CCL3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CCL3 [lipidosis],,,,,TXPO:0003630,,,,,,,,,,,,,,,,,,,,,,trichloromethyl(.) [NASH],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Cl[C](Cl)Cl,,,,,
http://purl.obolibrary.org/obo/CHEBI_24127,fungicide,fungicides,A substance used to destroy fungal pests.,false,,,http://purl.obolibrary.org/obo/CHEBI_25944|http://purl.obolibrary.org/obo/CHEBI_35718,,,,,,,,,,,,,,,,,,,,,,A substance used to destroy fungal pests.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,fungicides,,,,,,,,,,,,,,,,,,,,,CHEBI:24127,,,,fungicide,,CHEBI:24127,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_25935,hydroperoxyl,(HO2)(.),,false,,,http://purl.obolibrary.org/obo/TXPO_0000201,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,HO2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,(HO2)(.),,,CHEBI:25935,,,,,,,,,,,,,,,,,,,,,,hydroperoxyl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,[H]O[O],,,,,
http://purl.obolibrary.org/obo/OGG_3000003339,HSPG2,,Other designations: basement membrane-specific heparan sulfate proteoglycan core protein|endorepellin (domain V region)|perlecan proteoglycan,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,SJS1|PRCAN|HSPG|PLC|SJA|SJS,,,,,,,,,,,,1,,,,,,Vega:OTTHUMG00000002674|HGNC:5273|MIM:142461|HPRD:00804|Ensembl:ENSG00000142798,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,heparan sulfate proteoglycan 2,,,1p36.1-p34,,,,,,,,,,,,,,,,"GO_0001523 (EC: TAS); GO_0001525 (EC: IEA); GO_0001958 (EC: IEA); GO_0002062 (EC: IEA); GO_0005515 (EC: IPI, PMID: 11956183); GO_0005576 (EC: TAS); GO_0005605 (EC: IEA); GO_0005615 (EC: IDA); GO_0005796 (EC: TAS); GO_0005886 (EC: TAS); GO_0005975 (EC: TAS); GO_0006024 (EC: TAS); GO_0006027 (EC: TAS); GO_0007420 (EC: IEA); GO_0007603 (EC: TAS); GO_0008022 (EC: IPI, PMID: 12604605); GO_0008104 (EC: IEA); GO_0022617 (EC: TAS); GO_0030198 (EC: TAS); GO_0030203 (EC: TAS); GO_0030204 (EC: TAS); GO_0031012 (EC: IDA, Qualifier: colocalizes_with); GO_0031012 (EC: ISS, Qualifier: colocalizes_with); GO_0042157 (EC: TAS); GO_0043202 (EC: TAS); GO_0044281 (EC: TAS); GO_0046872 (EC: IEA); GO_0048704 (EC: IEA); GO_0048738 (EC: IEA); GO_0060351 (EC: IEA); GO_0070062 (EC: IDA, PMID: 19056867)",,,,,,,,,PMID: 1569102; 1679749; 1685141; 1730768; 2687294; 2745554; 7500359; 8234307; 8541852; 9136074; 9307034; 9313766; 9431988; 9688542; 9692901; 9733643; 10545953; 10579711; 10702276; 11101850; 11148217; 11279527; 11493006; 11574465; 11847210; 11847221; 11941538; 11956183; 11968010; 12036876; 12435733; 12477932; 12604605; 12754519; 12811819; 12900424; 14563633; 14625044; 14630925; 14702039; 14973356; 14974815; 15031130; 15081423; 15211644; 15231748; 15240572; 15567441; 15591058; 15657057; 15905187; 16129435; 16269412; 16283481; 16335952; 16407285; 16570819; 16620836; 16713569; 16914267; 16927315; 16984910; 17356275; 18024432; 18658137; 19056867; 19066875; 19380743; 19506372; 19553700; 19669783; 19738201; 19788922; 19789387; 19839757; 19889475; 19913121; 20053631; 20072119; 20074558; 20452482; 20507176; 20628086; 20673868; 20690028; 21078624; 21126803; 21255062; 21596751; 21808285; 22003087; 22076637; 22268729; 22457785; 22643235; 23060442; 23104139; 23161552; 23235151; 23336978; 23374253; 23436656; 23509972; 23568740; 23599406; 24101524,,,,,,,,,,,,,,,OGG:3000003339,,,,,,,heparan sulfate proteoglycan 2,,,,,,,,,,,,,Other designations: basement membrane-specific heparan sulfate proteoglycan core protein|endorepellin (domain V region)|perlecan proteoglycan,,HSPG2,,,,,,,,,,,,,,,,,,,,,,,3339,RP11-132G19.2,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,HSPG2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000003338,DNAJC4,,Other designations: dnaJ homolog subfamily C member 4|dnaJ-like protein HSPF2|heat shock 40kD protein 2|multiple endocrine neoplasia type 1 candidate protein number 18,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,DANJC4|MCG18|HSPF2,,,,,,,,,,,,11,,,,,,Vega:OTTHUMG00000167792|Ensembl:ENSG00000110011|HGNC:5271|MIM:604189,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"DnaJ (Hsp40) homolog, subfamily C, member 4",,,11q13,,,,,,,,,,,,,,,,"GO_0005515 (EC: IPI, PMID:17500595); GO_0005739 (EC: IEA); GO_0006457 (EC: NAS, PMID:9473517); GO_0006986 (EC: TAS, PMID:9473517); GO_0016020 (EC: NAS, PMID:9473517); GO_0016021 (EC: IEA); GO_0051082 (EC: NAS, PMID:9473517)",,,,,,,,,PMID:9473517; 11147971; 12477932; 15489334; 17207965; 17500595; 19913121; 20029029; 20237496; 20628086; 20877624; 21832049,,,,,,,,,,,,,,,OGG:3000003338,,,,,,,"DnaJ (Hsp40) homolog, subfamily C, member 4",,,,,,,,,,,,,Other designations: dnaJ homolog subfamily C member 4|dnaJ-like protein HSPF2|heat shock 40kD protein 2|multiple endocrine neoplasia type 1 candidate protein number 18,,DNAJC4,,,,,,,,,,,,,,,,,,,,,,,3338,,,,,,,,9606,,,,,,,,,,,,,,,,,,,DNAJC4,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000003337,DNAJB1,,"Other designations: DnaJ (Hsp40) homolog, subfmaily B, member 1|dnaJ homolog subfamily B member 1|dnaJ protein homolog 1|hDj-1|heat shock 40 kDa protein 1|heat shock 40kD protein 1|heat shock protein 40|human DnaJ protein 1|radial spoke 16 homolog B",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,RSPH16B|Hdj1|Sis1|Hsp40|HSPF1,,,,,,,,,,,,19,,,,,,HPRD:05198|MIM:604572|HGNC:5270|Vega:OTTHUMG00000183289|Ensembl:ENSG00000132002,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"DnaJ (Hsp40) homolog, subfamily B, member 1",,,19p13.2,,,,,,,,,,,,,,,,"GO_0005515 (EC: IPI, PMID:17024176); GO_0005730 (EC: IEA); GO_0005737 (EC: IEA); GO_0006986 (EC: TAS, PMID:8975727); GO_0051082 (EC: IEA); GO_0051085 (EC: IEA); GO_0070062 (EC: IDA, PMID:19056867); GO_0070389 (EC: IDA, PMID:18620420)",,,,,,,,,PMID:1586970; 1754405; 8250930; 8670798; 8764402; 8975727; 9499401; 9545528; 9727490; 9920933; 10075921; 10330192; 10593983; 10811660; 10816573; 11093761; 11147971; 11457725; 11500375; 11809754; 11821413; 12150907; 12417652; 12477932; 14499622; 14503850; 14702039; 14743183; 14752510; 15075330; 15194794; 15362566; 15489334; 16009940; 16179353; 16196087; 16842747; 16919237; 17012257; 17024176; 17601350; 18032501; 18187620; 18211704; 18457437; 18620420; 18624398; 18977241; 19056867; 19254810; 19615732; 19738201; 19779646; 19901540; 20026329; 20084477; 20360068; 20516149; 20562859; 20735358; 20801936; 20809635; 20811636; 20885985; 21044950; 21124777; 21139048; 21139202; 21145461; 21163940; 21249176; 21480956; 21639839; 21698289; 21763498; 21832049; 21890473; 21906983; 21987572; 22022600; 22075554; 22505724; 22779921; 22863883; 22990118; 23000965; 23395854; 23400395; 23482560; 24091676; 24196953; 24255178; 24318877; 24361594,,,,,,,,,,,,,,,OGG:3000003337,,,,,,,"DnaJ (Hsp40) homolog, subfamily B, member 1",,,,,,,,,,,,,"Other designations: DnaJ (Hsp40) homolog, subfmaily B, member 1|dnaJ homolog subfamily B member 1|dnaJ protein homolog 1|hDj-1|heat shock 40 kDa protein 1|heat shock 40kD protein 1|heat shock protein 40|human DnaJ protein 1|radial spoke 16 homolog B",,DNAJB1,,,,,,,,,,,,,,,,,,,,,,,3337,,,,,,,,9606,,,,,,,,,,,,,,,,,,,DNAJB1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/GO_0010628,positive regulation of gene expression,,"Any process that increases the frequency, rate or extent of gene expression. Gene expression is the process in which a gene's coding sequence is converted into a mature gene product or products (proteins or RNA). This includes the production of an RNA transcript as well as any processing to produce a mature RNA product or an mRNA or circRNA (for protein-coding genes) and the translation of that mRNA or circRNA into protein. Protein maturation is included when required to form an active form of a product from an inactive precursor form.",false,,,http://purl.obolibrary.org/obo/TXPO_0001223,,,,,,,,,,,,,,,,,,,,,,"Any process that increases the frequency, rate or extent of gene expression. Gene expression is the process in which a gene's coding sequence is converted into a mature gene product or products (proteins or RNA). This includes the production of an RNA transcript as well as any processing to produce a mature RNA product or an mRNA or circRNA (for protein-coding genes) and the translation of that mRNA or circRNA into protein. Protein maturation is included when required to form an active form of a product from an inactive precursor form.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0010628,,,,,,,,,,,,,,,,,,,,,,positive regulation of gene expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0010467,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0010629,negative regulation of gene expression,,"Any process that decreases the frequency, rate or extent of gene expression. Gene expression is the process in which a gene's coding sequence is converted into a mature gene product or products (proteins or RNA). This includes the production of an RNA transcript as well as any processing to produce a mature RNA product or an mRNA or circRNA (for protein-coding genes) and the translation of that mRNA or circRNA into protein. Protein maturation is included when required to form an active form of a product from an inactive precursor form.|This term covers any process that negatively regulates the rate of production of a mature gene product, and so includes processes that negatively regulate that rate by reducing the level, stability or availability of intermediates in the process of gene expression. For example, it covers any process that reduces the level, stability or availability of mRNA or circRNA for translation and thereby reduces the rate of production of the encoded protein via translation.",false,,,http://purl.obolibrary.org/obo/TXPO_0000369,,,,,,,,,,,,,,,,,,,,,,"Any process that decreases the frequency, rate or extent of gene expression. Gene expression is the process in which a gene's coding sequence is converted into a mature gene product or products (proteins or RNA). This includes the production of an RNA transcript as well as any processing to produce a mature RNA product or an mRNA or circRNA (for protein-coding genes) and the translation of that mRNA or circRNA into protein. Protein maturation is included when required to form an active form of a product from an inactive precursor form.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0045892|http://purl.obolibrary.org/obo/GO_0009386,,,,,,,,,,,,,,,,,,GO:0010629,,,,,,,,,,,,,,,,,,,,"This term covers any process that negatively regulates the rate of production of a mature gene product, and so includes processes that negatively regulate that rate by reducing the level, stability or availability of intermediates in the process of gene expression. For example, it covers any process that reduces the level, stability or availability of mRNA or circRNA for translation and thereby reduces the rate of production of the encoded protein via translation.",,negative regulation of gene expression,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0010467,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_65232,EC 3.4.21.5 (thrombin) inhibitor,thrombase inhibitor|fibrinogenase inhibitor|factor IIa inhibitor|blood-coagulation factor IIa inhibitor|tropostasin inhibitors|thrombin (EC 3.4.21.5) inhibitor|thrombin-C inhibitors|EC 3.4.21.5 inhibitor|thrombofort inhibitors|fibrinogenase inhibitors|E thrombin inhibitor|thrombin inhibitors|E thrombin inhibitors|beta-thrombin inhibitor|beta-thrombin inhibitors|gamma-thrombin inhibitor|EC 3.4.21.5 (thrombin) inhibitors|thrombofort inhibitor|gamma-thrombin inhibitors|thrombase inhibitors|activated blood-coagulation factor II inhibitor|activated blood-coagulation factor II inhibitors|thrombin (EC 3.4.21.5) inhibitors|blood-coagulation factor IIa inhibitors|thrombin-C inhibitor|tropostasin inhibitor|EC 3.4.21.5 inhibitors|factor IIa inhibitors|thrombin inhibitor,An  EC 3.4.21.* (serine endopeptidase) inhibitor that interferes with the action of thrombin (EC 3.4.21.5).,false,,,http://purl.obolibrary.org/obo/CHEBI_5924,,,,,,,,,,,,,,,,,,,,,,An  EC 3.4.21.* (serine endopeptidase) inhibitor that interferes with the action of thrombin (EC 3.4.21.5).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,thrombase inhibitor|fibrinogenase inhibitor|factor IIa inhibitor|blood-coagulation factor IIa inhibitor|tropostasin inhibitors|thrombin (EC 3.4.21.5) inhibitor|thrombin-C inhibitors|EC 3.4.21.5 inhibitor|thrombofort inhibitors|fibrinogenase inhibitors|E thrombin inhibitor|thrombin inhibitors|E thrombin inhibitors|beta-thrombin inhibitor|beta-thrombin inhibitors|gamma-thrombin inhibitor|EC 3.4.21.5 (thrombin) inhibitors|thrombofort inhibitor|gamma-thrombin inhibitors|thrombase inhibitors|activated blood-coagulation factor II inhibitor|activated blood-coagulation factor II inhibitors|thrombin (EC 3.4.21.5) inhibitors|blood-coagulation factor IIa inhibitors|thrombin-C inhibitor|tropostasin inhibitor|EC 3.4.21.5 inhibitors|factor IIa inhibitors|thrombin inhibitor,,,,,,,,,,,,,,,,,,,,,CHEBI:65232,,,,EC 3.4.21.5 (thrombin) inhibitor,,CHEBI:65232,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001073,Ctnnb1 -apoptosis inhibitor (mouse)[Ground glass appearance],Catenin Beta 1 [Ground glass appearance],,false,,,http://purl.obolibrary.org/obo/TXPO_0000986,,,,,,,,,,,,,,,,,,,,PMID:21822615|PMID:25661872,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_68494,,,,,Catenin Beta 1 [Ground glass appearance],,,,,TXPO:0001073,,,,,,,,,,,,,,,,,,,,,,Ctnnb1 -apoptosis inhibitor (mouse)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001079,CASP1 -IL1beta activator (canonical)[lipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001104|http://purl.obolibrary.org/obo/IMR_0100302,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:834|PMID:20303873,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001080,,,,,,,,,,TXPO:0001079,,,,,,,,,,,,,,,,,,,,,,CASP1 -IL1beta activator (canonical)[lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001077,eosinogranular degeneration dependent molecule  (rat),,"Eosinogranular degeneration dependent molecule is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of eosinogranular degeneration as a gene product.
Gene profile:Rat/Liver/",false,,,http://purl.obolibrary.org/obo/TXPO_0000835,,,,,,,,,,,,,,,,,,,,,,"Eosinogranular degeneration dependent molecule is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of eosinogranular degeneration as a gene product.
Gene profile:Rat/Liver/",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001077,,,,,,,,,,,,,,,,,,,,,,eosinogranular degeneration dependent molecule  (rat),,,,,,,,,,,http://purl.obolibrary.org/obo/NCBITaxon_10114,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001071,ground glass appearance dependent molecule (mouse),,"Ground glass appearance dependent molecule is a subtype of toxic course dependent chemical entity.
This molecule can participate in the course of ground glass appearance as a gene product.
Gene profile:Mouse/Liver/",false,,,http://purl.obolibrary.org/obo/TXPO_0000984,,,,,,,,,,,,,,,,,,,,,,"Ground glass appearance dependent molecule is a subtype of toxic course dependent chemical entity.
This molecule can participate in the course of ground glass appearance as a gene product.
Gene profile:Mouse/Liver/",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001071,,,,,,,,,,,,,,,,,,,,,,ground glass appearance dependent molecule (mouse),,,,,,,,,,,http://purl.obolibrary.org/obo/NCBITaxon_10090,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001074,Acaa1a (rat)[Eosinophilic granular degeneration],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001077|http://purl.obolibrary.org/obo/TXPO_1000017,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24157|NCBI-Mouse-GeneID:113868|PMID:17255113|PMID:2307679,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001074,,,,,,,,,,,,,,,,,,,,,,Acaa1a (rat)[Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001075,increasing lipid material,,Increasing lipid material is a subtype of increasing quantity: A process that changes the amount of lipid material to be larger.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing lipid material is a subtype of increasing quantity: A process that changes the amount of lipid material to be larger.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001075,,,,,,,,,,,,,,,,,,,,,,increasing lipid material,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001072,Ctnnb1 -tumor positive regulator (mouse)[Ground glass appearance],Catenin Beta 1 [Ground glass appearance],,false,,,http://purl.obolibrary.org/obo/TXPO_0000986,,,,,,,,,,,,,,,,,,,,PMID:21822615|PMID:25661872,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002271,,,,,Catenin Beta 1 [Ground glass appearance],,,,,TXPO:0001072,,,,,,,,,,,,,,,,,,,,,,Ctnnb1 -tumor positive regulator (mouse)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001078,increasing lipid material [lipidosis],,"Increasing lipid material is a subtype of increasing quantity: A process that changes the amount of lipid material to be larger.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis (normal condition).",false,,,http://purl.obolibrary.org/obo/TXPO_0001075|http://purl.obolibrary.org/obo/TXPO_0001720,,,,,,,,,,,,,,,,,,,,,,"Increasing lipid material is a subtype of increasing quantity: A process that changes the amount of lipid material to be larger.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis (normal condition).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001141,,,,,,,,,,,TXPO:0001078,,,,,,,,,,,,,,,,,,,,,,increasing lipid material [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001070,Hadhb (rat)[Eosinophilic granular degeneration],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001077|http://purl.obolibrary.org/obo/TXPO_1000193,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:171155,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001070,,,,,,,,,,,,,,,,,,,,,,Hadhb (rat)[Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001076,Ctnnb1 -cell senescence inhibitor (mouse)[Ground glass appearance],Catenin Beta 1 [Ground glass appearance],,false,,,http://purl.obolibrary.org/obo/TXPO_0000986,,,,,,,,,,,,,,,,,,,,PMID:21822615|PMID:25661872,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001139,,,,,Catenin Beta 1 [Ground glass appearance],,,,,TXPO:0001076,,,,,,,,,,,,,,,,,,,,,,Ctnnb1 -cell senescence inhibitor (mouse)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100569,FGF-19,,,false,,,http://purl.obolibrary.org/obo/IMR_0000049,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100569,,,,,,,,,,,,,,,,,,,,,,FGF-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_24432,biological role,biological function,A role played by the molecular entity or part thereof within a biological context.,false,,,http://purl.obolibrary.org/obo/BFO_0000023,,,,,,,,,,,,,,,,,,,,,,A role played by the molecular entity or part thereof within a biological context.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,biological function,,,,,,,,,,,,,,,,,,,,,CHEBI:24432,,,,biological role,,CHEBI:24432,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001350,jaundice (Process),,Jaundice is a changing process that generally changes the color of the skin or eyes into yellow.,false,,,http://purl.obolibrary.org/obo/TXPO_0001616,,,,,,,,,,,,,,,,,,,,,,Jaundice is a changing process that generally changes the color of the skin or eyes into yellow.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001350,,,,,,,,,,,,,,,,,,,,,,jaundice (Process),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001352,hypofunction of blood coagulation factor synthesis,,Hypofunction of blood coagulation factor synthesis is a subtype of hypofunction of biosynthesis: A process that performs a decreased or insufficient blood coagulation factor synthesis.,false,,,http://purl.obolibrary.org/obo/TXPO_0001910,,,,,,,,,,,,,,,,,,,,,,Hypofunction of blood coagulation factor synthesis is a subtype of hypofunction of biosynthesis: A process that performs a decreased or insufficient blood coagulation factor synthesis.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001353,,,,,,,,,,,TXPO:0001352,,,,,,,,,,,,,,,,,,,,,,hypofunction of blood coagulation factor synthesis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001356,VLDL release from hepatocyte,,"The directed movement of VLDL, out of a hepatocyte.",false,,,http://purl.obolibrary.org/obo/TXPO_0002588,,,,,,,,,,,,,,,,,,,,,,"The directed movement of VLDL, out of a hepatocyte.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_39027,,,,,,,,,,,,,,,,,,,TXPO:0001356,,,,,,,,,,,,,,,,,,,,,,VLDL release from hepatocyte,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000182,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001358,hepatic shunt formtion,,"Hepatic shunt formtion is a subtype of biological structure formation: A process that makes abnormal communications between the hepatic arteries, portal veins, and hepatic or systemic veins.",false,,,http://purl.obolibrary.org/obo/TXPO_0000134,,,,,,,,,,,,,,,,,,,,,,"Hepatic shunt formtion is a subtype of biological structure formation: A process that makes abnormal communications between the hepatic arteries, portal veins, and hepatic or systemic veins.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001358,,,,,,,"It makes abnormal communications between the hepatic arteries, portal veins, and hepatic or systemic veins.",,,,,,,,,,,,,,,hepatic shunt formtion,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001357,hepatic vascular circulation disorder   (toxic course),,The totality of all processes through which hepatic vascular circulation disorder is realized.,false,,,http://purl.obolibrary.org/obo/TXPO_0000009,,,,,,,,,,,,,,,,,,,,,,The totality of all processes through which hepatic vascular circulation disorder is realized.,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003617,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003457|http://purl.obolibrary.org/obo/TXPO_0003458|http://purl.obolibrary.org/obo/TXPO_0003459|http://purl.obolibrary.org/obo/TXPO_0003617|http://purl.obolibrary.org/obo/TXPO_0003619|http://purl.obolibrary.org/obo/TXPO_0003460|http://purl.obolibrary.org/obo/TXPO_0003461|http://purl.obolibrary.org/obo/TXPO_0003466,,,,,,,,,,,,,,,,,,TXPO:0001357,,,,,,,,,,,,,,,,,,,,,,hepatic vascular circulation disorder   (toxic course),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001359,increasing hepatic portal pressure,,Increasing hepatic portal pressure is a subtype of increasing pressure: A process that changes the hepatic portal pressure to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0001689,,,,,,,,,,,,,,,,,,,,,,Increasing hepatic portal pressure is a subtype of increasing pressure: A process that changes the hepatic portal pressure to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001359,,,,,,,,,,,,,,,,,,,,,,increasing hepatic portal pressure,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001353,bleeding,,A process that emits blood.,false,,,http://purl.obolibrary.org/obo/TXPO_0002588,,,,,,,,,,,,,,,,,,,,,,A process that emits blood.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0000178,,,,,,,,,,,,,,,,,,,TXPO:0001353,,,,,,,,,,,,,,,,,,,,,,bleeding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001354,hypofunction of detoxification,,Hypofunction of detoxification is a subtype of hypofunctioning: A process that performs a decreased or insufficient detoxification.,false,,,http://purl.obolibrary.org/obo/TXPO_0000436,,,,,,,,,,,,,,,,,,,,,,Hypofunction of detoxification is a subtype of hypofunctioning: A process that performs a decreased or insufficient detoxification.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001354,,,,,,,,,,,,,,,,,,,,,,hypofunction of detoxification,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001351,VLDL (canonical)[lipidosis],very-low-density lipoproteins,"A class of lipoproteins of large size (30-80 nm), very low density (0.93-1.006 g/ml) particles with a core composed mainly of triglycerides and a surface monolayer of phospholipids and cholesterol into which are imbedded the apolipoproteins B, E, and C. VLDL facilitate the transport of endogenously made triglycerides to extrahepatic tissues.",false,,,http://purl.obolibrary.org/obo/TXPO_0003516|http://purl.obolibrary.org/obo/CHEBI_39027,,,,,,,,,,,,,,,,,,,,,,"A class of lipoproteins of large size (30-80 nm), very low density (0.93-1.006 g/ml) particles with a core composed mainly of triglycerides and a surface monolayer of phospholipids and cholesterol into which are imbedded the apolipoproteins B, E, and C. VLDL facilitate the transport of endogenously made triglycerides to extrahepatic tissues.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003699,,,,,,,very-low-density lipoproteins,,,TXPO:0001351,,,,,,,,,,,,,,,,,,,,,,VLDL (canonical)[lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001355,increasing ammonia concentration in blood,,Increasing ammonia concentration in blood is a subtype of increasing concentration: A process that changes the ammonia concentration in  the blood to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000352,,,,,,,,,,,,,,,,,,,,,,Increasing ammonia concentration in blood is a subtype of increasing concentration: A process that changes the ammonia concentration in  the blood to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001355,,,,,,,,,,,,,,,,,,,,,,increasing ammonia concentration in blood,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_1904592,positive regulation of protein refolding,up-regulation of protein refolding|upregulation of protein refolding|up regulation of protein refolding,"Any process that activates or increases the frequency, rate or extent of protein refolding.",false,,,http://purl.obolibrary.org/obo/TXPO_0001223,,,,,,,,,,,,,,,,,,,,,,"Any process that activates or increases the frequency, rate or extent of protein refolding.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,up-regulation of protein refolding|upregulation of protein refolding|up regulation of protein refolding,,,,,GO:1904592,,,,,,,,,,,,,,,,,,,,,,positive regulation of protein refolding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0042026,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100064,beta-MSH,beta-Melanotropin,A peptide hormone of about 22 amino acids. It is derived from PRO-OPIOMELANOCORTIN and has natriuretic activity.,false,,,http://purl.obolibrary.org/obo/IMR_0100198,,,,,,,,,,,,,,,,,,,,MeSH:D019824,,A peptide hormone of about 22 amino acids. It is derived from PRO-OPIOMELANOCORTIN and has natriuretic activity.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,beta-Melanotropin,,,,,IMR:0100064,,,,,,,,,,,,,,,,,,,,,,beta-MSH,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010387,Mitochondrial ornithine transporter 1,"Solute carrier family 25, member 15",,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003697,,,,,"Solute carrier family 25, member 15",,,,,IMR:0010387,,,,,,,,,,,,,,,,,,,,,,Mitochondrial ornithine transporter 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000336,Crk I,,,false,,,http://purl.obolibrary.org/obo/IMR_0000335,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000336,,,,,,,,,,,,,,,,,,,,,,Crk I,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0002104,inflammatory,,"A compositional quality inhering in an bearer by virtue of the bearer's infiltration by leukocytes, local edema and accumulation of plasma proteins.",false,,,http://purl.obolibrary.org/obo/PATO_0000025,,,,,,,,,,,,,,,,,,,,,,"A compositional quality inhering in an bearer by virtue of the bearer's infiltration by leukocytes, local edema and accumulation of plasma proteins.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0002104,,,,,,,,,,,,,,,,,,,,,,inflammatory,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001564,Rab4A,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001564,,,,,,,,,,,,,,,,,,,,,,Rab4A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002274,hyperfunction of biological defense function,,Hyperfunction of biological defense function is a subtype of hyperfunction of defensive function: A process that performs an excessive biological defensive function.,false,,,http://purl.obolibrary.org/obo/TXPO_0002360,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of biological defense function is a subtype of hyperfunction of defensive function: A process that performs an excessive biological defensive function.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002275,,,,,,,,,,,,,,,,,,TXPO:0002274,,,,,,,,,,,,,,,,,,,,,,hyperfunction of biological defense function,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002272,positive regulator of tumor cell proliferation,,A role played by the entity which positively regulates the process of tumor cell proliferation.,false,,,http://purl.obolibrary.org/obo/TXPO_0002271|http://purl.obolibrary.org/obo/TXPO_0003534,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000339,,,,,,,,,,,,,,A role played by the entity which positively regulates the process of tumor cell proliferation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002272,,,,,,,,,,,,,,,,,,,,,,positive regulator of tumor cell proliferation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002273,maintaining phospholipid homeostasis [Phospholipidosis (latent)],,"Any process involved in the maintenance of an internal steady state of phospholipid within an organism or cell.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (latent).",false,,,http://purl.obolibrary.org/obo/GO_0055091|http://purl.obolibrary.org/obo/TXPO_0000951,,,,,,,,,,,,,,,,,,,,,,"Any process involved in the maintenance of an internal steady state of phospholipid within an organism or cell.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (latent).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002076,,,,,,,,,TXPO:0002273,,,,,,,,,,,,,,,,,,,,,,maintaining phospholipid homeostasis [Phospholipidosis (latent)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002276,hyperfunction of cell survival [Phospholipidosis (excessive defense)],,"Hyperfunction of cell survival is a subtype of hyperfunctioning: A process that performs an excesssive cell survival.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense).",false,,,http://purl.obolibrary.org/obo/TXPO_0002275|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of cell survival is a subtype of hyperfunctioning: A process that performs an excesssive cell survival.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001489|http://purl.obolibrary.org/obo/TXPO_0001490|http://purl.obolibrary.org/obo/TXPO_0000921|http://purl.obolibrary.org/obo/TXPO_0002281,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003547,,,,,,,,,,,TXPO:0002276,,,,,,,,,,,,,,,,,,,,,,hyperfunction of cell survival [Phospholipidosis (excessive defense)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002271,positive regulator of cell proliferation,,A role played by the entity which positively regulates the process of cell proliferation.,false,,,http://purl.obolibrary.org/obo/TXPO_0003159,,,,,,,,http://purl.obolibrary.org/obo/GO_0008283,,,,,,,,,,,,,,A role played by the entity which positively regulates the process of cell proliferation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002271,,,,,,,,,,,,,,,,,,,,,,positive regulator of cell proliferation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002270,positive regulator of cell cycle arrest role,,A role played by the entity that positively regulates the process of cell cycle arrest.,false,,,http://purl.obolibrary.org/obo/TXPO_0002247,,,,,,,,http://purl.obolibrary.org/obo/GO_0007050,,,,,,,,,,,,,,A role played by the entity that positively regulates the process of cell cycle arrest.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002270,,,,,,,,,,,,,,,,,,,,,,positive regulator of cell cycle arrest role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002275,hyperfunction of cell survival,,Hyperfunction of cell survival is a subtype of hyperfunctioning: A process that performs an excesssive cell survival.,false,,,http://purl.obolibrary.org/obo/TXPO_0000435,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of cell survival is a subtype of hyperfunctioning: A process that performs an excesssive cell survival.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002275,,,,,,,,,,,,,,,,,,,,,,hyperfunction of cell survival,,,,,,http://purl.obolibrary.org/obo/NCIT_C16407,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002277,hyperfunction of biological defense function [Phospholipidosis (excessive defense)],,"Hyperfunction of biological defense function is a subtype of hyperfunction of defensive function: A process that performs an excessive biological defensive function.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense).",false,,,http://purl.obolibrary.org/obo/TXPO_0002274|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of biological defense function is a subtype of hyperfunction of defensive function: A process that performs an excessive biological defensive function.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002277,,,,,,,,,,,,,,,,,,,,,,hyperfunction of biological defense function [Phospholipidosis (excessive defense)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002279,hyperfunction of removing,,Hyperfunction of removing is a subtype of hyperfunctioning: A process that performs an excessive removal function.,false,,,http://purl.obolibrary.org/obo/TXPO_0000435,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of removing is a subtype of hyperfunctioning: A process that performs an excessive removal function.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002279,,,,,,,,,,,,,,,,,,,,,,hyperfunction of removing,,,,,,http://purl.obolibrary.org/obo/TXPO_0000458,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002278,hyperfunction of removing [Phospholipidosis (excessive defense)],,"Hyperfunction of removing is a subtype of hyperfunctioning: A process that performs an excessive removal function.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense).",false,,,http://purl.obolibrary.org/obo/TXPO_0002279|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of removing is a subtype of hyperfunctioning: A process that performs an excessive removal function.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002278,,,,,,,,,,,,,,,,,,,,,,hyperfunction of removing [Phospholipidosis (excessive defense)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000225,JNK/SAPK,c-jun N-terminal kinase|stress-activated protein kinase,,false,,,http://purl.obolibrary.org/obo/IMR_0000224,,,,,,,,,,,,,,,,,,,,IPR:008351|GO:0016909,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,c-jun N-terminal kinase|stress-activated protein kinase,,,,,IMR:0000225,,,,,,,,,,,,,,,,,,,,,,JNK/SAPK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001672,RGS14,,,false,,,http://purl.obolibrary.org/obo/IMR_0000431,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001672,,,,,,,,,,,,,,,,,,,,,,RGS14,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_35856,lipoxygenase inhibitor,lipoxygenase inhibitors|lipooxygenase inhibitor,A compound or agent that combines with lipoxygenase and thereby prevents its substrate-enzyme combination with arachidonic acid and the formation of the icosanoid products hydroxyicosatetraenoic acid and various leukotrienes.,false,,,http://purl.obolibrary.org/obo/CHEBI_76837,,,,,,,,,,,,,,,,,,,,,,A compound or agent that combines with lipoxygenase and thereby prevents its substrate-enzyme combination with arachidonic acid and the formation of the icosanoid products hydroxyicosatetraenoic acid and various leukotrienes.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,lipoxygenase inhibitors|lipooxygenase inhibitor,,,,,,,,,,,,,,,,,,,,,CHEBI:35856,,,,lipoxygenase inhibitor,,CHEBI:35856,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76759,EC 3.* (hydrolase) inhibitor,hydrolase (EC 3.*) inhibitor|EC 3.* inhibitor|EC 3.* (hydrolase) inhibitors|hydrolase inhibitors|EC 3.*.*.* inhibitor|hydrolase (EC 3.*) inhibitors|EC 3.* inhibitors|hydrolase inhibitor|EC 3.*.*.* inhibitors|EC 3.* (hydrolase) inhibitor,Any enzyme inhibitor that interferes with the action of a hydrolase (EC 3.*.*.*).|Wikipedia:Hydrolase,false,,,http://purl.obolibrary.org/obo/CHEBI_23924,,,,,,,,,,,,,,,,,,,,,,Any enzyme inhibitor that interferes with the action of a hydrolase (EC 3.*.*.*).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,EC 3.* (hydrolase) inhibitor,,hydrolase (EC 3.*) inhibitor|EC 3.* inhibitor|EC 3.* (hydrolase) inhibitors|hydrolase inhibitors|EC 3.*.*.* inhibitor|hydrolase (EC 3.*) inhibitors|EC 3.* inhibitors|hydrolase inhibitor|EC 3.*.*.* inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:76759,,Wikipedia:Hydrolase,,EC 3.* (hydrolase) inhibitor,,CHEBI:76759,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000006319,SCD,,Other designations: acyl-CoA desaturase|delta(9)-desaturase|delta-9 desaturase|delta-9-desaturase|fatty acid desaturase|predicted protein of HQ0998|stearoyl-CoA desaturase opposite strand,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,MSTP008|FADS5|SCD1|SCDOS,,,,,,,,,,,,10,,,,,,MIM:604031|HPRD:04941|Ensembl:ENSG00000099194|Vega:OTTHUMG00000018906|HGNC:10571,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,stearoyl-CoA desaturase (delta-9-desaturase),,,10q24.31,,,,,,,,,,,,,,,,GO_0004768 (EC: IEA); GO_0005506 (EC: IEA); GO_0005783 (EC: IDA); GO_0005789 (EC: IEA); GO_0006633 (EC: IEA); GO_0016021 (EC: IEA),,,,,,,,,PMID: 21148; 6102994; 7909540; 8125298; 9362069; 10229681; 10922050; 11181995; 11397803; 11415448; 11677241; 12061775; 12401889; 12477932; 14683458; 14967817; 14967823; 15164054; 15489334; 15609334; 15610069; 15662557; 15708362; 15851470; 15855323; 15907797; 16213227; 16385451; 16723740; 17614770; 17636091; 17852835; 18029348; 18030445; 18286258; 18340007; 18499418; 18660489; 18697866; 18781797; 18813799; 18832746; 18952834; 19130493; 19154947; 19322201; 19478146; 19710915; 19913121; 19953087; 20032470; 20395685; 20565855; 20579763; 20599700; 20628086; 20639865; 20713121; 21045174; 21060977; 21139048; 21179554; 21331774; 21544602; 21658928; 21674150; 21775116; 21831035; 21832049; 21886157; 21890473; 21898701; 21906983; 21963094; 21987572; 22026420; 22046234; 22049297; 22082156; 22209225; 22457791; 22505724; 22819528; 22946088; 23000965; 23013158; 23015656; 23019225; 23139775; 23208590; 23221600; 23331615; 23362303; 23455922; 23613812; 23633458; 24135379; 24357007,,,,,,,,,,,,,,,OGG:3000006319,,,,,,,stearoyl-CoA desaturase (delta-9-desaturase),,,,,,,,,,,,,Other designations: acyl-CoA desaturase|delta(9)-desaturase|delta-9 desaturase|delta-9-desaturase|fatty acid desaturase|predicted protein of HQ0998|stearoyl-CoA desaturase opposite strand,,SCD,,,,,,,,,,,,,,,,,,,,,,,6319,PRO1933,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,SCD,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000083939,EIF2A,,Other designations: 65 kDa eukaryotic translation initiation factor 2A|eukaryotic translation initiation factor 2A,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,MSTP004|MST089|EIF-2A|MSTP089,,,,,,,,,,,,3,,,,,,Vega:OTTHUMG00000159775|HGNC:3254|MIM:609234|Ensembl:ENSG00000144895|HPRD:11739,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"eukaryotic translation initiation factor 2A, 65kDa",,,3q25.1,,,,,,,,,,,,,,,,"GO_0000049 (EC: IMP, PMID:12133843); GO_0003743 (EC: IMP, PMID:12133843); GO_0005515 (EC: IPI, PMID:18816594); GO_0005615 (EC: IDA); GO_0005737 (EC: IDA, PMID:12133843); GO_0005850 (EC: IDA, PMID:12133843); GO_0006417 (EC: IMP, PMID:12133843); GO_0006468 (EC: IEA); GO_0009967 (EC: IEA); GO_0032933 (EC: IEA); GO_0042255 (EC: IMP, PMID:12133843); GO_0043022 (EC: IMP, PMID:12133843); GO_0072562 (EC: IDA)",,,,,,,,,PMID:1620067; 12133843; 12370288; 12477932; 12687390; 14702039; 15341733; 15345721; 15475356; 15718232; 15781241; 15961545; 16373505; 16631606; 16717090; 16870703; 16928686; 17274640; 17407708; 17553788; 17715234; 17894550; 18063576; 18195013; 18274552; 18287093; 18337511; 18794359; 18816594; 19131336; 19190324; 19223463; 19229320; 19586904; 19605483; 19744687; 19913121; 20376341; 20434207; 20519500; 20628086; 20706999; 21085474; 21090173; 21139048; 21203563; 21622569; 21730287; 21832049; 21906983; 21963094; 22355666; 22505724; 22863883; 22915583; 22939629; 22948139; 23000965; 23046979; 23471998; 23690448,,,,,,,,,,,,,,,OGG:3000083939,,,,,,,"eukaryotic translation initiation factor 2A, 65kDa",,,,,,,,,,,,,Other designations: 65 kDa eukaryotic translation initiation factor 2A|eukaryotic translation initiation factor 2A,,EIF2A,,,,,,,,,,,,,,,,,,,,,,,83939,CDA02,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF2A,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_63608,maraviroc,"maraviroc|maravirocum|4,4-difluoro-N-{(1S)-3-[(3-exo)-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl}cyclohexanecarboxamide","A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 4,4-difluorocyclohexanecarboxylic acid and the primary amino group of (1S)-3-[(3-exo)-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropylamine. An antiretroviral drug, it prevents the interaction of HIV-1 gp120 and chemokine receptor 5 (CCR5) necessary for CCR5-tropic HIV-1 to enter cells.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,DrugBank:DB04835|PMID:22247337|PMID:21987241|PMID:25017682|PMID:22034870|PMID:24651825|PMID:22174038|PMID:24419064|PMID:21134404|Reaxys:10131963|PMID:22064539|PMID:21595497|PMID:21692669|CAS:376348-65-1|PMID:22236118|PMID:24652492|PMID:21505306|PMID:21393136|PMID:21383098|PMID:22090117|PMID:22118500|PMID:22017448,,"A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 4,4-difluorocyclohexanecarboxylic acid and the primary amino group of (1S)-3-[(3-exo)-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropylamine. An antiretroviral drug, it prevents the interaction of HIV-1 gp120 and chemokine receptor 5 (CCR5) necessary for CCR5-tropic HIV-1 to enter cells.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_59886|http://purl.obolibrary.org/obo/CHEBI_63673|http://purl.obolibrary.org/obo/CHEBI_36044,,,,,"4,4-difluoro-N-{(1S)-3-[(3-exo)-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl}cyclohexanecarboxamide",,maraviroc|maravirocum,,,,,,,,,,,,,,,,,,,,,CHEBI:63608,,,,maraviroc,,CHEBI:63608,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100291,BIM (mol),,,false,,,http://purl.obolibrary.org/obo/IMR_0100709,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100291,,,,,,,,,,,,,,,,,,,,,,BIM (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_24360,glycerophosphoglycerols,,,false,,,http://purl.obolibrary.org/obo/CHEBI_37739,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:24360,,,,,,,,,,,,,,,,,,,,,,glycerophosphoglycerols,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003603,mitochondrial damage dependent molecule (human in vitro),,"Mitochondrial damage dependent  molecule is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of Mitochondrial damage as a gene product.
Gene profile:Human/in vitro/Hepatocyte/",false,,,http://purl.obolibrary.org/obo/TXPO_0002012,,,,,,,,,,,,,,,,,,,,,,"Mitochondrial damage dependent  molecule is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of Mitochondrial damage as a gene product.
Gene profile:Human/in vitro/Hepatocyte/",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003603,,,,,,,,,,,,,,,,,,,,,,mitochondrial damage dependent molecule (human in vitro),,,,,,,,,,,http://purl.obolibrary.org/obo/NCBITaxon_9606,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003605,CYP3A5 (predicted)(human) [mitochondrial damage],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003603|http://purl.obolibrary.org/obo/TXPO_1000083,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1577,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000001577,,,,,,,,,,,,,TXPO:0003605,,,,,,,,,,,,,,,,,,,,,,CYP3A5 (predicted)(human) [mitochondrial damage],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003607,CXCL6 (predicted)(human) [mitochondrial damage],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003603|http://purl.obolibrary.org/obo/TXPO_1000509,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:6372,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000006372,,,,,,,,,,,,,TXPO:0003607,,,,,,,,,,,,,,,,,,,,,,CXCL6 (predicted)(human) [mitochondrial damage],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003602,ASAH1 (human) - apoptosis inducer [Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000529,,,,,,,,,,,,,,,,,,,,"ASAH1 is an estrogen-dependent member of the sphingolipid metabolism, which might provide further prognostic information in ER-positive breast cancers.|http://omim.org/entry/613468|PMID:23423838|PMID:29147025|PMID:17064658",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_68495,,,,,,,,,,TXPO:0003602,,,,,,,,,,,,,,,,,,,,,,ASAH1 (human) - apoptosis inducer [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001442,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003600,phospholipid metabolite,,Any intermediate or product resulting from phospholipid metabolism.,false,,,http://purl.obolibrary.org/obo/CHEBI_25212,,,,,,,,,,,,,,,,,,,,,,Any intermediate or product resulting from phospholipid metabolism.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003600,,,,,,,,,,,,,,,,,,,,,,phospholipid metabolite,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003608,RAD51AP1 (predicted)(human) [mitochondrial damage],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003603|http://purl.obolibrary.org/obo/TXPO_1000528,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:10635,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000010635,,,,,,,,,,,,,TXPO:0003608,,,,,,,,,,,,,,,,,,,,,,RAD51AP1 (predicted)(human) [mitochondrial damage],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003609,oranic anion export,,"Oranic anion export is a subtype of moving A to the outside of B: A process of the directed movement of organic anions into, out of a cell, or an organelle, by means of some agent such as a transporter or pore.",false,,,http://purl.obolibrary.org/obo/TXPO_0002588,,,,,,,,,,,,,,,,,,,,,,"Oranic anion export is a subtype of moving A to the outside of B: A process of the directed movement of organic anions into, out of a cell, or an organelle, by means of some agent such as a transporter or pore.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003609,,,,,,,,,,,,,,,,,,,,,,oranic anion export,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003604,PBLD (predicted)(human) [mitochondrial damage],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003603|http://purl.obolibrary.org/obo/TXPO_1000523,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:64081,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000064081,,,,,,,,,,,,,TXPO:0003604,,,,,,,,,,,,,,,,,,,,,,PBLD (predicted)(human) [mitochondrial damage],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003606,TNFSF10 (predicted)(human) [mitochondrial damage],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003603|http://purl.obolibrary.org/obo/TXPO_1000541,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:8743,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000008743,,,,,,,,,,,,,TXPO:0003606,,,,,,,,,,,,,,,,,,,,,,TNFSF10 (predicted)(human) [mitochondrial damage],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003601,decreasing ceramide,,Decreasing ceramide is a subtype of decreasing lipid: A process that changes the quantity of the ceramide to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000644,,,,,,,,,,,,,,,,,,,,,,Decreasing ceramide is a subtype of decreasing lipid: A process that changes the quantity of the ceramide to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003601,,,,,,,,,,,,,,,,,,,,,,decreasing ceramide,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010476,60S ribosomal protein L27,,,false,,,http://purl.obolibrary.org/obo/IMR_0000897,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0010476,,,,,,,,,,,,,,,,,,,,,,60S ribosomal protein L27,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000192,tropomyosin,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000188,,,,,,,,,,IMR:0000192,,,,,,,,,,,,,,,,,,,,,,tropomyosin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0001844,increased acidity,,An acidity which is relatively high.,false,,,http://purl.obolibrary.org/obo/PATO_0001842,,,,,,,,,,,,,,,,,,,,,,An acidity which is relatively high.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0001844,,,,,,,,,,,,,,,,,,,,,,increased acidity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0001842,acidity,pH,A concentration quality inhering in a bearer by virtue of the bearer's containing acid (hydrogen ions).,false,,,http://purl.obolibrary.org/obo/BFO_0000019,,,,,,,,,,,,,,,,,,,,,,A concentration quality inhering in a bearer by virtue of the bearer's containing acid (hydrogen ions).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pH,,,,PATO:0001842,,,,,,,,,,,,,,,,,,,,,,acidity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0001843,decreased acidity,,An acidity which is relatively low.,false,,,http://purl.obolibrary.org/obo/PATO_0001842,,,,,,,,,,,,,,,,,,,,,,An acidity which is relatively low.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0001843,,,,,,,,,,,,,,,,,,,,,,decreased acidity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001182,hyperfunction of drug metabolism phase I  by Cytochrome P450 [Glutathione depletion],hyperfunction of drug metabolism by P450 [Glutathione depletion],"Hyperfunction of drug metabolism phase I is a subtype of hyperfunctioning of drug metabolism: A process that performs an excessive drug metabolism phase I.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0001623|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of drug metabolism phase I is a subtype of hyperfunctioning of drug metabolism: A process that performs an excessive drug metabolism phase I.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001183|http://purl.obolibrary.org/obo/TXPO_0001178,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003173|http://purl.obolibrary.org/obo/TXPO_0001178,,,,,,hyperfunction of drug metabolism by P450 [Glutathione depletion],,,,,TXPO:0001182,,,,,,,,,,,,,,,,,,,,,,hyperfunction of drug metabolism phase I  by Cytochrome P450 [Glutathione depletion],,,,,,http://purl.obolibrary.org/obo/TXPO_0000117,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005790,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001183,cytochrome P450 activation [Glutathione depletion],P450 activation [Glutathione depletion]|Cytochrome P450 activation [Glutathione depletion],"Cytochrome P450 activation is a subtype of molecular activation: A process that changes the activity of the cytochrome P450 to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0001758|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Cytochrome P450 activation is a subtype of molecular activation: A process that changes the activity of the cytochrome P450 to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003170|http://purl.obolibrary.org/obo/TXPO_0003171|http://purl.obolibrary.org/obo/TXPO_0003389|http://purl.obolibrary.org/obo/TXPO_0003805|http://purl.obolibrary.org/obo/TXPO_0001918,,,,,,http://purl.obolibrary.org/obo/TXPO_0001184,,,,,,P450 activation [Glutathione depletion]|Cytochrome P450 activation [Glutathione depletion],,,,,TXPO:0001183,,,,,,,,,,,,,,,,,,,,,,cytochrome P450 activation [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001184,NAPQI production [Glutathione depletion],,"NAPQI production is a subtype of generating a substance : A process that synthesizes NAPQI (N-acetyl-p-benzoquinone imine) as output.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0000528|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,PMID:21177773,,"NAPQI production is a subtype of generating a substance : A process that synthesizes NAPQI (N-acetyl-p-benzoquinone imine) as output.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003170|http://purl.obolibrary.org/obo/TXPO_0003171|http://purl.obolibrary.org/obo/TXPO_0003805,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001922,,,,http://purl.obolibrary.org/obo/TXPO_0000974,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001920,,,,,,,,,,,TXPO:0001184,,,,,,,,,,,,,,,,,,,,,,NAPQI production [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001181,hyperfunction of cytochrome P450 gene expression [Glutathione depletion],hyperfunction of P450 gene expression [Glutathione depletion]|hyperfunction of Cytochrome P450 gene expression [Glutathione depletion],"Hyperfunction of cutochrome P450 gene expression is a subtype of hyperfunction of drug metabolizing enzyme gene expression: A process that performs an excesssive gene expression of cytochrome p450.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0002051|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of cutochrome P450 gene expression is a subtype of hyperfunction of drug metabolizing enzyme gene expression: A process that performs an excesssive gene expression of cytochrome p450.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001183,,,,,,hyperfunction of P450 gene expression [Glutathione depletion]|hyperfunction of Cytochrome P450 gene expression [Glutathione depletion],,,,,TXPO:0001181,,,,,,,,,,,,,,,,,,,,,,hyperfunction of cytochrome P450 gene expression [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001186,increasing demand for response to mitochondrial oxidative stres [Oxidative stress],,"Increasing demand for response to mitochondrial oxidative stress is a subtype of increasing the demand for response to oxidative stress: A process that changes the functional demand for the response to the mitochondrial oxidative stress to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Oxidative stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001730|http://purl.obolibrary.org/obo/TXPO_0002301,,,,,,,,,,,,,,,,,,,,,,"Increasing demand for response to mitochondrial oxidative stress is a subtype of increasing the demand for response to oxidative stress: A process that changes the functional demand for the response to the mitochondrial oxidative stress to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Oxidative stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000042,,,,,,,,,,,TXPO:0001186,,,,,,,,,,,,,,,,,,,,,,increasing demand for response to mitochondrial oxidative stres [Oxidative stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001188,negative regulation glutathione conjugation [Glutathione depletion],,"Any process that stops, prevents, or reduces the frequency, rate or extent of glutathione conjugation process.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0002056|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,ISBN:0071769234,,"Any process that stops, prevents, or reduces the frequency, rate or extent of glutathione conjugation process.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001924|http://purl.obolibrary.org/obo/TXPO_0001941|http://purl.obolibrary.org/obo/TXPO_0002065,,,,,,http://purl.obolibrary.org/obo/TXPO_0001191,,,,,,,,,,,TXPO:0001188,,,,,,,,,,,,,,,,,,,,,,negative regulation glutathione conjugation [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001185,increasing demand for glutathione conjugation [Glutathione depletion],,"Increasing demand for glutathione conjugation is a subtype of increasing functional demand: A process changes the functional demand for the for glutathione conjugation to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0000848|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Increasing demand for glutathione conjugation is a subtype of increasing functional demand: A process changes the functional demand for the for glutathione conjugation to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001191,,,,,,,,,,,TXPO:0001185,,,,,,,,,,,,,,,,,,,,,,increasing demand for glutathione conjugation [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001189,hypofunction of drug metabolism phase II [Glutathione depletion],,"Hypofunction of drug metabolism phase II is a subtype of hypofunction of drug metabolism: A process that performs a decreased or insufficient drug metabolism phase II.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0002330|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Hypofunction of drug metabolism phase II is a subtype of hypofunction of drug metabolism: A process that performs a decreased or insufficient drug metabolism phase II.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001189,,,,,,,,,,,,,,,,,,,,,,hypofunction of drug metabolism phase II [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001180,hyperfunction of drug metabolizing enzyme gene expression [Glutathione depletion],,"Hyperfunction of drug metabolizing enzyme gene expression is a subtype of hyperfunction of gene expression: A process that performs an excesssive drug metabolizing enzyme gene expression.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0002332|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of drug metabolizing enzyme gene expression is a subtype of hyperfunction of gene expression: A process that performs an excesssive drug metabolizing enzyme gene expression.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001181,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001182,,,,,,,,,,,TXPO:0001180,,,,,,,,,,,,,,,,,,,,,,hyperfunction of drug metabolizing enzyme gene expression [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001187,JNK translocation from cytoplasm to mitochondria  [Glutathione depletion],,"JNK translocation from cytoplasm to mitochondria is a subtype of transmitting: A process that of the directed movement of JNK from the cytoplasm to the mitochondria.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0001195|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,"chronic ethanol-induced activation of KCs is attributed to gut-sourced LPS, which is a major component of outer membrane of Gram-negative bacteria and passes through the intestinal epithelial barrier.
Chronic ethanol exposure can increase translocation of LPS from gut to liver by enhancing the intestinal permeability and altering the gut microflora.",,"JNK translocation from cytoplasm to mitochondria is a subtype of transmitting: A process that of the directed movement of JNK from the cytoplasm to the mitochondria.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002298,,,,,,http://purl.obolibrary.org/obo/TXPO_0001207,,,,,,,,,,,TXPO:0001187,,,,,,,,,,,,,,,,,,,,,,JNK translocation from cytoplasm to mitochondria  [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000172,integrin,,"Integrins comprise a large family of cell surface receptors that are found in many animal species, ranging from sponge to mammals. They are composed of two subunits, alpha and beta, and each alpha beta combination has its own binding specificity and signaling properties.",false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,"Integrins comprise a large family of cell surface receptors that are found in many animal species, ranging from sponge to mammals. They are composed of two subunits, alpha and beta, and each alpha beta combination has its own binding specificity and signaling properties.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003688,,,,,,,,,,IMR:0000172,,,,,,,,,,,,,,,,,,,,,,integrin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010280,GLUT1,"HepG2 glucose transporter|GTR1|Solute carrier family 2, facilitated glucose transporter, member 1|Glucose transporter type 1, erythrocyte/brain",,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003336,,,,,"HepG2 glucose transporter|GTR1|Solute carrier family 2, facilitated glucose transporter, member 1|Glucose transporter type 1, erythrocyte/brain",,,,,IMR:0010280,,,,,,,,,,,,,,,,,,,,,,GLUT1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002774,NfkB gene regulation pathway,GO:0007249,"A series of molecular signals transduced with the regulation of transcription of target genes by NF-kappaB. In a resting state, NF-kappaB dimers are bound to I-kappaB proteins, sequestering NF-kappaB in the cytoplasm. Phosphorylation of I-kappaB targets I-kappaB for ubiquitination and proteasomal degradation, thus releasing the NF-kappaB dimers, which can translocate to the nucleus to bind DNA and regulate transcription.",false,,,http://purl.obolibrary.org/obo/TXPO_0001902,,,,,,,,,,,,,,,,,,,,,,"A series of molecular signals transduced with the regulation of transcription of target genes by NF-kappaB. In a resting state, NF-kappaB dimers are bound to I-kappaB proteins, sequestering NF-kappaB in the cytoplasm. Phosphorylation of I-kappaB targets I-kappaB for ubiquitination and proteasomal degradation, thus releasing the NF-kappaB dimers, which can translocate to the nucleus to bind DNA and regulate transcription.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002770,,,,,,,,,,,,,,,,,,TXPO:0002774,,,,,,,,,,,,,,,,GO:0007249,,,,,,NfkB gene regulation pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002770,gene expression bu NF-kappaB,,Gene expression bu NF-kappaB is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) by NF-kappaB.,false,,,http://purl.obolibrary.org/obo/TXPO_0000375,,,,,,,,,,,,,,,,,,,,,,Gene expression bu NF-kappaB is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) by NF-kappaB.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002770,,,,,,,,,,,,,,,,,,,,,,gene expression bu NF-kappaB,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002772,I-kappaB phosphorylation [NfKB pathway],,"I-kappaB phosphorylation is a subtype of phosphorylation: The process of introducing a phosphate group into an inhibitor of kappa B (I-kappaB) protein. Phosphorylation of I-kappaB targets I-kappaB for ubiquitination and proteasomal degradation, thus releasing bound NF-kappaB dimers, which can translocate to the nucleus to bind DNA and regulate transcription.
This entity is a specific course-dependent process. This process can constitute the course of NfKB pathway.",false,,,http://purl.obolibrary.org/obo/TXPO_0002495,,,,,,,,,,,,,,,,,,,,PMID:12464174|PMID:21772278|GO:0007252|PMID:15134788,,"I-kappaB phosphorylation is a subtype of phosphorylation: The process of introducing a phosphate group into an inhibitor of kappa B (I-kappaB) protein. Phosphorylation of I-kappaB targets I-kappaB for ubiquitination and proteasomal degradation, thus releasing bound NF-kappaB dimers, which can translocate to the nucleus to bind DNA and regulate transcription.
This entity is a specific course-dependent process. This process can constitute the course of NfKB pathway.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002777,,,,,,,,,,,TXPO:0002772,,,,,,,,,,,,,,,,,,,,,,I-kappaB phosphorylation [NfKB pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002779,Translocation of NF-kappaB [NfKB pathway],,"NF-kappaB transport into nucleus is a subtype of nuclear transport: A process that of the directed movement of NF-kappaB from the cytoplasm to the nucleus.
This entity is a specific course-dependent process. This process can constitute the course of NfKB pathway.",false,,,http://purl.obolibrary.org/obo/HINO_0017769,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/HINO_0017769,,"NF-kappaB transport into nucleus is a subtype of nuclear transport: A process that of the directed movement of NF-kappaB from the cytoplasm to the nucleus.
This entity is a specific course-dependent process. This process can constitute the course of NfKB pathway.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002769,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002785,,,,,,,,,,,TXPO:0002779,,,,,,,,,,,,,,,,,,,,,,Translocation of NF-kappaB [NfKB pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002771,PDI (canonical)[ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000871|http://purl.obolibrary.org/obo/TXPO_1000276,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:18453|NCBI-Rat-GeneID:25506|NCBI-Human-GeneID:5034|PMID:23198585|PMID:15158710|PMID:23637286,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002771,,,,,,,,,,,,,,,,,,,,,,PDI (canonical)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002775,inflammatory gene expression by NF-kappa B [ER stress - inflammation - IRE1-TRAF-NfkB pathway],,"Inflammatory gene expression by NF-kappa B is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) related to the inflammation by NF-kappa B.
This process is dependent on the IRE1-TRAF2-NfkB pathway mediated inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002770|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"Inflammatory gene expression by NF-kappa B is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) related to the inflammation by NF-kappa B.
This process is dependent on the IRE1-TRAF2-NfkB pathway mediated inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002768,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002775,,,,,,,,,,,,,,,,,,,,,,inflammatory gene expression by NF-kappa B [ER stress - inflammation - IRE1-TRAF-NfkB pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002773,XBP1 splicing [ER stress - inflammation],,"XBP1 splicing is a subtype of removing: The process of removing sections of the XBP1 RNA transcript to remove sequences.
This process is dependent on the inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000726,,,,,,,,,,,,,,,,,,,,,,"XBP1 splicing is a subtype of removing: The process of removing sections of the XBP1 RNA transcript to remove sequences.
This process is dependent on the inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002773,,,,,,,,,,,,,,,,,,,,,,XBP1 splicing [ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002778,degradation of IKB [NfkB pathway],,"Degradation of I-kappaB is a subtype of protein catabolic process: A process of the chemical reactions resulting in the breakdown of inhibitor of kappa B (I-kappaB) protein
This entity is a specific course-dependent process. This process can constitute the course of NfKB pathway.",false,,,http://purl.obolibrary.org/obo/TXPO_0002758,,,,,,,,,,,,,,,,,,,,,,"Degradation of I-kappaB is a subtype of protein catabolic process: A process of the chemical reactions resulting in the breakdown of inhibitor of kappa B (I-kappaB) protein
This entity is a specific course-dependent process. This process can constitute the course of NfKB pathway.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002779,,,,,,,,,,,TXPO:0002778,,,,,,,,,,,,,,,,,,,,,,degradation of IKB [NfkB pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002776,ERDJ5 (canonical)[ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000871|http://purl.obolibrary.org/obo/TXPO_1000127,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:54431|NCBI-Mouse-GeneID:66861|NCBI-Rat-GeneID:295690|PMID:18653895,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002776,,,,,,,,,,,,,,,,,,,,,,ERDJ5 (canonical)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002777,ubiquitination of IkB [NfKB pathway],,"Ubiquitination of IkB is a subtype of protein ubiquitination: The process in which one or more ubiquitin groups are added to IkB.
This entity is a specific course-dependent process. This process can constitute the course of NfKB pathway.",false,,,http://purl.obolibrary.org/obo/TXPO_0002727,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/HINO_0017767|PMID:12464174,,"Ubiquitination of IkB is a subtype of protein ubiquitination: The process in which one or more ubiquitin groups are added to IkB.
This entity is a specific course-dependent process. This process can constitute the course of NfKB pathway.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002810,,,,,,,,,,,TXPO:0002777,,,,,,,,,,,,,,,,,,,,,,ubiquitination of IkB [NfKB pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000290,Ras,Ras GTPase,,false,,,http://purl.obolibrary.org/obo/IMR_0000289,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ras GTPase,,,,,IMR:0000290,,,,,,,,,,,,,,,,,,,,,,Ras,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000340665,CYP26C1,,Other designations: cytochrome P450 26C1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,FFDD4,,,,,,,,,,,,10,,,,,,HPRD:12230|MIM:608428|Vega:OTTHUMG00000018766|HGNC:20577|Ensembl:ENSG00000187553,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 26, subfamily C, polypeptide 1",,,10q23.33,,,,,,,,,,,,,,,,"GO_0001972 (EC: IDA, PMID:14532297); GO_0005506 (EC: IEA); GO_0005789 (EC: TAS); GO_0006766 (EC: TAS); GO_0006805 (EC: TAS); GO_0007417 (EC: ISS); GO_0008401 (EC: IDA, PMID:14532297); GO_0009952 (EC: ISS); GO_0014032 (EC: ISS); GO_0016021 (EC: IEA); GO_0020037 (EC: IEA); GO_0034653 (EC: IDA, PMID:14532297); GO_0044281 (EC: TAS); GO_0048284 (EC: ISS); GO_0048387 (EC: NAS, PMID:14532297); GO_0055114 (EC: IDA, PMID:14532297)",,,,,,,,,PMID:14532297; 15128046; 15164054; 16385451; 16933217; 19703508; 21139048; 21850183; 23161670,,,,,,,,,,,,,,,OGG:3000340665,,,,,,,"cytochrome P450, family 26, subfamily C, polypeptide 1",,,,,,,,,,,,,Other designations: cytochrome P450 26C1,,CYP26C1,,,,,,,,,,,,,,,,,,,,,,,340665,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP26C1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000351,IRS,insulin receptor substrate,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003684,,,,,insulin receptor substrate,,,,,IMR:0000351,,,,,,,,,,,,,,,,,,,,,,IRS,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0033344,cholesterol efflux,cholesterol export,"The directed movement of cholesterol, cholest-5-en-3-beta-ol, out of a cell or organelle.",false,,,http://purl.obolibrary.org/obo/TXPO_0002588,,,,,,,,,,,,,,,,,,,,,,"The directed movement of cholesterol, cholest-5-en-3-beta-ol, out of a cell or organelle.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_16113,,,,,,,,,,,,,,cholesterol export,,,,,GO:0033344,,,,,,,,,,,,,,,,,,,,,,cholesterol efflux,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0042775,mitochondrial ATP synthesis coupled electron transport,,"The transfer of electrons through a series of electron donors and acceptors, generating energy that is ultimately used for synthesis of ATP, as it occurs in the mitochondrial inner membrane or chloroplast thylakoid membrane.",false,,,http://purl.obolibrary.org/obo/GO_0042773,,,,,,,,,,,,,,,,,,,,,,"The transfer of electrons through a series of electron donors and acceptors, generating energy that is ultimately used for synthesis of ATP, as it occurs in the mitochondrial inner membrane or chloroplast thylakoid membrane.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0042775,,,,,,,,,,,,,,,,,,,,,,mitochondrial ATP synthesis coupled electron transport,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0042773,ATP synthesis coupled electron transport,,"The transfer of electrons through a series of electron donors and acceptors, generating energy that is ultimately used for synthesis of ATP.",false,,,http://purl.obolibrary.org/obo/GO_0022904,,,,,,,,,,,,,,,,,,,,,,"The transfer of electrons through a series of electron donors and acceptors, generating energy that is ultimately used for synthesis of ATP.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0042773,,,,,,,,,,,,,,,,,,,,,,ATP synthesis coupled electron transport,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100388,IFN beta,Interferon beta,,false,,,http://purl.obolibrary.org/obo/IMR_0000028,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Interferon beta,,,,,IMR:0100388,,,,,,,,,,,,,,,,,,,,,,IFN beta,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002746,positive regulation of cellular response to oxidative stress [ER stress],,"Any process that activates or increases the frequency, rate or extent of cellular response to oxidative stress.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/GO_1900409|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"Any process that activates or increases the frequency, rate or extent of cellular response to oxidative stress.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002618,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002747,,,,,,,,,,,TXPO:0002746,,,,,,,,,,,,,,,,,,,,,,positive regulation of cellular response to oxidative stress [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002748,oxidation-antioxidtion inbalance,,Oxidation-antioxidtion inbalance is a subtype of imbalance: A process that lacks a balance between oxidation and anti-oxidation that inhibits oxidation.,false,,,http://purl.obolibrary.org/obo/TXPO_0000567,,,,,,,,,,,,,,,,,,,,PMID:24641954,,Oxidation-antioxidtion inbalance is a subtype of imbalance: A process that lacks a balance between oxidation and anti-oxidation that inhibits oxidation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002748,,,,,,,,,,,,,,,,,,,,,,oxidation-antioxidtion inbalance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002743,PERK signaling to Nrf2 [ER stress],,"A process in which a signal to NRF2 is transduced PERK .
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002742,,,,,,,,,,,,,,,,,,,,,,"A process in which a signal to NRF2 is transduced PERK .
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002739,,,,,,,,,,,,,,,,,,TXPO:0002743,,,,,,,,,,,,,,,,,,,,,,PERK signaling to Nrf2 [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002747,oxidation-antioxidtion inbalance [ER stress],,"Oxidation-antioxidtion inbalance is a subtype of imbalance: A process that lacks a balance between oxidation and anti-oxidation that inhibits oxidation.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002748|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"Oxidation-antioxidtion inbalance is a subtype of imbalance: A process that lacks a balance between oxidation and anti-oxidation that inhibits oxidation.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002747,,,,,,,,,,,,,,,,,,,,,,oxidation-antioxidtion inbalance [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002741,receiving abnormal protein signal by PERK [ER stress],,"Receiving abnormal protein signal by PERK is a subtype of receiving signal: A process that recognizes another object and changes into an abnormal protein (e.g., misfolded protein, etc.) signal by PERK.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/TXPO_0001837,,,,,,,,,,,,,,,,,,,,,,"Receiving abnormal protein signal by PERK is a subtype of receiving signal: A process that recognizes another object and changes into an abnormal protein (e.g., misfolded protein, etc.) signal by PERK.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000301,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002449,,,,,,,,,,,TXPO:0002741,,,,,,,,,,,,,,,,,,,,,,receiving abnormal protein signal by PERK [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002745,NRF2 - transcriptional regulator (canonical)[ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000047,http://purl.obolibrary.org/obo/TXPO_0002744,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:83619|NCBI-Human-GeneID:4780,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_22586|http://purl.obolibrary.org/obo/TXPO_0003645,,,,,,,,,,TXPO:0002745,,,,,,,,,,,,,,,,,,,,,,NRF2 - transcriptional regulator (canonical)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002740,PERK-Nrf2 mediated pathway,,"PERK-NRF2 mediated pathway is a subtype of PERK signaling (integrated pathway): Sequence of linked reactions, which has PERK-NRF2 signaling and gene regulation pathway.
This pathway is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002735,,,,,,,,,,,,,,,,,,,,,,"PERK-NRF2 mediated pathway is a subtype of PERK signaling (integrated pathway): Sequence of linked reactions, which has PERK-NRF2 signaling and gene regulation pathway.
This pathway is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002749|http://purl.obolibrary.org/obo/TXPO_0002739|http://purl.obolibrary.org/obo/TXPO_0002765|http://purl.obolibrary.org/obo/TXPO_0002750,,http://purl.obolibrary.org/obo/TXPO_0000285,,,,,,,,,,,,,,,,TXPO:0002740,,,,,,,,,,,,,,,,,,,,,,PERK-Nrf2 mediated pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002749,receiving oxidative signal by PERK [ER stress],,"Receiving oxidative signal by PERK is a subtype of receiving signal: A process that recognizes another object and changes into a oxidative signal by PERK.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001837,,,,,,,,,,,,,,,,,,,,,,"Receiving oxidative signal by PERK is a subtype of receiving signal: A process that recognizes another object and changes into a oxidative signal by PERK.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002743,,,,,,,,,,,TXPO:0002749,,,,,,,,,,,,,,,,,,,,,,receiving oxidative signal by PERK [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002742,PERK signaling to Nrf2 [PERK - eIF2A pathway],,"A process in which a signal to NRF2 is transduced PERK.
This entity is a specific course-dependent process. This process can constitute the course of PERK - eIF2A pathway.",false,,,http://purl.obolibrary.org/obo/TXPO_0000454,,,,,,,,,,,,,,,,,,,,,,"A process in which a signal to NRF2 is transduced PERK.
This entity is a specific course-dependent process. This process can constitute the course of PERK - eIF2A pathway.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002736,,http://purl.obolibrary.org/obo/TXPO_0002490,,,,,,,,,,,,,,,,TXPO:0002742,,,,,,,,,,,,,,,,,,,,,,PERK signaling to Nrf2 [PERK - eIF2A pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002744,antioxidant gene expression by NRF2 [ER stress],,"Antioxidant gene expression by NRF2 is a subtype of gene expression: The process in which an antioxidant gene sequence is converted into a mature antioxidant gene product or products (proteins or RNA) by NRF2.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002618,,,,,,,,,,,,,,,,,,,,,,"Antioxidant gene expression by NRF2 is a subtype of gene expression: The process in which an antioxidant gene sequence is converted into a mature antioxidant gene product or products (proteins or RNA) by NRF2.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002745,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002749|http://purl.obolibrary.org/obo/TXPO_0002739|http://purl.obolibrary.org/obo/TXPO_0002750,,http://purl.obolibrary.org/obo/TXPO_0002740,,,,,,,,,,,,,,,,TXPO:0002744,,,,,,,,,,,,,,,,,,,,,,antioxidant gene expression by NRF2 [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_51372,neuromuscular agent,,A drug used for its actions on skeletal muscle.,false,,,http://purl.obolibrary.org/obo/CHEBI_23888,,,,,,,,,,,,,,,,,,,,,,A drug used for its actions on skeletal muscle.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:51372,,,,neuromuscular agent,,CHEBI:51372,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000440275,EIF2AK4,,Other designations: GCN2 eIF2alpha kinase|GCN2-like protein|eukaryotic translation initiation factor 2-alpha kinase 4|general control nonderepressible 2,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,PVOD2|GCN2,,,,,,,,,,,,15,,,,,,Vega:OTTHUMG00000172403|HGNC:19687|Ensembl:ENSG00000128829|HPRD:18447|MIM:609280,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,eukaryotic translation initiation factor 2 alpha kinase 4,,,15q15.1,,,,,,,,,,,,,,,,GO_0004674 (EC: ISS); GO_0004694 (EC: ISS); GO_0005524 (EC: IEA); GO_0006446 (EC: ISS); GO_0006468 (EC: ISS); GO_0009267 (EC: IEA); GO_0017148 (EC: IEA); GO_0022626 (EC: ISS); GO_0030968 (EC: IEA); GO_0042803 (EC: IEA); GO_0043558 (EC: IEA),,,,,,,,,PMID:10504407; 10718198; 12215525; 12477932; 14671302; 14702039; 15489334; 15761153; 15892049; 16121183; 16601681; 17081983; 17192257; 17202131; 17276353; 17620599; 18287093; 19029902; 19586904; 19615732; 20168091; 20473272; 20551969; 21076179; 21113813; 21139048; 21203563; 22301437; 22327514; 22435535; 22896630; 22969067; 23110064; 23129244; 23216249; 23354059; 23417324; 23908598; 24019515; 24113185; 24292273; 24310610,,,,,,,,,,,,,,,OGG:3000440275,,,,,,,eukaryotic translation initiation factor 2 alpha kinase 4,,,,,,,,,,,,,Other designations: GCN2 eIF2alpha kinase|GCN2-like protein|eukaryotic translation initiation factor 2-alpha kinase 4|general control nonderepressible 2,,EIF2AK4,,,,,,,,,,,,,,,,,,,,,,,440275,,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF2AK4,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0010550,40S ribosomal protein S25,40S small ribosomal protein 25,,false,,,http://purl.obolibrary.org/obo/IMR_0000896,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,40S small ribosomal protein 25,,,,,IMR:0010550,,,,,,,,,,,,,,,,,,,,,,40S ribosomal protein S25,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76932,pathway inhibitor,metabolic pathway inhibitor|pathway inhibitors|metabolic pathway inhibitors,An enzyme inhibitor that interferes with one or more steps in a signaling or metabolic pathway.|An enzyme inhibitor that interferes with one or more steps in a metabolic pathway.,false,,,http://purl.obolibrary.org/obo/TXPO_0003720|http://purl.obolibrary.org/obo/CHEBI_23924,,,,,,,,,,,,,,,,,,,,,,An enzyme inhibitor that interferes with one or more steps in a signaling or metabolic pathway.|An enzyme inhibitor that interferes with one or more steps in a metabolic pathway.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,metabolic pathway inhibitor|pathway inhibitors|metabolic pathway inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:76932,,,,pathway inhibitor,,CHEBI:76932,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000190,negative regulation of cytokine gene expression [Eosinophilic granular degeneration],,"Negative regulation of cytokine gene expression is a subtype of negative regulation of gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of inflammatory cytokine gene expression.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/TXPO_0003218|http://purl.obolibrary.org/obo/TXPO_0001729,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of cytokine gene expression is a subtype of negative regulation of gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of inflammatory cytokine gene expression.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001328,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003207,,,,,,,,,,,TXPO:0000190,,,,,,,,,,,,,,,,,,,,,,negative regulation of cytokine gene expression [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000198,oncogene mRNA stabilization [Eosinophilic granular degeneration],,"Oncogene mRNA stabilization is a subtype of keeping structure: A process that maintaing the mRNA structure of ongogenes.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/TXPO_0000197|http://purl.obolibrary.org/obo/TXPO_0001729,,,,,,,,,,,,,,,,,,,,,,"Oncogene mRNA stabilization is a subtype of keeping structure: A process that maintaing the mRNA structure of ongogenes.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000136,,,,,,,,,,,TXPO:0000198,,,,,,,,,,,,,,,,,,,,,,oncogene mRNA stabilization [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000194,accumulation of abnormal proteins in ER [ER stress],,"Accumulation of abnormal proteins in ER is a subtype of accumulation of abnormal proteins: A process that keeps abnormal protein(s) in the ER (endoplasmic reticulum).
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/TXPO_0002187,,,,,,,,,,,,,,,,,,,,,,"Accumulation of abnormal proteins in ER is a subtype of accumulation of abnormal proteins: A process that keeps abnormal protein(s) in the ER (endoplasmic reticulum).
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000194,,,,,,,,,,,,,,,,,,,,,,accumulation of abnormal proteins in ER [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005783,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000197,oncogene mRNA stabilization,,Oncogene mRNA stabilization is a subtype of keeping structure: A process that maintaing the mRNA structure of ongogenes.,false,,,http://purl.obolibrary.org/obo/TXPO_0003733,,,,,,,,,,,,,,,,,,,,,,Oncogene mRNA stabilization is a subtype of keeping structure: A process that maintaing the mRNA structure of ongogenes.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000197,,,,,,,,,,,,,,,,,,,,,,oncogene mRNA stabilization,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000196,regulation of gene expression by miRNA [Eosinophilic granular degeneration],,"Any process that modulates the frequency, rate or extent of gene expression by miRNA.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/TXPO_0000195|http://purl.obolibrary.org/obo/TXPO_0001729,,,,,,,,,,,,,,,,,,,,,,"Any process that modulates the frequency, rate or extent of gene expression by miRNA.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000198,,,,,,,,,,,TXPO:0000196,,,,,,,,,,,,,,,,,,,,,,regulation of gene expression by miRNA [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000195,regulation of gene expression by miRNA,,"Any process that modulates the frequency, rate or extent of gene expression by miRNA.",false,,,http://purl.obolibrary.org/obo/GO_0010468,,,,,,,,,,,,,,,,,,,,,,"Any process that modulates the frequency, rate or extent of gene expression by miRNA.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000195,,,,,,,,,,,,,,,,,,,,,,regulation of gene expression by miRNA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000192,inflammatory response,inflammation,"Inflammatory response is a subtype of changing material: The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages.",false,,,http://purl.obolibrary.org/obo/TXPO_0002590,,,,,,,,,,,,,,,,,,,,,,"Inflammatory response is a subtype of changing material: The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,inflammation,,,TXPO:0000192,,,,,,,,,,,,,,,,,,,,,,inflammatory response,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000193,GCLC (canonical)[Glutathione depletion],,ATP dependent,false,,,http://purl.obolibrary.org/obo/TXPO_0002045|http://purl.obolibrary.org/obo/TXPO_1000163,,,,,,,,,,,,,,,,,,,,PMID:23856494,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002394,,,,,,,,,,TXPO:0000193,,,,,,,,,,,,,,,,,,,,ATP dependent,,GCLC (canonical)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000191,inflammatory cytokine gene expression [Eosinophilic granular degeneration],,"Inflammatory cytokine gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature inflammatory cytokine gene product or products (proteins or RNA).
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.|PPARα inhibits NF-κB to express inflammatory cytokines (TNF-α, IL-1b, etc).",false,,,http://purl.obolibrary.org/obo/TXPO_0002266|http://purl.obolibrary.org/obo/TXPO_0001729,,,,,,,,,,,,,,,,,,,,,,"Inflammatory cytokine gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature inflammatory cytokine gene product or products (proteins or RNA).
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000191,,,,,,,,,,,,,,,,,,,,"PPARα inhibits NF-κB to express inflammatory cytokines (TNF-α, IL-1b, etc).",,inflammatory cytokine gene expression [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000199,liver cancer dependent chemical entity,,"Liver cacer dependent chemical entity is a subtype of toxic course dependent chemical entity.
This entity can participate in the course of liver cancer.|under construction",false,,,http://purl.obolibrary.org/obo/TXPO_0001731,,,,,,,,,,,,,,,,,,,,,,"Liver cacer dependent chemical entity is a subtype of toxic course dependent chemical entity.
This entity can participate in the course of liver cancer.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000199,,,,,,,,,,,,,,,,,,,,under construction,,liver cancer dependent chemical entity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_16325,lithocholic acid,,A monohydroxy-5β-cholanic acid with aα-hydroxy substituent at position 3. It is a bile acid obtained from chenodeoxycholic acid by bacterial action.,false,,,http://purl.obolibrary.org/obo/TXPO_0000509,,,,,,,,,,,,,,,,,,,,,,A monohydroxy-5β-cholanic acid with aα-hydroxy substituent at position 3. It is a bile acid obtained from chenodeoxycholic acid by bacterial action.,,,,,,,,,,,,C24H40O3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:16325,,,,,,,,,,,,,,,,,,,,,,lithocholic acid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,[H][C@]12CC[C@]3([H])[C@]([H])(CC[C@]4(C)[C@]([H])(CC[C@@]34[H])[C@H](C)CCC(O)=O)[C@@]1(C)CC[C@@H](O)C2,,,,,
http://purl.obolibrary.org/obo/PATO_0002129,"neoplastic, invasive",,A disposition inhering in a tumour by virtue of the bearer's disposition to invade surrounding tissues.,false,,,http://purl.obolibrary.org/obo/PATO_0002011,,,,,,,,,,,,,,,,,,,,,,A disposition inhering in a tumour by virtue of the bearer's disposition to invade surrounding tissues.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0002129,,,,,,,,,,,,,,,,,,,,,,"neoplastic, invasive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0030968,endoplasmic reticulum unfolded protein response,ER unfolded protein response,"The series of molecular signals generated as a consequence of the presence of unfolded proteins in the endoplasmic reticulum (ER) or other ER-related stress; results in changes in the regulation of transcription and translation.|Note that this term should not be confused with 'response to unfolded protein ; GO:0006986', which refers to any response to the presence of unfolded proteins anywhere in the cell or in multicellular organism. Also see 'ER-associated protein catabolic process ; GO:0030433'.",false,,,http://purl.obolibrary.org/obo/GO_0034976,,,,,,,,,,,,,,,,,,,,,,The series of molecular signals generated as a consequence of the presence of unfolded proteins in the endoplasmic reticulum (ER) or other ER-related stress; results in changes in the regulation of transcription and translation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ER unfolded protein response,,,,,GO:0030968,,,,,,,,,,,,,,,,,,,,"Note that this term should not be confused with 'response to unfolded protein ; GO:0006986', which refers to any response to the presence of unfolded proteins anywhere in the cell or in multicellular organism. Also see 'ER-associated protein catabolic process ; GO:0030433'.",,endoplasmic reticulum unfolded protein response,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000104,IL-6 receptor,interleukin-6 receptor,,false,,,http://purl.obolibrary.org/obo/IMR_0000096,,,,,,,,,,,,,,,,,,,,GO:0004915,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,interleukin-6 receptor,,,,,IMR:0000104,,,,,,,,,,,,,,,,,,,,,,IL-6 receptor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000006426,SRSF1,,"Other designations: ASF-1|SR splicing factor 1|alternative-splicing factor 1|pre-mRNA-splicing factor SF2, P33 subunit|splicing factor 2|splicing factor, arginine/serine-rich 1",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,ASF|SF2p33|SF2|SFRS1|SRp30a,,,,,,,,,,,,17,,,,,,MIM:600812|HGNC:10780|HPRD:02887,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,serine/arginine-rich splicing factor 1,,,17q22,,,,,,,,,,,,,,,,"GO_0000166 (EC: IEA); GO_0000395 (EC: IDA, PMID: 9885563); GO_0000398 (EC: IC, PMID: 11991638); GO_0000398 (EC: TAS); GO_0001701 (EC: IEA); GO_0003723 (EC: IDA, PMID: 19561594); GO_0003723 (EC: IPI); GO_0003729 (EC: IDA); GO_0005515 (EC: IPI, PMID: 10196197); GO_0005634 (EC: IDA); GO_0005654 (EC: IDA, PMID: 9885563); GO_0005654 (EC: TAS); GO_0005737 (EC: IEA); GO_0006366 (EC: TAS); GO_0006369 (EC: TAS); GO_0006376 (EC: TAS, PMID: 1830244); GO_0006397 (EC: TAS, PMID: 1830244); GO_0006406 (EC: TAS); GO_0008380 (EC: TAS); GO_0010467 (EC: TAS); GO_0016607 (EC: IDA); GO_0031124 (EC: TAS); GO_0035145 (EC: IDA, Qualifier: colocalizes_with, PMID: 16314458); GO_0044822 (EC: IDA); GO_0050733 (EC: IEA); GO_0060048 (EC: IEA); GO_0071013 (EC: IDA, PMID: 11991638)",,,,,,,,,PMID: 1577277; 1741384; 1830244; 1855257; 7512732; 7543047; 8125298; 8139654; 8189522; 8208298; 8223481; 8261509; 8530103; 8617202; 8626563; 8639538; 8798720; 8816452; 9023367; 9237760; 9420331; 9447963; 9472028; 9473574; 9611241; 9671816; 9685421; 9799243; 9885563; 10022843; 10196197; 10225947; 10366588; 10390541; 10713112; 10757789; 10843177; 11101529; 11285240; 11418604; 11683387; 11779509; 11790298; 11801589; 11825891; 11967326; 11991638; 12135490; 12215544; 12221105; 12226669; 12234937; 12270705; 12477932; 12525645; 12565863; 12612063; 14555757; 14559993; 14623875; 15123677; 15163745; 15184380; 15208309; 15210956; 15243141; 15367627; 15452250; 15456888; 15489334; 15546619; 15592455; 15635413; 15652350; 15782174; 15798186; 15848144; 15907217; 15998806; 16000324; 16051665; 16096057; 16189514; 16196087; 16210245; 16223727; 16260492; 16314458; 16344560; 16376875; 16505493; 16611940; 16721827; 16982639; 17081983; 17310252; 17332742; 17353931; 17361185; 17517895; 17609381; 17670832; 17786225; 17959926; 18155240; 18243119; 18315555; 18391021; 18439897; 18457437; 18495665; 18586677; 18687337; 18832178; 18841201; 18945764; 19004959; 19073146; 19111562; 19116412; 19250906; 19322201; 19441081; 19464723; 19477182; 19523114; 19561594; 19602482; 19608861; 19633418; 19657567; 19710015; 19716452; 19738201; 19857271; 19966273; 20085707; 20118245; 20120036; 20139984; 20211142; 20308322; 20360068; 20385090; 20508642; 20516191; 20519389; 20637698; 20639865; 20657585; 20668893; 20682707; 20805487; 20923760; 21045158; 21078624; 21081666; 21139048; 21145461; 21182205; 21297941; 21536904; 21549307; 21622622; 21668763; 21832049; 21853274; 21890473; 21906983; 21907836; 21963094; 21988832; 22053931; 22094256; 22245967; 22268729; 22365833; 22446626; 22454513; 22505724; 22545246; 22839530; 22855529; 22939629; 22952844; 22990118; 23000965; 23084401; 23184937; 23228155; 23319613; 23349975; 23398456; 23462647; 23478443; 23537643; 23592547; 23602568; 23658645; 23707382; 23748175; 24244333; 24250222; 24368769; 24457600,,,,,,,,,,,,,,,OGG:3000006426,,,,,,,serine/arginine-rich splicing factor 1,,,,,,,,,,,,,"Other designations: ASF-1|SR splicing factor 1|alternative-splicing factor 1|pre-mRNA-splicing factor SF2, P33 subunit|splicing factor 2|splicing factor, arginine/serine-rich 1",,SRSF1,,,,,,,,,,,,,,,,,,,,,,,6426,OK/SW-cl.3,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,SRSF1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0004077,energy supply,,Energy supply is a subtype of providing process to perform a meta-function “to provide energy.,false,,,http://purl.obolibrary.org/obo/TXPO_0000741,,,,,,,,,,,,,,,,,,,,,,Energy supply is a subtype of providing process to perform a meta-function “to provide energy.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004077,,,,,,,,,,,,,,,,,,,,,,energy supply,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004073,INHBE [Hepatocarcinogenesis],"inhibin, beta E [Hepatocarcinogenesis]",,false,,,http://purl.obolibrary.org/obo/TXPO_0000837|http://purl.obolibrary.org/obo/TXPO_1000203,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:83711|NCBI-Human-GeneID:83729|NCBI-Mouse-GeneID:16326|PMID:24280420|PMID:22935518|PMID:27939373,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"inhibin, beta E [Hepatocarcinogenesis]",,,,,TXPO:0004073,,,,,,,,,,,,,,,,,,,,,,INHBE [Hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004076,JMJD6 [Hepatocarcinogenesis],jumonji domain containing 6 [Hepatocarcinogenesis],,false,,,http://purl.obolibrary.org/obo/TXPO_1000214|http://purl.obolibrary.org/obo/TXPO_0000837,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:107817|NCBI-Rat-GeneID:360665|NCBI-Human-GeneID:23210|PMID:19574390|PMID:10811223,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,jumonji domain containing 6 [Hepatocarcinogenesis],,,,,TXPO:0004076,,,,,,,"This gene encodes a nuclear protein with a JmjC domain. JmjC domain-containing proteins are predicted to function as protein hydroxylases or histone demethylases. This protein was first identified as a putative phosphatidylserine receptor involved in phagocytosis of apoptotic cells; however, subsequent studies have indicated that it does not directly function in the clearance of apoptotic cells, and questioned whether it is a true phosphatidylserine receptor. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008",,,,,,,,,,,,,,,JMJD6 [Hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004079,positive regulation of cell death,,"Any process that increases the rate or frequency of cell death. Cell death is the specific activation or halting of processes within a cell so that its vital functions markedly cease, rather than simply deteriorating gradually over time, which culminates in cell death.",false,,,http://purl.obolibrary.org/obo/GO_0010941,,,,,,,,,,,,,,,,,,,,,,"Any process that increases the rate or frequency of cell death. Cell death is the specific activation or halting of processes within a cell so that its vital functions markedly cease, rather than simply deteriorating gradually over time, which culminates in cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004079,,,,,,,,,,,,,,,,,,,,,,positive regulation of cell death,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0008219,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004071,Hist2h2aa3 [Hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000195|http://purl.obolibrary.org/obo/TXPO_0000837,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:8337|NCBI-Rat-GeneID:365877|PMID:18001825|PMID:17914355|PMID:19203579|PMID:18001824,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004071,,,,,,,,,,,,,,,,,,,,,,Hist2h2aa3 [Hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004070,Hmox1 (human)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000196|http://purl.obolibrary.org/obo/TXPO_0001135,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:3162|PMID:27571925|PMID:28497199|PMID:30515391|PMID:30927048|PMID:10330231|PMID:30606233,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000003162,,,,,,,,,,,,,TXPO:0004070,,,,,,,,,,,,,,,,,,,,,,Hmox1 (human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004075,ITGB1 [Hepatocarcinogenesis],"integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12) [Hepatocarcinogenesis]",,false,,,http://purl.obolibrary.org/obo/TXPO_0000837|http://purl.obolibrary.org/obo/TXPO_1000206,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:3688|NCBI-Rat-GeneID:24511|NCBI-Mouse-GeneID:16412|PMID:21363926|PMID:14522949|http://omim.org/entry/135630,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12) [Hepatocarcinogenesis]",,,,,TXPO:0004075,,,,,,,,,,,,,,,,,,,,,,ITGB1 [Hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004078,Mybl2 [Hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000837|http://purl.obolibrary.org/obo/TXPO_1000246,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:296344|NCBI-Human-GeneID:4605|NCBI-Mouse-GeneID:17865|http://omim.org/entry/601415,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004078,,,,,,,,,,,,,,,,,,,,,,Mybl2 [Hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004074,Isyna1 [Hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000213|http://purl.obolibrary.org/obo/TXPO_0000837,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:290651|NCBI-Human-GeneID:51477|NCBI-Mouse-GeneID:71780,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004074,,,,,,,,,,,,,,,,,,,,,,Isyna1 [Hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004072,PLA2G15 (canonical) positively regulator of immune response[Phospholipidosis],,PLA2G15 is to date the first and only identified lysosomal phospholipase A.,false,,,http://purl.obolibrary.org/obo/TXPO_0003213|http://purl.obolibrary.org/obo/TXPO_0000775,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:23659|NCBI-Rat-GeneID:361401|NCBI-Mouse-GeneID:192654|http://omim.org/entry/609362|PMID:30077006|PMID:21074554,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000283,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003572|http://purl.obolibrary.org/obo/TXPO_0003671,,,,,,,,,,TXPO:0004072,,,,,,,,,,,,,,,,,,,,PLA2G15 is to date the first and only identified lysosomal phospholipase A.,,PLA2G15 (canonical) positively regulator of immune response[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004487,Increasing CXCR4 level [hepatocarcinogenesis],,"Increasing CXCR4 level is a subtype of increasing quantity: A process that changes the amount of CXCR4 level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0004485|http://purl.obolibrary.org/obo/TXPO_0002340,,,,,,,,,,,,,,,,,,,,PMID:28584306,,"Increasing CXCR4 level is a subtype of increasing quantity: A process that changes the amount of CXCR4 level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004488,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004489|http://purl.obolibrary.org/obo/TXPO_0004417,,,,,,,,,,,TXPO:0004487,,,,,,,,,,,,,,,,,,,,,,Increasing CXCR4 level [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004480,CXCR3 signaling [hepatocarcinogenesis],,"CXCR3 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by CXCR3.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0004481|http://purl.obolibrary.org/obo/TXPO_0002340,,,,,,,,,,,,,,,,,,,,PMID:28240761,,"CXCR3 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by CXCR3.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004482,http://purl.obolibrary.org/obo/TXPO_0004484,,,,,http://purl.obolibrary.org/obo/TXPO_0004483,,,,,,,,,,,TXPO:0004480,,,,,,,,,,,,,,,,,,,,,,CXCR3 signaling [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004483,endothelial progenitor cell mobilization [hepatocarcinogenesis],,"The movement of an endothelial progenitor cell (EPC) within or between different tissues and organs of the body.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0005045|http://purl.obolibrary.org/obo/TXPO_0002340,,,,,,,,,,,,,,,,,,,,PMID:28240761,,"The movement of an endothelial progenitor cell (EPC) within or between different tissues and organs of the body.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004603,,,,,,,,,,,TXPO:0004483,,,,,,,,,,,,,,,,,,,,,,endothelial progenitor cell mobilization [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004486,CXCR4 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:12767|NCBI-Rat-GeneID:60628|NCBI-Human-GeneID:7852,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004486,,,,,,,,,,,,,,,,,,,,,,CXCR4 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004481,CXCR3 signaling (primitive),,CXCR3 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by CXCR3.,false,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,,,CXCR3 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by CXCR3.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_1000077,http://purl.obolibrary.org/obo/TXPO_0004484,,,,,,,,,,,,,,,,TXPO:0004481,,,,,,,,,,,,,,,,,,,,,,CXCR3 signaling (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004488,CXCR4 (human) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004486|http://purl.obolibrary.org/obo/TXPO_0004185,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:7852|PMID:28584306,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004488,,,,,,,,,,,,,,,,,,,,,,CXCR4 (human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004484,CXCR3 signal transduction pathway,,A series of molecular signals mediated by CXCR3 (CXC chemokine receptor 3).,false,,,http://purl.obolibrary.org/obo/TXPO_0000609,,,,,,,,,,,,,,,,,,,,,,A series of molecular signals mediated by CXCR3 (CXC chemokine receptor 3).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004484,,,,,,,,,,,,,,,,,,,,,,CXCR3 signal transduction pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004489,JNK signaling (primitive) [hepatocarcinogenesis],,"JNK signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the JNK (a stress-activated protein kinase (SAPK) ).
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0000769,,,,,,,,,,,,,,,,,,,,PMID:30523154|PMID:28584306,,"JNK signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the JNK (a stress-activated protein kinase (SAPK) ).
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004394|http://purl.obolibrary.org/obo/TXPO_0004391,,,,,,,,,,,TXPO:0004489,,,,,,,,,,,,,,,,,,,,,,JNK signaling (primitive) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004482,CXCR3(canonical) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000077|http://purl.obolibrary.org/obo/TXPO_0005063,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:84475|NCBI-Human-GeneID:2833|NCBI-Mouse-GeneID:12766|PMID:28240761,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004482,,,,,,,,,,,,,,,,,,,,,,CXCR3(canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004485,Increasing CXCR4 level,,Increasing CXCR4 level is a subtype of increasing quantity: A process that changes the amount of CXCR4 level to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing CXCR4 level is a subtype of increasing quantity: A process that changes the amount of CXCR4 level to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004486,,,,,,,,,,,,,,,,,,,TXPO:0004485,,,,,,,,,,,,,,,,,,,,,,Increasing CXCR4 level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001040,lipid metabolism imbalance (moderate) [Lipidosis],,"Lipid metabolism imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance of lipid metabolism. The degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000893,,,,,,,,,,,,,,,,,,,,,,"Lipid metabolism imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance of lipid metabolism. The degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001043,,,,,,,,,,,TXPO:0001040,,,,,,,,,,,,,,,,,,,,,,lipid metabolism imbalance (moderate) [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001044,lipid metabolism imbalance (severe) [Lipidosis],,"Lipid metabolism imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance of lipid metabolism. The degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000893,,,,,,,,,,,,,,,,,,,,,,"Lipid metabolism imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance of lipid metabolism. The degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001038,,,,,,,,,,,TXPO:0001044,,,,,,,,,,,,,,,,,,,,,,lipid metabolism imbalance (severe) [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001042,lipid accumulation in hepatocyte (moderate) [Lipidosis],lipid storage in hepatocyte (moderate) [Lipidosis],"Lipid accumulation in hepatocyte (severe) is a subtype of lipid strorage in hepatocyte: A process that keeps lipids in hepatocytes. And the degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001129,,,,,,,,,,,,,,,,,,,,,,"Lipid accumulation in hepatocyte (severe) is a subtype of lipid strorage in hepatocyte: A process that keeps lipids in hepatocytes. And the degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003540,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001521,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003478,,,,,,lipid storage in hepatocyte (moderate) [Lipidosis],,,,,TXPO:0001042,,,,,,,,,,,,,,,,,,,,,,lipid accumulation in hepatocyte (moderate) [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001049,moving fatty acid to the hepatocyte [lipidosis],,"Moving free fatty acid to the hepatocyte is a subtype of moving A to the inside of B: A process of the movement of  free fatty acid into a hepatocyte.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0001466,,,,,,,,,,,,,,,,,,,,,,"Moving free fatty acid to the hepatocyte is a subtype of moving A to the inside of B: A process of the movement of  free fatty acid into a hepatocyte.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001049,,,,,,,,,,,,,,,,,,,,,,moving fatty acid to the hepatocyte [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001047,Elovl6 (rat)[Eosinophilic granular degeneration],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001077|http://purl.obolibrary.org/obo/TXPO_1000125,,,,,,,,,,,,,,,,,,,,"NCBI-Rat-GeneID:171402|The birth rate of Elovl6 knockout mice was lower, and the surviving mice were smaller in size and had reduced body weight.
Crucial role of a long-chain fatty acid elongase, Elovl6, in obesity-induced insulin resistance.
Secondary regulation of PPARa activity could be a part of SREBP-1c/Elovl6 regulation of lipogenesis.|PMID:27467521|PMID:17906635",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001047,,,,,,,,,,,,,,,,,,,,,,Elovl6 (rat)[Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001046,ACOT4 (human)[Eosinophilic granular degeneration],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001034|http://purl.obolibrary.org/obo/TXPO_1000024,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:171282|NCBI-Rat-GeneID:681337|NCBI-Human-GeneID:122970|PMID:16940157|PMID:28385385|PMID:23967086,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001046,,,,,,,,,,,,,,,,,,,,,,ACOT4 (human)[Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001041,alcoholic fatty liver,,The totality of all processes through which alcoholic fatty liver is realized.|under construction,false,,,http://purl.obolibrary.org/obo/TXPO_0000888,,,,,,,,,,,,,,,,,,,,PMID:17854140,,The totality of all processes through which alcoholic fatty liver is realized.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001259|http://purl.obolibrary.org/obo/TXPO_0001118|http://purl.obolibrary.org/obo/TXPO_0000279|http://purl.obolibrary.org/obo/TXPO_0004210|http://purl.obolibrary.org/obo/TXPO_0004207|http://purl.obolibrary.org/obo/TXPO_0004209|http://purl.obolibrary.org/obo/TXPO_0001150|http://purl.obolibrary.org/obo/TXPO_0001131|http://purl.obolibrary.org/obo/TXPO_0001132|http://purl.obolibrary.org/obo/TXPO_0001130|http://purl.obolibrary.org/obo/TXPO_0001246|http://purl.obolibrary.org/obo/TXPO_0002357,,,,,,,,,,,,,,,,,,TXPO:0001041,,,,,,,,,,,,,,,,,,,,under construction,,alcoholic fatty liver,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001043,lipid homeostasis imbalance (moderate) [Lipidosis],,"Lipid homeostasis imbalance is a subtype of chemical homeostasis imbalance: A process that becomes lacking a lipid homeostastasis balance. The degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003491|http://purl.obolibrary.org/obo/TXPO_0003488,,,,,,,,,,,,,,,,,,,,,,"Lipid homeostasis imbalance is a subtype of chemical homeostasis imbalance: A process that becomes lacking a lipid homeostastasis balance. The degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001040,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001042,,http://purl.obolibrary.org/obo/TXPO_0000680,,,,,,,,,TXPO:0001043,,,,,,,,,,,,,,,,,,,,,,lipid homeostasis imbalance (moderate) [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001045,Pex11a (mouse)[Eosinophilic granular degeneration],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000648|http://purl.obolibrary.org/obo/TXPO_1000278,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:18631|http://www.genecards.org/cgi-bin/carddisp.pl?gene=PEX11A|PMID:20826455|PMID:12417726|PMID:23169785|PMID:16534556,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002350,,,,,,,,,,TXPO:0001045,,,,,,,,,,,,,,,,,,,,,,Pex11a (mouse)[Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001048,Hsdl2 (rat)[Eosinophilic granular degeneration],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001077|http://purl.obolibrary.org/obo/TXPO_1000198,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:313200,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001048,,,,,,,,,,,,,,,,,,,,,,Hsdl2 (rat)[Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000079982,DNAJB14,,Other designations: dnaJ homolog subfamily B member 14,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,EGNR9427|PRO34683,,,,,,,,,,,,4,,,,,,HGNC:25881|Vega:OTTHUMG00000131049|Ensembl:ENSG00000164031|HPRD:07013,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"DnaJ (Hsp40) homolog, subfamily B, member 14",,,4q23,,,,,,,,,,,,,,,,GO_0016021 (EC: IEA),,,,,,,,,PMID:12477932; 12975309; 14702039; 15489334; 15815621; 16344560; 21139048; 21832049; 23018488,,,,,,,,,,,,,,,OGG:3000079982,,,,,,,"DnaJ (Hsp40) homolog, subfamily B, member 14",,,,,,,,,,,,,Other designations: dnaJ homolog subfamily B member 14,,DNAJB14,,,,,,,,,,,,,,,,,,,,,,,79982,UNQ9427/PRO34683,,,,,,,9606,,,,,,,,,,,,,,,,,,,DNAJB14,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0002063,Sos1,,,false,,,http://purl.obolibrary.org/obo/IMR_0000435,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0002063,,,,,,,,,,,,,,,,,,,,,,Sos1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100159,adrenorphin,,,false,,,http://purl.obolibrary.org/obo/IMR_0100157,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100159,,,,,,,,,,,,,,,,,,,,,,adrenorphin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_135706,niperotidine,niperotidine hydrochloride|piperonyl ranitidine hydrochloride|perultid|piperonyl ranitidine HCl|niperotidine HCl,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Drug_Central:4002|CAS:84845-75-0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,niperotidine hydrochloride|piperonyl ranitidine hydrochloride|perultid|piperonyl ranitidine HCl|niperotidine HCl,,,,,,,,,,,,,,,,,,,,,CHEBI:135706,,,,niperotidine,,CHEBI:135706,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000683,JNK1,SAPK-1|p54 gamma SAPK,,false,,,http://purl.obolibrary.org/obo/IMR_0000225,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,SAPK-1|p54 gamma SAPK,,,,,IMR:0000683,,,,,,,,,,,,,,,,,,,,,,JNK1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CL_0000168,insulin secreting cell,,insulin secreting cell is a secretory cell and  is capable of some insulin secretion,false,,,http://purl.obolibrary.org/obo/CL_0000151,,,,,,,,,,,,,,,,,,,,BTO:0000783,,insulin secreting cell is a secretory cell and  is capable of some insulin secretion,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CL:0000168,,,,,,,,,,,,,,,,,,,,,,insulin secreting cell,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CL_0000169,type B pancreatic cell,,"Pancreatic beta cells are also reportedly CD284-positive. Upon activation, they upregulate their CD14 expression. A cell that secretes insulin and is located towards the center of the islets of Langerhans.",false,,,http://purl.obolibrary.org/obo/CL_0000168,,,,,,,,,,,,,,,,,,,,FMA:70586|ncithesaurus:Beta_Cell,,"Pancreatic beta cells are also reportedly CD284-positive. Upon activation, they upregulate their CD14 expression. A cell that secretes insulin and is located towards the center of the islets of Langerhans.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CL:0000169,,,,,,,,,,,,,,,,,,,,,,type B pancreatic cell,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_50905,teratogenic agent,teratogeno|teratogen|agent teratogene,"A role played by a chemical compound  in biological systems with adverse consequences in embryo developments, leading to birth defects, embryo death or altered development, growth retardation and functional defect.",false,,,http://purl.obolibrary.org/obo/CHEBI_52209,,,,,,,,,,,,,,,,,,,,,,"A role played by a chemical compound  in biological systems with adverse consequences in embryo developments, leading to birth defects, embryo death or altered development, growth retardation and functional defect.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,teratogeno|teratogen|agent teratogene,,,,,,,,,,,,,,,,,,,,,CHEBI:50905,,,,teratogenic agent,,CHEBI:50905,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0010878,cholesterol storage,sequestration of cholesterol|cholesterol sequestration,"The accumulation and maintenance in cells or tissues of cholesterol, cholest-5-en-3 beta-ol, the principal sterol of vertebrates and the precursor of many steroids, including bile acids and steroid hormones.",false,,,http://purl.obolibrary.org/obo/GO_0019915,,,,,,,,,,,,,,,,,,,,GO:0010878,,"The accumulation and maintenance in cells or tissues of cholesterol, cholest-5-en-3 beta-ol, the principal sterol of vertebrates and the precursor of many steroids, including bile acids and steroid hormones.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_16113,,,,,,,,,,,,,,,,,,,sequestration of cholesterol|cholesterol sequestration,,,,GO:0010878,,,,,,,,,,,,,,,,,,,,,,cholesterol storage,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000025833,POU2F3,,"Other designations: POU domain transcription factor OCT11a|POU domain, class 2, transcription factor 3|octamer-binding protein 11|octamer-binding transcription factor 11|transcription factor PLA-1|transcription factor Skn-1",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,OTF-11|OCT-11|PLA-1|OCT11|PLA1|Skn-1a|Epoc-1,,,,,,,,,,,,11,,,,,,Vega:OTTHUMG00000166140|HGNC:19864|MIM:607394|Ensembl:ENSG00000137709|HPRD:09582,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,POU class 2 homeobox 3,,,11q23.3,,,,,,,,,,,,,,,,"GO_0003700 (EC: IEA); GO_0005515 (EC: IPI, PMID: 12624109); GO_0005634 (EC: IDA); GO_0005667 (EC: IEA); GO_0005730 (EC: IDA, Qualifier: NOT); GO_0005737 (EC: IDA); GO_0006351 (EC: IEA); GO_0006357 (EC: TAS, PMID: 10473598); GO_0008544 (EC: TAS, PMID: 10473598); GO_0030216 (EC: IEA); GO_0042060 (EC: IEA); GO_0043565 (EC: IDA, PMID: 9242494); GO_0043922 (EC: IDA, PMID: 14645924); GO_0045944 (EC: IEA); GO_0046983 (EC: IEA)",,,,,,,,,PMID: 8441607; 9242494; 10473598; 11429405; 12477932; 12624109; 14645924; 14702039; 15077167; 16005513; 16147992; 16607278; 17195013; 17562024; 17989732; 18029348; 18479461; 20379614; 20888799; 21074976; 21906983; 23000965,,,,,,,,,,,,,,,OGG:3000025833,,,,,,,POU class 2 homeobox 3,,,,,,,,,,,,,"Other designations: POU domain transcription factor OCT11a|POU domain, class 2, transcription factor 3|octamer-binding protein 11|octamer-binding transcription factor 11|transcription factor PLA-1|transcription factor Skn-1",,POU2F3,,,,,,,,,,,,,,,,,,,,,,,25833,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,POU2F3,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000381,STAT6,signal transducer and activator of transcription 6,,false,,,http://purl.obolibrary.org/obo/IMR_0000374,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,signal transducer and activator of transcription 6,,,,,IMR:0000381,,,,,,,,,,,,,,,,,,,,,,STAT6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000064241,ABCG8,,"Other designations: ATP-binding cassette sub-family G member 8|ATP-binding cassette, subfamily G, member 8|sterolin 2|sterolin-2",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,GBD4|STSL,,,,,,,,,,,,2,,,,,,HPRD:05679|HGNC:13887|Ensembl:ENSG00000143921|Vega:OTTHUMG00000128756|MIM:605460,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"ATP-binding cassette, sub-family G (WHITE), member 8",,,2p21,,,,,,,,,,,,,,,,"GO_0005515 (EC: IPI, PMID: 16870176); GO_0005524 (EC: IDA, Qualifier: contributes_to, PMID: 16893193); GO_0005886 (EC: TAS); GO_0006200 (EC: IDA, PMID: 16893193); GO_0007584 (EC: IEA); GO_0007588 (EC: IGI, PMID: 14504269); GO_0010949 (EC: IMP, PMID: 11099417); GO_0015914 (EC: IEA); GO_0015918 (EC: TAS); GO_0016021 (EC: IEA); GO_0016324 (EC: IMP, PMID: 14504269); GO_0016887 (EC: IDA, Qualifier: contributes_to, PMID: 16893193); GO_0017127 (EC: IGI, Qualifier: contributes_to, PMID: 14504269); GO_0030299 (EC: IC, PMID: 12208868); GO_0033344 (EC: IGI, PMID: 14504269); GO_0042493 (EC: IEA); GO_0042632 (EC: IMP, PMID: 11099417); GO_0044281 (EC: TAS); GO_0045796 (EC: IMP, PMID: 11099417); GO_0046982 (EC: IPI, PMID: 16870176); GO_0055085 (EC: TAS)",,,,,,,,,PMID: 11099417; 11452359; 11590207; 11668628; 11893785; 12111378; 12124998; 12150943; 12208867; 12208868; 12220438; 12477932; 14504269; 14703505; 15175352; 15262185; 15311998; 15331430; 15520451; 15611112; 15816807; 15930516; 16472606; 16518588; 16870176; 16893193; 16980816; 17055487; 17098593; 17102949; 17403900; 17612515; 17626266; 17632509; 17690481; 17827468; 18007013; 18457353; 18522623; 18581044; 18641716; 18660489; 18676680; 18850127; 18977479; 19005228; 19012522; 19018975; 19019257; 19056482; 19060906; 19060911; 19111681; 19170196; 19217458; 19270375; 19306529; 19343046; 19692168; 19692220; 19878569; 19936222; 20163776; 20170916; 20172523; 20210363; 20235787; 20370913; 20379614; 20403997; 20413122; 20497293; 20529992; 20581104; 20592455; 20594224; 20679960; 20686565; 20837016; 20854103; 21039838; 21062971; 21274884; 21988832; 22378727; 22548731; 22655090; 22869156; 22898925; 23179156; 23241408; 23406058; 23556150; 23707316; 23726366; 23790976; 23840693,,,,,,,,,,,,,,,OGG:3000064241,,,,,,,"ATP-binding cassette, sub-family G (WHITE), member 8",,,,,,,,,,,,,"Other designations: ATP-binding cassette sub-family G member 8|ATP-binding cassette, subfamily G, member 8|sterolin 2|sterolin-2",,ABCG8,,,,,,,,,,,,,,,,,,,,,,,64241,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,ABCG8,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_50502,EC 2.5.1.15 (dihydropteroate synthase) inhibitor,"7,8-dihydropteroate synthase inhibitors|dihydropteroate diphosphorylase inhibitor|dihydropteroate pyrophosphorylase inhibitor|EC 2.5.1.15 (dihydropteroate synthase) inhibitors|7,8-dihydropteroate synthase inhibitor|2-amino-4-hydroxy-6-hydroxymethyl-7,8-dihydropteridine-diphosphate:4-aminobenzoate 2-amino-4-hydroxydihydropteridine-6-methenyltransferase inhibitor|dihydropteroate synthetase inhibitors|dihydropteroic synthetase inhibitors|dihydropteroate diphosphorylase inhibitors|DHPS inhibitor|EC 2.5.1.15 inhibitors|7,8-dihydropteroic acid synthetase inhibitor|dihydropteroic synthetase inhibitor|(2-amino-4-hydroxy-7,8-dihydropteridin-6-yl)methyl-diphosphate:4-aminobenzoate 2-amino-4-hydroxydihydropteridine-6-methenyltransferase inhibitors|dihydropteroate synthase (EC 2.5.1.15) inhibitor|dihydropteroate pyrophosphorylase inhibitors|dihydropteroate synthase (EC 2.5.1.15) inhibitors|dihydropteroate synthase inhibitors|dihydropteroate synthase inhibitor|(2-amino-4-hydroxy-7,8-dihydropteridin-6-yl)methyl-diphosphate:4-aminobenzoate 2-amino-4-hydroxydihydropteridine-6-methenyltransferase inhibitor|2-amino-4-hydroxy-6-hydroxymethyl-7,8-dihydropteridine-diphosphate:4-aminobenzoate 2-amino-4-hydroxydihydropteridine-6-methenyltransferase inhibitors|dihydropteroate synthetase inhibitor|7,8-dihydropteroate synthetase inhibitor|7,8-dihydropteroate synthetase inhibitors|EC 2.5.1.15 inhibitor|7,8-dihydropteroic acid synthetase inhibitors|DHPS inhibitors","An EC 2.5.1.* (non-methyl-alkyl or aryl transferase) inhibitor that interferes with the action of  dihydropteroate synthase (EC 2.5.1.15), an enzyme that catalyzes the formation of dihydropteroate from p-aminobenzoic acid and dihydropteridine-hydroxymethyl-pyrophosphate.",false,,,http://purl.obolibrary.org/obo/CHEBI_76663,,,,,,,,,,,,,,,,,,,,,,"An EC 2.5.1.* (non-methyl-alkyl or aryl transferase) inhibitor that interferes with the action of  dihydropteroate synthase (EC 2.5.1.15), an enzyme that catalyzes the formation of dihydropteroate from p-aminobenzoic acid and dihydropteridine-hydroxymethyl-pyrophosphate.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"7,8-dihydropteroate synthase inhibitors|dihydropteroate diphosphorylase inhibitor|dihydropteroate pyrophosphorylase inhibitor|EC 2.5.1.15 (dihydropteroate synthase) inhibitors|7,8-dihydropteroate synthase inhibitor|2-amino-4-hydroxy-6-hydroxymethyl-7,8-dihydropteridine-diphosphate:4-aminobenzoate 2-amino-4-hydroxydihydropteridine-6-methenyltransferase inhibitor|dihydropteroate synthetase inhibitors|dihydropteroic synthetase inhibitors|dihydropteroate diphosphorylase inhibitors|DHPS inhibitor|EC 2.5.1.15 inhibitors|7,8-dihydropteroic acid synthetase inhibitor|dihydropteroic synthetase inhibitor|(2-amino-4-hydroxy-7,8-dihydropteridin-6-yl)methyl-diphosphate:4-aminobenzoate 2-amino-4-hydroxydihydropteridine-6-methenyltransferase inhibitors|dihydropteroate synthase (EC 2.5.1.15) inhibitor|dihydropteroate pyrophosphorylase inhibitors|dihydropteroate synthase (EC 2.5.1.15) inhibitors|dihydropteroate synthase inhibitors|dihydropteroate synthase inhibitor|(2-amino-4-hydroxy-7,8-dihydropteridin-6-yl)methyl-diphosphate:4-aminobenzoate 2-amino-4-hydroxydihydropteridine-6-methenyltransferase inhibitor|2-amino-4-hydroxy-6-hydroxymethyl-7,8-dihydropteridine-diphosphate:4-aminobenzoate 2-amino-4-hydroxydihydropteridine-6-methenyltransferase inhibitors|dihydropteroate synthetase inhibitor|7,8-dihydropteroate synthetase inhibitor|7,8-dihydropteroate synthetase inhibitors|EC 2.5.1.15 inhibitor|7,8-dihydropteroic acid synthetase inhibitors|DHPS inhibitors",,,,,,,,,,,,,,,,,,,,,CHEBI:50502,,,,EC 2.5.1.15 (dihydropteroate synthase) inhibitor,,CHEBI:50502,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100852,PKA beta catalytic subunit,"PKA C-beta|cAMP-dependent protein kinase, beta-catalytic subunit",,false,,,http://purl.obolibrary.org/obo/IMR_0100703,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"PKA C-beta|cAMP-dependent protein kinase, beta-catalytic subunit",,,,,IMR:0100852,,,,,,,,,,,,,,,,,,,,,,PKA beta catalytic subunit,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000025987,TSKU,,Other designations: E2-induced gene 4 protein|leucine rich repeat containing 54|leucine-rich repeat-containing protein 54|tsukushi homolog|tsukushi small leucine rich proteoglycan homolog|tsukushin,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,E2IG4|TSK|LRRC54,,,,,,,,,,,,11,,,,,,MIM:608015|Ensembl:ENSG00000182704|HGNC:28850|HPRD:12152|Vega:OTTHUMG00000165238,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"tsukushi, small leucine rich proteoglycan",,,11q13.5,,,,,,,,,,,,,,,,GO_0005615 (EC: IEA); GO_0010468 (EC: IEA); GO_0021540 (EC: IEA); GO_0021670 (EC: IEA); GO_0021960 (EC: IEA); GO_0030178 (EC: IEA); GO_0061073 (EC: IEA),,,,,,,,,PMID: 11085516; 12477932; 12975309; 14702039; 15231748; 15489334; 16303743; 16344560; 19710929; 22880013; 22995554,,,,,,,,,,,,,,,OGG:3000025987,,20140408,protein-coding,,,,"tsukushi, small leucine rich proteoglycan",,,,,,,,,,,,,Other designations: E2-induced gene 4 protein|leucine rich repeat containing 54|leucine-rich repeat-containing protein 54|tsukushi homolog|tsukushi small leucine rich proteoglycan homolog|tsukushin,,TSKU,,,,,,,,,,,,,,,,,,,,,,,25987,UNQ850/PRO1788,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,TSKU,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000002272,FHIT,,"Other designations: AP3A hydrolase|bis(5'-adenosyl)-triphosphatase|diadenosine 5',5'''-P1,P3-triphosphate hydrolase|dinucleosidetriphosphatase|tumor suppressor protein",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,FRA3B|AP3Aase,,,,,,,,,,,,3,,,,,,HPRD:03096|MIM:601153|Vega:OTTHUMG00000158591|Ensembl:ENSG00000189283|HGNC:3701,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,fragile histidine triad,,,3p14.2,,,,,,,,,,,,,,,,"GO_0000166 (EC: IEA); GO_0003824 (EC: TAS, PMID: 8598045); GO_0005515 (EC: IPI, PMID: 18319262); GO_0005737 (EC: IDA, PMID: 15007172); GO_0005829 (EC: IDA, PMID: 15313915); GO_0006163 (EC: IDA, PMID: 9323207); GO_0006260 (EC: IEA); GO_0006351 (EC: IEA); GO_0006355 (EC: IEA); GO_0009117 (EC: TAS, PMID: 8794732); GO_0016787 (EC: IDA, PMID: 8794732); GO_0031625 (EC: IPI, PMID: 15313915); GO_0032435 (EC: IMP, PMID: 15313915); GO_0042802 (EC: IPI, PMID: 16189514); GO_0047710 (EC: IDA, PMID: 8794732); GO_0072332 (EC: IMP, PMID: 15313915)",,,,,,,,,PMID: 3864602; 8598045; 8640789; 8661111; 8794732; 8824874; 9012482; 9261067; 9290949; 9323207; 9366528; 9537583; 9576908; 9583683; 9671749; 9824201; 10706123; 11085938; 11731438; 11768238; 11788890; 11809703; 11891319; 11902576; 11915181; 12007194; 12048684; 12057912; 12067991; 12090476; 12119013; 12169206; 12177781; 12231533; 12353263; 12362975; 12419158; 12452072; 12477932; 12483524; 12529969; 12627509; 12697969; 12698186; 12800227; 12833632; 12839965; 12890991; 12893195; 12926121; 12964015; 12969785; 14566838; 14569398; 14630947; 14660280; 14675322; 14702039; 14719066; 14719099; 14760383; 14991669; 15007172; 15026336; 15044096; 15060557; 15073846; 15080495; 15080505; 15182206; 15219888; 15231689; 15246872; 15313915; 15328196; 15361849; 15384174; 15480422; 15489334; 15489891; 15569992; 15633221; 15674328; 15798093; 15835917; 15902282; 15906520; 15929169; 15935551; 15949315; 15998374; 16115913; 16189514; 16217683; 16231322; 16242161; 16344560; 16359767; 16513840; 16533421; 16570269; 16698048; 16699861; 16733051; 16739375; 16740775; 16763940; 16773697; 16864578; 16963412; 16990010; 17029211; 17037022; 17119051; 17137614; 17142325; 17143956; 17164758; 17328863; 17348444; 17359554; 17373735; 17374991; 17380463; 17382535; 17393360; 17548701; 17562266; 17596760; 17609851; 17671701; 17694439; 17712558; 17846126; 18006149; 18029348; 18038314; 18077326; 18091387; 18097574; 18162546; 18221322; 18247301; 18299890; 18319262; 18338496; 18338497; 18367246; 18378390; 18426086; 18476633; 18494825; 18517280; 18567082; 18595145; 18608185; 18618300; 18690840; 18821565; 18953408; 18985481; 19004824; 19096006; 19130459; 19240061; 19267103; 19286306; 19339270; 19401904; 19414370; 19418484; 19419937; 19434452; 19452299; 19502167; 19620087; 19621594; 19622739; 19728916; 19730990; 19751438; 19760177; 19913121; 19931269; 20060354; 20060399; 20082323; 20083852; 20083853; 20095356; 20125088; 20306291; 20379614; 20399571; 20417865; 20435627; 20458975; 20510001; 20552362; 20606729; 20622329; 20628086; 20689140; 20690795; 20814237; 20864173; 20864512; 21095196; 21182207; 21223598; 21241597; 21258320; 21404710; 21557333; 21617227; 21668571; 21679157; 21685375; 21711110; 21830375; 21870644; 21928112; 21988832; 22315171; 22379998; 22393963; 22419666; 22425911; 22578181; 22613411; 22747683; 22760553; 22766745; 22843886; 22932087; 22952603; 23019410; 23049088; 23102829; 23131390; 23209436; 23404381; 23470693; 23724516; 23736021; 23780737; 23797051; 23897914; 23929738; 23947369,,,,,,,,,,,,,,,OGG:3000002272,,,,,,,fragile histidine triad,,,,,,,,,,,,,"Other designations: AP3A hydrolase|bis(5'-adenosyl)-triphosphatase|diadenosine 5',5'''-P1,P3-triphosphate hydrolase|dinucleosidetriphosphatase|tumor suppressor protein",,FHIT,,,,,,,,,,,,,,,,,,,,,,,2272,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,FHIT,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000178,ICAM,intercellular adhesion molecule,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003688,,,,,intercellular adhesion molecule,,,,,IMR:0000178,,,,,,,,,,,,,,,,,,,,,,ICAM,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000008884,SLC5A6,,"Other designations: Na(+)-dependent multivitamin transporter|Na+-dependent multivitamin transporter|sodium-dependent multivitamin transporter|solute carrier family 5 (sodium-dependent vitamin transporter), member 6|solute carrier family 5 member 6",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,SMVT,,,,,,,,,,,,2,,,,,,HPRD:04934|HGNC:11041|Ensembl:ENSG00000138074|Vega:OTTHUMG00000097075|MIM:604024,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"solute carrier family 5 (sodium/multivitamin and iodide cotransporter), member 6",,,2p23,,,,,,,,,,,,,,,,"GO_0005886 (EC: TAS); GO_0005887 (EC: TAS, PMID: 9516450); GO_0006766 (EC: TAS); GO_0006767 (EC: TAS); GO_0006768 (EC: TAS); GO_0006810 (EC: TAS, PMID: 9516450); GO_0008523 (EC: IEA); GO_0012506 (EC: IEA); GO_0015878 (EC: IEA); GO_0015887 (EC: IEA); GO_0015939 (EC: TAS); GO_0016020 (EC: TAS, PMID: 9516450); GO_0031526 (EC: IEA); GO_0044281 (EC: TAS); GO_0055085 (EC: TAS)",,,,,,,,,PMID: 9516450; 10329687; 10334869; 11834205; 11955628; 12477932; 12646417; 14702039; 15123239; 15561972; 16303743; 16344560; 16749865; 16751776; 16959947; 17135299; 17904341; 19211916; 19898482; 20962270; 20980265; 21139048; 21183659; 21570947; 21890473; 21906983; 21963094; 21988832; 22015582; 22304562; 22732670; 22927035; 23000965; 23142496,,,,,,,,,,,,,,,OGG:3000008884,,,,,,,"solute carrier family 5 (sodium/multivitamin and iodide cotransporter), member 6",,,,,,,,,,,,,"Other designations: Na(+)-dependent multivitamin transporter|Na+-dependent multivitamin transporter|sodium-dependent multivitamin transporter|solute carrier family 5 (sodium-dependent vitamin transporter), member 6|solute carrier family 5 member 6",,SLC5A6,,,,,,,,,,,,,,,,,,,,,,,8884,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,SLC5A6,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000112849,L3HYPDH,,Other designations: probable proline racemase|trans-3-hydroxy-l-proline dehydratase|trans-3-hydroxyl-L-proline dehydratase|trans-L-3-hydroxyproline dehydratase,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,C14orf149,,,,,,,,,,,,14,,,,,,HPRD:08065|MIM:614811|Vega:OTTHUMG00000028941|HGNC:20488|Ensembl:ENSG00000126790,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,L-3-hydroxyproline dehydratase (trans-),,,14q23.1,,,,,,,,,,,,,,,,"GO_0008152 (EC: IDA); GO_0016836 (EC: IDA); GO_0018112 (EC: IDA, Qualifier: NOT); GO_0050346 (EC: IEA)",,,,,,,,,PMID: 12477932; 20379614; 22528483; 22939629,,,,,,,,,,,,,,,OGG:3000112849,,,,,,,L-3-hydroxyproline dehydratase (trans-),,,,,,,,,,,,,Other designations: probable proline racemase|trans-3-hydroxy-l-proline dehydratase|trans-3-hydroxyl-L-proline dehydratase|trans-L-3-hydroxyproline dehydratase,,L3HYPDH,,,,,,,,,,,,,,,,,,,,,,,112849,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,L3HYPDH,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0003154,regulation of transporter gene expression by cytokine [Cholestasis],,"Regulation of transporter gene expression by cytokine is a subtype of regulation of transporter gene expression: A process that changes the the gene expression level of the transporter by cytokines.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000034|http://purl.obolibrary.org/obo/TXPO_0003138,,,,,,,,,,,,,,,,,,,,"IL-1beta, TNF-alpha or IL-6 alters human hepatic transporters expression.
Bile salt transporters as well as sinusoidal solute carrier transporters are usually repressed, whereas ATP-binding cassette drug efflux pumps remain unchanged or are either downregulated or upregulated.
They maight  alter drug pharmacokinetics, impairment of bile salt secretion and cholestasis caused by inflammation in humans.",,"Regulation of transporter gene expression by cytokine is a subtype of regulation of transporter gene expression: A process that changes the the gene expression level of the transporter by cytokines.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003154,,,,,,,,,,,,,,,,,,,,,,regulation of transporter gene expression by cytokine [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003151,increasing glutathione,,Increasing glutathione is a subtype of increasing quantity: A process that changes the amount of glutathione to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing glutathione is a subtype of increasing quantity: A process that changes the amount of glutathione to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003151,,,,,,,,,,,,,,,,,,,,,,increasing glutathione,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003152,excretion of drug metabolite from hepatocyte to bile tube,,Excretion of drug metabolite from hepatocyte to bile tube is a subtype of compound excretion: A process that excretes the drug metabolite from the hepatocyte to to the bile tube.,false,,,http://purl.obolibrary.org/obo/TXPO_0002077,,,,,,,,,,,,,,,,,,,,,,Excretion of drug metabolite from hepatocyte to bile tube is a subtype of compound excretion: A process that excretes the drug metabolite from the hepatocyte to to the bile tube.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003152,,,,,,,,,,,,,,,,,,,,,,excretion of drug metabolite from hepatocyte to bile tube,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003155,negative regulation of contractile movement of bile canaliculus,,"Negative regulation of contractile movement of bile canaliculus is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of contractile movement of bile canaliculus.",false,,,http://purl.obolibrary.org/obo/TXPO_0000369,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of contractile movement of bile canaliculus is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of contractile movement of bile canaliculus.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003155,,,,,,,,,,,,,,,,,,,,,,negative regulation of contractile movement of bile canaliculus,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002695,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003150,acumulation of bile pigment in hepatocyte,,Acumulation of bile pigment in hepatocyte is a subtype of bile pigment deposition: The aggregation of bile pigmentin a particular location in a hepatocyte.,false,,,http://purl.obolibrary.org/obo/TXPO_0000083,,,,,,,,,,,,,,,,,,,,,,Acumulation of bile pigment in hepatocyte is a subtype of bile pigment deposition: The aggregation of bile pigmentin a particular location in a hepatocyte.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003150,,,,,,,,,,,,,,,,,,,,,,acumulation of bile pigment in hepatocyte,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000182,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003159,regulator of cell proliferation,,A role played by the entity which regulates the process of cell proliferation.,false,,,http://purl.obolibrary.org/obo/TXPO_0003230,,,,,,,,,http://purl.obolibrary.org/obo/GO_0008283,,,,,,,,,,,,,A role played by the entity which regulates the process of cell proliferation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003159,,,,,,,,,,,,,,,,,,,,,,regulator of cell proliferation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003158,catenin,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003158,,,,,,,,,,,,,,,,,,,,,,catenin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003156,constituent of toxic course,,A role played by a process that consitutes the toxic course.,false,,,http://purl.obolibrary.org/obo/TXPO_0002178,,,,,,,,,,,,,,,,,,,,,,A role played by a process that consitutes the toxic course.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003156,,,,,,,,,,,,,,,,,,,,,,constituent of toxic course,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003157,Bip-unfolded protein complex [ER stress],,"Bip-unfolded protein is a subtype of a molecular complex.
This entity has sub-parts of molecules: BIP/GRP78, and an unfolded protein.
This entity is dependent on ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002115,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/HINO_0017506|https://identifiers.org/reactome:R-HSA-381062,,"Bip-unfolded protein is a subtype of a molecular complex.
This entity has sub-parts of molecules: BIP/GRP78, and an unfolded protein.
This entity is dependent on ER stress.",,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000132|http://purl.obolibrary.org/obo/TXPO_0002385,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003157,,,,,,,,,,,,,,,,,,,,,,Bip-unfolded protein complex [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003153,drug export from the hepatocyte to to bile tube,,Drug export from the hepatocyte to to bile tube is a subtype of compound excretion: A process that excretes the drug from the hepatocyte to the bile tube.,false,,,http://purl.obolibrary.org/obo/TXPO_0002077,,,,,,,,,,,,,,,,,,,,,,Drug export from the hepatocyte to to bile tube is a subtype of compound excretion: A process that excretes the drug from the hepatocyte to the bile tube.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003153,,,,,,,,,,,,,,,,,,,,,,drug export from the hepatocyte to to bile tube,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000340485,ACER2,,Other designations: alkCDase 2|alkaline CDase 2|ceramide hydrolase|haCER2,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,ALKCDase2|ASAH3L,,,,,,,,,,,,9,,,,,,HGNC:23675|MIM:613492|HPRD:16512,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,alkaline ceramidase 2,,,9p22.1,,,,,,,,,,,,,,,,"GO_0000139 (EC: TAS); GO_0001953 (EC: IDA, PMID: 18945876); GO_0005794 (EC: IDA, PMID: 16940153); GO_0006665 (EC: TAS); GO_0006672 (EC: IEA); GO_0006919 (EC: IMP); GO_0008284 (EC: IDA, PMID: 16940153); GO_0010942 (EC: IMP); GO_0017040 (EC: IDA, PMID: 16940153); GO_0030148 (EC: TAS); GO_0030173 (EC: IDA); GO_0032526 (EC: IDA, PMID: 18945876); GO_0033629 (EC: IDA, PMID: 18945876); GO_0035690 (EC: IEP); GO_0044281 (EC: TAS); GO_0046512 (EC: IDA, PMID: 16940153); GO_0071633 (EC: IDA); GO_0090285 (EC: IMP)",,,,,,,,,PMID: 12477932; 15164053; 15489334; 15498874; 16940153; 18945876; 20089856; 20379614; 20628055,,,,,,,,,,,,,,,OGG:3000340485,,,,,,,alkaline ceramidase 2,,,,,,,,,,,,,Other designations: alkCDase 2|alkaline CDase 2|ceramide hydrolase|haCER2,,ACER2,,,,,,,,,,,,,,,,,,,,,,,340485,RP11-363E7.1,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,ACER2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_142468,"1,2-dichloropropane",,A chloroalkane that is propane in which a hydrogen from each of two adjacent carbons has been replaced by chlorines.,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,,,A chloroalkane that is propane in which a hydrogen from each of two adjacent carbons has been replaced by chlorines.,,,,,,,,,,,,C3H6Cl2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:142468,,,,,,,,,,,,,,,,,,,,,,"1,2-dichloropropane",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CC(CCl)Cl,,,,,
http://purl.obolibrary.org/obo/PATO_0001309,duration,period,A process quality inhering in a bearer by virtue of the bearer's magnitude of the temporal extent between the starting and ending point.,false,,,http://purl.obolibrary.org/obo/BFO_0000019,,,,,,,,,,,,,,,,,,,,,,A process quality inhering in a bearer by virtue of the bearer's magnitude of the temporal extent between the starting and ending point.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,period,,,,,PATO:0001309,,,,,,,,,,,,,,,,,,,,,,duration,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_50469,phospholipase A2 inhibitor,EC 3.1.1.4 (phospholipase A2) inhibitor,An EC 3.1.1.* (carboxylic ester hydrolase) inhibitor that interferes with the action of phospholipase A2 (EC 3.1.1.4).,false,,,http://purl.obolibrary.org/obo/CHEBI_76759,,,,,,,,,,,,,,,,,,,,,,An EC 3.1.1.* (carboxylic ester hydrolase) inhibitor that interferes with the action of phospholipase A2 (EC 3.1.1.4).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,EC 3.1.1.4 (phospholipase A2) inhibitor,,,,,CHEBI:50469,,,,,,,,,,,,,,,,,,,,,,phospholipase A2 inhibitor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001768,sphingomyelin metabolism imbalance [Phospholipidosis - genetic- sphingomyelin disorder  ],,"A process that becomes lacking a homeostastasis balance of the sphingomyelin metabolism.
This process is dependent on the  genetic and can constitute the course of Phospholipidosis (genetic).",false,,,http://purl.obolibrary.org/obo/TXPO_0001776|http://purl.obolibrary.org/obo/TXPO_0001823,,,,,,,,,,,,,,,,,,,,,,"A process that becomes lacking a homeostastasis balance of the sphingomyelin metabolism.
This process is dependent on the  genetic and can constitute the course of Phospholipidosis (genetic).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001690,,,,,,,,,,,TXPO:0001768,,,,,,,,,,,,,,,,,,,,,,sphingomyelin metabolism imbalance [Phospholipidosis - genetic- sphingomyelin disorder  ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001764,sphingomyelin accumulation in lysosome,,Sphingomyelin accumulation in lysosome is a subtype of sphingophospholipid accumulation in lysosome: A process that keeps sphingomyelin in the lysosome.,false,,,http://purl.obolibrary.org/obo/TXPO_0001763,,,,,,,,,,,,,,,,,,,,,,Sphingomyelin accumulation in lysosome is a subtype of sphingophospholipid accumulation in lysosome: A process that keeps sphingomyelin in the lysosome.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001764,,,,,,,,,,,,,,,,,,,,,,sphingomyelin accumulation in lysosome,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001763,sphingophospholipid accumulation in lysosome,,Sphingophospholipid accumulation in lysosome is a subtype of phospholipid accumulation in lysosome: A process that keeps sphingophospholipid in the lysosome.,false,,,http://purl.obolibrary.org/obo/TXPO_0000281,,,,,,,,,,,,,,,,,,,,,,Sphingophospholipid accumulation in lysosome is a subtype of phospholipid accumulation in lysosome: A process that keeps sphingophospholipid in the lysosome.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35786,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001763,,,,,,,,,,,,,,,,,,,,,,sphingophospholipid accumulation in lysosome,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001765,calcium ion homeostasis imbalance,,Calcium ion homeostasis imbalance is a subtype of chemical homeostasis imbalance: A process that becomes lacking a calcium ion homeostastasis balance.,false,,,http://purl.obolibrary.org/obo/TXPO_0001656,,,,,,,,,,,,,,,,,,,,,,Calcium ion homeostasis imbalance is a subtype of chemical homeostasis imbalance: A process that becomes lacking a calcium ion homeostastasis balance.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001765,,,,,,,,,,,,,,,,,,,,,,calcium ion homeostasis imbalance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001766,hypofunction of xenobiotic glucuronidation,,Hypofunction of xenobiotic glucuronidation is a subtype of decreasing function of: A process that performs a decreased or insufficient xenobiotic glucuronidation.,false,,,http://purl.obolibrary.org/obo/TXPO_0002190,,,,,,,,,,,,,,,,,,,,hypofunction of glucuronic acid conjugation,,Hypofunction of xenobiotic glucuronidation is a subtype of decreasing function of: A process that performs a decreased or insufficient xenobiotic glucuronidation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001766,,,,,,,,,,,,,,,,,,,,,,hypofunction of xenobiotic glucuronidation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001767,phenobarbital - tumor promoting factor [Ground glass appearance],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001524,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002272,,,,,,,,,,TXPO:0001767,,,,,,,,,,,,,,,,,,,,,,phenobarbital - tumor promoting factor [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001762,increasing phospholipid material[Phospholipidosis ],,"Increasing phospholipid material is a subtype of increasing quantity: A process that changes the amount of phospholipid material to be larger.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001314|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Increasing phospholipid material is a subtype of increasing quantity: A process that changes the amount of phospholipid material to be larger.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001136,,,,,,http://purl.obolibrary.org/obo/TXPO_0001761,,,,,,,,,,,TXPO:0001762,,,,,,,,,,,,,,,,,,,,,,increasing phospholipid material[Phospholipidosis ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001761,positive regulation of phospholipid biosynthetic process [Phospholipidosis (moderate) ],,"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of phospholipids. And the degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (moderate).",false,,,http://purl.obolibrary.org/obo/TXPO_0001710,,,,,,,,,,,,,,,,,,,,,,"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of phospholipids. And the degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (moderate).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001704,,,,,,,,,,,TXPO:0001761,,,,,,,,,,,,,,,,,,,,,,positive regulation of phospholipid biosynthetic process [Phospholipidosis (moderate) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001760,ATF6-CHOP signal integration system,,"ATF6-CHOP signal integration system is a subtype of ATF6 pathway system.
This entity has sub-parts and has a goal of transmitting signals and a gene regulation via ATF6 and CHOP as a systemic context.",false,,,http://purl.obolibrary.org/obo/TXPO_0001750,,,,,,,,,,,,,,,,,,,,,,"ATF6-CHOP signal integration system is a subtype of ATF6 pathway system.
This entity has sub-parts and has a goal of transmitting signals and a gene regulation via ATF6 and CHOP as a systemic context.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001760,,,,,,,,,,,,,,,,,,,,,,ATF6-CHOP signal integration system,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001769,hypofunction of phospholipase transport to lysosome,,Hypofunction of phospholipase transport to lysosome   is a subtype of hypofunction of transport: A process that performs a decreased or insufficient phospholipase transport to lysosome  .,false,,,http://purl.obolibrary.org/obo/TXPO_0001911,,,,,,,,,,,,,,,,,,,,,,Hypofunction of phospholipase transport to lysosome   is a subtype of hypofunction of transport: A process that performs a decreased or insufficient phospholipase transport to lysosome  .,,,http://purl.obolibrary.org/obo/TXPO_0000002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001769,,,,,,,,,,,,,,,,,,,,,,hypofunction of phospholipase transport to lysosome,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_16602,trichloroethylene,"1,1,2-trichloroethene","A member of the class of chloroethenes that is ethene substituted by chloro groups at positions 1, 1 and 2.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:79-01-6|Wikipedia:Trichloroethylene,,"A member of the class of chloroethenes that is ethene substituted by chloro groups at positions 1, 1 and 2.",,,,,,,,,,,,C2HCl3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"1,1,2-trichloroethene",,,,,CHEBI:16602,,,,,,,,,,,,,,,,,,,,,,trichloroethylene,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ClC=C(Cl)Cl,,,,,
http://purl.obolibrary.org/obo/IMR_0100446,RelA,p65,,false,,,http://purl.obolibrary.org/obo/IMR_0000382,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p65,,,,,IMR:0100446,,,,,,,,,,,,,,,,,,,,,,RelA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000657,predicted (quality),,A physical quality that inheres in a bearer by calculation under some condition.,false,,,http://purl.obolibrary.org/obo/BFO_0000019,,,,,,,,,,,,,,,,,,,,,,A physical quality that inheres in a bearer by calculation under some condition.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000657,,,,,,,,,,,,,,,,,,,,,,predicted (quality),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000651,pathogen colonization,,Pathogen colonization is a subtype of making existence of xenobiotics. A process that makes the existence of the colony of a pathogen (after infection).,false,,,http://purl.obolibrary.org/obo/TXPO_0001851,,,,,,,,,,,,,,,,,,,,,,Pathogen colonization is a subtype of making existence of xenobiotics. A process that makes the existence of the colony of a pathogen (after infection).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000651,,,,,,,,,,,,,,,,,,,,,,pathogen colonization,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000659,MMAA (predicted)(human)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001135|http://purl.obolibrary.org/obo/TXPO_0003833,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:166785|http://www.reactome.org/content/detail/R-HSA-3359475,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000166785,,,,,,,,,,,,,TXPO:0000659,,,,,,,,,,,,,,,,,,,,,,MMAA (predicted)(human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000650,Nifib (rat)[Cell death],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000260|http://purl.obolibrary.org/obo/TXPO_0000839,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000329,,,,,,,,,,TXPO:0000650,,,,,,,,,,,,,,,,,,,,,,Nifib (rat)[Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000654,AKR7A3 (human)[Glutathione depletion],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000033|http://purl.obolibrary.org/obo/TXPO_0001916,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:22977|PMID:21688283,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000022977,,,,,,,,,,,,,TXPO:0000654,,,,,,,,,,,,,,,,,,,,,,AKR7A3 (human)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000656,antioxidant gene expression [Gutathione depletion],,"antixidant gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature  gene product or products (proteins or RNA) involved in antioxidant process.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0002061|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"antixidant gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature  gene product or products (proteins or RNA) involved in antioxidant process.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000855,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000654|http://purl.obolibrary.org/obo/TXPO_0001934,,,,,,http://purl.obolibrary.org/obo/TXPO_0000655,,,,,,,,,,,TXPO:0000656,,,,,,,,,,,,,,,,,,,,,,antioxidant gene expression [Gutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000652,glutathione biosynthetic pathway,,"The  pathways resulting in the formation of glutathione, the tripeptide glutamylcysteinylglycine, which acts as a coenzyme for some enzymes and as an antioxidant in the protection of sulfhydryl groups in enzymes and other proteins.",false,,,http://purl.obolibrary.org/obo/TXPO_0000610,,,,,,,,,,,,,,,,,,,,PW:0001277,,"The  pathways resulting in the formation of glutathione, the tripeptide glutamylcysteinylglycine, which acts as a coenzyme for some enzymes and as an antioxidant in the protection of sulfhydryl groups in enzymes and other proteins.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000652,,,,,,,,,,,,,,,,,,,,,,glutathione biosynthetic pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000658,hyperfunction of antioxidant gene expression,,"Hyperfunction of antioxidant gene expression is a subtype of hyperfunction of gene expression: A process that performs an excesssive antioxidant gene expression.
This entity is a specific course-dependent process. This process can constitute the course of glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0002345,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of antioxidant gene expression is a subtype of hyperfunction of gene expression: A process that performs an excesssive antioxidant gene expression.
This entity is a specific course-dependent process. This process can constitute the course of glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000658,,,,,,,,,,,,,,,,,,,,,,hyperfunction of antioxidant gene expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000653,JUN (canonical)[Cell death],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003195|http://purl.obolibrary.org/obo/IMR_0000416,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24516,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000653,,,,,,,,,,,,,,,,,,,,,,JUN (canonical)[Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000655,hyperfunction of antioxidant gene expression [Glutathione depletion],,"Hyperfunction of antioxidant gene expression is a subtype of hyperfunction of gene expression: A process that performs an excesssive antioxidant gene expression.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0000658|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of antioxidant gene expression is a subtype of hyperfunction of gene expression: A process that performs an excesssive antioxidant gene expression.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000656|http://purl.obolibrary.org/obo/TXPO_0000904|http://purl.obolibrary.org/obo/TXPO_0002216,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001194,,,,,,,,,,,TXPO:0000655,,,,,,,,,,,,,,,,,,,,,,hyperfunction of antioxidant gene expression [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000146,cytokeratin 4,,,false,,,http://purl.obolibrary.org/obo/IMR_0000050,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000146,,,,,,,,,,,,,,,,,,,,,,cytokeratin 4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_3216,buprenorphine,"(5alpha,6beta,14beta,18R)-17-(cyclopropylmethyl)-18-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-6-methoxy-18,19-dihydro-4,5-epoxy-6,14-ethenomorphinan-3-ol","A morphinane alkaloid that is 7,8-dihydromorphine 6-O-methyl ether in which positions 6 and 14 are joined by a -CH2CH2- bridge, one of the hydrogens of the N-methyl group is substituted by cyclopropyl, and a hydrogen at position 7 is substituted by a 2-hydroxy-3,3-dimethylbutan-2-yl group.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Wikipedia:Buprenorphine|DrugBank:DB00921|CAS:52485-79-7,,"A morphinane alkaloid that is 7,8-dihydromorphine 6-O-methyl ether in which positions 6 and 14 are joined by a -CH2CH2- bridge, one of the hydrogens of the N-methyl group is substituted by cyclopropyl, and a hydrogen at position 7 is substituted by a 2-hydroxy-3,3-dimethylbutan-2-yl group.",,,,,,,,,,,,C29H41NO4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003665,,,,,"(5alpha,6beta,14beta,18R)-17-(cyclopropylmethyl)-18-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-6-methoxy-18,19-dihydro-4,5-epoxy-6,14-ethenomorphinan-3-ol",,,,,CHEBI:3216,,,,,,,,,,,,,,,,,,,,,,buprenorphine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,[H][C@@]1(C[C@]23CC[C@]1(OC)[C@@H]1Oc4c(O)ccc5C[C@H]2N(CC[C@@]31c45)CC1CC1)[C@](C)(O)C(C)(C)C,,,,,
http://purl.obolibrary.org/obo/IMR_0000039,activin,,,false,,,http://purl.obolibrary.org/obo/IMR_0000036,,,,,,,,,,,,,,,,,,,,GO:0016915,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000039,,,,,,,,,,,,,,,,,,,,,,activin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000660,changing protein structure,,Changing protein structure is a subtype of changing structure: A process that changes the stucture of the protein.,false,,,http://purl.obolibrary.org/obo/TXPO_0002566,,,,,,,,,,,,,,,,,,,,,,Changing protein structure is a subtype of changing structure: A process that changes the stucture of the protein.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000660,,,,,,,,,,,,,,,,,,,,,,changing protein structure,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000662,cytoplasmic alternation  [Liver Pathological Findings],cytoplasmic change  [Liver PathologicalFindings],Cytoplasmic alternation  [Liver PathologicalFindings] is a type of finding observed in the liver. Lesions are observed as changes in cytoplasm based on pathological morphology.,false,,,http://purl.obolibrary.org/obo/TXPO_0001507,,,,,,,,,,,,,,,,,,,,,,Cytoplasmic alternation  [Liver PathologicalFindings] is a type of finding observed in the liver. Lesions are observed as changes in cytoplasm based on pathological morphology.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,cytoplasmic change  [Liver PathologicalFindings],,,,,TXPO:0000662,,,,,,,"Changes in cytoplasm in the hepatocytes.
Liver is responsible for drug metabolism; therefore these findings are most frequently observed results in drug safety studies.
  It shows various morphological images depending on the kind of chemical substance.",,,,,,,,,,,,,,,cytoplasmic alternation  [Liver Pathological Findings],,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005737,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000663,ALDOB (predicted)(human)[Glutathione depletion],,predicted gene  by Support Vector Machine (SVM) using human primary hepatocyte,false,,,http://purl.obolibrary.org/obo/TXPO_0000666|http://purl.obolibrary.org/obo/TXPO_0001916,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:229|PMID:26376879|PMID:28084435|PMID:28840186,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000000229,,,http://purl.obolibrary.org/obo/TXPO_0000676,,,,,,,,,,TXPO:0000663,,,,,,,,,,,,,,,,,,,,predicted gene  by Support Vector Machine (SVM) using human primary hepatocyte,,ALDOB (predicted)(human)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000664,caspase signaling (primitive) [Phospholipidosis (excessive defense) ],,"Caspase signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the caspase.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0000444,,,,,,,,,,,,,,,,,,,,PMID:15720040,,"Caspase signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the caspase.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003226|http://purl.obolibrary.org/obo/TXPO_0003225|http://purl.obolibrary.org/obo/TXPO_0003272|http://purl.obolibrary.org/obo/TXPO_0003273,,,,,,,,,,,,,,,,,TXPO:0000664,,,,,,,,,,,,,,,,,,,,,,caspase signaling (primitive) [Phospholipidosis (excessive defense) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000669,cell cycle G1/S phase transition [Ground glass appearance],,"The cell cycle process by which a cell in G1 phase commits to S phase.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/GO_0044843|http://purl.obolibrary.org/obo/TXPO_0001728,,,,,,,,,,,,,,,,,,,,PMID:22723046,,"The cell cycle process by which a cell in G1 phase commits to S phase.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001003,,,,,,http://purl.obolibrary.org/obo/TXPO_0000962,,,,,,,,,,,TXPO:0000669,,,,,,,,,,,,,,,,,,,,,,cell cycle G1/S phase transition [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000667,regulation of gene expression [Cell death],,"Any process that modulates the frequency, rate or extent of gene expression. Gene expression is the process in which a gene's coding sequence is converted into a mature gene product or products (proteins or RNA). This includes the production of an RNA transcript as well as any processing to produce a mature RNA product or an mRNA or circRNA (for protein-coding genes) and the translation of that mRNA or circRNA into protein. Protein maturation is included when required to form an active form of a product from an inactive precursor form.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/GO_0010468|http://purl.obolibrary.org/obo/TXPO_0001727,,,,,,,,,,,,,,,,,,,,,,"Any process that modulates the frequency, rate or extent of gene expression. Gene expression is the process in which a gene's coding sequence is converted into a mature gene product or products (proteins or RNA). This includes the production of an RNA transcript as well as any processing to produce a mature RNA product or an mRNA or circRNA (for protein-coding genes) and the translation of that mRNA or circRNA into protein. Protein maturation is included when required to form an active form of a product from an inactive precursor form.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000667,,,,,,,,,,,,,,,,,,,,,,regulation of gene expression [Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000666,ALDOB (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:229|NCBI-Mouse-GeneID: 230163|NCBI-Rat-GeneID: 24190|PMID:26376879,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000229,,,,,,,,,,,,,TXPO:0000666,,,,,,,,,,,,,,,,,,,,,,ALDOB (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000661,ECM2  (predicted)(human)[Glutathione depletion],,predicted gene  by Support Vector Machine (SVM) using human primary hepatocyte,false,,,http://purl.obolibrary.org/obo/TXPO_0000665|http://purl.obolibrary.org/obo/TXPO_0001916,,,,,,,,,,,,,,,,,,,,PMID:23766865|NCBI-Human-GeneID:1842|PMID:15189273|PMID:28840186,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000001842,,,,,,,,,,,,,TXPO:0000661,,,,,,,,,,,,,,,,,,,,predicted gene  by Support Vector Machine (SVM) using human primary hepatocyte,,ECM2  (predicted)(human)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000665,ECM2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:407800|NCBI-Rat-GeneID:100361383|NCBI-Human-GeneID:1842,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001842,,,,,,,,,,,,,TXPO:0000665,,,,,,,,,,,,,,,,,,,,,,ECM2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000668,oxidative stress responsive factor role,,"A role played by the entity which responses to any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of oxidative stress, a state often resulting from exposure to high levels of reactive oxygen species, e.g. superoxide anions, hydrogen peroxide (H2O2), and hydroxyl radicals.|related process GO:0006979 response to oxidative stress",false,,,http://purl.obolibrary.org/obo/TXPO_0003730,,,,,,,,,,,,,,,,,,,,,,"A role played by the entity which responses to any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of oxidative stress, a state often resulting from exposure to high levels of reactive oxygen species, e.g. superoxide anions, hydrogen peroxide (H2O2), and hydroxyl radicals.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000668,,,,,,,,,,,,,,,,,,,,related process GO:0006979 response to oxidative stress,,oxidative stress responsive factor role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000003688,ITGB1,,"Other designations: glycoprotein IIa|integrin VLA-4 beta subunit|integrin beta-1|very late activation protein, beta polypeptide",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,VLAB|MDF2|FNRB|MSK12|VLA-BETA|GPIIA|CD29,,,,,,,,,,,,10,,,,,,HPRD:00628|Vega:OTTHUMG00000017928|HGNC:6153|Ensembl:ENSG00000150093|MIM:135630,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12)",,,10p11.2,,,,,,,,,,,,,,,,"GO_0000082 (EC: IEA); GO_0001618 (EC: IEA); GO_0001669 (EC: IEA); GO_0001701 (EC: IEA); GO_0001708 (EC: IEA); GO_0001726 (EC: TAS, PMID: 11919189); GO_0001894 (EC: IEA); GO_0001948 (EC: IEA); GO_0001968 (EC: IEA); GO_0002020 (EC: IEA); GO_0002042 (EC: IEA); GO_0003779 (EC: IDA, PMID: 16803572); GO_0005178 (EC: IEA); GO_0005515 (EC: IPI, PMID: 10604475); GO_0005518 (EC: IEA); GO_0005604 (EC: IEA); GO_0005737 (EC: IDA, PMID: 16803572); GO_0005886 (EC: IDA, PMID: 12869515); GO_0005886 (EC: TAS); GO_0005925 (EC: IDA, PMID: 12417594); GO_0005925 (EC: IDA, Qualifier: colocalizes_with, PMID: 14970227); GO_0006874 (EC: IEA); GO_0006968 (EC: TAS, PMID: 10201960); GO_0007156 (EC: TAS, PMID: 10201960); GO_0007159 (EC: IDA, PMID: 1715889); GO_0007160 (EC: IMP, PMID: 18156211); GO_0007161 (EC: IGI, PMID: 19651211); GO_0007229 (EC: IEA); GO_0007411 (EC: TAS); GO_0007596 (EC: TAS); GO_0008277 (EC: IEA); GO_0008284 (EC: IEA); GO_0008285 (EC: IEA); GO_0008305 (EC: NAS, PMID: 9552005); GO_0008354 (EC: IEA); GO_0009897 (EC: IEA); GO_0009986 (EC: IDA, PMID: 1715889); GO_0010811 (EC: IEA); GO_0010976 (EC: IEA); GO_0014704 (EC: IEA); GO_0014823 (EC: IEA); GO_0016032 (EC: IEA); GO_0016477 (EC: TAS, PMID: 11919189); GO_0019901 (EC: IEA); GO_0019904 (EC: IEA); GO_0021943 (EC: IEA); GO_0030027 (EC: IEA); GO_0030056 (EC: IEA); GO_0030175 (EC: IDA, PMID: 16803572); GO_0030183 (EC: IC, PMID: 1715889); GO_0030198 (EC: TAS); GO_0030335 (EC: IEA); GO_0031345 (EC: IEA); GO_0031594 (EC: IDA, PMID: 9415431); GO_0032154 (EC: IEA); GO_0032587 (EC: IDA, Qualifier: colocalizes_with, PMID: 14970227); GO_0032594 (EC: IEA); GO_0033631 (EC: IEP, PMID: 17704059); GO_0034329 (EC: TAS); GO_0034667 (EC: IEA); GO_0034677 (EC: IEA); GO_0034678 (EC: TAS); GO_0034679 (EC: IEA); GO_0034698 (EC: IEA); GO_0035748 (EC: IEA); GO_0042277 (EC: IEA); GO_0042383 (EC: IDA, PMID: 9415431); GO_0042470 (EC: IEA); GO_0042493 (EC: IEA); GO_0043065 (EC: IGI, PMID: 19364818); GO_0043235 (EC: IDA); GO_0043236 (EC: IEA); GO_0043410 (EC: IEA); GO_0045121 (EC: IDA, PMID: 14559243); GO_0045214 (EC: IEA); GO_0045665 (EC: IEA); GO_0045666 (EC: IEA); GO_0045807 (EC: IEA); GO_0046872 (EC: IEA); GO_0046982 (EC: NAS, PMID: 9552005); GO_0050731 (EC: IEA); GO_0050776 (EC: TAS); GO_0050839 (EC: IPI, PMID: 12869515); GO_0050900 (EC: TAS); GO_0051393 (EC: IEA); GO_0051726 (EC: IEA); GO_0055007 (EC: IEA); GO_0055037 (EC: IEA); GO_0060135 (EC: IEA); GO_0070062 (EC: IDA, PMID: 19056867); GO_0070830 (EC: IEA); GO_0071260 (EC: IEA); GO_0071305 (EC: IEA); GO_0071479 (EC: IEA); GO_0071559 (EC: IEA); GO_2000811 (EC: IMP, PMID: 15006356)",,,,,,,,,PMID: 1551917; 1690718; 1693624; 1715889; 2116421; 2138612; 2156854; 2202737; 2249781; 2524991; 2527614; 2572537; 2649503; 2958481; 2967289; 3546305; 7504269; 7523423; 7539135; 7541634; 7544298; 7545396; 7559467; 7657702; 7681433; 7690138; 7768999; 8120056; 8163531; 8245132; 8387021; 8428973; 8444890; 8537347; 8538749; 8567725; 8630057; 8649427; 8757325; 8757349; 8757599; 8798654; 8831898; 8838570; 8889548; 9117345; 9281591; 9281592; 9295027; 9360995; 9360996; 9415431; 9425259; 9431988; 9442085; 9494094; 9501082; 9517988; 9547293; 9552005; 9565552; 9614184; 9645947; 9660880; 9685391; 9686320; 9688542; 9722563; 9736715; 9812906; 9813091; 9889149; 9914169; 9916748; 10065872; 10201960; 10209034; 10229664; 10388537; 10397731; 10397733; 10459022; 10464311; 10486209; 10506186; 10593924; 10604475; 10613898; 10623819; 10673366; 10676904; 10684262; 10694273; 10734060; 10741407; 10778855; 10804218; 10811835; 10852818; 10906324; 10944199; 10944520; 10982388; 11010812; 11054877; 11076863; 11149921; 11208159; 11230166; 11238109; 11256614; 11278628; 11278916; 11279249; 11309411; 11313964; 11358957; 11387256; 11435317; 11462216; 11507094; 11553610; 11668187; 11716783; 11728829; 11741908; 11751905; 11775028; 11776052; 11779688; 11805102; 11807098; 11861761; 11882657; 11884516; 11884618; 11888933; 11893752; 11907260; 11909975; 11914080; 11918217; 11919189; 11931654; 11932920; 11934885; 11941451; 11964076; 11967148; 11980922; 11981820; 11989791; 11996105; 11997396; 12020426; 12054567; 12070135; 12091396; 12097820; 12118253; 12138200; 12138201; 12140560; 12163503; 12171996; 12174366; 12175627; 12181350; 12181354; 12200131; 12209735; 12218055; 12221126; 12364323; 12372334; 12372459; 12376466; 12392763; 12393420; 12397374; 12397575; 12411441; 12417594; 12427871; 12435334; 12445830; 12456677; 12477932; 12480921; 12486108; 12496264; 12500944; 12509413; 12514714; 12517798; 12574205; 12578911; 12595495; 12606711; 12637511; 12639940; 12639965; 12662928; 12681287; 12682293; 12694355; 12695522; 12699087; 12788934; 12791669; 12799374; 12803239; 12807887; 12826661; 12844491; 12865438; 12869515; 12871973; 12883474; 12893184; 12893831; 12904899; 12907437; 12909644; 12915563; 12918102; 12919677; 12931024; 12941630; 12947314; 12954625; 12969374; 12970173; 14502569; 14512423; 14522909; 14525968; 14532964; 14550305; 14559243; 14559906; 14562042; 14563646; 14602071; 14607975; 14610084; 14612440; 14612932; 14623330; 14633626; 14645603; 14662754; 14666169; 14671618; 14675422; 14676841; 14679206; 14681217; 14699013; 14699139; 14722085; 14766759; 14963009; 14970227; 14983010; 14998999; 15006356; 15024036; 15070678; 15090462; 15100006; 15117962; 15156152; 15158122; 15166232; 15171717; 15181153; 15226304; 15231747; 15240572; 15247268; 15254262; 15256055; 15265786; 15276495; 15276642; 15280429; 15292185; 15292257; 15302884; 15304053; 15389531; 15466867; 15485856; 15489336; 15500293; 15507484; 15509657; 15514009; 15522237; 15539082; 15567743; 15572366; 15583842; 15590642; 15611085; 15633218; 15645131; 15647274; 15647827; 15677332; 15677455; 15684035; 15699160; 15713743; 15713750; 15723043; 15731179; 15737747; 15757908; 15777792; 15795318; 15805105; 15872091; 15878864; 15881415; 15905178; 15919367; 15947241; 15949469; 15961545; 15978109; 15978110; 15983209; 15987639; 16002725; 16005200; 16043429; 16055535; 16055706; 16076904; 16099422; 16103120; 16105875; 16113793; 16148152; 16157583; 16195423; 16213489; 16228294; 16247454; 16258728; 16275327; 16301336; 16326706; 16335952; 16341674; 16344560; 16357324; 16363250; 16365170; 16373174; 16381901; 16385340; 16385451; 16390868; 16415171; 16421008; 16430945; 16448724; 16457822; 16459165; 16501085; 16504015; 16510444; 16537545; 16547007; 16547500; 16569430; 16705158; 16707493; 16731529; 16732726; 16754661; 16754960; 16762342; 16773720; 16803572; 16807379; 16820945; 16878156; 16882656; 16908668; 16908762; 16916750; 16920931; 16940508; 16972245; 16984420; 17012251; 17015707; 17060328; 17081065; 17110618; 17116465; 17141917; 17170699; 17186162; 17286276; 17300927; 17311314; 17312461; 17318179; 17331499; 17352405; 17371832; 17380111; 17407140; 17408410; 17469136; 17481915; 17490870; 17498594; 17514628; 17515951; 17521731; 17530710; 17538005; 17560548; 17573778; 17597073; 17603494; 17609118; 17630833; 17634906; 17638891; 17664272; 17671519; 17704059; 17706641; 17726369; 17760843; 17868650; 17888902; 17899316; 17901052; 17960115; 17968567; 17991734; 17997226; 18026855; 18032709; 18037995; 18048360; 18048918; 18054915; 18057877; 18155697; 18156211; 18186923; 18230652; 18243286; 18250451; 18310319; 18322799; 18326820; 18341635; 18356158; 18375753; 18378436; 18383324; 18413316; 18425328; 18425341; 18445685; 18448666; 18462748; 18477477; 18491034; 18492066; 18499669; 18501656; 18512729; 18519809; 18549800; 18554474; 18567578; 18577581; 18583538; 18587047; 18611961; 18613064; 18614994; 18615555; 18632734; 18635536; 18644869; 18648521; 18676377; 18676743; 18687805; 18695939; 18707587; 18727519; 18755811; 18760454; 18787945; 18794852; 18820259; 18826391; 18844239; 18845630; 18846341; 18850009; 18940913; 18945876; 18947333; 18957620; 18973153; 18983487; 18984674; 18990704; 18992284; 19005162; 19020712; 19026687; 19056867; 19057841; 19064571; 19064666; 19073896; 19074826; 19087624; 19115199; 19123990; 19130304; 19164533; 19168626; 19169646; 19170051; 19176753; 19179533; 19190332; 19228923; 19240021; 19250636; 19261610; 19297531; 19297850; 19307303; 19322201; 19323811; 19342381; 19346516; 19350017; 19359599; 19364818; 19395705; 19397781; 19404550; 19411307; 19416892; 19434537; 19435806; 19448673; 19454674; 19458194; 19467326; 19469865; 19478484; 19502598; 19516006; 19527220; 19527712; 19564406; 19574430; 19579970; 19608669; 19617714; 19622836; 19641149; 19646550; 19651211; 19670701; 19679609; 19700757; 19710103; 19714342; 19717562; 19724904; 19725119; 19738201; 19747169; 19752234; 19755493; 19768654; 19775453; 19776755; 19780039; 19796635; 19811096; 19815047; 19822142; 19847290; 19850917; 19885568; 19887442; 19887601; 19889638; 19913121; 19927126; 19930715; 19940135; 19960514; 19995941; 20007695; 20051050; 20063417; 20063990; 20075392; 20127017; 20133364; 20145038; 20171211; 20178602; 20183869; 20213106; 20231384; 20232313; 20236590; 20237496; 20237901; 20333644; 20336352; 20337027; 20351310; 20352103; 20352300; 20362630; 20388801; 20407016; 20427540; 20432448; 20435742; 20472470; 20485444; 20510000; 20522645; 20531279; 20565758; 20598296; 20607601; 20613771; 20616308; 20624912; 20628086; 20628624; 20634879; 20639577; 20643357; 20650890; 20650901; 20660204; 20661303; 20678483; 20686611; 20693403; 20713715; 20714794; 20723423; 20725651; 20800221; 20802515; 20811680; 20826546; 20869114; 20877569; 20889506; 20947017; 21045155; 21048156; 21053345; 21067603; 21071450; 21112327; 21114537; 21119363; 21119598; 21134100; 21134644; 21135504; 21139048; 21149578; 21170718; 21178109; 21195710; 21217148; 21255062; 21298552; 21302295; 21320503; 21321939; 21325030; 21341269; 21344385; 21357540; 21359179; 21359644; 21363926; 21374738; 21400218; 21406228; 21426305; 21429937; 21441381; 21471204; 21474814; 21478906; 21501586; 21521694; 21524887; 21558392; 21567400; 21606500; 21613543; 21618249; 21630092; 21639857; 21642953; 21647271; 21652699; 21658756; 21691075; 21701559; 21705617; 21732280; 21747167; 21762625; 21772312; 21784851; 21787362; 21799154; 21850018; 21876768; 21890473; 21906983; 21947080; 21951552; 21961047; 21963094; 21967109; 21987572; 21988832; 22002573; 22015659; 22027826; 22045736; 22100988; 22114305; 22130661; 22136719; 22151306; 22160595; 22232555; 22241990; 22247553; 22266309; 22268729; 22287577; 22298882; 22304920; 22345562; 22349830; 22353524; 22361176; 22370635; 22374686; 22378044; 22378065; 22382453; 22384145; 22386417; 22388103; 22389402; 22396498; 22402981; 22422622; 22423313; 22449099; 22451694; 22454518; 22461623; 22472442; 22496232; 22505724; 22562249; 22590584; 22613833; 22614033; 22627583; 22648170; 22648415; 22711564; 22721769; 22723286; 22734003; 22735632; 22740085; 22829201; 22843693; 22863953; 22865233; 22869523; 22894137; 22898815; 22917688; 22936677; 22939629; 22940691; 22949126; 22986527; 22999999; 23000965; 23007402; 23023061; 23069938; 23074279; 23118221; 23125415; 23132859; 23139422; 23148235; 23160057; 23204528; 23208492; 23238518; 23242739; 23248240; 23284715; 23284937; 23289672; 23317506; 23359252; 23416109; 23436775; 23441154; 23444218; 23455756; 23482612; 23522389; 23532895; 23536555; 23541832; 23552693; 23558678; 23576567; 23590307; 23595626; 23613949; 23642664; 23664187; 23665237; 23677397; 23687274; 23704882; 23709605; 23762436; 23857544; 23884246; 23889963; 23936390; 23938462; 24056178; 24091324; 24135056; 24239175; 24244022; 24311785; 24455846; 24510996,,,,,,,,,,,,,,,OGG:3000003688,,,,,,,"integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12)",,,,,,,,,,,,,"Other designations: glycoprotein IIa|integrin VLA-4 beta subunit|integrin beta-1|very late activation protein, beta polypeptide",,ITGB1,,,,,,,,,,,,,,,,,,,,,,,3688,RP11-479G22.2,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,ITGB1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_64909,poison,poisonous agent|poisonous agents|toxic agent|toxic substances|poisonous substance|toxic agents|poisonous substances|poisons|toxic substance,"Any substance that causes disturbance to organisms by chemical reaction or other activity on the molecular scale, when a sufficient quantity is absorbed by the organism.",false,,,http://purl.obolibrary.org/obo/CHEBI_24432|http://purl.obolibrary.org/obo/CHEBI_52209,,,,,,,,,,,,,,,,,,,,Wikipedia:Poison,,"Any substance that causes disturbance to organisms by chemical reaction or other activity on the molecular scale, when a sufficient quantity is absorbed by the organism.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,poisonous agent|poisonous agents|toxic agent|toxic substances|poisonous substance|toxic agents|poisonous substances|poisons|toxic substance,,,,,,,,,,,,,,,,,,,,,CHEBI:64909,,,,poison,,CHEBI:64909,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000732,PLC gamma1,phospholipase C gamma 1,,false,,,http://purl.obolibrary.org/obo/IMR_0000285,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,phospholipase C gamma 1,,,,,IMR:0000732,,,,,,,,,,,,,,,,,,,,,,PLC gamma1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100074,peptide YY,,A 36-amino acid peptide produced by the L cells of the distal small intestine and colon. Peptide YY inhibits gastric and pancreatic secretion.,false,,,http://purl.obolibrary.org/obo/IMR_0100072,,,,,,,,,,,,,,,,,,,,MeSH:D019894,,A 36-amino acid peptide produced by the L cells of the distal small intestine and colon. Peptide YY inhibits gastric and pancreatic secretion.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100074,,,,,,,,,,,,,,,,,,,,,,peptide YY,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_50248,hematologic agent,hematologic agents,Drug that acts on blood and blood-forming organs and those that affect the hemostatic system.,false,,,http://purl.obolibrary.org/obo/CHEBI_23888,,,,,,,,,,,,,,,,,,,,,,Drug that acts on blood and blood-forming organs and those that affect the hemostatic system.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,hematologic agents,,,,,,,,,,,,,,,,,,,,,CHEBI:50248,,,,hematologic agent,,CHEBI:50248,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100736,GSK-3 alpha,,,false,,,http://purl.obolibrary.org/obo/IMR_0000257,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100736,,,,,,,,,,,,,,,,,,,,,,GSK-3 alpha,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CL_0000066,epithelial cell,,A cell that is usually found in a two-dimensional sheet with a free surface. The cell has a cytoskeleton that allows for tight cell to cell contact and for cell polarity where apical part is directed towards the lumen and the basal part to the basal lamina.,false,,,http://purl.obolibrary.org/obo/CL_0000000,,,,,,,,,,,,,,,,,,,,,,A cell that is usually found in a two-dimensional sheet with a free surface. The cell has a cytoskeleton that allows for tight cell to cell contact and for cell polarity where apical part is directed towards the lumen and the basal part to the basal lamina.,,,,,epithelial cell,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CL:0000066,,,,,,,,,,,,,,,,,,,,,,epithelial cell,,,,,,,http://purl.obolibrary.org/obo/cl.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002371,apoptotic process [Glutathione depletion],,"A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0000889|http://purl.obolibrary.org/obo/GO_0006915,,,,,,,,,,,,,,,,,,,,PMID:19662025,,"A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001932,,,,,,http://purl.obolibrary.org/obo/TXPO_0002372,,,,,,,,,,,TXPO:0002371,,,,,,,,,,,,,,,,,,,,,,apoptotic process [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002370,caspase signaling (primitive) [Glutathione depletion],,"Caspase signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the caspase.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0000889|http://purl.obolibrary.org/obo/TXPO_0000444,,,,,,,,,,,,,,,,,,,,,,"Caspase signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the caspase.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002371,,,,,,,,,,,TXPO:0002370,,,,,,,,,,,,,,,,,,,,,,caspase signaling (primitive) [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002377,Keap1 oxidative modification by electrophiles,,"Keap1 oxidative modification by electrophiles is a subtype of protein binding: Interacting between a protein and electrophiles.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/GO_0055114,,,,,,,,,,,,,,,,,,,,,,"Keap1 oxidative modification by electrophiles is a subtype of protein binding: Interacting between a protein and electrophiles.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002404,,,,,,,,,,,TXPO:0002377,,,,,,,,,,,,,,,,,,,,,,Keap1 oxidative modification by electrophiles,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002379,NADPH regeneration [Glutathione depletion],,"A metabolic process that generates a pool of NADPH by the reduction of NADP+.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/GO_0006740|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,PMID:24287781,,"A metabolic process that generates a pool of NADPH by the reduction of NADP+.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001936|http://purl.obolibrary.org/obo/TXPO_0000135|http://purl.obolibrary.org/obo/TXPO_0001917,,,,,,http://purl.obolibrary.org/obo/TXPO_0001194|http://purl.obolibrary.org/obo/TXPO_0002368,,,,,,,,,,,TXPO:0002379,,,,,,,,,,,,,,,,,,,,,,NADPH regeneration [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002374,p450 activator,,A role played by the entity  that activates the activity of cytochrome P450 involved in catalysis of organic substances.,false,,,http://purl.obolibrary.org/obo/TXPO_0003714,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001758,,,,,,,,,,,,,,A role played by the entity  that activates the activity of cytochrome P450 involved in catalysis of organic substances.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002374,,,,,,,,,,,,,,,,,,,,,,p450 activator,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002375,JNK signaling (primitive) [Glutathione depletion],,"JNK signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the JNK (a stress-activated protein kinase (SAPK) ).
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0000769|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,PMID:18337250,,"JNK signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the JNK (a stress-activated protein kinase (SAPK) ).
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000000|http://purl.obolibrary.org/obo/TXPO_0001948|http://purl.obolibrary.org/obo/TXPO_0002298,,,,,,http://purl.obolibrary.org/obo/TXPO_0001207|http://purl.obolibrary.org/obo/TXPO_0002369,,,,,,,,,,,TXPO:0002375,,,,,,,,,,,,,,,,,,,,,,JNK signaling (primitive) [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002378,changing activity of eIF2a by PERK [ER stress PERK - eIF2A pathway],,"A process that changes the activity of the eIF2a by PERK.
This process is dependent on the PERK-eIF2A pathway and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0003736|http://purl.obolibrary.org/obo/TXPO_0000696,,,,,,,,,,,,,,,,,,,,,,"A process that changes the activity of the eIF2a by PERK.
This process is dependent on the PERK-eIF2A pathway and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000700,,,,,,,,,,,,,,,,,,,,,TXPO:0002378,,,,,,,,,,,,,,,,,,,,,,changing activity of eIF2a by PERK [ER stress PERK - eIF2A pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002376,regulation of cell cycle [Glutathione depletion],,"Any process that modulates the rate or extent of progression through the cell cycle.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/GO_0051726|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Any process that modulates the rate or extent of progression through the cell cycle.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001945,,,,,,,,,,,,,,,,,TXPO:0002376,,,,,,,,,,,,,,,,,,,,,,regulation of cell cycle [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002373,liver dysfunction [Glutathione depletion],,"Liver dysfunction is a subtype of dysfunctioning: A process that performs an abnormal and incomplete liver function.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0000203|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Liver dysfunction is a subtype of dysfunctioning: A process that performs an abnormal and incomplete liver function.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002373,,,,,,,,,,,,,,,,,,,,,,liver dysfunction [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002372,increasing number of dead cells in liver [Glutathione depletion],,"Increasing number of dead cells in liver is a subtype of cell proliferation: A process that becomes larger in the number of dead cells in the liver.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0000341|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Increasing number of dead cells in liver is a subtype of cell proliferation: A process that becomes larger in the number of dead cells in the liver.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002373,,,,,,,,,,,TXPO:0002372,,,,,,,,,,,,,,,,,,,,,,increasing number of dead cells in liver [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0003909,sinusoid,,"small blood vessel similar to a capillary but with a fenestrated endothelium. Sinusoids are found in the liver, lymphoid tissue, endocrine organs, and hematopoietic organs such as the bone marrow and the spleen. Sinusoids found within terminal villi of the placenta are not comparable to these; they possess a continuous endothelium and complete basal lamina[WP].",false,,,http://purl.obolibrary.org/obo/UBERON_0001981,,,,,,,,,,,,,,,,,,,,,,"small blood vessel similar to a capillary but with a fenestrated endothelium. Sinusoids are found in the liver, lymphoid tissue, endocrine organs, and hematopoietic organs such as the bone marrow and the spleen. Sinusoids found within terminal villi of the placenta are not comparable to these; they possess a continuous endothelium and complete basal lamina[WP].",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,UBERON:0003909,,,,,,,,,,,,,,,,,,,,,,sinusoid,,,,,,,http://purl.obolibrary.org/obo/UBERON,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001134,agrin,,,false,,,http://purl.obolibrary.org/obo/IMR_0001125,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001134,,,,,,,,,,,,,,,,,,,,,,agrin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002611,Hyou gene expression by XBP1 [ER stress - refolding],,"Hyou gene expression by XBP1 is a subtype of gene expression by transcriptional factor: The process in which a Hyou gene sequence is converted into a mature gene product or products (proteins or RNA) by XBP1.
This process is dependent on the refolding and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002919,,,,,,,,,,,,,,,,,,,,,,"Hyou gene expression by XBP1 is a subtype of gene expression by transcriptional factor: The process in which a Hyou gene sequence is converted into a mature gene product or products (proteins or RNA) by XBP1.
This process is dependent on the refolding and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002611,,,,,,,,,,,,,,,,,,,,,,Hyou gene expression by XBP1 [ER stress - refolding],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002618,antioxidant gene expression [ER stress],,"Antioxidant gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature antioxidant gene product or products (proteins or RNA).
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/TXPO_0002061,,,,,,,,,,,,,,,,,,,,,,"Antioxidant gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature antioxidant gene product or products (proteins or RNA).
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002744|http://purl.obolibrary.org/obo/TXPO_0002739|http://purl.obolibrary.org/obo/TXPO_0000450,,http://purl.obolibrary.org/obo/TXPO_0002740,,,,,,,,,,,,,,,,TXPO:0002618,,,,,,,,,,,,,,,,,,,,,,antioxidant gene expression [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002612,DNAJB9 gene expression by XBP1 [ER stress - refolding],,"DNAJB9 gene expression by XBP1 is a subtype of gene expression by transcriptional factor: The process in which a DNAJB9 gene sequence is converted into a mature gene product or products (proteins or RNA) by XBP1.
This process is dependent on the refolding and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002919,,,,,,,,,,,,,,,,,,,,,,"DNAJB9 gene expression by XBP1 is a subtype of gene expression by transcriptional factor: The process in which a DNAJB9 gene sequence is converted into a mature gene product or products (proteins or RNA) by XBP1.
This process is dependent on the refolding and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002165,,,,,,,,,,,,,,,,,TXPO:0002612,,,,,,,,,,,,,,,,,,,,,,DNAJB9 gene expression by XBP1 [ER stress - refolding],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002616,ABCG8 (canonical)[Cholestasis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001506|http://purl.obolibrary.org/obo/TXPO_1000000,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002616,,,,,,,,,,,,,,,,,,,,,,ABCG8 (canonical)[Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002615,ABCG5 (canonical)[Cholestasis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001506,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002615,,,,,,,,,,,,,,,,,,,,,,ABCG5 (canonical)[Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002614,cholesterol efflux (from heptocyte menbrane to canaliculus) [cholestasis],,"A release process of the cholesterol from one side of a membrane of hepatocyte to the other side of canaliculus.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/GO_0033344|http://purl.obolibrary.org/obo/TXPO_0000034,,,,,,,,,,,,,,,,,,,,,,"A release process of the cholesterol from one side of a membrane of hepatocyte to the other side of canaliculus.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002615,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002614,,,,,,,,,,,,,,,,,,,,,,cholesterol efflux (from heptocyte menbrane to canaliculus) [cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002610,IRE1-XBP1 mediated pathway [ER stress - ERAD],,"IRE1-XBP1 mediated pathway is a subtype of IRE1 signaling (integrated pathway): Sequence of linked reactions, which has IRE1 signaling and gene regulation by XBP1.
This process is dependent on ERAD and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002563,,,,,,,,,,,,,,,,,,,,,,"IRE1-XBP1 mediated pathway is a subtype of IRE1 signaling (integrated pathway): Sequence of linked reactions, which has IRE1 signaling and gene regulation by XBP1.
This process is dependent on ERAD and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002709|http://purl.obolibrary.org/obo/TXPO_0002608|http://purl.obolibrary.org/obo/TXPO_0002710,,http://purl.obolibrary.org/obo/TXPO_0002960|http://purl.obolibrary.org/obo/TXPO_0002877,,,,,,,,,,,,,,,,TXPO:0002610,,,,,,,,,,,,,,,,,,,,,,IRE1-XBP1 mediated pathway [ER stress - ERAD],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002619,GRP78 - stress sensor inhibitor (canonical)[ER stress - proteinrefolding [short-term]],Heat Shock Protein Family A (Hsp70) Member 5|MIF2|BIP|HEL-S-89n|HSPA5,,false,,,http://purl.obolibrary.org/obo/TXPO_0002385,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002620,,,,,Heat Shock Protein Family A (Hsp70) Member 5|MIF2|BIP|HEL-S-89n|HSPA5,,,,,TXPO:0002619,,,,,,,,,,,,,,,,,,,,,,GRP78 - stress sensor inhibitor (canonical)[ER stress - proteinrefolding [short-term]],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002207,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002613,hyperfunction of glutathione conjugates excretion from hepatocyte [Glutathione depletion],,"Hyperfunctio of glutathione conjugates excretion from hepatocyte is a subtype of compound excretion: A process that excretes the glutathione conjugates from the hepatocyte.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0002701|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Hyperfunctio of glutathione conjugates excretion from hepatocyte is a subtype of compound excretion: A process that excretes the glutathione conjugates from the hepatocyte.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002493,,,,,,http://purl.obolibrary.org/obo/TXPO_0002733,,,,,,,,,,,TXPO:0002613,,,,,,,,,,,,,,,,,,,,,,hyperfunction of glutathione conjugates excretion from hepatocyte [Glutathione depletion],,,,,,http://purl.obolibrary.org/obo/TXPO_0002551,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002617,enabling translation,,Enabling translation is a subtype of enabling: A process that sets conditions for translation to work correctly.,false,,,http://purl.obolibrary.org/obo/TXPO_0001757,,,,,,,,,,,,,,,,,,,,,,Enabling translation is a subtype of enabling: A process that sets conditions for translation to work correctly.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002617,,,,,,,,,,,,,,,,,,,,,,enabling translation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0002481,bone tissue,mineralized bone tissue|bone|portion of bone tissue|osseous tissue|calcium tissue|osteogenic tissue,"Skeletal tissue with a collagen-rich extracellular matrix vascularized, mineralized with hydroxyapatite and typically including osteocytes located in lacunae that communicate with one another by cell processes (in canaliculi). Bone is deposited by osteoblasts.",false,,,http://purl.obolibrary.org/obo/UBERON_0004755,,,,,,,,,,,,,,,,,,,,http://en.wikipedia.org/wiki/Bone_tissue|http://purl.obolibrary.org/obo/NCIT_C13076|http://linkedlifedata.com/resource/umls/id/C0391978|FMA:224804|CALOHA:TS-2011|ZFA:0005621|EMAPA:35179|XAO:0004040|VSAO:0000047|galen:BoneTissue|UMLS:C0391978|MESH:D001842|MA:0002780,,"Skeletal tissue with a collagen-rich extracellular matrix vascularized, mineralized with hydroxyapatite and typically including osteocytes located in lacunae that communicate with one another by cell processes (in canaliculi). Bone is deposited by osteoblasts.",,,,see https://github.com/obophenotype/uberon/issues/27,,,,"Skeletal tissue with a collagen-rich extracellular matrix vascularized, mineralized with hydroxyapatite and typically including osteocytes located in lacunae that communicate with one another by cell processes (in canaliculi). Bone is deposited by osteoblasts.[VSAO]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,osseous tissue|calcium tissue|osteogenic tissue,mineralized bone tissue,bone|portion of bone tissue,,,UBERON:0002481,,,,,,,,,,,,,,,,,,,,,,bone tissue,,,,,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001116,RASAL1,,,false,,,http://purl.obolibrary.org/obo/IMR_0000443,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001116,,,,,,,,,,,,,,,,,,,,,,RASAL1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100712,Notch,N,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,IPR:008297,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,N,,,,,IMR:0100712,,,,,,,,,,,,,,,,,,,,,,Notch,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_24852,insecticide,insecticides,"Strictly, a substance intended to kill members of the class Insecta.  In common usage, any substance used for preventing, destroying, repelling or controlling insects.",false,,,http://purl.obolibrary.org/obo/CHEBI_25944,,,,,,,,,,,,,,,,,,,,,,"Strictly, a substance intended to kill members of the class Insecta.  In common usage, any substance used for preventing, destroying, repelling or controlling insects.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,insecticides,,,,,,,,,,,,,,,,,,,,,CHEBI:24852,,,,insecticide,,CHEBI:24852,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000084085,FBXO30,,"Other designations: F-box domain protein|F-box only protein 30|F-box only protein, helicase, 18",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,Fbx30,,,,,,,,,,,,6,,,,,,HGNC:15600|HPRD:10953|MIM:609101,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,F-box protein 30,,,6q24,,,,,,,,,,,,,,,,GO_0004842 (EC: IEA); GO_0008270 (EC: IEA),,,,,,,,,PMID: 12477932; 12536519; 12903040; 14574404; 14702039; 15489334; 15520277; 15761153; 18247557; 19322201; 20360068; 20936779; 21139048; 21145461,,,,,,,,,,,,,,,OGG:3000084085,,,,,,,F-box protein 30,,,,,,,,,,,,,"Other designations: F-box domain protein|F-box only protein 30|F-box only protein, helicase, 18",,FBXO30,,,,,,,,,,,,,,,,,,,,,,,84085,RP11-545I5.4,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,FBXO30,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000631,Integrin alpha-9,,,false,,,http://purl.obolibrary.org/obo/IMR_0000173,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000631,,,,,,,,,,,,,,,,,,,,,,Integrin alpha-9,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_00042181,ketone biosynthetic process,ketone synthesis|ketone anabolism|ketone formation|ketone biosynthesis,"The chemical reactions and pathways resulting in the formation of ketones, a class of organic compounds that contain the carbonyl group, CO, and in which the carbonyl group is bonded only to carbon atoms. The general formula for a ketone is RCOR, where R and R are alkyl or aryl groups.",false,,,http://purl.obolibrary.org/obo/GO_0009058,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways resulting in the formation of ketones, a class of organic compounds that contain the carbonyl group, CO, and in which the carbonyl group is bonded only to carbon atoms. The general formula for a ketone is RCOR, where R and R are alkyl or aryl groups.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_73693,,,,,,,,,,,,,,ketone synthesis|ketone anabolism|ketone formation|ketone biosynthesis,,,,,GO:00042181,,,,,,,,,,,,,,,,,,,,,,ketone biosynthetic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0001162,increased concentration,high concentration,A concentration which is higher relative to the normal or average.,false,,,http://purl.obolibrary.org/obo/TXPO_0000865|http://purl.obolibrary.org/obo/PATO_0001159,,,,,,,,,,,,,,,,,,,,,,A concentration which is higher relative to the normal or average.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,high concentration,,,,,PATO:0001162,,,,,,,,,,,,,,,,,,,,,,increased concentration,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0001163,decreased concentration,,A concentration which is lower relative to the normal or average.,false,,,http://purl.obolibrary.org/obo/TXPO_0000865|http://purl.obolibrary.org/obo/PATO_0001159,,,,,,,,,,,,,,,,,,,,,,A concentration which is lower relative to the normal or average.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0001163,,,,,,,,,,,,,,,,,,,,,,decreased concentration,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_1903427,negative regulation of ROS formation,negative regulation of reactive oxygen species biosynthetic process,"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of ROS.",false,,,http://purl.obolibrary.org/obo/TXPO_0000369,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of ROS.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,negative regulation of reactive oxygen species biosynthetic process,,,,,GO:1903427,,,,,,,,,,,,,,,,,,,,,,negative regulation of ROS formation,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_1903409,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001112,importin 4,,,false,,,http://purl.obolibrary.org/obo/IMR_0100010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001112,,,,,,,,,,,,,,,,,,,,,,importin 4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_75767,animal metabolite,animal metabolites,"Any eukaryotic metabolite produced during a metabolic reaction in animals that include diverse creatures from sponges, insects to mammals.",false,,,http://purl.obolibrary.org/obo/CHEBI_75763,,,,,,,,,,,,,,,,,,,,,,"Any eukaryotic metabolite produced during a metabolic reaction in animals that include diverse creatures from sponges, insects to mammals.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,animal metabolites,,,,,,,,,,,,,,,,,,,,,CHEBI:75767,,,,animal metabolite,,CHEBI:75767,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003146,gene expression by farnesoid X receptor,gene expression by FXR,Gene expression by farnesoid X receptor is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) by Farnesoid X receptor (FXR).,false,,,http://purl.obolibrary.org/obo/TXPO_0000375,,,,,,,,,,,,,,,,,,,,,,Gene expression by farnesoid X receptor is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) by Farnesoid X receptor (FXR).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,gene expression by FXR,,,,,TXPO:0003146,,,,,,,,,,,,,,,,,,,,,,gene expression by farnesoid X receptor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003140,decreasing bile acid production level,,Decreasing bile acid production level is a subtype of decreasing quantity: A process that changes the production amount of bile acid to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000396,,,,,,,,,,,,,,,,,,,,,,Decreasing bile acid production level is a subtype of decreasing quantity: A process that changes the production amount of bile acid to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003140,,,,,,,,,,,,,,,,,,,,,,decreasing bile acid production level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003142,bile thrombus formation in bile canaliculus,,Bile thrombus formation in bile canaliculus is a subtype of bile thrombus formation: A process that constructs bile thrombus in bile canaliculus.,false,,,http://purl.obolibrary.org/obo/TXPO_0003141,,,,,,,,,,,,,,,,,,,,,,Bile thrombus formation in bile canaliculus is a subtype of bile thrombus formation: A process that constructs bile thrombus in bile canaliculus.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003142,,,,,,,,,,,,,,,,,,,,,,bile thrombus formation in bile canaliculus,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003141,bile thrombus formation,,Bile thrombus formation is a subtype of biological structure formation: A process that construcyss bile thrombus.,false,,,http://purl.obolibrary.org/obo/TXPO_0000134,,,,,,,,,,,,,,,,,,,,,,Bile thrombus formation is a subtype of biological structure formation: A process that construcyss bile thrombus.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003141,,,,,,,,,,,,,,,,,,,,,,bile thrombus formation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003143,farnesoid X receptor activation,Farnesoid X Receptor activation|FxR activating|activating FXR,Farnesoid X receptor activation is a subtype of activating nuclear receptor: A process that changes the activity of the activating FxR (farnesoid X receptor) with a nuclear receptor role to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000158,,,,,,,,,,,,,,,,,,,,,,Farnesoid X receptor activation is a subtype of activating nuclear receptor: A process that changes the activity of the activating FxR (farnesoid X receptor) with a nuclear receptor role to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Farnesoid X Receptor activation|FxR activating|activating FXR,,,,,TXPO:0003143,,,,,,,,,,,,,,,,,,,,,,farnesoid X receptor activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003149,Farnesoid X Receptor Pathway [cholestasis],,"Farnesoid X Receptor Pathway is a subtype of gene regulation pathway: Sequence of reactions to regulate genes by nuclear receptor Farnesoid X Receptor.
This entity is a specific course-dependent process. This process can constitute the course of cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003145,,,,,,,,,,,,,,,,,,,,http://www.wikipathways.org/index.php/Pathway:WP2879,,"Farnesoid X Receptor Pathway is a subtype of gene regulation pathway: Sequence of reactions to regulate genes by nuclear receptor Farnesoid X Receptor.
This entity is a specific course-dependent process. This process can constitute the course of cholestasis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003147|http://purl.obolibrary.org/obo/TXPO_0002644,,,,,,,,,,,,,,,,,,TXPO:0003149,,,,,,,"Farnesoid X receptor (FXR, a.k.a. NR1H4) is a nuclear receptor that responds to levels of bile acids present in the body and regulates many processes related to bile acids synthesis and transport.",,,,,,,,,,,,,,,Farnesoid X Receptor Pathway [cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003144,increasing materials for bile formation,,Increasing materials for bile formation is a subtype of increasing quantity: A process that changes the amount of bile formation material to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing materials for bile formation is a subtype of increasing quantity: A process that changes the amount of bile formation material to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003144,,,,,,,,,,,,,,,,,,,,,,increasing materials for bile formation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003147,gene expression by farnesoid X receptor [Cholestasis],bile acid transport gene expression by FXR [cholestasis],"Gene expression by farnesoid X receptor is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) by Farnesoid X receptor (FXR).
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003146|http://purl.obolibrary.org/obo/TXPO_0000034,,,,,,,,,,,,,,,,,,,,,,"Gene expression by farnesoid X receptor is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) by Farnesoid X receptor (FXR).
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002643,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000299|http://purl.obolibrary.org/obo/TXPO_0000547|http://purl.obolibrary.org/obo/TXPO_0000724,,http://purl.obolibrary.org/obo/TXPO_0003148|http://purl.obolibrary.org/obo/TXPO_0002723,,,,,,,,,,,,bile acid transport gene expression by FXR [cholestasis],,,,,TXPO:0003147,,,,,,,,,,,,,,,,,,,,,,gene expression by farnesoid X receptor [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003148,FGF19 (canonical)[Cholestasis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000276|http://purl.obolibrary.org/obo/TXPO_1000143,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:9965|NCBI-Rat-GeneID:170582,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003148,,,,,,,,,,,,,,,,,,,,,,FGF19 (canonical)[Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003145,Farnesoid X Receptor Pathway,,Farnesoid X Receptor Pathway is a subtype of gene regulation pathway: Sequence of reactions to regulate genes by nuclear receptor Farnesoid X Receptor.,false,,,http://purl.obolibrary.org/obo/TXPO_0001902,,,,,,,,,,,,,,,,,,,,http://www.wikipathways.org/index.php/Pathway:WP2879,,Farnesoid X Receptor Pathway is a subtype of gene regulation pathway: Sequence of reactions to regulate genes by nuclear receptor Farnesoid X Receptor.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003146|http://purl.obolibrary.org/obo/TXPO_0003143,,,,,,,,,,,,,,,,,,TXPO:0003145,,,,,,,,,,,,,,,,,,,,,,Farnesoid X Receptor Pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0032259,methylation,,The process in which a methyl group is covalently attached to a molecule.,false,,,http://purl.obolibrary.org/obo/GO_0008152,,,,,,,,,,,,,,,,,,,,,,The process in which a methyl group is covalently attached to a molecule.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0032259,,,,,,,,,,,,,,,,,,,,,,methylation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_35470,central nervous system drug,CNS agent|CNS drugs|central nervous system agents,A class of drugs producing both physiological and psychological effects through a variety of mechanisms involving the central nervous system.,false,,,http://purl.obolibrary.org/obo/CHEBI_23888,,,,,,,,,,,,,,,,,,,,,,A class of drugs producing both physiological and psychological effects through a variety of mechanisms involving the central nervous system.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CNS agent|CNS drugs|central nervous system agents,,,,,,,,,,,,,,,,,,,,,CHEBI:35470,,,,central nervous system drug,,CHEBI:35470,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76775,EC 3.1.3.* (phosphoric monoester hydrolase) inhibitor,phosphoric monoester hydrolase inhibitor|inhibitor of phosphoric monoester hydrolase (EC 3.1.3.*)|phosphoric monoester hydrolase inhibitors|EC 3.1.3.* inhibitors|inhibitors of phosphoric monoester hydrolase|EC 3.1.3.* inhibitor|phosphoric monoester hydrolase (EC 3.1.3.*) inhibitor|inhibitor of phosphoric monoester hydrolase|EC 3.1.3.* (phosphoric monoester hydrolase) inhibitors|phosphoric monoester hydrolase (EC 3.1.3.*) inhibitors|inhibitors of phosphoric monoester hydrolase (EC 3.1.3.*),An EC 3.1.* (ester hydrolase) inhibitor that interferes with the action of any phosphoric monoester hydrolase (EC 3.1.3.*).,false,,,http://purl.obolibrary.org/obo/CHEBI_76760,,,,,,,,,,,,,,,,,,,,,,An EC 3.1.* (ester hydrolase) inhibitor that interferes with the action of any phosphoric monoester hydrolase (EC 3.1.3.*).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,phosphoric monoester hydrolase inhibitor|inhibitor of phosphoric monoester hydrolase (EC 3.1.3.*)|phosphoric monoester hydrolase inhibitors|EC 3.1.3.* inhibitors|inhibitors of phosphoric monoester hydrolase|EC 3.1.3.* inhibitor|phosphoric monoester hydrolase (EC 3.1.3.*) inhibitor|inhibitor of phosphoric monoester hydrolase|EC 3.1.3.* (phosphoric monoester hydrolase) inhibitors|phosphoric monoester hydrolase (EC 3.1.3.*) inhibitors|inhibitors of phosphoric monoester hydrolase (EC 3.1.3.*),,,,,,,,,,,,,,,,,,,,,CHEBI:76775,,,,EC 3.1.3.* (phosphoric monoester hydrolase) inhibitor,,CHEBI:76775,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0005840,ribosome,free ribosome|membrane bound ribosome|ribosomal RNA,"An intracellular organelle, about 200 A in diameter, consisting of RNA and protein. It is the site of protein biosynthesis resulting from translation of messenger RNA (mRNA). It consists of two subunits, one large and one small, each containing only protein and RNA. Both the ribosome and its subunits are characterized by their sedimentation coefficients, expressed in Svedberg units (symbol: S). Hence, the prokaryotic ribosome (70S) comprises a large (50S) subunit and a small (30S) subunit, while the eukaryotic ribosome (80S) comprises a large (60S) subunit and a small (40S) subunit. Two sites on the ribosomal large subunit are involved in translation, namely the aminoacyl site (A site) and peptidyl site (P site). Ribosomes from prokaryotes, eukaryotes, mitochondria, and chloroplasts have characteristically distinct ribosomal proteins.",false,,,http://purl.obolibrary.org/obo/GO_0043226,,,,,,,,,,,,,,,,,,,,NIF_Subcellular:sao1429207766|Wikipedia:Ribosome,,"An intracellular organelle, about 200 A in diameter, consisting of RNA and protein. It is the site of protein biosynthesis resulting from translation of messenger RNA (mRNA). It consists of two subunits, one large and one small, each containing only protein and RNA. Both the ribosome and its subunits are characterized by their sedimentation coefficients, expressed in Svedberg units (symbol: S). Hence, the prokaryotic ribosome (70S) comprises a large (50S) subunit and a small (30S) subunit, while the eukaryotic ribosome (80S) comprises a large (60S) subunit and a small (40S) subunit. Two sites on the ribosomal large subunit are involved in translation, namely the aminoacyl site (A site) and peptidyl site (P site). Ribosomes from prokaryotes, eukaryotes, mitochondria, and chloroplasts have characteristically distinct ribosomal proteins.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,free ribosome|membrane bound ribosome,ribosomal RNA,,http://purl.obolibrary.org/obo/GO_0005737,GO:0005840,http://purl.obolibrary.org/obo/GO_0005737,,,,,,,,,,,,,,,,,,,,,ribosome,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100673,M-cyclin,G2/M-cyclin,,false,,,http://purl.obolibrary.org/obo/IMR_0100606,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,G2/M-cyclin,,,,,IMR:0100673,,,,,,,,,,,,,,,,,,,,,,M-cyclin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000003586,IL10,,Other designations: T-cell growth inhibitory factor|cytokine synthesis inhibitory factor|interleukin-10,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,IL10A|IL-10|GVHDS|TGIF|CSIF,,,,,,,,,,,,1,,,,,,HGNC:5962|MIM:124092|Ensembl:ENSG00000136634|Vega:OTTHUMG00000036386|HPRD:00495,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,interleukin 10,,,1q31-q32,,,,,,,,,,,,,,,,"GO_0002237 (EC: IDA, PMID: 17449476); GO_0002740 (EC: IDA, PMID: 10443688); GO_0002875 (EC: IEA); GO_0002904 (EC: IDA, PMID: 9184696); GO_0005125 (EC: NAS, PMID: 10443688); GO_0005141 (EC: NAS, PMID: 1847510); GO_0005615 (EC: IDA, PMID: 10443688); GO_0006954 (EC: IDA, PMID: 10443688); GO_0007253 (EC: NAS, PMID: 10975994); GO_0007267 (EC: IC, PMID: 1847510); GO_0008083 (EC: NAS, PMID: 1371884); GO_0010468 (EC: IDA, PMID: 9184696); GO_0014823 (EC: IEA); GO_0014854 (EC: IEA); GO_0030097 (EC: TAS, PMID: 11244051); GO_0030183 (EC: NAS, PMID: 8228801); GO_0030595 (EC: TAS, PMID: 9405662); GO_0030886 (EC: IEA); GO_0030889 (EC: IDA, PMID: 9184696); GO_0032689 (EC: IEA); GO_0032695 (EC: IEA); GO_0032715 (EC: IDA, PMID: 10443688); GO_0032720 (EC: IEA); GO_0032800 (EC: IDA, PMID: 10443688); GO_0032868 (EC: IEA); GO_0034465 (EC: IEA); GO_0042092 (EC: TAS, PMID: 11244051); GO_0042100 (EC: NAS, PMID: 8228801); GO_0042130 (EC: NAS, PMID: 14971032); GO_0042493 (EC: IEA); GO_0042536 (EC: IEA); GO_0042742 (EC: IEA); GO_0043066 (EC: NAS, PMID: 8312229); GO_0044130 (EC: IEA); GO_0045019 (EC: IEA); GO_0045191 (EC: NAS, PMID: 8228801); GO_0045347 (EC: TAS, PMID: 11244051); GO_0045348 (EC: IEA); GO_0045355 (EC: NAS, PMID: 9637497); GO_0045893 (EC: IDA, PMID: 7749983); GO_0045944 (EC: IEA); GO_0050715 (EC: IDA, PMID: 10443688); GO_0051045 (EC: IDA, PMID: 18383040); GO_0051091 (EC: IDA, PMID: 7749983); GO_0051384 (EC: IDA, PMID: 10443688); GO_0051930 (EC: IEA); GO_0060670 (EC: IEA); GO_0071222 (EC: NAS, PMID: 14971032); GO_0071392 (EC: IEA)",,,,,,,,,PMID: 1121048; 1350294; 1371884; 1847510; 2173142; 7511078; 7527834; 7547951; 7553888; 7590988; 7591871; 7695626; 7749063; 7749983; 7759550; 7815507; 8037735; 8228801; 8248239; 8312229; 8364028; 8402911; 8499633; 8590020; 8764000; 8881045; 8897595; 8898665; 8910398; 9043871; 9096366; 9108403; 9143942; 9162098; 9184696; 9225992; 9234486; 9312047; 9334723; 9405662; 9463379; 9534962; 9637497; 9658081; 9689103; 9743208; 9788463; 10064624; 10089566; 10231374; 10443688; 10542212; 10714547; 10775602; 10807185; 10975994; 10985253; 11023480; 11023665; 11044099; 11087201; 11121048; 11137132; 11160847; 11163082; 11168433; 11192323; 11196656; 11196688; 11196718; 11212157; 11223972; 11230752; 11233912; 11238636; 11244051; 11260510; 11266927; 11266928; 11267084; 11271474; 11292301; 11294564; 11298547; 11307152; 11315919; 11316066; 11316069; 11354638; 11391238; 11404167; 11436536; 11441115; 11477472; 11478505; 11485736; 11493351; 11496247; 11517440; 11528523; 11544427; 11544434; 11544437; 11640949; 11689215; 11715070; 11717514; 11737614; 11740730; 11745479; 11758730; 11777537; 11792123; 11805149; 11820460; 11821159; 11828010; 11829538; 11833470; 11838849; 11852287; 11857058; 11869683; 11881827; 11883743; 11896938; 11906646; 11908705; 11919157; 11920312; 11922883; 11928840; 11929132; 11943322; 11952921; 11953141; 11953994; 11956022; 11960393; 11964134; 11964300; 11970958; 11986609; 11991675; 11994432; 12011375; 12020266; 12028020; 12039409; 12042661; 12047360; 12050565; 12060853; 12067976; 12069178; 12069391; 12078789; 12089333; 12089714; 12093676; 12095061; 12095128; 12097418; 12100571; 12100575; 12101075; 12104048; 12115622; 12117955; 12119553; 12121678; 12121679; 12124654; 12133353; 12133517; 12145682; 12151439; 12160736; 12164325; 12164877; 12165551; 12170266; 12189567; 12190181; 12197884; 12202153; 12203138; 12207099; 12207325; 12207353; 12209037; 12215823; 12219016; 12220553; 12220699; 12223518; 12232842; 12233881; 12239181; 12270545; 12370394; 12377950; 12389080; 12390476; 12392859; 12393426; 12393603; 12393699; 12394188; 12404162; 12420205; 12423294; 12438341; 12438348; 12438424; 12438965; 12444143; 12447749; 12451269; 12458048; 12477767; 12477932; 12486603; 12493739; 12495723; 12496396; 12496489; 12507818; 12509628; 12525572; 12526950; 12531774; 12534553; 12535204; 12538698; 12540792; 12544990; 12548511; 12554901; 12558814; 12578333; 12581488; 12590978; 12591385; 12594817; 12595905; 12595908; 12599058; 12609526; 12615834; 12616343; 12618859; 12626585; 12627487; 12631183; 12633940; 12640314; 12651071; 12654092; 12662377; 12663757; 12667161; 12668613; 12671741; 12676754; 12687213; 12687247; 12688341; 12700072; 12700599; 12705485; 12707018; 12709682; 12714267; 12714269; 12727335; 12727482; 12730860; 12738388; 12738467; 12743452; 12746253; 12746914; 12756345; 12761561; 12761564; 12765479; 12778475; 12782719; 12787424; 12788307; 12788980; 12791310; 12791313; 12791314; 12792880; 12799024; 12799207; 12802400; 12813360; 12818128; 12823999; 12824008; 12825869; 12826153; 12826369; 12828754; 12847677; 12847896; 12850811; 12851716; 12861049; 12864989; 12867583; 12909463; 12925485; 12926133; 12934185; 12938145; 12938195; 12940515; 12942209; 12944981; 12944983; 12945076; 12946990; 12959221; 12967650; 12971465; 13129651; 14512909; 14514772; 14522096; 14523823; 14550257; 14551598; 14562641; 14563376; 14566095; 14567558; 14572794; 14583474; 14585195; 14592815; 14597210; 14616291; 14625191; 14629328; 14630401; 14631168; 14638775; 14642153; 14646574; 14647192; 14657427; 14669219; 14675398; 14679088; 14682393; 14697748; 14697935; 14698136; 14701701; 14701704; 14722888; 14730222; 14742283; 14744383; 14746814; 14746878; 14748015; 14756669; 14872501; 14959851; 14969768; 14971032; 14978075; 14994383; 14999688; 15001471; 15007355; 15016829; 15021309; 15036247; 15039132; 15041164; 15042002; 15057267; 15057902; 15066699; 15070757; 15072702; 15078471; 15084933; 15085177; 15086488; 15100460; 15102771; 15104679; 15116066; 15120189; 15122773; 15122797; 15127646; 15129234; 15131577; 15135368; 15142213; 15144570; 15152368; 15155645; 15161508; 15170937; 15179129; 15180472; 15187110; 15188059; 15189946; 15191519; 15194284; 15194285; 15200436; 15200452; 15207246; 15212825; 15214940; 15221281; 15223609; 15223612; 15225432; 15235132; 15246967; 15247007; 15247172; 15265021; 15271933; 15288631; 15292002; 15292362; 15295621; 15304673; 15306847; 15316224; 15316663; 15325405; 15325406; 15340161; 15345120; 15345504; 15346339; 15351436; 15361124; 15361128; 15367225; 15368517; 15374585; 15381182; 15388260; 15452323; 15458467; 15462469; 15465816; 15466015; 15481145; 15485815; 15488737; 15497451; 15527169; 15530917; 15534100; 15547296; 15551142; 15561982; 15562761; 15566952; 15573087; 15579372; 15579481; 15581980; 15592292; 15596839; 15599305; 15599664; 15602175; 15603866; 15603899; 15607028; 15611648; 15621151; 15622443; 15643599; 15644127; 15650893; 15652446; 15659329; 15661939; 15663746; 15663966; 15674653; 15678510; 15682481; 15686588; 15690532; 15693804; 15694997; 15709194; 15711248; 15714121; 15718915; 15723707; 15728515; 15733644; 15747244; 15748779; 15749884; 15755291; 15761493; 15763337; 15772682; 15773449; 15780075; 15780879; 15784411; 15787640; 15800006; 15803357; 15809210; 15810889; 15811521; 15814696; 15814743; 15815688; 15815689; 15818327; 15837194; 15838798; 15841043; 15842590; 15843082; 15845862; 15848524; 15857508; 15863393; 15871134; 15884119; 15886526; 15894515; 15900488; 15901906; 15907845; 15910294; 15914210; 15915323; 15918171; 15919371; 15919456; 15925543; 15927351; 15927856; 15931634; 15932621; 15933064; 15933743; 15937090; 15940038; 15941525; 15951665; 15956545; 15964392; 15978325; 15979955; 15985167; 15990800; 15993715; 16008678; 16014616; 16024856; 16030091; 16030322; 16034145; 16038043; 16043753; 16043936; 16043989; 16051275; 16059673; 16076299; 16078336; 16083174; 16084491; 16091126; 16098562; 16100774; 16109775; 16114018; 16120761; 16122836; 16133175; 16148556; 16160188; 16162776; 16163478; 16164695; 16165702; 16171432; 16173237; 16182624; 16183136; 16184405; 16193177; 16202743; 16226734; 16230423; 16232344; 16243534; 16247433; 16249504; 16256199; 16259956; 16276011; 16279907; 16284379; 16287542; 16287924; 16305644; 16313808; 16323127; 16323614; 16331571; 16341266; 16343245; 16361810; 16362796; 16364177; 16375755; 16378074; 16378687; 16380445; 16389181; 16396704; 16403098; 16411061; 16412052; 16413199; 16424284; 16425360; 16429138; 16433832; 16435103; 16441483; 16449530; 16460885; 16461080; 16464746; 16481285; 16489646; 16493441; 16507146; 16522370; 16523426; 16525502; 16537004; 16537707; 16540751; 16547227; 16551363; 16566641; 16567828; 16570020; 16573560; 16573780; 16579847; 16584395; 16585075; 16600026; 16611358; 16618781; 16635219; 16638698; 16644716; 16672066; 16672072; 16672419; 16681592; 16690414; 16690518; 16698276; 16698426; 16699450; 16699452; 16702372; 16702858; 16707559; 16712948; 16720107; 16720211; 16722148; 16723241; 16730575; 16759385; 16762155; 16780675; 16781761; 16785496; 16803619; 16803995; 16803996; 16804000; 16807647; 16809636; 16815316; 16820326; 16820919; 16824070; 16824159; 16826368; 16842617; 16850164; 16859503; 16859504; 16861661; 16861684; 16863661; 16867043; 16872712; 16883528; 16889540; 16895750; 16905295; 16907941; 16908746; 16911685; 16920714; 16924108; 16930778; 16931134; 16933851; 16938461; 16940525; 16943796; 16945026; 16949747; 16959027; 16961803; 16962335; 16971956; 16973274; 16978071; 16984283; 16987066; 17003778; 17005410; 17006334; 17006724; 17015714; 17015751; 17041236; 17049666; 17051272; 17052299; 17052682; 17070109; 17083041; 17092253; 17097497; 17103073; 17107380; 17113632; 17122782; 17132891; 17133531; 17138053; 17138064; 17141301; 17145371; 17145373; 17152005; 17163451; 17173255; 17178344; 17178764; 17182240; 17188628; 17198275; 17202341; 17204399; 17207568; 17208210; 17209781; 17213232; 17215337; 17215862; 17220333; 17225142; 17230494; 17237407; 17237722; 17238853; 17241871; 17257312; 17261758; 17261759; 17263806; 17304105; 17307204; 17310845; 17314689; 17321603; 17321902; 17326156; 17331973; 17335372; 17336597; 17338374; 17351514; 17353161; 17355643; 17369174; 17373677; 17376198; 17380193; 17380888; 17388919; 17389013; 17389235; 17393023; 17407084; 17408400; 17412916; 17413867; 17420099; 17428673; 17431682; 17438520; 17444587; 17444864; 17448042; 17449476; 17454884; 17460178; 17463301; 17470530; 17483704; 17487426; 17490670; 17496310; 17498265; 17509455; 17510437; 17511783; 17522354; 17524861; 17530721; 17537769; 17543146; 17544514; 17544674; 17544800; 17546224; 17548183; 17552041; 17553352; 17559370; 17559576; 17565648; 17568575; 17572155; 17574964; 17576577; 17587429; 17587715; 17592300; 17597660; 17605296; 17607501; 17612762; 17617027; 17618436; 17627763; 17634568; 17640058; 17640324; 17645476; 17645589; 17652887; 17653830; 17654453; 17656331; 17665434; 17674321; 17678726; 17684137; 17686006; 17688234; 17689273; 17690160; 17690329; 17700165; 17703177; 17703412; 17704111; 17706223; 17711410; 17714919; 17716348; 17716608; 17717744; 17724799; 17761309; 17762971; 17763324; 17763336; 17804501; 17825889; 17845635; 17846855; 17869646; 17875118; 17875573; 17884957; 17889143; 17903648; 17908769; 17916230; 17917921; 17919702; 17923267; 17929139; 17932439; 17938902; 17945537; 17947295; 17960405; 17961177; 17965799; 17968299; 17974504; 17979488; 17980158; 17981284; 17983270; 17988266; 17990180; 17999153; 18023359; 18023521; 18024395; 18039196; 18041006; 18042256; 18049335; 18054497; 18056366; 18056971; 18057536; 18071035; 18071881; 18080762; 18086767; 18090276; 18093240; 18093541; 18093884; 18158121; 18163209; 18164040; 18165865; 18171291; 18173702; 18174230; 18174250; 18184461; 18191118; 18192685; 18199828; 18200504; 18201362; 18208460; 18212693; 18216090; 18218037; 18221542; 18230105; 18234565; 18234854; 18235016; 18239807; 18242340; 18249038; 18267346; 18271063; 18273643; 18283248; 18284424; 18286551; 18292506; 18299793; 18303205; 18304876; 18307517; 18310311; 18311435; 18312596; 18315435; 18318911; 18325328; 18337305; 18341210; 18347814; 18353715; 18361934; 18362084; 18362887; 18363812; 18366487; 18375254; 18382869; 18383040; 18383862; 18384906; 18387831; 18391721; 18391751; 18392953; 18393655; 18397303; 18400189; 18405249; 18408074; 18414898; 18416756; 18424735; 18424756; 18427872; 18430198; 18436572; 18436829; 18439592; 18440625; 18444945; 18447856; 18448485; 18456270; 18457043; 18479293; 18479302; 18485518; 18490728; 18490762; 18493769; 18502564; 18510721; 18512809; 18522869; 18523359; 18534084; 18538381; 18539537; 18541226; 18551071; 18554409; 18559596; 18560870; 18569989; 18576303; 18579697; 18582197; 18583979; 18589089; 18593434; 18597405; 18609361; 18612930; 18614592; 18616700; 18619701; 18627514; 18628242; 18628251; 18632425; 18633131; 18633332; 18633768; 18636124; 18638093; 18640487; 18641355; 18651178; 18665050; 18665932; 18668392; 18674658; 18676680; 18676870; 18680515; 18683035; 18687423; 18692180; 18703108; 18705845; 18707865; 18725394; 18753053; 18760861; 18781131; 18792803; 18793860; 18794066; 18796448; 18797896; 18798072; 18805892; 18815552; 18818748; 18819899; 18826950; 18832862; 18836448; 18843277; 18845324; 18923248; 18924213; 18930197; 18931463; 18936436; 18937577; 18945465; 18950592; 18952289; 18953879; 18956675; 18962896; 18972133; 18972297; 18974840; 18974842; 18976327; 18996999; 18997484; 18997828; 19001136; 19004675; 19005292; 19009622; 19011628; 19012493; 19013323; 19013788; 19019335; 19021042; 19026560; 19027043; 19028820; 19031431; 19034880; 19038787; 19039953; 19050632; 19055487; 19056482; 19058854; 19058987; 19064572; 19065724; 19066394; 19071030; 19074885; 19077731; 19082598; 19084429; 19086955; 19087313; 19089920; 19097982; 19099482; 19109192; 19110537; 19111610; 19117745; 19118909; 19124156; 19124506; 19126646; 19127455; 19131662; 19132772; 19145440; 19153889; 19157224; 19164257; 19170196; 19176318; 19183122; 19184348; 19196047; 19200845; 19201467; 19201880; 19208551; 19210299; 19210338; 19222424; 19225544; 19228651; 19237018; 19237638; 19238444; 19239428; 19244371; 19246943; 19247692; 19249119; 19258635; 19258923; 19259799; 19264973; 19267370; 19272082; 19272636; 19274101; 19275586; 19276283; 19279357; 19282863; 19284443; 19290853; 19295315; 19295440; 19295541; 19299022; 19300393; 19307576; 19308651; 19319950; 19321591; 19332120; 19334424; 19336263; 19336370; 19336475; 19337556; 19341387; 19347053; 19348329; 19349988; 19358670; 19365081; 19372622; 19375306; 19375805; 19376105; 19383027; 19383626; 19385959; 19386798; 19389111; 19401389; 19401395; 19401628; 19407822; 19408823; 19409109; 19412539; 19413695; 19415548; 19419334; 19420105; 19427781; 19430480; 19437115; 19437232; 19450147; 19458621; 19470040; 19474090; 19477525; 19478959; 19479237; 19480854; 19481774; 19481975; 19488421; 19495883; 19497711; 19501525; 19505916; 19505919; 19508433; 19527514; 19528258; 19534595; 19541591; 19543506; 19544559; 19552724; 19552919; 19555400; 19559392; 19561105; 19562463; 19565483; 19570392; 19573080; 19576194; 19578796; 19578817; 19579695; 19581835; 19585232; 19586841; 19591971; 19594368; 19596995; 19604093; 19608017; 19608431; 19614971; 19617629; 19620304; 19621425; 19621989; 19625176; 19625651; 19644155; 19652739; 19656776; 19658300; 19661010; 19661089; 19667950; 19669876; 19673019; 19683555; 19692168; 19692203; 19698128; 19698145; 19700159; 19700502; 19700864; 19706920; 19711225; 19733878; 19737632; 19738620; 19740314; 19744138; 19748989; 19753334; 19758163; 19758192; 19759281; 19760027; 19762082; 19762555; 19766898; 19771178; 19773279; 19773451; 19778488; 19779724; 19781301; 19782084; 19786281; 19796538; 19798061; 19802007; 19805095; 19811408; 19813110; 19817985; 19819209; 19821803; 19822020; 19823053; 19838195; 19852851; 19856416; 19860911; 19861958; 19882211; 19889024; 19889076; 19889475; 19890236; 19892918; 19895848; 19907653; 19908064; 19908237; 19912737; 19913121; 19915572; 19917162; 19934104; 19936625; 19938203; 19939284; 19948975; 19956635; 19957794; 19958312; 19996617; 19996656; 20001857; 20010527; 20012528; 20014019; 20015215; 20016407; 20016783; 20017308; 20018615; 20030788; 20032313; 20037209; 20042578; 20042580; 20044609; 20047977; 20051670; 20052801; 20059417; 20061995; 20070620; 20070836; 20072143; 20080912; 20082482; 20082647; 20083555; 20087644; 20087693; 20087947; 20089329; 20097948; 20102414; 20107186; 20138641; 20144201; 20145925; 20148913; 20150436; 20150742; 20163933; 20171114; 20176734; 20177758; 20178529; 20181890; 20184663; 20188863; 20189706; 20190550; 20191326; 20191386; 20195402; 20195716; 20196868; 20200511; 20202139; 20204402; 20207250; 20207982; 20213229; 20217044; 20227257; 20227772; 20228669; 20228798; 20228799; 20232770; 20233508; 20236506; 20236616; 20237496; 20299965; 20302034; 20305143; 20306684; 20335604; 20337945; 20339193; 20339966; 20349753; 20356901; 20359252; 20363151; 20367137; 20369436; 20370995; 20371920; 20378550; 20378664; 20381257; 20384861; 20385468; 20388088; 20388104; 20393813; 20395963; 20399512; 20404426; 20410487; 20413987; 20416077; 20418110; 20419805; 20421626; 20424473; 20424554; 20424918; 20430716; 20431935; 20438703; 20445748; 20447254; 20448110; 20452482; 20453000; 20454933; 20457266; 20459687; 20463618; 20470442; 20471133; 20472930; 20473875; 20477882; 20482524; 20484443; 20484876; 20485362; 20485444; 20486195; 20490277; 20490891; 20503287; 20509889; 20518833; 20518842; 20519163; 20523065; 20525402; 20527514; 20529592; 20530519; 20531015; 20536507; 20536548; 20551628; 20553628; 20558465; 20561040; 20564140; 20565774; 20567520; 20568250; 20570082; 20571871; 20576226; 20578820; 20587610; 20588103; 20588308; 20589076; 20591588; 20592893; 20595152; 20602615; 20603037; 20603050; 20617924; 20618176; 20622753; 20622878; 20622879; 20625422; 20628086; 20628373; 20638860; 20640364; 20644561; 20646924; 20650298; 20659236; 20661303; 20661604; 20662694; 20671651; 20673868; 20711808; 20714960; 20716621; 20720222; 20722024; 20723894; 20725607; 20732366; 20735825; 20737205; 20798845; 20804371; 20805562; 20807264; 20809522; 20809684; 20811626; 20825427; 20825636; 20830806; 20835611; 20838432; 20839488; 20860222; 20861424; 20863526; 20879862; 20880001; 20880267; 20880745; 20881642; 20883321; 20884746; 20889146; 20889800; 20922456; 20927126; 20934598; 20934961; 20942272; 20952070; 20953818; 20957732; 20970781; 20976276; 21030268; 21037509; 21040915; 21048327; 21052690; 21054877; 21055074; 21055733; 21057561; 21057730; 21061265; 21067483; 21067752; 21068755; 21076061; 21086908; 21088899; 21090240; 21098222; 21102463; 21107607; 21107665; 21123382; 21131395; 21135123; 21138342; 21160051; 21168854; 21183270; 21191065; 21205466; 21211963; 21215074; 21215285; 21216474; 21223691; 21227406; 21238445; 21239715; 21240493; 21254836; 21255795; 21267581; 21281983; 21297633; 21300911; 21303362; 21309719; 21314735; 21316985; 21317876; 21323660; 21328800; 21332458; 21339768; 21354456; 21357266; 21357402; 21358669; 21359250; 21372199; 21398611; 21398617; 21402594; 21406270; 21413929; 21424183; 21426411; 21439624; 21440743; 21455338; 21463487; 21466366; 21467695; 21468030; 21468579; 21478113; 21481602; 21508509; 21518800; 21519827; 21526166; 21527907; 21532858; 21549291; 21553228; 21558138; 21560494; 21567173; 21595995; 21609779; 21621860; 21624746; 21626471; 21641950; 21642542; 21658228; 21658363; 21669226; 21688665; 21689404; 21699407; 21721376; 21724486; 21725623; 21729106; 21730023; 21744325; 21756510; 21757655; 21764596; 21767236; 21777343; 21779975; 21786452; 21791113; 21792878; 21808111; 21812905; 21816135; 21829393; 21830424; 21839042; 21858117; 21861711; 21862302; 21863566; 21863628; 21869490; 21873118; 21876975; 21878338; 21901441; 21902578; 21909800; 21910858; 21917128; 21918473; 21923667; 21925952; 21926547; 21931651; 21936714; 21940055; 21968303; 21972680; 21986577; 21998459; 22010076; 22019000; 22032897; 22033829; 22038351; 22048455; 22050548; 22057691; 22057973; 22058059; 22070668; 22075762; 22077544; 22079540; 22081333; 22082370; 22092594; 22095765; 22100578; 22105495; 22116520; 22122951; 22123389; 22129927; 22140263; 22140472; 22144535; 22156547; 22157213; 22158873; 22160576; 22168225; 22172723; 22174866; 22176654; 22182686; 22184725; 22187388; 22189417; 22189756; 22205204; 22205395; 22213066; 22219323; 22225835; 22235320; 22239992; 22263663; 22279662; 22287022; 22288916; 22298356; 22307790; 22311038; 22323454; 22325340; 22335769; 22347492; 22350281; 22356904; 22358381; 22366404; 22371646; 22378604; 22387064; 22390924; 22393278; 22410761; 22416256; 22424164; 22425021; 22425265; 22427230; 22436502; 22442690; 22445549; 22466287; 22475179; 22484198; 22484241; 22487811; 22494514; 22503116; 22507621; 22520513; 22529524; 22535664; 22537067; 22537751; 22544931; 22547702; 22547705; 22549091; 22556042; 22565155; 22566507; 22572643; 22575708; 22578382; 22580886; 22582500; 22586040; 22592039; 22592860; 22594912; 22595646; 22628023; 22634719; 22644143; 22653776; 22655468; 22664006; 22673037; 22677268; 22678905; 22681958; 22682876; 22685028; 22687336; 22698805; 22710869; 22711892; 22715992; 22732092; 22740130; 22749664; 22753934; 22753938; 22763734; 22768144; 22784413; 22788775; 22795294; 22796266; 22805022; 22812212; 22812241; 22818022; 22825546; 22835429; 22835835; 22848356; 22850906; 22851691; 22859398; 22859944; 22880107; 22886309; 22897390; 22902304; 22911481; 22924705; 22931953; 22932817; 22940633; 22966128; 22972930; 22981868; 22986179; 22989497; 23013217; 23013641; 23017230; 23020144; 23021880; 23027536; 23028907; 23029361; 23034167; 23046616; 23046617; 23053983; 23062006; 23062580; 23069299; 23071313; 23073467; 23075771; 23079832; 23086275; 23088578; 23094074; 23095823; 23096091; 23118878; 23125413; 23128233; 23143946; 23149083; 23152883; 23159283; 23166328; 23168096; 23185315; 23192326; 23207823; 23209731; 23210681; 23220432; 23225254; 23232337; 23235789; 23237063; 23237776; 23251077; 23265747; 23272193; 23273903; 23273955; 23276701; 23294711; 23299779; 23300021; 23300769; 23325892; 23326478; 23334981; 23335974; 23343479; 23349310; 23355741; 23357299; 23363891; 23376084; 23379624; 23380741; 23415626; 23416458; 23430974; 23432860; 23438682; 23444260; 23449984; 23450495; 23453286; 23460834; 23485354; 23485538; 23485736; 23488731; 23498167; 23525950; 23541976; 23544075; 23556339; 23562725; 23570798; 23574339; 23582441; 23583365; 23591975; 23595519; 23602200; 23602201; 23607333; 23613317; 23623844; 23638863; 23640160; 23640982; 23645090; 23654353; 23663047; 23663500; 23668806; 23679256; 23690289; 23711712; 23712703; 23716201; 23720844; 23723980; 23725154; 23725178; 23733877; 23743567; 23749933; 23752129; 23752604; 23762097; 23768819; 23772925; 23777202; 23797738; 23798430; 23814099; 23818986; 23834952; 23838435; 23846686; 23875023; 23880295; 23880623; 23886125; 23897063; 23898109; 23901045; 23910644; 23936042; 23990628; 24015034; 24042116; 24043893; 24067460; 24077340; 24130510; 24174668; 24216477; 24327156; 24340926; 24379064,,,,,,,,,,,,,,,OGG:3000003586,,,,,,,interleukin 10,,,,,,,,,,,,,Other designations: T-cell growth inhibitory factor|cytokine synthesis inhibitory factor|interleukin-10,,IL10,,,,,,,,,,,,,,,,,,,,,,,3586,RP11-262N9.1,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,IL10,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0001921,glutathione depletion dependent chemical compound,,"Glutathione depletion dependent chemical compound is a subtype of toxic course dependent chemical entity.
This entity (drug) can participate in the course of glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0001915,,,,,,,,,,,,,,,,,,,,,,"Glutathione depletion dependent chemical compound is a subtype of toxic course dependent chemical entity.
This entity (drug) can participate in the course of glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001921,,,,,,,,,,,,,,,,,,,,,,glutathione depletion dependent chemical compound,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001926,negative regulation of DNA repair,,"Any process that stops, prevents, or reduces the frequency, rate or extent of DNA repair process.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance .",false,,,http://purl.obolibrary.org/obo/TXPO_0000965|http://purl.obolibrary.org/obo/GO_0043066,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents, or reduces the frequency, rate or extent of DNA repair process.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001939,,,,,,http://purl.obolibrary.org/obo/TXPO_0002320,,,,,,,,,,,TXPO:0001926,,,,,,,,,,,,,,,,,,,,,,negative regulation of DNA repair,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001927,glutathione depletion dependent molecule (rat),,"Glutathione depletion dependent molecule is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of glutathione depletion as a gene product.
Gene profile:Rat/Liver/",false,,,http://purl.obolibrary.org/obo/TXPO_0001915,,,,,,,,,,,,,,,,,,,,,,"Glutathione depletion dependent molecule is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of glutathione depletion as a gene product.
Gene profile:Rat/Liver/",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001927,,,,,,,,,,,,,,,,,,,,,,glutathione depletion dependent molecule (rat),,,,,,,,,,,http://purl.obolibrary.org/obo/NCBITaxon_10114,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001924,phorone [Glutathione depletion],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001921|http://purl.obolibrary.org/obo/CHEBI_35572,,,,,,,,,,,,,,,,,,,,ISBN:0071769234,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001924,,,,,,,,,,,,,,,,,,,,,,phorone [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001929,GSS (canonical)[Glutathione depletion],Glutathione Synthetase [Glutathione depletion],PMID:23856494|ATP dependent.,false,,,http://purl.obolibrary.org/obo/TXPO_0002045|http://purl.obolibrary.org/obo/TXPO_0001931,,,,,,,,,,,,,,,,,,,,,,PMID:23856494,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001937,,,,,Glutathione Synthetase [Glutathione depletion],,,,,TXPO:0001929,,,,,,,,,,,,,,,,,,,,ATP dependent.,,GSS (canonical)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001925,hyperfunction of glutathione conjugation  [Glutathione depletion],,"Hyperfunction of glutathione conjugation is a subtype of hyperfunction of drug metabolism phase II: A process that performs an excessive glutathione conjugation.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0001228|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of glutathione conjugation is a subtype of hyperfunction of drug metabolism phase II: A process that performs an excessive glutathione conjugation.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002613|http://purl.obolibrary.org/obo/TXPO_0002711,,,,,,,,,,,TXPO:0001925,,,,,,,,,,,,,,,,,,,,,,hyperfunction of glutathione conjugation  [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001920,electrophiles formation [Glutathione depletion],,"Electrophiles formation is a subtype of biosynthetic process: A process that that generates electrophiles. Electrophile is a reagent that forms a bond to its reaction partner (the nucleophile) by accepting both bonding electrons from that reaction partner.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0000212|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,PMID:21177773,,"Electrophiles formation is a subtype of biosynthetic process: A process that that generates electrophiles. Electrophile is a reagent that forms a bond to its reaction partner (the nucleophile) by accepting both bonding electrons from that reaction partner.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003170|http://purl.obolibrary.org/obo/TXPO_0003171|http://purl.obolibrary.org/obo/TXPO_0003805,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001922,,,,http://purl.obolibrary.org/obo/TXPO_0000974,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001185|http://purl.obolibrary.org/obo/TXPO_0002431|http://purl.obolibrary.org/obo/TXPO_0002407,,,,,,,,,,,TXPO:0001920,,,,,,,"A number of xenobiotics exert a toxic effect theough their metabolites.
Electrophiles are molecules that contain an electron-deficient atom with a partial or full positive charge that can react by sharing electron pairs with electron rich atoms in nucleophiles.
Electrophilic toxicants generally are detoxificated by conjugation of with the nucleophile, glutathione.
This reaction can be facilitated by glutathione S-trasferases.",,,,,,,,,,,,,,,electrophiles formation [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001922,Acetaminophen [Glutathione depletion],APAP|paracetamol [Glutathione depletion]|N-(4-hydroxyphenyl)acetamide,,false,,,http://purl.obolibrary.org/obo/TXPO_0001921|http://purl.obolibrary.org/obo/CHEBI_46195,,,,,,,,,,,,,,,,,,,,Wikipedia:Paracetamol|Wikipedia:Acetaminophen,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,paracetamol [Glutathione depletion]|N-(4-hydroxyphenyl)acetamide,,APAP,,,TXPO:0001922,,,,,,,,,,,,,,,,,,,,,,Acetaminophen [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001923,glutathione conjugation [Glutathione depletion],,"Glutathione conjugation is a subtype of drug metabolism phase II: Glutathione conjugation is a detoxication reaction. Four types of activation reaction have been recognized: direct-acting compounds, conjugates that are activated through cysteine conjugate beta-lyase, conjugates that are activated through redox cycling and lastly conjugates that release the original reactive parent compound. The glutathione S-transferases have three connections with the formation of biactivated conjugatesto make them more soluble for excretion.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0003991|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Glutathione conjugation is a subtype of drug metabolism phase II: Glutathione conjugation is a detoxication reaction. Four types of activation reaction have been recognized: direct-acting compounds, conjugates that are activated through cysteine conjugate beta-lyase, conjugates that are activated through redox cycling and lastly conjugates that release the original reactive parent compound. The glutathione S-transferases have three connections with the formation of biactivated conjugatesto make them more soluble for excretion.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001923,,,,,,,,,,,,,,,,,,,,,,glutathione conjugation [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001928,Srxn1 (rat)[Glutathione depletion],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001927|http://purl.obolibrary.org/obo/TXPO_1000365,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:296271|PMID:20621112,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001928,,,,,,,,,,,,,,,,,,,,,,Srxn1 (rat)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000000602,BCL3,,Other designations: B-cell leukemia/lymphoma 3|B-cell lymphoma 3 protein|B-cell lymphoma 3-encoded protein|BCL-3|chronic lymphatic leukemia protein|proto-oncogene BCL3,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,BCL4|D19S37,,,,,,,,,,,,19,,,,,,MIM:109560|HGNC:998|HPRD:00179|Vega:OTTHUMG00000151517|Ensembl:ENSG00000069399,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,B-cell CLL/lymphoma 3,,,19q13.1-q13.2,,,,,,,,,,,,,,,,"GO_0000060 (EC: IMP, PMID: 16280327); GO_0002268 (EC: IEA); GO_0002315 (EC: IEA); GO_0002455 (EC: IEA); GO_0002467 (EC: IEA); GO_0003677 (EC: IEA); GO_0003700 (EC: IEA); GO_0005515 (EC: IPI, PMID: 10362352); GO_0005634 (EC: IDA); GO_0005730 (EC: IDA, Qualifier: NOT); GO_0005737 (EC: IDA); GO_0006351 (EC: IDA, PMID: 16306601); GO_0006974 (EC: IDA, PMID: 16384933); GO_0007249 (EC: IDA, PMID: 8196632); GO_0008134 (EC: IPI, PMID: 11387332); GO_0009615 (EC: IDA, PMID: 16306601); GO_0010225 (EC: IDA, PMID: 16384933); GO_0019730 (EC: IEA); GO_0030198 (EC: IEA); GO_0030330 (EC: IMP, PMID: 16384933); GO_0030674 (EC: TAS, PMID: 16306601); GO_0032729 (EC: IEA); GO_0032996 (EC: IDA, PMID: 16280327); GO_0033257 (EC: IDA, PMID: 9407099); GO_0042088 (EC: IEA); GO_0042345 (EC: IEP, PMID: 8196632); GO_0042536 (EC: IEA); GO_0042742 (EC: IEA); GO_0042771 (EC: IMP, PMID: 16384933); GO_0042832 (EC: IEA); GO_0042981 (EC: IDA, PMID: 16732314); GO_0043066 (EC: IDA, PMID: 16384933); GO_0043234 (EC: IDA, PMID: 16280327); GO_0045064 (EC: IEA); GO_0045082 (EC: IEA); GO_0045171 (EC: IDA); GO_0045415 (EC: IMP, PMID: 16306601); GO_0045727 (EC: IMP, PMID: 16384933); GO_0045892 (EC: IDA, PMID: 16306601); GO_0045893 (EC: IDA, PMID: 16384933); GO_0045944 (EC: IEA); GO_0048471 (EC: IEA); GO_0048536 (EC: IEA); GO_0051101 (EC: IEP, PMID: 9407099); GO_0051457 (EC: NAS, PMID: 8196632)",,,,,,,,,PMID: 1406939; 1501714; 1923524; 2124350; 2180580; 7691160; 7896265; 8196632; 8330739; 8428580; 8453667; 8497270; 9218802; 9407099; 9576921; 9812988; 10362352; 10469655; 10497212; 10607713; 11387332; 11485202; 11707390; 12456498; 12477932; 12730195; 12808109; 14678988; 15105810; 15469820; 15489334; 15634875; 15829968; 16099425; 16108830; 16123212; 16280327; 16306601; 16311697; 16331275; 16384933; 16732314; 16940298; 17272867; 17495977; 17644518; 17881446; 17923499; 17962807; 17963943; 18025803; 18796561; 18940474; 19191868; 19229118; 19282837; 19383626; 19451226; 19494302; 19617629; 19806201; 19893491; 19913121; 20226764; 20414006; 20471052; 20547759; 20558726; 20572854; 20601676; 20634891; 20658525; 20672350; 20731879; 20737317; 20800578; 20974051; 21048031; 21912613; 21988832; 22580608; 22782967; 23115114; 23149915; 23494744; 23534762; 23565137; 23607276; 23669365; 23794716,,,,,,,,,,,,,,,OGG:3000000602,,,,,,,B-cell CLL/lymphoma 3,,,,,,,,,,,,,Other designations: B-cell leukemia/lymphoma 3|B-cell lymphoma 3 protein|B-cell lymphoma 3-encoded protein|BCL-3|chronic lymphatic leukemia protein|proto-oncogene BCL3,,BCL3,,,,,,,,,,,,,,,,,,,,,,,602,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,BCL3,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CL_0000632,hepatic stellate cell,hepatic perisinusoidal cell|Ito cell|perisinusoidal cell,"A cell that is found in the perisinusoidal space of the liver that is capable of multiple roles including storage of retinol, presentation of antigen to T cells (including CD1d-restricted NKT cells), and upon activation, production of extracellular matrix components that can contribute to liver fibrosis. This activated state has a myofibroblast-like phenotype, though it's not clear in the literature if this is terminally differentiated. This cell type comprises approximately 8-15% of total cells in the liver.",false,,,http://purl.obolibrary.org/obo/CL_0000057,,,,,,,,,,,,,,,,,,,,,,"A cell that is found in the perisinusoidal space of the liver that is capable of multiple roles including storage of retinol, presentation of antigen to T cells (including CD1d-restricted NKT cells), and upon activation, production of extracellular matrix components that can contribute to liver fibrosis. This activated state has a myofibroblast-like phenotype, though it's not clear in the literature if this is terminally differentiated. This cell type comprises approximately 8-15% of total cells in the liver.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,hepatic perisinusoidal cell|Ito cell|perisinusoidal cell,,,,,CL:0000632,,,,,,,,,,,,,,,,,,,,,,hepatic stellate cell,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000151056,PLB1,,"Other designations: lysophospholipase|phospholipase A2|phospholipase B|phospholipase B/lipase|phospholipase B1, membrane-associated",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,PLB/LIP|hPLB|PLB,,,,,,,,,,,,2,,,,,,HPRD:15141|Vega:OTTHUMG00000152014|Ensembl:ENSG00000163803|MIM:610179|HGNC:30041,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,phospholipase B1,,,2p23.2,,,,,,,,,,,,,,,,GO_0001523 (EC: TAS); GO_0004622 (EC: IEA); GO_0004623 (EC: IEA); GO_0005886 (EC: TAS); GO_0006644 (EC: TAS); GO_0007603 (EC: TAS); GO_0016021 (EC: IEA); GO_0016042 (EC: IEA); GO_0016324 (EC: IEA); GO_0036151 (EC: TAS); GO_0044281 (EC: TAS); GO_0046474 (EC: TAS),,,,,,,,,PMID: 8017323; 12150957; 12477932; 12804600; 14702039; 15583024,,,,,,,,,,,,,,,OGG:3000151056,,,,,,,phospholipase B1,,,,,,,,,,,,,"Other designations: lysophospholipase|phospholipase A2|phospholipase B|phospholipase B/lipase|phospholipase B1, membrane-associated",,PLB1,,,,,,,,,,,,,,,,,,,,,,,151056,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,PLB1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000010480,EIF3M,,Other designations: B5 receptor|PCI domain containing 1 (herpesvirus entry mediator)|PCI domain-containing protein 1|dendritic cell protein|eukaryotic translation initiation factor 3 subunit M|fetal lung protein B5|transport and golgi organization 7 homolog,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,hfl-B5|B5|PCID1|TANGO7,,,,,,,,,,,,11,,,,,,HPRD:09969|MIM:609641|HGNC:24460,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"eukaryotic translation initiation factor 3, subunit M",,,11p13,,,,,,,,,,,,,,,,"GO_0001731 (EC: IEA); GO_0002183 (EC: IBA); GO_0003743 (EC: IC, Qualifier: contributes_to, PMID:17322308); GO_0005515 (EC: IPI, PMID:18599441); GO_0005852 (EC: IDA, PMID:17322308); GO_0006413 (EC: IC, PMID:17322308); GO_0006446 (EC: IEA); GO_0016282 (EC: IEA); GO_0033290 (EC: IEA)",,,,,,,,,PMID:8125298; 12477932; 14702039; 15231747; 15919898; 15919899; 16169070; 17322308; 17353931; 17719568; 18599441; 18781797; 19471022; 19483676; 19615732; 20360068; 20379614; 20508642; 20676407; 20838379; 20972266; 21139048; 21832049; 21890473; 21906983; 21963094; 22022972; 22053931; 22174317; 22190034; 22505724; 22678362; 22863883; 22939629; 23000965; 23402259; 23455922; 23602568,,,,,,,,,,,,,,,OGG:3000010480,,,,,,,"eukaryotic translation initiation factor 3, subunit M",,,,,,,,,,,,,Other designations: B5 receptor|PCI domain containing 1 (herpesvirus entry mediator)|PCI domain-containing protein 1|dendritic cell protein|eukaryotic translation initiation factor 3 subunit M|fetal lung protein B5|transport and golgi organization 7 homolog,,EIF3M,,,,,,,,,,,,,,,,,,,,,,,10480,GA17,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF3M,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000445,CKI,cyclin-dependent protein kinase inhibitor|cyclin-dependent kinase inhibitor,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,GO:0004861,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003722,,,,,cyclin-dependent protein kinase inhibitor|cyclin-dependent kinase inhibitor,,,,,IMR:0000445,,,,,,,,,,,,,,,,,,,,,,CKI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001355,cyclic nucleotide,,,false,,,http://purl.obolibrary.org/obo/CHEBI_36976,,,,,,,,,,,,,,,,,,,,CHEBI:23447,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001355,,,,,,,,,,,,,,,,,,,,,,cyclic nucleotide,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001616,Rab30,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001616,,,,,,,,,,,,,,,,,,,,,,Rab30,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0001035,force (quality),,A physical quaility inhering in a bearer by virtue of the bearer's rate of change of momentum.,false,,,http://purl.obolibrary.org/obo/TXPO_0002419|http://purl.obolibrary.org/obo/BFO_0000019,,,,,,,,,,,,,,,,,,,,,,A physical quaility inhering in a bearer by virtue of the bearer's rate of change of momentum.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0001035,,,,,,,,,,,,,,,,,,,,,,force (quality),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001967,Epac,exchange protein directly activated by cAMP,"Epac1 (cAMP-GEFI) and Epac2 (cAMP-GEFII) are closely related guanine nucleotide exchange factors (GEFs) for the small GTPase Rap1 and Rap2, which are directly regulated by cAMP.",false,,,http://purl.obolibrary.org/obo/IMR_0001976,,,,,,,,,,,,,,,,,,,,,,"Epac1 (cAMP-GEFI) and Epac2 (cAMP-GEFII) are closely related guanine nucleotide exchange factors (GEFs) for the small GTPase Rap1 and Rap2, which are directly regulated by cAMP.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,exchange protein directly activated by cAMP,,,,,IMR:0001967,,,,,,,,,,,,,,,,,,,,,,Epac,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0034379,very-low-density lipoprotein particle assembly,,The non-covalent aggregation and arrangement of proteins and lipids in the liver to form a very-low-density lipoprotein particle.,false,,,http://purl.obolibrary.org/obo/GO_0065005,,,,,,,,,,,,,,,,,,,,,,The non-covalent aggregation and arrangement of proteins and lipids in the liver to form a very-low-density lipoprotein particle.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_39027,,,,,,,,,,,,,,,,,,,GO:0034379,,,,,,,,,,,,,,,,,,,,,,very-low-density lipoprotein particle assembly,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001565,amitriptyline metabolism phase I,,"Amitriptyline metabolism is a subtype of drug metabolism phase I by Cytochrome P450: A process that that is biotransformed of amitriptyline by cytochrome P450 (CYP) superfamily (CYP2D6, CYP1A2, and CYP2C9. )",false,,,http://purl.obolibrary.org/obo/TXPO_0001559,,,,,,,,,,,,,,,,,,,,,,"Amitriptyline metabolism is a subtype of drug metabolism phase I by Cytochrome P450: A process that that is biotransformed of amitriptyline by cytochrome P450 (CYP) superfamily (CYP2D6, CYP1A2, and CYP2C9. )",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001565,,,,,,,,,,,,,,,,,,,,,,amitriptyline metabolism phase I,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001560,imipramine _CAD [Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/CHEBI_47499|http://purl.obolibrary.org/obo/TXPO_0001849,,,,,,,,,,,,,,,,,,,,PMID:15720040,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001426,,,,,,,,,,TXPO:0001560,,,,,,,,,,,,,,,,,,,,,,imipramine _CAD [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001566,amitriptyline [Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001849|http://purl.obolibrary.org/obo/CHEBI_2666,,,,,,,,,,,,,,,,,,,,PMID:24003057|PMID:24980264,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001566,,,,,,,,,,,,,,,,,,,,,,amitriptyline [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001567,long (value),,A length quality value which is greater than the normal or average.,false,,,http://purl.obolibrary.org/obo/TXPO_0000286,,,,,,,,,,,,,,,,,,,,,,A length quality value which is greater than the normal or average.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001567,,,,,,,,,,,,,,,,,,,,,,long (value),,,,,,,,,,,,,short (value),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001561,DNA repair agent role,,A role played by the entity to repair the damaged DNA.,false,,,http://purl.obolibrary.org/obo/TXPO_0003712,,,,,,,,,,,,,,,,,,,,,,A role played by the entity to repair the damaged DNA.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001561,,,,,,,,,,,,,,,,,,,,,,DNA repair agent role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001569,decreasing ceramide [sphingomyelin disorder ],,"Decreasing ceramide is a subtype of decreasing lipid: A process that changes the quantity of the ceramide to be lower.
This entity is a specific course-dependent process. This process can constitute the course of sphingomyelin disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0003601|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Decreasing ceramide is a subtype of decreasing lipid: A process that changes the quantity of the ceramide to be lower.
This entity is a specific course-dependent process. This process can constitute the course of sphingomyelin disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003543,,,,,,http://purl.obolibrary.org/obo/TXPO_0001595|http://purl.obolibrary.org/obo/TXPO_0003445,,,,,,,,,,,TXPO:0001569,,,,,,,,,,,,,,,,,,,,,,decreasing ceramide [sphingomyelin disorder ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001568,CYP2D6 (human)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000080|http://purl.obolibrary.org/obo/TXPO_0001135,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1565|PMID:12695349|PMID:26296708|PMID:17470523|PMID:27440861,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001553,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001565,,,http://purl.obolibrary.org/obo/TXPO_0002262,,,,,,,,,,TXPO:0001568,,,,,,,,,,,,,,,,,,,,,,CYP2D6 (human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001551,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001564,amitriptyline metabolism [Phospholipidosis],,"Amitriptyline metabolism is a subtype of drug metabolism phase I by Cytochrome P450: A process that that is biotransformed of amitriptyline by cytochrome P450 (CYP) superfamily (CYP2D6, CYP1A2, and CYP2C9. )
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001565|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Amitriptyline metabolism is a subtype of drug metabolism phase I by Cytochrome P450: A process that that is biotransformed of amitriptyline by cytochrome P450 (CYP) superfamily (CYP2D6, CYP1A2, and CYP2C9. )
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001566|http://purl.obolibrary.org/obo/TXPO_0001563,,,,,,,,,,,,,,,,,TXPO:0001564,,,,,,,,,,,,,,,,,,,,,,amitriptyline metabolism [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001563,CYP2B6 (human)[Phospholipidosis],,"Orthologs of the human CYP2B6 genes can be found in other species including rats, mice, and dogs, which are termed Cyp2b1, Cyp2b10, and CYP2B11, respectively",false,,,http://purl.obolibrary.org/obo/TXPO_1000078|http://purl.obolibrary.org/obo/TXPO_0001135,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1555|http://omim.org/entry/123930|PMID:15128046|PMID:10784435|PMID:10199594,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001553,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001555,,,http://purl.obolibrary.org/obo/TXPO_0002262,,,,,,,,,,TXPO:0001563,,,,,,,,,,,,,,,,,,,,"Orthologs of the human CYP2B6 genes can be found in other species including rats, mice, and dogs, which are termed Cyp2b1, Cyp2b10, and CYP2B11, respectively",,CYP2B6 (human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/GO_0005886,plasma membrane,cellular membrane|cytoplasmic membrane|cell membrane,The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins,false,,,http://purl.obolibrary.org/obo/TXPO_0000895,,,,,,,,,,,,,,,,,,,,NIF_Subcellular:sao1663586795|Wikipedia:Cell_membrane,,The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,cellular membrane|cytoplasmic membrane|cell membrane,,,,http://purl.obolibrary.org/obo/CL_0000000,GO:0005886,http://purl.obolibrary.org/obo/CL_0000000,,,,,,,,,,,,,,,,,,,,,plasma membrane,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000000208,AKT2,,Other designations: PKB beta|RAC-PK-beta|RAC-beta serine/threonine-protein kinase|murine thymoma viral (v-akt) homolog-2|protein kinase Akt-2|protein kinase B beta|rac protein kinase beta,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,PKBBETA|HIHGHH|PRKBB|RAC-BETA|PKBB,,,,,,,,,,,,19,,,,,,HGNC:392|HPRD:01262|MIM:164731|Vega:OTTHUMG00000137375|Ensembl:ENSG00000105221,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,v-akt murine thymoma viral oncogene homolog 2,,,19q13.1-q13.2,,,,,,,,,,,,,,,,"GO_0001934 (EC: ISS); GO_0004674 (EC: IDA, PMID: 16540465); GO_0004674 (EC: TAS); GO_0005515 (EC: IPI, PMID: 10490823); GO_0005524 (EC: IDA, PMID: 16540465); GO_0005634 (EC: IDA); GO_0005634 (EC: TAS); GO_0005829 (EC: TAS); GO_0005886 (EC: ISS); GO_0005886 (EC: TAS); GO_0005938 (EC: ISS); GO_0005978 (EC: IEA); GO_0006006 (EC: IEA); GO_0006417 (EC: IEA); GO_0006464 (EC: TAS, PMID: 1409633); GO_0006915 (EC: IEA); GO_0007165 (EC: TAS); GO_0008286 (EC: IMP, PMID: 16814735); GO_0008286 (EC: TAS); GO_0008643 (EC: IEA); GO_0010748 (EC: IMP, PMID: 16814735); GO_0010907 (EC: IMP, PMID: 16814735); GO_0016301 (EC: TAS); GO_0030334 (EC: TAS); GO_0031340 (EC: ISS); GO_0032000 (EC: IMP, PMID: 16814735); GO_0032287 (EC: IEA); GO_0032587 (EC: ISS); GO_0032859 (EC: IEA); GO_0032869 (EC: IMP, PMID: 16814735); GO_0045444 (EC: TAS); GO_0045725 (EC: IMP, PMID: 16814735); GO_0046326 (EC: IMP, PMID: 16814735); GO_0060644 (EC: TAS); GO_0061024 (EC: TAS); GO_0065002 (EC: ISS); GO_0071156 (EC: TAS); GO_0072659 (EC: IEA); GO_0090314 (EC: ISS); GO_2000147 (EC: IMP, PMID: 17332325); GO_2001275 (EC: IEA)",,,,,,,,,PMID: 1409633; 1801921; 3037531; 8622988; 8889548; 9374542; 9394803; 9512493; 9528769; 9736715; 10490823; 10491192; 10869418; 10983986; 11139588; 11156964; 11208609; 11278835; 11313479; 11432835; 11445557; 11500317; 11507039; 11546794; 11707444; 11781143; 11903042; 11948187; 11988487; 11994280; 12048203; 12114503; 12149249; 12167664; 12176337; 12176997; 12181350; 12434148; 12477932; 12480711; 12482965; 12517337; 12517798; 12524439; 12545160; 12663464; 12697749; 12733712; 12791994; 12808085; 14500673; 14504284; 14612499; 14637151; 14645242; 14654898; 14699494; 14702039; 14735903; 14973226; 15010337; 15070827; 15102693; 15111130; 15144186; 15146197; 15166380; 15314020; 15489334; 15531580; 15557754; 15616007; 15678105; 15689238; 15890450; 15987444; 16221682; 16365168; 16402276; 16524887; 16540465; 16814735; 16841089; 16982699; 17012749; 17030088; 17157319; 17276404; 17327441; 17332325; 17349711; 17372934; 17482291; 17535800; 17576055; 17577629; 17804734; 17825284; 17895832; 17908691; 17914025; 17962807; 18048359; 18187620; 18281467; 18300076; 18316591; 18353613; 18660489; 18768676; 18826950; 18842333; 18996102; 19064572; 19074768; 19075230; 19079138; 19110052; 19164214; 19197940; 19261608; 19435822; 19453261; 19479051; 19713527; 19771908; 19797172; 19825827; 19843246; 19875456; 19913121; 19933843; 20012528; 20018949; 20019835; 20041213; 20056178; 20056908; 20059950; 20102399; 20109457; 20116920; 20133737; 20167810; 20186503; 20354455; 20398329; 20409325; 20447721; 20514445; 20602615; 20628086; 20661303; 20687898; 20688159; 20691427; 20818790; 20848774; 20856200; 21029719; 21048031; 21050850; 21092549; 21179235; 21182834; 21297943; 21423810; 21432781; 21483469; 21507933; 21518566; 21590431; 21606541; 21618512; 21636708; 21680733; 21697490; 21722267; 21763505; 21765914; 21832049; 21890473; 21906983; 21932427; 21979934; 21979951; 21988832; 22031698; 22107784; 22158034; 22261254; 22480544; 22556379; 22748472; 22778840; 22809628; 22904195; 22939624; 22952844; 23018889; 23092922; 23250987; 23305873; 23321478; 23444369; 23468863; 23567263; 23777806; 24030155; 24056770; 24250222; 24321521,,,,,,,,,,,,,,,OGG:3000000208,,,,,,,v-akt murine thymoma viral oncogene homolog 2,,,,,,,,,,,,,Other designations: PKB beta|RAC-PK-beta|RAC-beta serine/threonine-protein kinase|murine thymoma viral (v-akt) homolog-2|protein kinase Akt-2|protein kinase B beta|rac protein kinase beta,,AKT2,,,,,,,,,,,,,,,,,,,,,,,208,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,AKT2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000000207,AKT1,,Other designations: PKB alpha|RAC-PK-alpha|RAC-alpha serine/threonine-protein kinase|protein kinase B alpha|proto-oncogene c-Akt|rac protein kinase alpha,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CWS6|PRKBA|AKT|PKB-ALPHA|RAC-ALPHA|RAC|PKB,,,,,,,,,,,,14,,,,,,HPRD:01261|Ensembl:ENSG00000142208|Vega:OTTHUMG00000170795|MIM:164730|HGNC:391,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,v-akt murine thymoma viral oncogene homolog 1,,,14q32.32,,,,,,,,,,,,,,,,"GO_0000060 (EC: IMP, PMID: 16280327); GO_0001649 (EC: IEA); GO_0001893 (EC: IEA); GO_0001934 (EC: IDA, PMID: 19057511); GO_0001938 (EC: IMP, PMID: 19850054); GO_0004672 (EC: TAS, PMID: 10570282); GO_0004674 (EC: IDA, PMID: 10102273); GO_0004674 (EC: TAS); GO_0005080 (EC: IEA); GO_0005515 (EC: IPI, PMID: 11154276); GO_0005524 (EC: IC, PMID: 11994271); GO_0005524 (EC: IDA, PMID: 16540465); GO_0005547 (EC: IDA, PMID: 19203586); GO_0005634 (EC: IDA); GO_0005634 (EC: TAS); GO_0005654 (EC: TAS); GO_0005737 (EC: IDA, PMID: 19203586); GO_0005737 (EC: ISS); GO_0005737 (EC: TAS); GO_0005819 (EC: IEA); GO_0005829 (EC: IDA); GO_0005829 (EC: TAS); GO_0005886 (EC: IDA, PMID: 14749367); GO_0005886 (EC: TAS); GO_0005978 (EC: IEA); GO_0005979 (EC: IMP, PMID: 8940145); GO_0006006 (EC: IEA); GO_0006412 (EC: IEA); GO_0006417 (EC: IEA); GO_0006464 (EC: TAS, PMID: 10570282); GO_0006468 (EC: IDA, PMID: 11994271); GO_0006469 (EC: IMP, PMID: 9373175); GO_0006469 (EC: ISS); GO_0006809 (EC: TAS, PMID: 10376602); GO_0006915 (EC: TAS); GO_0006924 (EC: IMP, PMID: 14749367); GO_0006954 (EC: IEA); GO_0007165 (EC: TAS); GO_0007173 (EC: TAS); GO_0007186 (EC: TAS, PMID: 10570282); GO_0007281 (EC: IEA); GO_0007568 (EC: IEA); GO_0007596 (EC: TAS); GO_0008283 (EC: TAS); GO_0008286 (EC: IMP, PMID: 8978681); GO_0008543 (EC: TAS); GO_0008637 (EC: IEA); GO_0009408 (EC: TAS, PMID: 10958679); GO_0010467 (EC: TAS); GO_0010507 (EC: IMP, PMID: 18387192); GO_0010748 (EC: IMP, PMID: 16814735); GO_0010765 (EC: IEA); GO_0010907 (EC: IMP, PMID: 16814735); GO_0010951 (EC: IMP, PMID: 18387192); GO_0010975 (EC: ISS); GO_0015630 (EC: IDA); GO_0015758 (EC: IEA); GO_0016070 (EC: TAS); GO_0016071 (EC: TAS); GO_0016301 (EC: IDA, PMID: 14749367); GO_0016310 (EC: IDA); GO_0016567 (EC: IEA); GO_0018105 (EC: IDA, PMID: 16139227); GO_0019899 (EC: ISS); GO_0030030 (EC: IEA); GO_0030154 (EC: TAS); GO_0030163 (EC: IEA); GO_0030168 (EC: TAS); GO_0030212 (EC: IEA); GO_0030235 (EC: IMP, PMID: 10376603); GO_0030307 (EC: IDA, PMID: 19203586); GO_0030334 (EC: IMP, PMID: 19934221); GO_0030334 (EC: TAS); GO_0031018 (EC: TAS); GO_0031295 (EC: TAS); GO_0031659 (EC: IDA, PMID: 18483258); GO_0031999 (EC: IMP, PMID: 16814735); GO_0032094 (EC: IEA); GO_0032270 (EC: ISS); GO_0032287 (EC: IEA); GO_0032436 (EC: IEA); GO_0032869 (EC: IMP, PMID: 16814735); GO_0032869 (EC: ISS); GO_0033138 (EC: IDA, PMID: 19667065); GO_0034405 (EC: IMP, PMID: 10376603); GO_0035556 (EC: IDA, PMID: 14749367); GO_0038095 (EC: TAS); GO_0042593 (EC: IEA); GO_0042640 (EC: IEA); GO_0042802 (EC: IPI, PMID: 7891724); GO_0043065 (EC: IEA); GO_0043066 (EC: IDA, PMID: 19203586); GO_0043154 (EC: ISS); GO_0043325 (EC: IDA, PMID: 19203586); GO_0043491 (EC: IEA); GO_0043536 (EC: IDA); GO_0044281 (EC: TAS); GO_0045087 (EC: TAS); GO_0045429 (EC: IMP, PMID: 10376603); GO_0045600 (EC: IMP, PMID: 8940145); GO_0045725 (EC: IMP, PMID: 16814735); GO_0045725 (EC: NAS, PMID: 17925406); GO_0045792 (EC: IEA); GO_0045861 (EC: IMP, PMID: 18387192); GO_0045907 (EC: IEA); GO_0045944 (EC: IEA); GO_0046209 (EC: TAS); GO_0046326 (EC: IMP, PMID: 16814735); GO_0046329 (EC: IEA); GO_0046777 (EC: TAS, PMID: 16280327); GO_0046889 (EC: IMP, PMID: 8940145); GO_0048009 (EC: IMP, PMID: 8978681); GO_0048011 (EC: TAS); GO_0048015 (EC: TAS); GO_0050999 (EC: TAS); GO_0051000 (EC: IMP, PMID: 10376603); GO_0051091 (EC: IDA, PMID: 19057511); GO_0051146 (EC: IEA); GO_0060644 (EC: TAS); GO_0060709 (EC: IEA); GO_0060716 (EC: IEA); GO_0061024 (EC: TAS); GO_0070141 (EC: IDA, PMID: 18483258); GO_0071260 (EC: IEA); GO_0071364 (EC: IEA); GO_0071456 (EC: IEA); GO_0071889 (EC: IPI, PMID: 10102273); GO_0090004 (EC: IMP, PMID: 8940145); GO_0090201 (EC: ISS); GO_0097193 (EC: TAS); GO_0097194 (EC: IEA); GO_1900740 (EC: TAS); GO_1901976 (EC: TAS); GO_1902176 (EC: NAS, PMID: 16604263); GO_2001240 (EC: TAS, PMID: 10748004)",,,,,,,,,PMID: 1533586; 1718748; 1851997; 3037531; 3384441; 7774014; 7891724; 8524413; 8940145; 8978681; 9005852; 9019819; 9312003; 9368760; 9373175; 9381178; 9394803; 9395488; 9512493; 9736715; 9768361; 9812896; 9829964; 9973250; 10082674; 10085094; 10102273; 10217147; 10224060; 10226025; 10358014; 10376602; 10376603; 10438924; 10454575; 10485710; 10485711; 10490823; 10490848; 10491192; 10497255; 10527852; 10542266; 10570282; 10576742; 10617634; 10635328; 10698680; 10748004; 10833263; 10866658; 10869359; 10869418; 10872470; 10896934; 10910062; 10926925; 10930578; 10958679; 10983986; 10995457; 11035810; 11042204; 11116148; 11139588; 11154276; 11154281; 11156376; 11156964; 11162552; 11208609; 11274386; 11278835; 11278894; 11313365; 11313479; 11404460; 11410590; 11410591; 11425855; 11438723; 11445557; 11500364; 11504915; 11508278; 11509608; 11535620; 11546794; 11579209; 11583630; 11585925; 11598301; 11689711; 11696579; 11707444; 11707464; 11710897; 11715018; 11723139; 11756412; 11773441; 11777913; 11782427; 11809791; 11825911; 11828257; 11855836; 11877387; 11884598; 11902142; 11903042; 11923280; 11956222; 11960368; 11976320; 11994271; 11994280; 12009899; 12011046; 12042314; 12062056; 12062094; 12070137; 12077256; 12112022; 12124386; 12138087; 12138205; 12145204; 12149249; 12150915; 12167664; 12167717; 12176337; 12176338; 12176997; 12194869; 12218048; 12244133; 12244301; 12244302; 12244303; 12297295; 12376533; 12393747; 12438239; 12446767; 12446787; 12446789; 12458207; 12477932; 12524439; 12527373; 12529294; 12535517; 12586360; 12592338; 12621049; 12637511; 12722480; 12727836; 12734380; 12741986; 12750378; 12757707; 12768030; 12782295; 12783873; 12791994; 12808085; 12808093; 12853467; 12874217; 12888921; 12919677; 12952968; 12972603; 14499622; 14500673; 14505491; 14520710; 14523021; 14534536; 14560023; 14566704; 14568991; 14611643; 14612949; 14623889; 14625285; 14636889; 14645242; 14645548; 14647146; 14657000; 14679206; 14702039; 14713953; 14742298; 14749367; 14749388; 14749719; 14755253; 14761976; 14970221; 14973226; 14985374; 15001646; 15010337; 15016818; 15026145; 15047604; 15047866; 15060171; 15067058; 15102693; 15115729; 15118108; 15136501; 15146197; 15149849; 15156201; 15173318; 15183529; 15187088; 15187138; 15194442; 15203190; 15217935; 15231831; 15242771; 15262962; 15262978; 15263908; 15271644; 15283964; 15284024; 15306850; 15316080; 15326564; 15331441; 15342781; 15342917; 15385469; 15388791; 15389633; 15459205; 15465021; 15467757; 15470047; 15475446; 15489334; 15492215; 15522255; 15525681; 15527798; 15533996; 15539407; 15545269; 15545271; 15545519; 15546863; 15572689; 15574337; 15580267; 15581622; 15607733; 15609321; 15616007; 15665327; 15665818; 15668028; 15678105; 15688030; 15689238; 15705789; 15710591; 15718470; 15722337; 15723049; 15743789; 15778376; 15784622; 15800029; 15802268; 15806160; 15808505; 15809304; 15817639; 15818404; 15831676; 15833736; 15837948; 15840729; 15843522; 15845076; 15845651; 15856005; 15861136; 15879168; 15888491; 15896313; 15896703; 15905178; 15910284; 15911620; 15922745; 15961723; 15982448; 15987444; 15993382; 15994200; 15998799; 16007092; 16007163; 16007172; 16007182; 16009706; 16012720; 16019536; 16026766; 16027121; 16027165; 16027169; 16036916; 16049004; 16049961; 16055703; 16076959; 16091017; 16098514; 16099944; 16107690; 16114056; 16115861; 16123141; 16128748; 16139227; 16141217; 16142341; 16148125; 16160160; 16163388; 16174774; 16177823; 16186112; 16202996; 16210317; 16216590; 16224021; 16243840; 16263580; 16272144; 16274701; 16278380; 16280327; 16282323; 16293694; 16338927; 16354698; 16362038; 16365168; 16373405; 16395129; 16405925; 16407258; 16407271; 16412424; 16417524; 16428439; 16434970; 16453020; 16466644; 16474850; 16478297; 16508008; 16524887; 16532026; 16532036; 16537497; 16540465; 16543232; 16549426; 16551632; 16564100; 16568092; 16571745; 16583435; 16601838; 16603397; 16604263; 16613989; 16616456; 16644866; 16651639; 16670089; 16682946; 16684529; 16723503; 16732486; 16763222; 16774943; 16775835; 16785234; 16790501; 16790529; 16792529; 16797529; 16814735; 16818690; 16820098; 16820947; 16822839; 16836907; 16839745; 16840713; 16841089; 16842970; 16844778; 16849522; 16862180; 16897758; 16912864; 16916907; 16926151; 16932738; 16946008; 16951146; 16962653; 16972255; 16977260; 16981720; 16982329; 16987028; 16987250; 16988010; 16990258; 17006541; 17006756; 17008323; 17012749; 17015676; 17016437; 17024099; 17030608; 17041888; 17043653; 17050554; 17052453; 17060455; 17065200; 17068339; 17081983; 17088265; 17097759; 17098228; 17099727; 17113264; 17128418; 17136479; 17136481; 17141917; 17143278; 17148458; 17151107; 17157319; 17169805; 17173971; 17179152; 17210635; 17214972; 17215852; 17233643; 17235455; 17244606; 17274640; 17276404; 17287851; 17299206; 17300918; 17307335; 17310852; 17317726; 17317825; 17318185; 17318262; 17333095; 17335965; 17342093; 17349711; 17351066; 17360849; 17375124; 17383860; 17386267; 17400190; 17404186; 17406055; 17428466; 17443665; 17458890; 17461449; 17462862; 17468516; 17469127; 17470458; 17471535; 17478078; 17483438; 17493174; 17495954; 17495959; 17501982; 17504381; 17505062; 17507655; 17507800; 17512923; 17513297; 17513702; 17520698; 17521720; 17522055; 17522703; 17533377; 17535800; 17544405; 17544543; 17546049; 17549359; 17551921; 17553806; 17554339; 17565979; 17566113; 17569669; 17577629; 17580302; 17581609; 17584963; 17594810; 17599831; 17599906; 17601486; 17606718; 17609269; 17611497; 17612563; 17615157; 17616681; 17616684; 17616691; 17635910; 17638918; 17666398; 17681738; 17687643; 17696196; 17706139; 17712528; 17716861; 17721885; 17721920; 17725107; 17726016; 17761832; 17804197; 17804734; 17822324; 17823925; 17825267; 17825284; 17826033; 17827393; 17855350; 17868340; 17883592; 17890457; 17891137; 17892507; 17895832; 17898861; 17901375; 17906677; 17909223; 17914025; 17914096; 17915974; 17921701; 17924977; 17925406; 17925408; 17927847; 17928528; 17932490; 17935714; 17950696; 17951252; 17957242; 17959676; 17960583; 17962807; 17977950; 18021174; 18023414; 18029348; 18035048; 18037896; 18041764; 18046412; 18048359; 18048937; 18053070; 18059161; 18063683; 18064631; 18071906; 18072631; 18079201; 18083769; 18087195; 18097023; 18167217; 18172656; 18174256; 18182168; 18182859; 18184439; 18187454; 18187620; 18191226; 18194602; 18197291; 18198266; 18199533; 18199536; 18201823; 18204201; 18204829; 18216097; 18227124; 18231751; 18240972; 18247380; 18249092; 18256540; 18262492; 18264090; 18270579; 18273051; 18292230; 18300076; 18309287; 18316593; 18317451; 18319625; 18323784; 18331557; 18332138; 18332867; 18332868; 18339899; 18351386; 18353776; 18355439; 18355897; 18356162; 18374639; 18387192; 18392055; 18395956; 18395980; 18398749; 18400376; 18404535; 18409144; 18410456; 18411301; 18413665; 18420583; 18425364; 18434090; 18437054; 18439422; 18440314; 18450971; 18451027; 18451140; 18458059; 18458087; 18466879; 18469852; 18479604; 18483258; 18483275; 18487214; 18487454; 18490760; 18495460; 18497887; 18499442; 18504432; 18505677; 18505846; 18509361; 18512729; 18519641; 18519679; 18524825; 18550470; 18552504; 18562279; 18562319; 18566587; 18574502; 18583979; 18593948; 18596081; 18606817; 18611285; 18611860; 18617528; 18622039; 18624398; 18625725; 18635704; 18635812; 18639865; 18640717; 18644989; 18644990; 18650932; 18660489; 18665177; 18668138; 18673414; 18676680; 18676830; 18676874; 18678286; 18682509; 18686341; 18687691; 18689794; 18701703; 18701709; 18711014; 18711316; 18713840; 18714568; 18718903; 18720410; 18723000; 18725974; 18728011; 18728784; 18754328; 18767116; 18769058; 18769147; 18769720; 18771702; 18774962; 18776922; 18782222; 18782353; 18783292; 18790560; 18794113; 18798227; 18798258; 18802038; 18813808; 18813944; 18824170; 18826385; 18826950; 18829502; 18838169; 18838251; 18838536; 18841391; 18844239; 18855532; 18922901; 18924134; 18931307; 18936167; 18937284; 18948104; 18948272; 18949384; 18954143; 18974133; 18976975; 18981248; 18981303; 18996102; 18996844; 19002588; 19010915; 19011679; 19017490; 19017978; 19018001; 19020711; 19020728; 19029952; 19048112; 19050243; 19050262; 19051289; 19054571; 19057511; 19058874; 19059380; 19062713; 19067848; 19068477; 19068483; 19070520; 19073147; 19074768; 19074832; 19074868; 19074885; 19074894; 19078992; 19079342; 19091404; 19095734; 19098000; 19103742; 19107873; 19109741; 19110052; 19114998; 19115062; 19116269; 19116273; 19118218; 19124015; 19132987; 19136058; 19138978; 19142871; 19142997; 19144640; 19147496; 19147772; 19151754; 19158829; 19160403; 19162005; 19164214; 19170196; 19176054; 19176518; 19176689; 19179443; 19188658; 19193378; 19201817; 19203586; 19219602; 19219857; 19224164; 19229860; 19236051; 19239323; 19240722; 19240976; 19250936; 19250983; 19261608; 19261616; 19262695; 19267882; 19270310; 19270694; 19270695; 19276265; 19278624; 19286607; 19303863; 19318457; 19323811; 19324870; 19328625; 19339247; 19353338; 19356729; 19357198; 19367581; 19376889; 19377290; 19389506; 19405949; 19406989; 19407222; 19409087; 19415690; 19417030; 19418217; 19420344; 19428048; 19429661; 19435822; 19437103; 19447872; 19453261; 19453843; 19457567; 19458356; 19461960; 19473116; 19473971; 19479051; 19479902; 19481529; 19482076; 19483721; 19484147; 19487299; 19488783; 19489223; 19491896; 19492080; 19503105; 19520917; 19526459; 19533041; 19538940; 19541408; 19549627; 19553815; 19556867; 19560862; 19564927; 19567200; 19574087; 19584164; 19588500; 19589780; 19590514; 19592491; 19595713; 19596916; 19597469; 19609946; 19621391; 19622295; 19622752; 19625176; 19628576; 19633364; 19635908; 19636556; 19638627; 19639178; 19639199; 19641183; 19644051; 19646290; 19649722; 19655166; 19655410; 19655414; 19657064; 19662361; 19667065; 19676105; 19679016; 19681907; 19684620; 19692168; 19700402; 19713228; 19713527; 19721393; 19723094; 19723095; 19726550; 19726736; 19726747; 19727814; 19729990; 19736361; 19738422; 19744127; 19745829; 19747927; 19748889; 19754670; 19757167; 19764563; 19765303; 19767770; 19775474; 19776120; 19781633; 19787271; 19797085; 19799812; 19801633; 19801684; 19802009; 19802016; 19805522; 19815051; 19815552; 19815839; 19816934; 19820359; 19825827; 19833727; 19835871; 19836430; 19850036; 19850054; 19853286; 19855431; 19864499; 19875456; 19875696; 19878271; 19881543; 19882362; 19885574; 19885581; 19887561; 19887570; 19889638; 19889640; 19891769; 19897009; 19898424; 19903888; 19913121; 19917135; 19920252; 19922411; 19924282; 19925030; 19926313; 19931325; 19933775; 19934221; 19935854; 19940129; 19948975; 19953087; 19954644; 19956840; 19956847; 19965664; 19966853; 19995607; 19997873; 20003467; 20005908; 20008098; 20008289; 20012528; 20018888; 20018937; 20018949; 20019835; 20019839; 20022634; 20026048; 20026773; 20028853; 20030877; 20033742; 20041213; 20041238; 20042122; 20046382; 20048146; 20053726; 20054340; 20055757; 20056178; 20059950; 20067111; 20072648; 20081374; 20086095; 20086174; 20088406; 20093341; 20098747; 20100200; 20101210; 20102399; 20103602; 20106550; 20107185; 20109457; 20110348; 20126987; 20127017; 20127709; 20132317; 20133737; 20141546; 20154081; 20157733; 20159991; 20164223; 20164304; 20173664; 20182617; 20186153; 20186503; 20187936; 20190811; 20198299; 20201953; 20214684; 20216540; 20228224; 20231902; 20232298; 20237237; 20301425; 20306497; 20307589; 20308328; 20332111; 20333297; 20333651; 20336670; 20339081; 20339252; 20346214; 20346360; 20347887; 20354121; 20360004; 20361045; 20361981; 20362557; 20368287; 20371257; 20372801; 20372806; 20383191; 20388781; 20389136; 20395438; 20398329; 20400976; 20400979; 20407443; 20410674; 20412774; 20414143; 20416077; 20417028; 20419107; 20421846; 20432460; 20432929; 20436671; 20447721; 20453000; 20457218; 20458733; 20459571; 20471940; 20478633; 20484047; 20488790; 20490331; 20492754; 20493625; 20506505; 20506537; 20509930; 20512574; 20512787; 20513428; 20514448; 20514451; 20516073; 20520724; 20523723; 20525693; 20526288; 20530239; 20530298; 20530554; 20530982; 20534535; 20536315; 20541701; 20555032; 20557351; 20560677; 20562913; 20566894; 20574456; 20578837; 20585556; 20585984; 20586915; 20592362; 20595063; 20600027; 20605778; 20607350; 20620179; 20622004; 20622047; 20623644; 20628086; 20643654; 20648653; 20651405; 20657188; 20661303; 20671123; 20672329; 20679348; 20682768; 20687898; 20688159; 20693286; 20697673; 20703095; 20723296; 20725137; 20726858; 20731018; 20734064; 20805333; 20808831; 20818434; 20818790; 20826237; 20829512; 20837477; 20838929; 20844931; 20854947; 20856200; 20860430; 20863633; 20864106; 20872231; 20878056; 20886116; 20886414; 20921115; 20940316; 20947498; 20956948; 20957008; 20957047; 20959404; 20975834; 20978158; 20980511; 20980808; 21029719; 21035469; 21035497; 21040950; 21041608; 21042744; 21042767; 21044950; 21045156; 21045158; 21045808; 21048031; 21049487; 21059203; 21061022; 21062993; 21075859; 21078168; 21082206; 21087080; 21092549; 21093899; 21106245; 21110830; 21113787; 21118808; 21127195; 21127264; 21129241; 21131356; 21135252; 21139048; 21151116; 21151390; 21159778; 21168265; 21169559; 21177249; 21177334; 21185392; 21191179; 21209368; 21212269; 21212275; 21228233; 21238503; 21242970; 21253589; 21254169; 21255011; 21263216; 21266843; 21276823; 21284870; 21288887; 21289304; 21289308; 21290341; 21294052; 21295396; 21297666; 21308747; 21309701; 21320536; 21321111; 21321378; 21325624; 21333377; 21334199; 21339740; 21343617; 21355052; 21358672; 21365510; 21370247; 21380726; 21385902; 21390332; 21391741; 21394210; 21396404; 21405945; 21406404; 21407808; 21412012; 21423810; 21430300; 21432781; 21436142; 21437936; 21440011; 21440577; 21442372; 21444773; 21445305; 21454528; 21454539; 21454620; 21460223; 21464307; 21464312; 21464729; 21468601; 21474332; 21474915; 21478156; 21480388; 21482133; 21483469; 21487020; 21490677; 21499215; 21501368; 21507933; 21513698; 21521253; 21532145; 21536374; 21539865; 21557211; 21566129; 21570709; 21590431; 21592330; 21592956; 21606541; 21609291; 21621563; 21623170; 21624038; 21632881; 21633372; 21646299; 21646525; 21658387; 21659549; 21660042; 21667138; 21669872; 21670080; 21673026; 21673516; 21680733; 21685937; 21696297; 21697490; 21701506; 21705328; 21707707; 21708191; 21709150; 21713404; 21715568; 21718677; 21720709; 21722267; 21732363; 21741444; 21742779; 21742938; 21750652; 21757645; 21757743; 21763505; 21765914; 21767636; 21775008; 21775054; 21775285; 21775495; 21775978; 21777568; 21777670; 21778238; 21788944; 21793738; 21794903; 21799016; 21819378; 21824802; 21828040; 21828127; 21832049; 21837363; 21837670; 21840940; 21842521; 21849454; 21855541; 21856935; 21859846; 21862580; 21868077; 21869603; 21872252; 21873248; 21873430; 21874010; 21878648; 21878679; 21880746; 21881167; 21884932; 21887250; 21890473; 21890492; 21900206; 21901101; 21906983; 21908613; 21908615; 21908616; 21910869; 21913799; 21914810; 21915031; 21915327; 21925532; 21930127; 21939655; 21945955; 21949775; 21954225; 21959954; 21975932; 21975935; 21978279; 21980128; 21987722; 21991300; 21994334; 22005766; 22014666; 22021428; 22029423; 22031597; 22031698; 22033727; 22045027; 22051934; 22070874; 22072736; 22084251; 22093097; 22094587; 22095135; 22105580; 22107784; 22116552; 22116667; 22117074; 22131882; 22140653; 22146375; 22146979; 22150081; 22169232; 22171994; 22173970; 22174934; 22183914; 22184110; 22185283; 22189542; 22192357; 22198382; 22199277; 22199300; 22199303; 22208359; 22213015; 22213475; 22231444; 22234835; 22235305; 22249415; 22251423; 22268450; 22270359; 22271581; 22277669; 22280833; 22285928; 22297255; 22301279; 22309289; 22314363; 22315412; 22328503; 22328975; 22334668; 22335196; 22336203; 22337773; 22339676; 22340730; 22343475; 22345097; 22351695; 22354785; 22360859; 22363436; 22363598; 22366458; 22375056; 22384056; 22384099; 22384145; 22389405; 22391209; 22391563; 22393424; 22394200; 22394497; 22394561; 22410793; 22417847; 22426999; 22430898; 22445357; 22451658; 22455883; 22457005; 22463491; 22465665; 22471665; 22480519; 22480544; 22487681; 22488590; 22491319; 22494103; 22496232; 22505016; 22508044; 22525159; 22532149; 22535956; 22539090; 22547695; 22552281; 22552284; 22554284; 22562131; 22563025; 22563076; 22567126; 22569334; 22569400; 22571340; 22575839; 22577119; 22588279; 22590527; 22591684; 22607554; 22614013; 22619175; 22626691; 22647853; 22648906; 22674407; 22675553; 22682934; 22685591; 22687243; 22705004; 22706160; 22727668; 22728329; 22740686; 22748472; 22752602; 22760211; 22768179; 22805337; 22808143; 22809628; 22815832; 22831980; 22833150; 22837212; 22840496; 22842582; 22875023; 22876373; 22895070; 22895078; 22896661; 22897592; 22901187; 22904195; 22905202; 22905203; 22907434; 22910909; 22923366; 22928011; 22929028; 22936801; 22938585; 22945510; 22952709; 22954457; 22957045; 22961111; 22964641; 22967500; 22975685; 22990118; 22995914; 23021375; 23035900; 23039130; 23041284; 23043959; 23046567; 23047954; 23060458; 23069661; 23082158; 23092880; 23092893; 23095753; 23097134; 23107319; 23112296; 23125486; 23127761; 23133535; 23134728; 23135917; 23135998; 23138182; 23147115; 23167739; 23169238; 23176396; 23182717; 23185040; 23188060; 23192081; 23192871; 23195959; 23200933; 23205493; 23208492; 23225414; 23227138; 23235274; 23236232; 23237847; 23246288; 23249714; 23255608; 23261389; 23271397; 23272133; 23280503; 23297824; 23300340; 23300741; 23303682; 23314850; 23315288; 23318419; 23319332; 23321169; 23325864; 23334667; 23338526; 23340251; 23340270; 23348505; 23352210; 23354687; 23354912; 23379509; 23380710; 23383273; 23384770; 23386617; 23389849; 23409016; 23409128; 23417403; 23418602; 23419514; 23421998; 23424671; 23429328; 23430973; 23434580; 23437141; 23440515; 23442539; 23444215; 23457304; 23457334; 23459592; 23463506; 23463670; 23474367; 23499907; 23504323; 23507869; 23511556; 23512990; 23521913; 23525579; 23546174; 23546450; 23546602; 23547889; 23553960; 23558942; 23561972; 23563091; 23563706; 23567263; 23574721; 23580656; 23583197; 23603894; 23613227; 23615537; 23615713; 23624506; 23625205; 23626817; 23629924; 23639623; 23640046; 23667466; 23677479; 23684008; 23685151; 23686362; 23708780; 23710442; 23710710; 23711387; 23724143; 23725225; 23726842; 23728071; 23740762; 23741320; 23742646; 23743572; 23754751; 23757022; 23765166; 23786162; 23788636; 23791833; 23792459; 23792604; 23796964; 23811754; 23812726; 23824745; 23832540; 23838801; 23840064; 23841076; 23843462; 23852728; 23863161; 23867821; 23869765; 23876532; 23884311; 23884447; 23884910; 23886157; 23896866; 23898095; 23923067; 23934627; 23996929; 24001613; 24005670; 24015256; 24030155; 24081328; 24095799; 24099783; 24113181; 24120917; 24152492; 24154876; 24157255; 24225136; 24297901; 24314632; 24321521; 24458280; 24600969,,,,,,,,,,,,,,,OGG:3000000207,,,,,,,v-akt murine thymoma viral oncogene homolog 1,,,,,,,,,,,,,Other designations: PKB alpha|RAC-PK-alpha|RAC-alpha serine/threonine-protein kinase|protein kinase B alpha|proto-oncogene c-Akt|rac protein kinase alpha,,AKT1,,,,,,,,,,,,,,,,,,,,,,,207,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,AKT1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0001594,phosphatidylethanolamine metabolism imbalance,,Phosphatidylethanolamine metabolism imbalance is a subtype of glycerophospholipid metabolism imbalance : A process that becomes lacking a homeostastasis balance of phosphatidylethanolamine metabolism.,false,,,http://purl.obolibrary.org/obo/TXPO_0001295,,,,,,,,,,,,,,,,,,,,,,Phosphatidylethanolamine metabolism imbalance is a subtype of glycerophospholipid metabolism imbalance : A process that becomes lacking a homeostastasis balance of phosphatidylethanolamine metabolism.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001594,,,,,,,,,,,,,,,,,,,,,,phosphatidylethanolamine metabolism imbalance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001597,drug metabolism phase I [Ground glass appearance],,"Drug metabolism phase I is a subtype of drug metabolic process: A process that of biotransformation reactions involving hydrolysis, reduction, and oxidation or introduces a functional group (such as -OH, -NH2, -SH or -COOH) to increase in the water solubility of a xenobiotic.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/TXPO_0000173,,,,,,,,,,,,,,,,,,,,,,"Drug metabolism phase I is a subtype of drug metabolic process: A process that of biotransformation reactions involving hydrolysis, reduction, and oxidation or introduces a functional group (such as -OH, -NH2, -SH or -COOH) to increase in the water solubility of a xenobiotic.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000373,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001593,,,,,,,,,,,TXPO:0001597,,,,,,,,,,,,,,,,,,,,,,drug metabolism phase I [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001596,hyperfunctioning of phosphatidylethanolamine synthesis gene expression,,Hyperfunctioning of phosphatidylethanolamine synthesis gene expression is a subtype of hyperfunction of glycerophospholipid synthesis gene expression: A process that performs an excesssive phosphatidylethanolamine synthetic gene expression.,false,,,http://purl.obolibrary.org/obo/TXPO_0001264,,,,,,,,,,,,,,,,,,,,,,Hyperfunctioning of phosphatidylethanolamine synthesis gene expression is a subtype of hyperfunction of glycerophospholipid synthesis gene expression: A process that performs an excesssive phosphatidylethanolamine synthetic gene expression.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001596,,,,,,,,,,,,,,,,,,,,,,hyperfunctioning of phosphatidylethanolamine synthesis gene expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001593,drug metabolism phase II [Ground glass appearance],,"Drug metabolism phase II is a subtype of drug metabolic process: A process that of biotransformation reactions involving conjugate enabling efficient excretion.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001591|http://purl.obolibrary.org/obo/TXPO_0001728,,,,,,,,,,,,,,,,,,,,,,"Drug metabolism phase II is a subtype of drug metabolic process: A process that of biotransformation reactions involving conjugate enabling efficient excretion.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001599|http://purl.obolibrary.org/obo/TXPO_0001605,,,,,,,,,,,,,,,,,,TXPO:0001593,,,,,,,,,,,,,,,,,,,,,,drug metabolism phase II [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001590,increasing distance between hepatocytes,,Increasing distance between hepatocytes is a subtype of increasing distance between cells: A process that places  a distance between hepatocytes.|separating between hepatocytes,false,,,http://purl.obolibrary.org/obo/TXPO_0001617,,,,,,,,,,,,,,,,,,,,,,Increasing distance between hepatocytes is a subtype of increasing distance between cells: A process that places  a distance between hepatocytes.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001590,,,,,,,,,,,,,,,,,,,,separating between hepatocytes,,increasing distance between hepatocytes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001599,xenobiotic glucuronidation [Ground glass appearance],,"The modification of a xenobiotic substance by the conjugation of glucuronic acid. The resultant glucuronosides are often much more water-soluble than the xenobiotic precursor, enabling efficient excretion.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/GO_0052697,,,,,,,,,,,,,,,,,,,,,,"The modification of a xenobiotic substance by the conjugation of glucuronic acid. The resultant glucuronosides are often much more water-soluble than the xenobiotic precursor, enabling efficient excretion.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000953,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001599,,,,,,,"In the liver, bilirubin is conjugated with glucuronic acid by the enzyme glucuronyltransferase, making it soluble in water: the conjugated version is the main form of bilirubin present in the ""direct"" bilirubin fraction. Much of it goes into the bile and thus out into the small intestine.|UGT1A1 responsible for conjugating bilirubin is inducible by CAR activators such as phenobarbital and scoparone.",,,,,,,,,,,,,,,xenobiotic glucuronidation [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001592,increasing phosphatidylethanolamine material,,Increasing phosphatidylethanolamine material is a subtype of increasing glycerophospholipid material: A process that changes the amount of phosphatidylethanolamine material to be larger.,false,,,http://purl.obolibrary.org/obo/TXPO_0001317,,,,,,,,,,,,,,,,,,,,,,Increasing phosphatidylethanolamine material is a subtype of increasing glycerophospholipid material: A process that changes the amount of phosphatidylethanolamine material to be larger.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001592,,,,,,,,,,,,,,,,,,,,,,increasing phosphatidylethanolamine material,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001595,negative regulation of apoptotic process [Phospholipidosis-sphingomyelin disorder],,"Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptotic process.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (sphingomyelin disorder) .",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/GO_0043066,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptotic process.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (sphingomyelin disorder) .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001569,,,,,,,,,,,,,,,,,,TXPO:0001595,,,,,,,,,,,,,,,,,,,,,,negative regulation of apoptotic process [Phospholipidosis-sphingomyelin disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001598,negative regulation of phosphatidylethanolamine degradation,,"Negative regulation of phosphatidylethanolamine degradation is a subtype of Negative regulation of glycerophospholipid degradation: A process that stops, prevents, or reduces the frequency, rate or extent of phosphatidylethanolamine degradation.",false,,,http://purl.obolibrary.org/obo/TXPO_0001304,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of phosphatidylethanolamine degradation is a subtype of Negative regulation of glycerophospholipid degradation: A process that stops, prevents, or reduces the frequency, rate or extent of phosphatidylethanolamine degradation.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001598,,,,,,,,,,,,,,,,,,,,,,negative regulation of phosphatidylethanolamine degradation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001591,drug metabolism phase II,,Drug metabolism phase II is a subtype of drug metabolic process: A process that of biotransformation reactions involving conjugate enabling efficient excretion.,false,,,http://purl.obolibrary.org/obo/GO_0017144,,,,,,,,,,,,,,,,,,,,http://purl.bioontology.org/ontology/MESH/D050217,,Drug metabolism phase II is a subtype of drug metabolic process: A process that of biotransformation reactions involving conjugate enabling efficient excretion.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001591,,,,,,,,,,,,,,,,,,,,,,drug metabolism phase II,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_35337,central nervous system stimulant,CNS stimulant|analeptic agent|analeptics|central stimulant|analeptic|analeptic drug|central nervous system stimulant,Any drug that enhances the activity of the central nervous system.,false,,,http://purl.obolibrary.org/obo/CHEBI_35470,,,,,,,,,,,,,,,,,,,,,,Any drug that enhances the activity of the central nervous system.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,central nervous system stimulant,,CNS stimulant|analeptic agent|analeptics|central stimulant|analeptic|analeptic drug,,,,,,,,,,,,,,,,,,,,,CHEBI:35337,,,,central nervous system stimulant,,CHEBI:35337,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0001666,response to hypoxia,,"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating lowered oxygen tension. Hypoxia, defined as a decline in O2 levels below normoxic levels of 20.8 - 20.95%, results in metabolic adaptation at both the cellular and organismal level.",false,,,http://purl.obolibrary.org/obo/GO_0006950,,,,,,,,,,,,,,,,,,,,,,"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating lowered oxygen tension. Hypoxia, defined as a decline in O2 levels below normoxic levels of 20.8 - 20.95%, results in metabolic adaptation at both the cellular and organismal level.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0001666,,,,,,,,,,,,,,,,,,,,,,response to hypoxia,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100570,FGF-20,,,false,,,http://purl.obolibrary.org/obo/IMR_0000049,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100570,,,,,,,,,,,,,,,,,,,,,,FGF-20,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001340,hypofunction of retinol storage,,Hypofunction of retinol storage is a subtype of hypofunctioning: A process that performs a decreased or insufficient retinol storage.,false,,,http://purl.obolibrary.org/obo/TXPO_0000436,,,,,,,,,,,,,,,,,,,,,,Hypofunction of retinol storage is a subtype of hypofunctioning: A process that performs a decreased or insufficient retinol storage.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001340,,,,,,,,,,,,,,,,,,,,,,hypofunction of retinol storage,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001344,bile secretion malfunction,,Bile secretion malfunction is a subtype of organ malfunction: A process that does not perform bile secretion function correctly.,false,,,http://purl.obolibrary.org/obo/TXPO_0002073,,,,,,,,,,,,,,,,,,,,,,Bile secretion malfunction is a subtype of organ malfunction: A process that does not perform bile secretion function correctly.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001345|http://purl.obolibrary.org/obo/TXPO_0001347|http://purl.obolibrary.org/obo/TXPO_0001346,,,,,,,,,,,,,,,,,,TXPO:0001344,,,,,,,,,,,,,,,,,,,,,,bile secretion malfunction,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001341,fatty acid transporter role,,A role played by the molecule which transfers fatty acids.,false,,,http://purl.obolibrary.org/obo/TXPO_0003699,,,,,,,,,,,,,,,,,,,,,,A role played by the molecule which transfers fatty acids.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001341,,,,,,,,,,,,,,,,,,,,,,fatty acid transporter role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001345,cholestasis (primitive process),,Cholestasis (primitive process) is a subtype of stagnating: A process that changes the bile flow to be slower due to obstruction.,false,,,http://purl.obolibrary.org/obo/TXPO_0001581,,,,,,,,,,,,,,,,,,,,,,Cholestasis (primitive process) is a subtype of stagnating: A process that changes the bile flow to be slower due to obstruction.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001347|http://purl.obolibrary.org/obo/TXPO_0001346|http://purl.obolibrary.org/obo/TXPO_0001348,,,,,,,,,,,TXPO:0001345,,,,,,,,,,,,,,,,,,,,,,cholestasis (primitive process),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001343,bile acid biosynthetic malfunction,,Bile acid biosynthetic malfunction is a subtype of organ malfunction: A process that does not perform a bile acid biosynthetic function correctly.,false,,,http://purl.obolibrary.org/obo/TXPO_0002073,,,,,,,,,,,,,,,,,,,,,,Bile acid biosynthetic malfunction is a subtype of organ malfunction: A process that does not perform a bile acid biosynthetic function correctly.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001343,,,,,,,,,,,,,,,,,,,,,,bile acid biosynthetic malfunction,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001347,increasing γ-glutamyltransferase concentration in blood,,Increasing γ-glutamyltransferase concentration in blood is a subtype of increasing concentration: A process that changes the γ-glutamyltransferase (GGT) concentration  to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000352,,,,,,,,,,,,,,,,,,,,,,Increasing γ-glutamyltransferase concentration in blood is a subtype of increasing concentration: A process that changes the γ-glutamyltransferase (GGT) concentration  to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001347,,,,,,,,,,,,,,,,,,,,,,increasing γ-glutamyltransferase concentration in blood,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001342,hypofunction of liver's excretion,,Hypofunction of liver's excretion is a subtype of hypofunction of removing: A process that performs a decreased or insufficient liver's excretion.,false,,,http://purl.obolibrary.org/obo/TXPO_0002355,,,,,,,,,,,,,,,,,,,,,,Hypofunction of liver's excretion is a subtype of hypofunction of removing: A process that performs a decreased or insufficient liver's excretion.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001342,,,,,,,,,,,,,,,,,,,,,,hypofunction of liver's excretion,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001346,inreasing blood ALP concentration,,Inreasing blood ALP concentration is a subtype of increasing concentration: A process that changes the bilirubin concentration in  the blood to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000352,,,,,,,,,,,,,,,,,,,,http://purl.bioontology.org/ontology/OMIM/MTHU010336|http://purl.bioontology.org/ontology/MEDDRA/10001771,,Inreasing blood ALP concentration is a subtype of increasing concentration: A process that changes the bilirubin concentration in  the blood to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001346,,,,,,,,,,,,,,,,,,,,,,inreasing blood ALP concentration,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001348,hypofunction of bilirubin excretion,,Hypofunction of bilirubin excretion is a subtype of hypofunction of liver's excretion: A process that performs a decreased or insufficient bilirubin excretion.,false,,,http://purl.obolibrary.org/obo/TXPO_0001342,,,,,,,,,,,,,,,,,,,,,,Hypofunction of bilirubin excretion is a subtype of hypofunction of liver's excretion: A process that performs a decreased or insufficient bilirubin excretion.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001348,,,,,,,,,,,,,,,,,,,,,,hypofunction of bilirubin excretion,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001349,increasing bilirubin concentration in blood,,Increasing bilirubin concentration in blood is a subtype of increasing concentration: A process that changes the bilirubin concentration in  the blood to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000352,,,,,,,,,,,,,,,,,,,,,,Increasing bilirubin concentration in blood is a subtype of increasing concentration: A process that changes the bilirubin concentration in  the blood to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001349,,,,,,,,,,,,,,,,,,,,,,increasing bilirubin concentration in blood,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000060,TNFR1,"tumor necrosis factor receptor, type I",,false,,,http://purl.obolibrary.org/obo/IMR_0100674,,,,,,,,,,,,,,,,,,,,GO:0005032,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"tumor necrosis factor receptor, type I",,,,,IMR:0000060,,,,,,,,,,,,,,,,,,,,,,TNFR1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100352,Fyn,SYN|SLK|P59-FYN,,false,,,http://purl.obolibrary.org/obo/IMR_0000211,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,SYN|SLK|P59-FYN,,,,,IMR:0100352,,,,,,,,,,,,,,,,,,,,,,Fyn,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000863,14-3-3 sigma,,,false,,,http://purl.obolibrary.org/obo/IMR_0000456,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000863,,,,,,,,,,,,,,,,,,,,,,14-3-3 sigma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000056910,STARD7,,"Other designations: START domain containing 7|START domain-containing protein 7|gestational trophoblastic tumor protein 1|stAR-related lipid transfer protein 7, mitochondrial",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,GTT1,,,,,,,,,,,,2,,,,,,Ensembl:ENSG00000084090|HGNC:18063|Vega:OTTHUMG00000130457|HPRD:18118,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,StAR-related lipid transfer (START) domain containing 7,,,2q11.2,,,,,,,,,,,,,,,,GO_0005739 (EC: IEA); GO_0008289 (EC: IEA),,,,,,,,,PMID: 12477932; 14702039; 15013637; 15146197; 15489334; 17672918; 19679347; 20042613; 21622533; 21906983; 22063720; 22952907; 23247143; 23824909; 24250222,,,,,,,,,,,,,,,OGG:3000056910,,,,,,,StAR-related lipid transfer (START) domain containing 7,,,,,,,,,,,,,"Other designations: START domain containing 7|START domain-containing protein 7|gestational trophoblastic tumor protein 1|stAR-related lipid transfer protein 7, mitochondrial",,STARD7,,,,,,,,,,,,,,,,,,,,,,,56910,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,STARD7,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_9352,sulindac,cis-5-Fluoro-2-methyl-1-((4-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid|sulindaco|Sulindacum|cis-5-Fluoro-2-methyl-1-((p-methylsulfinyl)benzylidene)indene-3-acetic acid|sulindac|(Z)-5-Fluoro-2-methyl-1-((p-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid|Clinoril|Sulindac|{(1Z)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetic acid,"A monocarboxylic acid that is 1-benzylidene-1H-indene which is substituted at positions 2, 3, and 5 by methyl, carboxymethyl, and fluorine respectively, and in which the phenyl group of the benzylidene moiety is substituted at the para position by a methylsulfinyl group. It is a prodrug for the corresponding sulfide, a non-steroidal anti-inflammatory drug, used particularly in the treatment of acute and chronic inflammatory conditions.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:23804703|PMID:12406542|Drug_Central:2534|Wikipedia:Sulindac|PMID:11927004|PMID:11569947|Reaxys:2951842|PMID:15020200|DrugBank:DB00605|PMID:23689354|PMID:15123337|ATC:M01AB02|PMID:19884509|Beilstein:2951842|CAS:38194-50-2,,"A monocarboxylic acid that is 1-benzylidene-1H-indene which is substituted at positions 2, 3, and 5 by methyl, carboxymethyl, and fluorine respectively, and in which the phenyl group of the benzylidene moiety is substituted at the para position by a methylsulfinyl group. It is a prodrug for the corresponding sulfide, a non-steroidal anti-inflammatory drug, used particularly in the treatment of acute and chronic inflammatory conditions.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35610|http://purl.obolibrary.org/obo/CHEBI_35493|http://purl.obolibrary.org/obo/CHEBI_35544|http://purl.obolibrary.org/obo/CHEBI_66993|http://purl.obolibrary.org/obo/CHEBI_68495|http://purl.obolibrary.org/obo/CHEBI_35480|http://purl.obolibrary.org/obo/CHEBI_35475|http://purl.obolibrary.org/obo/CHEBI_50266|http://purl.obolibrary.org/obo/CHEBI_35481,,,,,Sulindac|{(1Z)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetic acid,,cis-5-Fluoro-2-methyl-1-((4-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid|sulindaco|Sulindacum|cis-5-Fluoro-2-methyl-1-((p-methylsulfinyl)benzylidene)indene-3-acetic acid|sulindac|(Z)-5-Fluoro-2-methyl-1-((p-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid|Clinoril,,,,,,,,,,,,,,,,,,,,,CHEBI:9352,,,,sulindac,,CHEBI:9352,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CC1=C(CC(O)=O)c2cc(F)ccc2C\1=C/c1ccc(cc1)S(C)=O,,,,,
http://purl.obolibrary.org/obo/CHEBI_37554,fatty acyl-CoA,,An acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of any fatty acid.,false,,,http://purl.obolibrary.org/obo/CHEBI_61697,,,,,,,,,,,,,,,,,,,,PMID:11524729|PMID:20442897|PMID:2079609,,An acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of any fatty acid.,,,,,,,,,,,,C22H35N7O17P3SR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:37554,,,,,,,,,,,,,,,,,,,,,,fatty acyl-CoA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CC(C)(COP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1OP(O)(O)=O)n1cnc2c(N)ncnc12)[C@@H](O)C(=O)NCCC(=O)NCCSC([*])=O,,,,,
http://purl.obolibrary.org/obo/IMR_0011158,eIF4B,eIF-4B|eukaryotic translation initiation factor 4B,,false,,,http://purl.obolibrary.org/obo/IMR_0010016,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,eIF-4B|eukaryotic translation initiation factor 4B,,,,,IMR:0011158,,,,,,,,,,,,,,,,,,,,,,eIF4B,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100033,steroid hormone,,,false,,,http://purl.obolibrary.org/obo/IMR_0000966,,,,,,,,,,,,,,,,,,,,CHEBI:26764,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100033,,,,,,,,,,,,,,,,,,,,,,steroid hormone,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000027102,EIF2AK1,,Other designations: heme regulated initiation factor 2 alpha kinase|heme sensitive initiation factor 2a kinase|heme-controlled repressor|heme-regulated eukaryotic initiation factor eIF-2-alpha kinase|heme-regulated inhibitor|heme-regulated initiation factor 2-alpha kinase|heme-regulated repressor|hemin-sensitive initiation factor 2-alpha kinase,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,HRI|HCR,,,,,,,,,,,,7,,,,,,Ensembl:ENSG00000086232|HGNC:24921|MIM:613635|HPRD:10684|Vega:OTTHUMG00000090689,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,eukaryotic translation initiation factor 2-alpha kinase 1,,,7p22,,,,,,,,,,,,,,,,"GO_0004694 (EC: IDA, PMID:11036079); GO_0005524 (EC: IEA); GO_0005737 (EC: IEA); GO_0006950 (EC: IEP, PMID:11036079); GO_0008285 (EC: IEA); GO_0009605 (EC: IEP, PMID:11036079); GO_0010999 (EC: IEA); GO_0020037 (EC: ISS); GO_0042803 (EC: ISS); GO_0045993 (EC: NAS, PMID:11036079); GO_0046501 (EC: IEA); GO_0046777 (EC: ISS); GO_0046986 (EC: ISS)",,,,,,,,,PMID:1677563; 7709427; 9819435; 10542257; 10718198; 10931946; 11036079; 11076863; 11101152; 11230166; 11256614; 12391722; 12477932; 12690205; 12767237; 12853948; 14702039; 15489334; 15489336; 16381901; 17081983; 19133234; 19851296; 20071449; 20198315; 21139048; 21906983; 21963094; 22939624; 22990118; 23357686; 23392680; 23874749; 24250222,,,,,,,,,,,,,,,OGG:3000027102,,,,,,,eukaryotic translation initiation factor 2-alpha kinase 1,,,,,,,,,,,,,Other designations: heme regulated initiation factor 2 alpha kinase|heme sensitive initiation factor 2a kinase|heme-controlled repressor|heme-regulated eukaryotic initiation factor eIF-2-alpha kinase|heme-regulated inhibitor|heme-regulated initiation factor 2-alpha kinase|heme-regulated repressor|hemin-sensitive initiation factor 2-alpha kinase,,EIF2AK1,,,,,,,,,,,,,,,,,,,,,,,27102,PRO1362,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF2AK1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/GO_0001676,long-chain fatty acid metabolic process,long-chain fatty acid metabolism,"The chemical reactions and pathways involving long-chain fatty acids, A long-chain fatty acid is a fatty acid with a chain length between C13 and C22.",false,,,http://purl.obolibrary.org/obo/GO_0006631,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways involving long-chain fatty acids, A long-chain fatty acid is a fatty acid with a chain length between C13 and C22.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,long-chain fatty acid metabolism,,,,,GO:0001676,,,,,,,,,,,,,,,,,,,,,,long-chain fatty acid metabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100431,RasGAP,p120GAP|Ras p21 protein activator|GTPase-activating protein|GAP,,false,,,http://purl.obolibrary.org/obo/IMR_0000443,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p120GAP|Ras p21 protein activator|GTPase-activating protein|GAP,,,,,IMR:0100431,,,,,,,,,,,,,,,,,,,,,,RasGAP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_48549,tolrestat,tolrestatum|N-((6-methoxy-5-(trifluoromethyl)-1-naphthalenyl)thioxomethyl)-N-methylglycine|N-{[6-methoxy-5-(trifluoromethyl)-1-naphthyl]carbonothioyl}-N-methylglycine|Alredase|tolrestat|N-{[6-methoxy-5-(trifluoromethyl)naphthalen-1-yl]carbonothioyl}-N-methylglycine|Tolrestat|TOLRESTAT,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,DrugBank:DB02383|CAS:82964-04-3|Drug_Central:2704|Beilstein:4208277,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_48550,,,,,N-{[6-methoxy-5-(trifluoromethyl)naphthalen-1-yl]carbonothioyl}-N-methylglycine|Tolrestat|TOLRESTAT,,tolrestatum|N-((6-methoxy-5-(trifluoromethyl)-1-naphthalenyl)thioxomethyl)-N-methylglycine|N-{[6-methoxy-5-(trifluoromethyl)-1-naphthyl]carbonothioyl}-N-methylglycine|Alredase|tolrestat,,,,,,,,,,,,,,,,,,,,,CHEBI:48549,,,,tolrestat,,CHEBI:48549,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100110,thymosin,,,false,,,http://purl.obolibrary.org/obo/IMR_0100089,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100110,,,,,,,,,,,,,,,,,,,,,,thymosin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001976,RapGEF,Rap guanine nucleotide exchange factor,,false,,,http://purl.obolibrary.org/obo/IMR_0100440,,,,,,,,,,,,,,,,,,,,GO:0017034,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Rap guanine nucleotide exchange factor,,,,,IMR:0001976,,,,,,,,,,,,,,,,,,,,,,RapGEF,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_77113,IkappaB kinase inhibitor,IKK inhibitor|ATP:[IkappaB protein] phosphotransferase inhibitor|IkappaB kinase inhibitor|EC 2.7.11.10 (IkappaB kinase) inhibitor,An EC 2.7.11.* (protein-serine/threonine kinase) inhibitor that interferes with the action of IkappaB kinase (EC 2.7.11.10).,false,,,http://purl.obolibrary.org/obo/CHEBI_23924,,,,,,,,,,,,,,,,,,,,Wikipedia:IkappaB_kinase,,An EC 2.7.11.* (protein-serine/threonine kinase) inhibitor that interferes with the action of IkappaB kinase (EC 2.7.11.10).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,EC 2.7.11.10 (IkappaB kinase) inhibitor,,IKK inhibitor|ATP:[IkappaB protein] phosphotransferase inhibitor|IkappaB kinase inhibitor,,,CHEBI:77113,,,,,,,,,,,,,,,,,,,,,,IkappaB kinase inhibitor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000411,Maf family,musculoaponeurotic fibrosarcoma,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,IPR:004826,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,musculoaponeurotic fibrosarcoma,,,,,IMR:0000411,,,,,,,,,,,,,,,,,,,,,,Maf family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001589,Rab11B,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001589,,,,,,,,,,,,,,,,,,,,,,Rab11B,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_64964,EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor,arachidonate 5-lipoxygenase inhibitors|C-5-lipoxygenase inhibitor|LTA synthase inhibitor|arachidonic 5-lipoxygenase inhibitors|5-lipoxygenase inhibitors|EC 1.13.11.34 inhibitor|EC 1.13.11.34 inhibitors|LTA synthase inhibitors|arachidonic acid 5-lipoxygenase inhibitor|arachidonate 5-lipoxygenase inhibitor|delta(5)-lipoxygenase inhibitor|5delta-lipoxygenase inhibitors|C-5-lipoxygenase inhibitors|arachidonic acid 5-lipoxygenase inhibitors|delta(5)-lipoxygenase inhibitors|arachidonic 5-lipoxygenase inhibitor|leukotriene-A4 synthase inhibitor|leukotriene-A4 synthase inhibitors|5-LOX inhibitor|EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitors|leukotriene A4 synthase inhibitors|leukotriene A4 synthase inhibitor|5-lipoxygenase inhibitor|5delta-lipoxygenase inhibitor|5-LOX inhibitors|arachidonate 5-lipoxygenase (EC 1.13.11.34) inhibitors|arachidonate 5-lipoxygenase (EC 1.13.11.34) inhibitor,A lipoxygenase inhibitor that interferes with the action of arachidonate 5-lipoxygenase (EC 1.13.11.34).,false,,,http://purl.obolibrary.org/obo/CHEBI_35856|http://purl.obolibrary.org/obo/CHEBI_76837,,,,,,,,,,,,,,,,,,,,,,A lipoxygenase inhibitor that interferes with the action of arachidonate 5-lipoxygenase (EC 1.13.11.34).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,arachidonate 5-lipoxygenase inhibitors|C-5-lipoxygenase inhibitor|LTA synthase inhibitor|arachidonic 5-lipoxygenase inhibitors|5-lipoxygenase inhibitors|EC 1.13.11.34 inhibitor|EC 1.13.11.34 inhibitors|LTA synthase inhibitors|arachidonic acid 5-lipoxygenase inhibitor|arachidonate 5-lipoxygenase inhibitor|delta(5)-lipoxygenase inhibitor|5delta-lipoxygenase inhibitors|C-5-lipoxygenase inhibitors|arachidonic acid 5-lipoxygenase inhibitors|delta(5)-lipoxygenase inhibitors|arachidonic 5-lipoxygenase inhibitor|leukotriene-A4 synthase inhibitor|leukotriene-A4 synthase inhibitors|5-LOX inhibitor|EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitors|leukotriene A4 synthase inhibitors|leukotriene A4 synthase inhibitor|5-lipoxygenase inhibitor|5delta-lipoxygenase inhibitor|5-LOX inhibitors|arachidonate 5-lipoxygenase (EC 1.13.11.34) inhibitors|arachidonate 5-lipoxygenase (EC 1.13.11.34) inhibitor,,,,,,,,,,,,,,,,,,,,,CHEBI:64964,,,,EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor,,CHEBI:64964,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003555,PLA2G1B(mol),,,false,,,http://purl.obolibrary.org/obo/IMR_0000283,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:5319|NCBI-Mouse-GeneID:18778|NCBI-Rat-GeneID:29526|PMID:15528384|PMID:16005851,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000283,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003671,,,,,,,,,,TXPO:0003555,,,,,,,,,,,,,,,,,,,,,,PLA2G1B(mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003551,changing cell homeostasis,,Changing cell homeostasis is a subtype of changing balance: A process that changes the steady state of cell within an organ or an organism.,false,,,http://purl.obolibrary.org/obo/TXPO_0001847,,,,,,,,,,,,,,,,,,,,,,Changing cell homeostasis is a subtype of changing balance: A process that changes the steady state of cell within an organ or an organism.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003551,,,,,,,,,,,,,,,,,,,,,,changing cell homeostasis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003559,PKIB (predicted)(human)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001135|http://purl.obolibrary.org/obo/TXPO_0003838,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:5570|PMID:27325557,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000005570,,,http://purl.obolibrary.org/obo/TXPO_0002272,,,,,,,,,,TXPO:0003559,,,,,,,,,,,,,,,,,,,,,,PKIB (predicted)(human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003556,PLA2G2A(mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0003213|http://purl.obolibrary.org/obo/IMR_0000283,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:18780|NCBI-Human-GeneID:5320|PMID:27060751,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000283,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003671,,,,,,,,,,TXPO:0003556,,,,,,,,,,,,,,,,,,,,,,PLA2G2A(mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003554,sequestering of calcium ion [ER stress],,"The process of binding or confining calcium ions such that they are separated from other components of a biological system.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/GO_0051208,,,,,,,,,,,,,,,,,,,,,,"The process of binding or confining calcium ions such that they are separated from other components of a biological system.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003554,,,,,,,,,,,,,,,,,,,,,,sequestering of calcium ion [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003558,HMOX1 (predicted)(human)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000196|http://purl.obolibrary.org/obo/TXPO_0001135,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:3162|PMID:27571925|PMID:28497199|PMID:30515391|PMID:30927048|PMID:30606233|Hmox1 (human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000003162,,,,,,,,,,,,,TXPO:0003558,,,,,,,PMID:10330231,,,,,,,,,,,,,,,HMOX1 (predicted)(human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003550,GRP78 - tumor cell enhanced survlival factor (canonical)[ER stress - tumor survival],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002385,,,,,,,,,,,,,,,,,,,,PMID:26481188,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003550,,,,,,,,,,,,,,,,,,,,,,GRP78 - tumor cell enhanced survlival factor (canonical)[ER stress - tumor survival],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003552,maintaining cell homeostasis,,Any process involved in the maintenance of an internal steady state of cell within an organ or an organism.,false,,,http://purl.obolibrary.org/obo/GO_0042592,,,,,,,,,,,,,,,,,,,,,,Any process involved in the maintenance of an internal steady state of cell within an organ or an organism.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003552,,,,,,,,,,,,,,,,,,,,,,maintaining cell homeostasis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003557,PLA2G2A(human)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003556,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:5320|PMID:27060751|PMID:28663239,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000283,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003671,,,,,,,,,,TXPO:0003557,,,,,,,,,,,,,,,,,,,,,,PLA2G2A(human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003553,cell homeostasis imbalance,,Cell homeostasis imbalance is a subtype of homeostasis imbalance: A process that becomes lacking a cell homeostastasis balance.,false,,,http://purl.obolibrary.org/obo/TXPO_0000568,,,,,,,,,,,,,,,,,,,,,,Cell homeostasis imbalance is a subtype of homeostasis imbalance: A process that becomes lacking a cell homeostastasis balance.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003553,,,,,,,,,,,,,,,,,,,,,,cell homeostasis imbalance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_35610,antineoplastic agent,anticancer agent|anticancer agents|antineoplastic|cytostatic|antineoplastic agents,A substance that inhibits or prevents the proliferation of neoplasms.,false,,,http://purl.obolibrary.org/obo/CHEBI_23888,,,,,,,,,,,,,,,,,,,,,,A substance that inhibits or prevents the proliferation of neoplasms.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,anticancer agent|anticancer agents|antineoplastic|cytostatic|antineoplastic agents,,,,,,,,,,,,,,,,,,,,,CHEBI:35610,,,,antineoplastic agent,,CHEBI:35610,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_30956,trichloroacetic acid,,A monocarboxylic acid that is acetic acid in which all three methyl hydrogens are substituted by chlorine.,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:76-03-9,,A monocarboxylic acid that is acetic acid in which all three methyl hydrogens are substituted by chlorine.,,,,,,,,,,,,C2HCl3O2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:30956,,,,,,,,,,,,,,,,,,,,,,trichloroacetic acid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,OC(=O)C(Cl)(Cl)Cl,,,,,
http://purl.obolibrary.org/obo/OGG_3000007458,EIF4H,,Other designations: Williams-Beuren syndrome chromosome region 1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,WSCR1|eIF-4H|WBSCR1,,,,,,,,,,,,7,,,,,,HGNC:12741|HPRD:11940|Vega:OTTHUMG00000023025|MIM:603431|Ensembl:ENSG00000106682,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,eukaryotic translation initiation factor 4H,,,7q11.23,,,,,,,,,,,,,,,,"GO_0000166 (EC: IEA); GO_0003723 (EC: TAS, PMID:8812460); GO_0003743 (EC: IEA); GO_0005515 (EC: IPI, PMID:19203580); GO_0005829 (EC: TAS); GO_0006412 (EC: TAS); GO_0006413 (EC: TAS); GO_0006446 (EC: TAS, PMID:9516461); GO_0008135 (EC: TAS, PMID:9516461); GO_0010467 (EC: TAS); GO_0016032 (EC: IEA); GO_0016281 (EC: TAS, PMID:9516461); GO_0019953 (EC: IEA); GO_0044267 (EC: TAS); GO_0044822 (EC: IDA); GO_0048471 (EC: IEA); GO_0048589 (EC: IEA)",,,,,,,,,PMID:7584026; 7584028; 8812460; 9516461; 10585411; 11003705; 11418588; 12477932; 12588972; 12665801; 12690205; 12853948; 15078951; 15489334; 15592455; 16014927; 16094384; 16189514; 18448541; 18719248; 19203580; 19369421; 19738201; 19847924; 20360068; 20473909; 20549515; 21139048; 21427765; 21906983; 22505724; 22863883; 22939629; 23776612; 24250222,,,,,,,,,,,,,,,OGG:3000007458,,,,,,,eukaryotic translation initiation factor 4H,,,,,,,,,,,,,Other designations: Williams-Beuren syndrome chromosome region 1,,EIF4H,,,,,,,,,,,,,,,,,,,,,,,7458,,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF4H,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_2948,azathioprine,6-(1'-Methyl-4'-nitro-5'-imidazolyl)-mercaptopurine|6-((1-Methyl-4-nitro-1H-imidazol-5-yl)thio)-1H-purine|Imuran (TN)|6-[(1-methyl-4-nitro-1H-imidazol-5-yl)sulfanyl]-7H-purine,"A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:9345422|PMID:16397313|PMID:9273463|PMID:19243907|PMID:25248004|PMID:28166217|PMID:15199672|PMID:8738760|PMID:17970886|PMID:18336531|PMID:20080917|PMID:11064448|Reaxys:1225351|PMID:25641386|CAS:446-86-6|PMID:15476481|PMID:25314066|PMID:18008354|PMID:25440430|PMID:15973722|PMID:17381669|PMID:16764353|PMID:25443086|PMID:25581826|PMID:16344342|PMID:16954801|Drug_Central:269|PMID:15628319|DrugBank:DB00993,,"A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35705|http://purl.obolibrary.org/obo/CHEBI_35610|http://purl.obolibrary.org/obo/CHEBI_59517|http://purl.obolibrary.org/obo/CHEBI_35221|http://purl.obolibrary.org/obo/CHEBI_50903|http://purl.obolibrary.org/obo/CHEBI_50908|http://purl.obolibrary.org/obo/CHEBI_50266,,,,,6-[(1-methyl-4-nitro-1H-imidazol-5-yl)sulfanyl]-7H-purine,,6-(1'-Methyl-4'-nitro-5'-imidazolyl)-mercaptopurine|6-((1-Methyl-4-nitro-1H-imidazol-5-yl)thio)-1H-purine|Imuran (TN),,,,,,,,,,,,,,,,,,,,,CHEBI:2948,,,,azathioprine,,CHEBI:2948,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000019,LIF,leukemia inhibitory factor,,false,,,http://purl.obolibrary.org/obo/IMR_0000010,,,,,,,,,,,,,,,,,,,,OMIM: 159540,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000622,,,,,leukemia inhibitory factor,,,,,IMR:0000019,,,,,,,,,,,,,,,,,,,,,,LIF,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000466,cytokeratin 20,,,false,,,http://purl.obolibrary.org/obo/IMR_0000035,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000466,,,,,,,,,,,,,,,,,,,,,,cytokeratin 20,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000233,positive regulation of mitochondrial membrane permeability [Phospholipidosis],,"Any process that increases the frequency, rate or extent of the passage or uptake of molecules by the mitochondrial membrane.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/GO_0035794|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Any process that increases the frequency, rate or extent of the passage or uptake of molecules by the mitochondrial membrane.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002233,,,,,,,,,,,TXPO:0000233,,,,,,,,,,,,,,,,,,,,,,positive regulation of mitochondrial membrane permeability [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0031966,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000237,gene expression by p53,,Gene expression by p53 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) by XBP1.,false,,,http://purl.obolibrary.org/obo/TXPO_0000375,,,,,,,,,,,,,,,,,,,,,,Gene expression by p53 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) by XBP1.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000237,,,,,,,,,,,,,,,,,,,,,,gene expression by p53,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000234,positive regulation of mitochondrial membrane permeability [Cell death],,"Any process that increases the frequency, rate or extent of the passage or uptake of molecules by the mitochondrial membrane.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0001727|http://purl.obolibrary.org/obo/GO_0035794,,,,,,,,,,,,,,,,,,,,GO:1902110,,"Any process that increases the frequency, rate or extent of the passage or uptake of molecules by the mitochondrial membrane.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003026,,,,,,,,,,,TXPO:0000234,,,,,,,,,,,,,,,,,,,,,,positive regulation of mitochondrial membrane permeability [Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000230,gene expression by AP-1,,Gene expression by AP-1 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) by AP-1.,false,,,http://purl.obolibrary.org/obo/TXPO_0000375,,,,,,,,,,,,,,,,,,,,,,Gene expression by AP-1 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) by AP-1.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000230,,,,,,,,,,,,,,,,,,,,,,gene expression by AP-1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000232,increasing membrane permeabilization,,Increasing membrane permeabilization is a subtype of changing permeability: A process that changes the permeability of the membrane to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0002704,,,,,,,,,,,,,,,,,,,,,,Increasing membrane permeabilization is a subtype of changing permeability: A process that changes the permeability of the membrane to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000895,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000232,,,,,,,,,,,,,,,,,,,,,,increasing membrane permeabilization,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0001577,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000895,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000235,dysregulation of apoptosis,,Dysregulation of apoptosis is a subtype of malfunctioning of controlling: A process that cannot perform a regulation of apoptotic process appropriately or cannot realize it at all.,false,,,http://purl.obolibrary.org/obo/TXPO_0000532,,,,,,,,,,,,,,,,,,,,,,Dysregulation of apoptosis is a subtype of malfunctioning of controlling: A process that cannot perform a regulation of apoptotic process appropriately or cannot realize it at all.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000235,,,,,,,,,,,,,,,,,,,,,,dysregulation of apoptosis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000231,membrane blebbing [Cell death],,"The assembly of a bleb, a cell extension caused by localized decoupling of the cytoskeleton from the plasma membrane and characterized by rapid formation, rounded shape, and scarcity of organelles within the protrusion.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0001727|http://purl.obolibrary.org/obo/GO_0032060,,,,,,,,,,,,,,,,,,,,,,"The assembly of a bleb, a cell extension caused by localized decoupling of the cytoskeleton from the plasma membrane and characterized by rapid formation, rounded shape, and scarcity of organelles within the protrusion.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000231,,,,,,,,,,,,,,,,,,,,,,membrane blebbing [Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000236,tumorigenesis [Cell death],,"A pathologic process that involves the transformation of normal cells to a neoplastic state and resulting in polyclonal or monoclonal neoplastic cell proliferation.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0001727|http://purl.obolibrary.org/obo/NCIT_C18121,,,,,,,,,,,,,,,,,,,,,,"A pathologic process that involves the transformation of normal cells to a neoplastic state and resulting in polyclonal or monoclonal neoplastic cell proliferation.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000236,,,,,,,,,,,,,,,,,,,,,,tumorigenesis [Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000238,changing cytoskeleton,,Changing cytoskeleton is a subtype of changing structure: A process that changes the structure of cytoskeleton.,false,,,http://purl.obolibrary.org/obo/TXPO_0002566,,,,,,,,,,,,,,,,,,,,,,Changing cytoskeleton is a subtype of changing structure: A process that changes the structure of cytoskeleton.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000238,,,,,,,,,,,,,,,,,,,,,,changing cytoskeleton,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000239,changing cytoskeleton [Cell death],,"Changing cytoskeleton is a subtype of changing structure: A process that changes the structure of cytoskeleton.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0000238|http://purl.obolibrary.org/obo/TXPO_0001727,,,,,,,,,,,,,,,,,,,,,,"Changing cytoskeleton is a subtype of changing structure: A process that changes the structure of cytoskeleton.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000241|http://purl.obolibrary.org/obo/TXPO_0000246,,,,,,,,,,,TXPO:0000239,,,,,,,,,,,,,,,,,,,,,,changing cytoskeleton [Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0035733,hepatic stellate cell activation,,"A change in the morphology or behavior of a hepatic stellate cell resulting from exposure to a cytokine, chemokine, hormone, cellular ligand or soluble factor.",false,,,http://purl.obolibrary.org/obo/GO_0001775,,,,,,,,,,,,,,,,,,,,,,"A change in the morphology or behavior of a hepatic stellate cell resulting from exposure to a cytokine, chemokine, hormone, cellular ligand or soluble factor.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000632,,,,,,,,,,,,,,,,,,,,,,,GO:0035733,,,,,,,,,,,,,,,,,,,,,,hepatic stellate cell activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000009470,EIF4E2,,Other designations: eIF-4E type 2|eIF4E-like cap-binding protein|eIF4E-like protein 4E-LP|eukaryotic translation initiation factor 4E homologous protein|eukaryotic translation initiation factor 4E type 2|eukaryotic translation initiation factor 4E-like 3|mRNA cap-binding protein type 3,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,EIF4EL3|IF4e|4EHP|4E-LP,,,,,,,,,,,,2,,,,,,HGNC:3293|Ensembl:ENSG00000135930|MIM:605895|Vega:OTTHUMG00000133256|HPRD:05798,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,eukaryotic translation initiation factor 4E family member 2,,,2q37.1,,,,,,,,,,,,,,,,"GO_0000339 (EC: TAS, PMID:9582349); GO_0001701 (EC: IEA); GO_0003743 (EC: IEA); GO_0005515 (EC: IPI, PMID:16189514); GO_0005829 (EC: TAS); GO_0005845 (EC: IDA, PMID:17368478); GO_0008135 (EC: TAS, PMID:9582349); GO_0017148 (EC: IMP); GO_0019221 (EC: TAS); GO_0031625 (EC: IPI, PMID:14623119); GO_0044822 (EC: IDA)",,,,,,,,,PMID:9582349; 9653160; 11042152; 12477932; 14623119; 14702039; 15094042; 15153109; 15489334; 16189514; 16344560; 17289916; 17353931; 17368478; 17369309; 17979178; 19060904; 19615732; 20379614; 20467438; 20531386; 21079520; 21139048; 21832049; 21890473; 22751931; 23940030; 24250222; 24255178,,,,,,,,,,,,,,,OGG:3000009470,,,,,,,eukaryotic translation initiation factor 4E family member 2,,,,,,,,,,,,,Other designations: eIF-4E type 2|eIF4E-like cap-binding protein|eIF4E-like protein 4E-LP|eukaryotic translation initiation factor 4E homologous protein|eukaryotic translation initiation factor 4E type 2|eukaryotic translation initiation factor 4E-like 3|mRNA cap-binding protein type 3,,EIF4E2,,,,,,,,,,,,,,,,,,,,,,,9470,,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF4E2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000151,TCR family,T-cell receptor,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,T-cell receptor,,,,,IMR:0000151,,,,,,,,,,,,,,,,,,,,,,TCR family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0002694,IGFBP-6,,,false,,,http://purl.obolibrary.org/obo/IMR_0002688,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0002694,,,,,,,,,,,,,,,,,,,,,,IGFBP-6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000000051,ACOX1,,"Other designations: AOX|acyl-CoA oxidase, straight-chain|acyl-Coenzyme A oxidase 1, palmitoyl|palmitoyl-CoA oxidase|peroxisomal acyl-coenzyme A oxidase 1|peroxisomal fatty acyl-CoA oxidase|straight-chain acyl-CoA oxidase",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,PALMCOX|SCOX|ACOX,,,,,,,,,,,,17,,,,,,MIM:609751|HPRD:02030|HGNC:119|Vega:OTTHUMG00000180027|Ensembl:ENSG00000161533,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"acyl-CoA oxidase 1, palmitoyl",,,17q25.1,,,,,,,,,,,,,,,,"GO_0000038 (EC: IMP, PMID:18536048); GO_0003995 (EC: IEA); GO_0003997 (EC: IDA, PMID:8117268); GO_0003997 (EC: IGI, PMID:17458872); GO_0003997 (EC: IMP, PMID:18536048); GO_0003997 (EC: TAS); GO_0005102 (EC: IPI); GO_0005504 (EC: IEA); GO_0005739 (EC: IEA); GO_0005777 (EC: IDA, PMID:17881773); GO_0005778 (EC: IEA); GO_0005782 (EC: TAS); GO_0006091 (EC: IMP, PMID:7876265); GO_0006629 (EC: IDA, PMID:8117268); GO_0006693 (EC: IMP, PMID:7876265); GO_0007283 (EC: IEA); GO_0016401 (EC: IDA, PMID:17603022); GO_0016401 (EC: IEA); GO_0016559 (EC: IGI); GO_0019395 (EC: IGI); GO_0019395 (EC: IMP, PMID:7876265); GO_0030165 (EC: IDA); GO_0033540 (EC: IEA); GO_0033540 (EC: IMP, PMID:18536048); GO_0033540 (EC: TAS); GO_0033559 (EC: TAS); GO_0036109 (EC: TAS); GO_0044255 (EC: TAS); GO_0044281 (EC: TAS); GO_0047485 (EC: IPI, PMID:18281296); GO_0050660 (EC: IEA); GO_0055088 (EC: IDA); GO_0055088 (EC: IGI); GO_0071949 (EC: IDA, PMID:17603022); GO_2000189 (EC: IGI)",,,,,,,,,PMID:1464743; 7668838; 7876265; 8040306; 8117268; 8125298; 8159712; 8507686; 8798738; 10856712; 10960480; 11076863; 11230166; 11815777; 12477932; 14702039; 15489334; 15489336; 16381901; 16396496; 16756494; 17081983; 17458872; 17603022; 17881773; 18281296; 18536048; 18660489; 20178365; 20195242; 21139048; 22002062; 22939629,,,,,,,,,,,,,,,OGG:3000000051,,,,,,,"acyl-CoA oxidase 1, palmitoyl",,,,,,,,,,,,,"Other designations: AOX|acyl-CoA oxidase, straight-chain|acyl-Coenzyme A oxidase 1, palmitoyl|palmitoyl-CoA oxidase|peroxisomal acyl-coenzyme A oxidase 1|peroxisomal fatty acyl-CoA oxidase|straight-chain acyl-CoA oxidase",,ACOX1,,,,,,,,,,,,,,,,,,,,,,,51,,,,,,,,9606,,,,,,,,,,,,,,,,,,,ACOX1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000080235,PIGZ,,"Other designations: GPI mannosyltransferase 4|GPI mannosyltransferase IV|SMP3 mannosyltransferase|dol-P-Man dependent GPI mannosyltransferase|phosphatidylinositol glycan, class Z|phosphatidylinositol-glycan biosynthesis class Z protein",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,GPI-MT-IV|PIG-Z|SMP3,,,,,,,,,,,,3,,,,,,Ensembl:ENSG00000119227|MIM:611671|HPRD:18076|Vega:OTTHUMG00000155522|HGNC:30596,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"phosphatidylinositol glycan anchor biosynthesis, class Z",,,3q29,,,,,,,,,,,,,,,,"GO_0000026 (EC: IMP, PMID: 15208306); GO_0000030 (EC: IGI, PMID: 15208306); GO_0005783 (EC: IDA, PMID: 15208306); GO_0005789 (EC: IEA); GO_0006506 (EC: IEA); GO_0006506 (EC: IGI, PMID: 15208306); GO_0006506 (EC: IMP, PMID: 15208306); GO_0016021 (EC: IEA); GO_0097502 (EC: IGI, PMID: 15208306); GO_0097502 (EC: IMP, PMID: 15208306)",,,,,,,,,PMID: 11356840; 12200473; 12477932; 12655644; 14702039; 15208306; 15489334; 16344560,,,,,,,,,,,,,,,OGG:3000080235,,,,,,,"phosphatidylinositol glycan anchor biosynthesis, class Z",,,,,,,,,,,,,"Other designations: GPI mannosyltransferase 4|GPI mannosyltransferase IV|SMP3 mannosyltransferase|dol-P-Man dependent GPI mannosyltransferase|phosphatidylinositol glycan, class Z|phosphatidylinositol-glycan biosynthesis class Z protein",,PIGZ,,,,,,,,,,,,,,,,,,,,,,,80235,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,PIGZ,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0010482,60S ribosomal protein L31,,,false,,,http://purl.obolibrary.org/obo/IMR_0000897,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0010482,,,,,,,,,,,,,,,,,,,,,,60S ribosomal protein L31,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000003491,CYR61,,"Other designations: CCN family member 1|IBP-10|IGF-binding protein 10|IGFBP-10|cysteine-rich heparin-binding protein 61|cysteine-rich, anigogenic inducer, 61|insulin-like growth factor-binding protein 10|protein CYR61",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,GIG1|CCN1|IGFBP10,,,,,,,,,,,,1,,,,,,Vega:OTTHUMG00000010577|HGNC:2654|HPRD:09089|MIM:602369|Ensembl:ENSG00000142871,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cysteine-rich, angiogenic inducer, 61",,,1p22.3,,,,,,,,,,,,,,,,"GO_0001558 (EC: IEA); GO_0001649 (EC: IEA); GO_0001934 (EC: IDA); GO_0002041 (EC: IEA); GO_0003181 (EC: IEA); GO_0003278 (EC: IEA); GO_0003281 (EC: IEA); GO_0005178 (EC: IEA); GO_0005520 (EC: IEA); GO_0005576 (EC: IEA); GO_0006935 (EC: IEA); GO_0008201 (EC: IEA); GO_0008283 (EC: TAS, PMID:9135077); GO_0009653 (EC: TAS, PMID:9135077); GO_0010518 (EC: IEA); GO_0010811 (EC: IEA); GO_0030198 (EC: IEA); GO_0030335 (EC: IDA); GO_0030513 (EC: IGI); GO_0033690 (EC: IDA); GO_0043065 (EC: IEA); GO_0043066 (EC: IEA); GO_0043280 (EC: IEA); GO_0044319 (EC: IDA); GO_0045669 (EC: IDA); GO_0045860 (EC: IDA); GO_0045944 (EC: IDA); GO_0050840 (EC: IEA); GO_0060413 (EC: IEA); GO_0060591 (EC: IEA); GO_0060710 (EC: IEA); GO_0060716 (EC: IEA); GO_0061036 (EC: IEA); GO_0070372 (EC: IDA); GO_0072593 (EC: IEA); GO_2000304 (EC: IEA)",,,,,,,,,PMID:8125298; 8635876; 9135077; 9446626; 9488038; 9528960; 9536281; 9600969; 10446209; 10821835; 10852911; 11120741; 11287419; 11584015; 11600415; 11751417; 11810026; 11840342; 12036876; 12217894; 12364323; 12374462; 12444554; 12477932; 12736251; 12826661; 12831056; 12899698; 12939282; 14702039; 14988385; 15041728; 15044484; 15044605; 15053922; 15077166; 15389821; 15471875; 15489334; 15526358; 15564459; 15592521; 15782120; 15878827; 15961723; 16243794; 16344560; 16581771; 16675545; 16804865; 16877350; 17056474; 17234971; 17314511; 17361185; 17429007; 17437852; 17579708; 17601910; 17626014; 17673559; 17699553; 17718860; 17765657; 18004727; 18025257; 18058471; 18089610; 18202125; 18212329; 18381294; 18575751; 18599605; 18687805; 18800188; 18819928; 18936953; 18941464; 18950845; 19007976; 19147534; 19180570; 19244129; 19288017; 19364818; 19542562; 19584265; 19632997; 19950293; 20010302; 20043874; 20056838; 20097175; 20195466; 20233866; 20237132; 20237496; 20360068; 20531301; 20628624; 20641097; 21081514; 21138874; 21139048; 21153366; 21159247; 21212405; 21232118; 21249313; 21312266; 21349946; 21393426; 21397653; 21447598; 21488975; 21505992; 21601497; 21618249; 21628462; 21711965; 21963094; 21976359; 21995436; 22023263; 22025384; 22056874; 22160564; 22253074; 22363611; 22401280; 22527715; 22532143; 22540002; 22547695; 22551568; 22566095; 22692860; 22694338; 22752926; 22797925; 23027863; 23045290; 23141184; 23196056; 23259998; 23316072; 23504324; 23528710; 23618859; 23623839; 23667531; 23744557; 23798676; 24449575,,,,,,,,,,,,,,,OGG:3000003491,,,,,,,"cysteine-rich, angiogenic inducer, 61",,,,,,,,,,,,,"Other designations: CCN family member 1|IBP-10|IGF-binding protein 10|IGFBP-10|cysteine-rich heparin-binding protein 61|cysteine-rich, anigogenic inducer, 61|insulin-like growth factor-binding protein 10|protein CYR61",,CYR61,,,,,,,,,,,,,,,,,,,,,,,3491,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYR61,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000003490,IGFBP7,,Other designations: IGF-binding protein 7|IGFBP-rP1|PGI2-stimulating factor|angiomodulin|insulin-like growth factor-binding protein 7|prostacyclin-stimulating factor|tumor-derived adhesion factor,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,IBP-7|FSTL2|IGFBP-7v|PSF|IGFBPRP1|AGM|RAMSVPS|TAF|IGFBP-7|MAC25,,,,,,,,,,,,4,,,,,,Ensembl:ENSG00000163453|MIM:602867|HPRD:04183|HGNC:5476,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,insulin-like growth factor binding protein 7,,,4q12,,,,,,,,,,,,,,,,"GO_0001558 (EC: IEA); GO_0005515 (EC: IPI, PMID:9388210); GO_0005520 (EC: IEA); GO_0005576 (EC: TAS); GO_0005615 (EC: IDA); GO_0007155 (EC: IDA, PMID:8117260); GO_0007566 (EC: IEA); GO_0008285 (EC: TAS, PMID:8939990); GO_0009408 (EC: IEA); GO_0031012 (EC: IDA, Qualifier: colocalizes_with); GO_0032526 (EC: IEA); GO_0032870 (EC: IEA); GO_0048839 (EC: IEA); GO_0050810 (EC: IEA); GO_0051414 (EC: IEA)",,,,,,,,,PMID:7538673; 7694637; 7980422; 8117260; 8939990; 9100611; 9313760; 9388210; 10502291; 10595934; 10820148; 10859029; 10985926; 11549700; 12065244; 12407018; 12477932; 12592389; 12679483; 12843194; 12847218; 14521955; 14633696; 15077158; 15340161; 15489334; 15708897; 16302002; 16873698; 17048309; 17136345; 17312390; 17465992; 17972510; 18160415; 18267069; 18711401; 18981723; 19019211; 19374835; 19542015; 19638426; 19710688; 19829302; 19919630; 20029996; 20407444; 20433702; 20440262; 20464481; 20478260; 20535151; 20599521; 20977730; 21040219; 21095038; 21139048; 21328580; 21413833; 21525788; 21562573; 21835307; 21908579; 21909106; 21988832; 22005787; 22173745; 22277373; 22383111; 22392074; 22544761; 22622471; 22750143; 22906661; 22939629; 23250396; 23381221; 23382691; 23543219; 23546957; 23600329; 23713052,,,,,,,,,,,,,,,OGG:3000003490,,,,,,,insulin-like growth factor binding protein 7,,,,,,,,,,,,,Other designations: IGF-binding protein 7|IGFBP-rP1|PGI2-stimulating factor|angiomodulin|insulin-like growth factor-binding protein 7|prostacyclin-stimulating factor|tumor-derived adhesion factor,,IGFBP7,,,,,,,,,,,,,,,,,,,,,,,3490,,,,,,,,9606,,,,,,,,,,,,,,,,,,,IGFBP7,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000583,IFN alpha-17,,,false,,,http://purl.obolibrary.org/obo/IMR_0100386,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000583,,,,,,,,,,,,,,,,,,,,,,IFN alpha-17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000677,cGMP-dependent protein kinase II,type II cGMP-dependent protein kinase,,false,,,http://purl.obolibrary.org/obo/IMR_0000251,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,type II cGMP-dependent protein kinase,,,,,IMR:0000677,,,,,,,,,,,,,,,,,,,,,,cGMP-dependent protein kinase II,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100628,cyclin T,,,false,,,http://purl.obolibrary.org/obo/IMR_0100606,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100628,,,,,,,,,,,,,,,,,,,,,,cyclin T,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_64915,antiplasmodial drug,antiplasmodial drugs|antiplasmodial agent|antiplasmodium drug|antiplasmodium agents|antiplasmodium drugs|antiplasmodium agent|antiplasmodial agents,An antiparasitic drug which is effective against Apicomplexan parasites in the genus Plasmodium. The genus contains over 200 species and includes those responsible for malaria.,false,,,http://purl.obolibrary.org/obo/CHEBI_35820|http://purl.obolibrary.org/obo/CHEBI_35442,,,,,,,,,,,,,,,,,,,,,,An antiparasitic drug which is effective against Apicomplexan parasites in the genus Plasmodium. The genus contains over 200 species and includes those responsible for malaria.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,antiplasmodial drugs|antiplasmodial agent|antiplasmodium drug|antiplasmodium agents|antiplasmodium drugs|antiplasmodium agent|antiplasmodial agents,,,,,,,,,,,,,,,,,,,,,CHEBI:64915,,,,antiplasmodial drug,,CHEBI:64915,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002786,Binding of NF-kappaB and I-kappaB in cytosol,,"Binding of NF-kappaB and I-kappaB in cytosol is a subtype of binding: The selective interaction of a inhibitory-kappaB (I-kappaB/IKB) protein with NF-kappaB.
In the resting state, NF-kappaB dimers are bound to I-kappaB proteins, sequestering NF-kappaB in the cytoplasm.",false,,,http://purl.obolibrary.org/obo/GO_0005515,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IEV_0000214 (obsolete),,"Binding of NF-kappaB and I-kappaB in cytosol is a subtype of binding: The selective interaction of a inhibitory-kappaB (I-kappaB/IKB) protein with NF-kappaB.
In the resting state, NF-kappaB dimers are bound to I-kappaB proteins, sequestering NF-kappaB in the cytoplasm.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002786,,,,,,,,,,,,,,,,,,,,,,Binding of NF-kappaB and I-kappaB in cytosol,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002785,regulation of gene expression by NfKB [NfKB pathway],,"Regulation of gene expression by NfKB is a subtype of regulation of gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of gene expression by NfkB.
This entity is a specific course-dependent process. This process can constitute the course of NfKB pathway.",false,,,http://purl.obolibrary.org/obo/TXPO_0002784,,,,,,,,,,,,,,,,,,,,,,"Regulation of gene expression by NfKB is a subtype of regulation of gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of gene expression by NfkB.
This entity is a specific course-dependent process. This process can constitute the course of NfKB pathway.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002785,,,,,,,,,,,,,,,,,,,,,,regulation of gene expression by NfKB [NfKB pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002781,IKK activation [NfKB pathway],,"IKK activation is a subtype of molecular activation: A process that changes the activity of the IIKK (kappaB Kinase) to be higher.
This entity is a specific course-dependent process. This process can constitute the course of NfKB pathway.",false,,,http://purl.obolibrary.org/obo/TXPO_0002780,,,,,,,,,,,,,,,,,,,,,,"IKK activation is a subtype of molecular activation: A process that changes the activity of the IIKK (kappaB Kinase) to be higher.
This entity is a specific course-dependent process. This process can constitute the course of NfKB pathway.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002783,,,,,,,,,,,TXPO:0002781,,,,,,,,,,,,,,,,,,,,,,IKK activation [NfKB pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002780,IKK activation,,IKK activation is a subtype of molecular activation: A process that changes the activity of the IKK (kappaB Kinase)  to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000023,,,,,,,,,,,,,,,,,,,,,,IKK activation is a subtype of molecular activation: A process that changes the activity of the IKK (kappaB Kinase)  to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002780,,,,,,,,,,,,,,,,,,,,,,IKK activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002789,cytoplasmic sequestering of NF-kappaB [NfKB pathway],,"The selective interaction of the transcription factor NF-kappaB with specific molecules in the cytoplasm, thereby inhibiting its translocation into the nucleus.
This entity is a specific course-dependent process. This process can constitute the course of NfKB pathway.",false,,,http://purl.obolibrary.org/obo/GO_0007253,,,,,,,,,,,,,,,,,,,,,,"The selective interaction of the transcription factor NF-kappaB with specific molecules in the cytoplasm, thereby inhibiting its translocation into the nucleus.
This entity is a specific course-dependent process. This process can constitute the course of NfKB pathway.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002790,,,,,,,,,,,,,,,,,,TXPO:0002789,,,,,,,,,,,,,,,,,,,,,,cytoplasmic sequestering of NF-kappaB [NfKB pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002783,NF-kappaB activation [NfKB pathway],,"NF-kappaB activation is a subtype of transcription factor activation: A process that changes the activity of the NF-kappaB to be higher.
This entity is a specific course-dependent process. This process can constitute the course of NfKB pathway.",false,,,http://purl.obolibrary.org/obo/TXPO_0002782,,,,,,,,,,,,,,,,,,,,,,"NF-kappaB activation is a subtype of transcription factor activation: A process that changes the activity of the NF-kappaB to be higher.
This entity is a specific course-dependent process. This process can constitute the course of NfKB pathway.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002791,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002779,,,,,,,,,,,TXPO:0002783,,,,,,,,,,,,,,,,,,,,,,NF-kappaB activation [NfKB pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002788,forming disulfide bond 2 [ER stress],,"Forming disulfide bond 2 is a subtype of binding: The interaction between molecules with interchain disulfide bonds.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/TXPO_0002118,,,,,,,,,,,,,,,,,,,,PMID:23198585|PMID:21091435|PMID:23637286,,"Forming disulfide bond 2 is a subtype of binding: The interaction between molecules with interchain disulfide bonds.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002771,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000805|http://purl.obolibrary.org/obo/TXPO_0002497,,,,,,,,,,,,,,,,,TXPO:0002788,,,,,,,,,,,,,,,,,,,,,,forming disulfide bond 2 [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002782,NF-kappaB activation,,NF-kappaB activation is a subtype of transcription factor activation: A process that changes the activity of the NF-kappaB to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000124,,,,,,,,,,,,,,,,,,,,,,NF-kappaB activation is a subtype of transcription factor activation: A process that changes the activity of the NF-kappaB to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002782,,,,,,,,,,,,,,,,,,,,,,NF-kappaB activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002787,ABCC4 (canonical)[Glutathione depletion],MRP4 [Glutathione depletion],,false,,,http://purl.obolibrary.org/obo/TXPO_0002045|http://purl.obolibrary.org/obo/TXPO_0003019,,,,,,,,,,,,,,,,,,,,PMID:23087145,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MRP4 [Glutathione depletion],,,,,TXPO:0002787,,,,,,,,,,,,,,,,,,,,,,ABCC4 (canonical)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002784,regulation of gene expression by NfKB,,"Regulation of gene expression by NfKB is a subtype of regulation of gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of gene expression by NfkB.",false,,,http://purl.obolibrary.org/obo/GO_0010468,,,,,,,,,,,,,,,,,,,,,,"Regulation of gene expression by NfKB is a subtype of regulation of gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of gene expression by NfkB.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002784,,,,,,,,,,,,,,,,,,,,,,regulation of gene expression by NfKB,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100320,JAK2,,,false,,,http://purl.obolibrary.org/obo/IMR_0000213,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100320,,,,,,,,,,,,,,,,,,,,,,JAK2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_5296,gemfibrozil,"Lopid|2,2-Dimethyl-5-(2,5-dimethylphenoxy)valeriansaeure|Gemfibrozilo|2,2-Dimethyl-5-(2,5-xylyloxy)valeriansaeure|gemfibrozilum|2,2-Dimethyl-5-(2,5-xylyloxy)valeric acid|gemfibrozil|Gemfibrozil|5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid",,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Wikipedia:Gemfibrozil|CAS:25812-30-0|LINCS:LSM-2227|Drug_Central:1285|DrugBank:DB01241|Beilstein:1881200,,,,,,,,,,,,,,C15H22O3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35679,,,,,"Gemfibrozil|5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid",,"Lopid|2,2-Dimethyl-5-(2,5-dimethylphenoxy)valeriansaeure|Gemfibrozilo|2,2-Dimethyl-5-(2,5-xylyloxy)valeriansaeure|gemfibrozilum|2,2-Dimethyl-5-(2,5-xylyloxy)valeric acid|gemfibrozil",,,,,,,,,,,,,,,,,,,,,CHEBI:5296,,,,gemfibrozil,,CHEBI:5296,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Cc1ccc(C)c(OCCCC(C)(C)C(O)=O)c1,,,,,
http://purl.obolibrary.org/obo/IMR_0000041,TGF-beta family,,,false,,,http://purl.obolibrary.org/obo/IMR_0000036,,,,,,,,,,,,,,,,,,,,GO:0005160,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000041,,,,,,,,,,,,,,,,,,,,,,TGF-beta family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000051,leptin,,,false,,,http://purl.obolibrary.org/obo/IMR_0000966,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_24621,,,,,,,,,,IMR:0000051,,,,,,,,,,,,,,,,,,,,,,leptin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0034635,glutathione transport,,"The directed movement of glutathione, the tripeptide glutamylcysteinylglycine, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.",false,,,http://purl.obolibrary.org/obo/GO_0006810,,,,,,,,,,,,,,,,,,,,,,"The directed movement of glutathione, the tripeptide glutamylcysteinylglycine, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0034635,,,,,,,,,,,,,,,,,,,,,,glutathione transport,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0034638,phosphatidylcholine catabolic process,phosphatidylcholine catabolism|phosphatidylcholine breakdown|phosphatidylcholine degradation,"The chemical reactions and pathways resulting in the breakdown of phosphatidylcholines, any of a class of glycerophospholipids in which the phosphatidyl group is esterified to the hydroxyl group of choline.",false,,,http://purl.obolibrary.org/obo/GO_0046470|http://purl.obolibrary.org/obo/GO_0046475,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways resulting in the breakdown of phosphatidylcholines, any of a class of glycerophospholipids in which the phosphatidyl group is esterified to the hydroxyl group of choline.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_64482,,,,,,,,,,,,,,,,,,phosphatidylcholine catabolism|phosphatidylcholine breakdown|phosphatidylcholine degradation,,,,,GO:0034638,,,,,,,,,,,,,,,,,,,,,,phosphatidylcholine catabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_2000773,negative regulation of cellular senescence,,"Any process that stops, prevents or reduces the frequency, rate or extent of cellular senescence.",false,,,http://purl.obolibrary.org/obo/TXPO_0000369,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents or reduces the frequency, rate or extent of cellular senescence.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:2000773,,,,,,,,,,,,,,,,,,,,,,negative regulation of cellular senescence,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0090398,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000825,ATF,activating transcription factor,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,activating transcription factor,,,,,IMR:0000825,,,,,,,,,,,,,,,,,,,,,,ATF,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001395,ASAH1 (human)[Phospholipidosis - tumor cell proliferation induction],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000529,,,,,,,,,,,,,,,,,,,,"ASAH1 is an estrogen-dependent member of the sphingolipid metabolism, which might provide further prognostic information in ER-positive breast cancers.|http://omim.org/entry/613468|PMID:23423838|PMID:29147025|PMID:17064658",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002397,,,,,,,,,,TXPO:0001395,,,,,,,,,,,,,,,,,,,,,,ASAH1 (human)[Phospholipidosis - tumor cell proliferation induction],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001442,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001390,mitochondrial fatty acid beta-oxidation [lipidosis],,"A fatty acid oxidation process that results in the complete beta oxidation of a fatty acid in the mitochondria.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0001388,,,,,,,,,,,,,,,,,,,,,,"A fatty acid oxidation process that results in the complete beta oxidation of a fatty acid in the mitochondria.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001390,,,,,,,,,,,,,,,,,,,,,,mitochondrial fatty acid beta-oxidation [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001394,FATTY Acid Synthase (canonical)[lipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003516|http://purl.obolibrary.org/obo/TXPO_0001424,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:2194|PMID:10962028,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0010252,,,,,,,,,,TXPO:0001394,,,,,,,,,,,,,,,,,,,,,,FATTY Acid Synthase (canonical)[lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001392,Bcl2 phosphorylation,,Bcl2 phosphorylation is a subtype of phosphorylation: A process that The process of introducing a phosphate group into Bcl2.,false,,,http://purl.obolibrary.org/obo/GO_0016310,,,,,,,,,,,,,,,,,,,,,,Bcl2 phosphorylation is a subtype of phosphorylation: A process that The process of introducing a phosphate group into Bcl2.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001392,,,,,,,,,,,,,,,,,,,,,,Bcl2 phosphorylation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001399,CAD insertion into phospholipase binding site to lysosomal inner membrane [Phospholipidosis],,"CAD insertion into phospholipase binding site to lysosomal inner membrane is a subtype of binding: A process that CAD inserts and replaces the phospholipase binding site in the lysosomal inner membrane.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001398|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,PMID:22960355,,"CAD insertion into phospholipase binding site to lysosomal inner membrane is a subtype of binding: A process that CAD inserts and replaces the phospholipase binding site in the lysosomal inner membrane.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001560,,,,,,,,,,,,,,,,,TXPO:0001399,,,,,,,,,,,,,,,,,,,,,,CAD insertion into phospholipase binding site to lysosomal inner membrane [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001393,transmitter role,,A role played by the entity which transmits from A to B.,false,,,http://purl.obolibrary.org/obo/TXPO_0003727,,,,,,,,,,,,,,,,,,,,,,A role played by the entity which transmits from A to B.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001393,,,,,,,,,,,,,,,,,,,,,,transmitter role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001396,microscopy assay,,An imaging assay that utilizes a microscope to magnify features of the visualized material of interest that are not visible to naked eye.,false,,,http://purl.obolibrary.org/obo/OBI_0000185,,,,,,,,,,,,,,,,,,,,,,An imaging assay that utilizes a microscope to magnify features of the visualized material of interest that are not visible to naked eye.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001396,,,,,,,,,,,,,,,,,,,,,,microscopy assay,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001391,negative regulation of lipid transport,,"Negative regulation of lipid transport is a subtype of negative regulation of transport:  Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of lipids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.",false,,,http://purl.obolibrary.org/obo/TXPO_0002682,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of lipid transport is a subtype of negative regulation of transport:  Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of lipids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001391,,,,,,,,,,,,,,,,,,,,,,negative regulation of lipid transport,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001397,histone acetyltransferase,histone acetylase|acetyl-CoA:histone acetyltransferase,Catalysis role of the reaction: acetyl-CoA + histone = CoA + acetyl-histone.|related molecular function GO:0004402,false,,,http://purl.obolibrary.org/obo/TXPO_0001385,,,,,,,,,,,,,,,,,,,,EC:2.3.1.48,,Catalysis role of the reaction: acetyl-CoA + histone = CoA + acetyl-histone.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,histone acetylase|acetyl-CoA:histone acetyltransferase,,,,,TXPO:0001397,,,,,,,,,,,,,,,,,,,,related molecular function GO:0004402,,histone acetyltransferase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001398,CAD insertion into phospholipase binding site to lysosomal inner membrane,,"CAD insertion into phospholipase binding site to lysosomal inner membrane is a subtype of binding: A process that CAD inserts and replaces the phospholipase binding site in the lysosomal inner membrane.|Under normal conditions, lysosomal phospholipase A2 is bound through electrostatic charge interactions to the inner membranes of the lysosome.
A cationic amphiphile, accumulates in the lysosome and inserts into the inner membrane decreasing or eliminating the anionic binding sites for the lipase.
The lipase is no longer able to bind to its substrates and is potentially susceptible to degradation by lysosomal proteases.",false,,,http://purl.obolibrary.org/obo/GO_0005488,,,,,,,,,,,,,,,,,,,,,,CAD insertion into phospholipase binding site to lysosomal inner membrane is a subtype of binding: A process that CAD inserts and replaces the phospholipase binding site in the lysosomal inner membrane.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001398,,,,,,,,,,,,,,,,,,,,"Under normal conditions, lysosomal phospholipase A2 is bound through electrostatic charge interactions to the inner membranes of the lysosome.
A cationic amphiphile, accumulates in the lysosome and inserts into the inner membrane decreasing or eliminating the anionic binding sites for the lipase.
The lipase is no longer able to bind to its substrates and is potentially susceptible to degradation by lysosomal proteases.",,CAD insertion into phospholipase binding site to lysosomal inner membrane,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0034925,anatomical collection,,A collection of anatomical structures that are alike in terms of their morphology or developmental origin.,false,,,http://purl.obolibrary.org/obo/UBERON_0001062,,,,,,,,,,,,,,,,,,,,,,A collection of anatomical structures that are alike in terms of their morphology or developmental origin.,,,,resolve if this should be a subclass of disconnected anatomical group. Some collections (e.g. the skeleton or skull) are arguably connected,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0000061,,,,,,,,,,,,,,,,,,,,,,UBERON:0034925,,,,,,,,,,,,,,,,,,,,,,anatomical collection,,,,,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_490877,didanosine,"ddI|2,3-dideoxyinosine|didanosine|9-((2R,5S)-5-Hydroxymethyl-tetrahydro-furan-2-yl)-1,9-dihydro-purin-6-one|9-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one|dideoxyinosine|9-((2S,5R)-5-Hydroxymethyl-tetrahydro-furan-2-yl)-9H-purin-6-ol|DDI|9-((2R,5S)-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-1H-purin-6(9H)-one|didanosina|ddIno|didanosinum|ddI|2',3'-dideoxyinosine|Didanosine","A purine 2',3'-dideoxyribonucleoside that is inosine in which the hydroxy groups at both the 2' and the 3' positions on the sugar moiety have been replaced by hydrogen. An antiviral drug, it is used as a medication to treat HIV/AIDS.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:10386939|DrugBank:DB00900|CAS:69655-05-6|Reaxys:3619529|PMID:1619614|Drug_Central:869|Beilstein:3619529|Wikipedia:Didanosine|LINCS:LSM-6017|PMID:18549801|PMID:17046264|PMID:29438107,,"A purine 2',3'-dideoxyribonucleoside that is inosine in which the hydroxy groups at both the 2' and the 3' positions on the sugar moiety have been replaced by hydrogen. An antiviral drug, it is used as a medication to treat HIV/AIDS.",,,,,,,,,,,,C10H12N4O3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_53756|http://purl.obolibrary.org/obo/CHEBI_35221|http://purl.obolibrary.org/obo/CHEBI_63090|http://purl.obolibrary.org/obo/CHEBI_36044,,,,,"ddI|2',3'-dideoxyinosine|Didanosine",,"ddI|2,3-dideoxyinosine|didanosine|9-((2R,5S)-5-Hydroxymethyl-tetrahydro-furan-2-yl)-1,9-dihydro-purin-6-one|9-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one|dideoxyinosine|9-((2S,5R)-5-Hydroxymethyl-tetrahydro-furan-2-yl)-9H-purin-6-ol|DDI|9-((2R,5S)-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-1H-purin-6(9H)-one|didanosina|ddIno|didanosinum",,,,,,,,,,,,,,,,,,,,,CHEBI:490877,,,,didanosine,,CHEBI:490877,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,OC[C@@H]1CC[C@@H](O1)n1cnc2c1nc[nH]c2=O,,,,,
http://purl.obolibrary.org/obo/IMR_0000432,Axin,Axin/conductin,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003721|http://purl.obolibrary.org/obo/TXPO_0003657,,,,,Axin/conductin,,,,,IMR:0000432,,,,,,,,,,,,,,,,,,,,,,Axin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100280,I-kappaB alpha,inhibitor of NF-kappaB alpha|IkB-alpha,,false,,,http://purl.obolibrary.org/obo/IMR_0000464,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,inhibitor of NF-kappaB alpha|IkB-alpha,,,,,IMR:0100280,,,,,,,,,,,,,,,,,,,,,,I-kappaB alpha,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100593,PI3-kinase p110 subunit beta,"Phosphatidylinositol 3-kinase catalytic subunit, beta isoform (EC 2.7.1.137) (PI3-kinase p110 subunit beta) (PtdIns-3-kinase p110) (PI3K) (PI3Kbeta)|PI3K|PtdIns-3-kinase p110|PI3Kbeta|Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit, beta isoform",,false,,,http://purl.obolibrary.org/obo/IMR_0000267,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0010390,"Phosphatidylinositol 3-kinase catalytic subunit, beta isoform (EC 2.7.1.137) (PI3-kinase p110 subunit beta) (PtdIns-3-kinase p110) (PI3K) (PI3Kbeta)|PI3K|PtdIns-3-kinase p110|PI3Kbeta|Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit, beta isoform",,,,,IMR:0100593,,,,,,,,,,,,,,,,,,,,,,PI3-kinase p110 subunit beta,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_135641,pipamazine,nausidol|mornidine|nometine,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:84-04-8|Drug_Central:2180,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,nausidol|mornidine|nometine,,,,,,,,,,,,,,,,,,,,,CHEBI:135641,,,,pipamazine,,CHEBI:135641,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_135649,alpidem,"ananxyl|Alpidem (Ananxyl) is an anxiolytic drug from the imidazopyridine family, related to the more well known sleeping medication zolpidem. (by Wikipedia)|Ananxyl",,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:82626-01-5|Drug_Central:134|Wikipedia:Alpidem,,,,,,,,,,,,,,C21H23Cl2N3O,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35474,,,,,"Alpidem (Ananxyl) is an anxiolytic drug from the imidazopyridine family, related to the more well known sleeping medication zolpidem. (by Wikipedia)|Ananxyl",,ananxyl,,,,,,,,,,,,,,,,,,,,,CHEBI:135649,,,,alpidem,,CHEBI:135649,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,C(C(N(CCC)CCC)=O)C1=C(N=C2N1C=C(C=C2)Cl)C3=CC=C(C=C3)Cl,,,,,
http://purl.obolibrary.org/obo/TXPO_0003825,Inflammasome activation [pyroptosis],,"Inflammasome activation is a subtype of activating: A process that changes the activity of the inflammasome to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0001727|http://purl.obolibrary.org/obo/TXPO_0001107,,,,,,,,,,,,,,,,,,,,PMID:21760595|Reactome: R-HSA-844456.2|PMID:18667412,,"Inflammasome activation is a subtype of activating: A process that changes the activity of the inflammasome to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003826,,,,,,http://purl.obolibrary.org/obo/TXPO_0003827,,,,,,,,,,,TXPO:0003825,,,,,,,,,,,,,,,,,,,,,,Inflammasome activation [pyroptosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003823,CREB1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1385,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003823,,,,,,,,,,,,,,,,,,,,,,CREB1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003820,lipofuscin granule,,,false,,,http://purl.obolibrary.org/obo/GO_0048770,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003820,,,,,,,,,,,,,,,,,,,,,,lipofuscin granule,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003826,CASP1 (canonical)[pyroptopsis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003195|http://purl.obolibrary.org/obo/IMR_0100302,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:834|PMID:20303873,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003826,,,,,,,,,,,,,,,,,,,,,,CASP1 (canonical)[pyroptopsis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003828,IL-1B (canonical)[pyroptosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003195|http://purl.obolibrary.org/obo/TXPO_1000200,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:3553|NCBI-Rat-GeneID:24494|NCBI-Mouse-GeneID:16176|PMID:21760595,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003041,,,,,,,,,,TXPO:0003828,,,,,,,,,,,,,,,,,,,,,,IL-1B (canonical)[pyroptosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003822,steatosis inducer role,lipidosis inducer role,A role played by the entity which involves in inducing lipidosis,false,,,http://purl.obolibrary.org/obo/TXPO_0003710,,,,,,,,,,,,,,,,,,,,,,A role played by the entity which involves in inducing lipidosis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,lipidosis inducer role,,,,,TXPO:0003822,,,,,,,,,,,,,,,,,,,,,,steatosis inducer role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003827,Inflammatory cytokine gene expression[pyroptosis],,"Inflammatory cytokine gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature inflammatory cytokine gene product or products (proteins or RNA).
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0002266|http://purl.obolibrary.org/obo/TXPO_0001727,,,,,,,,,,,,,,,,,,,,,,"Inflammatory cytokine gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature inflammatory cytokine gene product or products (proteins or RNA).
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003828,,,,,,,,,,,,,,,,,TXPO:0003827,,,,,,,,,,,,,,,,,,,,,,Inflammatory cytokine gene expression[pyroptosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003824,lysosomal cholesterol storage (severe)[Phospholipidosis],,"Lysosomal cholesterol storage is a subtype of cholesterol storage: A process that keeps cholesterol in the lysosome severely.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001537|http://purl.obolibrary.org/obo/TXPO_0000694,,,,,,,,,,,,,,,,,,,,,,"Lysosomal cholesterol storage is a subtype of cholesterol storage: A process that keeps cholesterol in the lysosome severely.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002094|http://purl.obolibrary.org/obo/TXPO_0003435,,,,,,,,,,,TXPO:0003824,,,,,,,,,,,,,,,,,,,,,,lysosomal cholesterol storage (severe)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003821,melanin granule,,,false,,,http://purl.obolibrary.org/obo/GO_0048770,,,,,,,,,,,,,,,,,,,,,,,Melanin granule is a sutype of pigment granule,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003821,,,,,,,,,,,,,,,,,,,,,,melanin granule,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003829,compound accumulation in liver [Cell death],,"Compound accumulation in liver is a subtype of accumulation of xenobiotics: A process that keeps compound in the liver.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0001727|http://purl.obolibrary.org/obo/TXPO_0002325,,,,,,,,,,,,,,,,,,,,,,"Compound accumulation in liver is a subtype of accumulation of xenobiotics: A process that keeps compound in the liver.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000008,,,,,,,,,,,TXPO:0003829,,,,,,,,,,,,,,,,,,,,,,compound accumulation in liver [Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_35786,phosphosphingolipid,sphingophospholipid,,false,,,http://purl.obolibrary.org/obo/CHEBI_16247|http://purl.obolibrary.org/obo/CHEBI_26739,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0001383,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sphingophospholipid,,,,,CHEBI:35786,,,,,,,,,,,,,,,,,,,,,,phosphosphingolipid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000596,IL-14,High molecular weight B-cell growth factor|interleukin-14,,false,,,http://purl.obolibrary.org/obo/IMR_0000007,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000622,,,,,High molecular weight B-cell growth factor|interleukin-14,,,,,IMR:0000596,,,,,,,,,,,,,,,,,,,,,,IL-14,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0001143,hepatic vein,,Vein that carries blood away from the liver.,false,,,http://purl.obolibrary.org/obo/UBERON_0015796,,,,,,,,,,,,,,,,,,,,http://en.wikipedia.org/wiki/Hepatic_vein,,Vein that carries blood away from the liver.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,UBERON:0001143,,,,,,,,,,,,,,,,,,,,,,hepatic vein,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004100,malfunctioning of cobalamin biosynthetic process,,Malfunctioning of cobalamin biosynthetic process is a subtype of malfunctioning process: A process that cannot perform cobalamin biosynthetic process appropriately or cannot realize it at all.,false,,,http://purl.obolibrary.org/obo/TXPO_0003267,,,,,,,,,,,,,,,,,,,,,,Malfunctioning of cobalamin biosynthetic process is a subtype of malfunctioning process: A process that cannot perform cobalamin biosynthetic process appropriately or cannot realize it at all.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004100,,,,,,,,,,,,,,,,,,,,,,malfunctioning of cobalamin biosynthetic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004104,IL32 (human)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004103,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:9235,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000003558,,,http://purl.obolibrary.org/obo/TXPO_0003041,,,,,,,,,,TXPO:0004104,,,,,,,,,,,,,,,,,,,,,,IL32 (human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004101,malfunctioning of cobalamin biosynthetic process[Phospholipidosis],,"Malfunctioning of cobalamin biosynthetic process is a subtype of malfunctioning process: A process that cannot perform cobalamin biosynthetic process appropriately or cannot realize it at all.
This entity is a specific course-dependent process. This process can constitute the course of Phosphoipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0004100|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Malfunctioning of cobalamin biosynthetic process is a subtype of malfunctioning process: A process that cannot perform cobalamin biosynthetic process appropriately or cannot realize it at all.
This entity is a specific course-dependent process. This process can constitute the course of Phosphoipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000659|http://purl.obolibrary.org/obo/TXPO_0004095,,,,,,http://purl.obolibrary.org/obo/TXPO_0001708,,,,,,,,,,,TXPO:0004101,,,,,,,,,,,,,,,,,,,,,,malfunctioning of cobalamin biosynthetic process[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004103,IL32 (mol),,,false,,,http://purl.obolibrary.org/obo/IMR_0000007,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:9235,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004103,,,,,,,,,,,,,,,,,,,,,,IL32 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004106,PKIB(human)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001135|http://purl.obolibrary.org/obo/TXPO_0003838,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:5570|PMID:27325557,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000005570,,,http://purl.obolibrary.org/obo/TXPO_0002272,,,,,,,,,,TXPO:0004106,,,,,,,,,,,,,,,,,,,,,,PKIB(human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004102,CAR - apotosis inhibitor (canonical)[Ground glass appearance],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003791,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_68494,,,,,,,,,,TXPO:0004102,,,,,,,,,,,,,,,,,,,,,,CAR - apotosis inhibitor (canonical)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004108,Rsad2(mouse)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003278|http://purl.obolibrary.org/obo/TXPO_0003835,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:58185|PMID:23758785,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004108,,,,,,,,,,,,,,,,,,,,,,Rsad2(mouse)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004107,protein modification by small protein conjugation,,"A protein modification process in which one or more groups of a small protein, such as ubiquitin or a ubiquitin-like protein, are covalently attached to a target protein.",false,,,http://purl.obolibrary.org/obo/GO_0070647,,,,,,,,,,,,,,,,,,,,,,"A protein modification process in which one or more groups of a small protein, such as ubiquitin or a ubiquitin-like protein, are covalently attached to a target protein.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004107,,,,,,,,,,,,,,,,,,,,,,protein modification by small protein conjugation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004105,NCR3LG1 (predicted)(human)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001135|http://purl.obolibrary.org/obo/TXPO_0003842,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:374383|PMID:26241657|PMID:19528259|http://www.reactome.org/content/detail/R-HSA-5683240|https://omim.org/entry/613714,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,,,,,,,,,,,,,,TXPO:0004105,,,,,,,,,,,,,,,,,,,,,,NCR3LG1 (predicted)(human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004109,"negative regulation of mitochondrial electron transport, NADH to ubiquinone [Mitochondrial disorder]",,"Any process that stops, prevents or reduces the frequency, rate or extent of mitochondrial electron transport, NADH to ubiquinone.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/GO_1902957,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents or reduces the frequency, rate or extent of mitochondrial electron transport, NADH to ubiquinone.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004109,,,,,,,,,,,,,,,,,,,,,,"negative regulation of mitochondrial electron transport, NADH to ubiquinone [Mitochondrial disorder]",,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006120,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_72768,aryl hydrocarbon receptor agonist,AHR agonist,An agonist that binds to and activates aryl hydrocarbon receptors (AhRs).,false,,,http://purl.obolibrary.org/obo/CHEBI_48705,,,,,,,,,,,,,,,,,,,,,,An agonist that binds to and activates aryl hydrocarbon receptors (AhRs).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,AHR agonist,,,CHEBI:72768,,,,,,,,,,,,,,,,,,,,,,aryl hydrocarbon receptor agonist,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000006782,HSPA13,,"Other designations: heat shock 70 kDa protein 13|microsomal stress 70 protein ATPase core|microsomal stress-70 protein ATPase core|stress 70 protein chaperone, microsome-associated, 60kD|stress 70 protein chaperone, microsome-associated, 60kDa|stress-70 protein chaperone microsome-associated 60 kDa protein",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,STCH,,,,,,,,,,,,21,,,,,,Vega:OTTHUMG00000074261|MIM:601100|Ensembl:ENSG00000155304|HPRD:03061|HGNC:11375,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"heat shock protein 70kDa family, member 13",,,21q11,,,,,,,,,,,,,,,,"GO_0005524 (EC: IEA); GO_0005783 (EC: IEA); GO_0043231 (EC: TAS, PMID: 8131751); GO_0070062 (EC: IDA, PMID: 19199708)",,,,,,,,,PMID: 8125298; 8131751; 8825657; 8889548; 8889549; 10675567; 10830953; 11319647; 12107410; 12477932; 14702039; 15489334; 16087163; 16189514; 16713569; 18793616; 19199708; 19793966; 21139048; 21900206; 21988832; 22190034; 23303189,,,,,,,,,,,,,,,OGG:3000006782,,,,,,,"heat shock protein 70kDa family, member 13",,,,,,,,,,,,,"Other designations: heat shock 70 kDa protein 13|microsomal stress 70 protein ATPase core|microsomal stress-70 protein ATPase core|stress 70 protein chaperone, microsome-associated, 60kD|stress 70 protein chaperone, microsome-associated, 60kDa|stress-70 protein chaperone microsome-associated 60 kDa protein",,HSPA13,,,,,,,,,,,,,,,,,,,,,,,6782,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,HSPA13,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0004944,Negative regulation of glutathione transport,,"Negative regulation of glutathione transport is a subtype of negative regulation of transport:  Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of glutathione into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.",false,,,http://purl.obolibrary.org/obo/TXPO_0002682,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of glutathione transport is a subtype of negative regulation of transport:  Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of glutathione into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004944,,,,,,,,,,,,,,,,,,,,,,Negative regulation of glutathione transport,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004948,gemfibrozil [hepatocarcinogenesis],"5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid",,false,,,http://purl.obolibrary.org/obo/CHEBI_5296|http://purl.obolibrary.org/obo/TXPO_0004455,,,,,,,,,,,,,,,,,,,,Wikipedia:Gemfibrozil|CAS:25812-30-0|PMID:9884324|DrugBank:DB01241,,,,,,,,,,,,,,C15H22O3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid",,,,,TXPO:0004948,,,,,,,,,,,,,,,,,,,,,,gemfibrozil [hepatocarcinogenesis],,,,,,,,,,,http://purl.obolibrary.org/obo/NCBITaxon_9989,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Cc1ccc(C)c(OCCCC(C)(C)C(O)=O)c1,,,,,
http://purl.obolibrary.org/obo/TXPO_0004947,induction of genomic instability,,Any process that results in induction of genomic instability.,false,,,http://purl.obolibrary.org/obo/TXPO_0001984,,,,,,,,,,,,,,,,,,,,,,Any process that results in induction of genomic instability.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004947,,,,,,,,,,,,,,,,,,,,,,induction of genomic instability,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004946,Increasing ketone body level [mitochondrial disorder],,"Increasing ketone body level is a subtype of increasing quantity: A process that changes the amount of ketone body level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0004945|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:23299992,,"Increasing ketone body level is a subtype of increasing quantity: A process that changes the amount of ketone body level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_73693,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004366,,,,,,,,,,,TXPO:0004946,,,,,,,,,,,,,,,,,,,,,,Increasing ketone body level [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004945,Increasing ketone body level,,Increasing ketone body level is a subtype of increasing quantity: A process that changes the amount of ketone body level to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing ketone body level is a subtype of increasing quantity: A process that changes the amount of ketone body level to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004945,,,,,,,,,,,,,,,,,,,,,,Increasing ketone body level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004943,decreasing glutathione level,,Decreasing glutathione level is a subtype of decreasing quantity: A process that changes the amount of glutathione level to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000396,,,,,,,,,,,,,,,,,,,,,,Decreasing glutathione level is a subtype of decreasing quantity: A process that changes the amount of glutathione level to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004943,,,,,,,,,,,,,,,,,,,,,,decreasing glutathione level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004940,decreasing glucose level,glucose depletion,Decreasing glucose level is a subtype of decreasing quantity: A process that changes the amount of glucose level to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000396,,,,,,,,,,,,,,,,,,,,,,Decreasing glucose level is a subtype of decreasing quantity: A process that changes the amount of glucose level to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,glucose depletion,,,TXPO:0004940,,,,,,,,,,,,,,,,,,,,,,decreasing glucose level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004941,Decreasing glucose level [mitochondrial disorder],glucose depletion,"Decreasing glucose level is a subtype of decreasing quantity: A process that changes the amount of glucose level to be lower.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0004940|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:29335519,,"Decreasing glucose level is a subtype of decreasing quantity: A process that changes the amount of glucose level to be lower.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001992,,,,,,,,glucose depletion,,,TXPO:0004941,,,,,,,,,,,,,,,,,,,,,,Decreasing glucose level [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004942,hyperfunction of gluconeogenesis,,Hyperfunction of gluconeogenesis is a subtype of hyperfunction of biosynthesis: A process that performs an excessive gluconeogenesis.,false,,,http://purl.obolibrary.org/obo/TXPO_0002346,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of gluconeogenesis is a subtype of hyperfunction of biosynthesis: A process that performs an excessive gluconeogenesis.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004942,,,,,,,,,,,,,,,,,,,,,,hyperfunction of gluconeogenesis,,,,,,http://purl.obolibrary.org/obo/GO_0006094,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004949,Connexin signaling (primitive) [hepatocarcinogenesis],,"Connexin signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by connexin.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0004495|http://purl.obolibrary.org/obo/TXPO_0002340,,,,,,,,,,,,,,,,,,,,PMID:30947731,,"Connexin signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by connexin.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004950|http://purl.obolibrary.org/obo/TXPO_0004951,http://purl.obolibrary.org/obo/TXPO_0004494,,,,,http://purl.obolibrary.org/obo/TXPO_0004526,,,,,,,,,,,TXPO:0004949,,,,,,,,,,,,,,,,,,,,,,Connexin signaling (primitive) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_9907,ursodeoxycholic acid,,"A bile acid found in the bile of bears (Ursidae) as a conjugate with taurine. Used therapeutically, it prevents the synthesis and absorption of cholesterol and can lead to the dissolution of gallstones.",false,,,http://purl.obolibrary.org/obo/TXPO_0000509,,,,,,,,,,,,,,,,,,,,InChIKey:RUDATBOHQWOJDD-UZVSRGJWSA-N,,"A bile acid found in the bile of bears (Ursidae) as a conjugate with taurine. Used therapeutically, it prevents the synthesis and absorption of cholesterol and can lead to the dissolution of gallstones.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:9907,,,,,,,,,,,,,,,,,,,,,,ursodeoxycholic acid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0045892,"negative regulation of transcription, DNA-templated","down regulation of transcription, DNA-dependent|down-regulation of transcription, DNA-dependent","Any process that stops, prevents, or reduces the frequency, rate or extent of cellular DNA-templated transcription.",false,,,http://purl.obolibrary.org/obo/GO_0006355,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents, or reduces the frequency, rate or extent of cellular DNA-templated transcription.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"down regulation of transcription, DNA-dependent|down-regulation of transcription, DNA-dependent",,,,,GO:0045892,,,,,,,,,,,,,,,,,,,,,,"negative regulation of transcription, DNA-templated",,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006351,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/DOID_9351,diabetes mellitus,,"A glucose metabolism disease characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both.",false,,,http://purl.obolibrary.org/obo/DOID_4,,,,,,,,,,,,,,,,,,,,MESH:D003920|NCI:C298,,"A glucose metabolism disease characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,DOID:9351,,,,,,,,,,,,,,,,,,,,,,diabetes mellitus,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001427,BMP-3b,Bone morphogenetic protein 3b|GDF10|GDF-10|BMP3b,,false,,,http://purl.obolibrary.org/obo/IMR_0000040,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Bone morphogenetic protein 3b|GDF10|GDF-10|BMP3b,,,,,IMR:0001427,,,,,,,,,,,,,,,,,,,,,,BMP-3b,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_50627,EC 3.2.1.1 (alpha-amylase) inhibitor,"EC 3.2.1.1 (alpha-amylase) inhibitors|alpha-amylase (EC 3.2.1.1) inhibitor|4-alpha-D-glucan glucanohydrolase inhibitor|alpha-amylase inhibitor|alpha-amylase (EC 3.2.1.1) inhibitors|Taka-amylase A inhibitors|endoamylase inhibitor|Taka-amylase A inhibitor|EC 3.2.1.1 inhibitor|1,4-alpha-D-glucan glucanohydrolase inhibitor|EC 3.2.1.1 inhibitors|alpha-amylase inhibitors|endoamylase inhibitors|glycogenase inhibitor|glycogenase inhibitors|1,4-alpha-D-glucan glucanohydrolase inhibitors|4-alpha-D-glucan glucanohydrolase inhibitors",An EC 3.2.1.* (glycosidase) inhibitor that interferes with the action of alpha-amylase (EC 3.2.1.1).,false,,,http://purl.obolibrary.org/obo/CHEBI_52424,,,,,,,,,,,,,,,,,,,,,,An EC 3.2.1.* (glycosidase) inhibitor that interferes with the action of alpha-amylase (EC 3.2.1.1).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"EC 3.2.1.1 (alpha-amylase) inhibitors|alpha-amylase (EC 3.2.1.1) inhibitor|4-alpha-D-glucan glucanohydrolase inhibitor|alpha-amylase inhibitor|alpha-amylase (EC 3.2.1.1) inhibitors|Taka-amylase A inhibitors|endoamylase inhibitor|Taka-amylase A inhibitor|EC 3.2.1.1 inhibitor|1,4-alpha-D-glucan glucanohydrolase inhibitor|EC 3.2.1.1 inhibitors|alpha-amylase inhibitors|endoamylase inhibitors|glycogenase inhibitor|glycogenase inhibitors|1,4-alpha-D-glucan glucanohydrolase inhibitors|4-alpha-D-glucan glucanohydrolase inhibitors",,,,,,,,,,,,,,,,,,,,,CHEBI:50627,,,,EC 3.2.1.1 (alpha-amylase) inhibitor,,CHEBI:50627,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_8107,phenytoin,"5,5-diphenyltetrahydro-1H-2,4-imidazoledione|phenytoin|fenitoina|phenytoine|5,5-Diphenyl-imidazolidine-2,4-dione|DILANTIN|phenytoinum|5,5-diphenylimidazolidine-2,4-dione|PHENTYTOIN|5,5-diphenylimidazolidine-2,4-dione","A imidazolidine-2,4-dione that consists of hydantoin bearing two phenyl substituents at position 5.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:7105825|PMID:12952753|PMID:7602118|PMID:16303054|PMID:9186244|CAS:57-41-0|PMID:15246836|PMID:15744730|Reaxys:384532|PMID:10698828|Beilstein:384532|DrugBank:DB00252|LINCS:LSM-5663|Drug_Central:2152,,"A imidazolidine-2,4-dione that consists of hydantoin bearing two phenyl substituents at position 5.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_50905|http://purl.obolibrary.org/obo/CHEBI_38633|http://purl.obolibrary.org/obo/CHEBI_88188|http://purl.obolibrary.org/obo/CHEBI_35623,,,,,"5,5-diphenylimidazolidine-2,4-dione",,"5,5-diphenyltetrahydro-1H-2,4-imidazoledione|phenytoin|fenitoina|phenytoine|5,5-Diphenyl-imidazolidine-2,4-dione|DILANTIN|phenytoinum|5,5-diphenylimidazolidine-2,4-dione|PHENTYTOIN",,,,,,,,,,,,,,,,,,,,,CHEBI:8107,,,,phenytoin,,CHEBI:8107,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006461,protein complex assembly,protein complex formation,"The aggregation, arrangement and bonding together of a set of components to form a protein complex.",false,,,http://purl.obolibrary.org/obo/GO_0065003,,,,,,,,,,,,,,,,,,,,,,"The aggregation, arrangement and bonding together of a set of components to form a protein complex.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,protein complex formation,,,,,GO:0006461,,,,,,,,,,,,,,,,,,,,,,protein complex assembly,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100087,gonadotropin,,"Hormones that stimulate gonadal functions such as GAMETOGENESIS and sex steroid hormone production in the OVARY and the TESTIS. Major gonadotropins are glycoproteins produced primarily by the adenohypophysis ( GONADOTROPINS, PITUITARY) and the placenta ( CHORIONIC GONADOTROPIN). In some species, pituitary PROLACTIN and PLACENTAL LACTOGEN exert some luteotropic activities.",false,,,http://purl.obolibrary.org/obo/IMR_0000966,,,,,,,,,,,,,,,,,,,,MeSH:D006062,,"Hormones that stimulate gonadal functions such as GAMETOGENESIS and sex steroid hormone production in the OVARY and the TESTIS. Major gonadotropins are glycoproteins produced primarily by the adenohypophysis ( GONADOTROPINS, PITUITARY) and the placenta ( CHORIONIC GONADOTROPIN). In some species, pituitary PROLACTIN and PLACENTAL LACTOGEN exert some luteotropic activities.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_24621,,,,,,,,,,IMR:0100087,,,,,,,,,,,,,,,,,,,,,,gonadotropin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001098,exportin 4,,,false,,,http://purl.obolibrary.org/obo/IMR_0100015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001098,,,,,,,,,,,,,,,,,,,,,,exportin 4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001217,increasing number of apoptotic cells in liver,,Increasing number of apoptotic cells in liver is a subtype of increasing number of dead cells in liver: A process that becomes larger in the number of apoptotic cells in the liver.,false,,,http://purl.obolibrary.org/obo/TXPO_0000341,,,,,,,,,,,,,,,,,,,,,,Increasing number of apoptotic cells in liver is a subtype of increasing number of dead cells in liver: A process that becomes larger in the number of apoptotic cells in the liver.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001217,,,,,,,,,,,,,,,,,,,,,,increasing number of apoptotic cells in liver,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001216,water accumulation,,"A process of liquid water accumulation in a particular location in an organism, tissue or cell.",false,,,http://purl.obolibrary.org/obo/TXPO_0000488,,,,,,,,,,,,,,,,,,,,,,"A process of liquid water accumulation in a particular location in an organism, tissue or cell.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001216,,,,,,,,,,,,,,,,,,,,,,water accumulation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001218,hyperfunction of lipase gene expression [lipidosis],,"Hyperfunction of lipase gene expression is a subtype of hyperfunction of gene expression: A process that performs an excesssive lipase gene expression.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001215|http://purl.obolibrary.org/obo/TXPO_0001720,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of lipase gene expression is a subtype of hyperfunction of gene expression: A process that performs an excesssive lipase gene expression.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001218,,,,,,,,,,,,,,,,,,,,,,hyperfunction of lipase gene expression [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001210,constitutive androstane receptor activation,activating CAR|CAR activating|CAR activation,Constitutive androstane receptor activation is a subtype of activating nuclear receptor: A process that changes the activity of the activating  CAR ( constitutive androstane receptor) with a nuclear receptor role to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000158,,,,,,,,,,,,,,,,,,,,,,Constitutive androstane receptor activation is a subtype of activating nuclear receptor: A process that changes the activity of the activating  CAR ( constitutive androstane receptor) with a nuclear receptor role to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,activating CAR|CAR activating|CAR activation,,,,,TXPO:0001210,,,,,,,,,,,,,,,,,,,,,,constitutive androstane receptor activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001213,p53 activation,,P53 activation is a subtype of activation of transcription factor: A process that changes the activity of one of the p53 family of proteins to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000124,,,,,,,,,,,,,,,,,,,,,,P53 activation is a subtype of activation of transcription factor: A process that changes the activity of one of the p53 family of proteins to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001213,,,,,,,,,,,,,,,,,,,,,,p53 activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001211,ATF4 gene expression regulation system,,"ATF4 gene expression regulation system is a subtype of pathway system.
This entity has sub-parts and has a goal of regulating gene expressions by ATF4 as a systemic context.",false,,,http://purl.obolibrary.org/obo/TXPO_0000887,,,,,,,,,,,,,,,,,,,,,,"ATF4 gene expression regulation system is a subtype of pathway system.
This entity has sub-parts and has a goal of regulating gene expressions by ATF4 as a systemic context.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001211,,,,,,,,,,,,,,,,,,,,,,ATF4 gene expression regulation system,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001214,retinoid X receptor activation,RXR activation|activating RXR,Retinoid X receptor activation is a subtype of activating nuclear receptor: A process that changes the activity of the RXR (retinoid X receptor) with a nuclear receptor role to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000158,,,,,,,,,,,,,,,,,,,,,,Retinoid X receptor activation is a subtype of activating nuclear receptor: A process that changes the activity of the RXR (retinoid X receptor) with a nuclear receptor role to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,activating RXR,RXR activation,,,,TXPO:0001214,,,,,,,,,,,,,,,,,,,,,,retinoid X receptor activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001212,forming a complex with Cyp,,"Forming a complex with Cyp is a subtype of protein complex assembly: The aggregation, arrangement and bonding together with Cyp (cytochrome P450) to form a complex.",false,,,http://purl.obolibrary.org/obo/GO_0006461,,,,,,,,,,,,,,,,,,,,,,"Forming a complex with Cyp is a subtype of protein complex assembly: The aggregation, arrangement and bonding together with Cyp (cytochrome P450) to form a complex.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001558,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001212,,,,,,,,,,,,,,,,,,,,,,forming a complex with Cyp,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001215,hyperfunction of lipase gene expression,,Hyperfunction of lipase gene expression is a subtype of hyperfunction of gene expression: A process that performs an excesssive lipase gene expression.,false,,,http://purl.obolibrary.org/obo/TXPO_0002345,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of lipase gene expression is a subtype of hyperfunction of gene expression: A process that performs an excesssive lipase gene expression.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001215,,,,,,,,,,,,,,,,,,,,,,hyperfunction of lipase gene expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001219,apoptosis inducer activation,,Apoptosis inducer activation is a subtype of molecular activation: A process that changes the activity of the molecule with an apoptosis inducer role to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000023,,,,,,,,,,,,,,,,,,,activating apoptosis inducer,,,Apoptosis inducer activation is a subtype of molecular activation: A process that changes the activity of the molecule with an apoptosis inducer role to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001219,,,,,,,,,,,,,,,,,,,,,,apoptosis inducer activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000633,Integrin alpha-11,,,false,,,http://purl.obolibrary.org/obo/IMR_0000173,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000633,,,,,,,,,,,,,,,,,,,,,,Integrin alpha-11,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000051594,NBAS,,Other designations: NAG/BC035112 fusion|NAG/FAM49A fusion|neuroblastoma-amplified gene protein|neuroblastoma-amplified sequence,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,SOPH|NAG,,,,,,,,,,,,2,,,,,,Ensembl:ENSG00000151779|Vega:OTTHUMG00000121153|HPRD:10473|MIM:608025|HGNC:15625,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,neuroblastoma amplified sequence,,,2p24,,,,,,,,,,,,,,,,GO_0000956 (EC: IMP); GO_0005737 (EC: IEA); GO_2000623 (EC: IMP),,,,,,,,,PMID: 9926938; 11329013; 11954550; 12477932; 12706883; 14702039; 16169070; 17028906; 19369418; 19407829; 20360068; 20379614; 20577004; 20585324; 21139048; 21697133; 21906983; 21963094; 23828042,,,,,,,,,,,,,,,OGG:3000051594,,,,,,,neuroblastoma amplified sequence,,,,,,,,,,,,,Other designations: NAG/BC035112 fusion|NAG/FAM49A fusion|neuroblastoma-amplified gene protein|neuroblastoma-amplified sequence,,NBAS,,,,,,,,,,,,,,,,,,,,,,,51594,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,NBAS,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/UBERON_0002371,bone marrow,,the soft tissue that fills the cavities of bones,false,,,http://purl.obolibrary.org/obo/UBERON_0000479,,,,,,,,,,,,,,,,,,,,,,the soft tissue that fills the cavities of bones,,,,,bone marrow,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,UBERON:0002371,,,,,,,,,,,,,,,,,,,,,,bone marrow,,,,,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100040,vitamin D,,,false,,,http://purl.obolibrary.org/obo/IMR_0000877,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100040,,,,,,,,,,,,,,,,,,,,,,vitamin D,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004891,"7,12-dimethyltetraphene [hepatocarcinogenesis]","7,12-dimethylbenzo[a]anthracene|DMBA|7,12-dimethylbenz(a)anthracene",A tetraphene having methyl substituents at the 7- and 12-positions. It is a potent carcinogen and is present in tobacco smoke.,false,,,http://purl.obolibrary.org/obo/TXPO_0004455|http://purl.obolibrary.org/obo/CHEBI_254496,,,,,,,,,,,,,,,,,,,,PMID:1596892|CAS:57-97-6,,A tetraphene having methyl substituents at the 7- and 12-positions. It is a potent carcinogen and is present in tobacco smoke.,,,,,,,,,,,,C20H16,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"7,12-dimethylbenzo[a]anthracene|DMBA|7,12-dimethylbenz(a)anthracene",,,,,TXPO:0004891,,,,,,,,,,,,,,,,,,,,,,"7,12-dimethyltetraphene [hepatocarcinogenesis]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Cc1c2ccccc2c(C)c2c1ccc1ccccc21,,,,,
http://purl.obolibrary.org/obo/TXPO_0004895,KRAS (mouse) [hepatocarcinogenesis],K-Ras|Ki-ras,,false,,,http://purl.obolibrary.org/obo/TXPO_0005072|http://purl.obolibrary.org/obo/IMR_0000291,,,,,,,,,,,,,,,,,,,,PMID:1596892|NCBI-Mouse-GeneID:16653,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,K-Ras|Ki-ras,,,,,TXPO:0004895,,,,,,,,,,,,,,,,,,,,,,KRAS (mouse) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004893,HRAS (mouse) [hepatocarcinogenesis],Ha-ras|c-H-ras|H-Ras,,false,,,http://purl.obolibrary.org/obo/IMR_0000695|http://purl.obolibrary.org/obo/TXPO_0005072,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:15461|PMID:1596892,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0011341,Ha-ras|c-H-ras|H-Ras,,,,,TXPO:0004893,,,,,,,,,,,,,,,,,,,,,,HRAS (mouse) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004894,KRAS (canonical) [hepatocarcinogenesis],K-Ras|Ki-ras,,false,,,http://purl.obolibrary.org/obo/IMR_0000291,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:3845|NCBI-Rat-GeneID:24525|PMID:21160980|NCBI-Mouse-GeneID:16653,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,K-Ras|Ki-ras,,,,,TXPO:0004894,,,,,,,,,,,,,,,,,,,,,,KRAS (canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004890,proto-oncogene mutation,,Proto-oncogene mutation is a subtype of changing an operand: A process that changes the nucleotide sequence of Tumor suppressor gene randomly and permanently.,false,,,http://purl.obolibrary.org/obo/TXPO_0001985,,,,,,,,,,,,,,,,,,,,,,Proto-oncogene mutation is a subtype of changing an operand: A process that changes the nucleotide sequence of Tumor suppressor gene randomly and permanently.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004890,,,,,,,,,,,,,,,,,,,,,,proto-oncogene mutation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004896,NRAS (mouse) [hepatocarcinogenesis],N-Ras|Transforming protein N-Ras,,false,,,http://purl.obolibrary.org/obo/IMR_0000696|http://purl.obolibrary.org/obo/TXPO_0005072,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:18176|PMID:1596892,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0011343,N-Ras|Transforming protein N-Ras,,,,,TXPO:0004896,,,,,,,,,,,,,,,,,,,,,,NRAS (mouse) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004892,4-(phenylazo)aniline [hepatocarcinogenesis],4-Aminoazobenzene|AAB|4-phenyldiazenylaniline|4-[(E)-phenyldiazenyl]aniline,,false,,,http://purl.obolibrary.org/obo/TXPO_0004455|http://purl.obolibrary.org/obo/CHEBI_233869,,,,,,,,,,,,,,,,,,,,PMID:1596892|CAS:60-09-3|Wikipedia:Aniline_Yellow,,,,,,,,,,,,,,C12H11N3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4-Aminoazobenzene|AAB|4-phenyldiazenylaniline|4-[(E)-phenyldiazenyl]aniline,,,,,TXPO:0004892,,,,,,,,,,,,,,,,,,,,,,4-(phenylazo)aniline [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,C1=CC=C(C=C1)N=NC2=CC=C(C=C2)N,,,,,
http://purl.obolibrary.org/obo/TXPO_0004898,cancer stem-like cell proliferation,,"Cancer-stem like cell proliferation is a subtype of cell proliferation: A process of the multiplication or reproduction of cancer-stem like cells, resulting in the rapid expansion of a cancer-stem like cell population.",false,,,http://purl.obolibrary.org/obo/GO_0008283,,,,,,,,,,,,,,,,,,,,,,"Cancer-stem like cell proliferation is a subtype of cell proliferation: A process of the multiplication or reproduction of cancer-stem like cells, resulting in the rapid expansion of a cancer-stem like cell population.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004898,,,,,,,,,,,,,,,,,,,,,,cancer stem-like cell proliferation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004899,Cancer-stem like cell proliferation [hepatocarcinogenesis],,"Cancer-stem like cell proliferation is a subtype of cell proliferation: A process of the multiplication or reproduction of cancer-stem like cells, resulting in the rapid expansion of a cancer-stem like cell population.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0004898|http://purl.obolibrary.org/obo/TXPO_0002340,,,,,,,,,,,,,,,,,,,,PMID:31781608|PMID:28584306,,"Cancer-stem like cell proliferation is a subtype of cell proliferation: A process of the multiplication or reproduction of cancer-stem like cells, resulting in the rapid expansion of a cancer-stem like cell population.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004557,,,,,,,,,,,TXPO:0004899,,,,,,,,,,,,,,,,,,,,,,Cancer-stem like cell proliferation [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004897,positive regulation of cancer stem cell division,,"Any process that activates or increases the frequency, rate or extent of cancer stem cell division.",false,,,http://purl.obolibrary.org/obo/GO_0051781,,,,,,,,,,,,,,,,,,,,,,"Any process that activates or increases the frequency, rate or extent of cancer stem cell division.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004897,,,,,,,,,,,,,,,,,,,,,,positive regulation of cancer stem cell division,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100811,CKI-gamma 1,"Casein kinase I, gamma 1 isoform",,false,,,http://purl.obolibrary.org/obo/IMR_0100809,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Casein kinase I, gamma 1 isoform",,,,,IMR:0100811,,,,,,,,,,,,,,,,,,,,,,CKI-gamma 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_4315,danazol,"Danocrine|Cyclomen|danazolum|danazol|[1,2]oxazolo[4',5':2,3]-17alpha-pregn-4-en-20-yn-17-ol",,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:17929794|Beilstein:4851114|PMID:18834112|CAS:17230-88-5|Drug_Central:779|DrugBank:DB01406,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_50751|http://purl.obolibrary.org/obo/CHEBI_50837,,,,,"[1,2]oxazolo[4',5':2,3]-17alpha-pregn-4-en-20-yn-17-ol",,Danocrine|Cyclomen|danazolum|danazol,,,,,,,,,,,,,,,,,,,,,CHEBI:4315,,,,danazol,,CHEBI:4315,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_4317,dantrolene,"1-((5-(p-nitrophenyl)furfurylidene)amino)hydantoin|dantroleno|dantrolenum|dantrolene|Dantrolene|1-({[5-(4-nitrophenyl)furan-2-yl]methylidene}amino)imidazolidine-2,4-dione",The hydrazone resulting from the formal condensation of 5-(4-nitrophenyl)furfural with 1-aminohydantoin.,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Beilstein:705189|CAS:7261-97-4|DrugBank:DB01219|LINCS:LSM-3823,,The hydrazone resulting from the formal condensation of 5-(4-nitrophenyl)furfural with 1-aminohydantoin.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_51371,,,,,"Dantrolene|1-({[5-(4-nitrophenyl)furan-2-yl]methylidene}amino)imidazolidine-2,4-dione",,1-((5-(p-nitrophenyl)furfurylidene)amino)hydantoin|dantroleno|dantrolenum|dantrolene,,,,,,,,,,,,,,,,,,,,,CHEBI:4317,,,,dantrolene,,CHEBI:4317,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001363,Gli1,,,false,,,http://purl.obolibrary.org/obo/IMR_0001372,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001363,,,,,,,,,,,,,,,,,,,,,,Gli1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CL_0000542,lymphocyte,,"A lymphocyte is a leukocyte commonly found in the blood and lymph that has the characteristics of a large nucleus, a neutral staining cytoplasm, and prominent heterochromatin.",false,,,http://purl.obolibrary.org/obo/CL_0000842,,,,,,,,,,,,,,,,,,,,,,"A lymphocyte is a leukocyte commonly found in the blood and lymph that has the characteristics of a large nucleus, a neutral staining cytoplasm, and prominent heterochromatin.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CL:0000542,,,,,,,,,,,,,,,,,,,,,,lymphocyte,,,,,,,http://purl.obolibrary.org/obo/cl.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_1905517,macrophage migration,,The orderly movement of a macrophage from one site to another.,false,,,http://purl.obolibrary.org/obo/GO_0050900,,,,,,,,,,,,,,,,,,,,,,The orderly movement of a macrophage from one site to another.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:1905517,,,,,,,,,,,,,,,,,,,,,,macrophage migration,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_28834,deoxycholic acid,,A bile acid that is 5β-cholan-24-oic acid substituted by hydroxy groups at positions 3 and 12 respectively.,false,,,http://purl.obolibrary.org/obo/TXPO_0000509,,,,,,,,,,,,,,,,,,,,InChIKey:KXGVEGMKQFWNSR-LLQZFEROSA-N,,A bile acid that is 5β-cholan-24-oic acid substituted by hydroxy groups at positions 3 and 12 respectively.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:28834,,,,,,,,,,,,,,,,,,,,,,deoxycholic acid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001024,"Retinal cone rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase gamma-subunit",GMP-PDE gamma,,false,,,http://purl.obolibrary.org/obo/IMR_0100002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GMP-PDE gamma,,,,,IMR:0001024,,,,,,,,,,,,,,,,,,,,,,"Retinal cone rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase gamma-subunit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76848,EC 1.17.4.* (oxidoreductase acting on CH or CH2 with a disulfide as acceptor) inhibitor,oxidoreductase acting on CH or CH2 with a disulfide as acceptor (EC 1.17.4.*) inhibitors|EC 1.17.4.* inhibitor|EC 1.17.4.* (oxidoreductase acting on CH or CH2 with a disulfide as acceptor) inhibitors|EC 1.17.4.* inhibitors|oxidoreductase acting on CH or CH2 with a disulfide as acceptor (EC 1.17.4.*) inhibitor,An EC 1.17.* (oxidoreductase acting on CH or CH2) inhibitor that interferes with the activity of any such enzyme that uses a disulfide as acceptor (EC 1.17.4.*).,false,,,http://purl.obolibrary.org/obo/CHEBI_76744,,,,,,,,,,,,,,,,,,,,,,An EC 1.17.* (oxidoreductase acting on CH or CH2) inhibitor that interferes with the activity of any such enzyme that uses a disulfide as acceptor (EC 1.17.4.*).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,oxidoreductase acting on CH or CH2 with a disulfide as acceptor (EC 1.17.4.*) inhibitors|EC 1.17.4.* inhibitor|EC 1.17.4.* (oxidoreductase acting on CH or CH2 with a disulfide as acceptor) inhibitors|EC 1.17.4.* inhibitors|oxidoreductase acting on CH or CH2 with a disulfide as acceptor (EC 1.17.4.*) inhibitor,,,,,,,,,,,,,,,,,,,,,CHEBI:76848,,,,EC 1.17.4.* (oxidoreductase acting on CH or CH2 with a disulfide as acceptor) inhibitor,,CHEBI:76848,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0002778,AMPK gamma subunit,,,false,,,http://purl.obolibrary.org/obo/TXPO_0003221,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003722,,,,,,,,,,IMR:0002778,,,,,,,,,,,,,,,,,,,,,,AMPK gamma subunit,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_10100,zafirlukast,zafirlukast|4-(5-cyclopentyloxycarbonylamino-1-methyl-1H-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide|Accolate|cyclopentyl 3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methylindole-5-carbamate|cyclopentyl 3-[2-methoxy-4-(2-methylphenylsulfonylcarbamoyl)benzyl]-1-methyl-1H-indol-5-ylcarbamate,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:24258705|PMID:11888331|Reaxys:3641829|PMID:25798389|LINCS:LSM-5792|PMID:25834030|Beilstein:3641829|Drug_Central:2855|PMID:22159431|PMID:22614107|CAS:107753-78-6|PMID:19331987|DrugBank:DB00549,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_65023|http://purl.obolibrary.org/obo/CHEBI_49159,,,,,cyclopentyl 3-[2-methoxy-4-(2-methylphenylsulfonylcarbamoyl)benzyl]-1-methyl-1H-indol-5-ylcarbamate,,zafirlukast|4-(5-cyclopentyloxycarbonylamino-1-methyl-1H-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide|Accolate|cyclopentyl 3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methylindole-5-carbamate,,,,,,,,,,,,,,,,,,,,,CHEBI:10100,,,,zafirlukast,,CHEBI:10100,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003903,smooth endoplasmic reticulum proliferation in hepatocyte [Ground glass appearance - Cyp - PB],,"Smooth endoplasmic reticulum proliferation in hepatocyte is a subtype of endoplasmic reticulum proliferation in hepatocyte: A process that becomes larger in the number of smooth endoplasmic reticulum in hepatocyte(s).
This process is dependent on the phenobarbital induced CYP activation and can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0003901|http://purl.obolibrary.org/obo/TXPO_0001230,,,,,,,,,,,,,,,,,,,,,,"Smooth endoplasmic reticulum proliferation in hepatocyte is a subtype of endoplasmic reticulum proliferation in hepatocyte: A process that becomes larger in the number of smooth endoplasmic reticulum in hepatocyte(s).
This process is dependent on the phenobarbital induced CYP activation and can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003953,,,,,,,,,,,,,,,,,,TXPO:0003903,,,,,,,,,,,,,,,,,,,,,,smooth endoplasmic reticulum proliferation in hepatocyte [Ground glass appearance - Cyp - PB],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003904,clonal expansion of preneoplastic cell [Ground glass appearance],,"Clonal expansion of preneoplastic cell is a subtype of clonal expansion: A process that becomes larger in the number of preneoplastic cells by cell division of a population of identical cells descended from a single progenitor.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/TXPO_0003867,,,,,,,,,,,,,,,,,,,,,,"Clonal expansion of preneoplastic cell is a subtype of clonal expansion: A process that becomes larger in the number of preneoplastic cells by cell division of a population of identical cells descended from a single progenitor.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002319,,,,,,,,,,,TXPO:0003904,,,,,,,Inhibition of apoptosis by phenobarbital promotes clonal expansion of preneoplastic cells.,,,,,,,,,,,,,,,clonal expansion of preneoplastic cell [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003901,smooth endoplasmic reticulum proliferation in hepatocyte [Ground glass appearance - Cyp],,"Smooth endoplasmic reticulum proliferation in hepatocyte is a subtype of endoplasmic reticulum proliferation in hepatocyte: A process that becomes larger in the number of smooth endoplasmic reticulum in hepatocyte(s).
This process is dependent on the Cyp activation and can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0000963|http://purl.obolibrary.org/obo/TXPO_0001230,,,,,,,,,,,,,,,,,,,,,,"Smooth endoplasmic reticulum proliferation in hepatocyte is a subtype of endoplasmic reticulum proliferation in hepatocyte: A process that becomes larger in the number of smooth endoplasmic reticulum in hepatocyte(s).
This process is dependent on the Cyp activation and can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003901,,,,,,,,,,,,,,,,,,,,,,smooth endoplasmic reticulum proliferation in hepatocyte [Ground glass appearance - Cyp],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003907,Cyp2b10 (mouse)[Ground glass appearance],,species:mice,false,,,http://purl.obolibrary.org/obo/TXPO_0001071|http://purl.obolibrary.org/obo/TXPO_1000102,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:13088|PMID:28546505|PMID:16684649,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003907,,,,,,,,,,,,,,,,,,,,species:mice,,Cyp2b10 (mouse)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003909,CYP3A4 (human)[Ground glass appearance],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001009|http://purl.obolibrary.org/obo/TXPO_1000082,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1576|ISBN:0071769234,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003909,,,,,,,,,,,,,,,,,,,,,,CYP3A4 (human)[Ground glass appearance],,,,,,,,,,,,http://purl.obolibrary.org/obo/NCBITaxon_9606,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003905,negative regulation of epidermal growth factor receptor signaling pathway [Ground glass appearance],,"Any process that stops, prevents, or reduces the frequency, rate or extent of epidermal growth factor receptor signaling pathway activity.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/GO_0042059,,,,,,,,,,,,,,,,,,,,PMID:28265001|PMID:23652203,,"Any process that stops, prevents, or reduces the frequency, rate or extent of epidermal growth factor receptor signaling pathway activity.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003906,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003912,,,,http://purl.obolibrary.org/obo/TXPO_0003913,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003918,,,,,,,,,,,TXPO:0003905,,,,,,,,,,,,,,,,,,,,,,negative regulation of epidermal growth factor receptor signaling pathway [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003902,hyperfunction of drug metabolism phase II  [Ground glass appearance - Cyp],,"Hyperfunction of drug metabolism phase II is a subtype of hyperfunction of drug metabolism: A process that performs an excessive drug metabolism phase II.
This process is dependent on the CYP activation and can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0000943,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of drug metabolism phase II is a subtype of hyperfunction of drug metabolism: A process that performs an excessive drug metabolism phase II.
This process is dependent on the CYP activation and can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003902,,,,,,,,,,,,,,,,,,,,,,hyperfunction of drug metabolism phase II  [Ground glass appearance - Cyp],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003900,DAB2(human)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001135|http://purl.obolibrary.org/obo/TXPO_0003841,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1601|PMID:25331956|PMID:23781020|PMID:11387212|PMID:27398911,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001601,,,,,,,,,,,,,TXPO:0003900,,,,,,,PMID:19000037,,,,,,,,,,,,,,,DAB2(human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003908,Cyp3a11 (mouse)[Ground glass appearance],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001071|http://purl.obolibrary.org/obo/TXPO_1000106,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:13112|ISBN:0071769234,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003908,,,,,,,,,,,,,,,,,,,,,,Cyp3a11 (mouse)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003906,phenobarbital -EGFR signalling inhibitor [Ground glass appearance],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001524,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003911,,,,,,,,,,TXPO:0003906,,,,,,,,,,,,,,,,,,,,,,phenobarbital -EGFR signalling inhibitor [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000589,IL-10 (mol),interleukin-10,,false,,,http://purl.obolibrary.org/obo/IMR_0000007,,,,,,,,,,,,,,,,,,,,GO:0005141,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000622,,,,,interleukin-10,,,,,IMR:0000589,,,,,,,,,,,,,,,,,,,,,,IL-10 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000061,TNFR2,"tumor necrosis factor receptor, type II",,false,,,http://purl.obolibrary.org/obo/IMR_0100674,,,,,,,,,,,,,,,,,,,,GO:0005033,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"tumor necrosis factor receptor, type II",,,,,IMR:0000061,,,,,,,,,,,,,,,,,,,,,,TNFR2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_53756,HIV-1 reverse transcriptase inhibitor,reverse transcriptase inhibitor|reverse transcriptase inhibitors|HIV-1 reverse transcriptase inhibitors,An entity which inhibits the activity of HIV-1 reverse transcriptase.,false,,,http://purl.obolibrary.org/obo/CHEBI_64947|http://purl.obolibrary.org/obo/CHEBI_52629,,,,,,,,,,,,,,,,,,,,,,An entity which inhibits the activity of HIV-1 reverse transcriptase.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,reverse transcriptase inhibitor|reverse transcriptase inhibitors|HIV-1 reverse transcriptase inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:53756,,,,HIV-1 reverse transcriptase inhibitor,,CHEBI:53756,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100271,MAPKAPK,MAP kinase-regulated protein kinase|MAP kinase-activated protein kinase|MAPK-activated protein kinase,"Four groups of kinases have been shown to be activated by MAP kinases, ribosomal S6 kinase (RSK also known as MAPKAPK1), MAP kinase-activated protein kinase 2/3 (MAPKAPK2/3), MAP kinase-interacting kinase or MAP kinase signal-integrating kinase (MNK) and MAPKAPK5 (PRAK).",false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,"Four groups of kinases have been shown to be activated by MAP kinases, ribosomal S6 kinase (RSK also known as MAPKAPK1), MAP kinase-activated protein kinase 2/3 (MAPKAPK2/3), MAP kinase-interacting kinase or MAP kinase signal-integrating kinase (MNK) and MAPKAPK5 (PRAK).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001966,,,,,MAP kinase-regulated protein kinase|MAP kinase-activated protein kinase|MAPK-activated protein kinase,,,,,IMR:0100271,,,,,,,,,,,,,,,,,,,,,,MAPKAPK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0002691,IGFBP-3,,,false,,,http://purl.obolibrary.org/obo/IMR_0002688,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0002691,,,,,,,,,,,,,,,,,,,,,,IGFBP-3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_474180,caspofungin,"(4R,5S)-5-((2-aminoethyl)amino)-N(2)-(10,12-dimethyltetradecanoyl)-4-hydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(p-hydroxyphenyl)-L-threonyl-threo-3-hydroxy-L-ornithyl-trans-3-hydroxy-L-proline cyclic (6-1)-peptide|1-[(4R,5S)-5-[(2-aminoethyl)amino]-N(2)-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]-pneumocandin B0|caspofungin|Caspofungin|(10R,12S)-N-{(2R,6S,9S,11R,12S,14aS,15S,20S,23S,25aS)-12-[(2-aminoethyl)amino]-20-[(1R)-3-amino-1-hydroxypropyl]-23-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-2,11,15-trihydroxy-6-[(1R)-1-hydroxyethyl]-5,8,14,19,22,25-hexaoxotetracosahydro-1H-dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacyclohenicosin-9-yl}-10,12-dimethyltetradecanamide","A semisynthetic cyclic hexapeptide echinocandin antibiotic which exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Beilstein:8471798|PMID:24270605|CAS:162808-62-0|DrugBank:DB00520|Drug_Central:2977,,"A semisynthetic cyclic hexapeptide echinocandin antibiotic which exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35441,,,,,"Caspofungin|(10R,12S)-N-{(2R,6S,9S,11R,12S,14aS,15S,20S,23S,25aS)-12-[(2-aminoethyl)amino]-20-[(1R)-3-amino-1-hydroxypropyl]-23-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-2,11,15-trihydroxy-6-[(1R)-1-hydroxyethyl]-5,8,14,19,22,25-hexaoxotetracosahydro-1H-dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacyclohenicosin-9-yl}-10,12-dimethyltetradecanamide",,"(4R,5S)-5-((2-aminoethyl)amino)-N(2)-(10,12-dimethyltetradecanoyl)-4-hydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(p-hydroxyphenyl)-L-threonyl-threo-3-hydroxy-L-ornithyl-trans-3-hydroxy-L-proline cyclic (6-1)-peptide|1-[(4R,5S)-5-[(2-aminoethyl)amino]-N(2)-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]-pneumocandin B0|caspofungin",,,,,,,,,,,,,,,,,,,,,CHEBI:474180,,,,caspofungin,,CHEBI:474180,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002897,CALRETICULIN (canonical)[ER stress],CALR [ER stress],,false,,,http://purl.obolibrary.org/obo/TXPO_0000871|http://purl.obolibrary.org/obo/TXPO_1000435,,,,,,,,,,,,,,,,,,,,PMID:8107808,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003997,,,,,CALR [ER stress],,,,,TXPO:0002897,,,,,,,,,,,,,,,,,,,,,,CALRETICULIN (canonical)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000413,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002899,ATF6 - transcriptional factor (canonical)[ER stress - Refolding],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002468,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000825,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,,,,,,TXPO:0002899,,,,,,,,,,,,,,,,,,,,,,ATF6 - transcriptional factor (canonical)[ER stress - Refolding],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002175,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002892,IRE1 - signaling factor (canonical)[ER stress -ERAD],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002603,http://purl.obolibrary.org/obo/TXPO_0002709,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UniProt_Q9NZJ5|http://www.uniprot.org/entry/Q9NZJ5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001898,,,,,,,,,,TXPO:0002892,,,,,,,,,,,,,,,,,,,,,,IRE1 - signaling factor (canonical)[ER stress -ERAD],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002893,IRE1 - signaling factor (canonical)[ER stress - inflammation -Xbp1],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002891,http://purl.obolibrary.org/obo/TXPO_0002831,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UniProt_Q9NZJ5|http://www.uniprot.org/entry/Q9NZJ5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001898,,,,,,,,,,TXPO:0002893,,,,,,,,,,,,,,,,,,,,,,IRE1 - signaling factor (canonical)[ER stress - inflammation -Xbp1],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002895,receiving abnormal protein signal by IRE1 [ER stress - inflammation - IRE1-XBP1 pathway],,"Receiving abnormal protein signal by IRE1 is a subtype of receiving signal: A process that recognizes another object and changes into an abnormal protein (e.g., misfolded protein, etc.) signal by IRE1.
This process is dependent on the IRE1-XBP1 pathway mediated inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002887,,,,,,,,,,,,,,,,,,,,,,"Receiving abnormal protein signal by IRE1 is a subtype of receiving signal: A process that recognizes another object and changes into an abnormal protein (e.g., misfolded protein, etc.) signal by IRE1.
This process is dependent on the IRE1-XBP1 pathway mediated inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002890,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002831,,,,,,,,,,,TXPO:0002895,,,,,,,,,,,,,,,,,,,,,,receiving abnormal protein signal by IRE1 [ER stress - inflammation - IRE1-XBP1 pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002898,CALRETICULIN - chaperone (canonical)[ER stress -Refolding [persist]],CALR  - chaperone [ER stress -Refolding [persist]],,false,,,http://purl.obolibrary.org/obo/TXPO_0002897,,,,,,,,,,,,,,,,,,,,PMID:27698029|http://omim.org/entry/109091|PMID:8107808|http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene&cmd=Retrieve&dopt=full_report&list_uids=811,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003997,,,,,CALR  - chaperone [ER stress -Refolding [persist]],,,,,TXPO:0002898,,,,,,,,,,,,,,,,,,,,,,CALRETICULIN - chaperone (canonical)[ER stress -Refolding [persist]],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002393,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002891,IRE1 - signaling factor (canonical)[ER stress - inflammation],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002603,http://purl.obolibrary.org/obo/TXPO_0002594,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UniProt_Q9NZJ5|http://www.uniprot.org/entry/Q9NZJ5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001898,,,,,,,,,,TXPO:0002891,,,,,,,,,,,,,,,,,,,,,,IRE1 - signaling factor (canonical)[ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002894,IRE1 - signaling factor (canonical)[ER stress - inflammation -TRAF2],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002891,http://purl.obolibrary.org/obo/TXPO_0002594,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UniProt_Q9NZJ5|http://www.uniprot.org/entry/Q9NZJ5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001898,,,,,,,,,,TXPO:0002894,,,,,,,,,,,,,,,,,,,,,,IRE1 - signaling factor (canonical)[ER stress - inflammation -TRAF2],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002896,P-EIF2A - translation initiation inhibitor (canonical)[ER stress - inflammation],phosphorylated eIF2A - translation initiation inhibitor [ER stress - inflammation],,false,,,http://purl.obolibrary.org/obo/TXPO_0000829,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001909,,,,,phosphorylated eIF2A - translation initiation inhibitor [ER stress - inflammation],,,,,TXPO:0002896,,,,,,,,,,,,,,,,,,,,,,P-EIF2A - translation initiation inhibitor (canonical)[ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002890,IRE1 - signal sensor (canonical)[ER stress - inflammation],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002602,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UniProt_Q9NZJ5|http://www.uniprot.org/entry/Q9NZJ5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000882,,,,,,,,,,TXPO:0002890,,,,,,,,,,,,,,,,,,,,,,IRE1 - signal sensor (canonical)[ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002887,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000047,Bip- stress sensor complex (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:3309|NCBI-Mouse-GeneID:14828|NCBI-Rat-GeneID:25617,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000003309,,,,,,,,,,,,,TXPO:1000047,,,,,,,,,,,,,,,,,,,,,,Bip- stress sensor complex (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000040,BAK1 (mol),,,false,,,http://purl.obolibrary.org/obo/IMR_0000452,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:578|NCBI-Mouse-GeneID:12018|NCBI-Rat-GeneID:116502,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000578,,,,,,,,,,,,,TXPO:1000040,,,,,,,,,,,,,,,,,,,,,,BAK1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000044,Bcl3 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:680611|NCBI-Mouse-GeneID:12051|NCBI-Human-GeneID:602,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000602,,,,,,,,,,,,,TXPO:1000044,,,,,,,,,,,,,,,,,,,,,,Bcl3 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000046,Bhmt (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:81508|NCBI-Human-GeneID:635|NCBI-Mouse-GeneID:12116,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000635,,,,,,,,,,,,,TXPO:1000046,,,,,,,,,,,,,,,,,,,,,,Bhmt (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000045,Bhlha15 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:25334|NCBI-Mouse-GeneID:17341|NCBI-Human-GeneID:168620,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000168620,,,,,,,,,,,,,TXPO:1000045,,,,,,,,,,,,,,,,,,,,,,Bhlha15 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000041,BCL2 (mol),,,false,,,http://purl.obolibrary.org/obo/IMR_0100706,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24224|NCBI-Mouse-GeneID:12043|NCBI-Human-GeneID:596,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000596,,,,,,,,,,,,,TXPO:1000041,,,,,,,,,,,,,,,,,,,,,,BCL2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000043,Bbs9 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:315484|NCBI-Mouse-GeneID:319845|NCBI-Human-GeneID:27241,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000027241,,,,,,,,,,,,,TXPO:1000043,,,,,,,,,,,,,,,,,,,,,,Bbs9 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000048,Brd2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:6046|NCBI-Rat-GeneID:294276|NCBI-Mouse-GeneID:14312,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000006046,,,,,,,,,,,,,TXPO:1000048,,,,,,,,,,,,,,,,,,,,,,Brd2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/NCIT_C18078,carcinogenesis,Carcinogenesis,A pathological process in which normal cells are transformed into malignant cancer cells within a primary tumor.,false,,,http://purl.obolibrary.org/obo/TXPO_0002703,,,,,,,,,,,,,,,,,,,,ncit:C18078|http://purl.obolibrary.org/obo/NCIT_C18078,,A pathological process in which normal cells are transformed into malignant cancer cells within a primary tumor.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Carcinogenesis,,,,,NCIT:C18078,,,,,,,,,,,,,,,,,,,,,,carcinogenesis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100197,lipotropin,LPH,"Lipotropic or pituitary lipotropic hormone. A pituitary hormone mobilizing fat from adipose tissue. Beta-lipotropin is a single-chain peptide of about 90 residues that contains the sequences of endorphins and metenkephalin, and may be a precursor of beta-melanotropin and beta-endorphin. Gamma-lipotropin is shorter and is identical in sequence to the first 58 residues of beta-lipotropin. Both contain sequences common to ACTH and beta-melanotropin.",false,,,http://purl.obolibrary.org/obo/IMR_0100096,,,,,,,,,,,,,,,,,,,,MeSH:D008083,,"Lipotropic or pituitary lipotropic hormone. A pituitary hormone mobilizing fat from adipose tissue. Beta-lipotropin is a single-chain peptide of about 90 residues that contains the sequences of endorphins and metenkephalin, and may be a precursor of beta-melanotropin and beta-endorphin. Gamma-lipotropin is shorter and is identical in sequence to the first 58 residues of beta-lipotropin. Both contain sequences common to ACTH and beta-melanotropin.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,LPH,,,,,IMR:0100197,,,,,,,,,,,,,,,,,,,,,,lipotropin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004456,Increasing CCND1 level,,Increasing CCND1 level is a subtype of increasing quantity: A process that changes the amount of CCND1 level to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing CCND1 level is a subtype of increasing quantity: A process that changes the amount of CCND1 level to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_1000088,,,,,,,,,,,,,,,,,,,TXPO:0004456,,,,,,,,,,,,,,,,,,,,,,Increasing CCND1 level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004459,positive regulation of cell cycle [hepatocarcinogenesis],,"Any process that activates or increases the rate or extent of progression through the cell cycle.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/GO_0045787|http://purl.obolibrary.org/obo/TXPO_0002340,,,,,,,,,,,,,,,,,,,,PMID:20101231|PMID:31239782|PMID:30309512|PMID:28060737,,"Any process that activates or increases the rate or extent of progression through the cell cycle.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004403,,,,,,,,,,,TXPO:0004459,,,,,,,,,,,,,,,,,,,,,,positive regulation of cell cycle [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0007049,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004450,CAR - activation state (mouse) [hepatocarcinogenesis],Constitutive Androstane Receptor|NR1I3,,false,,,http://purl.obolibrary.org/obo/TXPO_0005071,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:12355|PMID:23626729,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0002354,,,,,,,,,Constitutive Androstane Receptor|NR1I3,,,,,TXPO:0004450,,,,,,,,,,,,,,,,,,,,,,CAR - activation state (mouse) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004451,CCL2 signaling (primitive),,CCL2 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by CCL2.,false,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,,,CCL2 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by CCL2.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_1000086,http://purl.obolibrary.org/obo/GO_0038151,,,,,,,,,,,,,,,,TXPO:0004451,,,,,,,,,,,,,,,,,,,,,,CCL2 signaling (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004454,CCL4 [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004455|http://purl.obolibrary.org/obo/CHEBI_27385,,,,,,,,,,,,,,,,,,,,PMID:15511635,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003572|http://purl.obolibrary.org/obo/TXPO_0002250|http://purl.obolibrary.org/obo/TXPO_0004314,,,,,,,,,,TXPO:0004454,,,,,,,,,,,,,,,,,,,,,,CCL4 [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004452,CCL2 signaling (primitive) [hepatocarcinogenesis],,"CCL2 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by CCL2.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0004451|http://purl.obolibrary.org/obo/TXPO_0002340,,,,,,,,,,,,,,,,,,,,PMID:30894684,,"CCL2 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by CCL2.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004289,http://purl.obolibrary.org/obo/TXPO_0004291,http://purl.obolibrary.org/obo/GO_0038151,,,,,http://purl.obolibrary.org/obo/TXPO_0004453|http://purl.obolibrary.org/obo/TXPO_0004276,,,,,,,,,,,TXPO:0004452,,,,,,,,,,,,,,,,,,,,,,CCL2 signaling (primitive) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004458,CCND1 (human) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_1000088,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:595|PMID:31239782,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000595,,,,,,,,,,,,,TXPO:0004458,,,,,,,,,,,,,,,,,,,,,,CCND1 (human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004455,hepatocarcinogenesis dependent chemical compound,,"Hepatocarcinogenesis dependent chemical compound is a subtype of toxic course dependent chemical entity.
This entity (drug) can participate in the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000199,,,,,,,,,,,,,,,,,,,,,,"Hepatocarcinogenesis dependent chemical compound is a subtype of toxic course dependent chemical entity.
This entity (drug) can participate in the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004455,,,,,,,,,,,,,,,,,,,,,,hepatocarcinogenesis dependent chemical compound,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004453,hepatic cirrhosis [hepatocarcinogenesis],,"Hepatic cirrhosis is a subtype of changing hardness: A process that changes the hardness of the liver to become hard due to the replacement of normal liver tissue to scar tissue.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002202|http://purl.obolibrary.org/obo/TXPO_0002340,,,,,,,,,,,,,,,,,,,,PMID:31439937|PMID:26017875|PMID:15511635,,"Hepatic cirrhosis is a subtype of changing hardness: A process that changes the hardness of the liver to become hard due to the replacement of normal liver tissue to scar tissue.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004454,,,,,,http://purl.obolibrary.org/obo/TXPO_0004542|http://purl.obolibrary.org/obo/TXPO_0004392,,,,,,,,,,,TXPO:0004453,,,,,,,,,,,,,,,,,,,,,,hepatic cirrhosis [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004457,Increasing CCND1 level [hepatocarcinogenesis],,"Increasing CCND1 level is a subtype of increasing quantity: A process that changes the amount of CCND1 level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0004456|http://purl.obolibrary.org/obo/TXPO_0002340,,,,,,,,,,,,,,,,,,,,PMID:31239782,,"Increasing CCND1 level is a subtype of increasing quantity: A process that changes the amount of CCND1 level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004458,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004459,,,,,,,,,,,TXPO:0004457,,,,,,,,,,,,,,,,,,,,,,Increasing CCND1 level [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000007392,USF2,,Other designations: FOS-interacting protein|c-fos interacting protein|class B basic helix-loop-helix protein 12|major late transcription factor 2|upstream stimulatory factor 2,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,FIP|bHLHb12,,,,,,,,,,,,19,,,,,,Vega:OTTHUMG00000183182|Ensembl:ENSG00000105698|HGNC:12594|HPRD:02668|MIM:600390,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"upstream transcription factor 2, c-fos interacting",,,19q13,,,,,,,,,,,,,,,,"GO_0000430 (EC: IC, PMID: 8576131); GO_0000432 (EC: IMP, PMID: 7852331); GO_0000432 (EC: ISS); GO_0000978 (EC: IEA); GO_0003690 (EC: IEA); GO_0003700 (EC: IEA); GO_0003705 (EC: IMP, PMID: 8576131); GO_0005515 (EC: IPI, PMID: 19505873); GO_0005634 (EC: IDA); GO_0005730 (EC: IDA, Qualifier: NOT); GO_0006351 (EC: IEA); GO_0006366 (EC: IMP, PMID: 8576131); GO_0007595 (EC: IEA); GO_0019086 (EC: IC, PMID: 8576131); GO_0042803 (EC: IPI, PMID: 8576131); GO_0043425 (EC: IPI, PMID: 8576131); GO_0043565 (EC: IDA, PMID: 8576131); GO_0045944 (EC: IMP, PMID: 8576131); GO_0046982 (EC: IPI, PMID: 8576131); GO_0055088 (EC: ISS)",,,,,,,,,PMID: 1450663; 1589769; 7852331; 8576131; 8619474; 8954795; 9053857; 9070273; 9099698; 9108421; 9110174; 10434034; 11058604; 11583024; 11945176; 11948912; 12477932; 12611894; 12663044; 12791656; 12857727; 12917334; 12970752; 14502648; 15014447; 15042619; 15057824; 15187018; 15242350; 15276216; 15358760; 15489334; 15741164; 15767439; 15864740; 16199862; 16386222; 16870626; 16943425; 17081983; 17353931; 17379962; 17823260; 17846119; 18165439; 18167349; 18817855; 18845576; 18970934; 19074828; 19087304; 19089909; 19505873; 19730683; 19846536; 20180799; 20626032; 20814220; 20936779; 21139048; 21653943; 21813151; 21890473; 21921026; 22891280; 22966206; 23560079,,,,,,,,,,,,,,,OGG:3000007392,,,,,,,"upstream transcription factor 2, c-fos interacting",,,,,,,,,,,,,Other designations: FOS-interacting protein|c-fos interacting protein|class B basic helix-loop-helix protein 12|major late transcription factor 2|upstream stimulatory factor 2,,USF2,,,,,,,,,,,,,,,,,,,,,,,7392,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,USF2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_49668,gefitinib,N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine|ZD 1839|Irressat|gefitinib|ZD-1839|4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline|gefitinibum|Iressa|ZD1839|N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine,"A member of the class of quinazolines that is quinazoline which is substituted by a (3-chloro-4-fluorophenyl)nitrilo group, 3-(morpholin-4-yl)propoxy group and a methoxy group at positions 4,6 and 7, respectively. An EGFR kinase inhibitor used for the treatment of non-small cell lung cancer.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:29332330|PMID:20573926|PMID:29668619|CAS:184475-35-2|LINCS:LSM-1098|DrugBank:DB00317|PMID:15068398|PMID:27396387|Reaxys:8949523|PMID:28968167|PMID:30069771|PMID:30214852|PMID:14981586|PMID:30068310|Drug_Central:1282|PMID:29493460|PMID:29579334|PMID:20949670,,"A member of the class of quinazolines that is quinazoline which is substituted by a (3-chloro-4-fluorophenyl)nitrilo group, 3-(morpholin-4-yl)propoxy group and a methoxy group at positions 4,6 and 7, respectively. An EGFR kinase inhibitor used for the treatment of non-small cell lung cancer.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35610|http://purl.obolibrary.org/obo/CHEBI_74440,,,,,N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine,,N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine|ZD 1839|Irressat|gefitinib|ZD-1839|4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline|gefitinibum|Iressa|ZD1839,,,,,,,,,,,,,,,,,,,,,CHEBI:49668,,,,gefitinib,,CHEBI:49668,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010548,40S ribosomal protein S23,40S small ribosomal protein 23,,false,,,http://purl.obolibrary.org/obo/IMR_0000896,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,40S small ribosomal protein 23,,,,,IMR:0010548,,,,,,,,,,,,,,,,,,,,,,40S ribosomal protein S23,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100048,cholecystokinin,CCK,"A peptide, of about 33 amino acids, secreted by the upper INTESTINAL MUCOSA and also found in the central nervous system. It causes gallbladder contraction, release of pancreatic exocrine (or digestive) enzymes, and affects other gastrointestinal functions. Cholecystokinin may be the mediator of satiety.",false,,,http://purl.obolibrary.org/obo/IMR_0100072,,,,,,,,,,,,,,,,,,,,MeSH:D002766,,"A peptide, of about 33 amino acids, secreted by the upper INTESTINAL MUCOSA and also found in the central nervous system. It causes gallbladder contraction, release of pancreatic exocrine (or digestive) enzymes, and affects other gastrointestinal functions. Cholecystokinin may be the mediator of satiety.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CCK,,,,,IMR:0100048,,,,,,,,,,,,,,,,,,,,,,cholecystokinin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000094241,TP53INP1,,Other designations: p53-dependent damage-inducible nuclear protein 1|p53-inducible p53DINP1|stress-induced protein|tumor protein p53-inducible nuclear protein 1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,TP53DINP1|TP53INP1A|p53DINP1|Teap|TP53INP1B|SIP,,,,,,,,,,,,8,,,,,,MIM:606185|Ensembl:ENSG00000164938|HGNC:18022|Vega:OTTHUMG00000164697|HPRD:09367,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,tumor protein p53 inducible nuclear protein 1,,,8q22,,,,,,,,,,,,,,,,GO_0005515 (EC: IPI); GO_0005634 (EC: IDA); GO_0005776 (EC: IDA); GO_0005829 (EC: IDA); GO_0006351 (EC: IEA); GO_0006914 (EC: IEA); GO_0006915 (EC: IEA); GO_0006950 (EC: TAS); GO_0007050 (EC: TAS); GO_0008285 (EC: ISS); GO_0009408 (EC: IEA); GO_0010508 (EC: IMP); GO_0016209 (EC: ISS); GO_0016605 (EC: IEA); GO_0030336 (EC: ISS); GO_0031410 (EC: IEA); GO_0034644 (EC: IEA); GO_0043065 (EC: IEA); GO_0045893 (EC: IDA); GO_0048102 (EC: IMP); GO_0071361 (EC: IEA); GO_0071447 (EC: IEA); GO_0072703 (EC: IEA); GO_2001235 (EC: IEA),,,,,,,,,PMID: 11511362; 12067065; 12438758; 12477932; 12851404; 14702039; 15489334; 15706352; 16044147; 16344560; 16521180; 17393983; 17537403; 18277906; 18277909; 18974142; 19322201; 20581827; 20889853; 21219856; 21339733; 21538421; 22213058; 22421968; 22470510; 22730212; 23333058; 23568502,,,,,,,,,,,,,,,OGG:3000094241,,,,,,,tumor protein p53 inducible nuclear protein 1,,,,,,,,,,,,,Other designations: p53-dependent damage-inducible nuclear protein 1|p53-inducible p53DINP1|stress-induced protein|tumor protein p53-inducible nuclear protein 1,,TP53INP1,,,,,,,,,,,,,,,,,,,,,,,94241,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,TP53INP1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/GO_0008610,lipid biosynthetic process,lipid biosynthesis|lipid formation|lipid anabolism|lipogenesis,"The chemical reactions and pathways resulting in the formation of lipids, compounds soluble in an organic solvent but not, or sparingly, in an aqueous solvent.",false,,,http://purl.obolibrary.org/obo/GO_0009058,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways resulting in the formation of lipids, compounds soluble in an organic solvent but not, or sparingly, in an aqueous solvent.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_18059,,,,,,,,,,,,,,lipid biosynthesis|lipid formation|lipid anabolism|lipogenesis,,,,,GO:0008610,,,,,,,,,,,,,,,,,,,,,,lipid biosynthetic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76785,EC 3.1.26.* (endoribonucleases producing 5'-phosphomonoesters) inhibitor,endoribonuclease producing 5'-phosphomonoesters (EC 3.1.26.*) inhibitors|EC 3.1.26.* (endoribonucleases producing 5'-phosphomonoesters) inhibitors|EC 3.1.26.* inhibitor|endoribonuclease producing 5'-phosphomonoesters inhibitors|endoribonuclease producing 5'-phosphomonoesters (EC 3.1.26.*) inhibitor|endoribonuclease producing 5'-phosphomonoesters inhibitor|EC 3.1.26.* inhibitors,An EC 3.1.* (ester hydrolase) inhibitor that interferes with the action of any endoribonuclease producing 5'-phosphomonoesters (EC 3.1.26.*).,false,,,http://purl.obolibrary.org/obo/CHEBI_76760,,,,,,,,,,,,,,,,,,,,,,An EC 3.1.* (ester hydrolase) inhibitor that interferes with the action of any endoribonuclease producing 5'-phosphomonoesters (EC 3.1.26.*).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,endoribonuclease producing 5'-phosphomonoesters (EC 3.1.26.*) inhibitors|EC 3.1.26.* (endoribonucleases producing 5'-phosphomonoesters) inhibitors|EC 3.1.26.* inhibitor|endoribonuclease producing 5'-phosphomonoesters inhibitors|endoribonuclease producing 5'-phosphomonoesters (EC 3.1.26.*) inhibitor|endoribonuclease producing 5'-phosphomonoesters inhibitor|EC 3.1.26.* inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:76785,,,,EC 3.1.26.* (endoribonucleases producing 5'-phosphomonoesters) inhibitor,,CHEBI:76785,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003956,negative regulation of lipid biosynthetic process [Ground glass appearance],,"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of lipids.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/GO_0051055,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of lipids.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003957,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003958|http://purl.obolibrary.org/obo/TXPO_0003960|http://purl.obolibrary.org/obo/TXPO_0003961,,,,,,,,,,,,,,,,,,TXPO:0003956,,,,,,,,,,,,,,,,,,,,,,negative regulation of lipid biosynthetic process [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003957,AMPK - lipogenic inhibitor (canonical)[Ground glass appearance],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000944,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003957,,,,,,,,,,,,,,,,,,,,,,AMPK - lipogenic inhibitor (canonical)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003954,negative regulation of ATP consuming via CAR activation [Ground glass appearance],,"Any process that stops, prevents, or reduces the frequency, rate or extent of an ATP consuming process in the course of the ground glass degeneration via Constitutive Androstane Receptor (CAR).
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0000945,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents, or reduces the frequency, rate or extent of an ATP consuming process in the course of the ground glass degeneration via Constitutive Androstane Receptor (CAR).
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003956|http://purl.obolibrary.org/obo/TXPO_0003969|http://purl.obolibrary.org/obo/TXPO_0003926,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003951,,,,,,,,,,,TXPO:0003954,,,,,,,,,,,,,,,,,,,,,,negative regulation of ATP consuming via CAR activation [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003958,SREBP1 inactivation [Ground glass appearance],,"SREBP1 inactivation is a subtype of inactivating: A process that changes the activity of the SREBP1 to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0003959|http://purl.obolibrary.org/obo/TXPO_0001728,,,,,,,,,,,,,,,,,,,,ISBN:0071769234,,"SREBP1 inactivation is a subtype of inactivating: A process that changes the activity of the SREBP1 to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003964,,,,http://purl.obolibrary.org/obo/TXPO_0003965,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003960|http://purl.obolibrary.org/obo/TXPO_0003961,,,,,,,,,,,TXPO:0003958,,,,,,,,,,,,,,,,,,,,,,SREBP1 inactivation [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003951,increasing AMP/ATP ratio [Ground glass appearance],,"Increasing AMP/ATP ratio is a subtype of increasing ratio: A process that changes the ratio of AMP to ATP to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0003950|http://purl.obolibrary.org/obo/TXPO_0001728,,,,,,,,,,,,,,,,,,,,,,"Increasing AMP/ATP ratio is a subtype of increasing ratio: A process that changes the ratio of AMP to ATP to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003953,,,,,,,,,,,TXPO:0003951,,,,,,,,,,,,,,,,,,,,,,increasing AMP/ATP ratio [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003955,constitutive androstane receptor activation by phenobarbital_2 [Ground glass appearance],,"Constitutive androstane receptor activation by phenobarbital_2 is a subtype of activating nuclear receptor: A process that changes the activity of the activating CAR ( constitutive androstane receptor) with a nuclear receptor role to be higher by phenobarbital.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.|Phenobarbital indirectly activates CAR and CAR translocates from the cytoplasm to the nucleus.",false,,,http://purl.obolibrary.org/obo/TXPO_0000935,,,,,,,,,,,,,,,,,,,,PMID:28265001|ISBN:0071769234,,"Constitutive androstane receptor activation by phenobarbital_2 is a subtype of activating nuclear receptor: A process that changes the activity of the activating CAR ( constitutive androstane receptor) with a nuclear receptor role to be higher by phenobarbital.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003977,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003954,,,,,,,,,,,TXPO:0003955,,,,,,,,,,,,,,,,,,,,Phenobarbital indirectly activates CAR and CAR translocates from the cytoplasm to the nucleus.,,constitutive androstane receptor activation by phenobarbital_2 [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003953,regulation of generation of precursor metabolites and energy by phenobarbital [Ground glass appearance],,"Any process that modulates the frequency, rate or extent of the chemical reactions resulting in the formation of precursor metabolites, substances from which energy is derived, and the processes involved in the liberation of energy from these substances regulated by phenobarbital.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001619,,,,,,,,,,,,,,,,,,,,,,"Any process that modulates the frequency, rate or extent of the chemical reactions resulting in the formation of precursor metabolites, substances from which energy is derived, and the processes involved in the liberation of energy from these substances regulated by phenobarbital.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003954|http://purl.obolibrary.org/obo/TXPO_0003951,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003903,,,,,,,,,,,TXPO:0003953,,,,,,,,,,,,,,,,,,,,,,regulation of generation of precursor metabolites and energy by phenobarbital [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003952,increasing AMP/ATP ratio (sustained) [Ground glass appearance],,"Increasing AMP/ATP ratio is a subtype of increasing ratio: A process that changes the ratio of AMP to ATP to be higher. This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) .",false,,,http://purl.obolibrary.org/obo/TXPO_0003951,,,,,,,,,,,,,,,,,,,,,,"Increasing AMP/ATP ratio is a subtype of increasing ratio: A process that changes the ratio of AMP to ATP to be higher. This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003979|http://purl.obolibrary.org/obo/TXPO_0003865,,,,,,,,,,,TXPO:0003952,,,,,,,,,,,,,,,,,,,,,,increasing AMP/ATP ratio (sustained) [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003950,increasing AMP/ATP ratio,,Increasing AMP/ATP ratio is a subtype of increasing ratio: A process that changes the ratio of AMP to ATP to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000352,,,,,,,,,,,,,,,,,,,,,,Increasing AMP/ATP ratio is a subtype of increasing ratio: A process that changes the ratio of AMP to ATP to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003950,,,,,,,,,,,,,,,,,,,,,,increasing AMP/ATP ratio,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003959,SREBP1 inactivation,,SREBP1 inactivation is a subtype of inactivating: A process that changes the activity of the SREBP1 to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000021,,,,,,,,,,,,,,,,,,,,,,SREBP1 inactivation is a subtype of inactivating: A process that changes the activity of the SREBP1 to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003959,,,,,,,,,,,,,,,,,,,,,,SREBP1 inactivation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100132,angiotensin III,,,false,,,http://purl.obolibrary.org/obo/IMR_0100149,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100132,,,,,,,,,,,,,,,,,,,,,,angiotensin III,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000794,ER stress dependent chemical entity,,"ER stress dependent chemical entity is a subtype of toxic course dependent chemical entity.
This entity can participate in the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001731,,,,,,,,,,,,,,,,,,,,,,"ER stress dependent chemical entity is a subtype of toxic course dependent chemical entity.
This entity can participate in the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000794,,,,,,,,,,,,,,,,,,,,,,ER stress dependent chemical entity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000799,permeating mitochondrial membrane,,Permeating mitochondrial membrane is a subtype of moving.  A process that change the location of the operand thorough mitochondrial membrane.,false,,,http://purl.obolibrary.org/obo/TXPO_0000429,,,,,,,,,,,,,,,,,,,,,,Permeating mitochondrial membrane is a subtype of moving.  A process that change the location of the operand thorough mitochondrial membrane.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000799,,,,,,,,,,,,,,,,,,,,,,permeating mitochondrial membrane,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000796,FGF21 (human)[ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000793|http://purl.obolibrary.org/obo/TXPO_1000145,,,,,,,,,,,,,,,,,,,"ER stress and PPARα activation contribute to carcinogenesis in a fatty liver. PMID:22009939


Hepatosteatosis in peroxisome deficient liver despite increased beta-oxidation capacity and impaired lipogenesis. Biochimie (2011) 93:1828–38.

FGF21-FGFR1 coordinates phospholipid homeostasis, lipid droplet function and ER stress in obesity.Endocrinology. 2016 PMID:27690692


Fibroblast growth factor 21 (FGF21) is an endocrine growth factor, a regulator of fatty acids and glucose metabolism. Recently, it has been reported that FGF21 expression is regulated by activating transcription factor 4 (ATF4), a transcription factor activated by various stimuli such as endoplasmic reticulum (ER) stress. PMID:27010621

Endoplasmic reticulum stress induces up-regulation of hepatic beta-Klotho expression through ATF4 signaling pathway. PMID:25727012",NCBI-Human-GeneID:26291|PMID:25727012|PMID:22009939|PMID:27010621|PMID:17550777|PMID:27690692,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0100571,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000026291,,,,,,,,,,,,,TXPO:0000796,,,,,,,,,,,,,,,,,,,,,,FGF21 (human)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000795,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000798,MANF (human)[ER stress],Armet [ER stress]|mesencephalic astrocyte-derived neurotrophic factor [ER stress],,false,,,http://purl.obolibrary.org/obo/TXPO_0000793|http://purl.obolibrary.org/obo/TXPO_1000233,,,,,,,,,,,,,,,,,,,MANF is upregulated in ER stress in vitro and  protect cells from ER stress-induced cell death in vivo.,NCBI-Human-GeneID:7873|PMID:23956175|PMID:24726366|PMID:21047780|PMID:18561914,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000007873,,,http://purl.obolibrary.org/obo/TXPO_0000832,,,,,Armet [ER stress]|mesencephalic astrocyte-derived neurotrophic factor [ER stress],,,,,TXPO:0000798,,,,,,,,,,,,,,,,,,,,,,MANF (human)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000831|http://purl.obolibrary.org/obo/TXPO_0000376,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000797,positive regulation of lysophagy [Phospholipidosis],,"Any process that activates, maintains or increases the rate of lysophagy.
This entity is a specific course-dependent process. This process can constitute the course of phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000757|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Any process that activates, maintains or increases the rate of lysophagy.
This entity is a specific course-dependent process. This process can constitute the course of phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002245,,,,,,,,,,,TXPO:0000797,,,,,,,,,,,,,,,,,,,,,,positive regulation of lysophagy [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000792,Bhlha15 (mouse)[ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000045|http://purl.obolibrary.org/obo/TXPO_0000812,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:17341|PMID:27644325,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000792,,,,,,,,,,,,,,,,,,,,,,Bhlha15 (mouse)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000795,in vitro assay (human),,"A laboratory test or analysis of the biological activity of a substance performed by studying its effect in an experimental situation outside the human, e.g. in the test tube rather than in living systems.",false,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,,,,,,,,,,,,,,,"A laboratory test or analysis of the biological activity of a substance performed by studying its effect in an experimental situation outside the human, e.g. in the test tube rather than in living systems.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000795,,,,,,,,,,,,,,,,,,,,,,in vitro assay (human),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000791,Ddit3 (mouse)[ER stress],Chop [ER stress],,false,,,http://purl.obolibrary.org/obo/TXPO_0000812|http://purl.obolibrary.org/obo/TXPO_1000067,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:13198|PMID:15775988|PMID:25904325|PMID:15601821|http://www.omim.org/entry/126337|PMID:22761832,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_68495,,,,,Chop [ER stress],,,,,TXPO:0000791,,,,,,,,,,,,,,,,,,,,,,Ddit3 (mouse)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000790,Creld2 (mouse)[ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000075|http://purl.obolibrary.org/obo/TXPO_0000812,,,,,,,,,,,,,,,,,,,,"NCBI-Mouse-GeneID:76737|https://omim.org/entry/607171|Elucidation of a novel phenformin derivative on glucose-deprived stress responses in HT-29 cells.

2-(2-chlorophenyl)ethylbiguanide (2-Cl-Phen) down-regulated expression of several ER stress-related genes, with the exception of GADD153. The expression levels of ATF6α, GRP78, MANF, and CRELD2 mRNA were almost completely decreased by 2-Cl-Phen.|PMID:23956175|PMID:24019898",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000790,,,,,,,,,,,,,,,,,,,,,,Creld2 (mouse)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000719,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000793,ER stress dependent molecule (human in vitro),,"ER stress dependent molecule is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of ER stress as a gene product.
Gene profile:Human/in vitro/Hepatocyte/",false,,,http://purl.obolibrary.org/obo/TXPO_0000794,,,,,,,,,,,,,,,,,,,,,,"ER stress dependent molecule is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of ER stress as a gene product.
Gene profile:Human/in vitro/Hepatocyte/",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000793,,,,,,,,,,,,,,,,,,,,,,ER stress dependent molecule (human in vitro),,,,,,,,,,,http://purl.obolibrary.org/obo/NCBITaxon_9606,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000795,,,,,,,,
http://purl.obolibrary.org/obo/GO_0033617,mitochondrial respiratory chain complex IV assembly,mitochondrial cytochrome c oxidase biogenesis|mitochondrial cytochrome c oxidase complex assembly,"The aggregation, arrangement and bonding together of a set of components to form respiratory chain complex IV (also known as cytochrome c oxidase) in the mitochondrial inner membrane.",false,,,http://purl.obolibrary.org/obo/GO_0033108,,,,,,,,,,,,,,,,,,,,,,"The aggregation, arrangement and bonding together of a set of components to form respiratory chain complex IV (also known as cytochrome c oxidase) in the mitochondrial inner membrane.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,mitochondrial cytochrome c oxidase biogenesis|mitochondrial cytochrome c oxidase complex assembly,,,,,GO:0033617,,,,,,,,,,,,,,,,,,,,,,mitochondrial respiratory chain complex IV assembly,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000436,C3G,Crk SH3 domein binding GEF|Guanine nucleotide-releasing factor 2,,false,,,http://purl.obolibrary.org/obo/IMR_0100440,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Crk SH3 domein binding GEF|Guanine nucleotide-releasing factor 2,,,,,IMR:0000436,,,,,,,,,,,,,,,,,,,,,,C3G,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_25491,nematicide,nematocides|nematicides|nematocide,A substance used to destroy pests of the phylum Nematoda (roundworms).,false,,,http://purl.obolibrary.org/obo/CHEBI_25944,,,,,,,,,,,,,,,,,,,,,,A substance used to destroy pests of the phylum Nematoda (roundworms).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,nematocides|nematicides|nematocide,,,,,,,,,,,,,,,,,,,,,CHEBI:25491,,,,nematicide,,CHEBI:25491,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000387103,CENPW,,Other designations: cancer-up-regulated gene 2 protein|cancer-upregulated gene 2,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CENP-W|CUG2|C6orf173,,,,,,,,,,,,6,,,,,,MIM:611264|HPRD:16660|Ensembl:ENSG00000203760|Vega:OTTHUMG00000015518|HGNC:21488,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,centromere protein W,,,6q22.32,,,,,,,,,,,,,,,,"GO_0000278 (EC: IMP); GO_0000775 (EC: IDA, PMID: 19533040); GO_0000776 (EC: IDA); GO_0000777 (EC: IEA); GO_0003677 (EC: IEA); GO_0005515 (EC: IPI, PMID: 19070575); GO_0005730 (EC: IEA); GO_0007059 (EC: IMP); GO_0007059 (EC: TAS, PMID: 19533040); GO_0007067 (EC: IEA); GO_0016363 (EC: IEA); GO_0034080 (EC: TAS, PMID: 19533040); GO_0046982 (EC: IEA); GO_0051276 (EC: IMP); GO_0051382 (EC: IMP)",,,,,,,,,PMID: 12477932; 17610844; 18391951; 19070575; 19266077; 19430480; 19533040; 20075984; 20180024; 20546612; 20648695; 20846217; 20881960; 21102462; 21695110; 22002061; 22131368; 22504418; 23306614; 23563607; 23926101,,,,,,,,,,,,,,,OGG:3000387103,,,,,,,centromere protein W,,,,,,,,,,,,,Other designations: cancer-up-regulated gene 2 protein|cancer-upregulated gene 2,,CENPW,,,,,,,,,,,,,,,,,,,,,,,387103,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,CENPW,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0100330,c-IAP2,HIAP1|cellular inhibitor of apoptosis protein-2|mammalian IAP homologue C|MIHC,,false,,,http://purl.obolibrary.org/obo/IMR_0000454,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,HIAP1|cellular inhibitor of apoptosis protein-2|mammalian IAP homologue C|MIHC,,,,,IMR:0100330,,,,,,,,,,,,,,,,,,,,,,c-IAP2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100773,Wnt-6,,,false,,,http://purl.obolibrary.org/obo/IMR_0000003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100773,,,,,,,,,,,,,,,,,,,,,,Wnt-6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_23354,coenzyme,,"A low-molecular-weight, non-protein organic compound participating in enzymatic reactions as dissociable acceptor or donor of chemical groups or electrons.",false,,,http://purl.obolibrary.org/obo/CHEBI_23357,,,,,,,,,,,,,,,,,,,,,,"A low-molecular-weight, non-protein organic compound participating in enzymatic reactions as dissociable acceptor or donor of chemical groups or electrons.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:23354,,,,,,,,,,,,,,,,,,,,,,coenzyme,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100273,MNK,MAP kinase signal-integrating kinase|MAP kinase-interacting kinase,"MNK1/2 are regulated by p38 and ERK, but not by JNK. MNK1/2 can phosphorylate eukaryotic initiation factor-4E (eIF-4E).",false,,,http://purl.obolibrary.org/obo/IMR_0100271,,,,,,,,,,,,,,,,,,,,,,"MNK1/2 are regulated by p38 and ERK, but not by JNK. MNK1/2 can phosphorylate eukaryotic initiation factor-4E (eIF-4E).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MAP kinase signal-integrating kinase|MAP kinase-interacting kinase,,,,,IMR:0100273,,,,,,,,,,,,,,,,,,,,,,MNK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100605,CDK9(mol),C-2K|Cell division protein kinase 9|Cdk 9 protein|Serine/threonine-protein kinase PITALRE,,false,,,http://purl.obolibrary.org/obo/TXPO_0003241,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0010181,C-2K|Cell division protein kinase 9|Cdk 9 protein|Serine/threonine-protein kinase PITALRE,,,,,IMR:0100605,,,,,,,,,,,,,,,,,,,,,,CDK9(mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_8863,Riluzole,RP54274|riluzole hydrochloride|riluzole HCl|RP-54274|6-Trifluoromethoxybenzothiazol-2-ylamine|rilutor|rilutek|Riluzole,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:1744-22-5|LINCS:LSM-2471|Drug_Central:2382,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Riluzole,,RP54274|riluzole hydrochloride|riluzole HCl|RP-54274|6-Trifluoromethoxybenzothiazol-2-ylamine|rilutor|rilutek,,,,,,,,,,,,,,,,,,,,,CHEBI:8863,,,,Riluzole,,CHEBI:8863,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000122618,PLD4,,Other designations: PLD 4|choline phosphatase 4|phosphatidylcholine-hydrolyzing phospholipase D4|phospholipase D4,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,C14orf175,,,,,,,,,,,,14,,,,,,HGNC:23792|Ensembl:ENSG00000166428|Vega:OTTHUMG00000144167|HPRD:11230,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"phospholipase D family, member 4",,,14q32.33,,,,,,,,,,,,,,,,GO_0004435 (EC: TAS); GO_0004630 (EC: IEA); GO_0005789 (EC: TAS); GO_0006644 (EC: TAS); GO_0006655 (EC: TAS); GO_0016021 (EC: IEA); GO_0016042 (EC: IEA); GO_0043647 (EC: TAS); GO_0044281 (EC: TAS); GO_0046474 (EC: TAS); GO_0070290 (EC: IEA),,,,,,,,,PMID: 12477932; 12975309; 15489334; 16094384; 21890473; 22446963; 23124809,,,,,,,,,,,,,,,OGG:3000122618,,,,,,,"phospholipase D family, member 4",,,,,,,,,,,,,Other designations: PLD 4|choline phosphatase 4|phosphatidylcholine-hydrolyzing phospholipase D4|phospholipase D4,,PLD4,,,,,,,,,,,,,,,,,,,,,,,122618,UNQ2488/PRO5775,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,PLD4,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000472,NF-H,,,false,,,http://purl.obolibrary.org/obo/IMR_0000203,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000472,,,,,,,,,,,,,,,,,,,,,,NF-H,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000860,14-3-3 gamma,,,false,,,http://purl.obolibrary.org/obo/IMR_0000456,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000860,,,,,,,,,,,,,,,,,,,,,,14-3-3 gamma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0046034,ATP metabolic process,,"The chemical reactions and pathways involving ATP, adenosine triphosphate, a universally important coenzyme and enzyme regulator.",false,,,http://purl.obolibrary.org/obo/GO_0008152,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways involving ATP, adenosine triphosphate, a universally important coenzyme and enzyme regulator.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006754|http://purl.obolibrary.org/obo/TXPO_0001165,,,,,,,,,,,,,,,,,,GO:0046034,,,,,,,,,,,,,,,,,,,,,,ATP metabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76663,EC 2.5.1.* (non-methyl-alkyl or aryl transferase) inhibitor,non-methyl-alkyl or aryl transferase inhibitor|non-methyl alkyl/aryl transferase inhibitor|EC 2.5.1.* (non-methyl-alkyl or aryl transferase) inhibitors|alkyl/aryl (non-methyl) transferase inhibitors|non-methyl alkyl/aryl transferase inhibitors|alkyl/aryl (non-methyl) transferase inhibitor|EC 2.5.1.* inhibitor|non-methyl alkyl/aryl transferase (EC 2.5.1.*) inhibitors|non-methyl alkyl/aryl transferase (EC 2.5.1.*) inhibitor|EC 2.5.1.* inhibitors|non-methyl-alkyl or aryl transferase inhibitors,A transferase inhibitor that inhibits the transfer of an alkyl (other than methyl) or aryl group (EC 2.5.1.*).,false,,,http://purl.obolibrary.org/obo/CHEBI_76834,,,,,,,,,,,,,,,,,,,,,,A transferase inhibitor that inhibits the transfer of an alkyl (other than methyl) or aryl group (EC 2.5.1.*).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,non-methyl-alkyl or aryl transferase inhibitor|non-methyl alkyl/aryl transferase inhibitor|EC 2.5.1.* (non-methyl-alkyl or aryl transferase) inhibitors|alkyl/aryl (non-methyl) transferase inhibitors|non-methyl alkyl/aryl transferase inhibitors|alkyl/aryl (non-methyl) transferase inhibitor|EC 2.5.1.* inhibitor|non-methyl alkyl/aryl transferase (EC 2.5.1.*) inhibitors|non-methyl alkyl/aryl transferase (EC 2.5.1.*) inhibitor|EC 2.5.1.* inhibitors|non-methyl-alkyl or aryl transferase inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:76663,,,,EC 2.5.1.* (non-methyl-alkyl or aryl transferase) inhibitor,,CHEBI:76663,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000552,proteoglycan,,Proteoglycans are a diverse family of molecules characterized by a core protein to which is attached one or more glycosaminoglycan (GAG) side-chains.,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,Proteoglycans are a diverse family of molecules characterized by a core protein to which is attached one or more glycosaminoglycan (GAG) side-chains.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003695,,,,,,,,,,IMR:0000552,,,,,,,,,,,,,,,,,,,,,,proteoglycan,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_127342,atomoxetine,atomoxetine|tomoxetine|Tomoxetina|(-)-Tomoxetine|Tomoxetinum|(3R)-N-methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine,A  secondary amino compound having methyl and 3-(2-methylphenoxy)-3-phenylpropan-1-yl substituents.,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Reaxys:4318684|PMID:15338851|PMID:23048018|Drug_Central:256|Beilstein:4318684|DrugBank:DB00289|LINCS:LSM-2452|CAS:83015-26-3,,A  secondary amino compound having methyl and 3-(2-methylphenoxy)-3-phenylpropan-1-yl substituents.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35703|http://purl.obolibrary.org/obo/CHEBI_35640|http://purl.obolibrary.org/obo/CHEBI_35469|http://purl.obolibrary.org/obo/CHEBI_78298,,,,,(3R)-N-methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine,,atomoxetine|tomoxetine|Tomoxetina|(-)-Tomoxetine|Tomoxetinum,,,,,,,,,,,,,,,,,,,,,CHEBI:127342,,,,atomoxetine,,CHEBI:127342,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010495,60S ribosomal protein L4,L1,,false,,,http://purl.obolibrary.org/obo/IMR_0000897,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,L1,,,,,IMR:0010495,,,,,,,,,,,,,,,,,,,,,,60S ribosomal protein L4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100571,FGF-21,,,false,,,http://purl.obolibrary.org/obo/IMR_0000049,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100571,,,,,,,,,,,,,,,,,,,,,,FGF-21,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_38070,anti-arrhythmia drug,antiarrhythmic agent,"A drug used for the treatment or prevention of cardiac arrhythmias. Anti-arrhythmia drugs may affect the polarisation-repolarisation phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibres.",false,,,http://purl.obolibrary.org/obo/CHEBI_35554,,,,,,,,,,,,,,,,,,,,,,"A drug used for the treatment or prevention of cardiac arrhythmias. Anti-arrhythmia drugs may affect the polarisation-repolarisation phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibres.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,antiarrhythmic agent,,,,,,,,,,,,,,,,,,,,,CHEBI:38070,,,,anti-arrhythmia drug,,CHEBI:38070,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000672,PAK6,PAK5,,false,,,http://purl.obolibrary.org/obo/IMR_0000238,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PAK5,,,,,IMR:0000672,,,,,,,,,,,,,,,,,,,,,,PAK6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_50926,angiogenesis modulating agent,,An agent that modulates the physiologic angiogenesis process. This is accomplished by endogenous angiogenic proteins and a variety of other chemicals and pharmaceutical agents.,false,,,http://purl.obolibrary.org/obo/CHEBI_23888,,,,,,,,,,,,,,,,,,,,,,An agent that modulates the physiologic angiogenesis process. This is accomplished by endogenous angiogenic proteins and a variety of other chemicals and pharmaceutical agents.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:50926,,,,angiogenesis modulating agent,,CHEBI:50926,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100303,caspase-2 (mol),,,false,,,http://purl.obolibrary.org/obo/IMR_0000308,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100303,,,,,,,,,,,,,,,,,,,,,,caspase-2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002867,PERK dimerization [ER stress - refolding],,"PERK dimerization is a subtype of protein dimerization: The formation of a PERK dimer, a macromolecular structure consists of two noncovalently associated identical or nonidentical subunits.
This process is dependent on the refolding and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000713,,,,,,,,,,,,,,,,,,,,Reactome:R-HSA-381087|http://www.ncbi.nlm.nih.gov/pubmed/11907036,,"PERK dimerization is a subtype of protein dimerization: The formation of a PERK dimer, a macromolecular structure consists of two noncovalently associated identical or nonidentical subunits.
This process is dependent on the refolding and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002881,,,,,,http://purl.obolibrary.org/obo/TXPO_0002870,,,,,,,,,,,TXPO:0002867,,,,,,,,,,,,,,,,,,,,,,PERK dimerization [ER stress - refolding],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002861,PERK - autophosphorylation kinase (canonical)[ER stress - Refolding],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000878,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002861,,,,,,,,,,,,,,,,,,,,,,PERK - autophosphorylation kinase (canonical)[ER stress - Refolding],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002870,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002864,PERK - stress sensor (canonical)[ER stress - Refolding],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000878,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000881,,,,,,,,,,TXPO:0002864,,,,,,,,,,,,,,,,,,,,,,PERK - stress sensor (canonical)[ER stress - Refolding],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001826,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002868,PERK autophosphorylation [ER stress - inflammation],,"PERK autophosphorylation is a subtype of protein autophosphorylation: The phosphorylation by PERK of one or more of its own amino acid residues (cis-autophosphorylation), or residues on PERK (trans-autophosphorylation).
This process is dependent on the inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000674,,,,,,,,,,,,,,,,,,,,,,"PERK autophosphorylation is a subtype of protein autophosphorylation: The phosphorylation by PERK of one or more of its own amino acid residues (cis-autophosphorylation), or residues on PERK (trans-autophosphorylation).
This process is dependent on the inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002859,,,,,,,,,,,,,,,,,TXPO:0002868,,,,,,,,,,,,,,,,,,,,,,PERK autophosphorylation [ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002865,Dissociation of PERK:BIP Heterodimer [ER stress - inflammation],,"Dissociation of PERK:BIP heterodimer is a subtype of detaching: A process that disaggregates PERK-BIP heterodimers into BIP and PERK.
This process is dependent on the inflammation and can constitute the course of ER stress.|PERK (EIF2AK3) is a single-pass transmembrane protein located in the Endoplasmic Reticulum (ER) membrane. PERK has an N-terminal luminal domain and a C-terminal cytosolic domain. It is maintained in an inactive state by association of its luminal domain with BiP, a chaperone in the ER. Because BiP also binds unfolded proteins, BiP dissociates from PERK when unfolded proteins exceed chaperone activity in the ER.",false,,,http://purl.obolibrary.org/obo/TXPO_0002213,,,,,,,,,,,,,,,,,,,,PMID:10854322|PMID:11907036|Reactome:R-HSA-381086,,"Dissociation of PERK:BIP heterodimer is a subtype of detaching: A process that disaggregates PERK-BIP heterodimers into BIP and PERK.
This process is dependent on the inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002905|http://purl.obolibrary.org/obo/TXPO_0002846,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002855,,,,,,,,,,,TXPO:0002865,,,,,,,,,,,,,,,,,,,,"PERK (EIF2AK3) is a single-pass transmembrane protein located in the Endoplasmic Reticulum (ER) membrane. PERK has an N-terminal luminal domain and a C-terminal cytosolic domain. It is maintained in an inactive state by association of its luminal domain with BiP, a chaperone in the ER. Because BiP also binds unfolded proteins, BiP dissociates from PERK when unfolded proteins exceed chaperone activity in the ER.",,Dissociation of PERK:BIP Heterodimer [ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002862,PERK - kinase (canonical)[ER stress - apotosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000878,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002862,,,,,,,,,,,,,,,,,,,,,,PERK - kinase (canonical)[ER stress - apotosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002509,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002869,PERK autophosphorylation [ER stress - apoptosis],,"PERK autophosphorylation is a subtype of protein autophosphorylation: The phosphorylation by PERK of one or more of its own amino acid residues (cis-autophosphorylation), or residues on PERK (trans-autophosphorylation).
This process is dependent on the apoptosis and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000674,,,,,,,,,,,,,,,,,,,,,,"PERK autophosphorylation is a subtype of protein autophosphorylation: The phosphorylation by PERK of one or more of its own amino acid residues (cis-autophosphorylation), or residues on PERK (trans-autophosphorylation).
This process is dependent on the apoptosis and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002860,,,,,,,,,,,,,,,,,TXPO:0002869,,,,,,,,,,,,,,,,,,,,,,PERK autophosphorylation [ER stress - apoptosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002863,PERK - kinase (canonical)[ER stress - Refolding],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000878,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002863,,,,,,,,,,,,,,,,,,,,,,PERK - kinase (canonical)[ER stress - Refolding],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002508,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002860,PERK - autophosphorylation kinase (canonical)[ER stress - apotosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000878,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002860,,,,,,,,,,,,,,,,,,,,,,PERK - autophosphorylation kinase (canonical)[ER stress - apotosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002869,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002866,PERK dimerization [ER stress - apoptosis],,"PERK dimerization is a subtype of protein dimerization: The formation of a PERK dimer, a macromolecular structure consists of two noncovalently associated identical or nonidentical subunits.
This process is dependent on the apoptosis and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000713,,,,,,,,,,,,,,,,,,,,Reactome:R-HSA-381087|http://www.ncbi.nlm.nih.gov/pubmed/11907036,,"PERK dimerization is a subtype of protein dimerization: The formation of a PERK dimer, a macromolecular structure consists of two noncovalently associated identical or nonidentical subunits.
This process is dependent on the apoptosis and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002883,,,,,,http://purl.obolibrary.org/obo/TXPO_0002869,,,,,,,,,,,TXPO:0002866,,,,,,,,,,,,,,,,,,,,,,PERK dimerization [ER stress - apoptosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_17858,Glutathione disulfide,Oxiglutatione|Oxidized glutathione|GSSG,,false,,,http://purl.obolibrary.org/obo/CHEBI_23367,,,,,,,,,,,,,,,,,,,,CAS:27025-41-8|DrugBank:DB03310,,,,,,,,,,,,,,C20H32N6O12S2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Oxiglutatione|Oxidized glutathione|GSSG,,,,,CHEBI:17858,,,,,,,,,,,,,,,,,,,,,,Glutathione disulfide,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,N[C@@H](CCC(=O)N[C@@H](CSSC[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)NCC(O)=O)C(=O)NCC(O)=O)C(O)=O,,,,,
http://purl.obolibrary.org/obo/OGG_3000005608,MAP2K6,,"Other designations: MAPK/ERK kinase 6|MAPKK 6|MEK 6|SAPK kinase 3|dual specificity mitogen-activated protein kinase kinase 6|protein kinase, mitogen-activated, kinase 6 (MAP kinase kinase 6)|stress-activated protein kinase kinase 3",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,PRKMK6|MEK6|SAPKK3|MKK6|SAPKK-3|MAPKK6,,,,,,,,,,,,17,,,,,,HGNC:6846|MIM:601254|HPRD:03155,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,mitogen-activated protein kinase kinase 6,,,17q24.3,,,,,,,,,,,,,,,,"GO_0000187 (EC: TAS); GO_0002224 (EC: TAS); GO_0002755 (EC: TAS); GO_0002756 (EC: TAS); GO_0002931 (EC: IEA); GO_0004702 (EC: IBA); GO_0004708 (EC: IBA); GO_0004713 (EC: IEA); GO_0005515 (EC: IPI, PMID: 15229216); GO_0005524 (EC: IEA); GO_0005654 (EC: TAS); GO_0005737 (EC: IBA); GO_0005829 (EC: TAS); GO_0005856 (EC: IEA); GO_0006351 (EC: IEA); GO_0006355 (EC: IEA); GO_0006915 (EC: IEA); GO_0006975 (EC: TAS, PMID: 10848581); GO_0007050 (EC: TAS, PMID: 10848581); GO_0007165 (EC: TAS, PMID: 8621675); GO_0019901 (EC: IPI, PMID: 11279118); GO_0034134 (EC: TAS); GO_0034138 (EC: TAS); GO_0034142 (EC: TAS); GO_0034146 (EC: TAS); GO_0034162 (EC: TAS); GO_0034166 (EC: TAS); GO_0035666 (EC: TAS); GO_0035872 (EC: TAS); GO_0038123 (EC: TAS); GO_0038124 (EC: TAS); GO_0042493 (EC: IEA); GO_0042692 (EC: TAS); GO_0043065 (EC: IEA); GO_0045087 (EC: TAS); GO_0051149 (EC: TAS); GO_0051403 (EC: TAS); GO_0060048 (EC: IEA); GO_0070423 (EC: TAS); GO_0072709 (EC: IEA)",,,,,,,,,PMID: 7750576; 8125298; 8621675; 8622669; 8626699; 8663074; 8861944; 9218798; 9430721; 9768359; 9808624; 9841871; 10094049; 10497253; 10570156; 10702308; 10838074; 10848581; 10961885; 11062067; 11062068; 11104681; 11279118; 11460167; 11562357; 11689443; 11727828; 11836244; 11971971; 12054652; 12242293; 12477932; 12509443; 12556533; 12589052; 12609980; 12697810; 12761180; 12820963; 14633987; 15229216; 15276183; 15375157; 15489334; 15492008; 15516490; 15550393; 15590691; 15677464; 15717329; 15722372; 15764709; 15778394; 15790570; 15866172; 15923648; 16157600; 16313339; 16342939; 16344560; 16498455; 16728640; 16893890; 16960152; 17079228; 17255097; 17255949; 17363905; 17363973; 17384642; 18327563; 19047046; 19141286; 19234473; 19302196; 19672773; 19675569; 19737936; 19846005; 19913121; 20067578; 20162623; 20213747; 20364819; 20628086; 20706999; 20805296; 20869211; 20932476; 21078955; 21139048; 21308746; 21368234; 21890473; 21926646; 22154358; 22164285; 22383536; 22569225; 23606331; 23744074,,,,,,,,,,,,,,,OGG:3000005608,,,,,,,mitogen-activated protein kinase kinase 6,,,,,,,,,,,,,"Other designations: MAPK/ERK kinase 6|MAPKK 6|MEK 6|SAPK kinase 3|dual specificity mitogen-activated protein kinase kinase 6|protein kinase, mitogen-activated, kinase 6 (MAP kinase kinase 6)|stress-activated protein kinase kinase 3",,MAP2K6,,,,,,,,,,,,,,,,,,,,,,,5608,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,MAP2K6,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_59886,HIV fusion inhibitor,HIV fusion inhibitors|HIV entry inhibitor|HIV entry inhibitors,"A drug which interferes with the binding, fusion and entry of an HIV virion to a human cell. By blocking this step in HIV's replication cycle, such agents slow the progression from HIV infection to AIDS.",false,,,http://purl.obolibrary.org/obo/CHEBI_64946|http://purl.obolibrary.org/obo/CHEBI_36044,,,,,,,,,,,,,,,,,,,,PMID:22470838,,"A drug which interferes with the binding, fusion and entry of an HIV virion to a human cell. By blocking this step in HIV's replication cycle, such agents slow the progression from HIV infection to AIDS.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,HIV fusion inhibitors|HIV entry inhibitor|HIV entry inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:59886,,,,HIV fusion inhibitor,,CHEBI:59886,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000010539,GLRX3,,Other designations: PKC-interacting cousin of thioredoxin|PKC-theta-interacting protein|PKCq-interacting protein|glutaredoxin 4|glutaredoxin-3|thioredoxin-like protein 2,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,TXNL2|GLRX4|GRX3|TXNL3|GRX4|PICOT,,,,,,,,,,,,10,,,,,,Vega:OTTHUMG00000019267|Ensembl:ENSG00000108010|HGNC:15987|MIM:612754|HPRD:10153,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,glutaredoxin 3,,,10q26,,,,,,,,,,,,,,,,"GO_0002026 (EC: ISS); GO_0005080 (EC: IEA); GO_0005515 (EC: IPI, PMID: 10636891); GO_0005938 (EC: IEA); GO_0009055 (EC: IEA); GO_0010614 (EC: ISS); GO_0015035 (EC: IEA); GO_0030018 (EC: IEA); GO_0044822 (EC: IDA); GO_0045454 (EC: IEA); GO_0046872 (EC: IEA); GO_0051536 (EC: IEA)",,,,,,,,,PMID: 8125298; 10636891; 11124703; 11774602; 12477932; 14702039; 15231748; 15342556; 15489334; 16169070; 16189514; 16385451; 17353931; 18258855; 18528843; 19471022; 19738201; 19797004; 20170406; 20226171; 20498481; 20800603; 21123948; 21139048; 21160409; 21575136; 21890473; 21900206; 21906983; 22309771; 22623428; 22678362; 22863883; 23000965; 23415866; 23615448; 24250222,,,,,,,,,,,,,,,OGG:3000010539,,,,,,,glutaredoxin 3,,,,,,,,,,,,,Other designations: PKC-interacting cousin of thioredoxin|PKC-theta-interacting protein|PKCq-interacting protein|glutaredoxin 4|glutaredoxin-3|thioredoxin-like protein 2,,GLRX3,,,,,,,,,,,,,,,,,,,,,,,10539,HUSSY-22,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,GLRX3,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0005046,neovascularization,,neovascularization is a subtype of biological structure formation: A process that constructs an alternate blood vessels.,false,,,http://purl.obolibrary.org/obo/TXPO_0000134,,,,,,,,,,,,,,,,,,,,,,neovascularization is a subtype of biological structure formation: A process that constructs an alternate blood vessels.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005046,,,,,,,,,,,,,,,,,,,,,,neovascularization,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005047,KDR (canonical) [hepatocarcinogenesis],VEGFR2,,false,,,http://purl.obolibrary.org/obo/TXPO_0005063|http://purl.obolibrary.org/obo/TXPO_0005096,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:25589|NCBI-Human-GeneID:3791|NCBI-Mouse-GeneID:16542|PMID:31781608,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,VEGFR2,,,,,TXPO:0005047,,,,,,,,,,,,,,,,,,,,,,KDR (canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005043,increasing lipid concentration,hyperlipidemia,Increasing lipid concentration in blood is a subtype of increasing concentration: A process that changes the lipid concentration in  the blood to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000352,,,,,,,,,,,,,,,,,,,,,,Increasing lipid concentration in blood is a subtype of increasing concentration: A process that changes the lipid concentration in  the blood to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,hyperlipidemia,,,,,TXPO:0005043,,,,,,,,,,,,,,,,,,,,,,increasing lipid concentration,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005045,endothelial progenitor cell mobilization,,The movement of an endothelial progenitor cell (EPC) within or between different tissues and organs of the body.,false,,,http://purl.obolibrary.org/obo/GO_0016477,,,,,,,,,,,,,,,,,,,,,,The movement of an endothelial progenitor cell (EPC) within or between different tissues and organs of the body.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005045,,,,,,,,,,,,,,,,,,,,,,endothelial progenitor cell mobilization,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005040,tumor malignancy alteration,,"Tumor malignancy alteration is a subtype of changing quality of tumor: A process that changes the quality of the tumors to progress, invade surrounding tissues or metastasize.",false,,,http://purl.obolibrary.org/obo/TXPO_0005141,,,,,,,,,,,,,,,,,,,,,,"Tumor malignancy alteration is a subtype of changing quality of tumor: A process that changes the quality of the tumors to progress, invade surrounding tissues or metastasize.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005040,,,,,,,,,,,,,,,,,,,,,,tumor malignancy alteration,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0002097,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005044,Increasing cholesterol concentration in blood [mitochondrial disorder],hypercholesterolemia,"Increasing cholesterol concentration in blood is a subtype of increasing lipid concentration in blood: A process that changes the cholesterol concentration in  the blood to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0005042|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:31623280,,"Increasing cholesterol concentration in blood is a subtype of increasing lipid concentration in blood: A process that changes the cholesterol concentration in  the blood to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001993|http://purl.obolibrary.org/obo/TXPO_0004350|http://purl.obolibrary.org/obo/TXPO_0001988|http://purl.obolibrary.org/obo/TXPO_0004373|http://purl.obolibrary.org/obo/TXPO_0002004,,,,,,hypercholesterolemia,,,,,TXPO:0005044,,,,,,,,,,,,,,,,,,,,,,Increasing cholesterol concentration in blood [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005041,increased membrane potential,,A mebrane potential which is relatively high.,false,,,http://purl.obolibrary.org/obo/PATO_0001462|http://purl.obolibrary.org/obo/TXPO_0002420,,,,,,,,,,,,,,,,,,,,,,A mebrane potential which is relatively high.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005041,,,,,,,,,,,,,,,,,,,,,,increased membrane potential,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005042,Increasing cholesterol concentration in blood,hypercholesterolemia,Increasing cholesterol concentration in blood is a subtype of increasing lipid concentration in blood: A process that changes the cholesterol concentration in  the blood to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0005043,,,,,,,,,,,,,,,,,,,,,,Increasing cholesterol concentration in blood is a subtype of increasing lipid concentration in blood: A process that changes the cholesterol concentration in  the blood to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,hypercholesterolemia,,,,,TXPO:0005042,,,,,,,,,,,,,,,,,,,,,,Increasing cholesterol concentration in blood,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005048,enzyme production,,"Enzyme production is a subtype of protein production: A process that makes existent of enzyme due to biosynthesis, secretion, or membrane trafficking, resulting in an increase in its levels.",false,,,http://purl.obolibrary.org/obo/TXPO_0000382,,,,,,,,,,,,,,,,,,,,,,"Enzyme production is a subtype of protein production: A process that makes existent of enzyme due to biosynthesis, secretion, or membrane trafficking, resulting in an increase in its levels.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005048,,,,,,,,,,,,,,,,,,,,,,enzyme production,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005049,TP53(canonical) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/IMR_0100659|http://purl.obolibrary.org/obo/TXPO_0005063,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24842|PMID:24078988|PMID:31439937|PMID:10626230|NCBI-Human-GeneID:7157|PMID:21160980|NCBI-Mouse-GeneID:22059|PMID:19590965,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005049,,,,,,,,,,,,,,,,,,,,,,TP53(canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000239,MLK family,,,false,,,http://purl.obolibrary.org/obo/IMR_0000229,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000239,,,,,,,,,,,,,,,,,,,,,,MLK family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_41774,tamoxifen,"trans-Tamoxifen|Crisafeno|(Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine|1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene|1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene|(Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine|Diemon|Apo-Tamox|tamoxifeno|tamoxifenum|tamoxifen|tamoxifene|2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine|Tamoxifen","Tamoxifen, sold under the brand name Nolvadex among others, is a medication that is used to prevent breast cancer in women and treat breast cancer in women and men. (by Wikipedia)",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,DrugBank:DB00675|PMID:7688593|Drug_Central:2561|PMID:14681337|Beilstein:2062020|CAS:10540-29-1|PMID:18348622|PMID:14709804|PMID:12612646,,"Tamoxifen, sold under the brand name Nolvadex among others, is a medication that is used to prevent breast cancer in women and treat breast cancer in women and men. (by Wikipedia)",,,,,,,,,,,,C26H29NO,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35610|http://purl.obolibrary.org/obo/CHEBI_50739|http://purl.obolibrary.org/obo/CHEBI_37700|http://purl.obolibrary.org/obo/CHEBI_50646|http://purl.obolibrary.org/obo/CHEBI_62872|http://purl.obolibrary.org/obo/CHEBI_50837|http://purl.obolibrary.org/obo/CHEBI_50792|http://purl.obolibrary.org/obo/CHEBI_48422,,,,,"2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine|Tamoxifen",,"trans-Tamoxifen|Crisafeno|(Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine|1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene|1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene|(Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine|Diemon|Apo-Tamox|tamoxifeno|tamoxifenum|tamoxifen|tamoxifene",,,,,,,,,,,,,,,,,,,,,CHEBI:41774,,,,tamoxifen,,CHEBI:41774,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1,,,,,
http://purl.obolibrary.org/obo/OGG_3000008817,FGF18,,,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,FGF-18|ZFGF5,,,,,,,,,,,,5,,,,,,HGNC:3674|HPRD:04766|Vega:OTTHUMG00000130464|Ensembl:ENSG00000156427|MIM:603726,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,fibroblast growth factor 18,,,5q34,,,,,,,,,,,,,,,,"GO_0001525 (EC: IEA); GO_0001957 (EC: IEA); GO_0001958 (EC: IEA); GO_0002063 (EC: IEA); GO_0005105 (EC: IDA, PMID: 16384934); GO_0005111 (EC: IDA, PMID: 16384934); GO_0005576 (EC: TAS); GO_0005615 (EC: TAS, PMID: 9742123); GO_0005730 (EC: IDA); GO_0007165 (EC: TAS, PMID: 9742123); GO_0007173 (EC: TAS); GO_0007267 (EC: TAS, PMID: 9742123); GO_0007399 (EC: IEA); GO_0008083 (EC: IEA); GO_0008284 (EC: IEA); GO_0008286 (EC: TAS); GO_0008543 (EC: TAS); GO_0009653 (EC: TAS, PMID: 9742123); GO_0030324 (EC: IEA); GO_0030949 (EC: IEA); GO_0032332 (EC: IEA); GO_0038095 (EC: TAS); GO_0045087 (EC: TAS); GO_0048011 (EC: TAS); GO_0048015 (EC: TAS); GO_0070374 (EC: IEA)",,,,,,,,,PMID: 1697263; 9660775; 9742123; 10353607; 10579907; 10629055; 10751172; 11076863; 11124520; 11256614; 11294897; 12477932; 12975309; 15199049; 15489334; 15489336; 15749088; 16019430; 16381901; 16384934; 16597617; 16756958; 17128416; 17133345; 17360555; 17890768; 18978678; 19197348; 19453261; 19727229; 19909293; 20507176; 21048031; 21319186; 21988832; 24018557,,,,,,,,,,,,,,,OGG:3000008817,,,,,,,fibroblast growth factor 18,,,,,,,,,,,,,,,FGF18,,,,,,,,,,,,,,,,,,,,,,,8817,UNQ420/PRO856,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,FGF18,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0004585,HBV infection [hepatocarcinogenesis],,"HBV infection is a subtype of pathogen colonization: A process that makes HBV present in the liver to increase the number.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0004584|http://purl.obolibrary.org/obo/TXPO_0002340,,,,,,,,,,,,,,,,,,,,PMID:31439937|PMID:31507621|PMID:31781608|PMID:30704071,,"HBV infection is a subtype of pathogen colonization: A process that makes HBV present in the liver to increase the number.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004453|http://purl.obolibrary.org/obo/TXPO_0004588|http://purl.obolibrary.org/obo/TXPO_0004586|http://purl.obolibrary.org/obo/TXPO_0004587|http://purl.obolibrary.org/obo/TXPO_0004589|http://purl.obolibrary.org/obo/TXPO_0004507|http://purl.obolibrary.org/obo/TXPO_0004508|http://purl.obolibrary.org/obo/TXPO_0004417|http://purl.obolibrary.org/obo/TXPO_0004541|http://purl.obolibrary.org/obo/TXPO_0004591|http://purl.obolibrary.org/obo/TXPO_0004590|http://purl.obolibrary.org/obo/TXPO_0004593|http://purl.obolibrary.org/obo/TXPO_0004592|http://purl.obolibrary.org/obo/TXPO_0004557,,,,,,,,,,,TXPO:0004585,,,,,,,,,,,,,,,,,,,,,,HBV infection [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004588,TGF beta receptor signaling (primitive) [hepatocarcinogenesis],,"TGF beta receptor signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal transmitted by the TGF beta receptor (transforming growth factor beta receptor) on the surface of a cell, starting with a ligand binding to a TGFR.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0001854,,,,,,,,,,,,,,,,,,,,PMID:11359698|PMID:31507621|PMID:30690589|PMID:31781608,,"TGF beta receptor signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal transmitted by the TGF beta receptor (transforming growth factor beta receptor) on the surface of a cell, starting with a ligand binding to a TGFR.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004516|http://purl.obolibrary.org/obo/TXPO_0004827,,,,,,http://purl.obolibrary.org/obo/TXPO_0004422|http://purl.obolibrary.org/obo/TXPO_0004828|http://purl.obolibrary.org/obo/TXPO_0004392,,,,,,,,,,,TXPO:0004588,,,,,,,,,,,,,,,,,,,,,,TGF beta receptor signaling (primitive) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004586,Notch signaling [hepatocarcinogenesis],,"Notch signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by Notch.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0004724|http://purl.obolibrary.org/obo/TXPO_0002340,,,,,,,,,,,,,,,,,,,,PMID:28036048|PMID:30309512|PMID:31781608,,"Notch signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by Notch.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004725|http://purl.obolibrary.org/obo/TXPO_0004727|http://purl.obolibrary.org/obo/TXPO_0004726,http://purl.obolibrary.org/obo/GO_0007219,,,,,http://purl.obolibrary.org/obo/TXPO_0004459|http://purl.obolibrary.org/obo/TXPO_0004404|http://purl.obolibrary.org/obo/TXPO_0004728|http://purl.obolibrary.org/obo/TXPO_0004422|http://purl.obolibrary.org/obo/TXPO_0004298,,,,,,,,,,,TXPO:0004586,,,,,,,,,,,,,,,,,,,,,,Notch signaling [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004581,HBEGF (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:25433|NCBI-Human-GeneID:1839|NCBI-Mouse-GeneID:15200,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004581,,,,,,,,,,,,,,,,,,,,,,HBEGF (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004580,Increasing HBEGF level,,Increasing HBEGF level is a subtype of increasing quantity: A process that changes the amount of HBEGF level to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing HBEGF level is a subtype of increasing quantity: A process that changes the amount of HBEGF level to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004581,,,,,,,,,,,,,,,,,,,TXPO:0004580,,,,,,,,,,,,,,,,,,,,,,Increasing HBEGF level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004587,STAT3 signaling (primitive) [hepatocarcinogenesis],,"STAT3 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the STAT3 (signal transducer and activator of transcription 3) .
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004807,,,,,,,,,,,,,,,,,,,,PMID:25181692|PMID:28584306,,"STAT3 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the STAT3 (signal transducer and activator of transcription 3) .
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004787,http://purl.obolibrary.org/obo/TXPO_0004808,,,,,,http://purl.obolibrary.org/obo/TXPO_0004809|http://purl.obolibrary.org/obo/TXPO_0004518|http://purl.obolibrary.org/obo/TXPO_0004395,,,,,,,,,,,TXPO:0004587,,,,,,,,,,,,,,,,,,,,,,STAT3 signaling (primitive) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004584,HBV infection,,HBV infection is a subtype of pathogen colonization: A process that makes HBV present in the liver to increase the number.,false,,,http://purl.obolibrary.org/obo/TXPO_0002139,,,,,,,,,,,,,,,,,,,,,,HBV infection is a subtype of pathogen colonization: A process that makes HBV present in the liver to increase the number.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004584,,,,,,,,,,,,,,,,,,,,,,HBV infection,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004582,Increasing HBEGF level [hepatocarcinogenesis],,"Increasing HBEGF level is a subtype of increasing quantity: A process that changes the amount of HBEGF level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0004580|http://purl.obolibrary.org/obo/TXPO_0002340,,,,,,,,,,,,,,,,,,,,PMID:29270806,,"Increasing HBEGF level is a subtype of increasing quantity: A process that changes the amount of HBEGF level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004583,,http://purl.obolibrary.org/obo/TXPO_0004448,,,,,,http://purl.obolibrary.org/obo/TXPO_0004396,,,,,,,,,,,TXPO:0004582,,,,,,,,,,,,,,,,,,,,,,Increasing HBEGF level [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004583,HBEGF (rat) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004581|http://purl.obolibrary.org/obo/TXPO_0005070,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:25433|PMID:29270806,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004583,,,,,,,,,,,,,,,,,,,,,,HBEGF (rat) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004589,c-Src signaling (primitive) [hepatocarcinogenesis],,"c-Src signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by c-Src.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004875,,,,,,,,,,,,,,,,,,,,PMID:31781608,,"c-Src signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by c-Src.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004876,http://purl.obolibrary.org/obo/TXPO_0004805,,,,,http://purl.obolibrary.org/obo/TXPO_0004422,,,,,,,,,,,TXPO:0004589,,,,,,,,,,,,,,,,,,,,,,c-Src signaling (primitive) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0016197,endosomal transport,,"The directed movement of substances mediated by an endosome, a membrane-bounded organelle that carries materials enclosed in the lumen or located in the endosomal membrane.",false,,,http://purl.obolibrary.org/obo/GO_0016192,,,,,,,,,,,,,,,,,,,,,,"The directed movement of substances mediated by an endosome, a membrane-bounded organelle that carries materials enclosed in the lumen or located in the endosomal membrane.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0016197,,,,,,,,,,,,,,,,,,,,,,endosomal transport,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0016192,vesicle-mediated transport,vesicle trafficking|vesicle transport|vesicular transport,"A cellular transport process in which transported substances are moved in membrane-bounded vesicles; transported substances are enclosed in the vesicle lumen or located in the vesicle membrane. The process begins with a step that directs a substance to the forming vesicle, and includes vesicle budding and coating. Vesicles are then targeted to, and fuse with, an acceptor membrane.",false,,,http://purl.obolibrary.org/obo/GO_0006810,,,,,,,,,,,,,,,,,,,,,,"A cellular transport process in which transported substances are moved in membrane-bounded vesicles; transported substances are enclosed in the vesicle lumen or located in the vesicle membrane. The process begins with a step that directs a substance to the forming vesicle, and includes vesicle budding and coating. Vesicles are then targeted to, and fuse with, an acceptor membrane.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,vesicle transport|vesicular transport,,vesicle trafficking,,,GO:0016192,,,,,,,,,,,,,,,,,,,,,,vesicle-mediated transport,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000000,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_16991,deoxyribonucleic acid,DNA,"High molecular weight, linear polymers, composed of nucleotides containing deoxyribose and linked by phosphodiester bonds; DNA contain the genetic information of organisms.",false,,,http://purl.obolibrary.org/obo/CHEBI_33696,,,,,,,,,,,,,,,,,,,,,,"High molecular weight, linear polymers, composed of nucleotides containing deoxyribose and linked by phosphodiester bonds; DNA contain the genetic information of organisms.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,DNA,,,CHEBI:16991,,,,,,,,,,,,,,,,,,,,,,deoxyribonucleic acid,,,,,,,http://purl.obolibrary.org/obo/chebi.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000831,ATF-6 alpha,activating transcription factor 6 alpha,,false,,,http://purl.obolibrary.org/obo/TXPO_1000013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,activating transcription factor 6 alpha,,,,,IMR:0000831,,,,,,,,,,,,,,,,,,,,,,ATF-6 alpha,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000007112,TMPO,,Other designations: LEM domain containing 4|TP alpha|TP beta/gamma|lamina-associated polypeptide 2|thymopoietin-related peptide isoform alpha|thymopoietin-related peptide isoforms beta/gamma,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,TP|LEMD4|LAP2|CMD1T|PRO0868,,,,,,,,,,,,12,,,,,,HGNC:11875|MIM:188380|HPRD:01777|Vega:OTTHUMG00000170210|Ensembl:ENSG00000120802,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,thymopoietin,,,12q22,,,,,,,,,,,,,,,,"GO_0000785 (EC: IDA, PMID: 17284516); GO_0003677 (EC: IEA); GO_0005515 (EC: IPI, PMID: 17474147); GO_0005521 (EC: TAS, PMID: 8530026); GO_0005634 (EC: IDA, PMID: 17284516); GO_0005634 (EC: TAS, PMID: 8530026); GO_0005635 (EC: TAS, PMID: 8530026); GO_0005637 (EC: IEA); GO_0006355 (EC: IEA); GO_0016021 (EC: IEA); GO_0031965 (EC: IDA)",,,,,,,,,PMID: 302007; 2158125; 6364989; 7517549; 7703909; 8324822; 8530026; 8619474; 8743987; 9110174; 9461618; 9490046; 9707448; 10393804; 10430029; 10806084; 10984438; 11034899; 11435115; 11500367; 11591818; 12475961; 12477932; 12538639; 12950172; 15302935; 15489334; 15546916; 16083285; 16129885; 16196087; 16247757; 16344560; 16606692; 16713569; 16760672; 17081983; 17207965; 17213199; 17227891; 17284516; 17314511; 17364180; 17474147; 17558393; 17620599; 18029348; 18403046; 19135240; 19394292; 19454010; 19471022; 19727227; 19913121; 19928837; 19929986; 20237496; 20301486; 20360068; 20462248; 20562859; 20628086; 21139048; 21252943; 21549307; 21679440; 21693764; 21890473; 21906983; 21907836; 21963094; 21987572; 21990273; 22113938; 22145905; 22268729; 22412018; 22505724; 22751105; 22939629; 22990118; 23000965; 23182705; 23184937; 23463506; 23673662; 23752268; 24457600,,,,,,,,,,,,,,,OGG:3000007112,,20140408,protein-coding,,,,thymopoietin,,,,,,,,,,,,,Other designations: LEM domain containing 4|TP alpha|TP beta/gamma|lamina-associated polypeptide 2|thymopoietin-related peptide isoform alpha|thymopoietin-related peptide isoforms beta/gamma,,TMPO,,,,,,,,,,,,,,,,,,,,,,,7112,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,TMPO,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/GO_0036498,IRE1-mediated unfolded protein response,UPR signaling by IRE1 stress sensor|endoplasmic reticulum unfolded protein response; IRE1 signaling,"A series of molecular signals mediated by the endoplasmic reticulum stress sensor IRE1 (Inositol-requiring transmembrane kinase/endonuclease). Begins with activation of IRE1 in response to endoplasmic reticulum (ER) stress, and ends with regulation of a downstream cellular process, e.g. transcription. One target of activated IRE1 is the transcription factor HAC1 in yeast, or XBP1 in mammals; IRE1 cleaves an intron of a mRNA coding for HAC1/XBP1 to generate an activated HAC1/XBP1 transcription factor, which controls the up regulation of UPR-related genes. At least in mammals, IRE1 can also signal through additional intracellular pathways including JNK and NF-kappaB.",false,,,http://purl.obolibrary.org/obo/TXPO_0002155,,,,,,,,,,,,,,,,,,,,,,"A series of molecular signals mediated by the endoplasmic reticulum stress sensor IRE1 (Inositol-requiring transmembrane kinase/endonuclease). Begins with activation of IRE1 in response to endoplasmic reticulum (ER) stress, and ends with regulation of a downstream cellular process, e.g. transcription. One target of activated IRE1 is the transcription factor HAC1 in yeast, or XBP1 in mammals; IRE1 cleaves an intron of a mRNA coding for HAC1/XBP1 to generate an activated HAC1/XBP1 transcription factor, which controls the up regulation of UPR-related genes. At least in mammals, IRE1 can also signal through additional intracellular pathways including JNK and NF-kappaB.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,UPR signaling by IRE1 stress sensor|endoplasmic reticulum unfolded protein response; IRE1 signaling,,,,,GO:0036498,,,,,,,,,,,,,,,,,,,,,,IRE1-mediated unfolded protein response,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0036499,PERK-mediated unfolded protein response,UPR signaling by PERK stress sensor|endoplasmic reticulum unfolded protein response; PERK signaling,"A series of molecular signals mediated by the endoplasmic reticulum membrane stress sensor PERK (PKR-like ER kinase). Begins with activation of PERK in response to endoplasmic reticulum (ER) stress and ends with regulation of a downstream cellular process, e.g. transcription. The main substrate of PERK is the translation initiation factor eIF2alpha. Serine-phosphorylation of eIF2alpha by PERK inactivates eIF2alpha and inhibits general protein translation. In addition, eIF2alpha phosphorylation preferentially increases the translation of selective mRNAs such as ATF4 (activating transcription factor 4), which up regulates a subset of UPR genes required to restore folding capacity.",false,,,http://purl.obolibrary.org/obo/TXPO_0000285,,,,,,,,,,,,,,,,,,,,,,"A series of molecular signals mediated by the endoplasmic reticulum membrane stress sensor PERK (PKR-like ER kinase). Begins with activation of PERK in response to endoplasmic reticulum (ER) stress and ends with regulation of a downstream cellular process, e.g. transcription. The main substrate of PERK is the translation initiation factor eIF2alpha. Serine-phosphorylation of eIF2alpha by PERK inactivates eIF2alpha and inhibits general protein translation. In addition, eIF2alpha phosphorylation preferentially increases the translation of selective mRNAs such as ATF4 (activating transcription factor 4), which up regulates a subset of UPR genes required to restore folding capacity.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,UPR signaling by PERK stress sensor|endoplasmic reticulum unfolded protein response; PERK signaling,,,,,GO:0036499,,,,,,,,,,,,,,,,,,,,,,PERK-mediated unfolded protein response,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001707,phosphatidylglycerol accumulation in lysosome,,Phosphatidylglycerol accumulation in lysosome is a subtype of glycerophospholipid accumulation in lysosome: A process that keeps phosphatidylglycerol in the lysosome.,false,,,http://purl.obolibrary.org/obo/TXPO_0001697,,,,,,,,,,,,,,,,,,,,,,Phosphatidylglycerol accumulation in lysosome is a subtype of glycerophospholipid accumulation in lysosome: A process that keeps phosphatidylglycerol in the lysosome.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001707,,,,,,,,,,,,,,,,,,,,,,phosphatidylglycerol accumulation in lysosome,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001701,phosphatidic acid accumulation in lysosome,,Phosphatidic acid accumulation in lysosome is a subtype of glycerophospholipid accumulation in lysosome: A process that keeps phosphatidic acid in the lysosome.,false,,,http://purl.obolibrary.org/obo/TXPO_0001697,,,,,,,,,,,,,,,,,,,,,,Phosphatidic acid accumulation in lysosome is a subtype of glycerophospholipid accumulation in lysosome: A process that keeps phosphatidic acid in the lysosome.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001701,,,,,,,,,,,,,,,,,,,,,,phosphatidic acid accumulation in lysosome,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001700,increase in fatty acid inflow into hepatocyte [Phpspholipidosis(moderate)],,"Increase in fatty acid inflow into hepatocyte is a subtype of increasing quantity: A process that changes the fatty acid inflow into the hepatocyte to be larger. The digree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001673,,,,,,,,,,,,,,,,,,,,,,"Increase in fatty acid inflow into hepatocyte is a subtype of increasing quantity: A process that changes the fatty acid inflow into the hepatocyte to be larger. The digree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001702,,,,,,,,,,,TXPO:0001700,,,,,,,,,,,,,,,,,,,,,,increase in fatty acid inflow into hepatocyte [Phpspholipidosis(moderate)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001702,increasing phospholipid material[Phospholipidosis (moderate )],,"Increasing phospholipid material is a subtype of increasing quantity: A process that changes the amount of phospholipid material to be larger.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (moderate).",false,,,http://purl.obolibrary.org/obo/TXPO_0001762,,,,,,,,,,,,,,,,,,,,,,"Increasing phospholipid material is a subtype of increasing quantity: A process that changes the amount of phospholipid material to be larger.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (moderate).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001136,,,,,,http://purl.obolibrary.org/obo/TXPO_0001761,,,,,,,,,,,TXPO:0001702,,,,,,,,,,,,,,,,,,,,,,increasing phospholipid material[Phospholipidosis (moderate )],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001709,phosphatidylethanolamine accumulation in lysosome,,Phosphatidylethanolamine accumulation in lysosome is a subtype of glycerophospholipid accumulation in lysosome: A process that keeps phosphatidylethanolamine in the lysosome.,false,,,http://purl.obolibrary.org/obo/TXPO_0001697,,,,,,,,,,,,,,,,,,,,,,Phosphatidylethanolamine accumulation in lysosome is a subtype of glycerophospholipid accumulation in lysosome: A process that keeps phosphatidylethanolamine in the lysosome.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001709,,,,,,,,,,,,,,,,,,,,,,phosphatidylethanolamine accumulation in lysosome,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001708,hyperfunction of phospholipid biosynthesis [Phospholipidosis (severe) ],,"Hyperfunction of phospholipid biosynthesis is a subtype of hyperfunction of biosynthesis: A process that performs an excessive phospholipid biosynthesis.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",false,,,http://purl.obolibrary.org/obo/TXPO_0000908,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of phospholipid biosynthesis is a subtype of hyperfunction of biosynthesis: A process that performs an excessive phospholipid biosynthesis.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001778,,,,,,,,,,,TXPO:0001708,,,,,,,,,,,,,,,,,,,,,,hyperfunction of phospholipid biosynthesis [Phospholipidosis (severe) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001704,hyperfunction of phospholipid biosynthesis [Phospholipidosis (moderate) ],,"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of phospholipids.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (moderate).",false,,,http://purl.obolibrary.org/obo/TXPO_0000908,,,,,,,,,,,,,,,,,,,,,,"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of phospholipids.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (moderate).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003372,,,,,,,,,,,TXPO:0001704,,,,,,,,,,,,,,,,,,,,,,hyperfunction of phospholipid biosynthesis [Phospholipidosis (moderate) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001703,phosphatidylserine accumulation in lysosome,,Phosphatidylserine accumulation in lysosome is a subtype of glycerophospholipid accumulation in lysosome: A process that keeps phosphatidylserine in the lysosome.,false,,,http://purl.obolibrary.org/obo/TXPO_0001697,,,,,,,,,,,,,,,,,,,,,,Phosphatidylserine accumulation in lysosome is a subtype of glycerophospholipid accumulation in lysosome: A process that keeps phosphatidylserine in the lysosome.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001703,,,,,,,,,,,,,,,,,,,,,,phosphatidylserine accumulation in lysosome,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001705,phosphatidylcholine accumulation in lysosome,,Phosphatidylcholine accumulation in lysosome is a subtype of glycerophospholipid accumulation in lysosome: A process that keeps phosphatidylcholine in the lysosome.,false,,,http://purl.obolibrary.org/obo/TXPO_0001697,,,,,,,,,,,,,,,,,,,,,,Phosphatidylcholine accumulation in lysosome is a subtype of glycerophospholipid accumulation in lysosome: A process that keeps phosphatidylcholine in the lysosome.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001705,,,,,,,,,,,,,,,,,,,,,,phosphatidylcholine accumulation in lysosome,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001706,S1P inactivation,,S1P inactivation is a subtype of molecular inactivation: A process that  changes the activity of the S1P (Sphingosine-1-phosphate) to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000021,,,,,,,,,,,,,,,,,,,,,,S1P inactivation is a subtype of molecular inactivation: A process that  changes the activity of the S1P (Sphingosine-1-phosphate) to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001706,,,,,,,,,,,,,,,,,,,,,,S1P inactivation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000394,ICSBP,,,false,,,http://purl.obolibrary.org/obo/IMR_0000386,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000394,,,,,,,,,,,,,,,,,,,,,,ICSBP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003457,increasing hepatic portal pressure [hepatic blood circulatory disorder],,"Increasing hepatic portal pressure is a subtype of increasing pressure: A process that changes the hepatic portal pressure to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatic blood circulatory disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001359|http://purl.obolibrary.org/obo/TXPO_0003618,,,,,,,,,,,,,,,,,,,,,,"Increasing hepatic portal pressure is a subtype of increasing pressure: A process that changes the hepatic portal pressure to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatic blood circulatory disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003462|http://purl.obolibrary.org/obo/TXPO_0003461|http://purl.obolibrary.org/obo/TXPO_0003466|http://purl.obolibrary.org/obo/TXPO_0003463,,,,,,,,,,,TXPO:0003457,,,,,,,,,,,,,,,,,,,,,,increasing hepatic portal pressure [hepatic blood circulatory disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003450,negative regulation of phospholipase-mediated phospholipid degradation by CAD [Phospholipidosis (severe) ],,"Negative regulation of phospholipase-mediated phospholipid degradation by CAD is a subtype of negative regulation of phospholipid degradation: A process that stops, prevents, or reduces the frequency, rate or extent of phospholipase-mediated phospholipid deradation regulated by CAD. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",false,,,http://purl.obolibrary.org/obo/TXPO_0003414,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of phospholipase-mediated phospholipid degradation by CAD is a subtype of negative regulation of phospholipid degradation: A process that stops, prevents, or reduces the frequency, rate or extent of phospholipase-mediated phospholipid deradation regulated by CAD. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003227|http://purl.obolibrary.org/obo/TXPO_0003228|http://purl.obolibrary.org/obo/TXPO_0000319,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003449|http://purl.obolibrary.org/obo/TXPO_0003447,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004032|http://purl.obolibrary.org/obo/TXPO_0002217,,,,,,,,,,,TXPO:0003450,,,,,,,,,,,,,,,,,,,,,,negative regulation of phospholipase-mediated phospholipid degradation by CAD [Phospholipidosis (severe) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003458,increasing hepatic venous pressure [hepatic blood circulatory disorder],,"Increasing hepatic venous pressure is a subtype of increasing pressure: A process that changes the hpatic venous pressure to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatic blood circulatory disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0003618|http://purl.obolibrary.org/obo/TXPO_0001366,,,,,,,,,,,,,,,,,,,,,,"Increasing hepatic venous pressure is a subtype of increasing pressure: A process that changes the hpatic venous pressure to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatic blood circulatory disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003459,,,,,,,,,,,TXPO:0003458,,,,,,,,,,,,,,,,,,,,,,increasing hepatic venous pressure [hepatic blood circulatory disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003456,ASAH1 - inactivated (human)[Phospholipidosis - hypofunctioning of ceramide degradation],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000529,,,,,,,,,,,,,,,,,,,,http://omim.org/entry/613468,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0002355,,,,http://purl.obolibrary.org/obo/TXPO_0003351|http://purl.obolibrary.org/obo/TXPO_0003321,,,,,,,,,,TXPO:0003456,,,,,,,,,,,,,,,,,,,,,,ASAH1 - inactivated (human)[Phospholipidosis - hypofunctioning of ceramide degradation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001442,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003452,phospholipidosis (severe),,The totality of all processes through which the phospholipidosis is realized. The severity is severe.,false,,,http://purl.obolibrary.org/obo/TXPO_0002215,,,,,,,,,,,,,,,,,,,,PMID:16979167|PMID:22960355|PMID:15342952,,The totality of all processes through which the phospholipidosis is realized. The severity is severe.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003547|http://purl.obolibrary.org/obo/TXPO_0002276|http://purl.obolibrary.org/obo/TXPO_0003824|http://purl.obolibrary.org/obo/TXPO_0004101|http://purl.obolibrary.org/obo/TXPO_0000797|http://purl.obolibrary.org/obo/TXPO_0001708|http://purl.obolibrary.org/obo/TXPO_0003451|http://purl.obolibrary.org/obo/TXPO_0001488|http://purl.obolibrary.org/obo/TXPO_0001257|http://purl.obolibrary.org/obo/TXPO_0001542|http://purl.obolibrary.org/obo/TXPO_0001315|http://purl.obolibrary.org/obo/TXPO_0000911|http://purl.obolibrary.org/obo/TXPO_0000912|http://purl.obolibrary.org/obo/TXPO_0004154|http://purl.obolibrary.org/obo/TXPO_0000156|http://purl.obolibrary.org/obo/TXPO_0004132|http://purl.obolibrary.org/obo/TXPO_0001778|http://purl.obolibrary.org/obo/TXPO_0004144|http://purl.obolibrary.org/obo/TXPO_0004148|http://purl.obolibrary.org/obo/TXPO_0004040|http://purl.obolibrary.org/obo/TXPO_0000903|http://purl.obolibrary.org/obo/TXPO_0000717|http://purl.obolibrary.org/obo/TXPO_0004010|http://purl.obolibrary.org/obo/TXPO_0001695|http://purl.obolibrary.org/obo/TXPO_0001698|http://purl.obolibrary.org/obo/TXPO_0001497|http://purl.obolibrary.org/obo/TXPO_0004069|http://purl.obolibrary.org/obo/TXPO_0004065|http://purl.obolibrary.org/obo/TXPO_0002226|http://purl.obolibrary.org/obo/TXPO_0002227|http://purl.obolibrary.org/obo/TXPO_0002222|http://purl.obolibrary.org/obo/TXPO_0002220|http://purl.obolibrary.org/obo/TXPO_0003886|http://purl.obolibrary.org/obo/TXPO_0003889|http://purl.obolibrary.org/obo/TXPO_0000928|http://purl.obolibrary.org/obo/TXPO_0000927|http://purl.obolibrary.org/obo/TXPO_0000923|http://purl.obolibrary.org/obo/TXPO_0000920|http://purl.obolibrary.org/obo/TXPO_0002097|http://purl.obolibrary.org/obo/TXPO_0002098|http://purl.obolibrary.org/obo/TXPO_0002094|http://purl.obolibrary.org/obo/TXPO_0003592|http://purl.obolibrary.org/obo/TXPO_0003594|http://purl.obolibrary.org/obo/TXPO_0001294|http://purl.obolibrary.org/obo/TXPO_0001844|http://purl.obolibrary.org/obo/TXPO_0002297|http://purl.obolibrary.org/obo/TXPO_0003877|http://purl.obolibrary.org/obo/TXPO_0004001|http://purl.obolibrary.org/obo/TXPO_0000539|http://purl.obolibrary.org/obo/TXPO_0002239|http://purl.obolibrary.org/obo/TXPO_0002217|http://purl.obolibrary.org/obo/TXPO_0004084|http://purl.obolibrary.org/obo/TXPO_0000334|http://purl.obolibrary.org/obo/TXPO_0001400|http://purl.obolibrary.org/obo/TXPO_0001262|http://purl.obolibrary.org/obo/TXPO_0000555|http://purl.obolibrary.org/obo/TXPO_0000558|http://purl.obolibrary.org/obo/TXPO_0004053|http://purl.obolibrary.org/obo/TXPO_0004123|http://purl.obolibrary.org/obo/TXPO_0003431|http://purl.obolibrary.org/obo/TXPO_0003435,,,,,,,,,,,,,,,,,,TXPO:0003452,,,,,,,,,,,,,,,,,,,,,,phospholipidosis (severe),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003453,compound accumulation in lysosome [Phospholipidosis (mild)],,"Compound accumulation in lysosome is a subtype of accumulation of xenobiotics: A process that keeps compound in the lysosome.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (mild).",false,,,http://purl.obolibrary.org/obo/TXPO_0000930,,,,,,,,,,,,,,,,,,,,,,"Compound accumulation in lysosome is a subtype of accumulation of xenobiotics: A process that keeps compound in the lysosome.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (mild).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001241,http://purl.obolibrary.org/obo/TXPO_0001560|http://purl.obolibrary.org/obo/TXPO_0001566|http://purl.obolibrary.org/obo/TXPO_0001425|http://purl.obolibrary.org/obo/TXPO_0000081,,,,,,http://purl.obolibrary.org/obo/TXPO_0002087,,,,,,,,,,,TXPO:0003453,,,,,,,,,,,,,,,,,,,,,,compound accumulation in lysosome [Phospholipidosis (mild)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003451,CAD accumulation in lysosome [Phospholipidosis (severe)],,"CAD accumulation in lysosome is a subtype of compound accumulation in lysosome: A process that keeps CAD (Cationic Amphiphilic Drugs cationic amphiphile drug) in the lysosome. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",false,,,http://purl.obolibrary.org/obo/TXPO_0003367,,,,,,,,,,,,,,,,,,,,,,"CAD accumulation in lysosome is a subtype of compound accumulation in lysosome: A process that keeps CAD (Cationic Amphiphilic Drugs cationic amphiphile drug) in the lysosome. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001560|http://purl.obolibrary.org/obo/TXPO_0000081,,,,,,http://purl.obolibrary.org/obo/TXPO_0003450|http://purl.obolibrary.org/obo/TXPO_0003365,,,,,,,,,,,TXPO:0003451,,,,,,,,,,,,,,,,,,,,,,CAD accumulation in lysosome [Phospholipidosis (severe)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005764,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003454,compound accumulation in lysosome [Phospholipidosis (moderate) ],,"Compound accumulation in lysosome is a subtype of accumulation of xenobiotics: A process that keeps compound in the lysosome. And the degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (moderate).",false,,,http://purl.obolibrary.org/obo/TXPO_0000930,,,,,,,,,,,,,,,,,,,,,,"Compound accumulation in lysosome is a subtype of accumulation of xenobiotics: A process that keeps compound in the lysosome. And the degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (moderate).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002214,http://purl.obolibrary.org/obo/TXPO_0001560|http://purl.obolibrary.org/obo/TXPO_0001425,,,,,,http://purl.obolibrary.org/obo/TXPO_0003444,,,,,,,,,,,TXPO:0003454,,,,,,,,,,,,,,,,,,,,,,compound accumulation in lysosome [Phospholipidosis (moderate) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003459,hyperfunction of hepatic lymph production [hepatic blood circulatory disorder],,"Hyperfunction of hepatic lymph production is a subtype of hyperfunction of biosynthesis: A process that performs an excessive hepatic lymph production.
This entity is a specific course-dependent process. This process can constitute the course of hepatic blood circulatory disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0003618|http://purl.obolibrary.org/obo/TXPO_0001367,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of hepatic lymph production is a subtype of hyperfunction of biosynthesis: A process that performs an excessive hepatic lymph production.
This entity is a specific course-dependent process. This process can constitute the course of hepatic blood circulatory disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003460,,,,,,,,,,,TXPO:0003459,,,,,,,,,,,,,,,,,,,,,,hyperfunction of hepatic lymph production [hepatic blood circulatory disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003455,negative regulation of cell cycle gene expression,,"Negative regulation of cell cycle regulator gene expression is a subtype of negative regulation of gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of cell cycle regulator gene expression.",false,,,http://purl.obolibrary.org/obo/GO_0010629,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of cell cycle regulator gene expression is a subtype of negative regulation of gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of cell cycle regulator gene expression.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003455,,,,,,,,,,,,,,,,,,,,,,negative regulation of cell cycle gene expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100766,Wnt-2,IRP protein|Int-1 related protein,,false,,,http://purl.obolibrary.org/obo/IMR_0000003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IRP protein|Int-1 related protein,,,,,IMR:0100766,,,,,,,,,,,,,,,,,,,,,,Wnt-2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0002579,"inositol 1,4,5-trisphosphate 3-kinase C",IP3K-C,,false,,,http://purl.obolibrary.org/obo/IMR_0002576,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IP3K-C,,,,,IMR:0002579,,,,,,,,,,,,,,,,,,,,,,"inositol 1,4,5-trisphosphate 3-kinase C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000051378,ANGPT4,,Other designations: ANG-4|angiopoietin-3|angiopoietin-4|dJ824F16.2 (angiopoietin 4),false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,AGP4|ANG4|ANG-3,,,,,,,,,,,,20,,,,,,HPRD:04747|Ensembl:ENSG00000101280|MIM:603705|HGNC:487|Vega:OTTHUMG00000031652,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,angiopoietin 4,,,20p13,,,,,,,,,,,,,,,,"GO_0001525 (EC: IEA); GO_0001935 (EC: IDA, Qualifier: NOT, PMID:10025962); GO_0005576 (EC: TAS); GO_0005615 (EC: IDA, PMID:10025962); GO_0007171 (EC: IDA, PMID:10051567); GO_0007596 (EC: TAS); GO_0010595 (EC: IDA, PMID:12958144); GO_0016525 (EC: IDA, PMID:16790085); GO_0030297 (EC: IDA, PMID:10051567); GO_0030971 (EC: IDA, PMID:10051567); GO_0043066 (EC: IDA, PMID:12958144); GO_0043536 (EC: IDA, PMID:15284220); GO_0043537 (EC: IDA, PMID:16790085); GO_0045766 (EC: IDA, PMID:15284220); GO_0050731 (EC: IDA, PMID:15851516); GO_0050900 (EC: TAS); GO_0071456 (EC: IEP, PMID:12958144)",,,,,,,,,PMID:10025962; 10051567; 10218486; 10343124; 11076863; 11780052; 11856872; 12477932; 12624729; 12958144; 15198927; 15284220; 15489334; 15542434; 15851516; 16790085; 17724803; 19204726; 19913121; 20596041; 20628086; 20819778; 20823154; 21603628; 22267746,,,,,,,,,,,,,,,OGG:3000051378,,,,,,,angiopoietin 4,,,,,,,,,,,,,Other designations: ANG-4|angiopoietin-3|angiopoietin-4|dJ824F16.2 (angiopoietin 4),,ANGPT4,,,,,,,,,,,,,,,,,,,,,,,51378,,,,,,,,9606,,,,,,,,,,,,,,,,,,,ANGPT4,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/NCIT_C49508,high level,,The level of degree is high in comparison to medium.,false,,,http://purl.obolibrary.org/obo/TXPO_0004208,,,,,,,,,,,,,,,,,,,,,,The level of degree is high in comparison to medium.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,NCIT:C49508,,,,,,,,,,,,,,,,,,,,,,high level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000414,AP-1,,"The AP-1 (activator protein 1) transcription factor is a dimeric complex that comprises members of the JUN, FOS, ATF (activating transcription factor) and MAF (musculoaponeurotic fibrosarcoma) protein families. The AP-1 complex can therefore form many different combinations of heterodimers and homodimers, and this combination determines the genes that are regulated by AP-1.",false,,,http://purl.obolibrary.org/obo/TXPO_0002107,,,,,,,,,,,,,,,,,,,,,,"The AP-1 (activator protein 1) transcription factor is a dimeric complex that comprises members of the JUN, FOS, ATF (activating transcription factor) and MAF (musculoaponeurotic fibrosarcoma) protein families. The AP-1 complex can therefore form many different combinations of heterodimers and homodimers, and this combination determines the genes that are regulated by AP-1.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,,,,,,IMR:0000414,,,,,,,,,,,,,,,,,,,,,,AP-1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_37887,adrenergic antagonist,adrenergic antagonists|adrenoceptor antagonists|adrenergic blockaders|adrenergic receptor blockaders|adrenergic blocker|adrenergic blockers,An agent that binds to but does not activate adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists.,false,,,http://purl.obolibrary.org/obo/CHEBI_37962,,,,,,,,,,,,,,,,,,,,,,An agent that binds to but does not activate adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,adrenergic antagonists|adrenoceptor antagonists|adrenergic blockaders|adrenergic receptor blockaders|adrenergic blocker|adrenergic blockers,,,,,,,,,,,,,,,,,,,,,CHEBI:37887,,,,adrenergic antagonist,,CHEBI:37887,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001489,regulation of cell cycle [Phospholipidosis (excessive defense) ],,"Any process that modulates the rate or extent of progression through the cell cycle.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense) .",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/GO_0051726,,,,,,,,,,,,,,,,,,,,,,"Any process that modulates the rate or extent of progression through the cell cycle.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense) .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002268|http://purl.obolibrary.org/obo/TXPO_0002249,,,,,,http://purl.obolibrary.org/obo/TXPO_0002276|http://purl.obolibrary.org/obo/TXPO_0001491|http://purl.obolibrary.org/obo/TXPO_0001490,,,,,,,,,,,TXPO:0001489,,,,,,,,,,,,,,,,,,,,,,regulation of cell cycle [Phospholipidosis (excessive defense) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001481,pulmonary infection [Niemann Pick Disease Type A],,"Pulmonary infection is a subtype of pathogen colonization: A process that makes pathogen such as microorganism (bacteria, virus, mycoplasma, etc.) present in the lung to increase the number.
This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type A.",false,,,http://purl.obolibrary.org/obo/TXPO_0001478,,,,,,,,,,,,,,,,,,,,,,"Pulmonary infection is a subtype of pathogen colonization: A process that makes pathogen such as microorganism (bacteria, virus, mycoplasma, etc.) present in the lung to increase the number.
This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type A.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001481,,,,,,,,,,,,,,,,,,,,,,pulmonary infection [Niemann Pick Disease Type A],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001488,inflammatory response [Phospholipidosis (excessive defense)],iflammation [Phospholipidosis (excessive defense)],"Inflammatory response is a subtype of changing material: The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense).",false,,,http://purl.obolibrary.org/obo/TXPO_0000192|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Inflammatory response is a subtype of changing material: The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002265|http://purl.obolibrary.org/obo/TXPO_0000156|http://purl.obolibrary.org/obo/TXPO_0004113,http://purl.obolibrary.org/obo/TXPO_0004072|http://purl.obolibrary.org/obo/TXPO_0001138|http://purl.obolibrary.org/obo/TXPO_0002290|http://purl.obolibrary.org/obo/TXPO_0001143,,,,,,http://purl.obolibrary.org/obo/TXPO_0001850,,,,,,,,iflammation [Phospholipidosis (excessive defense)],,,TXPO:0001488,,,,,,,,,,,,,,,,,,,,,,inflammatory response [Phospholipidosis (excessive defense)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001485,lysophagy [Phospholipidosis (excessive defense) ],,"lysophagy is a subtype of autophagy: A process that becomes larger in the number of autodigestion of abnormal lysosome.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense) .",false,,,http://purl.obolibrary.org/obo/GO_0062093|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"lysophagy is a subtype of autophagy: A process that becomes larger in the number of autodigestion of abnormal lysosome.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense) .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001485,,,,,,,,,,,,,,,,,,,,,,lysophagy [Phospholipidosis (excessive defense) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001480,decrease in platelet count [Niemann Pick Disease Type B],,"Decrease in platelet count is a subtype of decreasing number of objects: A process that becomes smaller in platelet count.
This entity is a specific course-dependent process. This process can constitute the course of Niemann-Pick Disease Type B.",false,,,http://purl.obolibrary.org/obo/TXPO_0001479|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Decrease in platelet count is a subtype of decreasing number of objects: A process that becomes smaller in platelet count.
This entity is a specific course-dependent process. This process can constitute the course of Niemann-Pick Disease Type B.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001480,,,,,,,,,,,,,,,,,,,,,,decrease in platelet count [Niemann Pick Disease Type B],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001482,sphingomyelin metabolism imbalance [Niemann Pick Disease Type A],,"A process that becomes lacking a homeostastasis balance of the sphingomyelin metabolism.
This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type A.",false,,,http://purl.obolibrary.org/obo/TXPO_0001476,,,,,,,,,,,,,,,,,,,,,,"A process that becomes lacking a homeostastasis balance of the sphingomyelin metabolism.
This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type A.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000929,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001815,,http://purl.obolibrary.org/obo/TXPO_0002327,,,,,,,,,TXPO:0001482,,,,,,,,,,,,,,,,,,,,,,sphingomyelin metabolism imbalance [Niemann Pick Disease Type A],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001483,hyperfunction of phospholipid removing,,Hyperfunction of phospholipid removing is a subtype of hyperfunctioning: A process that performs an excessive removal of phospholipids.,false,,,http://purl.obolibrary.org/obo/TXPO_0002279,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of phospholipid removing is a subtype of hyperfunctioning: A process that performs an excessive removal of phospholipids.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001483,,,,,,,,,,,,,,,,,,,,,,hyperfunction of phospholipid removing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001484,hyperfunction of phospholipid removing [Phospholipidosis (excessive defense)],,"Hyperfunction of phospholipid removing is a subtype of hyperfunctioning: A process that performs an excessive removal of phospholipids.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense).",false,,,http://purl.obolibrary.org/obo/TXPO_0001483|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of phospholipid removing is a subtype of hyperfunctioning: A process that performs an excessive removal of phospholipids.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001485,,,,,,,,,,,,,,,,,,TXPO:0001484,,,,,,,,,,,,,,,,,,,,,,hyperfunction of phospholipid removing [Phospholipidosis (excessive defense)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001487,hyperfunction of immune response [Phospholipidosis (excessive defense)],,"Hyperfunction of immune response is a subtype of hyperfunctioning: A process that performs an excessive immune response.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense).",false,,,http://purl.obolibrary.org/obo/TXPO_0001486|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,PMID:26241657,,"Hyperfunction of immune response is a subtype of hyperfunctioning: A process that performs an excessive immune response.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000334|http://purl.obolibrary.org/obo/TXPO_0003431,http://purl.obolibrary.org/obo/TXPO_0004105|http://purl.obolibrary.org/obo/TXPO_0003586,,,,,,http://purl.obolibrary.org/obo/TXPO_0001488,,,,,,,,,,,TXPO:0001487,,,,,,,,,,,,,,,,,,,,,,hyperfunction of immune response [Phospholipidosis (excessive defense)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001486,hyperfunction of immune response,,Hyperfunction of immune response is a subtype of hyperfunctioning: A process that performs an excessive immune response.,false,,,http://purl.obolibrary.org/obo/TXPO_0000435,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of immune response is a subtype of hyperfunctioning: A process that performs an excessive immune response.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001486,,,,,,,,,,,,,,,,,,,,,,hyperfunction of immune response,,,,,,http://purl.obolibrary.org/obo/GO_0006955,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000374,STAT,signal tranducers and activators of transcription,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,signal tranducers and activators of transcription,,,,,IMR:0000374,,,,,,,,,,,,,,,,,,,,,,STAT,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_28509,chloroethene,塩化ビニル|クロロエチレン|Vinyl chloride,A monohaloethene that is ethene in which one of the hydrogens has been replaced by a chloro group.,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:75-01-4|Wikipedia:Chloroethene,,A monohaloethene that is ethene in which one of the hydrogens has been replaced by a chloro group.,,,,,,,,,,,,C2H3Cl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,塩化ビニル|クロロエチレン|Vinyl chloride,,,CHEBI:28509,,,,,,,,,,,,,,,,,,,,,,chloroethene,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ClC=C,,,,,
http://purl.obolibrary.org/obo/IMR_0000479,alpha-actinin 1,,,false,,,http://purl.obolibrary.org/obo/IMR_0000189,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000479,,,,,,,,,,,,,,,,,,,,,,alpha-actinin 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76744,EC 1.17.* (oxidoreductase acting on CH or CH2) inhibitor,oxidoreductase acting on CH or CH2 inhibitor|oxidoreductase acting on CH or CH2 (EC 1.17.*) inhibitors|EC 1.17.* inhibitor|oxidoreductase acting on CH or CH2 (EC 1.17.*) inhibitor|oxidoreductase acting on CH or CH2 inhibitors|EC 1.17.* inhibitors|EC 1.17.* (oxidoreductase acting on CH or CH2) inhibitors,An oxidoreductase inhibitor which interferes with the action of an oxidoreductase acting on CH or CH2 (EC 1.17.*.*).,false,,,http://purl.obolibrary.org/obo/CHEBI_76725,,,,,,,,,,,,,,,,,,,,,,An oxidoreductase inhibitor which interferes with the action of an oxidoreductase acting on CH or CH2 (EC 1.17.*.*).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,oxidoreductase acting on CH or CH2 inhibitor|oxidoreductase acting on CH or CH2 (EC 1.17.*) inhibitors|EC 1.17.* inhibitor|oxidoreductase acting on CH or CH2 (EC 1.17.*) inhibitor|oxidoreductase acting on CH or CH2 inhibitors|EC 1.17.* inhibitors|EC 1.17.* (oxidoreductase acting on CH or CH2) inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:76744,,,,EC 1.17.* (oxidoreductase acting on CH or CH2) inhibitor,,CHEBI:76744,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0022403,cell cycle phase,,One of the distinct periods or stages into which the cell cycle is divided. Each phase is characterized by the occurrence of specific biochemical and morphological events.,false,,,http://purl.obolibrary.org/obo/PATO_0000083,,,,,,,,,,,,,,,,,,,,,,One of the distinct periods or stages into which the cell cycle is divided. Each phase is characterized by the occurrence of specific biochemical and morphological events.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0022403,,,,,,,,,,,,,,,,,,,,,,cell cycle phase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000140809,SRXN1,,Other designations: sulfiredoxin-1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,SRX1|SRX|Npn3|C20orf139,,,,,,,,,,,,20,,,,,,HGNC:16132|Vega:OTTHUMG00000031644|HPRD:12747|Ensembl:ENSG00000271303,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,sulfiredoxin 1,,,20p13,,,,,,,,,,,,,,,,"GO_0005524 (EC: IEA); GO_0005829 (EC: IDA, PMID: 15448164); GO_0006979 (EC: IDA, PMID: 15448164); GO_0016667 (EC: IDA, PMID: 15448164); GO_0032542 (EC: IEA)",,,,,,,,,PMID: 11076863; 11181995; 11230166; 11780052; 12477932; 15448164; 15489334; 15489336; 15590625; 15952770; 16381901; 16565085; 16818657; 17176052; 18172504; 18579529; 18593714; 19027064; 19057013; 19561357; 19812042; 20718723; 21487000; 21742584; 21800051; 21943684; 22086924; 22879602; 22934964; 22939629; 22964583,,,,,,,,,,,,,,,OGG:3000140809,,,,,,,sulfiredoxin 1,,,,,,,,,,,,,Other designations: sulfiredoxin-1,,SRXN1,,,,,,,,,,,,,,,,,,,,,,,140809,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,SRXN1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/PATO_0015004,increased efficacy,,A increase in the ability of a process to produce its output.,false,,,http://purl.obolibrary.org/obo/PATO_0015002,,,,,,,,,,,,,,,,,,,,,,A increase in the ability of a process to produce its output.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0015004,,,,,,,,,,,,,,,,,,,,,,increased efficacy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0015003,decreased efficacy,,A decrease in the ability of a process to produce its output.,false,,,http://purl.obolibrary.org/obo/PATO_0015002,,,,,,,,,,,,,,,,,,,,,,A decrease in the ability of a process to produce its output.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0015003,,,,,,,,,,,,,,,,,,,,,,decreased efficacy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0015002,process efficacy,,The ability of a process to produce its output.,false,,,http://purl.obolibrary.org/obo/PATO_0001236,,,,,,,,,,,,,,,,,,,,,,The ability of a process to produce its output.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0015002,,,,,,,,,,,,,,,,,,,,,,process efficacy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_23899,icosanoid,eicosanoid,"Any member of the group of signalling molecules arising from oxidation of the three C20 essential fatty acids (EFAs) icosapentaenoic acid (EPA), arachidonic acid (AA) and dihomo-gamma-linolenic acid (DGLA).",false,,,http://purl.obolibrary.org/obo/CHEBI_61697,,,,,,,,,,,,,,,,,,,,IMR:0001381,,"Any member of the group of signalling molecules arising from oxidation of the three C20 essential fatty acids (EFAs) icosapentaenoic acid (EPA), arachidonic acid (AA) and dihomo-gamma-linolenic acid (DGLA).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,eicosanoid,,,,,CHEBI:23899,,,,,,,,,,,,,,,,,,,,,,icosanoid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000036,TGF-beta superfamily,transforming growth factor beta superfamily,"The TGF-beta superfamily of growth factors regulate many cellular functions, which includes TGF-betas, activins and inhibins, nodal, BMPs and GDFs. TGF-beta/BMP-like proteins are found in various species, including Xenopus, C.elegans and D.melanogaster.",false,,,http://purl.obolibrary.org/obo/TXPO_0001382,,,,,,,,,,,,,,,,,,,,GO:0005160,,"The TGF-beta superfamily of growth factors regulate many cellular functions, which includes TGF-betas, activins and inhibins, nodal, BMPs and GDFs. TGF-beta/BMP-like proteins are found in various species, including Xenopus, C.elegans and D.melanogaster.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002395|http://purl.obolibrary.org/obo/TXPO_0000624,,,,,transforming growth factor beta superfamily,,,,,IMR:0000036,,,,,,,,,,,,,,,,,,,,,,TGF-beta superfamily,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0001886,hydrophilicity,,A physical quality inhering in a bearer by virtue the bearer's disposition to having an affinity for water; it is readily absorbing or dissolving in water.,false,,,http://purl.obolibrary.org/obo/BFO_0000019|http://purl.obolibrary.org/obo/TXPO_0002422,,,,,,,,,,,,,,,,,,,,,,A physical quality inhering in a bearer by virtue the bearer's disposition to having an affinity for water; it is readily absorbing or dissolving in water.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0001886,,,,,,,,,,,,,,,,,,,,,,hydrophilicity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0001884,hydrophobicity,,A physical quality inhering in a bearer by virtue the bearer's disposition to being water-repellent; tending to repel and not absorb water.,false,,,http://purl.obolibrary.org/obo/BFO_0000019|http://purl.obolibrary.org/obo/TXPO_0002423,,,,,,,,,,,,,,,,,,,,,,A physical quality inhering in a bearer by virtue the bearer's disposition to being water-repellent; tending to repel and not absorb water.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0001884,,,,,,,,,,,,,,,,,,,,,,hydrophobicity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010480,60S ribosomal protein L23a,P29316,,false,,,http://purl.obolibrary.org/obo/IMR_0000897,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,P29316,,,,,IMR:0010480,,,,,,,,,,,,,,,,,,,,,,60S ribosomal protein L23a,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000885,TFIIE,,,false,,,http://purl.obolibrary.org/obo/IMR_0000888,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003645,,,,,,,,,,IMR:0000885,,,,,,,,,,,,,,,,,,,,,,TFIIE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100199,gamma-MSH,gamma-Melanotropin,A peptide hormone of about 11 amino acids derived from PRO-OPIOMELANOCORTIN that has natriuretic activity.,false,,,http://purl.obolibrary.org/obo/IMR_0100198,,,,,,,,,,,,,,,,,,,,MeSH:D019825,,A peptide hormone of about 11 amino acids derived from PRO-OPIOMELANOCORTIN that has natriuretic activity.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,gamma-Melanotropin,,,,,IMR:0100199,,,,,,,,,,,,,,,,,,,,,,gamma-MSH,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100722,Delta-like4,DLL4|Delta4,,false,,,http://purl.obolibrary.org/obo/IMR_0100718,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,DLL4|Delta4,,,,,IMR:0100722,,,,,,,,,,,,,,,,,,,,,,Delta-like4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001694,catecholamine,,,false,,,http://purl.obolibrary.org/obo/IMR_0002121,,,,,,,,,,,,,,,,,,,,CHEBI:33567,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001694,,,,,,,,,,,,,,,,,,,,,,catecholamine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100663,Cln3,G1/S-specific cyclin CLN3,,false,,,http://purl.obolibrary.org/obo/IMR_0100670,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,G1/S-specific cyclin CLN3,,,,,IMR:0100663,,,,,,,,,,,,,,,,,,,,,,Cln3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_28241,papaverine,"1-(3,4-dimethoxybenzyl)-6,7-dimethoxyisoquinoline","A benzylisoquinoline alkaloid that is isoquinoline substituted by methoxy groups at positions 6 and 7 and a 3,4-dimethoxybenzyl group at position 1. It has been isolated from Papaver somniferum.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,LINCS:LSM-2338|PMID:24414229|DrugBank:DB01113|Drug_Central:2056|Reaxys:312930|CAS:58-74-2|PMID:11971205,,"A benzylisoquinoline alkaloid that is isoquinoline substituted by methoxy groups at positions 6 and 7 and a 3,4-dimethoxybenzyl group at position 1. It has been isolated from Papaver somniferum.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_53784|http://purl.obolibrary.org/obo/CHEBI_35620,,,,,"1-(3,4-dimethoxybenzyl)-6,7-dimethoxyisoquinoline",,,,,,,,,,,,,,,,,,,,,,,CHEBI:28241,,,,papaverine,,CHEBI:28241,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100057,growth hormone-releasing hormone,SRH|GHRH|Somatoliberin|somatotropin-releasing hormone,Hypothalamic peptide that regulates the synthesis and secretion of GROWTH HORMONE in the anterior pituitary gland.,false,,,http://purl.obolibrary.org/obo/IMR_0100093,,,,,,,,,,,,,,,,,,,,MeSH:D013007,,Hypothalamic peptide that regulates the synthesis and secretion of GROWTH HORMONE in the anterior pituitary gland.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,SRH|GHRH|Somatoliberin|somatotropin-releasing hormone,,,,,IMR:0100057,,,,,,,,,,,,,,,,,,,,,,growth hormone-releasing hormone,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0011140,eIF2B-gamma,"eIF-2B GDP-GTP exchange factor, gamma subunit|translation initiation factor 2B gamma subunit|Translation initiation factor eIF-2B gamma subunit|eIF-2B GDP-GTP exchange factor",,false,,,http://purl.obolibrary.org/obo/IMR_0000915,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"eIF-2B GDP-GTP exchange factor, gamma subunit|translation initiation factor 2B gamma subunit|Translation initiation factor eIF-2B gamma subunit|eIF-2B GDP-GTP exchange factor",,,,,IMR:0011140,,,,,,,,,,,,,,,,,,,,,,eIF2B-gamma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002486,XBP1s gene regulation pathway,,XBP1s gene regulation pathway is a subtype of gene regulation pathway: A series of process in which XBP1s regulates the gene expression.,false,,,http://purl.obolibrary.org/obo/TXPO_0001902,,,,,,,,,,,,,,,,,,,,,,XBP1s gene regulation pathway is a subtype of gene regulation pathway: A series of process in which XBP1s regulates the gene expression.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002606,,,,,,,,,,,,,,,,,,TXPO:0002486,,,,,,,,,,,,,,,,,,,,,,XBP1s gene regulation pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002481,phosphatidylinositol 3-kinase signaling,PI3K signaling,"A series of reactions within the signal-receiving cell, mediated by the intracellular phosphatidylinositol 3-kinase (PI3K). Many cell surface receptor linked signaling pathways signal through PI3K to regulate numerous cellular functions.",false,,,http://purl.obolibrary.org/obo/TXPO_0000609,,,,,,,,,,,,,,,,,,,,GO:0014065,,"A series of reactions within the signal-receiving cell, mediated by the intracellular phosphatidylinositol 3-kinase (PI3K). Many cell surface receptor linked signaling pathways signal through PI3K to regulate numerous cellular functions.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PI3K signaling,,,,,TXPO:0002481,,,,,,,,,,,,,,,,,,,,,,phosphatidylinositol 3-kinase signaling,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002485,CHOP gene regulation pathway,,CHOP gene regulation pathway is a subtype of gene regulation pathway: Sequence of reactions to regulate genes by CHOP.,false,,,http://purl.obolibrary.org/obo/TXPO_0001902,,,,,,,,,,,,,,,,,,,,,,CHOP gene regulation pathway is a subtype of gene regulation pathway: Sequence of reactions to regulate genes by CHOP.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001874,,,,,,,,,,,,,,,,,,TXPO:0002485,,,,,,,,,,,,,,,,,,,,,,CHOP gene regulation pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002482,caspase pathway,,A series of molecular signals mediated by Caspase family.,false,,,http://purl.obolibrary.org/obo/TXPO_0000609,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IEV_0000128,,A series of molecular signals mediated by Caspase family.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000444,,,,,,,,,,,,,,,,,,TXPO:0002482,,,,,,,,,,,,,,,,,,,,,,caspase pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002487,IRE1-mediated unfolded protein response [ER stress],,"A series of molecular signals mediated by the endoplasmic reticulum stress sensor IRE1 (Inositol-requiring transmembrane kinase/endonuclease). Begins with activation of IRE1 in response to endoplasmic reticulum (ER) stress, and ends with regulation of a downstream cellular process, e.g. transcription. One target of activated IRE1 is the transcription factor HAC1 in yeast, or XBP1 in mammals; IRE1 cleaves an intron of a mRNA coding for HAC1/XBP1 to generate an activated HAC1/XBP1 transcription factor, which controls the up regulation of UPR-related genes. At least in mammals, IRE1 can also signal through additional intracellular pathways including JNK and NF-kappaB.",false,,,http://purl.obolibrary.org/obo/GO_0036498,,,,,,,,,,,,,,,,,,,,,,"A series of molecular signals mediated by the endoplasmic reticulum stress sensor IRE1 (Inositol-requiring transmembrane kinase/endonuclease). Begins with activation of IRE1 in response to endoplasmic reticulum (ER) stress, and ends with regulation of a downstream cellular process, e.g. transcription. One target of activated IRE1 is the transcription factor HAC1 in yeast, or XBP1 in mammals; IRE1 cleaves an intron of a mRNA coding for HAC1/XBP1 to generate an activated HAC1/XBP1 transcription factor, which controls the up regulation of UPR-related genes. At least in mammals, IRE1 can also signal through additional intracellular pathways including JNK and NF-kappaB.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002487,,,,,,,,,,,,,,,,,,,,,,IRE1-mediated unfolded protein response [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002489,PI3K-AKT signaling,,"PI3K-AKT signaling is a subtype of integrated signaling pathway: Sequence of linked reactions, which has PI3 signaling and activation of the AKT gene.",false,,,http://purl.obolibrary.org/obo/TXPO_0000027,,,,,,,,,,,,,,,,,,,,,,"PI3K-AKT signaling is a subtype of integrated signaling pathway: Sequence of linked reactions, which has PI3 signaling and activation of the AKT gene.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002481|http://purl.obolibrary.org/obo/GO_0043491,,,,,,,,,,,,,,,,TXPO:0002489,,,,,,,,,,,,,,,,,,,,,,PI3K-AKT signaling,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002488,glutathione export from hepatocyte,,glutathione export from hepatocyte is a subtype of glutathione transport: A process that exports the glutathione from the hepatocyte.,false,,,http://purl.obolibrary.org/obo/GO_0034635,,,,,,,,,,,,,,,,,,,,PMID:18786560|ISBN:0071769234,,glutathione export from hepatocyte is a subtype of glutathione transport: A process that exports the glutathione from the hepatocyte.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000182,,,,,,,TXPO:0002488,,,,,,,,,,,,,,,,,,,,,,glutathione export from hepatocyte,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002480,glutathione export from hepatocyte to bile tube,,glutathione export from hepatocyte to bile tube is a subtype of glutathione transport: A process that exports the glutathione from the hepatocyte to to the blood.,false,,,http://purl.obolibrary.org/obo/TXPO_0002488,,,,,,,,,,,,,,,,,,,,,,glutathione export from hepatocyte to bile tube is a subtype of glutathione transport: A process that exports the glutathione from the hepatocyte to to the blood.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002480,,,,,,,,,,,,,,,,,,,,,,glutathione export from hepatocyte to bile tube,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002483,ATF4 gene regulation pathway,,ATF4 gene regulation pathway is a subtype of gene regulation pathway: Sequence of reactions to regulate genes by ATF4.,false,,,http://purl.obolibrary.org/obo/TXPO_0001902,,,,,,,,,,,,,,,,,,,,,,ATF4 gene regulation pathway is a subtype of gene regulation pathway: Sequence of reactions to regulate genes by ATF4.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002964,,,,,,,,,,,,,,,,,,TXPO:0002483,,,,,,,,,,,,,,,,,,,,,,ATF4 gene regulation pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002484,ATF4 gene regulation pathway [ER stress - apoptosis],,"ATF4 gene regulation pathway is a subtype of gene regulation pathway: Sequence of reactions to regulate genes by ATF4.
This pathway is dependent on the apoptosis and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002483,,,,,,,,,,,,,,,,,,,,,,"ATF4 gene regulation pathway is a subtype of gene regulation pathway: Sequence of reactions to regulate genes by ATF4.
This pathway is dependent on the apoptosis and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002484,,,,,,,,,,,,,,,,,,,,,,ATF4 gene regulation pathway [ER stress - apoptosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000009144,SYNGR2,,Other designations: cellugyrin|synaptogyrin-2,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,17,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,synaptogyrin 2,,,17q25.3,,,,,,,,,,,,,,,,"GO_0006605 (EC: IEA); GO_0008021 (EC: IEA); GO_0016021 (EC: NAS, PMID: 9760194); GO_0070062 (EC: IDA)",,,,,,,,,PMID: 9446595; 9760194; 12477932; 12975309; 15489334; 17255364; 21139048; 21890473; 23000965,,,,,,,,,,,,,,,OGG:3000009144,,,,,,,synaptogyrin 2,,,,,,,,,,,,,Other designations: cellugyrin|synaptogyrin-2,,SYNGR2,,,,,,,,,,,,,,,,,,,,,,,9144,UNQ352/PRO615,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,SYNGR2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_50683,EC 1.5.1.3 (dihydrofolate reductase) inhibitor,"NADPH-dihydrofolate reductase inhibitor|7,8-dihydrofolate reductase inhibitors|DHFR inhibitors|dihydrofolic reductase inhibitors|EC 1.5.1.3 (dihydrofolate reductase) inhibitors|EC 1.5.1.3 inhibitor|dihydrofolic acid reductase inhibitors|7,8-dihydrofolate reductase inhibitor|folic reductase inhibitors|EC 1.5.1.3 inhibitors|dihydrofolic reductase inhibitor|NADPH-dihydrofolate reductase inhibitors|dihydrofolate reductase (EC 1.5.1.3) inhibitors|dihydrofolate reductase inhibitors|folic acid reductase inhibitor|tetrahydrofolate dehydrogenase inhibitors|dihydrofolic acid reductase inhibitor|folic acid reductase inhibitors|dihydrofolate reductase (EC 1.5.1.3) inhibitor|DHFR inhibitor|tetrahydrofolate dehydrogenase inhibitor|dihydrofolate reductase inhibitor|folic reductase inhibitor","An EC 1.5.1.* (oxidoreductase acting on donor CH-NH group, NAD(+) or NADP(+) as acceptor) inhibitor that interferes with the action of dihydrofolate reductase (EC 1.5.1.3).",false,,,http://purl.obolibrary.org/obo/CHEBI_73913|http://purl.obolibrary.org/obo/CHEBI_76863,,,,,,,,,,,,,,,,,,,,,,"An EC 1.5.1.* (oxidoreductase acting on donor CH-NH group, NAD(+) or NADP(+) as acceptor) inhibitor that interferes with the action of dihydrofolate reductase (EC 1.5.1.3).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"NADPH-dihydrofolate reductase inhibitor|7,8-dihydrofolate reductase inhibitors|DHFR inhibitors|dihydrofolic reductase inhibitors|EC 1.5.1.3 (dihydrofolate reductase) inhibitors|EC 1.5.1.3 inhibitor|dihydrofolic acid reductase inhibitors|7,8-dihydrofolate reductase inhibitor|folic reductase inhibitors|EC 1.5.1.3 inhibitors|dihydrofolic reductase inhibitor|NADPH-dihydrofolate reductase inhibitors|dihydrofolate reductase (EC 1.5.1.3) inhibitors|dihydrofolate reductase inhibitors|folic acid reductase inhibitor|tetrahydrofolate dehydrogenase inhibitors|dihydrofolic acid reductase inhibitor|folic acid reductase inhibitors|dihydrofolate reductase (EC 1.5.1.3) inhibitor|DHFR inhibitor|tetrahydrofolate dehydrogenase inhibitor|dihydrofolate reductase inhibitor|folic reductase inhibitor",,,,,,,,,,,,,,,,,,,,,CHEBI:50683,,,,EC 1.5.1.3 (dihydrofolate reductase) inhibitor,,CHEBI:50683,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010492,60S ribosomal protein L40,CEP52,,false,,,http://purl.obolibrary.org/obo/IMR_0000897,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CEP52,,,,,IMR:0010492,,,,,,,,,,,,,,,,,,,,,,60S ribosomal protein L40,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100098,"gonadotropin, pituitary",,"Hormones secreted by the adenohypophysis ( PITUITARY GLAND, ANTERIOR) that stimulate gonadal functions in both males and females. They include FOLLICLE STIMULATING HORMONE that stimulates germ cell maturation ( OOGENESIS; SPERMATOGENESIS), and LUTEINIZING HORMONE that stimulates the production of sex steroids ( ESTROGENS; PROGESTERONE; ANDROGENS).",false,,,http://purl.obolibrary.org/obo/IMR_0100087|http://purl.obolibrary.org/obo/IMR_0100096,,,,,,,,,,,,,,,,,,,,MeSH:D006065,,"Hormones secreted by the adenohypophysis ( PITUITARY GLAND, ANTERIOR) that stimulate gonadal functions in both males and females. They include FOLLICLE STIMULATING HORMONE that stimulates germ cell maturation ( OOGENESIS; SPERMATOGENESIS), and LUTEINIZING HORMONE that stimulates the production of sex steroids ( ESTROGENS; PROGESTERONE; ANDROGENS).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100098,,,,,,,,,,,,,,,,,,,,,,"gonadotropin, pituitary",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/BFO_0000015,process,,"p is a process = Def. p is an occurrent that has temporal proper parts and for some time t, p s-depends_on some material entity at t. (axiom label in BFO2 Reference: [083-003])",false,,,http://purl.obolibrary.org/obo/BFO_0000003,,,,,,,,,,,,,,,,,,,"Superclass of unit process(primitive process) and senquence processes.
It is dissective and has no unity, and hence it can change.
It follows A-series of time.",,,"p is a process = Def. p is an occurrent that has temporal proper parts and for some time t, p s-depends_on some material entity at t. (axiom label in BFO2 Reference: [083-003])",,,,"BFO 2 Reference: The realm of occurrents is less pervasively marked by the presence of natural units than is the case in the realm of independent continuants. Thus there is here no counterpart of ‘object’. In BFO 1.0 ‘process’ served as such a counterpart. In BFO 2.0 ‘process’ is, rather, the occurrent counterpart of ‘material entity’. Those natural – as contrasted with engineered, which here means: deliberately executed – units which do exist in the realm of occurrents are typically either parasitic on the existence of natural units on the continuant side, or they are fiat in nature. Thus we can count lives; we can count football games; we can count chemical reactions performed in experiments or in chemical manufacturing. We cannot count the processes taking place, for instance, in an episode of insect mating behavior.Even where natural units are identifiable, for example cycles in a cyclical process such as the beating of a heart or an organism’s sleep/wake cycle, the processes in question form a sequence with no discontinuities (temporal gaps) of the sort that we find for instance where billiard balls or zebrafish or planets are separated by clear spatial gaps. Lives of organisms are process units, but they too unfold in a continuous series from other, prior processes such as fertilization, and they unfold in turn in continuous series of post-life processes such as post-mortem decay. Clear examples of boundaries of processes are almost always of the fiat sort (midnight, a time of death as declared in an operating theater or on a death certificate, the initiation of a state of war)",,,"a process of cell-division, \ a beating of the heart|the life of an organism|your process of aging.|the course of a disease|a process of sleeping|a process of meiosis",,,,,,,,,,,(iff (Process a) (and (Occurrent a) (exists (b) (properTemporalPartOf b a)) (exists (c t) (and (MaterialEntity c) (specificallyDependsOnAt a c t))))) // axiom label in BFO2 CLIF: [083-003],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BFO:0000015,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/bfo.owl,process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0043467,regulation of generation of precursor metabolites and energy,,"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of precursor metabolites, substances from which energy is derived, and the processes involved in the liberation of energy from these substances.",false,,,http://purl.obolibrary.org/obo/TXPO_0000113,,,,,,,,,,,,,,,,,,,,,,"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of precursor metabolites, substances from which energy is derived, and the processes involved in the liberation of energy from these substances.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0043467,,,,,,,,,,,,,,,,,,,,,,regulation of generation of precursor metabolites and energy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006091,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0001816,cytokine production,,"The appearance of a cytokine due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.|Note that this term is intended for use when a gene product is seen to cause apparent increases in intracellular or extracellular cytokine levels, without specific regard as to whether the increase is due to increased biosynthesis, increased secretion of preexisting cytokine molecules, or increased conversion from precursor molecules.",false,,,http://purl.obolibrary.org/obo/TXPO_0000382,,,,,,,,,,,,,,,,,,,,,,"The appearance of a cytokine due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.",,,,,cytokine production,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0042089,,,,,,,,,,,,,,,,,,GO:0001816,,,,,,,,,,,,,,,,,,,,"Note that this term is intended for use when a gene product is seen to cause apparent increases in intracellular or extracellular cytokine levels, without specific regard as to whether the increase is due to increased biosynthesis, increased secretion of preexisting cytokine molecules, or increased conversion from precursor molecules.",,cytokine production,,,,,,,http://purl.obolibrary.org/obo/go.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0050776,regulation of immune response,,"Any process that modulates the frequency, rate or extent of the immune response, the immunological reaction of an organism to an immunogenic stimulus.",false,,,http://purl.obolibrary.org/obo/TXPO_0000113,,,,,,,,,,,,,,,,,,,,,,"Any process that modulates the frequency, rate or extent of the immune response, the immunological reaction of an organism to an immunogenic stimulus.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0050776,,,,,,,,,,,,,,,,,,,,,,regulation of immune response,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006955,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_70782,PPARalpha agonist,peroxisome proliferator-activated receptor-alpha agonist|PPAR-alpha agonist,A PPAR modulator which activates the peroxisome proliferator-activated receptor-alpha.,false,,,http://purl.obolibrary.org/obo/CHEBI_48705,,,,,,,,,,,,,,,,,,,,,,A PPAR modulator which activates the peroxisome proliferator-activated receptor-alpha.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,peroxisome proliferator-activated receptor-alpha agonist|PPAR-alpha agonist,,,,,CHEBI:70782,,,,,,,,,,,,,,,,,,,,,,PPARalpha agonist,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000029128,UHRF1,,"Other designations: E3 ubiquitin-protein ligase UHRF1|RING finger protein 106|inverted CCAAT box-binding protein of 90 kDa|nuclear phosphoprotein 95|nuclear protein 95|nuclear zinc finger protein Np95|transcription factor ICBP90|ubiquitin-like PHD and RING finger domain-containing protein 1|ubiquitin-like, containing PHD and RING finger domains, 1",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,RNF106|hNP95|huNp95|ICBP90|Np95|hUHRF1,,,,,,,,,,,,19,,,,,,HGNC:12556|HPRD:06992|MIM:607990,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,ubiquitin-like with PHD and ring finger domains 1,,,19p13.3,,,,,,,,,,,,,,,,"GO_0000122 (EC: IDA); GO_0000790 (EC: IDA, PMID: 17673620); GO_0000790 (EC: ISS); GO_0000791 (EC: IDA); GO_0000792 (EC: IDA, PMID: 17967883); GO_0000987 (EC: IDA, PMID: 10646863); GO_0003700 (EC: TAS, PMID: 1868030); GO_0004842 (EC: IDA, PMID: 17967883); GO_0004842 (EC: ISS); GO_0005515 (EC: IPI, PMID: 15361834); GO_0005634 (EC: IDA, PMID: 10646863); GO_0005657 (EC: IDA, PMID: 17673620); GO_0006281 (EC: IEA); GO_0006351 (EC: IEA); GO_0007049 (EC: IEA); GO_0008270 (EC: IDA); GO_0008283 (EC: IEP, PMID: 15361834); GO_0008327 (EC: IDA, PMID: 15361834); GO_0010216 (EC: IMP, PMID: 17673620); GO_0010390 (EC: ISS); GO_0016363 (EC: ISS); GO_0016574 (EC: IDA, PMID: 17967883); GO_0031493 (EC: ISS); GO_0032270 (EC: IDA, PMID: 10646863); GO_0035064 (EC: IDA, PMID: 17967883); GO_0042393 (EC: IDA); GO_0042787 (EC: IDA); GO_0042802 (EC: ISS); GO_0044729 (EC: IDA, PMID: 17673620); GO_0045944 (EC: IC, PMID: 10646863); GO_0051865 (EC: IDA, PMID: 17967883); GO_2000373 (EC: IC, PMID: 10646863)",,,,,,,,,PMID: 1868030; 8889549; 10646863; 11290415; 12477932; 12838312; 14702039; 14993289; 15009091; 15033738; 15057824; 15146197; 15178447; 15361834; 15964557; 16007129; 16195352; 16344560; 16964243; 17065439; 17067204; 17081983; 17370265; 17673620; 17934516; 17967883; 18005238; 18772889; 18781797; 18945682; 19056828; 19077538; 19270723; 19322201; 19328461; 19471022; 19491893; 19798101; 19800870; 19851296; 19943104; 20037778; 20198315; 20613874; 21045206; 21067293; 21139048; 21214517; 21252943; 21268065; 21296067; 21351083; 21489993; 21539450; 21611839; 21745816; 21777816; 21808300; 21890473; 21906983; 21963094; 22055183; 22064703; 22096602; 22100450; 22219067; 22285022; 22286757; 22294699; 22330138; 22411829; 22505724; 22552622; 22837395; 22939629; 22945642; 23000965; 23022729; 23023523; 23107467; 23161542; 23245651; 23281010; 23297342; 23463006; 23537643; 23677994; 23752590; 23943380; 24005809; 24013172; 24035451; 24134914; 24324066; 24368767; 24457600; 24469333; 24486181,,,,,,,,,,,,,,,OGG:3000029128,,20140408,protein-coding,,,,ubiquitin-like with PHD and ring finger domains 1,,,,,,,,,,,,,"Other designations: E3 ubiquitin-protein ligase UHRF1|RING finger protein 106|inverted CCAAT box-binding protein of 90 kDa|nuclear phosphoprotein 95|nuclear protein 95|nuclear zinc finger protein Np95|transcription factor ICBP90|ubiquitin-like PHD and RING finger domain-containing protein 1|ubiquitin-like, containing PHD and RING finger domains, 1",,UHRF1,,,,,,,,,,,,,,,,,,,,,,,29128,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,UHRF1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/GO_0010941,regulation of cell death,,"Any process that modulates the rate or frequency of cell death. Cell death is the specific activation or halting of processes within a cell so that its vital functions markedly cease, rather than simply deteriorating gradually over time, which culminates in cell death. [",false,,,http://purl.obolibrary.org/obo/TXPO_0000113,,,,,,,,,,,,,,,,,,,,,,"Any process that modulates the rate or frequency of cell death. Cell death is the specific activation or halting of processes within a cell so that its vital functions markedly cease, rather than simply deteriorating gradually over time, which culminates in cell death. [",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0010941,,,,,,,,,,,,,,,,,,,,,,regulation of cell death,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0008219,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000342,Nck family,,"The widely expressed Nck is a 47-kDa cytosolic protein exclusively composed of one SH2 and three SH3 domains. Recently, a second member of the Nck family has been isolated (Nck beta/Grb4) which shows 68% amino acid identity to Nck (Nck alpha).",false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,"The widely expressed Nck is a 47-kDa cytosolic protein exclusively composed of one SH2 and three SH3 domains. Recently, a second member of the Nck family has been isolated (Nck beta/Grb4) which shows 68% amino acid identity to Nck (Nck alpha).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003681,,,,,,,,,,IMR:0000342,,,,,,,,,,,,,,,,,,,,,,Nck family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0000020,sense organ,sensillum|Sinnesorgan|sensor|organ of sense organ system|organ of sensory organ system|sense organ system organ|organ of sensory system|sensory organ system organ|sensory system organ|sensory organ,An organ that is capable of transducing sensory stimulus to the nervous system.,false,,,http://purl.obolibrary.org/obo/UBERON_0000062,,,,,,,,,,,,,,,,,,,,http://www.snomedbrowser.com/Codes/Details/244485009|http://linkedlifedata.com/resource/umls/id/C0935626|http://purl.obolibrary.org/obo/NCIT_C33224|FBbt:00005155|VHOG:0001407|UMLS:C0935626|MESH:D012679|EMAPA:35955|BSA:0000121|EHDAA2:0001824|GAID:63|AEO:0000094|EHDAA:500|WBbt:0006929|EMAPA:16192|MA:0000017|BTO:0000202|HAO:0000930|CALOHA:TS-2043,,An organ that is capable of transducing sensory stimulus to the nervous system.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,organ of sense organ system|organ of sensory organ system|sense organ system organ|organ of sensory system|sensory organ system organ|sensory system organ|sensory organ,sensillum,Sinnesorgan|sensor,,http://purl.obolibrary.org/obo/UBERON_0001032,UBERON:0000020,http://purl.obolibrary.org/obo/UBERON_0001032,,,https://github.com/cmungall,,,,,,,,,,,,,,,,,,sense organ,,,,http://upload.wikimedia.org/wikipedia/commons/c/c0/Gray722.png,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0000025,tube (anatomical),anatomical tube,"Any hollow cylindrical anatomical structure containing a lumen through which substances are transported.|not every anatomical conduit is a tube - for example, a bone foramen is an opening in the bone, and there is no distinct separate tube structure. Tubes may transport large mixed objects (for example, a bolus of food in the digestive tube) or they may transport the secretions of a single gland (for example, gland ducts)",false,,,http://purl.obolibrary.org/obo/UBERON_0004111,,,,,,,,,,,,,,,,,,,,,,Any hollow cylindrical anatomical structure containing a lumen through which substances are transported.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,anatomical tube,,,,,UBERON:0000025,,,,,,,,,,,,,,,,,,,,"not every anatomical conduit is a tube - for example, a bone foramen is an opening in the bone, and there is no distinct separate tube structure. Tubes may transport large mixed objects (for example, a bolus of food in the digestive tube) or they may transport the secretions of a single gland (for example, gland ducts)",,tube (anatomical),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000212,Irf1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:3659|NCBI-Mouse-GeneID:16362|NCBI-Rat-GeneID:24508,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000003659,,,,,,,,,,,,,TXPO:1000212,,,,,,,,,,,,,,,,,,,,,,Irf1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000218,Kdelr2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:11014|NCBI-Mouse-GeneID:66913|NCBI-Rat-GeneID:304290,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000011014,,,,,,,,,,,,,TXPO:1000218,,,,,,,,,,,,,,,,,,,,,,Kdelr2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000210,Insig1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:64194|NCBI-Mouse-GeneID:231070|NCBI-Human-GeneID:3638,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000003638,,,,,,,,,,,,,TXPO:1000210,,,,,,,,,,,,,,,,,,,,,,Insig1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000219,Klf6 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1316|NCBI-Mouse-GeneID:23849|NCBI-Rat-GeneID:58954,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001316,,,,,,,,,,,,,TXPO:1000219,,,,,,,,,,,,,,,,,,,,,,Klf6 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000213,Isyna1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:290651|NCBI-Human-GeneID:51477|NCBI-Mouse-GeneID:71780,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000051477,,,,,,,,,,,,,TXPO:1000213,,,,,,,,,,,,,,,,,,,,,,Isyna1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000211,Insig2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:72999|NCBI-Rat-GeneID:288985|NCBI-Human-GeneID:51141,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000051141,,,,,,,,,,,,,TXPO:1000211,,,,,,,,,,,,,,,,,,,,,,Insig2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000216,MAPK8 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:5599|NCBI-Mouse-GeneID:26419|NCBI-Rat-GeneID:116554,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:1000216,,,,,,,,,,,,,,,,,,,,,,MAPK8 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000215,JMY (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:133746|NCBI-Mouse-GeneID:57748|NCBI-Rat-GeneID:683593,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000133746,,,,,,,,,,,,,TXPO:1000215,,,,,,,,,,,,,,,,,,,,,,JMY (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000214,JMJD6 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:107817|NCBI-Rat-GeneID:360665|NCBI-Human-GeneID:23210,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000023210,,,,,,,,,,,,,TXPO:1000214,,,,,,,,,,,,,,,,,,,,,,JMJD6 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000217,KIFC1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:294286|NCBI-Human-GeneID:3833|NCBI-Mouse-GeneID:100502766,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000003833,,,,,,,,,,,,,TXPO:1000217,,,,,,,,,,,,,,,,,,,,,,KIFC1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0000039,direction,,A physical quality inhering in a bearer by virtue of the bearer's orientation in space.,false,,,http://purl.obolibrary.org/obo/BFO_0000019,,,,,,,,,,,,,,,,,,,,,,A physical quality inhering in a bearer by virtue of the bearer's orientation in space.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0000039,,,,,,,,,,,,,,,,,,,,,,direction,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000005106,PCK2,,"Other designations: PEP carboxykinase|phosphoenolpyruvate carboxykinase [GTP], mitochondrial|phosphoenolpyruvate carboxylase|phosphopyruvate carboxylase",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,PEPCK2|PEPCK-M|PEPCK,,,,,,,,,,,,14,,,,,,MIM:614095|Vega:OTTHUMG00000028791|Ensembl:ENSG00000100889|HPRD:02026|HGNC:8725,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,phosphoenolpyruvate carboxykinase 2 (mitochondrial),,,14q11.2,,,,,,,,,,,,,,,,"GO_0004611 (EC: TAS, PMID: 8645161); GO_0004613 (EC: IEA); GO_0005515 (EC: IPI); GO_0005525 (EC: IEA); GO_0005739 (EC: IDA); GO_0005759 (EC: TAS); GO_0005975 (EC: TAS); GO_0006006 (EC: TAS); GO_0006090 (EC: IEA); GO_0006094 (EC: IEA); GO_0006094 (EC: TAS); GO_0006107 (EC: IEA); GO_0006116 (EC: IEA); GO_0032024 (EC: IEA); GO_0044281 (EC: TAS); GO_0046872 (EC: IEA); GO_0051384 (EC: IEA); GO_0071333 (EC: IEA)",,,,,,,,,PMID: 8645161; 9657976; 12477932; 12916001; 15315819; 15489334; 16132948; 17097062; 18660489; 19521512; 19587243; 20682687; 20797423; 20877624; 21139048; 21733854; 21832049; 21906983; 21988832; 22955269,,,,,,,,,,,,,,,OGG:3000005106,,,,,,,phosphoenolpyruvate carboxykinase 2 (mitochondrial),,,,,,,,,,,,,"Other designations: PEP carboxykinase|phosphoenolpyruvate carboxykinase [GTP], mitochondrial|phosphoenolpyruvate carboxylase|phosphopyruvate carboxylase",,PCK2,,,,,,,,,,,,,,,,,,,,,,,5106,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,PCK2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000005101,PCDH9,,Other designations: cadherin superfamily protein VR4-11|protocadherin-9,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,13,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,protocadherin 9,,,13q21.32,,,,,,,,,,,,,,,,GO_0005509 (EC: IEA); GO_0005886 (EC: IEA); GO_0007156 (EC: IEA); GO_0016021 (EC: IEA); GO_0030900 (EC: IEA),,,,,,,,,PMID: 9787079; 10716726; 10817752; 10835267; 12477932; 14702039; 15057823; 16147992; 16344560; 19322201; 19913121; 20379614; 20628086; 21552555; 21875946; 22300792; 22424883; 23064961; 24250222,,,,,,,,,,,,,,,OGG:3000005101,,,,,,,protocadherin 9,,,,,,,,,,,,,Other designations: cadherin superfamily protein VR4-11|protocadherin-9,,PCDH9,,,,,,,,,,,,,,,,,,,,,,,5101,RP11-335P18.3,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,PCDH9,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000005105,PCK1,,"Other designations: PEP carboxykinase|phosphoenolpyruvate carboxykinase, cytosolic|phosphoenolpyruvate carboxykinase, cytosolic [GTP]|phosphoenolpyruvate carboxylase|phosphopyruvate carboxylase",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,PEPCKC|PEPCK1|PEPCK-C,,,,,,,,,,,,20,,,,,,Ensembl:ENSG00000124253|Vega:OTTHUMG00000032825|HGNC:8724|MIM:614168|HPRD:02028,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,phosphoenolpyruvate carboxykinase 1 (soluble),,,20q13.31,,,,,,,,,,,,,,,,"GO_0000287 (EC: IDA, PMID: 11851336); GO_0004613 (EC: ISS); GO_0005525 (EC: IDA, PMID: 11851336); GO_0005737 (EC: ISS); GO_0005829 (EC: TAS); GO_0005975 (EC: TAS); GO_0006006 (EC: IMP, PMID: 14764811); GO_0006006 (EC: TAS); GO_0006094 (EC: IEA); GO_0006094 (EC: ISS); GO_0006094 (EC: TAS); GO_0006107 (EC: IEA); GO_0006475 (EC: IDA); GO_0014823 (EC: IEA); GO_0017144 (EC: TAS); GO_0019003 (EC: IEA); GO_0030145 (EC: IDA, PMID: 11851336); GO_0031406 (EC: IDA, PMID: 11851336); GO_0032868 (EC: IDA, PMID: 14764811); GO_0042593 (EC: ISS); GO_0044281 (EC: TAS); GO_0046327 (EC: ISS); GO_0070062 (EC: IDA, PMID: 19056867)",,,,,,,,,PMID: 1492743; 1657985; 2993287; 8325643; 8432541; 8490617; 8547315; 11689615; 11780052; 11851336; 11997389; 12237288; 12324453; 12477932; 14744869; 14764811; 15046742; 15489334; 15951444; 16132948; 16144962; 16282543; 16341674; 16344560; 16620271; 16978381; 17192490; 17440948; 17495004; 18029348; 18460190; 18492826; 18660489; 18801732; 18830724; 18976975; 18996102; 19021757; 19056482; 19056867; 19070910; 19329064; 19578796; 19725958; 19913121; 20098747; 20134411; 20574532; 20602615; 20628086; 20682687; 20691246; 20800603; 21145461; 21152065; 21726808; 21832049; 21906983; 21988832; 22489460; 23092637; 23149075; 23300278; 23465595; 23940030,,,,,,,,,,,,,,,OGG:3000005105,,20140408,protein-coding,,,,phosphoenolpyruvate carboxykinase 1 (soluble),,,,,,,,,,,,,"Other designations: PEP carboxykinase|phosphoenolpyruvate carboxykinase, cytosolic|phosphoenolpyruvate carboxykinase, cytosolic [GTP]|phosphoenolpyruvate carboxylase|phosphopyruvate carboxylase",,PCK1,,,,,,,,,,,,,,,,,,,,,,,5105,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,PCK1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000007410,VAV2,,Other designations: guanine nucleotide exchange factor VAV2|vav 2 oncogene,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,VAV-2,,,,,,,,,,,,9,,,,,,MIM:600428|HGNC:12658|Ensembl:ENSG00000160293|HPRD:02694|Vega:OTTHUMG00000020882,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,vav 2 guanine nucleotide exchange factor,,,9q34.1,,,,,,,,,,,,,,,,"GO_0001525 (EC: IEA); GO_0005085 (EC: EXP); GO_0005085 (EC: TAS); GO_0005089 (EC: IEA); GO_0005154 (EC: IEA); GO_0005515 (EC: IPI, PMID: 11390470); GO_0005829 (EC: TAS); GO_0005886 (EC: IEA); GO_0007165 (EC: TAS, PMID: 7762982); GO_0007264 (EC: TAS); GO_0007411 (EC: TAS); GO_0007596 (EC: TAS); GO_0016477 (EC: IEA); GO_0030032 (EC: IEA); GO_0030168 (EC: TAS); GO_0038095 (EC: TAS); GO_0038096 (EC: TAS); GO_0043065 (EC: TAS); GO_0043087 (EC: EXP); GO_0043087 (EC: TAS); GO_0043552 (EC: IEA); GO_0045087 (EC: TAS); GO_0046872 (EC: IEA); GO_0048011 (EC: TAS); GO_0051056 (EC: TAS); GO_0097190 (EC: TAS)",,,,,,,,,PMID: 7762982; 8621483; 8986718; 9115846; 9269777; 9399639; 9438848; 10022833; 10618391; 10938113; 10982832; 11076863; 11080163; 11262396; 11313921; 11390470; 11448999; 11516622; 11606575; 11756498; 11909943; 12376548; 12376551; 12454019; 12477932; 12787561; 12810717; 14702039; 15345594; 15479739; 15489336; 15618286; 15848800; 15850391; 16273093; 16381901; 16397238; 17234718; 17686471; 18067320; 18271526; 18654987; 18729074; 18829495; 19322201; 19451809; 19531499; 19826000; 19911011; 20140013; 20140222; 20298788; 20463313; 20598377; 20808760; 20940296; 21810271; 22554804; 22750419; 22939629; 22946057; 23033535; 23033540; 23382691; 23402756; 23615439; 23724134,,,,,,,,,,,,,,,OGG:3000007410,,,,,,,vav 2 guanine nucleotide exchange factor,,,,,,,,,,,,,Other designations: guanine nucleotide exchange factor VAV2|vav 2 oncogene,,VAV2,,,,,,,,,,,,,,,,,,,,,,,7410,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,VAV2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000079174,CRELD2,,Other designations: cysteine-rich with EGF-like domain protein 2,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,22,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,cysteine-rich with EGF-like domains 2,,,22q13.33,,,,,,,,,,,,,,,,GO_0005509 (EC: IEA); GO_0005515 (EC: IPI); GO_0005615 (EC: IEA); GO_0005783 (EC: IEA); GO_0005794 (EC: IEA),,,,,,,,,PMID: 8125298; 12137942; 12477932; 12975309; 14702039; 15340161; 15489334; 16238698; 16919896; 21900206; 21963094; 21988832; 23455924,,,,,,,,,,,,,,,OGG:3000079174,,,,,,,cysteine-rich with EGF-like domains 2,,,,,,,,,,,,,Other designations: cysteine-rich with EGF-like domain protein 2,,CRELD2,,,,,,,,,,,,,,,,,,,,,,,79174,CITF22-1A6.1,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,CRELD2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000356,Cbl,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003657,,,,,,,,,,IMR:0000356,,,,,,,,,,,,,,,,,,,,,,Cbl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100507,Smad1/5/8,,"Smads 1, 5, and 8 serve principally as substrates for the BMP and anti-Muellerian receptors.",false,,,http://purl.obolibrary.org/obo/IMR_0000371,,,,,,,,,,,,,,,,,,,,,,"Smads 1, 5, and 8 serve principally as substrates for the BMP and anti-Muellerian receptors.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100507,,,,,,,,,,,,,,,,,,,,,,Smad1/5/8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0005504,fatty acid binding,,"Interacting selectively and non-covalently with fatty acids, aliphatic monocarboxylic acids liberated from naturally occurring fats and oils by hydrolysis.",false,,,http://purl.obolibrary.org/obo/GO_0008289,,,,,,,,,,,,,,,,,,,,GO:0005504,,"Interacting selectively and non-covalently with fatty acids, aliphatic monocarboxylic acids liberated from naturally occurring fats and oils by hydrolysis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0005504,,,,,,,,,,,,,,,,,,,,,,fatty acid binding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CL_0000891,foam cell,,"A type of cell containing lipids in small vacuoles and typically seen in atherolosclerotic lesions, as well as other conditions.",false,,,http://purl.obolibrary.org/obo/CL_0000000,,,,,,,,,,,,,,,,,,,,,,"A type of cell containing lipids in small vacuoles and typically seen in atherolosclerotic lesions, as well as other conditions.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CL:0000891,,,,,,,,,,,,,,,,,,,,,,foam cell,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0005856,cytoskeleton,,"Any of the various filamentous elements that form the internal framework of cells, and typically remain after treatment of the cells with mild detergent to remove membrane constituents and soluble components of the cytoplasm. The term embraces intermediate filaments, microfilaments, microtubules, the microtrabecular lattice, and other structures characterized by a polymeric filamentous nature and long-range order within the cell. The various elements of the cytoskeleton not only serve in the maintenance of cellular shape but also have roles in other cellular functions, including cellular movement, cell division, endocytosis, and movement of organelles.",false,,,http://purl.obolibrary.org/obo/GO_0043226,,,,,,,,,,,,,,,,,,,,Wikipedia:Cytoskeleton,,"Any of the various filamentous elements that form the internal framework of cells, and typically remain after treatment of the cells with mild detergent to remove membrane constituents and soluble components of the cytoplasm. The term embraces intermediate filaments, microfilaments, microtubules, the microtrabecular lattice, and other structures characterized by a polymeric filamentous nature and long-range order within the cell. The various elements of the cytoskeleton not only serve in the maintenance of cellular shape but also have roles in other cellular functions, including cellular movement, cell division, endocytosis, and movement of organelles.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005622,GO:0005856,http://purl.obolibrary.org/obo/GO_0005622,,,,,,,,,,,,,,,,,,,,,cytoskeleton,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/BFO_0000001,entity,,,false,,,http://www.w3.org/2002/07/owl#Thing,,,,,,,,,,,,,,,,,,,,,,,,,,"BFO 2 Reference: In all areas of empirical inquiry we encounter general terms of two sorts. First are general terms which refer to universals or types:animaltuberculosissurgical procedurediseaseSecond, are general terms used to refer to groups of entities which instantiate a given universal but do not correspond to the extension of any subuniversal of that universal because there is nothing intrinsic to the entities in question by virtue of which they – and only they – are counted as belonging to the given group. Examples are: animal purchased by the Emperortuberculosis diagnosed on a Wednesdaysurgical procedure performed on a patient from Stockholmperson identified as candidate for clinical trial #2056-555person who is signatory of Form 656-PPVpainting by Leonardo da VinciSuch terms, which represent what are called ‘specializations’ in [81|Entity doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. For example Werner Ceusters 'portions of reality' include 4 sorts, entities (as BFO construes them), universals, configurations, and relations. It is an open question as to whether entities as construed in BFO will at some point also include these other portions of reality. See, for example, 'How to track absolutely everything' at http://www.referent-tracking.com/_RTU/papers/CeustersICbookRevised.pdf",,An entity is anything that exists or has existed or will exist. (axiom label in BFO2 Reference: [001-001]),the Second World War|your body mass index|Verdi’s Requiem|Julius Caesar,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BFO:0000001,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/bfo.owl,entity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001251,increasing phospholipid inflow,,Increasing phospholipid inflow is a subtype of increasing quantity: A process that changes the phospholipid inflow into the hepatocyte to be larger.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing phospholipid inflow is a subtype of increasing quantity: A process that changes the phospholipid inflow into the hepatocyte to be larger.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001251,,,,,,,,,,,,,,,,,,,,,,increasing phospholipid inflow,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001257,hyperfunction of dead cell phagocytosis by Kupffer cells (macrophages) [Phospholipidosis (excessive defense)],,"Hyperfunction of dead cell phagocytosis by Kupffer cells (macrophages) is a subtype of hyperfunctioning: A process that performs phagocytosis of dead cells by Kupffer cells or macrophages execessively.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense).",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0000884,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of dead cell phagocytosis by Kupffer cells (macrophages) is a subtype of hyperfunctioning: A process that performs phagocytosis of dead cells by Kupffer cells or macrophages execessively.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense).",,,http://purl.obolibrary.org/obo/TXPO_0003395,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000091|http://purl.obolibrary.org/obo/CL_0000235,,,,,,http://purl.obolibrary.org/obo/TXPO_0000558,,,,,,,,,,,TXPO:0001257,,,,,,,,,,,,,,,,,,,,,,hyperfunction of dead cell phagocytosis by Kupffer cells (macrophages) [Phospholipidosis (excessive defense)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001250,increasing phospholipid,,Increasing phospholipid  is a subtype of increasing quantity: A process that changes the amount of phospholipid to be larger.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing phospholipid  is a subtype of increasing quantity: A process that changes the amount of phospholipid to be larger.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001250,,,,,,,,,,,,,,,,,,,,,,increasing phospholipid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001252,Elovl6 (mouse)[lipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001105|http://purl.obolibrary.org/obo/TXPO_1000125,,,,,,,,,,,,,,,,,,,,"NCBI-Rat-GeneID:171402|The birth rate of Elovl6 knockout mice was lower, and the surviving mice were smaller in size and had reduced body weight.
Crucial role of a long-chain fatty acid elongase, Elovl6, in obesity-induced insulin resistance.
Secondary regulation of PPARa activity could be a part of SREBP-1c/Elovl6 regulation of lipogenesis.|PMID:27467521|PMID:17906635",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001252,,,,,,,,,,,,,,,,,,,,,,Elovl6 (mouse)[lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001259,increasing uptake amount of mitochondrial calcium [Lipidosis],,"Increasing uptake amount of mitochondrial calcium ion is a subtype of increasing quantity: A process that changes the uptake amount of mitochondrial calcium ion to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001255|http://purl.obolibrary.org/obo/TXPO_0001720,,,,,,,,,,,,,,,,,,,,,,"Increasing uptake amount of mitochondrial calcium ion is a subtype of increasing quantity: A process that changes the uptake amount of mitochondrial calcium ion to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000670,,,,,,http://purl.obolibrary.org/obo/TXPO_0001150,,,,,,,,,,,TXPO:0001259,,,,,,,,,,,,,,,,,,,,,,increasing uptake amount of mitochondrial calcium [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000182,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001254,forming a complex of drugs and biological substance,,"Forming a complex of drugs and biological substance is a subtype of protein complex assembly: The aggregation, arrangement and bonding together between drugs and biological molecules to form a complex.",false,,,http://purl.obolibrary.org/obo/GO_0065003,,,,,,,,,,,,,,,,,,,,,,"Forming a complex of drugs and biological substance is a subtype of protein complex assembly: The aggregation, arrangement and bonding together between drugs and biological molecules to form a complex.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001254,,,,,,,,,,,,,,,,,,,,,,forming a complex of drugs and biological substance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001256,negative regulation of phospholipid degradation,,"Negative regulation of phospholipid degradation is a subtype of negative regulation of decomposing: A process that stops, prevents, or reduces the frequency, rate or extent of phospholipid degradation.",false,,,http://purl.obolibrary.org/obo/TXPO_0000115,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of phospholipid degradation is a subtype of negative regulation of decomposing: A process that stops, prevents, or reduces the frequency, rate or extent of phospholipid degradation.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001256,,,,,,,,,,,,,,,,,,,,,,negative regulation of phospholipid degradation,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0009395,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001253,hypofunction of phospholipid degradation,,Hypofunction of phospholipid degradation is a subtype of hypofunction of decomposing: A process that performs a decreased or insufficient phospholipid degradation.,false,,,http://purl.obolibrary.org/obo/TXPO_0002006,,,,,,,,,,,,,,,,,,,,,,Hypofunction of phospholipid degradation is a subtype of hypofunction of decomposing: A process that performs a decreased or insufficient phospholipid degradation.,,,http://purl.obolibrary.org/obo/GO_0009395,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_16247,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001253,,,,,,,,,,,,,,,,,,,,,,hypofunction of phospholipid degradation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001255,increase in alcohol inflow into hepatocyte,,Increase in alcohol inflow into hepatocyte is a subtype of increasing quantity: A process that changes the alcohol inflow into the hepatocyte to be larger.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increase in alcohol inflow into hepatocyte is a subtype of increasing quantity: A process that changes the alcohol inflow into the hepatocyte to be larger.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001255,,,,,,,,,,,,,,,,,,,,,,increase in alcohol inflow into hepatocyte,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001258,negative regulation of lysophagy,,"Any process that stops, prevents, or reduces the frequency, rate or extent of lysophagy.",false,,,http://purl.obolibrary.org/obo/TXPO_0000755|http://purl.obolibrary.org/obo/GO_0010507,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents, or reduces the frequency, rate or extent of lysophagy.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001258,,,,,,,,,,,,,,,,,,,,,,negative regulation of lysophagy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0062093,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001689,MAPKAPK2/3,MAPK-activated protein kinase 2/3|MAP kinase-activated protein kinase 2/3,MAPKAPK2 and MAPKAPK3 can be activated by p38 and  activated MAPKAPK2/3 can phosphorylate small heat shock protein 27 (HSP27).,false,,,http://purl.obolibrary.org/obo/IMR_0100271,,,,,,,,,,,,,,,,,,,,,,MAPKAPK2 and MAPKAPK3 can be activated by p38 and  activated MAPKAPK2/3 can phosphorylate small heat shock protein 27 (HSP27).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MAPK-activated protein kinase 2/3|MAP kinase-activated protein kinase 2/3,,,,,IMR:0001689,,,,,,,,,,,,,,,,,,,,,,MAPKAPK2/3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000055819,RNF130,,Other designations: E3 ubiquitin-protein ligase RNF130|g1-related zinc finger protein|goliath homolog,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,G1RZFP|GOLIATH|GP,,,,,,,,,,,,5,,,,,,HGNC:18280|HPRD:11504|Ensembl:ENSG00000113269|Vega:OTTHUMG00000130909,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,ring finger protein 130,,,5q35.3,,,,,,,,,,,,,,,,"GO_0004842 (EC: IDA, PMID: 16549277); GO_0005634 (EC: IDA); GO_0005737 (EC: IDA); GO_0006915 (EC: IEA); GO_0008270 (EC: IEA); GO_0012501 (EC: ISS, PMID: 13679316); GO_0016021 (EC: IEA)",,,,,,,,,PMID: 7566098; 10806348; 12477932; 13679316; 15489334; 15761153; 16169070; 16549277; 16797685; 18029348; 19690564; 21139048; 21150319; 21347282; 22505724; 24250222,,,,,,,,,,,,,,,OGG:3000055819,,,,,,,ring finger protein 130,,,,,,,,,,,,,Other designations: E3 ubiquitin-protein ligase RNF130|g1-related zinc finger protein|goliath homolog,,RNF130,,,,,,,,,,,,,,,,,,,,,,,55819,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,RNF130,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_24783,imine,,"Compounds having the structure RN=CR2 (R = H, hydrocarbyl). Thus analogues of aldehydes or ketones, having NR doubly bonded to carbon; aldimines have the structure RCH=NR, ketimines have the structure R'2C=NR (where R' is not H). Imines include azomethines and Schiff bases. Imine is used as a suffix in systematic nomenclature to denote the C=NH group excluding the carbon atom.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,http://jglobal.jst.go.jp/en/detail?JGLOBAL_ID=200906016906308703|http://purl.jp/bio/4/id/200906016906308703|CHEBI:24783,,"Compounds having the structure RN=CR2 (R = H, hydrocarbyl). Thus analogues of aldehydes or ketones, having NR doubly bonded to carbon; aldimines have the structure RCH=NR, ketimines have the structure R'2C=NR (where R' is not H). Imines include azomethines and Schiff bases. Imine is used as a suffix in systematic nomenclature to denote the C=NH group excluding the carbon atom.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:24783,,,,,,,,,,,,,,,,,,,,,,imine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_50673,methimazole,"Favistan|tiamazol|1-Methylimidazole-2(3H)-thione|1-METHYL-1,3-DIHYDRO-2H-IMIDAZOLE-2-THIONE|thiamazol|USAF el-30|Tapazole|Danantizol|thiamazolum|Strumazol|Thacapzol|thiamazole|1-methyl-1,3-dihydro-2H-imidazole-2-thione|Methimazole",A member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen which is attached to a nitrogen.,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Drug_Central:1745|DrugBank:DB00763|LINCS:LSM-5646|PMID:17438883|CAS:60-56-0|Beilstein:108646|PMID:7454742|Reaxys:108646|PMID:24443787|PMID:9172960,,A member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen which is attached to a nitrogen.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_50671,,,,,"1-methyl-1,3-dihydro-2H-imidazole-2-thione|Methimazole",,"Favistan|tiamazol|1-Methylimidazole-2(3H)-thione|1-METHYL-1,3-DIHYDRO-2H-IMIDAZOLE-2-THIONE|thiamazol|USAF el-30|Tapazole|Danantizol|thiamazolum|Strumazol|Thacapzol|thiamazole",,,,,,,,,,,,,,,,,,,,,CHEBI:50673,,,,methimazole,,CHEBI:50673,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/DOID_9352,type 2 diabetes mellitus,non-insulin-dependent diabetes mellitus|type II diabetes mellitus|NIDDM,A diabetes mellitus that involves high blood glucose resulting from cells fail to use insulin properly.,false,,,http://purl.obolibrary.org/obo/DOID_9351,,,,,,,,,,,,,,,,,,,,NCI:C26747|MESH:D003924|ICD10CM:E11|SNOMEDCT_US_2018_03_01,,A diabetes mellitus that involves high blood glucose resulting from cells fail to use insulin properly.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,non-insulin-dependent diabetes mellitus|type II diabetes mellitus|NIDDM,,,,,DOID:9352,,,,,,,,,,,,,,,,,,,,,,type 2 diabetes mellitus,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_39867,valproic acid,acido valproico|Di-n-propylessigsaeure|n-DPA|acidum valproicum|2-PROPYL-PENTANOIC ACID|acide valproique|di-n-propylacetic acid|Valproinsaeure|DPA|2-propylpentanoic acid|valproic acid|2-n-propyl-n-valeric acid|dipropylacetic acid|2-propylvaleric acid|Depakene|VPA|4-heptanecarboxylic acid|VALPROIC ACID|2-propylpentanoic acid,A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Beilstein:1750447|PMID:19318486|Drug_Central:2803|PMID:12475192|Reaxys:1750447|LIPID_MAPS_instance:LMFA01020291|PMID:19280426|PMID:17273758|PMID:24135375|PMID:17156483|PMID:23949302|Wikipedia:Valproic_Acid|CAS:99-66-1|PMID:15560954|PMID:15578701|PMID:24348849|DrugBank:DB00313|PMID:11716839|PMID:23792104|LINCS:LSM-4620|PMID:16621443|PMID:23810771|PMID:8681902|PMID:15124690|PMID:16759735|PMID:8558327|PMID:16496131|PMID:24200999,,A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.,,,,,,,,,,,,C8H16O2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_50905|http://purl.obolibrary.org/obo/CHEBI_35477|http://purl.obolibrary.org/obo/CHEBI_35471|http://purl.obolibrary.org/obo/CHEBI_51374|http://purl.obolibrary.org/obo/CHEBI_61115|http://purl.obolibrary.org/obo/CHEBI_35623|http://purl.obolibrary.org/obo/CHEBI_63726,,,,,VALPROIC ACID|2-propylpentanoic acid,,acido valproico|Di-n-propylessigsaeure|n-DPA|acidum valproicum|2-PROPYL-PENTANOIC ACID|acide valproique|di-n-propylacetic acid|Valproinsaeure|DPA|2-propylpentanoic acid|valproic acid|2-n-propyl-n-valeric acid|dipropylacetic acid|2-propylvaleric acid|Depakene|VPA|4-heptanecarboxylic acid,,,,,,,,,,,,,,,,,,,,,CHEBI:39867,,,,valproic acid,,CHEBI:39867,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CCCC(CCC)C(O)=O,,,,,
http://purl.obolibrary.org/obo/TXPO_0001547,p53 signaling (primitive) [Phospholipidosis (excessive defense) ],,"P53 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by p53.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense) .",false,,,http://purl.obolibrary.org/obo/TXPO_0000001|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,PMID:17090686,,"P53 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by p53.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense) .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001586|http://purl.obolibrary.org/obo/TXPO_0003380|http://purl.obolibrary.org/obo/TXPO_0001158,,,,,,http://purl.obolibrary.org/obo/TXPO_0000928,,,,,,,,,,,TXPO:0001547,,,,,,,,,,,,,,,,,,,,,,p53 signaling (primitive) [Phospholipidosis (excessive defense) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001545,hypofunction of phosphoethanolamine degradation,,Hypofunction of phosphoethanolamine degradation is a subtype of hypofunction of decomposing: A process that performs a decreased or insufficient phosphoethanolamine degradation.,false,,,http://purl.obolibrary.org/obo/TXPO_0001418,,,,,,,,,,,,,,,,,,,,,,Hypofunction of phosphoethanolamine degradation is a subtype of hypofunction of decomposing: A process that performs a decreased or insufficient phosphoethanolamine degradation.,,,http://purl.obolibrary.org/obo/TXPO_0000114,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_36711,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001545,,,,,,,,,,,,,,,,,,,,,,hypofunction of phosphoethanolamine degradation,,,,,,,,,,,,,,Decreasing phosphoethanolamine degradation is a subtype of decreasing functioning process of breakdown of phosphoethanolamine.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001541,overeating,,Overeating is a subtype of increasing quantity: A process that changes the ingestion amount of food to be larger.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Overeating is a subtype of increasing quantity: A process that changes the ingestion amount of food to be larger.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001541,,,,,,,,,,,,,,,,,,,,,,overeating,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001546,regulation of hepatocyte cell cycle [Hypertrophy],,"Regulation of hepatocyte cell cycle is a subtype of regulation of cell cycle: A process that modulates the frequency, rate or extent of hepatocyte cell cycle.
This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy.",false,,,http://purl.obolibrary.org/obo/TXPO_0001580,,,,,,,,,,,,,,,,,,,,,,"Regulation of hepatocyte cell cycle is a subtype of regulation of cell cycle: A process that modulates the frequency, rate or extent of hepatocyte cell cycle.
This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000739,,,,,,,,,,,TXPO:0001546,,,,,,,,,,,,,,,,,,,,,,regulation of hepatocyte cell cycle [Hypertrophy],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001542,feeding behavior [Phospholipidosis (severe) ],,"A behavioral process associated with the intake of food. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",false,,,http://purl.obolibrary.org/obo/GO_0007631|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"A behavioral process associated with the intake of food. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003824|http://purl.obolibrary.org/obo/TXPO_0001315|http://purl.obolibrary.org/obo/TXPO_0000903,,,,,,,,,,,TXPO:0001542,,,,,,,,,,,,,,,,,,,,,,feeding behavior [Phospholipidosis (severe) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001543,CAR -cell senescence inhibitor (canonical)[Ground glass appearance],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003791,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001139,,,,,,,,,,TXPO:0001543,,,,,,,,,,,,,,,,,,,,,,CAR -cell senescence inhibitor (canonical)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001548,hydroxylysine kinase,,Catalysis role of the reaction: erythro-5-hydroxy-L-lysine + GTP = 5-phosphonooxy-L-lysine + GDP + 2 H(+),false,,,http://purl.obolibrary.org/obo/TXPO_0001515,,,,,,,,,,,,,,,,,,,,PMID:22241472,,Catalysis role of the reaction: erythro-5-hydroxy-L-lysine + GTP = 5-phosphonooxy-L-lysine + GDP + 2 H(+),EC:2.7.1.81,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001548,,,,,,,,,,,,,,,,,,,,,,hydroxylysine kinase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001540,hypofunction of ATP biosynthesis [lipidosis],,"Hypofunction of ATP biosynthesis is a subtype of hypofunction of biosynthesis: A process that performs a decreased or insufficient ATP biosynthesis.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0001722,,,,,,,,,,,,,,,,,,,,,,"Hypofunction of ATP biosynthesis is a subtype of hypofunction of biosynthesis: A process that performs a decreased or insufficient ATP biosynthesis.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001749|http://purl.obolibrary.org/obo/TXPO_0001748,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003495,,,,,,,,,,,TXPO:0001540,,,,,,,,,,,,,,,,,,,,,,hypofunction of ATP biosynthesis [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001544,anandamide amidohydrolase,,Catalysis role of the reaction: anandamide + H2O <=> arachidonate + ethanolaminium(1+),false,,,http://purl.obolibrary.org/obo/TXPO_0003663,,,,,,,,,,,,,,,,,,,,GO:0103073,,Catalysis role of the reaction: anandamide + H2O <=> arachidonate + ethanolaminium(1+),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001544,,,,,,,,,,,,,,,,,,,,,,anandamide amidohydrolase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001549,CYP2C19 (human)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000079|http://purl.obolibrary.org/obo/TXPO_0001135,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1557|PMID:21934639|PMID:12464799]|PMID:23193974|PMID:26477383|PMID:19651758,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001553,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001557,,,http://purl.obolibrary.org/obo/TXPO_0002262,,,,,,,,,,TXPO:0001549,,,,,,,,,,,,,,,,,,,,,,CYP2C19 (human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100305,caspase-5,,,false,,,http://purl.obolibrary.org/obo/IMR_0000305,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100305,,,,,,,,,,,,,,,,,,,,,,caspase-5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001608,phosphatidylglycerol metabolism imbalance,,Phosphatidylglycerol metabolism imbalance is a subtype of glycerophospholipid metabolism imbalance : A process that becomes lacking a homeostastasis balance of phosphatidylglycerol metabolism.,false,,,http://purl.obolibrary.org/obo/TXPO_0001295,,,,,,,,,,,,,,,,,,,,,,Phosphatidylglycerol metabolism imbalance is a subtype of glycerophospholipid metabolism imbalance : A process that becomes lacking a homeostastasis balance of phosphatidylglycerol metabolism.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001608,,,,,,,,,,,,,,,,,,,,,,phosphatidylglycerol metabolism imbalance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001602,hyperfunction of phosphatidylglycerol biosynthesis,,Hyperfunction of phosphatidylglycerol biosynthesis is a subtype of hyperfunction of glycerophospholipid biosynthesis: A process that performs an excessive phosphatidylglycerol biosynthesis.,false,,,http://purl.obolibrary.org/obo/TXPO_0001411,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of phosphatidylglycerol biosynthesis is a subtype of hyperfunction of glycerophospholipid biosynthesis: A process that performs an excessive phosphatidylglycerol biosynthesis.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001602,,,,,,,,,,,,,,,,,,,,,,hyperfunction of phosphatidylglycerol biosynthesis,,,,,,http://purl.obolibrary.org/obo/GO_0006655,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001603,hyperfunction of phosphatidylcholine biosynthesis,,Hyperfunction of phosphatidylcholine biosynthesis is a subtype of hyperfunction of glycerophospholipid biosynthesis: A process that performs an excessive phosphatidylcholine biosynthesis.,false,,,http://purl.obolibrary.org/obo/TXPO_0001411,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of phosphatidylcholine biosynthesis is a subtype of hyperfunction of glycerophospholipid biosynthesis: A process that performs an excessive phosphatidylcholine biosynthesis.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001603,,,,,,,,,,,,,,,,,,,,,,hyperfunction of phosphatidylcholine biosynthesis,,,,,,http://purl.obolibrary.org/obo/GO_0006656,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001601,hyperfunction of phosphatidylethanolamine biosynthesis,,Hyperfunction of phosphatidylethanolamine biosynthesis is a subtype of hyperfunction of glycerophospholipid biosynthesis: A process that performs an excessive phosphatidylethanolamine biosynthesis.,false,,,http://purl.obolibrary.org/obo/TXPO_0001411,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of phosphatidylethanolamine biosynthesis is a subtype of hyperfunction of glycerophospholipid biosynthesis: A process that performs an excessive phosphatidylethanolamine biosynthesis.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001601,,,,,,,,,,,,,,,,,,,,,,hyperfunction of phosphatidylethanolamine biosynthesis,,,,,,http://purl.obolibrary.org/obo/GO_0006646,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001609,S1P -apoptosis inhibitor (inactivated state)[Phospholipidosis - positive regulation of apoptosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001849|http://purl.obolibrary.org/obo/CHEBI_37550,,,,,,,,,,,,,,,,,,,,PMID:29147025,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0002355,,,,http://purl.obolibrary.org/obo/CHEBI_68494,,,,,,,,,,TXPO:0001609,,,,,,,,,,,,,,,,,,,,,,S1P -apoptosis inhibitor (inactivated state)[Phospholipidosis - positive regulation of apoptosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001600,hyperfunction of phosphatidylinositol biosynthesis,,Hyperfunction of phosphatidylinositol biosynthesis is a subtype of hyperfunction of glycerophospholipid biosynthesis: A process that performs an excessive phosphatidylinositol biosynthesis.,false,,,http://purl.obolibrary.org/obo/TXPO_0001411,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of phosphatidylinositol biosynthesis is a subtype of hyperfunction of glycerophospholipid biosynthesis: A process that performs an excessive phosphatidylinositol biosynthesis.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001600,,,,,,,,,,,,,,,,,,,,,,hyperfunction of phosphatidylinositol biosynthesis,,,,,,http://purl.obolibrary.org/obo/GO_0006661,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001607,gene expression of cytochrome p450 [Ground glass appearance],,"Gene expression of cytochrome p450 is a subtype of gene expression: The process in which a gene sequence is converted into a mature cytochrome p450 gene product or products (proteins or RNA) .
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/TXPO_0001611,,,,,,,,,,,,,,,,,,,,,,"Gene expression of cytochrome p450 is a subtype of gene expression: The process in which a gene sequence is converted into a mature cytochrome p450 gene product or products (proteins or RNA) .
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001607,,,,,,,,,,,,,,,,,,,,,,gene expression of cytochrome p450 [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001606,increasing phosphatidylglycerol material,,Increasing phosphatidylglycerol material is a subtype of increasing glycerophospholipid material: A process that changes the amount of phosphatidylglycerol material to be larger.,false,,,http://purl.obolibrary.org/obo/TXPO_0001317,,,,,,,,,,,,,,,,,,,,,,Increasing phosphatidylglycerol material is a subtype of increasing glycerophospholipid material: A process that changes the amount of phosphatidylglycerol material to be larger.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001606,,,,,,,,,,,,,,,,,,,,,,increasing phosphatidylglycerol material,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001604,hyperfunction of phosphatidyl-L-serine biosynthesis,,Hyperfunction of phosphatidyl-L-serine biosynthesis is a subtype of hyperfunction of glycerophospholipid biosynthesis: A process that performs an excessive phosphatidyl-L-serine biosynthesis.,false,,,http://purl.obolibrary.org/obo/TXPO_0001411,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of phosphatidyl-L-serine biosynthesis is a subtype of hyperfunction of glycerophospholipid biosynthesis: A process that performs an excessive phosphatidyl-L-serine biosynthesis.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001604,,,,,,,,,,,,,,,,,,,,,,hyperfunction of phosphatidyl-L-serine biosynthesis,,,,,,http://purl.obolibrary.org/obo/GO_0006659,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001605,glutathione conjugation [Ground glass appearance],,"Glutathione conjugation is a subtype of drug metabolism phase II: Glutathione conjugation is a detoxication reaction. Four types of activation reaction have been recognized: direct-acting compounds, conjugates that are activated through cysteine conjugate beta-lyase, conjugates that are activated through redox cycling and lastly conjugates that release the original reactive parent compound. The glutathione S-transferases have three connections with the formation of biactivated conjugatesto make them more soluble for excretion.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/TXPO_0003991,,,,,,,,,,,,,,,,,,,,,,"Glutathione conjugation is a subtype of drug metabolism phase II: Glutathione conjugation is a detoxication reaction. Four types of activation reaction have been recognized: direct-acting compounds, conjugates that are activated through cysteine conjugate beta-lyase, conjugates that are activated through redox cycling and lastly conjugates that release the original reactive parent compound. The glutathione S-transferases have three connections with the formation of biactivated conjugatesto make them more soluble for excretion.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001605,,,,,,,,,,,,,,,,,,,,,,glutathione conjugation [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000728689,EIF3CL,,"Other designations: eIF3 p110|eIF3c|eukaryotic translation initiation factor 3 subunit 8|eukaryotic translation initiation factor 3 subunit C|eukaryotic translation initiation factor 3 subunit C-like protein|eukaryotic translation initiation factor 3, subunit 8, 110kDa-like",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,16,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"eukaryotic translation initiation factor 3, subunit C-like",,,16p11.2,,,,,,,,,,,,,,,,GO_0001731 (EC: IEA); GO_0003743 (EC: IEA); GO_0005852 (EC: IEA); GO_0006446 (EC: IEA); GO_0016282 (EC: IEA); GO_0031369 (EC: IEA); GO_0033290 (EC: IEA),,,,,,,,,PMID:8995409; 10493829; 10504338; 12477932; 12588972; 14519125; 14702039; 15302935; 15489334; 15703437; 16083285; 16097034; 16286006; 16322461; 16766523; 16964243; 17081983; 17287340; 17322308; 17468741; 17581632; 18187866; 18599441; 18669648; 20360068; 20972266; 21145461; 21890473; 21906983; 21963094; 21987572; 22505724; 22863883; 23000965; 23463506; 23862649,,,,,,,,,,,,,,,OGG:3000728689,,,,,,,"eukaryotic translation initiation factor 3, subunit C-like",,,,,,,,,,,,,"Other designations: eIF3 p110|eIF3c|eukaryotic translation initiation factor 3 subunit 8|eukaryotic translation initiation factor 3 subunit C|eukaryotic translation initiation factor 3 subunit C-like protein|eukaryotic translation initiation factor 3, subunit 8, 110kDa-like",,EIF3CL,,,,,,,,,,,,,,,,,,,,,,,728689,,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF3CL,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000009068,ANGPTL1,,Other designations: ANG-3|angioarrestin|angiopoietin 3|angiopoietin Y1|angiopoietin-3|angiopoietin-like protein 1|angiopoietin-related protein 1|dJ595C2.2 (angiopoietin Y1),false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,UNQ162|AngY|dJ595C2.2|ANG3|ARP1|ANGPT3,,,,,,,,,,,,1,,,,,,HGNC:489|Vega:OTTHUMG00000035075|HPRD:04851|MIM:603874|Ensembl:ENSG00000116194,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,angiopoietin-like 1,,,1q25.2,,,,,,,,,,,,,,,,"GO_0005102 (EC: IEA); GO_0005615 (EC: IDA, PMID:10025962); GO_0007169 (EC: IEA); GO_0070062 (EC: IDA, PMID:19199708)",,,,,,,,,PMID:8125298; 8889548; 9286704; 10025962; 10051567; 10318855; 10473614; 12477932; 12624729; 15284220; 15489334; 15542434; 15940350; 15950186; 16303743; 16710414; 18182823; 18644593; 19199708; 20819778; 23434592,,,,,,,,,,,,,,,OGG:3000009068,,,,,,,angiopoietin-like 1,,,,,,,,,,,,,Other designations: ANG-3|angioarrestin|angiopoietin 3|angiopoietin Y1|angiopoietin-3|angiopoietin-like protein 1|angiopoietin-related protein 1|dJ595C2.2 (angiopoietin Y1),,ANGPTL1,,,,,,,,,,,,,,,,,,,,,,,9068,PSEC0154,,,,,,,9606,,,,,,,,,,,,,,,,,,,ANGPTL1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0100418,TR alpha 1,,,false,,,http://purl.obolibrary.org/obo/IMR_0000086,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100418,,,,,,,,,,,,,,,,,,,,,,TR alpha 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_26833,sulfur atom,sulfur,,false,,,http://purl.obolibrary.org/obo/CHEBI_33250,,,,,,,,,,,,,,,,,,,,CAS:7704-34-9,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sulfur,,,,,CHEBI:26833,,,,,,,,,,,,,,,,,,,,,,sulfur atom,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000908,eIF1 (mol),,,false,,,http://purl.obolibrary.org/obo/IMR_0010016,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000908,,,,,,,,,,,,,,,,,,,,,,eIF1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001844,S6K,ribosomal S6 protein kinase,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001966,,,,,ribosomal S6 protein kinase,,,,,IMR:0001844,,,,,,,,,,,,,,,,,,,,,,S6K,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000984,ground glass appearance dependent chemical entity,,"Ground glass appearance dependent chemical entity is a subtype of toxic course dependent chemical entity.
This entity can participate in the course of ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001731,,,,,,,,,,,,,,,,,,,,,,"Ground glass appearance dependent chemical entity is a subtype of toxic course dependent chemical entity.
This entity can participate in the course of ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000984,,,,,,,,,,,,,,,,,,,,,,ground glass appearance dependent chemical entity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000983,negative regulation of cell proliferation inhibitor expression [Ground glass appearance],,"Negative regulation of cell proliferation inhibitor expression is a subtype of negative regulation of gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of cell proliferation inhibitor expression.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/TXPO_0002057,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of cell proliferation inhibitor expression is a subtype of negative regulation of gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of cell proliferation inhibitor expression.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002320,,,,,,,,,,,TXPO:0000983,,,,,,,,,,,,,,,,,,,,,,negative regulation of cell proliferation inhibitor expression [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000985,ground glass appearance dependent molecule (rat invivo),,"Ground glass appearance dependent molecule is a subtype of toxic course dependent chemical entity.
This molecule can participate in the course of ground glass appearance as a gene product.
Gene profile:Rat/Liver/",false,,,http://purl.obolibrary.org/obo/TXPO_0000984,,,,,,,,,,,,,,,,,,,,,,"Ground glass appearance dependent molecule is a subtype of toxic course dependent chemical entity.
This molecule can participate in the course of ground glass appearance as a gene product.
Gene profile:Rat/Liver/",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000985,,,,,,,,,,,,,,,,,,,,,,ground glass appearance dependent molecule (rat invivo),,,,,,,,,,,http://purl.obolibrary.org/obo/NCBITaxon_10114,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000988,aryl hydrocarbon receptor activation [Ground glass appearance],activating aryl hydrocarbon receptor [Ground glass appearance],"Aryl hydrocarbon receptor activation is a subtype of activating nuclear receptor: A process that changes the activity of the activating AhR (aryl hydrocarbon receptor) with a nuclear receptor role to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001209|http://purl.obolibrary.org/obo/TXPO_0003855,,,,,,,,,,,,,,,,,,,,ISBN:0071769234,,"Aryl hydrocarbon receptor activation is a subtype of activating nuclear receptor: A process that changes the activity of the activating AhR (aryl hydrocarbon receptor) with a nuclear receptor role to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000989,,,,,,,,,,,,activating aryl hydrocarbon receptor [Ground glass appearance],,,,,TXPO:0000988,,,,,,,AhR activity is combining with an aryl hydrocarbon and transmitting the signal to initiate a change in cell activity. The aryl hydrocarbon receptor is a ligand-activated transcription factor which translocates to the nucleus to activate transcription upon ligand-binding.Combining with an aryl hydrocarbon and transmitting the signal to initiate a change in cell activity. The aryl hydrocarbon receptor is a ligand-activated transcription factor which translocates to the nucleus to activate transcription upon ligand-binding.,,,,,,,,,,,,,,,aryl hydrocarbon receptor activation [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000982,decreasing mitochondrial membrane potential [Ground glass appearance],,"Decreasing mitochondrial membrane potential is a subtype of decreasing membrane potential: A process that changes the electrical potential of a mitochondrial membrane to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/TXPO_0001855,,,,,,,,,,,,,,,,,,,,,,"Decreasing mitochondrial membrane potential is a subtype of decreasing membrane potential: A process that changes the electrical potential of a mitochondrial membrane to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001026,,,,,,,,,,,TXPO:0000982,,,,,,,,,,,,,,,,,,,,,,decreasing mitochondrial membrane potential [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0031966,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000980,CAR binding [Ground glass appearance],,"CAR binding is a subtype of binding: Interacting with CAR (constitutive androstane receptor) .
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/TXPO_0002066,,,,,,,,,,,,,,,,,,,,,,"CAR binding is a subtype of binding: Interacting with CAR (constitutive androstane receptor) .
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000986,,,,,,http://purl.obolibrary.org/obo/TXPO_0000967,,,,,,,,,,,TXPO:0000980,,,,,,,,,,,,,,,,,,,,,,CAR binding [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000981,positive regulation of mitochondrial membrane permeability [Ground glass appearance],,"Any process that increases the frequency, rate or extent of the passage or uptake of molecules by the mitochondrial membrane.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/GO_0035794,,,,,,,,,,,,,,,,,,,,,,"Any process that increases the frequency, rate or extent of the passage or uptake of molecules by the mitochondrial membrane.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000982,,,,,,,,,,,TXPO:0000981,,,,,,,,,,,,,,,,,,,,,,positive regulation of mitochondrial membrane permeability [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000986,Ctnnb1 (mouse)[Ground glass appearance],Catenin Beta 1 [Ground glass appearance],,false,,,http://purl.obolibrary.org/obo/TXPO_0001071|http://purl.obolibrary.org/obo/TXPO_1000094,,,,,,,,,,,,,,,,,,,,PMID:21822615|PMID:25661872,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Catenin Beta 1 [Ground glass appearance],,,,,TXPO:0000986,,,,,,,,,,,,,,,,,,,,,,Ctnnb1 (mouse)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000989,AHR (canonical)[Ground glass appearance],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000472|http://purl.obolibrary.org/obo/TXPO_1000030,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:25690|NCBI-Mouse-GeneID:11622|NCBI-Human-GeneID:196|UNIPROT:Q12778,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000989,,,,,,,,,,,,,,,,,,,,,,AHR (canonical)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000987,dioxins and dioxin-like compounds accumulation in liver [Ground glass appearance],,"Dioxins and dioxin-like compounds accumulation in liver is a subtype of compound accumulation in liver: A process that keeps dioxins and dioxin-like compoundsin the liver.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0002053,,,,,,,,,,,,,,,,,,,,,,"Dioxins and dioxin-like compounds accumulation in liver is a subtype of compound accumulation in liver: A process that keeps dioxins and dioxin-like compoundsin the liver.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000988,,,,,,,,,,,TXPO:0000987,,,,,,,,,,,,,,,,,,,,,,dioxins and dioxin-like compounds accumulation in liver [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_71554,PPARgamma agonist,peroxisome proliferator-activated receptor-gamma agonist|PPAR-gamma agonist,A PPAR modulator which activates the peroxisome proliferator-activated receptor-gamma.,false,,,http://purl.obolibrary.org/obo/CHEBI_48705,,,,,,,,,,,,,,,,,,,,,,A PPAR modulator which activates the peroxisome proliferator-activated receptor-gamma.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,peroxisome proliferator-activated receptor-gamma agonist|PPAR-gamma agonist,,,,,CHEBI:71554,,,,,,,,,,,,,,,,,,,,,,PPARgamma agonist,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001101,importin 5,RanBP5|karyopherin beta3,,false,,,http://purl.obolibrary.org/obo/IMR_0100010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,RanBP5|karyopherin beta3,,,,,IMR:0001101,,,,,,,,,,,,,,,,,,,,,,importin 5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0011155,eIF4E,mRNA cap-binding protein|eIF-4E|eIF-4F 25 kDa subunit|IF4E|eukaryotic translation initiation factor 4E,,false,,,http://purl.obolibrary.org/obo/IMR_0000912,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0011556,mRNA cap-binding protein|eIF-4E|eIF-4F 25 kDa subunit|IF4E|eukaryotic translation initiation factor 4E,,,,,IMR:0011155,,,,,,,,,,,,,,,,,,,,,,eIF4E,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000027329,ANGPTL3,,Other designations: angiopoietin 5|angiopoietin-related protein 3,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,FHBL2|ANGPT5|ANG-5|ANL3,,,,,,,,,,,,1,,,,,,Ensembl:ENSG00000132855|Vega:OTTHUMG00000009146|HPRD:10381|MIM:604774|HGNC:491,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,angiopoietin-like 3,,,1p31.3,,,,,,,,,,,,,,,,"GO_0004857 (EC: ISS); GO_0004859 (EC: IDA, PMID:17110602); GO_0005178 (EC: IPI, PMID:11877390); GO_0005615 (EC: IDA, PMID:17110602); GO_0006071 (EC: IDA, PMID:12565906); GO_0006631 (EC: IDA, PMID:12565906); GO_0006644 (EC: IDA, PMID:17110602); GO_0007160 (EC: IPI, PMID:11877390); GO_0007165 (EC: IDA, PMID:11877390); GO_0007229 (EC: NAS, PMID:11877390); GO_0008083 (EC: IDA, PMID:11877390); GO_0008203 (EC: IDA, PMID:17110602); GO_0009395 (EC: IDA, PMID:17110602); GO_0009725 (EC: IEA); GO_0009986 (EC: IDA, PMID:12565906); GO_0010519 (EC: IDA, PMID:17110602); GO_0019915 (EC: IDA, PMID:12565906); GO_0030335 (EC: IDA, PMID:11877390); GO_0042632 (EC: IDA, PMID:17110602); GO_0045766 (EC: IDA, PMID:11877390); GO_0048844 (EC: ISS); GO_0050996 (EC: IDA, PMID:12565906); GO_0051005 (EC: IDA, PMID:17110602); GO_0055088 (EC: IDA, PMID:17110602); GO_0055090 (EC: IDA, PMID:17110602); GO_0055091 (EC: IDA, PMID:17110602); GO_0070328 (EC: IGI); GO_0070328 (EC: ISS)",,,,,,,,,PMID:10644446; 11877390; 12477932; 12518032; 12565906; 12672813; 12909640; 12975309; 15094378; 15340161; 15489334; 16335952; 16505486; 16531751; 17110602; 17207965; 17681148; 18063851; 18193043; 18193044; 18279878; 18535744; 18596051; 18804459; 19028676; 19060906; 19075393; 19148283; 19282754; 19318355; 19474742; 19487539; 19540497; 19542565; 19656773; 19826106; 19890028; 19936222; 20139978; 20160193; 20360639; 20570916; 20571754; 20595410; 20679960; 20686565; 20714348; 20837471; 20855565; 20864672; 20942659; 20972250; 21691831; 21983347; 22062970; 22095935; 22155345; 22247256; 22286219; 22659251; 22732211; 22896670; 22916037; 23314748; 23661675; 23839332,,,,,,,,,,,,,,,OGG:3000027329,,,,,,,angiopoietin-like 3,,,,,,,,,,,,,Other designations: angiopoietin 5|angiopoietin-related protein 3,,ANGPTL3,,,,,,,,,,,,,,,,,,,,,,,27329,UNQ153/PRO179,,,,,,,9606,,,,,,,,,,,,,,,,,,,ANGPTL3,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_65023,anti-asthmatic agent,anti-asthmatic agents|antiasthmatic agent|antiasthmatic agents,Any compound that has anti-asthmatic effects.,false,,,http://purl.obolibrary.org/obo/CHEBI_23888,,,,,,,,,,,,,,,,,,,,,,Any compound that has anti-asthmatic effects.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,anti-asthmatic agents|antiasthmatic agent|antiasthmatic agents,,,,,,,,,,,,,,,,,,,,,CHEBI:65023,,,,anti-asthmatic agent,,CHEBI:65023,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000002114,ETS2,,Other designations: oncogene ETS-2|protein C-ets-2|v-ets avian erythroblastosis virus E2 oncogene homolog 2|v-ets erythroblastosis virus E26 oncogene homolog 2,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,ETS2IT1,,,,,,,,,,,,21,,,,,,HPRD:01263|MIM:164740|Ensembl:ENSG00000157557|Vega:OTTHUMG00000090769|HGNC:3489,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,v-ets avian erythroblastosis virus E26 oncogene homolog 2,,,21q22.2,,,,,,,,,,,,,,,,"GO_0000977 (EC: IEA); GO_0000981 (EC: IBA); GO_0001501 (EC: TAS, PMID: 8596630); GO_0003677 (EC: TAS, PMID: 10918595); GO_0003700 (EC: IDA, PMID: 11909962); GO_0005515 (EC: IPI, PMID: 11909962); GO_0005634 (EC: IDA, PMID: 16780588); GO_0005654 (EC: TAS); GO_0006357 (EC: IBA); GO_0006366 (EC: IBA); GO_0030154 (EC: IBA); GO_0035259 (EC: IEA); GO_0045893 (EC: IDA, PMID: 11909962); GO_0045944 (EC: IEA)",,,,,,,,,PMID: 2186967; 2250910; 2847145; 2997781; 3021321; 3285299; 8596630; 9334186; 9681824; 10212281; 10358095; 10377039; 10815800; 10830953; 10918595; 10942770; 11027273; 11279115; 11313931; 11689681; 11752456; 11909962; 12095911; 12174931; 12477932; 12511603; 12532432; 12637547; 12646185; 12743594; 12860972; 12894593; 14507917; 14702039; 14722092; 15231748; 15489334; 15572696; 15788656; 15806151; 15900611; 16263717; 16780588; 16953216; 17703088; 17921261; 17975022; 17986575; 18059336; 18094719; 18242510; 18374905; 18586674; 18598946; 18801734; 18848526; 18854154; 18942749; 19318269; 19407855; 19453261; 19939245; 20145133; 20379614; 20398657; 20554528; 20671229; 21079520; 21241890; 21526717; 21562315; 21693764; 21700929; 21763315; 21963094; 21987572; 22048266; 22128184; 22221250; 22298639; 22354960; 22446105; 22505724; 22615925; 22819965; 22826236; 22922762; 23343470; 23416888; 23530240; 23542016; 23589550; 23659968; 24024966,,,,,,,,,,,,,,,OGG:3000002114,,,,,,,v-ets avian erythroblastosis virus E26 oncogene homolog 2,,,,,,,,,,,,,Other designations: oncogene ETS-2|protein C-ets-2|v-ets avian erythroblastosis virus E2 oncogene homolog 2|v-ets erythroblastosis virus E26 oncogene homolog 2,,ETS2,,,,,,,,,,,,,,,,,,,,,,,2114,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,ETS2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000373,I-Smad,inhibitory Smad,Smad6 and Smad7 are inhibitory Smads that serve as decoys interfering with Smad-receptor or Smad-Smad interactions. Inhibitory Smads have also been detected in Drosophila (Dad).,false,,,http://purl.obolibrary.org/obo/IMR_0000370,,,,,,,,,,,,,,,,,,,,,,Smad6 and Smad7 are inhibitory Smads that serve as decoys interfering with Smad-receptor or Smad-Smad interactions. Inhibitory Smads have also been detected in Drosophila (Dad).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,inhibitory Smad,,,,,IMR:0000373,,,,,,,,,,,,,,,,,,,,,,I-Smad,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000165,cytokeratin 6A,cytokeratin 6D,,false,,,http://purl.obolibrary.org/obo/IMR_0000469,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000260,cytokeratin 6D,,,,,IMR:0000165,,,,,,,,,,,,,,,,,,,,,,cytokeratin 6A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004404,tumor cell invasion [hepatocarcinogenesis],,"A moving process of a tumor cell from the outside to the inside of other organ.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0001231,,,,,,,,,,,,,,,,,,,,PMID:30205391|PMID:30523154|PMID:28410205|PMID:17428255|PMID:28036048|PMID:29358721|PMID:29679563|PMID:28060737|PMID:28584306,,"A moving process of a tumor cell from the outside to the inside of other organ.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004404,,,,,,,,,,,,,,,,,,,,,,tumor cell invasion [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004406,ACSL4 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:50790|NCBI-Rat-GeneID:113976|NCBI-Human-GeneID:2182,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004406,,,,,,,,,,,,,,,,,,,,,,ACSL4 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004407,Increasing ACSL4 level [hepatocarcinogenesis],,"Increasing ACSL4 level is a subtype of increasing quantity: A process that changes the amount of ACSL4 level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0004405|http://purl.obolibrary.org/obo/TXPO_0002340,,,,,,,,,,,,,,,,,,,,PMID:30008815,,"Increasing ACSL4 level is a subtype of increasing quantity: A process that changes the amount of ACSL4 level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004408,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004404|http://purl.obolibrary.org/obo/TXPO_0004409|http://purl.obolibrary.org/obo/TXPO_0004403|http://purl.obolibrary.org/obo/TXPO_0004402|http://purl.obolibrary.org/obo/TXPO_0004410,,,,,,,,,,,TXPO:0004407,,,,,,,,,,,,,,,,,,,,,,Increasing ACSL4 level [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004405,Increasing ACSL4 level,,Increasing ACSL4 level is a subtype of increasing quantity: A process that changes the amount of ACSL4 level to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing ACSL4 level is a subtype of increasing quantity: A process that changes the amount of ACSL4 level to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004406,,,,,,,,,,,,,,,,,,,TXPO:0004405,,,,,,,,,,,,,,,,,,,,,,Increasing ACSL4 level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004408,ACSL4 (canonical) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004406|http://purl.obolibrary.org/obo/TXPO_0005063,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:50790|NCBI-Rat-GeneID:113976|NCBI-Human-GeneID:2182|PMID:30008815,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004408,,,,,,,,,,,,,,,,,,,,,,ACSL4 (canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004409,Increasing COX-2 level [hepatocarcinogenesis],,"Increasing COX-2 level is a subtype of increasing quantity: A process that changes the amount of COX-2 level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0004471|http://purl.obolibrary.org/obo/TXPO_0002340,,,,,,,,,,,,,,,,,,,,PMID:30008815,,"Increasing COX-2 level is a subtype of increasing quantity: A process that changes the amount of COX-2 level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004472,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004404|http://purl.obolibrary.org/obo/TXPO_0004410,,,,,,,,,,,TXPO:0004409,,,,,,,,,,,,,,,,,,,,,,Increasing COX-2 level [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004403,positive regulation of cell division [hepatocarcinogenesis],,"Any process that activates or increases the frequency, rate or extent of cell division.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/GO_0051781|http://purl.obolibrary.org/obo/TXPO_0002340,,,,,,,,,,,,,,,,,,,,PMID:25797246|PMID:28493839|PMID:8106389|PMID:20101231|PMID:2919404|PMID:31239782|PMID:30690589|PMID:30309512|PMID:23284992|PMID:28060737|PMID:30704071,,"Any process that activates or increases the frequency, rate or extent of cell division.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004498,,,,,,http://purl.obolibrary.org/obo/TXPO_0004633,,,,,,,,,,,TXPO:0004403,,,,,,,,,,,,,,,,,,,,,,positive regulation of cell division [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004402,HNF4A inactivation [hepatocarcinogenesis],,"HNF4A inactivation is a subtype of molecular inactivation: A process that  changes the activity of the HNF4A (hepatocyte nuclear factor 4 alpha) to be lower.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004620,,,,,,,,,,,,,,,,,,,,PMID:30008815,,"HNF4A inactivation is a subtype of molecular inactivation: A process that  changes the activity of the HNF4A (hepatocyte nuclear factor 4 alpha) to be lower.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004622,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004577|http://purl.obolibrary.org/obo/TXPO_0004422,,,,,,,,,,,TXPO:0004402,,,,,,,,,,,,,,,,,,,,,,HNF4A inactivation [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004400,Increasing ACSL1 level [hepatocarcinogenesis],,"Increasing ACSL1 level is a subtype of increasing quantity: A process that changes the amount of ACSL1 level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004398,,,,,,,,,,,,,,,,,,,,PMID:30008815,,"Increasing ACSL1 level is a subtype of increasing quantity: A process that changes the amount of ACSL1 level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004401,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004404|http://purl.obolibrary.org/obo/TXPO_0004403|http://purl.obolibrary.org/obo/TXPO_0004402|http://purl.obolibrary.org/obo/TXPO_0004396,,,,,,,,,,,TXPO:0004400,,,,,,,,,,,,,,,,,,,,,,Increasing ACSL1 level [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004401,ACSL1 (canonical) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0005063|http://purl.obolibrary.org/obo/TXPO_0004399,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:25288|NCBI-Human-GeneID:2180|NCBI-Mouse-GeneID:14081|PMID:30008815,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004401,,,,,,,,,,,,,,,,,,,,,,ACSL1 (canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_25512,neurotransmitter,,An endogenous compound that is used to transmit information across the synapse between a neuron and another cell.,false,,,http://purl.obolibrary.org/obo/CHEBI_33280,,,,,,,,,,,,,,,,,,,,IMR:0000967 (obsolete),,An endogenous compound that is used to transmit information across the synapse between a neuron and another cell.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:25512,,,,,,,,,,,,,,,,,,,,,,neurotransmitter,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100036,glucocorticoid,stress hormone,,false,,,http://purl.obolibrary.org/obo/IMR_0100033,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,stress hormone,,,,,IMR:0100036,,,,,,,,,,,,,,,,,,,,,,glucocorticoid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76853,EC 1.2.3.* (oxidoreductase acting on donor aldehyde/oxo group with oxygen as acceptor) inhibitor,EC 1.2.3.* inhibitors|oxidoreductase acting on donor aldehyde/oxo group with oxygen as acceptor (EC 1.2.3.*) inhibitor|EC 1.2.3.* (oxidoreductase acting on donor aldehyde/oxo group with oxygen as acceptor) inhibitors|EC 1.2.3.* inhibitor|oxidoreductase acting on donor aldehyde/oxo group with oxygen as acceptor (EC 1.2.3.*) inhibitors,An EC 1.2.* (oxidoreductase acting on donor aldehyde/oxo group) inhibitor that interferes with the action of any such enzyme using oxygen as acceptor (EC 1.2.3.*).,false,,,http://purl.obolibrary.org/obo/CHEBI_76727,,,,,,,,,,,,,,,,,,,,,,An EC 1.2.* (oxidoreductase acting on donor aldehyde/oxo group) inhibitor that interferes with the action of any such enzyme using oxygen as acceptor (EC 1.2.3.*).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,EC 1.2.3.* inhibitors|oxidoreductase acting on donor aldehyde/oxo group with oxygen as acceptor (EC 1.2.3.*) inhibitor|EC 1.2.3.* (oxidoreductase acting on donor aldehyde/oxo group with oxygen as acceptor) inhibitors|EC 1.2.3.* inhibitor|oxidoreductase acting on donor aldehyde/oxo group with oxygen as acceptor (EC 1.2.3.*) inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:76853,,,,EC 1.2.3.* (oxidoreductase acting on donor aldehyde/oxo group with oxygen as acceptor) inhibitor,,CHEBI:76853,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000576,IFN alpha-6,,,false,,,http://purl.obolibrary.org/obo/IMR_0100386,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000576,,,,,,,,,,,,,,,,,,,,,,IFN alpha-6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001437,GDF-2,BMP9|BMP-9|Bone morphogenetic protein 9|Growth/differentiation factor-2,,false,,,http://purl.obolibrary.org/obo/IMR_0000040,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BMP9|BMP-9|Bone morphogenetic protein 9|Growth/differentiation factor-2,,,,,IMR:0001437,,,,,,,,,,,,,,,,,,,,,,GDF-2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002147,hypofunction of fatty acid oxidation,,Hypofunction of fatty acid oxidation is a subtype of hypofunctioning of decomposing: A process that performs a decreased or insufficient fatty acid oxidation.,false,,,http://purl.obolibrary.org/obo/TXPO_0000436,,,,,,,,,,,,,,,,,,,,,,Hypofunction of fatty acid oxidation is a subtype of hypofunctioning of decomposing: A process that performs a decreased or insufficient fatty acid oxidation.,,,http://purl.obolibrary.org/obo/GO_0019395,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002147,,,,,,,,,,,,,,,,,,,,,,hypofunction of fatty acid oxidation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002149,netosis,,"In response to several stimuli, neutrophils and eosinophils can release the so-called neutrophil extracellular traps (NETs), that is, microbicidal structures composed of nuclear chromatin, histones and granular antimicrobial proteins.
Netotic cells exhibit massive vacuolization of the cytoplasm, rapid chromatin decondensation and breakdown of both the nuclear and granular membranes, which is required for proper NET formation.  Netosis is insensitive to caspase inhibitors and necrostatin-1, further demonstrating that it constitutes a cell death subroutine distinct from apoptosis and regulated necrosis.

Netosis might be defined as a cell death subroutine that is: (i) restricted to granulocytic cells; (ii) insensitive to (and perhaps dependent on)163 caspase inhibition; (iii) insensitive to necrostatin; (iv) dependent on NAPDH oxidase-mediated superoxide generation; and (v) dependent on (components of) the autophagic machinery

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3252826/",false,,,http://purl.obolibrary.org/obo/GO_0008219,,,,,,,,,,,,,,,,,,,,PMID:24009232,,"In response to several stimuli, neutrophils and eosinophils can release the so-called neutrophil extracellular traps (NETs), that is, microbicidal structures composed of nuclear chromatin, histones and granular antimicrobial proteins.
Netotic cells exhibit massive vacuolization of the cytoplasm, rapid chromatin decondensation and breakdown of both the nuclear and granular membranes, which is required for proper NET formation.  Netosis is insensitive to caspase inhibitors and necrostatin-1, further demonstrating that it constitutes a cell death subroutine distinct from apoptosis and regulated necrosis.

Netosis might be defined as a cell death subroutine that is: (i) restricted to granulocytic cells; (ii) insensitive to (and perhaps dependent on)163 caspase inhibition; (iii) insensitive to necrostatin; (iv) dependent on NAPDH oxidase-mediated superoxide generation; and (v) dependent on (components of) the autophagic machinery

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3252826/",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002149,,,,,,,,,,,,,,,,,,,,,,netosis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002146,decreasing proton motive force [Mitochondrial disorder],,"Decreasing proton motive force is a subtype of decreasing force: A process that changes the force of proton generated by electrochemical proton gradient to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0002064,,,,,,,,,,,,,,,,,,,,,,"Decreasing proton motive force is a subtype of decreasing force: A process that changes the force of proton generated by electrochemical proton gradient to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002146,,,,,,,,,,,,,,,,,,,,,,decreasing proton motive force [Mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002145,PERK-mediated unfolded protein response [ER stress],,"A series of molecular signals mediated by the endoplasmic reticulum membrane stress sensor PERK (PKR-like ER kinase).
This pathway is a specific course-dependent and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/GO_0036499,,,,,,,,,,,,,,,,,,,,,,"A series of molecular signals mediated by the endoplasmic reticulum membrane stress sensor PERK (PKR-like ER kinase).
This pathway is a specific course-dependent and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002145,,,,,,,,,,,,,,,,,,,,,,PERK-mediated unfolded protein response [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002143,ATF6-mediated unfolded protein response [ER stress],,A series of molecular signals mediated by the endoplasmic reticulum membrane stress sensor ATF6 (activating transcription factor 6). This pathway is a specific course-dependent and can constitute the course of ER stress.,false,,,http://purl.obolibrary.org/obo/GO_0036500,,,,,,,,,,,,,,,,,,,,,,A series of molecular signals mediated by the endoplasmic reticulum membrane stress sensor ATF6 (activating transcription factor 6). This pathway is a specific course-dependent and can constitute the course of ER stress.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002393|http://purl.obolibrary.org/obo/TXPO_0002447|http://purl.obolibrary.org/obo/TXPO_0000719,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002384,,,,,,,,,,,TXPO:0002143,,,,,,,,,,,,,,,,,,,,,,ATF6-mediated unfolded protein response [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002144,pyroptosis [Cell death],,"A caspase-1-dependent cell death subroutine that is associated with the generation of pyrogenic mediators such as IL-1beta and IL-18.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0000008|http://purl.obolibrary.org/obo/GO_0070269,,,,,,,,,,,,,,,,,,,,,,"A caspase-1-dependent cell death subroutine that is associated with the generation of pyrogenic mediators such as IL-1beta and IL-18.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002144,,,,,,,,,,,,,,,,,,,,,,pyroptosis [Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002148,anoikis (course),,Anoikis is a subtype of cell death triggered by inadequate or inappropriate adherence to substrate e.g. after disruption of the interactions between normal epithelial cells and the extracellular matrix.|under construction,false,,,http://purl.obolibrary.org/obo/TXPO_0000323,,,,,,,,,,,,,,,,,,,,"An adherent cell-restricted lethal cascade that is ignited by detachment from the matrix and that is characterized by (i) lack of beta1-integrin engagement, (ii) downregulation of EGFR expression, (iii) inhibition of extracellular-regulated kinase 1 (ERK1) signaling, and (iv) overexpression of the BCL-2 family member BIM.
 It should be noted that in most, if not all, instances, the cell death program ignited by anoikis is executed by the molecular machinery for intrinsic apoptosis.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3252826/",,Anoikis is a subtype of cell death triggered by inadequate or inappropriate adherence to substrate e.g. after disruption of the interactions between normal epithelial cells and the extracellular matrix.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000239|http://purl.obolibrary.org/obo/TXPO_0000246,,,,,,,,,,,,,,,,,,TXPO:0002148,,,,,,,,,,,,,,,,,,,,under construction,,anoikis (course),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002142,inflammatory response [Cell death],,"Inflammatory response is a subtype of changing material: The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0000192|http://purl.obolibrary.org/obo/TXPO_0001727,,,,,,,,,,,,,,,,,,,,,,"Inflammatory response is a subtype of changing material: The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002144,,,,,,,,,,,TXPO:0002142,,,,,,,,,,,,,,,,,,,,,,inflammatory response [Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002140,pathogen proliferation [Cell death],,"Pathogen proliferation is a subtype of increasing number of objects: A process becomes larger in the number of pathogen such as microorganism (bacteria, virus, mycoplasma, etc.) present in the body.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0001727|http://purl.obolibrary.org/obo/TXPO_0002139,,,,,,,,,,,,,,,,,,,,,,"Pathogen proliferation is a subtype of increasing number of objects: A process becomes larger in the number of pathogen such as microorganism (bacteria, virus, mycoplasma, etc.) present in the body.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002141,,,,,,,,,,,TXPO:0002140,,,,,,,,,,,,,,,,,,,,,,pathogen proliferation [Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002141,hyperfunction of immune response [Cell death],,"Hyperfunction of immune response is a subtype of hyperfunctioning: A process that performs an excessive immune response.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0001486|http://purl.obolibrary.org/obo/TXPO_0001727,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of immune response is a subtype of hyperfunctioning: A process that performs an excessive immune response.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003830,,,,,,,,,,,TXPO:0002141,,,,,,,,,,,,,,,,,,,,,,hyperfunction of immune response [Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100425,TRAF4,TNF receptor associated factor 4,,false,,,http://purl.obolibrary.org/obo/IMR_0000462,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TNF receptor associated factor 4,,,,,IMR:0100425,,,,,,,,,,,,,,,,,,,,,,TRAF4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001114,SREBP activation,,SREBP activation is a subtype of molecular activation: A process that changes the activity of the SREBP to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000124,,,,,,,,,,,,,,,,,,,,,,SREBP activation is a subtype of molecular activation: A process that changes the activity of the SREBP to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001114,,,,,,,,,,,,,,,,,,,,,,SREBP activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001110,USF1 (mol),upstream transcription factor 1,,false,,,http://purl.obolibrary.org/obo/TXPO_0001111,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:83586|NCBI-Human-GeneID:7391|NCBI-Mouse-GeneID:22278,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000007392,,,,,,,,upstream transcription factor 1,,,,,TXPO:0001110,,,,,,,,,,,,,,,,,,,,,,USF1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001111,USF (mol),upstream transcription factor,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,upstream transcription factor,,,,,TXPO:0001111,,,,,,,,,,,,,,,,,,,,,,USF (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001119,LXRA (canonical)[lipidosis],NR1H3 [lipidosis]|Liver X Receptor Alpha [lipidosis],,false,,,http://purl.obolibrary.org/obo/TXPO_0003516|http://purl.obolibrary.org/obo/TXPO_0001120,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:58852|NCBI-Mouse-GeneID:22259|NCBI-Human-GeneID:10062|PMID:21286345,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,NR1H3 [lipidosis]|Liver X Receptor Alpha [lipidosis],,,,,TXPO:0001119,,,,,,,,,,,,,,,,,,,,,,LXRA (canonical)[lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001112,USF1 activation,,USF1 activation is a subtype of molecular activation: A process that changes the activity of the USF1 to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000124,,,,,,,,,,,,,,,,,,,,,,USF1 activation is a subtype of molecular activation: A process that changes the activity of the USF1 to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000899,,,,,,,,,,,TXPO:0001112,,,,,,,,,,,,,,,,,,,,,,USF1 activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001115,SREBP activation [lipidosis],,"SREBP activation is a subtype of molecular activation: A process that changes the activity of the SREBP to be higher.
This entity is a specific course-dependent process. This process can constitute the course of lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001114|http://purl.obolibrary.org/obo/TXPO_0001720,,,,,,,,,,,,,,,,,,,,PMID:21286345,,"SREBP activation is a subtype of molecular activation: A process that changes the activity of the SREBP to be higher.
This entity is a specific course-dependent process. This process can constitute the course of lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003812,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000899,,,,,,,,,,,TXPO:0001115,,,,,,,,,,,,,,,,,,,,,,SREBP activation [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001116,malfunctioning of insulin signaling [lipidosis],,"Malfunctioning of insulin signaling is a subtype of malfunctioning process: A process that cannot perform insulin signaling [biological] appropriately or cannot realize it at all.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0001125,,,,,,,,,,,,,,,,,,,,PMID:30642126|PMID:26490400,,"Malfunctioning of insulin signaling is a subtype of malfunctioning process: A process that cannot perform insulin signaling [biological] appropriately or cannot realize it at all.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001115,http://purl.obolibrary.org/obo/TXPO_0001109,,,,,,http://purl.obolibrary.org/obo/TXPO_0001117|http://purl.obolibrary.org/obo/TXPO_0001113,,,,,,,,,,,TXPO:0001116,,,,,,,,,,,,,,,,,,,,,,malfunctioning of insulin signaling [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001118,increasing NAD/NAD+ ratio [Lipidosis],,"Increasing NAD/NAD+ ratio is a subtype of increasing ratio: A process that changes the ratio of NAD to NAD+ to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0001292,,,,,,,,,,,,,,,,,,,,,,"Increasing NAD/NAD+ ratio is a subtype of increasing ratio: A process that changes the ratio of NAD to NAD+ to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001130,,,,,,,,,,,TXPO:0001118,,,,,,,,,,,,,,,,,,,,,,increasing NAD/NAD+ ratio [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001117,LXRa activation [lipidosis],,"Liver X receptor activation is a subtype of activating nuclear receptor: A process that changes the activity of the activating  LXR ( liver X receptor) with a nuclear receptor role to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0000411,,,,,,,,,,,,,,,,,,,,PMID:30642126|PMID:29904174|PMID:21286345|PMID:26490400,,"Liver X receptor activation is a subtype of activating nuclear receptor: A process that changes the activity of the activating  LXR ( liver X receptor) with a nuclear receptor role to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001119,,,,,,http://purl.obolibrary.org/obo/TXPO_0001115|http://purl.obolibrary.org/obo/TXPO_0001121|http://purl.obolibrary.org/obo/TXPO_0001284|http://purl.obolibrary.org/obo/TXPO_0000899,,,,,,,,,,,TXPO:0001117,,,,,,,,,,,,,,,,,,,,,,LXRa activation [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001113,USF1 activation [lipidosis],,"USF1 activation is a subtype of molecular activation: A process that changes the activity of the USF1 to be higher.
This entity is a specific course-dependent process. This process can constitute the course of lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001112|http://purl.obolibrary.org/obo/TXPO_0001720,,,,,,,,,,,,,,,,,,,,PMID:7499393,,"USF1 activation is a subtype of molecular activation: A process that changes the activity of the USF1 to be higher.
This entity is a specific course-dependent process. This process can constitute the course of lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001108,,,,,,,,,,,,,,,,,,,TXPO:0001113,,,,,,,,,,,,,,,,,,,,,,USF1 activation [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76871,EC 2.1.1.* (methyltransferases) inhibitor,EC 2.1.1.* inhibitor|EC 2.1.1.* (methyltransferases) inhibitors|methyltransferase (EC 2.1.1.*) inhibitor|EC 2.1.1.* inhibitors|methyltransferase (EC 2.1.1.*) inhibitors|EC 2.1.1.* (methyltransferase) inhibitor|EC 2.1.1.* (methyltransferase) inhibitors,An EC 2.1.* (C1-transferase) inhibitor that interferes with the action of any methyltransferase (EC 2.1.1.*).,false,,,http://purl.obolibrary.org/obo/CHEBI_76655,,,,,,,,,,,,,,,,,,,,,,An EC 2.1.* (C1-transferase) inhibitor that interferes with the action of any methyltransferase (EC 2.1.1.*).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,EC 2.1.1.* inhibitor|EC 2.1.1.* (methyltransferases) inhibitors|methyltransferase (EC 2.1.1.*) inhibitor|EC 2.1.1.* inhibitors|methyltransferase (EC 2.1.1.*) inhibitors|EC 2.1.1.* (methyltransferase) inhibitor|EC 2.1.1.* (methyltransferase) inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:76871,,,,EC 2.1.1.* (methyltransferases) inhibitor,,CHEBI:76871,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000165721,DNAJB8,,Other designations: dnaJ homolog subfamily B member 8,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,DJ6|CT156,,,,,,,,,,,,3,,,,,,HPRD:06684|HGNC:23699|Vega:OTTHUMG00000159690|MIM:611337|HPRD:09921|Ensembl:ENSG00000179407,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"DnaJ (Hsp40) homolog, subfamily B, member 8",,,3q21.3,,,,,,,,,,,,,,,,GO_0044183 (EC: IDA); GO_0061077 (EC: IDA),,,,,,,,,PMID:11147971; 12477932; 15489334; 17207965; 20159555; 20556630; 22552285; 23612975,,,,,,,,,,,,,,,OGG:3000165721,,,,,,,"DnaJ (Hsp40) homolog, subfamily B, member 8",,,,,,,,,,,,,Other designations: dnaJ homolog subfamily B member 8,,DNAJB8,,,,,,,,,,,,,,,,,,,,,,,165721,,,,,,,,9606,,,,,,,,,,,,,,,,,,,DNAJB8,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/GO_0008152,metabolic process,metabolism,"The chemical reactions and pathways, including anabolism and catabolism, by which living organisms transform chemical substances. Metabolic processes typically transform small molecules, but also include macromolecular processes such as DNA repair and replication, and protein synthesis and degradation.|Note that metabolic processes do not include single functions or processes such as protein-protein interactions, protein-nucleic acids, nor receptor-ligand interactions.",false,,,http://purl.obolibrary.org/obo/TXPO_0000261,,,,,,,,,,,,,,,,,,,,Wikipedia:Metabolism,,"The chemical reactions and pathways, including anabolism and catabolism, by which living organisms transform chemical substances. Metabolic processes typically transform small molecules, but also include macromolecular processes such as DNA repair and replication, and protein synthesis and degradation.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,metabolism,,,,,GO:0008152,,,,,,,,,,,,,,,,,,,,"Note that metabolic processes do not include single functions or processes such as protein-protein interactions, protein-nucleic acids, nor receptor-ligand interactions.",,metabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000370,Smad,SMAD,"Smads is a conserved family of signal transducers. Functionally, Smads fall into three subfamilies:R-Smads; Co-Smads; I-Smads. Eight Smad proteins are encoded in vertebrate, four in Drosophila, and three in C. elegans.",false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,IPR:001132,,"Smads is a conserved family of signal transducers. Functionally, Smads fall into three subfamilies:R-Smads; Co-Smads; I-Smads. Eight Smad proteins are encoded in vertebrate, four in Drosophila, and three in C. elegans.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003720,,,,,SMAD,,,,,IMR:0000370,,,,,,,,,,,,,,,,,,,,,,Smad,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0042445,hormone metabolic process,"The chemical reactions and pathways involving any hormone, naturally occurring substances secreted by specialized cells that affects the metabolism or behavior of other cells possessing functional receptors for the hormone.|hormone metabolism",,false,,,http://purl.obolibrary.org/obo/GO_0008152,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways involving any hormone, naturally occurring substances secreted by specialized cells that affects the metabolism or behavior of other cells possessing functional receptors for the hormone.|hormone metabolism",,,,,GO:0042445,,,,,,,,,,,,,,,,,,,,,,hormone metabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004729,ORC1 inactivation,,ORC1 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the ORC1 (origin recognition complex subunit 1) to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000021,,,,,,,,,,,,,,,,,,,,,,ORC1 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the ORC1 (origin recognition complex subunit 1) to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004729,,,,,,,,,,,,,,,,,,,,,,ORC1 inactivation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004725,Notch 1 (canonical) [hepatocarcinogenesis],Notch1|Notch-1,,false,,,http://purl.obolibrary.org/obo/IMR_0100714|http://purl.obolibrary.org/obo/TXPO_0005063,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:4851|PMID:28036048|NCBI-Rat-GeneID:25496|NCBI-Mouse-GeneID:18128,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Notch1|Notch-1,,,,,TXPO:0004725,,,,,,,,,,,,,,,,,,,,,,Notch 1 (canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004727,Notch 3 (canonical) [hepatocarcinogenesis],Notch-3|Notch3|Neurogenic locus notch homolog protein 3 precursor,,false,,,http://purl.obolibrary.org/obo/IMR_0100716|http://purl.obolibrary.org/obo/TXPO_0005063,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:18131|NCBI-Human-GeneID:4854|NCBI-Rat-GeneID:56761|PMID:28036048,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Notch-3|Notch3|Neurogenic locus notch homolog protein 3 precursor,,,,,TXPO:0004727,,,,,,,,,,,,,,,,,,,,,,Notch 3 (canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004722,negative regulation of antioxidant enzyme activation [mitochondrial disorder],,"Negative regulation of antioxidant enzyme activation is a subtype of Negative regulation of enzyme activation: A process that stops, prevents, or reduces the frequency, rate or extent of antioxidant enzyme activation.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0005029|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:31623280|PMID:23299992,,"Negative regulation of antioxidant enzyme activation is a subtype of Negative regulation of enzyme activation: A process that stops, prevents, or reduces the frequency, rate or extent of antioxidant enzyme activation.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004370,,,,,,,,,,,TXPO:0004722,,,,,,,,,,,,,,,,,,,,,,negative regulation of antioxidant enzyme activation [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004721,NRF2 - inactive form (canonical) [mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/TXPO_0005120|http://purl.obolibrary.org/obo/TXPO_0004293,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:18024|NCBI-Rat-GeneID:83619|NCBI-Human-GeneID:4780|PMID:31623280,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0002355,,,,,,,,,,,,,,TXPO:0004721,,,,,,,,,,,,,,,,,,,,,,NRF2 - inactive form (canonical) [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004720,NRF2 inactivation [mitochondrial disorder],,"NRF2 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the NRF2 (nuclear factor 2) to be lower.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0004719,,,,,,,,,,,,,,,,,,,,PMID:31623280,,"NRF2 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the NRF2 (nuclear factor 2) to be lower.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004721,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004722|http://purl.obolibrary.org/obo/TXPO_0004723|http://purl.obolibrary.org/obo/TXPO_0002005,,,,,,,,,,,TXPO:0004720,,,,,,,,,,,,,,,,,,,,,,NRF2 inactivation [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004726,Notch 2 (canonical) [hepatocarcinogenesis],Notch2|Notch-2,,false,,,http://purl.obolibrary.org/obo/IMR_0100715|http://purl.obolibrary.org/obo/TXPO_0005063,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:18129|NCBI-Rat-GeneID:29492|NCBI-Human-GeneID:4853|PMID:28036048,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Notch2|Notch-2,,,,,TXPO:0004726,,,,,,,,,,,,,,,,,,,,,,Notch 2 (canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004723,hypofunction of lipid biosynthesis [mitochondrial disorder],,"Hypofunction of lipid biosynthesis is a subtype of hypofunction of biosynthesis: A process that performs a decreased or insufficient lipid biosynthesis.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0002195,,,,,,,,,,,,,,,,,,,,PMID:31623280,,"Hypofunction of lipid biosynthesis is a subtype of hypofunction of biosynthesis: A process that performs a decreased or insufficient lipid biosynthesis.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,http://purl.obolibrary.org/obo/GO_0008610,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004723,,,,,,,,,,,,,,,,,,,,,,hypofunction of lipid biosynthesis [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004724,Notch signaling (primitive),,Notch signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by Notch.,false,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,,,Notch signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by Notch.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0007219,,,,,,,,,,,,,,,,TXPO:0004724,,,,,,,,,,,,,,,,,,,,,,Notch signaling (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004728,UHRF1 production [hepatocarcinogenesis],,"UHRF1 production is a subtype of protein production: A process that makes existent of a UHRF1 protein due to biosynthesis or secretion resulting in an increase in its levels.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004641,,,,,,,,,,,,,,,,,,,,PMID:30309512|PMID:28060737,,"UHRF1 production is a subtype of protein production: A process that makes existent of a UHRF1 protein due to biosynthesis or secretion resulting in an increase in its levels.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004203,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004459|http://purl.obolibrary.org/obo/TXPO_0004404|http://purl.obolibrary.org/obo/TXPO_0004479|http://purl.obolibrary.org/obo/TXPO_0004422|http://purl.obolibrary.org/obo/TXPO_0004392,,,,,,,,,,,TXPO:0004728,,,,,,,,,,,,,,,,,,,,,,UHRF1 production [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000003690,ITGB3,,Other designations: integrin beta-3|platelet membrane glycoprotein IIIa,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,GP3A|GT|BDPLT2|BDPLT16|CD61|GPIIIa,,,,,,,,,,,,17,,,,,,Ensembl:ENSG00000259207|Vega:OTTHUMG00000171956|HPRD:01428|HGNC:6156|MIM:173470,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61)",,,17q21.32,,,,,,,,,,,,,,,,"GO_0001934 (EC: TAS, PMID: 19267251); GO_0001938 (EC: IMP, PMID: 10022831); GO_0002576 (EC: TAS); GO_0003756 (EC: IDA, PMID: 12204115); GO_0004872 (EC: IEA); GO_0005161 (EC: TAS, PMID: 19267251); GO_0005515 (EC: IPI, PMID: 10822899); GO_0005634 (EC: IDA); GO_0005886 (EC: IDA, PMID: 15466936); GO_0005886 (EC: TAS); GO_0005887 (EC: TAS, PMID: 2452834); GO_0005925 (EC: IEA); GO_0006457 (EC: IDA, PMID: 12204115); GO_0007044 (EC: IEA); GO_0007155 (EC: TAS, PMID: 10429193); GO_0007160 (EC: IEA); GO_0007229 (EC: TAS); GO_0007411 (EC: TAS); GO_0007596 (EC: TAS); GO_0008305 (EC: IDA, PMID: 15215180); GO_0010595 (EC: IMP, PMID: 10022831); GO_0010745 (EC: IMP, PMID: 15215180); GO_0010888 (EC: IMP, PMID: 15215180); GO_0014909 (EC: IMP, PMID: 8837777); GO_0016032 (EC: IEA); GO_0030168 (EC: IMP, PMID: 15466936); GO_0030168 (EC: TAS); GO_0030198 (EC: TAS); GO_0030949 (EC: TAS, PMID: 19267251); GO_0031092 (EC: TAS); GO_0031258 (EC: IEA); GO_0032147 (EC: IMP, PMID: 10022831); GO_0032369 (EC: IMP, PMID: 15215180); GO_0035295 (EC: TAS, PMID: 19267251); GO_0042060 (EC: IC, PMID: 8837777); GO_0042470 (EC: IDA, PMID: 15466936); GO_0042802 (EC: IPI, PMID: 11606749); GO_0043184 (EC: IPI, PMID: 10022831); GO_0043184 (EC: TAS, PMID: 19267251); GO_0043235 (EC: IDA); GO_0045124 (EC: TAS, PMID: 19267251); GO_0045715 (EC: IMP, PMID: 15215180); GO_0050731 (EC: IMP, PMID: 10022831); GO_0050748 (EC: IMP, PMID: 15215180); GO_0050839 (EC: IPI, PMID: 8837777); GO_0050900 (EC: TAS); GO_0060055 (EC: TAS, PMID: 19267251); GO_0070062 (EC: IDA); GO_0070527 (EC: IMP, PMID: 15466936); GO_0071062 (EC: TAS, PMID: 19267251)",,,,,,,,,PMID: 1371279; 1382574; 1429573; 1430225; 1438206; 1549507; 1602006; 1693624; 1693626; 1694173; 1953640; 1967954; 2001252; 2010551; 2138612; 2145280; 2202737; 2341395; 2345548; 2392682; 2452834; 2454952; 2478219; 2565345; 2787511; 3165296; 3494014; 3607284; 3801670; 3828395; 7505120; 7532190; 7539135; 7592818; 7593198; 7682219; 7690138; 7694683; 7878622; 8093349; 8132570; 8132607; 8198553; 8244378; 8298129; 8387021; 8400294; 8467233; 8631894; 8649427; 8663236; 8757599; 8781422; 8798654; 8831898; 8837777; 9030514; 9169439; 9195946; 9215749; 9256940; 9376589; 9517988; 9684783; 9686320; 9790984; 9916748; 10022831; 10037797; 10233432; 10391209; 10397733; 10429193; 10438928; 10497223; 10605720; 10640428; 10684262; 10747940; 10749942; 10822899; 10835423; 10837460; 10848816; 10896934; 10964917; 10964931; 10982404; 11028489; 11042121; 11053714; 11151063; 11235724; 11238109; 11257275; 11279932; 11331301; 11341749; 11397354; 11447076; 11454259; 11460491; 11470407; 11533523; 11545752; 11546839; 11568114; 11577104; 11583324; 11588040; 11606749; 11683411; 11686325; 11704375; 11714857; 11723131; 11739968; 11776310; 11807098; 11812069; 11812775; 11858476; 11858493; 11864709; 11867691; 11875117; 11877390; 11884718; 11891802; 11897046; 11927607; 11932255; 11934894; 11940607; 11953315; 11959660; 11962738; 11994301; 12008962; 12031826; 12036875; 12038797; 12049640; 12071877; 12073410; 12082590; 12082592; 12083483; 12140290; 12152649; 12152651; 12161360; 12168086; 12198771; 12200372; 12204115; 12209993; 12210725; 12218055; 12237112; 12237321; 12297512; 12353082; 12358597; 12362250; 12364323; 12370491; 12372433; 12372469; 12372811; 12393510; 12399420; 12426312; 12427871; 12460991; 12477932; 12486108; 12499711; 12511588; 12514663; 12518110; 12535520; 12553378; 12578602; 12586134; 12606711; 12609844; 12637342; 12639965; 12645863; 12660257; 12665801; 12668663; 12682293; 12690117; 12690916; 12691260; 12694355; 12714203; 12716314; 12719784; 12720308; 12730600; 12736272; 12738509; 12750158; 12765524; 12771130; 12791034; 12799374; 12807887; 12818249; 12818251; 12826159; 12827240; 12855229; 12871468; 12871600; 12874388; 12899665; 12902444; 12902636; 12911597; 12932598; 12941045; 12952967; 12957761; 13678940; 14499914; 14517343; 14521607; 14524530; 14525764; 14557872; 14593208; 14614355; 14629479; 14634961; 14669168; 14675395; 14681217; 14681220; 14690453; 14691438; 14691579; 14746139; 14963009; 14963283; 14966135; 14987913; 14992889; 15044441; 15045135; 15056669; 15067009; 15076187; 15131115; 15134555; 15147527; 15156152; 15166241; 15166939; 15166947; 15166949; 15178823; 15187087; 15215180; 15219201; 15226180; 15227729; 15299032; 15331787; 15344881; 15355503; 15355504; 15456946; 15466936; 15468167; 15489334; 15509546; 15546585; 15564935; 15565371; 15575508; 15583747; 15590407; 15609125; 15627799; 15634267; 15638730; 15663601; 15676177; 15695828; 15699036; 15701653; 15701721; 15705408; 15730528; 15748237; 15795319; 15817799; 15826939; 15834425; 15834589; 15840736; 15842360; 15847651; 15863506; 15886806; 15890274; 15897908; 15917997; 15921657; 15968394; 15970922; 15976180; 15978110; 15990752; 15998788; 16005200; 16005629; 16035619; 16051597; 16051604; 16091654; 16100725; 16102042; 16105876; 16113799; 16115959; 16133898; 16150802; 16153930; 16157382; 16158739; 16166568; 16195248; 16213489; 16228296; 16248996; 16263699; 16275649; 16307159; 16317099; 16317580; 16322334; 16322781; 16335952; 16339753; 16340127; 16353042; 16357324; 16359515; 16380674; 16385340; 16400188; 16407244; 16412752; 16444441; 16469512; 16504741; 16513293; 16567932; 16573563; 16581250; 16582881; 16634766; 16635210; 16636497; 16675000; 16676352; 16702043; 16716076; 16721604; 16723352; 16724005; 16731529; 16756721; 16790523; 16818691; 16822941; 16831169; 16859511; 16875034; 16877710; 16879215; 16895913; 16905953; 16933105; 16935858; 16969099; 17032655; 17034033; 17074516; 17092301; 17111197; 17127487; 17138951; 17146626; 17158881; 17160992; 17175151; 17192395; 17196570; 17203213; 17203304; 17206538; 17218263; 17220212; 17230042; 17258347; 17264806; 17272505; 17278970; 17290027; 17320454; 17332246; 17334320; 17337041; 17346829; 17357883; 17369840; 17376438; 17406648; 17414216; 17432927; 17439948; 17446174; 17468108; 17482311; 17483236; 17515951; 17538005; 17550972; 17556058; 17559347; 17561290; 17607710; 17615290; 17621633; 17630485; 17635696; 17641225; 17642204; 17644514; 17665449; 17679464; 17681328; 17714854; 17728329; 17763154; 17827388; 17854909; 17855352; 17907177; 17912026; 17928472; 17954176; 17957566; 17959856; 18021403; 18031296; 18035074; 18041653; 18045240; 18045606; 18045938; 18051367; 18056258; 18057877; 18062611; 18064323; 18065693; 18067652; 18084301; 18088350; 18156175; 18160561; 18160589; 18162078; 18174155; 18175315; 18191725; 18200665; 18201749; 18208809; 18211801; 18214290; 18230083; 18237139; 18247041; 18260892; 18310319; 18310446; 18312855; 18316775; 18317590; 18321071; 18331351; 18331836; 18334487; 18343248; 18345483; 18353318; 18353785; 18364349; 18375753; 18383324; 18396070; 18399841; 18405917; 18419255; 18433460; 18441324; 18458155; 18484951; 18503143; 18512729; 18513389; 18516040; 18549690; 18550570; 18573917; 18577523; 18635536; 18638089; 18641368; 18648521; 18657307; 18665040; 18673340; 18674955; 18685811; 18709641; 18712091; 18728123; 18791937; 18796633; 18803625; 18814143; 18821851; 18824633; 18826388; 18832906; 18836720; 18836731; 18841997; 18854176; 18927433; 18927546; 18930220; 18936436; 18974842; 18978678; 18979363; 18989530; 19001202; 19008959; 19017937; 19018779; 19019827; 19037107; 19038456; 19061491; 19071013; 19072566; 19074851; 19104837; 19106083; 19110485; 19117493; 19118033; 19118218; 19123042; 19131662; 19132198; 19141530; 19184277; 19197137; 19205270; 19207108; 19212436; 19212638; 19230252; 19232685; 19235843; 19238444; 19245802; 19255147; 19262211; 19263529; 19264973; 19267251; 19279667; 19286442; 19329429; 19334037; 19336355; 19336370; 19336737; 19345676; 19350519; 19350618; 19361361; 19366731; 19368146; 19371633; 19374152; 19388931; 19390575; 19395327; 19461049; 19463111; 19463119; 19469865; 19475568; 19487690; 19515580; 19526385; 19527712; 19527732; 19530321; 19541645; 19546854; 19559392; 19562259; 19570064; 19573311; 19588468; 19604247; 19617625; 19630800; 19633306; 19635510; 19637098; 19654300; 19656390; 19670701; 19691478; 19695571; 19702628; 19704023; 19729601; 19730003; 19740098; 19751734; 19765213; 19778317; 19789190; 19804783; 19805198; 19808093; 19808644; 19815712; 19816083; 19821948; 19824427; 19837659; 19860767; 19863457; 19876733; 19882657; 19888429; 19889638; 19903699; 19906129; 19913121; 19923980; 19934566; 19948007; 19956635; 19959486; 19996122; 20002543; 20020534; 20033473; 20048261; 20075254; 20076847; 20078877; 20106508; 20138334; 20149160; 20161734; 20162297; 20181715; 20192979; 20204402; 20230421; 20237496; 20306691; 20308600; 20339539; 20363746; 20369606; 20379614; 20406466; 20425806; 20438394; 20452482; 20458832; 20472470; 20477989; 20485444; 20492470; 20519501; 20532885; 20538554; 20546203; 20554778; 20565758; 20584077; 20592457; 20595101; 20600001; 20615878; 20628086; 20634891; 20638909; 20661303; 20667040; 20673868; 20679525; 20691446; 20702409; 20717043; 20739287; 20739877; 20802378; 20819594; 20826760; 20828133; 20837477; 20846430; 20857483; 20873239; 20929856; 20945385; 20978323; 21034162; 21039385; 21044892; 21054877; 21071690; 21080081; 21091771; 21102624; 21109038; 21122545; 21135163; 21143381; 21156831; 21182210; 21190668; 21241403; 21283814; 21325030; 21344378; 21353223; 21508388; 21529934; 21570717; 21590707; 21622897; 21626402; 21645227; 21645497; 21678053; 21764795; 21813062; 21832081; 21917754; 21935711; 21951552; 21966982; 21978494; 22002573; 22015616; 22015659; 22028352; 22078565; 22094875; 22095620; 22102273; 22116617; 22132110; 22136613; 22171266; 22174124; 22174684; 22190468; 22207115; 22268819; 22308022; 22328516; 22362758; 22407444; 22422622; 22448399; 22452684; 22456341; 22457811; 22461623; 22466811; 22484027; 22528484; 22531012; 22538781; 22581054; 22613710; 22641344; 22669259; 22698642; 22730538; 22879933; 22948415; 23003125; 23022044; 23022222; 23119061; 23125415; 23150579; 23161541; 23181508; 23184042; 23197154; 23204516; 23216754; 23234019; 23238957; 23243278; 23243309; 23253071; 23289212; 23300803; 23382103; 23382691; 23384292; 23386126; 23389628; 23451109; 23469002; 23494007; 23519467; 23527123; 23545624; 23571313; 23580774; 23628433; 23640055; 23725446; 23726972; 23744557; 23770013; 23840404; 23845726; 23857544; 23867618; 23929305; 23981581; 24023288; 24030382; 24037888; 24096143; 24109241; 24136164; 24176823; 24437179; 24437181,,,,,,,,,,,,,,,OGG:3000003690,,20140408,protein-coding,,,,"integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61)",,,,,,,,,,,,,Other designations: integrin beta-3|platelet membrane glycoprotein IIIa,,ITGB3,,,,,,,,,,,,,,,,,,,,,,,3690,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,ITGB3,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000003692,EIF6,,Other designations: B4 integrin interactor|eukaryotic translation initiation factor 3A|p27 beta-4 integrin-binding protein,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,p27BBP|CAB|b(2)gcn|eIF-6|p27(BBP)|ITGB4BP|EIF3A,,,,,,,,,,,,20,,,,,,Ensembl:ENSG00000242372|MIM:602912|Vega:OTTHUMG00000032328|HPRD:04221|HGNC:6159,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,eukaryotic translation initiation factor 6,,,20q12,,,,,,,,,,,,,,,,"GO_0003743 (EC: IEA); GO_0005515 (EC: IPI); GO_0005634 (EC: IDA); GO_0005638 (EC: IEA); GO_0005730 (EC: IDA, Qualifier: NOT); GO_0005737 (EC: IEA); GO_0042256 (EC: IMP); GO_0043022 (EC: IDA); GO_0070062 (EC: IDA, PMID:19056867)",,,,,,,,,PMID:9374518; 9405604; 9653160; 9740680; 10085284; 10348637; 10906324; 11042152; 11290417; 11780052; 11790298; 12477932; 12917340; 14654845; 15122657; 15146197; 15231747; 15489334; 15592455; 15635413; 15946946; 16169070; 16341674; 16530192; 17353931; 17507929; 17569113; 18029348; 18327211; 18391951; 18624398; 18781797; 19056867; 19738201; 20546612; 20585627; 21029697; 21084295; 21139048; 21145461; 21536732; 21832049; 21900206; 21903422; 21963094; 21988832; 22178446; 22295858; 22348144; 22365962; 22415777; 22586326; 22863883; 22939629; 22990118; 23115272; 23752268; 24457600,,,,,,,,,,,,,,,OGG:3000003692,,,,,,,eukaryotic translation initiation factor 6,,,,,,,,,,,,,Other designations: B4 integrin interactor|eukaryotic translation initiation factor 3A|p27 beta-4 integrin-binding protein,,EIF6,,,,,,,,,,,,,,,,,,,,,,,3692,RP4-614O4.1,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF6,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0001455,TLR6,Toll-like receptor 6,,false,,,http://purl.obolibrary.org/obo/IMR_0000124,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Toll-like receptor 6,,,,,IMR:0001455,,,,,,,,,,,,,,,,,,,,,,TLR6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0033700,phospholipid efflux,,The directed movement of a phospholipid out of a cell or organelle.,false,,,http://purl.obolibrary.org/obo/TXPO_0002588,,,,,,,,,,,,,,,,,,,,,,The directed movement of a phospholipid out of a cell or organelle.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_16247,,,,,,,,,,,,,,,,,,,GO:0033700,,,,,,,,,,,,,,,,,,,,,,phospholipid efflux,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006869,lipid transport,,"The directed movement of lipids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Lipids are compounds soluble in an organic solvent but not, or sparingly, in an aqueous solvent.",false,,,http://purl.obolibrary.org/obo/TXPO_0000111,,,,,,,,,,,,,,,,,,,,,,"The directed movement of lipids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Lipids are compounds soluble in an organic solvent but not, or sparingly, in an aqueous solvent.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0006869,,,,,,,,,,,,,,,,,,,,,,lipid transport,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_6717,mefenamic acid,"CI-473|INF-3355|acidum mefenamicum|Ponstel|N-(2,3-xylyl)-2-aminobenzoic acid|N-2,3-xylylanthranilic acid|INF 3355|CN 35355|Mefenaminsaeure|acide mefenamique|acido mefenamico|mefenamic acid|CN-35355|2-[(2,3-dimethylphenyl)amino]benzoic acid","An aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 2,3-dimethylphenyl group. Although classed as a non-steroidal anti-inflammatory drug, its anti-inflammatory properties are considered to be minor. It is used to relieve mild to moderate pain, including headaches, dental pain, osteoarthritis and rheumatoid arthritis.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:2684858|PMID:14001132|PMID:22369458|PMID:28166217|PMID:3304401|PMID:4916242|PMID:425903|PMID:17330662|PMID:23494912|DrugBank:DB00784|LINCS:LSM-4085|PMID:4212650|PMID:6155061|PMID:577447|PMID:22275128|PMID:23656341|Drug_Central:1663|CAS:61-68-7|PMID:23402341|PMID:5286553|Reaxys:2216243,,"An aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 2,3-dimethylphenyl group. Although classed as a non-steroidal anti-inflammatory drug, its anti-inflammatory properties are considered to be minor. It is used to relieve mild to moderate pain, including headaches, dental pain, osteoarthritis and rheumatoid arthritis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35493|http://purl.obolibrary.org/obo/CHEBI_35544|http://purl.obolibrary.org/obo/CHEBI_35703|http://purl.obolibrary.org/obo/CHEBI_35480|http://purl.obolibrary.org/obo/CHEBI_35475|http://purl.obolibrary.org/obo/CHEBI_78298|http://purl.obolibrary.org/obo/CHEBI_35842,,,,,"2-[(2,3-dimethylphenyl)amino]benzoic acid",,"CI-473|INF-3355|acidum mefenamicum|Ponstel|N-(2,3-xylyl)-2-aminobenzoic acid|N-2,3-xylylanthranilic acid|INF 3355|CN 35355|Mefenaminsaeure|acide mefenamique|acido mefenamico|mefenamic acid|CN-35355",,,,,,,,,,,,,,,,,,,,,CHEBI:6717,,,,mefenamic acid,,CHEBI:6717,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000008837,CFLAR,,Other designations: FADD-like anti-apoptotic molecule|FADD-like antiapoptotic molecule 1|MACH-related inducer of toxicity|caspase homolog|caspase-eight-related protein|caspase-like apoptosis regulatory protein|caspase-related inducer of apoptosis|cellular FLICE-like inhibitory protein|inhibitor of FLICE|usurpin beta,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CASP8AP1|c-FLIPL|CLARP|Casper|FLAME|c-FLIPR|CASH|FLAME-1|I-FLICE|c-FLIP|FLAME1|c-FLIPS|FLIP|MRIT,,,,,,,,,,,,2,,,,,,Ensembl:ENSG00000003402|HGNC:1876|Vega:OTTHUMG00000132819|MIM:603599|HPRD:04671,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,CASP8 and FADD-like apoptosis regulator,,,2q33-q34,,,,,,,,,,,,,,,,"GO_0002020 (EC: IPI, PMID: 9208847); GO_0004197 (EC: IKR, Qualifier: NOT); GO_0005515 (EC: IPI, PMID: 11741985); GO_0005737 (EC: IDA, PMID: 18073330); GO_0005829 (EC: TAS); GO_0006915 (EC: IMP); GO_0006915 (EC: TAS); GO_0007519 (EC: ISS); GO_0008047 (EC: IDA, PMID: 9208847); GO_0014732 (EC: ISS); GO_0014842 (EC: ISS); GO_0014866 (EC: ISS); GO_0016032 (EC: IEA); GO_0031264 (EC: IDA); GO_0031265 (EC: IEA); GO_0035877 (EC: IBA); GO_0043066 (EC: IEA); GO_0043085 (EC: IDA, PMID: 9208847); GO_0043123 (EC: IEP, PMID: 12761501); GO_0043403 (EC: ISS); GO_0051092 (EC: ISS); GO_0060544 (EC: IDA); GO_0097190 (EC: TAS); GO_0097342 (EC: IDA); GO_1901740 (EC: ISS); GO_1902042 (EC: IMP, PMID: 18202225); GO_2001237 (EC: IDA, PMID: 9208847); GO_2001237 (EC: IMP); GO_2001239 (EC: TAS)",,,,,,,,,PMID: 8889548; 9208847; 9211860; 9217161; 9219695; 9228018; 9289491; 9325248; 9326610; 9380701; 9560245; 9575181; 9880531; 9990034; 10069390; 10200473; 10227994; 10329646; 10837247; 11002417; 11161814; 11193041; 11741985; 11830587; 11877293; 11940602; 11965497; 12031968; 12060768; 12097160; 12115181; 12215447; 12220669; 12393527; 12407100; 12432255; 12477932; 12477972; 12496285; 12496481; 12496482; 12552004; 12556488; 12574377; 12592338; 12716387; 12746452; 12761501; 12820373; 12887920; 13679070; 14562111; 14578361; 14637155; 14662022; 14759258; 15024054; 15078899; 15096587; 15183989; 15258564; 15273717; 15280356; 15297424; 15304499; 15334061; 15354734; 15459191; 15485835; 15489334; 15540114; 15557152; 15644494; 15653751; 15686714; 15701649; 15701651; 15722350; 15731171; 15760909; 15761846; 15815586; 15832422; 15843523; 15864316; 15886205; 15899875; 15917295; 15956881; 16014121; 16052233; 16052516; 16077198; 16211288; 16246840; 16247474; 16298825; 16304056; 16403915; 16436054; 16441226; 16472594; 16537561; 16611896; 16712791; 16720717; 16740746; 16901543; 17003335; 17047155; 17056549; 17070520; 17106251; 17110930; 17159907; 17272514; 17353931; 17376892; 17440816; 17441421; 17450141; 17513603; 17559541; 17573774; 17581950; 17638906; 17646662; 17659339; 17697742; 17726263; 17762208; 17912957; 17922291; 17932249; 17982483; 17988665; 18073330; 18084329; 18189268; 18202225; 18243739; 18257744; 18264131; 18314443; 18339897; 18391984; 18398344; 18414015; 18509086; 18559494; 18593367; 18603835; 18726983; 18767116; 18820704; 18823309; 18838202; 18840411; 18976975; 19090833; 19109151; 19115040; 19161534; 19177145; 19203346; 19223508; 19243385; 19249545; 19282655; 19321593; 19339247; 19343040; 19363595; 19372246; 19398149; 19409438; 19433309; 19439735; 19476635; 19543235; 19573080; 19604093; 19710364; 19728335; 19734124; 19773279; 19798106; 19802016; 19808964; 19816511; 19838173; 19890350; 19896469; 19906927; 19913121; 19949310; 19956887; 20016063; 20087343; 20218968; 20224598; 20227749; 20335528; 20372864; 20449949; 20453000; 20484045; 20508645; 20561424; 20568250; 20595005; 20628086; 20628624; 20689807; 20696707; 20802294; 20812013; 20876284; 20876774; 20882347; 20975036; 21048031; 21071136; 21107885; 21153369; 21307400; 21324892; 21394196; 21403465; 21435442; 21454681; 21474069; 21480219; 21483669; 21525012; 21562857; 21638304; 21691254; 21737329; 21803845; 21822306; 21856935; 21868755; 21890473; 21912376; 21988832; 22027693; 22072062; 22126763; 22190004; 22219201; 22266862; 22288650; 22322857; 22345097; 22393362; 22504646; 22683265; 22753273; 22781394; 22842544; 22864571; 22884570; 22948392; 23028678; 23142077; 23167276; 23230268; 23235765; 23247197; 23255321; 23256568; 23319802; 23322903; 23371318; 23483900; 23518915; 23519470; 23615398; 23696271; 23853530,,,,,,,,,,,,,,,OGG:3000008837,,,,,,,CASP8 and FADD-like apoptosis regulator,,,,,,,,,,,,,Other designations: FADD-like anti-apoptotic molecule|FADD-like antiapoptotic molecule 1|MACH-related inducer of toxicity|caspase homolog|caspase-eight-related protein|caspase-like apoptosis regulatory protein|caspase-related inducer of apoptosis|cellular FLICE-like inhibitory protein|inhibitor of FLICE|usurpin beta,,CFLAR,,,,,,,,,,,,,,,,,,,,,,,8837,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,CFLAR,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_76731,EC 1.5.* (oxidoreductase acting on donor CH-NH group) inhibitor,EC 1.5.* inhibitors|inhibitors of oxidoreductase acting on CH-NH group of donor|inhibitor of oxidoreductase acting on CH-NH group of donors|inhibitors of oxidoreductase acting on CH-NH group of donors|oxidoreductase acting on donor CH-NH group (EC 1.5.*) inhibitors|inhibitor of oxidoreductase acting on CH-NH group of donor|oxidoreductase acting on donor CH-NH group (EC 1.5.*) inhibitor|EC 1.5.* (oxidoreductase acting on donor CH-NH group) inhibitors|EC 1.5.* inhibitor,An oxidoreductase inhibitor which interferes with the action of an oxidoreductase acting on the CH-NH group of donors (EC 1.5.*.*).,false,,,http://purl.obolibrary.org/obo/CHEBI_76725,,,,,,,,,,,,,,,,,,,,,,An oxidoreductase inhibitor which interferes with the action of an oxidoreductase acting on the CH-NH group of donors (EC 1.5.*.*).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,EC 1.5.* inhibitors|inhibitors of oxidoreductase acting on CH-NH group of donor|inhibitor of oxidoreductase acting on CH-NH group of donors|inhibitors of oxidoreductase acting on CH-NH group of donors|oxidoreductase acting on donor CH-NH group (EC 1.5.*) inhibitors|inhibitor of oxidoreductase acting on CH-NH group of donor|oxidoreductase acting on donor CH-NH group (EC 1.5.*) inhibitor|EC 1.5.* (oxidoreductase acting on donor CH-NH group) inhibitors|EC 1.5.* inhibitor,,,,,,,,,,,,,,,,,,,,,CHEBI:76731,,,,EC 1.5.* (oxidoreductase acting on donor CH-NH group) inhibitor,,CHEBI:76731,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000029118,DDX25,,Other designations: ATP-dependent RNA helicase DDX25|DEAD (Asp-Glu-Ala-Asp) box polypeptide 25|DEAD box protein 25|DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 25|gonadotropin-regulated testicular RNA helicase,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,GRTH,,,,,,,,,,,,11,,,,,,Vega:OTTHUMG00000165859|MIM:607663|HPRD:06367|Ensembl:ENSG00000109832|HGNC:18698,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,DEAD (Asp-Glu-Ala-Asp) box helicase 25,,,11q24,,,,,,,,,,,,,,,,GO_0003723 (EC: IEA); GO_0004004 (EC: ISS); GO_0005524 (EC: ISS); GO_0005634 (EC: ISS); GO_0005737 (EC: ISS); GO_0006200 (EC: ISS); GO_0006406 (EC: ISS); GO_0006417 (EC: ISS); GO_0007275 (EC: IEA); GO_0007286 (EC: ISS); GO_0033391 (EC: ISS),,,,,,,,,PMID: 10608860; 12477932; 15094194; 15096601; 15489334; 16293649; 17848414; 17889551; 19536092; 19875492; 20378615,,,,,,,,,,,,,,,OGG:3000029118,,,,,,,DEAD (Asp-Glu-Ala-Asp) box helicase 25,,,,,,,,,,,,,Other designations: ATP-dependent RNA helicase DDX25|DEAD (Asp-Glu-Ala-Asp) box polypeptide 25|DEAD box protein 25|DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 25|gonadotropin-regulated testicular RNA helicase,,DDX25,,,,,,,,,,,,,,,,,,,,,,,29118,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,DDX25,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0000963,smooth endoplasmic reticulum proliferation in hepatocyte [Ground glass appearance],increasing number of sER  [Ground glass appearance],"Smooth endoplasmic reticulum proliferation in hepatocyte is a subtype of endoplasmic reticulum proliferation in hepatocyte: A process that becomes larger in the number of smooth endoplasmic reticulum in hepatocyte(s).
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/TXPO_0001230,,,,,,,,,,,,,,,,,,,,,,"Smooth endoplasmic reticulum proliferation in hepatocyte is a subtype of endoplasmic reticulum proliferation in hepatocyte: A process that becomes larger in the number of smooth endoplasmic reticulum in hepatocyte(s).
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003522,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001619|http://purl.obolibrary.org/obo/TXPO_0001613,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000969|http://purl.obolibrary.org/obo/TXPO_0000970,,,,,,increasing number of sER  [Ground glass appearance],,,,,TXPO:0000963,,,,,,,,,,,,,,,,,,,,,,smooth endoplasmic reticulum proliferation in hepatocyte [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000967,constitutive androstane receptor activation by phenobarbital  (sustained)  [Ground glass appearance],continued CAR activation [Ground glass appearance]|CAR activating [sustained] [Ground glass appearance ],"Constitutive androstane receptor activation by phenobarbital is a subtype of activating nuclear receptor: A process that changes the activity of the activating CAR ( constitutive androstane receptor) with a nuclear receptor role to be higher by phenobarbital. This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) .",false,,,http://purl.obolibrary.org/obo/TXPO_0002309,,,,,,,,,,,,,,,,,,,,,,"Constitutive androstane receptor activation by phenobarbital is a subtype of activating nuclear receptor: A process that changes the activity of the activating CAR ( constitutive androstane receptor) with a nuclear receptor role to be higher by phenobarbital. This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) .",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001524,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003905,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001627|http://purl.obolibrary.org/obo/TXPO_0000965|http://purl.obolibrary.org/obo/TXPO_0001052,,,,,,continued CAR activation [Ground glass appearance]|CAR activating [sustained] [Ground glass appearance ],,,,,TXPO:0000967,,,,,,,,,,,,,,,,,,,,,,constitutive androstane receptor activation by phenobarbital  (sustained)  [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000965,negative regulation of apoptotic process [Ground glass appearance],,"Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptotic process.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/GO_0043066,,,,,,,,,,,,,,,,,,,,PMID:2379175|PMID:28356313|ISBN:0071769234,,"Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptotic process.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000976,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000975|http://purl.obolibrary.org/obo/TXPO_0000784,,,,,,http://purl.obolibrary.org/obo/TXPO_0000970,,,,,,,,,,,TXPO:0000965,,,,,,,,,,,,,,,,,,,,,,negative regulation of apoptotic process [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000964,negative regulation of signal transduction by p53 class mediator [Ground glass appearance],,"Any process that stops, prevents or reduces the frequency, rate or extent of signal transduction by p53 class mediator.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/GO_1901797,,,,,,,,,,,,,,,,,,,,PMID:21059794,,"Any process that stops, prevents or reduces the frequency, rate or extent of signal transduction by p53 class mediator.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001004,,,,,,http://purl.obolibrary.org/obo/TXPO_0000965,,,,,,,,,,,TXPO:0000964,,,,,,,,,,,,,,,,,,,,,,negative regulation of signal transduction by p53 class mediator [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000968,making existence of foreign substance,,Making existence of foreign substance is a subtype of making existence: A process that puts froreign substances with an object.,false,,,http://purl.obolibrary.org/obo/TXPO_0000380,,,,,,,,,,,,,,,,,,,,,,Making existence of foreign substance is a subtype of making existence: A process that puts froreign substances with an object.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000968,,,,,,,,,,,,,,,,,,,,,,making existence of foreign substance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000962,cell cycle DNA replication initiation [Ground glass appearance],,"Any DNA replication initiation that is involved in cell cycle DNA replication.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/GO_1902292|http://purl.obolibrary.org/obo/TXPO_0001728,,,,,,,,,,,,,,,,,,,,PMID:22723046,,"Any DNA replication initiation that is involved in cell cycle DNA replication.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002320,,,,,,,,,,,TXPO:0000962,,,,,,,,,,,,,,,,,,,,,,cell cycle DNA replication initiation [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000960,carbohydrate storage,,"Carbohydrate storage is a subtype of accumulation of substances in a biological object:  The accumulation and maintenance in cells or tissues of carbohydrates, any of a group of organic compounds based of the general formula Cx(H2O)y.",false,,,http://purl.obolibrary.org/obo/TXPO_0000247,,,,,,,,,,,,,,,,,,,,,,"Carbohydrate storage is a subtype of accumulation of substances in a biological object:  The accumulation and maintenance in cells or tissues of carbohydrates, any of a group of organic compounds based of the general formula Cx(H2O)y.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_16646,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000960,,,,,,,,,,,,,,,,,,,,,,carbohydrate storage,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000969,increasing hepatocellular volume [Ground glass appearance],,"Increasing hepatocellular volume is a changing process to change the volume of the hepatocyte to increase.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/TXPO_0000164,,,,,,,,,,,,,,,,,,,,,,"Increasing hepatocellular volume is a changing process to change the volume of the hepatocyte to increase.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001000,,,,,,http://purl.obolibrary.org/obo/TXPO_0000972|http://purl.obolibrary.org/obo/TXPO_0000973,,,,,,,,,,,TXPO:0000969,,,,,,,,,,,,,,,,,,,,,,increasing hepatocellular volume [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000961,cell proliferation [Ground glass appearance],,"The multiplication or reproduction of cells, resulting in the rapid expansion of a cell population.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/GO_0008283,,,,,,,,,,,,,,,,,,,,,,"The multiplication or reproduction of cells, resulting in the rapid expansion of a cell population.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000986,,,,,,,,,,,,,,,,,TXPO:0000961,,,,,,,,,,,,,,,,,,,,,,cell proliferation [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000966,phenobarbital accumulation in liver (sustained) [Ground glass appearance],,"Phenobarbital accumulation in liver is a subtype of compound accumulation in liver: A process that keeps phenobarbital in the liver. This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) .",false,,,http://purl.obolibrary.org/obo/TXPO_0000934,,,,,,,,,,,,,,,,,,,,,,"Phenobarbital accumulation in liver is a subtype of compound accumulation in liver: A process that keeps phenobarbital in the liver. This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0000498,,,,,,,,,,,,,,TXPO:0000966,,,,,,,,,,,,,,,,,,,,,,phenobarbital accumulation in liver (sustained) [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100616,cyclin D2,Vin-1 proto-oncogene|CGD2|G1/S-specific cyclin D2,,false,,,http://purl.obolibrary.org/obo/IMR_0100614,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0010668|IMR:0011614,Vin-1 proto-oncogene|CGD2|G1/S-specific cyclin D2,,,,,IMR:0100616,,,,,,,,,,,,,,,,,,,,,,cyclin D2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_134762,isaxonine,N-(Isopropylamino)-2-pyrimidine,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:4214-72-6|Drug_Central:1485,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,N-(Isopropylamino)-2-pyrimidine,,,,,,,,,,,,,,,,,,,,,CHEBI:134762,,,,isaxonine,,CHEBI:134762,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000305,caspase (family),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,GO:0030693,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000304,,,,,,,,,,IMR:0000305,,,,,,,,,,,,,,,,,,,,,,caspase (family),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_3655,chlorzoxazone,"5-chloro-2(3H)-benzoxazolone|2-hydroxy-5-chlorobenzoxazole|chlorzoxazona|5-chlorobenzoxazolin-2-one|chlorzoxazone|5-chloro-2-hydroxybenzoxazole|chlorzoxazonum|5-chloro-2-benzoxazolone|5-chloro-2-benzoxazolol|5-chlorobenzoxazolidone|chlorzoxane|5-chloro-2-benzoxazolinone|Chlorzoxazone|CHLORZOXAZONE|5-chloro-1,3-benzoxazol-2-ol","A member of the class of  1,3-benzoxazoles that is 1,3-benzoxazol-2-ol in which the hydrogen atom at position 5 is substituted by chlorine. A centrally acting muscle relaxant with sedative properties, it is used for the symptomatic treatment of painful muscle spasm.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:24210069|Drug_Central:626|CAS:95-25-0|PMID:23975871|PMID:10640318|PMID:11727787|DrugBank:DB00356|PMID:12437348|Reaxys:638882|PMID:16859676|PMID:25815637|PMID:6631711|Beilstein:638882|PMID:17621748|PMID:21195386|PMID:16763012|LINCS:LSM-6011,,"A member of the class of  1,3-benzoxazoles that is 1,3-benzoxazol-2-ol in which the hydrogen atom at position 5 is substituted by chlorine. A centrally acting muscle relaxant with sedative properties, it is used for the symptomatic treatment of painful muscle spasm.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_51371|http://purl.obolibrary.org/obo/CHEBI_35717,,,,,"Chlorzoxazone|CHLORZOXAZONE|5-chloro-1,3-benzoxazol-2-ol",,5-chloro-2(3H)-benzoxazolone|2-hydroxy-5-chlorobenzoxazole|chlorzoxazona|5-chlorobenzoxazolin-2-one|chlorzoxazone|5-chloro-2-hydroxybenzoxazole|chlorzoxazonum|5-chloro-2-benzoxazolone|5-chloro-2-benzoxazolol|5-chlorobenzoxazolidone|chlorzoxane|5-chloro-2-benzoxazolinone,,,,,,,,,,,,,,,,,,,,,CHEBI:3655,,,,chlorzoxazone,,CHEBI:3655,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100315,Smad4,,,false,,,http://purl.obolibrary.org/obo/IMR_0000372,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100315,,,,,,,,,,,,,,,,,,,,,,Smad4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_17761,ceramide,Cer|N-acylated sphingoid,"Ceramides (N-acyl-sphingoid bases) are a major subclass of sphingoid base derivatives with an amide-linked fatty acid. The fatty acids are typically saturated or monounsaturated with chain lengths from 14 to 26 carbon atoms; the presence of a hydroxyl group on carbon 2 is fairly common. Ceramides are generally precursors of more complex sphingolipids. In the illustrated generalised structure, R(1) = OH, OX (where X = acyl, glycosyl, phosphate, phosphonate, etc.), or H.",false,,,http://purl.obolibrary.org/obo/CHEBI_26739,,,,,,,,,,,,,,,,,,,,IMR:0100177,,"Ceramides (N-acyl-sphingoid bases) are a major subclass of sphingoid base derivatives with an amide-linked fatty acid. The fatty acids are typically saturated or monounsaturated with chain lengths from 14 to 26 carbon atoms; the presence of a hydroxyl group on carbon 2 is fairly common. Ceramides are generally precursors of more complex sphingolipids. In the illustrated generalised structure, R(1) = OH, OX (where X = acyl, glycosyl, phosphate, phosphonate, etc.), or H.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002401,,,,,Cer|N-acylated sphingoid,,,,,CHEBI:17761,,,,,,,,,,,,,,,,,,,,,,ceramide,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001601,Rab17,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001601,,,,,,,,,,,,,,,,,,,,,,Rab17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001426,BMP-3,Bone morphogenetic protein 3|BMP3,,false,,,http://purl.obolibrary.org/obo/IMR_0000040,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Bone morphogenetic protein 3|BMP3,,,,,IMR:0001426,,,,,,,,,,,,,,,,,,,,,,BMP-3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000189,alpha-actinin,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000188,,,,,,,,,,IMR:0000189,,,,,,,,,,,,,,,,,,,,,,alpha-actinin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100598,CDK2 (mol),Cdk2|cyclin-dependent kinase 2|p33 protein kinase|Cell division protein kinase 2|Cell division protein kinase 2 (EC 2.7.1.-)(p33 protein kinase)(CDK2),,false,,,http://purl.obolibrary.org/obo/TXPO_0003241,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0010671,Cdk2|cyclin-dependent kinase 2|p33 protein kinase|Cell division protein kinase 2|Cell division protein kinase 2 (EC 2.7.1.-)(p33 protein kinase)(CDK2),,,,,IMR:0100598,,,,,,,,,,,,,,,,,,,,,,CDK2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_37924,atazanavir,"dimethyl (3S,8S,9S,12S)-9-benzyl-3,12-di-tert-butyl-8-hydroxy-4,11-dioxo-6-[4-(2-pyridyl)benzyl]-2,5,6,10,13-pentaazatetradecanedioate",A heavily substituted carbohydrazide that is an antiretroviral drug of the protease inhibitor (PI) class used to treat infection of human immunodeficiency virus (HIV).,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,DrugBank:DB01072|Wikipedia:Atazanavir|CAS:198904-31-3,,A heavily substituted carbohydrazide that is an antiretroviral drug of the protease inhibitor (PI) class used to treat infection of human immunodeficiency virus (HIV).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35660|http://purl.obolibrary.org/obo/CHEBI_36044,,,,,"dimethyl (3S,8S,9S,12S)-9-benzyl-3,12-di-tert-butyl-8-hydroxy-4,11-dioxo-6-[4-(2-pyridyl)benzyl]-2,5,6,10,13-pentaazatetradecanedioate",,,,,CHEBI:37924,,,,,,,,,,,,,,,,,,,,,,atazanavir,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(cc1)-c1ccccn1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C,,,,,
http://purl.obolibrary.org/obo/IMR_0000526,connexin,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003691,,,,,,,,,,IMR:0000526,,,,,,,,,,,,,,,,,,,,,,connexin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000010580,SORBS1,,Other designations: Fas-ligand associated factor 2|SH3 domain protein 5|c-Cbl associated protein|ponsin|sorbin and SH3 domain-containing protein 1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CAP|SH3D5|R85FL|SH3P12|SORB1|FLAF2,,,,,,,,,,,,10,,,,,,Ensembl:ENSG00000095637|HPRD:05587|HGNC:14565|MIM:605264|Vega:OTTHUMG00000018812,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,sorbin and SH3 domain containing 1,,,10q23.33,,,,,,,,,,,,,,,,"GO_0001725 (EC: ISS); GO_0003779 (EC: TAS, PMID: 10085297); GO_0005070 (EC: IC, PMID: 11374898); GO_0005070 (EC: ISS, PMID: 9447983); GO_0005158 (EC: IDA, PMID: 11374898); GO_0005515 (EC: IPI, PMID: 11371513); GO_0005634 (EC: IDA, PMID: 11371513); GO_0005829 (EC: ISS, PMID: 9447983); GO_0005829 (EC: TAS); GO_0005899 (EC: IDA, Qualifier: colocalizes_with, PMID: 11374898); GO_0005913 (EC: ISS); GO_0005915 (EC: TAS, PMID: 10085297); GO_0005924 (EC: ISS); GO_0005925 (EC: IEA); GO_0006936 (EC: TAS); GO_0007160 (EC: TAS, PMID: 10085297); GO_0008092 (EC: TAS, PMID: 10085297); GO_0008286 (EC: ISS); GO_0009967 (EC: IC, PMID: 11374898); GO_0009967 (EC: ISS, PMID: 9447983); GO_0015758 (EC: ISS); GO_0016363 (EC: IEA); GO_0019901 (EC: IEA); GO_0032869 (EC: ISS, PMID: 11001060); GO_0043149 (EC: ISS); GO_0045121 (EC: ISS); GO_0045725 (EC: ISS, PMID: 11001060); GO_0046326 (EC: ISS, PMID: 11001060); GO_0046889 (EC: ISS, PMID: 11001060); GO_0048041 (EC: ISS); GO_0090004 (EC: ISS)",,,,,,,,,PMID: 9447983; 9461600; 10085297; 10583506; 10718198; 11001060; 11076863; 11230166; 11371513; 11374898; 11481476; 11532984; 11557983; 11997497; 12079283; 12395215; 12421765; 12477932; 12504111; 12510380; 12650714; 12690089; 12765336; 12849814; 14627618; 14702039; 15031295; 15128873; 15489334; 15489336; 15716063; 15777793; 15939299; 16374509; 16381901; 16385451; 17082770; 17353931; 17462669; 17548467; 18029348; 18394047; 18660489; 19165527; 19282865; 19891780; 20129698; 20201926; 20379614; 20936779; 21041247; 21988832; 22094256; 22235335; 22745667; 23251661; 23382691; 23793025; 23892081; 24255178,,,,,,,,,,,,,,,OGG:3000010580,,,,,,,sorbin and SH3 domain containing 1,,,,,,,,,,,,,Other designations: Fas-ligand associated factor 2|SH3 domain protein 5|c-Cbl associated protein|ponsin|sorbin and SH3 domain-containing protein 1,,SORBS1,,,,,,,,,,,,,,,,,,,,,,,10580,RP11-476E15.1,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,SORBS1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000010586,MAB21L2,,Other designations: protein mab-21-like 2,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,4,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,mab-21-like 2 (C. elegans),,,4q31,,,,,,,,,,,,,,,,"GO_0005634 (EC: IEA); GO_0007399 (EC: TAS, PMID: 10556287); GO_0008284 (EC: IEA); GO_0010172 (EC: IEA); GO_0043010 (EC: IEA)",,,,,,,,,PMID: 10556287; 12477932; 14702039; 17207965; 21832049; 23602568,,,,,,,,,,,,,,,OGG:3000010586,,,,,,,mab-21-like 2 (C. elegans),,,,,,,,,,,,,Other designations: protein mab-21-like 2,,MAB21L2,,,,,,,,,,,,,,,,,,,,,,,10586,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,MAB21L2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_50925,EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor,Raf kinase inhibitors|MKNK2 inhibitor|PAK-1 inhibitors|Raf kinase inhibitor|CKII inhibitor|WEE1Hu inhibitors|protein-aspartyl kinase inhibitors|cyclic monophosphate-dependent protein kinase inhibitor|protein phosphokinase inhibitor|cGMP-dependent protein kinase inhibitors|AP50 kinase inhibitors|CK-2 inhibitor|PAK1 inhibitors|serine protein kinase inhibitors|casein kinase I inhibitor|ATP-protein transphosphorylase inhibitors|protein kinase A inhibitors|glycogen synthase a kinase inhibitors|serine(threonine) protein kinase inhibitors|cyclic nucleotide-dependent protein kinase inhibitor|serine-specific protein kinase inhibitor|cyclic monophosphate-dependent protein kinase inhibitors|EC 2.7.11.1 inhibitor|hydroxyalkyl-protein kinase inhibitors|hydroxyalkyl-protein kinase inhibitor|casein kinase 2 inhibitors|Wee-kinase inhibitors|Raf-1 inhibitors|threonine-specific protein kinase inhibitor|protein glutamyl kinase inhibitors|PKA inhibitor|serine/threonine protein kinase inhibitor|protein-aspartyl kinase inhibitor|cAMP-dependent protein kinase A inhibitor|Wee 1-like kinase inhibitors|CKII inhibitors|CKI inhibitor|casein kinase inhibitors|ribosomal protein S6 kinase II inhibitors|mitogen-activated S6 kinase inhibitor|casein kinase 2 inhibitor|HIPK2 inhibitor|calcium-dependent protein kinase C inhibitors|PKA inhibitors|protein-serine kinase inhibitors|cyclin-dependent kinase inhibitors|ribosomal protein S6 kinase II inhibitor|EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitors|CK-2 inhibitors|glycogen synthase kinase inhibitors|WEE1Hu inhibitor|protein-serine kinase inhibitor|p82 kinase inhibitors|casein kinase (phosphorylating) inhibitor|AP50 kinase inhibitor|protein phosphokinase inhibitors|ribosomal S6 protein kinase inhibitors|CKI inhibitors|cAMP-dependent protein kinase inhibitors|cyclic nucleotide-dependent protein kinase inhibitors|betaIIPKC inhibitors|betaIIPKC inhibitor|casein kinase I inhibitors|protein kinase CK2 inhibitor|casein kinase (phosphorylating) inhibitors|protein serine kinase inhibitors|serine kinase inhibitors|cyclin-dependent kinase inhibitor|T-antigen kinase inhibitors|BR serine/threonine-protein kinase 2 inhibitors|Wee-kinase inhibitor|type-2 casein kinase inhibitor|calcium/phospholipid-dependent protein kinase inhibitors|cyclic AMP-dependent protein kinase A inhibitors|casein kinase II inhibitor|serine(threonine) protein kinase inhibitor|epsilon PKC inhibitors|non-specific serine/threonine protein kinase (EC 2.7.11.1) inhibitors|EC 2.7.11.1 inhibitors|protein serine kinase inhibitor|serine/threonine protein kinase inhibitors|protein kinase A inhibitor|twitchin kinase inhibitors|T-antigen kinase inhibitor|protein kinase CK2 inhibitors|cyclic AMP-dependent protein kinase A inhibitor|ATP-protein transphosphorylase inhibitor|protein glutamyl kinase inhibitor|serine-specific protein kinase inhibitors|serine kinase inhibitor|PAK-1 inhibitor|M phase-specific cdc2 kinase inhibitors|calcium/phospholipid-dependent protein kinase inhibitor|cyclic AMP-dependent protein kinase inhibitor|non-specific serine/threonine protein kinase inhibitor|A-kinase inhibitors|p21 activated kinase-1 inhibitor|phosphorylase b kinase kinase inhibitor|M phase-specific cdc2 kinase inhibitor|protein kinase p58 inhibitors|STK32 inhibitors|protein kinase (phosphorylating) inhibitors|Prp4 protein kinase inhibitors|ribosomal S6 protein kinase inhibitor|Raf-1 inhibitor|cAMP-dependent protein kinase inhibitor|phosphorylase b kinase kinase inhibitors|protein-cysteine kinase inhibitor|HIPK2 inhibitors|casein kinase II inhibitors|protein kinase p58 inhibitor|Wee 1-like kinase inhibitor|cGMP-dependent protein kinase inhibitor|Prp4 protein kinase inhibitor|glycogen synthase kinase inhibitor|protein kinase (phosphorylating) inhibitor|cAMP-dependent protein kinase A inhibitors|casein kinase inhibitor|Hpr kinase inhibitors|protein-serine/threonine kinase inhibitors|ATP:protein phosphotransferase (non-specific) inhibitors|dsk1 inhibitor|non-specific serine/threonine protein kinase inhibitors|p21 activated kinase-1 inhibitors|glycogen synthase a kinase inhibitor|BR serine/threonine-protein kinase 2 inhibitor|calcium-dependent protein kinase C inhibitor|protein serine-threonine kinase inhibitors|threonine-specific protein kinase inhibitors|protein-cysteine kinase inhibitors|MKNK2 inhibitors|serine protein kinase inhibitor|epsilon PKC inhibitor|A-kinase inhibitor|p82 kinase inhibitor|twitchin kinase inhibitor|Hpr kinase inhibitor|cyclic AMP-dependent protein kinase inhibitors|ATP:protein phosphotransferase (non-specific) inhibitor|protein serine-threonine kinase inhibitor|type-2 casein kinase inhibitors|STK32 inhibitor|mitogen-activated S6 kinase inhibitors|PAK1 inhibitor|non-specific serine/threonine protein kinase (EC 2.7.11.1) inhibitor|dsk1 inhibitors,"An EC 2.7.11.* (protein-serine/threonine kinase) inhibitor that interferes with the action of non-specific serine/threonine protein kinase (EC 2.7.11.1), a kinase enzyme involved in phosphorylation of hydroxy group of serine or threonine.",false,,,http://purl.obolibrary.org/obo/CHEBI_76812|http://purl.obolibrary.org/obo/CHEBI_23924,,,,,,,,,,,,,,,,,,,,,,"An EC 2.7.11.* (protein-serine/threonine kinase) inhibitor that interferes with the action of non-specific serine/threonine protein kinase (EC 2.7.11.1), a kinase enzyme involved in phosphorylation of hydroxy group of serine or threonine.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Raf kinase inhibitors|MKNK2 inhibitor|PAK-1 inhibitors|Raf kinase inhibitor|CKII inhibitor|WEE1Hu inhibitors|protein-aspartyl kinase inhibitors|cyclic monophosphate-dependent protein kinase inhibitor|protein phosphokinase inhibitor|cGMP-dependent protein kinase inhibitors|AP50 kinase inhibitors|CK-2 inhibitor|PAK1 inhibitors|serine protein kinase inhibitors|casein kinase I inhibitor|ATP-protein transphosphorylase inhibitors|protein kinase A inhibitors|glycogen synthase a kinase inhibitors|serine(threonine) protein kinase inhibitors|cyclic nucleotide-dependent protein kinase inhibitor|serine-specific protein kinase inhibitor|cyclic monophosphate-dependent protein kinase inhibitors|EC 2.7.11.1 inhibitor|hydroxyalkyl-protein kinase inhibitors|hydroxyalkyl-protein kinase inhibitor|casein kinase 2 inhibitors|Wee-kinase inhibitors|Raf-1 inhibitors|threonine-specific protein kinase inhibitor|protein glutamyl kinase inhibitors|PKA inhibitor|serine/threonine protein kinase inhibitor|protein-aspartyl kinase inhibitor|cAMP-dependent protein kinase A inhibitor|Wee 1-like kinase inhibitors|CKII inhibitors|CKI inhibitor|casein kinase inhibitors|ribosomal protein S6 kinase II inhibitors|mitogen-activated S6 kinase inhibitor|casein kinase 2 inhibitor|HIPK2 inhibitor|calcium-dependent protein kinase C inhibitors|PKA inhibitors|protein-serine kinase inhibitors|cyclin-dependent kinase inhibitors|ribosomal protein S6 kinase II inhibitor|EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitors|CK-2 inhibitors|glycogen synthase kinase inhibitors|WEE1Hu inhibitor|protein-serine kinase inhibitor|p82 kinase inhibitors|casein kinase (phosphorylating) inhibitor|AP50 kinase inhibitor|protein phosphokinase inhibitors|ribosomal S6 protein kinase inhibitors|CKI inhibitors|cAMP-dependent protein kinase inhibitors|cyclic nucleotide-dependent protein kinase inhibitors|betaIIPKC inhibitors|betaIIPKC inhibitor|casein kinase I inhibitors|protein kinase CK2 inhibitor|casein kinase (phosphorylating) inhibitors|protein serine kinase inhibitors|serine kinase inhibitors|cyclin-dependent kinase inhibitor|T-antigen kinase inhibitors|BR serine/threonine-protein kinase 2 inhibitors|Wee-kinase inhibitor|type-2 casein kinase inhibitor|calcium/phospholipid-dependent protein kinase inhibitors|cyclic AMP-dependent protein kinase A inhibitors|casein kinase II inhibitor|serine(threonine) protein kinase inhibitor|epsilon PKC inhibitors|non-specific serine/threonine protein kinase (EC 2.7.11.1) inhibitors|EC 2.7.11.1 inhibitors|protein serine kinase inhibitor|serine/threonine protein kinase inhibitors|protein kinase A inhibitor|twitchin kinase inhibitors|T-antigen kinase inhibitor|protein kinase CK2 inhibitors|cyclic AMP-dependent protein kinase A inhibitor|ATP-protein transphosphorylase inhibitor|protein glutamyl kinase inhibitor|serine-specific protein kinase inhibitors|serine kinase inhibitor|PAK-1 inhibitor|M phase-specific cdc2 kinase inhibitors|calcium/phospholipid-dependent protein kinase inhibitor|cyclic AMP-dependent protein kinase inhibitor|non-specific serine/threonine protein kinase inhibitor|A-kinase inhibitors|p21 activated kinase-1 inhibitor|phosphorylase b kinase kinase inhibitor|M phase-specific cdc2 kinase inhibitor|protein kinase p58 inhibitors|STK32 inhibitors|protein kinase (phosphorylating) inhibitors|Prp4 protein kinase inhibitors|ribosomal S6 protein kinase inhibitor|Raf-1 inhibitor|cAMP-dependent protein kinase inhibitor|phosphorylase b kinase kinase inhibitors|protein-cysteine kinase inhibitor|HIPK2 inhibitors|casein kinase II inhibitors|protein kinase p58 inhibitor|Wee 1-like kinase inhibitor|cGMP-dependent protein kinase inhibitor|Prp4 protein kinase inhibitor|glycogen synthase kinase inhibitor|protein kinase (phosphorylating) inhibitor|cAMP-dependent protein kinase A inhibitors|casein kinase inhibitor|Hpr kinase inhibitors|protein-serine/threonine kinase inhibitors|ATP:protein phosphotransferase (non-specific) inhibitors|dsk1 inhibitor|non-specific serine/threonine protein kinase inhibitors|p21 activated kinase-1 inhibitors|glycogen synthase a kinase inhibitor|BR serine/threonine-protein kinase 2 inhibitor|calcium-dependent protein kinase C inhibitor|protein serine-threonine kinase inhibitors|threonine-specific protein kinase inhibitors|protein-cysteine kinase inhibitors|MKNK2 inhibitors|serine protein kinase inhibitor|epsilon PKC inhibitor|A-kinase inhibitor|p82 kinase inhibitor|twitchin kinase inhibitor|Hpr kinase inhibitor|cyclic AMP-dependent protein kinase inhibitors|ATP:protein phosphotransferase (non-specific) inhibitor|protein serine-threonine kinase inhibitor|type-2 casein kinase inhibitors|STK32 inhibitor|mitogen-activated S6 kinase inhibitors|PAK1 inhibitor|non-specific serine/threonine protein kinase (EC 2.7.11.1) inhibitor|dsk1 inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:50925,,,,EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor,,CHEBI:50925,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001310,hypofunction of fatty acid beta-oxidation [Fibrosis],,"Hypofunction of fatty acid beta-oxidation is a subtype of hypofunction of fatty acid oxidation: A process that performs a decreased or insufficient fatty acid beta-oxidation.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003742|http://purl.obolibrary.org/obo/TXPO_0002008,,,,,,,,,,,,,,,,,,,,,,"Hypofunction of fatty acid beta-oxidation is a subtype of hypofunction of fatty acid oxidation: A process that performs a decreased or insufficient fatty acid beta-oxidation.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001387,,,,,,,,,,,TXPO:0001310,,,,,,,,,,,,,,,,,,,,,,hypofunction of fatty acid beta-oxidation [Fibrosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001317,increasing glycerophospholipid material,,Increasing glycerophospholipid material is a subtype of increasing materials for lipid formation: A process that changes the amount of glycerophospholipid material to be larger.,false,,,http://purl.obolibrary.org/obo/TXPO_0001314,,,,,,,,,,,,,,,,,,,,,,Increasing glycerophospholipid material is a subtype of increasing materials for lipid formation: A process that changes the amount of glycerophospholipid material to be larger.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001317,,,,,,,,,,,,,,,,,,,,,,increasing glycerophospholipid material,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001313,AP-1 activation,,AP-1 activation is a subtype of molecular activation: A process that changes the activity of the AP-1 to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000023,,,,,,,,,,,,,,,,,,,,,,AP-1 activation is a subtype of molecular activation: A process that changes the activity of the AP-1 to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001313,,,,,,,,,,,,,,,,,,,,,,AP-1 activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001314,increasing phospholipid material,,Increasing phospholipid material is a subtype of increasing quantity: A process that changes the amount of phospholipid material to be larger.,false,,,http://purl.obolibrary.org/obo/TXPO_0001075,,,,,,,,,,,,,,,,,,,,,,Increasing phospholipid material is a subtype of increasing quantity: A process that changes the amount of phospholipid material to be larger.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001314,,,,,,,,,,,,,,,,,,,,,,increasing phospholipid material,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001316,role related to molecular change,,A role played by the entity to change the molecule (activity).,false,,,http://purl.obolibrary.org/obo/TXPO_0003712,,,,,,,,,,,,,,,,,,,,,,A role played by the entity to change the molecule (activity).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001316,,,,,,,,,,,,,,,,,,,,,,role related to molecular change,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001315,increasing phospholipid material [Phospholipidosis  (severe)],,"Increasing phospholipid material is a subtype of increasing quantity: A process that changes the amount of phospholipid material to be larger. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",false,,,http://purl.obolibrary.org/obo/TXPO_0001762|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Increasing phospholipid material is a subtype of increasing quantity: A process that changes the amount of phospholipid material to be larger. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001136,,,,,,http://purl.obolibrary.org/obo/TXPO_0002223,,,,,,,,,,,TXPO:0001315,,,,,,,,,,,,,,,,,,,,,,increasing phospholipid material [Phospholipidosis  (severe)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001319,CD36 [lipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001312,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:29184|NCBI-Human-GeneID:948|NCBI-Mouse-GeneID:12491|PMID:15677505|PMID:18242221|PMID:21145849|PMID:16407588|PMID:27034954,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001341,,,,,,,,,,TXPO:0001319,,,,,,,,,,,,,,,,,,,,,,CD36 [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001312,CD36 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:29184|NCBI-Human-GeneID:948|NCBI-Mouse-GeneID:12491,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000084320,,,,,,,,,,,,,TXPO:0001312,,,,,,,,,,,,,,,,,,,,,,CD36 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001311,negative regulation of insulin secretion [ER stress],,"Any process that stops, prevents, or reduces the frequency, rate or extent of the regulated release of insulin.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/GO_0046676,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents, or reduces the frequency, rate or extent of the regulated release of insulin.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000805,,,,,,,,,,,,,,,,,TXPO:0001311,,,,,,,,,,,,,,,,,,,,,,negative regulation of insulin secretion [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001318,increasing glycerophospholipid material  [phospholipidosis - glycerophospholipid disorder (severe)],,"Increasing glycerophospholipid material is a subtype of increasing materials for lipid formation: A process that changes the amount of glycerophospholipid material to be larger.
This process is dependent on the glycerophospholipid disorder (severe) and can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001317,,,,,,,,,,,,,,,,,,,,,,"Increasing glycerophospholipid material is a subtype of increasing materials for lipid formation: A process that changes the amount of glycerophospholipid material to be larger.
This process is dependent on the glycerophospholipid disorder (severe) and can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001320,http://purl.obolibrary.org/obo/TXPO_0001136,,,,,,,,,,,,,,,,,TXPO:0001318,,,,,,,,,,,,,,,,,,,,,,increasing glycerophospholipid material  [phospholipidosis - glycerophospholipid disorder (severe)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001598,Rab15,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001598,,,,,,,,,,,,,,,,,,,,,,Rab15,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010506,Heterogeneous nuclear ribonucleoprotein A1,hnRNP A1|Helix-destabilizing protein|hnRNP core protein A1|ROA1|Single-strand binding protein,,false,,,http://purl.obolibrary.org/obo/IMR_0010024,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,hnRNP A1|Helix-destabilizing protein|hnRNP core protein A1|ROA1|Single-strand binding protein,,,,,IMR:0010506,,,,,,,,,,,,,,,,,,,,,,Heterogeneous nuclear ribonucleoprotein A1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_16247,phospholipid,C5H6O8PR3,A lipid containing phosphoric acid as a mono- or di-ester. The term encompasses phosphatidic acids and phosphoglycerides.,false,,,http://purl.obolibrary.org/obo/CHEBI_18059,,,,,,,,,,,,,,,,,,,,,,A lipid containing phosphoric acid as a mono- or di-ester. The term encompasses phosphatidic acids and phosphoglycerides.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,C5H6O8PR3,,,,,CHEBI:16247,,,,,,,,,,,,,,,,,,,,,,phospholipid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100154,endorphin,,,false,,,http://purl.obolibrary.org/obo/IMR_0100153,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_25512,,,,,,,,,,IMR:0100154,,,,,,,,,,,,,,,,,,,,,,endorphin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000000216,ALDH1A1,,"Other designations: ALDH class 1|ALHDII|RALDH 1|acetaldehyde dehydrogenase 1|aldehyde dehydrogenase 1, soluble|aldehyde dehydrogenase, liver cytosolic|epididymis luminal protein 12|epididymis luminal protein 9|epididymis secretory sperm binding protein Li 53e|retinal dehydrogenase 1|retinaldehyde dehydrogenase 1",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,HEL12|PUMB1|ALDH11|ALDH1|ALDC|ALDH-E1|HEL-S-53e|HEL-9|RALDH1,,,,,,,,,,,,9,,,,,,HGNC:402|Ensembl:ENSG00000165092|HPRD:00001|Vega:OTTHUMG00000020019|MIM:100640,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"aldehyde dehydrogenase 1 family, member A1",,,9q21.13,,,,,,,,,,,,,,,,"GO_0001758 (EC: IEA); GO_0004029 (EC: EXP); GO_0005099 (EC: TAS, PMID: 1709013); GO_0005497 (EC: TAS, PMID: 1709013); GO_0005737 (EC: TAS, PMID: 2987944); GO_0005829 (EC: TAS); GO_0006069 (EC: TAS); GO_0006081 (EC: TAS, PMID: 1709013); GO_0006805 (EC: TAS); GO_0032320 (EC: TAS, PMID: 1709013); GO_0042572 (EC: IEA); GO_0044281 (EC: TAS); GO_0070062 (EC: IDA, PMID: 19056867)",,,,,,,,,PMID: 224930; 730161; 1709013; 2591967; 2776714; 2987944; 3013004; 3397064; 3676276; 4015823; 6427007; 6723659; 8214422; 8493914; 9166904; 9240474; 9723161; 12081471; 12174908; 12477932; 14506398; 14678778; 15489334; 15597079; 15852347; 16189514; 16857736; 16878979; 17175089; 17222227; 17286337; 17502835; 17628022; 18029348; 18082256; 18331377; 18343808; 18371393; 18450747; 18496131; 18644979; 18848913; 18854779; 19018242; 19025616; 19056867; 19129088; 19296407; 19329942; 19343046; 19385968; 19447584; 19450560; 19478994; 19696793; 19703508; 19706361; 19774675; 19808966; 19874574; 19911270; 20010854; 20019840; 20142235; 20228222; 20379614; 20422001; 20516116; 20585849; 20596639; 20606680; 20634891; 20889728; 20959018; 20959469; 21045151; 21098716; 21118965; 21231983; 21282737; 21336637; 21371077; 21399615; 21441790; 21482329; 21695188; 21708005; 21804471; 21827011; 21907803; 21988832; 22005464; 22012766; 22014057; 22080062; 22098156; 22101256; 22115706; 22123295; 22131125; 22195027; 22260461; 22380773; 22417385; 22430847; 22544210; 22581680; 22591209; 22608744; 22617249; 22649953; 22710732; 22725270; 22782852; 22877687; 22878609; 22887839; 22899292; 22928012; 22930220; 22938492; 23084350; 23112116; 23132408; 23220285; 23236537; 23252868; 23267077; 23295229; 23332924; 23434145; 23438482; 23454351; 23465277; 23483187; 23585015; 23759596; 23762304; 23787917; 23799031; 23805041; 23845466; 24043631; 24080087; 24120944; 24289252; 24511023,,,,,,,,,,,,,,,OGG:3000000216,,,,,,,"aldehyde dehydrogenase 1 family, member A1",,,,,,,,,,,,,"Other designations: ALDH class 1|ALHDII|RALDH 1|acetaldehyde dehydrogenase 1|aldehyde dehydrogenase 1, soluble|aldehyde dehydrogenase, liver cytosolic|epididymis luminal protein 12|epididymis luminal protein 9|epididymis secretory sperm binding protein Li 53e|retinal dehydrogenase 1|retinaldehyde dehydrogenase 1",,ALDH1A1,,,,,,,,,,,,,,,,,,,,,,,216,RP11-151D14.2,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,ALDH1A1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000000211,ALAS1,,"Other designations: 5-aminolevulinate synthase, nonspecific, mitochondrial|5-aminolevulinic acid synthase 1|ALAS-H|delta-ALA synthase 1|delta-aminolevulinate synthase 1|migration-inducing protein 4",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,ALASH|ALAS|MIG4|ALAS3,,,,,,,,,,,,3,,,,,,HGNC:396|Vega:OTTHUMG00000158108|MIM:125290|Ensembl:ENSG00000023330|HPRD:00505,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"aminolevulinate, delta-, synthase 1",,,3p21.1,,,,,,,,,,,,,,,,"GO_0003870 (EC: IEA); GO_0005634 (EC: IDA); GO_0005730 (EC: IDA, Qualifier: NOT); GO_0005737 (EC: IDA); GO_0005739 (EC: IDA); GO_0005759 (EC: TAS); GO_0006778 (EC: TAS); GO_0006782 (EC: IEA); GO_0006783 (EC: TAS); GO_0030170 (EC: IEA); GO_0044255 (EC: TAS); GO_0044281 (EC: TAS)",,,,,,,,,PMID: 2095458; 2263504; 2347585; 3671094; 7698013; 8424176; 11267664; 11566198; 11929042; 11929048; 12433930; 12477932; 12878157; 15028279; 15123725; 15477213; 15489334; 15547665; 15710391; 15797241; 16234850; 16730941; 16751776; 17628775; 17672918; 18029348; 18719978; 19460752; 19477221; 19656447; 19913121; 20237496; 20628086; 20877624; 21048031; 21659532; 21900206; 21906983; 21926972; 21963094; 21987572; 21988832; 22505724; 23024262; 23974872; 24250222,,,,,,,,,,,,,,,OGG:3000000211,,,,,,,"aminolevulinate, delta-, synthase 1",,,,,,,,,,,,,"Other designations: 5-aminolevulinate synthase, nonspecific, mitochondrial|5-aminolevulinic acid synthase 1|ALAS-H|delta-ALA synthase 1|delta-aminolevulinate synthase 1|migration-inducing protein 4",,ALAS1,,,,,,,,,,,,,,,,,,,,,,,211,OK/SW-cl.121,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,ALAS1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_142593,4-hydroxynonenal,,A monounsaturated fatty aldehyde that is nonanal that has undergone dehydrogenation to introduce a double bond at any position in the aliphatic chain and in which a hydrogen at position 4 has been replaced by a hydroxy group.,false,,,http://purl.obolibrary.org/obo/TXPO_0004328,,,,,,,,,,,,,,,,,,,,,,A monounsaturated fatty aldehyde that is nonanal that has undergone dehydrogenation to introduce a double bond at any position in the aliphatic chain and in which a hydrogen at position 4 has been replaced by a hydroxy group.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:142593,,,,,,,,,,,,,,,,,,,,,,4-hydroxynonenal,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0051898,negative regulation of protein kinase B signaling,negative regulation of AKT signalling cascade|negative regulation of protein kinase B signaling|negative regulation of PKB signaling cascade,"Any process that stops, prevents, or reduces the frequency, rate or extent of protein kinase B signaling, a series of reactions mediated by the intracellular serine/threonine kinase protein kinase B.",false,,,http://purl.obolibrary.org/obo/GO_0023057,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents, or reduces the frequency, rate or extent of protein kinase B signaling, a series of reactions mediated by the intracellular serine/threonine kinase protein kinase B.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,negative regulation of AKT signalling cascade|negative regulation of protein kinase B signaling|negative regulation of PKB signaling cascade,,,,,GO:0051898,,,,,,,,,,,,,,,,,,,,,,negative regulation of protein kinase B signaling,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001494|http://purl.obolibrary.org/obo/GO_0043491,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_50739,estrogen receptor modulator,,A substance that possess antiestrogenic actions but can also produce estrogenic effects as well. It acts as complete or partial agonist or as antagonist. It can be either steroidal or nonsteroidal in structure.,false,,,http://purl.obolibrary.org/obo/CHEBI_23888,,,,,,,,,,,,,,,,,,,,,,A substance that possess antiestrogenic actions but can also produce estrogenic effects as well. It acts as complete or partial agonist or as antagonist. It can be either steroidal or nonsteroidal in structure.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:50739,,,,estrogen receptor modulator,,CHEBI:50739,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010518,Heterogeneous nuclear ribonucleoprotein R,ROR|hnRNP R,,false,,,http://purl.obolibrary.org/obo/IMR_0010024,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ROR|hnRNP R,,,,,IMR:0010518,,,,,,,,,,,,,,,,,,,,,,Heterogeneous nuclear ribonucleoprotein R,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/DOID_4,disease,,A disease is a disposition (i) to undergo pathological processes that (ii) exists in an organism because of one or more disorders in that organism.,false,,,http://purl.obolibrary.org/obo/BFO_0000016,,,,,,,,,,,,,,,,,,,,MESH:D004194|NCI:C2991|UMLS_CUI:C0012634|SNOMEDCT_US_2016_03_01:64572001,,A disease is a disposition (i) to undergo pathological processes that (ii) exists in an organism because of one or more disorders in that organism.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,DOID:4,,,,,,,,,,,,,,,,,,,,,,disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0031333,negative regulation of protein complex assembly,inhibition of protein complex assembly|negative regulation of protein complex assembly|down-regulation of protein complex assembly|downregulation of protein complex assembly|down regulation of protein complex assembly,"Any process that stops, prevents, or reduces the frequency, rate or extent of protein complex assembly.",false,,,http://purl.obolibrary.org/obo/TXPO_0004212,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents, or reduces the frequency, rate or extent of protein complex assembly.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,down-regulation of protein complex assembly|downregulation of protein complex assembly|down regulation of protein complex assembly,inhibition of protein complex assembly|negative regulation of protein complex assembly,,,,GO:0031333,,,,,,,,,,,,,,,,,,,,,,negative regulation of protein complex assembly,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006461,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_16664,albendazole,Albenza|O-methyl N-(5-(propylthio)-2-benzimidazolyl)carbamate|Zentel|Eskazole|5-(propylthio)-2-carbomethoxyaminobenzimidazole|(5-(propylthio)-1H-benzimidazol-2-yl)carbamic acid methyl ester|Valbazen|Proftril|methyl [5-(propylsulfanyl)-1H-benzimidazol-2-yl]carbamate|albendazole|Albendazole,A carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a propylsulfanyl group at position 5. It is commonly used in the treatment of parasitic worm infestations.,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Beilstein:752696|DrugBank:DB00518|Reaxys:752696|CAS:54965-21-8|Drug_Central:103|Pesticides:albendazole|PMID:24403707|LINCS:LSM-3782|PMID:22152396|PMID:24411094,,A carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a propylsulfanyl group at position 5. It is commonly used in the treatment of parasitic worm infestations.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_61951|http://purl.obolibrary.org/obo/CHEBI_60832|http://purl.obolibrary.org/obo/CHEBI_35443,,,,,methyl [5-(propylsulfanyl)-1H-benzimidazol-2-yl]carbamate|albendazole|Albendazole,,Albenza|O-methyl N-(5-(propylthio)-2-benzimidazolyl)carbamate|Zentel|Eskazole|5-(propylthio)-2-carbomethoxyaminobenzimidazole|(5-(propylthio)-1H-benzimidazol-2-yl)carbamic acid methyl ester|Valbazen|Proftril,,,,,,,,,,,,,,,,,,,,,CHEBI:16664,,,,albendazole,,CHEBI:16664,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000084675,TRIM55,,Other designations: muscle specific ring finger 2|muscle-specific RING finger protein 2|ring finger protein 29|tripartite motif-containing 55|tripartite motif-containing protein 55,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,MURF-2|RNF29|muRF2,,,,,,,,,,,,8,,,,,,Ensembl:ENSG00000147573|HGNC:14215|Vega:OTTHUMG00000164473|MIM:606469|HPRD:05927,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,tripartite motif containing 55,,,8q13.1,,,,,,,,,,,,,,,,"GO_0004871 (EC: NAS, PMID: 11243782); GO_0005634 (EC: IEA); GO_0005737 (EC: IEA); GO_0005874 (EC: NAS, PMID: 11243782); GO_0007165 (EC: NAS, PMID: 11243782); GO_0008270 (EC: IEA); GO_0042802 (EC: IPI)",,,,,,,,,PMID: 11243782; 11927605; 12414993; 12477932; 14702039; 15489334; 15782160; 15802564; 15967462; 18187620; 18854154; 19549727; 20379614; 22493164; 22626734; 22666496; 22939629,,,,,,,,,,,,,,,OGG:3000084675,,20140408,protein-coding,,,,tripartite motif containing 55,,,,,,,,,,,,,Other designations: muscle specific ring finger 2|muscle-specific RING finger protein 2|ring finger protein 29|tripartite motif-containing 55|tripartite motif-containing protein 55,,TRIM55,,,,,,,,,,,,,,,,,,,,,,,84675,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,TRIM55,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000489,alpha-actin 1,skeletal muscle alpha-actin,,false,,,http://purl.obolibrary.org/obo/IMR_0000490,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,skeletal muscle alpha-actin,,,,,IMR:0000489,,,,,,,,,,,,,,,,,,,,,,alpha-actin 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000456,14-3-3,,"The term 14-3-3 denotes a large family of ~30 kDa acidic proteins that exist primarily as homo- and heterodimers within all eukaryotic cells. Their unusual name refers to their elution position on DEAE-cellulose chromatography and gel electrophoresis during a systematic attempt at classifying bovine brain proteins. In humans, there are seven distinct 14-3-3 genes denoted beta, gamma, epsilon, eta, sigma, tau (theta) and zeta (as well as a number of potential pseudogenes), while yeast and plants contain between 2 and 15 genes.",false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PR_000003237|IPR:000308,,"The term 14-3-3 denotes a large family of ~30 kDa acidic proteins that exist primarily as homo- and heterodimers within all eukaryotic cells. Their unusual name refers to their elution position on DEAE-cellulose chromatography and gel electrophoresis during a systematic attempt at classifying bovine brain proteins. In humans, there are seven distinct 14-3-3 genes denoted beta, gamma, epsilon, eta, sigma, tau (theta) and zeta (as well as a number of potential pseudogenes), while yeast and plants contain between 2 and 15 genes.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003720|http://purl.obolibrary.org/obo/TXPO_0003721,,,,,,,,,,IMR:0000456,,,,,,,,,,,,,,,,,,,,,,14-3-3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001028,"Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase delta-subunit",GMP-PDE delta,,false,,,http://purl.obolibrary.org/obo/IMR_0100002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GMP-PDE delta,,,,,IMR:0001028,,,,,,,,,,,,,,,,,,,,,,"Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase delta-subunit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_6741,meloxicam,"4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide|MLX","A benzothiazine that is piroxicam in which the pyridin-2-yl group is replaced by a 5-methyl-1,3-thiazol-2-yl group. A non-steroidal anti-inflammatory drug and selective inhibitor of COX-2, it is used particularly for the management of rheumatoid arthritis.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,http://jglobal.jst.go.jp/en/redirect?Nikkaji_No=J22.773K|DrugBank:DB00814,,"A benzothiazine that is piroxicam in which the pyridin-2-yl group is replaced by a 5-methyl-1,3-thiazol-2-yl group. A non-steroidal anti-inflammatory drug and selective inhibitor of COX-2, it is used particularly for the management of rheumatoid arthritis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide|MLX",,,,,CHEBI:6741,,,,,,,,,,,,,,,,,,,,,,meloxicam,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CN1C(C(=O)Nc2ncc(C)s2)=C(O)c2ccccc2S1(=O)=O,,,,,
http://purl.obolibrary.org/obo/CHEBI_28901,busulfan,"busulfan|Mablin|busulfanum|Mitostan|busulfano|Tetramethylene bis(methanesulfonate)|Leucosulfan|Misulban|1,4-Bis(methanesulfonoxy)butane|Myleran|1,4-Dimethanesulfonoxybutane|1,4-Dimesyloxybutane|Mielucin|1,4-Butanediol dimethanesulfonate|Bisulfex|Myeloleukon|butane-1,4-diyl dimethanesulfonate|Busulfan","A methanesulfonate ester that is butane-1,4-diol in which the hydrogens of the hydroxy groups are replaced by methanesulfonyl groups. An alkylating antineoplastic agent, it is used for the treatment of chronic myeloid leukemia (although it has been largely replaced by newer drugs). It is also used as an insect sterilant.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,DrugBank:DB01008|PMID:19361744|CAS:55-98-1|PMID:19611402|PMID:10523796|Drug_Central:438|LINCS:LSM-5388|Reaxys:1791786|Beilstein:1791786,,"A methanesulfonate ester that is butane-1,4-diol in which the hydrogens of the hydroxy groups are replaced by methanesulfonyl groups. An alkylating antineoplastic agent, it is used for the treatment of chronic myeloid leukemia (although it has been largely replaced by newer drugs). It is also used as an insect sterilant.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_50905|http://purl.obolibrary.org/obo/CHEBI_35610|http://purl.obolibrary.org/obo/CHEBI_67105|http://purl.obolibrary.org/obo/CHEBI_22333|http://purl.obolibrary.org/obo/CHEBI_50903,,,,,"butane-1,4-diyl dimethanesulfonate|Busulfan",,"busulfan|Mablin|busulfanum|Mitostan|busulfano|Tetramethylene bis(methanesulfonate)|Leucosulfan|Misulban|1,4-Bis(methanesulfonoxy)butane|Myleran|1,4-Dimethanesulfonoxybutane|1,4-Dimesyloxybutane|Mielucin|1,4-Butanediol dimethanesulfonate|Bisulfex|Myeloleukon",,,,,,,,,,,,,,,,,,,,,CHEBI:28901,,,,busulfan,,CHEBI:28901,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003229,AKT - cell proliferation promoting factor (canonical)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001799,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000250,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002271,,,,,,,,,,TXPO:0003229,,,,,,,,,,,,,,,,,,,,,,AKT - cell proliferation promoting factor (canonical)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003222,molecular subpathway,,A set or series of molecular interactions.,false,,,http://purl.obolibrary.org/obo/NCIT_C54214,,,,,,,,,,,,,,,,,,,,,,A set or series of molecular interactions.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003222,,,,,,,,,,,,,,,,,,,,,,molecular subpathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003227,amiodarone - phospholipase competition inhibitor [Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001849|http://purl.obolibrary.org/obo/CHEBI_2663,,,,,,,,,,,,,,,,,,,,PMID:15720040|PMID:28552552|PMID:28904294|PMID:3663236,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003220|http://purl.obolibrary.org/obo/TXPO_0001426,,,,,,,,,,TXPO:0003227,,,,,,,,,,,,,,,,,,,,,,amiodarone - phospholipase competition inhibitor [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003226,amiodarone - apotosis inducing factor [Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001849|http://purl.obolibrary.org/obo/CHEBI_2663,,,,,,,,,,,,,,,,,,,,PMID:15720040|PMID:22960355|PMID:28552552,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_68495,,,,,,,,,,TXPO:0003226,,,,,,,,,,,,,,,,,,,,,,amiodarone - apotosis inducing factor [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003225,imipramine - apotosis inducing factor [Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/CHEBI_47499|http://purl.obolibrary.org/obo/TXPO_0001849,,,,,,,,,,,,,,,,,,,,PMID:15720040,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_68495,,,,,,,,,,TXPO:0003225,,,,,,,,,,,,,,,,,,,,,,imipramine - apotosis inducing factor [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003228,imipramine - phospholipase competition inhibitor [Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/CHEBI_47499|http://purl.obolibrary.org/obo/TXPO_0001849,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003220|http://purl.obolibrary.org/obo/TXPO_0001426,,,,,,,,,,TXPO:0003228,,,,,,,,,,,,,,,,,,,,,,imipramine - phospholipase competition inhibitor [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003221,AMPK (mol),gene name: PRKAA2,"AMPK is a highly evolutionarily conserved serine/threonine kinase, and orthologs of the AMPK subunits are found in all eukaryotic species. At the molecular level, AMPK is a heterotrimer complex comprising a catalytic alpha subunit, with a conventional serine/threonine protein kinase domain, and two regulatory subunits, beta and gamma. In mammals, each subunit is encoded by multiple genes (alpha1, alpha2, beta1, beta2, gamma1, gamma2, gamma3), which results in 12 possible combinations of AMPK complex.",false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:105787|NCBI-Human-GeneID:5562|NCBI-Rat-GeneID:65248|IMR:0002775 (obsolete),,"AMPK is a highly evolutionarily conserved serine/threonine kinase, and orthologs of the AMPK subunits are found in all eukaryotic species. At the molecular level, AMPK is a heterotrimer complex comprising a catalytic alpha subunit, with a conventional serine/threonine protein kinase domain, and two regulatory subunits, beta and gamma. In mammals, each subunit is encoded by multiple genes (alpha1, alpha2, beta1, beta2, gamma1, gamma2, gamma3), which results in 12 possible combinations of AMPK complex.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000005562,,,,,,,,,,gene name: PRKAA2,,,TXPO:0003221,,,,,,,"AMPK is a highly evolutionarily conserved serine/threonine kinase, and orthologs of the AMPK subunits are found in all eukaryotic species. At the molecular level, AMPK is a heterotrimer complex comprising a catalytic alpha subunit, with a conventional serine/threonine protein kinase domain, and two regulatory subunits, beta and gamma. In mammals, each subunit is encoded by multiple genes (alpha1, alpha2, beta1, beta2, gamma1, gamma2, gamma3), which results in 12 possible combinations of AMPK complex.",,,,,,,,,,,,,,,AMPK (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003223,PI3K (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:170911|NCBI-Mouse-GeneID:18706|NCBI-Human-GeneID:5290,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000005290,,,,,,,,,,,,,TXPO:0003223,,,,,,,,,,,,,,,,,,,,,,PI3K (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003220,conpetitive inhibitor of phospholipase,A role played by the entity that competitively inhibits the catalysis of the hydrolysis of a phospholipid.,,false,,,http://purl.obolibrary.org/obo/TXPO_0003989|http://purl.obolibrary.org/obo/TXPO_0000559,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,A role played by the entity that competitively inhibits the catalysis of the hydrolysis of a phospholipid.,,,,,TXPO:0003220,,,,,,,,,,,,,,,,,,,,,,conpetitive inhibitor of phospholipase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003224,nuclear receptor,,A combining role with a signal and transmitting the signal to the transcriptional machinery by interacting selectively and non-covalently with a specific DNA sequence in order to modulate transcription by RNA polymerase II.|hasrelated molecular function GO:0004879,false,,,http://purl.obolibrary.org/obo/TXPO_0002463,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006351,,,,,,,,,,,IMR:0000085 (obsolete),,A combining role with a signal and transmitting the signal to the transcriptional machinery by interacting selectively and non-covalently with a specific DNA sequence in order to modulate transcription by RNA polymerase II.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003224,,,,,,,,,,,,,,,,,,,,hasrelated molecular function GO:0004879,,nuclear receptor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000000427,ASAH1,,Other designations: acid CDase|acid ceramidase|acylsphingosine deacylase|putative 32 kDa heart protein,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,AC|SMAPME|PHP|ASAH|PHP32|ACDase,,,,,,,,,,,,8,,,,,,HPRD:01969|Ensembl:ENSG00000104763|MIM:613468|HGNC:735|Vega:OTTHUMG00000096997,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,N-acylsphingosine amidohydrolase (acid ceramidase) 1,,,8p22,,,,,,,,,,,,,,,,"GO_0003824 (EC: TAS, PMID: 8955159); GO_0006665 (EC: TAS); GO_0006672 (EC: TAS, PMID: 8955159); GO_0006687 (EC: TAS); GO_0008219 (EC: IEA); GO_0010033 (EC: IEA); GO_0017040 (EC: TAS); GO_0030324 (EC: IEA); GO_0043202 (EC: TAS); GO_0044281 (EC: TAS); GO_0070062 (EC: IDA, PMID: 19056867)",,,,,,,,,PMID: 7744740; 8125298; 8889549; 8955159; 9838138; 10610716; 10959093; 10974027; 11241842; 11451951; 12477932; 12638942; 12754519; 12764132; 12815059; 14702039; 15088070; 15210766; 15489334; 16169070; 16263699; 16335952; 16344560; 16500425; 16806233; 17713573; 17881906; 18245333; 18477771; 19056867; 19298866; 19905902; 19913121; 20360068; 20379614; 20520628; 20628086; 20871013; 21139048; 21335555; 21375364; 21493710; 21504271; 21552555; 21700700; 21846728; 21890473; 21893389; 21988832; 22079093; 22261821; 22268729; 22322590; 22515519; 22703880; 22927646; 23423838; 23518908; 23602568; 23707712; 23777806; 24091326,,,,,,,,,,,,,,,OGG:3000000427,,,,,,,N-acylsphingosine amidohydrolase (acid ceramidase) 1,,,,,,,,,,,,,Other designations: acid CDase|acid ceramidase|acylsphingosine deacylase|putative 32 kDa heart protein,,ASAH1,,,,,,,,,,,,,,,,,,,,,,,427,HSD33,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,ASAH1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/GO_0034389,lipid droplet organization,,"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a lipid particle.",false,,,http://purl.obolibrary.org/obo/TXPO_0000468,,,,,,,,,,,,,,,,,,,,,,"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a lipid particle.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0034389,,,,,,,,,,,,,,,,,,,,,,lipid droplet organization,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002461,PERK-NRF2 signal integration system,,"PERK-NRF2 signal integration system is a subtype of PERK pathway system.
This entity has sub-parts and has a goal of transmitting signals and a gene regulation via PERK and NRF2 as a systemic context.",false,,,http://purl.obolibrary.org/obo/TXPO_0001529,,,,,,,,,,,,,,,,,,,,,,"PERK-NRF2 signal integration system is a subtype of PERK pathway system.
This entity has sub-parts and has a goal of transmitting signals and a gene regulation via PERK and NRF2 as a systemic context.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002526,,,,,,,,,,,,,,,,,,,,,,TXPO:0002461,,,,,,,,,,,,,,,,,,,,,,PERK-NRF2 signal integration system,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002464,stress sensor activation,,"Stress sensor activation, is a subtype of molecular activation: A process that changes the activity of the molecule  with stress sensor role to be higher.",false,,,http://purl.obolibrary.org/obo/TXPO_0000023,,,,,,,,,,,,,,,,,,,,,,"Stress sensor activation, is a subtype of molecular activation: A process that changes the activity of the molecule  with stress sensor role to be higher.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002464,,,,,,,,,,,,,,,,,,,,,,stress sensor activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002468,ATF6F (canonical)[ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000879,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002468,,,,,,,,,,,,,,,,,,,,,,ATF6F (canonical)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002466,Transport ATF-6 from the endoplasmic reticulum (ER) to the Golgi [ER stress - refolding],,"Transport ATF-6 from the endoplasmic reticulum (ER) to the Golgi is a subtype of ER to Golgi transport: A process of the directed movement of ATF6 from the endoplasmic reticulum (ER) to the Golgi.
This process is dependent on the refolding and can constitute the course of ER stress.|The association between ATF6-alpha and BiP causes ATF6-alpha to be retained in the endoplasmic reticulum (ER). Once dissociated from BiP, the 2 Golgi Localization Sequences on ATF6-alpha are exposed and ATF6-alpha transits from the ER to the Golgi Apparatus.",false,,,http://purl.obolibrary.org/obo/TXPO_0002465|http://purl.obolibrary.org/obo/TXPO_0003736,,,,,,,,,,,,,,,,,,,,Reactome:R-HSA-381186|http://purl.obolibrary.org/obo/HINO_0008859|PMID:12110171|PMID:15657421|PMID:11821395,,"Transport ATF-6 from the endoplasmic reticulum (ER) to the Golgi is a subtype of ER to Golgi transport: A process of the directed movement of ATF6 from the endoplasmic reticulum (ER) to the Golgi.
This process is dependent on the refolding and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002900,,,,http://purl.obolibrary.org/obo/TXPO_0000044,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002467,,,http://purl.obolibrary.org/obo/GO_0005794,http://purl.obolibrary.org/obo/GO_0005783,,,,,,,TXPO:0002466,,,,,,,,,,,,,,,,,,,,"The association between ATF6-alpha and BiP causes ATF6-alpha to be retained in the endoplasmic reticulum (ER). Once dissociated from BiP, the 2 Golgi Localization Sequences on ATF6-alpha are exposed and ATF6-alpha transits from the ER to the Golgi Apparatus.",,Transport ATF-6 from the endoplasmic reticulum (ER) to the Golgi [ER stress - refolding],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002460,refolding-unfolding imbalance [ER stress (moderate) ],,"Refolding-unfolding imbalance is a subtype of imbalance: A process that lacks a balance between protein refolding and unfolding. And the degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of ER stress (moderate).",false,,,http://purl.obolibrary.org/obo/TXPO_0000147,,,,,,,,,,,,,,,,,,,,,,"Refolding-unfolding imbalance is a subtype of imbalance: A process that lacks a balance between protein refolding and unfolding. And the degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of ER stress (moderate).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002470,,http://purl.obolibrary.org/obo/TXPO_0001781,,,,,,,,,TXPO:0002460,,,,,,,,,,,,,,,,,,,,,,refolding-unfolding imbalance [ER stress (moderate) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005783,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002465,Transport ATF-6 from the endoplasmic reticulum (ER) to the Golgi,,Transport ATF-6 from the endoplasmic reticulum (ER) to the Golgi is a subtype of ER to Golgi transport: A process of the directed movement of ATF6 from the endoplasmic reticulum (ER) to the Golgi.,false,,,http://purl.obolibrary.org/obo/TXPO_0000460,,,,,,,,,,,,,,,,,,,,,,Transport ATF-6 from the endoplasmic reticulum (ER) to the Golgi is a subtype of ER to Golgi transport: A process of the directed movement of ATF6 from the endoplasmic reticulum (ER) to the Golgi.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001904,,,http://purl.obolibrary.org/obo/GO_0005794,http://purl.obolibrary.org/obo/GO_0005783,,,,,,,TXPO:0002465,,,,,,,,,,,,,,,,,,,,,,Transport ATF-6 from the endoplasmic reticulum (ER) to the Golgi,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002462,flow rate attribute,,A physical attribute inhering in a bearer by virtue of the bearer's motion characteristic.,false,,,http://purl.obolibrary.org/obo/PATO_0001906,,,,,,,,,,,,,,,,,,,,,,A physical attribute inhering in a bearer by virtue of the bearer's motion characteristic.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002462,,,,,,,,,,,,,,,,,,,,,,flow rate attribute,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002463,signaling receptor,,A role of receiving a signal and transmitting it in the cell to initiate a change in cell activity. A signal is a physical entity or change in state that is used to transfer information in order to trigger a response.|related molecular function GO:0004872,false,,,http://purl.obolibrary.org/obo/TXPO_0003728,,,,,,,,,,,,,,,,,,,,,,A role of receiving a signal and transmitting it in the cell to initiate a change in cell activity. A signal is a physical entity or change in state that is used to transfer information in order to trigger a response.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002463,,,,,,,,,,,,,,,,,,,,related molecular function GO:0004872,,signaling receptor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002467,ATF6 processing [ER stress - refolding],,"ATF6 processing is a subtype of protein processing: A process that ATF6 maturation process achieved by the cleavage of a peptide bond or bonds within ATF6 protein.
This process is dependent on the refolding and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0003063|http://purl.obolibrary.org/obo/TXPO_0003736,,,,,,,,,,,,,,,,,,,,,,"ATF6 processing is a subtype of protein processing: A process that ATF6 maturation process achieved by the cleavage of a peptide bond or bonds within ATF6 protein.
This process is dependent on the refolding and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002900,,http://purl.obolibrary.org/obo/TXPO_0000349|http://purl.obolibrary.org/obo/TXPO_0000049,,http://purl.obolibrary.org/obo/TXPO_0002901,,,,,,,,,,,,,,,,,,,TXPO:0002467,,,,,,,,,,,,,,,,,,,,,,ATF6 processing [ER stress - refolding],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002469,increasing demand for protein refolding [ER stress (sustained)],,"Increasing demand for protein refolding is a subtype of increasing functional demand: A process that changes the functional demand for protein refolding to be higher. This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of ER stress (sustained).",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/TXPO_0002211,,,,,,,,,,,,,,,,,,,,,,"Increasing demand for protein refolding is a subtype of increasing functional demand: A process that changes the functional demand for protein refolding to be higher. This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of ER stress (sustained).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002460,,,,,,,,,,,TXPO:0002469,,,,,,,,,,,,,,,,,,,,,,increasing demand for protein refolding [ER stress (sustained)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005783,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_4995,felbamate,"2-phenyl-1,3-propanediol dicarbamate|carbamic acid 2-phenyltrimethylene ester|felbamate|felbamatum|felbamato|Carbamic acid 3-carbamoyloxy-2-phenyl-propyl ester|Felbamate|2-phenylpropane-1,3-diyl dicarbamate","The bis(carbamate ester) of 2-phenylpropane-1,3-diol. An anticonvulsant, it is used in the treatment of epilepsy.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Drug_Central:1140|PMID:12873507|CAS:25451-15-4|PMID:12825948|LINCS:LSM-4232|DrugBank:DB00949|PMID:18311896|Reaxys:3345236,,"The bis(carbamate ester) of 2-phenylpropane-1,3-diol. An anticonvulsant, it is used in the treatment of epilepsy.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35623|http://purl.obolibrary.org/obo/CHEBI_63726,,,,,"Felbamate|2-phenylpropane-1,3-diyl dicarbamate",,"2-phenyl-1,3-propanediol dicarbamate|carbamic acid 2-phenyltrimethylene ester|felbamate|felbamatum|felbamato|Carbamic acid 3-carbamoyloxy-2-phenyl-propyl ester",,,,,,,,,,,,,,,,,,,,,CHEBI:4995,,,,felbamate,,CHEBI:4995,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76797,EC 2.5.1.18 (glutathione transferase) inhibitor,glutathione S-aryltransferase inhibitor|glutathione S-alkyl transferase inhibitor|EC 2.5.1.18 inhibitor|RX:glutathione R-transferase inhibitors|glutathione S-aralkyltransferase inhibitor|RX:glutathione R-transferase inhibitor|glutathione transferase (EC 2.5.1.18) inhibitor|glutathione S-transferase inhibitor|S-(hydroxyalkyl)glutathione lyase inhibitor|glutathione S-alkyltransferase inhibitor|EC 2.5.1.18 (glutathione transferase) inhibitors|EC 2.5.1.18 inhibitors|glutathione S-alkyltransferase inhibitors|glutathione S-aryltransferase inhibitors|glutathione S-aralkyltransferase inhibitors|glutathione S-alkyl transferase inhibitors|S-(hydroxyalkyl)glutathione lyase inhibitors|glutathione transferase inhibitors|glutathione transferase inhibitor|glutathione transferase (EC 2.5.1.18) inhibitors|glutathione S-transferase inhibitors,An EC 2.5.1.* (non-methyl-alkyl or aryl transferase) inhibitor that interferes with the action of a glutathione transferase (EC 2.5.1.18).,false,,,http://purl.obolibrary.org/obo/CHEBI_76663,,,,,,,,,,,,,,,,,,,,,,An EC 2.5.1.* (non-methyl-alkyl or aryl transferase) inhibitor that interferes with the action of a glutathione transferase (EC 2.5.1.18).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,glutathione S-aryltransferase inhibitor|glutathione S-alkyl transferase inhibitor|EC 2.5.1.18 inhibitor|RX:glutathione R-transferase inhibitors|glutathione S-aralkyltransferase inhibitor|RX:glutathione R-transferase inhibitor|glutathione transferase (EC 2.5.1.18) inhibitor|glutathione S-transferase inhibitor|S-(hydroxyalkyl)glutathione lyase inhibitor|glutathione S-alkyltransferase inhibitor|EC 2.5.1.18 (glutathione transferase) inhibitors|EC 2.5.1.18 inhibitors|glutathione S-alkyltransferase inhibitors|glutathione S-aryltransferase inhibitors|glutathione S-aralkyltransferase inhibitors|glutathione S-alkyl transferase inhibitors|S-(hydroxyalkyl)glutathione lyase inhibitors|glutathione transferase inhibitors|glutathione transferase inhibitor|glutathione transferase (EC 2.5.1.18) inhibitors|glutathione S-transferase inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:76797,,,,EC 2.5.1.18 (glutathione transferase) inhibitor,,CHEBI:76797,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000805,GADD45 alpha,,,false,,,http://purl.obolibrary.org/obo/IMR_0000559,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000805,,,,,,,,,,,,,,,,,,,,,,GADD45 alpha,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_1901889,negative regulation of cell junction assembly,inhibition of cell junction assembly,"Negative regulation of cell junction assembly is a subtype of negative regulation process:  Any process that stops, prevents or reduces the frequency, rate or extent of cell junction assembly.",false,,,http://purl.obolibrary.org/obo/TXPO_0000369,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of cell junction assembly is a subtype of negative regulation process:  Any process that stops, prevents or reduces the frequency, rate or extent of cell junction assembly.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,inhibition of cell junction assembly,,,,GO:1901889,,,,,,,,,,,,,,,,,,,,,,negative regulation of cell junction assembly,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0034329,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_4305,dacarbazine,"Dtic-Dome (TN)|NSC-45388|4-(dimethyltriazeno)imidazole-5-carboxamide|DIC|dacarbazinum|4-(5)-(3,3-dimethyl-1-triazeno)imidazole-5(4)-carboxamide|5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide|HSDB 3219|5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide|deticene|dacarbazina|5-(dimethyltriazeno)imidazole-4-carboxamide|5-(3,3-dimethyltriazeno)imidazole-4-carboxamide|ICDMT|dacarbazine|4-(3,3-dimethyl-1-triazeno)imidazole-5-carboxamide|NCI-C04717|Imidazole-4-carboxamide, 5-(3,3-dimethyl-1-triazeno)-|NSC 45388|DTIC|Di-me-triazenoimidazolecarboxamide|5-(3,3-dimethyltriaz-1-en-1-yl)-1H-imidazole-4-carboxamide","A monocarboxylic acid amide that is 1H-imidazole-4-carboxamide which is substituted at position 5 by a 3,3-dimethyltriaz-1-en-1-yl group. It is used for the treatment of metastatic malignant melanoma, and in combination with other drugs for the treatment of Hodgkin's disease and soft-tissue sarcoma.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:29287706|CAS:4342-03-4|PMID:10751609|PMID:28419676|PMID:29184162|PMID:20082117|PMID:12195827|DrugBank:DB00851|PMID:28250333|PMID:21471822|PMID:28387914|PMID:29305638|Drug_Central:773|PMID:11318431|PMID:29344241|Reaxys:521487|PMID:29076951|PMID:23029050|PMID:28096700|PMID:29296081|PMID:21654834|PMID:15010317|PMID:23318786|PMID:26940170|Beilstein:521487,,"A monocarboxylic acid amide that is 1H-imidazole-4-carboxamide which is substituted at position 5 by a 3,3-dimethyltriaz-1-en-1-yl group. It is used for the treatment of metastatic malignant melanoma, and in combination with other drugs for the treatment of Hodgkin's disease and soft-tissue sarcoma.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35610|http://purl.obolibrary.org/obo/CHEBI_22333|http://purl.obolibrary.org/obo/CHEBI_50903|http://purl.obolibrary.org/obo/CHEBI_50266,,,,,"5-(3,3-dimethyltriaz-1-en-1-yl)-1H-imidazole-4-carboxamide",,"Dtic-Dome (TN)|NSC-45388|4-(dimethyltriazeno)imidazole-5-carboxamide|DIC|dacarbazinum|4-(5)-(3,3-dimethyl-1-triazeno)imidazole-5(4)-carboxamide|5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide|HSDB 3219|5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide|deticene|dacarbazina|5-(dimethyltriazeno)imidazole-4-carboxamide|5-(3,3-dimethyltriazeno)imidazole-4-carboxamide|ICDMT|dacarbazine|4-(3,3-dimethyl-1-triazeno)imidazole-5-carboxamide|NCI-C04717|Imidazole-4-carboxamide, 5-(3,3-dimethyl-1-triazeno)-|NSC 45388|DTIC|Di-me-triazenoimidazolecarboxamide",,,,,,,,,,,,,,,,,,,,,CHEBI:4305,,,,dacarbazine,,CHEBI:4305,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000906,eIF4A,eukaryotic initiation factor 4A,eIF4A is a DEADbox helicase that can unwind RNA secondary structure in the cap-proximal region of the mRNA.,false,,,http://purl.obolibrary.org/obo/IMR_0000912,,,,,,,,,,,,,,,,,,,,,,eIF4A is a DEADbox helicase that can unwind RNA secondary structure in the cap-proximal region of the mRNA.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,eukaryotic initiation factor 4A,,,,,IMR:0000906,,,,,,,,,,,,,,,,,,,,,,eIF4A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_36976,nucleotide,,A nucleotide is a nucleoside phosphate resulting from the condensation of the 3 or 5 hydroxy group of a nucleoside with phosphoric acid.,false,,,http://purl.obolibrary.org/obo/IMR_0001698|http://purl.obolibrary.org/obo/CHEBI_72695,,,,,,,,,,,,,,,,,,,,"IMR:0001349|A nucleotide consists of a nitrogen-containing base, a five-carbon sugar, and one or more phosphate groups. Nucleotides can carry chemical energy (e.g. ATP), form coenzymes (e.g. CoA), be used as specific signaling molecules (e.g. cAMP) in the cell. Nucleotides are the subunits of the nucleic acids.",,A nucleotide is a nucleoside phosphate resulting from the condensation of the 3 or 5 hydroxy group of a nucleoside with phosphoric acid.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:36976,,,,,,,,,,,,,,,,,,,,,,nucleotide,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0007631,feeding behavior,,Behavior associated with the intake of food.,false,,,http://purl.obolibrary.org/obo/TXPO_0002587,,,,,,,,,,,,,,,,,,,,Wikipedia:List_of_feeding_behaviours,,Behavior associated with the intake of food.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0007631,,,,,,,,,,,,,,,,,,,,,,feeding behavior,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100746,TCF-3,mTCF-3|Transcription factor 7-like 1|TCF7L1|HMG-box transcription factor 3|TCF-3,,false,,,http://purl.obolibrary.org/obo/IMR_0000418,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,mTCF-3|Transcription factor 7-like 1|TCF7L1|HMG-box transcription factor 3|TCF-3,,,,,IMR:0100746,,,,,,,,,,,,,,,,,,,,,,TCF-3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0011148,eIF3d,eIF3 p66|eukaryotic translation initiation factor 3 subunit 7|eIF-3 zeta,,false,,,http://purl.obolibrary.org/obo/IMR_0000916,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,eIF3 p66|eukaryotic translation initiation factor 3 subunit 7|eIF-3 zeta,,,,,IMR:0011148,,,,,,,,,,,,,,,,,,,,,,eIF3d,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000739,ShcB,,,false,,,http://purl.obolibrary.org/obo/IMR_0000347,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000739,,,,,,,,,,,,,,,,,,,,,,ShcB,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000023475,QPRT,,Other designations: QAPRTase|epididymis secretory sperm binding protein Li 90n|nicotinate-nucleotide pyrophosphorylase (carboxylating)|nicotinate-nucleotide pyrophosphorylase [carboxylating],false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,QPRTase|HEL-S-90n,,,,,,,,,,,,16,,,,,,MIM:606248|HPRD:06950|HGNC:9755,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,quinolinate phosphoribosyltransferase,,,16p11.2,,,,,,,,,,,,,,,,"GO_0004514 (EC: IDA, PMID: 17868694); GO_0005829 (EC: TAS); GO_0006766 (EC: TAS); GO_0006767 (EC: TAS); GO_0009435 (EC: IEA); GO_0019674 (EC: TAS); GO_0034213 (EC: IDA, PMID: 3409840); GO_0042803 (EC: IDA, PMID: 17868694); GO_0044281 (EC: TAS); GO_0051259 (EC: IDA, PMID: 17868694)",,,,,,,,,PMID: 3409840; 9473669; 10721107; 12477932; 14704851; 15489334; 16189514; 17868694; 19321014; 21139048; 21963094; 21988832; 22505724; 23000965,,,,,,,,,,,,,,,OGG:3000023475,,,,,,,quinolinate phosphoribosyltransferase,,,,,,,,,,,,,Other designations: QAPRTase|epididymis secretory sperm binding protein Li 90n|nicotinate-nucleotide pyrophosphorylase (carboxylating)|nicotinate-nucleotide pyrophosphorylase [carboxylating],,QPRT,,,,,,,,,,,,,,,,,,,,,,,23475,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,QPRT,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0002701,hyperfunctioning of glutathione conjugates excretion from hepatocyte,,Hyperfunctioning of glutathione conjugates excretion from hepatocyte is a subtype of hyperfunctioning: A process that performs an excessive excretion of the glutathione conjugates from the hepatocyte.,false,,,http://purl.obolibrary.org/obo/TXPO_0002279,,,,,,,,,,,,,,,,,,,,,,Hyperfunctioning of glutathione conjugates excretion from hepatocyte is a subtype of hyperfunctioning: A process that performs an excessive excretion of the glutathione conjugates from the hepatocyte.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002701,,,,,,,,,,,,,,,,,,,,,,hyperfunctioning of glutathione conjugates excretion from hepatocyte,,,,,,http://purl.obolibrary.org/obo/TXPO_0002551,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002703,converting cell type,,Converting cell type is a subtype of converting type: A process that changes the type of the cell.,false,,,http://purl.obolibrary.org/obo/TXPO_0002282,,,,,,,,,,,,,,,,,,,,,,Converting cell type is a subtype of converting type: A process that changes the type of the cell.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002703,,,,,,,,,,,,,,,,,,,,,,converting cell type,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002709,IRE1 signaling to XBP1 [ER stress],,"A process in which a signal to XBP1 is transduced by the IRE1.
This entity is a specific course-dependent process. This process is dependent on ERAD and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002571,,,,,,,,,,,,,,,,,,,,,,"A process in which a signal to XBP1 is transduced by the IRE1.
This entity is a specific course-dependent process. This process is dependent on ERAD and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002685|http://purl.obolibrary.org/obo/TXPO_0002680,,,,,,,,,,,,,,,,,,TXPO:0002709,,,,,,,,,,,,,,,,,,,,,,IRE1 signaling to XBP1 [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002707,estrone [Cholestasis],,"An estrogen that has formula C18H22O2.
This compound might be participated in the process involved in the course of cholestasis.",false,,,http://purl.obolibrary.org/obo/CHEBI_17263|http://purl.obolibrary.org/obo/TXPO_0000749,,,,,,,,,,,,,,,,,,,,ATC:G03CC04|DrugBank:DB00655|ATC:G03CA07|CASRN:53-16-7|InChIKey:DNXHEGUUPJUMQT-CBZIJGRNSA-N,,"An estrogen that has formula C18H22O2.
This compound might be participated in the process involved in the course of cholestasis.",,,,,,,,,,,,estrone [cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002712,,,,,,,,,,TXPO:0002707,,,,,,,,,,,,,,,,,,,,,,estrone [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002704,changing permeability,,Changing permeability is a subtype of changing quality: A process that changes the temperature of the object.,false,,,http://purl.obolibrary.org/obo/TXPO_0000415,,,,,,,,,,,,,,,,,,,,,,Changing permeability is a subtype of changing quality: A process that changes the temperature of the object.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002704,,,,,,,,,,,,,,,,,,,,,,changing permeability,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002702,prostaglandin [Cholestasis],,,false,,,http://purl.obolibrary.org/obo/IMR_0100019|http://purl.obolibrary.org/obo/TXPO_0000749,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002702,,,,,,,,,,,,,,,,,,,,,,prostaglandin [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002706,increasing canalicular membrane permeability,,Increasing canalicular membrane permeability is a subtype of increasing membrane permeabilization: A process that changes the permeability of the canalicular membrane to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000232,,,,,,,,,,,,,,,,,,,,,,Increasing canalicular membrane permeability is a subtype of increasing membrane permeabilization: A process that changes the permeability of the canalicular membrane to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002706,,,,,,,,,,,,,,,,,,,,,,increasing canalicular membrane permeability,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002708,hyperfunction of glutathione export from hepatocyte,,Hyperfunction of glutathione export from hepatocyte  is a subtype of hyperfunction of transport: A process that performs an excesssive export of the glutathione from the hepatocyte.,false,,,http://purl.obolibrary.org/obo/TXPO_0002351,,,,,,,,,,,,,,,,,,,,PMID:18786560|ISBN:0071769234,,Hyperfunction of glutathione export from hepatocyte  is a subtype of hyperfunction of transport: A process that performs an excesssive export of the glutathione from the hepatocyte.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002708,,,,,,,,,,,,,,,,,,,,,,hyperfunction of glutathione export from hepatocyte,,,,,,http://purl.obolibrary.org/obo/TXPO_0002488,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002700,EDEM -ERAD promoting factor (canonical)[ER stress -ERAD],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002699,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002700,,,,,,,,,,,,,,,,,,,,,,EDEM -ERAD promoting factor (canonical)[ER stress -ERAD],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002705,changing size,,Changing size is a subtype of changing quality: A process that changes the size of the object.,false,,,http://purl.obolibrary.org/obo/TXPO_0000415,,,,,,,,,,,,,,,,,,,,,,Changing size is a subtype of changing quality: A process that changes the size of the object.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002705,,,,,,,,,,,,,,,,,,,,,,changing size,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001091,importin/exportin,Kap|inportin beta family|karyopherin|inportin beta-like family|karyopherin beta family|inportin beta-like receptor|inportin beta-like protein,"Members of importin beta family (importins/exportins, karyopherins) have been classified as importins or exportins on the basis of the direction they carry their cargo.",false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,"Members of importin beta family (importins/exportins, karyopherins) have been classified as importins or exportins on the basis of the direction they carry their cargo.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000885,,,,,Kap|inportin beta family|karyopherin|inportin beta-like family|karyopherin beta family|inportin beta-like receptor|inportin beta-like protein,,,,,IMR:0001091,,,,,,,,,,,,,,,,,,,,,,importin/exportin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100700,cAMP phosphodiesterase,cAMP-specific PDE|cAMP-specific phosphodiesterase|cyclic AMP phosphodiesterase,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,EC:3.1.4.17|GO:0004115,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003672,,,,,cAMP-specific PDE|cAMP-specific phosphodiesterase|cyclic AMP phosphodiesterase,,,,,IMR:0100700,,,,,,,,,,,,,,,,,,,,,,cAMP phosphodiesterase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0001264,pancreas,,An endoderm derived structure that produces precursors of digestive enzymes and blood glucose regulating enzymes[GO].,false,,,http://purl.obolibrary.org/obo/UBERON_0000062,,,,,,,,,,,,,,,,,,,,http://www.snomedbrowser.com/Codes/Details/181277001|http://purl.obolibrary.org/obo/NCIT_C12393|http://linkedlifedata.com/resource/umls/id/C0030274|http://en.wikipedia.org/wiki/Pancreas|OpenCyc:Mx4rvVimZZwpEbGdrcN5Y29ycA|XAO:0000136|TAO:0000140|CALOHA:TS-0736|UMLS:C0030274|MAT:0000075|BTO:0000988|AAO:0010112|VHOG:0000050|MESH:D010179|ZFA:0000140|FMA:7198|EMAPA:17503|GAID:334|MA:0000120|MIAA:0000075|EFO:0000855|EHDAA2:0001367|EV:0100092|EHDAA:6893|galen:Pancreas,,An endoderm derived structure that produces precursors of digestive enzymes and blood glucose regulating enzymes[GO].,,,,,,,,Organ which secretes a fluid containing enzymes that aid in the digestion of food.[AAO],,,,,,,"The mature pancreas of higher vertebrates and mammals comprises two major functional units: the exocrine pancreas, which is responsible for the production of digestive enzymes to be secreted into the gut lumen, and the endocrine pancreas, which has its role in the synthesis of several hormones with key regulatory functions in food uptake and metabolism. The exocrine portion constitutes the majority of the mass of the pancreas, and contains only two different cell types, the secretory acinar cells and the ductular cells. The endocrine portion, which comprises only 1-2% of the total mass, contains five different cell types, which are organized into mixed functional assemblies referred to as the islets of Langerhans",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"In the hagfish and lampreys (our most primitive vertebrate species of today), the first sign of 'a new organ' is found as collections of endocrine cells around the area of the bile duct connection with the duodenum. These endocrine organs are composed of 99% beta cells and 1% somatostatin-producing delta cells. Compared to the more primitive protochordates (e.g. amphioxus), this represents a stage where all previously scattered insulin-producing cells of the intestinal tissue have now quantitatively migrated to found a new organ involved in sensing blood glucose rather than gut glucose. Only later in evolution, the beta cells are joined by exocrine tissue and alpha cells (exemplified by the rat-, rabbit- and elephant-fishes). Finally, from sharks and onwards in evolution, we have the islet PP-cell entering to complete the pancreas.[well established][VHOG]",,UBERON:0001264,,,,,,,,,,,,,,,,,,,,,,pancreas,,,,https://upload.wikimedia.org/wikipedia/commons/7/7e/Blausen_0699_PancreasAnatomy2.png,,,http://purl.obolibrary.org/obo/oae.owl|http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"As a secretory organ serving exocrine and endocrine functions, the pancreas is specific to the vertebrates[PMID:16417468] Hagfishes and lampreys are unique in the complete separation of their endocrine pancreas (islet or- gan) and their exocrine pancreas (50). The endocrine and exocrine pancreas are coassociated in crown gnathostomes (50). In Branchiostoma and Ciona, there is no diverticulum as there is in hagfishes, lampreys, and gnathostomes, only dispersed insulin-secreting cells in the walls of the gastrointestinal tract (51, 52)",
http://purl.obolibrary.org/obo/IMR_0000698,K-Ras2B,K-Ras4B,,false,,,http://purl.obolibrary.org/obo/IMR_0000291,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,K-Ras4B,,,,,IMR:0000698,,,,,,,,,,,,,,,,,,,,,,K-Ras2B,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_18348,"1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate","PIP2|PI(4,5)P2|Phosphatidylinositol-4,5-bisphosphate|PtsIns-4,5-P2","PI(4,5)P2 is cleaved by phospholipase C-beta or gamma to generate IP3 and diacylglycerol.",false,,,http://purl.obolibrary.org/obo/CHEBI_37328,,,,,,,,,,,,,,,,,,,,IMR:0001350,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0200477,"PIP2|PI(4,5)P2|Phosphatidylinositol-4,5-bisphosphate|PtsIns-4,5-P2",,,,,CHEBI:18348,,,,,,,,,,,,,,,,,,,,"PI(4,5)P2 is cleaved by phospholipase C-beta or gamma to generate IP3 and diacylglycerol.",,"1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001472,DOCK4,,,false,,,http://purl.obolibrary.org/obo/IMR_0001469,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001472,,,,,,,,,,,,,,,,,,,,,,DOCK4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000002494,NR5A2,,"Other designations: CYP7A promoter-binding factor|alpha-1-fetoprotein transcription factor|b1-binding factor, hepatocyte transcription factor which activates enhancer II of hepatitis B virus|fetoprotein-alpha 1 (AFP) transcription factor|hepatocytic transcription factor hB1F-3|liver nuclear receptor homolog-1 variant 2|liver receptor homolog 1|liver receptor homolog-1|nuclear receptor NR5A2|nuclear receptor subfamily 5 group A member 2",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,FTF|hB1F-2|LRH1|B1F|CPF|FTZ-F1beta|B1F2|FTZ-F1|LRH-1,,,,,,,,,,,,1,,,,,,HPRD:06830|HGNC:7984|Vega:OTTHUMG00000035635|MIM:604453|Ensembl:ENSG00000116833,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"nuclear receptor subfamily 5, group A, member 2",,,1q32.1,,,,,,,,,,,,,,,,"GO_0003677 (EC: IDA, PMID: 16289203); GO_0003700 (EC: IDA, PMID: 15205472); GO_0003705 (EC: TAS, PMID: 9786908); GO_0003707 (EC: IEA); GO_0004879 (EC: TAS, PMID: 16271724); GO_0005515 (EC: IPI, PMID: 12040021); GO_0005543 (EC: IDA, PMID: 15723037); GO_0005634 (EC: IDA, PMID: 15143342); GO_0005654 (EC: TAS); GO_0005737 (EC: IDA, PMID: 15205472); GO_0006355 (EC: IDA, PMID: 15723037); GO_0006355 (EC: TAS, PMID: 16289203); GO_0006367 (EC: TAS); GO_0008206 (EC: IEA); GO_0008270 (EC: IEA); GO_0009790 (EC: TAS, PMID: 16289203); GO_0010467 (EC: TAS); GO_0030522 (EC: TAS, PMID: 16271724); GO_0031018 (EC: TAS); GO_0042127 (EC: IEA); GO_0042592 (EC: NAS, PMID: 16289203); GO_0042632 (EC: IEA); GO_0043565 (EC: IDA, PMID: 16289203); GO_0044212 (EC: IDA, PMID: 15205472); GO_0045070 (EC: IDA, PMID: 19264593); GO_0045893 (EC: IDA, PMID: 15143342); GO_0045893 (EC: TAS, PMID: 15205472); GO_0045944 (EC: IEA)",,,,,,,,,PMID: 7680097; 8938589; 9786908; 9858833; 10359768; 11030332; 11564608; 11595170; 11668176; 11927588; 12040021; 12198243; 12208674; 12477932; 12820970; 12852843; 12853459; 12972592; 14671206; 14701856; 14728801; 14963109; 15117876; 15121760; 15143151; 15143342; 15181096; 15205472; 15218078; 15327767; 15604093; 15613430; 15707893; 15723037; 15897460; 15923626; 15963945; 16091743; 16271724; 16282330; 16289203; 16439367; 16450584; 16469397; 16712791; 17036045; 17095585; 17522048; 17664281; 17895379; 17910058; 17952562; 17977826; 18029348; 18191017; 18270374; 18385139; 18410128; 18508634; 18665078; 19015525; 19022561; 19264593; 19359379; 19629617; 19692572; 19913121; 20101243; 20133449; 20159957; 20375098; 20379614; 20516075; 20607599; 20628086; 20811994; 20817789; 21129436; 21258413; 21262773; 21392518; 21536586; 21554248; 21566081; 21614002; 21949357; 21990348; 22048972; 22125638; 22187462; 22359603; 22504882; 23000165; 23038264; 23128233; 23471216; 23537609; 23637637; 23667258; 23737522; 23817023,,,,,,,,,,,,,,,OGG:3000002494,,,,,,,"nuclear receptor subfamily 5, group A, member 2",,,,,,,,,,,,,"Other designations: CYP7A promoter-binding factor|alpha-1-fetoprotein transcription factor|b1-binding factor, hepatocyte transcription factor which activates enhancer II of hepatitis B virus|fetoprotein-alpha 1 (AFP) transcription factor|hepatocytic transcription factor hB1F-3|liver nuclear receptor homolog-1 variant 2|liver receptor homolog 1|liver receptor homolog-1|nuclear receptor NR5A2|nuclear receptor subfamily 5 group A member 2",,NR5A2,,,,,,,,,,,,,,,,,,,,,,,2494,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,NR5A2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0100537,GCKR,GCK related|KHS1|germinal center kinase related,,false,,,http://purl.obolibrary.org/obo/IMR_0100535,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GCK related|KHS1|germinal center kinase related,,,,,IMR:0100537,,,,,,,,,,,,,,,,,,,,,,GCKR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0200292,GMP,,,false,,,http://purl.obolibrary.org/obo/CHEBI_36976,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0200292,,,,,,,,,,,,,,,,,,,,,,GMP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000245,PKC,protein kinase C,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,GO:0004697,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001966,,,,,protein kinase C,,,,,IMR:0000245,,,,,,,,,,,,,,,,,,,,,,PKC,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000279,dysfunction of fatty acid degradation [Alcoholic  fatty liver],,"Dysfunction of fatty acid degradation is a subtype of hypofunctioning: A process that performs a decreased or insufficient lipid degradation.
This entity is a specific course-dependent process. This process can constitute the course of Alcoholic  fatty liver.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0003361,,,,,,,,,,,,,,,,,,,,,,"Dysfunction of fatty acid degradation is a subtype of hypofunctioning: A process that performs a decreased or insufficient lipid degradation.
This entity is a specific course-dependent process. This process can constitute the course of Alcoholic  fatty liver.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001739,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004207,,,,,,,,,,,TXPO:0000279,,,,,,,,,,,,,,,,,,,,,,dysfunction of fatty acid degradation [Alcoholic  fatty liver],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000182,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000274,PERK signaling (primitive),,PERK signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the PERK. PERK generally plays a endoplasmic reticulum membrane stress sensor  role.,false,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0014065,,PERK signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the PERK. PERK generally plays a endoplasmic reticulum membrane stress sensor  role.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000285,,,,,,,,,,,,,,,,TXPO:0000274,,,,,,,,,,,,,,,,,,,,,,PERK signaling (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000273,cholestasis dependent chemical entity,,"Cholestasis dependent chemical entity is a subtype of toxic course dependent chemical entity.
This entity can participate in the course of cholestasis.|under construction",false,,,http://purl.obolibrary.org/obo/TXPO_0001731,,,,,,,,,,,,,,,,,,,,,,"Cholestasis dependent chemical entity is a subtype of toxic course dependent chemical entity.
This entity can participate in the course of cholestasis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000273,,,,,,,,,,,,,,,,,,,,under construction,,cholestasis dependent chemical entity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000277,categorical,,"This is essentially a value and non-quantitative, therefore, there is no ordering among values, unlike non-categorial values. Categorical quality has typicality which no quantity has.

It is generically dependent on entity because it is always referred to with something as a species.",false,,,http://purl.obolibrary.org/obo/TXPO_0000275,,,,,,,,,,,,,,,,,,,,,,"This is essentially a value and non-quantitative, therefore, there is no ordering among values, unlike non-categorial values. Categorical quality has typicality which no quantity has.

It is generically dependent on entity because it is always referred to with something as a species.",YAMATO Ontology,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000277,,,,,,,,,,,,,,,,,,,,,,categorical,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000271,primitive process,,"Primitive process is a unit of process.
Process series at a certain granular level can appear as one primitive process at the higher level.|Whether the process is a primitive process or not depends on the setting of the granularity.
When one does not consider the details more than a certain level, or a level as the minimum grain size, the process at that level becomes the primitive process.",false,,,http://purl.obolibrary.org/obo/BFO_0000015,,,,,,,,,,,,,,,,,,,,,,"Primitive process is a unit of process.
Process series at a certain granular level can appear as one primitive process at the higher level.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/BFO_0000015,,,,,,,,,,,,,,,,,,TXPO:0000271,,,,,,,,,,,,,,,,,,,,"Whether the process is a primitive process or not depends on the setting of the granularity.
When one does not consider the details more than a certain level, or a level as the minimum grain size, the process at that level becomes the primitive process.",,primitive process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000276,cholestasis dependent molecule (canonical),,"Cholestasis dependent gene is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of cholestasis as a gene product.
Gene profile:caonical that described in textbooks or articles.|under construction",false,,,http://purl.obolibrary.org/obo/TXPO_0000273,,,,,,,,,,,,,,,,,,,,,,"Cholestasis dependent gene is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of cholestasis as a gene product.
Gene profile:caonical that described in textbooks or articles.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000276,,,,,,,,,,,,,,,,,,,,under construction,,cholestasis dependent molecule (canonical),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000270,state,,"Location-independent.
State corresponds not to generic quality but to property.
It is possessed by continuants and processes.",false,,,http://purl.obolibrary.org/obo/BFO_0000003,,,,,,,,,,,,,,,,,,,,,,,YAMATO:ontology,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000270,,,,,,,,,,,,,,,,,,,,"Location-independent.
State corresponds not to generic quality but to property.
It is possessed by continuants and processes.",,state,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000275,quality value,,"Value of quality. Although this is essentially a role played by quantity, YAMATO doesn't deal with it so for simplicity.",false,,,http://purl.obolibrary.org/obo/BFO_0000031,,,,,,,,,,,,,,,,,,,,,,"Value of quality. Although this is essentially a role played by quantity, YAMATO doesn't deal with it so for simplicity.",YAMATO Ontology,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000275,,,,,,,,,,,,,,,,,,,,,,quality value,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000272,OATPS family (canonical)[Cholestasis],organic anion transporting polypeptides [Cholestasis],glibenclamide is a  potential substrate for OATPs.,false,,,http://purl.obolibrary.org/obo/TXPO_0000276|http://purl.obolibrary.org/obo/TXPO_1000270,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C107150,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,organic anion transporting polypeptides [Cholestasis],,,,,TXPO:0000272,,,,,,,OATPs have a preference for unconjugated bile acids over conjugated bile salts,,,,,,,,,,,,,glibenclamide is a  potential substrate for OATPs.,,OATPS family (canonical)[Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000278,quantity,,"It is just a quantity independent of what quantity it is of. That is, 10cm and 11cm exist just as it is in the quantity space and are just different. On the other hand, when a thing's length is 10cm long at time t1 and 11cm long at t2, we say the length of the thing CHANGED. The 10cm long of a thing has its identity which persists having possibly different values.

Note that quantity is not specifically dependent on anything, but generically dependent on physical entity.",false,,,http://purl.obolibrary.org/obo/TXPO_0000275,,,,,,,,,,,,,,,,,,,,,,"It is just a quantity independent of what quantity it is of. That is, 10cm and 11cm exist just as it is in the quantity space and are just different. On the other hand, when a thing's length is 10cm long at time t1 and 11cm long at t2, we say the length of the thing CHANGED. The 10cm long of a thing has its identity which persists having possibly different values.

Note that quantity is not specifically dependent on anything, but generically dependent on physical entity.",YAMATO Ontology,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000278,,,,,,,,,,,,,,,,,,,,,,quantity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0004288,skeleton,set of bones of body|set of all bones,"Anatomical cluster that consists of all the skeletal elements (eg., bone, cartilage, and teeth) of the body.",false,,,http://purl.obolibrary.org/obo/UBERON_0034925,,,,,,,,,,,,,,,,,,,,http://www.snomedbrowser.com/Codes/Details/361378004|http://en.wikipedia.org/wiki/Skeleton|https://github.com/obophenotype/uberon/wiki/The-skeletal-system|MIAA:0000032|EHDAA2:0001843|EHDAA:5047|OpenCyc:Mx4rvVi1rpwpEbGdrcN5Y29ycA|EMAPA:17213|FMA:23875|MAT:0000032|XAO:0004053|MA:0003006|MESH:D012863|galen:Skeleton|VSAO:0000026|GAID:177|AEO:0000168,,"Anatomical cluster that consists of all the skeletal elements (eg., bone, cartilage, and teeth) of the body.",,,,,,,,"Anatomical cluster that consists of all the skeletal elements (eg., bone, cartilage, and teeth) of the body.[VSAO]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,set of bones of body|set of all bones,,,,http://purl.obolibrary.org/obo/UBERON_0001434,UBERON:0004288,http://purl.obolibrary.org/obo/UBERON_0001434,,,,,,,,,,,,,,,,,,,,,skeleton,,,,,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001044,ubiquitin thiolesterase,ubiquitin carboxy-terminal esterase|ubiquitin carboxy-terminal hydrolase,,false,,,http://purl.obolibrary.org/obo/IMR_0001043,,,,,,,,,,,,,,,,,,,,EC:3.1.2.15,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ubiquitin carboxy-terminal esterase|ubiquitin carboxy-terminal hydrolase,,,,,IMR:0001044,,,,,,,,,,,,,,,,,,,,,,ubiquitin thiolesterase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_149836,tigecycline,"(4S,4aS,5aR,12aS)-9-(2-(tert-butylamino)acetamido)-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide|(4S,4aS,5aR,12aS)-9-[(N-tert-butylglycyl)amino]-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide","Tetracycline in which the hydroxy group at position 5 and the methyl group at position 6 are replaced by hydrogen, and with a dimethylamino substituent and an (N-tert-butylglycyl)amino substituent at positions 7 and 9, respectively. A glycylcycline antibiotic, it has activity against a broad range of Gram-positive and Gram-negative bacteria, including tetracycline-resistant organisms. It is used for the intravenous treatment of complicated skin and skin structure infections caused by susceptible organisms.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:17307973|Drug_Central:2661|Reaxys:8379453|PMID:17210772|PMID:17353238|DrugBank:DB00560|PMID:17194827|CAS:220620-09-7|PMID:17353249|PMID:17220399,,"Tetracycline in which the hydroxy group at position 5 and the methyl group at position 6 are replaced by hydrogen, and with a dimethylamino substituent and an (N-tert-butylglycyl)amino substituent at positions 7 and 9, respectively. A glycylcycline antibiotic, it has activity against a broad range of Gram-positive and Gram-negative bacteria, including tetracycline-resistant organisms. It is used for the intravenous treatment of complicated skin and skin structure infections caused by susceptible organisms.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_36047,,,,,"(4S,4aS,5aR,12aS)-9-[(N-tert-butylglycyl)amino]-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide",,"(4S,4aS,5aR,12aS)-9-(2-(tert-butylamino)acetamido)-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide",,,,,,,,,,,,,,,,,,,,,CHEBI:149836,,,,tigecycline,,CHEBI:149836,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/BFO_0000028,three-dimensional spatial region,,,false,,,http://purl.obolibrary.org/obo/BFO_0000006,,,,,,,,,,,,,,,,,,,,,,,,,,,,A three-dimensional spatial region is a spatial region that is of three dimensions. (axiom label in BFO2 Reference: [040-001]),"a sphere-shaped region of space,|a cube-shaped region of space",,,,,,,,,,,(forall (x) (if (ThreeDimensionalSpatialRegion x) (SpatialRegion x))) // axiom label in BFO2 CLIF: [040-001],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BFO:0000028,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/bfo.owl,three-dimensional spatial region,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100272,MAPKAPK5,PRAK|MAP kinase-activated protein kinase 5|MAPK-activated protein kinase 5,MAPKAPK5 (PRAK) activity is regulated by p38 and activated MAPKAPK5 in turn phosphorylates small heat shock protein 27 (HSP27).,false,,,http://purl.obolibrary.org/obo/IMR_0100271,,,,,,,,,,,,,,,,,,,,,,MAPKAPK5 (PRAK) activity is regulated by p38 and activated MAPKAPK5 in turn phosphorylates small heat shock protein 27 (HSP27).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PRAK|MAP kinase-activated protein kinase 5|MAPK-activated protein kinase 5,,,,,IMR:0100272,,,,,,,,,,,,,,,,,,,,,,MAPKAPK5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_71476,EC 2.3.1.85 (fatty acid synthase) inhibitor,"EC 2.3.1.85 inhibitors|acyl-CoA:malonyl-CoA C-acyltransferase (decarboxylating, oxoacyl- and enoyl-reducing and thioester-hydrolysing) inhibitors|fatty acid synthase inhibitor|acyl-CoA:malonyl-CoA C-acyltransferase (decarboxylating, oxoacyl- and enoyl-reducing and thioester-hydrolysing) inhibitor|fatty acid synthase (EC 2.3.1.85) inhibitor|fatty acid synthase inhibitors|(FAS) inhibitors|EC 2.3.1.85 (fatty acid synthase) inhibitors|fatty acid synthase (EC 2.3.1.85) inhibitors|EC 2.3.1.85 inhibitor","An EC 2.3.1.* (acyltransferase transferring other than amino-acyl group) inhibitor that interferes with the action of fatty acid synthase (EC 2.3.1.85), a multi-enzyme protein involved in fatty acid synthesis.",false,,,http://purl.obolibrary.org/obo/CHEBI_76878,,,,,,,,,,,,,,,,,,,,,,"An EC 2.3.1.* (acyltransferase transferring other than amino-acyl group) inhibitor that interferes with the action of fatty acid synthase (EC 2.3.1.85), a multi-enzyme protein involved in fatty acid synthesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"EC 2.3.1.85 inhibitors|acyl-CoA:malonyl-CoA C-acyltransferase (decarboxylating, oxoacyl- and enoyl-reducing and thioester-hydrolysing) inhibitors|fatty acid synthase inhibitor|acyl-CoA:malonyl-CoA C-acyltransferase (decarboxylating, oxoacyl- and enoyl-reducing and thioester-hydrolysing) inhibitor|fatty acid synthase (EC 2.3.1.85) inhibitor|fatty acid synthase inhibitors|(FAS) inhibitors|EC 2.3.1.85 (fatty acid synthase) inhibitors|fatty acid synthase (EC 2.3.1.85) inhibitors|EC 2.3.1.85 inhibitor",,,,,,,,,,,,,,,,,,,,,CHEBI:71476,,,,EC 2.3.1.85 (fatty acid synthase) inhibitor,,CHEBI:71476,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000484,alpha-actinin 3,,,false,,,http://purl.obolibrary.org/obo/IMR_0000189,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000484,,,,,,,,,,,,,,,,,,,,,,alpha-actinin 3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_35477,antimanic drug,antimanic drugs|antimanics|antimanic agent,Antimanic drugs are agents used to treat bipolar disorders or mania associated with other affective disorders.,false,,,http://purl.obolibrary.org/obo/CHEBI_35473,,,,,,,,,,,,,,,,,,,,,,Antimanic drugs are agents used to treat bipolar disorders or mania associated with other affective disorders.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,antimanic drugs|antimanics|antimanic agent,,,,,,,,,,,,,,,,,,,,,CHEBI:35477,,,,antimanic drug,,CHEBI:35477,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_26708,sodium atom,,,false,,,http://purl.obolibrary.org/obo/CHEBI_22314,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:26708,,,,,,,,,,,,,,,,,,,,,,sodium atom,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_16908,NADH,,"A coenzyme found in all living cells; consists of two nucleotides joined through their 5'-phosphate groups, with one nucleotide containing an adenine base and the other containing nicotinamide.",false,,,http://purl.obolibrary.org/obo/CHEBI_13389,,,,,,,,,,,,,,,,,,,,Wikipedia:Nicotinamide_adenine_dinucleotide|DrugBank:DB00157,,"A coenzyme found in all living cells; consists of two nucleotides joined through their 5'-phosphate groups, with one nucleotide containing an adenine base and the other containing nicotinamide.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:16908,,,,,,,,,,,,,,,,,,,,,,NADH,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_35634,EC 1.17.3.2 (xanthine oxidase) inhibitor,xanthine oxidoreductase inhibitor|xanthine:xanthine oxidase inhibitor|xanthine:O2 oxidoreductase inhibitor|hypoxanthine oxidase inhibitor|xanthine:O2 oxidoreductase inhibitors|xanthine:oxygen oxidoreductase inhibitors|hypoxanthine:oxygen oxidoreductase inhibitor|Schardinger enzyme inhibitors|xanthine oxidase inhibitors|xanthine oxidase (EC 1.17.3.2) inhibitors|hypoxanthine oxidase inhibitors|EC 1.17.3.2 (xanthine oxidase) inhibitors|xanthine oxidoreductase inhibitors|hypoxanthine-xanthine oxidase inhibitor|xanthine:oxygen oxidoreductase inhibitor|hypoxanthine:oxygen oxidoreductase inhibitors|hypoxanthine-xanthine oxidase inhibitors|EC 1.17.3.2 inhibitor|xanthine oxidase (EC 1.17.3.2) inhibitor|xanthine oxidase inhibitor|xanthine:xanthine oxidase inhibitors|EC 1.17.3.2 inhibitors|Schardinger enzyme inhibitor,An EC 1.17.3.* (oxidoreductase acting on CH or CH2 with oxygen as acceptor) inhibitor that interferes with the action of xanthine oxidase (EC 1.17.3.2).,false,,,http://purl.obolibrary.org/obo/CHEBI_76850,,,,,,,,,,,,,,,,,,,,,,An EC 1.17.3.* (oxidoreductase acting on CH or CH2 with oxygen as acceptor) inhibitor that interferes with the action of xanthine oxidase (EC 1.17.3.2).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,xanthine oxidoreductase inhibitor|xanthine:xanthine oxidase inhibitor|xanthine:O2 oxidoreductase inhibitor|hypoxanthine oxidase inhibitor|xanthine:O2 oxidoreductase inhibitors|xanthine:oxygen oxidoreductase inhibitors|hypoxanthine:oxygen oxidoreductase inhibitor|Schardinger enzyme inhibitors|xanthine oxidase inhibitors|xanthine oxidase (EC 1.17.3.2) inhibitors|hypoxanthine oxidase inhibitors|EC 1.17.3.2 (xanthine oxidase) inhibitors|xanthine oxidoreductase inhibitors|hypoxanthine-xanthine oxidase inhibitor|xanthine:oxygen oxidoreductase inhibitor|hypoxanthine:oxygen oxidoreductase inhibitors|hypoxanthine-xanthine oxidase inhibitors|EC 1.17.3.2 inhibitor|xanthine oxidase (EC 1.17.3.2) inhibitor|xanthine oxidase inhibitor|xanthine:xanthine oxidase inhibitors|EC 1.17.3.2 inhibitors|Schardinger enzyme inhibitor,,,,,,,,,,,,,,,,,,,,,CHEBI:35634,,,,EC 1.17.3.2 (xanthine oxidase) inhibitor,,CHEBI:35634,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0002521,leukocyte differentiation,leucocyte differentiation,"The process in which a relatively unspecialized hemopoietic precursor cell acquires the specialized features of a leukocyte. A leukocyte is an achromatic cell of the myeloid or lymphoid lineages capable of ameboid movement, found in blood or other tissue.",false,,,http://purl.obolibrary.org/obo/GO_0030154,,,,,,,,,,,,,,,,,,,,,,"The process in which a relatively unspecialized hemopoietic precursor cell acquires the specialized features of a leukocyte. A leukocyte is an achromatic cell of the myeloid or lymphoid lineages capable of ameboid movement, found in blood or other tissue.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,leucocyte differentiation,,,,,GO:0002521,,,,,,,,,,,,,,,,,,,,,,leukocyte differentiation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100561,FGF-11,FHF-3|Fibroblast growth factor homologous factor 3,,false,,,http://purl.obolibrary.org/obo/IMR_0000049,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FHF-3|Fibroblast growth factor homologous factor 3,,,,,IMR:0100561,,,,,,,,,,,,,,,,,,,,,,FGF-11,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100450,MEKK2,MEK kinase 2|MAPK/ERK kinase kinase 2,,false,,,http://purl.obolibrary.org/obo/IMR_0000234,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MEK kinase 2|MAPK/ERK kinase kinase 2,,,,,IMR:0100450,,,,,,,,,,,,,,,,,,,,,,MEKK2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100109,thymopoietin,,,false,,,http://purl.obolibrary.org/obo/IMR_0100089,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100109,,,,,,,,,,,,,,,,,,,,,,thymopoietin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000004830,NME1,,"Other designations: NDP kinase A|granzyme A-activated DNase|metastasis inhibition factor nm23|non-metastatic cells 1, protein (NM23A) expressed in|nucleoside diphosphate kinase A|tumor metastatic process-associated protein",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,NB|NM23-H1|GAAD|NDPKA|NDPK-A|NBS|NDKA|AWD|NM23,,,,,,,,,,,,17,,,,,,MIM:156490|Vega:OTTHUMG00000137474|HPRD:01131|HGNC:7849|Ensembl:ENSG00000239672,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,NME/NM23 nucleoside diphosphate kinase 1,,,17q21.3,,,,,,,,,,,,,,,,"GO_0000287 (EC: IDA, PMID: 11555662); GO_0000977 (EC: IEA); GO_0002762 (EC: IEA); GO_0003697 (EC: IEA); GO_0004536 (EC: IDA, PMID: 11555662); GO_0004550 (EC: IDA, PMID: 12972261); GO_0005515 (EC: IPI, PMID: 10602478); GO_0005524 (EC: IDA, PMID: 12972261); GO_0005525 (EC: IDA, PMID: 12972261); GO_0005634 (EC: IDA, PMID: 16814409); GO_0005634 (EC: TAS, PMID: 16130169); GO_0005737 (EC: TAS, PMID: 16130169); GO_0005739 (EC: IEA); GO_0005813 (EC: IEA); GO_0005829 (EC: IDA, PMID: 16814409); GO_0005829 (EC: TAS); GO_0006183 (EC: IEA); GO_0006228 (EC: IEA); GO_0006241 (EC: IEA); GO_0006308 (EC: IDA, PMID: 11555662); GO_0006897 (EC: IEA); GO_0007595 (EC: IEA); GO_0008285 (EC: TAS, PMID: 1851158); GO_0010629 (EC: IEA); GO_0010976 (EC: IEA); GO_0014075 (EC: IEA); GO_0015949 (EC: TAS); GO_0019215 (EC: IEA); GO_0019901 (EC: IEA); GO_0021766 (EC: IEA); GO_0032587 (EC: IDA, PMID: 16814409); GO_0033574 (EC: IEA); GO_0035690 (EC: IEA); GO_0042802 (EC: IPI, PMID: 10602478); GO_0042981 (EC: TAS, PMID: 16130169); GO_0043015 (EC: IEA); GO_0043024 (EC: IPI, PMID: 16814409); GO_0043388 (EC: IDA, PMID: 17975005); GO_0044281 (EC: TAS); GO_0044822 (EC: IDA); GO_0048471 (EC: IEA); GO_0050679 (EC: IMP, PMID: 16862176); GO_0051591 (EC: IEA); GO_0055086 (EC: TAS); GO_0071333 (EC: IEA); GO_0071398 (EC: IEA)",,,,,,,,,PMID: 1851158; 2015608; 2056128; 2509941; 2566996; 7916650; 8047138; 8245015; 8270257; 8392752; 8395939; 8810265; 8858107; 9480811; 9488696; 9513729; 9593706; 10512675; 10602478; 10611312; 10618642; 11042679; 11231635; 11274357; 11280768; 11319942; 11555662; 11687967; 11726210; 11776896; 11835509; 11918081; 11919189; 11935309; 11960382; 11963831; 11998956; 12007505; 12105213; 12135660; 12137595; 12163590; 12174914; 12200143; 12405283; 12452062; 12474051; 12477932; 12490715; 12524539; 12601555; 12624546; 12628186; 12669312; 12684753; 12859952; 12883690; 12910292; 12972261; 14499630; 14558955; 14664140; 14960567; 15040016; 15073128; 15129904; 15280446; 15334673; 15489334; 15512982; 15568401; 15592684; 15645378; 15650182; 15684389; 15757202; 15777972; 15833843; 15870434; 15882758; 16011248; 16044917; 16130169; 16189514; 16196087; 16232196; 16277028; 16313181; 16317582; 16415009; 16466905; 16531762; 16631833; 16739125; 16739379; 16759016; 16814409; 16848180; 16862176; 16891807; 16944571; 16957985; 17008916; 17103045; 17155928; 17197349; 17283532; 17314099; 17348207; 17359290; 17578003; 17591363; 17655525; 17688968; 17695492; 17885583; 17918157; 17975005; 18029348; 18058029; 18089805; 18154714; 18219290; 18239814; 18301251; 18307927; 18330957; 18408655; 18440302; 18457437; 18470881; 18476632; 18635542; 18668641; 18676749; 18700747; 18728402; 18781797; 18810774; 18815136; 18996649; 19024519; 19026164; 19060904; 19170058; 19183483; 19186179; 19263457; 19332021; 19513384; 19615732; 19619546; 19624895; 19655221; 19664043; 19664078; 19724852; 19852809; 19951590; 19956735; 20099494; 20101217; 20113651; 20145075; 20209495; 20301782; 20304626; 20403806; 20448457; 20508983; 20559153; 20560137; 20570897; 20599259; 20639865; 20671611; 20713695; 20841469; 20872186; 20877624; 20955383; 20959063; 21045303; 21080107; 21081666; 21085602; 21121676; 21139048; 21169412; 21176535; 21221850; 21265090; 21270158; 21273640; 21350102; 21442621; 21448569; 21469425; 21478336; 21484438; 21553004; 21575865; 21769563; 21846466; 21890473; 21906983; 21913743; 21963094; 21987572; 21988832; 22035418; 22053931; 22268729; 22290468; 22328561; 22349375; 22364921; 22421058; 22429576; 22451184; 22505724; 22531683; 22683585; 22718351; 22863883; 22869372; 22903495; 22920000; 22939629; 23000965; 23137649; 23158994; 23448979; 23464856; 23479363; 23519676; 23583378; 23679306; 23694823; 23725501; 23734265; 23768014; 23818346; 24457600,,,,,,,,,,,,,,,OGG:3000004830,,,,,,,NME/NM23 nucleoside diphosphate kinase 1,,,,,,,,,,,,,"Other designations: NDP kinase A|granzyme A-activated DNase|metastasis inhibition factor nm23|non-metastatic cells 1, protein (NM23A) expressed in|nucleoside diphosphate kinase A|tumor metastatic process-associated protein",,NME1,,,,,,,,,,,,,,,,,,,,,,,4830,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,NME1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0100661,Cln1,G1/S-specific cyclin CLN1,,false,,,http://purl.obolibrary.org/obo/IMR_0100671,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,G1/S-specific cyclin CLN1,,,,,IMR:0100661,,,,,,,,,,,,,,,,,,,,,,Cln1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/NCIT_C3340,polyp,,"A usually exophytic mass attached to the underlying tissue by a broad base or a thin stalk. Polyps can be neoplastic or non-neoplastic. Neoplastic polyps usually represent proliferations of the epithelium, and are commonly seen in the gastrointestinal tract. Polyps of the gastrointestinal tract are often called adenomas, are associated with dysplasia, and may eventually transform into carcinomas. Non-neoplastic polyps may be inflammatory, degenerative, or the result of malformations.",false,,,http://purl.obolibrary.org/obo/TXPO_0004047,,,,,,,,,,,,,,,,,,,,,,"A usually exophytic mass attached to the underlying tissue by a broad base or a thin stalk. Polyps can be neoplastic or non-neoplastic. Neoplastic polyps usually represent proliferations of the epithelium, and are commonly seen in the gastrointestinal tract. Polyps of the gastrointestinal tract are often called adenomas, are associated with dysplasia, and may eventually transform into carcinomas. Non-neoplastic polyps may be inflammatory, degenerative, or the result of malformations.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,NCIT:C3340,,,,,,,,,,,,,,,,,,,,,,polyp,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_5441,glyburide,glibenclamide,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CASRN:10238-21-8|InChIKeyZ:NNLBTZKUZBEKO-UHFFFAOYSA-N|Wikipedia:Glyburide|DrugBank:DB01016|An urea that has formula C23H28ClN3O5S.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,glibenclamide,,,,,CHEBI:5441,,,,,,,,,,,,,,,,,,,,,,glyburide,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010469,60S ribosomal protein L19,,,false,,,http://purl.obolibrary.org/obo/IMR_0000897,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0010469,,,,,,,,,,,,,,,,,,,,,,60S ribosomal protein L19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000023645,PPP1R15A,,"Other designations: growth arrest and DNA damage-inducible protein GADD34|growth arrest and DNA-damage-inducible 34|myeloid differentiation primary response protein MyD116 homolog|protein phosphatase 1 regulatory subunit 15A|protein phosphatase 1, regulatory (inhibitor) subunit 15A",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,GADD34,,,,,,,,,,,,19,,,,,,MIM:611048|Ensembl:ENSG00000087074|HGNC:14375|Vega:OTTHUMG00000183330|HPRD:06572,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"protein phosphatase 1, regulatory subunit 15A",,,19q13.2,,,,,,,,,,,,,,,,"GO_0005515 (EC: IPI, PMID: 11564868); GO_0005783 (EC: IEA); GO_0005829 (EC: TAS); GO_0006417 (EC: IEA); GO_0006915 (EC: IEA); GO_0006974 (EC: TAS, PMID: 9153226); GO_0007050 (EC: TAS, PMID: 9153226); GO_0007179 (EC: TAS); GO_0019901 (EC: IPI, PMID: 11517336); GO_0030512 (EC: TAS); GO_0030968 (EC: IEA)",,,,,,,,,PMID: 8125298; 9153226; 9413226; 10434033; 10490642; 10631107; 11104688; 11517336; 11564868; 12016208; 12168790; 12477932; 12556489; 12724406; 12813455; 14635187; 14670976; 14702039; 14718519; 15231748; 15541008; 16169070; 16337513; 16344560; 16455055; 17273797; 18362886; 18794359; 19131336; 19776135; 19901557; 20040105; 20467438; 20800603; 21145461; 21518769; 21988832; 22145905; 23412101; 24092754,,,,,,,,,,,,,,,OGG:3000023645,,,,,,,"protein phosphatase 1, regulatory subunit 15A",,,,,,,,,,,,,"Other designations: growth arrest and DNA damage-inducible protein GADD34|growth arrest and DNA-damage-inducible 34|myeloid differentiation primary response protein MyD116 homolog|protein phosphatase 1 regulatory subunit 15A|protein phosphatase 1, regulatory (inhibitor) subunit 15A",,PPP1R15A,,,,,,,,,,,,,,,,,,,,,,,23645,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,PPP1R15A,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000353322,ANKRD37,,Other designations: ankyrin repeat domain-containing protein 37|hLrp2bp|low density lipoprotein receptor-related protein binding protein|low-density lipoprotein receptor-related protein 2-binding protein,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,Lrp2bp,,,,,,,,,,,,4,,,,,,Vega:OTTHUMG00000160459|HGNC:29593|Ensembl:ENSG00000186352|HPRD:17461,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,ankyrin repeat domain 37,,,4q35.1,,,,,,,,,,,,,,,,GO_0005634 (EC: IEA); GO_0005737 (EC: IEA),,,,,,,,,PMID: 12477932; 15489334; 15809689; 19491311; 21890473; 24250222,,,,,,,,,,,,,,,OGG:3000353322,,,,,,,ankyrin repeat domain 37,,,,,,,,,,,,,Other designations: ankyrin repeat domain-containing protein 37|hLrp2bp|low density lipoprotein receptor-related protein binding protein|low-density lipoprotein receptor-related protein 2-binding protein,,ANKRD37,,,,,,,,,,,,,,,,,,,,,,,353322,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,ANKRD37,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OBI_1110008,occurrence of infectious disease,,Is an occurrence of a disease caused by an infection,false,,,http://purl.obolibrary.org/obo/OGMS_0000063,,,,,,,,,,,,,,,,,,,,,,Is an occurrence of a disease caused by an infection,IEDB,,,,occurrence of infectious disease,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IAO_0000123,,,,,,,,,,,,,,,,,,,,,,,,,,,,,OBI:1110008,,,,,,,,,,,,,,,,,,,,,,occurrence of infectious disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IEDB
http://purl.obolibrary.org/obo/OMIT_0003800,neoplastic cell Transformation,,A changing process in which cells become to have neoplastic quality.,false,,,http://purl.obolibrary.org/obo/GO_0030154,,,,,,,,,,,,,,,,,,,,,,A changing process in which cells become to have neoplastic quality.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,OMIT:0003800,,,,,,,,,,,,,,,,,,,,,,neoplastic cell Transformation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000578,IFN alpha-8,,,false,,,http://purl.obolibrary.org/obo/IMR_0100386,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000578,,,,,,,,,,,,,,,,,,,,,,IFN alpha-8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003579,sphingomyelin biosynthetic process[Niemann Pick Disease Type A],sphingomyelin anabolism|sphingomyelin formation|sphingomyelin biosynthesis|sphingomyelin synthesis,"The chemical reactions and pathways resulting in the formation of sphingomyelin, N-acyl-4-sphingenyl-1-O-phosphorylcholine.
This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type A.",false,,,http://purl.obolibrary.org/obo/GO_0006686|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways resulting in the formation of sphingomyelin, N-acyl-4-sphingenyl-1-O-phosphorylcholine.
This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type A.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_64583,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001482,,,,,,sphingomyelin anabolism|sphingomyelin formation|sphingomyelin biosynthesis|sphingomyelin synthesis,,,,,TXPO:0003579,,,,,,,,,,,,,,,,,,,,,,sphingomyelin biosynthetic process[Niemann Pick Disease Type A],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003573,ASPA (predicted)(human)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001135|http://purl.obolibrary.org/obo/TXPO_0003840,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:443|https://reactome.org/content/detail/R-HSA-5691507|https://omim.org/entry/608034|PMID:15784740,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000000443,,,,,,,,,,,,,TXPO:0003573,,,,,,,,,,,,,,,,,,,,,,ASPA (predicted)(human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003575,substance with cytokine role,,Substance with cytokine  role is a subtype of substance with role.|This entity is inferred from Description Logic.,false,,,http://purl.obolibrary.org/obo/CHEBI_24431,,,,,,,,,,,,,,,,,,,,,,Substance with cytokine  role is a subtype of substance with role.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003575,,,,,,,,,,,,,,,,,,,,This entity is inferred from Description Logic.,,substance with cytokine role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003576,Insulin resistance (process) [Type II Diabetes],,"Insulin resistance (process) is a subtype of decreasing sensitivity: A process that changes the sensitivity to the circulating insulin to be lower.
This entity is a specific course-dependent process. This process can constitute the course of type II diabetes.",false,,,http://purl.obolibrary.org/obo/TXPO_0003342|http://purl.obolibrary.org/obo/TXPO_0002189,,,,,,,,,,,,,,,,,,,,PMID:26006114,,"Insulin resistance (process) is a subtype of decreasing sensitivity: A process that changes the sensitivity to the circulating insulin to be lower.
This entity is a specific course-dependent process. This process can constitute the course of type II diabetes.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003581,,,,,,,,,,,TXPO:0003576,,,,,,,,,,,,,,,,,,,,,,Insulin resistance (process) [Type II Diabetes],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003570,S1P -apoptosis inhibitor[Phospholipidosis - positive regulation of apoptosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001849|http://purl.obolibrary.org/obo/CHEBI_37550,,,,,,,,,,,,,,,,,,,,PMID:29147025,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_68494,,,,,,,,,,TXPO:0003570,,,,,,,,,,,,,,,,,,,,,,S1P -apoptosis inhibitor[Phospholipidosis - positive regulation of apoptosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003571,PLA2positively regulator of immune response (canonical) [Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003213|http://purl.obolibrary.org/obo/TXPO_0001804,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000283,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003572|http://purl.obolibrary.org/obo/TXPO_0003671,,,,,,,,,,TXPO:0003571,,,,,,,,,,,,,,,,,,,,,,PLA2positively regulator of immune response (canonical) [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003578,negative regulation of phospholipid hydrolysis [Phospholipidosis (latent)],,"A process that stops, prevents, or reduces the frequency, rate or extent of phospholipid hydrolysis.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (latent).",false,,,http://purl.obolibrary.org/obo/TXPO_0003448,,,,,,,,,,,,,,,,,,,,,,"A process that stops, prevents, or reduces the frequency, rate or extent of phospholipid hydrolysis.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (latent).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001908,,,,,,,,,,,TXPO:0003578,,,,,,,,,,,,,,,,,,,,,,negative regulation of phospholipid hydrolysis [Phospholipidosis (latent)],,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003410,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003577,insulin absolute deficiency,,"Insulin deficiency is a subtype of malfunctioning process: A process that lacks performing the insulin function required absolutely.
This entity is a specific course-dependent process. This process can constitute the course of type I diabetes.",false,,,http://purl.obolibrary.org/obo/TXPO_0003289,,,,,,,,,,,,,,,,,,,,,,"Insulin deficiency is a subtype of malfunctioning process: A process that lacks performing the insulin function required absolutely.
This entity is a specific course-dependent process. This process can constitute the course of type I diabetes.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003290,,,,,,,,,,,TXPO:0003577,,,,,,,,,,,,,,,,,,,,,,insulin absolute deficiency,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003574,DAB2 (predicted)(human)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001135|http://purl.obolibrary.org/obo/TXPO_0003841,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1601|PMID:25331956|PMID:23781020|PMID:11387212|PMID:27398911,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000001601,,,http://purl.obolibrary.org/obo/TXPO_0003888,,,,,,,,,,TXPO:0003574,,,,,,,PMID:19000037,,,,,,,,,,,,,,,DAB2 (predicted)(human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003572,positive regulator of immune response,,,false,,,http://purl.obolibrary.org/obo/TXPO_0003726,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000192,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003572,,,,,,,A role played by the entity which positivey regulates the process of infmammatory response.,,,,,,,,,,,,,,,positive regulator of immune response,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000255,PDK,3-phosphoinositide dependent protein kinase-1|phosphatidylinositol-dependent kinase|hPDK1,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001966,,,,IMR:0010402,3-phosphoinositide dependent protein kinase-1|phosphatidylinositol-dependent kinase|hPDK1,,,,,IMR:0000255,,,,,,,,,,,,,,,,,,,,,,PDK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000058,CASP8 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:12370|NCBI-Human-GeneID:841|NCBI-Rat-GeneID:64044,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000841,,,,,,,,,,,,,TXPO:1000058,,,,,,,,,,,,,,,,,,,,,,CASP8 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000057,LRRC16B (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000090668,,,,,,,,,,,,,TXPO:1000057,,,,,,,,,,,,,,,,,,,,,,LRRC16B (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000050,Btg2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:12227|NCBI-Human-GeneID:7832|NCBI-Rat-GeneID:29619,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000007832,,,,,,,,,,,,,TXPO:1000050,,,,,,,,,,,,,,,,,,,,,,Btg2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000059,CASP8AP2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:313128|NCBI-Mouse-GeneID:26885|NCBI-Human-GeneID:9994,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000009994,,,,,,,,,,,,,TXPO:1000059,,,,,,,,,,,,,,,,,,,,,,CASP8AP2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000051,C18ORF (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:1000051,,,,,,,,,,,,,,,,,,,,,,C18ORF (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000055,CA12 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:771,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000771,,,,,,,,,,,,,TXPO:1000055,,,,,,,,,,,,,,,,,,,,,,CA12 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000052,C1orf162 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:128346,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000128346,,,,,,,,,,,,,TXPO:1000052,,,,,,,,,,,,,,,,,,,,,,C1orf162 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000053,C6orf203 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:51250,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000051250,,,,,,,,,,,,,TXPO:1000053,,,,,,,,,,,,,,,,,,,,,,C6orf203 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000054,C9orf72 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:73205|NCBI-Human-GeneID:203228,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000203228,,,,,,,,,,,,,TXPO:1000054,,,,,,,,,,,,,,,,,,,,,,C9orf72 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000056,CACNB1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:12295|NCBI-Rat-GeneID:50688|NCBI-Human-GeneID:782,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000782,,,,,,,,,,,,,TXPO:1000056,,,,,,,,,,,,,,,,,,,,,,CACNB1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100410,NT-4/5,NT-4|neurotrophin-5|neurotrophin-4|NT-5|neurotrophic factor 5|neurotrophic factor 4,,false,,,http://purl.obolibrary.org/obo/IMR_0000034,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,NT-4|neurotrophin-5|neurotrophin-4|NT-5|neurotrophic factor 5|neurotrophic factor 4,,,,,IMR:0100410,,,,,,,,,,,,,,,,,,,,,,NT-4/5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000081575,APOLD1,,Other designations: apolipoprotein L domain-containing protein 1|vascular early response gene protein,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,VERGE,,,,,,,,,,,,12,,,,,,Ensembl:ENSG00000178878|HGNC:25268|Vega:OTTHUMG00000153561|MIM:612456|HPRD:13153,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,apolipoprotein L domain containing 1,,,12p13.1,,,,,,,,,,,,,,,,GO_0001525 (EC: IEA); GO_0001666 (EC: IEA); GO_0005576 (EC: IEA); GO_0005886 (EC: IEA); GO_0006869 (EC: IEA); GO_0008289 (EC: IEA); GO_0016021 (EC: IEA); GO_0030154 (EC: IEA); GO_0042118 (EC: IEA); GO_0042157 (EC: IEA); GO_0045601 (EC: IEA),,,,,,,,,PMID: 8125298; 11076863; 11230166; 12477932; 14702039; 15102925; 15489334; 15489336; 16344560; 16381901; 19738201; 19913121; 20628086; 24250222,,,,,,,,,,,,,,,OGG:3000081575,,,,,,,apolipoprotein L domain containing 1,,,,,,,,,,,,,Other designations: apolipoprotein L domain-containing protein 1|vascular early response gene protein,,APOLD1,,,,,,,,,,,,,,,,,,,,,,,81575,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,APOLD1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0001428,BMP-4,Bone morphogenetic protein 4|BMP4,,false,,,http://purl.obolibrary.org/obo/IMR_0003083,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Bone morphogenetic protein 4|BMP4,,,,,IMR:0001428,,,,,,,,,,,,,,,,,,,,,,BMP-4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_35497,androgen antagonist,antiandrogen,A compound which inhibits or antagonises the biosynthesis or actions of androgens.,false,,,http://purl.obolibrary.org/obo/CHEBI_49020|http://purl.obolibrary.org/obo/CHEBI_23888,,,,,,,,,,,,,,,,,,,,,,A compound which inhibits or antagonises the biosynthesis or actions of androgens.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,antiandrogen,,,,,,,,,,,,,,,,,,,,,CHEBI:35497,,,,androgen antagonist,,CHEBI:35497,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100419,TR alpha 2,c-erbA-alpha 2,,false,,,http://purl.obolibrary.org/obo/IMR_0000086,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,c-erbA-alpha 2,,,,,IMR:0100419,,,,,,,,,,,,,,,,,,,,,,TR alpha 2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000479,hyperfunction of long-chain fatty acid import into peroxisome [Eosinophilic granular degeneration],,"Hyperfunction of long-chain fatty acid import into peroxisome is a subtype of hyperfunction of transport: A process that performs an excesssive long-chain fatty acid import into peroxisome.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/TXPO_0000478|http://purl.obolibrary.org/obo/TXPO_0001729,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of long-chain fatty acid import into peroxisome is a subtype of hyperfunction of transport: A process that performs an excesssive long-chain fatty acid import into peroxisome.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001046|http://purl.obolibrary.org/obo/TXPO_0001051|http://purl.obolibrary.org/obo/TXPO_0001057|http://purl.obolibrary.org/obo/TXPO_0001069|http://purl.obolibrary.org/obo/TXPO_0001067|http://purl.obolibrary.org/obo/TXPO_0001068,,,,,,http://purl.obolibrary.org/obo/TXPO_0000179,,,,,,,,,,,TXPO:0000479,,,,,,,,,,,,,,,,,,,,,,hyperfunction of long-chain fatty acid import into peroxisome [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000474,keeping quality,,Keeping quality is a subtype of changing quality: A process that keeps the quality of the object constant.,false,,,http://purl.obolibrary.org/obo/TXPO_0000415,,,,,,,,,,,,,,,,,,,,,,Keeping quality is a subtype of changing quality: A process that keeps the quality of the object constant.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000474,,,,,,,,,,,,,,,,,,,,,,keeping quality,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000470,lysosome homeostasis,,Lysosome homeostasis is a subtype of homeostatic process: A process that that preserves a lysosome in a stable functional or structural state.,false,,,http://purl.obolibrary.org/obo/GO_0042592,,,,,,,,,,,,,,,,,,,,,,Lysosome homeostasis is a subtype of homeostatic process: A process that that preserves a lysosome in a stable functional or structural state.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000470,,,,,,,"All of the lysosomal enzymes are acid hydrolases, which are active at the acidic pH (about 5) that is maintained within lysosomes but not at the neutral pH (about 7.2) characteristic of the rest of the cytoplasm (Figure 9.35). The requirement of these lysosomal hydrolases for acidic pH provides double protection against uncontrolled digestion of the contents of the cytosol; even if the lysosomal membrane were to break down, the released acid hydrolases would be inactive at the neutral pH of the cytosol.",,,,,,,,,,,,,,,lysosome homeostasis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000472,ground glass appearance dependent molecule (canonical),,"Ground glass appearance dependent molecule is a subtype of toxic course dependent chemical entity.
This molecule can participate in the course of ground glass appearance as a gene product.
Gene profile:caonical that described in textbooks or articles.",false,,,http://purl.obolibrary.org/obo/TXPO_0000984,,,,,,,,,,,,,,,,,,,,,,"Ground glass appearance dependent molecule is a subtype of toxic course dependent chemical entity.
This molecule can participate in the course of ground glass appearance as a gene product.
Gene profile:caonical that described in textbooks or articles.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000472,,,,,,,,,,,,,,,,,,,,,,ground glass appearance dependent molecule (canonical),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000477,insulin signaling (primitive),,"Insulin signaling (primitive) is a subtype of signaing (primitive), in which a signal mediated by insulin.",false,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,,,"Insulin signaling (primitive) is a subtype of signaing (primitive), in which a signal mediated by insulin.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0008286,,,,,,,,,,,,,,,,TXPO:0000477,,,,,,,,,,,,,,,,,,,,,,insulin signaling (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000471,signaling,,Signaling is a subtype of transmitting: A process that transmits signals from medium A to medium B.,false,,,http://purl.obolibrary.org/obo/TXPO_0000442,,,,,,,,,,,,,,,,,,,,,,Signaling is a subtype of transmitting: A process that transmits signals from medium A to medium B.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000471,,,,,,,,,,,,,,,,,,,,,,signaling,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000475,changing pressure,,Changing pressure is a subtype of changing quality: A process that changes the pressure of the object .,false,,,http://purl.obolibrary.org/obo/TXPO_0000415,,,,,,,,,,,,,,,,,,,,,,Changing pressure is a subtype of changing quality: A process that changes the pressure of the object .,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000475,,,,,,,,,,,,,,,,,,,,,,changing pressure,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000473,hyperfunction of increasing number,,"Hyperfunction of increasing number is a subtype of hyperfunction of increasing: A process that performs an excessive nu,ber of the object.",false,,,http://purl.obolibrary.org/obo/TXPO_0001724,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of increasing number is a subtype of hyperfunction of increasing: A process that performs an excessive nu,ber of the object.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000473,,,,,,,,,,,,,,,,,,,,,,hyperfunction of increasing number,,,,,,http://purl.obolibrary.org/obo/TXPO_0000093,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000478,hyperfunction of long-chain fatty acid import into peroxisome,,Hyperfunction of lipid transport to peroxisome is a subtype of hyperfunction of transport: A process that performs an excesssive lipid transport to peroxisome.,false,,,http://purl.obolibrary.org/obo/TXPO_0002351,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of lipid transport to peroxisome is a subtype of hyperfunction of transport: A process that performs an excesssive lipid transport to peroxisome.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000478,,,,,,,,,,,,,,,,,,,,,,hyperfunction of long-chain fatty acid import into peroxisome,,,,,,http://purl.obolibrary.org/obo/GO_0015910,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000476,changing temperature,,Changing temperature is a subtype of changing quality: A process that changes the temperature of the object.,false,,,http://purl.obolibrary.org/obo/TXPO_0000415,,,,,,,,,,,,,,,,,,,,,,Changing temperature is a subtype of changing quality: A process that changes the temperature of the object.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000476,,,,,,,,,,,,,,,,,,,,,,changing temperature,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100645,Sic1,CDK inhibitor p40|SIC1 protein,,false,,,http://purl.obolibrary.org/obo/IMR_0000445,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CDK inhibitor p40|SIC1 protein,,,,,IMR:0100645,,,,,,,,,,,,,,,,,,,,,,Sic1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001145,PKC alpha,,,false,,,http://purl.obolibrary.org/obo/IMR_0100486,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001145,,,,,,,,,,,,,,,,,,,,,,PKC alpha,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0044843,cell cycle G1/S phase transition,,The cell cycle process by which a cell in G1 phase commits to S phase.,false,,,http://purl.obolibrary.org/obo/GO_0044770,,,,,,,,,,,,,,,,,,,,,,The cell cycle process by which a cell in G1 phase commits to S phase.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0044843,,,,,,,,,,,,,,,,,,,,,,cell cycle G1/S phase transition,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000434,Vav,,,false,,,http://purl.obolibrary.org/obo/IMR_0001954,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000434,,,,,,,,,,,,,,,,,,,,,,Vav,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000408,Myb,c-Myb,,false,,,http://purl.obolibrary.org/obo/IMR_0000868,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,c-Myb,,,,,IMR:0000408,,,,,,,,,,,,,,,,,,,,,,Myb,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_37956,histamine antagonist,antihistaminics|antihistamine|antihistaminico|histamine receptor blocker|histamine receptor blockers|antihistamines,"Histamine antagonists are the drugs that bind to but do not activate histamine receptors, thereby blocking the actions of histamine or histamine agonists.",false,,,http://purl.obolibrary.org/obo/CHEBI_37957|http://purl.obolibrary.org/obo/CHEBI_48706,,,,,,,,,,,,,,,,,,,,PMID:22035879,,"Histamine antagonists are the drugs that bind to but do not activate histamine receptors, thereby blocking the actions of histamine or histamine agonists.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,antihistaminics|antihistamine|antihistaminico|histamine receptor blocker|histamine receptor blockers|antihistamines,,,,,,,,,,,,,,,,,,,,,CHEBI:37956,,,,histamine antagonist,,CHEBI:37956,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000064327,LMBR1,,Other designations: differentiation-related gene 14 protein|limb region 1 homolog|limb region 1 protein homolog,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,TPT|PPD2|ACHP|C7orf2|ZRS|DIF14,,,,,,,,,,,,7,,,,,,Ensembl:ENSG00000105983|HGNC:13243|MIM:605522|HPRD:05700,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,limb development membrane protein 1,,,7q36,,,,,,,,,,,,,,,,GO_0016021 (EC: IEA); GO_0042733 (EC: IEA),,,,,,,,,PMID: 8533803; 9847074; 10329000; 10945466; 11076863; 11090342; 11333865; 11606546; 12032320; 12477932; 12491086; 12690205; 12837695; 12853948; 14702039; 14727139; 15489334; 15489336; 16344560; 16381901; 17152067; 17300748; 18698406; 19136951; 20068592; 20379614; 20446115; 21139048; 21906983; 22495965; 22786669,,,,,,,,,,,,,,,OGG:3000064327,,,,,,,limb development membrane protein 1,,,,,,,,,,,,,Other designations: differentiation-related gene 14 protein|limb region 1 homolog|limb region 1 protein homolog,,LMBR1,,,,,,,,,,,,,,,,,,,,,,,64327,tcag7.573,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,LMBR1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/UBERON_0000966,retina,inner layer of eyeball,"The retina is the innermost layer or coating at the back of the eyeball, which is sensitive to light and in which the optic nerve terminates.",false,,,http://purl.obolibrary.org/obo/UBERON_0000064,,,,,,,,,,,,,,,,,,,,http://en.wikipedia.org/wiki/Retina|FMA:58301,,"The retina is the innermost layer or coating at the back of the eyeball, which is sensitive to light and in which the optic nerve terminates.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,inner layer of eyeball,,,,,UBERON:0000966,,,,,,,,,,,,,,,,,,,,,,retina,,,,http://upload.wikimedia.org/wikipedia/commons/e/ed/Human_eye_cross-sectional_view_grayscale.png,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000674,A-Raf,,,false,,,http://purl.obolibrary.org/obo/IMR_0000231,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000674,,,,,,,,,,,,,,,,,,,,,,A-Raf,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002930,JNK - signalling factor (canonical)[ER stress - inflammation],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001813,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001898,,,,,,,,,,TXPO:0002930,,,,,,,,,,,,,,,,,,,,,,JNK - signalling factor (canonical)[ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002932,EIF2A - translation initiation factor (canonical)[ER stress - translation],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001275,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002933,,,,,,,,,,TXPO:0002932,,,,,,,,,,,,,,,,,,,,,,EIF2A - translation initiation factor (canonical)[ER stress - translation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002939,ASK activation [ER stress - apoptosis - IRE1-TRAF2-ASK-JNK-Bcl2 pathway],,"ASK activation is a subtype of molecular activation: A process that changes the activity of one of the ASK (apoptosis signal-regulating kinase) family to be higher.
This process is dependent on the apoptosis and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002824,,,,,,,,,,,,,,,,,,,,PMID:25232821|PMID:12843613,,"ASK activation is a subtype of molecular activation: A process that changes the activity of one of the ASK (apoptosis signal-regulating kinase) family to be higher.
This process is dependent on the apoptosis and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002938,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002945,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002940,,,,,,,,,,,TXPO:0002939,,,,,,,,,,,,,,,,,,,,,,ASK activation [ER stress - apoptosis - IRE1-TRAF2-ASK-JNK-Bcl2 pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002937,TRAF2 activation by IRE1 [ER stress - apoptosis - IRE1−TRAF2-ASK-JNK-Bcl2 pathway],,"TRAF2 activation by IRE1 is a subtype of molecular activation: A process that changes the activity of the TARF2 to be higher by IRE1.
This process is dependent on the IRE1−TRAF2-ASK-JNK-Bcl2 pathway mediated apoptosis and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002820,,,,,,,,,,,,,,,,,,,,PMID:25232821,,"TRAF2 activation by IRE1 is a subtype of molecular activation: A process that changes the activity of the TARF2 to be higher by IRE1.
This process is dependent on the IRE1−TRAF2-ASK-JNK-Bcl2 pathway mediated apoptosis and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002941,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002938,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002939,,,,,,,,,,,TXPO:0002937,,,,,,,,,,,,,,,,,,,,,,TRAF2 activation by IRE1 [ER stress - apoptosis - IRE1−TRAF2-ASK-JNK-Bcl2 pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002934,GADD34 (canonical)[ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000150|http://purl.obolibrary.org/obo/TXPO_0000871,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:17872|NCBI-Human-GeneID:23645|NCBI-Rat-GeneID:171071,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003675,,,,,,,,,,TXPO:0002934,,,,,,,,,,,,,,,,,,,,,,GADD34 (canonical)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002931,P-EIF2A - translation initiation inhibitor (canonical)[ER stress - translation],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000829,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001909,,,,,,,,,,TXPO:0002931,,,,,,,,,,,,,,,,,,,,,,P-EIF2A - translation initiation inhibitor (canonical)[ER stress - translation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002933,positive regulator role of translational initiation,,"A role played by the entity that activates, or increases the frequency, rate or extent of translation initiation",false,,,http://purl.obolibrary.org/obo/TXPO_0002557,,,,,,,,,,,,,,,,,,,,,,"A role played by the entity that activates, or increases the frequency, rate or extent of translation initiation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002933,,,,,,,,,,,,,,,,,,,,,,positive regulator role of translational initiation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002936,IRE1-Traf2-ASK-JNK-Bcl2 pathway [ER stress - apoptosis],,"IRE1-Traf2-ASK-JNK-Bcl2 pathway is a subtype of IRE1 signaling (integrated pathway): Sequence of linked reactions, which has IRE1-Traf2-ASK-JNK-BCL2 pathway and gene regulation. This pathway is dependent on the apoptosis and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002563,,,,,,,,,,,,,,,,,,,"IRE1-TRAF2-ASK1 complex
A protein complex of the endoplasmic reticulum membrane that consists of IRE1 (Inositol-requiring enzyme-1), TRAF2 (TNF receptor-associated factor 2) and ASK1 (Apoptosis signal-regulating kinase 1, a MAP3K).
http://purl.obolibrary.org/obo/GO_1990604",,,"IRE1-Traf2-ASK-JNK-Bcl2 pathway is a subtype of IRE1 signaling (integrated pathway): Sequence of linked reactions, which has IRE1-Traf2-ASK-JNK-BCL2 pathway and gene regulation. This pathway is dependent on the apoptosis and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002939|http://purl.obolibrary.org/obo/TXPO_0002937|http://purl.obolibrary.org/obo/TXPO_0002940|http://purl.obolibrary.org/obo/TXPO_0002946,,http://purl.obolibrary.org/obo/TXPO_0002875,,,,,,,,,,,,,,,,TXPO:0002936,,,,,,,,,,,,,,,,,,,,,,IRE1-Traf2-ASK-JNK-Bcl2 pathway [ER stress - apoptosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002935,GADD34 - phosphatase (canonical)[ER stress - translation],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002934,,,,,,,,,,,,,,,,,,,,http://omim.org/entry/611048|http://www.ncbi.nlm.nih.gov/gene/23645,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002935,,,,,,,,,,,,,,,,,,,,,,GADD34 - phosphatase (canonical)[ER stress - translation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002938,TRAF2 -IRE1 adaptor protein (canonical)[ER stress - apotosis -IRE1-JNK],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002818,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000462,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003657,,,,,,,,,,TXPO:0002938,,,,,,,,,,,,,,,,,,,,,,TRAF2 -IRE1 adaptor protein (canonical)[ER stress - apotosis -IRE1-JNK],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000976,LRP10,LDL receptor-related protein 10,,false,,,http://purl.obolibrary.org/obo/IMR_0100798,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,LDL receptor-related protein 10,,,,,IMR:0000976,,,,,,,,,,,,,,,,,,,,,,LRP10,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0034478,phosphatidylglycerol catabolic process,phosphatidylglycerol degradation|phosphatidylglycerol catabolism|phosphatidylglycerol breakdown,"The chemical reactions and pathways resulting in the breakdown of phosphatidylglycerols, any of a class of glycerophospholipids in which the phosphatidyl group is esterified to the hydroxyl group of glycerol.",false,,,http://purl.obolibrary.org/obo/GO_0046471|http://purl.obolibrary.org/obo/GO_0046475,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways resulting in the breakdown of phosphatidylglycerols, any of a class of glycerophospholipids in which the phosphatidyl group is esterified to the hydroxyl group of glycerol.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_17517,,,,,,,,,,,,,,,,,,phosphatidylglycerol degradation|phosphatidylglycerol catabolism|phosphatidylglycerol breakdown,,,,,GO:0034478,,,,,,,,,,,,,,,,,,,,,,phosphatidylglycerol catabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000008647,ABCB11,,"Other designations: ABC member 16, MDR/TAP subfamily|ATP-binding cassette sub-family B member 11|bile salt export pump|progressive familial intrahepatic cholestasis 2|sister p-glycoprotein",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,PFIC-2|BRIC2|SPGP|BSEP|PFIC2|ABC16|PGY4,,,,,,,,,,,,,,,,,,http://omim.org/entry/603201,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"GO_0000139 (EC: IBA); GO_0005215 (EC: TAS, PMID:9806540); GO_0005524 (EC: IEA); GO_0005886 (EC: TAS); GO_0005887 (EC: TAS, PMID:9806540); GO_0006699 (EC: TAS); GO_0006810 (EC: TAS, PMID:9806540); GO_0008206 (EC: TAS); GO_0008554 (EC: TAS, PMID:9806540); GO_0015126 (EC: IBA); GO_0015432 (EC: TAS, PMID:9806540); GO_0015721 (EC: TAS); GO_0015722 (EC: IBA); GO_0016020 (EC: TAS, PMID:9806540); GO_0016021 (EC: IBA); GO_0016324 (EC: IBA); GO_0035725 (EC: TAS, PMID:9806540); GO_0042626 (EC: IBA); GO_0044281 (EC: TAS); GO_0046581 (EC: IBA); GO_0055085 (EC: IBA); GO_0070062 (EC: IDA, PMID:19056867)",,,,,,,,,PMID:9545351; 9806540; 10579978; 11172067; 11495894; 11600213; 11745042; 11783115; 11815775; 11829140; 12825874; 14762791; 14999697; 15077010; 15159385; 15300568; 15471871; 15791618; 16039748; 16290310; 16749857; 16763017; 16871584; 16890614; 16941683; 17264802; 17622941; 18176959; 18270374; 18395098; 18521185; 18660489; 18668439; 18676680; 18692205; 18987030; 19056867; 19060910; 19101985; 19170196; 19343046; 19408031; 19571440; 19625176; 19669124; 19692168; 19821532; 19833092; 19845854; 19888660; 19898482; 19913121; 19937311; 20010382; 20028269; 20147439; 20163776; 20232290; 20301474; 20379614; 20414253; 20447715; 20453000; 20628086; 20683201; 20702406; 20723035; 20855565; 20857261; 20858683; 20883210; 21139048; 21386085; 21490445; 21691112; 21766090; 21811948; 21909109; 21988832; 22001757; 22098322; 22161577; 22673116; 22681771; 23022423; 23279303; 23750872; 23876151; 23929842; 24058526; 24366234; 24378332,,,,,,,,,,,,,,,OGG:3000008647,,,,,,,"ATP-binding cassette, sub-family B (MDR/TAP), member 11",,,,,,,,,,,,,"Other designations: ABC member 16, MDR/TAP subfamily|ATP-binding cassette sub-family B member 11|bile salt export pump|progressive familial intrahepatic cholestasis 2|sister p-glycoprotein",,ABCB11,,,,,,,,,,,,,,,,,,,,,,,8647,,,,,,,,,,,,,,,,,,,,,,,,,,,"ATP-binding cassette, sub-family B (MDR/TAP), member 11",,
http://purl.obolibrary.org/obo/GO_0032981,mitochondrial respiratory chain complex I assembly,mitochondrial complex I assembly|mitochondrial NADH dehydrogenase complex (ubiquinone) assembly,"The aggregation, arrangement and bonding together of a set of components to form mitochondrial respiratory chain complex I.",false,,,http://purl.obolibrary.org/obo/GO_0033108,,,,,,,,,,,,,,,,,,,,,,"The aggregation, arrangement and bonding together of a set of components to form mitochondrial respiratory chain complex I.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,mitochondrial complex I assembly|mitochondrial NADH dehydrogenase complex (ubiquinone) assembly,,,,,GO:0032981,,,,,,,,,,,,,,,,,,,,,,mitochondrial respiratory chain complex I assembly,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_44185,methotrexate,"Trexall|N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid|methotrexate|4-amino-N(10)-methylpteroylglutamic acid|Ledertrexate|Rheumatrex|metotrexato|MTX|Emtexate|4-amino-10-methylfolic acid|methotrexatum|METHOTREXATE|Methotrexate|N-(4-{[(2,4-diaminopteridin-6-yl)methyl](methyl)amino}benzoyl)-L-glutamic acid",,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:59-05-2|LINCS:LSM-5690|Beilstein:70669|DrugBank:DB00563|Drug_Central:1751,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35705|http://purl.obolibrary.org/obo/CHEBI_35610|http://purl.obolibrary.org/obo/CHEBI_50683|http://purl.obolibrary.org/obo/CHEBI_59517|http://purl.obolibrary.org/obo/CHEBI_35221|http://purl.obolibrary.org/obo/CHEBI_50177|http://purl.obolibrary.org/obo/CHEBI_50691|http://purl.obolibrary.org/obo/CHEBI_35842,,,,,"METHOTREXATE|Methotrexate|N-(4-{[(2,4-diaminopteridin-6-yl)methyl](methyl)amino}benzoyl)-L-glutamic acid",,"Trexall|N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid|methotrexate|4-amino-N(10)-methylpteroylglutamic acid|Ledertrexate|Rheumatrex|metotrexato|MTX|Emtexate|4-amino-10-methylfolic acid|methotrexatum",,,,,,,,,,,,,,,,,,,,,CHEBI:44185,,,,methotrexate,,CHEBI:44185,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100465,MyD88,myeloid differentiation factor 88,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003682,,,,,myeloid differentiation factor 88,,,,,IMR:0100465,,,,,,,,,,,,,,,,,,,,,,MyD88,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004236,TLR9(human)[hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/IMR_0001464,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:54106|PMID:30894684,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004296,,,,,,,,,,TXPO:0004236,,,,,,,,,,,,,,,,,,,,,,TLR9(human)[hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004230,JNK (canonical)[mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/IMR_0000225|http://purl.obolibrary.org/obo/TXPO_1000216|http://purl.obolibrary.org/obo/TXPO_0004293,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:5599|NCBI-Mouse-GeneID:26419|NCBI-Rat-GeneID:116554|PMID:31623280|PMID:23299992|PMID:30898010|PMID:29222479|PMID:31649547,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004230,,,,,,,,,,,,,,,,,,,,,,JNK (canonical)[mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004235,TLR9(human)[mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003603|http://purl.obolibrary.org/obo/IMR_0001464,,,,,,,,,,,,,,,,,,,,PMID:31623280|NCBI-Human-GeneID:54106|PMID:30894684,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004296,,,,,,,,,,TXPO:0004235,,,,,,,,,,,,,,,,,,,,,,TLR9(human)[mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004239,cyclin B1-CDK1 complex - inactive form (canonical)[mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003603|http://purl.obolibrary.org/obo/TXPO_0004238,,,,,,,,,,,,,,,,,,,,PMID:24746669,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004220|http://purl.obolibrary.org/obo/TXPO_0003611,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0002355,,,,,,,,,,,,,,TXPO:0004239,,,,,,,,,,,,,,,,,,,,,,cyclin B1-CDK1 complex - inactive form (canonical)[mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004232,DNM1L(human)[mitochondrial disorder],DRP1(human)[mitochondrial disorder],,false,,,http://purl.obolibrary.org/obo/TXPO_0003603|http://purl.obolibrary.org/obo/TXPO_0004231,,,,,,,,,,,,,,,,,,,"PMID:30894684,  Hepatocarcinoma cell",NCBI-Human-GeneID:10059,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,DRP1(human)[mitochondrial disorder],,,,,TXPO:0004232,,,,,,,,,,,,,,,,,,,,,,DNM1L(human)[mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004231,DNM1L (mol),DRP1 (mol),,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:74006|NCBI-Rat-GeneID:114114|NCBI-Human-GeneID:10059,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,DRP1 (mol),,,,,TXPO:0004231,,,,,,,,,,,,,,,,,,,,,,DNM1L (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004237,cyclin B1-CDK1 complex,,A protein complex consisting of cyclin B1 and cyclin-dependent kinase 1 (CDK1). Cyclins are characterized by periodicity in protein abundance throughout the cell cycle. Cyclin-dependent kinases represent a family of serine/threonine protein kinases that become active upon binding to a cyclin regulatory partner.,false,,,http://purl.obolibrary.org/obo/TXPO_0002107,,,,,,,,,,,,,,,,,,,,,,A protein complex consisting of cyclin B1 and cyclin-dependent kinase 1 (CDK1). Cyclins are characterized by periodicity in protein abundance throughout the cell cycle. Cyclin-dependent kinases represent a family of serine/threonine protein kinases that become active upon binding to a cyclin regulatory partner.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004237,,,,,,,,,,,,,,,,,,,,,,cyclin B1-CDK1 complex,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004234,NEAT1 (predicted) - inactive form (human) [mitochondrial damage],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004177,,,,,,,,,,,,,,,,,,,,PMID:30250064,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657|http://purl.obolibrary.org/obo/PATO_0002355,,,,,,,,,,,,,,TXPO:0004234,,,,,,,,,,,,,,,,,,,,,,NEAT1 (predicted) - inactive form (human) [mitochondrial damage],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004233,DNM1L(human)[hepatocarcinogenesis],DRP1(human)[hepatocarcinogenesis],,false,,,http://purl.obolibrary.org/obo/TXPO_0004231|http://purl.obolibrary.org/obo/TXPO_0004185,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:10059|PMID:30894684,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,DRP1(human)[hepatocarcinogenesis],,,,,TXPO:0004233,,,,,,,,,,,,,,,,,,,,,,DNM1L(human)[hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004238,cyclin B1-CDK1 complex (human) [mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003603|http://purl.obolibrary.org/obo/TXPO_0004237,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004220|http://purl.obolibrary.org/obo/TXPO_0003611,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004238,,,,,,,,,,,,,,,,,,,,,,cyclin B1-CDK1 complex (human) [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0005739,mitochondrion,mitochondria,"A semiautonomous, self replicating organelle that occurs in varying numbers, shapes, and sizes in the cytoplasm of virtually all eukaryotic cells. It is notably the site of tissue respiration.",false,,,http://purl.obolibrary.org/obo/GO_0043227,,,,,,,,,,,,,,,,,,,,NIF_Subcellular:sao1860313010|Wikipedia:Mitochondrion,,"A semiautonomous, self replicating organelle that occurs in varying numbers, shapes, and sizes in the cytoplasm of virtually all eukaryotic cells. It is notably the site of tissue respiration.",,,,,mitochondrion,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0031966,,,,,,,,,,,,,mitochondria,,,,,GO:0005739,,,,,,,,,,,,,,,,,,,,,,mitochondrion,,,,,,,http://purl.obolibrary.org/obo/go.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0005737,cytoplasm,,"All of the contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures.",false,,,http://purl.obolibrary.org/obo/TXPO_0000065,,,,,,,,,,,,,,,,,,,,Wikipedia:Cytoplasm,,"All of the contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005622,GO:0005737,http://purl.obolibrary.org/obo/GO_0005622,,,,,,,,,,,,,,,,,,,,,cytoplasm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100213,somatostatin,growth hormone-release inhibiting factor|growth hormone-release inhibiting hormone|SRIH|somatotropin release-inhibiting hormone,"A polypeptide hormone produced in the HYPOTHALAMUS, and other tissues and organs. It inhibits the release of growth hormone ( SOMATOTROPIN), and also modulates important physiological functions of the kidney, pancreas, and gastrointestinal tract. Somatostatin receptors are widely expressed throughout the body. Somatostatin also acts as a neurotransmitter in the central and peripheral nervous systems.",false,,,http://purl.obolibrary.org/obo/IMR_0100090|http://purl.obolibrary.org/obo/IMR_0100076,,,,,,,,,,,,,,,,,,,,MeSH:D013004,,"A polypeptide hormone produced in the HYPOTHALAMUS, and other tissues and organs. It inhibits the release of growth hormone ( SOMATOTROPIN), and also modulates important physiological functions of the kidney, pancreas, and gastrointestinal tract. Somatostatin receptors are widely expressed throughout the body. Somatostatin also acts as a neurotransmitter in the central and peripheral nervous systems.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,growth hormone-release inhibiting factor|growth hormone-release inhibiting hormone|SRIH|somatotropin release-inhibiting hormone,,,,,IMR:0100213,,,,,,,,,,,,,,,,,,,,,,somatostatin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002262,drug-metabolizing enzyme role,,A role played by the entity within a pharmacological context.,false,,,http://purl.obolibrary.org/obo/CHEBI_52210,,,,,,,,,,,,,,,,,,,,,,A role played by the entity within a pharmacological context.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002262,,,,,,,,,,,,,,,,,,,,,,drug-metabolizing enzyme role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002267,IL2RB - apotosis inhibitor (human)[Phospholipidosis],"interleukin 2 receptor, beta - apotosis restricting factor [Phospholipidosis]",,false,,,http://purl.obolibrary.org/obo/TXPO_0001143,,,,,,,,,,,,,,,,,,,"IL2->IL2R->PI3K->Akt->Bcl2/c-myc->Cell cycle progression
IL2->IL2R->PI3K->Akt->Bcl2->anti-apoptosis",https://www.omim.org/entry/146710|PMID:10982827|PMID:9108028|PMID:12200137|PMID:10579998,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_68494,,,,,"interleukin 2 receptor, beta - apotosis restricting factor [Phospholipidosis]",,,,,TXPO:0002267,,,,,,,,,,,,,,,,,,,,,,IL2RB - apotosis inhibitor (human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001488|http://purl.obolibrary.org/obo/TXPO_0000833,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000795,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002265,inflammatory cytokine gene expression [Phospholipidosis],,"Inflammatory cytokine gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature inflammatory cytokine gene product or products (proteins or RNA).
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002266|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,PMID:26241657,,"Inflammatory cytokine gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature inflammatory cytokine gene product or products (proteins or RNA).
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003405,http://purl.obolibrary.org/obo/TXPO_0004104,,,,,,,,,,,,,,,,,TXPO:0002265,,,,,,,,,,,,,,,,,,,,,,inflammatory cytokine gene expression [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002264,hepatic cirrhosis [Phospholipidosis (excessive defense)],,"Hepatic cirrhosis is a subtype of changing hardness: A process that changes the hardness of the liver to become hard due to the replacement of normal liver tissue to scar tissue.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense).",false,,,http://purl.obolibrary.org/obo/TXPO_0002202|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Hepatic cirrhosis is a subtype of changing hardness: A process that changes the hardness of the liver to become hard due to the replacement of normal liver tissue to scar tissue.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002264,,,,,,,,,,,,,,,,,,,,,,hepatic cirrhosis [Phospholipidosis (excessive defense)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002263,increasing number of macrophage derived foam cell (niemann pick cell) [Niemann Pick Disease Type A/ B],,"Increasing number of macrophage derived foam cell (niemann pick cell) is a subtype of increasing number of objects: A process that becomes larger in the number of foam cell, a type of macrophage (niemann pick cell) containing lipids in small vacuoles, in the liver.
This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type A/ B.",false,,,http://purl.obolibrary.org/obo/TXPO_0000918,,,,,,,,,,,,,,,,,,,,,,"Increasing number of macrophage derived foam cell (niemann pick cell) is a subtype of increasing number of objects: A process that becomes larger in the number of foam cell, a type of macrophage (niemann pick cell) containing lipids in small vacuoles, in the liver.
This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type A/ B.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002263,,,,,,,,,,,,,,,,,,,,,,increasing number of macrophage derived foam cell (niemann pick cell) [Niemann Pick Disease Type A/ B],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002268,IL2RB - cell cycle progression promoting factor (human)[Phospholipidosis],"interleukin 2 receptor, beta - cell cycle progression promoting factor [Phospholipidosis]",,false,,,http://purl.obolibrary.org/obo/TXPO_0001143,,,,,,,,,,,,,,,,,,,"IL2->IL2R->PI3K->Akt->Bcl2/c-myc->Cell cycle progression
IL2->IL2R->PI3K->Akt->Bcl2->anti-apoptosis",https://www.omim.org/entry/146710|PMID:10982827|PMID:9108028|PMID:12200137|PMID:10579998,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002269,,,,,"interleukin 2 receptor, beta - cell cycle progression promoting factor [Phospholipidosis]",,,,,TXPO:0002268,,,,,,,,,,,,,,,,,,,,,,IL2RB - cell cycle progression promoting factor (human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001488|http://purl.obolibrary.org/obo/TXPO_0000833,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002269,positive regulator of cell cycle role,,A role played by the entity that positively regulates the process of cell cycle.,false,,,http://purl.obolibrary.org/obo/TXPO_0002247,,,,,,,,http://purl.obolibrary.org/obo/GO_0007049,,,,,,,,,,,,,,A role played by the entity that positively regulates the process of cell cycle.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002269,,,,,,,,,,,,,,,,,,,,,,positive regulator of cell cycle role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002266,inflammatory cytokine gene expression,,Inflammatory cytokine gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature inflammatory cytokine gene product or products (proteins or RNA).,false,,,http://purl.obolibrary.org/obo/GO_0010467,,,,,,,,,,,,,,,,,,,,,,Inflammatory cytokine gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature inflammatory cytokine gene product or products (proteins or RNA).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002266,,,,,,,,,,,,,,,,,,,,,,inflammatory cytokine gene expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002261,positive regulator of tumor growth,,A role played by the entity which positively regulates the process of tumor cell growth.,false,,,http://purl.obolibrary.org/obo/TXPO_0003230,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000766,,,,,,,,,,,,,A role played by the entity which positively regulates the process of tumor cell growth.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002261,,,,,,,,,,,,,,,,,,,,,,positive regulator of tumor growth,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0001155,colon,,"Last portion of the large intestine before it becomes the rectum.|Although all vertebrates have a digestive tract and accessory glands, various parts of this system are not necessarily homologous, analogous, or even present in all species. Therefore, broad comparisons can be best made under the listings of headgut, foregut, midgut, pancreas and biliary system, hindgut.[uncertain][VHOG]",false,,,http://purl.obolibrary.org/obo/UBERON_0000160,,,,,,,,,,,,,,,,,,,,UMLS:C0009368|NCIT:C12382|EFO:0000361,,Last portion of the large intestine before it becomes the rectum.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0000059,UBERON:0001155,http://purl.obolibrary.org/obo/UBERON_0000059,,,,,,,,,,,,,,,,,,,"Although all vertebrates have a digestive tract and accessory glands, various parts of this system are not necessarily homologous, analogous, or even present in all species. Therefore, broad comparisons can be best made under the listings of headgut, foregut, midgut, pancreas and biliary system, hindgut.[uncertain][VHOG]",,colon,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_16750,guanosine,,A purine nucleoside in which guanine is attached to ribofuranose via a beta-N(9)-glycosidic bond.,false,,,http://purl.obolibrary.org/obo/CHEBI_33838,,,,,,,,,,,,,,,,,,,,,,A purine nucleoside in which guanine is attached to ribofuranose via a beta-N(9)-glycosidic bond.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:16750,,,,,,,,,,,,,,,,,,,,,,guanosine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_48705,agonist,agoniste|agonista|agonists|agonist,Substance which binds to cell receptors normally responding to naturally occurring substances and which produces a response of its own.,false,,,http://purl.obolibrary.org/obo/CHEBI_52210,,,,,,,,,,,,,,,,,,,,,,Substance which binds to cell receptors normally responding to naturally occurring substances and which produces a response of its own.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,agonist,,agoniste|agonista|agonists,,,,,,,,,,,,,,,,,,,,,CHEBI:48705,,,,agonist,,CHEBI:48705,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000340,Grb2,SH2/SH3 adapter GRB2|abundant Src homology protein|growth factor receptor bound protein 2|Ash|GRB2 adapter protein|Growth factor receptor-bound protein 2|ASH protein,,false,,,http://purl.obolibrary.org/obo/IMR_0000339,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0010276,SH2/SH3 adapter GRB2|abundant Src homology protein|growth factor receptor bound protein 2|Ash|GRB2 adapter protein|Growth factor receptor-bound protein 2|ASH protein,,,,,IMR:0000340,,,,,,,,,,,,,,,,,,,,,,Grb2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000009695,EDEM1,,Other designations: ER degradation-enhancing alpha-mannosidase-like 1|ER degradation-enhancing alpha-mannosidase-like protein 1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,EDEM,,,,,,,,,,,,3,,,,,,HGNC:18967|Vega:OTTHUMG00000154896|HPRD:09644|Ensembl:ENSG00000134109|MIM:607673,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"ER degradation enhancer, mannosidase alpha-like 1",,,3p26.1,,,,,,,,,,,,,,,,"GO_0004571 (EC: IDA, Qualifier: NOT, PMID:12610306); GO_0005509 (EC: IEA); GO_0005515 (EC: IPI, PMID:16449189); GO_0005789 (EC: TAS); GO_0006457 (EC: TAS); GO_0006987 (EC: TAS); GO_0018279 (EC: TAS); GO_0030176 (EC: ISS); GO_0030433 (EC: ISS); GO_0030968 (EC: TAS); GO_0043687 (EC: TAS); GO_0044267 (EC: TAS); GO_0051787 (EC: IDA, PMID:19524542)",,,,,,,,,PMID:9039502; 11375934; 12477932; 12610305; 12610306; 15146197; 15489334; 15579471; 16449189; 16629899; 17353931; 17360537; 17380188; 17499246; 18303019; 18452703; 19266160; 19322201; 19524542; 19934218; 20065073; 21062743; 21388347; 21632540; 21917589; 22678362; 22905195; 23233672,,,,,,,,,,,,,,,OGG:3000009695,,,,,,,"ER degradation enhancer, mannosidase alpha-like 1",,,,,,,,,,,,,Other designations: ER degradation-enhancing alpha-mannosidase-like 1|ER degradation-enhancing alpha-mannosidase-like protein 1,,EDEM1,,,,,,,,,,,,,,,,,,,,,,,9695,,,,,,,,9606,,,,,,,,,,,,,,,,,,,EDEM1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_86328,antifungal agrochemical,antifungal agrichemical|agrichemical fungicide|antifungal agrichemicals|antifungal agrochemicals|agrochemical fungicide|anti-fungal agrochemical|agrichemical fungicides|anti-fungal agrichemicals|anti-fungal agrichemical|agrochemical fungicides|anti-fungal agrochemicals,"Any substance used in acriculture, horticulture, forestry, etc. for its fungicidal properties.",false,,,http://purl.obolibrary.org/obo/CHEBI_25944,,,,,,,,,,,,,,,,,,,,,,"Any substance used in acriculture, horticulture, forestry, etc. for its fungicidal properties.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,antifungal agrichemical|agrichemical fungicide|antifungal agrichemicals|antifungal agrochemicals|agrochemical fungicide|anti-fungal agrochemical|agrichemical fungicides|anti-fungal agrichemicals|anti-fungal agrichemical|agrochemical fungicides|anti-fungal agrochemicals,,,,,,,,,,,,,,,,,,,,,CHEBI:86328,,,,antifungal agrochemical,,CHEBI:86328,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000009926,LPGAT1,,"Other designations: acyl-CoA:lysophosphatidylglycerol acyltransferase 1|family with sequence similarity 34, member A",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,NET8|FAM34A1|FAM34A,,,,,,,,,,,,1,,,,,,HPRD:14304|Ensembl:ENSG00000123684|HGNC:28985|Vega:OTTHUMG00000037120|MIM:610473,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,lysophosphatidylglycerol acyltransferase 1,,,1q32,,,,,,,,,,,,,,,,"GO_0003674 (EC: ND); GO_0005737 (EC: IDA, PMID: 10942595); GO_0005789 (EC: TAS); GO_0006644 (EC: TAS); GO_0008150 (EC: ND); GO_0016021 (EC: IEA); GO_0016746 (EC: IEA); GO_0036148 (EC: TAS); GO_0044281 (EC: TAS); GO_0046474 (EC: TAS)",,,,,,,,,PMID: 9039502; 9637538; 10942595; 12477932; 15485873; 15489334; 17207965; 19322201; 21890473; 21903422; 21906983; 23362303; 23464991; 23505186,,,,,,,,,,,,,,,OGG:3000009926,,,,,,,lysophosphatidylglycerol acyltransferase 1,,,,,,,,,,,,,"Other designations: acyl-CoA:lysophosphatidylglycerol acyltransferase 1|family with sequence similarity 34, member A",,LPGAT1,,,,,,,,,,,,,,,,,,,,,,,9926,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,LPGAT1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000595,IL-13,interleukin-13,,false,,,http://purl.obolibrary.org/obo/IMR_0000007,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000622,,,,,interleukin-13,,,,,IMR:0000595,,,,,,,,,,,,,,,,,,,,,,IL-13,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_77105,EC 1.10.2.* (oxidoreductase acting on diphenols and related substances as donors with a cytochrome as acceptor) inhibitor,oxidoreductase acting on diphenols and related substances as donors with a cytochrome as acceptor (EC 1.10.2.*) inhibitor|inhibitors of an oxidoreductase acting on diphenols and related substances as donors with a cytochrome as acceptor (EC 1.10.2.*)|oxidoreductase acting on diphenols and related substances as donors with a cytochrome as acceptor (EC 1.10.2.*) inhibitors|EC 1.10.2.* inhibitors|EC 1.10.2.* inhibitor|EC 1.10.2.* (oxidoreductase acting on diphenols and related substances as donors with a cytochrome as acceptor) inhibitors|inhibitor of an oxidoreductase acting on diphenols and related substances as donors with a cytochrome as acceptor (EC 1.10.2.*),An EC 1.10.* (oxidoreductase acting on diphenols and related substances as donors) inhibitor that interferes with the action of any such enzyme using a cytochrome as acceptor (EC 1.10.2.*).,false,,,http://purl.obolibrary.org/obo/CHEBI_76737,,,,,,,,,,,,,,,,,,,,,,An EC 1.10.* (oxidoreductase acting on diphenols and related substances as donors) inhibitor that interferes with the action of any such enzyme using a cytochrome as acceptor (EC 1.10.2.*).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,oxidoreductase acting on diphenols and related substances as donors with a cytochrome as acceptor (EC 1.10.2.*) inhibitor|inhibitors of an oxidoreductase acting on diphenols and related substances as donors with a cytochrome as acceptor (EC 1.10.2.*)|oxidoreductase acting on diphenols and related substances as donors with a cytochrome as acceptor (EC 1.10.2.*) inhibitors|EC 1.10.2.* inhibitors|EC 1.10.2.* inhibitor|EC 1.10.2.* (oxidoreductase acting on diphenols and related substances as donors with a cytochrome as acceptor) inhibitors|inhibitor of an oxidoreductase acting on diphenols and related substances as donors with a cytochrome as acceptor (EC 1.10.2.*),,,,,,,,,,,,,,,,,,,,,CHEBI:77105,,,,EC 1.10.2.* (oxidoreductase acting on diphenols and related substances as donors with a cytochrome as acceptor) inhibitor,,CHEBI:77105,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_50846,immunomodulator,Biomodulator|immunomodulators|Immunologic factor|Immune factor|Immunological factor,Biologically active substance whose activity affects or plays a role in the functioning of the immune system.,false,,,http://purl.obolibrary.org/obo/CHEBI_24432|http://purl.obolibrary.org/obo/CHEBI_23888,,,,,,,,,,,,,,,,,,,,,,Biologically active substance whose activity affects or plays a role in the functioning of the immune system.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Biomodulator|immunomodulators|Immunologic factor|Immune factor|Immunological factor,,,,,,,,,,,,,,,,,,,,,CHEBI:50846,,,,immunomodulator,,CHEBI:50846,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000460,SOCS,CIS|STAT induced STAT inhibitor|Suppressor of cytokine signaling|SSI|Cytokine-inducible SH2 protein,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003720,,,,,CIS|STAT induced STAT inhibitor|Suppressor of cytokine signaling|SSI|Cytokine-inducible SH2 protein,,,,,IMR:0000460,,,,,,,,,,,,,,,,,,,,,,SOCS,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004189,ACSM2A (predicted)(human) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_1000500,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:123876,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000123876,,,,,,,,,,,,,TXPO:0004189,,,,,,,,,,,,,,,,,,,,,,ACSM2A (predicted)(human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004186,PTPRD (predicted)(human) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_1000527,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:5789,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,,,,,,,,,,,,,,TXPO:0004186,,,,,,,,,,,,,,,,,,,,,,PTPRD (predicted)(human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004184,UBE2T (predicted)(human) [mitochondrial damage],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003603|http://purl.obolibrary.org/obo/TXPO_1000545,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:29089,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000029089,,,,,,,,,,,,,TXPO:0004184,,,,,,,,,,,,,,,,,,,,,,UBE2T (predicted)(human) [mitochondrial damage],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004181,RHNO1 (predicted)(human) [mitochondrial damage],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003603|http://purl.obolibrary.org/obo/TXPO_1000529,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:83695,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000083695,,,,,,,,,,,,,TXPO:0004181,,,,,,,,,,,,,,,,,,,,,,RHNO1 (predicted)(human) [mitochondrial damage],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004180,SLC3A1 (predicted)(human) [mitochondrial damage],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003603|http://purl.obolibrary.org/obo/TXPO_1000535,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:6519,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000006519,,,,,,,,,,,,,TXPO:0004180,,,,,,,,,,,,,,,,,,,,,,SLC3A1 (predicted)(human) [mitochondrial damage],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004182,ORC6 (predicted)(human) [mitochondrial damage],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003603|http://purl.obolibrary.org/obo/TXPO_1000522,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:23594,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000023594,,,,,,,,,,,,,TXPO:0004182,,,,,,,,,,,,,,,,,,,,,,ORC6 (predicted)(human) [mitochondrial damage],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004185,liver cancer dependent molecule (human in vitro),,"Liver cancer dependent molecule is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of Liver cancer as a gene product.
Gene profile:Human/in vitro/Hepatocyte/",false,,,http://purl.obolibrary.org/obo/TXPO_0000837,,,,,,,,,,,,,,,,,,,,PMID:25592151,,"Liver cancer dependent molecule is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of Liver cancer as a gene product.
Gene profile:Human/in vitro/Hepatocyte/",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004185,,,,,,,,,,,,,,,,,,,,,,liver cancer dependent molecule (human in vitro),,,,,,,,,,,http://purl.obolibrary.org/obo/NCBITaxon_9606,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004187,SCAPER (predicted)(human) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_1000531,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:49855,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000049855,,,,,,,,,,,,,TXPO:0004187,,,,,,,,,,,,,,,,,,,,,,SCAPER (predicted)(human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004183,CDCA5 (predicted)(human) [mitochondrial damage],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003603|http://purl.obolibrary.org/obo/TXPO_1000506,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:113130,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000113130,,,,,,,,,,,,,TXPO:0004183,,,,,,,,,,,,,,,,,,,,,,CDCA5 (predicted)(human) [mitochondrial damage],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004188,GPHN (predicted)(human) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_1000517,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:10243|PMID:31239782,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000010243,,,,,,,,,,,,,TXPO:0004188,,,,,,,,,,,,,,,,,,,,,,GPHN (predicted)(human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004038,Pias3 [Hepatocarcinogenesis],Protein Inhibitor Of Activated STAT 3 [Hepatocarcinogenesis],,false,,,http://purl.obolibrary.org/obo/TXPO_0000837|http://purl.obolibrary.org/obo/TXPO_1000301,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:229615|NCBI-Rat-GeneID:83614|NCBI-Human-GeneID:10401|PMID:22136659|PMID:23959540|PMID:10319586,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Protein Inhibitor Of Activated STAT 3 [Hepatocarcinogenesis],,,,,TXPO:0004038,,,,,,,,,,,,,,,,,,,,,,Pias3 [Hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004034,TOR signaling (primitive)　[Phospholipidosis],,"TOR signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the TOR (Target of rapamycin) .
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis .",false,,,http://purl.obolibrary.org/obo/TXPO_0004028|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"TOR signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the TOR (Target of rapamycin) .
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis .",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004026,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0031929,,,,,,,,,,,,,,,,TXPO:0004034,,,,,,,,,,,,,,,,,,,,,,TOR signaling (primitive)　[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004030,Eif4a1 [Hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000837|http://purl.obolibrary.org/obo/TXPO_1000133,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:13681|NCBI-Human-GeneID:1973|NCBI-Rat-GeneID:287436,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004030,,,,,,,,,,,,,,,,,,,,,,Eif4a1 [Hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004031,Irf1 [Hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000212|http://purl.obolibrary.org/obo/TXPO_0000837,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:3659|NCBI-Mouse-GeneID:16362|NCBI-Rat-GeneID:24508,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004031,,,,,,,,,,,,,,,,,,,,,,Irf1 [Hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004033,HDGFRP3 [Hepatocarcinogenesis],"hepatoma-derived growth factor, related protein 3 [Hepatocarcinogenesis]|HRP-3 [Hepatocarcinogenesis]",Enhances DNA synthesis and may play a role in cell proliferation.,false,,,http://purl.obolibrary.org/obo/TXPO_0000837|http://purl.obolibrary.org/obo/TXPO_1000183,,,,,,,,,,,,,,,,,,,,PMID:10581169|PMID:26823754|http://omim.org/entry/616643|PMID:24012673,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"hepatoma-derived growth factor, related protein 3 [Hepatocarcinogenesis]|HRP-3 [Hepatocarcinogenesis]",,,,,TXPO:0004033,,,,,,,,,,,,,,,,,,,,Enhances DNA synthesis and may play a role in cell proliferation.,,HDGFRP3 [Hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004037,GDF15 [Hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000837|http://purl.obolibrary.org/obo/TXPO_1000164,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:9518|NCBI-Rat-GeneID:29455|NCBI-Mouse-GeneID:23886|PMID:25645911|PMID:21242297|PMID:10524241,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004037,,,,,,,,,,,,,,,,,,,,,,GDF15 [Hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004039,Ugt2b7 [Hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000398|http://purl.obolibrary.org/obo/TXPO_0000837,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:286989|NCBI-Human-GeneID:7364|PMID:25713207|PMID:26828111,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004039,,,,,,,,,,,,,,,,,,,,,,Ugt2b7 [Hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004032,negative regulation of release of arachidonic acid from cell membrane [Phospholipidosis],,"Negative regulation of release of arachidonic acid from cell membrane is a subtype of negative regulation process: A process  that stops, prevents, or reduces the frequency, rate or extent of the release of arachidonic acid from cell membrane. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0004014,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of release of arachidonic acid from cell membrane is a subtype of negative regulation process: A process  that stops, prevents, or reduces the frequency, rate or extent of the release of arachidonic acid from cell membrane. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,http://purl.obolibrary.org/obo/TXPO_0000457,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003886,,,,,,,,,,,TXPO:0004032,,,,,,,,,,,,,,,,,,,,,,negative regulation of release of arachidonic acid from cell membrane [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004035,release of tumor inhibitor from lysosome,,The directed movement of tumor inhibitor from the lysosome.,false,,,http://purl.obolibrary.org/obo/TXPO_0002588,,,,,,,,,,,,,,,,,,,,,,The directed movement of tumor inhibitor from the lysosome.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004035,,,,,,,,,,,,,,,,,,,,,,release of tumor inhibitor from lysosome,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004036,SESN1 [Hepatocarcinogenesis],sestrin 1,,false,,,http://purl.obolibrary.org/obo/TXPO_0000837|http://purl.obolibrary.org/obo/TXPO_1000337,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:140742|NCBI-Human-GeneID:27244|NCBI-Rat-GeneID:294518|PMID:27118659|PMID:17525332|PMID:25259925|PMID:9926927,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sestrin 1,,,,,TXPO:0004036,,,,,,,,,,,,,,,,,,,,,,SESN1 [Hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3100133790,MUC3,,,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PMID: 9334251; 22990020; 23316049,,,,,,,,,,,,,,,OGG:3100133790,,,,,,,intestinal mucin-like,,,,,,,,,,,,,,,MUC3,,,,,,,,,,,,,,,,,,,,,,,100133790,,,,NCBI-supplied,,,,9606,,,,,,,,,,,,,,,,,,,,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000000291,SLC25A4,,"Other designations: ADP,ATP carrier protein 1|ADP,ATP carrier protein, heart/skeletal muscle|ADP/ATP translocase 1|adenine nucleotide translocator 1 (skeletal muscle)|heart/skeletal muscle ATP/ADP translocator|solute carrier family 25 member 4",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,PEO3|AAC1|ANT 1|MTDPS12|1|T1|ANT|ANT1|PEO2,,,,,,,,,,,,4,,,,,,HGNC:10990|Vega:OTTHUMG00000134299|MIM:103220|Ensembl:ENSG00000151729|HPRD:00058,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 4",,,4q35,,,,,,,,,,,,,,,,"GO_0000002 (EC: TAS, PMID: 10926541); GO_0005515 (EC: IPI, PMID: 16507998); GO_0005739 (EC: IDA); GO_0005743 (EC: TAS); GO_0005887 (EC: TAS, PMID: 2823266); GO_0006091 (EC: TAS, PMID: 2823266); GO_0006112 (EC: TAS); GO_0006810 (EC: TAS, PMID: 2823266); GO_0008637 (EC: IEA); GO_0015207 (EC: TAS, PMID: 2823266); GO_0015853 (EC: TAS, PMID: 2823266); GO_0016032 (EC: TAS); GO_0044281 (EC: TAS); GO_0050796 (EC: TAS); GO_0060546 (EC: IMP, PMID: 16507998)",,,,,,,,,PMID: 1582253; 2541251; 2547778; 2823266; 2829183; 8103757; 8479824; 8619474; 8644740; 9110174; 9748162; 9874241; 10364542; 10620603; 10926541; 11175251; 11181702; 11193032; 11287411; 11756592; 11756613; 11809823; 12039962; 12112115; 12140186; 12149099; 12450408; 12477932; 12565915; 12663490; 12707443; 12750393; 12750404; 14729611; 15033717; 15142377; 15231833; 15489334; 15551024; 15638722; 15725353; 15792871; 15817944; 15832179; 16020522; 16107323; 16120388; 16155110; 16226712; 16236267; 16354571; 16429131; 16492162; 16507998; 16511342; 16556444; 16887100; 17203973; 17328670; 17331040; 17420318; 17586316; 17586317; 18094160; 18504126; 18575922; 18781797; 18852887; 19149577; 19232058; 19275580; 19275583; 19275588; 19425506; 19840444; 19965780; 20007455; 20012529; 20160640; 20181062; 20186120; 20504995; 20528917; 20698827; 20843780; 20877624; 20972266; 21139048; 21145461; 21196320; 21318276; 21319273; 21586654; 21890473; 21906983; 21918813; 21963094; 22178446; 22187496; 22350218; 22354994; 22797925; 22939629; 23000965; 23246001; 23266187; 23401503; 23464991; 24244333,,,,,,,,,,,,,,,OGG:3000000291,,,,,,,"solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 4",,,,,,,,,,,,,"Other designations: ADP,ATP carrier protein 1|ADP,ATP carrier protein, heart/skeletal muscle|ADP/ATP translocase 1|adenine nucleotide translocator 1 (skeletal muscle)|heart/skeletal muscle ATP/ADP translocator|solute carrier family 25 member 4",,SLC25A4,,,,,,,,,,,,,,,,,,,,,,,291,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,SLC25A4,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/PATO_0000016,color brightness quality,color intensity,"A scalar optical property that is the intensity, value or amount of perceived light.",false,,,http://purl.obolibrary.org/obo/BFO_0000019,,,,,,,,,,,,,,,,,,,,,,"A scalar optical property that is the intensity, value or amount of perceived light.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,color intensity,,,,,PATO:0000016,,,,,,,,,,,,,,,,,,,,,,color brightness quality,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0000014,color (quality),,"A composite chromatic quality composed of hue, saturation and intensity parts.",false,,,http://purl.obolibrary.org/obo/BFO_0000019|http://purl.obolibrary.org/obo/TXPO_0000311,,,,,,,,,,,,,,,,,,,,,,"A composite chromatic quality composed of hue, saturation and intensity parts.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0000014,,,,,,,,,,,,,,,,,,,,,,color (quality),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0000011,age (quality),,A time quality inhering in a bearer by virtue of how long the bearer has existed.,false,,,http://purl.obolibrary.org/obo/TXPO_0002424|http://purl.obolibrary.org/obo/PATO_0000165,,,,,,,,,,,,,,,,,,,,,,A time quality inhering in a bearer by virtue of how long the bearer has existed.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0000011,,,,,,,,,,,,,,,,,,,,,,age (quality),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000995,Por (rat)[Ground glass appearance],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000985|http://purl.obolibrary.org/obo/TXPO_1000309,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:29441,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000995,,,,,,,,,,,,,,,,,,,,,,Por (rat)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000991,Cyp1a1 (rat)[Ground glass appearance],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000985|http://purl.obolibrary.org/obo/TXPO_1000100,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24296,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000991,,,,,,,,,,,,,,,,,,,,,,Cyp1a1 (rat)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000997,Txnrd1 (rat)[Ground glass appearance],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000985|http://purl.obolibrary.org/obo/TXPO_1000389,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:58819,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000997,,,,,,,,,,,,,,,,,,,,,,Txnrd1 (rat)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000993,insulin receptor signaling pathway [ER stress],,"insulin receptor signaling pathway is a subtype of integrated signaling pathway: The series of molecular signals generated as a consequence of the insulin receptor binding to insulin.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/GO_0008286,,,,,,,,,,,,,,,,,,,,,,"insulin receptor signaling pathway is a subtype of integrated signaling pathway: The series of molecular signals generated as a consequence of the insulin receptor binding to insulin.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000993,,,,,,,,,,,,,,,,,,,,,,insulin receptor signaling pathway [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000992,Ugt2b1 (rat)[Ground glass appearance],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000985|http://purl.obolibrary.org/obo/TXPO_1000397,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:286954,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000992,,,,,,,,,,,,,,,,,,,,,,Ugt2b1 (rat)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000996,Gsta3 (rat)[Ground glass appearance],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000985|http://purl.obolibrary.org/obo/TXPO_1000179,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:494500,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000996,,,,,,,,,,,,,,,,,,,,,,Gsta3 (rat)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000999,TGF (canonical)[Ground glass appearance],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000472|http://purl.obolibrary.org/obo/TXPO_1000370,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000999,,,,,,,,,,,,,,,,,,,,,,TGF (canonical)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000990,Cyp2b1 (rat)[Ground glass appearance],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000985|http://purl.obolibrary.org/obo/TXPO_1000101,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24300,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000990,,,,,,,,,,,,,,,,,,,,,,Cyp2b1 (rat)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000994,Alas1 (rat)[Ground glass appearance],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000985|http://purl.obolibrary.org/obo/TXPO_1000034,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:65155,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000994,,,,,,,,,,,,,,,,,,,,,,Alas1 (rat)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000998,Srnx1 (rat)[Ground glass appearance],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000985|http://purl.obolibrary.org/obo/TXPO_1000364,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000998,,,,,,,,,,,,,,,,,,,,,,Srnx1 (rat)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001573,Rab6B,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001573,,,,,,,,,,,,,,,,,,,,,,Rab6B,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003786,negative regulation of apoptotic process [Fibrosis],,"Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptotic process.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003742|http://purl.obolibrary.org/obo/GO_0043066,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptotic process.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003786,,,,,,,,,,,,,,,,,,,,,,negative regulation of apoptotic process [Fibrosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003782,scarring [fibrosis],,"Scarring is a subtype of changing material: A process of keeping area replaced into fibrous tissue by injury.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003742|http://purl.obolibrary.org/obo/TXPO_0000681,,,,,,,,,,,,,,,,,,,,,,"Scarring is a subtype of changing material: A process of keeping area replaced into fibrous tissue by injury.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003782,,,,,,,,,,,,,,,,,,,,,,scarring [fibrosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003783,nodule formation [Fibrosis],,"The process in which the anatomical structures of the nodule are generated and organized.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003742|http://purl.obolibrary.org/obo/TXPO_0000612,,,,,,,,,,,,,,,,,,,,,,"The process in which the anatomical structures of the nodule are generated and organized.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003783,,,,,,,,,,,,,,,,,,,,,,nodule formation [Fibrosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003789,decreasing stored glycogen,,Decreasing stored glycogen is a subtype of decreasing glycogen level: A process that changes the stored amount of glycogen level to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0002050,,,,,,,,,,,,,,,,,,,,,,Decreasing stored glycogen is a subtype of decreasing glycogen level: A process that changes the stored amount of glycogen level to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003789,,,,,,,,,,,,,,,,,,,,,,decreasing stored glycogen,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003780,CCL3 production,,CCL3 production  is a subtype of generating a substance : A process that synthesizes trichloromethyl(.) as output.,false,,,http://purl.obolibrary.org/obo/TXPO_0000019,,,,,,,,,,,,,,,,,,,,,,CCL3 production  is a subtype of generating a substance : A process that synthesizes trichloromethyl(.) as output.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003780,,,,,,,,,,,,,,,,,,,,,,CCL3 production,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003784,TIMP2 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_1000431,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:7077,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003784,,,,,,,,,,,,,,,,,,,,,,TIMP2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003788,CTSB (predicted)(human)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001135|http://purl.obolibrary.org/obo/TXPO_0003843,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1508|PMID:27398911|PMID:1837142|PMID:11016923|PMID:1637335|PMID:10876156,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000001508,,,,,,,,,,,,,TXPO:0003788,,,,,,,,,,,,,,,,,,,,,,CTSB (predicted)(human)[Phospholipidosis],,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005764,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003787,CCL3 production [NASH],,"CCL3 production  is a subtype of generating a substance : A process that synthesizes trichloromethyl(.) as output.
This entity is a specific course-dependent process. This process can constitute the course of NASH.",false,,,http://purl.obolibrary.org/obo/TXPO_0003780|http://purl.obolibrary.org/obo/TXPO_0001720,,,,,,,,,,,,,,,,,,,,PMID:12708612,,"CCL3 production  is a subtype of generating a substance : A process that synthesizes trichloromethyl(.) as output.
This entity is a specific course-dependent process. This process can constitute the course of NASH.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003748,,,,http://purl.obolibrary.org/obo/TXPO_0003630,,http://purl.obolibrary.org/obo/TXPO_0003792,,,,,,http://purl.obolibrary.org/obo/TXPO_0001882,,,,,,,,,,,TXPO:0003787,,,,,,,,,,,,,,,,,,,,,,CCL3 production [NASH],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003781,decreasing blood flow [Fibrosis],,Decreasing blood flow is a subtype of decreasing flow: A process that changes the  blood flow to be smaller. This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.,false,,,http://purl.obolibrary.org/obo/TXPO_0003742|http://purl.obolibrary.org/obo/TXPO_0000359,,,,,,,,,,,,,,,,,,,,,,Decreasing blood flow is a subtype of decreasing flow: A process that changes the  blood flow to be smaller. This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003779,,,,,,,,,,,TXPO:0003781,,,,,,,,,,,,,,,,,,,,,,decreasing blood flow [Fibrosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003785,TIMP2 (canonical)[Fibrosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003784|http://purl.obolibrary.org/obo/TXPO_0003750,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003785,,,,,,,,,,,,,,,,,,,,,,TIMP2 (canonical)[Fibrosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_33184,long-chain fatty acyl-CoA,LCFA-coenzyme A,A fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of any long-chain (C13 to C22) fatty acid.,false,,,http://purl.obolibrary.org/obo/CHEBI_37554,,,,,,,,,,,,,,,,,,,,PMID:14516204|PMID:17652214|PMID:10224157|PMID:16357361,,A fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of any long-chain (C13 to C22) fatty acid.,,,,,,,,,,,,C22H35N7O17P3SR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,LCFA-coenzyme A,,,,,CHEBI:33184,,,,,,,,,,,,,,,,,,,,,,long-chain fatty acyl-CoA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CC(C)(COP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1OP(O)(O)=O)n1cnc2c(N)ncnc12)[C@@H](O)C(=O)NCCC(=O)NCCSC([*])=O,,,,,
http://purl.obolibrary.org/obo/IMR_0100755,Dsh family,dishevelled family,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,IPR:008339,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,dishevelled family,,,,,IMR:0100755,,,,,,,,,,,,,,,,,,,,,,Dsh family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000090,RAR,Retinoic acid receptor,,false,,,http://purl.obolibrary.org/obo/TXPO_0001509,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003224,,,,,Retinoic acid receptor,,,,,IMR:0000090,,,,,,,,,,,,,,,,,,,,,,RAR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100203,importin beta,karyopherin beta1,,false,,,http://purl.obolibrary.org/obo/IMR_0100010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,karyopherin beta1,,,,,IMR:0100203,,,,,,,,,,,,,,,,,,,,,,importin beta,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001662,hyperfunction of hosphatidic acid gene expression,,Hyperfunction of hosphatidic acid gene expression is a subtype of hyperfunction of glycerophospholipid synthesis gene expression: A process that performs an excesssive phosphatidic acid synthetic gene expression.,false,,,http://purl.obolibrary.org/obo/TXPO_0001264,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of hosphatidic acid gene expression is a subtype of hyperfunction of glycerophospholipid synthesis gene expression: A process that performs an excesssive phosphatidic acid synthetic gene expression.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001662,,,,,,,,,,,,,,,,,,,,,,hyperfunction of hosphatidic acid gene expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001668,chemcal compound accumulation in liver [Ground glass appearance (severe)],,"Compound accumulation in liver is a subtype of accumulation of xenobiotics: A process that keeps compound in the liver. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (severe).",false,,,http://purl.obolibrary.org/obo/TXPO_0002068,,,,,,,,,,,,,,,,,,,,,,"Compound accumulation in liver is a subtype of accumulation of xenobiotics: A process that keeps compound in the liver. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (severe).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000934,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003853,,,,,,,,,,,TXPO:0001668,,,,,,,,,,,,,,,,,,,,,,chemcal compound accumulation in liver [Ground glass appearance (severe)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001660,changing balance of drug metabolism [Ground glass appearance],,"Changing balance of drug metabolism is a subtype of changing balance: A process that that changes the balance between break down and the continued presence of the drug.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001658,,,,,,,,,,,,,,,,,,,,,,"Changing balance of drug metabolism is a subtype of changing balance: A process that that changes the balance between break down and the continued presence of the drug.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001660,,,,,,,,,,,,,,,,,,,,,,changing balance of drug metabolism [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005790,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001665,drug metabolism imbalance [Ground glass appearance],,"Drug metabolism imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance of drug metabolism.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001661|http://purl.obolibrary.org/obo/TXPO_0001728,,,,,,,,,,,,,,,,,,,,,,"Drug metabolism imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance of drug metabolism.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002068,,,,,,,,,,,TXPO:0001665,,,,,,,,,,,,,,,,,,,,,,drug metabolism imbalance [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001663,hyperfunction of glucuronic acid conjugation for phenobarbital intermediate metabolite [Ground glass appearance],,"Hyperfunction of glucuronic acid conjugation for phenobarbital intermediate metabolite is a subtype of hyperfunction of glucuronic acid conjugation: A process that performs an excessive glucuronic acid conjugation.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0003902|http://purl.obolibrary.org/obo/TXPO_0001227,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of glucuronic acid conjugation for phenobarbital intermediate metabolite is a subtype of hyperfunction of glucuronic acid conjugation: A process that performs an excessive glucuronic acid conjugation.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000992,,,,,,http://purl.obolibrary.org/obo/TXPO_0000106,,,,,,,,,,,TXPO:0001663,,,,,,,,,,,,,,,,,,,,,,hyperfunction of glucuronic acid conjugation for phenobarbital intermediate metabolite [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001661,drug metabolism imbalance,,Drug metabolism imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance of drug metabolism.,false,,,http://purl.obolibrary.org/obo/TXPO_0000567,,,,,,,,,,,,,,,,,,,,,,Drug metabolism imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance of drug metabolism.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001661,,,,,,,,,,,,,,,,,,,,,,drug metabolism imbalance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001669,increasing sphingophopholipid material,,Increasing sphingophopholipid material is a subtype of increasing materials for lipid formation: A process that changes the amount of sphingophopholipid material to be larger.,false,,,http://purl.obolibrary.org/obo/TXPO_0001314,,,,,,,,,,,,,,,,,,,,,,Increasing sphingophopholipid material is a subtype of increasing materials for lipid formation: A process that changes the amount of sphingophopholipid material to be larger.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001669,,,,,,,,,,,,,,,,,,,,,,increasing sphingophopholipid material,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001667,drug metabolism imbalance  [Ground glass appearance (severe) - tumorigenesis],,"Drug metabolism imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance of drug metabolism. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of liver tumor via ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001665,,,,,,,,,,,,,,,,,,,,,,"Drug metabolism imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance of drug metabolism. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of liver tumor via ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001668,,,,,,,,,,,TXPO:0001667,,,,,,,,,,,,,,,,,,,,,,drug metabolism imbalance  [Ground glass appearance (severe) - tumorigenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001664,hypofunction of phosphatidic acid degradation,,Hypofunction of phosphatidic acid degradation is a subtype of hypofunction of glycerophospholipid degradation: A process that performs a decreased or insufficient phosphatidic acid degradation.,false,,,http://purl.obolibrary.org/obo/TXPO_0001418,,,,,,,,,,,,,,,,,,,,,,Hypofunction of phosphatidic acid degradation is a subtype of hypofunction of glycerophospholipid degradation: A process that performs a decreased or insufficient phosphatidic acid degradation.,,,http://purl.obolibrary.org/obo/TXPO_0001620,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_16337,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001664,,,,,,,,,,,,,,,,,,,,,,hypofunction of phosphatidic acid degradation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001666,negative regulation of phosphatidic acid degradation,,"Negative regulation of phosphatidic acid degradation is a subtype of Negative regulation of glycerophospholipid degradation: A process that stops, prevents, or reduces the frequency, rate or extent of phosphatidic acid degradation.",false,,,http://purl.obolibrary.org/obo/TXPO_0001304,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of phosphatidic acid degradation is a subtype of Negative regulation of glycerophospholipid degradation: A process that stops, prevents, or reduces the frequency, rate or extent of phosphatidic acid degradation.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001666,,,,,,,,,,,,,,,,,,,,,,negative regulation of phosphatidic acid degradation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0002269,accumulation (quality),,A structural quality of the collection or massing of one physical object within another physical object.,false,,,http://purl.obolibrary.org/obo/PATO_0000141,,,,,,,,,,,,,,,,,,,,,,A structural quality of the collection or massing of one physical object within another physical object.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0002269,,,,,,,,,,,,,,,,,,,,,,accumulation (quality),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001090,CRM1,exportin 1,,false,,,http://purl.obolibrary.org/obo/IMR_0100015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,exportin 1,,,,,IMR:0001090,,,,,,,,,,,,,,,,,,,,,,CRM1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001035,ARID5A (human)[Ground glass appearance],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001009|http://purl.obolibrary.org/obo/TXPO_0001020,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:316327|NCBI-Mouse-GeneID:214855|NCBI-Human-GeneID:10865|PMID:15941852|PMID:29044508|PMID:29358370|OMIM:611583,,,,,,,,,,,,,,,AT-Rich Interaction Domain 5A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001035,,,,,,,,,,,,,,,,,,,,,,ARID5A (human)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000795,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001032,MRP2 (human)[Ground glass appearance],ABCC2 [Ground glass appearance],,false,,,http://purl.obolibrary.org/obo/TXPO_0001009|http://purl.obolibrary.org/obo/TXPO_0002496,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ABCC2 [Ground glass appearance],,,,,TXPO:0001032,,,,,,,,,,,,,,,,,,,,,,MRP2 (human)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001031,increasing number of dead cells in liver [Ground glass appearance],,"Increasing number of dead cells in liver is a subtype of cell proliferation: A process that becomes larger in the number of dead cells in the liver.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0000341|http://purl.obolibrary.org/obo/TXPO_0001728,,,,,,,,,,,,,,,,,,,,,,"Increasing number of dead cells in liver is a subtype of cell proliferation: A process that becomes larger in the number of dead cells in the liver.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000597|http://purl.obolibrary.org/obo/TXPO_0003597,,,,,,,,,,,TXPO:0001031,,,,,,,,,,,,,,,,,,,,,,increasing number of dead cells in liver [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001036,hypofunction of fatty acid degradation [Lipidosis],,"Hypofunction of fatty acid degradation is a subtype of hypofunctioning: A process that performs a decreased or insufficient lipid degradation.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002147|http://purl.obolibrary.org/obo/TXPO_0001720,,,,,,,,,,,,,,,,,,,,,,"Hypofunction of fatty acid degradation is a subtype of hypofunctioning: A process that performs a decreased or insufficient lipid degradation.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000901,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000893,,,,,,,,,,,TXPO:0001036,,,,,,,,,,,,,,,,,,,,,,hypofunction of fatty acid degradation [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001039,lipid metabolism imbalance (mild) [Lipidosis],,"Lipid metabolism imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance of lipid metabolism. The degree is mild.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000893,,,,,,,,,,,,,,,,,,,,,,"Lipid metabolism imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance of lipid metabolism. The degree is mild.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000919,,,,,,,,,,,TXPO:0001039,,,,,,,,,,,,,,,,,,,,,,lipid metabolism imbalance (mild) [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001034,eosinogranular degeneration dependent molecule  (human in vitro),,"Eosinogranular degeneration dependent molecule is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of eosinogranular degeneration as a gene product.
Gene profile:Human/in vitro/Hepatocyte/",false,,,http://purl.obolibrary.org/obo/TXPO_0000835,,,,,,,,,,,,,,,,,,,,,,"Eosinogranular degeneration dependent molecule is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of eosinogranular degeneration as a gene product.
Gene profile:Human/in vitro/Hepatocyte/",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001034,,,,,,,,,,,,,,,,,,,,,,eosinogranular degeneration dependent molecule  (human in vitro),,,,,,,,,,,http://purl.obolibrary.org/obo/NCBITaxon_9606,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001037,PTPN4 (human)[Eosinophilic granular degeneration],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001034|http://purl.obolibrary.org/obo/TXPO_1000293,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:5775|PMID:7874267|PMID:16619586,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000005775,,,,,,,,,,,,,TXPO:0001037,,,,,,,,,,,,,,,,,,,,,,PTPN4 (human)[Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000795,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001033,metastasis [Ground glass appearance],,"The spread or migration of cancer cells from one part of the body (the organ in which it first appeared) to another. The secondary tumor contains cells that are like those in the original (primary) tumor. [def-source: NCI]
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/NCIT_C19151,,,,,,,,,,,,,,,,,,,,ISBN:0071769234,,"The spread or migration of cancer cells from one part of the body (the organ in which it first appeared) to another. The secondary tumor contains cells that are like those in the original (primary) tumor. [def-source: NCI]
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001030,,,,,,,,,,,TXPO:0001033,,,,,,,,,,,,,,,,,,,,,,metastasis [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001030,tumor cell proliferation [Ground glass appearance],,"Tumor cell proliferation is a subtype of cell proliferation: A process of the multiplication or reproduction of tumor cells, resulting in the rapid expansion of a tumor cell population.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/TXPO_0000339,,,,,,,,,,,,,,,,,,,,PMID:2379175,,"Tumor cell proliferation is a subtype of cell proliferation: A process of the multiplication or reproduction of tumor cells, resulting in the rapid expansion of a tumor cell population.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000597,,,,,,,,,,,TXPO:0001030,,,,,,,,,,,,,,,,,,,,,,tumor cell proliferation [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107|http://purl.obolibrary.org/obo/NCBITaxon_9989,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001038,lipid homeostasis imbalance (severe) [Lipidosis],,"Lipid homeostasis imbalance is a subtype of chemical homeostasis imbalance: A process that becomes lacking a lipid homeostastasis balance.
This entity is a specific course-dependent process. The degree is severe. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003491|http://purl.obolibrary.org/obo/TXPO_0003488,,,,,,,,,,,,,,,,,,,,,,"Lipid homeostasis imbalance is a subtype of chemical homeostasis imbalance: A process that becomes lacking a lipid homeostastasis balance.
This entity is a specific course-dependent process. The degree is severe. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001044,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003476,,,,,,,,,,,TXPO:0001038,,,,,,,,,,,,,,,,,,,,,,lipid homeostasis imbalance (severe) [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100377,G-alpha-15,,,false,,,http://purl.obolibrary.org/obo/IMR_0000323,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100377,,,,,,,,,,,,,,,,,,,,,,G-alpha-15,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0001969,blood plasma,plasma|portion of plasma|blood plasm|portion of blood plasma,"The liquid component of blood, in which erythrocytes are suspended.",false,,,http://purl.obolibrary.org/obo/UBERON_0000179,,,,,,,,,,,,,,,,,,,,http://en.wikipedia.org/wiki/Blood_plasma|http://purl.obolibrary.org/obo/NCIT_C13356|http://linkedlifedata.com/resource/umls/id/C0032105|UMLS:C0032105|MESH:D010949|EFO:0001905|BTO:0000131|OpenCyc:Mx4rEg4ZYrIbEduAAAAOpmP6tw|MA:0002501|GAID:1178|CALOHA:TS-0800|EMAPA:35690|MAT:0000052|MIAA:0000052|FMA:62970,,"The liquid component of blood, in which erythrocytes are suspended.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,blood plasm|portion of blood plasma,,,,http://purl.obolibrary.org/obo/UBERON_0000178,UBERON:0001969,http://purl.obolibrary.org/obo/UBERON_0000178,,,,,,,,,,,,,,,plasma|portion of plasma,,,,,,blood plasma,,,,,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000000760,CA2,,Other designations: carbonate dehydratase II|carbonic anhydrase 2|carbonic anhydrase B|carbonic anhydrase C|carbonic dehydratase|epididymis luminal protein 76,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,HEL-76|CAII|Car2|CA-II|CAC,,,,,,,,,,,,8,,,,,,Ensembl:ENSG00000104267|HPRD:02023|MIM:611492|HGNC:1373|Vega:OTTHUMG00000164944,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,carbonic anhydrase II,,,8q22,,,,,,,,,,,,,,,,"GO_0001822 (EC: IEA); GO_0002009 (EC: IEA); GO_0004089 (EC: IEA); GO_0005515 (EC: IPI, PMID: 15990874); GO_0005615 (EC: IEA); GO_0005737 (EC: IDA, PMID: 114507); GO_0005829 (EC: TAS); GO_0005886 (EC: IDA, PMID: 15990874); GO_0005902 (EC: IEA); GO_0006730 (EC: IEA); GO_0008270 (EC: IDA, PMID: 3151020); GO_0009268 (EC: IEA); GO_0010043 (EC: IEA); GO_0015670 (EC: IEA); GO_0015701 (EC: TAS); GO_0016323 (EC: IEA); GO_0030424 (EC: IEA); GO_0032849 (EC: IEA); GO_0038166 (EC: IDA, PMID: 15990874); GO_0042475 (EC: IEA); GO_0043627 (EC: IEA); GO_0044070 (EC: IDA, PMID: 15990874); GO_0044281 (EC: TAS); GO_0045177 (EC: IDA, PMID: 14675051); GO_0045672 (EC: IEA); GO_0045780 (EC: IEA); GO_0046903 (EC: IEA); GO_0051453 (EC: ISS); GO_0070062 (EC: IDA, PMID: 19056867); GO_2001150 (EC: ISS)",,,,,,,,,PMID: 114507; 823150; 1301935; 1542674; 1602151; 1925679; 1928091; 1977133; 2117271; 2121671; 2123360; 2850697; 3000449; 3081869; 3107918; 3108857; 3121496; 3151019; 3151020; 3221988; 3925334; 4207120; 4621826; 4624444; 6407977; 6817747; 7574487; 7627193; 7930522; 8127074; 8128957; 8460098; 8834238; 9143915; 9150731; 9205766; 9336790; 9453381; 9541386; 9774471; 9890926; 10231836; 10333352; 10423017; 10811634; 10820026; 10821857; 11063570; 11076507; 11264157; 11457932; 11606574; 11956656; 12056894; 12138085; 12171926; 12411514; 12477932; 12501217; 12566520; 12826902; 12933803; 14567693; 14578124; 14675051; 14675565; 14718574; 14736710; 14760703; 15049705; 15062553; 15218065; 15300855; 15453828; 15489334; 15667203; 15836783; 15837316; 15837325; 15952740; 15990874; 16106378; 16169070; 16196087; 16265785; 16344560; 16475831; 16687407; 16825953; 16996812; 17202139; 17319692; 17319695; 17363915; 17631639; 17881426; 18029348; 18060825; 18083150; 18189416; 18247480; 18323598; 18539591; 18580434; 18942852; 18976975; 19012038; 19034380; 19056867; 19269136; 19371798; 19407386; 19415900; 19520834; 19583303; 19615732; 19634894; 19686046; 20000378; 20025241; 20081808; 20170095; 20297840; 20360068; 20398423; 20445237; 20445238; 20509747; 20578724; 20634585; 20637176; 20693695; 20849852; 21139048; 21145461; 21145876; 21243755; 21282642; 21543742; 21680735; 21890473; 21988105; 22001224; 22192857; 22386980; 22416960; 22732064; 22878862; 23030313; 23098192; 23181366; 23215152; 23360090; 23674848; 23720494; 23727877; 23953824; 24036123,,,,,,,,,,,,,,,OGG:3000000760,,,,,,,carbonic anhydrase II,,,,,,,,,,,,,Other designations: carbonate dehydratase II|carbonic anhydrase 2|carbonic anhydrase B|carbonic anhydrase C|carbonic dehydratase|epididymis luminal protein 76,,CA2,,,,,,,,,,,,,,,,,,,,,,,760,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,CA2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0004496,negative regulation of connexin signaling,,"Any process that stops, prevents, or reduces the frequency, rate or extent of connexin signaling, a series of reactions mediated by connexin.",false,,,http://purl.obolibrary.org/obo/GO_0023057,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents, or reduces the frequency, rate or extent of connexin signaling, a series of reactions mediated by connexin.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004496,,,,,,,,,,,,,,,,,,,,,,negative regulation of connexin signaling,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004494|http://purl.obolibrary.org/obo/TXPO_0004495,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004497,DNA alkylation [hepatocarcinogenesis],,"The addition of alkyl groups to many positions on all four bases of DNA. Alkylating agents can also modify the bases of incoming nucleotides in the course of DNA synthesis.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/GO_0006305,,,,,,,,,,,,,,,,,,,,PMID:2919404,,"The addition of alkyl groups to many positions on all four bases of DNA. Alkylating agents can also modify the bases of incoming nucleotides in the course of DNA synthesis.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004498,,,,,,http://purl.obolibrary.org/obo/TXPO_0004392,,,,,,,,,,,TXPO:0004497,,,,,,,,,,,,,,,,,,,,,,DNA alkylation [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004498,chloroethene [hepatocarcinogenesis],塩化ビニル|クロロエチレン|Vinyl chloride,A monohaloethene that is ethene in which one of the hydrogens has been replaced by a chloro group.,false,,,http://purl.obolibrary.org/obo/TXPO_0004455|http://purl.obolibrary.org/obo/CHEBI_28509,,,,,,,,,,,,,,,,,,,,CAS:75-01-4|PMID:21160980|Wikipedia:Chloroethene,,A monohaloethene that is ethene in which one of the hydrogens has been replaced by a chloro group.,,,,,,,,,,,,C2H3Cl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,塩化ビニル|クロロエチレン|Vinyl chloride,,,TXPO:0004498,,,,,,,,,,,,,,,,,,,,,,chloroethene [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ClC=C,,,,,
http://purl.obolibrary.org/obo/TXPO_0004499,Removing damaged DNA stress,,Removing damaged DNA stress is a subtype of removing damaged object: A process that takes a damaged DNA from an organism or tissue.,false,,,http://purl.obolibrary.org/obo/TXPO_0000619,,,,,,,,,,,,,,,,,,,,,,Removing damaged DNA stress is a subtype of removing damaged object: A process that takes a damaged DNA from an organism or tissue.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004499,,,,,,,,,,,,,,,,,,,,,,Removing damaged DNA stress,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004494,Connexin signal transduction pathway,,A series of molecular signals mediated by Cx (Connexin).,false,,,http://purl.obolibrary.org/obo/TXPO_0000609,,,,,,,,,,,,,,,,,,,,,,A series of molecular signals mediated by Cx (Connexin).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004494,,,,,,,,,,,,,,,,,,,,,,Connexin signal transduction pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004495,connexin signaling (primitive),,Connexin signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by connexin.,false,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,,,Connexin signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by connexin.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004494,,,,,,,,,,,,,,,,TXPO:0004495,,,,,,,,,,,,,,,,,,,,,,connexin signaling (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004491,Decreasing CYP1A2 level [hepatocarcinogenesis],,"Decreasing CYP1A2 level is a subtype of decreasing quantity: A process that changes the amount of CYP1A2 level to be lower.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0004490|http://purl.obolibrary.org/obo/TXPO_0002340,,,,,,,,,,,,,,,,,,,,PMID:27093553,,"Decreasing CYP1A2 level is a subtype of decreasing quantity: A process that changes the amount of CYP1A2 level to be lower.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004202,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004492,,,,,,,,,,,TXPO:0004491,,,,,,,,,,,,,,,,,,,,,,Decreasing CYP1A2 level [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004492,Hypofunction of 17β-Estradiol metabolic process [hepatocarcinogenesis],,"Hypofunction of 17β-Estradiol metabolic process is a subtype of hypofunction of metabolism: A process that performs a decreased or insufficient 17β-Estradiol metabolic process.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0005061,,,,,,,,,,,,,,,,,,,,PMID:27093553,,"Hypofunction of 17β-Estradiol metabolic process is a subtype of hypofunction of metabolism: A process that performs a decreased or insufficient 17β-Estradiol metabolic process.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_16469,,,,,,http://purl.obolibrary.org/obo/TXPO_0004202,,,,,,http://purl.obolibrary.org/obo/TXPO_0004518,,,,,,,,,,,TXPO:0004492,,,,,,,,,,,,,,,,,,,,,,Hypofunction of 17β-Estradiol metabolic process [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004490,Decreasing CYP1A2 level,,Decreasing CYP1A2 level is a subtype of decreasing quantity: A process that changes the amount of CYP1A2 level to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000396,,,,,,,,,,,,,,,,,,,,,,Decreasing CYP1A2 level is a subtype of decreasing quantity: A process that changes the amount of CYP1A2 level to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_1000512,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004490,,,,,,,,,,,,,,,,,,,,,,Decreasing CYP1A2 level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004493,Hyperfunction of CYP2E1 gene expression,,Hyperfunction of CYP2E1 gene expression is a subtype of hyperfunction of cytochrome 450 gene expression: A process that performs an excesssive gene expression of CYP2E1.,false,,,http://purl.obolibrary.org/obo/TXPO_0002051,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of CYP2E1 gene expression is a subtype of hyperfunction of cytochrome 450 gene expression: A process that performs an excesssive gene expression of CYP2E1.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004493,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of CYP2E1 gene expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000169,N-cadherin,cadherin-2|A-CAM|Neural-cadherin,,false,,,http://purl.obolibrary.org/obo/IMR_0000167,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,cadherin-2|A-CAM|Neural-cadherin,,,,,IMR:0000169,,,,,,,,,,,,,,,,,,,,,,N-cadherin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_16335,adenosine,Ribofuranosyladenine|Adenosine|Adenine riboside,A ribonucleoside composed of a molecule of adenine attached to a ribofuranose moiety via a beta-N(9)-glycosidic bond.,false,,,http://purl.obolibrary.org/obo/CHEBI_33838,,,,,,,,,,,,,,,,,,,,DrugBank:DB00640|A nucleoside that is composed of adenine and d-ribose. Adenosine or adenosine derivatives play many important biological roles in addition to being components of DNA and RNA. Adenosine itself is a neurotransmitter.,,A ribonucleoside composed of a molecule of adenine attached to a ribofuranose moiety via a beta-N(9)-glycosidic bond.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_25512,,,,,Ribofuranosyladenine|Adenosine|Adenine riboside,,,,,CHEBI:16335,,,,,,,,,,,,,,,,,,,,,,adenosine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_51039,dopamine uptake inhibitor,DRI|dopamine reuptake inhibitors|dopamine uptake inhibitors|dopamine reuptake inhibitor|DARI,A dopaminergic agent that blocks the transport of dopamine into axon terminals or into storage vesicles within terminals. Most of the adrenergic uptake inhibitors also inhibit dopamine uptake.,false,,,http://purl.obolibrary.org/obo/CHEBI_48560,,,,,,,,,,,,,,,,,,,,,,A dopaminergic agent that blocks the transport of dopamine into axon terminals or into storage vesicles within terminals. Most of the adrenergic uptake inhibitors also inhibit dopamine uptake.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,DRI|dopamine reuptake inhibitors|dopamine uptake inhibitors|dopamine reuptake inhibitor|DARI,,,,,,,,,,,,,,,,,,,,,CHEBI:51039,,,,dopamine uptake inhibitor,,CHEBI:51039,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000129607,CMPK2,,"Other designations: UMP-CMP kinase 2, mitochondrial|cytidylate kinase 2|mitochondrial UMP-CMP kinase|nucleoside-diphosphate kinase|thymidine monophosphate kinase 2|thymidylate kinase family LPS-inducible member",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,TMPK2|UMP-CMPK2|TYKi,,,,,,,,,,,,2,,,,,,HGNC:27015|Ensembl:ENSG00000134326|Vega:OTTHUMG00000151629|MIM:611787|HPRD:11233,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytidine monophosphate (UMP-CMP) kinase 2, mitochondrial",,,2p25.2,,,,,,,,,,,,,,,,"GO_0004127 (EC: IDA, PMID: 17999954); GO_0004550 (EC: IDA); GO_0004798 (EC: IEA); GO_0005524 (EC: IEA); GO_0005634 (EC: IDA); GO_0005730 (EC: IDA, Qualifier: NOT); GO_0005739 (EC: IDA); GO_0006165 (EC: IDA); GO_0006227 (EC: IEA); GO_0006233 (EC: IEA); GO_0009142 (EC: IDA); GO_0033862 (EC: IDA, PMID: 17999954); GO_0071222 (EC: IEA)",,,,,,,,,PMID: 12477932; 16344560; 17999954; 18029348; 18498354; 20379614; 22505724,,,,,,,,,,,,,,,OGG:3000129607,,20140408,protein-coding,,,,"cytidine monophosphate (UMP-CMP) kinase 2, mitochondrial",,,,,,,,,,,,,"Other designations: UMP-CMP kinase 2, mitochondrial|cytidylate kinase 2|mitochondrial UMP-CMP kinase|nucleoside-diphosphate kinase|thymidine monophosphate kinase 2|thymidylate kinase family LPS-inducible member",,CMPK2,,,,,,,,,,,,,,,,,,,,,,,129607,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,CMPK2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000069,alpha PDGF receptor,alpha platelet derived growth factor receptor,,false,,,http://purl.obolibrary.org/obo/IMR_0000068,,,,,,,,,,,,,,,,,,,,GO:0005018,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,alpha platelet derived growth factor receptor,,,,,IMR:0000069,,,,,,,,,,,,,,,,,,,,,,alpha PDGF receptor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_35766,glycerophosphoserine,,,false,,,http://purl.obolibrary.org/obo/CHEBI_37739,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:35766,,,,,,,,,,,,,,,,,,,,,,glycerophosphoserine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000004047,LSS,,"Other designations: 2,3-epoxysqualene--lanosterol cyclase|2,3-epoxysqualene-lanosterol cyclase|hOSC|lanosterol synthase|oxidosqualene--lanosterol cyclase",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,OSC,,,,,,,,,,,,21,,,,,,MIM:600909|HGNC:6708|Ensembl:ENSG00000160285|Vega:OTTHUMG00000090633|HPRD:02945,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"lanosterol synthase (2,3-oxidosqualene-lanosterol cyclase)",,,21q22.3,,,,,,,,,,,,,,,,"GO_0000250 (EC: IEA); GO_0005789 (EC: TAS); GO_0005811 (EC: IDA, PMID: 14741744); GO_0006695 (EC: IMP, PMID: 17186944); GO_0006695 (EC: TAS); GO_0008202 (EC: TAS, PMID: 7639730); GO_0044281 (EC: TAS)",,,,,,,,,PMID: 3515096; 7639730; 8593458; 8655142; 8820110; 8889548; 9763219; 10598817; 10830953; 11421484; 12477932; 14702039; 14741744; 14766201; 15489334; 15525992; 15790807; 16344560; 16806233; 17186944; 17255364; 18660489; 19119143; 19913121; 20379614; 20628086; 21139048; 21890473; 21906983; 21963094; 21987572; 21988832; 22053931; 22505724; 23000965; 24250222,,,,,,,,,,,,,,,OGG:3000004047,,,,,,,"lanosterol synthase (2,3-oxidosqualene-lanosterol cyclase)",,,,,,,,,,,,,"Other designations: 2,3-epoxysqualene--lanosterol cyclase|2,3-epoxysqualene-lanosterol cyclase|hOSC|lanosterol synthase|oxidosqualene--lanosterol cyclase",,LSS,,,,,,,,,,,,,,,,,,,,,,,4047,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,LSS,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0004224,IL-6 (mouse)[ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004226|http://purl.obolibrary.org/obo/IMR_0000010,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:16193,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004224,,,,,,,,,,,,,,,,,,,,,,IL-6 (mouse)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004221,COL1A1 (mouse) [mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004228|http://purl.obolibrary.org/obo/TXPO_0004226,,,,,,,,,,,,,,,,,,,,PMID:29222479|NCBI-Mouse-GeneID:12842,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004221,,,,,,,,,,,,,,,,,,,,,,COL1A1 (mouse) [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004225,Negative regulation of respiratory complex proteins synthesis,,"Any process that stops, prevents, or reduces the frequency, rate or extent of mitochondrial respiratory chain complex assembly.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0004213|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:31623280|PMID:23299992|PMID:29222479,,"Any process that stops, prevents, or reduces the frequency, rate or extent of mitochondrial respiratory chain complex assembly.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004265,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004125,,,,,,,,,,,TXPO:0004225,,,,,,,,,,,,,,,,,,,,,,Negative regulation of respiratory complex proteins synthesis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004228,COL1A1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:29393|NCBI-Human-GeneID:1277|NCBI-Mouse-GeneID:12842,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001284,,,,,,,,,,,,,TXPO:0004228,,,,,,,,,,,,,,,,,,,,,,COL1A1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004226,mitochondrial damage dependent molecule (mouse),,"Mitochondrial damage dependent  molecule is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of Mitochondrial damage as a gene product.
Gene profile:Mouse",false,,,http://purl.obolibrary.org/obo/TXPO_0002012,,,,,,,,,,,,,,,,,,,,,,"Mitochondrial damage dependent  molecule is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of Mitochondrial damage as a gene product.
Gene profile:Mouse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004226,,,,,,,,,,,,,,,,,,,,,,mitochondrial damage dependent molecule (mouse),,,,,,,,,,,http://purl.obolibrary.org/obo/NCBITaxon_10090,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004222,GDF15(mouse)[mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004226|http://purl.obolibrary.org/obo/TXPO_1000164,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:23886|PMID:29956733|PMID:29222479,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004222,,,,,,,,,,,,,,,,,,,,,,GDF15(mouse)[mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004220,CCNB1 (human) [mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003603|http://purl.obolibrary.org/obo/TXPO_0004227,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:891|PMID:24746669,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004220,,,,,,,,,,,,,,,,,,,,,,CCNB1 (human) [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004223,GDF15 - inactive form (mouse)[mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004222,,,,,,,,,,,,,,,,,,,,PMID:29222479,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0002355,,,,,,,,,,,,,,TXPO:0004223,,,,,,,,,,,,,,,,,,,,,,GDF15 - inactive form (mouse)[mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004227,CCNB1 (mol),,,false,,,http://purl.obolibrary.org/obo/IMR_0100611,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:268697|NCBI-Human-GeneID:891|NCBI-Rat-GeneID:25203,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004227,,,,,,,,,,,,,,,,,,,,,,CCNB1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004229,CYP2E1 (canonical)[mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000081|http://purl.obolibrary.org/obo/TXPO_0004293,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1571|NCBI-Mouse-GeneID:13106|NCBI-Rat-GeneID:25086|PMID:23299992|PMID:29222479,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004229,,,,,,,,,,,,,,,,,,,,,,CYP2E1 (canonical)[mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000049,FGF,Fibroblast growth factor|HBGF|Heparin-binding growth factor,,false,,,http://purl.obolibrary.org/obo/TXPO_0001382,,,,,,,,,,,,,,,,,,,,GO:0005104,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002395|http://purl.obolibrary.org/obo/TXPO_0000624,,,,,Fibroblast growth factor|HBGF|Heparin-binding growth factor,,,,,IMR:0000049,,,,,,,,,,,,,,,,,,,,,,FGF,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100662,Cln2,G1/S-specific cyclin CLN2,,false,,,http://purl.obolibrary.org/obo/IMR_0100671,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,G1/S-specific cyclin CLN2,,,,,IMR:0100662,,,,,,,,,,,,,,,,,,,,,,Cln2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/HINO_0016241,Activation of BH3-only proteins,,,false,,,http://purl.obolibrary.org/obo/TXPO_0003222,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,HINO:0016241,,,,,,,,,,,,,,,,,,,,,,Activation of BH3-only proteins,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000027241,BBS9,,Other designations: PTH-responsive osteosarcoma B1 protein|bardet-Biedl syndrome 9 protein|parathyroid hormone-responsive B1 gene protein|protein PTHB1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,PTHB1|C18|B1|D1,,,,,,,,,,,,7,,,,,,Vega:OTTHUMG00000128659|MIM:607968|HPRD:16262|Ensembl:ENSG00000122507|HGNC:30000,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,Bardet-Biedl syndrome 9,,,7p14,,,,,,,,,,,,,,,,"GO_0003674 (EC: ND); GO_0005515 (EC: IPI, PMID: 17574030); GO_0005737 (EC: IEA); GO_0005815 (EC: IEA); GO_0007601 (EC: IEA); GO_0015031 (EC: IEA); GO_0030030 (EC: IEA); GO_0034464 (EC: IDA, PMID: 17574030); GO_0045444 (EC: ISS); GO_0050896 (EC: IEA); GO_0060170 (EC: IEA)",,,,,,,,,PMID: 10221542; 12477932; 12618763; 12690205; 14702039; 15489334; 16380913; 17574030; 18029348; 18349106; 20161521; 20301537; 20379614; 20801516; 22479622; 23160099; 24250222,,,,,,,,,,,,,,,OGG:3000027241,,,,,,,Bardet-Biedl syndrome 9,,,,,,,,,,,,,Other designations: PTH-responsive osteosarcoma B1 protein|bardet-Biedl syndrome 9 protein|parathyroid hormone-responsive B1 gene protein|protein PTHB1,,BBS9,,,,,,,,,,,,,,,,,,,,,,,27241,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,BBS9,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000027244,SESN1,,Other designations: p53 activated gene 26|p53 regulated PA26 nuclear protein|sestrin-1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,SEST1|PA26,,,,,,,,,,,,6,,,,,,Ensembl:ENSG00000080546|Vega:OTTHUMG00000015338|MIM:606103|HPRD:07310|HGNC:21595,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,sestrin 1,,,6q21,,,,,,,,,,,,,,,,"GO_0005634 (EC: IEA); GO_0006974 (EC: TAS, PMID: 9926927); GO_0007050 (EC: IEA); GO_0008285 (EC: TAS, PMID: 9926927)",,,,,,,,,PMID: 7938006; 8889548; 9926927; 12477932; 12607115; 14702039; 15105503; 16751804; 18692468; 18703169; 19704005; 20800603; 21067298; 21890473; 21906983; 23000965; 23274085; 23535732; 24250222,,,,,,,,,,,,,,,OGG:3000027244,,,,,,,sestrin 1,,,,,,,,,,,,,Other designations: p53 activated gene 26|p53 regulated PA26 nuclear protein|sestrin-1,,SESN1,,,,,,,,,,,,,,,,,,,,,,,27244,RP11-787I22.2,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,SESN1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000027242,TNFRSF21,,Other designations: TNFR-related death receptor 6|death receptor 6|tumor necrosis factor receptor superfamily member 21,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,DR6|CD358|BM-018,,,,,,,,,,,,6,,,,,,Vega:OTTHUMG00000014796|HGNC:13469|MIM:605732|HPRD:05759|Ensembl:ENSG00000146072,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"tumor necrosis factor receptor superfamily, member 21",,,6p21.1,,,,,,,,,,,,,,,,"GO_0001783 (EC: ISS); GO_0002250 (EC: ISS); GO_0005515 (EC: IPI, PMID: 19225519); GO_0005886 (EC: TAS); GO_0005887 (EC: IDA, PMID: 19654028); GO_0006915 (EC: IMP); GO_0006959 (EC: ISS); GO_0030424 (EC: IEA); GO_0030889 (EC: ISS); GO_0031226 (EC: ISS); GO_0031642 (EC: IMP); GO_0042130 (EC: ISS); GO_0042552 (EC: ISS); GO_0044255 (EC: TAS); GO_0044281 (EC: TAS); GO_0048713 (EC: ISS); GO_0050852 (EC: ISS); GO_0051402 (EC: ISS); GO_0071356 (EC: IDA, PMID: 19654028); GO_0097252 (EC: ISS); GO_2000663 (EC: ISS); GO_2000666 (EC: ISS); GO_2001180 (EC: ISS)",,,,,,,,,PMID: 9714541; 11485735; 11714751; 11753679; 12477932; 12975309; 14574404; 14702039; 15301860; 15489334; 15623156; 16378686; 17962943; 18029348; 19165232; 19225519; 19322201; 19654028; 20237496; 20819778; 21337622; 21501873; 21900206; 22297296; 22525750; 22567163; 22761420; 24374337,,,,,,,,,,,,,,,OGG:3000027242,,,,,,,"tumor necrosis factor receptor superfamily, member 21",,,,,,,,,,,,,Other designations: TNFR-related death receptor 6|death receptor 6|tumor necrosis factor receptor superfamily member 21,,TNFRSF21,,,,,,,,,,,,,,,,,,,,,,,27242,UNQ437/PRO868,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,TNFRSF21,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_35471,psychotropic drug,psychoactive drugs|psychotropic drugs|psychoactive agent|psychopharmaceuticals,A loosely defined grouping of drugs that have effects on psychological function.,false,,,http://purl.obolibrary.org/obo/CHEBI_35470,,,,,,,,,,,,,,,,,,,,Wikipedia:Psychotropic_drug,,A loosely defined grouping of drugs that have effects on psychological function.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,psychoactive drugs|psychotropic drugs|psychoactive agent|psychopharmaceuticals,,,,,,,,,,,,,,,,,,,,,CHEBI:35471,,,,psychotropic drug,,CHEBI:35471,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100277,HB-EGF,heparin-binding EGF-like growth factor,,false,,,http://purl.obolibrary.org/obo/IMR_0000047,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,heparin-binding EGF-like growth factor,,,,,IMR:0100277,,,,,,,,,,,,,,,,,,,,,,HB-EGF,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000586,IL-7,interleukin-7,,false,,,http://purl.obolibrary.org/obo/IMR_0000007,,,,,,,,,,,,,,,,,,,,GO:0005139,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000622,,,,,interleukin-7,,,,,IMR:0000586,,,,,,,,,,,,,,,,,,,,,,IL-7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_3647,chlorpromazine,"3-(2-chloro-10H-phenothiazin-10-yl)-N,N-dimethylpropan-1-amine","A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,DrugBank:DB00477|CAS:50-53-3|LINCS:LSM-4017,,"A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety.",,,,,,,,,,,,C17H19ClN2S,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"3-(2-chloro-10H-phenothiazin-10-yl)-N,N-dimethylpropan-1-amine",,,,,CHEBI:3647,,,,,,,,,,,,,,,,,,,,,,chlorpromazine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc12,,,,,
http://purl.obolibrary.org/obo/CHEBI_26347,prostanoid,,The family of natural prostaglandins and prostaglandin-like compounds.,false,,,http://purl.obolibrary.org/obo/CHEBI_23899,,,,,,,,,,,,,,,,,,,,,,The family of natural prostaglandins and prostaglandin-like compounds.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:26347,,,,,,,,,,,,,,,,,,,,,,prostanoid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000032,PDGF,platelet derived growth factor,,false,,,http://purl.obolibrary.org/obo/TXPO_0001382,,,,,,,,,,,,,,,,,,,,GO:0005161,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002395|http://purl.obolibrary.org/obo/TXPO_0000624,,,,,platelet derived growth factor,,,,,IMR:0000032,,,,,,,,,,,,,,,,,,,,,,PDGF,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000056478,EIF4ENIF1,,Other designations: 2610509L04Rik|eIF4E transporter|eIF4E-transporter|eukaryotic translation initiation factor 4E transporter,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,4E-T|Clast4,,,,,,,,,,,,22,,,,,,Vega:OTTHUMG00000030793|Ensembl:ENSG00000184708|HPRD:10456|HGNC:16687|MIM:607445,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,eukaryotic translation initiation factor 4E nuclear import factor 1,,,22q11.2,,,,,,,,,,,,,,,,"GO_0005515 (EC: IPI, PMID:10856257); GO_0005634 (EC: TAS, PMID:10856257); GO_0005737 (EC: TAS, PMID:10856257); GO_0005829 (EC: IEA); GO_0008565 (EC: TAS, PMID:10856257); GO_0016605 (EC: IEA); GO_0016607 (EC: IEA); GO_0043231 (EC: IDA); GO_0044822 (EC: IDA)",,,,,,,,,PMID:10856257; 12477932; 14651998; 14702039; 15345747; 15461802; 15489334; 15840819; 16147992; 16157702; 16189514; 16343815; 16344560; 16699599; 16713569; 17314511; 17567994; 18029348; 18343217; 19060904; 19850929; 22094256; 22505724; 22751931; 22966201; 23902945; 24255178,,,,,,,,,,,,,,,OGG:3000056478,,,,,,,eukaryotic translation initiation factor 4E nuclear import factor 1,,,,,,,,,,,,,Other designations: 2610509L04Rik|eIF4E transporter|eIF4E-transporter|eukaryotic translation initiation factor 4E transporter,,EIF4ENIF1,,,,,,,,,,,,,,,,,,,,,,,56478,RP11-247I13.2,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF4ENIF1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000002673,GFPT1,,Other designations: D-fructose-6-phosphate amidotransferase 1|glucosamine--fructose-6-phosphate aminotransferase [isomerizing] 1|glutamine--fructose-6-phosphate aminotransferase [isomerizing] 1|glutamine:fructose-6-phosphate amidotransferase 1|hexosephosphate aminotransferase 1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,GFPT1L|GFA|GFAT1m|GFAT 1|MSLG|GFAT|GFAT1|CMSTA1|GFPT,,,,,,,,,,,,2,,,,,,HGNC:4241|Vega:OTTHUMG00000152666|MIM:138292|HPRD:00702|Ensembl:ENSG00000198380,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,glutamine--fructose-6-phosphate transaminase 1,,,2p13,,,,,,,,,,,,,,,,"GO_0004360 (EC: IEA); GO_0005829 (EC: TAS); GO_0006002 (EC: IEA); GO_0006042 (EC: IEA); GO_0006048 (EC: IEA); GO_0006048 (EC: TAS); GO_0006112 (EC: TAS, PMID: 1460020); GO_0006488 (EC: TAS); GO_0006541 (EC: IEA); GO_0006987 (EC: TAS); GO_0009744 (EC: IEA); GO_0016051 (EC: IEA); GO_0016597 (EC: IEA); GO_0018279 (EC: TAS); GO_0030246 (EC: IEA); GO_0030968 (EC: TAS); GO_0032869 (EC: IEA); GO_0032922 (EC: ISS); GO_0043687 (EC: TAS); GO_0044267 (EC: TAS); GO_0045719 (EC: IEA); GO_0051289 (EC: IEA); GO_0070062 (EC: IDA)",,,,,,,,,PMID: 1460020; 2037571; 7601477; 7607664; 8144040; 8619474; 9110174; 9519709; 10198162; 10806197; 10997685; 11587069; 11679416; 12477932; 12802498; 14988277; 15308130; 15489334; 15595739; 15613432; 15878746; 16341674; 16344560; 16964243; 17024311; 17081983; 17542649; 17941647; 18781797; 19059404; 19170765; 19322201; 20301347; 20562859; 20845477; 21139048; 21310273; 21890473; 21906983; 21988832; 22053931; 22505724; 22586326; 22863883; 22987706; 23000965; 23569079; 23794683; 24250222,,,,,,,,,,,,,,,OGG:3000002673,,,,,,,glutamine--fructose-6-phosphate transaminase 1,,,,,,,,,,,,,Other designations: D-fructose-6-phosphate amidotransferase 1|glucosamine--fructose-6-phosphate aminotransferase [isomerizing] 1|glutamine--fructose-6-phosphate aminotransferase [isomerizing] 1|glutamine:fructose-6-phosphate amidotransferase 1|hexosephosphate aminotransferase 1,,GFPT1,,,,,,,,,,,,,,,,,,,,,,,2673,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,GFPT1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000002674,GFRA1,,Other designations: GDNF family receptor alpha-1|GDNF receptor alpha-1|GDNFR-alpha-1|GPI-linked anchor protein|Glial cell line-derived neurotrophic factor receptor alpha|PI-linked cell-surface accessory protein|RET ligand 1|TGF-beta related neurotrophic factor receptor 1|TGF-beta-related neurotrophic factor receptor 1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,GFR-ALPHA-1|GDNFRA|RET1L|GDNFR|TRNR1|RETL1,,,,,,,,,,,,10,,,,,,Ensembl:ENSG00000151892|HPRD:03291|HGNC:4243|MIM:601496,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,GDNF family receptor alpha 1,,,10q26.11,,,,,,,,,,,,,,,,"GO_0005102 (EC: TAS, PMID: 9545641); GO_0005886 (EC: IEA); GO_0007166 (EC: NAS, PMID: 8674117); GO_0007411 (EC: TAS); GO_0016167 (EC: TAS, PMID: 10829012); GO_0019898 (EC: TAS, PMID: 10829012); GO_0031225 (EC: IEA); GO_0035860 (EC: TAS, PMID: 10829012); GO_0070062 (EC: IDA, PMID: 19056867)",,,,,,,,,PMID: 7829101; 8657309; 8674117; 8889548; 9108413; 9177201; 9182803; 9192898; 9407096; 9465905; 9482105; 9545641; 9600247; 9697851; 9740802; 10774729; 10821644; 10829012; 11182089; 11360200; 11932334; 12065680; 12477932; 12490080; 12624147; 12837245; 14514671; 14566559; 14702039; 14759258; 15310755; 15489334; 16175604; 16344560; 16385451; 16551639; 16644101; 16813162; 17298301; 17825269; 18089803; 18353777; 18394855; 18845535; 19019765; 19056867; 19188437; 19282698; 19896648; 20116071; 20347960; 20350599; 20379614; 20424473; 20669561; 21133924; 21988832; 22729463; 23351331; 23382691; 23793025; 23824909,,,,,,,,,,,,,,,OGG:3000002674,,20140408,protein-coding,,,,GDNF family receptor alpha 1,,,,,,,,,,,,,Other designations: GDNF family receptor alpha-1|GDNF receptor alpha-1|GDNFR-alpha-1|GPI-linked anchor protein|Glial cell line-derived neurotrophic factor receptor alpha|PI-linked cell-surface accessory protein|RET ligand 1|TGF-beta related neurotrophic factor receptor 1|TGF-beta-related neurotrophic factor receptor 1,,GFRA1,,,,,,,,,,,,,,,,,,,,,,,2674,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,GFRA1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000877,fat-soluble vitamin,,,false,,,http://purl.obolibrary.org/obo/IMR_0001656,,,,,,,,,,,,,,,,,,,,CHEBI:24020,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000877,,,,,,,,,,,,,,,,,,,,,,fat-soluble vitamin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_52717,bortezomib,N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE|Velcade|PS 341|bortezomib|PS-341|N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-N(alpha)-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide|[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid,L-Phenylalaninamide substituted at the amide nitrogen by a 1-(dihydroxyboranyl)-3-methylbutyl group and at N(alpha) by a pyrazin-2-ylcarbonyl group. It is a dipeptidyl boronic acid that reversibly inhibits the 26S proteasome.,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,DrugBank:DB00188|Reaxys:8723817|PMID:18980173|PMID:21504411|Drug_Central:391|PMID:18484921|PMID:21865767|CAS:179324-69-7|LINCS:LSM-6281|Wikipedia:Bortezomib,,L-Phenylalaninamide substituted at the amide nitrogen by a 1-(dihydroxyboranyl)-3-methylbutyl group and at N(alpha) by a pyrazin-2-ylcarbonyl group. It is a dipeptidyl boronic acid that reversibly inhibits the 26S proteasome.,,,,,,,,,,,,C19H25BN4O4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35610|http://purl.obolibrary.org/obo/CHEBI_37670|http://purl.obolibrary.org/obo/CHEBI_35820|http://purl.obolibrary.org/obo/CHEBI_52726,,,,,N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-N(alpha)-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide|[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid,,N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE|Velcade|PS 341|bortezomib|PS-341,,,,,,,,,,,,,,,,,,,,,CHEBI:52717,,,,bortezomib,,CHEBI:52717,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,,,,,
http://purl.obolibrary.org/obo/TXPO_0003375,phosphatidylethanolamine accumulation in lysosome [Phospholipidosis - phosphatidylethanolamine disorder],,"A process that keeps phosphatidylethanolamine in the lysosome.
This process can constitute the course of Phospholipidosis (phosphatidylethanolamine disorder).",false,,,http://purl.obolibrary.org/obo/TXPO_0001709,,,,,,,,,,,,,,,,,,,,,,"A process that keeps phosphatidylethanolamine in the lysosome.
This process can constitute the course of Phospholipidosis (phosphatidylethanolamine disorder).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003375,,,,,,,,,,,,,,,,,,,,,,phosphatidylethanolamine accumulation in lysosome [Phospholipidosis - phosphatidylethanolamine disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003378,phosphatidylserine accumulation in lysosome [Phospholipidosis - phosphatidylserine disorder ],,"A process that keeps phosphatidylserine in the lysosome.
This process can constitute the course of Phospholipidosis (phosphatidylserine disorder).",false,,,http://purl.obolibrary.org/obo/TXPO_0001703,,,,,,,,,,,,,,,,,,,,,,"A process that keeps phosphatidylserine in the lysosome.
This process can constitute the course of Phospholipidosis (phosphatidylserine disorder).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003378,,,,,,,,,,,,,,,,,,,,,,phosphatidylserine accumulation in lysosome [Phospholipidosis - phosphatidylserine disorder ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003377,phosphatidylcholine accumulation in lysosome [Phospholipidosis - phosphatidylcholine disorder],,"A process that keeps phosphatidylcholine in the lysosome.
This process can constitute the course of Phospholipidosis (phosphatidylethanolamine disorder).",false,,,http://purl.obolibrary.org/obo/TXPO_0001705,,,,,,,,,,,,,,,,,,,,,,"A process that keeps phosphatidylcholine in the lysosome.
This process can constitute the course of Phospholipidosis (phosphatidylethanolamine disorder).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003377,,,,,,,,,,,,,,,,,,,,,,phosphatidylcholine accumulation in lysosome [Phospholipidosis - phosphatidylcholine disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003372,phospholipid metabolism imbalance [Phospholipidosis (moderate) ],,"Phospholipid metabolism imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance of phospholipid metabolism. And the degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (moderate).",false,,,http://purl.obolibrary.org/obo/TXPO_0002324,,,,,,,,,,,,,,,,,,,,,,"Phospholipid metabolism imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance of phospholipid metabolism. And the degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (moderate).",,,http://purl.obolibrary.org/obo/TXPO_0001435,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003370|http://purl.obolibrary.org/obo/TXPO_0003371,,http://purl.obolibrary.org/obo/TXPO_0000680,,,,,,,,,TXPO:0003372,,,,,,,,,,,,,,,,,,,,,,phospholipid metabolism imbalance [Phospholipidosis (moderate) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003373,glycerophospholipid accumulation in lysosome  [Phospholipidosis - glycerophospholipid disorder ],,"Glycerophospholipid accumulation in lysosome is a subtype of phospholipid accumulation in lysosome: A process that keeps glycerophospholipid in the lysosome. And the degree is moderate.
This process is dependent on the glycerophospholipid disorder (moderate) and can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001697,,,,,,,,,,,,,,,,,,,,,,"Glycerophospholipid accumulation in lysosome is a subtype of phospholipid accumulation in lysosome: A process that keeps glycerophospholipid in the lysosome. And the degree is moderate.
This process is dependent on the glycerophospholipid disorder (moderate) and can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003373,,,,,,,,,,,,,,,,,,,,,,glycerophospholipid accumulation in lysosome  [Phospholipidosis - glycerophospholipid disorder ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003376,phosphatidylglycerol accumulation in lysosome  [Phospholipidosis - phosphatidylglycerol disorder],,"A process that keeps phosphatidylglycerol in the lysosome.
This process can constitute the course of Phospholipidosis (phosphatidylglycerol disorder ).",false,,,http://purl.obolibrary.org/obo/TXPO_0001707,,,,,,,,,,,,,,,,,,,,,,"A process that keeps phosphatidylglycerol in the lysosome.
This process can constitute the course of Phospholipidosis (phosphatidylglycerol disorder ).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003376,,,,,,,,,,,,,,,,,,,,,,phosphatidylglycerol accumulation in lysosome  [Phospholipidosis - phosphatidylglycerol disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003370,phospholipid homeostasis imbalance [Phospholipidosis (moderate) ],,"Phospholipid homeostasis imbalance is a subtype of lipid homeostasis imbalance: A process that becomes lacking a phospholipid homeostastasis balance. And the degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (moderate).",false,,,http://purl.obolibrary.org/obo/TXPO_0000907,,,,,,,,,,,,,,,,,,,,,,"Phospholipid homeostasis imbalance is a subtype of lipid homeostasis imbalance: A process that becomes lacking a phospholipid homeostastasis balance. And the degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (moderate).",,,http://purl.obolibrary.org/obo/TXPO_0001683,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003372,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003371,,http://purl.obolibrary.org/obo/TXPO_0000680,,,,,,,,,TXPO:0003370,,,,,,,,,,,,,,,,,,,,,,phospholipid homeostasis imbalance [Phospholipidosis (moderate) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003371,phospholipid accumulation in lysosome [Phospholipidosis (moderate) ],,"Phospholipid accumulation in lysosome is a subtype of phospholipid accumulation: A process that keeps phospholipid in the lysosome. And the degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (moderate).",false,,,http://purl.obolibrary.org/obo/TXPO_0000910,,,,,,,,,,,,,,,,,,,,,,"Phospholipid accumulation in lysosome is a subtype of phospholipid accumulation: A process that keeps phospholipid in the lysosome. And the degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (moderate).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003371,,,,,,,,,,,,,,,,,,,,,,phospholipid accumulation in lysosome [Phospholipidosis (moderate) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003379,phosphatidic acid accumulation in lysosome  [Phospholipidosis - phosphatidic acid disorder],,"A process that keeps phosphatidic acid in the lysosome.
This process can constitute the course of Phospholipidosis　phosphatidic acid disorder).",false,,,http://purl.obolibrary.org/obo/TXPO_0001701,,,,,,,,,,,,,,,,,,,,,,"A process that keeps phosphatidic acid in the lysosome.
This process can constitute the course of Phospholipidosis　phosphatidic acid disorder).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003379,,,,,,,,,,,,,,,,,,,,,,phosphatidic acid accumulation in lysosome  [Phospholipidosis - phosphatidic acid disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003374,phosphatidylinositol accumulation in lysosome  [Phospholipidosis -  phosphatidylinositol disorder],,"A process that keeps phosphatidylinositol in the lysosome.
This process can constitute the course of Phospholipidosis (phosphatidylinositol disorder ).",false,,,http://purl.obolibrary.org/obo/TXPO_0001831,,,,,,,,,,,,,,,,,,,,,,"A process that keeps phosphatidylinositol in the lysosome.
This process can constitute the course of Phospholipidosis (phosphatidylinositol disorder ).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003374,,,,,,,,,,,,,,,,,,,,,,phosphatidylinositol accumulation in lysosome  [Phospholipidosis -  phosphatidylinositol disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100091,MSH release-inhibiting hormone,MSHRIH|Melanostatin,,false,,,http://purl.obolibrary.org/obo/IMR_0100090,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MSHRIH|Melanostatin,,,,,IMR:0100091,,,,,,,,,,,,,,,,,,,,,,MSH release-inhibiting hormone,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_67105,insect sterilant,insect sterilants|insect chemosterilants|insect chemosterilant,A chemosterilant intended to sterilize insects.,false,,,http://purl.obolibrary.org/obo/CHEBI_24852|http://purl.obolibrary.org/obo/CHEBI_23092,,,,,,,,,,,,,,,,,,,,,,A chemosterilant intended to sterilize insects.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,insect sterilants|insect chemosterilants|insect chemosterilant,,,,,,,,,,,,,,,,,,,,,CHEBI:67105,,,,insect sterilant,,CHEBI:67105,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100674,TNF alpha receptor,,,false,,,http://purl.obolibrary.org/obo/IMR_0000056,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100674,,,,,,,,,,,,,,,,,,,,,,TNF alpha receptor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001208,Bmf,,,false,,,http://purl.obolibrary.org/obo/IMR_0100709,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001208,,,,,,,,,,,,,,,,,,,,,,Bmf,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_5937,Interferon alfa-2a,Interferon alpha-2A|Interferon alfa-2a,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:76543-88-9,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Interferon alfa-2a,,Interferon alpha-2A,,,,,,,,,,,,,,,,,,,,,CHEBI:5937,,,,Interferon alfa-2a,,CHEBI:5937,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_5938,Interferon beta-1b,Interferon beta-1b,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:145155-23-3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Interferon beta-1b,,,,,,,,,,,,,,,,,,,,,,,CHEBI:5938,,,,Interferon beta-1b,,CHEBI:5938,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0019915,lipid storage,storage of lipids|sequestration of lipids|retention of lipids|lipid retention|sequestration of lipid|lipid sequestering,"The accumulation and maintenance in cells or tissues of lipids, compounds soluble in organic solvents but insoluble or sparingly soluble in aqueous solvents. Lipid reserves can be accumulated during early developmental stages for mobilization and utilization at later stages of development.",false,,,http://purl.obolibrary.org/obo/TXPO_0000247,,,,,,,,,,,,,,,,,,,,,,"The accumulation and maintenance in cells or tissues of lipids, compounds soluble in organic solvents but insoluble or sparingly soluble in aqueous solvents. Lipid reserves can be accumulated during early developmental stages for mobilization and utilization at later stages of development.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_18059,,,,,,,,,,,,,,,,,,storage of lipids|sequestration of lipids|retention of lipids|lipid retention|sequestration of lipid|lipid sequestering,,,,,GO:0019915,,,,,,,,,,,,,,,,,,,,,,lipid storage,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000490,alpha-actin,,,false,,,http://purl.obolibrary.org/obo/IMR_0000190,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000490,,,,,,,,,,,,,,,,,,,,,,alpha-actin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0090398,cellular senescence,,"A cell aging process stimulated in response to cellular stress, whereby normal cells lose the ability to divide through irreversible cell cycle arrest.",false,,,http://purl.obolibrary.org/obo/TXPO_0000392,,,,,,,,,,,,,,,,,,,,,,"A cell aging process stimulated in response to cellular stress, whereby normal cells lose the ability to divide through irreversible cell cycle arrest.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0090398,,,,,,,,,,,,,,,,,,,,,,cellular senescence,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0011415,NDKB,,,false,,,http://purl.obolibrary.org/obo/IMR_0010012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0011415,,,,,,,,,,,,,,,,,,,,,,NDKB,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001612,Rab27A,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001612,,,,,,,,,,,,,,,,,,,,,,Rab27A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000001,p53 signaling (primitive),,P53 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the PERK. PERK generally plays a endoplasmic reticulum membrane stress sensor  role.,false,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,,,P53 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the PERK. PERK generally plays a endoplasmic reticulum membrane stress sensor  role.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0072331,,,,,,,,,,,,,,,,TXPO:0000001,,,,,,,,,,,,,,,,,,,,,,p53 signaling (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000000,MDM2 (canonical)[Glutathione depletion],,"This gene encodes a nuclear-localized E3 ubiquitin ligase. The encoded protein can promote tumor formation by targeting tumor suppressor proteins, such as p53, for proteasomal degradation. This gene is itself transcriptionally-regulated by p53. Overexpression or amplification of this locus is detected in a variety of different cancers. There is a pseudogene for this gene on chromosome 2. Alternative splicing results in a multitude of transcript variants, many of which may be expressed only in tumor cells. [provided by RefSeq, Jun 2013]",false,,,http://purl.obolibrary.org/obo/TXPO_0002045|http://purl.obolibrary.org/obo/IMR_0100660,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:17246|NCBI-Human-GeneID:4193|http://www.genecards.org/cgi-bin/carddisp.pl?gene=MDM2|NCBI-Rat-GeneID:314856,,"This gene encodes a nuclear-localized E3 ubiquitin ligase. The encoded protein can promote tumor formation by targeting tumor suppressor proteins, such as p53, for proteasomal degradation. This gene is itself transcriptionally-regulated by p53. Overexpression or amplification of this locus is detected in a variety of different cancers. There is a pseudogene for this gene on chromosome 2. Alternative splicing results in a multitude of transcript variants, many of which may be expressed only in tumor cells. [provided by RefSeq, Jun 2013]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002399,,,,,,,,,,TXPO:0000000,,,,,,,,,,,,,,,,,,,,,,MDM2 (canonical)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000009,toxic course,,"Toxic course is a subtype of process sequence: A series of process in an organism from latent to the manifestation of toxicity, which is not part of the life of the organism.",false,,,http://purl.obolibrary.org/obo/TXPO_0000608,,,,,,,,,,,,,,,,,,,,,,"Toxic course is a subtype of process sequence: A series of process in an organism from latent to the manifestation of toxicity, which is not part of the life of the organism.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001715,,,,,,,,,,,,,,,,,,TXPO:0000009,,,,,,,,,,,,,,,,,,,,,,toxic course,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000008,cell ceath [cell death (toxic course)],,"Any biological process that results in permanent cessation of all vital functions of a cell.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0001727|http://purl.obolibrary.org/obo/GO_0008219,,,,,,,,,,,,,,,,,,,,,,"Any biological process that results in permanent cessation of all vital functions of a cell.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000008,,,,,,,,,,,,,,,,,,,,,,cell ceath [cell death (toxic course)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000006,Abcb11,,,false,,,http://purl.obolibrary.org/obo/TXPO_1000014,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000006,,,,,,,,,,,,,,,,,,,,,,Abcb11,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000002,phospholipase transport to lysosome,,Phospholipase transport to lysosome is a subtype of molecule transport: A process of the directed movement of phospholipase to the lysosome.,false,,,http://purl.obolibrary.org/obo/TXPO_0000111,,,,,,,,,,,,,,,,,,,,,,Phospholipase transport to lysosome is a subtype of molecule transport: A process of the directed movement of phospholipase to the lysosome.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005764,,,,,,,,TXPO:0000002,,,,,,,,,,,,,,,,,,,,,,phospholipase transport to lysosome,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000003,moving solid,,"Moving solid is a subtype of moving. A process that change the location of the solid.
.",false,,,http://purl.obolibrary.org/obo/TXPO_0000429,,,,,,,,,,,,,,,,,,,,,,"Moving solid is a subtype of moving. A process that change the location of the solid.
.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000003,,,,,,,,,,,,,,,,,,,,,,moving solid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000007,generating periodic motion,,Generating periodic motion is a subtype of generating motion: A process that generates the directed movement in which the object decreases in volume.,false,,,http://purl.obolibrary.org/obo/TXPO_0000765,,,,,,,,,,,,,,,,,,,,,,Generating periodic motion is a subtype of generating motion: A process that generates the directed movement in which the object decreases in volume.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000007,,,,,,,,,,,,,,,,,,,,,,generating periodic motion,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100841,SOCS-5,Suppressor of cytokine signaling 5|CIS-6|Cytokine-inducible SH2 protein 6,,false,,,http://purl.obolibrary.org/obo/IMR_0000460,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Suppressor of cytokine signaling 5|CIS-6|Cytokine-inducible SH2 protein 6,,,,,IMR:0100841,,,,,,,,,,,,,,,,,,,,,,SOCS-5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100314,Smad8,Smad9,,false,,,http://purl.obolibrary.org/obo/IMR_0100507,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Smad9,,,,,IMR:0100314,,,,,,,,,,,,,,,,,,,,,,Smad8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001634,acetaldehyde [Lipidosis],,,false,,,http://purl.obolibrary.org/obo/CHEBI_15343|http://purl.obolibrary.org/obo/TXPO_0003508,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001634,,,,,,,,,,,,,,,,,,,,,,acetaldehyde [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001631,increasing amount of foreign substance,,Increasing amount of foreign substance is a subtype of increasing quantity: A process that changes the amount of foreign substance to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing amount of foreign substance is a subtype of increasing quantity: A process that changes the amount of foreign substance to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001631,,,,,,,,,,,,,,,,,,,,,,increasing amount of foreign substance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001632,PPAR alpha (canonical) [lipidosis],Peroxisome Proliferator-Activated Receptor Alpha [lipidosis],,false,,,http://purl.obolibrary.org/obo/TXPO_0000159|http://purl.obolibrary.org/obo/TXPO_0003516,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:19013|NCBI-Rat-GeneID:25747|NCBI-Human-GeneID:5465,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Peroxisome Proliferator-Activated Receptor Alpha [lipidosis],,,,,TXPO:0001632,,,,,,,,,,,,,,,,,,,,,,PPAR alpha (canonical) [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001630,increasing phosphatidylserine material,,Increasing phosphatidylserine material is a subtype of increasing glycerophospholipid material: A process that changes the amount of phosphatidylserine material to be larger.,false,,,http://purl.obolibrary.org/obo/TXPO_0001317,,,,,,,,,,,,,,,,,,,,,,Increasing phosphatidylserine material is a subtype of increasing glycerophospholipid material: A process that changes the amount of phosphatidylserine material to be larger.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001630,,,,,,,,,,,,,,,,,,,,,,increasing phosphatidylserine material,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001635,increasing amount of drug,,Increasing amount of drug is a subtype of increasing amount of xenobiotics: A process that changes the amount of drug to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0001633,,,,,,,,,,,,,,,,,,,,,,Increasing amount of drug is a subtype of increasing amount of xenobiotics: A process that changes the amount of drug to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001635,,,,,,,,,,,,,,,,,,,,,,increasing amount of drug,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001636,AMPK inactivation,,AMPK inactivation is a subtype of molecular inactivation: A process that  changes the activity of the AMPK (AMP-activated protein kinase) to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000021,,,,,,,,,,,,,,,,,,,,,,AMPK inactivation is a subtype of molecular inactivation: A process that  changes the activity of the AMPK (AMP-activated protein kinase) to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001636,,,,,,,,,,,,,,,,,,,,,,AMPK inactivation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001633,increasing amount of xenobiotics,,Increasing amount of xenobiotics is a subtype of increasing amount of foreign substance: A process that changes the amount of xenobiotics to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0001631,,,,,,,,,,,,,,,,,,,,,,Increasing amount of xenobiotics is a subtype of increasing amount of foreign substance: A process that changes the amount of xenobiotics to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001633,,,,,,,,,,,,,,,,,,,,,,increasing amount of xenobiotics,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001638,AMPK inactivation [lipidosis],,"AMPK inactivation is a subtype of molecular inactivation: A process that changes the activity of the AMPK (AMP-activated protein kinase) to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001636|http://purl.obolibrary.org/obo/TXPO_0001720,,,,,,,,,,,,,,,,,,,,PMID:17854140,,"AMPK inactivation is a subtype of molecular inactivation: A process that changes the activity of the AMPK (AMP-activated protein kinase) to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000670,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001652,,,,http://purl.obolibrary.org/obo/TXPO_0001711,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001115,,,,,,,,,,,TXPO:0001638,,,,,,,"AMPK is sensitive to energy charge, which is activated by an increase in the ratio of AMP/ATP.",,,,,,,,,,,,,,,AMPK inactivation [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001637,increasing amount of drug [Ground glass appearance],,"Increasing amount of drug is a subtype of increasing amount of xenobiotics: A process that changes the amount of drug to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001635|http://purl.obolibrary.org/obo/TXPO_0001728,,,,,,,,,,,,,,,,,,,,,,"Increasing amount of drug is a subtype of increasing amount of xenobiotics: A process that changes the amount of drug to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001714,,,,,,,,,,,,,,,,,,TXPO:0001637,,,,,,,,,,,,,,,,,,,,,,increasing amount of drug [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001639,decreasing amount of drug,,Decreasing amount of drug is a subtype of decreasing amount of xenobiotics: A process that changes the quantity of the drug  to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000822,,,,,,,,,,,,,,,,,,,,,,Decreasing amount of drug is a subtype of decreasing amount of xenobiotics: A process that changes the quantity of the drug  to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0017144,,,,,,,,,,,,,,,,,,TXPO:0001639,,,,,,,,,,,,,,,,,,,,,,decreasing amount of drug,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000292,R-Ras,related to Ras,,false,,,http://purl.obolibrary.org/obo/IMR_0000289,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,related to Ras,,,,,IMR:0000292,,,,,,,,,,,,,,,,,,,,,,R-Ras,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0002420,amphiphilic,,Having both hydrophilic and hydrophobic (or lipophilic) groups.,false,,,http://purl.obolibrary.org/obo/PATO_0002070,,,,,,,,,,,,,,,,,,,,,,Having both hydrophilic and hydrophobic (or lipophilic) groups.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0002420,,,,,,,,,,,,,,,,,,,,,,amphiphilic,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004218,tumorigenesis [Mitochondrial disorder],,"A pathologic process that involves the transformation of normal cells to a neoplastic state and resulting in polyclonal or monoclonal neoplastic cell proliferation.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/NCIT_C18121|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:25181692|PMID:31623280|PMID:30894684,,"A pathologic process that involves the transformation of normal cells to a neoplastic state and resulting in polyclonal or monoclonal neoplastic cell proliferation.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003610|http://purl.obolibrary.org/obo/TXPO_0004319|http://purl.obolibrary.org/obo/TXPO_0004318,,,,,,,,,,,,,,,,,TXPO:0004218,,,,,,,,,,,,,,,,,,,,,,tumorigenesis [Mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004219,ACTA2(mouse) [mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004226|http://purl.obolibrary.org/obo/TXPO_0004290,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:11475|PMID:29222479,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004219,,,,,,,,,,,,,,,,,,,,,,ACTA2(mouse) [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004211,toxicity (attribute),,An attribute of the finding of bodily harm due to the poisonous effects of something.,false,,,http://purl.obolibrary.org/obo/TXPO_0000305,,,,,,,,,,,,,,,,,,,,,,An attribute of the finding of bodily harm due to the poisonous effects of something.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004211,,,,,,,,,,,,,,,,,,,,,,toxicity (attribute),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004212,negative regulation of protein-containing complex assembly,inhibition of protein-containing complex assembly|downregulation of protein-containing complex assembly|down regulation of protein-containing complex assembly|down-regulation of protein-containing complex assembly,"Any process that stops, prevents, or reduces the frequency, rate or extent of protein-containing complex assembly.",false,,,http://purl.obolibrary.org/obo/TXPO_0000369,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents, or reduces the frequency, rate or extent of protein-containing complex assembly.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,downregulation of protein-containing complex assembly|down regulation of protein-containing complex assembly|down-regulation of protein-containing complex assembly,inhibition of protein-containing complex assembly,,,,TXPO:0004212,,,,,,,,,,,,,,,,,,,,,,negative regulation of protein-containing complex assembly,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0065003,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004213,negative regulation of mitochondrial respiratory chain complex assembly,,"Any process that stops, prevents, or reduces the frequency, rate or extent of mitochondrial respiratory chain complex assembly.",false,,,http://purl.obolibrary.org/obo/TXPO_0004212,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents, or reduces the frequency, rate or extent of mitochondrial respiratory chain complex assembly.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004213,,,,,,,,,,,,,,,,,,,,,,negative regulation of mitochondrial respiratory chain complex assembly,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0033108,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004210,lipid accumulation in hepatocyte (severe) [Alcoholic  fatty liver],lipid storage in hepatocyte (severe) [Lipidosis],"Lipid accumulation in hepatocyte (severe) is a subtype of lipid strorage in hepatocyte: A process that keeps lipids in hepatocytes. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Alcoholic  fatty liver.",false,,,http://purl.obolibrary.org/obo/TXPO_0003476,,,,,,,,,,,,,,,,,,,,,,"Lipid accumulation in hepatocyte (severe) is a subtype of lipid strorage in hepatocyte: A process that keeps lipids in hepatocytes. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Alcoholic  fatty liver.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003541,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001232,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003495|http://purl.obolibrary.org/obo/TXPO_0003511|http://purl.obolibrary.org/obo/TXPO_0003512|http://purl.obolibrary.org/obo/TXPO_0003480|http://purl.obolibrary.org/obo/TXPO_0003622|http://purl.obolibrary.org/obo/TXPO_0003478|http://purl.obolibrary.org/obo/TXPO_0000897,,,,,,lipid storage in hepatocyte (severe) [Lipidosis],,,,,TXPO:0004210,,,,,,,,,,,,,,,,,,,,,,lipid accumulation in hepatocyte (severe) [Alcoholic  fatty liver],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004215,negative regulation of mitochondrial respiratory chain complex II assembly,,"Any process that stops, prevents, or reduces the frequency, rate or extent of mitochondrial respiratory chain complex II assembly.",false,,,http://purl.obolibrary.org/obo/TXPO_0004213,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents, or reduces the frequency, rate or extent of mitochondrial respiratory chain complex II assembly.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004215,,,,,,,,,,,,,,,,,,,,,,negative regulation of mitochondrial respiratory chain complex II assembly,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0034553,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004214,negative regulation of mitochondrial respiratory chain complex I assembly,,"Any process that stops, prevents, or reduces the frequency, rate or extent of mitochondrial respiratory chain complex I assembly.",false,,,http://purl.obolibrary.org/obo/TXPO_0004213,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents, or reduces the frequency, rate or extent of mitochondrial respiratory chain complex I assembly.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004214,,,,,,,,,,,,,,,,,,,,,,negative regulation of mitochondrial respiratory chain complex I assembly,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0032981,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004216,negative regulation of mitochondrial respiratory chain complex III assembly,,"Any process that stops, prevents, or reduces the frequency, rate or extent of mitochondrial respiratory chain complex III assembly.",false,,,http://purl.obolibrary.org/obo/TXPO_0004213,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents, or reduces the frequency, rate or extent of mitochondrial respiratory chain complex III assembly.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004216,,,,,,,,,,,,,,,,,,,,,,negative regulation of mitochondrial respiratory chain complex III assembly,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0034551,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004217,negative regulation of mitochondrial respiratory chain complex IV assembly,,"Any process that stops, prevents, or reduces the frequency, rate or extent of mitochondrial respiratory chain complex IV assembly.",false,,,http://purl.obolibrary.org/obo/TXPO_0004213,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents, or reduces the frequency, rate or extent of mitochondrial respiratory chain complex IV assembly.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004217,,,,,,,,,,,,,,,,,,,,,,negative regulation of mitochondrial respiratory chain complex IV assembly,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0033617,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100428,GAP1m,,,false,,,http://purl.obolibrary.org/obo/IMR_0000443,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100428,,,,,,,,,,,,,,,,,,,,,,GAP1m,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100387,IFN omega,Interferon omega,,false,,,http://purl.obolibrary.org/obo/IMR_0000028,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Interferon omega,,,,,IMR:0100387,,,,,,,,,,,,,,,,,,,,,,IFN omega,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000830,ATF-5 (mol),activating transcription factor 5,,false,,,http://purl.obolibrary.org/obo/IMR_0000825,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,activating transcription factor 5,,,,,IMR:0000830,,,,,,,,,,,,,,,,,,,,,,ATF-5 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000003159,HMGA1,,Other designations: HMG-I(Y)|high mobility group protein A1|high mobility group protein HMG-I/HMG-Y|high mobility group protein R|high-mobility group (nonhistone chromosomal) protein isoforms I and Y|nonhistone chromosomal high-mobility group protein HMG-I/HMG-Y,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,HMGIY|HMGA1A|HMG-R,,,,,,,,,,,,6,,,,,,HGNC:5010|HPRD:02829|Ensembl:ENSG00000137309|MIM:600701|Vega:OTTHUMG00000014539,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,high mobility group AT-hook 1,,,6p21,,,,,,,,,,,,,,,,"GO_0000737 (EC: IDA, PMID: 19465398); GO_0003677 (EC: TAS, PMID: 10871404); GO_0003680 (EC: TAS, PMID: 10428834); GO_0003700 (EC: IMP, PMID: 10428834); GO_0003906 (EC: IDA, PMID: 19465398); GO_0005515 (EC: IPI, PMID: 10428834); GO_0005634 (EC: IDA, PMID: 16901784); GO_0005654 (EC: TAS); GO_0005667 (EC: TAS, PMID: 10428834); GO_0005829 (EC: TAS); GO_0006268 (EC: NAS, PMID: 10428834); GO_0006284 (EC: IDA, PMID: 19465398); GO_0006337 (EC: TAS, PMID: 10428834); GO_0006351 (EC: IEA); GO_0006355 (EC: TAS, PMID: 10871404); GO_0006461 (EC: TAS, PMID: 10428834); GO_0008134 (EC: IDA, PMID: 10428834); GO_0008285 (EC: IMP, PMID: 16901784); GO_0009615 (EC: IEP, PMID: 17005673); GO_0016032 (EC: TAS); GO_0019899 (EC: IPI, PMID: 16157300); GO_0030374 (EC: IMP, PMID: 10428834); GO_0031936 (EC: TAS, PMID: 10428834); GO_0035985 (EC: IDA, PMID: 16901784); GO_0035986 (EC: IDA, PMID: 16901784); GO_0042974 (EC: IDA, PMID: 10428834); GO_0042975 (EC: IDA, PMID: 10428834); GO_0045892 (EC: IMP, PMID: 16901784); GO_0045893 (EC: IMP, PMID: 10428834); GO_0046965 (EC: IDA, PMID: 10428834); GO_0051575 (EC: IDA, PMID: 19465398); GO_0075713 (EC: TAS); GO_0090402 (EC: IDA, PMID: 16901784); GO_2000774 (EC: IMP, PMID: 16901784)",,,,,,,,,PMID: 1692833; 1939057; 2505228; 2701943; 2806554; 2920035; 3619901; 7791781; 7862168; 8414980; 9038339; 9188609; 9253416; 9388234; 9545312; 9751634; 9809067; 9823775; 10074149; 10357819; 10428834; 10428835; 10428836; 10428837; 10713105; 10871404; 10889043; 10891489; 11034995; 11069991; 11076660; 11279116; 11406267; 11498590; 11593421; 11834421; 11978964; 12002338; 12091904; 12097287; 12228227; 12477932; 12653562; 12665574; 12700639; 12761578; 13680222; 14611647; 14702039; 14729942; 14960313; 15213251; 15231747; 15247513; 15302935; 15350136; 15378028; 15479846; 15489334; 15569996; 15591590; 15609325; 15631895; 15835918; 15875659; 15893306; 15901130; 15924147; 16033759; 16075307; 16157300; 16166307; 16189514; 16204234; 16256199; 16291214; 16293633; 16344560; 16403635; 16901784; 17005673; 17045586; 17081983; 17178855; 17434141; 17550233; 17616660; 17654722; 17723105; 17877762; 17903177; 17935122; 17960875; 18202751; 18234858; 18279675; 18310298; 18316571; 18391951; 18473350; 18670638; 18817785; 18850631; 19060921; 19074878; 19223528; 19250063; 19266077; 19343178; 19396169; 19454010; 19465398; 19609535; 19687300; 19729480; 19738201; 19739099; 19750561; 19759913; 19820691; 19848064; 19893584; 19903768; 19913121; 19956671; 20004941; 20189936; 20194618; 20201926; 20335021; 20347905; 20360068; 20379614; 20397748; 20530667; 20546612; 20628086; 20881960; 20935630; 20975707; 21087998; 21089648; 21138859; 21139048; 21156240; 21282977; 21300033; 21319273; 21329653; 21364139; 21573994; 21656127; 21906983; 21957495; 21984063; 21998595; 22106824; 22113938; 22139073; 22156211; 22199144; 22210315; 22214847; 22221703; 22249617; 22332738; 22379092; 22392906; 22411136; 22503056; 22505724; 22564666; 22745191; 22898640; 22932725; 22939624; 22939629; 22961697; 23000965; 23149213; 23166588; 23201162; 23275563; 23302499; 23311322; 23394223; 23398456; 23508853; 23530587; 23545254; 23563607; 23658826; 23796420; 23798998; 23935884; 24122990,,,,,,,,,,,,,,,OGG:3000003159,,,,,,,high mobility group AT-hook 1,,,,,,,,,,,,,Other designations: HMG-I(Y)|high mobility group protein A1|high mobility group protein HMG-I/HMG-Y|high mobility group protein R|high-mobility group (nonhistone chromosomal) protein isoforms I and Y|nonhistone chromosomal high-mobility group protein HMG-I/HMG-Y,,HMGA1,,,,,,,,,,,,,,,,,,,,,,,3159,RP11-513I15.2,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,HMGA1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000003157,HMGCS1,,"Other designations: 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) synthase|3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 (soluble)|hydroxymethylglutaryl-CoA synthase, cytoplasmic",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,HMGCS,,,,,,,,,,,,5,,,,,,HPRD:07515|Ensembl:ENSG00000112972|MIM:142940|Vega:OTTHUMG00000162231|HGNC:5007,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,3-hydroxy-3-methylglutaryl-CoA synthase 1 (soluble),,,5p14-p13,,,,,,,,,,,,,,,,"GO_0001101 (EC: IEA); GO_0001889 (EC: IEA); GO_0004421 (EC: IEA); GO_0005634 (EC: IDA); GO_0005730 (EC: IDA, Qualifier: NOT); GO_0005737 (EC: IDA); GO_0005829 (EC: TAS); GO_0005886 (EC: IDA); GO_0006629 (EC: NAS, PMID: 7913309); GO_0006695 (EC: TAS); GO_0007420 (EC: IEA); GO_0008144 (EC: IEA); GO_0008299 (EC: IEA); GO_0008584 (EC: IEA); GO_0009645 (EC: IEA); GO_0014074 (EC: IEA); GO_0016853 (EC: IEA); GO_0033197 (EC: IEA); GO_0042493 (EC: IEA); GO_0042803 (EC: IEA); GO_0043177 (EC: IEA); GO_0044255 (EC: TAS); GO_0044281 (EC: TAS); GO_0046690 (EC: IEA); GO_0055094 (EC: IEA); GO_0071372 (EC: IEA); GO_0071397 (EC: IEA)",,,,,,,,,PMID: 1358203; 1971108; 2870496; 2877984; 3470763; 7913309; 12477932; 14702039; 15489334; 16344560; 17081983; 18029348; 18636124; 18660489; 18854154; 19088433; 20346956; 21139048; 21890473; 21906983; 21963094; 22053931; 22505724; 22939629; 23000965; 23464991,,,,,,,,,,,,,,,OGG:3000003157,,,,,,,3-hydroxy-3-methylglutaryl-CoA synthase 1 (soluble),,,,,,,,,,,,,"Other designations: 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) synthase|3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 (soluble)|hydroxymethylglutaryl-CoA synthase, cytoplasmic",,HMGCS1,,,,,,,,,,,,,,,,,,,,,,,3157,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,HMGCS1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000003158,HMGCS2,,"Other designations: 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 (mitochondrial)|HMG-CoA synthase|hydroxymethylglutaryl-CoA synthase, mitochondrial",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,1,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,3-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial),,,1p13-p12,,,,,,,,,,,,,,,,"GO_0004421 (EC: IEA); GO_0005739 (EC: TAS, PMID: 7851882); GO_0005743 (EC: IEA); GO_0005759 (EC: TAS); GO_0006695 (EC: IEA); GO_0008299 (EC: IEA); GO_0044255 (EC: TAS); GO_0044281 (EC: TAS); GO_0046950 (EC: TAS); GO_0046951 (EC: TAS)",,,,,,,,,PMID: 6986618; 7851882; 7893153; 9305755; 11228257; 11479731; 12477932; 12647205; 15489334; 16940161; 17387528; 18636124; 18660489; 19913121; 20346956; 20549515; 20618440; 20628086; 20877624; 21502324; 21832049; 21890473; 21906983; 21952825; 22505724,,,,,,,,,,,,,,,OGG:3000003158,,,,,,,3-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial),,,,,,,,,,,,,"Other designations: 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 (mitochondrial)|HMG-CoA synthase|hydroxymethylglutaryl-CoA synthase, mitochondrial",,HMGCS2,,,,,,,,,,,,,,,,,,,,,,,3158,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,HMGCS2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/GO_0019216,regulation of lipid metabolic process,regulation of lipid metabolism,"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving lipids.",false,,,http://purl.obolibrary.org/obo/GO_0019222,,,,,,,,,,,,,,,,,,,,,,"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving lipids.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,regulation of lipid metabolism,,,,,GO:0019216,,,,,,,,,,,,,,,,,,,,,,regulation of lipid metabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006629,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000754,cxcl10 [ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003281,,,,,,,,,,,,,,,,,,,CHOP->NfKB->CXCL10->inflammation in beta cells PMID:22653339,NCBI-Human-GeneID:3627|http://www.ncbi.nlm.nih.gov/gene/3627|PMID:22653339,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000754,,,,,,,,,,,,,,,,,,,,,,cxcl10 [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000192,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000751,endoplasmic reticulum dysfunction,,Endoplasmic reticulum dysfunction is a subtype of dysfunctioning: A process that performs an abnormal and incomplete endoplasmic reticulum function.,false,,,http://purl.obolibrary.org/obo/TXPO_0000438,,,,,,,,,,,,,,,,,,,,,,Endoplasmic reticulum dysfunction is a subtype of dysfunctioning: A process that performs an abnormal and incomplete endoplasmic reticulum function.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005783,,,,,,,,,,,,,,,,,TXPO:0000751,,,,,,,,,,,,,,,,,,,,,,endoplasmic reticulum dysfunction,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000757,positive regulation of lysophagy,,"Any process that activates, maintains or increases the rate of lysophagy.",false,,,http://purl.obolibrary.org/obo/TXPO_0000755|http://purl.obolibrary.org/obo/GO_0010508,,,,,,,,,,,,,,,,,,,,,,"Any process that activates, maintains or increases the rate of lysophagy.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000757,,,,,,,,,,,,,,,,,,,,,,positive regulation of lysophagy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0062093,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000752,endoplasmic reticulum dysfunction [ER stress],,"Endoplasmic reticulum dysfunction is a subtype of dysfunctioning: A process that performs an abnormal and incomplete endoplasmic reticulum function.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000751|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"Endoplasmic reticulum dysfunction is a subtype of dysfunctioning: A process that performs an abnormal and incomplete endoplasmic reticulum function.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003276|http://purl.obolibrary.org/obo/TXPO_0002194|http://purl.obolibrary.org/obo/TXPO_0002199|http://purl.obolibrary.org/obo/TXPO_0002197|http://purl.obolibrary.org/obo/TXPO_0002191|http://purl.obolibrary.org/obo/TXPO_0002188,,,,,,,,,,,TXPO:0000752,,,,,,,,,,,,,,,,,,,,,,endoplasmic reticulum dysfunction [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005783,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000758,tumorigenesis [ER stress],,"A pathologic process that involves the transformation of normal cells to a neoplastic state and resulting in polyclonal or monoclonal neoplastic cell proliferation.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/NCIT_C18121,,,,,,,,,,,,,,,,,,,,PMID:27334111|PMID:22883813,,"A pathologic process that involves the transformation of normal cells to a neoplastic state and resulting in polyclonal or monoclonal neoplastic cell proliferation.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002534|http://purl.obolibrary.org/obo/TXPO_0002535|http://purl.obolibrary.org/obo/TXPO_0000767,http://purl.obolibrary.org/obo/TXPO_0000754|http://purl.obolibrary.org/obo/TXPO_0001968,,,,,,http://purl.obolibrary.org/obo/TXPO_0000764,,,,,,,,,,,TXPO:0000758,,,,,,,,,,,,,,,,,,,,,,tumorigenesis [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000755,regulation of lysophagy,,"Any process that modulates the frequency, rate or extent of lysophagy.",false,,,http://purl.obolibrary.org/obo/GO_0010506,,,,,,,,,,,,,,,,,,,,,,"Any process that modulates the frequency, rate or extent of lysophagy.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000755,,,,,,,,,,,,,,,,,,,,,,regulation of lysophagy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0062093,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000753,ER stress dependent molecule (rat),,"ER stress dependent molecule is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of ER stress as a gene product.
Gene profile:Rat/Liver/",false,,,http://purl.obolibrary.org/obo/TXPO_0000794,,,,,,,,,,,,,,,,,,,,,,"ER stress dependent molecule is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of ER stress as a gene product.
Gene profile:Rat/Liver/",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000753,,,,,,,,,,,,,,,,,,,,,,ER stress dependent molecule (rat),,,,,,,,,,,http://purl.obolibrary.org/obo/NCBITaxon_10114,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000759,activator of tumor cell activity role,,A role played by the entity that activates the activity of tumor cells.,false,,,http://purl.obolibrary.org/obo/TXPO_0003725,,,,,,,,,,,,,,,,,,,,,,A role played by the entity that activates the activity of tumor cells.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000759,,,,,,,,,,,,,,,,,,,,,,activator of tumor cell activity role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_1904294,positive regulation of ERAD,,"Any process that activates or increases the frequency, rate or extent of ERAD pathway.",false,,,http://purl.obolibrary.org/obo/GO_0045862,,,,,,,,,,,,,,,,,,,,,,"Any process that activates or increases the frequency, rate or extent of ERAD pathway.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:1904294,,,,,,,,,,,,,,,,,,,,,,positive regulation of ERAD,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0036503,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100123,serotonin,enteramine|3-(2-Aminoethyl)-1H-indol-5-ol|Serotonin|5-Hydroxytryptamine,,false,,,http://purl.obolibrary.org/obo/IMR_0002121,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_25512|http://purl.obolibrary.org/obo/CHEBI_24621,,,,IMR:0200412,enteramine|3-(2-Aminoethyl)-1H-indol-5-ol|Serotonin|5-Hydroxytryptamine,,,,,IMR:0100123,,,,,,,,,,,,,,,,,,,,,,serotonin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CL_0000056,myoblast,,"A cell that is commited to differentiating into a muscle cell.  Embryonic myoblasts develop from the mesoderm. They undergo proliferation, migrate to their various sites, and then differentiate into the appropriate form of myocytes.  Myoblasts also occur as transient populations of cells in muscles undergoing repair.",false,,,http://purl.obolibrary.org/obo/CL_0000000,,,,,,,,,,,,,,,,,,,,,,"A cell that is commited to differentiating into a muscle cell.  Embryonic myoblasts develop from the mesoderm. They undergo proliferation, migrate to their various sites, and then differentiate into the appropriate form of myocytes.  Myoblasts also occur as transient populations of cells in muscles undergoing repair.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CL:0000056,,,,,,,,,,,,,,,,,,,,,,myoblast,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CL_0000057,fibroblast,,A connective tissue cell which secretes an extracellular matrix rich in collagen and other macromolecules. Flattened and irregular in outline with branching processes; appear fusiform or spindle-shaped.,false,,,http://purl.obolibrary.org/obo/CL_0002320,,,,,,,,,,,,,,,,,,,,FMA:63877|BTO:0000452,,A connective tissue cell which secretes an extracellular matrix rich in collagen and other macromolecules. Flattened and irregular in outline with branching processes; appear fusiform or spindle-shaped.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CL:0000057,,,,,,,,,,,,,,,,,,,,,,fibroblast,,,,,,,http://purl.obolibrary.org/obo/cl.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100396,IRS-4,insulin receptor substrate-4,,false,,,http://purl.obolibrary.org/obo/IMR_0000351,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,insulin receptor substrate-4,,,,,IMR:0100396,,,,,,,,,,,,,,,,,,,,,,IRS-4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000699,Cdc42,,,false,,,http://purl.obolibrary.org/obo/IMR_0000295,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000699,,,,,,,,,,,,,,,,,,,,,,Cdc42,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004478,chemokine (C-X-C motif) ligand 8 production,CXCL8 production,"The appearance of chemokine (C-X-C motif) ligand 8 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.",false,,,http://purl.obolibrary.org/obo/GO_0032602,,,,,,,,,,,,,,,,,,,,,,"The appearance of chemokine (C-X-C motif) ligand 8 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_1000510,,,,,,,,,,,,,,CXCL8 production,,,,,TXPO:0004478,,,,,,,,,,,,,,,,,,,,,,chemokine (C-X-C motif) ligand 8 production,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004479,metastasis [hepatocarcinogenesis],,"The spread or migration of cancer cells from one part of the body (the organ in which it first appeared) to another. The secondary tumor contains cells that are like those in the original (primary) tumor. [def-source: NCI]
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/NCIT_C19151,,,,,,,,,,,,,,,,,,,,PMID:30205391|PMID:30523154|PMID:28410205|PMID:28493839|PMID:17428255|PMID:29358721|PMID:29679563|PMID:31781608|PMID:28060737|PMID:28584306,,"The spread or migration of cancer cells from one part of the body (the organ in which it first appeared) to another. The secondary tumor contains cells that are like those in the original (primary) tumor. [def-source: NCI]
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004479,,,,,,,,,,,,,,,,,,,,,,metastasis [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004471,Increasing COX-2 level,,Increasing COX-2 level is a subtype of increasing quantity: A process that changes the amount of COX-2 level to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing COX-2 level is a subtype of increasing quantity: A process that changes the amount of COX-2 level to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000735,,,,,,,,,,,,,,,,,,,TXPO:0004471,,,,,,,,,,,,,,,,,,,,,,Increasing COX-2 level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004470,Removing damaged DNA stress [hepatocarcinogenesis],,"Removing damaged DNA stress is a subtype of removing damaged object: A process that takes a damaged DNA from an organism or tissue.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0004499|http://purl.obolibrary.org/obo/TXPO_0002340,,,,,,,,,,,,,,,,,,,,PMID:25797246,,"Removing damaged DNA stress is a subtype of removing damaged object: A process that takes a damaged DNA from an organism or tissue.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004431,,,,,,,,,,,TXPO:0004470,,,,,,,,,,,,,,,,,,,,,,Removing damaged DNA stress [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004473,increasing CPT1 level,,Increasing CPT1 level is a subtype of increasing quantity: A process that changes the amount of CPT1 level to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing CPT1 level is a subtype of increasing quantity: A process that changes the amount of CPT1 level to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004473,,,,,,,,,,,,,,,,,,,,,,increasing CPT1 level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004477,negative regulation of cellular senescence [hepatocarcinogenesis],,"Any process that stops, prevents or reduces the frequency, rate or extent of cellular senescence.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/GO_2000773|http://purl.obolibrary.org/obo/TXPO_0002340,,,,,,,,,,,,,,,,,,,,PMID:28646235,,"Any process that stops, prevents or reduces the frequency, rate or extent of cellular senescence.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004392,,,,,,,,,,,TXPO:0004477,,,,,,,,,,,,,,,,,,,,,,negative regulation of cellular senescence [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004472,COX-2 (canonical) [hepatocarcinogenesis],prostaglandin endoperoxide synthase 2|cyclooxygenase 2,,false,,,http://purl.obolibrary.org/obo/TXPO_0005063|http://purl.obolibrary.org/obo/IMR_0000735,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:19225|NCBI-Human-GeneID:5743|NCBI-Rat-GeneID:29527|PMID:30008815,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,prostaglandin endoperoxide synthase 2|cyclooxygenase 2,,,,,TXPO:0004472,,,,,,,,,,,,,,,,,,,,,,COX-2 (canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004476,Decreasing CXCL8 level [hepatocarcinogenesis],,"Decreasing CXCL8 level is a subtype of decreasing quantity: A process that changes the amount of CXCL8 level to be lower.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0004475|http://purl.obolibrary.org/obo/TXPO_0002340,,,,,,,,,,,,,,,,,,,,PMID:28646235,,"Decreasing CXCL8 level is a subtype of decreasing quantity: A process that changes the amount of CXCL8 level to be lower.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004198,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004477,,,,,,,,,,,TXPO:0004476,,,,,,,,,,,,,,,,,,,,,,Decreasing CXCL8 level [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004475,Decreasing CXCL8 level,,Decreasing CXCL8 level is a subtype of decreasing quantity: A process that changes the amount of CXCL8 level to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000396,,,,,,,,,,,,,,,,,,,,,,Decreasing CXCL8 level is a subtype of decreasing quantity: A process that changes the amount of CXCL8 level to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_1000510,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004475,,,,,,,,,,,,,,,,,,,,,,Decreasing CXCL8 level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004474,CPT1(canonical) [mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004293|http://purl.obolibrary.org/obo/TXPO_1000097,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1374|NCBI-Mouse-GeneID:12894|NCBI-Rat-GeneID:25757|PMID:23299992,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004474,,,,,,,,,,,,,,,,,,,,,,CPT1(canonical) [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0001839,increased fluid flow (quality),,A flow that is relatively high.,false,,,http://purl.obolibrary.org/obo/TXPO_0003634|http://purl.obolibrary.org/obo/TXPO_0003747,,,,,,,,,,,,,,,,,,,,,,A flow that is relatively high.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0001839,,,,,,,,,,,,,,,,,,,,,,increased fluid flow (quality),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0001838,decreased fluid flow (quality),,A flow that is relatively low.,false,,,http://purl.obolibrary.org/obo/TXPO_0003634|http://purl.obolibrary.org/obo/TXPO_0003747,,,,,,,,,,,,,,,,,,,,,,A flow that is relatively low.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0001838,,,,,,,,,,,,,,,,,,,,,,decreased fluid flow (quality),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100090,pituitary hormone release inhibiting hormone,PHRIH,Polypeptide hormones produced in the hypothalamus which inhibit the release of pituitary hormones. Used for PHRIH in general or for which there is no specific heading.,false,,,http://purl.obolibrary.org/obo/IMR_0100082,,,,,,,,,,,,,,,,,,,,MeSH:D010905,,Polypeptide hormones produced in the hypothalamus which inhibit the release of pituitary hormones. Used for PHRIH in general or for which there is no specific heading.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PHRIH,,,,,IMR:0100090,,,,,,,,,,,,,,,,,,,,,,pituitary hormone release inhibiting hormone,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000113612,CYP2U1,,Other designations: cytochrome P450 2U1|spastic paraplegia 49,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,SPG56|SPG49|P450TEC,,,,,,,,,,,,4,,,,,,MIM:610670|Ensembl:ENSG00000155016|Vega:OTTHUMG00000161084|HGNC:20582|HPRD:13109,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 2, subfamily U, polypeptide 1",,,4q25,,,,,,,,,,,,,,,,GO_0005506 (EC: IEA); GO_0005789 (EC: TAS); GO_0006805 (EC: TAS); GO_0008219 (EC: IEA); GO_0016021 (EC: IEA); GO_0019369 (EC: TAS); GO_0020037 (EC: IEA); GO_0044281 (EC: TAS); GO_0070330 (EC: IEA); GO_0097267 (EC: TAS),,,,,,,,,PMID:12107412; 12477932; 14660610; 14975754; 15128046; 15588491; 20332099; 20630735; 21707071,,,,,,,,,,,,,,,OGG:3000113612,,,,,,,"cytochrome P450, family 2, subfamily U, polypeptide 1",,,,,,,,,,,,,Other designations: cytochrome P450 2U1|spastic paraplegia 49,,CYP2U1,,,,,,,,,,,,,,,,,,,,,,,113612,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP2U1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000616,neuregulin-3,NRG-3,,false,,,http://purl.obolibrary.org/obo/IMR_0000048,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,NRG-3,,,,,IMR:0000616,,,,,,,,,,,,,,,,,,,,,,neuregulin-3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010488,60S ribosomal protein L38,,,false,,,http://purl.obolibrary.org/obo/IMR_0000897,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0010488,,,,,,,,,,,,,,,,,,,,,,60S ribosomal protein L38,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005083,FZD5 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0004562,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:317674|NCBI-Mouse-GeneID:14367|NCBI-Human-GeneID:7855,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005083,,,,,,,,,,,,,,,,,,,,,,FZD5 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005080,FOXO1 (canonical)[mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000472|http://purl.obolibrary.org/obo/IMR_0002805,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:84482|NCBI-Human-GeneID:2308|NCBI-Mouse-GeneID:56458,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0002805,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003947,,,,,,,,,,TXPO:0005080,,,,,,,,,,,,,,,,,,,,,,FOXO1 (canonical)[mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005081,FZD1 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0004562,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:8321|NCBI-Rat-GeneID:58868|NCBI-Mouse-GeneID:14362,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005081,,,,,,,,,,,,,,,,,,,,,,FZD1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005086,FZD9 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0004562,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:266608|NCBI-Human-GeneID:8326|NCBI-Mouse-GeneID:14371,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005086,,,,,,,,,,,,,,,,,,,,,,FZD9 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005082,FZD2 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0004562,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:2535|NCBI-Mouse-GeneID:57265|NCBI-Rat-GeneID:64512,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005082,,,,,,,,,,,,,,,,,,,,,,FZD2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005084,FZD6 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0004562,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:8323|NCBI-Rat-GeneID:282581|NCBI-Mouse-GeneID:14368,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005084,,,,,,,,,,,,,,,,,,,,,,FZD6 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005087,GJA1 (mol),CX43,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:14609|NCBI-Rat-GeneID:24392|NCBI-Human-GeneID:2697,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CX43,,,,,TXPO:0005087,,,,,,,,,,,,,,,,,,,,,,GJA1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005085,FZD7 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0004562,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:8324|NCBI-Rat-GeneID:100360552|NCBI-Mouse-GeneID:14369,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005085,,,,,,,,,,,,,,,,,,,,,,FZD7 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005089,HHIP (human) [hepatocarcinogenesis],hedgehog interacting protein,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_0004608,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:64399,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,hedgehog interacting protein,,,,,TXPO:0005089,,,,,,,,,,,,,,,,,,,,,,HHIP (human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005088,GJB1 (mol),CX32,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:14618|NCBI-Rat-GeneID:29584|NCBI-Human-GeneID:2705,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CX32,,,,,TXPO:0005088,,,,,,,,,,,,,,,,,,,,,,GJB1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0000266,mitochondrial fission,mitochondrial division|mitochondrial proliferation,The division of a mitochondrion within a cell to form two or more separate mitochondrial compartments.,false,,,http://purl.obolibrary.org/obo/TXPO_0002576,,,,,,,,,,,,,,,,,,,,,,The division of a mitochondrion within a cell to form two or more separate mitochondrial compartments.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,,,,,,,,,,,mitochondrial proliferation,,mitochondrial division,,,GO:0000266,,,,,,,,,,,,,,,,,,,,,,mitochondrial fission,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_38323,cholinergic drug,cholinergic agent|cholinomimetic|cholinergic drugs,"Any drug used for its actions on cholinergic systems. Included here are agonists and antagonists, drugs that affect the life cycle of acetylcholine, and drugs that affect the survival of cholinergic neurons.",false,,,http://purl.obolibrary.org/obo/CHEBI_35942,,,,,,,,,,,,,,,,,,,,,,"Any drug used for its actions on cholinergic systems. Included here are agonists and antagonists, drugs that affect the life cycle of acetylcholine, and drugs that affect the survival of cholinergic neurons.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,cholinergic agent|cholinomimetic|cholinergic drugs,,,,,,,,,,,,,,,,,,,,,CHEBI:38323,,,,cholinergic drug,,CHEBI:38323,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000857,NF-ATc3,,,false,,,http://purl.obolibrary.org/obo/IMR_0000421,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000857,,,,,,,,,,,,,,,,,,,,,,NF-ATc3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_5958,Iproniazid,iproniazid phosphate|euphozid|marsilid|iproniazide phosphate|iproniazide|iprazide|iprazid|Iproniazid,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Drug_Central:1480|LINCS:LSM-5940|CAS:54-92-2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Iproniazid,,iproniazid phosphate|euphozid|marsilid|iproniazide phosphate|iproniazide|iprazide|iprazid,,,,,,,,,,,,,,,,,,,,,CHEBI:5958,,,,Iproniazid,,CHEBI:5958,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100618,cyclin E,,,false,,,http://purl.obolibrary.org/obo/IMR_0100671,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100618,,,,,,,,,,,,,,,,,,,,,,cyclin E,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000027000,DNAJC2,,Other designations: M-phase phosphoprotein 11|dnaJ homolog subfamily C member 2|zuotin related factor 1|zuotin-related factor 1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,ZUO1|MPP11|MPHOSPH11|ZRF1,,,,,,,,,,,,7,,,,,,MIM:605502|Ensembl:ENSG00000105821|Vega:OTTHUMG00000157202|HGNC:13192,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"DnaJ (Hsp40) homolog, subfamily C, member 2",,,7q22,,,,,,,,,,,,,,,,"GO_0003677 (EC: IEA); GO_0003682 (EC: IDA); GO_0005634 (EC: IDA); GO_0005737 (EC: IDA); GO_0005829 (EC: IDA, PMID:16002468); GO_0006260 (EC: IEA); GO_0006351 (EC: IEA); GO_0016568 (EC: IEA); GO_0030308 (EC: IEA); GO_0030544 (EC: IPI, PMID:16002468); GO_0031965 (EC: IDA); GO_0042393 (EC: IDA); GO_0043130 (EC: IDA); GO_0044822 (EC: IDA); GO_0045893 (EC: IDA); GO_0051083 (EC: TAS, PMID:16002468); GO_2000279 (EC: IEA)",,,,,,,,,PMID:8885239; 11034098; 12477932; 12800198; 14696097; 14702039; 15802566; 16002468; 16344560; 17081983; 18029348; 18399720; 20231810; 21139048; 21179169; 21906983; 22433847; 22733129; 24449271,,,,,,,,,,,,,,,OGG:3000027000,,,,,,,"DnaJ (Hsp40) homolog, subfamily C, member 2",,,,,,,,,,,,,Other designations: M-phase phosphoprotein 11|dnaJ homolog subfamily C member 2|zuotin related factor 1|zuotin-related factor 1,,DNAJC2,,,,,,,,,,,,,,,,,,,,,,,27000,,,,,,,,9606,,,,,,,,,,,,,,,,,,,DNAJC2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_27779,griseofulvin,"Sporostatin|Fulcin|Grysio|(+)-griseofulvin|griseofulvinum|Likuden|Lamoryl|Curling factor|griseofulvine|Fulvicin|Grifulvin|griseofulvina|griseofulvin|Grisactin|Poncyl|Spirofulvin|Grisovin|amudane|Griseofulvin|(2S,6'R)-7-chloro-2',4,6-trimethoxy-6'-methyl-3H,4'H-spiro[1-benzofuran-2,1'-cyclohex[2]ene]-3,4'-dione","An oxaspiro compound produced by Penicillium griseofulvum. It is used by mouth as an antifungal drug for infections involving the scalp, hair, nails and skin that do not respond to topical treatment.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,LINCS:LSM-5259|PMID:3277037|PMID:16922553|Reaxys:95226|PMID:14407521|PMID:25476923|DrugBank:DB00400|Drug_Central:1331|LIPID_MAPS_instance:LMPK13060001|PMID:15078340|CAS:126-07-8|Beilstein:95226|PMID:23111828,,"An oxaspiro compound produced by Penicillium griseofulvum. It is used by mouth as an antifungal drug for infections involving the scalp, hair, nails and skin that do not respond to topical treatment.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_33282|http://purl.obolibrary.org/obo/CHEBI_76964,,,,,"Griseofulvin|(2S,6'R)-7-chloro-2',4,6-trimethoxy-6'-methyl-3H,4'H-spiro[1-benzofuran-2,1'-cyclohex[2]ene]-3,4'-dione",,Sporostatin|Fulcin|Grysio|(+)-griseofulvin|griseofulvinum|Likuden|Lamoryl|Curling factor|griseofulvine|Fulvicin|Grifulvin|griseofulvina|griseofulvin|Grisactin|Poncyl|Spirofulvin|Grisovin|amudane,,,,,,,,,,,,,,,,,,,,,CHEBI:27779,,,,griseofulvin,,CHEBI:27779,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000264,Nrg1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:112400|NCBI-Human-GeneID:3084|NCBI-Mouse-GeneID:211323,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000003084,,,,,,,,,,,,,TXPO:1000264,,,,,,,,,,,,,,,,,,,,,,Nrg1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000263,Nr1h2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:58851|NCBI-Human-GeneID:7376|NCBI-Mouse-GeneID:22260,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000007376,,,,,,,,,,,,,TXPO:1000263,,,,,,,,,,,,,,,,,,,,,,Nr1h2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000260,Nifib (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:1000260,,,,,,,,,,,,,,,,,,,,,,Nifib (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000262,Nqo1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24314|NCBI-Mouse-GeneID:18104|NCBI-Human-GeneID:1728,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001728,,,,,,,,,,,,,TXPO:1000262,,,,,,,,,,,,,,,,,,,,,,Nqo1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000261,Nolc1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:9221|NCBI-Mouse-GeneID:70769|NCBI-Rat-GeneID:64896,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000009221,,,,,,,,,,,,,TXPO:1000261,,,,,,,,,,,,,,,,,,,,,,Nolc1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000268,Nup153 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:9972|NCBI-Rat-GeneID:25281|NCBI-Mouse-GeneID:218210,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000009972,,,,,,,,,,,,,TXPO:1000268,,,,,,,,,,,,,,,,,,,,,,Nup153 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000267,Nudt7 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:67528|NCBI-Rat-GeneID:361413|NCBI-Human-GeneID:283927,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000283927,,,,,,,,,,,,,TXPO:1000267,,,,,,,,,,,,,,,,,,,,,,Nudt7 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000269,Nus1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:116150|NCBI-Rat-GeneID:294400|NCBI-Mouse-GeneID:52014,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000116150,,,,,,,,,,,,,TXPO:1000269,,,,,,,,,,,,,,,,,,,,,,Nus1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000266,Nudt5 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:361274|NCBI-Mouse-GeneID:53893|NCBI-Human-GeneID:11164,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000011164,,,,,,,,,,,,,TXPO:1000266,,,,,,,,,,,,,,,,,,,,,,Nudt5 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000265,Nudt11 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:680248|NCBI-Human-GeneID:55190|NCBI-Mouse-GeneID:58242,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000055190,,,,,,,,,,,,,TXPO:1000265,,,,,,,,,,,,,,,,,,,,,,Nudt11 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100309,caspase-13,,,false,,,http://purl.obolibrary.org/obo/IMR_0000305,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100309,,,,,,,,,,,,,,,,,,,,,,caspase-13,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0004755,skeletal tissue,,"A specialized form of connective tissue in which the extracellular matrix is firm, providing the tissue with resilience, and/or mineralized and that functions in mechanical and structural support.[VSAO]|Four classes of mineralized tissues are found in vertebrates: bone, cartilage, dentine, and enamel. We think of cartilage and bone as skeletal tissues and of enamel and dentine as dental tissues, but enamel and dentine arose evolutionarily together with bone as skeletal tissues in the dermal skeleton (exoskeleton) of early vertebrates. Scales and teeth of sharks are examples of dermal skeletal elements that are still composed of the three ancient components-enamel, dentine, and bone. Cartilage, on the other hand, provided the basis for the second vertebrate skeletal system, the endoskeleton (Smith and Hall, 1990; Hall, 1998a,b). some invertebrate skeletal tissues have surprisingly bone-like features. Examples include chondrocytes interconnected by cell processes in cephalopod cartilages (Cole and Hall, 2004a,b), and the calcium phosphate layer in the shells of brachiopods (Rodland et al., 2003). However, neither bone nor mineralized cartilage have been found in invertebrates. Editors notes: TODO - develops_from",false,,,http://purl.obolibrary.org/obo/UBERON_0002384,,,,,,,,,,,,,,,,,,,,http://www.snomedbrowser.com/Codes/Details/309311006|XAO:0004038|ZFA:0005619|MA:0003047|VSAO:0000015,,"A specialized form of connective tissue in which the extracellular matrix is firm, providing the tissue with resilience, and/or mineralized and that functions in mechanical and structural support.[VSAO]",,,,,,,,"A specialized form of connective tissue in which the extracellular matrix is firm, providing the tissue with resilience, and/or mineralized and that functions in mechanical and structural support.[VSAO]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,UBERON:0004755,,,,,,,,,,,,,,,,,,,,"Four classes of mineralized tissues are found in vertebrates: bone, cartilage, dentine, and enamel. We think of cartilage and bone as skeletal tissues and of enamel and dentine as dental tissues, but enamel and dentine arose evolutionarily together with bone as skeletal tissues in the dermal skeleton (exoskeleton) of early vertebrates. Scales and teeth of sharks are examples of dermal skeletal elements that are still composed of the three ancient components-enamel, dentine, and bone. Cartilage, on the other hand, provided the basis for the second vertebrate skeletal system, the endoskeleton (Smith and Hall, 1990; Hall, 1998a,b). some invertebrate skeletal tissues have surprisingly bone-like features. Examples include chondrocytes interconnected by cell processes in cephalopod cartilages (Cole and Hall, 2004a,b), and the calcium phosphate layer in the shells of brachiopods (Rodland et al., 2003). However, neither bone nor mineralized cartilage have been found in invertebrates. Editors notes: TODO - develops_from",,skeletal tissue,,,,,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/BFO_0000006,spatial region,,,false,,,http://purl.obolibrary.org/obo/BFO_0000141,,,,,,,,,,,,,,,,,,,,,,,,,,"BFO 2 Reference: Spatial regions do not participate in processes.|Spatial region doesn't have a closure axiom because the subclasses don't exhaust all possibilites. An example would be the union of a spatial point and a spatial line that doesn't overlap the point, or two spatial lines that intersect at a single point. In both cases the resultant spatial region is neither 0-dimensional, 1-dimensional, 2-dimensional, or 3-dimensional.",,A spatial region is a continuant entity that is a continuant_part_of spaceR as defined relative to some frame R. (axiom label in BFO2 Reference: [035-001]),,,,,,,,,,,,(forall (x y t) (if (and (SpatialRegion x) (continuantPartOfAt y x t)) (SpatialRegion y))) // axiom label in BFO2 CLIF: [036-001]|(forall (x) (if (SpatialRegion x) (Continuant x))) // axiom label in BFO2 CLIF: [035-001],All continuant parts of spatial regions are spatial regions. (axiom label in BFO2 Reference: [036-001]),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BFO:0000006,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/bfo.owl,spatial region,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100583,syndecan-4,SYND4|Amphiglycan|Ryudocan core protein,,false,,,http://purl.obolibrary.org/obo/IMR_0100579,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,SYND4|Amphiglycan|Ryudocan core protein,,,,,IMR:0100583,,,,,,,,,,,,,,,,,,,,,,syndecan-4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_681569,clofarabine,"clofarabinum|clofarabina|2-chloro-9-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)adenine|2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine|CAFdA|clofarabine|Cl-F-Ara-A|(2R,3R,4S,5R)-5-(6-amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol|2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-9H-purin-6-amine|clofarabine","A purine nucleoside analogue consisting of a 6-amino-2-chloropurin-9-yl group attached to the 1beta position of 2'-deoxy-2'-fluoro-D-arabinofuranose. It is metabolized intracellularly to the active 5'-triphosphate metabolite, which inhibits DNA synthesisis and so stops the growth of cancer cells. Clofarabine is used as an antimetabolite antineoplastic agent in the treatment of relapsed or refractory acute lymphoblastic leukaemia.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:123318-82-1|Beilstein:4882539|DrugBank:DB00631|PMID:19929004,,"A purine nucleoside analogue consisting of a 6-amino-2-chloropurin-9-yl group attached to the 1beta position of 2'-deoxy-2'-fluoro-D-arabinofuranose. It is metabolized intracellularly to the active 5'-triphosphate metabolite, which inhibits DNA synthesisis and so stops the growth of cancer cells. Clofarabine is used as an antimetabolite antineoplastic agent in the treatment of relapsed or refractory acute lymphoblastic leukaemia.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35610|http://purl.obolibrary.org/obo/CHEBI_35221,,,,,2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-9H-purin-6-amine|clofarabine,,"clofarabinum|clofarabina|2-chloro-9-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)adenine|2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine|CAFdA|clofarabine|Cl-F-Ara-A|(2R,3R,4S,5R)-5-(6-amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol",,,,,,,,,,,,,,,,,,,,,CHEBI:681569,,,,clofarabine,,CHEBI:681569,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001038,group XIIA secretory phospholipase A2,,,false,,,http://purl.obolibrary.org/obo/IMR_0000283,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001038,,,,,,,,,,,,,,,,,,,,,,group XIIA secretory phospholipase A2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000319,G-alpha-i,,,false,,,http://purl.obolibrary.org/obo/IMR_0000318,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000319,,,,,,,,,,,,,,,,,,,,,,G-alpha-i,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003742,hepatic fibrosis dependent process,,Hepatic fibrosis dependent process is a subtype of toxic course dependent process: A process that can constitute the course of hepatic fibrosis.,false,,,http://purl.obolibrary.org/obo/TXPO_0001715,,,,,,,,,,,,,,,,,,,,,,Hepatic fibrosis dependent process is a subtype of toxic course dependent process: A process that can constitute the course of hepatic fibrosis.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003742,,,,,,,,,,,,,,,,,,,,,,hepatic fibrosis dependent process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003746,hepatic stellate cell activation [Fibrosis],,"A change in the morphology or behavior of a hepatic stellate cell resulting from exposure to a cytokine, chemokine, hormone, cellular ligand or soluble factor.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",false,,,http://purl.obolibrary.org/obo/GO_0035733|http://purl.obolibrary.org/obo/TXPO_0003742,,,,,,,,,,,,,,,,,,,,,,"A change in the morphology or behavior of a hepatic stellate cell resulting from exposure to a cytokine, chemokine, hormone, cellular ligand or soluble factor.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003757|http://purl.obolibrary.org/obo/TXPO_0000224,,,,,,,,,,,TXPO:0003746,,,,,,,,,,,,,,,,,,,,,,hepatic stellate cell activation [Fibrosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003749,hepatic fibrosis dependent chemical entity,,"Hepatic fibrosis dependent chemical entity is a subtype of toxic course dependent chemical entity.
This entity can participate in the course of hepatic fibrosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001731,,,,,,,,,,,,,,,,,,,,,,"Hepatic fibrosis dependent chemical entity is a subtype of toxic course dependent chemical entity.
This entity can participate in the course of hepatic fibrosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003749,,,,,,,,,,,,,,,,,,,,,,hepatic fibrosis dependent chemical entity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003744,permeability (attribute),,It is an attribute of structure inhering in a bearer by virtue of the bearer's disposition to being permeated or pervaded by a gas or liquid (as by osmosis or diffusion).,false,,,http://purl.obolibrary.org/obo/TXPO_0000305,,,,,,,,,,,,,,,,,,,,,,It is an attribute of structure inhering in a bearer by virtue of the bearer's disposition to being permeated or pervaded by a gas or liquid (as by osmosis or diffusion).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003744,,,,,,,,,,,,,,,,,,,,,,permeability (attribute),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003741,increasing organelle volume,,Increasing organelle volume is a subtype of increasing volume: A process that changes the volume of the organelle to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000139,,,,,,,,,,,,,,,,,,,,,,Increasing organelle volume is a subtype of increasing volume: A process that changes the volume of the organelle to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003741,,,,,,,,,,,,,,,,,,,,,,increasing organelle volume,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003747,fluid flow rate (attribute),,A physical attribute inhering in a fluid (liquid or gas) by virtue of the amount of fluid which passes through a given surface per unit time.,false,,,http://purl.obolibrary.org/obo/PATO_0001574,,,,,,,,,,,,,,,,,,,,,,A physical attribute inhering in a fluid (liquid or gas) by virtue of the amount of fluid which passes through a given surface per unit time.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003747,,,,,,,,,,,,,,,,,,,,,,fluid flow rate (attribute),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003748,CCL4 [NASH],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003509,,,,,,,,,,,,,,,,,,,,ISBN:0071769234,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003748,,,,,,,,,,,,,,,,,,,,,,CCL4 [NASH],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003743,kupffer cell activation [Fibrosis],,"Kupffer cell activation is a subtype of macrophage activation: A change in morphology and behavior of a kupffer cell resulting from exposure to a cytokine, chemokine, cellular ligand, or soluble factor.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003742|http://purl.obolibrary.org/obo/TXPO_0003184,,,,,,,,,,,,,,,,,,,,,,"Kupffer cell activation is a subtype of macrophage activation: A change in morphology and behavior of a kupffer cell resulting from exposure to a cytokine, chemokine, cellular ligand, or soluble factor.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003745,,,,,,,,,,,TXPO:0003743,,,,,,,,,,,,,,,,,,,,,,kupffer cell activation [Fibrosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003745,cytokine secretion [Fibrosis],,"The regulated release of cytokines from a cell. Cytokines are any of a group of proteins that function to control the survival, growth and differentiation of tissues and cells, and which have autocrine and paracrine activity.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003742|http://purl.obolibrary.org/obo/GO_0050663,,,,,,,,,,,,,,,,,,,,,,"The regulated release of cytokines from a cell. Cytokines are any of a group of proteins that function to control the survival, growth and differentiation of tissues and cells, and which have autocrine and paracrine activity.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000091,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003751|http://purl.obolibrary.org/obo/TXPO_0003752,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003746|http://purl.obolibrary.org/obo/TXPO_0003755,,,,,,,,,,,TXPO:0003745,,,,,,,,,,,,,,,,,,,,,,cytokine secretion [Fibrosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003740,inflammatory cell infiltration [Cholestasis],,Inflammatory cell infiltration is a subtype of moving A to the inside of B: A process that that moves the outside inflammatory cell to the inside in response to an inflammatory reaction. This entity is a specific course dependent process. This process can constitute the course of Cholestasis.,false,,,http://purl.obolibrary.org/obo/TXPO_0000540,,,,,,,,,,,,,,,,,,,,,,Inflammatory cell infiltration is a subtype of moving A to the inside of B: A process that that moves the outside inflammatory cell to the inside in response to an inflammatory reaction. This entity is a specific course dependent process. This process can constitute the course of Cholestasis.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002670,,,,,,,,,,,TXPO:0003740,,,,,,,,,,,,,,,,,,,,,,inflammatory cell infiltration [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000015,changing sensitivity,,Changing sensitivity is a subtype of changing quality: A process that changes the sensitivity of the object.,false,,,http://purl.obolibrary.org/obo/TXPO_0000415,,,,,,,,,,,,,,,,,,,,,,Changing sensitivity is a subtype of changing quality: A process that changes the sensitivity of the object.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000015,,,,,,,,,,,,,,,,,,,,,,changing sensitivity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000011,generating signal,,Generating signal is a subtype of generating: A process that produces a signal as an output.,false,,,http://purl.obolibrary.org/obo/TXPO_0000381,,,,,,,,,,,,,,,,,,,,,,Generating signal is a subtype of generating: A process that produces a signal as an output.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000011,,,,,,,,,,,,,,,,,,,,,,generating signal,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000016,hypofunction of detoxification [hepatic encephalopathy],,"Hypofunction of detoxification is a subtype of hypofunctioning: A process that performs a decreased or insufficient detoxification.
This entity is a specific course-dependent process. This process can constitute the course of Hepatic encephalopathy.",false,,,http://purl.obolibrary.org/obo/TXPO_0001354,,,,,,,,,,,,,,,,,,,,,,"Hypofunction of detoxification is a subtype of hypofunctioning: A process that performs a decreased or insufficient detoxification.
This entity is a specific course-dependent process. This process can constitute the course of Hepatic encephalopathy.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000017,,,,,,,,,,,TXPO:0000016,,,,,,,,,,,,,,,,,,,,,,hypofunction of detoxification [hepatic encephalopathy],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000014,Sgpl1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:8879|NCBI-Rat-GeneID:286896|NCBI-Mouse-GeneID:20397,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000008879,,,http://purl.obolibrary.org/obo/TXPO_0000308,,,,,,,,,,TXPO:0000014,,,,,,,,,,,,,,,,,,,,,,Sgpl1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000019,generating substance,,Generating substance is a subtype of generating: A process that produces a substance as an output.,false,,,http://purl.obolibrary.org/obo/TXPO_0000381,,,,,,,,,,,,,,,,,,,,,,Generating substance is a subtype of generating: A process that produces a substance as an output.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000019,,,,,,,,,,,,,,,,,,,,,,generating substance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000018,ubiquitin-conjugating enzyme,E2|ubiquitin-conjugating enzyme (E2),"Arole played by the entity that isoenergetic transfer of ubiquitin from one protein to another via the reaction X-ubiquitin + Y -> Y-ubiquitin + X, where both the X-ubiquitin and Y-ubiquitin linkages are thioester bonds between the C-terminal glycine of ubiquitin and a sulfhydryl side group of a cysteine residue.",false,,,http://purl.obolibrary.org/obo/TXPO_0003660,,,,,,,,,,,,,,,,,,,,IMR:0000328 (obsolete)|GO:0061631,,"Arole played by the entity that isoenergetic transfer of ubiquitin from one protein to another via the reaction X-ubiquitin + Y -> Y-ubiquitin + X, where both the X-ubiquitin and Y-ubiquitin linkages are thioester bonds between the C-terminal glycine of ubiquitin and a sulfhydryl side group of a cysteine residue.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,E2|ubiquitin-conjugating enzyme (E2),,,,,TXPO:0000018,,,,,,,,,,,,,,,,,,,,,,ubiquitin-conjugating enzyme,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000013,PPARalpha activation,activating peroxisome proliferator-activated receptor alpha|PPAR alpha activation,PPARalpha activation is a subtype of activating nuclear receptor: A process that changes the activity of the activating PPAR alpha ( (Peroxisome Proliferator Activated Receptor Alpha)) with a nuclear receptor role to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000158,,,,,,,,,,,,,,,,,,,,,,PPARalpha activation is a subtype of activating nuclear receptor: A process that changes the activity of the activating PPAR alpha ( (Peroxisome Proliferator Activated Receptor Alpha)) with a nuclear receptor role to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,activating peroxisome proliferator-activated receptor alpha|PPAR alpha activation,,,,,TXPO:0000013,,,,,,,,,,,,,,,,,,,,,,PPARalpha activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000010,changing membrane fluidity [Phospholipidosis],,"Changing membrane fluidity is a subtype of changing fluidity: A process that changes the fluidity of the membrane.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0000412,,,,,,,,,,,,,,,,,,,,PMID:22960355|PMID:2080227|PMID:1697167,,"Changing membrane fluidity is a subtype of changing fluidity: A process that changes the fluidity of the membrane.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001802,,,,,,http://purl.obolibrary.org/obo/TXPO_0002227|http://purl.obolibrary.org/obo/TXPO_0002222|http://purl.obolibrary.org/obo/TXPO_0000494,,,,,,,,,,,TXPO:0000010,,,,,,,,,,,,,,,,,,,,,,changing membrane fluidity [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000017,increasing ammonia concentration in blood [Hepatic encephalopathy],,"Increasing ammonia concentration in blood is a subtype of increasing concentration: A process that changes the ammonia concentration in the blood to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Hepatic encephalopathy.",false,,,http://purl.obolibrary.org/obo/TXPO_0001355,,,,,,,,,,,,,,,,,,,,,,"Increasing ammonia concentration in blood is a subtype of increasing concentration: A process that changes the ammonia concentration in the blood to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Hepatic encephalopathy.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000017,,,,,,,,,,,,,,,,,,,,,,increasing ammonia concentration in blood [Hepatic encephalopathy],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0015871,choline transport,,"The directed movement of choline into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Choline (2-hydroxyethyltrimethylammonium) is an amino alcohol that occurs widely in living organisms as a constituent of certain types of phospholipids and in the neurotransmitter acetylcholine.",false,,,http://purl.obolibrary.org/obo/TXPO_0000111,,,,,,,,,,,,,,,,,,,,,,"The directed movement of choline into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Choline (2-hydroxyethyltrimethylammonium) is an amino alcohol that occurs widely in living organisms as a constituent of certain types of phospholipids and in the neurotransmitter acetylcholine.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0015871,,,,,,,,,,,,,,,,,,,,,,choline transport,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001200,TRAIL,Apo-2 ligand|TNF-related apoptosis inducing ligand|TNFSF10|Apo2L,,false,,,http://purl.obolibrary.org/obo/IMR_0000021,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Apo-2 ligand|TNF-related apoptosis inducing ligand|TNFSF10|Apo2L,,,,,IMR:0001200,,,,,,,,,,,,,,,,,,,,,,TRAIL,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000167,cadherin,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003688,,,,,,,,,,IMR:0000167,,,,,,,,,,,,,,,,,,,,,,cadherin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100374,G-alpha-t 2,transducin alpha-2,,false,,,http://purl.obolibrary.org/obo/IMR_0000321,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,transducin alpha-2,,,,,IMR:0100374,,,,,,,,,,,,,,,,,,,,,,G-alpha-t 2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000915,hyperfunction of phospholipid synthesis gene expression [Phospholipidosis],,"Hyperfunction of phospholipid synthesis gene expression is a subtype of hyperfunction of gene expression: A process that performs an excesssive phospholipid synthetic gene expression.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001726|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of phospholipid synthesis gene expression is a subtype of hyperfunction of gene expression: A process that performs an excesssive phospholipid synthetic gene expression.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001171|http://purl.obolibrary.org/obo/TXPO_0001176|http://purl.obolibrary.org/obo/TXPO_0003261|http://purl.obolibrary.org/obo/TXPO_0003530,,,,,,http://purl.obolibrary.org/obo/TXPO_0000923,,,,,,,,,,,TXPO:0000915,,,,,,,,,,,,,,,,,,,,,,hyperfunction of phospholipid synthesis gene expression [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000910,phospholipid accumulation in lysosome [Phospholipidosis],,"Phospholipid accumulation in lysosome is a subtype of phospholipid accumulation: A process that keeps phospholipid in the lysosome.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0000281,,,,,,,,,,,,,,,,,,,,,,"Phospholipid accumulation in lysosome is a subtype of phospholipid accumulation: A process that keeps phospholipid in the lysosome.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000910,,,,,,,,,,,,,,,,,,,,,,phospholipid accumulation in lysosome [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000916,hyperfunction of accumulation,,Hyperfunction of accumulation is a subtype of hyperfunctioning: A process that performs accumulating excessively.,false,,,http://purl.obolibrary.org/obo/TXPO_0000435,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of accumulation is a subtype of hyperfunctioning: A process that performs accumulating excessively.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000916,,,,,,,,,,,,,,,,,,,,,,hyperfunction of accumulation,,,,,,http://purl.obolibrary.org/obo/TXPO_0000247,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000918,increasing number of macrophage derived foam cell [Phospholipidosis],,"Increasing number of macrophage derived foam cell is a subtype of increasing number of objects: A process that becomes larger in the number of foam cell, a type of macrophage containing lipids in small vacuoles, in the liver.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001412|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Increasing number of macrophage derived foam cell is a subtype of increasing number of objects: A process that becomes larger in the number of foam cell, a type of macrophage containing lipids in small vacuoles, in the liver.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000918,,,,,,,,,,,,,,,,,,,,,,increasing number of macrophage derived foam cell [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000917,undigested membrane material accumulation [Phospholipidosis],,"Undigested membrane material accumulation is a subtype of accumulation of substances in a biological object: A process that keeps undigested membrane material.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0001249,,,,,,,,,,,,,,,,,,,,,,"Undigested membrane material accumulation is a subtype of accumulation of substances in a biological object: A process that keeps undigested membrane material.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000917,,,,,,,,,,,,,,,,,,,,,,undigested membrane material accumulation [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000913,forming a complex of drugs and biological substance [Phospholipidosis (mild)],,"Forming a complex of drugs and biological substance is a subtype of protein complex assembly: The aggregation, arrangement and bonding together between drugs and biological molecules to form a complex.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (mild).",false,,,http://purl.obolibrary.org/obo/TXPO_0001254|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Forming a complex of drugs and biological substance is a subtype of protein complex assembly: The aggregation, arrangement and bonding together between drugs and biological molecules to form a complex.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (mild).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001560,,,,,,http://purl.obolibrary.org/obo/TXPO_0002087,,,,,,,,,,,TXPO:0000913,,,,,,,,,,,,,,,,,,,,,,forming a complex of drugs and biological substance [Phospholipidosis (mild)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000911,hypofunction of phospholipase transport to lysosome [Phospholipidosis (severe) ],,"Hypofunction of phospholipase transport to lysosome is a subtype of hypofunction of phospholipase transport to lysosome : A process that performs a decreased or insufficient phospholipase transport to lysosome severely. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",false,,,http://purl.obolibrary.org/obo/TXPO_0001769|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Hypofunction of phospholipase transport to lysosome is a subtype of hypofunction of phospholipase transport to lysosome : A process that performs a decreased or insufficient phospholipase transport to lysosome severely. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",,,http://purl.obolibrary.org/obo/TXPO_0003354,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002217,,,,,,,,,,,TXPO:0000911,,,,,,,,,,,,,,,,,,,,,,hypofunction of phospholipase transport to lysosome [Phospholipidosis (severe) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000919,lipid homeostasis imbalance (mild) [Lipidosis],,"Lipid homeostasis imbalance is a subtype of chemical homeostasis imbalance: A process that becomes lacking a lipid homeostastasis balance. The degree is mild.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003491|http://purl.obolibrary.org/obo/TXPO_0003488,,,,,,,,,,,,,,,,,,,,,,"Lipid homeostasis imbalance is a subtype of chemical homeostasis imbalance: A process that becomes lacking a lipid homeostastasis balance. The degree is mild.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001039,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003624,,http://purl.obolibrary.org/obo/TXPO_0000493,,,,,,,,,TXPO:0000919,,,,,,,,,,,,,,,,,,,,,,lipid homeostasis imbalance (mild) [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000912,increasing lysosomal pH [Phospholipidosis(severe)],,"Increasing lysosomal pH is a subtype of changing pH: A process that changes the pH in lysosome to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis(severe).",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0001247,,,,,,,,,,,,,,,,,,,,PMID:1697167,,"Increasing lysosomal pH is a subtype of changing pH: A process that changes the pH in lysosome to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis(severe).",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003345,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001778|http://purl.obolibrary.org/obo/TXPO_0002240|http://purl.obolibrary.org/obo/TXPO_0003435,,,,,,,,,,,TXPO:0000912,,,,,,,,,,,,,,,,,,,,,,increasing lysosomal pH [Phospholipidosis(severe)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000914,hypofunction of phospholipid deradation by phospholipase [Phospholipidosis],,"Hypofunction of phospholipid deradation by phospholipase is a subtype of hypofunction of phospholipid degradation: A process that performs a decreased or insufficient phospholipid deradation by phospholipase.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001723|http://purl.obolibrary.org/obo/TXPO_0000925,,,,,,,,,,,,,,,,,,,,,,"Hypofunction of phospholipid deradation by phospholipase is a subtype of hypofunction of phospholipid degradation: A process that performs a decreased or insufficient phospholipid deradation by phospholipase.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000775|http://purl.obolibrary.org/obo/TXPO_0001804,,,,,,http://purl.obolibrary.org/obo/TXPO_0000907,,,,,,,,,,,TXPO:0000914,,,,,,,,,,,,,,,,,,,,,,hypofunction of phospholipid deradation by phospholipase [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000028,Adam8 (mol),,,false,,,http://purl.obolibrary.org/obo/IMR_0001865,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:499285|NCBI-Mouse-GeneID:11501|NCBI-Human-GeneID:101,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000101,,,,,,,,,,,,,TXPO:1000028,,,,,,,,,,,,,,,,,,,,,,Adam8 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000021,Acot12 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0001146,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:74156|NCBI-Human-GeneID:134526|NCBI-Rat-GeneID:170570,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000134526,,,,,,,,,,,,,TXPO:1000021,,,,,,,,,,,,,,,,,,,,,,Acot12 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000020,Acer3 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0001148,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:55331|NCBI-Mouse-GeneID:66190|NCBI-Rat-GeneID:499210,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000055331,,,,,,,,,,,,,TXPO:1000020,,,,,,,,,,,,,,,,,,,,,,Acer3 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000023,Acot3 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0001146,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:314304|NCBI-Mouse-GeneID:171281,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:1000023,,,,,,,,,,,,,,,,,,,,,,Acot3 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000024,Acot4 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0001146,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:171282|NCBI-Rat-GeneID:681337|NCBI-Human-GeneID:122970,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000122970,,,,,,,,,,,,,TXPO:1000024,,,,,,,,,,,,,,,,,,,,,,Acot4 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000025,Acot7 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0001146,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:70025|NCBI-Human-GeneID:11332|NCBI-Rat-GeneID:26759,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000011332,,,,,,,,,,,,,TXPO:1000025,,,,,,,,,,,,,,,,,,,,,,Acot7 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000026,Acot8 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0001146,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:170789|NCBI-Rat-GeneID:170588|NCBI-Human-GeneID:10005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000010005,,,,,,,,,,,,,TXPO:1000026,,,,,,,,,,,,,,,,,,,,,,Acot8 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000029,Aen (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:64782|NCBI-Rat-GeneID:361594|NCBI-Mouse-GeneID:68048,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000064782,,,,,,,,,,,,,TXPO:1000029,,,,,,,,,,,,,,,,,,,,,,Aen (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000022,Acot2 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0001146,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:192272|NCBI-Mouse-GeneID:171210|NCBI-Human-GeneID:10965,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000010965,,,,,,,,,,,,,TXPO:1000022,,,,,,,,,,,,,,,,,,,,,,Acot2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000027,Acox1 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0000033,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:51|NCBI-Mouse-GeneID:11430|NCBI-Rat-GeneID:50681,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000051,,,,,,,,,,,,,TXPO:1000027,,,,,,,,,,,,,,,,,,,,,,Acox1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0016042,lipid catabolic process,lipid breakdown|lipid catabolism|lipolysis|lipid degradation,"The chemical reactions and pathways resulting in the breakdown of lipids, compounds soluble in an organic solvent but not, or sparingly, in an aqueous solvent.",false,,,http://purl.obolibrary.org/obo/GO_0009056,,,,,,,,,,,,,,,,,,,,Wikipedia:Lipid_catabolism,,"The chemical reactions and pathways resulting in the breakdown of lipids, compounds soluble in an organic solvent but not, or sparingly, in an aqueous solvent.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_18059,,,,,,,,,,,,,,,,,,lipid breakdown|lipid catabolism|lipolysis|lipid degradation,,,,,GO:0016042,,,,,,,,,,,,,,,,,,,,,,lipid catabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0016049,cell growth,cellular growth|growth of cell,The process in which a cell irreversibly increases in size over time by accretion and biosynthetic production of matter similar to that already present.,false,,,http://purl.obolibrary.org/obo/GO_0040007,,,,,,,,,,,,,,,,,,,,,,The process in which a cell irreversibly increases in size over time by accretion and biosynthetic production of matter similar to that already present.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,cellular growth|growth of cell,,,,,GO:0016049,,,,,,,,,,,,,,,,,,,,,,cell growth,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000000596,BCL2,,"Other designations: apoptosis regulator Bcl-2|protein phosphatase 1, regulatory subunit 50",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,Bcl-2|PPP1R50,,,,,,,,,,,,18,,,,,,Ensembl:ENSG00000171791|MIM:151430|HPRD:01045|HGNC:990,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,B-cell CLL/lymphoma 2,,,18q21.3,,,,,,,,,,,,,,,,"GO_0000209 (EC: IDA, PMID: 16717086); GO_0001101 (EC: IEA); GO_0001503 (EC: IEA); GO_0001541 (EC: IEA); GO_0001656 (EC: IEA); GO_0001658 (EC: IEA); GO_0001662 (EC: IEA); GO_0001782 (EC: IEA); GO_0001836 (EC: ISS, PMID: 9843949); GO_0001836 (EC: NAS, PMID: 9027314); GO_0001952 (EC: IEA); GO_0002020 (EC: IDA, PMID: 10620603); GO_0002320 (EC: IEA); GO_0002326 (EC: IEA); GO_0002931 (EC: IEA); GO_0003014 (EC: IEA); GO_0005515 (EC: IPI, PMID: 10837489); GO_0005634 (EC: IDA, PMID: 7546744); GO_0005737 (EC: IDA, PMID: 11530860); GO_0005739 (EC: IDA, PMID: 7896880); GO_0005741 (EC: IDA, PMID: 8402648); GO_0005741 (EC: TAS); GO_0005783 (EC: IDA, PMID: 8402648); GO_0005789 (EC: IEA); GO_0005829 (EC: IEA); GO_0006470 (EC: IEA); GO_0006582 (EC: IEA); GO_0006808 (EC: IEA); GO_0006915 (EC: TAS); GO_0006959 (EC: TAS, PMID: 1908951); GO_0006974 (EC: IMP, PMID: 17875758); GO_0007015 (EC: IEA); GO_0007409 (EC: IEA); GO_0007565 (EC: NAS, PMID: 11530860); GO_0007569 (EC: IEA); GO_0008134 (EC: IEA); GO_0008219 (EC: IDA, PMID: 36599); GO_0008584 (EC: IEA); GO_0008625 (EC: IDA, PMID: 10597216); GO_0008630 (EC: IBA); GO_0008631 (EC: IEA); GO_0009314 (EC: NAS, PMID: 15799693); GO_0009636 (EC: IDA, PMID: 16307838); GO_0009791 (EC: IEA); GO_0010039 (EC: IDA, PMID: 11264898); GO_0010224 (EC: IEA); GO_0010332 (EC: IEA); GO_0010507 (EC: TAS, PMID: 18309324); GO_0010523 (EC: IEA); GO_0010559 (EC: IEA); GO_0014031 (EC: IEA); GO_0014042 (EC: IEA); GO_0014911 (EC: IEA); GO_0015267 (EC: IDA, PMID: 9219694); GO_0016020 (EC: IDA, PMID: 7896880); GO_0016049 (EC: IEA); GO_0016248 (EC: IDA, PMID: 9219694); GO_0016337 (EC: IEA); GO_0018105 (EC: IEA); GO_0018107 (EC: IEA); GO_0021747 (EC: IEA); GO_0022612 (EC: IEA); GO_0022898 (EC: IDA, PMID: 9219694); GO_0030279 (EC: IEA); GO_0030307 (EC: IDA, PMID: 8022822); GO_0030308 (EC: IEA); GO_0030318 (EC: IEA); GO_0030336 (EC: IEA); GO_0030890 (EC: IMP, PMID: 17875758); GO_0031069 (EC: IEA); GO_0031103 (EC: IEA); GO_0031625 (EC: IPI); GO_0031647 (EC: IEA); GO_0031965 (EC: IDA, PMID: 1502141); GO_0032469 (EC: TAS, PMID: 18309324); GO_0032835 (EC: IEA); GO_0032848 (EC: IDA, PMID: 10506221); GO_0033033 (EC: IEA); GO_0033077 (EC: IEA); GO_0033138 (EC: IEA); GO_0033689 (EC: IEA); GO_0034097 (EC: IDA, PMID: 9184696); GO_0035094 (EC: IDA, PMID: 12421819); GO_0035265 (EC: IEA); GO_0035872 (EC: TAS); GO_0040018 (EC: IEA); GO_0042100 (EC: IDA, PMID: 1373874); GO_0042149 (EC: IEA); GO_0042493 (EC: IDA, PMID: 36599); GO_0042493 (EC: IMP, PMID: 17875758); GO_0042542 (EC: IEA); GO_0042802 (EC: IPI, PMID: 18835031); GO_0042803 (EC: IPI, PMID: 9111042); GO_0043029 (EC: IEA); GO_0043066 (EC: IDA, PMID: 10506221); GO_0043066 (EC: IMP, PMID: 17289999); GO_0043085 (EC: IEA); GO_0043209 (EC: IEA); GO_0043375 (EC: IEA); GO_0043496 (EC: IDA, PMID: 9111042); GO_0043497 (EC: IDA, PMID: 9111042); GO_0043524 (EC: IDA, PMID: 7546744); GO_0043565 (EC: IDA, PMID: 12086670); GO_0043583 (EC: IEA); GO_0045069 (EC: IEA); GO_0045087 (EC: TAS); GO_0045636 (EC: IEA); GO_0045930 (EC: IEA); GO_0046671 (EC: IEA); GO_0046902 (EC: ISS, PMID: 9843949); GO_0046930 (EC: IDA, PMID: 9219694); GO_0046982 (EC: IPI, PMID: 9111042); GO_0048041 (EC: IEA); GO_0048536 (EC: IEA); GO_0048538 (EC: IEA); GO_0048546 (EC: IEA); GO_0048589 (EC: IEA); GO_0048599 (EC: IEA); GO_0048743 (EC: IEA); GO_0048753 (EC: IEA); GO_0048873 (EC: IEA); GO_0050853 (EC: IMP, PMID: 17875758); GO_0051384 (EC: IEA); GO_0051402 (EC: TAS, PMID: 16167175); GO_0051434 (EC: IPI, PMID: 9111042); GO_0051607 (EC: IDA, PMID: 10620603); GO_0051721 (EC: IEA); GO_0051881 (EC: ISS, PMID: 9843949); GO_0051902 (EC: TAS, PMID: 9027314); GO_0051924 (EC: IDA, PMID: 8022822); GO_0055085 (EC: IDA, PMID: 9219694); GO_0070059 (EC: IDA, PMID: 15776018); GO_0071310 (EC: IEA); GO_0071456 (EC: IEA); GO_0072593 (EC: IEA); GO_0097192 (EC: IEA); GO_0097193 (EC: TAS); GO_1900740 (EC: TAS); GO_2000134 (EC: IEA); GO_2000811 (EC: IMP, PMID: 15006356); GO_2001234 (EC: IMP); GO_2001240 (EC: IGI, PMID: 8358790); GO_2001243 (EC: IDA, PMID: 11684014); GO_2001244 (EC: TAS)",,,,,,,,,PMID: 36599; 1339299; 1373874; 1453000; 1502141; 1508712; 1908951; 2250705; 2834197; 2875799; 3285301; 3523487; 3924412; 7546744; 7579350; 7593193; 7650367; 7753817; 7772249; 7834748; 7896880; 7929424; 7954800; 8022822; 8050499; 8080725; 8090743; 8183370; 8232588; 8358790; 8402618; 8402648; 8551385; 8668206; 8760290; 8790371; 8910675; 8929532; 8949945; 9027314; 9031086; 9070836; 9109491; 9111042; 9115213; 9119086; 9130713; 9184696; 9219694; 9226175; 9226228; 9305631; 9334338; 9389483; 9395403; 9430630; 9449720; 9463381; 9488477; 9525867; 9561195; 9660918; 9668078; 9727491; 9731710; 9738012; 9765397; 9788433; 9843949; 9852076; 9973195; 10072505; 10075695; 10198631; 10217402; 10329560; 10330179; 10354271; 10417825; 10467396; 10490827; 10506221; 10521466; 10567572; 10597216; 10620603; 10620799; 10622714; 10625696; 10669763; 10677502; 10679027; 10716992; 10807576; 10837489; 10848600; 10871848; 10949025; 11054413; 11060313; 11123279; 11126360; 11158204; 11175251; 11181702; 11206074; 11262395; 11264898; 11278245; 11323417; 11325850; 11326318; 11368354; 11390485; 11406564; 11437653; 11463391; 11463392; 11483855; 11495898; 11513873; 11527400; 11530860; 11546872; 11583631; 11642719; 11684014; 11728179; 11752215; 11759059; 11759062; 11774038; 11776759; 11787859; 11790116; 11804283; 11804688; 11815602; 11832478; 11839683; 11855781; 11856759; 11861644; 11864421; 11867266; 11871856; 11877091; 11877266; 11877309; 11877669; 11877670; 11908736; 11914580; 11929874; 11940482; 11948397; 11949842; 11949843; 11956602; 11959101; 11964319; 11971816; 11983915; 11986946; 11988841; 11994280; 11999565; 12000759; 12011972; 12019168; 12025227; 12031912; 12032828; 12032841; 12036852; 12036886; 12036888; 12039864; 12046064; 12054739; 12054916; 12070027; 12082633; 12086670; 12086875; 12095980; 12095993; 12096338; 12101183; 12112824; 12118096; 12133494; 12133517; 12137781; 12140755; 12151395; 12161031; 12162425; 12165497; 12167335; 12170763; 12171774; 12172977; 12174951; 12186923; 12189556; 12197229; 12197771; 12207028; 12209154; 12209955; 12214154; 12215338; 12217802; 12234263; 12270344; 12393707; 12400004; 12404120; 12420213; 12421819; 12431997; 12439925; 12440815; 12452037; 12477721; 12477729; 12477932; 12480939; 12481899; 12488548; 12490308; 12499093; 12510149; 12510191; 12513829; 12515824; 12530303; 12532420; 12533044; 12540563; 12575534; 12579337; 12581249; 12583439; 12613529; 12617962; 12624108; 12629413; 12637332; 12667443; 12670866; 12684626; 12686415; 12694817; 12698366; 12702730; 12720100; 12721288; 12721767; 12722479; 12729794; 12749011; 12751031; 12754350; 12756585; 12759537; 12815463; 12819863; 12821128; 12835724; 12839682; 12853473; 12879322; 12890751; 12890867; 12901880; 12937123; 12938158; 12939460; 12960134; 12960340; 12970736; 13130506; 14519627; 14529662; 14554083; 14555646; 14558950; 14572466; 14612291; 14627346; 14628086; 14631373; 14647416; 14647426; 14660675; 14679209; 14689061; 14698203; 14699151; 14714449; 14724650; 14737118; 14739602; 14754534; 14764541; 14767525; 14769789; 14964781; 14966123; 14971737; 14980220; 14999286; 15006356; 15024706; 15026553; 15033793; 15033825; 15033827; 15034060; 15051039; 15057274; 15061204; 15093750; 15115329; 15123638; 15124764; 15149157; 15149158; 15156398; 15179054; 15196944; 15203866; 15210690; 15225643; 15231068; 15231831; 15233914; 15235941; 15243561; 15245329; 15261486; 15263017; 15274378; 15280201; 15302859; 15303767; 15314290; 15314639; 15329319; 15339676; 15340216; 15344336; 15345651; 15351796; 15353294; 15367432; 15375594; 15467428; 15467450; 15478112; 15484294; 15489334; 15489891; 15492114; 15498929; 15520201; 15528355; 15541642; 15544840; 15545228; 15547950; 15561778; 15563082; 15572421; 15574335; 15577328; 15584904; 15593417; 15605273; 15613488; 15619620; 15633216; 15634885; 15638363; 15657349; 15657350; 15694340; 15716988; 15720412; 15720419; 15733859; 15735709; 15754411; 15757646; 15757977; 15763593; 15776018; 15799693; 15800682; 15803126; 15811121; 15817479; 15826766; 15830715; 15832179; 15832769; 15837573; 15840562; 15849194; 15876860; 15880952; 15889622; 15901672; 15907209; 15911345; 15929186; 15965276; 15981087; 15990872; 16007339; 16010987; 16120388; 16132718; 16133992; 16139338; 16148027; 16166262; 16167175; 16173075; 16181427; 16186627; 16186795; 16194898; 16195370; 16199534; 16204228; 16215670; 16215945; 16227396; 16228292; 16235026; 16243795; 16246184; 16273250; 16307838; 16308474; 16358373; 16434970; 16438077; 16443602; 16463650; 16469847; 16472763; 16479062; 16481323; 16520895; 16530191; 16533178; 16533807; 16538384; 16541314; 16545683; 16550596; 16554306; 16566921; 16568081; 16575548; 16636671; 16638854; 16638864; 16642033; 16648655; 16675913; 16690525; 16697956; 16707568; 16714000; 16717086; 16732934; 16733517; 16735440; 16750039; 16761743; 16777355; 16790527; 16799010; 16820876; 16832704; 16839413; 16840204; 16841088; 16850164; 16855163; 16874461; 16949642; 16950491; 16960146; 16980304; 16982461; 16984978; 16988783; 16998187; 17007374; 17015762; 17050165; 17074584; 17082179; 17090549; 17091766; 17097560; 17118768; 17145812; 17188136; 17191123; 17200714; 17203183; 17207023; 17241114; 17252199; 17259174; 17272502; 17274640; 17289999; 17290286; 17295204; 17301078; 17310847; 17325632; 17356300; 17360176; 17363905; 17372162; 17379544; 17379601; 17384650; 17404013; 17418785; 17426248; 17434928; 17438366; 17439414; 17464868; 17473827; 17507655; 17516030; 17516614; 17534194; 17536310; 17557568; 17561354; 17575222; 17588340; 17616686; 17626754; 17632732; 17652637; 17666167; 17670745; 17675494; 17692808; 17693666; 17701916; 17713095; 17727680; 17785366; 17785460; 17825790; 17848143; 17848408; 17852408; 17875758; 17880809; 17882791; 17893147; 17893875; 17905238; 17908970; 17909067; 17909078; 17912028; 17913397; 17916073; 17920946; 17936584; 17942410; 17957472; 17959858; 17960583; 17978676; 17981569; 17989874; 18006836; 18021997; 18023359; 18026954; 18037229; 18041310; 18046447; 18046449; 18046541; 18055344; 18059532; 18063429; 18069888; 18073527; 18079751; 18091321; 18156504; 18158619; 18160396; 18162459; 18174230; 18178565; 18182854; 18189268; 18199533; 18203018; 18215418; 18220834; 18228020; 18240345; 18248353; 18263880; 18279996; 18309324; 18313386; 18314333; 18327814; 18334006; 18342927; 18343029; 18357521; 18363112; 18367485; 18375822; 18382371; 18386458; 18398703; 18407350; 18410632; 18411730; 18415681; 18415689; 18426731; 18427947; 18428028; 18430249; 18438339; 18450493; 18458532; 18465329; 18468253; 18472157; 18474261; 18478476; 18493992; 18505729; 18508827; 18510726; 18516322; 18516673; 18534064; 18534994; 18538438; 18543286; 18561741; 18566606; 18568671; 18568776; 18568946; 18570871; 18572327; 18573594; 18594472; 18595518; 18622426; 18633450; 18636124; 18651163; 18652313; 18653721; 18657507; 18664350; 18675369; 18687309; 18692524; 18695675; 18695940; 18705844; 18712678; 18719108; 18727869; 18752503; 18758240; 18758641; 18769111; 18769121; 18788571; 18794804; 18806751; 18813857; 18818203; 18835031; 18838868; 18928586; 18928588; 18928590; 18929412; 18940474; 18949393; 18957415; 18983973; 18985814; 18998362; 19002577; 19020723; 19027288; 19035131; 19048366; 19050681; 19058789; 19060592; 19064571; 19074885; 19080514; 19107326; 19107575; 19107861; 19124070; 19138978; 19141121; 19141860; 19152170; 19157504; 19160418; 19168699; 19195736; 19196738; 19205434; 19228691; 19237173; 19238538; 19240654; 19250983; 19253527; 19260506; 19266703; 19269343; 19272801; 19276283; 19280241; 19287190; 19287965; 19298794; 19318089; 19336552; 19348791; 19351510; 19351886; 19360919; 19379569; 19380879; 19385591; 19390575; 19395874; 19398149; 19404232; 19417623; 19429088; 19448593; 19452318; 19453261; 19460716; 19473442; 19475409; 19477129; 19484260; 19495739; 19520430; 19520857; 19521340; 19535347; 19535901; 19537891; 19539330; 19540934; 19541585; 19549844; 19550126; 19556603; 19557638; 19560836; 19573080; 19576799; 19582475; 19585117; 19589501; 19597184; 19602458; 19605509; 19620938; 19625133; 19627536; 19634687; 19636371; 19655415; 19656156; 19664395; 19671677; 19676105; 19706527; 19717648; 19723039; 19723066; 19724860; 19725224; 19730103; 19737931; 19752028; 19762066; 19773279; 19774677; 19774948; 19783718; 19786087; 19789190; 19797069; 19798108; 19805519; 19813621; 19818125; 19823588; 19834492; 19838163; 19846939; 19854241; 19883311; 19890377; 19890662; 19895735; 19908860; 19913121; 19925052; 19931389; 19937732; 19938012; 19938958; 19940548; 19956635; 19968497; 19996270; 20001236; 20010526; 20010695; 20012528; 20023428; 20025478; 20032416; 20034411; 20036222; 20042890; 20045442; 20048149; 20068093; 20072652; 20082279; 20087644; 20090905; 20118770; 20128283; 20132430; 20139069; 20140889; 20142237; 20146885; 20157331; 20160358; 20177797; 20178647; 20180421; 20181625; 20189848; 20189983; 20193114; 20198332; 20200776; 20223826; 20233885; 20237496; 20307495; 20340172; 20350212; 20352431; 20352700; 20368071; 20368567; 20382751; 20392693; 20399529; 20400521; 20401641; 20404322; 20409521; 20411301; 20415745; 20416158; 20423464; 20423844; 20434805; 20442586; 20448381; 20453000; 20459572; 20459695; 20460269; 20468060; 20495005; 20503275; 20504155; 20514538; 20518070; 20530713; 20564216; 20571027; 20584903; 20594261; 20608924; 20610805; 20627094; 20628086; 20631638; 20644561; 20648653; 20652449; 20658730; 20664977; 20668314; 20668552; 20668868; 20683843; 20691103; 20699221; 20716276; 20716950; 20723294; 20723300; 20732674; 20822926; 20836993; 20841355; 20855536; 20865015; 20869096; 20877624; 20885445; 20889974; 20890735; 20929126; 20929130; 20929131; 20936988; 20951945; 20952062; 20959405; 20962079; 20969490; 20976415; 20981461; 21029589; 21060336; 21061795; 21067292; 21068757; 21072044; 21076048; 21090097; 21104343; 21107291; 21108607; 21110823; 21115898; 21117871; 21122152; 21130495; 21131755; 21148306; 21148799; 21151158; 21159314; 21167476; 21171016; 21174060; 21199860; 21203533; 21207420; 21212266; 21223758; 21233846; 21250804; 21258880; 21289092; 21317312; 21320251; 21320534; 21336967; 21358617; 21376256; 21380782; 21385902; 21388911; 21393866; 21412927; 21424069; 21434524; 21442307; 21444675; 21448217; 21454712; 21455217; 21457555; 21463514; 21474673; 21483469; 21506333; 21508398; 21518495; 21543763; 21556123; 21560251; 21560252; 21589877; 21597459; 21618512; 21621926; 21622563; 21624464; 21624955; 21628855; 21640157; 21640710; 21658611; 21659544; 21669575; 21674599; 21680733; 21682651; 21704150; 21706237; 21708043; 21713707; 21717192; 21729540; 21738398; 21748337; 21748764; 21753125; 21771706; 21772052; 21777944; 21778226; 21785112; 21793937; 21808961; 21819468; 21841772; 21850486; 21855110; 21861179; 21868312; 21878650; 21890444; 21901143; 21907236; 21914345; 21933893; 21936874; 21940310; 21949016; 21956116; 21971866; 21971985; 21978692; 21979585; 21988644; 21989054; 22002575; 22014978; 22020994; 22022968; 22024950; 22037714; 22038216; 22038727; 22054286; 22059351; 22065578; 22072615; 22081075; 22097606; 22109662; 22120515; 22121083; 22138435; 22139839; 22143931; 22143957; 22152474; 22160209; 22171982; 22174682; 22174832; 22187149; 22189900; 22194596; 22194861; 22198673; 22199279; 22207524; 22219597; 22252757; 22262057; 22275372; 22275374; 22277792; 22278385; 22285729; 22293115; 22309998; 22320961; 22322190; 22366560; 22366766; 22367371; 22372356; 22393362; 22395507; 22395508; 22395515; 22406486; 22414090; 22418857; 22433870; 22446832; 22462654; 22464442; 22484426; 22504301; 22504646; 22506026; 22517702; 22523079; 22524261; 22532139; 22562364; 22562824; 22563025; 22582499; 22591684; 22619347; 22622204; 22623155; 22629415; 22647378; 22650021; 22666341; 22668011; 22675938; 22684875; 22710204; 22727345; 22732796; 22739157; 22748563; 22749322; 22797576; 22804688; 22842544; 22848417; 22851565; 22855608; 22895528; 22896703; 22926545; 22929980; 22933114; 22936014; 22949148; 22951829; 22953646; 22965228; 22967897; 22968395; 22971934; 22976527; 22990545; 22995373; 23018213; 23030583; 23038985; 23064052; 23065465; 23072837; 23076250; 23091012; 23095743; 23115005; 23119114; 23126236; 23135964; 23138847; 23151078; 23152059; 23153525; 23160675; 23170075; 23174100; 23207618; 23216071; 23235765; 23243017; 23245210; 23247143; 23261425; 23263985; 23272207; 23283967; 23295106; 23301386; 23316052; 23316280; 23324193; 23334076; 23335369; 23341456; 23352961; 23355004; 23358890; 23359021; 23359184; 23363601; 23364242; 23364875; 23369735; 23403511; 23417836; 23421973; 23422486; 23437205; 23449635; 23463292; 23471820; 23479508; 23479509; 23480852; 23494176; 23497522; 23504944; 23509938; 23511489; 23514940; 23527542; 23553948; 23564079; 23568006; 23573235; 23588221; 23610963; 23612742; 23613399; 23613627; 23624503; 23628417; 23637776; 23671559; 23673452; 23673926; 23674504; 23688426; 23708869; 23719266; 23722017; 23724505; 23733877; 23770605; 23784204; 23802633; 23812727; 23818364; 23822101; 23832737; 23846229; 23850692; 23851330; 23861345; 23880928; 23900644; 23906301; 23907579; 23939148; 23960074; 23975374; 23991978; 23991993; 23994555; 24048795; 24091677; 24097825; 24127568; 24141421; 24157866; 24240096; 24256571; 24288815; 24293274; 24299314; 24314632; 24395794,,,,,,,,,,,,,,,OGG:3000000596,,,,,,,B-cell CLL/lymphoma 2,,,,,,,,,,,,,"Other designations: apoptosis regulator Bcl-2|protein phosphatase 1, regulatory subunit 50",,BCL2,,,,,,,,,,,,,,,,,,,,,,,596,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,BCL2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000000597,BCL2A1,,Other designations: bcl-2-like protein 5|bcl-2-related protein A1|bcl2-L-5|hematopoietic BCL2-related protein A1|hemopoietic-specific early response protein|protein BFL-1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,BCL2L5|ACC-2|HBPA1|BFL1|ACC-1|GRS,,,,,,,,,,,,15,,,,,,HGNC:991|MIM:601056|Ensembl:ENSG00000140379|HPRD:03034|Vega:OTTHUMG00000144173,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,BCL2-related protein A1,,,15q24.3,,,,,,,,,,,,,,,,"GO_0005515 (EC: IPI, PMID: 10753914); GO_0005741 (EC: IBA); GO_0008630 (EC: IBA); GO_0042803 (EC: IBA); GO_0043066 (EC: IBA); GO_0046982 (EC: IBA); GO_0051400 (EC: IEA); GO_0097192 (EC: IBA); GO_2001243 (EC: IBA)",,,,,,,,,PMID: 7478596; 8345191; 8589678; 8605321; 8910286; 8952545; 9050999; 9321477; 9356461; 9670936; 9731710; 10049353; 10198631; 10381646; 10430908; 10454539; 10545479; 10753914; 10849436; 11329013; 11483855; 11696595; 11929871; 12477932; 12665576; 12692420; 12771180; 14747545; 14966372; 14981542; 15489334; 15499630; 15501771; 15592513; 15617521; 15694340; 15696550; 16164629; 16551634; 16572199; 16697956; 16873269; 17121585; 17666431; 17724464; 17726463; 17907802; 17942758; 18093280; 18206119; 18414982; 18512730; 18812174; 18835031; 19336552; 19573080; 19759007; 19773279; 19913121; 20185581; 20353833; 20628086; 20800603; 20855536; 21167304; 21491422; 21832049; 21843371; 22231730; 22292048; 22510878; 22553204; 22615379; 22720045; 22745672; 22865454; 23118966; 23152563; 23447565,,,,,,,,,,,,,,,OGG:3000000597,,20140408,protein-coding,,,,BCL2-related protein A1,,,,,,,,,,,,,Other designations: bcl-2-like protein 5|bcl-2-related protein A1|bcl2-L-5|hematopoietic BCL2-related protein A1|hemopoietic-specific early response protein|protein BFL-1,,BCL2A1,,,,,,,,,,,,,,,,,,,,,,,597,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,BCL2A1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000000595,CCND1,,Other designations: B-cell CLL/lymphoma 1|B-cell lymphoma 1 protein|BCL-1 oncogene|G1/S-specific cyclin-D1|PRAD1 oncogene,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,PRAD1|D11S287E|BCL1|U21B31,,,,,,,,,,,,11,,,,,,HGNC:1582|Vega:OTTHUMG00000167877|MIM:168461|HPRD:01346|Ensembl:ENSG00000110092,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,cyclin D1,,,11q13,,,,,,,,,,,,,,,,"GO_0000082 (EC: IDA, PMID: 19412162); GO_0000082 (EC: TAS, PMID: 18483258); GO_0000122 (EC: IDA, PMID: 16569215); GO_0000278 (EC: TAS); GO_0000307 (EC: IDA, PMID: 17420273); GO_0000320 (EC: IEA); GO_0001889 (EC: IEA); GO_0001934 (EC: IDA, PMID: 8114739); GO_0003714 (EC: IDA, PMID: 16569215); GO_0004672 (EC: IEA); GO_0005515 (EC: IPI, PMID: 15232106); GO_0005622 (EC: IDA); GO_0005634 (EC: IDA); GO_0005654 (EC: TAS); GO_0005730 (EC: IDA, Qualifier: NOT); GO_0005829 (EC: TAS); GO_0005923 (EC: IEA); GO_0006351 (EC: IEA); GO_0006974 (EC: IDA, PMID: 19412162); GO_0007219 (EC: TAS); GO_0007595 (EC: IEA); GO_0008134 (EC: IPI, PMID: 16569215); GO_0010039 (EC: IEA); GO_0010165 (EC: IEA); GO_0010243 (EC: IEA); GO_0010971 (EC: IDA, PMID: 19124461); GO_0016020 (EC: IEA); GO_0016538 (EC: IEA); GO_0017053 (EC: IDA, PMID: 16569215); GO_0019899 (EC: IPI, PMID: 19412162); GO_0019901 (EC: IPI, PMID: 19124461); GO_0030178 (EC: IEA); GO_0030857 (EC: IEA); GO_0030968 (EC: IEA); GO_0031100 (EC: IEA); GO_0031571 (EC: IDA, PMID: 19412162); GO_0032026 (EC: IEA); GO_0032403 (EC: IEA); GO_0033197 (EC: IEA); GO_0033327 (EC: IEA); GO_0033598 (EC: IEA); GO_0033601 (EC: IEA); GO_0042493 (EC: IEP, PMID: 18291362); GO_0042826 (EC: IPI, PMID: 18417529); GO_0043627 (EC: IEA); GO_0045444 (EC: IEA); GO_0045471 (EC: IEA); GO_0045737 (EC: IDA, PMID: 8114739); GO_0051301 (EC: IEA); GO_0051412 (EC: IEA); GO_0051592 (EC: IEA); GO_0060070 (EC: IEA); GO_0060749 (EC: IEA); GO_0070064 (EC: IDA, PMID: 19124461); GO_0070141 (EC: IDA, PMID: 18483258); GO_0071157 (EC: IDA, PMID: 19124461)",,,,,,,,,PMID: 1386335; 1532244; 1535701; 1682919; 1826542; 1827756; 1833066; 1833629; 6610211; 7478582; 7568034; 7665234; 7687458; 7733934; 7739547; 7903056; 7908906; 8058338; 8058751; 8101826; 8114739; 8134134; 8136159; 8159685; 8204893; 8208539; 8259215; 8302605; 8490963; 8643455; 8647086; 8657154; 8662825; 8756624; 8826947; 8867812; 8887674; 8978686; 8999999; 9003781; 9039267; 9050835; 9106657; 9139732; 9150368; 9178893; 9190208; 9228064; 9244350; 9311993; 9372967; 9380698; 9426067; 9626345; 9632134; 9661876; 9736735; 9832502; 9832503; 9837900; 9926939; 10066798; 10202152; 10318892; 10344732; 10353443; 10371345; 10486249; 10491434; 10500095; 10580009; 10581175; 10645009; 10764802; 10766840; 10801854; 10850422; 10908655; 10910956; 10952989; 11042687; 11073968; 11076863; 11126356; 11256614; 11279133; 11311237; 11360184; 11470749; 11593423; 11642719; 11696452; 11698342; 11698641; 11739785; 11739795; 11751903; 11788592; 11793365; 11805292; 11813305; 11815623; 11836555; 11838966; 11860939; 11870667; 11872630; 11884610; 11896626; 11902820; 11923474; 11935308; 11940657; 11948404; 11958128; 11986316; 11992406; 12002755; 12006580; 12007188; 12024041; 12036888; 12036906; 12036934; 12036951; 12048199; 12067972; 12096344; 12097293; 12101670; 12127555; 12138206; 12150453; 12151312; 12164325; 12203362; 12209953; 12231535; 12237776; 12241561; 12364325; 12376514; 12379776; 12383116; 12388769; 12391146; 12394763; 12439750; 12444551; 12455063; 12477932; 12480939; 12515730; 12519773; 12529437; 12539042; 12554669; 12557224; 12569141; 12582032; 12589056; 12594215; 12601350; 12606305; 12607604; 12634633; 12673692; 12676926; 12680219; 12692418; 12694349; 12707028; 12738746; 12743597; 12746453; 12759391; 12761882; 12778072; 12807740; 12808109; 12824903; 12825853; 12867429; 12883688; 12883749; 12894561; 12896908; 12899785; 12914697; 12917336; 12917338; 12921950; 12930597; 12937137; 12955092; 12965081; 12972956; 14530270; 14612904; 14641107; 14645506; 14645576; 14646596; 14657069; 14666635; 14666673; 14666699; 14679024; 14688016; 14689059; 14701845; 14703063; 14720512; 14754892; 14759115; 14764597; 14767060; 14966901; 14981950; 15059606; 15060836; 15063389; 15090460; 15128059; 15133490; 15138714; 15153436; 15172998; 15203873; 15225161; 15226187; 15232106; 15239347; 15245939; 15277517; 15282324; 15297421; 15350626; 15355984; 15375804; 15377668; 15378006; 15485920; 15489334; 15489336; 15498584; 15505422; 15513923; 15538282; 15539430; 15544931; 15545188; 15551329; 15557280; 15557752; 15558026; 15578074; 15580291; 15592430; 15621754; 15652748; 15655836; 15659654; 15668481; 15684604; 15688030; 15695117; 15695403; 15709184; 15713663; 15734847; 15735724; 15754315; 15755896; 15776189; 15791567; 15808510; 15809880; 15811121; 15824172; 15845652; 15856299; 15861516; 15862753; 15863141; 15870300; 15878868; 15893730; 15896460; 15897899; 15900590; 15914210; 15923181; 15943036; 15949570; 15950906; 15951302; 15951563; 15971196; 15981100; 16051426; 16061635; 16082198; 16115225; 16123218; 16131791; 16142313; 16155412; 16163549; 16163738; 16166625; 16172916; 16174239; 16207592; 16226824; 16258726; 16258756; 16273238; 16287839; 16322291; 16328437; 16334487; 16341674; 16343742; 16357142; 16381901; 16399423; 16406195; 16407831; 16436505; 16461912; 16488657; 16490596; 16495921; 16507767; 16508013; 16547504; 16552496; 16568089; 16569215; 16600870; 16601140; 16614707; 16614728; 16616093; 16638786; 16644723; 16645724; 16672066; 16690963; 16691558; 16691626; 16699726; 16705174; 16723714; 16732330; 16758952; 16776827; 16782892; 16783567; 16788380; 16804724; 16815198; 16820873; 16829689; 16832876; 16843438; 16860316; 16865250; 16870553; 16884382; 16912209; 16916940; 16924241; 16940298; 16942622; 16959222; 16980615; 16985050; 17011980; 17018901; 17022831; 17046823; 17053782; 17060721; 17067457; 17070615; 17080657; 17081987; 17090192; 17106256; 17116943; 17129455; 17139501; 17188136; 17198740; 17203162; 17203214; 17205132; 17207971; 17208333; 17240151; 17254966; 17274640; 17278098; 17284370; 17299095; 17308274; 17310991; 17316413; 17334399; 17344214; 17374178; 17393422; 17398034; 17409409; 17420273; 17427198; 17437044; 17438373; 17447856; 17482347; 17486065; 17499716; 17509221; 17517369; 17517622; 17524364; 17525627; 17549378; 17556661; 17561354; 17600882; 17605237; 17606477; 17606765; 17607588; 17616526; 17616699; 17626745; 17629555; 17634024; 17653856; 17684142; 17693985; 17695500; 17698033; 17720094; 17724472; 17804732; 17848143; 17855508; 17868090; 17881732; 17882269; 17901853; 17906980; 17908995; 17912028; 17916995; 17922974; 17923265; 17927591; 17927853; 17934069; 17935714; 17941827; 17960397; 18006686; 18006821; 18019405; 18024283; 18027856; 18043898; 18047954; 18056951; 18061526; 18063576; 18067636; 18079202; 18171527; 18174243; 18180298; 18182398; 18187454; 18194492; 18194538; 18196581; 18197291; 18205772; 18212742; 18226366; 18237245; 18239461; 18240019; 18251939; 18281541; 18284543; 18291362; 18301453; 18306932; 18327210; 18327303; 18341653; 18343791; 18347178; 18349267; 18349392; 18355450; 18355918; 18358634; 18361427; 18367547; 18373498; 18379871; 18381935; 18393977; 18398822; 18404250; 18406353; 18413612; 18413728; 18413773; 18413827; 18417529; 18431519; 18437417; 18445313; 18456656; 18459109; 18467434; 18483258; 18483394; 18484097; 18491248; 18507837; 18514338; 18537972; 18547262; 18548202; 18562319; 18598945; 18604165; 18609126; 18616527; 18618300; 18625744; 18632615; 18640142; 18644870; 18650423; 18665038; 18665077; 18676680; 18677114; 18695042; 18695676; 18703151; 18710938; 18710949; 18713830; 18715616; 18715870; 18753363; 18758380; 18769147; 18787961; 18794045; 18794151; 18798551; 18799029; 18819000; 18822177; 18823025; 18829570; 18839518; 18842998; 18843022; 18844221; 18925698; 18936968; 18942117; 18942709; 18949380; 18950845; 18983468; 18988190; 18991334; 19009649; 19020753; 19034659; 19040567; 19047108; 19055446; 19064572; 19070887; 19071090; 19074853; 19074885; 19075005; 19080374; 19084934; 19086036; 19091404; 19096232; 19106611; 19106744; 19116388; 19124461; 19124506; 19129688; 19134409; 19136653; 19139013; 19142864; 19143767; 19147768; 19152247; 19166930; 19170196; 19183483; 19187116; 19203829; 19237565; 19242061; 19258477; 19287456; 19289374; 19302219; 19303206; 19321861; 19322201; 19324500; 19330026; 19336552; 19373442; 19375306; 19379556; 19386349; 19412162; 19415719; 19430707; 19440933; 19443866; 19448414; 19453261; 19467018; 19470470; 19470724; 19474518; 19475398; 19477949; 19489683; 19499154; 19502783; 19505905; 19525979; 19536092; 19538740; 19549773; 19550124; 19554511; 19556892; 19558863; 19564413; 19572978; 19573080; 19575018; 19578796; 19585495; 19589865; 19602458; 19625176; 19633425; 19634112; 19636701; 19638577; 19666237; 19666944; 19670700; 19679881; 19687314; 19690970; 19692168; 19706803; 19723065; 19724860; 19728335; 19738611; 19750108; 19757306; 19760977; 19773279; 19774638; 19779113; 19780858; 19787783; 19789190; 19795398; 19800042; 19801633; 19801969; 19802676; 19806481; 19821490; 19822419; 19823025; 19823825; 19826048; 19850937; 19883431; 19885547; 19898427; 19900369; 19903334; 19904758; 19915615; 19915977; 19917254; 19919588; 19921577; 19923826; 19933579; 19935879; 19940156; 19941161; 19956635; 19956831; 19967453; 20028857; 20062011; 20067552; 20072652; 20087644; 20101207; 20103831; 20113529; 20137349; 20154722; 20160059; 20172376; 20179208; 20181625; 20204303; 20204402; 20231315; 20232305; 20301636; 20304954; 20306448; 20338923; 20347627; 20359085; 20359118; 20372799; 20373052; 20380574; 20389301; 20392877; 20397048; 20401451; 20404095; 20407865; 20418097; 20426528; 20429623; 20437058; 20443083; 20453000; 20453838; 20459741; 20460515; 20466633; 20473525; 20484017; 20485284; 20503270; 20512928; 20515940; 20540739; 20543468; 20564361; 20575692; 20577923; 20578819; 20581865; 20586028; 20616110; 20618968; 20628002; 20631636; 20631637; 20631638; 20644561; 20662834; 20680537; 20680693; 20683026; 20683061; 20683643; 20699365; 20701069; 20714998; 20723296; 20727381; 20737317; 20801098; 20809334; 20822933; 20837141; 20839920; 20844743; 20856207; 20857402; 20890425; 20924203; 20950152; 20951943; 20971731; 21036743; 21042715; 21044962; 21056029; 21062395; 21079973; 21098327; 21107342; 21116504; 21131888; 21135252; 21139048; 21148318; 21159451; 21161398; 21179427; 21185249; 21187402; 21193919; 21200149; 21212260; 21242960; 21242966; 21254295; 21268129; 21273603; 21281227; 21300445; 21315112; 21315488; 21326383; 21327470; 21331989; 21343394; 21347341; 21385053; 21401699; 21410931; 21438905; 21447152; 21454057; 21455311; 21487939; 21492065; 21497295; 21498736; 21503589; 21517236; 21526487; 21537090; 21537837; 21544737; 21547408; 21548803; 21569306; 21594903; 21606015; 21654808; 21738001; 21745168; 21746927; 21777578; 21778791; 21783402; 21789902; 21799732; 21830375; 21850541; 21867613; 21890746; 21892090; 21906983; 21912938; 21946890; 21952639; 21955753; 21956468; 21963094; 21965784; 21972713; 21987572; 21988832; 21989330; 21989926; 22002566; 22024187; 22037875; 22050898; 22052559; 22065993; 22072615; 22100494; 22102309; 22133292; 22135025; 22150974; 22158041; 22204713; 22231956; 22234583; 22260073; 22261253; 22266466; 22289525; 22296356; 22304571; 22306268; 22307325; 22318732; 22321253; 22322158; 22336657; 22357515; 22369110; 22387541; 22391566; 22399638; 22406359; 22406644; 22451658; 22456513; 22460364; 22467101; 22467868; 22475046; 22484283; 22490843; 22528945; 22534667; 22553812; 22565393; 22581837; 22590809; 22606291; 22629227; 22640743; 22647349; 22647378; 22706868; 22707287; 22711989; 22722256; 22747683; 22760121; 22770229; 22776845; 22790016; 22801439; 22812184; 22814742; 22819905; 22833568; 22853846; 22864797; 22884659; 22884800; 22893700; 22901215; 22905217; 22905260; 22922827; 22926658; 22967707; 22976805; 22982899; 23000965; 23001925; 23020291; 23031786; 23044415; 23060014; 23108396; 23111452; 23125009; 23126531; 23135283; 23144465; 23161911; 23163571; 23201130; 23217712; 23222716; 23226276; 23244103; 23255553; 23261678; 23270726; 23292829; 23300886; 23311506; 23315417; 23322406; 23327593; 23354584; 23383003; 23383271; 23388457; 23390492; 23396251; 23400686; 23455922; 23502783; 23515614; 23525507; 23529990; 23540573; 23543735; 23562784; 23566410; 23568005; 23568006; 23613410; 23625206; 23625573; 23648671; 23653001; 23661346; 23664541; 23670132; 23674142; 23696923; 23707388; 23718855; 23720779; 23731275; 23733133; 23737530; 23741361; 23795354; 23804702; 23852369; 23861098; 23864650; 23873109; 23893383; 23897809; 23898488; 23920145; 23936312; 23949314; 23975835; 23985254; 23991960; 23991964; 24019069; 24060591; 24085301; 24088803; 24119401; 24134204; 24145651; 24282282; 24324055; 24403468,,,,,,,,,,,,,,,OGG:3000000595,,,,,,,cyclin D1,,,,,,,,,,,,,Other designations: B-cell CLL/lymphoma 1|B-cell lymphoma 1 protein|BCL-1 oncogene|G1/S-specific cyclin-D1|PRAD1 oncogene,,CCND1,,,,,,,,,,,,,,,,,,,,,,,595,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,CCND1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000009804,TOMM20,,Other designations: mitochondrial 20 kDa outer membrane protein|mitochondrial import receptor subunit TOM20 homolog|outer mitochondrial membrane receptor Tom20|translocase of outer mitochondrial membrane 20 homolog type II,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,MAS20|MOM19|TOM20,,,,,,,,,,,,1,,,,,,MIM:601848|HGNC:20947|HPRD:03507|Vega:OTTHUMG00000039619|Ensembl:ENSG00000173726,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,translocase of outer mitochondrial membrane 20 homolog (yeast),,,1q42,,,,,,,,,,,,,,,,"GO_0005515 (EC: IPI, PMID: 14557246); GO_0005739 (EC: IDA); GO_0005742 (EC: NAS, PMID: 7498524); GO_0005742 (EC: TAS, PMID: 14557246); GO_0006626 (EC: IDA, PMID: 14557246); GO_0006626 (EC: TAS); GO_0015450 (EC: IDA, PMID: 14557246); GO_0016021 (EC: IEA); GO_0044267 (EC: TAS); GO_0051082 (EC: IDA, PMID: 14557246); GO_0071806 (EC: IDA, PMID: 14557246)",,,,,,,,,PMID: 7498524; 7584026; 7584028; 7589431; 9119086; 9211931; 9748310; 9756929; 10548729; 10980201; 10982837; 11027586; 11913975; 12477932; 14557246; 14699115; 15489334; 15644312; 15733919; 16169070; 16710414; 17081983; 18029348; 19322201; 20686565; 20877624; 21771790; 21890473; 21906983; 21963094; 22280891; 22610502; 22939629; 23000965; 23165776; 23251661; 23275563; 23885119; 24250222,,,,,,,,,,,,,,,OGG:3000009804,,,,,,,translocase of outer mitochondrial membrane 20 homolog (yeast),,,,,,,,,,,,,Other designations: mitochondrial 20 kDa outer membrane protein|mitochondrial import receptor subunit TOM20 homolog|outer mitochondrial membrane receptor Tom20|translocase of outer mitochondrial membrane 20 homolog type II,,TOMM20,,,,,,,,,,,,,,,,,,,,,,,9804,RP4-597N16.2,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,TOMM20,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0000611,death domain signanaling pathway,,A series of molecular signals mediated by death-domain superfamily.,false,,,http://purl.obolibrary.org/obo/TXPO_0000609,,,,,,,,,,,,,,,,,,,,PMID:12189384,,A series of molecular signals mediated by death-domain superfamily.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000611,,,,,,,,,,,,,,,,,,,,,,death domain signanaling pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000617,polypeptide,,A peptide containing ten or more amino acid residues.,false,,,http://purl.obolibrary.org/obo/CHEBI_16670,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_15841,,A peptide containing ten or more amino acid residues.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000617,,,,,,,,,,,,,,,,,,,,,,polypeptide,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000612,nodule formation,,"The process in which the anatomical structures of the nodule are generated and organized.|GO:0009877 nodule morphogenesis is part of some nodulation. However, nodulation is defined as the formation of nitrogen-fixing root nodules on plant roots. Therefore, TXPO does not reuse GO terms and defines originally.",false,,,http://purl.obolibrary.org/obo/TXPO_0000134,,,,,,,,,,,,,,,,,,,,,,The process in which the anatomical structures of the nodule are generated and organized.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000612,,,,,,,,,,,,,,,,,,,,"GO:0009877 nodule morphogenesis is part of some nodulation. However, nodulation is defined as the formation of nitrogen-fixing root nodules on plant roots. Therefore, TXPO does not reuse GO terms and defines originally.",,nodule formation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000619,removing damaged object,,"Removing damaged object is a subtype of removing: A process that takes a damaged object from an organism, tissue, organelle, or cell.",false,,,http://purl.obolibrary.org/obo/TXPO_0000458,,,,,,,,,,,,,,,,,,,,,,"Removing damaged object is a subtype of removing: A process that takes a damaged object from an organism, tissue, organelle, or cell.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000619,,,,,,,,,,,,,,,,,,,,,,removing damaged object,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000613,GPC3 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:2719|NCBI-Mouse-GeneID:14734|NCBI-Rat-GeneID:25236,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000613,,,,,,,,,,,,,,,,,,,,,,GPC3 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000610,metabolic pathway,,"Metabolic pathway is a subtype of pathway: Sequence of enzyme reactions to change metabolism, including anabolism and catabolism.",false,,,http://purl.obolibrary.org/obo/NCIT_C54214,,,,,,,,,,,,,,,,,,,,,,"Metabolic pathway is a subtype of pathway: Sequence of enzyme reactions to change metabolism, including anabolism and catabolism.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000610,,,,,,,,,,,,,,,,,,,,,,metabolic pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000614,data item,,"A data item is an information content entity that is intended to be a truthful statement about something (modulo, e.g., measurement precision or other systematic errors) and is constructed/acquired by a method which reliably tends to produce (approximately) truthful statements.",false,,,http://purl.obolibrary.org/obo/IAO_0000030,,,,,,,,,,,,,,,,,,,,,,"A data item is an information content entity that is intended to be a truthful statement about something (modulo, e.g., measurement precision or other systematic errors) and is constructed/acquired by a method which reliably tends to produce (approximately) truthful statements.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000614,,,,,,,,,,,,,,,,,,,,,,data item,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000616,increasing volume of liver,,Increasing volume of liver is a subtype of increasing volume: A process that changes the volume of the liver to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000139,,,,,,,,,,,,,,,,,,,,,,Increasing volume of liver is a subtype of increasing volume: A process that changes the volume of the liver to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000616,,,,,,,,,,,,,,,,,,,,,,increasing volume of liver,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000618,increase of ROS and RNS production,,Increasing ROS/RNS is a process of changing amount to increase the magnitude of the ROS or RNS.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing ROS/RNS is a process of changing amount to increase the magnitude of the ROS or RNS.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000618,,,,,,,,,,,,,,,,,,,,,,increase of ROS and RNS production,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100382,Grb7/10/14 family,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003657,,,,,,,,,,IMR:0100382,,,,,,,,,,,,,,,,,,,,,,Grb7/10/14 family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100575,Src (mol),c-Src|p60-Src,,false,,,http://purl.obolibrary.org/obo/IMR_0000211,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:6714|NCBI-Mouse-GeneID:20779|NCBI-Rat-GeneID:83805,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,c-Src|p60-Src,,,,,IMR:0100575,,,,,,,,,,,,,,,,,,,,,,Src (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000028,IFN type I,type I Interferon,,false,,,http://purl.obolibrary.org/obo/IMR_0000027,,,,,,,,,,,,,,,,,,,,GO:0005132,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,type I Interferon,,,,,IMR:0000028,,,,,,,,,,,,,,,,,,,,,,IFN type I,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000892,IRAK-4,IL-1 receptor-associated kinase 4|Interleukin-1 receptor-associated kinase-4,,false,,,http://purl.obolibrary.org/obo/IMR_0100488,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IL-1 receptor-associated kinase 4|Interleukin-1 receptor-associated kinase-4,,,,,IMR:0000892,,,,,,,,,,,,,,,,,,,,,,IRAK-4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_38637,tyrosine kinase inhibitor,protein tyrosine kinase inhibitors|protein tyrosine kinase inhibitor|TKI inhibitors|TKI inhibitor|tyrphostin|tyrphostins|tyrosine kinase inhibitors,Any protein kinase inhibitor that interferes with the action of tyrosine kinase.,false,,,http://purl.obolibrary.org/obo/CHEBI_37699,,,,,,,,,,,,,,,,,,,,,,Any protein kinase inhibitor that interferes with the action of tyrosine kinase.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,protein tyrosine kinase inhibitors|protein tyrosine kinase inhibitor|TKI inhibitors|TKI inhibitor|tyrphostin|tyrphostins|tyrosine kinase inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:38637,,,,tyrosine kinase inhibitor,,CHEBI:38637,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0061702,inflammasome complex,,A cytosolic protein complex that is capable of activating caspase-1.,false,,,http://purl.obolibrary.org/obo/TXPO_0002107,,,,,,,,,,,,,,,,,,,,,,A cytosolic protein complex that is capable of activating caspase-1.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0061702,,,,,,,,,,,,,,,,,,,,,,inflammasome complex,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000055741,EDEM2,,Other designations: ER degradation-enhancing alpha-mannosidase-like 2|ER degradation-enhancing alpha-mannosidase-like protein 2|ER degradation-enhancing-mannosidase-like protein 2,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,C20orf49|C20orf31|bA4204.1,,,,,,,,,,,,20,,,,,,HGNC:15877|Ensembl:ENSG00000088298|HPRD:09841|MIM:610302|Vega:OTTHUMG00000032322,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"ER degradation enhancer, mannosidase alpha-like 2",,,20q11.22,,,,,,,,,,,,,,,,"GO_0004571 (EC: IDA, Qualifier: NOT, PMID:15537790); GO_0005509 (EC: IEA); GO_0005576 (EC: IEA); GO_0005788 (EC: IEA); GO_0005789 (EC: TAS); GO_0006457 (EC: TAS); GO_0006986 (EC: IEA); GO_0018279 (EC: TAS); GO_0043687 (EC: TAS); GO_0044267 (EC: TAS)",,,,,,,,,PMID:8619474; 9110174; 11780052; 12477932; 12975309; 14702039; 15342556; 15489334; 15537790; 15579471; 16169070; 17499246; 18303019; 20802025; 21822266; 21906983; 22703881; 24250222,,,,,,,,,,,,,,,OGG:3000055741,,,,,,,"ER degradation enhancer, mannosidase alpha-like 2",,,,,,,,,,,,,Other designations: ER degradation-enhancing alpha-mannosidase-like 2|ER degradation-enhancing alpha-mannosidase-like protein 2|ER degradation-enhancing-mannosidase-like protein 2,,EDEM2,,,,,,,,,,,,,,,,,,,,,,,55741,UNQ573/PRO1135,,,,,,,9606,,,,,,,,,,,,,,,,,,,EDEM2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_76817,EC 2.7.10.* (protein-tyrosine kinase) inhibitor,EC 2.7.10.* inhibitor|protein-tyrosine kinase (EC 2.7.10.*) inhibitor|protein-tyrosine kinase inhibitors|protein-tyrosine kinase (EC 2.7.10.*) inhibitors|protein-tyrosine kinase inhibitor|EC 2.7.10.* (protein-tyrosine kinase) inhibitors|EC 2.7.10.* inhibitors,An EC 2.7.* (P-containing group transferase) inhibitor that interferes with the action of any protein-tyrosine kinase (EC 2.7.10.*).,false,,,http://purl.obolibrary.org/obo/CHEBI_37699|http://purl.obolibrary.org/obo/CHEBI_76668,,,,,,,,,,,,,,,,,,,,,,An EC 2.7.* (P-containing group transferase) inhibitor that interferes with the action of any protein-tyrosine kinase (EC 2.7.10.*).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,EC 2.7.10.* inhibitor|protein-tyrosine kinase (EC 2.7.10.*) inhibitor|protein-tyrosine kinase inhibitors|protein-tyrosine kinase (EC 2.7.10.*) inhibitors|protein-tyrosine kinase inhibitor|EC 2.7.10.* (protein-tyrosine kinase) inhibitors|EC 2.7.10.* inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:76817,,,,EC 2.7.10.* (protein-tyrosine kinase) inhibitor,,CHEBI:76817,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_37962,adrenergic agent,adrenergic agents|adrenergic neuron agents|adrenergics|adrenergic drug|adrenergic drugs,Any agent that acts on an adrenergic receptor or affects the life cycle of an adrenergic transmitter.,false,,,http://purl.obolibrary.org/obo/CHEBI_35942,,,,,,,,,,,,,,,,,,,,,,Any agent that acts on an adrenergic receptor or affects the life cycle of an adrenergic transmitter.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,adrenergic agents|adrenergic neuron agents|adrenergics|adrenergic drug|adrenergic drugs,,,,,,,,,,,,,,,,,,,,,CHEBI:37962,,,,adrenergic agent,,CHEBI:37962,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_4885,ethionamide,2-ethylpyridine-4-carbothioamide,A thiocarboxamide that is pyridine-4-carbothioamide substituted by an ethyl group at position 2. A prodrug that undergoes metabolic activation by conversion to the corresponding S-oxide.,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Wikipedia:Ethionamide|DrugBank:DB00609|CAS:536-33-4,,A thiocarboxamide that is pyridine-4-carbothioamide substituted by an ethyl group at position 2. A prodrug that undergoes metabolic activation by conversion to the corresponding S-oxide.,,,,,,,,,,,,C8H10N2S,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001996|http://purl.obolibrary.org/obo/CHEBI_50185,,,,,2-ethylpyridine-4-carbothioamide,,,,,CHEBI:4885,,,,,,,,,,,,,,,,,,,,,,ethionamide,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CCc1cc(ccn1)C(N)=S,,,,,
http://purl.obolibrary.org/obo/GO_0046222,aflatoxin metabolic process,aflatoxin metabolism,"The chemical reactions and pathways involving aflatoxin, a fungal metabolite found as a contaminant in moldy grains that induces liver cancer. Aflatoxin induces a G to T transversion at codon 249 of p53, leading to its inactivation. Aflatoxin is converted to a chemical carcinogen by P450.",false,,,http://purl.obolibrary.org/obo/GO_0009404,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways involving aflatoxin, a fungal metabolite found as a contaminant in moldy grains that induces liver cancer. Aflatoxin induces a G to T transversion at codon 249 of p53, leading to its inactivation. Aflatoxin is converted to a chemical carcinogen by P450.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,aflatoxin metabolism,,,,,GO:0046222,,,,,,,,,,,,,,,,,,,,,,aflatoxin metabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/NCIT_C54214,pathway,,"A set or series of interactions, often forming a network, which biologists have found useful to group together for organizational, historic, biophysical, or other reasons.",false,,,http://purl.obolibrary.org/obo/TXPO_0000608,,,,,,,,,,,,,,,,,,,,,,"A set or series of interactions, often forming a network, which biologists have found useful to group together for organizational, historic, biophysical, or other reasons.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,NCIT:C54214,,,,,,,,,,,,,,,,,,,,,,pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_16152,"1-Phosphatidyl-1D-myo-inositol 3,4-bisphosphate","PtsIns-3,4-P2|PtsIns(3,4)P2|1-O-(3-sn-phosphatidyl)-1D-myo-inositol 3,4-bis(dihydrogen phosphate)|1-Phosphatidyl-1D-myo-inositol 3,4-bisphosphate",,false,,,http://purl.obolibrary.org/obo/CHEBI_37328,,,,,,,,,,,,,,,,,,,,IMR:0001353|ISBN:0815340729,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"1-O-(3-sn-phosphatidyl)-1D-myo-inositol 3,4-bis(dihydrogen phosphate)|1-Phosphatidyl-1D-myo-inositol 3,4-bisphosphate",,"PtsIns-3,4-P2|PtsIns(3,4)P2",,,CHEBI:16152,,,,,,,,,,,,,,,,,,,,,,"1-Phosphatidyl-1D-myo-inositol 3,4-bisphosphate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/BFO_0000140,continuant fiat boundary,,"b is a continuant fiat boundary = Def. b is an immaterial entity that is of zero, one or two dimensions and does not include a spatial region as part. (axiom label in BFO2 Reference: [029-001])",false,,,http://purl.obolibrary.org/obo/BFO_0000141,,,,,,,,,,,,,,,,,,,,,,"b is a continuant fiat boundary = Def. b is an immaterial entity that is of zero, one or two dimensions and does not include a spatial region as part. (axiom label in BFO2 Reference: [029-001])",,,,"BFO 2 Reference: In BFO 1.1 the assumption was made that the external surface of a material entity such as a cell could be treated as if it were a boundary in the mathematical sense. The new document propounds the view that when we talk about external surfaces of material objects in this way then we are talking about something fiat. To be dealt with in a future version: fiat boundaries at different levels of granularity.More generally, the focus in discussion of boundaries in BFO 2.0 is now on fiat boundaries, which means: boundaries for which there is no assumption that they coincide with physical discontinuities. The ontology of boundaries becomes more closely allied with the ontology of regions.|Continuant fiat boundary doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. An example would be the mereological sum of two-dimensional continuant fiat boundary and a one dimensional continuant fiat boundary that doesn't overlap it. The situation is analogous to temporal and spatial regions.|BFO 2 Reference: a continuant fiat boundary is a boundary of some material entity (for example: the plane separating the Northern and Southern hemispheres; the North Pole), or it is a boundary of some immaterial entity (for example of some portion of airspace). Three basic kinds of continuant fiat boundary can be distinguished (together with various combination kinds [29",,,,,,,,,,,,,,(iff (ContinuantFiatBoundary a) (and (ImmaterialEntity a) (exists (b) (and (or (ZeroDimensionalSpatialRegion b) (OneDimensionalSpatialRegion b) (TwoDimensionalSpatialRegion b)) (forall (t) (locatedInAt a b t)))) (not (exists (c t) (and (SpatialRegion c) (continuantPartOfAt c a t)))))) // axiom label in BFO2 CLIF: [029-001],Every continuant fiat boundary is located at some spatial region at every time at which it exists,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BFO:0000140,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/bfo.owl,continuant fiat boundary,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100135,beta-endorphin,,,false,,,http://purl.obolibrary.org/obo/IMR_0100154,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_25512,,,,,,,,,,IMR:0100135,,,,,,,,,,,,,,,,,,,,,,beta-endorphin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000300,Ran,Ras-like nuclear protein|TC4,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,IPR:002041,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003669|http://purl.obolibrary.org/obo/TXPO_0000885,,,,,Ras-like nuclear protein|TC4,,,,,IMR:0000300,,,,,,,,,,,,,,,,,,,,,,Ran,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_16359,cholic acid,,"A bile acid that is 5β-cholan-24-oic acid bearing threeα-hydroxy substituents at position 3, 7 and 12.",false,,,http://purl.obolibrary.org/obo/TXPO_0000509,,,,,,,,,,,,,,,,,,,,InChIKey:BHQCQFFYRZLCQQ-OELDTZBJSA-N,,"A bile acid that is 5β-cholan-24-oic acid bearing threeα-hydroxy substituents at position 3, 7 and 12.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:16359,,,,,,,,,,,,,,,,,,,,,,cholic acid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/HINO_0016364,amino acid conjugation,,"Xenobiotics that contain either a carboxylic group or an aromatic hydroxylamine group are possible substrates for amino acid conjugation. Xenobiotics with a carboxylic group conjugate with an amino group of amino acids such as glycine, taurine and glutamine. The hydroxylamine group conjugates with the carboxylic group of amino acids such as proline and serine.",false,,,http://purl.obolibrary.org/obo/GO_0006520,,,,,,,,,,,,,,,,,,,,,,"Xenobiotics that contain either a carboxylic group or an aromatic hydroxylamine group are possible substrates for amino acid conjugation. Xenobiotics with a carboxylic group conjugate with an amino group of amino acids such as glycine, taurine and glutamine. The hydroxylamine group conjugates with the carboxylic group of amino acids such as proline and serine.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,HINO:0016364,,,,,,,,,,,,,,,,,,,,,,amino acid conjugation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001514,continuousness (attribute),,,false,,,http://purl.obolibrary.org/obo/TXPO_0001536,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001514,,,,,,,,,,,,,,,,,,,,,,continuousness (attribute),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001512,non-neoplastic (value),,"An attribute value of a tumor that does not progress, not invade surrounding tissues or not metastasize.",false,,,http://purl.obolibrary.org/obo/TXPO_0001510,,,,,,,,,,,,,,,,,,,,,,"An attribute value of a tumor that does not progress, not invade surrounding tissues or not metastasize.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001512,,,,,,,,,,,,,,,,,,,,,,non-neoplastic (value),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001515,kinase,,"Catalysis role  of the transfer of a phosphate group, usually from ATP, to a substrate molecule.|related molecular function GO:0016301",false,,,http://purl.obolibrary.org/obo/TXPO_0000606,,,,,,,,,,,,,,,,,,,,EC:2.7.,,"Catalysis role  of the transfer of a phosphate group, usually from ATP, to a substrate molecule.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001515,,,,,,,,,,,,,,,,,,,,related molecular function GO:0016301,,kinase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001511,neoplastic (value),,"A value of the attribute of tumors that progress, invade surrounding tissues or metastasize.",false,,,http://purl.obolibrary.org/obo/TXPO_0001510,,,,,,,,,,,,,,,,,,,,,,"A value of the attribute of tumors that progress, invade surrounding tissues or metastasize.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001511,,,,,,,,,,,,,,,,,,,,,,neoplastic (value),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001510,tumor value,,"An attribute value of a tumor.
This entity is a subtype of categorical value, which is non-quantitative and is dependent on tumors.",false,,,http://purl.obolibrary.org/obo/TXPO_0000277,,,,,,,,,,,,,,,,,,,,,,"An attribute value of a tumor.
This entity is a subtype of categorical value, which is non-quantitative and is dependent on tumors.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001510,,,,,,,,,,,,,,,,,,,,,,tumor value,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001519,sequestering of triglyceride in hepatocyte (mild) [lipidosis],,"sequestering of triglyceride (mild) is a subtype of lipid strorage in hepatocyte: A process that keeps triglycerides in hepatocytes. And the degree is mild.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001522,,,,,,,,,,,,,,,,,,,,,,"sequestering of triglyceride (mild) is a subtype of lipid strorage in hepatocyte: A process that keeps triglycerides in hepatocytes. And the degree is mild.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001519,,,,,,,,,,,,,,,,,,,,,,sequestering of triglyceride in hepatocyte (mild) [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001513,signal integration system,,"Signal integration system is a subtype of pathway system.
This entity has sub-parts and has a goal of transmitting signals and a gene regulation as a systemic context.",false,,,http://purl.obolibrary.org/obo/TXPO_0000603,,,,,,,,,,,,,,,,,,,,,,"Signal integration system is a subtype of pathway system.
This entity has sub-parts and has a goal of transmitting signals and a gene regulation as a systemic context.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001513,,,,,,,,,,,,,,,,,,,,,,signal integration system,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001517,Ang (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:11727|NCBI-Rat-GeneID:305843|NCBI-Human-GeneID:283,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000283,,,,,,,,,,,,,TXPO:0001517,,,,,,,,,,,,,,,,,,,,,,Ang (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001516,negative regulation ofglycosylation,,"Negative regulation ofglycosylation is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of glycosylation.",false,,,http://purl.obolibrary.org/obo/TXPO_0000369,,,,,,,,,,,,,,,,,,,,,,"Negative regulation ofglycosylation is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of glycosylation.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001516,,,,,,,,,,,,,,,,,,,,,,negative regulation ofglycosylation,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0070085,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0034440,lipid oxidation,,"The removal of one or more electrons from a lipid, with or without the concomitant removal of a proton or protons, by reaction with an electron-accepting substance, by addition of oxygen or by removal of hydrogen.",false,,,http://purl.obolibrary.org/obo/GO_0055114,,,,,,,,,,,,,,,,,,,,,,"The removal of one or more electrons from a lipid, with or without the concomitant removal of a proton or protons, by reaction with an electron-accepting substance, by addition of oxygen or by removal of hydrogen.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0034440,,,,,,,,,,,,,,,,,,,,,,lipid oxidation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000040,BMP family,Bone morphogenetic protein family,"BMPs belong to the TGF-beta superfamily. BMP-like molecules have been identified in various species including D.melanogaster (Dpp, Gbb/60A and Scw) and C.elegans.",false,,,http://purl.obolibrary.org/obo/IMR_0000036,,,,,,,,,,,,,,,,,,,,,,"BMPs belong to the TGF-beta superfamily. BMP-like molecules have been identified in various species including D.melanogaster (Dpp, Gbb/60A and Scw) and C.elegans.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Bone morphogenetic protein family,,,,,IMR:0000040,,,,,,,,,,,,,,,,,,,,,,BMP family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002024,Fgf2 (rat)[Uncoupling],,"The protein encoded by this gene is a member of the fibroblast growth factor (FGF) family. FGF family members bind heparin and possess broad mitogenic and angiogenic activities. This protein has been implicated in diverse biological processes, such as limb and nervous system development, wound healing, and tumor growth. The mRNA for this gene contains multiple polyadenylation sites, and is alternatively translated from non-AUG (CUG) and AUG initiation codons, resulting in five different isoforms with distinct properties. The CUG-initiated isoforms are localized in the nucleus and are responsible for the intracrine effect, whereas, the AUG-initiated form is mostly cytosolic and is responsible for the paracrine and autocrine effects of this FGF. [provided by RefSeq, Jul 2008]",false,,,http://purl.obolibrary.org/obo/TXPO_1000144|http://purl.obolibrary.org/obo/TXPO_0002014,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:14173|NCBI-Rat-GeneID:54250|NCBI-Human-GeneID:2247|PMID:28544332|PMID:28006775,,"The protein encoded by this gene is a member of the fibroblast growth factor (FGF) family. FGF family members bind heparin and possess broad mitogenic and angiogenic activities. This protein has been implicated in diverse biological processes, such as limb and nervous system development, wound healing, and tumor growth. The mRNA for this gene contains multiple polyadenylation sites, and is alternatively translated from non-AUG (CUG) and AUG initiation codons, resulting in five different isoforms with distinct properties. The CUG-initiated isoforms are localized in the nucleus and are responsible for the intracrine effect, whereas, the AUG-initiated form is mostly cytosolic and is responsible for the paracrine and autocrine effects of this FGF. [provided by RefSeq, Jul 2008]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002024,,,,,,,,,,,,,,,,,,,,,,Fgf2 (rat)[Uncoupling],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002028,Stard7 (rat)[Uncoupling],,STARD7 (StAR Related Lipid Transfer Domain Containing 7) is a Protein Coding gene. Diseases associated with STARD7 include Gestational Trophoblastic Tumor. Among its related pathways are Metabolism and Glycerophospholipid biosynthesis. GO annotations related to this gene include lipid binding. An important paralog of this gene is PCTP.,false,,,http://purl.obolibrary.org/obo/TXPO_1000353|http://purl.obolibrary.org/obo/TXPO_0002014,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:296128|NCBI-Human-GeneID:56910|NCBI-Mouse-GeneID:99138|http://omim.org/entry/616712|PMID:27499296|PMID:20042613|PMID:15013637,,STARD7 (StAR Related Lipid Transfer Domain Containing 7) is a Protein Coding gene. Diseases associated with STARD7 include Gestational Trophoblastic Tumor. Among its related pathways are Metabolism and Glycerophospholipid biosynthesis. GO annotations related to this gene include lipid binding. An important paralog of this gene is PCTP.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002028,,,,,,,,,,,,,,,,,,,,,,Stard7 (rat)[Uncoupling],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002020,Smarcd3 (rat)[Uncoupling],,"The protein encoded by this gene is a member of the SWI/SNF family of proteins, whose members display helicase and ATPase activities and which are thought to regulate transcription of certain genes by altering the chromatin structure around those genes. The encoded protein is part of the large ATP-dependent chromatin remodeling complex SNF/SWI and has sequence similarity to the yeast Swp73 protein. Multiple alternatively spliced transcript variants have been found for this gene, but the biological validity of some variants has not been determined. [provided by RefSeq, Jul 2008]",false,,,http://purl.obolibrary.org/obo/TXPO_1000345|http://purl.obolibrary.org/obo/TXPO_0002014,,,,,,,,,,,,,,,,,,,,https://omim.org/entry/601737|PMID:23219531,,"The protein encoded by this gene is a member of the SWI/SNF family of proteins, whose members display helicase and ATPase activities and which are thought to regulate transcription of certain genes by altering the chromatin structure around those genes. The encoded protein is part of the large ATP-dependent chromatin remodeling complex SNF/SWI and has sequence similarity to the yeast Swp73 protein. Multiple alternatively spliced transcript variants have been found for this gene, but the biological validity of some variants has not been determined. [provided by RefSeq, Jul 2008]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002020,,,,,,,,,,,,,,,,,,,,,,Smarcd3 (rat)[Uncoupling],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002023,eosinophilic granular degeneration with hypertrophy　[toxic course],,The totality of all processes through which eosinogranular degeneration accompanied with hypertrophy is realized.,false,,,http://purl.obolibrary.org/obo/TXPO_0000028,,,,,,,,,,,,,,,,,,,,PMID:16332691,,The totality of all processes through which eosinogranular degeneration accompanied with hypertrophy is realized.,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001023,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002025|http://purl.obolibrary.org/obo/TXPO_0001023|http://purl.obolibrary.org/obo/TXPO_0000096|http://purl.obolibrary.org/obo/TXPO_0001010,,,,,,,,,,,,,,,,,,TXPO:0002023,,,,,,,,,,,,,,,,,,,,,,eosinophilic granular degeneration with hypertrophy　[toxic course],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002021,moving lipid to the hepatocye [Eosinophilic granular degeneration],,"Moving lipid to the hepatocyte is a subtype of moving A to the inside of B: A process of the movement of lipid into a hepatocyte.
This entity is a specific course-dependent process. This process can constitute the course of eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/TXPO_0001270|http://purl.obolibrary.org/obo/TXPO_0001729,,,,,,,,,,,,,,,,,,,,,,"Moving lipid to the hepatocyte is a subtype of moving A to the inside of B: A process of the movement of lipid into a hepatocyte.
This entity is a specific course-dependent process. This process can constitute the course of eosinogranular degeneration.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002021,,,,,,,,,,,,,,,,,,TXPO:0002021,,,,,,,,,,,,,,,,,,,,,,moving lipid to the hepatocye [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002025,increasing hepatocellular volume (moderate) [Eosinophilic granular degeneration],,"Increasing hepatocellular volume is a changing process to change the volume of the hepatocyte to increase. The degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/TXPO_0000165,,,,,,,,,,,,,,,,,,,,https://doi.org/10.1002/9780470744307.gat023,,"Increasing hepatocellular volume is a changing process to change the volume of the hepatocyte to increase. The degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000096,,,,,,,,,,,TXPO:0002025,,,,,,,,,,,,,,,,,,,,,,increasing hepatocellular volume (moderate) [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002026,amiodarone -mitochondrial respiratory chain inhibitor [lipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000880,,,,,,,,,,,,,,,,,,,,PMID:21145849|ISBN:0071769234,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_25355,,,,,,,,,,TXPO:0002026,,,,,,,,,,,,,,,,,,,,,,amiodarone -mitochondrial respiratory chain inhibitor [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002022,Angptl4 (rat)[Uncoupling],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000002|http://purl.obolibrary.org/obo/TXPO_0002014,,,,,,,,,,,,,,,,,,,,http://omim.org/entry/605910|NCBI-Rat-GeneID:362850|NCBI-Mouse-GeneID:57875|NCBI-Human-GeneID:51129|PMID:22660330|PMID:19075393|PMID:22458843|PMID:10866690|PMID:24465718|PMID:28371666|PMID:10862772,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002022,,,,,,,,,,,,,,,,,,,,,,Angptl4 (rat)[Uncoupling],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002029,increasing hepatocellular volume (severe) [Eosinophilic granular degeneration],,"Increasing hepatocellular volume is a changing process to change the volume of the hepatocyte to increase. The degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/TXPO_0000165,,,,,,,,,,,,,,,,,,,,https://doi.org/10.1002/9780470744307.gat023,,"Increasing hepatocellular volume is a changing process to change the volume of the hepatocyte to increase. The degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000096,,,,,,,,,,,TXPO:0002029,,,,,,,,,,,,,,,,,,,,,,increasing hepatocellular volume (severe) [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002027,increasing hepatocellular volume (mild) [Eosinophilic granular degeneration],,"Increasing hepatocellular volume is a changing process to change the volume of the hepatocyte to increase. The degree is mild.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/TXPO_0000165,,,,,,,,,,,,,,,,,,,,https://doi.org/10.1002/9780470744307.gat023,,"Increasing hepatocellular volume is a changing process to change the volume of the hepatocyte to increase. The degree is mild.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002027,,,,,,,,,,,,,,,,,,,,,,increasing hepatocellular volume (mild) [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000000355,FAS,,"Other designations: APO-1 cell surface antigen|CD95 antigen|Delta Fas/APO-1/CD95|FAS 827dupA|FAS receptor variant 9|FASLG receptor|Fas (TNF receptor superfamily, member 6)|Fas AMA|TNF receptor superfamily member 6|apoptosis antigen 1|apoptosis-mediating surface antigen FAS|tumor necrosis factor receptor superfamily member 6|tumor necrosis factor receptor superfamily, member 6",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CD95|APT1|FASTM|TNFRSF6|ALPS1A|FAS1|APO-1,,,,,,,,,,,,10,,,,,,HPRD:00609|Vega:OTTHUMG00000018701|Ensembl:ENSG00000026103|MIM:134637|HGNC:11920,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,Fas cell surface death receptor,,,10q24.1,,,,,,,,,,,,,,,,"GO_0002377 (EC: IEA); GO_0003014 (EC: IEA); GO_0004871 (EC: TAS, PMID: 10875918); GO_0004872 (EC: NAS, PMID: 7533181); GO_0004888 (EC: IEA); GO_0005515 (EC: IPI, PMID: 10918185); GO_0005634 (EC: IDA); GO_0005737 (EC: IDA); GO_0005829 (EC: NAS, PMID: 7533181); GO_0005886 (EC: IDA); GO_0005886 (EC: IMP); GO_0005886 (EC: TAS); GO_0006461 (EC: TAS, PMID: 10875918); GO_0006915 (EC: IDA, PMID: 9681877); GO_0006915 (EC: TAS); GO_0006919 (EC: TAS); GO_0006924 (EC: IEA); GO_0006925 (EC: IEA); GO_0006927 (EC: IEA); GO_0007165 (EC: TAS, PMID: 9360929); GO_0008625 (EC: IEA); GO_0009636 (EC: IEA); GO_0009897 (EC: IEA); GO_0009986 (EC: IDA); GO_0016021 (EC: IEA); GO_0019724 (EC: IEA); GO_0019900 (EC: IPI, PMID: 7538908); GO_0031264 (EC: IDA, PMID: 11101870); GO_0031265 (EC: IDA); GO_0032464 (EC: IEA); GO_0042802 (EC: IPI); GO_0042981 (EC: NAS, PMID: 7533181); GO_0043065 (EC: IDA); GO_0043065 (EC: IMP); GO_0043066 (EC: IEA); GO_0045060 (EC: IEA); GO_0045121 (EC: IDA); GO_0045619 (EC: IEA); GO_0045637 (EC: IEA); GO_0048536 (EC: IEA); GO_0050869 (EC: IEA); GO_0051260 (EC: IEA); GO_0051384 (EC: IEA); GO_0070062 (EC: IDA); GO_0071260 (EC: IEP, PMID: 19593445); GO_0071285 (EC: IEA); GO_0071455 (EC: IMP); GO_0097049 (EC: IEA); GO_0097190 (EC: TAS); GO_0097191 (EC: IMP); GO_0097192 (EC: IEA); GO_0097527 (EC: IMP, PMID: 16507998); GO_2001239 (EC: TAS); GO_2001241 (EC: IEA)",,,,,,,,,PMID: 1375228; 1385299; 1385309; 1713127; 2469768; 2787530; 7510905; 7514572; 7529798; 7530336; 7533181; 7536190; 7536343; 7538907; 7538908; 7539892; 7540117; 7542559; 7543095; 7575433; 7859281; 8521815; 8524870; 8598453; 8626376; 8648105; 8681376; 8780394; 8864141; 8906799; 8929361; 8940097; 8967952; 8976184; 9002959; 9028321; 9028957; 9039262; 9045686; 9079683; 9082980; 9126929; 9159204; 9199966; 9208847; 9215629; 9223324; 9226175; 9228058; 9247148; 9257699; 9263011; 9267021; 9268734; 9322534; 9325248; 9360929; 9427646; 9475352; 9560245; 9681877; 9721089; 9727492; 9740801; 9751072; 9787134; 9821419; 9835052; 9847311; 9857224; 9920849; 9927496; 9971775; 10068040; 10072505; 10090885; 10200300; 10235259; 10340403; 10462485; 10505674; 10506221; 10535980; 10542291; 10620127; 10625668; 10630977; 10671224; 10706119; 10709732; 10713117; 10799864; 10871852; 10875918; 10918185; 10978533; 11003656; 11034606; 11035039; 11036836; 11048727; 11048730; 11101867; 11101870; 11112409; 11129341; 11177389; 11193028; 11208609; 11298454; 11323689; 11418480; 11436125; 11483955; 11495919; 11550967; 11606059; 11692157; 11733515; 11771526; 11773067; 11779855; 11782802; 11786482; 11786908; 11788891; 11790791; 11809905; 11824955; 11830507; 11836578; 11857317; 11861273; 11864613; 11867183; 11877055; 11891278; 11895550; 11909874; 11920253; 11941452; 11949822; 11961305; 11965496; 11975981; 11986289; 11994542; 12021072; 12032668; 12034188; 12037669; 12040174; 12049185; 12060388; 12060768; 12064832; 12067476; 12096347; 12096925; 12098516; 12107169; 12131184; 12137598; 12139945; 12140383; 12150947; 12163388; 12169207; 12177303; 12185583; 12188927; 12196516; 12198154; 12207331; 12207908; 12220552; 12221075; 12234263; 12244143; 12270344; 12324452; 12372427; 12388693; 12393468; 12393649; 12393889; 12397013; 12414525; 12415011; 12419941; 12452031; 12455036; 12466128; 12477932; 12482410; 12482505; 12485855; 12497631; 12507389; 12513829; 12515395; 12515623; 12516573; 12557947; 12581154; 12583439; 12586732; 12587820; 12604424; 12623840; 12629150; 12646947; 12679613; 12698366; 12699879; 12702723; 12706861; 12710855; 12717632; 12724420; 12742662; 12742739; 12753742; 12757469; 12770553; 12783210; 12788915; 12794152; 12803240; 12824926; 12855571; 12855687; 12867600; 12874203; 12880639; 12883671; 12887920; 12907599; 12923319; 12952224; 12963547; 14506242; 14512182; 14514471; 14530312; 14533029; 14534720; 14557654; 14573612; 14585083; 14594800; 14625033; 14625298; 14625471; 14637155; 14638442; 14644092; 14644197; 14644318; 14647422; 14668794; 14672901; 14676203; 14694156; 14698859; 14714559; 14719092; 14719118; 14724564; 14736971; 14739003; 14739535; 14739941; 14745445; 14759258; 14967838; 14977837; 14981943; 14991945; 15016553; 15019807; 15039424; 15042330; 15054468; 15055260; 15078899; 15138553; 15159312; 15159409; 15160902; 15161716; 15183989; 15203866; 15207703; 15214041; 15215233; 15218339; 15220220; 15238425; 15240787; 15251990; 15277733; 15280387; 15287856; 15289903; 15297424; 15301860; 15345718; 15365741; 15383280; 15390286; 15459302; 15465831; 15467462; 15480430; 15489334; 15492869; 15497017; 15500551; 15502938; 15514680; 15542843; 15556626; 15556941; 15557123; 15563545; 15592292; 15617242; 15632129; 15637757; 15641141; 15645122; 15659383; 15665818; 15670977; 15672026; 15680394; 15688389; 15695771; 15704653; 15723707; 15726829; 15748958; 15786554; 15795317; 15803113; 15806311; 15808689; 15816832; 15818415; 15829968; 15833141; 15838728; 15843521; 15855233; 15858021; 15860671; 15894356; 15907374; 15911745; 15917238; 15929764; 15936090; 15937082; 15938782; 15944736; 15962371; 15963548; 15967797; 15968727; 15972662; 15975999; 15996722; 16000573; 16018969; 16081586; 16087126; 16091761; 16124644; 16129703; 16143308; 16148554; 16157125; 16158329; 16163374; 16169070; 16215672; 16215685; 16255757; 16273638; 16304056; 16306044; 16313826; 16343245; 16344560; 16358967; 16364925; 16368755; 16385451; 16393952; 16403915; 16436054; 16438619; 16441482; 16463650; 16469115; 16472594; 16473667; 16474169; 16507928; 16507998; 16515587; 16524887; 16538171; 16538172; 16643620; 16691186; 16723718; 16736614; 16741989; 16750039; 16765090; 16788566; 16808908; 16820946; 16822901; 16895904; 16899302; 16914910; 16917513; 16921240; 16936193; 16937440; 16948902; 16972019; 16987075; 17000697; 17006606; 17009393; 17014078; 17014925; 17053166; 17056024; 17062728; 17130290; 17135269; 17159907; 17159908; 17161551; 17174268; 17183065; 17194564; 17195092; 17198275; 17203787; 17219051; 17336828; 17376892; 17406980; 17465232; 17485109; 17487740; 17493146; 17504511; 17516614; 17544837; 17545588; 17559541; 17561354; 17564320; 17589525; 17597021; 17598974; 17603079; 17622942; 17657164; 17657791; 17667965; 17684774; 17692455; 17704746; 17704785; 17708363; 17724145; 17762757; 17853317; 17878356; 17891455; 17909299; 17912028; 17912957; 17916181; 17932249; 17938571; 17941899; 17962219; 17962369; 17970696; 17978477; 17982483; 17993614; 17997887; 18000680; 18003704; 18029348; 18045865; 18056484; 18057579; 18068525; 18078642; 18078929; 18088463; 18090928; 18162459; 18174230; 18208868; 18217400; 18220834; 18227168; 18234961; 18243739; 18268284; 18292515; 18302883; 18316328; 18324486; 18328427; 18337305; 18342935; 18361934; 18383830; 18411295; 18422813; 18427836; 18439588; 18441236; 18445624; 18463097; 18473402; 18483392; 18488389; 18494554; 18505906; 18508922; 18508927; 18512812; 18548110; 18552209; 18561948; 18582468; 18588573; 18609513; 18614439; 18635548; 18666137; 18676032; 18679533; 18685642; 18718055; 18727868; 18753860; 18754288; 18757527; 18787411; 18796602; 18800686; 18804468; 18813857; 18818748; 18844072; 18844210; 18851835; 18854777; 18923451; 18948840; 18949391; 18949744; 18972838; 19004284; 19009351; 19010354; 19012493; 19015953; 19019335; 19019483; 19020991; 19037097; 19043361; 19047119; 19067240; 19073786; 19076218; 19077906; 19103758; 19112091; 19118384; 19125371; 19141320; 19141860; 19146781; 19155494; 19161534; 19168581; 19170196; 19173804; 19181929; 19219602; 19225810; 19240174; 19241965; 19262492; 19263494; 19266094; 19270351; 19272297; 19293475; 19298528; 19305072; 19332441; 19336370; 19391241; 19404646; 19458913; 19480241; 19487421; 19509307; 19521670; 19527514; 19538867; 19538884; 19542541; 19561642; 19565204; 19572057; 19573080; 19593445; 19615968; 19625176; 19628789; 19634684; 19653342; 19669200; 19680267; 19692168; 19692467; 19698994; 19716115; 19718569; 19723039; 19726736; 19737931; 19751723; 19758996; 19759548; 19766542; 19773279; 19788921; 19789190; 19798106; 19810143; 19811416; 19812265; 19817952; 19826071; 19890662; 19895798; 19911702; 19913121; 19926197; 19927299; 19937732; 19940360; 19941645; 19950259; 19954064; 19966861; 20012528; 20052288; 20064083; 20074157; 20085233; 20101431; 20106900; 20137575; 20140262; 20164160; 20181888; 20187936; 20193111; 20204402; 20205514; 20219325; 20222173; 20237496; 20301287; 20352431; 20353032; 20359312; 20360470; 20378664; 20380574; 20385987; 20393185; 20394629; 20396760; 20396799; 20408337; 20416077; 20438363; 20438666; 20453000; 20470393; 20501759; 20505730; 20534173; 20547950; 20553075; 20558744; 20568250; 20572163; 20618494; 20620960; 20628086; 20629322; 20638642; 20658220; 20666744; 20673483; 20682001; 20694011; 20726226; 20737708; 20800603; 20802294; 20813889; 20819778; 20822933; 20842669; 20876301; 20934723; 20935634; 20936988; 20947025; 20951677; 20953611; 20959405; 20960177; 20981796; 21036138; 21041692; 21048031; 21049406; 21076068; 21081533; 21087335; 21103345; 21107705; 21120501; 21131755; 21145805; 21167737; 21173302; 21196076; 21233219; 21250890; 21257927; 21271302; 21286777; 21317766; 21321117; 21324892; 21354149; 21359408; 21382479; 21390503; 21430781; 21454681; 21466843; 21468569; 21485506; 21490157; 21516345; 21518761; 21526201; 21526501; 21528407; 21530489; 21549565; 21550977; 21557211; 21557277; 21613217; 21619451; 21625619; 21651830; 21691772; 21706480; 21717192; 21729539; 21741956; 21752354; 21757675; 21762074; 21792914; 21793106; 21803845; 21806408; 21808135; 21852034; 21864388; 21864851; 21869830; 21879377; 21885602; 21906983; 21910009; 21912376; 21917312; 21940365; 21961589; 21963094; 21971214; 21988832; 22027769; 22036455; 22042271; 22065776; 22076446; 22084312; 22095627; 22147197; 22173501; 22182632; 22183068; 22186140; 22194871; 22197557; 22199270; 22207003; 22211869; 22237435; 22252758; 22285488; 22299671; 22331638; 22344564; 22352690; 22357491; 22364882; 22386066; 22398398; 22422199; 22425739; 22431000; 22438247; 22492046; 22499988; 22508480; 22609371; 22622132; 22631677; 22645131; 22649200; 22669972; 22670178; 22677152; 22683265; 22698280; 22702044; 22706245; 22726303; 22752343; 22771321; 22805310; 22806078; 22815944; 22821704; 22842170; 22864571; 22891283; 22898262; 22934709; 22946667; 22983578; 22992806; 23033661; 23045958; 23053964; 23065220; 23114924; 23152563; 23153021; 23166734; 23234803; 23235765; 23240581; 23251661; 23269121; 23280017; 23285481; 23322903; 23326385; 23326448; 23326557; 23327061; 23330016; 23333919; 23338968; 23364796; 23372841; 23392773; 23420824; 23430061; 23434371; 23492187; 23499736; 23524443; 23580232; 23582102; 23582741; 23590971; 23618817; 23619472; 23636796; 23662689; 23667901; 23681795; 23697029; 23762329; 23770605; 23792529; 23846229; 23865866; 23880344; 23894399; 23900676; 23923075; 23932896; 23979975; 24014103; 24043286; 24091673; 24178789; 24331540,,,,,,,,,,,,,,,OGG:3000000355,,,,,,,Fas cell surface death receptor,,,,,,,,,,,,,"Other designations: APO-1 cell surface antigen|CD95 antigen|Delta Fas/APO-1/CD95|FAS 827dupA|FAS receptor variant 9|FASLG receptor|Fas (TNF receptor superfamily, member 6)|Fas AMA|TNF receptor superfamily member 6|apoptosis antigen 1|apoptosis-mediating surface antigen FAS|tumor necrosis factor receptor superfamily member 6|tumor necrosis factor receptor superfamily, member 6",,FAS,,,,,,,,,,,,,,,,,,,,,,,355,RP11-399O19.7,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,FAS,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000000356,FASLG,,"Other designations: CD95 ligand|apoptosis (APO-1) antigen ligand 1|apoptosis antigen ligand|fas antigen ligand|tumor necrosis factor (ligand) superfamily, member 6|tumor necrosis factor ligand superfamily member 6",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,TNFSF6|FASL|APTL|APT1LG1|CD178|ALPS1B|CD95L|CD95-L,,,,,,,,,,,,1,,,,,,HGNC:11936|MIM:134638|HPRD:00610|Ensembl:ENSG00000117560|Vega:OTTHUMG00000034841,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"Fas ligand (TNF superfamily, member 6)",,,1q23,,,,,,,,,,,,,,,,"GO_0000122 (EC: IDA, PMID: 17557115); GO_0005102 (EC: TAS, PMID: 7826947); GO_0005125 (EC: IEA); GO_0005164 (EC: IEA); GO_0005515 (EC: IPI, PMID: 12198154); GO_0005576 (EC: TAS); GO_0005615 (EC: IDA, PMID: 18835034); GO_0005634 (EC: IDA, PMID: 17557115); GO_0005887 (EC: TAS, PMID: 7826947); GO_0005901 (EC: IEA); GO_0006351 (EC: IEA); GO_0006915 (EC: TAS); GO_0006919 (EC: IGI, PMID: 19364818); GO_0006919 (EC: IMP, PMID: 18293083); GO_0006919 (EC: TAS); GO_0006925 (EC: IEA); GO_0006955 (EC: IEA); GO_0007165 (EC: TAS, PMID: 7826947); GO_0007267 (EC: TAS, PMID: 7826947); GO_0008284 (EC: IEA); GO_0008625 (EC: IDA, PMID: 18835034); GO_0009897 (EC: IEA); GO_0016525 (EC: IDA, PMID: 18835034); GO_0030644 (EC: IEA); GO_0032496 (EC: IEA); GO_0043065 (EC: IDA, PMID: 14749367); GO_0043123 (EC: IEP, PMID: 12761501); GO_0043202 (EC: IEA); GO_0043525 (EC: IEA); GO_0045742 (EC: IEA); GO_0046666 (EC: IEA); GO_0048388 (EC: IEA); GO_0048471 (EC: IEA); GO_0060205 (EC: IEA); GO_0070062 (EC: IDA, PMID: 17076679); GO_0070231 (EC: IDA, PMID: 17076679); GO_0070266 (EC: IDA, PMID: 11101870); GO_0070848 (EC: IEA); GO_0097190 (EC: IDA, PMID: 11101870); GO_0097190 (EC: TAS); GO_0097191 (EC: IDA); GO_0097527 (EC: IDA, PMID: 11101870); GO_2000353 (EC: IDA, PMID: 18835034); GO_2001239 (EC: TAS)",,,,,,,,,PMID: 7505205; 7528780; 7530336; 7536190; 7539892; 7566174; 7589480; 7826947; 7980502; 8521815; 8681376; 8787672; 8906799; 8910274; 9002959; 9022072; 9126929; 9215629; 9226175; 9228058; 9247148; 9261095; 9405425; 9427603; 9475352; 9672636; 9721089; 9801169; 9872321; 9920849; 9971775; 10072505; 10224289; 10318773; 10630977; 10671224; 10799864; 11013215; 11036836; 11048727; 11101870; 11208609; 11276204; 11438180; 11500835; 11559749; 11606059; 11716959; 11739488; 11741599; 11751256; 11786482; 11788891; 11801650; 11809905; 11830480; 11845233; 11856352; 11882326; 11895550; 11908702; 11909874; 11925103; 11961305; 11965496; 11994433; 11994542; 12009596; 12021072; 12021310; 12023017; 12100038; 12113885; 12137598; 12161534; 12198154; 12208869; 12220636; 12372468; 12393889; 12414525; 12414956; 12421989; 12454289; 12464266; 12477932; 12482410; 12482505; 12490654; 12507389; 12513781; 12515623; 12557947; 12559631; 12583439; 12594300; 12618758; 12629150; 12637505; 12651606; 12698366; 12700199; 12707034; 12710855; 12717632; 12742662; 12742739; 12753742; 12761501; 12783210; 12787425; 12794109; 12803240; 12807917; 12849704; 12854132; 12867600; 12884192; 12887920; 12918731; 12923319; 12928375; 12930319; 14514471; 14534535; 14560009; 14602201; 14625471; 14634098; 14642527; 14644197; 14668794; 14669310; 14698859; 14705811; 14739003; 14739407; 14739535; 14749367; 14962292; 14967838; 14977837; 14988839; 14996347; 15019279; 15042330; 15073283; 15078178; 15093732; 15138553; 15173177; 15178561; 15183989; 15195700; 15218339; 15240787; 15272306; 15277733; 15287856; 15302589; 15314293; 15337758; 15339846; 15358139; 15457562; 15480896; 15489334; 15492869; 15542843; 15557763; 15579659; 15653751; 15659383; 15674374; 15686714; 15694838; 15791651; 15795317; 15803113; 15806311; 15814666; 15816832; 15833141; 15843521; 15849828; 15858021; 15870081; 15870181; 15907374; 15928037; 15936090; 15937082; 15938782; 15962391; 15968727; 15975999; 15979995; 15991293; 15996722; 16000573; 16081306; 16087126; 16124644; 16133992; 16155003; 16157125; 16157266; 16158329; 16163374; 16181301; 16186185; 16204241; 16212902; 16273638; 16282344; 16298578; 16306044; 16313826; 16318909; 16332967; 16332972; 16364925; 16441482; 16474169; 16487513; 16498403; 16512757; 16514159; 16538171; 16538172; 16595635; 16595663; 16601838; 16627752; 16691186; 16710414; 16736614; 16767155; 16770006; 16808908; 16858424; 16868256; 16902496; 16972019; 16987075; 16990614; 17000697; 17008914; 17014925; 17053166; 17056762; 17071607; 17076679; 17101499; 17118988; 17123522; 17123604; 17136494; 17164290; 17173971; 17183065; 17198275; 17290285; 17381722; 17465232; 17491259; 17545588; 17557115; 17559541; 17564320; 17598974; 17605793; 17654480; 17667919; 17688234; 17703232; 17704118; 17704746; 17727731; 17762757; 17823283; 17853317; 17912957; 17916181; 17938571; 17941899; 17943461; 17961631; 17962219; 17966039; 17969524; 17997887; 18000680; 18045865; 18050226; 18057579; 18068525; 18069935; 18076022; 18078642; 18162459; 18174230; 18217400; 18220834; 18292515; 18293083; 18302883; 18314443; 18316328; 18324486; 18359029; 18361934; 18374107; 18383830; 18392917; 18422813; 18427836; 18473402; 18483392; 18501631; 18505906; 18509086; 18541195; 18548110; 18561948; 18567840; 18577653; 18666137; 18676680; 18727868; 18757527; 18789888; 18800686; 18813857; 18818748; 18835034; 18844072; 18854777; 19009351; 19010354; 19015953; 19019335; 19041431; 19052714; 19079288; 19124506; 19141860; 19146781; 19155494; 19170196; 19176318; 19181929; 19183163; 19219602; 19240174; 19244619; 19266094; 19305072; 19332441; 19337311; 19364818; 19390575; 19403301; 19434529; 19458913; 19505222; 19527514; 19531476; 19535642; 19538867; 19542541; 19565204; 19572057; 19573080; 19614955; 19625176; 19628789; 19641134; 19692168; 19773279; 19779494; 19789190; 19807924; 19810143; 19812265; 19826071; 19854829; 19890662; 19926197; 19937732; 19941645; 19960225; 20012528; 20013612; 20074157; 20101459; 20106900; 20150914; 20165911; 20190752; 20193111; 20204402; 20219325; 20222173; 20237496; 20301287; 20353032; 20359312; 20371612; 20378615; 20379197; 20379614; 20385987; 20393600; 20394629; 20406899; 20408337; 20438363; 20501759; 20533543; 20568250; 20572163; 20602615; 20618494; 20624652; 20650551; 20673483; 20675370; 20726934; 20842669; 20959405; 21087335; 21102463; 21107701; 21122378; 21152963; 21159039; 21227011; 21270445; 21271302; 21285513; 21286777; 21354149; 21368861; 21466843; 21516345; 21528407; 21605112; 21691772; 21725926; 21729539; 21746966; 21803845; 21806408; 21807637; 21808135; 21864388; 21864851; 21879377; 21909273; 21910009; 21940365; 21955608; 22027769; 22161157; 22172872; 22182632; 22199323; 22207003; 22211869; 22330070; 22331638; 22341864; 22344564; 22449797; 22461695; 22499988; 22535954; 22558309; 22609371; 22631677; 22645131; 22702044; 22706245; 22726303; 22732091; 22763913; 22821704; 22842170; 22860894; 22927007; 22946667; 23045958; 23065018; 23076876; 23128233; 23153021; 23177026; 23184030; 23192951; 23234803; 23269121; 23280017; 23285481; 23330016; 23392773; 23405244; 23420824; 23504349; 23534738; 23582102; 23618817; 23681795; 23682624; 23697029; 23923075; 24072745; 24178789; 24184557; 24265545; 24291222,,,,,,,,,,,,,,,OGG:3000000356,,,,,,,"Fas ligand (TNF superfamily, member 6)",,,,,,,,,,,,,"Other designations: CD95 ligand|apoptosis (APO-1) antigen ligand 1|apoptosis antigen ligand|fas antigen ligand|tumor necrosis factor (ligand) superfamily, member 6|tumor necrosis factor ligand superfamily member 6",,FASLG,,,,,,,,,,,,,,,,,,,,,,,356,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,FASLG,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0004307,collagen deposition [mitochondrial disorder],,"The aggregation of collagen in a particular location in an organism, tissue or cell, occurring in response to some external stimulus.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0004306|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:29222479,,"The aggregation of collagen in a particular location in an organism, tissue or cell, occurring in response to some external stimulus.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004279,,,,,,,,,,,TXPO:0004307,,,,,,,,,,,,,,,,,,,,,,collagen deposition [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004309,release of DNA from mitochondria [hepatocarcinogenesis],,"The process that results in the movement of mitochondriall DNA from the  mitochondria.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0001863,,,,,,,,,,,,,,,,,,,,PMID:30894684,,"The process that results in the movement of mitochondriall DNA from the  mitochondria.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004289,,,,,,,,,,,TXPO:0004309,,,,,,,,,,,,,,,,,,,,,,release of DNA from mitochondria [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004305,metabolic dysfunction of precursor metabolites and energy generation,,energy metabolic dysfunction is a subtype of Metabolic dysfunctioning: A process that performs an abnormal and incomplete energy metabolic function.,false,,,http://purl.obolibrary.org/obo/TXPO_0002131,,,,,,,,,,,,,,,,,,,,,,energy metabolic dysfunction is a subtype of Metabolic dysfunctioning: A process that performs an abnormal and incomplete energy metabolic function.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004305,,,,,,,,,,,,,,,,,,,,,,metabolic dysfunction of precursor metabolites and energy generation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004300,TLR9 signaling (primitive),,TLR9 signaling (primitive) is a subtype of TLR signaling [biological]: Any series of molecular signals generated as a consequence of binding to toll-like receptor 9.,false,,,http://purl.obolibrary.org/obo/TXPO_0004301,,,,,,,,,,,,,,,,,,,,,,TLR9 signaling (primitive) is a subtype of TLR signaling [biological]: Any series of molecular signals generated as a consequence of binding to toll-like receptor 9.,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0001464,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0034162,,,,,,,,,,,,,,,,TXPO:0004300,,,,,,,,,,,,,,,,,,,,,,TLR9 signaling (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004303,p38 signaling (primitive),,p38 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the p38 (a Mitogen-Activated Protein Kinase).,false,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,,,p38 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the p38 (a Mitogen-Activated Protein Kinase).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004302,,,,,,,,,,,,,,,,TXPO:0004303,,,,,,,,,,,,,,,,,,,,,,p38 signaling (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004301,TLR signaling (primitive),,TLR signaling (primitive) is a subtype of signaling [biological]: Any series of molecular signals generated as a consequence of binding to toll-like receptor.,false,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,,,TLR signaling (primitive) is a subtype of signaling [biological]: Any series of molecular signals generated as a consequence of binding to toll-like receptor.,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0001464,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0002224,,,,,,,,,,,,,,,,TXPO:0004301,,,,,,,,,,,,,,,,,,,,,,TLR signaling (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004306,collagen deposition,,"The aggregation of collagen in a particular location in an organism, tissue or cell, occurring in response to some external stimulus.",false,,,http://purl.obolibrary.org/obo/TXPO_0000247,,,,,,,,,,,,,,,,,,,,,,"The aggregation of collagen in a particular location in an organism, tissue or cell, occurring in response to some external stimulus.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004306,,,,,,,,,,,,,,,,,,,,,,collagen deposition,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004308,binding to mtDNA by radicals,,Process of binding by which radicals interact with mtDNA (mitochondrial deoxyribonucleic acid).,false,,,http://purl.obolibrary.org/obo/TXPO_0004244,,,,,,,,,,,,,,,,,,,,,,Process of binding by which radicals interact with mtDNA (mitochondrial deoxyribonucleic acid).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004308,,,,,,,,,,,,,,,,,,,,,,binding to mtDNA by radicals,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004304,interleukin-6 production,,"The appearance of interleukin-6 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.",false,,,http://purl.obolibrary.org/obo/GO_0001816,,,,,,,,,,,,,,,,,,,,,,"The appearance of interleukin-6 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004304,,,,,,,,,,,,,,,,,,,,,,interleukin-6 production,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004302,p38 signaling cascade,p38 signal transduction pathway|p38 cascade,"An intracellular protein kinase cascade containing at least a p38 MAPK, a MAPKK and a MAP3K. The cascade can also contain an additional tier: the upstream MAP4K. The kinases in each tier phosphorylate and activate the kinases in the downstream tier to transmit a signal within a cell. (by GO)",false,,,http://purl.obolibrary.org/obo/TXPO_0000609,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0038066,,"An intracellular protein kinase cascade containing at least a p38 MAPK, a MAPKK and a MAP3K. The cascade can also contain an additional tier: the upstream MAP4K. The kinases in each tier phosphorylate and activate the kinases in the downstream tier to transmit a signal within a cell. (by GO)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000769,,,,,,,,,,,,,p38 signal transduction pathway|p38 cascade,,,,,TXPO:0004302,,,,,,,,,,,,,,,,,,,,,,p38 signaling cascade,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000409,NF1 (mol),NFI|nuclear factor 1|CTF|CCAAT box-binding transcription factor,"The NFI family is composed of four members in vertebrates (NFI-A, NFI-B, NFI-C and NFI-X).",false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,IPR:000647,,"The NFI family is composed of four members in vertebrates (NFI-A, NFI-B, NFI-C and NFI-X).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,NFI|nuclear factor 1|CTF|CCAAT box-binding transcription factor,,,,,IMR:0000409,,,,,,,,,,,,,,,,,,,,,,NF1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003683,size (attribute),,An attribute of morphology inhering in a bearer by virtue of the bearer's physical magnitude.,false,,,http://purl.obolibrary.org/obo/TXPO_0000305,,,,,,,,,,,,,,,,,,,,,,An attribute of morphology inhering in a bearer by virtue of the bearer's physical magnitude.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003683,,,,,,,,,,,,,,,,,,,,,,size (attribute),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003688,adhesion molecule,cell adhesion mediator,A role played by the molecule to mediate adhesion of the cell to the external substrate or to another cell.|related molecular function GO:0098631,false,,,http://purl.obolibrary.org/obo/TXPO_0003691,,,,,,,,,,,,,,,,,,,,IMR:0000166 (obsolete),,A role played by the molecule to mediate adhesion of the cell to the external substrate or to another cell.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,cell adhesion mediator,,,,,TXPO:0003688,,,,,,,,,,,,,,,,,,,,related molecular function GO:0098631,,adhesion molecule,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003684,docking protein,,A role played by the entity that acts as docking sites for multiple signaling molecules.,false,,,http://purl.obolibrary.org/obo/TXPO_0003657,,,,,,,,,,,,,,,,,,,,IMR:0000345 (obsolete),,A role played by the entity that acts as docking sites for multiple signaling molecules.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003684,,,,,,,,,,,,,,,,,,,,,,docking protein,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003687,structural constituent of ribosome,ribosomal protein,The role of a molecule that contributes to the structural integrity of the ribosome.|reated molecular function GO:0003735,false,,,http://purl.obolibrary.org/obo/TXPO_0003691,,,,,,,,,,,,,,,,,,,,IMR:0100710 (obsolete),,The role of a molecule that contributes to the structural integrity of the ribosome.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ribosomal protein,,,TXPO:0003687,,,,,,,,,,,,,,,,,,,,reated molecular function GO:0003735,,structural constituent of ribosome,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003682,DD-containing adaptor protein role,death domain-containing adaptor protein,"A role played by the entity interacting selectively and non-covalently and simultaneously with one or more signal transduction molecules, usually acting as a scaffold to bring these molecules into close using Death Domains.",false,,,http://purl.obolibrary.org/obo/TXPO_0003657,,,,,,,,,,,,,,,,,,,,IMR:0000742 (obsolete),,"A role played by the entity interacting selectively and non-covalently and simultaneously with one or more signal transduction molecules, usually acting as a scaffold to bring these molecules into close using Death Domains.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,death domain-containing adaptor protein,,,,,TXPO:0003682,,,,,,,,,,,,,,,,,,,,,,DD-containing adaptor protein role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003685,translation initiation factor,,A role of involving the initiation of ribosome-mediated translation of mRNA into a polypeptide.|related molecular function GO:0003743,false,,,http://purl.obolibrary.org/obo/TXPO_0003730,,,,,,,,,,,,,,,,,,,,,,A role of involving the initiation of ribosome-mediated translation of mRNA into a polypeptide.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003685,,,,,,,,,,,,,,,,,,,,related molecular function GO:0003743,,translation initiation factor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003680,ligand-gated ion channel,,A role played by the entity which enables the transmembrane transfer of an ion by a channel that opens when a specific ligand has been bound by the channel complex or one of its constituent parts.|related molecular function GO:0015276,false,,,http://purl.obolibrary.org/obo/TXPO_0000328,,,,,,,,,,,,,,,,,,,,,,A role played by the entity which enables the transmembrane transfer of an ion by a channel that opens when a specific ligand has been bound by the channel complex or one of its constituent parts.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003680,,,,,,,,,,,,,,,,,,,,related molecular function GO:0015276,,ligand-gated ion channel,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003681,SH2/SH3 adaptor protein role,,"A role played by the entity interacting selectively and non-covalently and simultaneously with one or more signal transduction molecules, usually acting as a scaffold to bring these molecules into close proximity either using their own SH2/SH3 domains (e.g. Grb2) or those of their target molecules (e.g. SAM68).|related molecular function GO:0005070",false,,,http://purl.obolibrary.org/obo/TXPO_0003657,,,,,,,,,,,,,,,,,,,,IMR:0000334 (obsolete),,"A role played by the entity interacting selectively and non-covalently and simultaneously with one or more signal transduction molecules, usually acting as a scaffold to bring these molecules into close proximity either using their own SH2/SH3 domains (e.g. Grb2) or those of their target molecules (e.g. SAM68).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003681,,,,,,,"This term refers to the adaptor proteins that possesses both SH2 and SH3 domains, such as Grb2, Nck and Crk, and does not include adaptor proteins that contain only SH2 or PTB domains, such as the Shc family and the IRS family.",,,,,,,,,,,,,related molecular function GO:0005070,,SH2/SH3 adaptor protein role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003686,lipid mediator,,"Lipid Mediator role is played by a lipid having bioactivity, which is transiently produced locally, acts on a cell membrane receptor located in its place, transmits a signal, and usually is decomposed promptly.",false,,,http://purl.obolibrary.org/obo/CHEBI_33280,,,,,,,,,,,,,,,,,,,,IMR:0100181 (obsolete),,"Lipid Mediator role is played by a lipid having bioactivity, which is transiently produced locally, acts on a cell membrane receptor located in its place, transmits a signal, and usually is decomposed promptly.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003686,,,,,,,,,,,,,,,,,,,,,,lipid mediator,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003689,cytoskeletal protein,,The role played by the molecule that contributes to the structural integrity of a cytoskeletal structure.|related molecular function GO:0005200,false,,,http://purl.obolibrary.org/obo/TXPO_0003691,,,,,,,,,,,,,,,,,,,,IMR:0000185(obsolete),,The role played by the molecule that contributes to the structural integrity of a cytoskeletal structure.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003689,,,,,,,,,,,,,,,,,,,,related molecular function GO:0005200,,cytoskeletal protein,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0002950,CD80/CD86,B7.1/B7.2,"B7.1 (CD80) and B7.2 (CD86) - the two structurally homologous ligands of CD28 - are expressed by professional antigen-presenting cells (APCs), such as dendritic cells (DCs), macrophages and activated B cells, belong to the immunoglobulin superfamily and might exist as dimers and monomers, respectively.",false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,"B7.1 (CD80) and B7.2 (CD86) - the two structurally homologous ligands of CD28 - are expressed by professional antigen-presenting cells (APCs), such as dendritic cells (DCs), macrophages and activated B cells, belong to the immunoglobulin superfamily and might exist as dimers and monomers, respectively.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000624,,,,,B7.1/B7.2,,,,,IMR:0002950,,,,,,,,,,,,,,,,,,,,,,CD80/CD86,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000022861,NLRP1,,"Other designations: NACHT, LRR and PYD containing protein 1|NACHT, LRR and PYD domains-containing protein 1|NACHT, leucine rich repeat and PYD (pyrin domain) containing 1|NACHT, leucine rich repeat and PYD containing 1|caspase recruitment domain protein 7|caspase recruitment domain-containing protein 7|death effector filament-forming Ced-4-like apoptosis protein|nucleotide-binding domain and caspase recruitment domain|nucleotide-binding oligomerization domain, leucine rich repeat and pyrin domain containing 1",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CARD7|DEFCAP|NALP1|VAMAS1|SLEV1|CLR17.1|DEFCAP-L/S|CIDED|PP1044|NAC,,,,,,,,,,,,17,,,,,,HGNC:14374|HPRD:07364|Ensembl:ENSG00000091592|MIM:606636|Vega:OTTHUMG00000132419,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"NLR family, pyrin domain containing 1",,,17p13.2,,,,,,,,,,,,,,,,"GO_0005515 (EC: IPI, PMID: 11472070); GO_0005524 (EC: IDA, PMID: 15212762); GO_0005622 (EC: IC, PMID: 11076957); GO_0005634 (EC: IDA, PMID: 17164409); GO_0005829 (EC: TAS); GO_0006915 (EC: NAS, PMID: 11076957); GO_0006919 (EC: IDA, PMID: 15212762); GO_0006919 (EC: NAS, PMID: 11076957); GO_0008656 (EC: NAS, PMID: 11076957); GO_0019899 (EC: IPI, PMID: 11076957); GO_0019904 (EC: IPI, PMID: 16575408); GO_0032495 (EC: ISS); GO_0035872 (EC: TAS); GO_0042742 (EC: ISS); GO_0045087 (EC: TAS); GO_0050718 (EC: ISS); GO_0050727 (EC: IC, PMID: 15212762); GO_0051402 (EC: IDA, PMID: 15212762); GO_0072558 (EC: IDA, PMID: 12191486); GO_0072558 (EC: TAS)",,,,,,,,,PMID: 8619474; 8781126; 9110174; 10231032; 11076957; 11113115; 11250163; 11270363; 11472070; 11592035; 12191486; 12477932; 12563287; 14527388; 14691733; 14702039; 15107016; 15174051; 15212762; 15749123; 16575408; 17164409; 17377159; 17418785; 17620097; 17637824; 18263805; 18348116; 18854154; 18946481; 19001869; 19074885; 19120479; 19223160; 19337385; 19727120; 19913121; 20152874; 20370570; 20379614; 20403135; 20502346; 20574744; 20628086; 20697295; 20800603; 21098108; 21149496; 21245836; 21252346; 21331694; 21376416; 21946017; 21976003; 22087307; 22117610; 22227487; 22235789; 22507623; 22524199; 22665479; 23053059; 23253924; 23349227; 23374100; 23380025; 23382179; 23508996; 23563199; 23940760; 24008734,,,,,,,,,,,,,,,OGG:3000022861,,,,,,,"NLR family, pyrin domain containing 1",,,,,,,,,,,,,"Other designations: NACHT, LRR and PYD containing protein 1|NACHT, LRR and PYD domains-containing protein 1|NACHT, leucine rich repeat and PYD (pyrin domain) containing 1|NACHT, leucine rich repeat and PYD containing 1|caspase recruitment domain protein 7|caspase recruitment domain-containing protein 7|death effector filament-forming Ced-4-like apoptosis protein|nucleotide-binding domain and caspase recruitment domain|nucleotide-binding oligomerization domain, leucine rich repeat and pyrin domain containing 1",,NLRP1,,,,,,,,,,,,,,,,,,,,,,,22861,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,NLRP1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_33838,nucleoside,,"An N-glycosyl compound that has both a nucleobase, normally adenine, guanine, xanthine, thymine, cytosine or uracil, and either a ribose or deoxyribose as functional parents.",false,,,http://purl.obolibrary.org/obo/IMR_0001698|http://purl.obolibrary.org/obo/CHEBI_72695,,,,,,,,,,,,,,,,,,,,,,"An N-glycosyl compound that has both a nucleobase, normally adenine, guanine, xanthine, thymine, cytosine or uracil, and either a ribose or deoxyribose as functional parents.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:33838,,,,,,,,,,,,,,,,,,,,,,nucleoside,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000008672,EIF4G3,,Other designations: eIF-4-gamma 3|eIF-4-gamma II|eukaryotic translation initiation factor 4 gamma 3,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,eIF4GII|eIF4G 3|eIF-4G 3,,,,,,,,,,,,1,,,,,,HPRD:06802|Vega:OTTHUMG00000002624|Ensembl:ENSG00000075151|HGNC:3298|MIM:603929,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"eukaryotic translation initiation factor 4 gamma, 3",,,1p36.12,,,,,,,,,,,,,,,,"GO_0000339 (EC: TAS, PMID:9418880); GO_0001934 (EC: IEA); GO_0003743 (EC: IEA); GO_0005829 (EC: TAS); GO_0006446 (EC: TAS, PMID:9418880); GO_0007283 (EC: IEA); GO_0008135 (EC: TAS, PMID:9418880); GO_0016032 (EC: IEA); GO_0016281 (EC: TAS, PMID:9418880); GO_0019221 (EC: TAS); GO_0044822 (EC: IDA); GO_0045727 (EC: IEA); GO_0060903 (EC: IEA)",,,,,,,,,PMID:8125298; 9418880; 9857202; 9878069; 10022874; 10737800; 10872469; 11172724; 12477932; 12663812; 12975586; 14507913; 15016848; 15146197; 15361857; 15489334; 16344560; 16964243; 17081983; 17353931; 18654987; 19615732; 19805454; 20020773; 20379614; 21139048; 21182205; 21890473; 21900206; 21906983; 21963094; 22505724; 22586326; 22939629; 22990118; 23000965,,,,,,,,,,,,,,,OGG:3000008672,,,,,,,"eukaryotic translation initiation factor 4 gamma, 3",,,,,,,,,,,,,Other designations: eIF-4-gamma 3|eIF-4-gamma II|eukaryotic translation initiation factor 4 gamma 3,,EIF4G3,,,,,,,,,,,,,,,,,,,,,,,8672,RP11-190H11.1,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF4G3,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0100281,I-kappaB beta,IkB-beta|inhibitor of NF-kappaB beta,,false,,,http://purl.obolibrary.org/obo/IMR_0000464,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IkB-beta|inhibitor of NF-kappaB beta,,,,,IMR:0100281,,,,,,,,,,,,,,,,,,,,,,I-kappaB beta,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000195,Hist2h2aa3 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:8337|NCBI-Rat-GeneID:365877,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000008337,,,,,,,,,,,,,TXPO:1000195,,,,,,,,,,,,,,,,,,,,,,Hist2h2aa3 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000190,HSPA13 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:29734|NCBI-Human-GeneID:6782|NCBI-Mouse-GeneID:110920,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000006782,,,,,,,,,,,,,TXPO:1000190,,,,,,,,,,,,,,,,,,,,,,HSPA13 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000198,Hsdl2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:84263|NCBI-Mouse-GeneID:72479|NCBI-Rat-GeneID:313200,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000084263,,,,,,,,,,,,,TXPO:1000198,,,,,,,,,,,,,,,,,,,,,,Hsdl2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000194,Hist1h2bcl1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:680403,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000008339,,,,,,,,,,,,,TXPO:1000194,,,,,,,,,,,,,,,,,,,,,,Hist1h2bcl1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000196,Hmox1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:3162|NCBI-Rat-GeneID:24451|NCBI-Mouse-GeneID:15368,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000003162,,,,,,,,,,,,,TXPO:1000196,,,,,,,,,,,,,,,,,,,,,,Hmox1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000191,HYOU1 (mol),GRP170|HSP12A,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:10525|NCBI-Rat-GeneID:192235|NCBI-Mouse-GeneID:12282,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000010525,,,,,,,,GRP170|HSP12A,,,,,TXPO:1000191,,,,,,,,,,,,,,,,,,,,,,HYOU1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000199,Htatip2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:10553|NCBI-Mouse-GeneID:53415|NCBI-Rat-GeneID:292935,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000010553,,,,,,,,,,,,,TXPO:1000199,,,,,,,,,,,,,,,,,,,,,,Htatip2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000197,Hnrnpab (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:83498|NCBI-Human-GeneID:3182|NCBI-Mouse-GeneID:15384,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000003182,,,,,,,,,,,,,TXPO:1000197,,,,,,,,,,,,,,,,,,,,,,Hnrnpab (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000193,Hadhb (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:3032|NCBI-Rat-GeneID:171155|NCBI-Mouse-GeneID:231086,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000003032,,,,,,,,,,,,,TXPO:1000193,,,,,,,,,,,,,,,,,,,,,,Hadhb (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000192,Hacl1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:26061|NCBI-Mouse-GeneID:56794|NCBI-Rat-GeneID:85255,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000026061,,,,,,,,,,,,,TXPO:1000192,,,,,,,,,,,,,,,,,,,,,,Hacl1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000044,TGF-beta3,transforming growth factor-beta 3,,false,,,http://purl.obolibrary.org/obo/IMR_0000041,,,,,,,,,,,,,,,,,,,,GO:0005160,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,transforming growth factor-beta 3,,,,,IMR:0000044,,,,,,,,,,,,,,,,,,,,,,TGF-beta3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0011150,eIF3e,Mammary tumor-associated protein INT-6|eIF-3 p48|Viral integration site protein INT-6|Eukaryotic translation initiation factor 3 subunit 6,,false,,,http://purl.obolibrary.org/obo/IMR_0000916,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Mammary tumor-associated protein INT-6|eIF-3 p48|Viral integration site protein INT-6|Eukaryotic translation initiation factor 3 subunit 6,,,,,IMR:0011150,,,,,,,,,,,,,,,,,,,,,,eIF3e,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001026,"Rod cGMP-specific 3',5'-cyclic phosphodiesterase beta-subunit",GMP-PDE beta,,false,,,http://purl.obolibrary.org/obo/IMR_0100002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GMP-PDE beta,,,,,IMR:0001026,,,,,,,,,,,,,,,,,,,,,,"Rod cGMP-specific 3',5'-cyclic phosphodiesterase beta-subunit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_7640,nortriptyline,"Aventyl|Noritren|nortriptylina|10,11-dihydro-N-methyl-5H-dibenzo[a,d]cycloheptene-Delta(5,gamma)-propylamine|Sensaval|desmethylamitriptyline|3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine|Psychostyl|nortriptylinum|Ateben|Avantyl|nortriptyline|demethylamitriptyline|Nortriptyline|3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N-methylpropan-1-amine","An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(methylamino)propylidene group at position 5. It is an active metabolite of  amitriptyline.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:25707462|PMID:25592638|PMID:25480462|PMID:24037379|PMID:23280809|PMID:25749306|PMID:24368464|DrugBank:DB00540|LINCS:LSM-4039|PMID:10379421|PMID:25683584|PMID:25224004|PMID:14561440|CAS:72-69-5|Drug_Central:1971|Beilstein:2216786|PMID:26086857|PMID:17071817|PMID:25569864|Reaxys:2216786|PMID:26453560,,"An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(methylamino)propylidene group at position 5. It is an active metabolite of  amitriptyline.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35610|http://purl.obolibrary.org/obo/CHEBI_49103|http://purl.obolibrary.org/obo/CHEBI_68495|http://purl.obolibrary.org/obo/CHEBI_35480|http://purl.obolibrary.org/obo/CHEBI_35640|http://purl.obolibrary.org/obo/CHEBI_35469,,,,,"Nortriptyline|3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N-methylpropan-1-amine",,"Aventyl|Noritren|nortriptylina|10,11-dihydro-N-methyl-5H-dibenzo[a,d]cycloheptene-Delta(5,gamma)-propylamine|Sensaval|desmethylamitriptyline|3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine|Psychostyl|nortriptylinum|Ateben|Avantyl|nortriptyline|demethylamitriptyline",,,,,,,,,,,,,,,,,,,,,CHEBI:7640,,,,nortriptyline,,CHEBI:7640,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0002418,immune response to tumor cell,,An immune system process that functions in the response of an organism to a tumor cell.,false,,,http://purl.obolibrary.org/obo/GO_0006955,,,,,,,,,,,,,,,,,,,,,,An immune system process that functions in the response of an organism to a tumor cell.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0002418,,,,,,,,,,,,,,,,,,,,,,immune response to tumor cell,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_16670,peptide,,"Amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another with formal loss of water. The term is usually applied to structures formed from alpha-amino acids, but it includes those derived from any amino carboxylic acid. X = OH, OR, NH2, NHR, etc.",false,,,http://purl.obolibrary.org/obo/CHEBI_23367,,,,,,,,,,,,,,,,,,,,,,"Amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another with formal loss of water. The term is usually applied to structures formed from alpha-amino acids, but it includes those derived from any amino carboxylic acid. X = OH, OR, NH2, NHR, etc.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:16670,,,,,,,,,,,,,,,,,,,,,,peptide,,,,,,,http://purl.obolibrary.org/obo/chebi.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100200,thyrotropin,TSH|thyroid-stimulating hormone,"A glycoprotein hormone secreted by the adenohypophysis ( PITUITARY GLAND, ANTERIOR). Thyrotropin stimulates THYROID GLAND by increasing the iodide transport, synthesis and release of thyroid hormones ( THYROXINE and TRIIODOTHYRONINE). Thyrotropin consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the pituitary glycoprotein hormones (TSH; LUTEINIZING HORMONE and FSH), but the beta subunit is unique and confers its biological specificity.",false,,,http://purl.obolibrary.org/obo/IMR_0100096,,,,,,,,,,,,,,,,,,,,MeSH:D013972,,"A glycoprotein hormone secreted by the adenohypophysis ( PITUITARY GLAND, ANTERIOR). Thyrotropin stimulates THYROID GLAND by increasing the iodide transport, synthesis and release of thyroid hormones ( THYROXINE and TRIIODOTHYRONINE). Thyrotropin consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the pituitary glycoprotein hormones (TSH; LUTEINIZING HORMONE and FSH), but the beta subunit is unique and confers its biological specificity.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TSH|thyroid-stimulating hormone,,,,,IMR:0100200,,,,,,,,,,,,,,,,,,,,,,thyrotropin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000242,NIK,NF-kappa B-inducing kinase,,false,,,http://purl.obolibrary.org/obo/IMR_0000229,,,,,,,,,,,,,,,,,,,,GO:0004704,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,NF-kappa B-inducing kinase,,,,,IMR:0000242,,,,,,,,,,,,,,,,,,,,,,NIK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000605,hypofunction of ATP biosynthesis [Oxidative stress],,"Hypofunction of ATP biosynthesis is a subtype of hypofunction of biosynthesis: A process that performs a decreased or insufficient ATP biosynthesis.
This entity is a specific course-dependent process. This process can constitute the course of Oxidative stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001730|http://purl.obolibrary.org/obo/TXPO_0001722,,,,,,,,,,,,,,,,,,,,,,"Hypofunction of ATP biosynthesis is a subtype of hypofunction of biosynthesis: A process that performs a decreased or insufficient ATP biosynthesis.
This entity is a specific course-dependent process. This process can constitute the course of Oxidative stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000605,,,,,,,,,,,,,,,,,,,,,,hypofunction of ATP biosynthesis [Oxidative stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000609,signaling pathway,signaling cascade,"Signaling pathway is a subtype of pathway: Sequence of linked reactions in which a signal is transmitted to other(s).|1. signal detection (acceptance), 2. signal transduction, 3. gene regulation (genetic information conversion process), 4. celllular process execution
This entity covers from 1 to 2.",false,,,http://purl.obolibrary.org/obo/NCIT_C54214,,,,,,,,,,,,,,,,,,,,,,Signaling pathway is a subtype of pathway: Sequence of linked reactions in which a signal is transmitted to other(s).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0023052|http://purl.obolibrary.org/obo/TXPO_0002174,,,,,,,,,,,,,signaling cascade,,,,,TXPO:0000609,,,,,,,,,,,,,,,,,,,,"1. signal detection (acceptance), 2. signal transduction, 3. gene regulation (genetic information conversion process), 4. celllular process execution
This entity covers from 1 to 2.",,signaling pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000027,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000603,pathway system,,"Pathway system is a subtype of object aggregates.
This entity has sub-parts and has a goal of transmitting as a systemic context.",false,,,http://purl.obolibrary.org/obo/BFO_0000027,,,,,,,,,,,,,,,,,,,,,,"Pathway system is a subtype of object aggregates.
This entity has sub-parts and has a goal of transmitting as a systemic context.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000603,,,,,,,,,,,,,,,,,,,,,,pathway system,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000602,depleting,,Depleting is a subtype of decreasing quantity: A process that that lessens markedly in quantity of the object to nearly zero.,false,,,http://purl.obolibrary.org/obo/TXPO_0000396,,,,,,,,,,,,,,,,,,,,,,Depleting is a subtype of decreasing quantity: A process that that lessens markedly in quantity of the object to nearly zero.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000602,,,,,,,,,,,,,,,,,,,,,,depleting,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000601,storing,,Storing is a subtype of receiving: A process that keeps target object(s).,false,,,http://purl.obolibrary.org/obo/TXPO_0000379,,,,,,,,,,,,,,,,,,,,,,Storing is a subtype of receiving: A process that keeps target object(s).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000601,,,,,,,,,,,,,,,,,,,,,,storing,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0002269,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000608,process sequence,,Process sequence is a subtype of occurrents that is a series of process.,false,,,http://purl.obolibrary.org/obo/BFO_0000015,,,,,,,,,,,,,,,,,,,,,,Process sequence is a subtype of occurrents that is a series of process.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/BFO_0000015,,,,,,,,,,,,,,,,,,TXPO:0000608,,,,,,,,,,,,,,,,,,,,,,process sequence,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000604,CREB3L3 signaling,,CREB3L3 signaling is a subtype of signaling [biological]: A process that in which a signal transmitted by CREB3L3.,false,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,,,CREB3L3 signaling is a subtype of signaling [biological]: A process that in which a signal transmitted by CREB3L3.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000604,,,,,,,,,,,,,,,,,,,,,,CREB3L3 signaling,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000606,transferase,,"Catalysis role of the transfer of a group, e.g. a methyl group, glycosyl group, acyl group, phosphorus-containing, or other groups, from one compound (generally regarded as the donor) to another compound (generally regarded as the acceptor). Transferase is the systematic name for any enzyme of EC class 2.|related molecular function GO:0016740",false,,,http://purl.obolibrary.org/obo/TXPO_0003660,,,,,,,,,,,,,,,,,,,,EC:2.,,"Catalysis role of the transfer of a group, e.g. a methyl group, glycosyl group, acyl group, phosphorus-containing, or other groups, from one compound (generally regarded as the donor) to another compound (generally regarded as the acceptor). Transferase is the systematic name for any enzyme of EC class 2.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000606,,,,,,,,,,,,,,,,,,,,related molecular function GO:0016740,,transferase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000600,meta-functioning process,,"Meta-functioning process is a type of function-related process that executes a function for another function.|For example, the 'to vaporize' function of the boiler is to perform a meta-function to enable for the 'to rotate' function of the turbine.
 The meta-functions are result of teleological interpretation of causal relations among base-functions of different components (i.e., inter-components relations).",false,,,http://purl.obolibrary.org/obo/TXPO_0000145,,,,,,,,,,,,,,,,,,,,https://doi.org/10.1016/S1474-0346(02)00006-XK,,Meta-functioning process is a type of function-related process that executes a function for another function.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000600,,,,,,,,,,,,,,,,,,,,"For example, the 'to vaporize' function of the boiler is to perform a meta-function to enable for the 'to rotate' function of the turbine.
 The meta-functions are result of teleological interpretation of causal relations among base-functions of different components (i.e., inter-components relations).",,meta-functioning process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000607,maintaining mitochondrial membrane permeability,,Maintaining mitochondrial membrane permeability is a subtype of maintaining membrane permeability is a changing process to keep the permeability of the membrane: A process that keeps the permeability of the mitochondrial membrane.,false,,,http://purl.obolibrary.org/obo/TXPO_0000133,,,,,,,,,,,,,,,,,,,,,,Maintaining mitochondrial membrane permeability is a subtype of maintaining membrane permeability is a changing process to keep the permeability of the membrane: A process that keeps the permeability of the mitochondrial membrane.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000607,,,,,,,,,,,,,,,,,,,,,,maintaining mitochondrial membrane permeability,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/BFO_0000147,zero-dimensional continuant fiat boundary,,,false,,,http://purl.obolibrary.org/obo/BFO_0000140,,,,,,,,,,,,,,,,,,,,,,,,,,"zero dimension continuant fiat boundaries are not spatial points. Considering the example 'the quadripoint where the boundaries of Colorado, Utah, New Mexico, and Arizona meet' : There are many frames in which that point is zooming through many points in space. Whereas, no matter what the frame, the quadripoint is always in the same relation to the boundaries of Colorado, Utah, New Mexico, and Arizona.",,a zero-dimensional continuant fiat boundary is a fiat point whose location is defined in relation to some material entity. (axiom label in BFO2 Reference: [031-001]),"the point of origin of some spatial coordinate system.|the quadripoint where the boundaries of Colorado, Utah, New Mexico, and Arizona meet|the geographic North Pole",,,,,,,,,,,(iff (ZeroDimensionalContinuantFiatBoundary a) (and (ContinuantFiatBoundary a) (exists (b) (and (ZeroDimensionalSpatialRegion b) (forall (t) (locatedInAt a b t)))))) // axiom label in BFO2 CLIF: [031-001],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BFO:0000147,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/bfo.owl,zero-dimensional continuant fiat boundary,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100810,CKI-alpha,"Casein kinase I, alpha isoform|CK1",,false,,,http://purl.obolibrary.org/obo/IMR_0100809,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Casein kinase I, alpha isoform|CK1",,,,,IMR:0100810,,,,,,,,,,,,,,,,,,,,,,CKI-alpha,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_37670,protease inhibitor,protease inhibitors,A compound which inhibits or antagonizes the biosynthesis or actions of proteases (endopeptidases).,false,,,http://purl.obolibrary.org/obo/CHEBI_60258,,,,,,,,,,,,,,,,,,,,,,A compound which inhibits or antagonizes the biosynthesis or actions of proteases (endopeptidases).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,protease inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:37670,,,,protease inhibitor,,CHEBI:37670,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000641372,ACOT6,,Other designations: putative acyl-CoA thioesterase 6|putative acyl-coenzyme A thioesterase 6,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,C14orf42|c14_5530,,,,,,,,,,,,14,,,,,,HGNC:33159|Vega:OTTHUMG00000171609|Ensembl:ENSG00000205669|MIM:614267,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,acyl-CoA thioesterase 6,,,14q24.3,,,,,,,,,,,,,,,,"GO_0005829 (EC: IDA, PMID:16940157); GO_0016787 (EC: IEA)",,,,,,,,,PMID:12477932; 16103133; 16940157; 21822266,,,,,,,,,,,,,,,OGG:3000641372,,,,,,,acyl-CoA thioesterase 6,,,,,,,,,,,,,Other designations: putative acyl-CoA thioesterase 6|putative acyl-coenzyme A thioesterase 6,,ACOT6,,,,,,,,,,,,,,,,,,,,,,,641372,,,,,,,,9606,,,,,,,,,,,,,,,,,,,ACOT6,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000641371,ACOT1,,Other designations: CTE-I|CTE-Ib|acyl-coenzyme A thioesterase 1|inducible cytosolic acyl-coenzyme A thioester hydrolase|long chain acyl-CoA hydrolase|long chain acyl-CoA thioester hydrolase,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,ACH2|CTE-1|LACH2,,,,,,,,,,,,14,,,,,,HGNC:33128|MIM:614313|Vega:OTTHUMG00000171607|Ensembl:ENSG00000184227,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,acyl-CoA thioesterase 1,,,14q24.3,,,,,,,,,,,,,,,,"GO_0000038 (EC: IDA, PMID:16940157); GO_0001676 (EC: IDA, PMID:16940157); GO_0005829 (EC: IDA, PMID:16940157); GO_0006637 (EC: IDA, PMID:16940157); GO_0016290 (EC: IEA); GO_0047617 (EC: IDA, PMID:16940157)",,,,,,,,,PMID:12477932; 16103133; 16940157; 18029348; 20736409; 21890473; 21963094; 21987572; 22939629,,,,,,,,,,,,,,,OGG:3000641371,,,,,,,acyl-CoA thioesterase 1,,,,,,,,,,,,,Other designations: CTE-I|CTE-Ib|acyl-coenzyme A thioesterase 1|inducible cytosolic acyl-coenzyme A thioester hydrolase|long chain acyl-CoA hydrolase|long chain acyl-CoA thioester hydrolase,,ACOT1,,,,,,,,,,,,,,,,,,,,,,,641371,,,,,,,,9606,,,,,,,,,,,,,,,,,,,ACOT1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000054658,UGT1A1,,"Other designations: UDP glycosyltransferase 1 family, polypeptide A1|UDP-glucuronosyltransferase 1-1|UDP-glucuronosyltransferase 1-A|UDP-glucuronosyltransferase 1A1|UGT-1A|UGT1*1|UGT1-01|UGT1.1|bilirubin UDP-glucuronosyltransferase 1-1|bilirubin UDP-glucuronosyltransferase isozyme 1|bilirubin-specific UDPGT isozyme 1",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,UGT1A|UGT1|UDPGT 1-1|BILIQTL1|HUG-BR1|UDPGT|GNT1,,,,,,,,,,,,2,,,,,,HPRD:08933|Ensembl:ENSG00000242366|Vega:OTTHUMG00000059117|MIM:191740|HGNC:12530,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"UDP glucuronosyltransferase 1 family, polypeptide A1",,,2q37,,,,,,,,,,,,,,,,"GO_0001889 (EC: IEA); GO_0001972 (EC: IDA); GO_0004857 (EC: IDA, PMID: 19996319); GO_0005496 (EC: IDA, PMID: 19996319); GO_0005789 (EC: TAS); GO_0005887 (EC: IEA); GO_0006778 (EC: TAS); GO_0006789 (EC: TAS, PMID: 1339448); GO_0006805 (EC: TAS); GO_0006953 (EC: IEA); GO_0007584 (EC: IEA); GO_0007586 (EC: NAS, PMID: 1898728); GO_0008202 (EC: IC, PMID: 19996319); GO_0008210 (EC: TAS, PMID: 8780690); GO_0015020 (EC: IDA, PMID: 18052087); GO_0015020 (EC: TAS); GO_0017144 (EC: IC, PMID: 19996319); GO_0019899 (EC: IDA); GO_0031100 (EC: IEA); GO_0032496 (EC: IEA); GO_0042167 (EC: TAS); GO_0042493 (EC: IEA); GO_0042573 (EC: IC); GO_0042594 (EC: IEA); GO_0042803 (EC: IPI); GO_0043086 (EC: IDA, PMID: 19996319); GO_0044281 (EC: TAS); GO_0045939 (EC: IC, PMID: 19996319); GO_0046483 (EC: IC, PMID: 19996319); GO_0046982 (EC: IPI); GO_0051552 (EC: IDA, PMID: 18052087); GO_0052695 (EC: TAS); GO_0052696 (EC: IDA); GO_0052697 (EC: IDA); GO_0070069 (EC: IEA); GO_0070980 (EC: IEA); GO_0071361 (EC: IEA); GO_0071385 (EC: IEA); GO_2001030 (EC: IDA, PMID: 18004212)",,,,,,,,,PMID: 1339448; 1634050; 1634606; 1898728; 2108603; 3082969; 3141926; 7565971; 7715297; 7906695; 7936809; 7989045; 7989595; 8027054; 8226884; 8276413; 8280139; 8467709; 8514037; 8528206; 8706880; 8780690; 9039987; 9295054; 9375768; 9472029; 9497253; 9535849; 9621515; 9627603; 9639672; 10412811; 10498597; 10706110; 10748067; 10836148; 10946897; 11013440; 11061796; 11141380; 11156391; 11179460; 11370628; 11401924; 11434514; 11465080; 11764096; 11827650; 11855932; 11857560; 11878580; 11906189; 11915038; 11968090; 11987245; 12036456; 12078936; 12105841; 12139570; 12151360; 12185559; 12357057; 12402338; 12439228; 12477932; 12480553; 12480568; 12499798; 12502904; 12566446; 12602902; 12646172; 12677174; 12680285; 12695355; 12732365; 12732844; 12743455; 12800608; 12850481; 12850492; 12909459; 12925779; 12960109; 12969965; 12972027; 14550264; 14555305; 14586211; 14616765; 14647407; 14672974; 14871858; 15007088; 15049432; 15111762; 15179405; 15180166; 15247627; 15254716; 15280927; 15286088; 15297419; 15304120; 15318931; 15319294; 15319464; 15320866; 15388579; 15455371; 15472229; 15491385; 15519273; 15523087; 15557560; 15560369; 15572581; 15586176; 15684703; 15709212; 15710570; 15712364; 15746053; 15771689; 15815621; 15855726; 15857854; 15864124; 15864125; 15864130; 15867280; 15929176; 15931768; 16004608; 16135700; 16171463; 16210851; 16237771; 16255851; 16257834; 16257926; 16280036; 16399345; 16424820; 16456808; 16469709; 16513443; 16557566; 16609363; 16610035; 16636344; 16637266; 16712705; 16735790; 16771603; 16791115; 16792515; 16809730; 16849011; 16864595; 16865249; 16871576; 16896007; 16909274; 16951398; 16965601; 16969497; 16985250; 17000907; 17060921; 17138857; 17166930; 17185998; 17187418; 17192505; 17196409; 17229650; 17259171; 17273745; 17329852; 17372243; 17374650; 17406868; 17409981; 17426648; 17440429; 17459361; 17471158; 17478602; 17498780; 17506482; 17510208; 17530442; 17549067; 17555467; 17558305; 17576806; 17577039; 17578897; 17593033; 17611564; 17622938; 17627617; 17681105; 17700594; 17728214; 17762398; 17850628; 17888052; 17898154; 17909964; 17949292; 17952380; 17978490; 17981384; 17990575; 18004206; 18004212; 18043502; 18052087; 18081723; 18082937; 18161889; 18172616; 18181169; 18221820; 18223459; 18240903; 18300238; 18324905; 18335219; 18343383; 18349273; 18349289; 18375480; 18379174; 18392554; 18419642; 18430559; 18454993; 18491077; 18498916; 18509181; 18547414; 18558634; 18594531; 18597651; 18675828; 18685565; 18695635; 18756540; 18768784; 18781851; 18790042; 18797458; 18818748; 18832463; 18953066; 18981166; 18982743; 18990750; 18992148; 19019335; 19021734; 19077918; 19141701; 19204906; 19207584; 19217809; 19238116; 19243019; 19268007; 19279563; 19299905; 19303655; 19309288; 19325249; 19336732; 19343046; 19349540; 19349543; 19352303; 19356098; 19364970; 19371317; 19389676; 19390945; 19397531; 19406951; 19414484; 19419973; 19424794; 19430380; 19450125; 19482841; 19486253; 19513514; 19527514; 19546880; 19620808; 19636001; 19639031; 19674361; 19683255; 19712005; 19732760; 19771428; 19797611; 19830808; 19858149; 19858398; 19859999; 19861894; 19888426; 19891553; 19898482; 19913121; 19932091; 19948621; 19996319; 20028383; 20038727; 20057336; 20061399; 20063115; 20064729; 20070246; 20087647; 20096102; 20136364; 20140262; 20142249; 20173083; 20177420; 20197307; 20207827; 20214802; 20215562; 20216541; 20235787; 20297805; 20308029; 20335017; 20358470; 20371435; 20376058; 20377135; 20378551; 20381444; 20385995; 20389299; 20402064; 20430047; 20483464; 20485444; 20504240; 20528217; 20528568; 20529348; 20530282; 20546738; 20562211; 20562445; 20580994; 20600030; 20620155; 20628086; 20628391; 20639394; 20643254; 20647221; 20648548; 20650040; 20653675; 20679960; 20686835; 20709051; 20734064; 20823282; 20837016; 20860988; 20865252; 20890421; 20948202; 20975617; 21072184; 21080475; 21092520; 21150467; 21266593; 21272068; 21275655; 21317830; 21319362; 21342357; 21351260; 21411679; 21473286; 21513526; 21614935; 21646302; 21760472; 21771722; 21886157; 21911884; 21978357; 21983082; 21988832; 22050734; 22085899; 22169899; 22199302; 22212955; 22213983; 22214020; 22273851; 22299209; 22307138; 22318545; 22325916; 22340355; 22357454; 22367021; 22371261; 22398043; 22448797; 22450351; 22475179; 22511988; 22537951; 22558097; 22559977; 22648071; 22661630; 22676194; 22749334; 22808571; 22829544; 23014115; 23053265; 23130636; 23147267; 23148286; 23148825; 23207817; 23236239; 23281178; 23290513; 23303296; 23350445; 23371916; 23386248; 23461146; 23516488; 23517300; 23548653; 23580084; 23642732; 23647681; 23753274; 23781580; 23881212; 23892411; 23898114; 23926009; 23950218; 23964438; 24033692; 24195516; 24217933; 24341141; 24403462,,,,,,,,,,,,,,,OGG:3000054658,,,,,,,"UDP glucuronosyltransferase 1 family, polypeptide A1",,,,,,,,,,,,,"Other designations: UDP glycosyltransferase 1 family, polypeptide A1|UDP-glucuronosyltransferase 1-1|UDP-glucuronosyltransferase 1-A|UDP-glucuronosyltransferase 1A1|UGT-1A|UGT1*1|UGT1-01|UGT1.1|bilirubin UDP-glucuronosyltransferase 1-1|bilirubin UDP-glucuronosyltransferase isozyme 1|bilirubin-specific UDPGT isozyme 1",,UGT1A1,,,,,,,,,,,,,,,,,,,,,,,54658,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,UGT1A1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0002551,excretion of glutathione conjugates from hepatocyte,,Excretion of glutathione conjugates from hepatocyte is a subtype of compound excretion: A process that excretes the glutathione conjugates from the hepatocyte.,false,,,http://purl.obolibrary.org/obo/TXPO_0002077,,,,,,,,,,,,,,,,,,,,,,Excretion of glutathione conjugates from hepatocyte is a subtype of compound excretion: A process that excretes the glutathione conjugates from the hepatocyte.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002551,,,,,,,,,,,,,,,,,,,,,,excretion of glutathione conjugates from hepatocyte,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002550,ATF6 signaling (primitive) [ER stress - refolding],,"ATF6 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the ATF6 (activating transcription factor 6). ATF6 generally plays a endoplasmic reticulum membrane stress sensor role.
This process is dependent on the refolding and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000719,,,,,,,,,,,,,,,,,,,,,,"ATF6 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the ATF6 (activating transcription factor 6). ATF6 generally plays a endoplasmic reticulum membrane stress sensor role.
This process is dependent on the refolding and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002901,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001905,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002393,,,,,,,,,,,TXPO:0002550,,,,,,,,,,,,,,,,,,,,,,ATF6 signaling (primitive) [ER stress - refolding],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002553,CYP4A11 - tumor progression marker (human)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001859,,,,,,,,,,,,,,,,,,,"Cyp4a11 relates to cardiovascular abnormality (blood pressure, etc.).",NCBI-Human-GeneID:1579|PMID:16712844|PMID:30069903|PMID:18433732|PMID:21912424|PMID:12464261,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001579,,,http://purl.obolibrary.org/obo/TXPO_0000080,,,,,,,,,,TXPO:0002553,,,,,,,,,,,,,,,,,,,,,,CYP4A11 - tumor progression marker (human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002558,ATF4 - transcriptional regulator (canonical)[ER stress - apotosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001907,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,,,,,,TXPO:0002558,,,,,,,,,,,,,,,,,,,,,,ATF4 - transcriptional regulator (canonical)[ER stress - apotosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002555,P-EIF2A - translation initiation inhibitor (canonical)[ER stress - translation attenuation],phosphorylated eIF2A,"This gene encodes a eukaryotic translation initiation factor that catalyzes the formation of puromycin-sensitive 80 S preinitiation complexes and the poly(U)-directed synthesis of polyphenylalanine at low concentrations of Mg2+. This gene should not be confused with eIF2-alpha (EIF2S1, Gene ID: 1965), the alpha subunit of the eIF2 translation initiation complex. Although both of these proteins function in binding initiator tRNA to the 40 S ribosomal subunit, the encoded protein does so in a codon-dependent manner, whereas eIF2 complex requires GTP. Alternative splicing of this gene results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Jan 2016]",false,,,http://purl.obolibrary.org/obo/TXPO_0000829,,,,,,,,,,,,,,,,,,,,http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene&cmd=Retrieve&dopt=full_report&list_uids=83939,,"This gene encodes a eukaryotic translation initiation factor that catalyzes the formation of puromycin-sensitive 80 S preinitiation complexes and the poly(U)-directed synthesis of polyphenylalanine at low concentrations of Mg2+. This gene should not be confused with eIF2-alpha (EIF2S1, Gene ID: 1965), the alpha subunit of the eIF2 translation initiation complex. Although both of these proteins function in binding initiator tRNA to the 40 S ribosomal subunit, the encoded protein does so in a codon-dependent manner, whereas eIF2 complex requires GTP. Alternative splicing of this gene results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Jan 2016]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001909,,,,,phosphorylated eIF2A,,,,,TXPO:0002555,,,,,,,,,,,,,,,,,,,,,,P-EIF2A - translation initiation inhibitor (canonical)[ER stress - translation attenuation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002554,receiving signal by ATF6 [ATF6 pathway],,"Receiving signal in ATF6 signal transduction pathway is a subtype of receiving signal: A process that recognizes another object and changes into a signal in a ATF6 signal transduction pathway.
This entity is a specific course-dependent process. This process can constitute the course of ATF6 pathway.",false,,,http://purl.obolibrary.org/obo/TXPO_0002174,,,,,,,,,,,,,,,,,,,,,,"Receiving signal in ATF6 signal transduction pathway is a subtype of receiving signal: A process that recognizes another object and changes into a signal in a ATF6 signal transduction pathway.
This entity is a specific course-dependent process. This process can constitute the course of ATF6 pathway.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000879,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000718,,,,,,,,,,,TXPO:0002554,,,,,,,,,,,,,,,,,,,,,,receiving signal by ATF6 [ATF6 pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002557,translation regulator role,,"A role played by the entity which modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of proteins by the translation of mRNA or circRNA.",false,,,http://purl.obolibrary.org/obo/TXPO_0003230,,,,,,,,,,,,,,,,,,,,,,"A role played by the entity which modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of proteins by the translation of mRNA or circRNA.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002557,,,,,,,,,,,,,,,,,,,,,,translation regulator role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002552,blood coagulation factor synthesis,,Blood coagulation factor synthesis is a subtype of biosynthetic process: The chemical reactions resulting in the formation of substances with blood coagulation factor role.,false,,,http://purl.obolibrary.org/obo/GO_0009058,,,,,,,,,,,,,,,,,,,,,,Blood coagulation factor synthesis is a subtype of biosynthetic process: The chemical reactions resulting in the formation of substances with blood coagulation factor role.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002552,,,,,,,,,,,,,,,,,,,,,,blood coagulation factor synthesis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002559,ATF4 - transcriptional regulator (canonical)[ER stress - inflammation],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001907,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,,,,,,TXPO:0002559,,,,,,,,,,,,,,,,,,,,,,ATF4 - transcriptional regulator (canonical)[ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002556,P-EIF2A -ATF4 promoting factor (canonical)[ER stress - proteinrefolding],phosphorylated eIF2A -ATF4 promoting factor [ER stress - proteinrefolding],,false,,,http://purl.obolibrary.org/obo/TXPO_0000829,,,,,,,,,,,,,,,,,,,,http://www.ncbi.nlm.nih.gov/gene/83939,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002557,,,,,phosphorylated eIF2A -ATF4 promoting factor [ER stress - proteinrefolding],,,,,TXPO:0002556,,,,,,,,,,,,,,,,,,,,,,P-EIF2A -ATF4 promoting factor (canonical)[ER stress - proteinrefolding],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000010018,BCL2L11,,Other designations: bcl-2 interacting mediator of cell death|bcl-2 interacting protein Bim|bcl-2-like protein 11|bcl-2-related ovarian death agonist,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,BAM|BIM|BOD,,,,,,,,,,,,2,,,,,,HPRD:04828|Ensembl:ENSG00000153094|MIM:603827|Vega:OTTHUMG00000131256|HGNC:994,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,BCL2-like 11 (apoptosis facilitator),,,2q13,,,,,,,,,,,,,,,,"GO_0001701 (EC: IEA); GO_0001782 (EC: IEA); GO_0001783 (EC: IEA); GO_0001822 (EC: IEA); GO_0002262 (EC: IEA); GO_0005515 (EC: IPI, PMID: 14596824); GO_0005741 (EC: TAS); GO_0005829 (EC: IDA); GO_0005829 (EC: TAS); GO_0005874 (EC: IDA, Qualifier: colocalizes_with); GO_0006915 (EC: TAS, PMID: 10381623); GO_0006919 (EC: IDA); GO_0007160 (EC: IEA); GO_0007283 (EC: IEA); GO_0007420 (EC: IEA); GO_0008017 (EC: IDA, Qualifier: contributes_to); GO_0008017 (EC: IEA); GO_0008584 (EC: IEA); GO_0008630 (EC: IDA, PMID: 11546872); GO_0012505 (EC: IEA); GO_0019898 (EC: IEA); GO_0030879 (EC: IEA); GO_0032464 (EC: IDA); GO_0034976 (EC: IDA); GO_0035148 (EC: IEA); GO_0042475 (EC: IEA); GO_0043029 (EC: IEA); GO_0043065 (EC: IMP, PMID: 17289999); GO_0043065 (EC: TAS); GO_0043280 (EC: IEA); GO_0043525 (EC: IEA); GO_0043583 (EC: IEA); GO_0045787 (EC: IEA); GO_0046620 (EC: IEA); GO_0048011 (EC: TAS); GO_0048066 (EC: IEA); GO_0048070 (EC: IEA); GO_0048536 (EC: IEA); GO_0048538 (EC: IEA); GO_0048563 (EC: IEA); GO_0060139 (EC: IEA); GO_0060154 (EC: IEA); GO_0070242 (EC: IEA); GO_0090200 (EC: IGI); GO_0090200 (EC: IMP, PMID: 17289999); GO_0097140 (EC: IDA); GO_0097141 (EC: IDA); GO_0097190 (EC: TAS); GO_0097192 (EC: IEA); GO_0097193 (EC: TAS); GO_1900740 (EC: TAS); GO_1902110 (EC: IEA); GO_1902263 (EC: IEA); GO_2000271 (EC: IDA, PMID: 11997495); GO_2001244 (EC: IMP); GO_2001244 (EC: TAS)",,,,,,,,,PMID: 8918887; 8929531; 9430630; 9463381; 9731710; 10198631; 10381623; 10576740; 10837489; 11050388; 11210187; 11301022; 11435715; 11546872; 11583631; 11734221; 11859372; 11997495; 12019181; 12095614; 12118373; 12198137; 12376548; 12388545; 12477932; 12486001; 12591950; 12787561; 12818176; 12844146; 14527951; 14555991; 14561217; 14596824; 14676826; 14681225; 14732682; 14764673; 14769789; 14970329; 14996839; 15014070; 15030401; 15096481; 15146197; 15147734; 15193260; 15378010; 15459900; 15486195; 15489334; 15509554; 15653751; 15661735; 15688014; 15694340; 15711598; 15721256; 15728578; 15731037; 15731089; 15767553; 15824087; 15843898; 15899862; 15989957; 16022280; 16051596; 16091744; 16148027; 16183168; 16213503; 16260615; 16282323; 16373335; 16476732; 16478725; 16697956; 16773715; 16810067; 16888645; 16951744; 17051334; 17062728; 17067554; 17074758; 17105963; 17151701; 17158029; 17188240; 17203211; 17207965; 17218274; 17251431; 17276340; 17289999; 17486061; 17499214; 17525735; 17531220; 17538248; 17637819; 17653091; 17686764; 17692808; 17698840; 17716672; 17717606; 17927446; 18006817; 18063582; 18064628; 18089817; 18165867; 18182577; 18195012; 18246127; 18251703; 18345036; 18348176; 18354037; 18391004; 18398508; 18413764; 18420585; 18508762; 18549468; 18651223; 18668139; 18677096; 18715233; 18715501; 18758461; 18806830; 18812174; 18925930; 18949058; 18981303; 19050264; 19052714; 19064725; 19100522; 19101511; 19141860; 19148187; 19150432; 19285955; 19300516; 19305426; 19308286; 19330811; 19332026; 19336552; 19403302; 19407828; 19494111; 19541822; 19573080; 19574221; 19587239; 19622586; 19622774; 19641506; 19737817; 19773279; 19773546; 19805519; 19850739; 19881544; 19893569; 19914305; 20010785; 20066663; 20074640; 20082325; 20086250; 20160166; 20206402; 20231287; 20237869; 20332261; 20348947; 20404322; 20431602; 20697841; 20700448; 20705940; 20819778; 20821734; 20841506; 20855536; 20861305; 20877573; 20878914; 20885957; 20959405; 21041309; 21130142; 21148306; 21148799; 21151127; 21247487; 21333317; 21339291; 21367852; 21375523; 21378313; 21415216; 21478148; 21481848; 21507240; 21533175; 21555518; 21613222; 21625639; 21655183; 21659544; 21671007; 21673341; 21729544; 21732363; 21808067; 21832049; 21899728; 21924351; 21937453; 21958719; 21984578; 21988832; 22071694; 22076535; 22081075; 22093624; 22131152; 22145099; 22160382; 22245094; 22270368; 22349704; 22388891; 22391963; 22426421; 22430213; 22516966; 22572381; 22609401; 22622039; 22628193; 22645134; 22742832; 22762551; 22788963; 22802411; 22819074; 22895567; 22905229; 23012423; 23047821; 23138847; 23152053; 23152504; 23235460; 23243017; 23270470; 23295054; 23301543; 23358890; 23382048; 23394612; 23402819; 23441183; 23500081; 23532334; 23633923; 23648111; 23681223; 23737756; 23770605; 23824909; 23874387; 23912711; 24074954; 24227856; 24239173,,,,,,,,,,,,,,,OGG:3000010018,,,,,,,BCL2-like 11 (apoptosis facilitator),,,,,,,,,,,,,Other designations: bcl-2 interacting mediator of cell death|bcl-2 interacting protein Bim|bcl-2-like protein 11|bcl-2-related ovarian death agonist,,BCL2L11,,,,,,,,,,,,,,,,,,,,,,,10018,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,BCL2L11,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0002056,FGFR2,fibroblast growth factor receptor 2,,false,,,http://purl.obolibrary.org/obo/IMR_0000080,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,fibroblast growth factor receptor 2,,,,,IMR:0002056,,,,,,,,,,,,,,,,,,,,,,FGFR2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_50859,bexarotene,"p-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid|bexarotene|bexarotenum|bexaroteno|4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)vinyl]benzoic acid",,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:153559-49-0|Drug_Central:361|DrugBank:DB00307,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35610,,,,,"4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)vinyl]benzoic acid",,"p-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid|bexarotene|bexarotenum|bexaroteno",,,,,,,,,,,,,,,,,,,,,CHEBI:50859,,,,bexarotene,,CHEBI:50859,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000869,NF1-A,TGGCA-binding protein|NFI-A|Nuclear factor 1/A|NF1-A|CTF|Nuclear factor 1 A-type|CCAAT-box binding transcription factor|NF-I/A,,false,,,http://purl.obolibrary.org/obo/IMR_0000409,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0010365,TGGCA-binding protein|NFI-A|Nuclear factor 1/A|NF1-A|CTF|Nuclear factor 1 A-type|CCAAT-box binding transcription factor|NF-I/A,,,,,IMR:0000869,,,,,,,,,,,,,,,,,,,,,,NF1-A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006661,phosphatidylinositol biosynthetic process,phosphatidylinositol synthesis|phosphatidylinositol anabolism|PtdIns biosynthesis|PtdIns biosynthetic process|phosphoinositide biosynthesis|phosphatidylinositol biosynthesis|phosphoinositide biosynthetic process|phosphatidylinositol formation,"The chemical reactions and pathways resulting in the formation of phosphatidylinositol, any glycophospholipid in which the sn-glycerol 3-phosphate residue is esterified to the 1-hydroxyl group of 1D-myo-inositol.",false,,,http://purl.obolibrary.org/obo/GO_0046488|http://purl.obolibrary.org/obo/GO_0046474,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/HINO_0013926,,"The chemical reactions and pathways resulting in the formation of phosphatidylinositol, any glycophospholipid in which the sn-glycerol 3-phosphate residue is esterified to the 1-hydroxyl group of 1D-myo-inositol.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_28874,,,,,,,,,,,,,,phosphatidylinositol synthesis|phosphatidylinositol anabolism|PtdIns biosynthesis|PtdIns biosynthetic process|phosphoinositide biosynthesis|phosphatidylinositol biosynthesis|phosphoinositide biosynthetic process|phosphatidylinositol formation,,,,,GO:0006661,,,,,,,"Phosphatidylinositol (PI) is synthesized when phosphatidic acid (PA) and cytidine triphosphate (CTP) are converted into cytidine diphosphate-diacylglycerol (CDP-DAG) followed by conversion into PI and cytidine monophosphate (CMP) (Stuhne-Sekalec et al 1986, Lykidis et al. 1997).",,,,,,,,,,,,,,,phosphatidylinositol biosynthetic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006660,phosphatidylserine catabolic process,phosphatidylserine breakdown|phosphatidylserine catabolism|phosphatidylserine degradation,"The chemical reactions and pathways resulting in the breakdown of phosphatidylserines, any of a class of glycerophospholipids in which the phosphatidyl group is esterified to the hydroxyl group of L-serine.",false,,,http://purl.obolibrary.org/obo/GO_0046475|http://purl.obolibrary.org/obo/GO_0006658,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways resulting in the breakdown of phosphatidylserines, any of a class of glycerophospholipids in which the phosphatidyl group is esterified to the hydroxyl group of L-serine.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_18303,,,,,,,,,,,,,,,,,,phosphatidylserine breakdown|phosphatidylserine catabolism|phosphatidylserine degradation,,,,,GO:0006660,,,,,,,,,,,,,,,,,biological_process,,,,,phosphatidylserine catabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006665,sphingolipid metabolic process,sphingolipid metabolism,"The chemical reactions and pathways involving sphingolipids, any of a class of lipids containing the long-chain amine diol sphingosine or a closely related base (a sphingoid).",false,,,http://purl.obolibrary.org/obo/GO_0006629,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways involving sphingolipids, any of a class of lipids containing the long-chain amine diol sphingosine or a closely related base (a sphingoid).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sphingolipid metabolism,,,,,GO:0006665,,,,,,,,,,,,,,,,,,,,,,sphingolipid metabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000089,PPAR,Peroxisome proliferator activated receptor,transcription factors that are activated by ligands and heterodimerize with RETINOID X RECEPTORS and bind to peroxisome proliferator response elements in the promoter regions of target genes.,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,http://purl.bioontology.org/ontology/MESH/D047492,,transcription factors that are activated by ligands and heterodimerize with RETINOID X RECEPTORS and bind to peroxisome proliferator response elements in the promoter regions of target genes.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003224,,,,,Peroxisome proliferator activated receptor,,,,,IMR:0000089,,,,,,,,,,,,,,,,,,,,,,PPAR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006099,tricarboxylic acid cycle,citric acid cycle|Wikipedia:Tricarboxylic_acid_cycle|Krebs cycle|TCA cycle,"A nearly universal metabolic pathway in which the acetyl group of acetyl coenzyme A is effectively oxidized to two CO2 and four pairs of electrons are transferred to coenzymes. The acetyl group combines with oxaloacetate to form citrate, which undergoes successive transformations to isocitrate, 2-oxoglutarate, succinyl-CoA, succinate, fumarate, malate, and oxaloacetate again, thus completing the cycle. In eukaryotes the tricarboxylic acid is confined to the mitochondria.",false,,,http://purl.obolibrary.org/obo/GO_0008152,,,,,,,,,,,,,,,,,,,,Reactome: R-HSA-71403.2,,"A nearly universal metabolic pathway in which the acetyl group of acetyl coenzyme A is effectively oxidized to two CO2 and four pairs of electrons are transferred to coenzymes. The acetyl group combines with oxaloacetate to form citrate, which undergoes successive transformations to isocitrate, 2-oxoglutarate, succinyl-CoA, succinate, fumarate, malate, and oxaloacetate again, thus completing the cycle. In eukaryotes the tricarboxylic acid is confined to the mitochondria.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,citric acid cycle|Wikipedia:Tricarboxylic_acid_cycle|Krebs cycle|TCA cycle,,,,,GO:0006099,,,,,,,,,,,,,,,,,,,,,,tricarboxylic acid cycle,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006094,gluconeogenesis,glucose biosynthesis|glucose biosynthetic process,"The formation of glucose from noncarbohydrate precursors, such as pyruvate, amino acids and glycerol.",false,,,http://purl.obolibrary.org/obo/GO_0016051,,,,,,,,,,,,,,,,,,,,Reactome:R-HSA-70263,,"The formation of glucose from noncarbohydrate precursors, such as pyruvate, amino acids and glycerol.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_17234,,,,,,,,,,,,,,glucose biosynthesis|glucose biosynthetic process,,,,,GO:0006094,,,,,,,,,,,,,,,,,,,,,,gluconeogenesis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006091,generation of precursor metabolites and energy,,"The chemical reactions and pathways resulting in the formation of precursor metabolites, substances from which energy is derived, and any process involved in the liberation of energy from these substances.",false,,,http://purl.obolibrary.org/obo/GO_0008152,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways resulting in the formation of precursor metabolites, substances from which energy is derived, and any process involved in the liberation of energy from these substances.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0006091,,,,,,,,,,,,,,,,,,,,,,generation of precursor metabolites and energy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006096,glycolytic process,,"The chemical reactions and pathways resulting in the breakdown of a carbohydrate into pyruvate, with the concomitant production of a small amount of ATP and the reduction of NAD(P) to NAD(P)H. Glycolysis begins with the metabolism of a carbohydrate to generate products that can enter the pathway and ends with the production of pyruvate. Pyruvate may be converted to acetyl-coenzyme A, ethanol, lactate, or other small molecules.",false,,,http://purl.obolibrary.org/obo/GO_0016052,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways resulting in the breakdown of a carbohydrate into pyruvate, with the concomitant production of a small amount of ATP and the reduction of NAD(P) to NAD(P)H. Glycolysis begins with the metabolism of a carbohydrate to generate products that can enter the pathway and ends with the production of pyruvate. Pyruvate may be converted to acetyl-coenzyme A, ethanol, lactate, or other small molecules.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0006096,,,,,,,,,,,,,,,,,,,,,,glycolytic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_35493,antipyretic,anti-pyretic,A drug that prevents or reduces fever by lowering the body temperature from a raised state. An antipyretic will not affect the normal body temperature if one does not have fever. Antipyretics cause the hypothalamus to override an interleukin-induced increase in temperature. The body will then work to lower the temperature and the result is a reduction in fever.,false,,,http://purl.obolibrary.org/obo/CHEBI_23888,,,,,,,,,,,,,,,,,,,,,,A drug that prevents or reduces fever by lowering the body temperature from a raised state. An antipyretic will not affect the normal body temperature if one does not have fever. Antipyretics cause the hypothalamus to override an interleukin-induced increase in temperature. The body will then work to lower the temperature and the result is a reduction in fever.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,anti-pyretic,,,,,,,,,,,,,,,,,,,,,CHEBI:35493,,,,antipyretic,,CHEBI:35493,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100299,caspase-9,,,false,,,http://purl.obolibrary.org/obo/IMR_0000306,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100299,,,,,,,,,,,,,,,,,,,,,,caspase-9,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002625,PERK - signal sensor (canonical)[ER stress - translation attenuation],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001841,http://purl.obolibrary.org/obo/TXPO_0000123,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UniProt_Q9NZJ5|http://www.uniprot.org/entry/Q9NZJ5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000882,,,,,,,,,,TXPO:0002625,,,,,,,,,,,,,,,,,,,,,,PERK - signal sensor (canonical)[ER stress - translation attenuation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002622,GRP78 - stress sensor inhibitor (canonical)[ER stress - proteinrefolding [persist] -ATF6 pathway],Heat Shock Protein Family A (Hsp70) Member 5- stress sensor inhibitor [ER stress - proteinrefolding [persist] -ATF6 pathway]|MIF2- stress sensor inhibitor[ER stress - proteinrefolding [persist] -ATF6 pathway]|BIP- stress sensor inhibitor[ER stress - proteinrefolding [persist] -ATF6 pathway]|HEL-S-89n- stress sensor inhibitor [ER stress - proteinrefolding [persist] -ATF6 pathway]|HSPA5- stress sensor inhibitor [ER stress - proteinrefolding [persist] -ATF6 pathway],,false,,,http://purl.obolibrary.org/obo/TXPO_0002385,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002620,,,,,Heat Shock Protein Family A (Hsp70) Member 5- stress sensor inhibitor [ER stress - proteinrefolding [persist] -ATF6 pathway]|MIF2- stress sensor inhibitor[ER stress - proteinrefolding [persist] -ATF6 pathway]|BIP- stress sensor inhibitor[ER stress - proteinrefolding [persist] -ATF6 pathway]|HEL-S-89n- stress sensor inhibitor [ER stress - proteinrefolding [persist] -ATF6 pathway]|HSPA5- stress sensor inhibitor [ER stress - proteinrefolding [persist] -ATF6 pathway],,,,,TXPO:0002622,,,,,,,,,,,,,,,,,,,,,,GRP78 - stress sensor inhibitor (canonical)[ER stress - proteinrefolding [persist] -ATF6 pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002207,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002621,GRP78 - stress sensor inhibitor (canonical)[ER stress - proteinrefolding [persist] -IRE1 pathway],Heat Shock Protein Family A (Hsp70) Member 5 - stress sensor inhibitor [ER stress - proteinrefolding [persist] -IRE1 pathway]|HSPA5- stress sensor inhibitor [ER stress - proteinrefolding [persist] -IRE1 pathway]|BIP- stress sensor inhibitor [ER stress - proteinrefolding [persist] -IRE1 pathway],,false,,,http://purl.obolibrary.org/obo/TXPO_0002385,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002620,,,,,Heat Shock Protein Family A (Hsp70) Member 5 - stress sensor inhibitor [ER stress - proteinrefolding [persist] -IRE1 pathway]|HSPA5- stress sensor inhibitor [ER stress - proteinrefolding [persist] -IRE1 pathway]|BIP- stress sensor inhibitor [ER stress - proteinrefolding [persist] -IRE1 pathway],,,,,TXPO:0002621,,,,,,,,,,,,,,,,,,,,,,GRP78 - stress sensor inhibitor (canonical)[ER stress - proteinrefolding [persist] -IRE1 pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002207,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002628,intracellular ligand-gated ion channel,,A role played by the entity which enables the transmembrane transfer of an ion by a channel that opens when a specific intracellular ligand has been bound by the channel complex or one of its constituent parts.,false,,,http://purl.obolibrary.org/obo/TXPO_0003680,,,,,,,,,,,,,,,,,,,,IMR:0000746 (obsolete)|related molecular function GO:0005217,,A role played by the entity which enables the transmembrane transfer of an ion by a channel that opens when a specific intracellular ligand has been bound by the channel complex or one of its constituent parts.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002628,,,,,,,,,,,,,,,,,,,,,,intracellular ligand-gated ion channel,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002624,PERK-eIF2a-ATF4 pathway [ER stress - inflammation],,"PERK-eIF2a-ATF4 mediated pathway is a subtype of PERK-eIF2a signaling: Sequence of linked reactions, which has PERK-eIF2a signaling and gene regulation by ATF4.
This pathway is dependent on the  inflammation  and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002513,,,,,,,,,,,,,,,,,,,,,,"PERK-eIF2a-ATF4 mediated pathway is a subtype of PERK-eIF2a signaling: Sequence of linked reactions, which has PERK-eIF2a signaling and gene regulation by ATF4.
This pathway is dependent on the  inflammation  and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003036|http://purl.obolibrary.org/obo/TXPO_0003035,,http://purl.obolibrary.org/obo/TXPO_0002483|http://purl.obolibrary.org/obo/TXPO_0000285,,,,,,,,,,,,,,,,TXPO:0002624,,,,,,,,,,,,,,,,,,,,,,PERK-eIF2a-ATF4 pathway [ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002626,phosphatidylcholine efflux (from heptocyte menbrane to canaliculus) [cholestasis],,"A release process of the phosphatidylcholine from one side of a membrane of hepatocyte to the other side of canaliculus.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000034|http://purl.obolibrary.org/obo/TXPO_0003539,,,,,,,,,,,,,,,,,,,,,,"A release process of the phosphatidylcholine from one side of a membrane of hepatocyte to the other side of canaliculus.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002615,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002626,,,,,,,"Bile salts, by acting as detergents, release phosphatidylcholine from the outer can canalicular leaflet into the canaliculus",,,,,,,,,,,,,,,phosphatidylcholine efflux (from heptocyte menbrane to canaliculus) [cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002627,phospholipid efflux (from heptocyte menbrane to canaliculus) [cholestasis],,"A release process of the phospholipids from one side of a membrane of hepatocyte to the other side of canaliculus.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/GO_0033700|http://purl.obolibrary.org/obo/TXPO_0000034,,,,,,,,,,,,,,,,,,,,,,"A release process of the phospholipids from one side of a membrane of hepatocyte to the other side of canaliculus.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002631,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002627,,,,,,,"Lipophilic cationic drugs, estrogens, and lipids are exported by the canalicular multiple-drug resistance (MDR) P-glycoproteins, one of which is exclusive for phospholipids.|Bile is rich in phospholipids and organic anions such as bilirubin conjugates.
Phospholipids are the main component of biliary lipids and need MFR3 (multidrug resistance protein 3, ABCB4) to enter the canalicular bile .

This ABC transporter translocates the main biliary lipid phosphatidylcholine from the inner to the outer leaflet of the canalicular membrane.

Bile salts, by acting as detergents, release phosphatidylcholine from the outer can canalicular leaflet into the canaliculus.

 Cholesterol release from the canalicular membrane it; in part mediated by the heterodimeric ABC transporter ABCG5/ABCG8 (ABCG5/ABCG8)",,,,,,,,,,,,,,,phospholipid efflux (from heptocyte menbrane to canaliculus) [cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002620,negative regulator role of stress sensor,,"A role played by the entity that inhibits or desensitizes the stress sensor. By dissociating this inhibitor from the sensor, it can be received the stress and converted into a molecular signal.",false,,,http://purl.obolibrary.org/obo/TXPO_0003711,,,,,,,,,,,,,,,,,,,,,,"A role played by the entity that inhibits or desensitizes the stress sensor. By dissociating this inhibitor from the sensor, it can be received the stress and converted into a molecular signal.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002620,,,,,,,,,,,,,,,,,,,,,,negative regulator role of stress sensor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002623,nucleoside phosphate,,,false,,,http://purl.obolibrary.org/obo/CHEBI_37734,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002623,,,,,,,,,,,,,,,,,,,,,,nucleoside phosphate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002629,autophagy regulator role,,Autophagy regulator is a role played by any compound that regulates the process of autophagy (the self-digestion of one or more components of a cell through the action of enzymes originating within the same cell).,false,,,http://purl.obolibrary.org/obo/TXPO_0003230,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006914,,,,,,,,,,,,,Autophagy regulator is a role played by any compound that regulates the process of autophagy (the self-digestion of one or more components of a cell through the action of enzymes originating within the same cell).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002629,,,,,,,,,,,,,,,,,,,,,,autophagy regulator role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/BFO_0000023,role,,,false,,,http://purl.obolibrary.org/obo/BFO_0000017,,,,,,,,,,,,,,,,,,,,,,,,,,"BFO 2 Reference: One major family of examples of non-rigid universals involves roles, and ontologies developed for corresponding administrative purposes may consist entirely of representatives of entities of this sort. Thus ‘professor’, defined as follows,b instance_of professor at t =Def. there is some c, c instance_of professor role & c inheres_in b at t.denotes a non-rigid universal and so also do ‘nurse’, ‘student’, ‘colonel’, ‘taxpayer’, and so forth. (These terms are all, in the jargon of philosophy, phase sortals.) By using role terms in definitions, we can create a BFO conformant treatment of such entities drawing on the fact that, while an instance of professor may be simultaneously an instance of trade union member, no instance of the type professor role is also (at any time) an instance of the type trade union member role (any more than any instance of the type color is at any time an instance of the type length).If an ontology of employment positions should be defined in terms of roles following the above pattern, this enables the ontology to do justice to the fact that individuals instantiate the corresponding universals –  professor, sergeant, nurse – only during certain phases in their lives.",,"b is a role means: b is a realizable entity & b exists because there is some single bearer that is in some special physical, social, or institutional set of circumstances in which this bearer does not have to be& b is not such that, if it ceases to exist, then the physical make-up of the bearer is thereby changed. (axiom label in BFO2 Reference: [061-001])","the role of a stone in marking a property boundary|the role of a building in serving as a military target|the priest role|the role of subject in a clinical trial|the role of a boundary to demarcate two neighboring administrative territories|John’s role of husband to Mary is dependent on Mary’s role of wife to John, and both are dependent on the object aggregate comprising John and Mary as member parts joined together through the relational quality of being married.|the student role",,,,,,,,,,,(forall (x) (if (Role x) (RealizableEntity x))) // axiom label in BFO2 CLIF: [061-001],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BFO:0000023,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/bfo.owl,role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002164,Hyou1 (rat)[ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000753|http://purl.obolibrary.org/obo/TXPO_1000191,,,,,,,,,,,,,,,,,,,,R-HSA-1791066.1|NCBI-Rat-GeneID:192235|https://omim.org/entry/601746,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003997,,,,,,,,,,TXPO:0002164,,,,,,,,,,,,,,,,,,,,,,Hyou1 (rat)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002166,ATF3 (human)[ER stress],,"This gene encodes a member of the mammalian activation transcription factor/cAMP responsive element-binding (CREB) protein family of transcription factors. This gene is induced by a variety of signals, including many of those encountered by cancer cells, and is involved in the complex process of cellular stress response. Multiple transcript variants encoding different isoforms have been found for this gene. It is possible that alternative splicing of this gene may be physiologically important in the regulation of target genes. [provided by RefSeq, Apr 2011]|PERK->ATF4->ATF3 reactome",false,,,http://purl.obolibrary.org/obo/TXPO_0000793|http://purl.obolibrary.org/obo/TXPO_1000011,,,,,,,,,,,,,,,,,,,"stress induction ->ATF3 ->apotosis induction by activating pro-apoptic genesTNRSF1-B and BBC3
cancer development ->ATF3 ->apoptosis inhibition by repressing proapoptic genes CDKN1A

Systems analysis of ATF3 in stress response and cancer reveals opposing effects on pro-apoptotic genes in p53 pathway.
PMID:22046379

Stress-induced ATF3 binds to 40% of p53 targets and activates pro-apoptotic genes such as TNFRSF10B/DR5 and BBC3/PUMA. Cancer-associated ATF3, by contrast, represses these pro-apoptotic genes in addition to CDKN1A/p21.
ATF3 has opposing, cell context-dependent effects on p53 target genes in DNA damage response and cancer development.",NCBI-Human-GeneID:467|PMID:27484784|PMID:22046379|PMID:26917416|PMID:24939851|PMID:20485437|PMID:8622660,,"This gene encodes a member of the mammalian activation transcription factor/cAMP responsive element-binding (CREB) protein family of transcription factors. This gene is induced by a variety of signals, including many of those encountered by cancer cells, and is involved in the complex process of cellular stress response. Multiple transcript variants encoding different isoforms have been found for this gene. It is possible that alternative splicing of this gene may be physiologically important in the regulation of target genes. [provided by RefSeq, Apr 2011]",,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000825,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000467,,,http://purl.obolibrary.org/obo/TXPO_0003645|http://purl.obolibrary.org/obo/TXPO_0000329,,,,,,,,,,TXPO:0002166,,,,,,,,,,,,,,,,,,,,PERK->ATF4->ATF3 reactome,,ATF3 (human)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002160,fatty acid homeostasis imbalance in peroxisome (moderate) [Eosinophilic granular degeneration],,"Fatty acid homeostasis imbalance in peroxisome is a subtype of changing balance: A process that becomes lacking afatty acid homeostastasis balance. The degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/TXPO_0002158,,,,,,,,,,,,,,,,,,,,,,"Fatty acid homeostasis imbalance in peroxisome is a subtype of changing balance: A process that becomes lacking afatty acid homeostastasis balance. The degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002160,,,,,,,,,,,,,,,,,,,,,,fatty acid homeostasis imbalance in peroxisome (moderate) [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002167,DDIT3 (human)[ER stress],CHOP [ER stress],,false,,,http://purl.obolibrary.org/obo/TXPO_0000793|http://purl.obolibrary.org/obo/TXPO_1000067,,,,,,,,,,,,,,,,,,,,http://www.omim.org/entry/126337|NCBI-Human-GeneID:1649|PMID:15775988|PMID:25904325|PMID:15601821|PMID:22761832,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000422,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001649,,,http://purl.obolibrary.org/obo/CHEBI_68495,,,,,CHOP [ER stress],,,,,TXPO:0002167,,,,,,,,,,,,,,,,,,,,,,DDIT3 (human)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000795,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002169,CRELD2 (human)[ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000793|http://purl.obolibrary.org/obo/TXPO_1000075,,,,,,,,,,,,,,,,,,,,"NCBI-Human-GeneID:79174|https://omim.org/entry/607171|Elucidation of a novel phenformin derivative on glucose-deprived stress responses in HT-29 cells.

2-(2-chlorophenyl)ethylbiguanide (2-Cl-Phen) down-regulated expression of several ER stress-related genes, with the exception of GADD153. The expression levels of ATF6α, GRP78, MANF, and CRELD2 mRNA were almost completely decreased by 2-Cl-Phen.|PMID:23956175",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000079174,,,,,,,,,,,,,TXPO:0002169,,,,,,,,,,,,,,,,,,,,,,CRELD2 (human)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000719,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002163,lipid biosynthetic process [ER stress],,"The chemical reactions and pathways resulting in the formation of lipids, compounds soluble in an organic solvent but not, or sparingly, in an aqueous solvent.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/GO_0008610|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,PMID:26977301|PMID:18556558,,"The chemical reactions and pathways resulting in the formation of lipids, compounds soluble in an organic solvent but not, or sparingly, in an aqueous solvent.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001968|http://purl.obolibrary.org/obo/TXPO_0003819,,,,,,http://purl.obolibrary.org/obo/TXPO_0002172,,,,,,,,,,,TXPO:0002163,,,,,,,,,,,,,,,,,,,,,,lipid biosynthetic process [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002161,protein unfolding [ER stress],,"The process of assisting in the disassembly of non-covalent linkages in a protein or protein aggregate, often where the proteins are in a non-functional or denatured state.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/GO_0043335,,,,,,,,,,,,,,,,,,,,,,"The process of assisting in the disassembly of non-covalent linkages in a protein or protein aggregate, often where the proteins are in a non-functional or denatured state.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000037|http://purl.obolibrary.org/obo/TXPO_0001965,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002458,,,,,,,,,,,TXPO:0002161,,,,,,,,,,,,,,,,,,,,,,protein unfolding [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005783,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002162,PERK - signaling factor (canonical)[ER stress - translation attenuation],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002119,http://purl.obolibrary.org/obo/TXPO_0000061,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UniProt_Q9NZJ5|http://www.uniprot.org/entry/Q9NZJ5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002162,,,,,,,,,,,,,,,,,,,,,,PERK - signaling factor (canonical)[ER stress - translation attenuation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002165,DNAJB9 (human)[ER stress],ERDJ4 [ER stress],IRE1->Xbp1->DNAJB9,false,,,http://purl.obolibrary.org/obo/TXPO_0000793|http://purl.obolibrary.org/obo/TXPO_1000114,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:4189|https://omim.org/entry/602634|PMID:18400946|PMID:14559994|REACTOME: R-HSA-381038|PMID:25146923,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000004189,,,http://purl.obolibrary.org/obo/CHEBI_68494|http://purl.obolibrary.org/obo/TXPO_0003997,,,,,ERDJ4 [ER stress],,,,,TXPO:0002165,,,,,,,,,,,,,,,,,,,,IRE1->Xbp1->DNAJB9,,DNAJB9 (human)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000795,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002168,TRIB3 (human)[ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000793|http://purl.obolibrary.org/obo/TXPO_1000378,,,,,,,,,,,,,,,,,,,,http://omim.org/entry/607898|NCBI-Human-GeneID:57761|PMID:12791994|PMID:15775988|PMID:23695665|PMID:17369260,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000057761,,,,,,,,,,,,,TXPO:0002168,,,,,,,,,,,,,,,,,,,,,,TRIB3 (human)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000795,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0001430,alkaline,,An medium acidity quality inhering in a solution by virtue of the bearer's a low concentration of H+ ions.,false,,,http://purl.obolibrary.org/obo/PATO_0001842,,,,,,,,,,,,,,,,,,,,,,An medium acidity quality inhering in a solution by virtue of the bearer's a low concentration of H+ ions.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0001430,,,,,,,,,,,,,,,,,,,,,,alkaline,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000306,effector caspase,,,false,,,http://purl.obolibrary.org/obo/IMR_0000305,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000306,,,,,,,,,,,,,,,,,,,,,,effector caspase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100648,separase,Esp1|separin|Caspase-like protein ESPL1|Cut1|Extra spindle poles-like 1 protein,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000304,,,,,Esp1|separin|Caspase-like protein ESPL1|Cut1|Extra spindle poles-like 1 protein,,,,,IMR:0100648,,,,,,,,,,,,,,,,,,,,,,separase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003402,moving phopholipid to lysosome,,Moving phopholipid to lysosome is a subtype of moving A to the inside of B: A process that of the movement of phospholipids into lysosomes.,false,,,http://purl.obolibrary.org/obo/TXPO_0002587,,,,,,,,,,,,,,,,,,,,,,Moving phopholipid to lysosome is a subtype of moving A to the inside of B: A process that of the movement of phospholipids into lysosomes.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_16247,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003402,,,,,,,,,,,,,,,,,,,,,,moving phopholipid to lysosome,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005764,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003404,phosphholipid binding by phospholipase [Phospholipidosis],,"Phosphholipid binding by phospholipase is a subtype of phospholipid binding: Interacting selectively and non-covalently with phospholipids byphospholipases.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis(normal condition).",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0003640,,,,,,,,,,,,,,,,,,,,,,"Phosphholipid binding by phospholipase is a subtype of phospholipid binding: Interacting selectively and non-covalently with phospholipids byphospholipases.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis(normal condition).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003410,,,,,,,,,,,TXPO:0003404,,,,,,,,,,,,,,,,,,,,,,phosphholipid binding by phospholipase [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003407,IL-2 signaling (primitive) [Phospholipidosis (excessive defense) - cell cycle arrest ],,"IL-2 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the cytokine IL-2.
This process is dependent on the  cell cycle arrest  and can constitute the course of Phospholipidosis (excessive defense) .",false,,,http://purl.obolibrary.org/obo/TXPO_0000833,,,,,,,,,,,,,,,,,,,,Reactome:R-HSA-451927.2,,"IL-2 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the cytokine IL-2.
This process is dependent on the  cell cycle arrest  and can constitute the course of Phospholipidosis (excessive defense) .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002268|http://purl.obolibrary.org/obo/TXPO_0003429,,,,,,http://purl.obolibrary.org/obo/TXPO_0001495,,,,,,,,,,,TXPO:0003407,,,,,,,,,,,,,,,,,,,,,,IL-2 signaling (primitive) [Phospholipidosis (excessive defense) - cell cycle arrest ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003409,PPARA - glucose metabolism regulator (canonical)[Eosinophilic granular degeneration],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001328,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003949,,,,,,,,,,TXPO:0003409,,,,,,,,,,,,,,,,,,,,,,PPARA - glucose metabolism regulator (canonical)[Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003405,IL-2 signaling (primitive) [Phospholipidosis (excessive defense) - inflammation ],,"IL-2 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the cytokine IL-2.
This process is dependent on the  inflammation  and can constitute the course of Phospholipidosis (excessive defense) .",false,,,http://purl.obolibrary.org/obo/TXPO_0000833,,,,,,,,,,,,,,,,,,,,Reactome:R-HSA-451927.2|PMID:28732506,,"IL-2 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the cytokine IL-2.
This process is dependent on the  inflammation  and can constitute the course of Phospholipidosis (excessive defense) .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003408|http://purl.obolibrary.org/obo/TXPO_0003426,,,,,,,,,,,,,,,,,TXPO:0003405,,,,,,,,,,,,,,,,,,,,,,IL-2 signaling (primitive) [Phospholipidosis (excessive defense) - inflammation ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003401,moving phopholipid to lysosome [Phospholipidosis],,"Moving phopholipid to lysosome is a subtype of moving A to the inside of B: A process that of the movement of phospholipids into lysosomes.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003402|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Moving phopholipid to lysosome is a subtype of moving A to the inside of B: A process that of the movement of phospholipids into lysosomes.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003401,,,,,,,,,,,,,,,,,,,,,,moving phopholipid to lysosome [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003403,increasing phospholipid material  (normal condition) [Phospholipidosis],,"Increasing phospholipid material is a subtype of increasing quantity: A process that changes the amount of phospholipid material to be larger.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosisb(normal condition).",false,,,http://purl.obolibrary.org/obo/TXPO_0001314|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Increasing phospholipid material is a subtype of increasing quantity: A process that changes the amount of phospholipid material to be larger.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosisb(normal condition).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003387,,,,,,,,,,,TXPO:0003403,,,,,,,,,,,,,,,,,,,,,,increasing phospholipid material  (normal condition) [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003400,positive regulation of phospholipid biosynthetic process [Phospholipidosis (normal)],,"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of phospholipids.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis(normal condition).",false,,,http://purl.obolibrary.org/obo/GO_0071073|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of phospholipids.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis(normal condition).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003385,,,,,,,,,,,,,,,,,,TXPO:0003400,,,,,,,,,,,,,,,,,,,,,,positive regulation of phospholipid biosynthetic process [Phospholipidosis (normal)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003406,IL-2 signaling (primitive) [Phospholipidosis (excessive defense) - apoptosis inhibition ],,"IL-2 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the cytokine IL-2.
This process is dependent on the  apoptosis inhibition  and can constitute the course of Phospholipidosis (excessive defense) .",false,,,http://purl.obolibrary.org/obo/TXPO_0000833,,,,,,,,,,,,,,,,,,,,Reactome:R-HSA-451927.2,,"IL-2 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the cytokine IL-2.
This process is dependent on the  apoptosis inhibition  and can constitute the course of Phospholipidosis (excessive defense) .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002267|http://purl.obolibrary.org/obo/TXPO_0003427,,,,,,http://purl.obolibrary.org/obo/TXPO_0001495,,,,,,,,,,,TXPO:0003406,,,,,,,,,,,,,,,,,,,,,,IL-2 signaling (primitive) [Phospholipidosis (excessive defense) - apoptosis inhibition ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003408,IL2RB (human)[Phospholipidosis - inflammation],"interleukin 2 receptor, beta [Phospholipidosis - inflammation]",,false,,,http://purl.obolibrary.org/obo/TXPO_0001143,,,,,,,,,,,,,,,,,,,"IL2->IL2R->PI3K->Akt->Bcl2/c-myc->Cell cycle progression
IL2->IL2R->PI3K->Akt->Bcl2->anti-apoptosis",https://www.omim.org/entry/146710|PMID:10982827|PMID:9108028|PMID:12200137|PMID:10579998,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003041,,,,,"interleukin 2 receptor, beta [Phospholipidosis - inflammation]",,,,,TXPO:0003408,,,,,,,,,,,,,,,,,,,,,,IL2RB (human)[Phospholipidosis - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001488|http://purl.obolibrary.org/obo/TXPO_0000833,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_35498,diuretic,diuretics,An agent that promotes the excretion of urine through its effects on kidney function.,false,,,http://purl.obolibrary.org/obo/CHEBI_23888,,,,,,,,,,,,,,,,,,,,,,An agent that promotes the excretion of urine through its effects on kidney function.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,diuretics,,,,,,,,,,,,,,,,,,,,,CHEBI:35498,,,,diuretic,,CHEBI:35498,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001508,Rap2A,,,false,,,http://purl.obolibrary.org/obo/IMR_0001507,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001508,,,,,,,,,,,,,,,,,,,,,,Rap2A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001150,PKC eta,PKC-L,,false,,,http://purl.obolibrary.org/obo/IMR_0000246,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PKC-L,,,,,IMR:0001150,,,,,,,,,,,,,,,,,,,,,,PKC eta,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000399,VNN3 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:55350|NCBI-Mouse-GeneID:26464|NCBI-Rat-GeneID:498992,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000055350,,,,,,,,,,,,,TXPO:1000399,,,,,,,,,,,,,,,,,,,,,,VNN3 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000398,Ugt2b7 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:286989|NCBI-Human-GeneID:7364,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000007364,,,,,,,,,,,,,TXPO:1000398,,,,,,,,,,,,,,,,,,,,,,Ugt2b7 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000394,UGCG (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:22234|NCBI-Rat-GeneID:83626|NCBI-Human-GeneID:7357,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000007357,,,,,,,,,,,,,TXPO:1000394,,,,,,,,,,,,,,,,,,,,,,UGCG (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000397,Ugt2b1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:71773|NCBI-Rat-GeneID:286954,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:1000397,,,,,,,,,,,,,,,,,,,,,,Ugt2b1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000396,USF2 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0001111,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:81817|NCBI-Mouse-GeneID:22282|NCBI-Human-GeneID:7392,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000007392,,,,,,,,,,,,,TXPO:1000396,,,,,,,,,,,,,,,,,,,,,,USF2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000391,Tyms (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:22171|NCBI-Human-GeneID:7298|NCBI-Rat-GeneID:29261,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000007298,,,,,,,,,,,,,TXPO:1000391,,,,,,,,,,,,,,,,,,,,,,Tyms (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000392,UBE2I (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:25573|NCBI-Mouse-GeneID:22196|NCBI-Human-GeneID:7329,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000007329,,,,,,,,,,,,,TXPO:1000392,,,,,,,,,,,,,,,,,,,,,,UBE2I (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000395,UGT1a1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24861|NCBI-Mouse-GeneID:394436|NCBI-Human-GeneID:54658,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000054658,,,,,,,,,,,,,TXPO:1000395,,,,,,,,,,,,,,,,,,,,,,UGT1a1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000393,UCP3 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:22229|NCBI-Rat-GeneID:25708|NCBI-Human-GeneID:7352,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000007352,,,,,,,,,,,,,TXPO:1000393,,,,,,,,,,,,,,,,,,,,,,UCP3 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000390,Txrnd1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:1000390,,,,,,,,,,,,,,,,,,,,,,Txrnd1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000148,massive hepatic necrosis,,Massive hepatic necrosis is a subtype of classification of cell death by distribution: A hepatocyte necrosis localized around multiple lobules.,false,,,http://purl.obolibrary.org/obo/TXPO_0000520,,,,,,,,,,,,,,,,,,,,,,Massive hepatic necrosis is a subtype of classification of cell death by distribution: A hepatocyte necrosis localized around multiple lobules.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000148,,,,,,,,,,,,,,,,,,,,,,massive hepatic necrosis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000145,function-related process,,"Function-related process is a process that related to the execution of a function, a metafunction, and the malfunction.|This tree is based on a functional concept ontology (Kitamura 2002).",false,,,http://purl.obolibrary.org/obo/TXPO_0000271,,,,,,,,,,,,,,,,,,,,"doi:10.1115/DETC2006-9913|FBRL: A Function and Behavior Representation Language. Sasajima, M., Kitamura, Y., Ikeda, M. & Mizoguchi, R., In Proc. of IJCAI-95 (pp. 1830-1836), 1995|https://doi.org/10.1016/S1474-0346(02)00006-X",,"Function-related process is a process that related to the execution of a function, a metafunction, and the malfunction.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000145,,,,,,,,,,,,,,,,,,,,This tree is based on a functional concept ontology (Kitamura 2002).,,function-related process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000142,increasing cell volume,cell swelling,Increasing cell volume is a changing process to change the volume of the cell to increase.,false,,,http://purl.obolibrary.org/obo/TXPO_0000139,,,,,,,,,,,,,,,,,,,,,,Increasing cell volume is a changing process to change the volume of the cell to increase.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000000,,,,,,,,,,,,,,,,,,,,cell swelling,,,TXPO:0000142,,,,,,,,,,,,,,,,,,,,,,increasing cell volume,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000000,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000141,increasing length,,Increasing length is a subtype of changing length: A process that changes the length of the object to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000552,,,,,,,,,,,,,,,,,,,,,,Increasing length is a subtype of changing length: A process that changes the length of the object to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000141,,,,,,,,,,,,,,,,,,,,,,increasing length,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0000573,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000147,refolding-unfolding imbalance [ER stress],,"Refolding-unfolding imbalance is a subtype of imbalance: A process that lacks a balance between protein refolding and unfolding.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002459|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"Refolding-unfolding imbalance is a subtype of imbalance: A process that lacks a balance between protein refolding and unfolding.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001977,,http://purl.obolibrary.org/obo/TXPO_0003992,,,,,,,,,TXPO:0000147,,,,,,,,,,,,,,,,,,,,,,refolding-unfolding imbalance [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005783,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000143,increasing volume of mitochondria,,Increasing volume of mitochondria is a changing process to change the volume of the mitochondria to increase.,false,,,http://purl.obolibrary.org/obo/TXPO_0003741,,,,,,,,,,,,,,,,,,,,,,Increasing volume of mitochondria is a changing process to change the volume of the mitochondria to increase.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000143,,,,,,,,,,,,,,,,,,,,,,increasing volume of mitochondria,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000146,hyperfunction of mitochondrial fatty acid beta-oxidation [Eosinophilic granular degeneration],,"Hyperfunction of mitochondrial fatty acid beta-oxidation is a subtype of hyperfunction of fatty acid beta-oxidation: A process that performs an excessive mitochondrial fatty acid beta-oxidation.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/TXPO_0002344|http://purl.obolibrary.org/obo/TXPO_0001729,,,,,,,,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2948931/,,"Hyperfunction of mitochondrial fatty acid beta-oxidation is a subtype of hyperfunction of fatty acid beta-oxidation: A process that performs an excessive mitochondrial fatty acid beta-oxidation.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001070|http://purl.obolibrary.org/obo/TXPO_0001058|http://purl.obolibrary.org/obo/TXPO_0001050|http://purl.obolibrary.org/obo/TXPO_0001066|http://purl.obolibrary.org/obo/TXPO_0001064,,,,,,http://purl.obolibrary.org/obo/TXPO_0000151|http://purl.obolibrary.org/obo/TXPO_0000103,,,,,,,,,,,TXPO:0000146,,,,,,,,,,,,,,,,,,,,,,hyperfunction of mitochondrial fatty acid beta-oxidation [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000140,increasing area,,Increasing area is a subtype of changing area: A process that changes the area of the object to be larger.,false,,,http://purl.obolibrary.org/obo/TXPO_0000544,,,,,,,,,,,,,,,,,,,,,,Increasing area is a subtype of changing area: A process that changes the area of the object to be larger.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000140,,,,,,,,,,,,,,,,,,,,,,increasing area,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0002057,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000144,increasing energy,,Increasing energy is a subtype of increasing quantity: A process that changes the amount of energy to be larger.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing energy is a subtype of increasing quantity: A process that changes the amount of energy to be larger.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000144,,,,,,,,,,,,,,,,,,,,,,increasing energy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000149,regulation of carbohydrate metabolic process [Eosinophilic granular degeneration],,"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving carbohydrates.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/TXPO_0001729|http://purl.obolibrary.org/obo/GO_0006109,,,,,,,,,,,,,,,,,,,,,,"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving carbohydrates.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003409,,,,,,http://purl.obolibrary.org/obo/TXPO_0000153,,,,,,,,,,,TXPO:0000149,,,,,,,,,,,,,,,,,,,,,,regulation of carbohydrate metabolic process [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000515,caveolin,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003657,,,,,,,,,,IMR:0000515,,,,,,,,,,,,,,,,,,,,,,caveolin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000008309,ACOX2,,"Other designations: 3-alpha,7-alpha,12-alpha-trihydroxy-5-beta-cholestanoyl-CoA 24-hydroxylase|3-alpha,7-alpha,12-alpha-trihydroxy-5-beta-cholestanoyl-CoA oxidase|THCA-CoA oxidase|acyl-Coenzyme A oxidase 2, branched chain|peroxisomal acyl-coenzyme A oxidase 2|peroxisomal branched chain acyl-CoA oxidase|trihydroxycoprostanoyl-CoA oxidase",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,BCOX|THCCox|BRCOX|BRCACOX,,,,,,,,,,,,3,,,,,,HPRD:09037|Ensembl:ENSG00000168306|HGNC:120|MIM:601641|Vega:OTTHUMG00000159154,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"acyl-CoA oxidase 2, branched chain",,,3p14.3,,,,,,,,,,,,,,,,"GO_0003995 (EC: IEA); GO_0003997 (EC: TAS); GO_0005102 (EC: IPI); GO_0005777 (EC: IDA, PMID:2079609); GO_0005782 (EC: TAS); GO_0006699 (EC: TAS); GO_0008206 (EC: TAS); GO_0016402 (EC: TAS); GO_0033540 (EC: TAS); GO_0033791 (EC: IEA); GO_0044255 (EC: TAS); GO_0044281 (EC: TAS); GO_0050660 (EC: IEA)",,,,,,,,,PMID:2079609; 8387517; 8943006; 8993592; 9070889; 12477932; 15489334; 16756494; 20178365; 20379614; 21343950,,,,,,,,,,,,,,,OGG:3000008309,,,,,,,"acyl-CoA oxidase 2, branched chain",,,,,,,,,,,,,"Other designations: 3-alpha,7-alpha,12-alpha-trihydroxy-5-beta-cholestanoyl-CoA 24-hydroxylase|3-alpha,7-alpha,12-alpha-trihydroxy-5-beta-cholestanoyl-CoA oxidase|THCA-CoA oxidase|acyl-Coenzyme A oxidase 2, branched chain|peroxisomal acyl-coenzyme A oxidase 2|peroxisomal branched chain acyl-CoA oxidase|trihydroxycoprostanoyl-CoA oxidase",,ACOX2,,,,,,,,,,,,,,,,,,,,,,,8309,,,,,,,,9606,,,,,,,,,,,,,,,,,,,ACOX2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_59826,progestin,progestins,A synthetic progestogen.,false,,,http://purl.obolibrary.org/obo/CHEBI_50745,,,,,,,,,,,,,,,,,,,,,,A synthetic progestogen.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,progestins,,,,,,,,,,,,,,,,,,,,,CHEBI:59826,,,,progestin,,CHEBI:59826,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001206,cytochrome c,Cyt c,Cytochromes of the c type that are found in eukaryotic MITOCHONDRIA. They serve as redox intermediates that accept electrons from MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX III and transfer them to MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX IV.,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,MeSH:D045304,,Cytochromes of the c type that are found in eukaryotic MITOCHONDRIA. They serve as redox intermediates that accept electrons from MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX III and transfer them to MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX IV.,MeSH:D003574,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000154,,,,,Cyt c,,,,,IMR:0001206,,,,,,,,,,,,,,,,,,,,,,cytochrome c,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100815,CKI-epsilon,"Casein kinase I, epsilon isoform|CKIe",,false,,,http://purl.obolibrary.org/obo/IMR_0100809,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Casein kinase I, epsilon isoform|CKIe",,,,,IMR:0100815,,,,,,,,,,,,,,,,,,,,,,CKI-epsilon,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010496,60S ribosomal protein L5,P46777,,false,,,http://purl.obolibrary.org/obo/IMR_0000897,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,P46777,,,,,IMR:0010496,,,,,,,,,,,,,,,,,,,,,,60S ribosomal protein L5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000199974,CYP4Z1,,Other designations: CYPIVZ1|cytochrome P450 4Z1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CYP4A20,,,,,,,,,,,,1,,,,,,HPRD:13111|Ensembl:ENSG00000186160|Vega:OTTHUMG00000008019|HGNC:20583,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 4, subfamily Z, polypeptide 1",,,1p33,,,,,,,,,,,,,,,,GO_0005506 (EC: IEA); GO_0005789 (EC: IEA); GO_0016021 (EC: IEA); GO_0020037 (EC: IEA); GO_0070330 (EC: IEA),,,,,,,,,PMID:9068972; 12975309; 15059886; 15128046; 15797250; 19090726; 19473719; 22841774,,,,,,,,,,,,,,,OGG:3000199974,,,,,,,"cytochrome P450, family 4, subfamily Z, polypeptide 1",,,,,,,,,,,,,Other designations: CYPIVZ1|cytochrome P450 4Z1,,CYP4Z1,,,,,,,,,,,,,,,,,,,,,,,199974,UNQ3060/PRO9882,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP4Z1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_16113,cholesterol,,"A cholestanoid consisting of cholestane having a double bond at the 5,6-position as well as a 3β-hydroxy group.",false,,,http://purl.obolibrary.org/obo/CHEBI_35341,,,,,,,,,,,,,,,,,,,,Wikipedia:cholesterol,,"A cholestanoid consisting of cholestane having a double bond at the 5,6-position as well as a 3β-hydroxy group.",,,,,,,,,,,,C27H46O,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:16113,,,,,,,,,,,,,,,,,,,,,,cholesterol,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,C1[C@@]2([C@]3(CC[C@]4([C@]([C@@]3(CC=C2C[C@H](C1)O)[H])(CC[C@@]4([C@H](C)CCCC(C)C)[H])[H])C)[H])C,,,,,
http://purl.obolibrary.org/obo/IMR_0000047,EGF family,epidermal growth factor family,,false,,,http://purl.obolibrary.org/obo/TXPO_0001382,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002395|http://purl.obolibrary.org/obo/TXPO_0000624,,,,,epidermal growth factor family,,,,,IMR:0000047,,,,,,,,,,,,,,,,,,,,,,EGF family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100421,TR beta 2,,,false,,,http://purl.obolibrary.org/obo/IMR_0000086,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100421,,,,,,,,,,,,,,,,,,,,,,TR beta 2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000005288,PIK3C2G,,"Other designations: PTDINS-3-kinase C2 gamma|phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gamma|phosphatidylinositol-4-phosphate 3-kinase C2 domain-containing gamma polypeptide|phosphatidylinositol-4-phosphate 3-kinase C2 domain-containing subunit gamma|phosphoinositide-3-kinase, class 2, gamma polypeptide|ptdIns-3-kinase C2 subunit gamma",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,PI3K-C2GAMMA|PI3K-C2-gamma,,,,,,,,,,,,12,,,,,,MIM:609001|Ensembl:ENSG00000139144|HGNC:8973|HPRD:16416|Vega:OTTHUMG00000168841,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 gamma",,,12p12,,,,,,,,,,,,,,,,"GO_0005524 (EC: IEA); GO_0005829 (EC: TAS); GO_0005886 (EC: IBA); GO_0005942 (EC: IBA); GO_0006644 (EC: TAS); GO_0006661 (EC: TAS); GO_0006935 (EC: IEA); GO_0008150 (EC: ND); GO_0016303 (EC: NAS, PMID: 9878262); GO_0016307 (EC: NAS, PMID: 9878262); GO_0035005 (EC: IBA); GO_0035091 (EC: IEA); GO_0036092 (EC: NAS, PMID: 9878262); GO_0044281 (EC: TAS); GO_0048015 (EC: IEA)",,,,,,,,,PMID: 8636073; 8798481; 9247029; 9341793; 9394803; 9446795; 9514948; 9516481; 9708406; 9808187; 9878262; 10208934; 10985305; 11154208; 11156964; 11289809; 11994280; 12077252; 12477932; 12526811; 12551992; 12584329; 12960231; 14602571; 15689238; 16081599; 16524887; 17157319; 17632570; 17893707; 17991425; 18453587; 18854243; 18996102; 20019835; 20602615; 20818790; 21029719; 21114830; 22369086; 24086445,,,,,,,,,,,,,,,OGG:3000005288,,,,,,,"phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 gamma",,,,,,,,,,,,,"Other designations: PTDINS-3-kinase C2 gamma|phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gamma|phosphatidylinositol-4-phosphate 3-kinase C2 domain-containing gamma polypeptide|phosphatidylinositol-4-phosphate 3-kinase C2 domain-containing subunit gamma|phosphoinositide-3-kinase, class 2, gamma polypeptide|ptdIns-3-kinase C2 subunit gamma",,PIK3C2G,,,,,,,,,,,,,,,,,,,,,,,5288,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,PIK3C2G,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000057600,FNIP2,,Other designations: FNIP1-like protein|O6-methylguanine-induced apoptosis 1 protein|folliculin-interacting protein 2,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,MAPO1|FNIPL,,,,,,,,,,,,4,,,,,,Vega:OTTHUMG00000161983|HGNC:29280|Ensembl:ENSG00000052795|MIM:612768,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,folliculin interacting protein 2,,,4q32.1,,,,,,,,,,,,,,,,"GO_0000122 (EC: IDA); GO_0001932 (EC: IDA, PMID: 18663353); GO_0005515 (EC: IPI, PMID: 18403135); GO_0005634 (EC: IDA); GO_0005730 (EC: IDA, Qualifier: NOT); GO_0005737 (EC: IDA); GO_0005815 (EC: IDA); GO_0005886 (EC: IDA); GO_0006468 (EC: IDA, PMID: 18663353); GO_0008630 (EC: ISS); GO_0033138 (EC: IDA, PMID: 19914239)",,,,,,,,,PMID: 10819331; 12477932; 14702039; 18029348; 18403135; 18663353; 19914239; 20379614; 23201403,,,,,,,,,,,,,,,OGG:3000057600,,20140408,protein-coding,,,,folliculin interacting protein 2,,,,,,,,,,,,,Other designations: FNIP1-like protein|O6-methylguanine-induced apoptosis 1 protein|folliculin-interacting protein 2,,FNIP2,,,,,,,,,,,,,,,,,,,,,,,57600,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,FNIP2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_101278,diltiazem,"D-cis-diltiazem|diltiazem|Acetic acid (2S,3S)-5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester|(2S-cis)-3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one|(+)-cis-5-[2-(dimethylamino)ethyl]-2,3-dihydro-3-hydroxy-2-(p-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one acetate ester|(2S,3S)-5-(2-(dimethylamino)ethyl)-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-3-yl acetate|d-cis-diltiazem|diltiazemum|(2S,3S)-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate","A 5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate in which both stereocentres have S configuration. A calcium-channel blocker and vasodilator, it is used as the hydrochloride in the management of angina pectoris and hypertension.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:16651034|Drug_Central:897|PMID:25122162|PMID:23687551|CAS:42399-41-7|PMID:19167257|DrugBank:DB00343|PMID:24261918|PMID:8369596|Beilstein:3573079|PMID:11937779|LINCS:LSM-2523|Reaxys:3573079,,"A 5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate in which both stereocentres have S configuration. A calcium-channel blocker and vasodilator, it is used as the hydrochloride in the management of angina pectoris and hypertension.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35620|http://purl.obolibrary.org/obo/CHEBI_38215|http://purl.obolibrary.org/obo/CHEBI_35674,,,,,"(2S,3S)-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate",,"D-cis-diltiazem|diltiazem|Acetic acid (2S,3S)-5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester|(2S-cis)-3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one|(+)-cis-5-[2-(dimethylamino)ethyl]-2,3-dihydro-3-hydroxy-2-(p-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one acetate ester|(2S,3S)-5-(2-(dimethylamino)ethyl)-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-3-yl acetate|d-cis-diltiazem|diltiazemum",,,,,,,,,,,,,,,,,,,,,CHEBI:101278,,,,diltiazem,,CHEBI:101278,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001623,Rab33A,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001623,,,,,,,,,,,,,,,,,,,,,,Rab33A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000627,Integrin alpha-5,,,false,,,http://purl.obolibrary.org/obo/IMR_0000173,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000627,,,,,,,,,,,,,,,,,,,,,,Integrin alpha-5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000152,Faah (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:29347|NCBI-Human-GeneID:2166|NCBI-Mouse-GeneID:14073,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000002166,,,,,,,,,,,,,TXPO:1000152,,,,,,,,,,,,,,,,,,,,,,Faah (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000150,FNDC4 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:64339|NCBI-Human-GeneID:64838,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000064838,,,,,,,,,,,,,TXPO:1000150,,,,,,,,,,,,,,,,,,,,,,FNDC4 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000157,G2e3 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:299002|NCBI-Mouse-GeneID:217558|NCBI-Human-GeneID:55632,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000055632,,,,,,,,,,,,,TXPO:1000157,,,,,,,,,,,,,,,,,,,,,,G2e3 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000158,G6PD (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:2539|NCBI-Rat-GeneID:24377,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000002539,,,,,,,,,,,,,TXPO:1000158,,,,,,,,,,,,,,,,,,,,,,G6PD (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000153,Fabp5 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:16592|NCBI-Rat-GeneID:140868|NCBI-Human-GeneID:2171,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000002171,,,,,,,,,,,,,TXPO:1000153,,,,,,,,,,,,,,,,,,,,,,Fabp5 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000159,GABARAPL3 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:23766,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000023766,,,,,,,,,,,,,TXPO:1000159,,,,,,,,,,,,,,,,,,,,,,GABARAPL3 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000156,Fnta (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:14272|NCBI-Human-GeneID:2339|NCBI-Rat-GeneID:25318,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000002339,,,,,,,,,,,,,TXPO:1000156,,,,,,,,,,,,,,,,,,,,,,Fnta (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000154,Fat1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:2195|NCBI-Mouse-GeneID:14107|NCBI-Rat-GeneID:83720,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000002195,,,,,,,,,,,,,TXPO:1000154,,,,,,,,,,,,,,,,,,,,,,Fat1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000060312,AFAP1,,"Other designations: 110 kDa actin filament-associated protein|actin filament-associated protein 1|actin filament-associated protein, 110 kDa",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,AFAP110|AFAP-110|AFAP,,,,,,,,,,,,4,,,,,,Ensembl:ENSG00000196526|Vega:OTTHUMG00000125515|HPRD:09747|MIM:608252|HGNC:24017,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,actin filament associated protein 1,,,4p16,,,,,,,,,,,,,,,,GO_0003779 (EC: IEA); GO_0005737 (EC: IEA); GO_0005856 (EC: IEA),,,,,,,,,PMID: 7545969; 9619827; 9655255; 10666339; 11607843; 11641786; 12134071; 12477932; 14755689; 15146197; 15345747; 16344560; 16751776; 17520695; 18029348; 21150319; 23333711,,,,,,,,,,,,,,,OGG:3000060312,,,,,,,actin filament associated protein 1,,,,,,,,,,,,,"Other designations: 110 kDa actin filament-associated protein|actin filament-associated protein 1|actin filament-associated protein, 110 kDa",,AFAP1,,,,,,,,,,,,,,,,,,,,,,,60312,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,AFAP1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0001027,"Cone cGMP-specific 3',5'-cyclic phosphodiesterase alpha'-subunit",,,false,,,http://purl.obolibrary.org/obo/IMR_0100002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001027,,,,,,,,,,,,,,,,,,,,,,"Cone cGMP-specific 3',5'-cyclic phosphodiesterase alpha'-subunit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_16856,L-gamma-glutamyl-L-cysteinylglycine,5-L-Glutamyl-L-cysteinylglycine|Reduced glutathione|GSH|Glutathione,A tripeptide compound consisting of glutamic acid attached via its side chain to the N-terminus of cysteinylglycine.,false,,,http://purl.obolibrary.org/obo/CHEBI_16670,,,,,,,,,,,,,,,,,,,,Wikipedia:Glutathione|DrugBank:DB00143,,A tripeptide compound consisting of glutamic acid attached via its side chain to the N-terminus of cysteinylglycine.,,,,,,,,,,,,C10H17N3O6S,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Glutathione,,5-L-Glutamyl-L-cysteinylglycine|Reduced glutathione|GSH,,,CHEBI:16856,,,,,,,,,,,,,,,,,,,,,,L-gamma-glutamyl-L-cysteinylglycine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O)C(=O)O,,,,,
http://purl.obolibrary.org/obo/IMR_0000263,MKK3/6,,MKK3 and MKK6 phosphorylate and activate p38 MAP kinases.,false,,,http://purl.obolibrary.org/obo/IMR_0000259,,,,,,,,,,,,,,,,,,,,,,MKK3 and MKK6 phosphorylate and activate p38 MAP kinases.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000263,,,,,,,,,,,,,,,,,,,,,,MKK3/6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_37700,EC 2.7.11.13 (protein kinase C) inhibitor,PKCepsilon inhibitors|PKCgamma inhibitor|cPKCgamma inhibitors|PKN3 inhibitors|calcium-independent protein kinase C inhibitors|nPKCtheta inhibitors|EC 2.7.11.13 inhibitors|PKCgamma inhibitors|PKN3 inhibitor|nPKCtheta inhibitor|cPKCbeta inhibitor|protein kinase C (EC 2.7.11.13) inhibitors|PKC inhibitor|PKCbeta inhibitors|protein kinase C (EC 2.7.11.13) inhibitor|nPKCeta inhibitor|nPKCeta inhibitors|PKCzeta inhibitors|protein kinase C inhibitor|PKCdelta inhibitors|nPKC inhibitors|PKCbeta inhibitor|PKCzeta inhibitor|calcium-dependent protein kinase C inhibitors|ATP:protein phosphotransferase (diacylglycerol-dependent) inhibitors|nPKCepsilon inhibitor|Pkc1p inhibitors|cPKCgamma inhibitor|calcium/phospholipid dependent protein kinase inhibitor|cPKC inhibitors|EC 2.7.11.13 inhibitor|PKCepsilon inhibitor|calcium-independent protein kinase C inhibitor|nPKC inhibitor|PKCdelta inhibitor|protein kinase C inhibitors|STK24 inhibitors|STK24 inhibitor|ATP:protein phosphotransferase (diacylglycerol-dependent) inhibitor|nPKCdelta inhibitors|calcium/phospholipid dependent protein kinase inhibitors|cPKCbeta inhibitors|Pkc1p inhibitor|nPKCdelta inhibitor|cPKC inhibitor|protein kinase Cepsilon inhibitors|protein kinase Cepsilon inhibitor|nPKCepsilon inhibitors|PKCalpha inhibitors|cPKCalpha inhibitors|PKCalpha inhibitor|EC 2.7.11.13 (protein kinase C) inhibitors|calcium-dependent protein kinase C inhibitor|PKC inhibitors|cPKCalpha inhibitor,An EC 2.7.11.* (protein-serine/threonine kinase) inhibitor that interferes with the action of protein kinase C (EC 2.7.11.13).,false,,,http://purl.obolibrary.org/obo/CHEBI_76812,,,,,,,,,,,,,,,,,,,,,,An EC 2.7.11.* (protein-serine/threonine kinase) inhibitor that interferes with the action of protein kinase C (EC 2.7.11.13).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PKCepsilon inhibitors|PKCgamma inhibitor|cPKCgamma inhibitors|PKN3 inhibitors|calcium-independent protein kinase C inhibitors|nPKCtheta inhibitors|EC 2.7.11.13 inhibitors|PKCgamma inhibitors|PKN3 inhibitor|nPKCtheta inhibitor|cPKCbeta inhibitor|protein kinase C (EC 2.7.11.13) inhibitors|PKC inhibitor|PKCbeta inhibitors|protein kinase C (EC 2.7.11.13) inhibitor|nPKCeta inhibitor|nPKCeta inhibitors|PKCzeta inhibitors|protein kinase C inhibitor|PKCdelta inhibitors|nPKC inhibitors|PKCbeta inhibitor|PKCzeta inhibitor|calcium-dependent protein kinase C inhibitors|ATP:protein phosphotransferase (diacylglycerol-dependent) inhibitors|nPKCepsilon inhibitor|Pkc1p inhibitors|cPKCgamma inhibitor|calcium/phospholipid dependent protein kinase inhibitor|cPKC inhibitors|EC 2.7.11.13 inhibitor|PKCepsilon inhibitor|calcium-independent protein kinase C inhibitor|nPKC inhibitor|PKCdelta inhibitor|protein kinase C inhibitors|STK24 inhibitors|STK24 inhibitor|ATP:protein phosphotransferase (diacylglycerol-dependent) inhibitor|nPKCdelta inhibitors|calcium/phospholipid dependent protein kinase inhibitors|cPKCbeta inhibitors|Pkc1p inhibitor|nPKCdelta inhibitor|cPKC inhibitor|protein kinase Cepsilon inhibitors|protein kinase Cepsilon inhibitor|nPKCepsilon inhibitors|PKCalpha inhibitors|cPKCalpha inhibitors|PKCalpha inhibitor|EC 2.7.11.13 (protein kinase C) inhibitors|calcium-dependent protein kinase C inhibitor|PKC inhibitors|cPKCalpha inhibitor,,,,,,,,,,,,,,,,,,,,,CHEBI:37700,,,,EC 2.7.11.13 (protein kinase C) inhibitor,,CHEBI:37700,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76838,"EC 1.14.14.* (oxidoreductase acting on paired donors, incorporating of 1 atom of oxygen, with reduced flavin or flavoprotein as one donor) inhibitor","oxidoreductase acting on paired donors, with incorporation of 1 atom of oxygen, with reduced flavin or flavoprotein as one donor (EC 1.14.14.*) inhibitor|EC 1.14.14.* inhibitors|EC 1.14.14.* (oxidoreductase acting on paired donors, incorporating of 1 atom of oxygen, with reduced flavin or flavoprotein as one donor) inhibitors|EC 1.14.14.* (oxidoreductase acting on paired donors, with incorporation of 1 atom of oxygen, with reduced flavin or flavoprotein as one donor) inhibitors|EC 1.14.14.* (oxidoreductase acting on paired donors, with incorporation of 1 atom of oxygen, with reduced flavin or flavoprotein as one donor) inhibitor|oxidoreductase acting on paired donors, with incorporation of 1 atom of oxygen, with reduced flavin or flavoprotein as one donor (EC 1.14.14.*) inhibitors|EC 1.14.14.* inhibitor","An EC 1.14.* (oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen) inhibitor that interferes with the action of any such enzyme incorporating one atom of oxygen and using reduced flavin or flavoprotein as donor (EC 1.14.14.*).",false,,,http://purl.obolibrary.org/obo/CHEBI_76741,,,,,,,,,,,,,,,,,,,,,,"An EC 1.14.* (oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen) inhibitor that interferes with the action of any such enzyme incorporating one atom of oxygen and using reduced flavin or flavoprotein as donor (EC 1.14.14.*).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"oxidoreductase acting on paired donors, with incorporation of 1 atom of oxygen, with reduced flavin or flavoprotein as one donor (EC 1.14.14.*) inhibitor|EC 1.14.14.* inhibitors|EC 1.14.14.* (oxidoreductase acting on paired donors, incorporating of 1 atom of oxygen, with reduced flavin or flavoprotein as one donor) inhibitors|EC 1.14.14.* (oxidoreductase acting on paired donors, with incorporation of 1 atom of oxygen, with reduced flavin or flavoprotein as one donor) inhibitors|EC 1.14.14.* (oxidoreductase acting on paired donors, with incorporation of 1 atom of oxygen, with reduced flavin or flavoprotein as one donor) inhibitor|oxidoreductase acting on paired donors, with incorporation of 1 atom of oxygen, with reduced flavin or flavoprotein as one donor (EC 1.14.14.*) inhibitors|EC 1.14.14.* inhibitor",,,,,,,,,,,,,,,,,,,,,CHEBI:76838,,,,"EC 1.14.14.* (oxidoreductase acting on paired donors, incorporating of 1 atom of oxygen, with reduced flavin or flavoprotein as one donor) inhibitor",,CHEBI:76838,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100535,GCK family,,,false,,,http://purl.obolibrary.org/obo/IMR_0000253,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100535,,,,,,,,,,,,,,,,,,,,,,GCK family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000891,IRAK-2,Interleukin-1 receptor-associated kinase-2|IL-1 receptor-associated kinase 2,,false,,,http://purl.obolibrary.org/obo/IMR_0100488,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Interleukin-1 receptor-associated kinase-2|IL-1 receptor-associated kinase 2,,,,,IMR:0000891,,,,,,,,,,,,,,,,,,,,,,IRAK-2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000890,IRAK-1,IL-1 receptor-associated kinase 1|Interleukin-1 receptor-associated kinase 1,,false,,,http://purl.obolibrary.org/obo/IMR_0100488,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IL-1 receptor-associated kinase 1|Interleukin-1 receptor-associated kinase 1,,,,,IMR:0000890,,,,,,,,,,,,,,,,,,,,,,IRAK-1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_24431,chemical entity,chemical compound,"A chemical entity is a physical entity of interest in chemistry including molecular entities, parts thereof, and chemical substances.",false,,,http://purl.obolibrary.org/obo/BFO_0000030,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000947,,"A chemical entity is a physical entity of interest in chemistry including molecular entities, parts thereof, and chemical substances.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,chemical compound,,,,,CHEBI:24431,,,,,,,,,,,,,,,,,,,,,,chemical entity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000007,Interleukin,IL,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000007,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000622,,,,,IL,,,,,IMR:0000007,,,,,,,,,,,,,,,,,,,,,,Interleukin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0015990,electron transport coupled proton transport,,"The transport of protons against an electrochemical gradient, using energy from electron transport.",false,,,http://purl.obolibrary.org/obo/GO_1902600,,,,,,,,,,,,,,,,,,,,,,"The transport of protons against an electrochemical gradient, using energy from electron transport.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0015990,,,,,,,,,,,,,,,,,,,,,,electron transport coupled proton transport,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000010125,RASGRP1,,"Other designations: RAS guanyl nucleotide-releasing protein 1|RAS guanyl-releasing protein 1|calcium and DAG-regulated guanine nucleotide exchange factor II|guanine nucleotide exchange factor, calcium- and DAG-regulated, Rap1A|ras activator RasGRP",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CALDAG-GEFI|CALDAG-GEFII|RASGRP|V|hRasGRP1,,,,,,,,,,,,15,,,,,,HPRD:04909|Vega:OTTHUMG00000172379|MIM:603962|Ensembl:ENSG00000172575|HGNC:9878,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,RAS guanyl releasing protein 1 (calcium and DAG-regulated),,,15q14,,,,,,,,,,,,,,,,"GO_0000139 (EC: IEA); GO_0001816 (EC: IEA); GO_0002437 (EC: IEA); GO_0005085 (EC: TAS); GO_0005509 (EC: IEA); GO_0005789 (EC: IEA); GO_0005829 (EC: TAS); GO_0005886 (EC: TAS); GO_0007165 (EC: TAS, PMID: 9789079); GO_0007265 (EC: TAS, PMID: 9582122); GO_0007596 (EC: TAS); GO_0008289 (EC: TAS, PMID: 9582122); GO_0014066 (EC: IEA); GO_0016020 (EC: TAS, PMID: 9582122); GO_0030154 (EC: IEA); GO_0030168 (EC: TAS); GO_0032252 (EC: IEA); GO_0032862 (EC: IEA); GO_0038095 (EC: TAS); GO_0042629 (EC: IEA); GO_0043303 (EC: IEA); GO_0045087 (EC: TAS); GO_0047496 (EC: IEA)",,,,,,,,,PMID: 9582122; 9789079; 10087292; 11257115; 12477932; 12845332; 14583629; 15829980; 16344560; 17190838; 17283063; 17353931; 17576779; 17658605; 17702895; 17878389; 18711365; 18760455; 18840781; 19058789; 19100522; 19465406; 19960345; 20467438; 20670164; 21815871; 21829393; 21856938; 21966541; 21968647; 21976405; 22116551; 22939629; 22961080; 23128233,,,,,,,,,,,,,,,OGG:3000010125,,,,,,,RAS guanyl releasing protein 1 (calcium and DAG-regulated),,,,,,,,,,,,,"Other designations: RAS guanyl nucleotide-releasing protein 1|RAS guanyl-releasing protein 1|calcium and DAG-regulated guanine nucleotide exchange factor II|guanine nucleotide exchange factor, calcium- and DAG-regulated, Rap1A|ras activator RasGRP",,RASGRP1,,,,,,,,,,,,,,,,,,,,,,,10125,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,RASGRP1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000599,IL-17,cytotoxic T lymphocyte-associated antigen 8|CTLA-8|interleukin-17,,false,,,http://purl.obolibrary.org/obo/IMR_0000007,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000622,,,,,cytotoxic T lymphocyte-associated antigen 8|CTLA-8|interleukin-17,,,,,IMR:0000599,,,,,,,,,,,,,,,,,,,,,,IL-17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000080,CYP2D6 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0001553,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1565,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001565,,,,,,,,,,,,,TXPO:1000080,,,,,,,,,,,,,,,,,,,,,,CYP2D6 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000081,CYP2E1 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0001553,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1571|NCBI-Mouse-GeneID:13106|NCBI-Rat-GeneID:25086,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001571,,,,,,,,,,,,,TXPO:1000081,,,,,,,,,,,,,,,,,,,,,,CYP2E1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000082,CYP3A4 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0001554,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1576,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001576,,,,,,,,,,,,,TXPO:1000082,,,,,,,,,,,,,,,,,,,,,,CYP3A4 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000089,Ccng1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:900|NCBI-Rat-GeneID:25405|NCBI-Mouse-GeneID:12450,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000900,,,,,,,,,,,,,TXPO:1000089,,,,,,,,,,,,,,,,,,,,,,Ccng1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000083,CYP3A5 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0001554,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1577,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001577,,,,,,,,,,,,,TXPO:1000083,,,,,,,,,,,,,,,,,,,,,,CYP3A5 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000085,Car2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:760,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000760,,,,,,,,,,,,,TXPO:1000085,,,,,,,,,,,,,,,,,,,,,,Car2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000088,Cyclin D1 (mol),CCND1 (mol),,false,,,http://purl.obolibrary.org/obo/IMR_0100614,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:58919|NCBI-Human-GeneID:595|NCBI-Mouse-GeneID:12443,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000595,,,,,,,,CCND1 (mol),,,,,TXPO:1000088,,,,,,,,,,,,,,,,,,,,,,Cyclin D1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000086,CCL2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:20296|NCBI-Human-GeneID:6347|NCBI-Rat-GeneID:24770,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000006347,,,,,,,,,,,,,TXPO:1000086,,,,,,,,,,,,,,,,,,,,,,CCL2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000084,CYP4X1 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0001555,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:81906|NCBI-Rat-GeneID:246767|NCBI-Human-GeneID:260293,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000260293,,,,,,,,,,,,,TXPO:1000084,,,,,,,,,,,,,,,,,,,,,,CYP4X1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0099024,plasma membrane invagination,,An infolding of the plasma membrane.,false,,,http://purl.obolibrary.org/obo/GO_0010324,,,,,,,,,,,,,,,,,,,,,,An infolding of the plasma membrane.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0099024,,,,,,,,,,,,,,,,,,,,,,plasma membrane invagination,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002669,necrosis [Cholestasis],,"A type of cell death that is morphologically characterized by an increasingly translucent cytoplasm, swelling of organelles, minor ultrastructural modifications of the nucleus (specifically, dilatation of the nuclear membrane and condensation of chromatin into small, irregular, circumscribed patches) and increased cell volume (oncosis), culminating in the disruption of the plasma membrane and subsequent loss of intracellular contents. Necrotic cells do not fragment into discrete corpses as their apoptotic counterparts do. Moreover, their nuclei remain intact and can aggregate and accumulate in necrotic tissues.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000034|http://purl.obolibrary.org/obo/GO_0070265,,,,,,,,,,,,,,,,,,,,,,"A type of cell death that is morphologically characterized by an increasingly translucent cytoplasm, swelling of organelles, minor ultrastructural modifications of the nucleus (specifically, dilatation of the nuclear membrane and condensation of chromatin into small, irregular, circumscribed patches) and increased cell volume (oncosis), culminating in the disruption of the plasma membrane and subsequent loss of intracellular contents. Necrotic cells do not fragment into discrete corpses as their apoptotic counterparts do. Moreover, their nuclei remain intact and can aggregate and accumulate in necrotic tissues.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003739|http://purl.obolibrary.org/obo/TXPO_0000545,,,,,,,,,,,TXPO:0002669,,,,,,,,,,,,,,,,,,,,,,necrosis [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002665,regulation of cell survival,,"Regulation of cell survival is a subtype of controlling: A process that modulates the frequency, rate or extent of cell survival.",false,,,http://purl.obolibrary.org/obo/TXPO_0000113,,,,,,,,,,,,,,,,,,,,,,"Regulation of cell survival is a subtype of controlling: A process that modulates the frequency, rate or extent of cell survival.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002665,,,,,,,,,,,,,,,,,,,,,,regulation of cell survival,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C16407,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002666,contraction of bile canaliculus [Cholestasis],,"Contraction of bile canaliculus is a subtype of contraction: A process that generates the directed movement in which the bile canaliculus decreases in volume.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000034|http://purl.obolibrary.org/obo/TXPO_0002695,,,,,,,,,,,,,,,,,,,,,,"Contraction of bile canaliculus is a subtype of contraction: A process that generates the directed movement in which the bile canaliculus decreases in volume.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002666,,,,,,,,,,,,,,,,,,,,,,contraction of bile canaliculus [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002664,bile reflux [Cholestasis],,"Bile reflux is a subtype of back-flow: A process that changes the bile flow to the opposite direction.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000590|http://purl.obolibrary.org/obo/TXPO_0000034,,,,,,,,,,,,,,,,,,,,,,"Bile reflux is a subtype of back-flow: A process that changes the bile flow to the opposite direction.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002664,,,,,,,,,,,,,,,,,,,,,,bile reflux [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002662,increasing vomume of bile canaliculus [Cholestasis],,"Increasing vomume of bile canaliculus is a subtype of increasing volume: A process that changes the volume of the bile canaliculus to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000034|http://purl.obolibrary.org/obo/TXPO_0002717,,,,,,,,,,,,,,,,,,,,,,"Increasing vomume of bile canaliculus is a subtype of increasing volume: A process that changes the volume of the bile canaliculus to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002662,,,,,,,,,,,,,,,,,,,,,,increasing vomume of bile canaliculus [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002667,negative regulation of contractile movement of bile canaliculus [Cholestasis],,"Negative regulation of contractile movement of bile canaliculus is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of contractile movement of bile canaliculus.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003155,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of contractile movement of bile canaliculus is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of contractile movement of bile canaliculus.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002667,,,,,,,,,,,,,,,,,,,,,,negative regulation of contractile movement of bile canaliculus [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002661,protein aggregation,,"Protein aggregation is a subtype of molecular assembly: The aggregation, arrangement and bonding together of molecules.",false,,,http://purl.obolibrary.org/obo/TXPO_0003815,,,,,,,,,,,,,,,,,,,,http://purl.jp/bio/4/id/200906073816740790|http://jglobal.jst.go.jp/en/detail?JGLOBAL_ID=200906073816740790,,"Protein aggregation is a subtype of molecular assembly: The aggregation, arrangement and bonding together of molecules.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_36080,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002661,,,,,,,,,,,,,,,,,,,,,,protein aggregation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002660,bile thrombus formation in bile canaliculus [Cholestasis],,"Bile thrombus formation in bile canaliculus is a subtype of bile thrombus formation: A process that constructs bile thrombus in bile canaliculus.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003142|http://purl.obolibrary.org/obo/TXPO_0000034,,,,,,,,,,,,,,,,,,,,,,"Bile thrombus formation in bile canaliculus is a subtype of bile thrombus formation: A process that constructs bile thrombus in bile canaliculus.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002660,,,,,,,,,,,,,,,,,,,,,,bile thrombus formation in bile canaliculus [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002668,phospholipidosis dependent molecule  (HepG2_24h_sawada),,,false,,,http://purl.obolibrary.org/obo/TXPO_0001135,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002668,,,,,,,,,,,,,,,,,,,,,,phospholipidosis dependent molecule  (HepG2_24h_sawada),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002663,increasing canalicular membrane permeability [Cholestasis],,"Increasing canalicular membrane permeability is a subtype of increasing membrane permeabilization: A process that changes the permeability of the canalicular membrane to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002706|http://purl.obolibrary.org/obo/TXPO_0000034,,,,,,,,,,,,,,,,,,,,,,"Increasing canalicular membrane permeability is a subtype of increasing membrane permeabilization: A process that changes the permeability of the canalicular membrane to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002664,,,,,,,,,,,TXPO:0002663,,,,,,,,,,,,,,,,,,,,,,increasing canalicular membrane permeability [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_91079,purinergic receptor P2 antagonist,non-selective P2 purinergic antagonist|purinergic receptor P2 antagonists|non-selective P2 purinergic antagonists|P2 antagonists|P2 antagonist,An antagonist at purinergic P2 receptors,false,,,http://purl.obolibrary.org/obo/CHEBI_48706,,,,,,,,,,,,,,,,,,,,,,An antagonist at purinergic P2 receptors,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,non-selective P2 purinergic antagonist|purinergic receptor P2 antagonists|non-selective P2 purinergic antagonists|P2 antagonists|P2 antagonist,,,,,,,,,,,,,,,,,,,,,CHEBI:91079,,,,purinergic receptor P2 antagonist,,CHEBI:91079,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000001728,NQO1,,Other designations: DT-diaphorase|NAD(P)H dehydrogenase [quinone] 1|NAD(P)H:Quinone acceptor oxidoreductase type 1|NAD(P)H:menadione oxidoreductase 1|NAD(P)H:quinone oxidoreductase 1|NAD(P)H:quinone oxireductase|azoreductase|diaphorase (NADH/NADPH) (cytochrome b-5 reductase)|diaphorase-4|dioxin-inducible 1|menadione reductase|phylloquinone reductase|quinone reductase 1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,DHQU|NMORI|QR1|DTD|NMOR1|DIA4,,,,,,,,,,,,16,,,,,,Vega:OTTHUMG00000137575|MIM:125860|HPRD:00518|HGNC:2874|Ensembl:ENSG00000181019,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"NAD(P)H dehydrogenase, quinone 1",,,16q22.1,,,,,,,,,,,,,,,,"GO_0003955 (EC: IEA); GO_0004128 (EC: TAS, PMID: 9579781); GO_0004784 (EC: IEA); GO_0005515 (EC: IPI, PMID: 18388957); GO_0005737 (EC: IDA); GO_0005829 (EC: TAS); GO_0006521 (EC: TAS); GO_0006801 (EC: IEA); GO_0006805 (EC: TAS, PMID: 10393963); GO_0006809 (EC: TAS, PMID: 9579781); GO_0006979 (EC: IEA); GO_0007271 (EC: TAS, PMID: 9579781); GO_0007568 (EC: IEA); GO_0007584 (EC: IEA); GO_0009636 (EC: TAS, PMID: 10393963); GO_0032355 (EC: IEA); GO_0034641 (EC: TAS); GO_0043025 (EC: IEA); GO_0043086 (EC: IEA); GO_0043525 (EC: IEA); GO_0044281 (EC: TAS); GO_0044822 (EC: IDA); GO_0045471 (EC: IEA)",,,,,,,,,PMID: 1340765; 1657151; 1737339; 2071140; 2843525; 8125298; 9230185; 9579781; 10393963; 10447260; 10487530; 10543876; 10706635; 11051261; 11219774; 11319169; 11520401; 11551408; 11679176; 11688992; 11701227; 11722480; 11766168; 11773862; 11774269; 11810042; 11821413; 11840286; 11888914; 11894133; 11895912; 11943609; 11948402; 11956078; 11967624; 12018106; 12036913; 12037698; 12163326; 12164325; 12171070; 12171760; 12172217; 12232053; 12370194; 12383707; 12393447; 12393620; 12397416; 12417987; 12419832; 12439220; 12460800; 12468438; 12477932; 12480594; 12529318; 12694753; 12711112; 12713578; 12718576; 12718704; 12771035; 12777965; 12834817; 12854127; 12867492; 12960511; 13130177; 14506737; 14568289; 14592434; 14634213; 14634838; 14669229; 14675732; 14688016; 14694720; 14716779; 14720419; 14729580; 14985350; 15028279; 15061915; 15079792; 15111988; 15116053; 15138483; 15151706; 15184245; 15196853; 15219943; 15226677; 15279067; 15280903; 15298951; 15312971; 15334552; 15352038; 15355699; 15365958; 15370874; 15382274; 15385560; 15466980; 15489334; 15498787; 15590400; 15618957; 15640066; 15661231; 15694256; 15714076; 15727169; 15731166; 15734732; 15746160; 15747169; 15748501; 15749015; 15763338; 15767364; 15781212; 15808404; 15829318; 15838728; 15938845; 16003741; 16006997; 16038261; 16039674; 16054862; 16079101; 16157195; 16170238; 16172237; 16235982; 16235998; 16266898; 16284498; 16297214; 16321221; 16341674; 16343742; 16369108; 16385446; 16413497; 16520888; 16532285; 16595077; 16598069; 16610002; 16620556; 16702380; 16775388; 16818284; 16978807; 16985026; 17011189; 17027152; 17082176; 17113562; 17118447; 17119198; 17164365; 17166422; 17178637; 17179690; 17188257; 17332305; 17332311; 17337051; 17363580; 17367411; 17372252; 17378176; 17395013; 17400324; 17405841; 17424838; 17428572; 17449559; 17469025; 17476281; 17496311; 17507624; 17541156; 17575500; 17581325; 17603928; 17619904; 17644186; 17652311; 17669387; 17726138; 17869325; 17885617; 17901563; 18024413; 18029348; 18034618; 18061666; 18061941; 18074351; 18091324; 18098117; 18156703; 18203021; 18214807; 18218609; 18225579; 18253865; 18388957; 18393254; 18404535; 18407955; 18413200; 18416817; 18444152; 18444911; 18457324; 18510611; 18511948; 18569591; 18587252; 18601742; 18632753; 18636124; 18676018; 18676680; 18720901; 18784359; 18798003; 18813798; 18820947; 18836923; 18936436; 18945694; 18950733; 18977034; 18981090; 18986377; 18992148; 19012493; 19012698; 19017358; 19027876; 19027952; 19059883; 19074885; 19096102; 19138946; 19151739; 19162321; 19170196; 19174490; 19179423; 19214744; 19229058; 19251446; 19330589; 19336370; 19339270; 19360290; 19362588; 19382518; 19415745; 19456854; 19494791; 19549356; 19591959; 19593802; 19596483; 19625176; 19628038; 19651439; 19652895; 19657853; 19661089; 19671875; 19688691; 19692168; 19705749; 19715479; 19736056; 19738201; 19759547; 19778569; 19789190; 19808663; 19822020; 19899130; 19913121; 19952119; 20026093; 20027111; 20028737; 20049130; 20049212; 20056632; 20085630; 20091863; 20100551; 20110814; 20193673; 20194081; 20198579; 20200430; 20204281; 20214802; 20226854; 20331656; 20371868; 20373852; 20375710; 20391128; 20437850; 20453000; 20461808; 20480521; 20480816; 20511665; 20526719; 20526805; 20534171; 20568895; 20593958; 20599494; 20613985; 20628086; 20634891; 20663217; 20701904; 20819778; 20824655; 20851451; 20878130; 20935060; 20951227; 20962519; 20966810; 21041608; 21073132; 21117316; 21133623; 21139048; 21176850; 21211285; 21220432; 21253823; 21294640; 21329464; 21351093; 21479364; 21480392; 21502369; 21518531; 21524888; 21531452; 21577322; 21602889; 21605663; 21706157; 21718050; 21755707; 21756955; 21800014; 21861350; 21906983; 21946896; 21963094; 21964527; 21989715; 22016051; 22017531; 22021338; 22116627; 22215148; 22249251; 22272361; 22306249; 22387672; 22393995; 22483869; 22586705; 22623428; 22736108; 22770696; 22793692; 22853296; 22911602; 22925602; 22939629; 22960073; 22972504; 22976839; 22984577; 23000965; 23054000; 23065291; 23066387; 23066397; 23086932; 23110137; 23215885; 23249637; 23275341; 23276910; 23360829; 23390006; 23458878; 23468244; 23497461; 23643325; 23648480; 23651475; 23725139; 23749485; 23803694; 23824909; 23840148; 23852860; 23860519; 23873104; 23893397; 23918565; 24053646; 24140708,,,,,,,,,,,,,,,OGG:3000001728,,,,,,,"NAD(P)H dehydrogenase, quinone 1",,,,,,,,,,,,,Other designations: DT-diaphorase|NAD(P)H dehydrogenase [quinone] 1|NAD(P)H:Quinone acceptor oxidoreductase type 1|NAD(P)H:menadione oxidoreductase 1|NAD(P)H:quinone oxidoreductase 1|NAD(P)H:quinone oxireductase|azoreductase|diaphorase (NADH/NADPH) (cytochrome b-5 reductase)|diaphorase-4|dioxin-inducible 1|menadione reductase|phylloquinone reductase|quinone reductase 1,,NQO1,,,,,,,,,,,,,,,,,,,,,,,1728,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,NQO1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/GO_0007155,cell adhesion,Wikipedia:Cell_adhesion,"The attachment of a cell, either to another cell or to the extracellular matrix, via cell adhesion molecules.",false,,,http://purl.obolibrary.org/obo/TXPO_0002581,,,,,,,,,,,,,,,,,,,,,,"The attachment of a cell, either to another cell or to the extracellular matrix, via cell adhesion molecules.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000000,,,,,,,,,,,,Wikipedia:Cell_adhesion,,,,,GO:0007155,,,,,,,,,,,,,,,,,,,,,,cell adhesion,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000000,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_10110,zidovudine,AZT|zidovudine|Zidovudinum|Retrovir|Azidothymidine|Zidovudin|AZT|3'-azido-3'-deoxythymidine,"A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,DrugBank:DB00495|LINCS:LSM-5806|PMID:19112024|Wikipedia:Zidovudine|PMID:9203666|CAS:30516-87-1|Beilstein:763034|PMID:26859826|Drug_Central:2861|PMID:29438107,,"A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.",,,,,,,,,,,,C10H13N5O4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_53756|http://purl.obolibrary.org/obo/CHEBI_35221|http://purl.obolibrary.org/obo/CHEBI_36044,,,,,AZT|3'-azido-3'-deoxythymidine,,AZT|zidovudine|Zidovudinum|Retrovir|Azidothymidine|Zidovudin,,,,,,,,,,,,,,,,,,,,,CHEBI:10110,,,,zidovudine,,CHEBI:10110,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O,,,,,
http://purl.obolibrary.org/obo/GO_0035195,gene silencing by miRNA,,"Downregulation of gene expression through the action of microRNAs (miRNAs), endogenous 21-24 nucleotide small RNAs processed from stem-loop RNA precursors (pre-miRNAs). Once incorporated into a RNA-induced silencing complex (RISC), miRNAs can downregulate gene expression by either of two posttranscriptional mechanisms: endolytic cleavage of mRNA cleavage or translational repression, usually accompanied by poly-A tail shortening and subsequent degradation of the mRNA.",false,,,http://purl.obolibrary.org/obo/GO_0010468,,,,,,,,,,,,,,,,,,,,,,"Downregulation of gene expression through the action of microRNAs (miRNAs), endogenous 21-24 nucleotide small RNAs processed from stem-loop RNA precursors (pre-miRNAs). Once incorporated into a RNA-induced silencing complex (RISC), miRNAs can downregulate gene expression by either of two posttranscriptional mechanisms: endolytic cleavage of mRNA cleavage or translational repression, usually accompanied by poly-A tail shortening and subsequent degradation of the mRNA.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0035195,,,,,,,,,,,,,,,,,,,,,,gene silencing by miRNA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000057,CD40,,,false,,,http://purl.obolibrary.org/obo/IMR_0000056,,,,,,,,,,,,,,,,,,,,GO:0005028,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000057,,,,,,,,,,,,,,,,,,,,,,CD40,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000909,eIF4F,,eIF4F is a heterotrimeric complex that binds to the cap structure at the 50 end of the mRNA. It is composed of eIF4G and the cap-binding protein eIF4E and the ATPdependent RNA helicase eIF4A.,false,,,http://purl.obolibrary.org/obo/IMR_0010016,,,,,,,,,,,,,,,,,,,,,,eIF4F is a heterotrimeric complex that binds to the cap structure at the 50 end of the mRNA. It is composed of eIF4G and the cap-binding protein eIF4E and the ATPdependent RNA helicase eIF4A.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000909,,,,,,,,,,,,,,,,,,,,,,eIF4F,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0000970,eye,visual apparatus|light-detecting organ,"An organ that detects light.|Note that whilst this is classified as an organ, it is in fact more of a unit composed of different structures: in Drosophila, it includes the interommatidial bristle as a part; we consider here the vertebrate eye to include the eyeball/eye proper as a part, with the eye having as parts (when present): eyelids, conjuctiva,",false,,,http://purl.obolibrary.org/obo/UBERON_0000020,,,,,,,,,,,,,,,,,,,"This class encompasses a variety of light-detecting structures from different phyla with no implication of homology, from the compound insect eye to the vertebrate camera-type eye (distinct classes are provided for each)",http://en.wikipedia.org/wiki/Eye|MAT:0000140|FBbt:00005162|BTO:0000439|GAID:69|EV:0100336|MIAA:0000140|OpenCyc:Mx4rvViTvpwpEbGdrcN5Y29ycA|MESH:D005123|EFO:0000827|CALOHA:TS-0309|BILA:0000017,,An organ that detects light.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,visual apparatus|light-detecting organ,,,UBERON:0000970,,,,,,,,,,,,,,,,,,,,"Note that whilst this is classified as an organ, it is in fact more of a unit composed of different structures: in Drosophila, it includes the interommatidial bristle as a part; we consider here the vertebrate eye to include the eyeball/eye proper as a part, with the eye having as parts (when present): eyelids, conjuctiva,",,eye,,,,,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001438,loss of phospholipid degradation,,Loss of phospholipid degradation is a subtype of loss of function (process): A process that results in no longer having a phospholipid degradation function or the process that gradually loses it.,false,,,http://purl.obolibrary.org/obo/TXPO_0000439,,,,,,,,,,,,,,,,,,,,,,Loss of phospholipid degradation is a subtype of loss of function (process): A process that results in no longer having a phospholipid degradation function or the process that gradually loses it.,,,http://purl.obolibrary.org/obo/GO_0009395,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001438,,,,,,,,,,,,,,,,,,,,,,loss of phospholipid degradation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001437,phospholipidosis (genetic),,The totality of all processes through which the phospholipidosis is realized. This causal process is heredity.,false,,,http://purl.obolibrary.org/obo/TXPO_0002215,,,,,,,,,,,,,,,,,,,,,,The totality of all processes through which the phospholipidosis is realized. This causal process is heredity.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001776|http://purl.obolibrary.org/obo/TXPO_0003985|http://purl.obolibrary.org/obo/TXPO_0002070|http://purl.obolibrary.org/obo/TXPO_0001463|http://purl.obolibrary.org/obo/TXPO_0002069,,,,,,,,,,,,,,,,,,TXPO:0001437,,,,,,,,,,,,,,,,,,,,,,phospholipidosis (genetic),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001439,loss of phospholipid degradation [Phospholipidosis],,"Loss of phospholipid degradation is a subtype of loss of function (process): A process that results in no longer having a phospholipid degradation function or the process that gradually loses it.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001438|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Loss of phospholipid degradation is a subtype of loss of function (process): A process that results in no longer having a phospholipid degradation function or the process that gradually loses it.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001439,,,,,,,,,,,,,,,,,,,,,,loss of phospholipid degradation [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001436,ATF6 gene expression regulation system,,"ATF6 gene expression regulation system is a subtype of pathway system.
This entity has sub-parts and has a goal of regulating gene expressions by ATF6 as a systemic context.",false,,,http://purl.obolibrary.org/obo/TXPO_0000887,,,,,,,,,,,,,,,,,,,,,,"ATF6 gene expression regulation system is a subtype of pathway system.
This entity has sub-parts and has a goal of regulating gene expressions by ATF6 as a systemic context.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001436,,,,,,,,,,,,,,,,,,,,,,ATF6 gene expression regulation system,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001435,phospholipid metabolism balance [phopholipidosis - normal],,"Phospholipid metabolism balance is a subtype of maintaining balance: A process that keeps a balance of phospholipid metabolism.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (normal condition).",false,,,http://purl.obolibrary.org/obo/TXPO_0001434|http://purl.obolibrary.org/obo/TXPO_0000946,,,,,,,,,,,,,,,,,,,,,,"Phospholipid metabolism balance is a subtype of maintaining balance: A process that keeps a balance of phospholipid metabolism.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (normal condition).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001683,,http://purl.obolibrary.org/obo/TXPO_0002076,,,,,,,,,TXPO:0001435,,,,,,,,,,,,,,,,,,,,,,phospholipid metabolism balance [phopholipidosis - normal],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001431,hyperfunction of phospholipid degradation [Phospholipidosis (excessive defense)],,"Hyperfunction of phospholipid degradation is a subtype of hyperfunction of phospholipid degradation: A process that performs excessive phospholipid degradation as an excessive defense.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense).",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0003583,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of phospholipid degradation is a subtype of hyperfunction of phospholipid degradation: A process that performs excessive phospholipid degradation as an excessive defense.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001431,,,,,,,,,,,,,,,,,,,,,,hyperfunction of phospholipid degradation [Phospholipidosis (excessive defense)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001433,dysfunction of protein refolding,,Dysfunction of protein refolding is a subtype of dysfunctioning: A process that performs an abnormal and incomplete protein refolding.,false,,,http://purl.obolibrary.org/obo/TXPO_0000438,,,,,,,,,,,,,,,,,,,,,,Dysfunction of protein refolding is a subtype of dysfunctioning: A process that performs an abnormal and incomplete protein refolding.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001433,,,,,,,,,,,,,,,,,,,,,,dysfunction of protein refolding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001430,hyperfunction of phospholipid degradation,,Hyperfunction of phospholipid degradation is a subtype of hyperfunction of decompoing: A process that performs an excessive phospholipid degradation.,false,,,http://purl.obolibrary.org/obo/TXPO_0002349,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of phospholipid degradation is a subtype of hyperfunction of decompoing: A process that performs an excessive phospholipid degradation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001430,,,,,,,,,,,,,,,,,,,,,,hyperfunction of phospholipid degradation,,,,,,http://purl.obolibrary.org/obo/GO_0006644,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001432,ground glass apperance [toxic corse],cloudy swelling,The totality of all processes through which ground glass appearance is realized.,false,,,http://purl.obolibrary.org/obo/TXPO_0000009,,,,,,,,,,,,,,,,,,,,PMID:22723046|ISBN:0071769234|PMID:24180433,,The totality of all processes through which ground glass appearance is realized.,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000963,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000963|http://purl.obolibrary.org/obo/TXPO_0001665|http://purl.obolibrary.org/obo/TXPO_0002600|http://purl.obolibrary.org/obo/TXPO_0003859|http://purl.obolibrary.org/obo/TXPO_0001827|http://purl.obolibrary.org/obo/TXPO_0002068|http://purl.obolibrary.org/obo/TXPO_0000443,,,,,,,,,,,,,cloudy swelling,,,,,TXPO:0001432,,,,,,,,,,,,,,,,,,,,,,ground glass apperance [toxic corse],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001434,phospholipid metabolism balance,,Phospholipid metabolism balance is a subtype of maintaining balance: A process that keeps a balance of phospholipid metabolism.,false,,,http://purl.obolibrary.org/obo/TXPO_0000682,,,,,,,,,,,,,,,,,,,,,,Phospholipid metabolism balance is a subtype of maintaining balance: A process that keeps a balance of phospholipid metabolism.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001434,,,,,,,,,,,,,,,,,,,,,,phospholipid metabolism balance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001624,Rab33B (mol),,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001624,,,,,,,,,,,,,,,,,,,,,,Rab33B (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_52424,EC 3.2.1.* (glycosidase) inhibitor,glycosidase inhibitors|glycoside hydrolase inhibitors|glycosidase inhibitor|EC 3.2.1.* inhibitors|EC 3.2.1.* inhibitor|glycosidase (EC 3.2.1.*) inhibitors|EC 3.2.1.* (glycosidase) inhibitors|glycosidase (EC 3.2.1.*) inhibitor,"An EC 3.2.* (glycosylase) inhibitor that interferes with the action of any glycosidase (i.e. enzymes hydrolysing O- and S-glycosyl compounds, EC 3.2.1.*).",false,,,http://purl.obolibrary.org/obo/CHEBI_76761,,,,,,,,,,,,,,,,,,,,,,"An EC 3.2.* (glycosylase) inhibitor that interferes with the action of any glycosidase (i.e. enzymes hydrolysing O- and S-glycosyl compounds, EC 3.2.1.*).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,glycosidase inhibitors|glycoside hydrolase inhibitors|glycosidase inhibitor|EC 3.2.1.* inhibitors|EC 3.2.1.* inhibitor|glycosidase (EC 3.2.1.*) inhibitors|EC 3.2.1.* (glycosidase) inhibitors|glycosidase (EC 3.2.1.*) inhibitor,,,,,,,,,,,,,,,,,,,,,CHEBI:52424,,,,EC 3.2.1.* (glycosidase) inhibitor,,CHEBI:52424,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001882,electrophiles formation [NASH],,"Electrophiles formation is a subtype of biosynthetic process: A process that that generates electrophiles. Electrophile is a reagent that forms a bond to its reaction partner (the nucleophile) by accepting both bonding electrons from that reaction partner.
This entity is a specific course-dependent process. This process can constitute the course of lipidosis (NASH).",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0000212,,,,,,,,,,,,,,,,,,,,,,"Electrophiles formation is a subtype of biosynthetic process: A process that that generates electrophiles. Electrophile is a reagent that forms a bond to its reaction partner (the nucleophile) by accepting both bonding electrons from that reaction partner.
This entity is a specific course-dependent process. This process can constitute the course of lipidosis (NASH).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003748,,,,http://purl.obolibrary.org/obo/TXPO_0003630,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003512,,,,,,,,,,,TXPO:0001882,,,,,,,"A number of xenobiotics exert a toxic effect theough their metabolites.
Electrophiles are molecules that contain an electron-deficient atom with a partial or full positive charge that can react by sharing electron pairs with electron rich atoms in nucleophiles.
Electrophilic toxicants generally are detoxificated by conjugation of with the nucleophile, glutathione.
This reaction can be facilitated by glutathione S-trasferases.",,,,,,,,,,,,,,,electrophiles formation [NASH],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001884,FGF21 (canonical)[lipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003516|http://purl.obolibrary.org/obo/TXPO_1000145,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:26291|PMID:22009939|PMID:20451522|PMID:17550777|PMID:27690692,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0100571,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000026291,,,,,,,,,,,,,TXPO:0001884,,,,,,,,,,,,,,,,,,,,,,FGF21 (canonical)[lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001880,generating energy,,Generating energy is a subtype of generating: A process that produces energy as an output.,false,,,http://purl.obolibrary.org/obo/TXPO_0000381,,,,,,,,,,,,,,,,,,,,,,Generating energy is a subtype of generating: A process that produces energy as an output.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://www.w3.org/2002/07/owl#Thing,,,,,,,,,,,,,,,,,,,TXPO:0001880,,,,,,,,,,,,,,,,,,,,,,generating energy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001885,rifampicin [Cholestasis],,A rifamycin that is a a semisynthetic antibiotic derived from Amycolatopsis rifamycinica (previously known as Amycolatopsis mediterranei and Streptomyces mediterranei),false,,,http://purl.obolibrary.org/obo/CHEBI_28077|http://purl.obolibrary.org/obo/TXPO_0000749,,,,,,,,,,,,,,,,,,,,DrugBank:DB01045|CASRN:13292-46-1|Wikipedia:Rifampicin,,A rifamycin that is a a semisynthetic antibiotic derived from Amycolatopsis rifamycinica (previously known as Amycolatopsis mediterranei and Streptomyces mediterranei),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001866,,,,,,,,,,TXPO:0001885,,,,,,,"Rifampicin, bosentan, and troglitazone directly inhibit bile salt export pump (BSEP).",,,,,,,,,,,,,,,rifampicin [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001883,PYCARD  (mol),PYD And CARD Domain Containing|Caspase Recruitment Domain-Containing Protein 5|CARD5|ASC,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:29108,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PYD And CARD Domain Containing|Caspase Recruitment Domain-Containing Protein 5|CARD5|ASC,,,,,TXPO:0001883,,,,,,,,,,,,,,,,,,,,,,PYCARD  (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001889,cytochrome P450 inactivation,,Cytochrome P450 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the Cytochrome P450 to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000021,,,,,,,,,,,,,,,,,,,,,,Cytochrome P450 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the Cytochrome P450 to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001889,,,,,,,,,,,,,,,,,,,,,,cytochrome P450 inactivation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001888,CYP3A4 (human)[lipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000082|http://purl.obolibrary.org/obo/TXPO_0001786,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1576|PMID:26231377|PMID:28303724|PMID:29792708,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,,,,,,,,,,,,,,TXPO:0001888,,,,,,,,,,,,,,,,,,,,,,CYP3A4 (human)[lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001881,findings attribute,,An attribute inhering in a bearer by an observation.,false,,,http://purl.obolibrary.org/obo/TXPO_0000305,,,,,,,,,,,,,,,,,,,,,,An attribute inhering in a bearer by an observation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001881,,,,,,,,,,,,,,,,,,,,,,findings attribute,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001886,PYCARD (canonical)[lipidosis],PYD And CARD Domain Containing [lipidosis]|CARD5 [lipidosis]|Caspase Recruitment Domain-Containing Protein 5 [lipidosis]|ASC [lipidosis],,false,,,http://purl.obolibrary.org/obo/TXPO_0001883|http://purl.obolibrary.org/obo/TXPO_0003516,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:29108,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PYD And CARD Domain Containing [lipidosis]|CARD5 [lipidosis]|Caspase Recruitment Domain-Containing Protein 5 [lipidosis]|ASC [lipidosis],,,,,TXPO:0001886,,,,,,,,,,,,,,,,,,,,,,PYCARD (canonical)[lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0051301,cell division,,"The process resulting in division and partitioning of components of a cell to form more cells; may or may not be accompanied by the physical separation of a cell into distinct, individually membrane-bounded daughter cells.",false,,,http://purl.obolibrary.org/obo/TXPO_0002576,,,,,,,,,,,,,,,,,,,,Wikipedia:Cell_division|http://purl.obolibrary.org/obo/IEV_0003382　(obsolete),,"The process resulting in division and partitioning of components of a cell to form more cells; may or may not be accompanied by the physical separation of a cell into distinct, individually membrane-bounded daughter cells.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000000,,,,,,,,,,,,,,,,,,,,,,,GO:0051301,,,,,,,,,,,,,,,,,,,,,,cell division,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100718,Delta,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100718,,,,,,,,,,,,,,,,,,,,,,Delta,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000005095,PCCA,,"Other designations: PCCase alpha subunit|pccA complementation group|propanoyl-CoA:carbon dioxide ligase alpha subunit|propionyl Coenzyme A carboxylase, alpha polypeptide|propionyl-CoA carboxylase alpha chain, mitochondrial",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,13,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"propionyl CoA carboxylase, alpha polypeptide",,,13q32,,,,,,,,,,,,,,,,"GO_0004075 (EC: IEA); GO_0004658 (EC: IEA); GO_0005524 (EC: IEA); GO_0005759 (EC: TAS); GO_0005829 (EC: TAS); GO_0006635 (EC: TAS); GO_0006766 (EC: TAS); GO_0006767 (EC: TAS); GO_0006768 (EC: TAS); GO_0009374 (EC: TAS, PMID: 3460076); GO_0019626 (EC: TAS); GO_0019899 (EC: IPI, PMID: 19157941); GO_0044255 (EC: TAS); GO_0044281 (EC: TAS); GO_0046872 (EC: IEA)",,,,,,,,,PMID: 1427880; 2740237; 3460076; 3555348; 3687944; 7656816; 8125298; 8188292; 8434582; 8889548; 8895530; 10101253; 10329019; 10502773; 11136555; 11592820; 11749052; 12226704; 12385775; 12477932; 12559849; 14702039; 15059621; 15489334; 15890657; 16344560; 16751776; 17051315; 17966092; 18457437; 18678647; 19157941; 19157943; 19296078; 19913121; 20301313; 20379614; 20628086; 20725044; 20877624; 21139048; 21642987; 22156789; 22593918; 23396134; 23455922; 24244333,,,,,,,,,,,,,,,OGG:3000005095,,,,,,,"propionyl CoA carboxylase, alpha polypeptide",,,,,,,,,,,,,"Other designations: PCCase alpha subunit|pccA complementation group|propanoyl-CoA:carbon dioxide ligase alpha subunit|propionyl Coenzyme A carboxylase, alpha polypeptide|propionyl-CoA carboxylase alpha chain, mitochondrial",,PCCA,,,,,,,,,,,,,,,,,,,,,,,5095,RP11-151A6.1,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,PCCA,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0004175,SEL1L (predicted)(human) [mitochondrial damage],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003603|http://purl.obolibrary.org/obo/TXPO_1000532,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:6400|PMID: 28272341,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000006400,,,,,,,,,,,,,TXPO:0004175,,,,,,,,,,,,,,,,,,,,,,SEL1L (predicted)(human) [mitochondrial damage],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004173,SKA2 (predicted)(human) [mitochondrial damage],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003603|http://purl.obolibrary.org/obo/TXPO_1000533,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:348235,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000348235,,,,,,,,,,,,,TXPO:0004173,,,,,,,,,,,,,,,,,,,,,,SKA2 (predicted)(human) [mitochondrial damage],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004174,TSKU (predicted)(human) [mitochondrial damage],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003603|http://purl.obolibrary.org/obo/TXPO_1000543,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:25987,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000025987,,,,,,,,,,,,,TXPO:0004174,,,,,,,,,,,,,,,,,,,,,,TSKU (predicted)(human) [mitochondrial damage],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004170,ATAD2 (predicted)(human) [mitochondrial damage],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003603|http://purl.obolibrary.org/obo/TXPO_1000503,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:29028,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000029028,,,,,,,,,,,,,TXPO:0004170,,,,,,,,,,,,,,,,,,,,,,ATAD2 (predicted)(human) [mitochondrial damage],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004172,FEN1 (predicted)(human) [mitochondrial damage],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003603|http://purl.obolibrary.org/obo/TXPO_1000515,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:2237,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000002237,,,,,,,,,,,,,TXPO:0004172,,,,,,,,,,,,,,,,,,,,,,FEN1 (predicted)(human) [mitochondrial damage],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004171,C9orf72 (predicted)(human) [mitochondrial damage],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003603|http://purl.obolibrary.org/obo/TXPO_1000054,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:203228,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000203228,,,,,,,,,,,,,TXPO:0004171,,,,,,,,,,,,,,,,,,,,,,C9orf72 (predicted)(human) [mitochondrial damage],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004179,TMPO (predicted)(human) [mitochondrial damage],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003603|http://purl.obolibrary.org/obo/TXPO_1000540,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:7112,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000007112,,,,,,,,,,,,,TXPO:0004179,,,,,,,,,,,,,,,,,,,,,,TMPO (predicted)(human) [mitochondrial damage],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004178,SRPX2 (predicted)(human) [mitochondrial damage],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003603|http://purl.obolibrary.org/obo/TXPO_1000537,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:27286,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000027286,,,,,,,,,,,,,TXPO:0004178,,,,,,,,,,,,,,,,,,,,,,SRPX2 (predicted)(human) [mitochondrial damage],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004176,PCK1 (predicted)(human) [mitochondrial damage],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003603|http://purl.obolibrary.org/obo/TXPO_1000524,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:5105|PMID:29335519|PMID:26571396,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000005105,,,,,,,,,,,,,TXPO:0004176,,,,,,,,,,,,,,,,,,,,,,PCK1 (predicted)(human) [mitochondrial damage],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004177,NEAT1 (predicted)(human) [mitochondrial damage],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003603|http://purl.obolibrary.org/obo/TXPO_1000521,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:283131,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000283131,,,,,,,,,,,,,TXPO:0004177,,,,,,,,,,,,,,,,,,,,,,NEAT1 (predicted)(human) [mitochondrial damage],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000001388,ATF6B,,Other designations: Creb-related protein|cAMP response element-binding protein-related protein|cAMP responsive element binding protein-like 1|cAMP-dependent transcription factor ATF-6 beta|cAMP-responsive element-binding protein-like 1|cyclic AMP-dependent transcription factor ATF-6 beta|protein G13,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CREB-RP|G13|CREBL1,,,,,,,,,,,,6,,,,,,HPRD:02992|Ensembl:ENSG00000213676|MIM:600984|HGNC:2349|Vega:OTTHUMG00000031296,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,activating transcription factor 6 beta,,,6p21.3,,,,,,,,,,,,,,,,"GO_0003700 (EC: IEA); GO_0005515 (EC: IPI, PMID:12445808); GO_0005622 (EC: IDA, PMID:8870652); GO_0005634 (EC: IEA); GO_0005789 (EC: IEA); GO_0006351 (EC: IEA); GO_0006986 (EC: IEA); GO_0007165 (EC: TAS, PMID:8586413); GO_0016021 (EC: IEA); GO_0043565 (EC: IEA)",,,,,,,,,PMID:7686164; 8586413; 8870652; 8923003; 10644760; 11158310; 11163209; 11256944; 12445808; 12477932; 12782636; 14574404; 14656967; 14702039; 14973138; 18029348; 19693772; 19851445; 19913121; 20628086; 21139048; 21693764; 22094256; 23535732; 23577725; 23661758; 23886662; 24250222,,,,,,,,,,,,,,,OGG:3000001388,,,,,,,activating transcription factor 6 beta,,,,,,,,,,,,,Other designations: Creb-related protein|cAMP response element-binding protein-related protein|cAMP responsive element binding protein-like 1|cAMP-dependent transcription factor ATF-6 beta|cAMP-responsive element-binding protein-like 1|cyclic AMP-dependent transcription factor ATF-6 beta|protein G13,,ATF6B,,,,,,,,,,,,,,,,,,,,,,,1388,DADB-220I18.4,,,,,,,9606,,,,,,,,,,,,,,,,,,,ATF6B,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001386,ATF2,,"Other designations: activating transcription factor 2 splice variant ATF2-var2|cAMP response element-binding protein CRE-BP1|cAMP responsive element binding protein 2, formerly|cAMP-dependent transcription factor ATF-2|cAMP-responsive element-binding protein 2|cyclic AMP-dependent transcription factor ATF-2|cyclic AMP-responsive element-binding protein 2|histone acetyltransferase ATF2",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,TREB7|HB16|CREB-2|CREB2|CRE-BP1,,,,,,,,,,,,2,,,,,,MIM:123811|HPRD:00443|Vega:OTTHUMG00000132424|Ensembl:ENSG00000115966|HGNC:784,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,activating transcription factor 2,,,2q32,,,,,,,,,,,,,,,,"GO_0000980 (EC: IDA, PMID:19861239); GO_0001076 (EC: IC, PMID:19861239); GO_0001077 (EC: IEA); GO_0001102 (EC: IPI, PMID:19861239); GO_0002224 (EC: TAS); GO_0002755 (EC: TAS); GO_0002756 (EC: TAS); GO_0003151 (EC: IEA); GO_0003682 (EC: IEA); GO_0003700 (EC: IDA, PMID:8798441); GO_0003705 (EC: IC, PMID:19861239); GO_0003713 (EC: TAS, PMID:2529117); GO_0004402 (EC: IDA, PMID:10821277); GO_0005515 (EC: IPI, PMID:10327051); GO_0005634 (EC: IDA); GO_0005654 (EC: TAS); GO_0005730 (EC: IDA, Qualifier: NOT); GO_0005737 (EC: IDA); GO_0005741 (EC: IDA); GO_0006325 (EC: TAS); GO_0006355 (EC: IMP); GO_0006357 (EC: IC, PMID:19861239); GO_0006366 (EC: IC, PMID:19861239); GO_0006970 (EC: IDA); GO_0006974 (EC: IDA); GO_0006974 (EC: IMP, PMID:15916964); GO_0008140 (EC: IDA, PMID:19861239); GO_0016573 (EC: IDA, PMID:10821277); GO_0019901 (EC: IPI); GO_0031573 (EC: IMP, PMID:15916964); GO_0032915 (EC: IEA); GO_0034134 (EC: TAS); GO_0034138 (EC: TAS); GO_0034142 (EC: TAS); GO_0034146 (EC: TAS); GO_0034162 (EC: TAS); GO_0034166 (EC: TAS); GO_0035497 (EC: IDA, PMID:19861239); GO_0035666 (EC: TAS); GO_0035861 (EC: IDA, PMID:15916964); GO_0038123 (EC: TAS); GO_0038124 (EC: TAS); GO_0045087 (EC: TAS); GO_0045444 (EC: IEA); GO_0046872 (EC: IEA); GO_0046982 (EC: IEA); GO_0051090 (EC: TAS); GO_0051091 (EC: IMP, PMID:10821277); GO_0051403 (EC: TAS); GO_0060612 (EC: IEA); GO_1902110 (EC: IMP)",,,,,,,,,PMID:602896; 1641004; 1827203; 1828107; 1833307; 1838349; 2320002; 2521922; 2529117; 7535770; 7737129; 7737130; 7769693; 7774816; 8027667; 8440710; 8628277; 8654373; 8798441; 9030721; 9058782; 9110174; 9139739; 9155018; 9162092; 9207092; 9207191; 9235954; 9399639; 9405416; 9445037; 9488727; 9524124; 9628874; 9659924; 9671405; 9685505; 9748258; 9786917; 9873047; 9920921; 10066798; 10085140; 10207054; 10327051; 10357819; 10393177; 10567391; 10708586; 10821277; 10878576; 10909971; 11231009; 11259586; 11279118; 11302752; 11564156; 11566021; 11713276; 11836564; 11839738; 11932306; 12110590; 12200150; 12244047; 12270648; 12477932; 12592382; 12663670; 12697749; 12761180; 12788955; 12804775; 12805554; 12833146; 12874243; 12958075; 14499342; 14630918; 14678960; 14734562; 14988408; 15105425; 15276183; 15302935; 15304344; 15546613; 15691875; 15692053; 15878807; 15916964; 16049073; 16179804; 16303757; 16344560; 16418168; 16456540; 16511568; 16533805; 16869889; 16896160; 17036053; 17054722; 17081983; 17082618; 17244683; 17254968; 17258390; 17296604; 17337306; 17626013; 17681939; 17869487; 17875713; 18029348; 18077426; 18307971; 18348191; 18396163; 18397884; 18547788; 18671972; 18677098; 18700251; 19082758; 19135240; 19176525; 19184334; 19278424; 19331149; 19453261; 19487697; 19712049; 19822663; 19861239; 19913121; 19923798; 19944700; 20051382; 20068037; 20116378; 20195357; 20211142; 20213747; 20379614; 20398657; 20498639; 20507983; 20581861; 20619956; 20628086; 20675274; 20956942; 21098032; 21203491; 21278380; 21384452; 21444723; 21565167; 21832049; 21858082; 21890473; 21901137; 21988832; 21990224; 22275354; 22304920; 22351776; 22439931; 22685333; 22843696; 23000965; 23589174; 23591579; 23656735; 23661758; 23966864; 24289970,,,,,,,,,,,,,,,OGG:3000001386,,,,,,,activating transcription factor 2,,,,,,,,,,,,,"Other designations: activating transcription factor 2 splice variant ATF2-var2|cAMP response element-binding protein CRE-BP1|cAMP responsive element binding protein 2, formerly|cAMP-dependent transcription factor ATF-2|cAMP-responsive element-binding protein 2|cyclic AMP-dependent transcription factor ATF-2|cyclic AMP-responsive element-binding protein 2|histone acetyltransferase ATF2",,ATF2,,,,,,,,,,,,,,,,,,,,,,,1386,,,,,,,,9606,,,,,,,,,,,,,,,,,,,ATF2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/GO_0002228,natural killer cell mediated immunity,NK cell mediated immunity,The promotion of an immune response by natural killer cells through direct recognition of target cells or through the release of cytokines.,false,,,http://purl.obolibrary.org/obo/GO_0045087,,,,,,,,,,,,,,,,,,,,,,The promotion of an immune response by natural killer cells through direct recognition of target cells or through the release of cytokines.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001526,,,,,,,,,,,,NK cell mediated immunity,,,,,GO:0002228,,,,,,,,,,,,,,,,,,,,,,natural killer cell mediated immunity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0002224,TLR signaling pathway,toll-like receptor signaling pathway,Any series of molecular signals generated as a consequence of binding to a toll-like receptor. Toll-like receptors directly bind pattern motifs from a variety of microbial sources to initiate innate immune response.,false,,,http://purl.obolibrary.org/obo/TXPO_0000609,,,,,,,,,,,,,,,,,,,,,,Any series of molecular signals generated as a consequence of binding to a toll-like receptor. Toll-like receptors directly bind pattern motifs from a variety of microbial sources to initiate innate immune response.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,toll-like receptor signaling pathway,,,,,GO:0002224,,,,,,,,,,,,,,,,,,,,,,TLR signaling pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001649,caveolin-3,Cav-3,,false,,,http://purl.obolibrary.org/obo/IMR_0000515,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Cav-3,,,,,IMR:0001649,,,,,,,,,,,,,,,,,,,,,,caveolin-3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001039,group XIIB secretory phospholipase A2-like protein,,,false,,,http://purl.obolibrary.org/obo/IMR_0000283,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001039,,,,,,,,,,,,,,,,,,,,,,group XIIB secretory phospholipase A2-like protein,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100072,gastrointestinal hormones,Intestinal Hormone|Enteric Hormone,"HORMONES secreted by the gastrointestinal mucosa that affect the timing or the quality of secretion of digestive enzymes, and regulate the motor activity of the digestive system organs.",false,,,http://purl.obolibrary.org/obo/IMR_0000966,,,,,,,,,,,,,,,,,,,,MeSH:D005768,,"HORMONES secreted by the gastrointestinal mucosa that affect the timing or the quality of secretion of digestive enzymes, and regulate the motor activity of the digestive system organs.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_24621,,,,,Intestinal Hormone|Enteric Hormone,,,,,IMR:0100072,,,,,,,,,,,,,,,,,,,,,,gastrointestinal hormones,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100568,FGF-18,zFGF5,,false,,,http://purl.obolibrary.org/obo/IMR_0000049,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,zFGF5,,,,,IMR:0100568,,,,,,,,,,,,,,,,,,,,,,FGF-18,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0045595,regulation of cell differentiation,,"Any process that modulates the frequency, rate or extent of cell differentiation, the process in which relatively unspecialized cells acquire specialized structural and functional features.",false,,,http://purl.obolibrary.org/obo/TXPO_0000113,,,,,,,,,,,,,,,,,,,,,,"Any process that modulates the frequency, rate or extent of cell differentiation, the process in which relatively unspecialized cells acquire specialized structural and functional features.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0045595,,,,,,,,,,,,,,,,,,,,,,regulation of cell differentiation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0002473,"neoplastic, spontaneous",,A disposition inhering in a tumour by virtue of the bearer's disposition to spontaneously arise.,false,,,http://purl.obolibrary.org/obo/PATO_0002011,,,,,,,,,,,,,,,,,,,,,,A disposition inhering in a tumour by virtue of the bearer's disposition to spontaneously arise.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0002473,,,,,,,,,,,,,,,,,,,,,,"neoplastic, spontaneous",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_116225,nomifensine,"D,L-nomifensine|Nomiphensine|nomifensine|2-Methyl-4-phenyl-1,2,3,4-tetrahydro-isoquinolin-8-ylamine|Nomifensin|R/S-nomifensine|(+-)-Nomifensine|nomifensina|nomifensinum|8-Amino-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline|(+-)-Nomifensin|Nomifenison|Nomifensine|2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinolin-8-amine","An N-methylated tetrahydroisoquinoline carrying phenyl and amino substituents at positions C-4 and C-8, respectively.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Reaxys:484561|Drug_Central:1958|PMID:7189402|Beilstein:484561|PMID:1502708|DrugBank:DB04821|CAS:24526-64-5|LINCS:LSM-4388|PMID:24766210,,"An N-methylated tetrahydroisoquinoline carrying phenyl and amino substituents at positions C-4 and C-8, respectively.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_51039,,,,,"Nomifensine|2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinolin-8-amine",,"D,L-nomifensine|Nomiphensine|nomifensine|2-Methyl-4-phenyl-1,2,3,4-tetrahydro-isoquinolin-8-ylamine|Nomifensin|R/S-nomifensine|(+-)-Nomifensine|nomifensina|nomifensinum|8-Amino-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline|(+-)-Nomifensin|Nomifenison",,,,,,,,,,,,,,,,,,,,,CHEBI:116225,,,,nomifensine,,CHEBI:116225,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CL_0000789,alpha-beta T cell,,A T cell that expresses an alpha-beta T cell receptor complex.,false,,,http://purl.obolibrary.org/obo/CL_0000084,,,,,,,,,,,,,,,,,,,,,,A T cell that expresses an alpha-beta T cell receptor complex.,,,,,alpha-beta T cell,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CL:0000789,,,,,,,,,,,,,,,,,,,,,,alpha-beta T cell,,,,,,,http://purl.obolibrary.org/obo/cl.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CL_0000786,plasma cell,,"A terminally differentiated, post-mitotic, antibody secreting cell of the B cell lineage with the phenotype CD138-positive, surface immunonoglobulin-negative, and MHC Class II-negative. Plasma cells are oval or round with extensive rough endoplasmic reticulum, a well-developed Golgi apparatus, and a round nucleus having a characteristic cartwheel heterochromatin pattern and are devoted to producing large amounts of immunoglobulin.",false,,,http://purl.obolibrary.org/obo/CL_0000236,,,,,,,,,,,,,,,,,,,,http://purl.jp/bio/10/lsd/term/J089510,,"A terminally differentiated, post-mitotic, antibody secreting cell of the B cell lineage with the phenotype CD138-positive, surface immunonoglobulin-negative, and MHC Class II-negative. Plasma cells are oval or round with extensive rough endoplasmic reticulum, a well-developed Golgi apparatus, and a round nucleus having a characteristic cartwheel heterochromatin pattern and are devoted to producing large amounts of immunoglobulin.",,,,,plasma cell,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CL:0000786,,,,,,,,,,,,,,,,,,,,,,plasma cell,,,,,,,http://purl.obolibrary.org/obo/cl.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_50646,bone density conservation agent,anti-osteopenia drug|anti-osteoporotic drugs|anti-osteoporotics|bone density conservation drugs|anti-osteoporosis agent|antiosteoporotics|bone density conservation drug|anti-osteoporosis drugs|anti-osteoporotic agent|anti-osteoporotic drug|anti-osteoporotic agents|antiosteoporotic|anti-osteoporosis agents|bone density conservation agents|anti-osteopenia agents|anti-osteopenia drugs|anti-osteoporosis drug|anti-osteoporotic|anti-osteopenia agent,An agent that inhibits bone resorption and/or favor bone mineralization and bone regeneration. Used to heal bone fractures and to treat bone diseases such as osteopenia and osteoporosis.,false,,,http://purl.obolibrary.org/obo/CHEBI_23888,,,,,,,,,,,,,,,,,,,,,,An agent that inhibits bone resorption and/or favor bone mineralization and bone regeneration. Used to heal bone fractures and to treat bone diseases such as osteopenia and osteoporosis.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,anti-osteopenia drug|anti-osteoporotic drugs|anti-osteoporotics|bone density conservation drugs|anti-osteoporosis agent|antiosteoporotics|bone density conservation drug|anti-osteoporosis drugs|anti-osteoporotic agent|anti-osteoporotic drug|anti-osteoporotic agents|antiosteoporotic|anti-osteoporosis agents|bone density conservation agents|anti-osteopenia agents|anti-osteopenia drugs|anti-osteoporosis drug|anti-osteoporotic|anti-osteopenia agent,,,,,,,,,,,,,,,,,,,,,CHEBI:50646,,,,bone density conservation agent,,CHEBI:50646,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003161,calcium channel,,A role played by the entity which enables the facilitated diffusion of a calcium ion (by an energy-independent process) involving passage through a transmembrane aqueous pore or channel without evidence for a carrier-mediated mechanism.,false,,,http://purl.obolibrary.org/obo/TXPO_0002803,,,,,,,,,,,,,,,,,,,,IMR:0000499 (obsolete)|related molecular function GO:0005262,,A role played by the entity which enables the facilitated diffusion of a calcium ion (by an energy-independent process) involving passage through a transmembrane aqueous pore or channel without evidence for a carrier-mediated mechanism.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003161,,,,,,,,,,,,,,,,,,,,,,calcium channel,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003167,NFKB (canonical)[Glutathione depletion],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002045|http://purl.obolibrary.org/obo/TXPO_1000258,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000382,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,,,,,,TXPO:0003167,,,,,,,,,,,,,,,,,,,,,,NFKB (canonical)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003163,Activation and oligomerization of BAK protein [cell death],,"Activation and oligomerization of BAK protein is a subtype of molecular subpathway.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0001727|http://purl.obolibrary.org/obo/HINO_0016227,,,,,,,,,,,,,,,,,,,,PMID:29472455,,"Activation and oligomerization of BAK protein is a subtype of molecular subpathway.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003198|http://purl.obolibrary.org/obo/TXPO_0003199,,,,,,,,,,,,,,,,,TXPO:0003163,,,,,,,"Mitochondrial cytochrome c release can also be mediated by BAK and BAX which oligomerize and form a pore in the outer mitochondrial membrane, given the appropriate pro-apoptotic signals. BAX and BAK can also insert into the ER membrane to mediate Ca2+ release into the cytosol activating calpains.|Reactome:R-HSA-114294.2|tBID binds to its mitochondrial partner BAK to release cytochrome c.  Activated tBID results in an allosteric activation of BAK. This may induce its intramembranous oligomerization into a pore for cytochrome c efflux.",,,,,,,,,,,,,,,Activation and oligomerization of BAK protein [cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003166,CASPASE 3 (canonical)[Glutathione depletion],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002045|http://purl.obolibrary.org/obo/TXPO_0001145,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:12367|NCBI-Rat-GeneID:25402|NCBI-Human-GeneID:836,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003166,,,,,,,,,,,,,,,,,,,,,,CASPASE 3 (canonical)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003164,GLUTATHIONE (canonical)[Glutathione depletion],5-L-Glutamyl-L-cysteinylglycine|Reduced glutathione|L-Glutathione|GSH,"A tripeptide with many roles in cells. It conjugates to drugs to make them more soluble for excretion, is a cofactor for some enzymes, is involved in protein disulfide bond rearrangement and reduces peroxides.",false,,,http://purl.obolibrary.org/obo/CHEBI_16856|http://purl.obolibrary.org/obo/TXPO_0002045,,,,,,,,,,,,,,,,,,,,CHEBI:16856,,"A tripeptide with many roles in cells. It conjugates to drugs to make them more soluble for excretion, is a cofactor for some enzymes, is involved in protein disulfide bond rearrangement and reduces peroxides.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_22586,,,,,5-L-Glutamyl-L-cysteinylglycine|Reduced glutathione|L-Glutathione|GSH,,,,,TXPO:0003164,,,,,,,,,,,,,,,,,,,,,,GLUTATHIONE (canonical)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003162,JUN (canonical)[Glutathione depletion],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002045|http://purl.obolibrary.org/obo/IMR_0000416,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:16476|NCBI-Human-GeneID:3725|NCBI-Rat-GeneID:24516|PMID:14967141|PMID:18931691,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003162,,,,,,,,,,,,,,,,,,,,,,JUN (canonical)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003160,hypofunction of glycogen degradation,,Hypofunction of glycogen degradation is a subtype of hypofunction of decomposing: A process that performs a decreased or insufficient glycogen degradation.,false,,,http://purl.obolibrary.org/obo/TXPO_0000940,,,,,,,,,,,,,,,,,,,,,,Hypofunction of glycogen degradation is a subtype of hypofunction of decomposing: A process that performs a decreased or insufficient glycogen degradation.,,,http://purl.obolibrary.org/obo/GO_0005980,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_28087,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003160,,,,,,,,,,,,,,,,,,,,,,hypofunction of glycogen degradation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003165,GLUTATHIONE peroxidase (canonical)[Glutathione depletion],GSHPx-1 [Glutathione depletion]|GSHC [Glutathione depletion]|glutathione peroxidase monomer|Glutathione peroxidase 1 [Glutathione depletion],,false,,,http://purl.obolibrary.org/obo/TXPO_1000177|http://purl.obolibrary.org/obo/TXPO_0002045,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0010278,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GSHPx-1 [Glutathione depletion]|GSHC [Glutathione depletion]|glutathione peroxidase monomer|Glutathione peroxidase 1 [Glutathione depletion],,,,,TXPO:0003165,,,,,,,,,,,,,,,,,,,,,,GLUTATHIONE peroxidase (canonical)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003169,hepatic fibrosis [Glutathione depletion],,"Hepatic fibrosis is a subtype of fibrosis: A process that replaces liver tissues to fibrous connective tissues, usually as a consequence of inflammation or other injury.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0000816|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Hepatic fibrosis is a subtype of fibrosis: A process that replaces liver tissues to fibrous connective tissues, usually as a consequence of inflammation or other injury.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002373,,,,,,,,,,,TXPO:0003169,,,,,,,,,,,,,,,,,,,,,,hepatic fibrosis [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003168,inflammatory response [Glutathione depletion],,"Inflammatory response is a subtype of changing material: The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0000192|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Inflammatory response is a subtype of changing material: The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003208,,,,,,,,,,,,,,,,,,TXPO:0003168,,,,,,,,,,,,,,,,,,,,,,inflammatory response [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100783,Wnt-16,,,false,,,http://purl.obolibrary.org/obo/IMR_0000003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100783,,,,,,,,,,,,,,,,,,,,,,Wnt-16,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003305,smooth endoplasmic reticulum proliferation in hepatocyte [Hypertrophy],,"Smooth endoplasmic reticulum proliferation in hepatocyte is a subtype of endoplasmic reticulum proliferation in hepatocyte: A process that becomes larger in the number of smooth endoplasmic reticulum in hepatocyte(s).
This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy.",false,,,http://purl.obolibrary.org/obo/TXPO_0003279|http://purl.obolibrary.org/obo/TXPO_0001230,,,,,,,,,,,,,,,,,,,,,,"Smooth endoplasmic reticulum proliferation in hepatocyte is a subtype of endoplasmic reticulum proliferation in hepatocyte: A process that becomes larger in the number of smooth endoplasmic reticulum in hepatocyte(s).
This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003305,,,,,,,,,,,,,,,,,,,,,,smooth endoplasmic reticulum proliferation in hepatocyte [Hypertrophy],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003309,increasing osmotic pressure in cell [Hypertrophy],,"A process that changes the osmotic pressure of the cell to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy.",false,,,http://purl.obolibrary.org/obo/TXPO_0003308|http://purl.obolibrary.org/obo/TXPO_0003279,,,,,,,,,,,,,,,,,,,,,,"A process that changes the osmotic pressure of the cell to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003316,,,,,,,,,,,TXPO:0003309,,,,,,,,,,,,,,,,,,,,,,increasing osmotic pressure in cell [Hypertrophy],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000182,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003300,peroxisomal proliferation in hepatocyte [Hypertrophy],,"Peroxisomal proliferation in hepatocyte is a subtype of hepatocyte organelle proliferation: A process that becomes larger in the number of peroxisome in hepatocyte(s).
This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy.",false,,,http://purl.obolibrary.org/obo/TXPO_0000104|http://purl.obolibrary.org/obo/TXPO_0003279,,,,,,,,,,,,,,,,,,,,,,"Peroxisomal proliferation in hepatocyte is a subtype of hepatocyte organelle proliferation: A process that becomes larger in the number of peroxisome in hepatocyte(s).
This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003300,,,,,,,,,,,,,,,,,,,,,,peroxisomal proliferation in hepatocyte [Hypertrophy],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003301,mitochondria proliferation in hepatocyte,,Mitochondria proliferation in hepatocyte is a subtype of hepatocyte organelle proliferation: A process that becomes larger in the number of mitochondria in hepatocyte(s).,false,,,http://purl.obolibrary.org/obo/TXPO_0003303,,,,,,,,,,,,,,,,,,,,,,Mitochondria proliferation in hepatocyte is a subtype of hepatocyte organelle proliferation: A process that becomes larger in the number of mitochondria in hepatocyte(s).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003301,,,,,,,,,,,,,,,,,,,,,,mitochondria proliferation in hepatocyte,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003307,decreasing osmotic pressure.,,Decreasing osmotic pressure. is a subtype of decresing pressure: A process that changes the osmotic pressure to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0001913,,,,,,,,,,,,,,,,,,,,,,Decreasing osmotic pressure. is a subtype of decresing pressure: A process that changes the osmotic pressure to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003307,,,,,,,,,,,,,,,,,,,,,,decreasing osmotic pressure.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003302,mitochondria proliferation in hepatocyte [Hypertrophy],,"Mitochondria proliferation in hepatocyte is a subtype of hepatocyte organelle proliferation: A process that becomes larger in the number of mitochondria in hepatocyte(s).
This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy.",false,,,http://purl.obolibrary.org/obo/TXPO_0003301|http://purl.obolibrary.org/obo/TXPO_0003279,,,,,,,,,,,,,,,,,,,,,,"Mitochondria proliferation in hepatocyte is a subtype of hepatocyte organelle proliferation: A process that becomes larger in the number of mitochondria in hepatocyte(s).
This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003302,,,,,,,,,,,,,,,,,,,,,,mitochondria proliferation in hepatocyte [Hypertrophy],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003306,increasing osmotic pressure.,,Increasing osmotic pressure. is a subtype of increasing pressure: A process that changes the osmotic pressure of the object to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0001689,,,,,,,,,,,,,,,,,,,,,,Increasing osmotic pressure. is a subtype of increasing pressure: A process that changes the osmotic pressure of the object to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003306,,,,,,,,,,,,,,,,,,,,,,increasing osmotic pressure.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003308,increasing osmotic pressure in cell,,Increasing osmotic pressure in cell is a subtype of increasing osmotic pressure.: A process that changes the osmotic pressure of the cell to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0003306,,,,,,,,,,,,,,,,,,,,,,Increasing osmotic pressure in cell is a subtype of increasing osmotic pressure.: A process that changes the osmotic pressure of the cell to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003308,,,,,,,,,,,,,,,,,,,,,,increasing osmotic pressure in cell,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003303,hepatocyte organelle proliferation,,Hepatocyte organelle proliferation is a subtype of increasing number of organelle: A process that becomes larger in the number of organelles in hepatocyte(s).,false,,,http://purl.obolibrary.org/obo/TXPO_0000108,,,,,,,,,,,,,,,,,,,,,,Hepatocyte organelle proliferation is a subtype of increasing number of organelle: A process that becomes larger in the number of organelles in hepatocyte(s).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003303,,,,,,,,,,,,,,,,,,,,,,hepatocyte organelle proliferation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000182,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003304,hepatocyte organelle proliferation [Hypertrophy],,"Hepatocyte organelle proliferation is a subtype of increasing number of organelle: A process that becomes larger in the number of organelles in hepatocyte(s).
This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy.",false,,,http://purl.obolibrary.org/obo/TXPO_0003303|http://purl.obolibrary.org/obo/TXPO_0003279,,,,,,,,,,,,,,,,,,,,,,"Hepatocyte organelle proliferation is a subtype of increasing number of organelle: A process that becomes larger in the number of organelles in hepatocyte(s).
This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003305|http://purl.obolibrary.org/obo/TXPO_0003300|http://purl.obolibrary.org/obo/TXPO_0003302,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003297,,,,,,,,,,,TXPO:0003304,,,,,,,,,,,,,,,,,,,,,,hepatocyte organelle proliferation [Hypertrophy],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0000146,temperature (quality),,A physical attribure of the thermal energy of a system.,false,,,http://purl.obolibrary.org/obo/TXPO_0002417|http://purl.obolibrary.org/obo/BFO_0000019,,,,,,,,,,,,,,,,,,,,,,A physical attribure of the thermal energy of a system.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0000146,,,,,,,,,,,,,,,,,,,,,,temperature (quality),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0000141,structure (quality),,"A morphology quality inhering in a bearer by virtue of the bearer's relative position, shape, arrangements and connectivity of an organism's various parts; the pattern underlying its form.",false,,,http://purl.obolibrary.org/obo/BFO_0000019,,,,,,,,,,,,,,,,,,,,,,"A morphology quality inhering in a bearer by virtue of the bearer's relative position, shape, arrangements and connectivity of an organism's various parts; the pattern underlying its form.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0000141,,,,,,,,,,,,,,,,,,,,,,structure (quality),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100837,SOCS-1,TIP-3|STAT induced STAT inhibitor 1|Suppressor of cytokine signaling 1|JAK-binding protein|Tec-interacting protein 3|JAB|SSI-1,,false,,,http://purl.obolibrary.org/obo/IMR_0000460,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TIP-3|STAT induced STAT inhibitor 1|Suppressor of cytokine signaling 1|JAK-binding protein|Tec-interacting protein 3|JAB|SSI-1,,,,,IMR:0100837,,,,,,,,,,,,,,,,,,,,,,SOCS-1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0200140,L-Lysine,,,false,,,http://purl.obolibrary.org/obo/CHEBI_33709,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0200140,,,,,,,,,,,,,,,,,,,,,,L-Lysine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000386,IRF family,interferon regulatory factor family,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,interferon regulatory factor family,,,,,IMR:0000386,,,,,,,,,,,,,,,,,,,,,,IRF family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_29132,"N-acetyl-1,4-benzoquinone imine","InChI=1S/C8H7NO2/c1-6(10)9-7-2-4-8(11)5-3-7/h2-5H,1H3|NAPQI|N-(4-oxocyclohexa-2,5-dien-1-ylidene)acetamide",A ketoimine that has formula C8H7NO2.,false,,,http://purl.obolibrary.org/obo/CHEBI_24783,,,,,,,,,,,,,,,,,,,,CHEBI:29132|http://www.reactome.org/cgi-bin/eventbrowser_st_id?ST_ID=R-HSA-76397,,A ketoimine that has formula C8H7NO2.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"N-(4-oxocyclohexa-2,5-dien-1-ylidene)acetamide",,"InChI=1S/C8H7NO2/c1-6(10)9-7-2-4-8(11)5-3-7/h2-5H,1H3|NAPQI",,,CHEBI:29132,,,,,,,,,,,,,,,,,,,,,,"N-acetyl-1,4-benzoquinone imine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000418,TCF/LEF-1 family,T-cell factor/lymphoid-enhancer factor,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,T-cell factor/lymphoid-enhancer factor,,,,,IMR:0000418,,,,,,,,,,,,,,,,,,,,,,TCF/LEF-1 family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0001577,increased permeability,high permeability,A permeability which is relatively high.,false,,,http://purl.obolibrary.org/obo/TXPO_0003744|http://purl.obolibrary.org/obo/PATO_0000970,,,,,,,,,,,,,,,,,,,,,,A permeability which is relatively high.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,high permeability,,,,,PATO:0001577,,,,,,,,,,,,,,,,,,,,,,increased permeability,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0001575,decreased pressure,low pressure,A pressure which is relatively low.,false,,,http://purl.obolibrary.org/obo/TXPO_0002418|http://purl.obolibrary.org/obo/PATO_0001025,,,,,,,,,,,,,,,,,,,,,,A pressure which is relatively low.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,low pressure,,,,,PATO:0001575,,,,,,,,,,,,,,,,,,,,,,decreased pressure,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0001574,flow rate quality,,A physical quality inhering in a bearer by virtue of the bearer's motion characteristic.,false,,,http://purl.obolibrary.org/obo/PATO_0001906|http://purl.obolibrary.org/obo/TXPO_0002462,,,,,,,,,,,,,,,,,,,,,,A physical quality inhering in a bearer by virtue of the bearer's motion characteristic.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0001574,,,,,,,,,,,,,,,,,,,,,,flow rate quality,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0001578,decreased permeability,low permeability,A permeability which is relatively low.,false,,,http://purl.obolibrary.org/obo/TXPO_0003744|http://purl.obolibrary.org/obo/PATO_0000970,,,,,,,,,,,,,,,,,,,,,,A permeability which is relatively low.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,low permeability,,,,,PATO:0001578,,,,,,,,,,,,,,,,,,,,,,decreased permeability,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0001576,increased pressure,,A pressure which is relatively high.,false,,,http://purl.obolibrary.org/obo/TXPO_0002418|http://purl.obolibrary.org/obo/PATO_0001025,,,,,,,,,,,,,,,,,,,,,,A pressure which is relatively high.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0001576,,,,,,,,,,,,,,,,,,,,,,increased pressure,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/NCIT_C19427,hepatocarcinogenesis,liver carcinogenesis,The processes which result in cancers in the liver.,false,,,http://purl.obolibrary.org/obo/NCIT_C18078,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C19427|ncit:C19427,,The processes which result in cancers in the liver.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,liver carcinogenesis,,,,,NCIT:C19427,,,,,,,,,,,,,,,,,,,,,,hepatocarcinogenesis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000283927,NUDT7,,Other designations: peroxisomal coenzyme A diphosphatase NUDT7,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,16,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,nudix (nucleoside diphosphate linked moiety X)-type motif 7,,,16q23.1,,,,,,,,,,,,,,,,"GO_0000287 (EC: IEA); GO_0003674 (EC: ND); GO_0003986 (EC: ISS); GO_0005102 (EC: IPI); GO_0005777 (EC: ISS); GO_0008150 (EC: ND); GO_0009132 (EC: IEA); GO_0015938 (EC: ISS); GO_0030145 (EC: IEA); GO_0030515 (EC: ISS); GO_0046356 (EC: ISS); GO_0050072 (EC: ISS, Qualifier: NOT); GO_0050873 (EC: IEA)",,,,,,,,,PMID: 11415433; 15146197; 15616553; 19844255; 20178365; 21145461; 23251661; 24250222,,,,,,,,,,,,,,,OGG:3000283927,,,,,,,nudix (nucleoside diphosphate linked moiety X)-type motif 7,,,,,,,,,,,,,Other designations: peroxisomal coenzyme A diphosphatase NUDT7,,NUDT7,,,,,,,,,,,,,,,,,,,,,,,283927,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,NUDT7,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0001020,ARID5A [Ground glass appearance],MRF1,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:316327|NCBI-Mouse-GeneID:214855|NCBI-Human-GeneID:10865|OMIM: 611583|PMID:15941852|PMID:29358370,,,,,,,,,,,,,,,AT-Rich Interaction Domain 5A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MRF1,,,,,TXPO:0001020,,,,,,,,,,,,,,,,,,,,,,ARID5A [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001026,apoptotic process [Ground glass appearance],,"A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/GO_0006915,,,,,,,,,,,,,,,,,,,,,,"A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000781,http://purl.obolibrary.org/obo/TXPO_0000777,,,,,,,,,,,,,,,,,TXPO:0001026,,,,,,,,,,,,,,,,,,,,,,apoptotic process [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001023,peroxisomal proliferation in hepatocyte (moderate) [Eosinophilic granular degeneration],,"Peroxisomal proliferation in hepatocyte is a subtype of hepatocyte organelle proliferation: A process that becomes larger in the number of peroxisome in hepatocyte(s). The degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/TXPO_0000105,,,,,,,,,,,,,,,,,,,,,,"Peroxisomal proliferation in hepatocyte is a subtype of hepatocyte organelle proliferation: A process that becomes larger in the number of peroxisome in hepatocyte(s). The degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003536,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001045,,,,,,http://purl.obolibrary.org/obo/TXPO_0002025,,,,,,,,,,,TXPO:0001023,,,,,,,"Humanized mice (ie, PPARalpha-null mice transfected with human PPAR alpha) also fail to respond with hepatocellular and peroxisomal proliferation to fibrates, indicating that the human receptor cannot signal for proliferation.|Humans do not respond with hepatocellular and peroxisomal proliferation to fibrates and express PPARalpha at low levels and often in nonfunctional forms.

Casarett & Doull's Toxicology: The Basic Science of Poisons, Eighth Edition",,,,,,,,,,,,,,,peroxisomal proliferation in hepatocyte (moderate) [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCBITaxon_9989,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001029,increasing demand for response to mitochondrial oxidative stress [Mitochondrial disorder],,"Increasing demand for response to mitochondrial oxidative stress is a subtype of increasing the demand for response to oxidative stress: A process that changes the functional demand for the response to the mitochondrial oxidative stress to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0002301,,,,,,,,,,,,,,,,,,,,PMID:29335519|PMID:23299992,,"Increasing demand for response to mitochondrial oxidative stress is a subtype of increasing the demand for response to oxidative stress: A process that changes the functional demand for the response to the mitochondrial oxidative stress to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001990,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004271|http://purl.obolibrary.org/obo/TXPO_0004341|http://purl.obolibrary.org/obo/TXPO_0004343|http://purl.obolibrary.org/obo/TXPO_0004342|http://purl.obolibrary.org/obo/TXPO_0004344|http://purl.obolibrary.org/obo/TXPO_0004269,,,,,,,,,,,TXPO:0001029,,,,,,,,,,,,,,,,,,,,,,increasing demand for response to mitochondrial oxidative stress [Mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001022,GPT (mol),ALT1|glutamic--pyruvic transaminase,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:76282|NCBI-Rat-GeneID:81670|NCBI-Human-GeneID:2875,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001027,,,,,ALT1|glutamic--pyruvic transaminase,,,,,TXPO:0001022,,,,,,,,,,,,,,,,,,,,,,GPT (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001028,tumor growth [Ground glass appearance],,"Tumor growth is a subtype of cell growth: The process in which a tumor cell increases in size.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0000766|http://purl.obolibrary.org/obo/TXPO_0001728,,,,,,,,,,,,,,,,,,,,PMID:2379175|PMID:22460906|PMID:25956158,,"Tumor growth is a subtype of cell growth: The process in which a tumor cell increases in size.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003983|http://purl.obolibrary.org/obo/TXPO_0001524,,,,,,,,,,,,,,,,,TXPO:0001028,,,,,,,,,,,,,,,,,,,,,,tumor growth [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCBITaxon_9989,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001027,Alanine transaminase,Glutamic Pyruvic Transaminase|EC 2.6.1.2,An enzyme that catalyzes L-alanine + 2-oxoglutarate = pyruvate + L-glutamate,false,,,http://purl.obolibrary.org/obo/TXPO_0000606,,,,,,,,,,,,,,,,,,,,,,An enzyme that catalyzes L-alanine + 2-oxoglutarate = pyruvate + L-glutamate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Glutamic Pyruvic Transaminase|EC 2.6.1.2,,,,,TXPO:0001027,,,,,,,,,,,,,,,,,,,,,,Alanine transaminase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001024,GPT (canonical)[lipidosis],ALT1|glutamic--pyruvic transaminase,,false,,,http://purl.obolibrary.org/obo/TXPO_0001022|http://purl.obolibrary.org/obo/TXPO_0003516,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:76282|NCBI-Rat-GeneID:81670|NCBI-Human-GeneID:2875,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001027,,,,,ALT1|glutamic--pyruvic transaminase,,,,,TXPO:0001024,,,,,,,,,,,,,,,,,,,,,,GPT (canonical)[lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001021,aspartate transaminase,EC 2.6.1.1,An enzyme that catalyzes L-aspartate + 2-oxoglutarate = oxaloacetate + L-glutamate,false,,,http://purl.obolibrary.org/obo/TXPO_0000606,,,,,,,,,,,,,,,,,,,,Wikipedia:Aspartate_transaminase,,An enzyme that catalyzes L-aspartate + 2-oxoglutarate = oxaloacetate + L-glutamate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,EC 2.6.1.1,,,,,TXPO:0001021,,,,,,,,,,,,,,,,,,,,,,aspartate transaminase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001025,peroxisomal proliferation in hepatocyte (severe) [Eosinophilic granular degeneration],,"Peroxisomal proliferation in hepatocyte is a subtype of hepatocyte organelle proliferation: A process that becomes larger in the number of peroxisome in hepatocyte(s). The degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/TXPO_0000105,,,,,,,,,,,,,,,,,,,,,,"Peroxisomal proliferation in hepatocyte is a subtype of hepatocyte organelle proliferation: A process that becomes larger in the number of peroxisome in hepatocyte(s). The degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003537,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001045,,,,,,http://purl.obolibrary.org/obo/TXPO_0002029|http://purl.obolibrary.org/obo/TXPO_0000127,,,,,,,,,,,TXPO:0001025,,,,,,,"Humanized mice (ie, PPARalpha-null mice transfected with human PPAR alpha) also fail to respond with hepatocellular and peroxisomal proliferation to fibrates, indicating that the human receptor cannot signal for proliferation.|Humans do not respond with hepatocellular and peroxisomal proliferation to fibrates and express PPARalpha at low levels and often in nonfunctional forms.

Casarett & Doull's Toxicology: The Basic Science of Poisons, Eighth Edition",,,,,,,,,,,,,,,peroxisomal proliferation in hepatocyte (severe) [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCBITaxon_9989,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0045787,positive regulation of cell cycle,positive regulation of cell cycle progression|positive regulation of progression through cell cycle,Any process that activates or increases the rate or extent of progression through the cell cycle.,false,,,http://purl.obolibrary.org/obo/TXPO_0001223|http://purl.obolibrary.org/obo/GO_0051726,,,,,,,,,,,,,,,,,,,,,,Any process that activates or increases the rate or extent of progression through the cell cycle.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,positive regulation of cell cycle progression|positive regulation of progression through cell cycle,,,,,GO:0045787,,,,,,,,,,,,,,,,,,,,,,positive regulation of cell cycle,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0007049,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010567,40S ribosomal protein SA,40S small ribosomal protein P4|laminin receptor,,false,,,http://purl.obolibrary.org/obo/IMR_0000896,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,40S small ribosomal protein P4|laminin receptor,,,,,IMR:0010567,,,,,,,,,,,,,,,,,,,,,,40S ribosomal protein SA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_77402,EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor,"EC 1.8.1.12 inhibitors|NADPH2:trypanothione oxidoreductase inhibitors|N(1),N(8)-bis(glutathionyl)spermidine reductase inhibitor|NADPH:trypanothione oxidoreductase inhibitors|trypanothione:NADP(+) oxidoreductase inhibitors|EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitors|N(1),N(8)-bis(glutathionyl)spermidine reductase inhibitors|NADPH2:trypanothione oxidoreductase inhibitor|trypanothione-disulfide reductase (EC 1.8.1.12) inhibitors|trypanothione reductase inhibitors|trypanothione:NADP(+) oxidoreductase inhibitor|trypanothione reductase inhibitor|EC 1.8.1.12 inhibitor|trypanothione-disulfide reductase (EC 1.8.1.12) inhibitor|NADPH:trypanothione oxidoreductase inhibitor","An EC 1.8.1.* (oxidoreductase acting on sulfur group of donors, NAD+ or NADP+ as acceptor) inhibitor that interferes with the action of trypanothione-disulfide reductase (EC 1.8.1.12).",false,,,http://purl.obolibrary.org/obo/CHEBI_76869,,,,,,,,,,,,,,,,,,,,,,"An EC 1.8.1.* (oxidoreductase acting on sulfur group of donors, NAD+ or NADP+ as acceptor) inhibitor that interferes with the action of trypanothione-disulfide reductase (EC 1.8.1.12).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"EC 1.8.1.12 inhibitors|NADPH2:trypanothione oxidoreductase inhibitors|N(1),N(8)-bis(glutathionyl)spermidine reductase inhibitor|NADPH:trypanothione oxidoreductase inhibitors|trypanothione:NADP(+) oxidoreductase inhibitors|EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitors|N(1),N(8)-bis(glutathionyl)spermidine reductase inhibitors|NADPH2:trypanothione oxidoreductase inhibitor|trypanothione-disulfide reductase (EC 1.8.1.12) inhibitors|trypanothione reductase inhibitors|trypanothione:NADP(+) oxidoreductase inhibitor|trypanothione reductase inhibitor|EC 1.8.1.12 inhibitor|trypanothione-disulfide reductase (EC 1.8.1.12) inhibitor|NADPH:trypanothione oxidoreductase inhibitor",,,,,,,,,,,,,,,,,,,,,CHEBI:77402,,,,EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor,,CHEBI:77402,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100609,cyclin A2,cyclin A|CGA2|Cyclin A|Cyclin A2,,false,,,http://purl.obolibrary.org/obo/IMR_0100607,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0010768|IMR:0011591,cyclin A|CGA2|Cyclin A|Cyclin A2,,,,,IMR:0100609,,,,,,,,,,,,,,,,,,,,,,cyclin A2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000057546,PDP2,,"Other designations: PDPC 2|[Pyruvate dehydrogenase [acetyl-transferring]]-phosphatase 2, mitochondrial|protein phosphatase 2C, magnesium-dependent, catalytic subunit 2|pyruvate dehydrogenase phosphatase catalytic subunit 2|pyruvate dehydrogenase phosphatase isoenzyme 2|pyruvate dehydrogenase phosphatase, catalytic subunit 2",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,PPM2C2,,,,,,,,,,,,16,,,,,,Ensembl:ENSG00000172840|HPRD:15112|HGNC:30263|MIM:615499|Vega:OTTHUMG00000137512,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,pyruvate dehyrogenase phosphatase catalytic subunit 2,,,16q22.1,,,,,,,,,,,,,,,,GO_0004724 (EC: IEA); GO_0004741 (EC: IEA); GO_0005759 (EC: TAS); GO_0006090 (EC: TAS); GO_0010510 (EC: TAS); GO_0035970 (EC: IEA); GO_0044237 (EC: TAS); GO_0044281 (EC: TAS); GO_0046872 (EC: IEA),,,,,,,,,PMID: 8889548; 9651365; 10718198; 11577086; 12477932; 12676647; 15489334; 17207965; 20208177; 20525856; 20877624; 20972266; 21890473,,,,,,,,,,,,,,,OGG:3000057546,,,,,,,pyruvate dehyrogenase phosphatase catalytic subunit 2,,,,,,,,,,,,,"Other designations: PDPC 2|[Pyruvate dehydrogenase [acetyl-transferring]]-phosphatase 2, mitochondrial|protein phosphatase 2C, magnesium-dependent, catalytic subunit 2|pyruvate dehydrogenase phosphatase catalytic subunit 2|pyruvate dehydrogenase phosphatase isoenzyme 2|pyruvate dehydrogenase phosphatase, catalytic subunit 2",,PDP2,,,,,,,,,,,,,,,,,,,,,,,57546,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,PDP2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0002205,MGST1 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0002089,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:4257|NCBI-Rat-GeneID:171341|NCBI-Mouse-GeneID:56615,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000004257,,,,,,,,,,,,,TXPO:0002205,,,,,,,,,,,,,,,,,,,,,,MGST1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002200,necrosis [ER stress],,"A type of cell death that is morphologically characterized by an increasingly translucent cytoplasm, swelling of organelles, minor ultrastructural modifications of the nucleus (specifically, dilatation of the nuclear membrane and condensation of chromatin into small, irregular, circumscribed patches) and increased cell volume (oncosis), culminating in the disruption of the plasma membrane and subsequent loss of intracellular contents. Necrotic cells do not fragment into discrete corpses as their apoptotic counterparts do. Moreover, their nuclei remain intact and can aggregate and accumulate in necrotic tissues.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/GO_0070265,,,,,,,,,,,,,,,,,,,,,,"A type of cell death that is morphologically characterized by an increasingly translucent cytoplasm, swelling of organelles, minor ultrastructural modifications of the nucleus (specifically, dilatation of the nuclear membrane and condensation of chromatin into small, irregular, circumscribed patches) and increased cell volume (oncosis), culminating in the disruption of the plasma membrane and subsequent loss of intracellular contents. Necrotic cells do not fragment into discrete corpses as their apoptotic counterparts do. Moreover, their nuclei remain intact and can aggregate and accumulate in necrotic tissues.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000342,,,,,,,,,,,TXPO:0002200,,,,,,,,,,,,,,,,,,,,,,necrosis [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002209,hypofunction of ATP biosynthesis [ER stress],,"Hypofunction of ATP biosynthesis is a subtype of hypofunction of biosynthesis: A process that performs a decreased or insufficient ATP biosynthesis.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001722|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"Hypofunction of ATP biosynthesis is a subtype of hypofunction of biosynthesis: A process that performs a decreased or insufficient ATP biosynthesis.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002200,,,,,,,,,,,TXPO:0002209,,,,,,,,,,,,,,,,,,,,,,hypofunction of ATP biosynthesis [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002208,MGST3 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0002089,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:66447|NCBI-Human-GeneID:4259|NCBI-Rat-GeneID:289197,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000004259,,,,,,,,,,,,,TXPO:0002208,,,,,,,,,,,,,,,,,,,,,,MGST3 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002202,hepatic cirrhosis,,Hepatic cirrhosis is a subtype of changing hardness: A process that changes the hardness of the liver to become hard due to the replacement of normal liver tissue to scar tissue.,false,,,http://purl.obolibrary.org/obo/TXPO_0000424,,,,,,,,,,,,,,,,,,,,,,Hepatic cirrhosis is a subtype of changing hardness: A process that changes the hardness of the liver to become hard due to the replacement of normal liver tissue to scar tissue.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002202,,,,,,,,,,,,,,,,,,,,,,hepatic cirrhosis,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0000386,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002204,ER-associated misfolded protein catabolic process [ER stress],,"The chemical reactions and pathways resulting in the breakdown of misfolded proteins transported from the endoplasmic reticulum and targeted to cytoplasmic proteasomes for degradation.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/GO_0071712|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways resulting in the breakdown of misfolded proteins transported from the endoplasmic reticulum and targeted to cytoplasmic proteasomes for degradation.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000516|http://purl.obolibrary.org/obo/TXPO_0000456,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002479,,,,,,,,,,,TXPO:0002204,,,,,,,,,,,,,,,,,,,,,,ER-associated misfolded protein catabolic process [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005737,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002203,hepatic cirrhosis [ER stress],,"Hepatic cirrhosis is a subtype of changing hardness: A process that changes the hardness of the liver to become hard due to the replacement of normal liver tissue to scar tissue.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002202|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"Hepatic cirrhosis is a subtype of changing hardness: A process that changes the hardness of the liver to become hard due to the replacement of normal liver tissue to scar tissue.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002203,,,,,,,,,,,,,,,,,,,,,,hepatic cirrhosis [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002207,protein refolding [ER stress (early stage)],,"The process carried out by a cell that restores the biological activity of an unfolded or misfolded protein, using helper proteins such as chaperones.
This entity is a specific course-dependent process. This process can constitute the course of ER stress (early stage).",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/GO_0042026,,,,,,,,,,,,,,,,,,,,PMID:23637286,,"The process carried out by a cell that restores the biological activity of an unfolded or misfolded protein, using helper proteins such as chaperones.
This entity is a specific course-dependent process. This process can constitute the course of ER stress (early stage).",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002540,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002117,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002458,,,,,,,,,,,TXPO:0002207,,,,,,,,,,,,,,,,,,,,,,protein refolding [ER stress (early stage)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005783,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002201,insulin resistance (process) [ER stress],,"Insulin resistance (process) is a subtype of decreasing sensitivity: A process that changes the sensitivity to the circulating insulin to be lower.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/TXPO_0002189,,,,,,,,,,,,,,,,,,,,PMID:27325692,,"Insulin resistance (process) is a subtype of decreasing sensitivity: A process that changes the sensitivity to the circulating insulin to be lower.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001968|http://purl.obolibrary.org/obo/TXPO_0002411,,,,,,http://purl.obolibrary.org/obo/TXPO_0000074|http://purl.obolibrary.org/obo/TXPO_0002172,,,,,,,,,,,TXPO:0002201,,,,,,,,,,,,,,,,,,,,,,insulin resistance (process) [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002206,MGST2 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0002089,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:211666|NCBI-Human-GeneID:4258|NCBI-Rat-GeneID:295037,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000004258,,,,,,,,,,,,,TXPO:0002206,,,,,,,,,,,,,,,,,,,,,,MGST2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000422,C/EBP,CCAAT/enhancer binding protein,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,CCAAT/enhancer binding protein,,,,,IMR:0000422,,,,,,,,,,,,,,,,,,,,,,C/EBP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000168,E-cadherin,Arc-1|Uvomorulin|L-CAM|cadherin-1|cell-CAM120/80|Epithelial-cadherin,,false,,,http://purl.obolibrary.org/obo/IMR_0000167,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Arc-1|Uvomorulin|L-CAM|cadherin-1|cell-CAM120/80|Epithelial-cadherin,,,,,IMR:0000168,,,,,,,,,,,,,,,,,,,,,,E-cadherin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100069,melatonin,Melatonin|N-Acetyl-5-methoxytryptamine,,false,,,http://purl.obolibrary.org/obo/IMR_0002121,,,,,,,,,,,,,,,,,,,,MeSH:D008550,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_24621,,,,IMR:0200455,Melatonin|N-Acetyl-5-methoxytryptamine,,,,,IMR:0100069,,,,,,,,,,,,,,,,,,,,,,melatonin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000474,NF-L,,,false,,,http://purl.obolibrary.org/obo/IMR_0000203,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000474,,,,,,,,,,,,,,,,,,,,,,NF-L,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_55324,gastrointestinal drug,gastrointestinal drugs|gastrointestinal agents|gastrointestinal agent,"A drug used for its effects on the gastrointestinal system, e.g. controlling gastric acidity, regulating gastrointestinal motility and water flow, and improving digestion.",false,,,http://purl.obolibrary.org/obo/CHEBI_23888,,,,,,,,,,,,,,,,,,,,,,"A drug used for its effects on the gastrointestinal system, e.g. controlling gastric acidity, regulating gastrointestinal motility and water flow, and improving digestion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,gastrointestinal drugs|gastrointestinal agents|gastrointestinal agent,,,,,,,,,,,,,,,,,,,,,CHEBI:55324,,,,gastrointestinal drug,,CHEBI:55324,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001633,Rab39B,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001633,,,,,,,,,,,,,,,,,,,,,,Rab39B,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000811,CD80,B7.1,"B7.1 (CD80) and B7.2 (CD86) - the two structurally homologous ligands of CD28 - are expressed by professional antigen-presenting cells (APCs), such as dendritic cells (DCs), macrophages and activated B cells, belong to the immunoglobulin superfamily and might exist as dimers and monomers, respectively.",false,,,http://purl.obolibrary.org/obo/IMR_0002950,,,,,,,,,,,,,,,,,,,,,,"B7.1 (CD80) and B7.2 (CD86) - the two structurally homologous ligands of CD28 - are expressed by professional antigen-presenting cells (APCs), such as dendritic cells (DCs), macrophages and activated B cells, belong to the immunoglobulin superfamily and might exist as dimers and monomers, respectively.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,B7.1,,,,,IMR:0000811,,,,,,,,,,,,,,,,,,,,,,CD80,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000644,decreasing lipid,,Decreasing lipid is a subtype of decreasing quantity: A process that changes the quantity of the lipid to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000396,,,,,,,,,,,,,,,,,,,,,,Decreasing lipid is a subtype of decreasing quantity: A process that changes the quantity of the lipid to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000644,,,,,,,,,,,,,,,,,,,,,,decreasing lipid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000649,ACOT12 metastasis inhibitor (human)[Eosinophilic granular degeneration],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001034|http://purl.obolibrary.org/obo/TXPO_1000021,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:134526|PMID:30661930,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000649,,,,,,,,,,,,,,,,,,,,,,ACOT12 metastasis inhibitor (human)[Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000648,eosinogranular degeneration dependent molecule  (mice),,"Eosinogranular degeneration dependent molecule is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of eosinogranular degeneration as a gene product.
Gene profile:Mouse/Liver/",false,,,http://purl.obolibrary.org/obo/TXPO_0000835,,,,,,,,,,,,,,,,,,,,,,"Eosinogranular degeneration dependent molecule is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of eosinogranular degeneration as a gene product.
Gene profile:Mouse/Liver/",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000648,,,,,,,,,,,,,,,,,,,,,,eosinogranular degeneration dependent molecule  (mice),,,,,,,,,,,http://purl.obolibrary.org/obo/NCBITaxon_10090,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000643,inreasing blood AST concentration,inreasing blood GOT concentration,Increasing AST concentration in blood is a subtype of increasing concentration: A process that changes the aspartate amino transferase (AST) concentration  to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000352,,,,,,,,,,,,,,,,,,,,http://purl.bioontology.org/ontology/MEDDRA/10003544,,Increasing AST concentration in blood is a subtype of increasing concentration: A process that changes the aspartate amino transferase (AST) concentration  to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,inreasing blood GOT concentration,,,,,TXPO:0000643,,,,,,,,,,,,,,,,,,,,,,inreasing blood AST concentration,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000645,Hmox1 (rat)[Cell death],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000196|http://purl.obolibrary.org/obo/TXPO_0000839,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24451,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000645,,,,,,,,,,,,,,,,,,,,,,Hmox1 (rat)[Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000640,Eif2s1 (rat)[Cell death],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000839|http://purl.obolibrary.org/obo/TXPO_1000132,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:54318|PMID:24623724,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003685|http://purl.obolibrary.org/obo/CHEBI_68495,,,,,,,,,,TXPO:0000640,,,,,,,,,,,,,,,,,,,,,,Eif2s1 (rat)[Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000641,Osgin1 (rat)[Cell death],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000839|http://purl.obolibrary.org/obo/TXPO_1000272,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:171493,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000641,,,,,,,,,,,,,,,,,,,,,,Osgin1 (rat)[Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000642,Txrnd1 (rat)[Cell death],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000390|http://purl.obolibrary.org/obo/TXPO_0000839,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_22586,,,,,,,,,,TXPO:0000642,,,,,,,,,,,,,,,,,,,,,,Txrnd1 (rat)[Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000647,negative regulation of phospholipase C mediated phospholipid degradation [Phospholipidosis],,"Negative regulation of phospholipase C mediated phospholipid degradation is a subtype of negative regulation of phospholipid degradation: A process that stops, prevents, or reduces the frequency, rate or extent of phospholipase C mediated phospholipid degradation.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000556,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of phospholipase C mediated phospholipid degradation is a subtype of negative regulation of phospholipid degradation: A process that stops, prevents, or reduces the frequency, rate or extent of phospholipase C mediated phospholipid degradation.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000647,,,,,,,,,,,,,,,,,,,,,,negative regulation of phospholipase C mediated phospholipid degradation [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000646,negative regulation of phospholipase C mediated phosphatidylcholine degradation [Phospholipidosis - phosphatidylcholine disorder],,"Negative regulation of phospholipase C mediated phosphatidylcholine degradation is a subtype of negative regulation of phosphatidylcholine catabolic process: A process that stops, prevents, or reduces the frequency, rate or extent of phospholipase C mediated phosphatidylcholine degradation.
This process is dependent on the phosphatidylcholine disorder and can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000647|http://purl.obolibrary.org/obo/TXPO_0000621,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of phospholipase C mediated phosphatidylcholine degradation is a subtype of negative regulation of phosphatidylcholine catabolic process: A process that stops, prevents, or reduces the frequency, rate or extent of phospholipase C mediated phosphatidylcholine degradation.
This process is dependent on the phosphatidylcholine disorder and can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000646,,,,,,,,,,,,,,,,,,,,,,negative regulation of phospholipase C mediated phosphatidylcholine degradation [Phospholipidosis - phosphatidylcholine disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_35679,antilipemic drug,antihyperlipidemics|hypolipidemic agents|hypolipidemic agent|antihyperlipidemic|antihyperlipidemic agents|antihyperlipemic|antihyperlipidemic drugs|antilipemic drugs|antihyperlipidemic agent|antihyperlipemics|antilipemic|antihyperlipidemic drug|antilipemics,A substance used to treat hyperlipidemia (an excess of lipids in the blood).,false,,,http://purl.obolibrary.org/obo/CHEBI_23888,,,,,,,,,,,,,,,,,,,,,,A substance used to treat hyperlipidemia (an excess of lipids in the blood).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,antihyperlipidemics|hypolipidemic agents|hypolipidemic agent|antihyperlipidemic|antihyperlipidemic agents|antihyperlipemic|antihyperlipidemic drugs|antilipemic drugs|antihyperlipidemic agent|antihyperlipemics|antilipemic|antihyperlipidemic drug|antilipemics,,,,,,,,,,,,,,,,,,,,,CHEBI:35679,,,,antilipemic drug,,CHEBI:35679,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0048770,pigment granule,,"A small, subcellular membrane-bounded vesicle containing pigment and/or pigment precursor molecules. Pigment granule biogenesis is poorly understood, as pigment granules are derived from multiple sources including the endoplasmic reticulum, coated vesicles, lysosomes, and endosomes.",false,,,http://purl.obolibrary.org/obo/GO_0031982,,,,,,,,,,,,,,,,,,,,,,"A small, subcellular membrane-bounded vesicle containing pigment and/or pigment precursor molecules. Pigment granule biogenesis is poorly understood, as pigment granules are derived from multiple sources including the endoplasmic reticulum, coated vesicles, lysosomes, and endosomes.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0048770,,,,,,,,,,,,,,,,,,,,,,pigment granule,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001450,TLR2,Toll-like receptor 2,,false,,,http://purl.obolibrary.org/obo/IMR_0000124,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Toll-like receptor 2,,,,,IMR:0001450,,,,,,,,,,,,,,,,,,,,,,TLR2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0002806,FOXO3,,,false,,,http://purl.obolibrary.org/obo/IMR_0002804,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0002806,,,,,,,,,,,,,,,,,,,,,,FOXO3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_83056,Daphnia magna metabolite,Daphnia magna metabolites,A Daphnia metabolite produced by the species Daphnia magna.,false,,,http://purl.obolibrary.org/obo/CHEBI_83057,,,,,,,,,,,,,,,,,,,,,,A Daphnia metabolite produced by the species Daphnia magna.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Daphnia magna metabolites,,,,,,,,,,,,,,,,,,,,,CHEBI:83056,,,,Daphnia magna metabolite,,CHEBI:83056,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0002955,GRK2,,,false,,,http://purl.obolibrary.org/obo/IMR_0000254,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0002955,,,,,,,,,,,,,,,,,,,,,,GRK2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_134965,tilbroquinol,5-Methyl-7-bromo-8-hydroxyquinoline,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:7175-09-9|Drug_Central:2662,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5-Methyl-7-bromo-8-hydroxyquinoline,,,,,,,,,,,,,,,,,,,,,CHEBI:134965,,,,tilbroquinol,,CHEBI:134965,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006836,neurotransmitter transport,,"The directed movement of a neurotransmitter into, out of, within or between cells. Neurotransmitters are any chemical substance that is capable of transmitting (or inhibiting the transmission of) a nerve impulse from a neuron to another cell.",false,,,http://purl.obolibrary.org/obo/GO_0006810,,,,,,,,,,,,,,,,,,,,,,"The directed movement of a neurotransmitter into, out of, within or between cells. Neurotransmitters are any chemical substance that is capable of transmitting (or inhibiting the transmission of) a nerve impulse from a neuron to another cell.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0006836,,,,,,,,,,,,,,,,,,,,,,neurotransmitter transport,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001565,Rab4B,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001565,,,,,,,,,,,,,,,,,,,,,,Rab4B,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100165,kinin,plasmakinin,"The kinins are pharmacologically active polypeptides released in the tissues and body fluids as a result of the enzymatic action of kallikreins on kininogens. The kinin family includes bradykinin  (Arg-Pro-Pro-gly-Phe-Ser-Pro-Phe-Arg), kallidin (Lys-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg) and methionyl-lysyl-bradykinin (Met-Lys-Arg-Pro-Pro-Gly-Phe-Arg).",false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,MeSH:D007705,,"The kinins are pharmacologically active polypeptides released in the tissues and body fluids as a result of the enzymatic action of kallikreins on kininogens. The kinin family includes bradykinin  (Arg-Pro-Pro-gly-Phe-Ser-Pro-Phe-Arg), kallidin (Lys-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg) and methionyl-lysyl-bradykinin (Met-Lys-Arg-Pro-Pro-Gly-Phe-Arg).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,plasmakinin,,,,,IMR:0100165,,,,,,,,,,,,,,,,,,,,,,kinin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001473,DOCK5,,,false,,,http://purl.obolibrary.org/obo/IMR_0001469,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001473,,,,,,,,,,,,,,,,,,,,,,DOCK5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004155,phospholipid homeostasis imbalance [Phospholipidosis (mild) ],,"Phospholipid homeostasis imbalance is a subtype of lipid homeostasis imbalance: A process that becomes lacking a phospholipid homeostastasis balance. And the degree is mild.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (mild).",false,,,http://purl.obolibrary.org/obo/TXPO_0000907,,,,,,,,,,,,,,,,,,,,,,"Phospholipid homeostasis imbalance is a subtype of lipid homeostasis imbalance: A process that becomes lacking a phospholipid homeostastasis balance. And the degree is mild.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (mild).",,,http://purl.obolibrary.org/obo/TXPO_0001683,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001777,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001824,,http://purl.obolibrary.org/obo/TXPO_0000493,,,,,,,,,TXPO:0004155,,,,,,,,,,,,,,,,,,,,,,phospholipid homeostasis imbalance [Phospholipidosis (mild) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004150,Removing ceramide by Kupffer cell or macrophage,,Removing ceramide by Kupffer cell or macrophage is a subtype of removing: A process that takes ceramide from a cell by  Kupffer cells or macrophages .,false,,,http://purl.obolibrary.org/obo/TXPO_0000458,,,,,,,,,,,,,,,,,,,,,,Removing ceramide by Kupffer cell or macrophage is a subtype of removing: A process that takes ceramide from a cell by  Kupffer cells or macrophages .,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004150,,,,,,,,,,,,,,,,,,,,,,Removing ceramide by Kupffer cell or macrophage,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004159,sphingomyelin homeostasis imbalance [Phospholipidosis - sphingomyelin disorder],,"Sphingomyelin homeostasis imbalance is a subtype of phospholipid homeostasis imbalance: A process that becomes lacking asphingomyelin homeostastasis balance.
This process is dependent on the  genetic and can constitute the course of Phospholipidosis (sphingomyelin disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0000907,,,,,,,,,,,,,,,,,,,,,,"Sphingomyelin homeostasis imbalance is a subtype of phospholipid homeostasis imbalance: A process that becomes lacking asphingomyelin homeostastasis balance.
This process is dependent on the  genetic and can constitute the course of Phospholipidosis (sphingomyelin disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001823,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003381,,,,,,,,,,,TXPO:0004159,,,,,,,,,,,,,,,,,,,,,,sphingomyelin homeostasis imbalance [Phospholipidosis - sphingomyelin disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004152,acid ceramidase inactivation,,Acid ceramidase inactivation is a subtype of molecular inactivation: A process that  changes the activity of the acid ceramidase to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000021,,,,,,,,,,,,,,,,,,,,,,Acid ceramidase inactivation is a subtype of molecular inactivation: A process that  changes the activity of the acid ceramidase to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004152,,,,,,,,,,,,,,,,,,,,,,acid ceramidase inactivation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004153,acid ceramidase inactivation [Phospholipidosis],,"Acid ceramidase inactivation is a subtype of molecular inactivation: A process that  changes the activity of the acid ceramidase to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0004152|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Acid ceramidase inactivation is a subtype of molecular inactivation: A process that  changes the activity of the acid ceramidase to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003456,,,,,,,,,,,,,,,,,,,TXPO:0004153,,,,,,,,,,,,,,,,,,,,,,acid ceramidase inactivation [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004151,hyperfunction of ceramide phagocytosis by Kupffer cell or macrophage,,Hyperfunction of ceramide phagocytosis by Kupffer cell or macrophage  is a subtype of hyperfunctioning: A process that performs an excessive ceramide phagocytosis by Kupffer cells or macrophages.,false,,,http://purl.obolibrary.org/obo/TXPO_0001483,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of ceramide phagocytosis by Kupffer cell or macrophage  is a subtype of hyperfunctioning: A process that performs an excessive ceramide phagocytosis by Kupffer cells or macrophages.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004151,,,,,,,,,,,,,,,,,,,,,,hyperfunction of ceramide phagocytosis by Kupffer cell or macrophage,,,,,,http://purl.obolibrary.org/obo/TXPO_0004150,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004154,increasing number of macrophage derived foam cell [Phospholipidosis(severe)],,"Increasing number of macrophage derived foam cell is a subtype of increasing number of objects: A process that becomes larger in the number of foam cell, a type of macrophage containing lipids in small vacuoles, in the liver.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis(severe).",false,,,http://purl.obolibrary.org/obo/TXPO_0000918,,,,,,,,,,,,,,,,,,,,,,"Increasing number of macrophage derived foam cell is a subtype of increasing number of objects: A process that becomes larger in the number of foam cell, a type of macrophage containing lipids in small vacuoles, in the liver.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis(severe).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004154,,,,,,,,,,,,,,,,,,,,,,increasing number of macrophage derived foam cell [Phospholipidosis(severe)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004156,dysfunction of sphingomyelin degradation [Phospholipidosis-sphingomyelin disorder],,"Dysfunction of sphingomyelin degradation is a subtype of dysfunction of phosphosphingolipid degradation: A process that performs an abnormal and incomplete sphingomyelin degradation.
This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0004162|http://purl.obolibrary.org/obo/TXPO_0001686,,,,,,,,,,,,,,,,,,,,,,"Dysfunction of sphingomyelin degradation is a subtype of dysfunction of phosphosphingolipid degradation: A process that performs an abnormal and incomplete sphingomyelin degradation.
This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004156,,,,,,,,,,,,,,,,,,,,,,dysfunction of sphingomyelin degradation [Phospholipidosis-sphingomyelin disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004158,lysosomal cholesterol storage (moderate)[Phospholipidosis],,"Lysosomal cholesterol storage is a subtype of cholesterol storage: A process that keeps cholesterol in the lysosome moderately.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis(moderate).",false,,,http://purl.obolibrary.org/obo/TXPO_0000694,,,,,,,,,,,,,,,,,,,,,,"Lysosomal cholesterol storage is a subtype of cholesterol storage: A process that keeps cholesterol in the lysosome moderately.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis(moderate).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003370,,,,,,,,,,,TXPO:0004158,,,,,,,,,,,,,,,,,,,,,,lysosomal cholesterol storage (moderate)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004157,sphingomyelin disorder (phospholipidosis)　,,The totality of all processes through which the sphingomyelin disorder is realized.,false,,,http://purl.obolibrary.org/obo/TXPO_0002215,,,,,,,,,,,,,,,,,,,,,,The totality of all processes through which the sphingomyelin disorder is realized.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001569|http://purl.obolibrary.org/obo/TXPO_0001595|http://purl.obolibrary.org/obo/TXPO_0004159|http://purl.obolibrary.org/obo/TXPO_0004162|http://purl.obolibrary.org/obo/TXPO_0003445|http://purl.obolibrary.org/obo/TXPO_0003381|http://purl.obolibrary.org/obo/TXPO_0001788|http://purl.obolibrary.org/obo/TXPO_0001823,,,,,,,,,,,,,,,,,,TXPO:0004157,,,,,,,,,,,,,,,,,,,,,,sphingomyelin disorder (phospholipidosis)　,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000087,cytokeratin 3,,,false,,,http://purl.obolibrary.org/obo/IMR_0000050,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000087,,,,,,,,,,,,,,,,,,,,,,cytokeratin 3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0010508,positive regulation of autophagy,,"Any process that activates, maintains or increases the rate of autophagy. Autophagy is the process in which cells digest parts of their own cytoplasm.",false,,,http://purl.obolibrary.org/obo/GO_0010506,,,,,,,,,,,,,,,,,,,,,,"Any process that activates, maintains or increases the rate of autophagy. Autophagy is the process in which cells digest parts of their own cytoplasm.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0010508,,,,,,,,,,,,,,,,,,,,,,positive regulation of autophagy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006914,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0010507,negative regulation of autophagy,,"Any process that stops, prevents, or reduces the frequency, rate or extent of autophagy. Autophagy is the process in which cells digest parts of their own cytoplasm.",false,,,http://purl.obolibrary.org/obo/GO_0010506,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents, or reduces the frequency, rate or extent of autophagy. Autophagy is the process in which cells digest parts of their own cytoplasm.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0010507,,,,,,,,,,,,,,,,,,,,,,negative regulation of autophagy,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006914,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0010506,regulation of autophagy,,"Any process that modulates the frequency, rate or extent of autophagy. Autophagy is the process in which cells digest parts of their own cytoplasm.",false,,,http://purl.obolibrary.org/obo/TXPO_0000113,,,,,,,,,,,,,,,,,,,,,,"Any process that modulates the frequency, rate or extent of autophagy. Autophagy is the process in which cells digest parts of their own cytoplasm.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0010506,,,,,,,,,,,,,,,,,,,,,,regulation of autophagy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006914,,,,,,,,,,
http://purl.obolibrary.org/obo/NCIT_C116387,tumor-associated macrophage,CD163-positive cells|TAM,Non-neoplastic macrophages that are found in close proximity to or within a tumor mass. [ NCI ],false,,,http://purl.obolibrary.org/obo/CL_0000235,,,,,,,,,,,,,,,,,,,,,,Non-neoplastic macrophages that are found in close proximity to or within a tumor mass. [ NCI ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CD163-positive cells|TAM,,,,,NCIT:C116387,,,,,,,,,,,,,,,,,,,,,,tumor-associated macrophage,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000429,moving,,Moving is a subtype of changing an operand: A process that change the location of the operand.|act on one position,false,,,http://purl.obolibrary.org/obo/TXPO_0000392,,,,,,,,,,,,,,,,,,,,,,Moving is a subtype of changing an operand: A process that change the location of the operand.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000429,,,,,,,,,,,,,,,,,,,,act on one position,,moving,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000424,changing hardness,,Changing hardness is a subtype of changing quality: A process that changes the hardness of the object.,false,,,http://purl.obolibrary.org/obo/TXPO_0000415,,,,,,,,,,,,,,,,,,,,,,Changing hardness is a subtype of changing quality: A process that changes the hardness of the object.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000424,,,,,,,,,,,,,,,,,,,,,,changing hardness,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0000048,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000426,solidifying,,Solidifying is a subtype of changing phase: A process that changes the phase of the operand to a solid phase.,false,,,http://purl.obolibrary.org/obo/TXPO_0000425,,,,,,,,,,,,,,,,,,,,,,Solidifying is a subtype of changing phase: A process that changes the phase of the operand to a solid phase.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000426,,,,,,,,,,,,,,,,,,,,,,solidifying,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000422,changing density,,Changing density is a subtype of changing quality: A process that changes the density of the object.,false,,,http://purl.obolibrary.org/obo/TXPO_0000415,,,,,,,,,,,,,,,,,,,,,,Changing density is a subtype of changing quality: A process that changes the density of the object.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000422,,,,,,,,,,,,,,,,,,,,,,changing density,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000421,keeps volume,,Keeps volume is a subtype of changing volume: A process that keeps the volume of the object.,false,,,http://purl.obolibrary.org/obo/TXPO_0000417,,,,,,,,,,,,,,,,,,,,,,Keeps volume is a subtype of changing volume: A process that keeps the volume of the object.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000421,,,,,,,,,,,,,,,,,,,,,,keeps volume,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000425,changing phase,,Changing phase is a subtype of changing an operand: A process that changes the phase of the operand.,false,,,http://purl.obolibrary.org/obo/TXPO_0000392,,,,,,,,,,,,,,,,,,,,,,Changing phase is a subtype of changing an operand: A process that changes the phase of the operand.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000425,,,,,,,,,,,,,,,,,,,,,,changing phase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000428,liquefying,,Liquefying is a subtype of changing phase: A process that changes the phase of the operand to a liquid phase.,false,,,http://purl.obolibrary.org/obo/TXPO_0000425,,,,,,,,,,,,,,,,,,,,,,Liquefying is a subtype of changing phase: A process that changes the phase of the operand to a liquid phase.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000428,,,,,,,,,,,,,,,,,,,,,,liquefying,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000423,biological defense role,,,false,,,http://purl.obolibrary.org/obo/TXPO_0003230,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000423,,,,,,,,,,,,,,,,,,,,,,biological defense role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000420,process based on specific viewpoint,,,false,,,http://purl.obolibrary.org/obo/BFO_0000015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000420,,,,,,,,,,,,,,,,,,,,,,process based on specific viewpoint,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000427,vaporizing,,Vaporizing is a subtype of changing phase: A process that changes the phase of the operand to a vapor phase.,false,,,http://purl.obolibrary.org/obo/TXPO_0000425,,,,,,,,,,,,,,,,,,,,,,Vaporizing is a subtype of changing phase: A process that changes the phase of the operand to a vapor phase.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000427,,,,,,,,,,,,,,,,,,,,,,vaporizing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001505,Rap1A,,,false,,,http://purl.obolibrary.org/obo/IMR_0001504,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001505,,,,,,,,,,,,,,,,,,,,,,Rap1A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001699,peptidoglycan,murein|PGN,"Peptidoglycan (PGN) is a unique and essential component of the cell wall of virtually all bacteria, is not present in eukaryotes, and is an excellent target for the innate immune system.",false,,,http://purl.obolibrary.org/obo/CHEBI_18154,,,,,,,,,,,,,,,,,,,,MeSH:D010457,,"Peptidoglycan (PGN) is a unique and essential component of the cell wall of virtually all bacteria, is not present in eukaryotes, and is an excellent target for the innate immune system.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,murein|PGN,,,,,IMR:0001699,,,,,,,,,,,,,,,,,,,,,,peptidoglycan,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000156,inflammatory cell infiltration [Phospholipidosis],,Inflammatory cell infiltration is a subtype of moving A to the inside of B: A process that that moves the outside inflammatory cell to the inside in response to an inflammatory reaction. This entity is a specific course dependent process. This process can constitute the course of Phospholipidosis.,false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0000540,,,,,,,,,,,,,,,,,,,,,,Inflammatory cell infiltration is a subtype of moving A to the inside of B: A process that that moves the outside inflammatory cell to the inside in response to an inflammatory reaction. This entity is a specific course dependent process. This process can constitute the course of Phospholipidosis.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004113,http://purl.obolibrary.org/obo/TXPO_0004072,,,,,,http://purl.obolibrary.org/obo/TXPO_0001488,,,,,,,,,,,TXPO:0000156,,,,,,,,,,,,,,,,,,,,,,inflammatory cell infiltration [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000152,TIMP1 production,,TIMP1 production is a subtype of protein production: A process that makes existent of a TIMP1 protein due to biosynthesis or secretion resulting in an increase in its levels.,false,,,http://purl.obolibrary.org/obo/TXPO_0000382,,,,,,,,,,,,,,,,,,,,,,TIMP1 production is a subtype of protein production: A process that makes existent of a TIMP1 protein due to biosynthesis or secretion resulting in an increase in its levels.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000152,,,,,,,,,,,,,,,,,,,,,,TIMP1 production,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000157,decreasing sensitivity,,Decreasing sensitivity is a subtype of changing sensitivity: A process that changes the sensitivity to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000015,,,,,,,,,,,,,,,,,,,,,,Decreasing sensitivity is a subtype of changing sensitivity: A process that changes the sensitivity to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000157,,,,,,,,,,,,,,,,,,,,,,decreasing sensitivity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000158,nuclear receptor activation,nuclear receptor activation,Nuclear receptor activation is a subtype of activation of transcription factor: A process that changes the activity of the molecule with a nuclear receptor role to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000124,,,,,,,,,,,,,,,,,,,,,,Nuclear receptor activation is a subtype of activation of transcription factor: A process that changes the activity of the molecule with a nuclear receptor role to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,nuclear receptor activation,,,,,TXPO:0000158,,,,,,,,,,,,,,,,,,,,,,nuclear receptor activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000155,hematopoietic factor,,A role played by the entity that causes blood cells to grow and mature (Haematopoiesis).,false,,,http://purl.obolibrary.org/obo/TXPO_0000622,,,,,,,,,,,,,,,,,,,,,,A role played by the entity that causes blood cells to grow and mature (Haematopoiesis).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000155,,,,,,,,,,,,,,,,,,,,,,hematopoietic factor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000150,GADD34 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:17872|NCBI-Human-GeneID:23645|NCBI-Rat-GeneID:171071,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000023645,,,,,,,,,,,,,TXPO:0000150,,,,,,,,,,,,,,,,,,,,,,GADD34 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000151,increasing energy [Eosinophilic granular degeneration],,"Increasing energy is a subtype of increasing quantity: A process that changes the amount of energy to be larger.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/TXPO_0000144|http://purl.obolibrary.org/obo/TXPO_0001729,,,,,,,,,,,,,,,,,,,,,,"Increasing energy is a subtype of increasing quantity: A process that changes the amount of energy to be larger.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001047,,,,,,,,,,,,,,,,,TXPO:0000151,,,,,,,,,,,,,,,,,,,,,,increasing energy [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000154,electron transfer moecule,electron transporter|electron carrier,A role played by the entity that serves as an electron acceptor and electron donor in an electron transport chain. An electron transport chain is a process in which a series of electron carriers operate together to transfer electrons from donors to any of several different terminal electron acceptors to generate a transmembrane electrochemical gradient.|related molecular function GO:0009055,false,,,http://purl.obolibrary.org/obo/TXPO_0003638,,,,,,,,,,,,,,,,,,,,,,A role played by the entity that serves as an electron acceptor and electron donor in an electron transport chain. An electron transport chain is a process in which a series of electron carriers operate together to transfer electrons from donors to any of several different terminal electron acceptors to generate a transmembrane electrochemical gradient.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,electron transporter|electron carrier,,,TXPO:0000154,,,,,,,,,,,,,,,,,,,,related molecular function GO:0009055,,electron transfer moecule,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000159,PPARA (mol),PPAR alpha|Peroxisome Proliferator-Activated Receptor Alpha,,false,,,http://purl.obolibrary.org/obo/IMR_0000089,,,,,,,,,,,,,,,,,,,,PMID:25450203,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PPAR alpha|Peroxisome Proliferator-Activated Receptor Alpha,,,,,TXPO:0000159,,,,,,,,,,,,,,,,,,,,,,PPARA (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000153,glycolytic process [Eosinophilic granular degeneration],,"The chemical reactions and pathways resulting in the breakdown of a carbohydrate into pyruvate, with the concomitant production of a small amount of ATP and the reduction of NAD(P) to NAD(P)H. Glycolysis begins with the metabolism of a carbohydrate to generate products that can enter the pathway and ends with the production of pyruvate. Pyruvate may be converted to acetyl-coenzyme A, ethanol, lactate, or other small molecules.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/GO_0006096|http://purl.obolibrary.org/obo/TXPO_0001729,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways resulting in the breakdown of a carbohydrate into pyruvate, with the concomitant production of a small amount of ATP and the reduction of NAD(P) to NAD(P)H. Glycolysis begins with the metabolism of a carbohydrate to generate products that can enter the pathway and ends with the production of pyruvate. Pyruvate may be converted to acetyl-coenzyme A, ethanol, lactate, or other small molecules.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000151,,,,,,,,,,,TXPO:0000153,,,,,,,,,,,,,,,,,,,,,,glycolytic process [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_1902576,negative regulation of nuclear cell cycle DNA replication,down regulation of DNA replication involved in S phase,"Any process that stops, prevents or reduces the frequency, rate or extent of nuclear cell cycle DNA replication.",false,,,http://purl.obolibrary.org/obo/TXPO_0000369,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents or reduces the frequency, rate or extent of nuclear cell cycle DNA replication.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,down regulation of DNA replication involved in S phase,,,,,GO:1902576,,,,,,,,,,,,,,,,,,,,,,negative regulation of nuclear cell cycle DNA replication,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006260,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010502,60S acidic ribosomal protein P0,L10E,,false,,,http://purl.obolibrary.org/obo/IMR_0000897,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,L10E,,,,,IMR:0010502,,,,,,,,,,,,,,,,,,,,,,60S acidic ribosomal protein P0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000344,SLC44A2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:57153|NCBI-Mouse-GeneID:68682|NCBI-Rat-GeneID:363024,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000057153,,,,,,,,,,,,,TXPO:1000344,,,,,,,,,,,,,,,,,,,,,,SLC44A2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000348,SMPDL3A (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:10924|NCBI-Mouse-GeneID:57319|NCBI-Rat-GeneID:294422,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000010924,,,,,,,,,,,,,TXPO:1000348,,,,,,,,,,,,,,,,,,,,,,SMPDL3A (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000346,SMO (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:6608|NCBI-Mouse-GeneID:319757|NCBI-Rat-GeneID:25273,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000006608,,,,,,,,,,,,,TXPO:1000346,,,,,,,,,,,,,,,,,,,,,,SMO (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000342,SLC2A3 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:25551|NCBI-Human-GeneID:6515|NCBI-Mouse-GeneID:20527,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000006515,,,,,,,,,,,,,TXPO:1000342,,,,,,,,,,,,,,,,,,,,,,SLC2A3 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000341,SLC29A2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:65194|NCBI-Mouse-GeneID:13340|NCBI-Human-GeneID:3177,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000003177,,,,,,,,,,,,,TXPO:1000341,,,,,,,,,,,,,,,,,,,,,,SLC29A2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000340,SLC25A4 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:291|NCBI-Mouse-GeneID:11739|NCBI-Rat-GeneID:85333,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000291,,,,,,,,,,,,,TXPO:1000340,,,,,,,,,,,,,,,,,,,,,,SLC25A4 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000343,SLC35F5 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:74150|NCBI-Rat-GeneID:288993|NCBI-Human-GeneID:80255,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000080255,,,,,,,,,,,,,TXPO:1000343,,,,,,,,,,,,,,,,,,,,,,SLC35F5 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000345,SMARCD3 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:1000345,,,,,,,,,,,,,,,,,,,,,,SMARCD3 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000349,SORBS1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:20411|NCBI-Human-GeneID:10580|NCBI-Rat-GeneID:686098,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000010580,,,,,,,,,,,,,TXPO:1000349,,,,,,,,,,,,,,,,,,,,,,SORBS1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000347,SMPD1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:6609|NCBI-Rat-GeneID:308909|NCBI-Mouse-GeneID:20597,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000006609,,,,,,,,,,,,,TXPO:1000347,,,,,,,,,,,,,,,,,,,,,,SMPD1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001137,decorin,,,false,,,http://purl.obolibrary.org/obo/IMR_0001127,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001137,,,,,,,,,,,,,,,,,,,,,,decorin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_35441,antiinfective agent,antiinfective agents|antiinfective drug|anti-infective agents|anti-infective drugs,A substance used in the prophylaxis or therapy of infectious diseases.,false,,,http://purl.obolibrary.org/obo/CHEBI_23888,,,,,,,,,,,,,,,,,,,,,,A substance used in the prophylaxis or therapy of infectious diseases.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,antiinfective agents|antiinfective drug|anti-infective agents|anti-infective drugs,,,,,,,,,,,,,,,,,,,,,CHEBI:35441,,,,antiinfective agent,,CHEBI:35441,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_1902292,cell cycle DNA replication initiation,DNA-dependent DNA replication initiation involved in cell cycle DNA replication|DNA replication initiation involved in cell cycle DNA replication,Any DNA replication initiation that is involved in cell cycle DNA replication.,false,,,http://purl.obolibrary.org/obo/TXPO_0001984,,,,,,,,,,,,,,,,,,,,,,Any DNA replication initiation that is involved in cell cycle DNA replication.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,DNA-dependent DNA replication initiation involved in cell cycle DNA replication|DNA replication initiation involved in cell cycle DNA replication,,,,,GO:1902292,,,,,,,,,,,,,,,,,,,,,,cell cycle DNA replication initiation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002989,attenuation of Cyclin D1 translation by eIF2a [ER stress],,"Any process that stops, prevents, or reduces the frequency, rate or extent of Cyclin D1 translation by eIF2a.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000722,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents, or reduces the frequency, rate or extent of Cyclin D1 translation by eIF2a.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003588,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003006,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002989,,,,,,,,,,,,,,,,,,,,,,attenuation of Cyclin D1 translation by eIF2a [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002988,negative regulation of formation of cytoplasmic translation initiation complex by eIF2a [ER stress - inflammation],,"Negative regulation of formation of cytoplasmic translation initiation complex is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of formation of cytoplasmic translation initiation complex.
This process is dependent on the inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000068|http://purl.obolibrary.org/obo/TXPO_0003736,,,,,,,,,,,,,,,,,,,,PMID:9930704|PMID:23334697,,"Negative regulation of formation of cytoplasmic translation initiation complex is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of formation of cytoplasmic translation initiation complex.
This process is dependent on the inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002555,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002988,,,,,,,,,,,,,,,,,,,,,,negative regulation of formation of cytoplasmic translation initiation complex by eIF2a [ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002983,Translocation of XBP1s from the cytosol to the nucleus [ER stress - ERAD],,"Translocation of XBP1s from the cytosol to the nucleus is a subtype of nuclear transport: A process that of the directed movement of XBP1s from the cytoplasm to the nucleus.
This entity is a specific course-dependent process. This process is dependent on the ERAD and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002981,,,,,,,,,,,,,,,,,,,,,,"Translocation of XBP1s from the cytosol to the nucleus is a subtype of nuclear transport: A process that of the directed movement of XBP1s from the cytoplasm to the nucleus.
This entity is a specific course-dependent process. This process is dependent on the ERAD and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002605,http://purl.obolibrary.org/obo/TXPO_0002696,,,,,,,,,,,,,,,,,,TXPO:0002983,,,,,,,,,,,,,,,,,,,,,,Translocation of XBP1s from the cytosol to the nucleus [ER stress - ERAD],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002981,Translocation of XBP1s from the cytosol to the nucleus [ER stress],,"Translocation of XBP1s from the cytosol to the nucleus is a subtype of nuclear transport: A process that of the directed movement of XBP1s from the cytoplasm to the nucleus.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002980,,,,,,,,,,,,,,,,,,,,,,"Translocation of XBP1s from the cytosol to the nucleus is a subtype of nuclear transport: A process that of the directed movement of XBP1s from the cytoplasm to the nucleus.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002981,,,,,,,,,,,,,,,,,,,,,,Translocation of XBP1s from the cytosol to the nucleus [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002986,PERK-eIF2a-CyclinD1 pathway [ER stress - cell cycle arrest],,"PERK-eIF2a-CyclinD1 pathway is a subtype of PERK-eIF2a signaling: Sequence of linked reactions, which has PERK-eIF2a signaling and CyclinD1 gene regulation.
This pathway is dependent on the cell cycle arrest and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000701,,,,,,,,,,,,,,,,,,,,,,"PERK-eIF2a-CyclinD1 pathway is a subtype of PERK-eIF2a signaling: Sequence of linked reactions, which has PERK-eIF2a signaling and CyclinD1 gene regulation.
This pathway is dependent on the cell cycle arrest and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002989|http://purl.obolibrary.org/obo/TXPO_0002991|http://purl.obolibrary.org/obo/TXPO_0002992,,,,,,,,,,,,,,,,,,TXPO:0002986,,,,,,,,,,,,,,,,,,,,,,PERK-eIF2a-CyclinD1 pathway [ER stress - cell cycle arrest],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002980,Translocation of XBP1s from the cytosol to the nucleus,,Translocation of XBP1s from the cytosol to the nucleus is a subtype of nuclear transport: A process that of the directed movement of XBP1s from the cytoplasm to the nucleus.,false,,,http://purl.obolibrary.org/obo/GO_0051169,,,,,,,,,,,,,,,,,,,,,,Translocation of XBP1s from the cytosol to the nucleus is a subtype of nuclear transport: A process that of the directed movement of XBP1s from the cytoplasm to the nucleus.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005634,http://purl.obolibrary.org/obo/GO_0005829,,,,,,,TXPO:0002980,,,,,,,,,,,,,,,,,,,,,,Translocation of XBP1s from the cytosol to the nucleus,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002984,XBP1s gene regulation pathway[ER stress - inflammation],,"XBP1s gene regulation pathway is a subtype of gene regulation pathway: A series of process in which XBP1s regulates the gene expression.
This pathway is dependent on the  inflammation  and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002486,,,,,,,,,,,,,,,,,,,,,,"XBP1s gene regulation pathway is a subtype of gene regulation pathway: A series of process in which XBP1s regulates the gene expression.
This pathway is dependent on the  inflammation  and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002830,,,,,,,,,,,,,,,,,,TXPO:0002984,,,,,,,,,,,,,,,,,,,,,,XBP1s gene regulation pathway[ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002982,Translocation of XBP1s from the cytosol to the nucleus [ER stress - refolding],,"Translocation of XBP1s from the cytosol to the nucleus is a subtype of nuclear transport: A process that of the directed movement of XBP1s from the cytoplasm to the nucleus.
This process is dependent on the refolding and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002981,,,,,,,,,,,,,,,,,,,,,,"Translocation of XBP1s from the cytosol to the nucleus is a subtype of nuclear transport: A process that of the directed movement of XBP1s from the cytoplasm to the nucleus.
This process is dependent on the refolding and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002923,http://purl.obolibrary.org/obo/TXPO_0002760,,,,,,,,,,,,,,,,,,TXPO:0002982,,,,,,,,,,,,,,,,,,,,,,Translocation of XBP1s from the cytosol to the nucleus [ER stress - refolding],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002985,Translocation of XBP1s from the cytosol to the nucleus [ER stress - inflammation],,"Translocation of XBP1s from the cytosol to the nucleus is a subtype of nuclear transport: A process that of the directed movement of XBP1s from the cytoplasm to the nucleus.
This process is dependent on the inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002981,,,,,,,,,,,,,,,,,,,,,,"Translocation of XBP1s from the cytosol to the nucleus is a subtype of nuclear transport: A process that of the directed movement of XBP1s from the cytoplasm to the nucleus.
This process is dependent on the inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002605,http://purl.obolibrary.org/obo/TXPO_0002830,,,,,,,,,,,,,,,,,,TXPO:0002985,,,,,,,,,,,,,,,,,,,,,,Translocation of XBP1s from the cytosol to the nucleus [ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002987,regulation of cell cycle related gene expression [ER stress],,"Regulation of cell cycle related gene expression is a subtype of regulation of gene expression: A process that modulates the frequency, rate or extent of cel cycle related gene expression.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000183|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"Regulation of cell cycle related gene expression is a subtype of regulation of gene expression: A process that modulates the frequency, rate or extent of cel cycle related gene expression.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002987,,,,,,,,,,,,,,,,,,,,,,regulation of cell cycle related gene expression [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100324,IFNGR-2,IFNG receptor beta chain|accessory factor-1,,false,,,http://purl.obolibrary.org/obo/IMR_0000136,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IFNG receptor beta chain|accessory factor-1,,,,,IMR:0100324,,,,,,,,,,,,,,,,,,,,,,IFNGR-2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002397,cell death inducer,,A role played by the entity which induces the process of cell death.,false,,,http://purl.obolibrary.org/obo/TXPO_0002406,,,,,,,,http://purl.obolibrary.org/obo/GO_0008219,,,,,,,,,,,,,,A role played by the entity which induces the process of cell death.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002397,,,,,,,,,,,,,,,,,,,,,,cell death inducer,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002395,growth factor role,Growth Substance,A role that stimulates a cell to grow or proliferate. Most growth factors have other actions besides the induction of cell growth or proliferation.,false,,,http://purl.obolibrary.org/obo/TXPO_0003705,,,,,,,,,,,,,,,,,,,,GO:0008083|IMR:0000030 (obsolete),,A role that stimulates a cell to grow or proliferate. Most growth factors have other actions besides the induction of cell growth or proliferation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Growth Substance,,,,,TXPO:0002395,,,,,,,Extracellular polypeptide signal molecule that can stimulate a cell grow or proliferate. Examples are EGF and PDGF. Most growth factors also have other actions.,,,,,,,,,,,,,,,growth factor role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002390,hypoxia [Cell death],,"reduced oxygenation of body tissues resulting in the decreased pressure of this component of body gases; commonly due to hypoxemia
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0001727|http://purl.obolibrary.org/obo/MP_0005039,,,,,,,,,,,,,,,,,,,,,,"reduced oxygenation of body tissues resulting in the decreased pressure of this component of body gases; commonly due to hypoxemia
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000645,,,,,,http://purl.obolibrary.org/obo/TXPO_0002129|http://purl.obolibrary.org/obo/TXPO_0000453,,,,,,,,,,,TXPO:0002390,,,,,,,,,,,,,,,,,,,,,,hypoxia [Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002392,NRF2 (canonical)[Glutathione depletion],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002045|http://purl.obolibrary.org/obo/TXPO_0002527,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:18024|NCBI-Rat-GeneID:83619|NCBI-Human-GeneID:4780,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003645,,,,,,,,,,TXPO:0002392,,,,,,,,,,,,,,,,,,,,,,NRF2 (canonical)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002394,glutathione biosynthetic limiting enzyme agent role,,A role played by the entity which is a first rate-limiting enzyme and regulates the glutathione biosynthetic process.,false,,,http://purl.obolibrary.org/obo/TXPO_0003654,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006750,,,,,,,,,,,,,A role played by the entity which is a first rate-limiting enzyme and regulates the glutathione biosynthetic process.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002394,,,,,,,,,,,,,,,,,,,,,,glutathione biosynthetic limiting enzyme agent role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002391,fatty acid homeostasis imbalance in peroxisome (severe) [Eosinophilic granular degeneration],,"Fatty acid homeostasis imbalance in peroxisome is a subtype of changing balance: A process that becomes lacking afatty acid homeostastasis balance. The degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/TXPO_0002158,,,,,,,,,,,,,,,,,,,,,,"Fatty acid homeostasis imbalance in peroxisome is a subtype of changing balance: A process that becomes lacking afatty acid homeostastasis balance. The degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001025,,,,,,,,,,,TXPO:0002391,,,,,,,,,,,,,,,,,,,,,,fatty acid homeostasis imbalance in peroxisome (severe) [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002399,p53 inhibitor,,An enzyme inhibitor that interferes with the activity of p53.,false,,,http://purl.obolibrary.org/obo/CHEBI_23924,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001213,,,,,,,,,,,,,,,An enzyme inhibitor that interferes with the activity of p53.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002399,,,,,,,,,,,,,,,,,,,,,,p53 inhibitor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002396,glutathione expression positive regulator role,,A role played by the entity which involves in poritively regulating a gulutathione expression process.,false,,,http://purl.obolibrary.org/obo/TXPO_0003650,,,,,,,,,,,,,,,,,,,,,,A role played by the entity which involves in poritively regulating a gulutathione expression process.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002396,,,,,,,,,,,,,,,,,,,,,,glutathione expression positive regulator role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002398,CDK5R1(mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0003241,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002398,,,,,,,,,,,,,,,,,,,,,,CDK5R1(mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002393,refolding gene expression by ATF6 [ER stress - refolding],,"Refolding gene expression by ATF6 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) related to the protein refolding function by ATF6.
This process is dependent on the refolding and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0003736|http://purl.obolibrary.org/obo/TXPO_0002521,,,,,,,,,,,,,,,,,,,,PMID:17765679|PMID:11779464|PMID:27346803,,"Refolding gene expression by ATF6 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) related to the protein refolding function by ATF6.
This process is dependent on the refolding and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002899,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002898|http://purl.obolibrary.org/obo/TXPO_0003049|http://purl.obolibrary.org/obo/TXPO_0002677|http://purl.obolibrary.org/obo/TXPO_0003053|http://purl.obolibrary.org/obo/TXPO_0003050|http://purl.obolibrary.org/obo/TXPO_0003034,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002384,,,,,,,,,,,TXPO:0002393,,,,,,,,,,,,,,,,,,,,,,refolding gene expression by ATF6 [ER stress - refolding],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_17347,testosterone,4-androsten-17beta-ol-3-one|testosteronum|17beta-hydroxy-4-androsten-3-one|Testosteron|testosterone|testosterona|Androderm|17beta-Hydroxy-4-androsten-3-one|Testosterone|17beta-hydroxyandrost-4-en-3-one|TESTOSTERONE|testosterone,"An androstanoid having 17beta-hydroxy and 3-oxo groups, together with unsaturation at C-4-C-5..",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:24498482|Beilstein:3653705|PMID:10438974|DrugBank:DB00624|Beilstein:1915399|PMID:11786693|Drug_Central:2607|Gmelin:538843|PMID:18900503|Reaxys:1915399|LIPID_MAPS_instance:LMST02020002|CAS:58-22-0,,"An androstanoid having 17beta-hydroxy and 3-oxo groups, together with unsaturation at C-4-C-5..",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_83056|http://purl.obolibrary.org/obo/CHEBI_77746|http://purl.obolibrary.org/obo/CHEBI_50113|http://purl.obolibrary.org/obo/CHEBI_75771,,,,,Testosterone|17beta-hydroxyandrost-4-en-3-one|TESTOSTERONE|testosterone,,4-androsten-17beta-ol-3-one|testosteronum|17beta-hydroxy-4-androsten-3-one|Testosteron|testosterone|testosterona|Androderm|17beta-Hydroxy-4-androsten-3-one,,,,,,,,,,,,,,,,,,,,,CHEBI:17347,,,,testosterone,,CHEBI:17347,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_48873,cholinergic antagonist,agente anticolinergico|Anticholinergika|acetylcholine antagonists|anticholinergic agents|anticholinergiques|cholinergic-blocking agents|agent anticholinergique|agentes anticolinergicos|acetylcholine receptor antagonist|anticholinergics|Anticholinergikum|anticolinergicos,"Any drug that binds to but does not activate cholinergic receptors, thereby blocking the actions of acetylcholine or cholinergic agonists.",false,,,http://purl.obolibrary.org/obo/CHEBI_38323,,,,,,,,,,,,,,,,,,,,,,"Any drug that binds to but does not activate cholinergic receptors, thereby blocking the actions of acetylcholine or cholinergic agonists.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,agente anticolinergico|Anticholinergika|acetylcholine antagonists|anticholinergic agents|anticholinergiques|cholinergic-blocking agents|agent anticholinergique|agentes anticolinergicos|acetylcholine receptor antagonist|anticholinergics|Anticholinergikum|anticolinergicos,,,,,,,,,,,,,,,,,,,,,CHEBI:48873,,,,cholinergic antagonist,,CHEBI:48873,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000809,disabled-2,DOC-2,,false,,,http://purl.obolibrary.org/obo/IMR_0000558,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,DOC-2,,,,,IMR:0000809,,,,,,,,,,,,,,,,,,,,,,disabled-2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002889,receiving abnormal protein signal by IRE1 [ER stress - inflammation - IRE1-TRAF2-IKK-NfkB pathway],,"Receiving abnormal protein signal by IRE1 is a subtype of receiving signal: A process that recognizes another object and changes into an abnormal protein (e.g., misfolded protein, etc.) signal by IRE1.
This process is dependent on the IRE1-TRAF2-IKK-NfkB pathway mediated inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002887,,,,,,,,,,,,,,,,,,,,,,"Receiving abnormal protein signal by IRE1 is a subtype of receiving signal: A process that recognizes another object and changes into an abnormal protein (e.g., misfolded protein, etc.) signal by IRE1.
This process is dependent on the IRE1-TRAF2-IKK-NfkB pathway mediated inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002602,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002834,,,,,,,,,,,TXPO:0002889,,,,,,,,,,,,,,,,,,,,,,receiving abnormal protein signal by IRE1 [ER stress - inflammation - IRE1-TRAF2-IKK-NfkB pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002882,PERK dimer (canonical)[ER stress - inflammation],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002880,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002882,,,,,,,,,,,,,,,,,,,,,,PERK dimer (canonical)[ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002855,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002883,PERK dimer (canonical)[ER stress - apotosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002880,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002883,,,,,,,,,,,,,,,,,,,,,,PERK dimer (canonical)[ER stress - apotosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002866,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002881,PERK dimer (canonical)[ER stress - Refolding],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002880,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002881,,,,,,,,,,,,,,,,,,,,,,PERK dimer (canonical)[ER stress - Refolding],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002867,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002880,PERK dimer (canonical)[ER stress],EIF2AK3,,false,,,http://purl.obolibrary.org/obo/TXPO_0000871|http://purl.obolibrary.org/obo/TXPO_0001792,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:13666|NCBI-Human-GeneID:9451|NCBI-Rat-GeneID:29702|http://omim.org/entry/604032,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,EIF2AK3,,,,,TXPO:0002880,,,,,,,,,,,,,,,,,,,,,,PERK dimer (canonical)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000713,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002888,receiving abnormal protein signal by IRE1 [ER stress - inflammation - IRE1-TRAF2-ASK-JNK pathway],,"Receiving abnormal protein signal by IRE1 is a subtype of receiving signal: A process that recognizes another object and changes into an abnormal protein (e.g., misfolded protein, etc.) signal by IRE1.
This process is dependent on the IRE1-TRAF2-ASK-JNK pathway mediated inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002887,,,,,,,,,,,,,,,,,,,,,,"Receiving abnormal protein signal by IRE1 is a subtype of receiving signal: A process that recognizes another object and changes into an abnormal protein (e.g., misfolded protein, etc.) signal by IRE1.
This process is dependent on the IRE1-TRAF2-ASK-JNK pathway mediated inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002602,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002835,,,,,,,,,,,TXPO:0002888,,,,,,,,,,,,,,,,,,,,,,receiving abnormal protein signal by IRE1 [ER stress - inflammation - IRE1-TRAF2-ASK-JNK pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002885,Dissociation of IRE1:BIP Heterodimer [ER stress - inflammation],,"Dissociation of IRE1:BIP heterodimer is a subtype of detaching: A process that disaggregates IRE-1-BIP heterodimers into BIP and IRE1.
This process is dependent on the inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002176,,,,,,,,,,,,,,,,,,,,,,"Dissociation of IRE1:BIP heterodimer is a subtype of detaching: A process that disaggregates IRE-1-BIP heterodimers into BIP and IRE1.
This process is dependent on the inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002111,,,,http://purl.obolibrary.org/obo/TXPO_0002907|http://purl.obolibrary.org/obo/TXPO_0002846,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002855,,,,,,,,,,,TXPO:0002885,,,,,,,,,,,,,,,,,,,,,,Dissociation of IRE1:BIP Heterodimer [ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002886,IRE - stress sensor (canonical)[ER stress - inflammation],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002602,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000881,,,,,,,,,,TXPO:0002886,,,,,,,,,,,,,,,,,,,,,,IRE - stress sensor (canonical)[ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002710,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002884,PERK dimer (canonical)[ER stress - translation attenuation],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002880,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002884,,,,,,,,,,,,,,,,,,,,,,PERK dimer (canonical)[ER stress - translation attenuation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000063,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002887,receiving abnormal protein signal by IRE1 [ER stress - inflammation],,"Receiving abnormal protein signal by IRE1 is a subtype of receiving signal: A process that recognizes another object and changes into an abnormal protein (e.g., misfolded protein, etc.) signal by IRE1.
This process is dependent on the inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002604|http://purl.obolibrary.org/obo/TXPO_0003736,,,,,,,,,,,,,,,,,,,,,,"Receiving abnormal protein signal by IRE1 is a subtype of receiving signal: A process that recognizes another object and changes into an abnormal protein (e.g., misfolded protein, etc.) signal by IRE1.
This process is dependent on the inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002602,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002885,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002594,,,,,,,,,,,TXPO:0002887,,,,,,,,,,,,,,,,,,,,,,receiving abnormal protein signal by IRE1 [ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000135932,TMEM139,,,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,7,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,transmembrane protein 139,,,7q34,,,,,,,,,,,,,,,,GO_0016021 (EC: IEA),,,,,,,,,PMID: 8889548; 12477932; 12690205; 12975309; 15231748; 16303743; 16344560; 16712791; 17213182; 19773279; 24250222,,,,,,,,,,,,,,,OGG:3000135932,,20140408,protein-coding,,,,transmembrane protein 139,,,,,,,,,,,,,,,TMEM139,,,,,,,,,,,,,,,,,,,,,,,135932,UNQ1932/PRO4407,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,TMEM139,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/BFO_0000009,two-dimensional spatial region,,,false,,,http://purl.obolibrary.org/obo/BFO_0000006,,,,,,,,,,,,,,,,,,,,,,,,,,,,A two-dimensional spatial region is a spatial region that is of two dimensions. (axiom label in BFO2 Reference: [039-001]),an infinitely thin plane in space.|the surface of a sphere-shaped part of space,,,,,,,,,,,(forall (x) (if (TwoDimensionalSpatialRegion x) (SpatialRegion x))) // axiom label in BFO2 CLIF: [039-001],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BFO:0000009,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/bfo.owl,two-dimensional spatial region,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001032,group VI phospholipase A2,,,false,,,http://purl.obolibrary.org/obo/IMR_0000283,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001032,,,,,,,,,,,,,,,,,,,,,,group VI phospholipase A2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001604,Rab20,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001604,,,,,,,,,,,,,,,,,,,,,,Rab20,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010535,40S ribosomal protein S10,40S small ribosomal protein 10,,false,,,http://purl.obolibrary.org/obo/IMR_0000896,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,40S small ribosomal protein 10,,,,,IMR:0010535,,,,,,,,,,,,,,,,,,,,,,40S ribosomal protein S10,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004200,PMAIP1 (predicted)(human) [hepatocarcinogenesis],NOXA,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_1000526,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:5366,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000005366,,,,,,,,NOXA,,,,,TXPO:0004200,,,,,,,,,,,,,,,,,,,,,,PMAIP1 (predicted)(human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004203,UHRF1 (predicted)(human) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_1000547,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:29128|PMID:28060737|PMID:28584306,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000029128,,,,,,,,,,,,,TXPO:0004203,,,,,,,,,,,,,,,,,,,,,,UHRF1 (predicted)(human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004206,TMEM150C (predicted)(human) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_1000539,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:441027,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000441027,,,,,,,,,,,,,TXPO:0004206,,,,,,,,,,,,,,,,,,,,,,TMEM150C (predicted)(human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004208,degree level,,"The deree level is a subtype of qualitative value.
The extent or measure of the condition/action.",false,,,http://purl.obolibrary.org/obo/TXPO_0000288,,,,,,,,,,,,,,,,,,,,,,"The deree level is a subtype of qualitative value.
The extent or measure of the condition/action.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004208,,,,,,,,,,,,,,,,,,,,,,degree level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004205,TTC39A (predicted)(human) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_1000544,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:22996,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000022996,,,,,,,,,,,,,TXPO:0004205,,,,,,,,,,,,,,,,,,,,,,TTC39A (predicted)(human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004201,UGT2A3 (predicted)(human) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_1000546,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:79799,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000079799,,,,,,,,,,,,,TXPO:0004201,,,,,,,,,,,,,,,,,,,,,,UGT2A3 (predicted)(human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004202,CYP1A2 (predicted)(human) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_1000512,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1544|PMID:27093553,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000001544,,,,,,,,,,,,,TXPO:0004202,,,,,,,,,,,,,,,,,,,,,,CYP1A2 (predicted)(human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004207,lipid metabolism imbalance (severe) [Alcoholic  fatty liver],,"Lipid metabolism imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance of lipid metabolism. The degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Alcoholic  fatty liver.",false,,,http://purl.obolibrary.org/obo/TXPO_0001044,,,,,,,,,,,,,,,,,,,,,,"Lipid metabolism imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance of lipid metabolism. The degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Alcoholic  fatty liver.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004209,,,,,,,,,,,TXPO:0004207,,,,,,,,,,,,,,,,,,,,,,lipid metabolism imbalance (severe) [Alcoholic  fatty liver],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004204,TMEM139 (predicted)(human) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_1000538,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:135932,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000135932,,,,,,,,,,,,,TXPO:0004204,,,,,,,,,,,,,,,,,,,,,,TMEM139 (predicted)(human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004209,lipid homeostasis imbalance (severe) [Alcoholic  fatty liver],,"Lipid homeostasis imbalance is a subtype of chemical homeostasis imbalance: A process that becomes lacking a lipid homeostastasis balance. The degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Alcoholic fatty liver.",false,,,http://purl.obolibrary.org/obo/TXPO_0001038|http://purl.obolibrary.org/obo/TXPO_0003488,,,,,,,,,,,,,,,,,,,,,,"Lipid homeostasis imbalance is a subtype of chemical homeostasis imbalance: A process that becomes lacking a lipid homeostastasis balance. The degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Alcoholic fatty liver.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004207,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004210,,,,,,,,,,,TXPO:0004209,,,,,,,,,,,,,,,,,,,,,,lipid homeostasis imbalance (severe) [Alcoholic  fatty liver],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_65172,ximelagatran,ximelagatran (oxime form)|ximelagatranum|H 376-95|Exanta|H 376/95|ethyl 2-[[(1R)-1-cyclohexyl-2- [(2S)-2-[[4-(N'-hydroxycarbamimidoyl) phenyl]methylcarbamoyl]azetidin-1-yl]- 2-oxo-ethyl]amino]acetate|Exarta|ximelagatran|H 37695|ethyl N-{(1R)-1-cyclohexyl-2-[(2S)-2-{[4-(N'-hydroxycarbamimidoyl)benzyl]carbamoyl}azetidin-1-yl]-2-oxoethyl}glycinate,"A member of the class of azetidines that is melagatran in which the carboxylic acid group has been converted to the corresponding ethyl ester and in which the amidine group has been converted into the corresponding amidoxime. A prodrug for melagatran, ximelagatran was the first orally available direct thrombin inhibitor to be brought to market as an anticoagulant, but was withdrawn in 2006 following reports of it causing liver damage.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:17319469|PMID:16084146|DrugBank:DB04898|PMID:28338626|PMID:16106594|PMID:17636192|PMID:19028773|PMID:16123912|PMID:16511607|CAS:192939-46-1|PMID:15487959|Reaxys:14559655|Drug_Central:2852|PMID:16767816|PMID:20020269|PMID:12846595,,"A member of the class of azetidines that is melagatran in which the carboxylic acid group has been converted to the corresponding ethyl ester and in which the amidine group has been converted into the corresponding amidoxime. A prodrug for melagatran, ximelagatran was the first orally available direct thrombin inhibitor to be brought to market as an anticoagulant, but was withdrawn in 2006 following reports of it causing liver damage.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_50249|http://purl.obolibrary.org/obo/CHEBI_65232|http://purl.obolibrary.org/obo/CHEBI_64926|http://purl.obolibrary.org/obo/CHEBI_50266,,,,,ethyl N-{(1R)-1-cyclohexyl-2-[(2S)-2-{[4-(N'-hydroxycarbamimidoyl)benzyl]carbamoyl}azetidin-1-yl]-2-oxoethyl}glycinate,,ximelagatran (oxime form)|ximelagatranum|H 376-95|Exanta|H 376/95|ethyl 2-[[(1R)-1-cyclohexyl-2- [(2S)-2-[[4-(N'-hydroxycarbamimidoyl) phenyl]methylcarbamoyl]azetidin-1-yl]- 2-oxo-ethyl]amino]acetate|Exarta|ximelagatran|H 37695,,,,,,,,,,,,,,,,,,,,,CHEBI:65172,,,,ximelagatran,,CHEBI:65172,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100207,MAPKKKK,MAP kinase kinase kinase kinase,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,GO:0008349,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001966,,,,,MAP kinase kinase kinase kinase,,,,,IMR:0100207,,,,,,,,,,,,,,,,,,,,,,MAPKKKK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_35820,antiprotozoal drug,antiprotozoal agent|antiprotozoal drugs|antiprotozoal agents,Any antimicrobial drug which is used to treat or prevent protozoal infections.,false,,,http://purl.obolibrary.org/obo/CHEBI_36043|http://purl.obolibrary.org/obo/CHEBI_35442,,,,,,,,,,,,,,,,,,,,,,Any antimicrobial drug which is used to treat or prevent protozoal infections.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,antiprotozoal agent|antiprotozoal drugs|antiprotozoal agents,,,,,,,,,,,,,,,,,,,,,CHEBI:35820,,,,antiprotozoal drug,,CHEBI:35820,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000348158,ACSM2B,,"Other designations: acyl-CoA synthetase medium-chain family member 2|acyl-coenzyme A synthetase ACSM2B, mitochondrial|butyrate--CoA ligase 2B|butyryl-coenzyme A synthetase 2B|middle-chain acyl-CoA synthetase 2B|xenobiotic/medium-chain fatty acid-CoA ligase HXM-A|xenobiotic/medium-chain fatty acid:CoA ligase",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,ACSM2|HXMA,,,,,,,,,,,,16,,,,,,Vega:OTTHUMG00000131555|MIM:614359|HPRD:17124|Ensembl:ENSG00000066813|HGNC:30931,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,acyl-CoA synthetase medium-chain family member 2B,,,16p12.3,,,,,,,,,,,,,,,,"GO_0003674 (EC: ND); GO_0005524 (EC: IEA); GO_0005739 (EC: NAS, PMID: 19634011); GO_0005759 (EC: TAS); GO_0006631 (EC: IEA); GO_0006805 (EC: TAS); GO_0044281 (EC: TAS); GO_0046872 (EC: IEA); GO_0047760 (EC: IEA)",,,,,,,,,PMID: 8884467; 8934636; 10434065; 11415461; 12616642; 15122652; 15221005; 16521160; 19634011; 20679960,,,,,,,,,,,,,,,OGG:3000348158,,20140408,protein-coding,,,,acyl-CoA synthetase medium-chain family member 2B,,,,,,,,,,,,,"Other designations: acyl-CoA synthetase medium-chain family member 2|acyl-coenzyme A synthetase ACSM2B, mitochondrial|butyrate--CoA ligase 2B|butyryl-coenzyme A synthetase 2B|middle-chain acyl-CoA synthetase 2B|xenobiotic/medium-chain fatty acid-CoA ligase HXM-A|xenobiotic/medium-chain fatty acid:CoA ligase",,ACSM2B,,,,,,,,,,,,,,,,,,,,,,,348158,HYST1046,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,ACSM2B,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_59517,DNA synthesis inhibitor,DNA synthesis inhibitors,Any substance that inhibits the synthesis of DNA.,false,,,http://purl.obolibrary.org/obo/CHEBI_76932,,,,,,,http://purl.obolibrary.org/obo/GO_0071897,,,,,,,,,,,,,,,Any substance that inhibits the synthesis of DNA.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,DNA synthesis inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:59517,,,,DNA synthesis inhibitor,,CHEBI:59517,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004866,FZD9 (canonical) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0005086|http://purl.obolibrary.org/obo/TXPO_0005063,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:266608|NCBI-Human-GeneID:8326|NCBI-Mouse-GeneID:14371|PMID:29361730,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004866,,,,,,,,,,,,,,,,,,,,,,FZD9 (canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004862,FZD2 (canonical) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0005082|http://purl.obolibrary.org/obo/TXPO_0005063,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:2535|NCBI-Mouse-GeneID:57265|NCBI-Rat-GeneID:64512|PMID:29361730,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004862,,,,,,,,,,,,,,,,,,,,,,FZD2 (canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004867,YAP signal transduction pathway,,A series of molecular signals mediated by YAP (Yes associated protein).,false,,,http://purl.obolibrary.org/obo/TXPO_0000609,,,,,,,,,,,,,,,,,,,,,,A series of molecular signals mediated by YAP (Yes associated protein).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004867,,,,,,,,,,,,,,,,,,,,,,YAP signal transduction pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004863,FZD5 (canonical) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0005083|http://purl.obolibrary.org/obo/TXPO_0005063,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:317674|NCBI-Mouse-GeneID:14367|NCBI-Human-GeneID:7855|PMID:29361730,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004863,,,,,,,,,,,,,,,,,,,,,,FZD5 (canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004860,WNT signaling (primitive),,WNT signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by WNT.,false,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,,,WNT signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by WNT.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000003,http://purl.obolibrary.org/obo/TXPO_0004859,,,,,,,,,,,,,,,,TXPO:0004860,,,,,,,,,,,,,,,,,,,,,,WNT signaling (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004869,YAP1 (canonical) [hepatocarcinogenesis],YAP,,false,,,http://purl.obolibrary.org/obo/TXPO_0005137|http://purl.obolibrary.org/obo/TXPO_0005063,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:10413|NCBI-Rat-GeneID:363014|NCBI-Mouse-GeneID:22601|PMID:28493839|PMID:30700007,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,YAP,,,,,TXPO:0004869,,,,,,,,,,,,,,,,,,,,,,YAP1 (canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004865,FZD7 (canonical) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0005085|http://purl.obolibrary.org/obo/TXPO_0005063,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:8324|NCBI-Rat-GeneID:100360552|NCBI-Mouse-GeneID:14369|PMID:29361730,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004865,,,,,,,,,,,,,,,,,,,,,,FZD7 (canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004861,FZD1 (canonical) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0005081|http://purl.obolibrary.org/obo/TXPO_0005063,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:8321|NCBI-Rat-GeneID:58868|NCBI-Mouse-GeneID:14362|PMID:29361730,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004861,,,,,,,,,,,,,,,,,,,,,,FZD1 (canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004868,YAP signaling (primitive),,YAP signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by YAP.,false,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,,,YAP signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by YAP.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0005137,http://purl.obolibrary.org/obo/TXPO_0004867,,,,,,,,,,,,,,,,TXPO:0004868,,,,,,,,,,,,,,,,,,,,,,YAP signaling (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004864,FZD6 (canonical) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0005084|http://purl.obolibrary.org/obo/TXPO_0005063,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:8323|NCBI-Rat-GeneID:282581|NCBI-Mouse-GeneID:14368|PMID:29361730,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004864,,,,,,,,,,,,,,,,,,,,,,FZD6 (canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0007010,cytoskeleton organization,cytoskeleton organisation,"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of cytoskeletal structures.",false,,,http://purl.obolibrary.org/obo/GO_0006996,,,,,,,,,,,,,,,,,,,,,,"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of cytoskeletal structures.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,cytoskeleton organisation,,,,,GO:0007010,,,,,,,,,,,,,,,,,,,,,,cytoskeleton organization,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0007015,actin filament organization,,"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of cytoskeletal structures comprising actin filaments. Includes processes that control the spatial distribution of actin filaments, such as organizing filaments into meshworks, bundles, or other structures, as by cross-linking.",false,,,http://purl.obolibrary.org/obo/GO_0030036,,,,,,,,,,,,,,,,,,,,,,"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of cytoskeletal structures comprising actin filaments. Includes processes that control the spatial distribution of actin filaments, such as organizing filaments into meshworks, bundles, or other structures, as by cross-linking.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0007015,,,,,,,,,,,,,,,,,,,,,,actin filament organization,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100275,betacellulin,BTC,,false,,,http://purl.obolibrary.org/obo/IMR_0000047,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BTC,,,,,IMR:0100275,,,,,,,,,,,,,,,,,,,,,,betacellulin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100167,endothelin-1,ET-1,,false,,,http://purl.obolibrary.org/obo/IMR_0100166,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ET-1,,,,,IMR:0100167,,,,,,,,,,,,,,,,,,,,,,endothelin-1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000400,ETS2 (mol),E26 transformation-specific2,,false,,,http://purl.obolibrary.org/obo/IMR_0000397,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,E26 transformation-specific2,,,,,IMR:0000400,,,,,,,,,,,,,,,,,,,,,,ETS2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0000461,normal,,A quality inhering in a bearer by virtue of the bearer's exhibiting no deviation from normal or average.,false,,,http://purl.obolibrary.org/obo/PATO_0000069,,,,,,,,,,,,,,,,,,,,,,A quality inhering in a bearer by virtue of the bearer's exhibiting no deviation from normal or average.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0000461,,,,,,,,,,,,,,,,,,,,,,normal,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0000460,abnormal,,A quality inhering in a bearer by virtue of the bearer's deviation from normal or average.,false,,,http://purl.obolibrary.org/obo/PATO_0000069,,,,,,,,,,,,,,,,,,,,,,A quality inhering in a bearer by virtue of the bearer's deviation from normal or average.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0000460,,,,,,,,,,,,,,,,,,,,,,abnormal,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001618,Rab32,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001618,,,,,,,,,,,,,,,,,,,,,,Rab32,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000172,GSK2606414,,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:1337531-36-8|Wikipedia:GSK2606414|PubChem:53469448,,,,,,,,,,,,,,C24H20F3N5O,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:1000172,,,,,,,,,,,,,,,,,,,,,,GSK2606414,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000179,GSTA3 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0002089,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:14859|NCBI-Rat-GeneID:494500|NCBI-Human-GeneID:2940,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000002940,,,,,,,,,,,,,TXPO:1000179,,,,,,,,,,,,,,,,,,,,,,GSTA3 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000177,Glutathione peroxidase (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:1000177,,,,,,,,,,,,,,,,,,,,,,Glutathione peroxidase (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000173,GTSE1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:300126|NCBI-Human-GeneID:51512|NCBI-Mouse-GeneID:29870,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000051512,,,,,,,,,,,,,TXPO:1000173,,,,,,,,,,,,,,,,,,,,,,GTSE1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000178,Gpx2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:29326|NCBI-Human-GeneID:2877|NCBI-Mouse-GeneID:14776,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000002877,,,,,,,,,,,,,TXPO:1000178,,,,,,,,,,,,,,,,,,,,,,Gpx2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000170,GRM8 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:2918|NCBI-Mouse-GeneID:14823|NCBI-Rat-GeneID:60590,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000002918,,,,,,,,,,,,,TXPO:1000170,,,,,,,,,,,,,,,,,,,,,,GRM8 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000174,Gadd45a (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:13197|NCBI-Rat-GeneID:25112|NCBI-Human-GeneID:1647,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001647,,,,,,,,,,,,,TXPO:1000174,,,,,,,,,,,,,,,,,,,,,,Gadd45a (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000171,HSP90B1 (mol),GRP94,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:22027|NCBI-Rat-GeneID:362862|NCBI-Human-GeneID:7184,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000007184,,,,,,,,GRP94,,,,,TXPO:1000171,,,,,,,,,,,,,,,,,,,,,,HSP90B1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100849,PKA type II alpha regulatory subunit,cAMP-dependent protein kinase type II-alpha regulatory chain,,false,,,http://purl.obolibrary.org/obo/IMR_0100702,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,cAMP-dependent protein kinase type II-alpha regulatory chain,,,,,IMR:0100849,,,,,,,,,,,,,,,,,,,,,,PKA type II alpha regulatory subunit,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001108,transportin 2,karyopherin beta2b,,false,,,http://purl.obolibrary.org/obo/IMR_0100010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,karyopherin beta2b,,,,,IMR:0001108,,,,,,,,,,,,,,,,,,,,,,transportin 2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000168620,BHLHA15,,"Other designations: MIST-1|basic helix-loop-helix domain containing, class B, 8|class A basic helix-loop-helix protein 15|class B basic helix-loop-helix protein 8|class II bHLH protein MIST1|muscle, intestine and stomach expression 1",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,MIST1|BHLHB8,,,,,,,,,,,,7,,,,,,HGNC:22265|Vega:OTTHUMG00000154289|MIM:608606|HPRD:16356|Ensembl:ENSG00000180535,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"basic helix-loop-helix family, member a15",,,7q21.3,,,,,,,,,,,,,,,,GO_0003677 (EC: IEA); GO_0005634 (EC: IEA); GO_0006351 (EC: IEA); GO_0006355 (EC: IEA); GO_0046983 (EC: IEA),,,,,,,,,PMID: 9073453; 9482738; 12477932; 12617822; 12690205; 12853948; 14516699; 15489334; 16645041; 18557763; 20038531; 20382342; 20709804; 21098683; 21907708; 22354994; 22374815; 22495370,,,,,,,,,,,,,,,OGG:3000168620,,,,,,,"basic helix-loop-helix family, member a15",,,,,,,,,,,,,"Other designations: MIST-1|basic helix-loop-helix domain containing, class B, 8|class A basic helix-loop-helix protein 15|class B basic helix-loop-helix protein 8|class II bHLH protein MIST1|muscle, intestine and stomach expression 1",,BHLHA15,,,,,,,,,,,,,,,,,,,,,,,168620,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,BHLHA15,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000000997,CDC34,,Other designations: cell division cycle 34 homolog|ubiquitin carrier protein|ubiquitin-conjugating enzyme E2 R1|ubiquitin-conjugating enzyme E2-32 KDA complementing|ubiquitin-conjugating enzyme E2-CDC34|ubiquitin-protein ligase R1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,E2-CDC34|UBC3|UBCH3|UBE2R1,,,,,,,,,,,,19,,,,,,Vega:OTTHUMG00000180558|Ensembl:ENSG00000099804|HGNC:1734|MIM:116948|HPRD:00306,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,cell division cycle 34,,,19p13.3,,,,,,,,,,,,,,,,"GO_0000082 (EC: NAS, PMID: 8248134); GO_0000209 (EC: IDA); GO_0004842 (EC: IDA, PMID: 10373550); GO_0004842 (EC: NAS, PMID: 8248134); GO_0005515 (EC: IPI, PMID: 10373550); GO_0005524 (EC: IEA); GO_0005634 (EC: IDA); GO_0005634 (EC: NAS, PMID: 8248134); GO_0005730 (EC: IDA, Qualifier: NOT); GO_0005737 (EC: IDA); GO_0006270 (EC: NAS, PMID: 8248134); GO_0006464 (EC: NAS, PMID: 8248134); GO_0016567 (EC: IDA, PMID: 10373550); GO_0016567 (EC: NAS, PMID: 8248134); GO_0043161 (EC: IDA, PMID: 10373550); GO_0043525 (EC: IEA); GO_0043951 (EC: IDA, PMID: 10373550); GO_0070848 (EC: IEA); GO_0070936 (EC: IDA); GO_0090261 (EC: IEA)",,,,,,,,,PMID: 8248134; 8576261; 8939846; 9367342; 9430629; 9710583; 10329681; 10373550; 10385629; 10531035; 10713156; 10748083; 10769200; 10871850; 10918611; 11032804; 11054541; 11245432; 11463388; 11546811; 11566883; 11675391; 11689688; 12037680; 12060736; 12435635; 12477932; 12565873; 12813041; 12840033; 14532120; 14578910; 14645576; 14671314; 14690596; 14980219; 15327770; 15489334; 15611064; 15652359; 16123592; 16210246; 16322693; 16338364; 16472766; 16774918; 16861890; 16874460; 17274640; 17461777; 17597759; 17698585; 17785450; 17965458; 18029348; 18239684; 18458088; 18851830; 18950845; 19073596; 19084516; 19112177; 19123975; 19126550; 19240061; 19256485; 19471022; 19549727; 19581926; 19615732; 19875449; 19933270; 19945379; 20081843; 20160477; 20347421; 20353940; 20378537; 20379614; 20596027; 20638939; 20639865; 20663873; 20864041; 21098119; 21130766; 21139048; 21220517; 21296085; 21841822; 21890473; 21906983; 21963094; 22017877; 22053931; 22069333; 22087249; 22113614; 22145905; 22190037; 22210895; 22286100; 22334663; 22496338; 22669845; 22711876; 22748924; 22863883; 22959436; 23000965; 23250430; 23261596; 23297342; 23465077; 23478441; 23589337; 23604317; 23624912; 23910095; 23972993; 24129577; 24250222,,,,,,,,,,,,,,,OGG:3000000997,,,,,,,cell division cycle 34,,,,,,,,,,,,,Other designations: cell division cycle 34 homolog|ubiquitin carrier protein|ubiquitin-conjugating enzyme E2 R1|ubiquitin-conjugating enzyme E2-32 KDA complementing|ubiquitin-conjugating enzyme E2-CDC34|ubiquitin-protein ligase R1,,CDC34,,,,,,,,,,,,,,,,,,,,,,,997,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,CDC34,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000003485,IGFBP2,,Other designations: IBP-2|IGF-binding protein 2|IGFBP-2|insulin-like growth factor-binding protein 2,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,IGF-BP53|IBP2,,,,,,,,,,,,2,,,,,,Ensembl:ENSG00000115457|MIM:146731|HGNC:5471|HPRD:00898|Vega:OTTHUMG00000155341,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"insulin-like growth factor binding protein 2, 36kDa",,,2q33-q34,,,,,,,,,,,,,,,,"GO_0001558 (EC: IEA); GO_0005515 (EC: IPI, PMID:19095771); GO_0005576 (EC: ISS); GO_0005576 (EC: TAS); GO_0005615 (EC: IDA, PMID:15694994); GO_0007165 (EC: IEA); GO_0007565 (EC: IEA); GO_0007568 (EC: IEA); GO_0007584 (EC: IEA); GO_0009612 (EC: IEA); GO_0010226 (EC: IEA); GO_0016324 (EC: IEA); GO_0031410 (EC: IEA); GO_0031994 (EC: IDA, PMID:19081843); GO_0031995 (EC: ISS); GO_0032355 (EC: IEA); GO_0032526 (EC: IEA); GO_0032870 (EC: IEA); GO_0042104 (EC: IDA, PMID:15694994); GO_0042493 (EC: IEA); GO_0043567 (EC: IC, PMID:19081843); GO_0043567 (EC: ISS); GO_0044267 (EC: TAS); GO_0051384 (EC: IEA)",,,,,,,,,PMID:1376411; 1380437; 1697583; 1710112; 1712312; 1714916; 1716260; 1726837; 2465304; 2479552; 7511544; 7680905; 8675597; 8781553; 9156044; 9408744; 10407151; 10912521; 11063745; 11297622; 11358513; 12006706; 12102164; 12477932; 12519841; 12575534; 12672024; 12727212; 12794762; 12810534; 12839944; 12907597; 12955485; 14691340; 14710363; 14744083; 15147770; 15171717; 15489334; 15643522; 15651061; 15661050; 15686601; 15694994; 15735679; 15932773; 15956340; 15994346; 16183342; 16306230; 16444283; 16543235; 16569642; 16884361; 16893667; 16901920; 17020769; 17071580; 17072950; 17102589; 17113753; 17280861; 17285230; 17289850; 17341887; 17352648; 17369847; 17372210; 17395163; 17475624; 17485236; 17606927; 17655506; 17827400; 17970029; 17985932; 18210030; 18210156; 18217408; 18259111; 18373644; 18437351; 18461161; 18524796; 18556354; 18676680; 18952587; 18953566; 18980989; 19064572; 19081843; 19095771; 19124510; 19127217; 19164435; 19170196; 19276395; 19324937; 19453261; 19625176; 19679880; 19692168; 19764562; 19843326; 19845745; 19846739; 19862325; 19877176; 19948975; 19956906; 19962924; 20150439; 20306690; 20370577; 20468064; 20514406; 20515648; 20541521; 20634197; 20730703; 20731527; 20734064; 20810604; 20819778; 20858761; 21304397; 21339190; 21899885; 21951978; 21972778; 21988832; 22242132; 22253890; 22277732; 22293585; 22345562; 22459634; 22527168; 22554827; 22555360; 22571677; 22623219; 22672618; 22869145; 23071652; 23165420; 23233738; 23291564; 23397525; 23435424; 23515291; 23714241; 23767917; 23959956,,,,,,,,,,,,,,,OGG:3000003485,,,,,,,"insulin-like growth factor binding protein 2, 36kDa",,,,,,,,,,,,,Other designations: IBP-2|IGF-binding protein 2|IGFBP-2|insulin-like growth factor-binding protein 2,,IGFBP2,,,,,,,,,,,,,,,,,,,,,,,3485,,,,,,,,9606,,,,,,,,,,,,,,,,,,,IGFBP2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000003488,IGFBP5,,Other designations: IBP-5|IGF-binding protein 5|IGFBP-5|insulin-like growth factor-binding protein 5,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,IBP5,,,,,,,,,,,,2,,,,,,MIM:146734|Vega:OTTHUMG00000133058|HPRD:00901|Ensembl:ENSG00000115461|HGNC:5474,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,insulin-like growth factor binding protein 5,,,2q33-q36,,,,,,,,,,,,,,,,"GO_0001558 (EC: IEA); GO_0001649 (EC: IEA); GO_0001968 (EC: IEA); GO_0005515 (EC: IPI, PMID:15700281); GO_0005576 (EC: NAS, PMID:14718574); GO_0005576 (EC: TAS); GO_0006006 (EC: IEA); GO_0007165 (EC: NAS, PMID:7525452); GO_0010906 (EC: IEA); GO_0014912 (EC: IDA, PMID:10766744); GO_0016942 (EC: IC, PMID:10766744); GO_0017148 (EC: IDA, PMID:15700281); GO_0030336 (EC: IDA, PMID:15700281); GO_0031069 (EC: IEA); GO_0031994 (EC: IPI, PMID:10766744); GO_0035556 (EC: IEA); GO_0042593 (EC: IEA); GO_0043568 (EC: IEA); GO_0043569 (EC: IDA, PMID:10766744); GO_0044267 (EC: TAS); GO_0044342 (EC: IEA); GO_0045668 (EC: IEA); GO_0048630 (EC: IEA); GO_0048662 (EC: IDA, PMID:10766744); GO_0051146 (EC: IEA); GO_0051897 (EC: IEA); GO_0060056 (EC: IEA); GO_0071320 (EC: IDA, PMID:7559606); GO_0071407 (EC: IDA, PMID:7559606)",,,,,,,,,PMID:1147105; 1709938; 1710112; 1850257; 1850258; 7511544; 7511611; 7525452; 7559606; 8619474; 8817691; 9110174; 9202242; 9497324; 9528953; 9786878; 9822601; 9883900; 10336724; 10407151; 10698186; 10766744; 10811646; 11095942; 11264294; 11297622; 11751588; 11821401; 11874691; 11905402; 11923300; 11973331; 12005306; 12466191; 12477932; 12766061; 12777377; 12810534; 14645245; 14718574; 15001525; 15140223; 15155755; 15489334; 15534875; 15618969; 15650232; 15661050; 15681824; 15700281; 15777798; 15780948; 15802501; 15930103; 16007340; 16169070; 16195401; 16311053; 16344560; 16543235; 16716263; 16865675; 17067554; 17071587; 17242174; 17290407; 17312271; 17316888; 17496250; 17595320; 17651454; 17804819; 17823924; 17892529; 18085517; 18161051; 18210156; 18311789; 18373644; 18602100; 18624948; 18665784; 18676680; 18710598; 18762576; 18775916; 18805800; 18809517; 18957933; 19170196; 19250630; 19341485; 19453261; 19476635; 19610136; 19625176; 19628764; 19692168; 19808657; 19843326; 19877176; 19948051; 19950226; 20345844; 20354179; 20379614; 20416304; 20468064; 20508032; 20583135; 20628624; 20634197; 20734064; 20810604; 20819778; 20944648; 20949447; 21029365; 21191810; 21256825; 21460855; 21852217; 22246875; 22252554; 22328518; 22571677; 22589738; 23408906; 23499909; 23539739; 23576565; 23665505,,,,,,,,,,,,,,,OGG:3000003488,,,,,,,insulin-like growth factor binding protein 5,,,,,,,,,,,,,Other designations: IBP-5|IGF-binding protein 5|IGFBP-5|insulin-like growth factor-binding protein 5,,IGFBP5,,,,,,,,,,,,,,,,,,,,,,,3488,,,,,,,,9606,,,,,,,,,,,,,,,,,,,IGFBP5,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000003484,IGFBP1,,Other designations: IBP-1|IGF-binding protein 1|IGFBP-1|alpha-pregnancy-associated endometrial globulin|amniotic fluid binding protein|binding protein-25|binding protein-26|binding protein-28|growth hormone independent-binding protein|insulin-like growth factor-binding protein 1|placental protein 12,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,hIGFBP-1|IBP1|IGF-BP25|PP12|AFBP,,,,,,,,,,,,7,,,,,,MIM:146730|HGNC:5469|Vega:OTTHUMG00000152343|HPRD:00897|Ensembl:ENSG00000146678,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,insulin-like growth factor binding protein 1,,,7p13-p12,,,,,,,,,,,,,,,,"GO_0005520 (EC: IEA); GO_0005576 (EC: TAS); GO_0005615 (EC: IEA); GO_0006987 (EC: TAS); GO_0007165 (EC: TAS, PMID:2454104); GO_0008286 (EC: IEA); GO_0030307 (EC: IEA); GO_0030968 (EC: TAS); GO_0042246 (EC: IEA); GO_0044267 (EC: TAS)",,,,,,,,,PMID:1373120; 1691735; 1701175; 1718783; 2454104; 2457513; 2458522; 2461294; 2466665; 2474129; 2478445; 2849945; 2971653; 3419931; 7504269; 7678248; 7683522; 7683525; 7694877; 8754754; 9408744; 10329650; 10350456; 10352394; 10364674; 10407151; 10691413; 10810289; 10965886; 10987657; 11050672; 11297622; 11397868; 11752456; 11762714; 11793026; 11834727; 11956162; 11969341; 11972304; 12006706; 12082253; 12119297; 12135130; 12150454; 12153746; 12163461; 12351482; 12466191; 12477932; 12489207; 12493691; 12519841; 12556485; 12571183; 12679458; 12690205; 12746292; 12746836; 12843178; 12843192; 12853948; 12861174; 12870155; 12882925; 12933666; 14568572; 14624764; 14715837; 14718574; 14726451; 14764802; 15070833; 15070959; 15166120; 15489334; 15598684; 15613433; 15736102; 15797461; 15890677; 15959422; 15972819; 15987820; 15987847; 16002526; 16041536; 16118248; 16222695; 16293667; 16306374; 16337840; 16338475; 16404426; 16687408; 16776662; 16809446; 16868142; 16924115; 16973813; 17035411; 17062566; 17113753; 17164371; 17264182; 17300730; 17341623; 17465992; 17485842; 17566087; 17634530; 17640761; 17655506; 17803702; 17890489; 17914103; 17972051; 17972510; 18166823; 18259111; 18305566; 18496669; 18513511; 18596909; 18636124; 18665784; 18676680; 18701096; 18772238; 18793810; 18828733; 18924579; 19064572; 19124510; 19158202; 19170196; 19193607; 19308628; 19434535; 19453261; 19463807; 19539506; 19551864; 19625176; 19692168; 19730683; 19732896; 19765076; 19843326; 19858071; 19913121; 19917654; 19948975; 20039319; 20102313; 20143870; 20144192; 20149700; 20155489; 20413521; 20416304; 20453000; 20484221; 20587581; 20628086; 20634197; 20637724; 20711952; 20731527; 20734064; 20810604; 20884247; 20885978; 21078522; 21104586; 21140206; 21198359; 21212012; 21247237; 21378090; 21457161; 21521316; 21741060; 21852217; 21892205; 21930730; 21933314; 21940708; 22072736; 22104117; 22113073; 22187946; 22239027; 22325929; 22357965; 22442270; 22554827; 22745191; 22843786; 22894543; 23095194; 23190203; 23354097; 23377640; 23408645; 23585335; 23603247; 23815140; 23942851; 24132762; 24248464,,,,,,,,,,,,,,,OGG:3000003484,,,,,,,insulin-like growth factor binding protein 1,,,,,,,,,,,,,Other designations: IBP-1|IGF-binding protein 1|IGFBP-1|alpha-pregnancy-associated endometrial globulin|amniotic fluid binding protein|binding protein-25|binding protein-26|binding protein-28|growth hormone independent-binding protein|insulin-like growth factor-binding protein 1|placental protein 12,,IGFBP1,,,,,,,,,,,,,,,,,,,,,,,3484,tcag7.702,,,,,,,9606,,,,,,,,,,,,,,,,,,,IGFBP1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000003487,IGFBP4,,Other designations: IBP-4|IGF-binding protein 4|insulin-like growth factor-binding protein 4,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,IBP4|HT29-IGFBP|BP-4|IGFBP-4,,,,,,,,,,,,17,,,,,,Ensembl:ENSG00000141753|MIM:146733|HGNC:5473|Vega:OTTHUMG00000133326|HPRD:00900,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,insulin-like growth factor binding protein 4,,,17q12-q21.1,,,,,,,,,,,,,,,,"GO_0001501 (EC: TAS, PMID:1377672); GO_0001558 (EC: IEA); GO_0005520 (EC: IEA); GO_0005576 (EC: TAS); GO_0005615 (EC: IEA); GO_0006259 (EC: TAS, PMID:1377672); GO_0006954 (EC: IEA); GO_0007165 (EC: TAS, PMID:1377672); GO_0008283 (EC: TAS, PMID:1377672); GO_0010906 (EC: IEA); GO_0043410 (EC: IEA); GO_0043568 (EC: IEA); GO_0044267 (EC: TAS); GO_0044342 (EC: IEA)",,,,,,,,,PMID:1370941; 1375185; 1377672; 1380437; 1704481; 1707125; 1709161; 1709585; 7507078; 7511544; 7680905; 7683646; 7689953; 7778269; 8648179; 8889548; 8964576; 9138096; 9275067; 9408744; 9615225; 9722589; 9751498; 10407151; 11052994; 11068878; 11297622; 12163000; 12193384; 12241545; 12477932; 12733722; 12904166; 12970325; 14705967; 14767471; 14996716; 15062981; 15146197; 15146551; 15204833; 15489334; 15661050; 16540175; 16586492; 16685432; 16924115; 16973813; 17070193; 17071580; 17177834; 17312271; 17824980; 19025658; 19038974; 19453261; 19956906; 20628624; 20634197; 20654748; 20734064; 20810604; 21166939; 21207373; 21274331; 22134921; 22246875; 22332214; 22689691; 23079385; 23455924; 23499909; 23563607; 23603559,,,,,,,,,,,,,,,OGG:3000003487,,,,,,,insulin-like growth factor binding protein 4,,,,,,,,,,,,,Other designations: IBP-4|IGF-binding protein 4|insulin-like growth factor-binding protein 4,,IGFBP4,,,,,,,,,,,,,,,,,,,,,,,3487,,,,,,,,9606,,,,,,,,,,,,,,,,,,,IGFBP4,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000003486,IGFBP3,,Other designations: IBP-3|IGF-binding protein 3|IGFBP-3|acid stable subunit of the 140 K IGF complex|binding protein 29|binding protein 53|growth hormone-dependent binding protein|insulin-like growth factor-binding protein 3,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,IBP3|BP-53,,,,,,,,,,,,7,,,,,,Vega:OTTHUMG00000023769|HGNC:5472|Ensembl:ENSG00000146674|MIM:146732|HPRD:00899,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,insulin-like growth factor binding protein 3,,,7p13-p12,,,,,,,,,,,,,,,,"GO_0001558 (EC: IEA); GO_0001933 (EC: IDA, PMID:17591901); GO_0001968 (EC: IEA); GO_0005515 (EC: IPI, PMID:14561895); GO_0005520 (EC: NAS, PMID:12599210); GO_0005576 (EC: NAS, PMID:14718574); GO_0005576 (EC: TAS); GO_0005615 (EC: IDA, PMID:17119061); GO_0005634 (EC: IDA, PMID:17434920); GO_0006468 (EC: IDA, PMID:17434920); GO_0006915 (EC: IEA); GO_0008160 (EC: IDA, PMID:11940579); GO_0008285 (EC: IGI, PMID:19258508); GO_0009968 (EC: NAS, PMID:11940579); GO_0010906 (EC: IEA); GO_0014912 (EC: IDA, PMID:10766744); GO_0016942 (EC: IC, PMID:10766744); GO_0031994 (EC: IPI, PMID:10766744); GO_0043065 (EC: IMP, PMID:11971816); GO_0043085 (EC: IDA, PMID:11940579); GO_0043410 (EC: IEA); GO_0043568 (EC: IEA); GO_0044267 (EC: TAS); GO_0044342 (EC: IEA); GO_0045663 (EC: IDA, PMID:12599210); GO_0046872 (EC: NAS, PMID:14576163); GO_0048662 (EC: IDA, PMID:10766744)",,,,,,,,,PMID:1280211; 1293182; 1373120; 1383255; 1695633; 1697583; 2464130; 7508771; 7523391; 7538844; 7566179; 8550744; 8675597; 8708531; 8843739; 8964576; 9252371; 9275067; 9337997; 9388210; 9389554; 9408744; 9446566; 9497324; 9688635; 10076184; 10218588; 10226805; 10352394; 10407151; 10511594; 10512690; 10650937; 10766744; 10770214; 10811646; 10823924; 10849447; 10874028; 11095942; 11238520; 11264294; 11297622; 11319179; 11344214; 11375929; 11600567; 11749962; 11751851; 11762714; 11784719; 11801256; 11804742; 11886859; 11914023; 11914026; 11940579; 11948969; 11953210; 11959812; 11971816; 11997031; 12006706; 12011225; 12051736; 12054563; 12068000; 12111701; 12122101; 12127836; 12135130; 12150454; 12163384; 12200149; 12210764; 12213898; 12219010; 12220677; 12242693; 12473575; 12477932; 12506097; 12508918; 12519841; 12571183; 12571851; 12575534; 12590636; 12599210; 12690205; 12725526; 12730416; 12735930; 12810533; 12810534; 12853948; 12865482; 12870155; 12907612; 12925957; 12926118; 12937269; 12962157; 14561895; 14576163; 14576164; 14597676; 14598881; 14644829; 14674122; 14693733; 14702039; 14710345; 14718574; 14744783; 14751238; 14760718; 15014034; 15047131; 15059907; 15066922; 15067329; 15069073; 15070968; 15086466; 15126567; 15140235; 15178549; 15198293; 15221971; 15247132; 15247904; 15282325; 15298948; 15302288; 15340161; 15379965; 15448002; 15485880; 15489334; 15517912; 15625284; 15641262; 15641264; 15642160; 15642732; 15651061; 15661050; 15668470; 15681824; 15703779; 15734965; 15769996; 15781645; 15800934; 15802501; 15809062; 15817480; 15844718; 15894673; 15894694; 15927849; 15941947; 15959422; 15986122; 15987847; 16015705; 16030120; 16049980; 16169070; 16181731; 16189247; 16189260; 16210470; 16211216; 16215864; 16275148; 16303743; 16306136; 16322329; 16335952; 16394092; 16404426; 16448675; 16455777; 16489075; 16489531; 16540651; 16541420; 16543235; 16552541; 16614079; 16617154; 16645643; 16723126; 16763062; 16775172; 16776662; 16793770; 16825320; 16887362; 16915540; 16935391; 16965600; 16969385; 17018785; 17035411; 17044098; 17047053; 17051426; 17056474; 17063263; 17070193; 17085968; 17096329; 17113753; 17119061; 17172410; 17187018; 17210081; 17237715; 17264182; 17287408; 17289909; 17293864; 17297462; 17300730; 17350302; 17388800; 17396438; 17434446; 17434920; 17446556; 17447118; 17453001; 17457048; 17546465; 17555512; 17560154; 17566087; 17567756; 17577982; 17591901; 17593323; 17597108; 17624927; 17627014; 17635417; 17655506; 17668637; 17689128; 17719815; 17724372; 17761791; 17763192; 17803702; 17823260; 17827406; 17879951; 17912004; 17952116; 17957164; 17959403; 17972510; 17997337; 18006928; 18031946; 18059035; 18084616; 18162523; 18163429; 18171112; 18177247; 18178497; 18259111; 18287864; 18329388; 18335323; 18375957; 18398029; 18410545; 18450319; 18459102; 18471292; 18481170; 18498652; 18534134; 18562769; 18596909; 18602100; 18615538; 18618736; 18624627; 18636124; 18676680; 18812263; 18818748; 18929499; 18984657; 18992148; 18992263; 19004037; 19019335; 19020726; 19036873; 19064126; 19064572; 19077426; 19121847; 19124506; 19124510; 19127217; 19129715; 19138871; 19158946; 19170196; 19190540; 19194113; 19207313; 19217707; 19223521; 19240240; 19257984; 19258508; 19332270; 19414355; 19449212; 19453261; 19455605; 19477944; 19491931; 19492232; 19509068; 19527514; 19540231; 19551141; 19551864; 19556345; 19568604; 19588500; 19591553; 19596932; 19625176; 19633297; 19634593; 19672706; 19692168; 19734278; 19764562; 19784788; 19786462; 19786971; 19789190; 19800385; 19833751; 19845745; 19846909; 19858071; 19863750; 19913121; 19917654; 19919528; 19938081; 19941883; 19944347; 19948975; 19960406; 20003326; 20023704; 20039319; 20051649; 20084546; 20099974; 20102313; 20119675; 20121533; 20144192; 20145156; 20155489; 20204283; 20215856; 20219400; 20228135; 20302654; 20307522; 20350746; 20357812; 20378848; 20403354; 20416304; 20423985; 20427254; 20453000; 20468064; 20484221; 20501753; 20513670; 20540360; 20580999; 20587610; 20599318; 20613589; 20628086; 20628624; 20634197; 20677014; 20731527; 20734064; 20801067; 20810604; 20848532; 20851879; 20860465; 20884247; 20889360; 20920870; 20921904; 20945273; 21068693; 21076409; 21078522; 21140206; 21195059; 21216879; 21254935; 21347663; 21378090; 21383009; 21388950; 21392749; 21435441; 21447628; 21447640; 21455575; 21471542; 21474793; 21478207; 21520041; 21520165; 21521316; 21525788; 21529443; 21536375; 21536469; 21551235; 21562710; 21585623; 21636299; 21648284; 21697095; 21698457; 21701930; 21737444; 21761353; 21788435; 21823995; 21852217; 21892705; 21898383; 21930730; 21944866; 22001433; 22004906; 22026507; 22032863; 22085490; 22113073; 22128038; 22167391; 22246875; 22253890; 22278433; 22318747; 22328165; 22332214; 22347413; 22363400; 22381038; 22389159; 22415309; 22415807; 22441125; 22442270; 22475139; 22494072; 22500655; 22527168; 22543588; 22554827; 22565227; 22643116; 22739332; 22745191; 22751133; 22778398; 22801219; 22847383; 22879989; 22882716; 22884472; 22892437; 22894543; 22936258; 22951368; 23011725; 23041555; 23158139; 23174226; 23178489; 23185474; 23341348; 23348700; 23377640; 23383064; 23498137; 23527244; 23527725; 23592916; 23611528; 23619263; 23720424; 23748063; 23770368; 23789983; 23792502; 23831640; 23864804; 23962053; 24022308; 24250222,,,,,,,,,,,,,,,OGG:3000003486,,,,,,,insulin-like growth factor binding protein 3,,,,,,,,,,,,,Other designations: IBP-3|IGF-binding protein 3|IGFBP-3|acid stable subunit of the 140 K IGF complex|binding protein 29|binding protein 53|growth hormone-dependent binding protein|insulin-like growth factor-binding protein 3,,IGFBP3,,,,,,,,,,,,,,,,,,,,,,,3486,tcag7.703,,,,,,,9606,,,,,,,,,,,,,,,,,,,IGFBP3,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000003489,IGFBP6,,Other designations: IBP-6|IGF binding protein 6|IGF-binding protein 6|IGFBP-6|insulin-like growth factor-binding protein 6,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,IBP6,,,,,,,,,,,,12,,,,,,HPRD:00902|Vega:OTTHUMG00000169773|Ensembl:ENSG00000167779|MIM:146735|HGNC:5475,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,insulin-like growth factor binding protein 6,,,12q13,,,,,,,,,,,,,,,,"GO_0001558 (EC: IEA); GO_0005576 (EC: TAS); GO_0005615 (EC: IEA); GO_0005794 (EC: IEA); GO_0007165 (EC: NAS, PMID:10087296); GO_0008285 (EC: TAS, PMID:7539002); GO_0031994 (EC: IEA); GO_0044267 (EC: TAS)",,,,,,,,,PMID:1697583; 1709161; 1719383; 1850257; 1850258; 2154495; 2551732; 7511544; 7539002; 7683540; 7683646; 7692907; 9572875; 10087296; 10329650; 10407151; 10414596; 11267670; 11297622; 11914024; 12006706; 12477932; 12558805; 14710364; 15308688; 15366928; 15489334; 15661050; 15797461; 15889232; 16713569; 17519236; 17978469; 18039785; 18395833; 18676680; 18724896; 18957410; 18982452; 18985860; 19170196; 19453261; 19625176; 19692168; 19913121; 19950226; 20432455; 20628086; 20634197; 20734064; 20810604; 21054968; 21458526; 21548981; 21618524; 21820463; 21940310; 21997736; 23126425; 23623986; 24003225,,,,,,,,,,,,,,,OGG:3000003489,,,,,,,insulin-like growth factor binding protein 6,,,,,,,,,,,,,Other designations: IBP-6|IGF binding protein 6|IGF-binding protein 6|IGFBP-6|insulin-like growth factor-binding protein 6,,IGFBP6,,,,,,,,,,,,,,,,,,,,,,,3489,,,,,,,,9606,,,,,,,,,,,,,,,,,,,IGFBP6,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000736,Grb10,Growth factor receptor-bound protein 10|Insulin receptor binding protein GRB-IR|GRB10 adaptor protein,,false,,,http://purl.obolibrary.org/obo/IMR_0100382,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0010277,Growth factor receptor-bound protein 10|Insulin receptor binding protein GRB-IR|GRB10 adaptor protein,,,,,IMR:0000736,,,,,,,,,,,,,,,,,,,,,,Grb10,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000055350,VNN3,,,false,,,http://purl.obolibrary.org/obo/OGG_2070009606,,HSA238982,,,,,,,,,,,,6,,,,,,Ensembl:ENSG00000093134|HPRD:09420|MIM:606592|HGNC:16431|Vega:OTTHUMG00000015589,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,vanin 3,,,6q23.2,,,,,,,,,,,,,,,,"GO_0005575 (EC: ND); GO_0005615 (EC: IEA); GO_0005886 (EC: IEA); GO_0008150 (EC: ND); GO_0015939 (EC: IEA); GO_0017159 (EC: NAS, PMID: 11491533); GO_0031225 (EC: IEA)",,,,,,,,,PMID: 10501839; 11491533; 12477932; 14574404; 16344560; 18805469; 19322213; 19932582,,,,,,,,,,,,,,,OGG:3000055350,,,,,,,vanin 3,,,,,,,,,,,,,,,VNN3,,,,,,,,,,,,,,,,,,,,,,,55350,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,VNN3,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0100249,MLK,mixed lineage kinase,,false,,,http://purl.obolibrary.org/obo/IMR_0000239,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,mixed lineage kinase,,,,,IMR:0100249,,,,,,,,,,,,,,,,,,,,,,MLK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000010218,ANGPTL7,,Other designations: angiopoietin-like factor (CDT6)|angiopoietin-like protein 7|angiopoietin-related protein 7|cornea-derived transcript 6 protein,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,dJ647M16.1|AngX|CDT6,,,,,,,,,,,,1,,,,,,HPRD:10818|Vega:OTTHUMG00000002002|HGNC:24078|Ensembl:ENSG00000171819,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,angiopoietin-like 7,,,1p36,,,,,,,,,,,,,,,,"GO_0005576 (EC: IEA); GO_0006979 (EC: TAS, PMID:8026862)",,,,,,,,,PMID:8026862; 8144038; 9727400; 11426320; 11682471; 12107410; 12477932; 12975309; 15340161; 15489334; 16710414; 17695521; 18421092; 21199193; 21697133; 21832049,,,,,,,,,,,,,,,OGG:3000010218,,,,,,,angiopoietin-like 7,,,,,,,,,,,,,Other designations: angiopoietin-like factor (CDT6)|angiopoietin-like protein 7|angiopoietin-related protein 7|cornea-derived transcript 6 protein,,ANGPTL7,,,,,,,,,,,,,,,,,,,,,,,10218,RP4-647M16.2,,,,,,,9606,,,,,,,,,,,,,,,,,,,ANGPTL7,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/PATO_0001417,irregular duration,,A duration quality of a process inhering in a bearer by virtue of the bearer's duration which has irregular start and/or end times.,false,,,http://purl.obolibrary.org/obo/PATO_0001309,,,,,,,,,,,,,,,,,,,,,,A duration quality of a process inhering in a bearer by virtue of the bearer's duration which has irregular start and/or end times.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0001417,,,,,,,,,,,,,,,,,,,,,,irregular duration,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0001416,reguar duration,,A duration which has regular start and/or end times.,false,,,http://purl.obolibrary.org/obo/PATO_0001309,,,,,,,,,,,,,,,,,,,,,,A duration which has regular start and/or end times.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0001416,,,,,,,,,,,,,,,,,,,,,,reguar duration,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_35549,Perfluorooctanoic acid,perfluorooctanoate|PFOA|pentadecafluorooctanoic acid,A fluoroalkanoic acid that is perfluorinated octanoic acid.,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Wikipedia:Perfluorooctanoic_acid|CAS:335-67-1,,A fluoroalkanoic acid that is perfluorinated octanoic acid.,,,,,,,,,,,,C8HF15O2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,perfluorooctanoate|PFOA|pentadecafluorooctanoic acid,,,,,CHEBI:35549,,,,,,,,,,,,,,,,,,,,,,Perfluorooctanoic acid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,OC(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F,,,,,
http://purl.obolibrary.org/obo/IMR_0100771,Wnt-5a,,,false,,,http://purl.obolibrary.org/obo/IMR_0000003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100771,,,,,,,,,,,,,,,,,,,,,,Wnt-5a,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001647,caveolin-1,Cav-1,,false,,,http://purl.obolibrary.org/obo/IMR_0000515,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Cav-1,,,,,IMR:0001647,,,,,,,,,,,,,,,,,,,,,,caveolin-1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100331,XIAP,mammalian IAP homologue A|ILP-1|X-linked IAP|IAP-like protein|MIHA,,false,,,http://purl.obolibrary.org/obo/IMR_0000454,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,mammalian IAP homologue A|ILP-1|X-linked IAP|IAP-like protein|MIHA,,,,,IMR:0100331,,,,,,,,,,,,,,,,,,,,,,XIAP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000022996,TTC39A,,Other designations: TPR repeat protein 39A|differentially expressed in MCF7 with estradiol protein 6|tetratricopeptide repeat protein 39A,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,C1orf34|DEME-6,,,,,,,,,,,,1,,,,,,Vega:OTTHUMG00000008193|Ensembl:ENSG00000085831|HGNC:18657,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,tetratricopeptide repeat domain 39A,,,1p32.3,,,,,,,,,,,,,,,,GO_0003674 (EC: ND); GO_0005575 (EC: ND); GO_0008150 (EC: ND),,,,,,,,,PMID: 9455484; 9461476; 12477932,,,,,,,,,,,,,,,OGG:3000022996,,20140408,protein-coding,,,,tetratricopeptide repeat domain 39A,,,,,,,,,,,,,Other designations: TPR repeat protein 39A|differentially expressed in MCF7 with estradiol protein 6|tetratricopeptide repeat protein 39A,,TTC39A,,,,,,,,,,,,,,,,,,,,,,,22996,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,TTC39A,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/GO_0031965,nuclear membrane,,Either of the lipid bilayers that surround the nucleus and form the nuclear envelope; excludes the intermembrane space.,false,,,http://purl.obolibrary.org/obo/GO_0031090,,,,,,,,,,,,,,,,,,,,NIF_Subcellular:sao1687101204,,Either of the lipid bilayers that surround the nucleus and form the nuclear envelope; excludes the intermembrane space.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0031965,,,,,,,,,,,,,,,,,,,,,,nuclear membrane,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0031966,mitochondrial membrane,,Either of the lipid bilayers that surround the mitochondrion and form the mitochondrial envelope.,false,,,http://purl.obolibrary.org/obo/GO_0031090,,,,,,,,,,,,,,,,,,,,NIF_Subcellular:sao1045389829,,Either of the lipid bilayers that surround the mitochondrion and form the mitochondrial envelope.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0000970,,,,,,,,,,,,,,GO:0031966,,,,,,,,,,,,,,,,,,,,,,mitochondrial membrane,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001430,BMP-6,Vgr-1|Bone morphogenetic protein 6|BMP6,,false,,,http://purl.obolibrary.org/obo/IMR_0003084,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Vgr-1|Bone morphogenetic protein 6|BMP6,,,,,IMR:0001430,,,,,,,,,,,,,,,,,,,,,,BMP-6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001470,DOCK2,,,false,,,http://purl.obolibrary.org/obo/IMR_0001469,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001470,,,,,,,,,,,,,,,,,,,,,,DOCK2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000386,positive regulation of ERAD [ER stress],,"Any process that activates or increases the frequency, rate or extent of ERAD pathway.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/GO_1904294|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"Any process that activates or increases the frequency, rate or extent of ERAD pathway.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000728,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002204,,,,,,,,,,,TXPO:0000386,,,,,,,,,,,,,,,,,,,,,,positive regulation of ERAD [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000383,abnormal protein-degrading enzyme production [ER stress],,"Abnormal protein-degrading enzyme production is a subtype of protein production: A process that makes existent of an abnormal protein-degrading enzyme protein due to biosynthesis or secretion resulting in an increase in its levels.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000385|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"Abnormal protein-degrading enzyme production is a subtype of protein production: A process that makes existent of an abnormal protein-degrading enzyme protein due to biosynthesis or secretion resulting in an increase in its levels.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000383,,,,,,,,,,,,,,,,,,,,,,abnormal protein-degrading enzyme production [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000380,making existence,,Making existence is a subtype of functioning process: A process that makes a target object to be present in another object.,false,,,http://purl.obolibrary.org/obo/TXPO_0000378,,,,,,,,,,,,,,,,,,,,,,Making existence is a subtype of functioning process: A process that makes a target object to be present in another object.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000380,,,,,,,,,,,,,,,,,,,,,,making existence,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000381,generating,,Generating is a subtype of funcioning: A process that produces output from nothing.,false,,,http://purl.obolibrary.org/obo/TXPO_0000378,,,,,,,,,,,,,,,,,,,,,,Generating is a subtype of funcioning: A process that produces output from nothing.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/BFO_0000002,,,,,,,,,,,,,,,,,,,TXPO:0000381,,,,,,,,,,,,,,,,,,,,,,generating,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000388,PERK autophosphorylation [ER stress - translation attenuation],,"PERK autophosphorylation is a subtype of protein autophosphorylation: The phosphorylation by PERK of one or more of its own amino acid residues (cis-autophosphorylation), or residues on PERK (trans-autophosphorylation).
This process is dependent on the translation attenuation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000674,,,,,,,,,,,,,,,,,,,,,,"PERK autophosphorylation is a subtype of protein autophosphorylation: The phosphorylation by PERK of one or more of its own amino acid residues (cis-autophosphorylation), or residues on PERK (trans-autophosphorylation).
This process is dependent on the translation attenuation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002858,,,,,,,,,,,,,,,,,TXPO:0000388,,,,,,,,,,,,,,,,,,,,,,PERK autophosphorylation [ER stress - translation attenuation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000382,protein production,,Protein production is a subtype of generating: A process that synthesizes protein (s)  resulting in having output (s).,false,,,http://purl.obolibrary.org/obo/TXPO_0000019,,,,,,,,,,,,,,,,,,,,,,Protein production is a subtype of generating: A process that synthesizes protein (s)  resulting in having output (s).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_36080,http://purl.obolibrary.org/obo/GO_0006412,,,,,,,,,,,,,,,,,,TXPO:0000382,,,,,,,,,,,,,,,,,,,,,,protein production,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000385,abnormal protein-degrading enzyme production,,Abnormal protein-degrading enzyme production is a subtype of protein production: A process that makes existent of an abnormal protein-degrading enzyme protein due to biosynthesis or secretion resulting in an increase in its levels.,false,,,http://purl.obolibrary.org/obo/TXPO_0000382,,,,,,,,,,,,,,,,,,,,,,Abnormal protein-degrading enzyme production is a subtype of protein production: A process that makes existent of an abnormal protein-degrading enzyme protein due to biosynthesis or secretion resulting in an increase in its levels.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000385,,,,,,,,,,,,,,,,,,,,,,abnormal protein-degrading enzyme production,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000387,changing,,Changing is a subtype of making existence: A process that makes a target object different.,false,,,http://purl.obolibrary.org/obo/TXPO_0000380,,,,,,,,,,,,,,,,,,,,,,Changing is a subtype of making existence: A process that makes a target object different.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000387,,,,,,,,,,,,,,,,,,,,,,changing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000384,chaperon production,,Chaperon production is a subtype of protein production: A process that makes existent of a protein with a chaperon role due to biosynthesis or secretion resulting in an increase in its levels.,false,,,http://purl.obolibrary.org/obo/TXPO_0000382,,,,,,,,,,,,,,,,,,,,,,Chaperon production is a subtype of protein production: A process that makes existent of a protein with a chaperon role due to biosynthesis or secretion resulting in an increase in its levels.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000384,,,,,,,,,,,,,,,,,,,,,,chaperon production,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000389,converting signal to information,,Converting signal to information is a subtype of converting to information: A process that changes a signal to information.,false,,,http://purl.obolibrary.org/obo/TXPO_0002567,,,,,,,,,,,,,,,,,,,,,,Converting signal to information is a subtype of converting to information: A process that changes a signal to information.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0010467,,,,,,,,,,,TXPO:0000389,,,,,,,,,,,,,,,,,,,,,,converting signal to information,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0001775,cell activation,,A change in the morphology or behavior of a cell resulting from exposure to an activating factor such as a cellular or soluble ligand.,false,,,http://purl.obolibrary.org/obo/TXPO_0000401,,,,,,,,,,,,,,,,,,,,,,A change in the morphology or behavior of a cell resulting from exposure to an activating factor such as a cellular or soluble ligand.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0001775,,,,,,,,,,,,,,,,,,,,,,cell activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000135,IFNR type I,Interferon alpha/beta receptor|IFNAR,,false,,,http://purl.obolibrary.org/obo/IMR_0000134,,,,,,,,,,,,,,,,,,,,GO:0004905,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Interferon alpha/beta receptor|IFNAR,,,,,IMR:0000135,,,,,,,,,,,,,,,,,,,,,,IFNR type I,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0003509,arterial blood vessel,,"A blood vessel that is part of the arterial system. Includes artery, arteriole and aorta.|only in MA - supertype of artery, arteriole, aorta.",false,,,http://purl.obolibrary.org/obo/UBERON_0001981,,,,,,,,,,,,,,,,,,,,MA:0000061|EMAPA:35144,,"A blood vessel that is part of the arterial system. Includes artery, arteriole and aorta.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0004572,UBERON:0003509,http://purl.obolibrary.org/obo/UBERON_0004572,,,,,,,,,,,,,,,,,,,"only in MA - supertype of artery, arteriole, aorta.",,arterial blood vessel,,,,,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0003501,retina blood vessel,,A blood vessel that is part of a retina.,false,,,http://purl.obolibrary.org/obo/UBERON_0001981,,,,,,,,,,,,,,,,,,,,MESH:D012171|http://www.snomedbrowser.com/Codes/Details/280692003,,A blood vessel that is part of a retina.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,UBERON:0003501,,,,,,,,,,,,,,,,,,,,,,retina blood vessel,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001636,Rab40C,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001636,,,,,,,,,,,,,,,,,,,,,,Rab40C,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003354,lysosomal enzyme transport (to lysosome) [Phospholipidosis],,"lysosomal enzyme transport to lysosome is a subtype of transport: A process that of the transfer of a lysosomal enzyme (from the ribosome to the lysosome).
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003355|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"lysosomal enzyme transport to lysosome is a subtype of transport: A process that of the transfer of a lysosomal enzyme (from the ribosome to the lysosome).
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001406,,,,,,,,,,,TXPO:0003354,,,,,,,,,,,,,,,,,,,,,,lysosomal enzyme transport (to lysosome) [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005770,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003352,negative regulation of increasing insulin resistance [Phospholipidosis],,"Negative regulation of increasing insulin resistance is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of insulin resistance.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002537|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of increasing insulin resistance is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of insulin resistance.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003350,,,,,,,,,,,,,,,,,TXPO:0003352,,,,,,,,,,,,,,,,,,,,,,negative regulation of increasing insulin resistance [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003359,phospholipidosis (mild),,The totality of all processes through which the phospholipidosis is realized. The severity is mild.,false,,,http://purl.obolibrary.org/obo/TXPO_0002215,,,,,,,,,,,,,,,,,,,,PMID:16979167|PMID:22960355|PMID:15342952,,The totality of all processes through which the phospholipidosis is realized. The severity is mild.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003453|http://purl.obolibrary.org/obo/TXPO_0004155|http://purl.obolibrary.org/obo/TXPO_0001777|http://purl.obolibrary.org/obo/TXPO_0001241|http://purl.obolibrary.org/obo/TXPO_0001824|http://purl.obolibrary.org/obo/TXPO_0002088|http://purl.obolibrary.org/obo/TXPO_0002087,,,,,,,,,,,,,,,,,,TXPO:0003359,,,,,,,,,,,,,,,,,,,,,,phospholipidosis (mild),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003355,transportng lysosomal enzyme from ribosome to lysosome,,lysosomal enzyme transport (from ribosome to lysosome) is a subtype of transport: A process that of the transfer of a lysosomal enzyme (from the ribosome to the lysosome).,false,,,http://purl.obolibrary.org/obo/GO_0006810,,,,,,,,,,,,,,,,,,,,,,lysosomal enzyme transport (from ribosome to lysosome) is a subtype of transport: A process that of the transfer of a lysosomal enzyme (from the ribosome to the lysosome).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005764,http://purl.obolibrary.org/obo/GO_0005840,,,,,,,TXPO:0003355,,,,,,,,,,,,,,,,,,,,,,transportng lysosomal enzyme from ribosome to lysosome,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005770,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003357,keeping amount of phospholipid in lysosome,,Keeping amount of phospholipid in lysosome is a subtype of keeping amount: A process that maintaining the amount of lysosomal phospholipid.,false,,,http://purl.obolibrary.org/obo/TXPO_0000414,,,,,,,,,,,,,,,,,,,,,,Keeping amount of phospholipid in lysosome is a subtype of keeping amount: A process that maintaining the amount of lysosomal phospholipid.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003357,,,,,,,,,,,,,,,,,,,,,,keeping amount of phospholipid in lysosome,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003351,inhibitor of insulin resistance,,A role played by the entity that ihibits the insulin resistance.,false,,,http://purl.obolibrary.org/obo/TXPO_0003230,,,,,,,,,,,,,,,,,,,,,,A role played by the entity that ihibits the insulin resistance.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003351,,,,,,,,,,,,,,,,,,,,,,inhibitor of insulin resistance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003356,phospholipidosis (normal course),,Phospholipidosis (normal course) is a subtype of process sequences: The courses of processes through which phospholipid homeostasis balance is keeping.,false,,,http://purl.obolibrary.org/obo/TXPO_0003382,,,,,,,,,,,,,,,,,,,,,,Phospholipidosis (normal course) is a subtype of process sequences: The courses of processes through which phospholipid homeostasis balance is keeping.,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001772,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001435|http://purl.obolibrary.org/obo/TXPO_0001772|http://purl.obolibrary.org/obo/TXPO_0001683,,,,,,,,,,,,,,,,,,TXPO:0003356,,,,,,,,,,,,,,,,,,,,,,phospholipidosis (normal course),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003350,ASAH1 (human)[Phospholipidosis - insulin resistance inhibition],,"This gene encodes a member of the acid ceramidase family of proteins. Alternative splicing results in multiple transcript variants, at least one of which encodes a preproprotein that is proteolytically processed. Processing of this preproprotein generates alpha and beta subunits that heterodimerize to form the mature lysosomal enzyme, which catalyzes the degradation of ceramide into sphingosine and free fatty acid. This enzyme is overexpressed in multiple human cancers and may play a role in cancer progression. Mutations in this gene are associated with the lysosomal storage disorder, Farber lipogranulomatosis, and a neuromuscular disorder, spinal muscular atrophy with progressive myoclonic epilepsy. [provided by RefSeq, Oct 2015]",false,,,http://purl.obolibrary.org/obo/TXPO_0000529,,,,,,,,,,,,,,,,,,,,http://www.ncbi.nlm.nih.gov/gene/427|http://omim.org/entry/613468,,"This gene encodes a member of the acid ceramidase family of proteins. Alternative splicing results in multiple transcript variants, at least one of which encodes a preproprotein that is proteolytically processed. Processing of this preproprotein generates alpha and beta subunits that heterodimerize to form the mature lysosomal enzyme, which catalyzes the degradation of ceramide into sphingosine and free fatty acid. This enzyme is overexpressed in multiple human cancers and may play a role in cancer progression. Mutations in this gene are associated with the lysosomal storage disorder, Farber lipogranulomatosis, and a neuromuscular disorder, spinal muscular atrophy with progressive myoclonic epilepsy. [provided by RefSeq, Oct 2015]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003351,,,,,,,,,,TXPO:0003350,,,,,,,,,,,,,,,,,,,,,,ASAH1 (human)[Phospholipidosis - insulin resistance inhibition],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003353,substance with cationic amphiphilic drug role,,Substance with substance with cationic amphiphilic drug role is a subtype of substance with role. This entity is participating in a biological process and playing a cationic amphiphilic drug role.|This entity is inferred from Description Logic.,false,,,http://purl.obolibrary.org/obo/CHEBI_24431|http://purl.obolibrary.org/obo/GOCHE_50906,,,,,,,,,,,,,,,,,,,,PMID:9061852,,Substance with substance with cationic amphiphilic drug role is a subtype of substance with role. This entity is participating in a biological process and playing a cationic amphiphilic drug role.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0001886|http://purl.obolibrary.org/obo/PATO_0001884,,,,,,,,,,,,,,TXPO:0003353,,,,,,,,,,,,,,,,,,,,This entity is inferred from Description Logic.,,substance with cationic amphiphilic drug role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003358,keeping amount of phospholipid in lysosome [Phospholipidosis],,"Keeping amount of phospholipid in lysosome is a subtype of keeping amount: A process that maintaining the amount of lysosomal phospholipid.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003357|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Keeping amount of phospholipid in lysosome is a subtype of keeping amount: A process that maintaining the amount of lysosomal phospholipid.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003358,,,,,,,,,,,,,,,,,,,,,,keeping amount of phospholipid in lysosome [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005764,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OBI_0000017,regulatory role,,"a role which inheres in material entities and is realized in the processes of making, enforcing or being defined by legislation or orders issued by a governmental body.",false,,,http://purl.obolibrary.org/obo/BFO_0000023,,,,,,,,,,,,,,,,,,,govt agents responsible for creating regulations; proxies for enforcing regulations.  CDISC definition:  regulatory authorities. Bodies having the power to regulate. NOTE: In the ICH GCP guideline the term includes the authorities that review submitted clinical data and those that conduct inspections. These bodies are sometimes referred to as competent,,,"a role which inheres in material entities and is realized in the processes of making, enforcing or being defined by legislation or orders issued by a governmental body.","OBI, CDISC|Regulatory agency, Ethics committee, Approval letter; example:  Browse these EPA Regulatory Role subtopics  http://www.epa.gov/ebtpages/enviregulatoryrole.html  Feb 29, 2008",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,OBI:0000017,,,,,,,,,,,,,,,,,,,,,,regulatory role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000004018,LPA,,Other designations: antiangiogenic AK38 protein|apo(a)|apolipoprotein(a)|lp(a),false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,APOA|LP|AK38,,,,,,,,,,,,6,,,,,,MIM:152200|Ensembl:ENSG00000198670|HPRD:01063|HGNC:6667|Vega:OTTHUMG00000015956,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"lipoprotein, Lp(a)",,,6q26,,,,,,,,,,,,,,,,"GO_0001968 (EC: IPI, PMID: 2531657); GO_0004252 (EC: IDA, PMID: 2531657); GO_0004866 (EC: TAS, PMID: 8047165); GO_0005576 (EC: NAS, PMID: 14718574); GO_0005576 (EC: TAS); GO_0006629 (EC: NAS, PMID: 8047165); GO_0006869 (EC: IEA); GO_0006898 (EC: TAS); GO_0008015 (EC: TAS, PMID: 8047165); GO_0008201 (EC: NAS, PMID: 2531657); GO_0010951 (EC: TAS, PMID: 8047165); GO_0034185 (EC: IPI, PMID: 9269765); GO_0034358 (EC: IDA, PMID: 2531657); GO_0042157 (EC: TAS); GO_0044281 (EC: TAS)",,,,,,,,,PMID: 2530631; 2531657; 3410459; 3670400; 7918682; 8047165; 8642595; 8864963; 9111002; 9269765; 9548923; 9717723; 9925657; 10073957; 10187779; 10484779; 10672142; 10980194; 11126727; 11285247; 11294842; 11332648; 11440434; 11485023; 11816712; 11822583; 11833851; 11865151; 11947970; 11999088; 12082592; 12111551; 12127051; 12220441; 12359323; 12482643; 12562843; 12578871; 12738397; 12940514; 14718574; 14746139; 15041277; 15258620; 15479125; 15515480; 15523644; 15543335; 15654123; 15708348; 15905467; 15983325; 16053196; 16113787; 16122830; 16150826; 16197951; 16202171; 16403785; 16497311; 16625232; 16840570; 16893192; 17145597; 17460176; 17462619; 17478739; 17537433; 17569884; 17603063; 17683612; 17845920; 17908332; 17923276; 17942087; 17975119; 18086931; 18163888; 18198982; 18280807; 18304554; 18386550; 18464913; 18479303; 18513389; 18560444; 18582452; 18594118; 18599799; 18622136; 18660489; 18682748; 18682798; 18775538; 18776185; 18806883; 18848929; 18983515; 19014618; 19023099; 19124843; 19131662; 19198611; 19208510; 19222374; 19233690; 19263529; 19335423; 19348789; 19349573; 19479237; 19496273; 19509380; 19545557; 19564206; 19572086; 19636317; 19642912; 19646429; 19672030; 19808717; 19880117; 19913121; 19948975; 20014954; 20026018; 20032323; 20036902; 20106478; 20129380; 20129381; 20129382; 20129383; 20143106; 20160194; 20197188; 20303190; 20379614; 20444451; 20452482; 20580413; 20593350; 20601648; 20605575; 20628086; 20673868; 20679960; 20686565; 20691971; 20705065; 20971364; 21078622; 21086792; 21127300; 21149283; 21153771; 21179199; 21231777; 21252144; 21283670; 21300353; 21378990; 21404224; 21473861; 21484527; 21493818; 21519277; 21592478; 21749171; 21802535; 21900290; 21907882; 21914687; 21914962; 21970553; 21986921; 22010162; 22134617; 22192511; 22207727; 22283971; 22327610; 22331829; 22368281; 22387060; 22407494; 22422337; 22485129; 22516069; 22633661; 22710560; 22748161; 22753196; 22762941; 23010950; 23036009; 23040268; 23099120; 23118302; 23137279; 23165148; 23183511; 23202367; 23243000; 23357149; 23375930; 23388002; 23484137; 23652366; 23701995; 23726366; 23735648; 23903772; 23914433; 23973688; 24089516; 24092750,,,,,,,,,,,,,,,OGG:3000004018,,,,,,,"lipoprotein, Lp(a)",,,,,,,,,,,,,Other designations: antiangiogenic AK38 protein|apo(a)|apolipoprotein(a)|lp(a),,LPA,,,,,,,,,,,,,,,,,,,,,,,4018,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,LPA,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_575568,atovaquone,"Wellvone|Mepron|Acuvel|2-(trans-4-(p-Chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone|atovaquone|2-[trans-4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone",A naphthoquinone compound having a 4-(4-chlorophenyl)cyclohexyl group at the 2-position and a hydroxy substituent at the 3-position.,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:95233-18-4|PMID:10658902|Drug_Central:258|PMID:21735454|DrugBank:DB01117|PMID:23292347|Beilstein:8076827|PMID:15044733|PMID:12791689|PMID:11956677|PMID:15718226|PMID:14727190,,A naphthoquinone compound having a 4-(4-chlorophenyl)cyclohexyl group at the 2-position and a hydroxy substituent at the 3-position.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_77106|http://purl.obolibrary.org/obo/CHEBI_35718|http://purl.obolibrary.org/obo/CHEBI_77103|http://purl.obolibrary.org/obo/CHEBI_38068|http://purl.obolibrary.org/obo/CHEBI_38503,,,,,"2-[trans-4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone",,"Wellvone|Mepron|Acuvel|2-(trans-4-(p-Chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone|atovaquone",,,,,,,,,,,,,,,,,,,,,CHEBI:575568,,,,atovaquone,,CHEBI:575568,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_38807,calcium channel agonist,calcium channel activator,Agents that increase calcium influx into calcium channels of excitable tissues.,false,,,http://purl.obolibrary.org/obo/CHEBI_38808,,,,,,,,,,,,,,,,,,,,,,Agents that increase calcium influx into calcium channels of excitable tissues.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,calcium channel activator,,,CHEBI:38807,,,,,,,,,,,,,,,,,,,,,,calcium channel agonist,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010443,60S ribosomal protein L10a,CSA-19,,false,,,http://purl.obolibrary.org/obo/IMR_0000897,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CSA-19,,,,,IMR:0010443,,,,,,,,,,,,,,,,,,,,,,60S ribosomal protein L10a,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000640,Integrin alpha-X,,,false,,,http://purl.obolibrary.org/obo/IMR_0000173,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000640,,,,,,,,,,,,,,,,,,,,,,Integrin alpha-X,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_90454,lysophosphatidylglycerol,monoacylglycerophosphoglycerol,"A glycerophosphoglycerol resulting from partial hydrolysis of a phosphatidylglycerol, which removes one of the fatty acid groups. The structure is depicted in the image where R1 = acyl, R2 = H or where R1 = H, R2 = acyl.",false,,,http://purl.obolibrary.org/obo/CHEBI_24360,,,,,,,,,,,,,,,,,,,,,,"A glycerophosphoglycerol resulting from partial hydrolysis of a phosphatidylglycerol, which removes one of the fatty acid groups. The structure is depicted in the image where R1 = acyl, R2 = H or where R1 = H, R2 = acyl.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,monoacylglycerophosphoglycerol,,,,,CHEBI:90454,,,,,,,,,,,,,,,,,,,,,,lysophosphatidylglycerol,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001628,Rab37,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001628,,,,,,,,,,,,,,,,,,,,,,Rab37,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0011153,eIF4A-I,eIF4AI|eIF-4A-I|eukaryotic initiation factor 4A-I,,false,,,http://purl.obolibrary.org/obo/IMR_0000906,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,eIF4AI|eIF-4A-I|eukaryotic initiation factor 4A-I,,,,,IMR:0011153,,,,,,,,,,,,,,,,,,,,,,eIF4A-I,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006950,response to stress,,"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a disturbance in organismal or cellular homeostasis, usually, but not necessarily, exogenous (e.g. temperature, humidity, ionizing radiation).",false,,,http://purl.obolibrary.org/obo/GO_0050896,,,,,,,,,,,,,,,,,,,,,,"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a disturbance in organismal or cellular homeostasis, usually, but not necessarily, exogenous (e.g. temperature, humidity, ionizing radiation).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0006950,,,,,,,,,,,,,,,,,,,,,,response to stress,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006955,immune response,,Any immune system process that functions in the calibrated response of an organism to a potential internal or invasive threat.,false,,,http://purl.obolibrary.org/obo/GO_0050896,,,,,,,,,,,,,,,,,,,,,,Any immune system process that functions in the calibrated response of an organism to a potential internal or invasive threat.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000296|http://purl.obolibrary.org/obo/TXPO_0003646|http://purl.obolibrary.org/obo/TXPO_0003990,,,,,,,,,,,,,,,,,,GO:0006955,,,,,,,,,,,,,,,,,,,,,,immune response,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0002097,"neoplastic, malignant",,"A disposition inhering in a tumour by virtue of the bearer's disposition to progress, invade surrounding tissues or metastasize.",false,,,http://purl.obolibrary.org/obo/PATO_0002011,,,,,,,,,,,,,,,,,,,,,,"A disposition inhering in a tumour by virtue of the bearer's disposition to progress, invade surrounding tissues or metastasize.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0002097,,,,,,,,,,,,,,,,,,,,,,"neoplastic, malignant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0002091,subacute,,A quality of a single process inhering in a bearer by virtue of the bearer's having an onset and time course between acute and chronic.,false,,,http://purl.obolibrary.org/obo/PATO_0000389,,,,,,,,,,,,,,,,,,,,,,A quality of a single process inhering in a bearer by virtue of the bearer's having an onset and time course between acute and chronic.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0002091,,,,,,,,,,,,,,,,,,,,,,subacute,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0002094,basophilic,,An affinity inhering in a tissue constituent by virtue of the bearer exhibiting a molecular interaction for basic dyes under specific ph conditions.,false,,,http://purl.obolibrary.org/obo/PATO_0002070,,,,,,,,,,,,,,,,,,,,,,An affinity inhering in a tissue constituent by virtue of the bearer exhibiting a molecular interaction for basic dyes under specific ph conditions.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0002094,,,,,,,,,,,,,,,,,,,,,,basophilic,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0002098,"neoplastic, metastatic",,A disposition inhering in a tumour by virtue of the bearer's disposition to spread and invade distant tissues.,false,,,http://purl.obolibrary.org/obo/PATO_0002011,,,,,,,,,,,,,,,,,,,,,,A disposition inhering in a tumour by virtue of the bearer's disposition to spread and invade distant tissues.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0002098,,,,,,,,,,,,,,,,,,,,,,"neoplastic, metastatic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0002096,"neoplastic, non-malignant",,"A disposition inhering in a tumour by virtue of the bearer's disposition not to progress, invade surrounding tissues or metastasize.",false,,,http://purl.obolibrary.org/obo/PATO_0002011,,,,,,,,,,,,,,,,,,,,,,"A disposition inhering in a tumour by virtue of the bearer's disposition not to progress, invade surrounding tissues or metastasize.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0002096,,,,,,,,,,,,,,,,,,,,,,"neoplastic, non-malignant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000002826,CCR10,,Other designations: C-C CKR-10|C-C chemokine receptor type 10|CC chemokine receptor 10|CC-CKR-10|CCR-10|G protein-coupled receptor 2|G-protein coupled receptor 2,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,GPR2,,,,,,,,,,,,17,,,,,,HPRD:02586|HGNC:4474|MIM:600240,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,chemokine (C-C motif) receptor 10,,,17q21.1-q21.3,,,,,,,,,,,,,,,,"GO_0004930 (EC: TAS, PMID:7851889); GO_0005886 (EC: TAS); GO_0005887 (EC: TAS, PMID:7851889); GO_0006935 (EC: IEA); GO_0006955 (EC: IEA); GO_0007186 (EC: TAS, PMID:7851889); GO_0007204 (EC: IEA); GO_0016493 (EC: IEA)",,,,,,,,,PMID:7851889; 8889548; 9364936; 10706668; 10725696; 10725697; 10781587; 10975800; 11298490; 11821900; 12477932; 14667819; 15489334; 15700309; 16460738; 16675558; 16785557; 17071491; 17474147; 18240029; 18577758; 18782672; 20237496; 20947433; 21075690; 21937703; 22350183; 22526457; 22944692,,,,,,,,,,,,,,,OGG:3000002826,,,,,,,chemokine (C-C motif) receptor 10,,,,,,,,,,,,,Other designations: C-C CKR-10|C-C chemokine receptor type 10|CC chemokine receptor 10|CC-CKR-10|CCR-10|G protein-coupled receptor 2|G-protein coupled receptor 2,,CCR10,,,,,,,,,,,,,,,,,,,,,,,2826,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CCR10,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_71300,EC 2.* (transferase) inhibitor,transferase inhibitors|EC 2.* inhibitors|transferase inhibitor|EC 2 inhibitors|EC 2 inhibitor|EC 2.* (transferase) inhibitors|EC 2.* inhibitor,An enzyme inhibitor that inhibits the action of a transferase (EC 2.*),false,,,http://purl.obolibrary.org/obo/CHEBI_23924,,,,,,,,,,,,,,,,,,,,,,An enzyme inhibitor that inhibits the action of a transferase (EC 2.*),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,transferase inhibitors|EC 2.* inhibitors|transferase inhibitor|EC 2 inhibitors|EC 2 inhibitor|EC 2.* (transferase) inhibitors|EC 2.* inhibitor,,,,,,,,,,,,,,,,,,,,,CHEBI:71300,,,,EC 2.* (transferase) inhibitor,,CHEBI:71300,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0005615,extracellular space,intercellular space,"That part of a multicellular organism outside the cells proper, usually taken to be outside the plasma membranes, and occupied by fluid.|Note that for multicellular organisms, the extracellular space refers to everything outside a cell, but still within the organism (excluding the extracellular matrix). Gene products from a multi-cellular organism that are secreted from a cell into the interstitial fluid or blood can therefore be annotated to this term.",false,,,http://purl.obolibrary.org/obo/GO_0044464,,,,,,,,,,,,,,,,,,,,NIF_Subcellular:sao1425028079,,"That part of a multicellular organism outside the cells proper, usually taken to be outside the plasma membranes, and occupied by fluid.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,intercellular space,,http://purl.obolibrary.org/obo/GO_0005576,GO:0005615,http://purl.obolibrary.org/obo/GO_0005576,,,,,,,,,,,,,,,,,,,"Note that for multicellular organisms, the extracellular space refers to everything outside a cell, but still within the organism (excluding the extracellular matrix). Gene products from a multi-cellular organism that are secreted from a cell into the interstitial fluid or blood can therefore be annotated to this term.",,extracellular space,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0001723,tongue,glossus,A muscular organ in the floor of the mouth.,false,,,http://purl.obolibrary.org/obo/UBERON_0000020,,,,,,,,,,,,,,,,,,,,http://www.snomedbrowser.com/Codes/Details/181226008|http://en.wikipedia.org/wiki/Tongue|http://purl.obolibrary.org/obo/NCIT_C12422|http://linkedlifedata.com/resource/umls/id/C0040408|VHOG:0000419|MAT:0000040|EFO:0000833|MA:0000347|BTO:0001385|OpenCyc:Mx4rvVjmJ5wpEbGdrcN5Y29ycA_53KXLq9EdqAAAACs6hnmQ|UMLS:C0040408|AAO:0010360|EV:0100058|CALOHA:TS-1050|EHDAA:9144|TAO:0005333|XAO:0000446|GAID:816|EMAPA:17185|MIAA:0000040|MESH:D014059|ZFA:0005333|FMA:54640|EHDAA2:0002062,,A muscular organ in the floor of the mouth.,,"The tongue has contributions from all pharyngeal arches which changes with time. The tongue initially begins as swelling rostral to foramen cecum, the median tongue bud.. tongue muscles derive from the somites - http://php.med.unsw.edu.au/embryology/index.php?title=Tongue_Development#Pharyngeal_Arch_Contributions",,"in MA the tongue is part of the oral region, which in uberon is treated as the oral opening. consider revising oral opening - oral region equivalence.",,,,"The tongue is the movable, muscular organ on the floor of the mouth of most vertebrates, in many other mammals is the principal organ of taste, aids in the prehension of food, in swallowing, and in modifying the voice as in speech[GO][GO:0043586].|A mobile mass of muscular tissue that is covered with mucous membrane, occupies much of the cavity of the mouth, forms part of its floor, bears the organ of taste, and assists in chewing and swallowing. [TFD][VHOG]|Muscular organ in the floor of the mouth.[FEED]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,glossus,"Most adult amphibians have a tongue, as do all known reptiles, birds and mammals. Thus it is likely that the tongue appeared with the establishment of tetrapods and this structure seems to be related, to some extant, to the terrestrial lifestyle.[well established][VHOG]",,UBERON:0001723,,,,,,,,,,,,,,,,,,,,,,tongue,,,,http://upload.wikimedia.org/wikipedia/commons/a/a6/Tongue.agr.jpg,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Many species of fish have small folds at the base of their mouths that might informally be called tongues, but they lack a muscular structure like the true tongues found in most tetrapods",
http://purl.obolibrary.org/obo/IMR_0100457,MKK6,MAPKK 6|SAPKK3|MAPK/ERK kinase 6|MAP kinase kinase 6,,false,,,http://purl.obolibrary.org/obo/IMR_0000263,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MAPKK 6|SAPKK3|MAPK/ERK kinase 6|MAP kinase kinase 6,,,,,IMR:0100457,,,,,,,,,,,,,,,,,,,,,,MKK6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100366,G-alpha-s,,,false,,,http://purl.obolibrary.org/obo/IMR_0000317,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100366,,,,,,,,,,,,,,,,,,,,,,G-alpha-s,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000966,chemical hormone,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000966,,,,,,,,,,,,,,,,,,,,,,chemical hormone,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_6495,lipoprotein,,A clathrate complex consisting of a lipid enwrapped in a protein host without covalent binding in such a way that the complex has a hydrophilic outer surface consisting of all the protein and the polar ends of any phospholipids.,false,,,http://purl.obolibrary.org/obo/CHEBI_33694,,,,,,,,,,,,,,,,,,,,,,A clathrate complex consisting of a lipid enwrapped in a protein host without covalent binding in such a way that the complex has a hydrophilic outer surface consisting of all the protein and the polar ends of any phospholipids.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:6495,,,,,,,,,,,,,,,,,,,,,,lipoprotein,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0200146,Prostaglandin E2,,,false,,,http://purl.obolibrary.org/obo/IMR_0100019,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0200146,,,,,,,,,,,,,,,,,,,,,,Prostaglandin E2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0050663,cytokine secretion,,"The regulated release of cytokines from a cell. Cytokines are any of a group of proteins that function to control the survival, growth and differentiation of tissues and cells, and which have autocrine and paracrine activity.",false,,,http://purl.obolibrary.org/obo/TXPO_0002588,,,,,,,,,,,,,,,,,,,,,,"The regulated release of cytokines from a cell. Cytokines are any of a group of proteins that function to control the survival, growth and differentiation of tissues and cells, and which have autocrine and paracrine activity.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0050663,,,,,,,,,,,,,,,,,,,,,,cytokine secretion,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_51374,GABA agent,,"A substance, such as agonists, antagonists, degradation or uptake inhibitors, depleters, precursors, and modulators of receptor function, used for its pharmacological actions on GABAergic systems.",false,,,http://purl.obolibrary.org/obo/CHEBI_35942,,,,,,,,,,,,,,,,,,,,,,"A substance, such as agonists, antagonists, degradation or uptake inhibitors, depleters, precursors, and modulators of receptor function, used for its pharmacological actions on GABAergic systems.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:51374,,,,GABA agent,,CHEBI:51374,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100019,prostaglandin,,"Naturally occurring compounds derived from the parent C20 acid, prostanoic acid.",false,,,http://purl.obolibrary.org/obo/CHEBI_26347,,,,,,,,,,,,,,,,,,,,CAS:11000-26-3,,"Naturally occurring compounds derived from the parent C20 acid, prostanoic acid.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003686|http://purl.obolibrary.org/obo/TXPO_0002401,,,,,,,,,,IMR:0100019,,,,,,,,,,,,,,,,,,,,,,prostaglandin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003282,hypofunction of phospholipid degradation [Phospholipidosis (moderate)],,"Hypofunction of phospholipid degradation is a subtype of hypofunction of decomposing: A process that performs a decreased or insufficient phospholipid degradation.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (moderate).",false,,,http://purl.obolibrary.org/obo/TXPO_0000925,,,,,,,,,,,,,,,,,,,,,,"Hypofunction of phospholipid degradation is a subtype of hypofunction of decomposing: A process that performs a decreased or insufficient phospholipid degradation.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (moderate).",,,http://purl.obolibrary.org/obo/TXPO_0001406,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000775|http://purl.obolibrary.org/obo/TXPO_0001804,,,,,,http://purl.obolibrary.org/obo/TXPO_0003372,,,,,,,,,,,TXPO:0003282,,,,,,,,,,,,,,,,,,,,,,hypofunction of phospholipid degradation [Phospholipidosis (moderate)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003281,CXCL10 (mol),IP-10,,false,,,http://purl.obolibrary.org/obo/TXPO_1000419,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:15945|NCBI-Rat-GeneID:3627|NCBI-Human-GeneID:3627,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IP-10,,,,,TXPO:0003281,,,,,,,,,,,,,,,,,,,,,,CXCL10 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000192,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003284,NPC1 (mol),NPC Intracellular Cholesterol Transporter 1,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID: 18145|NCBI-Human-GeneID:4864|NCBI-Rat-GeneID:266732|OMIM: 607623,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,NPC Intracellular Cholesterol Transporter 1,,,,,TXPO:0003284,,,,,,,,,,,,,,,,,,,,,,NPC1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003283,NPC1  (canonical)[Niemann Pick Type C],NPC Intracellular Cholesterol Transporter 1 [Niemann Pick Type C],,false,,,http://purl.obolibrary.org/obo/TXPO_0003284|http://purl.obolibrary.org/obo/TXPO_0003516,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID: 18145|NCBI-Human-GeneID:4864|NCBI-Rat-GeneID:266732|PMID:18772377|OMIM: 607623,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001451,,,,,NPC Intracellular Cholesterol Transporter 1 [Niemann Pick Type C],,,,,TXPO:0003283,,,,,,,,,,,,,,,,,,,,,,NPC1  (canonical)[Niemann Pick Type C],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003286,cell proliferation [Hypertrophy],,"The multiplication or reproduction of cells, resulting in the rapid expansion of a cell population.
This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy.",false,,,http://purl.obolibrary.org/obo/TXPO_0003279|http://purl.obolibrary.org/obo/GO_0008283,,,,,,,,,,,,,,,,,,,,,,"The multiplication or reproduction of cells, resulting in the rapid expansion of a cell population.
This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003296|http://purl.obolibrary.org/obo/TXPO_0003298|http://purl.obolibrary.org/obo/TXPO_0003319,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003271,,,,,,,,,,,TXPO:0003286,,,,,,,,,,,,,,,,,,,,,,cell proliferation [Hypertrophy],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003289,insulin deficiency [diabetes course],,"Insulin deficiency is a subtype of malfunctioning process: A process that lacks performing the insulin function required.
This entity is a specific course-dependent process. This process can constitute the course of diabetes.",false,,,http://purl.obolibrary.org/obo/TXPO_0000072|http://purl.obolibrary.org/obo/TXPO_0003342,,,,,,,,,,,,,,,,,,,,,,"Insulin deficiency is a subtype of malfunctioning process: A process that lacks performing the insulin function required.
This entity is a specific course-dependent process. This process can constitute the course of diabetes.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003290,,,,,,,,,,,TXPO:0003289,,,,,,,,,,,,,,,,,,,,,,insulin deficiency [diabetes course],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003288,hypofunction of glutathione conjugation [Glutathione depletion],,"Hypofunction of alcohol metabolism is a subtype of hyperfunctioning: A process that performs a decreased or insufficient glutathione conjugation.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0001775|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Hypofunction of alcohol metabolism is a subtype of hyperfunctioning: A process that performs a decreased or insufficient glutathione conjugation.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001191,,,,,,,,,,,TXPO:0003288,,,,,,,,,,,,,,,,,,,,,,hypofunction of glutathione conjugation [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003285,NPC2 (canonical)[Niemann-Pick Type C],NPC Intracellular Cholesterol Transporter 2 [Niemann-Pick Type C],,false,,,http://purl.obolibrary.org/obo/TXPO_0003287|http://purl.obolibrary.org/obo/TXPO_0003516,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID: 67963|NCBI-Rat-GeneID:286898|NCBI-Human-GeneID:10577|PMID:18772377,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001451,,,,,NPC Intracellular Cholesterol Transporter 2 [Niemann-Pick Type C],,,,,TXPO:0003285,,,,,,,,,,,,,,,,,,,,,,NPC2 (canonical)[Niemann-Pick Type C],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003287,NPC2 (mol),NPC Intracellular Cholesterol Transporter 2 [Niemann-Pick Type C],,false,,,http://purl.obolibrary.org/obo/CHEBI_25367|http://purl.obolibrary.org/obo/TXPO_0003516,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID: 67963|NCBI-Rat-GeneID:286898|NCBI-Human-GeneID:10577|PMID:18772377,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001451,,,,,NPC Intracellular Cholesterol Transporter 2 [Niemann-Pick Type C],,,,,TXPO:0003287,,,,,,,,,,,,,,,,,,,,,,NPC2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003280,ANG (human)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001517|http://purl.obolibrary.org/obo/TXPO_0001135,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:305843|http://omim.org/entry/105850|NCBI-Human-GeneID:283|PMID:25604905|PMID:10334936|PMID:17125737|PMID:22021078|PMID:15776477,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002261,,,,,,,,,,TXPO:0003280,,,,,,,,,,,,,,,,,,,,,,ANG (human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100375,G-alpha-11,,,false,,,http://purl.obolibrary.org/obo/IMR_0000323,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100375,,,,,,,,,,,,,,,,,,,,,,G-alpha-11,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000439,RalGEF,Ral guanine nucleotide exchange factor,,false,,,http://purl.obolibrary.org/obo/IMR_0100440,,,,,,,,,,,,,,,,,,,,GO:0008321,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ral guanine nucleotide exchange factor,,,,,IMR:0000439,,,,,,,,,,,,,,,,,,,,,,RalGEF,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000294,many times,,,false,,,http://purl.obolibrary.org/obo/TXPO_0000293,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000294,,,,,,,,,,,,,,,,,,,,,,many times,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000299,ABCB11 (canonical)[Cholestasis],BSEP [cholestasis]|Bile salt export pump [cholestasis],,false,,,http://purl.obolibrary.org/obo/TXPO_0001506,,,,,,,,,,,,,,,,,,,別名BSEP。アミノ酸抱合胆汁酸の毛細胆管への排泄を行う。,PMID:10648470|http://omim.org/entry/603201|PMID:16039748|PMID:9806540|PMID:11179459,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000506,,,,,BSEP [cholestasis]|Bile salt export pump [cholestasis],,,,,TXPO:0000299,,,,,,,"Bosentan, cyclosporin, glibenclamide, rifampicin, and rifamycin inhibit human and rat BSEP/Bsep.",,,,,,,,,,,,,,,ABCB11 (canonical)[Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000291,many,,,false,,,http://purl.obolibrary.org/obo/TXPO_0000290,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000291,,,,,,,,,,,,,,,,,,,,,,many,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000298,EDEM (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:192193|NCBI-Rat-GeneID:297504|NCBI-Human-GeneID:9695,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000009695,,,,,,,,,,,,,TXPO:0000298,,,,,,,,,,,,,,,,,,,,,,EDEM (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000290,numbers quality value,,,false,,,http://purl.obolibrary.org/obo/TXPO_0000289,,,,,,,,,,,,,,,,,,,,,,,YAMATO Ontology,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000290,,,,,,,,,,,,,,,,,,,,,,numbers quality value,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000297,oxidative dependent chemical entity,,"Oxidative stress dependent chemical entity is a subtype of toxic course dependent chemical entity.
This entity can participate in the course of ER stress.|under construction",false,,,http://purl.obolibrary.org/obo/TXPO_0001731,,,,,,,,,,,,,,,,,,,,,,"Oxidative stress dependent chemical entity is a subtype of toxic course dependent chemical entity.
This entity can participate in the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000297,,,,,,,,,,,,,,,,,,,,under construction,,oxidative dependent chemical entity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000296,acute phase proteins coding gene expression via cytokine,,"Acute phase proteins coding gene expression via cytokine is a subtype of gene expression: A process that The process in which a gene sequence is converted into a mature acute phase proteins coding gene product or products (proteins or RNA) by cytokine.

Casarett & Doull's Toxicology: The Basic Science of Poisons, Eighth Edition|IL-1, TNF, IL-6 or other cytokines released from macrophages and endtherial cells act on  cell surface receptors to change transcriptions of genes involving tissue injury and repair.",false,,,http://purl.obolibrary.org/obo/GO_0010467,,,,,,,,,,,,,,,,,,,,,,"Acute phase proteins coding gene expression via cytokine is a subtype of gene expression: A process that The process in which a gene sequence is converted into a mature acute phase proteins coding gene product or products (proteins or RNA) by cytokine.

Casarett & Doull's Toxicology: The Basic Science of Poisons, Eighth Edition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000535,,,,,,,,,,,TXPO:0000296,,,,,,,,,,,,,,,,,,,,"IL-1, TNF, IL-6 or other cytokines released from macrophages and endtherial cells act on  cell surface receptors to change transcriptions of genes involving tissue injury and repair.",,acute phase proteins coding gene expression via cytokine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000292,few,,,false,,,http://purl.obolibrary.org/obo/TXPO_0000290,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000292,,,,,,,,,,,,,,,,,,,,,,few,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000293,times quality value,,Times quality value is a subtype of meta attribute value.,false,,,http://purl.obolibrary.org/obo/TXPO_0000289,,,,,,,,,,,,,,,,,,,,,,Times quality value is a subtype of meta attribute value.,YAMATO Ontology,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000293,,,,,,,,,,,,,,,,,,,,,,times quality value,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000295,few times,,,false,,,http://purl.obolibrary.org/obo/TXPO_0000293,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000295,,,,,,,,,,,,,,,,,,,,,,few times,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000006733,SRPK2,,Other designations: SFRS protein kinase 2|SR protein kinase 2|SR-protein-specific kinase 2|serine kinase SRPK2|serine/arginine-rich protein-specific kinase 2|serine/arginine-rich splicing factor kinase 2|serine/threonine-protein kinase SRPK2,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,SFRSK2,,,,,,,,,,,,7,,,,,,Vega:OTTHUMG00000157405|HPRD:04280|Ensembl:ENSG00000135250|HGNC:11306|MIM:602980,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,SRSF protein kinase 2,,,7q22-q31.1,,,,,,,,,,,,,,,,"GO_0000245 (EC: IDA, PMID: 9472028); GO_0000287 (EC: IDA, PMID: 9472028); GO_0001525 (EC: ISS); GO_0004674 (EC: IDA, PMID: 9472028); GO_0005515 (EC: IPI, PMID: 16189514); GO_0005524 (EC: IDA, PMID: 9472028); GO_0005634 (EC: IDA); GO_0005730 (EC: IDA); GO_0005730 (EC: IDA, Qualifier: NOT); GO_0005737 (EC: IDA); GO_0006468 (EC: IDA, PMID: 9472028); GO_0008284 (EC: IDA, PMID: 18559500); GO_0008380 (EC: IDA, PMID: 9472028); GO_0010628 (EC: ISS); GO_0030154 (EC: IEA); GO_0035063 (EC: ISS); GO_0035556 (EC: IDA, PMID: 9472028); GO_0043525 (EC: ISS); GO_0044822 (EC: IDA); GO_0045070 (EC: IDA); GO_0045071 (EC: IDA, PMID: 12417631); GO_0045087 (EC: IC, PMID: 12417631); GO_0045787 (EC: ISS); GO_0048024 (EC: TAS); GO_0071889 (EC: ISS)",,,,,,,,,PMID: 8208298; 9171351; 9446799; 9472028; 10196197; 12134018; 12417631; 12477932; 12565863; 12853948; 14702039; 15144186; 15489334; 15592455; 16122776; 16189514; 16344560; 17353931; 17620599; 18029348; 18425142; 18559500; 18654987; 19592491; 19902070; 20379614; 20498328; 21145461; 21157427; 21182205; 21832049; 21890473; 22365833; 22990118; 23000965; 23049088; 23326445; 23602568; 24457600,,,,,,,,,,,,,,,OGG:3000006733,,,,,,,SRSF protein kinase 2,,,,,,,,,,,,,Other designations: SFRS protein kinase 2|SR protein kinase 2|SR-protein-specific kinase 2|serine kinase SRPK2|serine/arginine-rich protein-specific kinase 2|serine/arginine-rich splicing factor kinase 2|serine/threonine-protein kinase SRPK2,,SRPK2,,,,,,,,,,,,,,,,,,,,,,,6733,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,SRPK2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/GO_0045321,leukocyte activation,immune cell activation|leucocyte activation,"A change in morphology and behavior of a leukocyte resulting from exposure to a specific antigen, mitogen, cytokine, cellular ligand, or soluble factor.",false,,,http://purl.obolibrary.org/obo/GO_0001775,,,,,,,,,,,,,,,,,,,,,,"A change in morphology and behavior of a leukocyte resulting from exposure to a specific antigen, mitogen, cytokine, cellular ligand, or soluble factor.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,immune cell activation|leucocyte activation,,,,,GO:0045321,,,,,,,,,,,,,,,,,,,,,,leukocyte activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002348,decreasing bile flow in bile canaliculus,,Decreasing bile flow in bile canaliculus is a subtype of decreasing bile flow: A process that changes the amount of bile flow in bile canaliculus to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0002673,,,,,,,,,,,,,,,,,,,,,,Decreasing bile flow in bile canaliculus is a subtype of decreasing bile flow: A process that changes the amount of bile flow in bile canaliculus to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002348,,,,,,,,,,,,,,,,,,,,,,decreasing bile flow in bile canaliculus,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002342,negative regulation of respiratory electron transport chain,,"Negative regulation of respiratory electron transport chain is a subtype of negative regulation process:  Any process that stops, prevents or reduces the frequency, rate or extent of mrespiratory electron transport chain.",false,,,http://purl.obolibrary.org/obo/TXPO_0000369,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of respiratory electron transport chain is a subtype of negative regulation process:  Any process that stops, prevents or reduces the frequency, rate or extent of mrespiratory electron transport chain.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002342,,,,,,,,,,,,,,,,,,,,,,negative regulation of respiratory electron transport chain,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0022904,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002345,hyperfunction of gene expression,,Hyperfunction of gene expression is a subtype of hyperfunctioning: A process that performs an excesssive gene expression.,false,,,http://purl.obolibrary.org/obo/TXPO_0000435,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of gene expression is a subtype of hyperfunctioning: A process that performs an excesssive gene expression.,,,http://purl.obolibrary.org/obo/GO_0010467,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002345,,,,,,,,,,,,,,,,,,,,,,hyperfunction of gene expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002340,liver carcinogenesis dependent process,,Liver carcinogenesis dependent process is a subtype of toxic course dependent process: A process that can constitute the course of liver carcinogenesis.,false,,,http://purl.obolibrary.org/obo/TXPO_0001715,,,,,,,,,,,,,,,,,,,,,,Liver carcinogenesis dependent process is a subtype of toxic course dependent process: A process that can constitute the course of liver carcinogenesis.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002340,,,,,,,,,,,,,,,,,,,,,,liver carcinogenesis dependent process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002341,leaking proton ion,,Leaking proton ion is a subtype of leaking: A process that leaks the proton from the mitochondria.,false,,,http://purl.obolibrary.org/obo/TXPO_0001699,,,,,,,,,,,,,,,,,,,,,,Leaking proton ion is a subtype of leaking: A process that leaks the proton from the mitochondria.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002341,,,,,,,,,,,,,,,,,,,,,,leaking proton ion,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002349,hyperfunction of decompoing,,Hyperfunction of decompoing is a subtype of hyperfunctioning: A process that performs an excessive decomposition.,false,,,http://purl.obolibrary.org/obo/TXPO_0000435,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of decompoing is a subtype of hyperfunctioning: A process that performs an excessive decomposition.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002349,,,,,,,,,,,,,,,,,,,,,,hyperfunction of decompoing,,,,,,http://purl.obolibrary.org/obo/TXPO_0000343,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002344,hyperfunction of mitochondrial fatty acid beta-oxidation,,Hyperfunction of mitochondrial fatty acid beta-oxidation is a subtype of hyperfunction of fatty acid beta-oxidation: A process that performs an excessive mitochondrial fatty acid beta-oxidation.,false,,,http://purl.obolibrary.org/obo/TXPO_0000095,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of mitochondrial fatty acid beta-oxidation is a subtype of hyperfunction of fatty acid beta-oxidation: A process that performs an excessive mitochondrial fatty acid beta-oxidation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002344,,,,,,,,,,,,,,,,,,,,,,hyperfunction of mitochondrial fatty acid beta-oxidation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002347,hyperfunction of drug metabolism,,Hyperfunction of drug metabolism is a subtype of hyperfunctioning of metabolism: A process that performs an excessive drug metabolism.,false,,,http://purl.obolibrary.org/obo/TXPO_0002352,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of drug metabolism is a subtype of hyperfunctioning of metabolism: A process that performs an excessive drug metabolism.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002347,,,,,,,,,,,,,,,,,,,,,,hyperfunction of drug metabolism,,,,,,http://purl.obolibrary.org/obo/GO_0017144,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002343,changing iron ion concentration,,Changing iron ion concentration is a subtype of changing concentration: A process that changes the iron (Fe) concentration in the blood to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0002438,,,,,,,,,,,,,,,,,,,,,,Changing iron ion concentration is a subtype of changing concentration: A process that changes the iron (Fe) concentration in the blood to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002343,,,,,,,,,,,,,,,,,,,,,,changing iron ion concentration,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002346,hyperfunction of biosynthesis,,Hyperfunction of biosynthesis is a subtype of hyperfunctioning: A process that performs an excessive biosynthesis.,false,,,http://purl.obolibrary.org/obo/TXPO_0000435,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of biosynthesis is a subtype of hyperfunctioning: A process that performs an excessive biosynthesis.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002346,,,,,,,,,,,,,,,,,,,,,,hyperfunction of biosynthesis,,,,,,http://purl.obolibrary.org/obo/GO_0009058,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0002384,hepatic immune response,,An immune response taking place in the liver.,false,,,http://purl.obolibrary.org/obo/GO_0006955,,,,,,,,,,,,,,,,,,,,,,An immune response taking place in the liver.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0002384,,,,,,,,,,,,,,,,,,,,,,hepatic immune response,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100556,FGF-6,HBGF-6|HST-2,,false,,,http://purl.obolibrary.org/obo/IMR_0000049,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,HBGF-6|HST-2,,,,,IMR:0100556,,,,,,,,,,,,,,,,,,,,,,FGF-6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0046488,phosphatidylinositol metabolic process,phosphoinositide metabolic process|phosphoinositide metabolism|PtdIns metabolic process|PtdIns metabolism|phosphatidylinositol metabolism,"The chemical reactions and pathways involving phosphatidylinositol, any glycophospholipid in which a sn-glycerol 3-phosphate residue is esterified to the 1-hydroxyl group of 1D-myo-inositol.",false,,,http://purl.obolibrary.org/obo/GO_0006650,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways involving phosphatidylinositol, any glycophospholipid in which a sn-glycerol 3-phosphate residue is esterified to the 1-hydroxyl group of 1D-myo-inositol.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_28874,,,,,,,,,,,,phosphoinositide metabolic process|phosphoinositide metabolism|PtdIns metabolic process|PtdIns metabolism|phosphatidylinositol metabolism,,,,,GO:0046488,,,,,,,,,,,,,,,,,,,,,,phosphatidylinositol metabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000558,disabled,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000558,,,,,,,,,,,,,,,,,,,,,,disabled,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000542,fibrillar collagen,fibrillar forming collagen,"Types I, II and III collagens constitute the classical fibrillar collagens and account for 80-90% of all the collagen in the body. Types V and XI collagens are also classified as fibrillar collagens on the basis of thier homology with types I-III collagens.",false,,,http://purl.obolibrary.org/obo/IMR_0000541,,,,,,,,,,,,,,,,,,,,GO:0005583,,"Types I, II and III collagens constitute the classical fibrillar collagens and account for 80-90% of all the collagen in the body. Types V and XI collagens are also classified as fibrillar collagens on the basis of thier homology with types I-III collagens.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,fibrillar forming collagen,,,,,IMR:0000542,,,,,,,,,,,,,,,,,,,,,,fibrillar collagen,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000491,alpha-actin 3,gamma-actin 2|smooth muscle (enteric type) gamma-actin|smooth muscle gamma-actin|gamma-enteric actin,,false,,,http://purl.obolibrary.org/obo/IMR_0000490,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,gamma-actin 2|smooth muscle (enteric type) gamma-actin|smooth muscle gamma-actin|gamma-enteric actin,,,,,IMR:0000491,,,,,,,,,,,,,,,,,,,,,,alpha-actin 3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000093,TGF-beta receptor type I,Transforming growth factor-beta receptor type I,,false,,,http://purl.obolibrary.org/obo/IMR_0000092,,,,,,,,,,,,,,,,,,,,GO:0005025,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Transforming growth factor-beta receptor type I,,,,,IMR:0000093,,,,,,,,,,,,,,,,,,,,,,TGF-beta receptor type I,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001099,exportin 7,RanBP16,,false,,,http://purl.obolibrary.org/obo/IMR_0100015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,RanBP16,,,,,IMR:0001099,,,,,,,,,,,,,,,,,,,,,,exportin 7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001610,Rab25,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001610,,,,,,,,,,,,,,,,,,,,,,Rab25,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000232,TAK1,TGF-bata activated kinase 1|MOM-4,,false,,,http://purl.obolibrary.org/obo/IMR_0000229,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TGF-bata activated kinase 1|MOM-4,,,,,IMR:0000232,,,,,,,,,,,,,,,,,,,,,,TAK1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001471,retinal degeneration [Niemann Pick Disease Type A],,"Retinal degeneration is a subtype of changing material: A process that degenerates retinal photoreceptors and pigmented epithelial cells.
This entity is a specific course-dependent process. This process can constitute the course of Niemann-Pick Disease Type A.",false,,,http://purl.obolibrary.org/obo/TXPO_0001470|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Retinal degeneration is a subtype of changing material: A process that degenerates retinal photoreceptors and pigmented epithelial cells.
This entity is a specific course-dependent process. This process can constitute the course of Niemann-Pick Disease Type A.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001471,,,,,,,,,,,,,,,,,,,,,,retinal degeneration [Niemann Pick Disease Type A],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001472,dysfunction of sphingomyelin degradation in the myelin sheath [Niemann Pick Disease Type A],,"Dysfunction of sphingomyelin degradation in the myelin sheath is a subtype of dysfunction of phosphosphingolipid degradation: A process that performs an abnormal and incomplete sphingomyelin degradation in the myelin sheath.
This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type A.",false,,,http://purl.obolibrary.org/obo/TXPO_0001475|http://purl.obolibrary.org/obo/TXPO_0001473,,,,,,,,,,,,,,,,,,,,,,"Dysfunction of sphingomyelin degradation in the myelin sheath is a subtype of dysfunction of phosphosphingolipid degradation: A process that performs an abnormal and incomplete sphingomyelin degradation in the myelin sheath.
This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type A.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000929,,,,,,,,,,,TXPO:0001472,,,,,,,,,,,,,,,,,,,,,,dysfunction of sphingomyelin degradation in the myelin sheath [Niemann Pick Disease Type A],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001475,dysfunction of sphingomyelin degradation [Niemann Pick Disease Type A/ B],,"Dysfunction of sphingomyelin degradation is a subtype of dysfunction of phosphosphingolipid degradation: A process that performs an abnormal and incomplete sphingomyelin degradation.
This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type A/ B.",false,,,http://purl.obolibrary.org/obo/TXPO_0001687,,,,,,,,,,,,,,,,,,,,,,"Dysfunction of sphingomyelin degradation is a subtype of dysfunction of phosphosphingolipid degradation: A process that performs an abnormal and incomplete sphingomyelin degradation.
This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type A/ B.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001476,,,,,,,,,,,TXPO:0001475,,,,,,,,,,,,,,,,,,,,,,dysfunction of sphingomyelin degradation [Niemann Pick Disease Type A/ B],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001476,sphingomyelin metabolism imbalance [Niemann Pick Disease Type A/ B],,"A process that becomes lacking a homeostastasis balance of the sphingomyelin metabolism.
This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type A/ B.",false,,,http://purl.obolibrary.org/obo/TXPO_0001768,,,,,,,,,,,,,,,,,,,,,,"A process that becomes lacking a homeostastasis balance of the sphingomyelin metabolism.
This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type A/ B.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001807,,,,,,,,,,,TXPO:0001476,,,,,,,,,,,,,,,,,,,,,,sphingomyelin metabolism imbalance [Niemann Pick Disease Type A/ B],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001474,dysfunction of phosphosphingolipid degradation,,Dysfunction of phosphosphingolipid degradation is a subtype of dysfunction of phospholipid degradation: A process that performs an abnormal and incomplete phosphosphingolipid degradation.,false,,,http://purl.obolibrary.org/obo/TXPO_0001447,,,,,,,,,,,,,,,,,,,,,,Dysfunction of phosphosphingolipid degradation is a subtype of dysfunction of phospholipid degradation: A process that performs an abnormal and incomplete phosphosphingolipid degradation.,,,http://purl.obolibrary.org/obo/TXPO_0001465,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001474,,,,,,,,,,,,,,,,,,,,,,dysfunction of phosphosphingolipid degradation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001470,retinal degeneration,,Retinal degeneration is a subtype of changing material: A process that degenerates retinal photoreceptors and pigmented epithelial cells.|Detinal degenration is usually caused by the progressive cell death.,false,,,http://purl.obolibrary.org/obo/TXPO_0002590,,,,,,,,,,,,,,,,,,,,,,Retinal degeneration is a subtype of changing material: A process that degenerates retinal photoreceptors and pigmented epithelial cells.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001470,,,,,,,,,,,,,,,,,,,,Detinal degenration is usually caused by the progressive cell death.,,retinal degeneration,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0000639,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001479,decrease in platelet count,,Decrease in platelet count is a subtype of decreasing number of objects: A process that becomes smaller in platelet count.,false,,,http://purl.obolibrary.org/obo/TXPO_0000348,,,,,,,,,,,,,,,,,,,,,,Decrease in platelet count is a subtype of decreasing number of objects: A process that becomes smaller in platelet count.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001479,,,,,,,,,,,,,,,,,,,,,,decrease in platelet count,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001478,pulmonary infection [Niemann Pick Disease Type A/ B],,"Pulmonary infection is a subtype of pathogen colonization: A process that makes pathogen such as microorganism (bacteria, virus, mycoplasma, etc.) present in the lung to increase the number.
This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type A/ B.",false,,,http://purl.obolibrary.org/obo/TXPO_0001477|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Pulmonary infection is a subtype of pathogen colonization: A process that makes pathogen such as microorganism (bacteria, virus, mycoplasma, etc.) present in the lung to increase the number.
This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type A/ B.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001478,,,,,,,,,,,,,,,,,,,,,,pulmonary infection [Niemann Pick Disease Type A/ B],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001473,dysfunction of sphingomyelin degradation in the myelin sheath,,Dysfunction of sphingomyelin degradation in the myelin sheath is a subtype of dysfunction of phosphosphingolipid degradation: A process that performs an abnormal and incomplete sphingomyelin degradation in the myelin sheath.,false,,,http://purl.obolibrary.org/obo/TXPO_0001474,,,,,,,,,,,,,,,,,,,,,,Dysfunction of sphingomyelin degradation in the myelin sheath is a subtype of dysfunction of phosphosphingolipid degradation: A process that performs an abnormal and incomplete sphingomyelin degradation in the myelin sheath.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001473,,,,,,,,,,,,,,,,,,,,,,dysfunction of sphingomyelin degradation in the myelin sheath,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001477,pulmonary infection,,"Pulmonary infection is a subtype of pathogen colonization: A process that makes pathogen such as microorganism (bacteria,  virus, mycoplasma, etc.) present in the lung to increase the number.",false,,,http://purl.obolibrary.org/obo/TXPO_0002139,,,,,,,,,,,,,,,,,,,,,,"Pulmonary infection is a subtype of pathogen colonization: A process that makes pathogen such as microorganism (bacteria,  virus, mycoplasma, etc.) present in the lung to increase the number.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001477,,,,,,,,,,,,,,,,,,,,,,pulmonary infection,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002048,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_22695,base,A molecular entity having an available pair of electrons capable of forming a covalent bond with a hydron (Bronsted base) or with the vacant orbital of some other molecular entity (Lewis base).,,false,,,http://purl.obolibrary.org/obo/CHEBI_51086,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,A molecular entity having an available pair of electrons capable of forming a covalent bond with a hydron (Bronsted base) or with the vacant orbital of some other molecular entity (Lewis base).,,,CHEBI:22695,,,,,,,,,,,,,,,,,,,,,,base,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000894,Tollip,Toll-interacting protein,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003657,,,,,Toll-interacting protein,,,,,IMR:0000894,,,,,,,,,,,,,,,,,,,,,,Tollip,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0001981,blood vessel,vas sanguineum|vascular element|region of vascular tree organ|vascular tree organ region|MESH:D001808,A vessel through which blood circulates in the body.|FMA:63183 Blood vessel is categorized as 'general anatomical term'. Suggestion to map to region of vascular tree from Terry H at JAX,false,,,http://purl.obolibrary.org/obo/UBERON_0000025,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0000178,,,,,,"should not be confused with the anatomic lobes of the liver (caudate lobe, quadrate lobe, left lobe, and right lobe), or any of the functional lobe classification systems.[WP]",http://purl.obolibrary.org/obo/NCIT_C12679|http://uri.neuinfo.org/nif/nifstd/nlx_anat_090901|http://linkedlifedata.com/resource/umls/id/C0005847|http://en.wikipedia.org/wiki/Blood_vessel|http://www.snomedbrowser.com/Codes/Details/361097006|ZFA:0005314|XAO:0001011|FMA:50722|CALOHA:TS-0080|EMAPA:35993|AEO:0000207|VHOG:0001250|EFO:0000817|EHDAA2:0003252|GAID:169|BTO:0001102|OpenCyc:Mx4rvVjxlpwpEbGdrcN5Y29ycA|FMA:63183|MAT:0000393|EHDAA:240|TAO:0002137|EMAPA:32743|MESH:D001808|AAO:0011004|MA:0000060|UMLS:C0005847|NCIT:C12679,,A vessel through which blood circulates in the body.,,,,"consider adopting the EMAPA superclass 'vascular element', which includes microvasculature (e.g. capillaries), vascular plexus",,,,Any of the vessels through which blood circulates in the body.[AAO]|Any of the vessels through which blood circulates in the body. [XAO:0001011_][VHOG],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,region of vascular tree organ|vascular tree organ region|MESH:D001808,,vas sanguineum,"The appearance of Chordata and subsequently the vertebrates is accompanied by a rapid structural diversification of this primitive linear heart: looping, unidirectional circulation, an enclosed vasculature, and the conduction system.[well established][VHOG]",,UBERON:0001981,,,,,,,,,,,,,,,,vascular element,,,,FMA:63183 Blood vessel is categorized as 'general anatomical term'. Suggestion to map to region of vascular tree from Terry H at JAX,,blood vessel,,,,http://upload.wikimedia.org/wikipedia/commons/2/29/Circulatory_System_en.svg,,,http://purl.obolibrary.org/obo/oae.owl|http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"annelids have blood vessels, but this class is not applicable to annelids.",
http://purl.obolibrary.org/obo/IMR_0000027,Interferon,IFN,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000622,,,,,IFN,,,,,IMR:0000027,,,,,,,,,,,,,,,,,,,,,,Interferon,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_64371,neurotransmitter transporter modulator,neurotransmitter transporter modulators,A membrane transport modulator that affects the transport of neurotransmitters.,false,,,http://purl.obolibrary.org/obo/CHEBI_38632|http://purl.obolibrary.org/obo/CHEBI_35942,,,,,,,,,,,,,,,,,,,,,,A membrane transport modulator that affects the transport of neurotransmitters.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,neurotransmitter transporter modulators,,,,,,,,,,,,,,,,,,,,,CHEBI:64371,,,,neurotransmitter transporter modulator,,CHEBI:64371,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_16914,salicylic acid,2-hydroxybenzoic acid,A monohydroxybenzoic acid that is benzoic acid with a hydroxy group at the ortho position. It is obtained from the bark of the white willow and wintergreen leaves.,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:69-72-7|DrugBank:DB00936|Wikipedia:Salicylic_acid,,A monohydroxybenzoic acid that is benzoic acid with a hydroxy group at the ortho position. It is obtained from the bark of the white willow and wintergreen leaves.,,,,,,,,,,,,C7H6O3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35718,,,,,2-hydroxybenzoic acid,,,,,CHEBI:16914,,,,,,,,,,,,,,,,,,,,,,salicylic acid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,OC(=O)c1ccccc1O,,,,,
http://purl.obolibrary.org/obo/IMR_0000855,NF-ATc1,,,false,,,http://purl.obolibrary.org/obo/IMR_0000421,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000855,,,,,,,,,,,,,,,,,,,,,,NF-ATc1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0036211,protein modification process,,"The covalent alteration of one or more amino acids occurring in proteins, peptides and nascent polypeptides (co-translational, post-translational modifications). Includes the modification of charged tRNAs that are destined to occur in a protein (pre-translation modification).",false,,,http://purl.obolibrary.org/obo/GO_0019538,,,,,,,,,,,,,,,,,,,,,,"The covalent alteration of one or more amino acids occurring in proteins, peptides and nascent polypeptides (co-translational, post-translational modifications). Includes the modification of charged tRNAs that are destined to occur in a protein (pre-translation modification).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0036211,,,,,,,,,,,,,,,,,,,,,,protein modification process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0002271,decreased accumulation (quality),,An accumulation which is relative low.,false,,,http://purl.obolibrary.org/obo/PATO_0002269,,,,,,,,,,,,,,,,,,,,,,An accumulation which is relative low.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0002271,,,,,,,,,,,,,,,,,,,,,,decreased accumulation (quality),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0002270,increased accumulation (quality),,An increased number of physical objects that are accumulated within another physical object usually as a result of a failure to break down or remove objects in a timely manner.,false,,,http://purl.obolibrary.org/obo/PATO_0002269,,,,,,,,,,,,,,,,,,,,,,An increased number of physical objects that are accumulated within another physical object usually as a result of a failure to break down or remove objects in a timely manner.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0002270,,,,,,,,,,,,,,,,,,,,,,increased accumulation (quality),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000865,14-3-3 zeta,,,false,,,http://purl.obolibrary.org/obo/IMR_0000456,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000865,,,,,,,,,,,,,,,,,,,,,,14-3-3 zeta,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0004582,venous system,vein system,"The part of the cardiovascular system consisting of all venous vessels. In vertebrates with a double circulation, this can be divided into systemic and pulmonary portions.",false,,,http://purl.obolibrary.org/obo/UBERON_0007798,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0001638,,,,http://www.snomedbrowser.com/Codes/Details/362060003|http://purl.obolibrary.org/obo/NCIT_C33858|http://linkedlifedata.com/resource/umls/id/C1267406|MA:0002720|BTO:0004692|UMLS:C1267406|EMAPA:16240|EHDAA:486|VHOG:0000277|EHDAA2:0002171,,"The part of the cardiovascular system consisting of all venous vessels. In vertebrates with a double circulation, this can be divided into systemic and pulmonary portions.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,vein system,,,"The appearance of Chordata and subsequently the vertebrates is accompanied by a rapid structural diversification of this primitive linear heart: looping, unidirectional circulation, an enclosed vasculature, and the conduction system.[well established][VHOG]",,UBERON:0004582,,,,,,,,,,,,,,,,,,,,,,venous system,,,,,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100720,Delta-like1,DLL1|Delta1,,false,,,http://purl.obolibrary.org/obo/IMR_0100718,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,DLL1|Delta1,,,,,IMR:0100720,,,,,,,,,,,,,,,,,,,,,,Delta-like1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000002817,GPC1,,Other designations: glypican proteoglycan 1|glypican-1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,glypican,,,,,,,,,,,,2,,,,,,MIM:600395|Ensembl:ENSG00000063660|Vega:OTTHUMG00000133349|HPRD:02671|HGNC:4449,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,glypican 1,,,2q35-q37,,,,,,,,,,,,,,,,"GO_0001523 (EC: TAS); GO_0005507 (EC: IDA, PMID: 12732622); GO_0005578 (EC: ISS); GO_0005615 (EC: IEA); GO_0005768 (EC: IEA); GO_0005796 (EC: TAS); GO_0005886 (EC: TAS); GO_0005887 (EC: TAS, PMID: 2148568); GO_0005975 (EC: TAS); GO_0006024 (EC: TAS); GO_0006027 (EC: TAS); GO_0007411 (EC: TAS); GO_0007603 (EC: TAS); GO_0014037 (EC: ISS); GO_0017134 (EC: ISS); GO_0030200 (EC: IDA, PMID: 12732622); GO_0030203 (EC: TAS); GO_0030204 (EC: TAS); GO_0031225 (EC: IEA); GO_0032288 (EC: ISS); GO_0040037 (EC: ISS); GO_0043202 (EC: TAS); GO_0043236 (EC: ISS); GO_0043395 (EC: IEA); GO_0044281 (EC: TAS); GO_0045121 (EC: IDA, Qualifier: colocalizes_with, PMID: 12732622); GO_0045121 (EC: ISS); GO_0070062 (EC: IDA, PMID: 19199708); GO_2001016 (EC: ISS)",,,,,,,,,PMID: 1417860; 2148568; 7774946; 8125298; 9802880; 10196157; 10364234; 10527946; 10892742; 11336704; 11375980; 11454708; 11968010; 12084716; 12477932; 12732622; 12972423; 14702039; 15084524; 15249209; 15297422; 15489334; 15547662; 16723715; 17016645; 18064304; 18536657; 18634034; 19023125; 19166823; 19199708; 19479373; 21139048; 21265098; 21932778; 22351761; 22863883; 23624389; 23736812; 24019070,,,,,,,,,,,,,,,OGG:3000002817,,,,,,,glypican 1,,,,,,,,,,,,,Other designations: glypican proteoglycan 1|glypican-1,,GPC1,,,,,,,,,,,,,,,,,,,,,,,2817,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,GPC1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_36315,glycerophosphoinositol,glycerophosphoinositols,Any glycerophospholipid having the polar alcohol inositol esterified to the phosphate group at the sn-3 position of the glycerol backbone.,false,,,http://purl.obolibrary.org/obo/CHEBI_37739,,,,,,,,,,,,,,,,,,,,PMID:14706866,,Any glycerophospholipid having the polar alcohol inositol esterified to the phosphate group at the sn-3 position of the glycerol backbone.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,glycerophosphoinositols,,,CHEBI:36315,,,,,,,,,,,,,,,,,,,,,,glycerophosphoinositol,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000257019,FRMD3,,Other designations: FERM domain-containing protein 3|band 4.1-like protein 4|band 4.1-like protein 4O|ovary type protein 4.1|protein 4.1O,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,4.1O|EPB41LO|P410|EPB41L4O,,,,,,,,,,,,9,,,,,,MIM:607619|HGNC:24125|Ensembl:ENSG00000172159|HPRD:07402|Vega:OTTHUMG00000020103,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,FERM domain containing 3,,,9q21.32,,,,,,,,,,,,,,,,GO_0005737 (EC: IEA); GO_0005856 (EC: IEA); GO_0008092 (EC: IEA); GO_0016021 (EC: IEA); GO_0019898 (EC: IEA),,,,,,,,,PMID: 8125298; 12477932; 12601556; 14702039; 17260017; 19252134; 20379614; 20460425; 21698141; 23434934,,,,,,,,,,,,,,,OGG:3000257019,,,,,,,FERM domain containing 3,,,,,,,,,,,,,Other designations: FERM domain-containing protein 3|band 4.1-like protein 4|band 4.1-like protein 4O|ovary type protein 4.1|protein 4.1O,,FRMD3,,,,,,,,,,,,,,,,,,,,,,,257019,RP11-439K3.2,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,FRMD3,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0001990,reactive oxygen species biosynthetic process [Mitochondrial disorder],,"The chemical reaction resulting in the formation of reactive oxygen species, any molecules or ions formed by the incomplete one-electron reduction of oxygen.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/GO_1903409|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:31623280|PMID:29335519|PMID:25339807|PMID:30232152|PMID:27151080|PMID:23299992|PMID:26571396|PMID:29222479|PMID:31649547,,"The chemical reaction resulting in the formation of reactive oxygen species, any molecules or ions formed by the incomplete one-electron reduction of oxygen.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001029|http://purl.obolibrary.org/obo/TXPO_0001991|http://purl.obolibrary.org/obo/TXPO_0004278|http://purl.obolibrary.org/obo/TXPO_0000933|http://purl.obolibrary.org/obo/TXPO_0000869|http://purl.obolibrary.org/obo/TXPO_0004324|http://purl.obolibrary.org/obo/TXPO_0004351|http://purl.obolibrary.org/obo/TXPO_0004350|http://purl.obolibrary.org/obo/TXPO_0004349|http://purl.obolibrary.org/obo/TXPO_0004347|http://purl.obolibrary.org/obo/TXPO_0004341|http://purl.obolibrary.org/obo/TXPO_0004348|http://purl.obolibrary.org/obo/TXPO_0004346|http://purl.obolibrary.org/obo/TXPO_0004264|http://purl.obolibrary.org/obo/TXPO_0004269|http://purl.obolibrary.org/obo/TXPO_0004249|http://purl.obolibrary.org/obo/TXPO_0004254|http://purl.obolibrary.org/obo/TXPO_0004259|http://purl.obolibrary.org/obo/TXPO_0004121|http://purl.obolibrary.org/obo/TXPO_0004125,,,,,,,,,,,TXPO:0001990,,,,,,,,,,,,,,,,,,,,,,reactive oxygen species biosynthetic process [Mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001994,bile acid and bile salt transport to hepatocyte [Cholestasis],,"Bile acid and bile salt transport to hepatocyte is a subtype of bile acid and bile salt transport: A process that transports bile acid and bile salts within a hepatocyte by means of some agent such as a transporter or pore.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000034|http://purl.obolibrary.org/obo/TXPO_0002693,,,,,,,,,,,,,,,,,,,,,,"Bile acid and bile salt transport to hepatocyte is a subtype of bile acid and bile salt transport: A process that transports bile acid and bile salts within a hepatocyte by means of some agent such as a transporter or pore.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001994,,,,,,,"After their uptake into hepatocytes, bile salts reach the canalicular plasma membrane, whch probably involves binding to cytoplasmic proteins.",,,,,,,,,,,,,,,bile acid and bile salt transport to hepatocyte [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001993,decreasing mitochondrial membrane potential [Mitochondrial disorder],,"Decreasing mitochondrial membrane potential is a subtype of decreasing membrane potential: A process that changes the electrical potential of a mitochondrial membrane to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001855|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:31623280|PMID:25339807,,"Decreasing mitochondrial membrane potential is a subtype of decreasing membrane potential: A process that changes the electrical potential of a mitochondrial membrane to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001992|http://purl.obolibrary.org/obo/TXPO_0004131|http://purl.obolibrary.org/obo/TXPO_0002230|http://purl.obolibrary.org/obo/TXPO_0004126,,,,,,,,,,,TXPO:0001993,,,,,,,,,,,,,,,,,,,,,,decreasing mitochondrial membrane potential [Mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001992,apoptotic process [Mitochondrial disorder],,"A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/GO_0006915,,,,,,,,,,,,,,,,,,,,PMID:31623280|PMID:29335519|PMID:25339807|PMID:23299992,,"A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003568,,,,,,,,,,,TXPO:0001992,,,,,,,,,,,,,,,,,,,,,,apoptotic process [Mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001991,positive regulation of mitochondrial membrane permeability [Mitochondrial disorder],,"Any process that increases the frequency, rate or extent of the passage or uptake of molecules by the mitochondrial membrane.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/GO_0035794|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:25339807|PMID:21145849|PMID:23299992,,"Any process that increases the frequency, rate or extent of the passage or uptake of molecules by the mitochondrial membrane.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004332|http://purl.obolibrary.org/obo/TXPO_0004333|http://purl.obolibrary.org/obo/TXPO_0004331|http://purl.obolibrary.org/obo/TXPO_0004337|http://purl.obolibrary.org/obo/TXPO_0004334|http://purl.obolibrary.org/obo/TXPO_0004358|http://purl.obolibrary.org/obo/TXPO_0004357|http://purl.obolibrary.org/obo/TXPO_0004356|http://purl.obolibrary.org/obo/TXPO_0004353|http://purl.obolibrary.org/obo/TXPO_0004354|http://purl.obolibrary.org/obo/TXPO_0004352|http://purl.obolibrary.org/obo/TXPO_0004355,,,,,,http://purl.obolibrary.org/obo/TXPO_0001993|http://purl.obolibrary.org/obo/TXPO_0000933|http://purl.obolibrary.org/obo/TXPO_0001879|http://purl.obolibrary.org/obo/TXPO_0001988|http://purl.obolibrary.org/obo/TXPO_0002039|http://purl.obolibrary.org/obo/TXPO_0004342|http://purl.obolibrary.org/obo/TXPO_0004263,,,,,,,,,,,TXPO:0001991,,,,,,,,,,,,,,,,,,,,,,positive regulation of mitochondrial membrane permeability [Mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001997,malfunctioning of uncoupling [Mitochondrial disorder],,"Malfunctioning of uncoupling is a subtype of malfunctioning process: A process that cannot perform uncoupling appropriately or cannot realize it at all.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0002156|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,,,"Malfunctioning of uncoupling is a subtype of malfunctioning process: A process that cannot perform uncoupling appropriately or cannot realize it at all.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004124,,,,,,,,,,,TXPO:0001997,,,,,,,,,,,,,,,,,,,,,,malfunctioning of uncoupling [Mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001999,negative regulation of mitochondrial gene expression [Mitochondrial disorder],,"Negative regulation of mitochondrial gene expression is a subtype of negative regulation of gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of mitochondrial gene expression.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0002001,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of mitochondrial gene expression is a subtype of negative regulation of gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of mitochondrial gene expression.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001999,,,,,,,,,,,,,,,,,,,,,,negative regulation of mitochondrial gene expression [Mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001995,decreasing membrane potential,,Decreasing membrane potential is a subtype of changing membrane potential: A process that changes the electrical potential across a membrane to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0001456,,,,,,,,,,,,,,,,,,,,,,Decreasing membrane potential is a subtype of changing membrane potential: A process that changes the electrical potential across a membrane to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001995,,,,,,,,,,,,,,,,,,,,,,decreasing membrane potential,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000481,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001996,antitubercular agent,,A substance that kills or slows the growth of Mycobacterium tuberculosis and is used in the treatment of tuberculosis.,false,,,http://purl.obolibrary.org/obo/CHEBI_64912,,,,,,,,,,,,,,,,,,,,,,A substance that kills or slows the growth of Mycobacterium tuberculosis and is used in the treatment of tuberculosis.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001996,,,,,,,,,,,,,,,,,,,,,,antitubercular agent,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001998,chloride channel,,A role played by the entity which enables the facilitated diffusion of a chloride (by an energy-independent process) involving passage through a transmembrane aqueous pore or channel without evidence for a carrier-mediated mechanism.,false,,,http://purl.obolibrary.org/obo/TXPO_0001900,,,,,,,,,,,,,,,,,,,,related molecular funcion GO:0005254,,A role played by the entity which enables the facilitated diffusion of a chloride (by an energy-independent process) involving passage through a transmembrane aqueous pore or channel without evidence for a carrier-mediated mechanism.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001998,,,,,,,,,,,,,,,,,,,,,,chloride channel,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100310,Smad1,,,false,,,http://purl.obolibrary.org/obo/IMR_0100507,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100310,,,,,,,,,,,,,,,,,,,,,,Smad1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_51371,muscle relaxant,muscle relaxants,"A drug used to produce muscle relaxation (excepting neuromuscular blocking agents). Its primary clinical and therapeutic use is the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. Also used for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in multiple sclerosis.",false,,,http://purl.obolibrary.org/obo/CHEBI_51372,,,,,,,,,,,,,,,,,,,,,,"A drug used to produce muscle relaxation (excepting neuromuscular blocking agents). Its primary clinical and therapeutic use is the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. Also used for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in multiple sclerosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,muscle relaxants,,,,,,,,,,,,,,,,,,,,,CHEBI:51371,,,,muscle relaxant,,CHEBI:51371,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001084,importin alpha1,importin alpha S1|karyopherin alpha1|KPNA1|NPI-1|importin alpha5,,false,,,http://purl.obolibrary.org/obo/IMR_0100202,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,importin alpha S1|karyopherin alpha1|KPNA1|NPI-1|importin alpha5,,,,,IMR:0001084,,,,,,,,,,,,,,,,,,,,,,importin alpha1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0005743,mitochondrial inner membrane,inner mitochondrial membrane,"The inner, i.e. lumen-facing, lipid bilayer of the mitochondrial envelope. It is highly folded to form cristae.",false,,,http://purl.obolibrary.org/obo/GO_0031966,,,,,,,,,,,,,,,,,,,,Wikipedia:Inner_mitochondrial_membrane|NIF_Subcellular:sao1371347282,,"The inner, i.e. lumen-facing, lipid bilayer of the mitochondrial envelope. It is highly folded to form cristae.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,inner mitochondrial membrane,,,,,GO:0005743,,,,,,,,,,,,,,,,,,,,,,mitochondrial inner membrane,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0005741,mitochondrial outer membrane,,"The outer, i.e. cytoplasm-facing, lipid bilayer of the mitochondrial envelope.",false,,,http://purl.obolibrary.org/obo/GO_0031966,,,,,,,,,,,,,,,,,,,,Wikipedia:Outer_mitochondrial_membrane|NIF_Subcellular:sao1289741256,,"The outer, i.e. cytoplasm-facing, lipid bilayer of the mitochondrial envelope.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0005741,,,,,,,,,,,,,,,,,,,,,,mitochondrial outer membrane,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0005747,mitochondrial respiratory chain complex I,,"A protein complex located in the mitochondrial inner membrane that forms part of the mitochondrial respiratory chain. It contains about 25 different polypeptide subunits, including NADH dehydrogenase (ubiquinone), flavin mononucleotide and several different iron-sulfur clusters containing non-heme iron. The iron undergoes oxidation-reduction between Fe(II) and Fe(III), and catalyzes proton translocation linked to the oxidation of NADH by ubiquinone.",false,,,http://purl.obolibrary.org/obo/GO_0098800,,,,,,,,,,,,,,,,,,,,,,"A protein complex located in the mitochondrial inner membrane that forms part of the mitochondrial respiratory chain. It contains about 25 different polypeptide subunits, including NADH dehydrogenase (ubiquinone), flavin mononucleotide and several different iron-sulfur clusters containing non-heme iron. The iron undergoes oxidation-reduction between Fe(II) and Fe(III), and catalyzes proton translocation linked to the oxidation of NADH by ubiquinone.",,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004329,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0005747,,,,,,,,,,,,,,,,,,,,,,mitochondrial respiratory chain complex I,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0002250,adaptive immune response,,"An immune response based on directed amplification of specific receptors for antigen produced through a somatic diversification process, and allowing for enhanced response to subsequent exposures to the same antigen (immunological memory).",false,,,http://purl.obolibrary.org/obo/GO_0006955,,,,,,,,,,,,,,,,,,,,,,"An immune response based on directed amplification of specific receptors for antigen produced through a somatic diversification process, and allowing for enhanced response to subsequent exposures to the same antigen (immunological memory).",,,,,adaptive immune response,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0002250,,,,,,,,,,,,,,,,,,,,,,adaptive immune response,,,,,,,http://purl.obolibrary.org/obo/go.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_63924,riddelliine,"(15Z)-12,18-dihydroxy-13,19-didehydrosenecionan-11,16-dione",,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:23246-96-0,,,,,,,,,,,,,,C18H23NO6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"(15Z)-12,18-dihydroxy-13,19-didehydrosenecionan-11,16-dione",,,,,CHEBI:63924,,,,,,,"A macrolide that is 13,19-didehydrosenecionan bearing two additional hydroxy substituents at positions 12 and 18 as well as two additional oxo groups at positions 11 and 16.",,,,,,,,,,,,,,,riddelliine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,[H][C@@]12[C@H]3CCN1CC=C2COC(=O)[C@@](O)(CO)C(=C)C\C(=C\C)C(=O)O3,,,,,
http://purl.obolibrary.org/obo/CHEBI_45409,ritonavir,"ritonavir|N-[(2S,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl]-N(2)-(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)-L-valinamide","An L-valine derivative that is an antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS, it is often used as a fixed-dose combination with another protease inhibitor, lopinavir. Also used in combination with dasabuvir sodium hydrate, ombitasvir and paritaprevir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:11363086|CAS:155213-67-5|PMID:9278209|Reaxys:768009|PMID:8568292|PMID:11996889|LINCS:LSM-5623|PMID:11363184|PMID:24202050|PMID:11363517|PMID:11363300|PMID:9140265|PMID:11363329|PMID:9585800|Drug_Central:2391|PMID:11363397,,"An L-valine derivative that is an antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS, it is often used as a fixed-dose combination with another protease inhibitor, lopinavir. Also used in combination with dasabuvir sodium hydrate, ombitasvir and paritaprevir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35703|http://purl.obolibrary.org/obo/CHEBI_35660|http://purl.obolibrary.org/obo/CHEBI_36044|http://purl.obolibrary.org/obo/CHEBI_78298,,,,,"N-[(2S,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl]-N(2)-(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)-L-valinamide",,ritonavir,,,,,,,,,,,,,,,,,,,,,CHEBI:45409,,,,ritonavir,,CHEBI:45409,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_35845,gout suppressant,gout suppressants,"A drug that increases uric acid excretion by the kidney (uricosuric drug), decreases uric acid production (antihyperuricemic), or alleviates the pain and inflammation of acute attacks of gout.",false,,,http://purl.obolibrary.org/obo/CHEBI_35842,,,,,,,,,,,,,,,,,,,,,,"A drug that increases uric acid excretion by the kidney (uricosuric drug), decreases uric acid production (antihyperuricemic), or alleviates the pain and inflammation of acute attacks of gout.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,gout suppressants,,,,,,,,,,,,,,,,,,,,,CHEBI:35845,,,,gout suppressant,,CHEBI:35845,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0002132,"neoplastic, non-invasive",,A disposition inhering in a tumour by virtue of the bearer's disposition not to invade surrounding tissues.,false,,,http://purl.obolibrary.org/obo/PATO_0002011,,,,,,,,,,,,,,,,,,,,,,A disposition inhering in a tumour by virtue of the bearer's disposition not to invade surrounding tissues.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0002132,,,,,,,,,,,,,,,,,,,,,,"neoplastic, non-invasive",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000621,ICAM-4,intercellular adhesion molecule 4,,false,,,http://purl.obolibrary.org/obo/IMR_0000178,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,intercellular adhesion molecule 4,,,,,IMR:0000621,,,,,,,,,,,,,,,,,,,,,,ICAM-4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_61910,very long-chain fatty acyl-CoA,VLCFA-CoA,A fatty acyl-CoA in which the fatty acyl group has a chain length greater than C22.,false,,,http://purl.obolibrary.org/obo/CHEBI_37554,,,,,,,,,,,,,,,,,,,,,,A fatty acyl-CoA in which the fatty acyl group has a chain length greater than C22.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,VLCFA-CoA,,,,,CHEBI:61910,,,,,,,,,,,,,,,,,,,,,,very long-chain fatty acyl-CoA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002908,ATF6 mediated proapoptic gene  production pathway [ER stress - apoptosis],,"ATF6 mediated proapoptic gene  production pathway is a subtype of ATF6 signaling (integrated pathway): Sequence of linked reactions, which has ATF6 signaling and gene regulation pathway.
This process is dependent on positive regulation of apoptosis and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002548,,,,,,,,,,,,,,,,,,,,,,"ATF6 mediated proapoptic gene  production pathway is a subtype of ATF6 signaling (integrated pathway): Sequence of linked reactions, which has ATF6 signaling and gene regulation pathway.
This process is dependent on positive regulation of apoptosis and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002909|http://purl.obolibrary.org/obo/TXPO_0002912|http://purl.obolibrary.org/obo/TXPO_0003030,,http://purl.obolibrary.org/obo/TXPO_0003033,,,,,,,,,,,,,,,,TXPO:0002908,,,,,,,,,,,,,,,,,,,,,,ATF6 mediated proapoptic gene  production pathway [ER stress - apoptosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002905,Bip-unfolded protein complex 1 [ER stress - refolding],,"Bip-unfolded protein is a subtype of a molecular complex.
This entity has sub-parts of molecules: BIP/GRP78, and an unfolded protein.
This entity can participate in the infmallation of ER stress via PERK pathway.",false,,,http://purl.obolibrary.org/obo/TXPO_0003157,,,,,,,,,,,,,,,,,,,,,,"Bip-unfolded protein is a subtype of a molecular complex.
This entity has sub-parts of molecules: BIP/GRP78, and an unfolded protein.
This entity can participate in the infmallation of ER stress via PERK pathway.",,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002106|http://purl.obolibrary.org/obo/TXPO_0002385,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002905,,,,,,,,,,,,,,,,,,,,,,Bip-unfolded protein complex 1 [ER stress - refolding],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002909,ATF6 signaling (primitive) [ER stress - apoptosis],,"ATF6 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the ATF6 (activating transcription factor 6). ATF6 generally plays a endoplasmic reticulum membrane stress sensor role.
This process is dependent on the apoptosis and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000719,,,,,,,,,,,,,,,,,,,,,,"ATF6 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the ATF6 (activating transcription factor 6). ATF6 generally plays a endoplasmic reticulum membrane stress sensor role.
This process is dependent on the apoptosis and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002910,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002911,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002912,,,,,,,,,,,TXPO:0002909,,,,,,,,,,,,,,,,,,,,,,ATF6 signaling (primitive) [ER stress - apoptosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002907,Bip-unfolded protein complex 3 [ER stress - inflammation],,"Bip-unfolded protein is a subtype of a molecular complex.
This entity has sub-parts of molecules: BIP/GRP78, and an unfolded protein.
This entity can participate in the inflammation of ER stress via IRE1 pathway.",false,,,http://purl.obolibrary.org/obo/TXPO_0003157,,,,,,,,,,,,,,,,,,,,,,"Bip-unfolded protein is a subtype of a molecular complex.
This entity has sub-parts of molecules: BIP/GRP78, and an unfolded protein.
This entity can participate in the inflammation of ER stress via IRE1 pathway.",,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002106|http://purl.obolibrary.org/obo/TXPO_0002385,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002907,,,,,,,,,,,,,,,,,,,,,,Bip-unfolded protein complex 3 [ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002902,ATF6 - signaling factor (canonical)[ER stress - inflammation],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000044,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001898,,,,,,,,,,TXPO:0002902,,,,,,,,,,,,,,,,,,,,,,ATF6 - signaling factor (canonical)[ER stress - inflammation],,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005794,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002924,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002900,ATF6 - stress sensor (canonical)[ER stress - Refolding],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000879,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000825,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000881,,,,,,,,,,TXPO:0002900,,,,,,,,,,,,,,,,,,,,,,ATF6 - stress sensor (canonical)[ER stress - Refolding],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002447,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002903,Dissociation of ATF6-alpha:BIP Complex [ER stress],,"Dissociation of ATF6:BIP heterodimer is a subtype of detaching: A process that disaggregates ATF6-BIP heterodimers into BIP and ATF6.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000505,,,,,,,,,,,,,,,,,,,,,,"Dissociation of ATF6:BIP heterodimer is a subtype of detaching: A process that disaggregates ATF6-BIP heterodimers into BIP and ATF6.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003157|http://purl.obolibrary.org/obo/TXPO_0000879,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000713,,,,,,,,,,,TXPO:0002903,,,,,,,,,,,,,,,,,,,,,,Dissociation of ATF6-alpha:BIP Complex [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002901,ATF6 - signaling factor (canonical)[ER stress - Refolding],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000044,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001898,,,,,,,,,,TXPO:0002901,,,,,,,,,,,,,,,,,,,,,,ATF6 - signaling factor (canonical)[ER stress - Refolding],,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005794,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001905,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002904,Dissociation of ATF6-alpha:BIP Complex [ER stress - refolding],,"Dissociation of ATF6:BIP heterodimer is a subtype of detaching: A process that disaggregates ATF6-BIP heterodimers into BIP and ATF6.
This process is dependent on the refolding and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002903,,,,,,,,,,,,,,,,,,,,,,"Dissociation of ATF6:BIP heterodimer is a subtype of detaching: A process that disaggregates ATF6-BIP heterodimers into BIP and ATF6.
This process is dependent on the refolding and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002110,,,,http://purl.obolibrary.org/obo/TXPO_0002900|http://purl.obolibrary.org/obo/TXPO_0002906,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001905,,,,,,,,,,,TXPO:0002904,,,,,,,,,,,,,,,,,,,,,,Dissociation of ATF6-alpha:BIP Complex [ER stress - refolding],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002906,Bip-Unfolded Protein complex 2 [ER stress - refolding],,"Bip-unfolded protein is a subtype of a molecular complex.
This entity has sub-parts of molecules: BIP/GRP78, and an unfolded protein.
This entity can participate in the protein refolding of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0003157,,,,,,,,,,,,,,,,,,,,,,"Bip-unfolded protein is a subtype of a molecular complex.
This entity has sub-parts of molecules: BIP/GRP78, and an unfolded protein.
This entity can participate in the protein refolding of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002106|http://purl.obolibrary.org/obo/TXPO_0002385,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002906,,,,,,,,,,,,,,,,,,,,,,Bip-Unfolded Protein complex 2 [ER stress - refolding],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100853,PKA gamma catalytic subunit,"PKA C-gamma|cAMP-dependent protein kinase, gamma-catalytic subunit",,false,,,http://purl.obolibrary.org/obo/IMR_0100703,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"PKA C-gamma|cAMP-dependent protein kinase, gamma-catalytic subunit",,,,,IMR:0100853,,,,,,,,,,,,,,,,,,,,,,PKA gamma catalytic subunit,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001501,Rac1,,,false,,,http://purl.obolibrary.org/obo/IMR_0000297,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001501,,,,,,,,,,,,,,,,,,,,,,Rac1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0001845,phagolysosome assembly,late phagosome biosynthesis|phagolysosome formation|late phagosome formation,"The process that results in the fusion of a phagosome, a vesicle formed by phagocytosis, with a lysosome.",false,,,http://purl.obolibrary.org/obo/GO_0071840,,,,,,,,,,,,,,,,,,,,,,"The process that results in the fusion of a phagosome, a vesicle formed by phagocytosis, with a lysosome.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,late phagosome biosynthesis|phagolysosome formation|late phagosome formation,,http://purl.obolibrary.org/obo/GO_0006909,GO:0001845,http://purl.obolibrary.org/obo/GO_0006909,,,,,,,,,,,,,,,,,,,,,phagolysosome assembly,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002603,IRE1 - signaling factor (canonical)[IRE1 signalling system],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002601,http://purl.obolibrary.org/obo/TXPO_0002593,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UniProt_Q9NZJ5|http://www.uniprot.org/entry/Q9NZJ5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001898,,,,,,,,,,TXPO:0002603,,,,,,,,,,,,,,,,,,,,,,IRE1 - signaling factor (canonical)[IRE1 signalling system],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002605,XBP1 - transcriptional regulator (canonical)[ER stress -ERAD],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001968,http://purl.obolibrary.org/obo/TXPO_0002608,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002605,,,,,,,,,,,,,,,,,,,,,,XBP1 - transcriptional regulator (canonical)[ER stress -ERAD],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002600,hyperfunction of moving drug to the inside of liver [Ground glass appearance],,"Hyperfunction of moving drug to the inside of liver is a subtype of hyperfunction of moving A to the inside of B: A process that performs an excesssive moving drug to the inside of liver.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/TXPO_0002359,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of moving drug to the inside of liver is a subtype of hyperfunction of moving A to the inside of B: A process that performs an excesssive moving drug to the inside of liver.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,http://purl.obolibrary.org/obo/TXPO_0001714,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001827,,,,,,,,,,,TXPO:0002600,,,,,,,,,,,,,,,,,,,,,,hyperfunction of moving drug to the inside of liver [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002607,gene expression by XBP1 [ER stress],,"Gene expression by XBP1 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) by XBP1.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002606,,,,,,,,,,,,,,,,,,,,,,"Gene expression by XBP1 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) by XBP1.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002607,,,,,,,,,,,,,,,,,,,,,,gene expression by XBP1 [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002604,receiving signal in IRE1 signal transduction pathway [ILE1 pathway],,"Receiving signal in IRE1 signal transduction pathway is a subtype of receiving signal: A process that recognizes another object and changes into a signal in a IRE1 signal transduction pathway.
This entity is a specific course-dependent process. This process can constitute the course of IRE1 pathway.",false,,,http://purl.obolibrary.org/obo/TXPO_0002174,,,,,,,,,,,,,,,,,,,,,,"Receiving signal in IRE1 signal transduction pathway is a subtype of receiving signal: A process that recognizes another object and changes into a signal in a IRE1 signal transduction pathway.
This entity is a specific course-dependent process. This process can constitute the course of IRE1 pathway.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002593,,,,,,,,,,,TXPO:0002604,,,,,,,,,,,,,,,,,,,,,,receiving signal in IRE1 signal transduction pathway [ILE1 pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002609,IRE1-XBP1 mediated pathway [ER stress - refolding],,"IRE1-XBP1 mediated pathway is a subtype of IRE1 signaling (integrated pathway): Sequence of linked reactions, which has IRE1 signaling and gene regulation by XBP1.
This process is dependent on refolding and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002563,,,,,,,,,,,,,,,,,,,,,,"IRE1-XBP1 mediated pathway is a subtype of IRE1 signaling (integrated pathway): Sequence of linked reactions, which has IRE1 signaling and gene regulation by XBP1.
This process is dependent on refolding and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002957|http://purl.obolibrary.org/obo/TXPO_0002919|http://purl.obolibrary.org/obo/TXPO_0002761,,http://purl.obolibrary.org/obo/TXPO_0002959|http://purl.obolibrary.org/obo/TXPO_0002956,,,,,,,,,,,,,,,,TXPO:0002609,,,,,,,,,,,,,,,,,,,,,,IRE1-XBP1 mediated pathway [ER stress - refolding],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002606,gene expression by XBP1,,Gene expression by XBP1 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) by XBP1.,false,,,http://purl.obolibrary.org/obo/TXPO_0000375,,,,,,,,,,,,,,,,,,,,,,Gene expression by XBP1 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) by XBP1.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002606,,,,,,,,,,,,,,,,,,,,,,gene expression by XBP1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002601,IRE1 (canonical)[ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000871|http://purl.obolibrary.org/obo/TXPO_0001528,http://purl.obolibrary.org/obo/TXPO_0002595|http://purl.obolibrary.org/obo/TXPO_0002597,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:498013|NCBI-Mouse-GeneID:78943|NCBI-Human-GeneID:2081|http://purl.obolibrary.org/obo/UniProt_Q9NZJ5|http://www.uniprot.org/entry/Q9NZJ5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002601,,,,,,,,,,,,,,,,,,,,,,IRE1 (canonical)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002608,ERAD gene expression by XBP1 [ER stress],,"ERAD gene expression by XBP1 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA)related to the ER associated degradation (ERAD) by XBP1.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002607,,,,,,,,,,,,,,,,,,,,,,"ERAD gene expression by XBP1 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA)related to the ER associated degradation (ERAD) by XBP1.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002608,,,,,,,,,,,,,,,,,,,,,,ERAD gene expression by XBP1 [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002602,IRE1 - signal sensor (canonical)[IRE1 signalling system],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002601,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UniProt_Q9NZJ5|http://www.uniprot.org/entry/Q9NZJ5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000882,,,,,,,,,,TXPO:0002602,,,,,,,,,,,,,,,,,,,,,,IRE1 - signal sensor (canonical)[IRE1 signalling system],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002604,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_35553,perhexiline,"Perhexilene|Perhexiline|2-(2,2-dicyclohexylethyl)piperidine",Perhexiline (Pexsig) is a prophylactic antianginal agent used primarily in Australia and New Zealand. Perhexiline is thought to act by inhibiting mitochondrial carnitine palmitoyltransferase-1. (by Wikipedia),false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Wikipedia:Perhexiline|CAS:6621-47-2|DrugBank:DB01074|Beilstein:4979856|LINCS:LSM-4353|Drug_Central:2106,,Perhexiline (Pexsig) is a prophylactic antianginal agent used primarily in Australia and New Zealand. Perhexiline is thought to act by inhibiting mitochondrial carnitine palmitoyltransferase-1. (by Wikipedia),,,,,,,,,,,,C19H35N,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35554,,,,,"Perhexiline|2-(2,2-dicyclohexylethyl)piperidine",,Perhexilene,,,,,,,,,,,,,,,,,,,,,CHEBI:35553,,,,perhexiline,,CHEBI:35553,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,C1CCC(CC1)C(CC1CCCCN1)C1CCCCC1,,,,,
http://purl.obolibrary.org/obo/UBERON_0003920,venous blood vessel,venous tree organ segment|segment of venous tree organ,A blood vessel that carries blood from the capillaries toward the heart|Compare to: vein,false,,,http://purl.obolibrary.org/obo/UBERON_0001981,,,,,,,,,,,,,,,,,,,,MA:0000066|FMA:86188|EMAPA:35932,,A blood vessel that carries blood from the capillaries toward the heart,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,venous tree organ segment|segment of venous tree organ,,,,http://purl.obolibrary.org/obo/UBERON_0004582,UBERON:0003920,http://purl.obolibrary.org/obo/UBERON_0004582,,,,,,,,,,,,,,,,,,,Compare to: vein,,venous blood vessel,,,,,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0003928,digestive system duct,duct of gastrointestinal system|duct of digestive system|gastrointestinal system duct,A duct that is part of a digestive system [Automatically generated definition].,false,,,http://purl.obolibrary.org/obo/UBERON_0000058,,,,,,,,,,,,,,,,,,,,,,A duct that is part of a digestive system [Automatically generated definition].,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,duct of gastrointestinal system|duct of digestive system|gastrointestinal system duct,,,,http://purl.obolibrary.org/obo/UBERON_0001007,UBERON:0003928,http://purl.obolibrary.org/obo/UBERON_0001007,,,,,,,,,,,,,,,,,,,,,digestive system duct,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001152,PKC lambda/iota,,,false,,,http://purl.obolibrary.org/obo/IMR_0000247,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001152,,,,,,,,,,,,,,,,,,,,,,PKC lambda/iota,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_135028,pirprofen,racemic pirprofen|rengasil,Pirprofen was a nonsteroidal anti-inflammatory drug (NSAID) that was brought to market by Ciba-Geigy in 1982 as a treatment for arthritis and pain. (by Wikipedia),false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:31793-07-4|DrugBank:DB13722|Wikipedia:Pirprofen|Drug_Central:2213,,Pirprofen was a nonsteroidal anti-inflammatory drug (NSAID) that was brought to market by Ciba-Geigy in 1982 as a treatment for arthritis and pain. (by Wikipedia),,,,,,,,,,,,C13H14ClNO2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35475,,,,,,,racemic pirprofen|rengasil,,,,,,,,,,,,,,,,,,,,,CHEBI:135028,,,,pirprofen,,CHEBI:135028,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ClC1=C(C=CC(=C1)C(C(O)=O)C)N2CC=CC2,,,,,
http://purl.obolibrary.org/obo/IMR_0003073,GDF-8,Growth/differentiation factor-8|myostatin,,false,,,http://purl.obolibrary.org/obo/IMR_0000040,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Growth/differentiation factor-8|myostatin,,,,,IMR:0003073,,,,,,,,,,,,,,,,,,,,,,GDF-8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_25442,mycotoxin,,Poisonous substance produced by fungi.,false,,,http://purl.obolibrary.org/obo/CHEBI_27026,,,,,,,,,,,,,,,,,,,,,,Poisonous substance produced by fungi.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:25442,,,,,,,,,,,,,,,,,,,,,,mycotoxin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_15996,GTP,guanosine 5'-triphosphate,,false,,,http://purl.obolibrary.org/obo/CHEBI_36976,,,,,,,,,,,,,,,,,,,,CAS:86-01-1|DrugBank:DB04137,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,guanosine 5'-triphosphate,,,,,CHEBI:15996,,,,,,,,,,,,,,,,,,,,,,GTP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0002011,neoplastic (quality),,A structural quality which is held by a bearer when the latter's disposition the presence of abnormally proliferating masses of cells.,false,,,http://purl.obolibrary.org/obo/BFO_0000019,,,,,,,,,,,,,,,,,,,,,,A structural quality which is held by a bearer when the latter's disposition the presence of abnormally proliferating masses of cells.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0002011,,,,,,,,,,,,,,,,,,,,,,neoplastic (quality),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_46787,solvent,,A liquid that can dissolve other substances (solutes) without any change in their chemical composition.,false,,,http://purl.obolibrary.org/obo/CHEBI_51086,,,,,,,,,,,,,,,,,,,,Wikipedia:Solvent,,A liquid that can dissolve other substances (solutes) without any change in their chemical composition.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:46787,,,,,,,,,,,,,,,,,,,,,,solvent,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0033209,tumor necrosis factor-mediated signaling pathway,,"A series of molecular signals initiated by the binding of a tumor necrosis factor to a receptor on the surface of a cell, and ending with regulation of a downstream cellular process, e.g. transcription.",false,,,http://purl.obolibrary.org/obo/TXPO_0000609,,,,,,,,,,,,,,,,,,,,,,"A series of molecular signals initiated by the binding of a tumor necrosis factor to a receptor on the surface of a cell, and ending with regulation of a downstream cellular process, e.g. transcription.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0033209,,,,,,,,,,,,,,,,,,,,,,tumor necrosis factor-mediated signaling pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000833,IL-2 signaling (primitive) [Phospholipidosis (excessive defense) ],,"IL-2 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the cytokine IL-2.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense) .",false,,,http://purl.obolibrary.org/obo/TXPO_0000830|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,Reactome:R-HSA-451927.2|PMID:28732506,,"IL-2 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the cytokine IL-2.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense) .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002288|http://purl.obolibrary.org/obo/TXPO_0001143,,,,,,http://purl.obolibrary.org/obo/TXPO_0001495,,,,,,,,,,,TXPO:0000833,,,,,,,,,,,,,,,,,,,,,,IL-2 signaling (primitive) [Phospholipidosis (excessive defense) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000839,cell death dependent molecule (rat),,"Cell death dependent molecule is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of cell death as a gene product.
Gene profile:Rat/Liver/",false,,,http://purl.obolibrary.org/obo/TXPO_0000838,,,,,,,,,,,,,,,,,,,,,,"Cell death dependent molecule is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of cell death as a gene product.
Gene profile:Rat/Liver/",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000839,,,,,,,,,,,,,,,,,,,,,,cell death dependent molecule (rat),,,,,,,,,,,http://purl.obolibrary.org/obo/NCBITaxon_10114,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000837,liver cancer dependent molecule,,"Liver cacer dependent gene is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of liver cancer as a gene product.|under construction",false,,,http://purl.obolibrary.org/obo/TXPO_0000199,,,,,,,,,,,,,,,,,,,,,,"Liver cacer dependent gene is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of liver cancer as a gene product.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000837,,,,,,,,,,,,,,,,,,,,under construction,,liver cancer dependent molecule,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000834,fatty acid,,,false,,,http://purl.obolibrary.org/obo/CHEBI_18059|http://purl.obolibrary.org/obo/TXPO_0001144,,,,,,,,,,,,,,,,,,,,fatty acid|http://purl.obolibrary.org/obo/CHEBI_35366,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000834,,,,,,,,,,,,,,,,,,,,,,fatty acid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000832,cell death inhibitor,,A role played by the entity which inhibits the process of cell death.,false,,,http://purl.obolibrary.org/obo/TXPO_0002406,,,,,,,http://purl.obolibrary.org/obo/GO_0008219,,,,,,,,,,,,,,,A role played by the entity which inhibits the process of cell death.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000832,,,,,,,,,,,,,,,,,,,,,,cell death inhibitor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000831,cell proliferation [ER stress],,"The multiplication or reproduction of cells, resulting in the rapid expansion of a cell population.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/GO_0008283,,,,,,,,,,,,,,,,,,,,,,"The multiplication or reproduction of cells, resulting in the rapid expansion of a cell population.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000831,,,,,,,,,,,,,,,,,,,,,,cell proliferation [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000836,tumor cell survial [Phospholipidosis (excessive defense)],,"Tumor cell survial is a subtype of cell survival: A process that keeps the viability of a tumor cell.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense).",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0000280,,,,,,,,,,,,,,,,,,,,,,"Tumor cell survial is a subtype of cell survival: A process that keeps the viability of a tumor cell.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002553|http://purl.obolibrary.org/obo/TXPO_0003582|http://purl.obolibrary.org/obo/TXPO_0001140,,,,,,,,,,,,,,,,,TXPO:0000836,,,,,,,,,,,,,,,,,,,,,,tumor cell survial [Phospholipidosis (excessive defense)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000835,eosinogranular degeneration dependent chemical entity,,"Eosinogranular degeneration dependent chemical entity is a subtype of toxic course dependent chemical entity.
This entity can participate in the course of eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/TXPO_0001731,,,,,,,,,,,,,,,,,,,,,,"Eosinogranular degeneration dependent chemical entity is a subtype of toxic course dependent chemical entity.
This entity can participate in the course of eosinogranular degeneration.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000835,,,,,,,,,,,,,,,,,,,,,,eosinogranular degeneration dependent chemical entity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000838,cell death dependent chemical entity,,"Cell death dependent chemical entity is a subtype of toxic course dependent chemical entity.
This entity can participate in the course of cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0001731,,,,,,,,,,,,,,,,,,,,,,"Cell death dependent chemical entity is a subtype of toxic course dependent chemical entity.
This entity can participate in the course of cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000838,,,,,,,,,,,,,,,,,,,,,,cell death dependent chemical entity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000830,IL-2 signaling (primitive),,IL-2 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the cytokine IL-2.,false,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,Reactomre:R-HSA-451927.2,,IL-2 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the cytokine IL-2.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0038110,,,,,,,,,,,,,,,,TXPO:0000830,,,,,,,,,,,,,,,,,,,,,,IL-2 signaling (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001742,medium level,,The level of degree is middle.,false,,,http://purl.obolibrary.org/obo/TXPO_0004208,,,,,,,,,,,,,,,,,,,,,,The level of degree is middle.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001742,,,,,,,,,,,,,,,,,,,,,,medium level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001744,inflammasome activation [lipidosis],,"Inflammasome activation is a subtype of activating: A process that changes the activity of the inflammasome to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0001107,,,,,,,,,,,,,,,,,,,,PMID:20303873|Reactome: R-HSA-844456.2,,"Inflammasome activation is a subtype of activating: A process that changes the activity of the inflammasome to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001886|http://purl.obolibrary.org/obo/TXPO_0001876|http://purl.obolibrary.org/obo/TXPO_0001104,,,,,,http://purl.obolibrary.org/obo/TXPO_0001065,,,,,,,,,,,TXPO:0001744,,,,,,,,,,,,,,,,,,,,,,inflammasome activation [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001745,oxidative phosphorylation [Lipidosis],,"The phosphorylation of ADP to ATP that accompanies the oxidation of a metabolite through the operation of the respiratory chain. Oxidation of compounds establishes a proton gradient across the membrane, providing the energy for ATP synthesis.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/GO_0006119,,,,,,,,,,,,,,,,,,,,,,"The phosphorylation of ADP to ATP that accompanies the oxidation of a metabolite through the operation of the respiratory chain. Oxidation of compounds establishes a proton gradient across the membrane, providing the energy for ATP synthesis.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001745,,,,,,,,,,,,,,,,,,,,,,oxidative phosphorylation [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001747,malfunctioning of mitochondrial ATP synthesis coupled electron transfer [lipidosis],,"Malfunctioning of mitochondrial ATP synthesis coupled electron transfer is a subtype of malfunctioning process: A process that cannot perform a respiratory electron transport chain appropriately or cannot realize it at all.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0001846,,,,,,,,,,,,,,,,,,,,,,"Malfunctioning of mitochondrial ATP synthesis coupled electron transfer is a subtype of malfunctioning process: A process that cannot perform a respiratory electron transport chain appropriately or cannot realize it at all.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001747,,,,,,,,,,,,,,,,,,,,,,malfunctioning of mitochondrial ATP synthesis coupled electron transfer [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001741,dysfunction of lipid degradation,,Dysfunction of lipid degradation is a subtype of dysfunctioning: A process that performs an abnormal and incomplete lipid degradation.,false,,,http://purl.obolibrary.org/obo/TXPO_0000438,,,,,,,,,,,,,,,,,,,,,,Dysfunction of lipid degradation is a subtype of dysfunctioning: A process that performs an abnormal and incomplete lipid degradation.,,,http://purl.obolibrary.org/obo/GO_0009395,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_16247,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001741,,,,,,,,,,,,,,,,,,,,,,dysfunction of lipid degradation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001746,functional demand state,,"In the imbalance model, the basic units are as follows:
1) a functioning process (supply) for biological defense and maintaining homeostasis;
2) a functional demand process (demand) as toxic activity;
3) balance/imbalance between toxic activity and defense processes; and
4) outcome from organelles, cells, or tissues to the organ exhibiting toxicity manifestations.

This entity indicates step 2: a state of functional demand as toxic activity.",false,,,http://purl.obolibrary.org/obo/TXPO_0000270,,,,,,,,,,,,,,,,,,,,,,"In the imbalance model, the basic units are as follows:
1) a functioning process (supply) for biological defense and maintaining homeostasis;
2) a functional demand process (demand) as toxic activity;
3) balance/imbalance between toxic activity and defense processes; and
4) outcome from organelles, cells, or tissues to the organ exhibiting toxicity manifestations.

This entity indicates step 2: a state of functional demand as toxic activity.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001746,,,,,,,,,,,,,,,,,,,,,,functional demand state,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001743,low level,,The level of degree is lower than medium.,false,,,http://purl.obolibrary.org/obo/TXPO_0004208,,,,,,,,,,,,,,,,,,,,,,The level of degree is lower than medium.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001743,,,,,,,,,,,,,,,,,,,,,,low level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001740,very high level,,The level of degree is very high in comparison to the medium.,false,,,http://purl.obolibrary.org/obo/TXPO_0004208,,,,,,,,,,,,,,,,,,,,,,The level of degree is very high in comparison to the medium.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001740,,,,,,,,,,,,,,,,,,,,,,very high level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001749,negative regulation of oxidative phosphorylation [Lipidosis],,"Negative regulation of oxidative phosphorylation is a subtype of negative regulation process: Any process that stops, prevents or reduces the frequency, rate or extent of the oxidative phosphorylation.
This entity is a specific course-dependent process. This process can constitute the course of lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001771|http://purl.obolibrary.org/obo/TXPO_0001720,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of oxidative phosphorylation is a subtype of negative regulation process: Any process that stops, prevents or reduces the frequency, rate or extent of the oxidative phosphorylation.
This entity is a specific course-dependent process. This process can constitute the course of lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002043|http://purl.obolibrary.org/obo/TXPO_0002036,,,,,,http://purl.obolibrary.org/obo/TXPO_0001540,,,,,,,,,,,TXPO:0001749,,,,,,,,,,,,,,,,,,,,,,negative regulation of oxidative phosphorylation [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006119,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001748,negative regulation of respiratory electron transport chain [lipidosis],,"Negative regulation of respiratory electron transport chain is a subtype of negative regulation process:  Any process that stops, prevents or reduces the frequency, rate or extent of mrespiratory electron transport chain.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002342|http://purl.obolibrary.org/obo/TXPO_0001720,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of respiratory electron transport chain is a subtype of negative regulation process:  Any process that stops, prevents or reduces the frequency, rate or extent of mrespiratory electron transport chain.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002026|http://purl.obolibrary.org/obo/TXPO_0002030|http://purl.obolibrary.org/obo/TXPO_0002019,,,,,,http://purl.obolibrary.org/obo/TXPO_0001540,,,,,,,,,,,TXPO:0001748,,,,,,,,,,,,,,,,,,,,,,negative regulation of respiratory electron transport chain [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100597,Cdc2 (mol),Cyclin-dependent kinase 1|CDK1|Cdc2|Cell division control protein 2 homolog (EC 2.7.1.-) (p34 protein kinase) (Cyclin-dependent kinase 1) (CDK1)|Cell division control protein 2 homolog (EC 2.7.1.-) (p34 protein kinase) (Cyclin-dependent kinase 1) (CDK1) form|p34 protein kinase|Cell division control protein 2 homolog|CDC28,,false,,,http://purl.obolibrary.org/obo/TXPO_0003241,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0010763,Cyclin-dependent kinase 1|CDK1|Cdc2|Cell division control protein 2 homolog (EC 2.7.1.-) (p34 protein kinase) (Cyclin-dependent kinase 1) (CDK1)|Cell division control protein 2 homolog (EC 2.7.1.-) (p34 protein kinase) (Cyclin-dependent kinase 1) (CDK1) form|p34 protein kinase|Cell division control protein 2 homolog|CDC28,,,,,IMR:0100597,,,,,,,,,,,,,,,,,,,,,,Cdc2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0011347,Elongin A1 protein,RNA polymerase II transcription factor SIII subunit A1|SIII p110|Elongin 110 kDa subunit|EloA|Transcription elongation factor B polypeptide 3|Elongin A|MSTP059,,false,,,http://purl.obolibrary.org/obo/IMR_0010020,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,RNA polymerase II transcription factor SIII subunit A1|SIII p110|Elongin 110 kDa subunit|EloA|Transcription elongation factor B polypeptide 3|Elongin A|MSTP059,,,,,IMR:0011347,,,,,,,,,,,,,,,,,,,,,,Elongin A1 protein,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000816,FRA-2,,,false,,,http://purl.obolibrary.org/obo/IMR_0000415,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000816,,,,,,,,,,,,,,,,,,,,,,FRA-2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0002268,olfactory organ,main olfactory organ|primary olfactory organ|organum olfactorium|olfactory neuroepithelium|organ olfactus|olfactory organ|olfactory sensory organ|olfactory sense organ,An organ that houses olfactory neurons and is responsible for the sense of smell. Examples include the vertebrate nose and the Drosophila dorsal organ.,false,,,http://purl.obolibrary.org/obo/UBERON_0000020,,,,,,,,,,,,,,,,,,,,BTO:0001772|VHOG:0000287|FMA:77659|AAO:0010180|FBbt:00005158|XAO:0000273,,An organ that houses olfactory neurons and is responsible for the sense of smell. Examples include the vertebrate nose and the Drosophila dorsal organ.,,,,"An olfactory organ overlaps with the olfactory system, because some parts of the nose (e.g. nasal skeleton) are parts of the skeletal system, which is spatially disjoint",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,olfactory organ|olfactory sensory organ|olfactory sense organ,main olfactory organ|primary olfactory organ,organum olfactorium|olfactory neuroepithelium|organ olfactus,,,UBERON:0002268,,,,,,,,,,,,,,,,,,,,,,olfactory organ,,,,,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_4031,cyclosporin A,"30-ethyl-33-[(4E)-1-hydroxy-2-methylhex-4-en-1-yl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-bis(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone","A cyclic nonribosomal peptide of eleven amino acids; an immunosuppressant drug widely used in post-allogeneic organ transplant to reduce the activity of the patient's immune system, and therefore the risk of organ rejection. Also causes reversible inhibition of immunocompetent lymphocytes in the G0- and G1-phase of the cell cycle.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,LINCS:LSM-1703|DrugBank:DB00091,,"A cyclic nonribosomal peptide of eleven amino acids; an immunosuppressant drug widely used in post-allogeneic organ transplant to reduce the activity of the patient's immune system, and therefore the risk of organ rejection. Also causes reversible inhibition of immunocompetent lymphocytes in the G0- and G1-phase of the cell cycle.",,,,,,,,,,,,C62H111N11O12,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"30-ethyl-33-[(4E)-1-hydroxy-2-methylhex-4-en-1-yl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-bis(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone",,,,,CHEBI:4031,,,,,,,,,,,,,,,,,,,,,,cyclosporin A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,,,,,
http://purl.obolibrary.org/obo/IMR_0100459,IKK beta,Inhibitor of nuclear factor kappa B kinase beta subunit,,false,,,http://purl.obolibrary.org/obo/IMR_0000701,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Inhibitor of nuclear factor kappa B kinase beta subunit,,,,,IMR:0100459,,,,,,,,,,,,,,,,,,,,,,IKK beta,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_48560,dopaminergic agent,dopamine agent|dopamine agents|dopamine drugs|dopaminergic agents|dopamine drug,"A drug used for its effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons.",false,,,http://purl.obolibrary.org/obo/CHEBI_35942,,,,,,,,,,,,,,,,,,,,,,"A drug used for its effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,dopamine agent|dopamine agents|dopamine drugs|dopaminergic agents|dopamine drug,,,,,,,,,,,,,,,,,,,,,CHEBI:48560,,,,dopaminergic agent,,CHEBI:48560,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100103,"pituitary hormone, posterior",Pituitrin,"Hormones released from the posterior lobe of the pituitary, including vasopressin (antidiuretic hormone) and oxytocin. They are formed in the neuronal cells of the hypothalamic nuclei and stored in nerve cell endings in the posterior pituitary (neurohypophysis).",false,,,http://purl.obolibrary.org/obo/IMR_0100084,,,,,,,,,,,,,,,,,,,,MeSH:D010909,,"Hormones released from the posterior lobe of the pituitary, including vasopressin (antidiuretic hormone) and oxytocin. They are formed in the neuronal cells of the hypothalamic nuclei and stored in nerve cell endings in the posterior pituitary (neurohypophysis).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Pituitrin,,,,,IMR:0100103,,,,,,,,,,,,,,,,,,,,,,"pituitary hormone, posterior",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0002805,FOXO1 (mol),,,false,,,http://purl.obolibrary.org/obo/IMR_0002804,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0002805,,,,,,,,,,,,,,,,,,,,,,FOXO1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000081,EGFR (mol),epidermal growth factor receptor,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,GO:0005006,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000823,,,,,epidermal growth factor receptor,,,,,IMR:0000081,,,,,,,,,,,,,,,,,,,,,,EGFR (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000006608,SMO,,"Other designations: frizzled family member 11|protein Gx|seven transmembrane helix receptor|smoothened homolog|smoothened, frizzled family receptor|smoothened, seven transmembrane spanning receptor",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,SMOH|Gx|FZD11,,,,,,,,,,,,7,,,,,,Ensembl:ENSG00000128602|MIM:601500|HGNC:11119|HPRD:03294|Vega:OTTHUMG00000158421,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"smoothened, frizzled class receptor",,,7q32.3,,,,,,,,,,,,,,,,"GO_0000122 (EC: IEA); GO_0001570 (EC: IBA); GO_0001649 (EC: IBA); GO_0001701 (EC: IEA); GO_0001708 (EC: IEA); GO_0001755 (EC: IBA); GO_0001947 (EC: ISS); GO_0002052 (EC: IBA); GO_0002053 (EC: IBA); GO_0003007 (EC: IBA); GO_0003140 (EC: ISS); GO_0003323 (EC: IEA); GO_0004930 (EC: IEA); GO_0005113 (EC: IPI, PMID: 9811851); GO_0005515 (EC: IPI, PMID: 19592253); GO_0005737 (EC: IBA); GO_0005794 (EC: IDA, Qualifier: colocalizes_with, PMID: 11278759); GO_0005886 (EC: IBA); GO_0005886 (EC: IDA, PMID: 19304771); GO_0005901 (EC: IDA, Qualifier: colocalizes_with, PMID: 11278759); GO_0005929 (EC: IBA); GO_0007224 (EC: IEP, PMID: 17850284); GO_0007224 (EC: IMP, PMID: 19304771); GO_0007228 (EC: ISS); GO_0007283 (EC: IBA); GO_0007368 (EC: IBA); GO_0007371 (EC: ISS); GO_0007494 (EC: ISS); GO_0008144 (EC: IDA, PMID: 19304771); GO_0008406 (EC: IBA); GO_0010002 (EC: IBA); GO_0010628 (EC: ISS); GO_0010629 (EC: ISS); GO_0016021 (EC: IEA); GO_0017147 (EC: IBA); GO_0021508 (EC: IBA); GO_0021561 (EC: IBA); GO_0021696 (EC: IBA); GO_0021794 (EC: IEA); GO_0021904 (EC: IBA); GO_0021910 (EC: IBA); GO_0021938 (EC: IBA); GO_0021953 (EC: IBA); GO_0021984 (EC: IBA); GO_0030165 (EC: IBA); GO_0030857 (EC: IEA); GO_0031017 (EC: IBA); GO_0031069 (EC: IEA); GO_0031076 (EC: IBA); GO_0031102 (EC: IBA); GO_0032474 (EC: IBA); GO_0034504 (EC: IEA); GO_0035264 (EC: IEA); GO_0042307 (EC: IEA); GO_0042475 (EC: IBA); GO_0042693 (EC: IBA); GO_0042813 (EC: IBA); GO_0043025 (EC: IBA); GO_0043066 (EC: IBA); GO_0043231 (EC: IDA, PMID: 11278759); GO_0043392 (EC: ISS); GO_0045880 (EC: IBA); GO_0045944 (EC: IEA); GO_0048557 (EC: IBA); GO_0048663 (EC: IBA); GO_0048702 (EC: IBA); GO_0048703 (EC: IBA); GO_0048752 (EC: IBA); GO_0048846 (EC: IBA); GO_0048853 (EC: ISS); GO_0050679 (EC: IBA); GO_0050821 (EC: IEA); GO_0051799 (EC: IEA); GO_0060070 (EC: IBA); GO_0060170 (EC: IEA); GO_0060248 (EC: IMP, PMID: 9422511); GO_0060413 (EC: IEA); GO_0060644 (EC: IEA); GO_0060684 (EC: IEA); GO_0060830 (EC: IBA); GO_0061053 (EC: ISS); GO_0061113 (EC: IEA); GO_0070062 (EC: IDA, PMID: 19056867); GO_0071397 (EC: ISS); GO_0072001 (EC: IEP, PMID: 17850284); GO_0072285 (EC: ISS); GO_0072372 (EC: TAS); GO_0090190 (EC: ISS); GO_2000036 (EC: IEA); GO_2000826 (EC: ISS)",,,,,,,,,PMID: 8898207; 8906787; 9422511; 9581815; 9628830; 9764827; 9799615; 9811851; 11042037; 11278759; 11748145; 12123571; 12165511; 12192414; 12241103; 12477932; 12499255; 12690205; 12773389; 15489334; 15618519; 16147992; 16339184; 16344560; 16804411; 16867986; 16945339; 17850284; 17884791; 18359851; 18502968; 18543049; 19056867; 19237606; 19304771; 19351817; 19401682; 19432668; 19453261; 19473442; 19564910; 19592253; 19726788; 19730683; 20050020; 20067614; 20215540; 20561215; 20603613; 20819778; 20937227; 21210262; 21338440; 21757753; 22114142; 22231273; 22253573; 22486854; 22535603; 22864913; 22901214; 23063129; 23098507; 23334667; 23341351; 23348505; 23349881; 23379358; 23448715; 23508962; 23599646; 23636324; 23915072; 24148123; 24277750,,,,,,,,,,,,,,,OGG:3000006608,,,,,,,"smoothened, frizzled class receptor",,,,,,,,,,,,,"Other designations: frizzled family member 11|protein Gx|seven transmembrane helix receptor|smoothened homolog|smoothened, frizzled family receptor|smoothened, seven transmembrane spanning receptor",,SMO,,,,,,,,,,,,,,,,,,,,,,,6608,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,SMO,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000006609,SMPD1,,Other designations: acid sphingomyelinase|sphingomyelin phosphodiesterase,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,NPD|ASMASE|ASM,,,,,,,,,,,,11,,,,,,HPRD:06353|HGNC:11120|MIM:607608|Vega:OTTHUMG00000165453|Ensembl:ENSG00000166311,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"sphingomyelin phosphodiesterase 1, acid lysosomal",,,11p15.4-p15.1,,,,,,,,,,,,,,,,"GO_0004767 (EC: IEA); GO_0005515 (EC: IPI); GO_0005615 (EC: IEA); GO_0006665 (EC: TAS); GO_0006684 (EC: TAS, PMID: 7670466); GO_0006685 (EC: IEA); GO_0006687 (EC: TAS); GO_0007165 (EC: TAS, PMID: 7670466); GO_0007399 (EC: TAS, PMID: 7670466); GO_0008219 (EC: IEA); GO_0016798 (EC: IEA); GO_0023021 (EC: IMP, PMID: 19279008); GO_0035307 (EC: IMP, PMID: 19279008); GO_0042220 (EC: IEA); GO_0042493 (EC: IEA); GO_0042599 (EC: IEA); GO_0043065 (EC: IEA); GO_0043202 (EC: TAS); GO_0043407 (EC: IMP, PMID: 19279008); GO_0044281 (EC: TAS); GO_0046513 (EC: IMP, PMID: 19279011)",,,,,,,,,PMID: 1292508; 1301192; 1391960; 1618760; 1711683; 1718266; 1740330; 1840600; 1885770; 2004772; 2023926; 2555181; 7670466; 8051942; 8407868; 8664904; 8680412; 8693491; 8889548; 9030779; 9110068; 11001565; 11238738; 11788605; 12208520; 12369017; 12477932; 12556236; 12631268; 12801930; 12815059; 12953170; 15175033; 15221801; 15241805; 15383576; 15509740; 15743760; 15769735; 15849201; 15877209; 15888438; 15997205; 16010684; 16051685; 16245071; 16472269; 16642440; 16787399; 17344303; 17381401; 17698617; 18052040; 18088425; 18264947; 18426979; 18628757; 18815062; 19050888; 19054571; 19059331; 19279008; 19279011; 19300439; 19322201; 19405096; 19817993; 19860808; 19878569; 19913121; 20137294; 20301544; 20386867; 20628086; 20807762; 20956541; 21098024; 21153367; 21294641; 21335555; 21900206; 22367733; 22558155; 22573858; 22613662; 22771321; 22824271; 22879933; 22890197; 22906436; 23356216; 23535491; 23618813; 23770692; 23871123,,,,,,,,,,,,,,,OGG:3000006609,,,,,,,"sphingomyelin phosphodiesterase 1, acid lysosomal",,,,,,,,,,,,,Other designations: acid sphingomyelinase|sphingomyelin phosphodiesterase,,SMPD1,,,,,,,,,,,,,,,,,,,,,,,6609,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,SMPD1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000006606,SMN1,,Other designations: component of gems 1|gemin-1|survival motor neuron 1 protein|survival motor neuron protein|tudor domain containing 16A,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,SMA4|SMNT|SMA1|GEMIN1|SMA|SMA2|TDRD16A|T-BCD541|SMA3|SMN|BCD541|SMA@,,,,,,,,,,,,5,,,,,,Vega:OTTHUMG00000099361|HGNC:11117|HPRD:02646|MIM:600354|Ensembl:ENSG00000172062,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"survival of motor neuron 1, telomeric",,,5q13.2,,,,,,,,,,,,,,,,,,,,,,,,,PMID: 7552146; 7581461; 7639755; 7813012; 8670859; 8808598; 8838816; 8922999; 9147655; 9158159; 9259265; 9302277; 9323129; 9389483; 9503025; 9600994; 9818944; 9837824; 9845364; 10205267; 10339583; 10369862; 10601333; 10725331; 10732802; 10732817; 10734235; 10767334; 10851237; 10942426; 11092763; 11135666; 11149922; 11313744; 11438536; 11448987; 11509230; 11522829; 11551898; 11574476; 11641277; 11704667; 11713266; 11714716; 11720283; 11748230; 11773003; 11791208; 11792806; 11835381; 11875052; 11907229; 11914277; 11935338; 11992267; 11996521; 12021369; 12065586; 12067652; 12095920; 12192051; 12221125; 12361597; 12374765; 12459587; 12477932; 12657835; 12663808; 12668731; 12679382; 12878704; 12975319; 14520560; 14697339; 14715275; 14742439; 14749338; 14972554; 15119481; 15222879; 15249625; 15304326; 15337310; 15345747; 15372022; 15459957; 15489334; 15494309; 15526170; 15580564; 15608400; 15726222; 15832310; 16087681; 16093455; 16118268; 16169070; 16189514; 16331551; 16439605; 16449646; 16481599; 16565220; 16617248; 16651888; 16786553; 16845275; 16931506; 16936383; 17023415; 17049859; 17081983; 17218272; 17250497; 17250498; 17392705; 17415510; 17475491; 17585203; 17592254; 17625510; 17635841; 17682539; 17850955; 17916631; 18071605; 18093976; 18172693; 18269687; 18332255; 18337729; 18533950; 18546169; 18624398; 18633133; 18651653; 18703124; 18752447; 18974562; 19050931; 19103745; 19134255; 19154529; 19179398; 19198020; 19215052; 19244360; 19271042; 19351384; 19447967; 19480685; 19538222; 19596235; 19625283; 19628962; 19648294; 19735367; 19922137; 19928837; 19997741; 20090376; 20188701; 20197730; 20301526; 20373854; 20442745; 20515750; 20563565; 20620147; 20637152; 20659551; 20696395; 20713032; 20947812; 21055263; 21082361; 21145461; 21172665; 21209906; 21233719; 21300694; 21333717; 21335981; 21338334; 21364876; 21462119; 21482919; 21496457; 21565611; 21610747; 21631299; 21672919; 21693563; 21705024; 21732698; 21785216; 21826391; 21890473; 21900206; 21906983; 21920940; 21924051; 21956898; 21963094; 22085534; 22101937; 22118674; 22124016; 22161088; 22190034; 22197680; 22323753; 22324632; 22363433; 22365833; 22454514; 22607171; 22669976; 22824686; 22884440; 22939629; 22990118; 22994313; 23000965; 23112048; 23136128; 23185376; 23221635; 23246001; 23315303; 23398456; 23438482; 23455922; 23455924; 23477310; 23496866; 23615451; 23752268; 24457600,,,,,,,,,,,,,,,OGG:3000006606,,,,,,,"survival of motor neuron 1, telomeric",,,,,,,,,,,,,Other designations: component of gems 1|gemin-1|survival motor neuron 1 protein|survival motor neuron protein|tudor domain containing 16A,,SMN1,,,,,,,,,,,,,,,,,,,,,,,6606,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,SMN1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0100589,PI3-kinase p85-alpha subunit,PI3K|PtdIns-3-kinase p85-alpha|Phosphatidylinositol 3-kinase regulatory alpha subunit,,false,,,http://purl.obolibrary.org/obo/IMR_0000266,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0010392,PI3K|PtdIns-3-kinase p85-alpha|Phosphatidylinositol 3-kinase regulatory alpha subunit,,,,,IMR:0100589,,,,,,,,,,,,,,,,,,,,,,PI3-kinase p85-alpha subunit,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_48278,serotonergic drug,serotonergic agents|serotonergic drugs|serotonin drugs,,false,,,http://purl.obolibrary.org/obo/CHEBI_35942,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,serotonergic agents|serotonergic drugs|serotonin drugs,,,,,,,,,,,,,,,,,,,,,CHEBI:48278,,,,serotonergic drug,,CHEBI:48278,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006473,protein acetylation,,"The addition of an acetyl group to a protein amino acid. An acetyl group is CH3CO-, derived from acetic [ethanoic] acid.",false,,,http://purl.obolibrary.org/obo/GO_0043543,,,,,,,,,,,,,,,,,,,,,,"The addition of an acetyl group to a protein amino acid. An acetyl group is CH3CO-, derived from acetic [ethanoic] acid.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0006473,,,,,,,,,,,,,,,,,,,,,,protein acetylation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006476,protein deacetylation,,"The removal of an acetyl group from a protein amino acid. An acetyl group is CH3CO-, derived from acetic [ethanoic] acid.",false,,,http://purl.obolibrary.org/obo/GO_0035601,,,,,,,,,,,,,,,,,,,,,,"The removal of an acetyl group from a protein amino acid. An acetyl group is CH3CO-, derived from acetic [ethanoic] acid.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0006476,,,,,,,,,,,,,,,,,,,,,,protein deacetylation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0000062,fatty-acyl-CoA binding,acyl-CoA or acyl binding,"Interacting selectively and non-covalently with acyl-CoA, any derivative of coenzyme A in which the sulfhydryl group is in thiolester linkage with a fatty acyl group.",false,,,http://purl.obolibrary.org/obo/GO_1901567,,,,,,,,,,,,,,,,,,,,,,"Interacting selectively and non-covalently with acyl-CoA, any derivative of coenzyme A in which the sulfhydryl group is in thiolester linkage with a fatty acyl group.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_37554,,,,,,,,,,,,,,,,,,,,,,,GO:0000062,,,,,,,,,,,,,,,,acyl-CoA or acyl binding,,,,,,fatty-acyl-CoA binding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010497,60S ribosomal protein L6,TAX-responsive enhancer element binding protein 107|Neoplasm-related protein C140|TAXREB107,,false,,,http://purl.obolibrary.org/obo/IMR_0000897,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TAX-responsive enhancer element binding protein 107|Neoplasm-related protein C140|TAXREB107,,,,,IMR:0010497,,,,,,,,,,,,,,,,,,,,,,60S ribosomal protein L6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003119,FXR (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367|http://purl.obolibrary.org/obo/TXPO_0001509,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:60351|NCBI-Mouse-GeneID:20186|NCBI-Human-GeneID:9971|PMID:30013008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000009971,,,http://purl.obolibrary.org/obo/TXPO_0003224,,,,,,,,,,TXPO:0003119,,,,,,,,,,,,,,,,,,,,,,FXR (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003112,allowing,,"Preventing is a type of functioning process of meta-function of ""ToPrevent"".

Two meta-functions ""ToAllow"" and  ""ToPrevent"" are concerned with the undesirable side effects of functions.

A function fa having positive effects on the side effect of a function ft1 is said to have a meta-function “to allow the side-effects of ft1”.
The “undesirable side effect” is defined in a relation with another function ft2 or the whole system.
The “positive effect” means such a causal relation that increase of the focused attribute of fa causes decrease of the side effect.

If a serious trouble (e.g., faults) will be caused in a function ft2 when a function fa is not achieved, function fa is said to have a meta-function “to prevent malfunction of ft2”.
For example, the “to super-heat” function of the boiler prevents malfunction of the turbine, because the steam of low temperature would damage the turbine blade by water particles. For almost all fa performing a ToAllow meta-function for ft1, in general, there exists a ToPrevent meta-function for another function ft2.",false,,,http://purl.obolibrary.org/obo/TXPO_0000600,,,,,,,,,,,,,,,,,,,,,,"Preventing is a type of functioning process of meta-function of ""ToPrevent"".

Two meta-functions ""ToAllow"" and  ""ToPrevent"" are concerned with the undesirable side effects of functions.

A function fa having positive effects on the side effect of a function ft1 is said to have a meta-function “to allow the side-effects of ft1”.
The “undesirable side effect” is defined in a relation with another function ft2 or the whole system.
The “positive effect” means such a causal relation that increase of the focused attribute of fa causes decrease of the side effect.

If a serious trouble (e.g., faults) will be caused in a function ft2 when a function fa is not achieved, function fa is said to have a meta-function “to prevent malfunction of ft2”.
For example, the “to super-heat” function of the boiler prevents malfunction of the turbine, because the steam of low temperature would damage the turbine blade by water particles. For almost all fa performing a ToAllow meta-function for ft1, in general, there exists a ToPrevent meta-function for another function ft2.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003112,,,,,,,,,,,,,,,,,,,,,,allowing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003110,apoptosome assembly [ER stress],,"The aggregation, arrangement and bonding together of the apoptosome, a multisubunit protein complex involved in the signaling phase of the apoptotic process.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.|Apoptosome formation in cytosol",false,,,http://purl.obolibrary.org/obo/GO_0097314|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"The aggregation, arrangement and bonding together of the apoptosome, a multisubunit protein complex involved in the signaling phase of the apoptotic process.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003103,,,,,,,,,,,TXPO:0003110,,,,,,,,,,,,,,,,,,,,Apoptosome formation in cytosol,,apoptosome assembly [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005737,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003114,Bax-Bak complex formation,,"Bax-Bak complex formation is a subtype of protein complex assembly: A process that forms a complex consisting of BAX/BAK, a member of the Bcl-2 family.",false,,,http://purl.obolibrary.org/obo/GO_0006461,,,,,,,,,,,,,,,,,,,,,,"Bax-Bak complex formation is a subtype of protein complex assembly: A process that forms a complex consisting of BAX/BAK, a member of the Bcl-2 family.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003114,,,,,,,,,,,,,,,,,,,,,,Bax-Bak complex formation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005741,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003115,esgtradiol‐17β‐ glucuronide [Cholestasis],,,false,,,http://purl.obolibrary.org/obo/CHEBI_791|http://purl.obolibrary.org/obo/TXPO_0000749,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001866,,,,,,,,,,TXPO:0003115,,,,,,,"Changes in Bsep localization are involved in E217G-induced impairment of bile flow and bile salt transport.a Mrp2 is required for E217G to induce its harmful effect.|estradiol-17beta-glucuronide inhibited ATP-dependent taurocholate transport only in normal canalicular plasma membrane and in Bsep/Mrp2-coexpressing Sf9 cell vesicles, but not in Mrp2-deficient, indicating trans-inhibitionof  Bsep only after its secretion into bile canaliculi by Mrp2.",,,,,,,,,,,,,,,esgtradiol‐17β‐ glucuronide [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003113,Bax/Bak complex formation [ER stress],,"Bax/Bak complex formation is a subtype of protein complex assembly: A process that forms a complex consisting of BAX/BAK, a member of the Bcl-2 family.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0003114|http://purl.obolibrary.org/obo/TXPO_0003736,,,,,,,,,,,,,,,,,,,,PMID:29472455,,"Bax/Bak complex formation is a subtype of protein complex assembly: A process that forms a complex consisting of BAX/BAK, a member of the Bcl-2 family.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003105,,,,,,,,,,,TXPO:0003113,,,,,,,"Mitochondrial cytochrome c release can also be mediated by BAK and BAX which oligomerize and form a pore in the outer mitochondrial membrane, given the appropriate pro-apoptotic signals. BAX and BAK can also insert into the ER membrane to mediate Ca2+ release into the cytosol activating calpains.|BAX and BAK homo-oligomerize at the ER membrane, leading to its permeabilization and the release of ER luminal proteins to the cytosol.|BAX/BAK formed a protein complex with the cytosolic domain of IRE1alpha that was essential for IRE1alpha activation. Thus, BAX and BAK function at the ER membrane to activate IRE1alpha signaling and to provide a physical link between members of the core apoptotic pathway and the UPR.",,,,,,,,,,,,,,,Bax/Bak complex formation [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005741,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003117,binding to bile canaliculus membrane transporter by drug,,Binding to bile canaliculus membrane transporter by drug is a subtype of protein binding: Interacting process with the membrane transporter of bile canaliculus by the drug.,false,,,http://purl.obolibrary.org/obo/GO_0005515,,,,,,,,,,,,,,,,,,,,,,Binding to bile canaliculus membrane transporter by drug is a subtype of protein binding: Interacting process with the membrane transporter of bile canaliculus by the drug.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003117,,,,,,,,,,,,,,,,,,,,,,binding to bile canaliculus membrane transporter by drug,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003118,sulindac [Cholestasis],,,false,,,http://purl.obolibrary.org/obo/CHEBI_9352|http://purl.obolibrary.org/obo/TXPO_0000749,,,,,,,,,,,,,,,,,,,,Wikipedia:Sulindac|InChIKey:MLKXDPUZXIRXEP-MFOYZWKCSA-N|ATC:M01AB02,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003118,,,,,,,"Sulindac is secreted into bile in unconjugated form by a canalicular bile acid transporter and is absorbed by cholangiocytes, inducing hypercholeresis.
 At high flux rates, sulindac competitively inhibits canalicular bile salt transport and may induce cholestasis in patients.",,,,,,,,,,,,,,,sulindac [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003116,positive regulation of gene expression via JNK signaling,,"Positive regulation of gene expression via JNK signaling is a subtype of positive regulation of gene expression: A process that that activates or increases the frequency, rate or extent of gene expression via JNK signaling.",false,,,http://purl.obolibrary.org/obo/GO_0010628,,,,,,,,,,,,,,,,,,,,,,"Positive regulation of gene expression via JNK signaling is a subtype of positive regulation of gene expression: A process that that activates or increases the frequency, rate or extent of gene expression via JNK signaling.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000769,,,,,,,,,,,,,,,,,,TXPO:0003116,,,,,,,,,,,,,,,,,,,,,,positive regulation of gene expression via JNK signaling,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003111,intrinsic apoptotic signaling pathway [cell death],,"A series of molecular signals in which an intracellular signal is conveyed to trigger the apoptotic death of a cell. The pathway starts with reception of an intracellular signal (e.g. DNA damage, endoplasmic reticulum stress, oxidative stress etc.), and ends when the execution phase of apoptosis is triggered. The intrinsic apoptotic signaling pathway is crucially regulated by permeabilization of the mitochondrial outer membrane (MOMP).
This pathway is a specific course-dependent and can constitute the course of cell death.",false,,,http://purl.obolibrary.org/obo/GO_0097193,,,,,,,,,,,,,,,,,,,,Reactome:Id: R-HSA-109606.3,,"A series of molecular signals in which an intracellular signal is conveyed to trigger the apoptotic death of a cell. The pathway starts with reception of an intracellular signal (e.g. DNA damage, endoplasmic reticulum stress, oxidative stress etc.), and ends when the execution phase of apoptosis is triggered. The intrinsic apoptotic signaling pathway is crucially regulated by permeabilization of the mitochondrial outer membrane (MOMP).
This pathway is a specific course-dependent and can constitute the course of cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003163|http://purl.obolibrary.org/obo/TXPO_0003235|http://purl.obolibrary.org/obo/TXPO_0002403,,,,,,,,,,,,,,,,,,TXPO:0003111,,,,,,,,,,,,,,,,,,,,,,intrinsic apoptotic signaling pathway [cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001410,Gab1 (mol),Grb2-associated binder 1,,false,,,http://purl.obolibrary.org/obo/IMR_0001409,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Grb2-associated binder 1,,,,,IMR:0001410,,,,,,,,,,,,,,,,,,,,,,Gab1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CL_0000136,fat cell,adipose cell|adipocyte,A fat-storing cell found mostly in the abdominal cavity and subcutaneous tissue of mammals. Fat is usually stored in the form of triglycerides.,false,,,http://purl.obolibrary.org/obo/CL_0002320,,,,,,,,,,,,,,,,,,,,BTO:0000443|FMA:63880|CALOHA:TS-0012,,A fat-storing cell found mostly in the abdominal cavity and subcutaneous tissue of mammals. Fat is usually stored in the form of triglycerides.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,adipose cell|adipocyte,,,,,CL:0000136,,,,,,,,,,,,,,,,,,,,,,fat cell,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010448,60S ribosomal protein L35a,P18077,,false,,,http://purl.obolibrary.org/obo/IMR_0000897,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,P18077,,,,,IMR:0010448,,,,,,,,,,,,,,,,,,,,,,60S ribosomal protein L35a,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_75596,EC 5.* (isomerase) inhibitor,isomerase (EC 5.*) inhibitors|isomerase inhibitors|EC 5.* (isomerase) inhibitors|EC 5.*.*.* inhibitor|EC 5.* inhibitors|EC 5.*.*.* inhibitors|isomerase inhibitor|EC 5.* inhibitor|isomerase (EC 5.*) inhibitor,An enzyme inhibitor that inhibits the action of an isomerase (EC 5.*.*.*).,false,,,http://purl.obolibrary.org/obo/CHEBI_23924,,,,,,,,,,,,,,,,,,,,,,An enzyme inhibitor that inhibits the action of an isomerase (EC 5.*.*.*).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,isomerase (EC 5.*) inhibitors|isomerase inhibitors|EC 5.* (isomerase) inhibitors|EC 5.*.*.* inhibitor|EC 5.* inhibitors|EC 5.*.*.* inhibitors|isomerase inhibitor|EC 5.* inhibitor|isomerase (EC 5.*) inhibitor,,,,,,,,,,,,,,,,,,,,,CHEBI:75596,,,,EC 5.* (isomerase) inhibitor,,CHEBI:75596,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000520,classification of cell death by distribution,,"The difference in distribution of cell death depends on the location of the toxic expression.|Zone 3 hepatocytes are rich in P450, which produce drug metabolites to cause cell death.",false,,,http://purl.obolibrary.org/obo/GO_0008219,,,,,,,,,,,,,,,,,,,,,,The difference in distribution of cell death depends on the location of the toxic expression.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000520,,,,,,,,,,,,,,,,,,,,"Zone 3 hepatocytes are rich in P450, which produce drug metabolites to cause cell death.",,classification of cell death by distribution,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000521,centrilobular necrosis,,Centrilobular necrosis is a subtype of classification of cell death by distribution: A hepatocyte necrosis localized around centrilobular zone.,false,,,http://purl.obolibrary.org/obo/TXPO_0000520,,,,,,,,,,,,,,,,,,,,,,Centrilobular necrosis is a subtype of classification of cell death by distribution: A hepatocyte necrosis localized around centrilobular zone.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000521,,,,,,,,,,,,,,,,,,,,,,centrilobular necrosis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000528,NAPQI production,,NAPQI production is a subtype of generating a substance : A process that synthesizes NAPQI (N-acetyl-p-benzoquinone imine) as output.,false,,,http://purl.obolibrary.org/obo/TXPO_0000019,,,,,,,,,,,,,,,,,,,,,,NAPQI production is a subtype of generating a substance : A process that synthesizes NAPQI (N-acetyl-p-benzoquinone imine) as output.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000528,,,,,,,,,,,,,,,,,,,,,,NAPQI production,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000522,periportal necrosis,,Periportal necrosis is a subtype of classification of cell death by distribution: A hepatocyte necrosis localized around the portal vein.,false,,,http://purl.obolibrary.org/obo/TXPO_0000520,,,,,,,,,,,,,,,,,,,,,,Periportal necrosis is a subtype of classification of cell death by distribution: A hepatocyte necrosis localized around the portal vein.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000522,,,,,,,,,,,,,,,,,,,,,,periportal necrosis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000526,leaking content from cell,,Leaking content from cell is a subtype of leaking: A process that leaks contents from the cell.,false,,,http://purl.obolibrary.org/obo/TXPO_0001699,,,,,,,,,,,,,,,,,,,,,,Leaking content from cell is a subtype of leaking: A process that leaks contents from the cell.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000526,,,,,,,,,,,,,,,,,,,,,,leaking content from cell,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000523,zonal necrosis,,"Zonal necrosis is a subtype of classification of cell death by distribution: A hepatocyte necrosis  localized around hepatic the lobule such as centrilobular (acinar zone 3) necrosis, midzonal (midlobular) necrosis, and periportal (perilobular) necrosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000520,,,,,,,,,,,,,,,,,,,,,,"Zonal necrosis is a subtype of classification of cell death by distribution: A hepatocyte necrosis  localized around hepatic the lobule such as centrilobular (acinar zone 3) necrosis, midzonal (midlobular) necrosis, and periportal (perilobular) necrosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000523,,,,,,,,,,,,,,,,,,,,,,zonal necrosis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000525,expanding inflammation [Cell death],,"Expanding inflammation is a subtype of increasing quantity: A process that changes the magnitude of the inflammation the object to be larger.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0000524,,,,,,,,,,,,,,,,,,,,,,"Expanding inflammation is a subtype of increasing quantity: A process that changes the magnitude of the inflammation the object to be larger.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000525,,,,,,,,,,,,,,,,,,,,,,expanding inflammation [Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000529,ASAH1 (human)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002668|http://purl.obolibrary.org/obo/TXPO_1000009,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:427|http://omim.org/entry/613468|PMID:11829492|PMID:26095250|PMID:10610716|PMID:23423838|PMID:17064658|PMID:19905902,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000427,,,http://purl.obolibrary.org/obo/TXPO_0003321,,,,,,,,,,TXPO:0000529,,,,,,,,,,,,,,,,,,,,,,ASAH1 (human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001442,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000524,expanding inflammation,,Expanding inflammation is a subtype of increasing quantity: A process that changes the magnitude of the inflammation the object to be larger.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Expanding inflammation is a subtype of increasing quantity: A process that changes the magnitude of the inflammation the object to be larger.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000524,,,,,,,,,,,,,,,,,,,,,,expanding inflammation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000527,leaking content from cell [Cell death],,"Leaking content from cell is a subtype of leaking: A process that leaks contents from the cell.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0000526|http://purl.obolibrary.org/obo/TXPO_0001727,,,,,,,,,,,,,,,,,,,,,,"Leaking content from cell is a subtype of leaking: A process that leaks contents from the cell.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000541,,,,,,,,,,,TXPO:0000527,,,,,,,,,,,,,,,,,,,,,,leaking content from cell [Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_73913,antifolate,antifolates|folic acid antagonist|folic acid antagonists,An antimetabolite that impairs the action of folic acids,false,,,http://purl.obolibrary.org/obo/CHEBI_35221,,,,,,,,,,,,,,,,,,,,,,An antimetabolite that impairs the action of folic acids,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,antifolates|folic acid antagonist|folic acid antagonists,,,,,,,,,,,,,,,,,,,,,CHEBI:73913,,,,antifolate,,CHEBI:73913,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000010741,RBBP9,,Other designations: B5T overexpressed gene protein|B5T-overexpressed gene protein|RBBP-10|RBBP-9|putative hydrolase RBBP9|retinoblastoma-binding protein 10|retinoblastoma-binding protein 9|retinoma-binding protein 9,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,BOG|RBBP10,,,,,,,,,,,,20,,,,,,HGNC:9892|Vega:OTTHUMG00000031972|MIM:602908|Ensembl:ENSG00000089050|HPRD:04217,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,retinoblastoma binding protein 9,,,20p11.2,,,,,,,,,,,,,,,,GO_0005634 (EC: IDA); GO_0005730 (EC: IDA); GO_0005737 (EC: IDA); GO_0016787 (EC: IEA); GO_0042127 (EC: IEA),,,,,,,,,PMID: 9697699; 10449909; 11780052; 12296629; 12477932; 12730717; 14702039; 15489334; 18029348; 19004028; 20080647; 21044950; 21139048; 21689726; 21890473; 21933118; 22430187,,,,,,,,,,,,,,,OGG:3000010741,,,,,,,retinoblastoma binding protein 9,,,,,,,,,,,,,Other designations: B5T overexpressed gene protein|B5T-overexpressed gene protein|RBBP-10|RBBP-9|putative hydrolase RBBP9|retinoblastoma-binding protein 10|retinoblastoma-binding protein 9|retinoma-binding protein 9,,RBBP9,,,,,,,,,,,,,,,,,,,,,,,10741,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,RBBP9,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000079789,CLMN,,Other designations: calmin|calponin like transmembrane domain protein|calponin-like transmembrane domain protein,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,14,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"calmin (calponin-like, transmembrane)",,,14q32.13,,,,,,,,,,,,,,,,GO_0003779 (EC: IEA); GO_0005737 (EC: IEA); GO_0008285 (EC: IEA); GO_0016021 (EC: IEA); GO_0031175 (EC: IEA),,,,,,,,,PMID: 9455484; 10574461; 11386753; 12477932; 12508121; 14702039; 16712791; 20195266; 20339536; 22747683; 23080069; 23535033,,,,,,,,,,,,,,,OGG:3000079789,,20140408,protein-coding,,,,"calmin (calponin-like, transmembrane)",,,,,,,,,,,,,Other designations: calmin|calponin like transmembrane domain protein|calponin-like transmembrane domain protein,,CLMN,,,,,,,,,,,,,,,,,,,,,,,79789,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,CLMN,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_55346,anidulafungin,"anidulafunginum|Eraxis|anidulafungin|anidulafungine|anidulafungina|N-{(2R,6S,9S,11R,12R,14aS,15S,16S,20S,23S,25aS)-23-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-2,11,12,15-tetrahydroxy-6,20-bis[(1R)-1-hydroxyethyl]-16-methyl-5,8,14,19,22,25-hexaoxotetracosahydro-1H-dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacyclohenicosin-9-yl}-4''-(pentyloxy)-1,1':4',1''-terphenyl-4-carboxamide",A semisynthetic echinocandin anti-fungal drug. It is active against Aspergillus and Candida species and is used for the treatment of invasive candidiasis.,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:19877739|PMID:16770294|CAS:166663-25-8|DrugBank:DB00362|PMID:15482216|Beilstein:7408417|Reaxys:7408417|PMID:19877741|PMID:17316149|PMID:19877740|PMID:19113794|PMID:24955796|PMID:25473029|PMID:19072176|PMID:19877742|PMID:24165173,,A semisynthetic echinocandin anti-fungal drug. It is active against Aspergillus and Candida species and is used for the treatment of invasive candidiasis.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"N-{(2R,6S,9S,11R,12R,14aS,15S,16S,20S,23S,25aS)-23-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-2,11,12,15-tetrahydroxy-6,20-bis[(1R)-1-hydroxyethyl]-16-methyl-5,8,14,19,22,25-hexaoxotetracosahydro-1H-dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacyclohenicosin-9-yl}-4''-(pentyloxy)-1,1':4',1''-terphenyl-4-carboxamide",,anidulafunginum|Eraxis|anidulafungin|anidulafungine|anidulafungina,,,,,,,,,,,,,,,,,,,,,CHEBI:55346,,,,anidulafungin,,CHEBI:55346,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000808,disabled-1,,,false,,,http://purl.obolibrary.org/obo/IMR_0000558,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000808,,,,,,,,,,,,,,,,,,,,,,disabled-1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0001621,coronary artery,coronary vessel|coronary arterial tree,An artery that supplies the myocardium.,false,,,http://purl.obolibrary.org/obo/UBERON_0003509,,,,,,,,,,,,,,,,,,,,http://www.snomedbrowser.com/Codes/Details/181294004|http://linkedlifedata.com/resource/umls/id/C0205042|http://purl.obolibrary.org/obo/NCIT_C12843|http://en.wikipedia.org/wiki/Coronary_circulation#Coronary_anatomy|ZFA:0005812|VHOG:0001557|EMAPA:19160|CALOHA:TS-0176|OpenCyc:Mx4rvoL56ZwpEbGdrcN5Y29ycA|UMLS:C0205042|galen:CoronaryArtery|EMAPA:25968|EV:0100383|MA:0002453|EFO:0002551|BTO:0000290|FMA:49893,,An artery that supplies the myocardium.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,coronary arterial tree,,coronary vessel,,,UBERON:0001621,,,,,,,,,,,,,,,,,,,,,,coronary artery,,,,http://upload.wikimedia.org/wikipedia/commons/4/46/Gray492.png,,,http://purl.obolibrary.org/obo/oae.owl|http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100137,bradykinin,,,false,,,http://purl.obolibrary.org/obo/IMR_0100165,,,,,,,,,,,,,,,,,,,,MeSH:D001920,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100137,,,,,,,,,,,,,,,,,,,,,,bradykinin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_47499,imipramine,,Imipramine is a tricyclic antidepressant that continues to be widely used in the therapy of depression.  Imipramine can cause mild and transient serum enzyme elevations and is rare cause of clinically apparent acute cholestatic liver injury.,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,https://livertox.nlm.nih.gov//Imipramine.htm|Open TG-Gates compound_id:00069|Wikipedia:Imipramine|DrugBank:DB00458,,Imipramine is a tricyclic antidepressant that continues to be widely used in the therapy of depression.  Imipramine can cause mild and transient serum enzyme elevations and is rare cause of clinically apparent acute cholestatic liver injury.,,,,,,,,,,,,C19H24N2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:47499,,,,,,,,,,,,,,,,,,,,,,imipramine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CN(C)CCCN1c2ccccc2CCc2ccccc12,,,,,
http://purl.obolibrary.org/obo/CHEBI_49103,drug metabolite,drug metabolites,Any human metabolite produced by metabolism of drugs in humans.,false,,,http://purl.obolibrary.org/obo/CHEBI_76967,,,,,,,,,,,,,,,,,,,,,,Any human metabolite produced by metabolism of drugs in humans.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,drug metabolites,,,,,,,,,,,,,,,,,,,,,CHEBI:49103,,,,drug metabolite,,CHEBI:49103,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002643,FXR (canonical)[Cholestasis],bile acid receptor  [cholestasis]|FARNESOID X-ACTIVATED RECEPTOR  [cholestasis],,false,,,http://purl.obolibrary.org/obo/TXPO_0000276|http://purl.obolibrary.org/obo/TXPO_0003119,,,,,,,,,,,,,,,,,,,,http://www.ncbi.nlm.nih.gov/gene/9971|NCBI-Rat-GeneID:60351|NCBI-Mouse-GeneID:20186|NCBI-Human-GeneID:9971|UniProt:Q96RI1|PMID:26888176|http://purl.bioontology.org/ontology/MESH/C094063,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,bile acid receptor  [cholestasis]|FARNESOID X-ACTIVATED RECEPTOR  [cholestasis],,,,,TXPO:0002643,,,,,,,"Bile salts activate a bile sil sensor, FXR (bile acid receptor; NR1H4) in hepatocytes.|https://omim.org/entry/603826",,,,,,,,,,,,,,,FXR (canonical)[Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002647,OCT family (canonical)[Cholestasis],oeganic cation transporter [Cholestasis],,false,,,http://purl.obolibrary.org/obo/TXPO_0000276|http://purl.obolibrary.org/obo/TXPO_1000271,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,oeganic cation transporter [Cholestasis],,,,,TXPO:0002647,,,,,,,,,,,,,,,,,,,,,,OCT family (canonical)[Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002649,bile acid secretion [Cholestasis],,"The regulated release of bile acid, composed of any of a group of steroid carboxylic acids occurring in bile, by a cell or a tissue.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000034|http://purl.obolibrary.org/obo/GO_0032782,,,,,,,,,,,,,,,,,,,,,,"The regulated release of bile acid, composed of any of a group of steroid carboxylic acids occurring in bile, by a cell or a tissue.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002649,,,,,,,"Bile contains bile acids, glutathione, phospholipids, cholesterol, bilirubin, and other organic anions, proteins, metals, ions, and xenobiotics.

Hepatocytes begins the formation of bile by transporting bile acids, glutathione, and other solutes including Xenobiotics and their metabolites into the canalicular lumen.

The major driving force of bile formation is the active transport of bile salts and other osmolytes into the canalicular lumen.

Most conjugated bile acids (taurine and glycine conjugates) and some unconjugated bile acids are transported into hepatocytes by sodium-dependent transporters.

Sodium-independent uptake of conjugated and unconjugated bile acids is performed by members of the organic anion-transporting polypeptides (OATPs).
OATPs also transport numerous drugs and hepatotoxicants.

Lipophilic cationic drugs, estrogens, and lipids are exported by the canalicular multiple-drug resistance (MDR) P-glycoproteins, one of which is exclusive for phospholipids.

Conjugates of glutathione, glucuronide, and sulfate are exported by multidrug resistance-associated protein2 (MRP2).",,,,,,,,,,,,,,,bile acid secretion [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002648,decreasing cross-sectional area,,Decreasing cross-sectional area is a subtype of decreasing area: A process that changes the cross-sectional area of the object to be smaller.,false,,,http://purl.obolibrary.org/obo/TXPO_0000242,,,,,,,,,,,,,,,,,,,,,,Decreasing cross-sectional area is a subtype of decreasing area: A process that changes the cross-sectional area of the object to be smaller.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002648,,,,,,,,,,,,,,,,,,,,,,decreasing cross-sectional area,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003625,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002646,negative regularuion of bile acid and bile salt transport [Cholestasis],,"Negative regularuion of bile acid and bile salt transport is a subtype of negative regulation of transport: Any process that stops, prevents, or reduces the frequency, rate or extent of a bile acid and bile salts transport .
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000034|http://purl.obolibrary.org/obo/TXPO_0003126,,,,,,,,,,,,,,,,,,,トランスポーター遺伝子の発現を変えることで阻害,,,"Negative regularuion of bile acid and bile salt transport is a subtype of negative regulation of transport: Any process that stops, prevents, or reduces the frequency, rate or extent of a bile acid and bile salts transport .
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002646,,,,,,,"FXR regulates of metabolic processes.
Activation of FXR by increased bile salt concentrations in hepatocytes downregulates the uptake systems for bile salts and maintains or upregulates bill salt efflux systems",,,,,,,,,,,,,,,negative regularuion of bile acid and bile salt transport [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002640,MRP3 (canonical)[Cholestasis],ABCC3 [Cholestasis],,false,,,http://purl.obolibrary.org/obo/TXPO_0001506,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ABCC3 [Cholestasis],,,,,TXPO:0002640,,,,,,,,,,,,,,,,,,,,,,MRP3 (canonical)[Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002641,bile tube occlusion [Cholestasis],,"Bile tube occlusion is a subtype of occlusion: Obstruction or a closure of bile tube.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000034|http://purl.obolibrary.org/obo/TXPO_0002713,,,,,,,,,,,,,,,,,,,,,,"Bile tube occlusion is a subtype of occlusion: Obstruction or a closure of bile tube.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002641,,,,,,,,,,,,,,,,,,,,,,bile tube occlusion [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002645,positive regulation of bile export [Cholestasis],,"Positive regulation of bile export is a subtype of positive regulation process: A process that that activates or increases the frequency, rate or extent of bile acid secretion.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002732|http://purl.obolibrary.org/obo/TXPO_0000034,,,,,,,,,,,,,,,,,,,,,,"Positive regulation of bile export is a subtype of positive regulation process: A process that that activates or increases the frequency, rate or extent of bile acid secretion.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002643,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000509,,,,,,,,,,,,,,,,,,,TXPO:0002645,,,,,,,"FXR regulates of metabolic processes.
Activation of FXR by increased bile salt concentrations in hepatocytes downregulates the uptake systems for bile salts and maintains or upregulates bill salt efflux systems",,,,,,,,,,,,,,,positive regulation of bile export [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002644,farnesoid X receptor activation [Cholestasis],activating FXR  [cholestasis]|FXR activation  [cholestasis],"Farnesoid X receptor activation is a subtype of activating nuclear receptor: A process that changes the activity of the activating FxR (farnesoid X receptor) with a nuclear receptor role to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003143|http://purl.obolibrary.org/obo/TXPO_0000034,,,,,,,,,,,,,,,,,,,,,,"Farnesoid X receptor activation is a subtype of activating nuclear receptor: A process that changes the activity of the activating FxR (farnesoid X receptor) with a nuclear receptor role to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000509,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002643,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003147,,,,,,activating FXR  [cholestasis]|FXR activation  [cholestasis],,,,,TXPO:0002644,,,,,,,"Bile salts activate a bile salt sensor, FXR (bile acid receptor; NR1H4) in hepatocytes.",,,,,,,,,,,,,,,farnesoid X receptor activation [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002642,MRP4 (canonical)[Cholestasis],ABCC4 [Cholestasis],,false,,,http://purl.obolibrary.org/obo/TXPO_0001506|http://purl.obolibrary.org/obo/TXPO_0003019,,,,,,,,,,,,,,,,,,,,PMID:17404579|PMID:21359593,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ABCC4 [Cholestasis],,,,,TXPO:0002642,,,,,,,,,,,,,,,,,,,,,,MRP4 (canonical)[Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0043266,regulation of potassium ion transport,,"Any process that modulates the frequency, rate or extent of the directed movement of potassium ions (K+) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.",false,,,http://purl.obolibrary.org/obo/GO_0051049,,,,,,,,,,,,,,,,,,,,,,"Any process that modulates the frequency, rate or extent of the directed movement of potassium ions (K+) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0043266,,,,,,,,,,,,,,,,,,,,,,regulation of potassium ion transport,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006813,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0043268,positive regulation of potassium ion transport,,"Any process that activates or increases the frequency, rate or extent of the directed movement of potassium ions (K+) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.",false,,,http://purl.obolibrary.org/obo/GO_0043266,,,,,,,,,,,,,,,,,,,,,,"Any process that activates or increases the frequency, rate or extent of the directed movement of potassium ions (K+) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0043268,,,,,,,,,,,,,,,,,,,,,,positive regulation of potassium ion transport,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0043267,negative regulation of potassium ion transport,,"Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of potassium ions (K+) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.",false,,,http://purl.obolibrary.org/obo/GO_0043266,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of potassium ions (K+) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0043267,,,,,,,,,,,,,,,,,,,,,,negative regulation of potassium ion transport,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001431,BMP-7,BMP7|OP-1|Bone morphogenetic protein 7,,false,,,http://purl.obolibrary.org/obo/IMR_0003084,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BMP7|OP-1|Bone morphogenetic protein 7,,,,,IMR:0001431,,,,,,,,,,,,,,,,,,,,,,BMP-7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0062093,lysophagy,,The selective autophagy process in which a damaged lysosome is degraded by macroautophagy.,false,,,http://purl.obolibrary.org/obo/GO_0006914,,,,,,,,,,,,,,,,,,,,,,The selective autophagy process in which a damaged lysosome is degraded by macroautophagy.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005764,,,,,,,,,,,,,,,,,,,,,,,GO:0062093,,,,,,,,,,,,,,,,,,,,,,lysophagy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005776,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_35569,alpha-adrenergic agonist,alpha-adrenergic receptor agonist|alpha-adrenergic agonists|alpha-adrenoceptor agonists,An agent that selectively binds to and activates alpha-adrenergic receptors.,false,,,http://purl.obolibrary.org/obo/CHEBI_48539|http://purl.obolibrary.org/obo/CHEBI_37886,,,,,,,,,,,,,,,,,,,,,,An agent that selectively binds to and activates alpha-adrenergic receptors.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,alpha-adrenergic receptor agonist|alpha-adrenergic agonists|alpha-adrenoceptor agonists,,,,,,,,,,,,,,,,,,,,,CHEBI:35569,,,,alpha-adrenergic agonist,,CHEBI:35569,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_6030,isoniazide,pyridine-4-carbohydrazide,A carbohydrazide obtained by formal condensation between pyridine-4-carboxylic acid and hydrazine.,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:54-85-3|DrugBank:DB00951|LINCS:LSM-6682,,A carbohydrazide obtained by formal condensation between pyridine-4-carboxylic acid and hydrazine.,,,,,,,,,,,,C6H7N3O,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pyridine-4-carbohydrazide,,,,,CHEBI:6030,,,,,,,,,,,,,,,,,,,,,,isoniazide,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,NNC(=O)c1ccncc1,,,,,
http://purl.obolibrary.org/obo/IMR_0003080,GDF-3,Vgr-2|Growth/differentiation factor-3,,false,,,http://purl.obolibrary.org/obo/IMR_0000040,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Vgr-2|Growth/differentiation factor-3,,,,,IMR:0003080,,,,,,,,,,,,,,,,,,,,,,GDF-3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_28794,coumarin,,A chromenone having the keto group located at the 2-position.,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,DrugBank:DB04665|PMID:28166217|Wikipedia:Coumarin,,A chromenone having the keto group located at the 2-position.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:28794,,,,,,,,,,,,,,,,,,,,,,coumarin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,C=1C=CC=C2C1C=CC(=O)O2,,,,,
http://purl.obolibrary.org/obo/BFO_0000008,temporal region,,,false,,,http://purl.obolibrary.org/obo/BFO_0000003,,,,,,,,,,,,,,,,,,,,,,,,,,Temporal region doesn't have a closure axiom because the subclasses don't exhaust all possibilites. An example would be the mereological sum of a temporal instant and a temporal interval that doesn't overlap the instant. In this case the resultant temporal region is neither 0-dimensional nor 1-dimensional,,A temporal region is an occurrent entity that is part of time as defined relative to some reference frame. (axiom label in BFO2 Reference: [100-001]),,,,,,,,,,,,(forall (r) (if (TemporalRegion r) (occupiesTemporalRegion r r))) // axiom label in BFO2 CLIF: [119-002]|(forall (x y) (if (and (TemporalRegion x) (occurrentPartOf y x)) (TemporalRegion y))) // axiom label in BFO2 CLIF: [101-001]|(forall (x) (if (TemporalRegion x) (Occurrent x))) // axiom label in BFO2 CLIF: [100-001],Every temporal region t is such that t occupies_temporal_region t. (axiom label in BFO2 Reference: [119-002])|All parts of temporal regions are temporal regions. (axiom label in BFO2 Reference: [101-001]),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BFO:0000008,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/bfo.owl,temporal region,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000409,Zfand2a (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:100494|NCBI-Human-GeneID:90637|NCBI-Rat-GeneID:360772,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000090637,,,,,,,,,,,,,TXPO:1000409,,,,,,,,,,,,,,,,,,,,,,Zfand2a (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000401,Vav2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:296603|NCBI-Mouse-GeneID:22325|NCBI-Human-GeneID:7410,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000007410,,,,,,,,,,,,,TXPO:1000401,,,,,,,,,,,,,,,,,,,,,,Vav2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000407,ZNF667 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:63934|NCBI-Rat-GeneID:308326,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000063934,,,,,,,,,,,,,TXPO:1000407,,,,,,,,,,,,,,,,,,,,,,ZNF667 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000408,Zc3h14 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:192359|NCBI-Mouse-GeneID:75553|NCBI-Human-GeneID:79882,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000079882,,,,,,,,,,,,,TXPO:1000408,,,,,,,,,,,,,,,,,,,,,,Zc3h14 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000403,Vnn1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:8876|NCBI-Mouse-GeneID:22361|NCBI-Rat-GeneID:29142,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000008876,,,,,,,,,,,,,TXPO:1000403,,,,,,,,,,,,,,,,,,,,,,Vnn1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000400,Vangl2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:93840|NCBI-Rat-GeneID:289229|NCBI-Human-GeneID:57216,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000057216,,,,,,,,,,,,,TXPO:1000400,,,,,,,,,,,,,,,,,,,,,,Vangl2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000405,XBP1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:289754|NCBI-Human-GeneID:7494|NCBI-Mouse-GeneID:22433,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000007494,,,,,,,,,,,,,TXPO:1000405,,,,,,,,,,,,,,,,,,,,,,XBP1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000406,ZNF385B (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:151126,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000151126,,,,,,,,,,,,,TXPO:1000406,,,,,,,,,,,,,,,,,,,,,,ZNF385B (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000134526,ACOT12,,Other designations: START domain-containing protein 15|StAR-related lipid transfer (START) domain containing 15|acyl-CoA thioester hydrolase 12|acyl-coenzyme A thioesterase 12|cytoplasmic acetyl-CoA hydrolase 1|cytosolic acetyl-CoA hydrolase|hCACH-1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,Cach|THEAL|STARD15|CACH-1,,,,,,,,,,,,5,,,,,,MIM:614315|Ensembl:ENSG00000172497|HGNC:24436|Vega:OTTHUMG00000131305|HPRD:16680,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,acyl-CoA thioesterase 12,,,5q14.1,,,,,,,,,,,,,,,,GO_0003986 (EC: ISS); GO_0005524 (EC: IEA); GO_0005829 (EC: ISS); GO_0006084 (EC: IEA); GO_0006090 (EC: IEA); GO_0006631 (EC: IEA); GO_0006637 (EC: ISS); GO_0008289 (EC: IEA),,,,,,,,,PMID:11322891; 12477932; 12767336; 14702039; 15489334; 16103133; 16951743; 20379614; 22863734,,,,,,,,,,,,,,,OGG:3000134526,,,,,,,acyl-CoA thioesterase 12,,,,,,,,,,,,,Other designations: START domain-containing protein 15|StAR-related lipid transfer (START) domain containing 15|acyl-CoA thioester hydrolase 12|acyl-coenzyme A thioesterase 12|cytoplasmic acetyl-CoA hydrolase 1|cytosolic acetyl-CoA hydrolase|hCACH-1,,ACOT12,,,,,,,,,,,,,,,,,,,,,,,134526,,,,,,,,9606,,,,,,,,,,,,,,,,,,,ACOT12,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0002815,Translocation of NF-kappaB from the Cytosol to the Nucleus [ER stress - inflammation - IRE1-TRAF2-NfkB pathway],,"Translocation of NF-kappaB from the Cytosol to the Nucleus is a subtype of nuclear transport: A process that of the directed movement of NF-kappaB from the cytoplasm to the nucleus.
This process is dependent on the IRE1-TRAF2-NfkB pathway mediated inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002633,,,,,,,,,,,,,,,,,,,,,,"Translocation of NF-kappaB from the Cytosol to the Nucleus is a subtype of nuclear transport: A process that of the directed movement of NF-kappaB from the cytoplasm to the nucleus.
This process is dependent on the IRE1-TRAF2-NfkB pathway mediated inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002768,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002805,,,,,,,,,,,TXPO:0002815,,,,,,,,,,,,,,,,,,,,,,Translocation of NF-kappaB from the Cytosol to the Nucleus [ER stress - inflammation - IRE1-TRAF2-NfkB pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002812,regulation of gene expression by NfKB [ER stress - inflammation - PERK-eIF2a-NfkB pathway],,"Regulation of gene expression by NfKB is a subtype of regulation of gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of gene expression by NfkB.
This process is dependent on the  PERK-eIF2a-NfkB pathway mediated inflammation  and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002784,,,,,,,,,,,,,,,,,,,,PMID:20303879,,"Regulation of gene expression by NfKB is a subtype of regulation of gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of gene expression by NfkB.
This process is dependent on the  PERK-eIF2a-NfkB pathway mediated inflammation  and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002805,,,,,,,,,,,,,,,,,,TXPO:0002812,,,,,,,,,,,,,,,,,,,,,,regulation of gene expression by NfKB [ER stress - inflammation - PERK-eIF2a-NfkB pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002813,regulation of gene expression by NfKB [ER stress - inflammation - IRE1-Traf2-NfkB pathway],,"Regulation of gene expression by NfKB is a subtype of regulation of gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of gene expression by NfkB.
This process is dependent on the IRE1-TARF2-NfkB pathway mediated inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002784,,,,,,,,,,,,,,,,,,,,,,"Regulation of gene expression by NfKB is a subtype of regulation of gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of gene expression by NfkB.
This process is dependent on the IRE1-TARF2-NfkB pathway mediated inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002811,,,,,,,,,,,,,,,,,,TXPO:0002813,,,,,,,,,,,,,,,,,,,,,,regulation of gene expression by NfKB [ER stress - inflammation - IRE1-Traf2-NfkB pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002810,degradation of I-kappaB [ER stress],,"Degradation of I-kappaB is a subtype of protein catabolic process: A process of the chemical reactions resulting in the breakdown of inhibitor of kappa B (I-kappaB) protein.
This process is dependent on the IRE1-NfkB pathway mediated inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002758,,,,,,,,,,,,,,,,,,,,,,"Degradation of I-kappaB is a subtype of protein catabolic process: A process of the chemical reactions resulting in the breakdown of inhibitor of kappa B (I-kappaB) protein.
This process is dependent on the IRE1-NfkB pathway mediated inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002815,,,,,,,,,,,TXPO:0002810,,,,,,,,,,,,,,,,,,,,,,degradation of I-kappaB [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002816,TRAF2 activation by IRE1 [ER stress - inflammation - IRE1-TRAF2-IKK-NfkB pathway],,"TRAF2 activation by IRE1 is a subtype of molecular activation: A process that changes the activity of the TARF2 to be higher by IRE1.
This process is dependent on the IRE1-TRAF2-IKK-NfkB pathway mediated inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002820,,,,,,,,,,,,,,,,,,,,PMID:25232821,,"TRAF2 activation by IRE1 is a subtype of molecular activation: A process that changes the activity of the TARF2 to be higher by IRE1.
This process is dependent on the IRE1-TRAF2-IKK-NfkB pathway mediated inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002819,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002817,,,,,,,,,,,TXPO:0002816,,,,,,,,,,,,,,,,,,,,,,TRAF2 activation by IRE1 [ER stress - inflammation - IRE1-TRAF2-IKK-NfkB pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002814,Translocation of NF-kappaB from the Cytosol to the Nucleus [ER stress - inflammation - Perk-eIF2a-NfkB pathway],,"Translocation of NF-kappaB from the Cytosol to the Nucleus is a subtype of nuclear transport: A process that of the directed movement of NF-kappaB from the cytoplasm to the nucleus.
This process is dependent on the Perk-eIF2a-NfkB pathway mediated inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002633,,,,,,,,,,,,,,,,,,,,,,"Translocation of NF-kappaB from the Cytosol to the Nucleus is a subtype of nuclear transport: A process that of the directed movement of NF-kappaB from the cytoplasm to the nucleus.
This process is dependent on the Perk-eIF2a-NfkB pathway mediated inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002768,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002805,,,,,,,,,,,TXPO:0002814,,,,,,,,,,,,,,,,,,,,,,Translocation of NF-kappaB from the Cytosol to the Nucleus [ER stress - inflammation - Perk-eIF2a-NfkB pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002811,inflammatory cytokine gene expression by NF-kappa B via IRE1 [ER stress - inflammation],,"Inflammatory gene expression by NF-kappa B via IRE1 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) related to the inflammation by NF-kappa B via IRE1.
This process is dependent on the inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002266|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"Inflammatory gene expression by NF-kappa B via IRE1 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) related to the inflammation by NF-kappa B via IRE1.
This process is dependent on the inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002795,,,,,http://purl.obolibrary.org/obo/TXPO_0002766,,,,,,,,,,,TXPO:0002811,,,,,,,,,,,,,,,,,,,,,,inflammatory cytokine gene expression by NF-kappa B via IRE1 [ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002818,TRAF2 (canonical)[ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000871|http://purl.obolibrary.org/obo/IMR_0100423,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:22030|NCBI-Rat-GeneID:311786|NCBI-Human-GeneID:7186,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000462,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002818,,,,,,,,,,,,,,,,,,,,,,TRAF2 (canonical)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002817,IKK activation [ER stress - inflammation - IRE1-TRAF2-NfkB pathway],,"IKK activation is a subtype of molecular activation: A process that changes the activity of the IIKK (kappaB Kinase) to be higher.
This process is dependent on the IRE1-TRAF2-NfkB pathway mediated inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002781,,,,,,,,,,,,,,,,,,,,PMID:25232821|PMID:12843613,,"IKK activation is a subtype of molecular activation: A process that changes the activity of the IIKK (kappaB Kinase) to be higher.
This process is dependent on the IRE1-TRAF2-NfkB pathway mediated inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002818,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002807,,,,,,,,,,,TXPO:0002817,,,,,,,,,,,,,,,,,,,,,,IKK activation [ER stress - inflammation - IRE1-TRAF2-NfkB pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002819,TRAF2 -IRE1 adaptor protein (canonical)[ER stress - inflammation -IRE1-NfkB],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002818,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000462,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003657,,,,,,,,,,TXPO:0002819,,,,,,,,,,,,,,,,,,,,,,TRAF2 -IRE1 adaptor protein (canonical)[ER stress - inflammation -IRE1-NfkB],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000022926,ATF6,,Other designations: cAMP-dependent transcription factor ATF-6 alpha|cyclic AMP-dependent transcription factor ATF-6 alpha,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,ATF6A,,,,,,,,,,,,1,,,,,,Vega:OTTHUMG00000023961|MIM:605537|HPRD:16118|Ensembl:ENSG00000118217|HGNC:791,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,activating transcription factor 6,,,1q22-q23,,,,,,,,,,,,,,,,"GO_0000139 (EC: TAS); GO_0003700 (EC: IEA); GO_0003713 (EC: TAS, PMID:10866666); GO_0005515 (EC: IPI, PMID:16469704); GO_0005634 (EC: TAS, PMID:10564271); GO_0005635 (EC: TAS, PMID:10866666); GO_0005654 (EC: TAS); GO_0005789 (EC: TAS); GO_0006351 (EC: IEA); GO_0006357 (EC: TAS, PMID:10564271); GO_0006457 (EC: TAS, PMID:10564271); GO_0006950 (EC: TAS, PMID:10866666); GO_0006987 (EC: TAS); GO_0006990 (EC: TAS, PMID:9837962); GO_0007165 (EC: TAS, PMID:9271374); GO_0016021 (EC: IEA); GO_0030968 (EC: TAS, PMID:19816510); GO_0043565 (EC: IEA); GO_0044267 (EC: TAS)",,,,,,,,,PMID:2516827; 8889548; 9271374; 9837962; 10564271; 10866666; 11158310; 11163209; 11256944; 11287625; 11483355; 11805088; 11821395; 11909875; 12014989; 12076252; 12097557; 12477932; 12713871; 12782636; 12805554; 12949534; 14699159; 14765107; 15063770; 15299016; 15342556; 15489334; 15598891; 15899857; 16196087; 16469704; 16505252; 16710414; 17092596; 17101776; 17327457; 17440018; 17442311; 17522056; 17686766; 18022401; 18635891; 18650380; 18840095; 19122331; 19304306; 19420237; 19667116; 19693772; 19722195; 19723703; 19772629; 19816510; 19822759; 19913121; 20160352; 20219975; 20628086; 20732420; 20800603; 20936779; 21106748; 21131360; 21150130; 21211013; 21329801; 21329806; 21345978; 21355074; 21385877; 21454619; 21521793; 21693764; 21809331; 21832049; 21841196; 21906983; 21963094; 21988832; 22013072; 22102412; 22146569; 22268729; 22354938; 22577136; 22872700; 22917505; 22956602; 23011799; 23037953; 23382691; 23661758; 23864652; 23924739; 24043630,,,,,,,,,,,,,,,OGG:3000022926,,,,,,,activating transcription factor 6,,,,,,,,,,,,,Other designations: cAMP-dependent transcription factor ATF-6 alpha|cyclic AMP-dependent transcription factor ATF-6 alpha,,ATF6,,,,,,,,,,,,,,,,,,,,,,,22926,,,,,,,,9606,,,,,,,,,,,,,,,,,,,ATF6,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000006045,RNF2,,Other designations: E3 ubiquitin-protein ligase RING2|HIP2-interacting protein 3|RING finger protein 1B|RING finger protein BAP-1|huntingtin-interacting protein 2-interacting protein 3|protein DinG,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,BAP-1|RING1B|BAP1|HIPI3|RING2|DING,,,,,,,,,,,,1,,,,,,MIM:608985|Vega:OTTHUMG00000035391|Ensembl:ENSG00000121481|HGNC:10061|HPRD:07028,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,ring finger protein 2,,,1q25.3,,,,,,,,,,,,,,,,"GO_0000122 (EC: ISS); GO_0000151 (EC: IDA, PMID: 16714294); GO_0000278 (EC: IEA); GO_0001702 (EC: IEA); GO_0001739 (EC: IEA); GO_0003682 (EC: IEA); GO_0004842 (EC: IDA, Qualifier: contributes_to, PMID: 16714294); GO_0005515 (EC: IPI, PMID: 10369680); GO_0005634 (EC: IDA); GO_0005654 (EC: TAS); GO_0005730 (EC: IDA, Qualifier: NOT); GO_0006351 (EC: IEA); GO_0008270 (EC: IDA, PMID: 16714294); GO_0009948 (EC: IEA); GO_0016604 (EC: IEA); GO_0031519 (EC: IDA, PMID: 16943429); GO_0035102 (EC: IDA, PMID: 12167701); GO_0035518 (EC: IDA, PMID: 16943429); GO_0036353 (EC: ISS); GO_0071339 (EC: IDA, PMID: 15960975); GO_0071535 (EC: IPI, PMID: 16714294)",,,,,,,,,PMID: 10369680; 11439343; 11513855; 11865070; 12167161; 12167701; 12183370; 12477932; 12589020; 14702039; 15009096; 15386022; 15489334; 15563468; 15761153; 15773819; 15931389; 15960975; 16169070; 16359901; 16624538; 16710298; 16710414; 16714294; 16751658; 16943429; 17070805; 17081983; 17088979; 17157253; 17379327; 17428788; 17468742; 17873902; 17936708; 18029348; 18051367; 18339675; 18616292; 18629613; 19337376; 19412891; 19549727; 19584075; 19636380; 19690564; 20237291; 20351251; 20601937; 20696397; 20800574; 20811636; 20854876; 21139048; 21179169; 21282530; 21347701; 21530438; 21596310; 21676867; 21772249; 21890473; 22031506; 22042911; 22099309; 22325352; 22427948; 22493164; 22797925; 22844243; 22902369; 22907436; 22910419; 23000965; 23022380; 23105109; 23207902; 23251661; 23318437; 23319651; 23383273; 23395003; 23455922; 23500468; 23671107; 23712474; 24163370; 24457600; 24614341,,,,,,,,,,,,,,,OGG:3000006045,,,,,,,ring finger protein 2,,,,,,,,,,,,,Other designations: E3 ubiquitin-protein ligase RING2|HIP2-interacting protein 3|RING finger protein 1B|RING finger protein BAP-1|huntingtin-interacting protein 2-interacting protein 3|protein DinG,,RNF2,,,,,,,,,,,,,,,,,,,,,,,6045,GS1-120K12.1,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,RNF2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000006046,BRD2,,Other designations: O27.1.1|bromodomain-containing 2|bromodomain-containing protein 2|female sterile homeotic-related gene 1|really interesting new gene 3 protein,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,RNF3|FSRG1|NAT|FSH|D6S113E|RING3,,,,,,,,,,,,6,,,,,,HGNC:1103|Vega:OTTHUMG00000031241|HPRD:03326|MIM:601540|Ensembl:ENSG00000204256,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,bromodomain containing 2,,,6p21.3,,,,,,,,,,,,,,,,"GO_0003682 (EC: IDA, PMID: 18406326); GO_0005515 (EC: IPI); GO_0005634 (EC: IEA); GO_0005737 (EC: IEA); GO_0006334 (EC: IMP, PMID: 18406326); GO_0006351 (EC: IEA); GO_0006357 (EC: IDA, PMID: 18406326); GO_0007283 (EC: TAS, PMID: 9693039); GO_0016568 (EC: IEA); GO_0070577 (EC: IDA, PMID: 18406326)",,,,,,,,,PMID: 1350857; 1352711; 1663500; 8595877; 8781126; 9373153; 9693039; 10934046; 10965846; 11502199; 11983150; 12145330; 12366783; 12477932; 12600283; 12830434; 14563639; 14574404; 14702039; 14731392; 15146197; 15302935; 15342556; 15489334; 15548137; 15949438; 16344560; 16512664; 16516380; 16786191; 16940503; 17081983; 17111193; 17148447; 17166848; 17848202; 17999746; 18406326; 19204726; 19322201; 19454010; 19766566; 19851445; 19953286; 20036832; 20048151; 20587610; 20709061; 20811636; 21139048; 21608014; 22035730; 22766109; 23115324; 23255218; 23455922; 23756480; 24049186; 24250222,,,,,,,,,,,,,,,OGG:3000006046,,,,,,,bromodomain containing 2,,,,,,,,,,,,,Other designations: O27.1.1|bromodomain-containing 2|bromodomain-containing protein 2|female sterile homeotic-related gene 1|really interesting new gene 3 protein,,BRD2,,,,,,,,,,,,,,,,,,,,,,,6046,DADB-17J1.3,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,BRD2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_45304,rifapentine,"3-(((4-Cyclopentyl-1-piperazinyl)imino)methyl)rifamycin|Cyclopentylrifampicin|Priftin (TN)|(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-26-{(E)-[(4-cyclopentylpiperazin-1-yl)imino]methyl}-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.1(4,7).0(5,28)]triaconta-1(28),1(29),2,4,9,19,21,25,27-nonaen-13-yl acetate|Rifapentine",,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,DrugBank:DB01201|CAS:61379-65-5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_33231|http://purl.obolibrary.org/obo/CHEBI_35816,,,,,"(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-26-{(E)-[(4-cyclopentylpiperazin-1-yl)imino]methyl}-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.1(4,7).0(5,28)]triaconta-1(28),1(29),2,4,9,19,21,25,27-nonaen-13-yl acetate|Rifapentine",,3-(((4-Cyclopentyl-1-piperazinyl)imino)methyl)rifamycin|Cyclopentylrifampicin|Priftin (TN),,,,,,,,,,,,,,,,,,,,,CHEBI:45304,,,,rifapentine,,CHEBI:45304,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000057834,CYP4F11,,"Other designations: cytochrome P450 4F11|cytochrome P450, subfamily IVF, polypeptide 11",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CYPIVF11,,,,,,,,,,,,19,,,,,,Ensembl:ENSG00000171903|MIM:611517|HPRD:07101|Vega:OTTHUMG00000182294|HGNC:13265,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 4, subfamily F, polypeptide 11",,,19p13.1,,,,,,,,,,,,,,,,"GO_0005506 (EC: IEA); GO_0005789 (EC: TAS); GO_0006805 (EC: TAS); GO_0006954 (EC: TAS, PMID:10964514); GO_0016021 (EC: IEA); GO_0020037 (EC: TAS, PMID:10964514); GO_0044281 (EC: TAS); GO_0055114 (EC: TAS, PMID:10964514); GO_0070330 (EC: IEA)",,,,,,,,,PMID:8889548; 9068972; 10964514; 12477932; 14702039; 15057824; 15128046; 15489334; 18065749; 18976975; 19812349; 20379614; 20689807; 21906983; 21988832; 24138531,,,,,,,,,,,,,,,OGG:3000057834,,,,,,,"cytochrome P450, family 4, subfamily F, polypeptide 11",,,,,,,,,,,,,"Other designations: cytochrome P450 4F11|cytochrome P450, subfamily IVF, polypeptide 11",,CYP4F11,,,,,,,,,,,,,,,,,,,,,,,57834,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP4F11,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_22586,antioxidant,antioxidants|antoxidant|antioxydant,A substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides.|A role that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides.,false,,,http://purl.obolibrary.org/obo/CHEBI_51086,,,,,,,,,,,,,,,,,,,,,,A substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides.|A role that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,antioxidants|antoxidant|antioxydant,,,,,,,,,,,,,,,,,,,,,CHEBI:22586,,,,antioxidant,,CHEBI:22586,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000010289,EIF1B,,Other designations: eukaryotic translation initiation factor 1b|protein translation factor SUI1 homolog GC20|translation factor sui1 homolog,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,GC20,,,,,,,,,,,,3,,,,,,HGNC:30792|HPRD:17032|Ensembl:ENSG00000114784|Vega:OTTHUMG00000131388,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,eukaryotic translation initiation factor 1B,,,3p22.1,,,,,,,,,,,,,,,,"GO_0003743 (EC: IEA); GO_0005575 (EC: ND); GO_0006446 (EC: NAS, PMID:7904817); GO_0044822 (EC: IDA)",,,,,,,,,PMID:7904817; 8125298; 10931946; 12477932; 15489334; 17353931; 19322201; 21139048; 21890473; 21906983; 21988832; 22053931; 22939629; 23000965; 23275563,,,,,,,,,,,,,,,OGG:3000010289,,,,,,,eukaryotic translation initiation factor 1B,,,,,,,,,,,,,Other designations: eukaryotic translation initiation factor 1b|protein translation factor SUI1 homolog GC20|translation factor sui1 homolog,,EIF1B,,,,,,,,,,,,,,,,,,,,,,,10289,,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF1B,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0001580,Rab8B,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001580,,,,,,,,,,,,,,,,,,,,,,Rab8B,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010514,Heterogeneous nuclear ribonucleoprotein H',ROH2|FTP-3|hnRNP H',,false,,,http://purl.obolibrary.org/obo/IMR_0010024,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ROH2|FTP-3|hnRNP H',,,,,IMR:0010514,,,,,,,,,,,,,,,,,,,,,,Heterogeneous nuclear ribonucleoprotein H',,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000634,Integrin alpha-IIb,,,false,,,http://purl.obolibrary.org/obo/IMR_0000173,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000634,,,,,,,,,,,,,,,,,,,,,,Integrin alpha-IIb,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000444,GDI,guanine nucleotide dissociation inhibitor|GDP-dissociation inhibitor,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,GO:0005092,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003722,,,,,guanine nucleotide dissociation inhibitor|GDP-dissociation inhibitor,,,,,IMR:0000444,,,,,,,,,,,,,,,,,,,,,,GDI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0005488,binding (with molecule),,"The selective, non-covalent, often stoichiometric, interaction of a molecule with one or more specific sites on another molecule.",false,,,http://purl.obolibrary.org/obo/TXPO_0000469,,,,,,,,,,,,,,,,,,,In the definition of GO:0005488 binding is a subtype of Molecular function.,,,"The selective, non-covalent, often stoichiometric, interaction of a molecule with one or more specific sites on another molecule.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0005488,,,,,,,,,,,,,,,,,,,,,,binding (with molecule),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004276,Tumor-associated macrophage activation@hepatocarcinogenesis,,"Tumor-associated macrophage (TAM) activation is a subtype of macrophage activation: A change in morphology and behavior of TAMs resulting from exposure to a cytokine, chemokine, cellular ligand, or soluble factor.
This entity is a specific course-dependent process. This process can constitute the course of Hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004277,,,,,,,,,,,,,,,,,,,,PMID:25181692|PMID:30894684|PMID:31781608,,"Tumor-associated macrophage (TAM) activation is a subtype of macrophage activation: A change in morphology and behavior of TAMs resulting from exposure to a cytokine, chemokine, cellular ligand, or soluble factor.
This entity is a specific course-dependent process. This process can constitute the course of Hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004391|http://purl.obolibrary.org/obo/TXPO_0004392,,,,,,,,,,,TXPO:0004276,,,,,,,,,,,,,,,,,,,,,,Tumor-associated macrophage activation@hepatocarcinogenesis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004279,hepatic fibrosis [mitochondrial disorder],,"Hepatic fibrosis is a subtype of fibrosis: A process that replaces liver tissues to fibrous connective tissues, usually as a consequence of inflammation or other injury.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0000816,,,,,,,,,,,,,,,,,,,,PMID:31623280|PMID:25339807|PMID:29222479,,"Hepatic fibrosis is a subtype of fibrosis: A process that replaces liver tissues to fibrous connective tissues, usually as a consequence of inflammation or other injury.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004316,,,,,,,,,,,,,,,,,TXPO:0004279,,,,,,,,,,,,,,,,,,,,,,hepatic fibrosis [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004273,Tumor-associated macrophage activation[Mitochondrial disorder],,"Tumor-associated macrophage (TAM) activation is a subtype of macrophage activation: A change in morphology and behavior of TAMs resulting from exposure to a cytokine, chemokine, cellular ligand, or soluble factor.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0004277|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:30894684,,"Tumor-associated macrophage (TAM) activation is a subtype of macrophage activation: A change in morphology and behavior of TAMs resulting from exposure to a cytokine, chemokine, cellular ligand, or soluble factor.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003610,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004218|http://purl.obolibrary.org/obo/TXPO_0004324,,,,,,,,,,,TXPO:0004273,,,,,,,,,,,,,,,,,,,,,,Tumor-associated macrophage activation[Mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004275,tumor-associated macrophage migration,TAM recruitment,The orderly movement of a TAM macrophage from one site to another.,false,,,http://purl.obolibrary.org/obo/GO_1905517,,,,,,,,,,,,,,,,,,,,,,The orderly movement of a TAM macrophage from one site to another.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TAM recruitment,,,,,TXPO:0004275,,,,,,,,,,,,,,,,,,,,,,tumor-associated macrophage migration,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004270,inflammatory cytokine gene expression [mitochondrial disorder],,"Inflammatory cytokine gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature inflammatory cytokine gene product or products (proteins or RNA).
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0002266|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,,,"Inflammatory cytokine gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature inflammatory cytokine gene product or products (proteins or RNA).
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004270,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004271,,,,,,,,,,,TXPO:0004270,,,,,,,,,,,,,,,,,,,,,,inflammatory cytokine gene expression [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004271,Inflammatory response [mitochondrial disorder],,"Inflammatory response is a subtype of changing material: The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0000192|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:31623280|PMID:26571396|PMID:29222479|PMID:31649547,,"Inflammatory response is a subtype of changing material: The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004316,,,,,,http://purl.obolibrary.org/obo/TXPO_0004218|http://purl.obolibrary.org/obo/TXPO_0004279|http://purl.obolibrary.org/obo/TXPO_0004281|http://purl.obolibrary.org/obo/TXPO_0004379|http://purl.obolibrary.org/obo/TXPO_0002004|http://purl.obolibrary.org/obo/TXPO_0004390,,,,,,,,,,,TXPO:0004271,,,,,,,,,,,,,,,,,,,,,,Inflammatory response [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004278,lipoperoxidation [mitochondrial disorder],,"Lipoperoxidation is a subtype of lipid oxidation: The degradation of lipids caused by an oxidative attack from free radicals.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0003514|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:31623280|PMID:23299992|PMID:29222479,,"Lipoperoxidation is a subtype of lipid oxidation: The degradation of lipids caused by an oxidative attack from free radicals.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004324|http://purl.obolibrary.org/obo/TXPO_0004262|http://purl.obolibrary.org/obo/TXPO_0004269|http://purl.obolibrary.org/obo/TXPO_0004393|http://purl.obolibrary.org/obo/TXPO_0004121,,,,,,,,,,,TXPO:0004278,,,,,,,,,,,,,,,,,,,,,,lipoperoxidation [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004277,Tumor-associated macrophage activation,Tumor-associated macrophage polarization,"Tumor-associated macrophage (TAM) activation is a subtype of macrophage activation: A change in morphology and behavior of TAMs resulting from exposure to a cytokine, chemokine, cellular ligand, or soluble factor.",false,,,http://purl.obolibrary.org/obo/GO_0042116,,,,,,,,,,,,,,,,,,,,,,"Tumor-associated macrophage (TAM) activation is a subtype of macrophage activation: A change in morphology and behavior of TAMs resulting from exposure to a cytokine, chemokine, cellular ligand, or soluble factor.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Tumor-associated macrophage polarization,,,,,TXPO:0004277,,,,,,,,,,,,,,,,,,,,,,Tumor-associated macrophage activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004274,tumor-associated macrophage migration [mitochondrial disorder],,"The orderly movement of a TAM macrophage from one site to another.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0004275|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:30894684,,"The orderly movement of a TAM macrophage from one site to another.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004274,,,,,,,,,,,,,,,,,,,,,,tumor-associated macrophage migration [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004272,cellular damage [mitochondrial disorder],,"Cellular damage is a subtype of damaging: A process that injuries the structure of the cell as the direct or indirect result of an external force.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0000225,,,,,,,,,,,,,,,,,,,,PMID:31623280|PMID:29222479,,"Cellular damage is a subtype of damaging: A process that injuries the structure of the cell as the direct or indirect result of an external force.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004218|http://purl.obolibrary.org/obo/TXPO_0004279|http://purl.obolibrary.org/obo/TXPO_0004281,,,,,,,,,,,TXPO:0004272,,,,,,,,,,,,,,,,,,,,,,cellular damage [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003514,lipoperoxidation,,Lipoperoxidation is a subtype of lipid oxidation:  The degradation of lipids caused by an oxidative attack from free radicals.,false,,,http://purl.obolibrary.org/obo/GO_0034440,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C81870,,Lipoperoxidation is a subtype of lipid oxidation:  The degradation of lipids caused by an oxidative attack from free radicals.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003514,,,,,,,,,,,,,,,,,,,,,,lipoperoxidation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003516,lipidosis dependent molecule (canonical),,"Lipidosis dependent molecule is a subtype of toxic course dependent chemical entity.
This molecule can participate in the course of lipidosis as a gene product.
Gene profile:caonical that described in textbooks or articles.",false,,,http://purl.obolibrary.org/obo/TXPO_0001089,,,,,,,,,,,,,,,,,,,,,,"Lipidosis dependent molecule is a subtype of toxic course dependent chemical entity.
This molecule can participate in the course of lipidosis as a gene product.
Gene profile:caonical that described in textbooks or articles.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003516,,,,,,,,,,,,,,,,,,,,,,lipidosis dependent molecule (canonical),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003519,Bhlha15(mouse)[Glutathione depletion],MIST1 [Glutathione depletion],,false,,,http://purl.obolibrary.org/obo/TXPO_1000045|http://purl.obolibrary.org/obo/TXPO_0002285,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:17341|PMID:26456005|PMID:9073453|PMID:27644325,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MIST1 [Glutathione depletion],,,,,TXPO:0003519,,,,,,,,,,,,,,,,,,,,,,Bhlha15(mouse)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003513,cellular membrane lipoperoxidation,,Cellular membrane lipoperoxidation is a subtype of lipoperoxidation: A process that the degradation of lipids of cellular membrane caused by an oxidative attack from free radicals.,false,,,http://purl.obolibrary.org/obo/TXPO_0003514,,,,,,,,,,,,,,,,,,,,,,Cellular membrane lipoperoxidation is a subtype of lipoperoxidation: A process that the degradation of lipids of cellular membrane caused by an oxidative attack from free radicals.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003513,,,,,,,,,,,,,,,,,,,,,,cellular membrane lipoperoxidation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003511,malfunctioning of cellular membrane [Lipidosis],,"Malfunctioning of cellular membrane is a subtype of malfunctioning process: A process that cannot perform a cellular membrane function appropriately or cannot realize it at all.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0002198,,,,,,,,,,,,,,,,,,,,,,"Malfunctioning of cellular membrane is a subtype of malfunctioning process: A process that cannot perform a cellular membrane function appropriately or cannot realize it at all.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003512,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003495,,,,,,,,,,,TXPO:0003511,,,,,,,,,,,,,,,,,,,,,,malfunctioning of cellular membrane [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003517,APOE (canonical)[Lipidosis],,"The protein encoded by this gene is a major apoprotein of the chylomicron. It binds to a specific liver and peripheral cell receptor, and is essential for the normal catabolism of triglyceride-rich lipoprotein constituents. This gene maps to chromosome 19 in a cluster with the related apolipoprotein C1 and C2 genes. Mutations in this gene result in familial dysbetalipoproteinemia, or type III hyperlipoproteinemia (HLP III), in which increased plasma cholesterol and triglycerides are the consequence of impaired clearance of chylomicron and VLDL remnants. [provided by RefSeq, Jun 2016]",false,,,http://purl.obolibrary.org/obo/TXPO_0003516|http://purl.obolibrary.org/obo/TXPO_1000006,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:25728|NCBI-Mouse-GeneID:11816|NCBI-Human-GeneID:348|http://omim.org/entry/107741,,"The protein encoded by this gene is a major apoprotein of the chylomicron. It binds to a specific liver and peripheral cell receptor, and is essential for the normal catabolism of triglyceride-rich lipoprotein constituents. This gene maps to chromosome 19 in a cluster with the related apolipoprotein C1 and C2 genes. Mutations in this gene result in familial dysbetalipoproteinemia, or type III hyperlipoproteinemia (HLP III), in which increased plasma cholesterol and triglycerides are the consequence of impaired clearance of chylomicron and VLDL remnants. [provided by RefSeq, Jun 2016]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003517,,,,,,,,,,,,,,,,,,,,,,APOE (canonical)[Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003515,eosinophilic change  [Liver Pathological Findings],acidophilic change,"Eosinophilic change  [Liver PathologicalFindings] is a type of finding observed in hepatocyte cytoplasm. Based on pathological morphology, lesions are stained with eosin.",false,,,http://purl.obolibrary.org/obo/TXPO_0000662,,,,,,,,,,,,,,,,,,,,,,"Eosinophilic change  [Liver PathologicalFindings] is a type of finding observed in hepatocyte cytoplasm. Based on pathological morphology, lesions are stained with eosin.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,acidophilic change,,,,,TXPO:0003515,,,,,,,"· Stained with eosinophilic (eosinophilic) dye of hepatic cytoplasm.
· Generally, it is caused by diffuse or focal increase of cytoplasmic organelle or excessive accumulation of eosinophilic substance.

· Eosinophilic staining area: It often corresponds to mitochondria, smooth endoplasmic reticulum, or peroxisome.
· Changes over the entire cytoplasm: granule degeneration, eosinophilic granular change, glute-like change
· Cytoplasmic local changes: vitreous, eosinophilic inclusion bodies etc.",,,,,,,,,,,,,,,eosinophilic change  [Liver Pathological Findings],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003512,cellular membrane lipoperoxidation [Lipidosis],,"Cellular membrane lipoperoxidation is a subtype of lipoperoxidation: A process that the degradation of lipids of cellular membrane caused by an oxidative attack from free radicals.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003513|http://purl.obolibrary.org/obo/TXPO_0001720,,,,,,,,,,,,,,,,,,,,,,"Cellular membrane lipoperoxidation is a subtype of lipoperoxidation: A process that the degradation of lipids of cellular membrane caused by an oxidative attack from free radicals.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000593,,,,,,http://purl.obolibrary.org/obo/TXPO_0003510|http://purl.obolibrary.org/obo/TXPO_0001086,,,,,,,,,,,TXPO:0003512,,,,,,,,,,,,,,,,,,,,,,cellular membrane lipoperoxidation [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003510,increasing demand for response to oxidative stress [Lipidosis],,"Increasing demand for response to oxidative stress is a subtype of increasing the demand for stress response : A process that changes the functional demand for the response to the oxidative stress to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.|Because the mitochondrial pathway is saturated, fatty acids are metabolized in peroxisomes, and Cyp2E1 enzyme induction occurs, resulting in oxidative stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0000102,,,,,,,,,,,,,,,,,,,,,,"Increasing demand for response to oxidative stress is a subtype of increasing the demand for stress response : A process that changes the functional demand for the response to the oxidative stress to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001086,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003620,,,,,,,,,,,TXPO:0003510,,,,,,,,,,,,,,,,,,,,"Because the mitochondrial pathway is saturated, fatty acids are metabolized in peroxisomes, and Cyp2E1 enzyme induction occurs, resulting in oxidative stress.",,increasing demand for response to oxidative stress [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003518,acidophilic,,An affinity inhering in a tissue constituent by virtue of the bearer exhibiting a molecular interaction for acidic dyes under specific ph conditions.,false,,,http://purl.obolibrary.org/obo/PATO_0002070,,,,,,,,,,,,,,,,,,,,,,An affinity inhering in a tissue constituent by virtue of the bearer exhibiting a molecular interaction for acidic dyes under specific ph conditions.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003518,,,,,,,,,,,,,,,,,,,,,,acidophilic,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100021,leukotriene,,"Any icosanoid from that family of C20 polyunsaturated fatty acids and their derivatives generated by leukocytes from arachidonic acid, each member having four double bonds of which three are conjugated.",false,,,http://purl.obolibrary.org/obo/CHEBI_23899,,,,,,,,,,,,,,,,,,,,,,"Any icosanoid from that family of C20 polyunsaturated fatty acids and their derivatives generated by leukocytes from arachidonic acid, each member having four double bonds of which three are conjugated.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003686|http://purl.obolibrary.org/obo/TXPO_0002401,,,,,,,,,,IMR:0100021,,,,,,,,,,,,,,,,,,,,,,leukotriene,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_38157,iron chelator,iron chelating agents|iron chelators,,false,,,http://purl.obolibrary.org/obo/CHEBI_38161,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,iron chelating agents|iron chelators,,,,,,,,,,,,,,,,,,,,,CHEBI:38157,,,,iron chelator,,CHEBI:38157,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_35526,hypoglycemic agent,antihyperglycemic agents|hypoglycemic drugs|antihyperglycemic|antihyperglycemic drugs|antihyperglycemic drug|antidiabetic|antihyperglycemic agent|hypoglycemic drug|hypoglycemic agents|antihyperglycemics,A drug which lowers the blood glucose level.,false,,,http://purl.obolibrary.org/obo/CHEBI_23888,,,,,,,,,,,,,,,,,,,,,,A drug which lowers the blood glucose level.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,antihyperglycemic agents|hypoglycemic drugs|antihyperglycemic|antihyperglycemic drugs|antihyperglycemic drug|antidiabetic|antihyperglycemic agent|hypoglycemic drug|hypoglycemic agents|antihyperglycemics,,,,,,,,,,,,,,,,,,,,,CHEBI:35526,,,,hypoglycemic agent,,CHEBI:35526,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006457,protein folding,,"The process of assisting in the covalent and noncovalent assembly of single chain polypeptides or multisubunit complexes into the correct tertiary structure.|Due to the crowded envirnoment within the cell, many proteins must interact with molecular chaperones to attain their native conformation (reviewed in Young et al., 2004). Chaperones recognize and associate with proteins in their non-native state and facilitate their folding by stabilizing the conformation of productive folding intermediates. Chaperones that take part broadly in de novo protein folding, such as the Hsp70s and the chaperonins, facilitate the folding process through cycles of substrate binding and release regulated by their ATPase activity (see Young et al., 2004; Spiess et al., 2004; Bigotti and Clarke, 2008).",false,,,http://purl.obolibrary.org/obo/TXPO_0002565,,,,,,,,,,,,,,,,,,,,Reactome:R-HSA-391251|Wikipedia:Protein_folding|PMID:15519848|PMID:15459659,,The process of assisting in the covalent and noncovalent assembly of single chain polypeptides or multisubunit complexes into the correct tertiary structure.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0006457,,,,,,,,,,,,,,,,,,,,"Due to the crowded envirnoment within the cell, many proteins must interact with molecular chaperones to attain their native conformation (reviewed in Young et al., 2004). Chaperones recognize and associate with proteins in their non-native state and facilitate their folding by stabilizing the conformation of productive folding intermediates. Chaperones that take part broadly in de novo protein folding, such as the Hsp70s and the chaperonins, facilitate the folding process through cycles of substrate binding and release regulated by their ATPase activity (see Young et al., 2004; Spiess et al., 2004; Bigotti and Clarke, 2008).",,protein folding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_28494,cardiolipin,,A phosphatidylglycerol composed of two molecules of phosphatidic acid covalently linked to a molecule of glycerol.,false,,,http://purl.obolibrary.org/obo/CHEBI_37739,,,,,,,,,,,,,,,,,,,,Wikipedia:cardiolipin,,A phosphatidylglycerol composed of two molecules of phosphatidic acid covalently linked to a molecule of glycerol.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:28494,,,,,,,,,,,,,,,,,,,,,,cardiolipin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_64482,phosphatidylcholine,,A glycerophosphocholine that is glycero-3-phosphocholine bearing two acyl substituents at positions 1 and 2.,false,,,http://purl.obolibrary.org/obo/CHEBI_137209,,,,,,,,,,,,,,,,,,,,,,A glycerophosphocholine that is glycero-3-phosphocholine bearing two acyl substituents at positions 1 and 2.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:64482,,,,,,,,,,,,,,,,,,,,,,phosphatidylcholine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000055109,AGGF1,,Other designations: G patch domain-containing protein 7|angiogenic factor VG5Q|vasculogenesis gene on 5q protein,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,GPATC7|GPATCH7|HUS84971|HSU84971|VG5Q,,,,,,,,,,,,5,,,,,,Ensembl:ENSG00000164252|HGNC:24684|Vega:OTTHUMG00000102132|MIM:608464|HPRD:07621,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,angiogenic factor with G patch and FHA domains 1,,,5q13.3,,,,,,,,,,,,,,,,"GO_0001525 (EC: IEA); GO_0001570 (EC: TAS, PMID: 15905966); GO_0001938 (EC: IDA, PMID: 14961121); GO_0003676 (EC: IEA); GO_0005515 (EC: IPI, PMID: 14961121); GO_0005576 (EC: IDA, PMID: 14961121); GO_0005737 (EC: IDA, PMID: 14961121); GO_0006396 (EC: TAS, PMID: 15486042); GO_0007155 (EC: IDA, PMID: 14961121); GO_0045766 (EC: IDA, PMID: 14961121); GO_0048471 (EC: IDA, PMID: 14961121)",,,,,,,,,PMID: 10737800; 12477932; 14702039; 14961121; 15486042; 15489334; 15905966; 16189514; 16443853; 16911369; 17103452; 17332742; 18564129; 19556247; 19615732; 20360068; 21576349; 22365833; 22990118; 23628701,,,,,,,,,,,,,,,OGG:3000055109,,20140408,protein-coding,,,,angiogenic factor with G patch and FHA domains 1,,,,,,,,,,,,,Other designations: G patch domain-containing protein 7|angiogenic factor VG5Q|vasculogenesis gene on 5q protein,,AGGF1,,,,,,,,,,,,,,,,,,,,,,,55109,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,AGGF1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000000900,CCNG1,,Other designations: cyclin-G|cyclin-G1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CCNG,,,,,,,,,,,,5,,,,,,MIM:601578|HPRD:03345|Vega:OTTHUMG00000130380|HGNC:1592|Ensembl:ENSG00000113328,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,cyclin G1,,,5q32-q34,,,,,,,,,,,,,,,,"GO_0000079 (EC: TAS, PMID: 8626390); GO_0005515 (EC: IPI); GO_0005634 (EC: IEA); GO_0006949 (EC: IEA); GO_0007067 (EC: IEA); GO_0007095 (EC: IEA); GO_0007420 (EC: IEA); GO_0010243 (EC: IEA); GO_0016049 (EC: IEA); GO_0019904 (EC: IEA); GO_0030425 (EC: IEA); GO_0043025 (EC: IEA); GO_0043066 (EC: IEA); GO_0048471 (EC: IEA)",,,,,,,,,PMID: 8626390; 8806701; 8887688; 8954786; 9013862; 10194136; 10196184; 11956189; 12214116; 12477932; 12556559; 12634633; 12642871; 12684677; 15077171; 15489334; 16322753; 17616664; 17868090; 18408012; 18632610; 18981217; 19584283; 19698214; 19738611; 21688120; 21832049; 21988832; 22105316; 22271581; 22649121; 22835824; 23589924,,,,,,,,,,,,,,,OGG:3000000900,,,,,,,cyclin G1,,,,,,,,,,,,,Other designations: cyclin-G|cyclin-G1,,CCNG1,,,,,,,,,,,,,,,,,,,,,,,900,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,CCNG1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_64018,protein kinase C agonist,protein kinase C agonists,An agonist that selectively binds to and activates a protein kinase C receptor,false,,,http://purl.obolibrary.org/obo/CHEBI_64106,,,,,,,,,,,,,,,,,,,,,,An agonist that selectively binds to and activates a protein kinase C receptor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,protein kinase C agonists,,,,,,,,,,,,,,,,,,,,,CHEBI:64018,,,,protein kinase C agonist,,CHEBI:64018,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76662,EC 2.4.* (glycosyltransferase) inhibitor,glycosyltransferase (EC 2.4.*) inhibitors|glycosyltransferase (EC 2.4.*) inhibitor|glycosyltransferase inhibitors|EC 2.4.* (glycosyltransferase) inhibitors|EC 2.4.* inhibitor|glycosyltransferase inhibitor|EC 2.4.* inhibitors,A transferase inhibitor inhibiting the action of a glycosyltransferase (EC 2.4.*.*).,false,,,http://purl.obolibrary.org/obo/CHEBI_71300,,,,,,,,,,,,,,,,,,,,,,A transferase inhibitor inhibiting the action of a glycosyltransferase (EC 2.4.*.*).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,glycosyltransferase (EC 2.4.*) inhibitors|glycosyltransferase (EC 2.4.*) inhibitor|glycosyltransferase inhibitors|EC 2.4.* (glycosyltransferase) inhibitors|EC 2.4.* inhibitor|glycosyltransferase inhibitor|EC 2.4.* inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:76662,,,,EC 2.4.* (glycosyltransferase) inhibitor,,CHEBI:76662,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000203,liver dysfunction,,Liver dysfunction is a subtype of dysfunctioning: A process that performs an abnormal and incomplete liver function.,false,,,http://purl.obolibrary.org/obo/TXPO_0000438,,,,,,,,,,,,,,,,,,,,,,Liver dysfunction is a subtype of dysfunctioning: A process that performs an abnormal and incomplete liver function.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001352|http://purl.obolibrary.org/obo/TXPO_0001354|http://purl.obolibrary.org/obo/TXPO_0001342|http://purl.obolibrary.org/obo/TXPO_0001323,,,,,,,,,,,,,,,,,,TXPO:0000203,,,,,,,,,,,,,,,,,,,,,,liver dysfunction,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000200,phospholipid transport from lysosome into cytosol [Phospholipidosis],,"Phospholipid transport from lysosome is a subtype of phospholipid transfer : A process of the transfer of a phospholipid from the lysosome.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0003388,,,,,,,,,,,,,,,,,,,,,,"Phospholipid transport from lysosome is a subtype of phospholipid transfer : A process of the transfer of a phospholipid from the lysosome.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000200,,,,,,,,,,,,,,,,,,,,,,phospholipid transport from lysosome into cytosol [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000206,liver dysfunction [ER stress],,"Liver dysfunction is a subtype of dysfunctioning: A process that performs an abnormal and incomplete liver function.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000203|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"Liver dysfunction is a subtype of dysfunctioning: A process that performs an abnormal and incomplete liver function.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000206,,,,,,,,,,,,,,,,,,,,,,liver dysfunction [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000201,oxygen radical,,An inorganic radical in which a free electron resides on one or more oxygen atoms of an oxygen species.,false,,,http://purl.obolibrary.org/obo/CHEBI_26519,,,,,,,,,,,,,,,,,,,,,,An inorganic radical in which a free electron resides on one or more oxygen atoms of an oxygen species.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000201,,,,,,,,,,,,,,,,,,,,,,oxygen radical,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000205,redox-active reactant formation,,Redox-active reactant formation is a subtype of biosynthetic process: A process that that generates a redox-active reactant.,false,,,http://purl.obolibrary.org/obo/GO_0009058,,,,,,,,,,,,,,,,,,,,,,Redox-active reactant formation is a subtype of biosynthetic process: A process that that generates a redox-active reactant.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000205,,,,,,,"A number of xenobiotics exert a toxic effect theough their metabolites.
The increased reactivity may be due to conversion into electrophiles, free radicals, nucleophiles, or redox-active reactants.

Casarett and Doull's toxicology 8th ed. Chapter 3 step1  Delibery:From the site to exposure to the target",,,,,,,,,,,,,,,redox-active reactant formation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000208,dysfunction of generating protein,,Dysfunction of generating protein is a subtype of dysfunctioning: A process that performs an abnormal and incomplete generating protein.,false,,,http://purl.obolibrary.org/obo/TXPO_0000438,,,,,,,,,,,,,,,,,,,,,,Dysfunction of generating protein is a subtype of dysfunctioning: A process that performs an abnormal and incomplete generating protein.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000208,,,,,,,,,,,,,,,,,,,,,,dysfunction of generating protein,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000209,free radicals formation,,"Free radicals formation is a subtype of biosynthetic process: A process that that generates a free radical, a highly reactive molecule with an unsatisfied electron valence pair.",false,,,http://purl.obolibrary.org/obo/GO_0009058,,,,,,,,,,,,,,,,,,,,,,"Free radicals formation is a subtype of biosynthetic process: A process that that generates a free radical, a highly reactive molecule with an unsatisfied electron valence pair.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000209,,,,,,,"A number of xenobiotics exert a toxic effect theough their metabolites.
The increased reactivity may be due to conversion into electrophiles, free radicals, nucleophiles, or redox-active reactants.

Casarett and Doull's toxicology 8th ed. Chapter 3 step1  Delibery:From the site to exposure to the target",,,,,,,,,,,,,,,free radicals formation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000207,dysfunction of sodium transport,,Dysfunction of sodium transport is a subtype of dysfunctioning: A process that performs an abnormal and incomplete sodium transport,false,,,http://purl.obolibrary.org/obo/TXPO_0000438,,,,,,,,,,,,,,,,,,,,,,Dysfunction of sodium transport is a subtype of dysfunctioning: A process that performs an abnormal and incomplete sodium transport,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000367|http://purl.obolibrary.org/obo/TXPO_0000368,,,,,,,,,,,TXPO:0000207,,,,,,,,,,,,,,,,,,,,,,dysfunction of sodium transport,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000204,autophagy [ER stress],,The cellular catabolic process in which cells digest parts of their own cytoplasm; allows for both recycling of macromolecular constituents under conditions of cellular stress and remodeling the intracellular structure for cell differentiation. This entity is a specific course-dependent process. This process can constitute the course of ER stress.,false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/GO_0006914,,,,,,,,,,,,,,,,,,,,,,The cellular catabolic process in which cells digest parts of their own cytoplasm; allows for both recycling of macromolecular constituents under conditions of cellular stress and remodeling the intracellular structure for cell differentiation. This entity is a specific course-dependent process. This process can constitute the course of ER stress.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000768,,,,,,http://purl.obolibrary.org/obo/TXPO_0002529,,,,,,,,,,,TXPO:0000204,,,,,,,,,,,,,,,,,,,,,,autophagy [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0030512,negative regulation of transforming growth factor beta receptor signaling pathway,,"Any process that stops, prevents, or reduces the frequency, rate or extent of any TGF-beta receptor signaling pathway.",false,,,http://purl.obolibrary.org/obo/GO_0023057,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents, or reduces the frequency, rate or extent of any TGF-beta receptor signaling pathway.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0030512,,,,,,,,,,,,,,,,,,,,,,negative regulation of transforming growth factor beta receptor signaling pathway,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001854|http://purl.obolibrary.org/obo/GO_0007179,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000003032,HADHB,,"Other designations: 2-enoyl-Coenzyme A (CoA) hydratase, beta subunit|3-ketoacyl-Coenzyme A (CoA) thiolase of mitochondrial trifunctional protein, beta subunit|acetyl-CoA acyltransferase|beta-ketothiolase|hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme A thiolase/enoyl-Coenzyme A hydratase (trifunctional protein), beta subunit|trifunctional enzyme subunit beta, mitochondrial",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,MTPB|TP-BETA|ECHB,,,,,,,,,,,,2,,,,,,HPRD:00887|MIM:143450|Ensembl:ENSG00000138029|HGNC:4803|Vega:OTTHUMG00000096978,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase (trifunctional protein), beta subunit",,,2p23,,,,,,,,,,,,,,,,"GO_0000062 (EC: IEA); GO_0003857 (EC: TAS, PMID: 1550553); GO_0003988 (EC: IEA); GO_0004300 (EC: IEA); GO_0005515 (EC: IPI); GO_0005739 (EC: NAS, PMID: 7958339); GO_0005740 (EC: TAS, PMID: 1550553); GO_0005741 (EC: IDA); GO_0005743 (EC: IDA); GO_0005743 (EC: TAS); GO_0005783 (EC: IDA); GO_0006635 (EC: IEA); GO_0006635 (EC: TAS); GO_0006644 (EC: TAS); GO_0016507 (EC: IEA); GO_0016508 (EC: IEA); GO_0016509 (EC: IEA); GO_0032403 (EC: IEA); GO_0035965 (EC: TAS); GO_0042645 (EC: IDA, PMID: 18063578); GO_0044255 (EC: TAS); GO_0044281 (EC: TAS); GO_0044822 (EC: IDA); GO_0046474 (EC: TAS); GO_0051287 (EC: IEA)",,,,,,,,,PMID: 1550553; 7958339; 8135828; 8163672; 8651282; 8921383; 9259266; 9605857; 9739053; 10075708; 11430884; 12477932; 12665801; 12721663; 12754706; 12933794; 14630990; 14702039; 15242332; 15489334; 15815621; 16196087; 16344560; 17199921; 17314511; 18063578; 19699128; 20305087; 20360068; 20562859; 20825197; 20877624; 21139048; 21319273; 21549624; 21565611; 21853274; 21890473; 21900206; 21988832; 22000755; 22079093; 22190034; 22268729; 22304920; 22375075; 22939629; 22952844; 23000159; 23398456; 23455922; 23798571; 24244333; 24255178,,,,,,,,,,,,,,,OGG:3000003032,,,,,,,"hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase (trifunctional protein), beta subunit",,,,,,,,,,,,,"Other designations: 2-enoyl-Coenzyme A (CoA) hydratase, beta subunit|3-ketoacyl-Coenzyme A (CoA) thiolase of mitochondrial trifunctional protein, beta subunit|acetyl-CoA acyltransferase|beta-ketothiolase|hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme A thiolase/enoyl-Coenzyme A hydratase (trifunctional protein), beta subunit|trifunctional enzyme subunit beta, mitochondrial",,HADHB,,,,,,,,,,,,,,,,,,,,,,,3032,MSTP029,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,HADHB,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0011146,eIF3h,eIF-3 gamma|eukaryotic translation initiation factor 3 subunit 3|eIF3 p40 subunit|eIF3 p40,,false,,,http://purl.obolibrary.org/obo/IMR_0000916,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,eIF-3 gamma|eukaryotic translation initiation factor 3 subunit 3|eIF3 p40 subunit|eIF3 p40,,,,,IMR:0011146,,,,,,,,,,,,,,,,,,,,,,eIF3h,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001030,group III secretory phospholipase A2,,,false,,,http://purl.obolibrary.org/obo/IMR_0000283,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001030,,,,,,,,,,,,,,,,,,,,,,group III secretory phospholipase A2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/HP_0000118,Phenotypic abnormality,,A phenotypic abnormality.,false,,,http://purl.obolibrary.org/obo/BFO_0000019,,,,,,,,,,,,,,,,,,,,,,A phenotypic abnormality.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,HP:0000118,,,,,,,,,,,,,,,,,,,,,,Phenotypic abnormality,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000005824,PEX19,,"Other designations: 33 kDa housekeeping protein|housekeeping gene, 33kD|peroxin-19|peroxisomal farnesylated protein",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,PXMP1|PMPI|PXF|D1S2223E|PBD12A|PMP1|HK33,,,,,,,,,,,,1,,,,,,Vega:OTTHUMG00000033112|MIM:600279|Ensembl:ENSG00000162735|HPRD:02610|HGNC:9713,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,peroxisomal biogenesis factor 19,,,1q23.2,,,,,,,,,,,,,,,,"GO_0005515 (EC: IPI, PMID: 10704444); GO_0005634 (EC: IDA); GO_0005634 (EC: IMP, PMID: 12924628); GO_0005730 (EC: IDA, Qualifier: NOT); GO_0005737 (EC: IDA); GO_0005737 (EC: IMP, PMID: 12924628); GO_0005737 (EC: ISS); GO_0005777 (EC: IDA, PMID: 19114594); GO_0005777 (EC: ISS); GO_0005778 (EC: IDA, PMID: 15713480); GO_0005829 (EC: IDA, PMID: 19114594); GO_0005829 (EC: TAS); GO_0006625 (EC: IDA, PMID: 16344115); GO_0006625 (EC: IMP, PMID: 10704444); GO_0007031 (EC: IMP, PMID: 11883941); GO_0007031 (EC: NAS, PMID: 9339377); GO_0016021 (EC: IDA, PMID: 10051604); GO_0016557 (EC: IDA, PMID: 10051604); GO_0016559 (EC: IMP, PMID: 18782765); GO_0031526 (EC: ISS); GO_0036105 (EC: IDA, PMID: 14709540); GO_0043231 (EC: IDA); GO_0043234 (EC: IDA, PMID: 18174172); GO_0045046 (EC: IDA, PMID: 11402059); GO_0047485 (EC: IPI, PMID: 19197237); GO_0050821 (EC: IDA, PMID: 14709540); GO_0051117 (EC: IPI, PMID: 11453642); GO_0055085 (EC: TAS); GO_0061077 (EC: IDA, PMID: 14709540); GO_0072321 (EC: IDA, PMID: 11402059); GO_0072663 (EC: IMP, PMID: 18782765); GO_1900131 (EC: IDA, PMID: 19715730)",,,,,,,,,PMID: 8076834; 9339377; 9418908; 10051604; 10704444; 10777694; 11259404; 11390669; 11402059; 11453642; 11590176; 11883941; 12096124; 12154087; 12477932; 12581788; 12924628; 14558883; 14709540; 14713233; 14715663; 15007061; 15231748; 15252024; 15489334; 15713480; 15781447; 16280322; 16344115; 16459329; 16582619; 16763195; 16791427; 16895967; 16980692; 17069900; 18174172; 18782765; 19114594; 19195843; 19197237; 19322201; 19715730; 20301621; 20531392; 20554521; 20615514; 20683989; 21102411; 21139048; 21525035; 21890473; 21906983; 21963094; 21987572; 21988832; 22053931; 22505724; 22624858; 22939629; 23000965; 23460677; 23956138,,,,,,,,,,,,,,,OGG:3000005824,,,,,,,peroxisomal biogenesis factor 19,,,,,,,,,,,,,"Other designations: 33 kDa housekeeping protein|housekeeping gene, 33kD|peroxin-19|peroxisomal farnesylated protein",,PEX19,,,,,,,,,,,,,,,,,,,,,,,5824,OK/SW-cl.22,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,PEX19,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000005820,PVT1,,,false,,,http://purl.obolibrary.org/obo/OGG_2100009606,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:5820,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,OGG:3000005820,,,,,,,olfactory receptor family 3 subfamily A member 4 pseudogene,,,,,,,,,,,,,,,PVT1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000001586,CYP17A1,,"Other designations: 17-alpha-hydroxyprogesterone aldolase|CYPXVII|cytochrome P450 17A1|cytochrome P450, subfamily XVII (steroid 17-alpha-hydroxylase), adrenal hyperplasia|cytochrome P450-C17|cytochrome P450c17|cytochrome p450 XVIIA1|steroid 17-alpha-hydroxylase/17,20 lyase|steroid 17-alpha-monooxygenase",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,P450C17|CPT7|S17AH|CYP17,,,,,,,,,,,,10,,,,,,MIM:609300|Vega:OTTHUMG00000018969|HGNC:2593|HPRD:01944|Ensembl:ENSG00000148795,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 17, subfamily A, polypeptide 1",,,10q24.3,,,,,,,,,,,,,,,,"GO_0004508 (EC: IDA); GO_0005506 (EC: IEA); GO_0005739 (EC: IEA); GO_0005783 (EC: NAS, PMID:9326943); GO_0005789 (EC: TAS); GO_0006694 (EC: TAS, PMID:3500022); GO_0006702 (EC: TAS); GO_0006704 (EC: TAS); GO_0006805 (EC: TAS); GO_0007548 (EC: TAS, PMID:9326943); GO_0008202 (EC: IDA); GO_0008202 (EC: TAS); GO_0009635 (EC: IEA); GO_0010034 (EC: IEA); GO_0010212 (EC: IEA); GO_0016125 (EC: TAS); GO_0017085 (EC: IEA); GO_0018879 (EC: IEA); GO_0018894 (EC: IEA); GO_0018958 (EC: IEA); GO_0018963 (EC: IEA); GO_0019825 (EC: TAS, PMID:2808364); GO_0020037 (EC: IDA); GO_0021766 (EC: IEA); GO_0030325 (EC: IEA); GO_0030424 (EC: IEA); GO_0030728 (EC: IEA); GO_0031667 (EC: IEA); GO_0032526 (EC: IEA); GO_0033327 (EC: IEA); GO_0034097 (EC: IEA); GO_0042446 (EC: IDA); GO_0042448 (EC: IDA); GO_0042493 (EC: IEA); GO_0043025 (EC: IEA); GO_0044281 (EC: TAS); GO_0047442 (EC: IEA); GO_0048545 (EC: IEA); GO_0051591 (EC: IEA); GO_0051597 (EC: IEA); GO_0060992 (EC: IEA); GO_0071222 (EC: IEA); GO_0071236 (EC: IEA); GO_0071371 (EC: IEA); GO_0090031 (EC: IEA)",,,,,,,,,PMID:1347802; 1478654; 1515452; 1577471; 1621662; 1665206; 1714904; 1740503; 1964490; 2335573; 2466376; 2786493; 2808364; 2843762; 3025870; 3274893; 3488328; 3500022; 6976525; 7629254; 8027220; 8245018; 8345056; 8396144; 8550762; 8675607; 8855840; 9177409; 9326943; 9360545; 9435441; 9601054; 9888582; 10406467; 10720067; 11036113; 11059764; 11094312; 11142420; 11145739; 11212283; 11221867; 11232039; 11248649; 11303586; 11341336; 11358812; 11379008; 11440959; 11470993; 11535545; 11549685; 11571725; 11668516; 11749050; 11834432; 11836339; 11839369; 11847524; 11867265; 11880540; 11888844; 11895872; 11897684; 11911969; 11925378; 11956159; 12036913; 12036914; 12164325; 12368392; 12370109; 12385014; 12444089; 12446594; 12464252; 12466376; 12477932; 12506119; 12517592; 12530262; 12530647; 12530662; 12530676; 12574216; 12582021; 12584742; 12602902; 12631293; 12631398; 12644832; 12645864; 12652520; 12692107; 12718576; 12719950; 12949806; 12954495; 12971967; 14504283; 14512432; 14552332; 14552333; 14561815; 14575568; 14634838; 14644808; 14665706; 14671162; 14684846; 14693733; 14702039; 14714492; 14715870; 14744739; 14985252; 14995917; 15072828; 15128046; 15129369; 15164054; 15195127; 15199113; 15235815; 15241822; 15341023; 15364798; 15372520; 15382051; 15466495; 15477877; 15482786; 15489334; 15536258; 15538743; 15539439; 15555906; 15583024; 15591802; 15598676; 15604994; 15609124; 15654505; 15663233; 15686129; 15687493; 15706422; 15711606; 15749482; 15761247; 15774541; 15799583; 15823822; 15824149; 15865082; 15878919; 15886251; 15916684; 15927351; 15941966; 15953542; 15987450; 15987458; 15999490; 16045239; 16202920; 16214922; 16232327; 16244490; 16260521; 16280037; 16306078; 16319265; 16344560; 16354159; 16381022; 16385451; 16411751; 16424004; 16515644; 16519145; 16527884; 16595228; 16595705; 16603433; 16604478; 16608396; 16616104; 16638864; 16702327; 16707883; 16716118; 16720291; 16730930; 16739881; 16782804; 16783967; 16850246; 16859836; 16875543; 16885156; 16887917; 16890174; 16896040; 16909599; 16969494; 16971197; 16977255; 17077994; 17108148; 17110639; 17119038; 17167982; 17218734; 17235448; 17307805; 17328668; 17359589; 17386955; 17484509; 17507624; 17588204; 17589376; 17606708; 17615053; 17664281; 17669147; 17704407; 17760252; 17765230; 17785571; 17786540; 17826473; 17875358; 17895316; 17961073; 17975119; 17986287; 18000308; 18006912; 18163429; 18172694; 18184656; 18187541; 18262808; 18281250; 18299473; 18305346; 18318428; 18411914; 18415690; 18422032; 18437511; 18483327; 18491956; 18495332; 18496127; 18499961; 18501301; 18503826; 18505908; 18510611; 18560445; 18593984; 18601603; 18618215; 18619494; 18629629; 18636124; 18636181; 18645709; 18676680; 18682255; 18707589; 18722876; 18725155; 18767927; 18781485; 18820009; 18930188; 18957719; 18980759; 19013303; 19015200; 19023099; 19064572; 19064581; 19127255; 19170196; 19174490; 19267349; 19330259; 19336370; 19379515; 19387820; 19415745; 19430479; 19430483; 19443382; 19453261; 19454579; 19469636; 19505920; 19508587; 19574343; 19598235; 19625176; 19627379; 19636199; 19642097; 19672705; 19692168; 19789190; 19805543; 19850690; 19863350; 19913121; 19915575; 19954068; 19956635; 20013047; 20033766; 20043206; 20043997; 20069306; 20072949; 20086173; 20099974; 20113968; 20133979; 20171624; 20173016; 20184498; 20193327; 20197673; 20200332; 20207836; 20214802; 20379614; 20381444; 20414254; 20432167; 20453000; 20479155; 20503394; 20534731; 20539301; 20595043; 20619364; 20628086; 20628746; 20634197; 20650774; 20677014; 20716560; 20720262; 20728566; 20729390; 20729792; 20734064; 20798986; 20852445; 20884100; 20886547; 21045733; 21094112; 21193363; 21300759; 21307141; 21338212; 21378990; 21420394; 21511288; 21572416; 21644229; 21656827; 21676446; 21848792; 21868758; 21896988; 21909110; 21909115; 21919858; 21948762; 21963141; 21966534; 21988832; 22001566; 22048715; 22057025; 22066265; 22071413; 22072737; 22103881; 22174412; 22217842; 22237020; 22238371; 22266943; 22309630; 22331461; 22419734; 22434081; 22456087; 22528335; 22653668; 22714708; 22873692; 22951291; 22954317; 22959498; 23015357; 23036723; 23129512; 23133444; 23229009; 23257735; 23291414; 23350368; 23467202; 23535732; 23551929; 23586722; 23609033; 23620596; 23649771; 23775394; 23809139; 23836902; 23974872; 24001895; 24140098; 24140493,,,,,,,,,,,,,,,OGG:3000001586,,,,,,,"cytochrome P450, family 17, subfamily A, polypeptide 1",,,,,,,,,,,,,"Other designations: 17-alpha-hydroxyprogesterone aldolase|CYPXVII|cytochrome P450 17A1|cytochrome P450, subfamily XVII (steroid 17-alpha-hydroxylase), adrenal hyperplasia|cytochrome P450-C17|cytochrome P450c17|cytochrome p450 XVIIA1|steroid 17-alpha-hydroxylase/17,20 lyase|steroid 17-alpha-monooxygenase",,CYP17A1,,,,,,,,,,,,,,,,,,,,,,,1586,RP11-753C18.1,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP17A1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001580,CYP4B1,,"Other designations: cytochrome P450 4B1|cytochrome P450, subfamily IVB, polypeptide 1|cytochrome P450-HP|microsomal monooxygenase",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,P-450HP|CYPIVB1,,,,,,,,,,,,1,,,,,,MIM:124075|Vega:OTTHUMG00000007984|HPRD:00491|HGNC:2644|Ensembl:ENSG00000142973,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 4, subfamily B, polypeptide 1",,,1p33,,,,,,,,,,,,,,,,"GO_0005506 (EC: IEA); GO_0005789 (EC: TAS); GO_0006805 (EC: TAS); GO_0008144 (EC: IEA); GO_0018585 (EC: IEA); GO_0018879 (EC: IEA); GO_0018917 (EC: IEA); GO_0019825 (EC: TAS, PMID:2574990); GO_0020037 (EC: IEA); GO_0042738 (EC: IEA); GO_0044281 (EC: TAS); GO_0070330 (EC: IEA)",,,,,,,,,PMID:2298205; 2574990; 7894498; 8125298; 8313365; 8694864; 8889548; 9202751; 9364212; 9493761; 9498238; 10768437; 11062028; 11669629; 11737226; 11767004; 12142726; 12477932; 12837283; 15006160; 15128046; 15499177; 16344560; 18660489; 18713828; 19040121; 19074885; 19343046; 19898482; 19913121; 20379614; 20628086; 22675492,,,,,,,,,,,,,,,OGG:3000001580,,,,,,,"cytochrome P450, family 4, subfamily B, polypeptide 1",,,,,,,,,,,,,"Other designations: cytochrome P450 4B1|cytochrome P450, subfamily IVB, polypeptide 1|cytochrome P450-HP|microsomal monooxygenase",,CYP4B1,,,,,,,,,,,,,,,,,,,,,,,1580,RP4-732G19.1,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP4B1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001588,CYP19A1,,"Other designations: aromatase|cytochrome P-450AROM|cytochrome P450 19A1|cytochrome P450, subfamily XIX (aromatization of androgens)|estrogen synthase|estrogen synthetase|flavoprotein-linked monooxygenase|microsomal monooxygenase",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CYP19|P-450AROM|ARO1|CPV1|CYPXIX|CYAR|ARO,,,,,,,,,,,,15,,,,,,Vega:OTTHUMG00000131747|HPRD:00488|HGNC:2594|MIM:107910|Ensembl:ENSG00000137869,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 19, subfamily A, polypeptide 1",,,15q21.1,,,,,,,,,,,,,,,,"GO_0005506 (EC: IEA); GO_0005783 (EC: IDA); GO_0005789 (EC: TAS); GO_0006694 (EC: TAS, PMID:2848247); GO_0006703 (EC: TAS); GO_0006805 (EC: TAS); GO_0008202 (EC: TAS); GO_0008209 (EC: IEA); GO_0009055 (EC: TAS, PMID:2848247); GO_0016020 (EC: TAS, PMID:2848247); GO_0016125 (EC: TAS); GO_0016712 (EC: TAS, PMID:1371509); GO_0019825 (EC: TAS, PMID:2848247); GO_0020037 (EC: IDA, PMID:19129847); GO_0044281 (EC: TAS); GO_0060736 (EC: IEA); GO_0070330 (EC: IDA, PMID:19129847)",,,,,,,,,PMID:1371509; 1472013; 1724289; 1825497; 2040633; 2171939; 2541021; 2691883; 2808431; 2848247; 2973313; 3018730; 3390233; 3653507; 3964273; 7690033; 8090165; 8117272; 8265607; 8477708; 8530621; 9177373; 9211678; 9696881; 10566648; 10837748; 11076863; 11140838; 11181459; 11216915; 11232039; 11256614; 11344237; 11469726; 11571725; 11595700; 11756225; 11826265; 11850203; 11850205; 11850206; 11850208; 11850209; 11850210; 11850219; 11850220; 11850221; 11850222; 11850224; 11850225; 11850230; 11850233; 11850235; 11897504; 11903314; 11904449; 11925378; 11927588; 11935306; 11997208; 12036913; 12053085; 12154211; 12160997; 12161013; 12161505; 12164325; 12204674; 12213901; 12351690; 12370109; 12385014; 12428207; 12451990; 12462076; 12462077; 12466340; 12477932; 12489562; 12517592; 12592380; 12602902; 12606587; 12618873; 12620480; 12639945; 12690088; 12705475; 12720534; 12734209; 12736278; 12759877; 12768436; 12788892; 12839940; 12843146; 12846271; 12864794; 12914527; 12917334; 12944421; 14508827; 14517714; 14580722; 14593077; 14602139; 14631363; 14634838; 14714492; 14715870; 14744739; 14747179; 14973387; 14981949; 14990865; 15046111; 15072827; 15072828; 15074077; 15079018; 15083376; 15083377; 15083380; 15083381; 15126575; 15128046; 15132727; 15177662; 15181061; 15183689; 15199113; 15207764; 15229337; 15241822; 15298966; 15319333; 15330195; 15358790; 15364411; 15449726; 15489336; 15582747; 15583024; 15613678; 15640252; 15668497; 15677755; 15688015; 15695318; 15748828; 15774541; 15788666; 15794932; 15800924; 15802318; 15840311; 15862960; 15862961; 15862962; 15955695; 16019206; 16020944; 16024248; 16039845; 16045239; 16086586; 16103457; 16128984; 16146740; 16199862; 16202920; 16213843; 16232327; 16244490; 16251630; 16251760; 16260521; 16269961; 16287071; 16302261; 16303757; 16306085; 16322405; 16344016; 16344560; 16381901; 16392624; 16395678; 16402077; 16406421; 16418790; 16424004; 16426763; 16467490; 16473000; 16498360; 16498361; 16498363; 16498364; 16541304; 16556483; 16566930; 16595205; 16604491; 16608396; 16621515; 16634644; 16641167; 16648498; 16684355; 16691199; 16723309; 16730930; 16733710; 16739881; 16741831; 16767510; 16782804; 16793950; 16798289; 16850246; 16875543; 16882736; 16894362; 16895991; 16896040; 16930994; 16949385; 16949391; 16964243; 16977255; 16997132; 17004113; 17065579; 17066438; 17118999; 17119036; 17158756; 17167982; 17176215; 17187946; 17216495; 17219197; 17325027; 17331471; 17336977; 17359589; 17372263; 17391072; 17400043; 17404019; 17405842; 17415442; 17482958; 17507620; 17507624; 17517397; 17562079; 17574328; 17584767; 17588204; 17589376; 17595315; 17615053; 17646720; 17657731; 17661084; 17662285; 17678915; 17681675; 17682677; 17687621; 17704407; 17766065; 17827443; 17893373; 17953943; 17962916; 17975727; 17979523; 17989043; 17989068; 18030614; 18048499; 18049890; 18083712; 18086758; 18157729; 18159088; 18163429; 18181018; 18182446; 18199708; 18201819; 18245543; 18274619; 18281655; 18299793; 18305346; 18426832; 18437511; 18445666; 18467089; 18483177; 18483761; 18491956; 18497059; 18501301; 18505907; 18510611; 18512790; 18559914; 18568448; 18593984; 18595017; 18601603; 18614276; 18614591; 18617186; 18622258; 18629629; 18636124; 18667686; 18676680; 18767927; 18817841; 18818748; 18820009; 18822378; 18847535; 18930188; 18941892; 18941913; 18955734; 18962445; 18980759; 19015200; 19019335; 19022561; 19064562; 19064572; 19064581; 19083124; 19093296; 19107851; 19116238; 19124504; 19124506; 19129847; 19137777; 19152063; 19158807; 19159688; 19170196; 19172223; 19174490; 19185610; 19194457; 19240151; 19282383; 19299445; 19324338; 19340622; 19366906; 19389254; 19415745; 19419293; 19438456; 19445691; 19453261; 19469636; 19470632; 19478482; 19491387; 19493871; 19500729; 19505920; 19514368; 19527514; 19549443; 19551860; 19555469; 19556341; 19558171; 19570444; 19573564; 19574343; 19589174; 19591804; 19598235; 19604497; 19625176; 19630952; 19639193; 19692168; 19776291; 19782135; 19789370; 19800002; 19800101; 19805543; 19808095; 19815003; 19818337; 19879925; 19883757; 19896534; 19906189; 19906814; 19913121; 19921206; 19933466; 19952760; 19956635; 19969081; 20004389; 20015405; 20026603; 20030115; 20048079; 20052540; 20053928; 20060879; 20064870; 20072949; 20133979; 20140262; 20144226; 20148360; 20164038; 20164294; 20173016; 20184498; 20186154; 20189936; 20193327; 20200332; 20211687; 20214802; 20231365; 20300828; 20305046; 20346360; 20351196; 20381444; 20385561; 20417295; 20430378; 20432167; 20453000; 20505544; 20526739; 20539301; 20546829; 20586553; 20588246; 20588308; 20628086; 20628746; 20634197; 20655525; 20668023; 20688833; 20716560; 20729390; 20734064; 20797716; 20819792; 20881004; 20881960; 20932310; 20937744; 20960227; 21125383; 21154336; 21170323; 21188138; 21198743; 21217768; 21251330; 21269619; 21282199; 21296134; 21300759; 21319151; 21319995; 21320735; 21356374; 21377485; 21392518; 21392519; 21392520; 21414724; 21479914; 21511357; 21622727; 21676395; 21757507; 21771722; 21807013; 21939764; 21948762; 21952832; 21972004; 22057025; 22079757; 22089263; 22104650; 22106445; 22119029; 22130322; 22160249; 22185650; 22217837; 22237979; 22300440; 22315456; 22320986; 22331461; 22335023; 22384274; 22407818; 22426781; 22448795; 22492871; 22508516; 22511967; 22578533; 22633539; 22634420; 22638611; 22675492; 22731640; 22759564; 22773874; 22843875; 22848710; 22887836; 22889864; 22902617; 22915343; 22982181; 23001776; 23029457; 23085504; 23090135; 23110082; 23116507; 23122578; 23129173; 23178495; 23229009; 23239821; 23253631; 23340254; 23342035; 23350368; 23400010; 23438603; 23456168; 23461365; 23518928; 23540392; 23584792; 23599027; 23625281; 23635391; 23643682; 23661022; 23669293; 23700878; 23727336; 23729401; 23747729; 23748068; 23809139; 23846226; 23873111; 24049095,,,,,,,,,,,,,,,OGG:3000001588,,,,,,,"cytochrome P450, family 19, subfamily A, polypeptide 1",,,,,,,,,,,,,"Other designations: aromatase|cytochrome P-450AROM|cytochrome P450 19A1|cytochrome P450, subfamily XIX (aromatization of androgens)|estrogen synthase|estrogen synthetase|flavoprotein-linked monooxygenase|microsomal monooxygenase",,CYP19A1,,,,,,,,,,,,,,,,,,,,,,,1588,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP19A1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001581,CYP7A1,,"Other designations: cholesterol 7-alpha-hydroxylase|cholesterol 7-alpha-monooxygenase|cytochrome P450 7A1|cytochrome P450, subfamily VIIA polypeptide 1",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CYP7|CYPVII|CP7A,,,,,,,,,,,,8,,,,,,MIM:118455|Ensembl:ENSG00000167910|HPRD:00324|HGNC:2651|Vega:OTTHUMG00000164301,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 7, subfamily A, polypeptide 1",,,8q11-q12,,,,,,,,,,,,,,,,"GO_0005506 (EC: IEA); GO_0005789 (EC: TAS); GO_0006699 (EC: IDA, PMID:19965590); GO_0006699 (EC: IEA); GO_0006699 (EC: ISS); GO_0006699 (EC: TAS); GO_0006707 (EC: ISS); GO_0006805 (EC: TAS); GO_0008123 (EC: ISS); GO_0008206 (EC: TAS); GO_0016125 (EC: TAS); GO_0020037 (EC: IEA); GO_0042632 (EC: ISS); GO_0043231 (EC: ISS); GO_0044255 (EC: TAS); GO_0044281 (EC: TAS); GO_0070857 (EC: IDA, PMID:19965590); GO_0070857 (EC: ISS); GO_0071333 (EC: IDA, PMID:19965590); GO_0071397 (EC: ISS)",,,,,,,,,PMID:1312351; 1358792; 1610352; 2384150; 7288293; 8020987; 8439551; 8504159; 9559267; 10359768; 10882719; 11257258; 11907135; 12011083; 12093884; 12093894; 12116231; 12202481; 12213890; 12477932; 12554795; 12721789; 12810154; 12815072; 12865425; 14515446; 14522988; 14592954; 14762172; 15128046; 15133863; 15205472; 15241483; 15262185; 15333704; 15489334; 15640003; 15707388; 15736936; 15752749; 15796896; 15805302; 15910869; 16115473; 16630139; 16709249; 16763159; 16892178; 16917677; 16937432; 17680536; 17920062; 18078817; 18178499; 18270374; 18307386; 18385139; 18660489; 18665040; 18728123; 18728290; 18996102; 19018779; 19185005; 19343046; 19448895; 19463968; 19537927; 19558216; 19598235; 19850125; 19956635; 19965590; 20005541; 20031551; 20235787; 20351063; 20403997; 20578904; 20602615; 20686565; 20717043; 20857261; 20872969; 20884100; 21039385; 21147774; 21346769; 21813643; 21902813; 22058145; 22235657; 22607622; 22713451; 23038264; 23458092; 23626788,,,,,,,,,,,,,,,OGG:3000001581,,,,,,,"cytochrome P450, family 7, subfamily A, polypeptide 1",,,,,,,,,,,,,"Other designations: cholesterol 7-alpha-hydroxylase|cholesterol 7-alpha-monooxygenase|cytochrome P450 7A1|cytochrome P450, subfamily VIIA polypeptide 1",,CYP7A1,,,,,,,,,,,,,,,,,,,,,,,1581,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP7A1,,
http://purl.obolibrary.org/obo/OGG_3000001584,CYP11B1,,"Other designations: CYPXIB1|cytochrome P-450c11|cytochrome P450 11B1, mitochondrial|cytochrome P450, subfamily XIB (steroid 11-beta-hydroxylase), polypeptide 1|cytochrome P450C11|cytochrome p450 XIB1|steroid 11-beta-hydroxylase|steroid 11-beta-monooxygenase",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CPN1|P450C11|CYP11B|FHI,,,,,,,,,,,,8,,,,,,HGNC:2591|MIM:610613|Ensembl:ENSG00000160882|HPRD:01943|Vega:OTTHUMG00000164637,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 11, subfamily B, polypeptide 1",,,8q21,,,,,,,,,,,,,,,,"GO_0004507 (EC: IDA, PMID:2256920); GO_0004507 (EC: IMP, PMID:2022736); GO_0005506 (EC: IEA); GO_0005739 (EC: IDA, PMID:2256920); GO_0005743 (EC: IC, PMID:8506298); GO_0005743 (EC: TAS, PMID:15026188); GO_0006700 (EC: IDA, PMID:2256920); GO_0006704 (EC: TAS); GO_0006705 (EC: TAS); GO_0006805 (EC: TAS); GO_0006955 (EC: TAS, PMID:12452430); GO_0008202 (EC: TAS); GO_0008217 (EC: IMP, PMID:2022736); GO_0016125 (EC: TAS); GO_0020037 (EC: IC, PMID:2256920); GO_0032342 (EC: IDA, PMID:2256920); GO_0032342 (EC: IMP, PMID:19342457); GO_0032870 (EC: IEP, PMID:19342457); GO_0034651 (EC: IDA, PMID:8506298); GO_0034651 (EC: IMP, PMID:19342457); GO_0035865 (EC: IEP, PMID:19342457); GO_0042593 (EC: TAS, PMID:16114325); GO_0044281 (EC: TAS)",,,,,,,,,PMID:1303253; 1430088; 1518866; 1741400; 2022736; 2256920; 2401360; 2592361; 3499608; 7903314; 8372604; 8506298; 9302260; 10391209; 10391210; 10411633; 10599751; 11095433; 11549669; 11549691; 11675945; 11903322; 11932209; 12452430; 12477932; 14682466; 14702039; 15026188; 15062555; 15128046; 15324322; 15507509; 15522937; 15583024; 15699546; 15751602; 15755848; 15793791; 16030166; 16110193; 16114325; 16396990; 16984984; 17075029; 17121536; 17296872; 17556864; 17651452; 17980006; 18215163; 18294861; 18397978; 18636124; 18661760; 18663314; 18974272; 19082699; 19336370; 19342457; 19453261; 19567537; 19598235; 19820005; 19844114; 19913121; 20089618; 20214802; 20331679; 20339375; 20486282; 20523022; 20529578; 20628086; 20634641; 20708777; 20808686; 20877624; 20947076; 21164264; 21625068; 21848792; 22083159; 22217843; 22921894; 22964742; 23146819; 23150505; 23345044; 23825130,,,,,,,,,,,,,,,OGG:3000001584,,,,,,,"cytochrome P450, family 11, subfamily B, polypeptide 1",,,,,,,,,,,,,"Other designations: CYPXIB1|cytochrome P-450c11|cytochrome P450 11B1, mitochondrial|cytochrome P450, subfamily XIB (steroid 11-beta-hydroxylase), polypeptide 1|cytochrome P450C11|cytochrome p450 XIB1|steroid 11-beta-hydroxylase|steroid 11-beta-monooxygenase",,CYP11B1,,,,,,,,,,,,,,,,,,,,,,,1584,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP11B1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001585,CYP11B2,,"Other designations: aldosterone synthase|aldosterone-synthesizing enzyme|cytochrome P-450Aldo|cytochrome P-450C18|cytochrome P450 11B2, mitochondrial|cytochrome P450, subfamily XIB (steroid 11-beta-hydroxylase), polypeptide 2|mitochondrial cytochrome P450, family 11, subfamily B, polypeptide 2|steroid 11-beta-monooxygenase|steroid 11-beta/18-hydroxylase|steroid 18-hydroxylase, aldosterone synthase, P450C18, P450aldo",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,ALDOS|CYP11BL|CYPXIB2|CYP11B|P-450C18|CPN2|P450C18|P450aldo,,,,,,,,,,,,8,,,,,,HPRD:00492|Ensembl:ENSG00000179142|Vega:OTTHUMG00000160254|MIM:124080|HGNC:2592,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 11, subfamily B, polypeptide 2",,,8q21-q22,,,,,,,,,,,,,,,,"GO_0002017 (EC: IMP, PMID:14614232); GO_0003091 (EC: IC, PMID:2256920); GO_0004507 (EC: IDA, PMID:1741400); GO_0005506 (EC: IEA); GO_0005739 (EC: IDA, PMID:1741400); GO_0005743 (EC: IC, PMID:2256920); GO_0005743 (EC: TAS); GO_0006700 (EC: IDA, PMID:2256920); GO_0006705 (EC: TAS); GO_0006805 (EC: TAS); GO_0008202 (EC: TAS); GO_0016125 (EC: TAS); GO_0020037 (EC: IC, PMID:2256920); GO_0020037 (EC: IDA); GO_0032342 (EC: IDA, PMID:1741400); GO_0032342 (EC: IMP, PMID:19342457); GO_0032870 (EC: IEP, PMID:19342457); GO_0034651 (EC: IMP, PMID:19342457); GO_0034651 (EC: IMP, Qualifier: NOT, PMID:9703385); GO_0035865 (EC: IEP, PMID:19342457); GO_0044281 (EC: TAS); GO_0047783 (EC: IEA); GO_0055075 (EC: IMP, PMID:9838244); GO_0055078 (EC: IMP, PMID:9838244)",,,,,,,,,PMID:1303253; 1346492; 1518866; 1594605; 1741400; 1775135; 2256920; 2592361; 3872685; 7792802; 8372604; 8439335; 8954040; 9177280; 9360501; 9506770; 9625333; 9703385; 9814506; 9838244; 9931115; 10371693; 10391209; 10391210; 10411633; 10902803; 11076863; 11116113; 11238478; 11245725; 11288810; 11325068; 11422106; 11422735; 11447495; 11518842; 11587161; 11696658; 11696688; 11711521; 11711524; 11725161; 11728005; 11728946; 11841224; 11856349; 11903322; 11910301; 11923700; 11932209; 11967817; 12022239; 12031704; 12065207; 12107246; 12133420; 12137808; 12161536; 12172317; 12193581; 12195120; 12205735; 12213905; 12376254; 12391843; 12444540; 12446192; 12446468; 12477932; 12544440; 12544508; 12611423; 12624609; 12627873; 12746403; 12783697; 12788845; 12788848; 12817181; 12832734; 14508191; 14530292; 14614232; 14643573; 14704730; 14736447; 15055249; 15062555; 15097233; 15102677; 15128046; 15135254; 15223724; 15230231; 15238568; 15272911; 15361760; 15378162; 15479186; 15505931; 15507509; 15522937; 15532370; 15545843; 15569322; 15573760; 15583024; 15583997; 15600184; 15611122; 15614025; 15643128; 15662219; 15699546; 15824464; 15882548; 15894890; 15894891; 15914614; 16078594; 16080804; 16080805; 16110193; 16126185; 16207322; 16208140; 16303227; 16396990; 16468060; 16485730; 16580565; 16615274; 16638864; 16672053; 16714246; 16759311; 16765146; 16767667; 16780672; 16796847; 16893516; 16979018; 16984984; 17003099; 17075029; 17143166; 17190732; 17261471; 17273158; 17296872; 17318792; 17334527; 17334644; 17383306; 17407071; 17519002; 17531119; 17546276; 17631084; 17633457; 17651452; 17664852; 17698557; 17762647; 17851694; 17980006; 17984617; 17987391; 18192839; 18202594; 18260840; 18260994; 18397978; 18413308; 18446309; 18636124; 18638595; 18660489; 18710464; 18771471; 18773126; 18855530; 18856058; 18974272; 19026620; 19093739; 19112833; 19116236; 19117407; 19151144; 19158234; 19166692; 19243623; 19253715; 19254215; 19262476; 19332265; 19342457; 19343046; 19407459; 19418629; 19609286; 19729965; 19776632; 19779464; 19786005; 19820005; 19853701; 19913121; 19948975; 19956635; 20094057; 20097716; 20123934; 20176774; 20182453; 20193236; 20193392; 20214802; 20224556; 20300066; 20339375; 20381197; 20413672; 20416077; 20486282; 20494601; 20535141; 20537417; 20560800; 20598712; 20628086; 20634641; 20659024; 20662731; 20708777; 20808686; 20831027; 20877624; 20878543; 20966514; 21092623; 21106862; 21125974; 21127960; 21163122; 21164264; 21228735; 21239432; 21269059; 21357309; 21476902; 21625068; 21682760; 21777344; 21846681; 22083159; 22134143; 22156739; 22217843; 22311496; 22331364; 22508051; 22652909; 22801770; 22885098; 23023242; 23133610; 23135028; 23150505; 23209837; 23257735; 23275203; 23322723; 23443813; 23479071; 23535359; 23701507; 23936266; 24015270,,,,,,,,,,,,,,,OGG:3000001585,,,,,,,"cytochrome P450, family 11, subfamily B, polypeptide 2",,,,,,,,,,,,,"Other designations: aldosterone synthase|aldosterone-synthesizing enzyme|cytochrome P-450Aldo|cytochrome P-450C18|cytochrome P450 11B2, mitochondrial|cytochrome P450, subfamily XIB (steroid 11-beta-hydroxylase), polypeptide 2|mitochondrial cytochrome P450, family 11, subfamily B, polypeptide 2|steroid 11-beta-monooxygenase|steroid 11-beta/18-hydroxylase|steroid 18-hydroxylase, aldosterone synthase, P450C18, P450aldo",,CYP11B2,,,,,,,,,,,,,,,,,,,,,,,1585,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP11B2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001589,CYP21A2,,"Other designations: 21-OHase|cytochrome P450 XXI|cytochrome P450, subfamily XXIA (steroid 21-hydroxylase, congenital adrenal hyperplasia), polypeptide 2|cytochrome P450-C21B|steroid 21-hydroxylase|steroid 21-monooxygenase",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CA21H|CYP21|CYP21B|CAH1|CPS1|P450c21B,,,,,,,,,,,,6,,,,,,Vega:OTTHUMG00000031069|MIM:613815|HGNC:2600|HPRD:01942|Ensembl:ENSG00000231852,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 21, subfamily A, polypeptide 2",,,6p21.3,,,,,,,,,,,,,,,,"GO_0004509 (EC: IEA); GO_0005496 (EC: IEA); GO_0005506 (EC: IEA); GO_0005789 (EC: TAS); GO_0006704 (EC: TAS); GO_0006705 (EC: TAS); GO_0006805 (EC: TAS); GO_0008202 (EC: TAS); GO_0008395 (EC: TAS, PMID:1406709); GO_0016125 (EC: TAS); GO_0020037 (EC: IEA); GO_0044281 (EC: TAS)",,,,,,,,,PMID:1351548; 1406699; 1406709; 1496017; 1605859; 1644925; 1864962; 1937474; 1985465; 2072928; 2249999; 2303461; 2325662; 2788081; 2827462; 2845408; 3038528; 3137812; 3257825; 3260007; 3260033; 3267225; 3486422; 3487786; 3497399; 3500473; 3871526; 5804199; 7096533; 7629224; 7635470; 7749410; 8081391; 8175971; 8372604; 8478006; 8485582; 8518786; 8675607; 8731325; 8968761; 8989258; 9067760; 9099896; 9187661; 9215318; 9497336; 9580109; 9661649; 10051010; 10072631; 10094562; 10198222; 10207042; 10229037; 10343159; 10364682; 10391209; 10408778; 10408786; 10443693; 10496074; 10720040; 11073721; 11093272; 11232002; 11287026; 11457572; 11581476; 11598371; 11600539; 11692155; 11739456; 11746135; 11836313; 12028996; 12038604; 12050231; 12050257; 12121677; 12213672; 12213891; 12220458; 12222711; 12370110; 12384784; 12464252; 12477932; 12746407; 12788866; 12788880; 12788889; 12855227; 12876419; 12887291; 12915679; 12966197; 14502362; 14514162; 14671153; 14676460; 14676461; 14702039; 14715874; 14733808; 15004406; 15027205; 15028279; 15110320; 15126570; 15128046; 15342556; 15493145; 15572419; 15583024; 15598692; 15608154; 15627780; 15705377; 15751603; 15761541; 15775714; 15793784; 15818055; 15830218; 15858147; 15988383; 16046588; 16238926; 16344560; 16427797; 16487445; 16500637; 16541276; 16648810; 16712666; 16728546; 16788163; 16984992; 17033937; 17047018; 17119906; 17275379; 17466088; 17505149; 17526939; 17551464; 17573904; 17666484; 17803691; 17878254; 18028896; 18039588; 18042312; 18179706; 18204270; 18319307; 18381579; 18392095; 18397975; 18445671; 18478071; 18505908; 18589890; 18636124; 18702679; 18787377; 18825878; 18973462; 19039234; 19058224; 19062540; 19085698; 19116923; 19135723; 19137635; 19158234; 19201236; 19208730; 19226270; 19272182; 19347184; 19420818; 19423540; 19449670; 19453261; 19501079; 19505723; 19531083; 19598235; 19624807; 19773403; 19799922; 19844122; 19856253; 19890026; 19925038; 19930153; 20029944; 20059433; 20070950; 20080860; 20110635; 20132843; 20201644; 20233785; 20301350; 20406964; 20423741; 20438785; 20587039; 20587610; 20617557; 20661889; 20671415; 20818501; 20838032; 20926536; 20970527; 21117955; 21134444; 21164261; 21164262; 21169732; 21175091; 21198393; 21264314; 21274396; 21446712; 21521936; 21534945; 21570420; 21609351; 21646284; 21750395; 21912141; 22001566; 22014889; 22017335; 22020670; 22127631; 22217838; 22308849; 22313422; 22497080; 22561756; 22802425; 22841790; 22873692; 22885098; 22886582; 23027774; 23044877; 23045419; 23073904; 23142378; 23155693; 23211577; 23298233; 23313747; 23322511; 23329749; 23342490; 23359706; 23370425; 23376085; 23386413; 23535732; 23586722; 23692712,,,,,,,,,,,,,,,OGG:3000001589,,,,,,,"cytochrome P450, family 21, subfamily A, polypeptide 2",,,,,,,,,,,,,"Other designations: 21-OHase|cytochrome P450 XXI|cytochrome P450, subfamily XXIA (steroid 21-hydroxylase, congenital adrenal hyperplasia), polypeptide 2|cytochrome P450-C21B|steroid 21-hydroxylase|steroid 21-monooxygenase",,CYP21A2,,,,,,,,,,,,,,,,,,,,,,,1589,DADB-112B14.10-001,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP21A2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001583,CYP11A1,,"Other designations: cholesterol 20-22 desmolase|cholesterol monooxygenase (side-chain cleaving)|cholesterol side-chain cleavage enzyme, mitochondrial|cytochrome P450 11A1|cytochrome P450(scc)|cytochrome P450, subfamily XIA (cholesterol side chain cleavage)|cytochrome P450C11A1|steroid 20-22-lyase",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CYPXIA1|P450SCC|CYP11A,,,,,,,,,,,,15,,,,,,Ensembl:ENSG00000140459|MIM:118485|Vega:OTTHUMG00000150716|HGNC:2590|HPRD:00326,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 11, subfamily A, polypeptide 1",,,15q23-q24,,,,,,,,,,,,,,,,"GO_0005506 (EC: IEA); GO_0005739 (EC: ISS); GO_0005759 (EC: TAS); GO_0006700 (EC: IDA, PMID:11502818); GO_0006700 (EC: TAS); GO_0006701 (EC: IEA); GO_0006703 (EC: IEA); GO_0006805 (EC: TAS); GO_0007617 (EC: IEA); GO_0008202 (EC: TAS); GO_0008203 (EC: IDA); GO_0008203 (EC: IMP, PMID:18182448); GO_0008203 (EC: ISS); GO_0008386 (EC: IDA, PMID:11502818); GO_0008386 (EC: ISS); GO_0009651 (EC: IEA); GO_0010332 (EC: IEA); GO_0014037 (EC: IEA); GO_0015485 (EC: IEA); GO_0016125 (EC: TAS); GO_0017085 (EC: IEA); GO_0018879 (EC: IEA); GO_0018894 (EC: IEA); GO_0018958 (EC: IEA); GO_0018963 (EC: IEA); GO_0020037 (EC: IDA); GO_0021549 (EC: IEA); GO_0021766 (EC: IEA); GO_0030061 (EC: IEA); GO_0033197 (EC: IEA); GO_0033327 (EC: IEA); GO_0033591 (EC: IEA); GO_0033595 (EC: IEA); GO_0042359 (EC: ISS); GO_0042493 (EC: IEA); GO_0042542 (EC: IEA); GO_0043204 (EC: IEA); GO_0043279 (EC: IEA); GO_0044281 (EC: TAS); GO_0044344 (EC: IEA); GO_0050756 (EC: IEA); GO_0051412 (EC: IEA); GO_0060014 (EC: IEA); GO_0060135 (EC: IEA); GO_0060992 (EC: IEA); GO_0061370 (EC: IEA); GO_0071222 (EC: IEA); GO_0071236 (EC: IEA); GO_0071276 (EC: IEA); GO_0071320 (EC: IEA); GO_0071347 (EC: IEA); GO_0071356 (EC: IEA); GO_0071372 (EC: IEA); GO_0071375 (EC: IEA); GO_0071560 (EC: IEA)",,,,,,,,,PMID:1429635; 1849407; 1863359; 1917982; 2419119; 3024157; 3038854; 8125298; 8372604; 9029710; 9147642; 9498238; 9685215; 10391209; 10411633; 10416690; 10644752; 10856721; 11008920; 11062177; 11137199; 11238527; 11502818; 11535251; 11701663; 11864972; 11997174; 12101186; 12137805; 12145340; 12161514; 12242026; 12385014; 12477932; 12517592; 12530663; 12530676; 14644808; 14702039; 15054879; 15126571; 15128046; 15159300; 15231748; 15323426; 15471945; 15489334; 15583024; 15613430; 15793791; 15927889; 16103457; 16116976; 16172228; 16195240; 16344560; 16391898; 16409859; 16764871; 16798289; 17065579; 17110639; 17178901; 17507624; 17575134; 17594537; 17615053; 18004979; 18182448; 18191841; 18307388; 18368131; 18437511; 18483327; 18490834; 18499961; 18505908; 18665078; 18725155; 18992638; 19064571; 19116240; 19197249; 19240061; 19300392; 19336370; 19342447; 19453261; 19543524; 19574343; 19598235; 19846611; 20066577; 20199803; 20200332; 20214802; 20381444; 20450755; 20634197; 20734064; 20877624; 21159840; 21164259; 21195129; 21391350; 21520051; 21557918; 21636783; 21771722; 21880796; 22199361; 22227097; 22585829; 22673022; 22699877; 22877869; 23158025; 23330251; 23337730; 23555723; 23756599,,,,,,,,,,,,,,,OGG:3000001583,,,,,,,"cytochrome P450, family 11, subfamily A, polypeptide 1",,,,,,,,,,,,,"Other designations: cholesterol 20-22 desmolase|cholesterol monooxygenase (side-chain cleaving)|cholesterol side-chain cleavage enzyme, mitochondrial|cytochrome P450 11A1|cytochrome P450(scc)|cytochrome P450, subfamily XIA (cholesterol side chain cleavage)|cytochrome P450C11A1|steroid 20-22-lyase",,CYP11A1,,,,,,,,,,,,,,,,,,,,,,,1583,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP11A1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001582,CYP8B1,,"Other designations: 7 alpha-hydroxy-4-cholesten-3-one 12-alpha-hydroxylase|7-alpha-hydroxy-4-cholesten-3-one 12-alpha-hydroxylase|7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase|CYPVIIIB1|cytochrome P450 8B1|cytochrome P450, subfamily VIIIB (sterol 12-alpha-hydroxylase), polypeptide 1|sterol 12-alpha-hydroxylase",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CYP12|CP8B,,,,,,,,,,,,3,,,,,,Ensembl:ENSG00000180432|HPRD:03705|MIM:602172|Vega:OTTHUMG00000133047|HGNC:2653,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 8, subfamily B, polypeptide 1",,,3p22.1,,,,,,,,,,,,,,,,"GO_0005506 (EC: IEA); GO_0005783 (EC: IBA); GO_0005789 (EC: TAS); GO_0006629 (EC: IBA); GO_0006699 (EC: TAS); GO_0006805 (EC: TAS); GO_0008206 (EC: TAS); GO_0008397 (EC: IBA); GO_0016021 (EC: IEA); GO_0016125 (EC: TAS); GO_0019825 (EC: TAS, PMID:10051404); GO_0020037 (EC: IBA); GO_0033778 (EC: IEA); GO_0044281 (EC: TAS)",,,,,,,,,PMID:10051404; 11535594; 12477932; 15128046; 15249218; 15489334; 15891895; 16937432; 17585019; 18660489; 19898482; 22093981; 23216301; 24226095,,,,,,,,,,,,,,,OGG:3000001582,,,,,,,"cytochrome P450, family 8, subfamily B, polypeptide 1",,,,,,,,,,,,,"Other designations: 7 alpha-hydroxy-4-cholesten-3-one 12-alpha-hydroxylase|7-alpha-hydroxy-4-cholesten-3-one 12-alpha-hydroxylase|7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase|CYPVIIIB1|cytochrome P450 8B1|cytochrome P450, subfamily VIIIB (sterol 12-alpha-hydroxylase), polypeptide 1|sterol 12-alpha-hydroxylase",,CYP8B1,,,,,,,,,,,,,,,,,,,,,,,1582,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP8B1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000023581,CASP14,,"Other designations: CASP-14|apoptosis-related cysteine protease|caspase 14, apoptosis-related cysteine protease|caspase-14",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,19,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"caspase 14, apoptosis-related cysteine peptidase",,,19p13.1,,,,,,,,,,,,,,,,"GO_0004197 (EC: IBA); GO_0005634 (EC: IEA); GO_0005737 (EC: IBA); GO_0008544 (EC: TAS, PMID:10203698); GO_0008630 (EC: IBA); GO_0031424 (EC: TAS, PMID:18309324); GO_0045095 (EC: IEA); GO_0070268 (EC: TAS, PMID:18309324); GO_0097192 (EC: IBA)",,,,,,,,,PMID:1286667; 9792675; 9823333; 10203698; 11062009; 11121154; 11175259; 12181750; 12200134; 12445205; 12477932; 15331408; 15489334; 15619438; 16061209; 16061862; 16168224; 16341674; 16854378; 17207965; 17359582; 17436577; 17558860; 18309324; 18424262; 18762957; 19269008; 19414860; 19573080; 19615732; 19747408; 19773279; 19960512; 20237496; 20402676; 20533828; 20562859; 21139048; 21145461; 21539619; 21567094; 21800051; 21930782; 22354994; 22548721; 22825846; 22876114; 23349634; 23362869; 23377137; 23408445; 23580611; 23750785; 24244333,,,,,,,,,,,,,,,OGG:3000023581,,,,,,,"caspase 14, apoptosis-related cysteine peptidase",,,,,,,,,,,,,"Other designations: CASP-14|apoptosis-related cysteine protease|caspase 14, apoptosis-related cysteine protease|caspase-14",,CASP14,,,,,,,,,,,,,,,,,,,,,,,23581,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CASP14,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000007266,DNAJC7,,Other designations: TPR repeat protein 2|dnaJ homolog subfamily C member 7|tetratricopeptide repeat domain 2|tetratricopeptide repeat protein 2,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,TPR2|TTC2|DJ11|DJC7,,,,,,,,,,,,17,,,,,,MIM:601964|Ensembl:ENSG00000168259|HGNC:12392|Vega:OTTHUMG00000180862,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"DnaJ (Hsp40) homolog, subfamily C, member 7",,,17q11.2,,,,,,,,,,,,,,,,"GO_0005515 (EC: IPI); GO_0005634 (EC: IDA); GO_0005730 (EC: IDA, Qualifier: NOT); GO_0005737 (EC: IDA); GO_0005856 (EC: IEA); GO_0006457 (EC: TAS, PMID:8836031); GO_0031072 (EC: IPI, PMID:12853476); GO_0070062 (EC: IDA, PMID:19056867); GO_0070389 (EC: IDA, PMID:12853476)",,,,,,,,,PMID:8836031; 10567422; 11076863; 11147971; 11230166; 11573955; 12477932; 12853476; 15189447; 15231748; 15342556; 15489334; 15489336; 15592455; 15761153; 16381901; 17043677; 18029348; 18620420; 19056867; 19875381; 20473970; 20562859; 20661446; 20936779; 21139048; 21145461; 21890473; 21906983; 21963094; 21987572; 22118674; 22190034; 22337587; 22623428; 22863883; 22944692; 22990118; 23000965; 23261415; 23438482; 23455922,,,,,,,,,,,,,,,OGG:3000007266,,,,,,,"DnaJ (Hsp40) homolog, subfamily C, member 7",,,,,,,,,,,,,Other designations: TPR repeat protein 2|dnaJ homolog subfamily C member 7|tetratricopeptide repeat domain 2|tetratricopeptide repeat protein 2,,DNAJC7,,,,,,,,,,,,,,,,,,,,,,,7266,,,,,,,,9606,,,,,,,,,,,,,,,,,,,DNAJC7,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000000196,AHR,,Other designations: AH-receptor|ah receptor|aromatic hydrocarbon receptor|class E basic helix-loop-helix protein 76,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,bHLHe76,,,,,,,,,,,,7,,,,,,HPRD:02596|MIM:600253|HGNC:348|Ensembl:ENSG00000106546|Vega:OTTHUMG00000149967,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,aryl hydrocarbon receptor,,,7p15,,,,,,,,,,,,,,,,"GO_0000122 (EC: IEA); GO_0001568 (EC: NAS, PMID: 19538249); GO_0003677 (EC: IDA, PMID: 15681594); GO_0003677 (EC: TAS, PMID: 19538249); GO_0003700 (EC: IDA, PMID: 11782478); GO_0003705 (EC: IEA); GO_0004871 (EC: IEA); GO_0004879 (EC: IDA, PMID: 10395741); GO_0005515 (EC: IPI, PMID: 10395741); GO_0005634 (EC: IDA); GO_0005667 (EC: TAS, PMID: 19538249); GO_0005730 (EC: IDA, Qualifier: NOT); GO_0005737 (EC: IDA); GO_0006355 (EC: IDA, PMID: 10395741); GO_0006357 (EC: IDA, PMID: 15681594); GO_0006366 (EC: IDA, PMID: 10395741); GO_0006805 (EC: TAS, PMID: 19538249); GO_0006915 (EC: TAS, PMID: 12213388); GO_0006950 (EC: IDA, PMID: 7961644); GO_0007049 (EC: TAS, PMID: 12213388); GO_0008134 (EC: IPI, PMID: 9079689); GO_0009410 (EC: IDA, PMID: 7961644); GO_0010468 (EC: IDA, PMID: 15681594); GO_0030522 (EC: IDA, PMID: 10395741); GO_0030850 (EC: IEA); GO_0030888 (EC: IDA, PMID: 15681594); GO_0034752 (EC: TAS, PMID: 19538249); GO_0043565 (EC: IEA); GO_0044212 (EC: IDA, PMID: 15681594); GO_0045899 (EC: IEA); GO_0046982 (EC: TAS, PMID: 19538249); GO_0046983 (EC: TAS, PMID: 19538249); GO_0051879 (EC: IDA, PMID: 9079689)",,,,,,,,,PMID: 7488247; 7515333; 7550366; 7566098; 7628454; 7716743; 7883760; 7961644; 7961671; 8074712; 8125016; 8246913; 8384309; 8393992; 8794892; 9079689; 9083006; 9111057; 9170146; 9446600; 9704006; 9712901; 9759704; 9787404; 9837941; 9887096; 9972449; 10048154; 10395741; 10428779; 10471301; 10497241; 10620335; 10644764; 10739168; 10903152; 10986286; 10999956; 11013261; 11032419; 11114727; 11207035; 11259606; 11259609; 11259615; 11393538; 11408954; 11425848; 11505220; 11689007; 11698344; 11742002; 11756572; 11768231; 11782478; 11805098; 11835227; 11866883; 12024042; 12065584; 12139968; 12181450; 12200463; 12203118; 12213388; 12213390; 12215427; 12237327; 12477932; 12480531; 12520072; 12566446; 12586752; 12592376; 12597446; 12612060; 12637498; 12690205; 12730383; 12774124; 12837759; 12852830; 12853948; 12917420; 14550747; 14560034; 14634838; 14973392; 14978034; 14985336; 15026081; 15069065; 15123621; 15190133; 15342792; 15474075; 15489334; 15499202; 15572374; 15641800; 15681594; 15728486; 15758562; 15774926; 15837795; 15863442; 15897893; 15917307; 15964790; 16084889; 16091746; 16103451; 16109480; 16153594; 16257957; 16337337; 16403814; 16480812; 16481407; 16538170; 16582008; 16619036; 16675542; 16762319; 16891617; 16922649; 16952353; 16985026; 16985033; 17053541; 17140257; 17174437; 17200336; 17209571; 17223712; 17244640; 17311112; 17392787; 17429315; 17490615; 17498780; 17502624; 17511620; 17552871; 17559847; 17596880; 17642299; 17823287; 17823304; 17900530; 17963696; 18029348; 18037991; 18059014; 18065768; 18259752; 18302886; 18303622; 18358233; 18359762; 18433817; 18483242; 18510611; 18515748; 18524851; 18628420; 18632753; 18636124; 18676680; 18677463; 18708059; 18708364; 18818557; 18923163; 18990750; 19013013; 19018768; 19027718; 19034627; 19114668; 19138996; 19158084; 19170196; 19255421; 19333233; 19340314; 19356061; 19356098; 19358281; 19360915; 19371443; 19380484; 19390533; 19415745; 19447902; 19460354; 19463884; 19465936; 19535631; 19536146; 19538249; 19556287; 19574409; 19592671; 19625176; 19651607; 19690180; 19692168; 19726680; 19736056; 19755661; 19789301; 19815066; 19821039; 19917880; 19941898; 20000589; 20032195; 20044593; 20053997; 20064835; 20130088; 20140206; 20146706; 20171126; 20237496; 20301892; 20354149; 20395535; 20401977; 20453000; 20460431; 20511231; 20619336; 20634891; 20676092; 20709182; 20804740; 20823264; 20878756; 20973933; 21072210; 21081473; 21205295; 21262915; 21316925; 21357676; 21374063; 21441140; 21462134; 21486221; 21490707; 21600206; 21613234; 21627536; 21640702; 21689841; 21693764; 21742528; 21804081; 21828262; 21878739; 21886157; 21906983; 21963094; 21976023; 21987572; 21988832; 21996739; 22052373; 22053597; 22071320; 22123295; 22138065; 22235307; 22273977; 22296396; 22311706; 22361730; 22388733; 22486318; 22495716; 22495806; 22539616; 22553215; 22596188; 22628113; 22649193; 22728919; 22754483; 22759865; 22761424; 22840970; 22854411; 22903824; 22915253; 23022626; 23030067; 23037589; 23141164; 23208493; 23228475; 23229511; 23288144; 23317198; 23370907; 23382382; 23419638; 23430108; 23439269; 23452206; 23492908; 23528250; 23583297; 23604401; 23614276; 23614742; 23723449; 23733406; 23802610; 23831623; 23994556; 24023334; 24091107; 24106308; 24302727; 24309559; 24316275; 24355420; 24380854,,,,,,,,,,,,,,,OGG:3000000196,,,,,,,aryl hydrocarbon receptor,,,,,,,,,,,,,Other designations: AH-receptor|ah receptor|aromatic hydrocarbon receptor|class E basic helix-loop-helix protein 76,,AHR,,,,,,,,,,,,,,,,,,,,,,,196,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,AHR,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000648,Integrin beta-8,,,false,,,http://purl.obolibrary.org/obo/IMR_0000174,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000648,,,,,,,,,,,,,,,,,,,,,,Integrin beta-8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000084,IP3 receptor,"IP3R|inositol-1,4,5-triphosphate receptor",,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,GO:0008095,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002628|http://purl.obolibrary.org/obo/TXPO_0003161,,,,,"IP3R|inositol-1,4,5-triphosphate receptor",,,,,IMR:0000084,,,,,,,,,,,,,,,,,,,,,,IP3 receptor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000126410,CYP4F22,,"Other designations: cytochrome P450 4F22|cytochrome P450, family 2, subfamily E, polypeptide 2 homolog",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,INLNE|ARCI5|LI3,,,,,,,,,,,,19,,,,,,HGNC:26820|MIM:611495|Vega:OTTHUMG00000182451|Ensembl:ENSG00000171954|HPRD:08256,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 4, subfamily F, polypeptide 22",,,19p13.12,,,,,,,,,,,,,,,,GO_0004497 (EC: IEA); GO_0005506 (EC: IEA); GO_0005789 (EC: IEA); GO_0016705 (EC: IEA); GO_0020037 (EC: IEA),,,,,,,,,PMID:10712205; 10712223; 12477932; 15128046; 16344560; 16436457; 18245815; 20301593; 21540472; 21906983; 22209317,,,,,,,,,,,,,,,OGG:3000126410,,,,,,,"cytochrome P450, family 4, subfamily F, polypeptide 22",,,,,,,,,,,,,"Other designations: cytochrome P450 4F22|cytochrome P450, family 2, subfamily E, polypeptide 2 homolog",,CYP4F22,,,,,,,,,,,,,,,,,,,,,,,126410,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP4F22,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/GO_0061736,engulfment of target by autophagosome,,The membrane invagination process by which an autophagosomal membrane surrounds an object that will be degraded by macroautophagy.,false,,,http://purl.obolibrary.org/obo/GO_0010324,,,,,,,,,,,,,,,,,,,,,,The membrane invagination process by which an autophagosomal membrane surrounds an object that will be degraded by macroautophagy.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0061736,,,,,,,,,,,,,,,,,,,,,,engulfment of target by autophagosome,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000548645,DNAJC25,,Other designations: DnaJ-like protein|dnaJ homolog subfamily C member 25,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,bA16L21.2.1,,,,,,,,,,,,9,,,,,,Ensembl:ENSG00000059769|HGNC:34187|Vega:OTTHUMG00000020491|HPRD:18685,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"DnaJ (Hsp40) homolog, subfamily C , member 25",,,9q31.3,,,,,,,,,,,,,,,,GO_0016021 (EC: IEA),,,,,,,,,PMID:12477932; 14702039; 24250222,,,,,,,,,,,,,,,OGG:3000548645,,,,,,,"DnaJ (Hsp40) homolog, subfamily C , member 25",,,,,,,,,,,,,Other designations: DnaJ-like protein|dnaJ homolog subfamily C member 25,,DNAJC25,,,,,,,,,,,,,,,,,,,,,,,548645,,,,,,,,9606,,,,,,,,,,,,,,,,,,,DNAJC25,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0100775,Wnt-7b,,,false,,,http://purl.obolibrary.org/obo/IMR_0000003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100775,,,,,,,,,,,,,,,,,,,,,,Wnt-7b,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100205,RCC1,Regulator of chromosome condensation,,false,,,http://purl.obolibrary.org/obo/IMR_0000433,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Regulator of chromosome condensation,,,,,IMR:0100205,,,,,,,,,,,,,,,,,,,,,,RCC1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000345,increasing autodigestion of abnormal lysosome,,Increasing autodigestion of abnormal lysosome  is a subtype of increasing autophagy: A process that becomes larger in the number of autodigestion of abnormal lysosome.,false,,,http://purl.obolibrary.org/obo/TXPO_0000484,,,,,,,,,,,,,,,,,,,,,,Increasing autodigestion of abnormal lysosome  is a subtype of increasing autophagy: A process that becomes larger in the number of autodigestion of abnormal lysosome.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000345,,,,,,,,,,,,,,,,,,,,,,increasing autodigestion of abnormal lysosome,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000349,cleavage of ATF6-alpha by S2P [ER stress],,"Cleavage of ATF6-alpha by S2P is a subtype of proteolysis: A process  n which ATF6-alpha is cleaved by  endopeptidase S2P( MBTPS2). Site-2 cleavage comes after site-1 cleavage.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0003736|http://purl.obolibrary.org/obo/TXPO_0000046,,,,,,,,,,,,,,,,,,,,,,"Cleavage of ATF6-alpha by S2P is a subtype of proteolysis: A process  n which ATF6-alpha is cleaved by  endopeptidase S2P( MBTPS2). Site-2 cleavage comes after site-1 cleavage.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000831,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000349,,,,,,,,,,,,,,,,,,,,,,cleavage of ATF6-alpha by S2P [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000342,increasing number of dead cells in liver [ER stress],,"Increasing number of dead cells in liver is a subtype of cell proliferation: A process that becomes larger in the number of dead cells in the liver.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000341|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"Increasing number of dead cells in liver is a subtype of cell proliferation: A process that becomes larger in the number of dead cells in the liver.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002533|http://purl.obolibrary.org/obo/TXPO_0000760|http://purl.obolibrary.org/obo/TXPO_0003598,,,,,,,,,,,TXPO:0000342,,,,,,,,,,,,,,,,,,,,,,increasing number of dead cells in liver [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000347,increasing number of bile duct in liver,,Increasing number of bile duct in liver is a subtype of increasing number of objects: A process that becomes larger in the number of bile duct in the liver.,false,,,http://purl.obolibrary.org/obo/TXPO_0000093,,,,,,,,,,,,,,,,,,,,,,Increasing number of bile duct in liver is a subtype of increasing number of objects: A process that becomes larger in the number of bile duct in the liver.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000347,,,,,,,,,,,,,,,,,,,,,,increasing number of bile duct in liver,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000341,increasing number of dead cells in liver,,Increasing number of dead cells in liver is a subtype of increasing number of objects: A process that becomes larger in the number of dead cells in the liver.,false,,,http://purl.obolibrary.org/obo/TXPO_0000093,,,,,,,,,,,,,,,,,,,,,,Increasing number of dead cells in liver is a subtype of increasing number of objects: A process that becomes larger in the number of dead cells in the liver.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000341,,,,,,,,,,,,,,,,,,,,,,increasing number of dead cells in liver,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000346,hypofunction of ATP biosynthesis [cell death],,"Hypofunction of ATP biosynthesis is a subtype of hypofunction of biosynthesis: A process that performs a decreased or insufficient ATP biosynthesis.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0001727|http://purl.obolibrary.org/obo/TXPO_0001722,,,,,,,,,,,,,,,,,,,,,,"Hypofunction of ATP biosynthesis is a subtype of hypofunction of biosynthesis: A process that performs a decreased or insufficient ATP biosynthesis.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000486,,,,,,,,,,,TXPO:0000346,,,,,,,,,,,,,,,,,,,,,,hypofunction of ATP biosynthesis [cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000340,tumor cell proliferation [Cell death],,"Tumor cell proliferation is a subtype of cell proliferation: A process of the multiplication or reproduction of tumor cells, resulting in the rapid expansion of a tumor cell population.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0001727|http://purl.obolibrary.org/obo/TXPO_0000339,,,,,,,,,,,,,,,,,,,,,,"Tumor cell proliferation is a subtype of cell proliferation: A process of the multiplication or reproduction of tumor cells, resulting in the rapid expansion of a tumor cell population.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000340,,,,,,,,,,,,,,,,,,,,,,tumor cell proliferation [Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000344,increasing number of action,,Increasing number of action is a subtype of changing: A process that becomes larger in the number of actions or activities.,false,,,http://purl.obolibrary.org/obo/TXPO_0000387,,,,,,,,,,,,,,,,,,,,,,Increasing number of action is a subtype of changing: A process that becomes larger in the number of actions or activities.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000344,,,,,,,,,,,,,,,,,,,,,,increasing number of action,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000348,decreasing number of objects,,Decreasing number of objects is a subtype of changing: A process that becomes smaller in number of physical objects.,false,,,http://purl.obolibrary.org/obo/TXPO_0000387,,,,,,,,,,,,,,,,,,,,,,Decreasing number of objects is a subtype of changing: A process that becomes smaller in number of physical objects.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000348,,,,,,,,,,,,,,,,,,,,,,decreasing number of objects,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003758,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000343,decomposing,,Decomposing is a subtype of separating: A process that divides a whole object into constituents.,false,,,http://purl.obolibrary.org/obo/TXPO_0000333,,,,,,,,,,,,,,,,,,,,,,Decomposing is a subtype of separating: A process that divides a whole object into constituents.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000343,,,,,,,,,,,,,,,,,,,,,,decomposing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100715,Notch 2 (mol),Notch2|Notch-2,,false,,,http://purl.obolibrary.org/obo/IMR_0100712,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:18129|NCBI-Rat-GeneID:29492|NCBI-Human-GeneID:4853,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Notch2|Notch-2,,,,,IMR:0100715,,,,,,,,,,,,,,,,,,,,,,Notch 2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0000229,cytoplasmic chromosome,cytoplasmic interphase chromosome,A chromosome found in the cytoplasm.,false,,,http://purl.obolibrary.org/obo/GO_0005694,,,,,,,,,,,,,,,,,,,,,,A chromosome found in the cytoplasm.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,cytoplasmic interphase chromosome,,,http://purl.obolibrary.org/obo/GO_0005737,GO:0000229,http://purl.obolibrary.org/obo/GO_0005737,,,,,,,,,,,,,,,,,,,,,cytoplasmic chromosome,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000591,polyphenol,,Members of the class of phenols that contain 2 or more benzene rings each of which is substituted by at least one hydroxy group,false,,,http://purl.obolibrary.org/obo/CHEBI_33853,,,,,,,,,,,,,,,,,,,,Wikipedia:Polyphenol,,Members of the class of phenols that contain 2 or more benzene rings each of which is substituted by at least one hydroxy group,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000591,,,,,,,,,,,,,,,,,,,,,,polyphenol,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000595,CCL4 -necrosis inducer [Lipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003509,,,,,,,,,,,,,,,,,,,,ISBN:0071769234,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002397,,,,,,,,,,TXPO:0000595,,,,,,,,,,,,,,,,,,,,,,CCL4 -necrosis inducer [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000594,oxidative stress dependent molecule (caonical),,"Oxidative stress dependent molecule is a subtype of toxic course dependent chemical entity.
This molecule can participate in the course of oxidative stress as a gene product.
Gene profile:caonical that described in textbooks or articles.",false,,,http://purl.obolibrary.org/obo/TXPO_0000297,,,,,,,,,,,,,,,,,,,,,,"Oxidative stress dependent molecule is a subtype of toxic course dependent chemical entity.
This molecule can participate in the course of oxidative stress as a gene product.
Gene profile:caonical that described in textbooks or articles.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000594,,,,,,,,,,,,,,,,,,,,,,oxidative stress dependent molecule (caonical),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000592,oxidative stress dependent molecule (human in vivo),,"Oxidative stress dependent molecule is a subtype of toxic course dependent chemical entity.
This molecule can participate in the course of oxidative stress as a gene product.
Gene profile:Human/in vitro/Hepatocyte/",false,,,http://purl.obolibrary.org/obo/TXPO_0000297,,,,,,,,,,,,,,,,,,,,,,"Oxidative stress dependent molecule is a subtype of toxic course dependent chemical entity.
This molecule can participate in the course of oxidative stress as a gene product.
Gene profile:Human/in vitro/Hepatocyte/",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000592,,,,,,,,,,,,,,,,,,,,,,oxidative stress dependent molecule (human in vivo),,,,,,,,,,,http://purl.obolibrary.org/obo/NCBITaxon_9606,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000593,CCL4_ [Lipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003509,,,,,,,,,,,,,,,,,,,,ISBN:0071769234,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000598|http://purl.obolibrary.org/obo/CHEBI_59739,,,,,,,,,,TXPO:0000593,,,,,,,,,,,,,,,,,,,,,,CCL4_ [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000598,lipoperoxidator role,,A role played by the entity to perform peroxiidation of the target object.,false,,,http://purl.obolibrary.org/obo/TXPO_0003712,,,,,,,,,,,,,,,,,,,,,,A role played by the entity to perform peroxiidation of the target object.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000598,,,,,,,,,,,,,,,,,,,,,,lipoperoxidator role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000597,hyperfunction of cell survival [Ground glass appearance],,"Hyperfunction of cell survival is a subtype of hyperfunctioning: A process that performs an excesssive cell survival.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (excessive defense).",false,,,http://purl.obolibrary.org/obo/TXPO_0002275|http://purl.obolibrary.org/obo/TXPO_0001728,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of cell survival is a subtype of hyperfunctioning: A process that performs an excesssive cell survival.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (excessive defense).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002319|http://purl.obolibrary.org/obo/TXPO_0002322|http://purl.obolibrary.org/obo/TXPO_0002320|http://purl.obolibrary.org/obo/TXPO_0000954,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003597,,,,,,,,,,,TXPO:0000597,,,,,,,,,,,,,,,,,,,,,,hyperfunction of cell survival [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000590,bile reflux,,Bile reflux is a subtype of back-flow: A process that changes the bile flow to the opposite direction.,false,,,http://purl.obolibrary.org/obo/TXPO_0003122,,,,,,,,,,,,,,,,,,,,MeSH:D001655,,Bile reflux is a subtype of back-flow: A process that changes the bile flow to the opposite direction.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000590,,,,,,,,,,,,,,,,,,,,,,bile reflux,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000596,oxidative stress dependent molecule (rat),,"Oxidative stress dependent molecule is a subtype of toxic course dependent chemical entity.
This molecule can participate in the course of oxidative stress as a gene product.
Gene profile:Rat/Liver",false,,,http://purl.obolibrary.org/obo/TXPO_0000297,,,,,,,,,,,,,,,,,,,,,,"Oxidative stress dependent molecule is a subtype of toxic course dependent chemical entity.
This molecule can participate in the course of oxidative stress as a gene product.
Gene profile:Rat/Liver",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000596,,,,,,,,,,,,,,,,,,,,,,oxidative stress dependent molecule (rat),,,,,,,,,,,http://purl.obolibrary.org/obo/NCBITaxon_10114,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000599,Plc gamma1 (rat)[Ground glass appearance],,,false,,,http://purl.obolibrary.org/obo/IMR_0000732|http://purl.obolibrary.org/obo/TXPO_0000985,,,,,,,,,,,,,,,,,,,,MeSH: C000607812,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000284,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003671,,,,,,,,,,TXPO:0000599,,,,,,,,,,,,,,,,,,,,,,Plc gamma1 (rat)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/GO_0030855,epithelial cell differentiation,,"The process in which a relatively unspecialized cell acquires specialized features of an epithelial cell, any of the cells making up an epithelium.",false,,,http://purl.obolibrary.org/obo/GO_0030154,,,,,,,,,,,,,,,,,,,,,,"The process in which a relatively unspecialized cell acquires specialized features of an epithelial cell, any of the cells making up an epithelium.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0030855,,,,,,,,,,,,,,,,,,,,,,epithelial cell differentiation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001149,PKC epsilon,,,false,,,http://purl.obolibrary.org/obo/IMR_0000246,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001149,,,,,,,,,,,,,,,,,,,,,,PKC epsilon,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004332,amiodarone [mitochondrial disorder]],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004312|http://purl.obolibrary.org/obo/CHEBI_2663,,,,,,,,,,,,,,,,,,,,PMID:21145849|ISBN:0071769234,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004332,,,,,,,,,,,,,,,,,,,,,,amiodarone [mitochondrial disorder]],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004336,tetracycline [mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004312|http://purl.obolibrary.org/obo/CHEBI_27902,,,,,,,,,,,,,,,,,,,,PMID:21145849|Wikipedia:Tetracycline,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004336,,,,,,,,,,,,,,,,,,,,,,tetracycline [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004333,alpidem [mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/CHEBI_135649|http://purl.obolibrary.org/obo/TXPO_0004312,,,,,,,,,,,,,,,,,,,,PMID:21145849|Wikipedia:Alpidem,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004333,,,,,,,,,,,,,,,,,,,,,,alpidem [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004335,tamoxifen [mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/CHEBI_41774|http://purl.obolibrary.org/obo/TXPO_0004312,,,,,,,,,,,,,,,,,,,,PMID:24003057|PMID:21145849,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001426,,,,,,,,,,TXPO:0004335,,,,,,,,,,,,,,,,,,,,,,tamoxifen [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004330,perhexiline [mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/CHEBI_35553|http://purl.obolibrary.org/obo/TXPO_0004312,,,,,,,,,,,,,,,,,,,,Wikipedia:Perhexiline|PMID:21145849|DrugBank:DB01074,,,,,,,,,,,,,,C19H35N,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004330,,,,,,,,,,,,,,,,,,,,,,perhexiline [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,C1CCC(CC1)C(CC1CCCCN1)C1CCCCC1,,,,,
http://purl.obolibrary.org/obo/TXPO_0004338,nilutamide [mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004312|http://purl.obolibrary.org/obo/CHEBI_7573,,,,,,,,,,,,,,,,,,,,PMID:21145849|Wikipedia:Nilutamide,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004338,,,,,,,,,,,,,,,,,,,,,,nilutamide [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004331,Acetaminophen [mitochondrial disorder],APAP|N-(4-hydroxyphenyl)acetamide|paracetamol [mitochondrial disorder],,false,,,http://purl.obolibrary.org/obo/TXPO_0004312|http://purl.obolibrary.org/obo/CHEBI_46195,,,,,,,,,,,,,,,,,,,,Wikipedia:Paracetamol|Wikipedia:Acetaminophen|PMID:21145849,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,N-(4-hydroxyphenyl)acetamide|paracetamol [mitochondrial disorder],,APAP,,,TXPO:0004331,,,,,,,,,,,,,,,,,,,,,,Acetaminophen [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004337,troglitazone [mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004312|http://purl.obolibrary.org/obo/CHEBI_9753,,,,,,,,,,,,,,,,,,,,PMID:11717175|PMID:21145849|ATC:A10BG01,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001866,,,,,,,,,,TXPO:0004337,,,,,,,"Rifampicin, bosentan, and troglitazone directly inhibit bile salt export pump (BSEP).|A chromane that has formula C24H27NO5S.|Direct competition of troglitazone metabolites with conjugated bilirubin at the level of MRP2 could result in conjugated hyperbilirubinemia.",,,,,,,,,,,,,,,troglitazone [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004339,buprenorphine [mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/CHEBI_3216|http://purl.obolibrary.org/obo/TXPO_0004312,,,,,,,,,,,,,,,,,,,,Wikipedia:Buprenorphine|PMID:21145849,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004339,,,,,,,,,,,,,,,,,,,,,,buprenorphine [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004334,disulfiram [mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004312|http://purl.obolibrary.org/obo/CHEBI_4659,,,,,,,,,,,,,,,,,,,,Wikipedia:Disulfiram|PMID:21145849,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004334,,,,,,,,,,,,,,,,,,,,,,disulfiram [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000128346,C1orf162,,Other designations: transmembrane protein C1orf162,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,1,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,chromosome 1 open reading frame 162,,,1p13.2,,,,,,,,,,,,,,,,GO_0016021 (EC: IEA),,,,,,,,,PMID: 12477932; 14702039,,,,,,,,,,,,,,,OGG:3000128346,,,,,,,chromosome 1 open reading frame 162,,,,,,,,,,,,,Other designations: transmembrane protein C1orf162,,C1orf162,,,,,,,,,,,,,,,,,,,,,,,128346,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,C1orf162,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000023452,ANGPTL2,,Other designations: angiopoietin-like protein 2|angiopoietin-related protein 2,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,ARP2|HARP,,,,,,,,,,,,9,,,,,,HGNC:490|Ensembl:ENSG00000136859|MIM:605001|HPRD:05415|Vega:OTTHUMG00000020695,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,angiopoietin-like 2,,,9q34,,,,,,,,,,,,,,,,"GO_0005102 (EC: TAS, PMID:10473614); GO_0005615 (EC: TAS, PMID:10473614); GO_0007275 (EC: TAS, PMID:10473614); GO_0070062 (EC: IDA, PMID:19056867)",,,,,,,,,PMID:8619474; 9110174; 10473614; 12477932; 12624729; 12975309; 15164053; 15489334; 16303743; 17207965; 17347581; 18593905; 19056867; 19723494; 20304962; 21983347; 22281496; 22345152; 22556334; 22966088; 23333801; 23469106; 23602322,,,,,,,,,,,,,,,OGG:3000023452,,,,,,,angiopoietin-like 2,,,,,,,,,,,,,Other designations: angiopoietin-like protein 2|angiopoietin-related protein 2,,ANGPTL2,,,,,,,,,,,,,,,,,,,,,,,23452,RP11-1M19.1,,,,,,,9606,,,,,,,,,,,,,,,,,,,ANGPTL2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_76811,sphingomyelin phosphodiesterase inhibitor role,sphingomyelin phosphodiesterase inhibitor|EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor,An EC 3.1.4.* (phosphoric diester hydrolase) inhibitor that interferes with the action of sphingomyelin phosphodiesterase (EC 3.1.4.12).,false,,,http://purl.obolibrary.org/obo/TXPO_0000559,,,,,,,,,,,,,,,,,,,,,,An EC 3.1.4.* (phosphoric diester hydrolase) inhibitor that interferes with the action of sphingomyelin phosphodiesterase (EC 3.1.4.12).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sphingomyelin phosphodiesterase inhibitor|EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor,,,,,CHEBI:76811,,,,,,,,,,,,,,,,,,,,,,sphingomyelin phosphodiesterase inhibitor role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010474,60S ribosomal protein L24,L30,,false,,,http://purl.obolibrary.org/obo/IMR_0000897,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,L30,,,,,IMR:0010474,,,,,,,,,,,,,,,,,,,,,,60S ribosomal protein L24,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_3750,clofibrate,ethyl 2-(4-chlorophenoxy)-2-methylpropanoate,The ethyl ester of clofibric acid.,false,,,http://purl.obolibrary.org/obo/TXPO_1000442,,,,,,,,,,,,,,,,,,,,LINCS:LSM-2996|Wikipedia:Clofibrate|Open TG-Gates compound_id:00006,,The ethyl ester of clofibric acid.,,,,,,,,,,,,C12H15ClO3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35679|http://purl.obolibrary.org/obo/CHEBI_35821,,,,,ethyl 2-(4-chlorophenoxy)-2-methylpropanoate,,,,,CHEBI:3750,,,,,,,,,,,,,,,,,,,,,,clofibrate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1,,,,,
http://purl.obolibrary.org/obo/TXPO_0004609,HHIP inactivation [hepatocarcinogenesis],,"HHIP inactivation is a subtype of molecular inactivation: A process that  changes the activity of the HHIP (hedgehog interacting protein) to be lower.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004607,,,,,,,,,,,,,,,,,,,,PMID:29507645,,"HHIP inactivation is a subtype of molecular inactivation: A process that  changes the activity of the HHIP (hedgehog interacting protein) to be lower.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004611,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004610,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004392,,,,,,,,,,,TXPO:0004609,,,,,,,,,,,,,,,,,,,,,,HHIP inactivation [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004600,Increasing HGF level [hepatocarcinogenesis],,"Increasing HGF level is a subtype of increasing quantity: A process that changes the amount of HGF level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004605,,,,,,,,,,,,,,,,,,,,PMID:29270806,,"Increasing HGF level is a subtype of increasing quantity: A process that changes the amount of HGF level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004606,,http://purl.obolibrary.org/obo/TXPO_0004504,,,,,,http://purl.obolibrary.org/obo/TXPO_0004517,,,,,,,,,,,TXPO:0004600,,,,,,,,,,,,,,,,,,,,,,Increasing HGF level [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004607,HHIP inactivation,,HHIP inactivation is a subtype of molecular inactivation: A process that  changes the activity of the HHIP (hedgehog interacting protein) to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000021,,,,,,,,,,,,,,,,,,,,,,HHIP inactivation is a subtype of molecular inactivation: A process that  changes the activity of the HHIP (hedgehog interacting protein) to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004607,,,,,,,,,,,,,,,,,,,,,,HHIP inactivation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004604,HGF (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24446|NCBI-Human-GeneID:3082|NCBI-Mouse-GeneID:15234,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004604,,,,,,,,,,,,,,,,,,,,,,HGF (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004608,HHIP (mol),hedgehog interacting protein,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:15245|NCBI-Human-GeneID:64399|NCBI-Rat-GeneID:291936,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,hedgehog interacting protein,,,,,TXPO:0004608,,,,,,,,,,,,,,,,,,,,,,HHIP (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004601,HGF (canonical) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004604|http://purl.obolibrary.org/obo/TXPO_0005063,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24446|NCBI-Human-GeneID:3082|NCBI-Mouse-GeneID:15234|PMID:31781608,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004601,,,,,,,,,,,,,,,,,,,,,,HGF (canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004605,Increasing HGF level,,Increasing HGF level is a subtype of increasing quantity: A process that changes the amount of HGF level to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing HGF level is a subtype of increasing quantity: A process that changes the amount of HGF level to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004604,,,,,,,,,,,,,,,,,,,TXPO:0004605,,,,,,,,,,,,,,,,,,,,,,Increasing HGF level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004603,neovascularization [hepatocarcinogenesis],,"neovascularization is a subtype of biological structure formation: A process that constructs an alternate blood vessels.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0000134,,,,,,,,,,,,,,,,,,,,PMID:28240761|PMID:30710550|PMID:25796501|PMID:29679563|PMID:20101231|PMID:29340079|PMID:31781608,,"neovascularization is a subtype of biological structure formation: A process that constructs an alternate blood vessels.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0005047,,,,,,http://purl.obolibrary.org/obo/TXPO_0004479|http://purl.obolibrary.org/obo/TXPO_0004518|http://purl.obolibrary.org/obo/TXPO_0004392,,,,,,,,,,,TXPO:0004603,,,,,,,,,,,,,,,,,,,,,,neovascularization [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004602,MET (canonical) [hepatocarcinogenesis],HGFR,,false,,,http://purl.obolibrary.org/obo/TXPO_0005063|http://purl.obolibrary.org/obo/TXPO_0005098,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24553|NCBI-Mouse-GeneID:17295|NCBI-Human-GeneID:4233|PMID:31781608,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,HGFR,,,,,TXPO:0004602,,,,,,,,,,,,,,,,,,,,,,MET (canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004606,HGF (rat) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004604|http://purl.obolibrary.org/obo/TXPO_0005070,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24446|PMID:29270806,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004606,,,,,,,,,,,,,,,,,,,,,,HGF (rat) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000022,FasL,Fas ligand|CD95L|CD178 antigen|Tumor necrosis factor ligand superfamily member 6|FasL,,false,,,http://purl.obolibrary.org/obo/IMR_0000021,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Fas ligand|CD95L|CD178 antigen|Tumor necrosis factor ligand superfamily member 6|FasL,,,,,IMR:0000022,,,,,,,,,,,,,,,,,,,,,,FasL,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001534,M-Ras,R-Ras3,,false,,,http://purl.obolibrary.org/obo/IMR_0000292,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,R-Ras3,,,,,IMR:0001534,,,,,,,,,,,,,,,,,,,,,,M-Ras,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0010716,negative regulation of extracellular matrix disassembly,,"Any process that decreases the rate, frequency or extent of extracellular matrix disassembly. Extracellular matrix disassembly is a process that results in the breakdown of the extracellular matrix.",false,,,http://purl.obolibrary.org/obo/TXPO_0000369,,,,,,,,,,,,,,,,,,,,,,"Any process that decreases the rate, frequency or extent of extracellular matrix disassembly. Extracellular matrix disassembly is a process that results in the breakdown of the extracellular matrix.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0010716,,,,,,,,,,,,,,,,,,,,,,negative regulation of extracellular matrix disassembly,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0022411,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000934,phenobarbital accumulation in liver [Ground glass appearance],,"Phenobarbital accumulation in liver is a subtype of compound accumulation in liver: A process that keeps phenobarbital in the liver.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001234|http://purl.obolibrary.org/obo/TXPO_0002068,,,,,,,,,,,,,,,,,,,,,,"Phenobarbital accumulation in liver is a subtype of compound accumulation in liver: A process that keeps phenobarbital in the liver.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001524,,,,,,,,,,,,,,,,,TXPO:0000934,,,,,,,,,,,,,,,,,,,,,,phenobarbital accumulation in liver [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000935,constitutive androstane receptor activation [Ground glass appearance],CAR activating [Ground glass ]|activating constitutive androstane receptor [Ground glass appearance]|activating CAR [Ground glass ],"Constitutive androstane receptor activation is a subtype of activating nuclear receptor: A process that changes the activity of the activating CAR ( constitutive androstane receptor) with a nuclear receptor role to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.|By activating CAR, CAR migrates from the cytoplasm to the nucleus and transcribes the drug metabolizing enzyme Cyp.",false,,,http://purl.obolibrary.org/obo/TXPO_0001210|http://purl.obolibrary.org/obo/TXPO_0003855,,,,,,,,,,,,,,,,,,,,PMID:28265001|ISBN:0071769234|PMID:16513849,,"Constitutive androstane receptor activation is a subtype of activating nuclear receptor: A process that changes the activity of the activating CAR ( constitutive androstane receptor) with a nuclear receptor role to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001524,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003791,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000937|http://purl.obolibrary.org/obo/TXPO_0003258,,,,,,CAR activating [Ground glass ]|activating constitutive androstane receptor [Ground glass appearance]|activating CAR [Ground glass ],,,,,TXPO:0000935,,,,,,,,,,,,,,,,,,,,"By activating CAR, CAR migrates from the cytoplasm to the nucleus and transcribes the drug metabolizing enzyme Cyp.",,constitutive androstane receptor activation [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000936,retinoid X receptor activation [Ground glass appearance],activating retinoid X receptor [Ground glass degeneration],"Retinoid X receptor activation is a subtype of activating nuclear receptor: A process that changes the activity of the RXR (retinoid X receptor) with a nuclear receptor role to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001214|http://purl.obolibrary.org/obo/TXPO_0001728,,,,,,,,,,,,,,,,,,,,,,"Retinoid X receptor activation is a subtype of activating nuclear receptor: A process that changes the activity of the RXR (retinoid X receptor) with a nuclear receptor role to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000937,,,,,,activating retinoid X receptor [Ground glass degeneration],,,,,TXPO:0000936,,,,,,,,,,,,,,,,,,,,,,retinoid X receptor activation [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000931,troglitazone [Cholestasis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000749|http://purl.obolibrary.org/obo/CHEBI_9753,,,,,,,,,,,,,,,,,,,,PMID:11717175|ATC:A10BG01,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001866,,,,,,,,,,TXPO:0000931,,,,,,,"Rifampicin, bosentan, and troglitazone directly inhibit bile salt export pump (BSEP).|A chromane that has formula C24H27NO5S.|Direct competition of troglitazone metabolites with conjugated bilirubin at the level of MRP2 could result in conjugated hyperbilirubinemia.",,,,,,,,,,,,,,,troglitazone [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000937,hyperfunction of cytochrome p450 gene expression [Ground glass appearance],,"Hyperfunction of cytochrome p450 gene expression is a subtype of hyperfunction of drug metabolizing enzyme gene expression: A process that performs an excesssive gene expression of cytochrome p450.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.|Cyp1a1, Cyp2b1, Cyp4x1",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/TXPO_0002051,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of cytochrome p450 gene expression is a subtype of hyperfunction of drug metabolizing enzyme gene expression: A process that performs an excesssive gene expression of cytochrome p450.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000991|http://purl.obolibrary.org/obo/TXPO_0000990,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001621,,,,,,,,,,,TXPO:0000937,,,,,,,,,,,,,,,,,,,,"Cyp1a1, Cyp2b1, Cyp4x1",,hyperfunction of cytochrome p450 gene expression [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000932,carbohydrate transport [Ground glass appearance],,"The directed movement of carbohydrate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Carbohydrates are any of a group of organic compounds based of the general formula Cx(H2O)y.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/GO_0008643,,,,,,,,,,,,,,,,,,,,,,"The directed movement of carbohydrate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Carbohydrates are any of a group of organic compounds based of the general formula Cx(H2O)y.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000932,,,,,,,,,,,,,,,,,,,,,,carbohydrate transport [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000933,mitochondrial dysfunction [Mitochondrial disorder],,"Mitochondrial dysfunction is a subtype of dysfunctioning: A process that performs an abnormal and incomplete mitochondrial function.
This entity is a specific course-dependent process. This process can constitute the Mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0002361,,,,,,,,,,,,,,,,,,,,PMID:31623280|PMID:25339807|PMID:30250064|PMID:23299992|PMID:29222479,,"Mitochondrial dysfunction is a subtype of dysfunctioning: A process that performs an abnormal and incomplete mitochondrial function.
This entity is a specific course-dependent process. This process can constitute the Mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004218|http://purl.obolibrary.org/obo/TXPO_0001997|http://purl.obolibrary.org/obo/TXPO_0004272|http://purl.obolibrary.org/obo/TXPO_0002040|http://purl.obolibrary.org/obo/TXPO_0002005|http://purl.obolibrary.org/obo/TXPO_0004340|http://purl.obolibrary.org/obo/TXPO_0004264|http://purl.obolibrary.org/obo/TXPO_0004263|http://purl.obolibrary.org/obo/TXPO_0002010,,,,,,,,,,,TXPO:0000933,,,,,,,,,,,,,,,,,,,,,,mitochondrial dysfunction [Mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000930,compound accumulation in lysosome [Phospholipidosis],,"Compound accumulation in lysosome is a subtype of accumulation of xenobiotics: A process that keeps compound in the lysosome.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0001242,,,,,,,,,,,,,,,,,,,,,,"Compound accumulation in lysosome is a subtype of accumulation of xenobiotics: A process that keeps compound in the lysosome.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003367,http://purl.obolibrary.org/obo/TXPO_0001560|http://purl.obolibrary.org/obo/TXPO_0001566|http://purl.obolibrary.org/obo/TXPO_0001425,,,,,,http://purl.obolibrary.org/obo/TXPO_0001551|http://purl.obolibrary.org/obo/TXPO_0000905,,,,,,,,,,,TXPO:0000930,,,,,,,,,,,,,,,,,,,,,,compound accumulation in lysosome [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000938,hyperfunction of drug metabolism phase I [Ground glass appearance],,"Hyperfunction of drug metabolism phase I is a subtype of hyperfunctioning of drug metabolism: A process that performs an excessive drug metabolism phase I.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0002049|http://purl.obolibrary.org/obo/TXPO_0001728,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of drug metabolism phase I is a subtype of hyperfunctioning of drug metabolism: A process that performs an excessive drug metabolism phase I.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000991|http://purl.obolibrary.org/obo/TXPO_0000990,,,,,,http://purl.obolibrary.org/obo/TXPO_0000963|http://purl.obolibrary.org/obo/TXPO_0000943,,,,,,,,,,,TXPO:0000938,,,,,,,,,,,,,,,,,,,,,,hyperfunction of drug metabolism phase I [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005790,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000939,hyperfunction of iron supply [Ground glass appearance],,"Hyperfunction of iron supply is a subtype of hyperfunctioning: A process that performs an excesssive iorn supply.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001237,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of iron supply is a subtype of hyperfunctioning: A process that performs an excesssive iorn supply.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000939,,,,,,,,,,,,,,,,,,,,,,hyperfunction of iron supply [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100538,GLK,GCK-like kinase,,false,,,http://purl.obolibrary.org/obo/IMR_0100535,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GCK-like kinase,,,,,IMR:0100538,,,,,,,,,,,,,,,,,,,,,,GLK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000296,Rho,,,false,,,http://purl.obolibrary.org/obo/IMR_0000295,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000296,,,,,,,,,,,,,,,,,,,,,,Rho,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0031649,heat generation,,"Any homeostatic process in which an organism produces heat, thereby raising its internal temperature.",false,,,http://purl.obolibrary.org/obo/TXPO_0000381,,,,,,,,,,,,,,,,,,,,,,"Any homeostatic process in which an organism produces heat, thereby raising its internal temperature.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0031649,,,,,,,,,,,,,,,,,,,,,,heat generation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004507,tumor suppressor gene mutation [hepatocarcinogenesis],,"Tumor suppressor gene mutation is a subtype of changing an operand: A process that changes the nucleotide sequence of Tumor suppressor gene randomly and permanently.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004902,,,,,,,,,,,,,,,,,,,,PMID:24078988|PMID:31439937|PMID:10626230|PMID:21160980|PMID:19590965,,"Tumor suppressor gene mutation is a subtype of changing an operand: A process that changes the nucleotide sequence of Tumor suppressor gene randomly and permanently.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0005049,,,,,,http://purl.obolibrary.org/obo/TXPO_0004498|http://purl.obolibrary.org/obo/TXPO_0004907,,,,,,http://purl.obolibrary.org/obo/TXPO_0004392,,,,,,,,,,,TXPO:0004507,,,,,,,,,,,,,,,,,,,,,,tumor suppressor gene mutation [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004506,proto-oncogene mutation [hepatocarcinogenesis],,"Proto-oncogene mutation is a subtype of changing an operand: A process that changes the nucleotide sequence of Proto-oncogene randomly and permanently.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0004890|http://purl.obolibrary.org/obo/TXPO_0002340,,,,,,,,,,,,,,,,,,,,PMID:31439937|PMID:1596892|PMID:10626230|PMID:21160980,,"Proto-oncogene mutation is a subtype of changing an operand: A process that changes the nucleotide sequence of Proto-oncogene randomly and permanently.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004895|http://purl.obolibrary.org/obo/TXPO_0004893|http://purl.obolibrary.org/obo/TXPO_0004894|http://purl.obolibrary.org/obo/TXPO_0004896|http://purl.obolibrary.org/obo/TXPO_0004873,,,,,,http://purl.obolibrary.org/obo/TXPO_0004705|http://purl.obolibrary.org/obo/TXPO_0004704|http://purl.obolibrary.org/obo/TXPO_0004891|http://purl.obolibrary.org/obo/TXPO_0004892|http://purl.obolibrary.org/obo/TXPO_0004498,,,,,,http://purl.obolibrary.org/obo/TXPO_0004392,,,,,,,,,,,TXPO:0004506,,,,,,,,,,,,,,,,,,,,,,proto-oncogene mutation [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004501,formation of DNA adducts [hepatocarcinogenesis],,"The process of a structure formation,  in n which a chemical is attatched to a segement of DNA. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004500,,,,,,,,,,,,,,,,,,,,PMID:9855003|PMID:28932315|PMID:21170807|PMID:10626230|PMID:11393581|PMID:15206902,,"The process of a structure formation,  in n which a chemical is attatched to a segement of DNA. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004498|http://purl.obolibrary.org/obo/TXPO_0004503|http://purl.obolibrary.org/obo/TXPO_0004504|http://purl.obolibrary.org/obo/TXPO_0004502,,,,,,http://purl.obolibrary.org/obo/TXPO_0004507|http://purl.obolibrary.org/obo/TXPO_0004506|http://purl.obolibrary.org/obo/TXPO_0004505,,,,,,,,,,,TXPO:0004501,,,,,,,"In molecular genetics, a DNA adduct is a segment of DNA bound to a cancer-causing chemical. This process could be the start of a cancerous cell, or carcinogenesis.",,,,,,,,,,,,,,,formation of DNA adducts [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004509,HOTAIR (canonical) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0005063|http://purl.obolibrary.org/obo/TXPO_0005092,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:100503872|NCBI-Human-GeneID:100124700,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004509,,,,,,,,,,,,,,,,,,,,,,HOTAIR (canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004503,riddelliine [hepatocarcinogenesis],"(15Z)-12,18-dihydroxy-13,19-didehydrosenecionan-11,16-dione",,false,,,http://purl.obolibrary.org/obo/TXPO_0004455|http://purl.obolibrary.org/obo/CHEBI_63924,,,,,,,,,,,,,,,,,,,,PMID:21170807|PMID:15206902|CAS:23246-96-0,,,,,,,,,,,,,,C18H23NO6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"(15Z)-12,18-dihydroxy-13,19-didehydrosenecionan-11,16-dione",,,,,TXPO:0004503,,,,,,,"A macrolide that is 13,19-didehydrosenecionan bearing two additional hydroxy substituents at positions 12 and 18 as well as two additional oxo groups at positions 11 and 16.",,,,,,,,,,,,,,,riddelliine [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,[H][C@@]12[C@H]3CCN1CC=C2COC(=O)[C@@](O)(CO)C(=C)C\C(=C\C)C(=O)O3,,,,,
http://purl.obolibrary.org/obo/TXPO_0004504,cyproterone acetate [hepatocarcinogenesis],"CPA|6-chloro-3,20-dioxo-1beta,2beta-dihydro-3'H-cyclopropa[1,2]pregna-4,6-dien-17-yl acetate",This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.,false,,,http://purl.obolibrary.org/obo/TXPO_0004455|http://purl.obolibrary.org/obo/CHEBI_50743,,,,,,,,,,,,,,,,,,,,PMID:29270806|Wikipedia:Cyproterone_Acetate|PMID:11393581|CAS:427-51-0,,This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.,,,,,,,,,,,,C24H29ClO4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35497,,,,,"CPA|6-chloro-3,20-dioxo-1beta,2beta-dihydro-3'H-cyclopropa[1,2]pregna-4,6-dien-17-yl acetate",,,,,TXPO:0004504,,,,,,,,,,,,,,,,,,,,,,cyproterone acetate [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,[H][C@@]12C[C@]1([H])[C@@]1(C)C(=CC2=O)C(Cl)=C[C@@]2([H])[C@]3([H])CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)CC[C@]12[H],,,,,
http://purl.obolibrary.org/obo/TXPO_0004508,negative regulation of DNA repair [hepatocarcinogenesis],,"Negative regulation of DNA repair is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of DNA repair.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/GO_0045738,,,,,,,,,,,,,,,,,,,,PMID:31439937|PMID:31781608,,"Negative regulation of DNA repair is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of DNA repair.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004509|http://purl.obolibrary.org/obo/TXPO_0004510|http://purl.obolibrary.org/obo/TXPO_0004511,,,,,,http://purl.obolibrary.org/obo/TXPO_0004512,,,,,,,,,,,TXPO:0004508,,,,,,,,,,,,,,,,,,,,,,negative regulation of DNA repair [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006281,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004500,formation of DNA adducts,,"The process of a structure formation,  in n which a chemical is attatched to a segement of DNA.",false,,,http://purl.obolibrary.org/obo/GO_0005488,,,,,,,,,,,,,,,,,,,,,,"The process of a structure formation,  in n which a chemical is attatched to a segement of DNA.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004500,,,,,,,,,,,,,,,,,,,,,,formation of DNA adducts,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004502,malondialdehyde [hepatocarcinogenesis],MDA,,false,,,http://purl.obolibrary.org/obo/TXPO_0004455|http://purl.obolibrary.org/obo/CHEBI_566274,,,,,,,,,,,,,,,,,,,,PMID:9855003|PMID:28932315,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MDA,,,,,TXPO:0004502,,,,,,,,,,,,,,,,,,,,,,malondialdehyde [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004505,DNA damage [hepatocarcinogenesis],,"Drug-, radiation-induced, or spontaneous injuries to DNA that introduce deviations from its normal double-helical conformation. These changes include structural distortions that interfere with replication and transcription, as well as point mutations that disrupt base pairs and exert damaging effects on future generations through changes in DNA sequence. If the damage is minor, it can often be repaired (DNA repair); extensive damage can induce apoptosis.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/NCIT_C16507,,,,,,,,,,,,,,,,,,,,PMID:28932315|PMID:30704071,,"Drug-, radiation-induced, or spontaneous injuries to DNA that introduce deviations from its normal double-helical conformation. These changes include structural distortions that interfere with replication and transcription, as well as point mutations that disrupt base pairs and exert damaging effects on future generations through changes in DNA sequence. If the damage is minor, it can often be repaired (DNA repair); extensive damage can induce apoptosis.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004513,,,,,,http://purl.obolibrary.org/obo/TXPO_0004392,,,,,,,,,,,TXPO:0004505,,,,,,,,,,,,,,,,,,,,,,DNA damage [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100381,G-alpha-13,,,false,,,http://purl.obolibrary.org/obo/IMR_0000324,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100381,,,,,,,,,,,,,,,,,,,,,,G-alpha-13,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0011151,eIF3k,Eukaryotic translation initiation factor 3 subunit 11|eukaryotic translation initiation factor 3 subunit 11|HSPC029|PTD001|Muscle specific gene M9 protein|ARG134|eIF-3 p25,,false,,,http://purl.obolibrary.org/obo/IMR_0000916,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Eukaryotic translation initiation factor 3 subunit 11|eukaryotic translation initiation factor 3 subunit 11|HSPC029|PTD001|Muscle specific gene M9 protein|ARG134|eIF-3 p25,,,,,IMR:0011151,,,,,,,,,,,,,,,,,,,,,,eIF3k,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004735,Increasing PANDA level [hepatocarcinogenesis],,"Increasing PANDA level is a subtype of increasing quantity: A process that changes the amount of PANDA level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004734,,,,,,,,,,,,,,,,,,,,PMID:28646235,,"Increasing PANDA level is a subtype of increasing quantity: A process that changes the amount of PANDA level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004736,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004476,,,,,,,,,,,TXPO:0004735,,,,,,,,,,,,,,,,,,,,,,Increasing PANDA level [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004738,PCK1 inactivation [hepatocarcinogenesis],,"PCK1 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the PCK1 (phosphoenolpyruvate carboxykinase 1) to be lower.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004737,,,,,,,,,,,,,,,,,,,,PMID:29335519,,"PCK1 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the PCK1 (phosphoenolpyruvate carboxykinase 1) to be lower.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004739,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004518,,,,,,,,,,,TXPO:0004738,,,,,,,,,,,,,,,,,,,,,,PCK1 inactivation [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004732,ORC1 - inactive form (human) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0005121,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:4998|PMID:25797246,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0002355,,,,,,,,,,,,,,TXPO:0004732,,,,,,,,,,,,,,,,,,,,,,ORC1 - inactive form (human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004733,PANDA,P21 associated ncRNA DNA damage activated,,false,,,http://purl.obolibrary.org/obo/OGG_2100009606,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:101154753,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,P21 associated ncRNA DNA damage activated,,,,,TXPO:0004733,,,,,,,,,,,,,,,,,,,,,,PANDA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004734,Increasing PANDA level,,Increasing PANDA level is a subtype of increasing quantity: A process that changes the amount of PANDA level to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing PANDA level is a subtype of increasing quantity: A process that changes the amount of PANDA level to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004733,,,,,,,,,,,,,,,,,,,TXPO:0004734,,,,,,,,,,,,,,,,,,,,,,Increasing PANDA level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004737,PCK1 inactivation,,PCK1 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the PCK1 (phosphoenolpyruvate carboxykinase 1) to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000021,,,,,,,,,,,,,,,,,,,,,,PCK1 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the PCK1 (phosphoenolpyruvate carboxykinase 1) to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004737,,,,,,,,,,,,,,,,,,,,,,PCK1 inactivation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004730,ORC1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:313479|NCBI-Mouse-GeneID:18392|NCBI-Human-GeneID:4998,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004730,,,,,,,,,,,,,,,,,,,,,,ORC1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004731,ORC1 inactivation [hepatocarcinogenesis],,"ORC1 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the ORC1 (origin recognition complex subunit 1) to be lower.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0004729|http://purl.obolibrary.org/obo/TXPO_0002340,,,,,,,,,,,,,,,,,,,,PMID:25797246,,"ORC1 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the ORC1 (origin recognition complex subunit 1) to be lower.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004732,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004470,,,,,,,,,,,TXPO:0004731,,,,,,,,,,,,,,,,,,,,,,ORC1 inactivation [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004739,PCK1 - inactive form (human) [Hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0005122,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:5105|PMID:29335519,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657|http://purl.obolibrary.org/obo/PATO_0002355,http://purl.obolibrary.org/obo/OGG_3000005105,,,,,,,,,,,,,TXPO:0004739,,,,,,,,,,,,,,,,,,,,,,PCK1 - inactive form (human) [Hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004736,PANDA (human) [hepatocarcinogenesis],P21 associated ncRNA DNA damage activated,,false,,,http://purl.obolibrary.org/obo/TXPO_0004733,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:101154753|PMID:28646235,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,P21 associated ncRNA DNA damage activated,,,,,TXPO:0004736,,,,,,,,,,,,,,,,,,,,,,PANDA (human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_66991,sympatholytic agent,sympatholytic|sympatholytics|sympatholytic drugs|sympatholytic drug|sympatholytic agents,Any compound which inhibits the postganglionic functioning of the sympathetic nervous system (SNS).,false,,,http://purl.obolibrary.org/obo/CHEBI_37962,,,,,,,,,,,,,,,,,,,,,,Any compound which inhibits the postganglionic functioning of the sympathetic nervous system (SNS).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sympatholytic|sympatholytics|sympatholytic drugs|sympatholytic drug|sympatholytic agents,,,,,,,,,,,,,,,,,,,,,CHEBI:66991,,,,sympatholytic agent,,CHEBI:66991,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000122970,ACOT4,,Other designations: PTE-2b|acyl-coenzyme A thioesterase 4|peroxisomal acyl coenzyme A thioester hydrolase Ib|peroxisomal acyl-CoA thioesterase 2B|peroxisomal long-chain acyl-CoA thioesterase Ib,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,PTE1B|PTE-Ib|PTE2B,,,,,,,,,,,,14,,,,,,HPRD:17928|MIM:614314|HGNC:19748,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,acyl-CoA thioesterase 4,,,14q24.3,,,,,,,,,,,,,,,,"GO_0000038 (EC: IDA, PMID:16940157); GO_0001676 (EC: IDA, PMID:16940157); GO_0004778 (EC: IDA, PMID:16141203); GO_0005102 (EC: IPI); GO_0005777 (EC: IDA, PMID:16141203); GO_0006104 (EC: IDA, PMID:16940157); GO_0006637 (EC: IDA, PMID:16940157); GO_0016290 (EC: IEA); GO_0019605 (EC: IDA, Qualifier: NOT, PMID:16940157); GO_0032788 (EC: IDA, PMID:16940157); GO_0032789 (EC: IDA, PMID:16940157); GO_0043648 (EC: IDA, PMID:16940157); GO_0043649 (EC: IDA, PMID:16141203); GO_0046459 (EC: IDA, PMID:16940157); GO_0047617 (EC: IDA, PMID:16141203)",,,,,,,,,PMID:7596406; 10567408; 10944470; 12477932; 14702039; 15489334; 16103133; 16141203; 16940157; 18029348; 20178365,,,,,,,,,,,,,,,OGG:3000122970,,,,,,,acyl-CoA thioesterase 4,,,,,,,,,,,,,Other designations: PTE-2b|acyl-coenzyme A thioesterase 4|peroxisomal acyl coenzyme A thioester hydrolase Ib|peroxisomal acyl-CoA thioesterase 2B|peroxisomal long-chain acyl-CoA thioesterase Ib,,ACOT4,,,,,,,,,,,,,,,,,,,,,,,122970,,,,,,,,9606,,,,,,,,,,,,,,,,,,,ACOT4,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0100452,MEK1(MKK1),MAPKK 1|ERK activator kinase 1|MKK1|MAPK/ERK kinase 1|MAP kinase kinase 1|MEK1,,false,,,http://purl.obolibrary.org/obo/IMR_0000261,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MAPKK 1|ERK activator kinase 1|MKK1|MAPK/ERK kinase 1|MAP kinase kinase 1|MEK1,,,,,IMR:0100452,,,,,,,,,,,,,,,,,,,,,,MEK1(MKK1),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_62872,EC 1.2.3.1 (aldehyde oxidase) inhibitor,retinoic acid synthase inhibitors|aldehyde oxidase (EC 1.2.3.1) inhibitors|retinal oxidase inhibitors|EC 1.2.3.1 inhibitor|quinoline oxidase inhibitor|aldehyde:oxygen oxidoreductase inhibitor|aldehyde oxidase (EC 1.2.3.1) inhibitor|EC 1.2.3.1 (aldehyde oxidase) inhibitors|aldehyde:oxygen oxidoreductase inhibitors|aldehyde oxidase inhibitors|retinoic acid synthase inhibitor|retinal oxidase inhibitor|quinoline oxidase inhibitors|aldehyde oxidase inhibitor|EC 1.2.3.1 inhibitors,An EC 1.2.3.* (oxidoreductase acting on donor aldehyde/oxo group with oxygen as acceptor) inhibitor which interferes with the action of aldehyde oxidase (EC 1.2.3.1).,false,,,http://purl.obolibrary.org/obo/CHEBI_76853,,,,,,,,,,,,,,,,,,,,,,An EC 1.2.3.* (oxidoreductase acting on donor aldehyde/oxo group with oxygen as acceptor) inhibitor which interferes with the action of aldehyde oxidase (EC 1.2.3.1).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,retinoic acid synthase inhibitors|aldehyde oxidase (EC 1.2.3.1) inhibitors|retinal oxidase inhibitors|EC 1.2.3.1 inhibitor|quinoline oxidase inhibitor|aldehyde:oxygen oxidoreductase inhibitor|aldehyde oxidase (EC 1.2.3.1) inhibitor|EC 1.2.3.1 (aldehyde oxidase) inhibitors|aldehyde:oxygen oxidoreductase inhibitors|aldehyde oxidase inhibitors|retinoic acid synthase inhibitor|retinal oxidase inhibitor|quinoline oxidase inhibitors|aldehyde oxidase inhibitor|EC 1.2.3.1 inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:62872,,,,EC 1.2.3.1 (aldehyde oxidase) inhibitor,,CHEBI:62872,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_7466,nandrolone,19-Norandrostenolone|19-Nortestosterone|17beta-hydroxy-4-estren-3-one|(17beta)-17-hydroxyestr-4-en-3-one|17beta-hydroxyestr-4-en-3-one|17beta-hydroxy-19-nor-4-androsten-3-one|4-estren-17beta-ol-3-one|Nandrolone|17beta-hydroxyestr-4-en-3-one,A 3-oxo Delta(4)-steroid that is estr-4-en-3-one substituted by a beta-hydroxy group at position 17.,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:434-22-0|DrugBank:DB00984|Gmelin:1228044|Drug_Central:1879|PMID:24405322|PMID:19055689|PMID:20020363|PMID:11888015|Beilstein:2055849|Reaxys:2055849|Beilstein:4690380,,A 3-oxo Delta(4)-steroid that is estr-4-en-3-one substituted by a beta-hydroxy group at position 17.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_77746,,,,,Nandrolone|17beta-hydroxyestr-4-en-3-one,,19-Norandrostenolone|19-Nortestosterone|17beta-hydroxy-4-estren-3-one|(17beta)-17-hydroxyestr-4-en-3-one|17beta-hydroxyestr-4-en-3-one|17beta-hydroxy-19-nor-4-androsten-3-one|4-estren-17beta-ol-3-one,,,,,,,,,,,,,,,,,,,,,CHEBI:7466,,,,nandrolone,,CHEBI:7466,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_33694,biomacromolecule,,A macromolecule formed by a living organism.,false,,,http://purl.obolibrary.org/obo/CHEBI_36357,,,,,,,,,,,,,,,,,,,,,,A macromolecule formed by a living organism.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:33694,,,,,,,,,,,,,,,,,,,,,,biomacromolecule,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_9516,thapsigargin,"(3S,3aR,4S,6S,6aR,7S,8S,9bS)-6-(acetyloxy)-4-(butanoyloxy)-3,3a-dihydroxy-3,6,9-trimethyl-8-{[(2Z)-2-methylbut-2-enoyl]oxy}-2-oxo-2,3,3a,4,5,6,6a,7,8,9b-decahydroazuleno[4,5-b]furan-7-yl octanoate","An organic heterotricyclic compound that is a hexa-oxygenated 6,7-guaianolide isolated fron the roots of Thapsia garganica L., Apiaceae. A potent skin irritant, it is used in traditional medicine as a counter-irritant. Thapsigargin inhibits Ca(2+)-transporting ATPase mediated uptake of calcium ions into sarcoplasmic reticulum and is used in experimentation examining the impacts of increasing cytosolic calcium concentrations.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:67526-95-8,,"An organic heterotricyclic compound that is a hexa-oxygenated 6,7-guaianolide isolated fron the roots of Thapsia garganica L., Apiaceae. A potent skin irritant, it is used in traditional medicine as a counter-irritant. Thapsigargin inhibits Ca(2+)-transporting ATPase mediated uptake of calcium ions into sarcoplasmic reticulum and is used in experimentation examining the impacts of increasing cytosolic calcium concentrations.",,,,,,,,,,,,C34H50O12,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_38215,,,,,"(3S,3aR,4S,6S,6aR,7S,8S,9bS)-6-(acetyloxy)-4-(butanoyloxy)-3,3a-dihydroxy-3,6,9-trimethyl-8-{[(2Z)-2-methylbut-2-enoyl]oxy}-2-oxo-2,3,3a,4,5,6,6a,7,8,9b-decahydroazuleno[4,5-b]furan-7-yl octanoate",,,,,CHEBI:9516,,,,,,,,,,,,,,,,,,,,,,thapsigargin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,[H][C@@]1(OC(=O)C(\C)=C/C)[C@@H](OC(=O)CCCCCCC)[C@@]2([H])C(=C1C)[C@]1([H])OC(=O)[C@@](C)(O)[C@@]1(O)[C@H](C[C@]2(C)OC(C)=O)OC(=O)CCC,,,,,
http://purl.obolibrary.org/obo/TXPO_0003215,Osgin1 - cancer repressor (rat)[Cell death],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000641,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000668|http://purl.obolibrary.org/obo/TXPO_0000329,,,,,,,,,,TXPO:0003215,,,,,,,,,,,,,,,,,,,,,,Osgin1 - cancer repressor (rat)[Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003212,liver dysfunction [Cholestasis],,"Liver dysfunction is a subtype of dysfunctioning: A process that performs an abnormal and incomplete liver function.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000203|http://purl.obolibrary.org/obo/TXPO_0000034,,,,,,,,,,,,,,,,,,,,,,"Liver dysfunction is a subtype of dysfunctioning: A process that performs an abnormal and incomplete liver function.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003212,,,,,,,,,,,,,,,,,,,,,,liver dysfunction [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003217,TP53 - apotosis inducing factor (canonical)[Cell death],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000843,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_68495,,,,,,,,,,TXPO:0003217,,,,,,,,,,,,,,,,,,,,,,TP53 - apotosis inducing factor (canonical)[Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003213,phospholipidosis dependent molecule  (canonical),,"Phospholipidosis dependent molecule is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of phospholipidosis as a gene product.
Gene profile:caonical that described in textbooks or articles.",false,,,http://purl.obolibrary.org/obo/TXPO_0001133,,,,,,,,,,,,,,,,,,,,,,"Phospholipidosis dependent molecule is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of phospholipidosis as a gene product.
Gene profile:caonical that described in textbooks or articles.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003213,,,,,,,,,,,,,,,,,,,,,,phospholipidosis dependent molecule  (canonical),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003214,Osgin1 - apotosis inducing factor (rat)[Cell death],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000641,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_68495,,,,,,,,,,TXPO:0003214,,,,,,,,,,,,,,,,,,,,,,Osgin1 - apotosis inducing factor (rat)[Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003210,lipid storage in liver [Cholestasis],,"Lipid storage in liver is a subtype of lipid storage: The accumulation and maintenance in cells or tissues of lipids in the liver.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001276|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"Lipid storage in liver is a subtype of lipid storage: The accumulation and maintenance in cells or tissues of lipids in the liver.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003210,,,,,,,,,,,,,,,,,,,,,,lipid storage in liver [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003216,Osgin1 - oxidative stress response protein (rat)[Cell death],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000641,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000668,,,,,,,,,,TXPO:0003216,,,,,,,,,,,,,,,,,,,,,,Osgin1 - oxidative stress response protein (rat)[Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003211,hepatic fibrosis [Cholestasis],,"Hepatic fibrosis is a subtype of fibrosis: A process that replaces liver tissues to fibrous connective tissues, usually as a consequence of inflammation or other injury.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000034|http://purl.obolibrary.org/obo/TXPO_0000816,,,,,,,,,,,,,,,,,,,,,,"Hepatic fibrosis is a subtype of fibrosis: A process that replaces liver tissues to fibrous connective tissues, usually as a consequence of inflammation or other injury.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003212,,,,,,,,,,,TXPO:0003211,,,,,,,,,,,,,,,,,,,,,,hepatic fibrosis [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003219,pexophagy [Eosinophilic granular degeneration],,"The selective autophagy process in which a peroxisome is degraded by macroautophagy.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/TXPO_0001729|http://purl.obolibrary.org/obo/GO_0000425,,,,,,,,,,,,,,,,,,,,PMID:26344566,,"The selective autophagy process in which a peroxisome is degraded by macroautophagy.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005777,,,,,,http://purl.obolibrary.org/obo/TXPO_0003255|http://purl.obolibrary.org/obo/TXPO_0003253,,,,,,http://purl.obolibrary.org/obo/TXPO_0003207,,,,,,,,,,,TXPO:0003219,,,,,,,,,,,,,,,,,,,,,,pexophagy [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003218,negative regulation of cytokine gene expression,,"Negative regulation of cytokine gene expression is a subtype of negative regulation of gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of inflammatory cytokine gene expression.",false,,,http://purl.obolibrary.org/obo/GO_0010629,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of cytokine gene expression is a subtype of negative regulation of gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of inflammatory cytokine gene expression.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003218,,,,,,,,,,,,,,,,,,,,,,negative regulation of cytokine gene expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000001316,KLF6,,Other designations: B-cell-derived protein 1|GC-rich binding factor|GC-rich sites-binding factor GBF|Krueppel-like factor 6|Kruppel-like zinc finger protein Zf9|core promoter element binding protein|core promoter element-binding protein|proto-oncogene BCD1|protooncogene B-cell derived 1|suppression of tumorigenicity 12 (prostate)|suppressor of tumorigenicity 12 protein|transcription factor Zf9,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,ST12|CPBP|BCD1|GBF|ZF9|COPEB|PAC1|CBA1,,,,,,,,,,,,10,,,,,,Ensembl:ENSG00000067082|Vega:OTTHUMG00000017567|HGNC:2235|MIM:602053|HPRD:03632,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,Kruppel-like factor 6,,,10p15,,,,,,,,,,,,,,,,"GO_0003677 (EC: IEA); GO_0005634 (EC: TAS, PMID: 9689109); GO_0005737 (EC: IEA); GO_0006351 (EC: IEA); GO_0019221 (EC: IEA); GO_0030183 (EC: NAS, PMID: 9000136); GO_0045893 (EC: TAS, PMID: 9083102); GO_0046872 (EC: IEA)",,,,,,,,,PMID: 8889548; 9000136; 9083102; 9503030; 9685731; 9689109; 10802067; 11752579; 12433697; 12477932; 12508640; 12590140; 12651597; 12651626; 12740910; 12794452; 15057748; 15064720; 15067324; 15131018; 15164054; 15172998; 15247715; 15342556; 15378003; 15486921; 15489334; 15735005; 15824733; 15917248; 15937668; 16044160; 16054710; 16169070; 16189514; 16385451; 16431954; 16500425; 16598737; 16702959; 16778100; 16856969; 16872311; 16972326; 16988269; 17071613; 17113081; 17125911; 17143513; 17207965; 17223258; 17347589; 17347668; 17514651; 17621627; 17636026; 17663506; 17893646; 18053161; 18174288; 18190240; 18250346; 18471523; 18515091; 18521079; 18596922; 18691883; 18719336; 18753303; 18755691; 18822210; 19020536; 19097929; 19101139; 19328586; 19333010; 19435908; 19808645; 19967571; 20014424; 20116377; 20126619; 20237496; 20453000; 20545576; 20660366; 20714872; 20801538; 20844588; 21056892; 21109018; 21154818; 21282102; 21309496; 21443094; 21470678; 21538018; 21799854; 21832049; 21849067; 21906983; 21928351; 21940380; 22095588; 22169644; 22277651; 22486562; 22535637; 22581522; 22653055; 22711891; 22782870; 22855058; 23048070; 23085750; 23219426; 23322324; 23345610; 23353867; 23508266; 23512538; 23831683; 23870195; 24130502,,,,,,,,,,,,,,,OGG:3000001316,,,,,,,Kruppel-like factor 6,,,,,,,,,,,,,Other designations: B-cell-derived protein 1|GC-rich binding factor|GC-rich sites-binding factor GBF|Krueppel-like factor 6|Kruppel-like zinc finger protein Zf9|core promoter element binding protein|core promoter element-binding protein|proto-oncogene BCD1|protooncogene B-cell derived 1|suppression of tumorigenicity 12 (prostate)|suppressor of tumorigenicity 12 protein|transcription factor Zf9,,KLF6,,,,,,,,,,,,,,,,,,,,,,,1316,RP11-184A2.1,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,KLF6,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000389,IRF-3,,,false,,,http://purl.obolibrary.org/obo/IMR_0000386,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000389,,,,,,,,,,,,,,,,,,,,,,IRF-3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100455,MKK7(JNKK2),JNKK 2|JNK activating kinase 2|SKK4|JNK kinase 2|MAPK/ERK kinase 7|JNKK2|c-Jun N-terminal kinase kinase 2|MAP kinase kinase 7|MKK7|MAPKK 7,,false,,,http://purl.obolibrary.org/obo/IMR_0000262,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,JNKK 2|JNK activating kinase 2|SKK4|JNK kinase 2|MAPK/ERK kinase 7|JNKK2|c-Jun N-terminal kinase kinase 2|MAP kinase kinase 7|MKK7|MAPKK 7,,,,,IMR:0100455,,,,,,,,,,,,,,,,,,,,,,MKK7(JNKK2),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006750,glutathione biosynthetic process,glutathione formation|glutathione anabolism|glutathione biosynthesis|glutathione synthesis,"The chemical reactions and pathways resulting in the formation of glutathione, the tripeptide glutamylcysteinylglycine, which acts as a coenzyme for some enzymes and as an antioxidant in the protection of sulfhydryl groups in enzymes and other proteins.",false,,,http://purl.obolibrary.org/obo/GO_0009058,,,,,,,,,,,,,,,,,,,,https://reactome.org/PathwayBrowser/#/R-HSA-174403|GO:0006750,,"The chemical reactions and pathways resulting in the formation of glutathione, the tripeptide glutamylcysteinylglycine, which acts as a coenzyme for some enzymes and as an antioxidant in the protection of sulfhydryl groups in enzymes and other proteins.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_16856,,,http://purl.obolibrary.org/obo/HINO_0016374|http://purl.obolibrary.org/obo/TXPO_0000652,,,,,,,,,,,glutathione formation|glutathione anabolism|glutathione biosynthesis|glutathione synthesis,,,,,GO:0006750,,,,,,,,,,,,,,,,,,,,,,glutathione biosynthetic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006754,ATP biosynthetic process,ATP regeneration|ATP formation|ATP synthesis|ATP biosynthesis|ATP anabolism,"The chemical reaction resulting in the formation of ATP, adenosine 5'-triphosphate, a universally important coenzyme and enzyme regulator.",false,,,http://purl.obolibrary.org/obo/GO_0009058,,,,,,,,,,,,,,,,,,,,GO:0006754,,"The chemical reaction resulting in the formation of ATP, adenosine 5'-triphosphate, a universally important coenzyme and enzyme regulator.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_15422,http://purl.obolibrary.org/obo/GO_0042773|http://purl.obolibrary.org/obo/GO_0006119,,,,,,,,,,,,,ATP formation|ATP synthesis|ATP biosynthesis|ATP anabolism,ATP regeneration,,,,GO:0006754,,,,,,,,,,,,,,,,,,,,,,ATP biosynthetic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002737,dissociation of Nrf2-Keap1 complex,,Dissociation of Nrf2-Keap1 complex is a subtype of detaching: A process that disaggregates  a Nrf2-Keap1 complexe into Nrf2 and Keap1.,false,,,http://purl.obolibrary.org/obo/TXPO_0000462,,,,,,,,,,,,,,,,,,,,,,Dissociation of Nrf2-Keap1 complex is a subtype of detaching: A process that disaggregates  a Nrf2-Keap1 complexe into Nrf2 and Keap1.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002737,,,,,,,,,,,,,,,,,,,,,,dissociation of Nrf2-Keap1 complex,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002734,cholestasis [Glutathione depletion],,"Cholestasis is a subtype of stagnating: A process that changes the bile flow to be slower due to obstruction.
This entity is a specific course-dependent process. This process can constitute the course of glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0001345|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Cholestasis is a subtype of stagnating: A process that changes the bile flow to be slower due to obstruction.
This entity is a specific course-dependent process. This process can constitute the course of glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002734,,,,,,,,,,,,,,,,,,,,,,cholestasis [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002736,NRF2 activation by PERK [PERK - NRF2 pathway],,"A process that changes the activity of the NRF2 to be higher by PERK.
This entity is a specific course-dependent process. This process can constitute the course of PERK - NRF2 pathway.",false,,,http://purl.obolibrary.org/obo/TXPO_0001370|http://purl.obolibrary.org/obo/TXPO_0001861,,,,,,,,,,,,,,,,,,,,PMID:14517290,,"A process that changes the activity of the NRF2 to be higher by PERK.
This entity is a specific course-dependent process. This process can constitute the course of PERK - NRF2 pathway.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002737,,,,,,,,,,,,,,,,,,,,,TXPO:0002736,,,,,,,,,,,,,,,,,,,,,,NRF2 activation by PERK [PERK - NRF2 pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002739,NRF2 activation by PERK [ER stress],,"A process that changes the activity of the NRF2 to be higher by PERK.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002736,,,,,,,,,,,,,,,,,,,,PMID:14517290,,"A process that changes the activity of the NRF2 to be higher by PERK.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002738,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002744,,,,,,,,,,,TXPO:0002739,,,,,,,,,,,,,,,,,,,,,,NRF2 activation by PERK [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002731,receiving abnormal protein signal by PERK [ER stress - apoptosis],,"Receiving abnormal protein signal by PERK is a subtype of receiving signal: A process that recognizes another object and changes into an abnormal protein (e.g., misfolded protein, etc.) signal by PERK.
This process is dependent on the apoptosis and can constitute the course of ER stress via apoptosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002741|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"Receiving abnormal protein signal by PERK is a subtype of receiving signal: A process that recognizes another object and changes into an abnormal protein (e.g., misfolded protein, etc.) signal by PERK.
This process is dependent on the apoptosis and can constitute the course of ER stress via apoptosis.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002730,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001839,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002440,,,,,,,,,,,TXPO:0002731,,,,,,,,,,,,,,,,,,,,,,receiving abnormal protein signal by PERK [ER stress - apoptosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002730,PERK - signal sensor (canonical)[ER stress - apotosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001841,http://purl.obolibrary.org/obo/TXPO_0002731,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UniProt_Q9NZJ5|http://www.uniprot.org/entry/Q9NZJ5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000882,,,,,,,,,,TXPO:0002730,,,,,,,,,,,,,,,,,,,,,,PERK - signal sensor (canonical)[ER stress - apotosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002732,positive regulation of bile export,,"Positive regulation of bile export is a subtype of positive regulation process: A process that that activates or increases the frequency, rate or extent of bile acid secretion.",false,,,http://purl.obolibrary.org/obo/TXPO_0001223,,,,,,,,,,,,,,,,,,,,,,"Positive regulation of bile export is a subtype of positive regulation process: A process that that activates or increases the frequency, rate or extent of bile acid secretion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002732,,,,,,,,,,,,,,,,,,,,,,positive regulation of bile export,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002683,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002735,PERK-Nrf2 mediated pathway (integrated pathway),,"PERK-Nrf2 mediated pathway is a subtype of PERK signaling (integrated pathway): Sequence of linked reactions, which has PERK signaling and gene regulation pathway.",false,,,http://purl.obolibrary.org/obo/TXPO_0000067,,,,,,,,,,,,,,,,,,,,,,"PERK-Nrf2 mediated pathway is a subtype of PERK signaling (integrated pathway): Sequence of linked reactions, which has PERK signaling and gene regulation pathway.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002742|http://purl.obolibrary.org/obo/TXPO_0002736|http://purl.obolibrary.org/obo/TXPO_0002764|http://purl.obolibrary.org/obo/TXPO_0001837,,http://purl.obolibrary.org/obo/TXPO_0000285|http://purl.obolibrary.org/obo/TXPO_0002490,,,,,,,,,,,,,,,,TXPO:0002735,,,,,,,,,,,,,,,,,,,,,,PERK-Nrf2 mediated pathway (integrated pathway),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002738,dissociation of Nrf2-Keap1 complex by PERK [ER stress],,"Dissociation of Nrf2-Keap1 complex by Perk is a subtype of detaching: A process that disaggregates a Nrf2-Keap1 complex into Nrf2 and Keap1 by Perk.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002737|http://purl.obolibrary.org/obo/TXPO_0003736,,,,,,,,,,,,,,,,,,,PERK activation->dissociation of Nrf2/Keap in ER stress,PERK-dependent phosphorylation triggers dissociation of Nrf2/Keap1 complexes and inhibits reassociation of Nrf2/Keap1 complexes in vitro.|PMID:14517290,,"Dissociation of Nrf2-Keap1 complex by Perk is a subtype of detaching: A process that disaggregates a Nrf2-Keap1 complex into Nrf2 and Keap1 by Perk.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002738,,,,,,,,,,,,,,,,,,,,,,dissociation of Nrf2-Keap1 complex by PERK [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002733,negative regulation of bile acid and bile salts export from the hepatocyte to bile tube [Glutathione depletion],,"Negative regulation of bile acid and bile salts export from the hepatocyte to bile tube is a subtype of negative regulation of transport: A process that stops, prevents, or reduces the frequency, rate or extent of bile acid and bile salts export from the hepatocyte to the bile tube.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0001892|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of bile acid and bile salts export from the hepatocyte to bile tube is a subtype of negative regulation of transport: A process that stops, prevents, or reduces the frequency, rate or extent of bile acid and bile salts export from the hepatocyte to the bile tube.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001190,,,,,,,,,,,TXPO:0002733,,,,,,,,,,,,,,,,,,,,,,negative regulation of bile acid and bile salts export from the hepatocyte to bile tube [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002692,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_18421,superoxide,dioxidanidyl,,false,,,http://purl.obolibrary.org/obo/TXPO_0000201,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,O2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,dioxidanidyl,,,,,CHEBI:18421,,,,,,,,,,,,,,,,,,,,,,superoxide,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,[O][O-],,,,,
http://purl.obolibrary.org/obo/TXPO_0004137,increasing energy [Phospholipidosis (normal)],,"Increasing energy is a subtype of increasing quantity: A process that changes the amount of energy to be larger.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (normal condition).",false,,,http://purl.obolibrary.org/obo/TXPO_0000144|http://purl.obolibrary.org/obo/TXPO_0003593,,,,,,,,,,,,,,,,,,,,,,"Increasing energy is a subtype of increasing quantity: A process that changes the amount of energy to be larger.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (normal condition).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004137,,,,,,,,,,,,,,,,,,,,,,increasing energy [Phospholipidosis (normal)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004133,oxidative phosphorylation uncoupling,,"Any process that enables the transfer of protons from mitochondrial intermembrane space into mitochondrial matrix, dissipating the proton gradient across the mitochondrial inner membrane established by the electron transport chain during the oxidative phosphorylation (proton leak). Proton leak uncouples the processes of electron transport/proton generation and ATP synthesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000369,,,,,,,,,,,,,,,,,,,,,,"Any process that enables the transfer of protons from mitochondrial intermembrane space into mitochondrial matrix, dissipating the proton gradient across the mitochondrial inner membrane established by the electron transport chain during the oxidative phosphorylation (proton leak). Proton leak uncouples the processes of electron transport/proton generation and ATP synthesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004133,,,,,,,,,,,,,,,,,,,,,,oxidative phosphorylation uncoupling,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006119,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004130,increasing uptake amount of mitochondrial proton ion,,Increasing uptake amount of mitochondrial proton is a subtype of increasing quantity: A process that changes the uptake amount of mitochondrial proton to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing uptake amount of mitochondrial proton is a subtype of increasing quantity: A process that changes the uptake amount of mitochondrial proton to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004130,,,,,,,,,,,,,,,,,,,,,,increasing uptake amount of mitochondrial proton ion,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004131,increasing uptake amount of mitochondrial proton ion [Mitochondrial disorder],,"Increasing uptake amount of mitochondrial proton is a subtype of increasing quantity: A process that changes the uptake amount of mitochondrial proton to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0004130|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,,,"Increasing uptake amount of mitochondrial proton is a subtype of increasing quantity: A process that changes the uptake amount of mitochondrial proton to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004135|http://purl.obolibrary.org/obo/TXPO_0001879,,,,,,,,,,,TXPO:0004131,,,,,,,,,,,,,,,,,,,,,,increasing uptake amount of mitochondrial proton ion [Mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004134,positive regulation of oxidative phosphorylation uncoupling,,"Any process that activates or increases the frequency, rate or extent of oxidative phosphorylation uncoupling.
 Oxidative phosphorylation uncoupling is a process that enables the transfer of protons from mitochondrial intermembrane space into mitochondrial matrix, dissipating the proton gradient across the mitochondrial inner membrane established by the electron transport chain during the oxidative phosphorylation (proton leak). Proton leak uncouples the processes of electron transport/proton generation and ATP synthesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001223,,,,,,,,,,,,,,,,,,,,,,"Any process that activates or increases the frequency, rate or extent of oxidative phosphorylation uncoupling.
 Oxidative phosphorylation uncoupling is a process that enables the transfer of protons from mitochondrial intermembrane space into mitochondrial matrix, dissipating the proton gradient across the mitochondrial inner membrane established by the electron transport chain during the oxidative phosphorylation (proton leak). Proton leak uncouples the processes of electron transport/proton generation and ATP synthesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004134,,,,,,,,,,,,,,,,,,,,,,positive regulation of oxidative phosphorylation uncoupling,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004133,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004138,decreasing energy,,Decreasing energy is a subtype of decreasing quantity: A process that changes the amount of energy to be smaller.,false,,,http://purl.obolibrary.org/obo/TXPO_0000396,,,,,,,,,,,,,,,,,,,,,,Decreasing energy is a subtype of decreasing quantity: A process that changes the amount of energy to be smaller.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004138,,,,,,,,,,,,,,,,,,,,,,decreasing energy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004136,energy supply [Phospholipidosis(normal)],,"Energy supply is a subtype of providing process to perform a meta-function “to provide energy.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (normal condition).",false,,,http://purl.obolibrary.org/obo/TXPO_0004077|http://purl.obolibrary.org/obo/TXPO_0003595,,,,,,,,,,,,,,,,,,,,,,"Energy supply is a subtype of providing process to perform a meta-function “to provide energy.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (normal condition).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004137,,,,,,,,,,,,,,,,,,TXPO:0004136,,,,,,,,,,,,,,,,,,,,,,energy supply [Phospholipidosis(normal)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004135,positive regulation of oxidative phosphorylation uncoupling [Mitochondrial disorder],,"Any process that activates or increases the frequency, rate or extent of oxidative phosphorylation uncoupling.
 Oxidative phosphorylation uncoupling is a process that enables the transfer of protons from mitochondrial intermembrane space into mitochondrial matrix, dissipating the proton gradient across the mitochondrial inner membrane established by the electron transport chain during the oxidative phosphorylation (proton leak). Proton leak uncouples the processes of electron transport/proton generation and ATP synthesis.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0004134|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,,,"Any process that activates or increases the frequency, rate or extent of oxidative phosphorylation uncoupling.
 Oxidative phosphorylation uncoupling is a process that enables the transfer of protons from mitochondrial intermembrane space into mitochondrial matrix, dissipating the proton gradient across the mitochondrial inner membrane established by the electron transport chain during the oxidative phosphorylation (proton leak). Proton leak uncouples the processes of electron transport/proton generation and ATP synthesis.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001989|http://purl.obolibrary.org/obo/TXPO_0004125,,,,,,,,,,,TXPO:0004135,,,,,,,,,,,,,,,,,,,,,,positive regulation of oxidative phosphorylation uncoupling [Mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004133,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004139,decreasing energy [Phospholipidosis],,"Decreasing energy is a subtype of decreasing quantity: A process that changes the amount of energy to be smaller.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0004138|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Decreasing energy is a subtype of decreasing quantity: A process that changes the amount of energy to be smaller.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004139,,,,,,,,,,,,,,,,,,,,,,decreasing energy [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004132,negative regulation of tumor cell proliferation [Phospholipidosis],,"Negative regulation of tumor cell proliferation is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of tumor cell proliferation.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002124|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of tumor cell proliferation is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of tumor cell proliferation.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004132,,,,,,,,,,,,,,,,,,,,,,negative regulation of tumor cell proliferation [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0022904,respiratory electron transport chain,electron transfer,A process in which a series of electron carriers operate together to transfer electrons from donors such as NADH and FADH2 to any of several different terminal electron acceptors to generate a transmembrane electrochemical gradient.,false,,,http://purl.obolibrary.org/obo/GO_0022900,,,,,,,,,,,,,,,,,,,,Wikipedia:Electron_transfer,,A process in which a series of electron carriers operate together to transfer electrons from donors such as NADH and FADH2 to any of several different terminal electron acceptors to generate a transmembrane electrochemical gradient.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,electron transfer,,,,,GO:0022904,,,,,,,,,,,,,,,,,,,,,,respiratory electron transport chain,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0022900,electron transport chain,,A process in which a series of electron carriers operate together to transfer electrons from donors to any of several different terminal electron acceptors to generate a transmembrane electrochemical gradient.,false,,,http://purl.obolibrary.org/obo/GO_0006810|http://purl.obolibrary.org/obo/GO_0055114,,,,,,,,,,,,,,,,,,,,Wikipedia:Electron_transport_chain,,A process in which a series of electron carriers operate together to transfer electrons from donors to any of several different terminal electron acceptors to generate a transmembrane electrochemical gradient.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0022900,,,,,,,,,,,,,,,,,,,,,,electron transport chain,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0002046,NDK6,,,false,,,http://purl.obolibrary.org/obo/IMR_0010012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0002046,,,,,,,,,,,,,,,,,,,,,,NDK6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0200137,L-Histidine,,,false,,,http://purl.obolibrary.org/obo/CHEBI_33709,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0200137,,,,,,,,,,,,,,,,,,,,,,L-Histidine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0200497,Prostaglandin G2,,,false,,,http://purl.obolibrary.org/obo/IMR_0100019,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0200497,,,,,,,,,,,,,,,,,,,,,,Prostaglandin G2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0071712,endoplasmic reticulum-associated degradation,ER-associated misfolded protein breakdown|endoplasmic reticulum-associated misfolded protein catabolism|endoplasmic reticulum-associated misfolded protein catabolic process|ER-associated misfolded protein degradation|ER-associated misfolded protein catabolism,The chemical reactions and pathways resulting in the breakdown of misfolded proteins transported from the endoplasmic reticulum and targeted to cytoplasmic proteasomes for degradation.,false,,,http://purl.obolibrary.org/obo/GO_0036503,,,,,,,,,,,,,,,,,,,,,,The chemical reactions and pathways resulting in the breakdown of misfolded proteins transported from the endoplasmic reticulum and targeted to cytoplasmic proteasomes for degradation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ER-associated misfolded protein breakdown|endoplasmic reticulum-associated misfolded protein catabolism|endoplasmic reticulum-associated misfolded protein catabolic process|ER-associated misfolded protein degradation|ER-associated misfolded protein catabolism,,,,,GO:0071712,,,,,,,,,,,,,,,,,,,,,,endoplasmic reticulum-associated degradation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_32509,pirinixic acid,"({4-chloro-6-[(2,3-dimethylphenyl)amino]pyrimidin-2-yl}sulfanyl)acetic acid|WY14643",,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:50892-23-4|LINCS:LSM-2015|PubChem:17396608|Wikipedia:Pirinixic_Acid,,,,,,,,,,,,,,C14H14ClN3O2S|Cc1cccc(Nc2cc(Cl)nc(SCC(O)=O)n2)c1C,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"({4-chloro-6-[(2,3-dimethylphenyl)amino]pyrimidin-2-yl}sulfanyl)acetic acid|WY14643",,,,,CHEBI:32509,,,,,,,,,,,,,,,,,,,,,,pirinixic acid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Cc1cccc(Nc2cc(Cl)nc(SCC(O)=O)n2)c1C,,,,,
http://purl.obolibrary.org/obo/GO_0046889,positive regulation of lipid biosynthetic process,,"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of lipids.",false,,,http://purl.obolibrary.org/obo/TXPO_0001223,,,,,,,,,,,,,,,,,,,,,,"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of lipids.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0046889,,,,,,,,,,,,,,,,,,,,,,positive regulation of lipid biosynthetic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0008610,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010444,60S ribosomal protein L13a,23 kDa highly basic protein,,false,,,http://purl.obolibrary.org/obo/IMR_0000897,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,23 kDa highly basic protein,,,,,IMR:0010444,,,,,,,,,,,,,,,,,,,,,,60S ribosomal protein L13a,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000163,cytokeratin 7,,,false,,,http://purl.obolibrary.org/obo/IMR_0000050,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000163,,,,,,,,,,,,,,,,,,,,,,cytokeratin 7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100153,opioid peptide,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_25512,,,,,,,,,,IMR:0100153,,,,,,,,,,,,,,,,,,,,,,opioid peptide,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005025,4-hydroxynonenal [mitochondrial disorder],4-hydroxy-trans-2-nonenal,A monounsaturated fatty aldehyde that is nonanal that has undergone dehydrogenation to introduce a double bond at any position in the aliphatic chain and in which a hydrogen at position 4 has been replaced by a hydroxy group.,false,,,http://purl.obolibrary.org/obo/CHEBI_142593|http://purl.obolibrary.org/obo/TXPO_0004312,,,,,,,,,,,,,,,,,,,,PMID:25339807|PMID:23299992,,A monounsaturated fatty aldehyde that is nonanal that has undergone dehydrogenation to introduce a double bond at any position in the aliphatic chain and in which a hydrogen at position 4 has been replaced by a hydroxy group.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4-hydroxy-trans-2-nonenal,,,,,TXPO:0005025,,,,,,,,,,,,,,,,,,,,,,4-hydroxynonenal [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005026,response to endoplasmic reticulum stress [hepatocarcinogenesis],,"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stress acting at the endoplasmic reticulum. ER stress usually results from the accumulation of unfolded or misfolded proteins in the ER lumen.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/GO_0034976,,,,,,,,,,,,,,,,,,,,PMID:28240761,,"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stress acting at the endoplasmic reticulum. ER stress usually results from the accumulation of unfolded or misfolded proteins in the ER lumen.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004434|http://purl.obolibrary.org/obo/TXPO_0004432,,,,,,,,,,,,,,,,,,TXPO:0005026,,,,,,,,,,,,,,,,,,,,,,response to endoplasmic reticulum stress [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005029,negative regulation of antioxidant enzyme activation,,"Negative regulation of antioxidant enzyme activation is a subtype of Negative regulation of enzyme activation: A process that stops, prevents, or reduces the frequency, rate or extent of antioxidant enzyme activation.",false,,,http://purl.obolibrary.org/obo/TXPO_0001787,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of antioxidant enzyme activation is a subtype of Negative regulation of enzyme activation: A process that stops, prevents, or reduces the frequency, rate or extent of antioxidant enzyme activation.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005029,,,,,,,,,,,,,,,,,,,,,,negative regulation of antioxidant enzyme activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005024,reactive aldehyde [mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003603|http://purl.obolibrary.org/obo/TXPO_0004328,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005024,,,,,,,,,,,,,,,,,,,,,,reactive aldehyde [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005023,increasing production amount of reactive aldehyde,,Increasing production amount of reactive aldehyde is a subtype of increasing quantity: A process that changes the production amount of reactive aldehyde to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing production amount of reactive aldehyde is a subtype of increasing quantity: A process that changes the production amount of reactive aldehyde to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005023,,,,,,,,,,,,,,,,,,,,,,increasing production amount of reactive aldehyde,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005020,regulatory T cell migration,,The orderly movement of a regulatory T cell from one site to another.,false,,,http://purl.obolibrary.org/obo/GO_0050900,,,,,,,,,,,,,,,,,,,,,,The orderly movement of a regulatory T cell from one site to another.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005020,,,,,,,,,,,,,,,,,,,,,,regulatory T cell migration,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005028,hypofunction of immune response to tumor cell,,Hypofunction of immune response to tumor cell is a subtype of hypofunctioning: A process that performs a decreased or insufficient immune response to tumor cell.,false,,,http://purl.obolibrary.org/obo/TXPO_0000436,,,,,,,,,,,,,,,,,,,,,,Hypofunction of immune response to tumor cell is a subtype of hypofunctioning: A process that performs a decreased or insufficient immune response to tumor cell.,,,http://purl.obolibrary.org/obo/GO_0002418,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005028,,,,,,,,,,,,,,,,,,,,,,hypofunction of immune response to tumor cell,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005022,protooncogene activation [hepatocarcinogenesis],,"Protooncogene activation is a subtype of molecular activation: A process that changes the activity of the protooncogene to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0005021,,,,,,,,,,,,,,,,,,,,,,"Protooncogene activation is a subtype of molecular activation: A process that changes the activity of the protooncogene to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004703|http://purl.obolibrary.org/obo/TXPO_0004681|http://purl.obolibrary.org/obo/TXPO_0004506|http://purl.obolibrary.org/obo/TXPO_0004673|http://purl.obolibrary.org/obo/TXPO_0004669|http://purl.obolibrary.org/obo/TXPO_0004791|http://purl.obolibrary.org/obo/TXPO_0004590|http://purl.obolibrary.org/obo/TXPO_0004698,,,,,,,,,,,,,,,,,,TXPO:0005022,,,,,,,,,,,,,,,,,,,,,,protooncogene activation [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005021,protooncogene activation,,protooncogene activation is a subtype of molecular activation: A process that changes the activity of the protooncogene to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000023,,,,,,,,,,,,,,,,,,,,,,protooncogene activation is a subtype of molecular activation: A process that changes the activity of the protooncogene to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005021,,,,,,,,,,,,,,,,,,,,,,protooncogene activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005027,Increasing uric acid level,,Increasing uric acid level is a subtype of increasing quantity: A process that changes the amount of uric acid level to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing uric acid level is a subtype of increasing quantity: A process that changes the amount of uric acid level to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005027,,,,,,,,,,,,,,,,,,,,,,Increasing uric acid level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001608,Rab24,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001608,,,,,,,,,,,,,,,,,,,,,,Rab24,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000000839,CASP6,,"Other designations: apoptotic protease MCH-2|caspase 6, apoptosis-related cysteine protease|caspase-6",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,MCH2,,,,,,,,,,,,4,,,,,,HGNC:1507|HPRD:03321|Vega:OTTHUMG00000131914|Ensembl:ENSG00000138794|MIM:601532,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"caspase 6, apoptosis-related cysteine peptidase",,,4q25,,,,,,,,,,,,,,,,"GO_0004197 (EC: IBA); GO_0004197 (EC: TAS); GO_0005515 (EC: IPI, PMID:12888622); GO_0005654 (EC: TAS); GO_0005829 (EC: IDA, PMID:17167422); GO_0005829 (EC: TAS); GO_0006508 (EC: IDA, PMID:12888622); GO_0006915 (EC: IBA); GO_0006915 (EC: TAS); GO_0006921 (EC: TAS); GO_0008234 (EC: TAS, PMID:7796396); GO_0030855 (EC: IEP); GO_0042802 (EC: IPI)",,,,,,,,,PMID:7796396; 7983002; 8710882; 8780721; 8812467; 8900201; 8962078; 8978814; 9219695; 9228018; 9298992; 9337844; 9463409; 9593687; 9857079; 9933635; 9990034; 10069390; 10103059; 10205159; 10409650; 10432301; 10438520; 10469173; 10481058; 10655504; 10734073; 10770929; 11016947; 11098060; 11246070; 11262188; 11331782; 11356849; 11387340; 11423904; 11438643; 11463840; 11514563; 11802788; 11832478; 11859414; 11901153; 11953316; 12052891; 12089322; 12145703; 12232792; 12477932; 12888622; 14713958; 15103018; 15200957; 15273717; 15280469; 15321985; 15356202; 15489334; 15500642; 15511269; 15654952; 15735701; 16123779; 16135563; 16169070; 16341674; 16518869; 16948818; 16977583; 17167422; 17337451; 17392160; 18029348; 18155731; 18408014; 18497562; 18723680; 18762957; 18820706; 18946722; 19022247; 19052714; 19219602; 19269008; 19414860; 19573080; 19694615; 19773279; 19897582; 19915487; 20097875; 20332099; 20402676; 20427671; 20437871; 20606168; 20661084; 20682790; 20702410; 20801175; 20855536; 20890311; 21098228; 21111746; 21139048; 21317160; 21621544; 21900206; 21906983; 21918813; 21936563; 21963094; 21988832; 22094081; 22433863; 22505724; 22683611; 22858542; 22891250; 23402898,,,,,,,,,,,,,,,OGG:3000000839,,,,,,,"caspase 6, apoptosis-related cysteine peptidase",,,,,,,,,,,,,"Other designations: apoptotic protease MCH-2|caspase 6, apoptosis-related cysteine protease|caspase-6",,CASP6,,,,,,,,,,,,,,,,,,,,,,,839,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CASP6,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000000836,CASP3,,"Other designations: CASP-3|CPP-32|PARP cleavage protease|SREBP cleavage activity 1|apopain|caspase 3, apoptosis-related cysteine protease|caspase-3|cysteine protease CPP32|procaspase3|protein Yama",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CPP32B|SCA-1|CPP32,,,,,,,,,,,,4,,,,,,HPRD:02799|MIM:600636|Vega:OTTHUMG00000133681|Ensembl:ENSG00000164305|HGNC:1504,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"caspase 3, apoptosis-related cysteine peptidase",,,4q34,,,,,,,,,,,,,,,,"GO_0001782 (EC: IEA); GO_0001836 (EC: IEA); GO_0004190 (EC: EXP); GO_0004197 (EC: IDA, PMID:19240112); GO_0004197 (EC: TAS); GO_0004861 (EC: IEA); GO_0005515 (EC: IPI, PMID:16501604); GO_0005634 (EC: IDA, PMID:17167422); GO_0005654 (EC: TAS); GO_0005829 (EC: IDA, PMID:17167422); GO_0005829 (EC: TAS); GO_0005886 (EC: TAS); GO_0006309 (EC: TAS); GO_0006508 (EC: IDA, PMID:12888622); GO_0006915 (EC: TAS); GO_0006921 (EC: TAS); GO_0006974 (EC: IEA); GO_0007507 (EC: IEA); GO_0007605 (EC: IEA); GO_0008233 (EC: IDA, PMID:17167422); GO_0008625 (EC: IEA); GO_0008631 (EC: IEA); GO_0008635 (EC: TAS); GO_0009411 (EC: IEA); GO_0009611 (EC: IEA); GO_0022617 (EC: TAS); GO_0030182 (EC: IBA); GO_0030198 (EC: TAS); GO_0030216 (EC: IBA); GO_0030218 (EC: IDA, PMID:17167422); GO_0030218 (EC: TAS, PMID:18309324); GO_0030220 (EC: TAS, PMID:18309324); GO_0030889 (EC: IEA); GO_0034349 (EC: IEA); GO_0034612 (EC: TAS, PMID:10521396); GO_0035329 (EC: TAS); GO_0042981 (EC: TAS); GO_0043029 (EC: IEA); GO_0043065 (EC: TAS); GO_0043066 (EC: IGI, PMID:9353287); GO_0043281 (EC: TAS); GO_0043525 (EC: IEA); GO_0045165 (EC: IEA); GO_0045736 (EC: IEA); GO_0046007 (EC: IEA); GO_0048011 (EC: TAS); GO_0051402 (EC: IEA); GO_0097153 (EC: IMP, PMID:10921886); GO_0097190 (EC: TAS, PMID:10521396); GO_0097192 (EC: IEA); GO_0097193 (EC: TAS); GO_0097194 (EC: IDA, PMID:8689682); GO_0097194 (EC: IMP, PMID:11350920); GO_0097200 (EC: IMP, PMID:17559062)",,,,,,,,,PMID:1067155; 7596430; 7774019; 7983002; 8044845; 8605870; 8626669; 8673606; 8689682; 8696339; 8755496; 8780721; 8804412; 8812467; 8900201; 8943232; 8962078; 8976194; 9021152; 9045680; 9108473; 9115219; 9206994; 9208847; 9219695; 9230442; 9233763; 9235961; 9252332; 9267021; 9278461; 9298992; 9323209; 9326610; 9334214; 9334240; 9334338; 9337844; 9348292; 9351817; 9353287; 9361003; 9367996; 9368003; 9384571; 9395403; 9422780; 9452471; 9525868; 9535906; 9545236; 9548463; 9593687; 9618490; 9624143; 9632733; 9660939; 9671712; 9685336; 9694885; 9705209; 9708895; 9736630; 9751706; 9786869; 9799125; 9811849; 9840926; 9850056; 9857079; 9875225; 9878167; 9894612; 9933635; 9990034; 10022118; 10066732; 10069390; 10082566; 10103059; 10200531; 10205158; 10205159; 10319819; 10364179; 10409750; 10430052; 10432301; 10435619; 10438581; 10454555; 10469173; 10479680; 10490026; 10510468; 10521396; 10556977; 10564664; 10579725; 10602493; 10602513; 10608812; 10611247; 10629060; 10671544; 10672017; 10675528; 10704341; 10708425; 10712510; 10713703; 10734073; 10748026; 10770929; 10777594; 10791974; 10799874; 10821855; 10823823; 10862606; 10896157; 10899937; 10921886; 10926122; 10942389; 10998058; 11002417; 11016947; 11024045; 11042212; 11053413; 11058115; 11076937; 11084335; 11098060; 11106668; 11123279; 11141237; 11149901; 11162250; 11162351; 11170436; 11175261; 11177389; 11222676; 11230124; 11242052; 11248093; 11257230; 11257232; 11261798; 11274152; 11278283; 11278287; 11278424; 11278572; 11278782; 11278797; 11283607; 11313965; 11331419; 11345898; 11350920; 11356849; 11359776; 11387340; 11399776; 11420704; 11423904; 11425872; 11437602; 11438643; 11447297; 11462036; 11470874; 11478781; 11479289; 11500511; 11509621; 11514563; 11517310; 11526478; 11550094; 11551979; 11555640; 11602184; 11675509; 11689006; 11696595; 11741893; 11748221; 11752060; 11752215; 11787859; 11788610; 11795487; 11802788; 11815631; 11825902; 11830582; 11832478; 11840332; 11854437; 11859414; 11866986; 11875078; 11901153; 11904443; 11927604; 11948397; 11960384; 11972398; 11981455; 11988074; 11989976; 11992386; 12004072; 12019321; 12032677; 12036886; 12044963; 12055227; 12070005; 12070657; 12080079; 12095993; 12107159; 12112012; 12118383; 12124386; 12145703; 12149654; 12150947; 12151338; 12169388; 12181128; 12181742; 12186978; 12190962; 12207967; 12210761; 12228224; 12235123; 12297281; 12390838; 12393901; 12397210; 12401855; 12404116; 12425945; 12438416; 12444137; 12477932; 12483536; 12490308; 12511568; 12515825; 12566444; 12576296; 12576443; 12579342; 12581734; 12598529; 12605885; 12606589; 12611892; 12621124; 12624662; 12643601; 12657644; 12677451; 12686427; 12700630; 12700660; 12707329; 12750393; 12750404; 12760639; 12787561; 12788227; 12788938; 12792782; 12804035; 12809603; 12821118; 12824190; 12833566; 12837287; 12854132; 12867600; 12874324; 12888622; 12897143; 14555204; 14570914; 14572611; 14612448; 14623896; 14657946; 14674699; 14678329; 14684629; 14710359; 14764700; 14960581; 14970175; 14971566; 14976035; 14982947; 14991812; 14993250; 15014070; 15015772; 15033720; 15033815; 15041704; 15087450; 15098015; 15153940; 15156398; 15178331; 15179054; 15186778; 15187159; 15200957; 15204919; 15205454; 15220451; 15241180; 15246206; 15254227; 15258591; 15280469; 15345747; 15375594; 15473998; 15489334; 15505416; 15507451; 15542841; 15564512; 15569669; 15569672; 15569692; 15578977; 15599395; 15617521; 15637055; 15638357; 15650747; 15657349; 15657356; 15670787; 15705385; 15706351; 15716280; 15725353; 15735701; 15748158; 15748808; 15767427; 15803189; 15806167; 15843892; 15848173; 15869582; 15935070; 15996160; 16009347; 16080782; 16083554; 16111829; 16120388; 16121124; 16179347; 16203739; 16204230; 16213496; 16227597; 16242324; 16286477; 16300929; 16320828; 16330530; 16337360; 16338743; 16344560; 16382148; 16455648; 16463650; 16480911; 16498457; 16501604; 16505307; 16511342; 16516911; 16520893; 16526059; 16529748; 16530181; 16530191; 16543147; 16567804; 16651613; 16689860; 16716256; 16781734; 16787777; 16791842; 16802364; 16808908; 16835231; 16869888; 16882668; 16884727; 16894574; 16897667; 16931214; 16935258; 16948902; 16949642; 16955788; 16977583; 16979168; 16983089; 17008916; 17013756; 17013758; 17023557; 17038954; 17065568; 17069460; 17071630; 17080552; 17114647; 17118559; 17121821; 17123522; 17124493; 17130234; 17140287; 17141888; 17143787; 17167422; 17172814; 17198755; 17217622; 17219053; 17235653; 17245643; 17261582; 17272816; 17283187; 17291493; 17301822; 17321792; 17324936; 17337451; 17340613; 17364171; 17379327; 17412564; 17413988; 17430778; 17436592; 17437405; 17462862; 17488272; 17495975; 17498346; 17505517; 17525639; 17534194; 17544405; 17559062; 17597071; 17606719; 17606900; 17616526; 17645689; 17653867; 17689858; 17698513; 17721932; 17724022; 17805550; 17823127; 17880920; 17908973; 17928446; 17936584; 17950632; 17967742; 17978580; 17981569; 17983802; 17989718; 18000616; 18029348; 18047842; 18054197; 18055116; 18058802; 18060501; 18074388; 18083346; 18086147; 18088367; 18092356; 18155705; 18155731; 18164959; 18171980; 18209072; 18211414; 18227733; 18256758; 18256791; 18266005; 18296636; 18297401; 18298948; 18300076; 18309324; 18330265; 18379198; 18381704; 18384375; 18415681; 18415689; 18427836; 18439040; 18441516; 18450750; 18473402; 18476631; 18521960; 18551626; 18561948; 18577580; 18585351; 18586680; 18623086; 18652315; 18658137; 18669646; 18676680; 18708163; 18712678; 18723680; 18727869; 18754867; 18759060; 18763039; 18768468; 18814044; 18818379; 18820371; 18821563; 18829519; 18838202; 18844072; 18946722; 18986328; 19013323; 19035131; 19043361; 19046417; 19052714; 19058789; 19074885; 19132366; 19141860; 19157504; 19157506; 19159073; 19170196; 19178812; 19200347; 19204086; 19219602; 19223905; 19236754; 19240112; 19241192; 19244543; 19258326; 19266703; 19269008; 19270727; 19272183; 19275584; 19275586; 19275587; 19281794; 19283487; 19289465; 19299722; 19319745; 19322201; 19351510; 19355923; 19379562; 19404232; 19414860; 19453261; 19458171; 19513559; 19519609; 19531679; 19544333; 19549685; 19550122; 19553679; 19557639; 19559790; 19567200; 19570417; 19573080; 19585117; 19598027; 19604093; 19610261; 19625176; 19626422; 19636556; 19655253; 19655254; 19655415; 19665028; 19692168; 19692467; 19698783; 19698994; 19715609; 19723039; 19724860; 19724907; 19730442; 19738422; 19759058; 19770576; 19770581; 19773279; 19774677; 19784808; 19788069; 19788411; 19807657; 19812265; 19826114; 19838207; 19840460; 19854241; 19878567; 19895210; 19913121; 19925402; 19937139; 19942343; 19956888; 19996122; 19996272; 19996275; 19996278; 20001963; 20012528; 20025478; 20038816; 20041182; 20042134; 20045442; 20060927; 20063052; 20068062; 20072652; 20085765; 20087649; 20101263; 20103643; 20104682; 20142237; 20150439; 20180022; 20198319; 20227371; 20299368; 20307198; 20340172; 20346214; 20383567; 20402676; 20404718; 20423928; 20424172; 20450729; 20453000; 20492341; 20512574; 20530714; 20566630; 20580881; 20598358; 20619728; 20628086; 20628645; 20632819; 20644561; 20661084; 20665667; 20667824; 20683021; 20683843; 20702410; 20722551; 20723300; 20738749; 20801175; 20814064; 20839416; 20855536; 20856198; 20862799; 20919853; 20929126; 20947770; 20950443; 20959405; 20962079; 20966960; 20981869; 21029675; 21048031; 21081164; 21098975; 21099290; 21099299; 21123175; 21123558; 21139048; 21142842; 21148072; 21151026; 21160486; 21178828; 21203962; 21216952; 21223758; 21237154; 21248767; 21255440; 21270757; 21307660; 21317880; 21319273; 21382445; 21441410; 21479362; 21483469; 21483669; 21484410; 21504623; 21506333; 21548803; 21555338; 21561870; 21624464; 21644054; 21644232; 21667042; 21668377; 21671484; 21682651; 21700414; 21706480; 21724551; 21725926; 21729540; 21756903; 21775054; 21785112; 21802116; 21819468; 21827945; 21859712; 21869592; 21875325; 21880013; 21890473; 21914347; 21926353; 21944661; 21959934; 21963094; 21987091; 21988832; 22013052; 22072751; 22094081; 22121772; 22136337; 22147199; 22184067; 22191568; 22216281; 22238643; 22242595; 22298410; 22302483; 22309278; 22320973; 22429811; 22429842; 22482362; 22496955; 22504224; 22541080; 22552851; 22568453; 22607239; 22629415; 22678593; 22683311; 22764223; 22796265; 22815893; 22832123; 22837201; 22844442; 22872644; 22885173; 22912727; 22926545; 22931643; 22939953; 22944165; 22949938; 22951837; 22952982; 22964638; 23000965; 23054082; 23103707; 23122728; 23152053; 23156805; 23170075; 23170789; 23220614; 23221544; 23271051; 23271418; 23295106; 23326121; 23345589; 23384723; 23386603; 23416147; 23421973; 23519117; 23531593; 23545262; 23555267; 23568731; 23591201; 23599180; 23650375; 23658722; 23686572; 23703388; 23708668; 23724505; 23765963; 23775301; 23781587; 23791066; 23846227; 23867824; 23892923; 23894522; 23900644; 23907941; 23949910; 23979166; 24009453; 24129493; 24161344; 24553140,,,,,,,,,,,,,,,OGG:3000000836,,,,,,,"caspase 3, apoptosis-related cysteine peptidase",,,,,,,,,,,,,"Other designations: CASP-3|CPP-32|PARP cleavage protease|SREBP cleavage activity 1|apopain|caspase 3, apoptosis-related cysteine protease|caspase-3|cysteine protease CPP32|procaspase3|protein Yama",,CASP3,,,,,,,,,,,,,,,,,,,,,,,836,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CASP3,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000000835,CASP2,,"Other designations: caspase-2|neural precursor cell expressed developmentally down-regulated protein 2|protease ICH-1|protein phosphatase 1, regulatory subunit 57",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,NEDD-2|ICH1|PPP1R57|NEDD2|CASP-2,,,,,,,,,,,,7,,,,,,HPRD:02800|MIM:600639|Ensembl:ENSG00000106144|Vega:OTTHUMG00000023641|HGNC:1503,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"caspase 2, apoptosis-related cysteine peptidase",,,7q34-q35,,,,,,,,,,,,,,,,"GO_0001554 (EC: IEA); GO_0003407 (EC: IEA); GO_0004197 (EC: IDA, PMID:10980123); GO_0005515 (EC: IPI, PMID:11076957); GO_0005634 (EC: TAS, PMID:18309324); GO_0005737 (EC: IBA); GO_0005739 (EC: IEA); GO_0005829 (EC: TAS); GO_0006915 (EC: NAS, PMID:11156409); GO_0006977 (EC: IMP); GO_0007420 (EC: IEA); GO_0007568 (EC: IEA); GO_0008630 (EC: IBA); GO_0008630 (EC: TAS, PMID:18309324); GO_0016020 (EC: IEA); GO_0016485 (EC: IDA, PMID:9044836); GO_0019899 (EC: ISS, PMID:11076957); GO_0019904 (EC: IPI, PMID:9044836); GO_0035234 (EC: IEA); GO_0043065 (EC: IDA, PMID:10980123); GO_0043281 (EC: TAS); GO_0043525 (EC: IEA); GO_0048011 (EC: TAS); GO_0071260 (EC: IEP, PMID:19593445); GO_0097153 (EC: IEA); GO_0097190 (EC: TAS, PMID:18309324); GO_0097192 (EC: IBA); GO_0097194 (EC: TAS, PMID:18309324); GO_2001235 (EC: IEA)",,,,,,,,,PMID:7789948; 8044845; 8087842; 8780721; 8962078; 8985253; 9044836; 9228018; 9261102; 9560245; 9695946; 9792675; 9847074; 10079193; 10329646; 10791974; 10980123; 11076957; 11156409; 11278287; 11313953; 11350957; 11399776; 11425872; 11823470; 11830582; 11832478; 11972030; 12011445; 12065594; 12107826; 12145703; 12193789; 12477715; 12477932; 12584573; 12598307; 12787561; 12837286; 12853948; 12920126; 14584591; 14623896; 14647455; 14701762; 14702039; 14713958; 14716300; 15073321; 15173176; 15262979; 15297885; 15489334; 15500642; 15511269; 15555560; 15590671; 15735701; 15817479; 15843892; 15882978; 16172118; 16193064; 16227610; 16344560; 16360037; 16387548; 16652156; 16701639; 16777994; 16822901; 16843824; 17079734; 17159900; 17195089; 17627033; 17637755; 17902043; 17945178; 18166155; 18238895; 18309324; 18375382; 18413747; 18418048; 18723680; 18840686; 19074885; 19269008; 19322201; 19347032; 19414860; 19453261; 19573080; 19593445; 19604093; 19715609; 19730412; 19738422; 19773279; 19935698; 20143425; 20158568; 20187765; 20208132; 20402676; 20453000; 20819778; 20855536; 20978129; 21051981; 21332795; 21415862; 21475302; 21726810; 21828056; 21900206; 21903589; 21906983; 21940110; 21988832; 22002103; 22077397; 22174370; 22201672; 22396545; 22486813; 22505724; 22531785; 22825847; 23042294; 23404198; 23469978; 23553630; 23568547; 24250222; 24321384,,,,,,,,,,,,,,,OGG:3000000835,,,,,,,"caspase 2, apoptosis-related cysteine peptidase",,,,,,,,,,,,,"Other designations: caspase-2|neural precursor cell expressed developmentally down-regulated protein 2|protease ICH-1|protein phosphatase 1, regulatory subunit 57",,CASP2,,,,,,,,,,,,,,,,,,,,,,,835,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CASP2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000000834,CASP1,,"Other designations: CASP1 nirs variant 1|IL-1 beta-converting enzyme|IL1B-convertase|caspase 1, apoptosis-related cysteine peptidase (interleukin 1, beta, convertase)|caspase-1|interleukin 1, beta, convertase|interleukin 1-B converting enzyme",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,IL1BC|P45|ICE,,,,,,,,,,,,11,,,,,,MIM:147678|HGNC:1499|HPRD:00977|Vega:OTTHUMG00000048072|Ensembl:ENSG00000137752,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"caspase 1, apoptosis-related cysteine peptidase",,,11q23,,,,,,,,,,,,,,,,"GO_0001666 (EC: IEA); GO_0004197 (EC: IBA); GO_0004197 (EC: TAS); GO_0005515 (EC: IPI, PMID:11374873); GO_0005576 (EC: IEA); GO_0005737 (EC: IBA); GO_0005829 (EC: TAS); GO_0006508 (EC: IDA, PMID:12888622); GO_0006915 (EC: TAS, PMID:7876192); GO_0006919 (EC: TAS, PMID:10799503); GO_0007165 (EC: TAS, PMID:1373520); GO_0008656 (EC: TAS, PMID:10799503); GO_0032496 (EC: IEA); GO_0032611 (EC: IEA); GO_0033198 (EC: IEA); GO_0035872 (EC: TAS); GO_0043123 (EC: IEP, PMID:12761501); GO_0045087 (EC: TAS); GO_0050717 (EC: IEA); GO_0050718 (EC: IEA); GO_0050727 (EC: IBA); GO_0051882 (EC: IEA); GO_0060081 (EC: IEA); GO_0070269 (EC: IEA); GO_0071260 (EC: IEP, PMID:19593445); GO_0071310 (EC: IDA, PMID:19158679); GO_0072557 (EC: IBA); GO_0072557 (EC: ISS); GO_0072558 (EC: IDA, PMID:12191486); GO_0072559 (EC: IDA, PMID:15030775); GO_0097169 (EC: IDA, PMID:19158676); GO_0097194 (EC: IBA)",,,,,,,,,PMID:1321594; 1373520; 1574116; 1919001; 7642516; 7721861; 7797510; 7876192; 8034320; 8035875; 8044845; 8125298; 8861900; 8962078; 8978814; 8999548; 9002959; 9070648; 9115219; 9190289; 9219695; 9250871; 9334240; 9334338; 9435230; 9535906; 9548463; 9593687; 9632733; 9705209; 9705938; 9727491; 9792675; 9804161; 9830039; 9875225; 9894612; 9987822; 9990034; 10069390; 10329646; 10353249; 10438581; 10477277; 10510468; 10660263; 10708425; 10799503; 11085743; 11226410; 11374873; 11390368; 11432859; 11437653; 11438643; 11472070; 11536016; 11684016; 11821383; 11953316; 11967258; 11997061; 12019269; 12096920; 12170183; 12191486; 12215842; 12387869; 12459189; 12459463; 12477932; 12628757; 12692130; 12761501; 12888622; 14584052; 14669344; 15030775; 15039421; 15107016; 15296730; 15326478; 15383541; 15471361; 15489334; 15498465; 15561713; 15749123; 15809717; 16037825; 16087165; 16123779; 16260731; 16286016; 16405550; 16428475; 16575408; 16621994; 16778130; 16780720; 16785446; 16817903; 16903774; 16920334; 17036048; 17173859; 17196042; 17207965; 17303764; 17360653; 17418785; 17477815; 17597823; 17623017; 17703412; 17959595; 18029348; 18209072; 18263705; 18263805; 18304957; 18329368; 18523309; 18550243; 18577712; 18590738; 18799371; 18828051; 18981155; 19013323; 19074885; 19117953; 19141860; 19158676; 19158679; 19258923; 19269008; 19275586; 19382257; 19414860; 19439663; 19573080; 19593445; 19648107; 19737897; 19773279; 19779610; 19825518; 19833722; 19913121; 20038581; 20048342; 20060974; 20170165; 20184726; 20197547; 20402676; 20485444; 20503287; 20628086; 20808838; 20852925; 20855536; 20959405; 21037509; 21048031; 21052690; 21311905; 21320026; 21463955; 21757759; 21792841; 21832064; 21862576; 21862623; 22046355; 22046441; 22195745; 22227487; 22491736; 22537218; 22833538; 22837397; 23021143; 23209292; 23226468; 23236067; 23278288; 23386603; 23508996; 23590971; 23637985; 23703390; 23793845; 23839215; 23884363; 24022484; 24356306,,,,,,,,,,,,,,,OGG:3000000834,,,,,,,"caspase 1, apoptosis-related cysteine peptidase",,,,,,,,,,,,,"Other designations: CASP1 nirs variant 1|IL-1 beta-converting enzyme|IL1B-convertase|caspase 1, apoptosis-related cysteine peptidase (interleukin 1, beta, convertase)|caspase-1|interleukin 1, beta, convertase|interleukin 1-B converting enzyme",,CASP1,,,,,,,,,,,,,,,,,,,,,,,834,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CASP1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000000837,CASP4,,"Other designations: CASP-4|ICE(rel)-II|apoptotic cysteine protease Mih1/TX|caspase 4, apoptosis-related cysteine protease|caspase-4|protease ICH-2|protease TX",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,ICEREL-II|ICE(rel)II|ICH-2|Mih1/TX|TX,,,,,,,,,,,,11,,,,,,HGNC:1505|Ensembl:ENSG00000196954|Vega:OTTHUMG00000166078|MIM:602664|HPRD:04047,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"caspase 4, apoptosis-related cysteine peptidase",,,11q22.2-q22.3,,,,,,,,,,,,,,,,"GO_0004197 (EC: IBA); GO_0005737 (EC: IBA); GO_0005739 (EC: IEA); GO_0005789 (EC: IEA); GO_0006508 (EC: TAS, PMID:7797510); GO_0006915 (EC: TAS, PMID:7743998); GO_0042981 (EC: IEA); GO_0050727 (EC: IBA); GO_0072557 (EC: IBA); GO_0072559 (EC: IBA); GO_0097169 (EC: IBA); GO_0097194 (EC: IBA)",,,,,,,,,PMID:1919001; 7743998; 7797510; 7797592; 8125298; 8962078; 9233763; 9250871; 9539746; 9694885; 9792675; 9875225; 10069390; 10329646; 10477277; 10872455; 11927604; 12096920; 12477932; 14702039; 15123740; 15146197; 15326478; 15489334; 15500642; 15975932; 16920334; 17353931; 17942194; 18029041; 18056395; 19269008; 19414860; 19573080; 19705160; 19773279; 20237496; 20402676; 20453000; 20514521; 20816908; 20855536; 21282934; 21317160; 21479362; 21781452; 21832049; 21984918; 21988832; 22246630; 22733992; 23661706; 23684308,,,,,,,,,,,,,,,OGG:3000000837,,,,,,,"caspase 4, apoptosis-related cysteine peptidase",,,,,,,,,,,,,"Other designations: CASP-4|ICE(rel)-II|apoptotic cysteine protease Mih1/TX|caspase 4, apoptosis-related cysteine protease|caspase-4|protease ICH-2|protease TX",,CASP4,,,,,,,,,,,,,,,,,,,,,,,837,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CASP4,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000000838,CASP5,,"Other designations: CASP-5|ICE(rel)-III|TY protease|caspase 5, apoptosis-related cysteine protease|caspase-5|protease ICH-3|protease TY",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,ICE(rel)III|ICH-3|ICEREL-III,,,,,,,,,,,,11,,,,,,HGNC:1506|MIM:602665|Vega:OTTHUMG00000048073|HPRD:04048|Ensembl:ENSG00000137757,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"caspase 5, apoptosis-related cysteine peptidase",,,11q22.2-q22.3,,,,,,,,,,,,,,,,"GO_0004197 (EC: IBA); GO_0005737 (EC: IBA); GO_0006508 (EC: TAS, PMID:7797592); GO_0006915 (EC: TAS, PMID:7797592); GO_0008234 (EC: TAS, PMID:7797592); GO_0021762 (EC: IEP); GO_0042981 (EC: IEA); GO_0050727 (EC: IBA); GO_0071260 (EC: IEP, PMID:19593445); GO_0072557 (EC: IBA, Qualifier: NOT); GO_0072558 (EC: IDA, PMID:12191486); GO_0072559 (EC: IBA, Qualifier: NOT); GO_0097169 (EC: IBA, Qualifier: NOT); GO_0097194 (EC: IBA)",,,,,,,,,PMID:7797592; 8617266; 9250871; 9298992; 9894612; 10872455; 10986288; 11356849; 11535131; 12191486; 12477932; 12479849; 12853457; 12964016; 15886296; 16886895; 16893518; 17418785; 17676485; 18430458; 19074885; 19203830; 19269008; 19270026; 19414860; 19573080; 19593445; 19604093; 19773279; 20237496; 20379614; 20402676; 20434535; 20635389; 20855536; 21051981; 21191419; 21454616; 21668377; 21700414; 21969293; 22906436,,,,,,,,,,,,,,,OGG:3000000838,,,,,,,"caspase 5, apoptosis-related cysteine peptidase",,,,,,,,,,,,,"Other designations: CASP-5|ICE(rel)-III|TY protease|caspase 5, apoptosis-related cysteine protease|caspase-5|protease ICH-3|protease TY",,CASP5,,,,,,,,,,,,,,,,,,,,,,,838,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CASP5,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_47780,clomipramine,"chlorimipramine|3-chloroimipramine|3-(3-CHLORO-5H-DIBENZO[B,F]AZEPIN-5-YL)-N,N-DIMETHYLPROPAN-1-AMINE|3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethyl-1-propanamine|monochlorimipramine|G 34586|Clomipramine|3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine","A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine which is substituted by chlorine at position 3 and in which the hydrogen attached to the nitrogen is replaced by a 3-(dimethylamino)propyl group. One of the more sedating tricyclic antidepressants, it is used as the hydrochloride salt for the treatment of depression as well as obsessive-compulsive disorder and phobias.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Drug_Central:701|PMID:17471183|Open TG-Gates compound_id:00121|CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc12|Beilstein:1323477|PMID:16085036|PMID:19747949|LINCS:LSM-3171|Patent:US3467650|DrugBank:DB01242|PMID:12084414|PMID:19810911|PMID:12007764|Reaxys:1323477|CAS:303-49-1,,"A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine which is substituted by chlorine at position 3 and in which the hydrogen attached to the nitrogen is replaced by a 3-(dimethylamino)propyl group. One of the more sedating tricyclic antidepressants, it is used as the hydrochloride salt for the treatment of depression as well as obsessive-compulsive disorder and phobias.",,,,,,,,,,,,C19H23ClN2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_77402|http://purl.obolibrary.org/obo/CHEBI_48278|http://purl.obolibrary.org/obo/CHEBI_50949|http://purl.obolibrary.org/obo/CHEBI_48279|http://purl.obolibrary.org/obo/CHEBI_35469,,,,,"Clomipramine|3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine",,"chlorimipramine|3-chloroimipramine|3-(3-CHLORO-5H-DIBENZO[B,F]AZEPIN-5-YL)-N,N-DIMETHYLPROPAN-1-AMINE|3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethyl-1-propanamine|monochlorimipramine|G 34586",,,,,,,,,,,,,,,,,,,,,CHEBI:47780,,,,clomipramine,,CHEBI:47780,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://www.ebi.ac.uk/efo/EFO_0008480,mitochondrial DNA,mtDNA,"Typically small, circular, intronless, and maternally inherited, mitochondrial DNA (mtDNA) is the multicopy deoxyribonucleic acid genome of mitochondria, intracellular organelles responsible for vital respiratory chain and oxidative phosphorylation reactions in higher eukaryotes. Replicated and transcribed by a separate enzymatic machinery from that of nuclear DNA, mtDNA encodes only a subset of mitochondrial functions. (by EFO)",false,,,http://purl.obolibrary.org/obo/CHEBI_16991,,,,,,,,,,,,,,,,,,,,http://www.ebi.ac.uk/efo/EFO_0008480,,"Typically small, circular, intronless, and maternally inherited, mitochondrial DNA (mtDNA) is the multicopy deoxyribonucleic acid genome of mitochondria, intracellular organelles responsible for vital respiratory chain and oxidative phosphorylation reactions in higher eukaryotes. Replicated and transcribed by a separate enzymatic machinery from that of nuclear DNA, mtDNA encodes only a subset of mitochondrial functions. (by EFO)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,mtDNA,,,,,,,,,,,,,,,,,,,,,,,,,,,mitochondrial DNA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000143,MHC class I molecule,classical MHC class I molecule|major histocompatibility complex class I molecule|MHC class Ia molecule,"MHC class Ia (classical) molecules, termed human leukocyte antigen (HLA)-A, HLA-B and HLA-C in humans and H2-K, H2-D and H2-L in mice, are highly polymorphic glycoproteins composed of a single membrane-spanning alpha chain paired with the soluble protein beta2 microglobulin.",false,,,http://purl.obolibrary.org/obo/IMR_0000142,,,,,,,,,,,,,,,,,,,,GO:0042612,,"MHC class Ia (classical) molecules, termed human leukocyte antigen (HLA)-A, HLA-B and HLA-C in humans and H2-K, H2-D and H2-L in mice, are highly polymorphic glycoproteins composed of a single membrane-spanning alpha chain paired with the soluble protein beta2 microglobulin.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,classical MHC class I molecule|major histocompatibility complex class I molecule|MHC class Ia molecule,,,,,IMR:0000143,,,,,,,,,,,,,,,,,,,,,,MHC class I molecule,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000002918,GRM8,,Other designations: metabotropic glutamate receptor 8,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,mGlu8|MGLUR8|GLUR8|GPRC1H,,,,,,,,,,,,7,,,,,,Vega:OTTHUMG00000022888|HPRD:03071|MIM:601116|HGNC:4600|Ensembl:ENSG00000179603,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"glutamate receptor, metabotropic 8",,,7q31.3-q32.1,,,,,,,,,,,,,,,,"GO_0001642 (EC: IEA); GO_0004930 (EC: IMP, PMID: 9473604); GO_0005886 (EC: TAS); GO_0005887 (EC: TAS, PMID: 9473604); GO_0007196 (EC: IMP, PMID: 9473604); GO_0007601 (EC: TAS, PMID: 9473604); GO_0007608 (EC: IEA); GO_0008066 (EC: IMP, PMID: 9473604); GO_0030818 (EC: IDA, PMID: 11166323)",,,,,,,,,PMID: 8824806; 9299241; 9473604; 10216218; 11166323; 11329013; 11912074; 11943148; 12477932; 15211621; 15452121; 15489334; 16144832; 17167337; 17684544; 17955477; 17975119; 18195715; 18618593; 19023099; 19058789; 19156168; 19268276; 20009918; 20201926; 20237162; 20379614; 20398908; 20560679; 20800221; 21493956; 23420844,,,,,,,,,,,,,,,OGG:3000002918,,,,,,,"glutamate receptor, metabotropic 8",,,,,,,,,,,,,Other designations: metabotropic glutamate receptor 8,,GRM8,,,,,,,,,,,,,,,,,,,,,,,2918,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,GRM8,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000382,NF-kappaB,Rel/NF-kappaB family|NFkB|NF-kappa-B|nuclear factor-kappa B,"Members of this family include p50, p52, p65, c-Rel, v-Rrel, RelB, and the Drosophila proteins, Dorsal, Dif and Relish. Most of these transcription factors bind as homo- and heterodimers to the consensus a DNA sequence motif termed kappa-B.",false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,IPR:000451,,"Members of this family include p50, p52, p65, c-Rel, v-Rrel, RelB, and the Drosophila proteins, Dorsal, Dif and Relish. Most of these transcription factors bind as homo- and heterodimers to the consensus a DNA sequence motif termed kappa-B.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,Rel/NF-kappaB family|NFkB|NF-kappa-B|nuclear factor-kappa B,,,,,IMR:0000382,,,,,,,,,,,,,,,,,,,,,,NF-kappaB,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_75142,N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal,MG-132,A tripeptide that is L-leucyl-L-leucyl-L-leucine in which the C-terminal carboxy group has been reduced to the corresponding aldehyde and the N-terminal amino group is protected as its benzyloxycarbonyl derivative.,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Wikipedia:MG132,,A tripeptide that is L-leucyl-L-leucyl-L-leucine in which the C-terminal carboxy group has been reduced to the corresponding aldehyde and the N-terminal amino group is protected as its benzyloxycarbonyl derivative.,,,,,,,,,,,,C26H41N3O5|PubChem:462382,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MG-132,,,,,CHEBI:75142,,,,,,,,,,,,,,,,,,,,,,N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,C([C@H](CC(C)C)NC([C@H](CC(C)C)NC([C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1)=O)=O)(=O)[H],,,,,
http://purl.obolibrary.org/obo/CHEBI_33853,phenols,Aryl alcohol,Organic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring.,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Wikipedia:Phenols,,Organic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring.,,,,,,,,,,,,C6HOR5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Aryl alcohol,,,CHEBI:33853,,,,,,,,,,,,,,,,,,,,,,phenols,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,C1(=C(C(=C(C(=C1*)*)*)*)*)O,,,,,
http://purl.obolibrary.org/obo/CHEBI_6076,itraconazole,"Itrizole (TN)|Sporanox (TN)|Oriconazole|2-(butan-2-yl)-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-2,4-dihydro-3H-1,2,4-triazol-3-one|Itraconazole|itraconazole","An N-arylpiperazine that is cis-ketoconazole in which the imidazol-1-yl group is replaced by a 1,2,4-triazol-1-yl group and in which the actyl group attached to the piperazine moiety is replaced by a p-[(+-)1-sec-butyl-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl]phenyl group. A potent P-glycoprotein and CYP3A4 inhibitor, it is used as an antifungal drug for the treatment of various fungal infections, including aspergillosis, blastomycosis, candidiasis, chromoblastomycosis, coccidioidomycosis, cryptococcosis, histoplasmosis, and sporotrichosis.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:11219548|CAS:84625-61-6|PMID:11403818|PMID:15521894|PMID:19025521|PMID:25326091|DrugBank:DB01167|PMID:20400651|PMID:11422002,,"An N-arylpiperazine that is cis-ketoconazole in which the imidazol-1-yl group is replaced by a 1,2,4-triazol-1-yl group and in which the actyl group attached to the piperazine moiety is replaced by a p-[(+-)1-sec-butyl-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl]phenyl group. A potent P-glycoprotein and CYP3A4 inhibitor, it is used as an antifungal drug for the treatment of various fungal infections, including aspergillosis, blastomycosis, candidiasis, chromoblastomycosis, coccidioidomycosis, cryptococcosis, histoplasmosis, and sporotrichosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_50183|http://purl.obolibrary.org/obo/CHEBI_77748|http://purl.obolibrary.org/obo/CHEBI_140921,,,,,"2-(butan-2-yl)-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-2,4-dihydro-3H-1,2,4-triazol-3-one|Itraconazole|itraconazole",,Itrizole (TN)|Sporanox (TN)|Oriconazole,,,,,,,,,,,,,,,,,,,,,CHEBI:6076,,,,itraconazole,,CHEBI:6076,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_566274,malondialdehyde,,"A dialdehyde that is propane substituted by two oxo groups at the terminal carbon atoms respectively. A biomarker of oxidative damage to lipids caused by smoking, it exists in vivo mainly in the enol form.",false,,,http://purl.obolibrary.org/obo/TXPO_0004328,,,,,,,,,,,,,,,,,,,,,,"A dialdehyde that is propane substituted by two oxo groups at the terminal carbon atoms respectively. A biomarker of oxidative damage to lipids caused by smoking, it exists in vivo mainly in the enol form.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:566274,,,,,,,,,,,,,,,,,,,,,,malondialdehyde,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0000592,decreased thickness,thin|low thickness,A thickness which is relatively low.,false,,,http://purl.obolibrary.org/obo/PATO_0000915,,,,,,,,,,,,,,,,,,,,,,A thickness which is relatively low.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,low thickness,,thin,,,PATO:0000592,,,,,,,,,,,,,,,,,,,,,,decreased thickness,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0000591,increased thickness,high thickness,A thickness which is relatively high.,false,,,http://purl.obolibrary.org/obo/PATO_0000915,,,,,,,,,,,,,,,,,,,,,,A thickness which is relatively high.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,high thickness,,,,,PATO:0000591,,,,,,,,,,,,,,,,,,,,,,increased thickness,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0000596,decreased volume,low volume|small volume,A volume which is relatively low.,false,,,http://purl.obolibrary.org/obo/TXPO_0002416|http://purl.obolibrary.org/obo/PATO_0000918,,,,,,,,,,,,,,,,,,,,,,A volume which is relatively low.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,low volume|small volume,,,,,PATO:0000596,,,,,,,,,,,,,,,,,,,,,,decreased volume,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0000595,increased volume,high volume|large volume,A volume which is relatively high.,false,,,http://purl.obolibrary.org/obo/TXPO_0002416|http://purl.obolibrary.org/obo/PATO_0000918,,,,,,,,,,,,,,,,,,,,,,A volume which is relatively high.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,high volume|large volume,,,,,PATO:0000595,,,,,,,,,,,,,,,,,,,,,,increased volume,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0003077,GDF-9,Growth/differentiation factor-9,,false,,,http://purl.obolibrary.org/obo/IMR_0000040,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Growth/differentiation factor-9,,,,,IMR:0003077,,,,,,,,,,,,,,,,,,,,,,GDF-9,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0005751,mitochondrial respiratory chain complex IV,,"A protein complex located in the mitochondrial inner membrane that forms part of the mitochondrial respiratory chain. Contains the 13 polypeptide subunits of cytochrome c oxidase, including cytochrome a and cytochrome a3. Catalyzes the oxidation of reduced cytochrome c by dioxygen (O2).",false,,,http://purl.obolibrary.org/obo/GO_0098800,,,,,,,,,,,,,,,,,,,,,,"A protein complex located in the mitochondrial inner membrane that forms part of the mitochondrial respiratory chain. Contains the 13 polypeptide subunits of cytochrome c oxidase, including cytochrome a and cytochrome a3. Catalyzes the oxidation of reduced cytochrome c by dioxygen (O2).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0005751,,,,,,,,,,,,,,,,,,,,,,mitochondrial respiratory chain complex IV,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_48539,alpha-adrenergic drug,alpha-adrenergic drugs,Any drug that acts on an alpha-adrenergic receptor.,false,,,http://purl.obolibrary.org/obo/CHEBI_37962,,,,,,,,,,,,,,,,,,,,,,Any drug that acts on an alpha-adrenergic receptor.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,alpha-adrenergic drugs,,,,,,,,,,,,,,,,,,,,,CHEBI:48539,,,,alpha-adrenergic drug,,CHEBI:48539,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_16474,NADPH,"InChI=1S/C21H30N7O17P3/c22-17-12-19(25-7-24-17)28(8-26-12)21-16(44-46(33,34)35)14(30)11(43-21)6-41-48(38,39)45-47(36,37)40-5-10-13(29)15(31)20(42-10)27-3-1-2-9(4-27)18(23)32/h1,3-4,7-8,10-11,13-16,20-21,29-31H,2,5-6H2,(H2,23,32)(H,36,37)(H,38,39)(H2,22,24,25)(H2,33,34,35)/t10-,11-,13-,14-,15-,16-,20-,21-/m1/s1|NADP-reduced|2'-O-phosphonoadenosine 5'-{3-[1-(3-carbamoyl-1,4-dihydropyridin-1-yl)-1,4-anhydro-D-ribitol-5-yl] dihydrogen diphosphate}","NADPH is the reduced form of NADP+; used in anabolic reactions, such as lipid and nucleic acid synthesis, which require NADPH as a reducing agent.",false,,,http://purl.obolibrary.org/obo/CHEBI_36976,,,,,,,,,,,,,,,,,,,,CHEBI:16474|Wikipedia:NADPH,,"NADPH is the reduced form of NADP+; used in anabolic reactions, such as lipid and nucleic acid synthesis, which require NADPH as a reducing agent.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"2'-O-phosphonoadenosine 5'-{3-[1-(3-carbamoyl-1,4-dihydropyridin-1-yl)-1,4-anhydro-D-ribitol-5-yl] dihydrogen diphosphate}",,"InChI=1S/C21H30N7O17P3/c22-17-12-19(25-7-24-17)28(8-26-12)21-16(44-46(33,34)35)14(30)11(43-21)6-41-48(38,39)45-47(36,37)40-5-10-13(29)15(31)20(42-10)27-3-1-2-9(4-27)18(23)32/h1,3-4,7-8,10-11,13-16,20-21,29-31H,2,5-6H2,(H2,23,32)(H,36,37)(H,38,39)(H2,22,24,25)(H2,33,34,35)/t10-,11-,13-,14-,15-,16-,20-,21-/m1/s1|NADP-reduced",,,CHEBI:16474,,,,,,,,,,,,,,,,,,,,,,NADPH,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000004,hedgehog,Hh,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,GO:0005113,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000624,,,,,Hh,,,,,IMR:0000004,,,,,,,,,,,,,,,,,,,,,,hedgehog,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010478,60S ribosomal protein L29,Cell surface heparin binding protein HIP,,false,,,http://purl.obolibrary.org/obo/IMR_0000897,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Cell surface heparin binding protein HIP,,,,,IMR:0010478,,,,,,,,,,,,,,,,,,,,,,60S ribosomal protein L29,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0015910,long-chain fatty acid import into peroxisome,,The directed movement of long-chain fatty acids into a peroxisome. A long-chain fatty acid is a fatty acid with a chain length between C13 and C22.,false,,,http://purl.obolibrary.org/obo/GO_0015909,,,,,,,,,,,,,,,,,,,,,,The directed movement of long-chain fatty acids into a peroxisome. A long-chain fatty acid is a fatty acid with a chain length between C13 and C22.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0015910,,,,,,,,,,,,,,,,,,,,,,long-chain fatty acid import into peroxisome,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0015914,phospholipid transport,,"The directed movement of phospholipids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Phospholipids are any lipids containing phosphoric acid as a mono- or diester.",false,,,http://purl.obolibrary.org/obo/GO_0006869,,,,,,,,,,,,,,,,,,,,,,"The directed movement of phospholipids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Phospholipids are any lipids containing phosphoric acid as a mono- or diester.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0015914,,,,,,,,,,,,,,,,,,,,,,phospholipid transport,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000037,inhibin,,,false,,,http://purl.obolibrary.org/obo/IMR_0000036,,,,,,,,,,,,,,,,,,,,GO:0016916,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000037,,,,,,,,,,,,,,,,,,,,,,inhibin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004877,negative regulation of caspase-3 activation,,"Negative regulation of caspase-3 activation is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of caspase-3 activation.",false,,,http://purl.obolibrary.org/obo/TXPO_0004878,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of caspase-3 activation is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of caspase-3 activation.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004877,,,,,,,,,,,,,,,,,,,,,,negative regulation of caspase-3 activation,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003098,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004873,Ctnnb1 (canonical) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0005063|http://purl.obolibrary.org/obo/TXPO_1000094,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:84353|NCBI-Mouse-GeneID:12387|NCBI-Human-GeneID:1499|PMID:29786110|PMID:31439937,,,,,,,,,,,,,,,catenin beta 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004873,,,,,,,,,,,,,,,,,,,,,,Ctnnb1 (canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004870,beta-catenin signal transduction pathway,,A series of molecular signals mediated by beta-catenin.,false,,,http://purl.obolibrary.org/obo/TXPO_0000609,,,,,,,,,,,,,,,,,,,,,,A series of molecular signals mediated by beta-catenin.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004870,,,,,,,,,,,,,,,,,,,,,,beta-catenin signal transduction pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004879,CASPASE-3(human) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_0001145,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:836|PMID:23284992,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000305,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000836,,,,,,,,,,,,,TXPO:0004879,,,,,,,,,,,,,,,,,,,,,,CASPASE-3(human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004875,c-Src signaling (primitive),,c-Src signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by c-Src.,false,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,,,c-Src signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by c-Src.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0100575,http://purl.obolibrary.org/obo/TXPO_0004805,,,,,,,,,,,,,,,,TXPO:0004875,,,,,,,,,,,,,,,,,,,,,,c-Src signaling (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004872,CDH1 - inactive form (canonical) [hepatocarcinogenesis],E-cadherin,,false,,,http://purl.obolibrary.org/obo/TXPO_0005063|http://purl.obolibrary.org/obo/TXPO_0005073,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:83502|NCBI-Human-GeneID:999|NCBI-Mouse-GeneID:12550|PMID:29787164|PMID:26017875,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0002355,,,,,,,,,E-cadherin,,,,,TXPO:0004872,,,,,,,,,,,,,,,,,,,,,,CDH1 - inactive form (canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004871,beta-catenin signal (primitive),,beta-catenin signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by beta-catenin.,false,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,,,beta-catenin signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by beta-catenin.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004870,,,,,,,,,,,,,,,,TXPO:0004871,,,,,,,,,,,,,,,,,,,,,,beta-catenin signal (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004876,Src (canonical) [hepatocarcinogenesis],c-Src|p60-Src,,false,,,http://purl.obolibrary.org/obo/IMR_0100575,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:6714|NCBI-Mouse-GeneID:20779|NCBI-Rat-GeneID:83805|PMID:31781608,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,c-Src|p60-Src,,,,,TXPO:0004876,,,,,,,,,,,,,,,,,,,,,,Src (canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004874,actin cytoskeleton reorganization [hepatocarcinogenesis],actin cytoskeleton remodeling,"A process that is carried out at the cellular level which results in dynamic structural changes to the arrangement of constituent parts of cytoskeletal structures comprising actin filaments and their associated proteins.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/GO_0031532,,,,,,,,,,,,,,,,,,,,PMID:31781608,,"A process that is carried out at the cellular level which results in dynamic structural changes to the arrangement of constituent parts of cytoskeletal structures comprising actin filaments and their associated proteins.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004422,,,,,,actin cytoskeleton remodeling,,,,,TXPO:0004874,,,,,,,,,,,,,,,,,,,,,,actin cytoskeleton reorganization [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004878,negative regulation of activation,,"Negative regulation of activation is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of activation.",false,,,http://purl.obolibrary.org/obo/TXPO_0000369,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of activation is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of activation.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004878,,,,,,,,,,,,,,,,,,,,,,negative regulation of activation,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000401,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_49020,hormone antagonist,hormone antagonists,"A chemical substance which inhibits the function of the endocrine glands, the biosynthesis of their secreted hormones, or the action of hormones upon their specific sites.",false,,,http://purl.obolibrary.org/obo/CHEBI_48706|http://purl.obolibrary.org/obo/CHEBI_51061,,,,,,,,,,,,,,,,,,,,,,"A chemical substance which inhibits the function of the endocrine glands, the biosynthesis of their secreted hormones, or the action of hormones upon their specific sites.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,hormone antagonists,,,,,,,,,,,,,,,,,,,,,CHEBI:49020,,,,hormone antagonist,,CHEBI:49020,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000806,GADD45 beta,MyD118,,false,,,http://purl.obolibrary.org/obo/IMR_0000559,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MyD118,,,,,IMR:0000806,,,,,,,,,,,,,,,,,,,,,,GADD45 beta,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000034,cholestasis dependent process,,Cholestasis dependent process is a subtype of toxic course dependent process: A process that can constitute the course of cholestasis.,false,,,http://purl.obolibrary.org/obo/TXPO_0001715,,,,,,,,,,,,,,,,,,,,,,Cholestasis dependent process is a subtype of toxic course dependent process: A process that can constitute the course of cholestasis.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000034,,,,,,,,,,,,,,,,,,,,,,cholestasis dependent process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000032,bosentan [Cholestasis],,,false,,,http://purl.obolibrary.org/obo/CHEBI_51450|http://purl.obolibrary.org/obo/TXPO_0000749,,,,,,,,,,,,,,,,,,,,https://en.wikipedia.org/wiki/Bosentan|DrugBank:DB00559|ATC:C02KX01|InChIKey:GJPICJJJRGTNOD-UHFFFAOYSA-N,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001866,,,,,,,,,,TXPO:0000032,,,,,,,"Rifampicin, bosentan, and troglitazone directly inhibit bile salt export pump (BSEP).|The endothelin antagonist bosentan inhibits the canalicular bile salt export pump BSEP, which causes intracellular accumulation of cytotoxic bile salts and bile salt induced liver cell damage",,,,,,,,,,,,,,,bosentan [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000037,changing disulfide bond [ER stress],,"Changing disulfide bond is a subtype of changing bond: A process that changes a disulfide bond which is a covalent bond mediated by 2 sulfur atoms.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000025|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"Changing disulfide bond is a subtype of changing bond: A process that changes a disulfide bond which is a covalent bond mediated by 2 sulfur atoms.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001980,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000037,,,,,,,,,,,,,,,,,,,,,,changing disulfide bond [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000038,toxic agent,,A role played by the  entity that has a toxic effect.,false,,,http://purl.obolibrary.org/obo/CHEBI_52209,,,,,,,,,,,,,,,,,,,,,,A role played by the  entity that has a toxic effect.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000038,,,,,,,,,,,,,,,,,,,,,,toxic agent,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000031,CREB3L3 activation,,CREBPH activation is a subtype of molecular activation: A process that  changes the activity of the CRBPH to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000023,,,,,,,,,,,,,,,,,,,,,,CREBPH activation is a subtype of molecular activation: A process that  changes the activity of the CRBPH to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000031,,,,,,,,,,,,,,,,,,,,,,CREB3L3 activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000036,tranport regulator role,,A role played by the entity which regulates tranport process.,false,,,http://purl.obolibrary.org/obo/TXPO_0003230,,,,,,,,,,,,,,,,,,,,,,A role played by the entity which regulates tranport process.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000036,,,,,,,,,,,,,,,,,,,,,,tranport regulator role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000033,ACOX family,EC 1.3.3.6|Acyl-CoA oxidase family,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Acyl-CoA oxidase family,,EC 1.3.3.6,,,TXPO:0000033,,,,,,,,,,,,,,,,,,,,,,ACOX family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000035,hypofunction of extracellular matrix disassembly,,Hypofunction of extracellular matrix disassembly is a subtype of hypofunction of decomposing: A process that performs a decreased or insufficient extracellular matrix disassembly.,false,,,http://purl.obolibrary.org/obo/TXPO_0000940,,,,,,,,,,,,,,,,,,,,,,Hypofunction of extracellular matrix disassembly is a subtype of hypofunction of decomposing: A process that performs a decreased or insufficient extracellular matrix disassembly.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000035,,,,,,,,,,,,,,,,,,,,,,hypofunction of extracellular matrix disassembly,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000030,dysfunction of calcium transport  [Cell death],,"Dysfunction of calcium transport is a subtype of dysfunctioning: A process that performs an abnormal and incomplete calcium transport.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0001727|http://purl.obolibrary.org/obo/TXPO_0000167,,,,,,,,,,,,,,,,,,,,,,"Dysfunction of calcium transport is a subtype of dysfunctioning: A process that performs an abnormal and incomplete calcium transport.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000355,,,,,,,,,,,TXPO:0000030,,,,,,,,,,,,,,,,,,,,,,dysfunction of calcium transport  [Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_37733,EC 3.1.1.8 (cholinesterase) inhibitor,pseudocholinesterase inhibitors|EC 3.1.1.8 inhibitors|BtChoEase inhibitors|cholinesterase inhibitor|benzoylcholinesterase inhibitor|anticholinesterase|propionylcholinesterase inhibitors|choline esterase inhibitors|BtChoEase inhibitor|choline esterase II (unspecific) inhibitors|pseudocholinesterase inhibitor|BChE inhibitors|anticholinesterases|butyrylcholine esterase inhibitor|butyrylcholinesterase inhibitors|propionylcholinesterase inhibitor|EC 3.1.1.8 (cholinesterase) inhibitors|BChE inhibitor|choline esterase inhibitor|non-specific cholinesterase inhibitor|non-specific cholinesterase inhibitors|anticholineesterase inhibitor|EC 3.1.1.8 inhibitor|butyrylcholine esterase inhibitors|butyrylcholinesterase inhibitor|benzoylcholinesterase inhibitors|choline esterase II (unspecific) inhibitor|cholinesterase (EC 3.1.1.8) inhibitors|cholinesterase (EC 3.1.1.8) inhibitor|anticholineesterase inhibitors,An EC 3.1.1.* (carboxylic ester hydrolase) inhibitor that interferes with the action of cholinesterase (EC 3.1.1.8).,false,,,http://purl.obolibrary.org/obo/CHEBI_76773,,,,,,,,,,,,,,,,,,,,,,An EC 3.1.1.* (carboxylic ester hydrolase) inhibitor that interferes with the action of cholinesterase (EC 3.1.1.8).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pseudocholinesterase inhibitors|EC 3.1.1.8 inhibitors|BtChoEase inhibitors|cholinesterase inhibitor|benzoylcholinesterase inhibitor|anticholinesterase|propionylcholinesterase inhibitors|choline esterase inhibitors|BtChoEase inhibitor|choline esterase II (unspecific) inhibitors|pseudocholinesterase inhibitor|BChE inhibitors|anticholinesterases|butyrylcholine esterase inhibitor|butyrylcholinesterase inhibitors|propionylcholinesterase inhibitor|EC 3.1.1.8 (cholinesterase) inhibitors|BChE inhibitor|choline esterase inhibitor|non-specific cholinesterase inhibitor|non-specific cholinesterase inhibitors|anticholineesterase inhibitor|EC 3.1.1.8 inhibitor|butyrylcholine esterase inhibitors|butyrylcholinesterase inhibitor|benzoylcholinesterase inhibitors|choline esterase II (unspecific) inhibitor|cholinesterase (EC 3.1.1.8) inhibitors|cholinesterase (EC 3.1.1.8) inhibitor|anticholineesterase inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:37733,,,,EC 3.1.1.8 (cholinesterase) inhibitor,,CHEBI:37733,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002448,regulation of beta oxidation related gene expression (severe) [Eosinophilic granular degeneration],,"Regulation of beta oxidation related gene expression is a subtype of regulation of gene expression: A process that modulates the frequency, rate or extent of fatty acid beta oxidation related gene expression.
This entity is a specific course-dependent process. The degree is severe. This process can constitute the course of Eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/TXPO_0000119|http://purl.obolibrary.org/obo/TXPO_0000118,,,,,,,,,,,,,,,,,,,,,,"Regulation of beta oxidation related gene expression is a subtype of regulation of gene expression: A process that modulates the frequency, rate or extent of fatty acid beta oxidation related gene expression.
This entity is a specific course-dependent process. The degree is severe. This process can constitute the course of Eosinogranular degeneration.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000128,http://purl.obolibrary.org/obo/TXPO_0001046|http://purl.obolibrary.org/obo/TXPO_0001055|http://purl.obolibrary.org/obo/TXPO_0001053|http://purl.obolibrary.org/obo/TXPO_0001051|http://purl.obolibrary.org/obo/TXPO_0001057|http://purl.obolibrary.org/obo/TXPO_0001058|http://purl.obolibrary.org/obo/TXPO_0001069|http://purl.obolibrary.org/obo/TXPO_0001067|http://purl.obolibrary.org/obo/TXPO_0001068|http://purl.obolibrary.org/obo/TXPO_0002017,,,,,,http://purl.obolibrary.org/obo/TXPO_0000146|http://purl.obolibrary.org/obo/TXPO_0000174,,,,,,,,,,,TXPO:0002448,,,,,,,,,,,,,,,,,,,,,,regulation of beta oxidation related gene expression (severe) [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002444,increasing insulin demand,,Increasing insulin demand is a subtype of increasing functional demand: A process changes the demand for insulin to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000633,,,,,,,,,,,,,,,,,,,,,,Increasing insulin demand is a subtype of increasing functional demand: A process changes the demand for insulin to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002444,,,,,,,,,,,,,,,,,,,,,,increasing insulin demand,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002441,negative regulation of proteasomal ubiquitin-dependent protein catabolic process,,"Any process that stops, prevents, or reduces the frequency, rate or extent of the breakdown of a protein or peptide by hydrolysis of its peptide bonds, initiated by the covalent attachment of ubiquitin, and mediated by the proteasome.",false,,,http://purl.obolibrary.org/obo/GO_1901799,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents, or reduces the frequency, rate or extent of the breakdown of a protein or peptide by hydrolysis of its peptide bonds, initiated by the covalent attachment of ubiquitin, and mediated by the proteasome.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002441,,,,,,,,,,,,,,,,,,,,,,negative regulation of proteasomal ubiquitin-dependent protein catabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0043161,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002443,overeating [Type II Diabetes mellitus],,"Overeating is a subtype of increasing quantity: A process that changes the ingestion amount of food to be larger.
This entity is a specific course-dependent process. This process can constitute the course of Type II Diabetes mellitus.",false,,,http://purl.obolibrary.org/obo/TXPO_0001541|http://purl.obolibrary.org/obo/TXPO_0003342,,,,,,,,,,,,,,,,,,,,,,"Overeating is a subtype of increasing quantity: A process that changes the ingestion amount of food to be larger.
This entity is a specific course-dependent process. This process can constitute the course of Type II Diabetes mellitus.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003581,,,,,,,,,,,TXPO:0002443,,,,,,,,,,,,,,,,,,,,,,overeating [Type II Diabetes mellitus],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002449,PERK signaling to eIF2a [ER stress],,"A process in which a signal to eIF2a is transduced by PERK.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000062|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"A process in which a signal to eIF2a is transduced by PERK.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002378|http://purl.obolibrary.org/obo/TXPO_0000402,,,,,,,,,,,,,,,,,,TXPO:0002449,,,,,,,,,,,,,,,,,,,,,,PERK signaling to eIF2a [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002440,PERK signaling to eIF2a [ER stress apoptosis],,"A process in which a signal to eIF2a is transduced by PERK.
This process is dependent on the apoptosis and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002449|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"A process in which a signal to eIF2a is transduced by PERK.
This process is dependent on the apoptosis and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002517|http://purl.obolibrary.org/obo/TXPO_0002515,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002721,,,,,,,,,,,TXPO:0002440,,,,,,,,,,,,,,,,,,,,,,PERK signaling to eIF2a [ER stress apoptosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002442,negative regulation of proteasomal ubiquitin-dependent NRF2 catabolic process,,"Any process that stops, prevents, or reduces the frequency, rate or extent of the breakdown of NRF2 by hydrolysis of its peptide bonds, initiated by the covalent attachment of ubiquitin, and mediated by the proteasome.",false,,,http://purl.obolibrary.org/obo/TXPO_0002441,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents, or reduces the frequency, rate or extent of the breakdown of NRF2 by hydrolysis of its peptide bonds, initiated by the covalent attachment of ubiquitin, and mediated by the proteasome.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002442,,,,,,,,,,,,,,,,,,,,,,negative regulation of proteasomal ubiquitin-dependent NRF2 catabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002432,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002445,autophagy dependent Keap1 catabolic process,,The cellular catabolic process in which cells digest parts of their own cytoplasm; allows for both recycling of macromolecular constituents under conditions of cellular stress and remodeling the intracellular structure for cell differentiation.,false,,,http://purl.obolibrary.org/obo/GO_0006914,,,,,,,,,,,,,,,,,,,,,,The cellular catabolic process in which cells digest parts of their own cytoplasm; allows for both recycling of macromolecular constituents under conditions of cellular stress and remodeling the intracellular structure for cell differentiation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002445,,,,,,,,,,,,,,,,,,,,,,autophagy dependent Keap1 catabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002447,receiving abnormal protein signal by ATF6 [ER stress - refolding],,"Receiving abnormal protein signal by ATF6 is a subtype of receiving signal: A process that recognizes another object and changes into an abnormal protein (e.g., misfolded protein, etc.) signal by ATF6.
This process is dependent on the refolding and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002554|http://purl.obolibrary.org/obo/TXPO_0003736,,,,,,,,,,,,,,,,,,,,,,"Receiving abnormal protein signal by ATF6 is a subtype of receiving signal: A process that recognizes another object and changes into an abnormal protein (e.g., misfolded protein, etc.) signal by ATF6.
This process is dependent on the refolding and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002900,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002904,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002550,,,,,,,,,,,TXPO:0002447,,,,,,,,,,,,,,,,,,,,,,receiving abnormal protein signal by ATF6 [ER stress - refolding],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002446,fatty acid homeostasis imbalance in peroxisome,,Fatty acid homeostasis imbalance in peroxisome is a subtype of changing balance: A process that becomes lacking afatty acid homeostastasis balance.,false,,,http://purl.obolibrary.org/obo/TXPO_0002133|http://purl.obolibrary.org/obo/TXPO_0003488,,,,,,,,,,,,,,,,,,,,,,Fatty acid homeostasis imbalance in peroxisome is a subtype of changing balance: A process that becomes lacking afatty acid homeostastasis balance.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002446,,,,,,,,,,,,,,,,,,,,,,fatty acid homeostasis imbalance in peroxisome,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0013756,venous blood,blood in vein|portion of venous blood|venous blood,A blood that is part of a vein.,false,,,http://purl.obolibrary.org/obo/UBERON_0000178,,,,,,,,,,,,,,,,,,,,FMA:83067,,A blood that is part of a vein.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,blood in vein|portion of venous blood|venous blood,,,,http://purl.obolibrary.org/obo/UBERON_0001638,UBERON:0013756,http://purl.obolibrary.org/obo/UBERON_0001638,,,,,,,,,,,,,,,,,,,,,venous blood,,,,,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000492,alpha-actin 2,smooth muscle alpha-actin (aortic type),,false,,,http://purl.obolibrary.org/obo/IMR_0000490,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,smooth muscle alpha-actin (aortic type),,,,,IMR:0000492,,,,,,,,,,,,,,,,,,,,,,alpha-actin 2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001606,Rab22A,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001606,,,,,,,,,,,,,,,,,,,,,,Rab22A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100323,IFNGR-1,CDw119|IFNG receptor alpha chain,,false,,,http://purl.obolibrary.org/obo/IMR_0000136,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CDw119|IFNG receptor alpha chain,,,,,IMR:0100323,,,,,,,,,,,,,,,,,,,,,,IFNGR-1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000737,Grb14,,,false,,,http://purl.obolibrary.org/obo/IMR_0100382,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000737,,,,,,,,,,,,,,,,,,,,,,Grb14,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000158,FcgammaRI,High affinity immunoglobulin gamma Fc receptor I,,false,,,http://purl.obolibrary.org/obo/IMR_0000156,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,High affinity immunoglobulin gamma Fc receptor I,,,,,IMR:0000158,,,,,,,,,,,,,,,,,,,,,,FcgammaRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100460,IKK gamma,NEMO|NF-kappaB essential modulator,,false,,,http://purl.obolibrary.org/obo/IMR_0000701,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003722,,,,,NEMO|NF-kappaB essential modulator,,,,,IMR:0100460,,,,,,,,,,,,,,,,,,,,,,IKK gamma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000275,SHP-1,HCP|PTP1C|Src homology 2-containing protein tyrosine phosphatase-1|SH-PTP1,,false,,,http://purl.obolibrary.org/obo/IMR_0000274,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,HCP|PTP1C|Src homology 2-containing protein tyrosine phosphatase-1|SH-PTP1,,,,,IMR:0000275,,,,,,,,,,,,,,,,,,,,,,SHP-1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100559,FGF-9,HBGF-9|Fibroblast growth factor-9|GAF,,false,,,http://purl.obolibrary.org/obo/IMR_0000049,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,HBGF-9|Fibroblast growth factor-9|GAF,,,,,IMR:0100559,,,,,,,,,,,,,,,,,,,,,,FGF-9,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0001836,release of cytochrome c from mitochondria,,"The process that results in the movement of cytochrome c from the mitochondrial intermembrane space into the cytosol, which is part of the apoptotic signaling pathway and leads to caspase activation.",false,,,http://purl.obolibrary.org/obo/TXPO_0002588,,,,,,,,,,,,,,,,,,,,PMID:20850011|http://purl.obolibrary.org/obo/HINO_0007325,,"The process that results in the movement of cytochrome c from the mitochondrial intermembrane space into the cytosol, which is part of the apoptotic signaling pathway and leads to caspase activation.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0001836,,,,,,,,,,,,,,,,,,,,,,release of cytochrome c from mitochondria,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0001837,epithelial to mesenchymal transition,,"A transition where an epithelial cell loses apical/basolateral polarity, severs intercellular adhesive junctions, degrades basement membrane components and becomes a migratory mesenchymal cell.",false,,,http://purl.obolibrary.org/obo/GO_0030154,,,,,,,,,,,,,,,,,,,,,,"A transition where an epithelial cell loses apical/basolateral polarity, severs intercellular adhesive junctions, degrades basement membrane components and becomes a migratory mesenchymal cell.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0001837,,,,,,,,,,,,,,,,,,,,,,epithelial to mesenchymal transition,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0034333,adherens junction assembly,,"The aggregation, arrangement and bonding together of a set of components to form an adherens junction. An adherens junction is a cell junction at which the cytoplasmic face of the plasma membrane is attached to actin filaments.",false,,,http://purl.obolibrary.org/obo/GO_0022607,,,,,,,,,,,,,,,,,,,,,,"The aggregation, arrangement and bonding together of a set of components to form an adherens junction. An adherens junction is a cell junction at which the cytoplasmic face of the plasma membrane is attached to actin filaments.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0034333,,,,,,,,,,,,,,,,,,,,,,adherens junction assembly,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0002835,insulin family,,"Insulin superfamily genes are ubiquitous in vertebrates, and have been identified in invertebrates, including insects, molluscs, and the nematode Caenorhabditis elegans. Seven members of the insulin superfamily have been identified in humans, including insulin, insulin-like growth factors (IGFs) I and II, relaxins HI and HII, early placenta insulin-like peptide (EPIL), and relaxin-like factor.",false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,"Insulin superfamily genes are ubiquitous in vertebrates, and have been identified in invertebrates, including insects, molluscs, and the nematode Caenorhabditis elegans. Seven members of the insulin superfamily have been identified in humans, including insulin, insulin-like growth factors (IGFs) I and II, relaxins HI and HII, early placenta insulin-like peptide (EPIL), and relaxin-like factor.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_24621,,,,,,,,,,IMR:0002835,,,,,,,,,,,,,,,,,,,,,,insulin family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002040,fatty acid strorage [Mitochondrial disorder],,"Fatty acid strorage is a subtype of accumulation of substances in a biological object: A process that keeps fatty acid in a biological object.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0000256,,,,,,,,,,,,,,,,,,,,PMID:23299992|PMID:26571396|PMID:31649547,,"Fatty acid strorage is a subtype of accumulation of substances in a biological object: A process that keeps fatty acid in a biological object.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002041|http://purl.obolibrary.org/obo/TXPO_0000869|http://purl.obolibrary.org/obo/TXPO_0004368|http://purl.obolibrary.org/obo/TXPO_0004367|http://purl.obolibrary.org/obo/TXPO_0004366|http://purl.obolibrary.org/obo/TXPO_0004249|http://purl.obolibrary.org/obo/TXPO_0004126|http://purl.obolibrary.org/obo/TXPO_0004125,,,,,,,,,,,TXPO:0002040,,,,,,,,,,,,,,,,,,,,,,fatty acid strorage [Mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002045,glutathione depletion dependent molecule (canonical),,"Glutathione depletion dependent molecule is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of glutathione depletion as a gene product.
Gene profile:caonical that described in textbooks or articles.",false,,,http://purl.obolibrary.org/obo/TXPO_0001915,,,,,,,,,,,,,,,,,,,,,,"Glutathione depletion dependent molecule is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of glutathione depletion as a gene product.
Gene profile:caonical that described in textbooks or articles.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002045,,,,,,,,,,,,,,,,,,,,,,glutathione depletion dependent molecule (canonical),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002041,PPARalpha activation [Mitochondrial disorder],,"PPARalpha activation is a subtype of activating nuclear receptor: A process that changes the activity of the activating PPAR alpha ( (Peroxisome Proliferator Activated Receptor Alpha)) with a nuclear receptor role to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0000013|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,"Reactome

The set of genes regulated by PPAR-alpha is not fully known in humans, however many examples have been found in mice. Genes directly activated by PPAR-alpha contain peroxisome proliferator receptor elements (PPREs) in their promoters and include:
1) genes involved in fatty acid oxidation and ketogenesis (Acox1, Cyp4a, Acadm, Hmgcs2);
2) genes involved in fatty acid transport (Cd36, , Slc27a1, Fabp1, Cpt1a, Cpt2);
3) genes involved in producing fatty acids and very low density lipoproteins (Me1, Scd1);
4) genes encoding apolipoproteins (Apoa1, Apoa2, Apoa5);
5) genes involved in triglyceride clearance ( Angptl4);
6) genes involved in glycerol metabolism (Gpd1 in mouse);",PMID:23299992,,"PPARalpha activation is a subtype of activating nuclear receptor: A process that changes the activity of the activating PPAR alpha ( (Peroxisome Proliferator Activated Receptor Alpha)) with a nuclear receptor role to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004369|http://purl.obolibrary.org/obo/TXPO_0004360,,,,,,,,,,,TXPO:0002041,,,,,,,,,,,,,,,,,,,,,,PPARalpha activation [Mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002048,hypofunction of carbohydrate transport,,Hypofunction of carbohydrate transport is a subtype of hypofunction of transport: A process that performs a decreased or insufficient carbohydrate transport.,false,,,http://purl.obolibrary.org/obo/TXPO_0001911,,,,,,,,,,,,,,,,,,,,,,Hypofunction of carbohydrate transport is a subtype of hypofunction of transport: A process that performs a decreased or insufficient carbohydrate transport.,,,http://purl.obolibrary.org/obo/GO_0008643,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002048,,,,,,,,,,,,,,,,,,,,,,hypofunction of carbohydrate transport,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002042,nimesulide [lipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003508|http://purl.obolibrary.org/obo/CHEBI_44445,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002042,,,,,,,,,,,,,,,,,,,,,,nimesulide [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002043,nimesulide [lipidosis - oxidative phosphorylation inhibitor],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002042,,,,,,,,,,,,,,,,,,,,PMID:21145849,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002031,,,,,,,,,,TXPO:0002043,,,,,,,,,,,,,,,,,,,,,,nimesulide [lipidosis - oxidative phosphorylation inhibitor],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002049,hyperfunction of drug metabolism phase I,,Hyperfunction of drug metabolism phase I is a subtype of hyperfunctioning of drug metabolism: A process that performs an excessive drug metabolism phase I.,false,,,http://purl.obolibrary.org/obo/TXPO_0002347,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of drug metabolism phase I is a subtype of hyperfunctioning of drug metabolism: A process that performs an excessive drug metabolism phase I.,,,http://purl.obolibrary.org/obo/TXPO_0000173,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002049,,,,,,,,,,,,,,,,,,,,,,hyperfunction of drug metabolism phase I,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002044,glutathione conjugation inhibotor role,,A compound which plays an inhibition of glutathione conjugation.,false,,,http://purl.obolibrary.org/obo/TXPO_0000638|http://purl.obolibrary.org/obo/TXPO_0002037,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003991,,,,,,,,,,,,,A compound which plays an inhibition of glutathione conjugation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002044,,,,,,,,,,,,,,,,,,,,,,glutathione conjugation inhibotor role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002046,changing force,,Changing force is a subtype of changing quality: A process that changes the force of the object.,false,,,http://purl.obolibrary.org/obo/TXPO_0000415,,,,,,,,,,,,,,,,,,,,,,Changing force is a subtype of changing quality: A process that changes the force of the object.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002046,,,,,,,,,,,,,,,,,,,,,,changing force,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002047,regulation of lipolytic gene expression [Eosinophilic granular degeneration],,"Regulation of lipolytic gene expression is a subtype of regulation of gene expression: A process that modulates the frequency, rate or extent of lipid degradation related gene expression.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/TXPO_0001729|http://purl.obolibrary.org/obo/TXPO_0002545,,,,,,,,,,,,,,,,,,,,,,"Regulation of lipolytic gene expression is a subtype of regulation of gene expression: A process that modulates the frequency, rate or extent of lipid degradation related gene expression.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002062,,,,,,,,,,,,,,,,,TXPO:0002047,,,,,,,,,,,,,,,,,,,,,,regulation of lipolytic gene expression [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_83039,crustacean metabolite,crustacean metabolites,"An animal metabolite produced by arthropods such as crabs, lobsters, crayfish, shrimps and krill.",false,,,http://purl.obolibrary.org/obo/CHEBI_75767,,,,,,,,,,,,,,,,,,,,,,"An animal metabolite produced by arthropods such as crabs, lobsters, crayfish, shrimps and krill.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,crustacean metabolites,,,,,,,,,,,,,,,,,,,,,CHEBI:83039,,,,crustacean metabolite,,CHEBI:83039,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000010049,DNAJB6,,Other designations: DnaJ-like 2 protein|dnaJ homolog subfamily B member 6|heat shock protein J2|limb girdle muscular dystrophy 1D (autosomal dominant),false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,DnaJ|HSJ-2|DJ4|HHDJ1|HSJ2|MRJ|LGMD1D|MSJ-1|LGMD1E,,,,,,,,,,,,7,,,,,,MIM:611332|Ensembl:ENSG00000105993|HGNC:14888|HPRD:07107|Vega:OTTHUMG00000157242,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"DnaJ (Hsp40) homolog, subfamily B, member 6",,,7q36.3,,,,,,,,,,,,,,,,"GO_0001671 (EC: IDA, PMID:11896048); GO_0003677 (EC: IEA); GO_0005515 (EC: IPI, PMID:10954706); GO_0005634 (EC: IDA); GO_0005730 (EC: IDA, Qualifier: NOT); GO_0005737 (EC: IDA); GO_0006457 (EC: IDA, PMID:11896048); GO_0030018 (EC: IDA); GO_0030036 (EC: IEA); GO_0030198 (EC: IEA); GO_0031072 (EC: IDA, PMID:10954706); GO_0032781 (EC: IDA, PMID:11896048); GO_0034504 (EC: IEA); GO_0043154 (EC: IDA, PMID:11896048); GO_0045109 (EC: IDA, PMID:10954706); GO_0045892 (EC: IEA); GO_0048471 (EC: IDA, PMID:10954706); GO_0051087 (EC: IDA, PMID:11896048); GO_0060710 (EC: IEA); GO_0060715 (EC: IEA); GO_0060717 (EC: IEA)",,,,,,,,,PMID:8125298; 10319584; 10954706; 11076863; 11147971; 11230166; 11256614; 11896048; 12069690; 12477932; 12690205; 12853948; 12974469; 14702039; 15182641; 15342353; 15489334; 15489336; 16196087; 16260608; 16381901; 16919237; 17081983; 17314511; 18029348; 18163532; 18184612; 18328103; 18373498; 18457437; 18624398; 18976975; 19002655; 20020773; 20159555; 20301582; 20301672; 20308539; 20372789; 20522561; 21139048; 21145461; 21832049; 21890473; 21906983; 21963094; 21988832; 22334415; 22366786; 22455953; 22504047; 22505724; 22710984; 23000965; 23133382; 23394708; 23455922; 23612975; 23667531; 23752268; 24047968; 24250222,,,,,,,,,,,,,,,OGG:3000010049,,,,,,,"DnaJ (Hsp40) homolog, subfamily B, member 6",,,,,,,,,,,,,Other designations: DnaJ-like 2 protein|dnaJ homolog subfamily B member 6|heat shock protein J2|limb girdle muscular dystrophy 1D (autosomal dominant),,DNAJB6,,,,,,,,,,,,,,,,,,,,,,,10049,tcag7.555,,,,,,,9606,,,,,,,,,,,,,,,,,,,DNAJB6,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000026291,FGF21,,,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,19,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,fibroblast growth factor 21,,,19q13.33,,,,,,,,,,,,,,,,"GO_0005515 (EC: IPI, PMID: 18829467); GO_0005576 (EC: IEA); GO_0007165 (EC: TAS, PMID: 10858549); GO_0007267 (EC: TAS, PMID: 10858549); GO_0008083 (EC: IEA); GO_0008284 (EC: IEA); GO_0010988 (EC: NAS); GO_0045716 (EC: NAS); GO_0046326 (EC: IDA, PMID: 17623664); GO_0070374 (EC: IDA, PMID: 17623664); GO_0090080 (EC: IEA)",,,,,,,,,PMID: 10858549; 12477932; 12975309; 15199049; 15340161; 15902306; 17068132; 17452648; 17623664; 17926232; 18252893; 18559909; 18680716; 18722685; 18829467; 18840768; 19059246; 19117008; 19318452; 19322201; 19401423; 19487637; 19528204; 19531592; 19681655; 19699495; 19702724; 19720803; 19926712; 19953087; 20332535; 20362303; 20451522; 20452080; 20566462; 20566587; 20629328; 20675007; 20682689; 20717167; 21060863; 21123446; 21206918; 21309058; 21373720; 21502324; 21505329; 21521346; 21521350; 21525989; 21596453; 21664250; 21691104; 21696361; 21712364; 21750278; 21767451; 21812521; 21820356; 21849508; 21889884; 21926274; 21926972; 21949781; 21988350; 21988832; 22013098; 22046277; 22136913; 22152380; 22190000; 22233381; 22248288; 22293928; 22344195; 22378787; 22398021; 22438225; 22442730; 22523080; 22529197; 22539584; 22701542; 22740503; 22881230; 23123503; 23129782; 23270727; 23283977; 23372041; 23533568; 23545215; 23626003; 23636237; 23667629; 23759753; 23768789; 23782039; 23824729; 23887638; 24142477; 24184811,,,,,,,,,,,,,,,OGG:3000026291,,,,,,,fibroblast growth factor 21,,,,,,,,,,,,,,,FGF21,,,,,,,,,,,,,,,,,,,,,,,26291,UNQ3115/PRO10196,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,FGF21,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0010516,Heterogeneous nuclear ribonucleoprotein L,hnRNP L|ROL,,false,,,http://purl.obolibrary.org/obo/IMR_0010024,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,hnRNP L|ROL,,,,,IMR:0010516,,,,,,,,,,,,,,,,,,,,,,Heterogeneous nuclear ribonucleoprotein L,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000701,IKK family,I-kappaB kinase family,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,GO:0008384,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001966,,,,,I-kappaB kinase family,,,,,IMR:0000701,,,,,,,,,,,,,,,,,,,,,,IKK family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_134891,sulfacarbamide,sulfaurea|sulphaurea|sulphacarbamide|sulfanilcarbamid|urosulfan|urosulfane|sulfanilylurea,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:547-44-4|Drug_Central:2496,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sulfaurea|sulphaurea|sulphacarbamide|sulfanilcarbamid|urosulfan|urosulfane|sulfanilylurea,,,,,,,,,,,,,,,,,,,,,CHEBI:134891,,,,sulfacarbamide,,CHEBI:134891,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_52209,aetiopathogenetic role,etiopathogenetic agent|etiopathogenetic role,A role played by the molecular entity or part thereof which causes the development of a pathological process.,false,,,http://purl.obolibrary.org/obo/CHEBI_24432,,,,,,,,,,,,,,,,,,,,,,A role played by the molecular entity or part thereof which causes the development of a pathological process.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,etiopathogenetic agent|etiopathogenetic role,,,,,,,,,,,,,,,,,,,,,CHEBI:52209,,,,aetiopathogenetic role,,CHEBI:52209,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000005308,PITX2,,Other designations: ALL1-responsive protein ARP1|all1-responsive gene 1|homeobox protein PITX2|paired-like homeodomain transcription factor 2|pituitary homeobox 2|rieg bicoid-related homeobox transcription factor 1|solurshin,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,IHG2|Brx1|RIEG1|ARP1|IGDS|RIEG|PTX2|Otlx2|IGDS2|IRID2|IDG2|RS|RGS,,,,,,,,,,,,4,,,,,,Vega:OTTHUMG00000132837|HGNC:9005|MIM:601542|Ensembl:ENSG00000164093|HPRD:03328,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,paired-like homeodomain 2,,,4q25,,,,,,,,,,,,,,,,"GO_0000122 (EC: IDA, PMID: 16449236); GO_0000976 (EC: IDA, PMID: 12612071); GO_0000978 (EC: IEA); GO_0001077 (EC: IEA); GO_0001078 (EC: IDA, PMID: 16449236); GO_0001085 (EC: IPI, PMID: 15466416); GO_0001102 (EC: IPI, PMID: 12612071); GO_0001105 (EC: IDA, PMID: 9685346); GO_0001191 (EC: IDA, PMID: 16449236); GO_0001569 (EC: IEA); GO_0001570 (EC: IEA); GO_0001701 (EC: IEA); GO_0001764 (EC: IEA); GO_0002074 (EC: IEA); GO_0003171 (EC: IEA); GO_0003253 (EC: ISS); GO_0003350 (EC: IEA); GO_0003700 (EC: IDA, PMID: 15385555); GO_0005515 (EC: IPI, PMID: 16449236); GO_0005634 (EC: IDA); GO_0005667 (EC: IDA, PMID: 15385555); GO_0005737 (EC: IEA); GO_0006355 (EC: IDA, PMID: 15385555); GO_0007368 (EC: ISS); GO_0007520 (EC: IEA); GO_0008134 (EC: IPI, PMID: 15385555); GO_0008584 (EC: IEA); GO_0008585 (EC: IEA); GO_0009725 (EC: IEA); GO_0016055 (EC: IEA); GO_0021763 (EC: IEA); GO_0021855 (EC: IEA); GO_0030334 (EC: IEA); GO_0031076 (EC: IEA); GO_0031490 (EC: IEA); GO_0033189 (EC: IEA); GO_0035116 (EC: IEA); GO_0035315 (EC: IC, PMID: 19251162); GO_0035886 (EC: IEA); GO_0035993 (EC: IMP, PMID: 18312615); GO_0042475 (EC: IEA); GO_0042476 (EC: IMP, PMID: 14630904); GO_0042803 (EC: IPI, PMID: 12612071); GO_0043010 (EC: IMP, PMID: 9618168); GO_0043021 (EC: IC, PMID: 19174163); GO_0043388 (EC: IEA); GO_0045944 (EC: IDA, PMID: 15466416); GO_0048536 (EC: ISS); GO_0048557 (EC: IEA); GO_0051219 (EC: IPI, PMID: 19174163); GO_0055009 (EC: IEA); GO_0055015 (EC: IEA); GO_0060126 (EC: TAS, PMID: 10372733); GO_0060127 (EC: TAS, PMID: 10372733); GO_0060412 (EC: IEA); GO_0060460 (EC: IEA); GO_0060577 (EC: IEA); GO_0060578 (EC: IEA); GO_0061031 (EC: IEA); GO_0061072 (EC: IMP, PMID: 9437321); GO_0061325 (EC: ISS); GO_0070986 (EC: ISS); GO_2000288 (EC: IEA)",,,,,,,,,PMID: 1303248; 7581385; 8942889; 8944018; 9437321; 9539779; 9618168; 9685346; 9708732; 10051017; 10372733; 11157981; 11487566; 11763998; 11774072; 11821690; 11948188; 12130547; 12223489; 12381896; 12464179; 12477932; 12612071; 12732450; 14630904; 14975719; 14985297; 15255117; 15342556; 15385555; 15466416; 15489334; 15591271; 15728254; 15895993; 16274491; 16449236; 16498627; 16638984; 16834779; 16876867; 16884686; 16936096; 17065505; 17167399; 17197537; 17486624; 17558846; 17603472; 17850355; 17965955; 18312615; 18331556; 18339718; 18616618; 18711169; 18775326; 18946986; 19052653; 19174163; 19218601; 19233404; 19251162; 19513095; 19597492; 19801652; 19913121; 19954729; 20022124; 20170812; 20173747; 20211142; 20301552; 20332099; 20372070; 20478579; 20628086; 20634891; 20875405; 20881290; 20881294; 20978111; 21221769; 21278591; 21282332; 21414601; 21427120; 21479692; 21498098; 21511879; 21531708; 21574119; 21617755; 21803613; 21810944; 21837767; 22224469; 22495974; 22544366; 22555092; 22569110; 22615897; 22735262; 23041239; 23042660; 23088713; 23132660; 23229549; 23354914; 23505501; 23913021; 24083357; 24162257; 24250222,,,,,,,,,,,,,,,OGG:3000005308,,,,,,,paired-like homeodomain 2,,,,,,,,,,,,,Other designations: ALL1-responsive protein ARP1|all1-responsive gene 1|homeobox protein PITX2|paired-like homeodomain transcription factor 2|pituitary homeobox 2|rieg bicoid-related homeobox transcription factor 1|solurshin,,PITX2,,,,,,,,,,,,,,,,,,,,,,,5308,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,PITX2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0100392,IFNAR-2,Interferon alpha/beta receptor-2,,false,,,http://purl.obolibrary.org/obo/IMR_0000135,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Interferon alpha/beta receptor-2,,,,,IMR:0100392,,,,,,,,,,,,,,,,,,,,,,IFNAR-2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000163590,TOR1AIP2,,Other designations: 15 kDa interferon-responsive protein|interferon responsive gene 15|lumenal domain like LAP1|lumenal domain-like LAP1|torsin-1A-interacting protein 2,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,LULL1|IFRG15|NET9,,,,,,,,,,,,1,,,,,,Vega:OTTHUMG00000035265|Ensembl:ENSG00000169905|HPRD:10048|MIM:614513|HGNC:24055,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,torsin A interacting protein 2,,,1q25.2,,,,,,,,,,,,,,,,GO_0001671 (EC: IDA); GO_0005789 (EC: IEA); GO_0016021 (EC: IEA); GO_0031965 (EC: IEA); GO_0032781 (EC: IDA); GO_0051117 (EC: IPI),,,,,,,,,PMID: 11181995; 12477932; 14702039; 15342556; 15489334; 15767459; 16710414; 16964240; 19295130; 19339278; 19615732; 19651773; 20861018; 21139048; 21145461; 21890473; 21906983; 21963094; 22190034; 22268729; 23569223,,,,,,,,,,,,,,,OGG:3000163590,,,,,,,torsin A interacting protein 2,,,,,,,,,,,,,Other designations: 15 kDa interferon-responsive protein|interferon responsive gene 15|lumenal domain like LAP1|lumenal domain-like LAP1|torsin-1A-interacting protein 2,,TOR1AIP2,,,,,,,,,,,,,,,,,,,,,,,163590,RP11-12M5.5,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,TOR1AIP2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_8069,phenobarbital,,"A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.",false,,,http://purl.obolibrary.org/obo/CHEBI_22693,,,,,,,,,,,,,,,,,,,,Open TG-Gates compound_id=00004|CAS:50-06-6|CHEBI:8069|DrugBank:DB01174|https://livertox.nlm.nih.gov//Phenobarbital.htm,,"A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.",,,,,,,,,,,,C12H12N2O3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35623,,,,,,,,,,CHEBI:8069,,,,,,,,,,,,,,,,,,,,,,phenobarbital,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CCC1(C(=O)NC(=O)NC1=O)c1ccccc1,,,,,
http://purl.obolibrary.org/obo/OGG_3000010923,SUB1,,Other designations: activated RNA polymerase II transcription cofactor 4|activated RNA polymerase II transcriptional coactivator p15|positive cofactor 4,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,P15|p14|PC4,,,,,,,,,,,,5,,,,,,Vega:OTTHUMG00000131071|HPRD:02737|HGNC:19985|Ensembl:ENSG00000113387|MIM:600503,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,SUB1 homolog (S. cerevisiae),,,5p13.3,,,,,,,,,,,,,,,,"GO_0003697 (EC: IDA, PMID: 8062391); GO_0003713 (EC: IDA, PMID: 8062391); GO_0005515 (EC: IPI, PMID: 11389848); GO_0005634 (EC: IDA); GO_0005667 (EC: IDA, PMID: 8062391); GO_0005730 (EC: IDA); GO_0006351 (EC: IEA); GO_0006357 (EC: IDA, PMID: 8062391); GO_0044822 (EC: IDA); GO_0070062 (EC: IDA)",,,,,,,,,PMID: 7628453; 7809103; 8062391; 8062392; 9360603; 9482861; 9632764; 9660784; 9660958; 9792714; 9885563; 10024883; 10887206; 11005381; 11279157; 11313979; 11389848; 11741883; 12477932; 12565890; 12590132; 14966284; 15199162; 15302935; 15489334; 15635413; 15893730; 16415882; 16982701; 17081983; 17130840; 17317687; 17361185; 17785449; 18029348; 18854154; 19038270; 19047459; 19322201; 19471022; 19525231; 19706510; 19738201; 19759913; 20080105; 20305379; 20360068; 21139048; 21193408; 21319273; 21586571; 21832049; 21890473; 21906983; 21907836; 21963094; 21987572; 22113938; 22174317; 22505724; 22939629; 23000965; 23184937; 23455922; 23602568,,,,,,,,,,,,,,,OGG:3000010923,,,,,,,SUB1 homolog (S. cerevisiae),,,,,,,,,,,,,Other designations: activated RNA polymerase II transcription cofactor 4|activated RNA polymerase II transcriptional coactivator p15|positive cofactor 4,,SUB1,,,,,,,,,,,,,,,,,,,,,,,10923,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,SUB1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000010926,DBF4,,"Other designations: DBF4 homolog|DBF4 zinc finger A|DBF4-type zinc finger-containing protein 1|activator of S phase kinase|chiffon homolog A|protein DBF4 homolog A|zinc finger, DBF-type containing 1",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,ZDBF1|DBF4A|CHIF|ASK,,,,,,,,,,,,7,,,,,,HPRD:10371|Ensembl:ENSG00000006634|HGNC:17364|MIM:604281|Vega:OTTHUMG00000131034,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,DBF4 zinc finger,,,7q21.3,,,,,,,,,,,,,,,,"GO_0000082 (EC: TAS); GO_0000278 (EC: TAS); GO_0003676 (EC: IEA); GO_0005654 (EC: TAS); GO_0006260 (EC: TAS); GO_0008047 (EC: TAS, PMID: 10373557); GO_0008270 (EC: IEA); GO_0043085 (EC: TAS, PMID: 10373557)",,,,,,,,,PMID: 10373557; 10517317; 10523313; 10846177; 12015319; 12420215; 12441400; 12477932; 12535533; 12614612; 12791985; 12853948; 12968034; 14702039; 15226314; 15231747; 15302935; 15374998; 15489334; 15707391; 16826239; 16899510; 16912045; 17276990; 17768177; 18286467; 18503552; 18536724; 18714392; 19111665; 19744312; 19864417; 21036905; 21536671; 22123827; 22990118; 24240236,,,,,,,,,,,,,,,OGG:3000010926,,,,,,,DBF4 zinc finger,,,,,,,,,,,,,"Other designations: DBF4 homolog|DBF4 zinc finger A|DBF4-type zinc finger-containing protein 1|activator of S phase kinase|chiffon homolog A|protein DBF4 homolog A|zinc finger, DBF-type containing 1",,DBF4,,,,,,,,,,,,,,,,,,,,,,,10926,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,DBF4,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000010924,SMPDL3A,,Other designations: 0610010C24Rik|ASM-like phosphodiesterase 3a|acid sphingomyelinase-like phosphodiesterase 3a,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,ASML3a|ASM3A|yR36GH4.1,,,,,,,,,,,,6,,,,,,Ensembl:ENSG00000172594|Vega:OTTHUMG00000015490|MIM:610728|HPRD:10244|HGNC:17389,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"sphingomyelin phosphodiesterase, acid-like 3A",,,6q22.31,,,,,,,,,,,,,,,,"GO_0004767 (EC: IEA); GO_0005515 (EC: IPI, PMID: 12442002); GO_0005615 (EC: IEA); GO_0006685 (EC: IEA); GO_0008150 (EC: ND); GO_0016798 (EC: IEA)",,,,,,,,,PMID: 12442002; 12477932; 14574404; 15174051; 15489334; 16344560; 22810003,,,,,,,,,,,,,,,OGG:3000010924,,,,,,,"sphingomyelin phosphodiesterase, acid-like 3A",,,,,,,,,,,,,Other designations: 0610010C24Rik|ASM-like phosphodiesterase 3a|acid sphingomyelinase-like phosphodiesterase 3a,,SMPDL3A,,,,,,,,,,,,,,,,,,,,,,,10924,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,SMPDL3A,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0100288,Bad (mol),,,false,,,http://purl.obolibrary.org/obo/IMR_0100709,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100288,,,,,,,,,,,,,,,,,,,,,,Bad (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001055,Plin2 (mouse)[Eosinophilic granular degeneration],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000648|http://purl.obolibrary.org/obo/TXPO_1000286,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:11520|NCBI-Human-GeneID:123|NCBI-Rat-GeneID:298199|PMID:25961502|PMID:16489205,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001055,,,,,,,,,,,,,,,,,,,,,,Plin2 (mouse)[Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001053,Cyp4a3 (rat)[Eosinophilic granular degeneration],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001077|http://purl.obolibrary.org/obo/TXPO_1000108,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:298423,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001053,,,,,,,,,,,,,,,,,,,,,,Cyp4a3 (rat)[Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001051,Mgll (rat)[Eosinophilic granular degeneration],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001077|http://purl.obolibrary.org/obo/TXPO_1000245,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:29254,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001051,,,,,,,,,,,,,,,,,,,,,,Mgll (rat)[Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001054,non-membrane spanning protein tyrosine kinase,,Catalysis role of the reaction: ATP + protein L-tyrosine = ADP + protein L-tyrosine phosphate by a non-membrane spanning protein.|related molecular function GO:0004715,false,,,http://purl.obolibrary.org/obo/TXPO_0002292,,,,,,,,,,,,,,,,,,,,,,Catalysis role of the reaction: ATP + protein L-tyrosine = ADP + protein L-tyrosine phosphate by a non-membrane spanning protein.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001054,,,,,,,,,,,,,,,,,,,,related molecular function GO:0004715,,non-membrane spanning protein tyrosine kinase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001052,negative regulation of cellular senescence [Ground glass appearance],,"Any process that stops, prevents or reduces the frequency, rate or extent of cellular senescence.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/GO_2000773|http://purl.obolibrary.org/obo/TXPO_0001728,,,,,,,,,,,,,,,,,,,,PMID:25661872,,"Any process that stops, prevents or reduces the frequency, rate or extent of cellular senescence.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001076|http://purl.obolibrary.org/obo/TXPO_0001543,,,,,,,,,,,,,,,,,TXPO:0001052,,,,,,,,,,,,,,,,,,,,,,negative regulation of cellular senescence [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001006,,,,http://purl.obolibrary.org/obo/NCBITaxon_10090,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001057,Acot3 (mouse)[Eosinophilic granular degeneration],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000023|http://purl.obolibrary.org/obo/TXPO_0000648,,,,,,,,,,,,,,,,,,,,"NCBI-Mouse-GeneID:171281|ACOT3 is involved in the transport of DCAdicarboxylic acids into the peroxisomes by hydrolysis of long-medium chain fatty acyl-CoA esters to FFA, which can be further transported out of peroxisomes to mitochondria for beta-oxidation or excreted in the urinPMID:23359794 At the gene level, this was reflected by the up-regulation of cytochrome P450 (Cyp) 4a10, Cyp4a14, Cyp4a31 and Acyl-CoA thioesterase 3 (Acot3). Two relevant regulators, cytochrome P450 oxidoreductase (Por, rate limiting for cytochrome P450s) and the transcription factor constitutive androstane receptor (Car; official symbol Nr1i3) were also up-regulated in the quercetin-fed mice.|PMID:28385385",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001057,,,,,,,,,,,,,,,,,,,,,,Acot3 (mouse)[Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001058,Acot2 (mouse)[Eosinophilic granular degeneration],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000022|http://purl.obolibrary.org/obo/TXPO_0000648,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:192272|PMID:21094633|PMID:25114170,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001058,,,,,,,,,,,,,,,,,,,,,,Acot2 (mouse)[Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001059,increasing lipid [lipidosis],,"Increasing lipid is a subtype of increasing quantity: A process that changes the amount of lipid to be larger.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0001062,,,,,,,,,,,,,,,,,,,,,,"Increasing lipid is a subtype of increasing quantity: A process that changes the amount of lipid to be larger.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001078|http://purl.obolibrary.org/obo/TXPO_0001386|http://purl.obolibrary.org/obo/TXPO_0001153|http://purl.obolibrary.org/obo/TXPO_0001141|http://purl.obolibrary.org/obo/TXPO_0001267,,,,,,,,,,,,,,,,,,TXPO:0001059,,,,,,,,,,,,,,,,,,,,,,increasing lipid [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001050,CPT1 (canonical)[Eosinophilic granular degeneration],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000097|http://purl.obolibrary.org/obo/TXPO_0001280,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1374,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001050,,,,,,,,,,,,,,,,,,,,,,CPT1 (canonical)[Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001056,decreasing lipid [lipidosis],,"Decreasing lipid is a subtype of decreasing quantity: A process that changes the quantity of the lipid to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis (normal condition).",false,,,http://purl.obolibrary.org/obo/TXPO_0000644|http://purl.obolibrary.org/obo/TXPO_0001720,,,,,,,,,,,,,,,,,,,,,,"Decreasing lipid is a subtype of decreasing quantity: A process that changes the quantity of the lipid to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis (normal condition).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001220|http://purl.obolibrary.org/obo/TXPO_0001221|http://purl.obolibrary.org/obo/TXPO_0001174|http://purl.obolibrary.org/obo/TXPO_0001379,,,,,,,,,,,,,,,,,,TXPO:0001056,,,,,,,,,,,,,,,,,,,,,,decreasing lipid [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0070988,demethylation,,The process of removing one or more methyl groups from a molecule.,false,,,http://purl.obolibrary.org/obo/GO_0008152,,,,,,,,,,,,,,,,,,,,,,The process of removing one or more methyl groups from a molecule.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0070988,,,,,,,,,,,,,,,,,,,,,,demethylation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100779,Wnt-9b,Wnt-14b|Wnt-15,,false,,,http://purl.obolibrary.org/obo/IMR_0000003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Wnt-14b|Wnt-15,,,,,IMR:0100779,,,,,,,,,,,,,,,,,,,,,,Wnt-9b,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000001508,CTSB,,Other designations: APP secretase|amyloid precursor protein secretase|cathepsin B1|cysteine protease,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,APPS|CPSB,,,,,,,,,,,,8,,,,,,Ensembl:ENSG00000164733|MIM:116810|HGNC:2527|HPRD:00287|Vega:OTTHUMG00000090799,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,cathepsin B,,,8p22,,,,,,,,,,,,,,,,"GO_0002224 (EC: TAS); GO_0004197 (EC: IDA); GO_0005515 (EC: IPI, PMID: 16364318); GO_0005518 (EC: IDA); GO_0005576 (EC: TAS); GO_0005615 (EC: IDA); GO_0005615 (EC: ISS); GO_0005622 (EC: TAS, PMID: 1645961); GO_0005730 (EC: IDA); GO_0005739 (EC: IEA); GO_0005764 (EC: IDA, PMID: 1837142); GO_0006508 (EC: IDA, PMID: 7890620); GO_0008233 (EC: IDA, PMID: 7890620); GO_0008234 (EC: IDA, PMID: 8811434); GO_0022617 (EC: TAS); GO_0030198 (EC: TAS); GO_0030574 (EC: IDA); GO_0030574 (EC: TAS); GO_0030855 (EC: IEP); GO_0036021 (EC: TAS); GO_0042470 (EC: IEA); GO_0042981 (EC: TAS, PMID: 16130169); GO_0043231 (EC: IDA); GO_0043394 (EC: IPI); GO_0045087 (EC: TAS); GO_0048471 (EC: IDA, PMID: 15614436); GO_0050790 (EC: IEA); GO_0051603 (EC: IDA); GO_0070062 (EC: IDA, PMID: 19199708); GO_0097067 (EC: IEP)",,,,,,,,,PMID: 417724; 1326552; 1577456; 1597471; 1637335; 1645961; 1837142; 1868826; 1900515; 1984484; 1996959; 2061332; 2476070; 3010323; 3463996; 3542996; 3972105; 6203523; 6351842; 7509303; 7622042; 7718586; 7890620; 8014475; 8083219; 8112600; 8617355; 8635854; 8811434; 9076588; 9295331; 9299326; 9360997; 9412840; 9539769; 9582368; 9585570; 9632704; 9733783; 9770500; 9776083; 9928950; 10353845; 10395917; 10512713; 10777578; 10849756; 10876156; 11016923; 11115496; 11134363; 11139332; 11162551; 11228542; 11241311; 11435427; 11513559; 11514663; 11536009; 11746262; 11815600; 11932257; 12057992; 12072442; 12086583; 12102727; 12185082; 12186841; 12189154; 12201820; 12437117; 12437120; 12477932; 12581740; 12589965; 12643545; 12677446; 12726991; 12887051; 12893746; 12926111; 14503883; 14702039; 14729603; 14730346; 14984956; 15016552; 15100281; 15122332; 15231747; 15255544; 15262981; 15274632; 15489334; 15512772; 15614436; 15679122; 15710602; 15799821; 15807897; 15816632; 15831716; 15832773; 16034129; 16051222; 16077201; 16130169; 16169070; 16303743; 16315320; 16364318; 16381007; 16492714; 16534247; 16709808; 16733801; 16894574; 16913838; 16914553; 17064696; 17081065; 17504810; 17507477; 17519890; 17724614; 17726009; 17982689; 17990360; 17991740; 18029348; 18163891; 18296264; 18314113; 18472965; 18515357; 18543249; 18566385; 18566436; 18598236; 18616803; 18706099; 18714186; 18718938; 18760860; 18949742; 19004543; 19040356; 19199708; 19331819; 19414800; 19434518; 19454696; 19615732; 19661440; 19692168; 19700239; 19774387; 19811804; 19913121; 19915865; 19930869; 20008285; 20042316; 20180636; 20302512; 20424577; 20536394; 20563251; 20567828; 20584670; 20627011; 20628086; 20661471; 20699092; 20706999; 20833970; 20880494; 20930303; 21060833; 21092200; 21112096; 21139048; 21199580; 21250859; 21323990; 21508263; 21541353; 21562164; 21585286; 21600167; 21742978; 21832049; 21835790; 21840777; 21850018; 21880013; 21890473; 21900206; 21925292; 21945151; 21948970; 21967108; 22066471; 22118674; 22127599; 22138708; 22190034; 22209964; 22222211; 22262857; 22266111; 22268729; 22278224; 22287159; 22322590; 22384200; 22464443; 22467319; 22571763; 22693552; 22695494; 22732093; 22745374; 22782900; 22851129; 22939629; 22949512; 23024364; 23063511; 23189279; 23195957; 23219593; 23222509; 23222817; 23292187; 23349634; 23362198; 23466190; 23591598; 23602568; 23603447; 23633927; 23667900; 23677785; 23708264; 23867824,,,,,,,,,,,,,,,OGG:3000001508,,20140408,protein-coding,,,,cathepsin B,,,,,,,,,,,,,Other designations: APP secretase|amyloid precursor protein secretase|cathepsin B1|cysteine protease,,CTSB,,,,,,,,,,,,,,,,,,,,,,,1508,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,CTSB,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0003891,TGFbeta (canonical)[Phospholipidosis - apotosis inhibitor],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003892,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_68494,,,,,,,,,,TXPO:0003891,,,,,,,,,,,,,,,,,,,,,,TGFbeta (canonical)[Phospholipidosis - apotosis inhibitor],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003899,degradation of Dab2 [Phospholipidosis],,"Degradation of Dab2 is a subtype of protein catabolic process: A process of the chemical reactions resulting in the breakdown of Dab2.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003898|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Degradation of Dab2 is a subtype of protein catabolic process: A process of the chemical reactions resulting in the breakdown of Dab2.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003574|http://purl.obolibrary.org/obo/TXPO_0003933|http://purl.obolibrary.org/obo/TXPO_0003914,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003899,,,,,,,,,,,,,,,,,,,,,,degradation of Dab2 [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003896,TGFB1(canonical)[Phospholipidosis - apotosis inhibitor],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003893,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000041,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_68494,,,,,,,,,,TXPO:0003896,,,,,,,,,,,,,,,,,,,,,,TGFB1(canonical)[Phospholipidosis - apotosis inhibitor],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003892,TGFB1(canonical)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003213|http://purl.obolibrary.org/obo/TXPO_1000371|http://purl.obolibrary.org/obo/IMR_0000042,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:|NCBI-Mouse-GeneID:|NCBI-Rat-GeneID:,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000041,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003892,,,,,,,,,,,,,,,,,,,,,,TGFB1(canonical)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003895,Tgfb1(mouse)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000371|http://purl.obolibrary.org/obo/IMR_0000042|http://purl.obolibrary.org/obo/TXPO_0003278,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000041,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003895,,,,,,,,,,,,,,,,,,,,,,Tgfb1(mouse)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003894,FNIP2(human)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001135|http://purl.obolibrary.org/obo/TXPO_0003837,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:57600|PMID:24272703|PMID:28039480|PMID:18403135|PMID:27353360|PMID:24095279,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000057600,,,,,,,,,,,,,TXPO:0003894,,,,,,,,,,,,,,,,,,,,,,FNIP2(human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003898,degradation of Dab2,,Degradation of Dab2 is a subtype of protein catabolic process: A process of the chemical reactions resulting in the breakdown of Dab2.,false,,,http://purl.obolibrary.org/obo/GO_0030163,,,,,,,,,,,,,,,,,,,,,,Degradation of Dab2 is a subtype of protein catabolic process: A process of the chemical reactions resulting in the breakdown of Dab2.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003898,,,,,,,,,,,,,,,,,,,,,,degradation of Dab2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003890,TGF beta receptor signaling (primitive) [Phospholipidosis (excessive defense) - apoptosis inhibition ],,"TGFbeta signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the cytokine TGFbeta.
This process is dependent on the  apoptosis inhibition  and can constitute the course of Phospholipidosis (excessive defense) .",false,,,http://purl.obolibrary.org/obo/TXPO_0001853,,,,,,,,,,,,,,,,,,,,,,"TGFbeta signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the cytokine TGFbeta.
This process is dependent on the  apoptosis inhibition  and can constitute the course of Phospholipidosis (excessive defense) .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003896|http://purl.obolibrary.org/obo/TXPO_0003897,,,,,,http://purl.obolibrary.org/obo/TXPO_0003899,,,,,,,,,,,TXPO:0003890,,,,,,,,,,,,,,,,,,,,,,TGF beta receptor signaling (primitive) [Phospholipidosis (excessive defense) - apoptosis inhibition ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003897,Tgfb1(mouse)[Phospholipidosis - apotosis inhibitor],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003895|http://purl.obolibrary.org/obo/IMR_0000042|http://purl.obolibrary.org/obo/TXPO_0003278,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000041,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003897,,,,,,,,,,,,,,,,,,,,,,Tgfb1(mouse)[Phospholipidosis - apotosis inhibitor],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003893,TGFB1(human)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000371|http://purl.obolibrary.org/obo/IMR_0000042|http://purl.obolibrary.org/obo/TXPO_0001135,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000041,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003893,,,,,,,,,,,,,,,,,,,,,,TGFB1(human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100089,thymus hormone,,,false,,,http://purl.obolibrary.org/obo/IMR_0000966,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_24621,,,,,,,,,,IMR:0100089,,,,,,,,,,,,,,,,,,,,,,thymus hormone,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000026061,HACL1,,Other designations: 1600020H07Rik|2-hydroxyphytanol-CoA lyase|2-hydroxyphytanoyl-CoA lyase|phytanoyl-CoA 2-hydroxylase 2|phytanoyl-CoA hydroxylase 2,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,2-HPCL|PHYH2|HPCL|HPCL2,,,,,,,,,,,,3,,,,,,Ensembl:ENSG00000131373|HGNC:17856|MIM:604300|HPRD:09183|Vega:OTTHUMG00000129862,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,2-hydroxyacyl-CoA lyase 1,,,3p25.1,,,,,,,,,,,,,,,,"GO_0000287 (EC: IEA); GO_0001561 (EC: IDA, PMID: 10468558); GO_0001561 (EC: TAS); GO_0005102 (EC: IPI); GO_0005777 (EC: IDA, PMID: 10468558); GO_0005782 (EC: TAS); GO_0016830 (EC: IDA, PMID: 10468558); GO_0016830 (EC: TAS); GO_0030976 (EC: IDA, PMID: 10468558); GO_0042802 (EC: IPI, PMID: 16189514); GO_0044255 (EC: TAS); GO_0044281 (EC: TAS); GO_0048037 (EC: IDA, PMID: 15644336); GO_0051259 (EC: IDA)",,,,,,,,,PMID: 10468558; 11042152; 12477932; 14561759; 14702039; 15489334; 15644336; 16189514; 16344560; 16756494; 17370265; 20178365; 21708296; 21890473; 21900206; 21906983; 21963094; 22002062; 22939629; 23000965,,,,,,,,,,,,,,,OGG:3000026061,,,,,,,2-hydroxyacyl-CoA lyase 1,,,,,,,,,,,,,Other designations: 1600020H07Rik|2-hydroxyphytanol-CoA lyase|2-hydroxyphytanoyl-CoA lyase|phytanoyl-CoA 2-hydroxylase 2|phytanoyl-CoA hydroxylase 2,,HACL1,,,,,,,,,,,,,,,,,,,,,,,26061,HSPC279,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,HACL1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/UBERON_0007798,vascular system,Gefaesssystem@ge,Anatomical system that consists of all blood and lymph vessels.,false,,,http://purl.obolibrary.org/obo/UBERON_0000467,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C33854|http://linkedlifedata.com/resource/umls/id/C0489903|EMAPA:35905|UMLS:C0489903|EHDAA2:0004520|MA:0002718|CALOHA:TS-2053|BTO:0001085,,Anatomical system that consists of all blood and lymph vessels.,,,,consider merging with vasculature,,,,"The cardiovascular and lymphatic systems, collectively[ncithesaurus:Vascular_System].",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Gefaesssystem@ge,,http://purl.obolibrary.org/obo/UBERON_0004535,UBERON:0007798,http://purl.obolibrary.org/obo/UBERON_0004535,,,,,,,,,,,,,,,,,,,,,vascular system,,,,,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000352,cytokeratin 9,,,false,,,http://purl.obolibrary.org/obo/IMR_0000035,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000352,,,,,,,,,,,,,,,,,,,,,,cytokeratin 9,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000978,LRP12,LDL receptor-related protein 12,,false,,,http://purl.obolibrary.org/obo/IMR_0100798,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,LDL receptor-related protein 12,,,,,IMR:0000978,,,,,,,,,,,,,,,,,,,,,,LRP12,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_50276,EC 5.99.1.2 (DNA topoisomerase) inhibitor,topoisomerase I inhibitors|DNA topoisomerase inhibitor|EC 5.99.1.2 (DNA topoisomerase) inhibitors|topoisomerase I (EC 5.99.1.2) inhibitors|topoisomerase I (EC 5.99.1.2) inhibitor|EC 5.99.1.2 (topoisomerase I) inhibitor|DNA topoisomerase inhibitors|type I DNA topoisomerase inhibitor|topoisomerase I inhibitor|EC 5.99.1.2 (topoisomerase I) inhibitors|EC 5.99.1.2 inhibitors|type I DNA topoisomerase inhibitors|EC 5.99.1.2 inhibitor,"A topoisomerase inhibitor that inhibits the bacterial enzymes of the DNA topoisomerases, Type I class (EC 5.99.1.2) that catalyze ATP-independent breakage of one of the two strands of DNA, passage of the unbroken strand through the break, and rejoining of the broken strand. These bacterial enzymes reduce the topological stress in the DNA structure by relaxing negatively, but not positively, supercoiled DNA.",false,,,http://purl.obolibrary.org/obo/CHEBI_70727,,,,,,,,,,,,,,,,,,,,,,"A topoisomerase inhibitor that inhibits the bacterial enzymes of the DNA topoisomerases, Type I class (EC 5.99.1.2) that catalyze ATP-independent breakage of one of the two strands of DNA, passage of the unbroken strand through the break, and rejoining of the broken strand. These bacterial enzymes reduce the topological stress in the DNA structure by relaxing negatively, but not positively, supercoiled DNA.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,topoisomerase I inhibitors|DNA topoisomerase inhibitor|EC 5.99.1.2 (DNA topoisomerase) inhibitors|topoisomerase I (EC 5.99.1.2) inhibitors|topoisomerase I (EC 5.99.1.2) inhibitor|EC 5.99.1.2 (topoisomerase I) inhibitor|DNA topoisomerase inhibitors|type I DNA topoisomerase inhibitor|topoisomerase I inhibitor|EC 5.99.1.2 (topoisomerase I) inhibitors|EC 5.99.1.2 inhibitors|type I DNA topoisomerase inhibitors|EC 5.99.1.2 inhibitor,,,,,,,,,,,,,,,,,,,,,CHEBI:50276,,,,EC 5.99.1.2 (DNA topoisomerase) inhibitor,,CHEBI:50276,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100093,pituitary hormone-releasing hormone,PHRH,"Hormones released by one structure (e.g., the hypothalamus or the thyroid gland) that effect the secretion of hormones from the pituitary gland.",false,,,http://purl.obolibrary.org/obo/IMR_0100082,,,,,,,,,,,,,,,,,,,,MeSH:D010906,,"Hormones released by one structure (e.g., the hypothalamus or the thyroid gland) that effect the secretion of hormones from the pituitary gland.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PHRH,,,,,IMR:0100093,,,,,,,,,,,,,,,,,,,,,,pituitary hormone-releasing hormone,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000000782,CACNB1,,"Other designations: calcium channel voltage-dependent subunit beta 1|calcium channel, L type, beta 1 polypeptide|dihydropyridine-sensitive L-type, calcium channel beta-1 subunit|voltage-dependent L-type calcium channel subunit beta-1",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CACNLB1|CCHLB1|CAB1,,,,,,,,,,,,17,,,,,,Ensembl:ENSG00000067191|Vega:OTTHUMG00000133217|HGNC:1401|MIM:114207|HPRD:11743,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"calcium channel, voltage-dependent, beta 1 subunit",,,17q21-q22,,,,,,,,,,,,,,,,"GO_0005245 (EC: TAS, PMID: 1385409); GO_0005891 (EC: IEA); GO_0006612 (EC: IEA); GO_0006810 (EC: TAS, PMID: 1385409); GO_0007411 (EC: TAS); GO_0008331 (EC: IEA); GO_0016529 (EC: IEA); GO_0030315 (EC: IEA)",,,,,,,,,PMID: 1309651; 1370480; 1385409; 1657644; 7916667; 8381767; 8395940; 8905728; 8943043; 10066897; 10465427; 10624822; 12477932; 14623965; 14760703; 14762176; 15342556; 16713569; 17081983; 19821165; 19953087; 21098446; 21832049; 21906983; 23382691; 23602568,,,,,,,,,,,,,,,OGG:3000000782,,,,,,,"calcium channel, voltage-dependent, beta 1 subunit",,,,,,,,,,,,,"Other designations: calcium channel voltage-dependent subunit beta 1|calcium channel, L type, beta 1 polypeptide|dihydropyridine-sensitive L-type, calcium channel beta-1 subunit|voltage-dependent L-type calcium channel subunit beta-1",,CACNB1,,,,,,,,,,,,,,,,,,,,,,,782,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,CACNB1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000000788,SLC25A20,,Other designations: mitochondrial carnitine/acylcarnitine carrier protein,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CACT|CAC,,,,,,,,,,,,3,,,,,,HGNC:1421|Ensembl:ENSG00000178537|HPRD:01953|MIM:613698|Vega:OTTHUMG00000133538,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"solute carrier family 25 (carnitine/acylcarnitine translocase), member 20",,,3p21.31,,,,,,,,,,,,,,,,GO_0005739 (EC: IDA); GO_0005743 (EC: TAS); GO_0006853 (EC: TAS); GO_0016021 (EC: IEA); GO_0044255 (EC: TAS); GO_0044281 (EC: TAS),,,,,,,,,PMID: 1598097; 9399886; 9533014; 9686371; 9733094; 9837782; 10384384; 10697964; 11257506; 11592821; 12477932; 12859414; 15057979; 15365988; 15489334; 15515015; 16054041; 16169070; 17508264; 18029348; 18307102; 19748481; 20877624; 21130740; 21890473; 22560224; 23178685; 23266187; 23322164,,,,,,,,,,,,,,,OGG:3000000788,,,,,,,"solute carrier family 25 (carnitine/acylcarnitine translocase), member 20",,,,,,,,,,,,,Other designations: mitochondrial carnitine/acylcarnitine carrier protein,,SLC25A20,,,,,,,,,,,,,,,,,,,,,,,788,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,SLC25A20,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0004754,PIM3 activation,,"PIM3 activation is a subtype of molecular activation: A process that  changes the activity of the PIM3 (Pim-3 proto-oncogene, serine/threonine kinase) to be higher.",false,,,http://purl.obolibrary.org/obo/TXPO_0000023,,,,,,,,,,,,,,,,,,,,,,"PIM3 activation is a subtype of molecular activation: A process that  changes the activity of the PIM3 (Pim-3 proto-oncogene, serine/threonine kinase) to be higher.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004754,,,,,,,,,,,,,,,,,,,,,,PIM3 activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004756,PIM3 (human) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000525,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:415116|PMID:20101231,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000415116,,,,,,,,,,,,,TXPO:0004756,,,,,,,,,,,,,,,,,,,,,,PIM3 (human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004753,PI3K signaling (primitive) [hepatocarcinogenesis],,"PI3K signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by PI3K.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004752,,,,,,,,,,,,,,,,,,,,PMID:28493839,,"PI3K signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by PI3K.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004751,,,,,http://purl.obolibrary.org/obo/TXPO_0004417,,,,,,,,,,,TXPO:0004753,,,,,,,,,,,,,,,,,,,,,,PI3K signaling (primitive) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004758,liver malfunction  [hepatocarcinogenesis],,"Liver malfunction is a subtype of organ malfunction: A process that does not perform liver function correctly or not functioning at all.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0002074,,,,,,,,,,,,,,,,,,,,PMID:28159835|PMID:20101231,,"Liver malfunction is a subtype of organ malfunction: A process that does not perform liver function correctly or not functioning at all.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004392,,,,,,,,,,,TXPO:0004758,,,,,,,,,,,,,,,,,,,,,,liver malfunction  [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004751,PI3K signal transduction pathway,,"A series of molecular signals mediated by PI3K (phosphatidylinositol-4,5-bisphosphate 3-kinase).",false,,,http://purl.obolibrary.org/obo/TXPO_0000609,,,,,,,,,,,,,,,,,,,,,,"A series of molecular signals mediated by PI3K (phosphatidylinositol-4,5-bisphosphate 3-kinase).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004751,,,,,,,,,,,,,,,,,,,,,,PI3K signal transduction pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004752,PI3K signaling (primitive),,PI3K signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by PI3K.,false,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,,,PI3K signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by PI3K.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004751,,,,,,,,,,,,,,,,TXPO:0004752,,,,,,,,,,,,,,,,,,,,,,PI3K signaling (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004750,PHB - inactive form (human) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_0005124,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:5245|PMID:30523154,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0002355,,,,,,,,,,,,,,TXPO:0004750,,,,,,,,,,,,,,,,,,,,,,PHB - inactive form (human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004759,lipid storage in liver [hepatocarcinogenesis],,"Lipid storage in liver is a subtype of lipid storage: The accumulation and maintenance in cells or tissues of lipids in the liver.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0001276,,,,,,,,,,,,,,,,,,,,PMID:20101231,,"Lipid storage in liver is a subtype of lipid storage: The accumulation and maintenance in cells or tissues of lipids in the liver.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004392,,,,,,,,,,,TXPO:0004759,,,,,,,,,,,,,,,,,,,,,,lipid storage in liver [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004755,PIM3 activation [hepatocarcinogenesis],,"PIM3 activation is a subtype of molecular activation: A process that  changes the activity of the PIM3 (Pim-3 proto-oncogene, serine/threonine kinase) to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004754,,,,,,,,,,,,,,,,,,,,PMID:20101231,,"PIM3 activation is a subtype of molecular activation: A process that  changes the activity of the PIM3 (Pim-3 proto-oncogene, serine/threonine kinase) to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004756,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004459|http://purl.obolibrary.org/obo/TXPO_0004603|http://purl.obolibrary.org/obo/TXPO_0004758|http://purl.obolibrary.org/obo/TXPO_0004759|http://purl.obolibrary.org/obo/TXPO_0004757,,,,,,,,,,,TXPO:0004755,,,,,,,,,,,,,,,,,,,,,,PIM3 activation [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004757,changing abnormal cellular structure [hepatocarcinogenesis],,"Changing abnormal cellular structure is a subtype of changing structure: A process that changes the structure of the cell abnormally.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0001770,,,,,,,,,,,,,,,,,,,,PMID:20101231,,"Changing abnormal cellular structure is a subtype of changing structure: A process that changes the structure of the cell abnormally.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0005036,,,,,,,,,,,TXPO:0004757,,,,,,,,,,,,,,,,,,,,,,changing abnormal cellular structure [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/BFO_0000024,fiat object part,,,false,,,http://purl.obolibrary.org/obo/BFO_0000040,,,,,,,,,,,,,,,,,,,,,,,,,,BFO 2 Reference: Most examples of fiat object parts are associated with theoretically drawn divisions,,"b is a fiat object part = Def. b is a material entity which is such that for all times t, if b exists at t then there is some object c such that b proper continuant_part of  c at t and c is demarcated from the remainder of c by a two-dimensional continuant fiat boundary. (axiom label in BFO2 Reference: [027-004])","the FMA:regional parts of an intact human body.|or with divisions drawn by cognitive subjects for practical reasons, such as the division of a cake (before slicing) into (what will become) slices (and thus member parts of an object aggregate). However, this does not mean that fiat object parts are dependent for their existence on divisions or delineations effected by cognitive subjects. If, for example, it is correct to conceive geological layers of the Earth as fiat object parts of the Earth, then even though these layers were first delineated in recent times, still existed long before such delineation and what holds of these layers (for example that the oldest layers are also the lowest layers) did not begin to hold because of our acts of delineation.Treatment of material entity in BFOExamples viewed by some as problematic cases for the trichotomy of fiat object part, object, and object aggregate include: a mussel on (and attached to) a rock, a slime mold, a pizza, a cloud, a galaxy, a railway train with engine and multiple carriages, a clonal stand of quaking aspen, a bacterial community (biofilm), a broken femur. Note that, as Aristotle already clearly recognized, such problematic cases – which lie at or near the penumbra of instances defined by the categories in question – need not invalidate these categories. The existence of grey objects does not prove that there are not objects which are black and objects which are white; the existence of mules does not prove that there are not objects which are donkeys and objects which are horses. It does, however, show that the examples in question need to be addressed carefully in order to show how they can be fitted into the proposed scheme, for example by recognizing additional subdivisions [29|the dorsal and ventral surfaces of the body|the division of the brain into regions|the upper and lower lobes of the left lung|the Western hemisphere of the Earth|the division of the planet into hemispheres",,,,,,,,,,,(forall (x) (if (FiatObjectPart x) (and (MaterialEntity x) (forall (t) (if (existsAt x t) (exists (y) (and (Object y) (properContinuantPartOfAt x y t)))))))) // axiom label in BFO2 CLIF: [027-004],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BFO:0000024,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/bfo.owl,fiat object part,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_65207,vascular endothelial growth factor receptor antagonist,VEGF receptor inhibitors|vascular endothelial growth factor receptor antagonists|vascular endothelial growth factor receptor inhibitors|vascular endothelial growth factor receptor inhibitor|VEGF receptor inhibitor|VEGFR inhibitors|VEGFR inhibitor,An antagonist at the vascular endothelial growth factor receptor.,false,,,http://purl.obolibrary.org/obo/CHEBI_48706,,,,,,,,,,,,,,,,,,,,,,An antagonist at the vascular endothelial growth factor receptor.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,VEGF receptor inhibitors|vascular endothelial growth factor receptor antagonists|vascular endothelial growth factor receptor inhibitors|vascular endothelial growth factor receptor inhibitor|VEGF receptor inhibitor|VEGFR inhibitors|VEGFR inhibitor,,,,,,,,,,,,,,,,,,,,,CHEBI:65207,,,,vascular endothelial growth factor receptor antagonist,,CHEBI:65207,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/BFO_0000148,zero-dimensional temporal region,,,false,,,http://purl.obolibrary.org/obo/BFO_0000008,,temporal instant.,,,,,,,,,,,,,,,,,,,,,,,,,,A zero-dimensional temporal region is a temporal region that is without extent. (axiom label in BFO2 Reference: [102-001]),a temporal region that is occupied by a process boundary|the moment at which a finger is detached in an industrial accident|right now|the moment of death.|the moment at which a child is born,,,,,,,,,,,(forall (x) (if (ZeroDimensionalTemporalRegion x) (TemporalRegion x))) // axiom label in BFO2 CLIF: [102-001],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BFO:0000148,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/bfo.owl,zero-dimensional temporal region,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000001191,CLU,,"Other designations: aging-associated protein 4|apolipoprotein J|complement cytolysis inhibitor|complement lysis inhibitor|complement-associated protein SP-40,40|ku70-binding protein 1|sulfated glycoprotein 2|testosterone-repressed prostate message 2",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,TRPM-2|APO-J|CLI|NA1/NA2|TRPM2|CLU1|SGP-2|SP-40|SGP2|CLU2|APOJ|KUB1,,,,,,,,,,,,8,,,,,,Ensembl:ENSG00000120885|Vega:OTTHUMG00000102114|MIM:185430|HGNC:2095|HPRD:01706,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,clusterin,,,8p21-p12,,,,,,,,,,,,,,,,"GO_0001836 (EC: IC, PMID: 16113678); GO_0002576 (EC: TAS); GO_0005515 (EC: IPI, PMID: 16113678); GO_0005576 (EC: TAS); GO_0005615 (EC: IDA, PMID: 11123922); GO_0005634 (EC: IEA); GO_0005739 (EC: IDA, PMID: 16113678); GO_0005783 (EC: IEA); GO_0005829 (EC: IEA); GO_0006629 (EC: NAS, PMID: 2387851); GO_0006956 (EC: TAS, PMID: 1585460); GO_0006958 (EC: IEA); GO_0007596 (EC: TAS); GO_0009615 (EC: IEP, PMID: 16548883); GO_0016887 (EC: IDA, Qualifier: NOT, PMID: 11123922); GO_0030168 (EC: TAS); GO_0031012 (EC: IDA, Qualifier: colocalizes_with); GO_0031093 (EC: TAS); GO_0031625 (EC: IDA); GO_0031966 (EC: IEA); GO_0032436 (EC: IMP); GO_0032463 (EC: IMP, PMID: 16113678); GO_0034366 (EC: IDA, PMID: 16682745); GO_0042583 (EC: IEA); GO_0043065 (EC: IMP); GO_0043691 (EC: TAS, PMID: 16682745); GO_0045087 (EC: IEA); GO_0048471 (EC: IDA); GO_0050821 (EC: IDA, PMID: 11123922); GO_0051092 (EC: IMP); GO_0051787 (EC: IDA, PMID: 11123922); GO_0051787 (EC: IPI, PMID: 19996109); GO_0051788 (EC: IDA, PMID: 19996109); GO_0061077 (EC: IDA, PMID: 11123922); GO_0070062 (EC: IDA, PMID: 19056867); GO_0072562 (EC: IDA); GO_0097193 (EC: IDA); GO_1902230 (EC: IMP, PMID: 16113678); GO_2000060 (EC: IMP); GO_2001244 (EC: IMP)",,,,,,,,,PMID: 1424805; 1491011; 1551440; 1585460; 1903064; 1924317; 1974459; 2185274; 2387851; 2454950; 2601725; 2721499; 2780565; 2780570; 3154963; 3167096; 7615015; 7626703; 7768901; 8181474; 8292612; 8314591; 8328966; 8345200; 8387101; 8555189; 8634259; 8752142; 8759347; 8843912; 8889548; 9228033; 9336835; 9537999; 10066740; 10219089; 10329371; 10694874; 11123922; 11186422; 11570883; 11714447; 11795992; 11813210; 11892985; 11904161; 11906815; 12082621; 12172907; 12176985; 12200037; 12393179; 12427144; 12429802; 12470829; 12477932; 12551933; 12679903; 12754519; 12824284; 12860995; 12867999; 12882985; 14618611; 14630798; 14702039; 14718574; 14760718; 15033782; 15133840; 15146195; 15158456; 15174051; 15247015; 15252304; 15304052; 15342556; 15389725; 15480429; 15489334; 15492264; 15499376; 15538973; 15591223; 15649646; 15689620; 15791650; 15809754; 15883054; 15925890; 15929184; 15955107; 16113678; 16179938; 16263699; 16331665; 16335952; 16421571; 16464517; 16490286; 16548883; 16675913; 16682745; 16709604; 16709934; 16740002; 16775601; 16806233; 16955214; 17043677; 17048076; 17056579; 17080454; 17148459; 17170699; 17203891; 17224269; 17260971; 17322305; 17407782; 17412999; 17420006; 17451556; 17512083; 17534116; 17535098; 17689225; 17855704; 17872975; 17974975; 18079682; 18082619; 18097679; 18239862; 18378577; 18458059; 18514801; 18542050; 18612545; 18624398; 18649357; 18709641; 18712185; 18714397; 18786636; 18806885; 18813793; 18842294; 19056867; 19118032; 19137541; 19165232; 19166932; 19177010; 19182256; 19220628; 19264665; 19289586; 19344414; 19353783; 19357365; 19391138; 19413638; 19446882; 19535339; 19542874; 19651157; 19664600; 19734902; 19734903; 19757199; 19793084; 19814590; 19878569; 19878770; 19878774; 19879420; 19879421; 19879422; 19879423; 19903339; 19903745; 19935703; 19940549; 19996109; 20000738; 20007348; 20009887; 20019877; 20028970; 20057494; 20058210; 20068069; 20096688; 20195357; 20209083; 20353268; 20360068; 20410100; 20460622; 20497247; 20534741; 20554627; 20570404; 20599866; 20603455; 20614220; 20674675; 20697030; 20738160; 20739100; 20842452; 20847305; 20850846; 20855565; 20873220; 20930273; 21042904; 21043527; 21059989; 21135756; 21163940; 21224044; 21240462; 21242307; 21280673; 21300948; 21347408; 21379329; 21397462; 21422520; 21447104; 21460841; 21460853; 21467232; 21467285; 21505792; 21508640; 21525168; 21527247; 21543606; 21567405; 21573492; 21627779; 21630085; 21633299; 21732348; 21761117; 21824521; 21892414; 21899841; 21900379; 21912625; 21953030; 21953454; 21980627; 21987172; 21988832; 21998749; 22012253; 22013110; 22015308; 22016805; 22068036; 22082661; 22122982; 22130675; 22145905; 22159129; 22166956; 22179788; 22232000; 22234156; 22236192; 22248099; 22258514; 22266332; 22268729; 22274961; 22296908; 22391565; 22402018; 22465014; 22506010; 22532874; 22539578; 22545109; 22569264; 22613415; 22617144; 22647452; 22689054; 22701550; 22795969; 22832520; 22863883; 22889670; 22896337; 22902018; 22906254; 22952074; 22975582; 22981431; 22990118; 23010347; 23051594; 23099883; 23174100; 23201481; 23208459; 23209684; 23276503; 23279642; 23411014; 23416242; 23455922; 23457489; 23538443; 23573206; 23589125; 23602568; 23621580; 23650005; 23673647; 23702390; 23769013; 23770713; 23786771; 23956692; 24073260,,,,,,,,,,,,,,,OGG:3000001191,,,,,,,clusterin,,,,,,,,,,,,,"Other designations: aging-associated protein 4|apolipoprotein J|complement cytolysis inhibitor|complement lysis inhibitor|complement-associated protein SP-40,40|ku70-binding protein 1|sulfated glycoprotein 2|testosterone-repressed prostate message 2",,CLU,,,,,,,,,,,,,,,,,,,,,,,1191,AAG4,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,CLU,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0002394,TCR gamma,T-cell receptor gamma,,false,,,http://purl.obolibrary.org/obo/IMR_0000151,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,T-cell receptor gamma,,,,,IMR:0002394,,,,,,,,,,,,,,,,,,,,,,TCR gamma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001452,TLR3,Toll-like receptor 3,,false,,,http://purl.obolibrary.org/obo/IMR_0000124,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Toll-like receptor 3,,,,,IMR:0001452,,,,,,,,,,,,,,,,,,,,,,TLR3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000008743,TNFSF10,,"Other designations: Apo-2 ligand|TNF-related apoptosis inducing ligand TRAIL|chemokine tumor necrosis factor ligand superfamily member 10|tumor necrosis factor (ligand) family, member 10|tumor necrosis factor apoptosis-inducing ligand splice variant delta|tumor necrosis factor ligand superfamily member 10",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,TL2|APO2L|TRAIL|CD253|Apo-2L,,,,,,,,,,,,3,,,,,,MIM:603598|Vega:OTTHUMG00000156917|HPRD:04670|Ensembl:ENSG00000121858|HGNC:11925,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"tumor necrosis factor (ligand) superfamily, member 10",,,3q26,,,,,,,,,,,,,,,,"GO_0005102 (EC: TAS, PMID: 8663110); GO_0005125 (EC: IEA); GO_0005164 (EC: IEA); GO_0005515 (EC: IPI, PMID: 10549288); GO_0005576 (EC: TAS); GO_0005615 (EC: IEA); GO_0005887 (EC: TAS, PMID: 8663110); GO_0006915 (EC: TAS); GO_0006919 (EC: TAS); GO_0006955 (EC: IEA); GO_0007165 (EC: TAS, PMID: 8663110); GO_0007267 (EC: TAS, PMID: 8777713); GO_0008584 (EC: IEA); GO_0032868 (EC: IEA); GO_0043065 (EC: IDA); GO_0043123 (EC: IEP, PMID: 12761501); GO_0043280 (EC: IDA); GO_0046872 (EC: IEA); GO_0070062 (EC: IDA, PMID: 19199708); GO_0090200 (EC: IDA); GO_0097190 (EC: TAS); GO_2001238 (EC: IDA); GO_2001239 (EC: TAS)",,,,,,,,,PMID: 8663110; 8777713; 8793301; 9082980; 9242610; 9311998; 9314565; 9325248; 9430226; 9520411; 9613612; 9754559; 9830064; 10485660; 10542098; 10549288; 10651627; 10894160; 10960444; 11022932; 11027498; 11059770; 11094155; 11095979; 11243698; 11385301; 11466352; 11553609; 11568006; 11677236; 11739488; 11781716; 11830480; 11844843; 11852102; 11877293; 11936954; 11940602; 11956660; 11964312; 11994437; 12029096; 12036888; 12082620; 12082629; 12097384; 12097388; 12118245; 12140294; 12198154; 12221720; 12351634; 12359235; 12398939; 12407100; 12414956; 12421926; 12421985; 12421989; 12429913; 12439929; 12445619; 12447876; 12477932; 12488957; 12496482; 12517970; 12532461; 12539042; 12556488; 12574346; 12576447; 12592338; 12604406; 12642868; 12663665; 12707267; 12715915; 12738989; 12761501; 12761581; 12767990; 12787570; 12808117; 12813457; 12839575; 12874246; 12907654; 12915532; 12915677; 12920112; 12927928; 12934102; 12969966; 14534533; 14601052; 14637151; 14644197; 14645705; 14647456; 14670183; 14675194; 14691451; 14715264; 14726404; 14729397; 14742697; 15030996; 15033706; 15041704; 15064358; 15077162; 15093732; 15094456; 15110168; 15137068; 15201983; 15205263; 15241475; 15251327; 15256058; 15257094; 15285015; 15286701; 15292354; 15308561; 15326479; 15339846; 15361826; 15451437; 15459016; 15459191; 15475369; 15489334; 15498932; 15509531; 15511228; 15520016; 15531913; 15539085; 15557763; 15558024; 15569667; 15607733; 15615731; 15619633; 15634757; 15637055; 15653751; 15655781; 15671071; 15681838; 15688023; 15757891; 15760909; 15767553; 15774464; 15792357; 15806163; 15809718; 15828026; 15884050; 15887227; 15916713; 15962328; 15990565; 15996036; 16007425; 16026644; 16037944; 16040132; 16041267; 16046522; 16082383; 16116625; 16166346; 16169070; 16174727; 16178278; 16180223; 16199534; 16206163; 16215673; 16226105; 16229016; 16245299; 16288714; 16289694; 16344560; 16368536; 16382051; 16436464; 16449964; 16455983; 16459719; 16478725; 16514644; 16518756; 16574768; 16607283; 16627981; 16645643; 16731632; 16751802; 16785986; 16807984; 16820090; 16831934; 16857810; 16863850; 16887991; 16941746; 16950202; 16951203; 17012835; 17070520; 17079165; 17110373; 17187253; 17195089; 17278883; 17314102; 17352408; 17356300; 17384675; 17420249; 17431115; 17431792; 17479107; 17495957; 17513605; 17525260; 17540725; 17544413; 17548900; 17553352; 17554866; 17558561; 17571163; 17579120; 17583676; 17617740; 17638906; 17683987; 17686764; 17697742; 17701086; 17702740; 17703232; 17765202; 17767167; 17803681; 17881904; 17884184; 17895594; 17900262; 17907960; 17913827; 17932312; 17938258; 17940338; 17947462; 17956986; 17982483; 17983809; 18006822; 18006832; 18006836; 18031928; 18057577; 18063697; 18089811; 18174230; 18178561; 18187663; 18202704; 18220834; 18233993; 18243765; 18266928; 18266968; 18284918; 18287563; 18314443; 18330721; 18338379; 18339897; 18341587; 18343496; 18348311; 18362888; 18362891; 18375389; 18385934; 18413764; 18424742; 18430896; 18451172; 18474604; 18483205; 18491232; 18502726; 18519235; 18522940; 18566412; 18599181; 18599488; 18640940; 18644981; 18723061; 18726983; 18772312; 18780288; 18802096; 18814951; 18834856; 18838202; 18922903; 18942021; 19050264; 19058836; 19074436; 19074831; 19106633; 19147771; 19197243; 19199708; 19203346; 19212626; 19221598; 19223770; 19236007; 19261616; 19265041; 19270498; 19281785; 19289465; 19294332; 19305384; 19309556; 19349211; 19361506; 19379558; 19385057; 19398149; 19404407; 19406930; 19407827; 19412666; 19418484; 19427028; 19435900; 19449143; 19453261; 19470406; 19476940; 19481529; 19519609; 19533303; 19540229; 19573080; 19587531; 19597472; 19629467; 19632771; 19671825; 19674787; 19690337; 19724854; 19749795; 19767219; 19773279; 19782681; 19802013; 19812265; 19854352; 19890662; 19896469; 19948942; 19954364; 19954896; 19956887; 19962668; 19962958; 19967427; 20007807; 20042498; 20119620; 20123409; 20150555; 20154087; 20189551; 20204286; 20237496; 20308427; 20334827; 20339295; 20354842; 20372797; 20379197; 20393185; 20394499; 20400979; 20417200; 20424169; 20430391; 20443055; 20560677; 20568250; 20580220; 20580868; 20628624; 20638129; 20638385; 20671119; 20734142; 20802294; 20811726; 20819778; 20838376; 20839416; 20852190; 20862322; 20961336; 20977779; 21047948; 21059290; 21064084; 21086019; 21107885; 21120579; 21125311; 21156789; 21160038; 21167276; 21183948; 21209944; 21211989; 21248767; 21255088; 21279373; 21291526; 21305500; 21308719; 21317160; 21368892; 21381010; 21426505; 21435442; 21437625; 21437722; 21454681; 21465464; 21480222; 21482133; 21483669; 21485546; 21525012; 21538027; 21554547; 21603612; 21622121; 21670755; 21695716; 21697087; 21706325; 21732015; 21760914; 21769428; 21769834; 21802664; 21822306; 21824395; 21846721; 21859711; 21864851; 21926463; 21941373; 21952139; 21988644; 21993926; 22023762; 22034880; 22072062; 22110611; 22159760; 22194780; 22202560; 22266862; 22310286; 22320196; 22322844; 22328338; 22345097; 22354145; 22384114; 22392486; 22398750; 22408249; 22449797; 22462553; 22471587; 22496450; 22542907; 22554587; 22585859; 22698523; 22719861; 22729471; 22783581; 22883061; 22898820; 22899350; 22914768; 22922789; 22948392; 23014529; 23018355; 23053497; 23071256; 23085529; 23096115; 23142077; 23228130; 23247197; 23258590; 23277172; 23290504; 23306613; 23319802; 23375756; 23384657; 23392805; 23408429; 23426404; 23428290; 23437333; 23441146; 23456625; 23457619; 23468057; 23472162; 23481489; 23492767; 23579274; 23615398; 23636231; 23667901; 23674352; 23686163; 23699397; 23699656; 23703388; 23732517; 23774624; 23792015; 23932896; 23937794; 23959437; 23974204; 23981753; 24019170; 24078627; 24100030; 24167941; 24184557; 24223304; 24299309; 24344047,,,,,,,,,,,,,,,OGG:3000008743,,20140408,protein-coding,,,,"tumor necrosis factor (ligand) superfamily, member 10",,,,,,,,,,,,,"Other designations: Apo-2 ligand|TNF-related apoptosis inducing ligand TRAIL|chemokine tumor necrosis factor ligand superfamily member 10|tumor necrosis factor (ligand) family, member 10|tumor necrosis factor apoptosis-inducing ligand splice variant delta|tumor necrosis factor ligand superfamily member 10",,TNFSF10,,,,,,,,,,,,,,,,,,,,,,,8743,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,TNFSF10,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/GO_0009404,toxin metabolic process,toxin metabolism,"The chemical reactions and pathways involving a toxin, a poisonous compound (typically a protein) that is produced by cells or organisms and that can cause disease when introduced into the body or tissues of an organism.",false,,,http://purl.obolibrary.org/obo/GO_0008152,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways involving a toxin, a poisonous compound (typically a protein) that is produced by cells or organisms and that can cause disease when introduced into the body or tissues of an organism.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,toxin metabolism,,,,,GO:0009404,,,,,,,,,,,,,,,,,,,,,,toxin metabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006735,NADH regeneration,NAD (reduced) regeneration|reduced NAD regeneration|reduced nicotinamide adenine dinucleotide regeneration,A metabolic process that generates a pool of NADH by the reduction of NAD+.,false,,,http://purl.obolibrary.org/obo/GO_0009058,,,,,,,,,,,,,,,,,,,,,,A metabolic process that generates a pool of NADH by the reduction of NAD+.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_16908,,http://purl.obolibrary.org/obo/CHEBI_15846,,,,,,,,,,,,NAD (reduced) regeneration|reduced NAD regeneration|reduced nicotinamide adenine dinucleotide regeneration,,,,,GO:0006735,,,,,,,,,,,,,,,,,,,,,,NADH regeneration,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000208,cytokeratin 6B,cytokeratin 6F,,false,,,http://purl.obolibrary.org/obo/IMR_0000469,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000302,cytokeratin 6F,,,,,IMR:0000208,,,,,,,,,,,,,,,,,,,,,,cytokeratin 6B,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0013686,anatomical conduit space,,"An anatomical space which is the lumen of some anatomical conduit and connects two or more spaces together [FMA,modified].",false,,,http://purl.obolibrary.org/obo/UBERON_0000464,,,,,,,,,,,,,,,,,,,,,,"An anatomical space which is the lumen of some anatomical conduit and connects two or more spaces together [FMA,modified].",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,UBERON:0013686,,,,,,,,,,,,,,,,,,,,,,anatomical conduit space,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_49603,lapatinib,N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine|N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE|GW 572016|Tykerb|N-[3-chloro-4-(3-fluorobenzyloxy)phenyl]-6-[5-({[2-(methanesulfonyl)ethyl]amino}methyl)furan-2-yl]quinazolin-4-amine,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:231277-92-2|Beilstein:10502247|LINCS:LSM-1051|Drug_Central:1548|DrugBank:DB01259,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35610|http://purl.obolibrary.org/obo/CHEBI_38637,,,,,N-[3-chloro-4-(3-fluorobenzyloxy)phenyl]-6-[5-({[2-(methanesulfonyl)ethyl]amino}methyl)furan-2-yl]quinazolin-4-amine,,N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine|N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE|GW 572016|Tykerb,,,,,,,,,,,,,,,,,,,,,CHEBI:49603,,,,lapatinib,,CHEBI:49603,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0046649,lymphocyte activation,,"A change in morphology and behavior of a lymphocyte resulting from exposure to a specific antigen, mitogen, cytokine, chemokine, cellular ligand, or soluble factor.",false,,,http://purl.obolibrary.org/obo/GO_0045321,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IEV_0003879,,"A change in morphology and behavior of a lymphocyte resulting from exposure to a specific antigen, mitogen, cytokine, chemokine, cellular ligand, or soluble factor.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0046649,,,,,,,,,,,,,,,,,,,,,,lymphocyte activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000488,accumulation of fluids,,"Accumulation of fluids is a subtype of accumulation of substances in a biological object: A process that keeps fluid in an organism, tissue, organelle, or cell.",false,,,http://purl.obolibrary.org/obo/TXPO_0000247,,,,,,,,,,,,,,,,,,,,,,"Accumulation of fluids is a subtype of accumulation of substances in a biological object: A process that keeps fluid in an organism, tissue, organelle, or cell.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000488,,,,,,,,,,,,,,,,,,,,,,accumulation of fluids,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000485,ATP depletion,,ATP depletion is a subtype of depleting: A process that lessens markedly in the amount of adenosine triphosphate (ATP) .,false,,,http://purl.obolibrary.org/obo/TXPO_0000602,,,,,,,,,,,,,,,,,,,,,,ATP depletion is a subtype of depleting: A process that lessens markedly in the amount of adenosine triphosphate (ATP) .,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000207|http://purl.obolibrary.org/obo/TXPO_0000167,,,,,,,,,,,TXPO:0000485,,,,,,,,,,,,,,,,,,,,,,ATP depletion,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000486,ATP depletion [Cell death],,"ATP depletion is a subtype of depleting: A process that lessens markedly in the amount of adenosine triphosphate (ATP) .
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0000485|http://purl.obolibrary.org/obo/TXPO_0001727,,,,,,,,,,,,,,,,,,,,,,"ATP depletion is a subtype of depleting: A process that lessens markedly in the amount of adenosine triphosphate (ATP) .
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000030|http://purl.obolibrary.org/obo/TXPO_0002387,,,,,,,,,,,TXPO:0000486,,,,,,,,,,,,,,,,,,,,,,ATP depletion [Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000487,autophagy inducer,,Autophagy inducer is a role played by any compound that promotes the process of autophagy (the self-digestion of one or more components of a cell through the action of enzymes originating within the same cell).,false,,,http://purl.obolibrary.org/obo/TXPO_0002629,,,,,,,,http://purl.obolibrary.org/obo/GO_0006914,,,,,,,,,,,,,,Autophagy inducer is a role played by any compound that promotes the process of autophagy (the self-digestion of one or more components of a cell through the action of enzymes originating within the same cell).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000487,,,,,,,,,,,,,,,,,,,,,,autophagy inducer,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000480,hyperfunction of lipid transport to mitochondria,,Hyperfunction of lipid transport to mitochondria is a subtype of hyperfunction of transport: A process that performs an excesssive lipid transport to mitochondria.,false,,,http://purl.obolibrary.org/obo/TXPO_0002351,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of lipid transport to mitochondria is a subtype of hyperfunction of transport: A process that performs an excesssive lipid transport to mitochondria.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000480,,,,,,,,,,,,,,,,,,,,,,hyperfunction of lipid transport to mitochondria,,,,,,http://purl.obolibrary.org/obo/TXPO_0000131,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000484,increasing autophagy,,Increasing autophagy is a subtype of increasing number of actions: A process that becomes larger in the number of autophagy.,false,,,http://purl.obolibrary.org/obo/TXPO_0000344,,,,,,,,,,,,,,,,,,,,,,Increasing autophagy is a subtype of increasing number of actions: A process that becomes larger in the number of autophagy.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000484,,,,,,,,,,,,,,,,,,,,,,increasing autophagy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000481,decreased membrane potential,,A mebrane potential which is relatively low.,false,,,http://purl.obolibrary.org/obo/PATO_0001462|http://purl.obolibrary.org/obo/TXPO_0002420,,,,,,,,,,,,,,,,,,,,,,A mebrane potential which is relatively low.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000481,,,,,,,,,,,,,,,,,,,,,,decreased membrane potential,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000482,insufficient functioning,,Insufficient functioning is a subtype of malfunctioning process: A process that lacks performing the function required.,false,,,http://purl.obolibrary.org/obo/TXPO_0000436,,,,,,,,,,,,,,,,,,,,,,Insufficient functioning is a subtype of malfunctioning process: A process that lacks performing the function required.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000482,,,,,,,,,,,,,,,,,,,,,,insufficient functioning,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000489,in vivo assay,,A laboratory test or analysis of the biological properties or activities of a substance performed by testing its effect on an organism.,false,,,http://purl.obolibrary.org/obo/OBI_0000070,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C18641,,A laboratory test or analysis of the biological properties or activities of a substance performed by testing its effect on an organism.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000489,,,,,,,,,,,,,,,,,,,,,,in vivo assay,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000483,glutathione depletion,,Glutathione depletion is a subtype of depleting: A process that lessens markedly in the amount of glutathione.,false,,,http://purl.obolibrary.org/obo/TXPO_0000602,,,,,,,,,,,,,,,,,,,,,,Glutathione depletion is a subtype of depleting: A process that lessens markedly in the amount of glutathione.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000483,,,,,,,,,,,,,,,,,,,,,,glutathione depletion,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000006400,SEL1L,,"Other designations: Suppressor of lin 12 (sel-1), C. elegans, homolog of|protein sel-1 homolog 1|sel-1 suppressor of lin-12-like 1|suppressor of lin-12-like protein 1",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,PRO1063|SEL1L1|SEL1-LIKE,,,,,,,,,,,,14,,,,,,Vega:OTTHUMG00000171419|HGNC:10717|HPRD:07532|MIM:602329|Ensembl:ENSG00000071537,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,sel-1 suppressor of lin-12-like (C. elegans),,,14q31,,,,,,,,,,,,,,,,"GO_0005515 (EC: IPI, PMID: 18264092); GO_0005789 (EC: IEA); GO_0007219 (EC: IEA); GO_0016021 (EC: IEA); GO_0034976 (EC: IEA)",,,,,,,,,PMID: 9417916; 9858735; 10051412; 10496078; 10746565; 11349831; 11544613; 11809711; 12030374; 12477932; 12553058; 12754519; 12975309; 14729273; 15307954; 15342556; 16186509; 16303743; 16331677; 16331889; 16344560; 16412574; 17822620; 17967421; 18264092; 18314878; 18502753; 18711132; 18811591; 19135427; 19204006; 19346256; 19524542; 19706418; 20416077; 21139048; 21359144; 21454652; 21632540; 21656579; 21857022; 21903092; 21903422; 21988832; 22119785; 22190034; 22268729; 22350780; 22905195; 22939629; 23097496; 23356641; 23363602; 23464991; 23867461; 23956138; 24043630,,,,,,,,,,,,,,,OGG:3000006400,,20140408,protein-coding,,,,sel-1 suppressor of lin-12-like (C. elegans),,,,,,,,,,,,,"Other designations: Suppressor of lin 12 (sel-1), C. elegans, homolog of|protein sel-1 homolog 1|sel-1 suppressor of lin-12-like 1|suppressor of lin-12-like protein 1",,SEL1L,,,,,,,,,,,,,,,,,,,,,,,6400,UNQ128/PRO1063,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,SEL1L,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/GO_1990922,hepatic stellate cell proliferation,Ito cell proliferation|perisinusoidal cell proliferation|hepatic perisinusoidal cell proliferation,"The multiplication or reproduction of hepatic stellate cells, resulting in the expansion of a hepatic stellate cell population. Hepatic stellate cells are found in the perisinusoidal space of the liver, and are capable of multiple roles including storage of retinol, presentation of antigen to T cells (including CD1d-restricted NKT cells), and upon activation, production of extracellular matrix components. This cell type comprises approximately 8-15% of total cells in the liver.",false,,,http://purl.obolibrary.org/obo/GO_0008283,,,,,,,,,,,,,,,,,,,,,,"The multiplication or reproduction of hepatic stellate cells, resulting in the expansion of a hepatic stellate cell population. Hepatic stellate cells are found in the perisinusoidal space of the liver, and are capable of multiple roles including storage of retinol, presentation of antigen to T cells (including CD1d-restricted NKT cells), and upon activation, production of extracellular matrix components. This cell type comprises approximately 8-15% of total cells in the liver.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000632,,,,,,,,,,,,,,,,,,Ito cell proliferation|perisinusoidal cell proliferation|hepatic perisinusoidal cell proliferation,,,,,GO:1990922,,,,,,,,,,,,,,,,,,,,,,hepatic stellate cell proliferation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001115,IQGAP2,,,false,,,http://purl.obolibrary.org/obo/IMR_0000443,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001115,,,,,,,,,,,,,,,,,,,,,,IQGAP2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001777,phospholipid metabolism imbalance [Phospholipidosis (mild)],,"Phospholipid metabolism imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance of phospholipid metabolism.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (mild).",false,,,http://purl.obolibrary.org/obo/TXPO_0002324,,,,,,,,,,,,,,,,,,,,,,"Phospholipid metabolism imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance of phospholipid metabolism.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (mild).",,,http://purl.obolibrary.org/obo/TXPO_0001435,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004155|http://purl.obolibrary.org/obo/TXPO_0001824,,http://purl.obolibrary.org/obo/TXPO_0000493,,,,,,,,,TXPO:0001777,,,,,,,,,,,,,,,,,,,,,,phospholipid metabolism imbalance [Phospholipidosis (mild)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001770,changing abnormal cellular structure,,Changing abnormal cellular structure is a subtype of changing structure: A process that changes the structure of the cell abnormally.,false,,,http://purl.obolibrary.org/obo/TXPO_0002566,,,,,,,,,,,,,,,,,,,,,,Changing abnormal cellular structure is a subtype of changing structure: A process that changes the structure of the cell abnormally.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001770,,,,,,,,,,,,,,,,,,,,,,changing abnormal cellular structure,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001774,ALAS1 (human)[lipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000034|http://purl.obolibrary.org/obo/TXPO_0001090,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:211|PMID:20018698|PMID:19710929,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000000211,,,,,,,,,,,,,TXPO:0001774,,,,,,,This gene encodes the mitochondrial enzyme which is catalyzes the rate-limiting step in heme (iron-protoporphyrin) biosynthesis.,,,,,,,,,,,,,,,ALAS1 (human)[lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001775,hypofunction of glutathione conjugation,,Hypofunction of glutathione conjugation is a subtype of hypofunction of drug metabolism: A process that performs a decreased or insufficient glutathione conjugation.,false,,,http://purl.obolibrary.org/obo/TXPO_0002190,,,,,,,,,,,,,,,,,,,,,,Hypofunction of glutathione conjugation is a subtype of hypofunction of drug metabolism: A process that performs a decreased or insufficient glutathione conjugation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001775,,,,,,,,,,,,,,,,,,,,,,hypofunction of glutathione conjugation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001778,phospholipid metabolism imbalance  [Phospholipidosis (severe) ],,"Phospholipid metabolism imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance of phospholipid metabolism. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",false,,,http://purl.obolibrary.org/obo/TXPO_0002324,,,,,,,,,,,,,,,,,,,,,,"Phospholipid metabolism imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance of phospholipid metabolism. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",,,http://purl.obolibrary.org/obo/TXPO_0001435,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000920|http://purl.obolibrary.org/obo/TXPO_0003435,,,,,,,,,,,TXPO:0001778,,,,,,,,,,,,,,,,,,,,,,phospholipid metabolism imbalance  [Phospholipidosis (severe) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001773,glutathione deficiency,,Glutathione deficiency is a subtype of malfunctioning process: A process that lacks performing the glutathione function required.,false,,,http://purl.obolibrary.org/obo/TXPO_0000482,,,,,,,,,,,,,,,,,,,,,,Glutathione deficiency is a subtype of malfunctioning process: A process that lacks performing the glutathione function required.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001773,,,,,,,,,,,,,,,,,,,,,,glutathione deficiency,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001779,toxicological imbalance VH (toxic action),,"In the imbalance model, the basic units are as follows:
1) a functioning process (supply) for biological defense and maintaining homeostasis;
2) a functional demand process (demand) as toxic activity;
3) balance/imbalance between toxic activity and defense processes; and
4) outcome from organelles, cells, or tissues to the organ exhibiting toxicity manifestations.

This entity is a compound state that includes step 1 to 4, and the toxic activity level is higher (Very High, VH) than usual to imbalance and toxicity manifestations.",false,,,http://purl.obolibrary.org/obo/TXPO_0003992,,,,,,,,,,,,,,,,,,,,,,"In the imbalance model, the basic units are as follows:
1) a functioning process (supply) for biological defense and maintaining homeostasis;
2) a functional demand process (demand) as toxic activity;
3) balance/imbalance between toxic activity and defense processes; and
4) outcome from organelles, cells, or tissues to the organ exhibiting toxicity manifestations.

This entity is a compound state that includes step 1 to 4, and the toxic activity level is higher (Very High, VH) than usual to imbalance and toxicity manifestations.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001735,,,,,,,,,,,,,,,,,,TXPO:0001779,,,,,,,,,,,,,,,,,,,,,,toxicological imbalance VH (toxic action),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001776,phospholipid metabolism imbalance [Phospholipidosis - genetic],,"Phospholipid metabolism imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance of phospholipid metabolism.
This process is dependent on the  genetic and can constitute the course of Phospholipidosis (genetic).",false,,,http://purl.obolibrary.org/obo/TXPO_0002324,,,,,,,,,,,,,,,,,,,,,,"Phospholipid metabolism imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance of phospholipid metabolism.
This process is dependent on the  genetic and can constitute the course of Phospholipidosis (genetic).",,,http://purl.obolibrary.org/obo/TXPO_0001435,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002070,,,,,,,,,,,TXPO:0001776,,,,,,,,,,,,,,,,,,,,,,phospholipid metabolism imbalance [Phospholipidosis - genetic],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001771,negative regulation of oxidative phosphorylation,,"Negative regulation of oxidative phosphorylation is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of oxodative phosphorylation.",false,,,http://purl.obolibrary.org/obo/TXPO_0000369,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of oxidative phosphorylation is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of oxodative phosphorylation.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001771,,,,,,,,,,,,,,,,,,,,,,negative regulation of oxidative phosphorylation,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006119,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001772,keeping amount of phospholipid in lysosome  (normal condition) [Phospholipidosis],,"Keeping amount of phospholipid in lysosome is a subtype of keeping amount: A process that maintaining the amount of lysosomal phospholipid.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (normal).",false,,,http://purl.obolibrary.org/obo/TXPO_0003358|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Keeping amount of phospholipid in lysosome is a subtype of keeping amount: A process that maintaining the amount of lysosomal phospholipid.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (normal).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003386|http://purl.obolibrary.org/obo/TXPO_0002085,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001683,,,,,,,,,,,TXPO:0001772,,,,,,,,,,,,,,,,,,,,,,keeping amount of phospholipid in lysosome  (normal condition) [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000055289,ACOXL,,Other designations: acyl-CoA oxidase-like protein|acyl-coenzyme A oxidase-like protein,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,2,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,acyl-CoA oxidase-like,,,2q13,,,,,,,,,,,,,,,,GO_0003674 (EC: ND); GO_0003995 (EC: IEA); GO_0003997 (EC: IEA); GO_0005575 (EC: ND); GO_0005777 (EC: IEA); GO_0006635 (EC: IEA); GO_0008150 (EC: ND),,,,,,,,,PMID:12477932; 14702039; 15146197; 18758461; 19773279; 20332261; 20731705; 21145461; 21738478; 22197929; 22219177; 22566634; 22700719; 23222517; 23770605,,,,,,,,,,,,,,,OGG:3000055289,,,,,,,acyl-CoA oxidase-like,,,,,,,,,,,,,Other designations: acyl-CoA oxidase-like protein|acyl-coenzyme A oxidase-like protein,,ACOXL,,,,,,,,,,,,,,,,,,,,,,,55289,,,,,,,,9606,,,,,,,,,,,,,,,,,,,ACOXL,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000547,elastin,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003695,,,,,,,,,,IMR:0000547,,,,,,,,,,,,,,,,,,,,,,elastin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002955,BIM (canonical)[ER stress],,,false,,,http://purl.obolibrary.org/obo/IMR_0100291|http://purl.obolibrary.org/obo/TXPO_0000871,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:10018|NCBI-Mouse-GeneID:12125|NCBI-Rat-GeneID:64547,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0100709,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000327,,,,,,,,,,TXPO:0002955,,,,,,,,,,,,,,,,,,,,,,BIM (canonical)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002957,receiving abnormal protein signal by IRE1 [ER stress - refolding],,"Receiving abnormal protein signal by IRE1 is a subtype of receiving signal: A process that recognizes another object and changes into an abnormal protein (e.g., misfolded protein, etc.) signal by IRE1.
This entity is a specific course-dependent process. This process can constitute the course of ER stress via protein refolding.",false,,,http://purl.obolibrary.org/obo/TXPO_0002604|http://purl.obolibrary.org/obo/TXPO_0003736,,,,,,,,,,,,,,,,,,,,,,"Receiving abnormal protein signal by IRE1 is a subtype of receiving signal: A process that recognizes another object and changes into an abnormal protein (e.g., misfolded protein, etc.) signal by IRE1.
This entity is a specific course-dependent process. This process can constitute the course of ER stress via protein refolding.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000824,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000463,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002761,,,,,,,,,,,TXPO:0002957,,,,,,,,,,,,,,,,,,,,,,receiving abnormal protein signal by IRE1 [ER stress - refolding],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002950,Bcl2 phosphorylation by JNK [ER stress - apoptosis],,"Bcl2 phosphorylation by JNK is a subtype of Bcl2 phosphorylation: A process that The process of introducing a phosphate group into Bcl2 by JNK.
This process is dependent on the apoptosis and can constitute the course of ER stress.|The C-terminal domain of PERK (EIF2AK3) has kinase activity when PERK homodimerizes. PERK kinase specifically phosphorylates Ser52 of eIF2-alpha, causing an arrest in translation. The result is that translation of ER-targeted proteins is halted on ribosomes in the vicinity of activated PERK. The general arrest of translation results in the loss of short-lived proteins such as Cyclin D1, causing an arrest of the cell cycle in G1.",false,,,http://purl.obolibrary.org/obo/TXPO_0002951,,,,,,,,,,,,,,,,,,,,Reactome:R-HSA-381111|PMID:9930704|PMID:23334697,,"Bcl2 phosphorylation by JNK is a subtype of Bcl2 phosphorylation: A process that The process of introducing a phosphate group into Bcl2 by JNK.
This process is dependent on the apoptosis and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002950,,,,,,,,,,,,,,,,,,,,"The C-terminal domain of PERK (EIF2AK3) has kinase activity when PERK homodimerizes. PERK kinase specifically phosphorylates Ser52 of eIF2-alpha, causing an arrest in translation. The result is that translation of ER-targeted proteins is halted on ribosomes in the vicinity of activated PERK. The general arrest of translation results in the loss of short-lived proteins such as Cyclin D1, causing an arrest of the cell cycle in G1.",,Bcl2 phosphorylation by JNK [ER stress - apoptosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002951,Bcl2 phosphorylation by JNK [ER stress],,"Bcl2 phosphorylation by JNK is a subtype of Bcl2 phosphorylation: A process that The process of introducing a phosphate group into Bcl2 by JNK.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002952|http://purl.obolibrary.org/obo/TXPO_0003736,,,,,,,,,,,,,,,,,,,,Reactome:R-HSA-381111|PMID:23334697,,"Bcl2 phosphorylation by JNK is a subtype of Bcl2 phosphorylation: A process that The process of introducing a phosphate group into Bcl2 by JNK.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002951,,,,,,,,,,,,,,,,,,,,,,Bcl2 phosphorylation by JNK [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002959,XBP1s gene regulation pathway [ER stress - refolding],,"XBP1s gene regulation pathway is a subtype of gene regulation pathway: A series of process in which XBP1s regulates the gene expression.
This process is dependent on the protein refolding and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002486,,,,,,,,,,,,,,,,,,,,,,"XBP1s gene regulation pathway is a subtype of gene regulation pathway: A series of process in which XBP1s regulates the gene expression.
This process is dependent on the protein refolding and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002919,,,,,,,,,,,,,,,,,,TXPO:0002959,,,,,,,,,,,,,,,,,,,,,,XBP1s gene regulation pathway [ER stress - refolding],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002953,IRE1 signaling (primitive) [ER stress - apoptosis],,"IRE1 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the IRE1 (Inositol-requiring transmembrane kinase/endonuclease). IRE1 generally plays a endoplasmic reticulum membrane stress sensor role.
This process is dependent on the apoptosis and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0003736|http://purl.obolibrary.org/obo/TXPO_0002571,,,,,,,,,,,,,,,,,,,,,,"IRE1 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the IRE1 (Inositol-requiring transmembrane kinase/endonuclease). IRE1 generally plays a endoplasmic reticulum membrane stress sensor role.
This process is dependent on the apoptosis and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002687,,,,,,,,,,,,,,,,,,TXPO:0002953,,,,,,,,,,,,,,,,,,,,,,IRE1 signaling (primitive) [ER stress - apoptosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002952,Bcl2 phosphorylation by JNK,,Bcl2 phosphorylation by JNK is a subtype of Bcl2 phosphorylation: A process that The process of introducing a phosphate group into Bcl2 by JNK.,false,,,http://purl.obolibrary.org/obo/TXPO_0001392,,,,,,,,,,,,,,,,,,,,,,Bcl2 phosphorylation by JNK is a subtype of Bcl2 phosphorylation: A process that The process of introducing a phosphate group into Bcl2 by JNK.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002952,,,,,,,,,,,,,,,,,,,,,,Bcl2 phosphorylation by JNK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002956,IRE1 pathway [ER stress - refolding],,"A series of molecular signals mediated by the endoplasmic reticulum stress sensor IRE1 (Inositol-requiring transmembrane kinase/endonuclease).
This process is dependent on the protein refolding that can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002487,,,,,,,,,,,,,,,,,,,,,,"A series of molecular signals mediated by the endoplasmic reticulum stress sensor IRE1 (Inositol-requiring transmembrane kinase/endonuclease).
This process is dependent on the protein refolding that can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002957|http://purl.obolibrary.org/obo/TXPO_0002761,,http://purl.obolibrary.org/obo/TXPO_0002155,,,,,,,,,,,,,,,,TXPO:0002956,,,,,,,,,,,,,,,,,,,,,,IRE1 pathway [ER stress - refolding],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002954,BIM (canonical)[ER stress - apotosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002955,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0100709,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000327,,,,,,,,,,TXPO:0002954,,,,,,,,,,,,,,,,,,,,,,BIM (canonical)[ER stress - apotosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002958,ATF6 - signaling factor (canonical)[ER stress -ERAD],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000044,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001898,,,,,,,,,,TXPO:0002958,,,,,,,,,,,,,,,,,,,,,,ATF6 - signaling factor (canonical)[ER stress -ERAD],,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005794,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002918,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001274,ethanolamine kinase,,Catalysis role of the reaction: ATP + ethanolamine = ADP + 2 H(+) + phosphoethanolamine.|related molecular function GO:0004305 ethanolamine kinase activity,false,,,http://purl.obolibrary.org/obo/TXPO_0001515,,,,,,,,,,,,,,,,,,,,EC:2.7.1.82,,Catalysis role of the reaction: ATP + ethanolamine = ADP + 2 H(+) + phosphoethanolamine.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001274,,,,,,,,,,,,,,,,,,,,related molecular function GO:0004305 ethanolamine kinase activity,,ethanolamine kinase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001277,cholestasis [toxic course],,"The totality of all processes through which cholestasis is realized.|This entity is under construction.

Drug induced liver injury (DILI) is categorized as drug induced cholestasis (DIC), drug-induced hepatitis, and is mixed liver injury.
Impairment of bile flow due to obstruction in small bile ducts (INTRAHEPATIC CHOLESTASIS) or obstruction in large bile ducts (EXTRAHEPATIC CHOLESTASIS).
phallodin, microsystin, amantin is facilitated by the uptake thpugh OATPs.
rifampicin, bosentan, troglitazone directly inhibit BSEP.",false,,,http://purl.obolibrary.org/obo/TXPO_0000009,,,,,,,,,,,,,,,,,,,,http://purl.bioontology.org/ontology/MESH/D002779|http://purl.obolibrary.org/obo/OAE_0000811|http://purl.bioontology.org/ontology/MEDDRA/10008635|,,The totality of all processes through which cholestasis is realized.,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000350,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000350,,,,,,,,,,,,,,,,,,TXPO:0001277,,,,,,,"BSEP inhibition : bosentan, cyclosporin, glibenclamide, rifampicin, rifamycin",,,,,,,,,,,,,"This entity is under construction.

Drug induced liver injury (DILI) is categorized as drug induced cholestasis (DIC), drug-induced hepatitis, and is mixed liver injury.
Impairment of bile flow due to obstruction in small bile ducts (INTRAHEPATIC CHOLESTASIS) or obstruction in large bile ducts (EXTRAHEPATIC CHOLESTASIS).
phallodin, microsystin, amantin is facilitated by the uptake thpugh OATPs.
rifampicin, bosentan, troglitazone directly inhibit BSEP.",,cholestasis [toxic course],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001275,EIF2A (canonical)[ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000871|http://purl.obolibrary.org/obo/TXPO_1000421,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:502531|NCBI-Mouse-GeneID:229317|NCBI-Human-GeneID:83939|http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene&cmd=Retrieve&dopt=full_report&list_uids=83939,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001275,,,,,,,,,,,,,,,,,,,,,,EIF2A (canonical)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001276,lipid storage in liver,,Lipid storage in liver is a subtype of lipid storage: The accumulation and maintenance in cells or tissues of lipids in the liver.,false,,,http://purl.obolibrary.org/obo/GO_0019915,,,,,,,,,,,,,,,,,,,,,,Lipid storage in liver is a subtype of lipid storage: The accumulation and maintenance in cells or tissues of lipids in the liver.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_18059,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001276,,,,,,,,,,,,,,,,,,,,,,lipid storage in liver,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001273,increaseing production quantity of catecholamine [lipidosis],,"Increaseing production quantity of catecholamine is a subtype of increasing quantity: A process that changes the production amount of catecholamine to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0001421,,,,,,,,,,,,,,,,,,,,,,"Increaseing production quantity of catecholamine is a subtype of increasing quantity: A process that changes the production amount of catecholamine to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000892,,,,,,,,,,,TXPO:0001273,,,,,,,,,,,,,,,,,,,,,,increaseing production quantity of catecholamine [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001270,moving lipid to the hepatocye,,Moving lipid to the hepatocye is a subtype of moving A to the inside of B: A process of the movement of lipid into a hepatocyte.,false,,,http://purl.obolibrary.org/obo/TXPO_0002587,,,,,,,,,,,,,,,,,,,,,,Moving lipid to the hepatocye is a subtype of moving A to the inside of B: A process of the movement of lipid into a hepatocyte.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_18059,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001270,,,,,,,,,,,,,,,,,,,,,,moving lipid to the hepatocye,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000182,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001279,intrahepatic billiary stasis,,Impairment of bile flow due to injury to the the intrahepatic bile ducts.|under construction,false,,,http://purl.obolibrary.org/obo/TXPO_0002650,,,,,,,,,,,,,,,,,,,,,,Impairment of bile flow due to injury to the the intrahepatic bile ducts.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001279,,,,,,,,,,,,,,,,,,,,under construction,,intrahepatic billiary stasis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001272,hyperfunction of alcohol metabolism,,Hyperfunction of alcohol metabolism is a subtype of hyperfunctioning: A process that performs an excessive alcohol metabolism.,false,,,http://purl.obolibrary.org/obo/TXPO_0000435,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of alcohol metabolism is a subtype of hyperfunctioning: A process that performs an excessive alcohol metabolism.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001272,,,,,,,,,,,,,,,,,,,,,,hyperfunction of alcohol metabolism,,,,,,http://purl.obolibrary.org/obo/GO_0006066,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001271,lipid efflux from hepatocyte,,"The directed movement of lipid, out of a hepatocyte.",false,,,http://purl.obolibrary.org/obo/TXPO_0002588,,,,,,,,,,,,,,,,,,,,,,"The directed movement of lipid, out of a hepatocyte.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_18059,,,,,,,,,,,,,,,,,,,TXPO:0001271,,,,,,,,,,,,,,,,,,,,,,lipid efflux from hepatocyte,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001278,canalicular cholestasis,,Impairment of bile flow due to injury to the the canalicular bile ducts.|under construction,false,,,http://purl.obolibrary.org/obo/TXPO_0002650,,,,,,,,,,,,,,,,,,,,http://purl.bioontology.org/ontology/OMIM/MTHU028080,,Impairment of bile flow due to injury to the the canalicular bile ducts.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001278,,,,,,,,,,,,,,,,,,,,under construction,,canalicular cholestasis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100669,Clb6,S-phase entry cyclin 6,,false,,,http://purl.obolibrary.org/obo/IMR_0100672,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,S-phase entry cyclin 6,,,,,IMR:0100669,,,,,,,,,,,,,,,,,,,,,,Clb6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000246,nPKC,novel protein kinase C,"novel PKC isoforms (delta, epsilon, eta and theta) are regulated by DAG and phospholipids.",false,,,http://purl.obolibrary.org/obo/IMR_0000245,,,,,,,,,,,,,,,,,,,,,,"novel PKC isoforms (delta, epsilon, eta and theta) are regulated by DAG and phospholipids.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,novel protein kinase C,,,,,IMR:0000246,,,,,,,,,,,,,,,,,,,,,,nPKC,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100620,cyclin E2,CGE2|G1/S-Specific cyclin E2,,false,,,http://purl.obolibrary.org/obo/IMR_0100618,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0011595|IMR:0010672,CGE2|G1/S-Specific cyclin E2,,,,,IMR:0100620,,,,,,,,,,,,,,,,,,,,,,cyclin E2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000861,14-3-3 epsilon,,,false,,,http://purl.obolibrary.org/obo/IMR_0000456,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000861,,,,,,,,,,,,,,,,,,,,,,14-3-3 epsilon,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000000317,APAF1,,Other designations: apoptotic protease-activating factor 1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CED4|APAF-1,,,,,,,,,,,,12,,,,,,Vega:OTTHUMG00000170214|MIM:602233|Ensembl:ENSG00000120868|HGNC:576|HPRD:03755,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,apoptotic peptidase activating factor 1,,,12q23,,,,,,,,,,,,,,,,"GO_0000166 (EC: TAS, PMID: 10383829); GO_0001843 (EC: IEA); GO_0005515 (EC: IPI, PMID: 10206961); GO_0005524 (EC: IEA); GO_0005634 (EC: IEA); GO_0005829 (EC: TAS); GO_0006309 (EC: IEA); GO_0006915 (EC: TAS); GO_0006919 (EC: IDA); GO_0006952 (EC: IEA); GO_0007399 (EC: TAS, PMID: 9753320); GO_0008635 (EC: IDA, PMID: 9267021); GO_0008635 (EC: TAS); GO_0008656 (EC: NAS, PMID: 15009102); GO_0030900 (EC: IEA); GO_0042802 (EC: IEA); GO_0042981 (EC: TAS, PMID: 10441496); GO_0043065 (EC: TAS, PMID: 18309324); GO_0043293 (EC: IDA); GO_0043293 (EC: TAS, PMID: 18309324); GO_0043531 (EC: IEA); GO_0051402 (EC: IEA); GO_0070062 (EC: IDA, PMID: 19056867); GO_0072432 (EC: TAS, PMID: 18309324); GO_0097193 (EC: TAS, PMID: 18309324); GO_2001235 (EC: IEA)",,,,,,,,,PMID: 9267021; 9390557; 9455477; 9488720; 9539746; 9651578; 9753320; 9829980; 9837928; 9878060; 9922454; 10206961; 10322433; 10364241; 10376594; 10383829; 10393175; 10441496; 10486928; 10543941; 10578182; 10702682; 10722681; 10764728; 10934467; 10949025; 11113115; 11230124; 11242052; 11389439; 11457460; 11550094; 11864614; 12021264; 12147322; 12149244; 12168954; 12477932; 12549820; 12615903; 12637514; 12804598; 12963020; 14566819; 14747474; 14993223; 15001356; 15009102; 15026369; 15033720; 15103018; 15262985; 15305193; 15378005; 15590702; 15649154; 15692060; 15703181; 15735003; 15829969; 15832174; 15832175; 15863166; 15972851; 16046141; 16098052; 16231040; 16232302; 16331630; 16420245; 16595687; 16951219; 16979168; 17081983; 17133271; 17274640; 17348858; 17361096; 17418785; 17534194; 17541304; 17603079; 17876870; 17882496; 17885667; 18029348; 18042457; 18093951; 18309324; 18373966; 18439902; 18587251; 18676680; 18719738; 18834886; 19056867; 19058789; 19074885; 19141860; 19170196; 19238172; 19322201; 19455599; 19603830; 19625176; 19662370; 19675677; 19692168; 19698783; 19801675; 19809088; 19913121; 20345447; 20379614; 20453000; 20628086; 20959405; 20977544; 21104989; 21139048; 21297999; 21528061; 21659556; 21890473; 21906983; 21922274; 22101335; 22143029; 22246185; 22335196; 22632162; 22996741; 23085065; 23207240; 23326121; 23521171; 23822711,,,,,,,,,,,,,,,OGG:3000000317,,,,,,,apoptotic peptidase activating factor 1,,,,,,,,,,,,,Other designations: apoptotic protease-activating factor 1,,APAF1,,,,,,,,,,,,,,,,,,,,,,,317,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,APAF1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0001419,increaseing production quantity of catecholamine [Fibrosis],,"Increaseing production quantity of catecholamine is a subtype of increasing quantity: A process that changes the production amount of catecholamine to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003742|http://purl.obolibrary.org/obo/TXPO_0001421,,,,,,,,,,,,,,,,,,,,,,"Increaseing production quantity of catecholamine is a subtype of increasing quantity: A process that changes the production amount of catecholamine to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001467,,,,,,,,,,,TXPO:0001419,,,,,,,,,,,,,,,,,,,,,,increaseing production quantity of catecholamine [Fibrosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001411,hyperfunction of glycerophospholipid biosynthesis,,Hyperfunction of glycerophospholipid biosynthesis is a subtype of hyperfunction of phospholipid biosynthesis: A process that performs an excessive glycerophospholipid biosynthesis.,false,,,http://purl.obolibrary.org/obo/TXPO_0001410,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of glycerophospholipid biosynthesis is a subtype of hyperfunction of phospholipid biosynthesis: A process that performs an excessive glycerophospholipid biosynthesis.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001411,,,,,,,,,,,,,,,,,,,,,,hyperfunction of glycerophospholipid biosynthesis,,,,,,http://purl.obolibrary.org/obo/GO_0046474,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001414,eIF2a translation regulation system,,"eIF2a translation regulation system is a subtype of pathway system.
This entity has sub-parts and has a goal of regulating translation by eIF2a as a systemic context.",false,,,http://purl.obolibrary.org/obo/TXPO_0000887,,,,,,,,,,,,,,,,,,,,,,"eIF2a translation regulation system is a subtype of pathway system.
This entity has sub-parts and has a goal of regulating translation by eIF2a as a systemic context.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001414,,,,,,,,,,,,,,,,,,,,,,eIF2a translation regulation system,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001416,hyperfunction of choline transport [Phospholipidosis - phosphatidylcholine disorder (severe) ],,"Hyperfunction of choline transport is a subtype of hyperfunction of choline transport: A process that performs an excesssive choline transport. And the degree is severe.
This process is dependent on the phosphatidylcholine disorder (severe) and can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001415|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of choline transport is a subtype of hyperfunction of choline transport: A process that performs an excesssive choline transport. And the degree is severe.
This process is dependent on the phosphatidylcholine disorder (severe) and can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001136,,,,,,,,,,,,,,,,,TXPO:0001416,,,,,,,,,,,,,,,,,,,,,,hyperfunction of choline transport [Phospholipidosis - phosphatidylcholine disorder (severe) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001417,DGAT(mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000084649,,,,,,,,,,,,,TXPO:0001417,,,,,,,,,,,,,,,,,,,,,,DGAT(mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001410,hyperfunction of phospholipid biosynthesis,,Hyperfunction of phospholipid biosynthesis is a subtype of hyperfunction of biosynthesis: A process that performs an excessive phospholipid biosynthesis.,false,,,http://purl.obolibrary.org/obo/TXPO_0002346,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of phospholipid biosynthesis is a subtype of hyperfunction of biosynthesis: A process that performs an excessive phospholipid biosynthesis.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001410,,,,,,,,,,,,,,,,,,,,,,hyperfunction of phospholipid biosynthesis,,,,,,http://purl.obolibrary.org/obo/GO_0008654,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001415,hyperfunction of choline transport,,Hyperfunction of choline transport is a subtype of hyperfunction of transport: A process that performs an excesssive choline transport.,false,,,http://purl.obolibrary.org/obo/TXPO_0002351,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of choline transport is a subtype of hyperfunction of transport: A process that performs an excesssive choline transport.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001415,,,,,,,,,,,,,,,,,,,,,,hyperfunction of choline transport,,,,,,http://purl.obolibrary.org/obo/GO_0015871,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001412,increasing number of macrophage derived foam cell,,"Increasing number of macrophage derived foam cell is a subtype of increasing number of objects: A process that becomes larger in the number of foam cell, a type of macrophage containing lipids in small vacuoles, in the liver.",false,,,http://purl.obolibrary.org/obo/TXPO_0000093,,,,,,,,,,,,,,,,,,,,,,"Increasing number of macrophage derived foam cell is a subtype of increasing number of objects: A process that becomes larger in the number of foam cell, a type of macrophage containing lipids in small vacuoles, in the liver.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001412,,,,,,,,,,,,,,,,,,,,,,increasing number of macrophage derived foam cell,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001418,hypofunction of glycerophospholipid degradation,,Hypofunction of glycerophospholipid degradation is a subtype of hypofunction of phospholipid degradation: A process that performs a decreased or insufficient glycerophospholipid degradation.,false,,,http://purl.obolibrary.org/obo/TXPO_0001253,,,,,,,,,,,,,,,,,,,,,,Hypofunction of glycerophospholipid degradation is a subtype of hypofunction of phospholipid degradation: A process that performs a decreased or insufficient glycerophospholipid degradation.,,,http://purl.obolibrary.org/obo/GO_0046475,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_37739,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001418,,,,,,,,,,,,,,,,,,,,,,hypofunction of glycerophospholipid degradation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001413,hypofunction of ceramide biosynthesis,,Hypofunction of ceramide synthesis is a subtype of hypofunction of lipid biosynthesis: A process that performs a decreased or insufficient ceramide biosynthesis.,false,,,http://purl.obolibrary.org/obo/TXPO_0002195,,,,,,,,,,,,,,,,,,,,,,Hypofunction of ceramide synthesis is a subtype of hypofunction of lipid biosynthesis: A process that performs a decreased or insufficient ceramide biosynthesis.,,,http://purl.obolibrary.org/obo/GO_0046513,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001330,,,,,,,,,,,TXPO:0001413,,,,,,,,,,,,,,,,,,,,,,hypofunction of ceramide biosynthesis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001451,TLR5,Toll-like receptor 5,,false,,,http://purl.obolibrary.org/obo/IMR_0000124,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Toll-like receptor 5,,,,,IMR:0001451,,,,,,,,,,,,,,,,,,,,,,TLR5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000293,Ral,Ras-like,,false,,,http://purl.obolibrary.org/obo/IMR_0000289,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ras-like,,,,,IMR:0000293,,,,,,,,,,,,,,,,,,,,,,Ral,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000620,ICAM-3,intercellular adhesion molecule 3,,false,,,http://purl.obolibrary.org/obo/IMR_0000178,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,intercellular adhesion molecule 3,,,,,IMR:0000620,,,,,,,,,,,,,,,,,,,,,,ICAM-3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_1901567,fatty acid derivative binding,,Interacting selectively and non-covalently with fatty acid derivative.,false,,,http://purl.obolibrary.org/obo/GO_0005488,,,,,,,,,,,,,,,,,,,,,,Interacting selectively and non-covalently with fatty acid derivative.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_61697,,,,,,,,,,,,,,,,,,,,,,,GO:1901567,,,,,,,,,,,,,,,,,,,,,,fatty acid derivative binding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_68508,diethyl malate,diethyl (2Z)-but-2-enedioate,"A maleate ester resulting from the formal condensation of both carboxy groups of maleic acid with ethanol. A colourless liquid at room temperature (m.p. -10degreeC) with boiling point 220degreeC at 1 atm., it is commonly used as a dienophile for Diels-Alder-type cycloaddition reactions in organic synthesis.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:3341033|PMID:1609410|CAS:141-05-9|PMID:1471155,,"A maleate ester resulting from the formal condensation of both carboxy groups of maleic acid with ethanol. A colourless liquid at room temperature (m.p. -10degreeC) with boiling point 220degreeC at 1 atm., it is commonly used as a dienophile for Diels-Alder-type cycloaddition reactions in organic synthesis.",,,,,,,,,,,,C8H12O4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,diethyl (2Z)-but-2-enedioate,,,,,CHEBI:68508,,,,,,,,,,,,,,,,,,,,,,diethyl malate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CCOC(=O)C=C/C(=O)OCC,,,,,
http://purl.obolibrary.org/obo/IMR_0010542,40S ribosomal protein S17,40S small ribosomal protein 17,,false,,,http://purl.obolibrary.org/obo/IMR_0000896,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,40S small ribosomal protein 17,,,,,IMR:0010542,,,,,,,,,,,,,,,,,,,,,,40S ribosomal protein S17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003064,IRE1 autophosphorylation [ER stress - RIDD],,"IRE1 autophosphorylation is a subtype of protein autophosphorylation: The phosphorylation by IRE1 of one or more of its own amino acid residues (cis-autophosphorylation), or residues on IRE1 (trans-autophosphorylation).
This entity is a specific course-dependent process. This process is dependent on RODD and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0003736|http://purl.obolibrary.org/obo/TXPO_0002598,,,,,,,,,,,,,,,,,,,,,,"IRE1 autophosphorylation is a subtype of protein autophosphorylation: The phosphorylation by IRE1 of one or more of its own amino acid residues (cis-autophosphorylation), or residues on IRE1 (trans-autophosphorylation).
This entity is a specific course-dependent process. This process is dependent on RODD and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002979,,,,,,,,,,,,,,,,,TXPO:0003064,,,,,,,,,,,,,,,,,,,,,,IRE1 autophosphorylation [ER stress - RIDD],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003060,peroxisome fatty acid beta oxidation gene expression(sustained) [Eosinophilic granular degeneration],,"Peroxisome fatty acid beta oxidation gene expression is a subtype of gene expression: A process that The process in which a gene sequence is converted into a mature peroxisome fatty acid beta oxidation gene product or products (proteins or RNA) persistently.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/TXPO_0000174|http://purl.obolibrary.org/obo/TXPO_0000175,,,,,,,,,,,,,,,,,,,,,,"Peroxisome fatty acid beta oxidation gene expression is a subtype of gene expression: A process that The process in which a gene sequence is converted into a mature peroxisome fatty acid beta oxidation gene product or products (proteins or RNA) persistently.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000110,http://purl.obolibrary.org/obo/TXPO_0001046|http://purl.obolibrary.org/obo/TXPO_0001057|http://purl.obolibrary.org/obo/TXPO_0001069|http://purl.obolibrary.org/obo/TXPO_0000846,,,,,,http://purl.obolibrary.org/obo/TXPO_0002451,,,,,,,,,,,TXPO:0003060,,,,,,,,,,,,,,,,,,,,,,peroxisome fatty acid beta oxidation gene expression(sustained) [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003062,TIMP1 (canonical)[Fibrosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000373|http://purl.obolibrary.org/obo/TXPO_0003750,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:116510|NCBI-Human-GeneID:7076|NCBI-Mouse-GeneID:21857,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003062,,,,,,,,,,,,,,,,,,,,,,TIMP1 (canonical)[Fibrosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003066,XBP1 - transcriptional regulator (canonical)[ER stress - inflammation],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001968,http://purl.obolibrary.org/obo/TXPO_0003065,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003066,,,,,,,,,,,,,,,,,,,,,,XBP1 - transcriptional regulator (canonical)[ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003067,IL-6 - inflammatory cytokine (canonical)[ER stress - inflammation -XBP1 pathway],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003037,,,,,,,,,,,,,,,,,,,,PMID:23990363,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003041,,,,,,,,,,TXPO:0003067,,,,,,,,,,,,,,,,,,,,,,IL-6 - inflammatory cytokine (canonical)[ER stress - inflammation -XBP1 pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003069,CRP (canonical)[ER stress],PTX1 [ER stress]|C-reactive protein [ER stress],,false,,,http://purl.obolibrary.org/obo/TXPO_0000871|http://purl.obolibrary.org/obo/TXPO_1000076,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:12944|NCBI-Rat-GeneID:25419|NCBI-Human-GeneID:1401|https://www.ncbi.nlm.nih.gov/gene/1401|https://omim.org/entry/123260,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PTX1 [ER stress]|C-reactive protein [ER stress],,,,,TXPO:0003069,,,,,,,,,,,,,,,,,,,,,,CRP (canonical)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003065,inflammatory gene expression by XBP1 [ER stress - inflammation],,"Inflammatory gene expression by XBP1 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) related to the inflammation by XBP1.
This process is dependent on the inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002607,,,,,,,,,,,,,,,,,,,,PMID:27346803,,"Inflammatory gene expression by XBP1 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) related to the inflammation by XBP1.
This process is dependent on the inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002923,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003067,,,,,,,,,,,,,,,,,TXPO:0003065,,,,,,,,,,,,,,,,,,,,,,inflammatory gene expression by XBP1 [ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003061,extrinsic apoptotic signaling pathway via death domain receptors [cell death],,"A series of molecular signals in which a signal is conveyed from the cell surface to trigger the apoptotic death of a cell. The pathway starts with a ligand binding to a death domain receptor on the cell surface, and ends when the execution phase of apoptosis is triggered.
This pathway is a specific course-dependent and can constitute the course of cell death.",false,,,http://purl.obolibrary.org/obo/GO_0008625,,,,,,,,,,,,,,,,,,,,PMID:21525013,,"A series of molecular signals in which a signal is conveyed from the cell surface to trigger the apoptotic death of a cell. The pathway starts with a ligand binding to a death domain receptor on the cell surface, and ends when the execution phase of apoptosis is triggered.
This pathway is a specific course-dependent and can constitute the course of cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003061,,,,,,,,,,,,,,,,,,,,,,extrinsic apoptotic signaling pathway via death domain receptors [cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003063,ATF6 processing,,ATF6 processing is a subtype of protein processing: A process that ATF6 maturation process achieved by the cleavage of a peptide bond or bonds within ATF6 protein.,false,,,http://purl.obolibrary.org/obo/GO_0016485,,,,,,,,,,,,,,,,,,,,,,ATF6 processing is a subtype of protein processing: A process that ATF6 maturation process achieved by the cleavage of a peptide bond or bonds within ATF6 protein.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003063,,,,,,,,,,,,,,,,,,,,,,ATF6 processing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003068,ARP related gene expression via ATF6 [ER stress],,"ARP related gene expression via ATF6 is a subtype of gene expression: The process in which a gene sequence is converted into a mature ARP gene product or products (proteins or RNA) ia ATF6.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0003071|http://purl.obolibrary.org/obo/TXPO_0003736,,,,,,,,,,,,,,,,,,,,,,"ARP related gene expression via ATF6 is a subtype of gene expression: The process in which a gene sequence is converted into a mature ARP gene product or products (proteins or RNA) ia ATF6.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003045,,http://purl.obolibrary.org/obo/TXPO_0002549,,,,,,,,,,,,,,,,TXPO:0003068,,,,,,,,,,,,,,,,,,,,,,ARP related gene expression via ATF6 [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000064838,FNDC4,,Other designations: fibronectin type III domain-containing protein 4|fibronectin type III repeat-containing protein 1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,FRCP1,,,,,,,,,,,,2,,,,,,HGNC:20239|Vega:OTTHUMG00000097787|HPRD:09965|Ensembl:ENSG00000115226|MIM:611905,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,fibronectin type III domain containing 4,,,2p23.3,,,,,,,,,,,,,,,,GO_0005783 (EC: ISS); GO_0005886 (EC: ISS); GO_0016021 (EC: IEA),,,,,,,,,PMID: 12384288; 12477932; 12975309; 14702039; 15489334; 15815621; 19913121; 20383146; 20628086; 20705733; 21988832; 22267201; 23022100; 23505323,,,,,,,,,,,,,,,OGG:3000064838,,,,,,,fibronectin type III domain containing 4,,,,,,,,,,,,,Other designations: fibronectin type III domain-containing protein 4|fibronectin type III repeat-containing protein 1,,FNDC4,,,,,,,,,,,,,,,,,,,,,,,64838,UNQ6389/PRO21134,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,FNDC4,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000009086,EIF1AY,,"Other designations: eIF-1A Y isoform|eukaryotic translation initiation factor 1A, Y chromosome|eukaryotic translation initiation factor 1A, Y-chromosomal|eukaryotic translation initiation factor 4C",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,eIF-4C,,,,,,,,,,,,Y,,,,,,HGNC:3252|Vega:OTTHUMG00000036544|MIM:400014|Ensembl:ENSG00000198692|HPRD:02455,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"eukaryotic translation initiation factor 1A, Y-linked",,,Yq11.223,,,,,,,,,,,,,,,,"GO_0003743 (EC: IEA); GO_0005515 (EC: IPI, PMID:12569173)",,,,,,,,,PMID:9381176; 10747295; 12477932; 12569173; 12815422; 14660691; 15064832; 15252450; 15342556; 15489334; 15613541; 16713569; 16936303; 18029348; 19605777; 20031959; 20823116; 21139048; 21145461; 21890473; 21906983; 22158087; 22365286; 22505724; 23000965; 23602568; 24319994,,,,,,,,,,,,,,,OGG:3000009086,,,,,,,"eukaryotic translation initiation factor 1A, Y-linked",,,,,,,,,,,,,"Other designations: eIF-1A Y isoform|eukaryotic translation initiation factor 1A, Y chromosome|eukaryotic translation initiation factor 1A, Y-chromosomal|eukaryotic translation initiation factor 4C",,EIF1AY,,,,,,,,,,,,,,,,,,,,,,,9086,,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF1AY,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0001200,lipoperoxidation [Glutathione depletion],,"Lipoperoxidation is a subtype of lipid oxidation: The degradation of lipids caused by an oxidative attack from free radicals.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0003514|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Lipoperoxidation is a subtype of lipid oxidation: The degradation of lipids caused by an oxidative attack from free radicals.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001201,,,,,,,,,,,TXPO:0001200,,,,,,,,,,,,,,,,,,,,,,lipoperoxidation [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001204,cell death [Glutathione depletion],,"Any biological process that results in permanent cessation of all vital functions of a cell.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/GO_0008219|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Any biological process that results in permanent cessation of all vital functions of a cell.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002372|http://purl.obolibrary.org/obo/TXPO_0003168,,,,,,,,,,,TXPO:0001204,,,,,,,,,,,,,,,,,,,,,,cell death [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001203,hypofunction of ATP biosynthesis [Glutathione depletion],,"Hypofunction of ATP biosynthesis is a subtype of hypofunction of biosynthesis: A process that performs a decreased or insufficient ATP biosynthesis.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0001722|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Hypofunction of ATP biosynthesis is a subtype of hypofunction of biosynthesis: A process that performs a decreased or insufficient ATP biosynthesis.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001204,,,,,,,,,,,TXPO:0001203,,,,,,,,,,,,,,,,,,,,,,hypofunction of ATP biosynthesis [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001205,abnormality of membrane [Glutathione depletion],,"Abnormality of membrane is a subtype of changing abnormal cellular structure: A process that changes the membrane stucture abnormally.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0001755|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Abnormality of membrane is a subtype of changing abnormal cellular structure: A process that changes the membrane stucture abnormally.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001206|http://purl.obolibrary.org/obo/TXPO_0001207,,,,,,,,,,,TXPO:0001205,,,,,,,,,,,,,,,,,,,,,,abnormality of membrane [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001208,toxicological imbalance M<VH,,"In the imbalance model, the basic units are as follows:
1) a functioning process (supply) for biological defense and maintaining homeostasis;
2) a functional demand process (demand) as toxic activity;
3) balance/imbalance between toxic activity and defense processes; and
4) outcome from organelles, cells, or tissues to the organ exhibiting toxicity manifestations.

This entity  is a compound state that inculdes step 1 to 4.
This entity  is a compound state that inculdes step 1 to 4.
The defense performance level is Moderate (M) in daily life; however, the functional demand level is Very high (VH), which leads to the imbalance and leads to toxicity manifestation.",false,,,http://purl.obolibrary.org/obo/TXPO_0001779,,,,,,,,,,,,,,,,,,,,,,"In the imbalance model, the basic units are as follows:
1) a functioning process (supply) for biological defense and maintaining homeostasis;
2) a functional demand process (demand) as toxic activity;
3) balance/imbalance between toxic activity and defense processes; and
4) outcome from organelles, cells, or tissues to the organ exhibiting toxicity manifestations.

This entity  is a compound state that inculdes step 1 to 4.
This entity  is a compound state that inculdes step 1 to 4.
The defense performance level is Moderate (M) in daily life; however, the functional demand level is Very high (VH), which leads to the imbalance and leads to toxicity manifestation.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001208,,,,,,,,,,,,,,,,,,,,,,toxicological imbalance M<VH,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001206,calcium ion homeostasis imbalance [Glutathione depletion],,"Calcium ion homeostasis imbalance is a subtype of chemical homeostasis imbalance: A process that becomes lacking a calcium ion homeostastasis balance.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0001765|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Calcium ion homeostasis imbalance is a subtype of chemical homeostasis imbalance: A process that becomes lacking a calcium ion homeostastasis balance.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001204,,,,,,,,,,,TXPO:0001206,,,,,,,,,,,,,,,,,,,,,,calcium ion homeostasis imbalance [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001209,aryl hydrocarbon receptor activation,aryl hydrocarbon receptor activity|AhR activation|AhR activating,Aryl hydrocarbon receptor activation is a subtype of activating nuclear receptor: A process that changes the activity of the activating AhR  (aryl hydrocarbon receptor) with a nuclear receptor role to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000158,,,,,,,,,,,,,,,,,,,,PMID:1325649,,Aryl hydrocarbon receptor activation is a subtype of activating nuclear receptor: A process that changes the activity of the activating AhR  (aryl hydrocarbon receptor) with a nuclear receptor role to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,AhR activation|AhR activating,,aryl hydrocarbon receptor activity,,,TXPO:0001209,,,,,,,AhR activity is combining with an aryl hydrocarbon and transmitting the signal to initiate a change in cell activity. The aryl hydrocarbon receptor is a ligand-activated transcription factor which translocates to the nucleus to activate transcription upon ligand-binding.Combining with an aryl hydrocarbon and transmitting the signal to initiate a change in cell activity. The aryl hydrocarbon receptor is a ligand-activated transcription factor which translocates to the nucleus to activate transcription upon ligand-binding.,,,,,,,,,,,,,,,aryl hydrocarbon receptor activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001201,increasing demand for response to mitochondrial oxidative stress [Glutathione depletion],,"Increasing demand for response to mitochondrial oxidative stress is a subtype of increasing the demand for response to oxidative stress: A process that changes the functional demand for the response to the mitochondrial oxidative stress to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0002301|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Increasing demand for response to mitochondrial oxidative stress is a subtype of increasing the demand for response to oxidative stress: A process that changes the functional demand for the response to the mitochondrial oxidative stress to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001935,,,,,,http://purl.obolibrary.org/obo/TXPO_0001202,,,,,,,,,,,TXPO:0001201,,,,,,,,,,,,,,,,,,,,,,increasing demand for response to mitochondrial oxidative stress [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001202,mitochondrial dysfunction [Glutathione depletion],,"Mitochondrial dysfunction is a subtype of dysfunctioning: A process that performs an abnormal and incomplete mitochondrial function.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0002361|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Mitochondrial dysfunction is a subtype of dysfunctioning: A process that performs an abnormal and incomplete mitochondrial function.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001204|http://purl.obolibrary.org/obo/TXPO_0001203,,,,,,,,,,,TXPO:0001202,,,,,,,,,,,,,,,,,,,,,,mitochondrial dysfunction [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001207,positive regulation of mitochondrial membrane permeability [Glutathione depletion],,"Any process that increases the frequency, rate or extent of the passage or uptake of molecules by the mitochondrial membrane.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/GO_0035794|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Any process that increases the frequency, rate or extent of the passage or uptake of molecules by the mitochondrial membrane.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001202,,,,,,,,,,,TXPO:0001207,,,,,,,,,,,,,,,,,,,,,,positive regulation of mitochondrial membrane permeability [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100610,cyclin B,,,false,,,http://purl.obolibrary.org/obo/IMR_0100673,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100610,,,,,,,,,,,,,,,,,,,,,,cyclin B,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006338,chromatin remodeling,,Dynamic structural changes to eukaryotic chromatin occurring throughout the cell division cycle. These changes range from the local changes necessary for transcriptional regulation to global changes necessary for chromosome segregation.,false,,,http://purl.obolibrary.org/obo/TXPO_0002566,,,,,,,,,,,,,,,,,,,,,,Dynamic structural changes to eukaryotic chromatin occurring throughout the cell division cycle. These changes range from the local changes necessary for transcriptional regulation to global changes necessary for chromosome segregation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0006338,,,,,,,,,,,,,,,,,,,,,,chromatin remodeling,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100055,prolactin-releasing hormone,prolactin-releasing factor|PRH|PRF|rolactin-releasing peptide|PrRP,A polypeptide hormone that originates in the hypothalamus and stimulates the secretion of prolactin in the pituitary gland.,false,,,http://purl.obolibrary.org/obo/IMR_0100093,,,,,,,,,,,,,,,,,,,,MeSH:D011390,,A polypeptide hormone that originates in the hypothalamus and stimulates the secretion of prolactin in the pituitary gland.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,prolactin-releasing factor|PRH|PRF|rolactin-releasing peptide|PrRP,,,,,IMR:0100055,,,,,,,,,,,,,,,,,,,,,,prolactin-releasing hormone,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_1901611,phosphatidylglycerol binding,,Interacting selectively and non-covalently with phosphatidylglycerol.,false,,,http://purl.obolibrary.org/obo/GO_0005543,,,,,,,,,,,,,,,,,,,,GO:1901611,,Interacting selectively and non-covalently with phosphatidylglycerol.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:1901611,,,,,,,,,,,,,,,,,,,,,,phosphatidylglycerol binding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76206,xenobiotic metabolite,xenobiotic metabolites,Any metabolite produced by metabolism of a xenobiotic compound.,false,,,http://purl.obolibrary.org/obo/CHEBI_25212,,,,,,,,,,,,,,,,,,,,,,Any metabolite produced by metabolism of a xenobiotic compound.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,xenobiotic metabolites,,,,,,,,,,,,,,,,,,,,,CHEBI:76206,,,,xenobiotic metabolite,,CHEBI:76206,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001532,R-Ras1,,,false,,,http://purl.obolibrary.org/obo/IMR_0000292,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001532,,,,,,,,,,,,,,,,,,,,,,R-Ras1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000023341,DNAJC16,,Other designations: dnaJ homolog subfamily C member 16|novel DnaJ domain-containing protein,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,1,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"DnaJ (Hsp40) homolog, subfamily C, member 16",,,1p36.1,,,,,,,,,,,,,,,,GO_0016021 (EC: IEA); GO_0045454 (EC: IEA),,,,,,,,,PMID:10231032; 12168954; 12477932; 14702039; 15489334; 16710414; 16751776; 19773279; 21906983; 21963094,,,,,,,,,,,,,,,OGG:3000023341,,,,,,,"DnaJ (Hsp40) homolog, subfamily C, member 16",,,,,,,,,,,,,Other designations: dnaJ homolog subfamily C member 16|novel DnaJ domain-containing protein,,DNAJC16,,,,,,,,,,,,,,,,,,,,,,,23341,RP4-680D5.1,,,,,,,9606,,,,,,,,,,,,,,,,,,,DNAJC16,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0002044,NDK5,,,false,,,http://purl.obolibrary.org/obo/IMR_0010012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0002044,,,,,,,,,,,,,,,,,,,,,,NDK5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100626,cyclin I,,,false,,,http://purl.obolibrary.org/obo/IMR_0100606,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100626,,,,,,,,,,,,,,,,,,,,,,cyclin I,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000055224,ETNK2,,Other designations: EKI 2|ethanolamine kinase-like protein,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,EKI2|HMFT1716,,,,,,,,,,,,1,,,,,,HPRD:13283|Ensembl:ENSG00000143845|Vega:OTTHUMG00000036061|MIM:609859|HGNC:25575,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,ethanolamine kinase 2,,,1q32.1,,,,,,,,,,,,,,,,GO_0001701 (EC: IEA); GO_0001890 (EC: IEA); GO_0004305 (EC: IEA); GO_0005524 (EC: IEA); GO_0005575 (EC: ND); GO_0005829 (EC: TAS); GO_0006644 (EC: TAS); GO_0006646 (EC: IEA); GO_0006646 (EC: TAS); GO_0008150 (EC: ND); GO_0009791 (EC: IEA); GO_0035264 (EC: IEA); GO_0044281 (EC: TAS); GO_0046474 (EC: TAS),,,,,,,,,PMID: 11044454; 12477932; 14702039; 15161093; 16189514; 16861741; 18953568; 19060904; 19536175; 21177773; 24024966,,,,,,,,,,,,,,,OGG:3000055224,,,,,,,ethanolamine kinase 2,,,,,,,,,,,,,Other designations: EKI 2|ethanolamine kinase-like protein,,ETNK2,,,,,,,,,,,,,,,,,,,,,,,55224,RP11-74C13.2,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,ETNK2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000051477,ISYNA1,,Other designations: MI-1-P synthase|MIP synthase|myo-inositol 1-phosphate synthase A1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,IPS-1|IPS|INO1|IPS 1|INOS,,,,,,,,,,,,19,,,,,,HGNC:29821|HPRD:17163|MIM:611670|Vega:OTTHUMG00000179027|Ensembl:ENSG00000105655,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,inositol-3-phosphate synthase 1,,,19p13.11,,,,,,,,,,,,,,,,GO_0004512 (EC: TAS); GO_0005829 (EC: TAS); GO_0006021 (EC: IEA); GO_0008654 (EC: IEA); GO_0043647 (EC: TAS); GO_0044281 (EC: TAS),,,,,,,,,PMID: 12477932; 12941308; 14702039; 15024000; 15464731; 16169070; 16344560; 21044950; 21139048; 21890473; 21906983; 21988832; 22707096; 23535729; 23902760,,,,,,,,,,,,,,,OGG:3000051477,,,,,,,inositol-3-phosphate synthase 1,,,,,,,,,,,,,Other designations: MI-1-P synthase|MIP synthase|myo-inositol 1-phosphate synthase A1,,ISYNA1,,,,,,,,,,,,,,,,,,,,,,,51477,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,ISYNA1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0001632,Rab39A,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001632,,,,,,,,,,,,,,,,,,,,,,Rab39A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0011416,NDK3,,,false,,,http://purl.obolibrary.org/obo/IMR_0010012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0011416,,,,,,,,,,,,,,,,,,,,,,NDK3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0010468,regulation of gene expression,regulation of protein expression,"Any process that modulates the frequency, rate or extent of gene expression. Gene expression is the process in which a gene's coding sequence is converted into a mature gene product or products (proteins or RNA). This includes the production of an RNA transcript as well as any processing to produce a mature RNA product or an mRNA or circRNA (for protein-coding genes) and the translation of that mRNA or circRNA into protein. Protein maturation is included when required to form an active form of a product from an inactive precursor form.|This class covers any process that regulates the rate of production of a mature gene product, and so includes processes that regulate that rate by regulating the level, stability or availability of intermediates in the process of gene expression.  For example, it covers any process that regulates the level, stability or availability of mRNA or circRNA for translation and thereby regulates the rate of production of the encoded protein via translation.",false,,,http://purl.obolibrary.org/obo/TXPO_0000113,,,,,,,,,,,,,,,,,,,,Wikipedia:Regulation_of_gene_expression,,"Any process that modulates the frequency, rate or extent of gene expression. Gene expression is the process in which a gene's coding sequence is converted into a mature gene product or products (proteins or RNA). This includes the production of an RNA transcript as well as any processing to produce a mature RNA product or an mRNA or circRNA (for protein-coding genes) and the translation of that mRNA or circRNA into protein. Protein maturation is included when required to form an active form of a product from an inactive precursor form.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0010628|http://purl.obolibrary.org/obo/GO_0010629,,,,,,,,,,,,,,regulation of protein expression,,,,GO:0010468,,,,,,,,,,,,,,,,,,,,"This class covers any process that regulates the rate of production of a mature gene product, and so includes processes that regulate that rate by regulating the level, stability or availability of intermediates in the process of gene expression.  For example, it covers any process that regulates the level, stability or availability of mRNA or circRNA for translation and thereby regulates the rate of production of the encoded protein via translation.",,regulation of gene expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0010467,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0010467,gene expression,,"The process in which a gene's sequence is converted into a mature gene product or products (proteins or RNA). This includes the production of an RNA transcript as well as any processing to produce a mature RNA product or an mRNA or circRNA (for protein-coding genes) and the translation of that mRNA or circRNA into protein. Protein maturation is included when required to form an active form of a product from an inactive precursor form.|A changing process to convert a gene's sequenes into a mature gene prduct(s), i.e., (m)RNA, or protein.",false,,,http://purl.obolibrary.org/obo/TXPO_0002282,,,,,,,,,,,,,,,,,,,,Wikipedia:Gene_expression,,The process in which a gene's sequence is converted into a mature gene product or products (proteins or RNA). This includes the production of an RNA transcript as well as any processing to produce a mature RNA product or an mRNA or circRNA (for protein-coding genes) and the translation of that mRNA or circRNA into protein. Protein maturation is included when required to form an active form of a product from an inactive precursor form.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000382,,,,,,,,,,,GO:0010467,,,,,,,,,,,,,,,,,,,,"A changing process to convert a gene's sequenes into a mature gene prduct(s), i.e., (m)RNA, or protein.",,gene expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000766,tumor growth,,Tumor growth is a subtype of cell growth: The process in which a tumor cell increases in size.,false,,,http://purl.obolibrary.org/obo/GO_0016049,,,,,,,,,,,,,,,,,,,,http://jglobal.jst.go.jp/en/detail?JGLOBAL_ID=200906011379989142|http://purl.obolibrary.org/obo/MP_0003721,,Tumor growth is a subtype of cell growth: The process in which a tumor cell increases in size.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000766,,,,,,,,,,,,,,,,,,,,,,tumor growth,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000760,inflammatory response [ER stress],,"Inflammatory response is a subtype of changing material: The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000192|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,PMID:25232821|https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2887297/|PMID:26609140|PMID:21038418|PMID:20303879|PMID:27814504|PMID:22883813|PMID:27346803|https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2887297/figure/F1/,,"Inflammatory response is a subtype of changing material: The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002766,http://purl.obolibrary.org/obo/TXPO_0000754|http://purl.obolibrary.org/obo/TXPO_0002768,,,,,,http://purl.obolibrary.org/obo/TXPO_0000758|http://purl.obolibrary.org/obo/TXPO_0000817,,,,,,,,,,,TXPO:0000760,,,,,,,,,,,,,,,,,,,,,,inflammatory response [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000768,Hmox1 (rat)[ER stress],Heme Oxygenase 1 [ER stress],,false,,,http://purl.obolibrary.org/obo/TXPO_0000753|http://purl.obolibrary.org/obo/TXPO_1000196,,,,,,,,,,,,,,,,,,,"oxidative stress ->oxidized lipids production ->ER stress induction (PERK(->eIF2a), JNK)->activation of autophagy->HO-1activation->cell survival

Oxidized lipids activate autophagy in a JNK-dependent manner by stimulating the endoplasmic reticulum stress response.

HNE modification of ER proteins results in the activation of the adaptive arm of the unfolded protein response. This HNE-mediated response is characterized by the phosphorylation of PERK, eIF2α, and JNK, activation of autophagy, and the induction of HO-1.

HNE-stimulated conversion of LC3 (an essential step in autophagosome formation and marker of autophagy) and HO-1 induction is shown to be mediated by ER stress via JNK activation.
PMID:24024137",NCBI-Rat-GeneID:24451|http://omim.org/entry/141250|PMID:12649161,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_22586,,,,,Heme Oxygenase 1 [ER stress],,,,,TXPO:0000768,,,,,,,,,,,,,,,,,,,,,,Hmox1 (rat)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000204|http://purl.obolibrary.org/obo/TXPO_0000376|http://purl.obolibrary.org/obo/TXPO_0000770,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000761,NfkB signaling (primitive),,NfkB signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transduced with the regulation of transcription of target genes by NF-kappaB.,false,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,PW:0000499|http://purl.obolibrary.org/obo/GO_0007249,,NfkB signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transduced with the regulation of transcription of target genes by NF-kappaB.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002774,,,,,http://purl.obolibrary.org/obo/TXPO_0000192|http://purl.obolibrary.org/obo/NCIT_C16407|http://purl.obolibrary.org/obo/GO_0008283|http://purl.obolibrary.org/obo/GO_0043066,,,,,,,,,,,TXPO:0000761,,,,,,,,,,,,,,,,,,,,,,NfkB signaling (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000767,tumor growth [ER stress],,"Tumor growth is a subtype of cell growth: The process in which a tumor cell increases in size.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000766|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,PMID:29198525,,"Tumor growth is a subtype of cell growth: The process in which a tumor cell increases in size.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000767,,,,,,,,,,,,,,,,,,,,,,tumor growth [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000763,bone-marrow-derived inhibitory cell migration,,Bone-marrow-derived inhibitory cell migration is a moving process of bone-marrow-derived inhibitory cell to inflammatory site.,false,,,http://purl.obolibrary.org/obo/GO_0016477,,,,,,,,,,,,,,,,,,,,,,Bone-marrow-derived inhibitory cell migration is a moving process of bone-marrow-derived inhibitory cell to inflammatory site.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000763,,,,,,,,,,,,,,,,,,,,,,bone-marrow-derived inhibitory cell migration,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000769,JNK signaling (primitive),,JNK signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the JNK (a stress-activated protein kinase (SAPK) ).,false,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,,,JNK signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the JNK (a stress-activated protein kinase (SAPK) ).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0031098,,,,,,,,,,,,,,,,TXPO:0000769,,,,,,,,,,,,,,,,,,,,,,JNK signaling (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000762,NfkB signaling (primitive) [ER stress],,"NfkB signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transduced with the regulation of transcription of target genes by NF-kappaB.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000761|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"NfkB signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transduced with the regulation of transcription of target genes by NF-kappaB.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000762,,,,,,,,,,,,,,,,,,,,,,NfkB signaling (primitive) [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000764,macrophage migration [ER stress],,"The orderly movement of a macrophage from one site to another.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/GO_1905517|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"The orderly movement of a macrophage from one site to another.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000764,,,,,,,,,,,,,,,,,,,,,,macrophage migration [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000765,generating motion,,Generating motion is a subtype of generating: A process that generates the directed movement.,false,,,http://purl.obolibrary.org/obo/TXPO_0000381,,,,,,,,,,,,,,,,,,,,,,Generating motion is a subtype of generating: A process that generates the directed movement.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000765,,,,,,,,,,,,,,,,,,,,,,generating motion,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_59285,EC 1.14.13.132 (squalene monooxygenase) inhibitor,"squalene oxydocyclase inhibitors|squalene-2,3-epoxide cyclase inhibitors|squalene 2,3-oxidocyclase inhibitors|squalene-2,3-epoxide cyclase inhibitor|squalene epoxidase inhibitors|squalene-2,3-epoxidase inhibitors|squalene monooxygenase inhibitors|squalene 2,3-oxidocyclase inhibitor|EC 1.14.13.132 (squalene monooxygenase) inhibitors|squalene monooxygenase (EC 1.14.13.132) inhibitors|squalene hydroxylase inhibitors|squalene oxydocyclase inhibitor|squalene epoxidase inhibitor|squalene monooxygenase inhibitor|squalene monooxygenase (EC 1.14.13.132) inhibitor|squalene hydroxylase inhibitor|squalene-2,3-epoxidase inhibitor","An EC 1.14.13.* (oxidoreductase acting on paired donors, incorporating 1 atom of oxygen, with NADH or NADPH as one donor) inhibitor that interferes with the action of squalene monooxygenase (EC 1.14.13.132).",false,,,http://purl.obolibrary.org/obo/CHEBI_76841,,,,,,,,,,,,,,,,,,,,,,"An EC 1.14.13.* (oxidoreductase acting on paired donors, incorporating 1 atom of oxygen, with NADH or NADPH as one donor) inhibitor that interferes with the action of squalene monooxygenase (EC 1.14.13.132).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"squalene oxydocyclase inhibitors|squalene-2,3-epoxide cyclase inhibitors|squalene 2,3-oxidocyclase inhibitors|squalene-2,3-epoxide cyclase inhibitor|squalene epoxidase inhibitors|squalene-2,3-epoxidase inhibitors|squalene monooxygenase inhibitors|squalene 2,3-oxidocyclase inhibitor|EC 1.14.13.132 (squalene monooxygenase) inhibitors|squalene monooxygenase (EC 1.14.13.132) inhibitors|squalene hydroxylase inhibitors|squalene oxydocyclase inhibitor|squalene epoxidase inhibitor|squalene monooxygenase inhibitor|squalene monooxygenase (EC 1.14.13.132) inhibitor|squalene hydroxylase inhibitor|squalene-2,3-epoxidase inhibitor",,,,,,,,,,,,,,,,,,,,,CHEBI:59285,,,,EC 1.14.13.132 (squalene monooxygenase) inhibitor,,CHEBI:59285,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000645,Integrin beta-5,,,false,,,http://purl.obolibrary.org/obo/IMR_0000174,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000645,,,,,,,,,,,,,,,,,,,,,,Integrin beta-5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000010952,SEC61B,,"Other designations: Sec61 complex, beta subunit|protein translocation complex beta|protein transport protein SEC61 beta subunit|protein transport protein Sec61 subunit beta",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,9,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,Sec61 beta subunit,,,9q22.32-q31.3,,,,,,,,,,,,,,,,"GO_0000060 (EC: IMP, PMID: 17215517); GO_0002474 (EC: TAS); GO_0002479 (EC: TAS); GO_0005515 (EC: IPI, PMID: 18555783); GO_0005783 (EC: IDA); GO_0006412 (EC: TAS); GO_0006614 (EC: TAS); GO_0010467 (EC: TAS); GO_0016020 (EC: IDA); GO_0016021 (EC: NAS, PMID: 8107851); GO_0030433 (EC: IDA, PMID: 8945469); GO_0030970 (EC: IMP, PMID: 17215517); GO_0031205 (EC: ISS); GO_0042590 (EC: TAS); GO_0043022 (EC: IEA); GO_0044267 (EC: TAS); GO_0044822 (EC: IDA); GO_0048408 (EC: IPI, PMID: 19602593)",,,,,,,,,PMID: 8107851; 8125298; 8945469; 9512475; 9565615; 9585408; 9631292; 9792704; 10212142; 10508919; 10601334; 10799540; 12477932; 15164053; 15489334; 16015337; 16083285; 17081983; 17215517; 17360537; 18555783; 19602593; 19738201; 20516149; 20676083; 20937808; 21139048; 21182205; 21255561; 21343306; 22623428; 22645275; 22710939; 23129660; 23533635; 23606741; 23874384,,,,,,,,,,,,,,,OGG:3000010952,,,,,,,Sec61 beta subunit,,,,,,,,,,,,,"Other designations: Sec61 complex, beta subunit|protein translocation complex beta|protein transport protein SEC61 beta subunit|protein transport protein Sec61 subunit beta",,SEC61B,,,,,,,,,,,,,,,,,,,,,,,10952,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,SEC61B,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0002153,collagenase inhibitor production,,Collagenase inhibitor production is a subtype of protein production: A process that makes existent of a substance with collagenase inhibitor role due to biosynthesis or secretion resulting in an increase in its levels.,false,,,http://purl.obolibrary.org/obo/TXPO_0000382,,,,,,,,,,,,,,,,,,,,,,Collagenase inhibitor production is a subtype of protein production: A process that makes existent of a substance with collagenase inhibitor role due to biosynthesis or secretion resulting in an increase in its levels.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002153,,,,,,,,,,,,,,,,,,,,,,collagenase inhibitor production,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002155,IRE1 signal transduction pathway,,A series of molecular signals mediated by IRE1 (Inositol-requiring transmembrane kinase/endonuclease).,false,,,http://purl.obolibrary.org/obo/TXPO_0000609,,,,,,,,,,,,,,,,,,,,,,A series of molecular signals mediated by IRE1 (Inositol-requiring transmembrane kinase/endonuclease).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002593,,,,,,,,,,,,,,,,,,TXPO:0002155,,,,,,,,,,,,,,,,,,,,,,IRE1 signal transduction pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002154,transmembrane receptor protein serine/threonine kinase,,"A role of combining with a signal and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity by catalysis of the reaction: ATP protein serine = ADP + protein serine phosphate, and ATP + protein threonine = ADP + protein threonine phosphate.|related molecular function GO:0004675",false,,,http://purl.obolibrary.org/obo/TXPO_0001966,,,,,,,,,,,,,,,,,,,,,,"A role of combining with a signal and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity by catalysis of the reaction: ATP protein serine = ADP + protein serine phosphate, and ATP + protein threonine = ADP + protein threonine phosphate.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002154,,,,,,,,,,,,,,,,,,,,related molecular function GO:0004675,,transmembrane receptor protein serine/threonine kinase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002158,fatty acid homeostasis imbalance in peroxisome [Eosinophilic granular degeneration],,"Fatty acid homeostasis imbalance in peroxisome is a subtype of changing balance: A process that becomes lacking afatty acid homeostastasis balance.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/TXPO_0002446|http://purl.obolibrary.org/obo/TXPO_0002134,,,,,,,,,,,,,,,,,,,,,,"Fatty acid homeostasis imbalance in peroxisome is a subtype of changing balance: A process that becomes lacking afatty acid homeostastasis balance.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000105,,,,,,,,,,,TXPO:0002158,,,,,,,,,,,,,,,,,,,,,,fatty acid homeostasis imbalance in peroxisome [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002159,fatty acid homeostasis imbalance in peroxisome (mild) [Eosinophilic granular degeneration],,"Fatty acid homeostasis imbalance in peroxisome is a subtype of changing balance: A process that becomes lacking afatty acid homeostastasis balance. The degree is mild.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/TXPO_0002158,,,,,,,,,,,,,,,,,,,,,,"Fatty acid homeostasis imbalance in peroxisome is a subtype of changing balance: A process that becomes lacking afatty acid homeostastasis balance. The degree is mild.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002159,,,,,,,,,,,,,,,,,,,,,,fatty acid homeostasis imbalance in peroxisome (mild) [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002152,collagenase inhibitor production [Fibrosis],,"Collagenase inhibitor production is a subtype of protein production: A process that makes existent of a substance with collagenase inhibitor role due to biosynthesis or secretion resulting in an increase in its levels.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003742|http://purl.obolibrary.org/obo/TXPO_0002153,,,,,,,,,,,,,,,,,,,,,,"Collagenase inhibitor production is a subtype of protein production: A process that makes existent of a substance with collagenase inhibitor role due to biosynthesis or secretion resulting in an increase in its levels.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002152,,,,,,,,,,,,,,,,,,,,,,collagenase inhibitor production [Fibrosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002151,GSTO2 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0002089,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:309465|NCBI-Mouse-GeneID:68214|NCBI-Human-GeneID:119391,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002151,,,,,,,,,,,,,,,,,,,,,,GSTO2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002150,importing cation into hepatocyte vascular side (sinusoidal side) membrane [Cholestasis],,"The directed movement of the organic cation into hepatocyte vascular side (sinusoidal side) membrane during cholestasis.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001759,,,,,,,,,,,,,,,,,,,,,,"The directed movement of the organic cation into hepatocyte vascular side (sinusoidal side) membrane during cholestasis.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002386,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002150,,,,,,,"Lipophilic cationic drugs, estrogens, and lipids are exported by the canalicular multiple-drug resistance (MDR) P-glycoproteins, one of which is exclusive for phospholipids.",,,,,,,,,,,,,,,importing cation into hepatocyte vascular side (sinusoidal side) membrane [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002157,PERK-eIF2a signaling (integrated pathway)[ER stress - translation attenuation],,"PERK-eIF2a signaling is a subtype of PERK signaling (integrated pathway): Sequence of linked reactions, which has PERK-eIF2a signaling and gene regulation pathway.
This pathway is dependent on the translation attenuation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000701,,,,,,,,,,,,,,,,,,,,,,"PERK-eIF2a signaling is a subtype of PERK signaling (integrated pathway): Sequence of linked reactions, which has PERK-eIF2a signaling and gene regulation pathway.
This pathway is dependent on the translation attenuation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000061|http://purl.obolibrary.org/obo/TXPO_0000123|http://purl.obolibrary.org/obo/TXPO_0002762,,,,,,,,,,,,,,,,,,TXPO:0002157,,,,,,,,,,,,,,,,,,,,,,PERK-eIF2a signaling (integrated pathway)[ER stress - translation attenuation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002156,malfunctioning of uncoupling,,Malfunctioning of electron transport coupled proton transport is a subtype of malfunctioning process: A process that cannot perform an electron transport coupled proton transport appropriately or cannot realize it at all.,false,,,http://purl.obolibrary.org/obo/TXPO_0000434,,,,,,,,,,,,,,,,,,,,,,Malfunctioning of electron transport coupled proton transport is a subtype of malfunctioning process: A process that cannot perform an electron transport coupled proton transport appropriately or cannot realize it at all.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002156,,,,,,,,,,,,,,,,,,,,,,malfunctioning of uncoupling,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100770,Wnt-4,,,false,,,http://purl.obolibrary.org/obo/IMR_0000003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100770,,,,,,,,,,,,,,,,,,,,,,Wnt-4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000740,ShcC,,,false,,,http://purl.obolibrary.org/obo/IMR_0000347,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000740,,,,,,,,,,,,,,,,,,,,,,ShcC,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76850,EC 1.17.3.* (oxidoreductase acting on CH or CH2 with oxygen as acceptor) inhibitor,oxidoreductase acting on CH or CH2 with oxygen as acceptor (EC 1.17.3.*) inhibitor|oxidoreductase acting on CH or CH2 with oxygen as acceptor (EC 1.17.3.*) inhibitors|EC 1.17.3.* inhibitors|EC 1.17.3.* (oxidoreductase acting on CH or CH2 with oxygen as acceptor) inhibitors|EC 1.17.3.* inhibitor,An EC 1.17.* (oxidoreductase acting on CH or CH2) inhibitor that interferes with the function of any such enzyme that uses oxygen as acceptor (EC 1.17.3.*).,false,,,http://purl.obolibrary.org/obo/CHEBI_76744,,,,,,,,,,,,,,,,,,,,,,An EC 1.17.* (oxidoreductase acting on CH or CH2) inhibitor that interferes with the function of any such enzyme that uses oxygen as acceptor (EC 1.17.3.*).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,oxidoreductase acting on CH or CH2 with oxygen as acceptor (EC 1.17.3.*) inhibitor|oxidoreductase acting on CH or CH2 with oxygen as acceptor (EC 1.17.3.*) inhibitors|EC 1.17.3.* inhibitors|EC 1.17.3.* (oxidoreductase acting on CH or CH2 with oxygen as acceptor) inhibitors|EC 1.17.3.* inhibitor,,,,,,,,,,,,,,,,,,,,,CHEBI:76850,,,,EC 1.17.3.* (oxidoreductase acting on CH or CH2 with oxygen as acceptor) inhibitor,,CHEBI:76850,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100621,cyclin F,G2/mitotic-specific cyclin F,,false,,,http://purl.obolibrary.org/obo/IMR_0100606,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,G2/mitotic-specific cyclin F,,,,,IMR:0100621,,,,,,,,,,,,,,,,,,,,,,cyclin F,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_37886,adrenergic agonist,adrenomimetic|adrenergic receptor agonist|adrenergic agonists|adrenoceptor agonists|adrenomimetics,An agent that selectively binds to and activates adrenergic receptors.,false,,,http://purl.obolibrary.org/obo/CHEBI_37962,,,,,,,,,,,,,,,,,,,,,,An agent that selectively binds to and activates adrenergic receptors.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,adrenomimetic|adrenergic receptor agonist|adrenergic agonists|adrenoceptor agonists|adrenomimetics,,,,,,,,,,,,,,,,,,,,,CHEBI:37886,,,,adrenergic agonist,,CHEBI:37886,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000398,ERG,ets-related gene,,false,,,http://purl.obolibrary.org/obo/IMR_0000397,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ets-related gene,,,,,IMR:0000398,,,,,,,,,,,,,,,,,,,,,,ERG,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000884,TFIID,,,false,,,http://purl.obolibrary.org/obo/IMR_0000888,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003645,,,,,,,,,,IMR:0000884,,,,,,,,,,,,,,,,,,,,,,TFIID,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76837,EC 1.13.11.* (oxidoreductase acting on single donors and incorporating 2 O atoms) inhibitor,EC 1.13.11.* (oxidoreductase acting on single donors and incorporating 2 atoms of oxygen) inhibitor|EC 1.13.11.* inhibitor|EC 1.13.11.* inhibitors|EC 1.13.11.* (oxidoreductase acting on single donors and incorporating 2 O atoms) inhibitors|oxidoreductase acting on single donors and incorporating 2 atoms of oxygen (EC 1.13.11.*) inhibitor|EC 1.13.11.* (oxidoreductase acting on single donors and incorporating 2 atoms of oxygen) inhibitors|oxidoreductase acting on single donors and incorporating 2 atoms of oxygen (EC 1.13.11.*) inhibitors,An EC 1.13.* [oxidoreductase acting on single donors with incorporation of molecular oxygen (oxygenases)] inhibitor that inhibits the action of any oxidoreductase incorporating 2 atoms of oxygen (EC 1.13.11.*).,false,,,http://purl.obolibrary.org/obo/CHEBI_76740,,,,,,,,,,,,,,,,,,,,,,An EC 1.13.* [oxidoreductase acting on single donors with incorporation of molecular oxygen (oxygenases)] inhibitor that inhibits the action of any oxidoreductase incorporating 2 atoms of oxygen (EC 1.13.11.*).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,EC 1.13.11.* (oxidoreductase acting on single donors and incorporating 2 atoms of oxygen) inhibitor|EC 1.13.11.* inhibitor|EC 1.13.11.* inhibitors|EC 1.13.11.* (oxidoreductase acting on single donors and incorporating 2 O atoms) inhibitors|oxidoreductase acting on single donors and incorporating 2 atoms of oxygen (EC 1.13.11.*) inhibitor|EC 1.13.11.* (oxidoreductase acting on single donors and incorporating 2 atoms of oxygen) inhibitors|oxidoreductase acting on single donors and incorporating 2 atoms of oxygen (EC 1.13.11.*) inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:76837,,,,EC 1.13.11.* (oxidoreductase acting on single donors and incorporating 2 O atoms) inhibitor,,CHEBI:76837,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000714,PLCbeta1,phospholipase C beta 1,,false,,,http://purl.obolibrary.org/obo/IMR_0000286,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,phospholipase C beta 1,,,,,IMR:0000714,,,,,,,,,,,,,,,,,,,,,,PLCbeta1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000001956,EGFR,,Other designations: avian erythroblastic leukemia viral (v-erb-b) oncogene homolog|cell growth inhibiting protein 40|cell proliferation-inducing protein 61|proto-oncogene c-ErbB-1|receptor tyrosine-protein kinase erbB-1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,ERBB1|mENA|HER1|ERBB|PIG61,,,,,,,,,,,,7,,,,,,Ensembl:ENSG00000146648|HPRD:00579|MIM:131550|Vega:OTTHUMG00000023661|HGNC:3236,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,epidermal growth factor receptor,,,7p12,,,,,,,,,,,,,,,,"GO_0000139 (EC: IEA); GO_0000165 (EC: NAS, PMID:15542601); GO_0001503 (EC: NAS, PMID:12925580); GO_0001889 (EC: IEA); GO_0001892 (EC: IEA); GO_0001934 (EC: IDA); GO_0001942 (EC: IEA); GO_0001948 (EC: IEA); GO_0003682 (EC: IDA); GO_0003690 (EC: NAS, PMID:6325948); GO_0004709 (EC: NAS, PMID:15542601); GO_0004713 (EC: IDA, PMID:17115032); GO_0004713 (EC: IMP, PMID:14702346); GO_0004713 (EC: TAS, PMID:16076471); GO_0004714 (EC: TAS); GO_0004716 (EC: IEA); GO_0004888 (EC: IDA, PMID:7736574); GO_0005006 (EC: IDA, PMID:12435727); GO_0005006 (EC: NAS, PMID:2790960); GO_0005178 (EC: IEA); GO_0005515 (EC: IPI, PMID:10026169); GO_0005524 (EC: IEA); GO_0005615 (EC: NAS, PMID:9103388); GO_0005634 (EC: IDA, PMID:12828935); GO_0005737 (EC: IDA); GO_0005768 (EC: IDA, PMID:14702346); GO_0005789 (EC: IEA); GO_0005886 (EC: IDA); GO_0005886 (EC: TAS); GO_0005976 (EC: IEA); GO_0006412 (EC: IEA); GO_0006950 (EC: NAS, PMID:12828935); GO_0006970 (EC: IEA); GO_0006979 (EC: IEA); GO_0007165 (EC: IDA, PMID:10572067); GO_0007165 (EC: TAS); GO_0007166 (EC: IDA, PMID:7736574); GO_0007173 (EC: IDA, PMID:12435727); GO_0007173 (EC: TAS); GO_0007202 (EC: TAS, PMID:12435727); GO_0007411 (EC: TAS); GO_0007435 (EC: IEA); GO_0007611 (EC: ISS); GO_0007623 (EC: IEA); GO_0008283 (EC: IDA, PMID:17115032); GO_0008284 (EC: IDA, PMID:7736574); GO_0008543 (EC: TAS); GO_0009986 (EC: IEA); GO_0010008 (EC: IEA); GO_0010960 (EC: IEA); GO_0016020 (EC: IDA, PMID:12435727); GO_0016021 (EC: IEA); GO_0016101 (EC: IEA); GO_0016323 (EC: IDA, PMID:12646923); GO_0016324 (EC: IEA); GO_0016337 (EC: IMP, PMID:12435727); GO_0018108 (EC: IDA, PMID:17115032); GO_0018108 (EC: IMP, PMID:14702346); GO_0018108 (EC: TAS, PMID:16076471); GO_0019694 (EC: IEA); GO_0019899 (EC: IPI, PMID:12009895); GO_0019901 (EC: IEA); GO_0019903 (EC: IPI, PMID:15899872); GO_0021795 (EC: IEA); GO_0030122 (EC: TAS, Qualifier: colocalizes_with, PMID:14702346); GO_0030235 (EC: IDA, Qualifier: contributes_to, PMID:12828935); GO_0030324 (EC: IEA); GO_0030335 (EC: IMP, PMID:12435727); GO_0031659 (EC: IDA, PMID:18483258); GO_0031965 (EC: IEA); GO_0032930 (EC: IEA); GO_0033590 (EC: IEA); GO_0033594 (EC: IEA); GO_0035413 (EC: IMP); GO_0035690 (EC: IEA); GO_0038095 (EC: TAS); GO_0042059 (EC: TAS); GO_0042177 (EC: IDA, PMID:17115032); GO_0042327 (EC: IDA, PMID:15082764); GO_0042698 (EC: IEA); GO_0042743 (EC: IEA); GO_0042802 (EC: IPI, PMID:16777603); GO_0043006 (EC: TAS, PMID:12435727); GO_0043066 (EC: IMP, PMID:18070883); GO_0043235 (EC: IDA); GO_0043406 (EC: IDA, PMID:10572067); GO_0043586 (EC: IEA); GO_0045087 (EC: TAS); GO_0045121 (EC: IDA, PMID:12009895); GO_0045429 (EC: IDA, PMID:12828935); GO_0045739 (EC: IDA, PMID:17115032); GO_0045740 (EC: IDA, PMID:17115032); GO_0045907 (EC: IEA); GO_0045909 (EC: IEA); GO_0045930 (EC: IEA); GO_0045944 (EC: IDA); GO_0046777 (EC: IMP, PMID:18070883); GO_0046982 (EC: IDA, PMID:10572067); GO_0048011 (EC: TAS); GO_0048015 (EC: TAS); GO_0048143 (EC: IEA); GO_0048146 (EC: IEA); GO_0048408 (EC: IEA); GO_0048471 (EC: IEA); GO_0048546 (EC: IEA); GO_0048661 (EC: IEA); GO_0050679 (EC: IDA, PMID:10572067); GO_0050729 (EC: IEA); GO_0050730 (EC: IMP, PMID:12435727); GO_0050999 (EC: IDA, PMID:12828935); GO_0051015 (EC: IDA, PMID:14702346); GO_0051205 (EC: TAS, PMID:12435727); GO_0051592 (EC: IEA); GO_0051897 (EC: IMP, PMID:17655843); GO_0051968 (EC: IEA); GO_0060571 (EC: IEA); GO_0070141 (EC: IDA, PMID:18483258); GO_0070374 (EC: IDA); GO_0070435 (EC: ISS); GO_0071260 (EC: IEA); GO_0071364 (EC: ISS); GO_0071392 (EC: IDA); GO_0071549 (EC: IEA)",,,,,,,,,PMID:1281549; 1301150; 1309762; 1322798; 1333047; 1372092; 1382070; 1383230; 1385407; 1501243; 1505215; 1623525; 1633149; 1647028; 1651322; 1689310; 1706616; 1808202; 1850098; 1988448; 2173144; 2176151; 2434500; 2543678; 2543683; 2790960; 2810532; 2984676; 2985580; 2987962; 2991749; 2991899; 3039909; 3138233; 3329716; 6093780; 6297856; 6324343; 6325948; 6326261; 6328312; 6330563; 7506413; 7510700; 7518560; 7527043; 7532293; 7535770; 7540771; 7543024; 7588596; 7592693; 7623846; 7640657; 7654368; 7657591; 7657660; 7673163; 7682059; 7690989; 7730382; 7736574; 7761838; 7782294; 7880396; 7903710; 8125298; 8305738; 8375396; 8413296; 8493579; 8497321; 8577769; 8596488; 8610109; 8610433; 8621392; 8638121; 8639530; 8647288; 8647858; 8650580; 8657103; 8662998; 8702572; 8729040; 8798643; 8810325; 8845374; 8875975; 8885868; 8887653; 8918811; 8940083; 8943228; 8962717; 9006901; 9049247; 9050991; 9079622; 9103388; 9115287; 9121472; 9130710; 9188692; 9207933; 9233779; 9307968; 9344857; 9346925; 9355745; 9356464; 9362449; 9363897; 9374534; 9416834; 9419975; 9425043; 9430697; 9447973; 9480911; 9488479; 9506989; 9506992; 9507002; 9528863; 9535896; 9544989; 9556602; 9617486; 9642287; 9658162; 9710451; 9733788; 9737977; 9756944; 9781061; 9815893; 9819414; 9837959; 9843575; 9872323; 9886492; 9890970; 9988678; 10026169; 10049786; 10075741; 10085134; 10086340; 10092522; 10187783; 10347170; 10358079; 10362357; 10369675; 10428778; 10435588; 10508618; 10523301; 10527633; 10558875; 10567358; 10571044; 10572067; 10595738; 10617627; 10618391; 10635327; 10648629; 10675333; 10722725; 10731668; 10734107; 10734310; 10777553; 10788520; 10799548; 10805725; 10806474; 10861448; 10888683; 10889023; 10913131; 10918300; 10918587; 10938113; 10953014; 10969083; 10971656; 10980697; 10985391; 10993906; 11094073; 11114724; 11116146; 11161793; 11172806; 11223155; 11226410; 11239464; 11278868; 11279102; 11286993; 11294897; 11349134; 11370743; 11375397; 11408594; 11432805; 11459228; 11467954; 11470832; 11483589; 11493652; 11500516; 11500850; 11504770; 11506178; 11516622; 11531336; 11533253; 11533659; 11602604; 11687594; 11696537; 11726515; 11751923; 11788593; 11796728; 11814623; 11823423; 11831486; 11839738; 11843178; 11853560; 11864992; 11875501; 11886870; 11887937; 11894095; 11897506; 11912208; 11916499; 11916981; 11935304; 11950845; 11953893; 11956190; 11960376; 11966576; 11968000; 11983694; 11983899; 11992543; 11994282; 12006493; 12006662; 12009895; 12018405; 12023273; 12061819; 12070153; 12093135; 12093292; 12095417; 12099646; 12099696; 12105206; 12127568; 12127695; 12133497; 12134064; 12134089; 12135609; 12147707; 12152785; 12153558; 12161422; 12167618; 12177062; 12180964; 12181310; 12192610; 12198159; 12218189; 12223352; 12226085; 12234920; 12243760; 12297049; 12297050; 12354693; 12354760; 12381737; 12388423; 12388817; 12397069; 12399475; 12419588; 12429632; 12429742; 12435727; 12444032; 12446727; 12454019; 12456372; 12471035; 12477932; 12479108; 12487410; 12488461; 12508124; 12517767; 12517803; 12522132; 12522133; 12527890; 12532415; 12534349; 12534934; 12543931; 12556561; 12560083; 12568494; 12573287; 12577067; 12579331; 12582944; 12586732; 12586780; 12588871; 12589790; 12593795; 12593796; 12601080; 12603863; 12604776; 12606307; 12606946; 12607604; 12614260; 12615082; 12620237; 12631599; 12637327; 12642595; 12643788; 12646923; 12653106; 12654182; 12657642; 12664617; 12672817; 12673202; 12681285; 12683217; 12686539; 12694196; 12704666; 12708474; 12708492; 12717448; 12719435; 12719950; 12722480; 12725245; 12733059; 12734385; 12743604; 12746449; 12746839; 12754251; 12754350; 12757445; 12768436; 12771190; 12782602; 12794748; 12795333; 12803489; 12807903; 12814937; 12817007; 12819035; 12824187; 12825853; 12828935; 12829707; 12839682; 12844146; 12853948; 12871937; 12873986; 12878187; 12879076; 12897150; 12900408; 12919676; 12925580; 12930839; 12939263; 12953068; 12953099; 12954170; 12955084; 13679441; 13679857; 14505571; 14506149; 14506242; 14507652; 14512423; 14520461; 14530278; 14551192; 14557654; 14560030; 14576349; 14592989; 14607699; 14627991; 14632199; 14647423; 14660604; 14665621; 14670955; 14676838; 14679214; 14681060; 14688027; 14690686; 14701753; 14702346; 14704150; 14711810; 14718570; 14729599; 14734462; 14764825; 14960328; 14963038; 14977086; 14977838; 14978035; 14988406; 14996911; 15009100; 15010475; 15026342; 15031710; 15039424; 15042583; 15054105; 15057284; 15063762; 15082004; 15082764; 15100232; 15107835; 15113837; 15117950; 15118073; 15118125; 15123705; 15134305; 15143334; 15144186; 15159412; 15166244; 15166495; 15182358; 15185528; 15192046; 15205458; 15210722; 15211117; 15212941; 15213840; 15215236; 15219825; 15219850; 15221011; 15225635; 15226397; 15233293; 15245434; 15248827; 15253134; 15253384; 15254267; 15254682; 15256501; 15269346; 15271882; 15273720; 15282306; 15282549; 15284024; 15284455; 15288768; 15298855; 15300588; 15302576; 15302935; 15305378; 15322115; 15329413; 15335267; 15337524; 15337756; 15340161; 15342520; 15345710; 15358139; 15364923; 15366372; 15383614; 15383630; 15389569; 15389641; 15447984; 15456872; 15465819; 15467833; 15469987; 15469991; 15475003; 15485674; 15485908; 15494003; 15507625; 15519654; 15522239; 15524283; 15540509; 15541730; 15542601; 15545271; 15556605; 15556944; 15557335; 15562026; 15572377; 15574420; 15580296; 15581623; 15588985; 15590694; 15592685; 15618223; 15620700; 15621729; 15623594; 15635092; 15652339; 15652750; 15657067; 15657358; 15665278; 15665299; 15665312; 15668240; 15672448; 15677445; 15695332; 15701692; 15701846; 15701973; 15705969; 15708852; 15709185; 15710947; 15728811; 15735691; 15735700; 15735736; 15736426; 15738541; 15741570; 15746034; 15748904; 15749523; 15755902; 15767552; 15772959; 15782189; 15784896; 15788655; 15791567; 15797859; 15798095; 15815931; 15828871; 15829495; 15829568; 15829704; 15837620; 15837743; 15838264; 15844661; 15855163; 15870435; 15896781; 15897877; 15899872; 15901872; 15913841; 15920544; 15921680; 15923435; 15950906; 15951569; 15956035; 15962011; 15963982; 15967033; 15967120; 15982634; 15986432; 15994311; 15994331; 15998907; 16000298; 16002952; 16003726; 16010411; 16011858; 16018936; 16024644; 16030116; 16032426; 16033132; 16037379; 16043828; 16052218; 16061871; 16076471; 16077899; 16082153; 16083266; 16097034; 16098054; 16098254; 16103229; 16103736; 16105029; 16105874; 16109531; 16115866; 16120644; 16126727; 16140420; 16140940; 16144838; 16151725; 16152581; 16161046; 16169070; 16184431; 16198442; 16199108; 16200342; 16203769; 16205628; 16207817; 16213893; 16226114; 16237757; 16240219; 16240846; 16242075; 16243431; 16246327; 16258541; 16263120; 16263724; 16273093; 16273187; 16274239; 16275144; 16278215; 16278407; 16282324; 16293617; 16299810; 16303044; 16305343; 16314000; 16318625; 16319309; 16322287; 16324836; 16329825; 16331686; 16344560; 16344724; 16353158; 16353237; 16355407; 16373414; 16376942; 16382132; 16397024; 16398612; 16401639; 16407214; 16407834; 16414009; 16424019; 16424381; 16429130; 16443754; 16445385; 16449241; 16453019; 16456542; 16461080; 16467085; 16467097; 16472761; 16478662; 16488447; 16489645; 16499958; 16503085; 16503086; 16505411; 16507511; 16514409; 16520378; 16521222; 16524970; 16524971; 16525633; 16531225; 16533793; 16543144; 16543231; 16545487; 16551849; 16552419; 16552725; 16554736; 16555991; 16565089; 16567021; 16569667; 16571657; 16574647; 16574793; 16584205; 16596188; 16596194; 16597832; 16609018; 16609045; 16614884; 16622417; 16629834; 16637508; 16641105; 16642476; 16646071; 16648628; 16683917; 16685269; 16685454; 16687414; 16702213; 16702519; 16702950; 16707764; 16712791; 16715136; 16722544; 16729043; 16735510; 16738552; 16741920; 16750403; 16757132; 16777603; 16778986; 16780213; 16785991; 16786197; 16788380; 16788982; 16795991; 16799092; 16799709; 16803894; 16806010; 16806170; 16815198; 16818686; 16820093; 16835231; 16842869; 16843263; 16845329; 16847054; 16849327; 16849543; 16857803; 16859684; 16870303; 16885506; 16899617; 16904111; 16912157; 16912159; 16912195; 16914641; 16923119; 16936259; 16937526; 16951222; 16956694; 16964397; 16968809; 16969069; 16970944; 16979526; 16980555; 16983337; 16984414; 17016520; 17018617; 17023689; 17047074; 17047316; 17052295; 17053785; 17054433; 17060486; 17062641; 17081983; 17092854; 17092939; 17101784; 17102595; 17106442; 17111374; 17112774; 17115032; 17121848; 17126326; 17130473; 17142003; 17142315; 17143527; 17143531; 17146284; 17148666; 17148776; 17149366; 17157295; 17158592; 17158602; 17164758; 17175376; 17177598; 17177839; 17178880; 17182860; 17183836; 17186532; 17192257; 17192792; 17192902; 17196962; 17200338; 17203166; 17203167; 17210462; 17211865; 17214962; 17215517; 17219440; 17223314; 17224267; 17227303; 17227756; 17227773; 17228128; 17234718; 17236582; 17237147; 17238183; 17242169; 17255257; 17261767; 17284372; 17284441; 17285230; 17285540; 17285735; 17289890; 17290443; 17295209; 17303584; 17307140; 17307332; 17310847; 17311283; 17311890; 17320394; 17320820; 17321325; 17328268; 17332501; 17334773; 17335953; 17337084; 17339316; 17339338; 17349623; 17354229; 17362940; 17368623; 17369752; 17372273; 17373877; 17375033; 17381163; 17382318; 17387341; 17390041; 17390112; 17403676; 17409827; 17409862; 17409866; 17409930; 17425591; 17426253; 17429313; 17431338; 17431415; 17440163; 17448210; 17448597; 17453000; 17453292; 17453416; 17455141; 17455987; 17459062; 17462600; 17468034; 17469127; 17473658; 17473659; 17475671; 17475774; 17482563; 17486068; 17487277; 17487398; 17487844; 17493174; 17493236; 17495959; 17504988; 17505415; 17508947; 17509661; 17510392; 17514628; 17516110; 17525128; 17525275; 17534846; 17537621; 17538160; 17538889; 17545148; 17545553; 17545606; 17548322; 17548351; 17548604; 17548638; 17549361; 17549377; 17561305; 17562274; 17562788; 17566601; 17573511; 17575133; 17575224; 17580276; 17581404; 17591931; 17594688; 17595327; 17596643; 17597605; 17599051; 17600311; 17607119; 17607370; 17610986; 17611648; 17616668; 17616694; 17616711; 17618248; 17622245; 17626639; 17631646; 17631905; 17636398; 17637750; 17638075; 17643093; 17643098; 17643426; 17644807; 17646270; 17646646; 17649787; 17650314; 17652160; 17654528; 17655843; 17661145; 17671201; 17673923; 17674766; 17685929; 17686547; 17699773; 17712488; 17713473; 17714760; 17720156; 17721266; 17760253; 17760255; 17761979; 17784875; 17804738; 17805209; 17822324; 17823122; 17845756; 17845757; 17848912; 17849451; 17852426; 17870017; 17875767; 17880946; 17881446; 17881501; 17885502; 17904685; 17907599; 17908966; 17909029; 17910038; 17912028; 17913857; 17917087; 17918158; 17918184; 17922051; 17922974; 17927446; 17927850; 17932690; 17941001; 17942395; 17947472; 17949425; 17950068; 17956637; 17960555; 17962724; 17964790; 17971399; 17972518; 17974918; 17989321; 17991782; 17995934; 17997974; 17998090; 18000506; 18006781; 18021194; 18025070; 18025312; 18028876; 18029348; 18030354; 18032821; 18032824; 18043914; 18045238; 18045646; 18046415; 18054376; 18057028; 18060032; 18067636; 18070883; 18080320; 18083120; 18084281; 18087285; 18089646; 18089823; 18093943; 18095139; 18097577; 18154448; 18154814; 18161656; 18172267; 18172732; 18176089; 18178562; 18180459; 18182111; 18186271; 18186961; 18187620; 18199332; 18199554; 18199957; 18202784; 18208799; 18208805; 18211286; 18216322; 18227705; 18231572; 18231801; 18234969; 18239063; 18240930; 18245470; 18245533; 18247373; 18253818; 18258923; 18261460; 18261621; 18262180; 18263768; 18269588; 18271526; 18271929; 18273061; 18276068; 18276593; 18281516; 18283321; 18285671; 18286687; 18288481; 18288638; 18289622; 18294142; 18302229; 18303429; 18304690; 18304967; 18307254; 18307528; 18307993; 18309947; 18313398; 18316398; 18317068; 18317074; 18317075; 18317076; 18317468; 18319245; 18325048; 18334834; 18337449; 18349392; 18355544; 18355939; 18358509; 18359760; 18372913; 18372921; 18374401; 18375753; 18379350; 18379357; 18379359; 18379370; 18379371; 18381415; 18381662; 18391747; 18391986; 18392851; 18396150; 18396688; 18397279; 18403609; 18407408; 18408761; 18413752; 18413774; 18413800; 18413808; 18418018; 18422739; 18424286; 18425114; 18429954; 18435854; 18440823; 18441011; 18443904; 18443966; 18448188; 18448545; 18448562; 18448997; 18448998; 18449007; 18449514; 18450321; 18451158; 18451246; 18455122; 18458038; 18463167; 18464244; 18472966; 18474653; 18478265; 18479591; 18483258; 18483367; 18497962; 18503159; 18507036; 18507100; 18508082; 18508816; 18508859; 18508924; 18509184; 18519677; 18519753; 18520805; 18522728; 18528288; 18528899; 18534028; 18534960; 18541260; 18541671; 18542056; 18542074; 18543225; 18544172; 18550772; 18558286; 18559552; 18559606; 18559607; 18568671; 18571764; 18577466; 18577517; 18577988; 18579759; 18580100; 18583573; 18587327; 18590726; 18593984; 18594011; 18594017; 18594314; 18594528; 18599591; 18602463; 18604200; 18617000; 18626007; 18632619; 18632638; 18632642; 18632722; 18637032; 18645679; 18650488; 18652519; 18653647; 18660793; 18664296; 18667434; 18670300; 18676680; 18676743; 18676744; 18676750; 18676761; 18676769; 18683042; 18683191; 18687326; 18687633; 18692120; 18694561; 18695910; 18700025; 18703609; 18704985; 18710625; 18710943; 18711136; 18712184; 18719212; 18722874; 18724389; 18726117; 18727093; 18751981; 18752056; 18754326; 18754871; 18758639; 18758819; 18760859; 18761794; 18762250; 18764928; 18768436; 18771282; 18772136; 18773861; 18776048; 18776588; 18782353; 18782770; 18785203; 18787418; 18787840; 18789131; 18789554; 18790560; 18794099; 18794545; 18799627; 18806258; 18811692; 18817771; 18819724; 18821783; 18824549; 18827604; 18827605; 18827621; 18829483; 18829487; 18829495; 18829558; 18832554; 18832597; 18839307; 18844239; 18932251; 18936523; 18937111; 18939958; 18942115; 18946768; 18949375; 18949739; 18950515; 18956645; 18957054; 18958173; 18978302; 18978556; 18983466; 18985033; 18985444; 18986301; 18987342; 18992959; 18995924; 18998063; 19002495; 19003996; 19005564; 19010870; 19014499; 19014905; 19016018; 19016767; 19016792; 19020749; 19020901; 19022848; 19026460; 19032382; 19033391; 19033715; 19034673; 19041782; 19047118; 19050706; 19054389; 19056486; 19057271; 19058870; 19060236; 19060928; 19061514; 19062522; 19063875; 19064572; 19064969; 19069650; 19070520; 19070659; 19074885; 19080004; 19086053; 19088172; 19088723; 19093231; 19094482; 19095777; 19096301; 19096302; 19096323; 19096324; 19102009; 19109251; 19110611; 19117057; 19118495; 19124464; 19129184; 19130320; 19133013; 19138820; 19138956; 19138957; 19141386; 19141999; 19143022; 19144635; 19145479; 19147502; 19147750; 19148516; 19148533; 19150933; 19153117; 19155296; 19156550; 19157151; 19158374; 19167335; 19169683; 19170196; 19172738; 19173907; 19174819; 19176518; 19179548; 19184415; 19185949; 19190079; 19190167; 19190334; 19196966; 19201048; 19201881; 19204207; 19213840; 19217205; 19218870; 19224850; 19225046; 19229860; 19234131; 19234440; 19235531; 19238210; 19238632; 19238633; 19247083; 19248552; 19250983; 19253367; 19254954; 19255323; 19255421; 19259093; 19260752; 19263517; 19265688; 19267104; 19267780; 19270482; 19270726; 19272638; 19276143; 19276157; 19276385; 19276677; 19283847; 19284481; 19287975; 19288191; 19289468; 19289583; 19294416; 19294521; 19297331; 19305428; 19307027; 19317849; 19318561; 19321755; 19329556; 19330625; 19331129; 19332363; 19332367; 19333077; 19336395; 19339632; 19342448; 19342999; 19347832; 19347870; 19348791; 19351721; 19351817; 19353596; 19353773; 19357847; 19360742; 19362747; 19364817; 19365146; 19366827; 19369630; 19371962; 19372140; 19374540; 19376842; 19380521; 19381876; 19391220; 19394555; 19403642; 19404216; 19404848; 19414352; 19414683; 19415121; 19415674; 19423651; 19427146; 19427850; 19429776; 19430813; 19432811; 19434314; 19435839; 19446582; 19447869; 19451802; 19453261; 19460345; 19460717; 19469909; 19473722; 19477549; 19479902; 19479974; 19483462; 19484958; 19487967; 19491261; 19491269; 19509284; 19515834; 19517135; 19525976; 19525979; 19529774; 19530244; 19531065; 19531499; 19531624; 19535298; 19538870; 19543508; 19544388; 19546243; 19550250; 19551138; 19558858; 19559406; 19563658; 19563760; 19568408; 19570984; 19578043; 19584155; 19584170; 19590514; 19596959; 19597153; 19597475; 19602593; 19602687; 19604315; 19609951; 19614729; 19617634; 19625176; 19631337; 19636371; 19640859; 19641380; 19643949; 19644445; 19648884; 19650855; 19657395; 19667264; 19669840; 19670535; 19670699; 19671676; 19671843; 19672706; 19673037; 19681124; 19687761; 19690143; 19692168; 19692652; 19692680; 19692684; 19697122; 19702827; 19704257; 19706809; 19713535; 19714638; 19716155; 19720911; 19723115; 19723633; 19723643; 19724844; 19724847; 19724887; 19726454; 19729990; 19735466; 19737945; 19740513; 19747398; 19751964; 19763255; 19763438; 19763916; 19766894; 19772171; 19776290; 19777258; 19777609; 19781441; 19786660; 19787273; 19789263; 19789347; 19789511; 19794963; 19798056; 19799519; 19799648; 19804359; 19808904; 19812598; 19815557; 19817696; 19820359; 19823871; 19825976; 19825997; 19826035; 19826477; 19830694; 19836242; 19840943; 19840952; 19841986; 19843645; 19844187; 19854533; 19855375; 19855437; 19859710; 19859802; 19860576; 19860811; 19861461; 19863329; 19864455; 19875972; 19878579; 19879874; 19881544; 19884551; 19884556; 19884861; 19886182; 19890352; 19893453; 19898258; 19903856; 19911255; 19911269; 19913121; 19917135; 19920104; 19922469; 19923826; 19923924; 19925033; 19946741; 19947250; 19947936; 19948031; 19948216; 19953087; 19954019; 19955396; 19956635; 19959837; 19963121; 19996104; 19997873; 20008630; 20009574; 20009914; 20010090; 20015198; 20018398; 20018733; 20022809; 20023269; 20027338; 20028750; 20029029; 20030876; 20035238; 20036807; 20036812; 20038312; 20038314; 20038315; 20038723; 20039046; 20040392; 20041268; 20044624; 20047592; 20048743; 20049516; 20050020; 20051017; 20056713; 20061986; 20062009; 20064931; 20068085; 20074357; 20075572; 20082263; 20082861; 20086093; 20086096; 20087229; 20093489; 20096104; 20100958; 20103621; 20107421; 20108024; 20113523; 20117855; 20117921; 20118913; 20118922; 20120857; 20120862; 20124108; 20124286; 20124471; 20127001; 20129251; 20131498; 20133782; 20133936; 20135199; 20135347; 20137294; 20137853; 20139181; 20140013; 20144468; 20144992; 20145033; 20146086; 20150826; 20154724; 20155428; 20156290; 20156584; 20156777; 20157331; 20159991; 20164030; 20167476; 20173022; 20183914; 20184776; 20186026; 20186030; 20188673; 20190820; 20193370; 20196851; 20197289; 20198317; 20198339; 20198342; 20199686; 20204273; 20207772; 20208477; 20208517; 20214974; 20215112; 20215522; 20216540; 20224722; 20236686; 20237940; 20302655; 20303140; 20303520; 20305620; 20332299; 20333651; 20335174; 20336783; 20347505; 20351035; 20351267; 20357714; 20359967; 20362227; 20367117; 20371674; 20372797; 20373052; 20381121; 20388507; 20388509; 20388781; 20395213; 20395290; 20398370; 20400478; 20405295; 20407013; 20408943; 20409020; 20409526; 20414936; 20418097; 20418893; 20421815; 20423982; 20424164; 20424473; 20428185; 20429940; 20430469; 20430735; 20439191; 20446891; 20447077; 20450543; 20453000; 20453886; 20458382; 20458561; 20459769; 20459770; 20459863; 20461251; 20462955; 20462956; 20462964; 20472851; 20473329; 20473902; 20473935; 20479403; 20489150; 20491625; 20491778; 20495538; 20497343; 20498858; 20502057; 20504250; 20506860; 20509930; 20509969; 20510673; 20512074; 20512075; 20512084; 20513767; 20519437; 20520724; 20522446; 20525715; 20530271; 20534535; 20534988; 20538600; 20540809; 20547458; 20548248; 20549828; 20552223; 20554524; 20554760; 20559149; 20559151; 20562913; 20563851; 20564212; 20565774; 20565817; 20570883; 20573926; 20579378; 20586028; 20586269; 20589169; 20592359; 20595147; 20595818; 20596631; 20604900; 20607659; 20608935; 20615575; 20615764; 20621735; 20622650; 20622897; 20624167; 20624322; 20627894; 20628086; 20630828; 20631634; 20631636; 20631637; 20634891; 20635387; 20637128; 20644561; 20647770; 20651357; 20653783; 20655838; 20661086; 20662834; 20664595; 20670598; 20671236; 20673501; 20674546; 20676128; 20685225; 20686428; 20688355; 20692258; 20693985; 20697298; 20702468; 20702788; 20705455; 20723374; 20723379; 20730556; 20734923; 20736164; 20739666; 20801220; 20802156; 20805561; 20808254; 20824716; 20824720; 20826789; 20828860; 20837704; 20838624; 20840671; 20840812; 20840818; 20842128; 20843314; 20844536; 20855820; 20855974; 20856226; 20859196; 20871266; 20871269; 20871631; 20873989; 20877636; 20877637; 20878056; 20881644; 20882990; 20884623; 20886633; 20887192; 20889674; 20923765; 20929928; 20933246; 20935677; 20937225; 20937558; 20937808; 20939760; 20940296; 20940297; 20942962; 20952227; 20956544; 20959404; 20959476; 20962551; 20962853; 20967766; 20973798; 20975603; 20978205; 20979823; 21029366; 21030498; 21036743; 21036744; 21040950; 21044682; 21046231; 21047778; 21052000; 21052789; 21057220; 21059755; 21059816; 21062933; 21067269; 21070477; 21078436; 21078678; 21080107; 21080109; 21080693; 21081655; 21083608; 21085658; 21087080; 21087480; 21094134; 21102258; 21104342; 21107284; 21107288; 21107857; 21109951; 21111811; 21122380; 21124760; 21127066; 21129606; 21132006; 21132379; 21135146; 21136383; 21139048; 21150674; 21155184; 21155880; 21156006; 21156237; 21157443; 21159244; 21159248; 21159653; 21165163; 21172876; 21173154; 21173787; 21178714; 21178715; 21187500; 21187519; 21190959; 21203460; 21209099; 21212278; 21214269; 21215239; 21220318; 21220477; 21221850; 21223687; 21225506; 21226813; 21227963; 21240064; 21243324; 21245103; 21252234; 21252719; 21252721; 21252723; 21257709; 21257711; 21257719; 21258250; 21258366; 21258405; 21262974; 21264347; 21264531; 21264542; 21266046; 21268077; 21268712; 21270615; 21273576; 21273581; 21275429; 21275903; 21276138; 21284055; 21289483; 21292787; 21292812; 21298351; 21300759; 21300824; 21315473; 21317742; 21317745; 21318227; 21320340; 21321939; 21325256; 21325639; 21343351; 21346384; 21352258; 21352589; 21354913; 21356164; 21356361; 21362302; 21365510; 21382632; 21383692; 21385353; 21388911; 21391216; 21393993; 21396117; 21400669; 21404106; 21407195; 21408138; 21409490; 21411223; 21411993; 21414214; 21419811; 21420271; 21423210; 21424032; 21426301; 21430781; 21436633; 21437912; 21439039; 21439278; 21440529; 21440548; 21441380; 21444121; 21444717; 21449913; 21454012; 21454519; 21455841; 21457545; 21467228; 21471286; 21472131; 21473138; 21474065; 21478220; 21478906; 21486282; 21487020; 21492463; 21495621; 21497370; 21498106; 21498706; 21501367; 21502435; 21505178; 21508312; 21508367; 21512404; 21516087; 21518597; 21524465; 21525012; 21527506; 21530363; 21531776; 21531791; 21532887; 21544811; 21546588; 21550229; 21556796; 21557297; 21558399; 21562037; 21570215; 21571640; 21573184; 21575252; 21586793; 21587084; 21590492; 21592614; 21592959; 21596750; 21597390; 21604062; 21604158; 21605009; 21606674; 21607772; 21610522; 21620944; 21622099; 21622718; 21622856; 21623266; 21635547; 21635552; 21635887; 21645455; 21645456; 21653320; 21655094; 21656832; 21665183; 21665306; 21665310; 21676478; 21680035; 21681118; 21681119; 21681971; 21684622; 21687954; 21690342; 21694725; 21701776; 21702909; 21704408; 21706016; 21709263; 21717480; 21720997; 21722621; 21725039; 21729650; 21729651; 21729655; 21730270; 21731744; 21733594; 21734175; 21737508; 21739478; 21741919; 21748758; 21750651; 21751261; 21757638; 21761100; 21761335; 21764376; 21768093; 21771097; 21772844; 21775008; 21778168; 21778941; 21782877; 21786419; 21791074; 21800041; 21805028; 21810691; 21811765; 21821699; 21822280; 21827828; 21829671; 21830212; 21831204; 21831696; 21832070; 21832242; 21839716; 21841502; 21845536; 21847041; 21847509; 21852109; 21853092; 21857648; 21858063; 21858220; 21865399; 21869714; 21874828; 21884205; 21890473; 21896743; 21896992; 21897861; 21903449; 21906983; 21909139; 21911055; 21921847; 21924037; 21925169; 21928319; 21933587; 21934107; 21934337; 21939503; 21945923; 21946890; 21947301; 21949687; 21949883; 21951562; 21953075; 21960689; 21963094; 21965733; 21966417; 21970318; 21975932; 21976538; 21979953; 21982220; 21982684; 21985857; 21986139; 21986942; 21989899; 21990321; 21994417; 21998569; 21999128; 22001862; 22005476; 22006985; 22007939; 22011285; 22017370; 22020299; 22025675; 22026926; 22029196; 22032640; 22034878; 22036089; 22037177; 22037462; 22039281; 22045810; 22048943; 22050898; 22053213; 22056021; 22056988; 22061963; 22069315; 22069319; 22072864; 22075159; 22077956; 22080568; 22081067; 22082529; 22087246; 22088438; 22089237; 22093627; 22101132; 22101325; 22101934; 22102283; 22103444; 22103903; 22110740; 22116317; 22117074; 22126484; 22128196; 22129360; 22130585; 22130903; 22132240; 22132735; 22134479; 22135231; 22137795; 22139077; 22139427; 22154363; 22157369; 22157681; 22157759; 22157931; 22158046; 22158416; 22159558; 22161771; 22161775; 22162832; 22173702; 22173705; 22177492; 22177532; 22178589; 22179693; 22179831; 22190593; 22192147; 22193779; 22194952; 22198508; 22198722; 22199274; 22199315; 22200661; 22200885; 22203672; 22203921; 22209037; 22209766; 22213299; 22213300; 22213301; 22217347; 22223435; 22228639; 22228640; 22231447; 22231449; 22232519; 22237259; 22237264; 22238366; 22238402; 22241957; 22247545; 22250084; 22252115; 22252323; 22256804; 22260659; 22260687; 22260689; 22260839; 22261712; 22264301; 22266821; 22267755; 22268729; 22271412; 22272264; 22281980; 22282022; 22285168; 22287728; 22292774; 22294553; 22298428; 22299055; 22300665; 22306870; 22311673; 22313637; 22315226; 22316125; 22316604; 22317764; 22321154; 22321541; 22321542; 22321543; 22321545; 22321546; 22321547; 22323579; 22323597; 22325225; 22327010; 22333974; 22335887; 22337768; 22340046; 22340169; 22343486; 22344462; 22348136; 22349823; 22349826; 22351687; 22359227; 22370483; 22384099; 22384257; 22386733; 22393153; 22394363; 22394513; 22397762; 22401280; 22406363; 22407299; 22410386; 22411794; 22412050; 22412142; 22417006; 22417132; 22422135; 22426079; 22426479; 22426987; 22429811; 22430133; 22430206; 22435662; 22437320; 22438585; 22441881; 22449226; 22450744; 22451676; 22451678; 22460425; 22471663; 22472120; 22472960; 22473698; 22475688; 22480520; 22490401; 22492281; 22492316; 22492960; 22493441; 22506430; 22510844; 22511543; 22516751; 22521649; 22523180; 22523351; 22524660; 22525557; 22525675; 22526156; 22528563; 22534548; 22537942; 22540299; 22546605; 22552271; 22552284; 22552355; 22553175; 22554477; 22562124; 22569898; 22573488; 22575880; 22577141; 22579287; 22581387; 22581837; 22586492; 22590625; 22591401; 22592160; 22593433; 22607702; 22610259; 22611165; 22613337; 22623992; 22626691; 22627040; 22643351; 22649008; 22653055; 22662165; 22662167; 22665120; 22666783; 22668015; 22672426; 22674781; 22677909; 22682934; 22684234; 22692198; 22693070; 22694907; 22700994; 22703031; 22704618; 22706026; 22706608; 22707299; 22710717; 22713695; 22718763; 22721997; 22722798; 22729835; 22729867; 22732145; 22732796; 22733137; 22733437; 22736493; 22751098; 22760226; 22770632; 22773576; 22773810; 22781040; 22784503; 22791816; 22797061; 22797070; 22797360; 22799630; 22800866; 22810499; 22810896; 22810899; 22815474; 22815900; 22818908; 22824264; 22825057; 22826274; 22826471; 22833420; 22833562; 22833676; 22836289; 22843317; 22843679; 22847519; 22848341; 22848739; 22851037; 22851748; 22854050; 22855173; 22855500; 22858585; 22859339; 22865467; 22868530; 22871376; 22882865; 22883469; 22883988; 22885469; 22886086; 22888118; 22895139; 22895145; 22899358; 22899566; 22901364; 22920680; 22923485; 22923609; 22936342; 22939629; 22946088; 22952062; 22952420; 22952709; 22952966; 22957061; 22963397; 22964225; 22968441; 22974559; 22975156; 22977193; 22982650; 22982659; 22982663; 22984561; 22988250; 22988345; 23000965; 23007009; 23011826; 23012408; 23014527; 23015403; 23018838; 23019362; 23021375; 23026641; 23027125; 23028094; 23028720; 23033949; 23036155; 23042483; 23045285; 23046567; 23046633; 23049743; 23055340; 23059777; 23064060; 23069713; 23074112; 23076445; 23086434; 23086695; 23088930; 23089711; 23093229; 23099361; 23100515; 23102841; 23110505; 23110940; 23114230; 23114924; 23115635; 23118721; 23119029; 23122929; 23123196; 23129763; 23133535; 23134665; 23136247; 23137868; 23142484; 23145173; 23152903; 23153332; 23153581; 23154542; 23154552; 23154553; 23154565; 23154768; 23158001; 23163584; 23172893; 23174662; 23174717; 23175185; 23181982; 23185433; 23188822; 23200589; 23205726; 23207070; 23207445; 23212463; 23212918; 23213241; 23219092; 23219876; 23220022; 23220854; 23222715; 23224067; 23225576; 23225805; 23232551; 23234355; 23236232; 23236348; 23238037; 23238254; 23239743; 23242174; 23242438; 23242442; 23242808; 23244191; 23246576; 23249714; 23250739; 23261144; 23265235; 23265711; 23265944; 23273428; 23273562; 23274758; 23274876; 23282210; 23287719; 23287850; 23291256; 23291982; 23297824; 23302304; 23302311; 23306155; 23307237; 23313171; 23313300; 23314677; 23317280; 23318430; 23318459; 23319610; 23328547; 23328701; 23333852; 23337026; 23341890; 23349873; 23350658; 23352033; 23358982; 23359207; 23359693; 23361279; 23363301; 23364874; 23370527; 23371026; 23371856; 23374155; 23374349; 23374350; 23378269; 23384599; 23384673; 23387315; 23387505; 23392229; 23397762; 23399900; 23404504; 23404538; 23407558; 23408463; 23410174; 23411345; 23413122; 23416450; 23418353; 23418425; 23419507; 23423768; 23425899; 23429996; 23435217; 23441167; 23443279; 23449277; 23456637; 23457600; 23461856; 23464964; 23465277; 23468578; 23468851; 23470965; 23472148; 23472669; 23477725; 23485129; 23486266; 23486275; 23486338; 23491080; 23494210; 23495083; 23499740; 23513863; 23514946; 23517177; 23520442; 23520446; 23521519; 23525704; 23532252; 23536719; 23540867; 23546020; 23548265; 23548963; 23555046; 23555641; 23558893; 23559009; 23563092; 23564810; 23564819; 23565769; 23569038; 23575413; 23575414; 23581229; 23583406; 23589287; 23590575; 23594562; 23595626; 23599147; 23601297; 23602387; 23608326; 23614656; 23617883; 23620765; 23620784; 23625205; 23628526; 23633480; 23635774; 23636329; 23638794; 23643362; 23644172; 23650389; 23651790; 23653350; 23661635; 23665199; 23668355; 23675485; 23677180; 23685782; 23686431; 23690991; 23693078; 23698466; 23700486; 23704979; 23707073; 23707413; 23710458; 23720781; 23721103; 23722667; 23729361; 23729401; 23731208; 23736812; 23744486; 23744832; 23746767; 23749785; 23754287; 23754386; 23757022; 23758840; 23763474; 23764002; 23764753; 23765179; 23765574; 23771370; 23774213; 23774386; 23780873; 23786162; 23786997; 23787814; 23790025; 23791006; 23791944; 23792604; 23799367; 23799848; 23806066; 23817698; 23822636; 23827764; 23841084; 23844533; 23850692; 23861540; 23866081; 23867504; 23871709; 23880166; 23886169; 23888049; 23892415; 23897813; 23897956; 23903906; 23908594; 23909080; 23909081; 23916913; 23921085; 23927961; 23932319; 23932718; 23938604; 23940030; 23945382; 23945384; 23945389; 23945392; 23948418; 23956138; 23966299; 23966300; 23972990; 23974272; 23986462; 23990774; 23991943; 23991992; 23994953; 23999497; 24002608; 24007863; 24012640; 24014028; 24015256; 24019463; 24034250; 24038070; 24043629; 24046058; 24053674; 24055032; 24058967; 24063894; 24067727; 24075601; 24076656; 24082147; 24091658; 24113009; 24120917; 24135280; 24142702; 24145651; 24170107; 24189400; 24200637; 24211838; 24216759; 24222141; 24222150; 24222153; 24240702; 24253040; 24278442; 24304721; 24369725; 24391216; 24404585; 24413169; 24439929; 24457318; 24510991,,,,,,,,,,,,,,,OGG:3000001956,,,,,,,epidermal growth factor receptor,,,,,,,,,,,,,Other designations: avian erythroblastic leukemia viral (v-erb-b) oncogene homolog|cell growth inhibiting protein 40|cell proliferation-inducing protein 61|proto-oncogene c-ErbB-1|receptor tyrosine-protein kinase erbB-1,,EGFR,,,,,,,,,,,,,,,,,,,,,,,1956,,,,,,,,9606,,,,,,,,,,,,,,,,,,,EGFR,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001958,EGR1,,Other designations: EGR-1|early growth response protein 1|nerve growth factor-induced protein A|transcription factor ETR103|transcription factor Zif268|zinc finger protein 225|zinc finger protein Krox-24,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,ZNF225|ZIF-268|KROX-24|G0S30|NGFI-A|TIS8|AT225,,,,,,,,,,,,5,,,,,,Ensembl:ENSG00000120738|HGNC:3238|HPRD:00549|MIM:128990|Vega:OTTHUMG00000129197,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,early growth response 1,,,5q31.1,,,,,,,,,,,,,,,,"GO_0000122 (EC: IEA); GO_0000976 (EC: IDA, PMID: 18718911); GO_0000979 (EC: IEA); GO_0001077 (EC: IEA); GO_0001975 (EC: IEA); GO_0003677 (EC: IDA, PMID: 12560508); GO_0003690 (EC: IEA); GO_0003700 (EC: IDA, PMID: 12560508); GO_0005515 (EC: IPI, PMID: 14979875); GO_0005634 (EC: IDA); GO_0005634 (EC: ISS); GO_0005654 (EC: TAS); GO_0005730 (EC: IDA, Qualifier: NOT); GO_0005737 (EC: IDA, PMID: 19057511); GO_0005737 (EC: ISS); GO_0006366 (EC: IDA, PMID: 19057511); GO_0007611 (EC: IEA); GO_0007623 (EC: IEA); GO_0008134 (EC: IEA); GO_0009749 (EC: IEA); GO_0019221 (EC: TAS); GO_0030217 (EC: IEA); GO_0030509 (EC: IEA); GO_0031667 (EC: IEA); GO_0032869 (EC: IEA); GO_0033233 (EC: IDA, PMID: 19057511); GO_0034465 (EC: IEA); GO_0035035 (EC: IPI); GO_0035690 (EC: IEA); GO_0035914 (EC: IBA); GO_0042220 (EC: IEA); GO_0043066 (EC: IBA); GO_0043525 (EC: IEA); GO_0043565 (EC: IDA, PMID: 1662794); GO_0045471 (EC: IEA); GO_0045893 (EC: IDA, PMID: 12560508); GO_0045944 (EC: IDA, PMID: 19057511); GO_0045944 (EC: IMP); GO_0046872 (EC: IEA); GO_0048169 (EC: IBA); GO_0048709 (EC: IEA); GO_0051602 (EC: IEA); GO_0060291 (EC: IEA); GO_0060337 (EC: TAS); GO_0070498 (EC: IMP); GO_0071236 (EC: IEA); GO_0071260 (EC: IEA); GO_0071317 (EC: IEA); GO_0071320 (EC: IBA); GO_0071363 (EC: IEA); GO_0071371 (EC: IBA); GO_0071372 (EC: IEA); GO_0071383 (EC: IEA); GO_0071455 (EC: IEA); GO_0071456 (EC: IEA); GO_0071480 (EC: IEA); GO_0071504 (EC: ISS); GO_0071506 (EC: ISS); GO_0071873 (EC: IEA); GO_0072110 (EC: ISS); GO_0072303 (EC: ISS); GO_0090090 (EC: IEA)",,,,,,,,,PMID: 1090709; 1383501; 1411083; 1569051; 1662794; 1702972; 2109185; 2110381; 2377485; 3127059; 3839394; 7624335; 8662759; 8668170; 9806899; 10049687; 10051405; 10079243; 10082522; 10409428; 10575214; 10671503; 10806043; 10849212; 11124866; 11251186; 11278640; 11795984; 11819815; 11830539; 11909874; 11925592; 11956220; 11978801; 12011097; 12065847; 12165491; 12235180; 12379479; 12384223; 12393577; 12433834; 12439908; 12456801; 12457461; 12470865; 12477932; 12507899; 12517959; 12543866; 12553019; 12553721; 12560487; 12560508; 12566441; 12569082; 12571843; 12618431; 12637574; 12690110; 12706485; 12729460; 12840049; 12872165; 12890669; 12947119; 12958075; 14522979; 14662774; 14722058; 14744935; 14966901; 14979875; 14985468; 15003938; 15023995; 15155664; 15211096; 15225550; 15231681; 15449318; 15486985; 15489334; 15517593; 15523672; 15545275; 15548700; 15611055; 15616591; 15640148; 15689620; 15709168; 15875316; 15910736; 15923644; 15999367; 16007175; 16079301; 16091742; 16093249; 16260776; 16382041; 16393964; 16464174; 16552541; 16702209; 16741963; 16831524; 16858414; 16995904; 17099140; 17257596; 17420284; 17448597; 17494953; 17502875; 17516844; 17559061; 17581316; 17599039; 17631285; 17631291; 17671831; 17932312; 17967787; 17975260; 17986608; 18027854; 18067864; 18068676; 18088351; 18171299; 18174470; 18204200; 18215136; 18247371; 18281035; 18281687; 18303024; 18316600; 18324520; 18434015; 18434089; 18435749; 18460021; 18469860; 18489490; 18507785; 18515748; 18525291; 18583706; 18604866; 18636116; 18675783; 18682391; 18704310; 18711316; 18718911; 18772333; 18780286; 18830406; 18842581; 18989526; 19032775; 19050264; 19057511; 19067769; 19074480; 19074849; 19112164; 19115247; 19131339; 19152168; 19245972; 19261809; 19276347; 19307156; 19307576; 19374776; 19426596; 19432968; 19435811; 19446747; 19467232; 19526316; 19724854; 19747485; 19765320; 19781349; 19786090; 19822898; 19833116; 19837667; 19837979; 19878561; 19885607; 19888474; 19913601; 19915002; 19940138; 20009530; 20016208; 20018936; 20053757; 20087343; 20121949; 20144677; 20190820; 20204305; 20348948; 20363028; 20372793; 20398657; 20403028; 20414733; 20448047; 20489156; 20506119; 20507991; 20578042; 20585888; 20621662; 20690147; 20811575; 20862322; 20864524; 20936779; 20945384; 21118966; 21160498; 21189327; 21212994; 21224049; 21297666; 21321112; 21325822; 21336263; 21354100; 21354147; 21365018; 21368226; 21419860; 21436631; 21479245; 21489990; 21506108; 21551235; 21596316; 21617851; 21688838; 21725089; 21743491; 21743958; 21791614; 21931594; 21968973; 21995436; 21998680; 22053691; 22095683; 22115966; 22127986; 22140445; 22198386; 22260630; 22316125; 22344601; 22354777; 22428032; 22431919; 22433566; 22455954; 22508482; 22531302; 22634339; 22659570; 22713211; 22721276; 22832523; 22878149; 22912725; 22918686; 23029358; 23103837; 23121767; 23127556; 23142458; 23152075; 23178451; 23363221; 23409769; 23416169; 23433111; 23468057; 23478574; 23592216; 23632636; 23696025; 23715767; 23718776; 23755764; 23857582; 23874821; 24076422; 24098051; 24106272,,,,,,,,,,,,,,,OGG:3000001958,,,,,,,early growth response 1,,,,,,,,,,,,,Other designations: EGR-1|early growth response protein 1|nerve growth factor-induced protein A|transcription factor ETR103|transcription factor Zif268|zinc finger protein 225|zinc finger protein Krox-24,,EGR1,,,,,,,,,,,,,,,,,,,,,,,1958,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,EGR1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001950,EGF,,Other designations: beta-urogastrone|pro-epidermal growth factor,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,HOMG4|URG,,,,,,,,,,,,4,,,,,,MIM:131530|HPRD:00578|Vega:OTTHUMG00000132044|Ensembl:ENSG00000138798|HGNC:3229,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,epidermal growth factor,,,4q25,,,,,,,,,,,,,,,,"GO_0000186 (EC: IEA); GO_0001525 (EC: IDA, PMID:15611079); GO_0002576 (EC: TAS); GO_0005154 (EC: TAS, PMID:15611079); GO_0005509 (EC: IEA); GO_0005515 (EC: IPI, PMID:12297050); GO_0005576 (EC: IC, PMID:9712850); GO_0005576 (EC: TAS); GO_0005615 (EC: IEA); GO_0005765 (EC: IDA, PMID:17897319); GO_0005886 (EC: IEA); GO_0006260 (EC: TAS, PMID:9482941); GO_0007165 (EC: TAS); GO_0007171 (EC: TAS, PMID:9712850); GO_0007173 (EC: TAS); GO_0007262 (EC: ISS); GO_0007596 (EC: TAS); GO_0008083 (EC: IDA, PMID:15611079); GO_0008284 (EC: IDA, PMID:15611079); GO_0008543 (EC: TAS); GO_0010800 (EC: IDA, PMID:16314496); GO_0016021 (EC: IEA); GO_0018108 (EC: IEA); GO_0021940 (EC: IEA); GO_0030168 (EC: TAS); GO_0030297 (EC: TAS, PMID:9712850); GO_0031093 (EC: TAS); GO_0035413 (EC: IDA); GO_0038095 (EC: TAS); GO_0042059 (EC: TAS); GO_0042327 (EC: IDA, PMID:15611079); GO_0043388 (EC: ISS); GO_0043406 (EC: IDA, PMID:15611079); GO_0045087 (EC: TAS); GO_0045741 (EC: IDA, PMID:15611079); GO_0045741 (EC: TAS, PMID:9712850); GO_0045840 (EC: IDA, PMID:15611079); GO_0045893 (EC: IDA, PMID:16314496); GO_0048011 (EC: TAS); GO_0048015 (EC: TAS); GO_0048754 (EC: IEA); GO_0051048 (EC: IDA, PMID:10559227); GO_0060749 (EC: IEA); GO_0070062 (EC: IDA, PMID:19056867); GO_0070371 (EC: IDA, PMID:16314496); GO_0090279 (EC: IDA, PMID:19996314); GO_0090370 (EC: IEA); GO_1900127 (EC: IDA, PMID:17324121); GO_2000008 (EC: IDA, PMID:19996314); GO_2000060 (EC: IEA)",,,,,,,,,PMID:300079; 1281549; 1334406; 1501243; 1522591; 1639032; 2789514; 2790960; 3486749; 3491360; 6290982; 6382023; 6603475; 7540053; 7558411; 7615511; 7640657; 7730382; 7736574; 8077234; 8123596; 8413296; 8419140; 8639530; 8796265; 8845374; 9188692; 9356464; 9482941; 9544989; 9661876; 9687510; 9712850; 9925763; 10085134; 10199559; 10436156; 10559227; 10567358; 10579352; 10648629; 10734310; 10748174; 10788520; 10913131; 10973965; 11438527; 11751923; 11786904; 11796824; 11823423; 11844511; 11894095; 11896055; 11903419; 11914075; 11925427; 11950840; 11971908; 11994282; 12009575; 12093292; 12138086; 12141529; 12163055; 12163506; 12192610; 12202942; 12218189; 12297050; 12368284; 12388817; 12397374; 12425525; 12477932; 12508124; 12531699; 12540376; 12593796; 12620237; 12637502; 12643788; 12667326; 12672817; 12722480; 12768436; 12788694; 12795334; 12879019; 12954631; 12960147; 14507446; 14520709; 14523024; 14560030; 14614718; 14651960; 14662770; 14665621; 14676838; 15003992; 15063762; 15081423; 15087376; 15129177; 15175028; 15180992; 15183666; 15192046; 15194442; 15252009; 15256384; 15260478; 15272014; 15329330; 15373781; 15373782; 15373802; 15475003; 15481560; 15485655; 15485674; 15488707; 15489334; 15491342; 15509542; 15536154; 15574420; 15611079; 15613483; 15620700; 15622242; 15659382; 15663953; 15675968; 15729146; 15735691; 15748906; 15798095; 15802268; 15837620; 15860930; 15886816; 15901830; 15913871; 15950078; 15950906; 15962011; 15982634; 16019439; 16033767; 16115648; 16134968; 16210470; 16214932; 16248985; 16274239; 16274250; 16282324; 16314496; 16316319; 16332692; 16344560; 16407418; 16407834; 16413767; 16428382; 16436184; 16584205; 16636672; 16691190; 16728406; 16762922; 16788380; 16820871; 16837648; 16847055; 16872636; 16885506; 16939220; 16946702; 16969495; 16979250; 17123472; 17175377; 17204151; 17223314; 17227756; 17311928; 17316357; 17324121; 17334773; 17392355; 17397984; 17433039; 17453000; 17473192; 17479438; 17545148; 17562024; 17567965; 17573555; 17578349; 17612563; 17617058; 17626784; 17634901; 17661145; 17673689; 17762162; 17851837; 17852426; 17897319; 17898861; 17912028; 17940864; 17943082; 17950068; 17962208; 17968796; 17986122; 17991726; 17991733; 18006148; 18036246; 18080773; 18088275; 18094008; 18096367; 18156174; 18167406; 18187620; 18212060; 18271526; 18271972; 18276761; 18292095; 18325497; 18349392; 18365874; 18382118; 18398039; 18434322; 18441095; 18463167; 18467441; 18483390; 18485152; 18487214; 18490463; 18511414; 18519765; 18543351; 18571008; 18583979; 18632979; 18676680; 18722874; 18757521; 18773861; 18813355; 18831963; 18844210; 18990689; 19010984; 19011936; 19014905; 19020743; 19032382; 19056867; 19064572; 19073827; 19074885; 19081071; 19086053; 19087984; 19110611; 19124506; 19127217; 19141999; 19144868; 19167371; 19170196; 19172394; 19179548; 19203995; 19236842; 19319135; 19336395; 19380191; 19388850; 19403524; 19415484; 19453261; 19460345; 19470771; 19484147; 19488063; 19491269; 19492417; 19520791; 19531499; 19544388; 19549686; 19549816; 19592671; 19604397; 19608641; 19619867; 19624835; 19625176; 19634110; 19670348; 19692168; 19708171; 19727227; 19749156; 19817957; 19823871; 19834535; 19840254; 19840943; 19853299; 19880507; 19887603; 19895983; 19896111; 19900104; 19913121; 19920151; 19921131; 19951549; 19953086; 19996314; 20033794; 20036812; 20092031; 20101173; 20108217; 20126978; 20127414; 20157331; 20158379; 20164030; 20169434; 20197289; 20201065; 20201926; 20203692; 20207214; 20303009; 20332099; 20351270; 20362419; 20364107; 20375273; 20379614; 20398806; 20412119; 20418097; 20423485; 20424473; 20429940; 20430735; 20444693; 20453000; 20466569; 20472833; 20482449; 20487573; 20498653; 20514023; 20564212; 20587610; 20598233; 20606012; 20621058; 20628086; 20628624; 20631636; 20634891; 20644561; 20674545; 20690902; 20714325; 20727496; 20727996; 20800603; 20818748; 20819124; 20830310; 20832399; 20851879; 20854793; 20889718; 20963824; 20969541; 21029725; 21048224; 21062739; 21087604; 21099256; 21123997; 21186997; 21187523; 21209099; 21212517; 21224998; 21236296; 21247755; 21273531; 21274378; 21309478; 21358296; 21376205; 21436680; 21439278; 21533003; 21567271; 21678081; 21752154; 21868386; 21872446; 21971700; 21982438; 22022452; 22033246; 22070650; 22087246; 22106858; 22122913; 22129558; 22236006; 22279551; 22293333; 22308022; 22401280; 22403631; 22404757; 22413835; 22416276; 22433566; 22457050; 22479527; 22479638; 22481252; 22493503; 22503865; 22504456; 22505024; 22532606; 22534548; 22574813; 22578596; 22621366; 22668508; 22677173; 22701712; 22721997; 22727668; 22745586; 22773267; 22782629; 22797360; 22829589; 22829952; 22852842; 22914212; 22925500; 22951723; 22990108; 23007402; 23090954; 23188118; 23201894; 23219876; 23229345; 23382691; 23403233; 23419149; 23457387; 23466131; 23542467; 23577098; 23608378; 23631828; 23645212; 23689072; 23711349; 23731208; 23790025; 23843455; 23869217; 23869762; 23899513; 23902938; 23936413; 23963773; 24036907; 24043306; 24045955,,,,,http://purl.obolibrary.org/obo/TXPO_0000624,,,,,,,,,,OGG:3000001950,,,,,,,epidermal growth factor,,,,,,,,,,,,,Other designations: beta-urogastrone|pro-epidermal growth factor,,EGF,,,,,,,,,,,,,,,,,,,,,,,1950,,,,,,,,9606,,,,,,,,,,,,,,,,,,,EGF,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0001968,Epac1,Epac|cAMP-GEFI,,false,,,http://purl.obolibrary.org/obo/IMR_0001967,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Epac|cAMP-GEFI,,,,,IMR:0001968,,,,,,,,,,,,,,,,,,,,,,Epac1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0002193,hemolymphoid system,haemolymphoid system|hematolymphoid system|lymphomyeloid complex,"Anatomical cluster consisting of the hematopoietic system and the lymphoid system, or its analogs.",false,,,http://purl.obolibrary.org/obo/UBERON_0000467,,,,,,,,,,,,,,,,,,,,EMAPA:18765|FMA:74562|EHDAA2:0004615|CALOHA:TS-2018|MA:0000013,,"Anatomical cluster consisting of the hematopoietic system and the lymphoid system, or its analogs.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,hematolymphoid system|lymphomyeloid complex,,haemolymphoid system,,,UBERON:0002193,,,,,,,,,,,,,,,,,,,,,,hemolymphoid system,,,,,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100119,glutamic acid,L-Glutaminic acid|L-Glutamic acid|L-Glutamate,,false,,,http://purl.obolibrary.org/obo/CHEBI_33709,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_25512,,,,IMR:0200156,L-Glutaminic acid|L-Glutamic acid|L-Glutamate,,,,,IMR:0100119,,,,,,,,,,,,,,,,,,,,,,glutamic acid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000083695,RHNO1,,"Other designations: RAD9, HUS1, RAD1-interacting nuclear orphan protein 1|Rad9, Rad1, Hus1 interacting nuclear orphan|rAD9, RAD1, HUS1-interacting nuclear orphan protein",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,C12orf32|RHINO,,,,,,,,,,,,12,,,,,,HGNC:28206|HPRD:17487|Vega:OTTHUMG00000158557|MIM:614085|Ensembl:ENSG00000171792,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,RAD9-HUS1-RAD1 interacting nuclear orphan 1,,,12p13.33,,,,,,,,,,,,,,,,GO_0000077 (EC: IMP); GO_0000725 (EC: IMP); GO_0005515 (EC: IPI); GO_0005634 (EC: IDA); GO_0005694 (EC: IDA); GO_0034644 (EC: IDA); GO_0070318 (EC: IMP); GO_0071479 (EC: IDA),,,,,,,,,PMID: 11414747; 12477932; 14702039; 15221005; 15489334; 16341674; 16344560; 17525332; 19322201; 20811708; 21145461; 21659603,,,,,,,,,,,,,,,OGG:3000083695,,20140408,protein-coding,,,,RAD9-HUS1-RAD1 interacting nuclear orphan 1,,,,,,,,,,,,,"Other designations: RAD9, HUS1, RAD1-interacting nuclear orphan protein 1|Rad9, Rad1, Hus1 interacting nuclear orphan|rAD9, RAD1, HUS1-interacting nuclear orphan protein",,RHNO1,,,,,,,,,,,,,,,,,,,,,,,83695,HKMT1188,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,RHNO1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_76807,EC 3.5.1.* (non-peptide linear amide C-N hydrolase) inhibitor,EC 3.5.1.* inhibitors|EC 3.5.1.* (non-peptide linear amide C-N hydrolase) inhibitors|non-peptide linear amide C-N hydrolase (EC 3.5.1.*) inhibitor|EC 3.5.1.* inhibitor|non-peptide linear amide C-N hydrolase (EC 3.5.1.*) inhibitors,An EC 3.5.* (hydrolases acting on non-peptide C-N bonds) inhibitor that interferes with the action of any non-peptide linear amide C-N hydrolase (EC 3.5.1.*).,false,,,http://purl.obolibrary.org/obo/CHEBI_76764,,,,,,,,,,,,,,,,,,,,,,An EC 3.5.* (hydrolases acting on non-peptide C-N bonds) inhibitor that interferes with the action of any non-peptide linear amide C-N hydrolase (EC 3.5.1.*).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,EC 3.5.1.* inhibitors|EC 3.5.1.* (non-peptide linear amide C-N hydrolase) inhibitors|non-peptide linear amide C-N hydrolase (EC 3.5.1.*) inhibitor|EC 3.5.1.* inhibitor|non-peptide linear amide C-N hydrolase (EC 3.5.1.*) inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:76807,,,,EC 3.5.1.* (non-peptide linear amide C-N hydrolase) inhibitor,,CHEBI:76807,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0005777,peroxisome,,"A small organelle enclosed by a single membrane, and found in most eukaryotic cells. Contains peroxidases and other enzymes involved in a variety of metabolic processes including free radical detoxification, lipid catabolism and biosynthesis, and hydrogen peroxide metabolism.",false,,,http://purl.obolibrary.org/obo/GO_0042579,,,,,,,,,,,,,,,,,,,,,,"A small organelle enclosed by a single membrane, and found in most eukaryotic cells. Contains peroxidases and other enzymes involved in a variety of metabolic processes including free radical detoxification, lipid catabolism and biosynthesis, and hydrogen peroxide metabolism.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005737,GO:0005777,http://purl.obolibrary.org/obo/GO_0005737,,,,,,,,,,,,,,,,,,,,,peroxisome,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0005773,vacuole,,"A closed structure, found only in eukaryotic cells, that is completely surrounded by unit membrane and contains liquid material. Cells contain one or several vacuoles, that may have different functions from each other. Vacuoles have a diverse array of functions. They can act as a storage organelle for nutrients or waste products, as a degradative compartment, as a cost-effective way of increasing cell size, and as a homeostatic regulator controlling both turgor pressure and pH of the cytosol.",false,,,http://purl.obolibrary.org/obo/GO_0043227,,,,,,,,,,,,,,,,,,,,Wikipedia:Vacuole,,"A closed structure, found only in eukaryotic cells, that is completely surrounded by unit membrane and contains liquid material. Cells contain one or several vacuoles, that may have different functions from each other. Vacuoles have a diverse array of functions. They can act as a storage organelle for nutrients or waste products, as a degradative compartment, as a cost-effective way of increasing cell size, and as a homeostatic regulator controlling both turgor pressure and pH of the cytosol.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005737,GO:0005773,http://purl.obolibrary.org/obo/GO_0005737,,,,,,,,,,,,,,,,,,,,,vacuole,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0005770,late endosome,,"A prelysosomal endocytic organelle differentiated from early endosomes by lower lumenal pH and different protein composition. Late endosomes are more spherical than early endosomes and are mostly juxtanuclear, being concentrated near the microtubule organizing center.",false,,,http://purl.obolibrary.org/obo/GO_0005768,,,,,,,,,,,,,,,,,,,,,,"A prelysosomal endocytic organelle differentiated from early endosomes by lower lumenal pH and different protein composition. Late endosomes are more spherical than early endosomes and are mostly juxtanuclear, being concentrated near the microtubule organizing center.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0005770,,,,,,,,,,,,,,,,,,,,,,late endosome,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0005776,autophagosome,,A double-membrane-bounded compartment that engulfs endogenous cellular material as well as invading microorganisms to target them to the vacuole/lysosome for degradation as part of macroautophagy.,false,,,http://purl.obolibrary.org/obo/GO_0005773,,,,,,,,,,,,,,,,,,,,,,A double-membrane-bounded compartment that engulfs endogenous cellular material as well as invading microorganisms to target them to the vacuole/lysosome for degradation as part of macroautophagy.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0005776,,,,,,,,,,,,,,,,,,,,,,autophagosome,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004853,UHRF1 inactivation,,UHRF1 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the UHRF1 (ubiquitin like with PHD and ring finger domains 1) to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000021,,,,,,,,,,,,,,,,,,,,,,UHRF1 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the UHRF1 (ubiquitin like with PHD and ring finger domains 1) to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004853,,,,,,,,,,,,,,,,,,,,,,UHRF1 inactivation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004855,UHRF1 - inactive form (predicted)(human) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_0004203,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:29128|PMID:28584306,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657|http://purl.obolibrary.org/obo/PATO_0002355,http://purl.obolibrary.org/obo/OGG_3000029128,,,,,,,,,,,,,TXPO:0004855,,,,,,,,,,,,,,,,,,,,,,UHRF1 - inactive form (predicted)(human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004856,Increasing VEGF level,,Increasing VEGF level is a subtype of increasing quantity: A process that changes the amount of VEGF level to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing VEGF level is a subtype of increasing quantity: A process that changes the amount of VEGF level to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_1000502,,,,,,,,,,,,,,,,,,,TXPO:0004856,,,,,,,,,,,,,,,,,,,,,,Increasing VEGF level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004858,VEGF (human) [hepatocarcinogenesis],VEGFA|vascular endothelial growth factor,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/IMR_0000031,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:7422|PMID:29340079,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002395|http://purl.obolibrary.org/obo/TXPO_0000624,,,,,VEGFA|vascular endothelial growth factor,,,,,TXPO:0004858,,,,,,,,,,,,,,,,,,,,,,VEGF (human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004854,UHRF1 inactivation [hepatocarcinogenesis],,"UHRF1 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the UHRF1 (ubiquitin like with PHD and ring finger domains 1) to be lower.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004853,,,,,,,,,,,,,,,,,,,,PMID:28584306,,"UHRF1 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the UHRF1 (ubiquitin like with PHD and ring finger domains 1) to be lower.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004855,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004487|http://purl.obolibrary.org/obo/TXPO_0004422,,,,,,,,,,,TXPO:0004854,,,,,,,,,,,,,,,,,,,,,,UHRF1 inactivation [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004859,WNT signal transduction pathway,,A series of molecular signals mediated by WNT (wingless/int-1).,false,,,http://purl.obolibrary.org/obo/TXPO_0000609,,,,,,,,,,,,,,,,,,,,,,A series of molecular signals mediated by WNT (wingless/int-1).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004859,,,,,,,,,,,,,,,,,,,,,,WNT signal transduction pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004850,trimeric UHRF1 repression complex,,,false,,,http://purl.obolibrary.org/obo/TXPO_0002107,,,,,,,,,,,,,,,,,,,,PMID:29507645,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,,,,,,TXPO:0004850,,,,,,,,,,,,,,,,,,,,,,trimeric UHRF1 repression complex,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004851,DNMT1 (human) [hepatocarcinogenesis],DNA methyltransferase 1,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_0004521,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1786,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,DNA methyltransferase 1,,,,,TXPO:0004851,,,,,,,,,,,,,,,,,,,,,,DNMT1 (human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004852,USP7 (human) [hepatocarcinogenesis],ubiquitin specific peptidase 7,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_0005136,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:7874,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ubiquitin specific peptidase 7,,,,,TXPO:0004852,,,,,,,,,,,,,,,,,,,,,,USP7 (human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004857,VEGF (canonical) [hepatocarcinogenesis],VEGFA|vascular endothelial growth factor,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/IMR_0000031,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:22339|NCBI-Human-GeneID:7422|NCBI-Rat-GeneID:83785,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002395|http://purl.obolibrary.org/obo/TXPO_0000624,,,,,VEGFA|vascular endothelial growth factor,,,,,TXPO:0004857,,,,,,,,,,,,,,,,,,,,,,VEGF (canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000057,transmembrane signaling receptor role,,Combining role with an extracellular or intracellular signal and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity or state as part of signal transduction.,false,,,http://purl.obolibrary.org/obo/TXPO_0002463,,,,,,,,,,,,,,,,,,,,,,Combining role with an extracellular or intracellular signal and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity or state as part of signal transduction.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000057,,,,,,,,,,,,,,,,,,,,,,transmembrane signaling receptor role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000052,cation,,A monoatomic or polyatomic species having one or more elementary charges of the proton.,false,,,http://purl.obolibrary.org/obo/CHEBI_24870,,,,,,,,,,,,,,,,,,,,,,A monoatomic or polyatomic species having one or more elementary charges of the proton.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000052,,,,,,,,,,,,,,,,,,,,,,cation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000053,Translocation of ATF6 from the cytosol to the nucleus,,Translocation of ATF6 from the cytosol to the nucleus is a subtype of nuclear transport: A process that of the directed movement of ATF6 from the cytoplasm to the nucleus.,false,,,http://purl.obolibrary.org/obo/GO_0051169,,,,,,,,,,,,,,,,,,,,,,Translocation of ATF6 from the cytosol to the nucleus is a subtype of nuclear transport: A process that of the directed movement of ATF6 from the cytoplasm to the nucleus.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005634,http://purl.obolibrary.org/obo/GO_0005829,,,,,,,TXPO:0000053,,,,,,,,,,,,,,,,,,,,,,Translocation of ATF6 from the cytosol to the nucleus,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000056,bile acid transport regulator role,,A role played by the entity which regulatess bile acid transport process.,false,,,http://purl.obolibrary.org/obo/TXPO_0000036,,,,,,,,,http://purl.obolibrary.org/obo/GO_0015721,,,,,,,,,,,,,A role played by the entity which regulatess bile acid transport process.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000056,,,,,,,,,,,,,,,,,,,,,,bile acid transport regulator role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000051,ChREBP activation,,ChREBP activation is a subtype of activating nuclear receptor: A process that changes the activity of the activating ChREBP to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000124,,,,,,,,,,,,,,,,,,,,,,ChREBP activation is a subtype of activating nuclear receptor: A process that changes the activity of the activating ChREBP to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000051,,,,,,,,,,,,,,,,,,,,,,ChREBP activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000058,death receptor role,,"Combining role with an extracellular messenger (called a death ligand), and transmitting the signal from one side of the plasma membrane to the other to initiate apoptotic or necrotic cell death.|related molecular function GO:0005035",false,,,http://purl.obolibrary.org/obo/TXPO_0000057,,,,,,,,,,,,,,,,,,,,,,"Combining role with an extracellular messenger (called a death ligand), and transmitting the signal from one side of the plasma membrane to the other to initiate apoptotic or necrotic cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000058,,,,,,,,,,,,,,,,,,,,related molecular function GO:0005035,,death receptor role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000059,lysosome damage,,lysosome damage is a subtype of organelle damage.,false,,,http://purl.obolibrary.org/obo/TXPO_0000070,,,,,,,,,,,,,,,,,,,,,,lysosome damage is a subtype of organelle damage.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000059,,,,,,,,,,,,,,,,,,,,,,lysosome damage,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000054,increasing liver weight,,Increasing liver weight is a subtype of increasing weight: A process that changes the weight of the liver to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000040,,,,,,,,,,,,,,,,,,,,,,Increasing liver weight is a subtype of increasing weight: A process that changes the weight of the liver to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000054,,,,,,,,,,,,,,,,,,,,,,increasing liver weight,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000055,Translocation of ATF6 from the cytosol to the nucleus [ER stress],,"Translocation of ATF6 from the cytosol to the nucleus is a subtype of nuclear transport: A process that of the directed movement of ATF6 from the cytoplasm to the nucleus.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000053|http://purl.obolibrary.org/obo/TXPO_0003736,,,,,,,,,,,,,,,,,,,,PMID:10564271|PMID:10856300|R-HSA-381026,,"Translocation of ATF6 from the cytosol to the nucleus is a subtype of nuclear transport: A process that of the directed movement of ATF6 from the cytoplasm to the nucleus.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000055,,,,,,,,,,,,,,,,,,,,,,Translocation of ATF6 from the cytosol to the nucleus [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000050,inflammatory cytokine gene expression [Lipidosis],,"Inflammatory cytokine gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature inflammatory cytokine gene product or products (proteins or RNA).
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002266|http://purl.obolibrary.org/obo/TXPO_0001720,,,,,,,,,,,,,,,,,,,,,,"Inflammatory cytokine gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature inflammatory cytokine gene product or products (proteins or RNA).
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000050,,,,,,,,,,,,,,,,,,,,,,inflammatory cytokine gene expression [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100420,TR beta 1,,,false,,,http://purl.obolibrary.org/obo/IMR_0000086,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100420,,,,,,,,,,,,,,,,,,,,,,TR beta 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0097314,apoptosome assembly,,"The aggregation, arrangement and bonding together of the apoptosome, a multisubunit protein complex involved in the signaling phase of the apoptotic process.",false,,,http://purl.obolibrary.org/obo/GO_0006461,,,,,,,,,,,,,,,,,,,,,,"The aggregation, arrangement and bonding together of the apoptosome, a multisubunit protein complex involved in the signaling phase of the apoptotic process.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0097314,,,,,,,,,,,,,,,,,,,,,,apoptosome assembly,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100301,caspase-10,,,false,,,http://purl.obolibrary.org/obo/IMR_0000308,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100301,,,,,,,,,,,,,,,,,,,,,,caspase-10,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000575,IFN alpha-5,,,false,,,http://purl.obolibrary.org/obo/IMR_0100386,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000575,,,,,,,,,,,,,,,,,,,,,,IFN alpha-5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000838,C/EBP epsilon,CCAAT/enhancer binding protein epsilon,,false,,,http://purl.obolibrary.org/obo/IMR_0000422,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CCAAT/enhancer binding protein epsilon,,,,,IMR:0000838,,,,,,,,,,,,,,,,,,,,,,C/EBP epsilon,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76841,"EC 1.14.13.* (oxidoreductase acting on paired donors, incorporating 1 atom of oxygen, with NADH or NADPH as one donor) inhibitor","EC 1.14.13.* inhibitors|oxidoreductase acting on paired donors, incorporating 1 atom of oxygen, with NADH or NADPH as one donor (EC 1.14.13.*) inhibitor|oxidoreductase acting on paired donors, incorporating 1 atom of oxygen, with NADH or NADPH as one donor (EC 1.14.13.*) inhibitors|EC 1.14.13.* inhibitor|EC 1.14.13.* (oxidoreductase acting on paired donors, incorporating 1 atom of oxygen, with NADH or NADPH as one donor) inhibitors","An EC 1.14.* (oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen) inhibitor that interferes with the action of any such enzyme incorporating one atom of oxygen and using NADH or NADPH as one donor (EC 1.14.13.*).",false,,,http://purl.obolibrary.org/obo/CHEBI_76741,,,,,,,,,,,,,,,,,,,,,,"An EC 1.14.* (oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen) inhibitor that interferes with the action of any such enzyme incorporating one atom of oxygen and using NADH or NADPH as one donor (EC 1.14.13.*).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"EC 1.14.13.* inhibitors|oxidoreductase acting on paired donors, incorporating 1 atom of oxygen, with NADH or NADPH as one donor (EC 1.14.13.*) inhibitor|oxidoreductase acting on paired donors, incorporating 1 atom of oxygen, with NADH or NADPH as one donor (EC 1.14.13.*) inhibitors|EC 1.14.13.* inhibitor|EC 1.14.13.* (oxidoreductase acting on paired donors, incorporating 1 atom of oxygen, with NADH or NADPH as one donor) inhibitors",,,,,,,,,,,,,,,,,,,,,CHEBI:76841,,,,"EC 1.14.13.* (oxidoreductase acting on paired donors, incorporating 1 atom of oxygen, with NADH or NADPH as one donor) inhibitor",,CHEBI:76841,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0048193,Golgi vesicle transport,,"The directed movement of substances into, out of or within the Golgi apparatus, mediated by vesicles.",false,,,http://purl.obolibrary.org/obo/GO_0006810,,,,,,,,,,,,,,,,,,,,,,"The directed movement of substances into, out of or within the Golgi apparatus, mediated by vesicles.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0048193,,,,,,,,,,,,,,,,,,,,,,Golgi vesicle transport,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0011137,eIF2B-beta,"translation initiation factor 2B beta subunit|eIF-2B GDP-GTP exchange factor, beta subunit|S20I15|Translation initiation factor eIF-2B beta subunit|eIF-2B GDP-GTP exchange factor|S20III15",,false,,,http://purl.obolibrary.org/obo/IMR_0000915,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"translation initiation factor 2B beta subunit|eIF-2B GDP-GTP exchange factor, beta subunit|S20I15|Translation initiation factor eIF-2B beta subunit|eIF-2B GDP-GTP exchange factor|S20III15",,,,,IMR:0011137,,,,,,,,,,,,,,,,,,,,,,eIF2B-beta,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001943,Gclc (rat)[Glutathione depletion],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001927|http://purl.obolibrary.org/obo/TXPO_1000163,,,,,,,,,,,,,,,,,,,,PMID:29039508|PMID:1784629|PMID:29549912,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002394,,,,,,,,,,TXPO:0001943,,,,,,,,,,,,,,,,,,,,,,Gclc (rat)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001949,Cyp2b1 (rat)[Glutathione depletion],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001927|http://purl.obolibrary.org/obo/TXPO_1000101,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24300,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001949,,,,,,,,,,,,,,,,,,,,,,Cyp2b1 (rat)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001940,Gsta3 (rat)[Glutathione depletion],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001927|http://purl.obolibrary.org/obo/TXPO_1000179,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:494500,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001940,,,,,,,,,,,,,,,,,,,,,,Gsta3 (rat)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001944,negative regulation of glutathione biosyntheric process [Glutathione depletion],,"Any process that stops, prevents, or reduces the frequency, rate or extent of glutathione biosynthetic process.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0001946|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents, or reduces the frequency, rate or extent of glutathione biosynthetic process.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001955,http://purl.obolibrary.org/obo/TXPO_0001942,,,,,,http://purl.obolibrary.org/obo/TXPO_0003288,,,,,,,,,,,TXPO:0001944,,,,,,,,,,,,,,,,,,,,,,negative regulation of glutathione biosyntheric process [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006750,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001942,BSO [Glutathione depletion],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001921|http://purl.obolibrary.org/obo/NCIT_C1029,,,,,,,,,,,,,,,,,,,,PMID:20463017|ISBN:0071769234|PMID:8097674,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001942,,,,,,,,,,,,,,,,,,,,,,BSO [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001948,Jun (rat)[Glutathione depletion],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001927|http://purl.obolibrary.org/obo/IMR_0000416,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24516|PMID:14967141|PMID:18931691,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001948,,,,,,,,,,,,,,,,,,,,,,Jun (rat)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001945,Gadd45a (rat)[Glutathione depletion],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001927|http://purl.obolibrary.org/obo/TXPO_1000174,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:25112|PMID:22033105,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000559,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001945,,,,,,,,,,,,,,,,,,,,,,Gadd45a (rat)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001941,diethyl malate [Glutathione depletion],DMA [glutathoine depletion],,false,,,http://purl.obolibrary.org/obo/TXPO_0001921|http://purl.obolibrary.org/obo/CHEBI_68508,,,,,,,,,,,,,,,,,,,,ISBN:0071769234,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/BFO_0000023,,,,,DMA [glutathoine depletion],,,,,TXPO:0001941,,,,,,,,,,,,,,,,,,,,,,diethyl malate [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001946,negative regulation of glutathione biosynthetic process,down regulation of glutathione anabolism|negative regulation of glutathione biosynthesis|negative regulation of glutathione anabolism|negative regulation of glutathione synthesis|negative regulation of glutathione formation|down regulation of glutathione biosynthesis,"Any process that stops, prevents, or reduces the frequency, rate or extent of glutathione biosynthetic process.",false,,,http://purl.obolibrary.org/obo/TXPO_0000369,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents, or reduces the frequency, rate or extent of glutathione biosynthetic process.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,down regulation of glutathione anabolism|negative regulation of glutathione biosynthesis|negative regulation of glutathione anabolism|negative regulation of glutathione synthesis|negative regulation of glutathione formation|down regulation of glutathione biosynthesis,,,,,TXPO:0001946,,,,,,,,,,,,,,,,,,,,,,negative regulation of glutathione biosynthetic process,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006750,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001947,GSTA1 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0002089,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24422|NCBI-Human-GeneID:2938,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001947,,,,,,,,,,,,,,,,,,,,,,GSTA1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001435,BMP-15,Growth/differentiation factor 9B|Bone morphogenetic protein 15|BMP15|GDF-9b|GDF9b,,false,,,http://purl.obolibrary.org/obo/IMR_0000040,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Growth/differentiation factor 9B|Bone morphogenetic protein 15|BMP15|GDF-9b|GDF9b,,,,,IMR:0001435,,,,,,,,,,,,,,,,,,,,,,BMP-15,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002990,negative regulation of cell cycle regulator gene expression [ER stress],,"Negative regulation of cell cycle regulator gene expression is a subtype of negative regulation of gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of cell cycle regulator gene expression.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0003455|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of cell cycle regulator gene expression is a subtype of negative regulation of gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of cell cycle regulator gene expression.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002989|http://purl.obolibrary.org/obo/TXPO_0002991|http://purl.obolibrary.org/obo/TXPO_0002992,,,,,,,,,,,,,,,,,,TXPO:0002990,,,,,,,,,,,,,,,,,,,,,,negative regulation of cell cycle regulator gene expression [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002996,PERK - stress sensor (canonical)[ER stress - cell cycle arrest],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000878,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000881,,,,,,,,,,TXPO:0002996,,,,,,,,,,,,,,,,,,,,,,PERK - stress sensor (canonical)[ER stress - cell cycle arrest],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002992,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002998,PERK - autophosphorylation kinase (canonical)[ER stress - cell cycle arrest],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000878,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002998,,,,,,,,,,,,,,,,,,,,,,PERK - autophosphorylation kinase (canonical)[ER stress - cell cycle arrest],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002997,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002994,PERK - signal sensor (canonical)[ER stress - Refolding],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001841,http://purl.obolibrary.org/obo/TXPO_0000123,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UniProt_Q9NZJ5|http://www.uniprot.org/entry/Q9NZJ5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000882,,,,,,,,,,TXPO:0002994,,,,,,,,,,,,,,,,,,,,,,PERK - signal sensor (canonical)[ER stress - Refolding],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002995,Dissociation of PERK:BIP Heterodimer [ER stress - cell cycle arrest],,"Dissociation of PERK:BIP heterodimer is a subtype of detaching: A process that disaggregates PERK-BIP heterodimers into BIP and PERK.
This process is dependent on the cell cycle arrest and can constitute the course of ER stress.|PERK (EIF2AK3) is a single-pass transmembrane protein located in the Endoplasmic Reticulum (ER) membrane. PERK has an N-terminal luminal domain and a C-terminal cytosolic domain. It is maintained in an inactive state by association of its luminal domain with BiP, a chaperone in the ER. Because BiP also binds unfolded proteins, BiP dissociates from PERK when unfolded proteins exceed chaperone activity in the ER.",false,,,http://purl.obolibrary.org/obo/TXPO_0002213,,,,,,,,,,,,,,,,,,,,PMID:10854322|Reactome PathwayStep4038|PMID:11907036,,"Dissociation of PERK:BIP heterodimer is a subtype of detaching: A process that disaggregates PERK-BIP heterodimers into BIP and PERK.
This process is dependent on the cell cycle arrest and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003157|http://purl.obolibrary.org/obo/TXPO_0002996,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000063,,,,,,,,,,,TXPO:0002995,,,,,,,,,,,,,,,,,,,,"PERK (EIF2AK3) is a single-pass transmembrane protein located in the Endoplasmic Reticulum (ER) membrane. PERK has an N-terminal luminal domain and a C-terminal cytosolic domain. It is maintained in an inactive state by association of its luminal domain with BiP, a chaperone in the ER. Because BiP also binds unfolded proteins, BiP dissociates from PERK when unfolded proteins exceed chaperone activity in the ER.",,Dissociation of PERK:BIP Heterodimer [ER stress - cell cycle arrest],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002993,PERK - signal sensor (canonical)[ER stress - cell cycle arrest],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001841,http://purl.obolibrary.org/obo/TXPO_0002992,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UniProt_Q9NZJ5|http://www.uniprot.org/entry/Q9NZJ5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000882,,,,,,,,,,TXPO:0002993,,,,,,,,,,,,,,,,,,,,,,PERK - signal sensor (canonical)[ER stress - cell cycle arrest],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002999,PERK - kinase (canonical)[ER stress - cell cycle arrest],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000878,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002999,,,,,,,,,,,,,,,,,,,,,,PERK - kinase (canonical)[ER stress - cell cycle arrest],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003000,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002997,PERK autophosphorylation [ER stress - cell cycle arrest],,"PERK autophosphorylation is a subtype of protein autophosphorylation: The phosphorylation by PERK of one or more of its own amino acid residues (cis-autophosphorylation), or residues on PERK (trans-autophosphorylation).
This process is dependent on the cell cycle arrest and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000674,,,,,,,,,,,,,,,,,,,,,,"PERK autophosphorylation is a subtype of protein autophosphorylation: The phosphorylation by PERK of one or more of its own amino acid residues (cis-autophosphorylation), or residues on PERK (trans-autophosphorylation).
This process is dependent on the cell cycle arrest and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002998,,,,,,,,,,,,,,,,,TXPO:0002997,,,,,,,,,,,,,,,,,,,,,,PERK autophosphorylation [ER stress - cell cycle arrest],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002991,PERK signaling to eIF2a [ER stress - cell cycle arrest],,"A process in which a signal to eIF2a is transduced by PERK.
This process is dependent on the cell cycle arrest and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002449,,,,,,,,,,,,,,,,,,,,,,"A process in which a signal to eIF2a is transduced by PERK.
This process is dependent on the cell cycle arrest and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003001|http://purl.obolibrary.org/obo/TXPO_0003002,http://purl.obolibrary.org/obo/TXPO_0003003,,,,,,http://purl.obolibrary.org/obo/TXPO_0002989,,,,,,,,,,,TXPO:0002991,,,,,,,,,,,,,,,,,,,,,,PERK signaling to eIF2a [ER stress - cell cycle arrest],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002992,receiving abnormal protein signal by PERK [ER stress - cell cycle arrest],,"Receiving abnormal protein signal by PERK is a subtype of receiving signal: A process that recognizes another object and changes into an abnormal protein (e.g., misfolded protein, etc.) signal by PERK.
This entity is a specific course-dependent process. This process can constitute the course of ER stress via cell cycle arrest.",false,,,http://purl.obolibrary.org/obo/TXPO_0002741|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"Receiving abnormal protein signal by PERK is a subtype of receiving signal: A process that recognizes another object and changes into an abnormal protein (e.g., misfolded protein, etc.) signal by PERK.
This entity is a specific course-dependent process. This process can constitute the course of ER stress via cell cycle arrest.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002993,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002995,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002991,,,,,,,,,,,TXPO:0002992,,,,,,,,,,,,,,,,,,,,,,receiving abnormal protein signal by PERK [ER stress - cell cycle arrest],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_17478,aldehyde,,"A compound RC(2O)H, in which a carbonyl group is bonded to one hydrogen atom and to one R group.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,,,"A compound RC(2O)H, in which a carbonyl group is bonded to one hydrogen atom and to one R group.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:17478,,,,,,,,,,,,,,,,,,,,,,aldehyde,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000009175,MAP3K13,,Other designations: leucine zipper-bearing kinase|mixed lineage kinase,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,MEKK13|LZK|MLK,,,,,,,,,,,,3,,,,,,HPRD:05372|HGNC:6852|MIM:604915|Vega:OTTHUMG00000156673|Ensembl:ENSG00000073803,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,mitogen-activated protein kinase kinase kinase 13,,,3q27,,,,,,,,,,,,,,,,"GO_0000186 (EC: IDA, PMID: 11726277); GO_0004674 (EC: IDA, PMID: 9353328); GO_0004709 (EC: IDA, PMID: 11726277); GO_0005515 (EC: IPI, PMID: 11726277); GO_0005524 (EC: IEA); GO_0006468 (EC: IDA, PMID: 11726277); GO_0007254 (EC: IDA, PMID: 11726277); GO_0008385 (EC: IDA, Qualifier: colocalizes_with, PMID: 12492477); GO_0016020 (EC: IDA, PMID: 9353328); GO_0019901 (EC: ISS, PMID: 9353328); GO_0042802 (EC: IPI, PMID: 11163770); GO_0042803 (EC: IDA, PMID: 11163770); GO_0046777 (EC: IDA, PMID: 9353328); GO_0046872 (EC: IEA); GO_0051092 (EC: IDA, PMID: 12492477)",,,,,,,,,PMID: 8274451; 9353328; 11163770; 11726277; 12186766; 12477932; 12492477; 14702039; 15489334; 20379614; 21988832; 22505724; 22623531; 22837378,,,,,,,,,,,,,,,OGG:3000009175,,,,,,,mitogen-activated protein kinase kinase kinase 13,,,,,,,,,,,,,Other designations: leucine zipper-bearing kinase|mixed lineage kinase,,MAP3K13,,,,,,,,,,,,,,,,,,,,,,,9175,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,MAP3K13,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0100617,cyclin D3,G1/S-specific cyclin D3|CGD3,,false,,,http://purl.obolibrary.org/obo/IMR_0100614,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0010666|IMR:0011615,G1/S-specific cyclin D3|CGD3,,,,,IMR:0100617,,,,,,,,,,,,,,,,,,,,,,cyclin D3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0009605,response to external stimulus,response to environmental stimulus,"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an external stimulus.|Note that this term is in the subset of terms that should not be used for direct gene product annotation. Instead, select a child term or, if no appropriate child term exists, please request a new term. Direct annotations to this term may be amended during annotation QC.",false,,,http://purl.obolibrary.org/obo/GO_0050896,,,,,,,,,,,,,,,,,,,,,,"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an external stimulus.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,response to environmental stimulus,,,,,GO:0009605,,,,,,,,,,,,,,,,,,,,"Note that this term is in the subset of terms that should not be used for direct gene product annotation. Instead, select a child term or, if no appropriate child term exists, please request a new term. Direct annotations to this term may be amended during annotation QC.",,response to external stimulus,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000858,NF-ATc4,,,false,,,http://purl.obolibrary.org/obo/IMR_0000421,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000858,,,,,,,,,,,,,,,,,,,,,,NF-ATc4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/DOID_14504,Niemann-Pick disease,sphingomyelin lipidosis|lipoid histiocytosis (classical phosphatide)|Sphingomyelinase Deficiency Disease,A sphingoliidosis characterized by the accumulation of the lipid sphingomyelin in lysosomes in cells.,false,,,http://purl.obolibrary.org/obo/DOID_4,,,,,,,,,,,,,,,,,,,,,,A sphingoliidosis characterized by the accumulation of the lipid sphingomyelin in lysosomes in cells.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sphingomyelin lipidosis|lipoid histiocytosis (classical phosphatide)|Sphingomyelinase Deficiency Disease,,,,,DOID:14504,,,,,,,,,,,,,,,,,,,,,,Niemann-Pick disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006121,"mitochondrial electron transport, succinate to ubiquinone","complex II (succinate to ubiquinone)|oxidative phosphorylation, succinate to ubiquinone|mitochondrial electron transport, succinate to coenzyme Q","The transfer of electrons from succinate to ubiquinone that occurs during oxidative phosphorylation, mediated by the multisubunit enzyme known as complex II.",false,,,http://purl.obolibrary.org/obo/GO_0022904,,,,,,,,,,,,,,,,,,,,,,"The transfer of electrons from succinate to ubiquinone that occurs during oxidative phosphorylation, mediated by the multisubunit enzyme known as complex II.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"mitochondrial electron transport, succinate to coenzyme Q",,"complex II (succinate to ubiquinone)|oxidative phosphorylation, succinate to ubiquinone",,,GO:0006121,,,,,,,,,,,,,,,,,,,,,,"mitochondrial electron transport, succinate to ubiquinone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006122,"mitochondrial electron transport, ubiquinol to cytochrome c",complex III (ubiquinone to cytochrome c),"The transfer of electrons from ubiquinol to cytochrome c that occurs during oxidative phosphorylation, mediated by the multisubunit enzyme known as complex III.",false,,,http://purl.obolibrary.org/obo/GO_0022904,,,,,,,,,,,,,,,,,,,,,,"The transfer of electrons from ubiquinol to cytochrome c that occurs during oxidative phosphorylation, mediated by the multisubunit enzyme known as complex III.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,complex III (ubiquinone to cytochrome c),,,GO:0006122,,,,,,,,,,,,,,,,,,,,,,"mitochondrial electron transport, ubiquinol to cytochrome c",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006120,"mitochondrial electron transport, NADH to ubiquinone","complex I (NADH to ubiquinone)|oxidative phosphorylation, NADH to ubiquinone","The transfer of electrons from NADH to ubiquinone that occurs during oxidative phosphorylation, mediated by the multisubunit enzyme known as complex I.",false,,,http://purl.obolibrary.org/obo/GO_0022904,,,,,,,,,,,,,,,,,,,,,,"The transfer of electrons from NADH to ubiquinone that occurs during oxidative phosphorylation, mediated by the multisubunit enzyme known as complex I.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"oxidative phosphorylation, NADH to ubiquinone",,complex I (NADH to ubiquinone),,,GO:0006120,,,,,,,,,,,,,,,,,,,,,,"mitochondrial electron transport, NADH to ubiquinone",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000377,TRA2A (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:29896|NCBI-Rat-GeneID:500116|NCBI-Mouse-GeneID:101214,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000029896,,,,,,,,,,,,,TXPO:1000377,,,,,,,,,,,,,,,,,,,,,,TRA2A (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000370,TGF (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:1000370,,,,,,,,,,,,,,,,,,,,,,TGF (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000373,TIMP1 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_1000431,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:116510|NCBI-Human-GeneID:7076|NCBI-Mouse-GeneID:21857,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000007076,,,,,,,,,,,,,TXPO:1000373,,,,,,,,,,,,,,,,,,,,,,TIMP1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000375,TNFRSF9 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:500590|NCBI-Human-GeneID:3604|NCBI-Mouse-GeneID:21942,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000003604,,,,,,,,,,,,,TXPO:1000375,,,,,,,,,,,,,,,,,,,,,,TNFRSF9 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000371,TGFbeta1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:|NCBI-Mouse-GeneID:|NCBI-Rat-GeneID:,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:1000371,,,,,,,,,,,,,,,,,,,,,,TGFbeta1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000374,TNF-a (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:21926|NCBI-Rat-GeneID:24835|NCBI-Human-GeneID:7124,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000007124,,,,,,,,,,,,,TXPO:1000374,,,,,,,,,,,,,,,,,,,,,,TNF-a (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000372,THBS1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:21825|NCBI-Rat-GeneID:445442|NCBI-Human-GeneID:7057,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000007057,,,,,,,,,,,,,TXPO:1000372,,,,,,,,,,,,,,,,,,,,,,THBS1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000378,TRIB3 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:246273|NCBI-Mouse-GeneID:228775|NCBI-Human-GeneID:57761,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000057761,,,,,,,,,,,,,TXPO:1000378,,,,,,,,,,,,,,,,,,,,,,TRIB3 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000379,TSHZ2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:228911|NCBI-Human-GeneID:128553|NCBI-Rat-GeneID:100911757,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000128553,,,,,,,,,,,,,TXPO:1000379,,,,,,,,,,,,,,,,,,,,,,TSHZ2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000376,TP53INP1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:94241|NCBI-Rat-GeneID:297822,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000094241,,,,,,,,,,,,,TXPO:1000376,,,,,,,,,,,,,,,,,,,,,,TP53INP1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_1990748,cellular detoxification,,Any process carried out at the cellular level that reduces or removes the toxicity of a toxic substance. These may include transport of the toxic substance away from sensitive areas and to compartments or complexes whose purpose is sequestration of the toxic substance.,false,,,http://purl.obolibrary.org/obo/GO_0098754,,,,,,,,,,,,,,,,,,,,,,Any process carried out at the cellular level that reduces or removes the toxicity of a toxic substance. These may include transport of the toxic substance away from sensitive areas and to compartments or complexes whose purpose is sequestration of the toxic substance.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:1990748,,,,,,,,,,,,,,,,,,,,,,cellular detoxification,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000000,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_38462,acetylcholinesterase inhibitor role,EC 3.1.1.7 (acetylcholinesterase) inhibitor role,"An EC 3.1.1.* (carboxylic ester hydrolase) inhibitor that interferes with the action of enzyme acetylcholinesterase (EC 3.1.1.7), which helps breaking down of acetylcholine into choline and acetic acid.",false,,,http://purl.obolibrary.org/obo/CHEBI_76759,,,,,,,,,,,,,,,,,,,,,,"An EC 3.1.1.* (carboxylic ester hydrolase) inhibitor that interferes with the action of enzyme acetylcholinesterase (EC 3.1.1.7), which helps breaking down of acetylcholine into choline and acetic acid.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,EC 3.1.1.7 (acetylcholinesterase) inhibitor role,,,,,CHEBI:38462,,,,,,,,,,,,,,,,,,,,,,acetylcholinesterase inhibitor role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_24636,proton,,"Nuclear particle of charge number +1, spin 1/2 and rest mass of 1.007276470(12) u.",false,,,http://purl.obolibrary.org/obo/CHEBI_23367,,,,,,,,,,,,,,,,,,,,,,"Nuclear particle of charge number +1, spin 1/2 and rest mass of 1.007276470(12) u.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:24636,,,,,,,,,,,,,,,,,,,,,,proton,,,,,,,http://purl.obolibrary.org/obo/chebi.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100378,G-alpha-q,,,false,,,http://purl.obolibrary.org/obo/IMR_0000323,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100378,,,,,,,,,,,,,,,,,,,,,,G-alpha-q,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001969,Epac2,cAMP-GEFII,,false,,,http://purl.obolibrary.org/obo/IMR_0001967,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,cAMP-GEFII,,,,,IMR:0001969,,,,,,,,,,,,,,,,,,,,,,Epac2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000064332,NFKBIZ,,Other designations: I-kappa-B-zeta|IL-1 inducible nuclear ankyrin-repeat protein|Ikappa B-zeta variant 3|IkappaB-zeta|NF-kappa-B inhibitor zeta|ikB-zeta|ikappaBzeta|molecule possessing ankyrin repeats induced by lipopolysaccharide,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,IKBZ|INAP|MAIL,,,,,,,,,,,,3,,,,,,HPRD:09217|MIM:608004|HGNC:29805|Vega:OTTHUMG00000159194|Ensembl:ENSG00000144802,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, zeta",,,3p12-q12,,,,,,,,,,,,,,,,GO_0005634 (EC: IEA); GO_0006351 (EC: IEA); GO_0006355 (EC: IEA); GO_0006954 (EC: IEA),,,,,,,,,PMID: 11278262; 11356851; 12477932; 12565889; 14702039; 15241416; 15522867; 15618216; 16344560; 16513645; 16622025; 17447895; 18362142; 18436238; 18813073; 18850010; 19595668; 19707556; 19783680; 19798075; 20211142; 20650996; 21224476; 21833088; 21988832; 22059479; 23869088; 24027435,,,,,,,,,,,,,,,OGG:3000064332,,,,,,,"nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, zeta",,,,,,,,,,,,,Other designations: I-kappa-B-zeta|IL-1 inducible nuclear ankyrin-repeat protein|Ikappa B-zeta variant 3|IkappaB-zeta|NF-kappa-B inhibitor zeta|ikB-zeta|ikappaBzeta|molecule possessing ankyrin repeats induced by lipopolysaccharide,,NFKBIZ,,,,,,,,,,,,,,,,,,,,,,,64332,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,NFKBIZ,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0001737,cell part damage,,Cell part damage is a subtype of damaging: A process that injuries the structure of the cellular part as the direct or indirect result of an external force.,false,,,http://purl.obolibrary.org/obo/TXPO_0000222,,,,,,,,,,,,,,,,,,,,,,Cell part damage is a subtype of damaging: A process that injuries the structure of the cellular part as the direct or indirect result of an external force.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001737,,,,,,,,,,,,,,,,,,,,,,cell part damage,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001730,oxidative stress dependent process,,Oxidative stress dependent process is a subtype of toxic course dependent process: A process that can constitute the course of oxidative stress.,false,,,http://purl.obolibrary.org/obo/TXPO_0001715,,,,,,,,,,,,,,,,,,,,,,Oxidative stress dependent process is a subtype of toxic course dependent process: A process that can constitute the course of oxidative stress.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001730,,,,,,,,,,,,,,,,,,,,,,oxidative stress dependent process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001731,toxic course dependent chemical entity,,"Toxic course dependent chemical entity is a subtype of chemical entity.
This entity can participate in a specific toxic course.",false,,,http://purl.obolibrary.org/obo/CHEBI_24431,,,,,,,,,,,,,,,,,,,,,,"Toxic course dependent chemical entity is a subtype of chemical entity.
This entity can participate in a specific toxic course.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001731,,,,,,,,,,,,,,,,,,,,,,toxic course dependent chemical entity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001736,state of functional supply,,"In the imbalance model, the basic units are as follows:
1) a functioning process (supply) for biological defense and maintaining homeostasis;
2) a functional demand process (demand) as toxic activity;
3) balance/imbalance between toxic activity and defense processes; and
4) outcome from organelles, cells, or tissues to the organ exhibiting toxicity manifestations.

This entity indicates step 1: a state of functioning (supply) for biological defense and maintaining homeostasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000270,,,,,,,,,,,,,,,,,,,,,,"In the imbalance model, the basic units are as follows:
1) a functioning process (supply) for biological defense and maintaining homeostasis;
2) a functional demand process (demand) as toxic activity;
3) balance/imbalance between toxic activity and defense processes; and
4) outcome from organelles, cells, or tissues to the organ exhibiting toxicity manifestations.

This entity indicates step 1: a state of functioning (supply) for biological defense and maintaining homeostasis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001736,,,,,,,,,,,,,,,,,,,,,,state of functional supply,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001738,membrane damage,,Membrane damage is a subtype of damaging: A process that injuries the structure of the membrane as the direct or indirect result of an external force.,false,,,http://purl.obolibrary.org/obo/TXPO_0001737,,,,,,,,,,,,,,,,,,,,,,Membrane damage is a subtype of damaging: A process that injuries the structure of the membrane as the direct or indirect result of an external force.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001738,,,,,,,,,,,,,,,,,,,,,,membrane damage,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001739,dysfunction of mitochondrial fatty acid degradation [Alchoric fatty liver],,"Dysfunction of mitochondrial fatty acid beta-oxidation (severe) is a subtype of hypofunction of fatty acid beta-oxidation: A process that performs a decreased or insufficient fatty acid beta-oxidation severely.
This entity is a specific course-dependent process. This process can constitute the course of Alcholic fatty liver.",false,,,http://purl.obolibrary.org/obo/TXPO_0000901|http://purl.obolibrary.org/obo/TXPO_0003652,,,,,,,,,,,,,,,,,,,,,,"Dysfunction of mitochondrial fatty acid beta-oxidation (severe) is a subtype of hypofunction of fatty acid beta-oxidation: A process that performs a decreased or insufficient fatty acid beta-oxidation severely.
This entity is a specific course-dependent process. This process can constitute the course of Alcholic fatty liver.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000279,,,,,,,,,,,TXPO:0001739,,,,,,,,,,,,,,,,,,,,,,dysfunction of mitochondrial fatty acid degradation [Alchoric fatty liver],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001735,imbalance state,,"In the imbalance model, the basic units are as follows:
1) a functioning process (supply) for biological defense and maintaining homeostasis;
2) a functional demand process (demand) as toxic activity;
3) balance/imbalance between toxic activity and defense processes; and
4) outcome from organelles, cells, or tissues to the organ exhibiting toxicity manifestations.

This entity indicates step 3: a state of imbalance between toxic activity and defense processes.",false,,,http://purl.obolibrary.org/obo/TXPO_0000270,,,,,,,,,,,,,,,,,,,,,,"In the imbalance model, the basic units are as follows:
1) a functioning process (supply) for biological defense and maintaining homeostasis;
2) a functional demand process (demand) as toxic activity;
3) balance/imbalance between toxic activity and defense processes; and
4) outcome from organelles, cells, or tissues to the organ exhibiting toxicity manifestations.

This entity indicates step 3: a state of imbalance between toxic activity and defense processes.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001735,,,,,,,,,,,,,,,,,,,,,,imbalance state,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001732,ATF6 signal transduction system,,"ATF6 signal transduction system is a subtype of pathway system.
This entity has sub-parts and has a goal of transmitting signals via ATF6 as a systemic context.",false,,,http://purl.obolibrary.org/obo/TXPO_0000634,,,,,,,,,,,,,,,,,,,,,,"ATF6 signal transduction system is a subtype of pathway system.
This entity has sub-parts and has a goal of transmitting signals via ATF6 as a systemic context.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001732,,,,,,,,,,,,,,,,,,,,,,ATF6 signal transduction system,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001734,balance state,,"In the imbalance model, the basic units are as follows:
1) a functioning process (supply) for biological defense and maintaining homeostasis;
2) a functional demand process (demand) as toxic activity;
3) balance/imbalance between toxic activity and defense processes; and
4) outcome from organelles, cells, or tissues to the organ exhibiting toxicity manifestations.

This entity is step 3: a state of balance between toxic activity and defense processes.",false,,,http://purl.obolibrary.org/obo/TXPO_0000270,,,,,,,,,,,,,,,,,,,,,,"In the imbalance model, the basic units are as follows:
1) a functioning process (supply) for biological defense and maintaining homeostasis;
2) a functional demand process (demand) as toxic activity;
3) balance/imbalance between toxic activity and defense processes; and
4) outcome from organelles, cells, or tissues to the organ exhibiting toxicity manifestations.

This entity is step 3: a state of balance between toxic activity and defense processes.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001734,,,,,,,,,,,,,,,,,,,,,,balance state,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100738,DHH (mol),HHG-3|Desert hedgehog,,false,,,http://purl.obolibrary.org/obo/IMR_0000004,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:84380|NCBI-Human-GeneID:50846|NCBI-Mouse-GeneID:13363,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,HHG-3|Desert hedgehog,,,,,IMR:0100738,,,,,,,,,,,,,,,,,,,,,,DHH (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000010769,PLK2,,Other designations: PLK-2|serine/threonine-protein kinase PLK2|serine/threonine-protein kinase SNK|serum-inducible kinase,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,hPlk2|SNK|hSNK,,,,,,,,,,,,5,,,,,,Vega:OTTHUMG00000097047|Ensembl:ENSG00000145632|HPRD:06118|MIM:607023|HGNC:19699,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,polo-like kinase 2,,,5q12.1-q13.2,,,,,,,,,,,,,,,,"GO_0000082 (EC: IMP, PMID: 15242618); GO_0004674 (EC: IDA, PMID: 19001868); GO_0004871 (EC: IMP, PMID: 12761501); GO_0005515 (EC: IPI); GO_0005524 (EC: IEA); GO_0005622 (EC: ISS); GO_0005813 (EC: IDA, PMID: 15242618); GO_0005814 (EC: IDA, PMID: 19001868); GO_0006468 (EC: IDA); GO_0007052 (EC: IDA, PMID: 19001868); GO_0007093 (EC: ISS); GO_0007265 (EC: ISS); GO_0007613 (EC: ISS); GO_0030425 (EC: ISS); GO_0032436 (EC: IEA); GO_0032486 (EC: ISS); GO_0043066 (EC: ISS); GO_0043123 (EC: IMP, PMID: 12761501); GO_0046599 (EC: IDA, PMID: 19001868); GO_0046599 (EC: IMP, PMID: 15242618); GO_0048167 (EC: ISS); GO_0060291 (EC: ISS); GO_0060292 (EC: ISS)",,,,,,,,,PMID: 8889549; 10523297; 10557092; 11039900; 11696980; 11716500; 12477932; 12651910; 12761501; 12897130; 12972611; 14702039; 15242618; 15489334; 16169070; 16203730; 16344560; 17671831; 17706602; 17912033; 19001868; 19004816; 19506885; 19597481; 19706541; 19834535; 19889641; 19953087; 20054236; 20056645; 20352051; 20360068; 20508983; 20531387; 21067440; 21340720; 21402713; 21832049; 21906983; 21963094; 21988832; 22100274; 22134238; 22138223; 22248692; 22289679; 22399798; 22828320; 22988096; 23466428; 23703673,,,,,,,,,,,,,,,OGG:3000010769,,,,,,,polo-like kinase 2,,,,,,,,,,,,,Other designations: PLK-2|serine/threonine-protein kinase PLK2|serine/threonine-protein kinase SNK|serum-inducible kinase,,PLK2,,,,,,,,,,,,,,,,,,,,,,,10769,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,PLK2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_35821,anticholesteremic drug,,A substance used to lower plasma cholesterol levels.,false,,,http://purl.obolibrary.org/obo/CHEBI_35679,,,,,,,,,,,,,,,,,,,,,,A substance used to lower plasma cholesterol levels.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:35821,,,,,,,,,,,,,,,,,,,,,,anticholesteremic drug,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CL_0000448,white fat cell,,Fat cells with light coloration and few mitochondria. They contain a scant ring of cytoplasm surrounding a single large lipid droplet or vacuole.,false,,,http://purl.obolibrary.org/obo/CL_0000136,,,,,,,,,,,,,,,,,,,,FMA:83434|CALOHA:TS-1119,,Fat cells with light coloration and few mitochondria. They contain a scant ring of cytoplasm surrounding a single large lipid droplet or vacuole.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CL:0000448,,,,,,,,,,,,,,,,,,,,,,white fat cell,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CL_0000449,brown fat cell,brown adipose cell|brown adipocyte,"A cell from the thermogenic form of adipose tissue found in many species, particularly in newborns and hibernating mammals, but also in lesser amounts in adults of other mammals including humans. Brown fat is capable of rapid liberation of energy and seems to be important in the maintenance of body temperature immediately after birth and upon waking from hibernation.",false,,,http://purl.obolibrary.org/obo/CL_0000136,,,,,,,,,,,,,,,,,,,,CALOHA:TS-0099|FMA:83435,,"A cell from the thermogenic form of adipose tissue found in many species, particularly in newborns and hibernating mammals, but also in lesser amounts in adults of other mammals including humans. Brown fat is capable of rapid liberation of energy and seems to be important in the maintenance of body temperature immediately after birth and upon waking from hibernation.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,brown adipose cell|brown adipocyte,,,,,CL:0000449,,,,,,,,,,,,,,,,,,,,,,brown fat cell,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0011141,eIF3j,eIF3 p35|eukaryotic translation initiation factor 3 subunit 1|eIF-3 alpha|eIF-3 30 kDa|Possible eukaryotic translation initiation factor 3 30 kDa subunit,This subunit is not part of the Saccharomyces cerevisiae core eIF3 complex.,false,,,http://purl.obolibrary.org/obo/IMR_0000916,,,,,,,,,,,,,,,,,,,,,,This subunit is not part of the Saccharomyces cerevisiae core eIF3 complex.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,eIF3 p35|eukaryotic translation initiation factor 3 subunit 1|eIF-3 alpha|eIF-3 30 kDa|Possible eukaryotic translation initiation factor 3 30 kDa subunit,,,,,IMR:0011141,,,,,,,,,,,,,,,,,,,,,,eIF3j,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002846,PERK - stress sensor (canonical)[ER stress - inflammation],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000878,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000881,,,,,,,,,,TXPO:0002846,,,,,,,,,,,,,,,,,,,,,,PERK - stress sensor (canonical)[ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002847,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002843,inflammatory cytokine gene expression by NF-kappa B via ATF6 [ER stress - inflammation],,"Inflammatory cytokine gene expression by NF-kappaB via ATF6 is a subtype of gene expression: The process in which a gene sequence is converted into a mature inflammatory cytokine gene product or products (proteins or RNA) by NF-kappaB via ATF6 signaling.
This process is dependent on the inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002266|http://purl.obolibrary.org/obo/TXPO_0000055,,,,,,,,,,,,,,,,,,,,,,"Inflammatory cytokine gene expression by NF-kappaB via ATF6 is a subtype of gene expression: The process in which a gene sequence is converted into a mature inflammatory cytokine gene product or products (proteins or RNA) by NF-kappaB via ATF6 signaling.
This process is dependent on the inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002796,,,,,http://purl.obolibrary.org/obo/TXPO_0002766,,,,,,,,,,,TXPO:0002843,,,,,,,,,,,,,,,,,,,,,,inflammatory cytokine gene expression by NF-kappa B via ATF6 [ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002842,decreasing I-kappaB production [ER stress -inflmmation- ATF6-NfkB],,"Decreasing I-kappaB production is a subtype of decreasing production quantity of protein: A process that changes the quantity of the Iinhibitor of kappa B (I-kappaB) to be lower.
This process is dependent on the ATF6-NfkB pathway mediated inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002799,,,,,,,,,,,,,,,,,,,,PMID:25232821|PMID:22249202,,"Decreasing I-kappaB production is a subtype of decreasing production quantity of protein: A process that changes the quantity of the Iinhibitor of kappa B (I-kappaB) to be lower.
This process is dependent on the ATF6-NfkB pathway mediated inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002842,,,,,,,,,,,,,,,,,,,,,,decreasing I-kappaB production [ER stress -inflmmation- ATF6-NfkB],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002848,PERK - signal sensor (canonical)[ER stress - inflammation],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001841,http://purl.obolibrary.org/obo/TXPO_0002847,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UniProt_Q9NZJ5|http://www.uniprot.org/entry/Q9NZJ5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000882,,,,,,,,,,TXPO:0002848,,,,,,,,,,,,,,,,,,,,,,PERK - signal sensor (canonical)[ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002845,PERK - stress sensor (canonical)[ER stress - apotosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000878,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000881,,,,,,,,,,TXPO:0002845,,,,,,,,,,,,,,,,,,,,,,PERK - stress sensor (canonical)[ER stress - apotosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002731,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002847,receiving abnormal protein signal by PERK [ER stress - inflammation],,"Receiving abnormal protein signal by PERK is a subtype of receiving signal: A process that recognizes another object and changes into an abnormal protein (e.g., misfolded protein, etc.) signal by PERK.
This process is dependent on the inflammation and can constitute the course of ER stress via inflammation.",false,,,http://purl.obolibrary.org/obo/TXPO_0002741|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"Receiving abnormal protein signal by PERK is a subtype of receiving signal: A process that recognizes another object and changes into an abnormal protein (e.g., misfolded protein, etc.) signal by PERK.
This process is dependent on the inflammation and can constitute the course of ER stress via inflammation.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002848,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000463,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002849,,,,,,,,,,,TXPO:0002847,,,,,,,,,,,,,,,,,,,,,,receiving abnormal protein signal by PERK [ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002844,ATF6 signaling (primitive) [ER stress - inflammation - ATF6-NfkB pathway],,"ATF6 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the ATF6 (activating transcription factor 6). ATF6 generally plays a endoplasmic reticulum membrane stress sensor role.
This process is dependent on the  ATF6-NfkB pathway mediated inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002838,,,,,,,,,,,,,,,,,,,,,,"ATF6 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the ATF6 (activating transcription factor 6). ATF6 generally plays a endoplasmic reticulum membrane stress sensor role.
This process is dependent on the  ATF6-NfkB pathway mediated inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002902,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002796,,,,,http://purl.obolibrary.org/obo/TXPO_0002843,,,,,,,,,,,TXPO:0002844,,,,,,,,,,,,,,,,,,,,,,ATF6 signaling (primitive) [ER stress - inflammation - ATF6-NfkB pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002841,NF-kappaB activation [ER stress - inflammation - ATF6-NfkB],,"NF-kappaB activation is a subtype of transcription factor activation: A process that changes the activity of the NF-kappaB to be higher.
This process is dependent on the ATF6-NfkB pathway mediated inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002782|http://purl.obolibrary.org/obo/TXPO_0003736,,,,,,,,,,,,,,,,,,,,,,"NF-kappaB activation is a subtype of transcription factor activation: A process that changes the activity of the NF-kappaB to be higher.
This process is dependent on the ATF6-NfkB pathway mediated inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002837,,,,,,,,,,,TXPO:0002841,,,,,,,,,,,,,,,,,,,,,,NF-kappaB activation [ER stress - inflammation - ATF6-NfkB],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002849,PERK signaling to eIF2a [ER stress - inflammation],,"A process in which a signal to eIF2a is transduced by PERK.
This process is dependent on the inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002449|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"A process in which a signal to eIF2a is transduced by PERK.
This process is dependent on the inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002854|http://purl.obolibrary.org/obo/TXPO_0002852,http://purl.obolibrary.org/obo/TXPO_0002850,,,,,,http://purl.obolibrary.org/obo/TXPO_0002853,,,,,,,,,,,TXPO:0002849,,,,,,,,,,,,,,,,,,,,,,PERK signaling to eIF2a [ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002840,regulation of gene expression by NfKB [ER stress - inflammation - ATF6-NfkB Pathway],,"Regulation of gene expression by NfKB is a subtype of regulation of gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of gene expression by NfkB.
This process is dependent on the ATF6-NfkB Pathway mediated inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002784,,,,,,,,,,,,,,,,,,,,,,"Regulation of gene expression by NfKB is a subtype of regulation of gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of gene expression by NfkB.
This process is dependent on the ATF6-NfkB Pathway mediated inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002843,,,,,,,,,,,,,,,,,,TXPO:0002840,,,,,,,,,,,,,,,,,,,,,,regulation of gene expression by NfKB [ER stress - inflammation - ATF6-NfkB Pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100317,Smad6,,,false,,,http://purl.obolibrary.org/obo/IMR_0000373,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100317,,,,,,,,,,,,,,,,,,,,,,Smad6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000049855,SCAPER,,Other designations: S phase cyclin A-associated protein in the ER|S phase cyclin A-associated protein in the endoplasmic reticulum|zinc finger protein 291,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,Zfp291|ZNF291,,,,,,,,,,,,15,,,,,,MIM:611611|Vega:OTTHUMG00000172655|HPRD:11704|Ensembl:ENSG00000140386|HGNC:13081,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,S-phase cyclin A-associated protein in the ER,,,15q24,,,,,,,,,,,,,,,,GO_0005634 (EC: IEA); GO_0005783 (EC: IEA); GO_0046872 (EC: IEA),,,,,,,,,PMID: 10819331; 12421765; 12477932; 14702039; 15161980; 15840729; 17553665; 17698606; 18245951; 19596686; 21139048; 22505724; 24163370,,,,,,,,,,,,,,,OGG:3000049855,,20140408,protein-coding,,,,S-phase cyclin A-associated protein in the ER,,,,,,,,,,,,,Other designations: S phase cyclin A-associated protein in the ER|S phase cyclin A-associated protein in the endoplasmic reticulum|zinc finger protein 291,,SCAPER,,,,,,,,,,,,,,,,,,,,,,,49855,MSTP063,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,SCAPER,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000000466,ATF1,,Other designations: cAMP-dependent transcription factor ATF-1|cyclic AMP-dependent transcription factor ATF-1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,FUS/ATF-1|EWS-ATF1|TREB36,,,,,,,,,,,,12,,,,,,HPRD:00440|HGNC:783|Ensembl:ENSG00000123268|Vega:OTTHUMG00000169482|MIM:123803,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,activating transcription factor 1,,,12q13,,,,,,,,,,,,,,,,"GO_0002224 (EC: TAS); GO_0002755 (EC: TAS); GO_0002756 (EC: TAS); GO_0003700 (EC: TAS, PMID:2196176); GO_0003705 (EC: IEA); GO_0005515 (EC: IPI, PMID:10722738); GO_0005634 (EC: IDA); GO_0005654 (EC: TAS); GO_0005667 (EC: IEA); GO_0005730 (EC: IDA, Qualifier: NOT); GO_0010976 (EC: IEA); GO_0014070 (EC: IEA); GO_0032025 (EC: IEA); GO_0032403 (EC: IEA); GO_0034134 (EC: TAS); GO_0034138 (EC: TAS); GO_0034142 (EC: TAS); GO_0034146 (EC: TAS); GO_0034162 (EC: TAS); GO_0034166 (EC: TAS); GO_0035666 (EC: TAS); GO_0038123 (EC: TAS); GO_0038124 (EC: TAS); GO_0043565 (EC: IEA); GO_0043623 (EC: IEA); GO_0045087 (EC: TAS); GO_0045740 (EC: IEA); GO_0045944 (EC: IEA); GO_0046982 (EC: IEA); GO_0048011 (EC: TAS); GO_0051403 (EC: TAS)",,,,,,,,,PMID:1655749; 2196176; 2516827; 7730336; 8384217; 8401579; 8570175; 8621702; 8663317; 8798441; 8889548; 9016641; 9671480; 9685505; 9824209; 10567391; 10585419; 10722738; 10945975; 11014230; 11018520; 11877423; 11909979; 11992546; 12195699; 12391222; 12444143; 12477932; 12527906; 12631284; 12734209; 12748173; 12760902; 12805554; 14767471; 15041276; 15276183; 15489334; 15806162; 15884099; 16227528; 16327442; 16344560; 16716376; 17565989; 18794154; 18950845; 19561568; 19714462; 19913121; 19950226; 20398657; 20413592; 20453000; 20536573; 20628086; 20945072; 20972440; 21484932; 21658281; 21890473; 21963094; 22052915; 22505724; 22510762; 22631637; 22939629; 23000965; 24051143,,,,,,,,,,,,,,,OGG:3000000466,,,,,,,activating transcription factor 1,,,,,,,,,,,,,Other designations: cAMP-dependent transcription factor ATF-1|cyclic AMP-dependent transcription factor ATF-1,,ATF1,,,,,,,,,,,,,,,,,,,,,,,466,,,,,,,,9606,,,,,,,,,,,,,,,,,,,ATF1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000000467,ATF3,,Other designations: cAMP-dependent transcription factor ATF-3|cyclic AMP-dependent transcription factor ATF-3,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,1,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,activating transcription factor 3,,,1q32.3,,,,,,,,,,,,,,,,"GO_0003700 (EC: IEA); GO_0003714 (EC: TAS, PMID:7515060); GO_0005515 (EC: IPI, PMID:16291753); GO_0005634 (EC: IDA); GO_0005654 (EC: TAS); GO_0005730 (EC: IDA); GO_0006094 (EC: IEA); GO_0006351 (EC: IEA); GO_0006987 (EC: TAS); GO_0008284 (EC: IEA); GO_0030968 (EC: TAS); GO_0035914 (EC: IEA); GO_0042802 (EC: IPI, PMID:18255255); GO_0043565 (EC: IEA); GO_0044267 (EC: TAS); GO_0045892 (EC: IEA)",,,,,,,,,PMID:1827203; 2516827; 7515060; 7692236; 8152431; 8576171; 8622660; 8649793; 11375399; 11726207; 11792711; 11810028; 12034827; 12161427; 12372430; 12386811; 12392999; 12477932; 12718878; 12805554; 12833146; 12881527; 14667575; 14673171; 14702039; 14759258; 15280448; 15385533; 15489334; 15670751; 15933712; 16079301; 16109718; 16169070; 16263788; 16286461; 16291753; 16306208; 16344560; 16484797; 16613840; 16912181; 16989641; 17014422; 17042743; 17102133; 17178897; 17295236; 17437852; 17599613; 17952119; 18001166; 18029348; 18192274; 18235102; 18255255; 18426833; 18692824; 18755691; 18802113; 18922905; 19050264; 19060337; 19136462; 19164757; 19219066; 19582787; 19647793; 19913121; 19932681; 20002170; 20110283; 20167600; 20180416; 20211142; 20215396; 20304822; 20351107; 20360311; 20398657; 20413626; 20423458; 20485437; 20581861; 20592017; 20628086; 20696134; 20930144; 21061913; 21129190; 21139048; 21191795; 21294679; 21300803; 21315420; 21324310; 21414204; 21421043; 21451046; 21454613; 21467165; 21495874; 21514952; 21554132; 21593605; 21629765; 21645504; 21668942; 21693764; 21801305; 21821004; 21844328; 21900211; 21906983; 21927023; 21986529; 22046379; 22179317; 22347845; 22475484; 22485215; 22665497; 22753726; 22764884; 22768301; 22851689; 22939624; 22978410; 22989952; 22991139; 23002211; 23088992; 23187734; 23269699; 23455924; 23536558; 23560949; 23661758; 23733932; 23868936; 23921126; 24098051,,,,,,,,,,,,,,,OGG:3000000467,,,,,,,activating transcription factor 3,,,,,,,,,,,,,Other designations: cAMP-dependent transcription factor ATF-3|cyclic AMP-dependent transcription factor ATF-3,,ATF3,,,,,,,,,,,,,,,,,,,,,,,467,RP11-338C15.1,,,,,,,9606,,,,,,,,,,,,,,,,,,,ATF3,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000000468,ATF4,,Other designations: DNA-binding protein TAXREB67|cAMP response element-binding protein 2|cAMP-dependent transcription factor ATF-4|cAMP-responsive element-binding protein 2|cyclic AMP-dependent transcription factor ATF-4|cyclic AMP-responsive element-binding protein 2|tax-responsive enhancer element B67|tax-responsive enhancer element-binding protein 67,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CREB-2|CREB2|TAXREB67|TXREB,,,,,,,,,,,,22,,,,,,MIM:604064|Vega:OTTHUMG00000151099|Ensembl:ENSG00000128272|HPRD:06817|HGNC:786,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,activating transcription factor 4,,,22q13.1,,,,,,,,,,,,,,,,"GO_0003677 (EC: IDA, PMID:15788408); GO_0003677 (EC: ISS); GO_0003700 (EC: ISS); GO_0003700 (EC: TAS, PMID:12689582); GO_0005515 (EC: IPI, PMID:11238952); GO_0005634 (EC: IDA, PMID:16682973); GO_0005634 (EC: ISS); GO_0005654 (EC: TAS); GO_0005667 (EC: IEA); GO_0005737 (EC: ISS); GO_0005815 (EC: IEA); GO_0006094 (EC: ISS); GO_0006355 (EC: ISS); GO_0006366 (EC: ISS); GO_0006520 (EC: TAS, PMID:12689582); GO_0006987 (EC: TAS); GO_0007214 (EC: IEA); GO_0008022 (EC: IEA); GO_0030968 (EC: TAS); GO_0032590 (EC: IEA); GO_0034976 (EC: IDA, PMID:19061639); GO_0043267 (EC: IEA); GO_0043525 (EC: ISS); GO_0043565 (EC: IEA); GO_0044267 (EC: TAS); GO_0045893 (EC: IDA, PMID:15775988); GO_0045893 (EC: IMP, PMID:11960987); GO_0045893 (EC: ISS); GO_0045893 (EC: NAS, PMID:9190894); GO_0045944 (EC: IMP, PMID:15788408); GO_0045944 (EC: ISS); GO_0070059 (EC: ISS)",,,,,,,,,PMID:1371974; 1534408; 1827203; 1847461; 2516827; 8939898; 9190894; 9295363; 9488481; 10419887; 10591208; 11018027; 11025215; 11087824; 11238952; 11274184; 11564156; 11960987; 12477932; 12689582; 12743605; 12805554; 12812986; 12860379; 14561767; 14623284; 14630807; 14630918; 14695168; 14747470; 15277680; 15314157; 15385533; 15461802; 15475356; 15489334; 15677469; 15775988; 15788408; 16169070; 16189514; 16219772; 16343488; 16682973; 16687408; 16751776; 17042743; 17346882; 17347301; 17369260; 17684156; 17707795; 17726049; 17822787; 17938202; 17996332; 18052253; 18163433; 18171674; 18189280; 18195013; 18255255; 18276110; 18408768; 18451308; 18635891; 18697751; 18940792; 19017641; 19053519; 19061639; 19073601; 19114033; 19164757; 19193809; 19251251; 19417138; 19447967; 19453261; 19509279; 19855386; 19922526; 19946894; 20022965; 20185790; 20211142; 20398657; 20473272; 20514020; 20551969; 20564243; 20592469; 20724472; 20732869; 20873783; 20936779; 21044953; 21087962; 21113145; 21203563; 21244365; 21683813; 21693764; 21706477; 21801305; 21832049; 21866569; 21906983; 21951999; 21963094; 21966512; 21988832; 22007000; 22016052; 22017875; 22050711; 22052162; 22082360; 22233381; 22246806; 22338651; 22363646; 22422769; 22435535; 22485215; 22609407; 22691366; 22813743; 22848420; 22915762; 22955275; 23001845; 23078367; 23090478; 23128233; 23153536; 23205607; 23241898; 23242184; 23339444; 23392669; 23471465; 23661758; 23665047; 23792164; 23908598; 23975372; 24021586,,,,,,,,,,,,,,,OGG:3000000468,,,,,,,activating transcription factor 4,,,,,,,,,,,,,Other designations: DNA-binding protein TAXREB67|cAMP response element-binding protein 2|cAMP-dependent transcription factor ATF-4|cAMP-responsive element-binding protein 2|cyclic AMP-dependent transcription factor ATF-4|cyclic AMP-responsive element-binding protein 2|tax-responsive enhancer element B67|tax-responsive enhancer element-binding protein 67,,ATF4,,,,,,,,,,,,,,,,,,,,,,,468,,,,,,,,9606,,,,,,,,,,,,,,,,,,,ATF4,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0100624,cyclin G2,,,false,,,http://purl.obolibrary.org/obo/IMR_0100622,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100624,,,,,,,,,,,,,,,,,,,,,,cyclin G2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0000004,nose,nasus|proboscis|olfactory apparatus|peripheral olfactory organ|nasal sac|nose,"The olfactory organ of vertebrates, consisting of nares, olfactory epithelia and the structures and skeletal framework of the nasal cavity.|the structure of the nose varies across vertebrates. In tetrapods the nose is part of the respiratory system.[PMID:25312359]",false,,,http://purl.obolibrary.org/obo/UBERON_0002268,,,,,,,,,,,,,,,,,,,,http://linkedlifedata.com/resource/umls/id/C0028429|http://en.wikipedia.org/wiki/Nose|http://www.snomedbrowser.com/Codes/Details/181195007|http://purl.obolibrary.org/obo/NCIT_C12756|EV:0100037|EV:0100370|BTO:0000840|MAT:0000139|MA:0000281|CALOHA:TS-2037|ZFA:0000047|EHDAA2:0001274|GAID:77|MIAA:0000139|MESH:D009666|FMA:46472|EMAPA:16542|galen:Nose|OpenCyc:Mx4rvViCbJwpEbGdrcN5Y29ycA|EHDAA:1502|UMLS:C0028429|TAO:0000047,,"The olfactory organ of vertebrates, consisting of nares, olfactory epithelia and the structures and skeletal framework of the nasal cavity.",,,,,,,,"the organ that is specialized for smell and is part of the respiratory system|Organ that is the specialized structure of the face that contains olfactory neurons. The peripheral olfactory organ is paired[ZFA:0000047].|a protuberance in vertebrates that houses the nostrils, or nares, which admit and expel air for respiration in conjunction with the mouth. Behind the nose are the olfactory mucosa and the sinuses. Behind the nasal cavity, air next passes through the pharynx, shared with the digestive system, and then into the rest of the respiratory system. In humans, the nose is located centrally on the face; on most other mammals, it is on the upper tip of the snout[WP]. GO: The nose is the specialized structure of the face that serves as the organ of the sense of smell and as part of the respiratory system. Includes the nasi externus (external nose) and cavitas nasi (nasal cavity)[Wikipedia:Nose].",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,peripheral olfactory organ|nasal sac|nose,,nasus|proboscis|olfactory apparatus,,http://purl.obolibrary.org/obo/UBERON_0001004,UBERON:0000004,http://purl.obolibrary.org/obo/UBERON_0001004,,,,,,,,,,,,,,,,,,,the structure of the nose varies across vertebrates. In tetrapods the nose is part of the respiratory system.[PMID:25312359],,nose,,,,,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004168,PIM3 (predicted)(human) [mitochondrial damage],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003603|http://purl.obolibrary.org/obo/TXPO_1000525,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:415116,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000415116,,,,,,,,,,,,,TXPO:0004168,,,,,,,,,,,,,,,,,,,,,,PIM3 (predicted)(human) [mitochondrial damage],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004166,TRIM55 (predicted)(human) [mitochondrial damage],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003603|http://purl.obolibrary.org/obo/TXPO_1000542,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:84675,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000084675,,,,,,,,,,,,,TXPO:0004166,,,,,,,,,,,,,,,,,,,,,,TRIM55 (predicted)(human) [mitochondrial damage],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004169,GFRA1 (predicted)(human) [mitochondrial damage],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003603|http://purl.obolibrary.org/obo/TXPO_1000516,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:2674,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000002674,,,,,,,,,,,,,TXPO:0004169,,,,,,,,,,,,,,,,,,,,,,GFRA1 (predicted)(human) [mitochondrial damage],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004167,CYP1A1 (predicted)(human) [mitochondrial damage],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003603|http://purl.obolibrary.org/obo/TXPO_1000511,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1543,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000001543,,,,,,,,,,,,,TXPO:0004167,,,,,,,,,,,,,,,,,,,,,,CYP1A1 (predicted)(human) [mitochondrial damage],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004164,SLC38A4 (predicted)(human) [mitochondrial damage],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003603|http://purl.obolibrary.org/obo/TXPO_1000534,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:55089,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000055089,,,,,,,,,,,,,TXPO:0004164,,,,,,,,,,,,,,,,,,,,,,SLC38A4 (predicted)(human) [mitochondrial damage],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004165,BCL2A1 (predicted)(human) [mitochondrial damage],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003603|http://purl.obolibrary.org/obo/TXPO_1000504,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:597,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000000597,,,,,,,,,,,,,TXPO:0004165,,,,,,,,,,,,,,,,,,,,,,BCL2A1 (predicted)(human) [mitochondrial damage],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004163,sphingomyelin metabolism imbalance [Phospholipidosis ],,"A process that becomes lacking a homeostastasis balance of the sphingomyelin metabolism.
This process is dependent on the sphingomyelin disorder and can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001672|http://purl.obolibrary.org/obo/TXPO_0002324,,,,,,,,,,,,,,,,,,,,,,"A process that becomes lacking a homeostastasis balance of the sphingomyelin metabolism.
This process is dependent on the sphingomyelin disorder and can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003381,,,,,,,,,,,TXPO:0004163,,,,,,,,,,,,,,,,,,,,,,sphingomyelin metabolism imbalance [Phospholipidosis ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004161,increasing number of macrophage derived foam cell [Phospholipidosis(sphingomyelin disorder )],,"Increasing number of macrophage derived foam cell is a subtype of increasing number of objects: A process that becomes larger in the number of foam cell, a type of macrophage containing lipids in small vacuoles, in the liver.
This entity is a specific course-dependent process. This process can constitute the course of sphingomyelin disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0000918,,,,,,,,,,,,,,,,,,,,,,"Increasing number of macrophage derived foam cell is a subtype of increasing number of objects: A process that becomes larger in the number of foam cell, a type of macrophage containing lipids in small vacuoles, in the liver.
This entity is a specific course-dependent process. This process can constitute the course of sphingomyelin disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000101,,,,,,,,,,,TXPO:0004161,,,,,,,,,,,,,,,,,,,,,,increasing number of macrophage derived foam cell [Phospholipidosis(sphingomyelin disorder )],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004162,hypofunction of sphingomyelin degradation [Phospholipidosis-sphingomyelin disorder],,"Dysfunction of  sphingomyelin degradation is a subtype of hypofunction of decomposing: A process that performs a decreased or insufficient  sphingomyelin degradation.
This process can constitute the course of sphingomyelin disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0000925|http://purl.obolibrary.org/obo/TXPO_0001676,,,,,,,,,,,,,,,,,,,,,,"Dysfunction of  sphingomyelin degradation is a subtype of hypofunction of decomposing: A process that performs a decreased or insufficient  sphingomyelin degradation.
This process can constitute the course of sphingomyelin disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003599,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001569|http://purl.obolibrary.org/obo/TXPO_0001823,,,,,,,,,,,TXPO:0004162,,,,,,,,,,,,,,,,,,,,,,hypofunction of sphingomyelin degradation [Phospholipidosis-sphingomyelin disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004160,positive regulation of macrophage derived foam cell differentiation [sphingomyelin disorder],,"Any process that increases the rate, frequency or extent of macrophage derived foam cell differentiation. Macrophage derived foam cell differentiation is the process in which a macrophage acquires the specialized features of a foam cell. A foam cell is a type of cell containing lipids in small vacuoles and typically seen in atherosclerotic lesions, as well as other conditions.
This entity is a specific course-dependent process. This process can constitute the course of sphingomyelin disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0004085,,,,,,,,,,,,,,,,,,,,,,"Any process that increases the rate, frequency or extent of macrophage derived foam cell differentiation. Macrophage derived foam cell differentiation is the process in which a macrophage acquires the specialized features of a foam cell. A foam cell is a type of cell containing lipids in small vacuoles and typically seen in atherosclerotic lesions, as well as other conditions.
This entity is a specific course-dependent process. This process can constitute the course of sphingomyelin disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004161,,,,,,,,,,,TXPO:0004160,,,,,,,,,,,,,,,,,,,,,,positive regulation of macrophage derived foam cell differentiation [sphingomyelin disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003717,transcriptional co-activator,,"A role played by the entity that interacts specifically and non-covalently with a DNA-bound DNA-binding transcription factor to activate the transcription of specific genes. Coactivators often act by altering chromatin structure and modifications. For example, one class of transcription coregulators modifies chromatin structure through covalent modification of histones. A second ATP-dependent class modifies the conformation of chromatin. Another type of coregulator activity is the bridging of a DNA-binding transcription factor to the basal transcription machinery. The Mediator complex, which bridges transcription factors and RNA polymerase, is also a transcription coactivator.|related molecular function GO:0003713",false,,,http://purl.obolibrary.org/obo/TXPO_0003716,,,,,,,,,,,,,,,,,,,,IMR:0000424 (obsolete),,"A role played by the entity that interacts specifically and non-covalently with a DNA-bound DNA-binding transcription factor to activate the transcription of specific genes. Coactivators often act by altering chromatin structure and modifications. For example, one class of transcription coregulators modifies chromatin structure through covalent modification of histones. A second ATP-dependent class modifies the conformation of chromatin. Another type of coregulator activity is the bridging of a DNA-binding transcription factor to the basal transcription machinery. The Mediator complex, which bridges transcription factors and RNA polymerase, is also a transcription coactivator.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003717,,,,,,,,,,,,,,,,,,,,related molecular function GO:0003713,,transcriptional co-activator,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003718,lysosomal process,,,false,,,http://purl.obolibrary.org/obo/BFO_0000015|http://purl.obolibrary.org/obo/TXPO_0000538,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003718,,,,,,,,,,,,,,,,,,,,,,lysosomal process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003719,mitochondrial procress,,,false,,,http://purl.obolibrary.org/obo/BFO_0000015|http://purl.obolibrary.org/obo/TXPO_0000538,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003719,,,,,,,,,,,,,,,,,,,,,,mitochondrial procress,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003714,molecular activator,,A role played by the entity that activates molecular activity.,false,,,http://purl.obolibrary.org/obo/TXPO_0003713,,,,,,,,,,,,,,,,,,,,,,A role played by the entity that activates molecular activity.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003714,,,,,,,,,,,,,,,,,,,,,,molecular activator,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003712,changer role,role related to changing,A role played by the entity involved in changing process.,false,,,http://purl.obolibrary.org/obo/TXPO_0003727,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,role related to changing,,,,,TXPO:0003712,,,,,,,,,,,,,,,,,,,,A role played by the entity involved in changing process.,,changer role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003711,molecular inhibitor,,A role played by the entity that inhibits molecular activity.,false,,,http://purl.obolibrary.org/obo/TXPO_0003713,,,,,,,,,,,,,,,,,,,,,,A role played by the entity that inhibits molecular activity.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003711,,,,,,,,,,,,,,,,,,,,,,molecular inhibitor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003713,molecular (activity) regulator,,A role played by the entity which regulates molecular activities.,false,,,http://purl.obolibrary.org/obo/TXPO_0003710,,,,,,,,,,,,,,,,,,,,,,A role played by the entity which regulates molecular activities.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003713,,,,,,,,,,,,,,,,,,,,,,molecular (activity) regulator,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003710,regulator role,role related to regulating,,false,,,http://purl.obolibrary.org/obo/TXPO_0003727,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,role related to regulating,,,,,TXPO:0003710,,,,,,,,,,,,,,,,,,,,,,regulator role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003715,type converter,,type converter is a role played by the entity to change the type of the operand(s),false,,,http://purl.obolibrary.org/obo/TXPO_0003712,,,,,,,,,,,,,,,,,,,,,,type converter is a role played by the entity to change the type of the operand(s),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003715,,,,,,,,,,,,,,,,,,,,,,type converter,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003716,transcription coregulator,,"A role played by the entity that interacts specifically and non-covalently with a DNA-bound DNA-binding transcription factor to either activate or repress the transcription of specific genes. Coregulators often act by altering chromatin structure and modifications. For example, one class of transcription coregulators modifies chromatin structure through covalent modification of histones. A second ATP-dependent class modifies the conformation of chromatin. A third class modulates interactions of DNA-binding transcription factor with other transcription coregulators.|related molecular function GO:0003712",false,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,,,,,,,,,,,,,,,,,,"A role played by the entity that interacts specifically and non-covalently with a DNA-bound DNA-binding transcription factor to either activate or repress the transcription of specific genes. Coregulators often act by altering chromatin structure and modifications. For example, one class of transcription coregulators modifies chromatin structure through covalent modification of histones. A second ATP-dependent class modifies the conformation of chromatin. A third class modulates interactions of DNA-binding transcription factor with other transcription coregulators.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003716,,,,,,,,,,,,,,,,,,,,related molecular function GO:0003712,,transcription coregulator,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100348,RasGRF2,,,false,,,http://purl.obolibrary.org/obo/IMR_0000440,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100348,,,,,,,,,,,,,,,,,,,,,,RasGRF2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000415116,PIM3,,Other designations: serine/threonine kinase Pim-3|serine/threonine-protein kinase pim-3,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,pim-3,,,,,,,,,,,,22,,,,,,Ensembl:ENSG00000198355|Vega:OTTHUMG00000150290|HPRD:15137|MIM:610580|HGNC:19310,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,pim-3 oncogene,,,22q13,,,,,,,,,,,,,,,,"GO_0004674 (EC: IDA, PMID: 18593906); GO_0005515 (EC: IPI, PMID: 17270021); GO_0005524 (EC: IEA); GO_0005737 (EC: IEA); GO_0006468 (EC: IDA, PMID: 18593906); GO_0006915 (EC: IEA); GO_0007049 (EC: IEA); GO_0007346 (EC: IMP, PMID: 17270021); GO_0016572 (EC: IEA); GO_0043066 (EC: IMP, PMID: 17270021); GO_0046777 (EC: IEA); GO_0061179 (EC: ISS)",,,,,,,,,PMID: 10713710; 12477932; 12798037; 15199164; 15489334; 15540201; 16403219; 17270021; 18593906; 19154409; 19266083; 19624871; 20101231; 20939820; 21187426; 21297633; 21646687; 21668797; 21870113; 21906983; 21963094; 22053931; 22939624; 23209281; 23760491; 23845873,,,,,,,,,,,,,,,OGG:3000415116,,20140408,protein-coding,,,,pim-3 oncogene,,,,,,,,,,,,,Other designations: serine/threonine kinase Pim-3|serine/threonine-protein kinase pim-3,,PIM3,,,,,,,,,,,,,,,,,,,,,,,415116,CITF22-49E9.1,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,PIM3,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000284,PLC (mol),phospholipase C,,false,,,http://purl.obolibrary.org/obo/TXPO_0000635,,,,,,,,,,,,,,,,,,,,EC:3.1.4.11|GO:0004629,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003671,,,,,phospholipase C,,,,,IMR:0000284,,,,,,,,,,,,,,,,,,,,,,PLC (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006684,sphingomyelin metabolic process,sphingomyelin metabolism,"The chemical reactions and pathways involving sphingomyelin, N-acyl-4-sphingenyl-1-O-phosphorylcholine, any of a class of phospholipids in which the amino group of sphingosine is in amide linkage with one of several fatty acids, while the terminal hydroxyl group of sphingosine is esterified to phosphorylcholine.",false,,,http://purl.obolibrary.org/obo/GO_0006644,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways involving sphingomyelin, N-acyl-4-sphingenyl-1-O-phosphorylcholine, any of a class of phospholipids in which the amino group of sphingosine is in amide linkage with one of several fatty acids, while the terminal hydroxyl group of sphingosine is esterified to phosphorylcholine.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_64583,,,,,,,,,,,,sphingomyelin metabolism,,,,,GO:0006684,,,,,,,,,,,,,,,,,biological_process,,,,,sphingomyelin metabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006686,sphingomyelin biosynthetic process,sphingomyelin anabolism|sphingomyelin formation|sphingomyelin biosynthesis|sphingomyelin synthesis,"The chemical reactions and pathways resulting in the formation of sphingomyelin, N-acyl-4-sphingenyl-1-O-phosphorylcholine.",false,,,http://purl.obolibrary.org/obo/GO_0006684|http://purl.obolibrary.org/obo/TXPO_0001291,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways resulting in the formation of sphingomyelin, N-acyl-4-sphingenyl-1-O-phosphorylcholine.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_64583,,,,,,,,,,,,,,sphingomyelin anabolism|sphingomyelin formation|sphingomyelin biosynthesis|sphingomyelin synthesis,,,,,GO:0006686,,,,,,,,,,,,,,,,,,,,,,sphingomyelin biosynthetic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006685,sphingomyelin catabolic process,sphingomyelin breakdown|sphingomyelin degradation|sphingomyelin catabolism,"The chemical reactions and pathways resulting in the breakdown of sphingomyelin, N-acyl-4-sphingenyl-1-O-phosphorylcholine.",false,,,http://purl.obolibrary.org/obo/GO_0006684|http://purl.obolibrary.org/obo/TXPO_0001465,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways resulting in the breakdown of sphingomyelin, N-acyl-4-sphingenyl-1-O-phosphorylcholine.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_64583,,,,,,,,,,,,,,,,,,sphingomyelin breakdown|sphingomyelin degradation|sphingomyelin catabolism,,,,,GO:0006685,,,,,,,,,,,,,,,,,biological_process,,,,,sphingomyelin catabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/BFO_0000016,disposition,,,false,,,http://purl.obolibrary.org/obo/BFO_0000017,,,,,,,,,,,,,,,,,,,,,,,,,,BFO 2 Reference: Dispositions exist along a strength continuum. Weaker forms of disposition are realized in only a fraction of triggering cases. These forms occur in a significant number of cases of a similar type.,,"b is a disposition means: b is a realizable entity & b’s bearer is some material entity & b is such that if it ceases to exist, then its bearer is physically changed, & b’s realization occurs when and because this bearer is in some special physical circumstances, & this realization occurs in virtue of the bearer’s physical make-up. (axiom label in BFO2 Reference: [062-002])",children are innately disposed to categorize objects in certain ways.|an atom of element X has the disposition to decay to an atom of element Y|certain people have a predisposition to colon cancer|the cell wall is disposed to filter chemicals in endocytosis and exocytosis,,,,,,,,,,,(forall (x t) (if (and (RealizableEntity x) (existsAt x t)) (exists (y) (and (MaterialEntity y) (specificallyDepends x y t))))) // axiom label in BFO2 CLIF: [063-002]|(forall (x) (if (Disposition x) (and (RealizableEntity x) (exists (y) (and (MaterialEntity y) (bearerOfAt x y t)))))) // axiom label in BFO2 CLIF: [062-002],"If b is a realizable entity then for all t at which b exists, b s-depends_on some material entity at t. (axiom label in BFO2 Reference: [063-002])",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BFO:0000016,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/bfo.owl,disposition,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000686,p38alpha,Mxi2|SAPK2a|RK|CSBP1|CSBP2|SAPK-2|p38/HOG1|p38 MAPK|p40|RK/p38|MPK2|CRK1,,false,,,http://purl.obolibrary.org/obo/IMR_0000226,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Mxi2|SAPK2a|RK|CSBP1|CSBP2|SAPK-2|p38/HOG1|p38 MAPK|p40|RK/p38|MPK2|CRK1,,,,,IMR:0000686,,,,,,,,,,,,,,,,,,,,,,p38alpha,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76761,EC 3.2.* (glycosylase) inhibitor,EC 3.2.* inhibitor|glycosylase inhibitor|glycosylase (EC 3.2.*) inhibitors|glycosylase inhibitors|glycosylase (EC 3.2.*) inhibitor|EC 3.2.* inhibitors|EC 3.2.* (glycosylase) inhibitors,A hydrolase inhibitor that interferes with the action of any glycosylase (EC 3.2.*.*).,false,,,http://purl.obolibrary.org/obo/CHEBI_76759,,,,,,,,,,,,,,,,,,,,,,A hydrolase inhibitor that interferes with the action of any glycosylase (EC 3.2.*.*).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,EC 3.2.* inhibitor|glycosylase inhibitor|glycosylase (EC 3.2.*) inhibitors|glycosylase inhibitors|glycosylase (EC 3.2.*) inhibitor|EC 3.2.* inhibitors|EC 3.2.* (glycosylase) inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:76761,,,,EC 3.2.* (glycosylase) inhibitor,,CHEBI:76761,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000000031,ACACA,,Other designations: ACC-alpha|acetyl-CoA carboxylase 1|acetyl-Coenzyme A carboxylase alpha,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,ACACAD|ACAC|ACC|ACC1|ACCA,,,,,,,,,,,,17,,,,,,MIM:200350|HGNC:84|Ensembl:ENSG00000132142|Vega:OTTHUMG00000133064|HPRD:01938,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,acetyl-CoA carboxylase alpha,,,17q21,,,,,,,,,,,,,,,,"GO_0001894 (EC: IEA); GO_0003989 (EC: ISS); GO_0003989 (EC: TAS); GO_0004075 (EC: IEA); GO_0005515 (EC: IPI, PMID: 16326698); GO_0005524 (EC: IEA); GO_0005739 (EC: IEA); GO_0005829 (EC: ISS); GO_0005829 (EC: TAS); GO_0006084 (EC: ISS); GO_0006112 (EC: TAS); GO_0006633 (EC: ISS); GO_0006766 (EC: TAS); GO_0006767 (EC: TAS); GO_0006768 (EC: TAS); GO_0006853 (EC: TAS); GO_0019432 (EC: TAS); GO_0031325 (EC: TAS); GO_0035338 (EC: TAS); GO_0044255 (EC: TAS); GO_0044268 (EC: IEA); GO_0044281 (EC: TAS); GO_0046872 (EC: IEA); GO_0051289 (EC: ISS); GO_0055088 (EC: IEA); GO_2001295 (EC: IEA)",,,,,,,,,PMID: 2900138; 2900140; 2906852; 7732023; 7905825; 7907095; 7915280; 8944226; 10677481; 10737800; 11052978; 12360400; 12477932; 12810950; 14643797; 15302935; 15333468; 15607423; 16169070; 16326698; 16698035; 16713569; 16794074; 16806233; 17081983; 17372234; 17521700; 17620599; 17631500; 18031993; 18056116; 18303054; 18452305; 18455495; 18487259; 18614941; 18614968; 18660489; 18678647; 18996102; 19061860; 19343720; 19380743; 19543203; 19710915; 19720090; 19723093; 19738201; 19842072; 19846279; 19913121; 20139635; 20379614; 20431927; 20457939; 20562859; 20602615; 20628086; 20877624; 20965718; 21139048; 21344388; 21471234; 21638027; 21642987; 21726077; 21890473; 21906983; 22238651; 22268729; 22505724; 22586326; 22863883; 22939629; 23000302; 23181366; 23383273; 23455922; 23535730; 23886516; 24457600,,,,,,,,,,,,,,,OGG:3000000031,,,,,,,acetyl-CoA carboxylase alpha,,,,,,,,,,,,,Other designations: ACC-alpha|acetyl-CoA carboxylase 1|acetyl-Coenzyme A carboxylase alpha,,ACACA,,,,,,,,,,,,,,,,,,,,,,,31,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,ACACA,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000000032,ACACB,,Other designations: ACC-beta|acetyl-CoA carboxylase 2|acetyl-Coenzyme A carboxylase beta,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,ACC2|HACC275|ACCB,,,,,,,,,,,,12,,,,,,Ensembl:ENSG00000076555|MIM:601557|Vega:OTTHUMG00000169250|HGNC:85|HPRD:07044,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,acetyl-CoA carboxylase beta,,,12q24.11,,,,,,,,,,,,,,,,"GO_0003989 (EC: IDA); GO_0004075 (EC: IEA); GO_0005515 (EC: IPI, PMID: 16794074); GO_0005524 (EC: IEA); GO_0005741 (EC: TAS); GO_0005829 (EC: TAS); GO_0006084 (EC: IDA); GO_0006112 (EC: TAS); GO_0006633 (EC: IEA); GO_0006766 (EC: TAS); GO_0006767 (EC: TAS); GO_0006768 (EC: TAS); GO_0006853 (EC: TAS); GO_0009374 (EC: IEA); GO_0012505 (EC: IEA); GO_0014070 (EC: IEA); GO_0031325 (EC: TAS); GO_0042493 (EC: IEA); GO_0044255 (EC: TAS); GO_0044281 (EC: TAS); GO_0046872 (EC: IEA); GO_0051289 (EC: IDA); GO_2001295 (EC: IEA)",,,,,,,,,PMID: 8670171; 8876158; 9099716; 9148944; 9284908; 10677481; 11257506; 12086953; 12413941; 12477932; 14532170; 14613924; 14627750; 15060529; 15590647; 16054041; 16794074; 16854592; 17223360; 17521700; 18029348; 18031993; 18455495; 18976975; 18996102; 19034549; 19190759; 19322201; 19390150; 19618481; 19720090; 19846279; 19900410; 20085763; 20139635; 20168990; 20379614; 20468064; 20514549; 20519229; 20599696; 20602615; 20799892; 20855566; 20877624; 20965718; 21139048; 21344388; 21553357; 21887335; 21906983; 21908218; 21953464; 23081748; 23156397; 23455922; 23460794; 24255178,,,,,,,,,,,,,,,OGG:3000000032,,,,,,,acetyl-CoA carboxylase beta,,,,,,,,,,,,,Other designations: ACC-beta|acetyl-CoA carboxylase 2|acetyl-Coenzyme A carboxylase beta,,ACACB,,,,,,,,,,,,,,,,,,,,,,,32,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,ACACB,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0003986,sphingomyelin homeostasis imbalance [Niemann Pick Disease Type A],,"Sphingomyelin homeostasis imbalance is a subtype of lipid homeostasis imbalance: A process that becomes lacking a phospholipid homeostastasis balance.
This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type A.",false,,,http://purl.obolibrary.org/obo/TXPO_0003988,,,,,,,,,,,,,,,,,,,,,,"Sphingomyelin homeostasis imbalance is a subtype of lipid homeostasis imbalance: A process that becomes lacking a phospholipid homeostastasis balance.
This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type A.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001482,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001815,,http://purl.obolibrary.org/obo/TXPO_0002327,,,,,,,,,TXPO:0003986,,,,,,,,,,,,,,,,,,,,,,sphingomyelin homeostasis imbalance [Niemann Pick Disease Type A],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003980,ARK5 (canonical)[Ground glass appearance],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000472|http://purl.obolibrary.org/obo/TXPO_0003982,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:299694|NCBI-Mouse-GeneID:77976|NCBI-Human-GeneID:9891|PMID:21317932,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003980,,,,,,,,,,,,,,,,,,,,,,ARK5 (canonical)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003982,NUAK1 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0003981,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003982,,,,,,,,,,,,,,,,,,,,,,NUAK1 (mol),,,,,,,,,,,,,,,,,,,,,,,9891,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003988,sphingomyelin homeostasis imbalance [Niemann Pick Disease Type A/ B],,"Sphingomyelin homeostasis imbalance is a subtype of lipid homeostasis imbalance: A process that becomes lacking a phospholipid homeostastasis balance.
This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type A/ B.",false,,,http://purl.obolibrary.org/obo/TXPO_0003984,,,,,,,,,,,,,,,,,,,,,,"Sphingomyelin homeostasis imbalance is a subtype of lipid homeostasis imbalance: A process that becomes lacking a phospholipid homeostastasis balance.
This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type A/ B.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001476,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001807,,,,,,,,,,,TXPO:0003988,,,,,,,,,,,,,,,,,,,,,,sphingomyelin homeostasis imbalance [Niemann Pick Disease Type A/ B],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003983,Myc (rat)[Ground glass appearance],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000985|http://purl.obolibrary.org/obo/IMR_0000383,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24577,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000383,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003983,,,,,,,,,,,,,,,,,,,,,,Myc (rat)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003984,sphingomyelin homeostasis imbalance [Phospholipidosis - genetic],,"Sphingomyelin homeostasis imbalance is a subtype of lipid homeostasis imbalance: A process that becomes lacking a phospholipid homeostastasis balance.
This process is dependent on the  genetic and can constitute the course of Phospholipidosis (genetic).",false,,,http://purl.obolibrary.org/obo/TXPO_0004159|http://purl.obolibrary.org/obo/TXPO_0000907,,,,,,,,,,,,,,,,,,,,,,"Sphingomyelin homeostasis imbalance is a subtype of lipid homeostasis imbalance: A process that becomes lacking a phospholipid homeostastasis balance.
This process is dependent on the  genetic and can constitute the course of Phospholipidosis (genetic).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001768,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001690,,,,,,,,,,,TXPO:0003984,,,,,,,,,,,,,,,,,,,,,,sphingomyelin homeostasis imbalance [Phospholipidosis - genetic],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003985,phospholipid homeostasis imbalance [Phospholipidosis - genetic],,"Phospholipid homeostasis imbalance is a subtype of lipid homeostasis imbalance: A process that becomes lacking a phospholipid homeostastasis balance.
This process is dependent on the  genetic and can constitute the course of Phospholipidosis (genetic).",false,,,http://purl.obolibrary.org/obo/TXPO_0000907,,,,,,,,,,,,,,,,,,,,,,"Phospholipid homeostasis imbalance is a subtype of lipid homeostasis imbalance: A process that becomes lacking a phospholipid homeostastasis balance.
This process is dependent on the  genetic and can constitute the course of Phospholipidosis (genetic).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001776,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002070,,,,,,,,,,,TXPO:0003985,,,,,,,,,,,,,,,,,,,,,,phospholipid homeostasis imbalance [Phospholipidosis - genetic],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003981,NUAK,NUAK Family Kinase,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,NUAK Family Kinase,,,,,TXPO:0003981,,,,,,,,,,,,,,,,,,,,,,NUAK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003989,competitive inhibitor,,A role played by the entity that diminishes the rate of a chemical reaction competitively.,false,,,http://purl.obolibrary.org/obo/CHEBI_35222,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/SBO_0000206,,A role played by the entity that diminishes the rate of a chemical reaction competitively.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003989,,,,,,,,,,,,,,,,,,,,,,competitive inhibitor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003987,sphingomyelin homeostasis imbalance [Niemann Pick Disease Type B],,"Sphingomyelin homeostasis imbalance is a subtype of lipid homeostasis imbalance: A process that becomes lacking a phospholipid homeostastasis balance.
This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type B.",false,,,http://purl.obolibrary.org/obo/TXPO_0003988,,,,,,,,,,,,,,,,,,,,,,"Sphingomyelin homeostasis imbalance is a subtype of lipid homeostasis imbalance: A process that becomes lacking a phospholipid homeostastasis balance.
This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type B.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001816,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001809,,,,,,,,,,,TXPO:0003987,,,,,,,,,,,,,,,,,,,,,,sphingomyelin homeostasis imbalance [Niemann Pick Disease Type B],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0007249,I-kappaB kinase/NF-kappaB signaling,I-kappaB kinase-NF-kappaB signal transduction pathway,"The process in which a signal is passed on to downstream components within the cell through the I-kappaB-kinase (IKK)-dependent activation of NF-kappaB. The cascade begins with activation of a trimeric IKK complex (consisting of catalytic kinase subunits IKKalpha and/or IKKbeta, and the regulatory scaffold protein NEMO) and ends with the regulation of transcription of target genes by NF-kappaB. In a resting state, NF-kappaB dimers are bound to I-kappaB proteins, sequestering NF-kappaB in the cytoplasm. Phosphorylation of I-kappaB targets I-kappaB for ubiquitination and proteasomal degradation, thus releasing the NF-kappaB dimers, which can translocate to the nucleus to bind DNA and regulate transcription. PMID:12773372",false,,,http://purl.obolibrary.org/obo/TXPO_0000027,,,,,,,,,,,,,,,,,,,,,,"The process in which a signal is passed on to downstream components within the cell through the I-kappaB-kinase (IKK)-dependent activation of NF-kappaB. The cascade begins with activation of a trimeric IKK complex (consisting of catalytic kinase subunits IKKalpha and/or IKKbeta, and the regulatory scaffold protein NEMO) and ends with the regulation of transcription of target genes by NF-kappaB. In a resting state, NF-kappaB dimers are bound to I-kappaB proteins, sequestering NF-kappaB in the cytoplasm. Phosphorylation of I-kappaB targets I-kappaB for ubiquitination and proteasomal degradation, thus releasing the NF-kappaB dimers, which can translocate to the nucleus to bind DNA and regulate transcription. PMID:12773372",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002779|http://purl.obolibrary.org/obo/TXPO_0002785|http://purl.obolibrary.org/obo/TXPO_0002781|http://purl.obolibrary.org/obo/TXPO_0002789|http://purl.obolibrary.org/obo/TXPO_0002783,,,,,,,,,,,,,I-kappaB kinase-NF-kappaB signal transduction pathway,,,,,GO:0007249,,,,,,,,,,,,,,,,,,,,,,I-kappaB kinase/NF-kappaB signaling,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100708,Bax subfamily,,,false,,,http://purl.obolibrary.org/obo/IMR_0100707,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100708,,,,,,,,,,,,,,,,,,,,,,Bax subfamily,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0007005,mitochondrion organization,,"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a mitochondrion; includes mitochondrial morphogenesis and distribution, and replication of the mitochondrial genome as well as synthesis of new mitochondrial components.",false,,,http://purl.obolibrary.org/obo/TXPO_0000468,,,,,,,,,,,,,,,,,,,,,,"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a mitochondrion; includes mitochondrial morphogenesis and distribution, and replication of the mitochondrial genome as well as synthesis of new mitochondrial components.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0007005,,,,,,,,,,,,,,,,,,,,,,mitochondrion organization,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_3179,bromobenzene,,"The simplest member of the class of bromobenzenes, that is benzene in which a single hydrogen has been substituted by a bromine. A liquid at room temperature (m.p. -30degreeC; b.p.760 156degreeC), it is used as a solvent, particularly for large-scale crystallisations, and for the introduction of phenyl groups in organic synthesis.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:10996478|MetaCyc:BROMOBENZENE|CAS:108-86-1|PMID:24318069|Reaxys:1236661|Wikipedia:Bromobenzene,,"The simplest member of the class of bromobenzenes, that is benzene in which a single hydrogen has been substituted by a bromine. A liquid at room temperature (m.p. -30degreeC; b.p.760 156degreeC), it is used as a solvent, particularly for large-scale crystallisations, and for the introduction of phenyl groups in organic synthesis.",,,,,,,,,,,,C6H5Br,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:3179,,,,,,,,,,,,,,,,,,,,,,bromobenzene,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Brc1ccccc1,,,,,
http://purl.obolibrary.org/obo/IMR_0000973,LRP8 (mol),low density lipoprotein receptor-related protein 8|LDL receptor-related protein 8,,false,,,http://purl.obolibrary.org/obo/IMR_0100798,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,low density lipoprotein receptor-related protein 8|LDL receptor-related protein 8,,,,,IMR:0000973,,,,,,,,,,,,,,,,,,,,,,LRP8 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000051390,AIG1,,Other designations: androgen-induced gene 1 protein,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,dJ95L4.1|AIG-1,,,,,,,,,,,,6,,,,,,Ensembl:ENSG00000146416|MIM:608514|Vega:OTTHUMG00000015721|HPRD:16346|HGNC:21607,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,androgen-induced 1,,,6q24.2,,,,,,,,,,,,,,,,GO_0005515 (EC: IPI); GO_0016021 (EC: IEA),,,,,,,,,PMID: 8125298; 8889548; 10810093; 11266118; 11329013; 12477932; 14574404; 14702039; 15489334; 16344560; 20379614; 21622095; 21988832,,,,,,,,,,,,,,,OGG:3000051390,,,,,,,androgen-induced 1,,,,,,,,,,,,,Other designations: androgen-induced gene 1 protein,,AIG1,,,,,,,,,,,,,,,,,,,,,,,51390,RP1-95L4.1,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,AIG1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/GO_0005829,cytosol,,"The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes.",false,,,http://purl.obolibrary.org/obo/TXPO_0000065,,,,,,,,,,,,,,,,,,,,NIF_Subcellular:sao101633890|Wikipedia:Cytosol,,"The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005737,GO:0005829,http://purl.obolibrary.org/obo/GO_0005737,,,,,,,,,,,,,,,,,,,,,cytosol,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_133190,fatty acid oxidation inhibitor,,A role played by the entity which inhibits the oxidation of any fatty acid.,false,,,http://purl.obolibrary.org/obo/TXPO_0003648,,,,,,,http://purl.obolibrary.org/obo/GO_0019395,,,,,,,,,,,,,,,A role played by the entity which inhibits the oxidation of any fatty acid.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:133190,,,,,,,,,,,,,,,,,,,,,,fatty acid oxidation inhibitor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_33709,amino acid,,A carboxylic acid containing one or more amino groups.|Organic compounds that generally contain an amino (-NH2) and a carboxyl (-COOH) group. Twenty alpha-amino acids are the subunits which are polymerized to form proteins.,false,,,http://purl.obolibrary.org/obo/CHEBI_72695,,,,,,,,,,,,,,,,,,,,,,A carboxylic acid containing one or more amino groups.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:33709,,,,,,,,,,,,,,,,,,,,Organic compounds that generally contain an amino (-NH2) and a carboxyl (-COOH) group. Twenty alpha-amino acids are the subunits which are polymerized to form proteins.,,amino acid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001572,Rab6A,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001572,,,,,,,,,,,,,,,,,,,,,,Rab6A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000090693,CCDC126,,Other designations: coiled-coil domain-containing protein 126,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,7,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,coiled-coil domain containing 126,,,7p15.3,,,,,,,,,,,,,,,,GO_0005576 (EC: IEA); GO_0006487 (EC: IEA); GO_0030144 (EC: IEA),,,,,,,,,PMID: 9847074; 12477932; 12690205; 12975309; 23275563,,,,,,,,,,,,,,,OGG:3000090693,,,,,,,coiled-coil domain containing 126,,,,,,,,,,,,,Other designations: coiled-coil domain-containing protein 126,,CCDC126,,,,,,,,,,,,,,,,,,,,,,,90693,UNQ786/PRO1605,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,CCDC126,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_7494,nefazodone,"nefazodonum|nefazodone|nefazodona|1-(3-(4-(m-Chlorophenyl)-1-piperazinyl)propyl)-3-ethyl-4-(2-phenoxyethyl)-delta2-1,2,4-triazolin-5-one|2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-5-ethyl-4-(2-phenoxyethyl)-2,4-dihydro-3H-1,2,4-triazol-3-one|nefazodone|Nefazodone",,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,LINCS:LSM-4031|CAS:83366-66-9|Beilstein:4728403|DrugBank:DB01149|Drug_Central:1890,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_50949|http://purl.obolibrary.org/obo/CHEBI_35480|http://purl.obolibrary.org/obo/CHEBI_48279|http://purl.obolibrary.org/obo/CHEBI_37890|http://purl.obolibrary.org/obo/CHEBI_35469,,,,,"2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-5-ethyl-4-(2-phenoxyethyl)-2,4-dihydro-3H-1,2,4-triazol-3-one|nefazodone|Nefazodone",,"nefazodonum|nefazodone|nefazodona|1-(3-(4-(m-Chlorophenyl)-1-piperazinyl)propyl)-3-ethyl-4-(2-phenoxyethyl)-delta2-1,2,4-triazolin-5-one",,,,,,,,,,,,,,,,,,,,,CHEBI:7494,,,,nefazodone,,CHEBI:7494,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_7496,nelfinavir,,An aryl sulfide that is used (as its mesylate salt) for treatment of HIV and also exhibits some anticancer properties.,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,,,An aryl sulfide that is used (as its mesylate salt) for treatment of HIV and also exhibits some anticancer properties.,,,,,,,,,,,,C32H45N3O4S,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35610|http://purl.obolibrary.org/obo/CHEBI_35660,,,,,,,,,,CHEBI:7496,,,,,,,,,,,,,,,,,,,,,,nelfinavir,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C,,,,,
http://purl.obolibrary.org/obo/IMR_0001845,p70S6K,70 kDa ribosomal S6 kinase,,false,,,http://purl.obolibrary.org/obo/IMR_0001844,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,70 kDa ribosomal S6 kinase,,,,,IMR:0001845,,,,,,,,,,,,,,,,,,,,,,p70S6K,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_50949,serotonin uptake inhibitor,serotonin reuptake inhibitor|SSRI,A compound that specifically inhibits the reuptake of serotonin in the brain. This increases the serotonin concentration in the synaptic cleft which then activates serotonin receptors to a greater extent.,false,,,http://purl.obolibrary.org/obo/CHEBI_48278,,,,,,,,,,,,,,,,,,,,,,A compound that specifically inhibits the reuptake of serotonin in the brain. This increases the serotonin concentration in the synaptic cleft which then activates serotonin receptors to a greater extent.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,serotonin reuptake inhibitor|SSRI,,,,,,,,,,,,,,,,,,,,,CHEBI:50949,,,,serotonin uptake inhibitor,,CHEBI:50949,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000454,IAP-family,inhibitor of apoptosis-family,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000327,,,,,inhibitor of apoptosis-family,,,,,IMR:0000454,,,,,,,,,,,,,,,,,,,,,,IAP-family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100099,follicle stimulating hormone,follitropin|FSH,"A major gonadotropin secreted by the adenohypophysis ( PITUITARY GLAND, ANTERIOR). Follicle-stimulating hormone stimulates GAMETOGENESIS and the supporting cells such as the ovarian GRANULOSA CELLS, the testicular SERTOLI CELLS, and LEYDIG CELLS. FSH consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the three pituitary glycoprotein hormones (TSH, LH, and FSH), but the beta subunit is unique and confers its biological specificity.",false,,,http://purl.obolibrary.org/obo/IMR_0100098,,,,,,,,,,,,,,,,,,,,MeSH:D005640,,"A major gonadotropin secreted by the adenohypophysis ( PITUITARY GLAND, ANTERIOR). Follicle-stimulating hormone stimulates GAMETOGENESIS and the supporting cells such as the ovarian GRANULOSA CELLS, the testicular SERTOLI CELLS, and LEYDIG CELLS. FSH consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the three pituitary glycoprotein hormones (TSH, LH, and FSH), but the beta subunit is unique and confers its biological specificity.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,follitropin|FSH,,,,,IMR:0100099,,,,,,,,,,,,,,,,,,,,,,follicle stimulating hormone,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000000012,SERPINA3,,"Other designations: alpha-1-antichymotrypsin|cell growth-inhibiting gene 24/25 protein|growth-inhibiting protein 24|growth-inhibiting protein 25|serine (or cysteine) proteinase inhibitor, clade A, member 3|serpin A3",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,AACT|GIG25|ACT,,,,,,,,,,,,14,,,,,,MIM:107280|Vega:OTTHUMG00000029851|Ensembl:ENSG00000196136|HGNC:16|HPRD:00120,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3",,,14q32.1,,,,,,,,,,,,,,,,"GO_0003677 (EC: TAS, PMID: 14668352); GO_0004867 (EC: IBA); GO_0004867 (EC: TAS, PMID: 2404007); GO_0005515 (EC: IPI, PMID: 12709365); GO_0005576 (EC: IBA); GO_0005576 (EC: NAS, PMID: 14718574); GO_0005622 (EC: NAS, PMID: 9880565); GO_0005634 (EC: TAS, PMID: 14668352); GO_0006953 (EC: IEA); GO_0006954 (EC: NAS, PMID: 12475184); GO_0010951 (EC: IBA); GO_0019216 (EC: NAS, PMID: 11835318); GO_0030162 (EC: IBA); GO_0030277 (EC: NAS, PMID: 8647626); GO_0070062 (EC: IDA, PMID: 19056867); GO_0072562 (EC: IDA)",,,,,,,,,PMID: 123121; 1311327; 1351206; 1618300; 2016749; 2190106; 2404007; 2432851; 2435303; 2456771; 2787670; 2945424; 3028924; 3257719; 3260956; 3485824; 3490907; 3492865; 3637050; 6547997; 6556193; 6606438; 6687683; 6762318; 7521171; 7528097; 7588564; 7759598; 7873202; 7924407; 7966721; 8011628; 8216224; 8226889; 8244391; 8267879; 8365378; 8376411; 8647626; 8718849; 8732755; 8739078; 8836107; 8849841; 9042371; 9261179; 9428387; 9521649; 9580375; 9635374; 9698370; 9824262; 9880565; 10048303; 10209959; 10228625; 10512690; 10618372; 10660528; 10759471; 10829039; 11096092; 11099722; 11132933; 11161981; 11274154; 11289720; 11290389; 11295654; 11317942; 11385264; 11692021; 11735417; 11769703; 11798857; 11835318; 11916200; 11936240; 11959399; 11992569; 12023832; 12126519; 12324297; 12475184; 12477932; 12600202; 12685871; 12709365; 12736093; 12754519; 12782964; 14668352; 14687906; 14702039; 14718574; 14760718; 15014966; 15131125; 15159602; 15482730; 15489334; 15530656; 15542006; 15546506; 15612581; 15638460; 15653173; 15659365; 15718509; 15907346; 15935385; 16099106; 16137793; 16278826; 16303762; 16335952; 16424370; 16453284; 16565071; 16712791; 16892178; 16968986; 17207965; 17608807; 17690329; 17854420; 18056971; 18078695; 18248459; 18383875; 18401426; 18408372; 18842294; 18991685; 19008959; 19056867; 19165527; 19247692; 19341158; 19390575; 19525388; 19578796; 19590686; 19789190; 19907165; 19913121; 19933216; 19959196; 20117085; 20158662; 20302328; 20378355; 20444200; 20628086; 21067581; 21296644; 21674799; 21693707; 21730889; 21988832; 22079093; 22246292; 22272609; 22294107; 22806587; 22869038; 23669352; 24172014,,,,,,,,,,,,,,,OGG:3000000012,,,,,,,"serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3",,,,,,,,,,,,,"Other designations: alpha-1-antichymotrypsin|cell growth-inhibiting gene 24/25 protein|growth-inhibiting protein 24|growth-inhibiting protein 25|serine (or cysteine) proteinase inhibitor, clade A, member 3|serpin A3",,SERPINA3,,,,,,,,,,,,,,,,,,,,,,,12,GIG24,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,SERPINA3,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0003706,GTP-binding protein,G-protein,re;ated molecular function GO:0005525,false,,,http://purl.obolibrary.org/obo/TXPO_0003709,,,,,,,,,,,,,,,,,,,,IMR:0000914 (obsolete),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,G-protein,,,,,TXPO:0003706,,,,,,,,,,,,,,,,,,,,re;ated molecular function GO:0005525,,GTP-binding protein,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003704,bile acid:sodium symporter,sodium/bile acid symporter,A role played by the entity which enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: bile acid(out) + Na+(out) = bile acid(in) + Na+(in).|related molecular function GO:0008508,false,,,http://purl.obolibrary.org/obo/TXPO_0003703,,,,,,,,,,,,,,,,,,,,,,A role played by the entity which enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: bile acid(out) + Na+(out) = bile acid(in) + Na+(in).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sodium/bile acid symporter,,,,,TXPO:0003704,,,,,,,,,,,,,,,,,,,,related molecular function GO:0008508,,bile acid:sodium symporter,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003709,role related to assembling,,A role played by the entity to make multiple components to an assembly,false,,,http://purl.obolibrary.org/obo/TXPO_0003727,,,,,,,,,,,,,,,,,,,,,,A role played by the entity to make multiple components to an assembly,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003709,,,,,,,,,,,,,,,,,,,,,,role related to assembling,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003700,phospholipid transporter,,"A role played by the entity which enables the directed movement of phospholipids into, out of or within a cell, or between cells. Phospholipids are a class of lipids containing phosphoric acid as a mono- or diester.|related molecular function GO:0005548",false,,,http://purl.obolibrary.org/obo/TXPO_0003699,,,,,,,,,,,,,,,,,,,,,,"A role played by the entity which enables the directed movement of phospholipids into, out of or within a cell, or between cells. Phospholipids are a class of lipids containing phosphoric acid as a mono- or diester.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003700,,,,,,,,,,,,,,,,,,,,related molecular function GO:0005548,,phospholipid transporter,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003705,role related to changing size,,A role played by the entity which changes the size of the operand(s).,false,,,http://purl.obolibrary.org/obo/TXPO_0003708,,,,,,,,,,,,,,,,,,,,,,A role played by the entity which changes the size of the operand(s).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003705,,,,,,,,,,,,,,,,,,,,,,role related to changing size,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003701,sugar transmembrane transporter,,"A role played by the entity which enables the transfer of a sugar from one side of a membrane to the other. A sugar is any member of a class of sweet, water-soluble, crystallizable carbohydrates, which are the monosaccharides and smaller oligosaccharides.",false,,,http://purl.obolibrary.org/obo/TXPO_0003698,,,,,,,,,,,,,,,,,,,,,,"A role played by the entity which enables the transfer of a sugar from one side of a membrane to the other. A sugar is any member of a class of sweet, water-soluble, crystallizable carbohydrates, which are the monosaccharides and smaller oligosaccharides.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003701,,,,,,,,,,,,,,,,,,,,,,sugar transmembrane transporter,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003702,ion transmembrane transporter,,A role played by the entity which enables the transfer of an ion from one side of a membrane to the other up the solute's concentration gradient. This is carried out by binding the solute and undergoing a series of conformational changes. Transport works equally well in either direction.|related molecular finction GO:0015075,false,,,http://purl.obolibrary.org/obo/TXPO_0003702|http://purl.obolibrary.org/obo/TXPO_0003698,,,,,,,,,,,,,,,,,,,,,,A role played by the entity which enables the transfer of an ion from one side of a membrane to the other up the solute's concentration gradient. This is carried out by binding the solute and undergoing a series of conformational changes. Transport works equally well in either direction.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003702,,,,,,,,,,,,,,,,,,,,related molecular finction GO:0015075,,ion transmembrane transporter,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003707,trimeric G-protein,trimeric GTP-binding protein|G-protein|heterotrimeric G-protein,"The entity of the alpha, beta, and gamma subunits (or beta-gamma dimers) of heterotrimeric guanine nucleotide binding (G) proteins.
It is an intracellular membrane-associated protein activated by various receptors (e.g., beta adrenergic). It serves as transducers of the receptor-initiated response linked to intracellular elements, such as enzymes, that generate second messengers to initiate an effect.",false,,,http://purl.obolibrary.org/obo/TXPO_0003706,,,,,,,,,,,,,,,,,,,,,,"The entity of the alpha, beta, and gamma subunits (or beta-gamma dimers) of heterotrimeric guanine nucleotide binding (G) proteins.
It is an intracellular membrane-associated protein activated by various receptors (e.g., beta adrenergic). It serves as transducers of the receptor-initiated response linked to intracellular elements, such as enzymes, that generate second messengers to initiate an effect.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,trimeric GTP-binding protein|G-protein|heterotrimeric G-protein,,,,,TXPO:0003707,,,,,,,,,,,,,,,,,,,,,,trimeric G-protein,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003708,role related to changing quality,,A role played by the entity which changes the quality of the operand(s).,false,,,http://purl.obolibrary.org/obo/TXPO_0003712,,,,,,,,,,,,,,,,,,,,,,A role played by the entity which changes the quality of the operand(s).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003708,,,,,,,,,,,,,,,,,,,,,,role related to changing quality,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003703,bile acid transmembrane transporter,,"A role played by the entity which enables the transfer of bile acid from one side of a membrane to the other. Bile acids are any of a group of steroid carboxylic acids occurring in bile, where they are present as the sodium salts of their amides with glycine or taurine.|related molecular function GO:0015125",false,,,http://purl.obolibrary.org/obo/TXPO_0003698,,,,,,,,,,,,,,,,,,,,Reactome:REACT_10072|Reactome:REACT_10124|Reactome:REACT_10091,,"A role played by the entity which enables the transfer of bile acid from one side of a membrane to the other. Bile acids are any of a group of steroid carboxylic acids occurring in bile, where they are present as the sodium salts of their amides with glycine or taurine.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003703,,,,,,,,,,,,,,,,,,,,related molecular function GO:0015125,,bile acid transmembrane transporter,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_3619,chlormezanone,"chlormethazanone|2-(p-chlorophenyl)tetrahydro-3-methyl-4H-1,3-thiazin-4-one 1,1-dioxide|chlormezanona|(+-)-chlormezanone|chlormezanonum|2-(p-chlorphenyl)-3-methyl-1,3-perhydrothiazin-4-on-1,1-dioxide|chlormezanone|2-(4-chlorophenyl)-3-methyl-1,3-thiazinan-4-one 1,1-dioxide","A 1,3-thiazine that is 1,3-thiazinan-4-one S,S-dioxide in which a hydrogen at position 2 is substituted by a 4-chlorophenyl group and the hydrogen attached to the nitrogen is substituted by methyl. A non-benzodiazepine muscle relaxant, it was used in the management of anxiety and in the treatment of muscle spasms until being discontinued worldwide by its manufacturer in 1996, due to rare but serious cutaneous reactions.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:3449070|PMID:15897685|DrugBank:DB01178|PMID:10412893|PMID:9770210|Reaxys:23033|PMID:3720548|PMID:3768082|LINCS:LSM-4356|PMID:6403110|PMID:7758315|PMID:10798243|Beilstein:23033|PMID:10191862|PMID:7104168|Drug_Central:603|CAS:80-77-3|PMID:29438107,,"A 1,3-thiazine that is 1,3-thiazinan-4-one S,S-dioxide in which a hydrogen at position 2 is substituted by a 4-chlorophenyl group and the hydrogen attached to the nitrogen is substituted by methyl. A non-benzodiazepine muscle relaxant, it was used in the management of anxiety and in the treatment of muscle spasms until being discontinued worldwide by its manufacturer in 1996, due to rare but serious cutaneous reactions.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_51371|http://purl.obolibrary.org/obo/CHEBI_35474|http://purl.obolibrary.org/obo/CHEBI_35476,,,,,"2-(4-chlorophenyl)-3-methyl-1,3-thiazinan-4-one 1,1-dioxide",,"chlormethazanone|2-(p-chlorophenyl)tetrahydro-3-methyl-4H-1,3-thiazin-4-one 1,1-dioxide|chlormezanona|(+-)-chlormezanone|chlormezanonum|2-(p-chlorphenyl)-3-methyl-1,3-perhydrothiazin-4-on-1,1-dioxide|chlormezanone",,,,,,,,,,,,,,,,,,,,,CHEBI:3619,,,,chlormezanone,,CHEBI:3619,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001923,MAM family,mastermind family,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003717,,,,,mastermind family,,,,,IMR:0001923,,,,,,,,,,,,,,,,,,,,,,MAM family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_135273,clomacran,clomacran phosphate,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:5310-55-4|Drug_Central:3717,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,clomacran phosphate,,,,,,,,,,,,,,,,,,,,,CHEBI:135273,,,,clomacran,,CHEBI:135273,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001505,changing time length,,Changing time length is a subtype of changing quality: A process that changes the length of time.,false,,,http://purl.obolibrary.org/obo/TXPO_0000415,,,,,,,,,,,,,,,,,,,,,,Changing time length is a subtype of changing quality: A process that changes the length of time.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001505,,,,,,,,,,,,,,,,,,,,,,changing time length,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001508,myelin figure [Liver Pathological Findings],myelinsome [Liver PathologicalFindings]|myeloid body [Liver PathologicalFindings]|membranous cytoplasmic body,"myelin figure [Liver PathologicalFindings] is a type of finding observed in the liver. Based on pathological morphology, lesions are observed as myelin-like layered structures under electron microscopy.",false,,,http://purl.obolibrary.org/obo/TXPO_0001507,,,,,,,,,,,,,,,,,,,,,,"myelin figure [Liver PathologicalFindings] is a type of finding observed in the liver. Based on pathological morphology, lesions are observed as myelin-like layered structures under electron microscopy.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,membranous cytoplasmic body,,myelinsome [Liver PathologicalFindings]|myeloid body [Liver PathologicalFindings],,,TXPO:0001508,,,,,,,,,,,,,,,,,,,,,,myelin figure [Liver Pathological Findings],,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005764,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001501,hyperfunction of uptaking fatty acid,,Hyperfunction of uptaking fatty acid into liver is a a process that performs an excesssive uptaking of fatty acids into the iver.,false,,,http://purl.obolibrary.org/obo/TXPO_0001681,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of uptaking fatty acid into liver is a a process that performs an excesssive uptaking of fatty acids into the iver.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001501,,,,,,,,,,,,,,,,,,,,,,hyperfunction of uptaking fatty acid,,,,,,http://purl.obolibrary.org/obo/TXPO_0001501,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001503,finding,,"Finding is a subtype of data item that  the result (output) of an investigation or an image finding, or some combination thereof.",false,,,http://purl.obolibrary.org/obo/TXPO_0000614,,,,,,,,,,,,,,,,,,,,,,"Finding is a subtype of data item that  the result (output) of an investigation or an image finding, or some combination thereof.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001503,,,,,,,,,,,,,,,,,,,,,,finding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001509,nuclear receptor family,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,GO:0004879,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001509,,,,,,,,,,,,,,,,,,,,,,nuclear receptor family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001507,pathological finding,,"A pathological finding is a subtype of finding, which is observed as the lesion based on the pathological morphology.",false,,,http://purl.obolibrary.org/obo/TXPO_0001503,,,,,,,,,,,,,,,,,,,,,,"A pathological finding is a subtype of finding, which is observed as the lesion based on the pathological morphology.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001507,,,,,,,,,,,,,,,,,,,,,,pathological finding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001506,ATP-BINDING cassette (ABC) transporter superfamily (canonical)[Cholestasis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000276|http://purl.obolibrary.org/obo/TXPO_0002694|http://purl.obolibrary.org/obo/TXPO_1000014,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001506,,,,,,,,,,,,,,,,,,,,,,ATP-BINDING cassette (ABC) transporter superfamily (canonical)[Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001500,hyperfunction of uptaking fatty acid  [lipidosis],,"Hyperfunction of uptaking fatty acid into liver is a a process that performs an excesssive uptaking of fatty acids into the iver.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001501|http://purl.obolibrary.org/obo/TXPO_0001720,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of uptaking fatty acid into liver is a a process that performs an excesssive uptaking of fatty acids into the iver.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001498,,,,,,http://purl.obolibrary.org/obo/TXPO_0003811,,,,,,,,,,,TXPO:0001500,,,,,,,,,,,,,,,,,,,,,,hyperfunction of uptaking fatty acid  [lipidosis],,,,,,http://purl.obolibrary.org/obo/TXPO_0001500,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001504,SLCO2B1 (canonical)[Cholestasis],OATP2B1,,false,,,http://purl.obolibrary.org/obo/TXPO_0000272,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C107150,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,OATP2B1,,,,,TXPO:0001504,,,,,,,"The sodium-independent portion of bile salt uptake is mediated by OATPs (organic anion transporting polypeptides). OATP1B1 (SLCO1B1), OATP1B3 (SLCO1B3), and OATP2B1 (SLCO2B1) are expressed at the basolateral plasma membrane of hepatocytes, although OATP2B1 appears not to be a bile Salt transporter.|monomeric FXR imight represss human SLCO2B1",,,,,,,,,,,,,,,SLCO2B1 (canonical)[Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_26995,thromboxane,TX,"A class of oxygenated oxane derivatives, originally derived from prostaglandin precursors in platelets, that stimulate aggregation of platelets and constriction of blood vessels.",false,,,http://purl.obolibrary.org/obo/CHEBI_26347,,,,,,,,,,,,,,,,,,,,IMR:0100020,,"A class of oxygenated oxane derivatives, originally derived from prostaglandin precursors in platelets, that stimulate aggregation of platelets and constriction of blood vessels.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003686|http://purl.obolibrary.org/obo/TXPO_0002401,,,,,TX,,,,,CHEBI:26995,,,,,,,,,,,,,,,,,,,,,,thromboxane,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000002168,FABP1,,"Other designations: fatty acid-binding protein 1|fatty acid-binding protein, liver|liver-type fatty acid-binding protein",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,FABPL|L-FABP,,,,,,,,,,,,2,,,,,,HGNC:3555|MIM:134650|HPRD:00612|Ensembl:ENSG00000163586|Vega:OTTHUMG00000130312,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"fatty acid binding protein 1, liver",,,2p11,,,,,,,,,,,,,,,,"GO_0003682 (EC: IEA); GO_0005324 (EC: IEA); GO_0005504 (EC: IEA); GO_0005543 (EC: IEA); GO_0005654 (EC: TAS); GO_0005782 (EC: ISS); GO_0005829 (EC: IEA); GO_0008144 (EC: IEA); GO_0008284 (EC: IEA); GO_0016209 (EC: IDA, PMID: 16175609); GO_0032000 (EC: IEA); GO_0032052 (EC: IEA); GO_0043066 (EC: IDA, PMID: 16175609); GO_0043154 (EC: IDA, PMID: 16175609); GO_0044255 (EC: TAS); GO_0044281 (EC: TAS); GO_0045179 (EC: IEA); GO_0050892 (EC: IEA); GO_0051345 (EC: IEA); GO_0070062 (EC: IDA, PMID: 19056867); GO_0070301 (EC: IDA, PMID: 16175609); GO_0071456 (EC: IDA, PMID: 16175609)",,,,,,,,,PMID: 1699834; 2824476; 3012800; 3838309; 3838313; 7566098; 7784447; 8232272; 9070383; 9250612; 9688651; 10684629; 11226238; 11354243; 11461829; 12121132; 12477932; 12646418; 14563446; 15123239; 15249972; 15308127; 15342556; 15489334; 15547295; 16175609; 16249547; 16772708; 16945373; 17003471; 17428383; 17485234; 17526850; 17605029; 17698986; 17826730; 18094680; 18506375; 18624398; 18660489; 18838948; 18854154; 19019918; 19056867; 19217864; 19330863; 19435794; 19441025; 19499240; 19622156; 19913121; 20185732; 20416077; 20550918; 20575163; 20628086; 20721681; 21153750; 21356355; 21504508; 21757748; 21767383; 21856370; 21996226; 22396741; 22465531; 22515481; 22525507; 22640736; 23144966; 23167703; 23223350; 23291381; 23349979; 23599408; 23893635; 24299557,,,,,,,,,,,,,,,OGG:3000002168,,,,,,,"fatty acid binding protein 1, liver",,,,,,,,,,,,,"Other designations: fatty acid-binding protein 1|fatty acid-binding protein, liver|liver-type fatty acid-binding protein",,FABP1,,,,,,,,,,,,,,,,,,,,,,,2168,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,FABP1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000002166,FAAH,,Other designations: anandamide amidohydrolase 1|fatty-acid amide hydrolase 1|oleamide hydrolase 1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,FAAH-1|PSAB,,,,,,,,,,,,1,,,,,,HPRD:04244|Vega:OTTHUMG00000007811|HGNC:3553|MIM:602935|Ensembl:ENSG00000117480,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,fatty acid amide hydrolase,,,1p35-p34,,,,,,,,,,,,,,,,"GO_0005737 (EC: IEA); GO_0005856 (EC: IEA); GO_0009062 (EC: IDA, PMID: 9122178); GO_0012505 (EC: IEA); GO_0016021 (EC: IEA); GO_0016884 (EC: IEA); GO_0017064 (EC: IDA, PMID: 9122178); GO_0031090 (EC: ISS); GO_0047372 (EC: IEA)",,,,,,,,,PMID: 9122178; 9790682; 9822713; 9871570; 9878243; 10036136; 10431820; 10788462; 10806398; 11352748; 11390466; 11818522; 12008024; 12060782; 12153574; 12477932; 12556536; 12665801; 12799380; 14657172; 15219977; 15254019; 15489334; 15721218; 15809662; 16710414; 16972078; 17065342; 17216208; 17290447; 17342744; 17449448; 17553686; 17621164; 17712725; 17962356; 17991615; 18029348; 18068305; 18295974; 18493729; 18497731; 18566995; 18705688; 18805581; 18819056; 19002671; 19014633; 19053981; 19086053; 19095868; 19103437; 19165169; 19193342; 19419760; 19659925; 19801960; 19859057; 19874574; 19890266; 19913121; 19958092; 20010552; 20010914; 20015515; 20044928; 20054193; 20056290; 20065978; 20080186; 20098695; 20099163; 20102775; 20189896; 20369362; 20628086; 20631561; 20716455; 20808855; 20870184; 20976246; 21037510; 21118518; 21442624; 21477106; 21519771; 21930339; 22035053; 22068813; 22442717; 22609216; 22701012; 22776995; 22826533; 22827915; 22832737; 23122699; 23211960; 23333123; 23372171; 23556448; 23616186,,,,,,,,,,,,,,,OGG:3000002166,,,,,,,fatty acid amide hydrolase,,,,,,,,,,,,,Other designations: anandamide amidohydrolase 1|fatty-acid amide hydrolase 1|oleamide hydrolase 1,,FAAH,,,,,,,,,,,,,,,,,,,,,,,2166,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,FAAH,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001656,DDX6,,"Other designations: ATP-dependent RNA helicase p54|DEAD (Asp-Glu-Ala-Asp) box polypeptide 6|DEAD box protein 6|DEAD box-6|DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 6 (RNA helicase, 54kD)|oncogene RCK|probable ATP-dependent RNA helicase DDX6",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,P54|RCK|HLR2,,,,,,,,,,,,11,,,,,,MIM:600326|HPRD:02638|HGNC:2747,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,DEAD (Asp-Glu-Ala-Asp) box helicase 6,,,11q23.3,,,,,,,,,,,,,,,,"GO_0000288 (EC: TAS); GO_0000932 (EC: IDA, PMID: 16699599); GO_0003724 (EC: TAS, PMID: 1579499); GO_0004386 (EC: TAS, PMID: 1394235); GO_0005515 (EC: IPI, PMID: 16364915); GO_0005524 (EC: IEA); GO_0005737 (EC: IDA); GO_0005829 (EC: TAS); GO_0008026 (EC: IEA); GO_0010467 (EC: TAS); GO_0010494 (EC: IDA, PMID: 17392519); GO_0016070 (EC: TAS); GO_0016071 (EC: TAS); GO_0016442 (EC: IDA); GO_0033962 (EC: IDA); GO_0043231 (EC: IDA); GO_0043928 (EC: TAS); GO_0044822 (EC: IDA)",,,,,,,,,PMID: 1394235; 1579499; 7614484; 8816452; 10319407; 10360675; 10737800; 11839790; 12477932; 12823589; 14684915; 14702039; 15489334; 16147992; 16344560; 16364915; 16611246; 16699599; 16756390; 17207965; 17353931; 17392519; 17898068; 18378046; 18769115; 19285948; 19297524; 19380743; 19542561; 19560422; 19738201; 20020773; 20158304; 20360068; 20392846; 20884783; 21030982; 21110914; 21139048; 21145461; 21383967; 21906983; 21957497; 22022269; 22190034; 22203041; 22268729; 22505724; 22797925; 22836354; 22851315; 22939629; 22951725; 22965301; 23293030; 23455922; 23535175; 23602568; 23826300; 23932921; 24130170; 24255178; 24457600,,,,,,,,,,,,,,,OGG:3000001656,,,,,,,DEAD (Asp-Glu-Ala-Asp) box helicase 6,,,,,,,,,,,,,"Other designations: ATP-dependent RNA helicase p54|DEAD (Asp-Glu-Ala-Asp) box polypeptide 6|DEAD box protein 6|DEAD box-6|DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 6 (RNA helicase, 54kD)|oncogene RCK|probable ATP-dependent RNA helicase DDX6",,DDX6,,,,,,,,,,,,,,,,,,,,,,,1656,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,DDX6,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/GO_0044464,cell part,cellular subcomponent,"Any constituent part of a cell, the basic structural and functional unit of all organisms.",false,,,http://purl.obolibrary.org/obo/GO_0005575,,,,,,,,,,,,,,,,,,,,,,"Any constituent part of a cell, the basic structural and functional unit of all organisms.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,cellular subcomponent,,,,http://purl.obolibrary.org/obo/CL_0000000,GO:0044464,http://purl.obolibrary.org/obo/CL_0000000,,,,,,,,,,,,,,,,,,,,,cell part,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_85010,eltrombopag,"3'-{(2Z)-2-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid|3'-{(2Z)-2-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene]hydrazinyl}-2'-hydroxy[1,1'-biphenyl]-3-carboxylic acid","A hydrazine in which each nitrogen atom is substituted, one by a 3'-carboxy-2-hydroxy[1,1'-biphenyl]-3-yl group and the other by a 1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene group.  A small molecule agonist of the c-mpl (TpoR) receptor (the physiological target of the hormone thrombopoietin), it has been developed as a medication for conditions that lead to thrombocytopenia (abnormally low platelet counts).",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:24433306|PMID:25063763|PMID:25170628|CAS:496775-61-2|Drug_Central:4399|PMID:25578417|PMID:25700916|PMID:25400215,,"A hydrazine in which each nitrogen atom is substituted, one by a 3'-carboxy-2-hydroxy[1,1'-biphenyl]-3-yl group and the other by a 1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene group.  A small molecule agonist of the c-mpl (TpoR) receptor (the physiological target of the hormone thrombopoietin), it has been developed as a medication for conditions that lead to thrombocytopenia (abnormally low platelet counts).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35703|http://purl.obolibrary.org/obo/CHEBI_85012,,,,,"3'-{(2Z)-2-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene]hydrazinyl}-2'-hydroxy[1,1'-biphenyl]-3-carboxylic acid",,"3'-{(2Z)-2-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid",,,,,,,,,,,,,,,,,,,,,CHEBI:85010,,,,eltrombopag,,CHEBI:85010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000144,MHC class II molecule,major histocompatibility complex class II molecule|classical MHC class II molecule,MHC class II molecules are composed of membrane-spanning alpha and beta chains.,false,,,http://purl.obolibrary.org/obo/IMR_0000142,,,,,,,,,,,,,,,,,,,,GO:0042613,,MHC class II molecules are composed of membrane-spanning alpha and beta chains.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,major histocompatibility complex class II molecule|classical MHC class II molecule,,,,,IMR:0000144,,,,,,,,,,,,,,,,,,,,,,MHC class II molecule,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001924,MAML1,,,false,,,http://purl.obolibrary.org/obo/IMR_0001923,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001924,,,,,,,,,,,,,,,,,,,,,,MAML1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0011152,eIF1A,"eIF-1A|eIF-4C|eukaryotic translation initiation factor 1A|Eukaryotic translation initiation factor 1A, Y-chromosomal|eIF-1A X isoform|eIF-1A Y isoform|Eukaryotic translation initiation factor 1A, X-chromosomal",,false,,,http://purl.obolibrary.org/obo/IMR_0010016,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"eIF-1A|eIF-4C|eukaryotic translation initiation factor 1A|Eukaryotic translation initiation factor 1A, Y-chromosomal|eIF-1A X isoform|eIF-1A Y isoform|Eukaryotic translation initiation factor 1A, X-chromosomal",,,,,IMR:0011152,,,,,,,,,,,,,,,,,,,,,,eIF1A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_37328,phosphatidylinositol bisphosphate,,,false,,,http://purl.obolibrary.org/obo/CHEBI_28765,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:37328,,,,,,,,,,,,,,,,,,,,,,phosphatidylinositol bisphosphate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000310,26S proteasome,,"The 26S proteasome is a 2.5-MDa molecular machine built from ~31 different subunits, which catalyzes protein degradation. It contains a barrel-shaped proteolytic core complex (the 20S proteasome), capped at one or both ends by 19S regulatory complexes, which recognize ubiquitinated proteins.",false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,GO:0000502,,"The 26S proteasome is a 2.5-MDa molecular machine built from ~31 different subunits, which catalyzes protein degradation. It contains a barrel-shaped proteolytic core complex (the 20S proteasome), capped at one or both ends by 19S regulatory complexes, which recognize ubiquitinated proteins.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000304,,,,,,,,,,IMR:0000310,,,,,,,,,,,,,,,,,,,,,,26S proteasome,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100463,FADD,MORT1|Fas-associated death domain|mediator of receptor-induced toxicity,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003682,,,,,MORT1|Fas-associated death domain|mediator of receptor-induced toxicity,,,,,IMR:0100463,,,,,,,,,,,,,,,,,,,,,,FADD,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000399,ETS1,E26 transformation-specific1,,false,,,http://purl.obolibrary.org/obo/IMR_0000397,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,E26 transformation-specific1,,,,,IMR:0000399,,,,,,,,,,,,,,,,,,,,,,ETS1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000120227,CYP2R1,,"Other designations: cytochrome P450 2R1|cytochrome P450, family 2, R1|vitamin D 25-hydroxylase",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,11,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 2, subfamily R, polypeptide 1",,,11p15.2,,,,,,,,,,,,,,,,GO_0004497 (EC: IEA); GO_0005506 (EC: IEA); GO_0005789 (EC: TAS); GO_0006766 (EC: TAS); GO_0006805 (EC: TAS); GO_0008202 (EC: TAS); GO_0010164 (EC: IEA); GO_0010212 (EC: IEA); GO_0016705 (EC: IEA); GO_0020037 (EC: IEA); GO_0030343 (EC: IEA); GO_0042359 (EC: TAS); GO_0044281 (EC: TAS),,,,,,,,,PMID:12464240; 12477932; 12867411; 14702039; 15128046; 15128933; 15465040; 15489334; 15583024; 15951480; 16600026; 17223345; 17607662; 18476984; 18511070; 19783860; 19852851; 20007432; 20418485; 20541252; 20619365; 20654748; 20809279; 21270327; 21441443; 22576297; 22801813; 22855339; 23047203; 23063903; 23190755; 23377224; 23734184; 23793229; 23826131; 24073854,,,,,,,,,,,,,,,OGG:3000120227,,,,,,,"cytochrome P450, family 2, subfamily R, polypeptide 1",,,,,,,,,,,,,"Other designations: cytochrome P450 2R1|cytochrome P450, family 2, R1|vitamin D 25-hydroxylase",,CYP2R1,,,,,,,,,,,,,,,,,,,,,,,120227,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP2R1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0100778,Wnt-9a,Wnt-14,,false,,,http://purl.obolibrary.org/obo/IMR_0000003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Wnt-14,,,,,IMR:0100778,,,,,,,,,,,,,,,,,,,,,,Wnt-9a,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/BFO_0000017,realizable entity,,,false,,,http://purl.obolibrary.org/obo/BFO_0000020,,,,,,,,,,,,,,,,,,,,,,,,,,,,To say that b is a realizable entity is to say that b is a specifically dependent continuant that inheres in some independent continuant which is not a spatial region and is of a type instances of which are realized in processes of a correlated type. (axiom label in BFO2 Reference: [058-002]),the disposition of your blood to coagulate|the role of this boundary to delineate where Utah and Colorado meet|the role of being a doctor|the disposition of this piece of metal to conduct electricity.|the function of your reproductive organs,,,,,,,,,,,(forall (x t) (if (RealizableEntity x) (exists (y) (and (IndependentContinuant y) (not (SpatialRegion y)) (bearerOfAt y x t))))) // axiom label in BFO2 CLIF: [060-002]|(forall (x) (if (RealizableEntity x) (and (SpecificallyDependentContinuant x) (exists (y) (and (IndependentContinuant y) (not (SpatialRegion y)) (inheresIn x y)))))) // axiom label in BFO2 CLIF: [058-002],All realizable dependent continuants have independent continuants that are not spatial regions as their bearers. (axiom label in BFO2 Reference: [060-002]),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BFO:0000017,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/bfo.owl,realizable entity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_36413,anabolic agent,,"A compound which stimulates anabolism and inhibits catabolism. Anabolic agents stimulate the development of muscle mass, strength, and power.",false,,,http://purl.obolibrary.org/obo/CHEBI_24621,,,,,,,,,,,,,,,,,,,,,,"A compound which stimulates anabolism and inhibits catabolism. Anabolic agents stimulate the development of muscle mass, strength, and power.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:36413,,,,anabolic agent,,CHEBI:36413,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000002730,GCLM,,,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,,,,,,,MIM:601176|HPRD:03106|HGNC:4312,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"glutamate-cysteine ligase, modifier subunit",,,,,,,,,,,,,,,,,,,"GO_0000096 (EC: TAS); GO_0004357 (EC: IDA, Qualifier: contributes_to, PMID: 9841880); GO_0004357 (EC: IMP, Qualifier: contributes_to, PMID: 16183645); GO_0005829 (EC: NAS, PMID: 9895302); GO_0005829 (EC: TAS); GO_0006534 (EC: IEA); GO_0006536 (EC: IDA, PMID: 9841880); GO_0006750 (EC: IDA, PMID: 10395918); GO_0006750 (EC: IEA); GO_0006750 (EC: IMP, PMID: 12081989); GO_0006750 (EC: TAS); GO_0006805 (EC: TAS); GO_0006979 (EC: IDA, PMID: 10395918); GO_0008637 (EC: IEA); GO_0017109 (EC: IEA); GO_0034641 (EC: TAS); GO_0035226 (EC: IPI, PMID: 9675072); GO_0035229 (EC: IEA); GO_0042493 (EC: IDA, PMID: 9895302); GO_0043524 (EC: IEA); ... (Note: Only 20 GO IDs shown. """,,,,,,,,,PMID: 7826375; 7829101; 8825659; 8978789; 9675072; 9841137; 9841880; 9895302; 10395918; 10674357; 12081989; 12477932; 12975258; 14532974; 15451055; 15489334; 15946948; 16081425; 16183645; 16599007; 16677451; 16710414; 16712791; 16766924; 16909399; 17333241; 17344309; 17353931; 17548779; 17643973; 17924854; 17961430; 18066575; 18449862; 18560528; 18614560; 18991850; 19056482; 19126404; 19153097; 19420105; 19455074; 19460752; 19578796; 19584774; 19808663; 19896490; 19913121; 20061124; 20200426,,,,,,,,,,,,,,,OGG:3000002730,,,,,,,"glutamate-cysteine ligase, modifier subunit",,,,,,,,,,,,,,,GCLM,,,,,,,,,,,,,,,,,,,,,,,2730,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0004140,Ctsb (mouse)[Niemann-Pick disease  - fibrosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003996,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:13030|PMID:22102288,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001508,,,http://purl.obolibrary.org/obo/CHEBI_68494,,,,,,,,,,TXPO:0004140,,,,,,,,,,,,,,,,,,,,,,Ctsb (mouse)[Niemann-Pick disease  - fibrosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004146,hypofunction of cholesterol efflux [Niemann-pick disease],,"A process that performs a decreased or insufficient cholesterol export.
This entity is a specific course-dependent process. This process can constitute the course of Niemann-Pick disease.",false,,,http://purl.obolibrary.org/obo/TXPO_0004145|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,PMID:29249985,,"A process that performs a decreased or insufficient cholesterol export.
This entity is a specific course-dependent process. This process can constitute the course of Niemann-Pick disease.",,,http://purl.obolibrary.org/obo/GO_0033344,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004147,,,,,,,,,,,,,,,,,TXPO:0004146,,,,,,,,,,,,,,,,,,,,,,hypofunction of cholesterol efflux [Niemann-pick disease],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004144,extracellular matrix disassembly [Phospholipidosis],,"A process that results in the breakdown of the extracellular matrix.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense).",false,,,http://purl.obolibrary.org/obo/GO_0022411|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,PMID:3458210|PMID:1540143,,"A process that results in the breakdown of the extracellular matrix.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0031012,,,,,,http://purl.obolibrary.org/obo/TXPO_0003788|http://purl.obolibrary.org/obo/TXPO_0003879|http://purl.obolibrary.org/obo/TXPO_0003999,,,,,,http://purl.obolibrary.org/obo/TXPO_0001497,,,,,,,,,,,TXPO:0004144,,,,,,,,,,,,,,,,,,,,,,extracellular matrix disassembly [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004142,CTSB (human)Niemann-Pick disease  - fibrosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003941,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1508|PMID:22102288,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001508,,,,,,,,,,,,,TXPO:0004142,,,,,,,,,,,,,,,,,,,,,,CTSB (human)Niemann-Pick disease  - fibrosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004141,hepatic fibrosis [Niemann-Pick disease],,"Hepatic fibrosis is a subtype of fibrosis: A process that replaces liver tissues to fibrous connective tissues, usually as a consequence of inflammation or other injury.
This entity is a specific course-dependent process. This process can constitute the course of Niemanne-Pick disease.",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0000816,,,,,,,,,,,,,,,,,,,,PMID:22102288,,"Hepatic fibrosis is a subtype of fibrosis: A process that replaces liver tissues to fibrous connective tissues, usually as a consequence of inflammation or other injury.
This entity is a specific course-dependent process. This process can constitute the course of Niemanne-Pick disease.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003788|http://purl.obolibrary.org/obo/TXPO_0004140|http://purl.obolibrary.org/obo/TXPO_0004142,,,,,,,,,,,,,,,,,TXPO:0004141,,,,,,,,,,,,,,,,,,,,,,hepatic fibrosis [Niemann-Pick disease],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004143,ceramide acumulation,,"ceramide accumulation is a subtype of accumulation of substances in a biological object: A process that keeps ceramide in an organism, tissue, organelle, or cell.",false,,,http://purl.obolibrary.org/obo/GO_0019915,,,,,,,,,,,,,,,,,,,,,,"ceramide accumulation is a subtype of accumulation of substances in a biological object: A process that keeps ceramide in an organism, tissue, organelle, or cell.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004143,,,,,,,,,,,,,,,,,,,,,,ceramide acumulation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004145,hypofunction of cholesterol efflux from hepatoyte,,A process that performs a decreased or insufficient cholesterol efflux,false,,,http://purl.obolibrary.org/obo/TXPO_0001911,,,,,,,,,,,,,,,,,,,,,,A process that performs a decreased or insufficient cholesterol efflux,,,http://purl.obolibrary.org/obo/GO_0033344,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004145,,,,,,,,,,,,,,,,,,,,,,hypofunction of cholesterol efflux from hepatoyte,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004147,sphingomyelin [Niemann-Pick disease],Ceramide phosphocholine,"Any of a class of phospholipids in which the amino group of a sphingoid base is in amide linkage with one of several fatty acids, while the terminal hydroxy group of the sphingoid base is esterified to phosphorylcholine.",false,,,http://purl.obolibrary.org/obo/TXPO_0001849|http://purl.obolibrary.org/obo/CHEBI_64583,,,,,,,,,,,,,,,,,,,,,,"Any of a class of phospholipids in which the amino group of a sphingoid base is in amide linkage with one of several fatty acids, while the terminal hydroxy group of the sphingoid base is esterified to phosphorylcholine.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ceramide phosphocholine,,,,,TXPO:0004147,,,,,,,,,,,,,,,,,,,,,,sphingomyelin [Niemann-Pick disease],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004148,myelin figureformation in lysosome  [Phospholipidosis],lamellar body formation in lysosome [Phospholipidosis],"A process that forms myelin-like layered structures
This process is dependent on the course of phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0000322,,,,,,,,,,,,,,,,,,,,,,"A process that forms myelin-like layered structures
This process is dependent on the course of phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003526,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003573,,,,,,http://purl.obolibrary.org/obo/TXPO_0001643,,,,,,lamellar body formation in lysosome [Phospholipidosis],,,,,TXPO:0004148,,,,,,,"The presence of phospholipid inclusions are characterized by the presence of cytoplasmic vacuoles seen under the electron microscope as dense cytoplasmic myelin-like bodies showing a concentric lamellar structure with  a periodicity of 4-4.5 nm along with an amorphorous matrix within a single membrane-bound lysosomal space.

Histopathology of preclinical toxicity studies : interpretation and relevance in drug safety studies, Peter Greaves.
4th ed. Amsterdam ; Boston : Elsevier/AP, 2012.",,,,,,,,,,,,,,,myelin figureformation in lysosome  [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005764,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004149,ASPA(human) [Phospholipidosis],,"ASPA relates to myelination in the CNS, but not observed in the liver.",false,,,http://purl.obolibrary.org/obo/TXPO_0001135|http://purl.obolibrary.org/obo/TXPO_0003840,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:443|https://reactome.org/content/detail/R-HSA-5691507|https://omim.org/entry/608034|PMID:15784740,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000000443,,,,,,,,,,,,,TXPO:0004149,,,,,,,,,,,,,,,,,,,,"ASPA relates to myelination in the CNS, but not observed in the liver.",,ASPA(human) [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000004747,NEFL,,"Other designations: light molecular weight neurofilament protein|neurofilament light polypeptide|neurofilament protein, light chain|neurofilament subunit NF-L|neurofilament triplet L protein|neurofilament, light polypeptide 68kDa",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,NF68|CMT2E|NFL|CMT1F|NF-L,,,,,,,,,,,,8,,,,,,MIM:162280|HPRD:01206|HGNC:7739,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"neurofilament, light polypeptide",,,8p21,,,,,,,,,,,,,,,,"GO_0005200 (EC: IDA, PMID: 12432080); GO_0005515 (EC: IPI, PMID: 12837694); GO_0005737 (EC: ISS); GO_0005829 (EC: TAS); GO_0005883 (EC: IDA, PMID: 15857389); GO_0007268 (EC: TAS); GO_0008022 (EC: IPI, PMID: 12226091); GO_0008089 (EC: IMP, PMID: 15857389); GO_0008090 (EC: IMP, PMID: 15857389); GO_0019896 (EC: IMP, PMID: 15857389); GO_0030424 (EC: IDA, PMID: 14662745); GO_0030674 (EC: ISS); GO_0033596 (EC: IDA, Qualifier: colocalizes_with, PMID: 12226091); GO_0033693 (EC: IDA, PMID: 12432080); GO_0033693 (EC: IMP, PMID: 15857389); GO_0042802 (EC: IPI, PMID: 12432080); GO_0045109 (EC: IMP, PMID: 12432080)",,,,,,,,,PMID: 1497855; 1902666; 2516804; 3034332; 3036423; 3121319; 3145240; 6135695; 8125298; 8180132; 8344946; 8530496; 8615909; 8621664; 8665664; 8863508; 9388258; 9425014; 9481670; 9763415; 10373510; 10841809; 11220745; 12133495; 12226091; 12231460; 12403814; 12432080; 12477167; 12477932; 12481988; 12566280; 12730211; 12815021; 12837694; 12911634; 14622581; 14662745; 14733962; 15111691; 15122254; 15241803; 15324660; 15383276; 15489334; 15654615; 15686490; 15857389; 16084104; 16169070; 16344560; 16452125; 16678934; 16930284; 17052987; 17290105; 17475803; 17620486; 17683050; 17903209; 17923616; 18023247; 18758688; 19034380; 19110265; 19123978; 19158810; 19286384; 19488899; 19678766; 19950375; 20039262; 20086018; 20201926; 20213320; 20301366; 20301384; 20301462; 20381070; 21039366; 21044950; 21139048; 21197541; 21860087; 21890473; 21983493; 22246235; 22288874; 22302611; 22319610; 22586326; 22680408; 22765307; 22797925; 23455924; 23705811; 23827424; 23870535; 24244333,,,,,,,,,,,,,,,OGG:3000004747,,,,,,,"neurofilament, light polypeptide",,,,,,,,,,,,,"Other designations: light molecular weight neurofilament protein|neurofilament light polypeptide|neurofilament protein, light chain|neurofilament subunit NF-L|neurofilament triplet L protein|neurofilament, light polypeptide 68kDa",,NEFL,,,,,,,,,,,,,,,,,,,,,,,4747,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,NEFL,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/UBERON_0001032,sensory system,organa sensuum|sensory organ system|set of sense organs|organa sensuum|sense organ subsystem|sensory subsystem|sense organs set|sense organs|sensory systems,Anatomical system that overlaps the nervous system and is responsible for receiving and processing sensory information.,false,,,http://purl.obolibrary.org/obo/UBERON_0000467,,,,,,,,,,,,,,,,,,,,http://en.wikipedia.org/wiki/Sensory_system|http://uri.neuinfo.org/nif/nifstd/nlx_anat_090816|BILA:0000099|VHOG:0001674|EFO:0000805|FBbt:00005827|XAO:0003194|MA:0002442|FMA:75259|EHDAA2:0003094|AAO:0000555|BAMS:SEN|MAT:0000031|ZFA:0000282|EMAPA:16192|MIAA:0000031|TAO:0000282,,Anatomical system that overlaps the nervous system and is responsible for receiving and processing sensory information.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,organa sensuum|sense organ subsystem|sensory subsystem|sense organs set|sense organs|sensory systems,,organa sensuum|sensory organ system|set of sense organs,"An early step in the evolution of neural crest, therefore, may have been the origin of a specific dorsal neural cell population contributing to sensory processing; this would predate the divergence of the amphioxus and vertebrate lineages.[well established][VHOG]",,UBERON:0001032,,,,,,,,,,,,,,,,,,,,,,sensory system,,,,http://upload.wikimedia.org/wikipedia/commons/c/c0/Gray722.png,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000056,TNFR family,tumor necrosis factor receptor family,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,GO:0005027,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,tumor necrosis factor receptor family,,,,,IMR:0000056,,,,,,,,,,,,,,,,,,,,,,TNFR family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001617,Rab31,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001617,,,,,,,,,,,,,,,,,,,,,,Rab31,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000542,TRIM55 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:365751|NCBI-Human-GeneID:84675|NCBI-Mouse-GeneID:381485,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000084675,,,,,,,,,,,,,TXPO:1000542,,,,,,,,,,,,,,,,,,,,,,TRIM55 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000544,TTC39A (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:298366|NCBI-Human-GeneID:22996|NCBI-Mouse-GeneID:230603,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000022996,,,,,,,,,,,,,TXPO:1000544,,,,,,,,,,,,,,,,,,,,,,TTC39A (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000543,TSKU (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:25987|NCBI-Rat-GeneID:308843|NCBI-Mouse-GeneID:244152,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000025987,,,,,,,,,,,,,TXPO:1000543,,,,,,,,,,,,,,,,,,,,,,TSKU (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000546,UGT2A3 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:79799|NCBI-Rat-GeneID:289533|NCBI-Mouse-GeneID:72094,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000079799,,,,,,,,,,,,,TXPO:1000546,,,,,,,,,,,,,,,,,,,,,,UGT2A3 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000541,TNFSF10 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:22035|NCBI-Rat-GeneID:246775|NCBI-Human-GeneID:8743,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000008743,,,,,,,,,,,,,TXPO:1000541,,,,,,,,,,,,,,,,,,,,,,TNFSF10 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000540,TMPO (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:7112|NCBI-Mouse-GeneID:21917|NCBI-Rat-GeneID:25359,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000007112,,,,,,,,,,,,,TXPO:1000540,,,,,,,,,,,,,,,,,,,,,,TMPO (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000547,UHRF1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:29128|NCBI-Mouse-GeneID:18140|NCBI-Rat-GeneID:316129,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000029128,,,,,,,,,,,,,TXPO:1000547,,,,,,,,,,,,,,,,,,,,,,UHRF1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000545,UBE2T (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:29089|NCBI-Rat-GeneID:360847|NCBI-Mouse-GeneID:67196,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000029089,,,,,,,,,,,,,TXPO:1000545,,,,,,,,,,,,,,,,,,,,,,UBE2T (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001477,DOCK9,,,false,,,http://purl.obolibrary.org/obo/IMR_0001469,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001477,,,,,,,,,,,,,,,,,,,,,,DOCK9,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000026027,ACOT11,,"Other designations: START domain containing 14|StAR-related lipid transfer (START) domain containing 14|acyl-CoA thioester hydrolase 11|acyl-coenzyme A thioesterase 11|adipose-associated thioesterase|brown fat-inducible thioesterase|thioesterase superfamily member 1|thioesterase, adipose associated",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,BFIT|THEM1|THEA|STARD14,,,,,,,,,,,,1,,,,,,HGNC:18156|HPRD:07075|MIM:606803|Ensembl:ENSG00000162390|Vega:OTTHUMG00000009891,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,acyl-CoA thioesterase 11,,,1p32.3,,,,,,,,,,,,,,,,"GO_0005737 (EC: IC, PMID:11696000); GO_0006631 (EC: NAS, PMID:11696000); GO_0008289 (EC: IEA); GO_0009266 (EC: ISS); GO_0009409 (EC: ISS, PMID:11696000); GO_0035556 (EC: NAS, PMID:11696000); GO_0047617 (EC: TAS, PMID:11696000); GO_0070062 (EC: IDA, PMID:19056867)",,,,,,,,,PMID:8125298; 9734811; 11696000; 12477932; 14702039; 15489334; 16103133; 16344560; 19056867; 19913121; 20379614; 20470824; 20628086; 21738568; 22897136,,,,,,,,,,,,,,,OGG:3000026027,,,,,,,acyl-CoA thioesterase 11,,,,,,,,,,,,,"Other designations: START domain containing 14|StAR-related lipid transfer (START) domain containing 14|acyl-CoA thioester hydrolase 11|acyl-coenzyme A thioesterase 11|adipose-associated thioesterase|brown fat-inducible thioesterase|thioesterase superfamily member 1|thioesterase, adipose associated",,ACOT11,,,,,,,,,,,,,,,,,,,,,,,26027,,,,,,,,9606,,,,,,,,,,,,,,,,,,,ACOT11,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001553,CYP2A13,,"Other designations: cytochrome P450 2A13|cytochrome P450, subfamily IIA (phenobarbital-inducible), polypeptide 13",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CYP2A|CYPIIA13|CPAD,,,,,,,,,,,,19,,,,,,HGNC:2608|HPRD:07454|MIM:608055|Ensembl:ENSG00000197838|Vega:OTTHUMG00000182762,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 2, subfamily A, polypeptide 13",,,19q13.2,,,,,,,,,,,,,,,,"GO_0005506 (EC: IEA); GO_0005789 (EC: TAS); GO_0006805 (EC: TAS); GO_0020037 (EC: IDA, PMID:17428784); GO_0044281 (EC: TAS); GO_0070330 (EC: IEA)",,,,,,,,,PMID:7581481; 7668294; 8587134; 8889548; 9890157; 10353262; 11016631; 12130698; 12721789; 12920161; 14633739; 15063809; 15115698; 15128046; 15196988; 15222883; 15333516; 15618722; 16316926; 16835796; 17428784; 18669584; 19290787; 19303722; 19343046; 19414505; 19789190; 19812523; 20431511; 20534012; 20568895; 20798279; 20846153; 21473878; 22315333; 22397853; 22696418; 22700965; 22798551; 22890016; 23463547; 23583631; 23602888; 23752126; 23917075,,,,,,,,,,,,,,,OGG:3000001553,,,,,,,"cytochrome P450, family 2, subfamily A, polypeptide 13",,,,,,,,,,,,,"Other designations: cytochrome P450 2A13|cytochrome P450, subfamily IIA (phenobarbital-inducible), polypeptide 13",,CYP2A13,,,,,,,,,,,,,,,,,,,,,,,1553,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP2A13,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001558,CYP2C8,,"Other designations: P450 form 1|cytochrome P450 2C8|cytochrome P450 IIC2|cytochrome P450 MP-12|cytochrome P450 MP-20|cytochrome P450 form 1|cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 8|flavoprotein-linked monooxygenase|microsomal monooxygenase|s-mephenytoin 4-hydroxylase|xenobiotic monooxygenase",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CPC8|CYPIIC8|MP-12/MP-20,,,,,,,,,,,,10,,,,,,MIM:601129|Ensembl:ENSG00000138115|Vega:OTTHUMG00000018804|HGNC:2622|HPRD:03083,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 2, subfamily C, polypeptide 8",,,10q23.33,,,,,,,,,,,,,,,,"GO_0004497 (EC: IDA, PMID:19651758); GO_0005506 (EC: IEA); GO_0005789 (EC: TAS); GO_0006082 (EC: IDA, PMID:19651758); GO_0006805 (EC: TAS); GO_0017144 (EC: IDA, PMID:19651758); GO_0019369 (EC: TAS); GO_0019373 (EC: TAS); GO_0020037 (EC: IEA); GO_0034875 (EC: IDA, PMID:18619574); GO_0042738 (EC: IDA, PMID:18619574); GO_0044281 (EC: TAS); GO_0055114 (EC: IDA, PMID:19651758); GO_0070330 (EC: IEA); GO_0070989 (EC: IDA, PMID:18619574); GO_0097267 (EC: TAS)",,,,,,,,,PMID:1707679; 2009263; 2216732; 2729895; 3196692; 3500169; 3697070; 7574697; 7704034; 7841444; 8530044; 8870687; 9586955; 9797707; 9842986; 9890157; 10487415; 10704292; 10768437; 10874126; 11668219; 12429347; 12435384; 12477932; 12756196; 12756206; 12920163; 12936704; 14534525; 14646690; 14676196; 15028279; 15039299; 15074466; 15128046; 15289789; 15319333; 15469410; 15469873; 15606441; 15716363; 15785959; 15864120; 15901749; 15933212; 15961978; 16025294; 16141797; 16164496; 16202848; 16253141; 16299241; 16359408; 16372821; 16385451; 16390351; 16475901; 16538176; 16646575; 16856883; 16957870; 17048007; 17175891; 17178266; 17224914; 17241877; 17373732; 17429317; 17558302; 17627038; 17635176; 17670841; 17701008; 17913794; 17923851; 17925548; 17975119; 18216720; 18303964; 18413310; 18496133; 18548238; 18574320; 18594024; 18619574; 18694831; 18769365; 18779360; 18992346; 19023099; 19064572; 19074885; 19129086; 19143748; 19290787; 19339270; 19343046; 19381162; 19415824; 19460752; 19470925; 19480553; 19504558; 19651758; 19706858; 19761371; 19773535; 19833260; 19913121; 19935798; 19954515; 20013305; 20031551; 20136364; 20173083; 20190184; 20212519; 20214592; 20368717; 20375710; 20379614; 20389299; 20436375; 20437850; 20523106; 20529763; 20602612; 20602615; 20628086; 20665013; 20808793; 20848147; 20857895; 20890775; 20970553; 21047199; 21054465; 21059750; 21081644; 21163940; 21173785; 21214863; 21245287; 21270106; 21375401; 21685474; 21697463; 21697548; 21778352; 21791871; 21798861; 21838784; 21977947; 22027337; 22028317; 22028915; 22242967; 22313047; 22339777; 22491019; 22527101; 22542470; 22625877; 22723340; 23118231; 23171856; 23307233; 23336573; 23413280; 23426382; 23755828,,,,,,,,,,,,,,,OGG:3000001558,,,,,,,"cytochrome P450, family 2, subfamily C, polypeptide 8",,,,,,,,,,,,,"Other designations: P450 form 1|cytochrome P450 2C8|cytochrome P450 IIC2|cytochrome P450 MP-12|cytochrome P450 MP-20|cytochrome P450 form 1|cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 8|flavoprotein-linked monooxygenase|microsomal monooxygenase|s-mephenytoin 4-hydroxylase|xenobiotic monooxygenase",,CYP2C8,,,,,,,,,,,,,,,,,,,,,,,1558,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP2C8,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001555,CYP2B6,,"Other designations: 1,4-cineole 2-exo-monooxygenase|cytochrome P450 2B6|cytochrome P450 IIB1|cytochrome P450, subfamily IIB (phenobarbital-inducible), polypeptide 6",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,IIB1|EFVM|CYP2B|CYP2B7|P450|CPB6|CYPIIB6|CYP2B7P,,,,,,,,,,,,19,,,,,,HPRD:00477|HGNC:2615|MIM:123930|Vega:OTTHUMG00000182714|Ensembl:ENSG00000197408,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 2, subfamily B, polypeptide 6",,,19q13.2,,,,,,,,,,,,,,,,"GO_0004497 (EC: IDA, PMID:19651758); GO_0005506 (EC: IEA); GO_0005789 (EC: TAS); GO_0006805 (EC: IDA); GO_0006805 (EC: TAS); GO_0008202 (EC: IMP, PMID:18356043); GO_0016712 (EC: IEA); GO_0017144 (EC: IDA, PMID:19651758); GO_0017144 (EC: IMP, PMID:18356043); GO_0020037 (EC: IDA); GO_0042180 (EC: IDA, PMID:19651758); GO_0042738 (EC: IDA, PMID:19029318); GO_0044281 (EC: TAS); GO_0055114 (EC: IDA, PMID:19651758)",,,,,,,,,PMID:2308828; 2573390; 2813061; 2899870; 7668294; 8432525; 8587134; 9179987; 9890157; 10037683; 10471061; 10768437; 11243870; 11298076; 11353758; 11470993; 11602525; 11991950; 12207635; 12242601; 12439223; 12477932; 12490624; 12571232; 12629583; 12642465; 12721789; 12738724; 12814665; 14515060; 14977870; 15039299; 15057824; 15128046; 15178651; 15190123; 15194512; 15248218; 15284537; 15319333; 15383491; 15469410; 15563456; 15572372; 15622315; 15825040; 15864119; 16116487; 16125881; 16183265; 16267764; 16338275; 16392089; 16433869; 16495778; 16506047; 16538176; 16623664; 16772608; 16815693; 16912957; 16951995; 17015050; 17047492; 17054410; 17178267; 17223085; 17235330; 17329992; 17352764; 17356468; 17391322; 17407229; 17455229; 17465455; 17502835; 17559344; 17638512; 17654295; 17682072; 17885627; 17900275; 17918089; 18004205; 18024866; 18057928; 18090046; 18171905; 18223457; 18281305; 18287571; 18303024; 18332083; 18356043; 18496131; 18621926; 18728241; 18784455; 18839779; 18854779; 18978480; 18979093; 18989234; 19005482; 19029318; 19074885; 19076156; 19106084; 19124658; 19144407; 19218571; 19225447; 19228205; 19239339; 19282874; 19290787; 19343046; 19371316; 19376514; 19414633; 19425200; 19433561; 19464434; 19467232; 19474465; 19474786; 19486190; 19531981; 19593168; 19651758; 19659438; 19682083; 19693007; 19696793; 19702527; 19704172; 19779319; 19797611; 19812066; 19833192; 19916993; 19926050; 19944064; 20017669; 20079471; 20089352; 20096935; 20136364; 20137387; 20173083; 20179710; 20307138; 20338069; 20350955; 20361990; 20418888; 20459744; 20517174; 20529763; 20583967; 20602615; 20610889; 20622021; 20624854; 20625352; 20639527; 20642445; 20662624; 20668445; 20677014; 20696882; 20720517; 20723261; 20734064; 20841522; 20860463; 20861742; 20876786; 20878158; 20881953; 20952238; 20952418; 20966044; 20970553; 21108329; 21156812; 21158011; 21169260; 21486104; 21694616; 21715435; 21741706; 21746968; 21790905; 21821736; 21886015; 22232427; 22281205; 22397853; 22462748; 22471906; 22519658; 22680342; 22685215; 22815312; 22909231; 22936314; 22942317; 22950382; 23238783; 23249875; 23254426; 23288240; 23298916; 23344581; 23418033; 23524664; 23539296; 23550066; 23615745; 23687222; 23746185; 23837472; 24128861,,,,,,,,,,,,,,,OGG:3000001555,,,,,,,"cytochrome P450, family 2, subfamily B, polypeptide 6",,,,,,,,,,,,,"Other designations: 1,4-cineole 2-exo-monooxygenase|cytochrome P450 2B6|cytochrome P450 IIB1|cytochrome P450, subfamily IIB (phenobarbital-inducible), polypeptide 6",,CYP2B6,,,,,,,,,,,,,,,,,,,,,,,1555,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP2B6,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001551,CYP3A7,,"Other designations: aryl hydrocarbon hydroxylase|cytochrome P450 3A7|cytochrome P450, subfamily IIIA, polypeptide 7|cytochrome P450-HFLA|flavoprotein-linked monooxygenase|microsomal monooxygenase|xenobiotic monooxygenase",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CYPIIIA7|CP37|P450-HFLA,,,,,,,,,,,,7,,,,,,Ensembl:ENSG00000160870|MIM:605340|HPRD:05630|Vega:OTTHUMG00000156726|HGNC:2640,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 3, subfamily A, polypeptide 7",,,7q21-q22.1,,,,,,,,,,,,,,,,"GO_0004497 (EC: ISS); GO_0005506 (EC: IEA); GO_0005789 (EC: TAS); GO_0006805 (EC: TAS); GO_0019825 (EC: TAS, PMID:2722762); GO_0020037 (EC: IEA); GO_0044281 (EC: TAS); GO_0070330 (EC: IEA)",,,,,,,,,PMID:1562592; 2492179; 2722762; 2786707; 7894497; 8694864; 9644715; 9890157; 10950848; 11093772; 11137287; 11266076; 11940601; 12406645; 12477932; 12485945; 12690205; 12865317; 14569421; 15128046; 15319333; 15489334; 15698577; 15937338; 15985487; 16041241; 16314882; 16430309; 16635807; 17334880; 17559345; 17582393; 17604264; 17885626; 17936930; 18406467; 18445661; 18537580; 18676680; 18978522; 19064572; 19170196; 19275551; 19343046; 19424794; 19585271; 19593168; 19625176; 19692168; 19801957; 19842932; 20118548; 20147896; 20345875; 20529763; 20615193; 20621111; 20634891; 20637317; 22253426; 22277676; 23143891,,,,,,,,,,,,,,,OGG:3000001551,,,,,,,"cytochrome P450, family 3, subfamily A, polypeptide 7",,,,,,,,,,,,,"Other designations: aryl hydrocarbon hydroxylase|cytochrome P450 3A7|cytochrome P450, subfamily IIIA, polypeptide 7|cytochrome P450-HFLA|flavoprotein-linked monooxygenase|microsomal monooxygenase|xenobiotic monooxygenase",,CYP3A7,,,,,,,,,,,,,,,,,,,,,,,1551,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP3A7,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001559,CYP2C9,,Other designations: cytochrome P-450 S-mephenytoin 4-hydroxylase|cytochrome P-450MP|cytochrome P450 2C9|cytochrome P450 PB-1|flavoprotein-linked monooxygenase|microsomal monooxygenase|xenobiotic monooxygenase,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CPC9|CYP2C10|P450IIC9|CYPIIC9|CYP2C,,,,,,,,,,,,10,,,,,,Vega:OTTHUMG00000018805|HGNC:2623|HPRD:03084|Ensembl:ENSG00000138109|MIM:601130,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 2, subfamily C, polypeptide 9",,,10q24,,,,,,,,,,,,,,,,"GO_0004497 (EC: IDA, PMID:19651758); GO_0004497 (EC: NAS, PMID:2827463); GO_0005506 (EC: IEA); GO_0005789 (EC: TAS); GO_0006805 (EC: TAS); GO_0008144 (EC: IDA, PMID:19448135); GO_0008202 (EC: IMP, PMID:18356043); GO_0008395 (EC: IMP, PMID:18356043); GO_0016098 (EC: IDA, PMID:16401082); GO_0016491 (EC: IDA, PMID:16401082); GO_0017144 (EC: IDA, PMID:19219744); GO_0017144 (EC: IMP); GO_0018675 (EC: IEA); GO_0018676 (EC: IEA); GO_0019369 (EC: TAS); GO_0019373 (EC: TAS); GO_0019627 (EC: IDA, PMID:19029318); GO_0020037 (EC: IEA); GO_0032787 (EC: IDA, PMID:19651758); GO_0034875 (EC: IDA, PMID:18619574); GO_0042737 (EC: IMP, PMID:18356043); GO_0042738 (EC: IDA, PMID:18619574); GO_0043231 (EC: IDA, PMID:9618440); GO_0043231 (EC: TAS, PMID:2827463); GO_0043603 (EC: IDA, PMID:19651758); GO_0044281 (EC: TAS); GO_0052741 (EC: IEA); GO_0055114 (EC: IDA, PMID:16401082); GO_0070989 (EC: IDA, PMID:18619574); GO_0097267 (EC: TAS)",,,,,,,,,PMID:1445376; 1857342; 2009263; 2025243; 2827463; 2963808; 3032244; 3079764; 3196692; 3243766; 3697070; 7704034; 7841444; 8095407; 8215449; 8333835; 8530044; 8809086; 8946475; 9110362; 9398194; 9618440; 9663807; 9890157; 10073515; 10704292; 10739176; 11127854; 11186133; 11298075; 11325819; 11372590; 11397381; 11422024; 11434505; 11455026; 11503012; 11588061; 11678789; 11697742; 11740344; 11833786; 11876753; 11893129; 11908757; 11911968; 11926893; 11950794; 11956512; 11960920; 11991950; 12010835; 12047484; 12152005; 12181452; 12207635; 12235454; 12359989; 12360109; 12406644; 12414349; 12419832; 12426520; 12435384; 12445031; 12451434; 12464247; 12477932; 12496751; 12509498; 12534640; 12559973; 12603175; 12621390; 12634980; 12668916; 12682803; 12698304; 12728288; 12732844; 12734606; 12800253; 12803577; 12805007; 12844136; 12861225; 12879168; 12891229; 12900870; 12913403; 12950145; 14500040; 14504850; 14520122; 14583800; 14614357; 14616425; 14634042; 14634838; 14646690; 14656880; 14661864; 14676821; 14691573; 14691574; 14707031; 14726986; 14739630; 15001971; 15001972; 15005635; 15024534; 15039299; 15048614; 15050794; 15061384; 15066644; 15070684; 15090156; 15100169; 15102864; 15116052; 15116053; 15128046; 15128048; 15145963; 15175798; 15177309; 15197523; 15199455; 15213846; 15222661; 15226678; 15229460; 15248218; 15260906; 15284535; 15284536; 15289788; 15290664; 15369736; 15370961; 15371982; 15385837; 15452553; 15469410; 15536456; 15569425; 15569819; 15588114; 15592327; 15606435; 15606441; 15608560; 15617742; 15632378; 15660966; 15691505; 15714076; 15742978; 15776277; 15790782; 15795654; 15813658; 15824753; 15841315; 15842554; 15855721; 15888487; 15889670; 15896241; 15900281; 15900282; 15919766; 15924351; 15940194; 15947090; 15961979; 15963101; 15970795; 16006997; 16025294; 16082538; 16094537; 16099926; 16111713; 16116487; 16141794; 16141797; 16160068; 16183265; 16187974; 16198655; 16198656; 16202848; 16220110; 16232205; 16236141; 16253141; 16268502; 16297214; 16303885; 16305586; 16305587; 16321620; 16325295; 16338275; 16342679; 16372821; 16385451; 16401082; 16413010; 16424822; 16432637; 16538176; 16541193; 16552506; 16580898; 16595916; 16611750; 16627267; 16630605; 16635054; 16638864; 16639745; 16646575; 16676068; 16699986; 16708125; 16740353; 16749864; 16771603; 16784736; 16797247; 16815313; 16847429; 16847664; 16863464; 16873909; 16878445; 16882880; 16890578; 16924387; 16957870; 16969365; 16985026; 16985032; 17015052; 17048007; 17049586; 17085674; 17110455; 17111199; 17157122; 17167248; 17178267; 17192772; 17201743; 17226852; 17269966; 17279092; 17298483; 17301738; 17304159; 17324110; 17325732; 17329986; 17332144; 17368604; 17391071; 17397249; 17413769; 17418993; 17419358; 17446262; 17460547; 17479200; 17504998; 17510308; 17558303; 17562299; 17572144; 17577464; 17596133; 17596671; 17597710; 17603219; 17627011; 17627038; 17635176; 17635181; 17635185; 17653141; 17681167; 17686967; 17721328; 17764537; 17827141; 17827526; 17849045; 17851566; 17868191; 17895500; 17899045; 17900275; 17955230; 17989110; 18021343; 18024866; 18030307; 18034618; 18034619; 18061941; 18154472; 18183038; 18204476; 18211048; 18216720; 18231117; 18240903; 18240905; 18252229; 18281915; 18303964; 18305455; 18310303; 18315785; 18322281; 18340006; 18356043; 18370846; 18375260; 18378563; 18399713; 18419640; 18425152; 18429757; 18466099; 18480003; 18485885; 18496131; 18496133; 18496682; 18510611; 18511451; 18516070; 18535201; 18542936; 18548238; 18552123; 18559094; 18570163; 18574025; 18597650; 18619574; 18629445; 18662264; 18669935; 18680736; 18681789; 18690342; 18694831; 18698879; 18754001; 18754597; 18756910; 18781852; 18793590; 18816302; 18836275; 18854779; 18855533; 18922023; 18936436; 18950464; 18971529; 18990750; 18992148; 18992263; 18992346; 18996102; 19005461; 19010418; 19018719; 19026171; 19029318; 19031075; 19053752; 19064572; 19074728; 19074885; 19077919; 19082874; 19099951; 19106084; 19117406; 19135231; 19136640; 19139476; 19151603; 19164093; 19177029; 19181737; 19192051; 19199010; 19202563; 19207028; 19219744; 19221727; 19223558; 19225451; 19233181; 19233910; 19258521; 19280158; 19290787; 19297219; 19300499; 19319511; 19324988; 19336370; 19337788; 19339270; 19343046; 19350405; 19369937; 19381162; 19381164; 19387626; 19414633; 19415745; 19415824; 19420105; 19424794; 19448135; 19450127; 19474452; 19480553; 19495518; 19534586; 19538716; 19538885; 19541511; 19541829; 19545555; 19546880; 19567378; 19578179; 19581657; 19593158; 19593168; 19593208; 19604036; 19605743; 19615687; 19617466; 19651758; 19652664; 19663669; 19663817; 19669737; 19692168; 19696793; 19706858; 19736056; 19745563; 19761366; 19794411; 19822571; 19823875; 19833260; 19847408; 19874474; 19881396; 19891553; 19891554; 19899329; 19903527; 19913121; 19925388; 19926050; 19934028; 19934793; 19935798; 19941044; 19942260; 19952982; 19954515; 19956635; 19958090; 19995889; 20020283; 20029944; 20031551; 20043560; 20064729; 20072124; 20073138; 20075209; 20088379; 20089352; 20102361; 20117066; 20121287; 20131310; 20136364; 20147896; 20149073; 20150829; 20167002; 20173083; 20179710; 20204461; 20207952; 20210733; 20226775; 20228265; 20235787; 20297661; 20339191; 20339978; 20351714; 20354686; 20359257; 20373852; 20375710; 20375999; 20376629; 20381283; 20386359; 20390258; 20403997; 20421126; 20430047; 20434758; 20436375; 20437850; 20442691; 20445534; 20453000; 20458343; 20459419; 20459744; 20488169; 20499136; 20504253; 20529763; 20553802; 20555338; 20569971; 20585445; 20585834; 20597268; 20602612; 20602615; 20602621; 20615525; 20628086; 20637959; 20653674; 20653676; 20656072; 20665013; 20677151; 20679960; 20709439; 20716240; 20722625; 20733952; 20808793; 20811787; 20815369; 20831047; 20831536; 20833655; 20833683; 20833980; 20842355; 20845310; 20852447; 20854800; 20857895; 20884456; 20885015; 20930419; 20937634; 20941486; 20946155; 20962433; 20970553; 21044367; 21047199; 21057703; 21063236; 21068649; 21071160; 21108610; 21110192; 21148049; 21160360; 21163940; 21167292; 21173785; 21213107; 21215088; 21248432; 21292004; 21334530; 21371265; 21375401; 21451434; 21493749; 21533175; 21537551; 21544933; 21597400; 21605066; 21638223; 21639946; 21651319; 21691805; 21692828; 21725053; 21757329; 21766908; 21768671; 21786578; 21798861; 21852944; 21861665; 21883387; 21977947; 21985811; 21988832; 22023024; 22075408; 22075505; 22108774; 22188360; 22198820; 22252093; 22272893; 22288731; 22289258; 22290467; 22294058; 22378156; 22393834; 22409277; 22452429; 22528326; 22533669; 22534826; 22542470; 22547083; 22571356; 22589111; 22641027; 22735459; 22808915; 22842957; 22854539; 22855348; 22918969; 22941809; 22952875; 23065265; 23081681; 23081704; 23089473; 23099353; 23113310; 23118231; 23145098; 23159358; 23159639; 23171336; 23183958; 23201087; 23279643; 23376925; 23446815; 23469989; 23473641; 23481074; 23556337; 23563037; 23577132; 23582453; 23586031; 23615745; 23651023; 23726967; 23732294; 23755828; 23774101; 23863877; 23930675,,,,,,,,,,,,,,,OGG:3000001559,,,,,,,"cytochrome P450, family 2, subfamily C, polypeptide 9",,,,,,,,,,,,,Other designations: cytochrome P-450 S-mephenytoin 4-hydroxylase|cytochrome P-450MP|cytochrome P450 2C9|cytochrome P450 PB-1|flavoprotein-linked monooxygenase|microsomal monooxygenase|xenobiotic monooxygenase,,CYP2C9,,,,,,,,,,,,,,,,,,,,,,,1559,RP11-208C17.6,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP2C9,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001557,CYP2C19,,"Other designations: (R)-limonene 6-monooxygenase|(S)-limonene 6-monooxygenase|(S)-limonene 7-monooxygenase|CYPIIC17|CYPIIC19|S-mephenytoin 4-hydroxylase|cytochrome P-450 II C|cytochrome P450 2C19|cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 19|cytochrome P450-11A|cytochrome P450-254C|flavoprotein-linked monooxygenase|mephenytoin 4'-hydroxylase|mephenytoin 4-hydroxylase|microsomal monooxygenase|xenobiotic monooxygenase",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,P450C2C|CYP2C|P450IIC19|CPCJ,,,,,,,,,,,,10,,,,,,HPRD:00486|MIM:124020|HGNC:2621,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 2, subfamily C, polypeptide 19",,,10q24,,,,,,,,,,,,,,,,"GO_0004497 (EC: IDA, PMID:19651758); GO_0005506 (EC: IEA); GO_0005789 (EC: TAS); GO_0006805 (EC: TAS); GO_0008202 (EC: IMP, PMID:18356043); GO_0008395 (EC: IMP, PMID:18356043); GO_0016098 (EC: IDA, PMID:16401082); GO_0016491 (EC: IDA, PMID:16401082); GO_0017144 (EC: IDA, PMID:19219744); GO_0018675 (EC: IEA); GO_0018676 (EC: IEA); GO_0019369 (EC: TAS); GO_0019373 (EC: TAS); GO_0019825 (EC: TAS, PMID:3442670); GO_0019899 (EC: IPI, PMID:15680923); GO_0020037 (EC: IDA); GO_0042738 (EC: IDA, PMID:19029318); GO_0043231 (EC: TAS, PMID:3442670); GO_0044281 (EC: TAS); GO_0046483 (EC: IDA, PMID:19651758); GO_0052741 (EC: IEA); GO_0055114 (EC: IDA, PMID:16401082); GO_0097267 (EC: TAS)",,,,,,,,,PMID:2009263; 3442670; 7704034; 7969038; 8095407; 8110777; 8195181; 8530044; 8647857; 8894508; 9103550; 9398194; 9435198; 9732415; 9890157; 10022751; 10233205; 10411572; 11037802; 11076863; 11207032; 11240980; 11263781; 11372584; 11474773; 11686476; 11713950; 11763000; 11773867; 11785712; 11791894; 11829201; 11836688; 11865668; 11908757; 11927837; 11950794; 11956668; 12047484; 12121503; 12130704; 12142727; 12171978; 12172336; 12222750; 12235924; 12360109; 12386647; 12419832; 12445035; 12464799; 12468438; 12477932; 12496751; 12534411; 12623762; 12642692; 12656699; 12698310; 12732844; 12809821; 12823155; 12835613; 12879168; 12900870; 12900872; 12919183; 12950145; 12963435; 12975335; 13680037; 14520122; 14583683; 14616425; 14634042; 14634838; 14636465; 14653835; 14659971; 14695703; 14990013; 14998561; 15017629; 15025747; 15039299; 15068562; 15090156; 15119530; 15128046; 15145965; 15164054; 15171646; 15177309; 15205367; 15222046; 15248218; 15284537; 15285851; 15301728; 15319333; 15327595; 15349706; 15371981; 15385836; 15385837; 15447734; 15448955; 15469410; 15496639; 15499191; 15569425; 15590749; 15608563; 15612662; 15639978; 15651900; 15660966; 15662508; 15680923; 15691303; 15691505; 15715938; 15752376; 15776277; 15813658; 15842554; 15855721; 15856433; 15903128; 15932363; 15952098; 15963082; 15963095; 15976989; 16006997; 16012079; 16021435; 16024198; 16025294; 16048566; 16116487; 16133961; 16141610; 16183265; 16198656; 16220110; 16231968; 16232205; 16236141; 16239354; 16261363; 16267764; 16268979; 16307177; 16338275; 16338278; 16338280; 16401082; 16413245; 16487224; 16487225; 16595916; 16638864; 16641871; 16740190; 16771603; 16772608; 16783561; 16789993; 16812949; 16815315; 16815316; 16855453; 16862439; 16863547; 16873909; 16890574; 16890578; 16908943; 16911688; 16912869; 16924387; 16937451; 16946555; 16960452; 17003844; 17047431; 17047492; 17048007; 17052843; 17112810; 17178267; 17201743; 17203292; 17215846; 17269966; 17279092; 17290075; 17295875; 17298483; 17304159; 17357148; 17358097; 17377957; 17407229; 17410461; 17417917; 17418993; 17424941; 17433262; 17439410; 17450472; 17455109; 17487889; 17502835; 17504998; 17559380; 17562299; 17623107; 17625515; 17635176; 17635181; 17666363; 17667801; 17667959; 17680025; 17681590; 17697139; 17697203; 17827141; 17868191; 17875119; 17900275; 17909762; 17922881; 17924835; 17934830; 17966194; 17978853; 17992535; 18004210; 18021343; 18024866; 18057705; 18061941; 18154472; 18205890; 18211619; 18214455; 18223462; 18224311; 18231117; 18240903; 18240905; 18241283; 18241287; 18294333; 18312490; 18319058; 18323861; 18346178; 18356043; 18382661; 18394438; 18399167; 18423013; 18425152; 18466100; 18482659; 18496131; 18496682; 18510611; 18511451; 18518848; 18520596; 18520598; 18521743; 18532997; 18551037; 18577829; 18581106; 18637061; 18641551; 18644391; 18654768; 18676680; 18677622; 18702650; 18751689; 18765869; 18781853; 18823430; 18854779; 18854824; 18936436; 18957504; 18979093; 18982321; 18996102; 19002442; 19025845; 19029318; 19033450; 19038035; 19069365; 19074885; 19102714; 19106083; 19106084; 19108880; 19129087; 19136640; 19139162; 19151603; 19156902; 19164093; 19166419; 19169185; 19170196; 19172254; 19176055; 19192051; 19193675; 19193970; 19199010; 19219744; 19220726; 19236548; 19238367; 19246508; 19259653; 19261446; 19268736; 19290787; 19299322; 19336370; 19337788; 19343046; 19348299; 19350405; 19398604; 19404631; 19407662; 19414633; 19415745; 19415824; 19424794; 19429918; 19430176; 19474452; 19496924; 19499406; 19516253; 19531897; 19534586; 19546880; 19552744; 19576320; 19578179; 19583677; 19593158; 19593168; 19617466; 19621685; 19624462; 19625176; 19636337; 19638460; 19651758; 19661214; 19692168; 19693007; 19696793; 19702490; 19706858; 19712984; 19745563; 19751749; 19761366; 19773541; 19817997; 19821196; 19823875; 19840783; 19841156; 19847408; 19881258; 19884907; 19890215; 19891553; 19904250; 19907421; 19926050; 19928008; 19932784; 19933691; 19934793; 19940233; 19942749; 19954515; 19954746; 19956635; 19961004; 19968574; 20002085; 20015960; 20040040; 20064729; 20078610; 20083681; 20088379; 20113968; 20147896; 20163283; 20173083; 20179710; 20206639; 20207952; 20223877; 20235787; 20236133; 20297661; 20309015; 20349052; 20350051; 20350136; 20351750; 20356512; 20358205; 20360782; 20373852; 20376628; 20390258; 20414645; 20430047; 20457439; 20460345; 20468063; 20492431; 20492467; 20492469; 20499227; 20510210; 20528170; 20529763; 20531370; 20533108; 20549256; 20549497; 20559522; 20565970; 20573087; 20581929; 20602612; 20602615; 20620727; 20633187; 20637959; 20650435; 20665013; 20669013; 20673183; 20679960; 20684753; 20708365; 20716239; 20716514; 20724801; 20801494; 20801498; 20804307; 20823393; 20826260; 20831535; 20831536; 20831548; 20833683; 20838991; 20845077; 20845310; 20857895; 20863179; 20885015; 20890775; 20924183; 20926021; 20941486; 20965456; 20970553; 20976881; 20978260; 20979470; 21038076; 21047200; 21054462; 21054464; 21071160; 21075428; 21079055; 21099121; 21108329; 21108610; 21132257; 21152987; 21160212; 21173785; 21192344; 21212520; 21215696; 21237322; 21247447; 21299635; 21302482; 21315147; 21332417; 21358751; 21380557; 21473286; 21497341; 21507170; 21511217; 21511219; 21527445; 21627593; 21628721; 21689142; 21692828; 21741706; 21766908; 21777277; 21778720; 21786436; 21794898; 21795468; 21798861; 21803320; 21806387; 21826689; 21831410; 21861665; 21862109; 21887904; 21913914; 21913948; 21916910; 21971440; 21972404; 21977947; 22007612; 22028352; 22030270; 22045970; 22070512; 22071359; 22088240; 22116003; 22118006; 22122271; 22123356; 22154242; 22180071; 22183943; 22228204; 22281205; 22304323; 22318618; 22324425; 22374717; 22377481; 22418828; 22425806; 22450429; 22469723; 22476388; 22491019; 22552318; 22585284; 22589111; 22591668; 22612904; 22624833; 22641027; 22648560; 22704413; 22747643; 22785462; 22839512; 22855348; 22873740; 22875498; 22875511; 22913530; 22929815; 22955794; 22971905; 22974728; 22984423; 23001453; 23016454; 23074110; 23081704; 23118231; 23148634; 23175667; 23179471; 23193974; 23257377; 23267857; 23337798; 23340030; 23364775; 23412869; 23413279; 23429358; 23469989; 23470885; 23474843; 23506580; 23517020; 23551241; 23555019; 23556336; 23588332; 23607088; 23618682; 23623526; 23640828; 23645039; 23646118; 23700873; 23736997; 23754447; 23755828; 23793025; 23872648; 23874401; 23886632; 23895809; 24015291; 24088005; 24169346; 24501942,,,,,,,,,,,,,,,OGG:3000001557,,,,,,,"cytochrome P450, family 2, subfamily C, polypeptide 19",,,,,,,,,,,,,"Other designations: (R)-limonene 6-monooxygenase|(S)-limonene 6-monooxygenase|(S)-limonene 7-monooxygenase|CYPIIC17|CYPIIC19|S-mephenytoin 4-hydroxylase|cytochrome P-450 II C|cytochrome P450 2C19|cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 19|cytochrome P450-11A|cytochrome P450-254C|flavoprotein-linked monooxygenase|mephenytoin 4'-hydroxylase|mephenytoin 4-hydroxylase|microsomal monooxygenase|xenobiotic monooxygenase",,CYP2C19,,,,,,,,,,,,,,,,,,,,,,,1557,RP11-400G3.4,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP2C19,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_37734,phosphoric ester,,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:37734,,,,,,,,,,,,,,,,,,,,,,phosphoric ester,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005136,USP7 (mol),ubiquitin specific peptidase 7,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:7874|NCBI-Mouse-GeneID:252870|NCBI-Rat-GeneID:360471,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ubiquitin specific peptidase 7,,,,,TXPO:0005136,,,,,,,,,,,,,,,,,,,,,,USP7 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005135,TGFA (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24827|NCBI-Mouse-GeneID:21802|NCBI-Human-GeneID:7039,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005135,,,,,,,,,,,,,,,,,,,,,,TGFA (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005137,YAP1 (mol),YAP,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:10413|NCBI-Rat-GeneID:363014|NCBI-Mouse-GeneID:22601,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,YAP,,,,,TXPO:0005137,,,,,,,,,,,,,,,,,,,,,,YAP1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005138,bis(2-ethylhexyl) phthalate [hepatocarcinogenesis],Diethylhexylphthalate|DEHP,"A phthalate ester that is the bis(2-ethylhexyl) ester of benzene-1,2-dicarboxylic acid.",false,,,http://purl.obolibrary.org/obo/TXPO_0004455|http://purl.obolibrary.org/obo/CHEBI_17747,,,,,,,,,,,,,,,,,,,,CAS:117-81-7|PMID:22584684,,"A phthalate ester that is the bis(2-ethylhexyl) ester of benzene-1,2-dicarboxylic acid.",,,,,,,,,,,,C24H38O4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Diethylhexylphthalate|DEHP,,,TXPO:0005138,,,,,,,,,,,,,,,,,,,,,,bis(2-ethylhexyl) phthalate [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CCCCC(CC)COC(=O)c1ccccc1C(=O)OCC(CC)CCCC,,,,,
http://purl.obolibrary.org/obo/TXPO_0005130,PTK2 (mol),FAK,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:5747|NCBI-Rat-GeneID:25614|NCBI-Mouse-GeneID:14083,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FAK,,,,,TXPO:0005130,,,,,,,,,,,,,,,,,,,,,,PTK2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005132,SNAI1 (mol),Snail,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:6615|NCBI-Rat-GeneID:116490|NCBI-Mouse-GeneID:20613,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Snail,,,,,TXPO:0005132,,,,,,,,,,,,,,,,,,,,,,SNAI1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005133,TERT (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:21752|NCBI-Human-GeneID:7015|NCBI-Rat-GeneID:301965,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005133,,,,,,,,,,,,,,,,,,,,,,TERT (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005131,SFRP1 (human) [hepatocarcinogenesis],secreted frizzled related protein 1,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_0004799,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:6422,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,secreted frizzled related protein 1,,,,,TXPO:0005131,,,,,,,,,,,,,,,,,,,,,,SFRP1 (human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005134,TFAM (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:83474|NCBI-Human-GeneID:7019|NCBI-Mouse-GeneID:21780,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005134,,,,,,,,,,,,,,,,,,,,,,TFAM (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005139,release of inflammatory DAMPs,,The process that results in the movement of inflammatory DAMPs from the  mitochondria.,false,,,http://purl.obolibrary.org/obo/TXPO_0002588,,,,,,,,,,,,,,,,,,,,,,The process that results in the movement of inflammatory DAMPs from the  mitochondria.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005139,,,,,,,,,,,,,,,,,,,,,,release of inflammatory DAMPs,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_35544,EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor,"cyclooxygenase (EC 1.14.99.1) inhibitors|(PG)H synthase inhibitor|cyclooxygenase (EC 1.14.99.1) inhibitor|EC 1.14.99.1 (cyclooxygenase) inhibitor|prostaglandin synthase inhibitor|EC 1.14.99.1 inhibitors|PG synthetase inhibitors|fatty acid cyclooxygenase inhibitor|cyclooxygenase inhibitors|EC 1.14.99.1 inhibitor|prostaglandin synthase inhibitors|prostaglandin endoperoxide synthetase inhibitor|(PG)H synthase inhibitors|PG synthetase inhibitor|EC 1.14.99.1 (cyclooxygenase) inhibitors|prostaglandin synthetase inhibitor|(5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate,hydrogen-donor:oxygen oxidoreductase inhibitors|prostaglandin G/H synthase inhibitor|COX inhibitor|prostaglandin endoperoxide synthetase inhibitors|(5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate,hydrogen-donor:oxygen oxidoreductase inhibitor|cyclooxygenase inhibitor|fatty acid cyclooxygenase inhibitors|prostaglandin G/H synthase inhibitors|EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitors|prostaglandin synthetase inhibitors","A compound or agent that combines with cyclooxygenases (EC 1.14.99.1) and thereby prevents its substrate-enzyme combination with arachidonic acid and the formation of icosanoids, prostaglandins, and thromboxanes.",false,,,http://purl.obolibrary.org/obo/CHEBI_76840,,,,,,,,,,,,,,,,,,,,,,"A compound or agent that combines with cyclooxygenases (EC 1.14.99.1) and thereby prevents its substrate-enzyme combination with arachidonic acid and the formation of icosanoids, prostaglandins, and thromboxanes.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"cyclooxygenase (EC 1.14.99.1) inhibitors|(PG)H synthase inhibitor|cyclooxygenase (EC 1.14.99.1) inhibitor|EC 1.14.99.1 (cyclooxygenase) inhibitor|prostaglandin synthase inhibitor|EC 1.14.99.1 inhibitors|PG synthetase inhibitors|fatty acid cyclooxygenase inhibitor|cyclooxygenase inhibitors|EC 1.14.99.1 inhibitor|prostaglandin synthase inhibitors|prostaglandin endoperoxide synthetase inhibitor|(PG)H synthase inhibitors|PG synthetase inhibitor|EC 1.14.99.1 (cyclooxygenase) inhibitors|prostaglandin synthetase inhibitor|(5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate,hydrogen-donor:oxygen oxidoreductase inhibitors|prostaglandin G/H synthase inhibitor|COX inhibitor|prostaglandin endoperoxide synthetase inhibitors|(5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate,hydrogen-donor:oxygen oxidoreductase inhibitor|cyclooxygenase inhibitor|fatty acid cyclooxygenase inhibitors|prostaglandin G/H synthase inhibitors|EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitors|prostaglandin synthetase inhibitors",,,,,,,,,,,,,,,,,,,,,CHEBI:35544,,,,EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor,,CHEBI:35544,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002072,spleen malfunction [Niemann Pick Disease Type A/ B],,"Spleen malfunction is a subtype of organ malfunction: A process that does not perform spleen function correctly.
This entity is a specific course-dependent process. This process can constitute the course of Niemann-Pick Disease Type A/ B.",false,,,http://purl.obolibrary.org/obo/TXPO_0002075|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Spleen malfunction is a subtype of organ malfunction: A process that does not perform spleen function correctly.
This entity is a specific course-dependent process. This process can constitute the course of Niemann-Pick Disease Type A/ B.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002072,,,,,,,,,,,,,,,,,,,,,,spleen malfunction [Niemann Pick Disease Type A/ B],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002070,phospholipid accumulation in lysosome [Phospholipidosis - genetic- sphingomyelin disorder  ],,"Phospholipid accumulation in lysosome is a subtype of phospholipid accumulation: A process that keeps phospholipid in the lysosome.
This process is dependent on the sphingomyelin disorder  and can constitute the course of Phospholipidosis (genetic).",false,,,http://purl.obolibrary.org/obo/TXPO_0000910,,,,,,,,,,,,,,,,,,,,,,"Phospholipid accumulation in lysosome is a subtype of phospholipid accumulation: A process that keeps phospholipid in the lysosome.
This process is dependent on the sphingomyelin disorder  and can constitute the course of Phospholipidosis (genetic).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002070,,,,,,,,,,,,,,,,,,,,,,phospholipid accumulation in lysosome [Phospholipidosis - genetic- sphingomyelin disorder  ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002073,organ malfunction,,Organ malfunction is a subtype of malfunctioning process: A process that cannot perform organ(s)  function appropriately or cannot realize it at all.,false,,,http://purl.obolibrary.org/obo/TXPO_0000434,,,,,,,,,,,,,,,,,,,,,,Organ malfunction is a subtype of malfunctioning process: A process that cannot perform organ(s)  function appropriately or cannot realize it at all.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002073,,,,,,,,,,,,,,,,,,,,,,organ malfunction,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000378,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0000062,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002071,liver malfunction [Niemann Pick Disease Type A/ B],,"Liver malfunction is a subtype of organ malfunction: A process that does not perform liver function correctly or not functioning at all.
This entity is a specific course-dependent process. This process can constitute the course of Niemann-Pick Disease Type A/ B.",false,,,http://purl.obolibrary.org/obo/TXPO_0002074|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Liver malfunction is a subtype of organ malfunction: A process that does not perform liver function correctly or not functioning at all.
This entity is a specific course-dependent process. This process can constitute the course of Niemann-Pick Disease Type A/ B.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002071,,,,,,,,,,,,,,,,,,,,,,liver malfunction [Niemann Pick Disease Type A/ B],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002079,decreasing demand for phospholipid degradation [Phospholipidosis],,"Decreasing demand for phospholipid degradation is a subtype of decreasing functional demand: A process that changes the functional demand for the phospholipid degradation to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0002082,,,,,,,,,,,,,,,,,,,,,,"Decreasing demand for phospholipid degradation is a subtype of decreasing functional demand: A process that changes the functional demand for the phospholipid degradation to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002079,,,,,,,,,,,,,,,,,,,,,,decreasing demand for phospholipid degradation [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002075,spleen malfunction,,Spleen malfunction is a subtype of organ malfunction: A process that does not perform spleen function correctly.,false,,,http://purl.obolibrary.org/obo/TXPO_0002073,,,,,,,,,,,,,,,,,,,,,,Spleen malfunction is a subtype of organ malfunction: A process that does not perform spleen function correctly.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002075,,,,,,,,,,,,,,,,,,,,,,spleen malfunction,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002078,chemical compound excretion [Phospholipidosis],,"Compound excretion is a subtype of xenobiotics excretion: A process that takes a compound from a cell, organelle, or makes a clearance of it from the body.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002077|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Compound excretion is a subtype of xenobiotics excretion: A process that takes a compound from a cell, organelle, or makes a clearance of it from the body.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002252,,,,,,,,,,,TXPO:0002078,,,,,,,,,,,,,,,,,,,,,,chemical compound excretion [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002074,liver malfunction,,Liver malfunction is a subtype of organ malfunction: A process that does not perform liver function correctly  or not functioning at all.,false,,,http://purl.obolibrary.org/obo/TXPO_0002073,,,,,,,,,,,,,,,,,,,,,,Liver malfunction is a subtype of organ malfunction: A process that does not perform liver function correctly  or not functioning at all.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002074,,,,,,,,,,,,,,,,,,,,,,liver malfunction,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002076,toxicological imbalance M=M (maintining homeostasis in the normal condition),,"In the imbalance model, the basic units are as follows:
1) a functioning process (supply) for biological defense and maintaining homeostasis;
2) a functional demand process (demand) as toxic activity;
3) balance/imbalance between toxic activity and defense processes; and
4) outcome from organelles, cells, or tissues to the organ exhibiting toxicity manifestations.

The defense performance level and the functional demand level are moderate (M) under the normal condition and keeping the balance.",false,,,http://purl.obolibrary.org/obo/TXPO_0003992,,,,,,,,,,,,,,,,,,,,,,"In the imbalance model, the basic units are as follows:
1) a functioning process (supply) for biological defense and maintaining homeostasis;
2) a functional demand process (demand) as toxic activity;
3) balance/imbalance between toxic activity and defense processes; and
4) outcome from organelles, cells, or tissues to the organ exhibiting toxicity manifestations.

The defense performance level and the functional demand level are moderate (M) under the normal condition and keeping the balance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001734,,,,,,,,,,,,,,,,,,TXPO:0002076,,,,,,,,,,,,,,,,,,,,,,toxicological imbalance M=M (maintining homeostasis in the normal condition),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002077,chemical compound excretion,,"Compound excretion is a subtype of xenobiotics excretion: A process that takes a compound from a cell, organelle,  or makes a clearance of it from the body.",false,,,http://purl.obolibrary.org/obo/TXPO_0000631,,,,,,,,,,,,,,,,,,,,,,"Compound excretion is a subtype of xenobiotics excretion: A process that takes a compound from a cell, organelle,  or makes a clearance of it from the body.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002077,,,,,,,,,,,,,,,,,,,,,,chemical compound excretion,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001122,type X collagen,,,false,,,http://purl.obolibrary.org/obo/IMR_0001118,,,,,,,,,,,,,,,,,,,,GO:0005599,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001122,,,,,,,,,,,,,,,,,,,,,,type X collagen,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0030154,cell differentiation,,"The process in which relatively unspecialized cells, e.g. embryonic or regenerative cells, acquire specialized structural and/or functional features that characterize the cells, tissues, or organs of the mature organism or some other relatively stable phase of the organism's life history. Differentiation includes the processes involved in commitment of a cell to a specific fate and its subsequent development to the mature state.",false,,,http://purl.obolibrary.org/obo/TXPO_0002282,,,,,,,,,,,,,,,,,,,,Wikipedia:Cellular_differentiation,,"The process in which relatively unspecialized cells, e.g. embryonic or regenerative cells, acquire specialized structural and/or functional features that characterize the cells, tissues, or organs of the mature organism or some other relatively stable phase of the organism's life history. Differentiation includes the processes involved in commitment of a cell to a specific fate and its subsequent development to the mature state.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000000,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0030154,,,,,,,,,,,,,,,,,,,,,,cell differentiation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000000,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100622,cyclin G,,,false,,,http://purl.obolibrary.org/obo/IMR_0100606,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100622,,,,,,,,,,,,,,,,,,,,,,cyclin G,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001507,Rap2,,,false,,,http://purl.obolibrary.org/obo/IMR_0000294,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001507,,,,,,,,,,,,,,,,,,,,,,Rap2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010491,60S ribosomal protein L3,HIV-1 TAR RNA binding protein B|TARBP-B,,false,,,http://purl.obolibrary.org/obo/IMR_0000897,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,HIV-1 TAR RNA binding protein B|TARBP-B,,,,,IMR:0010491,,,,,,,,,,,,,,,,,,,,,,60S ribosomal protein L3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76812,EC 2.7.11.* (protein-serine/threonine kinase) inhibitor,EC 2.7.11.* (protein-serine/threonine kinase) inhibitors|protein-serine/threonine kinase inhibitor|protein-serine/threonine kinase (EC 2.7.11.*) inhibitor|EC 2.7.11.* inhibitors|EC 2.7.11.* inhibitor|protein-serine/threonine kinase inhibitors|protein-serine/threonine kinase (EC 2.7.11.*) inhibitors,An EC 2.7.* (P-containing group transferase) inhibitor that interferes with the action of any protein-serine/threonine kinase (EC 2.7.11.*).,false,,,http://purl.obolibrary.org/obo/CHEBI_37699|http://purl.obolibrary.org/obo/CHEBI_76668,,,,,,,,,,,,,,,,,,,,,,An EC 2.7.* (P-containing group transferase) inhibitor that interferes with the action of any protein-serine/threonine kinase (EC 2.7.11.*).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,EC 2.7.11.* (protein-serine/threonine kinase) inhibitors|protein-serine/threonine kinase inhibitor|protein-serine/threonine kinase (EC 2.7.11.*) inhibitor|EC 2.7.11.* inhibitors|EC 2.7.11.* inhibitor|protein-serine/threonine kinase inhibitors|protein-serine/threonine kinase (EC 2.7.11.*) inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:76812,,,,EC 2.7.11.* (protein-serine/threonine kinase) inhibitor,,CHEBI:76812,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000212,Csk,C-terminal Src kinase,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001054,,,,,C-terminal Src kinase,,,,,IMR:0000212,,,,,,,,,,,,,,,,,,,,,,Csk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010501,60S ribosomal protein L9,60S ribosomal protein L9|P32969,,false,,,http://purl.obolibrary.org/obo/IMR_0000897,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,60S ribosomal protein L9|P32969,,,,,IMR:0010501,,,,,,,,,,,,,,,,,,,,,,60S ribosomal protein L9,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001107,IQGAP1,,,false,,,http://purl.obolibrary.org/obo/IMR_0000443,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001107,,,,,,,,,,,,,,,,,,,,,,IQGAP1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100562,FGF-12,Fibroblast growth factor homologous factor 1|FHF-1|Myocyte-activating factor,,false,,,http://purl.obolibrary.org/obo/IMR_0000049,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Fibroblast growth factor homologous factor 1|FHF-1|Myocyte-activating factor,,,,,IMR:0100562,,,,,,,,,,,,,,,,,,,,,,FGF-12,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000002833,CXCR3,,Other designations: C-X-C chemokine receptor type 3|CXC-R3|CXCR-3|G protein-coupled receptor 9|IP-10 receptor|IP10 receptor|Mig receptor|chemokine (C-X-C) receptor 3|interferon-inducible protein 10 receptor,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,IP10-R|MigR|CD183|Mig-R|CD182|GPR9|CMKAR3|CKR-L2,,,,,,,,,,,,X,,,,,,MIM:300574|HGNC:4540|Vega:OTTHUMG00000033326|HPRD:02936|Ensembl:ENSG00000186810,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,chemokine (C-X-C motif) receptor 3,,,Xq13,,,,,,,,,,,,,,,,"GO_0001525 (EC: IEA); GO_0001937 (EC: IDA, PMID: 12782716); GO_0002685 (EC: IEA); GO_0004872 (EC: IDA, PMID: 12782716); GO_0004950 (EC: TAS, PMID: 9064356); GO_0005737 (EC: TAS, PMID: 10903743); GO_0005886 (EC: IDA, PMID: 12782716); GO_0005886 (EC: TAS); GO_0005887 (EC: TAS, PMID: 9064356); GO_0006915 (EC: IEA); GO_0006928 (EC: TAS, PMID: 10741397); GO_0006935 (EC: TAS, PMID: 10903763); GO_0006954 (EC: IEA); GO_0007155 (EC: TAS, PMID: 10942362); GO_0007166 (EC: IDA, PMID: 11554781); GO_0007186 (EC: IMP, PMID: 12782716); GO_0007204 (EC: IEA); GO_0008284 (EC: IDA, PMID: 12782716); GO_0009897 (EC: IEA); GO_0010818 (EC: IEA); GO_0016494 (EC: IEA); GO_0016525 (EC: IDA, PMID: 12782716); GO_0019722 (EC: IEA); GO_0019956 (EC: IPI, PMID: 11554781); GO_0019958 (EC: IDA, PMID: 12782716); GO_0030816 (EC: IDA, PMID: 12782716); GO_0043950 (EC: IDA, PMID: 12782716); GO_0045766 (EC: IDA, PMID: 12782716); GO_0045944 (EC: IDA, PMID: 12782716); GO_0050921 (EC: IDA, PMID: 12782716); GO_0051281 (EC: IMP, PMID: 12782716); GO_0071954 (EC: IDA, PMID: 12782716); GO_1900118 (EC: IDA, PMID: 12782716); GO_1900119 (EC: IDA, PMID: 12782716)",,,,,,,,,PMID: 2834384; 8666380; 9064356; 9419219; 9466968; 9625760; 9660793; 10233762; 10393705; 10627472; 10666479; 10741397; 10900358; 10903743; 10903763; 10942362; 11083865; 11134180; 11160352; 11196695; 11554781; 11559369; 11714650; 11739530; 11966764; 11990865; 12016104; 12055238; 12070001; 12097412; 12270371; 12356205; 12425561; 12444109; 12445801; 12477932; 12517959; 12571234; 12688353; 12750173; 12782716; 12819030; 12884299; 12919091; 12953097; 12960247; 12960302; 14578618; 14618028; 14630801; 14657006; 14742268; 15126579; 15150261; 15155273; 15181567; 15254596; 15265234; 15273303; 15328188; 15489334; 15501397; 15518810; 15528361; 15578697; 15687242; 15713799; 15725351; 15808644; 15843529; 15856455; 15879427; 15885315; 16033640; 16034118; 16043121; 16127166; 16243485; 16339779; 16368892; 16455991; 16456020; 16679918; 16733654; 16787707; 16806233; 16847335; 16861617; 16930533; 16934957; 17018607; 17142783; 17142784; 17251291; 17339184; 17363734; 17457216; 17560677; 17615381; 17666357; 17703412; 17912012; 17947699; 18037659; 18174362; 18240029; 18280341; 18291705; 18375741; 18453591; 18485912; 18497951; 18616679; 18689270; 18729739; 18761554; 18798334; 18832436; 18962861; 19017998; 19106589; 19134328; 19232748; 19258923; 19344719; 19380511; 19539215; 19641142; 19703720; 19734217; 19735481; 19758167; 19767105; 19800124; 20041963; 20047517; 20059481; 20079227; 20096889; 20164417; 20185576; 20203286; 20228225; 20237496; 20377416; 20379873; 20429924; 20485444; 20503287; 20529825; 20733031; 20848514; 20855888; 20856926; 20980681; 21051441; 21087446; 21091908; 21148743; 21255008; 21274647; 21303425; 21303517; 21357438; 21426802; 21538345; 21645215; 21739422; 21811993; 21962843; 22079021; 22111598; 22236567; 22262158; 22369302; 22392992; 22401929; 22675496; 22685032; 22689289; 22792160; 22796894; 22798340; 22936405; 23121557; 23158864; 23179902; 23298254; 23600831; 23643635; 24129241; 24135023,,,,,,,,,,,,,,,OGG:3000002833,,,,,,,chemokine (C-X-C motif) receptor 3,,,,,,,,,,,,,Other designations: C-X-C chemokine receptor type 3|CXC-R3|CXCR-3|G protein-coupled receptor 9|IP-10 receptor|IP10 receptor|Mig receptor|chemokine (C-X-C) receptor 3|interferon-inducible protein 10 receptor,,CXCR3,,,,,,,,,,,,,,,,,,,,,,,2833,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,CXCR3,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000204,dystrophin,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003689,,,,,,,,,,IMR:0000204,,,,,,,,,,,,,,,,,,,,,,dystrophin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000262,MKK4/7(JNKK1/2),,MKK4 and MKK7 phosphorylate and activate JNK MAP kinases.,false,,,http://purl.obolibrary.org/obo/IMR_0000259,,,,,,,,,,,,,,,,,,,,,,MKK4 and MKK7 phosphorylate and activate JNK MAP kinases.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000262,,,,,,,,,,,,,,,,,,,,,,MKK4/7(JNKK1/2),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000000348,APOE,,Other designations: apo-E|apolipoprotein E3,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,AD2|LPG|LDLCQ5,,,,,,,,,,,,19,,,,,,HPRD:00135|Vega:OTTHUMG00000128901|MIM:107741|Ensembl:ENSG00000130203|HGNC:613,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,apolipoprotein E,,,19q13.2,,,,,,,,,,,,,,,,"GO_0000302 (EC: NAS, PMID: 11743999); GO_0001523 (EC: TAS); GO_0001540 (EC: IDA, PMID: 11305869); GO_0001937 (EC: IDA, PMID: 9685360); GO_0002021 (EC: IEA); GO_0005319 (EC: IDA, PMID: 17305370); GO_0005515 (EC: IPI, PMID: 12950167); GO_0005543 (EC: IDA, PMID: 4066713); GO_0005576 (EC: TAS); GO_0005615 (EC: IDA); GO_0005737 (EC: NAS, PMID: 8083695); GO_0005737 (EC: TAS, PMID: 9622609); GO_0005769 (EC: TAS); GO_0005770 (EC: IEA); GO_0005794 (EC: IEA); GO_0005886 (EC: TAS); GO_0006641 (EC: IDA, PMID: 9649566); GO_0006641 (EC: IMP, PMID: 3771793); GO_0006707 (EC: IEA); GO_0006874 (EC: IEA); GO_0006898 (EC: IDA, PMID: 1917954); GO_0007010 (EC: TAS, PMID: 9622609); GO_0007186 (EC: IDA, PMID: 16443932); GO_0007263 (EC: IDA, PMID: 8995232); GO_0007271 (EC: TAS, PMID: 9622609); GO_0007568 (EC: IEA); GO_0007603 (EC: TAS); GO_0008201 (EC: IDA, PMID: 2745454); GO_0008203 (EC: IDA, PMID: 9649566); GO_0008203 (EC: IMP, PMID: 3771793); GO_0008219 (EC: IEA); GO_0008289 (EC: IDA, PMID: 4066713); GO_0010544 (EC: IDA, PMID: 8995232); GO_0010873 (EC: IDA, PMID: 15654758); GO_0010875 (EC: IDA, PMID: 14754908); GO_0010875 (EC: IGI, PMID: 12401887); GO_0014012 (EC: IEA); GO_0016209 (EC: IDA, PMID: 9685360); GO_0017127 (EC: IEA); GO_0019934 (EC: IDA, PMID: 8995232); GO_0030195 (EC: IDA, PMID: 8995232); GO_0030425 (EC: NAS, PMID: 8083695); GO_0030516 (EC: TAS, PMID: 9622609); GO_0030828 (EC: IDA, PMID: 8995232); GO_0031232 (EC: IEA); GO_0032489 (EC: IDA, PMID: 16443932); GO_0032526 (EC: IEA); GO_0032805 (EC: IDA, PMID: 15950758); GO_0032868 (EC: IEA); GO_0033344 (EC: IDA, PMID: 11162594); GO_0033700 (EC: IDA, PMID: 11162594); GO_0034361 (EC: IDA, PMID: 17154273); GO_0034362 (EC: IDA, PMID: 8245722); GO_0034363 (EC: IDA, PMID: 17336988); GO_0034364 (EC: IDA, PMID: 210174); GO_0034372 (EC: IDA, PMID: 15654758); GO_0034372 (EC: IGI, PMID: 12401887); GO_0034374 (EC: IEA); GO_0034375 (EC: IGI, PMID: 12401887); GO_0034380 (EC: IDA, PMID: 17305370); GO_0034382 (EC: IMP, PMID: 7175379); GO_0034384 (EC: IDA, PMID: 210175); GO_0034447 (EC: IDA, PMID: 1917954); GO_0034447 (EC: IMP, PMID: 9649566); GO_0042157 (EC: TAS); GO_0042158 (EC: IEA); GO_0042159 (EC: IEA); GO_0042311 (EC: IEA); GO_0042627 (EC: IDA, PMID: 16935699); GO_0042632 (EC: IDA, PMID: 9649566); GO_0042802 (EC: IDA, PMID: 4066713); GO_0042803 (EC: IPI, PMID: 8245722); GO_0043025 (EC: NAS, PMID: 8083695); GO_0043407 (EC: IDA, PMID: 9685360); GO_0043524 (EC: IEA); GO_0043537 (EC: IDA, PMID: 9685360); GO_0043691 (EC: IDA, PMID: 8127890); GO_0044281 (EC: TAS); GO_0045471 (EC: IEA); GO_0045541 (EC: IDA, PMID: 1917954); GO_0045773 (EC: IEA); GO_0046848 (EC: IEA); GO_0046907 (EC: TAS, PMID: 9622609); GO_0046911 (EC: IDA, PMID: 9685360); GO_0048156 (EC: IPI, PMID: 7566652); GO_0048168 (EC: TAS, PMID: 9622609); GO_0048709 (EC: IEA); GO_0048844 (EC: IEA); GO_0050728 (EC: IC, PMID: 8995232); GO_0050750 (EC: IDA, PMID: 210175); GO_0050750 (EC: IPI, PMID: 17326667); GO_0051000 (EC: IDA, PMID: 8995232); GO_0051044 (EC: IDA, PMID: 15950758); GO_0051651 (EC: IEA); GO_0060228 (EC: IDA, PMID: 15654758); GO_0070062 (EC: IDA, PMID: 19056867); GO_0070326 (EC: IDA, PMID: 1384047); GO_0070326 (EC: IPI, PMID: 12950167); GO_0071347 (EC: IEA); GO_0071363 (EC: IEA); GO_0071397 (EC: IEA); GO_0071682 (EC: TAS); GO_0071813 (EC: IEA); GO_0072562 (EC: IDA)",,,,,,,,,PMID: 210174; 210175; 759055; 1356443; 1360898; 1361196; 1384047; 1617762; 1674745; 1713245; 1730728; 1917954; 2063194; 2101409; 2313204; 2341812; 2470732; 2498325; 2539388; 2556398; 2738044; 2745454; 2760009; 2779654; 2851587; 2987927; 2992507; 3038959; 3243553; 3283935; 3771793; 3922972; 3947350; 4066713; 4345202; 6199196; 6289314; 6323533; 6325438; 6327682; 6897404; 7068630; 7175379; 7263700; 7498414; 7566652; 7581381; 7586659; 7635945; 7761390; 7768901; 7797576; 7833947; 7972031; 8063017; 8083695; 8127890; 8245722; 8287539; 8300609; 8346443; 8488843; 8620924; 8624078; 8626535; 8756331; 8995232; 9012418; 9147408; 9218423; 9236223; 9360638; 9512010; 9622609; 9649566; 9685360; 9831625; 9869645; 9931331; 10520737; 10559559; 10662539; 10850798; 10962542; 10993992; 11030801; 11032626; 11033977; 11042151; 11055796; 11058710; 11060506; 11061249; 11063158; 11064931; 11072138; 11074789; 11076057; 11079660; 11095479; 11095526; 11096027; 11099722; 11100124; 11106322; 11109009; 11110974; 11113217; 11118024; 11118260; 11118404; 11118932; 11119301; 11121165; 11125748; 11126401; 11129109; 11129992; 11140838; 11140944; 11141572; 11143490; 11152862; 11153762; 11156623; 11157409; 11160955; 11162594; 11166913; 11166947; 11171287; 11171894; 11172628; 11173876; 11173877; 11173882; 11176958; 11177205; 11182472; 11204323; 11218879; 11229422; 11231028; 11236867; 11244490; 11254923; 11256794; 11257253; 11257255; 11259129; 11269459; 11269753; 11273849; 11273909; 11277566; 11280044; 11281447; 11281508; 11285089; 11295126; 11299424; 11302074; 11303757; 11305732; 11305851; 11305869; 11311499; 11315514; 11320185; 11326299; 11328206; 11332642; 11334266; 11334897; 11340230; 11341749; 11343612; 11343837; 11351136; 11354629; 11355019; 11357958; 11359065; 11360807; 11376902; 11378846; 11383910; 11388660; 11398147; 11401504; 11401610; 11412677; 11420577; 11420784; 11421127; 11421132; 11421580; 11422615; 11431078; 11434425; 11445282; 11445633; 11454010; 11456487; 11458997; 11463413; 11471927; 11472462; 11474482; 11475012; 11477126; 11482130; 11484169; 11484172; 11487204; 11494308; 11495026; 11495633; 11500190; 11501342; 11502364; 11504565; 11509287; 11512679; 11516561; 11526473; 11535238; 11546879; 11552016; 11553047; 11558492; 11559372; 11560764; 11563433; 11568917; 11571342; 11574101; 11580926; 11585357; 11589721; 11592046; 11592592; 11665324; 11673588; 11673590; 11676289; 11676291; 11684342; 11684904; 11698154; 11701639; 11702052; 11711204; 11714857; 11714860; 11720484; 11721184; 11722155; 11723294; 11730829; 11738493; 11739991; 11740190; 11743999; 11748362; 11755017; 11755252; 11756600; 11769625; 11769703; 11769724; 11775232; 11780357; 11780396; 11784357; 11784371; 11788473; 11788960; 11791620; 11793025; 11798896; 11803456; 11804199; 11804704; 11805010; 11807891; 11807900; 11814460; 11820771; 11823668; 11830396; 11834531; 11836653; 11840773; 11840804; 11844848; 11849659; 11849755; 11857554; 11860878; 11860925; 11862316; 11863377; 11873594; 11879722; 11882334; 11882335; 11882522; 11882743; 11882744; 11884656; 11884660; 11885754; 11889238; 11890580; 11893833; 11901276; 11903341; 11903399; 11904138; 11910554; 11912196; 11920850; 11921083; 11922198; 11931575; 11931577; 11936239; 11936240; 11939894; 11939896; 11940690; 11940706; 11949718; 11950276; 11952809; 11954859; 11959333; 11966948; 11971052; 11971084; 11981126; 11983298; 11983299; 11984219; 11987699; 11988589; 11988615; 11990879; 11992263; 11992569; 12000192; 12003251; 12003753; 12006218; 12006397; 12007670; 12009520; 12015813; 12015945; 12019933; 12023414; 12023438; 12028246; 12028507; 12030385; 12032151; 12036962; 12040140; 12042130; 12042142; 12042316; 12042669; 12042894; 12044628; 12049183; 12057992; 12059987; 12061406; 12069854; 12071547; 12074828; 12075916; 12077730; 12082592; 12086087; 12086099; 12086229; 12087994; 12093429; 12094820; 12095653; 12105308; 12107813; 12112161; 12113906; 12116196; 12116231; 12117364; 12118856; 12123486; 12123862; 12128082; 12133811; 12135350; 12138091; 12142731; 12143056; 12145452; 12148096; 12160362; 12164879; 12165926; 12166499; 12167620; 12167762; 12168771; 12175441; 12185156; 12185856; 12192621; 12192623; 12195533; 12196500; 12198535; 12200750; 12205106; 12205649; 12210279; 12213685; 12213863; 12214086; 12220441; 12221169; 12226739; 12231459; 12232782; 12243365; 12269825; 12270650; 12297572; 12325053; 12359980; 12364385; 12370113; 12379839; 12393935; 12394840; 12397634; 12398946; 12401887; 12405546; 12406021; 12411758; 12411763; 12413003; 12414984; 12417285; 12417379; 12417380; 12417381; 12417453; 12419494; 12433268; 12434887; 12438469; 12438664; 12439225; 12439291; 12444925; 12444983; 12454737; 12457072; 12459519; 12461692; 12471457; 12473860; 12475089; 12477932; 12480082; 12480755; 12486288; 12495080; 12495081; 12495082; 12497107; 12497631; 12498968; 12499050; 12500534; 12502505; 12507914; 12512226; 12518038; 12521230; 12527542; 12529167; 12533090; 12535745; 12536572; 12544508; 12552038; 12552039; 12556576; 12558712; 12561220; 12566177; 12567264; 12573381; 12576523; 12579507; 12580702; 12580859; 12581338; 12584430; 12587416; 12588864; 12588928; 12593496; 12593615; 12595762; 12600078; 12604387; 12605101; 12618306; 12624708; 12631135; 12632068; 12634288; 12636937; 12637699; 12638732; 12644914; 12647263; 12648751; 12649507; 12654974; 12656452; 12657090; 12657895; 12658367; 12658375; 12662159; 12666069; 12668918; 12669678; 12675686; 12677480; 12678662; 12682309; 12691171; 12701674; 12706318; 12707932; 12707937; 12707938; 12714797; 12715012; 12719629; 12722493; 12729008; 12736093; 12736801; 12739024; 12742846; 12746397; 12749052; 12753088; 12754278; 12769659; 12771320; 12774036; 12778454; 12778455; 12782148; 12782337; 12782964; 12787320; 12788901; 12794386; 12796755; 12798568; 12799433; 12809979; 12810154; 12810485; 12810796; 12810820; 12811635; 12812866; 12815750; 12817590; 12818409; 12818414; 12821037; 12821754; 12833399; 12833577; 12837283; 12837518; 12841538; 12845379; 12850485; 12857755; 12860263; 12864777; 12871600; 12873586; 12876232; 12876259; 12880539; 12881819; 12882872; 12883119; 12886039; 12889841; 12897404; 12899198; 12901521; 12901781; 12905860; 12915220; 12915699; 12917433; 12919138; 12920078; 12923233; 12923801; 12926843; 12928055; 12928512; 12930057; 12930912; 12935416; 12939405; 12940632; 12940873; 12946561; 12950167; 12951205; 12954489; 12957508; 12959500; 12960780; 12962909; 12963757; 12963763; 12964943; 12966036; 13129656; 13680463; 14500990; 14501969; 14504972; 14506116; 14512205; 14512206; 14512715; 14520543; 14523627; 14523999; 14530190; 14563588; 14566994; 14569045; 14570844; 14572957; 14583365; 14585838; 14587032; 14588111; 14593964; 14594022; 14596852; 14609807; 14612205; 14614898; 14615042; 14615272; 14624406; 14625044; 14638877; 14639046; 14646029; 14650352; 14656220; 14659862; 14672279; 14674716; 14675603; 14677138; 14680604; 14681851; 14681915; 14687732; 14688411; 14688681; 14694215; 14695944; 14695947; 14698449; 14705977; 14706682; 14709760; 14711551; 14718482; 14718574; 14720419; 14726545; 14734213; 14739281; 14739533; 14741429; 14743603; 14746139; 14754908; 14755445; 14757931; 14759632; 14763959; 14763962; 14766005; 14767871; 14769392; 14769603; 14966149; 14982742; 14986172; 14986436; 14989602; 14997020; 15000890; 15003956; 15007140; 15014128; 15018693; 15019539; 15023809; 15026113; 15031162; 15033184; 15034781; 15036621; 15045621; 15048651; 15048896; 15048897; 15050032; 15060087; 15060098; 15060316; 15066991; 15073531; 15076187; 15077085; 15079025; 15079806; 15084782; 15084783; 15090300; 15090562; 15093983; 15096402; 15098180; 15099158; 15102883; 15106838; 15109264; 15111581; 15111582; 15123333; 15123334; 15123497; 15124760; 15129156; 15131109; 15133863; 15135251; 15136700; 15138483; 15142050; 15144588; 15145993; 15146195; 15147594; 15152345; 15157846; 15159498; 15159600; 15159602; 15161645; 15161775; 15165699; 15167692; 15174051; 15174235; 15181244; 15181247; 15181372; 15181744; 15183747; 15184597; 15184600; 15184602; 15184605; 15184629; 15186949; 15186962; 15187200; 15193960; 15201366; 15201477; 15202770; 15202789; 15202933; 15207528; 15207892; 15210882; 15211066; 15211070; 15212826; 15213448; 15217762; 15220465; 15221639; 15222689; 15222690; 15222832; 15223114; 15224026; 15226466; 15227722; 15236771; 15239601; 15245790; 15246985; 15246987; 15247087; 15250257; 15252864; 15256516; 15258198; 15258208; 15258620; 15259389; 15262670; 15264189; 15264223; 15266206; 15266207; 15276243; 15276511; 15277615; 15286151; 15286454; 15286456; 15300423; 15311189; 15312249; 15312696; 15314125; 15319409; 15326233; 15326239; 15326261; 15326295; 15328426; 15331430; 15336915; 15337261; 15337270; 15339912; 15340366; 15345809; 15345810; 15358178; 15359535; 15362374; 15364413; 15364690; 15365129; 15370197; 15370375; 15374124; 15374172; 15375590; 15375600; 15377701; 15377739; 15379569; 15383745; 15448517; 15450205; 15452311; 15455263; 15461196; 15465089; 15465740; 15466371; 15468911; 15469418; 15477512; 15477533; 15477624; 15482730; 15485881; 15487712; 15488782; 15488872; 15489334; 15503099; 15505155; 15514092; 15519745; 15522251; 15523694; 15525904; 15526312; 15530909; 15531082; 15531693; 15534175; 15534246; 15538542; 15540997; 15543563; 15545327; 15548484; 15548496; 15549499; 15549644; 15554031; 15557508; 15559160; 15559755; 15562392; 15563891; 15569012; 15571629; 15571826; 15573849; 15576362; 15579298; 15583000; 15583995; 15584785; 15584908; 15585207; 15585342; 15585780; 15591802; 15592132; 15596614; 15598211; 15600186; 15607989; 15608561; 15611352; 15623696; 15627759; 15627763; 15634227; 15636076; 15636224; 15636592; 15641930; 15642911; 15642920; 15643038; 15644277; 15648787; 15653173; 15653176; 15654758; 15656760; 15657615; 15657798; 15660776; 15663009; 15664112; 15665311; 15668424; 15670698; 15674008; 15678256; 15679697; 15686675; 15689450; 15692115; 15696482; 15696494; 15697227; 15699298; 15699382; 15699383; 15699400; 15699916; 15702779; 15708851; 15713714; 15716154; 15721023; 15725730; 15726267; 15728313; 15730956; 15735320; 15739386; 15746021; 15748778; 15754975; 15754976; 15755832; 15760646; 15764642; 15767511; 15769204; 15769335; 15769795; 15774818; 15781953; 15785096; 15791170; 15793777; 15793794; 15804918; 15805147; 15809232; 15809899; 15817610; 15819712; 15820227; 15824354; 15825968; 15829498; 15830056; 15830139; 15834029; 15838630; 15841787; 15843343; 15852364; 15854776; 15860477; 15861030; 15862889; 15863833; 15867282; 15879922; 15880838; 15882073; 15882786; 15883313; 15895300; 15895461; 15896001; 15903153; 15904995; 15910869; 15919549; 15921030; 15925094; 15931081; 15931608; 15932949; 15935014; 15936307; 15936464; 15936467; 15939044; 15942165; 15942426; 15944651; 15950758; 15952022; 15953853; 15956166; 15956169; 15956634; 15961292; 15964100; 15975088; 15979312; 15983323; 15992403; 15998356; 16005361; 16013355; 16013913; 16015283; 16019571; 16021346; 16023140; 16027737; 16028714; 16030523; 16033781; 16033878; 16038892; 16039291; 16040191; 16043164; 16043796; 16051894; 16055229; 16082716; 16086293; 16092050; 16096813; 16099324; 16099779; 16100021; 16103669; 16103896; 16106048; 16107349; 16110302; 16113584; 16116137; 16116614; 16118069; 16122874; 16123547; 16127101; 16128374; 16131735; 16131797; 16133550; 16136540; 16142021; 16142566; 16143024; 16148883; 16152798; 16153291; 16157450; 16157749; 16161810; 16165272; 16166776; 16169331; 16170092; 16176061; 16176168; 16179831; 16182410; 16183800; 16185081; 16186632; 16188386; 16189709; 16193886; 16195918; 16199552; 16199891; 16201140; 16202217; 16202482; 16204452; 16207619; 16207841; 16210555; 16223550; 16233903; 16242874; 16248984; 16250071; 16251607; 16254254; 16254428; 16257094; 16258842; 16261623; 16266401; 16270124; 16275829; 16275840; 16276010; 16276176; 16278220; 16278853; 16282051; 16282567; 16288198; 16295048; 16298355; 16298992; 16299033; 16306239; 16306248; 16314757; 16317171; 16327942; 16328515; 16332659; 16334787; 16335008; 16337304; 16340087; 16343062; 16344478; 16351773; 16352910; 16358334; 16362800; 16367893; 16368754; 16374834; 16378065; 16380608; 16382017; 16385096; 16387995; 16388493; 16389198; 16389649; 16390369; 16390371; 16391475; 16399213; 16401069; 16401755; 16401842; 16402284; 16406547; 16410051; 16417614; 16418216; 16421115; 16421347; 16423463; 16426594; 16432152; 16433808; 16434658; 16443328; 16443932; 16445917; 16446541; 16449871; 16450255; 16453339; 16459141; 16459715; 16462203; 16465366; 16465461; 16466170; 16473016; 16475114; 16476806; 16480703; 16484411; 16484645; 16485778; 16487435; 16490049; 16497717; 16501668; 16503883; 16511213; 16511556; 16519597; 16520487; 16522905; 16524875; 16528057; 16533971; 16533972; 16537024; 16540406; 16540478; 16542392; 16543533; 16544732; 16545358; 16546302; 16557295; 16567081; 16574921; 16585474; 16595160; 16595618; 16599342; 16603077; 16606866; 16606914; 16608402; 16611016; 16614010; 16621107; 16626758; 16630553; 16631424; 16634464; 16635548; 16639317; 16644874; 16645276; 16650578; 16682670; 16682673; 16682795; 16684399; 16686878; 16697650; 16699281; 16699282; 16701920; 16713503; 16714010; 16714771; 16715842; 16720801; 16725228; 16738250; 16740268; 16740596; 16741934; 16752225; 16758323; 16760224; 16763159; 16763161; 16764677; 16766085; 16769085; 16770077; 16778644; 16796589; 16799145; 16799405; 16807921; 16813599; 16814428; 16815257; 16817024; 16823865; 16829344; 16831961; 16832771; 16839689; 16841077; 16842800; 16847429; 16848156; 16862278; 16866904; 16869227; 16869455; 16882462; 16888319; 16894123; 16896546; 16897605; 16900882; 16904828; 16908746; 16914837; 16916985; 16916989; 16917677; 16926234; 16926537; 16927707; 16928730; 16930470; 16930778; 16932075; 16933203; 16935699; 16936080; 16938285; 16943616; 16944667; 16945218; 16946187; 16951484; 16953165; 16954688; 16956959; 16959267; 16960022; 16968945; 16971231; 16973370; 16980336; 16988505; 16996683; 16996687; 16997460; 16997467; 17006673; 17010251; 17011669; 17012232; 17016617; 17020396; 17022778; 17023092; 17030756; 17038035; 17048007; 17050040; 17056835; 17069783; 17077159; 17077632; 17079229; 17089130; 17092867; 17094271; 17095737; 17100508; 17100509; 17101827; 17105389; 17106421; 17108687; 17111197; 17113231; 17115907; 17116317; 17121308; 17123304; 17124416; 17126308; 17127808; 17129575; 17130180; 17132969; 17133176; 17138935; 17140155; 17154273; 17158432; 17161508; 17171228; 17172560; 17174184; 17174555; 17183148; 17192785; 17198524; 17199722; 17200925; 17201525; 17202849; 17203511; 17204369; 17210134; 17210851; 17210854; 17217095; 17217375; 17218903; 17224309; 17224996; 17228342; 17230455; 17234631; 17234815; 17243563; 17244188; 17250852; 17250929; 17254710; 17264404; 17265535; 17272620; 17273655; 17278624; 17280645; 17283313; 17283328; 17287237; 17289397; 17293007; 17293537; 17294608; 17296843; 17299019; 17304721; 17305370; 17310023; 17310037; 17310043; 17317784; 17317888; 17318300; 17322072; 17325732; 17326667; 17328917; 17336705; 17336988; 17337010; 17339538; 17342071; 17350142; 17353005; 17356546; 17367583; 17367769; 17374951; 17376122; 17376543; 17378730; 17379005; 17384433; 17389798; 17393220; 17401152; 17408064; 17410707; 17418914; 17420099; 17420762; 17426996; 17427190; 17430597; 17431774; 17433475; 17433528; 17434289; 17436307; 17451062; 17454231; 17455988; 17460153; 17460172; 17460173; 17460724; 17462871; 17466415; 17474819; 17481771; 17484618; 17485234; 17488453; 17498878; 17503098; 17503475; 17506774; 17509484; 17509769; 17515539; 17518534; 17519358; 17524782; 17535270; 17537154; 17539949; 17540481; 17540618; 17541051; 17544378; 17545732; 17553421; 17553597; 17559337; 17559752; 17560689; 17562993; 17564514; 17565217; 17567623; 17570245; 17578972; 17579348; 17586559; 17594534; 17596691; 17597169; 17603766; 17606532; 17607431; 17611642; 17613540; 17614163; 17621165; 17622762; 17623814; 17624465; 17627113; 17628213; 17636061; 17640473; 17643539; 17653444; 17658295; 17659264; 17659844; 17660382; 17666042; 17669363; 17672902; 17676504; 17684217; 17689412; 17689519; 17696931; 17698206; 17700364; 17702883; 17702967; 17704619; 17706019; 17706090; 17709709; 17710250; 17711604; 17715945; 17716229; 17720148; 17721242; 17721898; 17727701; 17727891; 17728664; 17763167; 17767697; 17784784; 17822808; 17822846; 17822919; 17826340; 17846270; 17848120; 17848837; 17852827; 17854398; 17855807; 17878422; 17883422; 17888544; 17889142; 17890503; 17891567; 17893696; 17904251; 17911363; 17911980; 17913825; 17914184; 17918142; 17920160; 17921131; 17921435; 17932679; 17932993; 17934638; 17936795; 17938569; 17941342; 17957227; 17966072; 17967500; 17971433; 17974013; 17975299; 17975753; 17979899; 17982164; 17982892; 17985658; 17986098; 17986934; 17987251; 17994314; 17995970; 17996334; 17997273; 17998437; 18003940; 18022660; 18023277; 18023533; 18025782; 18027070; 18030173; 18033754; 18034366; 18036514; 18041613; 18046082; 18047842; 18051367; 18052682; 18055294; 18056683; 18056971; 18057084; 18057558; 18057979; 18058831; 18060780; 18063831; 18069348; 18071037; 18077821; 18078695; 18079687; 18081155; 18083276; 18083630; 18086568; 18087668; 18094576; 18155247; 18156727; 18157657; 18159095; 18159991; 18160145; 18161859; 18163216; 18163421; 18163432; 18164902; 18171282; 18179501; 18179845; 18179924; 18183499; 18185033; 18185940; 18187430; 18188530; 18189240; 18190728; 18191876; 18193043; 18193044; 18195144; 18195264; 18197377; 18198422; 18201068; 18201725; 18205760; 18210157; 18210832; 18216863; 18217885; 18219091; 18219093; 18235080; 18236001; 18236205; 18237822; 18239197; 18241317; 18241895; 18242850; 18242855; 18243212; 18248894; 18250093; 18253865; 18256266; 18256366; 18258338; 18258638; 18258839; 18262228; 18266965; 18272374; 18273624; 18274205; 18274923; 18275964; 18280677; 18280754; 18287165; 18289451; 18289550; 18296645; 18297189; 18298341; 18298348; 18301447; 18303265; 18305286; 18307033; 18307571; 18308428; 18317192; 18317248; 18318693; 18318702; 18320120; 18322386; 18324906; 18325076; 18326082; 18329006; 18332630; 18334538; 18334739; 18334912; 18334913; 18346114; 18346764; 18349428; 18354102; 18359130; 18359298; 18359537; 18360691; 18365330; 18367629; 18370334; 18373478; 18374494; 18376055; 18376061; 18376083; 18378026; 18378080; 18378884; 18381771; 18382765; 18388879; 18394363; 18395888; 18395955; 18396294; 18398670; 18401020; 18401023; 18401171; 18401173; 18407659; 18408364; 18416843; 18423577; 18423940; 18430993; 18430994; 18430999; 18439297; 18439548; 18439552; 18443545; 18443916; 18446027; 18452187; 18454345; 18458218; 18461138; 18464295; 18465245; 18468259; 18469278; 18477980; 18478972; 18484674; 18486114; 18486492; 18492292; 18494374; 18495299; 18498549; 18504448; 18505684; 18507396; 18511728; 18511754; 18511872; 18512131; 18513389; 18515697; 18520426; 18525129; 18525196; 18534867; 18549811; 18555606; 18560129; 18562290; 18572260; 18576210; 18580587; 18580594; 18581272; 18581664; 18583979; 18590026; 18593285; 18593777; 18596051; 18600472; 18603262; 18606479; 18607773; 18609102; 18609337; 18614883; 18615849; 18617739; 18619685; 18619712; 18620351; 18620605; 18631256; 18636124; 18641720; 18641859; 18645733; 18652551; 18653200; 18655030; 18656208; 18660489; 18664147; 18667124; 18668226; 18672349; 18676680; 18678795; 18685254; 18685811; 18690708; 18702945; 18705678; 18706476; 18707245; 18708484; 18715507; 18717723; 18718521; 18721259; 18721571; 18722591; 18723162; 18725658; 18728123; 18728174; 18753423; 18755411; 18757293; 18757771; 18760194; 18760504; 18762952; 18765933; 18774543; 18779276; 18779428; 18784741; 18786162; 18790459; 18802019; 18805361; 18808654; 18810496; 18813964; 18819891; 18823527; 18823563; 18823627; 18827228; 18829593; 18829694; 18838195; 18838196; 18839184; 18841008; 18843182; 18843194; 18843526; 18846579; 18848805; 18850190; 18851860; 18853460; 18926856; 18927546; 18930114; 18930458; 18936542; 18937849; 18938676; 18945448; 18946731; 18948255; 18957849; 18959431; 18971492; 18974580; 18974842; 18976728; 18976833; 18981067; 18982063; 18983893; 18983895; 18990452; 18991685; 18992263; 18997294; 19000312; 19001172; 19004527; 19006190; 19008959; 19010425; 19013250; 19013289; 19013689; 19014618; 19015224; 19017669; 19018779; 19020708; 19020798; 19025529; 19025720; 19034316; 19035714; 19047559; 19054180; 19054188; 19056482; 19056656; 19056867; 19057990; 19058936; 19059330; 19060906; 19060911; 19064751; 19066116; 19066720; 19072566; 19073159; 19086990; 19093949; 19094657; 19103187; 19105203; 19111900; 19116453; 19118814; 19124009; 19124691; 19125160; 19130493; 19131662; 19135213; 19136831; 19140312; 19140315; 19142571; 19145250; 19148283; 19148342; 19148546; 19154537; 19155747; 19155782; 19157170; 19158433; 19158597; 19159618; 19164761; 19165527; 19166449; 19169966; 19170196; 19172988; 19181718; 19184337; 19184578; 19187685; 19194887; 19195718; 19197348; 19199499; 19199875; 19207139; 19209940; 19210035; 19210038; 19217440; 19217759; 19218241; 19218599; 19221972; 19238444; 19241136; 19243844; 19244370; 19244396; 19245412; 19246912; 19250583; 19251191; 19251758; 19252179; 19255409; 19255410; 19259132; 19262954; 19262956; 19263529; 19266700; 19273753; 19274077; 19276544; 19276554; 19278396; 19278567; 19282863; 19285755; 19290744; 19293566; 19295164; 19297138; 19299407; 19300863; 19303604; 19304773; 19307174; 19307538; 19307863; 19308307; 19308965; 19321880; 19322689; 19326444; 19335933; 19336370; 19336475; 19339712; 19341173; 19349228; 19349827; 19357304; 19362884; 19363264; 19363267; 19363270; 19365373; 19367093; 19367581; 19368122; 19368142; 19368828; 19368854; 19368855; 19368858; 19372276; 19375284; 19377787; 19382113; 19384966; 19388128; 19394408; 19394849; 19398704; 19403283; 19405181; 19408164; 19409232; 19409447; 19420105; 19420940; 19421411; 19422789; 19429797; 19433657; 19433661; 19449451; 19450584; 19455140; 19457062; 19457069; 19459027; 19470200; 19473356; 19474452; 19477221; 19478482; 19479237; 19481150; 19484916; 19493541; 19494432; 19494437; 19494491; 19494537; 19499236; 19501493; 19504470; 19506792; 19515369; 19521084; 19524160; 19524323; 19529002; 19531688; 19534808; 19539034; 19539718; 19541455; 19542606; 19542737; 19545491; 19545933; 19551707; 19553347; 19554612; 19557866; 19560323; 19563454; 19564306; 19565203; 19567438; 19570164; 19578553; 19578796; 19583979; 19584447; 19584451; 19587357; 19589783; 19590821; 19591129; 19597098; 19602472; 19605830; 19615060; 19618379; 19619878; 19625176; 19625744; 19628211; 19629426; 19631387; 19631758; 19633944; 19635584; 19636640; 19639019; 19641318; 19642912; 19644067; 19645623; 19647324; 19653879; 19656773; 19660787; 19664276; 19664850; 19667110; 19667307; 19668025; 19668339; 19675403; 19679070; 19684401; 19685167; 19686716; 19689828; 19691831; 19692168; 19693485; 19698138; 19704080; 19713000; 19713976; 19716217; 19717024; 19720974; 19722128; 19725829; 19729601; 19732892; 19733021; 19733630; 19734902; 19734903; 19742390; 19744893; 19747047; 19748159; 19748619; 19750560; 19751943; 19752580; 19758344; 19761888; 19765634; 19766540; 19773416; 19786693; 19800705; 19804477; 19808960; 19812458; 19812463; 19812466; 19813626; 19816504; 19818961; 19819279; 19819468; 19822782; 19823059; 19824992; 19825914; 19828088; 19842071; 19845562; 19848197; 19851068; 19851649; 19852818; 19853876; 19857550; 19859025; 19859026; 19860767; 19879282; 19879666; 19884594; 19884614; 19884647; 19888660; 19888930; 19889709; 19890394; 19891383; 19896333; 19897004; 19899640; 19901170; 19901172; 19901249; 19904605; 19906129; 19907180; 19907191; 19910874; 19910883; 19911187; 19911804; 19913121; 19914339; 19915960; 19917453; 19924507; 19926167; 19928390; 19936222; 19939808; 19940477; 19940480; 19943806; 19946803; 19948975; 19951017; 19952867; 19955384; 19958090; 19960482; 19965518; 19965582; 19995442; 19996253; 19997085; 20002130; 20007524; 20014138; 20019593; 20020283; 20029386; 20029801; 20029940; 20030366; 20031273; 20031276; 20031551; 20031552; 20031582; 20032288; 20032478; 20034483; 20037210; 20044476; 20044903; 20058037; 20059631; 20060049; 20061606; 20061627; 20063946; 20065134; 20065135; 20072115; 20072124; 20073019; 20074462; 20074603; 20077482; 20079752; 20088621; 20090368; 20091341; 20094015; 20100581; 20107178; 20116212; 20129626; 20139413; 20145290; 20152880; 20153809; 20157257; 20160191; 20160192; 20160452; 20161734; 20164549; 20164573; 20167577; 20170526; 20172629; 20175773; 20177792; 20182051; 20182542; 20184726; 20186853; 20191120; 20196787; 20197062; 20198498; 20208369; 20213229; 20216394; 20217437; 20219963; 20221865; 20223480; 20227257; 20229631; 20298684; 20301340; 20301414; 20302621; 20304614; 20306566; 20308031; 20308781; 20331378; 20331911; 20332638; 20335123; 20338079; 20340021; 20346360; 20348244; 20350587; 20351714; 20354905; 20362697; 20373031; 20373342; 20373846; 20374396; 20375505; 20376800; 20377344; 20381076; 20381197; 20381392; 20381870; 20382449; 20385913; 20388089; 20389122; 20394740; 20395015; 20396431; 20401432; 20403997; 20406267; 20406466; 20409610; 20410080; 20413122; 20413671; 20413898; 20414590; 20416077; 20416362; 20417063; 20423919; 20425806; 20427016; 20429872; 20430066; 20430392; 20430468; 20430978; 20431431; 20432703; 20436440; 20436990; 20437058; 20437541; 20442634; 20444273; 20446941; 20450896; 20452482; 20453509; 20455859; 20455863; 20456244; 20459474; 20460622; 20463109; 20467002; 20468060; 20469680; 20471857; 20473139; 20479234; 20479360; 20488256; 20491609; 20493672; 20493925; 20498921; 20499136; 20502990; 20508347; 20514637; 20515477; 20523031; 20529013; 20533025; 20533968; 20534741; 20534961; 20535486; 20536507; 20537614; 20538124; 20538372; 20538373; 20538374; 20538375; 20538553; 20541374; 20541611; 20543710; 20546752; 20546958; 20547867; 20548041; 20552590; 20553853; 20554432; 20555142; 20558149; 20558387; 20560916; 20561715; 20562467; 20565774; 20567859; 20569235; 20570401; 20570406; 20571754; 20573574; 20574532; 20576093; 20577623; 20580132; 20583903; 20592257; 20592574; 20598287; 20599283; 20600372; 20602615; 20606435; 20619505; 20620663; 20620664; 20620666; 20625090; 20625167; 20628086; 20634590; 20634891; 20637261; 20640544; 20643407; 20644276; 20644562; 20658496; 20660919; 20663622; 20667498; 20667857; 20673868; 20674461; 20674675; 20677882; 20678545; 20679343; 20679960; 20682199; 20682673; 20682755; 20686185; 20686565; 20686979; 20687780; 20688498; 20689279; 20691505; 20691792; 20693183; 20693622; 20693633; 20697030; 20697334; 20697532; 20700462; 20700730; 20705142; 20709332; 20711061; 20713315; 20714348; 20715976; 20719944; 20723945; 20724907; 20725527; 20727736; 20729396; 20729559; 20733306; 20734064; 20734437; 20739349; 20739760; 20804847; 20808139; 20810250; 20810324; 20813341; 20813342; 20815153; 20817350; 20817608; 20818931; 20819998; 20820000; 20820167; 20822524; 20825268; 20826689; 20832534; 20833446; 20837363; 20838585; 20845403; 20847397; 20847408; 20847432; 20847553; 20847559; 20849521; 20850903; 20851099; 20855565; 20858958; 20858975; 20861163; 20861397; 20864672; 20868652; 20872969; 20876472; 20877692; 20880000; 20880354; 20880607; 20883677; 20884673; 20885792; 20888920; 20889503; 20919569; 20930274; 20930297; 20930301; 20932310; 20935323; 20940625; 20946940; 20947215; 20951391; 20951774; 20954076; 20961174; 20961200; 20964956; 20966513; 20971101; 20972250; 20975297; 20980669; 21033077; 21039385; 21048770; 21054877; 21059196; 21059989; 21061402; 21063236; 21073671; 21074899; 21079443; 21080234; 21084733; 21098974; 21108621; 21110240; 21114327; 21116912; 21116929; 21123754; 21124005; 21124030; 21132386; 21132529; 21143177; 21159973; 21163235; 21163916; 21163940; 21169230; 21184197; 21190051; 21192234; 21192235; 21208197; 21218563; 21219628; 21222606; 21224004; 21225522; 21228824; 21232817; 21240353; 21243303; 21244352; 21244662; 21245410; 21251163; 21252538; 21252539; 21252542; 21254242; 21254576; 21261723; 21263195; 21263443; 21266206; 21266538; 21276236; 21283692; 21283811; 21284913; 21289314; 21290252; 21296594; 21297273; 21297948; 21310412; 21317045; 21322570; 21324265; 21324458; 21325652; 21325775; 21332925; 21346330; 21346518; 21347323; 21350196; 21360299; 21372127; 21379329; 21380728; 21383266; 21388338; 21396385; 21401257; 21402364; 21407046; 21409287; 21418511; 21420681; 21435264; 21443265; 21443344; 21450082; 21451572; 21453125; 21454574; 21461956; 21464541; 21471207; 21474829; 21474934; 21478199; 21482441; 21488185; 21493755; 21500980; 21517181; 21533863; 21534737; 21541275; 21545304; 21549723; 21550086; 21552550; 21555604; 21555637; 21556001; 21570960; 21575667; 21576687; 21593560; 21595502; 21605063; 21606569; 21613490; 21617520; 21627779; 21651315; 21654062; 21659554; 21670560; 21676498; 21679970; 21685781; 21689001; 21701228; 21703254; 21710128; 21714002; 21714688; 21723395; 21724665; 21728427; 21740922; 21741316; 21743035; 21743131; 21756796; 21760580; 21763789; 21767357; 21768502; 21769591; 21782446; 21788110; 21790705; 21792545; 21798384; 21798539; 21799244; 21799773; 21803164; 21803501; 21819245; 21822540; 21825236; 21829380; 21835633; 21840004; 21845591; 21845926; 21848287; 21849821; 21851856; 21856047; 21857382; 21864519; 21869487; 21873229; 21882290; 21889115; 21892657; 21895520; 21905100; 21908077; 21909109; 21911656; 21934306; 21939561; 21943158; 21945984; 21952537; 21954452; 21958003; 21971450; 21973221; 21984189; 21988832; 21992747; 22005931; 22006422; 22010136; 22012848; 22013795; 22015765; 22016362; 22028770; 22039842; 22054870; 22055839; 22056199; 22056562; 22058162; 22068907; 22069463; 22069485; 22071360; 22074026; 22089642; 22100309; 22101739; 22101883; 22101914; 22102296; 22106308; 22108393; 22110642; 22113353; 22129783; 22130662; 22134129; 22138302; 22159055; 22159114; 22165672; 22173784; 22174202; 22178106; 22178110; 22179327; 22185986; 22189452; 22200909; 22204031; 22206590; 22206848; 22211488; 22221491; 22221592; 22225956; 22226379; 22226798; 22228589; 22232206; 22234866; 22238606; 22244650; 22245009; 22246233; 22251476; 22264578; 22266326; 22269984; 22272622; 22272623; 22285757; 22286219; 22291217; 22311091; 22322856; 22328704; 22329498; 22331829; 22334766; 22343410; 22344634; 22348880; 22349451; 22350157; 22353753; 22357643; 22359096; 22365656; 22381401; 22383234; 22383685; 22392034; 22394699; 22396775; 22398564; 22399527; 22410653; 22414761; 22414959; 22419519; 22440829; 22445724; 22462403; 22465377; 22481068; 22487820; 22490376; 22492035; 22502727; 22520940; 22532692; 22534472; 22535266; 22539578; 22542837; 22544617; 22549621; 22558310; 22562716; 22568769; 22580620; 22596266; 22612575; 22615372; 22621984; 22632920; 22633529; 22635103; 22637583; 22642392; 22675504; 22676395; 22689192; 22698480; 22699906; 22710912; 22712640; 22721421; 22728266; 22730380; 22735491; 22755192; 22760259; 22771913; 22784692; 22785395; 22787761; 22796460; 22815080; 22821396; 22825739; 22826377; 22832961; 22837136; 22844488; 22848551; 22862561; 22863665; 22868934; 22869155; 22874659; 22883220; 22883908; 22889670; 22890094; 22890095; 22898894; 22899317; 22902767; 22904031; 22914590; 22914594; 22916037; 22918225; 22921891; 22927174; 22935789; 22936261; 22949395; 22955176; 22961083; 22967844; 22971752; 22972946; 22976236; 22982410; 22984509; 22986607; 22991192; 23011382; 23022416; 23023254; 23031429; 23036023; 23040522; 23042108; 23042215; 23049877; 23050006; 23051684; 23051975; 23056479; 23060451; 23063453; 23064258; 23067351; 23071163; 23079898; 23088986; 23091810; 23096223; 23098561; 23100402; 23100439; 23102119; 23103838; 23110764; 23110818; 23113606; 23118302; 23123227; 23132858; 23134888; 23134962; 23142051; 23142524; 23146133; 23152815; 23159043; 23159296; 23171142; 23175721; 23183136; 23186985; 23204275; 23213264; 23232444; 23238736; 23242296; 23242623; 23247007; 23251595; 23255503; 23255822; 23270420; 23272070; 23273617; 23275593; 23286790; 23288845; 23289212; 23290018; 23291160; 23292450; 23293020; 23296339; 23302659; 23312054; 23317568; 23320904; 23321337; 23324992; 23326517; 23364031; 23371373; 23372804; 23380990; 23382465; 23384034; 23384292; 23385359; 23396426; 23407349; 23407718; 23408335; 23411028; 23413428; 23415434; 23419831; 23424640; 23429815; 23430611; 23430745; 23455636; 23466070; 23492875; 23503772; 23522842; 23525328; 23537987; 23546960; 23553344; 23562540; 23565137; 23571587; 23573206; 23576895; 23581910; 23583468; 23584199; 23587637; 23587689; 23588940; 23590983; 23593485; 23603214; 23612909; 23613766; 23620513; 23624169; 23631810; 23631828; 23642733; 23652625; 23660682; 23663404; 23669301; 23684315; 23687437; 23701536; 23723060; 23726366; 23729930; 23731072; 23737466; 23743349; 23769398; 23771217; 23773371; 23779114; 23786792; 23808899; 23815818; 23826174; 23844046; 23844141; 23855979; 23865355; 23876113; 23883936; 23888546; 23902934; 23902937; 23919842; 23965289; 24009459; 24023260; 24023310; 24023758; 24145446; 24145819; 24163986; 24239320; 24276092; 24291031; 24308640; 24340925; 24448836; 24464001,,,,,,,,,,,,,,,OGG:3000000348,,,,,,,apolipoprotein E,,,,,,,,,,,,,Other designations: apo-E|apolipoprotein E3,,APOE,,,,,,,,,,,,,,,,,,,,,,,348,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,APOE,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/PATO_0000427,recurrent,,A quality of a single process inhering in a bearer by virtue of the bearer's occurring or appearing again or repeatedly.,false,,,http://purl.obolibrary.org/obo/PATO_0001309,,,,,,,,,,,,,,,,,,,,,,A quality of a single process inhering in a bearer by virtue of the bearer's occurring or appearing again or repeatedly.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0000427,,,,,,,,,,,,,,,,,,,,,,recurrent,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100329,c-IAP1,HIAP2|mammalian IAP homologue B|MIHB|cellular inhibitor of apoptosis protein-1,,false,,,http://purl.obolibrary.org/obo/IMR_0000454,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,HIAP2|mammalian IAP homologue B|MIHB|cellular inhibitor of apoptosis protein-1,,,,,IMR:0100329,,,,,,,,,,,,,,,,,,,,,,c-IAP1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000008544,PIR,,"Other designations: pirin|probable quercetin 2,3-dioxygenase PIR|probable quercetinase",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,X,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,pirin (iron-binding nuclear protein),,,Xp22.2,,,,,,,,,,,,,,,,"GO_0003712 (EC: IMP); GO_0005515 (EC: IPI, PMID: 10362352); GO_0005634 (EC: IDA, PMID: 9079676); GO_0005737 (EC: IDA); GO_0006355 (EC: IEA); GO_0006366 (EC: TAS, PMID: 9079676); GO_0008127 (EC: IDA, PMID: 15951572); GO_0030224 (EC: IMP); GO_0046872 (EC: IDA)",,,,,,,,,PMID: 9079676; 10362352; 12477932; 12876364; 14573596; 15231748; 15489334; 15951572; 16344560; 17213182; 19766747; 20010624; 20089166; 20711196; 21514450; 22939629; 23716661; 24272884,,,,,,,,,,,,,,,OGG:3000008544,,,,,,,pirin (iron-binding nuclear protein),,,,,,,,,,,,,"Other designations: pirin|probable quercetin 2,3-dioxygenase PIR|probable quercetinase",,PIR,,,,,,,,,,,,,,,,,,,,,,,8544,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,PIR,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000626,Integrin alpha-4,,,false,,,http://purl.obolibrary.org/obo/IMR_0000173,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000626,,,,,,,,,,,,,,,,,,,,,,Integrin alpha-4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000010525,HYOU1,,Other designations: 150 kDa oxygen-regulated protein|170 kDa glucose-regulated protein|hypoxia up-regulated protein 1|oxygen regulated protein (150kD),false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,Grp170|HSP12A|ORP-150|GRP-170|ORP150,,,,,,,,,,,,11,,,,,,Vega:OTTHUMG00000166354|HGNC:16931|HPRD:03448|MIM:601746|Ensembl:ENSG00000149428,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,hypoxia up-regulated 1,,,11q23.1-q23.3,,,,,,,,,,,,,,,,"GO_0002931 (EC: IEA); GO_0005524 (EC: IEA); GO_0005576 (EC: TAS); GO_0005783 (EC: TAS, PMID: 9020069); GO_0005788 (EC: TAS); GO_0006950 (EC: TAS, PMID: 9020069); GO_0006987 (EC: TAS); GO_0030968 (EC: TAS); GO_0044267 (EC: TAS); GO_0070062 (EC: IDA, PMID: 19199708); GO_0071682 (EC: TAS)",,,,,,,,,PMID: 8125298; 8878445; 9006956; 9020069; 9645760; 10037731; 10837345; 10965054; 11231630; 11690552; 12477932; 12553534; 12754519; 15240565; 15342556; 15952740; 16263699; 16335952; 16543725; 17131193; 17330988; 17353931; 17481612; 18404158; 19106412; 19199708; 19225868; 19812200; 19913121; 20000738; 20626887; 20628086; 21139048; 21296878; 21319273; 21890473; 21903422; 21906983; 22190034; 22268729; 22586326; 22863883; 22939629; 23097496; 23645669; 23757447; 23862649; 24457600,,,,,,,,,,,,,,,OGG:3000010525,,,,,,,hypoxia up-regulated 1,,,,,,,,,,,,,Other designations: 150 kDa oxygen-regulated protein|170 kDa glucose-regulated protein|hypoxia up-regulated protein 1|oxygen regulated protein (150kD),,HYOU1,,,,,,,,,,,,,,,,,,,,,,,10525,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,HYOU1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/GO_0051320,S phase,,"The cell cycle phase, following G1, during which DNA synthesis takes place.",false,,,http://purl.obolibrary.org/obo/GO_0022403,,,,,,,,,,,,,,,,,,,,MeSH:D016196,,"The cell cycle phase, following G1, during which DNA synthesis takes place.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0051320,,,,,,,,,,,,,,,,,,,,,,S phase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000075,increasing GDF15 level [mitochondrial disorder],,"Increasing GDF15 level is a subtype of increasing quantity: A process that changes the amount of GDF15 level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0004569,,,,,,,,,,,,,,,,,,,,PMID:29222479,,"Increasing GDF15 level is a subtype of increasing quantity: A process that changes the amount of GDF15 level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004222|http://purl.obolibrary.org/obo/TXPO_0003613,,,,,,,,,,,,,,,,,TXPO:0000075,,,,,,,,,,,,,,,,,,,,,,increasing GDF15 level [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000072,insulin deficiency,,Insulin deficiency is a subtype of malfunctioning process: A process that lacks performing the insulin function required.,false,,,http://purl.obolibrary.org/obo/TXPO_0000482,,,,,,,,,,,,,,,,,,,,,,Insulin deficiency is a subtype of malfunctioning process: A process that lacks performing the insulin function required.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000072,,,,,,,,,,,,,,,,,,,,,,insulin deficiency,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000071,sphingolipid catabolic process,sphingolipid catabolism|sphingolipid degradation|sphingolipid breakdown,"The chemical reactions and pathways resulting in the breakdown of sphingolipids, any of a class of lipids containing the long-chain amine diol sphingosine or a closely related base (a sphingoid).",false,,,http://purl.obolibrary.org/obo/GO_0016042,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways resulting in the breakdown of sphingolipids, any of a class of lipids containing the long-chain amine diol sphingosine or a closely related base (a sphingoid).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_26739,,,,,,,,,,,,,,,,,,sphingolipid catabolism|sphingolipid degradation|sphingolipid breakdown,,,,,TXPO:0000071,,,,,,,,,,,,,,,,,,,,,,sphingolipid catabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000079,ECM2 - tumor progression marker  (predicted)(human)  [Glutathione depletion],,predicted gene  by Support Vector Machine (SVM) using human primary hepatocyte,false,,,http://purl.obolibrary.org/obo/TXPO_0000661|http://purl.obolibrary.org/obo/TXPO_0000665,,,,,,,,,,,,,,,,,,,,PMID:23766865|NCBI-Human-GeneID:1842|PMID:15189273|PMID:28840186,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,,,,http://purl.obolibrary.org/obo/TXPO_0000080,,,,,,,,,,TXPO:0000079,,,,,,,,,,,,,,,,,,,,predicted gene  by Support Vector Machine (SVM) using human primary hepatocyte,,ECM2 - tumor progression marker  (predicted)(human)  [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000070,organelle damage,,organelle damage is a subtype of damaging.,false,,,http://purl.obolibrary.org/obo/TXPO_0000222,,,,,,,,,,,,,,,,,,,,,,organelle damage is a subtype of damaging.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000070,,,,,,,,,,,,,,,,,,,,,,organelle damage,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000074,insulin deficiency [ER stress],,"Insulin deficiency is a subtype of malfunctioning process: A process that lacks performing the insulin function required.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000072|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"Insulin deficiency is a subtype of malfunctioning process: A process that lacks performing the insulin function required.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001245,,,,,,,,,,,TXPO:0000074,,,,,,,,,,,,,,,,,,,,,,insulin deficiency [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000077,ITGB3 (predicted)(human)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001135|http://purl.obolibrary.org/obo/TXPO_0003817,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:3690|PMID:15215180|PMID:8247041|PMID:15917997|PMID:22879933|PMID:22210111,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000003690,,,,,,,,,,,,,TXPO:0000077,,,,,,,,,,,,,,,,,,,,,,ITGB3 (predicted)(human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000073,natural killer cell activation [Phospholipidosis (excessive defense)],,"natural killer cell activation is a subtype of macrophage activation: A change in morphology and behavior of a natural killer (NK) cell resulting from exposure to a cytokine, chemokine, cellular ligand, or soluble factor.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense).",false,,,http://purl.obolibrary.org/obo/GO_0030101|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"natural killer cell activation is a subtype of macrophage activation: A change in morphology and behavior of a natural killer (NK) cell resulting from exposure to a cytokine, chemokine, cellular ligand, or soluble factor.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000073,,,,,,,,,,,,,,,,,,,,,,natural killer cell activation [Phospholipidosis (excessive defense)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000078,SULT1C2(predicted)(human)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001135|http://purl.obolibrary.org/obo/TXPO_0003832,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:6819|PMID:26427720|PMID:30885913|https://omim.org/entry/602385,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000006819,,,,,,,,,,,,,TXPO:0000078,,,,,,,,,,,,,,,,,,,,,,SULT1C2(predicted)(human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001139,glypican (mol),GPI-anchored membrane heparan sulfate proteoglycan,,false,,,http://purl.obolibrary.org/obo/IMR_0001125,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GPI-anchored membrane heparan sulfate proteoglycan,,,,,IMR:0001139,,,,,,,,,,,,,,,,,,,,,,glypican (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000700,p50:RelA,,,false,,,http://purl.obolibrary.org/obo/IMR_0000382,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000700,,,,,,,,,,,,,,,,,,,,,,p50:RelA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100251,MLK2,MST|MAP3K10|MKN28 derived serine / threonine kinase,,false,,,http://purl.obolibrary.org/obo/IMR_0100249,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MST|MAP3K10|MKN28 derived serine / threonine kinase,,,,,IMR:0100251,,,,,,,,,,,,,,,,,,,,,,MLK2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0042177,negative regulation of protein catabolic process,,"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of a protein by the destruction of the native, active configuration, with or without the hydrolysis of peptide bonds.",false,,,http://purl.obolibrary.org/obo/TXPO_0000115,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of a protein by the destruction of the native, active configuration, with or without the hydrolysis of peptide bonds.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0042177,,,,,,,,,,,,,,,,,,,,,,negative regulation of protein catabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0030163,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000026286,ARFGAP3,,Other designations: ADP-ribosylation factor GTPase activating protein 1|ADP-ribosylation factor GTPase-activating protein 3|ARF GAP 3,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,ARFGAP1,,,,,,,,,,,,22,,,,,,Vega:OTTHUMG00000150718|Ensembl:ENSG00000242247|HGNC:661|HPRD:06444|MIM:612439,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,ADP-ribosylation factor GTPase activating protein 3,,,22q13.2,,,,,,,,,,,,,,,,"GO_0000139 (EC: IEA); GO_0005737 (EC: IDA); GO_0005794 (EC: IDA); GO_0005829 (EC: IDA, PMID: 11172815); GO_0006886 (EC: NAS, PMID: 11172815); GO_0008060 (EC: IDA, PMID: 11172815); GO_0008270 (EC: IEA); GO_0008565 (EC: NAS, PMID: 11172815); GO_0009306 (EC: IEP, PMID: 11172815); GO_0016192 (EC: NAS, PMID: 11172815); GO_0032312 (EC: IEA); GO_0043547 (EC: IDA, PMID: 11172815)",,,,,,,,,PMID: 8076819; 10591208; 10704287; 11172815; 12477932; 12529303; 14702039; 15461802; 15489334; 15761153; 17081983; 17760859; 18029348; 19015319; 19299515; 20379614; 21139048; 21647875; 21832049; 21890473; 21988832; 23000965; 24250222,,,,,,,,,,,,,,,OGG:3000026286,,,,,,,ADP-ribosylation factor GTPase activating protein 3,,,,,,,,,,,,,Other designations: ADP-ribosylation factor GTPase activating protein 1|ADP-ribosylation factor GTPase-activating protein 3|ARF GAP 3,,ARFGAP3,,,,,,,,,,,,,,,,,,,,,,,26286,AL049757.1,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,ARFGAP3,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000022977,AKR7A3,,Other designations: AFB1 aldehyde reductase 2|AFB1-AR 2|aflatoxin B1 aldehyde reductase 2|aflatoxin B1 aldehyde reductase member 3,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,AFAR2,,,,,,,,,,,,1,,,,,,HPRD:07089|HGNC:390|MIM:608477,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"aldo-keto reductase family 7, member A3 (aflatoxin aldehyde reductase)",,,1p36.13,,,,,,,,,,,,,,,,"GO_0004032 (EC: IEA); GO_0004033 (EC: TAS, PMID: 10383892); GO_0005739 (EC: IEA); GO_0005829 (EC: TAS, PMID: 10383892); GO_0006081 (EC: TAS, PMID: 10383892); GO_0009055 (EC: TAS, PMID: 10383892); GO_0046223 (EC: IEA); GO_0070062 (EC: IDA, PMID: 19056867)",,,,,,,,,PMID: 10383892; 12477932; 12879023; 15489334; 16189514; 16341674; 16710414; 19056867; 20453000; 21044950; 23824909,,,,,,,,,,,,,,,OGG:3000022977,,,,,,,"aldo-keto reductase family 7, member A3 (aflatoxin aldehyde reductase)",,,,,,,,,,,,,Other designations: AFB1 aldehyde reductase 2|AFB1-AR 2|aflatoxin B1 aldehyde reductase 2|aflatoxin B1 aldehyde reductase member 3,,AKR7A3,,,,,,,,,,,,,,,,,,,,,,,22977,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,AKR7A3,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_94686,orlistat,"(2S)-2-formamido-4-methylpentanoic acid [(2S)-1-[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]tridecan-2-yl] ester|orlistat|orlistatum|Xenical|(-)-tetrahydrolipostatin|Ro-18-0647|Alli|orlipastat|N-formyl-L-leucine (1S)-1-{[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl}dodecyl ester|(2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl N-formyl-L-leucinate","A carboxylic ester resulting from the formal condensation of the carboxy group of N-formyl-L-leucine with the hydroxy group of (3S,4S)-3-hexyl-4-[(2S)-2-hydroxytridecyl]oxetan-2-one. A pancreatic lipase inhibitor, it is used as an anti-obesity drug.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:27793869|PMID:28260907|PMID:28097013|Drug_Central:1996|PMID:28559211|PMID:28588183|PMID:28624425|PMID:28191026|Reaxys:3658031|CAS:96829-58-2|PMID:28387458|LINCS:LSM-5724,,"A carboxylic ester resulting from the formal condensation of the carboxy group of N-formyl-L-leucine with the hydroxy group of (3S,4S)-3-hexyl-4-[(2S)-2-hydroxytridecyl]oxetan-2-one. A pancreatic lipase inhibitor, it is used as an anti-obesity drug.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_71476|http://purl.obolibrary.org/obo/CHEBI_65001|http://purl.obolibrary.org/obo/CHEBI_76969|http://purl.obolibrary.org/obo/CHEBI_74518,,,,,"(2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl N-formyl-L-leucinate",,"(2S)-2-formamido-4-methylpentanoic acid [(2S)-1-[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]tridecan-2-yl] ester|orlistat|orlistatum|Xenical|(-)-tetrahydrolipostatin|Ro-18-0647|Alli|orlipastat|N-formyl-L-leucine (1S)-1-{[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl}dodecyl ester",,,,,,,,,,,,,,,,,,,,,CHEBI:94686,,,,orlistat,,CHEBI:94686,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0098754,detoxification,,Any process that reduces or removes the toxicity of a toxic substance. These may include transport of the toxic substance away from sensitive areas and to compartments or complexes whose purpose is sequestration of the toxic substance.,false,,,http://purl.obolibrary.org/obo/TXPO_0000458,,,,,,,,,,,,,,,,,,,,,,Any process that reduces or removes the toxicity of a toxic substance. These may include transport of the toxic substance away from sensitive areas and to compartments or complexes whose purpose is sequestration of the toxic substance.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0098754,,,,,,,,,,,,,,,,,,,,,,detoxification,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000090637,ZFAND2A,,Other designations: AN1-type zinc finger protein 2A|arsenite inducible RNA associated protein,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,AIRAP,,,,,,,,,,,,7,,,,,,Ensembl:ENSG00000178381|HPRD:14277|HGNC:28073|Vega:OTTHUMG00000119019|MIM:610699,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"zinc finger, AN1-type domain 2A",,,7p22.3,,,,,,,,,,,,,,,,GO_0005634 (EC: IEA); GO_0005737 (EC: IEA); GO_0008270 (EC: IEA),,,,,,,,,PMID: 12477932; 15489334; 20185824; 21906983; 21988832; 22505724; 22990118; 24250222,,,,,,,,,,,,,,,OGG:3000090637,,,,,,,"zinc finger, AN1-type domain 2A",,,,,,,,,,,,,Other designations: AN1-type zinc finger protein 2A|arsenite inducible RNA associated protein,,ZFAND2A,,,,,,,,,,,,,,,,,,,,,,,90637,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,ZFAND2A,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0001727,cell death dependent process,,Cell death dependent process is a subtype of toxic course dependent process: A process that can constitute the course of hepatocyte cell death.,false,,,http://purl.obolibrary.org/obo/TXPO_0001715,,,,,,,,,,,,,,,,,,,,,,Cell death dependent process is a subtype of toxic course dependent process: A process that can constitute the course of hepatocyte cell death.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001727,,,,,,,,,,,,,,,,,,,,,,cell death dependent process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001724,hyperfunction of increasing,,Hyperfunction of increasing is a subtype of hyperfunctioning: A process that performs an excessive function of increasing.,false,,,http://purl.obolibrary.org/obo/TXPO_0000435,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of increasing is a subtype of hyperfunctioning: A process that performs an excessive function of increasing.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001724,,,,,,,,,,,,,,,,,,,,,,hyperfunction of increasing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001725,PERK-eIF2a signal transduction system,,"PERK-eIF2a signal transduction system is a subtype of pathway system.
This entity has sub-parts and has a goal of transmitting signals via PERK and eIF2a as a systemic context.
This entity is dependent on the translation attenuation of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001712,,,,,,,,,,,,,,,,,,,,,,"PERK-eIF2a signal transduction system is a subtype of pathway system.
This entity has sub-parts and has a goal of transmitting signals via PERK and eIF2a as a systemic context.
This entity is dependent on the translation attenuation of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002162,,,,,,,,,,,,,,,,,,,,,,TXPO:0001725,,,,,,,,,,,,,,,,,,,,,,PERK-eIF2a signal transduction system,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001728,ground glass degeneration dependent process,,Ground glass degeneration is a subtype of toxic course dependent process: A process that can constitute the course of ground glass appearance.,false,,,http://purl.obolibrary.org/obo/TXPO_0001715,,,,,,,,,,,,,,,,,,,,,,Ground glass degeneration is a subtype of toxic course dependent process: A process that can constitute the course of ground glass appearance.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001728,,,,,,,,,,,,,,,,,,,,,,ground glass degeneration dependent process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001723,hypofunction of phospholipid deradation by phospholipase,,Hypofunction of phospholipid deradation by phospholipase is a subtype of hypofunction of phospholipid degradation: A process that performs a decreased or insufficient phospholipid deradation by phospholipase.,false,,,http://purl.obolibrary.org/obo/TXPO_0001253,,,,,,,,,,,,,,,,,,,,,,Hypofunction of phospholipid deradation by phospholipase is a subtype of hypofunction of phospholipid degradation: A process that performs a decreased or insufficient phospholipid deradation by phospholipase.,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000635,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001723,,,,,,,,,,,,,,,,,,,,,,hypofunction of phospholipid deradation by phospholipase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001720,hepatic steatosis dependent process,,Hepatic steatosis dependent process is a subtype of toxic course dependent process: A process that can constitute the course of hepatic steatosis (fatty degeneration).,false,,,http://purl.obolibrary.org/obo/TXPO_0001715,,,,,,,,,,,,,,,,,,,,,,Hepatic steatosis dependent process is a subtype of toxic course dependent process: A process that can constitute the course of hepatic steatosis (fatty degeneration).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001720,,,,,,,,,,,,,,,,,,,,,,hepatic steatosis dependent process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001729,eosinophlic granular degeneration dependent process,,Eosinophlic granular degeneration dependent process is a subtype of toxic course dependent process: A process that can constitute the course of eosinophilicgranular degeneration.,false,,,http://purl.obolibrary.org/obo/TXPO_0001715,,,,,,,,,,,,,,,,,,,,,,Eosinophlic granular degeneration dependent process is a subtype of toxic course dependent process: A process that can constitute the course of eosinophilicgranular degeneration.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001729,,,,,,,,,,,,,,,,,,,,,,eosinophlic granular degeneration dependent process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001722,hypofunction of ATP biosynthesis,,Hypofunction of ATP biosynthesis is a subtype of hypofunction of biosynthesis: A process that performs a decreased or insufficient ATP biosynthesis.,false,,,http://purl.obolibrary.org/obo/TXPO_0001910,,,,,,,,,,,,,,,,,,,,,,Hypofunction of ATP biosynthesis is a subtype of hypofunction of biosynthesis: A process that performs a decreased or insufficient ATP biosynthesis.,,,http://purl.obolibrary.org/obo/GO_0006754,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001722,,,,,,,,,,,,,,,,,,,,,,hypofunction of ATP biosynthesis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001721,MMP inactivation by TIMP1 [Fibrosis],,"MMP inactivation by TIMP1 is a subtype of inactivating: A process that changes the activity of the MMP to be lower by TIMP1.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003742|http://purl.obolibrary.org/obo/TXPO_0001384,,,,,,,,,,,,,,,,,,,,,,"MMP inactivation by TIMP1 is a subtype of inactivating: A process that changes the activity of the MMP to be lower by TIMP1.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003062,,,,,,,,,,,,,,,,,TXPO:0001721,,,,,,,,,,,,,,,,,,,,,,MMP inactivation by TIMP1 [Fibrosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001726,hyperfunction of phospholipid synthesis gene expression,,Hyperfunction of phospholipid synthesis gene expression is a subtype of hyperfunction of gene expression: A process that performs an excesssive phospholipid synthetic gene expression.,false,,,http://purl.obolibrary.org/obo/TXPO_0002345,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of phospholipid synthesis gene expression is a subtype of hyperfunction of gene expression: A process that performs an excesssive phospholipid synthetic gene expression.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001726,,,,,,,,,,,,,,,,,,,,,,hyperfunction of phospholipid synthesis gene expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_15986,polynucleotide,,A nucleobase-containing molecular entity with a polymeric structure comprised of a linear sequence of 13 or more nucleotide residues.,false,,,http://purl.obolibrary.org/obo/CHEBI_33694,,,,,,,,,,,,,,,,,,,,,,A nucleobase-containing molecular entity with a polymeric structure comprised of a linear sequence of 13 or more nucleotide residues.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:15986,,,,,,,,,,,,,,,,,,,,,,polynucleotide,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100433,RalGDS,RalGEF,,false,,,http://purl.obolibrary.org/obo/IMR_0000439,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,RalGEF,,,,,IMR:0100433,,,,,,,,,,,,,,,,,,,,,,RalGDS,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000256,Plk,polo-like kinase,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001966,,,,,polo-like kinase,,,,,IMR:0000256,,,,,,,,,,,,,,,,,,,,,,Plk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000285,PLC gamma,phospholipase C gamma,,false,,,http://purl.obolibrary.org/obo/IMR_0000284,,,,,,,,,,,,,,,,,,,,MeSH: D051966,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,phospholipase C gamma,,,,,IMR:0000285,,,,,,,,,,,,,,,,,,,,,,PLC gamma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010466,60S ribosomal protein L15,P39030,,false,,,http://purl.obolibrary.org/obo/IMR_0000897,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,P39030,,,,,IMR:0010466,,,,,,,,,,,,,,,,,,,,,,60S ribosomal protein L15,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000001284,COL4A2,,Other designations: canstatin|collagen alpha-2(IV) chain,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,ICH|POREN2,,,,,,,,,,,,13,,,,,,Vega:OTTHUMG00000017344|HGNC:2203|HPRD:00355|Ensembl:ENSG00000134871|MIM:120090,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"collagen, type IV, alpha 2",,,13q34,,,,,,,,,,,,,,,,"GO_0001525 (EC: IEA); GO_0005201 (EC: TAS, PMID: 8317999); GO_0005515 (EC: IPI, PMID: 12011424); GO_0005576 (EC: TAS); GO_0005587 (EC: TAS, PMID: 2846280); GO_0005788 (EC: TAS); GO_0006351 (EC: IEA); GO_0007411 (EC: TAS); GO_0016525 (EC: IDA, PMID: 10625665); GO_0022617 (EC: TAS); GO_0030198 (EC: NAS, PMID: 8317999); GO_0030198 (EC: TAS); GO_0030574 (EC: TAS); GO_0031012 (EC: IDA, Qualifier: colocalizes_with); GO_0031012 (EC: ISS, Qualifier: colocalizes_with); GO_0031012 (EC: TAS, Qualifier: colocalizes_with); GO_0043231 (EC: IDA); GO_0071560 (EC: IEA)",,,,,,,,,PMID: 1377218; 1724753; 2211625; 2426947; 2439508; 2844531; 2846280; 3025878; 3089234; 3182844; 3198637; 3345760; 3582677; 3692475; 3997552; 6389236; 6811420; 6988303; 7495302; 7500359; 7827955; 8006028; 8317999; 8995276; 9136074; 9334230; 9409248; 9506531; 9673377; 9878537; 10382266; 10416788; 10625665; 10926178; 11259413; 11683410; 11711546; 11867580; 12011424; 12021518; 12180907; 12477932; 12878203; 15057823; 15146197; 15231748; 15489334; 15522229; 15743801; 16368877; 16712791; 17216253; 17339318; 17554254; 17557121; 18050191; 18706356; 19481338; 19913121; 20067797; 20080650; 20201926; 20452482; 20628086; 20673868; 20805453; 20889312; 21378990; 21527998; 21900206; 21942715; 22144573; 22209246; 22209247; 22268729; 22333902; 23818951,,,,,,,,,,,,,,,OGG:3000001284,,,,,,,"collagen, type IV, alpha 2",,,,,,,,,,,,,Other designations: canstatin|collagen alpha-2(IV) chain,,COL4A2,,,,,,,,,,,,,,,,,,,,,,,1284,RP11-90L1.2,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,COL4A2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0100306,caspase-11,,,false,,,http://purl.obolibrary.org/obo/IMR_0000305,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100306,,,,,,,,,,,,,,,,,,,,,,caspase-11,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000010803,CCR9,,Other designations: C-C chemokine receptor type 9|G protein-coupled receptor 28,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CDw199|GPR28|CC-CKR-9|GPR-9-6,,,,,,,,,,,,3,,,,,,MIM:604738|HPRD:09200|Vega:OTTHUMG00000133450|Ensembl:ENSG00000173585|HGNC:1610,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,chemokine (C-C motif) receptor 9,,,3p21.3,,,,,,,,,,,,,,,,"GO_0004950 (EC: TAS, PMID:10229797); GO_0005886 (EC: TAS); GO_0005887 (EC: TAS, PMID:10229797); GO_0006935 (EC: IEA); GO_0006955 (EC: IEA); GO_0006968 (EC: TAS, PMID:10544196); GO_0007186 (EC: TAS, PMID:10544196); GO_0007204 (EC: TAS, PMID:10229797); GO_0016493 (EC: IEA); GO_0070098 (EC: TAS, PMID:10229797)",,,,,,,,,PMID:2834384; 10229797; 10498628; 10544196; 10602049; 10640743; 10702689; 10974041; 11046037; 12477932; 12816994; 14559839; 15489334; 15623660; 15717282; 16344560; 17205512; 17570212; 18240029; 18245518; 18245522; 18577758; 19423540; 19525985; 19756884; 20036838; 20056178; 20081876; 20190752; 20406964; 20438785; 20738854; 20947433; 21075690; 21344163; 21511186; 21637913; 21984373; 23326330,,,,,,,,,,,,,,,OGG:3000010803,,,,,,,chemokine (C-C motif) receptor 9,,,,,,,,,,,,,Other designations: C-C chemokine receptor type 9|G protein-coupled receptor 28,,CCR9,,,,,,,,,,,,,,,,,,,,,,,10803,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CCR9,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_68542,EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor,dihydroorotate oxidase (fumarate) (EC 1.3.98.1) inhibitors|DHODH inhibitor|dihydroorotate dehydrogenase inhibitors|EC 1.3.3.1 inhibitor|EC 1.3.98.1 (dihydroorotate oxidase (fumarate)) inhibitor|(S)-dihydroorotate:fumarate oxidoreductase inhibitors|dihydroorotate dehydrogenase inhibitor|dihydroorotate oxidase (fumarate) (EC 1.3.98.1) inhibitor|EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitors|dihydroorotate oxidase (fumarate) inhibitor|EC 1.3.98.1 inhibitor|DHODH inhibitors|(S)-dihydroorotate:fumarate oxidoreductase inhibitor|dihydroorotate oxidase (fumarate) inhibitors|EC 1.3.98.1 inhibitors|EC 1.3.98.1 (dihydroorotate oxidase (fumarate)) inhibitors|EC 1.3.3.1 inhibitors,"An EC 1.3.98.* (oxidoreductase acting on CH-CH group of donors, with other, known, acceptors) inhibitor that interferes with the action of dihydroorotate oxidase (fumarate), EC 1.3.98.1 (formerly EC 1.3.3.1).",false,,,http://purl.obolibrary.org/obo/CHEBI_76858,,,,,,,,,,,,,,,,,,,,,,"An EC 1.3.98.* (oxidoreductase acting on CH-CH group of donors, with other, known, acceptors) inhibitor that interferes with the action of dihydroorotate oxidase (fumarate), EC 1.3.98.1 (formerly EC 1.3.3.1).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,dihydroorotate oxidase (fumarate) (EC 1.3.98.1) inhibitors|DHODH inhibitor|dihydroorotate dehydrogenase inhibitors|EC 1.3.3.1 inhibitor|EC 1.3.98.1 (dihydroorotate oxidase (fumarate)) inhibitor|(S)-dihydroorotate:fumarate oxidoreductase inhibitors|dihydroorotate dehydrogenase inhibitor|dihydroorotate oxidase (fumarate) (EC 1.3.98.1) inhibitor|EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitors|dihydroorotate oxidase (fumarate) inhibitor|EC 1.3.98.1 inhibitor|DHODH inhibitors|(S)-dihydroorotate:fumarate oxidoreductase inhibitor|dihydroorotate oxidase (fumarate) inhibitors|EC 1.3.98.1 inhibitors|EC 1.3.98.1 (dihydroorotate oxidase (fumarate)) inhibitors|EC 1.3.3.1 inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:68542,,,,EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor,,CHEBI:68542,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_135009,nitrefazole,altimol,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:21721-92-6|Drug_Central:1946,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,altimol,,,,,,,,,,,,,,,,,,,,,CHEBI:135009,,,,nitrefazole,,CHEBI:135009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_135005,milnacipran,milnacipran HCl|midalcipran|milnacipran hydrochloride|(+/-)-Milnacipran,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Drug_Central:1808|CAS:92623-85-3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,milnacipran HCl|midalcipran|milnacipran hydrochloride|(+/-)-Milnacipran,,,,,,,,,,,,,,,,,,,,,CHEBI:135005,,,,milnacipran,,CHEBI:135005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000276,SHP-2,PTP1D|Src homology 2-containing protein tyrosine phosphatase-2|Syp|SH-PTP2,,false,,,http://purl.obolibrary.org/obo/IMR_0000274,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PTP1D|Src homology 2-containing protein tyrosine phosphatase-2|Syp|SH-PTP2,,,,,IMR:0000276,,,,,,,,,,,,,,,,,,,,,,SHP-2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004935,Increasing glucagon level,,Increasing glucagon level is a subtype of increasing quantity: A process that changes the amount of glucagon level to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing glucagon level is a subtype of increasing quantity: A process that changes the amount of glucagon level to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004935,,,,,,,,,,,,,,,,,,,,,,Increasing glucagon level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004939,increasing glucose level [mitochondrial disorder],,"Increasing glucose level is a subtype of increasing quantity: A process that changes the amount of glucose level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0004938|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:31623280|PMID:23299992,,"Increasing glucose level is a subtype of increasing quantity: A process that changes the amount of glucose level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001990|http://purl.obolibrary.org/obo/TXPO_0001993|http://purl.obolibrary.org/obo/TXPO_0004350|http://purl.obolibrary.org/obo/TXPO_0001988,,,,,,,,,,,TXPO:0004939,,,,,,,,,,,,,,,,,,,,,,increasing glucose level [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004938,increasing glucose level,,Increasing glucose level is a subtype of increasing quantity: A process that changes the amount of glucose level to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing glucose level is a subtype of increasing quantity: A process that changes the amount of glucose level to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004938,,,,,,,,,,,,,,,,,,,,,,increasing glucose level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004933,negative regulation of phospholipid degradation [Phospholipidosis (latent)],,"A process that stops, prevents, or reduces the frequency, rate or extent of phospholipid degradation.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (latent).",false,,,http://purl.obolibrary.org/obo/TXPO_0000905,,,,,,,,,,,,,,,,,,,,,,"A process that stops, prevents, or reduces the frequency, rate or extent of phospholipid degradation.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (latent).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001908,,,,,,,http://purl.obolibrary.org/obo/TXPO_0005059,,,,,,,,,,,TXPO:0004933,,,,,,,,,,,,,,,,,,,,,,negative regulation of phospholipid degradation [Phospholipidosis (latent)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004936,Increasing glucagon level [mitochondrial disorder],,"Increasing glucagon level is a subtype of increasing quantity: A process that changes the amount of glucagon level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0004935|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:23299992,,"Increasing glucagon level is a subtype of increasing quantity: A process that changes the amount of glucagon level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004366,,,,,,,,,,,TXPO:0004936,,,,,,,,,,,,,,,,,,,,,,Increasing glucagon level [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004937,glucose homeostasis imbalance [mitochondrial disorder],,"Glucose homeostasis imbalance is a subtype of chemical homeostasis imbalance: A process that becomes lacking a glucose homeostastasis balance.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0001233,,,,,,,,,,,,,,,,,,,,PMID:31623280|PMID:31649547,,"Glucose homeostasis imbalance is a subtype of chemical homeostasis imbalance: A process that becomes lacking a glucose homeostastasis balance.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004379,,,,,,,,,,,TXPO:0004937,,,,,,,,,,,,,,,,,,,,,,glucose homeostasis imbalance [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004932,phospholipid peroxidation,,phospholipid peroxidation is a subtype of lipid oxidation:  The degradation of phospholipids caused by an oxidative attack from free radicals.,false,,,http://purl.obolibrary.org/obo/TXPO_0003514,,,,,,,,,,,,,,,,,,,,,,phospholipid peroxidation is a subtype of lipid oxidation:  The degradation of phospholipids caused by an oxidative attack from free radicals.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004932,,,,,,,,,,,,,,,,,,,,,,phospholipid peroxidation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004931,cardiolipin peroxidation,,cardiolipin peroxidation is a subtype of phospholipid oxidation:  The degradation of cardiolipin caused by an oxidative attack from free radicals.,false,,,http://purl.obolibrary.org/obo/TXPO_0004932,,,,,,,,,,,,,,,,,,,,,,cardiolipin peroxidation is a subtype of phospholipid oxidation:  The degradation of cardiolipin caused by an oxidative attack from free radicals.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_28494,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004931,,,,,,,,,,,,,,,,,,,,,,cardiolipin peroxidation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004934,Chlorendic Acid [hepatocarcinogenesis],"1,4,5,6,7,7-hexachlorobicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid",,false,,,http://purl.obolibrary.org/obo/TXPO_0004455|http://purl.obolibrary.org/obo/CHEBI_76603,,,,,,,,,,,,,,,,,,,,CAS:115-28-6|PMID:22584684,,,,,,,,,,,,,,C9H4Cl6O4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"1,4,5,6,7,7-hexachlorobicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid",,,,,TXPO:0004934,,,,,,,,,,,,,,,,,,,,,,Chlorendic Acid [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,OC(=O)C1C(C(O)=O)C2(Cl)C(Cl)=C(Cl)C1(Cl)C2(Cl)Cl,,,,,
http://purl.obolibrary.org/obo/TXPO_0004930,BECN1 (human) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_0005068,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:8678|PMID:25649430,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004930,,,,,,,,,,,,,,,,,,,,,,BECN1 (human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000055331,ACER3,,"Other designations: alkCDase 3|alkaline CDase 3|alkaline dihydroceramidase SB89|alkaline phytoceramidase|phytoceramidase, alkaline",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,APHC|PHCA,,,,,,,,,,,,11,,,,,,HPRD:17844|HGNC:16066,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,alkaline ceramidase 3,,,11q13.5,,,,,,,,,,,,,,,,"GO_0005789 (EC: TAS); GO_0006665 (EC: TAS); GO_0006672 (EC: IEA); GO_0008284 (EC: IMP); GO_0030148 (EC: TAS); GO_0030173 (EC: IDA, PMID: 11356846); GO_0030176 (EC: IDA, PMID: 11356846); GO_0044281 (EC: TAS); GO_0046512 (EC: IDA); GO_0070774 (EC: IDA, PMID: 11356846); GO_0071602 (EC: IDA, PMID: 11356846)",,,,,,,,,PMID: 11356846; 12477932; 14702039; 15489334; 17207965; 18619555; 19322201; 19834535; 19913121; 20068046; 20379614; 20628086; 20706999,,,,,,,,,,,,,,,OGG:3000055331,,,,,,,alkaline ceramidase 3,,,,,,,,,,,,,"Other designations: alkCDase 3|alkaline CDase 3|alkaline dihydroceramidase SB89|alkaline phytoceramidase|phytoceramidase, alkaline",,ACER3,,,,,,,,,,,,,,,,,,,,,,,55331,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,ACER3,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/GO_0045445,myoblast differentiation,myoblast cell differentiation,"The process in which a relatively unspecialized cell acquires specialized features of a myoblast. A myoblast is a mononucleate cell type that, by fusion with other myoblasts, gives rise to the myotubes that eventually develop into striated muscle fibers.",false,,,http://purl.obolibrary.org/obo/TXPO_0002703,,,,,,,,,,,,,,,,,,,,,,"The process in which a relatively unspecialized cell acquires specialized features of a myoblast. A myoblast is a mononucleate cell type that, by fusion with other myoblasts, gives rise to the myotubes that eventually develop into striated muscle fibers.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,myoblast cell differentiation,,,,,GO:0045445,,,,,,,,,,,,,,,,,,,,,,myoblast differentiation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0045444,Adipocyte differentiation,adipose cell differentiation|fat cell differentiation|adipocyte cell differentiation,"The process whereby a relatively unspecialized cell acquires specialized features of an adipocyte, an animal connective tissue cell specialized for the synthesis and storage of fat.",false,,,http://purl.obolibrary.org/obo/GO_0030154,,,,,,,,,,,,,,,,,,,,,,"The process whereby a relatively unspecialized cell acquires specialized features of an adipocyte, an animal connective tissue cell specialized for the synthesis and storage of fat.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000136,,,,,,,,,,,,adipose cell differentiation|fat cell differentiation|adipocyte cell differentiation,,,,,GO:0045444,,,,,,,,,,,,,,,,,,,,,,Adipocyte differentiation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0045446,endothelial cell differentiation,,"The process in which a mesodermal, bone marrow or neural crest cell acquires specialized features of an endothelial cell, a thin flattened cell. A layer of such cells lines the inside surfaces of body cavities, blood vessels, and lymph vessels, making up the endothelium.",false,,,http://purl.obolibrary.org/obo/GO_0030855,,,,,,,,,,,,,,,,,,,,,,"The process in which a mesodermal, bone marrow or neural crest cell acquires specialized features of an endothelial cell, a thin flattened cell. A layer of such cells lines the inside surfaces of body cavities, blood vessels, and lymph vessels, making up the endothelium.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0045446,,,,,,,,,,,,,,,,,,,,,,endothelial cell differentiation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000042,TGF-beta1,transforming growth factor-beta 1,,false,,,http://purl.obolibrary.org/obo/IMR_0000041,,,,,,,,,,,,,,,,,,,,GO:0005160,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,transforming growth factor-beta 1,,,,,IMR:0000042,,,,,,,,,,,,,,,,,,,,,,TGF-beta1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003172,IL-6 - inflammatory cytokine (canonical)[Glutathione depletion],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002045|http://purl.obolibrary.org/obo/IMR_0000010,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:3569|NCBI-Mouse-GeneID:16193|NCBI-Rat-GeneID:24498,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003041,,,,,,,,,,TXPO:0003172,,,,,,,,,,,,,,,,,,,,,,IL-6 - inflammatory cytokine (canonical)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003175,increasing anti-oxidation demand [Glutathione depletion],,"Increasing anti-oxidation demand is a subtype of increasing functional demand: A process changes the functional demand of oxidation to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0003176|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Increasing anti-oxidation demand is a subtype of increasing functional demand: A process changes the functional demand of oxidation to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003177,,,,,,,,,,,TXPO:0003175,,,,,,,,,,,,,,,,,,,,,,increasing anti-oxidation demand [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003177,oxidation-antioxidtion inbalance [Glutathione depletion],,"Oxidation-antioxidtion inbalance is a subtype of imbalance: A process that lacks a balance between oxidation and anti-oxidation that inhibits oxidation.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0002748|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Oxidation-antioxidtion inbalance is a subtype of imbalance: A process that lacks a balance between oxidation and anti-oxidation that inhibits oxidation.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001207,,,,,,,,,,,TXPO:0003177,,,,,,,,,,,,,,,,,,,,,,oxidation-antioxidtion inbalance [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003179,ROS accumulation,,ROS accumulation is a subtype of accumulation of substances in a biological object: A process that keeps ROS (Reactive Oxygen Species) in a biological object.,false,,,http://purl.obolibrary.org/obo/TXPO_0000247,,,,,,,,,,,,,,,,,,,,,,ROS accumulation is a subtype of accumulation of substances in a biological object: A process that keeps ROS (Reactive Oxygen Species) in a biological object.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_26523,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003179,,,,,,,,,,,,,,,,,,,,,,ROS accumulation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003173,reactive oxygen species biosynthetic process [Glutathione depletion],ROS biosynthetic process [Glutathione depletion],"The chemical reaction resulting in the formation of reactive oxygen species, any molecules or ions formed by the incomplete one-electron reduction of oxygen.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/GO_1903409|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"The chemical reaction resulting in the formation of reactive oxygen species, any molecules or ions formed by the incomplete one-electron reduction of oxygen.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003178,,,,,,ROS biosynthetic process [Glutathione depletion],,,,,TXPO:0003173,,,,,,,,,,,,,,,,,,,,,,reactive oxygen species biosynthetic process [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003178,ROS accumulation [Glutathione depletion],ROS accumulation [Glutathione depletion],"ROS accumulation is a subtype of accumulation of substances in a biological object: A process that keeps ROS (Reactive Oxygen Species) in a biological object.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0003179|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"ROS accumulation is a subtype of accumulation of substances in a biological object: A process that keeps ROS (Reactive Oxygen Species) in a biological object.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003174|http://purl.obolibrary.org/obo/TXPO_0001199,,,,,,ROS accumulation [Glutathione depletion],,,,,TXPO:0003178,,,,,,,,,,,,,,,,,,,,,,ROS accumulation [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003170,CYP2E1 (canonical)[Glutathione depletion],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000081|http://purl.obolibrary.org/obo/TXPO_0002045,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1571|NCBI-Mouse-GeneID:13106|NCBI-Rat-GeneID:25086|PMID:21177773,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003170,,,,,,,,,,,,,,,,,,,,,,CYP2E1 (canonical)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003171,CYP3A4 (canonical)[Glutathione depletion],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000082|http://purl.obolibrary.org/obo/TXPO_0002045,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1576|PMID:21177773,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003171,,,,,,,,,,,,,,,,,,,,,,CYP3A4 (canonical)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003174,increasing demand for response to oxidative stress [Glutathione depletion],,"Increasing demand for response to oxidative stress is a subtype of increasing the demand for response to stress: A process that changes the functional demand for the response to the oxidative stress to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0000102|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Increasing demand for response to oxidative stress is a subtype of increasing the demand for response to stress: A process that changes the functional demand for the response to the oxidative stress to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003177,,,,,,,,,,,TXPO:0003174,,,,,,,,,,,,,,,,,,,,,,increasing demand for response to oxidative stress [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003176,increasing anti-oxidation demand,,Increasing anti-oxidation demand is a subtype of increasing functional demand: A process changes the functional demand of oxidation to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000633,,,,,,,,,,,,,,,,,,,,,,Increasing anti-oxidation demand is a subtype of increasing functional demand: A process changes the functional demand of oxidation to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003176,,,,,,,,,,,,,,,,,,,,,,increasing anti-oxidation demand,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000055089,SLC38A4,,Other designations: N amino acid transporter 3|Na(+)-coupled neutral amino acid transporter 4|amino acid transporter A3|amino acid transporter system A3|sodium-coupled neutral amino acid transporter 4|system A amino acid transporter 3|system N amino acid transporter 3,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,ATA3|PAAT|NAT3,,,,,,,,,,,,12,,,,,,HGNC:14679|MIM:608065|Vega:OTTHUMG00000169518|HPRD:12159|Ensembl:ENSG00000139209,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"solute carrier family 38, member 4",,,12q13,,,,,,,,,,,,,,,,GO_0005886 (EC: TAS); GO_0006811 (EC: TAS); GO_0006814 (EC: IEA); GO_0006865 (EC: TAS); GO_0015171 (EC: IEA); GO_0015293 (EC: IEA); GO_0016021 (EC: IEA); GO_0055085 (EC: TAS),,,,,,,,,PMID: 11342143; 11414754; 12477932; 12845534; 14702039; 15489334; 16148032; 16344560; 16712791; 18195088; 18703994; 19015196; 21917917; 22945694,,,,,,,,,,,,,,,OGG:3000055089,,20140408,protein-coding,,,,"solute carrier family 38, member 4",,,,,,,,,,,,,Other designations: N amino acid transporter 3|Na(+)-coupled neutral amino acid transporter 4|amino acid transporter A3|amino acid transporter system A3|sodium-coupled neutral amino acid transporter 4|system A amino acid transporter 3|system N amino acid transporter 3,,SLC38A4,,,,,,,,,,,,,,,,,,,,,,,55089,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,SLC38A4,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000287,PLD,phospholipase D,,false,,,http://purl.obolibrary.org/obo/TXPO_0000635,,,,,,,,,,,,,,,,,,,,EC:3.1.4.4|GO:0004630,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003671,,,,,phospholipase D,,,,,IMR:0000287,,,,,,,,,,,,,,,,,,,,,,PLD,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0009236,cobalamin biosynthetic process,vitamin B12 biosynthesis,"The chemical reactions and pathways resulting in the formation of cobalamin (vitamin B12), a water-soluble vitamin characterized by possession of a corrin nucleus containing a cobalt atom.",false,,,http://purl.obolibrary.org/obo/GO_0009058,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways resulting in the formation of cobalamin (vitamin B12), a water-soluble vitamin characterized by possession of a corrin nucleus containing a cobalt atom.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,vitamin B12 biosynthesis,,,,,GO:0009236,,,,,,,,,,,,,,,,,,,,,,cobalamin biosynthetic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000823,MafK,,,false,,,http://purl.obolibrary.org/obo/IMR_0000411,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000823,,,,,,,,,,,,,,,,,,,,,,MafK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_2110009606,RNA gene of Homo sapiens,,A gene of Homo sapiens that has a RNA gene disposition,false,,,http://purl.obolibrary.org/obo/OGG_2000009606,,,,,,,,,,,,,,,,,,,,,,A gene of Homo sapiens that has a RNA gene disposition,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,OGG:2110009606,,,,,,,,,,,,,,,,,,,,,,RNA gene of Homo sapiens,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9606,,,,,,,,,,,,,,,,,,,,,"Bin Zhao, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001401,CRP,,Other designations: C-reactive protein|pentraxin 1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,PTX1,,,,,,,,,,,,1,,,,,,Ensembl:ENSG00000132693|Vega:OTTHUMG00000035344|HPRD:00422|HGNC:2367|MIM:123260,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"C-reactive protein, pentraxin-related",,,1q23.2,,,,,,,,,,,,,,,,"GO_0001666 (EC: IEA); GO_0005515 (EC: IPI, PMID: 17785206); GO_0005576 (EC: NAS, PMID: 14718574); GO_0005615 (EC: IEA); GO_0006953 (EC: TAS, PMID: 2477488); GO_0006954 (EC: TAS, PMID: 10408362); GO_0006958 (EC: IEA); GO_0007568 (EC: IEA); GO_0008228 (EC: TAS, PMID: 2477488); GO_0010288 (EC: IEA); GO_0010745 (EC: IDA, PMID: 18322245); GO_0010888 (EC: IDA, PMID: 18322245); GO_0015485 (EC: IEA); GO_0030169 (EC: IDA, PMID: 18322245); GO_0030175 (EC: IEA); GO_0030426 (EC: IEA); GO_0033265 (EC: TAS, PMID: 2477488); GO_0042060 (EC: IEA); GO_0042803 (EC: IEA); GO_0045471 (EC: IEA); GO_0046872 (EC: IEA); GO_0050830 (EC: TAS, PMID: 2477488); GO_0051258 (EC: IEA); GO_0071277 (EC: IEA); GO_1900006 (EC: IEA)",,,,,,,,,PMID: 265538; 403526; 762075; 1477104; 1989977; 2477447; 2477488; 2997165; 3759147; 3840479; 6427230; 6685157; 6693419; 6857266; 7881902; 8144569; 8482924; 8599761; 8613143; 10368284; 10408362; 10490997; 10675363; 11027634; 11739301; 11801683; 11857055; 11947917; 11964845; 11991668; 12033985; 12037301; 12055255; 12102655; 12104096; 12151853; 12186793; 12198121; 12213988; 12218140; 12234944; 12244213; 12351483; 12390313; 12393563; 12426217; 12426218; 12460042; 12471137; 12477932; 12529491; 12552583; 12563060; 12594844; 12616974; 12618085; 12637157; 12654086; 12663465; 12701054; 12716818; 12783932; 12819031; 12821545; 12835213; 12835218; 12842840; 12850811; 12869354; 12892901; 12934049; 12975260; 14500938; 14506615; 14508181; 14592848; 14634117; 14718574; 14744975; 14967730; 14967837; 14983228; 15044210; 15047644; 15078802; 15136507; 15271790; 15277326; 15286457; 15304023; 15306744; 15308783; 15337754; 15358216; 15380464; 15448085; 15456743; 15469865; 15472120; 15489334; 15517131; 15565375; 15579759; 15585208; 15585211; 15585215; 15585218; 15591095; 15653107; 15692104; 15735209; 15746456; 15766555; 15772777; 15777561; 15778807; 15795363; 15797975; 15798948; 15798966; 15808312; 15853546; 15859024; 15860734; 15866055; 15867284; 15878871; 15887860; 15894122; 15894827; 15897982; 15919817; 15920036; 15920065; 15920074; 15950309; 15955385; 15955391; 15993896; 15996056; 15997206; 16005364; 16005367; 16026589; 16051899; 16061741; 16087790; 16087807; 16109328; 16123325; 16131811; 16148535; 16151032; 16153429; 16170833; 16189249; 16213874; 16221209; 16257408; 16266402; 16306468; 16344720; 16352308; 16380821; 16405882; 16409458; 16417933; 16500582; 16501036; 16511556; 16534007; 16549465; 16550411; 16565153; 16580524; 16582918; 16603696; 16618976; 16643876; 16681424; 16682383; 16685271; 16698114; 16710414; 16719793; 16723442; 16731635; 16733231; 16751408; 16764962; 16765355; 16778366; 16803998; 16809555; 16809564; 16832147; 16832152; 16840032; 16847147; 16854501; 16858645; 16864904; 16879213; 16881737; 16908949; 16916777; 16963054; 16984505; 17003778; 17011566; 17044846; 17079491; 17082472; 17101857; 17110595; 17113035; 17113059; 17114654; 17126343; 17138933; 17141244; 17143564; 17148079; 17149558; 17157301; 17164456; 17185152; 17202380; 17211240; 17219082; 17220790; 17234298; 17261875; 17264952; 17279354; 17289011; 17292342; 17293598; 17325687; 17327459; 17335789; 17335903; 17343862; 17347578; 17350021; 17351284; 17355554; 17355643; 17369452; 17372148; 17380191; 17382928; 17383146; 17395501; 17400881; 17433639; 17449131; 17449922; 17452737; 17456635; 17459567; 17460724; 17477779; 17477815; 17498578; 17499233; 17511977; 17513778; 17519779; 17530289; 17531242; 17561469; 17573060; 17575367; 17581635; 17584642; 17588586; 17596285; 17597836; 17598370; 17600233; 17613401; 17615382; 17623721; 17623828; 17635239; 17641153; 17650829; 17652082; 17652155; 17653654; 17673235; 17676666; 17693973; 17697822; 17700210; 17702862; 17702963; 17706955; 17714716; 17714718; 17722225; 17763921; 17765290; 17785206; 17785926; 17806085; 17827818; 17845537; 17851127; 17851695; 17852082; 17852826; 17873311; 17878721; 17878753; 17880812; 17885262; 17888441; 17891599; 17900590; 17903293; 17909163; 17917609; 17920229; 17925606; 17934713; 17942113; 17943468; 17952446; 17956875; 17957146; 17981284; 17991470; 18000615; 18005189; 18023360; 18036188; 18054331; 18055473; 18055714; 18056120; 18060926; 18063701; 18071779; 18075240; 18078625; 18083122; 18096828; 18165866; 18167554; 18171282; 18172744; 18178503; 18182444; 18200582; 18206145; 18214695; 18216376; 18217154; 18218989; 18219371; 18219765; 18226363; 18226879; 18235049; 18241613; 18245530; 18250134; 18262272; 18263601; 18266777; 18279706; 18280482; 18285551; 18285696; 18288276; 18289549; 18296838; 18297417; 18305316; 18312679; 18316365; 18322245; 18327405; 18328265; 18332893; 18333373; 18344622; 18347271; 18347963; 18356846; 18359028; 18362454; 18365276; 18369665; 18372435; 18373721; 18378435; 18379563; 18383516; 18385179; 18385676; 18385743; 18385816; 18386294; 18388036; 18388037; 18389332; 18393253; 18394761; 18401567; 18403728; 18404970; 18412163; 18413218; 18414778; 18415802; 18418236; 18421029; 18422436; 18425592; 18428198; 18433460; 18436879; 18436884; 18439548; 18439552; 18443549; 18450770; 18458051; 18464913; 18476570; 18486609; 18489822; 18491455; 18493116; 18499652; 18500540; 18505467; 18508060; 18513241; 18513823; 18523031; 18541797; 18551710; 18556380; 18562472; 18566104; 18573122; 18573197; 18573495; 18577830; 18591402; 18605934; 18607165; 18609082; 18609102; 18616717; 18621860; 18622582; 18624398; 18632424; 18636307; 18650775; 18654020; 18654021; 18667998; 18675273; 18676680; 18685607; 18688084; 18695743; 18700811; 18702945; 18704199; 18704713; 18708524; 18710885; 18714381; 18714384; 18753723; 18753952; 18755462; 18757054; 18759279; 18764931; 18784972; 18785307; 18786923; 18790479; 18791482; 18793001; 18801352; 18805107; 18805592; 18810599; 18810717; 18818748; 18823889; 18829218; 18835219; 18836266; 18840622; 18841009; 18842294; 18842390; 18845301; 18852001; 18853099; 18853133; 18924263; 18937150; 18948966; 18952164; 18953261; 18957790; 18971492; 18974842; 18983663; 18996288; 18997194; 19004040; 19008293; 19010993; 19011614; 19019335; 19023151; 19025443; 19026696; 19029268; 19034331; 19040303; 19055599; 19060910; 19067532; 19072030; 19073362; 19074515; 19074985; 19075099; 19076828; 19077177; 19077918; 19078972; 19081678; 19084272; 19095725; 19096002; 19100387; 19101671; 19111610; 19117239; 19118119; 19122170; 19125286; 19128923; 19130414; 19136614; 19136826; 19138871; 19139603; 19139754; 19147740; 19155486; 19160050; 19168253; 19170196; 19170684; 19172699; 19178964; 19179966; 19188531; 19191811; 19193941; 19201044; 19201207; 19202332; 19203753; 19225207; 19228486; 19238141; 19240794; 19244088; 19248087; 19251259; 19252093; 19255512; 19262552; 19267250; 19267370; 19268605; 19268941; 19270348; 19272152; 19276622; 19281089; 19282426; 19282606; 19282863; 19297430; 19297456; 19322079; 19323703; 19328934; 19337791; 19343415; 19351632; 19358836; 19359657; 19360108; 19362308; 19369869; 19375128; 19377212; 19377253; 19387251; 19390179; 19394732; 19403254; 19410251; 19415164; 19415283; 19423540; 19426506; 19428053; 19433520; 19436122; 19436291; 19436676; 19436686; 19437230; 19439300; 19439303; 19461040; 19469014; 19473152; 19480860; 19482283; 19492468; 19494488; 19495883; 19499327; 19501581; 19501644; 19520972; 19521085; 19522741; 19523464; 19525580; 19527514; 19533498; 19534672; 19538326; 19545442; 19560102; 19565490; 19567438; 19568166; 19571581; 19576194; 19577754; 19578796; 19584180; 19594772; 19595394; 19602903; 19609738; 19614793; 19615354; 19617288; 19619902; 19620133; 19624831; 19625176; 19626399; 19631649; 19642908; 19643839; 19643942; 19644070; 19645035; 19667982; 19670170; 19680263; 19692124; 19692168; 19695857; 19706826; 19715516; 19719987; 19719993; 19728551; 19729797; 19736474; 19736479; 19751919; 19755616; 19760027; 19762396; 19762397; 19766699; 19783155; 19796676; 19800416; 19801321; 19806245; 19808368; 19816865; 19816870; 19818961; 19821022; 19833744; 19834334; 19850242; 19850925; 19851048; 19853918; 19855269; 19857655; 19857676; 19864399; 19874580; 19879773; 19900432; 19903811; 19906786; 19913121; 19914996; 19923014; 19929715; 19931932; 19942863; 19944144; 19946607; 19947988; 19948975; 19954777; 19956729; 19962488; 19965533; 20004425; 20005739; 20006362; 20017311; 20024640; 20031768; 20034371; 20036017; 20042240; 20047081; 20056225; 20056955; 20060752; 20068351; 20074254; 20075180; 20075509; 20075574; 20078870; 20078877; 20083961; 20131075; 20136960; 20138378; 20142117; 20145391; 20145925; 20170291; 20173307; 20179497; 20184510; 20184533; 20184536; 20186934; 20190687; 20200626; 20200627; 20211068; 20214668; 20215002; 20219150; 20220110; 20227257; 20227921; 20233980; 20237496; 20306065; 20333461; 20339115; 20339904; 20346360; 20346514; 20348053; 20359087; 20371432; 20386340; 20403997; 20406964; 20423474; 20423919; 20437055; 20438785; 20443669; 20453000; 20453690; 20465852; 20466978; 20485444; 20489166; 20494358; 20494378; 20502295; 20511616; 20522534; 20531240; 20537668; 20538124; 20538278; 20538960; 20539018; 20546810; 20552244; 20556836; 20573938; 20581772; 20587599; 20592333; 20596037; 20596713; 20599197; 20605213; 20610232; 20614004; 20618287; 20623261; 20626020; 20626239; 20626701; 20628086; 20638228; 20640440; 20651278; 20669343; 20670634; 20676960; 20679960; 20680929; 20683147; 20686879; 20690093; 20691829; 20703235; 20704541; 20706769; 20709501; 20722986; 20727736; 20730440; 20733302; 20734449; 20797493; 20805569; 20813565; 20819268; 20836727; 20843812; 20846522; 20846939; 20850446; 20852043; 20855282; 20855565; 20856253; 20874781; 20877716; 20881941; 20883364; 20929576; 20929699; 20930309; 20939118; 20949557; 20952358; 20967757; 20972697; 20974458; 20978825; 20979755; 21029360; 21029457; 21033124; 21034294; 21037097; 21037509; 21043803; 21044752; 21044781; 21054666; 21054877; 21059738; 21062467; 21067752; 21071964; 21080913; 21081932; 21086905; 21089116; 21094359; 21105323; 21108561; 21135979; 21136015; 21143859; 21143879; 21146168; 21149504; 21161711; 21162890; 21167068; 21172733; 21173097; 21173540; 21182750; 21190868; 21194909; 21195701; 21196492; 21203342; 21204606; 21215477; 21218608; 21226995; 21258804; 21270838; 21284020; 21287288; 21293934; 21294915; 21296145; 21296900; 21300955; 21305296; 21309051; 21309632; 21315565; 21323571; 21324310; 21325005; 21325757; 21357282; 21357824; 21360619; 21383176; 21402418; 21404895; 21406102; 21413847; 21414621; 21415385; 21444086; 21447704; 21455669; 21458205; 21465964; 21468168; 21476028; 21493089; 21508123; 21516340; 21519150; 21526633; 21536287; 21546857; 21553357; 21565862; 21570260; 21575917; 21592994; 21602602; 21617097; 21624120; 21625240; 21630214; 21640994; 21645137; 21647738; 21655904; 21658317; 21679689; 21685272; 21696613; 21697747; 21700090; 21714897; 21716910; 21719129; 21720757; 21729568; 21729973; 21730823; 21737650; 21740772; 21741099; 21757662; 21773944; 21794939; 21801245; 21804277; 21814873; 21816845; 21819975; 21821037; 21831326; 21832113; 21839826; 21843630; 21845926; 21856781; 21859817; 21868617; 21872279; 21883780; 21890096; 21901123; 21915265; 21923250; 21928234; 21931794; 21933586; 21934067; 21937998; 21951717; 21958326; 21970447; 21988832; 21993388; 22004660; 22014839; 22018511; 22019947; 22019953; 22025173; 22025360; 22038335; 22048011; 22055258; 22056216; 22079264; 22082888; 22095223; 22103876; 22104116; 22119118; 22134501; 22153152; 22158621; 22166506; 22178353; 22190020; 22192441; 22196954; 22203929; 22205174; 22208681; 22222005; 22241816; 22257305; 22260948; 22267327; 22267750; 22267767; 22277294; 22284830; 22291609; 22296194; 22297435; 22306563; 22311704; 22316266; 22316276; 22328138; 22329434; 22330622; 22357713; 22365588; 22392590; 22418747; 22418989; 22428468; 22430136; 22435454; 22437883; 22444955; 22446726; 22449109; 22457095; 22459389; 22464286; 22467322; 22474034; 22490475; 22492993; 22497530; 22529527; 22533665; 22545649; 22547903; 22552174; 22554299; 22556030; 22558327; 22562290; 22569431; 22569435; 22570140; 22576068; 22580582; 22588996; 22607374; 22614460; 22617158; 22641545; 22642594; 22645408; 22672862; 22676422; 22681496; 22683644; 22685243; 22685586; 22732721; 22748017; 22750226; 22763479; 22780440; 22783580; 22783989; 22796263; 22801596; 22813435; 22813921; 22816656; 22821639; 22828776; 22832641; 22836155; 22843654; 22847196; 22857740; 22867744; 22869540; 22875408; 22875596; 22884413; 22901456; 22906275; 22906998; 22911253; 22912790; 22914173; 22918393; 22939635; 22949303; 22957001; 22976070; 22982460; 22989605; 23013513; 23026925; 23046580; 23049543; 23066418; 23078984; 23087143; 23087294; 23104422; 23111890; 23116190; 23116196; 23124693; 23125484; 23126320; 23132698; 23139417; 23151748; 23158132; 23159256; 23166385; 23170819; 23182717; 23197238; 23197841; 23206444; 23212397; 23212764; 23220502; 23221172; 23224322; 23225486; 23228375; 23241067; 23254637; 23254959; 23257175; 23257395; 23263911; 23266263; 23270673; 23272049; 23274882; 23277135; 23285029; 23288467; 23306163; 23343124; 23361365; 23367494; 23375121; 23375154; 23379491; 23383155; 23393371; 23399387; 23401350; 23409097; 23425215; 23434327; 23440541; 23450030; 23463453; 23468212; 23484158; 23492986; 23516493; 23518675; 23527487; 23535585; 23547018; 23575330; 23576062; 23578742; 23579782; 23591413; 23592000; 23604041; 23618082; 23627410; 23635436; 23674518; 23692330; 23697277; 23702388; 23724031; 23724977; 23742758; 23766379; 23773138; 23784529; 23803251; 23808014; 23813138; 23813850; 23828261; 23835994; 23844046; 23852903; 23888317; 23910616; 23911413; 23935961; 23941472; 23968978; 24055729; 24072695; 24084772; 24097561; 24163955; 24206243; 24222149; 24222151; 24262327; 24347428; 24379064; 24403485; 24434384; 24440351,,,,,,,,,,,,,,,OGG:3000001401,,,,,,,"C-reactive protein, pentraxin-related",,,,,,,,,,,,,Other designations: C-reactive protein|pentraxin 1,,CRP,,,,,,,,,,,,,,,,,,,,,,,1401,RP11-419N10.4,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,CRP,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_50750,EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor,EC 5.99.1.3 (DNA topoisomerase (ATP-hydrolysing)) inhibitors|type II DNA topoisomerase inhibitors|inhibitors of type II topoisomerase|type II DNA topoisomerase inhibitor|DNA gyrase inhibitor|topoisomerase-II inhibitor|topoisomerase II inhibitors|EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitors|DNA topoisomerase II inhibitor|topoisomerase-II inhibitors|DNA topoisomerase (ATP-hydrolysing) inhibitor|inhibitor of type II topoisomerase|topoisomerase II inhibitor|DNA topoisomerase (ATP-hydrolysing) (EC 5.99.1.3) inhibitor|EC 5.99.1.3 inhibitor|DNA topoisomerase II inhibitors|DNA topoisomerase (ATP-hydrolysing) (EC 5.99.1.3) inhibitors|DNA topoisomerase (ATP-hydrolysing) inhibitors|DNA gyrase inhibitors|EC 5.99.1.3 inhibitors|EC 5.99.1.3 (DNA topoisomerase (ATP-hydrolysing)) inhibitor,"A topoisomerase inhibitor that inhibits DNA topoisomerase (ATP-hydrolysing), EC 5.99.1.3 (also known as topoisomerase II and as DNA gyrase), which catalyses ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands.",false,,,http://purl.obolibrary.org/obo/CHEBI_70727,,,,,,,,,,,,,,,,,,,,,,"A topoisomerase inhibitor that inhibits DNA topoisomerase (ATP-hydrolysing), EC 5.99.1.3 (also known as topoisomerase II and as DNA gyrase), which catalyses ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,EC 5.99.1.3 (DNA topoisomerase (ATP-hydrolysing)) inhibitors|type II DNA topoisomerase inhibitors|inhibitors of type II topoisomerase|type II DNA topoisomerase inhibitor|DNA gyrase inhibitor|topoisomerase-II inhibitor|topoisomerase II inhibitors|EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitors|DNA topoisomerase II inhibitor|topoisomerase-II inhibitors|DNA topoisomerase (ATP-hydrolysing) inhibitor|inhibitor of type II topoisomerase|topoisomerase II inhibitor|DNA topoisomerase (ATP-hydrolysing) (EC 5.99.1.3) inhibitor|EC 5.99.1.3 inhibitor|DNA topoisomerase II inhibitors|DNA topoisomerase (ATP-hydrolysing) (EC 5.99.1.3) inhibitors|DNA topoisomerase (ATP-hydrolysing) inhibitors|DNA gyrase inhibitors|EC 5.99.1.3 inhibitors|EC 5.99.1.3 (DNA topoisomerase (ATP-hydrolysing)) inhibitor,,,,,,,,,,,,,,,,,,,,,CHEBI:50750,,,,EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor,,CHEBI:50750,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0000479,tissue,simple tissue|portion of tissue|tissue portion,"Multicellular anatomical structure that consists of many cells of one or a few types, arranged in an extracellular matrix such that their long-range organisation is at least partly a repetition of their short-range organisation.",false,,,http://purl.obolibrary.org/obo/TXPO_0000065|http://purl.obolibrary.org/obo/UBERON_0010000,,,,,,,,,,,,,,,,,,,,http://linkedlifedata.com/resource/umls/id/C0040300|http://uri.neuinfo.org/nif/nifstd/birnlex_19|http://purl.obolibrary.org/obo/NCIT_C12801|BILA:0000043|FBbt:00007003|EMAPA:35868|TAO:0001477|UMLS:C0040300|galen:Tissue|AEO:0000043|CALOHA:TS-2090|FMA:9637|MA:0003002|VHOG:0001757|WBbt:0005729|AAO:0010054|HAO:0000043|MESH:D014024|AAO:0000607|XAO:0003040|EHDAA2:0003043|ZFA:0001477|TGMA:0001844|CARO:0000043,,"Multicellular anatomical structure that consists of many cells of one or a few types, arranged in an extracellular matrix such that their long-range organisation is at least partly a repetition of their short-range organisation.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,portion of tissue|tissue portion,simple tissue,,,,UBERON:0000479,,,,,,,,,,,,,,,,,,,,,,tissue,,,,,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000048,neuregulin,NRG,,false,,,http://purl.obolibrary.org/obo/IMR_0000047,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,NRG,,,,,IMR:0000048,,,,,,,,,,,,,,,,,,,,,,neuregulin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_44423,hydroxyurea,hydroxycarbamidum|hydroxycarbamide|Hydroxycarbamide|Hydroxycarbamid|N-carbamoylhydroxylamine|N-HYDROXYUREA|hydrea|carbamoyl oxime|carbamohydroxamic acid|oxyurea|carbamohydroximic acid|hidroxicarbamida|Hydroxyharnstoff|carbamyl hydroxamate|Hydroxyurea|N-hydroxyurea|hydroxyurea,A member of the class of ureas that is urea in which one of the hydrogens is replaced by a hydroxy group. An antineoplastic used in the treatment of chronic myeloid leukaemia as well as for sickle-cell disease.,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:22983419|PMID:11391710|PMID:14988684|CAS:127-07-1|PMID:23318979|PMID:11285159|PMID:23643402|DrugBank:DB01005|PMID:11365149|PMID:11298103|PMID:16356682|PMID:11364534|Drug_Central:1399|PMID:9271088|PMID:15994344|PMID:15772364|Reaxys:1741548|Gmelin:130423|Beilstein:1741548|PMID:23696560|PMID:12107454,,A member of the class of ureas that is urea in which one of the hydrogens is replaced by a hydroxy group. An antineoplastic used in the treatment of chronic myeloid leukaemia as well as for sickle-cell disease.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_50905|http://purl.obolibrary.org/obo/CHEBI_35610|http://purl.obolibrary.org/obo/CHEBI_50846|http://purl.obolibrary.org/obo/CHEBI_59517|http://purl.obolibrary.org/obo/CHEBI_35221|http://purl.obolibrary.org/obo/CHEBI_50902|http://purl.obolibrary.org/obo/CHEBI_64911|http://purl.obolibrary.org/obo/CHEBI_74213|http://purl.obolibrary.org/obo/CHEBI_48578,,,,,Hydroxyurea|N-hydroxyurea|hydroxyurea,,hydroxycarbamidum|hydroxycarbamide|Hydroxycarbamide|Hydroxycarbamid|N-carbamoylhydroxylamine|N-HYDROXYUREA|hydrea|carbamoyl oxime|carbamohydroxamic acid|oxyurea|carbamohydroximic acid|hidroxicarbamida|Hydroxyharnstoff|carbamyl hydroxamate,,,,,,,,,,,,,,,,,,,,,CHEBI:44423,,,,hydroxyurea,,CHEBI:44423,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0036503,ERAD pathway,protein degradation by ERAD|endoplasmic reticulum-associated degradation,"The protein catabolic pathway which targets endoplasmic reticulum (ER)-resident proteins for degradation by the cytoplasmic proteasome. It begins with recognition of the ER-resident protein, includes retrotranslocation (dislocation) of the protein from the ER to the cytosol, protein modifications necessary for correct substrate transfer (e.g. ubiquitination), transport of the protein to the proteasome, and ends with degradation of the protein by the cytoplasmic proteasome.|ER-associated protein degradation (ERAD) pathways target misfolded ER lumenal proteins (ERAD-L), ER membrane proteins (ERAD-M), and ER proteins with misfolded cytosolic domains (ERAD-C) by recognizing aberrant proteins, retrotranslocating these substrates to the cytosol, followed by substrate ubiquitination and proteosomal-mediated degradation. In contrast the stress-induced homeostatically regulated protein degradation (SHRED) pathway (GO:0120174), although inducible by stress, targets diverse ER membrane, and cytosolic proteins as well as numerous other native proteins in the absence of stress. Stress results in the protease-mediated (Nma111p) generation of a Roq1p cleavage product that then binds to the type-1 active site of Ubr1p, altering its substrate specificity, and leading to the proteasome-mediated degradation of both misfolded and native proteins. Although the SHRED pathway may contain some components in common with ERAD pathways (GO:0036503), such as UBR1, RAD6 and CDC48, other ERAD components, such as HRD1 and DOA10, do not appear to be involved, and as such these pathways are currently considered to be distinct.",false,,,http://purl.obolibrary.org/obo/GO_0010498,,,,,,,,,,,,,,,,,,,,,,"The protein catabolic pathway which targets endoplasmic reticulum (ER)-resident proteins for degradation by the cytoplasmic proteasome. It begins with recognition of the ER-resident protein, includes retrotranslocation (dislocation) of the protein from the ER to the cytosol, protein modifications necessary for correct substrate transfer (e.g. ubiquitination), transport of the protein to the proteasome, and ends with degradation of the protein by the cytoplasmic proteasome.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,protein degradation by ERAD|endoplasmic reticulum-associated degradation,,,,,GO:0036503,,,,,,,,,,,,,,,,,,,,"ER-associated protein degradation (ERAD) pathways target misfolded ER lumenal proteins (ERAD-L), ER membrane proteins (ERAD-M), and ER proteins with misfolded cytosolic domains (ERAD-C) by recognizing aberrant proteins, retrotranslocating these substrates to the cytosol, followed by substrate ubiquitination and proteosomal-mediated degradation. In contrast the stress-induced homeostatically regulated protein degradation (SHRED) pathway (GO:0120174), although inducible by stress, targets diverse ER membrane, and cytosolic proteins as well as numerous other native proteins in the absence of stress. Stress results in the protease-mediated (Nma111p) generation of a Roq1p cleavage product that then binds to the type-1 active site of Ubr1p, altering its substrate specificity, and leading to the proteasome-mediated degradation of both misfolded and native proteins. Although the SHRED pathway may contain some components in common with ERAD pathways (GO:0036503), such as UBR1, RAD6 and CDC48, other ERAD components, such as HRD1 and DOA10, do not appear to be involved, and as such these pathways are currently considered to be distinct.",,ERAD pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0036500,ATF6-mediated unfolded protein response,activating transcription factor 6 signaling in unfolded protein response|endoplasmic reticulum unfolded protein response; ATF6 signaling,"A series of molecular signals mediated by the endoplasmic reticulum membrane stress sensor ATF6 (activating transcription factor 6). Begins with activation of ATF6 in response to endoplasmic reticulum (ER) stress, and ends with regulation of a downstream cellular process, e.g. transcription. Under conditions of endoplasmic reticulum stress, ATF6 translocates to the Golgi where it is processed by proteases to release a cytoplasmic domain (ATF6f), which operates as a transcriptional activator of many genes required to restore folding capacity.",false,,,http://purl.obolibrary.org/obo/TXPO_0002126,,,,,,,,,,,,,,,,,,,,,,"A series of molecular signals mediated by the endoplasmic reticulum membrane stress sensor ATF6 (activating transcription factor 6). Begins with activation of ATF6 in response to endoplasmic reticulum (ER) stress, and ends with regulation of a downstream cellular process, e.g. transcription. Under conditions of endoplasmic reticulum stress, ATF6 translocates to the Golgi where it is processed by proteases to release a cytoplasmic domain (ATF6f), which operates as a transcriptional activator of many genes required to restore folding capacity.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,activating transcription factor 6 signaling in unfolded protein response|endoplasmic reticulum unfolded protein response; ATF6 signaling,,,,,GO:0036500,,,,,,,,,,,,,,,,,,,,,,ATF6-mediated unfolded protein response,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100429,GAP1(IP4BP),Ins P4-binding protein,,false,,,http://purl.obolibrary.org/obo/IMR_0000443,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ins P4-binding protein,,,,,IMR:0100429,,,,,,,,,,,,,,,,,,,,,,GAP1(IP4BP),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000010670,RRAGA,,Other designations: adenovirus E3 14.7 kDa-interacting protein 1|adenovirus E3-14.7K interacting protein 1|rag A|ras-related GTP-binding protein A,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,FIP1|FIP-1|RAGA,,,,,,,,,,,,9,,,,,,HPRD:10205|MIM:612194|Vega:OTTHUMG00000019621|Ensembl:ENSG00000155876|HGNC:16963,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,Ras-related GTP binding A,,,9p22.1,,,,,,,,,,,,,,,,"GO_0005515 (EC: IPI, PMID: 11073942); GO_0005525 (EC: IDA, PMID: 14660641); GO_0005634 (EC: IDA, PMID: 11073942); GO_0005737 (EC: IDA, PMID: 11073942); GO_0005764 (EC: IDA); GO_0005765 (EC: IDA, PMID: 17897319); GO_0005794 (EC: IDA); GO_0006915 (EC: IEA); GO_0008219 (EC: IDA, PMID: 8995684); GO_0019048 (EC: IDA, PMID: 8995684); GO_0032008 (EC: NAS); GO_0034613 (EC: IMP); GO_0042803 (EC: IDA, PMID: 14660641); GO_0043231 (EC: IDA); GO_0045919 (EC: IDA, PMID: 8995684); GO_0046982 (EC: IPI, PMID: 11073942); GO_0051219 (EC: IDA, PMID: 8995684); GO_0071230 (EC: IMP)",,,,,,,,,PMID: 7499430; 8995684; 9394008; 11073942; 12477932; 14660641; 14749727; 15164053; 15489334; 16189514; 17897319; 18029348; 18497260; 18685082; 19136632; 21816923; 21890473; 21981924; 23000965; 23151878; 23184942,,,,,,,,,,,,,,,OGG:3000010670,,,,,,,Ras-related GTP binding A,,,,,,,,,,,,,Other designations: adenovirus E3 14.7 kDa-interacting protein 1|adenovirus E3-14.7K interacting protein 1|rag A|ras-related GTP-binding protein A,,RRAGA,,,,,,,,,,,,,,,,,,,,,,,10670,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,RRAGA,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000378,STAT4,signal transducer and activator of transcription 4,,false,,,http://purl.obolibrary.org/obo/IMR_0000374,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,signal transducer and activator of transcription 4,,,,,IMR:0000378,,,,,,,,,,,,,,,,,,,,,,STAT4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000217,Fak/Pyk2,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001054,,,,,,,,,,IMR:0000217,,,,,,,,,,,,,,,,,,,,,,Fak/Pyk2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004021,Rad51b [Hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000837|http://purl.obolibrary.org/obo/TXPO_1000322,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:5890|NCBI-Rat-GeneID:500679|NCBI-Mouse-GeneID:19363|PMID:15065660|PMID:12427746,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004021,,,,,,,,,,,,,,,,,,,,,,Rad51b [Hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004024,FLCN [Hepatocarcinogenesis],folliculin [Hepatocarcinogenesis],,false,,,http://purl.obolibrary.org/obo/TXPO_0000837|http://purl.obolibrary.org/obo/TXPO_1000148,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:216805|NCBI-Rat-GeneID:303185|NCBI-Human-GeneID:201163|PMID:17028174|PMID:26334087,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,folliculin [Hepatocarcinogenesis],,,,,TXPO:0004024,,,,,,,"This gene is located within the Smith-Magenis syndrome region on chromosome 17. Mutations in this gene are associated with Birt-Hogg-Dube syndrome, which is characterized by fibrofolliculomas, renal tumors, lung cysts, and pneumothorax. Alternative splicing of this gene results in two transcript variants encoding different isoforms. [provided by RefSeq, Jul 2008]",,,,,,,,,,,,,,,FLCN [Hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004023,metabolic regulator role,,A role played by the entity  which regulates the metabolism.,false,,,http://purl.obolibrary.org/obo/TXPO_0003230,,,,,,,,,,,,,,,,,,,,,,A role played by the entity  which regulates the metabolism.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004023,,,,,,,,,,,,,,,,,,,,,,metabolic regulator role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004022,Abc1b1  [Hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000837|http://purl.obolibrary.org/obo/TXPO_1000015,,,,,,,,,,,,,,,,,,,,PMID:21039338|PMID:20075923|http://purl.obolibrary.org/obo/OGG_3000005243|http://omim.org/entry/171050|http://purl.obolibrary.org/obo/NCIT_C17966|PMID:17593618,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000331,,,,,,,,,,TXPO:0004022,,,,,,,,,,,,,,,,,,,,,,Abc1b1  [Hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004025,Cd44 [Hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000837|http://purl.obolibrary.org/obo/IMR_0000649,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:25406|NCBI-Mouse-GeneID:12505|NCBI-Human-GeneID:960,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004025,,,,,,,,,,,,,,,,,,,,,,Cd44 [Hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004028,TOR signaling (primitive),,TOR signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the TOR (Target of rapamycin) .,false,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,,,TOR signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the TOR (Target of rapamycin) .,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0031929,,,,,,,,,,,,,,,,TXPO:0004028,,,,,,,,,,,,,,,,,,,,,,TOR signaling (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004029,ZNF385B [Hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000837|http://purl.obolibrary.org/obo/TXPO_1000406,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:151126|PMID:23029477|PMID:22945289,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004029,,,,,,,,,,,,,,,,,,,,,,ZNF385B [Hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004020,MTOR (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,https://omim.org/entry/601231|NCBI-Mouse-GeneID:56717|NCBI-Rat-GeneID:56718|NCBI-Human-GeneID:2475,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004020,,,,,,,,,,,,,,,,,,,,,,MTOR (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004026,MTOR (canonical) [phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003213|http://purl.obolibrary.org/obo/TXPO_0004020,,,,,,,,,,,,,,,,,,,,PMID:17028174|https://omim.org/entry/601231|NCBI-Mouse-GeneID:56717|NCBI-Rat-GeneID:56718|NCBI-Human-GeneID:2475,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004026,,,,,,,,,,,,,,,,,,,,,,MTOR (canonical) [phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004027,Hist1h2bcl1 [Hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000194|http://purl.obolibrary.org/obo/TXPO_0000837,,,,,,,,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/gene/680403|NCBI-Rat-GeneID:680403,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004027,,,,,,,,,,,,,,,,,,,,,,Hist1h2bcl1 [Hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CL_0000451,dendritic cell,,"A cell of hematopoietic origin, typically resident in particular tissues, specialized in the uptake, processing, and transport of antigens to lymph nodes for the purpose of stimulating an immune response via T cell activation. These cells are lineage negative (CD3-negative, CD19-negative, CD34-negative, and CD56-negative).",false,,,http://purl.obolibrary.org/obo/CL_0000738,,,,,,,,,,,,,,,,,,,,,,"A cell of hematopoietic origin, typically resident in particular tissues, specialized in the uptake, processing, and transport of antigens to lymph nodes for the purpose of stimulating an immune response via T cell activation. These cells are lineage negative (CD3-negative, CD19-negative, CD34-negative, and CD56-negative).",,,,,dendritic cell,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CL:0000451,,,,,,,,,,,,,,,,,,,,,,dendritic cell,,,,,,,http://purl.obolibrary.org/obo/cl.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/NCIT_C16507,DNA damage,,"Drug-, radiation-induced, or spontaneous injuries to DNA that introduce deviations from its normal double-helical conformation. These changes include structural distortions that interfere with replication and transcription, as well as point mutations that disrupt base pairs and exert damaging effects on future generations through changes in DNA sequence. If the damage is minor, it can often be repaired (DNA repair); extensive damage can induce apoptosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000222,,,,,,,,,,,,,,,,,,,,MeSH:D004249|http://purl.obolibrary.org/obo/NCIT_C16507,,"Drug-, radiation-induced, or spontaneous injuries to DNA that introduce deviations from its normal double-helical conformation. These changes include structural distortions that interfere with replication and transcription, as well as point mutations that disrupt base pairs and exert damaging effects on future generations through changes in DNA sequence. If the damage is minor, it can often be repaired (DNA repair); extensive damage can induce apoptosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,NCIT:C16507,,,,,,,,,,,,,,,,,,,,,,DNA damage,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0030032,lamellipodium biogenesis,,"Formation of a lamellipodium, a thin sheetlike extension of the surface of a migrating cell.",false,,,http://purl.obolibrary.org/obo/GO_0071840,,,,,,,,,,,,,,,,,,,,,,"Formation of a lamellipodium, a thin sheetlike extension of the surface of a migrating cell.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0030032,,,,,,,,,,,,,,,,,,,,,,lamellipodium biogenesis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0030036,actin cytoskeleton organization and biogenesis,,"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of cytoskeletal structures comprising actin filaments and their associated proteins.",false,,,http://purl.obolibrary.org/obo/GO_0007010,,,,,,,,,,,,,,,,,,,,,,"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of cytoskeletal structures comprising actin filaments and their associated proteins.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0030036,,,,,,,,,,,,,,,,,,,,,,actin cytoskeleton organization and biogenesis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001574,Rab6C,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001574,,,,,,,,,,,,,,,,,,,,,,Rab6C,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000593,IL-1RI : IL-1R AcP,,,false,,,http://purl.obolibrary.org/obo/IMR_0000120,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000593,,,,,,,,,,,,,,,,,,,,,,IL-1RI : IL-1R AcP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_28680,cytarabine,cytarabinum|Cytosine arabinoside|4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone|cytosine-beta-D-arabinofuranoside|ara-C|1-beta-D-Arabinofuranosylcytosine|citarabina|arabinocytosine|Cytosine-1-beta-D-arabinofuranoside|cytarabine|Arabinoside C|Cytarabine|4-amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one,"A pyrimidine nucleoside in which cytosine is attached to D-arabinofuranose via a beta-N(1)-glycosidic bond. Used mainly in the treatment of leukaemia, especially acute non-lymphoblastic leukaemia, cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. It also has antiviral and immunosuppressant properties.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Beilstein:89175|Reaxys:89175|Drug_Central:770|DrugBank:DB00987|LINCS:LSM-5470|PMID:15492802|CAS:147-94-4,,"A pyrimidine nucleoside in which cytosine is attached to D-arabinofuranose via a beta-N(1)-glycosidic bond. Used mainly in the treatment of leukaemia, especially acute non-lymphoblastic leukaemia, cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. It also has antiviral and immunosuppressant properties.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35705|http://purl.obolibrary.org/obo/CHEBI_35610|http://purl.obolibrary.org/obo/CHEBI_35221|http://purl.obolibrary.org/obo/CHEBI_22587,,,,,Cytarabine|4-amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one,,cytarabinum|Cytosine arabinoside|4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone|cytosine-beta-D-arabinofuranoside|ara-C|1-beta-D-Arabinofuranosylcytosine|citarabina|arabinocytosine|Cytosine-1-beta-D-arabinofuranoside|cytarabine|Arabinoside C,,,,,,,,,,,,,,,,,,,,,CHEBI:28680,,,,cytarabine,,CHEBI:28680,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0097390,chemokine (C-X-C motif) ligand 12 production,,"The appearance of chemokine (C-X-C motif) ligand 12 (CXCL12) due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.",false,,,http://purl.obolibrary.org/obo/GO_0032602,,,,,,,,,,,,,,,,,,,,,,"The appearance of chemokine (C-X-C motif) ligand 12 (CXCL12) due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.",,,,,chemokine (C-X-C motif) ligand 12 production,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0097390,,,,,,,,,,,,,,,,,,,,,,chemokine (C-X-C motif) ligand 12 production,,,,,,,http://purl.obolibrary.org/obo/go.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OBI_0001631,electron microscopy imaging assay,,"An imaging assay in which an electrons are used to probe the density, shape and composition of an input material which are detected in an electron microscope and utilized to produce an image of the material.",false,,,http://purl.obolibrary.org/obo/TXPO_0001396,,,,,,,,,,,,,,,,,,,,,,"An imaging assay in which an electrons are used to probe the density, shape and composition of an input material which are detected in an electron microscope and utilized to produce an image of the material.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,OBI:0001631,,,,,,,,,,,,,,,,,,,,,,electron microscopy imaging assay,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000902,eIF2,eukaryotic initiation factor 2,"heterotrimer of alpha, beta, gamma subunits. binds the initiator Met-tRNA to the 40S ribosomal subunit. GTP binding to eIF2 is necessary for formation of a stable eIF2:GTP:Met-tRNA ternary complex (TC). Following TC binding to the ribosome triggers GTP hydrolysis by eIF2.",false,,,http://purl.obolibrary.org/obo/IMR_0010016,,,,,,,,,,,,,,,,,,,,,,"heterotrimer of alpha, beta, gamma subunits. binds the initiator Met-tRNA to the 40S ribosomal subunit. GTP binding to eIF2 is necessary for formation of a stable eIF2:GTP:Met-tRNA ternary complex (TC). Following TC binding to the ribosome triggers GTP hydrolysis by eIF2.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003706,,,,,eukaryotic initiation factor 2,,,,,IMR:0000902,,,,,,,,,,,,,,,,,,,,,,eIF2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0005543,phospholipid binding,,"Interacting selectively and non-covalently with phospholipids, a class of lipids containing phosphoric acid as a mono- or diester.",false,,,http://purl.obolibrary.org/obo/GO_0008289,,,,,,,,,,,,,,,,,,,,GO:0005543,,"Interacting selectively and non-covalently with phospholipids, a class of lipids containing phosphoric acid as a mono- or diester.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0005543,,,,,,,,,,,,,,,,,,,,,,phospholipid binding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006740,NADPH regeneration,reduced nicotinamide adenine dinucleotide phosphate regeneration|NADP (reduced) regeneration|reduced NADP regeneration,A metabolic process that generates a pool of NADPH by the reduction of NADP+.,false,,,http://purl.obolibrary.org/obo/GO_0009058,,,,,,,,,,,,,,,,,,,,Reactome:R-HSA-389542|https://reactome.org/PathwayBrowser/#/R-HSA-389542,,A metabolic process that generates a pool of NADPH by the reduction of NADP+.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_16474,,,,,,,,,,,,,,reduced nicotinamide adenine dinucleotide phosphate regeneration|NADP (reduced) regeneration|reduced NADP regeneration,,,,,GO:0006740,,,,,,,,,,,,,,,,,,,,,,NADPH regeneration,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006749,glutathione metabolic process,glutathione metabolism,"The chemical reactions and pathways involving glutathione, the tripeptide glutamylcysteinylglycine, which acts as a coenzyme for some enzymes and as an antioxidant in the protection of sulfhydryl groups in enzymes and other proteins; it has a specific role in the reduction of hydrogen peroxide (H2O2) and oxidized ascorbate, and it participates in the gamma-glutamyl cycle",false,,,http://purl.obolibrary.org/obo/GO_0008152,,,,,,,,,,,,,,,,,,,,CHEBI:16856|ISBN:0198506732,,"The chemical reactions and pathways involving glutathione, the tripeptide glutamylcysteinylglycine, which acts as a coenzyme for some enzymes and as an antioxidant in the protection of sulfhydryl groups in enzymes and other proteins; it has a specific role in the reduction of hydrogen peroxide (H2O2) and oxidized ascorbate, and it participates in the gamma-glutamyl cycle",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,glutathione metabolism,,,,,GO:0006749,,,,,,,,,,,,,,,,,,,,,,glutathione metabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_83057,Daphnia metabolite,Daphnia metabolites,"A crustacean metabolite produced by the genus of small planktonic arthropods, Daphnia",false,,,http://purl.obolibrary.org/obo/CHEBI_83039,,,,,,,,,,,,,,,,,,,,,,"A crustacean metabolite produced by the genus of small planktonic arthropods, Daphnia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Daphnia metabolites,,,,,,,,,,,,,,,,,,,,,CHEBI:83057,,,,Daphnia metabolite,,CHEBI:83057,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0060697,positive regulation of phospholipid catabolic process,,"Any process that increases the rate, frequency, or extent of phospholipid catabolism, the chemical reactions and pathways resulting in the breakdown of phospholipids, any lipid containing phosphoric acid as a mono- or diester.",false,,,http://purl.obolibrary.org/obo/TXPO_0001223,,,,,,,,,,,,,,,,,,,,,,"Any process that increases the rate, frequency, or extent of phospholipid catabolism, the chemical reactions and pathways resulting in the breakdown of phospholipids, any lipid containing phosphoric acid as a mono- or diester.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0060697,,,,,,,,,,,,,,,,,,,,,,positive regulation of phospholipid catabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0009395,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001867,TACE,a disintegrin and metalloproteinase 17|ADAM17|TNF-alpha converting enzyme,,false,,,http://purl.obolibrary.org/obo/IMR_0001865,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,a disintegrin and metalloproteinase 17|ADAM17|TNF-alpha converting enzyme,,,,,IMR:0001867,,,,,,,,,,,,,,,,,,,,,,TACE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_50427,platelet aggregation inhibitor,platelet aggregation inhibitors,"A drug or agent which antagonizes or impairs any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.",false,,,http://purl.obolibrary.org/obo/CHEBI_50248,,,,,,,,,,,,,,,,,,,,,,"A drug or agent which antagonizes or impairs any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,platelet aggregation inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:50427,,,,platelet aggregation inhibitor,,CHEBI:50427,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_132933,intermediate-density lipoprotein,IDL,A class of lipoproteins with a density between that of low-density and very-low-density lipoproteins. They are formed by the degradatiion of very-low-density lipoproteins.,false,,,http://purl.obolibrary.org/obo/CHEBI_6495,,,,,,,,,,,,,,,,,,,,,,A class of lipoproteins with a density between that of low-density and very-low-density lipoproteins. They are formed by the degradatiion of very-low-density lipoproteins.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IDL,,,CHEBI:132933,,,,,,,,,,,,,,,,,,,,,,intermediate-density lipoprotein,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_49159,leukotriene antagonist,leukotriene antagonists|leukotriene receptor antagonists|leukotriene receptor antagonist|LTRA,A drug designed to prevent leukotriene synthesis or activity by blocking binding at the receptor level.,false,,,http://purl.obolibrary.org/obo/CHEBI_49020,,,,,,,,,,,,,,,,,,,,,,A drug designed to prevent leukotriene synthesis or activity by blocking binding at the receptor level.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,leukotriene antagonists|leukotriene receptor antagonists|leukotriene receptor antagonist|LTRA,,,,,,,,,,,,,,,,,,,,,CHEBI:49159,,,,leukotriene antagonist,,CHEBI:49159,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0046473,phosphatidic acid metabolic process,phosphatidic acid metabolism,"The chemical reactions and pathways involving phosphatidic acid, any derivative of glycerol phosphate in which both the remaining hydroxyl groups of the glycerol moiety are esterified with fatty acids.",false,,,http://purl.obolibrary.org/obo/GO_0006650,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways involving phosphatidic acid, any derivative of glycerol phosphate in which both the remaining hydroxyl groups of the glycerol moiety are esterified with fatty acids.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_16337,,,,,,,,,,,,phosphatidic acid metabolism,,,,,GO:0046473,,,,,,,,,,,,,,,,,biological_process,,,,,phosphatidic acid metabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0046470,phosphatidylcholine metabolic process,phosphatidylcholine metabolism,"The chemical reactions and pathways involving phosphatidylcholines, any of a class of glycerophospholipids in which the phosphatidyl group is esterified to the hydroxyl group of choline. They are important constituents of cell membranes.",false,,,http://purl.obolibrary.org/obo/GO_0006650,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways involving phosphatidylcholines, any of a class of glycerophospholipids in which the phosphatidyl group is esterified to the hydroxyl group of choline. They are important constituents of cell membranes.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_64482,,,,,,,,,,,,phosphatidylcholine metabolism,,,,,GO:0046470,,,,,,,,,,,,,,,,,biological_process,,,,,phosphatidylcholine metabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0046471,phosphatidylglycerol metabolic process,phosphatidylglycerol metabolism,"The chemical reactions and pathways involving phosphatidylglycerols, any of a class of phospholipids in which the phosphatidyl group is esterified to the hydroxyl group of glycerol. They are important constituents of cell membranes.",false,,,http://purl.obolibrary.org/obo/GO_0006650,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways involving phosphatidylglycerols, any of a class of phospholipids in which the phosphatidyl group is esterified to the hydroxyl group of glycerol. They are important constituents of cell membranes.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_17517,,,,,,,,,,,,phosphatidylglycerol metabolism,,,,,GO:0046471,,,,,,,,,,,,,,,,,biological_process,,,,,phosphatidylglycerol metabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0046475,glycerophospholipid catabolic process,glycerophospholipid breakdown|phosphoglyceride catabolism|glycerophospholipid degradation|phosphoglyceride catabolic process|glycerophospholipid catabolism,"The chemical reactions and pathways resulting in the breakdown of glycerophospholipids, any derivative of glycerophosphate that contains at least one O-acyl, O-alkyl, or O-alkenyl group attached to the glycerol residue.",false,,,http://purl.obolibrary.org/obo/GO_0009395|http://purl.obolibrary.org/obo/GO_0006650,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways resulting in the breakdown of glycerophospholipids, any derivative of glycerophosphate that contains at least one O-acyl, O-alkyl, or O-alkenyl group attached to the glycerol residue.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_37739,,,,,,,,,,,,,,,,,,glycerophospholipid breakdown|phosphoglyceride catabolism|glycerophospholipid degradation|phosphoglyceride catabolic process|glycerophospholipid catabolism,,,,,GO:0046475,,,,,,,,,,,,,,,,,biological_process,,,,,glycerophospholipid catabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0046474,glycerophospholipid biosynthetic process,glycerophospholipid biosynthesis|phosphoglyceride biosynthesis|glycerophospholipid synthesis|glycerophospholipid formation|phosphoglyceride biosynthetic process|glycerophospholipid anabolism,"The chemical reactions and pathways resulting in the formation of glycerophospholipids, any derivative of glycerophosphate that contains at least one O-acyl, O-alkyl, or O-alkenyl group attached to the glycerol residue.",false,,,http://purl.obolibrary.org/obo/GO_0006650|http://purl.obolibrary.org/obo/GO_0008654,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways resulting in the formation of glycerophospholipids, any derivative of glycerophosphate that contains at least one O-acyl, O-alkyl, or O-alkenyl group attached to the glycerol residue.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_37739,,,,,,,,,,,,,,glycerophospholipid biosynthesis|phosphoglyceride biosynthesis|glycerophospholipid synthesis|glycerophospholipid formation|phosphoglyceride biosynthetic process|glycerophospholipid anabolism,,,,,GO:0046474,,,,,,,,,,,,,,,,,biological_process,,,,,glycerophospholipid biosynthetic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001429,BMP-5,Bone morphogenetic protein 5|BMP5,,false,,,http://purl.obolibrary.org/obo/IMR_0003084,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Bone morphogenetic protein 5|BMP5,,,,,IMR:0001429,,,,,,,,,,,,,,,,,,,,,,BMP-5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_26739,sphingolipid,,"Sphingolipids are a complex family of compounds that share a common structural feature, a sphingoid base backbone.",false,,,http://purl.obolibrary.org/obo/CHEBI_18059,,,,,,,,,,,,,,,,,,,,,,"Sphingolipids are a complex family of compounds that share a common structural feature, a sphingoid base backbone.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:26739,,,,,,,,,,,,,,,,,,,,,,sphingolipid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_240107,bromfenac,2-amino-3-(4-bromobenzoyl)benzeneacetic acid|bromfenaco|bromfenac|bromfenacum|[2-Amino-3-(4-bromo-benzoyl)-phenyl]-acetic acid|[2-amino-3-(4-bromobenzoyl)phenyl]acetic acid,"Amfenac in which the the hydrogen at the 4 position of the benzoyl group is substituted by bromine. It is used for the management of ocular pain and treatment of postoperative inflammation in patients who have undergone cataract extraction. It was withdrawn from the US market in 1998, following concerns over off-label abuse and hepatic failure.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,DrugBank:DB00963|Drug_Central:401|LINCS:LSM-5585|Beilstein:8335547|CAS:91714-94-2,,"Amfenac in which the the hydrogen at the 4 position of the benzoyl group is substituted by bromine. It is used for the management of ocular pain and treatment of postoperative inflammation in patients who have undergone cataract extraction. It was withdrawn from the US market in 1998, following concerns over off-label abuse and hepatic failure.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35475|http://purl.obolibrary.org/obo/CHEBI_35481,,,,,[2-amino-3-(4-bromobenzoyl)phenyl]acetic acid,,2-amino-3-(4-bromobenzoyl)benzeneacetic acid|bromfenaco|bromfenac|bromfenacum|[2-Amino-3-(4-bromo-benzoyl)-phenyl]-acetic acid,,,,,,,,,,,,,,,,,,,,,CHEBI:240107,,,,bromfenac,,CHEBI:240107,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100384,p27Kip1,cyclin-dependent kinase inhibitor p27,,false,,,http://purl.obolibrary.org/obo/IMR_0000446,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,cyclin-dependent kinase inhibitor p27,,,,,IMR:0100384,,,,,,,,,,,,,,,,,,,,,,p27Kip1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000000771,CA12,,Other designations: CA-XII|carbonate dehydratase XII|carbonic anhydrase 12|carbonic dehydratase|tumor antigen HOM-RCC-3.1.3,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,HsT18816|CAXII,,,,,,,,,,,,15,,,,,,HGNC:1371|HPRD:04464|MIM:603263,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,carbonic anhydrase XII,,,15q22,,,,,,,,,,,,,,,,GO_0004089 (EC: IEA); GO_0005886 (EC: TAS); GO_0006730 (EC: IEA); GO_0008270 (EC: IEA); GO_0015701 (EC: TAS); GO_0016021 (EC: IEA); GO_0044281 (EC: TAS),,,,,,,,,PMID: 8524854; 9636197; 9770531; 10512682; 10611263; 10666387; 11083462; 11101628; 11238049; 11420383; 11493685; 11680594; 12477932; 12676895; 12854129; 12923247; 14578124; 14702039; 15489334; 15849821; 16169070; 16416108; 18029348; 18322268; 18336315; 18451179; 19291313; 20132413; 20215053; 20398423; 20434230; 20509747; 21035102; 21040567; 21139048; 21184099; 21278619; 21900206; 22172588; 22439015; 22944692; 23348702,,,,,,,,,,,,,,,OGG:3000000771,,,,,,,carbonic anhydrase XII,,,,,,,,,,,,,Other designations: CA-XII|carbonate dehydratase XII|carbonic anhydrase 12|carbonic dehydratase|tumor antigen HOM-RCC-3.1.3,,CA12,,,,,,,,,,,,,,,,,,,,,,,771,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,CA12,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/GO_1903409,reactive oxygen species biosynthetic process,reactive oxygen species formation|reactive oxygen species synthesis|reactive oxygen species biosynthesis,"The chemical reaction resulting in the formation of reactive oxygen species, any molecules or ions formed by the incomplete one-electron reduction of oxygen.",false,,,http://purl.obolibrary.org/obo/GO_0009058,,,,,,,,,,,,,,,,,,,,,,"The chemical reaction resulting in the formation of reactive oxygen species, any molecules or ions formed by the incomplete one-electron reduction of oxygen.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_26523,,,,,,,,,,,,,,reactive oxygen species formation|reactive oxygen species synthesis|reactive oxygen species biosynthesis,,,,,GO:1903409,,,,,,,,,,,,,,,,,,,,,,reactive oxygen species biosynthetic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100056,thyrotropin-releasing hormone,thyroliberin|TRH|5-oxo-prolyl-histidyl-prolinamide|protirelin,"A tripeptide hormone that originates in the HYPOTHALAMUS and stimulates the secretion of THYROTROPIN from the PITUITARY GLAND. In humans, it also acts as a prolactin-releasing factor. It is also a neurotransmitter in the central nervous system.",false,,,http://purl.obolibrary.org/obo/IMR_0100093,,,,,,,,,,,,,,,,,,,,MeSH:D013973,,"A tripeptide hormone that originates in the HYPOTHALAMUS and stimulates the secretion of THYROTROPIN from the PITUITARY GLAND. In humans, it also acts as a prolactin-releasing factor. It is also a neurotransmitter in the central nervous system.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,thyroliberin|TRH|5-oxo-prolyl-histidyl-prolinamide|protirelin,,,,,IMR:0100056,,,,,,,,,,,,,,,,,,,,,,thyrotropin-releasing hormone,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010555,40S ribosomal protein S2,40S small ribosomal protein 2|S4|LLREP3 protein,,false,,,http://purl.obolibrary.org/obo/IMR_0000896,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,40S small ribosomal protein 2|S4|LLREP3 protein,,,,,IMR:0010555,,,,,,,,,,,,,,,,,,,,,,40S ribosomal protein S2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000911,eIF4GII,Eukaryotic translation initiation factor 4 gamma 3|eIF-4-gamma II|eIF4G 3|eIF-4G 3|eIF-4-gamma 3,,false,,,http://purl.obolibrary.org/obo/IMR_0000910,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Eukaryotic translation initiation factor 4 gamma 3|eIF-4-gamma II|eIF4G 3|eIF-4G 3|eIF-4-gamma 3,,,,,IMR:0000911,,,,,,,,,,,,,,,,,,,,,,eIF4GII,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100391,IFNAR-1,Interferon alpha/beta receptor-1,,false,,,http://purl.obolibrary.org/obo/IMR_0000135,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Interferon alpha/beta receptor-1,,,,,IMR:0100391,,,,,,,,,,,,,,,,,,,,,,IFNAR-1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001069,ACOT8 (human)[Eosinophilic granular degeneration],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001034|http://purl.obolibrary.org/obo/TXPO_1000026,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:10005|PMID:15194431|PMID:24788990|PMID:28385385,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001069,,,,,,,,,,,,,,,,,,,,,,ACOT8 (human)[Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001066,Slc25a20 (rat)[Eosinophilic granular degeneration],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001077|http://purl.obolibrary.org/obo/TXPO_1000360,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:117035,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001066,,,,,,,,,,,,,,,,,,,,,,Slc25a20 (rat)[Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001062,increasing lipid,,Increasing lipid  is a subtype of increasing quantity: A process that changes the amount of lipid to be larger.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing lipid  is a subtype of increasing quantity: A process that changes the amount of lipid to be larger.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001062,,,,,,,,,,,,,,,,,,,,,,increasing lipid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001065,IL-1beta processing [lipidosis],,"IL-1beta processing is a subtype of protein processing: A process that IL-1beta maturation process achieved by the cleavage of pro IL-1beta.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0001063,,,,,,,,,,,,,,,,,,,,,,"IL-1beta processing is a subtype of protein processing: A process that IL-1beta maturation process achieved by the cleavage of pro IL-1beta.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001079,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001875,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001878,,,,,,,,,,,TXPO:0001065,,,,,,,,,,,,,,,,,,,,,,IL-1beta processing [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001064,Cpt2 (rat)[Eosinophilic granular degeneration],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001077|http://purl.obolibrary.org/obo/TXPO_1000098,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:25413,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001064,,,,,,,,,,,,,,,,,,,,,,Cpt2 (rat)[Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001061,Ehhadh (rat)[Eosinophilic granular degeneration],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001077|http://purl.obolibrary.org/obo/TXPO_1000131,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:171142|PMID:17255113,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001061,,,,,,,,,,,,,,,,,,,,,,Ehhadh (rat)[Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001060,Acox1 (rat)[Eosinophilic granular degeneration],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001077|http://purl.obolibrary.org/obo/TXPO_1000027,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:50681|PMID:17255113,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001060,,,,,,,,,,,,,,,,,,,,,,Acox1 (rat)[Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001067,Acot12 (rat)[Eosinophilic granular degeneration],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001077|http://purl.obolibrary.org/obo/TXPO_1000021,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:74156|NCBI-Human-GeneID:134526|NCBI-Rat-GeneID:170570,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001067,,,,,,,,,,,,,,,,,,,,,,Acot12 (rat)[Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001068,Acot7 (rat)[Eosinophilic granular degeneration],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001077|http://purl.obolibrary.org/obo/TXPO_1000025,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:26759|PMID:26861785,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001068,,,,,,,,,,,,,,,,,,,,,,Acot7 (rat)[Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001063,IL-1beta processing,,IL-1beta processing is a subtype of protein processing: A process that IL-1beta maturation process achieved by the cleavage of pro IL-1beta.,false,,,http://purl.obolibrary.org/obo/GO_0016485,,,,,,,,,,,,,,,,,,,,,,IL-1beta processing is a subtype of protein processing: A process that IL-1beta maturation process achieved by the cleavage of pro IL-1beta.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001063,,,,,,,,,,,,,,,,,,,,,,IL-1beta processing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0011351,NELF-B protein,Negative elongation factor B|Cofactor of BRCA1|NELF-B,,false,,,http://purl.obolibrary.org/obo/IMR_0010013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Negative elongation factor B|Cofactor of BRCA1|NELF-B,,,,,IMR:0011351,,,,,,,,,,,,,,,,,,,,,,NELF-B protein,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100677,IGF-1 receptor,Insulin-like growth factor I receptor precursor|CD221 antigen,,false,,,http://purl.obolibrary.org/obo/IMR_0000075,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Insulin-like growth factor I receptor precursor|CD221 antigen,,,,,IMR:0100677,,,,,,,,,,,,,,,,,,,,,,IGF-1 receptor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100318,Smad7,,,false,,,http://purl.obolibrary.org/obo/IMR_0000373,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100318,,,,,,,,,,,,,,,,,,,,,,Smad7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0032623,interleukin-2 production,,"The appearance of interleukin-2 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.",false,,,http://purl.obolibrary.org/obo/GO_0001816,,,,,,,,,,,,,,,,,,,,,,"The appearance of interleukin-2 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0032623,,,,,,,,,,,,,,,,,,,,,,interleukin-2 production,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100254,DLK,dual leucine zipper bearing kinase,,false,,,http://purl.obolibrary.org/obo/IMR_0000239,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,dual leucine zipper bearing kinase,,,,,IMR:0100254,,,,,,,,,,,,,,,,,,,,,,DLK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001151,PKC zeta,,,false,,,http://purl.obolibrary.org/obo/IMR_0000247,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001151,,,,,,,,,,,,,,,,,,,,,,PKC zeta,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0011160,eIF5,Eukaryotic translation initiation factor 5|eIF-5,,false,,,http://purl.obolibrary.org/obo/IMR_0010016,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Eukaryotic translation initiation factor 5|eIF-5,,,,,IMR:0011160,,,,,,,,,,,,,,,,,,,,,,eIF5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100513,Smurf1,Ubiquitin-protein ligase|xSMURF1|Smad-specific E3 ubiquitin ligase 1|Ubiquitin--protein ligase SMURF1|E3 ubiquitin ligase|hSMURF1,,false,,,http://purl.obolibrary.org/obo/IMR_0100512,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ubiquitin-protein ligase|xSMURF1|Smad-specific E3 ubiquitin ligase 1|Ubiquitin--protein ligase SMURF1|E3 ubiquitin ligase|hSMURF1,,,,,IMR:0100513,,,,,,,,,,,,,,,,,,,,,,Smurf1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0016477,cell migration,,The controlled self-propelled movement of a cell from one site to a destination guided by molecular cues. Cell migration is a central process in the development and maintenance of multicellular organisms.,false,,,http://purl.obolibrary.org/obo/TXPO_0000003,,,,,,,,,,,,,,,,,,,,Wikipedia:Cell_migration,,The controlled self-propelled movement of a cell from one site to a destination guided by molecular cues. Cell migration is a central process in the development and maintenance of multicellular organisms.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0016477,,,,,,,,,,,,,,,,,,,,,,cell migration,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0200467,L-Cysteine,,,false,,,http://purl.obolibrary.org/obo/CHEBI_33709,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0200467,,,,,,,,,,,,,,,,,,,,,,L-Cysteine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100772,Wnt-5b,,,false,,,http://purl.obolibrary.org/obo/IMR_0000003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100772,,,,,,,,,,,,,,,,,,,,,,Wnt-5b,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0035794,positive regulation of mitochondrial membrane permeability,,"Any process that increases the frequency, rate or extent of the passage or uptake of molecules by the mitochondrial membrane.",false,,,http://purl.obolibrary.org/obo/TXPO_0001223,,,,,,,,,,,,,,,,,,,,,,"Any process that increases the frequency, rate or extent of the passage or uptake of molecules by the mitochondrial membrane.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0035794,,,,,,,,,,,,,,,,,,,,,,positive regulation of mitochondrial membrane permeability,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0031966,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000799,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000006506,SLC1A2,,Other designations: excitatory amino acid transporter 2|excitotoxic amino acid transporter 2|glutamate/aspartate transporter II|sodium-dependent glutamate/aspartate transporter 2,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,GLT-1|EAAT2,,,,,,,,,,,,11,,,,,,Ensembl:ENSG00000110436|HPRD:02625|Vega:OTTHUMG00000044391|MIM:600300|HGNC:10940,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"solute carrier family 1 (glial high affinity glutamate transporter), member 2",,,11p13-p12,,,,,,,,,,,,,,,,"GO_0005313 (EC: IDA, PMID: 7521911); GO_0005515 (EC: IPI, PMID: 19527721); GO_0005886 (EC: TAS); GO_0006811 (EC: TAS); GO_0007268 (EC: TAS, PMID: 7521911); GO_0007632 (EC: IEA); GO_0009611 (EC: IEA); GO_0010259 (EC: IEA); GO_0015501 (EC: IEA); GO_0016020 (EC: TAS, PMID: 7521911); GO_0016021 (EC: IEA); GO_0017153 (EC: IEA); GO_0021537 (EC: IEA); GO_0030534 (EC: IEA); GO_0030673 (EC: IEA); GO_0031668 (EC: IEA); GO_0035264 (EC: IEA); GO_0042493 (EC: IEA); GO_0043200 (EC: IEA); GO_0046326 (EC: IEA); GO_0051938 (EC: IDA, PMID: 7521911); GO_0055085 (EC: TAS); GO_0070779 (EC: IDA, PMID: 7521911)",,,,,,,,,PMID: 7521911; 7522567; 7587378; 8172925; 8619474; 9110174; 9450673; 9463476; 9539131; 9585360; 11031254; 11038258; 11071482; 11204345; 11357955; 11698255; 11744157; 11792462; 11860269; 11891650; 11994293; 12408226; 12477932; 12578975; 12890621; 12898275; 12950454; 14506254; 14662797; 14702039; 14982736; 15048885; 15135231; 15246112; 15265858; 15296513; 15337309; 15483603; 15494981; 15660126; 15822905; 15927426; 16061389; 16344560; 16567804; 16766085; 17311293; 17311320; 17535102; 17684493; 17823119; 17920768; 18314905; 18326497; 18378006; 18519826; 18658151; 18838545; 19023027; 19086053; 19151621; 19156168; 19268276; 19283393; 19338517; 19527721; 19660525; 19910676; 19998491; 20193040; 20379614; 20398908; 20399272; 20410850; 20416976; 20688910; 20936779; 21098017; 21110225; 21335552; 21471434; 21569822; 21707071; 21711518; 21792905; 21852380; 22069320; 22505712; 22513140; 22522966; 22561518; 22728822; 22750157; 22764253; 22903028; 23023733; 23356950; 23390085; 23415275; 23596072; 23706640; 24068947; 24334928,,,,,,,,,,,,,,,OGG:3000006506,,,,,,,"solute carrier family 1 (glial high affinity glutamate transporter), member 2",,,,,,,,,,,,,Other designations: excitatory amino acid transporter 2|excitotoxic amino acid transporter 2|glutamate/aspartate transporter II|sodium-dependent glutamate/aspartate transporter 2,,SLC1A2,,,,,,,,,,,,,,,,,,,,,,,6506,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,SLC1A2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0002120,aldosterone,"Aldosterone|11beta,21-Dihydroxy-3,20-dioxo-4-pregnen-18-al",,false,,,http://purl.obolibrary.org/obo/IMR_0100037,,,,,,,,,,,,,,,,,,,,CHEBI:27584,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Aldosterone|11beta,21-Dihydroxy-3,20-dioxo-4-pregnen-18-al",,,,,IMR:0002120,,,,,,,,,,,,,,,,,,,,,,aldosterone,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_66956,antidyskinesia agent,antidyskinesia drug|antidyskinetic drug|antidyskinetic agents|antidyskinesia agents|antidyskinetic drugs|antidyskinetic agent|antidyskinesia drugs,Any compound which can be used to treat or alleviate the symptoms of dyskinesia.,false,,,http://purl.obolibrary.org/obo/CHEBI_23888,,,,,,,,,,,,,,,,,,,,,,Any compound which can be used to treat or alleviate the symptoms of dyskinesia.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,antidyskinesia drug|antidyskinetic drug|antidyskinetic agents|antidyskinesia agents|antidyskinetic drugs|antidyskinetic agent|antidyskinesia drugs,,,,,,,,,,,,,,,,,,,,,CHEBI:66956,,,,antidyskinesia agent,,CHEBI:66956,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000835,C/EBP beta,CCAAT/enhancer binding protein beta,,false,,,http://purl.obolibrary.org/obo/IMR_0000422,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CCAAT/enhancer binding protein beta,,,,,IMR:0000835,,,,,,,,,,,,,,,,,,,,,,C/EBP beta,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001614,Rab28,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001614,,,,,,,,,,,,,,,,,,,,,,Rab28,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000001052,CEBPD,,Other designations: CCAAT/enhancer-binding protein delta|c/EBP delta|nuclear factor NF-IL6-beta,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CELF|CRP3|C/EBP-delta|NF-IL6-beta,,,,,,,,,,,,8,,,,,,MIM:116898|HPRD:00297|HGNC:1835,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"CCAAT/enhancer binding protein (C/EBP), delta",,,8p11.2-p11.1,,,,,,,,,,,,,,,,"GO_0003700 (EC: IEA); GO_0005634 (EC: IEA); GO_0006366 (EC: TAS, PMID: 8314590); GO_0043565 (EC: IEA)",,,,,,,,,PMID: 1638120; 1741402; 1840554; 1884998; 7594592; 7789168; 8314590; 8946919; 9570146; 11741938; 11851384; 12177065; 12477932; 12524424; 12554732; 12825852; 12857754; 12937035; 15212823; 15389878; 15389879; 15486993; 15588942; 15674331; 15718495; 15901830; 16195339; 16322893; 16397300; 16914534; 16997058; 17098861; 17234736; 17373909; 17562792; 17903252; 17910034; 18370833; 18477566; 18619497; 18660489; 18753137; 19471022; 19800021; 19806320; 19811452; 20385105; 20460359; 20467438; 20805509; 20829351; 20971808; 21072181; 21076392; 21112127; 21612582; 21666710; 21693764; 21980073; 22037769; 23028973; 23575666; 23603433; 23861541; 24128855; 24155666,,,,,,,,,,,,,,,OGG:3000001052,,,,,,,"CCAAT/enhancer binding protein (C/EBP), delta",,,,,,,,,,,,,Other designations: CCAAT/enhancer-binding protein delta|c/EBP delta|nuclear factor NF-IL6-beta,,CEBPD,,,,,,,,,,,,,,,,,,,,,,,1052,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,CEBPD,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000231,Raf,,,false,,,http://purl.obolibrary.org/obo/IMR_0000229,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000231,,,,,,,,,,,,,,,,,,,,,,Raf,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_29699,tunicamycin,,"A mixture of antiviral nucleoside antibiotics produced by Streptomyces lysosuperificus. It contains at least 10 homologues comprising uracil, N-acetylglucosamine, an 11-carbon aminodialdose called tunicamine, and a fatty acid linked to the amino group of the tunicamine. The homologues vary in the composition of the fatty acid moiety.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,http://purl.bioontology.org/ontology/MESH/D014415|Open TG-Gates compound_id:00A02|Wikipedia:Tunicamycin|CAS:11089-65-9,,"A mixture of antiviral nucleoside antibiotics produced by Streptomyces lysosuperificus. It contains at least 10 homologues comprising uracil, N-acetylglucosamine, an 11-carbon aminodialdose called tunicamine, and a fatty acid linked to the amino group of the tunicamine. The homologues vary in the composition of the fatty acid moiety.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:29699,,,,,,,,,,,,,,,,,,,,,,tunicamycin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000023,CD40L,gp39|CD154|CD40 ligand,,false,,,http://purl.obolibrary.org/obo/IMR_0000021,,,,,,,,,,,,,,,,,,,,GO:0005174,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,gp39|CD154|CD40 ligand,,,,,IMR:0000023,,,,,,,,,,,,,,,,,,,,,,CD40L,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_35474,anxiolytic drug,anti-anxiety drugs|anxiolytics|anxiolytic agents|minor tranquilisers|minor tranquilizing agents|minor tranquilizers|anti-anxiety agents,"Anxiolytic drugs are agents that alleviate anxiety, tension, and anxiety disorders, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions.",false,,,http://purl.obolibrary.org/obo/CHEBI_35473,,,,,,,,,,,,,,,,,,,,,,"Anxiolytic drugs are agents that alleviate anxiety, tension, and anxiety disorders, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,anti-anxiety drugs|anxiolytics|anxiolytic agents|minor tranquilisers|minor tranquilizing agents|minor tranquilizers|anti-anxiety agents,,,,,,,,,,,,,,,,,,,,,CHEBI:35474,,,,anxiolytic drug,,CHEBI:35474,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100386,IFN alpha,Interferon alpha,,false,,,http://purl.obolibrary.org/obo/IMR_0000028,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Interferon alpha,,,,,IMR:0100386,,,,,,,,,,,,,,,,,,,,,,IFN alpha,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000619,ICAM-2,intercellular adhesion molecule 2,,false,,,http://purl.obolibrary.org/obo/IMR_0000178,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,intercellular adhesion molecule 2,,,,,IMR:0000619,,,,,,,,,,,,,,,,,,,,,,ICAM-2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100158,leucine enkephalin,,,false,,,http://purl.obolibrary.org/obo/IMR_0100157,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100158,,,,,,,,,,,,,,,,,,,,,,leucine enkephalin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100717,Notch 4,Notch-4|Notch4,,false,,,http://purl.obolibrary.org/obo/IMR_0100712,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Notch-4|Notch4,,,,,IMR:0100717,,,,,,,,,,,,,,,,,,,,,,Notch 4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0005694,chromosome,chromatid,A structure composed of a very long molecule of DNA and associated proteins (e.g. histones) that carries hereditary information.|Chromosomes include parts that are not part of the chromatin.  Examples include the kinetochore.,false,,,http://purl.obolibrary.org/obo/GO_0043226,,,,,,,,,,,,,,,,,,,,Wikipedia:Chromosome,,A structure composed of a very long molecule of DNA and associated proteins (e.g. histones) that carries hereditary information.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,chromatid,,http://purl.obolibrary.org/obo/GO_0005622,GO:0005694,http://purl.obolibrary.org/obo/GO_0005622,,,,,,,,,,,,,,,,,,,Chromosomes include parts that are not part of the chromatin.  Examples include the kinetochore.,,chromosome,,,,,,,http://purl.obolibrary.org/obo/go.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000644,Integrin beta-4,,,false,,,http://purl.obolibrary.org/obo/IMR_0000174,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000644,,,,,,,,,,,,,,,,,,,,,,Integrin beta-4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001037,group X secretory phospholipase A2,,,false,,,http://purl.obolibrary.org/obo/IMR_0000283,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001037,,,,,,,,,,,,,,,,,,,,,,group X secretory phospholipase A2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0011147,eIF3a,"eIF3 p180|eIF3 p110|Translation initiation factor eIF3, p110 subunit|eukaryotic translation initiation factor 3 subunit 10|eIF3 p167|eIF3 p185|eIF-3 theta",,false,,,http://purl.obolibrary.org/obo/IMR_0000916,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"eIF3 p180|eIF3 p110|Translation initiation factor eIF3, p110 subunit|eukaryotic translation initiation factor 3 subunit 10|eIF3 p167|eIF3 p185|eIF-3 theta",,,,,IMR:0011147,,,,,,,,,,,,,,,,,,,,,,eIF3a,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_35846,renal agent,renal agents,A drug used for its effect on the kidneys' regulation of body fluid composition and volume.,false,,,http://purl.obolibrary.org/obo/CHEBI_23888,,,,,,,,,,,,,,,,,,,,,,A drug used for its effect on the kidneys' regulation of body fluid composition and volume.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,renal agents,,,,,,,,,,,,,,,,,,,,,CHEBI:35846,,,,renal agent,,CHEBI:35846,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000011283,CYP4F8,,"Other designations: cytochrome P450 4F8|cytochrome P450, subfamily IVF, polypeptide 8|flavoprotein-linked monooxygenase|microsomal monooxygenase",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CYPIVF8|CPF8,,,,,,,,,,,,19,,,,,,HPRD:08518|HGNC:2648|MIM:611545,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 4, subfamily F, polypeptide 8",,,19p13.1,,,,,,,,,,,,,,,,"GO_0005506 (EC: IEA); GO_0005789 (EC: TAS); GO_0006690 (EC: TAS); GO_0006693 (EC: TAS, PMID:10405341); GO_0006805 (EC: TAS); GO_0016021 (EC: IEA); GO_0018685 (EC: TAS, PMID:10405341); GO_0020037 (EC: IEA); GO_0044281 (EC: TAS); GO_0070330 (EC: IEA)",,,,,,,,,PMID:9068972; 10405341; 10791960; 11448449; 12464258; 14702039; 15128046; 15789615; 16112640; 16344560; 17353931; 19343046; 21281786; 22228203,,,,,,,,,,,,,,,OGG:3000011283,,,,,,,"cytochrome P450, family 4, subfamily F, polypeptide 8",,,,,,,,,,,,,"Other designations: cytochrome P450 4F8|cytochrome P450, subfamily IVF, polypeptide 8|flavoprotein-linked monooxygenase|microsomal monooxygenase",,CYP4F8,,,,,,,,,,,,,,,,,,,,,,,11283,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP4F8,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0001626,Rab35,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001626,,,,,,,,,,,,,,,,,,,,,,Rab35,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/HINO_0017769,Translocation of NF-kappaB from the cytosol to the nucleus,,"Transport of NF-kappaB, a transcription factor for eukaryotic RNA polymerase II promoters, from the cytoplasm into the nucleus, across the nuclear membrane.",false,,,http://purl.obolibrary.org/obo/TXPO_0002494,,,,,,,,,,,,,,,,,,,,,,"Transport of NF-kappaB, a transcription factor for eukaryotic RNA polymerase II promoters, from the cytoplasm into the nucleus, across the nuclear membrane.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002769,,,,,,,,,,,,,,,,,,,HINO:0017769,,,,,,,,,,,,,,,,,,,,,,Translocation of NF-kappaB from the cytosol to the nucleus,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100297,caspase-6,,,false,,,http://purl.obolibrary.org/obo/IMR_0000306,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100297,,,,,,,,,,,,,,,,,,,,,,caspase-6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006783,heme biosynthetic process,heme formation|heme biosynthesis|heme synthesis|heme anabolism,"The chemical reactions and pathways resulting in the formation of heme, any compound of iron complexed in a porphyrin (tetrapyrrole) ring, from less complex precursors.",false,,,http://purl.obolibrary.org/obo/GO_0009058,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways resulting in the formation of heme, any compound of iron complexed in a porphyrin (tetrapyrrole) ring, from less complex precursors.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_18248,,,,,,,,,,,,,,heme formation|heme biosynthesis|heme synthesis|heme anabolism,,,,,GO:0006783,,,,,,,,,,,,,,,,,,,,,,heme biosynthetic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001549,Rab1B,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001549,,,,,,,,,,,,,,,,,,,,,,Rab1B,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IAO_0000109,measurement datum,,A measurement datum is an information content entity that is a recording of the output of a measurement such as produced by a device.,false,,,http://purl.obolibrary.org/obo/TXPO_0000614,,,,,,,,,,,,,,,,,,,,,,A measurement datum is an information content entity that is a recording of the output of a measurement such as produced by a device.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IAO:0000109,,,,,,,,,,,,,,,,,,,,,,measurement datum,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100395,IRS-3,pp60|insulin receptor substrate-3,,false,,,http://purl.obolibrary.org/obo/IMR_0000351,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pp60|insulin receptor substrate-3,,,,,IMR:0100395,,,,,,,,,,,,,,,,,,,,,,IRS-3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0065005,protein-lipid complex assembly,,"The aggregation, arrangement and bonding together of proteins and lipids to form a protein-lipid complex.",false,,,http://purl.obolibrary.org/obo/GO_0065003,,,,,,,,,,,,,,,,,,,,,,"The aggregation, arrangement and bonding together of proteins and lipids to form a protein-lipid complex.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_18059,,,,,,,,,,,,,,,,,,,,,,,GO:0065005,,,,,,,,,,,,,,,,,,,,,,protein-lipid complex assembly,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0065003,protein-containing complex assembly,macromolecular complex assembly,"The aggregation, arrangement and bonding together of a set of macromolecules to form a complex.",false,,,http://purl.obolibrary.org/obo/TXPO_0003815,,,,,,,,,,,,,,,,,,,,,,"The aggregation, arrangement and bonding together of a set of macromolecules to form a complex.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_36080,,,,,,,,,,,,,,,,,,,,macromolecular complex assembly,,,GO:0065003,,,,,,,,,,,,,,,,,,,,,,protein-containing complex assembly,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000649,CD44 (mol),,,false,,,http://purl.obolibrary.org/obo/IMR_0001125,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000649,,,,,,,,,,,,,,,,,,,,,,CD44 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100619,cyclin E1,G1/S-specific cyclin E1|CGE1,,false,,,http://purl.obolibrary.org/obo/IMR_0100618,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0010670|IMR:0011462,G1/S-specific cyclin E1|CGE1,,,,,IMR:0100619,,,,,,,,,,,,,,,,,,,,,,cyclin E1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000026973,CHORDC1,,"Other designations: CHORD-containing protein 1|CHP-1|chord domain-containing protein 1|cysteine and histidine-rich domain (CHORD)-containing 1|cysteine and histidine-rich domain (CHORD)-containing, zinc-binding protein 1|cysteine and histidine-rich domain-containing protein 1|protein morgana",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CHP1,,,,,,,,,,,,11,,,,,,HPRD:05072|MIM:604353|HGNC:14525,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,cysteine and histidine-rich domain (CHORD) containing 1,,,11q14.3,,,,,,,,,,,,,,,,"GO_0005515 (EC: IPI, PMID: 19875381); GO_0005575 (EC: ND); GO_0006950 (EC: IEA); GO_0008270 (EC: IEA); GO_0010824 (EC: IEA); GO_0051879 (EC: IPI, PMID: 19875381); GO_0061077 (EC: ISS); GO_1900034 (EC: ISS); GO_2000299 (EC: IEA)",,,,,,,,,PMID: 8125298; 8889548; 10571178; 12477932; 12965203; 14702039; 15642353; 16083881; 16344560; 17207965; 18854154; 19875381; 19910486; 20360068; 20800603; 21139048; 21890473; 21906983; 21963094; 22190034; 22833565; 22863883; 23000965; 23184943; 24250222,,,,,,,,,,,,,,,OGG:3000026973,,,,,,,cysteine and histidine-rich domain (CHORD) containing 1,,,,,,,,,,,,,"Other designations: CHORD-containing protein 1|CHP-1|chord domain-containing protein 1|cysteine and histidine-rich domain (CHORD)-containing 1|cysteine and histidine-rich domain (CHORD)-containing, zinc-binding protein 1|cysteine and histidine-rich domain-containing protein 1|protein morgana",,CHORDC1,,,,,,,,,,,,,,,,,,,,,,,26973,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,CHORDC1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0100454,MKK4(JNKK1)(SEK1),JNKK 1|MKK4|SAPK/ERK kinase 1|JNKK1|SEK1|JNKK|MAP kinase kinase 4|c- Jun N-terminal kinase kinase 1|JNK activating kinase 1,,false,,,http://purl.obolibrary.org/obo/IMR_0000262,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,JNKK 1|MKK4|SAPK/ERK kinase 1|JNKK1|SEK1|JNKK|MAP kinase kinase 4|c- Jun N-terminal kinase kinase 1|JNK activating kinase 1,,,,,IMR:0100454,,,,,,,,,,,,,,,,,,,,,,MKK4(JNKK1)(SEK1),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000440,RasGRF,,,false,,,http://purl.obolibrary.org/obo/IMR_0100440,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000440,,,,,,,,,,,,,,,,,,,,,,RasGRF,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010559,"40S ribosomal protein S4, Y isoform",40S small ribosomal protein 4Y,,false,,,http://purl.obolibrary.org/obo/IMR_0000896,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,40S small ribosomal protein 4Y,,,,,IMR:0010559,,,,,,,,,,,,,,,,,,,,,,"40S ribosomal protein S4, Y isoform",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_59740,nucleophilic reagent,nucleophile,A reagent that forms a bond to its reaction partner (the electrophile) by donating both bonding electrons.,false,,,http://purl.obolibrary.org/obo/CHEBI_22695,,,,,,,,,,,,,,,,,,,,,,A reagent that forms a bond to its reaction partner (the electrophile) by donating both bonding electrons.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,nucleophile,,,,,CHEBI:59740,,,,,,,,,,,,,,,,,,,,,,nucleophilic reagent,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_39124,calcium ion,calcium(2+)|Ca(2+)|Ca++|Ca2+,A calcium cation that has formula Ca.,false,,,http://purl.obolibrary.org/obo/TXPO_0000052,,,,,,,,,,,,,,,,,,,,,,A calcium cation that has formula Ca.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002401,,,,,calcium(2+)|Ca(2+)|Ca++|Ca2+,,,,,CHEBI:39124,,,,,,,,,,,,,,,,,,,,,,calcium ion,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100448,ERK1,p44-ERK1|p44-MAPK|Mitogen-activated protein kinase 3 (EC 2.7.1.-) (Extracellular signal- regulated kinase 1) (ERK-1) (Insulin-stimulated MAP2 kinase) (MAP kinase 1) (MAPK 1) (p44-ERK1) (ERT2) (p44-MAPK) (Microtubule- associated protein-2 kinase)|Extracellular signal-regulated kinase 1|Mitogen-activated protein kinase 3|MAP kinase 1|ERK-1|Microtubule- associated protein-2 kinase|MAPK 1|Insulin-stimulated MAP2 kinase|ERT2,,false,,,http://purl.obolibrary.org/obo/IMR_0000227,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0010357,p44-ERK1|p44-MAPK|Mitogen-activated protein kinase 3 (EC 2.7.1.-) (Extracellular signal- regulated kinase 1) (ERK-1) (Insulin-stimulated MAP2 kinase) (MAP kinase 1) (MAPK 1) (p44-ERK1) (ERT2) (p44-MAPK) (Microtubule- associated protein-2 kinase)|Extracellular signal-regulated kinase 1|Mitogen-activated protein kinase 3|MAP kinase 1|ERK-1|Microtubule- associated protein-2 kinase|MAPK 1|Insulin-stimulated MAP2 kinase|ERT2,,,,,IMR:0100448,,,,,,,,,,,,,,,,,,,,,,ERK1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_53784,antispasmodic drug,antispasmodics,"A drug that suppresses spasms. These are usually caused by smooth muscle contraction, especially in tubular organs. The effect is to prevent spasms of the stomach, intestine or urinary bladder.",false,,,http://purl.obolibrary.org/obo/CHEBI_51371,,,,,,,,,,,,,,,,,,,,,,"A drug that suppresses spasms. These are usually caused by smooth muscle contraction, especially in tubular organs. The effect is to prevent spasms of the stomach, intestine or urinary bladder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,antispasmodics,,,,,,,,,,,,,,,,,,,,,CHEBI:53784,,,,antispasmodic drug,,CHEBI:53784,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001118,short chain collagen,,,false,,,http://purl.obolibrary.org/obo/IMR_0000541,,,,,,,,,,,,,,,,,,,,GO:0005598,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001118,,,,,,,,,,,,,,,,,,,,,,short chain collagen,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_48876,muscarinic antagonist,agents antimuscariniques|Antimuskarinika|agentes antimuscarinicos|antimuscarinic agents|agente antimuscarinico|muscarinic acetylcholine receptor antagonist|antimuscarinicos|muscarinic antagonists|Antimuskarinikum,"A drug that binds to but does not activate muscarinic cholinergic receptors, thereby blocking the actions of endogenous acetylcholine or exogenous agonists.",false,,,http://purl.obolibrary.org/obo/CHEBI_48873,,,,,,,,,,,,,,,,,,,,,,"A drug that binds to but does not activate muscarinic cholinergic receptors, thereby blocking the actions of endogenous acetylcholine or exogenous agonists.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,agents antimuscariniques|Antimuskarinika|agentes antimuscarinicos|antimuscarinic agents|agente antimuscarinico|muscarinic acetylcholine receptor antagonist|antimuscarinicos|muscarinic antagonists|Antimuskarinikum,,,,,,,,,,,,,,,,,,,,,CHEBI:48876,,,,muscarinic antagonist,,CHEBI:48876,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003798,maintaining cyclicity,,Maintaining cyclicity is a subtype of changing cyclicity: A process that keepss the repeating values in regular cycles (periods).,false,,,http://purl.obolibrary.org/obo/TXPO_0003797,,,,,,,,,,,,,,,,,,,,,,Maintaining cyclicity is a subtype of changing cyclicity: A process that keepss the repeating values in regular cycles (periods).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003798,,,,,,,,,,,,,,,,,,,,,,maintaining cyclicity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003791,CAR (canonical)[Ground glass appearance],Gene name: NR1I3,"This gene encodes a member of the nuclear receptor superfamily, and is a key regulator of xenobiotic and endobiotic metabolism. The protein binds to DNA as a monomer or a heterodimer with the retinoid X receptor and regulates the transcription of target genes involved in drug metabolism and bilirubin clearance, such as cytochrome P450 family members. Unlike most nuclear receptors, this transcriptional regulator is constitutively active in the absence of ligand but is regulated by both agonists and inverse agonists. Ligand binding results in translocation of this protein to the nucleus, where it activates or represses target gene transcription. These ligands include bilirubin, a variety of foreign compounds, steroid hormones, and prescription drugs. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]",false,,,http://purl.obolibrary.org/obo/TXPO_0000472|http://purl.obolibrary.org/obo/TXPO_0003862,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:65035|NCBI-Human-GeneID:9970|NCBI-Mouse-GeneID:12355|http://omim.org/entry/603881,,"This gene encodes a member of the nuclear receptor superfamily, and is a key regulator of xenobiotic and endobiotic metabolism. The protein binds to DNA as a monomer or a heterodimer with the retinoid X receptor and regulates the transcription of target genes involved in drug metabolism and bilirubin clearance, such as cytochrome P450 family members. Unlike most nuclear receptors, this transcriptional regulator is constitutively active in the absence of ligand but is regulated by both agonists and inverse agonists. Ligand binding results in translocation of this protein to the nucleus, where it activates or represses target gene transcription. These ligands include bilirubin, a variety of foreign compounds, steroid hormones, and prescription drugs. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003863,,,,,,,Gene name: NR1I3,,,TXPO:0003791,,,,,,,,,,,,,,,,,,,,,,CAR (canonical)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,9970,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003795,positive regulation of cell division [Ground glass appearance],,"Any process that activates or increases the frequency, rate or extent of cell division.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/GO_0051781|http://purl.obolibrary.org/obo/TXPO_0001728,,,,,,,,,,,,,,,,,,,,,,"Any process that activates or increases the frequency, rate or extent of cell division.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003795,,,,,,,,,,,,,,,,,,,,,,positive regulation of cell division [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003792,CYP2E1 (canonical)[Lipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000081|http://purl.obolibrary.org/obo/TXPO_0003516,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1571|NCBI-Mouse-GeneID:13106|NCBI-Rat-GeneID:25086,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003792,,,,,,,,,,,,,,,,,,,,,,CYP2E1 (canonical)[Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003794,negative regulation of mRNA degradation,,"Prevention of degradation of mRNA molecules. In the absence of compensating changes in other processes, the slowing of mRNA degradation can result in an overall increase in the population of active mRNA molecules.",false,,,http://purl.obolibrary.org/obo/TXPO_0000126,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0048255,,"Prevention of degradation of mRNA molecules. In the absence of compensating changes in other processes, the slowing of mRNA degradation can result in an overall increase in the population of active mRNA molecules.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003794,,,,,,,,,,,,,,,,,,,,,,negative regulation of mRNA degradation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003797,changing cycle phase,changing periodicity,Changing cycle phase is a subtype of changing quality: A process that changes the cycle phase.,false,,,http://purl.obolibrary.org/obo/TXPO_0000415,,,,,,,,,,,,,,,,,,,,,,Changing cycle phase is a subtype of changing quality: A process that changes the cycle phase.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,changing periodicity,,,,,TXPO:0003797,,,,,,,,,,,,,,,,,,,,,,changing cycle phase,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0000083,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003796,negative regulation of adherens junction assembly [Ground glass appearance],,"Negative regulation of adherens junction assembly is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of adherens junction assembly.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/TXPO_0003813,,,,,,,,,,,,,,,,,,,,ISBN:0071769234,,"Negative regulation of adherens junction assembly is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of adherens junction assembly.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001524,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001582,,,,,,,,,,,TXPO:0003796,,,,,,,,,,,,,,,,,,,,,,negative regulation of adherens junction assembly [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003793,cell division [Ground glass appearance],,"The process resulting in division and partitioning of components of a cell to form more cells.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/GO_0051301|http://purl.obolibrary.org/obo/TXPO_0001728,,,,,,,,,,,,,,,,,,,,,,"The process resulting in division and partitioning of components of a cell to form more cells.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000961|http://purl.obolibrary.org/obo/TXPO_0001030,,,,,,,,,,,TXPO:0003793,,,,,,,,,,,,,,,,,,,,,,cell division [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003790,negative regulation of gap junction assembly [Ground glass appearance],,"Any process that stops, prevents or reduces the frequency, rate or extent of gap junction assembly.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/GO_1903597,,,,,,,,,,,,,,,,,,,,PMID:12563100|ISBN:0071769234,,"Any process that stops, prevents or reduces the frequency, rate or extent of gap junction assembly.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001524,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003793,,,,,,,,,,,TXPO:0003790,,,,,,,,,,,,,,,,,,,,,,negative regulation of gap junction assembly [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003799,Cytochrome P450 activation [NASH],P450 activation [Glutathione depletion]|Cytochrome P450 activation [Glutathione depletion],"Cytochrome P450 activation is a subtype of molecular activation: A process that changes the activity of the cytochrome P450 to be higher.
This entity is a specific course-dependent process. This process can constitute the course of NASH.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0001758,,,,,,,,,,,,,,,,,,,,PMID:2708612,,"Cytochrome P450 activation is a subtype of molecular activation: A process that changes the activity of the cytochrome P450 to be higher.
This entity is a specific course-dependent process. This process can constitute the course of NASH.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003792,,,,,,http://purl.obolibrary.org/obo/TXPO_0003787|http://purl.obolibrary.org/obo/TXPO_0001856,,,,,,P450 activation [Glutathione depletion]|Cytochrome P450 activation [Glutathione depletion],,,,,TXPO:0003799,,,,,,,,,,,,,,,,,,,,,,Cytochrome P450 activation [NASH],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002124,negative regulation of tumor cell proliferation,,"Negative regulation of tumor cell proliferation is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of tumor cell proliferation.",false,,,http://purl.obolibrary.org/obo/TXPO_0000369,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of tumor cell proliferation is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of tumor cell proliferation.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002124,,,,,,,,,,,,,,,,,,,,,,negative regulation of tumor cell proliferation,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000339,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002120,GSTM4 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0002089,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:499689|NCBI-Mouse-GeneID:14865|NCBI-Human-GeneID:2948,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002120,,,,,,,,,,,,,,,,,,,,,,GSTM4 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002128,negative regulation of autophagy [Cell death],,"Any process that stops, prevents, or reduces the frequency, rate or extent of autophagy. Autophagy is the process in which cells digest parts of their own cytoplasm.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/GO_0010507|http://purl.obolibrary.org/obo/TXPO_0001727,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents, or reduces the frequency, rate or extent of autophagy. Autophagy is the process in which cells digest parts of their own cytoplasm.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002128,,,,,,,,,,,,,,,,,,,,,,negative regulation of autophagy [Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002123,cell invasion into other cell,,Cell invasion into other cell is a subtype of moving A to the inside of B: A process of the movement of a cell into other different cells.,false,,,http://purl.obolibrary.org/obo/TXPO_0002587,,,,,,,,,,,,,,,,,,,,,,Cell invasion into other cell is a subtype of moving A to the inside of B: A process of the movement of a cell into other different cells.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002123,,,,,,,,,,,,,,,,,,,,,,cell invasion into other cell,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002125,negative regulation of tumor cell proliferation [Cell death],,"Negative regulation of tumor cell proliferation is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of tumor cell proliferation.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0001727|http://purl.obolibrary.org/obo/TXPO_0002124,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of tumor cell proliferation is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of tumor cell proliferation.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002125,,,,,,,,,,,,,,,,,,,,,,negative regulation of tumor cell proliferation [Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002121,GSTM5 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0002089,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24423|NCBI-Human-GeneID:2949|NCBI-Mouse-GeneID:14862,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002121,,,,,,,,,,,,,,,,,,,,,,GSTM5 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002122,cell invasion into other cell [Cell death],,"Cell invasion into other cell is a subtype of moving A to the inside of B: A process of the movement of a cell into other different cells.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0001727|http://purl.obolibrary.org/obo/TXPO_0002123,,,,,,,,,,,,,,,,,,,,,,"Cell invasion into other cell is a subtype of moving A to the inside of B: A process of the movement of a cell into other different cells.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002387,,,,,,,,,,,TXPO:0002122,,,,,,,,,,,,,,,,,,,,,,cell invasion into other cell [Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002126,ATF6 signal transduction pathway,,A series of molecular signals mediated by ATF6 (activating transcription factor 6).,false,,,http://purl.obolibrary.org/obo/TXPO_0000609,,,,,,,,,,,,,,,,,,,,,,A series of molecular signals mediated by ATF6 (activating transcription factor 6).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000718,,,,,,,,,,,,,,,,,,TXPO:0002126,,,,,,,,,,,,,,,,,,,,,,ATF6 signal transduction pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002129,metabolic dysfunction [Cell death],,"Metabolic dysfunction is a subtype of dysfunctioning: A process that performs an abnormal and incomplete metabolic function.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0001727|http://purl.obolibrary.org/obo/TXPO_0002131,,,,,,,,,,,,,,,,,,,,,,"Metabolic dysfunction is a subtype of dysfunctioning: A process that performs an abnormal and incomplete metabolic function.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002387,,,,,,,,,,,TXPO:0002129,,,,,,,,,,,,,,,,,,,,,,metabolic dysfunction [Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002127,GSTO1 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0002089,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:14873|NCBI-Human-GeneID:9446|NCBI-Rat-GeneID:114846,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002127,,,,,,,,,,,,,,,,,,,,,,GSTO1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000608,IL-10 receptor,interleukin-10 receptor,,false,,,http://purl.obolibrary.org/obo/IMR_0000096,,,,,,,,,,,,,,,,,,,,GO:0004920,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,interleukin-10 receptor,,,,,IMR:0000608,,,,,,,,,,,,,,,,,,,,,,IL-10 receptor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_50629,cyclooxygenase 2 inhibitor,cyclo-oxygenase-2 inhibitors|prostaglandin-endoperoxide synthase 2 inhibitor|prostaglandin H synthase-2 inhibitors|cyclo-oxygenase 2 inhibitors|COX-2 inhibitor|PGHS-2 inhibitors|cyclooxygenase-2 inhibitors|cyclo-oxygenase-2 inhibitor|cyclooxygenase 2 inhibitors|prostaglandin H synthase-2 inhibitor|cyclooxygenase-2 inhibitor|PGHS-2 inhibitor|prostaglandin-endoperoxide synthase 2 inhibitors|COX-2 inhibitors|cyclo-oxygenase 2 inhibitor,A cyclooxygenase inhibitor that interferes with the action of cyclooxygenase 2.,false,,,http://purl.obolibrary.org/obo/CHEBI_35544,,,,,,,,,,,,,,,,,,,,,,A cyclooxygenase inhibitor that interferes with the action of cyclooxygenase 2.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,cyclo-oxygenase-2 inhibitors|prostaglandin-endoperoxide synthase 2 inhibitor|prostaglandin H synthase-2 inhibitors|cyclo-oxygenase 2 inhibitors|COX-2 inhibitor|PGHS-2 inhibitors|cyclooxygenase-2 inhibitors|cyclo-oxygenase-2 inhibitor|cyclooxygenase 2 inhibitors|prostaglandin H synthase-2 inhibitor|cyclooxygenase-2 inhibitor|PGHS-2 inhibitor|prostaglandin-endoperoxide synthase 2 inhibitors|COX-2 inhibitors|cyclo-oxygenase 2 inhibitor,,,,,,,,,,,,,,,,,,,,,CHEBI:50629,,,,cyclooxygenase 2 inhibitor,,CHEBI:50629,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000007329,UBE2I,,"Other designations: SUMO-1-protein ligase|SUMO-conjugating enzyme UBC9|SUMO-protein ligase|ubiquitin carrier protein 9|ubiquitin carrier protein I|ubiquitin conjugating enzyme 9|ubiquitin-conjugating enzyme E2I (UBC9 homolog, yeast)|ubiquitin-conjugating enzyme E2I (homologous to yeast UBC9)|ubiquitin-conjugating enzyme UbcE2A|ubiquitin-like protein SUMO-1 conjugating enzyme|ubiquitin-protein ligase E2I|ubiquitin-protein ligase I",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,C358B7.1|P18|UBC9,,,,,,,,,,,,16,,,,,,HPRD:09045|MIM:601661|HGNC:12485|Vega:OTTHUMG00000047845|Ensembl:ENSG00000103275,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,ubiquitin-conjugating enzyme E2I,,,16p13.3,,,,,,,,,,,,,,,,"GO_0000122 (EC: IMP, PMID: 19955185); GO_0000795 (EC: TAS, PMID: 8610150); GO_0001650 (EC: IEA); GO_0004842 (EC: TAS, PMID: 19955185); GO_0005515 (EC: IPI, PMID: 10871618); GO_0005524 (EC: IEA); GO_0005634 (EC: IDA, PMID: 14752048); GO_0005654 (EC: TAS); GO_0005737 (EC: IDA); GO_0006464 (EC: TAS, PMID: 8798754); GO_0006511 (EC: TAS, PMID: 8565643); GO_0007059 (EC: IEA); GO_0007067 (EC: IEA); GO_0008022 (EC: IEA); GO_0008134 (EC: IPI, PMID: 19744555); GO_0010469 (EC: IEA); GO_0016032 (EC: IEA); GO_0016605 (EC: IDA, PMID: 9885291); GO_0016925 (EC: IDA, PMID: 19955185); GO_0016925 (EC: IEA); GO_0016925 (EC: TAS); GO_0019789 (EC: IDA, Qualifier: contributes_to, PMID: 19955185); GO_0019899 (EC: IPI, PMID: 17087506); GO_0030425 (EC: IEA); GO_0033145 (EC: IEA); GO_0043161 (EC: IEA); GO_0043398 (EC: IEA); GO_0043425 (EC: IEA); GO_0043687 (EC: TAS); GO_0044267 (EC: TAS); GO_0044822 (EC: IDA); GO_0045202 (EC: IEA); GO_0045892 (EC: IDA, PMID: 16631117); GO_0051091 (EC: IEA); GO_0071535 (EC: IPI, PMID: 19407830)",,,,,,,,,PMID: 8565643; 8610150; 8668125; 8668529; 8733011; 8798622; 8798754; 8824223; 8921390; 8940097; 9067428; 9197546; 9223484; 9257699; 9261152; 9333025; 9334332; 9353268; 9488727; 9497385; 9514881; 9563508; 9855622; 9885291; 9920803; 10377438; 10380882; 10383460; 10497239; 10535925; 10655495; 10694430; 10737800; 10759568; 10788439; 10806190; 10871618; 10961991; 11025202; 11085938; 11112409; 11157797; 11278381; 11278694; 11367701; 11384992; 11447110; 11451954; 11583632; 11709548; 11735126; 11779867; 11792325; 11812797; 11842083; 11853669; 11867732; 11877416; 11927605; 11960997; 12021447; 12023963; 12072434; 12082530; 12110916; 12150977; 12177000; 12192048; 12200128; 12354770; 12356736; 12419227; 12477932; 12565873; 12615929; 12620973; 12621041; 12633878; 12641448; 12674497; 12679040; 12727872; 12761287; 12788062; 12813045; 12887893; 12924945; 14516784; 14517060; 14517261; 14527952; 14531806; 14556380; 14578449; 14609633; 14673145; 14702039; 14752048; 14765993; 15087395; 15105549; 15123615; 15192080; 15210726; 15231748; 15246872; 15312759; 15327968; 15378033; 15489334; 15539951; 15546615; 15588942; 15592428; 15604093; 15608651; 15611122; 15611636; 15613319; 15616553; 15635413; 15637059; 15637079; 15666801; 15723523; 15735760; 15802564; 15806172; 15809060; 15820677; 15829507; 15876874; 15881673; 15882978; 15896780; 15931224; 15952105; 15958389; 15983381; 16029420; 16061479; 16098147; 16120648; 16148010; 16154161; 16166628; 16169070; 16189514; 16212558; 16248985; 16421094; 16421255; 16455055; 16455490; 16469311; 16494873; 16524884; 16566921; 16620772; 16631117; 16713569; 16730941; 16732283; 16998888; 17005699; 17036045; 17037517; 17087506; 17087659; 17105732; 17261810; 17283066; 17297476; 17314004; 17336575; 17353931; 17391059; 17466333; 17491593; 17498654; 17533377; 17548468; 17646165; 17671234; 17698038; 17704809; 17709345; 17823119; 17956732; 17967884; 17987106; 18087039; 18211895; 18321803; 18359863; 18408014; 18455188; 18538659; 18624398; 18625722; 18628979; 18655774; 18660489; 18684836; 18691969; 18706886; 18819927; 18946085; 19218564; 19287951; 19343802; 19358266; 19407830; 19471022; 19549727; 19553542; 19597476; 19616115; 19640976; 19684601; 19727227; 19744555; 19760037; 19765634; 19766626; 19836047; 19843541; 19859084; 19946338; 19955185; 19965618; 20016594; 20016603; 20023705; 20209145; 20351170; 20359522; 20360068; 20501649; 20555024; 20561671; 20671745; 20696768; 20797634; 20805487; 20863840; 20936779; 20972456; 21047957; 21070824; 21113135; 21120624; 21139048; 21139563; 21147068; 21174150; 21203974; 21216249; 21288202; 21319273; 21336309; 21344391; 21467194; 21510985; 21518904; 21693764; 21795333; 21829513; 21836637; 21880185; 21890473; 21906983; 21940674; 21949651; 21965678; 21971700; 21988832; 21998312; 22114711; 22155184; 22162396; 22194619; 22214662; 22403398; 22407595; 22411991; 22464730; 22578841; 22614022; 22623531; 22731716; 22797925; 22825850; 22863883; 22910413; 22939629; 23000965; 23128241; 23131550; 23155000; 23187003; 23264041; 23381475; 23395904; 23404503; 23417673; 23455924; 23470653; 23628505; 23686912; 23788427; 23860269; 23861967; 23871147; 23990779; 24068740; 24086615; 24260396; 24362530,,,,,,,,,,,,,,,OGG:3000007329,,,,,,,ubiquitin-conjugating enzyme E2I,,,,,,,,,,,,,"Other designations: SUMO-1-protein ligase|SUMO-conjugating enzyme UBC9|SUMO-protein ligase|ubiquitin carrier protein 9|ubiquitin carrier protein I|ubiquitin conjugating enzyme 9|ubiquitin-conjugating enzyme E2I (UBC9 homolog, yeast)|ubiquitin-conjugating enzyme E2I (homologous to yeast UBC9)|ubiquitin-conjugating enzyme UbcE2A|ubiquitin-like protein SUMO-1 conjugating enzyme|ubiquitin-protein ligase E2I|ubiquitin-protein ligase I",,UBE2I,,,,,,,,,,,,,,,,,,,,,,,7329,LA16c-358B7.1,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,UBE2I,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/NCIT_C50678,occlusion,,"Obstruction or a closure of hollow organ, passageway or vessel; also the transient approximation of the edges of a natural opening; imperforation.",false,,,http://purl.obolibrary.org/obo/TXPO_0002656,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C50678,,"Obstruction or a closure of hollow organ, passageway or vessel; also the transient approximation of the edges of a natural opening; imperforation.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,NCIT:C50678,,,,,,,"The act of closure or the state of being closed; an obstruction; the relationship between all of the components of the masticatory system in normal function, dysfunction, and parafunction; momentary complete closure of some area in the vocal tract, causing stoppage of the breath and accumulation of pressure.",,,,,,,,,,,,,,,occlusion,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0005769,early endosome,,A membrane-bounded organelle that receives incoming material from primary endocytic vesicles that have been generated by clathrin-dependent and clathrin-independent endocytosis; vesicles fuse with the early endosome to deliver cargo for sorting into recycling or degradation pathways.,false,,,http://purl.obolibrary.org/obo/GO_0005768,,,,,,,,,,,,,,,,,,,,,,A membrane-bounded organelle that receives incoming material from primary endocytic vesicles that have been generated by clathrin-dependent and clathrin-independent endocytosis; vesicles fuse with the early endosome to deliver cargo for sorting into recycling or degradation pathways.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0005769,,,,,,,,,,,,,,,,,,,,,,early endosome,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0005768,endosome,,A vacuole to which materials ingested by endocytosis are delivered.,false,,,http://purl.obolibrary.org/obo/GO_0031982,,,,,,,,,,,,,,,,,,,,Wikipedia:Endosome|NIF_Subcellular:sao1720343330,,A vacuole to which materials ingested by endocytosis are delivered.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0005768,,,,,,,,,,,,,,,,,,,,,,endosome,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0005764,lysosome,,"A small lytic vacuole that has cell cycle-independent morphology and is found in most animal cells and that contains a variety of hydrolases, most of which have their maximal activities in the pH range 5-6. The contained enzymes display latency if properly isolated. About 40 different lysosomal hydrolases are known and lysosomes have a great variety of morphologies and functions.|Another function of the ER in eucaryotic cells is to sequester Ca2+ from the cytosol. Cell",false,,,http://purl.obolibrary.org/obo/GO_0005773,,,,,,,,,,,,,,,,,,,,Wikipedia:Lysosome|PMID:10751143,,"A small lytic vacuole that has cell cycle-independent morphology and is found in most animal cells and that contains a variety of hydrolases, most of which have their maximal activities in the pH range 5-6. The contained enzymes display latency if properly isolated. About 40 different lysosomal hydrolases are known and lysosomes have a great variety of morphologies and functions.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005765,,,,http://purl.obolibrary.org/obo/PATO_0001429,,,,,,,,,,,,,,GO:0005764,,,,,,,,,,,,,,,,,,,,Another function of the ER in eucaryotic cells is to sequester Ca2+ from the cytosol. Cell,,lysosome,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0005765,lysosomal membrane,,The lipid bilayer surrounding the lysosome and separating its contents from the cell cytoplasm.,false,,,http://purl.obolibrary.org/obo/GO_0031090,,,,,,,,,,,,,,,,,,,,,,The lipid bilayer surrounding the lysosome and separating its contents from the cell cytoplasm.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005764,GO:0005765,http://purl.obolibrary.org/obo/GO_0005764,,,,,,,,,,,,,,,,,,,,,lysosomal membrane,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_59739,electrophilic reagent,electrophile|electrophiles|electrophilic reagents,A reagent that forms a bond to its reaction partner (the nucleophile) by accepting both bonding electrons from that reaction partner.,false,,,http://purl.obolibrary.org/obo/CHEBI_37527,,,,,,,,,,,,,,,,,,,,,,A reagent that forms a bond to its reaction partner (the nucleophile) by accepting both bonding electrons from that reaction partner.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,electrophile|electrophiles|electrophilic reagents,,,,,CHEBI:59739,,,,,,,,,,,,,,,,,,,,,,electrophilic reagent,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000234,MEKK,MAPK/ERK kinase kinase,,false,,,http://purl.obolibrary.org/obo/IMR_0000229,,,,,,,,,,,,,,,,,,,,GO:0004710,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MAPK/ERK kinase kinase,,,,,IMR:0000234,,,,,,,,,,,,,,,,,,,,,,MEKK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001138,keratocan,,,false,,,http://purl.obolibrary.org/obo/IMR_0001128,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001138,,,,,,,,,,,,,,,,,,,,,,keratocan,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000670,PAK3,,,false,,,http://purl.obolibrary.org/obo/IMR_0000238,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000670,,,,,,,,,,,,,,,,,,,,,,PAK3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000008431,NR0B2 (mol),"nuclear receptor subfamily 0, group B, member 2|SHP1","The protein encoded by this gene is an unusual orphan receptor that contains a putative ligand-binding domain but lacks a conventional DNA-binding domain. The gene product is a member of the nuclear hormone receptor family, a group of transcription factors regulated by small hydrophobic hormones, a subset of which do not have known ligands and are referred to as orphan nuclear receptors. The protein has been shown to interact with retinoid and thyroid hormone receptors, inhibiting their ligand-dependent transcriptional activation. In addition, interaction with estrogen receptors has been demonstrated, leading to inhibition of function. Studies suggest that the protein represses nuclear hormone receptor-mediated transactivation via two separate steps: competition with coactivators and the direct effects of its transcriptional repressor function. [provided by RefSeq, Jul 2008]",false,,,http://purl.obolibrary.org/obo/CHEBI_25367|http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:8431|OMIM:604630,,"The protein encoded by this gene is an unusual orphan receptor that contains a putative ligand-binding domain but lacks a conventional DNA-binding domain. The gene product is a member of the nuclear hormone receptor family, a group of transcription factors regulated by small hydrophobic hormones, a subset of which do not have known ligands and are referred to as orphan nuclear receptors. The protein has been shown to interact with retinoid and thyroid hormone receptors, inhibiting their ligand-dependent transcriptional activation. In addition, interaction with estrogen receptors has been demonstrated, leading to inhibition of function. Studies suggest that the protein represses nuclear hormone receptor-mediated transactivation via two separate steps: competition with coactivators and the direct effects of its transcriptional repressor function. [provided by RefSeq, Jul 2008]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000008431,,,,,,,,"nuclear receptor subfamily 0, group B, member 2|SHP1",,,,,OGG:3000008431,,,,,,,,,,,,,,,,,,,,,,NR0B2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100028,IP3,"Inositol 1,4,5-Trisphosphate|D-myo-Inositol 1,4,5-trisphosphate|1D-myo-Inositol 1,4,5-trisphosphate|1,4,5-InsP3",,false,,,http://purl.obolibrary.org/obo/IMR_0001385,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002401,,,,IMR:0200332,"Inositol 1,4,5-Trisphosphate|D-myo-Inositol 1,4,5-trisphosphate|1D-myo-Inositol 1,4,5-trisphosphate|1,4,5-InsP3",,,,,IMR:0100028,,,,,,,,,,,,,,,,,,,,,,IP3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000283131,NEAT1,,,false,,,http://purl.obolibrary.org/obo/OGG_2100009606,,TncRNA|LINC00084|NCRNA00084|VINC,,,,,,,,,,,,11,,,,,,HGNC:30815|MIM:612769,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,nuclear paraspeckle assembly transcript 1 (non-protein coding),,,11q13.1,,,,,,,,,,,,,,,,,,,,,,,,,PMID: 9253601; 9858482; 11458881; 12565840; 17270048; 19217333; 19716791; 20881053; 21170033; 21532345; 22960638; 23362321; 23835137,,,,,,,,,,,,,,,OGG:3000283131,,20140408,ncRNA,,,,nuclear paraspeckle assembly transcript 1 (non-protein coding),,,,,,,,,,,,,,,NEAT1,,,,,,,,,,,,,,,,,,,,,,,283131,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,NEAT1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_25435,mutagen,mutagenes|mutagene|mutagens|mutagenic agent|mutagenos|mutageno,"An agent that increases the frequency of mutations above the normal background level, usually by interacting directly with DNA and causing it damage, including base substitution.",false,,,http://purl.obolibrary.org/obo/CHEBI_50902,,,,,,,,,,,,,,,,,,,,Wikipedia:Mutagen,,"An agent that increases the frequency of mutations above the normal background level, usually by interacting directly with DNA and causing it damage, including base substitution.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,mutagenes|mutagene|mutagens|mutagenic agent|mutagenos|mutageno,,,,,,,,,,,,,,,,,,,,,CHEBI:25435,,,,mutagen,,CHEBI:25435,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000339,Grb2 family,,"The best characterised member of the SH2/SH3 adaptor protein family is Grb2, the human homologue of the nematode Caenorhabditis elegans protein Sem-5. The structure of Grb2 consists of one SH2 domain flanked by two SH3 domains. Recently, further members of the Grb2 family have been isolated, Grap protein and Gads.",false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,"The best characterised member of the SH2/SH3 adaptor protein family is Grb2, the human homologue of the nematode Caenorhabditis elegans protein Sem-5. The structure of Grb2 consists of one SH2 domain flanked by two SH3 domains. Recently, further members of the Grb2 family have been isolated, Grap protein and Gads.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003681,,,,,,,,,,IMR:0000339,,,,,,,,,,,,,,,,,,,,,,Grb2 family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000000635,BHMT,,Other designations: betaine--homocysteine S-methyltransferase 1|epididymis secretory sperm binding protein Li 61p,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,BHMT1|HEL-S-61p,,,,,,,,,,,,5,,,,,,HGNC:1047|Ensembl:ENSG00000145692|MIM:602888|HPRD:04200|Vega:OTTHUMG00000108157,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,betaine--homocysteine S-methyltransferase,,,5q14.1,,,,,,,,,,,,,,,,"GO_0000096 (EC: TAS); GO_0005737 (EC: IDA); GO_0005829 (EC: TAS); GO_0006479 (EC: NAS, PMID: 10075673); GO_0006579 (EC: IEA); GO_0008270 (EC: IEA); GO_0008898 (EC: IEA); GO_0009086 (EC: IEA); GO_0010243 (EC: IEA); GO_0032403 (EC: IEA); GO_0034641 (EC: TAS); GO_0043234 (EC: IEA); GO_0044281 (EC: TAS); GO_0047150 (EC: NAS, PMID: 10075673); GO_0047150 (EC: TAS); GO_0050666 (EC: NAS, PMID: 10075673)",,,,,,,,,PMID: 1657504; 8798461; 8889548; 9281325; 9681996; 10075673; 10529246; 11223523; 11516176; 11883905; 12071701; 12220488; 12475213; 12477932; 12749058; 12818402; 15122900; 15489334; 16189514; 16344560; 16816108; 16953798; 17035141; 17119116; 17376725; 17436311; 17705221; 17993766; 18000879; 18029348; 18230680; 18262489; 18427977; 18457970; 18498552; 18635682; 18676680; 18708404; 18830263; 18988749; 19048631; 19161160; 19170196; 19336437; 19493349; 19625176; 19635752; 19683694; 19692168; 19737740; 19777601; 19913121; 19936946; 19948975; 20031554; 20346360; 20453000; 20458436; 20628086; 20634891; 20662904; 20664391; 20737570; 21093336; 21349258; 21564312; 21565678; 21630102; 21988832; 22138536; 22339686; 22339736; 23378610; 23645037; 23720494,,,,,,,,,,,,,,,OGG:3000000635,,,,,,,betaine--homocysteine S-methyltransferase,,,,,,,,,,,,,Other designations: betaine--homocysteine S-methyltransferase 1|epididymis secretory sperm binding protein Li 61p,,BHMT,,,,,,,,,,,,,,,,,,,,,,,635,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,BHMT,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000000637,BID,,Other designations: BH3-interacting domain death agonist|BID isoform ES(1b)|BID isoform L(2)|BID isoform Si6|Human BID coding sequence|apoptic death agonist|desmocollin type 4|p22 BID,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,FP497,,,,,,,,,,,,22,,,,,,HGNC:1050|Ensembl:ENSG00000015475|MIM:601997|HPRD:03590|Vega:OTTHUMG00000150087,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,BH3 interacting domain death agonist,,,22q11.1,,,,,,,,,,,,,,,,"GO_0001836 (EC: IDA, PMID: 17052454); GO_0005123 (EC: TAS, PMID: 8918887); GO_0005515 (EC: IPI, PMID: 12624108); GO_0005739 (EC: TAS, PMID: 9727491); GO_0005741 (EC: TAS); GO_0005829 (EC: TAS); GO_0006626 (EC: IEA); GO_0006915 (EC: TAS); GO_0006919 (EC: IEA); GO_0007420 (EC: IEA); GO_0008625 (EC: TAS, PMID: 9727491); GO_0008637 (EC: TAS, PMID: 9727492); GO_0016020 (EC: TAS, PMID: 8918887); GO_0031625 (EC: IEA); GO_0032355 (EC: IEA); GO_0032461 (EC: IDA, PMID: 19074440); GO_0032464 (EC: IDA); GO_0032592 (EC: IEA); GO_0034349 (EC: IEA); GO_0042127 (EC: IEA); GO_0042770 (EC: TAS, PMID: 18309324); GO_0043065 (EC: IMP, PMID: 17289999); GO_0051260 (EC: IEA); GO_0051402 (EC: TAS, PMID: 16167175); GO_0090150 (EC: IDA); GO_0090200 (EC: IGI); GO_0090200 (EC: IMP, PMID: 17289999); GO_0097193 (EC: TAS); GO_1900740 (EC: TAS); GO_1901030 (EC: TAS); GO_1902108 (EC: IEA); GO_2000045 (EC: IEA); GO_2001238 (EC: IMP); GO_2001244 (EC: TAS)",,,,,,,,,PMID: 7774948; 7929347; 8918887; 9463381; 9721221; 9727491; 9727492; 9790773; 10089877; 10364179; 10629050; 10950869; 11085743; 11099414; 11114298; 11399776; 11544326; 11583622; 11583631; 11585909; 11741882; 11790791; 11805084; 11832478; 11929871; 11940658; 11971973; 12000759; 12061801; 12097160; 12193163; 12196516; 12404116; 12419244; 12477932; 12598529; 12624108; 12754217; 12766488; 12804595; 12808108; 12871587; 12934063; 14581476; 14583606; 14702039; 14716828; 14769944; 15024076; 15117953; 15123718; 15146197; 15173176; 15231831; 15323553; 15353804; 15461802; 15489334; 15501827; 15520201; 15574335; 15592455; 15615731; 15637055; 15659383; 15692567; 15694340; 15721256; 15772077; 15809076; 16077201; 16167175; 16172118; 16341674; 16344560; 16380381; 16475813; 16485030; 16697956; 16908521; 16964285; 16987815; 17052454; 17200714; 17226776; 17283187; 17289999; 17308307; 17431792; 17488272; 17534194; 17549073; 17635912; 17666167; 17762183; 17765974; 17855051; 18029348; 18089817; 18165867; 18166654; 18173728; 18195012; 18297401; 18309324; 18317451; 18373075; 18469004; 18593990; 18648372; 18665919; 18723680; 18838202; 18925930; 19029793; 19046991; 19052714; 19074440; 19074885; 19219602; 19233849; 19246452; 19381674; 19423537; 19454696; 19640637; 19641510; 19670908; 19711428; 19820711; 19890662; 19913121; 19918914; 19929986; 20140092; 20187936; 20356928; 20379614; 20392206; 20404718; 20453000; 20628086; 20801175; 20802294; 20855536; 20877624; 21041309; 21060336; 21072056; 21113148; 21139048; 21148306; 21178828; 21223573; 21367852; 21382479; 21613222; 21642428; 21751259; 21856753; 21859891; 21900206; 21906983; 22052011; 22115752; 22130162; 22189507; 22213163; 22246181; 22339673; 22354970; 22393005; 22416135; 22464442; 22860893; 22939629; 22964611; 23019260; 23192964; 23333919; 23352961; 23383273; 23418437; 23604079; 23744079; 23824909; 24074954; 24158446,,,,,,,,,,,,,,,OGG:3000000637,,,,,,,BH3 interacting domain death agonist,,,,,,,,,,,,,Other designations: BH3-interacting domain death agonist|BID isoform ES(1b)|BID isoform L(2)|BID isoform Si6|Human BID coding sequence|apoptic death agonist|desmocollin type 4|p22 BID,,BID,,,,,,,,,,,,,,,,,,,,,,,637,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,BID,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000000639,PRDM1,,Other designations: B-lymphocyte-induced maturation protein 1|BLIMP-1|PR domain zinc finger protein 1|PRDI-binding factor-1|beta-interferon gene positive-regulatory domain I binding factor,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,PRDI-BF1|BLIMP1,,,,,,,,,,,,6,,,,,,MIM:603423|HGNC:9346|Vega:OTTHUMG00000015299|Ensembl:ENSG00000057657|HPRD:04572,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"PR domain containing 1, with ZNF domain",,,6q21,,,,,,,,,,,,,,,,"GO_0000122 (EC: IEA); GO_0001893 (EC: IEA); GO_0003700 (EC: TAS, PMID: 1851123); GO_0005515 (EC: IPI); GO_0005634 (EC: IEA); GO_0005737 (EC: IDA); GO_0006351 (EC: IEA); GO_0007281 (EC: IEA); GO_0008168 (EC: IEA); GO_0010628 (EC: IEA); GO_0030889 (EC: IEA); GO_0031665 (EC: IEA); GO_0042462 (EC: IEA); GO_0042826 (EC: IEA); GO_0043565 (EC: IEA); GO_0045165 (EC: IEA); GO_0045579 (EC: IEA); GO_0046872 (EC: IEA); GO_0060707 (EC: IEA)",,,,,,,,,PMID: 1851123; 8033216; 8168136; 8921366; 9887105; 10713181; 11067898; 11342629; 11877292; 12150891; 12165517; 12453881; 12477932; 12626569; 14985713; 16002735; 16424392; 16492805; 16547239; 16585013; 16699504; 16713569; 16765445; 16849320; 17043021; 17213024; 17264218; 17379744; 17682124; 17877160; 18071884; 18089822; 18192112; 18235046; 18256039; 18354204; 18370921; 18400362; 18552212; 18583325; 18596541; 18604866; 18845144; 18992153; 19047678; 19124609; 19194464; 19234190; 19269192; 19322201; 19433448; 19460752; 19530237; 19563034; 19717648; 19735688; 19760754; 19788443; 19828629; 19828640; 19838193; 19838195; 19898481; 19915048; 20047096; 20379614; 20530581; 20800019; 20859709; 20944005; 20966935; 21102463; 21103670; 21216962; 21411757; 21622776; 21690554; 21722313; 21722636; 21785431; 22020966; 22040493; 22143801; 22278826; 22438909; 22555612; 22580854; 22585398; 22593617; 22634616; 22939624; 23028907; 23129528; 23273568; 23348703; 23624108; 23648065; 23911415; 24004669; 24009228,,,,,,,,,,,,,,,OGG:3000000639,,,,,,,"PR domain containing 1, with ZNF domain",,,,,,,,,,,,,Other designations: B-lymphocyte-induced maturation protein 1|BLIMP-1|PR domain zinc finger protein 1|PRDI-binding factor-1|beta-interferon gene positive-regulatory domain I binding factor,,PRDM1,,,,,,,,,,,,,,,,,,,,,,,639,RP1-134E15.1,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,PRDM1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0001222,hydoroxy acid,,,false,,,http://purl.obolibrary.org/obo/TXPO_0001144,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001222,,,,,,,,,,,,,,,,,,,,,,hydoroxy acid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001229,increasing hepatic vascular lumen area,,Increasing hepatic vascular lumen area is a subtype of increasing area: A process that changes the area of the hepatic vascular lumen area to be larger.,false,,,http://purl.obolibrary.org/obo/TXPO_0000140,,,,,,,,,,,,,,,,,,,,,,Increasing hepatic vascular lumen area is a subtype of increasing area: A process that changes the area of the hepatic vascular lumen area to be larger.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001229,,,,,,,,,,,,,,,,,,,,,,increasing hepatic vascular lumen area,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001228,hyperfunction of glutathione conjugation,,Hyperfunction of glutathione conjugation is a subtype of hyperfunction of drug metabolism phase II: A process that performs an excessive glutathione conjugation.,false,,,http://purl.obolibrary.org/obo/TXPO_0000435,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of glutathione conjugation is a subtype of hyperfunction of drug metabolism phase II: A process that performs an excessive glutathione conjugation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001228,,,,,,,,,,,,,,,,,,,,,,hyperfunction of glutathione conjugation,,,,,,http://purl.obolibrary.org/obo/TXPO_0003991,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001226,Acaa1a (rat)[lipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001088|http://purl.obolibrary.org/obo/TXPO_1000017,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24157|PMID:17255113|PMID:2307679,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001226,,,,,,,,,,,,,,,,,,,,,,Acaa1a (rat)[lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001225,toxicity prediction related role,,A role played by the entity within a toxicity prediction context.,false,,,http://purl.obolibrary.org/obo/BFO_0000023,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001225,,,,,,,,,,,,,,,,,,,,A role played by the entity within a toxicity prediction context.,,toxicity prediction related role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001220,lipid catabolic process [lipidosis],,"The chemical reactions and pathways resulting in the breakdown of lipids, compounds soluble in an organic solvent but not, or sparingly, in an aqueous solvent.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/GO_0016042|http://purl.obolibrary.org/obo/TXPO_0001720,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways resulting in the breakdown of lipids, compounds soluble in an organic solvent but not, or sparingly, in an aqueous solvent.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001390,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001157,,,,,,,,,,,TXPO:0001220,,,,,,,,,,,,,,,,,,,,,,lipid catabolic process [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001221,lipid transport from hepatocyte to extrahepatic [lipidosis],,"Lipid transport from liver is a subtype of lipid transport.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001271|http://purl.obolibrary.org/obo/TXPO_0001720,,,,,,,,,,,,,,,,,,,,,,"Lipid transport from liver is a subtype of lipid transport.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003487|http://purl.obolibrary.org/obo/TXPO_0001457,,,,,,,,,,,,,,,,,,TXPO:0001221,,,,,,,,,,,,,,,,,,,,,,lipid transport from hepatocyte to extrahepatic [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001227,hyperfunction of glucuronic acid conjugation,,Hyperfunction of glucuronic acid conjugation is a subtype of hyperfunction of drug metabolism phase II: A process that performs an excessive glucuronic acid conjugation.,false,,,http://purl.obolibrary.org/obo/TXPO_0000435,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of glucuronic acid conjugation is a subtype of hyperfunction of drug metabolism phase II: A process that performs an excessive glucuronic acid conjugation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001227,,,,,,,,,,,,,,,,,,,,,,hyperfunction of glucuronic acid conjugation,,,,,,http://purl.obolibrary.org/obo/GO_0052697,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001223,positive regulation process,,"Positive regulation process is a subtype of controlling: A process that activates or increases the frequency, rate or extent of function.|Any process that activates, maintains or increases the  rate or extent of a process.",false,,,http://purl.obolibrary.org/obo/TXPO_0000113,,,,,,,,,,,,,,,,,,,,,,"Positive regulation process is a subtype of controlling: A process that activates or increases the frequency, rate or extent of function.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001223,,,,,,,,,,,,,,,,,,,,"Any process that activates, maintains or increases the  rate or extent of a process.",,positive regulation process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/BFO_0000015,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001224,alcohol intake,,A moving process of alcohol from the outside to the inside of a body.,false,,,http://purl.obolibrary.org/obo/TXPO_0002587,,,,,,,,,,,,,,,,,,,,,,A moving process of alcohol from the outside to the inside of a body.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_30879,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001224,,,,,,,,,,,,,,,,,,,,,,alcohol intake,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000008339,HIST1H2BG,,"Other designations: H2B histone family, member A|histone 1, H2bg|histone H2B type 1-C/E/F/G/I|histone H2B.1 A|histone H2B.a",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,H2BFA|H2B/a|dJ221C16.8|H2B.1A,,,,,,,,,,,,6,,,,,,HPRD:11897|Ensembl:ENSG00000187990|Vega:OTTHUMG00000014446|MIM:602798|HGNC:4746,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"histone cluster 1, H2bg",,,6p21.3,,,,,,,,,,,,,,,,,,,,,,,,,PMID: 422550; 1916825; 8620898; 8814229; 9119399; 9439656; 9566873; 9973324; 11080476; 11689053; 11790298; 11859126; 12408966; 12477932; 12757711; 12860195; 14574404; 14595808; 14657027; 15019208; 15161933; 15489334; 16196087; 16283522; 16307923; 16319397; 16457587; 16627869; 16713563; 16916647; 18247557; 18457437; 20639865; 21130743; 21139048; 21890473; 21906983; 21907836; 21963094; 21987572; 22053931; 22505724; 22616001; 22623428; 23000965,,,,,,,,,,,,,,,OGG:3000008339,,20140408,protein-coding,,,,"histone cluster 1, H2bg",,,,,,,,,,,,,"Other designations: H2B histone family, member A|histone 1, H2bg|histone H2B type 1-C/E/F/G/I|histone H2B.1 A|histone H2B.a",,HIST1H2BG,,,,,,,,,,,,,,,,,,,,,,,8339,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,HIST1H2BG,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000008337,HIST2H2AA3,,"Other designations: H2A histone family, member O|histone 2, H2aa3|histone H2A type 2-A",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,H2AFO|H2A/O|H2a-615|HIST2H2AA|H2A.2|H2A|H2A/q,,,,,,,,,,,,1,,,,,,MIM:142720|HPRD:08851|HGNC:4736,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"histone cluster 2, H2aa3",,,1q21.2,,,,,,,,,,,,,,,,,,,,,,,,,PMID: 2071153; 6326092; 8179821; 8543049; 8858345; 9439656; 9566873; 11080476; 11181995; 11375490; 11689053; 12408966; 12477932; 12628926; 14657027; 14759373; 14992727; 15010469; 15078818; 15386022; 15489334; 15527963; 15635413; 15823041; 16159877; 16319397; 16322561; 16359901; 16457589; 16702407; 16710414; 18688256; 19615732; 20525793; 20599239; 20639865; 20972266; 21041483; 21139048; 21179169; 21443952; 21693764; 21726816; 21772249; 21832049; 21890473; 21906983; 21963094; 21987572; 22053931; 22505724; 22810585; 22980979; 23000965; 23349634; 24457600,,,,,,,,,,,,,,,OGG:3000008337,,,,,,,"histone cluster 2, H2aa3",,,,,,,,,,,,,"Other designations: H2A histone family, member O|histone 2, H2aa3|histone H2A type 2-A",,HIST2H2AA3,,,,,,,,,,,,,,,,,,,,,,,8337,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,HIST2H2AA3,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0000215,dysfunction of protein quality control,,Dysfunction of protein quality control is a subtype of dysfunctioning: A process that performs an abnormal and incomplete  protein quality control function.,false,,,http://purl.obolibrary.org/obo/TXPO_0000438,,,,,,,,,,,,,,,,,,,,,,Dysfunction of protein quality control is a subtype of dysfunctioning: A process that performs an abnormal and incomplete  protein quality control function.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000215,,,,,,,,,,,,,,,,,,,,,,dysfunction of protein quality control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000000,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000217,hepatocyte proliferation [Hypertrophy],,"A process that results in an increase in hepatic cell number by cell division, often leading to an increase in the size of an liver.
This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy.",false,,,http://purl.obolibrary.org/obo/TXPO_0003279|http://purl.obolibrary.org/obo/GO_0072574,,,,,,,,,,,,,,,,,,,,,,"A process that results in an increase in hepatic cell number by cell division, often leading to an increase in the size of an liver.
This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001546|http://purl.obolibrary.org/obo/TXPO_0001422|http://purl.obolibrary.org/obo/TXPO_0000739,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003271,,,,,,,,,,,TXPO:0000217,,,,,,,,,,,,,,,,,,,,,,hepatocyte proliferation [Hypertrophy],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000214,protein quality control for unfolded via gene expression regulation [ER stress],,"Protein quality control for misfolded or incompletely synthesized proteins is a subtype of keeping quality: A process that maintains the protein quality mediated by the gene expression regulation.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000213|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"Protein quality control for misfolded or incompletely synthesized proteins is a subtype of keeping quality: A process that maintains the protein quality mediated by the gene expression regulation.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000386|http://purl.obolibrary.org/obo/TXPO_0000413,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002544,,,,,,,,,,,TXPO:0000214,,,,,,,,,,,,,,,,,,,,,,protein quality control for unfolded via gene expression regulation [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000000,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000212,electrophiles formation,,Electrophiles formation is a subtype of biosynthetic process: A process that that generates electrophiles. Electrophile is a reagent that forms a bond to its reaction partner (the nucleophile) by accepting both bonding electrons from that reaction partner..,false,,,http://purl.obolibrary.org/obo/GO_0009058,,,,,,,,,,,,,,,,,,,,,,Electrophiles formation is a subtype of biosynthetic process: A process that that generates electrophiles. Electrophile is a reagent that forms a bond to its reaction partner (the nucleophile) by accepting both bonding electrons from that reaction partner..,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000212,,,,,,,"A number of xenobiotics exert a toxic effect theough their metabolites.
Electrophiles are molecules that contain an electron-deficient atom with a partial or full positive charge that can react by sharing electron pairs with electron rich atoms in nucleophiles.
Electrophilic toxicants generally are detoxificated by conjugation of with the nucleophile, glutathione.
This reaction can be facilitated by glutathione S-trasferases.",,,,,,,,,,,,,,,electrophiles formation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000219,fibrosis,,Fibrosis is a subtype of changing material: A process that replaces tissues to fibrous connective tissues/,false,,,http://purl.obolibrary.org/obo/TXPO_0002590,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/MPATH_181,,Fibrosis is a subtype of changing material: A process that replaces tissues to fibrous connective tissues/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000219,,,,,,,,,,,,,,,,,,,,,,fibrosis,,,,,,,,,,,,,,,,,,http://www.w3.org/2002/07/owl#Thing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000218,icreasing volume of endoplasmic reticulum,,Icreasing volume of endoplasmic reticulum is a subtype of increasing organelle volume: A process that changes the volume of the endoplasmic reticulum to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0003741,,,,,,,,,,,,,,,,,,,,,,Icreasing volume of endoplasmic reticulum is a subtype of increasing organelle volume: A process that changes the volume of the endoplasmic reticulum to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000218,,,,,,,,,,,,,,,,,,,,,,icreasing volume of endoplasmic reticulum,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000211,IL-2 gene expression,,IL-2 gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature IL-2 gene product or products (proteins or RNA).,false,,,http://purl.obolibrary.org/obo/TXPO_0002266,,,,,,,,,,,,,,,,,,,,,,IL-2 gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature IL-2 gene product or products (proteins or RNA).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000211,,,,,,,,,,,,,,,,,,,,,,IL-2 gene expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000213,protein quality control for unfolded proteins,protein quality control for misfolded or incompletely synthesized proteins,"Protein quality control for misfolded or incompletely synthesized proteins is a subtype of keeping quality: A process that maintains  the protein quality.|GO:0006515 (protein quality control for misfolded or incompletely synthesized proteins) focuses on ERAD process. Our entity includes the process such as protein folding, ERAD and translation attenuation for unfolded protein response.",false,,,http://purl.obolibrary.org/obo/TXPO_0000474,,,,,,,,,,,,,,,,,,,,,,Protein quality control for misfolded or incompletely synthesized proteins is a subtype of keeping quality: A process that maintains  the protein quality.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,protein quality control for misfolded or incompletely synthesized proteins,,,,TXPO:0000213,,,,,,,,,,,,,,,,,,,,"GO:0006515 (protein quality control for misfolded or incompletely synthesized proteins) focuses on ERAD process. Our entity includes the process such as protein folding, ERAD and translation attenuation for unfolded protein response.",,protein quality control for unfolded proteins,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000216,increasing number of stress responses,,Increasing number of stress responses is a subtype of increasing number of actions: A process that becomes larger in the number of stress responses.,false,,,http://purl.obolibrary.org/obo/TXPO_0000344,,,,,,,,,,,,,,,,,,,,,,Increasing number of stress responses is a subtype of increasing number of actions: A process that becomes larger in the number of stress responses.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000216,,,,,,,,,,,,,,,,,,,,,,increasing number of stress responses,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000210,nucleophiles formation,,Nucleophiles formation is a subtype of biosynthetic process: The chemical reaction resulting in the formation of nucleophiles by donating  electrons.,false,,,http://purl.obolibrary.org/obo/GO_0009058,,,,,,,,,,,,,,,,,,,,,,Nucleophiles formation is a subtype of biosynthetic process: The chemical reaction resulting in the formation of nucleophiles by donating  electrons.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000210,,,,,,,"Nucleophiles generally are detoxificated by conjugation of a functinal group to the nucleophilic atom.
Sulfonation, glucuronidation, methylation, and acetylation are common reactions.|A number of xenobiotics exert a toxic effect theough their metabolites.
The increased reactivity may be due to conversion into electrophiles, free radicals, nucleophiles, or redox-active reactants.

Casarett and Doull's toxicology 8th ed. Chapter 3 step1  Delibery:From the site to exposure to the target",,,,,,,,,,,,,,,nucleophiles formation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100250,MLK1,MAP3K9,,false,,,http://purl.obolibrary.org/obo/IMR_0100249,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MAP3K9,,,,,IMR:0100250,,,,,,,,,,,,,,,,,,,,,,MLK1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000035,type I cytokeratin,acidic cytokeratin,,false,,,http://purl.obolibrary.org/obo/IMR_0000202,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,acidic cytokeratin,,,,,IMR:0000035,,,,,,,,,,,,,,,,,,,,,,type I cytokeratin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000289,Ras family,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,IPR:003577,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003669,,,,,,,,,,IMR:0000289,,,,,,,,,,,,,,,,,,,,,,Ras family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002685,IRE1 activation [ER stress - ERAD],,"IRE1 activation is a subtype of molecular activation: A process that changes the activity of the IRE1 to be higher.
This entity is a specific course-dependent process. This process is dependent on ERAD and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000730,,,,,,,,,,,,,,,,,,,,,,"IRE1 activation is a subtype of molecular activation: A process that changes the activity of the IRE1 to be higher.
This entity is a specific course-dependent process. This process is dependent on ERAD and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002598|http://purl.obolibrary.org/obo/TXPO_0002596,,,,,,,,,,,,,,,,,,,,,TXPO:0002685,,,,,,,,,,,,,,,,,,,,,,IRE1 activation [ER stress - ERAD],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002684,IRE1 signaling (primitive) [ER stress - ERAD],,"IRE1 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the IRE1 (Inositol-requiring transmembrane kinase/endonuclease). IRE1 generally plays a endoplasmic reticulum membrane stress sensor role.
This entity is a specific course-dependent process. This process is dependent on ERAD and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0003736|http://purl.obolibrary.org/obo/TXPO_0002571,,,,,,,,,,,,,,,,,,,,,,"IRE1 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the IRE1 (Inositol-requiring transmembrane kinase/endonuclease). IRE1 generally plays a endoplasmic reticulum membrane stress sensor role.
This entity is a specific course-dependent process. This process is dependent on ERAD and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002685,,,,,,,,,,,,,,,,,,TXPO:0002684,,,,,,,,,,,,,,,,,,,,,,IRE1 signaling (primitive) [ER stress - ERAD],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002687,IRE1 activation [ER stress - apoptosis],,"IRE1 activation is a subtype of molecular activation: A process that changes the activity of the IRE1 to be higher.
This process is dependent on the apoptosis and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000730,,,,,,,,,,,,,,,,,,,,,,"IRE1 activation is a subtype of molecular activation: A process that changes the activity of the IRE1 to be higher.
This process is dependent on the apoptosis and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002598|http://purl.obolibrary.org/obo/TXPO_0002596,,,,,,,,,,,,,,,,,,,,,TXPO:0002687,,,,,,,,,,,,,,,,,,,,,,IRE1 activation [ER stress - apoptosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002681,negative regulation of bile acid and bile salts export from the hepatocyte to bile tube [Cholestasis],,"Negative regulation of bile acid and bile salts export from the hepatocyte to bile tube is a subtype of negative regulation of transport: A process that stops, prevents, or reduces the frequency, rate or extent of bile acid and bile salts export from the hepatocyte to the bile tube.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000034|http://purl.obolibrary.org/obo/TXPO_0001892,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of bile acid and bile salts export from the hepatocyte to bile tube is a subtype of negative regulation of transport: A process that stops, prevents, or reduces the frequency, rate or extent of bile acid and bile salts export from the hepatocyte to the bile tube.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001885|http://purl.obolibrary.org/obo/TXPO_0000931|http://purl.obolibrary.org/obo/TXPO_0000032,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000264,,,,,,,,,,,TXPO:0002681,,,,,,,"Export into the canaliculus is mediated by the BSEP (bile salt export pump, ABCB11) .
Rifampicin, bosentan, and troglitazone directly inhibit bile salt export pump (BSEP).",,,,,,,,,,,,,,,negative regulation of bile acid and bile salts export from the hepatocyte to bile tube [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002630,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002686,IRE1 activation [ER stress - refolding],,"IRE1 activation is a subtype of molecular activation: A process that changes the activity of the IRE1 to be higher.
This process is dependent on the refolding and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000730,,,,,,,,,,,,,,,,,,,,,,"IRE1 activation is a subtype of molecular activation: A process that changes the activity of the IRE1 to be higher.
This process is dependent on the refolding and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002598|http://purl.obolibrary.org/obo/TXPO_0002596,,,,,,,,,,,,,,,,,,,,,TXPO:0002686,,,,,,,,,,,,,,,,,,,,,,IRE1 activation [ER stress - refolding],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002680,XBP1 activation by IRE1 [ER stress - ERAD],,"XBP1 activation by IRE1 is a subtype of activation of transcription factor: A process that changes the activity of XBP1 (X-Box Binding Protein 1) to be higher by IRE1.
This entity is a specific course-dependent process. This process is dependent on the ERAD process and can constitute the course of ER stress.|The XBP1 gene is transcribed to yield mRNA, the mRNA is spliced to yield Xbp(s) mRNA, and the mRNA is translated to yield protein.",false,,,http://purl.obolibrary.org/obo/TXPO_0002690,,,,,,,,,,,,,,,,,,,,"http://www.reactome.org/PathwayBrowser/#/R-HSA-381183&SEL=R-HSA-1791121&PATH=R-HSA-392499,R-HSA-381119,R-HSA-381033",,"XBP1 activation by IRE1 is a subtype of activation of transcription factor: A process that changes the activity of XBP1 (X-Box Binding Protein 1) to be higher by IRE1.
This entity is a specific course-dependent process. This process is dependent on the ERAD process and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002871,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000728,,,,,,,,,,,TXPO:0002680,,,,,,,,,,,,,,,,,,,,"The XBP1 gene is transcribed to yield mRNA, the mRNA is spliced to yield Xbp(s) mRNA, and the mRNA is translated to yield protein.",,XBP1 activation by IRE1 [ER stress - ERAD],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002688,IRE1 activation [ER stress - inflammation],,"IRE1 activation is a subtype of molecular activation: A process that changes the activity of the IRE1 to be higher.
This process is dependent on the inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000730,,,,,,,,,,,,,,,,,,,,,,"IRE1 activation is a subtype of molecular activation: A process that changes the activity of the IRE1 to be higher.
This process is dependent on the inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002598|http://purl.obolibrary.org/obo/TXPO_0002596,,,,,,,,,,,,,,,,,,,,,TXPO:0002688,,,,,,,,,,,,,,,,,,,,,,IRE1 activation [ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002689,XBP1 activation by IRE1 [ER stress - refolding],,"XBP1 activation by IRE1 is a subtype of activation of transcription factor: A process that changes the activity of XBP1 (X-Box Binding Protein 1) to be higher by IRE1.
This process is dependent on the refolding and can constitute the course of ER stress.|The XBP1 gene is transcribed to yield mRNA, the mRNA is spliced to yield Xbp(s) mRNA, and the mRNA is translated to yield protein.",false,,,http://purl.obolibrary.org/obo/TXPO_0002690,,,,,,,,,,,,,,,,,,,,"http://www.reactome.org/PathwayBrowser/#/R-HSA-381183&SEL=R-HSA-1791121&PATH=R-HSA-392499,R-HSA-381119,R-HSA-381033",,"XBP1 activation by IRE1 is a subtype of activation of transcription factor: A process that changes the activity of XBP1 (X-Box Binding Protein 1) to be higher by IRE1.
This process is dependent on the refolding and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002851,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002919,,,,,,,,,,,TXPO:0002689,,,,,,,,,,,,,,,,,,,,"The XBP1 gene is transcribed to yield mRNA, the mRNA is spliced to yield Xbp(s) mRNA, and the mRNA is translated to yield protein.",,XBP1 activation by IRE1 [ER stress - refolding],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002682,negative regulation of transport,,"Negative regulation of transport is a subtype of negative regulation process:  Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of substances (such as macromolecules, small molecules, ions) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.",false,,,http://purl.obolibrary.org/obo/TXPO_0000369,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of transport is a subtype of negative regulation process:  Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of substances (such as macromolecules, small molecules, ions) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002682,,,,,,,,,,,,,,,,,,,,,,negative regulation of transport,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000441,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002683,bile secretion,,Bile secretion is a subtype of moving A to the outside of B: A process of the release of the bile to the outside of the liver.,false,,,http://purl.obolibrary.org/obo/TXPO_0002588,,,,,,,,,,,,,,,,,,,,,,Bile secretion is a subtype of moving A to the outside of B: A process of the release of the bile to the outside of the liver.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0001970,,,,,,,,,,,,,,,,,,,TXPO:0002683,,,,,,,,,,,,,,,,,,,,,,bile secretion,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/BFO_0000029,site,,,false,,,http://purl.obolibrary.org/obo/BFO_0000141,,,,,,,,,,,,,,,,,,,,,,,,,,,,b is a site means: b is a three-dimensional immaterial entity that is (partially or wholly) bounded by a material entity or it is a three-dimensional immaterial part thereof. (axiom label in BFO2 Reference: [034-002]),your left nostril (a fiat part – the opening – of your left nasal cavity)|the interior of your bedroom|the interior of your office|the Grand Canyon|the interior of a kangaroo pouch|the hold of a ship|a rabbit hole|Manhattan Canyon)|a hole in the interior of a portion of cheese|the interior of the trunk of your car|the lumen of your gut|the Piazza San Marco|the interior of your refrigerator|an air traffic control region defined in the airspace above an airport|the cockpit of an aircraft,,,,,,,,,,,(forall (x) (if (Site x) (ImmaterialEntity x))) // axiom label in BFO2 CLIF: [034-002],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BFO:0000029,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/bfo.owl,site,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000011332,ACOT7,,"Other designations: CTE-IIa|acyl-CoA thioesterase 2|acyl-CoA thioesterase, long chain|brain acyl CoA hydrolase|brain acyl-CoA hydrolase|cytosolic acyl coenzyme A thioester hydrolase|long chain acyl-CoA thioester hydrolase",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CTE-II|LACH|ACH1|ACT|hBACH|LACH1|BACH,,,,,,,,,,,,1,,,,,,HPRD:12517|HGNC:24157|Vega:OTTHUMG00000001295|MIM:602587|Ensembl:ENSG00000097021,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,acyl-CoA thioesterase 7,,,1p36,,,,,,,,,,,,,,,,"GO_0000062 (EC: IDA, PMID:10578051); GO_0005515 (EC: IPI, PMID:10578051); GO_0005634 (EC: IDA); GO_0005730 (EC: IDA, Qualifier: NOT); GO_0005737 (EC: IDA); GO_0005739 (EC: IEA); GO_0005829 (EC: IDA, PMID:10578051); GO_0009062 (EC: IEA); GO_0015937 (EC: IDA, PMID:10578051); GO_0016290 (EC: IDA, PMID:10578051); GO_0036042 (EC: IDA, PMID:10578051); GO_0036114 (EC: IDA, PMID:10578051); GO_0036116 (EC: IDA, PMID:10578051); GO_0042803 (EC: IPI, PMID:10578051); GO_0043005 (EC: IEA); GO_0044297 (EC: IEA); GO_0051792 (EC: IDA, PMID:10578051); GO_0070062 (EC: IDA, PMID:19056867); GO_1900535 (EC: IDA, PMID:10578051)",,,,,,,,,PMID:10578051; 12435388; 12477932; 14702039; 15489334; 15592755; 15731883; 16103133; 16710414; 16713569; 18029348; 19056867; 19305408; 19724895; 19851296; 20198315; 21044950; 21110914; 21139048; 21319273; 21890473; 21906983; 21963094; 22053931; 22505724; 22863883; 23000965,,,,,,,,,,,,,,,OGG:3000011332,,,,,,,acyl-CoA thioesterase 7,,,,,,,,,,,,,"Other designations: CTE-IIa|acyl-CoA thioesterase 2|acyl-CoA thioesterase, long chain|brain acyl CoA hydrolase|brain acyl-CoA hydrolase|cytosolic acyl coenzyme A thioester hydrolase|long chain acyl-CoA thioester hydrolase",,ACOT7,,,,,,,,,,,,,,,,,,,,,,,11332,RP1-120G22.10,,,,,,,9606,,,,,,,,,,,,,,,,,,,ACOT7,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001996,ELAVL4,,"Other designations: ELAV (embryonic lethal, abnormal vision, Drosophila)-like 4 (Hu antigen D)|ELAV-like protein 4|Embryonic lethal, abnormal vision, Drosophila, homolog of, like-4|Hu antigen D|hu-antigen D|paraneoplastic encephalomyelitis antigen HuD",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,PNEM|HUD,,,,,,,,,,,,1,,,,,,MIM:168360|HGNC:3315|Ensembl:ENSG00000162374|HPRD:01343|Vega:OTTHUMG00000007877,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,ELAV like neuron-specific RNA binding protein 4,,,1p34,,,,,,,,,,,,,,,,"GO_0000166 (EC: IEA); GO_0003723 (EC: TAS, PMID: 1655278); GO_0003730 (EC: TAS, PMID: 10848602); GO_0006396 (EC: TAS, PMID: 1655278); GO_0006397 (EC: TAS, PMID: 10348344); GO_0017091 (EC: IDA, PMID: 10710437)",,,,,,,,,PMID: 1415481; 1655278; 2166930; 8069866; 8222755; 9065557; 10348344; 10710437; 10848602; 11175903; 11803489; 12034726; 12209604; 12235292; 12384599; 12388589; 12468554; 12477932; 14512168; 15358174; 15735910; 15827745; 16189514; 16278682; 16508003; 16710414; 17230446; 17234598; 17577668; 18218628; 18493953; 18587682; 18607064; 19252764; 19410329; 21110914; 21282516; 21491091; 21890473; 21988832; 22387028; 22965691; 23251661; 23618873,,,,,,,,,,,,,,,OGG:3000001996,,,,,,,ELAV like neuron-specific RNA binding protein 4,,,,,,,,,,,,,"Other designations: ELAV (embryonic lethal, abnormal vision, Drosophila)-like 4 (Hu antigen D)|ELAV-like protein 4|Embryonic lethal, abnormal vision, Drosophila, homolog of, like-4|Hu antigen D|hu-antigen D|paraneoplastic encephalomyelitis antigen HuD",,ELAVL4,,,,,,,,,,,,,,,,,,,,,,,1996,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,ELAVL4,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000008935,SKAP2,,Other designations: Fyn-associated phosphoprotein SKAP55 homologue|Pyk2/RAFTK-associated protein|SKAP-55HOM|SKAP55 homolog|retinoic acid-induced protein 70|src family associated phosphoprotein 2|src family-associated phosphoprotein 2|src kinase-associated phosphoprotein 2|src kinase-associated phosphoprotein 55-related protein|src kinase-associated phosphoprotein of 55-related protein|src-associated adapter protein with PH and SH3 domains|src-associated adaptor protein,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,SCAP2|SAPS|RA70|PRAP|SKAP55R|SKAP-HOM,,,,,,,,,,,,7,,,,,,HGNC:15687|MIM:605215|HPRD:05558|Ensembl:ENSG00000005020|Vega:OTTHUMG00000023495,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,src kinase associated phosphoprotein 2,,,7p15.2,,,,,,,,,,,,,,,,"GO_0005070 (EC: TAS, PMID: 9671755); GO_0005634 (EC: IDA); GO_0005730 (EC: IDA, Qualifier: NOT); GO_0005737 (EC: IDA); GO_0005829 (EC: TAS); GO_0005886 (EC: IDA, PMID: 11390434); GO_0006461 (EC: TAS, PMID: 9671755); GO_0007165 (EC: TAS, PMID: 9837776); GO_0008285 (EC: IEA); GO_0009967 (EC: TAS, PMID: 9671755); GO_0042113 (EC: IEA)",,,,,,,,,PMID: 8125298; 9671755; 9755858; 9837776; 10469599; 10527689; 10942756; 11063873; 11301322; 11390434; 12477932; 12690205; 12853948; 12893833; 15166227; 15489334; 15761153; 17081983; 17952125; 19380743; 19430480; 19807924; 19913121; 20378605; 20628086; 21719704; 21832049; 21906983; 22745667; 23128233; 23161539,,,,,,,,,,,,,,,OGG:3000008935,,,,,,,src kinase associated phosphoprotein 2,,,,,,,,,,,,,Other designations: Fyn-associated phosphoprotein SKAP55 homologue|Pyk2/RAFTK-associated protein|SKAP-55HOM|SKAP55 homolog|retinoic acid-induced protein 70|src family associated phosphoprotein 2|src family-associated phosphoprotein 2|src kinase-associated phosphoprotein 2|src kinase-associated phosphoprotein 55-related protein|src kinase-associated phosphoprotein of 55-related protein|src-associated adapter protein with PH and SH3 domains|src-associated adaptor protein,,SKAP2,,,,,,,,,,,,,,,,,,,,,,,8935,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,SKAP2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/GO_0070102,interleukin-6-mediated signaling pathway,interleukin-6-mediated signalling pathway|IL-6-mediated signaling pathway,"A series of molecular signals initiated by the binding of interleukin-6 to a receptor on the surface of a cell, and ending with regulation of a downstream cellular process, e.g. transcription.",false,,,http://purl.obolibrary.org/obo/TXPO_0000609,,,,,,,,,,,,,,,,,,,,,,"A series of molecular signals initiated by the binding of interleukin-6 to a receptor on the surface of a cell, and ending with regulation of a downstream cellular process, e.g. transcription.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,interleukin-6-mediated signalling pathway|IL-6-mediated signaling pathway,,,,,GO:0070102,,,,,,,,,,,,,,,,,,,,,,interleukin-6-mediated signaling pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000150353,DNAJB7,,Other designations: dnaJ homolog subfamily B member 7|novel DnaJ domain protein,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,HSC3|DJ5,,,,,,,,,,,,22,,,,,,Vega:OTTHUMG00000151202|HGNC:24986|MIM:611336|HPRD:07010|Ensembl:ENSG00000172404,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"DnaJ (Hsp40) homolog, subfamily B, member 7",,,22q13.2,,,,,,,,,,,,,,,,,,,,,,,,,PMID:10591208; 11147971; 12477932; 15461802; 15489334; 18029348,,,,,,,,,,,,,,,OGG:3000150353,,,,,,,"DnaJ (Hsp40) homolog, subfamily B, member 7",,,,,,,,,,,,,Other designations: dnaJ homolog subfamily B member 7|novel DnaJ domain protein,,DNAJB7,,,,,,,,,,,,,,,,,,,,,,,150353,,,,,,,,9606,,,,,,,,,,,,,,,,,,,DNAJB7,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000008529,CYP4F2,,"Other designations: CYPIVF2|cytochrome P450 4F2|cytochrome P450, subfamily IVF, polypeptide 2|cytochrome P450-LTB-omega|leukotriene B4 omega-hydroxylase|leukotriene-B(4) 20-monooxygenase 1|leukotriene-B(4) omega-hydroxylase 1|leukotriene-B4 20-monooxygenase",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CPF2,,,,,,,,,,,,19,,,,,,Ensembl:ENSG00000186115|MIM:604426|HPRD:05112|Vega:OTTHUMG00000185995|HGNC:2645,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 4, subfamily F, polypeptide 2",,,19p13.12,,,,,,,,,,,,,,,,"GO_0000038 (EC: IDA, PMID:18433732); GO_0001676 (EC: IDA, PMID:18433732); GO_0003091 (EC: IEP, PMID:10660572); GO_0003095 (EC: IEP, PMID:10660572); GO_0005506 (EC: IEA); GO_0005515 (EC: IPI, PMID:17474147); GO_0005737 (EC: IDA, PMID:10660572); GO_0005789 (EC: TAS); GO_0006690 (EC: TAS); GO_0006691 (EC: TAS); GO_0006805 (EC: TAS); GO_0008217 (EC: IMP, PMID:18391101); GO_0008392 (EC: IDA); GO_0016324 (EC: IDA, PMID:10660572); GO_0017144 (EC: IMP); GO_0018685 (EC: IDA, PMID:18433732); GO_0019369 (EC: IDA, PMID:10660572); GO_0019369 (EC: TAS); GO_0019373 (EC: IDA); GO_0020037 (EC: IEA); GO_0030195 (EC: IMP, PMID:19297518); GO_0032304 (EC: IMP, PMID:18391101); GO_0032305 (EC: IMP, PMID:17341693); GO_0036101 (EC: IDA, PMID:10492403); GO_0042360 (EC: IDA); GO_0042371 (EC: IMP, PMID:19297518); GO_0043231 (EC: IDA, PMID:10660572); GO_0044281 (EC: TAS); GO_0047057 (EC: IMP, PMID:19297518); GO_0050051 (EC: IDA, PMID:8026587); GO_0052869 (EC: IDA, PMID:10660572); GO_0052871 (EC: IDA); GO_0052872 (EC: IDA); GO_0055078 (EC: IEP, PMID:10660572); GO_0055114 (EC: IDA); GO_0097267 (EC: TAS)",,,,,,,,,PMID:8026587; 8424651; 9068972; 9618440; 9799565; 10492403; 10660572; 10860554; 11162441; 11715494; 12477932; 12736711; 15057824; 15128046; 15489334; 16733892; 17142457; 17284776; 17341693; 17474147; 18065749; 18235092; 18250228; 18391101; 18433732; 18574070; 18662666; 18787519; 18971550; 19097922; 19207028; 19270263; 19279555; 19297518; 19297519; 19300499; 19343046; 19545555; 19578179; 19741565; 19794411; 19913121; 19957603; 19958090; 20072124; 20130494; 20149073; 20182420; 20227456; 20421126; 20442691; 20499136; 20504253; 20553802; 20555338; 20628086; 20653676; 20833655; 20861217; 21063236; 21084764; 21127708; 21150635; 21475774; 21562135; 21625857; 21729881; 21883387; 21887457; 21906983; 22188360; 22198820; 22393834; 22437554; 22452429; 22484021; 22528326; 22534826; 22549502; 22854539; 22855348; 23013706; 23018470; 23132553; 23215885; 23281178; 23510058; 23726967; 24138531,,,,,,,,,,,,,,,OGG:3000008529,,,,,,,"cytochrome P450, family 4, subfamily F, polypeptide 2",,,,,,,,,,,,,"Other designations: CYPIVF2|cytochrome P450 4F2|cytochrome P450, subfamily IVF, polypeptide 2|cytochrome P450-LTB-omega|leukotriene B4 omega-hydroxylase|leukotriene-B(4) 20-monooxygenase 1|leukotriene-B(4) omega-hydroxylase 1|leukotriene-B4 20-monooxygenase",,CYP4F2,,,,,,,,,,,,,,,,,,,,,,,8529,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP4F2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0200272,L-Isoleucine,,,false,,,http://purl.obolibrary.org/obo/CHEBI_33709,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0200272,,,,,,,,,,,,,,,,,,,,,,L-Isoleucine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000734,COX-1,prostaglandin endoperoxide synthase 2,,false,,,http://purl.obolibrary.org/obo/IMR_0000331,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,prostaglandin endoperoxide synthase 2,,,,,IMR:0000734,,,,,,,,,,,,,,,,,,,,,,COX-1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005002,MMP2(canonical) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000238|http://purl.obolibrary.org/obo/TXPO_0005063,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:4313|NCBI-Mouse-GeneID:17390|NCBI-Rat-GeneID:81686|PMID:28706416,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005002,,,,,,,,,,,,,,,,,,,,,,MMP2(canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005009,phospholipid peroxidation [mitochondrial disorder],,"phospholipid peroxidation is a subtype of lipid oxidation:  The degradation of phospholipids caused by an oxidative attack from free radicals.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0004932|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:25339807,,"phospholipid peroxidation is a subtype of lipid oxidation:  The degradation of phospholipids caused by an oxidative attack from free radicals.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001991,,,,,,,,,,,TXPO:0005009,,,,,,,,,,,,,,,,,,,,,,phospholipid peroxidation [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005001,metalloprotease activation,,Metalloprotease activation is a subtype of activating: A process that changes the activity of the metalloprotease to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000401,,,,,,,,,,,,,,,,,,,,,,Metalloprotease activation is a subtype of activating: A process that changes the activity of the metalloprotease to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005001,,,,,,,,,,,,,,,,,,,,,,metalloprotease activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005003,MMP9(canonical) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000239|http://purl.obolibrary.org/obo/TXPO_0005063,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:4318|NCBI-Mouse-GeneID:17395|NCBI-Rat-GeneID:81687|PMID:28706416,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005003,,,,,,,,,,,,,,,,,,,,,,MMP9(canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005004,Negative regulation of methionine metabolic process,,"Negative regulation of methionine metabolic process is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of methionine metabolic process.",false,,,http://purl.obolibrary.org/obo/TXPO_0000369,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of methionine metabolic process is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of methionine metabolic process.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005004,,,,,,,,,,,,,,,,,,,,,,Negative regulation of methionine metabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006555,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005005,Negative regulation of methionine metabolic process [hepatocarcinogenesis],,"Negative regulation of methionine metabolic process is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of methionine metabolic process.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0005004,,,,,,,,,,,,,,,,,,,,PMID:15511635,,"Negative regulation of methionine metabolic process is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of methionine metabolic process.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004454|http://purl.obolibrary.org/obo/TXPO_0005007|http://purl.obolibrary.org/obo/TXPO_0005006,,,,,,http://purl.obolibrary.org/obo/TXPO_0004392,,,,,,,,,,,TXPO:0005005,,,,,,,,,,,,,,,,,,,,,,Negative regulation of methionine metabolic process [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006555,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005000,Increasing membrane potential,,Increasing membrane potential is a subtype of changing membrane potential: A process that changes the electrical potential across a membrane to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0001456,,,,,,,,,,,,,,,,,,,,,,Increasing membrane potential is a subtype of changing membrane potential: A process that changes the electrical potential across a membrane to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005000,,,,,,,,,,,,,,,,,,,,,,Increasing membrane potential,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0005041,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005008,Monuron [hepatocarcinogenesis],"3-(4-chlorophenyl)-1,1-dimethylurea",A member of the class of phhenylureas that is urea in which one of the nitrogens is substituted by a p-chlorophenyl group while the other is substituted by two methyl groups.,false,,,http://purl.obolibrary.org/obo/TXPO_0004455|http://purl.obolibrary.org/obo/CHEBI_38214,,,,,,,,,,,,,,,,,,,,CAS:150-68-5|PMID:22584684,,A member of the class of phhenylureas that is urea in which one of the nitrogens is substituted by a p-chlorophenyl group while the other is substituted by two methyl groups.,,,,,,,,,,,,C9H11ClN2O,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"3-(4-chlorophenyl)-1,1-dimethylurea",,,,,TXPO:0005008,,,,,,,,,,,,,,,,,,,,,,Monuron [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CN(C)C(=O)Nc1ccc(Cl)cc1,,,,,
http://purl.obolibrary.org/obo/TXPO_0005007,MTAP (rat) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0005103|http://purl.obolibrary.org/obo/TXPO_0005070,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:298227|PMID:15511635,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005007,,,,,,,,,,,,,,,,,,,,,,MTAP (rat) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005006,MTAP (human) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_0005103,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:4507|PMID:15511635,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005006,,,,,,,,,,,,,,,,,,,,,,MTAP (human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100224,MEK5(MKK5),MAPK/ERK kinase 5|MEK5|MAP kinase kinase 5|MAPKK 5|MKK5,,false,,,http://purl.obolibrary.org/obo/IMR_0000259,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MAPK/ERK kinase 5|MEK5|MAP kinase kinase 5|MAPKK 5|MKK5,,,,,IMR:0100224,,,,,,,,,,,,,,,,,,,,,,MEK5(MKK5),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_9337,sulfathiazole,"2-(p-Aminobenzenesulphonamido)thiazole|4-Amino-N-2-thiazolylbenzenesulfonamide|Sulfatiazol|N(1)-2-Thiazolylsulfanilamide|sulfathiazole|sulfathiazolum|Sulfanilamidothiazole|2-(p-Aminobenzenesulfonamido)thiazole|2-Sulfonamidothiazole|2-Sulfanilamidothiazol|2-Sulfanilamidothiazole|sulfathiazol|sulfthiazole|2-(Sulfanilylamino)thiazole|Sulphathiazole|4-amino-N-1,3-thiazol-2-ylbenzenesulfonamide","A 1,3-thiazole compound having a 4-aminobenzenesulfonamido group at the 2-position.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,DrugBank:DB06147|Reaxys:226178|Gmelin:218965|PMID:7486915|Drug_Central:2527|Beilstein:226178|CAS:72-14-0|PMID:11431418|LINCS:LSM-5327,,"A 1,3-thiazole compound having a 4-aminobenzenesulfonamido group at the 2-position.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_50502|http://purl.obolibrary.org/obo/CHEBI_35441|http://purl.obolibrary.org/obo/CHEBI_35703|http://purl.obolibrary.org/obo/CHEBI_88188|http://purl.obolibrary.org/obo/CHEBI_78298,,,,,"4-amino-N-1,3-thiazol-2-ylbenzenesulfonamide",,2-(p-Aminobenzenesulphonamido)thiazole|4-Amino-N-2-thiazolylbenzenesulfonamide|Sulfatiazol|N(1)-2-Thiazolylsulfanilamide|sulfathiazole|sulfathiazolum|Sulfanilamidothiazole|2-(p-Aminobenzenesulfonamido)thiazole|2-Sulfonamidothiazole|2-Sulfanilamidothiazol|2-Sulfanilamidothiazole|sulfathiazol|sulfthiazole|2-(Sulfanilylamino)thiazole|Sulphathiazole,,,,,,,,,,,,,,,,,,,,,CHEBI:9337,,,,sulfathiazole,,CHEBI:9337,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_9334,sulfasalazine,Sulfasalazina|2-Hydroxy-5-((4-((2-pyridinylamino)sulfonyl)phenyl)azo)benzoic acid|4-(Pyridyl-2-amidosulfonyl)-3'-carboxy-4'-hydroxyazobenzene|Salicylazosulfapyridine|5-((p-(2-Pyridylsulfamoyl)phenyl)azo)salicylic acid|Salazosulfapyridine|Salazosulfapiridina|5-(4-(2-Pyridylsulfamoyl)phenylazo)-2-hydroxybenzoic acid|Salazosulfapyridinum|Sulfasalazinum|sulfasalazine|Azulfidine|2-Hydroxy-5-[4-(pyridin-2-ylsulfamoyl)-phenylazo]-benzoic acid|5-(p-(2-Pyridylsulfamyl)phenylazo)salicylic acid|2-hydroxy-5-{[4-(pyridin-2-ylsulfamoyl)phenyl]diazenyl}benzoic acid|Sulfasalazine,"An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:16322111|Gmelin:2666050|PMID:11587223|CAS:599-79-1|PMID:2434548|PMID:11362329|DrugBank:DB00795|PMID:14981898|Beilstein:356241|Reaxys:8132868|PMID:11485124|PMID:15248210|PMID:17386570|Beilstein:8132868|PMID:7720170,,"An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_76797|http://purl.obolibrary.org/obo/CHEBI_55324|http://purl.obolibrary.org/obo/CHEBI_35441|http://purl.obolibrary.org/obo/CHEBI_35475|http://purl.obolibrary.org/obo/CHEBI_88188,,,,,2-hydroxy-5-{[4-(pyridin-2-ylsulfamoyl)phenyl]diazenyl}benzoic acid|Sulfasalazine,,Sulfasalazina|2-Hydroxy-5-((4-((2-pyridinylamino)sulfonyl)phenyl)azo)benzoic acid|4-(Pyridyl-2-amidosulfonyl)-3'-carboxy-4'-hydroxyazobenzene|Salicylazosulfapyridine|5-((p-(2-Pyridylsulfamoyl)phenyl)azo)salicylic acid|Salazosulfapyridine|Salazosulfapiridina|5-(4-(2-Pyridylsulfamoyl)phenylazo)-2-hydroxybenzoic acid|Salazosulfapyridinum|Sulfasalazinum|sulfasalazine|Azulfidine|2-Hydroxy-5-[4-(pyridin-2-ylsulfamoyl)-phenylazo]-benzoic acid|5-(p-(2-Pyridylsulfamyl)phenylazo)salicylic acid,,,,,,,,,,,,,,,,,,,,,CHEBI:9334,,,,sulfasalazine,,CHEBI:9334,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000347,Shc,src homology and collagen,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003684,,,,,src homology and collagen,,,,,IMR:0000347,,,,,,,,,,,,,,,,,,,,,,Shc,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0030301,cholesterol transport,,"The directed movement of cholesterol, cholest-5-en-3-beta-ol, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.",false,,,http://purl.obolibrary.org/obo/GO_0006869,,,,,,,,,,,,,,,,,,,,,,"The directed movement of cholesterol, cholest-5-en-3-beta-ol, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0030301,,,,,,,,,,,,,,,,,,,,,,cholesterol transport,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_29688,telithromycin,"HMR3647|RU66647|HMR-3647|RU-66647|RU 66647|(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-11-methoxy-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-1-[4-(4-pyridin-3-yl-1H-imidazol-1-yl)butyl]tetradecahydro-2H-oxacyclotetradecino[4,3-d][1,3]oxazol-10-yl 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranoside|HMR 3647|TELITHROMYCIN|Telithromycin",,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:191114-48-4|Drug_Central:2581,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TELITHROMYCIN|Telithromycin,,"HMR3647|RU66647|HMR-3647|RU-66647|RU 66647|(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-11-methoxy-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-1-[4-(4-pyridin-3-yl-1H-imidazol-1-yl)butyl]tetradecahydro-2H-oxacyclotetradecino[4,3-d][1,3]oxazol-10-yl 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranoside|HMR 3647",,,,,,,,,,,,,,,,,,,,,CHEBI:29688,,,,telithromycin,,CHEBI:29688,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000861,increasing blood AST concentration [lipidosis],inreasing blood GOT concentration [lipidosis],"Increasing AST concentration in blood is a subtype of increasing concentration: A process that changes the aspartate amino transferase (AST) concentration  to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000643|http://purl.obolibrary.org/obo/TXPO_0001720,,,,,,,,,,,,,,,,,,,,http://purl.bioontology.org/ontology/MEDDRA/10003544,,"Increasing AST concentration in blood is a subtype of increasing concentration: A process that changes the aspartate amino transferase (AST) concentration  to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001017,,,,,,,,,,,,,,inreasing blood GOT concentration [lipidosis],,,,,TXPO:0000861,,,,,,,,,,,,,,,,,,,,,,increasing blood AST concentration [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000867,FASLG (human)[Cell death],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000140|http://purl.obolibrary.org/obo/TXPO_0000840,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:356,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000356,,,,,,,,,,,,,TXPO:0000867,,,,,,,,,,,,,,,,,,,,,,FASLG (human)[Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000864,BCL2 (human)[Cell death],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000041|http://purl.obolibrary.org/obo/TXPO_0000840,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:596,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000596,,,,,,,,,,,,,TXPO:0000864,,,,,,,,,,,,,,,,,,,,,,BCL2 (human)[Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000868,Acot5 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0001146,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:217698|NCBI-Rat-GeneID:503049,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000868,,,,,,,,,,,,,,,,,,,,,,Acot5 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000862,leaking content from cell [Lipidosis],,"Leaking content from cell is a subtype of leaking: A process that leaks contents from the cell.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000526|http://purl.obolibrary.org/obo/TXPO_0001720,,,,,,,,,,,,,,,,,,,,,,"Leaking content from cell is a subtype of leaking: A process that leaks contents from the cell.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000861|http://purl.obolibrary.org/obo/TXPO_0000860|http://purl.obolibrary.org/obo/TXPO_0000859|http://purl.obolibrary.org/obo/TXPO_0003622,,,,,,,,,,,TXPO:0000862,,,,,,,,,,,,,,,,,,,,,,leaking content from cell [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000860,increasing blood ALT concentration [lipidosis],increasing blood GPT concentration [lipidosis],"Increasing ALT concentration in blood is a subtype of increasing concentration: A process that changes the alanine aminotransferase (ALT) concentration  to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0000852,,,,,,,,,,,,,,,,,,,,http://purl.bioontology.org/ontology/MEDDRA/10001845,,"Increasing ALT concentration in blood is a subtype of increasing concentration: A process that changes the alanine aminotransferase (ALT) concentration  to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001024,,,,,,,,,,,,,,increasing blood GPT concentration [lipidosis],,,,,TXPO:0000860,,,,,,,,,,,,,,,,,,,,,,increasing blood ALT concentration [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000866,BAD (human)[Cell death],,,false,,,http://purl.obolibrary.org/obo/IMR_0100288|http://purl.obolibrary.org/obo/TXPO_0000840,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:572,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000572,,,,,,,,,,,,,TXPO:0000866,,,,,,,,,,,,,,,,,,,,,,BAD (human)[Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000863,TNF (human)[Cell death],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000374|http://purl.obolibrary.org/obo/TXPO_0000840,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:7124,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000007124,,,,,,,,,,,,,TXPO:0000863,,,,,,,,,,,,,,,,,,,,,,TNF (human)[Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000865,concentration (attribute),,A concentration attribute inhering in a bearer by virtue of the bearer's exhibiting concentration.,false,,,http://purl.obolibrary.org/obo/TXPO_0000305,,,,,,,,,,,,,,,,,,,,,,A concentration attribute inhering in a bearer by virtue of the bearer's exhibiting concentration.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000865,,,,,,,,,,,,,,,,,,,,,,concentration (attribute),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000869,mitochondrial respiratory chain abnormality [Mitochondrial disorder],,"Malfunctioning of mitochondrial ATP synthesis coupled electron transferr is a subtype of malfunctioning process: A process that cannot perform a respiratory electron transport chain appropriately or cannot realize it at all.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0001846,,,,,,,,,,,,,,,,,,,,PMID:31623280|PMID:25339807|PMID:21145849|PMID:23299992|PMID:31649547,,"Malfunctioning of mitochondrial ATP synthesis coupled electron transferr is a subtype of malfunctioning process: A process that cannot perform a respiratory electron transport chain appropriately or cannot realize it at all.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004225,http://purl.obolibrary.org/obo/TXPO_0004332|http://purl.obolibrary.org/obo/TXPO_0004336|http://purl.obolibrary.org/obo/TXPO_0004333|http://purl.obolibrary.org/obo/TXPO_0004335|http://purl.obolibrary.org/obo/TXPO_0004330|http://purl.obolibrary.org/obo/TXPO_0004338|http://purl.obolibrary.org/obo/TXPO_0004331|http://purl.obolibrary.org/obo/TXPO_0004337|http://purl.obolibrary.org/obo/TXPO_0004339|http://purl.obolibrary.org/obo/TXPO_0004334,,,,,,http://purl.obolibrary.org/obo/TXPO_0001990|http://purl.obolibrary.org/obo/TXPO_0002004|http://purl.obolibrary.org/obo/TXPO_0004264,,,,,,,,,,,TXPO:0000869,,,,,,,,,,,,,,,,,,,,,,mitochondrial respiratory chain abnormality [Mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000001906,EDN1,,Other designations: endothelin-1|preproendothelin-1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,ET1|ARCND3|HDLCQ7|QME|PPET1,,,,,,,,,,,,6,,,,,,HPRD:07030|HGNC:3176|MIM:131240|Ensembl:ENSG00000078401|Vega:OTTHUMG00000014266,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,endothelin 1,,,6p24.1,,,,,,,,,,,,,,,,"GO_0000122 (EC: IDA, PMID: 19767294); GO_0001516 (EC: IDA, PMID: 9492062); GO_0001569 (EC: IEA); GO_0001666 (EC: IEA); GO_0001701 (EC: IEA); GO_0001821 (EC: IEA); GO_0003100 (EC: IDA, PMID: 2649896); GO_0005125 (EC: IDA, PMID: 19767294); GO_0005179 (EC: IDA, PMID: 10770212); GO_0005515 (EC: IPI); GO_0005576 (EC: TAS); GO_0005615 (EC: IDA, PMID: 10770212); GO_0005737 (EC: IDA, PMID: 12379507); GO_0006885 (EC: IEA); GO_0007166 (EC: IDA, PMID: 1713452); GO_0007186 (EC: IDA, PMID: 17078114); GO_0007204 (EC: IDA, PMID: 1917960); GO_0007205 (EC: IEA); GO_0007267 (EC: IDA, PMID: 12379507); GO_0007507 (EC: IEA); GO_0007585 (EC: IEA); GO_0007589 (EC: IEA); GO_0008284 (EC: IDA, PMID: 17078114); GO_0009953 (EC: IEA); GO_0010259 (EC: IEA); GO_0010460 (EC: IDA, PMID: 2649896); GO_0010595 (EC: TAS, PMID: 8999856); GO_0010613 (EC: IDA, PMID: 12847114); GO_0010870 (EC: IDA, PMID: 17178876); GO_0014032 (EC: IEA); GO_0014065 (EC: IDA, PMID: 17078114); GO_0014824 (EC: IDA, PMID: 8982507); GO_0014824 (EC: TAS, PMID: 1725334); GO_0014826 (EC: IDA, PMID: 9422810); GO_0015758 (EC: IEA); GO_0016049 (EC: IEA); GO_0019229 (EC: IEA); GO_0019233 (EC: IEA); GO_0019722 (EC: IDA, PMID: 10770212); GO_0030072 (EC: IDA, PMID: 10770212); GO_0030185 (EC: IDA, PMID: 16820593); GO_0030195 (EC: TAS, PMID: 16820593); GO_0030335 (EC: IDA, PMID: 9696419); GO_0030593 (EC: IDA, Qualifier: NOT, PMID: 9696419); GO_0030818 (EC: IEA); GO_0031583 (EC: IEA); GO_0031707 (EC: IDA, PMID: 10770212); GO_0031708 (EC: IDA, PMID: 10770212); GO_0032269 (EC: IDA, PMID: 19767294); GO_0032496 (EC: IEA); GO_0033574 (EC: IEA); GO_0034392 (EC: IEA); GO_0035094 (EC: IEA); GO_0035810 (EC: IEA); GO_0035815 (EC: IEA); GO_0042045 (EC: IEA); GO_0042310 (EC: IDA, PMID: 11410113); GO_0042313 (EC: IDA, PMID: 16820593); GO_0042474 (EC: IEA); GO_0042482 (EC: IEA); GO_0042554 (EC: IEA); GO_0043179 (EC: IEA); GO_0043200 (EC: IEA); GO_0043406 (EC: IDA, PMID: 10770212); GO_0043507 (EC: IDA, PMID: 12847114); GO_0045321 (EC: TAS, PMID: 16820593); GO_0045429 (EC: TAS, PMID: 8999856); GO_0045793 (EC: IDA, PMID: 12847114); GO_0045840 (EC: IDA, PMID: 10770212); GO_0045987 (EC: IEA); GO_0046887 (EC: IDA, PMID: 10770212); GO_0046888 (EC: IEA); GO_0048016 (EC: IDA, PMID: 1917960); GO_0048661 (EC: IDA, PMID: 10393673); GO_0051216 (EC: IEA); GO_0051482 (EC: IEA); GO_0051771 (EC: IDA, PMID: 16820593); GO_0051899 (EC: IEA); GO_0051930 (EC: IEA); GO_0060137 (EC: IEA); GO_0060298 (EC: IMP, PMID: 12847114); GO_0060585 (EC: IMP, PMID: 9492062); GO_0070101 (EC: IC, PMID: 17178876); GO_0071347 (EC: IEA); GO_0071356 (EC: IEA); GO_0090023 (EC: IEA)",,,,,,,,,PMID: 1280264; 1422154; 1515112; 1713452; 1725334; 1736987; 1859417; 1864385; 1917960; 2005113; 2018043; 2201681; 2649896; 2659594; 2670930; 2678110; 3282927; 7509919; 7664037; 7773179; 8125160; 8144511; 8450044; 8482849; 8889548; 8982507; 8999856; 9257865; 9284755; 9324057; 9422810; 9453574; 9492062; 9595387; 9696419; 10220569; 10231710; 10334806; 10391210; 10393673; 10438732; 10620363; 10770212; 11179511; 11210078; 11399938; 11410113; 11448123; 11593097; 11601839; 11693192; 11742499; 11751711; 11795667; 11831453; 11858185; 11866544; 11932487; 11934840; 11991554; 11991733; 12009599; 12011762; 12013496; 12068797; 12077518; 12082592; 12087564; 12107733; 12117726; 12137974; 12144123; 12151765; 12189238; 12230494; 12379507; 12446192; 12459174; 12477932; 12508654; 12511547; 12529269; 12557940; 12565798; 12588850; 12620701; 12629276; 12657945; 12695528; 12721154; 12746758; 12750312; 12847114; 12855940; 12861161; 12887757; 12907686; 12941866; 12963677; 12972292; 13680553; 14514737; 14519635; 14523636; 14558091; 14574404; 14578413; 14587645; 14602502; 14634722; 14636060; 14639018; 14660616; 14685288; 14692644; 14733410; 14735061; 14736087; 14763917; 14769714; 15009217; 15041798; 15044479; 15047866; 15073116; 15093707; 15126915; 15139053; 15161426; 15188945; 15194301; 15198485; 15213100; 15224360; 15240857; 15269821; 15319532; 15347673; 15369130; 15466627; 15481145; 15489334; 15505112; 15518541; 15558022; 15568807; 15610525; 15621731; 15623376; 15643502; 15646831; 15652492; 15691296; 15699938; 15702240; 15743480; 15817494; 15818445; 15838269; 15838299; 15838323; 15838328; 15838333; 15838334; 15838336; 15838337; 15838340; 15838344; 15838351; 15838357; 15838368; 15838369; 15838370; 15864745; 15946241; 15946919; 15979050; 15988412; 16002759; 16021085; 16026642; 16076689; 16095497; 16097909; 16098041; 16169070; 16217751; 16234608; 16291872; 16320159; 16336267; 16357176; 16452160; 16466695; 16521405; 16526196; 16531800; 16582543; 16597412; 16648553; 16713569; 16720059; 16754659; 16769575; 16778329; 16809784; 16815566; 16820593; 16864942; 16931893; 16943682; 16947775; 16956834; 16971893; 16982943; 16986361; 17016610; 17016617; 17020466; 17078114; 17122448; 17123690; 17148661; 17178876; 17197385; 17203161; 17221318; 17222082; 17264805; 17274718; 17291632; 17328840; 17335511; 17340622; 17345061; 17353514; 17357073; 17357519; 17395629; 17404040; 17438153; 17444275; 17460393; 17470272; 17497038; 17497041; 17497362; 17505299; 17525706; 17535295; 17549358; 17556493; 17569300; 17575543; 17576235; 17664075; 17664854; 17681742; 17693542; 17701914; 17703412; 17850909; 17855483; 17875064; 17884295; 17893002; 17913962; 17938376; 17960156; 17967707; 17969585; 17996929; 18005077; 18023202; 18025413; 18031458; 18050250; 18063846; 18080871; 18212505; 18260253; 18288492; 18326921; 18346810; 18378042; 18379872; 18390205; 18395679; 18398338; 18401297; 18411415; 18436890; 18441204; 18442814; 18447854; 18463805; 18484695; 18489822; 18550016; 18568290; 18579320; 18579652; 18580062; 18603063; 18623111; 18660489; 18663623; 18676680; 18752143; 18764935; 18772174; 18794727; 18806884; 18809573; 18814847; 18822124; 18923236; 18945274; 18945538; 18953265; 18974277; 18991099; 18991188; 19012521; 19014602; 19046960; 19056482; 19057845; 19073831; 19074885; 19077312; 19086031; 19086263; 19087492; 19103606; 19116719; 19150882; 19170196; 19171135; 19188658; 19188660; 19212702; 19217622; 19225824; 19247692; 19254215; 19258923; 19264973; 19336370; 19358249; 19367425; 19369451; 19371341; 19391127; 19415232; 19416273; 19420105; 19446279; 19460784; 19475602; 19479828; 19520685; 19520754; 19526396; 19527488; 19536618; 19543207; 19558538; 19564455; 19578796; 19592490; 19625176; 19626996; 19634784; 19640695; 19661472; 19672034; 19687345; 19692168; 19717811; 19729965; 19730395; 19764340; 19767294; 19808370; 19862540; 19887561; 19899414; 19907721; 19913121; 19927348; 19948975; 19996987; 20015663; 20016521; 20028935; 20031624; 20051644; 20055532; 20055806; 20082271; 20083228; 20083432; 20091488; 20150570; 20188614; 20204072; 20217138; 20308035; 20339975; 20346360; 20368210; 20370579; 20416077; 20437399; 20452482; 20452970; 20485444; 20495015; 20497976; 20503287; 20537417; 20538124; 20538960; 20559285; 20562228; 20565774; 20572854; 20587610; 20588001; 20594474; 20594999; 20602615; 20608808; 20628086; 20628425; 20628428; 20634595; 20634796; 20634891; 20652766; 20663522; 20664700; 20670842; 20672350; 20673868; 20678167; 20685405; 20707291; 20725135; 20725137; 20725140; 20725141; 20725143; 20728421; 20837776; 20837906; 20873151; 20952631; 20952681; 20971496; 20974279; 21045115; 21059990; 21087804; 21129745; 21169360; 21174590; 21183790; 21208707; 21214096; 21217075; 21219832; 21251377; 21334758; 21356562; 21406182; 21418087; 21445967; 21490504; 21498707; 21498912; 21499502; 21515378; 21531894; 21557930; 21601190; 21637825; 21638248; 21656314; 21659661; 21666117; 21673044; 21677436; 21681744; 21701170; 21701423; 21712053; 21730058; 21741393; 21767690; 21773759; 21777246; 21786569; 21801587; 21801592; 21813388; 21826669; 21851036; 21896842; 21908890; 21932697; 21952518; 21959927; 22006997; 22045428; 22082020; 22113444; 22165675; 22175913; 22232246; 22265324; 22299030; 22321643; 22330820; 22341591; 22377253; 22406080; 22412088; 22415226; 22483689; 22483692; 22503784; 22504006; 22520393; 22525370; 22527528; 22545467; 22552325; 22553998; 22569256; 22580289; 22666926; 22675930; 22727793; 22759779; 22770822; 22796455; 22856221; 22856224; 22869459; 22907118; 22960172; 22965194; 22971991; 22994522; 23002189; 23018104; 23103494; 23142694; 23163519; 23208497; 23227981; 23233754; 23255664; 23273644; 23290569; 23329136; 23344160; 23372172; 23381795; 23401650; 23436272; 23436727; 23457411; 23523690; 23565184; 23643051; 23683481; 23713736; 23720837; 23815989; 23828677; 23832707; 23887640; 23902937; 24015303; 24056654; 24088894; 24184161; 24196534; 24268655,,,,,,,,,,,,,,,OGG:3000001906,,,,,,,endothelin 1,,,,,,,,,,,,,Other designations: endothelin-1|preproendothelin-1,,EDN1,,,,,,,,,,,,,,,,,,,,,,,1906,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,EDN1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000622,ICAM-5,intercellular adhesion molecule 5,,false,,,http://purl.obolibrary.org/obo/IMR_0000178,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,intercellular adhesion molecule 5,,,,,IMR:0000622,,,,,,,,,,,,,,,,,,,,,,ICAM-5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000134,IFNR,interferon receptor,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,GO:0004904,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003331,,,,,interferon receptor,,,,,IMR:0000134,,,,,,,,,,,,,,,,,,,,,,IFNR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0071073,positive regulation of phospholipid biosynthetic process,,"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of phospholipids.",false,,,http://purl.obolibrary.org/obo/TXPO_0001223,,,,,,,,,,,,,,,,,,,,,,"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of phospholipids.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0071073,,,,,,,,,,,,,,,,,,,,,,positive regulation of phospholipid biosynthetic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0008654,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100581,syndecan-2,SYND2|HSPG|fibroglycan|Heparan sulfate proteoglycan core protein,,false,,,http://purl.obolibrary.org/obo/IMR_0100579,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,SYND2|HSPG|fibroglycan|Heparan sulfate proteoglycan core protein,,,,,IMR:0100581,,,,,,,,,,,,,,,,,,,,,,syndecan-2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001033,group IIA phospholipase A2,,,false,,,http://purl.obolibrary.org/obo/IMR_0000283,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001033,,,,,,,,,,,,,,,,,,,,,,group IIA phospholipase A2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003072,ATF6 signaling (primitive) [ER stress - inflammation - ATF6-ARP],,"ATF6 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the ATF6 (activating transcription factor 6). ATF6 generally plays a endoplasmic reticulum membrane stress sensor role.
This process is dependent on the ATF6-ARP mediated inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002838,,,,,,,,,,,,,,,,,,,,PMID:16469704,,"ATF6 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the ATF6 (activating transcription factor 6). ATF6 generally plays a endoplasmic reticulum membrane stress sensor role.
This process is dependent on the ATF6-ARP mediated inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003073,,http://purl.obolibrary.org/obo/TXPO_0003044,,,,,http://purl.obolibrary.org/obo/TXPO_0003068,,,,,,,,,,,TXPO:0003072,,,,,,,,,,,,,,,,,,,,,,ATF6 signaling (primitive) [ER stress - inflammation - ATF6-ARP],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003076,cleavage of CREB by S1P,,Cleavage of CREB by S1P is a subtype of proteolysis: A process in which CREB is cleaved by  endopeptidase S1P( MBTPS1).,false,,,http://purl.obolibrary.org/obo/TXPO_0000333,,,,,,,,,,,,,,,,,,,,,,Cleavage of CREB by S1P is a subtype of proteolysis: A process in which CREB is cleaved by  endopeptidase S1P( MBTPS1).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003076,,,,,,,,,,,,,,,,,,,,,,cleavage of CREB by S1P,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003078,cleavage of CREB by S2P [ER stress],,"Cleavage of CREB by S2P is a subtype of proteolysis: A process in which CREB is cleaved by endopeptidase S2P( MBTPS2). Site-2 cleavage comes after site-1 cleavage
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0003077|http://purl.obolibrary.org/obo/TXPO_0003736,,,,,,,,,,,,,,,,,,,,Reactome:R-HSA-420818|PMID:15299016|PMID:10564271|PMID:11163209|http://purl.obolibrary.org/obo/HINO_0008876,,"Cleavage of CREB by S2P is a subtype of proteolysis: A process in which CREB is cleaved by endopeptidase S2P( MBTPS2). Site-2 cleavage comes after site-1 cleavage
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003078,,,,,,,,,,,,,,,,,,,,,,cleavage of CREB by S2P [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003071,ARP related gene expression,,ARP related gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature ARP gene product or products (proteins or RNA) by PERK.,false,,,http://purl.obolibrary.org/obo/GO_0010467,,,,,,,,,,,,,,,,,,,,,,ARP related gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature ARP gene product or products (proteins or RNA) by PERK.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003071,,,,,,,,,,,,,,,,,,,,,,ARP related gene expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003079,CERB processing [ER stress - inflammation -ARP],,"CERB processing is a subtype of protein processing: CREB maturation process achieved by the cleavage of a peptide bond or bonds within CREB protein.
This process is dependent on the ARP mediated inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0003736|http://purl.obolibrary.org/obo/TXPO_0003766,,,,,,,,,,,,,,,,,,,,,,"CERB processing is a subtype of protein processing: CREB maturation process achieved by the cleavage of a peptide bond or bonds within CREB protein.
This process is dependent on the ARP mediated inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003078|http://purl.obolibrary.org/obo/TXPO_0003075,,,,,,,,,,,,,,,,,,,,,TXPO:0003079,,,,,,,,,,,,,,,,,,,,,,CERB processing [ER stress - inflammation -ARP],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003074,ATF6 processing [ER stress - inflammation],,"ATF6 processing is a subtype of protein processing: A process that ATF6 maturation process achieved by the cleavage of a peptide bond or bonds within ATF6 protein.
This process is dependent on the inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0003063|http://purl.obolibrary.org/obo/TXPO_0003736,,,,,,,,,,,,,,,,,,,,,,"ATF6 processing is a subtype of protein processing: A process that ATF6 maturation process achieved by the cleavage of a peptide bond or bonds within ATF6 protein.
This process is dependent on the inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003074,,,,,,,,,,,,,,,,,,,,,,ATF6 processing [ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003070,CRP - inflammatory substance (canonical)[ER stress],C-reactive protein - inflammatory substance [ER stress],,false,,,http://purl.obolibrary.org/obo/TXPO_0003069,,,,,,,,,,,,,,,,,,,C-reactive protein,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003041,,,,,C-reactive protein - inflammatory substance [ER stress],,,,,TXPO:0003070,,,,,,,,,,,,,,,,,,,,,,CRP - inflammatory substance (canonical)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003075,cleavage of CREB by S1P [ER stress],,"Cleavage of CREB by S1P is a subtype of proteolysis: A process in which CREB is cleaved by endopeptidase S1P( MBTPS1).
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0003076|http://purl.obolibrary.org/obo/TXPO_0003736,,,,,,,,,,,,,,,,,,,,PMID:27346803,,"Cleavage of CREB by S1P is a subtype of proteolysis: A process in which CREB is cleaved by endopeptidase S1P( MBTPS1).
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003078,,,,,,,,,,,TXPO:0003075,,,,,,,,,,,,,,,,,,,,,,cleavage of CREB by S1P [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003077,cleavage of CREB by S2P,,Cleavage of CREB by S2P is a subtype of proteolysis: A process  in which CREB is cleaved by  endopeptidase S2P( MBTPS2). Site-2 cleavage comes after site-1 cleavage,false,,,http://purl.obolibrary.org/obo/TXPO_0000333,,,,,,,,,,,,,,,,,,,,,,Cleavage of CREB by S2P is a subtype of proteolysis: A process  in which CREB is cleaved by  endopeptidase S2P( MBTPS2). Site-2 cleavage comes after site-1 cleavage,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003077,,,,,,,,,,,,,,,,,,,,,,cleavage of CREB by S2P,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003073,ATF6 activation [ER stress - inflammation - ARP],,"ATF6 activation is a subtype of molecular activation: A process that changes the activity of the ATF6 (Activating Transcription Factor 6) to be higher.
This process is dependent on the ARP mediated inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002924,,,,,,,,,,,,,,,,,,,,,,"ATF6 activation is a subtype of molecular activation: A process that changes the activity of the ATF6 (Activating Transcription Factor 6) to be higher.
This process is dependent on the ARP mediated inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003074,,,,,,,,,,,,,,,,,,TXPO:0003073,,,,,,,,,,,,,,,,,,,,,,ATF6 activation [ER stress - inflammation - ARP],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000111,IL-7 receptor,interleukin-7 receptor,,false,,,http://purl.obolibrary.org/obo/IMR_0000096,,,,,,,,,,,,,,,,,,,,GO:0004917,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,interleukin-7 receptor,,,,,IMR:0000111,,,,,,,,,,,,,,,,,,,,,,IL-7 receptor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0071610,chemokine (C-C motif) ligand 1 production,TCA-3 production|CCL1 production|T cell activation 3 production,"The appearance of chemokine (C-C motif) ligand 1 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.",false,,,http://purl.obolibrary.org/obo/GO_0032602,,,,,,,,,,,,,,,,,,,,,,"The appearance of chemokine (C-C motif) ligand 1 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TCA-3 production|CCL1 production|T cell activation 3 production,,,,,GO:0071610,,,,,,,,,,,,,,,,,,,,,,chemokine (C-C motif) ligand 1 production,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_77731,p53 activator,,A role played by the entity that activates p53.,false,,,http://purl.obolibrary.org/obo/TXPO_0003714,,,,,,,,,,,,,,,,,,,,,,A role played by the entity that activates p53.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:77731,,,,,,,,,,,,,,,,,,,,,,p53 activator,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_35703,xenobiotic,xenobiotic compounds|xenobiotics|Xenobiotic|xenobiotic,"A xenobiotic (Greek, xenos ""foreign""; bios ""life"") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.",false,,,http://purl.obolibrary.org/obo/CHEBI_24432,,,,,,,,,,,,,,,,,,,,Wikipedia:Xenobiotic,,"A xenobiotic (Greek, xenos ""foreign""; bios ""life"") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,xenobiotics|Xenobiotic|xenobiotic,,xenobiotic compounds,,,,,,,,,,,,,,,,,,,,,CHEBI:35703,,,,xenobiotic,,CHEBI:35703,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000904,eIF3,eukaryotic initiation factor 3,"consists of a core of five non-identical subunits (eIF3a, eIF3b, eIF3c, eIF3i and eIF3g in yeast) and up to six additional subunits in mammals (eIF3d, eIF3e, eIF3f, eIF3h, eIFj and eIF3k). binding to and stabilization of ternary complex, binding to the 40S ribosome, facilitating the binding of mRNA to the 40S ribosome, and promoting dissociation of 40S and 60S ribosomal subunits",false,,,http://purl.obolibrary.org/obo/IMR_0010016,,,,,,,,,,,,,,,,,,,,,,"consists of a core of five non-identical subunits (eIF3a, eIF3b, eIF3c, eIF3i and eIF3g in yeast) and up to six additional subunits in mammals (eIF3d, eIF3e, eIF3f, eIF3h, eIFj and eIF3k). binding to and stabilization of ternary complex, binding to the 40S ribosome, facilitating the binding of mRNA to the 40S ribosome, and promoting dissociation of 40S and 60S ribosomal subunits",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,eukaryotic initiation factor 3,,,,,IMR:0000904,,,,,,,,,,,,,,,,,,,,,,eIF3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000009400,RECQL5,,"Other designations: ATP-dependent DNA helicase Q5|DNA helicase, RecQ-like type 5",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,RECQ5,,,,,,,,,,,,17,,,,,,HGNC:9950|HPRD:04806|MIM:603781|Vega:OTTHUMG00000179795|Ensembl:ENSG00000108469,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,RecQ protein-like 5,,,17q25,,,,,,,,,,,,,,,,"GO_0000993 (EC: IDA); GO_0003676 (EC: IEA); GO_0003678 (EC: IDA); GO_0003678 (EC: NAS, PMID: 10710432); GO_0005524 (EC: IEA); GO_0005634 (EC: IDA); GO_0005654 (EC: NAS, PMID: 10710432); GO_0005730 (EC: IDA); GO_0005737 (EC: IDA); GO_0005737 (EC: NAS, PMID: 10710432); GO_0006259 (EC: NAS, PMID: 10710432); GO_0006260 (EC: IMP); GO_0006281 (EC: IMP); GO_0006310 (EC: IEA); GO_0007067 (EC: IMP); GO_0008026 (EC: IEA); GO_0016591 (EC: IDA); GO_0031965 (EC: IDA); GO_0032508 (EC: IDA); GO_0032508 (EC: NAS, PMID: 10710432); GO_0032508 (EC: TAS, PMID: 9878247); GO_0034244 (EC: IDA); GO_0051304 (EC: IMP)",,,,,,,,,PMID: 9878247; 10471747; 10710432; 12477932; 15241474; 15342556; 15489334; 16169070; 16344560; 17003056; 18003859; 18029348; 18290761; 18419580; 18562274; 19270065; 19570979; 20081208; 20231364; 20348101; 20643585; 21145461; 21402780; 21890473; 21988832; 22633600; 22645136; 22939629; 22973052; 22990118; 23180761; 23627586; 23748380,,,,,,,,,,,,,,,OGG:3000009400,,,,,,,RecQ protein-like 5,,,,,,,,,,,,,"Other designations: ATP-dependent DNA helicase Q5|DNA helicase, RecQ-like type 5",,RECQL5,,,,,,,,,,,,,,,,,,,,,,,9400,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,RECQL5,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000003309,HSPA5,,Other designations: 78 kDa glucose-regulated protein|endoplasmic reticulum lumenal Ca(2+)-binding protein grp78|epididymis secretory sperm binding protein Li 89n|immunoglobulin heavy chain-binding protein,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,MIF2|GRP78|BIP|HEL-S-89n,,,,,,,,,,,,9,,,,,,HPRD:00682|HGNC:5238|Vega:OTTHUMG00000020672|Ensembl:ENSG00000044574|MIM:138120,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)",,,9q33.3,,,,,,,,,,,,,,,,"GO_0002576 (EC: TAS); GO_0005509 (EC: TAS, PMID: 16130169); GO_0005515 (EC: IPI, PMID: 11907036); GO_0005524 (EC: IEA); GO_0005634 (EC: IMP, PMID: 11943137); GO_0005783 (EC: IDA, PMID: 16223484); GO_0005783 (EC: IMP, PMID: 11943137); GO_0005783 (EC: TAS, PMID: 16130169); GO_0005788 (EC: TAS); GO_0005789 (EC: TAS); GO_0005793 (EC: IDA, PMID: 15308636); GO_0006200 (EC: ISS); GO_0006983 (EC: IEA); GO_0006987 (EC: TAS); GO_0007596 (EC: TAS); GO_0008180 (EC: IDA, Qualifier: colocalizes_with, PMID: 18850735); GO_0009986 (EC: IEA); GO_0016887 (EC: ISS); GO_0019904 (EC: IPI, PMID: 12411443); GO_0021589 (EC: IEA); GO_0021680 (EC: IEA); GO_0021762 (EC: IEP); GO_0030168 (EC: TAS); GO_0030176 (EC: IDA, PMID: 11181571); GO_0030335 (EC: IMP); GO_0030433 (EC: TAS, PMID: 19816510); GO_0030496 (EC: IDA, PMID: 15166316); GO_0030512 (EC: IEA); GO_0030968 (EC: TAS, PMID: 19816510); GO_0031398 (EC: IEA); GO_0031625 (EC: IPI, PMID: 8666824); GO_0034663 (EC: IDA, PMID: 18400946); GO_0035437 (EC: IMP); GO_0042149 (EC: IDA, PMID: 10085239); GO_0042470 (EC: IEA); GO_0043022 (EC: IEA); GO_0043066 (EC: IMP, PMID: 10760948); GO_0043066 (EC: TAS, PMID: 16130169); GO_0044267 (EC: TAS); GO_0051082 (EC: TAS, PMID: 16130169); GO_0051087 (EC: TAS, PMID: 19816510); GO_0051787 (EC: IDA, PMID: 18400946); GO_0060904 (EC: TAS, PMID: 19816510); GO_0070062 (EC: IDA, PMID: 19056867); GO_0071236 (EC: IEA); GO_0071353 (EC: IEA)",,,,,,,,,PMID: 1480470; 1602151; 1649196; 1900540; 2294010; 2840249; 3087629; 3122216; 7724523; 7878056; 7906708; 7957306; 8020977; 8666824; 9006956; 9150946; 9150948; 9305856; 9409741; 9492298; 9885241; 10049727; 10085239; 10197448; 10397760; 10461883; 10514465; 10588643; 10617616; 10708769; 10760948; 10777498; 10887119; 10906332; 10964507; 10964928; 10970892; 11013075; 11160188; 11162507; 11162551; 11181571; 11294872; 11476899; 11719466; 11751874; 11752154; 11765911; 11790298; 11907036; 11932435; 11943137; 12076252; 12097557; 12194978; 12356756; 12359150; 12383251; 12397072; 12411443; 12471035; 12475965; 12477932; 12480769; 12493773; 12514190; 12516782; 12552023; 12621026; 12637535; 12643545; 12665508; 12713871; 12832005; 12840015; 15009096; 15077298; 15146195; 15150263; 15166316; 15280358; 15308636; 15324660; 15456888; 15489334; 15514946; 15525676; 15618547; 15635413; 15657421; 15664986; 15778089; 15817150; 15899857; 15908432; 15949590; 15952740; 16027165; 16051665; 16130169; 16168956; 16169070; 16182273; 16196087; 16212417; 16223484; 16236267; 16257961; 16282978; 16329989; 16344560; 16400691; 16428306; 16472112; 16488447; 16497268; 16522924; 16543232; 16731524; 16912156; 16912197; 17002502; 17062670; 17081065; 17139257; 17184779; 17215244; 17220478; 17337485; 17380188; 17431395; 17601350; 17620599; 17640713; 17643375; 17670764; 17683050; 17721549; 17725712; 17728248; 17765891; 17805346; 17848573; 17906960; 17931354; 17932454; 17936241; 17942541; 17979178; 17991893; 18022401; 18064632; 18083346; 18192872; 18264092; 18268478; 18278507; 18331622; 18343577; 18400946; 18403493; 18411300; 18457437; 18482745; 18502753; 18556570; 18654987; 18708056; 18708359; 18720263; 18757373; 18776923; 18781276; 18781797; 18790759; 18840615; 18842681; 18850735; 18977241; 19014922; 19017364; 19056867; 19097122; 19103594; 19107326; 19128512; 19135240; 19151922; 19164805; 19165527; 19167051; 19188365; 19193609; 19212831; 19228285; 19236758; 19275587; 19287380; 19296942; 19309398; 19343720; 19380743; 19386345; 19411306; 19421146; 19470730; 19471022; 19482905; 19533686; 19546472; 19596686; 19616278; 19626590; 19632185; 19659607; 19671925; 19674193; 19713465; 19718440; 19722195; 19738201; 19741001; 19765186; 19776128; 19786088; 19815544; 19815549; 19816510; 19823030; 19838160; 19838163; 19842229; 19845896; 19850743; 19875381; 19950238; 20017148; 20020773; 20028516; 20072656; 20082722; 20085233; 20145413; 20171186; 20176102; 20204278; 20208072; 20213805; 20360535; 20371724; 20457808; 20473863; 20473970; 20484513; 20492754; 20497865; 20506407; 20508642; 20525207; 20605795; 20628775; 20651985; 20664690; 20672702; 20720212; 20735358; 20739513; 20936779; 20979610; 21056970; 21080038; 21081666; 21112319; 21118962; 21137052; 21139048; 21145461; 21156321; 21189163; 21199322; 21203488; 21221131; 21252943; 21319273; 21343306; 21374734; 21382870; 21389343; 21418596; 21467168; 21472681; 21479362; 21503958; 21516372; 21565611; 21597391; 21622563; 21642380; 21673190; 21738476; 21745816; 21763498; 21779363; 21800051; 21825151; 21840908; 21853274; 21890413; 21890473; 21903092; 21906983; 21940774; 21947079; 21947694; 21963094; 21965664; 21987572; 21988832; 22004425; 22076227; 22079093; 22146569; 22178446; 22215138; 22234250; 22268729; 22297694; 22306319; 22425662; 22427667; 22430489; 22438978; 22446326; 22460328; 22472071; 22495374; 22505724; 22527697; 22528773; 22536838; 22543280; 22546345; 22564965; 22581315; 22613557; 22627132; 22689054; 22735594; 22751133; 22752300; 22796945; 22801219; 22810585; 22851173; 22855534; 22863883; 22889453; 22912664; 22939629; 22945507; 22963397; 22996014; 23000965; 23056589; 23085757; 23089287; 23097496; 23123197; 23161089; 23182705; 23184937; 23200913; 23220234; 23233672; 23246001; 23277564; 23280503; 23314748; 23318453; 23322163; 23349634; 23363602; 23378021; 23383273; 23398456; 23402259; 23402331; 23416888; 23428871; 23438482; 23455922; 23456958; 23457489; 23470966; 23485528; 23544152; 23569248; 23575540; 23578665; 23703321; 23721263; 23759331; 23760505; 23798571; 23818965; 23862649; 23922175; 23956138; 24030972; 24080088; 24113185; 24113381; 24155957; 24239288; 24244333; 24457600,,,,,,,,,,,,,,,OGG:3000003309,,,,,,,"heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)",,,,,,,,,,,,,Other designations: 78 kDa glucose-regulated protein|endoplasmic reticulum lumenal Ca(2+)-binding protein grp78|epididymis secretory sperm binding protein Li 89n|immunoglobulin heavy chain-binding protein,,HSPA5,,,,,,,,,,,,,,,,,,,,,,,3309,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,HSPA5,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000003300,DNAJB2,,"Other designations: dnaJ homolog subfamily B member 2|dnaJ protein homolog 1|heat shock 40 kDa protein 3|heat shock protein J1|heat shock protein, neuronal DNAJ-like 1",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,HSPF3|DSMA5|HSJ1|HSJ-1,,,,,,,,,,,,2,,,,,,HGNC:5228|Vega:OTTHUMG00000133134|Ensembl:ENSG00000135924|HPRD:07249|MIM:604139,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"DnaJ (Hsp40) homolog, subfamily B, member 2",,,2q32-q34,,,,,,,,,,,,,,,,"GO_0000502 (EC: IDA, Qualifier: colocalizes_with, PMID:15936278); GO_0005515 (EC: IPI, PMID:15936278); GO_0006457 (EC: TAS, PMID:1599432); GO_0006986 (EC: TAS, PMID:1599432); GO_0008219 (EC: IEA); GO_0008285 (EC: IGI, PMID:9553041); GO_0016234 (EC: IDA, PMID:15936278); GO_0030308 (EC: IGI, PMID:9553041); GO_0030433 (EC: IDA, PMID:15936278); GO_0030544 (EC: IPI, PMID:15936278); GO_0031398 (EC: IDA, PMID:15936278); GO_0031593 (EC: IDA, PMID:15936278); GO_0032436 (EC: IDA, PMID:15936278); GO_0051082 (EC: TAS, PMID:1599432); GO_0070628 (EC: IDA, PMID:15936278); GO_0090084 (EC: IDA, PMID:15936278); GO_0090086 (EC: IDA, PMID:15936278)",,,,,,,,,PMID:1599432; 8889548; 9553041; 10516435; 11147971; 12107410; 12477932; 12754272; 14751250; 14759258; 15231748; 15489334; 15936278; 16604191; 17082820; 17207965; 17601350; 17847007; 18321953; 18977241; 19285159; 20395441; 21139048; 21625540; 21890473; 21906983; 21963094; 21987572; 22190034; 22522442; 23000965; 23752268; 23940030; 24023695; 24250222,,,,,,,,,,,,,,,OGG:3000003300,,,,,,,"DnaJ (Hsp40) homolog, subfamily B, member 2",,,,,,,,,,,,,"Other designations: dnaJ homolog subfamily B member 2|dnaJ protein homolog 1|heat shock 40 kDa protein 3|heat shock protein J1|heat shock protein, neuronal DNAJ-like 1",,DNAJB2,,,,,,,,,,,,,,,,,,,,,,,3300,,,,,,,,9606,,,,,,,,,,,,,,,,,,,DNAJB2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_61697,fatty acid derivative,FA derivative,Any organic molecular entity derived from a fatty acid.,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,,,Any organic molecular entity derived from a fatty acid.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FA derivative,,,,,CHEBI:61697,,,,,,,,,,,,,,,,,,,,,,fatty acid derivative,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_68543,pyrimidine synthesis inhibitor,pyrimidine synthesis inhibitors,A pathway inhibitor that inhibits the synthesis of pyrimidine.,false,,,http://purl.obolibrary.org/obo/CHEBI_76932,,,,,,,,,,,,,,,,,,,,,,A pathway inhibitor that inhibits the synthesis of pyrimidine.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pyrimidine synthesis inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:68543,,,,pyrimidine synthesis inhibitor,,CHEBI:68543,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002940,JNK activation [ER stress - apoptosis - IRE1−TRAF2-ASK-JNK-Bcl2 pathway],,"JNK activation is a subtype of molecular activation: A process that changes the activity of the JNK to be higher.
This process is dependent on the IRE1−TRAF2-ASK-JNK-Bcl2 pathway mediated apoptosis and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0003736|http://purl.obolibrary.org/obo/TXPO_0002828,,,,,,,,,,,,,,,,,,,,PMID:25232821,,"JNK activation is a subtype of molecular activation: A process that changes the activity of the JNK to be higher.
This process is dependent on the IRE1−TRAF2-ASK-JNK-Bcl2 pathway mediated apoptosis and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002946,,,,,,,,,,,TXPO:0002940,,,,,,,,,,,,,,,,,,,,,,JNK activation [ER stress - apoptosis - IRE1−TRAF2-ASK-JNK-Bcl2 pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002949,BIM activation,,"BIM activation is a subtype of molecular activation: A process that changes the activity of the BIM (BCL2L11), BH3-only BCL-2 family,  to be higher.",false,,,http://purl.obolibrary.org/obo/TXPO_0000023,,,,,,,,,,,,,,,,,,,,,,"BIM activation is a subtype of molecular activation: A process that changes the activity of the BIM (BCL2L11), BH3-only BCL-2 family,  to be higher.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002949,,,,,,,,,,,,,,,,,,,,,,BIM activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002941,IRE1 - signaling factor (canonical)[ER stress - apotosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002603,http://purl.obolibrary.org/obo/TXPO_0002594,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UniProt_Q9NZJ5|http://www.uniprot.org/entry/Q9NZJ5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001898,,,,,,,,,,TXPO:0002941,,,,,,,,,,,,,,,,,,,,,,IRE1 - signaling factor (canonical)[ER stress - apotosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002942,ASK (canonical)[ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000871|http://purl.obolibrary.org/obo/TXPO_1000010,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:10926|NCBI-Rat-GeneID:312046|NCBI-Mouse-GeneID:27214,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002942,,,,,,,,,,,,,,,,,,,,,,ASK (canonical)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002946,Bcl2 inactivation by JNK [ER stress - apoptosis - IRE1-TRAF2-JNK pathway],,"A process that changes the activity of the Bcl2 to be lower by JNK.
This process is dependent on the IRE1-TRAF2-JNK pathway mediated apoptosis and can constitute the course of ER stress.|Inhibition of anti-apoptotic factor Bcl-2 results in the promotion of apoptosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002947,,,,,,,,,,,,,,,,,,,,,,"A process that changes the activity of the Bcl2 to be lower by JNK.
This process is dependent on the IRE1-TRAF2-JNK pathway mediated apoptosis and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002951,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002948,,,,,,,,,,,TXPO:0002946,,,,,,,,,,,,,,,,,,,,Inhibition of anti-apoptotic factor Bcl-2 results in the promotion of apoptosis.,,Bcl2 inactivation by JNK [ER stress - apoptosis - IRE1-TRAF2-JNK pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002948,BIM activation [ER stress - apoptosis - IRE1−TRAF2-JNK-Bcl2 pathway],,"BIM activation is a subtype of molecular activation: A process that changes the activity of the BIM (BCL2L11), BH3-only BCL-2 family, to be higher.
This process is dependent on the IRE1−TRAF2-JNK-Bcl2 pathway mediated apoptosis and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002949,,,,,,,,,,,,,,,,,,,,PMID:12818176,,"BIM activation is a subtype of molecular activation: A process that changes the activity of the BIM (BCL2L11), BH3-only BCL-2 family, to be higher.
This process is dependent on the IRE1−TRAF2-JNK-Bcl2 pathway mediated apoptosis and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002948,,,,,,,,,,,,,,,,,,,,,,BIM activation [ER stress - apoptosis - IRE1−TRAF2-JNK-Bcl2 pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002945,ASK - signaling factor (canonical)[ER stress - apotosis -TRAF2],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002942,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UniProt_Q9NZJ5|http://www.uniprot.org/entry/Q9NZJ5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001898,,,,,,,,,,TXPO:0002945,,,,,,,,,,,,,,,,,,,,,,ASK - signaling factor (canonical)[ER stress - apotosis -TRAF2],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002944,ASK - signaling factor (canonical)[ER stress - inflammation -TRAF2],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002942,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UniProt_Q9NZJ5|http://www.uniprot.org/entry/Q9NZJ5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001898,,,,,,,,,,TXPO:0002944,,,,,,,,,,,,,,,,,,,,,,ASK - signaling factor (canonical)[ER stress - inflammation -TRAF2],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002947,Bcl2 inactivation by JNK,,Bcl2 inactivation by JNK is a subtype of inactivating: A process that changes the activity of the Bcl2 to be lower by JNK.,false,,,http://purl.obolibrary.org/obo/TXPO_0000021,,,,,,,,,,,,,,,,,,,,,,Bcl2 inactivation by JNK is a subtype of inactivating: A process that changes the activity of the Bcl2 to be lower by JNK.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002947,,,,,,,,,,,,,,,,,,,,,,Bcl2 inactivation by JNK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002943,ASK - signaling factor (canonical)[ER stress - inflammation],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002942,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UniProt_Q9NZJ5|http://www.uniprot.org/entry/Q9NZJ5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001898,,,,,,,,,,TXPO:0002943,,,,,,,,,,,,,,,,,,,,,,ASK - signaling factor (canonical)[ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000817,c-JUN,AP-1,,false,,,http://purl.obolibrary.org/obo/IMR_0000416,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,AP-1,,,,,IMR:0000817,,,,,,,,,,,,,,,,,,,,,,c-JUN,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0001173,biliary tree,biliary tract,"A complex network of conduits that begins with the canals of Hering (intralobar bile duct) and progressively merges into a system of interlobular, septal, and major ducts which then coalesce to form the extrahepatic bile ducts, which finally deliver bile to the intestine, and in some species to the gallbladder.|The path in many species is as follows: Bile canaliculi -> Canals of Hering (intralobar bile duct) -> interlobular bile ducts -> intrahepatic bile ducts -> left and right hepatic ducts merge to form -> common hepatic duct *exits liver* and joins -> cystic duct (from gall bladder) forming -> common bile duct -> joins with pancreatic duct -> forming ampulla of Vater -> enters duodenum [WP]",false,,,http://purl.obolibrary.org/obo/UBERON_0011216,,,,,,,,,,,,,,,,,,,,http://www.snomedbrowser.com/Codes/Details/181267003|http://linkedlifedata.com/resource/umls/id/C0005423|http://en.wikipedia.org/wiki/Biliary_tract|XAO:0000455|AAO:0011020|EMAPA:35172|UMLS:C0005423|FMA:14665,,"A complex network of conduits that begins with the canals of Hering (intralobar bile duct) and progressively merges into a system of interlobular, septal, and major ducts which then coalesce to form the extrahepatic bile ducts, which finally deliver bile to the intestine, and in some species to the gallbladder.",,,,,,,,"Hollow tree organ, the organ parts of which consist of the bile ducts.[AAO]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,biliary tract,,http://purl.obolibrary.org/obo/UBERON_0002294,UBERON:0001173,http://purl.obolibrary.org/obo/UBERON_0002294,,,,,,,,,,,,,,,,,,,The path in many species is as follows: Bile canaliculi -> Canals of Hering (intralobar bile duct) -> interlobular bile ducts -> intrahepatic bile ducts -> left and right hepatic ducts merge to form -> common hepatic duct *exits liver* and joins -> cystic duct (from gall bladder) forming -> common bile duct -> joins with pancreatic duct -> forming ampulla of Vater -> enters duodenum [WP],,biliary tree,,,,,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_77326,androstane receptor agonist,CAR agonist|constitutive androstane receptor agonist,An agonist that selectively binds to and activates androstane receptors.,false,,,http://purl.obolibrary.org/obo/CHEBI_48705,,,,,,,,,,,,,,,,,,,,Wikipedia:Constitutive_androstane_receptor,,An agonist that selectively binds to and activates androstane receptors.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CAR agonist|constitutive androstane receptor agonist,,,CHEBI:77326,,,,,,,,,,,,,,,,,,,,,,androstane receptor agonist,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000113,DGAT2 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0001417,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:252900|NCBI-Mouse-GeneID:67800|NCBI-Human-GeneID:84649,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000084649,,,,,,,,,,,,,TXPO:1000113,,,,,,,,,,,,,,,,,,,,,,DGAT2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000110,DDIT4 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:74747|NCBI-Human-GeneID:54541|NCBI-Rat-GeneID:140942,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000054541,,,,,,,,,,,,,TXPO:1000110,,,,,,,,,,,,,,,,,,,,,,DDIT4 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000111,DDRGK1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:65992|NCBI-Mouse-GeneID:77006|NCBI-Rat-GeneID:296162,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000065992,,,,,,,,,,,,,TXPO:1000111,,,,,,,,,,,,,,,,,,,,,,DDRGK1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000119,Ddx21 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:9188|NCBI-Rat-GeneID:317399|NCBI-Mouse-GeneID:56200,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000009188,,,,,,,,,,,,,TXPO:1000119,,,,,,,,,,,,,,,,,,,,,,Ddx21 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000115,DNAJC3 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:100037258|NCBI-Rat-GeneID:63880|NCBI-Human-GeneID:5611,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000005611,,,,,,,,,,,,,TXPO:1000115,,,,,,,,,,,,,,,,,,,,,,DNAJC3 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000112,DDX25 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:58856|NCBI-Mouse-GeneID:30959|NCBI-Human-GeneID:29118,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000029118,,,,,,,,,,,,,TXPO:1000112,,,,,,,,,,,,,,,,,,,,,,DDX25 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000118,Ddit4l (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:115265|NCBI-Rat-GeneID:100363484|NCBI-Mouse-GeneID:73284,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000115265,,,,,,,,,,,,,TXPO:1000118,,,,,,,,,,,,,,,,,,,,,,Ddit4l (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000114,DNAJB9 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:4189|NCBI-Mouse-GeneID:27362|NCBI-Rat-GeneID:24908,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000004189,,,,,,,,,,,,,TXPO:1000114,,,,,,,,,,,,,,,,,,,,,,DNAJB9 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000116,DPH6 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:66632|NCBI-Rat-GeneID:362191|NCBI-Human-GeneID:89978,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000089978,,,,,,,,,,,,,TXPO:1000116,,,,,,,,,,,,,,,,,,,,,,DPH6 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000331,COX,prostaglandin endoperoxide synthase,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,EC:1.14.99.1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000519,,,,,prostaglandin endoperoxide synthase,,,,,IMR:0000331,,,,,,,,,,,,,,,,,,,,,,COX,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_13389,NAD,,Abbreviation for nicotinamide-adenine dinucleotide when its oxidation state is unknown or unspecified. It is used in metabolic pathways like glycolysis and citric acid cycle.,false,,,http://purl.obolibrary.org/obo/CHEBI_36976,,,,,,,,,,,,,,,,,,,,Wikipedia:Nicotinamide_adenine_dinucleotide,,Abbreviation for nicotinamide-adenine dinucleotide when its oxidation state is unknown or unspecified. It is used in metabolic pathways like glycolysis and citric acid cycle.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:13389,,,,,,,,,,,,,,,,,,,,,,NAD,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003083,CREBPH - signaling factor (canonical)[ER stress - inflammation],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003082,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001898,,,,,,,,,,TXPO:0003083,,,,,,,,,,,,,,,,,,,,,,CREBPH - signaling factor (canonical)[ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003080,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003080,CREB3L3  activation [ER stress - inflammation - ARP],,"CREB3L3  activation is a subtype of molecular activation: A process that  changes the activity of the CREBL3 to be higher.
This process is dependent on the rinflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000031|http://purl.obolibrary.org/obo/TXPO_0003736,,,,,,,,,,,,,,,,,,,,PMID:16469704,,"CREB3L3  activation is a subtype of molecular activation: A process that  changes the activity of the CREBL3 to be higher.
This process is dependent on the rinflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003079,,,,,,,,,,,,,,,,,,TXPO:0003080,,,,,,,,,,,,,,,,,,,,,,CREB3L3  activation [ER stress - inflammation - ARP],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003086,SAP (canonical)[ER stress],serum amyloid P-component [ER stress]|APCS [ER stress],,false,,,http://purl.obolibrary.org/obo/TXPO_0000871|http://purl.obolibrary.org/obo/TXPO_1000331,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:29339|NCBI-Human-GeneID:325|NCBI-Mouse-GeneID:20219|https://omim.org/entry/104770,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,serum amyloid P-component [ER stress]|APCS [ER stress],,,,,TXPO:0003086,,,,,,,,,,,,,,,,,,,,,,SAP (canonical)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003082,CRBPH (canonical)[ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000871|http://purl.obolibrary.org/obo/TXPO_1000074,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003082,,,,,,,,,,,,,,,,,,,,,,CRBPH (canonical)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003085,CREBPH -APR transcriptional factor (canonical)[ER stress - inflammation -APR],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003082,,,,,,,,,,,,,,,,,,,Creb3l3,PMID:16469704,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000825,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,,,,,,TXPO:0003085,,,,,,,,,,,,,,,,,,,,,,CREBPH -APR transcriptional factor (canonical)[ER stress - inflammation -APR],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003081,CREB3L3 signaling [ER stress - inflammation],,"CREB3L3 signaling is a subtype of signaling [biological]: A process that in which a signal transmitted by CREB3L3.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000604|http://purl.obolibrary.org/obo/TXPO_0003736,,,,,,,,,,,,,,,,,,,,,,"CREB3L3 signaling is a subtype of signaling [biological]: A process that in which a signal transmitted by CREB3L3.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002902,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003080,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002841,,,,,,,,,,,TXPO:0003081,,,,,,,,,,,,,,,,,,,,,,CREB3L3 signaling [ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003087,SAP - inflammatory factor (canonical)[ER stress],serum amyloid P-component - inflammatory factor [ER stress],,false,,,http://purl.obolibrary.org/obo/TXPO_0003086,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003041,,,,,serum amyloid P-component - inflammatory factor [ER stress],,,,,TXPO:0003087,,,,,,,,,,,,,,,,,,,,,,SAP - inflammatory factor (canonical)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003088,IRE1 - autophosphorylation kinase (canonical)[ER stress -RIDD],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002601,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003088,,,,,,,,,,,,,,,,,,,,,,IRE1 - autophosphorylation kinase (canonical)[ER stress -RIDD],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002975,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003084,ARP gene regulation pathway by ATF6 [ER stress],,ARP gene regulation pathway by ATF6 is a subtype of ATF6 gene regulation pathway: Sequence of reactions to regulate acute response protein (ARP) genes by ATF6. This process can constitute the course of ER stress.,false,,,http://purl.obolibrary.org/obo/TXPO_0002520,,,,,,,,,,,,,,,,,,,,,,ARP gene regulation pathway by ATF6 is a subtype of ATF6 gene regulation pathway: Sequence of reactions to regulate acute response protein (ARP) genes by ATF6. This process can constitute the course of ER stress.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003045,,,,,,,,,,,,,,,,,,TXPO:0003084,,,,,,,,,,,,,,,,,,,,,,ARP gene regulation pathway by ATF6 [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003089,IRE1 dimerization [ER stress - RIDD],,"IRE1 dimerization is a subtype of protein dimerization: The formation of a IRE1 dimer, a macromolecular structure consists of two noncovalently associated identical or nonidentical subunits.
This entity is a specific course-dependent process. This process is dependent on RIDD and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002596,,,,,,,,,,,,,,,,,,,,PMID:23236464|PMID:11897784|Reactome:R-HSA-381109,,"IRE1 dimerization is a subtype of protein dimerization: The formation of a IRE1 dimer, a macromolecular structure consists of two noncovalently associated identical or nonidentical subunits.
This entity is a specific course-dependent process. This process is dependent on RIDD and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003090,,,,,,http://purl.obolibrary.org/obo/TXPO_0003064,,,,,,,,,,,TXPO:0003089,,,,,,,,,,,,,,,,,,,,,,IRE1 dimerization [ER stress - RIDD],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_52210,pharmacological role,,A biological role which describes how a drug interacts within a biological system and how the interactions affect its medicinal properties.,false,,,http://purl.obolibrary.org/obo/CHEBI_24432|http://purl.obolibrary.org/obo/BFO_0000023,,,,,,,,,,,,,,,,,,,,,,A biological role which describes how a drug interacts within a biological system and how the interactions affect its medicinal properties.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:52210,,,,pharmacological role,,CHEBI:52210,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_22333,alkylating agent,,"Highly reactive chemical that introduces alkyl radicals into biologically active molecules and thereby prevents their proper functioning. It could be used as an antineoplastic agent, but it might be very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. It could also be used as a component of poison gases.",false,,,http://purl.obolibrary.org/obo/TXPO_0001316|http://purl.obolibrary.org/obo/CHEBI_25435,,,,,,,,,,,,,,,,,,,,,,"Highly reactive chemical that introduces alkyl radicals into biologically active molecules and thereby prevents their proper functioning. It could be used as an antineoplastic agent, but it might be very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. It could also be used as a component of poison gases.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:22333,,,,alkylating agent,,CHEBI:22333,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004322,toxicity value,,,false,,,http://purl.obolibrary.org/obo/TXPO_0000277,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004322,,,,,,,,,,,,,,,,,,,,,,toxicity value,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004325,STAT3 activation[Mitochondrial disorder],,"STAT3 activation is a subtype of molecular activation: A process that changes the activity of the STAT3 to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0004326|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:25181692,,"STAT3 activation is a subtype of molecular activation: A process that changes the activity of the STAT3 to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004318,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004218,,,,,,,,,,,TXPO:0004325,,,,,,,,,,,,,,,,,,,,,,STAT3 activation[Mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004320,drug toxicity,,An attribute of the finding of bodily injury due to the poisonous effects of drugs.,false,,,http://purl.obolibrary.org/obo/TXPO_0004211,,,,,,,,,,,,,,,,,,,,,,An attribute of the finding of bodily injury due to the poisonous effects of drugs.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004320,,,,,,,,,,,,,,,,,,,,,,drug toxicity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004328,reactive aldehyde,,,false,,,http://purl.obolibrary.org/obo/CHEBI_17478,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004328,,,,,,,,,,,,,,,,,,,,,,reactive aldehyde,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004321,drug liver toxicity,,An attribute of the finding of liver injury due to the poisonous effects of drugs.,false,,,http://purl.obolibrary.org/obo/TXPO_0004320,,,,,,,,,,,,,,,,,,,,,,An attribute of the finding of liver injury due to the poisonous effects of drugs.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004321,,,,,,,,,,,,,,,,,,,,,,drug liver toxicity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004324,IL6 signaling [Mitochondrial disorder],,IL6 signaling is a subtype of signaling [biological]: Any series of molecular signals generated as a consequence of binding to Interleukin 6. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.,false,,,http://purl.obolibrary.org/obo/TXPO_0004327|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:25181692|PMID:31623280|PMID:23299992,,IL6 signaling is a subtype of signaling [biological]: Any series of molecular signals generated as a consequence of binding to Interleukin 6. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004256,http://purl.obolibrary.org/obo/TXPO_0004319|http://purl.obolibrary.org/obo/TXPO_0004385,http://purl.obolibrary.org/obo/GO_0070102,,,,,http://purl.obolibrary.org/obo/TXPO_0004271|http://purl.obolibrary.org/obo/TXPO_0002041|http://purl.obolibrary.org/obo/TXPO_0004325|http://purl.obolibrary.org/obo/TXPO_0004397,,,,,,,,,,,TXPO:0004324,,,,,,,,,,,,,,,,,,,,,,IL6 signaling [Mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004329,mitochondrial respiratory chain complex I subunit,,,false,,,http://purl.obolibrary.org/obo/GO_0098800,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004329,,,,,,,,,,,,,,,,,,,,,,mitochondrial respiratory chain complex I subunit,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004327,IL-6 signaling (primitive),,IL-6 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the cytokine IL-6.,false,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,,,IL-6 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the cytokine IL-6.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0070102,,,,,,,,,,,,,,,,TXPO:0004327,,,,,,,,,,,,,,,,,,,,,,IL-6 signaling (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004323,Most-DILI-Concern,,"From Drug Induced Liver Injury Rank (DILIrank) Dataset.
 DILIrank consists of 1,036 FDA-approved drugs that are divided into four classes according to their potential for causing drug-induced liver injury (DILI).",false,,,http://purl.obolibrary.org/obo/TXPO_0004322,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004323,,,,,,,,,,,,,,,,,,,,"From Drug Induced Liver Injury Rank (DILIrank) Dataset.
 DILIrank consists of 1,036 FDA-approved drugs that are divided into four classes according to their potential for causing drug-induced liver injury (DILI).",,Most-DILI-Concern,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004326,STAT3 activation,,STAT3 activation is a subtype of molecular activation: A process that changes the activity of the STAT3 to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000023,,,,,,,,,,,,,,,,,,,,,,STAT3 activation is a subtype of molecular activation: A process that changes the activity of the STAT3 to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003113,,,,,,,,,,,TXPO:0004326,,,,,,,,,,,,,,,,,,,,,,STAT3 activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0001062,anatomical entity,,Biological entity that is either an individual member of a biological species or constitutes the structural organization of an individual member of a biological species.,false,,,http://purl.obolibrary.org/obo/BFO_0000030,,,,,,,,,,,,,,,,,,,,,,Biological entity that is either an individual member of a biological species or constitutes the structural organization of an individual member of a biological species.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,UBERON:0001062,,,,,,,,,,,,,,,,,,,,,,anatomical entity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001025,"Rod cGMP-specific 3',5'-cyclic phosphodiesterase alpha-subunit",,,false,,,http://purl.obolibrary.org/obo/IMR_0100002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001025,,,,,,,,,,,,,,,,,,,,,,"Rod cGMP-specific 3',5'-cyclic phosphodiesterase alpha-subunit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000009221,NOLC1,,Other designations: 140 kDa nucleolar phosphoprotein|HCV NS5A trans-regulated protein 13|HCV NS5A-transactivated protein 13|hepatitis C virus NS5A-transactivated protein 13|nucleolar 130 kDa protein|nucleolar and coiled-body phosphprotein 1|nucleolar phosphoprotein p130|nucleolar protein p130,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,NOPP130|NOPP140|NS5ATP13|P130,,,,,,,,,,,,10,,,,,,MIM:602394|Ensembl:ENSG00000166197|HGNC:15608|Vega:OTTHUMG00000018944,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,nucleolar and coiled-body phosphoprotein 1,,,10q24.32,,,,,,,,,,,,,,,,"GO_0005515 (EC: IPI, PMID: 17620599); GO_0005524 (EC: IEA); GO_0005525 (EC: IEA); GO_0005730 (EC: IDA); GO_0005737 (EC: IEA); GO_0006364 (EC: TAS, PMID: 7657714); GO_0007000 (EC: IEA); GO_0007049 (EC: TAS, PMID: 7657714); GO_0007067 (EC: TAS, PMID: 7657714); GO_0015030 (EC: IEA); GO_0044822 (EC: IDA)",,,,,,,,,PMID: 7584026; 7584028; 7657714; 8125298; 8630004; 8657117; 8889548; 8972203; 9013635; 9016786; 9553145; 9679133; 10567578; 11571651; 12167624; 12446766; 12477932; 12777385; 14702039; 15144186; 15146197; 15161933; 15302935; 15324660; 15385968; 16341674; 16344560; 16385451; 16964243; 17001309; 17038328; 17081983; 17342744; 17353931; 17531812; 17620599; 18029348; 18253863; 18790693; 19129172; 19381672; 19471022; 19541936; 19608861; 20360068; 21139048; 21264300; 21266110; 21693764; 21832049; 21890473; 21906983; 22178446; 22190034; 22586326; 22751105; 22863883; 22906532; 22939629; 22952844; 23000965; 23188192; 23398456; 23455922; 24218616; 24457600,,,,,,,,,,,,,,,OGG:3000009221,,,,,,,nucleolar and coiled-body phosphoprotein 1,,,,,,,,,,,,,Other designations: 140 kDa nucleolar phosphoprotein|HCV NS5A trans-regulated protein 13|HCV NS5A-transactivated protein 13|hepatitis C virus NS5A-transactivated protein 13|nucleolar 130 kDa protein|nucleolar and coiled-body phosphprotein 1|nucleolar phosphoprotein p130|nucleolar protein p130,,NOLC1,,,,,,,,,,,,,,,,,,,,,,,9221,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,NOLC1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0001357,GDP,,,false,,,http://purl.obolibrary.org/obo/CHEBI_36976,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0200191,,,,,,IMR:0001357,,,,,,,,,,,,,,,,,,,,,,GDP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001434,BMP-10,Bone morphogenetic protein 10|BMP10,,false,,,http://purl.obolibrary.org/obo/IMR_0000040,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Bone morphogenetic protein 10|BMP10,,,,,IMR:0001434,,,,,,,,,,,,,,,,,,,,,,BMP-10,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100025,cGMP,"Guanosine 3',5'-cyclic phosphate|Guanosine 3',5'-cyclic monophosphate|Cyclic GMP|3',5'-Cyclic GMP",,false,,,http://purl.obolibrary.org/obo/IMR_0001355,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002401,,,,IMR:0200372,"Guanosine 3',5'-cyclic phosphate|Guanosine 3',5'-cyclic monophosphate|Cyclic GMP|3',5'-Cyclic GMP",,,,,IMR:0100025,,,,,,,,,,,,,,,,,,,,,,cGMP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000005290,PIK3CA,,"Other designations: PI3-kinase p110 subunit alpha|PI3K-alpha|phosphatidylinositol 3-kinase, catalytic, 110-KD, alpha|phosphatidylinositol 3-kinase, catalytic, alpha polypeptide|phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform|phosphatidylinositol-4,5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha|phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit, alpha isoform|phosphoinositide-3-kinase, catalytic, alpha polypeptide|ptdIns-3-kinase subunit p110-alpha|serine/threonine protein kinase PIK3CA",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CWS5|p110-alpha|MCAP|MCMTC|PI3K|MCM|CLOVE,,,,,,,,,,,,3,,,,,,HGNC:8975|MIM:171834|HPRD:01382,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha",,,3q26.3,,,,,,,,,,,,,,,,"GO_0001525 (EC: IEA); GO_0001944 (EC: TAS, PMID: 19200708); GO_0004674 (EC: IEA); GO_0005515 (EC: IPI, PMID: 10490823); GO_0005524 (EC: IEA); GO_0005829 (EC: TAS); GO_0005886 (EC: IBA); GO_0005942 (EC: ISS); GO_0005943 (EC: IDA); GO_0006006 (EC: IEA); GO_0006644 (EC: TAS); GO_0006661 (EC: TAS); GO_0007173 (EC: TAS); GO_0007596 (EC: TAS); GO_0008286 (EC: TAS); GO_0008543 (EC: TAS); GO_0016301 (EC: TAS); GO_0016303 (EC: IDA, PMID: 2174051); GO_0030027 (EC: IEA); GO_0030168 (EC: TAS); GO_0030295 (EC: IEA); GO_0031295 (EC: TAS); GO_0033138 (EC: IEA); GO_0035004 (EC: ISS); GO_0035004 (EC: TAS, PMID: 19200708); GO_0035005 (EC: IBA); GO_0036092 (EC: IDA, PMID: 2174051); GO_0038028 (EC: TAS, PMID: 19200708); GO_0038095 (EC: TAS); GO_0038096 (EC: TAS); GO_0040014 (EC: IEA); GO_0043491 (EC: IEA); GO_0043524 (EC: IEA); GO_0043542 (EC: TAS, PMID: 19200708); GO_0043560 (EC: IEA); GO_0044029 (EC: IEA); GO_0044281 (EC: TAS); GO_0045087 (EC: TAS); GO_0046854 (EC: ISS); GO_0046934 (EC: TAS); GO_0048011 (EC: TAS); GO_0048015 (EC: TAS); GO_0050852 (EC: TAS); GO_0050900 (EC: TAS); GO_0060048 (EC: TAS, PMID: 19147653); GO_2000270 (EC: IEA); GO_2000653 (EC: IEA); GO_2000811 (EC: IMP)",,,,,,,,,PMID: 1322797; 2174051; 7713498; 7820549; 7929193; 8020561; 8246987; 8636073; 8665852; 8702949; 8798481; 9043658; 9113989; 9119889; 9150145; 9247029; 9341793; 9394803; 9415396; 9446795; 9708406; 9808187; 9915850; 9916799; 10208934; 10213474; 10357815; 10358930; 10490823; 10571082; 10608806; 10620012; 10648629; 10783161; 10803462; 10921882; 10949031; 10985305; 11029009; 11154208; 11156964; 11157475; 11278864; 11279232; 11289809; 11334418; 11353842; 11438544; 11577104; 11606067; 11676480; 11912194; 11959846; 11969417; 11994280; 12077252; 12167717; 12477932; 12526811; 12538664; 12551992; 12584329; 12637493; 12660731; 12704201; 12754211; 12890670; 12893243; 12933652; 12954600; 12960231; 14511371; 14583609; 14602571; 14724584; 14729945; 15016963; 15213298; 15254419; 15289301; 15377662; 15467468; 15489334; 15520168; 15605984; 15632060; 15647370; 15664519; 15689238; 15707590; 15712344; 15784156; 15805248; 15834429; 15837735; 15924253; 15928251; 15930273; 15940673; 15950905; 15994075; 16034135; 16043515; 16081599; 16114017; 16135792; 16150119; 16150444; 16168105; 16203798; 16287065; 16288007; 16317585; 16322209; 16339173; 16339315; 16341083; 16344560; 16353168; 16354680; 16376301; 16380997; 16397024; 16406609; 16432179; 16522324; 16524887; 16533766; 16569657; 16582596; 16618717; 16627990; 16682946; 16728507; 16764926; 16775835; 16778113; 16788758; 16790501; 16806069; 16815198; 16820791; 16822308; 16837650; 16839745; 16840732; 16885334; 16930767; 16949921; 16968743; 17006756; 17050665; 17052259; 17060456; 17062663; 17141917; 17157319; 17202311; 17219054; 17222361; 17235514; 17237249; 17307335; 17314276; 17317825; 17332342; 17341442; 17363507; 17369495; 17376864; 17377809; 17426084; 17449641; 17468516; 17471559; 17487277; 17507466; 17546593; 17549376; 17575221; 17586693; 17590872; 17632570; 17635910; 17657213; 17669465; 17673550; 17681398; 17803655; 17827385; 17855350; 17875942; 17877460; 17923698; 17924977; 17936563; 17942548; 17947469; 17971428; 17982280; 17986027; 17990317; 18000091; 18022911; 18029348; 18064631; 18070887; 18074223; 18079394; 18084252; 18097548; 18180098; 18181165; 18183466; 18193083; 18216097; 18221484; 18224685; 18262558; 18270270; 18285463; 18317450; 18335034; 18343945; 18355852; 18371219; 18382359; 18418043; 18449193; 18453587; 18503601; 18516290; 18621636; 18624398; 18641990; 18660489; 18669866; 18676830; 18679714; 18691552; 18757405; 18769113; 18782444; 18794094; 18794883; 18798071; 18829572; 18835245; 18852163; 18854243; 18951408; 18980969; 18990689; 18996102; 19003996; 19012001; 19027487; 19029838; 19029981; 19064572; 19069650; 19076977; 19143676; 19147653; 19148475; 19164214; 19172191; 19196980; 19200708; 19223544; 19233141; 19234438; 19237633; 19240718; 19261849; 19272638; 19276248; 19305151; 19330652; 19349352; 19351817; 19366826; 19380724; 19380743; 19383818; 19394761; 19411071; 19418217; 19420344; 19440000; 19440799; 19443396; 19487299; 19549383; 19573809; 19584164; 19603024; 19608668; 19622295; 19633047; 19638206; 19654299; 19671852; 19679877; 19685490; 19686742; 19701705; 19704056; 19706770; 19735264; 19789314; 19789368; 19805105; 19807924; 19815551; 19818761; 19822807; 19826477; 19839777; 19844234; 19844788; 19845664; 19853286; 19861897; 19874421; 19891769; 19898424; 19903786; 19903845; 19913121; 20008098; 20018188; 20019835; 20022634; 20028853; 20030946; 20034918; 20041213; 20056178; 20098682; 20101210; 20103642; 20107891; 20130133; 20167866; 20177704; 20186503; 20237496; 20301425; 20308328; 20308428; 20331378; 20368287; 20379197; 20398348; 20407443; 20413299; 20416077; 20416519; 20447721; 20453000; 20479250; 20491626; 20493625; 20495538; 20508983; 20514448; 20526288; 20535651; 20551053; 20557351; 20569675; 20571907; 20593314; 20602615; 20616362; 20619739; 20622004; 20628086; 20629536; 20629539; 20652941; 20691427; 20699365; 20702582; 20703095; 20713702; 20718712; 20736745; 20813562; 20813970; 20818790; 20824703; 20826237; 20827662; 20838624; 20857497; 20860430; 20881644; 20937558; 20940279; 20953381; 20954287; 20959404; 21029719; 21035469; 21042767; 21048031; 21051183; 21062993; 21071597; 21072204; 21092549; 21093899; 21103049; 21113138; 21113787; 21123564; 21127054; 21139048; 21168197; 21169263; 21179398; 21185392; 21191416; 21209852; 21209903; 21225506; 21228233; 21252315; 21255011; 21258250; 21266528; 21290341; 21300060; 21303542; 21310649; 21332555; 21345071; 21355052; 21357506; 21358673; 21367892; 21372221; 21377268; 21406404; 21407159; 21408138; 21412012; 21419810; 21424126; 21440011; 21442372; 21454528; 21468554; 21469098; 21474066; 21480388; 21482133; 21482677; 21490305; 21499215; 21501368; 21507233; 21531001; 21531708; 21538027; 21557211; 21558396; 21594665; 21595858; 21617917; 21620836; 21620963; 21622527; 21646525; 21660567; 21663621; 21667306; 21673026; 21676217; 21682666; 21706016; 21708979; 21711108; 21713404; 21725367; 21735444; 21765914; 21768115; 21769475; 21788516; 21789382; 21822287; 21824802; 21829508; 21830111; 21861134; 21872252; 21887250; 21893189; 21899695; 21906875; 21932420; 21937609; 21945955; 21949775; 21970855; 21990951; 21991326; 21994334; 21997360; 22006429; 22020193; 22026810; 22033276; 22037177; 22039088; 22045127; 22064833; 22072736; 22095222; 22105580; 22107784; 22120431; 22135231; 22146375; 22146979; 22157930; 22172323; 22185283; 22188534; 22188813; 22190283; 22208359; 22209294; 22212451; 22214007; 22227580; 22258409; 22271473; 22285706; 22285928; 22287190; 22301279; 22302350; 22315990; 22325221; 22330809; 22336203; 22336586; 22340730; 22351695; 22355357; 22357840; 22363436; 22363598; 22383975; 22417847; 22430133; 22430209; 22460814; 22463491; 22471665; 22488590; 22495819; 22498935; 22522453; 22522847; 22552288; 22556157; 22556379; 22575839; 22579930; 22586484; 22619175; 22623730; 22635024; 22640628; 22648906; 22649008; 22658544; 22662165; 22675430; 22675553; 22683270; 22689060; 22704443; 22705003; 22705004; 22723903; 22729222; 22729223; 22729224; 22736407; 22737248; 22744290; 22768164; 22768179; 22779686; 22782554; 22798500; 22807617; 22840496; 22842715; 22851869; 22863784; 22870241; 22875023; 22880054; 22897848; 22897902; 22905202; 22912864; 22923510; 22928013; 22931052; 22936809; 22938585; 22940133; 22949056; 22949682; 22955107; 22964641; 22982396; 22988297; 22994622; 22994717; 22997091; 22998445; 23013731; 23021375; 23028762; 23051731; 23066026; 23066039; 23071680; 23082158; 23085752; 23092874; 23094721; 23100325; 23107319; 23110163; 23115297; 23125007; 23136191; 23136247; 23172887; 23182717; 23184205; 23185308; 23192871; 23219661; 23224067; 23233531; 23237847; 23243017; 23246288; 23248156; 23261389; 23266353; 23275335; 23292187; 23300780; 23301057; 23318440; 23335533; 23341541; 23345407; 23352210; 23374602; 23383294; 23386617; 23392229; 23401445; 23409016; 23417417; 23418602; 23429328; 23435830; 23453624; 23475955; 23523798; 23532889; 23538402; 23546602; 23548132; 23549875; 23563091; 23564819; 23568272; 23580570; 23583669; 23588386; 23592373; 23604317; 23612454; 23615713; 23624506; 23625205; 23626817; 23633456; 23640046; 23643389; 23660947; 23680019; 23684925; 23695676; 23708425; 23709421; 23725225; 23728071; 23734265; 23739063; 23743572; 23785428; 23787421; 23813545; 23832540; 23851329; 23867512; 23867821; 23884447; 23886157; 23891627; 23936502; 23946963; 23981382; 24001613; 24011934; 24062397; 24077110; 24099783; 24231454; 24233241; 24299208; 24314632; 24323026; 24323028; 24360885; 24364210; 24374682,,,,,,,,,,,,,,,OGG:3000005290,,,,,,,"phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha",,,,,,,,,,,,,"Other designations: PI3-kinase p110 subunit alpha|PI3K-alpha|phosphatidylinositol 3-kinase, catalytic, 110-KD, alpha|phosphatidylinositol 3-kinase, catalytic, alpha polypeptide|phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform|phosphatidylinositol-4,5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha|phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit, alpha isoform|phosphoinositide-3-kinase, catalytic, alpha polypeptide|ptdIns-3-kinase subunit p110-alpha|serine/threonine protein kinase PIK3CA",,PIK3CA,,,,,,,,,,,,,,,,,,,,,,,5290,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,PIK3CA,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0000109,long-chain fatty acid import into peroxisome [Eosinophilic granular degeneration],,"The directed movement of long-chain fatty acids into a peroxisome. A long-chain fatty acid is a fatty acid with a chain length between C13 and C22.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/GO_0015910|http://purl.obolibrary.org/obo/TXPO_0001729,,,,,,,,,,,,,,,,,,,,,,"The directed movement of long-chain fatty acids into a peroxisome. A long-chain fatty acid is a fatty acid with a chain length between C13 and C22.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000179,,,,,,,,,,,TXPO:0000109,,,,,,,,,,,,,,,,,,,,,,long-chain fatty acid import into peroxisome [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000108,organelle proliferation,,Organelle proliferation is a subtype of increasing number of objects: A process that becomes larger in the number of organelles.,false,,,http://purl.obolibrary.org/obo/TXPO_0000093,,,,,,,,,,,,,,,,,,,,,,Organelle proliferation is a subtype of increasing number of objects: A process that becomes larger in the number of organelles.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000108,,,,,,,,,,,,,,,,,,,,,,organelle proliferation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000000,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000105,peroxisomal proliferation in hepatocyte [Eosinophilic granular degeneration],,"Peroxisomal proliferation in hepatocyte is a subtype of hepatocyte organelle proliferation: A process that becomes larger in the number of peroxisome in hepatocyte(s).
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/TXPO_0001729|http://purl.obolibrary.org/obo/TXPO_0000104,,,,,,,,,,,,,,,,,,,,,,"Peroxisomal proliferation in hepatocyte is a subtype of hepatocyte organelle proliferation: A process that becomes larger in the number of peroxisome in hepatocyte(s).
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003523,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001045,,,,,,http://purl.obolibrary.org/obo/TXPO_0000165,,,,,,,,,,,TXPO:0000105,,,,,,,"Humanized mice (ie, PPARalpha-null mice transfected with human PPAR alpha) also fail to respond with hepatocellular and peroxisomal proliferation to fibrates, indicating that the human receptor cannot signal for proliferation.|Humans do not respond with hepatocellular and peroxisomal proliferation to fibrates and express PPARalpha at low levels and often in nonfunctional forms.

Casarett & Doull's Toxicology: The Basic Science of Poisons, Eighth Edition",,,,,,,,,,,,,,,peroxisomal proliferation in hepatocyte [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCBITaxon_9989,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000106,hyperfunction of phenobarbital metabolism [Ground glass appearance],,"hyperfunction of phenobarbital metabolism is a subtype of hyperfunctioning of drug metabolism: A process that performs an excessive phenobarbital metabolism.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/TXPO_0000443,,,,,,,,,,,,,,,,,,,,,,"hyperfunction of phenobarbital metabolism is a subtype of hyperfunctioning of drug metabolism: A process that performs an excessive phenobarbital metabolism.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001663|http://purl.obolibrary.org/obo/TXPO_0003864,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003860,,,,,,,,,,,TXPO:0000106,,,,,,,,,,,,,,,,,,,,,,hyperfunction of phenobarbital metabolism [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000107,peroxisomal Acox biosynthetic process,,Peroxisomal Acox biosynthetic process is a subtype of protein production: A process that makes existent of a Peroxisomal acyl -coenzyme A oxidase (ACOX) due to biosynthesis or secretion resulting in an increase in its levels.,false,,,http://purl.obolibrary.org/obo/TXPO_0000382,,,,,,,,,,,,,,,,,,,,,,Peroxisomal Acox biosynthetic process is a subtype of protein production: A process that makes existent of a Peroxisomal acyl -coenzyme A oxidase (ACOX) due to biosynthesis or secretion resulting in an increase in its levels.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000107,,,,,,,,,,,,,,,,,,,,,,peroxisomal Acox biosynthetic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000101,hyperfunction of cerramide phagocytosis by Kupffer cells or macrophges [Phospholipidosis-sphingomyelin disorder],,"Removing ceramide by Kupffer cell or macrophage is a subtype of removing: A process that takes a ceramide from a cell by Kupffer cells or macrophages .
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (sphingomyelin disorder).",false,,,http://purl.obolibrary.org/obo/TXPO_0004151|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Removing ceramide by Kupffer cell or macrophage is a subtype of removing: A process that takes a ceramide from a cell by Kupffer cells or macrophages .
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (sphingomyelin disorder).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000091|http://purl.obolibrary.org/obo/CL_0000235,,,,,,http://purl.obolibrary.org/obo/TXPO_0004160,,,,,,,,,,,TXPO:0000101,,,,,,,,,,,,,,,,,,,,,,hyperfunction of cerramide phagocytosis by Kupffer cells or macrophges [Phospholipidosis-sphingomyelin disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000100,hyperfunction of lipid degradation,,Hyperfunction of lipid degradation is a subtype of hyperfunction of decompoing: A process that performs an excessive lipid degradation.,false,,,http://purl.obolibrary.org/obo/TXPO_0002349,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/MP_0008034,,Hyperfunction of lipid degradation is a subtype of hyperfunction of decompoing: A process that performs an excessive lipid degradation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000100,,,,,,,,,,,,,,,,,,,,,,hyperfunction of lipid degradation,,,,,,http://purl.obolibrary.org/obo/GO_0016042,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000103,increasing demand for response to oxidative stress [Eosinophilic granular degeneration],,"Increasing demand for response to oxidative stress is a subtype of increasing the demand for response to stress: A process that changes the functional demand for the response to the oxidative stress to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/TXPO_0001729|http://purl.obolibrary.org/obo/TXPO_0000102,,,,,,,,,,,,,,,,,,,,PMID:26344566,,"Increasing demand for response to oxidative stress is a subtype of increasing the demand for response to stress: A process that changes the functional demand for the response to the oxidative stress to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003219,,,,,,,,,,,TXPO:0000103,,,,,,,,,,,,,,,,,,,,,,increasing demand for response to oxidative stress [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000102,increasing demand for response to oxidative stress,,Increasing demand for response to oxidative stress is a subtype of increasing the demand for response to stress: A process that changes the functional demand for the response to the oxidative stress to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000361,,,,,,,,,,,,,,,,,,,,,,Increasing demand for response to oxidative stress is a subtype of increasing the demand for response to stress: A process that changes the functional demand for the response to the oxidative stress to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000102,,,,,,,,,,,,,,,,,,,,,,increasing demand for response to oxidative stress,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000104,peroxisomal proliferation in hepatocyte,increasing peroxisome number in hepatocytes,Peroxisomal proliferation in hepatocyte is a subtype of hepatocyte organelle proliferation: A process that becomes larger in the number of peroxisome in hepatocyte(s).,false,,,http://purl.obolibrary.org/obo/TXPO_0003303,,,,,,,,,,,,,,,,,,,,,,Peroxisomal proliferation in hepatocyte is a subtype of hepatocyte organelle proliferation: A process that becomes larger in the number of peroxisome in hepatocyte(s).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,increasing peroxisome number in hepatocytes,,,,,TXPO:0000104,,,,,,,,,,,,,,,,,,,,,,peroxisomal proliferation in hepatocyte,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0005815,microtubule organizing center,MOC|microtubule organising centre,"An intracellular structure that can catalyze gamma-tubulin-dependent microtubule nucleation and that can anchor microtubules by interacting with their minus ends, plus ends or sides.",false,,,http://purl.obolibrary.org/obo/GO_0044464,,,,,,,,,,,,,,,,,,,,Wikipedia:Microtubule_organizing_center,,"An intracellular structure that can catalyze gamma-tubulin-dependent microtubule nucleation and that can anchor microtubules by interacting with their minus ends, plus ends or sides.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MOC|microtubule organising centre,,,,http://purl.obolibrary.org/obo/GO_0005856,GO:0005815,http://purl.obolibrary.org/obo/GO_0005856,,,,,,,,,,,,,,,,,,,,,microtubule organizing center,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0001865,NK T cell differentiation,,The process in which a precursor cell type acquires the specialized features of a NK T cell.|Note that NK T cells are a distinct lineage of T cells expressing natural killer cell markers and having T cell receptors characterized by the usage of a restricted repertoire of variable region gene segments. Note that immunologists typically use the word 'development' to refer to cells of B or T cell lineages undergoing the process that GO describes as 'cell differentiation'.,false,,,http://purl.obolibrary.org/obo/GO_0030217,,,,,,,,,,,,,,,,,,,,,,The process in which a precursor cell type acquires the specialized features of a NK T cell.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0001865,,,,,,,,,,,,,,,,,,,,Note that NK T cells are a distinct lineage of T cells expressing natural killer cell markers and having T cell receptors characterized by the usage of a restricted repertoire of variable region gene segments. Note that immunologists typically use the word 'development' to refer to cells of B or T cell lineages undergoing the process that GO describes as 'cell differentiation'.,,NK T cell differentiation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_70727,topoisomerase inhibitor,topoisomerase inhibitors,An EC 5.99.1.* (miscellaneous isomerase) inhibitor that interferes with the action of any of the topoisomerases (enzymes that regulate the overwinding or underwinding of DNA).,false,,,http://purl.obolibrary.org/obo/CHEBI_76830,,,,,,,,,,,,,,,,,,,,,,An EC 5.99.1.* (miscellaneous isomerase) inhibitor that interferes with the action of any of the topoisomerases (enzymes that regulate the overwinding or underwinding of DNA).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,topoisomerase inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:70727,,,,topoisomerase inhibitor,,CHEBI:70727,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004364,pirprofen [mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/CHEBI_135028|http://purl.obolibrary.org/obo/TXPO_0004312,,,,,,,,,,,,,,,,,,,,PMID:21145849|Wikipedia:Pirprofen,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004364,,,,,,,,,,,,,,,,,,,,,,pirprofen [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004369,increasing CPT1 level [mitochondrial disorder],,"Increasing CPT1 level is a subtype of increasing quantity: A process that changes the amount of CPT1 level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0004473|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:23299992,,"Increasing CPT1 level is a subtype of increasing quantity: A process that changes the amount of CPT1 level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004474,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004360,,,,,,,,,,,TXPO:0004369,,,,,,,,,,,,,,,,,,,,,,increasing CPT1 level [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004368,Increasing damaged mitochondria [mitochondrial disorder],,"Increasing damaged mitochondria is a subtype of decreasing quantity: A process that changes the amount of damaged mitochondria to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0005030,,,,,,,,,,,,,,,,,,,,PMID:31623280|PMID:31649547,,"Increasing damaged mitochondria is a subtype of decreasing quantity: A process that changes the amount of damaged mitochondria to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001990|http://purl.obolibrary.org/obo/TXPO_0000869|http://purl.obolibrary.org/obo/TXPO_0002005|http://purl.obolibrary.org/obo/TXPO_0004342|http://purl.obolibrary.org/obo/TXPO_0005031|http://purl.obolibrary.org/obo/TXPO_0004263,,,,,,,,,,,TXPO:0004368,,,,,,,,,,,,,,,,,,,,,,Increasing damaged mitochondria [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004361,amineptine [mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004312|http://purl.obolibrary.org/obo/CHEBI_32499,,,,,,,,,,,,,,,,,,,,PMID:21145849|Wikipedia:Amineptine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004361,,,,,,,,,,,,,,,,,,,,,,amineptine [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004367,hyperfunction of gluconeogenesis [mitochondrial disorder],,"Hyperfunction of glucose biosynthesis is a subtype of hyperfunction of biosynthesis: A process that performs an excessive glucose biosynthesis.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0004942|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of glucose biosynthesis is a subtype of hyperfunction of biosynthesis: A process that performs an excessive glucose biosynthesis.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004937,,,,,,,,,,,TXPO:0004367,,,,,,,,,,,,,,,,,,,,,,hyperfunction of gluconeogenesis [mitochondrial disorder],,,,,,http://purl.obolibrary.org/obo/GO_0006094,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004360,mitochondrial fatty acid beta-oxidation [mitochondrial disorder],,"A fatty acid oxidation process that results in the complete beta oxidation of a fatty acid in the mitochondria.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001388|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:23299992,,"A fatty acid oxidation process that results in the complete beta oxidation of a fatty acid in the mitochondria.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001990|http://purl.obolibrary.org/obo/TXPO_0004127,,,,,,,,,,,TXPO:0004360,,,,,,,,,,,,,,,,,,,,,,mitochondrial fatty acid beta-oxidation [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004362,ibuprofen [mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/CHEBI_5855|http://purl.obolibrary.org/obo/TXPO_0004312,,,,,,,,,,,,,,,,,,,,PMID:21145849,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004362,,,,,,,,,,,,,,,,,,,,,,ibuprofen [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004366,hyperfunction of CYP2E1 gene expression [mitochondrial disorder],,"Hyperfunction of CYP2E1 gene expression is a subtype of hyperfunction of cytochrome 450 gene expression: A process that performs an excesssive gene expression of CYP2E1.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0004493|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:23299992,,"Hyperfunction of CYP2E1 gene expression is a subtype of hyperfunction of cytochrome 450 gene expression: A process that performs an excesssive gene expression of CYP2E1.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004229,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001990,,,,,,,,,,,TXPO:0004366,,,,,,,,,,,,,,,,,,,,,,hyperfunction of CYP2E1 gene expression [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004363,panadiplon [mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004312|http://purl.obolibrary.org/obo/TXPO_0004970,,,,,,,,,,,,,,,,,,,,PMID:21145849|Wikipedia:Panadiplon,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004363,,,,,,,,,,,,,,,,,,,,,,panadiplon [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004365,tacrine [mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004312|http://purl.obolibrary.org/obo/CHEBI_45980,,,,,,,,,,,,,,,,,,,,PMID:21145849|Wikipedia:Tacrine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004365,,,,,,,,,,,,,,,,,,,,,,tacrine [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003277,Ero1lb (mouse)[ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000812|http://purl.obolibrary.org/obo/TXPO_1000126,,,,,,,,,,,,,,,,,,,,https://omim.org/entry/615437|http://www.uniprot.org/uniprot/Q86YB8#function|PMID:10818100|PMID:23334697|PMID:21091435|PMID:24469402,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003277,,,,,,,,,,,,,,,,,,,,,,Ero1lb (mouse)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000795,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003274,Fgf21 (mouse)[ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000145|http://purl.obolibrary.org/obo/TXPO_0000812,,,,,,,,,,,,,,,,,,,"ER stress and PPARα activation contribute to carcinogenesis in a fatty liver. PMID:22009939


Hepatosteatosis in peroxisome deficient liver despite increased beta-oxidation capacity and impaired lipogenesis. Biochimie (2011) 93:1828–38.

FGF21-FGFR1 coordinates phospholipid homeostasis, lipid droplet function and ER stress in obesity.Endocrinology. 2016 PMID:27690692


Fibroblast growth factor 21 (FGF21) is an endocrine growth factor, a regulator of fatty acids and glucose metabolism. Recently, it has been reported that FGF21 expression is regulated by activating transcription factor 4 (ATF4), a transcription factor activated by various stimuli such as endoplasmic reticulum (ER) stress. PMID:27010621

Endoplasmic reticulum stress induces up-regulation of hepatic beta-Klotho expression through ATF4 signaling pathway. PMID:25727012",NCBI-Mouse-GeneID:56636|PMID:25727012|PMID:22009939|PMID:27010621|PMID:17550777|PMID:27690692,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0100571,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000026291,,,,,,,,,,,,,TXPO:0003274,,,,,,,,,,,,,,,,,,,,,,Fgf21 (mouse)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003278,phospholipidosis dependent molecule (mouse),,"Phospholipidosis dependent molecule is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of phospholipidosis as a gene product.
Gene profile:Mouse/Liver/",false,,,http://purl.obolibrary.org/obo/TXPO_0001133,,,,,,,,,,,,,,,,,,,,,,"Phospholipidosis dependent molecule is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of phospholipidosis as a gene product.
Gene profile:Mouse/Liver/",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003278,,,,,,,,,,,,,,,,,,,,,,phospholipidosis dependent molecule (mouse),,,,,,,,,,,http://purl.obolibrary.org/obo/NCBITaxon_10090,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003272,CASPASE-2 (canonical)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/IMR_0100303|http://purl.obolibrary.org/obo/TXPO_0003213,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:12366|NCBI-Rat-GeneID:64314|NCBI-Human-GeneID:835,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000305,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000835,,,,,,,,,,,,,TXPO:0003272,,,,,,,,,,,,,,,,,,,,,,CASPASE-2 (canonical)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003270,hypofunction of phospholipid transport from ER to mitochondrial membrane [ER stress],,"Hypofunction of phospholipid transport from ER to mitochondrial membrane is a subtype of hypofunction of transport: A process that performs a decreased or insufficient phospholipid transport from ER to mitochondrial membrane.
This entity is a specific course-dependent process. This process can constitute the course of ER stress",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/TXPO_0003269,,,,,,,,,,,,,,,,,,,,,,"Hypofunction of phospholipid transport from ER to mitochondrial membrane is a subtype of hypofunction of transport: A process that performs a decreased or insufficient phospholipid transport from ER to mitochondrial membrane.
This entity is a specific course-dependent process. This process can constitute the course of ER stress",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001810,,,,,,,,,,,TXPO:0003270,,,,,,,,,,,,,,,,,,,,,,hypofunction of phospholipid transport from ER to mitochondrial membrane [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003275,malfunction of phospholipid biosynthesis,,Malfunction of phospholipid biosynthesis is a subtype of malfunctioning: A process that cannot perform  the phospholipid biosynthesis function appropriately or cannot realize it at all.,false,,,http://purl.obolibrary.org/obo/TXPO_0003267,,,,,,,,,,,,,,,,,,,,,,Malfunction of phospholipid biosynthesis is a subtype of malfunctioning: A process that cannot perform  the phospholipid biosynthesis function appropriately or cannot realize it at all.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003275,,,,,,,,,,,,,,,,,,,,,,malfunction of phospholipid biosynthesis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005783,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003273,CASPASE-3 (canonical)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003213|http://purl.obolibrary.org/obo/TXPO_0001145,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:12367|NCBI-Rat-GeneID:25402|NCBI-Human-GeneID:836,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000305,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000836,,,,,,,,,,,,,TXPO:0003273,,,,,,,,,,,,,,,,,,,,,,CASPASE-3 (canonical)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003276,malfunction of phospholipid biosynthesis [ER stress],,Malfunction of phospholipid biosynthesis is a subtype of malfunctioning: A process that cannot perform  the phospholipid biosynthesis function appropriately or cannot realize it at all. This entity is a specific course-dependent process. This process can constitute the course of ER stress.,false,,,http://purl.obolibrary.org/obo/TXPO_0003275|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,Malfunction of phospholipid biosynthesis is a subtype of malfunctioning: A process that cannot perform  the phospholipid biosynthesis function appropriately or cannot realize it at all. This entity is a specific course-dependent process. This process can constitute the course of ER stress.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003270|http://purl.obolibrary.org/obo/TXPO_0002199,,,,,,,,,,,TXPO:0003276,,,,,,,,,,,,,,,,,,,,,,malfunction of phospholipid biosynthesis [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005783,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003279,increasing liver weight dependent process,,Increasing liver weight dependent process is a subtype of toxic course dependent process: A process that can constitute the course of liver hypertrophy.,false,,,http://purl.obolibrary.org/obo/TXPO_0001715,,,,,,,,,,,,,,,,,,,,,,Increasing liver weight dependent process is a subtype of toxic course dependent process: A process that can constitute the course of liver hypertrophy.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003279,,,,,,,,,,,,,,,,,,,,,,increasing liver weight dependent process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003271,increasing liver weight [Hypertrophy],,"Increasing liver weight is a subtype of increasing weight: A process that changes the weight of the liver to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy.",false,,,http://purl.obolibrary.org/obo/TXPO_0000054|http://purl.obolibrary.org/obo/TXPO_0003279,,,,,,,,,,,,,,,,,,,,,,"Increasing liver weight is a subtype of increasing weight: A process that changes the weight of the liver to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003286|http://purl.obolibrary.org/obo/TXPO_0000217|http://purl.obolibrary.org/obo/TXPO_0003297,,,,,,,,,,,,,,,,,,TXPO:0003271,,,,,,,,,,,,,,,,,,,,,,increasing liver weight [Hypertrophy],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_33282,antibacterial agent,antibacterials|bactericides|bactericide|antibacterial agents,A substance (or active part thereof) that kills or slows the growth of bacteria.|A substance that kills or slows the growth of bacteria.,false,,,http://purl.obolibrary.org/obo/CHEBI_33281,,,,,,,,,,,,,,,,,,,,,,A substance (or active part thereof) that kills or slows the growth of bacteria.|A substance that kills or slows the growth of bacteria.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,antibacterials|bactericides|bactericide|antibacterial agents,,,,,,,,,,,,,,,,,,,,,CHEBI:33282,,,,antibacterial agent,,CHEBI:33282,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000555,kalinin,,,false,,,http://purl.obolibrary.org/obo/IMR_0000554,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000555,,,,,,,,,,,,,,,,,,,,,,kalinin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_22314,alkali metal atom,,,false,,,http://purl.obolibrary.org/obo/CHEBI_33521,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:22314,,,,,,,,,,,,,,,,,,,,,,alkali metal atom,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000606,IL-8RA,interleukin-8 receptor A,,false,,,http://purl.obolibrary.org/obo/IMR_0000605,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,interleukin-8 receptor A,,,,,IMR:0000606,,,,,,,,,,,,,,,,,,,,,,IL-8RA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000614,neuregulin-1,NRG-1,,false,,,http://purl.obolibrary.org/obo/IMR_0000048,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,NRG-1,,,,,IMR:0000614,,,,,,,,,,,,,,,,,,,,,,neuregulin-1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0034162,TLR9 signaling pathway,toll-like receptor 9 signaling pathway,Any series of molecular signals generated as a consequence of binding to toll-like receptor 9.,false,,,http://purl.obolibrary.org/obo/GO_0002224,,,,,,,,,,,,,,,,,,,,,,Any series of molecular signals generated as a consequence of binding to toll-like receptor 9.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,toll-like receptor 9 signaling pathway,,,,,GO:0034162,,,,,,,,,,,,,,,,,,,,,,TLR9 signaling pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001853,TGF beta receptor signaling (primitive) [Phospholipidosis (excessive defense)],,"TGF beta receptor signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal transmitted by the TGF beta receptor (transforming growth factor beta receptor) on the surface of a cell, starting with a ligand binding to a TGFR.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense).",false,,,http://purl.obolibrary.org/obo/TXPO_0001854|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"TGF beta receptor signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal transmitted by the TGF beta receptor (transforming growth factor beta receptor) on the surface of a cell, starting with a ligand binding to a TGFR.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001853,,,,,,,,,,,,,,,,,,,,,,TGF beta receptor signaling (primitive) [Phospholipidosis (excessive defense)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001855,decreasing mitochondrial membrane potential,reduction of membrane potential,Decreasing mitochondrial membrane potential is a subtype of decreasing membrane potential: A process that changes the electrical potential of a mitochondrial membrane to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0001995,,,,,,,,,,,,,,,,,,,,,,Decreasing mitochondrial membrane potential is a subtype of decreasing membrane potential: A process that changes the electrical potential of a mitochondrial membrane to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,reduction of membrane potential,,,,,TXPO:0001855,,,,,,,,,,,,,,,,,,,,,,decreasing mitochondrial membrane potential,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001850,hepatic fibrosis [Phospholipidosis (excessive defense)],,"Hepatic fibrosis is a subtype of fibrosis: A process that replaces liver tissues to fibrous connective tissues, usually as a consequence of inflammation or other injury.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense).",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0000816,,,,,,,,,,,,,,,,,,,,,,"Hepatic fibrosis is a subtype of fibrosis: A process that replaces liver tissues to fibrous connective tissues, usually as a consequence of inflammation or other injury.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001853,http://purl.obolibrary.org/obo/TXPO_0003788,,,,,,http://purl.obolibrary.org/obo/TXPO_0002264,,,,,,,,,,,TXPO:0001850,,,,,,,,,,,,,,,,,,,,,,hepatic fibrosis [Phospholipidosis (excessive defense)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001851,making existence of xenobiotics,,"Making existence of xenobiotics is a subtype of making existence of foreign substance: A process that makes xenobiotics to be present in a cell, organelle, or an organism.",false,,,http://purl.obolibrary.org/obo/TXPO_0000968,,,,,,,,,,,,,,,,,,,,,,"Making existence of xenobiotics is a subtype of making existence of foreign substance: A process that makes xenobiotics to be present in a cell, organelle, or an organism.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001851,,,,,,,,,,,,,,,,,,,,,,making existence of xenobiotics,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001852,PERK - signaling factor (canonical)[Perk signalling system],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000878,http://purl.obolibrary.org/obo/TXPO_0000454,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UniProt_Q9NZJ5|http://www.uniprot.org/entry/Q9NZJ5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001898,,,,,,,,,,TXPO:0001852,,,,,,,,,,,,,,,,,,,,,,PERK - signaling factor (canonical)[Perk signalling system],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001854,TGF beta receptor signaling (primitive),,"TGF beta receptor signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal transmitted by the TGF beta receptor (transforming growth factor beta receptor) on the surface of a cell, starting with a ligand binding to a TGFR.",false,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,,,"TGF beta receptor signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal transmitted by the TGF beta receptor (transforming growth factor beta receptor) on the surface of a cell, starting with a ligand binding to a TGFR.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0007179,,,,,,,,,,,,,,,,TXPO:0001854,,,,,,,,,,,,,,,,,,,,,,TGF beta receptor signaling (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001857,LPA [Phospholipidosis],lysophosphatidic acid [Phospholipidosis],,false,,,http://purl.obolibrary.org/obo/TXPO_0001849|http://purl.obolibrary.org/obo/CHEBI_132742,,,,,,,,,,,,,,,,,,,,MeSH:C032881,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002271|http://purl.obolibrary.org/obo/TXPO_0003686|http://purl.obolibrary.org/obo/TXPO_0002401,,,,,lysophosphatidic acid [Phospholipidosis],,,,,TXPO:0001857,,,,,,,,,,,,,,,,,,,,,,LPA [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001497,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001856,heme biosynthetic process [lipidosis],,"The chemical reactions and pathways resulting in the formation of heme, any compound of iron complexed in a porphyrin (tetrapyrrole) ring, from less complex precursors.
This entity is a specific course-dependent process. This process can constitute the course of lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0004004,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways resulting in the formation of heme, any compound of iron complexed in a porphyrin (tetrapyrrole) ring, from less complex precursors.
This entity is a specific course-dependent process. This process can constitute the course of lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001774|http://purl.obolibrary.org/obo/TXPO_0004003|http://purl.obolibrary.org/obo/TXPO_0003915,,,,,,http://purl.obolibrary.org/obo/TXPO_0003510,,,,,,,,,,,TXPO:0001856,,,,,,,,,,,,,,,,,,,,,,heme biosynthetic process [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001859,CYP4A11(human)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001135|http://purl.obolibrary.org/obo/TXPO_0003836,,,,,,,,,,,,,,,,,,,"Cyp4a11 relates to cardiovascular abnormality (blood pressure, etc.).",NCBI-Human-GeneID:1579|PMID:16712844|PMID:30069903|PMID:18433732|PMID:21912424|PMID:12464261,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001579,,,,,,,,,,,,,TXPO:0001859,,,,,,,,,,,,,,,,,,,,,,CYP4A11(human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001858,hypofunction of PPARa regulated gene expression [NASH],,"Hypofunction of PPAR alpha regulated gene expression is a subtype of hyporfunction of gene expression: A process that performs an PPARa trgulated gene expression.
This entity is a specific course-dependent process. This process can constitute the course of NASH.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0001860,,,,,,,,,,,,,,,,,,,,,,"Hypofunction of PPAR alpha regulated gene expression is a subtype of hyporfunction of gene expression: A process that performs an PPARa trgulated gene expression.
This entity is a specific course-dependent process. This process can constitute the course of NASH.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001884|http://purl.obolibrary.org/obo/TXPO_0001774|http://purl.obolibrary.org/obo/TXPO_0001961|http://purl.obolibrary.org/obo/TXPO_0003915|http://purl.obolibrary.org/obo/TXPO_0001808,,,,,,,,,,,,,,,,,TXPO:0001858,,,,,,,,,,,,,,,,,,,,,,hypofunction of PPARa regulated gene expression [NASH],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003611,CDK1 (predicted)(human) [mitochondrial damage],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003603|http://purl.obolibrary.org/obo/TXPO_1000507,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:983|PMID:24746669,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000000983,,,,,,,,,,,,,TXPO:0003611,,,,,,,,,,,,,,,,,,,,,,CDK1 (predicted)(human) [mitochondrial damage],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003618,hepatic vascular circulation disorder dependent process,,Hepatic vascular circulation disorder dependent process is a subtype of toxic course dependent process: A process that can constitute the course of hepatic vascular circulation disorder.,false,,,http://purl.obolibrary.org/obo/TXPO_0001715,,,,,,,,,,,,,,,,,,,,,,Hepatic vascular circulation disorder dependent process is a subtype of toxic course dependent process: A process that can constitute the course of hepatic vascular circulation disorder.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003618,,,,,,,,,,,,,,,,,,,,,,hepatic vascular circulation disorder dependent process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003610,CCL2 (predicted)(human) [mitochondrial damage],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003603|http://purl.obolibrary.org/obo/TXPO_1000086,,,,,,,,,,,,,,,,,,,"PMID:30894684,  Hepatocarcinoma cell",NCBI-Human-GeneID:6347|PMID:30894684,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000006347,,,,,,,,,,,,,TXPO:0003610,,,,,,,,,,,,,,,,,,,,,,CCL2 (predicted)(human) [mitochondrial damage],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003613,GDF15 (predicted)(human) [mitochondrial damage],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003603|http://purl.obolibrary.org/obo/TXPO_1000164,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:9518|PMID:29222479,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000009518,,,,,,,,,,,,,TXPO:0003613,,,,,,,,,,,,,,,,,,,,,,GDF15 (predicted)(human) [mitochondrial damage],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003617,malfunctioning of hepatic blood circulation [hepatic blood circulatory disorder],,"Malfunctioning of hepatic blood circulation is a subtype of malfunctioning process: A process that cannot perform hepatic blood circulation function appropriately or cannot realize it at all.
This entity is a specific course-dependent process. This process can constitute the course of hepatic blood circulatory disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0003618|http://purl.obolibrary.org/obo/TXPO_0001718,,,,,,,,,,,,,,,,,,,,,,"Malfunctioning of hepatic blood circulation is a subtype of malfunctioning process: A process that cannot perform hepatic blood circulation function appropriately or cannot realize it at all.
This entity is a specific course-dependent process. This process can constitute the course of hepatic blood circulatory disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003457|http://purl.obolibrary.org/obo/TXPO_0003458|http://purl.obolibrary.org/obo/TXPO_0003619,,,,,,,,,,,TXPO:0003617,,,,,,,,,,,,,,,,,,,,,,malfunctioning of hepatic blood circulation [hepatic blood circulatory disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003614,DHFR (predicted)(human) [mitochondrial damage],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003603|http://purl.obolibrary.org/obo/TXPO_1000513,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1719,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000001719,,,,,,,,,,,,,TXPO:0003614,,,,,,,,,,,,,,,,,,,,,,DHFR (predicted)(human) [mitochondrial damage],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003619,hepatic shunt formtion [hepatic blood circulatory disorder],,"Hepatic shunt formtion is a subtype of biological structure formation: A process that makes abnormal communications between the hepatic arteries, portal veins, and hepatic or systemic veins.
This entity is a specific course-dependent process. This process can constitute the course of hepatic blood circulatory disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001358|http://purl.obolibrary.org/obo/TXPO_0003618,,,,,,,,,,,,,,,,,,,,,,"Hepatic shunt formtion is a subtype of biological structure formation: A process that makes abnormal communications between the hepatic arteries, portal veins, and hepatic or systemic veins.
This entity is a specific course-dependent process. This process can constitute the course of hepatic blood circulatory disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003619,,,,,,,,,,,,,,,,,,,,,,hepatic shunt formtion [hepatic blood circulatory disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003615,severe sphingomyelin accumulation in lysosome of nervous system,,Severe sphingomyelin accumulation in lysosome of nervous system is a subtype of sphingomyelin accumulation in lysosome of nervous system: A process that keeps sphingomyelin in the lysosome of nervous system severely.,false,,,http://purl.obolibrary.org/obo/TXPO_0001691,,,,,,,,,,,,,,,,,,,,,,Severe sphingomyelin accumulation in lysosome of nervous system is a subtype of sphingomyelin accumulation in lysosome of nervous system: A process that keeps sphingomyelin in the lysosome of nervous system severely.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003615,,,,,,,,,,,,,,,,,,,,,,severe sphingomyelin accumulation in lysosome of nervous system,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003612,HMMR (predicted)(human) [mitochondrial damage],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003603|http://purl.obolibrary.org/obo/TXPO_1000519,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:3161,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000003161,,,,,,,,,,,,,TXPO:0003612,,,,,,,,,,,,,,,,,,,,,,HMMR (predicted)(human) [mitochondrial damage],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003616,spleen hyperfunction [hepatic blood circulatory disorder],,"Spleen hyperfunction is a subtype of hyperfunctioning: A process that performs an excessive spleen function.
This entity is a specific course-dependent process. This process can constitute the course of hepatic blood circulatory disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001361,,,,,,,,,,,,,,,,,,,,,,"Spleen hyperfunction is a subtype of hyperfunctioning: A process that performs an excessive spleen function.
This entity is a specific course-dependent process. This process can constitute the course of hepatic blood circulatory disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003616,,,,,,,,,,,,,,,,,,,,,,spleen hyperfunction [hepatic blood circulatory disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006897,endocytosis,,A vesicle-mediated transport process in which cells take up external materials or membrane constituents by the invagination of a small region of the plasma membrane to form a new membrane-bounded vesicle.,false,,,http://purl.obolibrary.org/obo/TXPO_0002587,,,,,,,,,,,,,,,,,,,,Wikipedia:Endocytosis,,A vesicle-mediated transport process in which cells take up external materials or membrane constituents by the invagination of a small region of the plasma membrane to form a new membrane-bounded vesicle.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0006897,,,,,,,,,,,,,,,,,,,,,,endocytosis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000143244,EIF5AL1,,Other designations: eukaryotic translation initiation factor 5A pseudogene 1|eukaryotic translation initiation factor 5A-1-like,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,EIF5AP1|bA342M3.3,,,,,,,,,,,,10,,,,,,Vega:OTTHUMG00000018563|HGNC:17419|Ensembl:ENSG00000253626,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,eukaryotic translation initiation factor 5A-like 1,,,10q22.3,,,,,,,,,,,,,,,,GO_0003746 (EC: IEA); GO_0005643 (EC: IEA); GO_0005789 (EC: IEA); GO_0006452 (EC: IEA); GO_0008612 (EC: IEA); GO_0015031 (EC: IEA); GO_0043022 (EC: IEA); GO_0045901 (EC: IEA); GO_0045905 (EC: IEA); GO_0051028 (EC: IEA),,,,,,,,,PMID:1286667; 2492279; 3095320; 7545941; 7622067; 7759117; 8253832; 10944119; 11742107; 12477932; 15489334; 16519677; 16916647; 20639865; 21139048; 21890473; 21906983; 21963094; 22053931; 22505724; 23000965,,,,,,,,,,,,,,,OGG:3000143244,,,,,,,eukaryotic translation initiation factor 5A-like 1,,,,,,,,,,,,,Other designations: eukaryotic translation initiation factor 5A pseudogene 1|eukaryotic translation initiation factor 5A-1-like,,EIF5AL1,,,,,,,,,,,,,,,,,,,,,,,143244,RP11-342M3.3,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF5AL1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000294,Rap,Ras proximal,,false,,,http://purl.obolibrary.org/obo/IMR_0000289,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ras proximal,,,,,IMR:0000294,,,,,,,,,,,,,,,,,,,,,,Rap,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000119,regulation of beta oxidation related gene expression,,"Regulation of beta oxidation related gene expression is a subtype of regulation of gene expression: A process that modulates the frequency, rate or extent of fatty acid beta oxidation related gene expression.",false,,,http://purl.obolibrary.org/obo/GO_0010468,,,,,,,,,,,,,,,,,,,,,,"Regulation of beta oxidation related gene expression is a subtype of regulation of gene expression: A process that modulates the frequency, rate or extent of fatty acid beta oxidation related gene expression.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000119,,,,,,,,,,,,,,,,,,,,,,regulation of beta oxidation related gene expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000117,drug metabolism phase I by Cytochrome P450 [Glutathione depletion],xenobiotic metabolism phase I by CyP [Glutathione depletion]|xenobiotic metabolism phase I by P450 [Glutathione depletion],"Drug metabolism phase I by Cytochrome P450 is a subtype of drug metabolism phase I: A process that is biotransformed by cytochrome P450 (CYP) superfamily .
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0001559|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Drug metabolism phase I by Cytochrome P450 is a subtype of drug metabolism phase I: A process that is biotransformed by cytochrome P450 (CYP) superfamily .
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001922,,,,http://purl.obolibrary.org/obo/TXPO_0000974,,,,,,,,,,,,,,xenobiotic metabolism phase I by CyP [Glutathione depletion]|xenobiotic metabolism phase I by P450 [Glutathione depletion],,,,,TXPO:0000117,,,,,,,,,,,,,,,,,,,,,,drug metabolism phase I by Cytochrome P450 [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005790,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000114,phosphoethanolamine catabolic process,,Phosphoethanolamine catabolic process is a subtype of catabolic process: A process of the chemical reactions resulting in the breakdown of  phosphoethanolamine.,false,,,http://purl.obolibrary.org/obo/GO_0009056,,,,,,,,,,,,,,,,,,,,,,Phosphoethanolamine catabolic process is a subtype of catabolic process: A process of the chemical reactions resulting in the breakdown of  phosphoethanolamine.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_36711,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000114,,,,,,,,,,,,,,,,,,,,,,phosphoethanolamine catabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000112,fatty acid alpha-oxidation,,"A metabolic process by which 3-methyl branched fatty acids are degraded. These compounds are not degraded by the normal peroxisomal beta-oxidation pathway, because the 3-methyl blocks the dehydrogenation of the hydroxyl group by hydroxyacyl-CoA dehydrogenase. The 3-methyl branched fatty acid is converted in several steps to pristenic acid, which can then feed into the beta-oxidative pathway.",false,,,http://purl.obolibrary.org/obo/GO_0019395,,,,,,,,,,,,,,,,,,,,GO:0001561,,"A metabolic process by which 3-methyl branched fatty acids are degraded. These compounds are not degraded by the normal peroxisomal beta-oxidation pathway, because the 3-methyl blocks the dehydrogenation of the hydroxyl group by hydroxyacyl-CoA dehydrogenase. The 3-methyl branched fatty acid is converted in several steps to pristenic acid, which can then feed into the beta-oxidative pathway.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000112,,,,,,,,,,,,,,,,,,,,,,fatty acid alpha-oxidation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000118,regulation of beta oxidation related gene expression [Eosinophilic granular degeneration],,"Regulation of beta oxidation related gene expression is a subtype of regulation of gene expression: A process that modulates the frequency, rate or extent of fatty acid beta oxidation related gene expression.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/TXPO_0001729|http://purl.obolibrary.org/obo/TXPO_0000119,,,,,,,,,,,,,,,,,,,,,,"Regulation of beta oxidation related gene expression is a subtype of regulation of gene expression: A process that modulates the frequency, rate or extent of fatty acid beta oxidation related gene expression.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000128,http://purl.obolibrary.org/obo/TXPO_0001046|http://purl.obolibrary.org/obo/TXPO_0001055|http://purl.obolibrary.org/obo/TXPO_0001053|http://purl.obolibrary.org/obo/TXPO_0001051|http://purl.obolibrary.org/obo/TXPO_0001057|http://purl.obolibrary.org/obo/TXPO_0001058|http://purl.obolibrary.org/obo/TXPO_0001069|http://purl.obolibrary.org/obo/TXPO_0001067|http://purl.obolibrary.org/obo/TXPO_0001068|http://purl.obolibrary.org/obo/TXPO_0002017,,,,,,http://purl.obolibrary.org/obo/TXPO_0000146|http://purl.obolibrary.org/obo/TXPO_0000174,,,,,,,,,,,TXPO:0000118,,,,,,,,,,,,,,,,,,,,,,regulation of beta oxidation related gene expression [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000110,peroxisomal Acox biosynthetic process [Eosinophilic granular degeneration],,"Peroxisomal Acox biosynthetic process is a subtype of protein production: A process that makes existent of a Peroxisomal acyl -coenzyme A oxidase (ACOX) due to biosynthesis or secretion resulting in an increase in its levels.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/TXPO_0001729|http://purl.obolibrary.org/obo/TXPO_0000107,,,,,,,,,,,,,,,,,,,,,,"Peroxisomal Acox biosynthetic process is a subtype of protein production: A process that makes existent of a Peroxisomal acyl -coenzyme A oxidase (ACOX) due to biosynthesis or secretion resulting in an increase in its levels.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001060|http://purl.obolibrary.org/obo/TXPO_0003248|http://purl.obolibrary.org/obo/TXPO_0003249,,,,,,http://purl.obolibrary.org/obo/TXPO_0000176,,,,,,,,,,,TXPO:0000110,,,,,,,,,,,,,,,,,,,,,,peroxisomal Acox biosynthetic process [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000111,molecule transport,,"Molecule transport is a subtype of transport: A process of the directed movement of molecules into, out of or within a cell, or between cells, or within a multicellular organism by means of some agent such as a transporter or pore..",false,,,http://purl.obolibrary.org/obo/GO_0006810,,,,,,,,,,,,,,,,,,,,,,"Molecule transport is a subtype of transport: A process of the directed movement of molecules into, out of or within a cell, or between cells, or within a multicellular organism by means of some agent such as a transporter or pore..",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000111,,,,,,,,,,,,,,,,,,,,,,molecule transport,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000113,controlling,,"Controlling is a subtype of meta-function of ""ToControl"".
When a function fa regularizes the behavior of ft, its meta-function is said to be 'to control ft'.",false,,,http://purl.obolibrary.org/obo/TXPO_0002541,,,,,,,,,,,,,,,,,,,,,,"Controlling is a subtype of meta-function of ""ToControl"".
When a function fa regularizes the behavior of ft, its meta-function is said to be 'to control ft'.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000113,,,,,,,,,,,,,,,,,,,,,,controlling,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/BFO_0000015,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000115,negative regulation of decomposing,,"Negative regulation of decomposing is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of decomposing.",false,,,http://purl.obolibrary.org/obo/TXPO_0000369,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of decomposing is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of decomposing.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000115,,,,,,,,,,,,,,,,,,,,,,negative regulation of decomposing,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000343,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000116,regulation of lipid metabolic process [Eosinophilic granular degeneration],,"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving lipids.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/GO_0019216|http://purl.obolibrary.org/obo/TXPO_0001729,,,,,,,,,,,,,,,,,,,,,,"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving lipids.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004006,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000118,,,,,,,,,,,,,,,,,,TXPO:0000116,,,,,,,,,,,,,,,,,,,,,,regulation of lipid metabolic process [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001506,Rap1B,,,false,,,http://purl.obolibrary.org/obo/IMR_0001504,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001506,,,,,,,,,,,,,,,,,,,,,,Rap1B,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0010498,proteasomal protein catabolic process,proteasome-mediated protein catabolism|proteasome-mediated protein catabolic process,The chemical reactions and pathways resulting in the breakdown of a protein or peptide by hydrolysis of its peptide bonds that is mediated by the proteasome.,false,,,http://purl.obolibrary.org/obo/GO_0030163,,,,,,,,,,,,,,,,,,,,,,The chemical reactions and pathways resulting in the breakdown of a protein or peptide by hydrolysis of its peptide bonds that is mediated by the proteasome.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,proteasome-mediated protein catabolism|proteasome-mediated protein catabolic process,,,,,GO:0010498,,,,,,,,,,,,,,,,,,,,,,proteasomal protein catabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000862,14-3-3 eta,,,false,,,http://purl.obolibrary.org/obo/IMR_0000456,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000862,,,,,,,,,,,,,,,,,,,,,,14-3-3 eta,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000202,keratin,cytokeratin,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003693,,,,,cytokeratin,,,,,IMR:0000202,,,,,,,,,,,,,,,,,,,,,,keratin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003230,process regulator role,,A role played by the entity which involves in regulating a process.,false,,,http://purl.obolibrary.org/obo/TXPO_0003710,,,,,,,,,,,,,,,,,,,,,,A role played by the entity which involves in regulating a process.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003230,,,,,,,,,,,,,,,,,,,,,,process regulator role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003239,Cdk1 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0003241,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:54237|NCBI-Mouse-GeneID:12534|NCBI-Human-GeneID:983|OMIM:116940,,,,,,,,,,,,,,,cyclin dependent kinase 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003239,,,,,,,,,,,,,,,,,,,,,,Cdk1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003231,regulation of cell cycle [Eosinophilic granular degeneration],,"Any process that modulates the rate or extent of progression through the cell cycle.
This entity is a specific course-dependent process. This process can constitute the course of eosinogranular dgeneration.",false,,,http://purl.obolibrary.org/obo/TXPO_0001729|http://purl.obolibrary.org/obo/GO_0051726,,,,,,,,,,,,,,,,,,,,PMID:9855014,,"Any process that modulates the rate or extent of progression through the cell cycle.
This entity is a specific course-dependent process. This process can constitute the course of eosinogranular dgeneration.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003232|http://purl.obolibrary.org/obo/TXPO_0002173,,,,,,,,,,,TXPO:0003231,,,,,,,,,,,,,,,,,,,,,,regulation of cell cycle [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003238,Cdk1 (mouse)[Eosinophilic granular degeneration],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000648|http://purl.obolibrary.org/obo/TXPO_0003239,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:12534|OMIM:116940,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003238,,,,,,,,,,,,,,,,,,,,,,Cdk1 (mouse)[Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003233,increasing liver weight [toxic course],,The totality of all processes through which increasing liver weight is realized.,false,,,http://purl.obolibrary.org/obo/TXPO_0000009,,,,,,,,,,,,,,,,,,,,PMID:22723046,,The totality of all processes through which increasing liver weight is realized.,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003271,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003309|http://purl.obolibrary.org/obo/TXPO_0003304|http://purl.obolibrary.org/obo/TXPO_0003286|http://purl.obolibrary.org/obo/TXPO_0000217|http://purl.obolibrary.org/obo/TXPO_0003271|http://purl.obolibrary.org/obo/TXPO_0003297|http://purl.obolibrary.org/obo/TXPO_0003299|http://purl.obolibrary.org/obo/TXPO_0003316,,,,,,,,,,,,,,,,,,TXPO:0003233,,,,,,,,,,,,,,,,,,,,,,increasing liver weight [toxic course],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003237,intrinsic apoptosis signaling (primitive),,"Intrinsic apoptosis signaling (primitive) is a subtype of signaling [biological]: A processin which an intracellular signal is conveyed to trigger the apoptotic death of a cell. The process starts with reception of an intracellular signal (e.g. DNA damage, endoplasmic reticulum stress, oxidative stress etc.).
This process is crucially regulated by permeabilization of the mitochondrial outer membrane (MOMP).",false,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,,,"Intrinsic apoptosis signaling (primitive) is a subtype of signaling [biological]: A processin which an intracellular signal is conveyed to trigger the apoptotic death of a cell. The process starts with reception of an intracellular signal (e.g. DNA damage, endoplasmic reticulum stress, oxidative stress etc.).
This process is crucially regulated by permeabilization of the mitochondrial outer membrane (MOMP).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000653,http://purl.obolibrary.org/obo/GO_0097193,,,,,http://purl.obolibrary.org/obo/TXPO_0000514,,,,,,,,,,,TXPO:0003237,,,,,,,,,,,,,,,,,,,,,,intrinsic apoptosis signaling (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003232,tumor cell proliferation [Eosinophilic granular degeneration],,"Tumor cell proliferation is a subtype of cell proliferation: A process of the multiplication or reproduction of tumor cells, resulting in the rapid expansion of a tumor cell population.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/TXPO_0001729|http://purl.obolibrary.org/obo/TXPO_0000339,,,,,,,,,,,,,,,,,,,,PMID:9855014|PMID:15172993,,"Tumor cell proliferation is a subtype of cell proliferation: A process of the multiplication or reproduction of tumor cells, resulting in the rapid expansion of a tumor cell population.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003245,,,,,,,,,,,,,,,,,TXPO:0003232,,,,,,,,,,,,,,,,,,,,,,tumor cell proliferation [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCBITaxon_9989,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003234,tumorigenesis via eosinophilic granular degeneration [toxic course],,"The totality of all processes through which eosinogranular degeneration and is realized and finally, tumorigenesis can be occured.",false,,,http://purl.obolibrary.org/obo/TXPO_0000028,,,,,,,,,,,,,,,,,,,,PMID:22318237|PMID:1637780,,"The totality of all processes through which eosinogranular degeneration and is realized and finally, tumorigenesis can be occured.",,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000136,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000187|http://purl.obolibrary.org/obo/TXPO_0000182|http://purl.obolibrary.org/obo/TXPO_0000184|http://purl.obolibrary.org/obo/TXPO_0000190|http://purl.obolibrary.org/obo/TXPO_0000198|http://purl.obolibrary.org/obo/TXPO_0000196|http://purl.obolibrary.org/obo/TXPO_0000479|http://purl.obolibrary.org/obo/TXPO_0002029|http://purl.obolibrary.org/obo/TXPO_0000146|http://purl.obolibrary.org/obo/TXPO_0000149|http://purl.obolibrary.org/obo/TXPO_0001025|http://purl.obolibrary.org/obo/TXPO_0000151|http://purl.obolibrary.org/obo/TXPO_0000153|http://purl.obolibrary.org/obo/TXPO_0002391|http://purl.obolibrary.org/obo/TXPO_0003219|http://purl.obolibrary.org/obo/TXPO_0002448|http://purl.obolibrary.org/obo/TXPO_0003060|http://purl.obolibrary.org/obo/TXPO_0000109|http://purl.obolibrary.org/obo/TXPO_0000103|http://purl.obolibrary.org/obo/TXPO_0000110|http://purl.obolibrary.org/obo/TXPO_0000116|http://purl.obolibrary.org/obo/TXPO_0003231|http://purl.obolibrary.org/obo/TXPO_0003232|http://purl.obolibrary.org/obo/TXPO_0002451|http://purl.obolibrary.org/obo/TXPO_0000127|http://purl.obolibrary.org/obo/TXPO_0000128|http://purl.obolibrary.org/obo/TXPO_0000125|http://purl.obolibrary.org/obo/TXPO_0000136|http://purl.obolibrary.org/obo/TXPO_0002100|http://purl.obolibrary.org/obo/TXPO_0000179|http://purl.obolibrary.org/obo/TXPO_0003207|http://purl.obolibrary.org/obo/TXPO_0002173|http://purl.obolibrary.org/obo/TXPO_0000746,,,,,,,,,,,,,,,,,,TXPO:0003234,,,,,,,,,,,,,,,,,,,,,,tumorigenesis via eosinophilic granular degeneration [toxic course],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003236,BAX (canonical)[cell death],,,false,,,http://purl.obolibrary.org/obo/IMR_0000453|http://purl.obolibrary.org/obo/TXPO_0003195,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24887|NCBI-Human-GeneID:581|NCBI-Mouse-GeneID:12028,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000327,,,,,,,,,,TXPO:0003236,,,,,,,,,,,,,,,,,,,,,,BAX (canonical)[cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003235,"Activation, translocation and oligomerization of BAX [cell death]",,"The activation, translocation and oligomerization of BAX involved in the apoptosis.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0001727|http://purl.obolibrary.org/obo/HINO_0016226,,,,,,,,,,,,,,,,,,,,Reactome:R-HSA-114294.2,,"The activation, translocation and oligomerization of BAX involved in the apoptosis.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003236,,,,,,,,,,,,,,,,,TXPO:0003235,,,,,,,"As a result of binding to Bid, Bax oligomerizes and   integrates in the outer mitochondrial membrane that triggers cytochrome c release. Bax mitochondrial membrane insertion triggered by Bid may represent a key step in pathways leading to apoptosis (Eskes et al., 2000)",,,,,,,,,,,,,,,"Activation, translocation and oligomerization of BAX [cell death]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001461,TLR8,Toll-like receptor 8,,false,,,http://purl.obolibrary.org/obo/IMR_0000124,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Toll-like receptor 8,,,,,IMR:0001461,,,,,,,,,,,,,,,,,,,,,,TLR8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000366,cytokeratin 15,,,false,,,http://purl.obolibrary.org/obo/IMR_0000035,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000366,,,,,,,,,,,,,,,,,,,,,,cytokeratin 15,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_33231,antitubercular agent,antitubercular drug|antitubercular agents|tuberculostatic agent|antitubercular drugs|antitubercular,A substance that kills or slows the growth of Mycobacterium tuberculosis and is used in the treatment of tuberculosis.,false,,,http://purl.obolibrary.org/obo/CHEBI_64912,,,,,,,,,,,,,,,,,,,,,,A substance that kills or slows the growth of Mycobacterium tuberculosis and is used in the treatment of tuberculosis.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,antitubercular drug|antitubercular agents|tuberculostatic agent|antitubercular drugs|antitubercular,,,,,,,,,,,,,,,,,,,,,CHEBI:33231,,,,antitubercular agent,,CHEBI:33231,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100192,kinesin superfamily,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000186|http://purl.obolibrary.org/obo/TXPO_0003690,,,,,,,,,,IMR:0100192,,,,,,,,,,,,,,,,,,,,,,kinesin superfamily,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000079962,DNAJC22,,Other designations: dnaJ homolog subfamily C member 22|wurst homolog,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,wus,,,,,,,,,,,,12,,,,,,Vega:OTTHUMG00000169487|HGNC:25802|HPRD:08580|Ensembl:ENSG00000178401,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"DnaJ (Hsp40) homolog, subfamily C, member 22",,,12q13.12,,,,,,,,,,,,,,,,GO_0016021 (EC: IEA),,,,,,,,,PMID:12477932; 14702039; 17558392; 19460752; 21906983,,,,,,,,,,,,,,,OGG:3000079962,,,,,,,"DnaJ (Hsp40) homolog, subfamily C, member 22",,,,,,,,,,,,,Other designations: dnaJ homolog subfamily C member 22|wurst homolog,,DNAJC22,,,,,,,,,,,,,,,,,,,,,,,79962,,,,,,,,9606,,,,,,,,,,,,,,,,,,,DNAJC22,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0000350,cholestasis process [Cholestasis],,"Cholestasis (primitive process) is a subtype of stagnating: A process that changes the bile flow to be slower due to obstruction.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001345|http://purl.obolibrary.org/obo/TXPO_0000034,,,,,,,,,,,,,,,,,,,,,,"Cholestasis (primitive process) is a subtype of stagnating: A process that changes the bile flow to be slower due to obstruction.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000264,,,,,,,,,,,TXPO:0000350,,,,,,,,,,,,,,,,,,,,,,cholestasis process [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000355,increase in intracellular calcium level [Cell death],,"Increase in intracellular calcium level is a subtype of increase in calcium level: A process that changes the calcium ion concentration within a cell to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0001727|http://purl.obolibrary.org/obo/TXPO_0000354,,,,,,,,,,,,,,,,,,,,,,"Increase in intracellular calcium level is a subtype of increase in calcium level: A process that changes the calcium ion concentration within a cell to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002381,,,,,,,,,,,TXPO:0000355,,,,,,,,,,,,,,,,,,,,,,increase in intracellular calcium level [Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000356,amino acid conjugatied bile acid transport into bile canaliculus [Cholestasis],,"Amino acid conjugatied bile acid transport into bile canaliculus is a subtype of canalicular bile acid transport: A process that enables the transfer of amino acid conjugated bile acid from one side of a hepatocyte plasma membrane into a bile canaliculus.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000336,,,,,,,,,,,,,,,,,,,,,,"Amino acid conjugatied bile acid transport into bile canaliculus is a subtype of canalicular bile acid transport: A process that enables the transfer of amino acid conjugated bile acid from one side of a hepatocyte plasma membrane into a bile canaliculus.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000356,,,,,,,,,,,,,,,,,,,,,,amino acid conjugatied bile acid transport into bile canaliculus [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000354,increase in intracellular calcium level,,Increase in intracellular calcium level is a subtype of increase in calcium level: A process that changes the calcium ion concentration within a cell to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000353,,,,,,,,,,,,,,,,,,,,,,Increase in intracellular calcium level is a subtype of increase in calcium level: A process that changes the calcium ion concentration within a cell to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000354,,,,,,,,,,,,,,,,,,,,,,increase in intracellular calcium level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000358,AMPK activation [ER stress],,"AMPK activation is a subtype of molecular activation: A process that changes the activity of the AMPK (AMP-activated protein kinase) to be higher.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000405|http://purl.obolibrary.org/obo/TXPO_0003736,,,,,,,,,,,,,,,,,,,,PMID:26481188,,"AMPK activation is a subtype of molecular activation: A process that changes the activity of the AMPK (AMP-activated protein kinase) to be higher.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000451,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000873,,,,,,http://purl.obolibrary.org/obo/TXPO_0001455,,,,,,,,,,,TXPO:0000358,,,,,,,,,,,,,,,,,,,,,,AMPK activation [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000351,decreasing number of cells,,Decreasing number of cells is a subtype of decreasing number of objects: A process that becomes smaller in number of cells.,false,,,http://purl.obolibrary.org/obo/TXPO_0000348,,,,,,,,,,,,,,,,,,,,,,Decreasing number of cells is a subtype of decreasing number of objects: A process that becomes smaller in number of cells.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000351,,,,,,,,,,,,,,,,,,,,,,decreasing number of cells,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000359,decreasing blood flow,,Decreasing blood flow is a subtype of decreasing flow: A process that changes the  blood flow to be smaller.,false,,,http://purl.obolibrary.org/obo/TXPO_0002672,,,,,,,,,,,,,,,,,,,,,,Decreasing blood flow is a subtype of decreasing flow: A process that changes the  blood flow to be smaller.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000359,,,,,,,,,,,,,,,,,,,,,,decreasing blood flow,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000352,increasing concentration,,Increasing concentration is a subtype of changing concentration: A process that changes the concentration of the object to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0002438,,,,,,,,,,,,,,,,,,,,,,Increasing concentration is a subtype of changing concentration: A process that changes the concentration of the object to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000352,,,,,,,,,,,,,,,,,,,,,,increasing concentration,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0001162,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000357,PERK activation,,PERK activation is a subtype of Molecular activation: A process that changes the activity of PERK to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000023,,,,,,,,,,,,,,,,,,,,,,PERK activation is a subtype of Molecular activation: A process that changes the activity of PERK to be higher.,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001852,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000712|http://purl.obolibrary.org/obo/TXPO_0000742,,,,,,,,,,,,,,,,,,,,,TXPO:0000357,,,,,,,,,,,,,,,,,,,,,,PERK activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000353,increasing calcium ion concentration in blood,,Increasing calcium ion concentration in blood is a subtype of increasing concentration: A process that changes the calcium ion concentration in the blood to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000352,,,,,,,,,,,,,,,,,,,,,,Increasing calcium ion concentration in blood is a subtype of increasing concentration: A process that changes the calcium ion concentration in the blood to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000353,,,,,,,,,,,,,,,,,,,,,,increasing calcium ion concentration in blood,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004041,SRSF1 [Hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000837|http://purl.obolibrary.org/obo/TXPO_1000352,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:689890|NCBI-Mouse-GeneID:110809|NCBI-Human-GeneID:6426|PMID:24468535|PMID:26018840,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004041,,,,,,,,,,,,,,,,,,,,,,SRSF1 [Hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004040,release of tumor inhibitor from lysosome [Phospholipidosis],,"The directed movement of tumor inhibitor from the lysosome.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0004035|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"The directed movement of tumor inhibitor from the lysosome.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004019,http://purl.obolibrary.org/obo/TXPO_0004034|http://purl.obolibrary.org/obo/TXPO_0004015,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001491,,,,,,,,,,,TXPO:0004040,,,,,,,,,,,,,,,,,,,,,,release of tumor inhibitor from lysosome [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004048,proteasome-mediated ubiquitin-dependent FNIP2 catabolic process,,"The chemical reaction resulting in the breakdown of FNIP2, which is mediated by the proteasome.",false,,,http://purl.obolibrary.org/obo/GO_0043161,,,,,,,,,,,,,,,,,,,,,,"The chemical reaction resulting in the breakdown of FNIP2, which is mediated by the proteasome.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004048,,,,,,,,,,,,,,,,,,,,,,proteasome-mediated ubiquitin-dependent FNIP2 catabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004043,negative regulator of tumor cell proliferation,,A role played by the entity which negatively regulates the process of tumor cell proliferation.,false,,,http://purl.obolibrary.org/obo/TXPO_0004045|http://purl.obolibrary.org/obo/TXPO_0003534,,,,,,,,http://purl.obolibrary.org/obo/GO_0008283,,,,,,,,,,,,,,A role played by the entity which negatively regulates the process of tumor cell proliferation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004043,,,,,,,,,,,,,,,,,,,,,,negative regulator of tumor cell proliferation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004047,abnormal cell tissue,,Abnormal cell tissue is a subtype of cellular tissue that consists of abnormal cells and tissues.,false,,,http://purl.obolibrary.org/obo/TXPO_0000065,,,,,,,,,,,,,,,,,,,,,,Abnormal cell tissue is a subtype of cellular tissue that consists of abnormal cells and tissues.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004047,,,,,,,,,,,,,,,,,,,,,,abnormal cell tissue,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004046,forming adduct,,Forming adduct is a subtype of having extra parts: A process that changes to have connection or association with another entity.,false,,,http://purl.obolibrary.org/obo/TXPO_0000168,,,,,,,,,,,,,,,,,,,,,,Forming adduct is a subtype of having extra parts: A process that changes to have connection or association with another entity.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004046,,,,,,,,,,,,,,,,,,,,,,forming adduct,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004045,negative regulator of cell proliferation,,A role played by the entity which negatively regulates the process of cell proliferation.,false,,,http://purl.obolibrary.org/obo/TXPO_0003159,,,,,,,,http://purl.obolibrary.org/obo/GO_0008283,,,,,,,,,,,,,,A role played by the entity which negatively regulates the process of cell proliferation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004045,,,,,,,,,,,,,,,,,,,,,,negative regulator of cell proliferation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004042,COL4A2 [Hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000837|http://purl.obolibrary.org/obo/TXPO_1000072,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1284|NCBI-Mouse-GeneID:12827|NCBI-Rat-GeneID:306628|http://omim.org/entry/120090|PMID:25169943,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004042,,,,,,,,,,,,,,,,,,,,,,COL4A2 [Hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004044,Aen (rat)[Cell death],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000029|http://purl.obolibrary.org/obo/TXPO_0000839,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:361594|PMID:20429933|PMID:16171785,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004044,,,,,,,,,,,,,,,,,,,,,,Aen (rat)[Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004049,proteasome-mediated FNIP2 degradation [Phospholipidosis],,"The chemical reaction resulting in the breakdown of FNIP2, which is mediated by the proteasome.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis",false,,,http://purl.obolibrary.org/obo/TXPO_0004048|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"The chemical reaction resulting in the breakdown of FNIP2, which is mediated by the proteasome.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003894|http://purl.obolibrary.org/obo/TXPO_0004018,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004049,,,,,,,,,,,,,,,,,,,,,,proteasome-mediated FNIP2 degradation [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000023210,JMJD6,,Other designations: bifunctional arginine demethylase and lysyl-hydroxylase JMJD6|histone arginine demethylase JMJD6|jmjC domain-containing protein 6|jumonji domain-containing protein 6|lysyl-hydroxylase JMJD6|peptide-lysine 5-dioxygenase JMJD6|phosphatidylserine receptor,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,PTDSR|PTDSR1|PSR,,,,,,,,,,,,17,,,,,,MIM:604914|Vega:OTTHUMG00000169267|HGNC:19355|HPRD:05371|Ensembl:ENSG00000070495,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,jumonji domain containing 6,,,17q25,,,,,,,,,,,,,,,,"GO_0001822 (EC: IEA); GO_0002040 (EC: ISS); GO_0003723 (EC: TAS); GO_0003727 (EC: IDA); GO_0004872 (EC: IEA); GO_0005506 (EC: IDA); GO_0005515 (EC: IPI, PMID: 19574390); GO_0005634 (EC: IDA, PMID: 14729065); GO_0005654 (EC: IDA); GO_0005730 (EC: IDA); GO_0005886 (EC: IEA); GO_0006351 (EC: IEA); GO_0006355 (EC: IEA); GO_0006397 (EC: IEA); GO_0007166 (EC: IEA); GO_0007507 (EC: IEA); GO_0008380 (EC: IEA); GO_0018395 (EC: IDA, PMID: 19574390); GO_0030324 (EC: IEA); GO_0033077 (EC: IEA); GO_0033746 (EC: IDA, PMID: 17947579); GO_0033749 (EC: IDA, PMID: 17947579); GO_0042116 (EC: IEA); GO_0042802 (EC: IDA, PMID: 17534701); GO_0042802 (EC: IPI); GO_0043654 (EC: IEA); GO_0048024 (EC: IMP, PMID: 19574390); GO_0048821 (EC: IEA); GO_0060041 (EC: IEA); GO_0070078 (EC: IDA, PMID: 17947579); GO_0070079 (EC: IDA, PMID: 17947579); GO_0070782 (EC: IEA); GO_0070815 (EC: IDA, PMID: 19574390)",,,,,,,,,PMID: 9628581; 10811223; 11877474; 12477932; 12559004; 12898702; 14645848; 14702039; 14729065; 15072554; 15193161; 15345036; 15453906; 15469976; 15489334; 15622002; 16983801; 17534701; 17947579; 18564434; 19492415; 19574390; 20574068; 20679243; 20684070; 21139048; 21300889; 21890473; 21906983; 21963094; 22189873; 22505724; 22621393; 22701020; 22863883; 23303181; 23455924; 23595221; 23688307; 23776548; 24360279,,,,,,,,,,,,,,,OGG:3000023210,,,,,,,jumonji domain containing 6,,,,,,,,,,,,,Other designations: bifunctional arginine demethylase and lysyl-hydroxylase JMJD6|histone arginine demethylase JMJD6|jmjC domain-containing protein 6|jumonji domain-containing protein 6|lysyl-hydroxylase JMJD6|peptide-lysine 5-dioxygenase JMJD6|phosphatidylserine receptor,,JMJD6,,,,,,,,,,,,,,,,,,,,,,,23210,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,JMJD6,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000003659,IRF1,,Other designations: interferon regulatory factor 1 isoform d78,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,MAR|IRF-1,,,,,,,,,,,,5,,,,,,MIM:147575|Vega:OTTHUMG00000059497|HGNC:6116|HPRD:00961|Ensembl:ENSG00000125347,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,interferon regulatory factor 1,,,5q31.1,,,,,,,,,,,,,,,,"GO_0000790 (EC: IDA, PMID: 18035482); GO_0000978 (EC: IDA, PMID: 18035482); GO_0002819 (EC: TAS, PMID: 11846971); GO_0003677 (EC: TAS, PMID: 11846971); GO_0003700 (EC: IEA); GO_0005515 (EC: IPI, PMID: 10702232); GO_0005634 (EC: TAS, PMID: 11846971); GO_0005654 (EC: TAS); GO_0005737 (EC: ISS); GO_0005829 (EC: TAS); GO_0006366 (EC: TAS, PMID: 2475256); GO_0006915 (EC: IDA, PMID: 19851330); GO_0007050 (EC: IDA); GO_0007596 (EC: TAS); GO_0008285 (EC: TAS, PMID: 11846974); GO_0019221 (EC: TAS); GO_0032481 (EC: ISS); GO_0032728 (EC: IMP); GO_0034124 (EC: ISS); GO_0035458 (EC: IDA, PMID: 18035482); GO_0043374 (EC: IEA); GO_0045084 (EC: IEA); GO_0045088 (EC: TAS, PMID: 11846971); GO_0045590 (EC: ISS); GO_0045892 (EC: IMP, PMID: 18084608); GO_0045893 (EC: IDA); GO_0045893 (EC: IMP, PMID: 15509808); GO_0045944 (EC: IEA); GO_0051607 (EC: IDA); GO_0051726 (EC: TAS, PMID: 11846974); GO_0060333 (EC: ISS); GO_0060333 (EC: TAS); GO_0060337 (EC: TAS); GO_0071260 (EC: IEP, PMID: 19593445); GO_2000564 (EC: ISS)",,,,,,,,,PMID: 1382447; 1680796; 2475256; 2726461; 3409321; 7507207; 7768900; 8438156; 8746784; 9593745; 9649509; 9659924; 9679752; 9742224; 9865486; 9865487; 10022868; 10094406; 10357819; 10438822; 10702232; 10764778; 11069564; 11240951; 11304541; 11315919; 11483597; 11559933; 11675348; 11716756; 11721695; 11804954; 11846971; 11846972; 11846974; 11909852; 11948194; 11970993; 12021315; 12067985; 12105194; 12115600; 12162881; 12191570; 12420205; 12420214; 12433281; 12477932; 12479817; 12482935; 12545159; 12677441; 12711307; 12732645; 12759449; 12788988; 12799427; 14599866; 14662860; 14675396; 14764039; 14993214; 15078941; 15173018; 15226432; 15241475; 15265939; 15331704; 15489234; 15489334; 15509808; 15511228; 15548708; 15560761; 15576464; 15710386; 15778351; 15863386; 15878912; 15893730; 15907481; 16085646; 16195385; 16195814; 16223733; 16483648; 16512786; 16636311; 16679314; 16703666; 16857162; 16894313; 16914093; 16944293; 16961714; 17016442; 17121613; 17177148; 17213842; 17255955; 17328074; 17498560; 17516545; 17617740; 17703412; 17852336; 17869652; 17918184; 17924060; 17942705; 17947510; 17970693; 17985330; 18035482; 18079498; 18084608; 18200030; 18216101; 18316378; 18338947; 18381204; 18401423; 18454680; 18641303; 18655181; 18676680; 18678606; 18688264; 18694960; 18986693; 19012493; 19028144; 19056926; 19129219; 19131452; 19145247; 19170196; 19247692; 19258923; 19295429; 19345417; 19404407; 19426920; 19428110; 19433065; 19450680; 19463200; 19482358; 19502235; 19536153; 19548631; 19574175; 19593445; 19625176; 19642896; 19692168; 19697121; 19805480; 19845895; 19851330; 19858727; 19880820; 20031576; 20031577; 20177805; 20177960; 20211142; 20435892; 20457620; 20459687; 20485362; 20503287; 20525893; 20533260; 20588308; 20817723; 20846942; 20861350; 20947504; 20980339; 21102463; 21200019; 21245151; 21257209; 21288140; 21300955; 21389130; 21411754; 21586271; 21683060; 21725055; 21740303; 21790247; 21803131; 21834067; 21903422; 21988832; 22096509; 22139419; 22213332; 22345458; 22367195; 22401175; 22874466; 22879909; 23040881; 23046934; 23071666; 23128233; 23134341; 23226549; 23255602; 23378427; 23487038; 23554911; 23729439; 23746807; 23799084; 23807161; 23811275; 23934855; 23969696,,,,,,,,,,,,,,,OGG:3000003659,,,,,,,interferon regulatory factor 1,,,,,,,,,,,,,Other designations: interferon regulatory factor 1 isoform d78,,IRF1,,,,,,,,,,,,,,,,,,,,,,,3659,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,IRF1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/PATO_0002057,increased area,,An area which is relatively high.,false,,,http://purl.obolibrary.org/obo/PATO_0001323|http://purl.obolibrary.org/obo/TXPO_0000310,,,,,,,,,,,,,,,,,,,,,,An area which is relatively high.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0002057,,,,,,,,,,,,,,,,,,,,,,increased area,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0002058,decreased area,,An area which is relatively low.,false,,,http://purl.obolibrary.org/obo/PATO_0001323|http://purl.obolibrary.org/obo/TXPO_0000310,,,,,,,,,,,,,,,,,,,,,,An area which is relatively low.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0002058,,,,,,,,,,,,,,,,,,,,,,decreased area,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000560,presenilin,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000304,,,,,,,,,,IMR:0000560,,,,,,,,,,,,,,,,,,,,,,presenilin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_35620,vasodilator agent,vasodilator|vasodilator agents,A drug used to cause dilation of the blood vessels.,false,,,http://purl.obolibrary.org/obo/CHEBI_35554,,,,,,,,,,,,,,,,,,,,,,A drug used to cause dilation of the blood vessels.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,vasodilator|vasodilator agents,,,,,,,,,,,,,,,,,,,,,CHEBI:35620,,,,vasodilator agent,,CHEBI:35620,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_7820,oxandrolone,oxandrolona|oxandrolone|oxandrolonum|Oxandrolone|17beta-hydroxy-17alpha-methyl-2-oxa-5alpha-androstan-3-one,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Beilstein:5480667|Drug_Central:2011|DrugBank:DB00621,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_36413|http://purl.obolibrary.org/obo/CHEBI_50113,,,,,Oxandrolone|17beta-hydroxy-17alpha-methyl-2-oxa-5alpha-androstan-3-one,,oxandrolona|oxandrolone|oxandrolonum,,,,,,,,,,,,,,,,,,,,,CHEBI:7820,,,,oxandrolone,,CHEBI:7820,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_33281,antimicrobial agent,microbicide|antimicrobial agents|antibiotic|antibiotique|antimicrobials|antibiotics|antimicrobial|Antibiotika|Antibiotikum|microbicides,"A substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.",false,,,http://purl.obolibrary.org/obo/CHEBI_24432|http://purl.obolibrary.org/obo/CHEBI_52210,,,,,,,,,,,,,,,,,,,,PMID:22849276|PMID:22439833|PMID:12964249|PMID:22117953|PMID:22849268|PMID:22958833,,"A substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,microbicide|antimicrobial agents|antibiotic|antibiotique|antimicrobials|antibiotics|antimicrobial|Antibiotika|Antibiotikum|microbicides,,,,,,,,,,,,,,,,,,,,,CHEBI:33281,,,,antimicrobial agent,,CHEBI:33281,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010484,60S ribosomal protein L34,P49207,,false,,,http://purl.obolibrary.org/obo/IMR_0000897,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,P49207,,,,,IMR:0010484,,,,,,,,,,,,,,,,,,,,,,60S ribosomal protein L34,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000362,Smn1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:6606|NCBI-Rat-GeneID:64301|NCBI-Mouse-GeneID:20595,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000006606,,,,,,,,,,,,,TXPO:1000362,,,,,,,,,,,,,,,,,,,,,,Smn1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000368,Sub1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:20024|NCBI-Human-GeneID:10923|NCBI-Rat-GeneID:192269,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000010923,,,,,,,,,,,,,TXPO:1000368,,,,,,,,,,,,,,,,,,,,,,Sub1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000360,Slc25a20 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:117035|NCBI-Mouse-GeneID:57279|NCBI-Human-GeneID:788,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000788,,,,,,,,,,,,,TXPO:1000360,,,,,,,,,,,,,,,,,,,,,,Slc25a20 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000361,Slc5a6 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:330064|NCBI-Human-GeneID:8884|NCBI-Rat-GeneID:170551,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000008884,,,,,,,,,,,,,TXPO:1000361,,,,,,,,,,,,,,,,,,,,,,Slc5a6 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000365,Srxn1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:76650|NCBI-Human-GeneID:140809|NCBI-Rat-GeneID:296271,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000140809,,,,,,,,,,,,,TXPO:1000365,,,,,,,,,,,,,,,,,,,,,,Srxn1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000369,TAGLN (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:21345|NCBI-Rat-GeneID:25123|NCBI-Human-GeneID:6876,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000006876,,,,,,,,,,,,,TXPO:1000369,,,,,,,,,,,,,,,,,,,,,,TAGLN (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000367,Ssr3 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:67437|NCBI-Human-GeneID:6747|NCBI-Rat-GeneID:81784,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000006747,,,,,,,,,,,,,TXPO:1000367,,,,,,,,,,,,,,,,,,,,,,Ssr3 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000366,Ssbp1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:381760|NCBI-Rat-GeneID:54304|NCBI-Human-GeneID:6742,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000006742,,,,,,,,,,,,,TXPO:1000366,,,,,,,,,,,,,,,,,,,,,,Ssbp1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000364,Srnx1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:1000364,,,,,,,,,,,,,,,,,,,,,,Srnx1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000883,TFIIA,,,false,,,http://purl.obolibrary.org/obo/IMR_0000888,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003645,,,,,,,,,,IMR:0000883,,,,,,,,,,,,,,,,,,,,,,TFIIA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0008429,phosphatidylethanolamine binding,,"Interacting selectively and non-covalently with phosphatidylethanolamine, any of a class of glycerophospholipids in which a phosphatidyl group is esterified to the hydroxyl group of ethanolamine.",false,,,http://purl.obolibrary.org/obo/GO_0005543,,,,,,,,,,,,,,,,,,,,"GO:0008429|Interacting selectively and non-covalently with phosphatidylethanolamine, any of a class of glycerophospholipids in which a phosphatidyl group is esterified to the hydroxyl group of ethanolamine.",,"Interacting selectively and non-covalently with phosphatidylethanolamine, any of a class of glycerophospholipids in which a phosphatidyl group is esterified to the hydroxyl group of ethanolamine.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0008429,,,,,,,,,,,,,,,,,,,,,,phosphatidylethanolamine binding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0001159,concentrated,,A concentration quality inhering in a bearer by virtue of the bearer's exhibiting concentration.,false,,,http://purl.obolibrary.org/obo/TXPO_0000865|http://purl.obolibrary.org/obo/BFO_0000019,,,,,,,,,,,,,,,,,,,,,,A concentration quality inhering in a bearer by virtue of the bearer's exhibiting concentration.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0001159,,,,,,,,,,,,,,,,,,,,,,concentrated,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001865,ADAM family,a disintegrin and metalloproteinase,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000304,,,,,a disintegrin and metalloproteinase,,,,,IMR:0001865,,,,,,,,,,,,,,,,,,,,,,ADAM family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_38808,calcium channel modulator,calcium channel modulators,A membrane transport modulator that is able to regulate intracellular calcium levels.,false,,,http://purl.obolibrary.org/obo/CHEBI_38632,,,,,,,,,,,,,,,,,,,,,,A membrane transport modulator that is able to regulate intracellular calcium levels.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,calcium channel modulators,,,,,,,,,,,,,,,,,,,,,CHEBI:38808,,,,calcium channel modulator,,CHEBI:38808,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001117,RASA4,,,false,,,http://purl.obolibrary.org/obo/IMR_0000443,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001117,,,,,,,,,,,,,,,,,,,,,,RASA4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0002057,FGFR3,fibroblast growth factor receptor 3,,false,,,http://purl.obolibrary.org/obo/IMR_0000080,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,fibroblast growth factor receptor 3,,,,,IMR:0002057,,,,,,,,,,,,,,,,,,,,,,FGFR3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000324,G-alpha-12/13 class,,,false,,,http://purl.obolibrary.org/obo/IMR_0000316,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000324,,,,,,,,,,,,,,,,,,,,,,G-alpha-12/13 class,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100781,Wnt-10b,Wnt-12,,false,,,http://purl.obolibrary.org/obo/IMR_0000003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Wnt-12,,,,,IMR:0100781,,,,,,,,,,,,,,,,,,,,,,Wnt-10b,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000023234,DNAJC9,,Other designations: DnaJ protein SB73|dnaJ homolog subfamily C member 9,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,HDJC9|SB73|JDD1,,,,,,,,,,,,10,,,,,,HGNC:19123|MIM:611206|HPRD:13237,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"DnaJ (Hsp40) homolog, subfamily C, member 9",,,10q22.2,,,,,,,,,,,,,,,,GO_0035176 (EC: IEP),,,,,,,,,PMID:10231032; 11444854; 12477932; 14702039; 17182002; 19410544; 19710015; 19862764; 20099975; 20379614; 21139048; 21145461; 21531385; 21906983; 21963094; 22939629; 23000965; 24457600,,,,,,,,,,,,,,,OGG:3000023234,,,,,,,"DnaJ (Hsp40) homolog, subfamily C, member 9",,,,,,,,,,,,,Other designations: DnaJ protein SB73|dnaJ homolog subfamily C member 9,,DNAJC9,,,,,,,,,,,,,,,,,,,,,,,23234,,,,,,,,9606,,,,,,,,,,,,,,,,,,,DNAJC9,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0001427,cell proliferation [Phospholipidosis],,"The multiplication or reproduction of cells, resulting in the rapid expansion of a cell population.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/GO_0008283,,,,,,,,,,,,,,,,,,,,,,"The multiplication or reproduction of cells, resulting in the rapid expansion of a cell population.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001427,,,,,,,,,,,,,,,,,,,,,,cell proliferation [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001421,increaseing production quantity of catecholamine,,Increaseing production quantity of catecholamine is a subtype of increasing quantity: A process that changes the production amount of catecholamine to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increaseing production quantity of catecholamine is a subtype of increasing quantity: A process that changes the production amount of catecholamine to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001421,,,,,,,,,,,,,,,,,,,,,,increaseing production quantity of catecholamine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001420,hypofunction of phosphatidylcholine degradation,,Hypofunction of phosphatidylcholine degradation is a subtype of hypofunction of glycerophospholipid degradation: A process that performs a decreased or insufficient phosphatidylserine  degradation.,false,,,http://purl.obolibrary.org/obo/TXPO_0001418,,,,,,,,,,,,,,,,,,,,,,Hypofunction of phosphatidylcholine degradation is a subtype of hypofunction of glycerophospholipid degradation: A process that performs a decreased or insufficient phosphatidylserine  degradation.,,,http://purl.obolibrary.org/obo/GO_0034638,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_64482,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001420,,,,,,,,,,,,,,,,,,,,,,hypofunction of phosphatidylcholine degradation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001426,Cationic Amphiphilic Drug role,CAD role,Arole played by the entity that has both hydrophobic and hydrophilic properties with a charged cationic amine group.,false,,,http://purl.obolibrary.org/obo/CHEBI_52210,,,,,,,,,,,,,,,,,,,,PMID:9061852,,Arole played by the entity that has both hydrophobic and hydrophilic properties with a charged cationic amine group.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CAD role,,,,,TXPO:0001426,,,,,,,"CADs exhibit the property of lysosomotropism, the property of a molecule to specifically associate with lysosomes.

In theory, CADs could enter the lysosome through endocytosis, autophagy, or a drug-specific transporter. However, passive diffusion has been invoked as the major mechanism whereby CADs accumulate within the lysosome .
CADs bind directly to phospholipids to result in indigestible drug–lipid complexes, which accumulate and are stored in the form of lysosomal lamellar bodies.
Production of lamellar bodies was associated with inhibition of phospholipase activity; either due to direct inhibition or interaction of CAD at the phospholipid bilayer of the lysosome.",,,,,,,,,,,,,,,Cationic Amphiphilic Drug role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001424,FASN,Fatty Acid Synthase,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Fatty Acid Synthase,,,,,TXPO:0001424,,,,,,,,,,,,,,,,,,,,,,FASN,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001429,CHOP gene expression regulation system,,"CHOP gene expression regulation system is a subtype of pathway system.
This entity has sub-parts and has a goal of regulating gene expressions by CHOP as a systemic context.",false,,,http://purl.obolibrary.org/obo/TXPO_0000887,,,,,,,,,,,,,,,,,,,,,,"CHOP gene expression regulation system is a subtype of pathway system.
This entity has sub-parts and has a goal of regulating gene expressions by CHOP as a systemic context.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001429,,,,,,,,,,,,,,,,,,,,,,CHOP gene expression regulation system,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001423,DGAT1 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0001417,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:13350|NCBI-Human-GeneID:8694|NCBI-Rat-GeneID:84497,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000084649,,,,,,,,,,,,,TXPO:0001423,,,,,,,,,,,,,,,,,,,,,,DGAT1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001422,heoatocyte growth [Hypertrophy],,"Heoatocyte growth is a subtype of cell growth: A process that The process in which a hepatocyte, the main structural component of the liver, increases in size.
This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy.",false,,,http://purl.obolibrary.org/obo/TXPO_0003279|http://purl.obolibrary.org/obo/TXPO_0001578,,,,,,,,,,,,,,,,,,,,,,"Heoatocyte growth is a subtype of cell growth: A process that The process in which a hepatocyte, the main structural component of the liver, increases in size.
This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000217,,,,,,,,,,,TXPO:0001422,,,,,,,,,,,,,,,,,,,,,,heoatocyte growth [Hypertrophy],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001425,gentamicin_phospholipase inhibitor [Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/CHEBI_17833|http://purl.obolibrary.org/obo/TXPO_0001849,,,,,,,,,,,,,,,,,,,,PMID:16979167|PMID:7159463|PMID:3342096,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000562,,,,,,,,,,TXPO:0001425,,,,,,,,,,,,,,,,,,,,,,gentamicin_phospholipase inhibitor [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001428,ABCA1 (canonical)[lipidosis],ATP Binding Cassette Subfamily A Member 1 [lipidosis],,false,,,http://purl.obolibrary.org/obo/TXPO_0001443|http://purl.obolibrary.org/obo/TXPO_0003516,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:107476|NCBI-Human-GeneID:19|NCBI-Rat-GeneID:60581|PMID:28290443,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001451,,,,,ATP Binding Cassette Subfamily A Member 1 [lipidosis],,,,,TXPO:0001428,,,,,,,,,,,,,,,,,,,,,,ABCA1 (canonical)[lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000009775,EIF4A3,,Other designations: ATP-dependent RNA helicase DDX48|ATP-dependent RNA helicase eIF4A-3|DEAD (Asp-Glu-Ala-Asp) box polypeptide 48|DEAD box protein 48|NMP 265|eIF-4A-III|eIF4A-III|eukaryotic initiation factor 4A-III|eukaryotic initiation factor 4A-like NUK-34|eukaryotic translation initiation factor 4A|hNMP 265|nuclear matrix protein 265,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,NMP265|DDX48|NUK34|RCPS|eIF4AIII|MUK34,,,,,,,,,,,,17,,,,,,Vega:OTTHUMG00000177538|HPRD:06482|HGNC:18683|Ensembl:ENSG00000141543|MIM:608546,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,eukaryotic translation initiation factor 4A3,,,17q25.3,,,,,,,,,,,,,,,,"GO_0000184 (EC: IMP, PMID:16209946); GO_0000184 (EC: TAS); GO_0000288 (EC: TAS); GO_0000289 (EC: TAS); GO_0000398 (EC: IC, PMID:11991638); GO_0003729 (EC: IDA); GO_0004004 (EC: IDA, PMID:10523622); GO_0005515 (EC: IPI, PMID:10523622); GO_0005524 (EC: IDA, PMID:10523622); GO_0005634 (EC: IDA); GO_0005730 (EC: IDA, Qualifier: NOT); GO_0005737 (EC: IDA, PMID:10523622); GO_0005829 (EC: TAS); GO_0006200 (EC: IDA, PMID:10523622); GO_0006364 (EC: IEA); GO_0008143 (EC: IDA, PMID:10523622); GO_0010467 (EC: TAS); GO_0016070 (EC: TAS); GO_0016071 (EC: TAS); GO_0016607 (EC: IEA); GO_0017148 (EC: IDA, PMID:10523622); GO_0019221 (EC: TAS); GO_0035145 (EC: IDA, PMID:16601204); GO_0044822 (EC: IDA); GO_0045727 (EC: IMP, PMID:18423201); GO_0051028 (EC: IEA); GO_0071013 (EC: IDA, PMID:11991638)",,,,,,,,,PMID:7788527; 10523622; 10623621; 11991638; 12127692; 12477932; 14730019; 14973490; 15024115; 15034551; 15324660; 15489334; 15635413; 15796914; 16159877; 16170325; 16189514; 16196087; 16209946; 16344560; 16452507; 16601204; 16923391; 16931718; 17190602; 17361185; 17456004; 17606899; 17632064; 17643375; 18337751; 18423201; 18427545; 18781797; 18954305; 18974867; 19417104; 19435936; 19471022; 19738201; 19884259; 20360068; 20371770; 20639865; 20972266; 21081666; 21110914; 21139048; 21145460; 21145461; 21319273; 21576267; 21853274; 21890473; 21906983; 21963094; 21987572; 22053931; 22178446; 22268729; 22365833; 22505724; 22623428; 22863883; 22939629; 22952844; 22961380; 23000965; 23084401; 23602568; 24218557; 24360810; 24457600,,,,,,,,,,,,,,,OGG:3000009775,,,,,,,eukaryotic translation initiation factor 4A3,,,,,,,,,,,,,Other designations: ATP-dependent RNA helicase DDX48|ATP-dependent RNA helicase eIF4A-3|DEAD (Asp-Glu-Ala-Asp) box polypeptide 48|DEAD box protein 48|NMP 265|eIF-4A-III|eIF4A-III|eukaryotic initiation factor 4A-III|eukaryotic initiation factor 4A-like NUK-34|eukaryotic translation initiation factor 4A|hNMP 265|nuclear matrix protein 265,,EIF4A3,,,,,,,,,,,,,,,,,,,,,,,9775,,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF4A3,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000006093,ROCK1,,"Other designations: Rho kinase|p160 ROCK-1|p160-ROCK|renal carcinoma antigen NY-REN-35|rho-associated protein kinase 1|rho-associated, coiled-coil-containing protein kinase 1|rho-associated, coiled-coil-containing protein kinase I",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,ROCK-I|P160ROCK,,,,,,,,,,,,18,,,,,,HPRD:03414|HGNC:10251|MIM:601702,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"Rho-associated, coiled-coil containing protein kinase 1",,,18q11.1,,,,,,,,,,,,,,,,"GO_0000139 (EC: IEA); GO_0001726 (EC: ISS); GO_0003383 (EC: IEA); GO_0004672 (EC: TAS, PMID: 10436159); GO_0004674 (EC: IDA, PMID: 10652353); GO_0005515 (EC: IPI, PMID: 10652353); GO_0005524 (EC: IEA); GO_0005814 (EC: IEA); GO_0005829 (EC: TAS); GO_0005856 (EC: ISS); GO_0005886 (EC: ISS); GO_0006468 (EC: TAS, PMID: 10436159); GO_0006915 (EC: TAS); GO_0006921 (EC: TAS); GO_0006939 (EC: TAS, PMID: 12778124); GO_0007159 (EC: IDA, PMID: 12082081); GO_0007165 (EC: TAS, PMID: 10436159); GO_0007266 (EC: TAS, PMID: 8798490); GO_0007411 (EC: TAS); GO_0016525 (EC: IMP, PMID: 19181962); GO_0017048 (EC: IEA); GO_0022614 (EC: IDA, PMID: 12082081); GO_0030027 (EC: ISS); GO_0030036 (EC: IEA); GO_0030155 (EC: TAS, PMID: 12778124); GO_0032059 (EC: IEA); GO_0032060 (EC: IEA); GO_0032956 (EC: TAS, PMID: 12778124); GO_0043524 (EC: IEA); GO_0045616 (EC: IMP, PMID: 19997641); GO_0046872 (EC: IEA); GO_0050900 (EC: IDA, PMID: 12082081); GO_0050901 (EC: IDA, PMID: 12082081); GO_0051451 (EC: ISS); GO_0051492 (EC: TAS, PMID: 12778124); GO_0051893 (EC: TAS, PMID: 12778124); GO_0051894 (EC: ISS); GO_2000114 (EC: TAS); GO_2000145 (EC: TAS, PMID: 12778124)",,,,,,,,,PMID: 2114109; 2155236; 7822264; 8617235; 8798490; 8816443; 9099667; 9354661; 9456324; 9516463; 9565595; 9722579; 9856983; 10209029; 10436159; 10508479; 10559936; 10574968; 10579722; 10601309; 10652353; 10818093; 10970850; 11018042; 11283607; 11340065; 11387207; 11739394; 11751986; 11818523; 11893932; 11931630; 11992112; 12034773; 12082081; 12177195; 12193698; 12220642; 12477932; 12482610; 12563012; 12600888; 12729902; 12748184; 12749591; 12773565; 12778124; 12850840; 14517206; 14610060; 14657354; 14660612; 14702039; 14716844; 14718574; 14962675; 15044207; 15096506; 15208091; 15231748; 15247219; 15252450; 15494373; 15611088; 15647781; 15665056; 15713824; 15723050; 15793569; 15797222; 15843433; 15855233; 15910744; 15956119; 16123592; 16141422; 16249185; 16344560; 16371346; 16407310; 16413470; 16543245; 16687572; 16712513; 16760434; 16772336; 16784244; 16825579; 16862148; 16891369; 16978606; 16983089; 17012370; 17028776; 17044646; 17138966; 17167780; 17172270; 17174923; 17244674; 17344417; 17346310; 17572668; 17620599; 17643375; 17651694; 17673200; 17728102; 17853893; 17855350; 18079197; 18187541; 18204440; 18239683; 18331468; 18353901; 18396681; 18477564; 18495812; 18499753; 18615591; 18648664; 18668558; 18684864; 18694941; 18695890; 18713748; 18723680; 18780293; 18852895; 18922892; 18941185; 18946488; 18948190; 18952846; 19001122; 19036714; 19131646; 19160018; 19167712; 19181962; 19403695; 19404162; 19406912; 19420982; 19549780; 19573309; 19590140; 19667069; 19913121; 19997641; 20039424; 20053635; 20056178; 20056645; 20064505; 20068229; 20070312; 20126978; 20130732; 20140017; 20223287; 20364104; 20379197; 20558775; 20682776; 20734064; 20801872; 20801873; 21035804; 21048031; 21051874; 21085597; 21119662; 21139048; 21206971; 21265091; 21305317; 21387396; 21417762; 21423810; 21445309; 21575520; 21739156; 21747168; 21840487; 21847509; 21906983; 21907926; 21908715; 21986457; 21994419; 22010828; 22031287; 22041269; 22085929; 22155728; 22197032; 22206673; 22232555; 22262769; 22328514; 22348083; 22363817; 22462535; 22493320; 22558309; 22563075; 22584506; 22798677; 22813839; 22846914; 22863883; 22913419; 22942252; 22975682; 22986902; 23022380; 23066013; 23094262; 23097497; 23168335; 23184937; 23188716; 23233531; 23328676; 23350987; 23355470; 23479079; 23602568; 23615712; 23665024; 23670799; 23720748; 23726972; 23775364; 23782575; 23789633; 23828571; 23872151; 23877263; 23936026; 24019071; 24149105; 24240172; 24250222; 24297045; 24324133,,,,,,,,,,,,,,,OGG:3000006093,,,,,,,"Rho-associated, coiled-coil containing protein kinase 1",,,,,,,,,,,,,"Other designations: Rho kinase|p160 ROCK-1|p160-ROCK|renal carcinoma antigen NY-REN-35|rho-associated protein kinase 1|rho-associated, coiled-coil-containing protein kinase 1|rho-associated, coiled-coil-containing protein kinase I",,ROCK1,,,,,,,,,,,,,,,,,,,,,,,6093,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,ROCK1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/GO_0042100,B cell proliferation,B-lymphocyte proliferation|B-cell proliferation|B lymphocyte proliferation,The expansion of a B cell population by cell division. Follows B cell activation.,false,,,http://purl.obolibrary.org/obo/GO_0046651,,,,,,,,,,,,,,,,,,,,,,The expansion of a B cell population by cell division. Follows B cell activation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,B-lymphocyte proliferation|B-cell proliferation|B lymphocyte proliferation,,,,,GO:0042100,,,,,,,,,,,,,,,,,,,,,,B cell proliferation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76946,fungal metabolite,fungal metabolites,"Any eukaryotic metabolite produced during a metabolic reaction in fungi, the kingdom that includes microorganisms such as the yeasts and moulds.",false,,,http://purl.obolibrary.org/obo/CHEBI_75763,,,,,,,,,,,,,,,,,,,,,,"Any eukaryotic metabolite produced during a metabolic reaction in fungi, the kingdom that includes microorganisms such as the yeasts and moulds.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,fungal metabolites,,,,,,,,,,,,,,,,,,,,,CHEBI:76946,,,,fungal metabolite,,CHEBI:76946,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_31941,oxaliplatin,"oxaliplatin|oxaliplatine|oxaliplatinum|oxaliplatino|oxalato(1,2-diaminocyclohexane)platinum(II)|(SP-4-2-(1R-trans))-(1,2-cyclohexanediamine-N,N')(ethanedioato(2-)-O,O')platinum|Eloxatin|(SP-4-2)[(1R,2R)-cyclohexane-1,2-diamine-kappa(2)N,N'][ethanedioato(2-)-kappa(2)O(1),O(2)]platinum|Oxaliplatin",A platinum coordination entity that is a commonly used chemothrepeutic drug for treatment of colorectal cancer.,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:28811232|PMID:28642473|Gmelin:1046012|PMID:28695397|PMID:28876454|PMID:19138416|PMID:28800641|PMID:28654098|PMID:28881481|CAS:61825-94-3|PMID:17347561|PMID:28762171|PMID:11300320|PMID:15477639|PMID:28881354|PMID:28894576|Gmelin:28892|PMID:28837658|PMID:28777427|PMID:28884286|Reaxys:15700099|PMID:28924870|PMID:28415810|PMID:28398406|PMID:18440088|PMID:28499428|PMID:27756654|PMID:28938919|PMID:28186109|CAS:63121-00-6|PMID:28505615|PMID:28812173|PMID:14755010|LINCS:LSM-6352|PMID:19735649|PMID:28624791|DrugBank:DB00526,,A platinum coordination entity that is a commonly used chemothrepeutic drug for treatment of colorectal cancer.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35610|http://purl.obolibrary.org/obo/CHEBI_25435,,,,,"(SP-4-2)[(1R,2R)-cyclohexane-1,2-diamine-kappa(2)N,N'][ethanedioato(2-)-kappa(2)O(1),O(2)]platinum|Oxaliplatin",,"oxaliplatin|oxaliplatine|oxaliplatinum|oxaliplatino|oxalato(1,2-diaminocyclohexane)platinum(II)|(SP-4-2-(1R-trans))-(1,2-cyclohexanediamine-N,N')(ethanedioato(2-)-O,O')platinum|Eloxatin",,,,,,,,,,,,,,,,,,,,,CHEBI:31941,,,,oxaliplatin,,CHEBI:31941,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100161,rimorphin,,,false,,,http://purl.obolibrary.org/obo/IMR_0100157,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100161,,,,,,,,,,,,,,,,,,,,,,rimorphin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100194,prolactin,PRL,"A lactogenic hormone secreted by the adenohypophysis ( PITUITARY GLAND, ANTERIOR). It is a polypeptide of approximately 23 kD. Besides its major action on lactation, in some species prolactin exerts effects on reproduction, maternal behavior, fat metabolism, immunomodulation and osmoregulation. Prolactin receptors are present in the mammary gland, hypothalamus, liver, ovary, testis, and prostate.",false,,,http://purl.obolibrary.org/obo/IMR_0100098,,,,,,,,,,,,,,,,,,,,MeSH:D011388,,"A lactogenic hormone secreted by the adenohypophysis ( PITUITARY GLAND, ANTERIOR). It is a polypeptide of approximately 23 kD. Besides its major action on lactation, in some species prolactin exerts effects on reproduction, maternal behavior, fat metabolism, immunomodulation and osmoregulation. Prolactin receptors are present in the mammary gland, hypothalamus, liver, ovary, testis, and prostate.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PRL,,,,,IMR:0100194,,,,,,,,,,,,,,,,,,,,,,prolactin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100447,p50,NF-kappaB1|p105|NFKB1,,false,,,http://purl.obolibrary.org/obo/IMR_0000382,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,NF-kappaB1|p105|NFKB1,,,,,IMR:0100447,,,,,,,,,,,,,,,,,,,,,,p50,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0048012,HGFR signal transduction pathway,hepatocyte growth factor receptor signaling pathway,The series of molecular signals generated as a consequence of the hepatocyte growth factor receptor binding to one of its physiological ligands.,false,,,http://purl.obolibrary.org/obo/TXPO_0000609,,,,,,,,,,,,,,,,,,,,,,The series of molecular signals generated as a consequence of the hepatocyte growth factor receptor binding to one of its physiological ligands.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,hepatocyte growth factor receptor signaling pathway,,,,,GO:0048012,,,,,,,,,,,,,,,,,,,,,,HGFR signal transduction pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0002957,beta-arrestin 2,,,false,,,http://purl.obolibrary.org/obo/IMR_0000520,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0002957,,,,,,,,,,,,,,,,,,,,,,beta-arrestin 2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_63581,stavudine,"2',3'-Didehydro-3'-deoxythimidine|estavudina|STV|1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine|Sanilvudine|3'-Deoxy-2'-thymidinene|d4T|stavudinum|stavudine|d4T|1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4(1H,3H)-dione|Stavudine",A nucleoside analogue obtained by formal dehydration across positions 2 and 3 of thymidine. An inhibitor of HIV-1 reverse transcriptase,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Drug_Central:2478|CAS:3056-17-5|DrugBank:DB00649|LINCS:LSM-5983|Wikipedia:Stavudine|Reaxys:618327,,A nucleoside analogue obtained by formal dehydration across positions 2 and 3 of thymidine. An inhibitor of HIV-1 reverse transcriptase,,,,,,,,,,,,C10H12N2O4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35221|http://purl.obolibrary.org/obo/CHEBI_59897|http://purl.obolibrary.org/obo/CHEBI_36044|http://purl.obolibrary.org/obo/CHEBI_22587,,,,,"d4T|1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4(1H,3H)-dione|Stavudine",,"2',3'-Didehydro-3'-deoxythimidine|estavudina|STV|1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine|Sanilvudine|3'-Deoxy-2'-thymidinene|d4T|stavudinum|stavudine",,,,,,,,,,,,,,,,,,,,,CHEBI:63581,,,,stavudine,,CHEBI:63581,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Cc1cn([C@@H]2O[C@H](CO)C=C2)c(=O)[nH]c1=O,,,,,
http://purl.obolibrary.org/obo/OBI_0000070,assay,scientific observation,"A planned process with the objective to produce information about the material entity that is the evaluant, by physically examining it or its proxies.",false,,,http://purl.obolibrary.org/obo/BFO_0000015,,,,,,,,,,,,,,,,,,,,,,"A planned process with the objective to produce information about the material entity that is the evaluant, by physically examining it or its proxies.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,scientific observation,,,,,OBI:0000070,,,,,,,,,,,,,,,,,,,,,,assay,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000004780,NFE2L2,,,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,NRF2,,,,,,,,,,,,2,,,,,,HPRD:02732|MIM:600492|Ensembl:ENSG00000116044|HGNC:7782|Vega:OTTHUMG00000133620,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"nuclear factor, erythroid 2-like 2",,,2q31,,,,,,,,,,,,,,,,"GO_0000785 (EC: IEA); GO_0001102 (EC: IPI); GO_0003677 (EC: IDA, PMID: 18554677); GO_0003700 (EC: IEA); GO_0005515 (EC: IPI, PMID: 16888629); GO_0005634 (EC: IDA); GO_0005737 (EC: IDA); GO_0005813 (EC: IDA); GO_0005829 (EC: IDA); GO_0005886 (EC: IDA); GO_0006366 (EC: TAS, PMID: 7937919); GO_0010499 (EC: IDA, PMID: 19424503); GO_0016567 (EC: IDA, PMID: 15983046); GO_0019904 (EC: IPI, PMID: 11256947); GO_0030194 (EC: IEA); GO_0030968 (EC: IEA); GO_0036003 (EC: IMP); GO_0043161 (EC: IDA, PMID: 15983046); GO_0043565 (EC: IEA); GO_0045944 (EC: IMP, PMID: 18202225)",,,,,,,,,PMID: 7868116; 7937919; 9150357; 9872330; 9887101; 10419538; 10510468; 10747902; 10930400; 11013233; 11035812; 11256947; 11274184; 11439354; 11683914; 11909699; 12020345; 12084617; 12084707; 12145307; 12198130; 12360409; 12370194; 12435735; 12441344; 12446695; 12477932; 12490281; 12506115; 12556532; 12805554; 12947090; 14517290; 14517554; 14529549; 14565864; 14585973; 14612418; 14985350; 15020583; 15282312; 15358217; 15367669; 15379550; 15475350; 15489334; 15525690; 15572695; 15601839; 15734732,,,,,,,,,,,,,,,OGG:3000004780,,,,,,,abhydrolase domain containing 1,,,,,,,,,,,,,,,NFE2L2,,,,,,,,,,,,,,,,,,,,,,,4780,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/BFO_0000018,zero-dimensional spatial region,,,false,,,http://purl.obolibrary.org/obo/BFO_0000006,,,,,,,,,,,,,,,,,,,,,,,,,,,,A zero-dimensional spatial region is a point in space. (axiom label in BFO2 Reference: [037-001]),,,,,,,,,,,,(forall (x) (if (ZeroDimensionalSpatialRegion x) (SpatialRegion x))) // axiom label in BFO2 CLIF: [037-001],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BFO:0000018,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/bfo.owl,zero-dimensional spatial region,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0035601,protein deacylation,,"The removal of an acyl group, any group or radical of the form RCO- where R is an organic group, from a protein amino acid.",false,,,http://purl.obolibrary.org/obo/GO_0036211,,,,,,,,,,,,,,,,,,,,,,"The removal of an acyl group, any group or radical of the form RCO- where R is an organic group, from a protein amino acid.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0035601,,,,,,,,,,,,,,,,,,,,,,protein deacylation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001552,Rab2A,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001552,,,,,,,,,,,,,,,,,,,,,,Rab2A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000745,Crk family,,"Alternative splicing of the mammal crk gene yields two translation products designated the 28-kDa Crk-I and the 42-kDa Crk-II protein. The Crk-II protein contains an amino-terminal SH2 domain followed by two SH3 domains. The Crk-I protein does not contain the second SH3 domain. The 36-kDa Crk-L protein is similar to CrkII, but is encoded by a separate gene.",false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,"Alternative splicing of the mammal crk gene yields two translation products designated the 28-kDa Crk-I and the 42-kDa Crk-II protein. The Crk-II protein contains an amino-terminal SH2 domain followed by two SH3 domains. The Crk-I protein does not contain the second SH3 domain. The 36-kDa Crk-L protein is similar to CrkII, but is encoded by a separate gene.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003681,,,,,,,,,,IMR:0000745,,,,,,,,,,,,,,,,,,,,,,Crk family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0002345,beta lipotropin,beta-LPH,,false,,,http://purl.obolibrary.org/obo/IMR_0100197,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,beta-LPH,,,,,IMR:0002345,,,,,,,,,,,,,,,,,,,,,,beta lipotropin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_63598,levofloxacin,"Ofloxacin S-(-)-form|(S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylic acid|(S)-Ofloxacin|(3S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid|(-)-Ofloxacin|L-Ofloxacin|levofloxacinum|levofloxacin|(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid|levofloxacino|levofloxacine|(3S)-9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid",An optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:21965436|PMID:22221614|Reaxys:5385660|PMID:22088660|PMID:21075586|CAS:100986-85-4|PMID:21974858|LINCS:LSM-5270|DrugBank:DB01137|Drug_Central:1569,,An optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_59517|http://purl.obolibrary.org/obo/CHEBI_36047|http://purl.obolibrary.org/obo/CHEBI_53559,,,,,"(3S)-9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid",,"Ofloxacin S-(-)-form|(S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylic acid|(S)-Ofloxacin|(3S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid|(-)-Ofloxacin|L-Ofloxacin|levofloxacinum|levofloxacin|(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid|levofloxacino|levofloxacine",,,,,,,,,,,,,,,,,,,,,CHEBI:63598,,,,levofloxacin,,CHEBI:63598,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000729230,CCR2,,Other designations: C-C chemokine receptor type 2|MCP-1 receptor|monocyte chemoattractant protein 1 receptor|monocyte chemotactic protein 1 receptor,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,MCP-1-R|CD192|CKR2B|CKR2A|CC-CKR-2|CKR2|CCR-2|CCR2B|CMKBR2|CCR2A,,,,,,,,,,,,3,,,,,,Vega:OTTHUMG00000156466|HGNC:1603|MIM:601267|Ensembl:ENSG00000121807,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,chemokine (C-C motif) receptor 2,,,3p21.31,,,,,,,,,,,,,,,,"GO_0001974 (EC: ISS); GO_0002407 (EC: TAS, PMID:16621978); GO_0002827 (EC: ISS); GO_0002829 (EC: ISS); GO_0004950 (EC: TAS, PMID:10623817); GO_0005737 (EC: IDA, PMID:15995708); GO_0005829 (EC: ISS); GO_0005886 (EC: IDA, PMID:15995708); GO_0005886 (EC: TAS); GO_0005887 (EC: TAS, PMID:8146186); GO_0006874 (EC: ISS); GO_0006935 (EC: TAS, PMID:10623817); GO_0006954 (EC: IEA); GO_0006955 (EC: TAS, PMID:10751368); GO_0006968 (EC: TAS, PMID:10201901); GO_0007194 (EC: TAS, PMID:8995400); GO_0007204 (EC: TAS, PMID:9548499); GO_0007259 (EC: TAS, PMID:9670957); GO_0009611 (EC: TAS, PMID:8146186); GO_0010574 (EC: ISS); GO_0010820 (EC: ISS); GO_0016021 (EC: TAS, PMID:8530354); GO_0016032 (EC: IEA); GO_0016493 (EC: IEA); GO_0016525 (EC: ISS); GO_0019221 (EC: IDA, PMID:15995708); GO_0019725 (EC: ISS); GO_0030425 (EC: ISS); GO_0031727 (EC: IDA, PMID:15995708); GO_0032729 (EC: ISS); GO_0032743 (EC: ISS); GO_0035705 (EC: ISS); GO_0042535 (EC: ISS); GO_0042803 (EC: ISS); GO_0043025 (EC: ISS); GO_0043204 (EC: ISS); GO_0043310 (EC: ISS); GO_0045087 (EC: TAS); GO_0046641 (EC: ISS); GO_0048471 (EC: ISS); GO_0050729 (EC: ISS); GO_0050870 (EC: ISS); GO_0070098 (EC: ISS); GO_0090026 (EC: IDA, PMID:18587271); GO_0090026 (EC: ISS); GO_0090265 (EC: ISS); GO_2000439 (EC: ISS); GO_2000451 (EC: ISS); GO_2000464 (EC: IDA, PMID:12271471); GO_2000473 (EC: ISS)",,,,,,,,,PMID:2834384; 8048929; 8146186; 8530354; 8884276; 8995400; 9058802; 9115216; 9143512; 9195948; 9225989; 9252328; 9287323; 9501202; 9548499; 9653051; 9662369; 9670957; 9710230; 9736741; 9789057; 9886417; 10201901; 10479649; 10486323; 10529171; 10623817; 10741397; 10751368; 10877489; 10888629; 10985245; 11023492; 11046064; 11115360; 11120855; 11175286; 11181995; 11264152; 11350939; 11377705; 11385319; 11468722; 11470772; 11477473; 11485615; 11500196; 11590385; 11596075; 11694103; 11696224; 11709782; 11729511; 11752157; 11756347; 11779135; 11782014; 11804551; 11856781; 11860793; 11860823; 11873083; 11898620; 11958683; 11964548; 11988632; 12001056; 12010355; 12032878; 12070001; 12078856; 12079277; 12082592; 12149192; 12192431; 12201365; 12215924; 12239249; 12271471; 12374865; 12399623; 12403355; 12426226; 12436194; 12445801; 12447757; 12469616; 12477932; 12556692; 12557141; 12571520; 12584049; 12651900; 12654703; 12680626; 12719858; 12837756; 12853162; 12853745; 12882757; 12884524; 12889997; 12913933; 13678532; 14533004; 14533983; 14624371; 14644039; 14647058; 14742283; 14981141; 15053339; 15076247; 15086346; 15086398; 15135805; 15140377; 15192276; 15230854; 15236615; 15257681; 15319853; 15362666; 15458467; 15465089; 15466648; 15472820; 15488313; 15489334; 15575507; 15579296; 15585333; 15602133; 15611878; 15639953; 15721423; 15750046; 15754978; 15769362; 15793370; 15863470; 15929697; 15976001; 15980693; 15992849; 15995708; 16033640; 16055130; 16095529; 16123688; 16140745; 16196460; 16206074; 16207551; 16261210; 16286054; 16286055; 16305685; 16314800; 16320328; 16323127; 16344560; 16356504; 16415174; 16426243; 16461193; 16478397; 16480760; 16485782; 16524739; 16529059; 16598837; 16621978; 16631114; 16641997; 16733654; 16781696; 16831471; 16858645; 16865553; 16903979; 16908772; 16950632; 17060059; 17091019; 17094383; 17135764; 17216598; 17240189; 17295203; 17298432; 17355643; 17361671; 17364026; 17395051; 17413295; 17417600; 17426779; 17428349; 17464174; 17465499; 17482150; 17499741; 17504503; 17558413; 17560067; 17596666; 17604544; 17615573; 17653321; 17664883; 17672867; 17688234; 17703277; 17703412; 17704101; 17715128; 17786209; 17845302; 17917677; 17934338; 17989610; 18055544; 18060801; 18093816; 18096169; 18164016; 18172114; 18186797; 18197127; 18240029; 18306985; 18332000; 18391751; 18513341; 18577758; 18587271; 18615095; 18633131; 18676680; 18763111; 18829011; 18845960; 18846510; 18855658; 18928397; 18936436; 18974840; 18977759; 18996288; 19002595; 19017998; 19028820; 19032065; 19037908; 19055601; 19064579; 19082218; 19098363; 19124913; 19131662; 19170196; 19196047; 19225544; 19258923; 19263529; 19411748; 19420105; 19433914; 19465829; 19479237; 19506371; 19520154; 19526283; 19527467; 19535619; 19559392; 19578796; 19625176; 19643177; 19669591; 19692168; 19693089; 19720836; 19841162; 19904283; 19917610; 19942750; 19950235; 19958843; 19965779; 20017911; 20038229; 20066125; 20153665; 20181074; 20182805; 20190752; 20220260; 20231199; 20339010; 20364004; 20380698; 20411675; 20442634; 20449800; 20452482; 20483750; 20485444; 20503287; 20531015; 20536507; 20537184; 20603037; 20605053; 20628649; 20637631; 20673868; 20681057; 20726788; 20740585; 20808917; 20842059; 20947712; 21054877; 21091093; 21097527; 21097672; 21146687; 21148810; 21220372; 21264360; 21322034; 21348591; 21396623; 21429204; 21440726; 21450101; 21461583; 21527853; 21570337; 21602126; 21667221; 21682549; 21868018; 21883707; 21890375; 22026334; 22041342; 22081934; 22086059; 22159219; 22183310; 22197827; 22218121; 22226505; 22276574; 22285384; 22479344; 22554651; 22607625; 22612293; 22615942; 22685564; 22752804; 22815949; 22842622; 22909007; 22927430; 23007133; 23041556; 23057571; 23090289; 23185481; 23185512; 23251661; 23298254; 23325742; 23374597; 23376609; 23408426; 23454776; 23612252; 23632061; 23657965; 23686489; 23880174; 24078580; 24128342,,,,,,,,,,,,,,,OGG:3000729230,,,,,,,chemokine (C-C motif) receptor 2,,,,,,,,,,,,,Other designations: C-C chemokine receptor type 2|MCP-1 receptor|monocyte chemoattractant protein 1 receptor|monocyte chemotactic protein 1 receptor,,CCR2,,,,,,,,,,,,,,,,,,,,,,,729230,hCG_14621,,,,,,,9606,,,,,,,,,,,,,,,,,,,CCR2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000541,collagen,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,GO:0005581,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003695,,,,,,,,,,IMR:0000541,,,,,,,,,,,,,,,,,,,,,,collagen,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_61115,EC 3.5.1.98 (histone deacetylase) inhibitor,HDACi|histone deacetylase (EC 3.5.1.98) inhibitor|HDAC inhibitor|HDACis|HDIs|HDI|EC 3.5.1.98 inhibitors|HDAC inhibitors|histone deacetylase inhibitor|histone deacetylase (EC 3.5.1.98) inhibitors|histone amidohydrolase inhibitor|histone amidohydrolase inhibitors|EC 3.5.1.98 (histone deacetylase) inhibitors|EC 3.5.1.98 inhibitor|histone deacetylase inhibitors,An EC 3.5.1.* (non-peptide linear amide C-N hydrolase) inhibitor that interferes with the function of histone deacetylase (EC 3.5.1.98).,false,,,http://purl.obolibrary.org/obo/CHEBI_76807,,,,,,,,,,,,,,,,,,,,,,An EC 3.5.1.* (non-peptide linear amide C-N hydrolase) inhibitor that interferes with the function of histone deacetylase (EC 3.5.1.98).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,HDACi|histone deacetylase (EC 3.5.1.98) inhibitor|HDAC inhibitor|HDACis|HDIs|HDI|EC 3.5.1.98 inhibitors|HDAC inhibitors|histone deacetylase inhibitor|histone deacetylase (EC 3.5.1.98) inhibitors|histone amidohydrolase inhibitor|histone amidohydrolase inhibitors|EC 3.5.1.98 (histone deacetylase) inhibitors|EC 3.5.1.98 inhibitor|histone deacetylase inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:61115,,,,EC 3.5.1.98 (histone deacetylase) inhibitor,,CHEBI:61115,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001179,compound accumulation in liver [Glutathione depletion],,"Compound accumulation in liver is a subtype of accumulation of xenobiotics: A process that keeps compound in the liver.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0001694|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Compound accumulation in liver is a subtype of accumulation of xenobiotics: A process that keeps compound in the liver.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001180,,,,,,,,,,,TXPO:0001179,,,,,,,,,,,,,,,,,,,,,,compound accumulation in liver [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001171,Etnk2 (rat)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001134|http://purl.obolibrary.org/obo/TXPO_1000136,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:360843|http://omim.org/entry/609859|PMID:11044454,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002362,,,,,,,,,,TXPO:0001171,,,,,,,,,,,,,,,,,,,,,,Etnk2 (rat)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000915,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001178,increasing drug metabolite [Glutathione depletion],,"Increasing drug metabolite is a subtype of increasing quantity: A process that changes the amount of drug metabolites to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0002364|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Increasing drug metabolite is a subtype of increasing quantity: A process that changes the amount of drug metabolites to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001184,,,,,,,,,,,,,,,,,,TXPO:0001178,,,,,,,,,,,,,,,,,,,,,,increasing drug metabolite [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001170,keeping amount of lipid in liver [Lipidosis],,"Keeping amount of lipid in liver is a subtype of keeping amount: A process that maintaining the amount of lipid in the liver.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis (normal condition).",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0001169,,,,,,,,,,,,,,,,,,,,,,"Keeping amount of lipid in liver is a subtype of keeping amount: A process that maintaining the amount of lipid in the liver.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis (normal condition).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001059|http://purl.obolibrary.org/obo/TXPO_0001056,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001168,,,,,,,,,,,TXPO:0001170,,,,,,,,,,,,,,,,,,,,,,keeping amount of lipid in liver [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001176,Lpgat1 (rat)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001308|http://purl.obolibrary.org/obo/TXPO_1000231|http://purl.obolibrary.org/obo/TXPO_0001134,,,,,,,,,,,,,,,,,,,,"NCBI-Rat-GeneID:679692|http://omim.org/entry/610473|http://www.reactome.org/PathwayBrowser/#/R-HSA-1483206&SEL=R-HSA-1482539&PATH=R-HSA-1430728,R-HSA-556833,R-HSA-1483257|PMID:15485873",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001176,,,,,,,,,,,,,,,,,,,,,,Lpgat1 (rat)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001174,positive regulation of lipid catabolic process [lipidosis - normal],,"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of lipids.  This process can constitute the course of Lipidosis (normal condition).",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/GO_0050996,,,,,,,,,,,,,,,,,,,,,,"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of lipids.  This process can constitute the course of Lipidosis (normal condition).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001218,,,,,,,,,,,,,,,,,,TXPO:0001174,,,,,,,,,,,,,,,,,,,,,,positive regulation of lipid catabolic process [lipidosis - normal],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001173,Cyp2c6v1 (rat)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001134|http://purl.obolibrary.org/obo/TXPO_1000103,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:293989|http://rgd.mcw.edu/rgdweb/report/gene/main.html?id=619934|PMID:23193974|PMID:26477383|PMID:26918316|PMID:19651758,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001553,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002262,,,,,,,,,,TXPO:0001173,,,,,,,,,,,,,,,,,,,,,,Cyp2c6v1 (rat)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001551,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001172,KEAP1 [Glutathione depletion],Kelch Like ECH Associated Protein 1,,false,,,http://purl.obolibrary.org/obo/TXPO_0002045|http://purl.obolibrary.org/obo/TXPO_0000877,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:117519|NCBI-Mouse-GeneID:50868|NCBI-Human-GeneID:9817,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Kelch Like ECH Associated Protein 1,,,,,TXPO:0001172,,,,,,,,,,,,,,,,,,,,,,KEAP1 [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001177,Cholesterol homeostasis imbalance [Niemann-Pick C],,"Cholesterol homeostasis imbalance is a subtype of chemical homeostasis imbalance: A process that becomes lacking a cholesterol homeostastasis balance.
This entity is a specific course-dependent process. This process can constitute the course of Niemann-Pick C.",false,,,http://purl.obolibrary.org/obo/TXPO_0003491,,,,,,,,,,,,,,,,,,,,,,"Cholesterol homeostasis imbalance is a subtype of chemical homeostasis imbalance: A process that becomes lacking a cholesterol homeostastasis balance.
This entity is a specific course-dependent process. This process can constitute the course of Niemann-Pick C.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001538,,http://purl.obolibrary.org/obo/TXPO_0002327,,,,,,,,,TXPO:0001177,,,,,,,,,,,,,,,,,,,,,,Cholesterol homeostasis imbalance [Niemann-Pick C],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001175,Faah (rat)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000152|http://purl.obolibrary.org/obo/TXPO_0001134,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:29347|https://www.ncbi.nlm.nih.gov/biosystems/142420|PMID:24811863|PMID:20098695|https://biocyc.org/HUMAN/NEW-IMAGE?type=PATHWAY&object=PWY6666-1,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001544,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002272,,,,,,,,,,TXPO:0001175,,,,,,,,,,,,,,,,,,,,,,Faah (rat)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001495|http://purl.obolibrary.org/obo/TXPO_0001491|http://purl.obolibrary.org/obo/TXPO_0001493|http://purl.obolibrary.org/obo/TXPO_0001796,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001848,RSK3,90 kDa ribosomal S6 kinase3|p90RSK3,,false,,,http://purl.obolibrary.org/obo/IMR_0000248,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,90 kDa ribosomal S6 kinase3|p90RSK3,,,,,IMR:0001848,,,,,,,,,,,,,,,,,,,,,,RSK3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003664,ATPase,complex V (mitochondrial electron transport)|ATP hydrolase|adenosine 5'-triphosphatase|adenosine triphosphatase,Catalysis role of the reaction: ATP + H2O = ADP + phosphate + 2 H+. May or may not be coupled to another reaction.|related molecular function GO:0016887,false,,,http://purl.obolibrary.org/obo/TXPO_0003663,,,,,,,,,,,,,,,,,,,,IMR:0000918 (obsolete),,Catalysis role of the reaction: ATP + H2O = ADP + phosphate + 2 H+. May or may not be coupled to another reaction.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ATP hydrolase|adenosine 5'-triphosphatase|adenosine triphosphatase,,complex V (mitochondrial electron transport),,,TXPO:0003664,,,,,,,,,,,,,,,,,,,,related molecular function GO:0016887,,ATPase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003665,opioid analgesic,,"A narcotic or opioid substance, synthetic or semisynthetic agent producing profound analgesia, drowsiness, and changes in mood.",false,,,http://purl.obolibrary.org/obo/CHEBI_35480,,,,,,,,,,,,,,,,,,,,,,"A narcotic or opioid substance, synthetic or semisynthetic agent producing profound analgesia, drowsiness, and changes in mood.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003665,,,,,,,,,,,,,,,,,,,,,,opioid analgesic,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003663,hydrolase,,"Catalysis role of the hydrolysis of various bonds, e.g. C-O, C-N, C-C, phosphoric anhydride bonds, etc. Hydrolase is the systematic name for any enzyme of EC class 3.|related molecular function GO:0016787",false,,,http://purl.obolibrary.org/obo/TXPO_0003660,,,,,,,,,,,,,,,,,,,,EC:3.-.-.-|IMR:0010044 (obsolete),,"Catalysis role of the hydrolysis of various bonds, e.g. C-O, C-N, C-C, phosphoric anhydride bonds, etc. Hydrolase is the systematic name for any enzyme of EC class 3.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003663,,,,,,,,,,,,,,,,,,,,related molecular function GO:0016787,,hydrolase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003666,glycosylase,,Catalysis role of the hydrolysis of any glycosyl bond.,false,,,http://purl.obolibrary.org/obo/TXPO_0003663,,,,,,,,,,,,,,,,,,,,EC:3.2.-.-|IMR:0010049 (obsolete),,Catalysis role of the hydrolysis of any glycosyl bond.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003666,,,,,,,,,,,,,,,,,,,,,,glycosylase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003668,GTPase,,Catalysis role of the reaction: GTP + H2O = GDP + phosphate.|related moleular function: GO:0003924,false,,,http://purl.obolibrary.org/obo/TXPO_0003663,,,,,,,,,,,,,,,,,,,,EC:3.6.5.-|IMR:0000960 (obsolete),,Catalysis role of the reaction: GTP + H2O = GDP + phosphate.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003668,,,,,,,,,,,,,,,,,,,,related moleular function: GO:0003924,,GTPase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003669,small GTPase,Ras superfamily|small GTP-binding protein|small GTPase|small G-protein,"A role of the RAS superfamily of GTP (guanosine triphosphate) hydrolysis-coupled signal transduction relay protein.
It can be subclassified into RAS, RHO, RAB, and ARF families, as well as the closely related G alpha family. The members of each family can, in turn, be arranged into evolutionarily conserved branches. These groupings reflect structural, biochemical, and functional conservation.",false,,,http://purl.obolibrary.org/obo/TXPO_0003668,,,,,,,,,,,,,,,,,,,,EC:3.6.5.2,,"A role of the RAS superfamily of GTP (guanosine triphosphate) hydrolysis-coupled signal transduction relay protein.
It can be subclassified into RAS, RHO, RAB, and ARF families, as well as the closely related G alpha family. The members of each family can, in turn, be arranged into evolutionarily conserved branches. These groupings reflect structural, biochemical, and functional conservation.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,small GTP-binding protein|small GTPase|small G-protein,,Ras superfamily,,,TXPO:0003669,,,,,,,,,,,,,,,,,,,,,,small GTPase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003660,enzyme,,Protein that catalyze a specific chemical reaction.|related molecular function GO:0003824,false,,,http://purl.obolibrary.org/obo/CHEBI_51086,,,,,,,,,,,,,,,,,,,,IMR:0000207 (obsolete),,Protein that catalyze a specific chemical reaction.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003660,,,,,,,,,,,,,,,,,,,,related molecular function GO:0003824,,enzyme,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003662,helicase,,"Catalysis role of the reaction: NTP + H2O = NDP + phosphate, to drive the unwinding of a DNA or RNA helix.|related molecular function: GO:0004386",false,,,http://purl.obolibrary.org/obo/TXPO_0003660,,,,,,,,,,,,,,,,,,,,IMR:0010034 (obsolete),,"Catalysis role of the reaction: NTP + H2O = NDP + phosphate, to drive the unwinding of a DNA or RNA helix.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003662,,,,,,,,,,,,,,,,,,,,related molecular function: GO:0004386,,helicase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003667,DNA N-glycosylase,DNA glycosylase,Catalysis role of the removal of damaged bases by cleaving the N-C1' glycosidic bond between the target damaged DNA base and the deoxyribose sugar. The reaction releases a free base and leaves an apurinic/apyrimidinic (AP) site.,false,,,http://purl.obolibrary.org/obo/TXPO_0003666,,,,,,,,,,,,,,,,,,,,EC:3.2.2,,Catalysis role of the removal of damaged bases by cleaving the N-C1' glycosidic bond between the target damaged DNA base and the deoxyribose sugar. The reaction releases a free base and leaves an apurinic/apyrimidinic (AP) site.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,DNA glycosylase,,,,,TXPO:0003667,,,,,,,,,,,,,,,,,,,,,,DNA N-glycosylase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003661,phenothiazine antipsychotic drug,,,false,,,http://purl.obolibrary.org/obo/TXPO_0003659,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003661,,,,,,,,,,,,,,,,,,,,,,phenothiazine antipsychotic drug,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000442,GAP family,GTPase activating protein,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,GO:0005096,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003722,,,,,GTPase activating protein,,,,,IMR:0000442,,,,,,,,,,,,,,,,,,,,,,GAP family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0032043,mitochondrial DNA catabolic process,,The chemical reactions and pathways resulting in the breakdown of mitochondrial DNA.,false,,,http://purl.obolibrary.org/obo/GO_0006308,,,,,,,,,,,,,,,,,,,,,,The chemical reactions and pathways resulting in the breakdown of mitochondrial DNA.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0032043,,,,,,,,,,,,,,,,,,,,,,mitochondrial DNA catabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0032049,cardiolipin biosynthetic process,diphosphatidylglycerol biosynthetic process|diphosphatidylglycerol biosynthesis,"The chemical reactions and pathways resulting in the formation of cardiolipin, 1,3-bis(3-phosphatidyl)glycerol.",false,,,http://purl.obolibrary.org/obo/GO_0006655,,,,,,,,,,,,,,,,,,,,MetaCyc:PWY-5269,,"The chemical reactions and pathways resulting in the formation of cardiolipin, 1,3-bis(3-phosphatidyl)glycerol.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_28494,,,,,,,,,,,,,,,,diphosphatidylglycerol biosynthetic process|diphosphatidylglycerol biosynthesis,,,GO:0032049,,,,,,,,,,,,,,,,,,,,,,cardiolipin biosynthetic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000266,PI3-kinase p85 subunit,Phosphatidylinositol 3-kinase p85 regulatory subunit,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003722,,,,,Phosphatidylinositol 3-kinase p85 regulatory subunit,,,,,IMR:0000266,,,,,,,,,,,,,,,,,,,,,,PI3-kinase p85 subunit,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_52214,ligand,ligands,Any molecule or ion capable of binding to a central metal atom to form coordination complexes.,false,,,http://purl.obolibrary.org/obo/CHEBI_51086,,,,,,,,,,,,,,,,,,,,,,Any molecule or ion capable of binding to a central metal atom to form coordination complexes.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ligands,,,,,,,,,,,,,,,,,,,,,CHEBI:52214,,,,ligand,,CHEBI:52214,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006909,phagocytosis,,"A vesicle-mediated transport process that results in the engulfment of external particulate material by phagocytes and their delivery to the lysosome. The particles are initially contained within phagocytic vacuoles (phagosomes), which then fuse with primary lysosomes to effect digestion of the particles.",false,,,http://purl.obolibrary.org/obo/TXPO_0002587,,,,,,,,,,,,,,,,,,,,Wikipedia:Phagocytosis,,"A vesicle-mediated transport process that results in the engulfment of external particulate material by phagocytes and their delivery to the lysosome. The particles are initially contained within phagocytic vacuoles (phagosomes), which then fuse with primary lysosomes to effect digestion of the particles.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0001845|http://purl.obolibrary.org/obo/GO_0006910,,,,,,,,,,,,,,,,,,GO:0006909,,,,,,,,,,,,,,,,,,,,,,phagocytosis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001585,phosphatidylcholine metabolism imbalance,,Phosphatidylcholine metabolism imbalance is a subtype of glycerophospholipid metabolism imbalance : A process that becomes lacking a homeostastasis balance of phosphatidylcholine metabolism.,false,,,http://purl.obolibrary.org/obo/TXPO_0001295,,,,,,,,,,,,,,,,,,,,,,Phosphatidylcholine metabolism imbalance is a subtype of glycerophospholipid metabolism imbalance : A process that becomes lacking a homeostastasis balance of phosphatidylcholine metabolism.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001585,,,,,,,,,,,,,,,,,,,,,,phosphatidylcholine metabolism imbalance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001586,Sgpl1 - apoptosis inducer (mouse)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003529,,,,,,,,,,,,,,,,,,,,http://omim.org/entry/603729|PMID:17090686,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_68495|http://purl.obolibrary.org/obo/TXPO_0002358,,,,,,,,,,TXPO:0001586,,,,,,,,,,,,,,,,,,,,,,Sgpl1 - apoptosis inducer (mouse)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001583,increasing phosphatidylcholine material,,Increasing phosphatidylcholine material is a subtype of increasing glycerophospholipid material: A process that changes the amount of phosphatidylcholine material to be larger.,false,,,http://purl.obolibrary.org/obo/TXPO_0001317,,,,,,,,,,,,,,,,,,,,,,Increasing phosphatidylcholine material is a subtype of increasing glycerophospholipid material: A process that changes the amount of phosphatidylcholine material to be larger.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001583,,,,,,,,,,,,,,,,,,,,,,increasing phosphatidylcholine material,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001581,stagnating,,Stagnating is a subtype of decreasing velocity: A process that changes the flow velocity to be slower or stops it in progress.,false,,,http://purl.obolibrary.org/obo/TXPO_0000711,,,,,,,,,,,,,,,,,,,,,,Stagnating is a subtype of decreasing velocity: A process that changes the flow velocity to be slower or stops it in progress.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001581,,,,,,,,,,,,,,,,,,,,,,stagnating,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001588,ground glass appearance with Cytochrome P450 activation by phenobarbital,,"The totality of all processes through which ground glass appearance is realized.
This toxic course has a process of Cytochrome P450 (CYP) activation by phenobarbital.",false,,,http://purl.obolibrary.org/obo/TXPO_0003857,,,,,,,,,,,,,,,,,,,,,,"The totality of all processes through which ground glass appearance is realized.
This toxic course has a process of Cytochrome P450 (CYP) activation by phenobarbital.",,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003864,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003903|http://purl.obolibrary.org/obo/TXPO_0000982|http://purl.obolibrary.org/obo/TXPO_0000981|http://purl.obolibrary.org/obo/TXPO_0001663|http://purl.obolibrary.org/obo/TXPO_0001026|http://purl.obolibrary.org/obo/TXPO_0000934|http://purl.obolibrary.org/obo/TXPO_0000781|http://purl.obolibrary.org/obo/TXPO_0001840|http://purl.obolibrary.org/obo/TXPO_0003864|http://purl.obolibrary.org/obo/TXPO_0003860|http://purl.obolibrary.org/obo/TXPO_0000948|http://purl.obolibrary.org/obo/TXPO_0002719,,,,,,,,,,,,,,,,,,TXPO:0001588,,,,,,,,,,,,,,,,,,,,,,ground glass appearance with Cytochrome P450 activation by phenobarbital,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001587,hyperfunction of Phosphatidylcholine synthesis gene expression,,Hyperfunction of Phosphatidylcholine synthesis gene expression is a subtype of hyperfunction of glycerophospholipid synthesis gene expression: A process that performs an excesssive phosphatidylcholine ssynthetic gene expression.,false,,,http://purl.obolibrary.org/obo/TXPO_0001264,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of Phosphatidylcholine synthesis gene expression is a subtype of hyperfunction of glycerophospholipid synthesis gene expression: A process that performs an excesssive phosphatidylcholine ssynthetic gene expression.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001587,,,,,,,,,,,,,,,,,,,,,,hyperfunction of Phosphatidylcholine synthesis gene expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001580,regulation of hepatocyte cell cycle [hypertrophy],,"Regulation of hepatocyte cell cycle [hypertrophy] is a subtype of regulation of cell cycle: A process that modulates the frequency, rate or extent of hepatocyte cell cycle.",false,,,http://purl.obolibrary.org/obo/GO_0051726,,,,,,,,,,,,,,,,,,,,,,"Regulation of hepatocyte cell cycle [hypertrophy] is a subtype of regulation of cell cycle: A process that modulates the frequency, rate or extent of hepatocyte cell cycle.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001580,,,,,,,,,,,,,,,,,,,,,,regulation of hepatocyte cell cycle [hypertrophy],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001589,nuclear receptor inactivation,nuclear receptor inactivation,Nuclear receptor inactivation is a subtype of inactivation : A process that changes the activity of the molecule with a nuclear receptor role to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000021,,,,,,,,,,,,,,,,,,,,,,Nuclear receptor inactivation is a subtype of inactivation : A process that changes the activity of the molecule with a nuclear receptor role to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,nuclear receptor inactivation,,,,,TXPO:0001589,,,,,,,,,,,,,,,,,,,,,,nuclear receptor inactivation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001584,drug metabolic process [Ground glass appearance],,"The chemical reactions and pathways involving a drug, a substance used in the diagnosis, treatment or prevention of a disease; as used here antibiotic substances (see antibiotic metabolism) are considered to be drugs, even if not used in medical or veterinary practice.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/GO_0017144,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways involving a drug, a substance used in the diagnosis, treatment or prevention of a disease; as used here antibiotic substances (see antibiotic metabolism) are considered to be drugs, even if not used in medical or veterinary practice.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001597|http://purl.obolibrary.org/obo/TXPO_0001593,,,,,,,,,,,,,,,,,,TXPO:0001584,,,,,,,,,,,,,,,,,,,,,,drug metabolic process [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001582,increasing distance between hepatocytes [Ground glass appearance],,"Increasing distance between hepatocytes is a subtype of increasing distance between cells: A process that places a distance between hepatocytes.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.|separating between hepatocytes [Ground glass appearance]",false,,,http://purl.obolibrary.org/obo/TXPO_0001590|http://purl.obolibrary.org/obo/TXPO_0001728,,,,,,,,,,,,,,,,,,,,,,"Increasing distance between hepatocytes is a subtype of increasing distance between cells: A process that places a distance between hepatocytes.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001524,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001033,,,,,,,,,,,TXPO:0001582,,,,,,,,,,,,,,,,,,,,separating between hepatocytes [Ground glass appearance],,increasing distance between hepatocytes [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000365,cytokeratin 14,,,false,,,http://purl.obolibrary.org/obo/IMR_0000035,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000365,,,,,,,,,,,,,,,,,,,,,,cytokeratin 14,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_22271,aflatoxin,,"Any of a group of related and highly toxic secondary metabolites (mycotoxins) whose main structural feature is a fused coumarin-bis(dihydrofuran) ring system and which are produced by strains of the moulds Aspergillus flavus or A. parasiticus, together with further metabolites of these mycotoxins.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,,,"Any of a group of related and highly toxic secondary metabolites (mycotoxins) whose main structural feature is a fused coumarin-bis(dihydrofuran) ring system and which are produced by strains of the moulds Aspergillus flavus or A. parasiticus, together with further metabolites of these mycotoxins.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:22271,,,,,,,,,,,,,,,,,,,,,,aflatoxin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_64106,protein kinase agonist,protein kinase agonists,An agonist that selectively binds to and activates a protein kinase receptor.,false,,,http://purl.obolibrary.org/obo/CHEBI_48705,,,,,,,,,,,,,,,,,,,,,,An agonist that selectively binds to and activates a protein kinase receptor.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,protein kinase agonists,,,,,,,,,,,,,,,,,,,,,CHEBI:64106,,,,protein kinase agonist,,CHEBI:64106,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000697,K-Ras2A,c-K-ras|KRAS2|Transforming protein p21A|Ki-Ras|K-Ras4A|K-Ras 2A,,false,,,http://purl.obolibrary.org/obo/IMR_0000291,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0011342,c-K-ras|KRAS2|Transforming protein p21A|Ki-Ras|K-Ras4A|K-Ras 2A,,,,,IMR:0000697,,,,,,,,,,,,,,,,,,,,,,K-Ras2A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000870,Acot8 (mouse)[Eosinophilic granular degeneration],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000026|http://purl.obolibrary.org/obo/TXPO_0000648,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:170789|PMID:15194431|PMID:24788990|PMID:28385385,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000870,,,,,,,,,,,,,,,,,,,,,,Acot8 (mouse)[Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000877,KEAP1 (mol),Kelch Like ECH Associated Protein 1,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:117519|NCBI-Mouse-GeneID:50868|NCBI-Human-GeneID:9817,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Kelch Like ECH Associated Protein 1,,,,,TXPO:0000877,,,,,,,,,,,,,,,,,,,,,,KEAP1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000878,PERK (canonical)[ER stress],EIF2AK3,,false,,,http://purl.obolibrary.org/obo/TXPO_0000871|http://purl.obolibrary.org/obo/TXPO_0001792,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:13666|NCBI-Human-GeneID:9451|NCBI-Rat-GeneID:29702|http://omim.org/entry/604032,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000009451,,,,,,,,EIF2AK3,,,,,TXPO:0000878,,,,,,,,,,,,,,,,,,,,,,PERK (canonical)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002741,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000872,dissociation of BIP complex,,Dissociation of Bip complex is a subtype of detaching: A process that disaggregates a Bip complex into Bip and other molecule(s).,false,,,http://purl.obolibrary.org/obo/TXPO_0000462,,,,,,,,,,,,,,,,,,,,,,Dissociation of Bip complex is a subtype of detaching: A process that disaggregates a Bip complex into Bip and other molecule(s).,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002106,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001002,,,,,,,,,,,,,,,,,,,TXPO:0000872,,,,,,,,,,,,,,,,,,,,,,dissociation of BIP complex,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005789,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000874,negative regulation of endoplasmic reticulum-associated degradation,,"Negative regulation of endoplasmic reticulum-associated degradation is a subtype of negative regulation of protein catabolic process: A process that stops, prevents, or reduces the frequency, rate or extent of endoplasmic reticulum-associated degradation.",false,,,http://purl.obolibrary.org/obo/GO_0042177,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of endoplasmic reticulum-associated degradation is a subtype of negative regulation of protein catabolic process: A process that stops, prevents, or reduces the frequency, rate or extent of endoplasmic reticulum-associated degradation.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000874,,,,,,,,,,,,,,,,,,,,,,negative regulation of endoplasmic reticulum-associated degradation,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0071712,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000873,AMPK (canonical)[ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003221|http://purl.obolibrary.org/obo/TXPO_0000871,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:105787|NCBI-Human-GeneID:5562|NCBI-Rat-GeneID:65248,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003221,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000873,,,,,,,,,,,,,,,,,,,,,,AMPK (canonical)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000879,ATF6 (canonical)[ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000871|http://purl.obolibrary.org/obo/TXPO_1000013,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:304962|NCBI-Mouse-GeneID:226641|NCBI-Human-GeneID:22926,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000825,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000879,,,,,,,,,,,,,,,,,,,,,,ATF6 (canonical)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000875,IRE - stress sensor (canonical)[ER stress -ERAD],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002602,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000881,,,,,,,,,,TXPO:0000875,,,,,,,,,,,,,,,,,,,,,,IRE - stress sensor (canonical)[ER stress -ERAD],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002710,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000871,ER stress dependent molecule (canonical),,"ER stress dependent molecule is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of ER stress as a gene product.
Gene profile:caonical that described in textbooks or articles.",false,,,http://purl.obolibrary.org/obo/TXPO_0000794,,,,,,,,,,,,,,,,,,,,,,"ER stress dependent molecule is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of ER stress as a gene product.
Gene profile:caonical that described in textbooks or articles.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000871,,,,,,,,,,,,,,,,,,,,,,ER stress dependent molecule (canonical),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000876,PERK inhibitor,,A role played by the entity which interferes with the activity of PERK.,false,,,http://purl.obolibrary.org/obo/TXPO_0003711,,,,,,,,,,,,,,,,,,,,,,A role played by the entity which interferes with the activity of PERK.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000876,,,,,,,,,,,,,,,,,,,,,,PERK inhibitor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010545,40S ribosomal protein S15a,40S small ribosomal protein 1A,,false,,,http://purl.obolibrary.org/obo/IMR_0000896,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,40S small ribosomal protein 1A,,,,,IMR:0010545,,,,,,,,,,,,,,,,,,,,,,40S ribosomal protein S15a,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0002294,biliary system,biliary tract|biliary apparatus,Organ system subdivision that consists of the organs and ducts that are involved in the production and transportation of bile. In most species this is the gallbladder and the bile ducts (biliary tree).,false,,,http://purl.obolibrary.org/obo/UBERON_0011216,,,,,,,,,,,,,,,,,,,,http://www.snomedbrowser.com/Codes/Details/361354009|http://purl.obolibrary.org/obo/NCIT_C12678|http://en.wikipedia.org/wiki/Biliary_system|GAID:279|MESH:D001659|MA:0001273|FMA:79646,,Organ system subdivision that consists of the organs and ducts that are involved in the production and transportation of bile. In most species this is the gallbladder and the bile ducts (biliary tree).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0001173,,,,,,,,,,,,,biliary apparatus,,biliary tract,,http://purl.obolibrary.org/obo/UBERON_0002423,UBERON:0002294,http://purl.obolibrary.org/obo/UBERON_0002423,,,,,,,,,,,,,,,,,,,,,biliary system,,,,http://upload.wikimedia.org/wikipedia/commons/5/5d/Digestive_system_showing_bile_duct.png,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001690,MNK1,MAP kinase signal-integrating kinase 1|MAP kinase-interacting kinase 1,,false,,,http://purl.obolibrary.org/obo/IMR_0100273,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MAP kinase signal-integrating kinase 1|MAP kinase-interacting kinase 1,,,,,IMR:0001690,,,,,,,,,,,,,,,,,,,,,,MNK1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_50860,organic molecular entity,organic compounds|organic entity,Any molecular entity that contains carbon.,false,,,http://purl.obolibrary.org/obo/CHEBI_24431,,,,,,,,,,,,,,,,,,,,,,Any molecular entity that contains carbon.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,organic compounds|organic entity,,,,,CHEBI:50860,,,,,,,,,,,,,,,,,,,,,,organic molecular entity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_35381,monosaccharide,monosaccharide|monosaccharides|Monosaccharide,"Parent monosaccharides are polyhydroxy aldehydes H[CH(OH)]nC(=O)H or polyhydroxy ketones H-[CHOH]n-C(=O)[CHOH]m-H with three or more carbon atoms. The generic term 'monosaccharide' (as opposed to oligosaccharide or polysaccharide) denotes a single unit, without glycosidic connection to other such units. It includes aldoses, dialdoses, aldoketoses, ketoses and diketoses, as well as deoxy sugars, provided that the parent compound has a (potential) carbonyl group.",false,,,http://purl.obolibrary.org/obo/CHEBI_16646,,,,,,,,,,,,,,,,,,,,,,"Parent monosaccharides are polyhydroxy aldehydes H[CH(OH)]nC(=O)H or polyhydroxy ketones H-[CHOH]n-C(=O)[CHOH]m-H with three or more carbon atoms. The generic term 'monosaccharide' (as opposed to oligosaccharide or polysaccharide) denotes a single unit, without glycosidic connection to other such units. It includes aldoses, dialdoses, aldoketoses, ketoses and diketoses, as well as deoxy sugars, provided that the parent compound has a (potential) carbonyl group.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,monosaccharide|monosaccharides|Monosaccharide,,,,,CHEBI:35381,,,,,,,,,,,,,,,,,,,,,,monosaccharide,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001691,MNK2,MAP kinase signal-integrating kinase 2|MAP kinase-interacting kinase 2,,false,,,http://purl.obolibrary.org/obo/IMR_0100273,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MAP kinase signal-integrating kinase 2|MAP kinase-interacting kinase 2,,,,,IMR:0001691,,,,,,,,,,,,,,,,,,,,,,MNK2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_2070009606,pseudo gene of Homo sapiens,,A gene of Homo sapiens that has a pseudo gene disposition,false,,,http://purl.obolibrary.org/obo/OGG_2000009606,,,,,,,,,,,,,,,,,,,,,,A gene of Homo sapiens that has a pseudo gene disposition,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,OGG:2070009606,,,,,,,,,,,,,,,,,,,,,,pseudo gene of Homo sapiens,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9606,,,,,,,,,,,,,,,,,,,,,"Bin Zhao, Oliver He"
http://purl.obolibrary.org/obo/IMR_0100266,MAPKAPK2,MK2|MAPK- activated protein kinase 2|MAP kinase-activated protein kinase 2,,false,,,http://purl.obolibrary.org/obo/IMR_0001689,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MK2|MAPK- activated protein kinase 2|MAP kinase-activated protein kinase 2,,,,,IMR:0100266,,,,,,,,,,,,,,,,,,,,,,MAPKAPK2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_37845,growth hormone,,A hormone that specifically regulates growth.,false,,,http://purl.obolibrary.org/obo/CHEBI_24621,,,,,,,,,,,,,,,,,,,,CAS:9002-72-6,,A hormone that specifically regulates growth.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:37845,,,,,,,,,,,,,,,,,,,,,,growth hormone,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100290,Bik,Bcl-2 interacting killer,,false,,,http://purl.obolibrary.org/obo/IMR_0100709,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Bcl-2 interacting killer,,,,,IMR:0100290,,,,,,,,,,,,,,,,,,,,,,Bik,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100282,I-kappaB epsilon,inhibitor of NF-kappaB epsilon|IkB-epsilon,,false,,,http://purl.obolibrary.org/obo/IMR_0000464,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,inhibitor of NF-kappaB epsilon|IkB-epsilon,,,,,IMR:0100282,,,,,,,,,,,,,,,,,,,,,,I-kappaB epsilon,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_66993,tocolytic agent,anti-contraction drug|labour repressant|tocolytic drugs|labour repressants|anti-contraction medication|tocolytic agents|tocolytic|anti-contraction medications|tocolytics|anti-contraction drugs|tocolytic drug,Any compound used to suppress premature labour and immature birth by suppressing uterine contractions.,false,,,http://purl.obolibrary.org/obo/CHEBI_50689,,,,,,,,,,,,,,,,,,,,,,Any compound used to suppress premature labour and immature birth by suppressing uterine contractions.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,anti-contraction drug|labour repressant|tocolytic drugs|labour repressants|anti-contraction medication|tocolytic agents|tocolytic|anti-contraction medications|tocolytics|anti-contraction drugs|tocolytic drug,,,,,,,,,,,,,,,,,,,,,CHEBI:66993,,,,tocolytic agent,,CHEBI:66993,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0071840,cellular component organization or biogenesis,,"A process that results in the biosynthesis of constituent macromolecules, assembly, arrangement of constituent parts, or disassembly of a cellular component.",false,,,http://purl.obolibrary.org/obo/TXPO_0000134,,,,,,,,,,,,,,,,,,,,,,"A process that results in the biosynthesis of constituent macromolecules, assembly, arrangement of constituent parts, or disassembly of a cellular component.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0071840,,,,,,,,,,,,,,,,,,,,,,cellular component organization or biogenesis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001083,positive regulation of mitochondrial membrane permeability [lipidosis],,"Any process that increases the frequency, rate or extent of the passage or uptake of molecules by the mitochondrial membrane.
This entity is a specific course-dependent process. This process can constitute the course of lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/GO_0035794,,,,,,,,,,,,,,,,,,,,,,"Any process that increases the frequency, rate or extent of the passage or uptake of molecules by the mitochondrial membrane.
This entity is a specific course-dependent process. This process can constitute the course of lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001085|http://purl.obolibrary.org/obo/TXPO_0004128,,,,,,,,,,,TXPO:0001083,,,,,,,,,,,,,,,,,,,,,,positive regulation of mitochondrial membrane permeability [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001089,lipidosis dependent chemical entity,,"Lipidosis dependent chemical entity is a subtype of toxic course dependent chemical entity.
This entity can participate in the course of lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001731,,,,,,,,,,,,,,,,,,,,,,"Lipidosis dependent chemical entity is a subtype of toxic course dependent chemical entity.
This entity can participate in the course of lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001089,,,,,,,,,,,,,,,,,,,,,,lipidosis dependent chemical entity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001081,Cyp4a1 (rat)[Eosinophilic granular degeneration],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001077|http://purl.obolibrary.org/obo/TXPO_1000107,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:50549,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001081,,,,,,,,,,,,,,,,,,,,,,Cyp4a1 (rat)[Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001085,decreasing mitochondrial membrane potential [lipidosis],,"Decreasing mitochondrial membrane potential is a subtype of decreasing membrane potential: A process that changes the electrical potential of a mitochondrial membrane to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0001855,,,,,,,,,,,,,,,,,,,,,,"Decreasing mitochondrial membrane potential is a subtype of decreasing membrane potential: A process that changes the electrical potential of a mitochondrial membrane to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001540|http://purl.obolibrary.org/obo/TXPO_0001749,,,,,,,,,,,TXPO:0001085,,,,,,,,,,,,,,,,,,,,,,decreasing mitochondrial membrane potential [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0031966,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001080,IL-1b activator role,,A role played by the entity  that activates the activity of the cytokine IL-1b.,false,,,http://purl.obolibrary.org/obo/TXPO_0003714,,,,,,,,,,,,,,,,,,,,,,A role played by the entity  that activates the activity of the cytokine IL-1b.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001080,,,,,,,,,,,,,,,,,,,,,,IL-1b activator role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001084,PLIN2 (human)[Eosinophilic granular degeneration],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001034|http://purl.obolibrary.org/obo/TXPO_1000286,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:123|PMID:25961502|PMID:16735577|PMID:16489205,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000123,,,,,,,,,,,,,TXPO:0001084,,,,,,,,,,,,,,,,,,,,,,PLIN2 (human)[Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000795|http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001087,apoptosis [lipidosis],,"A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/GO_0006915,,,,,,,,,,,,,,,,,,,,PMID:17090686,,"A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001087,,,,,,,,,,,,,,,,,,,,,,apoptosis [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001082,cellular senescence regulator,,A role played by the entity which regulates the cellular senescence.,false,,,http://purl.obolibrary.org/obo/TXPO_0003230,,,,,,,,,,,,,,,,,,,,,,A role played by the entity which regulates the cellular senescence.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001082,,,,,,,,,,,,,,,,,,,,,,cellular senescence regulator,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001086,reactive oxygen species biosynthetic process [lipidosis],,"The chemical reaction resulting in the formation of reactive oxygen species, any molecules or ions formed by the incomplete one-electron reduction of oxygen.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/GO_1903409,,,,,,,,,,,,,,,,,,,,,,"The chemical reaction resulting in the formation of reactive oxygen species, any molecules or ions formed by the incomplete one-electron reduction of oxygen.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003510|http://purl.obolibrary.org/obo/TXPO_0001083,,,,,,,,,,,TXPO:0001086,,,,,,,,,,,,,,,,,,,,,,reactive oxygen species biosynthetic process [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001088,lipidosis dependent molecule (rat),,"Lipidosis dependent molecule is a subtype of toxic course dependent chemical entity.
This molecule can participate in the course of lipidosis as a gene product.
Gene profile:Rat/Liver/",false,,,http://purl.obolibrary.org/obo/TXPO_0001089,,,,,,,,,,,,,,,,,,,,,,"Lipidosis dependent molecule is a subtype of toxic course dependent chemical entity.
This molecule can participate in the course of lipidosis as a gene product.
Gene profile:Rat/Liver/",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001088,,,,,,,,,,,,,,,,,,,,,,lipidosis dependent molecule (rat),,,,,,,,,,,http://purl.obolibrary.org/obo/NCBITaxon_10114,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000029896,TRA2A,,Other designations: TRA-2 alpha|TRA2-alpha|Tra2alpha|htra-2 alpha|htra-2-alpha|putative MAPK activating protein PM24|transformer-2 alpha|transformer-2 protein homolog A|transformer-2 protein homolog alpha,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,HSU53209|AWMS1,,,,,,,,,,,,7,,,,,,MIM:602718|Ensembl:ENSG00000164548|Vega:OTTHUMG00000128459|HGNC:16645|HPRD:04096,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,transformer 2 alpha homolog (Drosophila),,,7p15.3,,,,,,,,,,,,,,,,"GO_0000166 (EC: IEA); GO_0000398 (EC: IDA, PMID: 9546399); GO_0005634 (EC: IDA, PMID: 9546399); GO_0005730 (EC: IDA); GO_0043231 (EC: IDA); GO_0044822 (EC: IDA)",,,,,,,,,PMID: 8799144; 9546399; 9847074; 12477932; 12761501; 14729963; 14765198; 15324660; 15342556; 15489334; 16097034; 16964243; 17081983; 19322201; 19471022; 20508642; 21110914; 21139048; 21145461; 21382349; 21447598; 21890473; 21900206; 21906983; 21988832; 22094256; 22365833; 22939629; 22990118; 23000965; 23084401; 23255807; 23602568; 24457600,,,,,,,,,,,,,,,OGG:3000029896,,,,,,,transformer 2 alpha homolog (Drosophila),,,,,,,,,,,,,Other designations: TRA-2 alpha|TRA2-alpha|Tra2alpha|htra-2 alpha|htra-2-alpha|putative MAPK activating protein PM24|transformer-2 alpha|transformer-2 protein homolog A|transformer-2 protein homolog alpha,,TRA2A,,,,,,,,,,,,,,,,,,,,,,,29896,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,TRA2A,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/GO_0042158,lipoprotein biosynthetic process,lipoprotein biosynthesis|lipoprotein anabolism,"The chemical reaction resulting in the formation of any conjugated, water-soluble protein in which the covalently attached nonprotein group consists of a lipid or lipids.",false,,,http://purl.obolibrary.org/obo/TXPO_0000306,,,,,,,,,,,,,,,,,,,,,,"The chemical reaction resulting in the formation of any conjugated, water-soluble protein in which the covalently attached nonprotein group consists of a lipid or lipids.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,lipoprotein biosynthesis|lipoprotein anabolism,,,,,GO:0042158,,,,,,,,,,,,,,,,,,,,,,lipoprotein biosynthetic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_16961,monoacylglycerol phosphate,Lysophospholipid|monoacylglycerol phosphates|lysophospholipids|monoacylglycerophosphates|monoacylglycerophosphate,Derivatives of phosphoglycerols which have only one of the alcohol groups of the glycerol backbone ester-linked with a fatty acid.,false,,,http://purl.obolibrary.org/obo/CHEBI_37739,,,,,,,,,,,,,,,,,,,,,,Derivatives of phosphoglycerols which have only one of the alcohol groups of the glycerol backbone ester-linked with a fatty acid.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,monoacylglycerol phosphates|lysophospholipids|monoacylglycerophosphates|monoacylglycerophosphate,,Lysophospholipid,,,CHEBI:16961,,,,,,,,,,,,,,,,,,,,,,monoacylglycerol phosphate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010483,60S ribosomal protein L32,,,false,,,http://purl.obolibrary.org/obo/IMR_0000897,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0010483,,,,,,,,,,,,,,,,,,,,,,60S ribosomal protein L32,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100551,FGF-1,Beta-endothelial cell growth factor|AFGF|HBGF-1|ECGF-beta|Acidic fibroblast growth factor,,false,,,http://purl.obolibrary.org/obo/IMR_0000049,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Beta-endothelial cell growth factor|AFGF|HBGF-1|ECGF-beta|Acidic fibroblast growth factor,,,,,IMR:0100551,,,,,,,,,,,,,,,,,,,,,,FGF-1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_20854,ATP synthase inhibitor (mitochondrial respiratory-chain inhibitor),,A mitochondrial respiratory-chain inhibitor that interferes with the action of ATP synthase.,false,,,http://purl.obolibrary.org/obo/CHEBI_25355,,,,,,,,,,,,,,,,,,,,,,A mitochondrial respiratory-chain inhibitor that interferes with the action of ATP synthase.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:20854,,,,,,,,,,,,,,,,,,,,,,ATP synthase inhibitor (mitochondrial respiratory-chain inhibitor),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000080063,ATF7IP2,,Other designations: ATF7-interacting protein 2|MBD1-containing chromatin associated factor 2|MBD1-containing chromatin-associated factor 2|activating transcription factor 7-interacting protein 2,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,MCAF2,,,,,,,,,,,,16,,,,,,MIM:613645|HGNC:20397|Ensembl:ENSG00000166669|HPRD:16517|Vega:OTTHUMG00000129749,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,activating transcription factor 7 interacting protein 2,,,16p13.13,,,,,,,,,,,,,,,,GO_0005634 (EC: IEA); GO_0006351 (EC: IEA); GO_0006355 (EC: IEA),,,,,,,,,PMID:8125298; 12477932; 14702039; 15489334; 15691849; 18029348; 20195266,,,,,,,,,,,,,,,OGG:3000080063,,,,,,,activating transcription factor 7 interacting protein 2,,,,,,,,,,,,,Other designations: ATF7-interacting protein 2|MBD1-containing chromatin associated factor 2|MBD1-containing chromatin-associated factor 2|activating transcription factor 7-interacting protein 2,,ATF7IP2,,,,,,,,,,,,,,,,,,,,,,,80063,,,,,,,,9606,,,,,,,,,,,,,,,,,,,ATF7IP2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0010429,Polypyrimidine tract-binding protein 1,57 kDa RNA-binding protein PPTB-1|PTB|hnRNP I|Heterogeneous nuclear ribonucleoprotein I,,false,,,http://purl.obolibrary.org/obo/IMR_0010024,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,57 kDa RNA-binding protein PPTB-1|PTB|hnRNP I|Heterogeneous nuclear ribonucleoprotein I,,,,,IMR:0010429,,,,,,,,,,,,,,,,,,,,,,Polypyrimidine tract-binding protein 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000004345,CD200,,Other designations: CD200 antigen|MRC OX-2 antigen|OX-2 membrane glycoprotein|antigen identified by monoclonal antibody MRC OX-2,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,MOX1|OX-2|MOX2|MRC,,,,,,,,,,,,3,,,,,,MIM:155970|Ensembl:ENSG00000091972|Vega:OTTHUMG00000159248|HGNC:7203,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,CD200 molecule,,,3q13.2,,,,,,,,,,,,,,,,"GO_0005515 (EC: IPI); GO_0005886 (EC: TAS); GO_0005887 (EC: TAS, PMID: 3032785); GO_0050776 (EC: TAS)",,,,,,,,,PMID: 2902568; 3032785; 10981966; 11099416; 11260322; 11726033; 12477932; 12960329; 15489334; 15699757; 15955564; 16177086; 16303743; 16344560; 16354172; 17964286; 18008004; 18040859; 18060403; 18060862; 18164423; 18838168; 18946351; 19086995; 19151626; 19230971; 19386363; 20050020; 20375636; 20379614; 20442224; 20959655; 21164290; 21206086; 21982860; 21988832; 22064604; 22319630; 22334534; 22363701; 22430636; 22462561; 22496920; 22575528; 22621248; 22875025; 22899296; 23179394; 23206327; 23489112; 23541619; 23560298; 23643150; 23690219; 23841472; 24045551; 24183830; 24344047,,,,,,,,,,,,,,,OGG:3000004345,,,,,,,CD200 molecule,,,,,,,,,,,,,Other designations: CD200 antigen|MRC OX-2 antigen|OX-2 membrane glycoprotein|antigen identified by monoclonal antibody MRC OX-2,,CD200,,,,,,,,,,,,,,,,,,,,,,,4345,My033,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,CD200,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000812,CD86,B7.2,"B7.1 (CD80) and B7.2 (CD86) - the two structurally homologous ligands of CD28 - are expressed by professional antigen-presenting cells (APCs), such as dendritic cells (DCs), macrophages and activated B cells, belong to the immunoglobulin superfamily and might exist as dimers and monomers, respectively.",false,,,http://purl.obolibrary.org/obo/IMR_0002950,,,,,,,,,,,,,,,,,,,,,,"B7.1 (CD80) and B7.2 (CD86) - the two structurally homologous ligands of CD28 - are expressed by professional antigen-presenting cells (APCs), such as dendritic cells (DCs), macrophages and activated B cells, belong to the immunoglobulin superfamily and might exist as dimers and monomers, respectively.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,B7.2,,,,,IMR:0000812,,,,,,,,,,,,,,,,,,,,,,CD86,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000334,SEC24D (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:69608|NCBI-Rat-GeneID:310843|NCBI-Human-GeneID:9871,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000009871,,,,,,,,,,,,,TXPO:1000334,,,,,,,,,,,,,,,,,,,,,,SEC24D (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000339,SLC1A2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:20511|NCBI-Human-GeneID:6506|NCBI-Rat-GeneID:29482,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000006506,,,,,,,,,,,,,TXPO:1000339,,,,,,,,,,,,,,,,,,,,,,SLC1A2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000337,SESN1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:140742|NCBI-Human-GeneID:27244|NCBI-Rat-GeneID:294518,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000027244,,,,,,,,,,,,,TXPO:1000337,,,,,,,,,,,,,,,,,,,,,,SESN1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000332,SCO1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:6341|NCBI-Rat-GeneID:497930|NCBI-Mouse-GeneID:52892,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000006341,,,,,,,,,,,,,TXPO:1000332,,,,,,,,,,,,,,,,,,,,,,SCO1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000331,APCS (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:29339|NCBI-Human-GeneID:325|NCBI-Mouse-GeneID:20219,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000325,,,,,,,,,,,,,TXPO:1000331,,,,,,,,,,,,,,,,,,,,,,APCS (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000335,SEC61B (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:10952|NCBI-Rat-GeneID:298068|NCBI-Mouse-GeneID:66212,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000010952,,,,,,,,,,,,,TXPO:1000335,,,,,,,,,,,,,,,,,,,,,,SEC61B (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000330,Rraga (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:68441|NCBI-Rat-GeneID:117044|NCBI-Human-GeneID:10670,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000010670,,,,,,,,,,,,,TXPO:1000330,,,,,,,,,,,,,,,,,,,,,,Rraga (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000333,SDF2L1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:64136|NCBI-Rat-GeneID:680945|NCBI-Human-GeneID:23753,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000023753,,,,,,,,,,,,,TXPO:1000333,,,,,,,,,,,,,,,,,,,,,,SDF2L1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000338,SLC10A1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:6554|NCBI-Mouse-GeneID:20493|NCBI-Rat-GeneID:24777,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000006554,,,,,,,,,,,,,TXPO:1000338,,,,,,,,,,,,,,,,,,,,,,SLC10A1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000336,SERPINA3 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:12,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000012,,,,,,,,,,,,,TXPO:1000336,,,,,,,,,,,,,,,,,,,,,,SERPINA3 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_39669,diflunisal,"2-(hydroxy)-5-(2,4-difluorophenyl)benzoic acid|5-(2,4-difluorophenyl)salicylic acid|Dolobid|2',4'-difluoro-4-hydroxy-3-biphenylcarboxylic acid|Diflunisal|2',4'-difluoro-4-hydroxy-[1,1'-biphenyl]-3-carboxylic acid","An organofluorine compound comprising salicylic acid having a 2,4-difluorophenyl group at the 5-position.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:22494-42-4|Reaxys:2654431|PMID:28166217|LINCS:LSM-2490|PMID:23416065|PMID:23144359|DrugBank:DB00861|Drug_Central:880,,"An organofluorine compound comprising salicylic acid having a 2,4-difluorophenyl group at the 5-position.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35475|http://purl.obolibrary.org/obo/CHEBI_35481,,,,,"Diflunisal|2',4'-difluoro-4-hydroxy-[1,1'-biphenyl]-3-carboxylic acid",,"2-(hydroxy)-5-(2,4-difluorophenyl)benzoic acid|5-(2,4-difluorophenyl)salicylic acid|Dolobid|2',4'-difluoro-4-hydroxy-3-biphenylcarboxylic acid",,,,,,,,,,,,,,,,,,,,,CHEBI:39669,,,,diflunisal,,CHEBI:39669,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000265,PI3-kinase,phosphatidylinositol 3-kinase|PI3K,,false,,,http://purl.obolibrary.org/obo/TXPO_0003223,,,,,,,,,,,,,,,,,,,,Catalysis of the reaction: 1-phosphatidyl-1D-myo-inositol + ATP = a 1-phosphatidyl-1D-myo-inositol 3-phosphate + ADP + 2 H(+).|GO:0016303,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,phosphatidylinositol 3-kinase|PI3K,,,,,IMR:0000265,,,,,,,,,,,,,,,,,,,,,,PI3-kinase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001085,importin alpha2,KPNA2|importin alpha P1|karyopherin alpha2|importin alpha1,,false,,,http://purl.obolibrary.org/obo/IMR_0100202,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,KPNA2|importin alpha P1|karyopherin alpha2|importin alpha1,,,,,IMR:0001085,,,,,,,,,,,,,,,,,,,,,,importin alpha2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100029,IP4,"Inositol 1,3,4,5-tetrakisphosphate|1D-myo-Inositol 1,3,4,5-tetrakisphosphate|D-myo-Inositol 1,3,4,5-tetrakisphosphate|Ins(1,3,4,5)P4",,false,,,http://purl.obolibrary.org/obo/IMR_0001385,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002401,,,,IMR:0200210,"Inositol 1,3,4,5-tetrakisphosphate|1D-myo-Inositol 1,3,4,5-tetrakisphosphate|D-myo-Inositol 1,3,4,5-tetrakisphosphate|Ins(1,3,4,5)P4",,,,,IMR:0100029,,,,,,,,,,,,,,,,,,,,,,IP4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0051318,G1 phase,,The cell cycle 'gap' phase which is the interval between the completion of DNA segregation (usually by mitosis or meiosis) and the beginning of DNA synthesis.,false,,,http://purl.obolibrary.org/obo/GO_0022403,,,,,,,,,,,,,,,,,,,,MeSH:D016193,,The cell cycle 'gap' phase which is the interval between the completion of DNA segregation (usually by mitosis or meiosis) and the beginning of DNA synthesis.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0051318,,,,,,,,,,,,,,,,,,,,,,G1 phase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0051319,G2 phase,,"The cell cycle 'gap' phase which is the interval between the completion of DNA synthesis and the beginning of DNA segregation (usually by mitosis or meiosis).|Note that this term should not be used for direct annotation. If you are trying to make an annotation to x phase, it is likely that the correct annotation is 'regulation of x/y phase transition' or to a process which occurs during the reported phase (i.e mitotic DNA replication for mitotic S-phase). To capture the phase when a specific location or process is observed, the phase term can be used in an annotation extension (PMID:24885854) applied to a cellular component term (with the relation exists_during) or a biological process term (with the relation happens_during).",false,,,http://purl.obolibrary.org/obo/GO_0022403,,,,,,,,,,,,,,,,,,,,Wikipedia:G2_phase|PMID:24885854|MeSH:D016195,,The cell cycle 'gap' phase which is the interval between the completion of DNA synthesis and the beginning of DNA segregation (usually by mitosis or meiosis).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0051319,,,,,,,,,,,,,,,,,,,,"Note that this term should not be used for direct annotation. If you are trying to make an annotation to x phase, it is likely that the correct annotation is 'regulation of x/y phase transition' or to a process which occurs during the reported phase (i.e mitotic DNA replication for mitotic S-phase). To capture the phase when a specific location or process is observed, the phase term can be used in an annotation extension (PMID:24885854) applied to a cellular component term (with the relation exists_during) or a biological process term (with the relation happens_during).",,G2 phase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0002048,lung,pulmo,"Respiration organ that develops as an oupocketing of the esophagus.|Snakes and limbless lizards typically possess only the right lung as a major respiratory organ; the left lung is greatly reduced, or even absent. Amphisbaenians, however, have the opposite arrangement, with a major left lung, and a reduced or absent right lung [WP]",false,,,http://purl.obolibrary.org/obo/UBERON_0000171,,,,,,,,,,,,,,,,,,,,http://linkedlifedata.com/resource/umls/id/C0024109|https://github.com/obophenotype/uberon/issues/701|http://en.wikipedia.org/wiki/Lung|http://purl.obolibrary.org/obo/NCIT_C12468|http://www.snomedbrowser.com/Codes/Details/181216001|AAO:0000275|EHDAA:2205|VHOG:0000310|EHDAA:1554|MESH:D008168|EV:0100042|OpenCyc:Mx4rvVjKy5wpEbGdrcN5Y29ycA|MA:0000415|EHDAA2:0001042|FMA:7195|MIAA:0000135|galen:Lung|BTO:0000763|MAT:0000135|AAO:0010567|CALOHA:TS-0568|GAID:345|UMLS:C0024109|XAO:0000119|EMAPA:16728|EFO:0000934,,Respiration organ that develops as an oupocketing of the esophagus.,,,,,,,,Either of two organs which allow gas exchange absorbing oxygen from inhaled air and releasing carbon dioxide with exhaled air.[AAO],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pulmo,,,"Lungs had already developed as paired ventral pockets from the intestine in the ancestor of Osteognathostomata. (...) In actinopterygian fishes, apart from Cladistia, the ventral intestinal pocket migrates dorsally and becomes the swim-bladder, a mainly hydrostatical organ (reference 1); Comparative transcriptome analyses indicate molecular homology of zebrafish swimbladder and Mammalian lung (reference 2).[well established][VHOG]",http://purl.obolibrary.org/obo/UBERON_0001004,UBERON:0002048,http://purl.obolibrary.org/obo/UBERON_0001004,,,,,,,,,,,,,,,,,,,"Snakes and limbless lizards typically possess only the right lung as a major respiratory organ; the left lung is greatly reduced, or even absent. Amphisbaenians, however, have the opposite arrangement, with a major left lung, and a reduced or absent right lung [WP]",,lung,,,,,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"respiration organ in all air-breathing animals, including most tetrapods, a few fish and a few snails. In mammals and the more complex life forms, the two lungs are located in the chest on either side of the heart. Their principal function is to transport oxygen from the atmosphere into the bloodstream, and to release carbon dioxide from the bloodstream into the atmosphere. This exchange of gases is accomplished in the mosaic of specialized cells that form millions of tiny, exceptionally thin-walled air sacs called alveoli. // Avian lungs do not have alveoli as mammalian lungs do, they have Faveolar lungs. They contain millions of tiny passages known as para-bronchi, connected at both ends by the dorsobronchi",
http://purl.obolibrary.org/obo/IMR_0100777,Wnt-8b,,,false,,,http://purl.obolibrary.org/obo/IMR_0000003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100777,,,,,,,,,,,,,,,,,,,,,,Wnt-8b,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_3766,clozapine,"clozapina|Clozapin|clozapine|clozapinum|8-chloro-11-(4-methylpiperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine|Clozapine","A benzodiazepine that is 5H-dibenzo[b,e][1,4]diazepine substituted by a chloro group at position 8 and a 4-methylpiperazin-1-yl group at position 11. It is a second generation antipsychotic used in the treatment of psychiatric disorders like  schizophrenia.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Beilstein:0764984|Drug_Central:722|PMID:18690109|DrugBank:DB00363|PMID:20825390|Reaxys:764984|PMID:24219174|CAS:5786-21-0|PMID:18766167,,"A benzodiazepine that is 5H-dibenzo[b,e][1,4]diazepine substituted by a chloro group at position 8 and a 4-methylpiperazin-1-yl group at position 11. It is a second generation antipsychotic used in the treatment of psychiatric disorders like  schizophrenia.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_37887|http://purl.obolibrary.org/obo/CHEBI_37956|http://purl.obolibrary.org/obo/CHEBI_48876|http://purl.obolibrary.org/obo/CHEBI_35703|http://purl.obolibrary.org/obo/CHEBI_76779|http://purl.obolibrary.org/obo/CHEBI_48561|http://purl.obolibrary.org/obo/CHEBI_48279|http://purl.obolibrary.org/obo/CHEBI_65259|http://purl.obolibrary.org/obo/CHEBI_65191|http://purl.obolibrary.org/obo/CHEBI_78298,,,,,"8-chloro-11-(4-methylpiperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine|Clozapine",,clozapina|Clozapin|clozapine|clozapinum,,,,,,,,,,,,,,,,,,,,,CHEBI:3766,,,,clozapine,,CHEBI:3766,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001528,RalB,,,false,,,http://purl.obolibrary.org/obo/IMR_0000293,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001528,,,,,,,,,,,,,,,,,,,,,,RalB,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000305,Plbd2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:71772|NCBI-Human-GeneID:196463|NCBI-Rat-GeneID:246120,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000196463,,,,,,,,,,,,,TXPO:1000305,,,,,,,,,,,,,,,,,,,,,,Plbd2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000301,Pias3 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:229615|NCBI-Rat-GeneID:83614|NCBI-Human-GeneID:10401,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000010401,,,,,,,,,,,,,TXPO:1000301,,,,,,,,,,,,,,,,,,,,,,Pias3 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000307,Pmm1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:5372|NCBI-Rat-GeneID:300089|NCBI-Mouse-GeneID:29858,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000005372,,,,,,,,,,,,,TXPO:1000307,,,,,,,,,,,,,,,,,,,,,,Pmm1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000300,Pex19 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:19298|NCBI-Rat-GeneID:289233|NCBI-Human-GeneID:5824,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000005824,,,,,,,,,,,,,TXPO:1000300,,,,,,,,,,,,,,,,,,,,,,Pex19 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000303,Pik3c2g (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:18705|NCBI-Human-GeneID:5288|NCBI-Rat-GeneID:116720,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000005288,,,,,,,,,,,,,TXPO:1000303,,,,,,,,,,,,,,,,,,,,,,Pik3c2g (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000306,Pln (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:18821|NCBI-Rat-GeneID:64672|NCBI-Human-GeneID:5350,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000005350,,,,,,,,,,,,,TXPO:1000306,,,,,,,,,,,,,,,,,,,,,,Pln (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000302,Pigz (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:303872|NCBI-Mouse-GeneID:239827|NCBI-Human-GeneID:80235,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000080235,,,,,,,,,,,,,TXPO:1000302,,,,,,,,,,,,,,,,,,,,,,Pigz (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000308,Pnrc2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:52830|NCBI-Rat-GeneID:100125373|NCBI-Human-GeneID:55629,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000055629,,,,,,,,,,,,,TXPO:1000308,,,,,,,,,,,,,,,,,,,,,,Pnrc2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000304,Pir (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:69656|NCBI-Rat-GeneID:363465|NCBI-Human-GeneID:8544,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000008544,,,,,,,,,,,,,TXPO:1000304,,,,,,,,,,,,,,,,,,,,,,Pir (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000309,Por (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:29441|NCBI-Human-GeneID:5447|NCBI-Mouse-GeneID:18984,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000005447,,,,,,,,,,,,,TXPO:1000309,,,,,,,,,,,,,,,,,,,,,,Por (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000624,Integrin alpha-2,,,false,,,http://purl.obolibrary.org/obo/IMR_0000173,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000624,,,,,,,,,,,,,,,,,,,,,,Integrin alpha-2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004577,beta-catenin signaling (primitive) [hepatocarcinogenesis],,"beta-catenin signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by beta-catenin.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004871,,,,,,,,,,,,,,,,,,,,PMID:29786110|PMID:28493839|PMID:29679563|PMID:26017875|PMID:30008815|PMID:31781608,,"beta-catenin signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by beta-catenin.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004873|http://purl.obolibrary.org/obo/TXPO_0004872,,,,,,http://purl.obolibrary.org/obo/TXPO_0004538|http://purl.obolibrary.org/obo/TXPO_0004453|http://purl.obolibrary.org/obo/TXPO_0004874|http://purl.obolibrary.org/obo/TXPO_0004422|http://purl.obolibrary.org/obo/TXPO_0004818|http://purl.obolibrary.org/obo/TXPO_0004695,,,,,,,,,,,TXPO:0004577,,,,,,,,,,,,,,,,,,,,,,beta-catenin signaling (primitive) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004579,cisplatin resistance [hepatocarcinogenesis],,"cisplatin resistance (process) is a subtype of decreasing sensitivity: A process that changes the sensitivity to cisplatin to be lower.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004957,,,,,,,,,,,,,,,,,,,,PMID:28240761,,"cisplatin resistance (process) is a subtype of decreasing sensitivity: A process that changes the sensitivity to cisplatin to be lower.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004518,,,,,,,,,,,TXPO:0004579,,,,,,,,,,,,,,,,,,,,,,cisplatin resistance [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004578,GRP78 (canonical)[hepatocarcinogenesis],HSPA5 [ER stress]|HEL-S-89n [ER stress]|BIP [ER stress]|Heat Shock Protein Family A (Hsp70) Member 5 [ER stress]|MIF2 [ER stress],,false,,,http://purl.obolibrary.org/obo/TXPO_0001002|http://purl.obolibrary.org/obo/TXPO_0000871,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:3309|NCBI-Mouse-GeneID:14828|NCBI-Rat-GeneID:25617|PMID:28240761,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003997,,,,,HSPA5 [ER stress]|HEL-S-89n [ER stress]|BIP [ER stress]|Heat Shock Protein Family A (Hsp70) Member 5 [ER stress]|MIF2 [ER stress],,,,,TXPO:0004578,,,,,,,,,,,,,,,,,,,,,,GRP78 (canonical)[hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004571,GDF15(rat) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000164|http://purl.obolibrary.org/obo/TXPO_0005070,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:29455|PMID:29270806,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004571,,,,,,,,,,,,,,,,,,,,,,GDF15(rat) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004570,Increasing GDF15 level [hepatocarcinogenesis],,"Increasing GDF15 level is a subtype of increasing quantity: A process that changes the amount of GDF15 level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004569,,,,,,,,,,,,,,,,,,,,PMID:29270806,,"Increasing GDF15 level is a subtype of increasing quantity: A process that changes the amount of GDF15 level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004571,,http://purl.obolibrary.org/obo/TXPO_0004448,,,,,,http://purl.obolibrary.org/obo/TXPO_0004396,,,,,,,,,,,TXPO:0004570,,,,,,,,,,,,,,,,,,,,,,Increasing GDF15 level [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004572,negative regulation of gap-junctional intercellular communication,negative regulation of GJIC,"Negative regulation of gap-junctional intercellular communication is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of gap-junctional intercellular communication.",false,,,http://purl.obolibrary.org/obo/TXPO_0000369,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of gap-junctional intercellular communication is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of gap-junctional intercellular communication.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,negative regulation of GJIC,,,,,TXPO:0004572,,,,,,,,,,,,,,,,,,,,,,negative regulation of gap-junctional intercellular communication,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004575,GSK3beta signal transduction pathway,,A series of molecular signals mediated by GSK3beta (glycogen synthase kinase 3 beta).,false,,,http://purl.obolibrary.org/obo/TXPO_0000609,,,,,,,,,,,,,,,,,,,,,,A series of molecular signals mediated by GSK3beta (glycogen synthase kinase 3 beta).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004575,,,,,,,,,,,,,,,,,,,,,,GSK3beta signal transduction pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004576,GSK3beta signal (primitive),,GSK3beta signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by GSK3beta.,false,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,,,GSK3beta signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by GSK3beta.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004575,,,,,,,,,,,,,,,,TXPO:0004576,,,,,,,,,,,,,,,,,,,,,,GSK3beta signal (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004573,Decreasing GPHN level,,Decreasing GPHN level is a subtype of decreasing quantity: A process that changes the amount of GPHN level to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000396,,,,,,,,,,,,,,,,,,,,,,Decreasing GPHN level is a subtype of decreasing quantity: A process that changes the amount of GPHN level to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_1000517,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004573,,,,,,,,,,,,,,,,,,,,,,Decreasing GPHN level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004574,Decreasing GPHN level [hepatocarcinogenesis],,"Decreasing GPHN level is a subtype of decreasing quantity: A process that changes the amount of GPHN level to be lower.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004573,,,,,,,,,,,,,,,,,,,,PMID:31239782,,"Decreasing GPHN level is a subtype of decreasing quantity: A process that changes the amount of GPHN level to be lower.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004188,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004419,,,,,,,,,,,TXPO:0004574,,,,,,,,,,,,,,,,,,,,,,Decreasing GPHN level [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000520,arrestin,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003691,,,,,,,,,,IMR:0000520,,,,,,,,,,,,,,,,,,,,,,arrestin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000407,GRP78 activation by MLX,,GRP78 activation by MLX is a subtype of molecular activation: A process that changes the activity of the GRP78/ HSPA5 (Heat Shock Protein Family A (Hsp70) Member 5) to be higher by MLX.,false,,,http://purl.obolibrary.org/obo/TXPO_0000023,,,,,,,,,,,,,,,,,,,,,,GRP78 activation by MLX is a subtype of molecular activation: A process that changes the activity of the GRP78/ HSPA5 (Heat Shock Protein Family A (Hsp70) Member 5) to be higher by MLX.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000405,,,,,,,,,,,TXPO:0000407,,,,,,,,,,,,,,,,,,,,,,GRP78 activation by MLX,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000403,NRF2 activation by PERK [ER stress (mild)],,"NRF2 activation by PERK is a subtype of NRF2 activation: A process that changes the activity of NRF2 (Nuclear Factor, Erythroid 2 Like 2) to be higher by PERK.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.|Mild ER stress activates Nrf2 and the antiapoptotic factor BI-1.
Activation of Nrf2 through its phosphorylation by PERK,and BI-1 protect the endoplasmic reticulum from further damage by inhibiting the production of ROS by CYP2E1(Lee et al., 2007; Kim et al., 2009).",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/TXPO_0001370,,,,,,,,,,,,,,,,,,,,,,"NRF2 activation by PERK is a subtype of NRF2 activation: A process that changes the activity of NRF2 (Nuclear Factor, Erythroid 2 Like 2) to be higher by PERK.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002746|http://purl.obolibrary.org/obo/TXPO_0000450,,,,,,,,,,,TXPO:0000403,,,,,,,,,,,,,,,,,,,,"Mild ER stress activates Nrf2 and the antiapoptotic factor BI-1.
Activation of Nrf2 through its phosphorylation by PERK,and BI-1 protect the endoplasmic reticulum from further damage by inhibiting the production of ROS by CYP2E1(Lee et al., 2007; Kim et al., 2009).",,NRF2 activation by PERK [ER stress (mild)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000402,PERK activation [ER stress],,"PERK activation is a subtype of Molecular activation: A process that changes the activity of PERK to be higher.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/TXPO_0000586,,,,,,,,,,,,,,,,,,,,,,"PERK activation is a subtype of Molecular activation: A process that changes the activity of PERK to be higher.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000713|http://purl.obolibrary.org/obo/TXPO_0000674,,,,,,,,,,,,,,,,,,,,,TXPO:0000402,,,,,,,,,,,,,,,,,,,,,,PERK activation [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000408,PLA2 activation,,PLA2 activation is a subtype of molecular activation: A process that changes the activity of the member of the phospholipase A2 family (PLA2) to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000023,,,,,,,,,,,,,,,,,,,,,,PLA2 activation is a subtype of molecular activation: A process that changes the activity of the member of the phospholipase A2 family (PLA2) to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000408,,,,,,,,,,,,,,,,,,,,,,PLA2 activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000405,AMPK activation,,AMPK activation is a subtype of molecular activation: A process that  changes the activity of the AMPK (AMP-activated protein kinase) to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000023,,,,,,,,,,,,,,,,,,,,,,AMPK activation is a subtype of molecular activation: A process that  changes the activity of the AMPK (AMP-activated protein kinase) to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000405,,,,,,,,,,,,,,,,,,,,,,AMPK activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000401,activating,inceasing activity,Activating is a subtype of changing activity: A process that changes the activity of the object to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000020,,,,,,,,,,,,,,,,,,,,,,Activating is a subtype of changing activity: A process that changes the activity of the object to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,inceasing activity,,,,,TXPO:0000401,,,,,,,,,,,,,,,,,,,,,,activating,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000400,uncoupling dependent chemical entity,,"Uncoupling dependent chemical entity  is a subtype of toxic course dependent chemical entity.
This entity can participate in the course of uncoupling of mitochondrial damage.|under construction",false,,,http://purl.obolibrary.org/obo/TXPO_0002012,,,,,,,,,,,,,,,,,,,,,,"Uncoupling dependent chemical entity  is a subtype of toxic course dependent chemical entity.
This entity can participate in the course of uncoupling of mitochondrial damage.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000400,,,,,,,,,,,,,,,,,,,,under construction,,uncoupling dependent chemical entity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000409,protease activation,,Protease activation is a subtype of molecular activation: A process that changes the activity of the molecule with a protease role to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000023,,,,,,,,,,,,,,,,,,,,,,Protease activation is a subtype of molecular activation: A process that changes the activity of the molecule with a protease role to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000409,,,,,,,,,,,,,,,,,,,,,,protease activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000404,Cyp7a1 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0001558,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000404,,,,,,,,,,,,,,,,,,,,,,Cyp7a1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000406,positive regulation of autophagy by AMPK,,"Positive regulation of autophagy by AMPK is a subtype of positive regulation of autophagy: A process that that activates or increases the frequency, rate or extent of autophagy by AMPK.",false,,,http://purl.obolibrary.org/obo/GO_0010508,,,,,,,,,,,,,,,,,,,,PMID:18439900,,"Positive regulation of autophagy by AMPK is a subtype of positive regulation of autophagy: A process that that activates or increases the frequency, rate or extent of autophagy by AMPK.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000406,,,,,,,,,,,,,,,,,,,,,,positive regulation of autophagy by AMPK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001476,DOCK8,,,false,,,http://purl.obolibrary.org/obo/IMR_0001469,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001476,,,,,,,,,,,,,,,,,,,,,,DOCK8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000123,IL-18 receptor,Interleukin-18 receptor|IL-1Rrp|IL1 receptor-related protein,,false,,,http://purl.obolibrary.org/obo/IMR_0000096,,,,,,,,,,,,,,,,,,,,GO:0042008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Interleukin-18 receptor|IL-1Rrp|IL1 receptor-related protein,,,,,IMR:0000123,,,,,,,,,,,,,,,,,,,,,,IL-18 receptor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000088,Estrogen receptor,,,false,,,http://purl.obolibrary.org/obo/TXPO_0001509,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003224,,,,,,,,,,IMR:0000088,,,,,,,,,,,,,,,,,,,,,,Estrogen receptor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0042089,cytokine biosynthetic process,cytokine formation|cytokine anabolism|cytokine biosynthesis,"The chemical reactions and pathways resulting in the formation of cytokines, any of a group of proteins that function to control the survival, growth and differentiation of tissues and cells, and which have autocrine and paracrine activity.",false,,,http://purl.obolibrary.org/obo/GO_0009058,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways resulting in the formation of cytokines, any of a group of proteins that function to control the survival, growth and differentiation of tissues and cells, and which have autocrine and paracrine activity.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,cytokine formation|cytokine anabolism|cytokine biosynthesis,,,,,GO:0042089,,,,,,,,,,,,,,,,,,,,,,cytokine biosynthetic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000054788,DNAJB12,,Other designations: dnaJ homolog subfamily B member 12,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,DJ10,,,,,,,,,,,,10,,,,,,HPRD:07086|Ensembl:ENSG00000148719|HGNC:14891|MIM:608376|Vega:OTTHUMG00000018436,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"DnaJ (Hsp40) homolog, subfamily B, member 12",,,10q22.1,,,,,,,,,,,,,,,,GO_0016021 (EC: IEA),,,,,,,,,PMID:8125298; 11147971; 12477932; 14702039; 15489334; 17207965; 17342744; 18029348; 18781797; 21139048; 21148293; 21150129; 21150319; 21890473; 21906983; 21963094; 21987572; 22939629; 23000965; 23956138; 24250222,,,,,,,,,,,,,,,OGG:3000054788,,,,,,,"DnaJ (Hsp40) homolog, subfamily B, member 12",,,,,,,,,,,,,Other designations: dnaJ homolog subfamily B member 12,,DNAJB12,,,,,,,,,,,,,,,,,,,,,,,54788,,,,,,,,9606,,,,,,,,,,,,,,,,,,,DNAJB12,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0011423,NDKM,,,false,,,http://purl.obolibrary.org/obo/IMR_0010012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0011423,,,,,,,,,,,,,,,,,,,,,,NDKM,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_5855,ibuprofen,2-[4-(2-methylpropyl)phenyl]propanoic acid,A monocarboxylic acid that is propionic acid in which one of the hydrogens at position 2 is substituted by a 4-(2-methylpropyl)phenyl group.,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:15687-27-1|DrugBank:DB01050,,A monocarboxylic acid that is propionic acid in which one of the hydrogens at position 2 is substituted by a 4-(2-methylpropyl)phenyl group.,,,,,,,,,,,,C13H18O2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35475,,,,,2-[4-(2-methylpropyl)phenyl]propanoic acid,,,,,CHEBI:5855,,,,,,,,,,,,,,,,,,,,,,ibuprofen,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CC(C)Cc1ccc(cc1)C(C)C(O)=O,,,,,
http://purl.obolibrary.org/obo/IMR_0001141,cerebroglycan,HSPG-M13,,false,,,http://purl.obolibrary.org/obo/IMR_0001139,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,HSPG-M13,,,,,IMR:0001141,,,,,,,,,,,,,,,,,,,,,,cerebroglycan,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004777,Increasing PROM1 level,,Increasing PROM1 level is a subtype of increasing quantity: A process that changes the amount of PROM1 level to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing PROM1 level is a subtype of increasing quantity: A process that changes the amount of PROM1 level to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004778,,,,,,,,,,,,,,,,,,,TXPO:0004777,,,,,,,,,,,,,,,,,,,,,,Increasing PROM1 level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004778,PROM1 (mol),CD133,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:19126|NCBI-Human-GeneID:8842|NCBI-Rat-GeneID:60357,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CD133,,,,,TXPO:0004778,,,,,,,,,,,,,,,,,,,,,,PROM1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004774,PROC (rat)＠肝発癌 [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004772|http://purl.obolibrary.org/obo/TXPO_0005070,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:25268|PMID:30690589,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004774,,,,,,,,,,,,,,,,,,,,,,PROC (rat)＠肝発癌 [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004770,PPARA - activation state (mouse) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0005126|http://purl.obolibrary.org/obo/TXPO_0005072,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:19013|PMID:18188449,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0002354,,,,,,,,,,,,,,TXPO:0004770,,,,,,,,,,,,,,,,,,,,,,PPARA - activation state (mouse) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004772,PROC (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:19123|NCBI-Rat-GeneID:25268|NCBI-Human-GeneID:5624,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004772,,,,,,,,,,,,,,,,,,,,,,PROC (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004771,Decreasing PROC level,,Decreasing PROC level is a subtype of decreasing quantity: A process that changes the amount of PROC level to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000396,,,,,,,,,,,,,,,,,,,,,,Decreasing PROC level is a subtype of decreasing quantity: A process that changes the amount of PROC level to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004772,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004771,,,,,,,,,,,,,,,,,,,,,,Decreasing PROC level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004775,PROC gene promoter methylation,,The covalent transfer of a methyl group to PROC gene promoter.,false,,,http://purl.obolibrary.org/obo/GO_0006306,,,,,,,,,,,,,,,,,,,,,,The covalent transfer of a methyl group to PROC gene promoter.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004775,,,,,,,,,,,,,,,,,,,,,,PROC gene promoter methylation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004773,Decreasing PROC level [hepatocarcinogenesis],,"Decreasing PROC level is a subtype of decreasing quantity: A process that changes the amount of PROC level to be lower.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004771,,,,,,,,,,,,,,,,,,,,PMID:30690589,,"Decreasing PROC level is a subtype of decreasing quantity: A process that changes the amount of PROC level to be lower.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004774,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004427|http://purl.obolibrary.org/obo/TXPO_0004426,,,,,,,,,,,TXPO:0004773,,,,,,,,,,,,,,,,,,,,,,Decreasing PROC level [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004776,PROC gene promoter methylation [hepatocarcinogenesis],,"The covalent transfer of a methyl group to PROC gene promoter.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004775,,,,,,,,,,,,,,,,,,,,PMID:30690589,,"The covalent transfer of a methyl group to PROC gene promoter.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004774,,,,,,http://purl.obolibrary.org/obo/TXPO_0004454,,,,,,http://purl.obolibrary.org/obo/TXPO_0004773,,,,,,,,,,,TXPO:0004776,,,,,,,,,,,,,,,,,,,,,,PROC gene promoter methylation [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004779,Increasing PROM1 level [hepatocarcinogenesis],,"Increasing PROM1 level is a subtype of increasing quantity: A process that changes the amount of PROM1 level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004777,,,,,,,,,,,,,,,,,,,,PMID:28584306,,"Increasing PROM1 level is a subtype of increasing quantity: A process that changes the amount of PROM1 level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004780,,,,,,,,,,,,,,,,,,,TXPO:0004779,,,,,,,,,,,,,,,,,,,,,,Increasing PROM1 level [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000091543,RSAD2,,"Other designations: cytomegalovirus-induced gene 5 protein|radical S-adenosyl methionine domain-containing protein 2|viperin|virus inhibitory protein, endoplasmic reticulum-associated, interferon-inducible",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,cig33|cig5|2510004L01Rik|vig1,,,,,,,,,,,,2,,,,,,HPRD:07423|MIM:607810|HGNC:30908|Vega:OTTHUMG00000090352|Ensembl:ENSG00000134321,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,radical S-adenosyl methionine domain containing 2,,,2p25.2,,,,,,,,,,,,,,,,"GO_0001503 (EC: IEA); GO_0003824 (EC: IEA); GO_0005515 (EC: IPI); GO_0005739 (EC: IDA); GO_0005741 (EC: IDA); GO_0005743 (EC: IDA); GO_0005783 (EC: IDA, PMID: 11752458); GO_0005789 (EC: IDA, PMID: 19074433); GO_0005794 (EC: IEA); GO_0005811 (EC: ISS); GO_0009615 (EC: IDA); GO_0016032 (EC: IEA); GO_0030278 (EC: IEA); GO_0034157 (EC: ISS); GO_0034165 (EC: ISS); GO_0035710 (EC: ISS); GO_0043367 (EC: ISS); GO_0043621 (EC: IDA, PMID: 19074433); GO_0045071 (EC: IDA); GO_0045087 (EC: IEA); GO_0046872 (EC: IEA); GO_0050709 (EC: IDA, PMID: 19074433); GO_0051539 (EC: IDA); GO_0051607 (EC: IDA, PMID: 16108059); GO_2000553 (EC: ISS)",,,,,,,,,PMID: 9391139; 11752458; 12477932; 15890971; 16108059; 16849320; 16982913; 17626075; 18005724; 18077728; 18768981; 19074433; 19920176; 20026307; 20176015; 20534863; 20628624; 21053045; 21527675; 21957124; 22045669; 22182524; 22363738; 22377585; 22647704; 22734835; 22896602; 23018837; 23160199; 23509962; 23638199; 23935494,,,,,,,,,,,,,,,OGG:3000091543,,20140408,protein-coding,,,,radical S-adenosyl methionine domain containing 2,,,,,,,,,,,,,"Other designations: cytomegalovirus-induced gene 5 protein|radical S-adenosyl methionine domain-containing protein 2|viperin|virus inhibitory protein, endoplasmic reticulum-associated, interferon-inducible",,RSAD2,,,,,,,,,,,,,,,,,,,,,,,91543,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,RSAD2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_36043,antimicrobial drug,antimicrobial drugs,A drug used to treat or prevent microbial infections.,false,,,http://purl.obolibrary.org/obo/CHEBI_35441|http://purl.obolibrary.org/obo/CHEBI_33281,,,,,,,,,,,,,,,,,,,,,,A drug used to treat or prevent microbial infections.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,antimicrobial drugs,,,,,,,,,,,,,,,,,,,,,CHEBI:36043,,,,antimicrobial drug,,CHEBI:36043,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000003055,HCK,,Other designations: hematopoietic cell kinase|p59-HCK/p60-HCK|tyrosine-protein kinase HCK,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,JTK9|p59Hck|p61Hck,,,,,,,,,,,,20,,,,,,HGNC:4840|Vega:OTTHUMG00000032204|Ensembl:ENSG00000101336|HPRD:00796|MIM:142370,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,hemopoietic cell kinase,,,20q11-q12,,,,,,,,,,,,,,,,"GO_0002522 (EC: TAS, PMID: 18538446); GO_0002758 (EC: TAS, PMID: 18538446); GO_0004713 (EC: IMP, PMID: 10092522); GO_0004715 (EC: IEA); GO_0005515 (EC: IPI, PMID: 11278465); GO_0005524 (EC: IEA); GO_0005634 (EC: IEA); GO_0005764 (EC: IDA, PMID: 15998323); GO_0005794 (EC: IEA); GO_0005829 (EC: TAS); GO_0005884 (EC: IDA, Qualifier: colocalizes_with, PMID: 15998323); GO_0005901 (EC: IDA, PMID: 7791757); GO_0005925 (EC: IMP, PMID: 11904303); GO_0006468 (EC: TAS, PMID: 3496523); GO_0006954 (EC: IEA); GO_0007155 (EC: TAS, PMID: 18538446); GO_0007229 (EC: TAS, PMID: 18538446); GO_0007498 (EC: TAS, PMID: 3453117); GO_0008284 (EC: IMP, PMID: 10092522); GO_0008360 (EC: IMP, PMID: 10092522); GO_0016032 (EC: TAS); GO_0018108 (EC: IMP, PMID: 10092522); GO_0019221 (EC: TAS, PMID: 18538446); GO_0030133 (EC: IEA); GO_0030838 (EC: TAS, PMID: 18538446); GO_0031234 (EC: IMP, PMID: 11904303); GO_0031663 (EC: TAS, PMID: 18538446); GO_0038096 (EC: TAS); GO_0042995 (EC: IEA); GO_0043066 (EC: IMP, PMID: 17535448); GO_0043299 (EC: TAS, PMID: 18538446); GO_0045087 (EC: TAS); GO_0045728 (EC: TAS, PMID: 18538446); GO_0046777 (EC: IMP, PMID: 10092522); GO_0050690 (EC: TAS); GO_0050727 (EC: TAS, PMID: 18538446); GO_0050764 (EC: IMP, PMID: 11904303); GO_0051090 (EC: IMP, PMID: 17535448); GO_0060333 (EC: TAS, PMID: 18538446); GO_0071801 (EC: IDA, PMID: 15998323); GO_2000251 (EC: IDA, PMID: 15998323); GO_2000251 (EC: IMP, PMID: 11904303)",,,,,,,,,PMID: 1373873; 1572549; 1689310; 1720539; 1875927; 3453117; 3496523; 7588629; 7682059; 7782336; 7791757; 7859737; 8058772; 8064233; 8125298; 8599760; 8626374; 8657103; 8885868; 8955135; 8995358; 9020138; 9024658; 9109402; 9178913; 9195918; 9218412; 9268059; 9400828; 9407116; 9571048; 9656992; 9705913; 9742969; 9778343; 9790917; 9837776; 9890970; 10068673; 10092522; 10318861; 10364375; 10388555; 10428862; 10527858; 10544125; 10547288; 10574946; 10586033; 10642173; 10749872; 10799548; 10849448; 10858437; 10918587; 10934191; 10967098; 10973280; 11071635; 11097855; 11239464; 11278465; 11294897; 11328823; 11350938; 11448168; 11463741; 11500821; 11533201; 11689697; 11741929; 11780052; 11896602; 11904303; 11940572; 11976726; 11994282; 12029088; 12033791; 12076760; 12138090; 12181444; 12235133; 12244095; 12477932; 12496276; 12522270; 12538589; 12576423; 12592324; 12600646; 12626508; 12734187; 12734410; 12748290; 12769846; 12900520; 14506255; 14551197; 14551213; 14702039; 14969582; 14993658; 15010462; 15078178; 15144186; 15263807; 15489334; 15491611; 15595833; 15626739; 15638726; 15707590; 15784897; 15952790; 15998323; 16169070; 16210316; 16271895; 16273093; 16344560; 16374509; 16454711; 16849330; 16964398; 17024369; 17081983; 17141806; 17535448; 17668209; 17868192; 17893228; 18005690; 18042718; 18067320; 18538446; 18794796; 19149577; 19211505; 19234535; 19585521; 19807124; 19807924; 20056178; 20181660; 20488787; 20670214; 20702582; 20798061; 20810664; 20936779; 21309750; 21365684; 21477083; 21567396; 21625496; 21696586; 21738584; 21763503; 21832049; 21878628; 21886773; 21890473; 21988832; 21993313; 22021612; 22110726; 22185326; 22345475; 22364282; 22393415; 22537596; 22623531; 22641034; 22651890; 22745667; 22939624; 22974441; 23128233; 23439650; 23896410; 24051604,,,,,,,,,,,,,,,OGG:3000003055,,,,,,,hemopoietic cell kinase,,,,,,,,,,,,,Other designations: hematopoietic cell kinase|p59-HCK/p60-HCK|tyrosine-protein kinase HCK,,HCK,,,,,,,,,,,,,,,,,,,,,,,3055,RP5-836N17.3,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,HCK,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0000370,negative regulation of cell cycle G2/M phase transition,,"Negative regulation of cell cycle G2/M phase transition is a subtype of negative regulation of cell cycle:  Any process that stops, prevents or reduces the frequency, rate or extent of cell cycle G2/M phase transition.",false,,,http://purl.obolibrary.org/obo/TXPO_0000548,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of cell cycle G2/M phase transition is a subtype of negative regulation of cell cycle:  Any process that stops, prevents or reduces the frequency, rate or extent of cell cycle G2/M phase transition.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000370,,,,,,,,,,,,,,,,,,,,,,negative regulation of cell cycle G2/M phase transition,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000379,receiving,,Receiving is a subtype of functioning process: A process that that gets an object as input.,false,,,http://purl.obolibrary.org/obo/TXPO_0000378,,,,,,,,,,,,,,,,,,,,,,Receiving is a subtype of functioning process: A process that that gets an object as input.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/BFO_0000002,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000379,,,,,,,,,,,,,,,,,,,,,,receiving,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000376,cell survival [ER stress],,"Cell survial is a subtype of keeong quantity: A process that keeps the viability of a cell.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/NCIT_C16407,,,,,,,,,,,,,,,,,,,,cell survival [ER stress],,"Cell survial is a subtype of keeong quantity: A process that keeps the viability of a cell.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000798|http://purl.obolibrary.org/obo/TXPO_0000768,,,,,,,,,,,,,,,,,TXPO:0000376,,,,,,,,,,,,,,,,,,,,,,cell survival [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000371,negative regulation of apoptotic process [ER stress (mild)],,"Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptotic process.
This entity is a specific course-dependent process. This process can constitute the course of ER stress (mild).",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/GO_0043066,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptotic process.
This entity is a specific course-dependent process. This process can constitute the course of ER stress (mild).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000087|http://purl.obolibrary.org/obo/TXPO_0003471,,,,,,,,,,,,,,,,,TXPO:0000371,,,,,,,,,,,,,,,,,,,,,,negative regulation of apoptotic process [ER stress (mild)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000378,functioning process,,Functioning process is a subtype of function-related process: A process that executes and manifests function.,false,,,http://purl.obolibrary.org/obo/TXPO_0000145,,,,,,,,,,,,,,,,,,,,,,Functioning process is a subtype of function-related process: A process that executes and manifests function.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000378,,,,,,,,,,,,,,,,,,,,,,functioning process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000373,drug metabolism phase I by Cytochrome P450 [Ground glass appearance],,"Drug metabolism phase I by Cytochrome P450 is a subtype of drug metabolism phase I: A process that is biotransformed by cytochrome P450 (CYP) superfamily .
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001559|http://purl.obolibrary.org/obo/TXPO_0001728,,,,,,,,,,,,,,,,,,,,,,"Drug metabolism phase I by Cytochrome P450 is a subtype of drug metabolism phase I: A process that is biotransformed by cytochrome P450 (CYP) superfamily .
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001607,,,,,,,,,,,,,,,,,,TXPO:0000373,,,,,,,,,,,,,,,,,,,,,,drug metabolism phase I by Cytochrome P450 [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005790,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000377,normal cell survival [Cell death],,"Cell survial is a subtype of keeong quantity: A process that keeps the viability of a cell.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0001727|http://purl.obolibrary.org/obo/NCIT_C16407,,,,,,,,,,,,,,,,,,,,,,"Cell survial is a subtype of keeong quantity: A process that keeps the viability of a cell.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000377,,,,,,,,,,,,,,,,,,,,,,normal cell survival [Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000375,Gene expression by transcriptional regulator,,The process in which a gene's sequence is converted into a mature gene product or products (proteins or RNA) by transcription factor,false,,,http://purl.obolibrary.org/obo/GO_0010467,,,,,,,,,,,,,,,,,,,,,,The process in which a gene's sequence is converted into a mature gene product or products (proteins or RNA) by transcription factor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000375,,,,,,,,,,,,,,,,,,,,,,Gene expression by transcriptional regulator,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000374,regulation of cell cycle [Cell death],,"Any process that modulates the rate or extent of progression through the cell cycle.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0001727|http://purl.obolibrary.org/obo/GO_0051726,,,,,,,,,,,,,,,,,,,,,,"Any process that modulates the rate or extent of progression through the cell cycle.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002137,,,,,,,,,,,TXPO:0000374,,,,,,,,,,,,,,,,,,,,,,regulation of cell cycle [Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000372,EVOL6,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000372,,,,,,,,,,,,,,,,,,,,,,EVOL6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_77746,human metabolite,Homo sapiens metabolites|H. sapiens metabolite|H. sapiens metabolites|Homo sapiens metabolite,Any mammalian metabolite  produced during a metabolic reaction in humans (Homo sapiens).,false,,,http://purl.obolibrary.org/obo/CHEBI_75768,,,,,,,,,,,,,,,,,,,,,,Any mammalian metabolite  produced during a metabolic reaction in humans (Homo sapiens).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Homo sapiens metabolites|H. sapiens metabolite|H. sapiens metabolites|Homo sapiens metabolite,,,,,,,,,,,,,,,,,,,,,CHEBI:77746,,,,human metabolite,,CHEBI:77746,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0002167,right lung,,"Lung which consists of the right upper lobe, middle lobe and right lower lobe.[FMA]|https://github.com/obophenotype/uberon/wiki/Modeling-paired-structures-Design-Pattern",false,,,http://purl.obolibrary.org/obo/UBERON_0002048,,,,,,,,,,,,,,,,,,,,http://www.snomedbrowser.com/Codes/Details/361967000|http://en.wikipedia.org/wiki/Right_lung|http://purl.obolibrary.org/obo/NCIT_C33483|http://linkedlifedata.com/resource/umls/id/C0225706|MA:0000426|OpenCyc:Mx8Ngh4rvgHsHZwpEbGdrcN5Y29ycB4rvVjKy5wpEbGdrcN5Y29ycA|FMA:7309|EHDAA:4969|VHOG:0000301|UMLS:C0225706|EHDAA2:0001730|EMAPA:17661,,"Lung which consists of the right upper lobe, middle lobe and right lower lobe.[FMA]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Lungs had already developed as paired ventral pockets from the intestine in the ancestor of Osteognathostomata.[well established][VHOG],http://purl.obolibrary.org/obo/UBERON_0000170,UBERON:0002167,http://purl.obolibrary.org/obo/UBERON_0000170,,,,,,,,,,,,,,,,,,,https://github.com/obophenotype/uberon/wiki/Modeling-paired-structures-Design-Pattern,,right lung,,,,,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0002168,left lung,,Lung which consists of the left upper lobe and left lower lobe.[FMA]|https://github.com/obophenotype/uberon/wiki/Modeling-paired-structures-Design-Pattern,false,,,http://purl.obolibrary.org/obo/UBERON_0002048,,,,,,,,,,,,,,,,,,,,http://linkedlifedata.com/resource/umls/id/C0225730|http://www.snomedbrowser.com/Codes/Details/361982005|http://en.wikipedia.org/wiki/Left_lung|http://purl.obolibrary.org/obo/NCIT_C32967|OpenCyc:Mx8Ngh4rvgIFoJwpEbGdrcN5Y29ycB4rvVjKy5wpEbGdrcN5Y29ycA|VHOG:0000618|EHDAA2:0000943|MA:0000425|EHDAA:4947|UMLS:C0225730|FMA:7310|EMAPA:17653,,Lung which consists of the left upper lobe and left lower lobe.[FMA],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Lungs had already developed as paired ventral pockets from the intestine in the ancestor of Osteognathostomata.[well established][VHOG],http://purl.obolibrary.org/obo/UBERON_0000170,UBERON:0002168,http://purl.obolibrary.org/obo/UBERON_0000170,,,,,,,,,,,,,,,,,,,https://github.com/obophenotype/uberon/wiki/Modeling-paired-structures-Design-Pattern,,left lung,,,,,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_48001,protein synthesis inhibitor,protein synthesis antagonist|protein synthesis inhibitors|protein synthesis antagonists,"A compound, usually an anti-bacterial agent or a toxin, which inhibits the synthesis of a protein.",false,,,http://purl.obolibrary.org/obo/CHEBI_76932,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000382,,,,,,,,,,,,,,,"A compound, usually an anti-bacterial agent or a toxin, which inhibits the synthesis of a protein.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,protein synthesis antagonist|protein synthesis inhibitors|protein synthesis antagonists,,,,,,,,,,,,,,,,,,,,,CHEBI:48001,,,,protein synthesis inhibitor,,CHEBI:48001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001671,RGS13,,,false,,,http://purl.obolibrary.org/obo/IMR_0000431,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001671,,,,,,,,,,,,,,,,,,,,,,RGS13,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000235,MAP3K13 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:71751|NCBI-Human-GeneID:9175|NCBI-Rat-GeneID:303823,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000009175,,,,,,,,,,,,,TXPO:1000235,,,,,,,,,,,,,,,,,,,,,,MAP3K13 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000230,Lmnb1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:16906|NCBI-Rat-GeneID:116685|NCBI-Human-GeneID:4001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000004001,,,,,,,,,,,,,TXPO:1000230,,,,,,,,,,,,,,,,,,,,,,Lmnb1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000236,MED23 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:9439|NCBI-Mouse-GeneID:70208|NCBI-Rat-GeneID:309565,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000009439,,,,,,,,,,,,,TXPO:1000236,,,,,,,,,,,,,,,,,,,,,,MED23 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000238,MMP2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:4313|NCBI-Mouse-GeneID:17390|NCBI-Rat-GeneID:81686,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000004313,,,,,,,,,,,,,TXPO:1000238,,,,,,,,,,,,,,,,,,,,,,MMP2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000231,Lpgat1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:9926|NCBI-Mouse-GeneID:226856|NCBI-Rat-GeneID:679692,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000009926,,,,,,,,,,,,,TXPO:1000231,,,,,,,,,,,,,,,,,,,,,,Lpgat1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000239,MMP9 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:4318|NCBI-Mouse-GeneID:17395|NCBI-Rat-GeneID:81687,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000004318,,,,,,,,,,,,,TXPO:1000239,,,,,,,,,,,,,,,,,,,,,,MMP9 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000234,MAP2K6 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:26399|NCBI-Human-GeneID:5608|NCBI-Rat-GeneID:114495,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000005608,,,,,,,,,,,,,TXPO:1000234,,,,,,,,,,,,,,,,,,,,,,MAP2K6 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000232,MAB21L2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:680102|NCBI-Human-GeneID:10586|NCBI-Mouse-GeneID:23937,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000010586,,,,,,,,,,,,,TXPO:1000232,,,,,,,,,,,,,,,,,,,,,,MAB21L2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000233,MANF (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:7873|NCBI-Mouse-GeneID:74840|NCBI-Rat-GeneID:315989,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000007873,,,,,,,,,,,,,TXPO:1000233,,,,,,,,,,,,,,,,,,,,,,MANF (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0001623,atrophied,atrophic,A size quality inhering in a bearer by virtue of a part or parts of the bearer's being decreased in size due to reduction in tissue mass through wasting.,false,,,http://purl.obolibrary.org/obo/PATO_0000587,,,,,,,,,,,,,,,,,,,,,,A size quality inhering in a bearer by virtue of a part or parts of the bearer's being decreased in size due to reduction in tissue mass through wasting.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,atrophic,,,,,PATO:0001623,,,,,,,,,,,,,,,,,,,,,,atrophied,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0001629,aggregated,,A spatial pattern inhering in a bearer by virtue of the bearer's being gathered or tending to gather into a mass or whole.,false,,,http://purl.obolibrary.org/obo/PATO_0000060,,,,,,,,,,,,,,,,,,,,,,A spatial pattern inhering in a bearer by virtue of the bearer's being gathered or tending to gather into a mass or whole.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0001629,,,,,,,,,,,,,,,,,,,,,,aggregated,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000009994,CASP8AP2,,Other designations: CASP8 associated protein 2|CASP8-associated protein 2|FLASH homolog RIP25|FLICE associated huge|FLICE-associated huge protein|human FLASH,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,RIP25|FLASH|CED-4,,,,,,,,,,,,6,,,,,,MIM:606880|HPRD:06048|HGNC:1510,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,caspase 8 associated protein 2,,,6q15,,,,,,,,,,,,,,,,"GO_0003677 (EC: IEA); GO_0003714 (EC: IDA, PMID:12477726); GO_0005123 (EC: TAS, PMID:10235259); GO_0005515 (EC: IPI, PMID:12477726); GO_0005634 (EC: IDA, PMID:12477726); GO_0005737 (EC: IDA, PMID:12477726); GO_0005739 (EC: IDA, PMID:17245429); GO_0006351 (EC: IEA); GO_0006355 (EC: IEA); GO_0006919 (EC: IMP, PMID:17245429); GO_0006919 (EC: ISS); GO_0007049 (EC: IEA); GO_0007165 (EC: TAS, PMID:10235259); GO_0008625 (EC: IMP, PMID:17245429); GO_0008625 (EC: ISS); GO_0008656 (EC: ISS); GO_0016505 (EC: ISS); GO_0016605 (EC: IDA, PMID:17245429); GO_0032184 (EC: IDA); GO_0036337 (EC: IMP, PMID:17245429); GO_0071260 (EC: IEP, PMID:19593445); GO_0097190 (EC: TAS, PMID:10235259)",,,,,,,,,PMID:10235259; 10537104; 10718198; 11340079; 12168954; 12477726; 12477932; 14702039; 15069192; 15342556; 15489334; 15561718; 15592525; 15698540; 15840729; 16627760; 17003125; 17003126; 17245429; 17370265; 17696945; 18038312; 18408764; 18677100; 19406988; 19414860; 19471022; 19546234; 19573080; 19593445; 19615980; 19773279; 19854135; 20109966; 20237496; 20697732; 20801175; 20936779; 21139048; 21245389; 21338522; 21693764; 21696825; 21725362; 21906983; 21988832; 22216762; 22427918; 22595458; 23071092; 23086935; 23673342; 23953914,,,,,,,,,,,,,,,OGG:3000009994,,,,,,,caspase 8 associated protein 2,,,,,,,,,,,,,Other designations: CASP8 associated protein 2|CASP8-associated protein 2|FLASH homolog RIP25|FLICE associated huge|FLICE-associated huge protein|human FLASH,,CASP8AP2,,,,,,,,,,,,,,,,,,,,,,,9994,RP11-63K6.3,,,,,,,9606,,,,,,,,,,,,,,,,,,,CASP8AP2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0011145,eIF3b,eIF3 p110|eIF3 p116|eIF-3 eta|Cell cycle regulation and translation initiation protein|eIF3 p90|eukaryotic translation initiation factor 3 subunit 9|Eukaryotic translation initiation factor 3 90 kDa subunit,,false,,,http://purl.obolibrary.org/obo/IMR_0000916,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,eIF3 p110|eIF3 p116|eIF-3 eta|Cell cycle regulation and translation initiation protein|eIF3 p90|eukaryotic translation initiation factor 3 subunit 9|Eukaryotic translation initiation factor 3 90 kDa subunit,,,,,IMR:0011145,,,,,,,,,,,,,,,,,,,,,,eIF3b,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001468,course of Niemann–Pick disease type A,,The totality of all processes through which the Niemann–Pick disease type A is realized. This causal process is heredity.,false,,,http://purl.obolibrary.org/obo/TXPO_0001462,,,,,,,,,,,,,,,,,,,,https://omim.org/entry/257200|https://ghr.nlm.nih.gov/condition/niemann-pick-disease|PMID:24488099|PMID:16434659,,The totality of all processes through which the Niemann–Pick disease type A is realized. This causal process is heredity.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001481|http://purl.obolibrary.org/obo/TXPO_0001482|http://purl.obolibrary.org/obo/TXPO_0003579|http://purl.obolibrary.org/obo/TXPO_0001471|http://purl.obolibrary.org/obo/TXPO_0003986|http://purl.obolibrary.org/obo/TXPO_0001818|http://purl.obolibrary.org/obo/TXPO_0001815|http://purl.obolibrary.org/obo/TXPO_0001817|http://purl.obolibrary.org/obo/TXPO_0003468|http://purl.obolibrary.org/obo/TXPO_0003474,,,,,,,,,,,,,,,,,,TXPO:0001468,,,,,,,,,,,,,,,,,,,,,,course of Niemann–Pick disease type A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/DOID_0070111,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001469,course of Niemann–Pick disease type B,,The totality of all processes through which the Niemann–Pick disease type B is realized. This causal process is heredity.,false,,,http://purl.obolibrary.org/obo/TXPO_0001462,,,,,,,,,,,,,,,,,,,,https://omim.org/entry/607616|https://ghr.nlm.nih.gov/condition/niemann-pick-disease|PMID:20111001,,The totality of all processes through which the Niemann–Pick disease type B is realized. This causal process is heredity.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001480|http://purl.obolibrary.org/obo/TXPO_0003987|http://purl.obolibrary.org/obo/TXPO_0003580|http://purl.obolibrary.org/obo/TXPO_0001816|http://purl.obolibrary.org/obo/TXPO_0001814|http://purl.obolibrary.org/obo/TXPO_0001811|http://purl.obolibrary.org/obo/TXPO_0003475|http://purl.obolibrary.org/obo/TXPO_0003473|http://purl.obolibrary.org/obo/TXPO_0001809,,,,,,,,,,,,,,,,,,TXPO:0001469,,,,,,,,,,,,,,,,,,,,,,course of Niemann–Pick disease type B,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001467,increaing in fatty acid inflow into hepatocyte [Fibrosis],,"Increaing in fatty acid inflow into hepatocyte is a subtype of increasing quantity: A process that changes the fatty acid inflow into the hepatocyte to be larger.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003492|http://purl.obolibrary.org/obo/TXPO_0003742,,,,,,,,,,,,,,,,,,,,,,"Increaing in fatty acid inflow into hepatocyte is a subtype of increasing quantity: A process that changes the fatty acid inflow into the hepatocyte to be larger.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001265,,,,,,,,,,,TXPO:0001467,,,,,,,,,,,,,,,,,,,,,,increaing in fatty acid inflow into hepatocyte [Fibrosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001463,phopholipase gene mutation [Phospholipidosis - genetic],,"Phopholipase gene mutation is a subtype of gene mutation: A process thatchanges the sequence of a phospholipase gene.
This process is dependent on the  genetic and can constitute the course of Phospholipidosis (genetic).",false,,,http://purl.obolibrary.org/obo/TXPO_0001444|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Phopholipase gene mutation is a subtype of gene mutation: A process thatchanges the sequence of a phospholipase gene.
This process is dependent on the  genetic and can constitute the course of Phospholipidosis (genetic).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002069,,,,,,,,,,,TXPO:0001463,,,,,,,,,,,,,,,,,,,,,,phopholipase gene mutation [Phospholipidosis - genetic],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001461,relative small (value),,A value  which is greater in comparison to something else.,false,,,http://purl.obolibrary.org/obo/TXPO_0001459,,,,,,,,,,,,,,,,,,,,,,A value  which is greater in comparison to something else.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001461,,,,,,,,,,,,,,,,,,,,,,relative small (value),,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001460,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001466,moving fatty acid to the hepatocyte,,Moving fatty axid to the hepatocyte is a subtype of moving A to the inside of B: A process of the movement of fatty acid into a hepatocyte.,false,,,http://purl.obolibrary.org/obo/TXPO_0001270,,,,,,,,,,,,,,,,,,,,,,Moving fatty axid to the hepatocyte is a subtype of moving A to the inside of B: A process of the movement of fatty acid into a hepatocyte.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001466,,,,,,,,,,,,,,,,,,,,,,moving fatty acid to the hepatocyte,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001465,sphingophospholipid catabolic process,sphingophospholipid breakdown|sphingophospholipid catacolism|sphingophospholipid degradation,The chemical reactions and pathways resulting in the breakdown of sphingophospholipids.,false,,,http://purl.obolibrary.org/obo/TXPO_0000071|http://purl.obolibrary.org/obo/GO_0009395,,,,,,,,,,,,,,,,,,,,,,The chemical reactions and pathways resulting in the breakdown of sphingophospholipids.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35786,,,,,,,,,,,,,,,,,,sphingophospholipid breakdown|sphingophospholipid catacolism|sphingophospholipid degradation,,,,,TXPO:0001465,,,,,,,,,,,,,,,,,,,,,,sphingophospholipid catabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001460,relative large (value),,A value which is greater in comparison to something else.,false,,,http://purl.obolibrary.org/obo/TXPO_0001459,,,,,,,,,,,,,,,,,,,,,,A value which is greater in comparison to something else.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001460,,,,,,,,,,,,,,,,,,,,,,relative large (value),,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001461,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001464,SMPD1 (canonical)[Phospholipidosis],Sphingomyelin Phosphodiesterase 1 [Phospholipidosis],,false,,,http://purl.obolibrary.org/obo/TXPO_1000347|http://purl.obolibrary.org/obo/TXPO_0003213,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:6609|NCBI-Rat-GeneID:308909|NCBI-Mouse-GeneID:20597|https://www.ncbi.nlm.nih.gov/gene/6609,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003671,,,,,Sphingomyelin Phosphodiesterase 1 [Phospholipidosis],,,,,TXPO:0001464,,,,,,,,,,,,,,,,,,,,,,SMPD1 (canonical)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001462,course of Niemann–Pick disease type A and type B,,The totality of all processes through which the Niemann–Pick disease type A or type B is realized. This causal process is heredity.,false,,,http://purl.obolibrary.org/obo/TXPO_0001685|http://purl.obolibrary.org/obo/TXPO_0003587,,,,,,,,,,,,,,,,,,,,PMID:20111001|https://ghr.nlm.nih.gov/condition/niemann-pick-disease,,The totality of all processes through which the Niemann–Pick disease type A or type B is realized. This causal process is heredity.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001446|http://purl.obolibrary.org/obo/TXPO_0002263|http://purl.obolibrary.org/obo/TXPO_0001475|http://purl.obolibrary.org/obo/TXPO_0001476|http://purl.obolibrary.org/obo/TXPO_0001478|http://purl.obolibrary.org/obo/TXPO_0003988|http://purl.obolibrary.org/obo/TXPO_0004146|http://purl.obolibrary.org/obo/TXPO_0004141|http://purl.obolibrary.org/obo/TXPO_0002072|http://purl.obolibrary.org/obo/TXPO_0002071|http://purl.obolibrary.org/obo/TXPO_0001807,,,,,,,,,,,,,,,,,,TXPO:0001462,,,,,,,"Niemann–Pick disease type A and type B are inherited as autosomal recessive deficiency of the enzyme sphingomyelinase, in the lysosomes of the reticuloendothelial system. This results in the lysosomal storage of sphingomyelin. The liver and spleen are predominantly involved.

Sherlock's Diseases of the Liver and Biliary System, 12th Edition",,,,,,,,,,,,,,,course of Niemann–Pick disease type A and type B,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000421,eIF2a (mol),,,false,,,http://purl.obolibrary.org/obo/IMR_0010016,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:502531|NCBI-Mouse-GeneID:229317|NCBI-Human-GeneID:83939,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000083939,,,,,,,,,,,,,TXPO:1000421,,,,,,,,,,,,,,,,,,,,,,eIF2a (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000422,gentamicin (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:1000422,,,,,,,,,,,,,,,,,,,,,,gentamicin (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100512,Smurf,Smad ubiquitin regulatory factors,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000266,,,,,Smad ubiquitin regulatory factors,,,,,IMR:0100512,,,,,,,,,,,,,,,,,,,,,,Smurf,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_15343,acetaldehyde,,The aldehyde formed from acetic acid by reduction of the carboxy group. It is the most abundant carcinogen in tobacco smoke.,false,,,http://purl.obolibrary.org/obo/CHEBI_17478,,,,,,,,,,,,,,,,,,,,Wikipedia:Acetaldehyde,,The aldehyde formed from acetic acid by reduction of the carboxy group. It is the most abundant carcinogen in tobacco smoke.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:15343,,,,,,,,,,,,,,,,,,,,,,acetaldehyde,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_52726,proteasome inhibitor,proteasome inhibitors,"A drug that blocks the action of proteasomes, cellular complexes that break down proteins.",false,,,http://purl.obolibrary.org/obo/CHEBI_23888,,,,,,,,,,,,,,,,,,,,,,"A drug that blocks the action of proteasomes, cellular complexes that break down proteins.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,proteasome inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:52726,,,,proteasome inhibitor,,CHEBI:52726,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_61951,microtubule-destabilising agent,microtubule-destabilizing agent|microtubule destabilising agents|microtubule-destabilizing agents|microtubule-destabilising agents|microtubule destabilising agent|microtubule destabilising role|microtubule destabilizing role,Any substance that interacts with tubulin to inhibit polymerisation of microtubules.,false,,,http://purl.obolibrary.org/obo/CHEBI_64911|http://purl.obolibrary.org/obo/CHEBI_60832,,,,,,,,,,,,,,,,,,,,PMID:17099073,,Any substance that interacts with tubulin to inhibit polymerisation of microtubules.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,microtubule-destabilizing agent|microtubule destabilising agents|microtubule-destabilizing agents|microtubule-destabilising agents|microtubule destabilising agent|microtubule destabilising role|microtubule destabilizing role,,,,,,,,,,,,,,,,,,,,,CHEBI:61951,,,,microtubule-destabilising agent,,CHEBI:61951,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0002716,IL-23,interleukin-23,,false,,,http://purl.obolibrary.org/obo/IMR_0000007,,,,,,,,,,,,,,,,,,,,GO:0045519,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000622,,,,,interleukin-23,,,,,IMR:0002716,,,,,,,,,,,,,,,,,,,,,,IL-23,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0005515,protein binding,protein amino acid binding,Interacting selectively and non-covalently with any protein or protein complex (a complex of two or more proteins that may include other nonprotein molecules).,false,,,http://purl.obolibrary.org/obo/GO_0005488,,,,,,,,,,,,,,,,,,,,GO:0005515,,Interacting selectively and non-covalently with any protein or protein complex (a complex of two or more proteins that may include other nonprotein molecules).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,protein amino acid binding,,,,,GO:0005515,,,,,,,,,,,,,,,,,,,,,,protein binding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000007057,THBS1,,Other designations: thrombospondin-1|thrombospondin-1p180,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,TSP1|THBS|THBS-1|TSP-1|TSP,,,,,,,,,,,,15,,,,,,HGNC:11785|HPRD:01765|MIM:188060,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,thrombospondin 1,,,15q15,,,,,,,,,,,,,,,,"GO_0000187 (EC: IMP, PMID: 17413041); GO_0001666 (EC: NAS, PMID: 9304800); GO_0001786 (EC: IDA, PMID: 18940719); GO_0001937 (EC: IDA, PMID: 17996481); GO_0001937 (EC: IMP, PMID: 17413041); GO_0001948 (EC: NAS, PMID: 6438154); GO_0001953 (EC: IDA, PMID: 17416590); GO_0001968 (EC: IDA, PMID: 6693501); GO_0002040 (EC: IMP, PMID: 17879962); GO_0002544 (EC: IEP, PMID: 18674744); GO_0002576 (EC: TAS); GO_0002581 (EC: IDA, PMID: 16882710); GO_0002605 (EC: IDA, PMID: 16882710); GO_0003151 (EC: IEA); GO_0003197 (EC: IEA); GO_0003417 (EC: IEA); GO_0005178 (EC: IMP, PMID: 17413041); GO_0005509 (EC: NAS, PMID: 9304800); GO_0005515 (EC: IPI, PMID: 11134179); GO_0005576 (EC: TAS); GO_0005577 (EC: IDA, PMID: 3997886); GO_0005615 (EC: IDA); GO_0005783 (EC: ISS); GO_0006955 (EC: IEP, PMID: 18674744); GO_0006986 (EC: IEA); GO_0007050 (EC: IDA, PMID: 17596205); GO_0007155 (EC: NAS, PMID: 9304800); GO_0007596 (EC: TAS); GO_0008201 (EC: IDA, PMID: 101549); GO_0009612 (EC: IEA); GO_0009749 (EC: IDA, PMID: 18096704); GO_0009897 (EC: IDA, PMID: 6777381); GO_0009986 (EC: IDA, PMID: 2435757); GO_0010595 (EC: IDA, PMID: 18555217); GO_0010596 (EC: IDA, PMID: 18555217); GO_0010748 (EC: IDA, PMID: 17416590); GO_0010751 (EC: IDA, PMID: 17416590); GO_0010754 (EC: IDA, PMID: 17416590); GO_0010757 (EC: IDA, PMID: 6438154); GO_0010759 (EC: ISS); GO_0010763 (EC: IDA, PMID: 18555217); GO_0010811 (EC: IEA); GO_0016477 (EC: IDA, PMID: 18555217); GO_0016525 (EC: IDA, PMID: 17596205); GO_0016529 (EC: ISS); GO_0017134 (EC: IDA, PMID: 17996481); GO_0018149 (EC: IDA, PMID: 3997886); GO_0030141 (EC: IDA, PMID: 101549); GO_0030168 (EC: TAS); GO_0030169 (EC: IDA, PMID: 6693501); GO_0030194 (EC: IDA, PMID: 3997886); GO_0030198 (EC: TAS); GO_0030335 (EC: IDA, PMID: 15700281); GO_0030335 (EC: IMP, PMID: 17413041); GO_0030511 (EC: IDA, PMID: 18555217); GO_0031012 (EC: IDA, Qualifier: colocalizes_with); GO_0031012 (EC: ISS, Qualifier: colocalizes_with); GO_0031012 (EC: TAS, PMID: 9304800); GO_0031091 (EC: IDA, PMID: 6777381); GO_0031093 (EC: TAS); GO_0032026 (EC: IDA, PMID: 6777381); GO_0032570 (EC: TAS, PMID: 9304800); GO_0032695 (EC: IDA, PMID: 16882710); GO_0032914 (EC: ISS); GO_0033574 (EC: IEA); GO_0034605 (EC: NAS, PMID: 9304800); GO_0034976 (EC: ISS); GO_0040037 (EC: IDA, PMID: 17996481); GO_0042327 (EC: IMP, PMID: 17413041); GO_0042493 (EC: IEP, PMID: 19738618); GO_0042535 (EC: IDA, PMID: 18726995); GO_0042802 (EC: NAS, PMID: 9304800); GO_0043032 (EC: IDA, PMID: 18757424); GO_0043066 (EC: IDA, PMID: 18653767); GO_0043154 (EC: IDA, PMID: 18653767); GO_0043236 (EC: IDA, PMID: 6693501); GO_0043394 (EC: TAS, PMID: 9304800); GO_0043536 (EC: IDA, PMID: 18555217); GO_0043537 (EC: IDA, PMID: 18555217); GO_0043652 (EC: IDA, PMID: 16882710); GO_0045727 (EC: IDA, PMID: 15700281); GO_0045766 (EC: IMP, PMID: 17413041); GO_0048266 (EC: ISS); GO_0050431 (EC: ISS); GO_0050431 (EC: TAS, PMID: 9304800); GO_0050921 (EC: IDA, PMID: 18555217); GO_0051592 (EC: IDA, PMID: 18757424); GO_0051895 (EC: TAS, PMID: 9304800); GO_0051897 (EC: IDA, PMID: 18653767); GO_0051918 (EC: IDA, PMID: 6438154); GO_0070051 (EC: IDA, PMID: 6693501); GO_0070052 (EC: IDA, PMID: 6693501); GO_0070062 (EC: IDA, PMID: 19056867); GO_0071356 (EC: IEA); GO_0071363 (EC: IEA); GO_1902043 (EC: IDA, PMID: 18726995); GO_2000353 (EC: IDA, PMID: 18726995); GO_2000379 (EC: IDA, PMID: 18757424); GO_2001237 (EC: TAS, PMID: 17879962)",,,,,,,,,PMID: 101549; 1350660; 1550960; 2010551; 2335352; 2341158; 2430973; 2435757; 2478219; 2522013; 2544587; 2745554; 2918029; 3030396; 3084490; 3402455; 3461443; 3571333; 3997886; 6338048; 6438154; 6693501; 6777381; 7521539; 7775583; 8288588; 8408036; 8463250; 8550562; 8751720; 9045712; 9169439; 9304800; 9328841; 9334164; 9419208; 9459346; 9478926; 9657149; 9840442; 9867861; 10397731; 10398144; 10487979; 10698186; 10749676; 10772961; 10900205; 10922378; 10982388; 11023976; 11067851; 11094060; 11134179; 11358957; 11606713; 11773026; 11801541; 11820799; 11882904; 11920574; 11964147; 11980922; 11986954; 12054567; 12147243; 12147682; 12220191; 12358136; 12391027; 12443715; 12444143; 12450399; 12477932; 12482844; 12530526; 12553016; 12598312; 12609716; 12643280; 12658547; 12676576; 12679131; 12718556; 12759541; 12782324; 12824298; 12878157; 12902472; 12909644; 12927044; 12947001; 12964017; 14555767; 14557872; 14559817; 14561896; 14568985; 14583433; 14683523; 14718574; 14963009; 14991768; 15007078; 15014436; 15034804; 15037654; 15095410; 15113588; 15140581; 15166498; 15217952; 15258909; 15292271; 15342643; 15347840; 15356163; 15456750; 15503824; 15522326; 15583827; 15634279; 15634883; 15665307; 15696166; 15700281; 15730804; 15792551; 15799029; 15817447; 15820829; 15833768; 15855645; 15890262; 15907858; 15908066; 15927849; 15945504; 16006654; 16037098; 16100012; 16141331; 16147889; 16148025; 16150726; 16166434; 16263699; 16270194; 16335952; 16344560; 16388804; 16465407; 16478297; 16495290; 16618977; 16650813; 16684956; 16732887; 16740002; 16835379; 16882710; 16951312; 16962673; 17106256; 17175378; 17198740; 17289869; 17363705; 17374440; 17378161; 17413041; 17416590; 17487836; 17507668; 17572512; 17596205; 17620335; 17638877; 17706282; 17709727; 17879962; 17917789; 17996481; 18021253; 18035072; 18057090; 18089612; 18096704; 18178577; 18208671; 18222489; 18226512; 18275041; 18319354; 18321763; 18336597; 18384112; 18413367; 18425817; 18499674; 18515748; 18555217; 18641687; 18653767; 18661355; 18674744; 18675774; 18676351; 18688696; 18700275; 18712840; 18726995; 18757424; 18788631; 18853485; 18855616; 18855618; 18940719; 19056867; 19239428; 19250552; 19271751; 19322201; 19351925; 19383251; 19396698; 19414528; 19422532; 19435835; 19447890; 19485899; 19509293; 19531495; 19542224; 19570906; 19581582; 19584238; 19661269; 19687096; 19698122; 19706610; 19710505; 19715883; 19721725; 19732880; 19738618; 19747478; 19762163; 19805200; 19826414; 19906510; 19913121; 19958625; 19959938; 19998449; 20016205; 20056600; 20103648; 20182908; 20203415; 20204299; 20300551; 20346360; 20360068; 20372793; 20449626; 20452482; 20453000; 20458281; 20467328; 20470445; 20485444; 20492458; 20494556; 20498063; 20546609; 20625903; 20628086; 20655775; 20673868; 20705333; 20876797; 20923780; 20927579; 21107877; 21139048; 21142150; 21148423; 21152035; 21157449; 21161418; 21193465; 21217824; 21296375; 21307796; 21317461; 21343308; 21378271; 21402050; 21420687; 21437286; 21474793; 21501375; 21518247; 21526452; 21531776; 21565611; 21659549; 21762961; 21822266; 21845757; 21883885; 21899841; 22011138; 22014686; 22024541; 22028325; 22028813; 22035632; 22037878; 22136730; 22194599; 22198906; 22207555; 22231149; 22238753; 22247259; 22268819; 22308318; 22311024; 22318901; 22383169; 22403705; 22583901; 22592401; 22672426; 22796565; 22971480; 22982001; 23030305; 23085760; 23119050; 23145312; 23202046; 23315169; 23350987; 23380452; 23528972; 23614916; 23660684; 23667531; 23995838; 24314882,,,,,,,,,,,,,,,OGG:3000007057,,,,,,,thrombospondin 1,,,,,,,,,,,,,Other designations: thrombospondin-1|thrombospondin-1p180,,THBS1,,,,,,,,,,,,,,,,,,,,,,,7057,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,THBS1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0011134,eIF2-beta,"eIF-2-beta|eukaryotic translation initiation factor 2 beta subunit|Eukaryotic translation initiation factor 2 subunit 2|eukaryotic translation initiation factor 2, subunit 2",,false,,,http://purl.obolibrary.org/obo/IMR_0000913,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"eIF-2-beta|eukaryotic translation initiation factor 2 beta subunit|Eukaryotic translation initiation factor 2 subunit 2|eukaryotic translation initiation factor 2, subunit 2",,,,,IMR:0011134,,,,,,,,,,,,,,,,,,,,,,eIF2-beta,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010509,Heterogeneous nuclear ribonucleoproteins C1/C2,hnRNP C1/C2|hnRNP C1 / hnRNP C2|ROC,,false,,,http://purl.obolibrary.org/obo/IMR_0010024,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,hnRNP C1/C2|hnRNP C1 / hnRNP C2|ROC,,,,,IMR:0010509,,,,,,,,,,,,,,,,,,,,,,Heterogeneous nuclear ribonucleoproteins C1/C2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000233,Tpl2,Est|Tumor progression locus 2|cancer Osaka thyroid oncogene|Cot,,false,,,http://purl.obolibrary.org/obo/IMR_0000229,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Est|Tumor progression locus 2|cancer Osaka thyroid oncogene|Cot,,,,,IMR:0000233,,,,,,,,,,,,,,,,,,,,,,Tpl2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/NCBITaxon_40674,mammalia,mammals|mammal,,false,,,http://purl.obolibrary.org/obo/NCBITaxon_7742,,,,,,,,,,,,,,,,,,,,http://purl.bioontology.org/ontology/STY/T015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,mammals|mammal,,,,,NCBITaxon:40674,,,,,,,,,,,,,,,,,,,,,,mammalia,,,,,,,http://purl.obolibrary.org/obo/ncbitaxon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100760,Dvl-1-like,DSH homolog 1-like|Dishevelled-1-like,,false,,,http://purl.obolibrary.org/obo/IMR_0100755,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,DSH homolog 1-like|Dishevelled-1-like,,,,,IMR:0100760,,,,,,,,,,,,,,,,,,,,,,Dvl-1-like,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100144,insulin-like growth factor I,IGF-I,,false,,,http://purl.obolibrary.org/obo/IMR_0002835|http://purl.obolibrary.org/obo/IMR_0100143,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IGF-I,,,,,IMR:0100144,,,,,,,,,,,,,,,,,,,,,,insulin-like growth factor I,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000573,increasing demand for response to ER stress [Cell death],,"Increasing demand for response to ER stress is a subtype of increasing the demand for response to stress: A process that changes the functional demand for the response to the endoplasmic reticulum (ER) stress to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0001727|http://purl.obolibrary.org/obo/TXPO_0000362,,,,,,,,,,,,,,,,,,,,,,"Increasing demand for response to ER stress is a subtype of increasing the demand for response to stress: A process that changes the functional demand for the response to the endoplasmic reticulum (ER) stress to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000640,,,,,,http://purl.obolibrary.org/obo/TXPO_0000453,,,,,,,,,,,TXPO:0000573,,,,,,,,,,,,,,,,,,,,,,increasing demand for response to ER stress [Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000572,protein quality control imbalance,,Protein quality control imbalance is a subtype of imbalance: A process that lacks a balance between abnormal protein (misfolded or attenuated proteins) production and breakdown.,false,,,http://purl.obolibrary.org/obo/TXPO_0000567,,,,,,,,,,,,,,,,,,,,,,Protein quality control imbalance is a subtype of imbalance: A process that lacks a balance between abnormal protein (misfolded or attenuated proteins) production and breakdown.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000572,,,,,,,,,,,,,,,,,,,,,,protein quality control imbalance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000578,decreasing cellular pH,,Decreasing cellular pH is a subtype of decreasing pH: A process that changes the celular pH to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000577,,,,,,,,,,,,,,,,,,,,,,Decreasing cellular pH is a subtype of decreasing pH: A process that changes the celular pH to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000578,,,,,,,,,,,,,,,,,,,,,,decreasing cellular pH,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000579,decreasing cellular pH [Cell death],,"Decreasing cellular pH is a subtype of decreasing pH: A process that changes the celular pH to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0001727|http://purl.obolibrary.org/obo/TXPO_0000578,,,,,,,,,,,,,,,,,,,,,,"Decreasing cellular pH is a subtype of decreasing pH: A process that changes the celular pH to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000579,,,,,,,,,,,,,,,,,,,,,,decreasing cellular pH [Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000571,endoplasmic reticulum stress response imbalance,,Endoplasmic reticulum stress response imbalance is a subtype of stress response imbalance: A process that lacks a balance between the stimulation (stress) acting on the endoplasmic reticulum and the biological defence response.,false,,,http://purl.obolibrary.org/obo/TXPO_0000570,,,,,,,,,,,,,,,,,,,,,,Endoplasmic reticulum stress response imbalance is a subtype of stress response imbalance: A process that lacks a balance between the stimulation (stress) acting on the endoplasmic reticulum and the biological defence response.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000571,,,,,,,,,,,,,,,,,,,,,,endoplasmic reticulum stress response imbalance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000575,bile acid and bile salt transporter,,,false,,,http://purl.obolibrary.org/obo/TXPO_0003703,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000575,,,,,,,,,,,,,,,,,,,,,,bile acid and bile salt transporter,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000574,increasing demand for response to oxidative stress [cell death],,"Increasing demand for response to oxidative stress is a subtype of increasing the demand for response to stress: A process that changes the functional demand for the response to the oxidative stress to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0001727|http://purl.obolibrary.org/obo/TXPO_0000102,,,,,,,,,,,,,,,,,,,,,,"Increasing demand for response to oxidative stress is a subtype of increasing the demand for response to stress: A process that changes the functional demand for the response to the oxidative stress to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000645|http://purl.obolibrary.org/obo/TXPO_0000641|http://purl.obolibrary.org/obo/TXPO_0000642,,,,,,http://purl.obolibrary.org/obo/TXPO_0000234|http://purl.obolibrary.org/obo/TXPO_0002381,,,,,,,,,,,TXPO:0000574,,,,,,,,,,,,,,,,,,,,,,increasing demand for response to oxidative stress [cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000576,metabolic intermediate accumulation,,"Metabolic intermediate accumulation is a subtype of accumulation of substances in a biological object: A process that keeps intermediate(s) of metabolism in an organism, tissue, organelle, or cell.",false,,,http://purl.obolibrary.org/obo/TXPO_0000247,,,,,,,,,,,,,,,,,,,,,,"Metabolic intermediate accumulation is a subtype of accumulation of substances in a biological object: A process that keeps intermediate(s) of metabolism in an organism, tissue, organelle, or cell.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000576,,,,,,,,,,,,,,,,,,,,,,metabolic intermediate accumulation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000570,stress response imbalance,,Stress response imbalance is a subtype of imbalance: A process that lacks a balance between the stimulation (stress) and the response.,false,,,http://purl.obolibrary.org/obo/TXPO_0000567,,,,,,,,,,,,,,,,,,,,,,Stress response imbalance is a subtype of imbalance: A process that lacks a balance between the stimulation (stress) and the response.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000570,,,,,,,,,,,,,,,,,,,,,,stress response imbalance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000577,decreasing pH,,Decreasing pH is a subtype of changing pH: A process that changes the pH to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0001520,,,,,,,,,,,,,,,,,,,,,,Decreasing pH is a subtype of changing pH: A process that changes the pH to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000577,,,,,,,,,,,,,,,,,,,,,,decreasing pH,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010507,Heterogeneous nuclear ribonucleoproteins A2/B1,ROA2|hnRNP A2 / hnRNP B1|hnRNP A2,,false,,,http://purl.obolibrary.org/obo/IMR_0010024,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ROA2|hnRNP A2 / hnRNP B1|hnRNP A2,,,,,IMR:0010507,,,,,,,,,,,,,,,,,,,,,,Heterogeneous nuclear ribonucleoproteins A2/B1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_35221,antimetabolite,antimetabolites|antimetabolite,"A substance which is structurally similar to a metabolite but which competes with it or replaces it, and so prevents or reduces its normal utilization.",false,,,http://purl.obolibrary.org/obo/CHEBI_52206,,,,,,,,,,,,,,,,,,,,,,"A substance which is structurally similar to a metabolite but which competes with it or replaces it, and so prevents or reduces its normal utilization.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,antimetabolite,,antimetabolites,,,,,,,,,,,,,,,,,,,,,CHEBI:35221,,,,antimetabolite,,CHEBI:35221,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000320,G-alpha-o,,"Galphao, the most abundant G protein in mammalian brain, occurs at least in two subforms, i.e., Galphao1 and Galphao2, derived by alternative splicing of the mRNA.",false,,,http://purl.obolibrary.org/obo/IMR_0000318,,,,,,,,,,,,,,,,,,,,,,"Galphao, the most abundant G protein in mammalian brain, occurs at least in two subforms, i.e., Galphao1 and Galphao2, derived by alternative splicing of the mRNA.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100371|IMR:0100372,,,,,,IMR:0000320,,,,,,,,,,,,,,,,,,,,,,G-alpha-o,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_51006,unsaturated fatty acyl-CoA,,A fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of any unsaturated fatty acid.,false,,,http://purl.obolibrary.org/obo/CHEBI_37554,,,,,,,,,,,,,,,,,,,,PMID:13152086,,A fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of any unsaturated fatty acid.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:51006,,,,,,,,,,,,,,,,,,,,,,unsaturated fatty acyl-CoA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76603,Chlorendic Acid,"1,4,5,6,7,7-hexachlorobicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid",A bridged organochlorine compound resulting from the Diels-Alder reaction of hexachlorocyclopentadiene with maleic anhydride followed by hydrolysis of the resulting anhydride. A chemical intermediate used in the preparation of fire-retardant polyester resins and plasticisers.,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:115-28-6,,A bridged organochlorine compound resulting from the Diels-Alder reaction of hexachlorocyclopentadiene with maleic anhydride followed by hydrolysis of the resulting anhydride. A chemical intermediate used in the preparation of fire-retardant polyester resins and plasticisers.,,,,,,,,,,,,C9H4Cl6O4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"1,4,5,6,7,7-hexachlorobicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid",,,,,CHEBI:76603,,,,,,,,,,,,,,,,,,,,,,Chlorendic Acid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,OC(=O)C1C(C(O)=O)C2(Cl)C(Cl)=C(Cl)C1(Cl)C2(Cl)Cl,,,,,
http://purl.obolibrary.org/obo/IMR_0100034,progesterone,"4-Pregnene-3,20-dione",,false,,,http://purl.obolibrary.org/obo/IMR_0100033,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"4-Pregnene-3,20-dione",,,,,IMR:0100034,,,,,,,,,,,,,,,,,,,,,,progesterone,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0001690,ear,auditory apparatus|auris,"Sense organ in vertebrates that is specialized for the detection of sound, and the maintenance of balance. Includes the outer ear and middle ear, which collect and transmit sound waves; and the inner ear, which contains the organs of balance and (except in fish) hearing. Also includes the pinna, the visible part of the outer ear, present in some mammals.",false,,,http://purl.obolibrary.org/obo/UBERON_0000020,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C12394|http://www.snomedbrowser.com/Codes/Details/1910005|http://uri.neuinfo.org/nif/nifstd/birnlex_1062|http://en.wikipedia.org/wiki/Ear|http://linkedlifedata.com/resource/umls/id/C0521421|http://linkedlifedata.com/resource/umls/id/C0013443|FMA:52780|UMLS:C0521421|AAO:0011014|GAID:62|EHDAA:502|EV:0100353|MESH:D004423|EHDAA2:0000423|MA:0000236|MIAA:0000138|UMLS:C0013443|XAO:0000189|OpenCyc:Mx4rvViXS5wpEbGdrcN5Y29ycA|OpenCyc:Mx4rvVjL05wpEbGdrcN5Y29ycA|VHOG:0000330|BTO:0000368|galen:Ear|CALOHA:TS-1165|EFO:0000826|EMAPA:16193|MAT:0000138,,"Sense organ in vertebrates that is specialized for the detection of sound, and the maintenance of balance. Includes the outer ear and middle ear, which collect and transmit sound waves; and the inner ear, which contains the organs of balance and (except in fish) hearing. Also includes the pinna, the visible part of the outer ear, present in some mammals.",,,,,,,,The organ of hearing and of equilibrium. [TFD][VHOG],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,auditory apparatus|auris,"Both vertebrate and invertebrate auditory organs are thought to have evolved from primitive mechanosensors, but the nature of the ancestral structure and the evolutionary trajectories followed in distinct animal lineages remain unknown. In particular, we do not know how many types of mechanosensor existed in the protostome-deuterostome ancestor from which insects and vertebrates evolved or whether the PDA had an auditory organ.[well established][VHOG]",,UBERON:0001690,,,,,,,,,,,,,,,,,,,,,,ear,,,,http://upload.wikimedia.org/wikipedia/commons/b/b8/Ear.jpg,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100409,NT-3,neurotrophin-3|neurotrophic factor 3,,false,,,http://purl.obolibrary.org/obo/IMR_0000034,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,neurotrophin-3|neurotrophic factor 3,,,,,IMR:0100409,,,,,,,,,,,,,,,,,,,,,,NT-3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000443,Ras GAP,Ras GTPase-activating protein,,false,,,http://purl.obolibrary.org/obo/IMR_0000442,,,,,,,,,,,,,,,,,,,,GO:0005099,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ras GTPase-activating protein,,,,,IMR:0000443,,,,,,,,,,,,,,,,,,,,,,Ras GAP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003751,TGFB1 (canonical)[Fibrosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000371|http://purl.obolibrary.org/obo/IMR_0000042|http://purl.obolibrary.org/obo/TXPO_0003750,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:|NCBI-Mouse-GeneID:|NCBI-Rat-GeneID:,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000041,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003751,,,,,,,,,,,,,,,,,,,,,,TGFB1 (canonical)[Fibrosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003754,addition of xenobiotics,,"Addition of xenobiotics is a subtype of addition of foreign substance: A process that xenobiotics to make an addition to a cell, organelle, or an organism.",false,,,http://purl.obolibrary.org/obo/TXPO_0000166,,,,,,,,,,,,,,,,,,,,,,"Addition of xenobiotics is a subtype of addition of foreign substance: A process that xenobiotics to make an addition to a cell, organelle, or an organism.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003754,,,,,,,,,,,,,,,,,,,,,,addition of xenobiotics,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003750,hepatic fibrosis dependent molecule (canonical),,"Hepatic fibrosis dependent gene is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of hepatic fibrosis as a gene product.
Gene profile:caonical that described in textbooks or articles.",false,,,http://purl.obolibrary.org/obo/TXPO_0003749,,,,,,,,,,,,,,,,,,,,,,"Hepatic fibrosis dependent gene is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of hepatic fibrosis as a gene product.
Gene profile:caonical that described in textbooks or articles.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003750,,,,,,,,,,,,,,,,,,,,,,hepatic fibrosis dependent molecule (canonical),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003755,hepatic stellate cell proliferation [Fibrosis],,"The multiplication or reproduction of hepatic stellate cells, resulting in the expansion of a hepatic stellate cell population. Hepatic stellate cells are found in the perisinusoidal space of the liver, and are capable of multiple roles including storage of retinol, presentation of antigen to T cells (including CD1d-restricted NKT cells), and upon activation, production of extracellular matrix components. This cell type comprises approximately 8-15% of total cells in the liver.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003742|http://purl.obolibrary.org/obo/GO_1990922,,,,,,,,,,,,,,,,,,,,,,"The multiplication or reproduction of hepatic stellate cells, resulting in the expansion of a hepatic stellate cell population. Hepatic stellate cells are found in the perisinusoidal space of the liver, and are capable of multiple roles including storage of retinol, presentation of antigen to T cells (including CD1d-restricted NKT cells), and upon activation, production of extracellular matrix components. This cell type comprises approximately 8-15% of total cells in the liver.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003755,,,,,,,,,,,,,,,,,,,,,,hepatic stellate cell proliferation [Fibrosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003752,PDGF (canonical)[Fibrosis],,,false,,,http://purl.obolibrary.org/obo/IMR_0000032|http://purl.obolibrary.org/obo/TXPO_0003750|http://purl.obolibrary.org/obo/TXPO_1000275,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000032,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003752,,,,,,,,,,,,,,,,,,,,,,PDGF (canonical)[Fibrosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003759,extracellular structure organization [Fibrosis],,"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of structures in the space external to the outermost structure of a cell. For cells without external protective or external encapsulating structures this refers to space outside of the plasma membrane, and also covers the host cell environment outside an intracellular parasite.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003742|http://purl.obolibrary.org/obo/GO_0030198,,,,,,,,,,,,,,,,,,,,,,"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of structures in the space external to the outermost structure of a cell. For cells without external protective or external encapsulating structures this refers to space outside of the plasma membrane, and also covers the host cell environment outside an intracellular parasite.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003800,,,,,,,,,,,TXPO:0003759,,,,,,,,,,,,,,,,,,,,,,extracellular structure organization [Fibrosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003756,Increasing drug metabolite [lipidosis],,"Increasing drug metabolite is a subtype of increasing quantity: A process that changes the amount of drug metabolites to be higher.
This entity is a specific course-dependent process. This process can constitute the course of lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0002364,,,,,,,,,,,,,,,,,,,,,,"Increasing drug metabolite is a subtype of increasing quantity: A process that changes the amount of drug metabolites to be higher.
This entity is a specific course-dependent process. This process can constitute the course of lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003787,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001882,,,,,,,,,,,TXPO:0003756,,,,,,,,,,,,,,,,,,,,,,Increasing drug metabolite [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003757,myoblast differentiation [Fibrosis],,"The process in which a relatively unspecialized cell acquires specialized features of a myoblast. A myoblast is a mononucleate cell type that, by fusion with other myoblasts, gives rise to the myotubes that eventually develop into striated muscle fibers.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003742|http://purl.obolibrary.org/obo/GO_0045445,,,,,,,,,,,,,,,,,,,,,,"The process in which a relatively unspecialized cell acquires specialized features of a myoblast. A myoblast is a mononucleate cell type that, by fusion with other myoblasts, gives rise to the myotubes that eventually develop into striated muscle fibers.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003759|http://purl.obolibrary.org/obo/TXPO_0003761,,,,,,,,,,,TXPO:0003757,,,,,,,,,,,,,,,,,,,,,,myoblast differentiation [Fibrosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003753,counting quality,,Counting numbers of objects and how many times an event happens are essential not to individuals in them but to collectives of objects or events.,false,,,http://purl.obolibrary.org/obo/TXPO_0000304|http://purl.obolibrary.org/obo/BFO_0000019,,,,,,,,,,,,,,,,,,,,,,Counting numbers of objects and how many times an event happens are essential not to individuals in them but to collectives of objects or events.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003753,,,,,,,,,,,,,,,,,,,,,,counting quality,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003758,decreased number (quality),,A number quality which is relatively few.,false,,,http://purl.obolibrary.org/obo/TXPO_0000304|http://purl.obolibrary.org/obo/TXPO_0003753,,,,,,,,,,,,,,,,,,,,,,A number quality which is relatively few.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003758,,,,,,,,,,,,,,,,,,,,,,decreased number (quality),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001143,biglycan,,,false,,,http://purl.obolibrary.org/obo/IMR_0001127,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001143,,,,,,,,,,,,,,,,,,,,,,biglycan,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000051330,TNFRSF12A,,Other designations: FGF-inducible 14|fibroblast growth factor-inducible immediate-early response protein 14|tumor necrosis factor receptor superfamily member 12A|tweak-receptor|type I transmembrane protein Fn14,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CD266|FN14|TWEAKR,,,,,,,,,,,,16,,,,,,Ensembl:ENSG00000006327|MIM:605914|HPRD:05801|HGNC:18152|Vega:OTTHUMG00000129001,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"tumor necrosis factor receptor superfamily, member 12A",,,16p13.3,,,,,,,,,,,,,,,,"GO_0001525 (EC: IEA); GO_0001726 (EC: IEA); GO_0005515 (EC: IPI); GO_0005886 (EC: IEA); GO_0006915 (EC: IEA); GO_0006928 (EC: TAS, PMID: 10551889); GO_0006931 (EC: IEA); GO_0007275 (EC: TAS, PMID: 10551889); GO_0009986 (EC: IEA); GO_0016021 (EC: IEA); GO_0043065 (EC: IDA); GO_0045773 (EC: IEA); GO_2001238 (EC: IMP)",,,,,,,,,PMID: 10551889; 10751351; 11728344; 12445828; 12477932; 12496418; 12529173; 12651623; 14573547; 15140220; 15353286; 15489334; 15611130; 16341674; 16503147; 16526941; 16809572; 17018610; 17124496; 17383968; 17594693; 18505918; 19018248; 19241374; 19349318; 19573080; 19773279; 19828625; 19895311; 19963275; 20004376; 20189297; 20237496; 20487651; 20557950; 20568250; 20610643; 20628624; 20810696; 20844036; 20927042; 21153335; 21303425; 21435232; 21483105; 21525013; 21708117; 21828059; 21963094; 21982860; 21993017; 22055894; 22081603; 22521346; 22634180; 22637703; 22672874; 22767506; 22896023; 23107828; 23288170; 23300011; 23320797; 23438059; 23443741; 23469193; 23722548; 23775076; 23886137; 23999007; 24056367; 24122208,,,,,,,,,,,,,,,OGG:3000051330,,,,,,,"tumor necrosis factor receptor superfamily, member 12A",,,,,,,,,,,,,Other designations: FGF-inducible 14|fibroblast growth factor-inducible immediate-early response protein 14|tumor necrosis factor receptor superfamily member 12A|tweak-receptor|type I transmembrane protein Fn14,,TNFRSF12A,,,,,,,,,,,,,,,,,,,,,,,51330,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,TNFRSF12A,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000374383,NCR3LG1,,Other designations: B7 homolog 6|natural cytotoxicity triggering receptor 3 ligand 1|putative Ig-like domain-containing protein DKFZp686O24166/DKFZp686I21167,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,B7H6|DKFZp686O24166|B7-H6,,,,,,,,,,,,11,,,,,,MIM:613714|HPRD:16820|Vega:OTTHUMG00000165913|Ensembl:ENSG00000188211|HGNC:42400,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,natural killer cell cytotoxicity receptor 3 ligand 1,,,11p15.1,,,,,,,,,,,,,,,,GO_0005198 (EC: IEA); GO_0005886 (EC: IEA); GO_0016021 (EC: IEA); GO_0019028 (EC: IEA),,,,,,,,,PMID: 12477932; 18187620; 19528259; 21422170; 21444796; 21875946; 21877119; 23066150; 23687088,,,,,,,,,,,,,,,OGG:3000374383,,20140408,protein-coding,,,,natural killer cell cytotoxicity receptor 3 ligand 1,,,,,,,,,,,,,Other designations: B7 homolog 6|natural cytotoxicity triggering receptor 3 ligand 1|putative Ig-like domain-containing protein DKFZp686O24166/DKFZp686I21167,,NCR3LG1,,,,,,,,,,,,,,,,,,,,,,,374383,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,NCR3LG1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000451,Bcl-2 family,B cell lymphoma/leukemia-2 family,The Bcl-2 family consists of about 20 homologues of important pro- and anti-apoptotic regulators of programmed cell death.,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,The Bcl-2 family consists of about 20 homologues of important pro- and anti-apoptotic regulators of programmed cell death.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000327,,,,,B cell lymphoma/leukemia-2 family,,,,,IMR:0000451,,,,,,,,,,,,,,,,,,,,,,Bcl-2 family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000005562,PRKAA1,,"Other designations: 5'-AMP-activated protein kinase catalytic subunit alpha-1|5'-AMP-activated protein kinase, catalytic alpha-1 chain|ACACA kinase|AMP -activate kinase alpha 1 subunit|AMP-activated protein kinase, catalytic, alpha-1|AMPK alpha 1|AMPK subunit alpha-1|HMGCR kinase|acetyl-CoA carboxylase kinase|hydroxymethylglutaryl-CoA reductase kinase|tau-protein kinase PRKAA1",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,AMPK|AMPKa1,,,,,,,,,,,,5,,,,,,Vega:OTTHUMG00000162269|Ensembl:ENSG00000132356|HGNC:9376|HPRD:04115|MIM:602739,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"protein kinase, AMP-activated, alpha 1 catalytic subunit",,,5p12,,,,,,,,,,,,,,,,"GO_0000187 (EC: NAS, PMID: 11546797); GO_0001666 (EC: NAS, PMID: 8557660); GO_0003682 (EC: ISS); GO_0004672 (EC: IDA, PMID: 17028174); GO_0004679 (EC: IDA, PMID: 18439900); GO_0004691 (EC: NAS, PMID: 8557660); GO_0005515 (EC: IPI, PMID: 16306228); GO_0005524 (EC: IEA); GO_0005622 (EC: IC, PMID: 8557660); GO_0005634 (EC: IDA); GO_0005634 (EC: ISS); GO_0005737 (EC: IDA); GO_0005829 (EC: TAS); GO_0006006 (EC: IEA); GO_0006351 (EC: IEA); GO_0006355 (EC: IEA); GO_0006468 (EC: IDA, PMID: 17028174); GO_0006633 (EC: IEA); GO_0006695 (EC: IEA); GO_0006914 (EC: IEA); GO_0007050 (EC: TAS); GO_0007165 (EC: TAS, PMID: 8557660); GO_0008022 (EC: IEA); GO_0008284 (EC: IEA); GO_0008286 (EC: TAS); GO_0008610 (EC: ISS); GO_0009631 (EC: IEA); GO_0010332 (EC: ISS); GO_0010508 (EC: ISS); GO_0010628 (EC: IDA, PMID: 17028174); GO_0014823 (EC: IEA); GO_0016055 (EC: IEA); GO_0016324 (EC: IEA); GO_0019395 (EC: IEA); GO_0019900 (EC: IEA); GO_0031000 (EC: IEA); GO_0031588 (EC: ISS); GO_0031669 (EC: ISS); GO_0032007 (EC: ISS); GO_0035174 (EC: ISS); GO_0042149 (EC: ISS); GO_0042593 (EC: ISS); GO_0042752 (EC: ISS); GO_0043066 (EC: ISS); GO_0045542 (EC: NAS, PMID: 8557660); GO_0045821 (EC: ISS); GO_0046318 (EC: NAS, PMID: 11165240); GO_0046872 (EC: IEA); GO_0047322 (EC: IEA); GO_0048511 (EC: IEA); GO_0050321 (EC: IEA); GO_0050405 (EC: IEA); GO_0050995 (EC: ISS); GO_0051291 (EC: IEA); GO_0055089 (EC: ISS); GO_0060627 (EC: IEA); GO_0070301 (EC: IEA); GO_0071361 (EC: IEA); GO_0071456 (EC: IEA); GO_2000505 (EC: ISS); GO_2001274 (EC: IEA)",,,,,,,,,PMID: 1322130; 2900138; 7907095; 8094892; 8163463; 8557660; 8626596; 8663446; 8910387; 9091312; 9224708; 9710607; 9845345; 9857077; 10698692; 10760274; 10862786; 11042152; 11052978; 11165240; 11171059; 11500364; 11546797; 11903059; 11913976; 11971957; 11997383; 12091379; 12194824; 12368907; 12391032; 12477932; 12788940; 12791703; 12847291; 12853467; 12869384; 12890675; 14557259; 14651849; 14702039; 14709557; 14970221; 14976552; 14985344; 14985505; 15024086; 15261145; 15485651; 15489334; 16054041; 16054095; 16306228; 16344560; 16405649; 16466905; 16806233; 17028174; 17088252; 17584647; 18195011; 18276112; 18303014; 18347656; 18359290; 18403135; 18439900; 18614941; 18663353; 18674809; 18781797; 18801964; 18836454; 18950855; 18976975; 18996102; 19020741; 19049348; 19050283; 19138981; 19197243; 19211918; 19322201; 19442239; 19491292; 19502591; 19556893; 19616115; 19720090; 19723093; 19723094; 19723101; 19723105; 19728147; 19887561; 19913121; 19923924; 19948975; 19966861; 20080969; 20103647; 20167678; 20170185; 20217115; 20368287; 20368732; 20392842; 20421294; 20462511; 20538596; 20562859; 20564492; 20602615; 20622004; 20628086; 20660302; 20682687; 20821366; 20861072; 20876741; 21048031; 21072212; 21079763; 21088205; 21139048; 21209024; 21232561; 21344388; 21416543; 21432774; 21474997; 21651489; 21670147; 21678424; 21728993; 21768291; 21775054; 21807092; 21892142; 21906983; 21909354; 21963094; 21987572; 21988832; 21994947; 22007913; 22021095; 22037551; 22065577; 22212710; 22363791; 22378745; 22406815; 22419736; 22434430; 22462548; 22480519; 22553202; 22564965; 22607554; 22674476; 22688514; 22815988; 22833096; 22869372; 22897928; 22935535; 22939624; 22939629; 22988252; 23000302; 23022380; 23171948; 23221389; 23228943; 23291726; 23306156; 23324179; 23367447; 23376776; 23417417; 23418352; 23455922; 23463002; 23475945; 23506848; 23589839; 23592276; 23602568; 23625915; 23648710; 23671028; 23677989; 23712032; 23716691; 23723070; 23800577; 23819460; 23861218; 23878245; 23904275; 24047437; 24072697; 24095280; 24371122,,,,,,,,,,,,,,,OGG:3000005562,,,,,,,"protein kinase, AMP-activated, alpha 1 catalytic subunit",,,,,,,,,,,,,"Other designations: 5'-AMP-activated protein kinase catalytic subunit alpha-1|5'-AMP-activated protein kinase, catalytic alpha-1 chain|ACACA kinase|AMP -activate kinase alpha 1 subunit|AMP-activated protein kinase, catalytic, alpha-1|AMPK alpha 1|AMPK subunit alpha-1|HMGCR kinase|acetyl-CoA carboxylase kinase|hydroxymethylglutaryl-CoA reductase kinase|tau-protein kinase PRKAA1",,PRKAA1,,,,,,,,,,,,,,,,,,,,,,,5562,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,PRKAA1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0002581,making contact between A and B,,Making contact between A and B is a subtype of decreasing distance: A process that brings object A close to object B to set the distance to 0.,false,,,http://purl.obolibrary.org/obo/TXPO_0002580,,,,,,,,,,,,,,,,,,,,,,Making contact between A and B is a subtype of decreasing distance: A process that brings object A close to object B to set the distance to 0.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002581,,,,,,,,,,,,,,,,,,,,,,making contact between A and B,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002587,moving A to the inside of B,,Moving A to the inside of B is a subtype of changing the relationship between inside and outside: A process that that places an object from the outside to the inside of the boundary.,false,,,http://purl.obolibrary.org/obo/TXPO_0002586,,,,,,,,,,,,,,,,,,,,,,Moving A to the inside of B is a subtype of changing the relationship between inside and outside: A process that that places an object from the outside to the inside of the boundary.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/BFO_0000002,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002587,,,,,,,,,,,,,,,,,,,,,,moving A to the inside of B,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002580,decreasing distance,,Decreasing distance is a subtype of changing distance: A process that brings object A close to object B.,false,,,http://purl.obolibrary.org/obo/TXPO_0000465,,,,,,,,,,,,,,,,,,,,,,Decreasing distance is a subtype of changing distance: A process that brings object A close to object B.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002580,,,,,,,,,,,,,,,,,,,,,,decreasing distance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002582,Glutathione conjugation (supply) - function demand imbalance (severe)  [Glutathione depletion],,"Glutathione conjugation (supply) - function demand imbalance (severe) is a subtype of imbalance: A process that becomes lacking a homeostastasis balance between glutathione conjugation supply and demand. The degree is severe
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0002302|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Glutathione conjugation (supply) - function demand imbalance (severe) is a subtype of imbalance: A process that becomes lacking a homeostastasis balance between glutathione conjugation supply and demand. The degree is severe
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002582,,,,,,,,,,,,,,,,,,,,,,Glutathione conjugation (supply) - function demand imbalance (severe)  [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002585,keeping distance (>0),,Keeping distance (d>0) is a subtype of keeping distance: A process that maintains the relative positional relationship between objects with a certain distance (>0) .,false,,,http://purl.obolibrary.org/obo/TXPO_0002583,,,,,,,,,,,,,,,,,,,,,,Keeping distance (d>0) is a subtype of keeping distance: A process that maintains the relative positional relationship between objects with a certain distance (>0) .,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002585,,,,,,,,,,,,,,,,,,,,,,keeping distance (>0),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002584,keeping adhesivity,,Keeping adhesivity is a subtype of keeping distance: A process that maintains the relative positional relationship between objects with no distance.,false,,,http://purl.obolibrary.org/obo/TXPO_0002583,,,,,,,,,,,,,,,,,,,,,,Keeping adhesivity is a subtype of keeping distance: A process that maintains the relative positional relationship between objects with no distance.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002584,,,,,,,,,,,,,,,,,,,,,,keeping adhesivity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002586,changing the relationship between inside and outside,,Changing the relationship between inside and outside is a subtype of changing position: A process that that changes the relative position between an inside object and an outside object.,false,,,http://purl.obolibrary.org/obo/TXPO_0000464,,,,,,,,,,,,,,,,,,,,,,Changing the relationship between inside and outside is a subtype of changing position: A process that that changes the relative position between an inside object and an outside object.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002586,,,,,,,,,,,,,,,,,,,,,,changing the relationship between inside and outside,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002588,moving A to the outside of B,,Moving A to the outside of B is a subtype of changing the relationship between inside and outside: A process that that places an object from the inside to the outside of the boundary.,false,,,http://purl.obolibrary.org/obo/TXPO_0002586,,,,,,,,,,,,,,,,,,,,,,Moving A to the outside of B is a subtype of changing the relationship between inside and outside: A process that that places an object from the inside to the outside of the boundary.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/BFO_0000002,,,,,,,,,,,,,,,,,,,TXPO:0002588,,,,,,,,,,,,,,,,,,,,,,moving A to the outside of B,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002583,keeping distance,,Keeping distance is a subtype of changing distance: A process that maintains the relative positional relationship between objects.,false,,,http://purl.obolibrary.org/obo/TXPO_0000465,,,,,,,,,,,,,,,,,,,,,,Keeping distance is a subtype of changing distance: A process that maintains the relative positional relationship between objects.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002583,,,,,,,,,,,,,,,,,,,,,,keeping distance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002589,discharging unnecessary object,,Discharging unnecessary object is a subtype of giving: A process that sends out an unnecessary object to an other medium.,false,,,http://purl.obolibrary.org/obo/TXPO_0000459,,,,,,,,,,,,,,,,,,,,,,Discharging unnecessary object is a subtype of giving: A process that sends out an unnecessary object to an other medium.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002589,,,,,,,,,,,,,,,,,,,,,,discharging unnecessary object,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0002980,TEL1,TEL|ETV6,,false,,,http://purl.obolibrary.org/obo/IMR_0000397,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TEL|ETV6,,,,,IMR:0002980,,,,,,,,,,,,,,,,,,,,,,TEL1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OBI_0100026,organism,,"An organism is material entity that is an individual living system, such as animal, plant, bacteria or virus, that is capable of replicating or reproducing, growth and maintenance in the right environment. An organism may be unicellular or made up, like humans, of many billions of cells divided into specialized tissues and organs. A material entity that is an individual living system, such as animal, plant, bacteria or virus, that is capable of replicating or reproducing, growth and maintenance in the right environment. An organism may be unicellular or made up, like humans, of many billions of cells divided into specialized tissues and organs.|Its function is to do life activity.",false,,,http://purl.obolibrary.org/obo/BFO_0000040,,,,,,,,,,,,,,,,,,,,,,"An organism is material entity that is an individual living system, such as animal, plant, bacteria or virus, that is capable of replicating or reproducing, growth and maintenance in the right environment. An organism may be unicellular or made up, like humans, of many billions of cells divided into specialized tissues and organs. A material entity that is an individual living system, such as animal, plant, bacteria or virus, that is capable of replicating or reproducing, growth and maintenance in the right environment. An organism may be unicellular or made up, like humans, of many billions of cells divided into specialized tissues and organs.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://www.w3.org/2002/07/owl#Thing,,,,,,,,,,,,,,OBI:0100026,,,,,,,,,,,,,,,,,,,,Its function is to do life activity.,,organism,,,,,,,http://purl.obolibrary.org/obo/obi.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010630,TFIIB,RNA polymerase II alpha initiation factor|General transcription factor TFIIB|Transcription initiation factor IIB|Transcription factor E|S300-II,,false,,,http://purl.obolibrary.org/obo/IMR_0000888,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003645,,,,,RNA polymerase II alpha initiation factor|General transcription factor TFIIB|Transcription initiation factor IIB|Transcription factor E|S300-II,,,,,IMR:0010630,,,,,,,,,,,,,,,,,,,,,,TFIIB,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000006819,SULT1C2,,"Other designations: SULT1C#1|sulfotransferase 1C1|sulfotransferase 1C2|sulfotransferase family, cytosolic, 1C, member 1",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,ST1C1|SULT1C1|humSULTC2|ST1C2,,,,,,,,,,,,2,,,,,,HGNC:11456|HPRD:03858|MIM:602385|Ensembl:ENSG00000198203|Vega:OTTHUMG00000153215,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"sulfotransferase family, cytosolic, 1C, member 2",,,2q12.3,,,,,,,,,,,,,,,,"GO_0005737 (EC: TAS, PMID: 9169148); GO_0005829 (EC: TAS); GO_0006805 (EC: TAS); GO_0008146 (EC: IDA); GO_0009308 (EC: TAS, PMID: 9169148); GO_0044281 (EC: TAS); GO_0050427 (EC: TAS); GO_0051923 (EC: IDA)",,,,,,,,,PMID: 7642552; 9034160; 9169148; 9635888; 9852044; 10481272; 10720750; 10783263; 11077054; 11154739; 11535246; 11740338; 12477932; 15489334; 16341674; 16507781; 16804942; 17425406; 18029348; 19343046; 19898482; 20453000; 20819778; 21044950; 21139048; 21988832,,,,,,,,,,,,,,,OGG:3000006819,,20140408,protein-coding,,,,"sulfotransferase family, cytosolic, 1C, member 2",,,,,,,,,,,,,"Other designations: SULT1C#1|sulfotransferase 1C1|sulfotransferase 1C2|sulfotransferase family, cytosolic, 1C, member 1",,SULT1C2,,,,,,,,,,,,,,,,,,,,,,,6819,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,SULT1C2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000689,p38delta,SAPK-4,,false,,,http://purl.obolibrary.org/obo/IMR_0000226,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,SAPK-4,,,,,IMR:0000689,,,,,,,,,,,,,,,,,,,,,,p38delta,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_4439,dermatan,Dermatan L-iduronate|Dermatan,A mucopolysaccharide consisting of repeating beta-(1->4)-linked L-iduronyl-(beta1->3)-N-acetyl-D-galactosamine units.,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,,,A mucopolysaccharide consisting of repeating beta-(1->4)-linked L-iduronyl-(beta1->3)-N-acetyl-D-galactosamine units.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Dermatan,,Dermatan L-iduronate,,,,,,,,,,,,,,,,,,,,,CHEBI:4439,,,,dermatan,,CHEBI:4439,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_33280,molecular messenger,chemical messenger,,false,,,http://purl.obolibrary.org/obo/CHEBI_24432|http://purl.obolibrary.org/obo/TXPO_0001393,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,chemical messenger,,,,,,,,,,,,,,,,,,,,,CHEBI:33280,,,,molecular messenger,,CHEBI:33280,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_50903,carcinogenic agent,agente carcinogeno|carcinogene|cancerogene|cancerigene|carcinogenic agents|carcinogen|carcinogens|carcinogeno,"A role played by a chemical compound which is known to  induce a process of carcinogenesis  by corrupting  normal cellular pathways, leading to the acquistion of tumoral capabilities.",false,,,http://purl.obolibrary.org/obo/CHEBI_52209,,,,,,,,,,,,,,,,,,,,,,"A role played by a chemical compound which is known to  induce a process of carcinogenesis  by corrupting  normal cellular pathways, leading to the acquistion of tumoral capabilities.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,agente carcinogeno|carcinogene|cancerogene|cancerigene|carcinogenic agents|carcinogen|carcinogens|carcinogeno,,,,,,,,,,,,,,,,,,,,,CHEBI:50903,,,,carcinogenic agent,,CHEBI:50903,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_49323,contraceptive drug,contraceptive drugs|contraceptive agent,A chemical substance that prevents or reduces the probability of conception.,false,,,http://purl.obolibrary.org/obo/CHEBI_50689,,,,,,,,,,,,,,,,,,,,,,A chemical substance that prevents or reduces the probability of conception.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,contraceptive drugs|contraceptive agent,,,,,,,,,,,,,,,,,,,,,CHEBI:49323,,,,contraceptive drug,,CHEBI:49323,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0090077,foam cell differentiation,,"The process in which a relatively unspecialized cell acquires the specialized features of a foam cell. A foam cell is a type of cell containing lipids in small vacuoles and typically seen in atherosclerotic lesions, as well as other conditions.",false,,,http://purl.obolibrary.org/obo/GO_0030154,,,,,,,,,,,,,,,,,,,,,,"The process in which a relatively unspecialized cell acquires the specialized features of a foam cell. A foam cell is a type of cell containing lipids in small vacuoles and typically seen in atherosclerotic lesions, as well as other conditions.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0090077,,,,,,,,,,,,,,,,,,,,,,foam cell differentiation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000084320,ACBD6,,Other designations: acyl-CoA-binding domain-containing protein 6|acyl-Coenzyme A binding domain containing 6,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,1,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,acyl-CoA binding domain containing 6,,,1q25.1,,,,,,,,,,,,,,,,GO_0000062 (EC: IEA); GO_0005737 (EC: IEA); GO_0008289 (EC: IEA),,,,,,,,,PMID: 8889549; 12477932; 15489334; 16710414; 18029348; 18268358; 19471022; 20098747; 20379614; 21139048; 21832049; 21890473; 21963094; 22053931,,,,,,,,,,,,,,,OGG:3000084320,,,,,,,acyl-CoA binding domain containing 6,,,,,,,,,,,,,Other designations: acyl-CoA-binding domain-containing protein 6|acyl-Coenzyme A binding domain containing 6,,ACBD6,,,,,,,,,,,,,,,,,,,,,,,84320,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,ACBD6,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0003045,BMP-1/TLD family,bone morphogenetic protein-1/tolloid family,"The BMP-1/TLD metalloproteinases, conserved in species ranging from Drosophila to humans, act in dorsal-ventral patterning via activation of BMP2, BMP4 (vertebrates) and Dpp (arthropods).

There are four mammalian BMP-1/TLD-like proteinases, including BMP-1/mTLD, which is encoded by alternatively spliced mRNA produced by the Bmp1 gene, and TLL1 and TLL2, which are genetically distinct.",false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,"The BMP-1/TLD metalloproteinases, conserved in species ranging from Drosophila to humans, act in dorsal-ventral patterning via activation of BMP2, BMP4 (vertebrates) and Dpp (arthropods).

There are four mammalian BMP-1/TLD-like proteinases, including BMP-1/mTLD, which is encoded by alternatively spliced mRNA produced by the Bmp1 gene, and TLL1 and TLL2, which are genetically distinct.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000304,,,,,bone morphogenetic protein-1/tolloid family,,,,,IMR:0003045,,,,,,,,,,,,,,,,,,,,,,BMP-1/TLD family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001016,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A",,,false,,,http://purl.obolibrary.org/obo/IMR_0100700,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001016,,,,,,,,,,,,,,,,,,,,,,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001588,Rab11A,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001588,,,,,,,,,,,,,,,,,,,,,,Rab11A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000413,cytokeratin 17,,,false,,,http://purl.obolibrary.org/obo/IMR_0000035,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000413,,,,,,,,,,,,,,,,,,,,,,cytokeratin 17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100383,Cip1,p21|cyclin-dependent kinase inhibitor 1|Cdk inhibitor protein,,false,,,http://purl.obolibrary.org/obo/IMR_0000446,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p21|cyclin-dependent kinase inhibitor 1|Cdk inhibitor protein,,,,,IMR:0100383,,,,,,,,,,,,,,,,,,,,,,Cip1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000010417,SPON2,,Other designations: differentially expressed in cancerous and non-cancerous lung cells 1|spondin-2,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,M-SPONDIN|DIL1|MINDIN|DIL-1,,,,,,,,,,,,4,,,,,,HPRD:16174|MIM:605918|Ensembl:ENSG00000159674|HGNC:11253|Vega:OTTHUMG00000089002,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"spondin 2, extracellular matrix protein",,,4p16.3,,,,,,,,,,,,,,,,"GO_0005578 (EC: IEA); GO_0007155 (EC: IEA); GO_0007411 (EC: TAS, PMID: 10512675); GO_0045087 (EC: IEA); GO_0046872 (EC: IEA); GO_0070062 (EC: IDA, PMID: 19056867)",,,,,,,,,PMID: 10512675; 12477932; 12975309; 14702039; 15094111; 15489334; 16303743; 16344560; 16368877; 18239089; 19056867; 19153605; 19903741; 20379614; 21098016; 21632881; 22615945,,,,,,,,,,,,,,,OGG:3000010417,,20140408,protein-coding,,,,"spondin 2, extracellular matrix protein",,,,,,,,,,,,,Other designations: differentially expressed in cancerous and non-cancerous lung cells 1|spondin-2,,SPON2,,,,,,,,,,,,,,,,,,,,,,,10417,UNQ435/PRO866,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,SPON2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000010419,PRMT5,,Other designations: 72 kDa ICln-binding protein|HMT1 hnRNP methyltransferase-like 5|SKB1 homolog|histone-arginine N-methyltransferase PRMT5|jak-binding protein 1|protein arginine N-methyltransferase 5|shk1 kinase-binding protein 1 homolog,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,IBP72|HRMT1L5|SKB1Hs|SKB1|JBP1,,,,,,,,,,,,14,,,,,,Vega:OTTHUMG00000028709|HGNC:10894|HPRD:04955|MIM:604045|Ensembl:ENSG00000100462,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,protein arginine methyltransferase 5,,,14q11.2,,,,,,,,,,,,,,,,"GO_0000122 (EC: IEA); GO_0000387 (EC: IMP, PMID: 17709427); GO_0000387 (EC: TAS); GO_0003682 (EC: IEA); GO_0005515 (EC: IPI, PMID: 16087681); GO_0005634 (EC: IDA); GO_0005634 (EC: NAS, PMID: 18404153); GO_0005737 (EC: IDA); GO_0005829 (EC: IDA, PMID: 18984161); GO_0005829 (EC: TAS); GO_0006351 (EC: IEA); GO_0006355 (EC: IBA); GO_0007088 (EC: TAS, PMID: 9843966); GO_0008168 (EC: IDA, PMID: 15369763); GO_0008283 (EC: TAS, PMID: 9843966); GO_0008469 (EC: IBA); GO_0010467 (EC: TAS); GO_0016070 (EC: TAS); GO_0018216 (EC: IMP, PMID: 17709427); GO_0019918 (EC: IMP, PMID: 17709427); GO_0034660 (EC: TAS); GO_0034709 (EC: IDA, PMID: 18984161); GO_0035243 (EC: IMP, PMID: 17709427); GO_0035246 (EC: IDA, PMID: 15369763); GO_0042118 (EC: IMP); GO_0043021 (EC: IPI, PMID: 17709427); GO_0043985 (EC: NAS, PMID: 18404153)",,,,,,,,,PMID: 9556550; 9843966; 10531356; 10734105; 11152681; 11713266; 11720283; 11747828; 11756452; 12101096; 12358155; 12477932; 12665801; 12718890; 12972618; 14559996; 14583623; 14702039; 15130578; 15324660; 15369763; 15485929; 15489334; 15654770; 15670829; 15701830; 15737618; 16087681; 16169070; 16300736; 16428440; 16699504; 16712789; 16969126; 16980624; 17409432; 17437848; 17452440; 17573539; 17620599; 17627275; 17643375; 17707232; 17709427; 17925232; 17974993; 18029348; 18347060; 18404153; 18562274; 18694959; 18781797; 18984161; 18992153; 19032343; 19086919; 19167051; 19188441; 19234465; 19380743; 19520849; 19738201; 19741270; 20195544; 20360068; 20421892; 20473970; 20495075; 20811636; 20951943; 21081503; 21081666; 21118156; 21139048; 21145461; 21159818; 21262773; 21316606; 21385873; 21592330; 21700716; 21890473; 21906983; 21907836; 21917714; 21963094; 21975038; 21987572; 22143770; 22169276; 22179613; 22193545; 22199349; 22231400; 22266372; 22268729; 22269951; 22354994; 22365833; 22586326; 22708516; 22726390; 22797925; 22863883; 22939629; 22952863; 23071334; 23084401; 23133559; 23184937; 23246001; 23261437; 23292799; 23398456; 23455922; 23455924; 23569248; 23671120; 23862649; 23904475; 23912080; 24121109; 24163370; 24189068,,,,,,,,,,,,,,,OGG:3000010419,,,,,,,protein arginine methyltransferase 5,,,,,,,,,,,,,Other designations: 72 kDa ICln-binding protein|HMT1 hnRNP methyltransferase-like 5|SKB1 homolog|histone-arginine N-methyltransferase PRMT5|jak-binding protein 1|protein arginine N-methyltransferase 5|shk1 kinase-binding protein 1 homolog,,PRMT5,,,,,,,,,,,,,,,,,,,,,,,10419,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,PRMT5,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/GO_0019222,regulation of metabolic process,regulation of metabolism,"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways within a cell or an organism.",false,,,http://purl.obolibrary.org/obo/TXPO_0000113,,,,,,,,,,,,,,,,,,,,,,"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways within a cell or an organism.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,regulation of metabolism,,,,,GO:0019222,,,,,,,,,,,,,,,,,,,,,,regulation of metabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0008152,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_37739,glycerophospholipid,phosphoglyceride|phosphatide,Any glycerolipid having a phosphate group ester-linked to a terminal carbon of the glycerol backbone.,false,,,http://purl.obolibrary.org/obo/CHEBI_16247|http://purl.obolibrary.org/obo/CHEBI_35741,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0001384|PMID:17393491,,Any glycerolipid having a phosphate group ester-linked to a terminal carbon of the glycerol backbone.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,phosphoglyceride|phosphatide,,,,,CHEBI:37739,,,,,,,,,,,,,,,,,,,,,,glycerophospholipid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000900,alcohol metabolic process [Lipidosis],,"The chemical reactions and pathways involving alcohols, any of a class of compounds containing one or more hydroxyl groups attached to a saturated carbon atom.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/GO_0006066,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways involving alcohols, any of a class of compounds containing one or more hydroxyl groups attached to a saturated carbon atom.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000892,,,,,,,,,,,TXPO:0000900,,,,,,,,,,,,,,,,,,,,,,alcohol metabolic process [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000904,NRF2 signaling (primitive) [Glutathione depletion],,"NRF2 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal transmitted by the NRF2.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0000889|http://purl.obolibrary.org/obo/TXPO_0000449,,,,,,,,,,,,,,,,,,,,,,"NRF2 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal transmitted by the NRF2.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002392|http://purl.obolibrary.org/obo/TXPO_0001934,,,,,,http://purl.obolibrary.org/obo/TXPO_0002379|http://purl.obolibrary.org/obo/TXPO_0001194|http://purl.obolibrary.org/obo/TXPO_0002430|http://purl.obolibrary.org/obo/TXPO_0002363|http://purl.obolibrary.org/obo/TXPO_0002367|http://purl.obolibrary.org/obo/TXPO_0002368|http://purl.obolibrary.org/obo/TXPO_0000813|http://purl.obolibrary.org/obo/TXPO_0001149|http://purl.obolibrary.org/obo/TXPO_0000844,,,,,,,,,,,TXPO:0000904,,,,,,,,,,,,,,,,,,,,,,NRF2 signaling (primitive) [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000907,phospholipid homeostasis imbalance [Phospholipidosis],,"Phospholipid homeostasis imbalance is a subtype of lipid homeostasis imbalance: A process that becomes lacking a phospholipid homeostastasis balance.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001243|http://purl.obolibrary.org/obo/TXPO_0000951,,,,,,,,,,,,,,,,,,,,,,"Phospholipid homeostasis imbalance is a subtype of lipid homeostasis imbalance: A process that becomes lacking a phospholipid homeostastasis balance.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002324,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000910,,,,,,,,,,,TXPO:0000907,,,,,,,,,,,,,,,,,,,,,,phospholipid homeostasis imbalance [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000902,changing abnormal cellular structure [Phospholipidosis],,"Changing abnormal cellular structure is a subtype of changing structure: A process that changes the structure of the cell abnormally.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001770|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Changing abnormal cellular structure is a subtype of changing structure: A process that changes the structure of the cell abnormally.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000902,,,,,,,,,,,,,,,,,,,,,,changing abnormal cellular structure [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000905,negative regulation of phospholipid degradation [Phospholipidosis],,"Negative regulation of phospholipid degradation is a subtype of negative regulation of decomposing: A process that stops, prevents, or reduces the frequency, rate or extent of phospholipid degradation.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001256|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of phospholipid degradation is a subtype of negative regulation of decomposing: A process that stops, prevents, or reduces the frequency, rate or extent of phospholipid degradation.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000925,,,,,,,,,,,TXPO:0000905,,,,,,,,,,,,,,,,,,,,,,negative regulation of phospholipid degradation [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000903,increasing phospholipid inflow (severe) [Phospholipidosis (severe) ],,"Increasing phospholipid inflow (severe) is a subtype of increase in phospholipid inflow: A process that changes the phospholipid inflow into the hepatocyte to be larger. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",false,,,http://purl.obolibrary.org/obo/TXPO_0001251|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Increasing phospholipid inflow (severe) is a subtype of increase in phospholipid inflow: A process that changes the phospholipid inflow into the hepatocyte to be larger. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003435,,,,,,,,,,,TXPO:0000903,,,,,,,,,,,,,,,,,,,,,,increasing phospholipid inflow (severe) [Phospholipidosis (severe) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000909,increasing demand for phospholipid degradation [Phospholipidosis],,"Increasing demand for phospholipid degradation is a subtype of increasing functional demand: A process that changes the functional demand for the phospholipid degradation to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0001248,,,,,,,,,,,,,,,,,,,,,,"Increasing demand for phospholipid degradation is a subtype of increasing functional demand: A process that changes the functional demand for the phospholipid degradation to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000907,,,,,,,,,,,TXPO:0000909,,,,,,,,,,,,,,,,,,,,,,increasing demand for phospholipid degradation [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000906,IRE - stress sensor (canonical)[ER stress - apotosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002602,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000881,,,,,,,,,,TXPO:0000906,,,,,,,,,,,,,,,,,,,,,,IRE - stress sensor (canonical)[ER stress - apotosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002710,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000908,hyperfunction of phospholipid biosynthesis [Phospholipidosis],,"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of phospholipids.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001410|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of phospholipids.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002324,,,,,,,,,,,TXPO:0000908,,,,,,,,,,,,,,,,,,,,,,hyperfunction of phospholipid biosynthesis [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000901,hypofunction of mitochondrial fatty acid beta-oxidation [Lipidosis],,"Hypofunction of mitochondrial fatty acid beta-oxidation is a subtype of hypofunction of fatty acid beta-oxidation: A process that performs a decreased or insufficient fatty acid beta-oxidation.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0002112,,,,,,,,,,,,,,,,,,,,,,"Hypofunction of mitochondrial fatty acid beta-oxidation is a subtype of hypofunction of fatty acid beta-oxidation: A process that performs a decreased or insufficient fatty acid beta-oxidation.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001036,,,,,,,,,,,TXPO:0000901,,,,,,,,,,,,,,,,,,,,,,hypofunction of mitochondrial fatty acid beta-oxidation [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002459,refolding-unfolding imbalance,,Refolding-unfolding imbalance is a subtype of imbalance: A process that lacks a balance between protein refolding and unfolding.,false,,,http://purl.obolibrary.org/obo/TXPO_0000567,,,,,,,,,,,,,,,,,,,,,,Refolding-unfolding imbalance is a subtype of imbalance: A process that lacks a balance between protein refolding and unfolding.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002459,,,,,,,,,,,,,,,,,,,,,,refolding-unfolding imbalance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002453,Gclc (mouse)[Glutathione depletion],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000163|http://purl.obolibrary.org/obo/TXPO_0002285,,,,,,,,,,,,,,,,,,,,PMID:18078705|PMID:29039508|PMID:1784629|PMID:29549912,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002394,,,,,,,,,,TXPO:0002453,,,,,,,,,,,,,,,,,,,,,,Gclc (mouse)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002456,excretion of glutathione conjugates from hepatocyte to blood,,Excretion of glutathione conjugates from hepatocyte to blood is a subtype of compound excretion: A process that excretes the glutathione conjugates from the hepatocyte to to blood.,false,,,http://purl.obolibrary.org/obo/TXPO_0002551,,,,,,,,,,,,,,,,,,,,,,Excretion of glutathione conjugates from hepatocyte to blood is a subtype of compound excretion: A process that excretes the glutathione conjugates from the hepatocyte to to blood.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002456,,,,,,,,,,,,,,,,,,,,,,excretion of glutathione conjugates from hepatocyte to blood,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002454,signaling molecule activation,,Signaling molecule activation is a subtype of molecular activation: A process that changes the activity of the molecule with a signaling molecule role to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000023,,,,,,,,,,,,,,,,,,,,,,Signaling molecule activation is a subtype of molecular activation: A process that changes the activity of the molecule with a signaling molecule role to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,TXPO:0002454,,,,,,,,,,,,,,,,,,,,,,signaling molecule activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002452,bromobenzene [Glutathione depletion],,"The simplest member of the class of bromobenzenes, that is benzene in which a single hydrogen has been substituted by a bromine. A liquid at room temperature (m.p. -30degreeC; b.p.760 156degreeC), it is used as a solvent, particularly for large-scale crystallisations, and for the introduction of phenyl groups in organic synthesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001921|http://purl.obolibrary.org/obo/CHEBI_3179,,,,,,,,,,,,,,,,,,,,MetaCyc:BROMOBENZENE|PMID:569914|CAS:108-86-1|PMID:20621112|PMID:18078705|Wikipedia:Bromobenzene,,"The simplest member of the class of bromobenzenes, that is benzene in which a single hydrogen has been substituted by a bromine. A liquid at room temperature (m.p. -30degreeC; b.p.760 156degreeC), it is used as a solvent, particularly for large-scale crystallisations, and for the introduction of phenyl groups in organic synthesis.",,,,,,,,,,,,C6H5Br,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002452,,,,,,,,,,,,,,,,,,,,,,bromobenzene [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Brc1ccccc1,,,,,
http://purl.obolibrary.org/obo/TXPO_0002455,excretion of glutathione conjugates from hepatocyte to bile tube,,Excretion of glutathione conjugates from hepatocyte to bile tube is a subtype of compound excretion: A process that excretes the glutathione conjugates from the hepatocyte to to the bile tube.,false,,,http://purl.obolibrary.org/obo/TXPO_0002551,,,,,,,,,,,,,,,,,,,,,,Excretion of glutathione conjugates from hepatocyte to bile tube is a subtype of compound excretion: A process that excretes the glutathione conjugates from the hepatocyte to to the bile tube.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002455,,,,,,,,,,,,,,,,,,,,,,excretion of glutathione conjugates from hepatocyte to bile tube,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002457,glutathione export from hepatocyte to blood,,glutathione export from hepatocyte to blood is a subtype of glutathione transport: A process that exports the glutathione from the hepatocyte to to the blood.,false,,,http://purl.obolibrary.org/obo/TXPO_0002480,,,,,,,,,,,,,,,,,,,,,,glutathione export from hepatocyte to blood is a subtype of glutathione transport: A process that exports the glutathione from the hepatocyte to to the blood.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002457,,,,,,,,,,,,,,,,,,,,,,glutathione export from hepatocyte to blood,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002451,hyperfunction of peroxisomal fatty acid beta-oxidation (severe) [Eosinophilic granular degeneration],,"Hyperfunction of peroxisomal fatty acid beta-oxidation is a subtype of hyperfunction of fatty acid beta-oxidation: A process that performs an excessive peroxisomal fatty acid beta-oxidation. The degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/TXPO_0000177|http://purl.obolibrary.org/obo/TXPO_0000176,,,,,,,,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2948931/,,"Hyperfunction of peroxisomal fatty acid beta-oxidation is a subtype of hyperfunction of fatty acid beta-oxidation: A process that performs an excessive peroxisomal fatty acid beta-oxidation. The degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001074|http://purl.obolibrary.org/obo/TXPO_0001061|http://purl.obolibrary.org/obo/TXPO_0001060|http://purl.obolibrary.org/obo/TXPO_0003250,,,,,,http://purl.obolibrary.org/obo/TXPO_0002391|http://purl.obolibrary.org/obo/TXPO_0000103,,,,,,,,,,,TXPO:0002451,,,,,,,,,,,,,,,,,,,,,,hyperfunction of peroxisomal fatty acid beta-oxidation (severe) [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005777,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002450,decreased amount,,An amount which is relatively low.,false,,,http://purl.obolibrary.org/obo/PATO_0000070,,,,,,,,,,,,,,,,,,,,,,An amount which is relatively low.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002450,,,,,,,,,,,,,,,,,,,,,,decreased amount,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002458,refolding-unfolding imbalance [ER stress (mild) ],,"Refolding-unfolding imbalance is a subtype of imbalance: A process that lacks a balance between protein refolding and unfolding.
This entity is a specific course-dependent process. This process can constitute the course of ER stress (mild).",false,,,http://purl.obolibrary.org/obo/TXPO_0000147,,,,,,,,,,,,,,,,,,,,,,"Refolding-unfolding imbalance is a subtype of imbalance: A process that lacks a balance between protein refolding and unfolding.
This entity is a specific course-dependent process. This process can constitute the course of ER stress (mild).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001977,,http://purl.obolibrary.org/obo/TXPO_0000680,,,,,,,,,TXPO:0002458,,,,,,,,,,,,,,,,,,,,,,refolding-unfolding imbalance [ER stress (mild) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005783,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_24195,gamma-glutamylcysteine,gamma-GC,,false,,,http://purl.obolibrary.org/obo/CHEBI_23367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,gamma-GC,,,,,CHEBI:24195,,,,,,,,,,,,,,,,,,,,,,gamma-glutamylcysteine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000502,AGGF1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:55109|NCBI-Rat-GeneID:310005|NCBI-Mouse-GeneID:66549,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000055109,,,,,,,,,,,,,TXPO:1000502,,,,,,,,,,,,,,,,,,,,,,AGGF1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000504,BCL2A1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:12044|NCBI-Human-GeneID:597|NCBI-Rat-GeneID:170929,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000597,,,,,,,,,,,,,TXPO:1000504,,,,,,,,,,,,,,,,,,,,,,BCL2A1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000500,ACSM2A (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:123876|NCBI-Rat-GeneID:246263,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000123876,,,,,,,,,,,,,TXPO:1000500,,,,,,,,,,,,,,,,,,,,,,ACSM2A (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000507,CDK1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:54237|NCBI-Mouse-GeneID:12534|NCBI-Human-GeneID:983,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000983,,,,,,,,,,,,,TXPO:1000507,,,,,,,,,,,,,,,,,,,,,,CDK1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000509,CXCL6 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:60665|NCBI-Human-GeneID:6372,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000006372,,,,,,,,,,,,,TXPO:1000509,,,,,,,,,,,,,,,,,,,,,,CXCL6 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000501,ACSM2B (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:348158,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000348158,,,,,,,,,,,,,TXPO:1000501,,,,,,,,,,,,,,,,,,,,,,ACSM2B (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000508,CLMN (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:299285|NCBI-Human-GeneID:79789|NCBI-Mouse-GeneID:94040,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000079789,,,,,,,,,,,,,TXPO:1000508,,,,,,,,,,,,,,,,,,,,,,CLMN (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000506,CDCA5 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:67849|NCBI-Rat-GeneID:684771|NCBI-Human-GeneID:113130,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000113130,,,,,,,,,,,,,TXPO:1000506,,,,,,,,,,,,,,,,,,,,,,CDCA5 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000503,ATAD2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:70472|NCBI-Rat-GeneID:314993|NCBI-Human-GeneID:29028,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000029028,,,,,,,,,,,,,TXPO:1000503,,,,,,,,,,,,,,,,,,,,,,ATAD2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000772,group XV phospholipaseA2,lysosomal phospholopase A2,,false,,,http://purl.obolibrary.org/obo/IMR_0000283,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,lysosomal phospholopase A2,,,,,TXPO:0000772,,,,,,,,,,,,,,,,,,,,,,group XV phospholipaseA2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000773,DNA damage (severe) [necrosis],,"Drug-, radiation-induced, or spontaneous injuries to DNA that introduce deviations from its normal double-helical conformation. These changes include structural distortions that interfere with replication and transcription, as well as point mutations that disrupt base pairs and exert damaging effects on future generations through changes in DNA sequence. If the damage is minor, it can often be repaired (DNA repair); extensive damage can induce apoptosis. The degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of necrosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001727|http://purl.obolibrary.org/obo/NCIT_C16507,,,,,,,,,,,,,,,,,,,,,,"Drug-, radiation-induced, or spontaneous injuries to DNA that introduce deviations from its normal double-helical conformation. These changes include structural distortions that interfere with replication and transcription, as well as point mutations that disrupt base pairs and exert damaging effects on future generations through changes in DNA sequence. If the damage is minor, it can often be repaired (DNA repair); extensive damage can induce apoptosis. The degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of necrosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002387,,,,,,,,,,,TXPO:0000773,,,,,,,,,,,,,,,,,,,,,,DNA damage (severe) [necrosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000771,Cebpd (rat)[ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000753|http://purl.obolibrary.org/obo/TXPO_1000415,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:25695|http://omim.org/entry/116898|PMID:17011499|PMID:9492058|PMID:22347430|PMID:24155666,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003645,,,,,,,,,,TXPO:0000771,,,,,,,,,,,,,,,,,,,,,,Cebpd (rat)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000760,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000777,Arrb2 (mouse)[Ground glass appearance],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001071|http://purl.obolibrary.org/obo/TXPO_0000780,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:409|PMID:30283336|PMID:26582201|PMID:24658455,,,,,,,,,,,,,,,arrestin beta 2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_68495,,,,,,,,,,TXPO:0000777,,,,,,,,,,,,,,,,,,,,,,Arrb2 (mouse)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000770,JNK signaling (primitive) [ER stress],,"JNK signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the JNK (a stress-activated protein kinase (SAPK) ).
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000769|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"JNK signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the JNK (a stress-activated protein kinase (SAPK) ).
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000768,,,,,,http://purl.obolibrary.org/obo/TXPO_0000204,,,,,,,,,,,TXPO:0000770,,,,,,,,,,,,,,,,,,,,,,JNK signaling (primitive) [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000778,CCL2 (human)[ER stress],,PERK->ATF4->CCl2 reactome,false,,,http://purl.obolibrary.org/obo/TXPO_0000793|http://purl.obolibrary.org/obo/TXPO_1000086,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24770,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000778,,,,,,,,,,,,,,,,,,,,PERK->ATF4->CCl2 reactome,,CCL2 (human)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000779,Trib3 (rat)[ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000753|http://purl.obolibrary.org/obo/TXPO_1000378,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:246273|http://omim.org/entry/607898|PMID:12791994|PMID:15775988|PMID:17369260,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000779,,,,,,,,,,,,,,,,,,,,,,Trib3 (rat)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000775,PLA2G15 (canonical)[Phospholipidosis],Phospholipase A2 Group XV [Phospholipidosis],,false,,,http://purl.obolibrary.org/obo/TXPO_0003213|http://purl.obolibrary.org/obo/TXPO_1000281,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:23659|NCBI-Rat-GeneID:361401|NCBI-Mouse-GeneID:192654|http://omim.org/entry/609362|PMID:30077006|PMID:21074554,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003671,,,,,Phospholipase A2 Group XV [Phospholipidosis],,,,,TXPO:0000775,,,,,,,,,,,,,,,,,,,,,,PLA2G15 (canonical)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000776,IGFBP1 (human)[ER stress],,"This gene is a member of the insulin-like growth factor binding protein (IGFBP) family and encodes a protein with an IGFBP domain and a thyroglobulin type-I domain. The protein binds both insulin-like growth factors (IGFs) I and II and circulates in the plasma. Binding of this protein prolongs the half-life of the IGFs and alters their interaction with cell surface receptors. [provided by RefSeq, Jul 2008]",false,,,http://purl.obolibrary.org/obo/TXPO_0000793|http://purl.obolibrary.org/obo/TXPO_1000208,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:3484|PMID:16687408|http://purl.bioontology.org/ontology/MESH/D018970,,"This gene is a member of the insulin-like growth factor binding protein (IGFBP) family and encodes a protein with an IGFBP domain and a thyroglobulin type-I domain. The protein binds both insulin-like growth factors (IGFs) I and II and circulates in the plasma. Binding of this protein prolongs the half-life of the IGFs and alters their interaction with cell surface receptors. [provided by RefSeq, Jul 2008]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000776,,,,,,,,,,,,,,,,,,,,,,IGFBP1 (human)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000009133,CCNB2,,Other designations: G2/mitotic-specific cyclin-B2,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,HsT17299,,,,,,,,,,,,15,,,,,,HPRD:04131|Ensembl:ENSG00000157456|HGNC:1580|MIM:602755|Vega:OTTHUMG00000132715,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,cyclin B2,,,15q22.2,,,,,,,,,,,,,,,,"GO_0000079 (EC: IEA); GO_0000086 (EC: TAS); GO_0000278 (EC: TAS); GO_0001701 (EC: IEA); GO_0005515 (EC: IPI, PMID: 15232106); GO_0005654 (EC: TAS); GO_0005813 (EC: IDA); GO_0005829 (EC: TAS); GO_0007067 (EC: IEA); GO_0007077 (EC: TAS); GO_0015630 (EC: IDA); GO_0016020 (EC: IEA); GO_0019901 (EC: IEA); GO_0040007 (EC: IEA); GO_0043029 (EC: IEA); GO_0048538 (EC: IEA); GO_0051726 (EC: TAS)",,,,,,,,,PMID: 1717476; 7474080; 7474100; 7494303; 7666531; 7737117; 8070405; 8125298; 9094673; 9356466; 9520381; 9539739; 9560267; 9926943; 10958988; 11076863; 11230166; 11256614; 11531413; 11878934; 11960377; 12477932; 12482752; 12727876; 14702039; 14718574; 15232106; 15489334; 15489336; 16381901; 17289878; 17388661; 17533373; 17549666; 18591933; 18692784; 19223528; 19454010; 19664331; 19738611; 19786724; 20360068; 20660152; 20972266; 21139048; 21161946; 21890473; 22916037; 22939629; 23282137; 23455922; 23602568,,,,,,,,,,,,,,,OGG:3000009133,,,,,,,cyclin B2,,,,,,,,,,,,,Other designations: G2/mitotic-specific cyclin-B2,,CCNB2,,,,,,,,,,,,,,,,,,,,,,,9133,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,CCNB2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_1000298,Pdk4 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:5166|NCBI-Rat-GeneID:89813|NCBI-Mouse-GeneID:27273,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000005166,,,,,,,,,,,,,TXPO:1000298,,,,,,,,,,,,,,,,,,,,,,Pdk4 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000292,PTGER4 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:5734|NCBI-Rat-GeneID:84023|NCBI-Mouse-GeneID:19219,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000005734,,,,,,,,,,,,,TXPO:1000292,,,,,,,,,,,,,,,,,,,,,,PTGER4 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000299,Pdp2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:246311|NCBI-Human-GeneID:57546|NCBI-Mouse-GeneID:382051,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000057546,,,,,,,,,,,,,TXPO:1000299,,,,,,,,,,,,,,,,,,,,,,Pdp2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000296,Pcsk7 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:9159|NCBI-Rat-GeneID:29606|NCBI-Mouse-GeneID:18554,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000009159,,,,,,,,,,,,,TXPO:1000296,,,,,,,,,,,,,,,,,,,,,,Pcsk7 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000293,PTPN4 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:5775|NCBI-Rat-GeneID:246116|NCBI-Mouse-GeneID:19258,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000005775,,,,,,,,,,,,,TXPO:1000293,,,,,,,,,,,,,,,,,,,,,,PTPN4 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000295,Pcca (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:687008|NCBI-Human-GeneID:5095|NCBI-Mouse-GeneID:110821,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000005095,,,,,,,,,,,,,TXPO:1000295,,,,,,,,,,,,,,,,,,,,,,Pcca (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000290,PRDM1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:639|NCBI-Mouse-GeneID:12142|NCBI-Rat-GeneID:309871,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000639,,,,,,,,,,,,,TXPO:1000290,,,,,,,,,,,,,,,,,,,,,,PRDM1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000294,Pank1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:53354|NCBI-Mouse-GeneID:75735|NCBI-Rat-GeneID:294088,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000053354,,,,,,,,,,,,,TXPO:1000294,,,,,,,,,,,,,,,,,,,,,,Pank1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000297,Pde2A (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:5138|NCBI-Mouse-GeneID:207728|NCBI-Rat-GeneID:81743,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000005138,,,,,,,,,,,,,TXPO:1000297,,,,,,,,,,,,,,,,,,,,,,Pde2A (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100847,PKA type I alpha regulatory subunit,cAMP-dependent protein kinase type I-alpha regulatory chain|Tissue-specific extinguisher-1|TSE1,,false,,,http://purl.obolibrary.org/obo/IMR_0100702,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,cAMP-dependent protein kinase type I-alpha regulatory chain|Tissue-specific extinguisher-1|TSE1,,,,,IMR:0100847,,,,,,,,,,,,,,,,,,,,,,PKA type I alpha regulatory subunit,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0005975,carbohydrate metabolic process,,"The chemical reactions and pathways involving carbohydrates, any of a group of organic compounds based of the general formula Cx(H2O)y. Includes the formation of carbohydrate derivatives by the addition of a carbohydrate residue to another molecule.",false,,,http://purl.obolibrary.org/obo/GO_0008152,,,,,,,,,,,,,,,,,,,,Wikipedia:Carbohydrate_metabolism,,"The chemical reactions and pathways involving carbohydrates, any of a group of organic compounds based of the general formula Cx(H2O)y. Includes the formation of carbohydrate derivatives by the addition of a carbohydrate residue to another molecule.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0016051|http://purl.obolibrary.org/obo/GO_0016052,,,,,,,,,,,,,,,,,,GO:0005975,,,,,,,,,,,,,,,,,,,,,,carbohydrate metabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0005978,glycogen biosynthetic process,glycogen formation|glycogen anabolism|glycogen synthesis|glycogen biosynthesis,"The chemical reactions and pathways resulting in the formation of glycogen, a polydisperse, highly branched glucan composed of chains of D-glucose residues.",false,,,http://purl.obolibrary.org/obo/GO_0016051,,,,,,,,,,,,,,,,,,,,Reactome:REACT_1736,,"The chemical reactions and pathways resulting in the formation of glycogen, a polydisperse, highly branched glucan composed of chains of D-glucose residues.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_28087,,,,,,,,,,,,,,glycogen formation|glycogen anabolism|glycogen synthesis|glycogen biosynthesis,,,,,GO:0005978,,,,,,,,,,,,,,,,,,,,,,glycogen biosynthetic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0005977,glycogen metabolic process,,"The chemical reactions and pathways involving glycogen, a polydisperse, highly branched glucan composed of chains of D-glucose residues in alpha-(1->4) glycosidic linkage, joined together by alpha-(1->6) glycosidic linkages.",false,,,http://purl.obolibrary.org/obo/GO_0005975,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways involving glycogen, a polydisperse, highly branched glucan composed of chains of D-glucose residues in alpha-(1->4) glycosidic linkage, joined together by alpha-(1->6) glycosidic linkages.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005978|http://purl.obolibrary.org/obo/GO_0005980,,,,,,,,,,,,,,,,,,GO:0005977,,,,,,,,,,,,,,,,,,,,,,glycogen metabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004358,valproic acid [mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/CHEBI_39867|http://purl.obolibrary.org/obo/TXPO_0004312,,,,,,,,,,,,,,,,,,,,PMID:21145849|ISBN:0071769234,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004358,,,,,,,,,,,,,,,,,,,,,,valproic acid [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004359,nagative regulation of mitophagy [mitochondrial disorder],,"Any process that activates or decreases the frequency, rate or extent of mitophagy.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0004977,,,,,,,,,,,,,,,,,,,,PMID:31623280|PMID:31649547,,"Any process that activates or decreases the frequency, rate or extent of mitophagy.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002040|http://purl.obolibrary.org/obo/TXPO_0004368|http://purl.obolibrary.org/obo/TXPO_0004340|http://purl.obolibrary.org/obo/TXPO_0004978,,,,,,,,,,,TXPO:0004359,,,,,,,,,,,,,,,,,,,,,,nagative regulation of mitophagy [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0000423,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004357,BID(canonical) [mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/IMR_0100289|http://purl.obolibrary.org/obo/TXPO_0004293,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:64625|NCBI-Mouse-GeneID:12122|NCBI-Human-GeneID:637|PMID:25339807,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004357,,,,,,,,,,,,,,,,,,,,,,BID(canonical) [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004356,BAX(canonical) [mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/IMR_0000453|http://purl.obolibrary.org/obo/TXPO_0004293,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24887|NCBI-Human-GeneID:581|NCBI-Mouse-GeneID:12028|PMID:25339807,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000327,,,,,,,,,,TXPO:0004356,,,,,,,,,,,,,,,,,,,,,,BAX(canonical) [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004351,redox changes [mitochondrial disorder],,"Any process that results in a change in state of redox.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0005011,,,,,,,,,,,,,,,,,,,,PMID:31623280|PMID:30232152,,"Any process that results in a change in state of redox.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004373|http://purl.obolibrary.org/obo/TXPO_0002230,,,,,,,,,,,TXPO:0004351,,,,,,,,,,,,,,,,,,,,,,redox changes [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004353,diclofenac [mitochondrial disorder],,"A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.",false,,,http://purl.obolibrary.org/obo/TXPO_0004312|http://purl.obolibrary.org/obo/CHEBI_47381,,,,,,,,,,,,,,,,,,,,Wikipedia:Diclofenac|PMID:21145849|ATC:D11AX18|ATC:M02AA15|ATC:M01AB05|ATC:S01BC03,,"A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004353,,,,,,,,,,,,,,,,,,,,,,diclofenac [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004350,mitochondria morphology change [mitochondrial disorder],,"mitochondria morphology changes is a subtype of changing shape: A process that changes the morphology of the mitochondria.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0004888,,,,,,,,,,,,,,,,,,,,PMID:31623280|PMID:27151080,,"mitochondria morphology changes is a subtype of changing shape: A process that changes the morphology of the mitochondria.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000933,,,,,,,,,,,TXPO:0004350,,,,,,,,,,,,,,,,,,,,,,mitochondria morphology change [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004354,nimesulide [mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004312|http://purl.obolibrary.org/obo/CHEBI_44445,,,,,,,,,,,,,,,,,,,,PMID:21145849,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004354,,,,,,,,,,,,,,,,,,,,,,nimesulide [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004352,salicylic acid [mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/CHEBI_16914|http://purl.obolibrary.org/obo/TXPO_0004312,,,,,,,,,,,,,,,,,,,,PMID:21145849|Wikipedia:Salicylic_acid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004352,,,,,,,,,,,,,,,,,,,,,,salicylic acid [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004355,BAK1(canonical) [mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000040|http://purl.obolibrary.org/obo/TXPO_0004293,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:578|NCBI-Mouse-GeneID:12018|NCBI-Rat-GeneID:116502|PMID:25339807,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004355,,,,,,,,,,,,,,,,,,,,,,BAK1(canonical) [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0045234,protein palmitoleylation,,The covalent attachment of a palmitoleyl group to a protein.,false,,,http://purl.obolibrary.org/obo/GO_0006497,,,,,,,,,,,,,,,,,,,,,,The covalent attachment of a palmitoleyl group to a protein.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0045234,,,,,,,,,,,,,,,,,,,,,,protein palmitoleylation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100267,MAPKAPK3,MAPK- activated protein kinase 3|3PK|MAP kinase-activated protein kinase 3,,false,,,http://purl.obolibrary.org/obo/IMR_0001689,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MAPK- activated protein kinase 3|3PK|MAP kinase-activated protein kinase 3,,,,,IMR:0100267,,,,,,,,,,,,,,,,,,,,,,MAPKAPK3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010541,40S ribosomal protein S16,40S small ribosomal protein 16,,false,,,http://purl.obolibrary.org/obo/IMR_0000896,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,40S small ribosomal protein 16,,,,,IMR:0010541,,,,,,,,,,,,,,,,,,,,,,40S ribosomal protein S16,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100204,CAS/CSE,,,false,,,http://purl.obolibrary.org/obo/IMR_0100015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100204,,,,,,,,,,,,,,,,,,,,,,CAS/CSE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000872,NF1-X,TGGCA-binding protein|NF1-X|Nuclear factor 1 X-type|NFI-X|CTF|Nuclear factor 1/X|NF-I/X|CCAAT-box binding transcription factor,,false,,,http://purl.obolibrary.org/obo/IMR_0000409,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0010368,TGGCA-binding protein|NF1-X|Nuclear factor 1 X-type|NFI-X|CTF|Nuclear factor 1/X|NF-I/X|CCAAT-box binding transcription factor,,,,,IMR:0000872,,,,,,,,,,,,,,,,,,,,,,NF1-X,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100043,thyroxine,"T4 Thyroid Hormone|L-Thyroxine|O-(4-Hydroxy-3,5-diidophenyl)-3,5-diiodo-L-tyrosine|Levothyroxin|3,5,3'5'-Tetraiiodo-L-thyronine",,false,,,http://purl.obolibrary.org/obo/CHEBI_33709|http://purl.obolibrary.org/obo/IMR_0100042,,,,,,,,,,,,,,,,,,,,MeSH:D013974,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"T4 Thyroid Hormone|L-Thyroxine|O-(4-Hydroxy-3,5-diidophenyl)-3,5-diiodo-L-tyrosine|Levothyroxin|3,5,3'5'-Tetraiiodo-L-thyronine",,,,,IMR:0100043,,,,,,,,,,,,,,,,,,,,,,thyroxine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001979,enterohepatic circulation,,"Enterohepatic circulation is a subtype of changing between operands: Bile salts secreted by the liver pass into the intestine, are absorbed in large part by the ileum, and return to the liver by way of the portal vein.",false,,,http://purl.obolibrary.org/obo/TXPO_0000261,,,,,,,,,,,,,,,,,,,,PMID:4627839|MeSH:D004764,,"Enterohepatic circulation is a subtype of changing between operands: Bile salts secreted by the liver pass into the intestine, are absorbed in large part by the ileum, and return to the liver by way of the portal vein.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001979,,,,,,,"Bile salts (>90%) are absorbed along the small intestine and transported back by the portal blood to the liver.
They are taken up into hepatocytes and re-secreted into the canaliculi.
This round trip of bile salts between the intestine and the liver is termed enterohepatic circulation.",,,,,,,,,,,,,,,enterohepatic circulation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001972,negative regulation of mitochondrial beta oxidation,,"Negative regulation of mitochondrial beta oxidation is a subtype of negative regulation of decomposing:  Any process that stops, prevents or reduces the frequency, rate or extent of mitochondrial fatty acid beta oxidation.",false,,,http://purl.obolibrary.org/obo/TXPO_0000115,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of mitochondrial beta oxidation is a subtype of negative regulation of decomposing:  Any process that stops, prevents or reduces the frequency, rate or extent of mitochondrial fatty acid beta oxidation.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001972,,,,,,,,,,,,,,,,,,,,,,negative regulation of mitochondrial beta oxidation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001975,tamoxifen -fatty acid oxidation inhibitor [Lipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000787,,,,,,,,,,,,,,,,,,,,PMID:21145849|ISBN:0071769234,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_133190,,,,,,,,,,TXPO:0001975,,,,,,,,,,,,,,,,,,,,,,tamoxifen -fatty acid oxidation inhibitor [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001971,CPT1 inactivation,,CPT1 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the CPT1 to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000021,,,,,,,,,,,,,,,,,,,,,,CPT1 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the CPT1 to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001971,,,,,,,,,,,,,,,,,,,,,,CPT1 inactivation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001970,CPT1  inactivation [Lipidosis],,"CPT1 inactivation is a subtype of is a subtype of molecular inactivation: A process that changes the activity of the activating CPT1 with a nuclear receptor role to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0001971,,,,,,,,,,,,,,,,,,,"Reactome

The set of genes regulated by PPAR-alpha is not fully known in humans, however many examples have been found in mice. Genes directly activated by PPAR-alpha contain peroxisome proliferator receptor elements (PPREs) in their promoters and include:
1) genes involved in fatty acid oxidation and ketogenesis (Acox1, Cyp4a, Acadm, Hmgcs2);
2) genes involved in fatty acid transport (Cd36, , Slc27a1, Fabp1, Cpt1a, Cpt2);
3) genes involved in producing fatty acids and very low density lipoproteins (Me1, Scd1);
4) genes encoding apolipoproteins (Apoa1, Apoa2, Apoa5);
5) genes involved in triglyceride clearance ( Angptl4);
6) genes involved in glycerol metabolism (Gpd1 in mouse);",PMID:21145849,,"CPT1 inactivation is a subtype of is a subtype of molecular inactivation: A process that changes the activity of the activating CPT1 with a nuclear receptor role to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000788,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001974,,,,,,http://purl.obolibrary.org/obo/TXPO_0000901,,,,,,,,,,,TXPO:0001970,,,,,,,,,,,,,,,,,,,,,,CPT1  inactivation [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001976,valproic acid - fatty acid oxidation inhibitor [Lipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000788,,,,,,,,,,,,,,,,,,,,PMID:21145849|ISBN:0071769234,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_133190,,,,,,,,,,TXPO:0001976,,,,,,,,,,,,,,,,,,,,,,valproic acid - fatty acid oxidation inhibitor [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001974,CPT1 -inactivation state(canonical)[lipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001961,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1374|https://www.ncbi.nlm.nih.gov/books/NBK1527/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0002355,,,,http://purl.obolibrary.org/obo/TXPO_0001969|http://purl.obolibrary.org/obo/TXPO_0001967,,,,,,,,,,TXPO:0001974,,,,,,,,,,,,,,,,,,,,,,CPT1 -inactivation state(canonical)[lipidosis],,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001973,negative regulation of mitochondrial beta oxidation [lipidosis],,"Negative regulation of mitochondrial beta oxidation is a subtype of negative regulation of decomposing:  Any process that stops, prevents or reduces the frequency, rate or extent of mitochondrial fatty acid beta oxidation.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0001972,,,,,,,,,,,,,,,,,,,,PMID:21145849,,"Negative regulation of mitochondrial beta oxidation is a subtype of negative regulation of decomposing:  Any process that stops, prevents or reduces the frequency, rate or extent of mitochondrial fatty acid beta oxidation.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000787|http://purl.obolibrary.org/obo/TXPO_0000788|http://purl.obolibrary.org/obo/TXPO_0000880,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001970,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000901,,,,,,,,,,,TXPO:0001973,,,,,,,,,,,,,,,,,,,,,,negative regulation of mitochondrial beta oxidation [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001978,feature gene role,,A role played by the gene which has a characteristic profile of gene expression change in a specific toxic mechanism.,false,,,http://purl.obolibrary.org/obo/TXPO_0001225,,,,,,,,,,,,,,,,,,,,,,A role played by the gene which has a characteristic profile of gene expression change in a specific toxic mechanism.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001978,,,,,,,,,,,,,,,,,,,,,,feature gene role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001977,accumulation of abnormal proteins in ER [ER stress  (mild) ],,"Accumulation of abnormal proteins in ER is a subtype of accumulation of abnormal proteins: A process that keeps abnormal protein(s) in the ER (endoplasmic reticulum).
This entity is a specific course-dependent process. This process can constitute the course of ER stress (mild).",false,,,http://purl.obolibrary.org/obo/TXPO_0000194|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"Accumulation of abnormal proteins in ER is a subtype of accumulation of abnormal proteins: A process that keeps abnormal protein(s) in the ER (endoplasmic reticulum).
This entity is a specific course-dependent process. This process can constitute the course of ER stress (mild).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002460|http://purl.obolibrary.org/obo/TXPO_0000403,,,,,,,,,,,TXPO:0001977,,,,,,,,,,,,,,,,,,,,,,accumulation of abnormal proteins in ER [ER stress  (mild) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005783,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000837,C/EBP gamma,CCAAT/enhancer binding protein gamma,,false,,,http://purl.obolibrary.org/obo/IMR_0000422,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CCAAT/enhancer binding protein gamma,,,,,IMR:0000837,,,,,,,,,,,,,,,,,,,,,,C/EBP gamma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_9448,terbinafine,"terbinafinum|(E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalene methanamine|terbinafine|(E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethylamine|terbinafina|(2E)-N,6,6-trimethyl-N-(1-naphthylmethyl)hept-2-en-4-yn-1-amine|terbinafine",A tertiary amine that is N-methyl-1-naphthalenemethylamine in which the amino hydrogen is replaced by a 3-(tertbutylethynyl)allyl group. An antifungal agent administered orally (generally as the hydrochloride salt) for the treatment of skin and nail infections.,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:24563892|PMID:24389279|PMID:24490976|PMID:24410098|PMID:24126579|CAS:91161-71-6|PMID:24533442|PMID:24447130|PMID:23802806|PMID:23750489|PMID:24581620|PMID:23841559|PMID:23895037|Reaxys:4256376|PMID:24497012|PMID:24452843|PMID:24477462|PMID:24576265|PMID:24352873|PMID:24588014|Drug_Central:2597|DrugBank:DB00857,,A tertiary amine that is N-methyl-1-naphthalenemethylamine in which the amino hydrogen is replaced by a 3-(tertbutylethynyl)allyl group. An antifungal agent administered orally (generally as the hydrochloride salt) for the treatment of skin and nail infections.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_50183|http://purl.obolibrary.org/obo/CHEBI_59285|http://purl.obolibrary.org/obo/CHEBI_83317,,,,,"(2E)-N,6,6-trimethyl-N-(1-naphthylmethyl)hept-2-en-4-yn-1-amine|terbinafine",,"terbinafinum|(E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalene methanamine|terbinafine|(E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethylamine|terbinafina",,,,,,,,,,,,,,,,,,,,,CHEBI:9448,,,,terbinafine,,CHEBI:9448,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100156,gamma-endorphin,,,false,,,http://purl.obolibrary.org/obo/IMR_0100154,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100156,,,,,,,,,,,,,,,,,,,,,,gamma-endorphin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76815,EC 2.7.7.* (nucleotidyltransferase) inhibitor,nucleotidyltransferase inhibitor|nucleotidyltransferase inhibitors|nucleotidyltransferase (EC 2.7.7.*) inhibitor|EC 2.7.7.* (nucleotidyltransferase) inhibitors|inhibitor of nucleotidyltransferases (EC 2.7.7.*)|nucleotidyltransferase (EC 2.7.7.*) inhibitors|inhibitors of nucleotidyltransferases|inhibitor of nucleotidyltransferases|inhibitors of nucleotidyltransferases (EC 2.7.7.*),An EC 2.7.* (P-containing group transferase) inhibitor that interferes with the action of any nucleotidyltransferase (EC 2.7.7.*).,false,,,http://purl.obolibrary.org/obo/CHEBI_76668,,,,,,,,,,,,,,,,,,,,,,An EC 2.7.* (P-containing group transferase) inhibitor that interferes with the action of any nucleotidyltransferase (EC 2.7.7.*).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,nucleotidyltransferase inhibitor|nucleotidyltransferase inhibitors|nucleotidyltransferase (EC 2.7.7.*) inhibitor|EC 2.7.7.* (nucleotidyltransferase) inhibitors|inhibitor of nucleotidyltransferases (EC 2.7.7.*)|nucleotidyltransferase (EC 2.7.7.*) inhibitors|inhibitors of nucleotidyltransferases|inhibitor of nucleotidyltransferases|inhibitors of nucleotidyltransferases (EC 2.7.7.*),,,,,,,,,,,,,,,,,,,,,CHEBI:76815,,,,EC 2.7.7.* (nucleotidyltransferase) inhibitor,,CHEBI:76815,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000418,chloroquine,"N(4)-(7-chloroquinolin-4-yl)-N(1),N(1)-diethylpentane-1,4-diamine","An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.",false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,DrugBank:DB00608|MeSH:D002738|LINCS:LSM-1901|CAS:54-05-7|Patent:US2233970,,"An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.",,,,,,,,,,,,Wikipedia:Chloroquine|C18H26ClN3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"N(4)-(7-chloroquinolin-4-yl)-N(1),N(1)-diethylpentane-1,4-diamine",,,,,TXPO:1000418,,,,,,,,,,,,,,,,,,,,,,chloroquine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12,,,,,
http://purl.obolibrary.org/obo/TXPO_1000414,caspase (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:1000414,,,,,,,,,,,,,,,,,,,,,,caspase (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000419,cxc family (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,http://purl.bioontology.org/ontology/MESH/D019743,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:1000419,,,,,,,,,,,,,,,,,,,,,,cxc family (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000415,cebpd (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:25695|NCBI-Human-GeneID:1052|NCBI-Mouse-GeneID:12609,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001052,,,,,,,,,,,,,TXPO:1000415,,,,,,,,,,,,,,,,,,,,,,cebpd (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0001323,area,,A 2-D extent quality inhering in a bearer by virtue of the bearer's two dimensional extent.,false,,,http://purl.obolibrary.org/obo/TXPO_0000310|http://purl.obolibrary.org/obo/PATO_0000117,,,,,,,,,,,,,,,,,,,,,,A 2-D extent quality inhering in a bearer by virtue of the bearer's two dimensional extent.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0001323,,,,,,,,,,,,,,,,,,,,,,area,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_50743,cyproterone acetate,"CPA|6-chloro-3,20-dioxo-1beta,2beta-dihydro-3'H-cyclopropa[1,2]pregna-4,6-dien-17-yl acetate",,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Wikipedia:Cyproterone_Acetate|CAS:427-51-0,,,,,,,,,,,,,,C24H29ClO4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"CPA|6-chloro-3,20-dioxo-1beta,2beta-dihydro-3'H-cyclopropa[1,2]pregna-4,6-dien-17-yl acetate",,,,,CHEBI:50743,,,,,,,,,,,,,,,,,,,,,,cyproterone acetate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,[H][C@@]12C[C@]1([H])[C@@]1(C)C(=CC2=O)C(Cl)=C[C@@]2([H])[C@]3([H])CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)CC[C@]12[H],,,,,
http://purl.obolibrary.org/obo/CHEBI_50902,genotoxin,genotoxic agent|genotoxic agents|genotoxins,"A role played by a chemical compound to induce direct or indirect DNA damage. Such damage can potentially lead to the formation of a malignant tumour, but DNA damage does not lead inevitably to the creation of cancerous cells.",false,,,http://purl.obolibrary.org/obo/TXPO_0000038|http://purl.obolibrary.org/obo/CHEBI_52209,,,,,,,,,,,,,,,,,,,,Wikipedia:Genotoxicity,,"A role played by a chemical compound to induce direct or indirect DNA damage. Such damage can potentially lead to the formation of a malignant tumour, but DNA damage does not lead inevitably to the creation of cancerous cells.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,genotoxic agent|genotoxic agents|genotoxins,,,,,,,,,,,,,,,,,,,,,CHEBI:50902,,,,genotoxin,,CHEBI:50902,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010552,40S ribosomal protein S27,40S small ribosomal protein 27|Metallopan-stimulin 1|MPS-1,,false,,,http://purl.obolibrary.org/obo/IMR_0000896,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,40S small ribosomal protein 27|Metallopan-stimulin 1|MPS-1,,,,,IMR:0010552,,,,,,,,,,,,,,,,,,,,,,40S ribosomal protein S27,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_5120,fluoxymesterone,"fluoximesterona|17alpha-Methyl-9alpha-fluoro-11beta-hydroxytesterone|fluoxymesterone|fluoxymesteronum|9alpha-Fluoro-11beta-hydroxy-17-methyltestosterone|Testosterone, 9-fluoro-11beta-hydroxy-17-methyl-|9-Fluoro-11beta,17beta-dihydroxy-17-methylandrost-4-en-3-one|11beta,17beta-Dihydroxy-9alpha-fluoro-17alpha-methyl-4-androster-3-one|9-fluoro-11beta,17beta-dihydroxy-17alpha-methylandrost-4-en-3-one",,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,DrugBank:DB01185|Drug_Central:1210|Beilstein:2008796|LIPID_MAPS_instance:LMST02020025|CAS:76-43-7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35610|http://purl.obolibrary.org/obo/CHEBI_36413,,,,,"9-fluoro-11beta,17beta-dihydroxy-17alpha-methylandrost-4-en-3-one",,"fluoximesterona|17alpha-Methyl-9alpha-fluoro-11beta-hydroxytesterone|fluoxymesterone|fluoxymesteronum|9alpha-Fluoro-11beta-hydroxy-17-methyltestosterone|Testosterone, 9-fluoro-11beta-hydroxy-17-methyl-|9-Fluoro-11beta,17beta-dihydroxy-17-methylandrost-4-en-3-one|11beta,17beta-Dihydroxy-9alpha-fluoro-17alpha-methyl-4-androster-3-one",,,,,,,,,,,,,,,,,,,,,CHEBI:5120,,,,fluoxymesterone,,CHEBI:5120,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0200457,Prostaglandin D2,,,false,,,http://purl.obolibrary.org/obo/IMR_0100019,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0200457,,,,,,,,,,,,,,,,,,,,,,Prostaglandin D2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000383,Myc (mol),c-Myc,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:17869|NCBI-Human-GeneID:4609|NCBI-Rat-GeneID:24577,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,c-Myc,,,,,IMR:0000383,,,,,,,,,,,,,,,,,,,,,,Myc (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100623,cyclin G1,cyclin G,,false,,,http://purl.obolibrary.org/obo/IMR_0100622,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,cyclin G,,,,,IMR:0100623,,,,,,,,,,,,,,,,,,,,,,cyclin G1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006979,response to oxidative stress,,"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of oxidative stress, a state often resulting from exposure to high levels of reactive oxygen species, e.g. superoxide anions, hydrogen peroxide (H2O2), and hydroxyl radicals.",false,,,http://purl.obolibrary.org/obo/GO_0006950,,,,,,,,,,,,,,,,,,,,,,"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of oxidative stress, a state often resulting from exposure to high levels of reactive oxygen species, e.g. superoxide anions, hydrogen peroxide (H2O2), and hydroxyl radicals.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0006979,,,,,,,,,,,,,,,,,,,,,,response to oxidative stress,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006974,cellular response to DNA damage stimulus,,"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating damage to its DNA from environmental insults or errors during metabolism.",false,,,http://purl.obolibrary.org/obo/GO_0050896,,,,,,,,,,,,,,,,,,,,,,"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating damage to its DNA from environmental insults or errors during metabolism.",,,,,cellular response to DNA damage stimulus,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0006974,,,,,,,,,,,,,,,,,,,,,,cellular response to DNA damage stimulus,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000374407,DNAJB13,,"Other designations: 1700014P03Rik|DnaJ (Hsp40) related, subfamily B, member 13|DnaJ-like protein|dnaJ homolog subfamily B member 13|radial spoke 16 homolog A|testis and spermatogenesis cell-related protein 6|testis spermatocyte apoptosis-related gene 6 protein|testis spermatogenesis apoptosis-related gene 3 protein|testis spermatogenesis apoptosis-related gene 6 protein|testis spermatogenesis apoptosis-related protein 6",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,RSPH16A|TSARG5|TSARG6,,,,,,,,,,,,11,,,,,,Vega:OTTHUMG00000168093|MIM:610263|HPRD:15573|HGNC:30718|Ensembl:ENSG00000187726,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"DnaJ (Hsp40) homolog, subfamily B, member 13",,,11q13.4,,,,,,,,,,,,,,,,GO_0003674 (EC: ND); GO_0005575 (EC: ND); GO_0006457 (EC: IEA); GO_0051082 (EC: IEA),,,,,,,,,PMID:12673577; 14702039; 14970903; 20677014,,,,,,,,,,,,,,,OGG:3000374407,,,,,,,"DnaJ (Hsp40) homolog, subfamily B, member 13",,,,,,,,,,,,,"Other designations: 1700014P03Rik|DnaJ (Hsp40) related, subfamily B, member 13|DnaJ-like protein|dnaJ homolog subfamily B member 13|radial spoke 16 homolog A|testis and spermatogenesis cell-related protein 6|testis spermatocyte apoptosis-related gene 6 protein|testis spermatogenesis apoptosis-related gene 3 protein|testis spermatogenesis apoptosis-related gene 6 protein|testis spermatogenesis apoptosis-related protein 6",,DNAJB13,,,,,,,,,,,,,,,,,,,,,,,374407,,,,,,,,9606,,,,,,,,,,,,,,,,,,,DNAJB13,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000964,LRP5,low density lipoprotein receptor-related protein 5|LRP7|LDL receptor-related protein 5,,false,,,http://purl.obolibrary.org/obo/IMR_0002954|http://purl.obolibrary.org/obo/IMR_0100798,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,low density lipoprotein receptor-related protein 5|LRP7|LDL receptor-related protein 5,,,,,IMR:0000964,,,,,,,,,,,,,,,,,,,,,,LRP5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000166785,MMAA,,"Other designations: methylmalonic aciduria type A protein, mitochondrial",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,cblA,,,,,,,,,,,,4,,,,,,Vega:OTTHUMG00000161369|MIM:607481|HPRD:07394|Ensembl:ENSG00000151611|HGNC:18871,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,methylmalonic aciduria (cobalamin deficiency) cblA type,,,4q31.21,,,,,,,,,,,,,,,,GO_0005525 (EC: IEA); GO_0005759 (EC: TAS); GO_0006635 (EC: TAS); GO_0006766 (EC: TAS); GO_0006767 (EC: TAS); GO_0009235 (EC: TAS); GO_0009236 (EC: IEA); GO_0017111 (EC: IEA); GO_0019626 (EC: TAS); GO_0044255 (EC: TAS); GO_0044281 (EC: TAS),,,,,,,,,PMID: 12438653; 12477932; 14702039; 15308131; 15489334; 15523652; 16641088; 17597648; 17957493; 19371216; 20301409; 20876572; 21138732; 23026888; 24250222,,,,,,,,,,,,,,,OGG:3000166785,,20140408,protein-coding,,,,methylmalonic aciduria (cobalamin deficiency) cblA type,,,,,,,,,,,,,"Other designations: methylmalonic aciduria type A protein, mitochondrial",,MMAA,,,,,,,,,,,,,,,,,,,,,,,166785,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,MMAA,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0011154,eIF4A-II,eIF4AII|eIF-4A-II|eukaryotic initiation factor 4A-II,,false,,,http://purl.obolibrary.org/obo/IMR_0000906,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0011606,eIF4AII|eIF-4A-II|eukaryotic initiation factor 4A-II,,,,,IMR:0011154,,,,,,,,,,,,,,,,,,,,,,eIF4A-II,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003100,caspase-12 activation,,"Caspase-12 activation is a subtype of caspase activation: A process that changes the activity of the caspase-12, intracellular cysteine endopeptidase family members, to be higher.",false,,,http://purl.obolibrary.org/obo/TXPO_0003095,,,,,,,,,,,,,,,,,,,,,,"Caspase-12 activation is a subtype of caspase activation: A process that changes the activity of the caspase-12, intracellular cysteine endopeptidase family members, to be higher.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003100,,,,,,,,,,,,,,,,,,,,,,caspase-12 activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003104,caspase 3 signaling (primitive) [ER stress - apoptosis],,"Caspase 3 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the caspase 3.
This process is dependent on the apoptosis and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0003736|http://purl.obolibrary.org/obo/TXPO_0000444,,,,,,,,,,,,,,,,,,,,PMID:19737514,,"Caspase 3 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the caspase 3.
This process is dependent on the apoptosis and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003097,http://purl.obolibrary.org/obo/TXPO_0000502,,,,,,,,,,,,,,,,,TXPO:0003104,,,,,,,,,,,,,,,,,,,,,,caspase 3 signaling (primitive) [ER stress - apoptosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003109,BAX activation [ER stress],,"BAX activation is a subtype of molecular activation: A process that changes the activity of the BAX (BCL2 Associated X, Apoptosis Regulator), BCL-2 family, to be higher.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0003108|http://purl.obolibrary.org/obo/TXPO_0003736,,,,,,,,,,,,,,,,,,,,PMID:23334697,,"BAX activation is a subtype of molecular activation: A process that changes the activity of the BAX (BCL2 Associated X, Apoptosis Regulator), BCL-2 family, to be higher.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003113,,,,,,,,,,,TXPO:0003109,,,,,,,,,,,,,,,,,,,,,,BAX activation [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003103,caspase 9 signaling (primitive) [ER stress - apoptosis],,"Caspase 9 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the caspase 9.
This process is dependent on the apoptosis and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0003736|http://purl.obolibrary.org/obo/TXPO_0000444,,,,,,,,,,,,,,,,,,,,PMID:19737514|PMID:23334697,,"Caspase 9 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the caspase 9.
This process is dependent on the apoptosis and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003096,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003104,,,,,,,,,,,TXPO:0003103,,,,,,,,,,,,,,,,,,,,,,caspase 9 signaling (primitive) [ER stress - apoptosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003101,caspase-4 activation,,"Caspase-4 activation is a subtype of caspase activation: A process that changes the activity of the caspase-4, intracellular cysteine endopeptidase family members, to be higher.",false,,,http://purl.obolibrary.org/obo/TXPO_0003095,,,,,,,,,,,,,,,,,,,,,,"Caspase-4 activation is a subtype of caspase activation: A process that changes the activity of the caspase-4, intracellular cysteine endopeptidase family members, to be higher.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003101,,,,,,,,,,,,,,,,,,,,,,caspase-4 activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003106,BAK activation,,"BAK activation is a subtype of molecular activation: A process that changes the activity of the BAK1 (BCL2 Antagonist/Killer 1), BCL-2 family,  to be higher.",false,,,http://purl.obolibrary.org/obo/TXPO_0000023,,,,,,,,,,,,,,,,,,,,,,"BAK activation is a subtype of molecular activation: A process that changes the activity of the BAK1 (BCL2 Antagonist/Killer 1), BCL-2 family,  to be higher.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003106,,,,,,,,,,,,,,,,,,,,,,BAK activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003102,caspase pathway [ER stress - apoptosis],,"A series of molecular signals mediated by Caspase family. This pathway is a specific course-dependent and can constitute the course of ER stress.
This pathway is dependent on the apoptosis and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002482,,,,,,,,,,,,,,,,,,,,,,"A series of molecular signals mediated by Caspase family. This pathway is a specific course-dependent and can constitute the course of ER stress.
This pathway is dependent on the apoptosis and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003104|http://purl.obolibrary.org/obo/TXPO_0003109|http://purl.obolibrary.org/obo/TXPO_0003103|http://purl.obolibrary.org/obo/TXPO_0003107|http://purl.obolibrary.org/obo/TXPO_0003091|http://purl.obolibrary.org/obo/TXPO_0003092|http://purl.obolibrary.org/obo/TXPO_0000445,,,,,,,,,,,,,,,,,,TXPO:0003102,,,,,,,,,,,,,,,,,,,,,,caspase pathway [ER stress - apoptosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003108,BAX activation,,"BAX activation is a subtype of molecular activation: A process that changes the activity of the BAX (BCL2 Associated X, Apoptosis Regulator), BCL-2 family,  to be higher.",false,,,http://purl.obolibrary.org/obo/TXPO_0000023,,,,,,,,,,,,,,,,,,,,,,"BAX activation is a subtype of molecular activation: A process that changes the activity of the BAX (BCL2 Associated X, Apoptosis Regulator), BCL-2 family,  to be higher.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003108,,,,,,,,,,,,,,,,,,,,,,BAX activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003105,release of cytochrome c from mitochondria [ER stress],,"The process that results in the movement of cytochrome c from the mitochondrial intermembrane space into the cytosol, which is part of the apoptotic signaling pathway and leads to caspase activation.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/GO_0001836|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,"Permeabilization of the outer mitochondrial membrane by pro-apoptotic BCL2 family proteins, such as BAK and BAX, allows cytochrome c eflux from the mitochondrial intermembrane space into the cytosol (Arnoult et al. 2003).",Reactome:R-HSA-114284,,"The process that results in the movement of cytochrome c from the mitochondrial intermembrane space into the cytosol, which is part of the apoptotic signaling pathway and leads to caspase activation.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003110,,,,,,,,,,,TXPO:0003105,,,,,,,,,,,,,,,,,,,,,,release of cytochrome c from mitochondria [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003107,BAK activation [ER stress],,"BAK activation is a subtype of molecular activation: A process that changes the activity of the BAK1 (BCL2 Antagonist/Killer 1), BCL-2 family, to be higher.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0003106|http://purl.obolibrary.org/obo/TXPO_0003736,,,,,,,,,,,,,,,,,,,,PMID:23334697,,"BAK activation is a subtype of molecular activation: A process that changes the activity of the BAK1 (BCL2 Antagonist/Killer 1), BCL-2 family, to be higher.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003113,,,,,,,,,,,TXPO:0003107,,,,,,,,,,,,,,,,,,,,,,BAK activation [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0015481,left hepatic artery,ramus sinister (arteria hepatica propria)|left part of hepatic artery proper|left branch of hepatic artery,A hepatic artery that is part of a left lobe of liver.,false,,,http://purl.obolibrary.org/obo/UBERON_0001193,,,,,,,,,,,,,,,,,,,,FMA:14779,,A hepatic artery that is part of a left lobe of liver.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ramus sinister (arteria hepatica propria)|left part of hepatic artery proper|left branch of hepatic artery,,,,,UBERON:0015481,,,,,,,,,,,,,,,,,,,,,,left hepatic artery,,,,http://upload.wikimedia.org/wikipedia/commons/a/a3/Gray1087-liver.png,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0015482,right hepatic artery,,A hepatic artery that is part of a right lobe of liver.,false,,,http://purl.obolibrary.org/obo/UBERON_0001193,,,,,,,,,,,,,,,,,,,,,,A hepatic artery that is part of a right lobe of liver.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,UBERON:0015482,,,,,,,,,,,,,,,,,,,,,,right hepatic artery,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0015480,hepatic artery proper,,"The hepatic artery proper (also proper hepatic artery), arises from the common hepatic artery and runs alongside the portal vein and the common bile duct to form the portal triad. The hepatic artery proper gives off a small supraduodenal artery to the duodenal bulb. Then the right gastric artery comes off and runs to the left along the lesser curvature of the stomach to meet the left gastric artery, which is a branch of the celiac trunk. It subsequently gives off the cystic artery, which feeds the gallbladder, before bifurcating into the right and left hepatic arteries. Of note, the right and left hepatic arteries may demonstrate variant anatomy. A replaced right hepatic artery may arise from the superior mesenteric artery (SMA) and a replaced left hepatic artery may arise from the left gastric artery.",false,,,http://purl.obolibrary.org/obo/UBERON_0001193,,,,,,,,,,,,,,,,,,,,http://en.wikipedia.org/wiki/Hepatic_artery_proper,,"The hepatic artery proper (also proper hepatic artery), arises from the common hepatic artery and runs alongside the portal vein and the common bile duct to form the portal triad. The hepatic artery proper gives off a small supraduodenal artery to the duodenal bulb. Then the right gastric artery comes off and runs to the left along the lesser curvature of the stomach to meet the left gastric artery, which is a branch of the celiac trunk. It subsequently gives off the cystic artery, which feeds the gallbladder, before bifurcating into the right and left hepatic arteries. Of note, the right and left hepatic arteries may demonstrate variant anatomy. A replaced right hepatic artery may arise from the superior mesenteric artery (SMA) and a replaced left hepatic artery may arise from the left gastric artery.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,UBERON:0015480,,,,,,,,,,,,,,,,,,,,,,hepatic artery proper,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/BFO_0000003,occurrent,,,false,,,http://purl.obolibrary.org/obo/BFO_0000001,,,,,,,,,,,,,,,,,,,,,,,,,,"Simons uses different terminology for relations of occurrents to regions: Denote the spatio-temporal location of a given occurrent e by 'spn[e]' and call this region its span. We may say an occurrent is at its span, in any larger region, and covers any smaller region. Now suppose we have fixed a frame of reference so that we can speak not merely of spatio-temporal but also of spatial regions (places) and temporal regions (times). The spread of an occurrent, (relative to a frame of reference) is the space it exactly occupies, and its spell is likewise the time it exactly occupies. We write 'spr[e]' and `spl[e]' respectively for the spread and spell of e, omitting mention of the frame.|Occurrent doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. An example would be the sum of a process and the process boundary of another process.|BFO 2 Reference: every occurrent that is not a temporal or spatiotemporal region is s-dependent on some independent continuant that is not a spatial region|BFO 2 Reference: s-dependence obtains between every process and its participants in the sense that, as a matter of necessity, this process could not have existed unless these or those participants existed also. A process may have a succession of participants at different phases of its unfolding. Thus there may be different players on the field at different times during the course of a football game; but the process which is the entire game s-depends_on all of these players nonetheless. Some temporal parts of this process will s-depend_on on only some of the players.",,An occurrent is an entity that unfolds itself in time or it is the instantaneous boundary of such an entity (for example a beginning or an ending) or it is a temporal or spatiotemporal region which such an entity occupies_temporal_region or occupies_spatiotemporal_region. (axiom label in BFO2 Reference: [077-002]),,,,,,,,,,,,(forall (x) (iff (Occurrent x) (and (Entity x) (exists (y) (temporalPartOf y x))))) // axiom label in BFO2 CLIF: [079-001]|(forall (x) (if (Occurrent x) (exists (r) (and (SpatioTemporalRegion r) (occupiesSpatioTemporalRegion x r))))) // axiom label in BFO2 CLIF: [108-001],Every occurrent occupies_spatiotemporal_region some spatiotemporal region. (axiom label in BFO2 Reference: [108-001])|b is an occurrent entity iff b is an entity that has temporal parts. (axiom label in BFO2 Reference: [079-001]),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BFO:0000003,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/bfo.owl,occurrent,,,occurrent,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003443,negative regulation of phospholipid hydrolysis [Phospholipidosis (moderate) ],,"A process that stops, prevents, or reduces the frequency, rate or extent of phospholipid hydrolysis moderately. And the degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (moderate).",false,,,http://purl.obolibrary.org/obo/TXPO_0003448,,,,,,,,,,,,,,,,,,,,,,"A process that stops, prevents, or reduces the frequency, rate or extent of phospholipid hydrolysis moderately. And the degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (moderate).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003442,,,,,,,,,,,TXPO:0003443,,,,,,,,,,,,,,,,,,,,,,negative regulation of phospholipid hydrolysis [Phospholipidosis (moderate) ],,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003410,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003442,negative regulation of phospholipase-mediated phospholipid degradation by CAD [Phospholipidosis (moderate) ],,"Negative regulation of phospholipase-mediated phospholipid degradation by CAD is a subtype of negative regulation of phospholipid degradation: A process that stops, prevents, or reduces the frequency, rate or extent of phospholipase-mediated phospholipid deradation regulated by CAD. And the degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (moderate).",false,,,http://purl.obolibrary.org/obo/TXPO_0003414,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of phospholipase-mediated phospholipid degradation by CAD is a subtype of negative regulation of phospholipid degradation: A process that stops, prevents, or reduces the frequency, rate or extent of phospholipase-mediated phospholipid deradation regulated by CAD. And the degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (moderate).",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003227|http://purl.obolibrary.org/obo/TXPO_0003228|http://purl.obolibrary.org/obo/TXPO_0000319,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003443|http://purl.obolibrary.org/obo/TXPO_0003368,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003444,,,,,,,,,,,TXPO:0003442,,,,,,,,,,,,,,,,,,,,,,negative regulation of phospholipase-mediated phospholipid degradation by CAD [Phospholipidosis (moderate) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003449,CAD insertion into phospholipase binding site to lysosomal inner membrane [Phospholipidosis (severe) ],,"CAD insertion into phospholipase binding site to lysosomal inner membrane is a subtype of binding: A process that CAD inserts and replaces the phospholipase binding site in the lysosomal inner membrane. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",false,,,http://purl.obolibrary.org/obo/TXPO_0001399,,,,,,,,,,,,,,,,,,,,PMID:22960355,,"CAD insertion into phospholipase binding site to lysosomal inner membrane is a subtype of binding: A process that CAD inserts and replaces the phospholipase binding site in the lysosomal inner membrane. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001560,,,,,,http://purl.obolibrary.org/obo/TXPO_0003450,,,,,,,,,,,TXPO:0003449,,,,,,,,,,,,,,,,,,,,,,CAD insertion into phospholipase binding site to lysosomal inner membrane [Phospholipidosis (severe) ],,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003404,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003447,negative regulation of phospholipid hydrolysis [Phospholipidosis (severe) ],,"A process that stops, prevents, or reduces the frequency, rate or extent of phospholipid hydrolysis severely. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",false,,,http://purl.obolibrary.org/obo/TXPO_0003448,,,,,,,,,,,,,,,,,,,"Phospholipases hydrolyze phospholipids into fatty acids and other lipophilic substances.
This entity indicates mainly to the process of inhibiting phospholipases.",,,"A process that stops, prevents, or reduces the frequency, rate or extent of phospholipid hydrolysis severely. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003450,,,,,,,,,,,TXPO:0003447,,,,,,,,,,,,,,,,,,,,,,negative regulation of phospholipid hydrolysis [Phospholipidosis (severe) ],,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003410,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003444,negative regulation of phospholipid degradation [Phospholipidosis (moderate) ],,"A process that stops, prevents, or reduces the frequency, rate or extent of phospholipid degradation. And the degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (moderate).",false,,,http://purl.obolibrary.org/obo/TXPO_0000905,,,,,,,,,,,,,,,,,,,,,,"A process that stops, prevents, or reduces the frequency, rate or extent of phospholipid degradation. And the degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (moderate).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003442,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003372|http://purl.obolibrary.org/obo/TXPO_0003282,,,,,,,,,,,TXPO:0003444,,,,,,,,,,,,,,,,,,,,,,negative regulation of phospholipid degradation [Phospholipidosis (moderate) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003446,negative regulation of phospholipase-mediated phospholipid degradation by CAD,,"Negative regulation of phospholipase-mediated phospholipid degradation by CAD is a subtype of negative regulation of phospholipid degradation: A process that stops, prevents, or reduces the frequency, rate or extent of phospholipid deradation by phospholipase.",false,,,http://purl.obolibrary.org/obo/TXPO_0001256,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of phospholipase-mediated phospholipid degradation by CAD is a subtype of negative regulation of phospholipid degradation: A process that stops, prevents, or reduces the frequency, rate or extent of phospholipid deradation by phospholipase.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003446,,,,,,,,,,,,,,,,,,,,,,negative regulation of phospholipase-mediated phospholipid degradation by CAD,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0009395,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003445,hypofunction of ceramide degradation [sphingomyelin disorder ],,"Hypofunction of ceramide degradation is a subtype of hypofunction of lipid degradation: A process that performs a decreased or insufficient ceramide degradation.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (sphingomyelin disorder).",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0001829,,,,,,,,,,,,,,,,,,,,,,"Hypofunction of ceramide degradation is a subtype of hypofunction of lipid degradation: A process that performs a decreased or insufficient ceramide degradation.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (sphingomyelin disorder).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003456,,,,,,,,,,,,,,,,,TXPO:0003445,,,,,,,,,,,,,,,,,,,,,,hypofunction of ceramide degradation [sphingomyelin disorder ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003440,hyperfunction of phospholipid material transport,,Hyperfunction of phospholipid material transport is a subtype of hyperfunction of transport: A process that performs an excesssive phospholipid material transport.,false,,,http://purl.obolibrary.org/obo/TXPO_0002351,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of phospholipid material transport is a subtype of hyperfunction of transport: A process that performs an excesssive phospholipid material transport.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003440,,,,,,,,,,,,,,,,,,,,,,hyperfunction of phospholipid material transport,,,,,,http://purl.obolibrary.org/obo/TXPO_0002225,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003441,pattern recognition receptor,PRR,"Combining role with a pathogen-associated molecular pattern (PAMP), a structure conserved among microbial species, or damage-associated molecular pattern (DAMP), an endogenous molecule released from damaged cells), to initiate a change in cell activity.|related molecular function GO:0038187",false,,,http://purl.obolibrary.org/obo/TXPO_0002463,,,,,,,,,,,,,,,,,,,,IMR:0001791 (obsolete),,"Combining role with a pathogen-associated molecular pattern (PAMP), a structure conserved among microbial species, or damage-associated molecular pattern (DAMP), an endogenous molecule released from damaged cells), to initiate a change in cell activity.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PRR,,,,,TXPO:0003441,,,,,,,"Receptors of the innate immune system that recognize pathogen associated molecular patterns (PAMPs, e.g. LPS) are called pattern recognition receptors (PRRs).",,,,,,,,,,,,,related molecular function GO:0038187,,pattern recognition receptor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003448,negative regulation of phospholipid hydrolysis [Phospholipidosis],,"Negative regulation of phospholipid hydrolysis is a subtype of negative regulation of phospholipid degradation: A process that stops, prevents, or reduces the frequency, rate or extent of phospholipid hydrolysis.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0003413,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of phospholipid hydrolysis is a subtype of negative regulation of phospholipid degradation: A process that stops, prevents, or reduces the frequency, rate or extent of phospholipid hydrolysis.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003414,,,,,,,,,,,TXPO:0003448,,,,,,,,,,,,,,,,,,,,,,negative regulation of phospholipid hydrolysis [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000710,ATF6 activation [ER stress],,"ATF6 activation is a subtype of molecular activation: A process that changes the activity of the ATF6 (Activating Transcription Factor 6) to be higher.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0003736|http://purl.obolibrary.org/obo/TXPO_0001904,,,,,,,,,,,,,,,,,,,,,,"ATF6 activation is a subtype of molecular activation: A process that changes the activity of the ATF6 (Activating Transcription Factor 6) to be higher.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002901,http://purl.obolibrary.org/obo/TXPO_0002466|http://purl.obolibrary.org/obo/TXPO_0002467,,,,,,,,,,,,,,,,,,TXPO:0000710,,,,,,,,,,,,,,,,,,,,,,ATF6 activation [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000713,PERK dimerization [ER stress],,"PERK dimerization is a subtype of protein dimerization: The formation of a PERK dimer, a macromolecular structure consists of two noncovalently associated identical or nonidentical subunits.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000712|http://purl.obolibrary.org/obo/TXPO_0003736,,,,,,,,,,,,,,,,,,,,Reactome:R-HSA-381087|http://www.ncbi.nlm.nih.gov/pubmed/11907036,,"PERK dimerization is a subtype of protein dimerization: The formation of a PERK dimer, a macromolecular structure consists of two noncovalently associated identical or nonidentical subunits.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002880,,,,,,http://purl.obolibrary.org/obo/TXPO_0000674,,,,,,,,,,,TXPO:0000713,,,,,,,,,,,,,,,,,,,,,,PERK dimerization [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000714,hypofunction of cholesterol transport,,Hypofunction of cholesterol transport is a subtype of hypofunction of transport: A process that performs a decreased or insufficient cholesterol transport.,false,,,http://purl.obolibrary.org/obo/TXPO_0001911,,,,,,,,,,,,,,,,,,,,,,Hypofunction of cholesterol transport is a subtype of hypofunction of transport: A process that performs a decreased or insufficient cholesterol transport.,,,http://purl.obolibrary.org/obo/GO_0030301,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000714,,,,,,,,,,,,,,,,,,,,,,hypofunction of cholesterol transport,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000717,hypofunction of cholesterol transport from lysosome [Phospholipidosis (severe) ],,"Hypofunction of cholesterol transport from lysosome is a subtype of hypofunction of transport: A process that performs a decreased or insufficient cholestsrol transport from lysosomes.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0000731,,,,,,,,,,,,,,,,,,,,,,"Hypofunction of cholesterol transport from lysosome is a subtype of hypofunction of transport: A process that performs a decreased or insufficient cholestsrol transport from lysosomes.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003824,,,,,,,,,,,TXPO:0000717,,,,,,,,,,,,,,,,,,,,,,hypofunction of cholesterol transport from lysosome [Phospholipidosis (severe) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000715,CYP7A1 (canonical)[Cholestasis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000276|http://purl.obolibrary.org/obo/TXPO_0000404,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1581|NCBI-Rat-GeneID:25428|NCBI-Mouse-GeneID:13122|http://omim.org/entry/118455,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001581,,,,,,,,,,,,,TXPO:0000715,,,,,,,"Bile acids repress the transcription of cytochrome P450 7A1 (CYP7A1), which catalyzes the rate-limiting step in bile acid biosynthesis.
FXR induces expression of SHP-1, a member of the nuclear receptor family that lacks a DNA-binding domain.
SHP-1 represses expression of CYP7A1 by inhibiting the activity of liver receptor homolog 1 (LRH-1).|RXR heterodimers regulates absorption and ABC1-mediated efflux of cholesterol.
Oxysterol receptors (LXRs) and the bile acid receptor (FXR) are the RXR heterodimer by regulating expression of the reverse cholesterol transporter, ABC1, and the enzyme of bile acid synthesis, CYP7A1, respectively.",,,,,,,,,,,,,,,CYP7A1 (canonical)[Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000711,Deacreasing velocity,,Deacreasing velocity is a subtype of changing velocity: A process that changes the velocity of the object to be slower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000699,,,,,,,,,,,,,,,,,,,,,,Deacreasing velocity is a subtype of changing velocity: A process that changes the velocity of the object to be slower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000711,,,,,,,,,,,,,,,,,,,,,,Deacreasing velocity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000718,ATF6 signaling (primitive) [ATF6 pathway],,"ATF6 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the ATF6 (activating transcription factor 6). ATF6 generally plays a endoplasmic reticulum membrane stress sensor role.
This entity is a specific course-dependent process. This process can constitute the course of ATF6 pathway.",false,,,http://purl.obolibrary.org/obo/TXPO_0000335,,,,,,,,,,,,,,,,,,,,,,"ATF6 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the ATF6 (activating transcription factor 6). ATF6 generally plays a endoplasmic reticulum membrane stress sensor role.
This entity is a specific course-dependent process. This process can constitute the course of ATF6 pathway.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000879,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000718,,,,,,,,,,,,,,,,,,,,,,ATF6 signaling (primitive) [ATF6 pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000719,ATF6 signaling (primitive) [ER stress],,"ATF6 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the ATF6 (activating transcription factor 6). ATF6 generally plays a endoplasmic reticulum membrane stress sensor role.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000718|http://purl.obolibrary.org/obo/TXPO_0003736,,,,,,,,,,,,,,,,,,,,,,"ATF6 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the ATF6 (activating transcription factor 6). ATF6 generally plays a endoplasmic reticulum membrane stress sensor role.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000879,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000710,,,,,,,,,,,,,,,,,,TXPO:0000719,,,,,,,,,,,,,,,,,,,,,,ATF6 signaling (primitive) [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000712,PERK dimerization,,"PERK dimerization is a subtype of protein dimerization: The formation of a PERK dimer, a macromolecular structure consists of two noncovalently associated identical or nonidentical subunits.",false,,,http://purl.obolibrary.org/obo/TXPO_0003641,,,,,,,,,,,,,,,,,,,,,,"PERK dimerization is a subtype of protein dimerization: The formation of a PERK dimer, a macromolecular structure consists of two noncovalently associated identical or nonidentical subunits.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000712,,,,,,,,,,,,,,,,,,,,,,PERK dimerization,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000327,ritonavir,"N-[(2S,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl]-N(2)-(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)-L-valinamide","An L-valine derivative that is an antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS, it is often used as a fixed-dose combination with another protease inhibitor, lopinavir. Also used in combination with dasabuvir sodium hydrate, ombitasvir and paritaprevir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:11363086|LINCS:LSM-5623,,"An L-valine derivative that is an antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS, it is often used as a fixed-dose combination with another protease inhibitor, lopinavir. Also used in combination with dasabuvir sodium hydrate, ombitasvir and paritaprevir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.",,,,,,,,,,,,C37H48N6O5S2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_36044,,,,,"N-[(2S,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl]-N(2)-(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)-L-valinamide",,,,,TXPO:1000327,,,,,,,,,,,,,,,,,,,,,,ritonavir,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CC(C)[C@H](NC(=O)N(C)Cc1csc(n1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1,,,,,
http://purl.obolibrary.org/obo/TXPO_1000322,Rad51b (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:5890|NCBI-Rat-GeneID:500679|NCBI-Mouse-GeneID:19363,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000005890,,,,,,,,,,,,,TXPO:1000322,,,,,,,,,,,,,,,,,,,,,,Rad51b (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000323,Rasgef1b (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:153020|NCBI-Mouse-GeneID:320292|NCBI-Rat-GeneID:100361238,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000153020,,,,,,,,,,,,,TXPO:1000323,,,,,,,,,,,,,,,,,,,,,,Rasgef1b (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000320,RNF2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:304850|NCBI-Human-GeneID:6045|NCBI-Mouse-GeneID:19821,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000006045,,,,,,,,,,,,,TXPO:1000320,,,,,,,,,,,,,,,,,,,,,,RNF2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000325,Rem2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:140743|NCBI-Rat-GeneID:64626|NCBI-Human-GeneID:161253,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000161253,,,,,,,,,,,,,TXPO:1000325,,,,,,,,,,,,,,,,,,,,,,Rem2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000328,Rnase1l2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:305844,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:1000328,,,,,,,,,,,,,,,,,,,,,,Rnase1l2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000321,RT1-CE5 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:309607,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:1000321,,,,,,,,,,,,,,,,,,,,,,RT1-CE5 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000324,Rbm8a (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:60365|NCBI-Rat-GeneID:295284|NCBI-Human-GeneID:9939,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000009939,,,,,,,,,,,,,TXPO:1000324,,,,,,,,,,,,,,,,,,,,,,Rbm8a (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000329,Rock1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:81762|NCBI-Human-GeneID:6093|NCBI-Mouse-GeneID:19877,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000006093,,,,,,,,,,,,,TXPO:1000329,,,,,,,,,,,,,,,,,,,,,,Rock1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/BFO_0000004,independent continuant,,b is an independent continuant = Def. b is a continuant which is such that there is no c and no t such that b s-depends_on c at t. (axiom label in BFO2 Reference: [017-002]),false,,,http://purl.obolibrary.org/obo/BFO_0000002,,,,,,,,,,,,,,,,,,,,,,b is an independent continuant = Def. b is a continuant which is such that there is no c and no t such that b s-depends_on c at t. (axiom label in BFO2 Reference: [017-002]),,,,,,,a leg|a molecule|an organism|a heart|an atom|a spatial region|an orchestra.|the bottom right portion of a human torso|the interior of your mouth|a chair,,,,,,,,,,,(forall (x t) (if (IndependentContinuant x) (exists (r) (and (SpatialRegion r) (locatedInAt x r t))))) // axiom label in BFO2 CLIF: [134-001]|(iff (IndependentContinuant a) (and (Continuant a) (not (exists (b t) (specificallyDependsOnAt a b t))))) // axiom label in BFO2 CLIF: [017-002]|(forall (x t) (if (and (IndependentContinuant x) (existsAt x t)) (exists (y) (and (Entity y) (specificallyDependsOnAt y x t))))) // axiom label in BFO2 CLIF: [018-002],"For any independent continuant b and any time t there is some spatial region r such that b is located_in r at t. (axiom label in BFO2 Reference: [134-001])|For every independent continuant b and time t during the region of time spanned by its life, there are entities which s-depends_on b during t. (axiom label in BFO2 Reference: [018-002])",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BFO:0000004,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/bfo.owl,independent continuant,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000085479,DNAJC5B,,Other designations: beta cysteine string protein|beta-CSP|cysteine string protein beta|dnaJ homolog subfamily C member 5B|dnaJ homolog subfamily C member X,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CSP-beta,,,,,,,,,,,,8,,,,,,HPRD:07474|Ensembl:ENSG00000147570|MIM:613945|HGNC:24138|Vega:OTTHUMG00000164470,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"DnaJ (Hsp40) homolog, subfamily C, member 5 beta",,,8q13.1,,,,,,,,,,,,,,,,GO_0016020 (EC: IEA),,,,,,,,,PMID:12477932; 15489334; 17034881; 17207965; 22174851; 22666496,,,,,,,,,,,,,,,OGG:3000085479,,,,,,,"DnaJ (Hsp40) homolog, subfamily C, member 5 beta",,,,,,,,,,,,,Other designations: beta cysteine string protein|beta-CSP|cysteine string protein beta|dnaJ homolog subfamily C member 5B|dnaJ homolog subfamily C member X,,DNAJC5B,,,,,,,,,,,,,,,,,,,,,,,85479,,,,,,,,9606,,,,,,,,,,,,,,,,,,,DNAJC5B,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000007124,TNF,,"Other designations: APC1 protein|TNF, macrophage-derived|TNF, monocyte-derived|TNF-a|cachectin|tumor necrosis factor ligand superfamily member 2|tumor necrosis factor-alpha",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,TNF-alpha|TNFA|TNFSF2|DIF,,,,,,,,,,,,6,,,,,,MIM:191160|HGNC:11892|Ensembl:ENSG00000232810|Vega:OTTHUMG00000031194|HPRD:01855,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,tumor necrosis factor,,,6p21.3,,,,,,,,,,,,,,,,"GO_0000060 (EC: IDA, PMID: 16280327); GO_0000122 (EC: IDA, PMID: 15345745); GO_0000165 (EC: IMP); GO_0000185 (EC: IDA, PMID: 15310755); GO_0000187 (EC: IDA, PMID: 10748004); GO_0001666 (EC: IEA); GO_0001775 (EC: IEA); GO_0001819 (EC: IDA, PMID: 17922812); GO_0001891 (EC: ISS); GO_0001934 (EC: IDA, PMID: 10748004); GO_0002020 (EC: IPI, PMID: 12777399); GO_0002037 (EC: IEA); GO_0002439 (EC: IMP, PMID: 14512626); GO_0002740 (EC: IDA, PMID: 10443688); GO_0002876 (EC: IEA); GO_0002925 (EC: IEA); GO_0003009 (EC: IEA); GO_0005125 (EC: IDA, PMID: 10748004); GO_0005164 (EC: IDA, PMID: 14512626); GO_0005515 (EC: IPI, PMID: 11878931); GO_0005576 (EC: TAS); GO_0005615 (EC: IDA, PMID: 10443688); GO_0005886 (EC: TAS); GO_0005887 (EC: IDA, PMID: 18355445); GO_0006006 (EC: IEA); GO_0006915 (EC: TAS); GO_0006919 (EC: IDA, PMID: 16723520); GO_0006927 (EC: IDA, PMID: 3883195); GO_0006954 (EC: IDA, PMID: 10748004); GO_0006959 (EC: IEA); GO_0007254 (EC: IEA); GO_0008285 (EC: IEA); GO_0008625 (EC: IDA, PMID: 10521396); GO_0008625 (EC: NAS); GO_0008630 (EC: IEA); GO_0008652 (EC: IEA); GO_0009612 (EC: IEA); GO_0009615 (EC: IDA, PMID: 10490959); GO_0009651 (EC: TAS, PMID: 18355445); GO_0009887 (EC: IEA); GO_0009897 (EC: ISS); GO_0009986 (EC: IDA, PMID: 18355445); GO_0010629 (EC: IDA, PMID: 15345745); GO_0010693 (EC: IEA); GO_0010888 (EC: NAS, PMID: 16464856); GO_0014823 (EC: IEA); GO_0019722 (EC: IEA); GO_0030198 (EC: IEA); GO_0030316 (EC: IEA); GO_0030730 (EC: IDA, PMID: 19032770); GO_0031334 (EC: IDA, PMID: 12813029); GO_0031622 (EC: ISS); GO_0031663 (EC: IDA); GO_0032715 (EC: IDA, PMID: 10443688); GO_0032722 (EC: IDA, PMID: 10490959); GO_0032729 (EC: IEA); GO_0032741 (EC: IEA); GO_0032755 (EC: IEA); GO_0032800 (EC: IDA, PMID: 10443688); GO_0033138 (EC: IDA, PMID: 17389591); GO_0033209 (EC: IMP, PMID: 10748004); GO_0034116 (EC: IDA, PMID: 10604883); GO_0042346 (EC: IDA, PMID: 17922812); GO_0042493 (EC: IEA); GO_0042802 (EC: IDA, PMID: 14512626); GO_0043065 (EC: IDA, PMID: 16723520); GO_0043068 (EC: IDA, PMID: 16611992); GO_0043122 (EC: IDA, PMID: 10748004); GO_0043123 (EC: IDA, PMID: 15310755); GO_0043242 (EC: IDA, PMID: 17389591); GO_0043243 (EC: IDA, PMID: 12813029); GO_0043280 (EC: IDA, PMID: 11577081); GO_0043406 (EC: IDA, PMID: 12813029); GO_0043491 (EC: IMP); GO_0043507 (EC: IDA, PMID: 17389591); GO_0043525 (EC: IEA); GO_0044130 (EC: IEA); GO_0044212 (EC: IDA, PMID: 17350185); GO_0045071 (EC: IDA, PMID: 10490959); GO_0045080 (EC: IDA, PMID: 10490959); GO_0045121 (EC: IDA, PMID: 17010968); GO_0045416 (EC: IDA); GO_0045429 (EC: IDA, PMID: 8383325); GO_0045599 (EC: NAS, PMID: 16464856); GO_0045668 (EC: IEA); GO_0045672 (EC: IDA, PMID: 17888176); GO_0045840 (EC: IEA); GO_0045892 (EC: IDA, PMID: 16895791); GO_0045893 (EC: IDA, PMID: 10748004); GO_0045944 (EC: IDA, PMID: 15345745); GO_0045944 (EC: IGI, PMID: 16803872); GO_0045994 (EC: IEA); GO_0046325 (EC: IEA); GO_0046330 (EC: IEA); GO_0048566 (EC: IEP); GO_0048661 (EC: IDA, PMID: 16518841); GO_0050715 (EC: IDA, PMID: 10443688); GO_0050796 (EC: IDA, PMID: 8383325); GO_0050806 (EC: IEA); GO_0050830 (EC: IEA); GO_0050901 (EC: IDA, PMID: 10820279); GO_0050995 (EC: IDA, PMID: 19032770); GO_0051023 (EC: IEA); GO_0051044 (EC: IDA, PMID: 18373975); GO_0051091 (EC: IDA, PMID: 10748004); GO_0051092 (EC: IDA, PMID: 10383454); GO_0051222 (EC: IDA, PMID: 15310755); GO_0051384 (EC: IDA, PMID: 10443688); GO_0051533 (EC: IDA, PMID: 16803872); GO_0051798 (EC: IEA); GO_0051897 (EC: IEA); GO_0055037 (EC: ISS); GO_0060557 (EC: IDA, PMID: 1690216); GO_0060559 (EC: IDA, PMID: 1690216); GO_0060664 (EC: IEA); GO_0060693 (EC: IEA); GO_0061048 (EC: IDA, PMID: 17350185); GO_0070374 (EC: NAS, PMID: 18606301); GO_0071230 (EC: IEA); GO_0071316 (EC: IDA, PMID: 18676776); GO_0071407 (EC: IDA); GO_0071677 (EC: NAS); GO_0071803 (EC: IDA, PMID: 15220135); GO_0097190 (EC: TAS); GO_0097191 (EC: IDA, PMID: 11577081); GO_0097527 (EC: IDA, PMID: 11101870); GO_1902043 (EC: IEA); GO_2000010 (EC: IDA, PMID: 19366699); GO_2000343 (EC: IDA); GO_2001240 (EC: IDA, PMID: 10666185)",,,,,,,,,PMID: 1279199; 1310388; 1331108; 1380260; 1402651; 1548758; 1550865; 1690216; 1905933; 1918997; 1918999; 1964681; 1993354; 2009860; 2158863; 2170559; 2413547; 2537468; 2551905; 2848815; 2922050; 2995927; 3001529; 3031624; 3139842; 3351931; 3417634; 3464978; 3552045; 3555974; 3856324; 3883195; 3932069; 6392892; 7494249; 7511078; 7523444; 7526541; 7536422; 7561697; 7664431; 7693046; 7695626; 7704970; 7706435; 7739525; 7758105; 7815507; 7818827; 7852363; 7859743; 7930591; 7935762; 7966397; 8182064; 8267288; 8288897; 8336080; 8336118; 8381971; 8383325; 8482849; 8499947; 8590321; 8597870; 8707350; 8724035; 8764000; 8806809; 8852605; 8869635; 8870842; 9034191; 9108403; 9110146; 9223523; 9225992; 9226228; 9230816; 9269771; 9269777; 9278385; 9334723; 9344703; 9378998; 9438495; 9442056; 9449720; 9488135; 9552007; 9568681; 9639071; 9651389; 9658081; 9670843; 9730685; 9744279; 9828130; 9920899; 10202016; 10205166; 10339575; 10369255; 10376933; 10383454; 10388525; 10415019; 10438928; 10443688; 10450718; 10490959; 10521396; 10604883; 10634209; 10666185; 10669763; 10747938; 10748004; 10775602; 10799478; 10820279; 10839541; 10843712; 10929056; 10964543; 11000208; 11023480; 11023482; 11023485; 11035665; 11037831; 11045789; 11057907; 11072751; 11083263; 11092520; 11097747; 11101870; 11106199; 11113269; 11118029; 11120931; 11121160; 11138328; 11144293; 11145126; 11153078; 11153913; 11157631; 11163081; 11163083; 11165717; 11167813; 11176446; 11179110; 11179116; 11192323; 11196671; 11196686; 11199329; 11211945; 11223972; 11230752; 11233912; 11241233; 11243953; 11244489; 11246532; 11250044; 11257271; 11258696; 11264025; 11266856; 11266927; 11266928; 11267084; 11273064; 11278695; 11285131; 11294926; 11298547; 11316066; 11316069; 11319038; 11319647; 11319665; 11324946; 11325850; 11328953; 11334675; 11349201; 11354638; 11371414; 11379335; 11389006; 11391238; 11401868; 11401880; 11404167; 11409121; 11411907; 11423177; 11427627; 11453117; 11500363; 11506397; 11506478; 11508580; 11522182; 11528523; 11533078; 11544427; 11544434; 11570978; 11571703; 11576577; 11577081; 11579140; 11585553; 11600224; 11602715; 11602932; 11607791; 11640949; 11640992; 11668577; 11689215; 11689614; 11697432; 11704803; 11715861; 11716174; 11722460; 11724772; 11725485; 11730934; 11735091; 11737072; 11737221; 11743056; 11744409; 11748357; 11751963; 11752507; 11756988; 11759867; 11774563; 11774822; 11775944; 11776328; 11781187; 11781708; 11792123; 11796554; 11798757; 11798770; 11799112; 11800584; 11801679; 11808761; 11816715; 11820636; 11824966; 11826759; 11828995; 11830340; 11830425; 11830590; 11831440; 11831864; 11832442; 11838837; 11841482; 11841484; 11841486; 11846846; 11847479; 11849390; 11849463; 11851889; 11852287; 11857057; 11858187; 11860474; 11861275; 11864973; 11868623; 11874184; 11874815; 11877397; 11878931; 11884401; 11886974; 11888514; 11891016; 11891022; 11893711; 11893712; 11896460; 11904678; 11906646; 11907116; 11909956; 11911478; 11916086; 11920321; 11922568; 11923482; 11924527; 11940577; 11954826; 11956055; 11958572; 11958574; 11960393; 11961180; 11962732; 11966578; 11968047; 11968052; 11971816; 11971973; 11975986; 11979305; 11980617; 11981433; 11983108; 11983212; 11988644; 11990931; 11991675; 12004062; 12006387; 12006640; 12009575; 12010662; 12011375; 12014672; 12019209; 12021142; 12022360; 12028020; 12030367; 12030733; 12031914; 12031976; 12032749; 12032830; 12034045; 12036088; 12039524; 12042033; 12047333; 12047360; 12048203; 12049175; 12050189; 12050565; 12054739; 12055326; 12058258; 12067299; 12067756; 12067976; 12074713; 12078789; 12082592; 12084660; 12086951; 12086962; 12089333; 12089610; 12089714; 12090473; 12091169; 12091338; 12091490; 12095061; 12097398; 12099552; 12100025; 12100575; 12101072; 12101079; 12102486; 12105273; 12107724; 12115605; 12115625; 12116197; 12117921; 12117943; 12117953; 12123862; 12124654; 12126516; 12133353; 12133434; 12135128; 12135369; 12135427; 12135759; 12142377; 12144133; 12145682; 12148593; 12149604; 12153747; 12160518; 12161098; 12161427; 12162435; 12162437; 12162871; 12163195; 12163370; 12164325; 12165487; 12165799; 12167698; 12169181; 12170268; 12171600; 12171811; 12173300; 12180762; 12183057; 12185082; 12187026; 12190096; 12192111; 12195699; 12198621; 12200397; 12202945; 12205044; 12213594; 12215823; 12220546; 12230503; 12232842; 12234707; 12235090; 12237295; 12240899; 12244188; 12270547; 12270556; 12296856; 12297049; 12297050; 12297113; 12297724; 12351419; 12368210; 12370346; 12370360; 12370403; 12370499; 12370503; 12372982; 12378118; 12383455; 12383917; 12387878; 12387879; 12390476; 12391248; 12391840; 12392301; 12392859; 12393608; 12393619; 12393699; 12393755; 12395215; 12396374; 12396377; 12396555; 12397597; 12404162; 12406900; 12411040; 12414751; 12415586; 12420104; 12423676; 12424537; 12438348; 12438370; 12438440; 12438965; 12439617; 12441140; 12441346; 12444137; 12445207; 12445803; 12447749; 12451269; 12451465; 12453902; 12457980; 12459320; 12459639; 12472577; 12472598; 12475426; 12477932; 12478078; 12482669; 12483736; 12485196; 12485861; 12488366; 12490310; 12492251; 12496175; 12496396; 12501066; 12504564; 12506026; 12507818; 12508775; 12513816; 12526952; 12528108; 12530117; 12530118; 12537602; 12538692; 12542496; 12545006; 12548461; 12548511; 12553033; 12554901; 12555203; 12558814; 12559632; 12559634; 12566517; 12568117; 12574335; 12574344; 12574959; 12579167; 12580317; 12581498; 12587980; 12590978; 12590981; 12591385; 12591926; 12594207; 12595628; 12595908; 12601524; 12603009; 12606947; 12607668; 12609060; 12609526; 12620429; 12622777; 12626032; 12626603; 12631070; 12632436; 12637641; 12640117; 12641410; 12644006; 12644590; 12645577; 12651071; 12653732; 12654235; 12654703; 12655064; 12657115; 12661999; 12663241; 12673844; 12679941; 12682890; 12687213; 12687247; 12690081; 12691703; 12691705; 12691826; 12692009; 12692291; 12694213; 12699902; 12702205; 12707271; 12707358; 12709814; 12714268; 12714269; 12714560; 12715715; 12717265; 12718576; 12720537; 12727482; 12730860; 12732844; 12743452; 12744771; 12746914; 12747595; 12749050; 12750172; 12750939; 12751024; 12753658; 12753742; 12756345; 12762136; 12768019; 12770792; 12770796; 12773519; 12777399; 12782345; 12783130; 12783210; 12787424; 12788886; 12792476; 12794406; 12794527; 12795334; 12795791; 12799216; 12802423; 12802709; 12804035; 12809834; 12810683; 12811429; 12811828; 12813029; 12815949; 12816730; 12818128; 12818408; 12823767; 12824709; 12826369; 12828656; 12828754; 12829646; 12829659; 12834858; 12837287; 12839521; 12839942; 12842760; 12847678; 12849705; 12850624; 12850808; 12850811; 12851716; 12854077; 12855762; 12858454; 12859597; 12864989; 12867430; 12869351; 12870175; 12871600; 12871882; 12876073; 12878172; 12880679; 12882963; 12887920; 12888330; 12888880; 12889993; 12891537; 12892736; 12898475; 12899665; 12906716; 12909463; 12911663; 12915440; 12915457; 12917036; 12919285; 12923493; 12925536; 12928370; 12930304; 12933883; 12934185; 12938195; 12940442; 12940515; 12941546; 12944979; 12945076; 12947552; 12952969; 12953135; 12954601; 12957651; 12959221; 12959973; 12960156; 12960255; 12960355; 12960751; 12962917; 12966432; 12967650; 12969378; 12970400; 13679820; 14500138; 14500462; 14500687; 14512626; 14514692; 14514772; 14517700; 14519430; 14519761; 14530204; 14530285; 14530313; 14530362; 14530365; 14532277; 14534724; 14550782; 14555463; 14563376; 14566095; 14567462; 14572449; 14572618; 14572794; 14581470; 14592496; 14593215; 14606512; 14607690; 14607966; 14612430; 14613268; 14615042; 14615367; 14616291; 14617036; 14617046; 14623370; 14623371; 14625134; 14625191; 14630568; 14633738; 14635012; 14636244; 14637275; 14642160; 14643088; 14644777; 14646574; 14651518; 14651527; 14652008; 14655898; 14656967; 14657427; 14657629; 14659806; 14662866; 14662883; 14671137; 14674935; 14681231; 14681301; 14681891; 14685701; 14688105; 14693849; 14696796; 14698136; 14701704; 14703611; 14708348; 14714556; 14715628; 14716517; 14718619; 14718719; 14720421; 14722888; 14723749; 14727453; 14731353; 14732222; 14732344; 14734776; 14734780; 14741380; 14743216; 14744383; 14744790; 14756669; 14758530; 14760938; 14761884; 14766265; 14767724; 14872499; 14960532; 14962095; 14962963; 14963043; 14963369; 14966591; 14967554; 14969768; 14978035; 14978132; 14979058; 14982742; 14986816; 14987295; 14988320; 14990112; 14992821; 14994383; 15003925; 15007139; 15009068; 15009105; 15009176; 15009808; 15013759; 15014429; 15014438; 15016407; 15017311; 15018649; 15019283; 15027477; 15030461; 15036247; 15036607; 15041705; 15043686; 15044327; 15055475; 15055529; 15056081; 15057268; 15057902; 15059302; 15061799; 15063602; 15066699; 15068388; 15070815; 15071492; 15077289; 15084940; 15086488; 15100460; 15104370; 15104672; 15104679; 15111313; 15112338; 15120188; 15120189; 15124210; 15124762; 15127646; 15127972; 15128741; 15128916; 15131465; 15135368; 15137526; 15140018; 15142214; 15142381; 15142990; 15145213; 15145954; 15146559; 15149631; 15152368; 15157159; 15158680; 15161508; 15161830; 15162831; 15163120; 15167972; 15174288; 15175153; 15182332; 15184943; 15188512; 15189946; 15191888; 15194284; 15194285; 15200452; 15201584; 15202783; 15203561; 15207246; 15212671; 15214940; 15217507; 15219382; 15219383; 15220135; 15220553; 15221977; 15223011; 15223607; 15223609; 15223612; 15223716; 15223990; 15230290; 15232637; 15235132; 15236174; 15236755; 15238257; 15239085; 15246652; 15247172; 15248209; 15251463; 15254878; 15256287; 15256977; 15257049; 15257453; 15263792; 15265021; 15269840; 15271127; 15271933; 15272094; 15273551; 15273737; 15276234; 15277733; 15279067; 15280021; 15280623; 15284722; 15286263; 15288392; 15288471; 15288631; 15289017; 15292002; 15301589; 15301860; 15304089; 15306845; 15307952; 15308304; 15308875; 15310755; 15313687; 15315967; 15316669; 15319168; 15319381; 15325795; 15326480; 15327404; 15331607; 15331795; 15332393; 15334474; 15337758; 15339882; 15340354; 15341923; 15342556; 15345185; 15345745; 15347683; 15351436; 15354858; 15355698; 15358608; 15361124; 15361128; 15366429; 15367225; 15370717; 15371770; 15374002; 15380900; 15381184; 15387905; 15388258; 15388264; 15449074; 15452110; 15457442; 15458430; 15458467; 15468911; 15469436; 15469865; 15474092; 15479128; 15481145; 15482484; 15485576; 15485837; 15486341; 15489334; 15489542; 15492857; 15495570; 15495787; 15504546; 15504978; 15507966; 15507967; 15513316; 15515013; 15516323; 15517637; 15520404; 15523649; 15523691; 15524285; 15526004; 15526005; 15531184; 15533517; 15537425; 15540224; 15542843; 15543003; 15545623; 15545823; 15546338; 15548263; 15550384; 15555301; 15555625; 15556647; 15560757; 15564333; 15565405; 15565953; 15570075; 15572357; 15576488; 15579481; 15583831; 15585313; 15587751; 15592292; 15592496; 15597152; 15599305; 15600254; 15603866; 15604419; 15611081; 15614591; 15619425; 15620462; 15621151; 15622443; 15623376; 15626980; 15627647; 15629131; 15632117; 15638425; 15640107; 15640148; 15641051; 15641080; 15644653; 15647276; 15649304; 15650331; 15650893; 15652446; 15654990; 15660126; 15661163; 15663746; 15663966; 15667484; 15667501; 15667866; 15667911; 15668241; 15670287; 15670770; 15677734; 15679580; 15681825; 15685549; 15686588; 15690532; 15691236; 15693080; 15694363; 15694386; 15695296; 15699425; 15701637; 15704154; 15708894; 15710474; 15710602; 15712606; 15713215; 15714129; 15717274; 15717635; 15718915; 15722350; 15722553; 15723199; 15723707; 15725578; 15726267; 15727562; 15728381; 15730950; 15731048; 15733644; 15733973; 15748898; 15750822; 15754412; 15755722; 15763337; 15766528; 15766560; 15773449; 15777836; 15780075; 15780175; 15780879; 15784408; 15784410; 15784411; 15787640; 15788755; 15790514; 15790681; 15790988; 15797745; 15797957; 15798948; 15799583; 15800006; 15800781; 15803022; 15809210; 15809899; 15810887; 15811521; 15813606; 15814282; 15816837; 15817702; 15817713; 15817944; 15818327; 15820084; 15825968; 15828019; 15832029; 15837333; 15841043; 15842262; 15842590; 15842659; 15842729; 15845475; 15845648; 15847100; 15848524; 15851552; 15854776; 15854959; 15860935; 15866693; 15870936; 15875188; 15878915; 15879291; 15885323; 15890243; 15894515; 15895461; 15896304; 15901240; 15901845; 15901906; 15902922; 15903021; 15904673; 15910294; 15917409; 15919211; 15919456; 15923644; 15925543; 15927351; 15927374; 15927855; 15929757; 15931230; 15932622; 15935956; 15937090; 15940715; 15941417; 15941525; 15951664; 15955385; 15956282; 15956727; 15958080; 15963988; 15964333; 15967797; 15968724; 15969671; 15971421; 15972386; 15976383; 15978325; 15978856; 15979578; 15979955; 15984988; 15985479; 15986200; 15987860; 15988006; 15990085; 15992611; 15993097; 15994321; 15999154; 16004996; 16006475; 16009345; 16011481; 16021081; 16024973; 16027740; 16029496; 16030091; 16039994; 16040075; 16046099; 16046471; 16051275; 16051302; 16075747; 16081933; 16082153; 16083851; 16086278; 16087126; 16091223; 16095006; 16095118; 16096333; 16098388; 16099338; 16100725; 16100774; 16105652; 16105945; 16107336; 16107511; 16107886; 16109906; 16110031; 16115611; 16116311; 16120761; 16123045; 16124898; 16127755; 16132956; 16133992; 16134057; 16135717; 16135957; 16135983; 16137184; 16138112; 16140265; 16141456; 16143422; 16148157; 16148556; 16159730; 16160188; 16164695; 16164697; 16166621; 16170833; 16172101; 16173529; 16174285; 16176285; 16181755; 16182624; 16183136; 16191343; 16193177; 16199883; 16202081; 16202743; 16202847; 16203766; 16204594; 16204600; 16207331; 16210389; 16211257; 16215460; 16224057; 16224188; 16227624; 16232344; 16235536; 16239914; 16243340; 16246225; 16246259; 16249504; 16251478; 16252073; 16253303; 16254197; 16259478; 16260352; 16260427; 16260783; 16263419; 16269080; 16269960; 16272296; 16276011; 16277898; 16279907; 16280327; 16282562; 16284098; 16284099; 16286275; 16293872; 16298864; 16299685; 16301860; 16313253; 16313297; 16313841; 16314440; 16317381; 16318585; 16319143; 16319659; 16322490; 16322943; 16323137; 16323614; 16324093; 16325265; 16331275; 16339571; 16339574; 16340448; 16343069; 16343435; 16359550; 16368349; 16369102; 16374139; 16375755; 16378074; 16386594; 16386648; 16388753; 16389181; 16391465; 16393214; 16393721; 16393767; 16397758; 16400484; 16400883; 16403098; 16407614; 16410066; 16410254; 16411061; 16413198; 16418737; 16421346; 16423623; 16424170; 16424284; 16425360; 16426238; 16427155; 16427740; 16427798; 16428794; 16429233; 16430709; 16431125; 16433832; 16438713; 16444434; 16445909; 16446172; 16454711; 16456144; 16458016; 16463424; 16464740; 16464741; 16464856; 16467041; 16473522; 16474009; 16475830; 16476505; 16503400; 16505113; 16507146; 16507998; 16516271; 16517578; 16518755; 16518841; 16519772; 16520888; 16522396; 16533817; 16534418; 16538176; 16538639; 16538877; 16539678; 16539828; 16540751; 16543241; 16545485; 16545788; 16547255; 16549165; 16552356; 16554734; 16564576; 16564703; 16567828; 16567888; 16569263; 16571778; 16572445; 16573780; 16574427; 16579840; 16580225; 16581306; 16581430; 16585076; 16585124; 16596274; 16596276; 16601113; 16603398; 16611251; 16611992; 16614115; 16617094; 16621960; 16622749; 16622779; 16628468; 16633737; 16635219; 16638698; 16641217; 16643431; 16647242; 16672072; 16681592; 16688007; 16691430; 16697675; 16698276; 16699450; 16699452; 16701011; 16702372; 16702858; 16707559; 16707968; 16711541; 16716376; 16718633; 16720051; 16720107; 16720636; 16722148; 16723255; 16723520; 16728705; 16730227; 16730575; 16741147; 16751383; 16757480; 16762155; 16775170; 16778150; 16785565; 16786763; 16786764; 16788244; 16788246; 16793930; 16796744; 16798739; 16803872; 16803995; 16803996; 16804395; 16814297; 16815316; 16820326; 16820919; 16820934; 16824064; 16824070; 16824159; 16827183; 16827185; 16829620; 16835229; 16835238; 16846840; 16857678; 16859504; 16859780; 16861224; 16863613; 16864906; 16865291; 16867312; 16872485; 16875346; 16879054; 16879221; 16882065; 16882174; 16885196; 16890076; 16891799; 16895750; 16895791; 16896069; 16897113; 16907849; 16908592; 16908746; 16909270; 16911569; 16916598; 16919469; 16919536; 16926287; 16930761; 16930778; 16931032; 16931134; 16932925; 16935932; 16936264; 16937502; 16938178; 16938460; 16938461; 16950634; 16951360; 16951943; 16952484; 16952987; 16953332; 16960936; 16961803; 16962335; 16970270; 16971410; 16979413; 16980557; 16982833; 16984280; 16984283; 16984517; 16987073; 16987811; 16988194; 16998242; 17001213; 17003486; 17003844; 17005410; 17006329; 17007883; 17010968; 17014432; 17014622; 17016618; 17018637; 17020650; 17020651; 17030448; 17034639; 17036337; 17047287; 17049565; 17052277; 17052682; 17052690; 17053845; 17054908; 17055360; 17057944; 17062130; 17063315; 17064665; 17068065; 17069807; 17070109; 17071494; 17074545; 17074928; 17077296; 17079017; 17079667; 17082635; 17084384; 17086054; 17087110; 17087739; 17090647; 17097497; 17101473; 17101499; 17103073; 17105909; 17108674; 17109502; 17113059; 17113632; 17114809; 17115419; 17117950; 17119950; 17123322; 17123692; 17129465; 17130566; 17130569; 17132473; 17133355; 17138053; 17139467; 17141242; 17141246; 17141882; 17142509; 17143972; 17145371; 17145373; 17160953; 17164537; 17166738; 17167711; 17171665; 17173255; 17174749; 17185628; 17192490; 17192785; 17192953; 17194482; 17196641; 17198275; 17201881; 17205128; 17207378; 17207568; 17207711; 17208210; 17208287; 17208993; 17209781; 17213232; 17213876; 17216494; 17220333; 17221211; 17222850; 17223386; 17227768; 17234183; 17234379; 17238853; 17244513; 17255827; 17257312; 17261759; 17268200; 17272816; 17277048; 17277102; 17285966; 17287608; 17295710; 17298451; 17298885; 17303222; 17303559; 17304101; 17304103; 17305696; 17307728; 17311253; 17312171; 17314689; 17315188; 17324969; 17328044; 17330135; 17332138; 17335072; 17335371; 17336597; 17343250; 17346438; 17347550; 17348243; 17349210; 17349875; 17350022; 17350185; 17351514; 17353161; 17355643; 17356374; 17356550; 17359518; 17360657; 17360787; 17362351; 17367855; 17369174; 17373637; 17373677; 17376903; 17376917; 17380115; 17380888; 17382880; 17388919; 17389591; 17395331; 17397790; 17397798; 17397847; 17400536; 17401435; 17405915; 17408448; 17408492; 17412556; 17415203; 17416344; 17426528; 17428349; 17428620; 17428673; 17431682; 17434489; 17439892; 17442953; 17444864; 17445540; 17446901; 17448042; 17449468; 17450233; 17451964; 17452160; 17452460; 17452560; 17452777; 17454170; 17454884; 17458901; 17460948; 17471239; 17471286; 17472990; 17475642; 17475896; 17476188; 17477779; 17477815; 17479109; 17482757; 17483581; 17483704; 17493155; 17493863; 17495957; 17496310; 17497030; 17497035; 17498265; 17498268; 17499233; 17503085; 17505301; 17507924; 17509030; 17509552; 17510437; 17511783; 17513605; 17515611; 17516296; 17521325; 17522703; 17530646; 17530706; 17531241; 17532082; 17532302; 17536219; 17541791; 17541951; 17543146; 17544514; 17544674; 17550423; 17553030; 17554369; 17559370; 17559942; 17560079; 17560652; 17562093; 17562931; 17564320; 17565648; 17565649; 17568575; 17572155; 17573384; 17576577; 17579071; 17581202; 17581788; 17583675; 17584976; 17586554; 17587429; 17589947; 17592115; 17592300; 17592954; 17593951; 17595314; 17597660; 17599062; 17599736; 17600229; 17606294; 17607501; 17607547; 17612762; 17618436; 17624216; 17626836; 17627763; 17631138; 17631734; 17631742; 17635596; 17635597; 17635859; 17638785; 17640324; 17641010; 17645589; 17646145; 17653830; 17654453; 17656331; 17657677; 17660390; 17665457; 17666321; 17667716; 17668322; 17671691; 17672967; 17673491; 17674321; 17678725; 17681786; 17684700; 17686006; 17686102; 17686222; 17686276; 17689273; 17689932; 17690329; 17697145; 17698217; 17700165; 17700364; 17701456; 17701768; 17702576; 17703412; 17704111; 17705580; 17706953; 17707405; 17708628; 17710405; 17710577; 17711410; 17712006; 17712635; 17714554; 17714763; 17716775; 17717744; 17724799; 17727652; 17728075; 17728221; 17761309; 17763205; 17763324; 17763852; 17763921; 17767555; 17768594; 17785317; 17785864; 17823082; 17823083; 17823284; 17823444; 17845635; 17846855; 17850436; 17851856; 17854800; 17873294; 17877801; 17879952; 17881124; 17881900; 17881920; 17888176; 17889143; 17890880; 17892998; 17895302; 17895594; 17896809; 17900510; 17903994; 17906092; 17907045; 17908769; 17910605; 17911088; 17913045; 17913961; 17920036; 17921876; 17922812; 17927494; 17927932; 17928988; 17935818; 17936906; 17937745; 17938134; 17942758; 17947510; 17952840; 17953695; 17960400; 17971052; 17974504; 17976926; 17978470; 17981284; 17981921; 17986934; 17988266; 17988528; 17988552; 17988588; 17988804; 17989340; 17989610; 17990358; 17996648; 17996942; 17997607; 17999785; 18000721; 18001298; 18003704; 18004767; 18006630; 18021367; 18021981; 18023359; 18029463; 18030367; 18032780; 18036648; 18040839; 18041006; 18048771; 18049448; 18051225; 18055234; 18055729; 18055871; 18056971; 18060802; 18061975; 18062795; 18063307; 18063379; 18068948; 18069935; 18070287; 18071035; 18071881; 18076359; 18078481; 18078928; 18079408; 18080320; 18081437; 18083042; 18083240; 18083784; 18086782; 18088017; 18088351; 18088549; 18088554; 18089811; 18090276; 18091521; 18092345; 18093792; 18094051; 18094730; 18095602; 18097033; 18155667; 18156701; 18157711; 18158110; 18158121; 18164590; 18165865; 18174230; 18174250; 18176176; 18176993; 18177545; 18180317; 18182917; 18187448; 18194515; 18196539; 18199670; 18199828; 18202225; 18205195; 18206417; 18209523; 18215180; 18219322; 18222174; 18223493; 18224289; 18231755; 18231758; 18234086; 18234565; 18240225; 18240960; 18249219; 18251167; 18252868; 18256059; 18260730; 18263601; 18266953; 18271063; 18272527; 18273051; 18273643; 18274637; 18274638; 18275007; 18275506; 18278185; 18279834; 18281372; 18283248; 18284424; 18286287; 18289203; 18292233; 18292388; 18292749; 18294286; 18295546; 18297686; 18299433; 18300111; 18301299; 18303186; 18303205; 18307033; 18307517; 18307978; 18308368; 18308930; 18309109; 18309487; 18311806; 18312445; 18312678; 18314537; 18316608; 18319718; 18320014; 18322311; 18328265; 18328809; 18330749; 18331441; 18334870; 18335579; 18336259; 18336639; 18336852; 18337305; 18337563; 18341619; 18344712; 18344999; 18345002; 18346639; 18346907; 18348163; 18350251; 18353715; 18354232; 18354254; 18355201; 18355445; 18356846; 18361934; 18362084; 18363738; 18363879; 18364273; 18366487; 18373975; 18375254; 18381783; 18381799; 18383524; 18384390; 18384449; 18385169; 18385757; 18388249; 18391721; 18391842; 18392953; 18394614; 18396154; 18396294; 18398712; 18404970; 18405969; 18405996; 18408074; 18409070; 18413212; 18416134; 18416756; 18418000; 18422436; 18426866; 18427872; 18428025; 18433468; 18434886; 18437285; 18438653; 18438841; 18439101; 18440775; 18441098; 18442814; 18444945; 18446055; 18447907; 18450464; 18451575; 18452158; 18454664; 18463678; 18472000; 18483465; 18484240; 18485518; 18485876; 18489434; 18493210; 18495419; 18496214; 18496506; 18499473; 18502564; 18502965; 18510721; 18511747; 18512781; 18513389; 18515978; 18521569; 18524817; 18534053; 18534084; 18535206; 18538149; 18543247; 18544535; 18545091; 18546202; 18547669; 18547996; 18549718; 18550063; 18550705; 18550789; 18551071; 18551993; 18552856; 18558283; 18560870; 18563738; 18565022; 18566306; 18566436; 18566561; 18566867; 18571009; 18573564; 18574677; 18575614; 18577652; 18579335; 18580445; 18580852; 18581940; 18583979; 18584048; 18587204; 18589089; 18591313; 18596918; 18597405; 18600213; 18600307; 18603357; 18606301; 18606850; 18608123; 18610831; 18610832; 18613029; 18615253; 18618239; 18619701; 18620570; 18621737; 18624881; 18624934; 18627514; 18628756; 18631256; 18632424; 18632425; 18633131; 18633332; 18633768; 18634156; 18634161; 18635549; 18635873; 18639610; 18640487; 18640689; 18643840; 18645056; 18645461; 18646527; 18649336; 18656701; 18658144; 18660489; 18665050; 18665387; 18665932; 18666029; 18667537; 18668392; 18668547; 18670216; 18673406; 18673463; 18675783; 18675993; 18676404; 18676680; 18676776; 18676870; 18678243; 18678874; 18679053; 18680515; 18685607; 18689851; 18692180; 18698679; 18700166; 18702109; 18703994; 18705845; 18708672; 18709160; 18710329; 18710415; 18710885; 18711258; 18715339; 18715507; 18716131; 18716928; 18717726; 18719920; 18720901; 18726101; 18728048; 18752500; 18753141; 18754435; 18755269; 18755511; 18755820; 18758806; 18763028; 18764880; 18766139; 18768512; 18773331; 18773665; 18778820; 18792803; 18794066; 18796448; 18797411; 18797991; 18804983; 18805021; 18807256; 18809684; 18811622; 18814905; 18815054; 18815552; 18815866; 18818748; 18820938; 18821672; 18825399; 18826950; 18827481; 18832862; 18834321; 18834925; 18838202; 18839132; 18846826; 18852869; 18854757; 18926711; 18930140; 18930330; 18931463; 18931892; 18936436; 18937577; 18942752; 18942754; 18945465; 18947693; 18949133; 18949366; 18949385; 18949619; 18951205; 18952604; 18953879; 18962899; 18971284; 18974840; 18974842; 18981134; 18989801; 18990758; 18990769; 18992196; 18992723; 18996102; 18996288; 18996291; 18997459; 18997986; 19002558; 19004142; 19005292; 19008611; 19009622; 19012493; 19013788; 19017992; 19019335; 19021060; 19022640; 19023492; 19026125; 19026135; 19028820; 19031138; 19031816; 19032770; 19032806; 19035456; 19035492; 19036374; 19038328; 19050632; 19052146; 19055487; 19056482; 19057521; 19058789; 19058987; 19060367; 19060757; 19064125; 19064572; 19065318; 19066187; 19072030; 19073786; 19076989; 19082505; 19082897; 19084540; 19086955; 19088256; 19089489; 19091593; 19091752; 19094228; 19099590; 19103526; 19104039; 19107725; 19107922; 19109170; 19109523; 19110660; 19115949; 19117726; 19117745; 19120272; 19121222; 19122175; 19126414; 19126646; 19127455; 19129484; 19131662; 19131814; 19133041; 19135670; 19142017; 19143814; 19144181; 19144193; 19147919; 19148387; 19151112; 19152111; 19152246; 19155075; 19156215; 19164257; 19164476; 19167443; 19167444; 19167759; 19168721; 19168815; 19169931; 19170196; 19175398; 19180470; 19180512; 19180798; 19183163; 19193342; 19196314; 19196817; 19200845; 19201028; 19201038; 19201817; 19203796; 19208590; 19212208; 19213875; 19214380; 19218098; 19218353; 19218687; 19219422; 19223152; 19223501; 19225544; 19225954; 19229070; 19230022; 19230467; 19231997; 19233472; 19234184; 19236316; 19238444; 19238748; 19242068; 19242354; 19244371; 19246452; 19247692; 19247707; 19248089; 19249901; 19250144; 19250279; 19250650; 19253056; 19257928; 19257990; 19258635; 19258923; 19260858; 19261809; 19263529; 19264393; 19267370; 19272692; 19276869; 19278365; 19279689; 19281305; 19282863; 19286392; 19289181; 19289468; 19292050; 19295440; 19298660; 19299722; 19301111; 19309429; 19318316; 19322919; 19328242; 19328558; 19332120; 19333723; 19336370; 19336475; 19338208; 19338485; 19338536; 19339243; 19339270; 19339767; 19340565; 19344623; 19347053; 19347588; 19351958; 19353239; 19358670; 19358850; 19360326; 19365401; 19366699; 19367093; 19367363; 19369902; 19374512; 19374589; 19375766; 19375805; 19376428; 19385047; 19386363; 19386798; 19390969; 19392621; 19392789; 19392797; 19393188; 19394608; 19405090; 19407154; 19407822; 19408823; 19409515; 19411070; 19411391; 19413740; 19419979; 19420105; 19421420; 19423537; 19424555; 19427781; 19436686; 19436689; 19439012; 19445962; 19448410; 19450147; 19453261; 19453840; 19455469; 19459480; 19461480; 19467887; 19468203; 19469656; 19470040; 19470238; 19470239; 19472212; 19474090; 19474452; 19477545; 19478694; 19479051; 19479237; 19480843; 19481774; 19483297; 19488421; 19491251; 19491387; 19493496; 19495883; 19497039; 19498318; 19500335; 19500510; 19501525; 19505222; 19505916; 19505919; 19508433; 19508602; 19522649; 19524512; 19527514; 19527699; 19528505; 19530270; 19531281; 19531474; 19533439; 19538860; 19542367; 19542865; 19543846; 19544559; 19545551; 19546559; 19546880; 19548417; 19550417; 19551157; 19553068; 19555357; 19556613; 19556827; 19559392; 19563465; 19564826; 19573080; 19574026; 19576194; 19578796; 19581111; 19584886; 19585232; 19586939; 19592490; 19594368; 19602845; 19606693; 19608431; 19614955; 19615068; 19618378; 19619514; 19619938; 19621989; 19625176; 19626584; 19635931; 19637776; 19638314; 19643162; 19644155; 19645041; 19649705; 19650780; 19651533; 19654554; 19657354; 19657406; 19658300; 19659788; 19659809; 19661089; 19664671; 19665818; 19672706; 19673019; 19679065; 19683483; 19683526; 19683555; 19692168; 19692203; 19695094; 19697035; 19698992; 19700502; 19706048; 19706600; 19707465; 19708125; 19710156; 19710421; 19714324; 19714631; 19716548; 19717436; 19717938; 19720680; 19723083; 19723394; 19723627; 19728295; 19729601; 19729797; 19729799; 19732761; 19732770; 19732956; 19733878; 19735075; 19735272; 19738171; 19738620; 19741298; 19742166; 19744138; 19752769; 19755636; 19758199; 19758203; 19760027; 19760502; 19762398; 19764567; 19769302; 19769745; 19771178; 19772798; 19773279; 19773451; 19774383; 19775068; 19776336; 19776629; 19778488; 19779724; 19784808; 19787624; 19789190; 19789454; 19789511; 19790045; 19790073; 19796538; 19799649; 19800032; 19800767; 19801788; 19803352; 19803813; 19804405; 19806584; 19811435; 19811436; 19811499; 19813110; 19815509; 19817985; 19818126; 19818512; 19819209; 19822082; 19823053; 19825522; 19830555; 19830738; 19833626; 19836613; 19837795; 19840475; 19844779; 19845893; 19846139; 19846171; 19846277; 19847187; 19849941; 19850087; 19850743; 19851445; 19851831; 19860001; 19860911; 19861860; 19874800; 19876004; 19879772; 19880327; 19885605; 19889458; 19890236; 19890474; 19892918; 19894308; 19897767; 19900796; 19903048; 19909503; 19910467; 19910617; 19910749; 19913121; 19922107; 19933216; 19934104; 19941336; 19945777; 19948975; 19949084; 19951374; 19954656; 19954777; 19956564; 19956635; 19957794; 19959217; 19966052; 19966089; 20001857; 20002873; 20004605; 20004646; 20005085; 20005846; 20007453; 20007938; 20009360; 20012441; 20012959; 20012999; 20014019; 20015215; 20015663; 20020446; 20022049; 20027315; 20029655; 20032122; 20035378; 20035431; 20037209; 20038579; 20039412; 20043171; 20047977; 20051654; 20053569; 20056178; 20056442; 20059579; 20061995; 20063037; 20064200; 20064526; 20067407; 20067853; 20068037; 20070603; 20070836; 20074459; 20074664; 20078877; 20080841; 20080912; 20082482; 20082645; 20083555; 20083573; 20085599; 20086025; 20087644; 20087947; 20088864; 20096599; 20097868; 20097948; 20100586; 20100935; 20103767; 20104750; 20104757; 20106534; 20107186; 20113413; 20118277; 20120526; 20121167; 20124101; 20126546; 20128678; 20131287; 20132806; 20132814; 20133817; 20140872; 20145387; 20145925; 20146672; 20147981; 20156727; 20157068; 20160043; 20162115; 20163933; 20166876; 20173430; 20177069; 20177654; 20178529; 20178622; 20178892; 20180006; 20181653; 20181891; 20184663; 20186155; 20187770; 20188863; 20189261; 20189706; 20191326; 20191386; 20193596; 20194454; 20194818; 20200422; 20202153; 20203691; 20206339; 20206550; 20207250; 20210814; 20213229; 20213805; 20214763; 20217044; 20217072; 20224758; 20224765; 20227257; 20228669; 20228833; 20229266; 20231691; 20231985; 20237236; 20237317; 20237426; 20299515; 20299531; 20300049; 20301193; 20304956; 20305143; 20306665; 20306666; 20306684; 20307265; 20307542; 20307689; 20331378; 20333386; 20334849; 20334922; 20335604; 20335630; 20337945; 20339904; 20339974; 20346360; 20348510; 20349238; 20349753; 20352242; 20353421; 20354226; 20355242; 20356387; 20357201; 20357716; 20361391; 20363151; 20363332; 20364405; 20368273; 20370995; 20371430; 20372910; 20372945; 20373002; 20380698; 20381257; 20381376; 20383177; 20384434; 20386917; 20388088; 20388617; 20388705; 20393185; 20395963; 20396411; 20396431; 20398373; 20399210; 20399512; 20399529; 20404426; 20407468; 20418110; 20419805; 20420684; 20422754; 20423777; 20424554; 20430728; 20430958; 20431935; 20437058; 20441409; 20449757; 20450741; 20452482; 20453000; 20454933; 20456305; 20459604; 20459687; 20460119; 20463618; 20465445; 20470442; 20470944; 20472930; 20473875; 20484443; 20484876; 20485444; 20486195; 20486865; 20486867; 20487628; 20490891; 20491592; 20492333; 20493182; 20493832; 20495148; 20499285; 20502044; 20503287; 20509143; 20511226; 20512382; 20514989; 20518833; 20518840; 20518842; 20521320; 20522203; 20522558; 20526020; 20533298; 20534169; 20535510; 20535794; 20535924; 20536507; 20536548; 20536609; 20537163; 20537485; 20538960; 20541027; 20548340; 20563362; 20564140; 20565774; 20566643; 20568250; 20573209; 20574005; 20576226; 20576301; 20578265; 20578820; 20580040; 20587610; 20588103; 20588308; 20596903; 20599393; 20599735; 20600447; 20603037; 20603050; 20608170; 20609223; 20617584; 20618340; 20619088; 20621566; 20625422; 20626741; 20627040; 20628086; 20628624; 20637704; 20639461; 20640364; 20640910; 20644561; 20646084; 20650298; 20650301; 20652825; 20659236; 20661026; 20662065; 20662694; 20663564; 20665551; 20668555; 20673868; 20682333; 20682687; 20683885; 20695192; 20701626; 20702406; 20703737; 20709566; 20714375; 20720222; 20722470; 20725607; 20729202; 20731043; 20731121; 20731689; 20731692; 20732366; 20733583; 20734064; 20736038; 20796230; 20798494; 20798956; 20802378; 20805562; 20805766; 20810691; 20811626; 20811902; 20814201; 20814569; 20816195; 20817073; 20817730; 20819413; 20825556; 20826751; 20830806; 20835611; 20846452; 20846669; 20848459; 20849900; 20854131; 20854863; 20857483; 20860222; 20864106; 20870895; 20872355; 20874489; 20878356; 20880267; 20880607; 20882404; 20883322; 20884746; 20886274; 20887379; 20888911; 20920206; 20929536; 20931685; 20932773; 20933106; 20935448; 20936699; 20937002; 20937806; 20942272; 20942594; 20944558; 20946339; 20946625; 20947251; 20951096; 20952689; 20953524; 20953611; 20956574; 20957367; 20960273; 20961668; 20963496; 20964626; 20965572; 20966071; 20967696; 20971923; 20973681; 20978325; 20979861; 20980264; 21029472; 21033124; 21033253; 21037509; 21040915; 21042029; 21044752; 21046226; 21048327; 21052690; 21054877; 21057163; 21057561; 21059493; 21060270; 21061265; 21067752; 21068403; 21075101; 21078874; 21080879; 21082024; 21082225; 21086908; 21090238; 21091999; 21093436; 21094815; 21097392; 21102463; 21103669; 21103885; 21107607; 21107701; 21112094; 21120488; 21120500; 21127983; 21129244; 21130787; 21135495; 21136171; 21147638; 21147642; 21148792; 21149504; 21153318; 21153326; 21153349; 21153361; 21153921; 21160173; 21165572; 21167738; 21169032; 21173731; 21177755; 21178846; 21181166; 21185609; 21186276; 21187523; 21192298; 21205918; 21211511; 21211655; 21212278; 21212403; 21212994; 21215285; 21218642; 21219546; 21226932; 21228323; 21228685; 21228795; 21229844; 21237555; 21237580; 21245386; 21246243; 21246958; 21249467; 21253506; 21254282; 21256190; 21266470; 21271217; 21271873; 21274647; 21275162; 21282514; 21286722; 21292512; 21296384; 21296591; 21297077; 21298033; 21307151; 21313996; 21316358; 21316985; 21317641; 21319595; 21319995; 21323572; 21331077; 21336601; 21341430; 21344384; 21346237; 21346775; 21350240; 21350819; 21355310; 21357402; 21362045; 21367920; 21370248; 21373785; 21377791; 21380730; 21382272; 21384095; 21385538; 21385558; 21386799; 21393356; 21396892; 21400214; 21400614; 21401328; 21403867; 21403886; 21408088; 21408173; 21411417; 21412035; 21420089; 21423726; 21431944; 21441465; 21442077; 21443923; 21450487; 21454254; 21455632; 21457223; 21458669; 21465273; 21469124; 21473134; 21474332; 21474440; 21476000; 21477635; 21478032; 21482826; 21486440; 21494616; 21498926; 21499693; 21508505; 21509504; 21521472; 21525886; 21527635; 21527853; 21527907; 21535954; 21542902; 21544635; 21551367; 21553055; 21553284; 21559086; 21559479; 21559831; 21562054; 21569377; 21572952; 21573018; 21573932; 21575121; 21586325; 21591983; 21593777; 21596021; 21600698; 21604171; 21606490; 21609779; 21611196; 21616679; 21620750; 21621418; 21621860; 21623992; 21624061; 21626471; 21631181; 21631297; 21633892; 21637953; 21639826; 21640790; 21641234; 21658307; 21658310; 21658326; 21659535; 21668366; 21670314; 21670923; 21670964; 21675251; 21679760; 21682548; 21688665; 21693096; 21697747; 21701244; 21702700; 21703188; 21712100; 21714933; 21716128; 21722904; 21729551; 21729562; 21733366; 21735105; 21741441; 21749603; 21752952; 21756957; 21762706; 21776298; 21777517; 21777909; 21782178; 21784129; 21784970; 21788151; 21789799; 21798984; 21802960; 21806780; 21809123; 21810022; 21811986; 21812905; 21813066; 21818296; 21820422; 21826654; 21828047; 21830421; 21833533; 21845541; 21845872; 21846573; 21846948; 21847627; 21849807; 21849907; 21851198; 21854221; 21858100; 21858117; 21860020; 21860543; 21865054; 21870243; 21873076; 21875833; 21878338; 21880216; 21885496; 21886773; 21898706; 21900165; 21904873; 21906436; 21907587; 21912593; 21915486; 21917899; 21920667; 21922073; 21924074; 21931646; 21933669; 21933882; 21937453; 21945535; 21948112; 21949132; 21965637; 21966220; 21966367; 21967963; 21969554; 21970639; 21978000; 21978003; 21980981; 21983349; 21985478; 21988415; 21995333; 22001640; 22004920; 22010076; 22010829; 22012292; 22015686; 22016814; 22019000; 22019249; 22021194; 22021612; 22025632; 22027829; 22035595; 22045868; 22047608; 22053594; 22053613; 22053710; 22057071; 22057691; 22059991; 22068351; 22070668; 22072539; 22081334; 22086907; 22088456; 22088844; 22093255; 22093778; 22095071; 22095602; 22096007; 22097889; 22099304; 22100609; 22104567; 22105495; 22106856; 22127698; 22142046; 22151084; 22151832; 22153345; 22156348; 22172512; 22177457; 22183425; 22187701; 22188951; 22195005; 22199285; 22200181; 22200508; 22205204; 22207023; 22207455; 22217359; 22219323; 22221522; 22223068; 22225778; 22227290; 22228181; 22230689; 22239507; 22239528; 22243719; 22246057; 22257833; 22258491; 22262846; 22264991; 22265273; 22266116; 22266275; 22268119; 22269998; 22271589; 22276993; 22280559; 22284365; 22287006; 22289556; 22294627; 22301094; 22301607; 22301786; 22311210; 22320863; 22321707; 22321809; 22326557; 22327199; 22330622; 22338227; 22340390; 22341723; 22350281; 22351606; 22363611; 22363701; 22365967; 22366404; 22366579; 22369788; 22382194; 22384111; 22385244; 22386367; 22387051; 22389764; 22393042; 22395607; 22404198; 22405769; 22407921; 22410150; 22420891; 22422499; 22426431; 22431252; 22434667; 22436801; 22454477; 22461198; 22463742; 22465880; 22466076; 22468900; 22470014; 22471589; 22473048; 22475215; 22479352; 22481167; 22484242; 22484483; 22486303; 22487393; 22487520; 22488302; 22496218; 22496489; 22504646; 22504829; 22506067; 22507624; 22509108; 22512415; 22513115; 22515582; 22525685; 22526394; 22527933; 22528837; 22532631; 22534470; 22534629; 22536381; 22538781; 22542718; 22554453; 22558919; 22562260; 22562290; 22563871; 22564606; 22565852; 22566686; 22569435; 22572643; 22577092; 22579868; 22580582; 22580620; 22581210; 22591361; 22593232; 22595285; 22609212; 22610275; 22616715; 22619347; 22621205; 22629855; 22634176; 22649007; 22655468; 22658256; 22661088; 22661255; 22664006; 22664325; 22673037; 22673732; 22675546; 22675954; 22678805; 22680042; 22682513; 22683888; 22684480; 22691114; 22695741; 22696185; 22698992; 22702470; 22703762; 22707636; 22708547; 22711844; 22714118; 22714811; 22727980; 22729740; 22733992; 22738830; 22742591; 22742857; 22749237; 22749533; 22749718; 22752116; 22759465; 22759859; 22766105; 22767148; 22772094; 22778029; 22783580; 22797138; 22798670; 22801493; 22802339; 22808100; 22808497; 22810465; 22814248; 22826629; 22835835; 22836756; 22863952; 22869322; 22872022; 22883217; 22883518; 22884017; 22884417; 22884981; 22891927; 22897390; 22897480; 22898217; 22902304; 22903530; 22905199; 22913362; 22917968; 22918199; 22921153; 22921402; 22922291; 22922824; 22923002; 22927431; 22937208; 22937788; 22940143; 22944040; 22945416; 22947142; 22947907; 22948157; 22949029; 22950839; 22960943; 22964479; 22982041; 22983646; 22984233; 22986484; 22986613; 22986753; 22990108; 22990365; 22990627; 22992806; 22995913; 22999526; 23009757; 23011034; 23013131; 23021488; 23028059; 23028877; 23029405; 23032186; 23032187; 23033000; 23034253; 23036097; 23046723; 23050663; 23057546; 23058031; 23065208; 23066418; 23067363; 23068962; 23069299; 23070544; 23071313; 23073259; 23077985; 23079033; 23081800; 23082052; 23086255; 23089051; 23092582; 23092711; 23096596; 23100065; 23100272; 23103767; 23110185; 23122308; 23137321; 23139429; 23141142; 23142559; 23159355; 23159874; 23164102; 23167810; 23168096; 23169178; 23176610; 23179933; 23183825; 23192010; 23193891; 23195574; 23204162; 23209346; 23209731; 23212700; 23217179; 23225254; 23229544; 23233369; 23246833; 23249640; 23254337; 23255681; 23258148; 23258237; 23265967; 23275336; 23276701; 23280137; 23281720; 23284977; 23288922; 23290099; 23294492; 23294973; 23294975; 23297421; 23298660; 23300810; 23305356; 23313255; 23315809; 23317256; 23317877; 23322904; 23326309; 23326472; 23327497; 23328497; 23331923; 23333028; 23333893; 23333920; 23334278; 23335080; 23338599; 23339186; 23343370; 23349048; 23349093; 23349721; 23357300; 23359411; 23359428; 23359489; 23363891; 23376082; 23377880; 23378732; 23380141; 23388693; 23393163; 23394901; 23396208; 23403273; 23406059; 23413901; 23425028; 23432860; 23437179; 23451177; 23459075; 23462597; 23465534; 23466425; 23470607; 23472126; 23484124; 23484152; 23485383; 23485538; 23487197; 23489698; 23494178; 23498057; 23500081; 23500159; 23503445; 23507260; 23527193; 23527710; 23532748; 23542051; 23546865; 23550407; 23552949; 23553861; 23555579; 23557460; 23559847; 23567762; 23576453; 23577187; 23581259; 23588423; 23590297; 23592910; 23593411; 23593415; 23594457; 23597429; 23601741; 23602201; 23607333; 23615914; 23619127; 23625043; 23630220; 23630362; 23632060; 23634661; 23638863; 23639307; 23639700; 23640160; 23643268; 23651237; 23651848; 23657597; 23657600; 23658704; 23661556; 23661584; 23663047; 23669395; 23673311; 23677169; 23680697; 23682387; 23683942; 23703343; 23704210; 23712703; 23713409; 23717605; 23720844; 23723980; 23732752; 23732909; 23740956; 23745338; 23746176; 23746843; 23748363; 23751348; 23768164; 23774701; 23777202; 23785756; 23785788; 23793505; 23795660; 23800059; 23816715; 23821300; 23828749; 23834030; 23861398; 23864804; 23870134; 23877857; 23880295; 23884763; 23900678; 23911749; 23918043; 23923372; 23925283; 23935096; 23936398; 23936458; 23940760; 23943369; 23943614; 23965971; 23989985; 24012198; 24018067; 24041577; 24049437; 24067962; 24077340; 24078775; 24140406; 24145654; 24186266; 24265545; 24294778; 24299316; 24307062; 24307172; 24313836; 24314919; 24316671; 24338609; 24340926; 24371310; 24403490; 24409675; 24459820; 24611333; 24611335,,,,,,,,,,,,,,,OGG:3000007124,,,,,,,tumor necrosis factor,,,,,,,,,,,,,"Other designations: APC1 protein|TNF, macrophage-derived|TNF, monocyte-derived|TNF-a|cachectin|tumor necrosis factor ligand superfamily member 2|tumor necrosis factor-alpha",,TNF,,,,,,,,,,,,,,,,,,,,,,,7124,DADB-70P7.1,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,TNF,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_50908,hepatotoxic agent,hepatoxicant|hepatotoxic agents|hepatotoxin|hepatotoxicant|hepatotoxins|hepatotoxicants|hepatoxic agent|agente hepatotoxico,A role played by an entity exihibiting itself through the ability to induce damage to the liver in animals.|A role played by a chemical compound exihibiting itself through the ability to induce damage to the liver in animals.,false,,,http://purl.obolibrary.org/obo/TXPO_0000038|http://purl.obolibrary.org/obo/CHEBI_52209,,,,,,,,,,,,,,,,,,,,,,A role played by an entity exihibiting itself through the ability to induce damage to the liver in animals.|A role played by a chemical compound exihibiting itself through the ability to induce damage to the liver in animals.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,hepatoxicant|hepatotoxic agents|hepatotoxin|hepatotoxicant|hepatotoxins|hepatotoxicants|hepatoxic agent|agente hepatotoxico,,,,,,,,,,,,,,,,,,,,,CHEBI:50908,,,,hepatotoxic agent,,CHEBI:50908,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_28087,glycogen,,"A polydisperse, highly branched glucan composed of chains of D-glucopyranose residues in alpha(1->4) glycosidic linkage, joined together by alpha(1->6) glycosidic linkages. A small number of alpha(1->3) glycosidic linkages and some cumulative alpha(1->6) links also may occur. The branches in glycogen typically contain 8 to 12 glucose residues.",false,,,http://purl.obolibrary.org/obo/CHEBI_18154,,,,,,,,,,,,,,,,,,,,CAS:9005-79-2,,"A polydisperse, highly branched glucan composed of chains of D-glucopyranose residues in alpha(1->4) glycosidic linkage, joined together by alpha(1->6) glycosidic linkages. A small number of alpha(1->3) glycosidic linkages and some cumulative alpha(1->6) links also may occur. The branches in glycogen typically contain 8 to 12 glucose residues.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:28087,,,,,,,,,,,,,,,,,,,,,,glycogen,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100611,cyclin B1,CGB1|G2/mitotic-specific cyclin B1,,false,,,http://purl.obolibrary.org/obo/IMR_0100610,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0010767|IMR:0011592,CGB1|G2/mitotic-specific cyclin B1,,,,,IMR:0100611,,,,,,,,,,,,,,,,,,,,,,cyclin B1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001436,GDF-11,Growth/differentiation factor 11|BMP11|GDF11|BMP-11|Bone morphogenetic protein 11,,false,,,http://purl.obolibrary.org/obo/IMR_0000040,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Growth/differentiation factor 11|BMP11|GDF11|BMP-11|Bone morphogenetic protein 11,,,,,IMR:0001436,,,,,,,,,,,,,,,,,,,,,,GDF-11,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006497,protein lipidation,lipid:protein modification,The covalent attachment of lipid groups to an amino acid in a protein.,false,,,http://purl.obolibrary.org/obo/GO_0036211,,,,,,,,,,,,,,,,,,,,,,The covalent attachment of lipid groups to an amino acid in a protein.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,lipid:protein modification,,,,,GO:0006497,,,,,,,,,,,,,,,,,,,,,,protein lipidation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100355,Raf-1,c-Raf-1|c-Raf,,false,,,http://purl.obolibrary.org/obo/IMR_0000231,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,c-Raf-1|c-Raf,,,,,IMR:0100355,,,,,,,,,,,,,,,,,,,,,,Raf-1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001937,glutathione synthase,,An enzyme that catalysis of the reaction: L-gamma-glutamyl-L-cysteine + ATP + glycine = ADP + glutathione + 2 H(+) + phosphate.,false,,,http://purl.obolibrary.org/obo/TXPO_0000171,,,,,,,,,,,,,,,,,,,,,,An enzyme that catalysis of the reaction: L-gamma-glutamyl-L-cysteine + ATP + glycine = ADP + glutathione + 2 H(+) + phosphate.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001937,,,,,,,,,,,,,,,,,,,,,,glutathione synthase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001938,Aldh1a1 (rat)[Glutathione depletion],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001927|http://purl.obolibrary.org/obo/TXPO_1000035,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24188,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002396,,,,,,,,,,TXPO:0001938,,,,,,,,,,,,,,,,,,,,,,Aldh1a1 (rat)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001936,Me1 (rat)[Glutathione depletion],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001927|http://purl.obolibrary.org/obo/TXPO_1000244,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24552|PMID:23334421|PMID:24287781,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001936,,,,,,,,,,,,,,,,,,,,,,Me1 (rat)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001930,Txnrd1 (rat)[Glutathione depletion],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001927|http://purl.obolibrary.org/obo/TXPO_1000389,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:58819|PMID:24287781|PMID:26058897,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001930,,,,,,,,,,,,,,,,,,,,,,Txnrd1 (rat)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001935,Osgin1 (rat)[Glutathione depletion],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001927|http://purl.obolibrary.org/obo/TXPO_1000272,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:171493,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001935,,,,,,,,,,,,,,,,,,,,,,Osgin1 (rat)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001932,Mdm2 (rat)[Glutathione depletion],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001927|http://purl.obolibrary.org/obo/IMR_0100660,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:314856,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002399,,,,,,,,,,TXPO:0001932,,,,,,,,,,,,,,,,,,,,,,Mdm2 (rat)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001931,GSS (mol),Glutathione Synthetase,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:14854|NCBI-Human-GeneID:2937|NCBI-Rat-GeneID:25458,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000002937,,,,,,,,Glutathione Synthetase,,,,,TXPO:0001931,,,,,,,,,,,,,,,,,,,,,,GSS (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001933,hyperfunction of glutathione synthetic gene expression [Glutathione depletion],,"Hyperfunction of glutathione synthetic gene expression is a subtype of hyperfunction of gene expression: A process that performs an excesssive glutathione synthetic gene expression.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0001378|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of glutathione synthetic gene expression is a subtype of hyperfunction of gene expression: A process that performs an excesssive glutathione synthetic gene expression.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000904|http://purl.obolibrary.org/obo/TXPO_0002254|http://purl.obolibrary.org/obo/TXPO_0002404|http://purl.obolibrary.org/obo/TXPO_0002216,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001194,,,,,,,,,,,TXPO:0001933,,,,,,,,,,,,,,,,,,,,,,hyperfunction of glutathione synthetic gene expression [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001939,DDB2 -inactivation (canonical)[Ground glass appearance],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001019,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:107986|NCBI-Rat-GeneID:100362121|NCBI-Human-GeneID:1643|PMID:22334663|PMID:30297359|PMID:19428948,,,,,,,,,,,,,,,Damage Specific DNA Binding Protein 2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001561,http://purl.obolibrary.org/obo/PATO_0002355,,,,,,,,,TXPO:0001939,,,,,,,,,,,,,,,,,,,,,,DDB2 -inactivation (canonical)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001934,Akr7a3 (rat)[Glutathione depletion],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001927|http://purl.obolibrary.org/obo/TXPO_1000033,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:26760|PMID:20621112|PMID:21688283,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001934,,,,,,,,,,,,,,,,,,,,,,Akr7a3 (rat)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100426,TRAF5,TNF receptor associated factor 5,,false,,,http://purl.obolibrary.org/obo/IMR_0000462,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TNF receptor associated factor 5,,,,,IMR:0100426,,,,,,,,,,,,,,,,,,,,,,TRAF5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000091,endoplasmic reticulum proliferation in hepatocyte,increasing number of  hepatocellular endoplasmic reticulum,Endoplasmic reticulum proliferation in hepatocyte is a subtype of increasing number of hepatocyte organelle: A process that becomes larger in the number of endoplasmic reticulum in hepatocyte(s).,false,,,http://purl.obolibrary.org/obo/TXPO_0003303,,,,,,,,,,,,,,,,,,,,,,Endoplasmic reticulum proliferation in hepatocyte is a subtype of increasing number of hepatocyte organelle: A process that becomes larger in the number of endoplasmic reticulum in hepatocyte(s).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,increasing number of  hepatocellular endoplasmic reticulum,,,,TXPO:0000091,,,,,,,,,,,,,,,,,,,,,,endoplasmic reticulum proliferation in hepatocyte,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000094,maintaining permeability,,Maintaining permeability is a subtype of changing permeability: A process that changes the permeability of the membrane to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0002704,,,,,,,,,,,,,,,,,,,,,,Maintaining permeability is a subtype of changing permeability: A process that changes the permeability of the membrane to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000094,,,,,,,,,,,,,,,,,,,,,,maintaining permeability,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000095,hyperfunction of fatty acid beta-oxidation,,Hyperfunction of fatty acid beta-oxidation is a subtype of hyperfunction of fatty acid oxidation: A process that performs an excessive  fatty acid beta-oxidation.,false,,,http://purl.obolibrary.org/obo/TXPO_0000099,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of fatty acid beta-oxidation is a subtype of hyperfunction of fatty acid oxidation: A process that performs an excessive  fatty acid beta-oxidation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000095,,,,,,,,,,,,,,,,,,,,,,hyperfunction of fatty acid beta-oxidation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000098,hyperfunction of lipid oxidation,,Hyperfunction of lipid oxidation is a subtype of hyperfunction of lipid catabolic process: A process that performs an excessive lipid degradation.,false,,,http://purl.obolibrary.org/obo/TXPO_0000435,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of lipid oxidation is a subtype of hyperfunction of lipid catabolic process: A process that performs an excessive lipid degradation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000098,,,,,,,,,,,,,,,,,,,,,,hyperfunction of lipid oxidation,,,,,,http://purl.obolibrary.org/obo/GO_0034440,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000093,increasing number of objects,,Increasing number of objects is a subtype of changing: A process that becomes larger in the number of physical objects.,false,,,http://purl.obolibrary.org/obo/TXPO_0000387,,,,,,,,,,,,,,,,,,,,,,Increasing number of objects is a subtype of changing: A process that becomes larger in the number of physical objects.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000093,,,,,,,,,,,,,,,,,,,,,,increasing number of objects,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0002002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000097,fatty acid omega-oxidation,,"A fatty acid oxidation process in which the methyl group at the end of the fatty acid molecule (the omega carbon) is first oxidized to a hydroxyl group, then to an oxo group, and finally to a carboxyl group. The long chain dicarboxylates derived from omega-oxidation then enter the beta-oxidation pathway for further degradation.",false,,,http://purl.obolibrary.org/obo/GO_0019395,,,,,,,,,,,,,,,,,,,,,,"A fatty acid oxidation process in which the methyl group at the end of the fatty acid molecule (the omega carbon) is first oxidized to a hydroxyl group, then to an oxo group, and finally to a carboxyl group. The long chain dicarboxylates derived from omega-oxidation then enter the beta-oxidation pathway for further degradation.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000097,,,,,,,,,,,,,,,,,,,,,,fatty acid omega-oxidation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000092,increasing number of hepatocellular endoplasmic reticulum This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.,,"Endoplasmic reticulum proliferation in hepatocyte is a subtype of increasing number of hepatocyte organelle: A process that becomes larger in the number of endoplasmic reticulum in hepatocyte(s).
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/TXPO_0000091,,,,,,,,,,,,,,,,,,,,,,"Endoplasmic reticulum proliferation in hepatocyte is a subtype of increasing number of hepatocyte organelle: A process that becomes larger in the number of endoplasmic reticulum in hepatocyte(s).
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000092,,,,,,,,,,,,,,,,,,,,,,increasing number of hepatocellular endoplasmic reticulum This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000090,meloxicam - apotosis inducing factor [ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001982,,,,,,,,,,,,,,,,,,,,PMID:26481188,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_68495,,,,,,,,,,TXPO:0000090,,,,,,,,,,,,,,,,,,,,,,meloxicam - apotosis inducing factor [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000099,hyperfunction of fatty acid oxidation,,Hyperfunction of fatty acid oxidation is a subtype of hyperfunction of lipid oxidation: A process that performs an excessive lipid oxidation.,false,,,http://purl.obolibrary.org/obo/TXPO_0000098,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/MP_0014171,,Hyperfunction of fatty acid oxidation is a subtype of hyperfunction of lipid oxidation: A process that performs an excessive lipid oxidation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000099,,,,,,,,,,,,,,,,,,,,,,hyperfunction of fatty acid oxidation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000096,increasing liver weight [Eosinophilic granular degeneration],,"Increasing liver weight is a subtype of increasing weight: A process that changes the weight of the liver to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/TXPO_0000054|http://purl.obolibrary.org/obo/TXPO_0001729,,,,,,,,,,,,,,,,,,,,,,"Increasing liver weight is a subtype of increasing weight: A process that changes the weight of the liver to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000096,,,,,,,,,,,,,,,,,,,,,,increasing liver weight [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_64911,antimitotic,antimitotics|mitotic inhibitors|mitotic inhibitor|mitosis inhibitors|mitosis inhibitor,Any compound that inhibits cell division (mitosis).,false,,,http://purl.obolibrary.org/obo/CHEBI_52210,,,,,,,,,,,,,,,,,,,,,,Any compound that inhibits cell division (mitosis).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,antimitotics|mitotic inhibitors|mitotic inhibitor|mitosis inhibitors|mitosis inhibitor,,,,,,,,,,,,,,,,,,,,,CHEBI:64911,,,,antimitotic,,CHEBI:64911,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_27136,triol,,A chemical compound containing three hydroxy groups.,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,,,A chemical compound containing three hydroxy groups.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:27136,,,,,,,,,,,,,,,,,,,,,,triol,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003932,negative regulation of gluconeogenesis (sustained) [Ground glass appearance],,"Any process that stops, prevents, or reduces the frequency, rate or extent of gluconeogenesis in the course of ground grlass appearence. This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) .",false,,,http://purl.obolibrary.org/obo/TXPO_0003926,,,,,,,,,,,,,,,,,,,,ISBN:0071769234,,"Any process that stops, prevents, or reduces the frequency, rate or extent of gluconeogenesis in the course of ground grlass appearence. This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003945|http://purl.obolibrary.org/obo/TXPO_0003944,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000977|http://purl.obolibrary.org/obo/TXPO_0003925,,,,,,,,,,,TXPO:0003932,,,,,,,,,,,,,,,,,,,,,,negative regulation of gluconeogenesis (sustained) [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003939,negative regulation of gluconeogenesis gene expression [Ground glass appearance],,"Negative regulation of gluconeogenesis gene expression is a subtype of regulation of gluconeogenesis gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of gluconeogenesis gene expression.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0003938,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of gluconeogenesis gene expression is a subtype of regulation of gluconeogenesis gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of gluconeogenesis gene expression.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003939,,,,,,,,,,,,,,,,,,,,,,negative regulation of gluconeogenesis gene expression [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003931,AMPK - inhibitor (canonical)[Ground glass appearance],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000944,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003929,,,,,,,,,,TXPO:0003931,,,,,,,,,,,,,,,,,,,,,,AMPK - inhibitor (canonical)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003935,FOXO1 inactivation,,FOXO1 inactivation is a subtype of inactivating: A process that changes the activity of the FOXO1 to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000021,,,,,,,,,,,,,,,,,,,,,,FOXO1 inactivation is a subtype of inactivating: A process that changes the activity of the FOXO1 to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003935,,,,,,,,,,,,,,,,,,,,,,FOXO1 inactivation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003938,negative regulation of gluconeogenesis gene expression,,"Negative regulation of gluconeogenesis gene expression is a subtype of regulation of gluconeogenesis gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of gluconeogenesis gene expression.",false,,,http://purl.obolibrary.org/obo/TXPO_0003937,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of gluconeogenesis gene expression is a subtype of regulation of gluconeogenesis gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of gluconeogenesis gene expression.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003938,,,,,,,,,,,,,,,,,,,,,,negative regulation of gluconeogenesis gene expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003937,regulation of gluconeogenesis gene expression,,"Regulation of gluconeogenesis gene expression is a subtype of regulation of gene expression: A process that modulates the frequency, rate or extent of gluconeogenesis gene expression.",false,,,http://purl.obolibrary.org/obo/GO_0010468,,,,,,,,,,,,,,,,,,,,,,"Regulation of gluconeogenesis gene expression is a subtype of regulation of gene expression: A process that modulates the frequency, rate or extent of gluconeogenesis gene expression.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003937,,,,,,,,,,,,,,,,,,,,,,regulation of gluconeogenesis gene expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003930,CAR -FOXO1 transcriptional repression factor (canonical)[Ground glass appearance],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003791,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003946,,,,,,,,,,TXPO:0003930,,,,,,,,,,,,,,,,,,,,,,CAR -FOXO1 transcriptional repression factor (canonical)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003933,Dab2(mouse)[Phospholipidosis - apotosis inhibitor],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003916,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:13132|PMID:25331956|PMID:23781020|PMID:11387212|PMID:27398911,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001601,,,http://purl.obolibrary.org/obo/CHEBI_68495,,,,,,,,,,TXPO:0003933,,,,,,,PMID:19000037,,,,,,,,,,,,,,,Dab2(mouse)[Phospholipidosis - apotosis inhibitor],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003936,FOXO1 inactivation [Ground glass appearance],,"FOXO1 inactivation is a subtype of inactivating: A process that changes the activity of the FOXO1 to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/TXPO_0003935,,,,,,,,,,,,,,,,,,,,ISBN:0071769234,,"FOXO1 inactivation is a subtype of inactivating: A process that changes the activity of the FOXO1 to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003930,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003923,,,,http://purl.obolibrary.org/obo/TXPO_0003924,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003942,,,,,,,,,,,TXPO:0003936,,,,,,,,,,,,,,,,,,,,,,FOXO1 inactivation [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003934,AMPK activator,,A role played by the entity that activates AMPK activity.,false,,,http://purl.obolibrary.org/obo/TXPO_0003714,,,,,,,,,,,,,,,,,,,,,,A role played by the entity that activates AMPK activity.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003934,,,,,,,,,,,,,,,,,,,,,,AMPK activator,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010505,Heterogeneous nuclear ribonucleoprotein A0,ROA0|hnRNP A0,,false,,,http://purl.obolibrary.org/obo/IMR_0010024,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ROA0|hnRNP A0,,,,,IMR:0010505,,,,,,,,,,,,,,,,,,,,,,Heterogeneous nuclear ribonucleoprotein A0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000252,Ste20 homolog family,,,false,,,http://purl.obolibrary.org/obo/IMR_0100207,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000252,,,,,,,,,,,,,,,,,,,,,,Ste20 homolog family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000020,changing activity,,Changing activity is a subtype of changing quality: A process that changes the activity of the object.,false,,,http://purl.obolibrary.org/obo/TXPO_0000415,,,,,,,,,,,,,,,,,,,,,,Changing activity is a subtype of changing quality: A process that changes the activity of the object.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000020,,,,,,,,,,,,,,,,,,,,,,changing activity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000022,changing direction,,Changing direction is a subtype of changing quality: A process that changes the direction of the object.,false,,,http://purl.obolibrary.org/obo/TXPO_0000415,,,,,,,,,,,,,,,,,,,,,,Changing direction is a subtype of changing quality: A process that changes the direction of the object.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000022,,,,,,,,,,,,,,,,,,,,,,changing direction,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0000039,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000027,integrated signaling pathway,,"Integrated signaling pathway is a subtype of pathway: Sequence of linked reactions, which has signaling pathway and gene regulated pathway.|1. signal detection (acceptance), 2. signal transduction, 3. gene regulation (genetic information conversion process), 4. celllular process execution
This entity covers from 1, 2, and 3.",false,,,http://purl.obolibrary.org/obo/NCIT_C54214,,,,,,,,,,,,,,,,,,,,,,"Integrated signaling pathway is a subtype of pathway: Sequence of linked reactions, which has signaling pathway and gene regulated pathway.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000609,,,,,,,,,,,,,,,,TXPO:0000027,,,,,,,,,,,,,,,,,,,,"1. signal detection (acceptance), 2. signal transduction, 3. gene regulation (genetic information conversion process), 4. celllular process execution
This entity covers from 1, 2, and 3.",,integrated signaling pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000025,changing disulfide bond,,Changing disulfide bond is a subtype of changing bond: A process that changes a disulfide bond which is a covalent bond mediated by 2 sulfur atoms.,false,,,http://purl.obolibrary.org/obo/TXPO_0000024,,,,,,,,,,,,,,,,,,,,,,Changing disulfide bond is a subtype of changing bond: A process that changes a disulfide bond which is a covalent bond mediated by 2 sulfur atoms.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000025,,,,,,,,,,,,,,,,,,,,,,changing disulfide bond,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000021,inactivation,,Inactivation is a subtype of changing activity: A process that changes the activity of the object to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000020,,,,,,,,,,,,,,,,,,,,,,Inactivation is a subtype of changing activity: A process that changes the activity of the object to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000021,,,,,,,,,,,,,,,,,,,,,,inactivation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000029,hepatic fibrosis dependent molecule (human in vitro),,"Hepatic fibrosis dependent gene is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of hepatic fibrosis as a gene product.
Gene profile:Human/in vitro/Hepatocyte/",false,,,http://purl.obolibrary.org/obo/TXPO_0003749,,,,,,,,,,,,,,,,,,,,,,"Hepatic fibrosis dependent gene is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of hepatic fibrosis as a gene product.
Gene profile:Human/in vitro/Hepatocyte/",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000029,,,,,,,,,,,,,,,,,,,,,,hepatic fibrosis dependent molecule (human in vitro),,,,,,,,,,,http://purl.obolibrary.org/obo/NCBITaxon_9606,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000024,changing bond,,Changing bond is a subtype of changing between operands: A process that changes a bond between objects.,false,,,http://purl.obolibrary.org/obo/TXPO_0000261,,,,,,,,,,,,,,,,,,,,,,Changing bond is a subtype of changing between operands: A process that changes a bond between objects.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000024,,,,,,,,,,,,,,,,,,,,,,changing bond,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000028,eosinophilic granular degeneration [toxic course],,The totality of all processes through which eosinogranular degeneration is realized.,false,,,http://purl.obolibrary.org/obo/TXPO_0000009,,,,,,,,,,,,,,,,,,,,PMID:25689681|PMID:26967755|PMID:16332691|PMID:22318237|PMID:28581332|PMID:20936127|PMID:20101262|PMID:28538669|PMID:17034877|PMID:16377806,,The totality of all processes through which eosinogranular degeneration is realized.,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000105,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001005|http://purl.obolibrary.org/obo/TXPO_0002158|http://purl.obolibrary.org/obo/TXPO_0000109|http://purl.obolibrary.org/obo/TXPO_0000105|http://purl.obolibrary.org/obo/TXPO_0000118|http://purl.obolibrary.org/obo/TXPO_0000110|http://purl.obolibrary.org/obo/TXPO_0000174|http://purl.obolibrary.org/obo/TXPO_0000176|http://purl.obolibrary.org/obo/TXPO_0000179|http://purl.obolibrary.org/obo/TXPO_0000746,,,,,,,,,,,,,,,,,,TXPO:0000028,,,,,,,,,,,,,,,,,,,,,,eosinophilic granular degeneration [toxic course],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000023,molecular activation,,Molecular activation is a subtype of activating: A process that changes the activity of the moleule to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000401,,,,,,,,,,,,,,,,,,,,,,Molecular activation is a subtype of activating: A process that changes the activity of the moleule to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000023,,,,,,,,,,,,,,,,,,,,,,molecular activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010473,60S ribosomal protein L23,L17,,false,,,http://purl.obolibrary.org/obo/IMR_0000897,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,L17,,,,,IMR:0010473,,,,,,,,,,,,,,,,,,,,,,60S ribosomal protein L23,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010537,40S ribosomal protein S12,40S small ribosomal protein 12,,false,,,http://purl.obolibrary.org/obo/IMR_0000896,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,40S small ribosomal protein 12,,,,,IMR:0010537,,,,,,,,,,,,,,,,,,,,,,40S ribosomal protein S12,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100370,G-alpha-i 3,,,false,,,http://purl.obolibrary.org/obo/IMR_0000319,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100370,,,,,,,,,,,,,,,,,,,,,,G-alpha-i 3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000008517,IKBKG,,Other designations: I-kappa-B kinase subunit gamma|IKKAP1|IKKG|IkB kinase gamma subunit|NF-kappa-B essential modifier|NF-kappa-B essential modulator|NFkappaB essential modulator|ikB kinase subunit gamma|ikB kinase-associated protein 1|incontinentia pigmenti|inhibitor of nuclear factor kappa-B kinase subunit gamma,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,IP|IKK-gamma|IPD2|NEMO|Fip3p|IP2|IP1|AMCBX1|FIP-3|ZC2HC9|FIP3,,,,,,,,,,,,X,,,,,,HPRD:02217|Ensembl:ENSG00000073009|HGNC:5961|MIM:300248|Vega:OTTHUMG00000024234,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase gamma",,,Xq28,,,,,,,,,,,,,,,,"GO_0000187 (EC: TAS); GO_0001782 (EC: IEA); GO_0002224 (EC: TAS); GO_0002755 (EC: TAS); GO_0002756 (EC: TAS); GO_0004871 (EC: TAS, PMID:9927690); GO_0005515 (EC: IPI, PMID:11113112); GO_0005622 (EC: IDA); GO_0005634 (EC: IDA, PMID:14651848); GO_0005737 (EC: IDA); GO_0005829 (EC: TAS); GO_0006351 (EC: IEA); GO_0006915 (EC: TAS, PMID:9927690); GO_0006954 (EC: TAS, PMID:18626576); GO_0006955 (EC: TAS, PMID:9751060); GO_0006974 (EC: IDA, PMID:14651848); GO_0007249 (EC: TAS, PMID:18626576); GO_0007250 (EC: IEA); GO_0007254 (EC: TAS); GO_0008385 (EC: TAS, PMID:18626576); GO_0008385 (EC: TAS, Qualifier: colocalizes_with, PMID:16831874); GO_0009615 (EC: TAS, PMID:18626576); GO_0016032 (EC: IEA); GO_0019904 (EC: IPI, PMID:15341735); GO_0032481 (EC: TAS); GO_0034134 (EC: TAS); GO_0034138 (EC: TAS); GO_0034142 (EC: TAS); GO_0034146 (EC: TAS); GO_0034162 (EC: TAS); GO_0034166 (EC: TAS); GO_0035666 (EC: TAS); GO_0035872 (EC: TAS); GO_0038095 (EC: TAS); GO_0038123 (EC: TAS); GO_0038124 (EC: TAS); GO_0042803 (EC: IDA); GO_0043123 (EC: TAS); GO_0045087 (EC: TAS, PMID:18626576); GO_0045944 (EC: IDA); GO_0046872 (EC: IEA); GO_0046982 (EC: IDA); GO_0050852 (EC: NAS, PMID:15125833); GO_0050852 (EC: TAS, PMID:16831874); GO_0051092 (EC: IDA, PMID:15620648); GO_0051092 (EC: TAS, PMID:18626576); GO_0051403 (EC: TAS); GO_0070423 (EC: TAS)",,,,,,,,,PMID:9744859; 9751060; 9891086; 9927690; 10087442; 10364167; 10723127; 10733566; 10755617; 10839543; 10880512; 10944468; 10962024; 10962033; 10968790; 10980203; 11002417; 11047757; 11057907; 11064457; 11080499; 11113112; 11224521; 11242109; 11256614; 11262391; 11389905; 11410370; 11418127; 11485410; 11495908; 11551959; 11590134; 11673821; 11709543; 11830587; 11864612; 11877453; 11971901; 11971985; 12045264; 12133833; 12138192; 12192055; 12244103; 12435599; 12459277; 12477932; 12486103; 12530972; 12612076; 12657630; 12808104; 12867425; 12917689; 12917690; 12917691; 12943667; 14585847; 14585990; 14597638; 14651848; 14653779; 14684825; 14695475; 14726382; 14743216; 14748687; 14754897; 14764716; 15043934; 15100680; 15125833; 15184390; 15218148; 15229184; 15231748; 15276183; 15327770; 15341735; 15356572; 15371500; 15456791; 15474016; 15489334; 15578091; 15601829; 15601896; 15620648; 15670770; 15749833; 15802604; 15833158; 15870263; 16051665; 16126728; 16148947; 16227629; 16267042; 16301747; 16311516; 16319058; 16360037; 16379012; 16424386; 16497931; 16543241; 16547522; 16583354; 16603398; 16611882; 16627981; 16684768; 16697380; 16737960; 16794254; 16831874; 16874300; 16906147; 17000764; 17043643; 17047224; 17135271; 17145747; 17244613; 17314097; 17314283; 17363905; 17363973; 17401323; 17401626; 17468758; 17568778; 17626013; 17693255; 17702576; 17728323; 17766391; 17891179; 17910706; 17932497; 17939994; 17942533; 17948050; 17977820; 17997719; 18029035; 18029348; 18037881; 18079694; 18180283; 18187620; 18201555; 18207244; 18212736; 18216269; 18266324; 18266467; 18287044; 18313693; 18347055; 18350553; 18429822; 18511905; 18583959; 18617513; 18620544; 18625728; 18626576; 18685082; 18841575; 18851874; 18931663; 18949366; 18952891; 18957422; 19033441; 19064727; 19149237; 19185524; 19285159; 19303852; 19305025; 19327867; 19365808; 19373245; 19373254; 19404319; 19422324; 19453261; 19494296; 19531477; 19603533; 19609363; 19656162; 19656241; 19675569; 19687056; 19763089; 19815509; 19820708; 19854204; 19875381; 19880420; 19897484; 19948975; 19956647; 20005846; 20010814; 20026645; 20065354; 20098747; 20161788; 20164171; 20167598; 20211142; 20301198; 20301645; 20353939; 20368414; 20380930; 20412081; 20434027; 20484576; 20499091; 20529958; 20542322; 20586999; 20724660; 20837477; 20890435; 20923877; 20932475; 20932476; 20959607; 20970423; 21057728; 21097508; 21109981; 21113135; 21131783; 21139048; 21153314; 21184742; 21212807; 21217772; 21220427; 21286028; 21309033; 21383699; 21458669; 21474709; 21486954; 21512573; 21513986; 21518757; 21538482; 21606198; 21622571; 21622647; 21703539; 21704885; 21709223; 21722947; 21777808; 21790911; 21803029; 21811235; 21862579; 21862596; 21890473; 21896478; 21903422; 21906983; 21963094; 21988832; 22054014; 22081069; 22099304; 22118674; 22176836; 22300264; 22341466; 22505724; 22513115; 22517901; 22525270; 22547678; 22605335; 22607974; 22732732; 22848449; 22863883; 22901541; 22939629; 22990857; 23000965; 23000966; 23007157; 23028469; 23032186; 23032187; 23102662; 23123196; 23131831; 23453969; 23483900; 23506214; 23524849; 23575687; 23690623; 23732909; 23746843; 23776175; 23807287; 23950712; 23986494; 24030825; 24100029; 24109239; 24240172; 24266532; 24270572,,,,,,,,,,,,,,,OGG:3000008517,,,,,,,"inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase gamma",,,,,,,,,,,,,Other designations: I-kappa-B kinase subunit gamma|IKKAP1|IKKG|IkB kinase gamma subunit|NF-kappa-B essential modifier|NF-kappa-B essential modulator|NFkappaB essential modulator|ikB kinase subunit gamma|ikB kinase-associated protein 1|incontinentia pigmenti|inhibitor of nuclear factor kappa-B kinase subunit gamma,,IKBKG,,,,,,,,,,,,,,,,,,,,,,,8517,,,,,,,,9606,,,,,,,,,,,,,,,,,,,IKBKG,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000084649,DGAT2,,Other designations: acyl-CoA retinol O-fatty-acyltransferase|diacylglycerol O-acyltransferase homolog 2|diacylglycerol O-acyltransferase-like protein 2|diglyceride acyltransferase 2|retinol O-fatty-acyltransferase,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,GS1999FULL|ARAT,,,,,,,,,,,,11,,,,,,MIM:606983|Vega:OTTHUMG00000165338|HPRD:07376|HGNC:16940|Ensembl:ENSG00000062282,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,diacylglycerol O-acyltransferase 2,,,11q13.5,,,,,,,,,,,,,,,,"GO_0003846 (EC: IEA); GO_0004144 (EC: IDA, PMID: 11481335); GO_0005739 (EC: ISS, Qualifier: colocalizes_with); GO_0005783 (EC: IDA, PMID: 14521909); GO_0005789 (EC: TAS); GO_0005811 (EC: ISS, Qualifier: colocalizes_with); GO_0006071 (EC: IEA); GO_0006644 (EC: TAS); GO_0016021 (EC: IDA, PMID: 11481335); GO_0019432 (EC: IDA, PMID: 11481335); GO_0019432 (EC: IEA); GO_0019432 (EC: TAS); GO_0019915 (EC: ISS); GO_0030176 (EC: IC, PMID: 14521909); GO_0030176 (EC: ISS); GO_0034383 (EC: ISS); GO_0035336 (EC: IDA, PMID: 11481335); GO_0035356 (EC: ISS); GO_0036155 (EC: TAS); GO_0042632 (EC: ISS); GO_0042803 (EC: ISS); GO_0044255 (EC: TAS); GO_0044281 (EC: TAS); GO_0046339 (EC: IDA, PMID: 11481335); GO_0046474 (EC: TAS); GO_0048471 (EC: ISS); GO_0050252 (EC: IEA); GO_0055089 (EC: ISS); GO_0060613 (EC: ISS); GO_0071400 (EC: ISS); GO_0097006 (EC: ISS)",,,,,,,,,PMID: 8944226; 11481335; 12477932; 12975309; 14521909; 14702039; 14970677; 15221005; 15258194; 15489334; 16870193; 17207965; 17477860; 17504763; 17940217; 18757836; 18980578; 19049983; 19913121; 20379614; 20628086; 20679960; 20739640; 21933415; 22315393; 22748069; 23489367,,,,,,,,,,,,,,,OGG:3000084649,,,,,,,diacylglycerol O-acyltransferase 2,,,,,,,,,,,,,Other designations: acyl-CoA retinol O-fatty-acyltransferase|diacylglycerol O-acyltransferase homolog 2|diacylglycerol O-acyltransferase-like protein 2|diglyceride acyltransferase 2|retinol O-fatty-acyltransferase,,DGAT2,,,,,,,,,,,,,,,,,,,,,,,84649,HMFN1045,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,DGAT2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000446,Cip/Kip family,,,false,,,http://purl.obolibrary.org/obo/IMR_0000445,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000446,,,,,,,,,,,,,,,,,,,,,,Cip/Kip family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0001043,esophagus,oesophagus|gullet,"Tube that connects the pharynx to the stomach. In mammals, the oesophagus connects the buccal cavity with the stomach. The stratified squamous non-keratinised epithelium lining the buccal cavity is continued through the pharynx down into the oesophagus. The lowest part of the oesophagus (ca. 2 cm) is lined with gastric mucosa and covered by peritoneum. The main body of the oesophagus is lined with small, simple mucous glands. Each gland opens into the lumen by a long duct which pierces the muscularis mucosae (Wilson and Washington, 1989). A sphincter is situated at the point where the oesophagus enters the stomach to prevent gastro-oesophageal reflux, i.e. to prevent acidic gastric contents from reaching stratified epithelia of the oesophagus, where they can cause inflammation and irritation (Wilson and Washington, 1989; Brown et al., 1993).",false,,,http://purl.obolibrary.org/obo/UBERON_0013765,,,,,,,,,,,,,,,,,,,,http://linkedlifedata.com/resource/umls/id/C0014876|http://www.snomedbrowser.com/Codes/Details/181245004|http://en.wikipedia.org/wiki/Esophagus|http://purl.obolibrary.org/obo/NCIT_C12389|TAO:0000204|MAT:0000048|EFO:0000835|AAO:0000145|EMAPA:16833|VHOG:0000450|UMLS:C0014876|OpenCyc:Mx4rvVj9Q5wpEbGdrcN5Y29ycA|MA:0000352|EHDAA2:0001285|EHDAA:2937|galen:Esophagus|FMA:7131|ANISEED:1235301|BTO:0000959|GAID:291|CALOHA:TS-0700|XAO:0000127|MESH:A03.365|EV:0100069|MIAA:0000048|ZFA:0000204,,"Tube that connects the pharynx to the stomach. In mammals, the oesophagus connects the buccal cavity with the stomach. The stratified squamous non-keratinised epithelium lining the buccal cavity is continued through the pharynx down into the oesophagus. The lowest part of the oesophagus (ca. 2 cm) is lined with gastric mucosa and covered by peritoneum. The main body of the oesophagus is lined with small, simple mucous glands. Each gland opens into the lumen by a long duct which pierces the muscularis mucosae (Wilson and Washington, 1989). A sphincter is situated at the point where the oesophagus enters the stomach to prevent gastro-oesophageal reflux, i.e. to prevent acidic gastric contents from reaching stratified epithelia of the oesophagus, where they can cause inflammation and irritation (Wilson and Washington, 1989; Brown et al., 1993).",,,,,,,,Anterior end of the alimentary canal lined with smooth muscle. Bounded anteriorly by a constriction in the pharynx. Bounded posteriorly by and increase in circular and/or longitudinal smooth muscle associated with the stomach.[AAO],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,oesophagus|gullet,,,"The few structural specializations in (adult lampreys) pharynx include complex valves on the external gill openings that direct the tidal flow, and the division of the ancestral pharynx into an oesophagus and a respiratory pharynx.[well established][VHOG]",http://purl.obolibrary.org/obo/UBERON_0001007,UBERON:0001043,http://purl.obolibrary.org/obo/UBERON_0001007,,,,,,,,,,,,,,,,,,,,,esophagus,,,,http://upload.wikimedia.org/wikipedia/commons/d/d4/Illu01_head_neck.jpg,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000116150,NUS1,,Other designations: nogo-B receptor|transport and golgi organization 14 homolog,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,MGC:7199|NgBR|C6orf68|TANGO14,,,,,,,,,,,,6,,,,,,MIM:610463|Ensembl:ENSG00000153989|HPRD:12894|HGNC:21042|Vega:OTTHUMG00000015458,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,nuclear undecaprenyl pyrophosphate synthase 1 homolog (S. cerevisiae),,,6q22.1,,,,,,,,,,,,,,,,"GO_0001525 (EC: IEA); GO_0003674 (EC: ND); GO_0005515 (EC: IPI); GO_0005789 (EC: IDA, PMID: 19723497); GO_0006486 (EC: IEA); GO_0016021 (EC: IEA); GO_0016765 (EC: IEA); GO_0030154 (EC: IEA); GO_0032367 (EC: IGI, PMID: 19723497); GO_0055092 (EC: IEA)",,,,,,,,,PMID: 9294218; 12477932; 14574404; 15489334; 16835300; 17764014; 19723497; 21572394,,,,,,,,,,,,,,,OGG:3000116150,,,,,,,nuclear undecaprenyl pyrophosphate synthase 1 homolog (S. cerevisiae),,,,,,,,,,,,,Other designations: nogo-B receptor|transport and golgi organization 14 homolog,,NUS1,,,,,,,,,,,,,,,,,,,,,,,116150,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,NUS1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0100606,cyclin,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003722,,,,,,,,,,IMR:0100606,,,,,,,,,,,,,,,,,,,,,,cyclin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000006880,TAF9,,Other designations: RNA polymerase II TBP-associated factor subunit G|transcription initiation factor TFIID 31 kD subunit|transcription initiation factor TFIID 31 kDa subunit|transcription initiation factor TFIID 32 kDa subunit|transcription initiation factor TFIID subunit 9,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,MGC:5067|TAFII32|TAFII-31|TAF2G|STAF31/32|TAFIID32|TAFII31|TAFII-32,,,,,,,,,,,,5,,,,,,HGNC:11542|HPRD:15983|Vega:OTTHUMG00000099359|MIM:600822|Ensembl:ENSG00000085231,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"TAF9 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 32kDa",,,5q13.2,,,,,,,,,,,,,,,,"GO_0000125 (EC: IDA, PMID: 9674425); GO_0002039 (EC: IPI, PMID: 11278372); GO_0003677 (EC: IDA, PMID: 15601843); GO_0003713 (EC: IDA, PMID: 11564863); GO_0003713 (EC: IMP, PMID: 11278372); GO_0004402 (EC: IDA, Qualifier: contributes_to, PMID: 11564863); GO_0005515 (EC: IPI, PMID: 15489227); GO_0005654 (EC: TAS); GO_0005669 (EC: IDA, PMID: 14580349); GO_0006325 (EC: TAS); GO_0006366 (EC: TAS); GO_0006367 (EC: TAS); GO_0006368 (EC: TAS); GO_0006974 (EC: IC, PMID: 11278372); GO_0010467 (EC: TAS); GO_0016032 (EC: TAS); GO_0030307 (EC: IMP, PMID: 15899866); GO_0030914 (EC: IDA, PMID: 11564863); GO_0032435 (EC: IDA, PMID: 11278372); GO_0033276 (EC: IDA, PMID: 15899866); GO_0033613 (EC: IPI, PMID: 19251649); GO_0043066 (EC: IMP, PMID: 15899866); GO_0043966 (EC: IDA, PMID: 11564863); GO_0044212 (EC: IDA, PMID: 19251649); GO_0045944 (EC: IDA, PMID: 11278372); GO_0046982 (EC: IEA); GO_0050821 (EC: IDA, PMID: 15899866); GO_0060760 (EC: IMP, PMID: 15489227); GO_0070555 (EC: IMP, PMID: 15489227); GO_0070742 (EC: IPI, PMID: 19251649); GO_0070761 (EC: IDA, PMID: 17636026); GO_0071339 (EC: IDA, PMID: 15960975); GO_1902166 (EC: IC, PMID: 15899866)",,,,,,,,,PMID: 1939271; 2449431; 7597030; 7667268; 7761466; 7809597; 7835343; 7836461; 7933101; 8121496; 8401585; 8680883; 8764009; 8764062; 8849451; 8946909; 9045704; 9054383; 9153318; 9171108; 9177216; 9405375; 9611234; 9674425; 9792714; 9885574; 10191103; 10449590; 10810093; 10821850; 10931946; 11005381; 11278372; 11406595; 11564863; 12101418; 12453419; 12477932; 12601814; 12660246; 12837753; 14580349; 15081896; 15489227; 15489334; 15601843; 15641800; 15899866; 15932940; 15960975; 16079131; 16169070; 16189514; 16713569; 17081983; 17636026; 17643375; 17884155; 17967894; 18250150; 19240132; 19251649; 19471022; 19615732; 19643037; 20186459; 20195357; 20946988; 21139048; 21693764; 21729782; 21832049; 21890473; 21963094; 21988832; 22053931; 22505724; 22696218; 22939629; 23000965; 23246961,,,,,,,,,,,,,,,OGG:3000006880,,,,,,,"TAF9 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 32kDa",,,,,,,,,,,,,Other designations: RNA polymerase II TBP-associated factor subunit G|transcription initiation factor TFIID 31 kD subunit|transcription initiation factor TFIID 31 kDa subunit|transcription initiation factor TFIID 32 kDa subunit|transcription initiation factor TFIID subunit 9,,TAF9,,,,,,,,,,,,,,,,,,,,,,,6880,AD-004,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,TAF9,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0100666,Clb3,G2/mitotic-specific cyclin 3,,false,,,http://purl.obolibrary.org/obo/IMR_0100673,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,G2/mitotic-specific cyclin 3,,,,,IMR:0100666,,,,,,,,,,,,,,,,,,,,,,Clb3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CLO_0000001,cell line cell,,A cultured cell that is part of a cell line - a stable and homogeneous population of cells with a common biological origin and propagation history in culture,false,,,http://purl.obolibrary.org/obo/OBI_0001866,,,,,,,,,,,,,,,,,,,,,,A cultured cell that is part of a cell line - a stable and homogeneous population of cells with a common biological origin and propagation history in culture,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CLO:0000001,,,,,,,,,,,,,,,,,,,,,,cell line cell,,,,,,,http://purl.obolibrary.org/obo/clo.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0009386,attenuation of translation,,"Translational attenuation is a regulatory mechanism analogous to ribosome-mediated transcriptional attenuation. the system requires the presence of a short orf, called a leader peptide, encoded in the mrna upstream of the ribosome-binding site and start codon of the gene whose translation is to be regulated. certain conditions, such as presence of the antibiotic tetracycline in bacteria or amino acid starvation, may cause slowing or stalling of the ribosome translating the leader peptide. the stalled ribosome masks a region of the mrna and affects which of two alternative mrna folded structures will form, therefore controlling whether or not a ribosome will bind and initiate translation of the downstream gene. translational attenuation is analogous to ribosome-mediated transcriptional attenuation, in which mrna remodeling caused by ribosome stalling regulates transcriptional termination rather than translational initiation.",false,,,http://purl.obolibrary.org/obo/GO_0006417,,,,,,,,,,,,,,,,,,,,,,"Translational attenuation is a regulatory mechanism analogous to ribosome-mediated transcriptional attenuation. the system requires the presence of a short orf, called a leader peptide, encoded in the mrna upstream of the ribosome-binding site and start codon of the gene whose translation is to be regulated. certain conditions, such as presence of the antibiotic tetracycline in bacteria or amino acid starvation, may cause slowing or stalling of the ribosome translating the leader peptide. the stalled ribosome masks a region of the mrna and affects which of two alternative mrna folded structures will form, therefore controlling whether or not a ribosome will bind and initiate translation of the downstream gene. translational attenuation is analogous to ribosome-mediated transcriptional attenuation, in which mrna remodeling caused by ribosome stalling regulates transcriptional termination rather than translational initiation.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0009386,,,,,,,,,,,,,,,,,,,,,,attenuation of translation,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006412,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000005034,P4HB,,"Other designations: cellular thyroid hormone-binding protein|collagen prolyl 4-hydroxylase beta|glutathione-insulin transhydrogenase|p55|procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), beta polypeptide|prolyl 4-hydroxylase subunit beta|protein disulfide isomerase family A, member 1|protein disulfide isomerase-associated 1|protein disulfide isomerase/oxidoreductase|protein disulfide-isomerase|protocollagen hydroxylase|thyroid hormone-binding protein p55",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,PO4DB|GIT|PO4HB|PROHB|P4Hbeta|ERBA2L|PDIA1|DSI|PDI|PHDB,,,,,,,,,,,,17,,,,,,HGNC:8548|Ensembl:ENSG00000185624|Vega:OTTHUMG00000150269|HPRD:07181|MIM:176790,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"prolyl 4-hydroxylase, beta polypeptide",,,17q25,,,,,,,,,,,,,,,,"GO_0003756 (EC: IBA); GO_0004656 (EC: IDA, Qualifier: contributes_to, PMID: 7753822); GO_0005515 (EC: IPI, PMID: 12095988); GO_0005576 (EC: NAS, PMID: 14718574); GO_0005783 (EC: IDA, PMID: 12095988); GO_0005788 (EC: TAS); GO_0005793 (EC: IDA, PMID: 15308636); GO_0005886 (EC: IEA); GO_0006457 (EC: IBA); GO_0006662 (EC: IEA); GO_0015035 (EC: IEA); GO_0016222 (EC: IDA, PMID: 7753822); GO_0018401 (EC: IDA, PMID: 7753822); GO_0030198 (EC: TAS); GO_0034976 (EC: IMP, PMID: 12095988); GO_0042157 (EC: TAS); GO_0042470 (EC: IEA); GO_0044281 (EC: TAS); GO_0044822 (EC: IDA); GO_0045454 (EC: IEA); GO_0046982 (EC: IEA); GO_0055114 (EC: IDA, PMID: 7753822); GO_0055114 (EC: TAS, PMID: 2846539); GO_0070062 (EC: IDA, PMID: 19199708); GO_0071456 (EC: IMP, PMID: 12095988); GO_1902175 (EC: IMP, PMID: 12095988)",,,,,,,,,PMID: 1286669; 1339453; 1559965; 1597478; 1667665; 1677563; 1699755; 2079031; 2846539; 3032969; 3034602; 3342239; 3467900; 3611107; 7753822; 8111381; 8580850; 8672469; 9150948; 9399589; 10329688; 10383197; 10436013; 10636893; 11181151; 11257307; 11707400; 11790298; 11847130; 12095988; 12218051; 12218052; 12475965; 12477932; 12485997; 12493773; 12643545; 12665801; 12874193; 14500733; 14592831; 14702039; 14718574; 14871477; 15146195; 15158710; 15231747; 15308636; 15324660; 15358778; 15489334; 15590633; 15611098; 15644496; 15695804; 15952740; 16169070; 16303743; 16344560; 16847061; 17055437; 17081065; 17301129; 17353931; 17620599; 18029348; 18781797; 19199708; 19471022; 19890397; 19913121; 20000738; 20360068; 20628086; 20668226; 21081666; 21139048; 21145461; 21299467; 21319273; 21373848; 21693764; 21890473; 21906983; 21963094; 21988832; 22079093; 22174317; 22190034; 22268729; 22304920; 22337587; 22536838; 22586326; 22863883; 22936677; 22939629; 23000965; 23141538; 23246001; 23337974; 23444257; 23455922; 23824909; 23862649; 23956138; 24244333; 24250222; 24457600,,,,,,,,,,,,,,,OGG:3000005034,,,,,,,"prolyl 4-hydroxylase, beta polypeptide",,,,,,,,,,,,,"Other designations: cellular thyroid hormone-binding protein|collagen prolyl 4-hydroxylase beta|glutathione-insulin transhydrogenase|p55|procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), beta polypeptide|prolyl 4-hydroxylase subunit beta|protein disulfide isomerase family A, member 1|protein disulfide isomerase-associated 1|protein disulfide isomerase/oxidoreductase|protein disulfide-isomerase|protocollagen hydroxylase|thyroid hormone-binding protein p55",,P4HB,,,,,,,,,,,,,,,,,,,,,,,5034,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,P4HB,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0001713,PERK signal transduction system [ER stress],,"PERK signal transduction system is a subtype of pathway system.
This entity has sub-parts and has a goal of transmitting signals via PERK as a systemic context.
This entity is dependent on ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001696,,,,,,,,,,,,,,,,,,,,,,"PERK signal transduction system is a subtype of pathway system.
This entity has sub-parts and has a goal of transmitting signals via PERK as a systemic context.
This entity is dependent on ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001713,,,,,,,,,,,,,,,,,,,,,,PERK signal transduction system [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001716,phospholipidosis dependent process,,Phospholipidosis dependent process is a subtype of toxic course dependent process: A process that can constitute the course of phospholipidosis .,false,,,http://purl.obolibrary.org/obo/TXPO_0001715,,,,,,,,,,,,,,,,,,,,PMID:1697167,,Phospholipidosis dependent process is a subtype of toxic course dependent process: A process that can constitute the course of phospholipidosis .,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001716,,,,,,,,,,,,,,,,,,,,,,phospholipidosis dependent process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001719,moving phenobarbital to the inside of liver [Ground glass appearance],,"Moving phenobarbital to the inside of liver is a subtype of moving A to the inside of B: A process that of the movement of phenobarbital into a liver.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/TXPO_0001714,,,,,,,,,,,,,,,,,,,,,,"Moving phenobarbital to the inside of liver is a subtype of moving A to the inside of B: A process that of the movement of phenobarbital into a liver.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001524,,,,,,,,,,,,,,,,,TXPO:0001719,,,,,,,,,,,,,,,,,,,,,,moving phenobarbital to the inside of liver [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001714,moving drug to the inside of liver [Ground glass appearance],,"Moving drug to the inside of liver is a subtype of moving A to the inside of B: A process that of the movement of drug into a liver.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/TXPO_0000312,,,,,,,,,,,,,,,,,,,,,,"Moving drug to the inside of liver is a subtype of moving A to the inside of B: A process that of the movement of drug into a liver.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001637,,,,,,,,,,,TXPO:0001714,,,,,,,,,,,,,,,,,,,,,,moving drug to the inside of liver [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001712,PERK-eIF2a signal transduction system,,PERK-eIF2a signal transduction system is a subtype of pathway system. This entity has sub-parts and has a goal of transmitting signals via PERK and eIF2a as a systemic context.,false,,,http://purl.obolibrary.org/obo/TXPO_0001696,,,,,,,,,,,,,,,,,,,,,,PERK-eIF2a signal transduction system is a subtype of pathway system. This entity has sub-parts and has a goal of transmitting signals via PERK and eIF2a as a systemic context.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002119,,,,,,,,,,,,,,,,,,,,,,TXPO:0001712,,,,,,,,,,,,,,,,,,,,,,PERK-eIF2a signal transduction system,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001717,ER stress dependent process,,ER stress dependent process is a subtype of toxic course dependent process: A process that can constitute the course of endoplasmic reticulum stress.,false,,,http://purl.obolibrary.org/obo/TXPO_0001715,,,,,,,,,,,,,,,,,,,,,,ER stress dependent process is a subtype of toxic course dependent process: A process that can constitute the course of endoplasmic reticulum stress.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001717,,,,,,,,,,,,,,,,,,,,,,ER stress dependent process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001710,positive regulation of phospholipid biosynthetic process [Phospholipidosis],,"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of phospholipids. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/GO_0071073,,,,,,,,,,,,,,,,,,,,,,"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of phospholipids. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000908,,,,,,,,,,,TXPO:0001710,,,,,,,,,,,,,,,,,,,,,,positive regulation of phospholipid biosynthetic process [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001711,AMPK - inactivation state (canonical)[lipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001652,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0002355,,,,http://purl.obolibrary.org/obo/TXPO_0001682,,,,,,,,,,TXPO:0001711,,,,,,,,,,,,,,,,,,,,,,AMPK - inactivation state (canonical)[lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001715,toxic course dependent process,,Toxic course dependent process is a subtype of primitive  process: A process that can constitute the toxic course.,false,,,http://purl.obolibrary.org/obo/TXPO_0000271,,,,,,,,,,,,,,,,,,,,,,Toxic course dependent process is a subtype of primitive  process: A process that can constitute the toxic course.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001715,,,,,,,,,,,,,,,,,,,,,,toxic course dependent process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001718,malfunctioning of hepatic blood circulation,,Malfunctioning of hepatic blood circulation is a subtype of malfunctioning process: A process that cannot perform hepatic blood circulation function appropriately or cannot realize it at all.,false,,,http://purl.obolibrary.org/obo/TXPO_0000434,,,,,,,,,,,,,,,,,,,,,,Malfunctioning of hepatic blood circulation is a subtype of malfunctioning process: A process that cannot perform hepatic blood circulation function appropriately or cannot realize it at all.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001358|http://purl.obolibrary.org/obo/TXPO_0001359|http://purl.obolibrary.org/obo/TXPO_0001366,,,,,,,,,,,TXPO:0001718,,,,,,,,,,,,,,,,,,,,,,malfunctioning of hepatic blood circulation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0005622,intracellular,internal to cell|protoplasm,"The living contents of a cell; the matter contained within (but not including) the plasma membrane, usually taken to exclude large vacuoles and masses of secretory or ingested material. In eukaryotes it includes the nucleus and cytoplasm.",false,,,http://purl.obolibrary.org/obo/GO_0044464,,,,,,,,,,,,,,,,,,,,Wikipedia:Intracellular,,"The living contents of a cell; the matter contained within (but not including) the plasma membrane, usually taken to exclude large vacuoles and masses of secretory or ingested material. In eukaryotes it includes the nucleus and cytoplasm.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,internal to cell|protoplasm,,,,,GO:0005622,,,,,,,,,,,,,,,,,,,,,,intracellular,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001089,importin alpha7,karyopherin alpha6|KPNA6|importin alpha S2,,false,,,http://purl.obolibrary.org/obo/IMR_0100202,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,karyopherin alpha6|KPNA6|importin alpha S2,,,,,IMR:0001089,,,,,,,,,,,,,,,,,,,,,,importin alpha7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001675,RGS18,,,false,,,http://purl.obolibrary.org/obo/IMR_0000431,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001675,,,,,,,,,,,,,,,,,,,,,,RGS18,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001040,group IVA phospholipase A2,,,false,,,http://purl.obolibrary.org/obo/IMR_0000283,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001040,,,,,,,,,,,,,,,,,,,,,,group IVA phospholipase A2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100105,placental lactogen,Choriomammotropin,"A polypeptide hormone of approximately 25 kDa that is produced by the SYNCYTIOTROPHOBLASTS of the PLACENTA, also known as chorionic somatomammotropin. It has both GROWTH HORMONE and PROLACTIN activities on growth, lactation, and luteal steroid production.",false,,,http://purl.obolibrary.org/obo/IMR_0100086,,,,,,,,,,,,,,,,,,,,MeSH:D010928,,"A polypeptide hormone of approximately 25 kDa that is produced by the SYNCYTIOTROPHOBLASTS of the PLACENTA, also known as chorionic somatomammotropin. It has both GROWTH HORMONE and PROLACTIN activities on growth, lactation, and luteal steroid production.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Choriomammotropin,,,,,IMR:0100105,,,,,,,,,,,,,,,,,,,,,,placental lactogen,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000201163,FLCN,,Other designations: BHD skin lesion fibrofolliculoma protein|birt-Hogg-Dube syndrome protein,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,BHD|FLCL,,,,,,,,,,,,17,,,,,,Vega:OTTHUMG00000059275|HGNC:27310|Ensembl:ENSG00000154803|HPRD:06278|MIM:607273,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,folliculin,,,17p11.2,,,,,,,,,,,,,,,,"GO_0000122 (EC: IDA); GO_0000122 (EC: IMP); GO_0001701 (EC: ISS); GO_0001932 (EC: IDA, PMID: 18663353); GO_0001934 (EC: ISS); GO_0005515 (EC: IPI, PMID: 17028174); GO_0005634 (EC: IDA, PMID: 17028174); GO_0005737 (EC: IDA); GO_0005886 (EC: IDA); GO_0007043 (EC: ISS); GO_0010628 (EC: ISS); GO_0010629 (EC: ISS); GO_0010823 (EC: ISS); GO_0030097 (EC: ISS); GO_0030308 (EC: IDA); GO_0030336 (EC: IMP); GO_0030496 (EC: IDA, Qualifier: colocalizes_with); GO_0030511 (EC: IDA); GO_0030511 (EC: ISS); GO_0031929 (EC: IMP, PMID: 17028174); GO_0032006 (EC: ISS); GO_0032007 (EC: ISS); GO_0032008 (EC: ISS); GO_0032403 (EC: IDA, PMID: 17028174); GO_0032465 (EC: IMP); GO_0035024 (EC: IMP); GO_0035065 (EC: ISS); GO_0043065 (EC: ISS); GO_0044291 (EC: IDA, Qualifier: colocalizes_with); GO_0045785 (EC: IMP); GO_0045944 (EC: IDA); GO_0045944 (EC: IMP); GO_0051898 (EC: ISS); GO_0070373 (EC: ISS); GO_1900181 (EC: IDA); GO_1901723 (EC: ISS); GO_2000506 (EC: ISS); GO_2000973 (EC: ISS); GO_2001170 (EC: ISS)",,,,,,,,,PMID: 11526515; 11533913; 12204536; 12471204; 12477932; 12746401; 12843323; 12907635; 14627671; 14702039; 14961590; 15489334; 15579035; 15657874; 15852235; 15956655; 16344560; 16636660; 16870330; 17028174; 17149965; 17207965; 17496196; 18029348; 18206534; 18234728; 18403135; 18505456; 18573707; 18579543; 18663353; 18709329; 19116017; 19234517; 19327534; 19483054; 20227563; 20301695; 20413710; 20522427; 20562859; 20618353; 21079084; 21139048; 21209915; 21258407; 21412933; 21496834; 21538689; 21832049; 21890473; 22146830; 22190034; 22211584; 22446046; 22709692; 22965878; 22977732; 22990118; 23077212; 23139756; 23150719; 23155228; 23414156; 23784378; 23824909; 24095279,,,,,,,,,,,,,,,OGG:3000201163,,,,,,,folliculin,,,,,,,,,,,,,Other designations: BHD skin lesion fibrofolliculoma protein|birt-Hogg-Dube syndrome protein,,FLCN,,,,,,,,,,,,,,,,,,,,,,,201163,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,FLCN,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/PATO_0000574,decreased length,shortened|short,A length quality which is relatively small.,false,,,http://purl.obolibrary.org/obo/PATO_0000122|http://purl.obolibrary.org/obo/TXPO_0002415,,,,,,,,,,,,,,,,,,,,,,A length quality which is relatively small.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,short,,shortened,,,PATO:0000574,,,,,,,,,,,,,,,,,,,,,,decreased length,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0000573,increased length,,A length quality which is relatively large.,false,,,http://purl.obolibrary.org/obo/PATO_0000122|http://purl.obolibrary.org/obo/TXPO_0002415,,,,,,,,,,,,,,,,,,,,,,A length quality which is relatively large.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0000573,,,,,,,,,,,,,,,,,,,,,,increased length,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0017144,drug metabolic process,drug metabolism,"The chemical reactions and pathways involving a drug, a substance used in the diagnosis, treatment or prevention of a disease; as used here antibiotic substances (see antibiotic metabolism) are considered to be drugs, even if not used in medical or veterinary practice.",false,,,http://purl.obolibrary.org/obo/GO_0006805,,,,,,,,,,,,,,,,,,,,Wikipedia:Drug_metabolism,,"The chemical reactions and pathways involving a drug, a substance used in the diagnosis, treatment or prevention of a disease; as used here antibiotic substances (see antibiotic metabolism) are considered to be drugs, even if not used in medical or veterinary practice.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,drug metabolism,,,,,GO:0017144,,,,,,,,,,,,,,,,,,,,,,drug metabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100113,dopamine,"2-(3,4-Dihydroxyphenyl)ethylamine|3,4-Dihydroxyphenethylamine|Dopamine|4-(2-Aminoethyl)-1,2-benzenediol|4-(2-Aminoethyl)benzene-1,2-diol",,false,,,http://purl.obolibrary.org/obo/IMR_0001694,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_25512,,,,IMR:0200003,"2-(3,4-Dihydroxyphenyl)ethylamine|3,4-Dihydroxyphenethylamine|Dopamine|4-(2-Aminoethyl)-1,2-benzenediol|4-(2-Aminoethyl)benzene-1,2-diol",,,,,IMR:0100113,,,,,,,,,,,,,,,,,,,,,,dopamine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001892,negative regulation of bile acid and bile salts export from the hepatocyte,,"Negative regulation of bile acid and bile salts export from the hepatocyte is a subtype of negative regulation of transport: A process that stops, prevents, or reduces the frequency, rate or extent of bile acid and bile salts export from the hepatocyte.",false,,,http://purl.obolibrary.org/obo/TXPO_0002682,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of bile acid and bile salts export from the hepatocyte is a subtype of negative regulation of transport: A process that stops, prevents, or reduces the frequency, rate or extent of bile acid and bile salts export from the hepatocyte.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001892,,,,,,,,,,,,,,,,,,,,,,negative regulation of bile acid and bile salts export from the hepatocyte,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002683,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001891,CYP3A4 -inactitication state (human)[lipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001888,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1576|PMID:26231377|PMID:28303724|PMID:29792708,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,,,,,,,,,,,,,,TXPO:0001891,,,,,,,,,,,,,,,,,,,,,,CYP3A4 -inactitication state (human)[lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001890,cytochrome P450 inactivation [lipidosis],,"Cytochrome P450 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the Cytochrome P450 to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001889|http://purl.obolibrary.org/obo/TXPO_0001720,,,,,,,,,,,,,,,,,,,,PMID:28303724,,"Cytochrome P450 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the Cytochrome P450 to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001888,,,,http://purl.obolibrary.org/obo/TXPO_0001891,,,,,,,,,,,,,,,,,,,TXPO:0001890,,,,,,,,,,,,,,,,,,,,,,cytochrome P450 inactivation [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001898,signal transducer,,A role played by the entity which transmits signals.,false,,,http://purl.obolibrary.org/obo/CHEBI_33280,,,,,,,,,,,,,,,,,,,,,,A role played by the entity which transmits signals.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001898,,,,,,,,,,,,,,,,,,,,,,signal transducer,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001899,eIF2a phosphorylation,,EIF2a phosphorylation is a subtype of phosphorylation: The process of introducing a phosphate group into eIF2a.,false,,,http://purl.obolibrary.org/obo/GO_0016310,,,,,,,,,,,,,,,,,,,,,,EIF2a phosphorylation is a subtype of phosphorylation: The process of introducing a phosphate group into eIF2a.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001899,,,,,,,,,,,,,,,,,,,,,,eIF2a phosphorylation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001897,clofibrate [Eosinophilic granular degeneration],,,false,,,http://purl.obolibrary.org/obo/CHEBI_3750|http://purl.obolibrary.org/obo/TXPO_0000121,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001897,,,,,,,Clofibrate is a fibric acid derivative used in the therapy of hypertriglyceridemia and dyslipidemia.  Clofibrate therapy is associated with mild and transient serum aminotransferase elevations and with rare instances of acute liver injury.,,,,,,,,,,,,,,,clofibrate [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001895,fenofibrate [Eosinophilic granular degeneration],,"Fenofibrate is a fibric acid derivative used in the therapy of hypertriglyceridemia and dyslipidemia.  Fenofibrate therapy is associated with mild and transient serum aminotransferase elevations and with rare instances of acute liver injury, which can be severe and prolonged and lead to significant hepatic fibrosis.",false,,,http://purl.obolibrary.org/obo/CHEBI_5001|http://purl.obolibrary.org/obo/TXPO_0000121,,,,,,,,,,,,,,,,,,,,,,"Fenofibrate is a fibric acid derivative used in the therapy of hypertriglyceridemia and dyslipidemia.  Fenofibrate therapy is associated with mild and transient serum aminotransferase elevations and with rare instances of acute liver injury, which can be severe and prolonged and lead to significant hepatic fibrosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001895,,,,,,,,,,,,,,,,,,,,,,fenofibrate [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001894,protein unfolding [lipidosis],,"The process of assisting in the disassembly of non-covalent linkages in a protein or protein aggregate, often where the proteins are in a non-functional or denatured state.
This entity is a specific course-dependent process. This process can constitute the course of lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/GO_0043335,,,,,,,,,,,,,,,,,,,,PMID:24132155|PMID:25132496,,"The process of assisting in the disassembly of non-covalent linkages in a protein or protein aggregate, often where the proteins are in a non-functional or denatured state.
This entity is a specific course-dependent process. This process can constitute the course of lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001115,,,,,,,,,,,TXPO:0001894,,,,,,,,,,,,,,,,,,,,,,protein unfolding [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005783,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000023659,PLA2G15,,Other designations: 1-O-acylceramide synthase|LCAT-like lysophospholipase|group XV phospholipase A2|lysophospholipase 3 (lysosomal phospholipase A2)|lysosomal phospholipase A2,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,GXVPLA2|LLPL|LYPLA3|LPLA2|ACS,,,,,,,,,,,,16,,,,,,HPRD:07128|HGNC:17163|MIM:609362|Ensembl:ENSG00000103066|Vega:OTTHUMG00000137554,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"phospholipase A2, group XV",,,16q22.1,,,,,,,,,,,,,,,,"GO_0004622 (EC: TAS, PMID: 10092508); GO_0005543 (EC: TAS, PMID: 10092508); GO_0005576 (EC: IEA); GO_0005739 (EC: IEA); GO_0005764 (EC: ISS); GO_0005764 (EC: NAS, PMID: 11790796); GO_0006672 (EC: IEA); GO_0008374 (EC: ISS); GO_0009062 (EC: TAS, PMID: 10092508); GO_0046470 (EC: IEA); GO_0047499 (EC: ISS)",,,,,,,,,PMID: 8125298; 10092508; 10230407; 10395961; 11790796; 12477932; 12975309; 14702039; 14754907; 15340161; 15489334; 16169070; 16303743; 16973413; 18029348; 18983494; 19461040; 19913121; 20628086; 20877624; 21906983; 22268729,,,,,,,,,,,,,,,OGG:3000023659,,,,,,,"phospholipase A2, group XV",,,,,,,,,,,,,Other designations: 1-O-acylceramide synthase|LCAT-like lysophospholipase|group XV phospholipase A2|lysophospholipase 3 (lysosomal phospholipase A2)|lysosomal phospholipase A2,,PLA2G15,,,,,,,,,,,,,,,,,,,,,,,23659,UNQ341/PRO540,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,PLA2G15,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000011343,MGLL,,Other designations: lysophospholipase homolog|monoacylglycerol lipase,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,HUK5|MGL|MAGL|HU-K5,,,,,,,,,,,,3,,,,,,Vega:OTTHUMG00000159641|HGNC:17038|HPRD:17574|Ensembl:ENSG00000074416|MIM:609699,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,monoglyceride lipase,,,3q21.3,,,,,,,,,,,,,,,,"GO_0004622 (EC: TAS, PMID: 9495531); GO_0005789 (EC: TAS); GO_0005886 (EC: TAS); GO_0006629 (EC: TAS, PMID: 9495531); GO_0006633 (EC: IEA); GO_0006644 (EC: TAS); GO_0006954 (EC: TAS, PMID: 9495531); GO_0007596 (EC: TAS); GO_0008289 (EC: IEA); GO_0009966 (EC: ISS); GO_0019369 (EC: ISS); GO_0019433 (EC: IEA); GO_0019433 (EC: TAS); GO_0030168 (EC: TAS); GO_0036155 (EC: TAS); GO_0042803 (EC: IPI, PMID: 19957260); GO_0044281 (EC: TAS); GO_0045202 (EC: IEA); GO_0046464 (EC: ISS); GO_0046474 (EC: TAS); GO_0047372 (EC: ISS); GO_0047372 (EC: TAS); GO_0050727 (EC: ISS); GO_0051930 (EC: ISS); GO_0060292 (EC: IEA); GO_2000124 (EC: ISS)",,,,,,,,,PMID: 8619474; 8889548; 9110174; 9495531; 11470505; 12477932; 14702039; 15342556; 15489334; 16169070; 16344560; 16806233; 17621164; 18452279; 18721756; 19014633; 19233690; 19913121; 19957260; 19962385; 20079333; 20464001; 20628086; 20855465; 20976246; 21118518; 21308848; 21543155; 21802006; 22349814; 22664939; 22827915; 23455058; 23509962; 23553709; 24368842,,,,,,,,,,,,,,,OGG:3000011343,,,,,,,monoglyceride lipase,,,,,,,,,,,,,Other designations: lysophospholipase homolog|monoacylglycerol lipase,,MGLL,,,,,,,,,,,,,,,,,,,,,,,11343,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,MGLL,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/UBERON_0002097,skin of body,integumental organ|skin|entire integument|pelt|integument|skin organ|entire skin,The organ covering the body that consists of the dermis and epidermis.,false,,,http://purl.obolibrary.org/obo/UBERON_0000062,,,,,,,,,,,,,,,,,,,consider 'integumentary system' for invertebrates,http://en.wikipedia.org/wiki/Skin|http://linkedlifedata.com/resource/umls/id/C1123023|http://purl.obolibrary.org/obo/NCIT_C12470|http://www.snomedbrowser.com/Codes/Details/181469002|EHDAA2:0001844|FMA:7163|EMAPA:17525|UMLS:C1123023|OpenCyc:Mx4rvVjX3ZwpEbGdrcN5Y29ycA|MESH:D012867|CALOHA:TS-0934|galen:Skin|XAO:0000023|EFO:0000962|BTO:0001253|MFMO:0000099,,The organ covering the body that consists of the dermis and epidermis.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,skin organ|entire skin,,integumental organ|skin|entire integument|pelt|integument,,,UBERON:0002097,,,,,,,,,,,,,,,,,,,,,,skin of body,,,,http://upload.wikimedia.org/wikipedia/commons/6/6d/Skin.svg,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000160,FcgammaRII,Low affinity immunoglobulin gamma Fc region receptor II,,false,,,http://purl.obolibrary.org/obo/IMR_0000156,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Low affinity immunoglobulin gamma Fc region receptor II,,,,,IMR:0000160,,,,,,,,,,,,,,,,,,,,,,FcgammaRII,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003015,thapsigargin [ER stress],,,false,,,http://purl.obolibrary.org/obo/CHEBI_9516|http://purl.obolibrary.org/obo/TXPO_0003012,,,,,,,,,,,,,,,,,,,,PMID:20587749|PMID:30254132|PMID:30396238|PMID:29142472|PMID:19444596,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003015,,,,,,,,,,,,,,,,,,,,,,thapsigargin [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003013,negative regulation of SERCA gene expression,,"Negative regulation of SERCA gene expression is a subtype of negative regulation of gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of SERCA gene expression.",false,,,http://purl.obolibrary.org/obo/GO_0010629,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of SERCA gene expression is a subtype of negative regulation of gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of SERCA gene expression.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003013,,,,,,,,,,,,,,,,,,,,,,negative regulation of SERCA gene expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003019,ABCC4 (mol),"Multidrug Resistance-Associated Protein 4|MRP/CMOAT-Related ABC Transporter|MOATB|MRP4|ATP Binding Cassette Subfamily C Member 4|ATP-Binding Cassette, Sub-Family C (CFTR/MRP), Member 4",,false,,,http://purl.obolibrary.org/obo/TXPO_0002694,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:170924|NCBI-Human-GeneID:10257|NCBI-Mouse-GeneID:239273,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Multidrug Resistance-Associated Protein 4|MRP/CMOAT-Related ABC Transporter|MOATB|MRP4|ATP Binding Cassette Subfamily C Member 4|ATP-Binding Cassette, Sub-Family C (CFTR/MRP), Member 4",,,,,TXPO:0003019,,,,,,,,,,,,,,,,,,,,,,ABCC4 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003017,negative regulation of proteasomal protein catabolic process [ER stress],,"Any process that stops, prevents or reduces the frequency, rate or extent of proteasomal protein catabolic process.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/GO_1901799,,,,,,,,,,,,,,,,,,,,PMID:19520899,,"Any process that stops, prevents or reduces the frequency, rate or extent of proteasomal protein catabolic process.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002479,,,,,,,,,,,TXPO:0003017,,,,,,,,,,,,,,,,,,,,,,negative regulation of proteasomal protein catabolic process [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003010,ritonavir [ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000327|http://purl.obolibrary.org/obo/TXPO_0003012,,,,,,,,,,,,,,,,,,,,PMID:27993242,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003010,,,,,,,,,,,,,,,,,,,,,,ritonavir [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003016,negative regulation of endoplasmic reticulum-associated degradation [ER stress],,"Negative regulation of endoplasmic reticulum-associated degradation is a subtype of negative regulation of protein catabolic process: A process that stops, prevents, or reduces the frequency, rate or extent of endoplasmic reticulum-associated degradation.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000874|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of endoplasmic reticulum-associated degradation is a subtype of negative regulation of protein catabolic process: A process that stops, prevents, or reduces the frequency, rate or extent of endoplasmic reticulum-associated degradation.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003017,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002479,,,,,,,,,,,TXPO:0003016,,,,,,,,,,,,,,,,,,,,,,negative regulation of endoplasmic reticulum-associated degradation [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003014,negative regulation of SERCA gene expression [ER stress],,"Negative regulation of SERCA gene expression is a subtype of negative regulation of gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of SERCA gene expression.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/TXPO_0003013,,,,,,,,,,,,,,,,,,,,PMID:22407670|PMID:23334697,,"Negative regulation of SERCA gene expression is a subtype of negative regulation of gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of SERCA gene expression.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003010|http://purl.obolibrary.org/obo/TXPO_0003011,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002101,,,,,,,,,,,TXPO:0003014,,,,,,,,,,,,,,,,,,,,,,negative regulation of SERCA gene expression [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003012,ER stress dependent chemical compound,,"ER stress dependent chemical compound is a subtype of toxic course dependent chemical entity.
This entity (drug) can participate in the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000794,,,,,,,,,,,,,,,,,,,,,,"ER stress dependent chemical compound is a subtype of toxic course dependent chemical entity.
This entity (drug) can participate in the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003012,,,,,,,,,,,,,,,,,,,,,,ER stress dependent chemical compound,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003011,lopinavir [ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003012|http://purl.obolibrary.org/obo/CHEBI_31781,,,,,,,,,,,,,,,,,,,,PMID:19447225|PMID:19732776,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003011,,,,,,,,,,,,,,,,,,,,,,lopinavir [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003018,ABCC5 (mol),"ATP-Binding Cassette, Sub-Family C (CFTR/MRP), Member 5|Multidrug Resistance-Associated Protein 5|Multi-Specific Organic Anion Transporter C|MRP5|ATP Binding Cassette Subfamily C Member 5",,false,,,http://purl.obolibrary.org/obo/TXPO_0002694,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:116721|NCBI-Human-GeneID:10057|NCBI-Mouse-GeneID:27416,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"ATP-Binding Cassette, Sub-Family C (CFTR/MRP), Member 5|Multidrug Resistance-Associated Protein 5|Multi-Specific Organic Anion Transporter C|MRP5|ATP Binding Cassette Subfamily C Member 5",,,,,TXPO:0003018,,,,,,,,,,,,,,,,,,,,,,ABCC5 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010283,GLUT4,"Glucose transporter type 4, insulin-responsive|Solute carrier family 2, facilitated glucose transporter, member 4|GTR4",,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003336,,,,,"Glucose transporter type 4, insulin-responsive|Solute carrier family 2, facilitated glucose transporter, member 4|GTR4",,,,,IMR:0010283,,,,,,,,,,,,,,,,,,,,,,GLUT4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0016925,protein sumoylation,sumoylation|protein sumolation|SUMO-protein conjugation,The process in which a SUMO protein (small ubiquitin-related modifier) is conjugated to a target protein via an isopeptide bond between the carboxyl terminus of SUMO with an epsilon-amino group of a lysine residue of the target protein.,false,,,http://purl.obolibrary.org/obo/TXPO_0004107,,,,,,,,,,,,,,,,,,,,Wikipedia:SUMO_protein,,The process in which a SUMO protein (small ubiquitin-related modifier) is conjugated to a target protein via an isopeptide bond between the carboxyl terminus of SUMO with an epsilon-amino group of a lysine residue of the target protein.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sumoylation|protein sumolation|SUMO-protein conjugation,,,,,GO:0016925,,,,,,,,,,,,,,,,,,,,,,protein sumoylation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001684,moving drug to inside of hepatocyte,,Moving drug to the inside of liver is a subtype of moving A to the inside of B: A process that of the movement of drug into hepatocytes.,false,,,http://purl.obolibrary.org/obo/TXPO_0002587,,,,,,,,,,,,,,,,,,,,,,Moving drug to the inside of liver is a subtype of moving A to the inside of B: A process that of the movement of drug into hepatocytes.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001684,,,,,,,,,,,,,,,,,,,,,,moving drug to inside of hepatocyte,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000182,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001689,increasing pressure,,Increasing pressure is a subtype of changing pressure: A process that changes the pressure of the object to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000475,,,,,,,,,,,,,,,,,,,related quality: http://purl.obolibrary.org/obo/PATO_0001576,,,Increasing pressure is a subtype of changing pressure: A process that changes the pressure of the object to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001689,,,,,,,,,,,,,,,,,,,,,,increasing pressure,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0001576,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001680,negative regulation of sphingomyelin catabolic process,,"Negative regulation of sphingomyelin catabolic process is a subtype of negative regulation of sphingophopholipid degradation: Any process that stops, prevents, or reduces the frequency, rate or extent of the sphingomyelin catabolic process.",false,,,http://purl.obolibrary.org/obo/TXPO_0001678,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of sphingomyelin catabolic process is a subtype of negative regulation of sphingophopholipid degradation: Any process that stops, prevents, or reduces the frequency, rate or extent of the sphingomyelin catabolic process.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001680,,,,,,,,,,,,,,,,,,,,,,negative regulation of sphingomyelin catabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001682,energy sensor,,A role played by the entity which receives energy and transmits operand(s).,false,,,http://purl.obolibrary.org/obo/TXPO_0000882,,,,,,,,,,,,,,,,,,,,,,A role played by the entity which receives energy and transmits operand(s).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001682,,,,,,,,,,,,,,,,,,,,,,energy sensor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001688,sphingomyelinase gene mutation [Phospholipidosis - genetic- sphingomyelin disorder  ],,"Sphingomyelinase gene mutation is a subtype of phopholipase gene mutation: A process that changes the sequence of a sphingomyelinase gene.
This process is dependent on the  genetic and can constitute the course of Phospholipidosis (genetic).",false,,,http://purl.obolibrary.org/obo/TXPO_0001445|http://purl.obolibrary.org/obo/TXPO_0001463,,,,,,,,,,,,,,,,,,,,,,"Sphingomyelinase gene mutation is a subtype of phopholipase gene mutation: A process that changes the sequence of a sphingomyelinase gene.
This process is dependent on the  genetic and can constitute the course of Phospholipidosis (genetic).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001687,,,,,,,,,,,TXPO:0001688,,,,,,,,,,,,,,,,,,,,,,sphingomyelinase gene mutation [Phospholipidosis - genetic- sphingomyelin disorder  ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001687,dysfunction of sphingomyelin degradation [Phospholipidosis - genetic- sphingomyelin disorder],,"Dysfunction of sphingomyelin degradation is a subtype of dysfunction of phosphosphingolipid degradation: A process that performs an abnormal and incomplete sphingomyelin degradation.
This process is dependent on the sphingomyelin disorder and can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0004156|http://purl.obolibrary.org/obo/TXPO_0002069,,,,,,,,,,,,,,,,,,,,,,"Dysfunction of sphingomyelin degradation is a subtype of dysfunction of phosphosphingolipid degradation: A process that performs an abnormal and incomplete sphingomyelin degradation.
This process is dependent on the sphingomyelin disorder and can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001768,,,,,,,,,,,TXPO:0001687,,,,,,,,,,,,,,,,,,,,,,dysfunction of sphingomyelin degradation [Phospholipidosis - genetic- sphingomyelin disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001683,maintaining phospholipid homeostasis [Phospholipidosis],,"Any process involved in the maintenance of an internal steady state of phospholipid within an organism or cell.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/GO_0055091|http://purl.obolibrary.org/obo/TXPO_0000951,,,,,,,,,,,,,,,,,,,,,,"Any process involved in the maintenance of an internal steady state of phospholipid within an organism or cell.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002076,,,,,,,,,TXPO:0001683,,,,,,,,,,,,,,,,,,,,,,maintaining phospholipid homeostasis [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001681,hyperfunction of moving A to the inside of B,,Hyperfunction of moving A to the inside of B is a subtype of hyperfunctioning: A process that performs an excesssive moving A to the inside of B.,false,,,http://purl.obolibrary.org/obo/TXPO_0000435,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of moving A to the inside of B is a subtype of hyperfunctioning: A process that performs an excesssive moving A to the inside of B.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001681,,,,,,,,,,,,,,,,,,,,,,hyperfunction of moving A to the inside of B,,,,,,http://purl.obolibrary.org/obo/TXPO_0002587,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001685,sphingomyelin disorder (genetic),,The totality of all processes through which the sphingomyelin disorder is realized. This causal process is heredity.,false,,,http://purl.obolibrary.org/obo/TXPO_0001437|http://purl.obolibrary.org/obo/TXPO_0004157,,,,,,,,,,,,,,,,,,,,,,The totality of all processes through which the sphingomyelin disorder is realized. This causal process is heredity.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001768|http://purl.obolibrary.org/obo/TXPO_0003984|http://purl.obolibrary.org/obo/TXPO_0001688|http://purl.obolibrary.org/obo/TXPO_0001687|http://purl.obolibrary.org/obo/TXPO_0001690,,,,,,,,,,,,,,,,,,TXPO:0001685,,,,,,,,,,,,,,,,,,,,,,sphingomyelin disorder (genetic),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001686,dysfunction of sphingomyelin degradation,,Dysfunction of sphingomyelin degradation is a subtype of dysfunction of phosphosphingolipid degradation: A process that performs an abnormal and incomplete sphingomyelin degradation.,false,,,http://purl.obolibrary.org/obo/TXPO_0001474,,,,,,,,,,,,,,,,,,,,,,Dysfunction of sphingomyelin degradation is a subtype of dysfunction of phosphosphingolipid degradation: A process that performs an abnormal and incomplete sphingomyelin degradation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001686,,,,,,,,,,,,,,,,,,,,,,dysfunction of sphingomyelin degradation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001693,amine,,"A group of compounds derived from ammonia by substituting organic radicals for the hydrogens. (From Grant & Hackh's Chemical Dictionary, 5th ed)",false,,,http://purl.obolibrary.org/obo/CHEBI_72695,,,,,,,,,,,,,,,,,,,,CHEBI:32952|MeSH:D000588,,"A group of compounds derived from ammonia by substituting organic radicals for the hydrogens. (From Grant & Hackh's Chemical Dictionary, 5th ed)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001693,,,,,,,,,,,,,,,,,,,,,,amine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000888,TFII,pol II general transcription factor|transcription factor for RNA polymerase II,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003645,,,,,pol II general transcription factor|transcription factor for RNA polymerase II,,,,,IMR:0000888,,,,,,,,,,,,,,,,,,,,,,TFII,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_36047,antibacterial drug,antibacterial drugs,A drug used to treat or prevent bacterial infections.,false,,,http://purl.obolibrary.org/obo/CHEBI_33282|http://purl.obolibrary.org/obo/CHEBI_36043,,,,,,,,,,,,,,,,,,,,Wikipedia:Antibacterial,,A drug used to treat or prevent bacterial infections.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,antibacterial drugs,,,,,,,,,,,,,,,,,,,,,CHEBI:36047,,,,antibacterial drug,,CHEBI:36047,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_50267,protective agent,chemoprotectants|chemoprotective agent|chemoprotectant|chemoprotective agents|protective agents,Synthetic or natural substance which is given to prevent a disease or disorder or are used in the process of treating a disease or injury due to a poisonous agent.,false,,,http://purl.obolibrary.org/obo/CHEBI_23888,,,,,,,,,,,,,,,,,,,,,,Synthetic or natural substance which is given to prevent a disease or disorder or are used in the process of treating a disease or injury due to a poisonous agent.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,chemoprotectants|chemoprotective agent|chemoprotectant|chemoprotective agents|protective agents,,,,,,,,,,,,,,,,,,,,,CHEBI:50267,,,,protective agent,,CHEBI:50267,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76834,EC 2.5.* (non-methyl-alkyl or aryl transferase) inhibitor,non-methyl-alkyl or aryl transferase (EC 2.5.*) inhibitors|EC 2.5.* (non-methyl-alkyl or aryl transferase) inhibitors|EC 2.5.* inhibitors|EC 2.5.* inhibitor|non-methyl-alkyl or aryl transferase (EC 2.5.*) inhibitor,An EC 2.5.* (transferase) inhibitor that inhibits the action of any transferase that transfers an alkyl (other than methyl) or aryl group (EC 2.5.*).,false,,,http://purl.obolibrary.org/obo/CHEBI_71300,,,,,,,,,,,,,,,,,,,,,,An EC 2.5.* (transferase) inhibitor that inhibits the action of any transferase that transfers an alkyl (other than methyl) or aryl group (EC 2.5.*).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,non-methyl-alkyl or aryl transferase (EC 2.5.*) inhibitors|EC 2.5.* (non-methyl-alkyl or aryl transferase) inhibitors|EC 2.5.* inhibitors|EC 2.5.* inhibitor|non-methyl-alkyl or aryl transferase (EC 2.5.*) inhibitor,,,,,,,,,,,,,,,,,,,,,CHEBI:76834,,,,EC 2.5.* (non-methyl-alkyl or aryl transferase) inhibitor,,CHEBI:76834,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000680,Plk3,,,false,,,http://purl.obolibrary.org/obo/IMR_0000256,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000680,,,,,,,,,,,,,,,,,,,,,,Plk3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000559,GADD45,growth arrest and DNA damage inducible 45,"The MyD118/CR6/Gadd45 gene family (also termed Gadd45b, Gadd45g, Gadd45a) encodes for small (18 kd), evolutionary conserved proteins that are highly homologous to each other (55 57% overall identity at the amino acid level), are highly acidic (pI=4.0  4.2), and are primarily localized within the cell nucleus. MyD118/CR6/GADD45 serve similar, but not identical, functions along different apoptotic and growth inhibitory pathways. They interact with cell cycle proteins.",false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,"The MyD118/CR6/Gadd45 gene family (also termed Gadd45b, Gadd45g, Gadd45a) encodes for small (18 kd), evolutionary conserved proteins that are highly homologous to each other (55 57% overall identity at the amino acid level), are highly acidic (pI=4.0  4.2), and are primarily localized within the cell nucleus. MyD118/CR6/GADD45 serve similar, but not identical, functions along different apoptotic and growth inhibitory pathways. They interact with cell cycle proteins.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,growth arrest and DNA damage inducible 45,,,,,IMR:0000559,,,,,,,,,,,,,,,,,,,,,,GADD45,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_31653,glafenine,"Glaphenin|Glifanan|glafenina|glafeninum|Glafenin|Glifan|glafenine|2,3-Dihydroxypropyl N-(7-chloro-4-quinolyl) anthranilate|4-(2'-beta,gamma-Dihydroxypropoxycarbonylphenylamino)-7-chloroquinoline|Glycerylaminophenaquine|Glicafan|Glaphenine|4-((2-Carboxyphenyl)amino)-7-chloroquinoline alpha-monoglyceride|2,3-dihydroxypropyl 2-[(7-chloroquinolin-4-yl)amino]benzoate","A carboxylic ester that is 2,3-dihydroxypropyl anthranilate in which the amino group is substituted by a 7-chloroquinolin-4-yl group. A non-steroidal anti-inflammatory drug, glafenine and its hydrochloride salt were used for the relief of all types of pain, but high incidence of anaphylactic reactions resulted in their withdrawal from the market.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Beilstein:497124|Drug_Central:1297|Reaxys:497124|LINCS:LSM-4419|PMID:2210868|CAS:3820-67-5|PMID:19567678,,"A carboxylic ester that is 2,3-dihydroxypropyl anthranilate in which the amino group is substituted by a 7-chloroquinolin-4-yl group. A non-steroidal anti-inflammatory drug, glafenine and its hydrochloride salt were used for the relief of all types of pain, but high incidence of anaphylactic reactions resulted in their withdrawal from the market.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35222|http://purl.obolibrary.org/obo/CHEBI_35475|http://purl.obolibrary.org/obo/CHEBI_35481,,,,,"2,3-dihydroxypropyl 2-[(7-chloroquinolin-4-yl)amino]benzoate",,"Glaphenin|Glifanan|glafenina|glafeninum|Glafenin|Glifan|glafenine|2,3-Dihydroxypropyl N-(7-chloro-4-quinolyl) anthranilate|4-(2'-beta,gamma-Dihydroxypropoxycarbonylphenylamino)-7-chloroquinoline|Glycerylaminophenaquine|Glicafan|Glaphenine|4-((2-Carboxyphenyl)amino)-7-chloroquinoline alpha-monoglyceride",,,,,,,,,,,,,,,,,,,,,CHEBI:31653,,,,glafenine,,CHEBI:31653,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001569,Rab5C,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001569,,,,,,,,,,,,,,,,,,,,,,Rab5C,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002969,ATF4 - transcriptional regulator (canonical)[ER stress - glucose metabolism disorder],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001907,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,,,,,,TXPO:0002969,,,,,,,,,,,,,,,,,,,,,,ATF4 - transcriptional regulator (canonical)[ER stress - glucose metabolism disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002968,lipid metabolism gene expression by ATF4 [ER stress],,"Lipid metabolism gene expression by ATF4 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) related to the lipid metabolism by ATF4.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000698,,,,,,,,,,,,,,,,,,,,,,"Lipid metabolism gene expression by ATF4 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) related to the lipid metabolism by ATF4.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002970,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002968,,,,,,,,,,,,,,,,,,,,,,lipid metabolism gene expression by ATF4 [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002960,XBP1s gene regulation pathway [ER stress - ERAD],,"XBP1s gene regulation pathway is a subtype of gene regulation pathway: A series of process in which XBP1s regulates the gene expression.
This process is dependent on the inflammation that can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002486,,,,,,,,,,,,,,,,,,,,,,"XBP1s gene regulation pathway is a subtype of gene regulation pathway: A series of process in which XBP1s regulates the gene expression.
This process is dependent on the inflammation that can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002608,,,,,,,,,,,,,,,,,,TXPO:0002960,,,,,,,,,,,,,,,,,,,,,,XBP1s gene regulation pathway [ER stress - ERAD],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002964,refolding gene expression by ATF4 [ER stress],,"Refolding gene expression by ATF4 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) related to the refolding by ATF4.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000698,,,,,,,,,,,,,,,,,,,,PMID:26977301,,"Refolding gene expression by ATF4 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) related to the refolding by ATF4.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002965,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002964,,,,,,,,,,,,,,,,,,,,,,refolding gene expression by ATF4 [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002966,apoptotic gene expression by ATF4 [ER stress - apoptosis],,"Inflammatiory gene expression by ATF4 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) related to apoptosis by ATF4.
This process is dependent on the apoptosis and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000698,,,,,,,,,,,,,,,,,,,,PMID:26977301,,"Inflammatiory gene expression by ATF4 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) related to apoptosis by ATF4.
This process is dependent on the apoptosis and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002558,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002722,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002916,,,,,,,,,,,TXPO:0002966,,,,,,,,,,,,,,,,,,,,,,apoptotic gene expression by ATF4 [ER stress - apoptosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002963,Refolding gene regulation pathway by ATF4 [ER stress],,"Refolding gene regulation pathway by ATF4 is a subtype of ATF4 gene regulation pathway: Sequence of reactions to regulate refolding genes by ATF4.
This pathway can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002483,,,,,,,,,,,,,,,,,,,,,,"Refolding gene regulation pathway by ATF4 is a subtype of ATF4 gene regulation pathway: Sequence of reactions to regulate refolding genes by ATF4.
This pathway can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002964,,,,,,,,,,,,,,,,,,TXPO:0002963,,,,,,,,,,,,,,,,,,,,,,Refolding gene regulation pathway by ATF4 [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002961,CHOP gene regulation pathway [ER stress - apoptosis],,"CHOP gene regulation pathway is a subtype of gene regulation pathway: Sequence of reactions to regulate genes by CHOP.
This pathway is dependent on the apoptosis and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002485,,,,,,,,,,,,,,,,,,,,,,"CHOP gene regulation pathway is a subtype of gene regulation pathway: Sequence of reactions to regulate genes by CHOP.
This pathway is dependent on the apoptosis and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002767,,,,,,,,,,,,,,,,,,TXPO:0002961,,,,,,,,,,,,,,,,,,,,,,CHOP gene regulation pathway [ER stress - apoptosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002967,carbohydrate metabolism gene expression by ATF4 [ER stress],,"Carbohydrate metabolism related gene expression by ATF4 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA)  related carbohydrate metabolism  by ATF4.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000698,,,,,,,,,,,,,,,,,,,,,,"Carbohydrate metabolism related gene expression by ATF4 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA)  related carbohydrate metabolism  by ATF4.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002969,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002967,,,,,,,,,,,,,,,,,,,,,,carbohydrate metabolism gene expression by ATF4 [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002965,ATF4 - transcriptional regulator (canonical)[ER stress - Refolding],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001907,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,,,,,,TXPO:0002965,,,,,,,,,,,,,,,,,,,,,,ATF4 - transcriptional regulator (canonical)[ER stress - Refolding],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002962,NRF2 gene regulation pathway [ER stress],,"NRF2 signaling (integrated pathway) is a subtype of integrated signaling pathway: Sequence of linked reactions, which has NRF2 signaling and gene regulation pathway.
This pathway is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002490,,,,,,,,,,,,,,,,,,,,,,"NRF2 signaling (integrated pathway) is a subtype of integrated signaling pathway: Sequence of linked reactions, which has NRF2 signaling and gene regulation pathway.
This pathway is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002765,,,,,,,,,,,,,,,,,,TXPO:0002962,,,,,,,,,,,,,,,,,,,,,,NRF2 gene regulation pathway [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_64926,serine protease inhibitor,serine proteinase inhibitors|serine proteinase inhibitor|serine protease inhibitors,Any protease inhibitor that restricts the action of a serine protease.,false,,,http://purl.obolibrary.org/obo/CHEBI_37670,,,,,,,,,,,,,,,,,,,,,,Any protease inhibitor that restricts the action of a serine protease.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,serine proteinase inhibitors|serine proteinase inhibitor|serine protease inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:64926,,,,serine protease inhibitor,,CHEBI:64926,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_6367,lamotrigine,"3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine|Lamictal|lamotrigine|lamotriginum|lamotrigina|6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine","A member of the class of 1,2,4-triazines in which the triazene skeleton is substituted by amino groups at positions 3 and 5, and by a 2,3-dichlorophenyl group at position 6.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,LINCS:LSM-4104|PMID:20825390|PMID:21242744|CAS:84057-84-1|Reaxys:7589268|Drug_Central:1540|DrugBank:DB00555,,"A member of the class of 1,2,4-triazines in which the triazene skeleton is substituted by amino groups at positions 3 and 5, and by a 2,3-dichlorophenyl group at position 6.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35477|http://purl.obolibrary.org/obo/CHEBI_35703|http://purl.obolibrary.org/obo/CHEBI_76779|http://purl.obolibrary.org/obo/CHEBI_60798|http://purl.obolibrary.org/obo/CHEBI_38215|http://purl.obolibrary.org/obo/CHEBI_35623|http://purl.obolibrary.org/obo/CHEBI_35469|http://purl.obolibrary.org/obo/CHEBI_78298|http://purl.obolibrary.org/obo/CHEBI_35481,,,,,"6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine",,"3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine|Lamictal|lamotrigine|lamotriginum|lamotrigina",,,,,,,,,,,,,,,,,,,,,CHEBI:6367,,,,lamotrigine,,CHEBI:6367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100293,Bcl-xL,,,false,,,http://purl.obolibrary.org/obo/IMR_0100706,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100293,,,,,,,,,,,,,,,,,,,,,,Bcl-xL,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/NCIT_C107150,OATP family,OATP|SLCO|Solute Carrier Organic Anion,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,OATP|SLCO|Solute Carrier Organic Anion,,,,,NCIT:C107150,,,,,,,A family of transmembrane proteins that play a role in the transport of organic anions including bile acids and bilirubin.,,,,,,,,,,,,,,,OATP family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000203,neurofilament protein,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,GO:0005883,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003693,,,,,,,,,,IMR:0000203,,,,,,,,,,,,,,,,,,,,,,neurofilament protein,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000112476,PRRT2,,Other designations: dispanin subfamily B member 3|infantile convulsions and paroxysmal choreoathetosis|interferon induced transmembrane protein domain containing 1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,BFIC2|PKC|DYT10|EKD1|IFITMD1|DSPB3|ICCA|FICCA|BFIS2,,,,,,,,,,,,16,,,,,,Ensembl:ENSG00000167371|HPRD:13995|MIM:614386|Vega:OTTHUMG00000177142|HGNC:30500,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,proline-rich transmembrane protein 2,,,16p11.2,,,,,,,,,,,,,,,,GO_0005886 (EC: IEA); GO_0009607 (EC: IEA); GO_0016021 (EC: IEA); GO_0030054 (EC: IEA); GO_0045202 (EC: IEA); GO_0050884 (EC: IMP),,,,,,,,,PMID: 8125298; 12477932; 14702039; 16169070; 16303743; 16344560; 17207965; 20301633; 22101681; 22120146; 22131361; 22209761; 22243967; 22360420; 22363774; 22386217; 22399141; 22464846; 22543779; 22623405; 22744660; 22752065; 22782515; 22832103; 22845787; 22870186; 22875091; 22877996; 22902423; 22985072; 23063574; 23073245; 23077016; 23077017; 23077018; 23077019; 23077024; 23077026; 23126439; 23176561; 23180180; 23182655; 23190448; 23299620; 23343561; 23352743; 23360469; 23363396; 23398397; 23456995; 23529024; 23535490; 23566103; 23771590; 23963607; 24250222,,,,,,,,,,,,,,,OGG:3000112476,,,,,,,proline-rich transmembrane protein 2,,,,,,,,,,,,,Other designations: dispanin subfamily B member 3|infantile convulsions and paroxysmal choreoathetosis|interferon induced transmembrane protein domain containing 1,,PRRT2,,,,,,,,,,,,,,,,,,,,,,,112476,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,PRRT2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0001582,Rab9B,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001582,,,,,,,,,,,,,,,,,,,,,,Rab9B,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_50113,androgen,androgeno|androgenos|androgene|androgenes|androgens|Androgene|Androgen,A sex hormone that stimulates or controls the development and maintenance of masculine characteristics in vertebrates by binding to androgen receptors.,false,,,http://purl.obolibrary.org/obo/CHEBI_50112,,,,,,,,,,,,,,,,,,,,,,A sex hormone that stimulates or controls the development and maintenance of masculine characteristics in vertebrates by binding to androgen receptors.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Androgen,,androgeno|androgenos|androgene|androgenes|androgens|Androgene,,,,,,,,,,,,,,,,,,,,,CHEBI:50113,,,,androgen,,CHEBI:50113,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100552,FGF-2,BFGF|HBGF-2|Basic fibroblast growth factor|Prostatropin,,false,,,http://purl.obolibrary.org/obo/IMR_0000049,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BFGF|HBGF-2|Basic fibroblast growth factor|Prostatropin,,,,,IMR:0100552,,,,,,,,,,,,,,,,,,,,,,FGF-2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010479,60S ribosomal protein L27a,P46776,,false,,,http://purl.obolibrary.org/obo/IMR_0000897,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,P46776,,,,,IMR:0010479,,,,,,,,,,,,,,,,,,,,,,60S ribosomal protein L27a,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000871,NF1-C,TGGCA-binding protein|Nuclear factor 1 C-type|CTF|NF1-C|NFI-C|Nuclear factor 1/C|CCAAT-box binding transcription factor|NF-I/C,,false,,,http://purl.obolibrary.org/obo/IMR_0000409,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0010367,TGGCA-binding protein|Nuclear factor 1 C-type|CTF|NF1-C|NFI-C|Nuclear factor 1/C|CCAAT-box binding transcription factor|NF-I/C,,,,,IMR:0000871,,,,,,,,,,,,,,,,,,,,,,NF1-C,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001422,ISGF3,interferon-stimulated gene factor 3|IFN-stimulated gene factor 3,"ISGF3 is a heterotrimer of STAT1, STAT2 and p48/ISGF3gamma/IRF9.",false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,"ISGF3 is a heterotrimer of STAT1, STAT2 and p48/ISGF3gamma/IRF9.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,interferon-stimulated gene factor 3|IFN-stimulated gene factor 3,,,,,IMR:0001422,,,,,,,,,,,,,,,,,,,,,,ISGF3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003730,changing state role,,A role played by the entity involved in changing some state.,false,,,http://purl.obolibrary.org/obo/TXPO_0003712,,,,,,,,,,,,,,,,,,,,,,A role played by the entity involved in changing some state.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003730,,,,,,,,,,,,,,,,,,,,,,changing state role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003736,ER stress dependent process (molecular level),,ER stress dependent process (molecular level) is a subtype of ER stress dependent process: A process that can constitute the course of endoplasmic reticulum stress and specifies the molecular level.,false,,,http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,ER stress dependent process (molecular level) is a subtype of ER stress dependent process: A process that can constitute the course of endoplasmic reticulum stress and specifies the molecular level.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003736,,,,,,,,,,,,,,,,,,,,,,ER stress dependent process (molecular level),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003739,leaking content from cell [Cholestasis],,"Leaking content from cell is a subtype of leaking: A process that leaks contents from the cell.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000526,,,,,,,,,,,,,,,,,,,,,,"Leaking content from cell is a subtype of leaking: A process that leaks contents from the cell.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003740,,,,,,,,,,,TXPO:0003739,,,,,,,,,,,,,,,,,,,,,,leaking content from cell [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003735,HSP90B1 - tumor cell production promoting factor (human)[ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000802,,,,,,,,,,,,,,,,,,,,PMID:25463537,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003735,,,,,,,,,,,,,,,,,,,,,,HSP90B1 - tumor cell production promoting factor (human)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003734,GRP94 - tumor cell enhanced survlival factor (canonical)[ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002410,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003734,,,,,,,,,,,,,,,,,,,,,,GRP94 - tumor cell enhanced survlival factor (canonical)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003733,keeping structure,,Keeping structure is a subtype of changing structure: A process that maintains the structure of the object at a constant level .,false,,,http://purl.obolibrary.org/obo/TXPO_0002566,,,,,,,,,,,,,,,,,,,,,,Keeping structure is a subtype of changing structure: A process that maintains the structure of the object at a constant level .,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003733,,,,,,,,,,,,,,,,,,,,,,keeping structure,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003731,keeping structure role,,A role played by the entity that contributes to keep the structural integrity.,false,,,http://purl.obolibrary.org/obo/TXPO_0003712,,,,,,,,,,,,,,,,,,,,,,A role played by the entity that contributes to keep the structural integrity.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003731,,,,,,,,,,,,,,,,,,,,,,keeping structure role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003732,molecular (activity) co-regulator,,A role played by the entity which assists the molecule activity.,false,,,http://purl.obolibrary.org/obo/TXPO_0003727,,,,,,,,,,,,,,,,,,,,,,A role played by the entity which assists the molecule activity.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003732,,,,,,,,,,,,,,,,,,,,,,molecular (activity) co-regulator,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003738,AP1M2 (canonical)[Lipidosis],,Subunit of clathrin-associated adaptor protein complex 1 that plays a role in protein sorting in the trans-Golgi network (TGN) and endosomes. The AP complexes mediate the recruitment of clathrin to membranes and the recognition of sorting signals within the cytosolic tails of transmembrane cargo molecules.,false,,,http://purl.obolibrary.org/obo/TXPO_0003516|http://purl.obolibrary.org/obo/TXPO_1000003,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:367038|NCBI-Mouse-GeneID:11768|NCBI-Human-GeneID:10053|PMID:2335054,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003638,,,,,,,,,,TXPO:0003738,,,,,,,,,,,,,,,,,,,,Subunit of clathrin-associated adaptor protein complex 1 that plays a role in protein sorting in the trans-Golgi network (TGN) and endosomes. The AP complexes mediate the recruitment of clathrin to membranes and the recognition of sorting signals within the cytosolic tails of transmembrane cargo molecules.,,AP1M2 (canonical)[Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003737,apoptosome assembly [Cell death],,"The aggregation, arrangement and bonding together of the apoptosome, a multisubunit protein complex involved in the signaling phase of the apoptotic process.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/GO_0097314|http://purl.obolibrary.org/obo/TXPO_0001727,,,,,,,,,,,,,,,,,,,,,,"The aggregation, arrangement and bonding together of the apoptosome, a multisubunit protein complex involved in the signaling phase of the apoptotic process.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000446,,,,,,,,,,,TXPO:0003737,,,,,,,,,,,,,,,,,,,,,,apoptosome assembly [Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003260,hyperfunction of bile acid transport [Ground glass appearance],,"Hyperfunction of bile acid transport  is a subtype of hyperfunction of transport: A process that performs an excesssive bile acid transport.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/TXPO_0003259,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of bile acid transport  is a subtype of hyperfunction of transport: A process that performs an excesssive bile acid transport.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001032|http://purl.obolibrary.org/obo/TXPO_0003263,,,,,,,,,,,,,,,,,TXPO:0003260,,,,,,,,,,,,,,,,,,,,,,hyperfunction of bile acid transport [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003263,Mrp2 (mouse)[Ground glass appearance],Abcc2 [Ground glass appearance],,false,,,http://purl.obolibrary.org/obo/TXPO_0001071|http://purl.obolibrary.org/obo/TXPO_0002496,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Abcc2 [Ground glass appearance],,,,,TXPO:0003263,,,,,,,,,,,,,,,,,,,,,,Mrp2 (mouse)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003261,Sgpl1 - lipid metabolism regulator (rat)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001151,,,,,,,,,,,,,,,,,,,,http://omim.org/entry/603729|PMID:2061324,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002358,,,,,,,,,,TXPO:0003261,,,,,,,,,,,,,,,,,,,,,,Sgpl1 - lipid metabolism regulator (rat)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003262,Sgpl1 - tumor cell proliferationregulating factor (mouse) [Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003529,,,,,,,,,,,,,,,,,,,,http://omim.org/entry/603729|PMID:17090686,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003534,,,,,,,,,,TXPO:0003262,,,,,,,,,,,,,,,,,,,,,,Sgpl1 - tumor cell proliferationregulating factor (mouse) [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003264,Farnesoid X Receptor inactivation [lipidosis],FXR inactivation [lipidosis],"Farnesoid X receptor inactivation is a subtype of inactivating nuclear receptor: A process that changes the activity of the activating FxR (farnesoid X receptor) with a nuclear receptor role to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0003256,,,,,,,,,,,,,,,,,,,,PMID:15146238|PMID:21286345,,"Farnesoid X receptor inactivation is a subtype of inactivating nuclear receptor: A process that changes the activity of the activating FxR (farnesoid X receptor) with a nuclear receptor role to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003265,,,,http://purl.obolibrary.org/obo/TXPO_0003266,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001117|http://purl.obolibrary.org/obo/TXPO_0001121,,,,,,FXR inactivation [lipidosis],,,,,TXPO:0003264,,,,,,,,,,,,,,,,,,,,,,Farnesoid X Receptor inactivation [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003265,FXR (canonical)[lipidosis],farnesoid x-activated receptor [lipidosis],,false,,,http://purl.obolibrary.org/obo/TXPO_0003119|http://purl.obolibrary.org/obo/TXPO_0003516,,,,,,,,,,,,,,,,,,,,http://www.ncbi.nlm.nih.gov/gene/9971|NCBI-Rat-GeneID:60351|NCBI-Mouse-GeneID:20186|NCBI-Human-GeneID:9971|UniProt:Q96RI1|PMID:26888176|http://purl.bioontology.org/ontology/MESH/C094063,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,farnesoid x-activated receptor [lipidosis],,,,,TXPO:0003265,,,,,,,"Bile salts activate a bile sil sensor, FXR (bile acid receptor; NR1H4) in hepatocytes.|https://omim.org/entry/603826",,,,,,,,,,,,,,,FXR (canonical)[lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003269,hypofunction of phospholipid transport from ER to mitochondrial membrane,,Hypofunction of phospholipid transport from ER to mitochondrial membrane is a subtype of hypofunction of transport: A process that performs a decreased or insufficient phospholipid transport from ER to mitochondrial membrane.,false,,,http://purl.obolibrary.org/obo/TXPO_0001911,,,,,,,,,,,,,,,,,,,,,,Hypofunction of phospholipid transport from ER to mitochondrial membrane is a subtype of hypofunction of transport: A process that performs a decreased or insufficient phospholipid transport from ER to mitochondrial membrane.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003269,,,,,,,,,,,,,,,,,,,,,,hypofunction of phospholipid transport from ER to mitochondrial membrane,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003268,malfunction of lipid biosynthesis,,Malfunction of lipid biosynthesis is a subtype of malfunctioning: A process that cannot perform  the lipid biosynthesis function appropriately or cannot realize it at all.,false,,,http://purl.obolibrary.org/obo/TXPO_0003267,,,,,,,,,,,,,,,,,,,,,,Malfunction of lipid biosynthesis is a subtype of malfunctioning: A process that cannot perform  the lipid biosynthesis function appropriately or cannot realize it at all.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003268,,,,,,,,,,,,,,,,,,,,,,malfunction of lipid biosynthesis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005783,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003266,FXR -inactivated state (canonical)[lipidosis],farnesoid x-activated receptor -inactivated state [lipidosis]|bile acid receptor  [cholestasis],,false,,,http://purl.obolibrary.org/obo/TXPO_0003265,,,,,,,,,,,,,,,,,,,,http://www.ncbi.nlm.nih.gov/gene/9971|NCBI-Rat-GeneID:60351|NCBI-Mouse-GeneID:20186|NCBI-Human-GeneID:9971|UniProt:Q96RI1|PMID:26888176|http://purl.bioontology.org/ontology/MESH/C094063,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0002355,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,farnesoid x-activated receptor -inactivated state [lipidosis]|bile acid receptor  [cholestasis],,,,,TXPO:0003266,,,,,,,"Bile salts activate a bile sil sensor, FXR (bile acid receptor; NR1H4) in hepatocytes.|https://omim.org/entry/603826",,,,,,,,,,,,,,,FXR -inactivated state (canonical)[lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003267,malfunction of biosynthesis,,Malfunction of biosynthesis is a subtype of malfunctioning: A process that cannot perform  the biosynthesis function appropriately or cannot realize it at all.,false,,,http://purl.obolibrary.org/obo/TXPO_0000434,,,,,,,,,,,,,,,,,,,,,,Malfunction of biosynthesis is a subtype of malfunctioning: A process that cannot perform  the biosynthesis function appropriately or cannot realize it at all.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003267,,,,,,,,,,,,,,,,,,,,,,malfunction of biosynthesis,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0009058,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000244,cytokeratin 6C,cytokeratin 6E,,false,,,http://purl.obolibrary.org/obo/IMR_0000469,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000270,cytokeratin 6E,,,,,IMR:0000244,,,,,,,,,,,,,,,,,,,,,,cytokeratin 6C,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005187,natalizumab,,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,DrugBank:DB00108,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005187,,,,,,,,,,,,,,,,,,,,,,natalizumab,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005188,sitaxsentan,,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,DrugBank:DB06268,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005188,,,,,,,,,,,,,,,,,,,,,,sitaxsentan,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005186,peginterferon alfa-2b,,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,DrugBank:DB00022,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005186,,,,,,,,,,,,,,,,,,,,,,peginterferon alfa-2b,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005184,interferon alfacon-1,,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,DrugBank:DB00069,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005184,,,,,,,,,,,,,,,,,,,,,,interferon alfacon-1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005181,asparaginase,,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,DrugBank:DB00023,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005181,,,,,,,,,,,,,,,,,,,,,,asparaginase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005183,interferon beta-1a,,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,DrugBank:DB00060,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005183,,,,,,,,,,,,,,,,,,,,,,interferon beta-1a,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005185,infliximab,,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,DrugBank:DB00065,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005185,,,,,,,,,,,,,,,,,,,,,,infliximab,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005180,gemtuzumab ozogamicin,,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,DrugBank:DB00056,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005180,,,,,,,,,,,,,,,,,,,,,,gemtuzumab ozogamicin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005182,interferon alfa-2b,,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,DrugBank:DB00105,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005182,,,,,,,,,,,,,,,,,,,,,,interferon alfa-2b,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005189,phospholipid biosynthetic process [Phospholipidosis(latent)],,"The chemical reactions and pathways resulting in the formation of phospholipids, any lipid containing phosphoric acid as a mono- or diester.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis(latent).",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/GO_0008654,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways resulting in the formation of phospholipids, any lipid containing phosphoric acid as a mono- or diester.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis(latent).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002293,,,,,,,,,,,TXPO:0005189,,,,,,,,,,,,,,,,,,,,,,phospholipid biosynthetic process [Phospholipidosis(latent)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000453,BAX (mol),,,false,,,http://purl.obolibrary.org/obo/IMR_0100708,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000453,,,,,,,,,,,,,,,,,,,,,,BAX (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001660,RGS2,,,false,,,http://purl.obolibrary.org/obo/IMR_0000431,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001660,,,,,,,,,,,,,,,,,,,,,,RGS2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/NCIT_C20613,clonal expansion,,"Multiplication or reproduction by cell division of a population of identical cells descended from a single progenitor. In immunology, may refer to the clonal proliferation of cells responsive to a specific antigen as part of an immune response. (NCI)",false,,,http://purl.obolibrary.org/obo/GO_0008283,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C20613,,"Multiplication or reproduction by cell division of a population of identical cells descended from a single progenitor. In immunology, may refer to the clonal proliferation of cells responsive to a specific antigen as part of an immune response. (NCI)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,NCIT:C20613,,,,,,,,,,,,,,,,,,,,,,clonal expansion,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010564,40S ribosomal protein S8,40S small ribosomal protein 8,,false,,,http://purl.obolibrary.org/obo/IMR_0000896,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,40S small ribosomal protein 8,,,,,IMR:0010564,,,,,,,,,,,,,,,,,,,,,,40S ribosomal protein S8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0071606,chemokine (C-C motif) ligand 4 production,,"The appearance of chemokine (C-C motif) ligand 4 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.",false,,,http://purl.obolibrary.org/obo/GO_0032602,,,,,,,,,,,,,,,,,,,,,,"The appearance of chemokine (C-C motif) ligand 4 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.",,,,,chemokine (C-C motif) ligand 4 production,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0071606,,,,,,,,,,,,,,,,,,,,,,chemokine (C-C motif) ligand 4 production,,,,,,,http://purl.obolibrary.org/obo/go.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0071604,transforming growth factor beta production,,"The appearance of any member of the transforming growth factor-beta family of cytokines due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels. Transforming growth factor-beta family members include TGF-B1, TGF-B2, and TGF-B3.",false,,,http://purl.obolibrary.org/obo/GO_0001816,,,,,,,,,,,,,,,,,,,,,,"The appearance of any member of the transforming growth factor-beta family of cytokines due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels. Transforming growth factor-beta family members include TGF-B1, TGF-B2, and TGF-B3.",,,,,transforming growth factor beta production,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0071604,,,,,,,,,,,,,,,,,,,,,,transforming growth factor beta production,,,,,,,http://purl.obolibrary.org/obo/go.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000142,MHC family,major histocompatibility complex,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,GO:0042611,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003691,,,,,major histocompatibility complex,,,,,IMR:0000142,,,,,,,,,,,,,,,,,,,,,,MHC family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_75787,prokaryotic metabolite,prokaryotic metabolites,"Any metabolite produced during a metabolic reaction in prokaryotes, the taxon that include members of domains such as the bacteria and archaea.",false,,,http://purl.obolibrary.org/obo/CHEBI_25212,,,,,,,,,,,,,,,,,,,,,,"Any metabolite produced during a metabolic reaction in prokaryotes, the taxon that include members of domains such as the bacteria and archaea.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,prokaryotic metabolites,,,,,,,,,,,,,,,,,,,,,CHEBI:75787,,,,prokaryotic metabolite,,CHEBI:75787,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001677,RGS20,,,false,,,http://purl.obolibrary.org/obo/IMR_0000431,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001677,,,,,,,,,,,,,,,,,,,,,,RGS20,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0003083,BMP-2 subfamily,BMP-2/4 group,"BMP-related proteins can be subdivided into several groups based on their structures and functions. BMP-2, BMP-4, and the Drosophila Dpp form one subgroup.",false,,,http://purl.obolibrary.org/obo/IMR_0000040,,,,,,,,,,,,,,,,,,,,,,"BMP-related proteins can be subdivided into several groups based on their structures and functions. BMP-2, BMP-4, and the Drosophila Dpp form one subgroup.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BMP-2/4 group,,,,,IMR:0003083,,,,,,,,,,,,,,,,,,,,,,BMP-2 subfamily,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000000545,ATR,,"Other designations: FRAP-related protein 1|FRAP-related protein-1|MEC1, mitosis entry checkpoint 1, homolog|Rad3 related protein|ataxia telangiectasia and Rad3-related protein|protein kinase ATR|serine/threonine-protein kinase ATR",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,FRP1|SCKL|FCTCS|MEC1|SCKL1,,,,,,,,,,,,3,,,,,,HPRD:08369|Ensembl:ENSG00000175054|MIM:601215|HGNC:882|Vega:OTTHUMG00000159234,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,ataxia telangiectasia and Rad3 related,,,3q23,,,,,,,,,,,,,,,,"GO_0000077 (EC: IDA, PMID: 14657349); GO_0001741 (EC: IEA); GO_0003677 (EC: IEA); GO_0004672 (EC: IDA, PMID: 14657349); GO_0004674 (EC: IDA, PMID: 9733515); GO_0005515 (EC: IPI, PMID: 14657349); GO_0005524 (EC: IEA); GO_0005654 (EC: TAS); GO_0005694 (EC: ISS); GO_0006260 (EC: TAS); GO_0006281 (EC: TAS); GO_0006974 (EC: TAS, PMID: 15538388); GO_0007049 (EC: TAS, PMID: 9590286); GO_0007275 (EC: TAS, PMID: 9590286); GO_0008156 (EC: IMP, PMID: 14657349); GO_0016605 (EC: IDA, PMID: 12814551); GO_0018105 (EC: IDA, PMID: 9733515); GO_0032405 (EC: IDA, PMID: 16713580); GO_0032407 (EC: IDA, PMID: 16713580); GO_0034644 (EC: IMP, PMID: 9925639); GO_0042493 (EC: IEA); GO_0043393 (EC: IEA); GO_0043517 (EC: IMP, PMID: 9925639); GO_0046777 (EC: IDA, PMID: 9733515); GO_0071480 (EC: IDA, PMID: 9925639); GO_0090399 (EC: IMP, PMID: 15149599)",,,,,,,,,PMID: 8610130; 8843195; 8978690; 9427750; 9590286; 9636169; 9733515; 9765199; 9766667; 9857181; 9925639; 10435622; 10545197; 10597277; 10608806; 10673501; 10747897; 10749680; 10859164; 10889046; 10951572; 10973490; 11016625; 11114888; 11163154; 11252893; 11278964; 11390642; 11393670; 11418864; 11459832; 11470508; 11551930; 11673449; 11688760; 11709713; 11715017; 11721054; 11790298; 11799063; 11865061; 11883897; 11927575; 12011431; 12024051; 12147700; 12446774; 12493754; 12519769; 12526805; 12629512; 12640452; 12679521; 12738771; 12766152; 12773400; 12791699; 12791985; 12814551; 12915485; 12959929; 14657349; 14724280; 14729972; 14729973; 14742437; 14755251; 14871897; 14988723; 15050919; 15149599; 15159397; 15195100; 15210935; 15235112; 15279777; 15282542; 15302935; 15314022; 15374968; 15451423; 15456891; 15466211; 15485898; 15496423; 15527801; 15533933; 15538388; 15539948; 15616588; 15635413; 15640246; 15650165; 15650754; 15680327; 15707391; 15734998; 15743907; 15758953; 15775976; 15854902; 15933716; 15987455; 16009130; 16051665; 16086026; 16122425; 16122426; 16195237; 16260606; 16293623; 16306615; 16354571; 16431910; 16436511; 16461339; 16474843; 16488880; 16530042; 16540648; 16675950; 16705183; 16713580; 16738325; 16741947; 16757521; 16827800; 16872911; 16880517; 16909103; 16943440; 16951182; 16956949; 16968694; 17010193; 17015476; 17030982; 17035231; 17118963; 17124492; 17140287; 17148452; 17157788; 17210576; 17260016; 17272271; 17292679; 17376433; 17384638; 17384681; 17409144; 17478428; 17526493; 17616578; 17616665; 17620599; 17638878; 17686975; 17716975; 17879369; 17934520; 17976513; 18003706; 18025301; 18032786; 18160036; 18162465; 18202016; 18245444; 18283122; 18344416; 18357388; 18381943; 18434539; 18451105; 18451257; 18480045; 18495871; 18514189; 18519640; 18536714; 18550533; 18583959; 18625709; 18642075; 18664457; 18757420; 18931676; 18936170; 18950845; 18985806; 18995830; 19004803; 19064565; 19064572; 19074885; 19097996; 19109555; 19116388; 19119425; 19124506; 19146767; 19154794; 19197236; 19242509; 19244116; 19275579; 19275588; 19285939; 19330022; 19351817; 19372558; 19444312; 19470935; 19477925; 19527713; 19536649; 19570909; 19584262; 19586908; 19633697; 19690177; 19714462; 19798433; 19805520; 19828454; 19889979; 19903823; 20005840; 20008788; 20012529; 20029092; 20048340; 20060399; 20084458; 20103595; 20147462; 20233725; 20301772; 20347598; 20368801; 20424596; 20427275; 20427287; 20453000; 20469721; 20496165; 20513533; 20515729; 20566845; 20616048; 20634891; 20731661; 20798688; 20801936; 20810650; 20818375; 20847938; 20861269; 20930849; 21034966; 21139048; 21144835; 21224401; 21242293; 21270107; 21284603; 21285353; 21294646; 21308861; 21383502; 21502314; 21566061; 21659603; 21680529; 21705319; 21857991; 21859891; 21874023; 21890473; 21906983; 21908846; 21963094; 21976111; 21994772; 21995812; 21998596; 22053931; 22084169; 22123827; 22159421; 22174788; 22179839; 22184063; 22341969; 22435685; 22505724; 22535492; 22556425; 22621920; 22713662; 22735644; 22740051; 22797063; 22807682; 22842784; 22939629; 22948311; 23000965; 23029527; 23085754; 23135710; 23144622; 23176708; 23178497; 23255133; 23272087; 23284306; 23345434; 23401567; 23438602; 23447674; 23447702; 23451157; 23454212; 23548269; 23592782; 23592994; 23600770; 23684611; 23696651; 23698467; 23733185; 23807228; 23844225; 23861882; 23873943; 23874235; 23897887; 23901102; 23956138; 24005565; 24045107; 24267891,,,,,,,,,,,,,,,OGG:3000000545,,,,,,,ataxia telangiectasia and Rad3 related,,,,,,,,,,,,,"Other designations: FRAP-related protein 1|FRAP-related protein-1|MEC1, mitosis entry checkpoint 1, homolog|Rad3 related protein|ataxia telangiectasia and Rad3-related protein|protein kinase ATR|serine/threonine-protein kinase ATR",,ATR,,,,,,,,,,,,,,,,,,,,,,,545,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,ATR,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/NCIT_C16407,cell survival,,,false,,,http://purl.obolibrary.org/obo/TXPO_0000414,,,,,,,,,,,,,,,,,,,,http://purl.bioontology.org/ontology/MESH/D002470|http://jglobal.jst.go.jp/en/detail?JGLOBAL_ID=200906081082476489,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000000,,,,,,,,,,,,,,,,,NCIT:C16407,,,,,,,,,,,,,,,,,,,,,,cell survival,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0022607,cellular component assembly,cellular component assembly at cellular level,"The aggregation, arrangement and bonding together of a cellular component.",false,,,http://purl.obolibrary.org/obo/TXPO_0000468,,,,,,,,,,,,,,,,,,,,,,"The aggregation, arrangement and bonding together of a cellular component.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,cellular component assembly at cellular level,,,,,GO:0022607,,,,,,,,,,,,,,,,,,,,,,cellular component assembly,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000000,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001140,glypican-1,,,false,,,http://purl.obolibrary.org/obo/IMR_0001139,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001140,,,,,,,,,,,,,,,,,,,,,,glypican-1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_63673,chemokine receptor 5 antagonist,CCR-5 antagonist|CCR5 antagonists|chemokine receptor 5 antagonists|CCR-5 antagonists|CCR5 antagonist,An antogonist that blocks chemokine receptor 5 (CCR5).,false,,,http://purl.obolibrary.org/obo/CHEBI_48706,,,,,,,,,,,,,,,,,,,,,,An antogonist that blocks chemokine receptor 5 (CCR5).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CCR-5 antagonist|CCR5 antagonists|chemokine receptor 5 antagonists|CCR-5 antagonists|CCR5 antagonist,,,,,,,,,,,,,,,,,,,,,CHEBI:63673,,,,chemokine receptor 5 antagonist,,CHEBI:63673,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000513,apoptotic process [ER stress],,"A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/GO_0006915,,,,,,,,,,,,,,,,,,,,ISBN:0123878179,,"A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003110|http://purl.obolibrary.org/obo/TXPO_0003113|http://purl.obolibrary.org/obo/TXPO_0002948|http://purl.obolibrary.org/obo/TXPO_0003104|http://purl.obolibrary.org/obo/TXPO_0003109|http://purl.obolibrary.org/obo/TXPO_0003103|http://purl.obolibrary.org/obo/TXPO_0003105|http://purl.obolibrary.org/obo/TXPO_0003107|http://purl.obolibrary.org/obo/TXPO_0003091|http://purl.obolibrary.org/obo/TXPO_0003092,,http://purl.obolibrary.org/obo/TXPO_0003102,,,,,http://purl.obolibrary.org/obo/TXPO_0000342,,,,,,,,,,,TXPO:0000513,,,,,,,,,,,,,,,,,,,,,,apoptotic process [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000515,apoptotic process [Oxidative stress],,"A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died.
This entity is a specific course-dependent process. This process can constitute the course of Oxidative stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001730|http://purl.obolibrary.org/obo/GO_0006915,,,,,,,,,,,,,,,,,,,,,,"A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died.
This entity is a specific course-dependent process. This process can constitute the course of Oxidative stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002333,,,,,,,,,,,TXPO:0000515,,,,,,,,,,,,,,,,,,,,,,apoptotic process [Oxidative stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000519,oxidoreductase,,"Catalysis role of an oxidation-reduction (redox) reaction, a reversible chemical reaction in which the oxidation state of an atom or atoms within a molecule is altered. One substrate acts as a hydrogen or electron donor and becomes oxidized, while the other acts as hydrogen or electron acceptor and becomes reduced.|related molecular function GO:0016491",false,,,http://purl.obolibrary.org/obo/TXPO_0003660,,,,,,,,,,,,,,,,,,,,EC:1.,,"Catalysis role of an oxidation-reduction (redox) reaction, a reversible chemical reaction in which the oxidation state of an atom or atoms within a molecule is altered. One substrate acts as a hydrogen or electron donor and becomes oxidized, while the other acts as hydrogen or electron acceptor and becomes reduced.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000519,,,,,,,,,,,,,,,,,,,,related molecular function GO:0016491,,oxidoreductase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000516,protein catabolic process [ER stress],,"The chemical reactions and pathways resulting in the breakdown of a protein by the destruction of the native, active configuration, with or without the hydrolysis of peptide bonds.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/GO_0030163,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways resulting in the breakdown of a protein by the destruction of the native, active configuration, with or without the hydrolysis of peptide bonds.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002479,,,,,,,,,,,TXPO:0000516,,,,,,,,,,,,,,,,,,,,,,protein catabolic process [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000518,GDF15 (human)[Cell death],,"This gene encodes a secreted ligand of the TGF-beta (transforming growth factor-beta) superfamily of proteins. Ligands of this family bind various TGF-beta receptors leading to recruitment and activation of SMAD family transcription factors that regulate gene expression. The encoded preproprotein is proteolytically processed to generate each subunit of the disulfide-linked homodimer. The protein is expressed in a broad range of cell types, acts as a pleiotropic cytokine and is involved in the stress response program of cells after cellular injury. Increased protein levels are associated with disease states such as tissue hypoxia, inflammation, acute injury and oxidative stress. [provided by RefSeq, Aug 2016]",false,,,http://purl.obolibrary.org/obo/TXPO_1000164|http://purl.obolibrary.org/obo/TXPO_0000840,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:9518|PMID:25698447|PMID:21242297|PMID:23799024,,"This gene encodes a secreted ligand of the TGF-beta (transforming growth factor-beta) superfamily of proteins. Ligands of this family bind various TGF-beta receptors leading to recruitment and activation of SMAD family transcription factors that regulate gene expression. The encoded preproprotein is proteolytically processed to generate each subunit of the disulfide-linked homodimer. The protein is expressed in a broad range of cell types, acts as a pleiotropic cytokine and is involved in the stress response program of cells after cellular injury. Increased protein levels are associated with disease states such as tissue hypoxia, inflammation, acute injury and oxidative stress. [provided by RefSeq, Aug 2016]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000009518,,,,,,,,,,,,,TXPO:0000518,,,,,,,,,,,,,,,,,,,,,,GDF15 (human)[Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000512,anoikis [Cell death],,"Apoptosis triggered by inadequate or inappropriate adherence to substrate e.g. after disruption of the interactions between normal epithelial cells and the extracellular matrix.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0000008|http://purl.obolibrary.org/obo/GO_0043276,,,,,,,,,,,,,,,,,,,,,,"Apoptosis triggered by inadequate or inappropriate adherence to substrate e.g. after disruption of the interactions between normal epithelial cells and the extracellular matrix.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000512,,,,,,,,,,,,,,,,,,,,,,anoikis [Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000514,apoptotic process [Cell death],,"A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0000008|http://purl.obolibrary.org/obo/GO_0006915,,,,,,,,,,,,,,,,,,,,,,"A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000231|http://purl.obolibrary.org/obo/TXPO_0002388,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002128|http://purl.obolibrary.org/obo/TXPO_0002125,,,,,,,,,,,TXPO:0000514,,,,,,,,,,,,,,,,,,,,,,apoptotic process [Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000517,increasing demand for response to oxidative stress [ER stress],,"Increasing demand for response to oxidative stress is a subtype of increasing the demand for response to stress: A process that changes the functional demand for the response to the oxidative stress to be higher.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000102|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"Increasing demand for response to oxidative stress is a subtype of increasing the demand for response to stress: A process that changes the functional demand for the response to the oxidative stress to be higher.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002747,,,,,,,,,,,TXPO:0000517,,,,,,,,,,,,,,,,,,,,,,increasing demand for response to oxidative stress [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0051170,import into nucleus,nuclear import|substance nuclear import|nucleus import,The directed movement of substances into the nucleus.,false,,,http://purl.obolibrary.org/obo/GO_0051169,,,,,,,,,,,,,,,,,,,,,,The directed movement of substances into the nucleus.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005634,,,nuclear import|substance nuclear import|nucleus import,,,,,GO:0051170,,,,,,,,,,,,,,,,,,,,,,import into nucleus,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000064081,PBLD,,Other designations: MAWD-binding protein|phenazine biosynthesis-like domain-containing protein,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,MAWDBP|MAWBP,,,,,,,,,,,,10,,,,,,MIM:612189|HGNC:23301|Vega:OTTHUMG00000073949|HPRD:14366|Ensembl:ENSG00000108187,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,phenazine biosynthesis-like protein domain containing,,,10q21.3,,,,,,,,,,,,,,,,"GO_0003674 (EC: ND); GO_0005515 (EC: IPI, PMID: 17929853); GO_0005737 (EC: IDA, PMID: 17929853); GO_0009058 (EC: IEA); GO_0010633 (EC: IMP); GO_0010719 (EC: IMP); GO_0016853 (EC: IEA); GO_0030277 (EC: IMP, PMID: 17929853); GO_0030512 (EC: IMP); GO_0050680 (EC: IMP); GO_0060392 (EC: IGI); GO_0060394 (EC: IMP); GO_0070062 (EC: IDA, PMID: 19056867)",,,,,,,,,PMID: 1286669; 11355021; 12477932; 14702039; 15489334; 15806103; 16189514; 16385451; 16712791; 17929853; 19056867; 19850743; 20395239; 20548946; 23687415; 23824909,,,,,,,,,,,,,,,OGG:3000064081,,20140408,protein-coding,,,,phenazine biosynthesis-like protein domain containing,,,,,,,,,,,,,Other designations: MAWD-binding protein|phenazine biosynthesis-like domain-containing protein,,PBLD,,,,,,,,,,,,,,,,,,,,,,,64081,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,PBLD,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_86327,antifungal drug,,Any antifungal agent used to prevent or treat fungal infections in humans or animals.,false,,,http://purl.obolibrary.org/obo/CHEBI_35718,,,,,,,,,,,,,,,,,,,,Wikipedia:Antifungal,,Any antifungal agent used to prevent or treat fungal infections in humans or animals.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:86327,,,,,,,,,,,,,,,,,,,,,,antifungal drug,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001503,Rac3,,,false,,,http://purl.obolibrary.org/obo/IMR_0000297,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001503,,,,,,,,,,,,,,,,,,,,,,Rac3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OBI_0000185,imaging assay,,An imaging assay is an assay to produce a picture of an entity.,false,,,http://purl.obolibrary.org/obo/OBI_0000070,,,,,,,,,,,,,,,,,,,,,,An imaging assay is an assay to produce a picture of an entity.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,OBI:0000185,,,,,,,,,,,,,,,,,,,,,,imaging assay,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000064344,HIF3A,,Other designations: HIF3-alpha-1|PAS domain-containing protein 7|basic-helix-loop-helix-PAS protein MOP7|class E basic helix-loop-helix protein 17|hypoxia-inducible factor 3-alpha|inhibitory PAS domain protein|member of PAS protein 7,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,PASD7|IPAS|MOP7|bHLHe17|HIF-3A,,,,,,,,,,,,19,,,,,,HGNC:15825|Ensembl:ENSG00000124440|Vega:OTTHUMG00000141296|MIM:609976|HPRD:17104,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"hypoxia inducible factor 3, alpha subunit",,,19q13.32,,,,,,,,,,,,,,,,"GO_0003677 (EC: IEA); GO_0003700 (EC: IEA); GO_0003713 (EC: IDA, PMID: 11573933); GO_0003714 (EC: IDA, PMID: 11573933); GO_0004871 (EC: IEA); GO_0005654 (EC: TAS); GO_0005829 (EC: TAS); GO_0006357 (EC: IDA, PMID: 11573933); GO_0006366 (EC: IEA); GO_0046983 (EC: IEA); GO_0061418 (EC: TAS); GO_0071456 (EC: IDA, Qualifier: NOT, PMID: 11573933); GO_0071456 (EC: TAS)",,,,,,,,,PMID: 8889548; 11573933; 11734856; 12119283; 12477932; 12538644; 14702039; 15319539; 15474027; 16126907; 16182248; 16344560; 16775626; 17121608; 17998805; 18029348; 19694616; 20416395; 20551700; 21069422; 21404626; 21479871; 23451260; 23485455,,,,,,,,,,,,,,,OGG:3000064344,,,,,,,"hypoxia inducible factor 3, alpha subunit",,,,,,,,,,,,,Other designations: HIF3-alpha-1|PAS domain-containing protein 7|basic-helix-loop-helix-PAS protein MOP7|class E basic helix-loop-helix protein 17|hypoxia-inducible factor 3-alpha|inhibitory PAS domain protein|member of PAS protein 7,,HIF3A,,,,,,,,,,,,,,,,,,,,,,,64344,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,HIF3A,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0003536,eosinophilic granular degeneration [Liver Pathological Findings] [eosinogranular degeneration (moderate) ],,"Eosinophilic granular degeneration [Liver PathologicalFindings]  is a type of finding observed in hepatocytes. Lesions are observed in the form that the cytoplasm presents eosinophilic granules based on pathological morphology.  The degree is moderate.
This finding is observable as a result of increasing peroxisome caused by PPAR.",false,,,http://purl.obolibrary.org/obo/TXPO_0003523,,,,,,,,,,,,,,,,,,,,,,"Eosinophilic granular degeneration [Liver PathologicalFindings]  is a type of finding observed in hepatocytes. Lesions are observed in the form that the cytoplasm presents eosinophilic granules based on pathological morphology.  The degree is moderate.
This finding is observable as a result of increasing peroxisome caused by PPAR.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003536,,,,,,,,,,,,,,,,,,,,,,eosinophilic granular degeneration [Liver Pathological Findings] [eosinogranular degeneration (moderate) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003539,phosphatidylcholine efflux,,Phosphatidylcholine efflux is a subtype of moving A to the outside of B: A process that excretes phosphatidylcholine to the outside of a cell or organelle.,false,,,http://purl.obolibrary.org/obo/TXPO_0002588,,,,,,,,,,,,,,,,,,,,,,Phosphatidylcholine efflux is a subtype of moving A to the outside of B: A process that excretes phosphatidylcholine to the outside of a cell or organelle.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_64482,,,,,,,,,,,,,,,,,,,TXPO:0003539,,,,,,,,,,,,,,,,,,,,,,phosphatidylcholine efflux,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003537,eosinophilic granular degeneration [Liver Pathological Findings] [eosinogranular degeneration (severe) ],,"Eosinophilic granular degeneration [Liver PathologicalFindings]  is a type of finding observed in hepatocytes. Lesions are observed in the form that the cytoplasm presents eosinophilic granules based on pathological morphology. The degree is severe.
This finding is observable as a result of increasing peroxisome caused by PPAR.",false,,,http://purl.obolibrary.org/obo/TXPO_0003523,,,,,,,,,,,,,,,,,,,,,,"Eosinophilic granular degeneration [Liver PathologicalFindings]  is a type of finding observed in hepatocytes. Lesions are observed in the form that the cytoplasm presents eosinophilic granules based on pathological morphology. The degree is severe.
This finding is observable as a result of increasing peroxisome caused by PPAR.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003537,,,,,,,,,,,,,,,,,,,,,,eosinophilic granular degeneration [Liver Pathological Findings] [eosinogranular degeneration (severe) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003534,regulator of tumor cell proliferation,,A role played by the entity which regulates the process of tumor cell proliferation.,false,,,http://purl.obolibrary.org/obo/TXPO_0003159,,,,,,,,,http://purl.obolibrary.org/obo/GO_0008283,,,,,,,,,,,,,A role played by the entity which regulates the process of tumor cell proliferation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003534,,,,,,,,,,,,,,,,,,,,,,regulator of tumor cell proliferation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003531,SGPL1 - tumor cell proliferation regulating factor (human) [Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002090,,,,,,,,,,,,,,,,,,,,http://omim.org/entry/603729|PMID:17090686|PMID:26886371,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003534,,,,,,,,,,TXPO:0003531,,,,,,,,,,,,,,,,,,,,,,SGPL1 - tumor cell proliferation regulating factor (human) [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003535,eosinophilic granular degeneration [Liver Pathological Findings] [eosinogranular degeneration (mild) ],,"Eosinophilic granular degeneration [Liver PathologicalFindings]  is a type of finding observed in hepatocytes. Lesions are observed in the form that the cytoplasm presents eosinophilic granules based on pathological morphology.  The degree is mild.
This finding is observable as a result of increasing peroxisome caused by PPAR.",false,,,http://purl.obolibrary.org/obo/TXPO_0003523,,,,,,,,,,,,,,,,,,,,,,"Eosinophilic granular degeneration [Liver PathologicalFindings]  is a type of finding observed in hepatocytes. Lesions are observed in the form that the cytoplasm presents eosinophilic granules based on pathological morphology.  The degree is mild.
This finding is observable as a result of increasing peroxisome caused by PPAR.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003535,,,,,,,,,,,,,,,,,,,,,,eosinophilic granular degeneration [Liver Pathological Findings] [eosinogranular degeneration (mild) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003533,refolding-unfolding imbalance (moderate),,Refolding-unfolding imbalance (moderate) is a subtype of refolding-unfolding imbalance: A process that lacks a balance between protein refolding and unfolding moderately.,false,,,http://purl.obolibrary.org/obo/TXPO_0002459,,,,,,,,,,,,,,,,,,,,,,Refolding-unfolding imbalance (moderate) is a subtype of refolding-unfolding imbalance: A process that lacks a balance between protein refolding and unfolding moderately.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003533,,,,,,,,,,,,,,,,,,,,,,refolding-unfolding imbalance (moderate),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003532,refolding-unfolding imbalance (mild),,Refolding-unfolding imbalance (mild) is a subtype of refolding-unfolding imbalance: A process that lacks a balance between protein refolding and unfolding mildly.,false,,,http://purl.obolibrary.org/obo/TXPO_0002459,,,,,,,,,,,,,,,,,,,,,,Refolding-unfolding imbalance (mild) is a subtype of refolding-unfolding imbalance: A process that lacks a balance between protein refolding and unfolding mildly.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003532,,,,,,,,,,,,,,,,,,,,,,refolding-unfolding imbalance (mild),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003538,vacuolation [Liver Pathological Findings][Lipidosis(mild)],,"Fatty change [Liver PathologicalFindings] is a type of finding observed in hepatocytes. Lesions are observed as lipid droplets consisting of neutral fat in the hepatocyte based on pathological morphology.
This finding is observable in the course of lipidosis. The degree is mild.",false,,,http://purl.obolibrary.org/obo/TXPO_0003499,,,,,,,,,,,,,,,,,,,,,,"Fatty change [Liver PathologicalFindings] is a type of finding observed in hepatocytes. Lesions are observed as lipid droplets consisting of neutral fat in the hepatocyte based on pathological morphology.
This finding is observable in the course of lipidosis. The degree is mild.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003538,,,,,,,"A metabolic disorder of neutral fat causes fatty change.
Lipid droplets consisting of large and small neutral fats (triglycerides) increase in the cytoplasm of hepatocytes.
In the case of large lipid droplets, the uneven distribution of nuclei is observed, but in the case of small loose droplets (microvesicular fatty change), uneven distribution of nuclei is not observed.
According to the distribution, it classifies into centrilobular, periportal, and diffuse type.",,,,,,,,,,,,,,,vacuolation [Liver Pathological Findings][Lipidosis(mild)],,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005737,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003530,Sgpl1 - lipid metabolism regulator (mouse)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003529,,,,,,,,,,,,,,,,,,,,http://omim.org/entry/603729|PMID:20097939,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002358,,,,,,,,,,TXPO:0003530,,,,,,,,,,,,,,,,,,,,,,Sgpl1 - lipid metabolism regulator (mouse)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010540,40S ribosomal protein S15,RIG protein|40S small ribosomal protein 15,,false,,,http://purl.obolibrary.org/obo/IMR_0000896,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,RIG protein|40S small ribosomal protein 15,,,,,IMR:0010540,,,,,,,,,,,,,,,,,,,,,,40S ribosomal protein S15,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010517,Heterogeneous nuclear ribonucleoprotein M,ROM|hnRNP M,,false,,,http://purl.obolibrary.org/obo/IMR_0010024,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ROM|hnRNP M,,,,,IMR:0010517,,,,,,,,,,,,,,,,,,,,,,Heterogeneous nuclear ribonucleoprotein M,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001102,importin 7,RanBP7,,false,,,http://purl.obolibrary.org/obo/IMR_0100010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,RanBP7,,,,,IMR:0001102,,,,,,,,,,,,,,,,,,,,,,importin 7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001954,RhoGEF,Rho guanine nucleotide exchange factor,,false,,,http://purl.obolibrary.org/obo/IMR_0000433,,,,,,,,,,,,,,,,,,,,GO:0005089,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Rho guanine nucleotide exchange factor,,,,,IMR:0001954,,,,,,,,,,,,,,,,,,,,,,RhoGEF,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/NCIT_C18121,tumorigenesis,Oncogenesis,A pathologic process that involves the transformation of normal cells to a neoplastic state and resulting in polyclonal or monoclonal neoplastic cell proliferation.,false,,,http://purl.obolibrary.org/obo/TXPO_0000134,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C18121|ncit:C18121,,A pathologic process that involves the transformation of normal cells to a neoplastic state and resulting in polyclonal or monoclonal neoplastic cell proliferation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Oncogenesis,,,A pathologic process that involves the transformation of normal cells to a neoplastic state and resulting in polyclonal or monoclonal neoplastic cell proliferation.,,NCIT:C18121,,,,,,,,,,,,,,,,,,,,,,tumorigenesis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000051129,ANGPTL4,,Other designations: PPARG angiopoietin related protein|angiopoietin-related protein 4|fasting-induced adipose factor|hepatic angiopoietin-related protein|hepatic fibrinogen/angiopoietin-related protein|peroxisome proliferator-activated receptor (PPAR) gamma induced angiopoietin-related protein,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,HARP|HFARP|NL2|UNQ171|ARP4|pp1158|FIAF|ANGPTL2|PGAR,,,,,,,,,,,,19,,,,,,HPRD:16173|MIM:605910|Vega:OTTHUMG00000182273|Ensembl:ENSG00000167772|HGNC:16039,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,angiopoietin-like 4,,,19p13.3,,,,,,,,,,,,,,,,"GO_0001525 (EC: IEA); GO_0001666 (EC: NAS, PMID:12707035); GO_0004857 (EC: ISS); GO_0005515 (EC: IPI); GO_0005576 (EC: IDA, PMID:10698685); GO_0005576 (EC: TAS); GO_0005578 (EC: IEA); GO_0005615 (EC: IDA, PMID:10698685); GO_0030154 (EC: IEA); GO_0043066 (EC: IDA, PMID:10698685); GO_0044255 (EC: TAS); GO_0044281 (EC: TAS); GO_0045766 (EC: TAS, PMID:11953136); GO_0051005 (EC: IDA, PMID:19542565); GO_0051260 (EC: IEA); GO_0070328 (EC: ISS); GO_0072562 (EC: IDA); GO_2000352 (EC: IEA)",,,,,,,,,PMID:8125298; 10698685; 10866690; 11953136; 12015030; 12438262; 12477932; 12707035; 12975309; 14570927; 14583458; 15190076; 15284220; 15292369; 15489334; 15579652; 15837923; 15863837; 15870027; 16049480; 16081640; 16272564; 16303743; 16531751; 17049073; 17068295; 17088546; 17130448; 17207965; 17322881; 18029348; 18340008; 18394990; 18433990; 18442626; 18599063; 18634015; 18728224; 18809343; 18940399; 18974381; 19019854; 19028676; 19060906; 19074989; 19246456; 19270337; 19318355; 19342599; 19542565; 19628874; 19775228; 19826106; 19878569; 19890028; 19913121; 20025870; 20162021; 20454689; 20595396; 20628086; 20660728; 20664963; 20667978; 20686565; 20729546; 20829508; 20927337; 20972945; 21109191; 21151138; 21212665; 21217681; 21308352; 21397862; 21398697; 21421336; 21489049; 21518214; 21596930; 21674552; 21709421; 21714923; 21841165; 21860410; 21937683; 21966511; 22078753; 22086875; 22307217; 22458843; 22462789; 22549372; 22573825; 22639947; 22661548; 22729570; 22732211; 22773878; 22791755; 22820186; 22972030; 23056264; 23183503; 23208498; 23283507; 23319744; 23339868; 23387337; 23518684; 23617883; 23640487; 23959876; 23960078; 24317117,,,,,,,,,,,,,,,OGG:3000051129,,,,,,,angiopoietin-like 4,,,,,,,,,,,,,Other designations: PPARG angiopoietin related protein|angiopoietin-related protein 4|fasting-induced adipose factor|hepatic angiopoietin-related protein|hepatic fibrinogen/angiopoietin-related protein|peroxisome proliferator-activated receptor (PPAR) gamma induced angiopoietin-related protein,,ANGPTL4,,,,,,,,,,,,,,,,,,,,,,,51129,PP1158,,,,,,,9606,,,,,,,,,,,,,,,,,,,ANGPTL4,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000177,beta-catenin,,named 'beta-catenin family' formerly.,false,,,http://purl.obolibrary.org/obo/TXPO_0003158,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003688|http://purl.obolibrary.org/obo/TXPO_0000330,,,,,,,,,,IMR:0000177,,,,,,,,,,,,,,,,,,,,named 'beta-catenin family' formerly.,,beta-catenin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_63248,oxidising agent,oxidiser|oxidant|oxidizer,A substance that removes electrons from another reactant in a redox reaction.,false,,,http://purl.obolibrary.org/obo/CHEBI_51086,,,,,,,,,,,,,,,,,,,,,,A substance that removes electrons from another reactant in a redox reaction.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,oxidiser|oxidant|oxidizer,,,CHEBI:63248,,,,,,,,,,,,,,,,,,,,,,oxidising agent,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004016,Dissociation of FLCN:FNIP complex,,Dissociation of FLCN:FNIP complex is a subtype of detaching: A process that disaggregates the FLCN:FNIP complex.,false,,,http://purl.obolibrary.org/obo/TXPO_0000462,,,,,,,,,,,,,,,,,,,,,,Dissociation of FLCN:FNIP complex is a subtype of detaching: A process that disaggregates the FLCN:FNIP complex.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003157|http://purl.obolibrary.org/obo/TXPO_0000878,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000713,,,,,,,,,,,TXPO:0004016,,,,,,,,,,,,,,,,,,,,,,Dissociation of FLCN:FNIP complex,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004013,MAP2K6 [Hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000837|http://purl.obolibrary.org/obo/TXPO_1000234,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:26399|NCBI-Human-GeneID:5608|NCBI-Rat-GeneID:114495|PMID:24619413|PMID:12784337|PMID:16951197,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004013,,,,,,,,,,,,,,,,,,,,,,MAP2K6 [Hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004017,FAS (canonical) [Hepatocarcinogenesis],CD95 [Hepatocarcinogenesis]|Fas cell surface death receptor [Hepatocarcinogenesis],,false,,,http://purl.obolibrary.org/obo/TXPO_0000837|http://purl.obolibrary.org/obo/TXPO_1000139,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:355|NCBI-Mouse-GeneID:14102|NCBI-Rat-GeneID:246097|PMID:31623280|PMID:20505730,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CD95 [Hepatocarcinogenesis]|Fas cell surface death receptor [Hepatocarcinogenesis],,,,,TXPO:0004017,,,,,,,,,,,,,,,,,,,,,,FAS (canonical) [Hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004012,Adh1 (mouse)[lipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001094,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:11522,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000125,,,,,,,,,,,,,TXPO:0004012,,,,,,,,,,,,,,,,,,,,,,Adh1 (mouse)[lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004010,hypofunction of endocytic recycling [Phospholipidosis (severe) ],,"Hypofunction of eidocytic recycling from ER to mitochondrial membrane is a subtype of hypofunction of transport: A process that performs a decreased or insufficient endocytic recycling.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0004009,,,,,,,,,,,,,,,,,,,,,,"Hypofunction of eidocytic recycling from ER to mitochondrial membrane is a subtype of hypofunction of transport: A process that performs a decreased or insufficient endocytic recycling.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,http://purl.obolibrary.org/obo/GO_0032456,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004010,,,,,,,,,,,,,,,,,,,,,,hypofunction of endocytic recycling [Phospholipidosis (severe) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004018,Fnip2(mouse)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003278|http://purl.obolibrary.org/obo/TXPO_0003837,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:329679|PMID:24272703|PMID:28039480,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004018,,,,,,,,,,,,,,,,,,,,,,Fnip2(mouse)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004014,negative regulation of release of arachidonic acid from cell membrane,,"Negative regulation of release of arachidonic acid from cell membrane is a subtype of negative regulation process: A process  that stops, prevents, or reduces the frequency, rate or extent of the release of arachidonic acid from cell membrane.",false,,,http://purl.obolibrary.org/obo/TXPO_0000369,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of release of arachidonic acid from cell membrane is a subtype of negative regulation process: A process  that stops, prevents, or reduces the frequency, rate or extent of the release of arachidonic acid from cell membrane.",,,http://purl.obolibrary.org/obo/TXPO_0000457,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004014,,,,,,,,,,,,,,,,,,,,,,negative regulation of release of arachidonic acid from cell membrane,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004015,Dissociation of FLCN:FNIP complex [Phospholipidosis (severe)],,"Dissociation of FLCN:FNIP complex is a subtype of detaching: A process that disaggregates the FLCN:FNIP complex.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0004016,,,,,,,,,,,,,,,,,,,,PMID:25775561,,"Dissociation of FLCN:FNIP complex is a subtype of detaching: A process that disaggregates the FLCN:FNIP complex.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004049,http://purl.obolibrary.org/obo/TXPO_0003894|http://purl.obolibrary.org/obo/TXPO_0004018|http://purl.obolibrary.org/obo/TXPO_0002579,,,,,,http://purl.obolibrary.org/obo/TXPO_0004034,,,,,,,,,,,TXPO:0004015,,,,,,,,,,,,,,,,,,,,,,Dissociation of FLCN:FNIP complex [Phospholipidosis (severe)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004011,ADH1 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0001094,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:11522,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000125,,,,,,,,,,,,,TXPO:0004011,,,,,,,,,,,,,,,,,,,,,,ADH1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004019,FLCN(canonical)[Phospholipidosis],folliculin [Phospholipidosis],,false,,,http://purl.obolibrary.org/obo/TXPO_0003213|http://purl.obolibrary.org/obo/TXPO_1000148,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:216805|NCBI-Rat-GeneID:303185|NCBI-Human-GeneID:201163|PMID:17028174|PMID:26334087|PMID:29848618,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004043,,,,,folliculin [Phospholipidosis],,,,,TXPO:0004019,,,,,,,"This gene is located within the Smith-Magenis syndrome region on chromosome 17. Mutations in this gene are associated with Birt-Hogg-Dube syndrome, which is characterized by fibrofolliculomas, renal tumors, lung cysts, and pneumothorax. Alternative splicing of this gene results in two transcript variants encoding different isoforms. [provided by RefSeq, Jul 2008]",,,,,,,,,,,,,,,FLCN(canonical)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000029078,NDUFAF4,,"Other designations: NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, assembly factor 4|NADH dehydrogenase [ubiquinone] 1 alpha subcomplex assembly factor 4|hormone-regulated proliferation-associated protein of 20 kDa|hormone-regulated proliferation-associated protein, 20 kDa",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,HRPAP20|My013|bA22L21.1|C6orf66,,,,,,,,,,,,6,,,,,,Ensembl:ENSG00000123545|Vega:OTTHUMG00000015246|HPRD:10795|MIM:611776|HGNC:21034,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"NADH dehydrogenase (ubiquinone) complex I, assembly factor 4",,,6q16.1,,,,,,,,,,,,,,,,"GO_0005515 (EC: IPI, PMID: 19463981); GO_0005516 (EC: IEA); GO_0005739 (EC: IDA); GO_0031966 (EC: IDA, PMID: 19463981); GO_0032981 (EC: IMP, PMID: 18179882)",,,,,,,,,PMID: 11042152; 12477932; 14574404; 14871833; 15342556; 15489334; 16344560; 17001319; 17909269; 18029348; 18179882; 19352385; 19463981; 20877624; 21890473; 21906983; 21963094; 22939629; 23670274; 24250222,,,,,,,,,,,,,,,OGG:3000029078,,,,,,,"NADH dehydrogenase (ubiquinone) complex I, assembly factor 4",,,,,,,,,,,,,"Other designations: NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, assembly factor 4|NADH dehydrogenase [ubiquinone] 1 alpha subcomplex assembly factor 4|hormone-regulated proliferation-associated protein of 20 kDa|hormone-regulated proliferation-associated protein, 20 kDa",,NDUFAF4,,,,,,,,,,,,,,,,,,,,,,,29078,HSPC125,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,NDUFAF4,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0100767,Wnt-2b,Wnt-13,,false,,,http://purl.obolibrary.org/obo/IMR_0000003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Wnt-13,,,,,IMR:0100767,,,,,,,,,,,,,,,,,,,,,,Wnt-2b,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100449,ERK2,Extracellular signal-regulated kinase 2|MAPK 2|p42 MAPK|MAP kinase 2,,false,,,http://purl.obolibrary.org/obo/IMR_0000227,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Extracellular signal-regulated kinase 2|MAPK 2|p42 MAPK|MAP kinase 2,,,,,IMR:0100449,,,,,,,,,,,,,,,,,,,,,,ERK2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100470,SCF ubiquitin ligase complex,Skp1/Cul1/F-box protein complex,SCF ubiquitin ligase complex is a subtype of molecular complex.,false,,,http://purl.obolibrary.org/obo/TXPO_0002107,,,,,,,,,,,,,,,,,,,,,,SCF ubiquitin ligase complex is a subtype of molecular complex.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000266,,,,,Skp1/Cul1/F-box protein complex,,,,,IMR:0100470,,,,,,,,,,,,,,,,,,,,,,SCF ubiquitin ligase complex,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000253314,EIF4E1B,,Other designations: eukaryotic translation initiation factor 4E type 1B,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,5,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,eukaryotic translation initiation factor 4E family member 1B,,,5q35.2,,,,,,,,,,,,,,,,GO_0003743 (EC: IEA); GO_0005737 (EC: IEA); GO_0005845 (EC: ISS); GO_0006417 (EC: IEA),,,,,,,,,PMID:8889548; 14702039; 15372022; 16191198; 16344560,,,,,,,,,,,,,,,OGG:3000253314,,,,,,,eukaryotic translation initiation factor 4E family member 1B,,,,,,,,,,,,,Other designations: eukaryotic translation initiation factor 4E type 1B,,EIF4E1B,,,,,,,,,,,,,,,,,,,,,,,253314,,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF4E1B,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_76840,"EC 1.14.99.* (miscellaneous oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen) inhibitor","EC 1.14.99.* inhibitors|EC 1.14.99.* inhibitor|miscellaneous oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen (EC 1.14.99.*) inhibitor|miscellaneous oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen (EC 1.14.99.*) inhibitors|EC 1.14.99.* (miscellaneous oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen) inhibitors","An EC 1.14.* (oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen) inhibitor that interferes with the action of any enzyme in the EC 1.14.99.* (miscellaneous) category.",false,,,http://purl.obolibrary.org/obo/CHEBI_76741,,,,,,,,,,,,,,,,,,,,,,"An EC 1.14.* (oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen) inhibitor that interferes with the action of any enzyme in the EC 1.14.99.* (miscellaneous) category.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"EC 1.14.99.* inhibitors|EC 1.14.99.* inhibitor|miscellaneous oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen (EC 1.14.99.*) inhibitor|miscellaneous oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen (EC 1.14.99.*) inhibitors|EC 1.14.99.* (miscellaneous oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen) inhibitors",,,,,,,,,,,,,,,,,,,,,CHEBI:76840,,,,"EC 1.14.99.* (miscellaneous oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen) inhibitor",,CHEBI:76840,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000002259,FGF14,,Other designations: bA397O8.2|fibroblast growth factor homologous factor 4,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,FHF-4|FHF4|FGF-14|SCA27,,,,,,,,,,,,13,,,,,,MIM:601515|HGNC:3671|HPRD:03305,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,fibroblast growth factor 14,,,13q34,,,,,,,,,,,,,,,,"GO_0005104 (EC: IDA, Qualifier: NOT, PMID: 12815063); GO_0005576 (EC: IEA); GO_0005634 (EC: IEA); GO_0007165 (EC: TAS, PMID: 8790420); GO_0007254 (EC: IPI, PMID: 12815063); GO_0007267 (EC: TAS, PMID: 8790420); GO_0007268 (EC: IEA); GO_0007399 (EC: IEA); GO_0008083 (EC: IEA); GO_0008201 (EC: IDA, PMID: 12815063); GO_0008219 (EC: IEA); GO_0008344 (EC: IEA); GO_0008543 (EC: IDA, Qualifier: NOT, PMID: 12815063); GO_0010765 (EC: IEA); GO_0050905 (EC: IEA)",,,,,,,,,PMID: 8790420; 12123606; 12364586; 12477932; 12489043; 12815063; 15057823; 15148151; 15199049; 15365159; 15470364; 16166153; 16211615; 17221845; 17236779; 20379614; 22579694; 23166209; 23509962; 23551011; 23640885,,,,,,,,,,,,,,,OGG:3000002259,,,,,,,fibroblast growth factor 14,,,,,,,,,,,,,Other designations: bA397O8.2|fibroblast growth factor homologous factor 4,,FGF14,,,,,,,,,,,,,,,,,,,,,,,2259,RP11-397O8.6,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,FGF14,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0100117,gamma-aminobutyric acid,4-Amino-butanoic acid|GABA|4-aminobutanoic acid,,false,,,http://purl.obolibrary.org/obo/CHEBI_33709,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_25512,,,,IMR:0200145,4-Amino-butanoic acid|GABA|4-aminobutanoic acid,,,,,IMR:0100117,,,,,,,,,,,,,,,,,,,,,,gamma-aminobutyric acid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000001806,DPYD,,Other designations: dihydropyrimidine dehydrogenase [NADP(+)]|dihydrothymine dehydrogenase|dihydrouracil dehydrogenase,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,DHP|DHPDHASE|DPD,,,,,,,,,,,,1,,,,,,MIM:612779|HGNC:3012|Vega:OTTHUMG00000039683|Ensembl:ENSG00000188641|HPRD:02036,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,dihydropyrimidine dehydrogenase,,,1p22,,,,,,,,,,,,,,,,"GO_0004158 (EC: IEA); GO_0005737 (EC: IDA, PMID: 1512248); GO_0005829 (EC: IDA, PMID: 9348115); GO_0005829 (EC: TAS); GO_0006145 (EC: IMP, PMID: 11988088); GO_0006206 (EC: TAS); GO_0006208 (EC: IMP, PMID: 11988088); GO_0006208 (EC: ISS); GO_0006210 (EC: IDA, PMID: 10410956); GO_0006212 (EC: IDA, PMID: 1512248); GO_0006214 (EC: IDA, PMID: 1512248); GO_0006222 (EC: IEA); GO_0017113 (EC: IDA, PMID: 10410956); GO_0017113 (EC: IMP, PMID: 11988088); GO_0017113 (EC: ISS); GO_0017113 (EC: TAS); GO_0019483 (EC: IEA); GO_0042803 (EC: IDA, PMID: 1512248); GO_0042803 (EC: ISS); GO_0044281 (EC: TAS); GO_0046135 (EC: TAS); GO_0046872 (EC: IEA); GO_0050660 (EC: ISS); GO_0050661 (EC: ISS); GO_0051539 (EC: IEA); GO_0055086 (EC: TAS)",,,,,,,,,PMID: 1512248; 1544906; 1901022; 2319593; 2528450; 3335642; 7713523; 8083224; 8221682; 8892022; 9135003; 9170156; 9266349; 9348115; 9439663; 9464498; 10410956; 10606257; 10923099; 11072080; 11267945; 11555601; 11862480; 11895907; 11988088; 11992400; 12025228; 12047484; 12209976; 12360106; 12477932; 12576451; 12822071; 12844478; 12851836; 14519634; 14562021; 14654904; 14702180; 15017333; 15025795; 15069545; 15102667; 15132136; 15254700; 15316940; 15709212; 15939134; 15993511; 15999119; 16021908; 16132996; 16328315; 16344560; 16361556; 16771603; 16786143; 16806531; 16820886; 16969493; 17000685; 17046731; 17121937; 17165084; 17203168; 17335544; 17375478; 17377791; 17397246; 17417073; 17445431; 17582309; 17582310; 17612628; 17699798; 17828463; 17848752; 17876700; 17905396; 18004243; 18075467; 18225548; 18299612; 18347391; 18443386; 18452418; 18537153; 18619742; 18705276; 18937829; 19020767; 19104657; 19154585; 19178088; 19288105; 19295264; 19296131; 19343046; 19473056; 19530960; 19546880; 19571608; 19636001; 19724871; 19795123; 19822137; 19858398; 19898482; 19956635; 20037211; 20157331; 20379614; 20385995; 20407238; 20453000; 20507294; 20530282; 20544545; 20570913; 20647221; 20647710; 20653680; 20665215; 20714149; 20714877; 20803296; 20809970; 20819423; 20837458; 21057378; 21111509; 21114665; 21498394; 21507922; 21612699; 21822266; 21919605; 21963094; 21965773; 21987572; 22003227; 22006578; 22143355; 22199347; 22270332; 22306127; 22339448; 22490566; 22505724; 22510597; 22593457; 22641663; 22688191; 22939629; 23313143; 23401991; 23453885; 23588312; 23603345; 23736036; 23781135; 23930673; 23960437; 23974872; 24104963,,,,,,,,,,,,,,,OGG:3000001806,,,,,,,dihydropyrimidine dehydrogenase,,,,,,,,,,,,,Other designations: dihydropyrimidine dehydrogenase [NADP(+)]|dihydrothymine dehydrogenase|dihydrouracil dehydrogenase,,DPYD,,,,,,,,,,,,,,,,,,,,,,,1806,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,DPYD,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001939,EIF2D,,Other designations: hepatocellular carcinoma-associated antigen 56|ligatin,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,HCA56|LGTN,,,,,,,,,,,,1,,,,,,Vega:OTTHUMG00000036344|HPRD:01057|Ensembl:ENSG00000143486|HGNC:6583|MIM:613709,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,eukaryotic translation initiation factor 2D,,,1q32.1,,,,,,,,,,,,,,,,"GO_0003743 (EC: IDA); GO_0004872 (EC: TAS, PMID:2482295); GO_0005634 (EC: IDA); GO_0005737 (EC: IDA); GO_0006886 (EC: TAS, PMID:2482295)",,,,,,,,,PMID:2482295; 7085778; 7299841; 8125298; 12097419; 12477932; 14702039; 15302935; 17353931; 20566627; 21145461; 22939629; 23277564; 24250222,,,,,,,,,,,,,,,OGG:3000001939,,,,,,,eukaryotic translation initiation factor 2D,,,,,,,,,,,,,Other designations: hepatocellular carcinoma-associated antigen 56|ligatin,,EIF2D,,,,,,,,,,,,,,,,,,,,,,,1939,RP11-534L20.3,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF2D,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_76773,EC 3.1.1.* (carboxylic ester hydrolase) inhibitor,EC 3.1.1.* inhibitors|EC 3.1.1.* (carboxylic ester hydrolase) inhibitors|carboxylic ester hydrolase (EC 3.1.1.*) inhibitors|carboxylic ester hydrolase (EC 3.1.1.*) inhibitor|EC 3.1.1.* inhibitor,An EC 3.1.* (ester hydrolase) inhibitor that interferes with the action of a carboxylic ester hydrolase (EC 3.1.1.*).,false,,,http://purl.obolibrary.org/obo/CHEBI_76760,,,,,,,,,,,,,,,,,,,,,,An EC 3.1.* (ester hydrolase) inhibitor that interferes with the action of a carboxylic ester hydrolase (EC 3.1.1.*).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,EC 3.1.1.* inhibitors|EC 3.1.1.* (carboxylic ester hydrolase) inhibitors|carboxylic ester hydrolase (EC 3.1.1.*) inhibitors|carboxylic ester hydrolase (EC 3.1.1.*) inhibitor|EC 3.1.1.* inhibitor,,,,,,,,,,,,,,,,,,,,,CHEBI:76773,,,,EC 3.1.1.* (carboxylic ester hydrolase) inhibitor,,CHEBI:76773,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_37527,acid,,An acid is a molecular entity capable of donating a hydron (Bronsted acid) or capable of forming a covalent bond with an electron pair (Lewis acid).,false,,,http://purl.obolibrary.org/obo/CHEBI_51086,,,,,,,,,,,,,,,,,,,,,,An acid is a molecular entity capable of donating a hydron (Bronsted acid) or capable of forming a covalent bond with an electron pair (Lewis acid).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:37527,,,,,,,,,,,,,,,,,,,,,,acid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000007364,UGT2B7,,"Other designations: 3,4-catechol estrogen specific|3,4-catechol estrogen-specific UDPGT|UDP glucuronosyltransferase 2B7|UDP-glucuronosyltransferase 2B7|UDP-glucuronosyltransferase 2B9|UDP-glucuronyltransferase, family 2, beta-7|UDPGT 2B7|UDPGTh-2",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,UDPGTH2|UDPGT2B7|UDPGT 2B9|UGT2B9,,,,,,,,,,,,4,,,,,,Ensembl:ENSG00000171234|MIM:600068|Vega:OTTHUMG00000129404|HGNC:12554|HPRD:02508,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"UDP glucuronosyltransferase 2 family, polypeptide B7",,,4q13,,,,,,,,,,,,,,,,"GO_0001972 (EC: IDA, Qualifier: NOT); GO_0005789 (EC: IEA); GO_0006629 (EC: TAS, PMID: 2159463); GO_0008209 (EC: IDA, PMID: 17442341); GO_0015020 (EC: IDA, PMID: 17442341); GO_0016020 (EC: TAS, PMID: 2159463); GO_0016021 (EC: IEA); GO_0052695 (EC: IDA, PMID: 17442341)",,,,,,,,,PMID: 2159463; 7835904; 8125298; 8674824; 10024527; 10222050; 10748067; 10779377; 10833461; 11186130; 11883901; 12185559; 12477932; 12623074; 12629580; 12695355; 12746330; 12811366; 14660172; 14871856; 15001974; 15318931; 15319348; 15320866; 15472229; 15489334; 15611481; 15615884; 15689421; 15815621; 16103897; 16397224; 16466707; 16580900; 16595916; 16849011; 17115150; 17178267; 17241877; 17263731; 17329852; 17339869; 17363580; 17429314; 17440429; 17442341; 17446261; 17579197; 17670842; 17687269; 17706742; 17724700; 17924828; 17965522; 17978490; 18052087; 18161889; 18315786; 18496127; 18569595; 18597651; 18622261; 18622263; 18641546; 18647858; 18719619; 18946804; 19116784; 19225446; 19244109; 19289110; 19343046; 19352303; 19408577; 19424794; 19494809; 19574343; 19628728; 19644937; 19730281; 19779319; 19898482; 19956635; 20008037; 20056642; 20064729; 20142249; 20147615; 20216122; 20297805; 20379614; 20565459; 20567810; 20634197; 20679960; 20734064; 20814162; 20860463; 20973683; 21044367; 21056984; 21123165; 21415305; 21856742; 21881541; 21988832; 22028316; 22092298; 22188362; 22240840; 22462748; 22676193; 23099353; 23131697; 23223495; 23230132; 23251661; 23263737; 23700788; 23726609,,,,,,,,,,,,,,,OGG:3000007364,,,,,,,"UDP glucuronosyltransferase 2 family, polypeptide B7",,,,,,,,,,,,,"Other designations: 3,4-catechol estrogen specific|3,4-catechol estrogen-specific UDPGT|UDP glucuronosyltransferase 2B7|UDP-glucuronosyltransferase 2B7|UDP-glucuronosyltransferase 2B9|UDP-glucuronyltransferase, family 2, beta-7|UDPGT 2B7|UDPGTh-2",,UGT2B7,,,,,,,,,,,,,,,,,,,,,,,7364,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,UGT2B7,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0001618,PPAR alpha inactivation [Lipidosis],,"PPARalpha inactivation is a subtype of inactivation: A process that changes the activity of the activating PPAR alpha (Peroxisome Proliferator Activated Receptor Alpha) with a nuclear receptor role to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.|PMID:25450203",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0001571,,,,,,,,,,,,,,,,,,,"Reactome

The set of genes regulated by PPAR-alpha is not fully known in humans, however many examples have been found in mice. Genes directly activated by PPAR-alpha contain peroxisome proliferator receptor elements (PPREs) in their promoters and include:
1) genes involved in fatty acid oxidation and ketogenesis (Acox1, Cyp4a, Acadm, Hmgcs2);
2) genes involved in fatty acid transport (Cd36, , Slc27a1, Fabp1, Cpt1a, Cpt2);
3) genes involved in producing fatty acids and very low density lipoproteins (Me1, Scd1);
4) genes encoding apolipoproteins (Apoa1, Apoa2, Apoa5);
5) genes involved in triglyceride clearance ( Angptl4);
6) genes involved in glycerol metabolism (Gpd1 in mouse);",PMID:25703085,,"PPARalpha inactivation is a subtype of inactivation: A process that changes the activity of the activating PPAR alpha (Peroxisome Proliferator Activated Receptor Alpha) with a nuclear receptor role to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003022,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001858|http://purl.obolibrary.org/obo/TXPO_0000901|http://purl.obolibrary.org/obo/TXPO_0001126,,,,,,,,,,,TXPO:0001618,,,,,,,,,,,,,,,,,,,,PMID:25450203,,PPAR alpha inactivation [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001619,regulation of generation of precursor metabolites and energy [Ground glass appearance],,"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of precursor metabolites, substances from which energy is derived, and the processes involved in the liberation of energy from these substances.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/GO_0043467|http://purl.obolibrary.org/obo/TXPO_0001728,,,,,,,,,,,,,,,,,,,,,,"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of precursor metabolites, substances from which energy is derived, and the processes involved in the liberation of energy from these substances.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000786,,,,,,http://purl.obolibrary.org/obo/TXPO_0000963,,,,,,,,,,,TXPO:0001619,,,,,,,,,,,,,,,,,,,,,,regulation of generation of precursor metabolites and energy [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001617,increasing distance between cells,,Increasing distance between cells is a subtype of increasing distance: A process that places  a distance between cells.|separating between cells,false,,,http://purl.obolibrary.org/obo/TXPO_0000466,,,,,,,,,,,,,,,,,,,,,,Increasing distance between cells is a subtype of increasing distance: A process that places  a distance between cells.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001617,,,,,,,,,,,,,,,,,,,,separating between cells,,increasing distance between cells,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001610,hypofunction of phosphatidylglycerol degradation,,Hypofunction of phosphatidylglycerol degradation is a subtype of hypofunction of glycerophospholipid degradation: A process that performs a decreased or insufficient phosphatidylglycerol degradation.,false,,,http://purl.obolibrary.org/obo/TXPO_0001418,,,,,,,,,,,,,,,,,,,,,,Hypofunction of phosphatidylglycerol degradation is a subtype of hypofunction of glycerophospholipid degradation: A process that performs a decreased or insufficient phosphatidylglycerol degradation.,,,http://purl.obolibrary.org/obo/GO_0034478,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_17517,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001610,,,,,,,,,,,,,,,,,,,,,,hypofunction of phosphatidylglycerol degradation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001612,hyperfunction of phosphatidylglycerol synthesis gene expression,,Hyperfunction of phosphatidylglycerol synthesis gene expression is a subtype of hyperfunction of glycerophospholipid synthesis gene expression: A process that performs an excesssive phosphatidylglycerol synthetic gene expression.,false,,,http://purl.obolibrary.org/obo/TXPO_0001264,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of phosphatidylglycerol synthesis gene expression is a subtype of hyperfunction of glycerophospholipid synthesis gene expression: A process that performs an excesssive phosphatidylglycerol synthetic gene expression.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001612,,,,,,,,,,,,,,,,,,,,,,hyperfunction of phosphatidylglycerol synthesis gene expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001616,changing color,,Changing color is a subtype of changing quality: A process that chnges the color of the object.,false,,,http://purl.obolibrary.org/obo/TXPO_0000415,,,,,,,,,,,,,,,,,,,,,,Changing color is a subtype of changing quality: A process that chnges the color of the object.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001616,,,,,,,,,,,,,,,,,,,,,,changing color,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001614,negative regulation of phosphatidylglycerol degradation,,"Negative regulation of phosphatidylglycerol degradation is a subtype of Negative regulation of glycerophospholipid degradation: A process that stops, prevents, or reduces the frequency, rate or extent of phosphatidylglycerol degradation.",false,,,http://purl.obolibrary.org/obo/TXPO_0001304,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of phosphatidylglycerol degradation is a subtype of Negative regulation of glycerophospholipid degradation: A process that stops, prevents, or reduces the frequency, rate or extent of phosphatidylglycerol degradation.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001614,,,,,,,,,,,,,,,,,,,,,,negative regulation of phosphatidylglycerol degradation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001611,gene expression of cytochrome p450,,Gene expression of cytochrome p450 is a subtype of gene expression: The process in which a gene sequence is converted into a mature cytochrome p450 gene product or products (proteins or RNA) .,false,,,http://purl.obolibrary.org/obo/GO_0010467,,,,,,,,,,,,,,,,,,,,,,Gene expression of cytochrome p450 is a subtype of gene expression: The process in which a gene sequence is converted into a mature cytochrome p450 gene product or products (proteins or RNA) .,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001611,,,,,,,,,,,,,,,,,,,,,,gene expression of cytochrome p450,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001615,smooth endoplasmic reticulum membrane organization,,"Smooth endoplasmic reticulum membrane organization is a subtype of endoplasmic reticulum membrane organization: A process that  is carried out at the cellular level which results in the assembly, arrangement of constituent parts of a smooth endoplasmic reticulum membrane.",false,,,http://purl.obolibrary.org/obo/GO_0090158,,,,,,,,,,,,,,,,,,,,,,"Smooth endoplasmic reticulum membrane organization is a subtype of endoplasmic reticulum membrane organization: A process that  is carried out at the cellular level which results in the assembly, arrangement of constituent parts of a smooth endoplasmic reticulum membrane.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001615,,,,,,,,,,,,,,,,,,,,,,smooth endoplasmic reticulum membrane organization,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001613,smooth endoplasmic reticulum membrane organization [Ground glass appearance],,"Smooth endoplasmic reticulum membrane organization is a subtype of endoplasmic reticulum membrane organization: A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts of a smooth endoplasmic reticulum membrane.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/TXPO_0001615,,,,,,,,,,,,,,,,,,,,,,"Smooth endoplasmic reticulum membrane organization is a subtype of endoplasmic reticulum membrane organization: A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts of a smooth endoplasmic reticulum membrane.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001613,,,,,,,,,,,,,,,,,,,,,,smooth endoplasmic reticulum membrane organization [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_77106,EC 1.10.2.2 (quinol--cytochrome-c reductase) inhibitor,inhibitors of quinol--cytochrome-c reductase (EC 1.10.2.2)|EC 1.10.2.2 inhibitors|EC 1.10.2.2 (quinol--cytochrome-c reductase) inhibitors|quinol--cytochrome-c reductase (EC 1.10.2.2) inhibitors|EC 1.10.2.2 inhibitor|inhibitor of quinol--cytochrome-c reductase (EC 1.10.2.2)|quinol--cytochrome-c reductase (EC 1.10.2.2) inhibitor,An EC 1.10.2.* (oxidoreductase acting on diphenols and related substances as donors with a cytochrome as acceptor) inhibitor that interferes with the action of quinol--cytochrome-c reductase (EC 1.10.2.2).,false,,,http://purl.obolibrary.org/obo/CHEBI_77105,,,,,,,,,,,,,,,,,,,,,,An EC 1.10.2.* (oxidoreductase acting on diphenols and related substances as donors with a cytochrome as acceptor) inhibitor that interferes with the action of quinol--cytochrome-c reductase (EC 1.10.2.2).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,inhibitors of quinol--cytochrome-c reductase (EC 1.10.2.2)|EC 1.10.2.2 inhibitors|EC 1.10.2.2 (quinol--cytochrome-c reductase) inhibitors|quinol--cytochrome-c reductase (EC 1.10.2.2) inhibitors|EC 1.10.2.2 inhibitor|inhibitor of quinol--cytochrome-c reductase (EC 1.10.2.2)|quinol--cytochrome-c reductase (EC 1.10.2.2) inhibitor,,,,,,,,,,,,,,,,,,,,,CHEBI:77106,,,,EC 1.10.2.2 (quinol--cytochrome-c reductase) inhibitor,,CHEBI:77106,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100573,FGF-23,Tumor-derived hypophosphatemia inducing factor,,false,,,http://purl.obolibrary.org/obo/IMR_0000049,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Tumor-derived hypophosphatemia inducing factor,,,,,IMR:0100573,,,,,,,,,,,,,,,,,,,,,,FGF-23,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010498,60S ribosomal protein L7a,PLA-X polypeptide|Surfeit locus protein 3,,false,,,http://purl.obolibrary.org/obo/IMR_0000897,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PLA-X polypeptide|Surfeit locus protein 3,,,,,IMR:0010498,,,,,,,,,,,,,,,,,,,,,,60S ribosomal protein L7a,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000051277,DNAJC27,,Other designations: Ras-associated protein Rap1|dnaJ homolog subfamily C member 27|rab and DnaJ domain-containing protein,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,RabJS|RBJ,,,,,,,,,,,,2,,,,,,Vega:OTTHUMG00000125524|Ensembl:ENSG00000115137|HGNC:30290|MIM:613527|HPRD:15221,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"DnaJ (Hsp40) homolog, subfamily C, member 27",,,2p23.3,,,,,,,,,,,,,,,,GO_0005525 (EC: IEA); GO_0005739 (EC: IEA); GO_0007264 (EC: IEA),,,,,,,,,PMID:9564038; 12477932; 14980719; 18391951; 20877624; 20881960; 20935630; 21980299; 22344219; 23449627,,,,,,,,,,,,,,,OGG:3000051277,,,,,,,"DnaJ (Hsp40) homolog, subfamily C, member 27",,,,,,,,,,,,,Other designations: Ras-associated protein Rap1|dnaJ homolog subfamily C member 27|rab and DnaJ domain-containing protein,,DNAJC27,,,,,,,,,,,,,,,,,,,,,,,51277,,,,,,,,9606,,,,,,,,,,,,,,,,,,,DNAJC27,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000004790,NFKB1,,Other designations: DNA binding factor KBF1|DNA-binding factor KBF1|NF-kappabeta|nuclear factor NF-kappa-B p105 subunit|nuclear factor NF-kappa-B p50 subunit|nuclear factor kappa-B DNA binding subunit,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,p50|NF-kB1|NFkappaB|NF-kappaB|NF-kappa-B|p105|NFKB-p50|NFKB-p105|EBP-1|KBF1,,,,,,,,,,,,4,,,,,,HPRD:01238|MIM:164011|Ensembl:ENSG00000109320|Vega:OTTHUMG00000161080|HGNC:7794,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,nuclear factor of kappa light polypeptide gene enhancer in B-cells 1,,,4q24,,,,,,,,,,,,,,,,"GO_0000122 (EC: IC, PMID:16938301); GO_0000122 (EC: IMP, PMID:19881551); GO_0000975 (EC: IDA, PMID:17426251); GO_0000976 (EC: IDA, PMID:18718911); GO_0001071 (EC: IDA, PMID:17426251); GO_0001818 (EC: IEA); GO_0002224 (EC: TAS); GO_0002755 (EC: TAS); GO_0002756 (EC: TAS); GO_0003690 (EC: IEA); GO_0003700 (EC: IEA); GO_0005515 (EC: IPI, PMID:10023675); GO_0005634 (EC: IDA); GO_0005654 (EC: TAS); GO_0005730 (EC: IDA, Qualifier: NOT); GO_0005737 (EC: IDA); GO_0005739 (EC: IDA); GO_0005829 (EC: TAS); GO_0006366 (EC: TAS, PMID:1992489); GO_0006915 (EC: IEA); GO_0006954 (EC: TAS, PMID:1992489); GO_0006979 (EC: IEA); GO_0008134 (EC: IDA, PMID:18270204); GO_0009617 (EC: IEA); GO_0010744 (EC: IC, PMID:16938301); GO_0010884 (EC: IC, PMID:16938301); GO_0010956 (EC: IDA, PMID:15243130); GO_0010957 (EC: IC, PMID:15243130); GO_0031072 (EC: IEA); GO_0031293 (EC: TAS); GO_0032269 (EC: IC, PMID:16938301); GO_0032375 (EC: IC, PMID:16938301); GO_0032481 (EC: TAS); GO_0033256 (EC: TAS, PMID:16938301); GO_0034134 (EC: TAS); GO_0034138 (EC: TAS); GO_0034142 (EC: TAS); GO_0034146 (EC: TAS); GO_0034162 (EC: TAS); GO_0034166 (EC: TAS); GO_0035666 (EC: TAS); GO_0038095 (EC: TAS); GO_0038123 (EC: TAS); GO_0038124 (EC: TAS); GO_0042803 (EC: IEA); GO_0043066 (EC: TAS, PMID:10811897); GO_0044212 (EC: IDA, PMID:16938301); GO_0045083 (EC: IEA); GO_0045087 (EC: TAS); GO_0045893 (EC: IDA, PMID:17426251); GO_0045893 (EC: IMP); GO_0045893 (EC: NAS, PMID:8096091); GO_0045944 (EC: IEA); GO_0046688 (EC: IEA); GO_0048011 (EC: TAS); GO_0050728 (EC: IEA); GO_0050852 (EC: TAS); GO_0051092 (EC: TAS); GO_0071260 (EC: IEP, PMID:19593445); GO_0071347 (EC: IEP, PMID:12958148); GO_0090263 (EC: IMP); GO_1900127 (EC: IDA, PMID:17324121)",,,,,,,,,PMID:1505523; 1508666; 1518839; 1527859; 1583734; 1612589; 1992489; 2017258; 2050119; 2108863; 2203531; 2234062; 2497520; 7494249; 7651415; 7690421; 7692236; 7694229; 7729429; 7739549; 7742037; 7788295; 7800480; 7823959; 7830764; 7838536; 7859743; 7862168; 7891711; 7933095; 7957556; 8087845; 8096091; 8113688; 8139561; 8151786; 8178481; 8196632; 8207793; 8246997; 8255759; 8290595; 8319912; 8423996; 8428580; 8441377; 8550813; 8615004; 8621941; 8627654; 8628291; 8631829; 8642313; 8649779; 8676466; 8692272; 8709193; 8717528; 8724035; 8746784; 8790371; 8798655; 8814265; 8825636; 8834464; 8870842; 8887676; 8997639; 9094628; 9110146; 9135156; 9218802; 9223487; 9235945; 9250404; 9252186; 9278385; 9315679; 9334723; 9368006; 9468519; 9510190; 9525916; 9529257; 9535861; 9556555; 9560267; 9566873; 9566883; 9572494; 9584180; 9621091; 9722548; 9730685; 9738011; 9792375; 9809067; 9837938; 9865693; 9865694; 9895331; 9950430; 9990852; 10023675; 10075655; 10207088; 10225209; 10235509; 10357819; 10362352; 10384093; 10393859; 10400814; 10426996; 10446807; 10469655; 10480634; 10498867; 10562553; 10580107; 10625680; 10635328; 10644332; 10644726; 10646849; 10671224; 10704334; 10723127; 10775602; 10777532; 10799874; 10811897; 10835356; 10847592; 10856288; 10928981; 10931834; 10969074; 10970863; 11020244; 11036073; 11044099; 11094166; 11158290; 11160671; 11241736; 11278695; 11297557; 11299302; 11313474; 11356851; 11385624; 11418662; 11425860; 11468175; 11511100; 11522182; 11526476; 11579140; 11590148; 11607785; 11696595; 11704662; 11739381; 11756416; 11779220; 11819787; 11827962; 11830587; 11830590; 11833470; 11859566; 11880271; 11931769; 11942414; 11943214; 11953428; 11959143; 11970949; 11971907; 11972054; 11976329; 11980335; 11983170; 12019209; 12021045; 12032828; 12032830; 12040437; 12052823; 12057007; 12058256; 12067898; 12077118; 12077347; 12086956; 12089148; 12091382; 12115625; 12122011; 12133438; 12135603; 12145210; 12150710; 12150997; 12166787; 12167619; 12173051; 12181421; 12195699; 12198114; 12203044; 12230568; 12237108; 12244126; 12296854; 12297126; 12297724; 12297725; 12365017; 12388747; 12393603; 12396456; 12406554; 12419805; 12427593; 12428105; 12431991; 12433922; 12444143; 12444202; 12470471; 12471041; 12473373; 12477932; 12482504; 12482669; 12482991; 12485413; 12488445; 12495677; 12496256; 12496485; 12496486; 12538487; 12574335; 12592338; 12594215; 12594338; 12604365; 12606501; 12606947; 12618429; 12620896; 12623850; 12637324; 12644014; 12646168; 12646204; 12667451; 12673201; 12676577; 12693954; 12699902; 12700228; 12709429; 12711606; 12715098; 12727023; 12738634; 12743697; 12743709; 12748173; 12767057; 12771144; 12771929; 12783888; 12820969; 12821113; 12829026; 12832450; 12839942; 12843241; 12855659; 12857898; 12859994; 12860389; 12867284; 12871932; 12872153; 12878172; 12883671; 12884915; 12914931; 12917325; 12919943; 12921778; 12944982; 12947093; 12952968; 12958148; 12958623; 12958678; 12960163; 12963997; 12966099; 12972430; 12972607; 12972622; 12973300; 13679070; 13680285; 14530285; 14534291; 14550290; 14558943; 14561767; 14570916; 14572449; 14573617; 14576361; 14578856; 14581467; 14585847; 14593105; 14597672; 14613970; 14624448; 14625285; 14625298; 14645533; 14647412; 14657027; 14662860; 14663476; 14676829; 14678988; 14679201; 14679213; 14684616; 14685242; 14689584; 14690596; 14691449; 14697238; 14715628; 14729568; 14737065; 14739303; 14743216; 14743471; 14744759; 14747545; 14760757; 14769797; 14963043; 14966375; 15013753; 15016307; 15020601; 15039334; 15043934; 15044484; 15047705; 15053878; 15056731; 15063762; 15068390; 15073126; 15073170; 15078930; 15084608; 15087454; 15090542; 15093615; 15102862; 15103018; 15130920; 15137059; 15142381; 15143182; 15147743; 15169888; 15173174; 15175625; 15178248; 15179048; 15184376; 15184390; 15187159; 15188354; 15190178; 15203187; 15208298; 15217951; 15218148; 15226292; 15226448; 15238257; 15241416; 15242768; 15243130; 15251447; 15252018; 15254772; 15257133; 15258149; 15276183; 15280372; 15280531; 15297971; 15310755; 15314185; 15315758; 15319438; 15327770; 15337758; 15345718; 15351720; 15358208; 15364309; 15373762; 15383283; 15383523; 15389633; 15457532; 15459191; 15466412; 15467918; 15469820; 15471861; 15477018; 15485865; 15486815; 15489334; 15494311; 15496460; 15498932; 15501771; 15514680; 15521376; 15522218; 15528271; 15532722; 15535802; 15543947; 15545823; 15550679; 15561713; 15563086; 15564333; 15569630; 15569997; 15578154; 15591054; 15591119; 15597152; 15601829; 15610077; 15618021; 15618216; 15623625; 15627743; 15638726; 15640523; 15642694; 15642734; 15647756; 15650392; 15650393; 15650394; 15653692; 15657065; 15661045; 15670752; 15677444; 15678501; 15687488; 15688415; 15694363; 15701651; 15713218; 15713234; 15718492; 15722350; 15722553; 15725353; 15725474; 15727562; 15735699; 15735750; 15743789; 15746262; 15746428; 15757899; 15767394; 15780175; 15799966; 15802604; 15809302; 15811852; 15817944; 15827086; 15829968; 15830705; 15869598; 15870177; 15876358; 15894171; 15905616; 15905705; 15920558; 15922296; 15940251; 15941782; 15944151; 15951441; 15955209; 15964798; 15964800; 15972330; 15972853; 15979574; 15979856; 15982633; 15991283; 16001969; 16004996; 16005433; 16029077; 16039990; 16039994; 16044154; 16046401; 16046415; 16079148; 16081580; 16082226; 16087150; 16088959; 16105840; 16108830; 16116232; 16123212; 16142329; 16142871; 16155293; 16167336; 16199137; 16203728; 16204234; 16206345; 16207722; 16210649; 16212965; 16219794; 16223733; 16234240; 16236134; 16237100; 16243842; 16258173; 16260783; 16266460; 16270046; 16280329; 16285952; 16288847; 16289658; 16291755; 16299251; 16299518; 16303162; 16305395; 16306043; 16306601; 16308565; 16313306; 16318585; 16319921; 16319923; 16325763; 16341093; 16364464; 16380507; 16387424; 16397577; 16397579; 16407234; 16408727; 16410801; 16410802; 16410803; 16418290; 16424045; 16429131; 16429138; 16436380; 16439988; 16441485; 16452479; 16455661; 16465659; 16476711; 16485028; 16490783; 16491128; 16497967; 16498458; 16504042; 16513645; 16514159; 16519794; 16519819; 16528384; 16543241; 16554660; 16569657; 16571778; 16601113; 16616657; 16624823; 16630341; 16631615; 16635909; 16644866; 16651450; 16651613; 16678126; 16680372; 16684768; 16690938; 16697675; 16709572; 16722389; 16728660; 16740634; 16740744; 16751281; 16756716; 16757480; 16769768; 16771709; 16774937; 16778171; 16799643; 16804398; 16804400; 16816390; 16820889; 16822500; 16835229; 16840782; 16840786; 16857678; 16879221; 16891304; 16893890; 16906147; 16907704; 16912315; 16914552; 16919057; 16919536; 16926151; 16927804; 16928771; 16938301; 16951147; 16973832; 16979873; 16979925; 16980310; 16984419; 16984731; 16997282; 17000776; 17002577; 17003112; 17005562; 17011110; 17013094; 17039240; 17046972; 17047155; 17047486; 17049230; 17052690; 17053167; 17054067; 17062574; 17079333; 17085785; 17088249; 17103034; 17111814; 17114179; 17117949; 17129456; 17132229; 17133356; 17159900; 17174275; 17192276; 17194723; 17197380; 17200110; 17222798; 17242904; 17244613; 17255362; 17255956; 17256751; 17266559; 17276726; 17292586; 17296734; 17303384; 17303559; 17312171; 17314097; 17316355; 17318773; 17324121; 17334226; 17340152; 17354234; 17376917; 17387583; 17401435; 17405920; 17405935; 17409218; 17418100; 17419715; 17420005; 17426251; 17447895; 17452475; 17452529; 17462862; 17466952; 17468103; 17468848; 17471012; 17471239; 17475880; 17485237; 17490702; 17492467; 17495961; 17496784; 17498291; 17499812; 17502349; 17502353; 17507309; 17507655; 17521736; 17522703; 17530443; 17532054; 17538633; 17540609; 17543500; 17545521; 17545551; 17548685; 17549794; 17555878; 17565687; 17577783; 17583675; 17590380; 17590503; 17597077; 17600378; 17602748; 17603079; 17604336; 17607147; 17607549; 17611682; 17620428; 17622249; 17626072; 17627037; 17638883; 17638900; 17644514; 17644577; 17644777; 17652082; 17671417; 17684021; 17690684; 17692805; 17693123; 17700572; 17701919; 17702576; 17702846; 17704737; 17709376; 17712623; 17719653; 17725175; 17728102; 17761976; 17766391; 17785586; 17827154; 17828582; 17852842; 17873517; 17876541; 17878161; 17878165; 17882263; 17895971; 17896809; 17904523; 17908953; 17908957; 17910475; 17918160; 17925880; 17927847; 17928629; 17929131; 17932106; 17936701; 17938575; 17942533; 17947462; 17947496; 17950943; 17953212; 17959673; 17962196; 17962807; 17963943; 17967787; 17975552; 17978477; 17982228; 17986144; 17991734; 17997719; 17999917; 18006812; 18006844; 18008176; 18025803; 18029348; 18031796; 18032824; 18035048; 18039660; 18045535; 18050214; 18054783; 18064631; 18070982; 18070983; 18073330; 18074095; 18079108; 18082293; 18083845; 18090157; 18092345; 18158619; 18160848; 18163488; 18171526; 18172861; 18174252; 18178551; 18184402; 18199400; 18201555; 18202112; 18203956; 18212740; 18215660; 18216101; 18219313; 18224252; 18224424; 18226221; 18230685; 18234964; 18242184; 18248671; 18252714; 18252806; 18253935; 18260825; 18270204; 18275043; 18279996; 18292749; 18304423; 18305042; 18307978; 18308615; 18316375; 18316378; 18316606; 18316610; 18316612; 18322992; 18325349; 18329615; 18330586; 18331465; 18331590; 18336259; 18336908; 18341653; 18344086; 18347181; 18352974; 18356846; 18367547; 18375836; 18398749; 18422166; 18424438; 18425349; 18425350; 18426800; 18429822; 18433717; 18434448; 18436431; 18443042; 18443271; 18444250; 18450748; 18461473; 18466468; 18474259; 18476609; 18502748; 18504431; 18505918; 18508109; 18515093; 18523147; 18533190; 18538010; 18549623; 18550666; 18563317; 18566297; 18571457; 18573890; 18583989; 18593918; 18593939; 18593997; 18606063; 18613029; 18614013; 18615578; 18616724; 18621011; 18625728; 18627789; 18635966; 18636124; 18636537; 18640717; 18660489; 18661398; 18666137; 18668140; 18670233; 18670883; 18672082; 18675932; 18676680; 18690006; 18692180; 18694960; 18700166; 18703796; 18710415; 18715846; 18716880; 18718911; 18725314; 18753141; 18755269; 18761086; 18771702; 18776589; 18779315; 18780829; 18782346; 18782542; 18782567; 18786178; 18787102; 18796561; 18801463; 18804908; 18811964; 18818748; 18822207; 18824170; 18829502; 18832525; 18840709; 18849568; 18928570; 18928584; 18928599; 18931595; 18942706; 18945182; 18947494; 18948189; 18952281; 18952893; 18971284; 18976975; 18981184; 18982452; 18983609; 18984593; 18988918; 18989459; 18990758; 18996370; 18997828; 19006646; 19017490; 19019335; 19020743; 19021048; 19027925; 19043560; 19043589; 19052146; 19058794; 19066594; 19070859; 19087197; 19089909; 19095643; 19095738; 19096761; 19097143; 19103749; 19109741; 19112497; 19122653; 19123467; 19129458; 19132086; 19138976; 19140318; 19141126; 19144268; 19156129; 19157479; 19158244; 19158250; 19167713; 19169254; 19169266; 19170196; 19173301; 19190178; 19196344; 19198608; 19200568; 19204936; 19215923; 19218102; 19223549; 19223558; 19231232; 19231233; 19231580; 19234489; 19239434; 19243308; 19258598; 19270264; 19275583; 19275588; 19278584; 19279104; 19281832; 19287189; 19289835; 19291302; 19296848; 19296948; 19299748; 19301259; 19303852; 19304510; 19306295; 19319478; 19319745; 19331697; 19336468; 19351492; 19371952; 19380626; 19381070; 19387490; 19393188; 19398263; 19399830; 19403415; 19403642; 19407222; 19411070; 19412164; 19414075; 19414653; 19421711; 19423540; 19426600; 19427341; 19430878; 19432811; 19434718; 19435811; 19436306; 19446037; 19446741; 19447876; 19448592; 19453261; 19454659; 19457567; 19460752; 19460784; 19469019; 19470463; 19475568; 19479051; 19480714; 19496172; 19497202; 19502793; 19503105; 19507243; 19509001; 19524538; 19527514; 19531477; 19533666; 19533738; 19538528; 19539971; 19540595; 19543231; 19543524; 19548306; 19553005; 19554506; 19558775; 19558856; 19562673; 19565503; 19570036; 19570822; 19573080; 19573161; 19584059; 19591457; 19593445; 19594441; 19614983; 19616539; 19618291; 19619938; 19625176; 19627002; 19628242; 19631649; 19638614; 19639214; 19648110; 19655301; 19656241; 19662350; 19666475; 19666608; 19668231; 19671685; 19672210; 19673747; 19674131; 19675099; 19681904; 19682689; 19683526; 19683540; 19686049; 19691956; 19692168; 19692203; 19693652; 19695220; 19702828; 19703278; 19706447; 19706536; 19709433; 19711042; 19720604; 19723036; 19723087; 19723088; 19723089; 19723090; 19723091; 19724876; 19725919; 19732770; 19733238; 19734419; 19736361; 19738286; 19746155; 19747262; 19752553; 19757154; 19758175; 19765958; 19773279; 19778281; 19783786; 19786027; 19787057; 19787256; 19795416; 19797428; 19800021; 19801678; 19805303; 19811499; 19812265; 19815424; 19817957; 19820695; 19821157; 19826638; 19829671; 19837667; 19838207; 19838218; 19844776; 19845758; 19862523; 19878981; 19879919; 19881551; 19884766; 19885551; 19885592; 19885862; 19887846; 19892748; 19897484; 19898747; 19901262; 19903813; 19903815; 19909783; 19911254; 19913121; 19915152; 19917706; 19928652; 19932734; 19940361; 19941056; 19943112; 19947250; 19948975; 19954665; 19955102; 19956647; 19956670; 19956890; 19958645; 19959479; 19966852; 19995347; 20004763; 20004764; 20006706; 20008294; 20009901; 20012522; 20027638; 20030038; 20038977; 20042710; 20043910; 20051109; 20051532; 20052674; 20061391; 20064526; 20065107; 20065354; 20066092; 20066093; 20066094; 20066113; 20068069; 20069553; 20073580; 20074357; 20086239; 20097762; 20100571; 20102618; 20103633; 20106524; 20107185; 20110362; 20110513; 20124446; 20126979; 20127012; 20127709; 20129940; 20130217; 20133937; 20138641; 20139130; 20139322; 20139419; 20140262; 20145198; 20148897; 20149620; 20154269; 20160043; 20164171; 20171262; 20172018; 20172044; 20194722; 20195357; 20198307; 20204281; 20211142; 20213318; 20218898; 20224721; 20226764; 20226854; 20228198; 20230666; 20230686; 20231411; 20237496; 20237821; 20298930; 20299603; 20301198; 20304615; 20307555; 20331378; 20332099; 20333648; 20336759; 20337891; 20346059; 20346360; 20350779; 20351780; 20353025; 20353939; 20354190; 20356387; 20356841; 20360864; 20367887; 20368414; 20372806; 20372820; 20375583; 20376775; 20379146; 20379614; 20380698; 20380700; 20385556; 20388715; 20389059; 20391111; 20392247; 20392262; 20398057; 20406326; 20406964; 20414006; 20414373; 20416077; 20416168; 20418905; 20419804; 20424119; 20424169; 20432452; 20433755; 20436512; 20438785; 20439115; 20448038; 20448286; 20449947; 20450542; 20451919; 20452482; 20453000; 20454998; 20458747; 20460684; 20470938; 20479762; 20482842; 20483790; 20484576; 20485444; 20492683; 20498636; 20501937; 20506652; 20507572; 20509140; 20511226; 20512787; 20514026; 20516073; 20519510; 20519647; 20521099; 20522558; 20523058; 20529849; 20534156; 20538607; 20547752; 20547759; 20558726; 20564628; 20564897; 20568106; 20568250; 20573281; 20573493; 20573495; 20573801; 20576420; 20587610; 20588308; 20592241; 20596086; 20599492; 20599623; 20600004; 20628086; 20631305; 20634424; 20644561; 20647010; 20652762; 20654108; 20657549; 20660165; 20665665; 20672329; 20673868; 20685965; 20688330; 20688878; 20688919; 20711808; 20713621; 20715085; 20716114; 20716621; 20717930; 20723297; 20723418; 20734064; 20735436; 20737960; 20739528; 20800578; 20803413; 20805787; 20810208; 20813154; 20817876; 20818133; 20825713; 20825717; 20826751; 20829347; 20833730; 20836841; 20850164; 20855151; 20855880; 20856938; 20862591; 20872151; 20882529; 20884048; 20890036; 20890592; 20932173; 20937840; 20946117; 20952681; 20957413; 20966071; 20977779; 20980497; 21035162; 21035469; 21037509; 21046104; 21048031; 21051440; 21054790; 21055061; 21061265; 21062959; 21067753; 21071608; 21081469; 21081472; 21091507; 21098302; 21098640; 21108840; 21110852; 21113131; 21132531; 21138333; 21139048; 21145111; 21145461; 21148792; 21149600; 21150337; 21155242; 21155719; 21159881; 21166501; 21172429; 21190575; 21203561; 21220295; 21222514; 21228323; 21242888; 21242976; 21245992; 21264233; 21266470; 21273489; 21293511; 21293853; 21300060; 21308734; 21324206; 21331078; 21333439; 21334713; 21338484; 21343618; 21344487; 21352816; 21364020; 21383007; 21387831; 21389131; 21389697; 21390241; 21399635; 21399639; 21402921; 21406399; 21408173; 21411116; 21411444; 21411734; 21414799; 21417823; 21423202; 21424730; 21434324; 21448225; 21451109; 21463955; 21464588; 21468605; 21471377; 21472776; 21479189; 21483817; 21486470; 21490402; 21490927; 21491088; 21501152; 21503877; 21507981; 21511059; 21518763; 21525354; 21526963; 21527635; 21527913; 21528358; 21529841; 21531730; 21535601; 21540330; 21547539; 21549062; 21569377; 21570865; 21571356; 21573030; 21573053; 21574100; 21575498; 21576089; 21592054; 21602448; 21604024; 21606198; 21613824; 21617575; 21617851; 21621419; 21623171; 21625939; 21626144; 21627565; 21628073; 21628458; 21629247; 21637819; 21641936; 21642544; 21646373; 21658842; 21663472; 21664164; 21674474; 21682737; 21689853; 21708986; 21712995; 21715489; 21715600; 21720550; 21726863; 21729627; 21731707; 21734368; 21738780; 21743832; 21743958; 21749603; 21752354; 21754991; 21760911; 21762706; 21763497; 21764057; 21765619; 21768353; 21777808; 21782444; 21782857; 21782934; 21787758; 21789858; 21803029; 21810613; 21811235; 21813290; 21820300; 21822306; 21826700; 21830064; 21833088; 21835421; 21842098; 21845735; 21846842; 21856935; 21857917; 21873235; 21882225; 21884980; 21886773; 21887310; 21889270; 21895511; 21895606; 21896491; 21902578; 21906983; 21910343; 21914069; 21918864; 21925591; 21929290; 21945445; 21951562; 21963094; 21979374; 21979375; 21980157; 21985363; 21987421; 21987722; 21988832; 21993017; 21994759; 21996578; 22001530; 22005258; 22005259; 22007481; 22009151; 22013068; 22013908; 22017875; 22021368; 22027397; 22046080; 22046434; 22063737; 22066734; 22067113; 22068612; 22072831; 22077140; 22083956; 22090103; 22090112; 22092568; 22093097; 22095071; 22096476; 22102915; 22118627; 22123322; 22131135; 22132199; 22132240; 22138609; 22138672; 22139845; 22145100; 22147524; 22152775; 22153345; 22156489; 22157716; 22170554; 22171160; 22172699; 22174879; 22184967; 22185489; 22187158; 22199285; 22207455; 22211660; 22212641; 22217202; 22226472; 22226621; 22226679; 22227305; 22229121; 22229442; 22248180; 22252121; 22258247; 22261743; 22264835; 22267549; 22284893; 22286758; 22287454; 22293503; 22306268; 22307688; 22320942; 22320981; 22321707; 22327383; 22328149; 22331067; 22334708; 22341466; 22343628; 22346248; 22347372; 22348310; 22354461; 22359280; 22362744; 22380486; 22384099; 22384168; 22386866; 22388891; 22394598; 22396537; 22406367; 22406815; 22417709; 22427141; 22429999; 22430136; 22450687; 22461522; 22464415; 22465880; 22479419; 22484638; 22490020; 22490899; 22496225; 22505595; 22507528; 22509384; 22513115; 22521419; 22526587; 22527100; 22528837; 22530801; 22534017; 22537555; 22538516; 22547075; 22552288; 22558282; 22562129; 22566686; 22581854; 22593154; 22593207; 22597534; 22605335; 22613333; 22614238; 22618514; 22641218; 22645312; 22674419; 22685329; 22685373; 22698986; 22699931; 22707304; 22735811; 22740410; 22742857; 22742859; 22749179; 22749770; 22749879; 22760211; 22762947; 22763043; 22764136; 22767505; 22768179; 22776619; 22798425; 22801426; 22806547; 22815893; 22825241; 22828805; 22833150; 22836752; 22843550; 22846605; 22849850; 22851693; 22851696; 22855173; 22855490; 22859938; 22863753; 22869145; 22874821; 22874878; 22880008; 22884975; 22887854; 22891614; 22898922; 22902396; 22917497; 22924768; 22927965; 22933289; 22936809; 22941344; 22945510; 22949302; 22952582; 22954486; 22955189; 22967049; 22967106; 22975586; 22984526; 22988296; 22995914; 23000144; 23001849; 23006728; 23009565; 23017833; 23027537; 23027628; 23028875; 23039130; 23041324; 23044494; 23053371; 23061681; 23066037; 23091063; 23092922; 23096115; 23110043; 23117246; 23123205; 23125120; 23128233; 23132271; 23132857; 23135727; 23152563; 23152895; 23153769; 23155052; 23160072; 23170789; 23174100; 23176038; 23178493; 23185316; 23193970; 23205493; 23219896; 23221546; 23224146; 23226410; 23230212; 23237063; 23249930; 23259994; 23261678; 23266528; 23269488; 23269842; 23271730; 23275439; 23280137; 23296075; 23299027; 23299493; 23310954; 23317209; 23319823; 23322360; 23322721; 23322906; 23322997; 23327061; 23328932; 23331079; 23332158; 23334076; 23339870; 23357300; 23364895; 23369793; 23378274; 23386606; 23392668; 23399035; 23402362; 23405894; 23416929; 23426622; 23428345; 23437386; 23439561; 23444213; 23451236; 23452206; 23457512; 23496811; 23503472; 23503975; 23504987; 23510475; 23530144; 23552418; 23563313; 23576799; 23577181; 23583295; 23585913; 23603894; 23615072; 23615397; 23616277; 23616566; 23618653; 23634218; 23634661; 23636254; 23656347; 23659359; 23664977; 23669642; 23671649; 23675986; 23684722; 23687337; 23690573; 23708311; 23715268; 23724129; 23728913; 23732112; 23732909; 23744075; 23751348; 23752607; 23754270; 23756813; 23757261; 23774208; 23791017; 23791833; 23806437; 23821202; 23831825; 23843455; 23861985; 23869088; 23880092; 23887394; 23900863; 23908590; 23911423; 23921373; 23935876; 23942618; 23954632; 23969028; 23982206; 24008839; 24027435; 24035972; 24041570; 24045046; 24048682; 24054986; 24065232; 24067962; 24077340; 24097561; 24098051; 24099783; 24109220; 24109241; 24113181; 24145029; 24145431; 24152244; 24175631; 24258200; 24270572; 24282904; 24297735; 24316229; 24321067; 24352326; 24367071; 24368180; 24436266; 24510559,,,,,,,,,,,,,,,OGG:3000004790,,,,,,,nuclear factor of kappa light polypeptide gene enhancer in B-cells 1,,,,,,,,,,,,,Other designations: DNA binding factor KBF1|DNA-binding factor KBF1|NF-kappabeta|nuclear factor NF-kappa-B p105 subunit|nuclear factor NF-kappa-B p50 subunit|nuclear factor kappa-B DNA binding subunit,,NFKB1,,,,,,,,,,,,,,,,,,,,,,,4790,,,,,,,,9606,,,,,,,,,,,,,,,,,,,NFKB1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000004791,NFKB2,,"Other designations: DNA-binding factor KBF2|NFKB, p52/p100 subunit|lymphocyte translocation chromosome 10 protein|nuclear factor Kappa-B, subunit 2|nuclear factor NF-kappa-B p100 subunit|nuclear factor of Kappa light chain gene enhancer in B cells 2|oncogene Lyt-10|transcription factor NFKB2",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,H2TF1|LYT10|p105|LYT-10|NF-kB2|CVID10|p52,,,,,,,,,,,,10,,,,,,HGNC:7795|Vega:OTTHUMG00000018962|HPRD:01239|MIM:164012|Ensembl:ENSG00000077150,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100),,,10q24,,,,,,,,,,,,,,,,"GO_0002224 (EC: TAS); GO_0002268 (EC: IEA); GO_0002467 (EC: IEA); GO_0002755 (EC: TAS); GO_0002756 (EC: TAS); GO_0003677 (EC: IEA); GO_0003700 (EC: IEA); GO_0003713 (EC: TAS, PMID:1876189); GO_0005515 (EC: IPI, PMID:11239468); GO_0005634 (EC: IDA); GO_0005654 (EC: TAS); GO_0005730 (EC: IDA, Qualifier: NOT); GO_0005737 (EC: IDA); GO_0005829 (EC: TAS); GO_0006351 (EC: IEA); GO_0006355 (EC: IDA, PMID:8360178); GO_0030198 (EC: IEA); GO_0032481 (EC: TAS); GO_0033257 (EC: IDA, PMID:9407099); GO_0034134 (EC: TAS); GO_0034138 (EC: TAS); GO_0034142 (EC: TAS); GO_0034146 (EC: TAS); GO_0034162 (EC: TAS); GO_0034166 (EC: TAS); GO_0035666 (EC: TAS); GO_0038123 (EC: TAS); GO_0038124 (EC: TAS); GO_0045087 (EC: TAS); GO_0048536 (EC: IEA); GO_0051092 (EC: TAS)",,,,,,,,,PMID:1473734; 1505523; 1531086; 1583734; 1612589; 1760839; 1876189; 7478612; 7494249; 7541912; 7597296; 7690421; 7729429; 7800480; 7823959; 7838536; 7859743; 7925301; 7933095; 7949142; 7969113; 8036016; 8108127; 8108136; 8113688; 8152812; 8207793; 8208540; 8336950; 8360178; 8378093; 8413211; 8423996; 8441377; 8453667; 8615004; 8627654; 8676466; 8709193; 8717528; 8724035; 8834464; 8887665; 9021684; 9110146; 9135156; 9264393; 9278385; 9315679; 9359707; 9384586; 9407099; 9510190; 9523851; 9525916; 9529131; 9566873; 9730685; 9792375; 9895331; 10207088; 10225209; 10384093; 10393859; 10400814; 10446807; 10480634; 10562553; 10580107; 10597218; 10644332; 10644726; 10671224; 10713675; 10723127; 10799874; 10823818; 10830747; 11044099; 11160671; 11239468; 11241736; 11299302; 11385624; 11468175; 11511100; 11522182; 11526476; 11579140; 11704662; 11707390; 11827962; 11833470; 11980335; 11994270; 12040437; 12167619; 12185077; 12351572; 12352969; 12374738; 12389034; 12427593; 12473373; 12477932; 12482669; 12485413; 12505990; 12524526; 12697057; 12808109; 12835724; 12874295; 12894228; 12917325; 12927781; 14532284; 14576817; 14676825; 14678988; 14743216; 15103018; 15140882; 15164054; 15258149; 15310758; 15469820; 15485830; 15489334; 15629778; 15677444; 15677466; 15782119; 15799966; 16009713; 16108830; 16223731; 16260623; 16303288; 16344560; 16368877; 16385451; 16477006; 16613850; 16651533; 16751281; 16940298; 16990795; 17003035; 17028057; 17039258; 17183367; 17197385; 17237370; 17254973; 17292587; 17363471; 17476277; 17548614; 17563756; 17703412; 17715223; 17962807; 18025196; 18025803; 18029348; 18160848; 18321863; 18377428; 18383001; 18434448; 18466468; 18538010; 18550535; 18617892; 18660489; 18781579; 18818748; 18971284; 19098713; 19219072; 19258923; 19302050; 19471022; 19479051; 19524538; 19527514; 19542561; 19573080; 19591173; 19773279; 19860880; 19913121; 19948975; 20037209; 20038584; 20211142; 20301476; 20346360; 20353939; 20388792; 20448286; 20460684; 20503287; 20558726; 20568250; 20598117; 20628086; 20628624; 20708837; 20734064; 20800578; 21048223; 21131783; 21139048; 21228035; 21325409; 21846842; 21871426; 21906983; 21963094; 21987572; 21988832; 22017875; 22083306; 22096027; 22198284; 22341466; 22388891; 22435556; 22642622; 22708077; 22734038; 22797925; 22864569; 22879398; 23211527; 23219896; 23301098; 23383273; 23389097; 23524849; 23699654; 23873932; 24008839; 24140114,,,,,,,,,,,,,,,OGG:3000004791,,,,,,,nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100),,,,,,,,,,,,,"Other designations: DNA-binding factor KBF2|NFKB, p52/p100 subunit|lymphocyte translocation chromosome 10 protein|nuclear factor Kappa-B, subunit 2|nuclear factor NF-kappa-B p100 subunit|nuclear factor of Kappa light chain gene enhancer in B cells 2|oncogene Lyt-10|transcription factor NFKB2",,NFKB2,,,,,,,,,,,,,,,,,,,,,,,4791,,,,,,,,9606,,,,,,,,,,,,,,,,,,,NFKB2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_64297,reaction intermediate,,Any chemical substance produced during the conversion of a reactant to a product.,false,,,http://purl.obolibrary.org/obo/CHEBI_51086,,,,,,,,,,,,,,,,,,,,Wikipedia:Reaction_intermediate,,Any chemical substance produced during the conversion of a reactant to a product.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:64297,,,,,,,,,,,,,,,,,,,,,,reaction intermediate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100458,IKK alpha,Inhibitor of nuclear factor kappa-B kinase alpha subunit,,false,,,http://purl.obolibrary.org/obo/IMR_0000701,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Inhibitor of nuclear factor kappa-B kinase alpha subunit,,,,,IMR:0100458,,,,,,,,,,,,,,,,,,,,,,IKK alpha,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000638,Integrin alpha-M,,,false,,,http://purl.obolibrary.org/obo/IMR_0000173,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000638,,,,,,,,,,,,,,,,,,,,,,Integrin alpha-M,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_17234,glucose,,An aldohexose used as a source of energy and metabolic intermediate.,false,,,http://purl.obolibrary.org/obo/CHEBI_35381,,,,,,,,,,,,,,,,,,,,,,An aldohexose used as a source of energy and metabolic intermediate.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:17234,,,,,,,,,,,,,,,,,,,,,,glucose,,,,,,,http://purl.obolibrary.org/obo/chebi.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100613,cyclin C,,,false,,,http://purl.obolibrary.org/obo/IMR_0100606,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100613,,,,,,,,,,,,,,,,,,,,,,cyclin C,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_28765,phosphatidylinositol phosphate,,"Any member of the phosphoinositide family of compounds, of which seven occur naturally.",false,,,http://purl.obolibrary.org/obo/CHEBI_18179,,,,,,,,,,,,,,,,,,,,,,"Any member of the phosphoinositide family of compounds, of which seven occur naturally.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:28765,,,,,,,,,,,,,,,,,,,,,,phosphatidylinositol phosphate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_38496,electron-transport chain inhibitor,,A role played by the entity  that inhibits the electron-transport chain,false,,,http://purl.obolibrary.org/obo/CHEBI_76932,,,,,,,,,,,,,,,,,,,,,,A role played by the entity  that inhibits the electron-transport chain,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:38496,,,,electron-transport chain inhibitor,,CHEBI:38496,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003720,pathway regulator,,A role of the entity which positively/negatively regulates a signaling pathway or metabolic pathway.,false,,,http://purl.obolibrary.org/obo/TXPO_0003230,,,,,,,,,,,,,,,,,,,,IMR:0000428 (obsolete),,A role of the entity which positively/negatively regulates a signaling pathway or metabolic pathway.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003720,,,,,,,,,,,,,,,,,,,,,,pathway regulator,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003722,enzyme regulator,enzyme modulator|catalytic regulator,A role played by the entity which binds to and modulates the activity of an enzyme.,false,,,http://purl.obolibrary.org/obo/TXPO_0003713,,,,,,,,,,,,,,,,,,,,IMR:0000429 (obsolete)|related molecular function GO:0030234,,A role played by the entity which binds to and modulates the activity of an enzyme.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,enzyme modulator|catalytic regulator,,,,,TXPO:0003722,,,,,,,,,,,,,,,,,,,,,,enzyme regulator,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003721,negative regulator of Wnt signaling pathway,inhibitor  of Wnt signaling pathway,,false,,,http://purl.obolibrary.org/obo/CHEBI_76932,,,,,,,,,,,,,,,,,,,,IMR:0001160 (obsolete),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,inhibitor  of Wnt signaling pathway,,,,,TXPO:0003721,,,,,,,,,,,,,,,,,,,,,,negative regulator of Wnt signaling pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003725,regulator of tumor cell activity role,,A role played by the entity that regulates the activity of tumor cells.,false,,,http://purl.obolibrary.org/obo/TXPO_0003230,,,,,,,,,,,,,,,,,,,,,,A role played by the entity that regulates the activity of tumor cells.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003725,,,,,,,,,,,,,,,,,,,,,,regulator of tumor cell activity role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003724,positive regulator of tumorigenesis role,,A role played by the entity which positively regulates the process of tumorigenesis.,false,,,http://purl.obolibrary.org/obo/TXPO_0003230,,,,,,,,,,,,,,,,,,,,,,A role played by the entity which positively regulates the process of tumorigenesis.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003724,,,,,,,,,,,,,,,,,,,,,,positive regulator of tumorigenesis role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003728,role related to receiving,receiver,,false,,,http://purl.obolibrary.org/obo/TXPO_0003727,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,receiver,,,,,TXPO:0003728,,,,,,,,,,,,,,,,,,,,,,role related to receiving,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003729,hardness (attribute),,"A physical attribute inhering in a bearer by virtue of the bearer's resistance to pressure, being broken, or pierced",false,,,http://purl.obolibrary.org/obo/TXPO_0000305,,,,,,,,,,,,,,,,,,,,,,"A physical attribute inhering in a bearer by virtue of the bearer's resistance to pressure, being broken, or pierced",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003729,,,,,,,,,,,,,,,,,,,,,,hardness (attribute),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003723,molecular carrier,,A role of the entity of binding to a specific ion or molecule and delivering it either to an acceptor molecule or to a specific location.,false,,,http://purl.obolibrary.org/obo/TXPO_0001393,,,,,,,,,,,,,,,,,,,,related molecular function GO:0140104,,A role of the entity of binding to a specific ion or molecule and delivering it either to an acceptor molecule or to a specific location.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003723,,,,,,,,,,,,,,,,,,,,,,molecular carrier,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003727,functional role,,A role played by the entity of funtion as realizable entity.,false,,,http://purl.obolibrary.org/obo/BFO_0000023,,,,,,,,,,,,,,,,,,,,,,A role played by the entity of funtion as realizable entity.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003727,,,,,,,,,,,,,,,,,,,,,,functional role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003726,regulator of immune response,,A role played by the entity which regulates the process of infmammatory response.,false,,,http://purl.obolibrary.org/obo/TXPO_0003230,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000192,,,,,,,,,,,,,A role played by the entity which regulates the process of infmammatory response.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003726,,,,,,,,,,,,,,,,,,,,,,regulator of immune response,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000859,14-3-3 beta,Protein kinase C inhibitor protein-1|KCIP-1|14-3-3 protein beta/alpha|Protein 1054,,false,,,http://purl.obolibrary.org/obo/IMR_0000456,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0010101,Protein kinase C inhibitor protein-1|KCIP-1|14-3-3 protein beta/alpha|Protein 1054,,,,,IMR:0000859,,,,,,,,,,,,,,,,,,,,,,14-3-3 beta,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000115,IL-13 receptor,interleukin-13 receptor,,false,,,http://purl.obolibrary.org/obo/IMR_0000096,,,,,,,,,,,,,,,,,,,,GO:0016515,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,interleukin-13 receptor,,,,,IMR:0000115,,,,,,,,,,,,,,,,,,,,,,IL-13 receptor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000887,TFIIH,,,false,,,http://purl.obolibrary.org/obo/IMR_0000888,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003645,,,,,,,,,,IMR:0000887,,,,,,,,,,,,,,,,,,,,,,TFIIH,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_27690,acetazolamide,"N-[5-(aminosulfonyl)-1,3,4-thiadiazol-2-yl]acetamide|N-[5-(aminosulfonyl)-1,3,5-thiadiazol-2-yl]acetamide|acetazolamidum|Defiltran|Diamox|5-acetylamino-1,3,4-thiadiazole-2-sulfonamide|Diluran|Glaupax|acetazolamide|acetazolamida|5-ACETAMIDO-1,3,4-THIADIAZOLE-2-SULFONAMIDE|2-acetylamino-1,3,4-thiadiazole-5-sulfonamide|Diacarb|Acetazolamide|N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)acetamide",,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Gmelin:365421|CAS:59-66-5|DrugBank:DB00819|Beilstein:212994|Drug_Central:56|LINCS:LSM-5543,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35498|http://purl.obolibrary.org/obo/CHEBI_35623|http://purl.obolibrary.org/obo/CHEBI_23018,,,,,"Acetazolamide|N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)acetamide",,"N-[5-(aminosulfonyl)-1,3,4-thiadiazol-2-yl]acetamide|N-[5-(aminosulfonyl)-1,3,5-thiadiazol-2-yl]acetamide|acetazolamidum|Defiltran|Diamox|5-acetylamino-1,3,4-thiadiazole-2-sulfonamide|Diluran|Glaupax|acetazolamide|acetazolamida|5-ACETAMIDO-1,3,4-THIADIAZOLE-2-SULFONAMIDE|2-acetylamino-1,3,4-thiadiazole-5-sulfonamide|Diacarb",,,,,,,,,,,,,,,,,,,,,CHEBI:27690,,,,acetazolamide,,CHEBI:27690,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_26216,potassium atom,potassium,,false,,,http://purl.obolibrary.org/obo/CHEBI_22314,,,,,,,,,,,,,,,,,,,,CAS:7440-09-7|DrugBank:DB01345,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,potassium,,,,,CHEBI:26216,,,,,,,,,,,,,,,,,,,,,,potassium atom,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100464,TRADD (mol),tumor necrosis factor receptor-associated death domain|TNFR-associated death domain|TNF receptor-associated death domain,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003682,,,,,tumor necrosis factor receptor-associated death domain|TNFR-associated death domain|TNF receptor-associated death domain,,,,,IMR:0100464,,,,,,,,,,,,,,,,,,,,,,TRADD (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0045721,negative regulation of gluconeogenesis,down regulation of gluconeogenesis|downregulation of gluconeogenesis|down-regulation of gluconeogenesis,"Any process that stops, prevents, or reduces the frequency, rate or extent of gluconeogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000369,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents, or reduces the frequency, rate or extent of gluconeogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,down regulation of gluconeogenesis|downregulation of gluconeogenesis|down-regulation of gluconeogenesis,,,,,GO:0045721,,,,,,,,,,,,,,,,,,,,,,negative regulation of gluconeogenesis,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006094,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010485,60S ribosomal protein L35,P42766,,false,,,http://purl.obolibrary.org/obo/IMR_0000897,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,P42766,,,,,IMR:0010485,,,,,,,,,,,,,,,,,,,,,,60S ribosomal protein L35,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001691,sphingomyelin accumulation in lysosome of nervous system,,Sphingomyelin accumulation in lysosome of nervous system is a subtype of sphingomyelin accumulation in lysosome: A process that keeps sphingomyelin in the lysosome of nervous system.,false,,,http://purl.obolibrary.org/obo/TXPO_0001764,,,,,,,,,,,,,,,,,,,,,,Sphingomyelin accumulation in lysosome of nervous system is a subtype of sphingomyelin accumulation in lysosome: A process that keeps sphingomyelin in the lysosome of nervous system.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001691,,,,,,,,,,,,,,,,,,,,,,sphingomyelin accumulation in lysosome of nervous system,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001696,PERK signal transduction system,,"PERK signal transduction system is a subtype of pathway system.
This entity has sub-parts and has a goal of transmitting signals via PERK as a systemic context.",false,,,http://purl.obolibrary.org/obo/TXPO_0000634,,,,,,,,,,,,,,,,,,,,,,"PERK signal transduction system is a subtype of pathway system.
This entity has sub-parts and has a goal of transmitting signals via PERK as a systemic context.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001852|http://purl.obolibrary.org/obo/TXPO_0001841,,,,,,,,,,,,,,,,,,,,,,TXPO:0001696,,,,,,,,,,,,,,,,,,,,,,PERK signal transduction system,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001695,chemical compound accumulation in lysosome [Phospholipidosis (severe)],,"Compound accumulation in lysosome is a subtype of accumulation of xenobiotics: A process that keeps compound in the lysosome. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",false,,,http://purl.obolibrary.org/obo/TXPO_0000930,,,,,,,,,,,,,,,,,,,,PMID:24003057,,"Compound accumulation in lysosome is a subtype of accumulation of xenobiotics: A process that keeps compound in the lysosome. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003451,http://purl.obolibrary.org/obo/TXPO_0001560|http://purl.obolibrary.org/obo/TXPO_0001425|http://purl.obolibrary.org/obo/TXPO_0000081,,,,,,http://purl.obolibrary.org/obo/TXPO_0003824|http://purl.obolibrary.org/obo/TXPO_0002217,,,,,,,,,,,TXPO:0001695,,,,,,,,,,,,,,,,,,,,,,chemical compound accumulation in lysosome [Phospholipidosis (severe)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001692,sphingomyelin accumulation in lysosome of nervous system [Niemann Pick Disease Type A (severe) ],,"Severe sphingomyelin accumulation in lysosome of nervous system is a subtype of sphingomyelin accumulation in lysosome of nervous system: A process that keeps sphingomyelin in the lysosome of nervous system severely. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type A (severe).",false,,,http://purl.obolibrary.org/obo/TXPO_0003615|http://purl.obolibrary.org/obo/TXPO_0001807,,,,,,,,,,,,,,,,,,,,,,"Severe sphingomyelin accumulation in lysosome of nervous system is a subtype of sphingomyelin accumulation in lysosome of nervous system: A process that keeps sphingomyelin in the lysosome of nervous system severely. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type A (severe).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001471|http://purl.obolibrary.org/obo/TXPO_0001818,,,,,,,,,,,TXPO:0001692,,,,,,,,,,,,,,,,,,,,,,sphingomyelin accumulation in lysosome of nervous system [Niemann Pick Disease Type A (severe) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001693,protein binding by NAPQI,,Protein binding by NAPQI is a subtype of protein binding: Interacting between a protein and NAPQI.,false,,,http://purl.obolibrary.org/obo/GO_0005515,,,,,,,,,,,,,,,,,,,,,,Protein binding by NAPQI is a subtype of protein binding: Interacting between a protein and NAPQI.,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_29132,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001693,,,,,,,,,,,,,,,,,,,,,,protein binding by NAPQI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001697,glycerophospholipid accumulation in lysosome,,Glycerophospholipid accumulation in lysosome is a subtype of phospholipid accumulation in lysosome: A process that keeps glycerophospholipid in the lysosome.,false,,,http://purl.obolibrary.org/obo/TXPO_0000281,,,,,,,,,,,,,,,,,,,,,,Glycerophospholipid accumulation in lysosome is a subtype of phospholipid accumulation in lysosome: A process that keeps glycerophospholipid in the lysosome.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_37739,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001697,,,,,,,,,,,,,,,,,,,,,,glycerophospholipid accumulation in lysosome,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001699,leaking,,Leaking is a subtype of moving A to the outside of B: A process that lets gas or liquid flow through.,false,,,http://purl.obolibrary.org/obo/TXPO_0002588,,,,,,,,,,,,,,,,,,,,,,Leaking is a subtype of moving A to the outside of B: A process that lets gas or liquid flow through.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001699,,,,,,,,,,,,,,,,,,,,,,leaking,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001694,chemical compound accumulation in liver,,Compound accumulation in liver is a subtype of accumulation of xenobiotics: A process that keeps compound in the liver.,false,,,http://purl.obolibrary.org/obo/TXPO_0000169,,,,,,,,,,,,,,,,,,,,,,Compound accumulation in liver is a subtype of accumulation of xenobiotics: A process that keeps compound in the liver.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001694,,,,,,,,,,,,,,,,,,,,,,chemical compound accumulation in liver,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001698,increaing in fatty acid inflow into hepatocyte [Phpspholipidosis (severe)],,"Increase in fatty acid inflow into hepatocyte is a subtype of increasing quantity: A process that changes the fatty acid inflow into the hepatocyte to be larger. The degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001673,,,,,,,,,,,,,,,,,,,,,,"Increase in fatty acid inflow into hepatocyte is a subtype of increasing quantity: A process that changes the fatty acid inflow into the hepatocyte to be larger. The degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001315,,,,,,,,,,,TXPO:0001698,,,,,,,,,,,,,,,,,,,,,,increaing in fatty acid inflow into hepatocyte [Phpspholipidosis (severe)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001690,sphingomyelin accumulation in lysosome [Phospholipidosis - genetic- sphingomyelin disorder],,"Sphingomyelin accumulation in lysosome is a subtype of sphingophospholipid accumulation in lysosome: A process that keeps sphingomyelin in the lysosome.
This process is dependent on the sphingomyelin disorder  and can constitute the course of Phospholipidosis (genetic).",false,,,http://purl.obolibrary.org/obo/TXPO_0002070|http://purl.obolibrary.org/obo/TXPO_0003381,,,,,,,,,,,,,,,,,,,,,,"Sphingomyelin accumulation in lysosome is a subtype of sphingophospholipid accumulation in lysosome: A process that keeps sphingomyelin in the lysosome.
This process is dependent on the sphingomyelin disorder  and can constitute the course of Phospholipidosis (genetic).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001690,,,,,,,,,,,,,,,,,,,,,,sphingomyelin accumulation in lysosome [Phospholipidosis - genetic- sphingomyelin disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0009058,biosynthetic process,synthesis|biosynthesis|anabolism,The chemical reactions and pathways resulting in the formation of substances; typically the energy-requiring part of metabolism in which simpler substances are transformed into more complex ones.,false,,,http://purl.obolibrary.org/obo/TXPO_0000019,,,,,,,,,,,,,,,,,,,,,,The chemical reactions and pathways resulting in the formation of substances; typically the energy-requiring part of metabolism in which simpler substances are transformed into more complex ones.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000387,,,,,,,,,,,,,synthesis|biosynthesis|anabolism,,,,,GO:0009058,,,,,,,,,,,,,,,,,,,,,,biosynthetic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0009056,catabolic process,,"The chemical reactions and pathways resulting in the breakdown of substances, including the breakdown of carbon compounds with the liberation of energy for use by the cell or organism.",false,,,http://purl.obolibrary.org/obo/TXPO_0000185,,,,,,,,,,,,,,,,,,,,Wikipedia:Catabolism,,"The chemical reactions and pathways resulting in the breakdown of substances, including the breakdown of carbon compounds with the liberation of energy for use by the cell or organism.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0009056,,,,,,,,,,,,,,,,,,,,,,catabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_34873,N-nitrosodiethylamine,DEN|Diethylnitrosamine|N-ethyl-N-nitrosoethanamine,A nitrosamine that is N-ethylethanamine substituted by a nitroso group at the N-atom.,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:55-18-5,,A nitrosamine that is N-ethylethanamine substituted by a nitroso group at the N-atom.,,,,,,,,,,,,C4H10N2O,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,N-ethyl-N-nitrosoethanamine,,DEN|Diethylnitrosamine,,,CHEBI:34873,,,,,,,,,,,,,,,,,,,,,,N-nitrosodiethylamine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CCN(CC)N=O,,,,,
http://purl.obolibrary.org/obo/CHEBI_88230,autophagy inhibitor,autophagocytosis inhibitor,Any compound that inhibits the process of autophagy (the self-digestion of one or more components of a cell through the action of enzymes originating within the same cell).,false,,,http://purl.obolibrary.org/obo/TXPO_0002629,,,,,,,http://purl.obolibrary.org/obo/GO_0006914,,,,,,,,,,,,,PMID:25793774|PMID:25896709|PMID:24830781|Wikipedia:Autophagy|PMID:25727221,,Any compound that inhibits the process of autophagy (the self-digestion of one or more components of a cell through the action of enzymes originating within the same cell).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,autophagocytosis inhibitor,,,CHEBI:88230,,,,,,,,,,,,,,,,,,,,,,autophagy inhibitor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0051208,sequestering of calcium ion,retention of calcium ion (Ca2+)|calcium ion (Ca2+) storage|calcium ion (Ca2+) retention|calcium ion (Ca2+) sequestration|calcium ion (Ca2+) sequestering|sequestering of calcium ion (Ca2+)|storage of calcium ion (Ca2+),The process of binding or confining calcium ions such that they are separated from other components of a biological system.,false,,,http://purl.obolibrary.org/obo/TXPO_0000247,,,,,,,,,,,,,,,,,,,,,,The process of binding or confining calcium ions such that they are separated from other components of a biological system.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_39124,,,,,,,,,,,,,,,,,,retention of calcium ion (Ca2+)|calcium ion (Ca2+) storage|calcium ion (Ca2+) retention|calcium ion (Ca2+) sequestration|calcium ion (Ca2+) sequestering|sequestering of calcium ion (Ca2+)|storage of calcium ion (Ca2+),,,,,GO:0051208,,,,,,,,,,,,,,,,,,,,,,sequestering of calcium ion,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0009395,phospholipid catabolic process,phospholipid breakdown|phospholipid catabolism|phospholipid degradation,"The chemical reactions and pathways resulting in the breakdown of phospholipids, any lipid containing phosphoric acid as a mono- or diester.",false,,,http://purl.obolibrary.org/obo/GO_0016042,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways resulting in the breakdown of phospholipids, any lipid containing phosphoric acid as a mono- or diester.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_16247,,,,,,,,,,,,,,,,,,phospholipid breakdown|phospholipid catabolism|phospholipid degradation,,,,,GO:0009395,,,,,,,,,,,,,,,,,,,,,,phospholipid catabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001962,tunicamycin-protein glycosylation inhibitor  [ER stress],,,false,,,http://purl.obolibrary.org/obo/CHEBI_29699|http://purl.obolibrary.org/obo/TXPO_0003012,,,,,,,,,,,,,,,,,,,,http://purl.bioontology.org/ontology/MESH/D014415|Open TG-Gates compound_id:00A02,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002184,,,,,,,,,,TXPO:0001962,,,,,,,,,,,,,,,,,,,,,,tunicamycin-protein glycosylation inhibitor  [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001968,XBP1 (canonical)[ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000405|http://purl.obolibrary.org/obo/TXPO_0000871,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:289754|NCBI-Human-GeneID:7494|NCBI-Mouse-GeneID:22433|PMID:25629003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002196,,,,,,,,,,TXPO:0001968,,,,,,,,,,,,,,,,,,,,,,XBP1 (canonical)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001966,protein serine/threonine kinase,,"Catalysis role of the reactions: ATP + protein serine = ADP + protein serine phosphate, and ATP + protein threonine = ADP + protein threonine phosphate.",false,,,http://purl.obolibrary.org/obo/TXPO_0001865,,,,,,,,,,,,,,,,,,,,EC:2.7.11.1|related molecular function GO:0004674,,"Catalysis role of the reactions: ATP + protein serine = ADP + protein serine phosphate, and ATP + protein threonine = ADP + protein threonine phosphate.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001966,,,,,,,,,,,,,,,,,,,,,,protein serine/threonine kinase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001964,phospholipidosis (latent),,"The totality of all processes through which the phospholipidosis is realized. This entity represents latent phospholipidosis, which describes the course of processes before toxic manifestation.
 In the drug exposure situation in phospholipidosis, it is known that CADs affect biological functioning. CADs bind to lysosomal membranes and form a complex with phospholipids, which negatively regulates phospholipid degradation. Therefore, the defence system cannot perform a ‘high’ level, i.e. there is a lack of adaptation. Under normal conditions, although the cell system can maintain the balance between increasing and decreasing phospholipid at a ‘medium’ level, in this state, the cellular system is in what is called the latent stage.",false,,,http://purl.obolibrary.org/obo/TXPO_0003382,,,,,,,,,,,,,,,,,,,,PMID:16979167|PMID:22960355|PMID:15342952,,"The totality of all processes through which the phospholipidosis is realized. This entity represents latent phospholipidosis, which describes the course of processes before toxic manifestation.
 In the drug exposure situation in phospholipidosis, it is known that CADs affect biological functioning. CADs bind to lysosomal membranes and form a complex with phospholipids, which negatively regulates phospholipid degradation. Therefore, the defence system cannot perform a ‘high’ level, i.e. there is a lack of adaptation. Under normal conditions, although the cell system can maintain the balance between increasing and decreasing phospholipid at a ‘medium’ level, in this state, the cellular system is in what is called the latent stage.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002273|http://purl.obolibrary.org/obo/TXPO_0004933|http://purl.obolibrary.org/obo/TXPO_0005189|http://purl.obolibrary.org/obo/TXPO_0002522|http://purl.obolibrary.org/obo/TXPO_0002293|http://purl.obolibrary.org/obo/TXPO_0003678|http://purl.obolibrary.org/obo/TXPO_0005059,,,,,,,,,,,,,,,,,,TXPO:0001964,,,,,,,,,,,,,,,,,,,,,,phospholipidosis (latent),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001960,HSP90B1 (canonical)[ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000171|http://purl.obolibrary.org/obo/TXPO_0000871,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:7184|PMID:23334697,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000007184,,,http://purl.obolibrary.org/obo/TXPO_0003997,,,,,,,,,,TXPO:0001960,,,,,,,,,,,,,,,,,,,,,,HSP90B1 (canonical)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000795,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001965,negative regulation of glycosylation [ER stress],,"Negative regulation ofglycosylation is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of glycosylation.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001516|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"Negative regulation ofglycosylation is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of glycosylation.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002161,,,,,,,,,,,TXPO:0001965,,,,,,,,,,,,,,,,,,,,,,negative regulation of glycosylation [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001961,CPT1 (canonical)[lipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003516|http://purl.obolibrary.org/obo/TXPO_1000097,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1374|https://www.ncbi.nlm.nih.gov/books/NBK1527/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001969|http://purl.obolibrary.org/obo/TXPO_0001967,,,,,,,,,,TXPO:0001961,,,,,,,,,,,,,,,,,,,,,,CPT1 (canonical)[lipidosis],,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001969,mitochondrial fatty acid βbeta-oxidation rate-limiting enzyme role,,A role played by the entity which determines the rate of a reaction by the slowest step.,false,,,http://purl.obolibrary.org/obo/TXPO_0003230,,,,,,,,,,,,,,,,,,,,,,A role played by the entity which determines the rate of a reaction by the slowest step.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001969,,,,,,,,,,,,,,,,,,,,,,mitochondrial fatty acid βbeta-oxidation rate-limiting enzyme role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001967,carnitine palmitoyltransferase,,,false,,,http://purl.obolibrary.org/obo/TXPO_0001385,,,,,,,,,,,,,,,,,,,,related molecular function GO:0004095,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001967,,,,,,,,,,,,,,,,,,,,,,carnitine palmitoyltransferase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001963,hypofunction of protein glycosylation,,Hypofunction of protein glycosylation is a subtype of hypofunctioning: A process that performs a decreased or insufficient protein glycosylation.,false,,,http://purl.obolibrary.org/obo/TXPO_0000436,,,,,,,,,,,,,,,,,,,,,,Hypofunction of protein glycosylation is a subtype of hypofunctioning: A process that performs a decreased or insufficient protein glycosylation.,,,http://purl.obolibrary.org/obo/GO_0006486,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001963,,,,,,,,,,,,,,,,,,,,,,hypofunction of protein glycosylation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000003,Wnt,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,GO:0005110,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000624,,,,,,,,,,IMR:0000003,,,,,,,,,,,,,,,,,,,,,,Wnt,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0001236,process quality,,A quality which inheres in an process.,false,,,http://purl.obolibrary.org/obo/BFO_0000019,,,,,,,,,,,,,,,,,,,,,,A quality which inheres in an process.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0001236,,,,,,,,,,,,,,,,,,,,,,process quality,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0001230,strength quality,,A quality inhering in a bearer by virtue of the bearer's power or force.,false,,,http://purl.obolibrary.org/obo/TXPO_0002413|http://purl.obolibrary.org/obo/BFO_0000019,,,,,,,,,,,,,,,,,,,,,,A quality inhering in a bearer by virtue of the bearer's power or force.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0001230,,,,,,,,,,,,,,,,,,,,,,strength quality,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_27026,toxin,,"Poisonous substance produced by a biological organism such as a microbe, animal or plant.",false,,,http://purl.obolibrary.org/obo/CHEBI_64909,,,,,,,,,,,,,,,,,,,,Wikipedia:Toxin,,"Poisonous substance produced by a biological organism such as a microbe, animal or plant.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:27026,,,,,,,,,,,,,,,,,,,,,,toxin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001383,lipid synthesis gene expression,,Lipid synthesis gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature lipid synthesis gene product or products (proteins or RNA).,false,,,http://purl.obolibrary.org/obo/GO_0010467,,,,,,,,,,,,,,,,,,,,,,Lipid synthesis gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature lipid synthesis gene product or products (proteins or RNA).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001383,,,,,,,,,,,,,,,,,,,,,,lipid synthesis gene expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001388,mitochondrial fatty acid beta-oxidation,,"A fatty acid oxidation process that results in the complete oxidation of a long-chain fatty acid in the mitochondria. Fatty acid beta-oxidation begins with the addition of coenzyme A to a fatty acid, and occurs by successive cycles of reactions during each of which the fatty acid is shortened by a two-carbon fragment removed as acetyl coenzyme A; the cycle continues until only two or three carbons remain (as acetyl-CoA or propionyl-CoA respectively).",false,,,http://purl.obolibrary.org/obo/GO_0006635,,,,,,,,,,,,,,,,,,,,,,"A fatty acid oxidation process that results in the complete oxidation of a long-chain fatty acid in the mitochondria. Fatty acid beta-oxidation begins with the addition of coenzyme A to a fatty acid, and occurs by successive cycles of reactions during each of which the fatty acid is shortened by a two-carbon fragment removed as acetyl coenzyme A; the cycle continues until only two or three carbons remain (as acetyl-CoA or propionyl-CoA respectively).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001388,,,,,,,,,,,,,,,,,,,,,,mitochondrial fatty acid beta-oxidation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001382,growth factor family,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001382,,,,,,,,,,,,,,,,,,,,,,growth factor family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001389,negative regulation of lipid transport from liver to peripheral tissue [Fibrosis],,"Negative regulation of lipid transport from liver to peripheral tissue is a subtype of negative regulation of lipid transport: A process that stops, prevents, or reduces the frequency, rate or extent of lipid transport from liver to peripheral tissue.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003742|http://purl.obolibrary.org/obo/TXPO_0001407,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of lipid transport from liver to peripheral tissue is a subtype of negative regulation of lipid transport: A process that stops, prevents, or reduces the frequency, rate or extent of lipid transport from liver to peripheral tissue.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001265,,,,,,,,,,,TXPO:0001389,,,,,,,,,,,,,,,,,,,,,,negative regulation of lipid transport from liver to peripheral tissue [Fibrosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001385,acyltransferase,,Catalysis role of the transfer of an acyl group from one compound (donor) to another (acceptor).,false,,,http://purl.obolibrary.org/obo/TXPO_0000606,,,,,,,,,,,,,,,,,,,,GO:0008415|EC:2.3.,,Catalysis role of the transfer of an acyl group from one compound (donor) to another (acceptor).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001385,,,,,,,,,,,,,,,,,,,,,,acyltransferase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001381,lipid degradation related gene expression,,Lipid degradtion related gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature lipid degradation related gene product or products (proteins or RNA).,false,,,http://purl.obolibrary.org/obo/GO_0010467,,,,,,,,,,,,,,,,,,,,,,Lipid degradtion related gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature lipid degradation related gene product or products (proteins or RNA).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001381,,,,,,,,,,,,,,,,,,,,,,lipid degradation related gene expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001384,MMP inactivation by TIMP1,,MMP inactivation by TIMP1 is a subtype of inactivating: A process that changes the activity of the MMP to be lower by TIMP1.,false,,,http://purl.obolibrary.org/obo/TXPO_0000021,,,,,,,,,,,,,,,,,,,,,,MMP inactivation by TIMP1 is a subtype of inactivating: A process that changes the activity of the MMP to be lower by TIMP1.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001384,,,,,,,,,,,,,,,,,,,,,,MMP inactivation by TIMP1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001387,fatty acid strorage [Fibrosis],,"Fatty acid strorage is a subtype of accumulation of substances in a biological object: A process that keeps fatty acid in a biological object.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003742|http://purl.obolibrary.org/obo/TXPO_0000256,,,,,,,,,,,,,,,,,,,,,,"Fatty acid strorage is a subtype of accumulation of substances in a biological object: A process that keeps fatty acid in a biological object.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001387,,,,,,,,,,,,,,,,,,,,,,fatty acid strorage [Fibrosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001380,leaking fluid from blood vessel,,Leaking fluid from blood vessel is a subtype of leaking: A process that leaks fluid out from the blood vessel.,false,,,http://purl.obolibrary.org/obo/TXPO_0001699,,,,,,,,,,,,,,,,,,,,,,Leaking fluid from blood vessel is a subtype of leaking: A process that leaks fluid out from the blood vessel.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001374,,,,,,,,,,,TXPO:0001380,,,,,,,,,,,,,,,,,,,,,,leaking fluid from blood vessel,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001386,lipid synthesis gene expression [lipidosis],,"Lipid synthesis gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature lipid synthesis gene product or products (proteins or RNA).
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.""",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0001383,,,,,,,,,,,,,,,,,,,,,,"Lipid synthesis gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature lipid synthesis gene product or products (proteins or RNA).
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.""",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003812,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001301|http://purl.obolibrary.org/obo/TXPO_0001394|http://purl.obolibrary.org/obo/TXPO_0001401,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001141,,,,,,,,,,,TXPO:0001386,,,,,,,,,,,,,,,,,,,,,,lipid synthesis gene expression [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005634,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100311,Smad2,,,false,,,http://purl.obolibrary.org/obo/IMR_0100504,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100311,,,,,,,,,,,,,,,,,,,,,,Smad2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001195,JNK translocation from cytoplasm to mitochondria,,JNK translocation from cytoplasm to mitochondria is a subtype of molecule transport: A process that of the directed movement of JNK from the cytoplasm to the mitochondria.,false,,,http://purl.obolibrary.org/obo/TXPO_0000111,,,,,,,,,,,,,,,,,,,,,,JNK translocation from cytoplasm to mitochondria is a subtype of molecule transport: A process that of the directed movement of JNK from the cytoplasm to the mitochondria.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001207,,,http://purl.obolibrary.org/obo/GO_0005739,http://purl.obolibrary.org/obo/GO_0005737,,,,,,,TXPO:0001195,,,,,,,,,,,,,,,,,,,,,,JNK translocation from cytoplasm to mitochondria,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001191,Glutathione  conjugation (supply) - function demand imbalance [Glutathione depletion],,"Glutathione conjugation (supply) - function demand imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance between glutathione conjugation supply and demand.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0002302|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Glutathione conjugation (supply) - function demand imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance between glutathione conjugation supply and demand.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001193,,,,,,,,,,,TXPO:0001191,,,,,,,,,,,,,,,,,,,,,,Glutathione  conjugation (supply) - function demand imbalance [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001197,malfunctioning of mitochondrial ATP synthesis coupled electron transpor [Glutathione depletion],,"Malfunctioning of mitochondrial ATP synthesis coupled electron transpor is a subtype of malfunctioning process: A process that cannot perform a respiratory electron transport chain appropriately or cannot realize it at all.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0001846|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Malfunctioning of mitochondrial ATP synthesis coupled electron transpor is a subtype of malfunctioning process: A process that cannot perform a respiratory electron transport chain appropriately or cannot realize it at all.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001202,,,,,,,,,,,TXPO:0001197,,,,,,,,,,,,,,,,,,,,,,malfunctioning of mitochondrial ATP synthesis coupled electron transpor [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001196,protein binding by NAPQI [Glutathione depletion],,"Protein binding by NAPQI is a subtype of protein binding: Interacting between a protein and NAPQI.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0001693|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Protein binding by NAPQI is a subtype of protein binding: Interacting between a protein and NAPQI.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000974,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001197,,,,,,,,,,,TXPO:0001196,,,,,,,,,,,,,,,,,,,,,,protein binding by NAPQI [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001198,DNA damage [Glutathione depletion],,"Drug-, radiation-induced, or spontaneous injuries to DNA that introduce deviations from its normal double-helical conformation. These changes include structural distortions that interfere with replication and transcription, as well as point mutations that disrupt base pairs and exert damaging effects on future generations through changes in DNA sequence. If the damage is minor, it can often be repaired (DNA repair); extensive damage can induce apoptosis.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/NCIT_C16507|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Drug-, radiation-induced, or spontaneous injuries to DNA that introduce deviations from its normal double-helical conformation. These changes include structural distortions that interfere with replication and transcription, as well as point mutations that disrupt base pairs and exert damaging effects on future generations through changes in DNA sequence. If the damage is minor, it can often be repaired (DNA repair); extensive damage can induce apoptosis.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001935,,,,,,http://purl.obolibrary.org/obo/TXPO_0001204|http://purl.obolibrary.org/obo/TXPO_0002369,,,,,,,,,,,TXPO:0001198,,,,,,,,,,,,,,,,,,,,,,DNA damage [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001194,glutathione biosynthetic process [Glutathione depletion],,"The chemical reactions and pathways resulting in the formation of glutathione, the tripeptide glutamylcysteinylglycine, which acts as a coenzyme for some enzymes and as an antioxidant in the protection of sulfhydryl groups in enzymes and other proteins.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/GO_0006750|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,https://reactome.org/PathwayBrowser/#/R-HSA-174403,,"The chemical reactions and pathways resulting in the formation of glutathione, the tripeptide glutamylcysteinylglycine, which acts as a coenzyme for some enzymes and as an antioxidant in the protection of sulfhydryl groups in enzymes and other proteins.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000193|http://purl.obolibrary.org/obo/TXPO_0001929|http://purl.obolibrary.org/obo/TXPO_0001928|http://purl.obolibrary.org/obo/TXPO_0001943,,,,,,http://purl.obolibrary.org/obo/TXPO_0001925|http://purl.obolibrary.org/obo/TXPO_0002368,,,,,,,,,,,TXPO:0001194,,,,,,,"The formation of glutathione, the tripeptide glutamylcysteinylglycine, which acts as a coenzyme for some enzymes and as an antioxidant in the protection of sulfhydryl groups in enzymes and other protein.",,,,,,,,,,,,,,,glutathione biosynthetic process [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001193,glutathione depletion [Glutathione depletion],,"Glutathione depletion is a subtype of depleting: A process that lessens markedly in the amount of glutathione.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0000483|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Glutathione depletion is a subtype of depleting: A process that lessens markedly in the amount of glutathione.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003178|http://purl.obolibrary.org/obo/TXPO_0001194|http://purl.obolibrary.org/obo/TXPO_0001192,,,,,,,,,,,TXPO:0001193,,,,,,,,,,,,,,,,,,,,,,glutathione depletion [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001192,NAPQI accumulation [Glutathione depletion],,"NAPQI accumulation is a subtype of accumulation of substances in a biological object: A process that keeps NAPQI (N-acetyl-p-benzoquinone imine) within a biological object(s). NAPQI is an intermediate metabolite of the paracetamol and plays a role as a toxic substance in the body.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0001751|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"NAPQI accumulation is a subtype of accumulation of substances in a biological object: A process that keeps NAPQI (N-acetyl-p-benzoquinone imine) within a biological object(s). NAPQI is an intermediate metabolite of the paracetamol and plays a role as a toxic substance in the body.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000974,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001196,,,,,,,,,,,TXPO:0001192,,,,,,,,,,,,,,,,,,,,,,NAPQI accumulation [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001190,decreasing excretion quantity of the conjugates [Glutathione depletion],,"Decreasing excretion quantity of bile acid is a subtype of decreasing quantity: A process that changes the excretion quantity of of bile acids to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0002305|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Decreasing excretion quantity of bile acid is a subtype of decreasing quantity: A process that changes the excretion quantity of of bile acids to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002759,,,,,,,,,,,TXPO:0001190,,,,,,,,,,,,,,,,,,,,,,decreasing excretion quantity of the conjugates [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001199,increasing free radical [Glutathione depletion],,"Increasing free radical is a subtype of increasing quantity: A process that changes the amount of free radicals to be larger.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0000889|http://purl.obolibrary.org/obo/TXPO_0001790,,,,,,,,,,,,,,,,,,,,,,"Increasing free radical is a subtype of increasing quantity: A process that changes the amount of free radicals to be larger.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002375|http://purl.obolibrary.org/obo/TXPO_0001200|http://purl.obolibrary.org/obo/TXPO_0001205,,,,,,,,,,,TXPO:0001199,,,,,,,,,,,,,,,,,,,,,,increasing free radical [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_52290,mitogen,mitogens,"A chemical substance that encourages a cell to commence cell division, triggering mitosis.",false,,,http://purl.obolibrary.org/obo/CHEBI_24432,,,,,,,,,,,,,,,,,,,,,,"A chemical substance that encourages a cell to commence cell division, triggering mitosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,mitogens,,,,,,,,,,,,,,,,,,,,,CHEBI:52290,,,,mitogen,,CHEBI:52290,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000676,cGMP-dependent protein kinase I,type I beta cGMP-dependent protein kinase|type I alpha cGMP-dependent protein kinase,,false,,,http://purl.obolibrary.org/obo/IMR_0000251,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000678,type I beta cGMP-dependent protein kinase|type I alpha cGMP-dependent protein kinase,,,,,IMR:0000676,,,,,,,,,,,,,,,,,,,,,,cGMP-dependent protein kinase I,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001433,BMP-8b,OP-3|BMP8b|Bone morphogenetic protein 8b,,false,,,http://purl.obolibrary.org/obo/IMR_0003084,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,OP-3|BMP8b|Bone morphogenetic protein 8b,,,,,IMR:0001433,,,,,,,,,,,,,,,,,,,,,,BMP-8b,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000187,HMGA1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:3159|NCBI-Mouse-GeneID:15361|NCBI-Rat-GeneID:117062,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000003159,,,,,,,,,,,,,TXPO:1000187,,,,,,,,,,,,,,,,,,,,,,HMGA1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000183,HDGFRP3 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000050810,,,,,,,,,,,,,TXPO:1000183,,,,,,,,,,,,,,,,,,,,,,HDGFRP3 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000185,HIF3A (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:64344|NCBI-Mouse-GeneID:53417|NCBI-Rat-GeneID:64345,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000064344,,,,,,,,,,,,,TXPO:1000185,,,,,,,,,,,,,,,,,,,,,,HIF3A (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000181,H3f3b (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:3021|NCBI-Rat-GeneID:117056|NCBI-Mouse-GeneID:15081,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000003021,,,,,,,,,,,,,TXPO:1000181,,,,,,,,,,,,,,,,,,,,,,H3f3b (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000182,HCK (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:15162|NCBI-Rat-GeneID:25734|NCBI-Human-GeneID:3055,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000003055,,,,,,,,,,,,,TXPO:1000182,,,,,,,,,,,,,,,,,,,,,,HCK (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000189,HMGCS2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24450|NCBI-Mouse-GeneID:15360|NCBI-Human-GeneID:3158|PMID:11479731|PMID:27816970|PMID:19710929,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000003158,,,,,,,,,,,,,TXPO:1000189,,,,,,,,,,,,,,,,,,,,,,HMGCS2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000180,GSTM3 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0002089,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:14864|NCBI-Rat-GeneID:108348148|NCBI-Human-GeneID:2947,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000002947,,,,,,,,,,,,,TXPO:1000180,,,,,,,,,,,,,,,,,,,,,,GSTM3 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000188,HMGCS1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:29637|NCBI-Human-GeneID:3157|NCBI-Mouse-GeneID:208715,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000003157,,,,,,,,,,,,,TXPO:1000188,,,,,,,,,,,,,,,,,,,,,,HMGCS1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000184,HERPUD1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:85430|NCBI-Mouse-GeneID:64209|NCBI-Human-GeneID:9709,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000009709,,,,,,,,,,,,,TXPO:1000184,,,,,,,,,,,,,,,,,,,,,,HERPUD1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000186,HLADPB2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000003116,,,,,,,,,,,,,TXPO:1000186,,,,,,,,,,,,,,,,,,,,,,HLADPB2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0032782,bile acid secretion,,"The regulated release of bile acid, composed of any of a group of steroid carboxylic acids occurring in bile, by a cell or a tissue.",false,,,http://purl.obolibrary.org/obo/TXPO_0002588,,,,,,,,,,,,,,,,,,,,,,"The regulated release of bile acid, composed of any of a group of steroid carboxylic acids occurring in bile, by a cell or a tissue.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000509,,,,,,,,,,,,,,,,,,,GO:0032782,,,,,,,"Bile contains bile acids, glutathione, phospholipids, cholesterol, bilirubin, and other organic anions, proteins, metals, ions, and xenobiotics.

Hepatocytes begins the formation of bile by transporting bile acids, glutathione, and other solutes including Xenobiotics and their metabolites into the canalicular lumen.

The major driving force of bile formation is the active transport of bile salts and other osmolytes into the canalicular lumen.

Most conjugated bile acids (taurine and glycine conjugates) and some unconjugated bile acids are transported into hepatocytes by sodium-dependent transporters.

Sodium-independent uptake of conjugated and unconjugated bile acids is performed by members of the organic anion-transporting polypeptides (OATPs).
OATPs also transport numerous drugs and hepatotoxicants.

Lipophilic cationic drugs, estrogens, and lipids are exported by the canalicular multiple-drug resistance (MDR) P-glycoproteins, one of which is exclusive for phospholipids.

Conjugates of glutathione, glucuronide, and sulfate are exported by multidrug resistance-associated protein2 (MRP2).",,,,,,,,,,,,,,,bile acid secretion,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100041,retinoic acid,vitamin A acid|Tretinoin|all-trans-Retinoic Acid|Retin A|all-trans-Vitamin A acid,,false,,,http://purl.obolibrary.org/obo/IMR_0000877,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,vitamin A acid|Tretinoin|all-trans-Retinoic Acid|Retin A|all-trans-Vitamin A acid,,,,,IMR:0100041,,,,,,,,,,,,,,,,,,,,,,retinoic acid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002130,malfunctioning of metabolism,,Malfunctioning of metabolism is a subtype of malfunctioning process: A process that cannot perform a metabolism appropriately or cannot realize it at all.,false,,,http://purl.obolibrary.org/obo/TXPO_0000434,,,,,,,,,,,,,,,,,,,,,,Malfunctioning of metabolism is a subtype of malfunctioning process: A process that cannot perform a metabolism appropriately or cannot realize it at all.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002130,,,,,,,,,,,,,,,,,,,,,,malfunctioning of metabolism,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0008152,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002135,regulation of gene expression by p53 [Cell death],,"Regulation of gene expression by p53 is a subtype of regulation of gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of gene expression.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0001727|http://purl.obolibrary.org/obo/TXPO_0002136,,,,,,,,,,,,,,,,,,,,,,"Regulation of gene expression by p53 is a subtype of regulation of gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of gene expression.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000650|http://purl.obolibrary.org/obo/TXPO_0000653|http://purl.obolibrary.org/obo/TXPO_0000640|http://purl.obolibrary.org/obo/TXPO_0000845|http://purl.obolibrary.org/obo/TXPO_0000843,,,,,,http://purl.obolibrary.org/obo/TXPO_0000374|http://purl.obolibrary.org/obo/TXPO_0000448,,,,,,,,,,,TXPO:0002135,,,,,,,,,,,,,,,,,,,,,,regulation of gene expression by p53 [Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002136,regulation of gene expression by p53,,"Regulation of gene expression by p53 is a subtype of regulation of gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of gene expression.",false,,,http://purl.obolibrary.org/obo/GO_0010468,,,,,,,,,,,,,,,,,,,,,,"Regulation of gene expression by p53 is a subtype of regulation of gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of gene expression.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000843,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002136,,,,,,,,,,,,,,,,,,,,,,regulation of gene expression by p53,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002138,membrane phospholipid catabolic process [Cell death],,"Membrane phospholipid catabolic process is a subtype of lipid catabolic process: The chemical reactions resulting in the breakdown of membrane phopholipids
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0001727|http://purl.obolibrary.org/obo/TXPO_0000393,,,,,,,,,,,,,,,,,,,,,,"Membrane phospholipid catabolic process is a subtype of lipid catabolic process: The chemical reactions resulting in the breakdown of membrane phopholipids
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002138,,,,,,,,,,,,,,,,,,,,,,membrane phospholipid catabolic process [Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002137,DNA repair [Cell death],,"The process of restoring DNA after damage. Genomes are subject to damage by chemical and physical agents in the environment (e.g. UV and ionizing radiations, chemical mutagens, fungal and bacterial toxins, etc.) and by free radicals or alkylating agents endogenously generated in metabolism. DNA is also damaged because of errors during its replication. A variety of different DNA repair pathways have been reported that include direct reversal, base excision repair, nucleotide excision repair, photoreactivation, bypass, double-strand break repair pathway, and mismatch repair pathway.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0001727|http://purl.obolibrary.org/obo/GO_0006281,,,,,,,,,,,,,,,,,,,,,,"The process of restoring DNA after damage. Genomes are subject to damage by chemical and physical agents in the environment (e.g. UV and ionizing radiations, chemical mutagens, fungal and bacterial toxins, etc.) and by free radicals or alkylating agents endogenously generated in metabolism. DNA is also damaged because of errors during its replication. A variety of different DNA repair pathways have been reported that include direct reversal, base excision repair, nucleotide excision repair, photoreactivation, bypass, double-strand break repair pathway, and mismatch repair pathway.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000377,,,,,,,,,,,TXPO:0002137,,,,,,,,,,,,,,,,,,,,,,DNA repair [Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002133,changing fatty acid homeostasis in peroxisome,,Changing fatty acid homeostasis in peroxisome is a subtype of changing balance: A process that changes the steady state of fatty acid within peroxisomes.,false,,,http://purl.obolibrary.org/obo/TXPO_0002132,,,,,,,,,,,,,,,,,,,,,,Changing fatty acid homeostasis in peroxisome is a subtype of changing balance: A process that changes the steady state of fatty acid within peroxisomes.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002133,,,,,,,,,,,,,,,,,,,,,,changing fatty acid homeostasis in peroxisome,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002134,changing fatty acid homeostasis in peroxisome [Eosinophilic granular degeneration],,"Changing fatty acid homeostasis in peroxisome is a subtype of lipid homeostasis imbalance: A process that changes the steady state of fatty acid within peroxisomes.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/TXPO_0001729|http://purl.obolibrary.org/obo/TXPO_0002133,,,,,,,,,,,,,,,,,,,,,,"Changing fatty acid homeostasis in peroxisome is a subtype of lipid homeostasis imbalance: A process that changes the steady state of fatty acid within peroxisomes.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000105,,,,,,,,,,,TXPO:0002134,,,,,,,,,,,,,,,,,,,,,,changing fatty acid homeostasis in peroxisome [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002131,metabolic dysfunction,,Metabolic dysfunction is a subtype of dysfunctioning: A process that performs an abnormal and incomplete metabolic function.,false,,,http://purl.obolibrary.org/obo/TXPO_0000438,,,,,,,,,,,,,,,,,,,,,,Metabolic dysfunction is a subtype of dysfunctioning: A process that performs an abnormal and incomplete metabolic function.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002131,,,,,,,,,,,,,,,,,,,,,,metabolic dysfunction,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002132,changing fatty acid homeostasis,,Changing fatty acid homeostasis is a subtype of changing balance: A process that changes the steady state of fatty acid within an organism or cell.,false,,,http://purl.obolibrary.org/obo/TXPO_0001847,,,,,,,,,,,,,,,,,,,,,,Changing fatty acid homeostasis is a subtype of changing balance: A process that changes the steady state of fatty acid within an organism or cell.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002132,,,,,,,,,,,,,,,,,,,,,,changing fatty acid homeostasis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002139,pathogen proliferation,,"Pathogen proliferation is a subtype of increasing number of objects: A process becomes larger in the number of pathogen such as microorganism (bacteria,  virus, mycoplasma, etc.) present in the body.",false,,,http://purl.obolibrary.org/obo/TXPO_0000093,,,,,,,,,,,,,,,,,,,,,,"Pathogen proliferation is a subtype of increasing number of objects: A process becomes larger in the number of pathogen such as microorganism (bacteria,  virus, mycoplasma, etc.) present in the body.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002139,,,,,,,,,,,,,,,,,,,,,,pathogen proliferation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000190,actin,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003692,,,,,,,,,,IMR:0000190,,,,,,,,,,,,,,,,,,,,,,actin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010020,Elongin,SIII,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003644,,,,,SIII,,,,,IMR:0010020,,,,,,,,,,,,,,,,,,,,,,Elongin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000083452,RAB33B,,Other designations: ras-related protein Rab-33B,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,SMC2,,,,,,,,,,,,4,,,,,,HGNC:16075|Ensembl:ENSG00000172007|MIM:605950|Vega:OTTHUMG00000133384|HPRD:05808,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"RAB33B, member RAS oncogene family",,,4q28,,,,,,,,,,,,,,,,"GO_0000139 (EC: IEA); GO_0005525 (EC: IEA); GO_0005794 (EC: IDA); GO_0005796 (EC: IDA, PMID: 18448665); GO_0006914 (EC: IEA); GO_0007264 (EC: IEA); GO_0015031 (EC: IEA); GO_2000156 (EC: IMP); GO_2000785 (EC: ISS)",,,,,,,,,PMID: 9512502; 11230166; 11256614; 11718716; 12477932; 15489334; 15761153; 15815621; 16923123; 18448665; 21139048; 22178446; 22652534; 23091056; 24250222,,,,,,,,,,,,,,,OGG:3000083452,,,,,,,"RAB33B, member RAS oncogene family",,,,,,,,,,,,,Other designations: ras-related protein Rab-33B,,RAB33B,,,,,,,,,,,,,,,,,,,,,,,83452,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,RAB33B,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000016,EPO,erythropoietin,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,GO:0005128|Wikipedia:Erythropoietin|OMIM: 133170,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000155|http://purl.obolibrary.org/obo/TXPO_0000622,,,,,erythropoietin,,,,,IMR:0000016,,,,,,,,,,,,,,,,,,,,,,EPO,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_83317,sterol biosynthesis inhibitor,sterol biosynthesis inhibitors,Any compound that inhibits the biosynthesis of any sterol.,false,,,http://purl.obolibrary.org/obo/CHEBI_35222|http://purl.obolibrary.org/obo/CHEBI_52206,,,,,,,,,,,,,,,,,,,,,,Any compound that inhibits the biosynthesis of any sterol.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sterol biosynthesis inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:83317,,,,sterol biosynthesis inhibitor,,CHEBI:83317,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0002395,TCR delta,T-cell receptor delta,,false,,,http://purl.obolibrary.org/obo/IMR_0000151,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,T-cell receptor delta,,,,,IMR:0002395,,,,,,,,,,,,,,,,,,,,,,TCR delta,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000003021,H3F3B,,"Other designations: H3 histone, family 3A|histone H3.3",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,H3.3B,,,,,,,,,,,,17,,,,,,Vega:OTTHUMG00000179842|Ensembl:ENSG00000132475|HGNC:4765|HPRD:03036|MIM:601058,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"H3 histone, family 3B (H3.3B)",,,17q25.1,,,,,,,,,,,,,,,,"GO_0000786 (EC: IEA); GO_0003677 (EC: IEA); GO_0005515 (EC: IPI, PMID: 19494831); GO_0005576 (EC: TAS); GO_0005654 (EC: TAS); GO_0006334 (EC: IEA); GO_0007420 (EC: IEA); GO_0007596 (EC: TAS); GO_0009725 (EC: IEA); GO_0046982 (EC: IEA); GO_0070062 (EC: IDA)",,,,,,,,,PMID: 1748304; 7557364; 8586426; 8889548; 9188772; 9334241; 9566873; 9731536; 10096020; 11076863; 11080476; 11230166; 11278789; 11591653; 11689053; 11751582; 12477932; 12909349; 14527345; 14657027; 14702039; 15489336; 15616580; 15664198; 15674325; 16189514; 16381901; 16728976; 17620599; 18029348; 18760861; 19494831; 20110566; 20504901; 22174317; 22505724; 22623428; 23463506; 24162739,,,,,,,,,,,,,,,OGG:3000003021,,,,,,,"H3 histone, family 3B (H3.3B)",,,,,,,,,,,,,"Other designations: H3 histone, family 3A|histone H3.3",,H3F3B,,,,,,,,,,,,,,,,,,,,,,,3021,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,H3F3B,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/GO_0045806,negative regulation of endocytosis,,"Any process that stops, prevents, or reduces the frequency, rate or extent of endocytosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000369,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents, or reduces the frequency, rate or extent of endocytosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0045806,,,,,,,,,,,,,,,,,,,,,,negative regulation of endocytosis,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006897,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004675,trichloroethylene [hepatocarcinogenesis],"1,1,2-trichloroethene","A member of the class of chloroethenes that is ethene substituted by chloro groups at positions 1, 1 and 2.",false,,,http://purl.obolibrary.org/obo/CHEBI_16602|http://purl.obolibrary.org/obo/TXPO_0004455,,,,,,,,,,,,,,,,,,,,PMID:10774822|CAS:79-01-6|Wikipedia:Trichloroethylene,,"A member of the class of chloroethenes that is ethene substituted by chloro groups at positions 1, 1 and 2.",,,,,,,,,,,,C2HCl3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"1,1,2-trichloroethene",,,,,TXPO:0004675,,,,,,,,,,,,,,,,,,,,,,trichloroethylene [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ClC=C(Cl)Cl,,,,,
http://purl.obolibrary.org/obo/TXPO_0004674,dichloroacetic acid [hepatocarcinogenesis],,"An organochlorine compound comprising acetic acid carrying two chloro substituents at the 2-position. It occurs in nature in seaweed, Asparagopsis taxiformis.",false,,,http://purl.obolibrary.org/obo/TXPO_0004455|http://purl.obolibrary.org/obo/CHEBI_36386,,,,,,,,,,,,,,,,,,,,PMID:10774822|CAS:79-43-6|Wikipedia:Dichloroacetic_acid,,"An organochlorine compound comprising acetic acid carrying two chloro substituents at the 2-position. It occurs in nature in seaweed, Asparagopsis taxiformis.",,,,,,,,,,,,C2H2Cl2O2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004674,,,,,,,,,,,,,,,,,,,,,,dichloroacetic acid [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,OC(=O)C(Cl)Cl,,,,,
http://purl.obolibrary.org/obo/TXPO_0004676,trichloroacetic acid [hepatocarcinogenesis],,A monocarboxylic acid that is acetic acid in which all three methyl hydrogens are substituted by chlorine.,false,,,http://purl.obolibrary.org/obo/CHEBI_30956|http://purl.obolibrary.org/obo/TXPO_0004455,,,,,,,,,,,,,,,,,,,,PMID:10774822|CAS:76-03-9,,A monocarboxylic acid that is acetic acid in which all three methyl hydrogens are substituted by chlorine.,,,,,,,,,,,,C2HCl3O2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004676,,,,,,,,,,,,,,,,,,,,,,trichloroacetic acid [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,OC(=O)C(Cl)(Cl)Cl,,,,,
http://purl.obolibrary.org/obo/TXPO_0004678,KIAA0101 - inactive form (predicted)(human) [hepatocarcinogenesis],NS5ATP9|PCLAF,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_0004193,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:9768|PMID:29227529,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000009768,,,,,,,,NS5ATP9|PCLAF,,,,,TXPO:0004678,,,,,,,,,,,,,,,,,,,,,,KIAA0101 - inactive form (predicted)(human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004677,KIAA0101 inactivation,,"KIAA0101 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the KIAA0101 (PCLAF, PCNA clamp associated factor) to be lower.",false,,,http://purl.obolibrary.org/obo/TXPO_0000021,,,,,,,,,,,,,,,,,,,,,,"KIAA0101 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the KIAA0101 (PCLAF, PCNA clamp associated factor) to be lower.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004677,,,,,,,,,,,,,,,,,,,,,,KIAA0101 inactivation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004672,proto-oncogene promoter demethylation,,The process of removing one or more methyl groups from proto-oncogene promoter.,false,,,http://purl.obolibrary.org/obo/GO_0070988,,,,,,,,,,,,,,,,,,,,,,The process of removing one or more methyl groups from proto-oncogene promoter.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004672,,,,,,,,,,,,,,,,,,,,,,proto-oncogene promoter demethylation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004670,JUN(mouse) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/IMR_0000416|http://purl.obolibrary.org/obo/TXPO_0005072,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:16476|PMID:10774822,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004670,,,,,,,,,,,,,,,,,,,,,,JUN(mouse) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004673,JUN gene promoter demethylation [hepatocarcinogenesis],,"The process of removing one or more methyl groups from JUN gene promoter.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004671,,,,,,,,,,,,,,,,,,,,PMID:10774822,,"The process of removing one or more methyl groups from JUN gene promoter.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004670,,,,,,http://purl.obolibrary.org/obo/TXPO_0004675|http://purl.obolibrary.org/obo/TXPO_0004674|http://purl.obolibrary.org/obo/TXPO_0004676,,,,,,http://purl.obolibrary.org/obo/TXPO_0004669,,,,,,,,,,,TXPO:0004673,,,,,,,,,,,,,,,,,,,,,,JUN gene promoter demethylation [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004679,negative regulation of autophagy [hepatocarcinogenesis],,"Any process that stops, prevents, or reduces the frequency, rate or extent of autophagy. Autophagy is the process in which cells digest parts of their own cytoplasm.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/GO_0010507|http://purl.obolibrary.org/obo/TXPO_0002340,,,,,,,,,,,,,,,,,,,,PMID:29227529,,"Any process that stops, prevents, or reduces the frequency, rate or extent of autophagy. Autophagy is the process in which cells digest parts of their own cytoplasm.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004919,,,,,,,,,,,TXPO:0004679,,,,,,,,,,,,,,,,,,,,,,negative regulation of autophagy [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004671,JUN gene promoter demethylation,,The process of removing one or more methyl groups from JUN gene promoter.,false,,,http://purl.obolibrary.org/obo/TXPO_0004672,,,,,,,,,,,,,,,,,,,,,,The process of removing one or more methyl groups from JUN gene promoter.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004671,,,,,,,,,,,,,,,,,,,,,,JUN gene promoter demethylation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001533,R-Ras2,,,false,,,http://purl.obolibrary.org/obo/IMR_0000292,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001533,,,,,,,,,,,,,,,,,,,,,,R-Ras2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000253,mammalian Ste20-like kinases (MAPKKKK),,,false,,,http://purl.obolibrary.org/obo/IMR_0000252,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000253,,,,,,,,,,,,,,,,,,,,,,mammalian Ste20-like kinases (MAPKKKK),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100461,IKK epsilon,,,false,,,http://purl.obolibrary.org/obo/IMR_0000701,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100461,,,,,,,,,,,,,,,,,,,,,,IKK epsilon,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004745,Increasing PCNA level [hepatocarcinogenesis],,"Increasing PCNA level is a subtype of increasing quantity: A process that changes the amount of PCNA level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004743,,,,,,,,,,,,,,,,,,,,PMID:31239782,,"Increasing PCNA level is a subtype of increasing quantity: A process that changes the amount of PCNA level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004746,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004403,,,,,,,,,,,TXPO:0004745,,,,,,,,,,,,,,,,,,,,,,Increasing PCNA level [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004748,PHB (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:5245|NCBI-Mouse-GeneID:18673|NCBI-Rat-GeneID:25344,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004748,,,,,,,,,,,,,,,,,,,,,,PHB (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004743,Increasing PCNA level,,Increasing PCNA level is a subtype of increasing quantity: A process that changes the amount of PCNA level to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing PCNA level is a subtype of increasing quantity: A process that changes the amount of PCNA level to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004744,,,,,,,,,,,,,,,,,,,TXPO:0004743,,,,,,,,,,,,,,,,,,,,,,Increasing PCNA level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004744,PCNA (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:5111|NCBI-Rat-GeneID:25737|NCBI-Mouse-GeneID:18538,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004744,,,,,,,,,,,,,,,,,,,,,,PCNA (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004742,negative regulation of gluconeogenesis [mitochondrial disorder],,"Any process that stops, prevents, or reduces the frequency, rate or extent of gluconeogenesis.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/GO_0045721|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:29335519,,"Any process that stops, prevents, or reduces the frequency, rate or extent of gluconeogenesis.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004941|http://purl.obolibrary.org/obo/TXPO_0004264,,,,,,,,,,,TXPO:0004742,,,,,,,,,,,,,,,,,,,,,,negative regulation of gluconeogenesis [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004741,PCK1 activation [mitochondrial disorder],,"PCK1 activation is a subtype of molecular activation: A process that  changes the activity of the PCK1 (phosphoenolpyruvate carboxykinase 1) to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0004740|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:29335519|PMID:26571396,,"PCK1 activation is a subtype of molecular activation: A process that  changes the activity of the PCK1 (phosphoenolpyruvate carboxykinase 1) to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004176,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001990|http://purl.obolibrary.org/obo/TXPO_0004742|http://purl.obolibrary.org/obo/TXPO_0004126,,,,,,,,,,,TXPO:0004741,,,,,,,,,,,,,,,,,,,,,,PCK1 activation [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004740,PCK1 activation,,PCK1 activation is a subtype of molecular activation: A process that  changes the activity of the PCK1 (phosphoenolpyruvate carboxykinase 1) to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000023,,,,,,,,,,,,,,,,,,,,,,PCK1 activation is a subtype of molecular activation: A process that  changes the activity of the PCK1 (phosphoenolpyruvate carboxykinase 1) to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004740,,,,,,,,,,,,,,,,,,,,,,PCK1 activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004747,PHB inactivation,,PHB inactivation is a subtype of molecular inactivation: A process that  changes the activity of the PHB (prohibitin) to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000021,,,,,,,,,,,,,,,,,,,,,,PHB inactivation is a subtype of molecular inactivation: A process that  changes the activity of the PHB (prohibitin) to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004747,,,,,,,,,,,,,,,,,,,,,,PHB inactivation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004746,PCNA (human) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_0004744,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:5111|PMID:31239782,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004746,,,,,,,,,,,,,,,,,,,,,,PCNA (human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004749,PHB inactivation [hepatocarcinogenesis],,"PHB inactivation is a subtype of molecular inactivation: A process that  changes the activity of the PHB (prohibitin) to be lower.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004747,,,,,,,,,,,,,,,,,,,,PMID:30523154,,"PHB inactivation is a subtype of molecular inactivation: A process that  changes the activity of the PHB (prohibitin) to be lower.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004750,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004489|http://purl.obolibrary.org/obo/TXPO_0004298,,,,,,,,,,,TXPO:0004749,,,,,,,,,,,,,,,,,,,,,,PHB inactivation [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000001964,EIF1AX,,"Other designations: Putative eukaryotic translation initiation factor 1A|eIF-1A X isoform|eukaryotic translation initiation factor 1A, X chromosome|eukaryotic translation initiation factor 1A, X-chromosomal|eukaryotic translation initiation factor 4C",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,eIF-1A|EIF1AP1|EIF1A|eIF-4C|EIF4C,,,,,,,,,,,,X,,,,,,HPRD:02174|HGNC:3250|Vega:OTTHUMG00000022704|MIM:300186|Ensembl:ENSG00000173674,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"eukaryotic translation initiation factor 1A, X-linked",,,Xp22.12,,,,,,,,,,,,,,,,"GO_0003743 (EC: IEA); GO_0005829 (EC: TAS); GO_0006412 (EC: TAS); GO_0006413 (EC: TAS); GO_0008135 (EC: TAS, PMID:8106356); GO_0010467 (EC: TAS); GO_0044267 (EC: TAS); GO_0044822 (EC: IDA)",,,,,,,,,PMID:8106356; 9381176; 10678173; 10982835; 11447110; 11699879; 12426392; 12477932; 12514125; 12569173; 12588972; 14660691; 15489334; 15772651; 16710414; 17784828; 18029348; 19322201; 20060839; 20098747; 20434207; 21832049; 21890473; 21906983; 22505724; 22863883; 22939629; 23000965; 23293029; 23793026; 24250222,,,,,,,,,,,,,,,OGG:3000001964,,,,,,,"eukaryotic translation initiation factor 1A, X-linked",,,,,,,,,,,,,"Other designations: Putative eukaryotic translation initiation factor 1A|eIF-1A X isoform|eukaryotic translation initiation factor 1A, X chromosome|eukaryotic translation initiation factor 1A, X-chromosomal|eukaryotic translation initiation factor 4C",,EIF1AX,,,,,,,,,,,,,,,,,,,,,,,1964,RP11-393H10.1,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF1AX,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001962,EHHADH,,"Other designations: 3,2-trans-enoyl-CoA isomerase|L-3-hydroxyacyl-CoA dehydrogenase|L-bifunctional protein, peroxisomal|PBE|enoyl-Coenzyme A, hydratase/3-hydroxyacyl Coenzyme A dehydrogenase|peroxisomal bifunctional enzyme|peroxisomal enoyl-CoA hydratase",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,FRTS3|LBP|L-PBE|ECHD|PBFE|LBFP,,,,,,,,,,,,3,,,,,,Vega:OTTHUMG00000156698|HPRD:06125|Ensembl:ENSG00000113790|MIM:607037|HGNC:3247,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"enoyl-CoA, hydratase/3-hydroxyacyl CoA dehydrogenase",,,3q26.3-q28,,,,,,,,,,,,,,,,"GO_0003857 (EC: NAS, PMID: 8188243); GO_0004165 (EC: IEA); GO_0004300 (EC: NAS, PMID: 8188243); GO_0005102 (EC: IPI); GO_0005634 (EC: IDA); GO_0005730 (EC: IDA, Qualifier: NOT); GO_0005737 (EC: IDA); GO_0005739 (EC: IEA); GO_0005777 (EC: IDA, PMID: 1651711); GO_0005777 (EC: NAS, PMID: 8188243); GO_0005829 (EC: IEA); GO_0006475 (EC: IDA); GO_0006635 (EC: IEA); GO_0006635 (EC: NAS, PMID: 8188243); GO_0019899 (EC: IPI, PMID: 16781659); GO_0043231 (EC: IDA); GO_0050662 (EC: IEA)",,,,,,,,,PMID: 1651711; 2895531; 8125298; 8188243; 9053548; 10856712; 12477932; 16781659; 18029348; 18660489; 19240061; 19734545; 20178365; 20877624; 21042317; 22002062; 24401050,,,,,,,,,,,,,,,OGG:3000001962,,,,,,,"enoyl-CoA, hydratase/3-hydroxyacyl CoA dehydrogenase",,,,,,,,,,,,,"Other designations: 3,2-trans-enoyl-CoA isomerase|L-3-hydroxyacyl-CoA dehydrogenase|L-bifunctional protein, peroxisomal|PBE|enoyl-Coenzyme A, hydratase/3-hydroxyacyl Coenzyme A dehydrogenase|peroxisomal bifunctional enzyme|peroxisomal enoyl-CoA hydratase",,EHHADH,,,,,,,,,,,,,,,,,,,,,,,1962,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,EHHADH,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001965,EIF2S1,,Other designations: eIF-2-alpha|eukaryotic translation initiation factor 2 subunit 1|eukaryotic translation initiation factor 2 subunit alpha,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,EIF2|EIF-2|EIF2A|EIF-2alpha|EIF-2A,,,,,,,,,,,,14,,,,,,HGNC:3265|MIM:603907|Ensembl:ENSG00000134001|Vega:OTTHUMG00000029800|HPRD:04881,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"eukaryotic translation initiation factor 2, subunit 1 alpha, 35kDa",,,14q23.3,,,,,,,,,,,,,,,,"GO_0003743 (EC: IDA, PMID:16289705); GO_0005515 (EC: IPI, PMID:11500362); GO_0005634 (EC: IEA); GO_0005829 (EC: TAS); GO_0005844 (EC: TAS, PMID:2948954); GO_0005850 (EC: IEA); GO_0005851 (EC: IDA, Qualifier: colocalizes_with, PMID:11323413); GO_0006412 (EC: TAS); GO_0006413 (EC: TAS); GO_0006987 (EC: TAS); GO_0010467 (EC: TAS); GO_0010494 (EC: ISS); GO_0030968 (EC: TAS); GO_0043022 (EC: IDA, PMID:17894550); GO_0043558 (EC: IEA); GO_0044267 (EC: TAS); GO_0044822 (EC: IDA); GO_0046777 (EC: IEA); GO_0070062 (EC: IDA)",,,,,,,,,PMID:1104615; 1400363; 1677563; 1748310; 1883206; 2116318; 2948954; 7821789; 8098621; 8099443; 8099444; 8645159; 8887689; 9079663; 9442054; 9446619; 9819435; 10432301; 10504407; 10542257; 10620360; 10648795; 10734073; 11323413; 11331597; 11500362; 11555640; 11739746; 11859078; 11985496; 12186496; 12370288; 12447867; 12477932; 12499843; 12514125; 12556489; 12588972; 12601012; 12686399; 12687390; 14747531; 15060162; 15207627; 15330758; 15341733; 15476887; 15489334; 15635413; 15650164; 16210351; 16216881; 16288713; 16289705; 16289913; 16418533; 16500424; 16720581; 16982605; 17113348; 17210633; 17274640; 17290288; 17353931; 17361185; 17393484; 17488873; 17894550; 18082745; 18234281; 18423202; 18457437; 18604219; 18639529; 18664456; 18781797; 19009018; 19017641; 19188486; 19189853; 19244104; 19322201; 19364808; 19369421; 19470760; 19559055; 19733181; 19738201; 19754954; 19800319; 19846675; 20154146; 20361218; 20428777; 20457808; 20467438; 20521618; 20660158; 21139048; 21145461; 21385877; 21556050; 21575865; 21699776; 21715487; 21787283; 21853274; 21890473; 21906983; 21907836; 21963094; 21987572; 22053000; 22053931; 22102852; 22113938; 22145905; 22306812; 22623428; 22652449; 22678362; 22705549; 22833567; 22863883; 22939629; 23000965; 23293029; 23402259; 23405127; 23455922; 23741361; 24250222; 24457600,,,,,,,,,,,,,,,OGG:3000001965,,,,,,,"eukaryotic translation initiation factor 2, subunit 1 alpha, 35kDa",,,,,,,,,,,,,Other designations: eIF-2-alpha|eukaryotic translation initiation factor 2 subunit 1|eukaryotic translation initiation factor 2 subunit alpha,,EIF2S1,,,,,,,,,,,,,,,,,,,,,,,1965,,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF2S1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001967,EIF2B1,,Other designations: eIF-2B GDP-GTP exchange factor subunit alpha|translation initiation factor eIF-2B subunit alpha,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,EIF2BA|EIF2B,,,,,,,,,,,,12,,,,,,HPRD:09458|MIM:606686|HGNC:3257,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"eukaryotic translation initiation factor 2B, subunit 1 alpha, 26kDa",,,12q24.31,,,,,,,,,,,,,,,,"GO_0003743 (EC: IDA, Qualifier: contributes_to, PMID:16289705); GO_0005085 (EC: IDA, Qualifier: contributes_to, PMID:11323413); GO_0005515 (EC: IPI, PMID:9235896); GO_0005525 (EC: IEA); GO_0005737 (EC: IDA, PMID:11323413); GO_0005829 (EC: TAS); GO_0005851 (EC: IDA, PMID:11323413); GO_0005886 (EC: IDA, PMID:9235896); GO_0006412 (EC: TAS); GO_0006413 (EC: IDA, PMID:16289705); GO_0006413 (EC: TAS); GO_0006446 (EC: IBA); GO_0009408 (EC: ISS); GO_0009408 (EC: TAS, PMID:12499492); GO_0009749 (EC: ISS); GO_0010467 (EC: TAS); GO_0014003 (EC: IMP, PMID:15217090); GO_0016020 (EC: IDA, PMID:9235896); GO_0019003 (EC: IEA); GO_0019509 (EC: IBA, Qualifier: NOT); GO_0030234 (EC: IEA); GO_0032057 (EC: IEA); GO_0043087 (EC: IDA, PMID:11323413); GO_0043434 (EC: ISS); GO_0044267 (EC: TAS); GO_0046523 (EC: IBA, Qualifier: NOT); GO_0051716 (EC: IDA, PMID:8626696)",,,,,,,,,PMID:1883206; 7495858; 8626696; 8887689; 9235896; 9446619; 10805739; 10858531; 11323413; 11835386; 12477932; 12499492; 12707859; 14566705; 14993275; 15060152; 15217090; 15489334; 15752756; 15776425; 16169070; 16289705; 16344560; 17353931; 18263758; 18330844; 18632786; 19631657; 19913121; 20301435; 20368287; 20434207; 20628086; 21139048; 21795329; 21890473; 21906983,,,,,,,,,,,,,,,OGG:3000001967,,,,,,,"eukaryotic translation initiation factor 2B, subunit 1 alpha, 26kDa",,,,,,,,,,,,,Other designations: eIF-2B GDP-GTP exchange factor subunit alpha|translation initiation factor eIF-2B subunit alpha,,EIF2B1,,,,,,,,,,,,,,,,,,,,,,,1967,,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF2B1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001968,EIF2S3,,Other designations: eIF-2-gamma X|eIF-2gX|eukaryotic translation initiation factor 2 subunit 3|eukaryotic translation initiation factor 2 subunit gamma X|eukaryotic translation initiation factor 2G,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,EIF2|EIF2G|eIF-2gA|EIF2gamma,,,,,,,,,,,,X,,,,,,HGNC:3267|HPRD:02155|MIM:300161,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"eukaryotic translation initiation factor 2, subunit 3 gamma, 52kDa",,,Xp22.2-p22.1,,,,,,,,,,,,,,,,"GO_0003743 (EC: IDA, PMID:10900014); GO_0003924 (EC: IEA); GO_0005515 (EC: IPI, PMID:16288713); GO_0005525 (EC: IEA); GO_0005829 (EC: TAS); GO_0006184 (EC: TAS, PMID:8106381); GO_0006412 (EC: TAS); GO_0006413 (EC: IDA, PMID:10900014); GO_0006413 (EC: TAS); GO_0008135 (EC: IDA, PMID:10900014); GO_0010467 (EC: TAS); GO_0044267 (EC: TAS); GO_0070062 (EC: IDA)",,,,,,,,,PMID:1104615; 8098621; 8106381; 8125298; 9079663; 9736774; 10620360; 10648795; 10900014; 12477932; 12588972; 12665801; 15489334; 15635413; 15669143; 16196087; 16201836; 16288713; 16289705; 16712791; 17220478; 17353931; 18781797; 19322201; 19723899; 19738201; 20020773; 20434207; 21110914; 21139048; 21145461; 21252943; 21319273; 21693764; 21853274; 21890473; 21906983; 21907836; 21963094; 21987572; 22145905; 22174317; 22505724; 22797925; 22863883; 22939629; 22952844; 23000965; 23063529; 23455922; 23602568; 24457600,,,,,,,,,,,,,,,OGG:3000001968,,,,,,,"eukaryotic translation initiation factor 2, subunit 3 gamma, 52kDa",,,,,,,,,,,,,Other designations: eIF-2-gamma X|eIF-2gX|eukaryotic translation initiation factor 2 subunit 3|eukaryotic translation initiation factor 2 subunit gamma X|eukaryotic translation initiation factor 2G,,EIF2S3,,,,,,,,,,,,,,,,,,,,,,,1968,,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF2S3,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_37957,histaminergic drug,histamine agents|histaminergic agent|histaminergic drugs|histaminergic agents|histamine drugs,Drugs used for their actions on histaminergic systems.,false,,,http://purl.obolibrary.org/obo/CHEBI_35942,,,,,,,,,,,,,,,,,,,,,,Drugs used for their actions on histaminergic systems.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,histamine agents|histaminergic agent|histaminergic drugs|histaminergic agents|histamine drugs,,,,,,,,,,,,,,,,,,,,,CHEBI:37957,,,,histaminergic drug,,CHEBI:37957,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0090117,endosome to lysosome transport of low-density lipoprotein particle,endosome to lysosome transport of LDL,The directed movement of low-density lipoprotein particle from endosomes to lysosomes.,false,,,http://purl.obolibrary.org/obo/GO_0030301,,,,,,,,,,,,,,,,,,,,,,The directed movement of low-density lipoprotein particle from endosomes to lysosomes.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,endosome to lysosome transport of LDL,,,,,GO:0090117,,,,,,,,,,,,,,,,,,,,,,endosome to lysosome transport of low-density lipoprotein particle,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001496,moving free fatty acid to the hepatocyte [eosinogranular degeneration],,"Moving free fatty acid to the hepatocyte is a subtype of moving A to the inside of B: A process of the movement of  free fatty acid into a hepatocyte.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/TXPO_0001729|http://purl.obolibrary.org/obo/TXPO_0001466,,,,,,,,,,,,,,,,,,,,,,"Moving free fatty acid to the hepatocyte is a subtype of moving A to the inside of B: A process of the movement of  free fatty acid into a hepatocyte.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001496,,,,,,,,,,,,,,,,,,,,,,moving free fatty acid to the hepatocyte [eosinogranular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001499,free fatty acid transporter role,,A role played by the molecule which transfers free fatty acids.,false,,,http://purl.obolibrary.org/obo/TXPO_0001341,,,,,,,,,,,,,,,,,,,,,,A role played by the molecule which transfers free fatty acids.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001499,,,,,,,,,,,,,,,,,,,,,,free fatty acid transporter role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001494,AKT signaling (primitive),PKB signaling (primitive),AKT signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal transmitted by the intracellular serine/threonine kinase protein kinase B (also called AKT).,false,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0043491,,AKT signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal transmitted by the intracellular serine/threonine kinase protein kinase B (also called AKT).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000250,http://purl.obolibrary.org/obo/GO_0043491,,,,,,,,,,,PKB signaling (primitive),,,,,TXPO:0001494,,,,,,,,,,,,,,,,,,,,,,AKT signaling (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001495,phosphatidylinositol 3-kinase signaling (primitive) [Phospholipidosis (excessive defense) ],,"Phosphatidylinositol 3-kinase signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal transmitted by the phosphatidylinositol 3-kinase (PI3K).
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense) .",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0001795,,,,,,,,,,,,,,,,,,,,,,"Phosphatidylinositol 3-kinase signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal transmitted by the phosphatidylinositol 3-kinase (PI3K).
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense) .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001857|http://purl.obolibrary.org/obo/TXPO_0001175|http://purl.obolibrary.org/obo/TXPO_0001137|http://purl.obolibrary.org/obo/TXPO_0001800,,,,,,http://purl.obolibrary.org/obo/TXPO_0001796,,,,,,,,,,,TXPO:0001495,,,,,,,,,,,,,,,,,,,,,,phosphatidylinositol 3-kinase signaling (primitive) [Phospholipidosis (excessive defense) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001498,CD36 -translocator role [lipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001319,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:29184|NCBI-Human-GeneID:948|NCBI-Mouse-GeneID:12491|PMID:15677505|PMID:18242221|PMID:21145849|PMID:16407588|PMID:27034954,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001341,,,,,,,,,,TXPO:0001498,,,,,,,,,,,,,,,,,,,,,,CD36 -translocator role [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001497,metastasis [Phospholipidosis (excessive defense)],,"The spread or migration of cancer cells from one part of the body (the organ in which it first appeared) to another. The secondary tumor contains cells that are like those in the original (primary) tumor. [def-source: NCI]
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense).",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/NCIT_C19151,,,,,,,,,,,,,,,,,,,,,,"The spread or migration of cancer cells from one part of the body (the organ in which it first appeared) to another. The secondary tumor contains cells that are like those in the original (primary) tumor. [def-source: NCI]
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004070|http://purl.obolibrary.org/obo/TXPO_0003558|http://purl.obolibrary.org/obo/TXPO_0003788|http://purl.obolibrary.org/obo/TXPO_0004112|http://purl.obolibrary.org/obo/TXPO_0004114|http://purl.obolibrary.org/obo/TXPO_0003879|http://purl.obolibrary.org/obo/TXPO_0003999|http://purl.obolibrary.org/obo/TXPO_0004052|http://purl.obolibrary.org/obo/TXPO_0004050,,,,,,http://purl.obolibrary.org/obo/TXPO_0001491,,,,,,,,,,,TXPO:0001497,,,,,,,,,,,,,,,,,,,,,,metastasis [Phospholipidosis (excessive defense)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001491,tumor cell proliferation [Phospholipidosis (excessive defense) ],,"Tumor cell proliferation is a subtype of cell proliferation: A process of the multiplication or reproduction of tumor cells, resulting in the rapid expansion of a tumor cell population.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense) .",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0000339,,,,,,,,,,,,,,,,,,,,PMID:12069817|PMID:12414665,,"Tumor cell proliferation is a subtype of cell proliferation: A process of the multiplication or reproduction of tumor cells, resulting in the rapid expansion of a tumor cell population.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense) .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003423|http://purl.obolibrary.org/obo/TXPO_0003421|http://purl.obolibrary.org/obo/TXPO_0003416,http://purl.obolibrary.org/obo/TXPO_0004070|http://purl.obolibrary.org/obo/TXPO_0003559|http://purl.obolibrary.org/obo/TXPO_0003558|http://purl.obolibrary.org/obo/TXPO_0004106|http://purl.obolibrary.org/obo/TXPO_0003280|http://purl.obolibrary.org/obo/TXPO_0001175|http://purl.obolibrary.org/obo/TXPO_0003262|http://purl.obolibrary.org/obo/TXPO_0003531|http://purl.obolibrary.org/obo/TXPO_0003349|http://purl.obolibrary.org/obo/TXPO_0001137|http://purl.obolibrary.org/obo/TXPO_0002294|http://purl.obolibrary.org/obo/TXPO_0002244,,,,,,,,,,,,,,,,,TXPO:0001491,,,,,,,,,,,,,,,,,,,,,,tumor cell proliferation [Phospholipidosis (excessive defense) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001492,EGFR signaling (primitive),,"EGFR signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal transmitted by the EGFR (epidermal growth factor receptor) on the surface of a cell, starting with a ligand binding to a EGFR",false,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,https://reactome.org/PathwayBrowser/#/R-HSA-177929|http://purl.obolibrary.org/obo/GO_0007173,,"EGFR signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal transmitted by the EGFR (epidermal growth factor receptor) on the surface of a cell, starting with a ligand binding to a EGFR",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000081,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0007173,,,,,,,,,,,,,,,,TXPO:0001492,,,,,,,,,,,,,,,,,,,,,,EGFR signaling (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001490,cell proliferation [Phospholipidosis (excessive defense) ],,"The multiplication or reproduction of cells, resulting in the rapid expansion of a cell population.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense) .",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/GO_0008283,,,,,,,,,,,,,,,,,,,,,,"The multiplication or reproduction of cells, resulting in the rapid expansion of a cell population.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense) .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003422|http://purl.obolibrary.org/obo/TXPO_0003418|http://purl.obolibrary.org/obo/TXPO_0003415,http://purl.obolibrary.org/obo/TXPO_0001137|http://purl.obolibrary.org/obo/TXPO_0002244,,,,,,http://purl.obolibrary.org/obo/TXPO_0002276|http://purl.obolibrary.org/obo/TXPO_0002281,,,,,,,,,,,TXPO:0001490,,,,,,,,,,,,,,,,,,,,,,cell proliferation [Phospholipidosis (excessive defense) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001493,EGFR signaling (primitive) [Phospholipidosis (excessive defense) ],,"EGFR signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal transmitted by the EGFR (epidermal growth factor receptor) on the surface of a cell, starting with a ligand binding to a EGFR
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense) .",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0001492,,,,,,,,,,,,,,,,,,,,,,"EGFR signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal transmitted by the EGFR (epidermal growth factor receptor) on the surface of a cell, starting with a ligand binding to a EGFR
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense) .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001175|http://purl.obolibrary.org/obo/TXPO_0001137|http://purl.obolibrary.org/obo/TXPO_0001798,,,,,,http://purl.obolibrary.org/obo/TXPO_0001495,,,,,,,,,,,TXPO:0001493,,,,,,,,,,,,,,,,,,,,,,EGFR signaling (primitive) [Phospholipidosis (excessive defense) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000051386,EIF3L,,Other designations: eIEF associated protein HSPC021|eukaryotic translation initiation factor 3 subunit 6-interacting protein|eukaryotic translation initiation factor 3 subunit E-interacting protein|eukaryotic translation initiation factor 3 subunit L,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,EIF3S6IP|EIF3EIP|HSPC021|HSPC025|MSTP005|EIF3S11,,,,,,,,,,,,22,,,,,,Vega:OTTHUMG00000150671|Ensembl:ENSG00000100129|HGNC:18138|HPRD:10932,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"eukaryotic translation initiation factor 3, subunit L",,,22q,,,,,,,,,,,,,,,,"GO_0001650 (EC: IEA); GO_0001731 (EC: IEA); GO_0003743 (EC: IC, Qualifier: contributes_to, PMID:17322308); GO_0003743 (EC: IDA, Qualifier: contributes_to, PMID:17581632); GO_0005515 (EC: IPI, PMID:18599441); GO_0005654 (EC: IEA); GO_0005852 (EC: IDA, PMID:17322308); GO_0006413 (EC: IC, PMID:17322308); GO_0006413 (EC: IDA, PMID:17581632); GO_0006446 (EC: IEA); GO_0016282 (EC: IEA); GO_0033290 (EC: IEA); GO_0044822 (EC: IDA)",,,,,,,,,PMID:8125298; 11042152; 11590142; 11592397; 12393749; 12477932; 14702039; 15231747; 15231748; 15461802; 15489334; 16169070; 16189514; 16344560; 16522924; 17322308; 17353931; 17403899; 17581632; 18029348; 18599441; 18781797; 19167051; 19615732; 19738201; 20360068; 20508642; 21081666; 21139048; 21145461; 21890473; 21900206; 21906983; 21963094; 21987572; 22190034; 22505724; 22586326; 22623428; 22863883; 22939629; 23455922; 23463506; 23800076; 24250222; 24457600,,,,,,,,,,,,,,,OGG:3000051386,,,,,,,"eukaryotic translation initiation factor 3, subunit L",,,,,,,,,,,,,Other designations: eIEF associated protein HSPC021|eukaryotic translation initiation factor 3 subunit 6-interacting protein|eukaryotic translation initiation factor 3 subunit E-interacting protein|eukaryotic translation initiation factor 3 subunit L,,EIF3L,,,,,,,,,,,,,,,,,,,,,,,51386,AL022311.1,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF3L,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000023594,ORC6,,Other designations: origin recognition complex subunit 6,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,ORC6L,,,,,,,,,,,,16,,,,,,Vega:OTTHUMG00000132539|HGNC:17151|Ensembl:ENSG00000091651|MIM:607213|HPRD:06237,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"origin recognition complex, subunit 6",,,16q12,,,,,,,,,,,,,,,,"GO_0000082 (EC: TAS); GO_0000278 (EC: TAS); GO_0000808 (EC: IDA, PMID: 17716973); GO_0003677 (EC: IEA); GO_0005515 (EC: IPI, PMID: 15232106); GO_0005654 (EC: TAS); GO_0005664 (EC: IEA); GO_0006260 (EC: TAS); GO_0006261 (EC: IEA)",,,,,,,,,PMID: 8266075; 10436018; 10523313; 10945994; 11076863; 11095689; 11125146; 11323433; 11593009; 11931757; 12004060; 12045100; 12169736; 12477932; 12614612; 14702039; 15226314; 15232106; 15489334; 15489336; 15684404; 15707391; 15910003; 16381901; 17081983; 17716973; 18234858; 18761675; 19112505; 19471022; 19541634; 21358632; 21461783; 21502537; 21832049; 21906983; 21963094; 22505724; 23000965; 24250222,,,,,,,,,,,,,,,OGG:3000023594,,20140408,protein-coding,,,,"origin recognition complex, subunit 6",,,,,,,,,,,,,Other designations: origin recognition complex subunit 6,,ORC6,,,,,,,,,,,,,,,,,,,,,,,23594,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,ORC6,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000023597,ACOT9,,"Other designations: acyl-CoA thioester hydrolase 9|acyl-Coenzyme A thioesterase 2, mitochondrial|acyl-coenzyme A thioesterase 9, mitochondrial|mitochondrial Acyl-CoA Thioesterase",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,ACATE2|MTACT48|MT-ACT48,,,,,,,,,,,,X,,,,,,Ensembl:ENSG00000123130|HPRD:06438|HGNC:17152|MIM:300862|Vega:OTTHUMG00000021257,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,acyl-CoA thioesterase 9,,,Xp22.11,,,,,,,,,,,,,,,,GO_0003986 (EC: ISS); GO_0005739 (EC: ISS); GO_0006637 (EC: ISS),,,,,,,,,PMID:10383425; 10810093; 12477932; 14702039; 16103133; 18781797; 20186120; 20360068; 21139048; 21890473; 21906983; 21963094; 22114354; 22268729; 22323290; 22797925; 23956138,,,,,,,,,,,,,,,OGG:3000023597,,,,,,,acyl-CoA thioesterase 9,,,,,,,,,,,,,"Other designations: acyl-CoA thioester hydrolase 9|acyl-Coenzyme A thioesterase 2, mitochondrial|acyl-coenzyme A thioesterase 9, mitochondrial|mitochondrial Acyl-CoA Thioesterase",,ACOT9,,,,,,,,,,,,,,,,,,,,,,,23597,CGI-16,,,,,,,9606,,,,,,,,,,,,,,,,,,,ACOT9,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0001659,RGS1,,,false,,,http://purl.obolibrary.org/obo/IMR_0000431,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001659,,,,,,,,,,,,,,,,,,,,,,RGS1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006306,DNA methylation,,The covalent transfer of a methyl group to either N-6 of adenine or C-5 or N-4 of cytosine.,false,,,http://purl.obolibrary.org/obo/GO_0032259,,,,,,,,,,,,,,,,,,,,,,The covalent transfer of a methyl group to either N-6 of adenine or C-5 or N-4 of cytosine.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0006306,,,,,,,,,,,,,,,,,,,,,,DNA methylation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006308,DNA catabolic process,,"The cellular DNA metabolic process resulting in the breakdown of DNA, deoxyribonucleic acid, one of the two main types of nucleic acid, consisting of a long unbranched macromolecule formed from one or two strands of linked deoxyribonucleotides, the 3'-phosphate group of each constituent deoxyribonucleotide being joined in 3',5'-phosphodiester linkage to the 5'-hydroxyl group of the deoxyribose moiety of the next one.",false,,,http://purl.obolibrary.org/obo/GO_0009056,,,,,,,,,,,,,,,,,,,,,,"The cellular DNA metabolic process resulting in the breakdown of DNA, deoxyribonucleic acid, one of the two main types of nucleic acid, consisting of a long unbranched macromolecule formed from one or two strands of linked deoxyribonucleotides, the 3'-phosphate group of each constituent deoxyribonucleotide being joined in 3',5'-phosphodiester linkage to the 5'-hydroxyl group of the deoxyribose moiety of the next one.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0006308,,,,,,,,,,,,,,,,,,,,,,DNA catabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006305,DNA alkylation,,The addition of alkyl groups to many positions on all four bases of DNA. Alkylating agents can also modify the bases of incoming nucleotides in the course of DNA synthesis.,false,,,http://purl.obolibrary.org/obo/GO_0008152,,,,,,,,,,,,,,,,,,,,,,The addition of alkyl groups to many positions on all four bases of DNA. Alkylating agents can also modify the bases of incoming nucleotides in the course of DNA synthesis.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0006305,,,,,,,,,,,,,,,,,,,,,,DNA alkylation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006309,apoptotic DNA fragmentation,Apoptosis induced DNA fragmentation,"The cleavage of DNA during apoptosis, which usually occurs in two stages: cleavage into fragments of about 50 kbp followed by cleavage between nucleosomes to yield 200 bp fragments.|DNA fragmentation in response to apoptotic signals is achieved through the activity of apoptotic nucleases. In human, these include DNA fragmentation factor (DFF) or caspase-activated DNase (CAD) and endonuclease G (Endo G) (reviewed in PMID:15723341). Caution is needed when apoptotic DNA laddering assays show presence of fragmented DNA. A positive assay may simply reflect the end point of a whole apoptotic process. Unless clear experimental evidence is available to show that a gene product is directly involved in fragmenting DNA, please do not annotate to GO:0006309 'apoptotic DNA fragmentation' and consider annotating instead to a more upstream process such as, e.g., GO:0042981 'regulation of apoptotic process', GO:0006915 'apoptotic process', GO:0097190 'apoptotic signaling pathway'. Also, note that gene products involved in compartmentalization of apoptotic nucleases and in activation or repression of their enzymatic activity should be annotated to the regulation term GO:1902510 'regulation of apoptotic DNA fragmentation' or to one of its children (see PMID:15723341).",false,,,http://purl.obolibrary.org/obo/GO_0006308,,,,,,,,,,,,,,,,,,,,PMID:15723341,,"The cleavage of DNA during apoptosis, which usually occurs in two stages: cleavage into fragments of about 50 kbp followed by cleavage between nucleosomes to yield 200 bp fragments.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Apoptosis induced DNA fragmentation,,,,,GO:0006309,,,,,,,,,,,,,,,,,,,,"DNA fragmentation in response to apoptotic signals is achieved through the activity of apoptotic nucleases. In human, these include DNA fragmentation factor (DFF) or caspase-activated DNase (CAD) and endonuclease G (Endo G) (reviewed in PMID:15723341). Caution is needed when apoptotic DNA laddering assays show presence of fragmented DNA. A positive assay may simply reflect the end point of a whole apoptotic process. Unless clear experimental evidence is available to show that a gene product is directly involved in fragmenting DNA, please do not annotate to GO:0006309 'apoptotic DNA fragmentation' and consider annotating instead to a more upstream process such as, e.g., GO:0042981 'regulation of apoptotic process', GO:0006915 'apoptotic process', GO:0097190 'apoptotic signaling pathway'. Also, note that gene products involved in compartmentalization of apoptotic nucleases and in activation or repression of their enzymatic activity should be annotated to the regulation term GO:1902510 'regulation of apoptotic DNA fragmentation' or to one of its children (see PMID:15723341).",,apoptotic DNA fragmentation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0030098,lymphocyte differentiation,lymphocyte development|lymphocytic blood cell differentiation|lymphocyte cell differentiation,"The process in which a relatively unspecialized precursor cell acquires specialized features of a lymphocyte. A lymphocyte is a leukocyte commonly found in the blood and lymph that has the characteristics of a large nucleus, a neutral staining cytoplasm, and prominent heterochromatin.|Note that immunologists typically use the word 'development' to refer to cells of B or T cell lineages undergoing the process that GO describes as 'cell differentiation'.",false,,,http://purl.obolibrary.org/obo/GO_0002521,,,,,,,,,,,,,,,,,,,,,,"The process in which a relatively unspecialized precursor cell acquires specialized features of a lymphocyte. A lymphocyte is a leukocyte commonly found in the blood and lymph that has the characteristics of a large nucleus, a neutral staining cytoplasm, and prominent heterochromatin.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,lymphocytic blood cell differentiation|lymphocyte cell differentiation,,lymphocyte development,,,GO:0030098,,,,,,,,,,,,,,,,,,,,Note that immunologists typically use the word 'development' to refer to cells of B or T cell lineages undergoing the process that GO describes as 'cell differentiation'.,,lymphocyte differentiation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0030091,protein repair,,The process of restoring a protein to its original state after damage by such things as oxidation or spontaneous decomposition of residues.,false,,,http://purl.obolibrary.org/obo/TXPO_0000535,,,,,,,,,,,,,,,,,,,,,,The process of restoring a protein to its original state after damage by such things as oxidation or spontaneous decomposition of residues.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0030091,,,,,,,,,,,,,,,,,,,,,,protein repair,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000229,Lamtor5 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:10542|NCBI-Mouse-GeneID:68576|NCBI-Rat-GeneID:295357,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000010542,,,,,,,,,,,,,TXPO:1000229,,,,,,,,,,,,,,,,,,,,,,Lamtor5 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000222,LEMD1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:93273|NCBI-Mouse-GeneID:213409|NCBI-Rat-GeneID:100360142,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000093273,,,,,,,,,,,,,TXPO:1000222,,,,,,,,,,,,,,,,,,,,,,LEMD1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000228,LSS (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:81681|NCBI-Mouse-GeneID:16987|NCBI-Human-GeneID:4047,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000004047,,,,,,,,,,,,,TXPO:1000228,,,,,,,,,,,,,,,,,,,,,,LSS (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000220,L3hypdh (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:112849|NCBI-Rat-GeneID:314214|NCBI-Mouse-GeneID:67217,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000112849,,,,,,,,,,,,,TXPO:1000220,,,,,,,,,,,,,,,,,,,,,,L3hypdh (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000221,LEAP2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:497901|NCBI-Human-GeneID:116842|NCBI-Mouse-GeneID:259301,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000116842,,,,,,,,,,,,,TXPO:1000221,,,,,,,,,,,,,,,,,,,,,,LEAP2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000223,LGALS1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:3956|NCBI-Rat-GeneID:56646|NCBI-Mouse-GeneID:16852,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000003956,,,,,,,,,,,,,TXPO:1000223,,,,,,,,,,,,,,,,,,,,,,LGALS1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000227,NR5A2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:60349|NCBI-Human-GeneID:2494|NCBI-Mouse-GeneID:26424,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000002494,,,,,,,,,,,,,TXPO:1000227,,,,,,,,,,,,,,,,,,,,,,NR5A2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000224,LINC00342 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:150759,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000150759,,,,,,,,,,,,,TXPO:1000224,,,,,,,,,,,,,,,,,,,,,,LINC00342 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000225,LMBR1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:64327|NCBI-Rat-GeneID:362295|NCBI-Mouse-GeneID:56873,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000064327,,,,,,,,,,,,,TXPO:1000225,,,,,,,,,,,,,,,,,,,,,,LMBR1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000084277,DNAJC30,,Other designations: Williams Beuren syndrome chromosome region 18|dnaJ homolog subfamily C member 30|williams-Beuren syndrome chromosomal region 18 protein,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,WBSCR18,,,,,,,,,,,,7,,,,,,HGNC:16410|HPRD:10303|Ensembl:ENSG00000176410|Vega:OTTHUMG00000023290,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"DnaJ (Hsp40) homolog, subfamily C, member 30",,,7q11.23,,,,,,,,,,,,,,,,GO_0005739 (EC: IEA),,,,,,,,,PMID:12073013; 12477932; 12853948; 14702039; 15231747; 15489334; 17207965; 20877624,,,,,,,,,,,,,,,OGG:3000084277,,,,,,,"DnaJ (Hsp40) homolog, subfamily C, member 30",,,,,,,,,,,,,Other designations: Williams Beuren syndrome chromosome region 18|dnaJ homolog subfamily C member 30|williams-Beuren syndrome chromosomal region 18 protein,,DNAJC30,,,,,,,,,,,,,,,,,,,,,,,84277,,,,,,,,9606,,,,,,,,,,,,,,,,,,,DNAJC30,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_50176,keratolytic drug,desquamating agent|keratolytic agent|skin-peeling agent|keratolytic drugs,"A drug that softens, separates, and causes desquamation of the cornified epithelium or horny layer of skin. Keratolytic drugs are used to expose mycelia of infecting fungi or to treat corns, warts, and certain other skin diseases.",false,,,http://purl.obolibrary.org/obo/CHEBI_50177,,,,,,,,,,,,,,,,,,,,,,"A drug that softens, separates, and causes desquamation of the cornified epithelium or horny layer of skin. Keratolytic drugs are used to expose mycelia of infecting fungi or to treat corns, warts, and certain other skin diseases.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,desquamating agent|keratolytic agent|skin-peeling agent|keratolytic drugs,,,,,,,,,,,,,,,,,,,,,CHEBI:50176,,,,keratolytic drug,,CHEBI:50176,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_17833,gentamicin,,"Gentamicin is a parenterally administered, broad spectrum aminoglycoside antibiotic typically used for moderate to severe gram negative infections. Despite its wide use, gentamicin has not been definitively linked to instances of clinically apparent liver injury.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Open TG-Gates compound_id=00147|https://pubchem.ncbi.nlm.nih.gov/compound/3467|https://livertox.nlm.nih.gov//Gentamicin.htm|DrugBank:DB00798|MeSH:D005839|CAS:1403-66-3,,"Gentamicin is a parenterally administered, broad spectrum aminoglycoside antibiotic typically used for moderate to severe gram negative infections. Despite its wide use, gentamicin has not been definitively linked to instances of clinically apparent liver injury.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:17833,,,,,,,,,,,,,,,,,,,,,,gentamicin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000006720,SREBF1,,Other designations: SREBP-1|class D basic helix-loop-helix protein 1|sterol regulatory element-binding protein 1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,bHLHd1|SREBP1|SREBP-1c,,,,,,,,,,,,17,,,,,,Ensembl:ENSG00000072310|Vega:OTTHUMG00000059313|HPRD:01701|HGNC:11289|MIM:184756,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,sterol regulatory element binding transcription factor 1,,,17p11.2,,,,,,,,,,,,,,,,"GO_0000122 (EC: IEA); GO_0000139 (EC: TAS); GO_0003062 (EC: IEA); GO_0003677 (EC: ISS); GO_0003682 (EC: IEA); GO_0003700 (EC: IDA, PMID: 16407292); GO_0005515 (EC: IPI, PMID: 14701856); GO_0005634 (EC: IDA, PMID: 12202038); GO_0005635 (EC: TAS, PMID: 8156598); GO_0005654 (EC: TAS); GO_0005737 (EC: ISS); GO_0005783 (EC: IDA, PMID: 12202038); GO_0005789 (EC: TAS); GO_0005829 (EC: TAS); GO_0006351 (EC: IEA); GO_0006357 (EC: TAS, PMID: 8156598); GO_0006629 (EC: TAS, PMID: 8156598); GO_0007568 (EC: IEA); GO_0008203 (EC: IEA); GO_0008286 (EC: IEA); GO_0008610 (EC: ISS); GO_0009267 (EC: ISS, PMID: 16407292); GO_0009749 (EC: IEA); GO_0010867 (EC: ISS); GO_0012507 (EC: IEA); GO_0016021 (EC: IEA); GO_0019217 (EC: IEA); GO_0019901 (EC: IEA); GO_0030324 (EC: IEA); GO_0031065 (EC: IEA); GO_0032094 (EC: IEA); GO_0032403 (EC: IEA); GO_0032526 (EC: IEA); GO_0032570 (EC: IEA); GO_0032810 (EC: IDA, PMID: 16407292); GO_0033762 (EC: IEA); GO_0042493 (EC: IEA); GO_0043234 (EC: IEA); GO_0043565 (EC: IEA); GO_0044255 (EC: TAS); GO_0044281 (EC: TAS); GO_0045542 (EC: IEA); GO_0045944 (EC: IDA, PMID: 12242332); GO_0045944 (EC: IEA); GO_0046676 (EC: IEA); GO_0046983 (EC: IEA); GO_0051591 (EC: IEA); GO_0071398 (EC: IEA)",,,,,,,,,PMID: 7759101; 7903453; 8006035; 8156598; 8314806; 8402897; 8626610; 8918891; 9062340; 9070916; 9242699; 9634703; 9651391; 9765204; 10224053; 10235267; 10585876; 10619424; 10627507; 10915800; 10949029; 11257259; 11334418; 11485982; 11713202; 11834832; 11916923; 11929849; 11997338; 12021179; 12145339; 12177166; 12202038; 12213084; 12242332; 12436350; 12477932; 12531699; 12615929; 12640139; 12657626; 12730330; 12752570; 14615581; 14633850; 14654692; 14701856; 14702039; 14722127; 14742839; 14744869; 14747281; 14748724; 14988272; 15026365; 15085196; 15102555; 15123650; 15161980; 15277400; 15286454; 15317819; 15340088; 15358760; 15388640; 15550381; 15677507; 15769984; 15794649; 15798184; 15809359; 15833942; 16005884; 16007182; 16054087; 16055439; 16141315; 16153721; 16158080; 16162944; 16198472; 16249184; 16303770; 16306078; 16387548; 16407292; 16429400; 16480961; 16713569; 16799563; 16804073; 16806233; 16817902; 16825193; 16880739; 16885156; 17019602; 17081983; 17141191; 17160088; 17198935; 17296605; 17331464; 17344645; 17452746; 17636037; 17655842; 17681345; 17989724; 18065496; 18068676; 18072016; 18192539; 18195716; 18245227; 18267114; 18272927; 18281474; 18304434; 18334917; 18360697; 18385733; 18403372; 18420801; 18435918; 18559965; 18635549; 18654640; 18660489; 18682402; 18692268; 18727921; 18752865; 18774944; 18835813; 18854425; 18936756; 18996102; 19008011; 19032865; 19040658; 19048273; 19056350; 19056482; 19062325; 19126544; 19242521; 19252981; 19292868; 19303849; 19323650; 19336475; 19360318; 19470430; 19533843; 19578796; 19621387; 19720801; 19727213; 19727227; 19733654; 19811452; 19876004; 19878569; 19913121; 19913854; 19948975; 19966780; 20005944; 20026048; 20028734; 20031551; 20067991; 20071336; 20130133; 20145241; 20167577; 20171215; 20173757; 20235787; 20376806; 20466882; 20513236; 20534441; 20554776; 20595232; 20615871; 20628086; 20648548; 20655124; 20817729; 20863500; 20868688; 20965718; 20971080; 20980003; 21093473; 21139048; 21145868; 21146170; 21310851; 21325464; 21540177; 21609284; 21619898; 21645898; 21652712; 21664250; 21693764; 21738487; 21757781; 21775116; 21826653; 21836065; 21871872; 21906983; 21963094; 21987572; 21993218; 22035958; 22059152; 22064655; 22152380; 22153697; 22258239; 22311022; 22331133; 22363740; 22384276; 22425645; 22429355; 22474125; 22505724; 22672904; 22678801; 22690709; 22786746; 22939624; 22966071; 22969152; 22984430; 23000965; 23106379; 23147115; 23208501; 23226416; 23422505; 23465592; 23515281; 23610160; 23680128; 23703028; 23825667; 23913732; 23985808; 24298052,,,,,,,,,,,,,,,OGG:3000006720,,,,,,,sterol regulatory element binding transcription factor 1,,,,,,,,,,,,,Other designations: SREBP-1|class D basic helix-loop-helix protein 1|sterol regulatory element-binding protein 1,,SREBF1,,,,,,,,,,,,,,,,,,,,,,,6720,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,SREBF1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_27385,tetrachloromethane,CCl4|Carbon tetrachloride,A chlorocarbon that is methane in which all the hydrogens have been replaced by chloro groups.,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Wikipedia:Carbon_Tetrachloride|LINCS:LSM-37019|CAS:56-23-5,,A chlorocarbon that is methane in which all the hydrogens have been replaced by chloro groups.,,,,,,,,,,,,CCl4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CCl4|Carbon tetrachloride,,,CHEBI:27385,,,,,,,,,,,,,,,,,,,,,,tetrachloromethane,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ClC(Cl)(Cl)Cl,,,,,
http://purl.obolibrary.org/obo/IMR_0010461,60S ribosomal protein L10,Laminin receptor homolog|Tumor suppressor QM|QM protein,,false,,,http://purl.obolibrary.org/obo/IMR_0000897,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Laminin receptor homolog|Tumor suppressor QM|QM protein,,,,,IMR:0010461,,,,,,,,,,,,,,,,,,,,,,60S ribosomal protein L10,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100603,CDK7(mol),39 protein kinase|Cdk7|STK1|Cell division protein kinase 7|P39 Mo15|Protein-tyrosine kinase MPK-7|TFIIH basal transcription factor complex kinase subunit|CDK-activating kinase|CAK1|CR4 protein kinase|Cell division protein kinase 7 (EC 2.7.1.-) (CDK-activating kinase) (CAK)(TFIIH) (basal transcription factor complex kinase subunit) (39 kDa protein kinase) (P39 Mo15)(STK1)(CAK1)|39 kDa protein kinase|CAK,,false,,,http://purl.obolibrary.org/obo/TXPO_0003241,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0010771,39 protein kinase|Cdk7|STK1|Cell division protein kinase 7|P39 Mo15|Protein-tyrosine kinase MPK-7|TFIIH basal transcription factor complex kinase subunit|CDK-activating kinase|CAK1|CR4 protein kinase|Cell division protein kinase 7 (EC 2.7.1.-) (CDK-activating kinase) (CAK)(TFIIH) (basal transcription factor complex kinase subunit) (39 kDa protein kinase) (P39 Mo15)(STK1)(CAK1)|39 kDa protein kinase|CAK,,,,,IMR:0100603,,,,,,,,,,,,,,,,,,,,,,CDK7(mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000568,P-cadherin,cadherin-3|Placental-cadherin,,false,,,http://purl.obolibrary.org/obo/IMR_0000167,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,cadherin-3|Placental-cadherin,,,,,IMR:0000568,,,,,,,,,,,,,,,,,,,,,,P-cadherin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000371,R-Smad,receptor-activated Smad|receptor-regulated Smad,"There are five vertebrate R-Smads, Smad1, Smad2, Smad3, Smad5 and Smad8 and they are phosphorylated in response to different types of TGF-beta ligands. Phosphorylated R-Smads can form complexes with Smad4 and  positively or negatively regulate transcription.
The Mad protein in Drosophila is the ortholog of Smad1/5, whereas dSmad2 is the ortholog of Smad2/3. In C. elegans, sma-2 and sma-3 proved to be homologous to Mad of Drosophila.",false,,,http://purl.obolibrary.org/obo/IMR_0000370,,,,,,,,,,,,,,,,,,,,,,"There are five vertebrate R-Smads, Smad1, Smad2, Smad3, Smad5 and Smad8 and they are phosphorylated in response to different types of TGF-beta ligands. Phosphorylated R-Smads can form complexes with Smad4 and  positively or negatively regulate transcription.
The Mad protein in Drosophila is the ortholog of Smad1/5, whereas dSmad2 is the ortholog of Smad2/3. In C. elegans, sma-2 and sma-3 proved to be homologous to Mad of Drosophila.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,receptor-activated Smad|receptor-regulated Smad,,,,,IMR:0000371,,,,,,,,,,,,,,,,,,,,,,R-Smad,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76655,EC 2.1.* (C1-transferase) inhibitor,C1-transferase (EC 2.1.*) inhibitors|C1-transferase (EC 2.1.*) inhibitor|C1-transferase inhibitor|C1-transferase inhibitors|EC 2.1.* (C1-transferase) inhibitors|one-carbon-containing group transferase inhibitors|EC 2.1.* inhibitors|EC 2.1.* inhibitor|one-carbon-containing group transferase inhibitor,A transferase inhibitor inhibiting the action of transferase of a one-carbon-containing group (EC 2.1.*.*).,false,,,http://purl.obolibrary.org/obo/CHEBI_71300,,,,,,,,,,,,,,,,,,,,,,A transferase inhibitor inhibiting the action of transferase of a one-carbon-containing group (EC 2.1.*.*).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,C1-transferase (EC 2.1.*) inhibitors|C1-transferase (EC 2.1.*) inhibitor|C1-transferase inhibitor|C1-transferase inhibitors|EC 2.1.* (C1-transferase) inhibitors|one-carbon-containing group transferase inhibitors|EC 2.1.* inhibitors|EC 2.1.* inhibitor|one-carbon-containing group transferase inhibitor,,,,,,,,,,,,,,,,,,,,,CHEBI:76655,,,,EC 2.1.* (C1-transferase) inhibitor,,CHEBI:76655,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000000325,APCS,,Other designations: 9.5S alpha-1-glycoprotein|epididymis secretory sperm binding protein Li 92n|pentaxin-related|serum amyloid P-component,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,PTX2|SAP|HEL-S-92n,,,,,,,,,,,,1,,,,,,HGNC:584|MIM:104770|Ensembl:ENSG00000132703|HPRD:00101|Vega:OTTHUMG00000022741,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"amyloid P component, serum",,,1q21-q23,,,,,,,,,,,,,,,,"GO_0005576 (EC: NAS, PMID: 14718574); GO_0005576 (EC: TAS); GO_0005615 (EC: IDA); GO_0006457 (EC: TAS, PMID: 10812074); GO_0006953 (EC: TAS, PMID: 2987268); GO_0031012 (EC: IDA, Qualifier: colocalizes_with); GO_0043234 (EC: IEA); GO_0046872 (EC: IEA); GO_0051082 (EC: TAS, PMID: 10812074); GO_0051131 (EC: TAS, PMID: 10972085); GO_0070062 (EC: IDA, PMID: 19056867); GO_0072562 (EC: IDA)",,,,,,,,,PMID: 81686; 1477104; 1602151; 2987268; 3029048; 3172210; 3211159; 3759147; 3915434; 4055725; 7592941; 8114934; 8144569; 8202534; 8417122; 8662978; 8999915; 9217261; 10631319; 10812074; 10972085; 11359830; 11441067; 11984001; 12015594; 12100475; 12126626; 12432394; 12477932; 12528126; 12767937; 14500533; 14519527; 14607961; 14718574; 15031287; 15174148; 15489334; 15649951; 15837583; 16335952; 16380821; 16643876; 16710414; 16784490; 17138933; 17530641; 17630380; 17676666; 18174230; 18624398; 19011614; 19052452; 19056867; 19948975; 20189569; 20237496; 20300636; 20930309; 20932823; 21044893; 21106539; 21223953; 21278351; 21360619; 21900206; 21988832; 22205573; 22396542; 22493081; 22867744; 22939635; 23385359; 23390551; 23423137; 23527487; 23544079; 23600950; 23966633,,,,,,,,,,,,,,,OGG:3000000325,,,,,,,"amyloid P component, serum",,,,,,,,,,,,,Other designations: 9.5S alpha-1-glycoprotein|epididymis secretory sperm binding protein Li 92n|pentaxin-related|serum amyloid P-component,,APCS,,,,,,,,,,,,,,,,,,,,,,,325,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,APCS,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CL_0000010,cultured cell,,A cell in vitro that is or has been maintained or propagated as part of a cell culture.,false,,,http://purl.obolibrary.org/obo/CL_0000578,,,,,,,,,,,,,,,,,,,,,,A cell in vitro that is or has been maintained or propagated as part of a cell culture.,,,,,cultured cell,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CL:0000010,,,,,,,,,,,,,,,,,,,,,,cultured cell,,,,,,,http://purl.obolibrary.org/obo/cl.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100845,Akt2 (mol),protein kinase B beta|RAC-beta serine/threonine protein kinase|RAC-PK-beta|PKB beta,,false,,,http://purl.obolibrary.org/obo/IMR_0000250,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,protein kinase B beta|RAC-beta serine/threonine protein kinase|RAC-PK-beta|PKB beta,,,,,IMR:0100845,,,,,,,,,,,,,,,,,,,,,,Akt2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0200428,L-Arginine,,,false,,,http://purl.obolibrary.org/obo/CHEBI_33709,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0200428,,,,,,,,,,,,,,,,,,,,,,L-Arginine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001874,"gene expression by CHOP (DDIT3, GADD153)",,"Gene expression by CHOP (DDIT3, GADD153) is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) by CHOP (DDIT3, GADD153).",false,,,http://purl.obolibrary.org/obo/TXPO_0000375,,,,,,,,,,,,,,,,,,,,,,"Gene expression by CHOP (DDIT3, GADD153) is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) by CHOP (DDIT3, GADD153).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001874,,,,,,,,,,,,,,,,,,,,,,"gene expression by CHOP (DDIT3, GADD153)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001876,NLRP3 (canonical)[lipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003516|http://purl.obolibrary.org/obo/TXPO_0001877,,,,,,,,,,,,,,,,,,,NLRP3 is a inflammasome component,NCBI-Rat-GeneID:287362|NCBI-Human-GeneID:114548|NCBI-Mouse-GeneID:216799,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001876,,,,,,,,,,,,,,,,,,,,,,NLRP3 (canonical)[lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001878,IL-1beta production [lipidosis],,"The appearance of interleukin-1 beta due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/GO_0032611,,,,,,,,,,,,,,,,,,,,,,"The appearance of interleukin-1 beta due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001079,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001875,http://purl.obolibrary.org/obo/TXPO_0001065,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003620,,,,,,,,,,,TXPO:0001878,,,,,,,,,,,,,,,,,,,,,,IL-1beta production [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000091,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001875,IL-1B (canonical)[lipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003516|http://purl.obolibrary.org/obo/TXPO_1000200,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:3553|NCBI-Rat-GeneID:24494|NCBI-Mouse-GeneID:16176,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003041,,,,,,,,,,TXPO:0001875,,,,,,,,,,,,,,,,,,,,,,IL-1B (canonical)[lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001879,increasing volume of mitochondria [Mitochondrial disorder],,"Increasing volume of mitochondria is a changing process to change the volume of the mitochondria to increase.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0000143|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:25339807,,"Increasing volume of mitochondria is a changing process to change the volume of the mitochondria to increase.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004345,,,,,,,,,,,TXPO:0001879,,,,,,,,,,,,,,,,,,,,,,increasing volume of mitochondria [Mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001877,NLRP3 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367|http://purl.obolibrary.org/obo/TXPO_0000871,,,,,,,,,,,,,,,,,,,NLRP3 is a inflammasome component,NCBI-Rat-GeneID:287362|NCBI-Human-GeneID:114548|NCBI-Mouse-GeneID:216799,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001877,,,,,,,,,,,,,,,,,,,,,,NLRP3 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000577,IFN alpha-7,,,false,,,http://purl.obolibrary.org/obo/IMR_0100386,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000577,,,,,,,,,,,,,,,,,,,,,,IFN alpha-7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IAO_0000030,information content entity,,A generically dependent continuant that is about some thing.,false,,,http://purl.obolibrary.org/obo/BFO_0000031,,,,,,,,,,,,,,,,,,,,,,A generically dependent continuant that is about some thing.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IAO:0000030,,,,,,,,,,,,,,,,,,,,,,information content entity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000977,LRP11,LDL receptor-related protein 11,,false,,,http://purl.obolibrary.org/obo/IMR_0100798,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,LDL receptor-related protein 11,,,,,IMR:0000977,,,,,,,,,,,,,,,,,,,,,,LRP11,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010471,60S ribosomal protein L21,P46778,,false,,,http://purl.obolibrary.org/obo/IMR_0000897,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,P46778,,,,,IMR:0010471,,,,,,,,,,,,,,,,,,,,,,60S ribosomal protein L21,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0008283,cell proliferation,,"The multiplication or reproduction of cells, resulting in the rapid expansion of a cell population.|This term was moved out from being a child of 'cellular process' because it is a cell population-level process, and cellular processes are restricted to those processes that involve individual cells. Also note that this term is intended to be used for the proliferation of cells within a multicellular organism, not for the expansion of a population of single-celled organisms.",false,,,http://purl.obolibrary.org/obo/TXPO_0000093,,,,,,,,,,,,,,,,,,,,,,"The multiplication or reproduction of cells, resulting in the rapid expansion of a cell population.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000000,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0008283,,,,,,,,,,,,,,,,,,,,"This term was moved out from being a child of 'cellular process' because it is a cell population-level process, and cellular processes are restricted to those processes that involve individual cells. Also note that this term is intended to be used for the proliferation of cells within a multicellular organism, not for the expansion of a population of single-celled organisms.",,cell proliferation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0000062,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0008286,insulin receptor signaling pathway,insulin receptor signalling pathway,The series of molecular signals generated as a consequence of the insulin receptor binding to insulin.,false,,,http://purl.obolibrary.org/obo/TXPO_0000027,,,,,,,,,,,,,,,,,,,,https://reactome.org/PathwayBrowser/#/R-HSA-74752,,The series of molecular signals generated as a consequence of the insulin receptor binding to insulin.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,insulin receptor signalling pathway,,,,,GO:0008286,,,,,,,,,,,,,,,,,,,,,,insulin receptor signaling pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0008289,lipid binding,,Interacting selectively and non-covalently with a lipid.,false,,,http://purl.obolibrary.org/obo/GO_0005488,,,,,,,,,,,,,,,,,,,,,,Interacting selectively and non-covalently with a lipid.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0008289,,,,,,,,,,,,,,,,,,,,,,lipid binding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001129,lumican,,,false,,,http://purl.obolibrary.org/obo/IMR_0001128,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001129,,,,,,,,,,,,,,,,,,,,,,lumican,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_36386,dichloroacetic acid,,"An organochlorine compound comprising acetic acid carrying two chloro substituents at the 2-position. It occurs in nature in seaweed, Asparagopsis taxiformis.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:79-43-6|Wikipedia:Dichloroacetic_acid,,"An organochlorine compound comprising acetic acid carrying two chloro substituents at the 2-position. It occurs in nature in seaweed, Asparagopsis taxiformis.",,,,,,,,,,,,C2H2Cl2O2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:36386,,,,,,,,,,,,,,,,,,,,,,dichloroacetic acid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,OC(=O)C(Cl)Cl,,,,,
http://purl.obolibrary.org/obo/CHEBI_63090,EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor,purine deoxynucleoside phosphorylase inhibitors|purine-nucleoside phosphorylase inhibitors|PUNPII inhibitor|PNPase inhibitors|purine-nucleoside phosphorylase inhibitor|PUNPI inhibitors|purine deoxyribonucleoside phosphorylase inhibitors|EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitors|nucleotide phosphatase inhibitor|purine nucleoside phosphorylase inhibitor|PUNPII inhibitors|purine deoxyribonucleoside phosphorylase inhibitor|purine-nucleoside:phosphate ribosyltransferase inhibitor|purine nucleoside phosphorylase inhibitors|EC 2.4.2.1 inhibitor|nucleotide phosphatase inhibitors|purine-nucleoside phosphorylase (EC 2.4.2.1) inhibitor|inosine phosphorylase inhibitor|purine ribonucleoside phosphorylase inhibitors|purine deoxynucleoside phosphorylase inhibitor|purine ribonucleoside phosphorylase inhibitor|EC 2.4.2.1 inhibitors|inosine-guanosine phosphorylase inhibitor|purine-nucleoside phosphorylase (EC 2.4.2.1) inhibitors|inosine-guanosine phosphorylase inhibitors|purine-nucleoside:phosphate ribosyltransferase inhibitors|PUNPI inhibitor|PNPase inhibitor|inosine phosphorylase inhibitors,An EC 2.4.2.* (pentosyltransferase) inhibitor that interferes with the action of purine nucleoside phosphorylase (EC 2.4.2.1).,false,,,http://purl.obolibrary.org/obo/CHEBI_76790,,,,,,,,,,,,,,,,,,,,,,An EC 2.4.2.* (pentosyltransferase) inhibitor that interferes with the action of purine nucleoside phosphorylase (EC 2.4.2.1).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,purine deoxynucleoside phosphorylase inhibitors|purine-nucleoside phosphorylase inhibitors|PUNPII inhibitor|PNPase inhibitors|purine-nucleoside phosphorylase inhibitor|PUNPI inhibitors|purine deoxyribonucleoside phosphorylase inhibitors|EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitors|nucleotide phosphatase inhibitor|purine nucleoside phosphorylase inhibitor|PUNPII inhibitors|purine deoxyribonucleoside phosphorylase inhibitor|purine-nucleoside:phosphate ribosyltransferase inhibitor|purine nucleoside phosphorylase inhibitors|EC 2.4.2.1 inhibitor|nucleotide phosphatase inhibitors|purine-nucleoside phosphorylase (EC 2.4.2.1) inhibitor|inosine phosphorylase inhibitor|purine ribonucleoside phosphorylase inhibitors|purine deoxynucleoside phosphorylase inhibitor|purine ribonucleoside phosphorylase inhibitor|EC 2.4.2.1 inhibitors|inosine-guanosine phosphorylase inhibitor|purine-nucleoside phosphorylase (EC 2.4.2.1) inhibitors|inosine-guanosine phosphorylase inhibitors|purine-nucleoside:phosphate ribosyltransferase inhibitors|PUNPI inhibitor|PNPase inhibitor|inosine phosphorylase inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:63090,,,,EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor,,CHEBI:63090,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0043161,proteasome-mediated ubiquitin-dependent protein catabolic process,,"The chemical reactions and pathways resulting in the breakdown of a protein or peptide by hydrolysis of its peptide bonds, initiated by the covalent attachment of ubiquitin, and mediated by the proteasome.",false,,,http://purl.obolibrary.org/obo/GO_0010498,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways resulting in the breakdown of a protein or peptide by hydrolysis of its peptide bonds, initiated by the covalent attachment of ubiquitin, and mediated by the proteasome.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0043161,,,,,,,,,,,,,,,,,,,,,,proteasome-mediated ubiquitin-dependent protein catabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100097,"glycoprotein hormone, alpha subunit",,"The alpha chain of pituitary glycoprotein hormones ( THYROTROPIN; FOLLICLE STIMULATING HORMONE; LUTEINIZING HORMONE) and the placental CHORIONIC GONADOTROPIN. Within a species, the alpha subunits of these four hormones are identical; the distinct functional characteristics of these glycoprotein hormones are determined by the unique beta subunits. Both subunits, the non-covalently bound heterodimers, are required for full biologic activity.",false,,,http://purl.obolibrary.org/obo/IMR_0100200|http://purl.obolibrary.org/obo/IMR_0100099|http://purl.obolibrary.org/obo/IMR_0100106|http://purl.obolibrary.org/obo/IMR_0100100,,,,,,,,,,,,,,,,,,,,MeSH:D015292,,"The alpha chain of pituitary glycoprotein hormones ( THYROTROPIN; FOLLICLE STIMULATING HORMONE; LUTEINIZING HORMONE) and the placental CHORIONIC GONADOTROPIN. Within a species, the alpha subunits of these four hormones are identical; the distinct functional characteristics of these glycoprotein hormones are determined by the unique beta subunits. Both subunits, the non-covalently bound heterodimers, are required for full biologic activity.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100097,,,,,,,,,,,,,,,,,,,,,,"glycoprotein hormone, alpha subunit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000347252,IGFBPL1,,Other designations: IGFBP-related protein 10|insulin-like growth factor binding protein related protein 4|insulin-like growth factor-binding protein-like 1|insulin-like growth factor-binding-related protein 4,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,IGFBP-RP4|bA113O24.1|IGFBPRP4,,,,,,,,,,,,9,,,,,,MIM:610413|HPRD:17138|HGNC:20081,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,insulin-like growth factor binding protein-like 1,,,9p13.1,,,,,,,,,,,,,,,,GO_0001558 (EC: IEA); GO_0005520 (EC: IEA); GO_0005576 (EC: IEA),,,,,,,,,PMID:14702039; 15845387; 17634530; 17884839; 24250222,,,,,,,,,,,,,,,OGG:3000347252,,,,,,,insulin-like growth factor binding protein-like 1,,,,,,,,,,,,,Other designations: IGFBP-related protein 10|insulin-like growth factor binding protein related protein 4|insulin-like growth factor-binding protein-like 1|insulin-like growth factor-binding-related protein 4,,IGFBPL1,,,,,,,,,,,,,,,,,,,,,,,347252,,,,,,,,9606,,,,,,,,,,,,,,,,,,,IGFBPL1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/GO_0031090,organelle membrane,intracellular membrane,A membrane that is one of the two lipid bilayers of an organelle envelope or the outermost membrane of single membrane bound organelle.,false,,,http://purl.obolibrary.org/obo/TXPO_0000895,,,,,,,,,,,,,,,,,,,,,,A membrane that is one of the two lipid bilayers of an organelle envelope or the outermost membrane of single membrane bound organelle.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,intracellular membrane,,,GO:0031090,,,,,,,,,,,,,,,,,,,,,,organelle membrane,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0031098,stress-activated protein kinase signaling cascade,JNK signal transduction pathway,A series of molecular signals in which a stress-activated protein kinase (SAPK) cascade relays one or more of the signals.,false,,,http://purl.obolibrary.org/obo/TXPO_0000609,,,,,,,,,,,,,,,,,,,,PMID:11790549,,A series of molecular signals in which a stress-activated protein kinase (SAPK) cascade relays one or more of the signals.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000769,,,,,,,,,,,,,JNK signal transduction pathway,,,,,GO:0031098,,,,,,,,,,,,,,,,,,,,,,stress-activated protein kinase signaling cascade,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000188,actin cytoskeleton protein,actin filament cytoskeletal protein,A role played by the protein contributes to the integrity of the actin cytoskeleton.|related cellular component GO:0015629,false,,,http://purl.obolibrary.org/obo/TXPO_0003689,,,,,,,,,,,,,,,,,,,,IMR:0000188 (obsolete),,A role played by the protein contributes to the integrity of the actin cytoskeleton.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,actin filament cytoskeletal protein,,,,,IMR:0000188,,,,,,,,,,,,,,,,,,,,related cellular component GO:0015629,,actin cytoskeleton protein,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0003134,female reproductive organ,female reproductive system organ|reproductive system organ of female organism|female organism reproductive structure|female reproductive gland/organ|female organism reproductive system organ|female organism sex organ|reproductive structure of female organism|female organism reproductive organ|female sex organ|reproductive organ of female organism|sex organ of female organism,A female organ involved in reproduction,false,,,http://purl.obolibrary.org/obo/UBERON_0003133,,,,,,,,,,,,,,,,,,,,EMAPA:28540|MA:0000544,,A female organ involved in reproduction,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,female reproductive system organ|reproductive system organ of female organism|female organism reproductive structure|female reproductive gland/organ|female organism reproductive system organ|female organism sex organ|reproductive structure of female organism|female organism reproductive organ|female sex organ|reproductive organ of female organism|sex organ of female organism,,,,,UBERON:0003134,,,,,,,,,,,,,,,,,,,,,,female reproductive organ,,,,,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0003133,reproductive organ,genitalia|genital organ|reproductive system organ|sex organ,An organ involved in reproduction,false,,,http://purl.obolibrary.org/obo/UBERON_0000062,,,,,,,,,,,,,,,,,,,,http://www.snomedbrowser.com/Codes/Details/128181006|http://linkedlifedata.com/resource/umls/id/C0017420|http://purl.obolibrary.org/obo/NCIT_C25177|OpenCyc:Mx4rwO39aJwpEbGdrcN5Y29ycA|UMLS:C0017420|TGMA:0000591|EMAPA:17381|MA:0001752|MESH:D005835|WBbt:0008422,,An organ involved in reproduction,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,genital organ|reproductive system organ|sex organ,,genitalia,,http://purl.obolibrary.org/obo/UBERON_0000990,UBERON:0003133,http://purl.obolibrary.org/obo/UBERON_0000990,,,,,,,,,,,,,,,,,,,,,reproductive organ,,,,,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100075,secretin,,A peptide hormone of about 27 amino acids from the duodenal mucosa that activates pancreatic secretion and lowers the blood sugar level.,false,,,http://purl.obolibrary.org/obo/IMR_0100072,,,,,,,,,,,,,,,,,,,,MeSH:D012633,,A peptide hormone of about 27 amino acids from the duodenal mucosa that activates pancreatic secretion and lowers the blood sugar level.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100075,,,,,,,,,,,,,,,,,,,,,,secretin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100160,alpha-neoendorphin,,,false,,,http://purl.obolibrary.org/obo/IMR_0100157,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100160,,,,,,,,,,,,,,,,,,,,,,alpha-neoendorphin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000979,LDL receptor,low density lipoprotein receptor|low-density lipoprotein receptor,,false,,,http://purl.obolibrary.org/obo/IMR_0000974,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,low density lipoprotein receptor|low-density lipoprotein receptor,,,,,IMR:0000979,,,,,,,,,,,,,,,,,,,,,,LDL receptor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_48706,antagonist,antagonista|antagoniste|antagonists|antagonist,Substance that attaches to and blocks cell receptors that normally bind naturally occurring substances.,false,,,http://purl.obolibrary.org/obo/CHEBI_52210,,,,,,,,,,,,,,,,,,,,,,Substance that attaches to and blocks cell receptors that normally bind naturally occurring substances.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,antagonist,,antagonista|antagoniste|antagonists,,,,,,,,,,,,,,,,,,,,,CHEBI:48706,,,,antagonist,,CHEBI:48706,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001101,increasing free fatty acid,,Increasing free fatty acid is a subtype of increasing quantity: A process that changes the amount of free fatty acid to be larger.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing free fatty acid is a subtype of increasing quantity: A process that changes the amount of free fatty acid to be larger.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001101,,,,,,,,,,,,,,,,,,,,,,increasing free fatty acid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001109,insulin(canonical)[lipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003516|http://purl.obolibrary.org/obo/IMR_0000052,,,,,,,,,,,,,,,,,,,,PMID:20817607,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001109,,,,,,,,,,,,,,,,,,,,,,insulin(canonical)[lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001107,inflammasome activation,,Inflammasome activation is a subtype of activating: A process that changes the activity of the inflammasome to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000401,,,,,,,,,,,,,,,,,,,,,,Inflammasome activation is a subtype of activating: A process that changes the activity of the inflammasome to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001107,,,,,,,,,,,,,,,,,,,,,,inflammasome activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001106,CMPK2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:129607|NCBI-Mouse-GeneID:22169|NCBI-Rat-GeneID:314004,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000129607,,,,,,,,,,,,,TXPO:0001106,,,,,,,,,,,,,,,,,,,,,,CMPK2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001104,CASP1 (canonical)[lipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003516|http://purl.obolibrary.org/obo/IMR_0100302,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:834|PMID:20303873,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001104,,,,,,,,,,,,,,,,,,,,,,CASP1 (canonical)[lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001102,CMPK2 (human)[lipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001106|http://purl.obolibrary.org/obo/TXPO_0001786,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:129607|PMID:30046112|PMID:28167322|PMID:24858832,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000129607,,,,,,,,,,,,,TXPO:0001102,,,,,,,,,,,,,,,,,,,,,,CMPK2 (human)[lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001100,fatty acid beta-oxidation in adipose tissue [lipidosis],,"A fatty acid oxidation process that results in the complete oxidation of a long-chain fatty acid. Fatty acid beta-oxidation begins with the addition of coenzyme A to a fatty acid, and occurs by successive cycles of reactions during each of which the fatty acid is shortened by a two-carbon fragment removed as acetyl coenzyme A; the cycle continues until only two or three carbons remain (as acetyl-CoA or propionyl-CoA respectively).
This entity is a specific course-dependent process. This process can constitute the course of lipidosis in the adipose tissuees.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/GO_0006635,,,,,,,,,,,,,,,,,,,,PMID:21980491,,"A fatty acid oxidation process that results in the complete oxidation of a long-chain fatty acid. Fatty acid beta-oxidation begins with the addition of coenzyme A to a fatty acid, and occurs by successive cycles of reactions during each of which the fatty acid is shortened by a two-carbon fragment removed as acetyl coenzyme A; the cycle continues until only two or three carbons remain (as acetyl-CoA or propionyl-CoA respectively).
This entity is a specific course-dependent process. This process can constitute the course of lipidosis in the adipose tissuees.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001100,,,,,,,,,,,,,,,,,,,,,,fatty acid beta-oxidation in adipose tissue [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0001013,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001108,USF1 (canonical)[lipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001110|http://purl.obolibrary.org/obo/TXPO_0003516,,,,,,,,,,,,,,,,,,,,PMID:20817607|PMID:19303849|PMID:9334210|PMID:9890958|PMID:7499393,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,,,,,,TXPO:0001108,,,,,,,,,,,,,,,,,,,,,,USF1 (canonical)[lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001105,Lipidosis dependent molecule (mouse),,"Lipidosis dependent molecule is a subtype of toxic course dependent chemical entity.
This molecule can participate in the course of lipidosis as a gene product.
Gene profile:Mouse/Liver/",false,,,http://purl.obolibrary.org/obo/TXPO_0001089,,,,,,,,,,,,,,,,,,,,,,"Lipidosis dependent molecule is a subtype of toxic course dependent chemical entity.
This molecule can participate in the course of lipidosis as a gene product.
Gene profile:Mouse/Liver/",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001105,,,,,,,,,,,,,,,,,,,,,,Lipidosis dependent molecule (mouse),,,,,,,,,,,http://purl.obolibrary.org/obo/NCBITaxon_9606,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001103,USF2 (human)[Lipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000396|http://purl.obolibrary.org/obo/TXPO_0001090,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:81817|NCBI-Mouse-GeneID:22282|NCBI-Human-GeneID:7392,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001103,,,,,,,,,,,,,,,,,,,,,,USF2 (human)[Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000114827,FHAD1,,Other designations: FHA domain-containing protein 1|forkhead-associated domain-containing protein 1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,1,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,forkhead-associated (FHA) phosphopeptide binding domain 1,,,1p36.21,,,,,,,,,,,,,,,,,,,,,,,,,PMID: 11572484; 12477932; 14702039; 15489334; 16344560; 16710414; 20379614,,,,,,,,,,,,,,,OGG:3000114827,,,,,,,forkhead-associated (FHA) phosphopeptide binding domain 1,,,,,,,,,,,,,Other designations: FHA domain-containing protein 1|forkhead-associated domain-containing protein 1,,FHAD1,,,,,,,,,,,,,,,,,,,,,,,114827,RP3-467K16.1,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,FHAD1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000003592,IL12A,,"Other designations: CLMF p35|IL-12, subunit p35|IL35 subunit|NF cell stimulatory factor chain 1|NK cell stimulatory factor chain 1|cytotoxic lymphocyte maturation factor 1, p35|cytotoxic lymphocyte maturation factor 35 kDa subunit|interleukin 12, p35|interleukin 12A (natural killer cell stimulatory factor 1, cytotoxic lymphocyte maturation factor 1, p35)|interleukin-12 alpha chain|interleukin-12 subunit alpha",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,NKSF1|CLMF|NFSK|P35|IL-12A,,,,,,,,,,,,3,,,,,,Vega:OTTHUMG00000158942|HGNC:5969|HPRD:01193|Ensembl:ENSG00000168811|MIM:161560,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,interleukin 12A,,,3q25.33,,,,,,,,,,,,,,,,"GO_0001916 (EC: IDA, PMID:1674604); GO_0002860 (EC: IDA, PMID:7903063); GO_0005125 (EC: IDA, Qualifier: contributes_to, PMID:1674604); GO_0005125 (EC: TAS, Qualifier: contributes_to, PMID:1673147); GO_0005143 (EC: NAS, PMID:1674604); GO_0005515 (EC: IPI, PMID:10899108); GO_0005615 (EC: IDA, PMID:16456693); GO_0005737 (EC: IEA); GO_0006955 (EC: TAS, PMID:9789052); GO_0007050 (EC: IDA, PMID:16942485); GO_0008083 (EC: IDA, Qualifier: contributes_to, PMID:1674604); GO_0008083 (EC: NAS, Qualifier: contributes_to, PMID:1673147); GO_0009615 (EC: IEP, PMID:16548883); GO_0010224 (EC: IDA, PMID:8992506); GO_0016477 (EC: IDA, PMID:7903063); GO_0032496 (EC: IDA, PMID:7605994); GO_0032700 (EC: IDA, PMID:16482511); GO_0032729 (EC: IDA, PMID:11114383); GO_0032816 (EC: IDA, PMID:1674604); GO_0034393 (EC: IDA, PMID:16942485); GO_0042102 (EC: IEA); GO_0042163 (EC: IEA); GO_0042520 (EC: IDA, PMID:12372421); GO_0042832 (EC: IEA); GO_0043514 (EC: IDA, PMID:11114383); GO_0043514 (EC: NAS, PMID:14718574); GO_0045513 (EC: IPI, PMID:9342359); GO_0045582 (EC: IEA); GO_0045785 (EC: IDA, PMID:7903063); GO_0045954 (EC: IDA, PMID:2204066); GO_0046982 (EC: IPI, PMID:1674604); GO_0048662 (EC: IDA, PMID:16942485); GO_0050671 (EC: IDA, PMID:1674604); GO_0050830 (EC: IEP, PMID:1357073); GO_0051135 (EC: IDA, PMID:19088061); GO_0097191 (EC: IDA, PMID:16942485)",,,,,,,,,PMID:934235; 1350290; 1357073; 1358798; 1673147; 1674604; 2204066; 7516408; 7527811; 7605994; 7695626; 7867080; 7903063; 8557999; 8648753; 8700208; 8760829; 8992506; 9108403; 9158092; 9225992; 9334723; 9342359; 9516412; 9603732; 9616161; 9671213; 9712080; 9789052; 10089131; 10320373; 10352291; 10899108; 11087201; 11114383; 11751963; 11940489; 12117904; 12213961; 12242445; 12270766; 12358856; 12370346; 12372421; 12444143; 12472178; 12477932; 12542496; 12558814; 12576336; 12633940; 12672403; 12719551; 12911539; 12944981; 14566095; 14597672; 14629328; 14660053; 14675394; 14718574; 14764743; 14962816; 15051764; 15087447; 15142381; 15170937; 15331709; 15356557; 15361128; 15448160; 15489234; 15643599; 15741223; 15780175; 15810889; 15817944; 15863393; 15937086; 15956545; 15963597; 16230423; 16456693; 16482511; 16544245; 16548883; 16573560; 16702372; 16754651; 16803996; 16862120; 16885196; 16938461; 16942485; 16961803; 17002904; 17007011; 17062130; 17077296; 17152005; 17225924; 17236132; 17257312; 17304101; 17361014; 17431094; 17444864; 17461482; 17509455; 17553352; 17564777; 17586317; 17627763; 17640324; 17653830; 17671745; 17703412; 17846855; 17881511; 17922692; 17947455; 18050195; 18092318; 18159163; 18190588; 18260379; 18300344; 18311140; 18385764; 18413324; 18417583; 18419254; 18554158; 18566447; 18588867; 18606709; 18628242; 18632425; 18633131; 18671862; 18672993; 18676680; 18717726; 18773331; 18805825; 18972297; 18976327; 19012493; 19013323; 19031096; 19073967; 19074885; 19088061; 19117745; 19118071; 19126646; 19144161; 19148899; 19170196; 19200845; 19230467; 19234184; 19253530; 19258923; 19275586; 19297619; 19299334; 19332120; 19339796; 19376105; 19408823; 19454678; 19458352; 19470040; 19505916; 19508433; 19516896; 19525953; 19543959; 19566870; 19573080; 19594368; 19625176; 19646340; 19692168; 19693089; 19710469; 19773279; 19789190; 19797506; 19798410; 19879194; 19885559; 19913121; 19950173; 19956842; 20012528; 20027291; 20054003; 20060272; 20061784; 20082482; 20190752; 20213229; 20231901; 20237496; 20331378; 20350312; 20372811; 20418110; 20446002; 20452482; 20453000; 20485444; 20503287; 20521253; 20544370; 20551083; 20555355; 20568250; 20581146; 20603050; 20628086; 20634089; 20639880; 20647273; 20673868; 20714168; 20716621; 20818961; 20881642; 20960273; 21044109; 21086908; 21145044; 21177981; 21285006; 21387004; 21397857; 21399635; 21402701; 21513752; 21518507; 21518761; 21606320; 21689404; 21833088; 21878338; 22005588; 22011063; 22038227; 22040814; 22133036; 22438968; 22581790; 22614250; 22655069; 22656398; 22691562; 22734699; 22819329; 22940148; 23053983; 23065210; 23154182; 23285065; 23291587; 23297419; 23377640; 23388728; 23619469; 23657466; 23717436; 23734222; 23752604; 23755218; 24273881,,,,,,,,,,,,,,,OGG:3000003592,,,,,,,interleukin 12A,,,,,,,,,,,,,"Other designations: CLMF p35|IL-12, subunit p35|IL35 subunit|NF cell stimulatory factor chain 1|NK cell stimulatory factor chain 1|cytotoxic lymphocyte maturation factor 1, p35|cytotoxic lymphocyte maturation factor 35 kDa subunit|interleukin 12, p35|interleukin 12A (natural killer cell stimulatory factor 1, cytotoxic lymphocyte maturation factor 1, p35)|interleukin-12 alpha chain|interleukin-12 subunit alpha",,IL12A,,,,,,,,,,,,,,,,,,,,,,,3592,,,,,,,,9606,,,,,,,,,,,,,,,,,,,IL12A,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_15846,NAD(+),,"The oxidised form of nicotinamide adenine dinucleotide found in all living cells. In metabolism, NAD(+) is involved in redox reactions, carrying electrons from one reaction to another.",false,,,http://purl.obolibrary.org/obo/CHEBI_13389,,,,,,,,,,,,,,,,,,,,,,"The oxidised form of nicotinamide adenine dinucleotide found in all living cells. In metabolism, NAD(+) is involved in redox reactions, carrying electrons from one reaction to another.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:15846,,,,,,,,,,,,,,,,,,,,,,NAD(+),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_26523,reactive oxygen species,,"Molecules or ions formed by the incomplete one-electron reduction of oxygen. They contribute to the microbicidal activity of phagocytes, regulation of signal transduction and gene expression, and the oxidative damage to biopolymers.",false,,,http://purl.obolibrary.org/obo/CHEBI_25806,,,,,,,,,,,,,,,,,,,,Wikipedia:Reactive_oxygen_species,,"Molecules or ions formed by the incomplete one-electron reduction of oxygen. They contribute to the microbicidal activity of phagocytes, regulation of signal transduction and gene expression, and the oxidative damage to biopolymers.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:26523,,,,,,,,,,,,,,,,,,,,,,reactive oxygen species,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004803,Increasing SPTLC3 level [hepatocarcinogenesis],,"Increasing SPTLC3 level is a subtype of increasing quantity: A process that changes the amount of SPTLC3 level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004802,,,,,,,,,,,,,,,,,,,,PMID:25607821,,"Increasing SPTLC3 level is a subtype of increasing quantity: A process that changes the amount of SPTLC3 level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004804,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004392,,,,,,,,,,,TXPO:0004803,,,,,,,,,,,,,,,,,,,,,,Increasing SPTLC3 level [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004802,Increasing SPTLC3 level,,Increasing SPTLC3 level is a subtype of increasing quantity: A process that changes the amount of SPTLC3 level to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing SPTLC3 level is a subtype of increasing quantity: A process that changes the amount of SPTLC3 level to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_1000536,,,,,,,,,,,,,,,,,,,TXPO:0004802,,,,,,,,,,,,,,,,,,,,,,Increasing SPTLC3 level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004809,positive regulation of cancer stem cell division [hepatocarcinogenesis],,"Any process that activates or increases the frequency, rate or extent of cancer stem cell division.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0004897|http://purl.obolibrary.org/obo/TXPO_0002340,,,,,,,,,,,,,,,,,,,,PMID:25181692,,"Any process that activates or increases the frequency, rate or extent of cancer stem cell division.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004809,,,,,,,,,,,,,,,,,,,,,,positive regulation of cancer stem cell division [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004808,STAT3(human) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/IMR_0000377,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:|PMID:25181692|PMID:28584306,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003724,,,,,,,,,,TXPO:0004808,,,,,,,,,,,,,,,,,,,,,,STAT3(human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004806,STAT3 signal transduction pathway,,A series of molecular signals mediated by STAT3 (signal transducer and activator of transcription 3).,false,,,http://purl.obolibrary.org/obo/TXPO_0000609,,,,,,,,,,,,,,,,,,,,,,A series of molecular signals mediated by STAT3 (signal transducer and activator of transcription 3).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004806,,,,,,,,,,,,,,,,,,,,,,STAT3 signal transduction pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004800,SFRP1 inactivation [hepatocarcinogenesis],,"SFRP1 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the SFRP1 (secreted frizzled related protein 1) to be lower.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004798,,,,,,,,,,,,,,,,,,,,PMID:29507645,,"SFRP1 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the SFRP1 (secreted frizzled related protein 1) to be lower.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004611,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004801,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004392,,,,,,,,,,,TXPO:0004800,,,,,,,,,,,,,,,,,,,,,,SFRP1 inactivation [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004805,SRC signal transduction pathway,,A series of molecular signals mediated by SRC.,false,,,http://purl.obolibrary.org/obo/TXPO_0000609,,,,,,,,,,,,,,,,,,,,,,A series of molecular signals mediated by SRC.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004805,,,,,,,,,,,,,,,,,,,,,,SRC signal transduction pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004804,SPTLC3 (mouse) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000536|http://purl.obolibrary.org/obo/TXPO_0005072,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:228677|PMID:25607821,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004804,,,,,,,,,,,,,,,,,,,,,,SPTLC3 (mouse) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004801,SFRP1 - inactive form (human) [hepatocarcinogenesis],secreted frizzled related protein 1,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_0005131,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:6422|PMID:29507645,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0002355,,,,,,,,,secreted frizzled related protein 1,,,,,TXPO:0004801,,,,,,,,,,,,,,,,,,,,,,SFRP1 - inactive form (human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004807,STAT3 signaling (primitive),,STAT3 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the STAT3 (signal transducer and activator of transcription 3) .,false,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,,,STAT3 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the STAT3 (signal transducer and activator of transcription 3) .,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004806,,,,,,,,,,,,,,,,TXPO:0004807,,,,,,,,,,,,,,,,,,,,,,STAT3 signaling (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001629,Rab38,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001629,,,,,,,,,,,,,,,,,,,,,,Rab38,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000007296,TXNRD1,,"Other designations: KM-102-derived reductase-like factor|gene associated with retinoic and IFN-induced mortality 12 protein|gene associated with retinoic and interferon-induced mortality 12 protein|oxidoreductase|thioredoxin reductase 1, cytoplasmic|thioredoxin reductase GRIM-12|thioredoxin reductase TR1",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,GRIM-12|TR|TRXR1|TR1|TXNR,,,,,,,,,,,,12,,,,,,Vega:OTTHUMG00000166481|MIM:601112|HPRD:03068|Ensembl:ENSG00000198431|HGNC:12437,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,thioredoxin reductase 1,,,12q23-q24.1,,,,,,,,,,,,,,,,"GO_0001707 (EC: IEA); GO_0004791 (EC: EXP); GO_0005515 (EC: IPI, PMID: 19820694); GO_0005634 (EC: IDA); GO_0005730 (EC: IDA); GO_0005730 (EC: IDA, Qualifier: NOT); GO_0005739 (EC: IEA); GO_0005829 (EC: TAS); GO_0007165 (EC: NAS, PMID: 8921404); GO_0008283 (EC: IEA); GO_0009055 (EC: IEA); GO_0015035 (EC: IEA); GO_0015949 (EC: TAS); GO_0044255 (EC: TAS); GO_0044281 (EC: TAS); GO_0045454 (EC: IEA); GO_0050660 (EC: IEA); GO_0050661 (EC: IEA); GO_0055086 (EC: TAS)",,,,,,,,,PMID: 2064786; 7589432; 8554614; 8577704; 8650234; 8921404; 8999974; 9177183; 9207062; 9671710; 9774665; 10383413; 10432307; 10786696; 11353774; 11375392; 11410332; 11737861; 11782468; 11953436; 12214272; 12435734; 12477932; 12574159; 12668662; 12949356; 12968334; 13679440; 14607844; 14676218; 14980707; 15123685; 15183196; 15199063; 15489334; 15592455; 15824742; 15879598; 16009940; 16169070; 16344560; 16424062; 16481328; 16750198; 16815975; 16868544; 16977661; 17382897; 17512005; 17601350; 17634480; 18029348; 18042542; 18163424; 18187038; 18267104; 18382651; 18483336; 18835810; 18977241; 18996185; 19020731; 19059456; 19124506; 19322201; 19555664; 19595745; 19620238; 19654027; 19766715; 19820694; 19896490; 20160040; 20536427; 20584310; 20877624; 20920480; 21139048; 21172426; 21206984; 21593104; 21693764; 21890473; 21906983; 21963094; 21988832; 22053931; 22230366; 22505724; 22863883; 22939629; 22977247; 23000965; 23063346; 23223577; 23413027; 23512591; 23603921; 24515614,,,,,,,,,,,,,,,OGG:3000007296,,,,,,,thioredoxin reductase 1,,,,,,,,,,,,,"Other designations: KM-102-derived reductase-like factor|gene associated with retinoic and IFN-induced mortality 12 protein|gene associated with retinoic and interferon-induced mortality 12 protein|oxidoreductase|thioredoxin reductase 1, cytoplasmic|thioredoxin reductase GRIM-12|thioredoxin reductase TR1",,TXNRD1,,,,,,,,,,,,,,,,,,,,,,,7296,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,TXNRD1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000007298,TYMS,,Other designations: TSase|thymidylate synthase,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,TS|TMS|HST422,,,,,,,,,,,,18,,,,,,HPRD:01774|Ensembl:ENSG00000176890|MIM:188350|Vega:OTTHUMG00000131473|HGNC:12441,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,thymidylate synthetase,,,18p11.32,,,,,,,,,,,,,,,,"GO_0000082 (EC: TAS); GO_0000083 (EC: TAS); GO_0000166 (EC: IEA); GO_0000278 (EC: TAS); GO_0003729 (EC: IEA); GO_0004799 (EC: TAS); GO_0005542 (EC: IEA); GO_0005634 (EC: IDA); GO_0005654 (EC: TAS); GO_0005730 (EC: IEA); GO_0005737 (EC: IDA); GO_0005739 (EC: IDA); GO_0005743 (EC: IDA); GO_0005759 (EC: IDA); GO_0005829 (EC: TAS); GO_0005976 (EC: IEA); GO_0006139 (EC: TAS, PMID: 2987839); GO_0006206 (EC: TAS); GO_0006231 (EC: IEA); GO_0006235 (EC: IEA); GO_0006260 (EC: NAS, PMID: 15504738); GO_0006281 (EC: NAS, PMID: 15504738); GO_0007568 (EC: IEA); GO_0007623 (EC: IEA); GO_0008144 (EC: IEA); GO_0009157 (EC: TAS, PMID: 2987839); GO_0009636 (EC: IEA); GO_0019088 (EC: IEA); GO_0019860 (EC: IEA); GO_0031100 (EC: IEA); GO_0032570 (EC: IEA); GO_0033189 (EC: IEA); GO_0034097 (EC: IEA); GO_0042493 (EC: IEA); GO_0042803 (EC: IEA); GO_0044281 (EC: TAS); GO_0045471 (EC: IEA); GO_0046078 (EC: IEA); GO_0046134 (EC: TAS); GO_0046653 (EC: IEA); GO_0046683 (EC: IEP, PMID: 16079077); GO_0048015 (EC: NAS, PMID: 15504738); GO_0048037 (EC: IEA); GO_0048589 (EC: IEA); GO_0051216 (EC: IEA); GO_0051384 (EC: IEA); GO_0051593 (EC: IEA); GO_0055086 (EC: TAS); GO_0060574 (EC: IEA)",,,,,,,,,PMID: 1720706; 2243092; 2532645; 2656695; 2987839; 3839505; 8125298; 8449516; 8845352; 9148948; 11102983; 11251009; 11251164; 11278511; 11316879; 11329255; 11445856; 11697906; 11747337; 11799066; 11804689; 11937185; 11989786; 11992400; 12018454; 12067974; 12084458; 12084459; 12084460; 12084461; 12084462; 12147691; 12215845; 12220503; 12239455; 12466474; 12477932; 12530000; 12576451; 12576452; 12604405; 12640689; 12684695; 12706868; 12782596; 12845668; 12859954; 12907731; 12972956; 14519634; 14519641; 14576935; 14578129; 14586640; 14656021; 14702180; 14745930; 14760062; 14967037; 14970324; 14977639; 15093541; 15115918; 15161716; 15198953; 15213713; 15231747; 15244514; 15251465; 15259039; 15260847; 15284183; 15316940; 15355920; 15386366; 15386371; 15457444; 15459215; 15489334; 15504738; 15510613; 15571262; 15571263; 15571283; 15579479; 15585623; 15598787; 15677700; 15682292; 15713801; 15735113; 15736425; 15788669; 15797993; 15817609; 15897576; 15930032; 15952572; 15953655; 15985285; 15993511; 15999119; 16030402; 16045580; 16051637; 16077970; 16079077; 16130010; 16132996; 16141798; 16162288; 16182121; 16188144; 16219137; 16234002; 16242255; 16259621; 16284371; 16317430; 16328059; 16328315; 16333305; 16334126; 16365025; 16424979; 16447238; 16456808; 16467096; 16575011; 16580699; 16596248; 16609021; 16617381; 16622263; 16675565; 16722845; 16723031; 16773218; 16920564; 16929515; 17000685; 17018589; 17065089; 17181924; 17187508; 17201138; 17203168; 17220568; 17273745; 17290389; 17311259; 17317154; 17367411; 17369151; 17372271; 17377791; 17385677; 17395259; 17410198; 17417073; 17439323; 17449906; 17454638; 17512053; 17546637; 17549369; 17551301; 17581305; 17596206; 17655928; 17659576; 17661145; 17684410; 17684476; 17688376; 17716232; 17854149; 17891500; 17971770; 18095031; 18098291; 18174236; 18177869; 18192902; 18203297; 18221821; 18245544; 18267032; 18274813; 18281538; 18285546; 18299612; 18322994; 18336674; 18365142; 18370400; 18381794; 18406541; 18427977; 18430179; 18448328; 18458991; 18498133; 18505590; 18510611; 18540691; 18584349; 18589584; 18593893; 18597678; 18600534; 18607581; 18629514; 18635682; 18636124; 18642643; 18669903; 18676680; 18676755; 18677108; 18704422; 18722050; 18728661; 18781797; 18785313; 18830263; 18855534; 18976010; 18983896; 18985814; 18988749; 18989779; 18990369; 18992148; 19020309; 19020759; 19020767; 19048631; 19064578; 19074750; 19082493; 19147506; 19154585; 19159907; 19161160; 19162321; 19170196; 19190136; 19295264; 19306093; 19307503; 19332728; 19339270; 19339911; 19374805; 19384296; 19426394; 19427504; 19444465; 19460136; 19471022; 19493349; 19513514; 19546880; 19568409; 19571608; 19619240; 19621386; 19625176; 19632929; 19636001; 19651439; 19672780; 19692168; 19722231; 19724871; 19738201; 19748501; 19750576; 19751277; 19774638; 19822515; 19837268; 19850635; 19858398; 19858780; 19885596; 19888426; 19898266; 19913121; 19917450; 19956635; 19998340; 20012317; 20047592; 20061047; 20101025; 20112501; 20122156; 20151707; 20165956; 20177420; 20180013; 20216541; 20235210; 20237949; 20306339; 20310006; 20331623; 20368715; 20371218; 20372850; 20372856; 20381446; 20385995; 20387074; 20447923; 20453000; 20458436; 20501373; 20504250; 20515563; 20530282; 20531375; 20544798; 20565774; 20570913; 20571234; 20580582; 20615890; 20628086; 20628382; 20628391; 20634891; 20638924; 20647221; 20647341; 20651387; 20665215; 20670920; 20714149; 20714877; 20734048; 20737570; 20815815; 20819423; 20824655; 20837458; 20932673; 20944490; 20962453; 20966539; 20970877; 21036767; 21043562; 21048041; 21057378; 21064161; 21111509; 21131780; 21139048; 21167658; 21188629; 21206062; 21245530; 21254360; 21262916; 21269855; 21282454; 21321092; 21347782; 21362378; 21460376; 21463130; 21471424; 21550658; 21570215; 21603981; 21605004; 21618517; 21643952; 21716147; 21730794; 21788964; 21811101; 21824439; 21848426; 21890473; 21900206; 21906983; 21919605; 21947036; 21948461; 21956592; 21963094; 21965773; 21987572; 22006578; 22074251; 22110208; 22143355; 22166040; 22172489; 22233820; 22270332; 22307944; 22384047; 22388795; 22397721; 22407825; 22486600; 22496803; 22502681; 22505724; 22551903; 22576918; 22580655; 22593457; 22623428; 22641663; 22713864; 22763757; 22819905; 22825513; 22863883; 22866924; 22882943; 22887475; 22895141; 22901148; 22938428; 22939629; 23000965; 23098521; 23148637; 23217244; 23249808; 23263912; 23336575; 23350714; 23468971; 23523421; 23645741; 23652803; 23675481; 23710599; 23722170; 23726796; 23736036; 23810585; 23838799; 23930679; 24067998; 24100087; 24123038,,,,,,,,,,,,,,,OGG:3000007298,,,,,,,thymidylate synthetase,,,,,,,,,,,,,Other designations: TSase|thymidylate synthase,,TYMS,,,,,,,,,,,,,,,,,,,,,,,7298,OK/SW-cl.29,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,TYMS,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000007291,TWIST1,,Other designations: B-HLH DNA binding protein|H-twist|TWIST homolog of drosophila|class A basic helix-loop-helix protein 38|craniosynostosis|twist basic helix-loop-helix transcription factor 1|twist homolog 1|twist-related protein 1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,BPES3|CRS1|ACS3|BPES2|CRS|bHLHa38|TWIST|SCS,,,,,,,,,,,,7,,,,,,HGNC:12428|Ensembl:ENSG00000122691|Vega:OTTHUMG00000090821|MIM:601622|HPRD:03374,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,twist family bHLH transcription factor 1,,,7p21.2,,,,,,,,,,,,,,,,"GO_0000122 (EC: IMP, PMID: 17690110); GO_0000981 (EC: IDA, PMID: 17332325); GO_0001503 (EC: TAS, PMID: 11001584); GO_0001649 (EC: IEA); GO_0001701 (EC: IEA); GO_0001764 (EC: IEA); GO_0001843 (EC: IEA); GO_0003180 (EC: IMP); GO_0003183 (EC: IEA); GO_0003203 (EC: IEA); GO_0003253 (EC: IEA); GO_0005515 (EC: IPI, PMID: 18504427); GO_0005634 (EC: IDA, PMID: 10749989); GO_0006366 (EC: IDA, PMID: 17332325); GO_0007517 (EC: IEA); GO_0008134 (EC: IPI, PMID: 15545268); GO_0010628 (EC: IMP, PMID: 17003487); GO_0010718 (EC: IMP, PMID: 18297062); GO_0014067 (EC: IMP, PMID: 17003487); GO_0019904 (EC: IEA); GO_0030500 (EC: IMP, PMID: 19597909); GO_0032000 (EC: IMP); GO_0032720 (EC: IEA); GO_0032760 (EC: IMP); GO_0033128 (EC: IMP, PMID: 17690110); GO_0035067 (EC: IEA); GO_0035115 (EC: IEA); GO_0035116 (EC: IEA); GO_0035359 (EC: IEA); GO_0042473 (EC: TAS, PMID: 11001584); GO_0042476 (EC: IEA); GO_0042733 (EC: TAS, PMID: 11001584); GO_0042803 (EC: IEA); GO_0043066 (EC: IEA); GO_0043425 (EC: IPI, PMID: 10749989); GO_0043433 (EC: IEA); GO_0043518 (EC: IMP, PMID: 17690110); GO_0045668 (EC: IMP, PMID: 16888803); GO_0045766 (EC: NAS, PMID: 17987801); GO_0045944 (EC: IDA, PMID: 17332325); GO_0045944 (EC: IMP, PMID: 12270142); GO_0046982 (EC: IEA); GO_0048642 (EC: IEA); GO_0048701 (EC: IMP, PMID: 8988166); GO_0050679 (EC: IEA); GO_0060021 (EC: IEA); GO_0060363 (EC: TAS, PMID: 11001584); GO_0060900 (EC: IMP, PMID: 17070479); GO_0061029 (EC: IMP, PMID: 17070479); GO_0070888 (EC: IDA, PMID: 17332325); GO_0071363 (EC: IEA); GO_0071456 (EC: IMP, PMID: 18297062); GO_0071639 (EC: IMP); GO_2000147 (EC: IMP, PMID: 17332325); GO_2000147 (EC: NAS, PMID: 17332324); GO_2000276 (EC: IEA); GO_2000679 (EC: IMP, PMID: 12270142); GO_2000773 (EC: IMP, PMID: 17690110); GO_2000778 (EC: IMP); GO_2000780 (EC: IMP, PMID: 17690110); GO_2000793 (EC: IMP); GO_2000802 (EC: IEA)",,,,,,,,,PMID: 1433226; 7296937; 7987323; 8968762; 8988166; 8988167; 8995765; 9073070; 9215678; 9259286; 9343420; 9934984; 10025406; 10465122; 10485844; 10749989; 11001584; 11062344; 11474656; 11748846; 11754069; 11854168; 11948912; 11977182; 12015302; 12142027; 12218784; 12270142; 12477932; 12553906; 12690205; 12791045; 12853948; 14513358; 14724576; 15210113; 15313894; 15489334; 15545268; 15555546; 15607966; 15735646; 15880747; 15900593; 15958559; 16229805; 16293629; 16322226; 16412561; 16502419; 16540516; 16737925; 16831897; 16888803; 17003487; 17070479; 17157810; 17236203; 17332324; 17332325; 17343269; 17394502; 17403902; 17414280; 17487558; 17512904; 17690110; 17785550; 17886095; 17893140; 17925286; 17967182; 17987801; 18062917; 18172301; 18231738; 18255367; 18297062; 18349132; 18353781; 18391499; 18440840; 18480983; 18504427; 18519689; 18549475; 18598946; 18663125; 18974133; 19051271; 19064546; 19094228; 19276370; 19345188; 19373776; 19381684; 19412634; 19453261; 19470737; 19513566; 19534813; 19597909; 19609939; 19644484; 19802001; 19816777; 19821482; 19851501; 19860490; 19863427; 19893041; 19954024; 20007935; 20019840; 20025748; 20079104; 20140954; 20219012; 20301368; 20388391; 20400975; 20400976; 20496080; 20505321; 20562331; 20564230; 20628624; 20634891; 20643727; 20646316; 20696219; 20714342; 20804746; 20818389; 20838384; 20857420; 20920982; 20943789; 20970163; 21083641; 21123820; 21138866; 21199805; 21208645; 21316706; 21317430; 21324165; 21333765; 21389145; 21397860; 21461979; 21464926; 21478681; 21502402; 21503964; 21532573; 21539816; 21559372; 21559426; 21594904; 21677079; 21732143; 21740802; 21748764; 21796367; 21822911; 21834956; 21854747; 21864967; 21866569; 21883379; 21884981; 21914771; 21919891; 21931630; 21983900; 21994965; 22002117; 22006115; 22006371; 22007485; 22020939; 22050045; 22056872; 22060274; 22102471; 22110753; 22155737; 22166980; 22178381; 22184289; 22241470; 22245869; 22253230; 22266852; 22272264; 22288519; 22290439; 22331730; 22349827; 22354994; 22360285; 22407364; 22457607; 22515221; 22532563; 22544111; 22576709; 22581441; 22581828; 22654667; 22668877; 22797064; 22820497; 22847601; 22896337; 22899291; 22961111; 22965800; 22974478; 22974479; 22975381; 22982861; 22983574; 23029385; 23052737; 23056278; 23095743; 23150175; 23158991; 23161342; 23167357; 23222305; 23232513; 23251661; 23329645; 23354436; 23375009; 23429988; 23500436; 23530115; 23613408; 23623921; 23664538; 23682613; 23684708; 23691243; 23696034; 23741524; 23775496; 23815808; 23825006; 23845905; 23873099; 23889968; 23928864; 23935104; 23990016; 23994666; 24051309; 24085799; 24148247; 24150986; 24157255; 24457449,,,,,,,,,,,,,,,OGG:3000007291,,,,,,,twist family bHLH transcription factor 1,,,,,,,,,,,,,Other designations: B-HLH DNA binding protein|H-twist|TWIST homolog of drosophila|class A basic helix-loop-helix protein 38|craniosynostosis|twist basic helix-loop-helix transcription factor 1|twist homolog 1|twist-related protein 1,,TWIST1,,,,,,,,,,,,,,,,,,,,,,,7291,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,TWIST1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0002912,apoptotic gene expression by ATF6 [ER stress - apoptosis],,"Refolding gene expression by ATF6 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) related to the apoptosis by ATF6.
This process is dependent on the apoptosis and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002521,,,,,,,,,,,,,,,,,,,,PMID:26960794|PMID:23334697,,"Refolding gene expression by ATF6 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) related to the apoptosis by ATF6.
This process is dependent on the apoptosis and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002913,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002915,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002916,,,,,,,,,,,TXPO:0002912,,,,,,,,,,,,,,,,,,,,,,apoptotic gene expression by ATF6 [ER stress - apoptosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002914,CHOP (canonical)[ER stress],DDIT3 [ER stress],,false,,,http://purl.obolibrary.org/obo/TXPO_0000871|http://purl.obolibrary.org/obo/TXPO_1000067,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:29467|NCBI-Mouse-GeneID:13198|NCBI-Human-GeneID:1649|PMID:15775988|PMID:25904325|PMID:15601821|PMID:22761832,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,DDIT3 [ER stress],,,,,TXPO:0002914,,,,,,,,,,,,,,,,,,,,,,CHOP (canonical)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002918,ATF6 activation [ER stress - ERAD],,"ATF6 activation is a subtype of molecular activation: A process that changes the activity of the ATF6 (Activating Transcription Factor 6) to be higher.
This process is dependent on ERAD and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000710|http://purl.obolibrary.org/obo/TXPO_0003736,,,,,,,,,,,,,,,,,,,,,,"ATF6 activation is a subtype of molecular activation: A process that changes the activity of the ATF6 (Activating Transcription Factor 6) to be higher.
This process is dependent on ERAD and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002958,,,,,,,,,,,,,,,,,,,TXPO:0002918,,,,,,,,,,,,,,,,,,,,,,ATF6 activation [ER stress - ERAD],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002910,ATF6 - signaling factor (canonical)[ER stress - apotosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000044,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001898,,,,,,,,,,TXPO:0002910,,,,,,,,,,,,,,,,,,,,,,ATF6 - signaling factor (canonical)[ER stress - apotosis],,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005794,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002911,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002913,ATF6 - transcriptional factor (canonical)[ER stress - apotosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002468,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000825,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,,,,,,TXPO:0002913,,,,,,,,,,,,,,,,,,,,,,ATF6 - transcriptional factor (canonical)[ER stress - apotosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002916,apoptosis promoting gene expression [ER stress],,"Apoptosis inducing gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature apoptosis inducing  gene product or products (proteins or RNA).
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/TXPO_0002917,,,,,,,,,,,,,,,,,,,,,,"Apoptosis inducing gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature apoptosis inducing  gene product or products (proteins or RNA).
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002909|http://purl.obolibrary.org/obo/TXPO_0002440|http://purl.obolibrary.org/obo/TXPO_0002912|http://purl.obolibrary.org/obo/TXPO_0002767|http://purl.obolibrary.org/obo/TXPO_0002721|http://purl.obolibrary.org/obo/TXPO_0002722|http://purl.obolibrary.org/obo/TXPO_0003030,,http://purl.obolibrary.org/obo/TXPO_0002519|http://purl.obolibrary.org/obo/TXPO_0002908,,,,,http://purl.obolibrary.org/obo/TXPO_0002114,,,,,,,,,,,TXPO:0002916,,,,,,,,,,,,,,,,,,,,,,apoptosis promoting gene expression [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002917,apoptosis promoting gene expression,,Apoptosis inducing gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature apoptosis inducing  gene product or products (proteins or RNA).,false,,,http://purl.obolibrary.org/obo/GO_0010467,,,,,,,,,,,,,,,,,,,,,,Apoptosis inducing gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature apoptosis inducing  gene product or products (proteins or RNA).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002917,,,,,,,,,,,,,,,,,,,,,,apoptosis promoting gene expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002911,ATF6 activation [ER stress - apoptosis],,"ATF6 activation is a subtype of molecular activation: A process that changes the activity of the ATF6 (Activating Transcription Factor 6) to be higher.
This process is dependent on the apoptosis and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000710|http://purl.obolibrary.org/obo/TXPO_0003736,,,,,,,,,,,,,,,,,,,,,,"ATF6 activation is a subtype of molecular activation: A process that changes the activity of the ATF6 (Activating Transcription Factor 6) to be higher.
This process is dependent on the apoptosis and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002910,,,,,,,,,,,,,,,,,,,TXPO:0002911,,,,,,,,,,,,,,,,,,,,,,ATF6 activation [ER stress - apoptosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002915,CHOP - apotosis inducing factor (canonical)[ER stress - apotosis],DDIT3 [ER stress - apoptosis - apoptosis inducer ],,false,,,http://purl.obolibrary.org/obo/TXPO_0002914,,,,,,,,,,,,,,,,,,,,PMID:15775988|PMID:25904325|PMID:15601821|http://www.omim.org/entry/126337|PMID:22761832,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_68495|http://purl.obolibrary.org/obo/TXPO_0000330,,,,,DDIT3 [ER stress - apoptosis - apoptosis inducer ],,,,,TXPO:0002915,,,,,,,,,,,,,,,,,,,,,,CHOP - apotosis inducing factor (canonical)[ER stress - apotosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002919,refolding gene expression by XBP1 [ER stress - refolding],,"Refolding gene expression by XBP1 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) related to the protein refolding function by XBP1.
This process is dependent on the refolding and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002607,,,,,,,,,,,,,,,,,,,,,,"Refolding gene expression by XBP1 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) related to the protein refolding function by XBP1.
This process is dependent on the refolding and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002923,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002920,,http://purl.obolibrary.org/obo/TXPO_0002165|http://purl.obolibrary.org/obo/TXPO_0000783,,,,,,http://purl.obolibrary.org/obo/TXPO_0002384,,,,,,,,,,,TXPO:0002919,,,,,,,,,,,,,,,,,,,,,,refolding gene expression by XBP1 [ER stress - refolding],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000057404,CYP20A1,,Other designations: cytochrome P450 20A1|cytochrome P450 monooxygenase,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CYP-M,,,,,,,,,,,,2,,,,,,HPRD:07100|Vega:OTTHUMG00000132854|Ensembl:ENSG00000119004|HGNC:20576,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 20, subfamily A, polypeptide 1",,,2q33.2,,,,,,,,,,,,,,,,GO_0004497 (EC: IEA); GO_0005506 (EC: IEA); GO_0016021 (EC: IEA); GO_0016705 (EC: IEA); GO_0020037 (EC: IEA),,,,,,,,,PMID:9890157; 11178272; 12477932; 12975309; 14702039; 15128046; 15191668; 19898482; 20966902; 21832049,,,,,,,,,,,,,,,OGG:3000057404,,,,,,,"cytochrome P450, family 20, subfamily A, polypeptide 1",,,,,,,,,,,,,Other designations: cytochrome P450 20A1|cytochrome P450 monooxygenase,,CYP20A1,,,,,,,,,,,,,,,,,,,,,,,57404,UNQ667/PRO1301,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP20A1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_17984,acyl-CoA,Acyl-CoA|CC(C)(COP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1OP(O)(O)=O)n1cnc2c(N)ncnc12)[C@@H](O)C(=O)NCCC(=O)NCCSC([*])=O|Acyl coenzyme A,A thioester that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of any carboxylic acid.,false,,,http://purl.obolibrary.org/obo/CHEBI_72695,,,,,,,,,,,,,,,,,,,,PMID:11264983|PMID:11524729|CAS:9029-97-4,,A thioester that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of any carboxylic acid.,,,,,,,,,,,,C22H35N7O17P3SR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Acyl-CoA|CC(C)(COP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1OP(O)(O)=O)n1cnc2c(N)ncnc12)[C@@H](O)C(=O)NCCC(=O)NCCSC([*])=O|Acyl coenzyme A,,,,,CHEBI:17984,,,,,,,,,,,,,,,,,,,,,,acyl-CoA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0000279,M phase,,"A cell cycle phase during which nuclear division occurs, and which is comprises the phases: prophase, metaphase, anaphase and telophase.",false,,,http://purl.obolibrary.org/obo/GO_0022403,,,,,,,,,,,,,,,,,,,,Wikipedia:M_phase,,"A cell cycle phase during which nuclear division occurs, and which is comprises the phases: prophase, metaphase, anaphase and telophase.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0000279,,,,,,,,,,,,,,,,,,,,,,M phase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004063,CYP3A5 [Hepatocarcinogenesis],"cytochrome P450, family 3, subfamily A, polypeptide 5 [Hepatocarcinogenesis]",,false,,,http://purl.obolibrary.org/obo/TXPO_1000083|http://purl.obolibrary.org/obo/TXPO_0000837,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1577|PMID:25649767|PMID:17827782,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"cytochrome P450, family 3, subfamily A, polypeptide 5 [Hepatocarcinogenesis]",,,,,TXPO:0004063,,,,,,,,,,,,,,,,,,,,,,CYP3A5 [Hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004069,hypofunction of anti-oxidative stress[Phospholipidosis],,"Hypofunction of anti-oxidative stress is a subtype of hypofunctioning: A process that performs a decreased or insufficient anti-oxidative stress function.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0004066,,,,,,,,,,,,,,,,,,,,,,"Hypofunction of anti-oxidative stress is a subtype of hypofunctioning: A process that performs a decreased or insufficient anti-oxidative stress function.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004070|http://purl.obolibrary.org/obo/TXPO_0003558,,,,,,http://purl.obolibrary.org/obo/TXPO_0001497|http://purl.obolibrary.org/obo/TXPO_0001491,,,,,,,,,,,TXPO:0004069,,,,,,,,,,,,,,,,,,,,,,hypofunction of anti-oxidative stress[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004062,Cpq [Hepatocarcinogenesis],carboxypeptidase Q [Hepatocarcinogenesis],,false,,,http://purl.obolibrary.org/obo/TXPO_0000837|http://purl.obolibrary.org/obo/TXPO_1000096,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:54381|NCBI-Human-GeneID:10404|NCBI-Rat-GeneID:58952,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,carboxypeptidase Q [Hepatocarcinogenesis],,,,,TXPO:0004062,,,,,,,,,,,,,,,,,,,,,,Cpq [Hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004061,PPAR alpha [Phospholipidosis],Peroxisome Proliferator-Activated Receptor Alpha [Eosinophilic granular degeneration],,false,,,http://purl.obolibrary.org/obo/TXPO_0000159|http://purl.obolibrary.org/obo/TXPO_0003213,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:19013|NCBI-Rat-GeneID:25747|NCBI-Human-GeneID:5465|PMID:27816970,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Peroxisome Proliferator-Activated Receptor Alpha [Eosinophilic granular degeneration],,,,,TXPO:0004061,,,,,,,,,,,,,,,,,,,,,,PPAR alpha [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004068,GPC3 [Hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000613|http://purl.obolibrary.org/obo/TXPO_0000837,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:2719|PMID:8589713|PMID:24498024|PMID:23598528|PMID:18413366,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004068,,,,,,,,,,,,,,,,,,,,,,GPC3 [Hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004064,EIF1 [Hepatocarcinogenesis],eukaryotic translation initiation factor 1 [Hepatocarcinogenesis],,false,,,http://purl.obolibrary.org/obo/IMR_0000908|http://purl.obolibrary.org/obo/TXPO_0000837,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:10209|NCBI-Mouse-GeneID:20918|NCBI-Rat-GeneID:287703,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,eukaryotic translation initiation factor 1 [Hepatocarcinogenesis],,,,,TXPO:0004064,,,,,,,"EIF1 (Eukaryotic Translation Initiation Factor 1) is a Protein Coding gene. Among its related pathways are Translation Factors and RNA transport. GO annotations related to this gene include poly(A) RNA binding and translation factor activity, RNA binding. An important paralog of this gene is EIF1B.",,,,,,,,,,,,,,,EIF1 [Hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004066,hypofunction of anti-oxidative stress,,Hypofunction of anti-oxidative stress is a subtype of hypofunctioning: A process that performs a decreased or insufficient anti-oxidative stress function.,false,,,http://purl.obolibrary.org/obo/TXPO_0000436,,,,,,,,,,,,,,,,,,,,,,Hypofunction of anti-oxidative stress is a subtype of hypofunctioning: A process that performs a decreased or insufficient anti-oxidative stress function.,,,http://purl.obolibrary.org/obo/GO_0006979,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004066,,,,,,,,,,,,,,,,,,,,,,hypofunction of anti-oxidative stress,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004065,ketone biosynthetic process[Phospholipidosis],ketone synthesis|ketone anabolism|ketone formation|ketone biosynthesis,"The chemical reactions and pathways resulting in the formation of ketones, a class of organic compounds that contain the carbonyl group, CO, and in which the carbonyl group is bonded only to carbon atoms. The general formula for a ketone is RCOR, where R and R are alkyl or aryl groups.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/GO_00042181|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,PMID:24140022|PMID:31442404|PMID:21502324,,"The chemical reactions and pathways resulting in the formation of ketones, a class of organic compounds that contain the carbonyl group, CO, and in which the carbonyl group is bonded only to carbon atoms. The general formula for a ketone is RCOR, where R and R are alkyl or aryl groups.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004052|http://purl.obolibrary.org/obo/TXPO_0004050,,,,,,http://purl.obolibrary.org/obo/TXPO_0003592,,,,,,ketone synthesis|ketone anabolism|ketone formation|ketone biosynthesis,,,,,TXPO:0004065,,,,,,,,,,,,,,,,,,,,,,ketone biosynthetic process[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004060,Cenpw [Hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000837|http://purl.obolibrary.org/obo/TXPO_1000092,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:689399|NCBI-Human-GeneID:387103|NCBI-Mouse-GeneID:66311|PMID:21695110|PMID:17610844|PMID:23917355,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004060,,,,,,,,,,,,,,,,,,,,,,Cenpw [Hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004067,Glypican [Hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000837|http://purl.obolibrary.org/obo/IMR_0001139,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:58920|NCBI-Mouse-GeneID:14733|NCBI-Human-GeneID:2817,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004067,,,,,,,,,,,,,,,,,,,,,,Glypican [Hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000009439,MED23,,Other designations: 130 kDa transcriptional co-activator|133 kDa transcriptional co-activator|activator-recruited cofactor 130 kDa component|cofactor required for Sp1 transcriptional activation subunit 3|mediator of RNA polymerase II transcription subunit 23|vitamin D3 receptor interacting protein,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,SUR-2|ARC130|CRSP130|CRSP133|SUR2|CRSP3|MRT18|DRIP130,,,,,,,,,,,,6,,,,,,Vega:OTTHUMG00000015565|HPRD:05436|HGNC:2372|Ensembl:ENSG00000112282|MIM:605042,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,mediator complex subunit 23,,,6q22.33-q24.1,,,,,,,,,,,,,,,,"GO_0003713 (EC: TAS, PMID: 9989412); GO_0005515 (EC: IPI, PMID: 17438371); GO_0005654 (EC: TAS); GO_0005667 (EC: IDA, PMID: 9989412); GO_0006355 (EC: IDA, PMID: 9989412); GO_0006357 (EC: TAS, PMID: 9989412); GO_0006367 (EC: TAS); GO_0010467 (EC: TAS); GO_0016592 (EC: IEA)",,,,,,,,,PMID: 9989412; 10235266; 10235267; 10353252; 10574462; 10823961; 10993082; 11076863; 11230166; 11416138; 11834832; 11867769; 11934987; 12089346; 12242338; 12421765; 12477932; 12543799; 14574404; 14638676; 14657022; 14759369; 15175163; 15489336; 15572696; 15893730; 15989967; 16147992; 16204234; 16239144; 16381901; 16799563; 16964286; 17438371; 18418385; 18660489; 18691967; 19322201; 19913121; 20098423; 20133760; 20508642; 20628086; 20720539; 21139048; 21729782; 21868677; 21890473; 21906983; 22505724; 22797925; 22939629; 22988093; 23022380; 23275444; 23322298; 23340209; 23602568,,,,,,,,,,,,,,,OGG:3000009439,,,,,,,mediator complex subunit 23,,,,,,,,,,,,,Other designations: 130 kDa transcriptional co-activator|133 kDa transcriptional co-activator|activator-recruited cofactor 130 kDa component|cofactor required for Sp1 transcriptional activation subunit 3|mediator of RNA polymerase II transcription subunit 23|vitamin D3 receptor interacting protein,,MED23,,,,,,,,,,,,,,,,,,,,,,,9439,RP5-914N13.2,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,MED23,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000390,IRF-4,,,false,,,http://purl.obolibrary.org/obo/IMR_0000386,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000390,,,,,,,,,,,,,,,,,,,,,,IRF-4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001981,Ccl4 [ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003012|http://purl.obolibrary.org/obo/CHEBI_27385,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_64909,,,,,,,,,,TXPO:0001981,,,,,,,,,,,,,,,,,,,,,,Ccl4 [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001985,mutation,,Mutation is a subtype of changing an operand: A process that changes the nucleotide sequence of DNA randomly and permanently.,false,,,http://purl.obolibrary.org/obo/TXPO_0000392,,,,,,,,,,,,,,,,,,,,,,Mutation is a subtype of changing an operand: A process that changes the nucleotide sequence of DNA randomly and permanently.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001985,,,,,,,,,,,,,,,,,,,,,,mutation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001986,mitochondrial damage [toxic course],,The totality of all processes through which mitochondrial damage is realized.|under construction,false,,,http://purl.obolibrary.org/obo/TXPO_0000009,,,,,,,,,,,,,,,,,,,,,,The totality of all processes through which mitochondrial damage is realized.,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001993,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004761|http://purl.obolibrary.org/obo/TXPO_0004109|http://purl.obolibrary.org/obo/TXPO_0004946|http://purl.obolibrary.org/obo/TXPO_0004941|http://purl.obolibrary.org/obo/TXPO_0005044|http://purl.obolibrary.org/obo/TXPO_0002146|http://purl.obolibrary.org/obo/TXPO_0004722|http://purl.obolibrary.org/obo/TXPO_0004720|http://purl.obolibrary.org/obo/TXPO_0004723|http://purl.obolibrary.org/obo/TXPO_0004225|http://purl.obolibrary.org/obo/TXPO_0004218|http://purl.obolibrary.org/obo/TXPO_0004307|http://purl.obolibrary.org/obo/TXPO_0001029|http://purl.obolibrary.org/obo/TXPO_0001990|http://purl.obolibrary.org/obo/TXPO_0001992|http://purl.obolibrary.org/obo/TXPO_0001991|http://purl.obolibrary.org/obo/TXPO_0001997|http://purl.obolibrary.org/obo/TXPO_0001999|http://purl.obolibrary.org/obo/TXPO_0004279|http://purl.obolibrary.org/obo/TXPO_0004273|http://purl.obolibrary.org/obo/TXPO_0004270|http://purl.obolibrary.org/obo/TXPO_0004271|http://purl.obolibrary.org/obo/TXPO_0004278|http://purl.obolibrary.org/obo/TXPO_0004274|http://purl.obolibrary.org/obo/TXPO_0004272|http://purl.obolibrary.org/obo/TXPO_0000933|http://purl.obolibrary.org/obo/TXPO_0004131|http://purl.obolibrary.org/obo/TXPO_0004135|http://purl.obolibrary.org/obo/TXPO_0002040|http://purl.obolibrary.org/obo/TXPO_0002041|http://purl.obolibrary.org/obo/TXPO_0004939|http://purl.obolibrary.org/obo/TXPO_0004936|http://purl.obolibrary.org/obo/TXPO_0004937|http://purl.obolibrary.org/obo/TXPO_0005009|http://purl.obolibrary.org/obo/TXPO_0000869|http://purl.obolibrary.org/obo/TXPO_0004325|http://purl.obolibrary.org/obo/TXPO_0004324|http://purl.obolibrary.org/obo/TXPO_0004369|http://purl.obolibrary.org/obo/TXPO_0004368|http://purl.obolibrary.org/obo/TXPO_0004367|http://purl.obolibrary.org/obo/TXPO_0004360|http://purl.obolibrary.org/obo/TXPO_0004366|http://purl.obolibrary.org/obo/TXPO_0004359|http://purl.obolibrary.org/obo/TXPO_0004351|http://purl.obolibrary.org/obo/TXPO_0004350|http://purl.obolibrary.org/obo/TXPO_0004742|http://purl.obolibrary.org/obo/TXPO_0004741|http://purl.obolibrary.org/obo/TXPO_0001879|http://purl.obolibrary.org/obo/TXPO_0001988|http://purl.obolibrary.org/obo/TXPO_0001989|http://purl.obolibrary.org/obo/TXPO_0004436|http://purl.obolibrary.org/obo/TXPO_0002039|http://purl.obolibrary.org/obo/TXPO_0002038|http://purl.obolibrary.org/obo/TXPO_0004119|http://purl.obolibrary.org/obo/TXPO_0004561|http://purl.obolibrary.org/obo/TXPO_0004416|http://purl.obolibrary.org/obo/TXPO_0004281|http://purl.obolibrary.org/obo/TXPO_0004956|http://purl.obolibrary.org/obo/TXPO_0004955|http://purl.obolibrary.org/obo/TXPO_0004370|http://purl.obolibrary.org/obo/TXPO_0004379|http://purl.obolibrary.org/obo/TXPO_0004377|http://purl.obolibrary.org/obo/TXPO_0004373|http://purl.obolibrary.org/obo/TXPO_0004372|http://purl.obolibrary.org/obo/TXPO_0004378|http://purl.obolibrary.org/obo/TXPO_0004376|http://purl.obolibrary.org/obo/TXPO_0004375|http://purl.obolibrary.org/obo/TXPO_0004371|http://purl.obolibrary.org/obo/TXPO_0004374|http://purl.obolibrary.org/obo/TXPO_0005106|http://purl.obolibrary.org/obo/TXPO_0005109|http://purl.obolibrary.org/obo/TXPO_0005013|http://purl.obolibrary.org/obo/TXPO_0003568|http://purl.obolibrary.org/obo/TXPO_0003569|http://purl.obolibrary.org/obo/TXPO_0002005|http://purl.obolibrary.org/obo/TXPO_0002009|http://purl.obolibrary.org/obo/TXPO_0002004|http://purl.obolibrary.org/obo/TXPO_0004461|http://purl.obolibrary.org/obo/TXPO_0004349|http://purl.obolibrary.org/obo/TXPO_0004347|http://purl.obolibrary.org/obo/TXPO_0004340|http://purl.obolibrary.org/obo/TXPO_0004341|http://purl.obolibrary.org/obo/TXPO_0004343|http://purl.obolibrary.org/obo/TXPO_0004342|http://purl.obolibrary.org/obo/TXPO_0004344|http://purl.obolibrary.org/obo/TXPO_0004345|http://purl.obolibrary.org/obo/TXPO_0004348|http://purl.obolibrary.org/obo/TXPO_0004346|http://purl.obolibrary.org/obo/TXPO_0004990|http://purl.obolibrary.org/obo/TXPO_0004992|http://purl.obolibrary.org/obo/TXPO_0005034|http://purl.obolibrary.org/obo/TXPO_0005031|http://purl.obolibrary.org/obo/TXPO_0005039|http://purl.obolibrary.org/obo/TXPO_0004718|http://purl.obolibrary.org/obo/TXPO_0004717|http://purl.obolibrary.org/obo/TXPO_0004821|http://purl.obolibrary.org/obo/TXPO_0004549|http://purl.obolibrary.org/obo/TXPO_0004830|http://purl.obolibrary.org/obo/TXPO_0004833|http://purl.obolibrary.org/obo/TXPO_0004261|http://purl.obolibrary.org/obo/TXPO_0004264|http://purl.obolibrary.org/obo/TXPO_0004263|http://purl.obolibrary.org/obo/TXPO_0004260|http://purl.obolibrary.org/obo/TXPO_0004265|http://purl.obolibrary.org/obo/TXPO_0004268|http://purl.obolibrary.org/obo/TXPO_0004267|http://purl.obolibrary.org/obo/TXPO_0004266|http://purl.obolibrary.org/obo/TXPO_0004262|http://purl.obolibrary.org/obo/TXPO_0004269|http://purl.obolibrary.org/obo/TXPO_0002230|http://purl.obolibrary.org/obo/TXPO_0004796|http://purl.obolibrary.org/obo/TXPO_0004797|http://purl.obolibrary.org/obo/TXPO_0002010|http://purl.obolibrary.org/obo/TXPO_0004906|http://purl.obolibrary.org/obo/TXPO_0004975|http://purl.obolibrary.org/obo/TXPO_0004976|http://purl.obolibrary.org/obo/TXPO_0004974|http://purl.obolibrary.org/obo/TXPO_0004978|http://purl.obolibrary.org/obo/TXPO_0004551|http://purl.obolibrary.org/obo/TXPO_0004559|http://purl.obolibrary.org/obo/TXPO_0005118|http://purl.obolibrary.org/obo/TXPO_0005115|http://purl.obolibrary.org/obo/TXPO_0005112|http://purl.obolibrary.org/obo/TXPO_0005057|http://purl.obolibrary.org/obo/TXPO_0005055|http://purl.obolibrary.org/obo/TXPO_0004444|http://purl.obolibrary.org/obo/TXPO_0004442|http://purl.obolibrary.org/obo/TXPO_0004440|http://purl.obolibrary.org/obo/TXPO_0004445|http://purl.obolibrary.org/obo/TXPO_0004443|http://purl.obolibrary.org/obo/TXPO_0004928|http://purl.obolibrary.org/obo/TXPO_0004927|http://purl.obolibrary.org/obo/TXPO_0004246|http://purl.obolibrary.org/obo/TXPO_0004243|http://purl.obolibrary.org/obo/TXPO_0004245|http://purl.obolibrary.org/obo/TXPO_0004242|http://purl.obolibrary.org/obo/TXPO_0004247|http://purl.obolibrary.org/obo/TXPO_0004241|http://purl.obolibrary.org/obo/TXPO_0004249|http://purl.obolibrary.org/obo/TXPO_0004987|http://purl.obolibrary.org/obo/TXPO_0004981|http://purl.obolibrary.org/obo/TXPO_0004985|http://purl.obolibrary.org/obo/TXPO_0004960|http://purl.obolibrary.org/obo/TXPO_0004964|http://purl.obolibrary.org/obo/TXPO_0004295|http://purl.obolibrary.org/obo/TXPO_0004255|http://purl.obolibrary.org/obo/TXPO_0004251|http://purl.obolibrary.org/obo/TXPO_0004252|http://purl.obolibrary.org/obo/TXPO_0004250|http://purl.obolibrary.org/obo/TXPO_0004257|http://purl.obolibrary.org/obo/TXPO_0004254|http://purl.obolibrary.org/obo/TXPO_0004258|http://purl.obolibrary.org/obo/TXPO_0004259|http://purl.obolibrary.org/obo/TXPO_0004253|http://purl.obolibrary.org/obo/TXPO_0004256|http://purl.obolibrary.org/obo/TXPO_0004383|http://purl.obolibrary.org/obo/TXPO_0004382|http://purl.obolibrary.org/obo/TXPO_0004380|http://purl.obolibrary.org/obo/TXPO_0004390|http://purl.obolibrary.org/obo/TXPO_0004393|http://purl.obolibrary.org/obo/TXPO_0004397|http://purl.obolibrary.org/obo/TXPO_0004127|http://purl.obolibrary.org/obo/TXPO_0004120|http://purl.obolibrary.org/obo/TXPO_0004126|http://purl.obolibrary.org/obo/TXPO_0004124|http://purl.obolibrary.org/obo/TXPO_0004121|http://purl.obolibrary.org/obo/TXPO_0004125,,,,,,,,,,,,,,,,,,TXPO:0001986,,,,,,,,,,,,,,,,,,,,under construction,,mitochondrial damage [toxic course],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001988,ATP depletion [Mitochondrial disorder],,"ATP depletion is a subtype of depleting: A process that lessens markedly in the amount of adenosine triphosphate (ATP) .
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0000485|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:31623280|PMID:25339807,,"ATP depletion is a subtype of depleting: A process that lessens markedly in the amount of adenosine triphosphate (ATP) .
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001991|http://purl.obolibrary.org/obo/TXPO_0004263,,,,,,,,,,,TXPO:0001988,,,,,,,,,,,,,,,,,,,,,,ATP depletion [Mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001980,DTT [ER stress],"1,4-dithiothreitol [ER stress]",,false,,,http://purl.obolibrary.org/obo/TXPO_0003012|http://purl.obolibrary.org/obo/CHEBI_18320,,,,,,,,,,,,,,,,,,,,PMID:25937070|PMID:21888831,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_64909,,,,,"1,4-dithiothreitol [ER stress]",,,,,TXPO:0001980,,,,,,,,,,,,,,,,,,,,,,DTT [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001983,amiodarone - fatty acid oxidation inhibitor,,,false,,,http://purl.obolibrary.org/obo/TXPO_0000880,,,,,,,,,,,,,,,,,,,,PMID:21145849|ISBN:0071769234,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_133190,,,,,,,,,,TXPO:0001983,,,,,,,,,,,,,,,,,,,,,,amiodarone - fatty acid oxidation inhibitor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001982,meloxicam [ER stress],MLX [ER stress],"Meloxicam is a long acting nonsteroidal antiinflammatory drug (NSAID) available by prescription only and used in therapy of chronic arthritis.  Meloxicam has been linked to rare instances of acute, clinically apparent liver injury.",false,,,http://purl.obolibrary.org/obo/CHEBI_6741|http://purl.obolibrary.org/obo/TXPO_0003012,,,,,,,,,,,,,,,,,,,,PMID:26481188,,"Meloxicam is a long acting nonsteroidal antiinflammatory drug (NSAID) available by prescription only and used in therapy of chronic arthritis.  Meloxicam has been linked to rare instances of acute, clinically apparent liver injury.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_64909,,,,,MLX [ER stress],,,,,TXPO:0001982,,,,,,,,,,,,,,,,,,,,,,meloxicam [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001987,mitochondrial disorder dependent process,,Mitochondrial disorder dependent process is a subtype of toxic course dependent process: A process that can constitute the course of mitochondrial disorder.,false,,,http://purl.obolibrary.org/obo/TXPO_0001715,,,,,,,,,,,,,,,,,,,,,,Mitochondrial disorder dependent process is a subtype of toxic course dependent process: A process that can constitute the course of mitochondrial disorder.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001987,,,,,,,,,,,,,,,,,,,,,,mitochondrial disorder dependent process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001984,changing state,,Changing state is a subtype of changing an operand: A process that changes the state of the object.,false,,,http://purl.obolibrary.org/obo/TXPO_0000392,,,,,,,,,,,,,,,,,,,,,,Changing state is a subtype of changing an operand: A process that changes the state of the object.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001984,,,,,,,,,,,,,,,,,,,,,,changing state,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001989,negative regulation of respiratory electron transport chain [Mitochondrial disorder],,"Negative regulation of respiratory electron transport chain is a subtype of negative regulation process:  Any process that stops, prevents or reduces the frequency, rate or extent of mrespiratory electron transport chain.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0002342|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of respiratory electron transport chain is a subtype of negative regulation process:  Any process that stops, prevents or reduces the frequency, rate or extent of mrespiratory electron transport chain.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004109|http://purl.obolibrary.org/obo/TXPO_0004119|http://purl.obolibrary.org/obo/TXPO_0004120,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002230,,,,,,,,,,,TXPO:0001989,,,,,,,,,,,,,,,,,,,,,,negative regulation of respiratory electron transport chain [Mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000360,Oxidative dependent chemical compound,,"Oxidative stress dependent chemical compound is a subtype of toxic course dependent chemical entity.
This entity (drug) can participate in the course of Oxidative stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000297,,,,,,,,,,,,,,,,,,,,,,"Oxidative stress dependent chemical compound is a subtype of toxic course dependent chemical entity.
This entity (drug) can participate in the course of Oxidative stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000360,,,,,,,,,,,,,,,,,,,,,,Oxidative dependent chemical compound,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000364,increasing production quantity of ROS,,"Increaseing production quantity of ROS is a subtype of increasing quantity: A process that changes the production amount of reactive oxygen species, any molecules or ions formed by the incomplete one-electron reduction of oxygen, to be higher.",false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,"Increaseing production quantity of ROS is a subtype of increasing quantity: A process that changes the production amount of reactive oxygen species, any molecules or ions formed by the incomplete one-electron reduction of oxygen, to be higher.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000364,,,,,,,,,,,,,,,,,,,,,,increasing production quantity of ROS,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000366,increasing calcium ion inflow into cell,,Increasing calcium ion  is a subtype of increasing quantity: A process that changes the calcium ion becomes larger.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing calcium ion  is a subtype of increasing quantity: A process that changes the calcium ion becomes larger.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000354,,,,,,,,,,,TXPO:0000366,,,,,,,,,,,,,,,,,,,,,,increasing calcium ion inflow into cell,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000363,increasing demand for response to ER stress [ER stress (severe) ],,"Increasing demand for response to ER stress is a subtype of increasing the demand for response to stress: A process that changes the functional demand for the response to the edoplasmic reticulum (ER) stress to be higher.
This entity is a specific course-dependent process. This process can constitute the course of ER stress (severe) .",false,,,http://purl.obolibrary.org/obo/TXPO_0000734,,,,,,,,,,,,,,,,,,,,,,"Increasing demand for response to ER stress is a subtype of increasing the demand for response to stress: A process that changes the functional demand for the response to the edoplasmic reticulum (ER) stress to be higher.
This entity is a specific course-dependent process. This process can constitute the course of ER stress (severe) .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000363,,,,,,,,,,,,,,,,,,,,,,increasing demand for response to ER stress [ER stress (severe) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000362,increasing demand for response to ER stress,,Increasing demand for response to ER stress is a subtype of increasing the demand for response to stress: A process that changes the functional demand for the response to the endoplasmic reticulum (ER) stress to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000361,,,,,,,,,,,,,,,,,,,,,,Increasing demand for response to ER stress is a subtype of increasing the demand for response to stress: A process that changes the functional demand for the response to the endoplasmic reticulum (ER) stress to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002211,,,,,,,,,,,,,,,,,,TXPO:0000362,,,,,,,,,,,,,,,,,,,,,,increasing demand for response to ER stress,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005783,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000365,increasing production quantity of RNS,,Increasing production quantity of RNS  is a subtype of increasing quantity: A process that changes the production amount of reactive nitrogen species (RNS) to be higher,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing production quantity of RNS  is a subtype of increasing quantity: A process that changes the production amount of reactive nitrogen species (RNS) to be higher,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000365,,,,,,,,,,,,,,,,,,,,,,increasing production quantity of RNS,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000361,increasing demand for response to stress,,Increasing demand for response to stress is a subtype of increasing functional demand: A process that changes the functional demand for the response to the stress to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000633,,,,,,,,,,,,,,,,,,,,,,Increasing demand for response to stress is a subtype of increasing functional demand: A process that changes the functional demand for the response to the stress to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000361,,,,,,,,,,,,,,,,,,,,,,increasing demand for response to stress,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000367,increasing sodium ion inflow into cell,,Increasing sodium ion inflow into cell is a subtype of increasing quantity: A process that changes the sodium ion inflow into the cell to be larger.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing sodium ion inflow into cell is a subtype of increasing quantity: A process that changes the sodium ion inflow into the cell to be larger.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000218,,,,,,,,,,,TXPO:0000367,,,,,,,,,,,,,,,,,,,,,,increasing sodium ion inflow into cell,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000369,negative regulation process,,"Negative regulation process is a subtype of controlling: A process that that stops, prevents, or reduces the frequency, rate or extent of function.|Controlling to the negative (-) direction.",false,,,http://purl.obolibrary.org/obo/TXPO_0000113,,,,,,,,,,,,,,,,,,,,,,"Negative regulation process is a subtype of controlling: A process that that stops, prevents, or reduces the frequency, rate or extent of function.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000369,,,,,,,,,,,,,,,,,,,,Controlling to the negative (-) direction.,,negative regulation process,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/BFO_0000015,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000368,increasing extracellular potassium outflow,,increasing extracellular potassium outflow is a subtype of increasing quantity: A process that changes the phospholipid inflow into the hepatocyte to be larger.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,increasing extracellular potassium outflow is a subtype of increasing quantity: A process that changes the phospholipid inflow into the hepatocyte to be larger.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000218,,,,,,,,,,,TXPO:0000368,,,,,,,,,,,,,,,,,,,,,,increasing extracellular potassium outflow,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100369,G-alpha-i 2,,,false,,,http://purl.obolibrary.org/obo/IMR_0000319,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100369,,,,,,,,,,,,,,,,,,,,,,G-alpha-i 2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0043491,protein kinase B signaling,AKT signaling,"A series of reactions, mediated by the intracellular serine/threonine kinase protein kinase B (also called AKT), which occurs as a result of a single trigger reaction or compound. PMID:20517722",false,,,http://purl.obolibrary.org/obo/TXPO_0000609,,,,,,,,,,,,,,,,,,,,GO:004349,,"A series of reactions, mediated by the intracellular serine/threonine kinase protein kinase B (also called AKT), which occurs as a result of a single trigger reaction or compound. PMID:20517722",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,AKT signaling,,,,,GO:0043491,,,,,,,,,,,,,,,,,,,,,,protein kinase B signaling,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000131118,DNAJC19,,Other designations: homolog of yeast TIM14|mitochondrial import inner membrane translocase subunit TIM14,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,TIM14|PAM18|TIMM14,,,,,,,,,,,,3,,,,,,Ensembl:ENSG00000205981|HGNC:30528|MIM:608977|HPRD:12349|Vega:OTTHUMG00000158180,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"DnaJ (Hsp40) homolog, subfamily C, member 19",,,3q26.33,,,,,,,,,,,,,,,,"GO_0005739 (EC: IDA, PMID:12592411); GO_0005743 (EC: IEA); GO_0006457 (EC: NAS, PMID:16055927); GO_0006626 (EC: NAS, PMID:16055927); GO_0006626 (EC: TAS); GO_0007601 (EC: IMP, PMID:16055927); GO_0016021 (EC: NAS, PMID:16055927); GO_0044267 (EC: TAS); GO_0048806 (EC: IMP, PMID:16055927)",,,,,,,,,PMID:8889548; 10737800; 12477932; 12592411; 14517234; 15489334; 16055927; 16344560; 16712791; 17244376; 19564938; 20053669; 21139048; 21832049; 21890473; 22544056; 22797137; 22939629,,,,,,,,,,,,,,,OGG:3000131118,,,,,,,"DnaJ (Hsp40) homolog, subfamily C, member 19",,,,,,,,,,,,,Other designations: homolog of yeast TIM14|mitochondrial import inner membrane translocase subunit TIM14,,DNAJC19,,,,,,,,,,,,,,,,,,,,,,,131118,,,,,,,,9606,,,,,,,,,,,,,,,,,,,DNAJC19,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000339761,CYP27C1,,"Other designations: cytochrome P450 27C1|cytochrome P450, family 27, subfamily C, polypeptide 13",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,2,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 27, subfamily C, polypeptide 1",,,2q14.3,,,,,,,,,,,,,,,,GO_0004497 (EC: IEA); GO_0005506 (EC: IEA); GO_0016020 (EC: IEA); GO_0016705 (EC: IEA); GO_0020037 (EC: IEA),,,,,,,,,PMID:12477932; 15128046; 20707712; 21890473,,,,,,,,,,,,,,,OGG:3000339761,,,,,,,"cytochrome P450, family 27, subfamily C, polypeptide 1",,,,,,,,,,,,,"Other designations: cytochrome P450 27C1|cytochrome P450, family 27, subfamily C, polypeptide 13",,CYP27C1,,,,,,,,,,,,,,,,,,,,,,,339761,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP27C1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0003776,TNFΑ (canonical)[Fibrosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000374|http://purl.obolibrary.org/obo/TXPO_0003750,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:21926|NCBI-Rat-GeneID:24835|NCBI-Human-GeneID:7124,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003776,,,,,,,,,,,,,,,,,,,,,,TNFΑ (canonical)[Fibrosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003770,cytoplasm protein quality control by the ubiquitin-proteasome system,cytoplasm-associated proteasomal ubiquitin-dependent protein catabolism|cytoplasm-associated proteasomal ubiquitin-dependent protein degradation,"The chemical reactions resulting in the breakdown of misfolded proteins in the cytoplasm, which are targeted to cytoplasmic proteasomes for degradation.|See also the biological process terms 'unfolded protein response ; GO:0030968' and 'retrograde protein transport, ER to cytosol ; GO:0030970'.",false,,,http://purl.obolibrary.org/obo/GO_0043161,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions resulting in the breakdown of misfolded proteins in the cytoplasm, which are targeted to cytoplasmic proteasomes for degradation.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,cytoplasm-associated proteasomal ubiquitin-dependent protein catabolism|cytoplasm-associated proteasomal ubiquitin-dependent protein degradation,,,,,TXPO:0003770,,,,,,,,,,,,,,,,,,,,"See also the biological process terms 'unfolded protein response ; GO:0030968' and 'retrograde protein transport, ER to cytosol ; GO:0030970'.",,cytoplasm protein quality control by the ubiquitin-proteasome system,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003774,IL-1 (canonical)[Fibrosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003750|http://purl.obolibrary.org/obo/IMR_0000011,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:3552|NCBI-Rat-GeneID:24493|NCBI-Mouse-GeneID:16175,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003774,,,,,,,,,,,,,,,,,,,,,,IL-1 (canonical)[Fibrosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003771,hepatic fibrosis dependent chemical compound,,"Hepatic fibrosis dependent chemical compound is a subtype of toxic course dependent chemical entity.
This entity (drug) can participate in the course of hepatic fibrosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003749,,,,,,,,,,,,,,,,,,,,,,"Hepatic fibrosis dependent chemical compound is a subtype of toxic course dependent chemical entity.
This entity (drug) can participate in the course of hepatic fibrosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003771,,,,,,,,,,,,,,,,,,,,,,hepatic fibrosis dependent chemical compound,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003772,CCL4 [Fibrosis],,,false,,,http://purl.obolibrary.org/obo/CHEBI_27385|http://purl.obolibrary.org/obo/TXPO_0003771,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003772,,,,,,,,,,,,,,,,,,,,,,CCL4 [Fibrosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003773,MMP9 (canonical)[Fibrosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000239|http://purl.obolibrary.org/obo/TXPO_0003750,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:4318|NCBI-Mouse-GeneID:17395|NCBI-Rat-GeneID:81687,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003773,,,,,,,,,,,,,,,,,,,,,,MMP9 (canonical)[Fibrosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003777,MMP2 (canonical)[Fibrosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000238|http://purl.obolibrary.org/obo/TXPO_0003750,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:4313|NCBI-Mouse-GeneID:17390|NCBI-Rat-GeneID:81686,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003777,,,,,,,,,,,,,,,,,,,,,,MMP2 (canonical)[Fibrosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003775,IL-6 (canonical)[Fibrosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003750|http://purl.obolibrary.org/obo/IMR_0000010,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:3569|NCBI-Mouse-GeneID:16193|NCBI-Rat-GeneID:24498,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003775,,,,,,,,,,,,,,,,,,,,,,IL-6 (canonical)[Fibrosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003778,CXCR3 (canonical)[Fibrosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003750|http://purl.obolibrary.org/obo/TXPO_1000077,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:84475|NCBI-Human-GeneID:2833|NCBI-Mouse-GeneID:12766,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003778,,,,,,,,,,,,,,,,,,,,,,CXCR3 (canonical)[Fibrosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003779,necrosis [Fibrosis],,"A type of cell death that is morphologically characterized by an increasingly translucent cytoplasm, swelling of organelles, minor ultrastructural modifications of the nucleus (specifically, dilatation of the nuclear membrane and condensation of chromatin into small, irregular, circumscribed patches) and increased cell volume (oncosis), culminating in the disruption of the plasma membrane and subsequent loss of intracellular contents. Necrotic cells do not fragment into discrete corpses as their apoptotic counterparts do. Moreover, their nuclei remain intact and can aggregate and accumulate in necrotic tissues.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003742|http://purl.obolibrary.org/obo/GO_0070265,,,,,,,,,,,,,,,,,,,,,,"A type of cell death that is morphologically characterized by an increasingly translucent cytoplasm, swelling of organelles, minor ultrastructural modifications of the nucleus (specifically, dilatation of the nuclear membrane and condensation of chromatin into small, irregular, circumscribed patches) and increased cell volume (oncosis), culminating in the disruption of the plasma membrane and subsequent loss of intracellular contents. Necrotic cells do not fragment into discrete corpses as their apoptotic counterparts do. Moreover, their nuclei remain intact and can aggregate and accumulate in necrotic tissues.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003743,,,,,,,,,,,TXPO:0003779,,,,,,,,,,,,,,,,,,,,,,necrosis [Fibrosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001756,driving,,"Driving is a type of functioning process of meta-function.
The function which generates or transfers a driving energy is said to have meta-function “driving”.

For example, the “to heat water” function of the boiler has a ToDrive meta-function for the “to generate torque” function of the turbine , because the amount of the heat energy transferred by the heating has a proportional causal relation to the torque and is consumed by the rotation.",false,,,http://purl.obolibrary.org/obo/TXPO_0000600,,,,,,,,,,,,,,,,,,,,,,"Driving is a type of functioning process of meta-function.
The function which generates or transfers a driving energy is said to have meta-function “driving”.

For example, the “to heat water” function of the boiler has a ToDrive meta-function for the “to generate torque” function of the turbine , because the amount of the heat energy transferred by the heating has a proportional causal relation to the torque and is consumed by the rotation.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001756,,,,,,,,,,,,,,,,,,,,,,driving,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001755,abnormality of membrane,,Abnormality of membrane is a subtype of changing abnormal cellular structure: A process that changes the membrane stucture abnormally.,false,,,http://purl.obolibrary.org/obo/TXPO_0001770,,,,,,,,,,,,,,,,,,,,,,Abnormality of membrane is a subtype of changing abnormal cellular structure: A process that changes the membrane stucture abnormally.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001755,,,,,,,,,,,,,,,,,,,,,,abnormality of membrane,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001754,providing,,"Providing is a subtype of metafunctioning process.
When a function fa generates (or transfers) the materials which another function ft intentionally processes, the function fa is said to perform a meta-function “to provide material” for the function ft.
The material of ft can be basically defined as input objects (entity or energy) which will be a part of the output objects on which the function ft focuses.",false,,,http://purl.obolibrary.org/obo/TXPO_0000600,,,,,,,,,,,,,,,,,,,,,,"Providing is a subtype of metafunctioning process.
When a function fa generates (or transfers) the materials which another function ft intentionally processes, the function fa is said to perform a meta-function “to provide material” for the function ft.
The material of ft can be basically defined as input objects (entity or energy) which will be a part of the output objects on which the function ft focuses.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001754,,,,,,,,,,,,,,,,,,,,,,providing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001752,hypofunction of maintaining lysosome homeostasis [Phospholipidosis (severe) ],,"Hypofunction of maintaining lysosome homeostasis is a subtype of hypofunctioning: A process that performs a decreased or insufficient maintaining lysosome homeostasis. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0001297,,,,,,,,,,,,,,,,,,,,,,"Hypofunction of maintaining lysosome homeostasis is a subtype of hypofunctioning: A process that performs a decreased or insufficient maintaining lysosome homeostasis. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",,,http://purl.obolibrary.org/obo/TXPO_0000470,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001752,,,,,,,,,,,,,,,,,,,,,,hypofunction of maintaining lysosome homeostasis [Phospholipidosis (severe) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001751,NAPQI accumulation,,NAPQI accumulation is a subtype of accumulation of substances in a biological object: A process that keeps NAPQI (N-acetyl-p-benzoquinone imine) within a biological object(s). NAPQI is an intermediate metabolite of the paracetamol and plays a role as a toxic substance in the body.,false,,,http://purl.obolibrary.org/obo/TXPO_0000247,,,,,,,,,,,,,,,,,,,,,,NAPQI accumulation is a subtype of accumulation of substances in a biological object: A process that keeps NAPQI (N-acetyl-p-benzoquinone imine) within a biological object(s). NAPQI is an intermediate metabolite of the paracetamol and plays a role as a toxic substance in the body.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_29132,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001751,,,,,,,,,,,,,,,,,,,,,,NAPQI accumulation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001750,ATF6 signal integration system,,"ATF6 signal integration system is a subtype of pathway system.
This entity has sub-parts and has a goal of transmitting signals and a gene regulation via ATF6 as a systemic context.",false,,,http://purl.obolibrary.org/obo/TXPO_0001513,,,,,,,,,,,,,,,,,,,,,,"ATF6 signal integration system is a subtype of pathway system.
This entity has sub-parts and has a goal of transmitting signals and a gene regulation via ATF6 as a systemic context.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001750,,,,,,,,,,,,,,,,,,,,,,ATF6 signal integration system,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001753,preventing,,"Preventing is a type of functioning process of meta-function of ""ToPrevent"".
Two meta-functions ""ToAllow"" and  ""Toprevent"" are concerned with the undesirable side effects of functions.

A function fa having positive effects on the side effect of a function ft1 is said to have a meta-function “to allow the side-effects of ft1”.
The “undesirable side effect” is defined in a relation with another function ft2 or the whole system.
The “positive effect” means such a causal relation that increase of the focused attribute of fa causes decrease of the side effect.

If a serious trouble (e.g., faults) will be caused in a function ft2 when a function fa is not achieved, function fa is said to have a meta-function “to prevent malfunction of ft2”.
For example, the “to super-heat” function of the boiler prevents malfunction of the turbine, because the steam of low temperature would damage the turbine blade by water particles. For almost all fa performing a ToAllow meta-function for ft1, in general, there exists a ToPrevent meta-function for another function ft2.",false,,,http://purl.obolibrary.org/obo/TXPO_0000600,,,,,,,,,,,,,,,,,,,,,,"Preventing is a type of functioning process of meta-function of ""ToPrevent"".
Two meta-functions ""ToAllow"" and  ""Toprevent"" are concerned with the undesirable side effects of functions.

A function fa having positive effects on the side effect of a function ft1 is said to have a meta-function “to allow the side-effects of ft1”.
The “undesirable side effect” is defined in a relation with another function ft2 or the whole system.
The “positive effect” means such a causal relation that increase of the focused attribute of fa causes decrease of the side effect.

If a serious trouble (e.g., faults) will be caused in a function ft2 when a function fa is not achieved, function fa is said to have a meta-function “to prevent malfunction of ft2”.
For example, the “to super-heat” function of the boiler prevents malfunction of the turbine, because the steam of low temperature would damage the turbine blade by water particles. For almost all fa performing a ToAllow meta-function for ft1, in general, there exists a ToPrevent meta-function for another function ft2.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001753,,,,,,,,,,,,,,,,,,,,,,preventing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001757,enabling,,"Enabling is a subtype of meta-functioning process.
To enable is a meta-function that sets conditions for other functions to work correctly.",false,,,http://purl.obolibrary.org/obo/TXPO_0000600,,,,,,,,,,,,,,,,,,,,,,"Enabling is a subtype of meta-functioning process.
To enable is a meta-function that sets conditions for other functions to work correctly.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001757,,,,,,,,,,,,,,,,,,,,,,enabling,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001758,cytochrome P450 activation,p450 activaion,Cytochrome P450 activation is a subtype of molecular activation: A process that changes the activity of the cytochrome P450 to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000023,,,,,,,,,,,,,,,,,,,,,,Cytochrome P450 activation is a subtype of molecular activation: A process that changes the activity of the cytochrome P450 to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p450 activaion,,,,,TXPO:0001758,,,,,,,,,,,,,,,,,,,,,,cytochrome P450 activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001759,importing substances into hepatocyte vascular side (sinusoidal side) membrane [Cholestasis],,"Importing substances into hepatocyte vascular side (sinusoidal side) membrane is a subtype of transport: A process of the directed movement of substances into hepatocyte vascular side (sinusoidal side) membrane.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000034|http://purl.obolibrary.org/obo/TXPO_0003124,,,,,,,,,,,,,,,,,,,,,,"Importing substances into hepatocyte vascular side (sinusoidal side) membrane is a subtype of transport: A process of the directed movement of substances into hepatocyte vascular side (sinusoidal side) membrane.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001759,,,,,,,"Bile contains bile acids, glutathione, phospholipids, cholesterol, bilirubin, and other organic anions, proteins, metals, ions, and xenobiotics.

Hepatocytes begins the formation of bile by transporting bile acids, glutathione, and other solutes including Xenobiotics and their metabolites into the canalicular lumen.

The major driving force of bile formation is the active transport of bile salts and other osmolytes into the canalicular lumen.

Most conjugated bile acids (taurine and glycine conjugates) and some unconjugated bile acids are transported into hepatocytes by sodium-dependent transporters.

Sodium-independent uptake of conjugated and unconjugated bile acids is performed by members of the organic anion-transporting polypeptides (OATPs).
OATPs also transport numerous drugs and hepatotoxicants.

Lipophilic cationic drugs, estrogens, and lipids are exported by the canalicular multiple-drug resistance (MDR) P-glycoproteins, one of which is exclusive for phospholipids.

Conjugates of glutathione, glucuronide, and sulfate are exported by multidrug resistance-associated protein2 (MRP2).|Uptake of bile salts from sinusoidal blood into hepatocyte is predominantly sodium dependent",,,,,,,,,,,,,,,importing substances into hepatocyte vascular side (sinusoidal side) membrane [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_74213,EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor,RR inhibitor|UDP reductase inhibitor|EC 1.17.4.1 inhibitor|nucleoside diphosphate reductase inhibitors|nucleoside diphosphate reductase inhibitor|ribonucleotide diphosphate reductase inhibitors|EC 1.17.4.1 inhibitors|ADP reductase inhibitors|ribonucleoside diphosphate reductase inhibitors|2'-deoxyribonucleoside-diphosphate:thioredoxin-disulfide 2'-oxidoreductase inhibitors|ribonucleoside-diphosphate reductase inhibitor|ribonucleotide reductase inhibitors|ribonucleoside-diphosphate reductase inhibitors|RR inhibitors|ribonucleoside-diphosphate reductase (EC 1.17.4.1) inhibitors|ribonucleoside diphosphate reductase inhibitor|UDP reductase inhibitors|CDP reductase inhibitor|ribonucleotide reductase inhibitor|EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitors|2'-deoxyribonucleoside-diphosphate:thioredoxin-disulfide 2'-oxidoreductase inhibitor|ADP reductase inhibitor|ribonucleotide diphosphate reductase inhibitor|CDP reductase inhibitors|ribonucleoside-diphosphate reductase (EC 1.17.4.1) inhibitor,An  EC 1.17.* (oxidoreductase acting on CH or CH2) inhibitor that inhibits the action of ribonucleoside-diphosphate reductase (EC 1.17.4.1).,false,,,http://purl.obolibrary.org/obo/CHEBI_76848,,,,,,,,,,,,,,,,,,,,,,An  EC 1.17.* (oxidoreductase acting on CH or CH2) inhibitor that inhibits the action of ribonucleoside-diphosphate reductase (EC 1.17.4.1).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,RR inhibitor|UDP reductase inhibitor|EC 1.17.4.1 inhibitor|nucleoside diphosphate reductase inhibitors|nucleoside diphosphate reductase inhibitor|ribonucleotide diphosphate reductase inhibitors|EC 1.17.4.1 inhibitors|ADP reductase inhibitors|ribonucleoside diphosphate reductase inhibitors|2'-deoxyribonucleoside-diphosphate:thioredoxin-disulfide 2'-oxidoreductase inhibitors|ribonucleoside-diphosphate reductase inhibitor|ribonucleotide reductase inhibitors|ribonucleoside-diphosphate reductase inhibitors|RR inhibitors|ribonucleoside-diphosphate reductase (EC 1.17.4.1) inhibitors|ribonucleoside diphosphate reductase inhibitor|UDP reductase inhibitors|CDP reductase inhibitor|ribonucleotide reductase inhibitor|EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitors|2'-deoxyribonucleoside-diphosphate:thioredoxin-disulfide 2'-oxidoreductase inhibitor|ADP reductase inhibitor|ribonucleotide diphosphate reductase inhibitor|CDP reductase inhibitors|ribonucleoside-diphosphate reductase (EC 1.17.4.1) inhibitor,,,,,,,,,,,,,,,,,,,,,CHEBI:74213,,,,EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor,,CHEBI:74213,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004439,C9ORF72 inactivation,,C9ORF72 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the C9ORF72 (C9orf72-SMCR8 complex subunit) to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000021,,,,,,,,,,,,,,,,,,,,,,C9ORF72 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the C9ORF72 (C9orf72-SMCR8 complex subunit) to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004439,,,,,,,,,,,,,,,,,,,,,,C9ORF72 inactivation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004436,Negative regulation of ATP transport [mitochondrial disorder],,"Negative regulation of ATP transport is a subtype of negative regulation of transport:  Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of ATP into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0004435,,,,,,,,,,,,,,,,,,,,PMID:25339807,,"Negative regulation of ATP transport is a subtype of negative regulation of transport:  Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of ATP into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004436,,,,,,,,,,,,,,,,,,,,,,Negative regulation of ATP transport [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004437,Increasing BCL-2 level,,Increasing BCL-2 level is a subtype of increasing quantity: A process that changes the amount of BCL-2 level to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing BCL-2 level is a subtype of increasing quantity: A process that changes the amount of BCL-2 level to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004437,,,,,,,,,,,,,,,,,,,,,,Increasing BCL-2 level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004430,ATF4 - inactive form (human) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0005067,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:468|PMID:23284992,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000825,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0002355,http://purl.obolibrary.org/obo/OGG_3000000468,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,,,,,,TXPO:0004430,,,,,,,,,,,,,,,,,,,,,,ATF4 - inactive form (human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004431,PMAIP1 inactivation [hepatocarcinogenesis],,"PMAIP1 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the PMAIP1 (phorbol-12-myristate-13-acetate-induced protein 1) to be lower.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0004762|http://purl.obolibrary.org/obo/TXPO_0002340,,,,,,,,,,,,,,,,,,,,PMID:25797246|PMID:23284992,,"PMAIP1 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the PMAIP1 (phorbol-12-myristate-13-acetate-induced protein 1) to be lower.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004763,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004764|http://purl.obolibrary.org/obo/TXPO_0004403|http://purl.obolibrary.org/obo/TXPO_0004396,,,,,,,,,,,TXPO:0004431,,,,,,,,,,,,,,,,,,,,,,PMAIP1 inactivation [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004438,Increasing BCL-2 level [hepatocarcinogenesis],,"Increasing BCL-2 level is a subtype of increasing quantity: A process that changes the amount of BCL-2 level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004437,,,,,,,,,,,,,,,,,,,,PMID:29679563,,"Increasing BCL-2 level is a subtype of increasing quantity: A process that changes the amount of BCL-2 level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004417,,,,,,,,,,,TXPO:0004438,,,,,,,,,,,,,,,,,,,,,,Increasing BCL-2 level [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004435,Negative regulation of ATP transpot,,"Negative regulation of ATP transport is a subtype of negative regulation of transport:  Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of ATP into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.",false,,,http://purl.obolibrary.org/obo/TXPO_0002682,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of ATP transport is a subtype of negative regulation of transport:  Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of ATP into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004435,,,,,,,,,,,,,,,,,,,,,,Negative regulation of ATP transpot,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004434,Grp78 signaling (primitive) [hepatocarcinogenesis],,"Grp78 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by Grp78.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0004539|http://purl.obolibrary.org/obo/TXPO_0002340,,,,,,,,,,,,,,,,,,,,PMID:28240761,,"Grp78 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by Grp78.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004578,http://purl.obolibrary.org/obo/TXPO_0004540,,,,,http://purl.obolibrary.org/obo/TXPO_0004579,,,,,,,,,,,TXPO:0004434,,,,,,,,,,,,,,,,,,,,,,Grp78 signaling (primitive) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004432,ATF6 signaling (primitive) [hepatocarcinogenesis],,"ATF6 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the ATF6 (activating transcription factor 6). ATF6 generally plays a endoplasmic reticulum membrane stress sensor role.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0000718,,,,,,,,,,,,,,,,,,,,PMID:28240761,,"ATF6 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the ATF6 (activating transcription factor 6). ATF6 generally plays a endoplasmic reticulum membrane stress sensor role.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004433,,,,,,http://purl.obolibrary.org/obo/TXPO_0004434,,,,,,,,,,,TXPO:0004432,,,,,,,,,,,,,,,,,,,,,,ATF6 signaling (primitive) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004433,ATF6(canonical) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000013|http://purl.obolibrary.org/obo/TXPO_0005063,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:304962|NCBI-Mouse-GeneID:226641|NCBI-Human-GeneID:22926,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000825,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004433,,,,,,,,,,,,,,,,,,,,,,ATF6(canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000004,AP1S1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:11769|NCBI-Human-GeneID:1174|NCBI-Rat-GeneID:360785,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001174,,,,,,,,,,,,,TXPO:1000004,,,,,,,,,,,,,,,,,,,,,,AP1S1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000005,APAF1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:317|NCBI-Rat-GeneID:78963|NCBI-Mouse-GeneID:11783,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000317,,,,,,,,,,,,,TXPO:1000005,,,,,,,,,,,,,,,,,,,,,,APAF1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000000,ABCG8 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0002694,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:67470|NCBI-Human-GeneID:64241|NCBI-Rat-GeneID:155192,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000064241,,,,,,,,,,,,,TXPO:1000000,,,,,,,,,,,,,,,,,,,,,,ABCG8 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000003,AP1M2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:367038|NCBI-Mouse-GeneID:11768|NCBI-Human-GeneID:10053,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000010053,,,,,,,,,,,,,TXPO:1000003,,,,,,,,,,,,,,,,,,,,,,AP1M2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000006,APOE (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:25728|NCBI-Mouse-GeneID:11816|NCBI-Human-GeneID:348,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000348,,,,,,,,,,,,,TXPO:1000006,,,,,,,,,,,,,,,,,,,,,,APOE (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000009,ASAH1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:11886|NCBI-Human-GeneID:427|NCBI-Rat-GeneID:84431,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000427,,,,,,,,,,,,,TXPO:1000009,,,,,,,,,,,,,,,,,,,,,,ASAH1 (mol),,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005764,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000008,APR molecule,Acute Phase Response gene,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000320,,,,,Acute Phase Response gene,,,,,TXPO:1000008,,,,,,,,,,,,,,,,,,,,,,APR molecule,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000001,AFAP1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:60312|NCBI-Mouse-GeneID:70292|NCBI-Rat-GeneID:140935,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000060312,,,,,,,,,,,,,TXPO:1000001,,,,,,,,,,,,,,,,,,,,,,AFAP1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000002,ANGPTL4 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:362850|NCBI-Mouse-GeneID:57875|NCBI-Human-GeneID:51129,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000051129,,,,,,,,,,,,,TXPO:1000002,,,,,,,,,,,,,,,,,,,,,,ANGPTL4 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000007,APOLD1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:381823|NCBI-Rat-GeneID:444983|NCBI-Human-GeneID:81575,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000081575,,,,,,,,,,,,,TXPO:1000007,,,,,,,,,,,,,,,,,,,,,,APOLD1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000003116,HLA-DPB2,,,false,,,http://purl.obolibrary.org/obo/OGG_2070009606,,DPB2|DP2B|HLA-DP2B|DPbeta2,,,,,,,,,,,,6,,,,,,Ensembl:ENSG00000224557|HGNC:4941,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"major histocompatibility complex, class II, DP beta 2 (pseudogene)",,,6p21.3,,,,,,,,,,,,,,,,,,,,,,,,,PMID: 3036829; 12477932; 18682748; 19950302; 20031603; 20587610; 21399633; 23482656; 23740775; 23817570,,,,,,,,,,,,,,,OGG:3000003116,,,,,,,"major histocompatibility complex, class II, DP beta 2 (pseudogene)",,,,,,,,,,,,,,,HLA-DPB2,,,,,,,,,,,,,,,,,,,,,,,3116,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,HLA-DPB2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000055304,SPTLC3,,"Other designations: LCB 3|SPT 3|long chain base biosynthesis protein 2b|long chain base biosynthesis protein 3|serine palmitoyltransferase 3|serine palmitoyltransferase, long chain base subunit 2-like (aminotransferase 2)|serine-palmitoyl-CoA transferase 3",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,C20orf38|SPTLC2L|hLCB2b|dJ718P11.1|LCB3|SPT3|LCB2B|dJ718P11,,,,,,,,,,,,20,,,,,,Ensembl:ENSG00000172296|HPRD:12765|HGNC:16253|Vega:OTTHUMG00000031899|MIM:611120,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"serine palmitoyltransferase, long chain base subunit 3",,,20p12.1,,,,,,,,,,,,,,,,"GO_0004758 (EC: IDA, PMID: 19416851); GO_0005789 (EC: TAS); GO_0006665 (EC: TAS); GO_0016021 (EC: IEA); GO_0017059 (EC: IDA, PMID: 17331073); GO_0030148 (EC: TAS, PMID: 19416851); GO_0030170 (EC: IEA); GO_0044281 (EC: TAS); GO_0046520 (EC: IDA, PMID: 19648650)",,,,,,,,,PMID: 11780052; 12477932; 14702039; 15489334; 16303743; 17023427; 17331073; 19416851; 19648650; 19798445; 19913121; 20037589; 20379614; 20628086; 20920666; 21368711; 22359512; 23192594,,,,,,,,,,,,,,,OGG:3000055304,,20140408,protein-coding,,,,"serine palmitoyltransferase, long chain base subunit 3",,,,,,,,,,,,,"Other designations: LCB 3|SPT 3|long chain base biosynthesis protein 2b|long chain base biosynthesis protein 3|serine palmitoyltransferase 3|serine palmitoyltransferase, long chain base subunit 2-like (aminotransferase 2)|serine-palmitoyl-CoA transferase 3",,SPTLC3,,,,,,,,,,,,,,,,,,,,,,,55304,RP5-1077I2.1,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,SPTLC3,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000585,IL-4 (mol),interleukin-4,,false,,,http://purl.obolibrary.org/obo/IMR_0000007,,,,,,,,,,,,,,,,,,,,GO:0005136,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000622,,,,,interleukin-4,,,,,IMR:0000585,,,,,,,,,,,,,,,,,,,,,,IL-4 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_6916,mexiletine,"mexiletine|1-(2,6-dimethylphenoxy)-2-propanamine|mexiletina|1-methyl-2-(2,6-xylyloxy)ethanamine|1-(2',6'-dimethylphenoxy)-2-aminopropane|mexiletinum|(+-)-1-(2,6-dimethylphenoxy)propan-2-amine|(2RS)-1-(2,6-dimethylphenoxy)-2-aminopropane|1-(2,6-dimethylphenoxy)propan-2-amine|Mexiletine","An aromatic ether which is 2,6-dimethylphenyl ether of 2-aminopropan-1-ol.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Reaxys:2092205|Drug_Central:1794|CAS:31828-71-4|PMID:11009230|DrugBank:DB00379|PMID:10883344|LINCS:LSM-1700,,"An aromatic ether which is 2,6-dimethylphenyl ether of 2-aminopropan-1-ol.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_38070,,,,,"1-(2,6-dimethylphenoxy)propan-2-amine|Mexiletine",,"mexiletine|1-(2,6-dimethylphenoxy)-2-propanamine|mexiletina|1-methyl-2-(2,6-xylyloxy)ethanamine|1-(2',6'-dimethylphenoxy)-2-aminopropane|mexiletinum|(+-)-1-(2,6-dimethylphenoxy)propan-2-amine|(2RS)-1-(2,6-dimethylphenoxy)-2-aminopropane",,,,,,,,,,,,,,,,,,,,,CHEBI:6916,,,,mexiletine,,CHEBI:6916,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_35572,phorone,"2,6-dimethylhepta-2,5-dien-4-one",,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:504-20-1,,,,,,,,,,,,,,C9H14O,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"2,6-dimethylhepta-2,5-dien-4-one",,,,,CHEBI:35572,,,,,,,,,,,,,,,,,,,,,,phorone,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CC(C)=CC(=O)C=C(C)C,,,,,
http://purl.obolibrary.org/obo/IMR_0002759,TSC2,,,false,,,http://purl.obolibrary.org/obo/IMR_0000442,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0002759,,,,,,,,,,,,,,,,,,,,,,TSC2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000261,MEK1/2(MKK1/2),MEK|MEK1/2|MKK1/2|MAPKK1/2,MEK1 and MEK2 phosphorylate and activate ERK1 and ERK2 MAP kinases.,false,,,http://purl.obolibrary.org/obo/IMR_0000259,,,,,,,,,,,,,,,,,,,,,,MEK1 and MEK2 phosphorylate and activate ERK1 and ERK2 MAP kinases.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MEK|MEK1/2|MKK1/2|MAPKK1/2,,,,,IMR:0000261,,,,,,,,,,,,,,,,,,,,,,MEK1/2(MKK1/2),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_23888,drug,drugs|medicine,"Intended use of the molecular entity or part thereof by humans.|Any substance which when absorbed into a living organism may modify one or more of its functions. The term is generally accepted for a substance taken for a therapeutic purpose, but is also commonly used for abused substances.",false,,,http://purl.obolibrary.org/obo/CHEBI_52210|http://purl.obolibrary.org/obo/CHEBI_52217,,,,,,,,,,,,,,,,,,,,,,"Intended use of the molecular entity or part thereof by humans.|Any substance which when absorbed into a living organism may modify one or more of its functions. The term is generally accepted for a substance taken for a therapeutic purpose, but is also commonly used for abused substances.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,drugs|medicine,,,,,,,,,,,,,,,,,,,,,CHEBI:23888,,,,drug,,CHEBI:23888,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001106,PU.1,,,false,,,http://purl.obolibrary.org/obo/IMR_0000397,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001106,,,,,,,,,,,,,,,,,,,,,,PU.1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004661,Iron accumulation [hepatocarcinogenesis],,"Iron accumulation is a subtype of accumulation of substances in a biological object: A process that keeps iron in an organism, tissue, organelle, or cell.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0003182,,,,,,,,,,,,,,,,,,,,PMID:31623280,,"Iron accumulation is a subtype of accumulation of substances in a biological object: A process that keeps iron in an organism, tissue, organelle, or cell.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_18248,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004543,,,,,,,,,,,TXPO:0004661,,,,,,,,,,,,,,,,,,,,,,Iron accumulation [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004666,JAK signal transduction pathway,,A series of molecular signals mediated by JAK (Janus kinase).,false,,,http://purl.obolibrary.org/obo/TXPO_0000609,,,,,,,,,,,,,,,,,,,,,,A series of molecular signals mediated by JAK (Janus kinase).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004666,,,,,,,,,,,,,,,,,,,,,,JAK signal transduction pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004668,Increasing JUN level,,Increasing JUN level is a subtype of increasing quantity: A process that changes the amount of JUN level to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing JUN level is a subtype of increasing quantity: A process that changes the amount of JUN level to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000416,,,,,,,,,,,,,,,,,,,TXPO:0004668,,,,,,,,,,,,,,,,,,,,,,Increasing JUN level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004667,JAK signaling (primitive),,JAK signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the JAK (Janus kinase) .,false,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,,,JAK signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the JAK (Janus kinase) .,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004666,,,,,,,,,,,,,,,,TXPO:0004667,,,,,,,,,,,,,,,,,,,,,,JAK signaling (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004663,IP-10 signaling (primitive),,IP-10 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by IP-10.,false,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,,,IP-10 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by IP-10.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003281,http://purl.obolibrary.org/obo/TXPO_0004662,,,,,,,,,,,,,,,,TXPO:0004663,,,,,,,,,,,,,,,,,,,,,,IP-10 signaling (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004660,IL-6(canonical) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0005063|http://purl.obolibrary.org/obo/IMR_0000010,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:3569|NCBI-Mouse-GeneID:16193|NCBI-Rat-GeneID:24498|PMID:25181692|PMID:31623280,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004660,,,,,,,,,,,,,,,,,,,,,,IL-6(canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004662,IP-10 signal transduction pathway,,A series of molecular signals mediated by IP-10 (Interferon Gamma Induced Protein 10kDa).,false,,,http://purl.obolibrary.org/obo/TXPO_0000609,,,,,,,,,,,,,,,,,,,,,,A series of molecular signals mediated by IP-10 (Interferon Gamma Induced Protein 10kDa).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004662,,,,,,,,,,,,,,,,,,,,,,IP-10 signal transduction pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004665,CXCL10 (canonical) [hepatocarcinogenesis],IP-10,,false,,,http://purl.obolibrary.org/obo/TXPO_0003281|http://purl.obolibrary.org/obo/TXPO_0005063,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:15945|NCBI-Rat-GeneID:3627|NCBI-Human-GeneID:3627|PMID:28240761,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IP-10,,,,,TXPO:0004665,,,,,,,,,,,,,,,,,,,,,,CXCL10 (canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000192,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004669,Increasing JUN level [hepatocarcinogenesis],,"Increasing JUN level is a subtype of increasing quantity: A process that changes the amount of JUN level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004668,,,,,,,,,,,,,,,,,,,,PMID:10774822,,"Increasing JUN level is a subtype of increasing quantity: A process that changes the amount of JUN level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004670,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004392,,,,,,,,,,,TXPO:0004669,,,,,,,,,,,,,,,,,,,,,,Increasing JUN level [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004664,IP-10 signaling (primitive) [hepatocarcinogenesis],,"IP-10 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by IP-10.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004663,,,,,,,,,,,,,,,,,,,,PMID:28240761,,"IP-10 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by IP-10.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004665,http://purl.obolibrary.org/obo/TXPO_0004662,,,,,http://purl.obolibrary.org/obo/TXPO_0004480|http://purl.obolibrary.org/obo/TXPO_0004432,,,,,,,,,,,TXPO:0004664,,,,,,,,,,,,,,,,,,,,,,IP-10 signaling (primitive) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001656,vitamin,,,false,,,http://purl.obolibrary.org/obo/CHEBI_72695,,,,,,,,,,,,,,,,,,,,CHEBI:27305,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001656,,,,,,,,,,,,,,,,,,,,,,vitamin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0011144,eIF3f,eIF3 p47|eukaryotic translation initiation factor 3 subunit 5|eIF3 p47 subunit|eIF-3 epsilon,,false,,,http://purl.obolibrary.org/obo/IMR_0000916,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,eIF3 p47|eukaryotic translation initiation factor 3 subunit 5|eIF3 p47 subunit|eIF-3 epsilon,,,,,IMR:0011144,,,,,,,,,,,,,,,,,,,,,,eIF3f,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000008800,PEX11A,,Other designations: 28 kDa peroxisomal integral membrane protein|peroxin-11A|peroxisomal biogenesis factor 11A|peroxisomal membrane protein 11A|protein PEX11 homolog alpha,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,PEX11-ALPHA|PMP28|hsPEX11p,,,,,,,,,,,,15,,,,,,Vega:OTTHUMG00000149809|HGNC:8852|HPRD:04843|MIM:603866|Ensembl:ENSG00000166821,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,peroxisomal biogenesis factor 11 alpha,,,15q26.1,,,,,,,,,,,,,,,,"GO_0005515 (EC: IPI); GO_0005777 (EC: IDA, PMID: 18782765); GO_0005778 (EC: TAS); GO_0005779 (EC: IDA, PMID: 9714566); GO_0007031 (EC: IMP, PMID: 9792670); GO_0007165 (EC: IMP, PMID: 9792670); GO_0016557 (EC: IEA); GO_0016559 (EC: IDA); GO_0042803 (EC: IDA); GO_0043234 (EC: IDA); GO_0044255 (EC: TAS); GO_0044281 (EC: TAS); GO_0044375 (EC: IDA); GO_0050873 (EC: IEA)",,,,,,,,,PMID: 9714566; 9792670; 9922452; 10704444; 11839773; 12417726; 12477932; 14702039; 15489334; 16344560; 16567422; 17220199; 18782765; 20531392; 20826455; 21419861,,,,,,,,,,,,,,,OGG:3000008800,,,,,,,peroxisomal biogenesis factor 11 alpha,,,,,,,,,,,,,Other designations: 28 kDa peroxisomal integral membrane protein|peroxin-11A|peroxisomal biogenesis factor 11A|peroxisomal membrane protein 11A|protein PEX11 homolog alpha,,PEX11A,,,,,,,,,,,,,,,,,,,,,,,8800,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,PEX11A,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000322,G-alpha-z,,,false,,,http://purl.obolibrary.org/obo/IMR_0000318,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000322,,,,,,,,,,,,,,,,,,,,,,G-alpha-z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000163,GCLC [canonical] (mol),Glutamate-Cysteine Ligase Catalytic Subunit,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:14629|NCBI-Rat-GeneID:25283|NCBI-Human-GeneID:2729,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000002729,,,,,,,,Glutamate-Cysteine Ligase Catalytic Subunit,,,,,TXPO:1000163,,,,,,,,,,,,,,,,,,,,,,GCLC [canonical] (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000165,GDPD1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:303407|NCBI-Mouse-GeneID:66569|NCBI-Human-GeneID:284161,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000284161,,,,,,,,,,,,,TXPO:1000165,,,,,,,,,,,,,,,,,,,,,,GDPD1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000166,GFPT1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:297417|NCBI-Human-GeneID:2673|NCBI-Mouse-GeneID:14583,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000002673,,,,,,,,,,,,,TXPO:1000166,,,,,,,,,,,,,,,,,,,,,,GFPT1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000160,GADD45B (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:17873|NCBI-Human-GeneID:4616|NCBI-Rat-GeneID:299626,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000004616,,,,,,,,,,,,,TXPO:1000160,,,,,,,,,,,,,,,,,,,,,,GADD45B (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000167,GLIPR1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:11010|NCBI-Rat-GeneID:299783|NCBI-Mouse-GeneID:73690,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000011010,,,,,,,,,,,,,TXPO:1000167,,,,,,,,,,,,,,,,,,,,,,GLIPR1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000168,GNE (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:50798|NCBI-Human-GeneID:10020|NCBI-Rat-GeneID:114711,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000010020,,,,,,,,,,,,,TXPO:1000168,,,,,,,,,,,,,,,,,,,,,,GNE (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000164,GDF15 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:9518|NCBI-Rat-GeneID:29455|NCBI-Mouse-GeneID:23886,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000009518,,,,,,,,,,,,,TXPO:1000164,,,,,,,,,,,,,,,,,,,,,,GDF15 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000162,GCC2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:70297|NCBI-Human-GeneID:9648|NCBI-Rat-GeneID:309798,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000009648,,,,,,,,,,,,,TXPO:1000162,,,,,,,,,,,,,,,,,,,,,,GCC2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000161,GAS1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:14451|NCBI-Rat-GeneID:683470|NCBI-Human-GeneID:2619,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000002619,,,,,,,,,,,,,TXPO:1000161,,,,,,,,,,,,,,,,,,,,,,GAS1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000169,GPR39 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:288995|NCBI-Human-GeneID:2863|NCBI-Mouse-GeneID:71111,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000002863,,,,,,,,,,,,,TXPO:1000169,,,,,,,,,,,,,,,,,,,,,,GPR39 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001146,PKC beta,,,false,,,http://purl.obolibrary.org/obo/IMR_0100486,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001146,,,,,,,,,,,,,,,,,,,,,,PKC beta,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100015,exportin,,,false,,,http://purl.obolibrary.org/obo/IMR_0001091,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100015,,,,,,,,,,,,,,,,,,,,,,exportin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76733,EC 1.6.* (oxidoreductase acting on NADH or NADPH) inhibitor,oxidoreductase acting on NADH or NADPH inhibitor|inhibitors of oxidoreductase acting on NADH or NADPH|inhibitor of oxidoreductase acting on NADH or NADPH|inhibitors of oxidoreductase acting on NADH or NADPH (EC 1.6.*)|inhibitor of oxidoreductase acting on NADH or NADPH (EC 1.6.*)|EC 1.6.* (oxidoreductase acting on NADH or NADPH) inhibitors|oxidoreductase acting on NADH or NADPH (EC 1.6.*) inhibitors|oxidoreductase acting on NADH or NADPH (EC 1.6.*) inhibitor|oxidoreductase acting on NADH or NADPH inhibitors,An oxidoreductase inhibitor which interferes with the action of an oxidoreductase acting on  NADH or NADPH (EC 1.6.*.*).,false,,,http://purl.obolibrary.org/obo/CHEBI_76725,,,,,,,,,,,,,,,,,,,,,,An oxidoreductase inhibitor which interferes with the action of an oxidoreductase acting on  NADH or NADPH (EC 1.6.*.*).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,oxidoreductase acting on NADH or NADPH inhibitor|inhibitors of oxidoreductase acting on NADH or NADPH|inhibitor of oxidoreductase acting on NADH or NADPH|inhibitors of oxidoreductase acting on NADH or NADPH (EC 1.6.*)|inhibitor of oxidoreductase acting on NADH or NADPH (EC 1.6.*)|EC 1.6.* (oxidoreductase acting on NADH or NADPH) inhibitors|oxidoreductase acting on NADH or NADPH (EC 1.6.*) inhibitors|oxidoreductase acting on NADH or NADPH (EC 1.6.*) inhibitor|oxidoreductase acting on NADH or NADPH inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:76733,,,,EC 1.6.* (oxidoreductase acting on NADH or NADPH) inhibitor,,CHEBI:76733,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_66987,radiation protective agent,,,false,,,http://purl.obolibrary.org/obo/CHEBI_50267,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:66987,,,,radiation protective agent,,CHEBI:66987,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001125,heparan sulfate proteoglycan,HSPG,,false,,,http://purl.obolibrary.org/obo/IMR_0000552,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,HSPG,,,,,IMR:0001125,,,,,,,,,,,,,,,,,,,,,,heparan sulfate proteoglycan,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_1901526,positive regulation of mitophagy,,"Any process that activates or increases the frequency, rate or extent of mitophagy.",false,,,http://purl.obolibrary.org/obo/GO_1901524,,,,,,,,,,,,,,,,,,,,,,"Any process that activates or increases the frequency, rate or extent of mitophagy.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:1901526,,,,,,,,,,,,,,,,,,,,,,positive regulation of mitophagy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0000423,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_1901524,regulation of mitophagy,,"Any process that modulates the frequency, rate or extent of macromitophagy.",false,,,http://purl.obolibrary.org/obo/GO_0010506,,,,,,,,,,,,,,,,,,,,,,"Any process that modulates the frequency, rate or extent of macromitophagy.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:1901524,,,,,,,,,,,,,,,,,,,,,,regulation of mitophagy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0000423,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000587,IL-8,interleukin-8,,false,,,http://purl.obolibrary.org/obo/IMR_0000007,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000622,,,,,interleukin-8,,,,,IMR:0000587,,,,,,,,,,,,,,,,,,,,,,IL-8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002223,positive regulation of phospholipid biosynthetic process [Phospholipidosis (severe) ],,"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of phospholipids. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",false,,,http://purl.obolibrary.org/obo/TXPO_0001710,,,,,,,,,,,,,,,,,,,,,,"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of phospholipids. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001708,,,,,,,,,,,TXPO:0002223,,,,,,,,,,,,,,,,,,,,,,positive regulation of phospholipid biosynthetic process [Phospholipidosis (severe) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002225,phospholipid material transport,,Phospholipid material transport is a subtype of molecule transport: A process that of the directed movement of phospholipid materials into a peroxisome.,false,,,http://purl.obolibrary.org/obo/TXPO_0000111,,,,,,,,,,,,,,,,,,,,,,Phospholipid material transport is a subtype of molecule transport: A process that of the directed movement of phospholipid materials into a peroxisome.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002225,,,,,,,,,,,,,,,,,,,,,,phospholipid material transport,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002224,glutathione synthetic gene expression,,glutathione synthetic gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature  gene product or products (proteins or RNA) involved in glutathione synthesis.,false,,,http://purl.obolibrary.org/obo/GO_0010467,,,,,,,,,,,,,,,,,,,,,,glutathione synthetic gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature  gene product or products (proteins or RNA) involved in glutathione synthesis.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002224,,,,,,,,,,,,,,,,,,,,,,glutathione synthetic gene expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002226,hyperfunction of phospholipid material transport [Phospholipidosis (severe) ],,"Hyperfunction of phospholipid material transport is a subtype of hyperfunction of transport: A process that performs an excesssive phospholipid material transport. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",false,,,http://purl.obolibrary.org/obo/TXPO_0003440|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of phospholipid material transport is a subtype of hyperfunction of transport: A process that performs an excesssive phospholipid material transport. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001315,,,,,,,,,,,TXPO:0002226,,,,,,,,,,,,,,,,,,,,,,hyperfunction of phospholipid material transport [Phospholipidosis (severe) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002227,increase in intracellular calcium level [Phospholipidosis],,"Increase in intracellular calcium level is a subtype of increase in calcium level: A process that changes the calcium ion concentration within a cell to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000354|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Increase in intracellular calcium level is a subtype of increase in calcium level: A process that changes the calcium ion concentration within a cell to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002232|http://purl.obolibrary.org/obo/TXPO_0004084,,,,,,,,,,,TXPO:0002227,,,,,,,,,,,,,,,,,,,,,,increase in intracellular calcium level [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002222,malfunctioning of cellular membrane [Phospholipidosis (severe) ],,"Malfunctioning of cellular membrane is a subtype of malfunctioning process: A process that cannot perform a cellular membrane function appropriately or cannot realize it at all. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0002198,,,,,,,,,,,,,,,,,,,,,,"Malfunctioning of cellular membrane is a subtype of malfunctioning process: A process that cannot perform a cellular membrane function appropriately or cannot realize it at all. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000077|http://purl.obolibrary.org/obo/TXPO_0004086,,,,,,http://purl.obolibrary.org/obo/TXPO_0000927,,,,,,,,,,,TXPO:0002222,,,,,,,,,,,,,,,,,,,,,,malfunctioning of cellular membrane [Phospholipidosis (severe) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002228,toxicological balance L=L (maintining homeostasis at lower level),,"In the imbalance model, the basic units are as follows:
1) a functioning process (supply) for biological defense and maintaining homeostasis;
2) a functional demand process (demand) as toxic activity;
3) balance/imbalance between toxic activity and defense processes; and
4) outcome from organelles, cells, or tissues to the organ exhibiting toxicity manifestations.

This entity is a compound state that inculdes step 1 to 4.
The defense performance level and the functional demand level are low, as a result, keeping the balance. This state reflects the adaptation in the body.",false,,,http://purl.obolibrary.org/obo/TXPO_0003992,,,,,,,,,,,,,,,,,,,,,,"In the imbalance model, the basic units are as follows:
1) a functioning process (supply) for biological defense and maintaining homeostasis;
2) a functional demand process (demand) as toxic activity;
3) balance/imbalance between toxic activity and defense processes; and
4) outcome from organelles, cells, or tissues to the organ exhibiting toxicity manifestations.

This entity is a compound state that inculdes step 1 to 4.
The defense performance level and the functional demand level are low, as a result, keeping the balance. This state reflects the adaptation in the body.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001734,,,,,,,,,,,,,,,,,,TXPO:0002228,,,,,,,,,,,,,,,,,,,,,,toxicological balance L=L (maintining homeostasis at lower level),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002221,lysosomal dysfunction,,Lysosomal dysfunction is a subtype of dysfunctioning: A process that performs an abnormal and incomplete lysosomal function.,false,,,http://purl.obolibrary.org/obo/TXPO_0000438,,,,,,,,,,,,,,,,,,,,,,Lysosomal dysfunction is a subtype of dysfunctioning: A process that performs an abnormal and incomplete lysosomal function.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002221,,,,,,,,,,,,,,,,,,,,,,lysosomal dysfunction,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005764,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002220,lysosomal dysfunction [Phospholipidosis (severe) ],,"Lysosomal dysfunction is a subtype of dysfunctioning: A process that performs an abnormal and incomplete lysosomal function. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0002221,,,,,,,,,,,,,,,,,,,,,,"Lysosomal dysfunction is a subtype of dysfunctioning: A process that performs an abnormal and incomplete lysosomal function. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002220,,,,,,,,,,,,,,,,,,,,,,lysosomal dysfunction [Phospholipidosis (severe) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002229,increasing uptake amount of mitochondrial calcium ion,,Increasing uptake amount of mitochondrial calcium ion is a subtype of increasing quantity: A process that changes the uptake amount of mitochondrial calcium ion to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing uptake amount of mitochondrial calcium ion is a subtype of increasing quantity: A process that changes the uptake amount of mitochondrial calcium ion to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_39124,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005739,http://purl.obolibrary.org/obo/GO_0005737,,,,,,,TXPO:0002229,,,,,,,,,,,,,,,,,,,,,,increasing uptake amount of mitochondrial calcium ion,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0004770,articular system,set of joints of body|set of all joints|set of all joints of body|joint system,Anatomical system that consists of all the joints of the body.,false,,,http://purl.obolibrary.org/obo/UBERON_0034925,,,,,,,,,,,,,,,,,,,,http://www.snomedbrowser.com/Codes/Details/361827000|FMA:23878|VSAO:0000181|EMAPA:35150|MA:0003007,,Anatomical system that consists of all the joints of the body.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,set of all joints of body|joint system,,set of joints of body|set of all joints,,http://purl.obolibrary.org/obo/UBERON_0001434,UBERON:0004770,http://purl.obolibrary.org/obo/UBERON_0001434,,,,,,,,,,,,,,,,,,,,,articular system,,,,,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_48923,erythromycin,erythromycine|eritromicina|erthromycin,Any of several wide-spectrum macrolide antibiotics obtained from actinomycete Saccharopolyspora erythraea (formerly known as Streptomyces erythraeus).,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,DrugBank:DB00199,,Any of several wide-spectrum macrolide antibiotics obtained from actinomycete Saccharopolyspora erythraea (formerly known as Streptomyces erythraeus).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35703|http://purl.obolibrary.org/obo/CHEBI_78298|http://purl.obolibrary.org/obo/CHEBI_76969,,,,,,,erythromycine|eritromicina|erthromycin,,,,,,,,,,,,,,,,,,,,,CHEBI:48923,,,,erythromycin,,CHEBI:48923,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0011135,eIF2-gamma,"eukaryotic translation initiation factor 2, subunit 3|eukaryotic translation initiation factor 2 gamma subunit|eIF-2-gamma|Eukaryotic translation initiation factor 2 subunit 3",,false,,,http://purl.obolibrary.org/obo/IMR_0000913,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"eukaryotic translation initiation factor 2, subunit 3|eukaryotic translation initiation factor 2 gamma subunit|eIF-2-gamma|Eukaryotic translation initiation factor 2 subunit 3",,,,,IMR:0011135,,,,,,,,,,,,,,,,,,,,,,eIF2-gamma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PR_000009897,lipoprotein lipase,LPL,A protein that is a translation product of the human LPL gene or a 1:1 ortholog thereof. Category=gene.,false,,,http://purl.obolibrary.org/obo/TXPO_0002283,,,,,,,,,,,,,,,,,,,,,,A protein that is a translation product of the human LPL gene or a 1:1 ortholog thereof. Category=gene.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,LPL,,,,,PR:000009897,,,,,,,,,,,,,,,,,,,,,,lipoprotein lipase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_50671,antithyroid drug,antithyroid agents|antithyroid agent|antithyroid drugs,A drug used to treat hyperthyroidism by reducing the excessive production of thyroid hormones.,false,,,http://purl.obolibrary.org/obo/CHEBI_49020,,,,,,,,,,,,,,,,,,,,,,A drug used to treat hyperthyroidism by reducing the excessive production of thyroid hormones.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,antithyroid agents|antithyroid agent|antithyroid drugs,,,,,,,,,,,,,,,,,,,,,CHEBI:50671,,,,antithyroid drug,,CHEBI:50671,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0010000,multicellular anatomical structure,multicellular structure,An anatomical structure that has more than one cell as a part.,false,,,http://purl.obolibrary.org/obo/UBERON_0000061,,,,,,,,,,,,,,,,,,,,CARO:0010000|FBbt:00100313,,An anatomical structure that has more than one cell as a part.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,multicellular structure,,,,,UBERON:0010000,,,,,,,,,,,,,,,,,,,,,,multicellular anatomical structure,,,,,,,http://purl.obolibrary.org/obo/oae.owl|http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/BFO_0000034,function,,,false,,,http://purl.obolibrary.org/obo/BFO_0000016,,,,,,,,,,,,,,,,,,,,,,,,,,"BFO 2 Reference: In the past, we have distinguished two varieties of function, artifactual function and biological function. These are not asserted subtypes of BFO:function however, since the same function – for example: to pump, to transport – can exist both in artifacts and in biological entities. The asserted subtypes of function that would be needed in order to yield a separate monoheirarchy are not artifactual function, biological function, etc., but rather transporting function, pumping function, etc.",,"A function is a disposition that exists in virtue of the bearer’s physical make-up and this physical make-up is something the bearer possesses because it came into being, either through evolution (in the case of natural biological entities) or through intentional design (in the case of artifacts), in order to realize processes of a certain sort. (axiom label in BFO2 Reference: [064-001])",the function of a heart pacemaker to regulate the beating of a heart through electricity|the function of amylase in saliva to break down starch into sugar|the function of a hammer to drive in nails,,,,,,,,,,,(forall (x) (if (Function x) (Disposition x))) // axiom label in BFO2 CLIF: [064-001],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BFO:0000034,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/bfo.owl,function,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100671,G1/S-cyclin,,,false,,,http://purl.obolibrary.org/obo/IMR_0100606,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100671,,,,,,,,,,,,,,,,,,,,,,G1/S-cyclin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000358,PTPN6 (mol),SHP1,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:15170|NCBI-Human-GeneID:5777|NCBI-Rat-GeneID:116689,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000005777,,,,,,,,SHP1,,,,,TXPO:1000358,,,,,,,,,,,,,,,,,,,,,,PTPN6 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000353,STARD7 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:296128|NCBI-Human-GeneID:56910|NCBI-Mouse-GeneID:99138,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000056910,,,,,,,,,,,,,TXPO:1000353,,,,,,,,,,,,,,,,,,,,,,STARD7 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000352,SRSF1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:689890|NCBI-Mouse-GeneID:110809|NCBI-Human-GeneID:6426,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000006426,,,,,,,,,,,,,TXPO:1000352,,,,,,,,,,,,,,,,,,,,,,SRSF1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000354,STF-083010,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:1000354,,,,,,,,,,,,,,,,,,,,,,STF-083010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000355,STK11 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:6794|NCBI-Mouse-GeneID:20869|NCBI-Rat-GeneID:314621,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000006794,,,,,,,,,,,,,TXPO:1000355,,,,,,,,,,,,,,,,,,,,,,STK11 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000351,SRPK2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:296753|NCBI-Human-GeneID:6733|NCBI-Mouse-GeneID:20817,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000006733,,,,,,,,,,,,,TXPO:1000351,,,,,,,,,,,,,,,,,,,,,,SRPK2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000356,STUB1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:10273|NCBI-Mouse-GeneID:56424|NCBI-Rat-GeneID:287155,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000010273,,,,,,,,,,,,,TXPO:1000356,,,,,,,,,,,,,,,,,,,,,,STUB1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000357,SYNGR2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:89815|NCBI-Mouse-GeneID:20973|NCBI-Human-GeneID:9144,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000009144,,,,,,,,,,,,,TXPO:1000357,,,,,,,,,,,,,,,,,,,,,,SYNGR2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000350,SPTLC2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:366697|NCBI-Human-GeneID:9517|NCBI-Mouse-GeneID:20773,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000009517,,,,,,,,,,,,,TXPO:1000350,,,,,,,,,,,,,,,,,,,,,,SPTLC2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000359,Skap2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:54353|NCBI-Rat-GeneID:155183|NCBI-Human-GeneID:8935,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000008935,,,,,,,,,,,,,TXPO:1000359,,,,,,,,,,,,,,,,,,,,,,Skap2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100407,NGF,nerve growth factor,,false,,,http://purl.obolibrary.org/obo/IMR_0000034,,,,,,,,,,,,,,,,,,,,GO:0005163,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,nerve growth factor,,,,,IMR:0100407,,,,,,,,,,,,,,,,,,,,,,NGF,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006281,DNA repair,,"The process of restoring DNA after damage. Genomes are subject to damage by chemical and physical agents in the environment (e.g. UV and ionizing radiations, chemical mutagens, fungal and bacterial toxins, etc.) and by free radicals or alkylating agents endogenously generated in metabolism. DNA is also damaged because of errors during its replication. A variety of different DNA repair pathways have been reported that include direct reversal, base excision repair, nucleotide excision repair, photoreactivation, bypass, double-strand break repair pathway, and mismatch repair pathway.",false,,,http://purl.obolibrary.org/obo/TXPO_0000535,,,,,,,,,,,,,,,,,,,,,,"The process of restoring DNA after damage. Genomes are subject to damage by chemical and physical agents in the environment (e.g. UV and ionizing radiations, chemical mutagens, fungal and bacterial toxins, etc.) and by free radicals or alkylating agents endogenously generated in metabolism. DNA is also damaged because of errors during its replication. A variety of different DNA repair pathways have been reported that include direct reversal, base excision repair, nucleotide excision repair, photoreactivation, bypass, double-strand break repair pathway, and mismatch repair pathway.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0006281,,,,,,,,,,,,,,,,,,,,,,DNA repair,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000013,IL-11,interleukin-11,,false,,,http://purl.obolibrary.org/obo/IMR_0000007,,,,,,,,,,,,,,,,,,,,GO:0005142,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000622,,,,,interleukin-11,,,,,IMR:0000013,,,,,,,,,,,,,,,,,,,,,,IL-11,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100252,MLK3,protein tyrosine kinase 1|SH3 domain containing proline rich kinase|MAP3K11|SPRK|PTK1,,false,,,http://purl.obolibrary.org/obo/IMR_0100249,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,protein tyrosine kinase 1|SH3 domain containing proline rich kinase|MAP3K11|SPRK|PTK1,,,,,IMR:0100252,,,,,,,,,,,,,,,,,,,,,,MLK3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002599,IRE1-Traf2-ASK-JNK-AP1 pathway [ER stress - inflammation],,"IRE1-Traf2-ASK-JNK-AP1 pathway is a subtype of IRE1 signaling (integrated pathway): Sequence of linked reactions, which has IRE1-Traf2-ASK-JNK signaling and gene regulation by AP1. This pathway is dependent on the inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002563,,,,,,,,,,,,,,,,,,,"IRE1-TRAF2-ASK1 complex
A protein complex of the endoplasmic reticulum membrane that consists of IRE1 (Inositol-requiring enzyme-1), TRAF2 (TNF receptor-associated factor 2) and ASK1 (Apoptosis signal-regulating kinase 1, a MAP3K).
http://purl.obolibrary.org/obo/GO_1990604",PMID:27346803,,"IRE1-Traf2-ASK-JNK-AP1 pathway is a subtype of IRE1 signaling (integrated pathway): Sequence of linked reactions, which has IRE1-Traf2-ASK-JNK signaling and gene regulation by AP1. This pathway is dependent on the inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002833|http://purl.obolibrary.org/obo/TXPO_0002821|http://purl.obolibrary.org/obo/TXPO_0002827|http://purl.obolibrary.org/obo/TXPO_0002823,,http://purl.obolibrary.org/obo/TXPO_0002878,,,,,,,,,,,,,,,,TXPO:0002599,,,,,,,,,,,,,,,,,,,,,,IRE1-Traf2-ASK-JNK-AP1 pathway [ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002598,IRE1 autophosphorylation [ER stress],,"IRE1 autophosphorylation is a subtype of protein autophosphorylation: The phosphorylation by IRE1 of one or more of its own amino acid residues (cis-autophosphorylation), or residues on IRE1 (trans-autophosphorylation).
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0003736|http://purl.obolibrary.org/obo/TXPO_0002597,,,,,,,,,,,,,,,,,,,,,,"IRE1 autophosphorylation is a subtype of protein autophosphorylation: The phosphorylation by IRE1 of one or more of its own amino acid residues (cis-autophosphorylation), or residues on IRE1 (trans-autophosphorylation).
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002601,,,,,,,,,,,,,,,,,TXPO:0002598,,,,,,,,,,,,,,,,,,,,,,IRE1 autophosphorylation [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002590,changing material,,Changing material is a subtype of changing relationship between operands: A process that replaces the old material into new material.,false,,,http://purl.obolibrary.org/obo/TXPO_0000261,,,,,,,,,,,,,,,,,,,,,,Changing material is a subtype of changing relationship between operands: A process that replaces the old material into new material.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002590,,,,,,,,,,,,,,,,,,,,,,changing material,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002595,IRE1 dimerization,,"IRE1 dimerization is a subtype of protein dimerization: The formation of a IRE1 dimer, a macromolecular structure consists of two noncovalently associated identical or nonidentical subunits.",false,,,http://purl.obolibrary.org/obo/TXPO_0003641,,,,,,,,,,,,,,,,,,,,,,"IRE1 dimerization is a subtype of protein dimerization: The formation of a IRE1 dimer, a macromolecular structure consists of two noncovalently associated identical or nonidentical subunits.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002883,,,,,,,,,,,,,,,,,TXPO:0002595,,,,,,,,,,,,,,,,,,,,,,IRE1 dimerization,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002596,IRE1 dimerization [ER stress],,"IRE1 dimerization is a subtype of protein dimerization: The formation of a IRE1 dimer, a macromolecular structure consists of two noncovalently associated identical or nonidentical subunits.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0003736|http://purl.obolibrary.org/obo/TXPO_0002595,,,,,,,,,,,,,,,,,,,,Reactome:R-HSA-381109|PMID:16365312|PMID:23236464|PMID:11897784,,"IRE1 dimerization is a subtype of protein dimerization: The formation of a IRE1 dimer, a macromolecular structure consists of two noncovalently associated identical or nonidentical subunits.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002972,,,,,,http://purl.obolibrary.org/obo/TXPO_0002598,,,,,,,,,,,TXPO:0002596,,,,,,,,,,,,,,,,,,,,,,IRE1 dimerization [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002592,XBP1 activation by IRE1 [IRE1 pathway],,"XBP1 activation by IRE1 is a subtype of activation of transcription factor: A process that changes the activity of XBP1 (X-Box Binding Protein 1) to be higher by IRE1.
This entity is a specific course-dependent process. This process can constitute the course of IRE1 pathway.|The XBP1 gene is transcribed to yield mRNA, which is spliced and translated to transcription factor Xbp(s).",false,,,http://purl.obolibrary.org/obo/TXPO_0000723,,,,,,,,,,,,,,,,,,,,Reactome:R-HSA-1791121.3,,"XBP1 activation by IRE1 is a subtype of activation of transcription factor: A process that changes the activity of XBP1 (X-Box Binding Protein 1) to be higher by IRE1.
This entity is a specific course-dependent process. This process can constitute the course of IRE1 pathway.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000725,,,,,,,,,,,,,,,,,,,,,TXPO:0002592,,,,,,,,,,,,,,,,,,,,"The XBP1 gene is transcribed to yield mRNA, which is spliced and translated to transcription factor Xbp(s).",,XBP1 activation by IRE1 [IRE1 pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002591,IRE1 activation [IRE1 pathway],,"IRE1 activation is a subtype of molecular activation: A process that changes the activity of the IRE1 to be higher.
This entity is a specific course-dependent process. This process can constitute the course of IRE1 pathway.",false,,,http://purl.obolibrary.org/obo/TXPO_0000729,,,,,,,,,,,,,,,,,,,,,,"IRE1 activation is a subtype of molecular activation: A process that changes the activity of the IRE1 to be higher.
This entity is a specific course-dependent process. This process can constitute the course of IRE1 pathway.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002595|http://purl.obolibrary.org/obo/TXPO_0002597,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002592,,,,,,,,,,,TXPO:0002591,,,,,,,,,,,,,,,,,,,,,,IRE1 activation [IRE1 pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002597,IRE1 autophosphorylation,,"IRE1 autophosphorylation is a subtype of protein autophosphorylation: The phosphorylation by IRE1 of one or more of its own amino acid residues (cis-autophosphorylation), or residues on IRE1 (trans-autophosphorylation).",false,,,http://purl.obolibrary.org/obo/GO_0046777,,,,,,,,,,,,,,,,,,,,,,"IRE1 autophosphorylation is a subtype of protein autophosphorylation: The phosphorylation by IRE1 of one or more of its own amino acid residues (cis-autophosphorylation), or residues on IRE1 (trans-autophosphorylation).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002597,,,,,,,,,,,,,,,,,,,,,,IRE1 autophosphorylation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002594,IRE1 signaling to TRAF2 [ER stress - inflammation],,"A process in which a signal to TRAF2 is transduced by the IRE1.
This process is dependent on the inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002571,,,,,,,,,,,,,,,,,,,,,,"A process in which a signal to TRAF2 is transduced by the IRE1.
This process is dependent on the inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002816,,,,,,,,,,,,,,,,,,TXPO:0002594,,,,,,,,,,,,,,,,,,,,,,IRE1 signaling to TRAF2 [ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002593,IRE1 signaling (primitive) [IRE1 pathway],,"IRE1 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the IRE1 (Inositol-requiring transmembrane kinase/endonuclease). IRE1 generally plays a endoplasmic reticulum membrane stress sensor role.
This entity is a specific course-dependent process. This process can constitute the course of IRE1 pathway.",false,,,http://purl.obolibrary.org/obo/TXPO_0000720,,,,,,,,,,,,,,,,,,,,,,"IRE1 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the IRE1 (Inositol-requiring transmembrane kinase/endonuclease). IRE1 generally plays a endoplasmic reticulum membrane stress sensor role.
This entity is a specific course-dependent process. This process can constitute the course of IRE1 pathway.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002591,,,,,,,,,,,,,,,,,,TXPO:0002593,,,,,,,,,,,,,,,,,,,,,,IRE1 signaling (primitive) [IRE1 pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000006774,STAT3,,Other designations: DNA-binding protein APRF|acute-phase response factor|signal transducer and activator of transcription 3,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,APRF|HIES,,,,,,,,,,,,17,,,,,,MIM:102582|HGNC:11364|Vega:OTTHUMG00000150645|Ensembl:ENSG00000168610|HPRD:00026,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,signal transducer and activator of transcription 3 (acute-phase response factor),,,17q21.31,,,,,,,,,,,,,,,,"GO_0000122 (EC: TAS, PMID: 8675499); GO_0001103 (EC: IPI); GO_0001659 (EC: ISS); GO_0001754 (EC: ISS); GO_0003677 (EC: ISS); GO_0003700 (EC: TAS, PMID: 7512451); GO_0004871 (EC: IEA); GO_0004879 (EC: IDA, PMID: 17324931); GO_0005509 (EC: IEA); GO_0005515 (EC: IPI, PMID: 10688651); GO_0005634 (EC: IDA); GO_0005634 (EC: ISS); GO_0005654 (EC: TAS); GO_0005730 (EC: IDA, Qualifier: NOT); GO_0005737 (EC: IDA); GO_0005737 (EC: ISS); GO_0005829 (EC: TAS); GO_0005886 (EC: ISS); GO_0006355 (EC: IDA, PMID: 15664994); GO_0006357 (EC: ISS); GO_0006606 (EC: IDA, PMID: 18234692); GO_0006928 (EC: TAS, PMID: 9670957); GO_0006953 (EC: IEA); GO_0007165 (EC: TAS, PMID: 10205054); GO_0007259 (EC: TAS, PMID: 15664994); GO_0007399 (EC: TAS, PMID: 10205054); GO_0008134 (EC: IPI, PMID: 15664994); GO_0008283 (EC: IEA); GO_0016032 (EC: IEA); GO_0016310 (EC: ISS); GO_0019221 (EC: NAS, PMID: 15664994); GO_0019827 (EC: IEA); GO_0019901 (EC: ISS); GO_0019903 (EC: IPI, PMID: 12359225); GO_0019953 (EC: ISS); GO_0030522 (EC: IDA, PMID: 17324931); GO_0031730 (EC: IEA); GO_0032355 (EC: IDA, PMID: 12552091); GO_0032870 (EC: IDA, PMID: 12552091); GO_0035259 (EC: IEA); GO_0040014 (EC: IEA); GO_0042493 (EC: IEA); GO_0042593 (EC: ISS); GO_0042755 (EC: ISS); GO_0043565 (EC: IEA); GO_0044212 (EC: IDA, PMID: 17324931); GO_0045471 (EC: IEA); GO_0045747 (EC: ISS); GO_0045893 (EC: ISS); GO_0045944 (EC: IDA, PMID: 17324931); GO_0046983 (EC: ISS); GO_0048011 (EC: TAS); GO_0048708 (EC: ISS); GO_0060019 (EC: ISS); GO_0060396 (EC: IDA, PMID: 10925297); GO_0060397 (EC: IDA, PMID: 12552091); GO_0060397 (EC: ISS); GO_0060397 (EC: TAS); GO_0060548 (EC: IEA); GO_0070102 (EC: IDA, PMID: 12359225); GO_2001223 (EC: IEA)",,,,,,,,,PMID: 3031469; 7512451; 7624343; 7701321; 7719938; 8140422; 8272872; 8608603; 8626374; 8626489; 8631962; 8657134; 8675499; 8889548; 8921406; 8923468; 9162009; 9211920; 9343414; 9373245; 9388192; 9398404; 9440692; 9484840; 9566874; 9584171; 9630560; 9647732; 9670957; 9714332; 9724754; 9756944; 9864141; 9872331; 9917912; 9923604; 9989503; 10037026; 10205054; 10358079; 10441580; 10446219; 10458605; 10464281; 10490649; 10506573; 10521505; 10570284; 10602027; 10660304; 10688651; 10764767; 10809230; 10825200; 10875894; 10878010; 10918587; 10925297; 10954736; 10982829; 11021801; 11076863; 11134330; 11163768; 11171987; 11239394; 11279133; 11294897; 11322786; 11328823; 11335711; 11350938; 11350939; 11418668; 11429412; 11438698; 11463827; 11470914; 11536047; 11585385; 11594781; 11722592; 11739197; 11751884; 11751994; 11773079; 11809683; 11815625; 11827956; 11843291; 11853668; 11856732; 11859072; 11861277; 11861839; 11872739; 11882364; 11923478; 11929748; 11940567; 11940572; 11959895; 11960372; 11987152; 12023369; 12039028; 12057007; 12060494; 12061840; 12067972; 12070153; 12089333; 12105218; 12168776; 12193474; 12207328; 12208879; 12235142; 12244095; 12359225; 12361954; 12389630; 12393476; 12396456; 12426389; 12444102; 12444174; 12466961; 12477932; 12506013; 12531804; 12540842; 12545153; 12547716; 12551922; 12552091; 12555068; 12556536; 12559950; 12562765; 12576423; 12600988; 12615922; 12623850; 12626508; 12628925; 12629155; 12629515; 12637318; 12637586; 12640143; 12670499; 12707028; 12738762; 12743296; 12748293; 12763138; 12775419; 12777975; 12782602; 12789269; 12804609; 12821944; 12824284; 12832402; 12833138; 12846741; 12865928; 12865943; 12867595; 12873986; 12900415; 12947115; 12960275; 12963127; 12969979; 14515142; 14522952; 14551213; 14593105; 14647442; 14672334; 14674010; 14688368; 14701810; 14702039; 14704793; 14712222; 14715251; 14715258; 14736711; 14737107; 14963038; 14966128; 14968112; 15007380; 15034082; 15064716; 15070700; 15077160; 15141228; 15143062; 15145953; 15150111; 15156153; 15161657; 15162527; 15163742; 15165826; 15184909; 15194700; 15194868; 15198092; 15207733; 15223310; 15229229; 15242774; 15254691; 15277698; 15284024; 15284113; 15286705; 15297310; 15313931; 15336564; 15343382; 15378007; 15465816; 15474458; 15476590; 15485908; 15489334; 15489336; 15522880; 15530426; 15575898; 15588985; 15590419; 15592455; 15604419; 15615703; 15629435; 15638726; 15643501; 15649887; 15650183; 15653507; 15659654; 15664994; 15665295; 15673499; 15677471; 15677474; 15682485; 15688010; 15735682; 15735720; 15735721; 15736426; 15764709; 15809078; 15821101; 15837065; 15845643; 15870198; 15878791; 15882975; 15894558; 15895073; 15905571; 15912144; 15917293; 15923602; 15935090; 15936715; 15944400; 15950906; 15951569; 15958548; 15979846; 15994929; 16007214; 16036105; 16061629; 16061651; 16081048; 16082218; 16098628; 16107692; 16125646; 16140268; 16142329; 16174774; 16186805; 16192633; 16231698; 16236134; 16236267; 16260903; 16273093; 16278387; 16285960; 16298512; 16306601; 16331268; 16377083; 16381901; 16382134; 16401721; 16407171; 16425286; 16432158; 16503733; 16512876; 16524883; 16531398; 16557588; 16568091; 16571725; 16619044; 16636048; 16651533; 16685378; 16709613; 16732314; 16807407; 16825495; 16828865; 16835372; 16840717; 16841088; 16861352; 16871275; 16877361; 16887796; 16904741; 16926159; 16931573; 16935931; 16946298; 16948814; 16951221; 16959370; 16984731; 17008315; 17012261; 17015686; 17077296; 17078813; 17142261; 17145757; 17151100; 17151125; 17182572; 17194701; 17203226; 17204573; 17209045; 17220301; 17225522; 17241887; 17276988; 17289576; 17311011; 17318196; 17324931; 17333334; 17341611; 17341659; 17344214; 17360477; 17374439; 17376889; 17379849; 17404258; 17438134; 17441424; 17459060; 17460772; 17463090; 17471507; 17519976; 17525530; 17531096; 17533050; 17540176; 17543278; 17543500; 17545518; 17572495; 17597020; 17602083; 17603019; 17616678; 17626740; 17634553; 17636030; 17636079; 17639043; 17640230; 17668881; 17670892; 17671686; 17672932; 17676033; 17686614; 17689208; 17700521; 17702747; 17703412; 17716862; 17720094; 17726017; 17726064; 17764814; 17822622; 17824789; 17855361; 17855663; 17869487; 17875724; 17875759; 17880940; 17881745; 17888401; 17895321; 17911113; 17911267; 17918184; 17920763; 17923090; 17927847; 17938255; 17951530; 17956865; 17959148; 17961551; 17967179; 17971300; 17975158; 18024124; 18024479; 18029348; 18037959; 18047677; 18058821; 18059167; 18060032; 18069631; 18077446; 18079966; 18096869; 18097150; 18160665; 18171991; 18172037; 18172861; 18184402; 18189193; 18192274; 18192275; 18198175; 18200666; 18203738; 18204781; 18234692; 18239666; 18242580; 18247337; 18255255; 18276758; 18305569; 18307254; 18310224; 18320073; 18348986; 18353781; 18354204; 18386001; 18390202; 18398416; 18408167; 18411043; 18413761; 18424427; 18426800; 18438405; 18441325; 18443354; 18448488; 18448545; 18451776; 18456658; 18457738; 18463684; 18474224; 18483213; 18483262; 18483365; 18503159; 18503751; 18504423; 18505768; 18519681; 18523665; 18524891; 18535750; 18547788; 18550668; 18556750; 18573283; 18577706; 18583177; 18587394; 18591410; 18591412; 18592012; 18602572; 18602747; 18614255; 18636124; 18639471; 18644974; 18652313; 18662321; 18676737; 18684866; 18695911; 18700251; 18703315; 18706697; 18729804; 18752497; 18755267; 18755494; 18758380; 18768494; 18777586; 18779368; 18782771; 18787400; 18789715; 18821062; 18829483; 18829527; 18841165; 18851787; 18922788; 18939995; 18947877; 18948751; 18950011; 18978467; 18978678; 18985005; 18985028; 18987331; 18988190; 18988672; 19010822; 19017763; 19020709; 19032945; 19049975; 19064501; 19068194; 19068216; 19070595; 19074878; 19077438; 19088064; 19088198; 19088723; 19109129; 19110536; 19118011; 19121623; 19144991; 19147543; 19147545; 19147578; 19148533; 19151334; 19153190; 19157144; 19175826; 19176463; 19203349; 19223541; 19248116; 19249008; 19251695; 19254694; 19255588; 19258923; 19259951; 19264844; 19265112; 19272804; 19272817; 19273247; 19278424; 19284568; 19287190; 19288493; 19322201; 19329556; 19331815; 19341726; 19345327; 19348930; 19360334; 19362457; 19372705; 19385051; 19390056; 19393627; 19399415; 19403642; 19414409; 19421230; 19421717; 19422935; 19423540; 19424782; 19429240; 19435463; 19447160; 19457567; 19484147; 19491198; 19492417; 19503092; 19506034; 19509418; 19556508; 19574718; 19577286; 19578748; 19595668; 19601808; 19601811; 19603082; 19608729; 19608866; 19616333; 19616846; 19623660; 19626047; 19632985; 19638983; 19642906; 19647363; 19652645; 19653082; 19658181; 19664131; 19667218; 19667270; 19684620; 19691533; 19717292; 19718269; 19723038; 19724924; 19730683; 19741197; 19741199; 19751774; 19758315; 19760754; 19764561; 19764570; 19776189; 19781773; 19781967; 19789190; 19789299; 19796718; 19817957; 19819066; 19824884; 19825993; 19834108; 19843641; 19851315; 19861436; 19861958; 19875458; 19876927; 19878271; 19889776; 19900287; 19901082; 19901516; 19903771; 19913121; 19913854; 19915152; 19934272; 19951849; 19968719; 19995546; 20012909; 20015877; 20019835; 20032196; 20032313; 20032975; 20038814; 20043094; 20048285; 20052595; 20053726; 20053772; 20059466; 20065083; 20068065; 20069389; 20072651; 20072652; 20106947; 20107204; 20109474; 20113333; 20120862; 20124472; 20128024; 20132164; 20145033; 20149042; 20149460; 20154216; 20159113; 20159251; 20159255; 20160059; 20164027; 20167868; 20185553; 20196786; 20197401; 20199106; 20200543; 20204302; 20209132; 20211142; 20213502; 20222910; 20229017; 20232316; 20237496; 20301786; 20331378; 20331635; 20348091; 20351189; 20356901; 20359118; 20368117; 20371693; 20379614; 20380698; 20388777; 20399615; 20406964; 20422486; 20431064; 20438785; 20446017; 20447714; 20456494; 20459702; 20463008; 20463292; 20473906; 20483734; 20484656; 20490271; 20490331; 20503287; 20507639; 20514402; 20515335; 20516069; 20516148; 20519510; 20546860; 20558345; 20562100; 20568281; 20585009; 20618440; 20627814; 20628086; 20628624; 20634891; 20652679; 20661303; 20663948; 20668024; 20686606; 20691278; 20709283; 20716621; 20797623; 20802378; 20807804; 20816194; 20826784; 20830236; 20830487; 20860602; 20872151; 20873541; 20873543; 20881637; 20886065; 20888416; 20929863; 20930550; 20939893; 20942237; 20943775; 20962850; 20974051; 20977777; 20978825; 21058221; 21068102; 21072187; 21072904; 21085192; 21098664; 21098725; 21102463; 21115047; 21122157; 21131551; 21138684; 21139048; 21148399; 21148800; 21152001; 21166956; 21174186; 21177324; 21178271; 21183735; 21184768; 21209620; 21211286; 21216930; 21224490; 21245987; 21252943; 21257710; 21268011; 21282107; 21288777; 21293887; 21307288; 21310444; 21310826; 21311318; 21316706; 21320693; 21321954; 21325026; 21325207; 21333372; 21339300; 21343371; 21346774; 21364020; 21382889; 21385272; 21385902; 21398617; 21399864; 21402692; 21408055; 21410405; 21415216; 21418908; 21420464; 21426892; 21430300; 21436461; 21442485; 21443800; 21444672; 21447682; 21468569; 21470923; 21479358; 21481787; 21481788; 21481791; 21486470; 21486864; 21490132; 21494893; 21502401; 21518725; 21520044; 21539622; 21546410; 21549414; 21552420; 21562161; 21573184; 21575192; 21577321; 21586612; 21590492; 21607287; 21611796; 21619877; 21624746; 21625522; 21632716; 21633165; 21637744; 21643014; 21651859; 21658842; 21661417; 21668356; 21671179; 21674558; 21677772; 21681336; 21684622; 21684758; 21685938; 21689417; 21689689; 21690253; 21701559; 21711111; 21715323; 21720710; 21726118; 21726833; 21731057; 21733558; 21747171; 21749449; 21750002; 21779366; 21782857; 21788516; 21792878; 21796151; 21806788; 21818116; 21833088; 21835143; 21835168; 21866460; 21871555; 21875334; 21876460; 21886773; 21890473; 21890685; 21892329; 21897114; 21900397; 21903422; 21906983; 21913828; 21926348; 21937440; 21938013; 21948258; 21948749; 21953450; 21954831; 21957129; 21963094; 21977994; 21985363; 21987572; 21988832; 21991388; 21994466; 21997191; 22004076; 22006329; 22021169; 22030463; 22046235; 22050790; 22069317; 22074823; 22078209; 22082308; 22084247; 22093834; 22095036; 22095154; 22098470; 22104200; 22104307; 22104727; 22105366; 22108192; 22110249; 22116549; 22118528; 22120672; 22123322; 22126101; 22140473; 22147524; 22154363; 22168497; 22171994; 22174695; 22180308; 22189341; 22190364; 22190485; 22194466; 22194600; 22197944; 22203730; 22205606; 22205702; 22206672; 22208386; 22211709; 22218594; 22221142; 22233524; 22238455; 22252296; 22260073; 22269120; 22273698; 22279540; 22289525; 22301404; 22302289; 22303479; 22311708; 22312430; 22317895; 22319590; 22322297; 22328572; 22330135; 22331430; 22336225; 22340714; 22342309; 22349830; 22350508; 22364921; 22369852; 22374428; 22376160; 22378781; 22381273; 22394639; 22394684; 22396544; 22401280; 22407921; 22417306; 22417709; 22418867; 22418922; 22438130; 22450744; 22467101; 22480875; 22484976; 22488042; 22491065; 22492280; 22504301; 22504904; 22505724; 22506067; 22509288; 22521547; 22528488; 22532166; 22532634; 22535619; 22542455; 22547065; 22547799; 22562532; 22574813; 22575502; 22581330; 22581828; 22591296; 22613986; 22614117; 22624714; 22630347; 22634616; 22644781; 22656398; 22693070; 22709411; 22711165; 22712053; 22723956; 22735740; 22736176; 22743617; 22745305; 22750444; 22751114; 22751495; 22753649; 22753872; 22760497; 22761423; 22777388; 22783022; 22786753; 22789685; 22791907; 22799634; 22802294; 22808266; 22814105; 22842992; 22843679; 22844427; 22859607; 22863883; 22891351; 22895078; 22904633; 22905257; 22911368; 22927445; 22932892; 22938476; 22941903; 22959364; 22967106; 22967991; 22984561; 22987449; 23000965; 23007731; 23018644; 23018838; 23030674; 23042197; 23043161; 23056300; 23056515; 23063454; 23065274; 23066027; 23068100; 23074171; 23079657; 23083634; 23084476; 23089473; 23094050; 23097472; 23108098; 23108375; 23111066; 23124042; 23125416; 23127549; 23128233; 23134344; 23149124; 23158658; 23161342; 23166300; 23166328; 23172665; 23178493; 23185365; 23192865; 23193966; 23207521; 23220625; 23221979; 23226098; 23226414; 23228483; 23243289; 23246576; 23250732; 23253440; 23266558; 23266857; 23271731; 23274199; 23288901; 23295773; 23303450; 23317146; 23318430; 23322197; 23322822; 23326564; 23326583; 23329056; 23333300; 23333463; 23340171; 23351302; 23361365; 23364389; 23376640; 23378274; 23386590; 23386605; 23391827; 23402362; 23403044; 23406316; 23408403; 23416296; 23424038; 23434585; 23437123; 23438478; 23446809; 23454751; 23461823; 23483208; 23496892; 23504318; 23514705; 23526220; 23531596; 23531921; 23533997; 23545262; 23548897; 23555696; 23555719; 23563237; 23573315; 23583378; 23590971; 23590999; 23591770; 23604529; 23612755; 23613996; 23614738; 23618357; 23622344; 23623921; 23628554; 23633489; 23636127; 23636231; 23639951; 23650499; 23653350; 23659370; 23665025; 23665320; 23673666; 23674871; 23676499; 23677069; 23681230; 23703790; 23704922; 23716595; 23725032; 23734190; 23736381; 23740979; 23741012; 23756862; 23768868; 23782265; 23788661; 23791019; 23807222; 23820254; 23824569; 23824571; 23830147; 23856509; 23861822; 23874455; 23902772; 23904224; 23907460; 23911788; 23919497; 23920124; 23923047; 23926297; 23941832; 23941877; 23953057; 23956138; 23962558; 23966384; 23982944; 23984931; 23995109; 24004609; 24005672; 24027425; 24036113; 24048798; 24067369; 24082147; 24101550; 24114793; 24122993; 24123009; 24127267; 24135280; 24157808; 24158981; 24159173; 24184145; 24211205; 24218138; 24307657; 24315995; 24328557; 24342613; 24374144; 24395800; 24462277,,,,,,,,,,,,,,,OGG:3000006774,,,,,,,signal transducer and activator of transcription 3 (acute-phase response factor),,,,,,,,,,,,,Other designations: DNA-binding protein APRF|acute-phase response factor|signal transducer and activator of transcription 3,,STAT3,,,,,,,,,,,,,,,,,,,,,,,6774,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,STAT3,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000006772,STAT1,,Other designations: signal transducer and activator of transcription 1-alpha/beta|signal transducer and activator of transcription-1|transcription factor ISGF-3 components p91/p84,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,ISGF-3|CANDF7|STAT91,,,,,,,,,,,,2,,,,,,Ensembl:ENSG00000115415|MIM:600555|Vega:OTTHUMG00000132699|HPRD:02777|HGNC:11362,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"signal transducer and activator of transcription 1, 91kDa",,,2q32.2,,,,,,,,,,,,,,,,"GO_0000122 (EC: ISS); GO_0000790 (EC: IDA, PMID: 18035482); GO_0000978 (EC: IDA, PMID: 18035482); GO_0000979 (EC: IDA); GO_0000983 (EC: IDA); GO_0001937 (EC: IMP, PMID: 16585190); GO_0002053 (EC: ISS); GO_0003340 (EC: ISS); GO_0003690 (EC: IDA, PMID: 9630226); GO_0003700 (EC: IDA, PMID: 10820245); GO_0003700 (EC: IDA, Qualifier: NOT, PMID: 10820245); GO_0004871 (EC: IEA); GO_0005164 (EC: IPI, PMID: 10848577); GO_0005509 (EC: IEA); GO_0005515 (EC: IPI, PMID: 10848577); GO_0005634 (EC: IDA); GO_0005654 (EC: TAS); GO_0005730 (EC: IDA); GO_0005730 (EC: IDA, Qualifier: NOT); GO_0005737 (EC: IDA); GO_0005829 (EC: TAS); GO_0006357 (EC: IDA, Qualifier: NOT, PMID: 10820245); GO_0006366 (EC: IDA); GO_0006915 (EC: ISS); GO_0007259 (EC: IDA); GO_0007584 (EC: IEA); GO_0008015 (EC: ISS); GO_0009612 (EC: IEA); GO_0016032 (EC: IEA); GO_0016525 (EC: IMP, PMID: 16585190); GO_0019221 (EC: TAS); GO_0019899 (EC: IPI); GO_0030424 (EC: ISS); GO_0030425 (EC: ISS); GO_0031663 (EC: IEA); GO_0031730 (EC: IEA); GO_0032869 (EC: IEA); GO_0033209 (EC: IDA, PMID: 10848577); GO_0034097 (EC: ISS); GO_0034240 (EC: IEA); GO_0035458 (EC: IMP, PMID: 18035482); GO_0042493 (EC: IEA); GO_0042542 (EC: IEA); GO_0042802 (EC: IPI, PMID: 8605877); GO_0042803 (EC: IDA, PMID: 9630226); GO_0042981 (EC: TAS, PMID: 12108949); GO_0043124 (EC: IMP, PMID: 10848577); GO_0043330 (EC: IEA); GO_0043434 (EC: ISS); GO_0043542 (EC: IMP, Qualifier: NOT, PMID: 16585190); GO_0045893 (EC: IDA, PMID: 10973496); GO_0045944 (EC: IDA, PMID: 10820245); GO_0045944 (EC: IMP, PMID: 18035482); GO_0048661 (EC: ISS); GO_0051591 (EC: ISS); GO_0051607 (EC: IEA); GO_0060333 (EC: IDA); GO_0060333 (EC: ISS); GO_0060333 (EC: TAS); GO_0060334 (EC: TAS); GO_0060337 (EC: ISS); GO_0060337 (EC: TAS); GO_0060338 (EC: TAS); GO_0060397 (EC: TAS); GO_0061326 (EC: IMP); GO_0072136 (EC: ISS); GO_0072162 (EC: ISS); GO_0072308 (EC: ISS)",,,,,,,,,PMID: 1496401; 1502203; 7510216; 7514165; 7543024; 7657660; 7690989; 7885841; 8125298; 8232552; 8549654; 8605877; 8608597; 8621447; 8631962; 8889548; 8943351; 8986769; 9037008; 9069288; 9121453; 9135145; 9205132; 9284918; 9344858; 9355737; 9373245; 9452495; 9484840; 9584171; 9630226; 9724754; 9804857; 9843502; 9880553; 9925928; 9989503; 10067896; 10358045; 10358079; 10446176; 10464260; 10490649; 10490982; 10506573; 10602027; 10652206; 10692450; 10702714; 10764778; 10792030; 10805787; 10820245; 10848577; 10848598; 10851046; 10851062; 10918587; 10954736; 10961983; 10964507; 10973496; 10982844; 11152457; 11226159; 11238845; 11248027; 11257227; 11278462; 11278865; 11294897; 11301323; 11418623; 11438544; 11442634; 11452125; 11520787; 11594781; 11675348; 11722592; 11752148; 11777927; 11804954; 11815625; 11835405; 11839738; 11843291; 11886859; 11909852; 11909970; 11923478; 11927559; 11932384; 11972023; 11981818; 12039028; 12048190; 12070153; 12108949; 12130529; 12138178; 12161037; 12165521; 12167251; 12171910; 12191570; 12223098; 12232043; 12232802; 12270932; 12356736; 12388709; 12403783; 12426389; 12447867; 12459177; 12477932; 12539042; 12551969; 12590259; 12610144; 12629155; 12634403; 12637327; 12722480; 12734330; 12748293; 12759242; 12777975; 12788789; 12804771; 12807916; 12817007; 12832402; 12846741; 12855573; 12855578; 12856330; 12867595; 12917439; 12923054; 12948935; 12960323; 12963127; 12967644; 14499622; 14500749; 14517261; 14557668; 14599788; 14600148; 14623896; 14654078; 14654702; 14656722; 14657353; 14674010; 14688135; 14690454; 14702039; 14704793; 14746803; 14751560; 14755057; 14963018; 14976049; 14978237; 15010467; 15055356; 15123634; 15140960; 15146197; 15165826; 15210729; 15213094; 15217838; 15221897; 15280488; 15284024; 15284440; 15322115; 15467722; 15489334; 15494521; 15527154; 15604419; 15638726; 15650219; 15695802; 15778351; 15780933; 15784679; 15795279; 15824515; 15825084; 15894584; 15919942; 15979846; 15996661; 15998520; 16009940; 16077199; 16148108; 16148142; 16189514; 16195225; 16195385; 16223733; 16236267; 16254375; 16257975; 16260419; 16273093; 16298512; 16306601; 16318585; 16335966; 16344560; 16388135; 16467883; 16481475; 16501077; 16511123; 16512786; 16531398; 16571725; 16572323; 16574066; 16585190; 16628196; 16703666; 16773129; 16799645; 16878149; 16897667; 16904741; 16918696; 16934001; 16935931; 16940534; 16951379; 16978698; 17030574; 17075845; 17145596; 17182865; 17196131; 17227821; 17237409; 17266440; 17287281; 17346710; 17351669; 17353931; 17371985; 17386941; 17427945; 17442890; 17475642; 17486072; 17490620; 17523873; 17538964; 17561467; 17596301; 17617740; 17620599; 17640695; 17680769; 17686504; 17703412; 17726060; 17804871; 17878351; 17897103; 17909067; 17918184; 17923090; 17928350; 17933493; 17938255; 17983380; 17986321; 18003888; 18029348; 18035482; 18037959; 18062835; 18218993; 18225539; 18280748; 18305014; 18305569; 18338947; 18348986; 18370868; 18381204; 18401423; 18424756; 18463151; 18483262; 18500930; 18566411; 18579584; 18586252; 18591661; 18633131; 18660489; 18676680; 18723680; 18771758; 18775329; 18787082; 18787531; 18789440; 18803832; 18818378; 18832710; 18950845; 18989459; 19007958; 19012493; 19017763; 19041714; 19046253; 19074829; 19088846; 19100922; 19124747; 19131965; 19170196; 19171783; 19211553; 19223260; 19231233; 19258923; 19279332; 19333953; 19342095; 19351818; 19380416; 19393742; 19404407; 19423540; 19424608; 19434718; 19436109; 19437244; 19439556; 19453261; 19464956; 19471022; 19478064; 19479051; 19502801; 19508864; 19515782; 19553685; 19561067; 19574556; 19582813; 19594299; 19596857; 19604093; 19622834; 19625176; 19646959; 19647793; 19652026; 19656875; 19667270; 19691533; 19692168; 19781967; 19801665; 19802007; 19834108; 19853614; 19857525; 19891767; 19913121; 19915063; 19915608; 19935876; 20011528; 20045654; 20065083; 20093796; 20098684; 20103601; 20180146; 20195357; 20211142; 20225206; 20331378; 20345984; 20347693; 20353823; 20379614; 20380698; 20403236; 20406964; 20428775; 20438785; 20457620; 20503287; 20519510; 20523058; 20562129; 20568281; 20576130; 20588308; 20624457; 20628086; 20628624; 20662656; 20798561; 20802378; 20810735; 20814891; 20829351; 20832538; 20833730; 20841510; 20936779; 20937132; 20937272; 20949125; 20974984; 20980339; 21056555; 21057861; 21079652; 21084836; 21091911; 21099673; 21115047; 21139048; 21207025; 21288140; 21303487; 21307288; 21311224; 21321110; 21346151; 21354905; 21362620; 21368418; 21372127; 21385873; 21466707; 21477834; 21533215; 21571862; 21572044; 21576370; 21593149; 21674123; 21689637; 21690236; 21697347; 21714643; 21727188; 21734056; 21752694; 21772053; 21795355; 21796151; 21886773; 21890473; 21903422; 21906983; 21937453; 21988832; 22002246; 22022391; 22025054; 22038351; 22065572; 22115721; 22174846; 22178447; 22193460; 22194871; 22195034; 22217266; 22242177; 22253910; 22262126; 22320867; 22326919; 22381273; 22383882; 22401175; 22407921; 22425562; 22437822; 22474288; 22479354; 22488367; 22505724; 22514085; 22526675; 22535619; 22539792; 22558273; 22573496; 22647704; 22674974; 22693070; 22730530; 22748021; 22748593; 22757586; 22797925; 22805310; 22808166; 22811740; 22828446; 22833565; 22838736; 22844427; 22863883; 22920460; 22939629; 22942432; 22973045; 23000965; 23043228; 23068100; 23072252; 23076242; 23086340; 23108375; 23128233; 23153456; 23154639; 23180800; 23240025; 23271704; 23274199; 23306614; 23349666; 23363816; 23378427; 23383273; 23401241; 23403048; 23452095; 23471820; 23486482; 23487038; 23534974; 23541320; 23554911; 23582260; 23585528; 23588992; 23609054; 23621408; 23703473; 23704922; 23708675; 23740952; 23741352; 23756862; 23856440; 23910645; 23920124; 23940278; 23941832; 23956138; 23958647; 23984931; 24449862,,,,,,,,,,,,,,,OGG:3000006772,,,,,,,"signal transducer and activator of transcription 1, 91kDa",,,,,,,,,,,,,Other designations: signal transducer and activator of transcription 1-alpha/beta|signal transducer and activator of transcription-1|transcription factor ISGF-3 components p91/p84,,STAT1,,,,,,,,,,,,,,,,,,,,,,,6772,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,STAT1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001591,CYP24A1,,"Other designations: 1,25-@dihydroxyvitamin D3 24-hydroxylase|1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial|24-OHase|cytochrome P450 24A1|cytochrome P450, subfamily XXIV (vitamin D 24-hydroxylase)|cytochrome P450-CC24|exo-mitochondrial protein|vitamin D 24-hydroxylase|vitamin D(3) 24-hydroxylase",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CYP24|CP24|P450-CC24|HCAI,,,,,,,,,,,,20,,,,,,Vega:OTTHUMG00000032773|HPRD:00522|Ensembl:ENSG00000019186|MIM:126065|HGNC:2602,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 24, subfamily A, polypeptide 1",,,20q13,,,,,,,,,,,,,,,,"GO_0001649 (EC: IEP, PMID:17023519); GO_0005506 (EC: IEA); GO_0005743 (EC: TAS); GO_0006766 (EC: TAS); GO_0006805 (EC: TAS); GO_0008202 (EC: TAS); GO_0008403 (EC: IEA); GO_0016491 (EC: NAS, PMID:7632726); GO_0020037 (EC: TAS, PMID:8506296); GO_0030342 (EC: IDA, PMID:8506296); GO_0033280 (EC: IDA, PMID:16720713); GO_0042359 (EC: TAS); GO_0042369 (EC: NAS, PMID:16720713); GO_0044281 (EC: TAS); GO_0055114 (EC: IDA, PMID:8506296); GO_0070561 (EC: NAS, PMID:16720713)",,,,,,,,,PMID:7595086; 7632726; 7829101; 7938037; 8266831; 8440135; 8506296; 10218951; 11149490; 11780052; 12477932; 12485911; 12641633; 12855575; 14665637; 14760115; 15078099; 15128046; 15146197; 15358094; 15583024; 15630458; 15788398; 15919092; 15951480; 16457885; 16516540; 16600026; 16617161; 16691293; 16708384; 16720713; 17023519; 17079137; 17223345; 17244366; 17254772; 17368180; 17426122; 17475215; 17585873; 17606874; 17646648; 17875655; 17932346; 18467787; 18676680; 18824104; 18843020; 19097033; 19170196; 19237542; 19255064; 19343046; 19393625; 19453261; 19454612; 19505920; 19625176; 19667160; 19692168; 19706847; 19852851; 19891555; 19901270; 19913121; 19922790; 20007432; 20304053; 20304056; 20304059; 20394945; 20398751; 20450955; 20453000; 20460683; 20467438; 20541252; 20587525; 20591973; 20628086; 20654748; 20687218; 20809279; 20831823; 20847308; 20877624; 21169243; 21385079; 21440908; 21441443; 21675912; 21697097; 21725204; 21828234; 21833088; 21906983; 22213328; 22285938; 22511602; 22612324; 22648713; 22649517; 22690899; 22841393; 22871965; 22940288; 22984610; 23042114; 23059474; 23155244; 23169318; 23293122; 23377224; 23393347; 23423976; 23435876; 23456391; 23463632; 23485543; 23674869; 23826131; 24068962,,,,,,,,,,,,,,,OGG:3000001591,,,,,,,"cytochrome P450, family 24, subfamily A, polypeptide 1",,,,,,,,,,,,,"Other designations: 1,25-@dihydroxyvitamin D3 24-hydroxylase|1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial|24-OHase|cytochrome P450 24A1|cytochrome P450, subfamily XXIV (vitamin D 24-hydroxylase)|cytochrome P450-CC24|exo-mitochondrial protein|vitamin D 24-hydroxylase|vitamin D(3) 24-hydroxylase",,CYP24A1,,,,,,,,,,,,,,,,,,,,,,,1591,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP24A1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001592,CYP26A1,,"Other designations: P450, retinoic acid-inactivating, 1|cytochrome P450 26A1|cytochrome P450 retinoic acid-inactivating 1|cytochrome P450, subfamily XXVIA, polypeptide 1|cytochrome P450RAI|hP450RAI|retinoic acid 4-hydroxylase|retinoic acid-metabolizing cytochrome",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,P450RAI1|P450RAI|CYP26|CP26,,,,,,,,,,,,10,,,,,,Vega:OTTHUMG00000018765|HGNC:2603|MIM:602239|HPRD:03759|Ensembl:ENSG00000095596,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 26, subfamily A, polypeptide 1",,,10q23-q24,,,,,,,,,,,,,,,,"GO_0001972 (EC: IDA, PMID:10823918); GO_0005506 (EC: IEA); GO_0005789 (EC: TAS); GO_0006766 (EC: TAS); GO_0006805 (EC: TAS); GO_0007417 (EC: IEA); GO_0008152 (EC: TAS, PMID:9228017); GO_0008401 (EC: IDA, PMID:10823918); GO_0009952 (EC: IEA); GO_0014032 (EC: IEA); GO_0019825 (EC: TAS, PMID:9228017); GO_0020037 (EC: NAS, PMID:9228017); GO_0034653 (EC: IDA, PMID:10823918); GO_0044281 (EC: TAS); GO_0048384 (EC: IEA); GO_0048387 (EC: TAS, PMID:14532297); GO_0071300 (EC: IEA)",,,,,,,,,PMID:8601734; 9228017; 9228041; 9521883; 9716180; 9826557; 10583049; 10823918; 10874126; 10976925; 12727970; 14532297; 14702039; 15128046; 15281009; 16053444; 16194896; 16463413; 16778795; 16933217; 17059167; 17218384; 17460545; 18059332; 18992717; 19519282; 19553612; 19703508; 20167577; 20375987; 20513361; 20682464; 20686565; 20693622; 21521770; 21850183; 21975512; 22020119; 22179182; 23396134; 24043786,,,,,,,,,,,,,,,OGG:3000001592,,,,,,,"cytochrome P450, family 26, subfamily A, polypeptide 1",,,,,,,,,,,,,"Other designations: P450, retinoic acid-inactivating, 1|cytochrome P450 26A1|cytochrome P450 retinoic acid-inactivating 1|cytochrome P450, subfamily XXVIA, polypeptide 1|cytochrome P450RAI|hP450RAI|retinoic acid 4-hydroxylase|retinoic acid-metabolizing cytochrome",,CYP26A1,,,,,,,,,,,,,,,,,,,,,,,1592,RP11-348J12.1,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP26A1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001595,CYP51A1,,"Other designations: CYPLI|cytochrome P450 51A1|cytochrome P450, 51 (lanosterol 14-alpha-demethylase)|cytochrome P450-14DM|cytochrome P45014DM|cytochrome P450LI|lanosterol 14-alpha demethylase|lanosterol 14-alpha-demethylase|sterol 14-alpha demethylase",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CYPL1|CYP51|P450-14DM|CP51|LDM|P450L1,,,,,,,,,,,,7,,,,,,Ensembl:ENSG00000001630|HPRD:03381|HGNC:2649|Vega:OTTHUMG00000131131|MIM:601637,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 51, subfamily A, polypeptide 1",,,7q21.2,,,,,,,,,,,,,,,,GO_0005506 (EC: IEA); GO_0005783 (EC: IDA); GO_0005789 (EC: TAS); GO_0006694 (EC: IDA); GO_0006695 (EC: TAS); GO_0006805 (EC: TAS); GO_0008398 (EC: IDA); GO_0016021 (EC: IEA); GO_0016125 (EC: TAS); GO_0020037 (EC: IDA); GO_0033488 (EC: IEA); GO_0044281 (EC: TAS); GO_0070988 (EC: IDA),,,,,,,,,PMID:8024575; 8619637; 8797093; 8809088; 8845856; 8975714; 11678326; 12145339; 12477932; 12690205; 12824470; 12853948; 14702039; 15128046; 15489334; 15611056; 16344560; 18660489; 18676367; 19322201; 20149798; 20547249; 21139048; 21890473; 21906983; 21963094; 21987572; 21988832; 22053931; 22180046; 23000965; 24362992; 24502137,,,,,,,,,,,,,,,OGG:3000001595,,,,,,,"cytochrome P450, family 51, subfamily A, polypeptide 1",,,,,,,,,,,,,"Other designations: CYPLI|cytochrome P450 51A1|cytochrome P450, 51 (lanosterol 14-alpha-demethylase)|cytochrome P450-14DM|cytochrome P45014DM|cytochrome P450LI|lanosterol 14-alpha demethylase|lanosterol 14-alpha-demethylase|sterol 14-alpha demethylase",,CYP51A1,,,,,,,,,,,,,,,,,,,,,,,1595,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP51A1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001593,CYP27A1,,"Other designations: 5-beta-cholestane-3-alpha, 7-alpha, 12-alpha-triol 26-hydroxylase|5-beta-cholestane-3-alpha, 7-alpha, 12-alpha-triol 27-hydroxylase|5-beta-cholestane-3-alpha,7-alpha,12-alpha-triol 27-hydroxylase|cholestanetriol 26-monooxygenase|cytochrome P-450C27/25|cytochrome P450 27|cytochrome P450, subfamily XXVIIA (steroid 27-hydroxylase, cerebrotendinous xanthomatosis), polypeptide 1|sterol 26-hydroxylase, mitochondrial|sterol 27-hydroxylase|vitamin D(3) 25-hydroxylase",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CTX|CYP27|CP27,,,,,,,,,,,,2,,,,,,HPRD:05939|Ensembl:ENSG00000135929|MIM:606530|Vega:OTTHUMG00000048238|HGNC:2605,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 27, subfamily A, polypeptide 1",,,2q35,,,,,,,,,,,,,,,,"GO_0005506 (EC: IEA); GO_0005743 (EC: IEA); GO_0005759 (EC: TAS); GO_0006699 (EC: TAS); GO_0006805 (EC: TAS); GO_0008203 (EC: IEA); GO_0008206 (EC: TAS); GO_0008395 (EC: TAS, PMID:9790667); GO_0016125 (EC: TAS); GO_0020037 (EC: IEA); GO_0030343 (EC: IEA); GO_0031073 (EC: IEA); GO_0044281 (EC: TAS); GO_0047749 (EC: IEA)",,,,,,,,,PMID:1708392; 2019602; 7690968; 7915755; 8125298; 8514861; 9186905; 9215552; 9790667; 10519880; 11167933; 11604260; 11903362; 12000359; 12011083; 12117727; 12119285; 12242561; 12477932; 12777473; 14672608; 14741198; 15128046; 15340076; 15489334; 15533057; 15708352; 16157755; 16372260; 16584175; 16930540; 17088262; 17292862; 17482558; 17697869; 17875655; 18227423; 18791760; 19255064; 19343046; 19671838; 19852851; 19913121; 20149624; 20301583; 20402754; 20450308; 20558929; 20628086; 20654748; 20809279; 20855565; 20877624; 21049985; 21134350; 21258856; 21411718; 21498512; 21958693; 21988832; 22018287; 22185844; 22227097; 22509407; 24096962,,,,,,,,,,,,,,,OGG:3000001593,,,,,,,"cytochrome P450, family 27, subfamily A, polypeptide 1",,,,,,,,,,,,,"Other designations: 5-beta-cholestane-3-alpha, 7-alpha, 12-alpha-triol 26-hydroxylase|5-beta-cholestane-3-alpha, 7-alpha, 12-alpha-triol 27-hydroxylase|5-beta-cholestane-3-alpha,7-alpha,12-alpha-triol 27-hydroxylase|cholestanetriol 26-monooxygenase|cytochrome P-450C27/25|cytochrome P450 27|cytochrome P450, subfamily XXVIIA (steroid 27-hydroxylase, cerebrotendinous xanthomatosis), polypeptide 1|sterol 26-hydroxylase, mitochondrial|sterol 27-hydroxylase|vitamin D(3) 25-hydroxylase",,CYP27A1,,,,,,,,,,,,,,,,,,,,,,,1593,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP27A1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001594,CYP27B1,,"Other designations: 1alpha(OH)ase|25 hydroxyvitamin D3-1-alpha hydroxylase|25-OHD-1 alpha-hydroxylase|25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial|VD3 1A hydroxylase|calcidiol 1-monooxygenase|cytochrome P450 subfamily XXVIIB polypeptide 1|cytochrome P450C1 alpha|cytochrome P450VD1-alpha|cytochrome p450 27B1",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,VDDRI|CYP1|PDDR|VDDR|CYP1alpha|CP2B|VDR|CYP27B|P450c1|VDD1,,,,,,,,,,,,12,,,,,,Ensembl:ENSG00000111012|MIM:609506|HGNC:2606|HPRD:02031|Vega:OTTHUMG00000170457,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 27, subfamily B, polypeptide 1",,,12q14.1,,,,,,,,,,,,,,,,"GO_0004498 (EC: IDA, PMID:15795327); GO_0005506 (EC: IEA); GO_0005737 (EC: IDA, PMID:15589699); GO_0005739 (EC: ISS); GO_0005739 (EC: TAS, PMID:9333115); GO_0005741 (EC: TAS); GO_0006766 (EC: TAS); GO_0006805 (EC: TAS); GO_0006816 (EC: ISS); GO_0008202 (EC: TAS); GO_0008285 (EC: IDA, PMID:16549446); GO_0010956 (EC: IDA, PMID:16549446); GO_0010980 (EC: IDA, PMID:16549446); GO_0020037 (EC: IEA); GO_0030282 (EC: IEP, PMID:17023519); GO_0030308 (EC: IMP, PMID:12496369); GO_0030500 (EC: IMP, PMID:9415400); GO_0032496 (EC: IDA, PMID:12855575); GO_0033280 (EC: IDA, PMID:16549446); GO_0034341 (EC: IDA, PMID:9282826); GO_0036378 (EC: IDA, PMID:15795327); GO_0042359 (EC: IDA, PMID:9415400); GO_0042359 (EC: TAS); GO_0042369 (EC: IEA); GO_0043627 (EC: IEP, PMID:15795327); GO_0044281 (EC: TAS); GO_0045618 (EC: IMP, PMID:12496369); GO_0046697 (EC: IEP, PMID:16720713); GO_0055074 (EC: IMP, PMID:9415400); GO_0070314 (EC: IMP, PMID:12496369); GO_0070564 (EC: IDA, PMID:16549446)",,,,,,,,,PMID:1662663; 1690216; 1971995; 9282826; 9295274; 9333115; 9344864; 9415400; 9428799; 9486994; 9837822; 10320521; 10359826; 10566658; 11799066; 12039697; 12050193; 12050281; 12107095; 12137802; 12161526; 12386916; 12457456; 12477932; 12496369; 12520522; 12746631; 12855575; 14671156; 15225751; 15243130; 15296474; 15331405; 15342556; 15583024; 15589699; 15795327; 15934135; 15947108; 15951480; 15956353; 16061850; 16549446; 16720713; 17023519; 17079137; 17207990; 17207994; 17223345; 17236759; 17250953; 17254772; 17267208; 17287116; 17368179; 17395559; 17395703; 17426122; 17488797; 17606874; 17878529; 17932346; 18476984; 18495603; 18676680; 18689381; 18767073; 18767934; 18768522; 18843020; 19064572; 19154546; 19170196; 19219539; 19255064; 19343046; 19453261; 19454612; 19505920; 19524013; 19525955; 19625176; 19667158; 19706847; 19783860; 19852851; 19891555; 19913121; 19951419; 19966181; 19998245; 20007432; 20082271; 20152900; 20304056; 20453000; 20518841; 20534770; 20619365; 20628086; 20648053; 20654748; 20687218; 20701904; 20809279; 20831823; 20847308; 20877624; 21107545; 21145801; 21440908; 21441443; 21542014; 21833088; 21869486; 22190362; 22326730; 22443290; 22446158; 22511602; 22516854; 22547098; 22588163; 22612324; 22963605; 22995334; 23045480; 23063903; 23149444; 23286944; 23334593; 23423976; 23444327; 23483640; 23614044; 23894780; 24308945,,,,,,,,,,,,,,,OGG:3000001594,,,,,,,"cytochrome P450, family 27, subfamily B, polypeptide 1",,,,,,,,,,,,,"Other designations: 1alpha(OH)ase|25 hydroxyvitamin D3-1-alpha hydroxylase|25-OHD-1 alpha-hydroxylase|25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial|VD3 1A hydroxylase|calcidiol 1-monooxygenase|cytochrome P450 subfamily XXVIIB polypeptide 1|cytochrome P450C1 alpha|cytochrome P450VD1-alpha|cytochrome p450 27B1",,CYP27B1,,,,,,,,,,,,,,,,,,,,,,,1594,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP27B1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/UBERON_0001630,muscle organ,muscle,Organ consisting of a tissue made up of various elongated cells that are specialized to contract and thus to produce movement and mechanical work[GO].,false,,,http://purl.obolibrary.org/obo/UBERON_0000062,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002385,,,,http://www.snomedbrowser.com/Codes/Details/71616004|MA:0000015|ZFA:0005145|VHOG:0001245|AAO:0011066|galen:Muscle|OpenCyc:Mx4rv2kf-5wpEbGdrcN5Y29ycA|FMA:5022|XAO:0000172|EV:0100146|GAID:131|TAO:0005145|EMAPA:32715,,Organ consisting of a tissue made up of various elongated cells that are specialized to contract and thus to produce movement and mechanical work[GO].,,,,,,,,Portion of tissue composed of contractile fibers.[TAO],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"It seems clear that the metazoan ancestor inherited from its unicellular descendants an actin cytoskeleton and motor-proteins of the myosin superfamily. Within metazoans, these two molecules were arranged into effective contractile units, the muscles. The basic trends for muscle evolution are already expressed in the diploblastic taxa.[well established][VHOG]",,UBERON:0001630,,,,,,,,,,,,,,,,muscle,,,,,,muscle organ,,,,,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0001637,artery,arterial system|arterial vessel|arterial subtree|arteries|arterial tree organ part,An epithelial tube or tree of tibes that transports blood away from the heart[modified from AEO definition].,false,,,http://purl.obolibrary.org/obo/UBERON_0003509,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C12372|http://www.snomedbrowser.com/Codes/Details/362877004|http://en.wikipedia.org/wiki/Artery|http://linkedlifedata.com/resource/umls/id/C0003842|MA:0000064|XAO:0000114|VHOG:0001251|BTO:0000573|MIAA:0000034|EHDAA2:0003253|EHDAA2:0000143|EV:0100026|TAO:0000005|OpenCyc:Mx4rvVjknZwpEbGdrcN5Y29ycA|CALOHA:TS-0054|AAO:0010211|MESH:D001158|EFO:0000814|AEO:0000208|FMA:50720|UMLS:C0003842|MAT:0000034|galen:Artery|ZFA:0000005|GAID:468|EMAPA:35147,,An epithelial tube or tree of tibes that transports blood away from the heart[modified from AEO definition].,,,,"Note that in FMA an artery is a tree, whereas AEO/JB defines it as a tube; FMA includes a separate class for what it calls the trunk. Classification in this ontology may currently (Jan 2012) represent a mix of both schemes, although we are gradually revising in the direction of the AEO scheme.",,,,Part of the circulatory system composed of blood vessels which carry oxygenated blood away from the heart to the rest of the body.[AAO],,,http://purl.obolibrary.org/obo/FMA_63812,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,arterial subtree|arteries|arterial tree organ part,,arterial system|arterial vessel,"The appearance of Chordata and subsequently the vertebrates is accompanied by a rapid structural diversification of this primitive linear heart: looping, unidirectional circulation, an enclosed vasculature, and the conduction system.[well established][VHOG]",http://purl.obolibrary.org/obo/UBERON_0004572,UBERON:0001637,http://purl.obolibrary.org/obo/UBERON_0004572,,,,,,,,,,,,,,,,,,,,,artery,,,,,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0001638,vein,venae|vascular element|vena|venous vessel|venous subtree|venous tree organ part,Any of the tubular branching vessels that carry blood from the capillaries toward the heart.,false,,,http://purl.obolibrary.org/obo/UBERON_0003920,,,,,,,,,,,,,,,,,,,,http://www.snomedbrowser.com/Codes/Details/181367001|http://linkedlifedata.com/resource/umls/id/C0042449|http://purl.obolibrary.org/obo/NCIT_C12814|http://en.wikipedia.org/wiki/Vein|BTO:0000234|UMLS:C0042449|MA:0000067|OpenCyc:Mx4rvVjkWpwpEbGdrcN5Y29ycA|EFO:0000816|VHOG:0001743|TAO:0000082|MAT:0000037|FMA:50723|EMAPA:35906|ZFA:0000082|MIAA:0000037|CALOHA:TS-1108|EHDAA2:0003254|EV:0100031|MESH:D014680|AEO:0000209|XAO:0000115|AAO:0010212|GAID:492|galen:Vein,,Any of the tubular branching vessels that carry blood from the capillaries toward the heart.,,,,TODO - check with MA - vein vs venous blood vessel,,,,"Part of the circulatory system composed of blood vessels which carry blood from other organs, tissues, and cells to the heart.[AAO]",,,http://purl.obolibrary.org/obo/FMA_63814,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,venous tree organ part,,venae|vascular element|vena,"The appearance of Chordata and subsequently the vertebrates is accompanied by a rapid structural diversification of this primitive linear heart: looping, unidirectional circulation, an enclosed vasculature, and the conduction system.[well established][VHOG]",,UBERON:0001638,,,,,,,,,,,,,,,,venous vessel|venous subtree,,,,,,vein,,,,http://upload.wikimedia.org/wikipedia/commons/c/c2/Venous_system_en.svg,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002039,oxidative phosphorylation uncoupling [mitochondrial disorder],,"Enables the transfer of protons from mitochondrial intermembrane space into mitochondrial matrix, dissipating the proton gradient across the mitochondrial inner membrane established by the electron transport chain during the oxidative phosphorylation (proton leak). Proton leak uncouples the processes of electron transport/proton generation and ATP synthesis.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0004133|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:25339807|PMID:21145849,,"Enables the transfer of protons from mitochondrial intermembrane space into mitochondrial matrix, dissipating the proton gradient across the mitochondrial inner membrane established by the electron transport chain during the oxidative phosphorylation (proton leak). Proton leak uncouples the processes of electron transport/proton generation and ATP synthesis.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004332|http://purl.obolibrary.org/obo/TXPO_0004333|http://purl.obolibrary.org/obo/TXPO_0004335|http://purl.obolibrary.org/obo/TXPO_0004330|http://purl.obolibrary.org/obo/TXPO_0004339|http://purl.obolibrary.org/obo/TXPO_0004362|http://purl.obolibrary.org/obo/TXPO_0004365|http://purl.obolibrary.org/obo/TXPO_0004353|http://purl.obolibrary.org/obo/TXPO_0004354|http://purl.obolibrary.org/obo/TXPO_0004352,,,,,,,,,,,,,,,,,TXPO:0002039,,,,,,,,,,,,,,,,,,,,,,oxidative phosphorylation uncoupling [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002038,leaking proton ion [Mitochondrial disorder],,"Leaking proton ion is a subtype of leaking: A process that leaks the proton from the mitochondria.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0002341|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,,,"Leaking proton ion is a subtype of leaking: A process that leaks the proton from the mitochondria.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_24636,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002038,,,,,,,,,,,,,,,,,,,,,,leaking proton ion [Mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002032,GSTA2 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0002089,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:2939|NCBI-Rat-GeneID:501110,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002032,,,,,,,,,,,,,,,,,,,,,,GSTA2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002030,pergexiline -mitochondrial respiratory chain inhibitor [lipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002013,,,,,,,,,,,,,,,,,,,,Wikipedia:Perhexiline|PMID:21145849|DrugBank:DB01074,,,,,,,,,,,,,,C19H35N,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_25355,,,,,,,,,,TXPO:0002030,,,,,,,,,,,,,,,,,,,,,,pergexiline -mitochondrial respiratory chain inhibitor [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,C1CCC(CC1)C(CC1CCCCN1)C1CCCCC1,,,,,
http://purl.obolibrary.org/obo/TXPO_0002031,oxidative phosphorylation inhibitor role,,A role played by the entity which negative regulates the oxidative phosphorylation.,false,,,http://purl.obolibrary.org/obo/TXPO_0004023,,,,,,,http://purl.obolibrary.org/obo/GO_0006119,,,,,,,,,,,,,,,A role played by the entity which negative regulates the oxidative phosphorylation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002031,,,,,,,,,,,,,,,,,,,,,,oxidative phosphorylation inhibitor role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002035,ibuprofen [lipidosis],,,false,,,http://purl.obolibrary.org/obo/CHEBI_5855|http://purl.obolibrary.org/obo/TXPO_0003508,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002035,,,,,,,,,,,,,,,,,,,,,,ibuprofen [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002033,diabetes course,,The totality of all processes through which a given diabetes instance is realized.,false,,,http://purl.obolibrary.org/obo/OGMS_0000063,,,,,,,,,,,,,,,,,,,,,,The totality of all processes through which a given diabetes instance is realized.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003289|http://purl.obolibrary.org/obo/TXPO_0003290,,,,,,,,,,,,,,,,,,TXPO:0002033,,,,,,,,,,,,,,,,,,,,,,diabetes course,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/DOID_9351,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002037,glutathione conjuation regulating agent role,,A role played by the entity which regulates the glutathione conjugation.,false,,,http://purl.obolibrary.org/obo/TXPO_0004023,,,,,,,,,,,,,,,,,,,,,,A role played by the entity which regulates the glutathione conjugation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002037,,,,,,,,,,,,,,,,,,,,,,glutathione conjuation regulating agent role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002036,ibuprofen - oxidative phosphorylation inhibitor [lipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002035,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002031,,,,,,,,,,TXPO:0002036,,,,,,,,,,,,,,,,,,,,,,ibuprofen - oxidative phosphorylation inhibitor [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002034,hypofunction of electron transport coupled proton transport,,Hypofunction of electron transport coupled proton transport is a subtype of hypofunction of ion transport: A process that performs a decreased or insufficient electron transport coupled proton transport.,false,,,http://purl.obolibrary.org/obo/TXPO_0000495,,,,,,,,,,,,,,,,,,,,,,Hypofunction of electron transport coupled proton transport is a subtype of hypofunction of ion transport: A process that performs a decreased or insufficient electron transport coupled proton transport.,,,http://purl.obolibrary.org/obo/GO_0015990,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002034,,,,,,,,,,,,,,,,,,,,,,hypofunction of electron transport coupled proton transport,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000319118,EIF4BP1,,,false,,,http://purl.obolibrary.org/obo/OGG_2070009606,,EIF4BP,,,,,,,,,,,,14,,,,,,HGNC:19929,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,eukaryotic translation initiation factor 4B pseudogene 1,,,14q21.2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,OGG:3000319118,,,,,,,eukaryotic translation initiation factor 4B pseudogene 1,,,,,,,,,,,,,,,EIF4BP1,,,,,,,,,,,,,,,,,,,,,,,319118,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,EIF4BP1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_100241,ciprofloxacin,"1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid|1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-quinoline-3-carboxylic acid|1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid|ciprofloxacine|ciprofloxacin|1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid|1-CYCLOPROPYL-6-FLUORO-4-OXO-7-PIPERAZIN-1-YL-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID|1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid|1-Cyclopropyl-6-fluoro-7-(4-methyl-piperazin-1-yl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid|ciprofloxacinum|ciprofloxacino|1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid|ciprofloxacin|Ciprofloxacin","A  quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Reaxys:3568352|DrugBank:DB00537|PMID:10737746|Beilstein:3568352|CAS:85721-33-1|PMID:10397494|Drug_Central:659|LINCS:LSM-5226,,"A  quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35441|http://purl.obolibrary.org/obo/CHEBI_59517|http://purl.obolibrary.org/obo/CHEBI_50750|http://purl.obolibrary.org/obo/CHEBI_35703|http://purl.obolibrary.org/obo/CHEBI_33281|http://purl.obolibrary.org/obo/CHEBI_36047|http://purl.obolibrary.org/obo/CHEBI_53559|http://purl.obolibrary.org/obo/CHEBI_78298,,,,,"1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid|ciprofloxacin|Ciprofloxacin",,"1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid|1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-quinoline-3-carboxylic acid|1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid|ciprofloxacine|ciprofloxacin|1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid|1-CYCLOPROPYL-6-FLUORO-4-OXO-7-PIPERAZIN-1-YL-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID|1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid|1-Cyclopropyl-6-fluoro-7-(4-methyl-piperazin-1-yl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid|ciprofloxacinum|ciprofloxacino",,,,,,,,,,,,,,,,,,,,,CHEBI:100241,,,,ciprofloxacin,,CHEBI:100241,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000023753,SDF2L1,,Other designations: OTTHUMT00000075032|PWP1-interacting protein 8|SDF2-like 1|SDF2-like protein 1|dihydropyrimidinase-like 2|stromal cell-derived factor 2-like protein 1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,22,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,stromal cell-derived factor 2-like 1,,,22q11.21,,,,,,,,,,,,,,,,GO_0005788 (EC: IEA); GO_0016020 (EC: IEA),,,,,,,,,PMID: 10591208; 11162531; 12477932; 12975309; 15461802; 15489334; 16396496; 18781797; 19710015; 20811636; 21139048; 21145461; 22190034; 22268729; 22863883; 23444373; 24457600,,,,,,,,,,,,,,,OGG:3000023753,,,,,,,stromal cell-derived factor 2-like 1,,,,,,,,,,,,,Other designations: OTTHUMT00000075032|PWP1-interacting protein 8|SDF2-like 1|SDF2-like protein 1|dihydropyrimidinase-like 2|stromal cell-derived factor 2-like protein 1,,SDF2L1,,,,,,,,,,,,,,,,,,,,,,,23753,UNQ1941/PRO4424,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,SDF2L1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0004116,SPON2(human) - immune responsor[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001789,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:10417|https://omim.org/entry/605918|PMID:29440144,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000010417,,,http://purl.obolibrary.org/obo/TXPO_0002284,,,,,,,,,,TXPO:0004116,,,,,,,,,,,,,,,,,,,,,,SPON2(human) - immune responsor[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004113,macrophage migration [Phospholipidosis],,"The orderly movement of a macrophage from one site to another.
This entity is a specific course-dependent process. This process can constitute the course of phospholipidosis.",false,,,http://purl.obolibrary.org/obo/GO_1905517|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"The orderly movement of a macrophage from one site to another.
This entity is a specific course-dependent process. This process can constitute the course of phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004116|http://purl.obolibrary.org/obo/TXPO_0004112,,,,,,http://purl.obolibrary.org/obo/TXPO_0001257|http://purl.obolibrary.org/obo/TXPO_0000156,,,,,,,,,,,TXPO:0004113,,,,,,,,,,,,,,,,,,,,,,macrophage migration [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004112,SPON2(predicted)(human)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001135|http://purl.obolibrary.org/obo/TXPO_0003834,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:10417|PMID:30318967|https://omim.org/entry/605918|PMID:29440144,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000010417,,,,,,,,,,,,,TXPO:0004112,,,,,,,,,,,,,,,,,,,,,,SPON2(predicted)(human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004118,SULT1C2(human)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001135|http://purl.obolibrary.org/obo/TXPO_0003832,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:6819|PMID:26427720|PMID:30885913|https://omim.org/entry/602385,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000006819,,,,,,,,,,,,,TXPO:0004118,,,,,,,,,,,,,,,,,,,,,,SULT1C2(human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004115,tumor metastasis inhibitor,,A role played by the entity which negatively regulates the tumor metastasis.,false,,,http://purl.obolibrary.org/obo/TXPO_0003230,,,,,,,,,,,,,,,,,,,,,,A role played by the entity which negatively regulates the tumor metastasis.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004115,,,,,,,,,,,,,,,,,,,,,,tumor metastasis inhibitor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004111,lipid droplet formation [Phospholipidosis],adiposome formation,"A process that results in the assembly, arrangement of constituent parts of a lipid droplet.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0004110,,,,,,,,,,,,,,,,,,,,,,"A process that results in the assembly, arrangement of constituent parts of a lipid droplet.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004108|http://purl.obolibrary.org/obo/CHEBI_18059|http://purl.obolibrary.org/obo/TXPO_0001903,,,,,,,,,,,,adiposome formation,,,,,TXPO:0004111,,,,,,,,,,,,,,,,,,,,,,lipid droplet formation [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004110,lipid droplet formation,adiposome formation,"A process that results in the assembly, arrangement of constituent parts of a lipid droplet.",false,,,http://purl.obolibrary.org/obo/GO_0034389,,,,,,,,,,,,,,,,,,,,,,"A process that results in the assembly, arrangement of constituent parts of a lipid droplet.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_18059,,,,,,,,,,,,adiposome formation,,,,,TXPO:0004110,,,,,,,,,,,,,,,,,,,,,,lipid droplet formation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004117,hyperfunction of drug metabolism phase II [Phospholipidosis],,"Hyperfunction of drug metabolism phase II is a subtype of hyperfunction of drug metabolism: A process that performs an excessive drug metabolism phase II.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0001236,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of drug metabolism phase II is a subtype of hyperfunction of drug metabolism: A process that performs an excessive drug metabolism phase II.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000078|http://purl.obolibrary.org/obo/TXPO_0004118,,,,,,,,,,,,,,,,,TXPO:0004117,,,,,,,,,,,,,,,,,,,,,,hyperfunction of drug metabolism phase II [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004119,"negative regulation of mitochondrial electron transport, succinate to ubiquinone [Mitochondrial disorder]",,"Any process that stops, prevents or reduces the frequency, rate or extent of the transfer of electrons from succinate to ubiquinone.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0004099,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents or reduces the frequency, rate or extent of the transfer of electrons from succinate to ubiquinone.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004119,,,,,,,,,,,,,,,,,,,,,,"negative regulation of mitochondrial electron transport, succinate to ubiquinone [Mitochondrial disorder]",,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006121,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004114,SPON2(human) - tumor metastasis inhibitor[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001789,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:10417|PMID:30318967|https://omim.org/entry/605918|PMID:29440144|PMID:24445216,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000010417,,,http://purl.obolibrary.org/obo/TXPO_0004115,,,,,,,,,,TXPO:0004114,,,,,,,,,,,,,,,,,,,,,,SPON2(human) - tumor metastasis inhibitor[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0200459,L-Aspartic acid,,,false,,,http://purl.obolibrary.org/obo/CHEBI_33709,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0200459,,,,,,,,,,,,,,,,,,,,,,L-Aspartic acid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001579,Rab8A,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001579,,,,,,,,,,,,,,,,,,,,,,Rab8A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_17931,N-hydroxy-2-acetamidofluorene,N-(9H-fluoren-2-yl)-N-hydroxyacetamide|N-hydroxy-2-acetylaminofluorene|N-OH-AAF,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:53-95-2,,,,,,,,,,,,,,C15H13NO2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,N-(9H-fluoren-2-yl)-N-hydroxyacetamide|N-hydroxy-2-acetylaminofluorene|N-OH-AAF,,,,,CHEBI:17931,,,,,,,,,,,,,,,,,,,,,,N-hydroxy-2-acetamidofluorene,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CC(=O)N(O)c1ccc-2c(Cc3ccccc-23)c1,,,,,
http://purl.obolibrary.org/obo/IMR_0100590,PI3-kinase p85-beta subunit,PtdIns-3-kinase p85-beta|Phosphatidylinositol 3-kinase regulatory beta subunit,,false,,,http://purl.obolibrary.org/obo/IMR_0000266,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0010393,PtdIns-3-kinase p85-beta|Phosphatidylinositol 3-kinase regulatory beta subunit,,,,,IMR:0100590,,,,,,,,,,,,,,,,,,,,,,PI3-kinase p85-beta subunit,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000598,IL-16,lymphocyte chemoattractant factor|LCF|interleukin-16,,false,,,http://purl.obolibrary.org/obo/IMR_0000007,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000622,,,,,lymphocyte chemoattractant factor|LCF|interleukin-16,,,,,IMR:0000598,,,,,,,,,,,,,,,,,,,,,,IL-16,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000974,NAPQI [Glutathione depletion],"N-acetyl-1,4-benzoquinone imine [Glutathione depletion]|N-(4-oxocyclohexa-2,5-dien-1-ylidene)acetamide [Glutathione depletion]",A ketoimine that has formula C8H7NO2.|CHEBI:29132,false,,,http://purl.obolibrary.org/obo/TXPO_0001921|http://purl.obolibrary.org/obo/CHEBI_29132,,,,,,,,,,,,,,,,,,,,PMID:21177773|http://www.reactome.org/cgi-bin/eventbrowser_st_id?ST_ID=R-HSA-76397|PMID:10741631,,A ketoimine that has formula C8H7NO2.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_59739,,,,,"N-acetyl-1,4-benzoquinone imine [Glutathione depletion]|N-(4-oxocyclohexa-2,5-dien-1-ylidene)acetamide [Glutathione depletion]",,,,,TXPO:0000974,,,,,,,,,,,,,,,,,,,,CHEBI:29132,,NAPQI [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000976,phenobarbital - apotosis inhibitor [Ground glass appearance],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001524,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_68494,,,,,,,,,,TXPO:0000976,,,,,,,,,,,,,,,,,,,,,,phenobarbital - apotosis inhibitor [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000977,glucose homeostasis imbalance [Ground glass appearance],,"Glucose homeostasis imbalance is a subtype of chemical homeostasis imbalance: A process that becomes lacking a glucose homeostastasis balance.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/TXPO_0001233,,,,,,,,,,,,,,,,,,,,,,"Glucose homeostasis imbalance is a subtype of chemical homeostasis imbalance: A process that becomes lacking a glucose homeostastasis balance.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001001,,,,,,,,,,,,,,,,,TXPO:0000977,,,,,,,,,,,,,,,,,,,,,,glucose homeostasis imbalance [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000975,GADD45B (canonical)[Ground glass appearance],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000472|http://purl.obolibrary.org/obo/TXPO_1000160,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:17873|NCBI-Human-GeneID:4616|NCBI-Rat-GeneID:299626,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_68494,,,,,,,,,,TXPO:0000975,,,,,,,,,,,,,,,,,,,,,,GADD45B (canonical)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000970,hepatocyte proliferation [Ground glass appearance],,"A process that results in an increase in hepatic cell number by cell division, often leading to an increase in the size of an liver.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/GO_0072574,,,,,,,,,,,,,,,,,,,,PMID:21822615,,"A process that results in an increase in hepatic cell number by cell division, often leading to an increase in the size of an liver.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000986,,,,,,http://purl.obolibrary.org/obo/TXPO_0000972|http://purl.obolibrary.org/obo/TXPO_0000973,,,,,,,,,,,TXPO:0000970,,,,,,,,,,,,,,,,,,,,,,hepatocyte proliferation [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000972,increasing liver weight [Ground glass appearance],,"Increasing liver weight is a subtype of increasing weight: A process that changes the weight of the liver to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0000054|http://purl.obolibrary.org/obo/TXPO_0001728,,,,,,,,,,,,,,,,,,,,,,"Increasing liver weight is a subtype of increasing weight: A process that changes the weight of the liver to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000972,,,,,,,,,,,,,,,,,,,,,,increasing liver weight [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000971,increasing hepatic vascular lumen area [Ground glass appearance],,"Increasing hepatic vascular lumen area is a subtype of increasing area: A process that changes the area of the hepatic vascular lumen area to be larger.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/TXPO_0001229,,,,,,,,,,,,,,,,,,,,,,"Increasing hepatic vascular lumen area is a subtype of increasing area: A process that changes the area of the hepatic vascular lumen area to be larger.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000973,,,,,,,,,,,TXPO:0000971,,,,,,,,,,,,,,,,,,,,,,increasing hepatic vascular lumen area [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000978,hypoxia [Ground glass appearance],,"reduced oxygenation of body tissues resulting in the decreased pressure of this component of body gases; commonly due to hypoxemia
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/MP_0005039,,,,,,,,,,,,,,,,,,,,,,"reduced oxygenation of body tissues resulting in the decreased pressure of this component of body gases; commonly due to hypoxemia
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001008,,,,,,http://purl.obolibrary.org/obo/TXPO_0002319,,,,,,,,,,,TXPO:0000978,,,,,,,,,,,,,,,,,,,,,,hypoxia [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000979,CYP2B6 (human)[Ground glass appearance],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001009|http://purl.obolibrary.org/obo/TXPO_1000078,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1555|ISBN:0071769234,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000979,,,,,,,,,,,,,,,,,,,,,,CYP2B6 (human)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000795,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000973,increasing volume of liver [Ground glass appearance],,"Increasing volume of liver is a subtype of increasing volume: A process that changes the volume of the liver to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0000616|http://purl.obolibrary.org/obo/TXPO_0001728,,,,,,,,,,,,,,,,,,,,,,"Increasing volume of liver is a subtype of increasing volume: A process that changes the volume of the liver to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000986,,,,,,,,,,,,,,,,,TXPO:0000973,,,,,,,,,,,,,,,,,,,,,,increasing volume of liver [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_16236,ethanol,,A primary alcohol that is ethane in which one of the hydrogens is substituted by a hydroxy group.,false,,,http://purl.obolibrary.org/obo/CHEBI_30879,,,,,,,,,,,,,,,,,,,,,,A primary alcohol that is ethane in which one of the hydrogens is substituted by a hydroxy group.,,,,,,,,,,,,C2H6O,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:16236,,,,,,,,,,,,,,,,,,,,,,ethanol,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CCO,,,,,
http://purl.obolibrary.org/obo/IMR_0100543,CaMK,Ca2+/calmodulin-dependent protein kinase|CaM-kinase,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,GO:0004685,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001966,,,,,Ca2+/calmodulin-dependent protein kinase|CaM-kinase,,,,,IMR:0100543,,,,,,,,,,,,,,,,,,,,,,CaMK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76858,"EC 1.3.98.* (oxidoreductase acting on donor CH-CH group, with other, known, acceptors) inhibitor","EC 1.3.98.* inhibitors|EC 1.3.98.* inhibitor|EC 1.3.98.* (oxidoreductase acting on donor CH-CH group, with other, known, acceptors) inhibitors|oxidoreductase acting on CH-CH group of donors, with other, known, acceptors (EC 1.3.98.*) inhibitor|EC 1.3.98.* (oxidoreductase acting on CH-CH group of donors, with other, known, acceptors) inhibitors|EC 1.3.98.* (oxidoreductase acting on CH-CH group of donors, with other, known, acceptors) inhibitor|oxidoreductase acting on CH-CH group of donors, with other, known, acceptors (EC 1.3.98.*) inhibitors","An EC 1.3.* (oxidoreductase acting on donor CH-CH group) inhibitor that interferes with the function of any such enzyme in the EC 1.3.98.* (with other, known, acceptors) category.",false,,,http://purl.obolibrary.org/obo/CHEBI_76729,,,,,,,,,,,,,,,,,,,,,,"An EC 1.3.* (oxidoreductase acting on donor CH-CH group) inhibitor that interferes with the function of any such enzyme in the EC 1.3.98.* (with other, known, acceptors) category.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"EC 1.3.98.* inhibitors|EC 1.3.98.* inhibitor|EC 1.3.98.* (oxidoreductase acting on donor CH-CH group, with other, known, acceptors) inhibitors|oxidoreductase acting on CH-CH group of donors, with other, known, acceptors (EC 1.3.98.*) inhibitor|EC 1.3.98.* (oxidoreductase acting on CH-CH group of donors, with other, known, acceptors) inhibitors|EC 1.3.98.* (oxidoreductase acting on CH-CH group of donors, with other, known, acceptors) inhibitor|oxidoreductase acting on CH-CH group of donors, with other, known, acceptors (EC 1.3.98.*) inhibitors",,,,,,,,,,,,,,,,,,,,,CHEBI:76858,,,,"EC 1.3.98.* (oxidoreductase acting on donor CH-CH group, with other, known, acceptors) inhibitor",,CHEBI:76858,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000245,decreasing contact area with ECM,,Decreasing contact area with ECM is a subtype of decreasing area: A process that changes the contact area with extracellular matrix (ECM) to be smaller.,false,,,http://purl.obolibrary.org/obo/TXPO_0000242,,,,,,,,,,,,,,,,,,,,,,Decreasing contact area with ECM is a subtype of decreasing area: A process that changes the contact area with extracellular matrix (ECM) to be smaller.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000245,,,,,,,,,,,,,,,,,,,,,,decreasing contact area with ECM,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000241,hypofunction of keeping structure [Cell death],,"Hypofunction of keeping structure is a subtype of hypofunctioning: A process that performs a decreased or insufficient keeping structure.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0001727|http://purl.obolibrary.org/obo/TXPO_0000240,,,,,,,,,,,,,,,,,,,,,,"Hypofunction of keeping structure is a subtype of hypofunctioning: A process that performs a decreased or insufficient keeping structure.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000241,,,,,,,,,,,,,,,,,,,,,,hypofunction of keeping structure [Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000248,protein accumulation,,Protein accumulation is a subtype of accumulation of substances in a biological object: A process that keeps protein(s) in a biological object.,false,,,http://purl.obolibrary.org/obo/TXPO_0000247,,,,,,,,,,,,,,,,,,,,,,Protein accumulation is a subtype of accumulation of substances in a biological object: A process that keeps protein(s) in a biological object.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_36080,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000248,,,,,,,,,,,,,,,,,,,,,,protein accumulation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000246,decreasing contact area with ECM [Cell death],,"Decreasing contact area with ECM is a subtype of decreasing area: A process that changes the contact area with extracellular matrix (ECM) to be smaller.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0001727|http://purl.obolibrary.org/obo/TXPO_0000245,,,,,,,,,,,,,,,,,,,,,,"Decreasing contact area with ECM is a subtype of decreasing area: A process that changes the contact area with extracellular matrix (ECM) to be smaller.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002122|http://purl.obolibrary.org/obo/TXPO_0000512,,,,,,,,,,,TXPO:0000246,,,,,,,,,,,,,,,,,,,,,,decreasing contact area with ECM [Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000240,hypofunction of keeping structure,,Hypofunction of keeping structure is a subtype of hypofunctioning: A process that performs a decreased or insufficient keeping structure.,false,,,http://purl.obolibrary.org/obo/TXPO_0000436,,,,,,,,,,,,,,,,,,,,,,Hypofunction of keeping structure is a subtype of hypofunctioning: A process that performs a decreased or insufficient keeping structure.,,,http://purl.obolibrary.org/obo/TXPO_0003733,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000240,,,,,,,,,,,,,,,,,,,,,,hypofunction of keeping structure,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000243,decreasing volume,,Decreasing volume is a subtype of changing volume: A process that changes the volume of the object to be relatively low,false,,,http://purl.obolibrary.org/obo/TXPO_0000220|http://purl.obolibrary.org/obo/TXPO_0000417,,,,,,,,,,,,,,,,,,,,,,Decreasing volume is a subtype of changing volume: A process that changes the volume of the object to be relatively low,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000243,,,,,,,,,,,,,,,,,,,,,,decreasing volume,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0000596,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000242,decreasing area,,Decreasing area is a subtype of changing area: A process that changes the area of the object to be smaller.,false,,,http://purl.obolibrary.org/obo/TXPO_0000544,,,,,,,,,,,,,,,,,,,,,,Decreasing area is a subtype of changing area: A process that changes the area of the object to be smaller.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000242,,,,,,,,,,,,,,,,,,,,,,decreasing area,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0002058,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000249,increasing sensitivity,,Increasing sensitivity is a subtype of changing sensitivity: A process that changes the sensitivity to be lhigher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000015,,,,,,,,,,,,,,,,,,,,,,Increasing sensitivity is a subtype of changing sensitivity: A process that changes the sensitivity to be lhigher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000249,,,,,,,,,,,,,,,,,,,,,,increasing sensitivity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000247,accumulation of substances in a biological object,,"Accumulation of substances in a biological object is a subtype of storing: A process that keeps substances in an organism, tissue, organelle, or cell.|related quality http://purl.obolibrary.org/obo/PATO_0002269",false,,,http://purl.obolibrary.org/obo/TXPO_0000601,,,,,,,,,,,,,,,,,,,,,,"Accumulation of substances in a biological object is a subtype of storing: A process that keeps substances in an organism, tissue, organelle, or cell.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000247,,,,,,,,,,,,,,,,,,,,related quality http://purl.obolibrary.org/obo/PATO_0002269,,accumulation of substances in a biological object,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0001062,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000244,decreasing length,,Decreasing length is a subtype of changing length: A process that changes the length of the object to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000552,,,,,,,,,,,,,,,,,,,,,,Decreasing length is a subtype of changing length: A process that changes the length of the object to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000244,,,,,,,,,,,,,,,,,,,,,,decreasing length,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0000574,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000229,GSTA3 (canonical)[Glutathione depletion],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000179|http://purl.obolibrary.org/obo/TXPO_0002045,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:14859|NCBI-Rat-GeneID:494500|NCBI-Human-GeneID:2940,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000229,,,,,,,,,,,,,,,,,,,,,,GSTA3 (canonical)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000228,GSTM3 (canonical)[Glutathione depletion],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002045|http://purl.obolibrary.org/obo/TXPO_1000180,,,,,,,,,,,,,,,,,,,"Six proteins were regulated at both basal and inducible levels exhibiting the largest dynamic range of Nrf2 regulation: cytochrome P4502A5 (CYP2A5; 17.2-fold), glutathione-S-transferase-Mu 3 (GSTM3; 6.4-fold), glutathione-S-transferase Mu 1 (GSTM1; 5.9-fold), ectonucleoside-triphosphate diphosphohydrolase (ENTPD5; 4.6-fold), UDP-glucose-6-dehydrogenase (UDPGDH; 4.1-fold) and epoxide hydrolase (EPHX1; 3.0-fold). These proteins, or their products, thus provide a potential source of biomarkers for Nrf2 activity.",NCBI-Mouse-GeneID:14864|NCBI-Rat-GeneID:108348148|NCBI-Human-GeneID:2947|PMID:22496397|PMID:25202346,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000228,,,,,,,,,,,,,,,,,,,,,,GSTM3 (canonical)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000224,TIMP1 production [Fibrosis],,"TIMP1 production is a subtype of protein production: A process that makes existent of a TIMP1 protein due to biosynthesis or secretion resulting in an increase in its levels.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003742|http://purl.obolibrary.org/obo/TXPO_0000152,,,,,,,,,,,,,,,,,,,,,,"TIMP1 production is a subtype of protein production: A process that makes existent of a TIMP1 protein due to biosynthesis or secretion resulting in an increase in its levels.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003062,,,,,,,,,,,,,,,,,,,TXPO:0000224,,,,,,,,,,,,,,,,,,,,,,TIMP1 production [Fibrosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000223,DNA damage [Cell death],,"Drug-, radiation-induced, or spontaneous injuries to DNA that introduce deviations from its normal double-helical conformation. These changes include structural distortions that interfere with replication and transcription, as well as point mutations that disrupt base pairs and exert damaging effects on future generations through changes in DNA sequence. If the damage is minor, it can often be repaired (DNA repair); extensive damage can induce apoptosis.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0001727|http://purl.obolibrary.org/obo/NCIT_C16507,,,,,,,,,,,,,,,,,,,,,,"Drug-, radiation-induced, or spontaneous injuries to DNA that introduce deviations from its normal double-helical conformation. These changes include structural distortions that interfere with replication and transcription, as well as point mutations that disrupt base pairs and exert damaging effects on future generations through changes in DNA sequence. If the damage is minor, it can often be repaired (DNA repair); extensive damage can induce apoptosis.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000641,,,,,,http://purl.obolibrary.org/obo/TXPO_0000234|http://purl.obolibrary.org/obo/TXPO_0000453,,,,,,,,,,,TXPO:0000223,,,,,,,,,,,,,,,,,,,,,,DNA damage [Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000227,cytoskeleton damage,,Cytoskeleton damage is a subtype of cellular damage: A process that injuries the structure of the cytoskeleton as the direct or indirect result of an external force.,false,,,http://purl.obolibrary.org/obo/TXPO_0000225,,,,,,,,,,,,,,,,,,,,,,Cytoskeleton damage is a subtype of cellular damage: A process that injuries the structure of the cytoskeleton as the direct or indirect result of an external force.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000227,,,,,,,,,,,,,,,,,,,,,,cytoskeleton damage,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000221,hepatocellular atrophy,,Hepatocellular atrophy is a subtype of decreasing volume: A process that changes the volume of the hepatocyte to be relatively low.,false,,,http://purl.obolibrary.org/obo/TXPO_0000243,,,,,,,,,,,,,,,,,,,,,,Hepatocellular atrophy is a subtype of decreasing volume: A process that changes the volume of the hepatocyte to be relatively low.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000221,,,,,,,,,,,,,,,,,,,,,,hepatocellular atrophy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000226,cellular damage [Cell death],,"Cellular damage is a subtype of damaging: A process that injuries the structure of the cell as the direct or indirect result of an external force.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0001727|http://purl.obolibrary.org/obo/TXPO_0000225,,,,,,,,,,,,,,,,,,,,,,"Cellular damage is a subtype of damaging: A process that injuries the structure of the cell as the direct or indirect result of an external force.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000239|http://purl.obolibrary.org/obo/TXPO_0002129,,,,,,,,,,,TXPO:0000226,,,,,,,,,,,,,,,,,,,,,,cellular damage [Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000225,cellular damage,cell and tissue damage,Cellular damage is a subtype of damaging: A process that injuries the structure of the cell as the direct or indirect result of an external force.,false,,,http://purl.obolibrary.org/obo/TXPO_0000222,,,,,,,,,,,,,,,,,,,,"http://purl.jp/bio/4/id/200906069918862451|PMID:8703628|https://en.wikipedia.org/wiki/Cell_damage|Cell damage (also known as cell injury) is a variety or changes of stress that a cell suffers due to external as well internal environmental changes. Among other causes, this can be due to physical, chemical, infectious, biological, nutritional or immunological factors. Cell damage can be reversible or irreversible. Depending on the extent of injury, the cellular response may be adaptive and where possible, homeostasis is restored. Cell death occurs when the severity of the injury exceeds the cell’s ability to repair itself. Cell death is relative to both the length of exposure to a harmful stimulus and the severity of the damage caused. Cell death may occur by necrosis or apoptosis.",,Cellular damage is a subtype of damaging: A process that injuries the structure of the cell as the direct or indirect result of an external force.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000225,,,,,,,,,,,,,,,,cell and tissue damage,,,,,,cellular damage,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000222,damaging,,Damaging is a subtype of changing structure: A process that injuries the structure as the direct or indirect result of an external force.|injury http://purl.obolibrary.org/obo/OGMS_0000102,false,,,http://purl.obolibrary.org/obo/TXPO_0002566,,,,,,,,,,,,,,,,,,,,http://purl.bioontology.org/ontology/MESH/D014947,,Damaging is a subtype of changing structure: A process that injuries the structure as the direct or indirect result of an external force.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000222,,,,,,,,,,,,,,,,,,,,injury http://purl.obolibrary.org/obo/OGMS_0000102,,damaging,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000220,deacreasing size,,Deacreasing size is a subtype of changing size: A process that changes the size of the object to be smaller.,false,,,http://purl.obolibrary.org/obo/TXPO_0002705,,,,,,,,,,,,,,,,,,,,,,Deacreasing size is a subtype of changing size: A process that changes the size of the object to be smaller.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000220,,,,,,,,,,,,,,,,,,,,,,deacreasing size,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000076,ALK,anaplastic lymphoma kinase,,false,,,http://purl.obolibrary.org/obo/IMR_0000075,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,anaplastic lymphoma kinase,,,,,IMR:0000076,,,,,,,,,,,,,,,,,,,,,,ALK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CL_0000182,hepatocyte,,"The main structural component of the liver. They are specialized epithelial cells that are organized into interconnected plates called lobules. Majority of cell population of liver, polygonal in shape, arranged in plates or trabeculae between sinusoids; may have single nucleus or binucleated.",false,,,http://purl.obolibrary.org/obo/CL_0000066,,,,,,,,,,,,,,,,,,,,,,"The main structural component of the liver. They are specialized epithelial cells that are organized into interconnected plates called lobules. Majority of cell population of liver, polygonal in shape, arranged in plates or trabeculae between sinusoids; may have single nucleus or binucleated.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CL:0000182,,,,,,,,,,,,,,,,,,,,,,hepatocyte,,,,,,,http://purl.obolibrary.org/obo/cl.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000269,RIP,Receptor interacting protein|Receptor-interacting serine/threonine protein kinase,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001966,,,,,Receptor interacting protein|Receptor-interacting serine/threonine protein kinase,,,,,IMR:0000269,,,,,,,,,,,,,,,,,,,,,,RIP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0097707,feroptosis,,"A programmed cell death characterized morphologically by the presence of smaller than normal mitochondria with condensed mitochondrial membrane densities, reduction or vanishing of mitochondria crista, and outer mitochondrial membrane rupture. Activation of mitochondrial voltage-dependent anion channels and mitogen-activated protein kinases, upregulation of endoplasmic reticulum stress, and inhibition of cystine/glutamate antiporter are involved in the induction of ferroptosis. This process is characterized by the accumulation of lipid peroxidation products and lethal reactive oxygen species (ROS) derived from iron metabolism. Glutathione peroxidase 4 (GPX4), heat shock protein beta-1, and nuclear factor erythroid 2-related factor 2 function as negative regulators of ferroptosis by limiting ROS production and reducing cellular iron uptake, respectively. In contrast, NADPH oxidase and p53 act as positive regulators of ferroptosis by promotion of ROS production and inhibition of expression of SLC7A11 (a specific light-chain subunit of the cystine/glutamate antiporter), respectively. Misregulated ferroptosis has been implicated in multiple physiological and pathological processes.",false,,,http://purl.obolibrary.org/obo/GO_0008219,,,,,,,,,,,,,,,,,,,,pmid:25236395|pmid:26794443,,"A programmed cell death characterized morphologically by the presence of smaller than normal mitochondria with condensed mitochondrial membrane densities, reduction or vanishing of mitochondria crista, and outer mitochondrial membrane rupture. Activation of mitochondrial voltage-dependent anion channels and mitogen-activated protein kinases, upregulation of endoplasmic reticulum stress, and inhibition of cystine/glutamate antiporter are involved in the induction of ferroptosis. This process is characterized by the accumulation of lipid peroxidation products and lethal reactive oxygen species (ROS) derived from iron metabolism. Glutathione peroxidase 4 (GPX4), heat shock protein beta-1, and nuclear factor erythroid 2-related factor 2 function as negative regulators of ferroptosis by limiting ROS production and reducing cellular iron uptake, respectively. In contrast, NADPH oxidase and p53 act as positive regulators of ferroptosis by promotion of ROS production and inhibition of expression of SLC7A11 (a specific light-chain subunit of the cystine/glutamate antiporter), respectively. Misregulated ferroptosis has been implicated in multiple physiological and pathological processes.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0097707,,,,,,,,,,,,,,,,,,,,,,feroptosis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000820,c-Maf,,,false,,,http://purl.obolibrary.org/obo/IMR_0000411,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000820,,,,,,,,,,,,,,,,,,,,,,c-Maf,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000124,transcription factor activation,,Transcription factor activation is a subtype of molecular activation: A process that changes the activity of the molecule with a transcription factor role to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000023,,,,,,,,,,,,,,,,,,,,,,Transcription factor activation is a subtype of molecular activation: A process that changes the activity of the molecule with a transcription factor role to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000124,,,,,,,,,,,,,,,,,,,,,,transcription factor activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000120,PLA1 (mol),phospholipase A1,phosphatidylcholine + H2O = 2-acylglycerophosphocholine + a carboxylate.,false,,,http://purl.obolibrary.org/obo/CHEBI_25367|http://purl.obolibrary.org/obo/TXPO_0000635,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:25833|NCBI-Rat-GeneID:116544|NCBI-Mouse-GeneID:18988,,phosphatidylcholine + H2O = 2-acylglycerophosphocholine + a carboxylate.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000025833,,,http://purl.obolibrary.org/obo/TXPO_0003671,,,,,phospholipase A1,,,,,TXPO:0000120,,,,,,,,,,,,,,,,,,,,,,PLA1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000127,autophagy [Eosinophilic granular degeneration],,"The cellular catabolic process in which cells digest parts of their own cytoplasm; allows for both recycling of macromolecular constituents under conditions of cellular stress and remodeling the intracellular structure for cell differentiation
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/TXPO_0001729|http://purl.obolibrary.org/obo/GO_0006914,,,,,,,,,,,,,,,,,,,,PMID:25165883,,"The cellular catabolic process in which cells digest parts of their own cytoplasm; allows for both recycling of macromolecular constituents under conditions of cellular stress and remodeling the intracellular structure for cell differentiation
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003219,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000187|http://purl.obolibrary.org/obo/TXPO_0003207,,,,,,,,,,,TXPO:0000127,,,,,,,,,,,,,,,,,,,,,,autophagy [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000126,negative regulation of mRNA catabolic process,down regulation of mRNA breakdown|down regulation of mRNA degradation|down regulation of mRNA catabolism|down regulation of mRNA catabolic process,"Negative regulation of mRNA catabolic process is a subtype of negative regulation of decomposing:  Any process that stops, prevents or reduces the frequency, rate or extent of mRNA catabolic process.",false,,,http://purl.obolibrary.org/obo/TXPO_0000115,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of mRNA catabolic process is a subtype of negative regulation of decomposing:  Any process that stops, prevents or reduces the frequency, rate or extent of mRNA catabolic process.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,down regulation of mRNA breakdown|down regulation of mRNA degradation|down regulation of mRNA catabolism|down regulation of mRNA catabolic process,,,,,TXPO:0000126,,,,,,,,,,,,,,,,,,,,,,negative regulation of mRNA catabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006402,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000122,WY14643 [Eosinophilic granular degeneration],,"Pirinixic Acid is a synthetic thiacetic acid derivative used in biomedical research, carcinogenic Pirinixic acid is a peroxisome proliferator that activates specific peroxisome proliferator-activated receptors (PPAR). PPARs play an important role in diverse cellular functions, including lipid metabolism, cell proliferation, differentiation, adipogenesis, and inflammatory signaling. (NCI04).
Pirinixic Acid was discovered as WY-14,643 in 1974.",false,,,http://purl.obolibrary.org/obo/CHEBI_32509|http://purl.obolibrary.org/obo/TXPO_0002383,,,,,,,,,,,,,,,,,,,,Open TG-Gates compound_id=00030|PMID:16434500,,"Pirinixic Acid is a synthetic thiacetic acid derivative used in biomedical research, carcinogenic Pirinixic acid is a peroxisome proliferator that activates specific peroxisome proliferator-activated receptors (PPAR). PPARs play an important role in diverse cellular functions, including lipid metabolism, cell proliferation, differentiation, adipogenesis, and inflammatory signaling. (NCI04).
Pirinixic Acid was discovered as WY-14,643 in 1974.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000122,,,,,,,,,,,,,,,,,,,,,,WY14643 [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000123,receiving abnormal protein signal by PERK [ER stress - translation attenuation],,"Receiving abnormal protein signal by PERK is a subtype of receiving signal: A process that recognizes another object and changes into an abnormal protein (e.g., misfolded protein, etc.) signal by PERK.
This process is dependent on the translation attenuation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002741|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"Receiving abnormal protein signal by PERK is a subtype of receiving signal: A process that recognizes another object and changes into an abnormal protein (e.g., misfolded protein, etc.) signal by PERK.
This process is dependent on the translation attenuation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002625,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000463,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000061,,,,,,,,,,,TXPO:0000123,,,,,,,,,,,,,,,,,,,,,,receiving abnormal protein signal by PERK [ER stress - translation attenuation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000121,fibrate [Eosinophilic granular degeneration],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000442|http://purl.obolibrary.org/obo/TXPO_0002383,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000121,,,,,,,,,,,,,,,,,,,,,,fibrate [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000128,regulation of mitochondrial beta oxidation related gene [Eosinophilic granular degeneration],,"Regulation of mitochondrial beta oxidation related gene is a subtype of regulation of beta oxidation related gene expression: A process that modulates the frequency, rate or extent of mitochondrial fatty acid beta oxidation related gene expression.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/TXPO_0001729|http://purl.obolibrary.org/obo/TXPO_0000129,,,,,,,,,,,,,,,,,,,,,,"Regulation of mitochondrial beta oxidation related gene is a subtype of regulation of beta oxidation related gene expression: A process that modulates the frequency, rate or extent of mitochondrial fatty acid beta oxidation related gene expression.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001058,,,,,,http://purl.obolibrary.org/obo/TXPO_0000146,,,,,,,,,,,TXPO:0000128,,,,,,,,,,,,,,,,,,,,,,regulation of mitochondrial beta oxidation related gene [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000125,PPARalpha activation (severe) [Eosinophilic granular degeneration],,"PPARalpha activation is a subtype of activating nuclear receptor: A process that changes the activity of the activating PPAR alpha (Peroxisome Proliferator Activated Receptor Alpha) with a nuclear receptor role to be higher. The degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/TXPO_0001005,,,,,,,,,,,,,,,,,,,,PMID:20414453|https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2948931/|PMID:20101262,,"PPARalpha activation is a subtype of activating nuclear receptor: A process that changes the activity of the activating PPAR alpha (Peroxisome Proliferator Activated Receptor Alpha) with a nuclear receptor role to be higher. The degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001048|http://purl.obolibrary.org/obo/TXPO_0000122|http://purl.obolibrary.org/obo/TXPO_0000121|http://purl.obolibrary.org/obo/TXPO_0001328,,,,,,http://purl.obolibrary.org/obo/TXPO_0000182|http://purl.obolibrary.org/obo/TXPO_0000184|http://purl.obolibrary.org/obo/TXPO_0000190|http://purl.obolibrary.org/obo/TXPO_0000196|http://purl.obolibrary.org/obo/TXPO_0000149|http://purl.obolibrary.org/obo/TXPO_0001025|http://purl.obolibrary.org/obo/TXPO_0002448|http://purl.obolibrary.org/obo/TXPO_0002047|http://purl.obolibrary.org/obo/TXPO_0000116|http://purl.obolibrary.org/obo/TXPO_0000127,,,,,,,,,,,TXPO:0000125,,,,,,,,,,,,,,,,,,,,,,PPARalpha activation (severe) [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000129,regulation of mitochondrial beta oxidation related gene,,"Regulation of mitochondrial beta oxidation related gene is a subtype of regulation of beta oxidation related gene expression: A process that modulates the frequency, rate or extent of mitochondrial fatty acid beta oxidation related gene expression.",false,,,http://purl.obolibrary.org/obo/TXPO_0000119,,,,,,,,,,,,,,,,,,,,,,"Regulation of mitochondrial beta oxidation related gene is a subtype of regulation of beta oxidation related gene expression: A process that modulates the frequency, rate or extent of mitochondrial fatty acid beta oxidation related gene expression.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000129,,,,,,,,,,,,,,,,,,,,,,regulation of mitochondrial beta oxidation related gene,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0011348,Elongin B protein,EloC|RNA polymerase II transcription factor SIII subunit C|Elongin 15 kDa subunit|Elongin C|SIII p15|Transcription elongation factor B polypeptide 1,,false,,,http://purl.obolibrary.org/obo/IMR_0010020,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,EloC|RNA polymerase II transcription factor SIII subunit C|Elongin 15 kDa subunit|Elongin C|SIII p15|Transcription elongation factor B polypeptide 1,,,,,IMR:0011348,,,,,,,,,,,,,,,,,,,,,,Elongin B protein,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100466,CRADD,RAIDD|caspase and RIP adaptor with death domain|RIP-associated ICH-1/CED-3-homologous protein with a death domain,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003682,,,,,RAIDD|caspase and RIP adaptor with death domain|RIP-associated ICH-1/CED-3-homologous protein with a death domain,,,,,IMR:0100466,,,,,,,,,,,,,,,,,,,,,,CRADD,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/MP_0005039,hypoxia,decreased tissue partial O2 level,reduced oxygenation of body tissues resulting in the decreased pressure of this component of body gases; commonly due to hypoxemia,false,,,http://purl.obolibrary.org/obo/TXPO_0000671,,,,,,,,,,,,,,,,,,,,,,reduced oxygenation of body tissues resulting in the decreased pressure of this component of body gases; commonly due to hypoxemia,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,decreased tissue partial O2 level,,,,,MP:0005039,,,,,,,,,,,,,,,,,,,,,,hypoxia,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002417,temperature attribute,,A physical attribure of the thermal energy of a system.,false,,,http://purl.obolibrary.org/obo/TXPO_0000305,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0000146,,A physical attribure of the thermal energy of a system.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002417,,,,,,,,,,,,,,,,,,,,,,temperature attribute,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002415,length attribute,,A 1-D extent attribute which is equal to the distance between two points.,false,,,http://purl.obolibrary.org/obo/TXPO_0000305,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0000122,,A 1-D extent attribute which is equal to the distance between two points.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002415,,,,,,,,,,,,,,,,,,,,,,length attribute,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002411,PKCΕ (canonical)[ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000871|http://purl.obolibrary.org/obo/TXPO_1000280,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:112476|NCBI-Rat-GeneID:361651|NCBI-Mouse-GeneID:69017,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002411,,,,,,,,,,,,,,,,,,,,,,PKCΕ (canonical)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002413,strength (attribute),,An attribute related to the power or force.,false,,,http://purl.obolibrary.org/obo/TXPO_0000305,,,,,,,,,,,,,,,,,,,,,,An attribute related to the power or force.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002413,,,,,,,,,,,,,,,,,,,,,,strength (attribute),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002416,volume attribute,,A 3-D extent attribute related to amount of 3-dimensional space it occupies.,false,,,http://purl.obolibrary.org/obo/TXPO_0000305,,,,,,,,,,,,,,,,,,,,,,A 3-D extent attribute related to amount of 3-dimensional space it occupies.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002416,,,,,,,,,,,,,,,,,,,,,,volume attribute,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002419,force attribute,,A physical attribute entity inhering in a bearer by virtue of the bearer's rate of change of momentum.,false,,,http://purl.obolibrary.org/obo/TXPO_0000305,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0001035,,A physical attribute entity inhering in a bearer by virtue of the bearer's rate of change of momentum.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002419,,,,,,,,,,,,,,,,,,,,,,force attribute,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002418,pressure attribute,,A physical attribute relaeted to the amount of force per unit area the bearer exerts.,false,,,http://purl.obolibrary.org/obo/TXPO_0000305,,,,,,,,,,,,,,,,,,,,,,A physical attribute relaeted to the amount of force per unit area the bearer exerts.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002418,,,,,,,,,,,,,,,,,,,,,,pressure attribute,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002412,PERK signaling to eIF2a [ER stress - refolding],,"A process in which a signal to eIF2a is transduced by PERK.
This process is dependent on the refolding and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002449|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"A process in which a signal to eIF2a is transduced by PERK.
This process is dependent on the refolding and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002518|http://purl.obolibrary.org/obo/TXPO_0002516,,,,,,,,,,,,,,,,,,TXPO:0002412,,,,,,,,,,,,,,,,,,,,,,PERK signaling to eIF2a [ER stress - refolding],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002410,GRP94 (canonical)[ER stress],HSP90B1 [ER stress],,false,,,http://purl.obolibrary.org/obo/TXPO_1000171|http://purl.obolibrary.org/obo/TXPO_0000871,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:22027|NCBI-Rat-GeneID:362862|NCBI-Human-GeneID:7184,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003997,,,,,HSP90B1 [ER stress],,,,,TXPO:0002410,,,,,,,,,,,,,,,,,,,,,,GRP94 (canonical)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002414,mass attribute,,A physical attribute that inheres in a bearer by virtue of the proportion of the bearer's amount of matter.,false,,,http://purl.obolibrary.org/obo/TXPO_0000305,,,,,,,,,,,,,,,,,,,,,,A physical attribute that inheres in a bearer by virtue of the proportion of the bearer's amount of matter.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002414,,,,,,,,,,,,,,,,,,,,,,mass attribute,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001105,importin 13,,,false,,,http://purl.obolibrary.org/obo/IMR_0100015|http://purl.obolibrary.org/obo/IMR_0100010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001105,,,,,,,,,,,,,,,,,,,,,,importin 13,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003940,negative regulation of G6Pase expression,,"Negative regulation of G6Pase expression is a subtype of negative regulation of gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of G6Pase expression.",false,,,http://purl.obolibrary.org/obo/GO_0010629,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of G6Pase expression is a subtype of negative regulation of gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of G6Pase expression.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003940,,,,,,,,,,,,,,,,,,,,,,negative regulation of G6Pase expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003943,hypofunction of gluconeogenesis (sustained) [Ground glass appearance],,"Hypofunction of gluconeogenesis is a subtype of hypofunction of biosynthesis: A process that performs a decreased or insufficient gluconeogenesis. This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) .",false,,,http://purl.obolibrary.org/obo/TXPO_0003919,,,,,,,,,,,,,,,,,,,,,,"Hypofunction of gluconeogenesis is a subtype of hypofunction of biosynthesis: A process that performs a decreased or insufficient gluconeogenesis. This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003932,,,,,,,,,,,TXPO:0003943,,,,,,,,,,,,,,,,,,,,,,hypofunction of gluconeogenesis (sustained) [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003941,CTSB (human)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001135|http://purl.obolibrary.org/obo/TXPO_0003843,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1508|PMID:22102288|PMID:27398911|PMID:1837142|PMID:11016923|PMID:1637335|PMID:10876156,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001508,,,,,,,,,,,,,TXPO:0003941,,,,,,,,,,,,,,,,,,,,,,CTSB (human)[Phospholipidosis],,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005764,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003946,trannscriptional repressor of FOXO1,,"A role that represses the rate, timing and/or magnitude of transcription of FOXO1.",false,,,http://purl.obolibrary.org/obo/TXPO_0001531,,,,,,,,,,,,,,,,,,,,,,"A role that represses the rate, timing and/or magnitude of transcription of FOXO1.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003946,,,,,,,,,,,,,,,,,,,,,,trannscriptional repressor of FOXO1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003949,carbohydrate sysnthesis regulator role,,A role played by the entity which regulates carbohydrate metabolic process.,false,,,http://purl.obolibrary.org/obo/TXPO_0004023,,,,,,,,,,,,,,,,,,,,,,A role played by the entity which regulates carbohydrate metabolic process.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003949,,,,,,,,,,,,,,,,,,,,,,carbohydrate sysnthesis regulator role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003942,negative regulation of glucogenesis related gene expression [Ground glass appearance],,"Negative regulation of glucogenesis related gene expression is a subtype of negative regulation of gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of glucogenesis related gene expression expression.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/TXPO_0003940,,,,,,,,,,,,,,,,,,,,ISBN:0071769234,,"Negative regulation of glucogenesis related gene expression is a subtype of negative regulation of gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of glucogenesis related gene expression expression.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003919,,,,,,,,,,,TXPO:0003942,,,,,,,,,,,,,,,,,,,,,,negative regulation of glucogenesis related gene expression [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003948,AMPK - activation state (canonical)[Ground glass appearance],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000944,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003948,,,,,,,,,,,,,,,,,,,,,,AMPK - activation state (canonical)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003945,FOXO1 inactivation (sustained) [Ground glass appearance],,"FOXO1 inactivation is a subtype of inactivating: A process that changes the activity of the FOXO1 to be lower.This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) .",false,,,http://purl.obolibrary.org/obo/TXPO_0003936,,,,,,,,,,,,,,,,,,,,,,"FOXO1 inactivation is a subtype of inactivating: A process that changes the activity of the FOXO1 to be lower.This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) .",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003930,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003923,,,,http://purl.obolibrary.org/obo/TXPO_0003924,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003944,,,,,,,,,,,TXPO:0003945,,,,,,,,,,,,,,,,,,,,,,FOXO1 inactivation (sustained) [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003947,positive regulator of gluconeogenic gene transcription role,,"A role that activates, or increases the rate, timing and/or magnitude of transcription of gluconeogenic gene.",false,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,,,,,,,,,,,,,,,,,,"A role that activates, or increases the rate, timing and/or magnitude of transcription of gluconeogenic gene.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003947,,,,,,,,,,,,,,,,,,,,,,positive regulator of gluconeogenic gene transcription role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003944,negative regulation of glucogenesis related gene expression (sustained) [Ground glass appearance],,"Negative regulation of glucogenesis related gene expression is a subtype of negative regulation of gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of glucogenesis related gene expression expression. This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) .",false,,,http://purl.obolibrary.org/obo/TXPO_0003942,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of glucogenesis related gene expression is a subtype of negative regulation of gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of glucogenesis related gene expression expression. This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003943,,,,,,,,,,,TXPO:0003944,,,,,,,,,,,,,,,,,,,,,,negative regulation of glucogenesis related gene expression (sustained) [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000285440,CYP4V2,,Other designations: cytochrome P450 4V2,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,BCD|CYP4AH1,,,,,,,,,,,,4,,,,,,MIM:608614|HGNC:23198|HPRD:16777,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 4, subfamily V, polypeptide 2",,,4q35.2,,,,,,,,,,,,,,,,"GO_0004497 (EC: IEA); GO_0005506 (EC: IEA); GO_0005789 (EC: IEA); GO_0007601 (EC: IEA); GO_0010430 (EC: IDA, PMID:19661213); GO_0016021 (EC: IEA); GO_0016705 (EC: IEA); GO_0020037 (EC: IEA); GO_0050896 (EC: IEA)",,,,,,,,,PMID:11001583; 12477932; 12975309; 14702039; 15042513; 15128046; 15489334; 15860296; 16030350; 16088246; 16179904; 16186368; 17013694; 17249554; 17962476; 18349091; 19278955; 19508456; 19583818; 19661213; 20205591; 20379614; 21385027; 21540472; 21565171; 21850171; 21892605; 21988832; 22497028; 22605929; 22693542; 22916037; 23221965; 23242590; 23503679; 23538635,,,,,,,,,,,,,,,OGG:3000285440,,,,,,,"cytochrome P450, family 4, subfamily V, polypeptide 2",,,,,,,,,,,,,Other designations: cytochrome P450 4V2,,CYP4V2,,,,,,,,,,,,,,,,,,,,,,,285440,UNQ2560,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP4V2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_76998,aryl hydrocarbon receptor antagonist,AhR receptor antagonist|AhR antagonist,An antagonist that binds to and inactivates aryl hydrocarbon receptors (AhRs).,false,,,http://purl.obolibrary.org/obo/CHEBI_48706,,,,,,,,,,,,,,,,,,,,,,An antagonist that binds to and inactivates aryl hydrocarbon receptors (AhRs).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,AhR antagonist,,AhR receptor antagonist,,,CHEBI:76998,,,,,,,,,,,,,,,,,,,,,,aryl hydrocarbon receptor antagonist,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_35444,antinematodal drug,antinematodals|antinematodal agent|antinematodal drugs,A substance used in the treatment or control of nematode infestations.,false,,,http://purl.obolibrary.org/obo/CHEBI_25491|http://purl.obolibrary.org/obo/CHEBI_35443,,,,,,,,,,,,,,,,,,,,,,A substance used in the treatment or control of nematode infestations.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,antinematodals|antinematodal agent|antinematodal drugs,,,,,,,,,,,,,,,,,,,,,CHEBI:35444,,,,antinematodal drug,,CHEBI:35444,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0000470,increased amount,,An amount which is relatively high.,false,,,http://purl.obolibrary.org/obo/PATO_0000070,,,,,,,,,,,,,,,,,,,,,,An amount which is relatively high.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0000470,,,,,,,,,,,,,,,,,,,,,,increased amount,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000602,IL-12 receptor,interleukin-12 receptor,,false,,,http://purl.obolibrary.org/obo/IMR_0000096,,,,,,,,,,,,,,,,,,,,GO:0016517,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,interleukin-12 receptor,,,,,IMR:0000602,,,,,,,,,,,,,,,,,,,,,,IL-12 receptor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_17907,styrene oxide,"styrene-7,8-oxide|2-phenyloxirane",An epoxide that is oxirane in which one of the hydrogens has been replaced by a phenyl group.,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:96-09-3|Wikipedia:Styrene_oxide,,An epoxide that is oxirane in which one of the hydrogens has been replaced by a phenyl group.,,,,,,,,,,,,C8H8O,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2-phenyloxirane,,"styrene-7,8-oxide",,,CHEBI:17907,,,,,,,,,,,,,,,,,,,,,,styrene oxide,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,C1OC1c1ccccc1,,,,,
http://purl.obolibrary.org/obo/OGG_3000004613,MYCN,,Other designations: N-myc proto-oncogene protein|class E basic helix-loop-helix protein 37|neuroblastoma MYC oncogene|neuroblastoma-derived v-myc avian myelocytomatosis viral related oncogene|oncogene NMYC|pp65/67,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,NMYC|MODED|ODED|N-myc|MYCNOT|bHLHe37,,,,,,,,,,,,2,,,,,,Vega:OTTHUMG00000039579|HPRD:01278|MIM:164840|HGNC:7559|Ensembl:ENSG00000134323,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog,,,2p24.3,,,,,,,,,,,,,,,,"GO_0000785 (EC: TAS, PMID: 3796607); GO_0001502 (EC: IEA); GO_0002053 (EC: IEA); GO_0003677 (EC: TAS, PMID: 10597290); GO_0003700 (EC: IEA); GO_0005515 (EC: IPI, PMID: 10597290); GO_0005634 (EC: IDA, PMID: 10597290); GO_0006357 (EC: TAS, PMID: 3796607); GO_0010942 (EC: IEA); GO_0030324 (EC: IEA); GO_0042733 (EC: IEA); GO_0045944 (EC: IEA); GO_0046983 (EC: IEA); GO_0048704 (EC: IEA); GO_0048712 (EC: IEA); GO_0048754 (EC: IEA); GO_2000378 (EC: IEA)",,,,,,,,,PMID: 1419902; 1425701; 1549498; 1695323; 2006410; 2582423; 2834684; 2869488; 2987858; 3008339; 3299258; 3437890; 3510398; 3552210; 3796607; 3940169; 6575396; 6700732; 6719137; 6728001; 8668343; 9856457; 10229200; 10407192; 10597290; 10677303; 11593398; 11602341; 11826111; 11850545; 11861392; 11881792; 12153570; 12192602; 12219017; 12232763; 12438307; 12477932; 12545167; 12569580; 12660036; 12670915; 12808116; 12819037; 12907629; 14645238; 14647433; 14719101; 14737110; 15117961; 15198123; 15218241; 15258910; 15302935; 15314226; 15316056; 15331636; 15489334; 15547663; 15632181; 15644444; 15660126; 15833843; 16166307; 16278682; 16516635; 16596176; 16906565; 16912187; 16912192; 17020972; 17023822; 17055458; 17172827; 17213019; 17289033; 17327229; 17464317; 17495526; 17506115; 17525631; 17535087; 17554788; 17611020; 17643814; 17704800; 17710228; 18004567; 18059033; 18097563; 18165268; 18198336; 18278068; 18281664; 18335505; 18348317; 18391076; 18470948; 18488021; 18504438; 18591937; 18610847; 18671284; 18769732; 18785023; 18851746; 18949372; 18955045; 19006223; 19047142; 19047152; 19061778; 19111882; 19208763; 19301388; 19401549; 19495417; 19608868; 19615087; 19649205; 19656550; 19724862; 19766596; 19852433; 19885598; 19924232; 19946337; 19956635; 19997598; 20007697; 20017904; 20080637; 20103633; 20144241; 20145147; 20173740; 20179233; 20180881; 20190806; 20236072; 20301770; 20332316; 20395439; 20409325; 20424123; 20425471; 20478998; 20575024; 20607354; 20697349; 20719933; 20811720; 20946988; 20961996; 20980091; 21046119; 21073496; 21112821; 21123453; 21173028; 21214410; 21224895; 21258086; 21288077; 21297076; 21304178; 21370425; 21378543; 21384249; 21498633; 21501490; 21508638; 21533284; 21572098; 21646478; 21698133; 21725357; 21731748; 21750863; 21796614; 21796619; 21822304; 21856782; 21862876; 21882282; 21908575; 21929510; 21963094; 22035742; 22052359; 22065083; 22068108; 22090452; 22120721; 22123490; 22146831; 22202125; 22218692; 22286764; 22337647; 22383024; 22439933; 22484425; 22544364; 22623531; 22624711; 22751132; 22907398; 22907436; 22921766; 22952844; 22975311; 23042116; 23091029; 23152863; 23186832; 23284291; 23284678; 23308108; 23317189; 23320395; 23341988; 23358695; 23362253; 23430699; 23498719; 23563570; 23578955; 23639551; 23812427; 23901000; 23962557; 24011394; 24130166; 24260886,,,,,,,,,,,,,,,OGG:3000004613,,,,,,,v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog,,,,,,,,,,,,,Other designations: N-myc proto-oncogene protein|class E basic helix-loop-helix protein 37|neuroblastoma MYC oncogene|neuroblastoma-derived v-myc avian myelocytomatosis viral related oncogene|oncogene NMYC|pp65/67,,MYCN,,,,,,,,,,,,,,,,,,,,,,,4613,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,MYCN,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000004616,GADD45B,,Other designations: growth arrest and DNA damage-inducible protein GADD45 beta|myeloid differentiation primary response protein MyD118|negative growth regulatory protein MyD118,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,GADD45BETA|MYD118,,,,,,,,,,,,19,,,,,,HGNC:4096|Ensembl:ENSG00000099860|HPRD:05382|Vega:OTTHUMG00000180434|MIM:604948,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"growth arrest and DNA-damage-inducible, beta",,,19p13.3,,,,,,,,,,,,,,,,"GO_0000185 (EC: IDA, PMID: 9827804); GO_0000186 (EC: IEA); GO_0005515 (EC: IPI, PMID: 12052864); GO_0005634 (EC: IDA, PMID: 9827804); GO_0005737 (EC: IDA, PMID: 9827804); GO_0006469 (EC: IEA); GO_0006915 (EC: IEA); GO_0006950 (EC: IEA); GO_0007275 (EC: IEA); GO_0030154 (EC: IEA); GO_0043065 (EC: IDA, PMID: 9827804); GO_0046330 (EC: IDA, PMID: 9827804); GO_0051726 (EC: IEA); GO_1900745 (EC: IDA, PMID: 9827804)",,,,,,,,,PMID: 1899477; 8700517; 8889548; 9151207; 9827804; 10101024; 10773677; 10828065; 10872826; 10973963; 11078829; 11498536; 12052864; 12124778; 12162804; 12477932; 12716909; 12759252; 12855571; 14630914; 14743220; 15057824; 15342556; 15489334; 15509538; 15546867; 15616591; 15642734; 16144844; 16256071; 17437852; 17485467; 17591973; 18343408; 18515079; 18576389; 19064572; 19834918; 19877043; 20530689; 20558744; 20942912; 21062976; 21127053; 21139048; 21810943; 22048458; 22096849; 22797925; 23110778; 24104471; 24104474,,,,,,,,,,,,,,,OGG:3000004616,,,,,,,"growth arrest and DNA-damage-inducible, beta",,,,,,,,,,,,,Other designations: growth arrest and DNA damage-inducible protein GADD45 beta|myeloid differentiation primary response protein MyD118|negative growth regulatory protein MyD118,,GADD45B,,,,,,,,,,,,,,,,,,,,,,,4616,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,GADD45B,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0000490,ligand molecule [signal transduction system],,"Ligand molecule is a subtype of signaling dependent molecule.
This entity is dependent on a signal transduction system and can participate in signaling process.",false,,,http://purl.obolibrary.org/obo/TXPO_0001821,,,,,,,,,,,,,,,,,,,,,,"Ligand molecule is a subtype of signaling dependent molecule.
This entity is dependent on a signal transduction system and can participate in signaling process.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000624,,,,,,,,,,TXPO:0000490,,,,,,,,,,,,,,,,,,,,,,ligand molecule [signal transduction system],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001793,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000491,excretory tube,,A tube that is part of a excretory system.,false,,,http://purl.obolibrary.org/obo/UBERON_0000025,,,,,,,,,,,,,,,,,,,,,,A tube that is part of a excretory system.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000491,,,,,,,,,,,,,,,,,,,,,,excretory tube,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000493,toxicological imbalance L<M,,"In the imbalance model, the basic units are as follows:
1) a functioning process (supply) for biological defense and maintaining homeostasis;
2) a functional demand process (demand) as toxic activity;
3) balance/imbalance between toxic activity and defense processes; and
4) outcome from organelles, cells, or tissues to the organ exhibiting toxicity manifestations.

This entity  is a compound state that inculdes step 1 to 4.
The defense performance level is lower (L) than the medium (M) in the normal condition . Threfore even if the functional demand level is Medium level (M) in the daily life, which leads to the imbalance and leads to toxicity manifestation.",false,,,http://purl.obolibrary.org/obo/TXPO_0003992,,,,,,,,,,,,,,,,,,,,,,"In the imbalance model, the basic units are as follows:
1) a functioning process (supply) for biological defense and maintaining homeostasis;
2) a functional demand process (demand) as toxic activity;
3) balance/imbalance between toxic activity and defense processes; and
4) outcome from organelles, cells, or tissues to the organ exhibiting toxicity manifestations.

This entity  is a compound state that inculdes step 1 to 4.
The defense performance level is lower (L) than the medium (M) in the normal condition . Threfore even if the functional demand level is Medium level (M) in the daily life, which leads to the imbalance and leads to toxicity manifestation.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001735,,,,,,,,,,,,,,,,,,TXPO:0000493,,,,,,,,,,,,,,,,,,,,,,toxicological imbalance L<M,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000494,hypofunction of ion transport [Phospholipidosis],,"Hypofunction of ion transport is a subtype of hypofunction of transport: A process that performs a decreased or insufficient ion transport.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0000495,,,,,,,,,,,,,,,,,,,,PMID: 9061852,,"Hypofunction of ion transport is a subtype of hypofunction of transport: A process that performs a decreased or insufficient ion transport.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000494,,,,,,,,,,,,,,,,,,,,,,hypofunction of ion transport [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000499,chloropromazine・CAD [Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/CHEBI_3647|http://purl.obolibrary.org/obo/TXPO_0001849,,,,,,,,,,,,,,,,,,,,PMID:24003057|PMID:6732837,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001426,,,,,,,,,,TXPO:0000499,,,,,,,,,,,,,,,,,,,,,,chloropromazine・CAD [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000492,glycogen accumulation,,Glycogen accumulation is a subtype of accumulation of substances in a biological object: A process that keeps glycogen in a biological object.,false,,,http://purl.obolibrary.org/obo/TXPO_0000247,,,,,,,,,,,,,,,,,,,,,,Glycogen accumulation is a subtype of accumulation of substances in a biological object: A process that keeps glycogen in a biological object.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_28087,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000492,,,,,,,,,,,,,,,,,,,,,,glycogen accumulation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000495,hypofunction of ion transport,,Hypofunction of ion transport is a subtype of hypofunction of transport: A process that performs a decreased or insufficient ion transport.,false,,,http://purl.obolibrary.org/obo/TXPO_0001911,,,,,,,,,,,,,,,,,,,,,,Hypofunction of ion transport is a subtype of hypofunction of transport: A process that performs a decreased or insufficient ion transport.,,,http://purl.obolibrary.org/obo/GO_0006811,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000495,,,,,,,,,,,,,,,,,,,,,,hypofunction of ion transport,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000496,hypofunction of phospholipid degradation by PLA1,,Hypofunction of phospholipid degradation by PLA1 is a subtype of hypofunction of phospholipid deradation by phospholipase: A process that performs a decreased or insufficient phospholipid degradation by PLA1.,false,,,http://purl.obolibrary.org/obo/TXPO_0000914,,,,,,,,,,,,,,,,,,,,,,Hypofunction of phospholipid degradation by PLA1 is a subtype of hypofunction of phospholipid deradation by phospholipase: A process that performs a decreased or insufficient phospholipid degradation by PLA1.,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001803,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000499|http://purl.obolibrary.org/obo/TXPO_0000500,,,,,,,,,,,,,,,,,TXPO:0000496,,,,,,,,,,,,,,,,,,,,,,hypofunction of phospholipid degradation by PLA1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000498,hypofunction of phospholipid degradation by phospholipase C [Phospholipidosis],,"Hypofunction of phospholipid deradation by phospholipase C is a subtype of hypofunction of phospholipid degradation: A process that performs a decreased or insufficient phospholipid deradation by phospholipase C.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000914,,,,,,,,,,,,,,,,,,,,,,"Hypofunction of phospholipid deradation by phospholipase C is a subtype of hypofunction of phospholipid degradation: A process that performs a decreased or insufficient phospholipid deradation by phospholipase C.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001805,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000499|http://purl.obolibrary.org/obo/TXPO_0000500,,,,,,,,,,,,,,,,,TXPO:0000498,,,,,,,,,,,,,,,,,,,,,,hypofunction of phospholipid degradation by phospholipase C [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000497,hypofunction of phospholipid degradation by phospholipase A2 [Phospholipidosis],,"Hypofunction of phospholipid deradation by phospholipase A2 is a subtype of hypofunction of phospholipid degradation: A process that performs a decreased or insufficient phospholipid deradation by phospholipase A2.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000914,,,,,,,,,,,,,,,,,,,,,,"Hypofunction of phospholipid deradation by phospholipase A2 is a subtype of hypofunction of phospholipid degradation: A process that performs a decreased or insufficient phospholipid deradation by phospholipase A2.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001804,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000499|http://purl.obolibrary.org/obo/TXPO_0000500,,,,,,,,,,,,,,,,,TXPO:0000497,,,,,,,,,,,,,,,,,,,,,,hypofunction of phospholipid degradation by phospholipase A2 [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100716,Notch 3 (mol),Notch-3|Notch3|Neurogenic locus notch homolog protein 3 precursor,,false,,,http://purl.obolibrary.org/obo/IMR_0100712,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:18131|NCBI-Human-GeneID:4854|NCBI-Rat-GeneID:56761,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Notch-3|Notch3|Neurogenic locus notch homolog protein 3 precursor,,,,,IMR:0100716,,,,,,,,,,,,,,,,,,,,,,Notch 3 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000897,60S ribosomal protein,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003687,,,,,,,,,,IMR:0000897,,,,,,,,,,,,,,,,,,,,,,60S ribosomal protein,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/NCIT_C21204,Organic Cation Transporter,OCT family|Organic Cation Transport Protein,"Organic Cation Transporter proteins carry positively charged chemical substances containing covalently bound carbon atoms through solubility barriers, such as lipid membranes or across epithelial layers. After binding substrate, transmembrane transporters often undergo an energy-dependent conformational change that moves the substrate across the membrane with (symport) or against (antiport) concentration gradients.",false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,"Organic Cation Transporter proteins carry positively charged chemical substances containing covalently bound carbon atoms through solubility barriers, such as lipid membranes or across epithelial layers. After binding substrate, transmembrane transporters often undergo an energy-dependent conformational change that moves the substrate across the membrane with (symport) or against (antiport) concentration gradients.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,OCT family|Organic Cation Transport Protein,,,,,NCIT:C21204,,,,,,,,,,,,,,,,,,,,,,Organic Cation Transporter,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0002658,BCL10,CIPER|CLAP|CARMEN|mE10|c-E10,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CIPER|CLAP|CARMEN|mE10|c-E10,,,,,IMR:0002658,,,,,,,,,,,,,,,,,,,,,,BCL10,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000974,LDL receptor family,low density lipoprotein receptor family|LDLR family|low-density lipoprotein receptor family,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,GO:0005041,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,low density lipoprotein receptor family|LDLR family|low-density lipoprotein receptor family,,,,,IMR:0000974,,,,,,,,,,,,,,,,,,,,,,LDL receptor family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000580,IFN alpha-10,,,false,,,http://purl.obolibrary.org/obo/IMR_0100386,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000580,,,,,,,,,,,,,,,,,,,,,,IFN alpha-10,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0023051,regulation of signaling,,"Any process that modulates the frequency, rate or extent of a signaling process.",false,,,http://purl.obolibrary.org/obo/TXPO_0000113,,,,,,,,,,,,,,,,,,,,,,"Any process that modulates the frequency, rate or extent of a signaling process.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0023051,,,,,,,,,,,,,,,,,,,,,,regulation of signaling,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000471,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0023052,signaling [biological] (primitive),biological signaling (primitive)|signalling (primitive),"The entirety of a process in which information is transmitted within a biological system. This process begins with an active signal and ends when a cellular response has been triggered.|Note that a signal is any variable property or parameter that serves to convey information, and may be a physical entity such as a gene product or small molecule, a photon, or a change in state such as movement or voltage change.",false,,,http://purl.obolibrary.org/obo/TXPO_0000471,,,,,,,,,,,,,,,,,,,,,,The entirety of a process in which information is transmitted within a biological system. This process begins with an active signal and ends when a cellular response has been triggered.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000020,,,,,,,,,,,,,biological signaling (primitive)|signalling (primitive),,,,,GO:0023052,,,,,,,,,,,,,,,,,,,,"Note that a signal is any variable property or parameter that serves to convey information, and may be a physical entity such as a gene product or small molecule, a photon, or a change in state such as movement or voltage change.",,signaling [biological] (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0023057,negative regulation of signaling,,"Any process that stops, prevents, or reduces the frequency, rate or extent of a signaling process.",false,,,http://purl.obolibrary.org/obo/TXPO_0000369,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents, or reduces the frequency, rate or extent of a signaling process.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0023057,,,,,,,,,,,,,,,,,,,,,,negative regulation of signaling,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000609|http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_31781,lopinavir,"(2S)-N-[(2S,4S,5S)-5-{[(2,6-dimethylphenoxy)acetyl]amino}-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxotetrahydropyrimidin-1(2H)-yl)butanamide","A dicarboxylic acid amide in which a parent structure of amphetamine is substituted on nitrogen by a (2,6-dimethylphenoxy)acetyl group and on the carbon alpha to nitrogen by a (1S,3S)-1-hydroxy-3-{[(2S)-3-methyl-2-(2-oxotetrahydropyrimidin-1(2H)-yl)butanoyl]amino}-4-phenylbutyl group. An antiretroviral of the protease inhibitor class. It is used against HIV infections as a fixed-dose combination with another protease inhibitor, ritonavir.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:192725-17-0|DrugBank:DB01601|LINCS:LSM-6027|MeSH:D061466,,"A dicarboxylic acid amide in which a parent structure of amphetamine is substituted on nitrogen by a (2,6-dimethylphenoxy)acetyl group and on the carbon alpha to nitrogen by a (1S,3S)-1-hydroxy-3-{[(2S)-3-methyl-2-(2-oxotetrahydropyrimidin-1(2H)-yl)butanoyl]amino}-4-phenylbutyl group. An antiretroviral of the protease inhibitor class. It is used against HIV infections as a fixed-dose combination with another protease inhibitor, ritonavir.",,,,,,,,,,,,C37H48N4O5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"(2S)-N-[(2S,4S,5S)-5-{[(2,6-dimethylphenoxy)acetyl]amino}-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxotetrahydropyrimidin-1(2H)-yl)butanamide",,,,,CHEBI:31781,,,,,,,,,,,,,,,,,,,,,,lopinavir,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)COc1c(C)cccc1C)Cc1ccccc1,,,,,
http://purl.obolibrary.org/obo/TXPO_0000137,GADD45A (canonical)[Glutathione depletion],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000174|http://purl.obolibrary.org/obo/TXPO_0002045,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:13197|NCBI-Rat-GeneID:25112|NCBI-Human-GeneID:1647,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000559,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000137,,,,,,,,,,,,,,,,,,,,,,GADD45A (canonical)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000130,negative regulation of lipid storage [Eosinophilic granular degeneration],,"Any process that decreases the rate, frequency or extent of lipid storage. Lipid storage is the accumulation and maintenance in cells or tissues of lipids, compounds soluble in organic solvents but insoluble or sparingly soluble in aqueous solvents. Lipid reserves can be accumulated during early developmental stages for mobilization and utilization at later stages of development.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/TXPO_0001729|http://purl.obolibrary.org/obo/GO_0010888,,,,,,,,,,,,,,,,,,,,PMID:19114110,,"Any process that decreases the rate, frequency or extent of lipid storage. Lipid storage is the accumulation and maintenance in cells or tissues of lipids, compounds soluble in organic solvents but insoluble or sparingly soluble in aqueous solvents. Lipid reserves can be accumulated during early developmental stages for mobilization and utilization at later stages of development.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000130,,,,,,,,,,,,,,,,,,,,,,negative regulation of lipid storage [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000139,increasing volume,,Increasing volume is a subtype of increasing size: A process that changes the volume of the object to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000138|http://purl.obolibrary.org/obo/TXPO_0000417,,,,,,,,,,,,,,,,,,,,,,Increasing volume is a subtype of increasing size: A process that changes the volume of the object to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/BFO_0000040,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000139,,,,,,,,,,,,,,,,,,,,,,increasing volume,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0000595,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000134,biological structure formation,,Biological structure formation is a subtype of having extra parts: A process that changes to form a structure component.,false,,,http://purl.obolibrary.org/obo/TXPO_0000168,,,,,,,,,,,,,,,,,,,,,,Biological structure formation is a subtype of having extra parts: A process that changes to form a structure component.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000134,,,,,,,,,,,,,,,,,,,,,,biological structure formation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000131,lipid transport to mitochondria,,Lipid transport to mitochondria is a subtype of lipid transport: A process that of the directed movement of lipids into a mitochondrion.,false,,,http://purl.obolibrary.org/obo/GO_0006869,,,,,,,,,,,,,,,,,,,,,,Lipid transport to mitochondria is a subtype of lipid transport: A process that of the directed movement of lipids into a mitochondrion.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,TXPO:0000131,,,,,,,,,,,,,,,,,,,,,,lipid transport to mitochondria,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000133,maintaining membrane permeability,,Maintaining membrane permeability is a subtype of maintaining permeability: A process that keeps the permeability of the membrane.,false,,,http://purl.obolibrary.org/obo/TXPO_0000094,,,,,,,,,,,,,,,,,,,,,,Maintaining membrane permeability is a subtype of maintaining permeability: A process that keeps the permeability of the membrane.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000133,,,,,,,,,,,,,,,,,,,,,,maintaining membrane permeability,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000136,tumorigenesis [Eosinophilic granular degeneration],,"A pathologic process that involves the transformation of normal cells to a neoplastic state and resulting in polyclonal or monoclonal neoplastic cell proliferation.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/TXPO_0001729|http://purl.obolibrary.org/obo/NCIT_C18121,,,,,,,,,,,,,,,,,,,,PMID:9395198|PMID:29983595|PMID:10839530,,"A pathologic process that involves the transformation of normal cells to a neoplastic state and resulting in polyclonal or monoclonal neoplastic cell proliferation.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000136,,,,,,,,,,,,,,,,,,,,,,tumorigenesis [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107|http://purl.obolibrary.org/obo/NCBITaxon_9989,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000132,unfolded protein [ER stress],,Unfolded protein is a subtype of substance with role. This entity can participate in a unfolded protein response in the course of ER stress.,false,,,http://purl.obolibrary.org/obo/CHEBI_25367|http://purl.obolibrary.org/obo/TXPO_0002106,,,,,,,,,,,,,,,,,,,,,,Unfolded protein is a subtype of substance with role. This entity can participate in a unfolded protein response in the course of ER stress.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000132,,,,,,,,,,,,,,,,,,,,,,unfolded protein [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000135,G6PD (canonical)[Glutathione depletion],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000158|http://purl.obolibrary.org/obo/TXPO_0002045,,,,,,,,,,,,,,,,,,,,http://omim.org/entry/305900|NCBI-Human-GeneID:2539|NCBI-Rat-GeneID:24377|PMID:24287781,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002402,,,,,,,,,,TXPO:0000135,,,,,,,,,,,,,,,,,,,,,,G6PD (canonical)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000138,increasing size,,Increasing size is a subtype of changing size: A process that changes the size of the object to be larger.,false,,,http://purl.obolibrary.org/obo/TXPO_0002705,,,,,,,,,,,,,,,,,,,,A size change process in which the size is increasing.,,Increasing size is a subtype of changing size: A process that changes the size of the object to be larger.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000138,,,,,,,,,,,,,,,,,,,,,,increasing size,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006711,estrogen catabolic process,estrogen catabolism|estrogen degradation|estrogen breakdown,"The chemical reactions and pathways resulting in the breakdown of estrogens, C18 steroid hormones that can stimulate the development of female sexual characteristics. Also found in plants",false,,,http://purl.obolibrary.org/obo/GO_0009056|http://purl.obolibrary.org/obo/GO_0008210,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways resulting in the breakdown of estrogens, C18 steroid hormones that can stimulate the development of female sexual characteristics. Also found in plants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,estrogen catabolism|estrogen degradation|estrogen breakdown,,,,,GO:0006711,,,,,,,,,,,,,,,,,,,,,,estrogen catabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003190,BAX (canonical)[Glutathione depletion],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002045|http://purl.obolibrary.org/obo/IMR_0000453,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24887|NCBI-Human-GeneID:581|NCBI-Mouse-GeneID:12028,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000327,,,,,,,,,,TXPO:0003190,,,,,,,,,,,,,,,,,,,,,,BAX (canonical)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003191,IL-1B (canonical)[Glutathione depletion],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002045|http://purl.obolibrary.org/obo/TXPO_1000200,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:3553|NCBI-Rat-GeneID:24494|NCBI-Mouse-GeneID:16176,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003041,,,,,,,,,,TXPO:0003191,,,,,,,,,,,,,,,,,,,,,,IL-1B (canonical)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003198,BAK1 (canonical)[apotosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000040|http://purl.obolibrary.org/obo/TXPO_0003195,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:578|NCBI-Mouse-GeneID:12018|NCBI-Rat-GeneID:116502,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003198,,,,,,,,,,,,,,,,,,,,,,BAK1 (canonical)[apotosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003193,IL-4 (canonical)[Glutathione depletion],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002045|http://purl.obolibrary.org/obo/IMR_0000585,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:16189|NCBI-Rat-GeneID:287287|NCBI-Human-GeneID:3565,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003041,,,,,,,,,,TXPO:0003193,,,,,,,,,,,,,,,,,,,,,,IL-4 (canonical)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003199,BID (canonical)[apotosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003195|http://purl.obolibrary.org/obo/IMR_0100289,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:64625|NCBI-Mouse-GeneID:12122|NCBI-Human-GeneID:637,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003199,,,,,,,,,,,,,,,,,,,,,,BID (canonical)[apotosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003195,cell death dependent dependent molecule (canonical),,"Cell death dependent molecule is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of cell death as a gene product.
Gene profile:caonical that described in textbooks or articles.",false,,,http://purl.obolibrary.org/obo/TXPO_0000838,,,,,,,,,,,,,,,,,,,,,,"Cell death dependent molecule is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of cell death as a gene product.
Gene profile:caonical that described in textbooks or articles.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003195,,,,,,,,,,,,,,,,,,,,,,cell death dependent dependent molecule (canonical),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003194,TNF-A (canonical)[Glutathione depletion],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002045|http://purl.obolibrary.org/obo/TXPO_1000374,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:21926|NCBI-Rat-GeneID:24835|NCBI-Human-GeneID:7124,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003194,,,,,,,,,,,,,,,,,,,,,,TNF-A (canonical)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003196,APAF1 (canonical)[apotosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000005|http://purl.obolibrary.org/obo/TXPO_0003195,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:317|NCBI-Rat-GeneID:78963|NCBI-Mouse-GeneID:11783,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003196,,,,,,,,,,,,,,,,,,,,,,APAF1 (canonical)[apotosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003197,BAD (canonical)[apotosis],,,false,,,http://purl.obolibrary.org/obo/IMR_0100288|http://purl.obolibrary.org/obo/TXPO_0003195,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:572|NCBI-Rat-GeneID:64639|NCBI-Mouse-GeneID:12015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003197,,,,,,,,,,,,,,,,,,,,,,BAD (canonical)[apotosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003192,IL-10 (canonical)[Glutathione depletion],,,false,,,http://purl.obolibrary.org/obo/IMR_0000589|http://purl.obolibrary.org/obo/TXPO_0002045,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:25325|NCBI-Human-GeneID:3586|NCBI-Mouse-GeneID:16153,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003041,,,,,,,,,,TXPO:0003192,,,,,,,,,,,,,,,,,,,,,,IL-10 (canonical)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100083,parathyroid hormone,Parathormone,,false,,,http://purl.obolibrary.org/obo/IMR_0000966,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_24621,,,,,Parathormone,,,,,IMR:0100083,,,,,,,,,,,,,,,,,,,,,,parathyroid hormone,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003381,sphingomyelin accumulation in lysosome [Phospholipidosis -  sphingomyelin disorder ],,"Sphingomyelin accumulation in lysosome is a subtype of phospholipid accumulation in lysosome: A process that keeps sphingomyelin in the lysosome.
This process can constitute the course of  sphingomyelin disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001764|http://purl.obolibrary.org/obo/TXPO_0000910,,,,,,,,,,,,,,,,,,,,,,"Sphingomyelin accumulation in lysosome is a subtype of phospholipid accumulation in lysosome: A process that keeps sphingomyelin in the lysosome.
This process can constitute the course of  sphingomyelin disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003381,,,,,,,,,,,,,,,,,,,,,,sphingomyelin accumulation in lysosome [Phospholipidosis -  sphingomyelin disorder ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003384,phosholipase gene expression [Phospholipidosis],,"Phosholipase gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature phospholipase gene product or products (proteins or RNA).
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0003383,,,,,,,,,,,,,,,,,,,,,,"Phosholipase gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature phospholipase gene product or products (proteins or RNA).
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001406,,,,,,,,,,,TXPO:0003384,,,,,,,,,,,,,,,,,,,,,,phosholipase gene expression [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005634,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003385,hyperfunction of phospholipid synthesis gene expression [Phospholipidosis - normal],,"Hyperfunction of phospholipid synthesis gene expression is a subtype of hyperfunction of gene expression: A process that performs an excesssive phospholipid synthetic gene expression.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (normal condition).",false,,,http://purl.obolibrary.org/obo/TXPO_0001726|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of phospholipid synthesis gene expression is a subtype of hyperfunction of gene expression: A process that performs an excesssive phospholipid synthetic gene expression.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (normal condition).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003385,,,,,,,,,,,,,,,,,,,,,,hyperfunction of phospholipid synthesis gene expression [Phospholipidosis - normal],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003382,phospholipidosis (course),,Phosphoipidosis is a subtype of process sequences: The courses of processes through which phospholipidosis is realized.,false,,,http://purl.obolibrary.org/obo/TXPO_0000009,,,,,,,,,,,,,,,,,,,,PMID:16979167|PMID:22960355|PMID:15342952,,Phosphoipidosis is a subtype of process sequences: The courses of processes through which phospholipidosis is realized.,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000946,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000951|http://purl.obolibrary.org/obo/TXPO_0000946,,,,,,,,,,,,,,,,,,TXPO:0003382,,,,,,,,,,,,,,,,,,,,,,phospholipidosis (course),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003380,SGPL1 - apoptosis inducer (human)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002090,,,,,,,,,,,,,,,,,,,,http://omim.org/entry/603729|PMID:2061324|PMID:17090686|PMID:20097939,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_68495|http://purl.obolibrary.org/obo/TXPO_0002358,,,,,,,,,,TXPO:0003380,,,,,,,,,,,,,,,,,,,,,,SGPL1 - apoptosis inducer (human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001547|http://purl.obolibrary.org/obo/TXPO_0000928,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003383,phosholipase gene expression,,Phosholipase gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature phospholipase gene product or products (proteins or RNA).,false,,,http://purl.obolibrary.org/obo/GO_0010467,,,,,,,,,,,,,,,,,,,,,,Phosholipase gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature phospholipase gene product or products (proteins or RNA).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003383,,,,,,,,,,,,,,,,,,,,,,phosholipase gene expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003386,increasing phospholipid [Phospholipidosis (normal condition)],,"Increasing phospholipid is a subtype of increasing quantity: A process that changes the amount of phospholipid to be larger.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (normal condition).",false,,,http://purl.obolibrary.org/obo/TXPO_0001250|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Increasing phospholipid is a subtype of increasing quantity: A process that changes the amount of phospholipid to be larger.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (normal condition).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003401|http://purl.obolibrary.org/obo/TXPO_0003403|http://purl.obolibrary.org/obo/TXPO_0003400|http://purl.obolibrary.org/obo/TXPO_0004136|http://purl.obolibrary.org/obo/TXPO_0001427|http://purl.obolibrary.org/obo/TXPO_0003387|http://purl.obolibrary.org/obo/TXPO_0003397,,,,,,,,,,,,,,,,,,TXPO:0003386,,,,,,,,,,,,,,,,,,,,,,increasing phospholipid [Phospholipidosis (normal condition)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003389,Cyp3a11 (mouse)[Glutathione depletion],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002285|http://purl.obolibrary.org/obo/TXPO_1000106,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:13112,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003389,,,,,,,,,,,,,,,,,,,,,,Cyp3a11 (mouse)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003387,phospholipid biosynthetic process [Phospholipidosis(normal)],,"The chemical reactions and pathways resulting in the formation of phospholipids, any lipid containing phosphoric acid as a mono- or diester.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/GO_0008654,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways resulting in the formation of phospholipids, any lipid containing phosphoric acid as a mono- or diester.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001435,,,,,,,,,,,TXPO:0003387,,,,,,,,,,,,,,,,,,,,,,phospholipid biosynthetic process [Phospholipidosis(normal)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003388,phospholipid transport from lysosome,,Phospholipid transport from lysosome into cytosol is a subtype of phospholipid transfer to membrane: A process of the transfer of a phospholipid from the lysosome to the plasma membrane.,false,,,http://purl.obolibrary.org/obo/GO_0015914,,,,,,,,,,,,,,,,,,,,,,Phospholipid transport from lysosome into cytosol is a subtype of phospholipid transfer to membrane: A process of the transfer of a phospholipid from the lysosome to the plasma membrane.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005829,http://purl.obolibrary.org/obo/GO_0005764,,,,,,,TXPO:0003388,,,,,,,,,,,,,,,,,,,,,,phospholipid transport from lysosome,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100732,presenilin 2,AD3LP|E5-1|PS-2|AD5|Alzheimer disease 4 homolog|ALG-3|STM-2,,false,,,http://purl.obolibrary.org/obo/IMR_0000560,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,AD3LP|E5-1|PS-2|AD5|Alzheimer disease 4 homolog|ALG-3|STM-2,,,,,IMR:0100732,,,,,,,,,,,,,,,,,,,,,,presenilin 2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100799,LRP1,low density lipoprotein receptor-related protein 1|low-density lipoprotein receptor-related protein 1|LDL receptor-related protein 1,,false,,,http://purl.obolibrary.org/obo/IMR_0100798,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,low density lipoprotein receptor-related protein 1|low-density lipoprotein receptor-related protein 1|LDL receptor-related protein 1,,,,,IMR:0100799,,,,,,,,,,,,,,,,,,,,,,LRP1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003582,CYP4A11(predicted)(human)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001135|http://purl.obolibrary.org/obo/TXPO_0003836,,,,,,,,,,,,,,,,,,,"Cyp4a11 relates to cardiovascular abnormality (blood pressure, etc.).",NCBI-Human-GeneID:1579|PMID:16712844|PMID:30069903|PMID:18433732|PMID:21912424|PMID:12464261,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000001579,,,,,,,,,,,,,TXPO:0003582,,,,,,,,,,,,,,,,,,,,,,CYP4A11(predicted)(human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003587,Niemann–Pick disease course,,The totality of all processes through which a given Niepamnn-pick disease instance is realized.,false,,,http://purl.obolibrary.org/obo/OGMS_0000063,,,,,,,,,,,,,,,,,,,,,,The totality of all processes through which a given Niepamnn-pick disease instance is realized.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003635,,,,,,,,,,,,,,,,,,TXPO:0003587,,,,,,,,,,,,,,,,,,,,,,Niemann–Pick disease course,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/DOID_14504,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003583,hyperfunction of phospholipid degradation (severe),,Hyperfunction of phospholipid degradation (severe) is a subtype of hyperfunction of phospholipid degradation: A process that performs an excessive phospholipid degradation severely.,false,,,http://purl.obolibrary.org/obo/TXPO_0001430,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of phospholipid degradation (severe) is a subtype of hyperfunction of phospholipid degradation: A process that performs an excessive phospholipid degradation severely.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003583,,,,,,,,,,,,,,,,,,,,,,hyperfunction of phospholipid degradation (severe),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003586,NCR3LG1 (human)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001135|http://purl.obolibrary.org/obo/TXPO_0003842,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:374383|PMID:26241657|PMID:19528259|http://www.reactome.org/content/detail/R-HSA-5683240|https://omim.org/entry/613714,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003586,,,,,,,,,,,,,,,,,,,,,,NCR3LG1 (human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003581,insulin relative deficiency [diabetes course],,"Insulin deficiency is a subtype of malfunctioning process: A process that lacks performing the insulin function required.
This entity is a specific course-dependent process. This process can constitute the course of type II diabetes.",false,,,http://purl.obolibrary.org/obo/TXPO_0003289,,,,,,,,,,,,,,,,,,,,,,"Insulin deficiency is a subtype of malfunctioning process: A process that lacks performing the insulin function required.
This entity is a specific course-dependent process. This process can constitute the course of type II diabetes.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003290,,,,,,,,,,,TXPO:0003581,,,,,,,,,,,,,,,,,,,,,,insulin relative deficiency [diabetes course],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003584,increasing phospholipid inflow (severe),,Increasing phospholipid inflow (severe) is a subtype of increase in phospholipid inflow: A process that changes the phospholipid inflow into the hepatocyte to be larger.,false,,,http://purl.obolibrary.org/obo/TXPO_0001251,,,,,,,,,,,,,,,,,,,,,,Increasing phospholipid inflow (severe) is a subtype of increase in phospholipid inflow: A process that changes the phospholipid inflow into the hepatocyte to be larger.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003584,,,,,,,,,,,,,,,,,,,,,,increasing phospholipid inflow (severe),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003580,sphingomyelin biosynthetic process[Niemann Pick Disease Type B],sphingomyelin anabolism|sphingomyelin formation|sphingomyelin biosynthesis|sphingomyelin synthesis,"The chemical reactions and pathways resulting in the formation of sphingomyelin, N-acyl-4-sphingenyl-1-O-phosphorylcholine.
This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type B.",false,,,http://purl.obolibrary.org/obo/GO_0006686|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways resulting in the formation of sphingomyelin, N-acyl-4-sphingenyl-1-O-phosphorylcholine.
This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type B.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_64583,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001816,,,,,,sphingomyelin anabolism|sphingomyelin formation|sphingomyelin biosynthesis|sphingomyelin synthesis,,,,,TXPO:0003580,,,,,,,,,,,,,,,,,,,,,,sphingomyelin biosynthetic process[Niemann Pick Disease Type B],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003589,cell homeostasis imbalance [Phospholipidosis (severe)],,"Cell homeostasis imbalance is a subtype of homeostasis imbalance: A process that becomes lacking a cell homeostastasis balance.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",false,,,http://purl.obolibrary.org/obo/TXPO_0003553|http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0003590,,,,,,,,,,,,,,,,,,,,,,"Cell homeostasis imbalance is a subtype of homeostasis imbalance: A process that becomes lacking a cell homeostastasis balance.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003589,,,,,,,,,,,,,,,,,,,,,,cell homeostasis imbalance [Phospholipidosis (severe)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003588,EIF2A - cell cycle arresr inducer (canonical)[ER stress - translation],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001275,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002270,,,,,,,,,,TXPO:0003588,,,,,,,,,,,,,,,,,,,,,,EIF2A - cell cycle arresr inducer (canonical)[ER stress - translation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000025,TNF alpha,TNF|tumor necrosis factor alpha,,false,,,http://purl.obolibrary.org/obo/IMR_0000021,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TNF|tumor necrosis factor alpha,,,,,IMR:0000025,,,,,,,,,,,,,,,,,,,,,,TNF alpha,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000050810,HDGFRP3,,Other designations: hepatoma-derived growth factor 2|hepatoma-derived growth factor-related protein 3,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,HDGF2|HRP-3|HDGF-2,,,,,,,,,,,,15,,,,,,Vega:OTTHUMG00000172685|HPRD:17096|Ensembl:ENSG00000166503,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,,,,15q25.2,,,,,,,,,,,,,,,,"GO_0005634 (EC: IDA); GO_0005730 (EC: IDA, Qualifier: NOT); GO_0005737 (EC: IEA); GO_0008083 (EC: IEA); GO_0008283 (EC: NAS, PMID: 10581169)",,,,,,,,,PMID: 10581169; 10810093; 12477932; 14702039; 15371438; 15489334; 15761153; 16337983; 18029348; 19237540; 21044950; 21706016; 21890473; 23000965; 23503679; 24012673,,,,,,,,,,,,,,,OGG:3000050810,,,,,,,"hepatoma-derived growth factor, related protein 3",,,,,,,,,,,,,Other designations: hepatoma-derived growth factor 2|hepatoma-derived growth factor-related protein 3,,HDGFRP3,,,,,,,,,,,,,,,,,,,,,,,50810,CGI-142,,,NCBI-supplied,,,,9606,,,,,,,,,,,,,,,,,,,,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_50904,allergen,alergeno|allergene|allergenic agent,"A chemical compound, or part thereof, which causes the onset of an allergic reaction by interacting with any of the molecular pathways involved in an allergy.|A chemical compound which causes the onset of an allergic reaction by interacting with any of the molecular pathways involved in an allergy.",false,,,http://purl.obolibrary.org/obo/CHEBI_52209,,,,,,,,,,,,,,,,,,,,Wikipedia:Allergen,,"A chemical compound, or part thereof, which causes the onset of an allergic reaction by interacting with any of the molecular pathways involved in an allergy.|A chemical compound which causes the onset of an allergic reaction by interacting with any of the molecular pathways involved in an allergy.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,alergeno|allergene|allergenic agent,,,,,,,,,,,,,,,,,,,,,CHEBI:50904,,,,allergen,,CHEBI:50904,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001366,Gli2,,,false,,,http://purl.obolibrary.org/obo/IMR_0001372,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001366,,,,,,,,,,,,,,,,,,,,,,Gli2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001133,aggrecan,,,false,,,http://purl.obolibrary.org/obo/IMR_0001126,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001133,,,,,,,,,,,,,,,,,,,,,,aggrecan,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_5132,flutamide,"flutamide|flutamidum|alpha,alpha,alpha-trifluoro-2-methyl-4'-nitro-m-propionotoluidide|Eulexin|niftolid|Niftolide|4'-nitro-3'-trifluoromethylisobutyranilide|flutamida|Flutamide|2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide",,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,LINCS:LSM-2621|Beilstein:2157663|DrugBank:DB00499|Drug_Central:1223|CAS:13311-84-7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35610|http://purl.obolibrary.org/obo/CHEBI_35497,,,,,Flutamide|2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide,,"flutamide|flutamidum|alpha,alpha,alpha-trifluoro-2-methyl-4'-nitro-m-propionotoluidide|Eulexin|niftolid|Niftolide|4'-nitro-3'-trifluoromethylisobutyranilide|flutamida",,,,,,,,,,,,,,,,,,,,,CHEBI:5132,,,,flutamide,,CHEBI:5132,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0004535,cardiovascular system,Herz und Gefaesssystem|CV system,Anatomical system that has as its parts the heart and blood vessels.,false,,,http://purl.obolibrary.org/obo/UBERON_0000467,,,,,,,,,,,,,,,,,,,"we treat cardiovascular as part of circulatory system, with the latter including other kinds of circulation, including lymph.",http://purl.obolibrary.org/obo/NCIT_C12686|http://linkedlifedata.com/resource/umls/id/C0007226|http://www.snomedbrowser.com/Codes/Details/278198007|EMAPA:16104|MIAA:0000016|UMLS:C0007226|CALOHA:TS-1297|AAO:0011001|ZFA:0000010|GAID:467|VHOG:0000302|MESH:D002319|OpenCyc:Mx4rvVjzG5wpEbGdrcN5Y29ycA|EHDAA:394|EMAPA:16370|BILA:0000016|EHDAA2:0000216|MA:0000010|MAT:0000016|XAO:0000100|TAO:0000010|XAO:0001010|WikipediaCategory:Cardiovascular_system|FMA:7161|BTO:0000088|EFO:0000791|EV:0100017,,Anatomical system that has as its parts the heart and blood vessels.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0001981,,,,,,,,,,,,,,,Herz und Gefaesssystem|CV system,"The vessels of the cardiovascular system are as varied as the diverse organs they supply. However, these variations are based on modifications of a fundamental plan of organization common to vertebrates.[well established][VHOG]",http://purl.obolibrary.org/obo/UBERON_0001009,UBERON:0004535,http://purl.obolibrary.org/obo/UBERON_0001009,,,,,,,,,,,,,,,,,,,,,cardiovascular system,,,,,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100629,cyclin T1,Cyclin T1|CycT1|cyclin T|Cyclin T|CCT1,,false,,,http://purl.obolibrary.org/obo/IMR_0100628,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0010177|IMR:0011619,Cyclin T1|CycT1|cyclin T|Cyclin T|CCT1,,,,,IMR:0100629,,,,,,,,,,,,,,,,,,,,,,cyclin T1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005141,changing quality of tumor,,"Tumor malignancy alteration is a subtype of changing quality: A process that changes the tumor malignancy.
Changing quality of tumor is a subtype of changing quality: A process that changes the quailty of tumor cells.",false,,,http://purl.obolibrary.org/obo/TXPO_0000415,,,,,,,,,,,,,,,,,,,,,,"Tumor malignancy alteration is a subtype of changing quality: A process that changes the tumor malignancy.
Changing quality of tumor is a subtype of changing quality: A process that changes the quailty of tumor cells.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005141,,,,,,,,,,,,,,,,,,,,,,changing quality of tumor,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0002011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005148,propylthiouracil,,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005148,,,,,,,,,,,,,,,,,,,,,,propylthiouracil,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005149,isoniazid,,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005149,,,,,,,,,,,,,,,,,,,,,,isoniazid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005140,Less-DILI-Concern,,"From Drug Induced Liver Injury Rank (DILIrank) Dataset.
 DILIrank consists of 1,036 FDA-approved drugs that are divided into four classes according to their potential for causing drug-induced liver injury (DILI).",false,,,http://purl.obolibrary.org/obo/TXPO_0004322,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005140,,,,,,,,,,,,,,,,,,,,"From Drug Induced Liver Injury Rank (DILIrank) Dataset.
 DILIrank consists of 1,036 FDA-approved drugs that are divided into four classes according to their potential for causing drug-induced liver injury (DILI).",,Less-DILI-Concern,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005145,rifampin,,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005145,,,,,,,,,,,,,,,,,,,,,,rifampin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005142,No-DILI-Concern,,"From Drug Induced Liver Injury Rank (DILIrank) Dataset.
 DILIrank consists of 1,036 FDA-approved drugs that are divided into four classes according to their potential for causing drug-induced liver injury (DILI).",false,,,http://purl.obolibrary.org/obo/TXPO_0004322,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005142,,,,,,,,,,,,,,,,,,,,"From Drug Induced Liver Injury Rank (DILIrank) Dataset.
 DILIrank consists of 1,036 FDA-approved drugs that are divided into four classes according to their potential for causing drug-induced liver injury (DILI).",,No-DILI-Concern,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005147,methyldopa,,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005147,,,,,,,,,,,,,,,,,,,,,,methyldopa,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005146,dactinomycin,,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005146,,,,,,,,,,,,,,,,,,,,,,dactinomycin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005144,indomethacin,,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005144,,,,,,,,,,,,,,,,,,,,,,indomethacin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005143,central nervous system sphingomyelin homeostasis imbalance [Niemann Pick Disease Type A],,"Sphingomyelin homeostasis imbalance is a subtype of lipid homeostasis imbalance: A process that becomes lacking a phospholipid homeostastasis balance.
This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type A.",false,,,http://purl.obolibrary.org/obo/TXPO_0003988,,,,,,,,,,,,,,,,,,,,,,"Sphingomyelin homeostasis imbalance is a subtype of lipid homeostasis imbalance: A process that becomes lacking a phospholipid homeostastasis balance.
This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type A.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001482|http://purl.obolibrary.org/obo/TXPO_0005143,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001692,,http://purl.obolibrary.org/obo/TXPO_0002327,,,,,,,,,TXPO:0005143,,,,,,,,,,,,,,,,,,,,,,central nervous system sphingomyelin homeostasis imbalance [Niemann Pick Disease Type A],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100812,CKI-gamma 2,"Casein kinase I, gamma 2 isoform",,false,,,http://purl.obolibrary.org/obo/IMR_0100809,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Casein kinase I, gamma 2 isoform",,,,,IMR:0100812,,,,,,,,,,,,,,,,,,,,,,CKI-gamma 2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000001601,DAB2,,"Other designations: differentially-expressed protein 2|disabled homolog 2|disabled homolog 2, mitogen-responsive phosphoprotein",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,DOC2|DOC-2,,,,,,,,,,,,5,,,,,,MIM:601236|HPRD:03139|Vega:OTTHUMG00000162043|HGNC:2662|Ensembl:ENSG00000153071,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"Dab, mitogen-responsive phosphoprotein, homolog 2 (Drosophila)",,,5p13.1,,,,,,,,,,,,,,,,"GO_0000904 (EC: IEA); GO_0001701 (EC: IEA); GO_0001921 (EC: IEA); GO_0001934 (EC: IMP, PMID: 12805222); GO_0005178 (EC: IEA); GO_0005515 (EC: IPI, PMID: 11387212); GO_0005546 (EC: IEA); GO_0005730 (EC: IDA); GO_0005765 (EC: TAS); GO_0005886 (EC: IDA); GO_0005886 (EC: TAS); GO_0005905 (EC: IDA, PMID: 12857860); GO_0006907 (EC: IEA); GO_0006915 (EC: IEA); GO_0007257 (EC: IEA); GO_0007492 (EC: IEA); GO_0007588 (EC: IEA); GO_0008022 (EC: IPI, PMID: 15837803); GO_0008283 (EC: TAS, PMID: 9620555); GO_0010718 (EC: IDA, PMID: 15734730); GO_0010862 (EC: IDA, PMID: 11387212); GO_0015031 (EC: IEA); GO_0016055 (EC: IEA); GO_0016324 (EC: IEA); GO_0030099 (EC: IEA); GO_0030132 (EC: IEA); GO_0030335 (EC: IEA); GO_0030511 (EC: IDA, PMID: 11387212); GO_0030665 (EC: IEA); GO_0032091 (EC: IMP, PMID: 12805222); GO_0032436 (EC: IMP, PMID: 12805222); GO_0032968 (EC: IEA); GO_0035612 (EC: IEA); GO_0035615 (EC: IMP, PMID: 16984970); GO_0038024 (EC: IMP, PMID: 16984970); GO_0043066 (EC: IDA, PMID: 15734730); GO_0043231 (EC: IDA); GO_0045807 (EC: IMP); GO_0045892 (EC: IMP, PMID: 12805222); GO_0045893 (EC: IMP, PMID: 12805222); GO_0046332 (EC: IDA, PMID: 11387212); GO_0048268 (EC: IEA); GO_0060391 (EC: IDA, PMID: 11387212); GO_0060766 (EC: IMP, PMID: 16267015); GO_0061024 (EC: TAS); GO_0070022 (EC: IDA, Qualifier: colocalizes_with, PMID: 11387212); GO_0071560 (EC: IEA); GO_0090090 (EC: IMP, PMID: 12805222); GO_1900026 (EC: IEA); GO_2000096 (EC: IMP, PMID: 12805222); GO_2000370 (EC: IMP, PMID: 16984970); GO_2000643 (EC: IMP); GO_2001046 (EC: IEA); GO_2001237 (EC: IEA)",,,,,,,,,PMID: 8314147; 8660969; 8889548; 9569023; 9620555; 10340382; 10542228; 10769163; 11039902; 11161789; 11247302; 11371563; 11387212; 11812785; 11906161; 11927540; 11967127; 12473651; 12477932; 12606711; 12805222; 12853125; 12857860; 12881709; 14596919; 14669280; 15134832; 15231748; 15247260; 15280374; 15302935; 15489334; 15734730; 15837803; 15894542; 16061224; 16267015; 16713569; 16870701; 16964243; 16984970; 17009406; 17081983; 17110338; 17115114; 17187061; 17474147; 17671122; 18070591; 18354201; 18429820; 18582465; 19204726; 19423540; 19531213; 19581412; 19738201; 19767570; 19855435; 19956625; 20379614; 20383146; 20406964; 20438785; 20448150; 20525238; 20592473; 20628624; 20936779; 21063401; 21097498; 21139048; 21496867; 21573318; 21725366; 21963094; 21987572; 21988832; 21995445; 22158540; 22218591; 22265793; 22323290; 22399289; 22558309; 22648170; 22705885; 22898784; 22977233; 23005040; 23263486; 23817569; 23909735; 24186266,,,,,,,,,,,,,,,OGG:3000001601,,20140408,protein-coding,,,,"Dab, mitogen-responsive phosphoprotein, homolog 2 (Drosophila)",,,,,,,,,,,,,"Other designations: differentially-expressed protein 2|disabled homolog 2|disabled homolog 2, mitogen-responsive phosphoprotein",,DAB2,,,,,,,,,,,,,,,,,,,,,,,1601,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,DAB2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0100659,p53 (mol),Cellular tumor antigen p53|Antigen NY-CO-13|Tumor suppressor p53|P53|Phosphoprotein p53|p53 protein,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PR_000003035,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,IMR:0010777|IMR:0011713,Cellular tumor antigen p53|Antigen NY-CO-13|Tumor suppressor p53|P53|Phosphoprotein p53|p53 protein,,,,,IMR:0100659,,,,,,,,,,,,,,,,,,,,,,p53 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000327,ubiquitin activating enzyme,E1 ubiquitin-activating enzyme|ubiquitin-activating enzyme (E1),"Catalysis role of the reaction: E1 + ubiquitin + ATP--> E1-ubiquitin + AMP + PPi, where the E1-ubiquitin linkage is a thioester bond between the C-terminal glycine of Ub and a sulfhydryl side group of an E1 cysteine residue. This is the first step in a cascade of reactions in which ubiquitin is ultimately added to a protein substrate.|related molecular function GO:0004839",false,,,http://purl.obolibrary.org/obo/TXPO_0003660,,,,,,,,,,,,,,,,,,,,IMR:0000327 (obsolete)|Wikipedia:Ubiquitin-activating_enzyme|EC:6.2.1.45,,"Catalysis role of the reaction: E1 + ubiquitin + ATP--> E1-ubiquitin + AMP + PPi, where the E1-ubiquitin linkage is a thioester bond between the C-terminal glycine of Ub and a sulfhydryl side group of an E1 cysteine residue. This is the first step in a cascade of reactions in which ubiquitin is ultimately added to a protein substrate.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,E1 ubiquitin-activating enzyme|ubiquitin-activating enzyme (E1),,,,,IMR:0000327,,,,,,,,,,,,,,,,,,,,related molecular function GO:0004839,,ubiquitin activating enzyme,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://www.w3.org/2002/07/owl#Thing,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_50112,sex hormone,hormone sexuelle|Sexualhormone|Geschlechtshormone|hormones sexuelles|sex hormones|Sexualhormon|Geschlechtshormon,Any hormone that is responsible for controlling sexual characteristics and reproductive function.,false,,,http://purl.obolibrary.org/obo/CHEBI_24621,,,,,,,,,,,,,,,,,,,,,,Any hormone that is responsible for controlling sexual characteristics and reproductive function.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,hormone sexuelle|Sexualhormone|Geschlechtshormone|hormones sexuelles|sex hormones|Sexualhormon|Geschlechtshormon,,,,,,,,,,,,,,,,,,,,,CHEBI:50112,,,,sex hormone,,CHEBI:50112,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_16990,bilirubin,,"A member of the class of biladienes that is a linear tetrapyrrole with the dipyrrole units being of both exovinyl and endovinyl type. A product of heme degradation, it is produced in the reticuloendothelial system by the reduction of biliverdin and transported to the liver as a complex with serum albumin.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Wikipedia:Bilirubin,,"A member of the class of biladienes that is a linear tetrapyrrole with the dipyrrole units being of both exovinyl and endovinyl type. A product of heme degradation, it is produced in the reticuloendothelial system by the reduction of biliverdin and transported to the liver as a complex with serum albumin.",,,,,,,,,,,,C33H36N4O6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:16990,,,,,,,,,,,,,,,,,,,,,,bilirubin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CC1=C(C=C)\C(NC1=O)=C\c1[nH]c(Cc2[nH]c(\C=C3NC(=O)C(C=C)=C/3C)c(C)c2CCC(O)=O)c(CCC(O)=O)c1C,,,,,
http://purl.obolibrary.org/obo/IMR_0001100,exportin-t,,,false,,,http://purl.obolibrary.org/obo/IMR_0100015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001100,,,,,,,,,,,,,,,,,,,,,,exportin-t,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000002947,GSTM3,,"Other designations: GST class-mu 3|S-(hydroxyalkyl)glutathione lyase M3|brain GST|brain type mu-glutathione S-transferase|glutathione S-alkyltransferase M3|glutathione S-aralkyltransferase M3|glutathione S-aryltransferase M3|glutathione S-transferase M3 (brain)|glutathione S-transferase Mu 3|glutathione S-transferase, Mu-3|hGSTM3-3",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,GSTB|GSTM3-3|GST5|GTM3,,,,,,,,,,,,1,,,,,,HPRD:00712|Ensembl:ENSG00000134202|HGNC:4635|MIM:138390,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,glutathione S-transferase mu 3 (brain),,,1p13.3,,,,,,,,,,,,,,,,"GO_0004364 (EC: IDA, PMID: 10587441); GO_0005737 (EC: IDA, PMID: 8373352); GO_0005829 (EC: TAS); GO_0006749 (EC: IDA, PMID: 10587441); GO_0006805 (EC: TAS); GO_0008065 (EC: TAS, PMID: 2345169); GO_0018916 (EC: IDA, PMID: 8373352); GO_0019899 (EC: IPI, PMID: 8373352); GO_0042178 (EC: IDA, PMID: 8373352); GO_0042802 (EC: IPI, PMID: 16189514); GO_0042803 (EC: IDA, PMID: 9545290); GO_0042803 (EC: IPI, PMID: 8373352); GO_0043295 (EC: IDA, PMID: 8373352); GO_0043627 (EC: IEP, PMID: 10037815); GO_0044281 (EC: TAS); GO_0070458 (EC: IDA, PMID: 8373352); GO_1901687 (EC: TAS)",,,,,,,,,PMID: 1530570; 2345169; 8218382; 8242618; 8317488; 8373352; 8404061; 8473333; 8824514; 9230131; 9545290; 9797707; 9882431; 10037815; 10587441; 11040079; 11081456; 11173863; 11289100; 11303592; 11408349; 11511301; 11535247; 11692073; 11740339; 11927838; 12016153; 12063626; 12359356; 12477932; 12548461; 14634838; 14735473; 14968442; 15069685; 15115915; 15338373; 15459020; 15489334; 15525789; 15621212; 15654505; 15665284; 15829318; 15914277; 16006997; 16112301; 16172217; 16189514; 16328000; 16488179; 16509765; 16598069; 16760134; 16765145; 16886896; 16985026; 17034008; 17083362; 17220350; 17259654; 17290392; 17353931; 17372252; 17449559; 17565746; 17601350; 17617661; 17716224; 17904251; 17922434; 18065725; 18177825; 18204928; 18258609; 18423940; 18447907; 18510611; 18551009; 18569590; 18668224; 18676680; 18850183; 18977241; 18990750; 18992148; 19060904; 19062541; 19074885; 19151192; 19170196; 19336475; 19339270; 19343046; 19407363; 19424794; 19486347; 19521675; 19692168; 19696791; 19751749; 19786980; 19789190; 19822571; 19856098; 19860743; 19898482; 19913121; 19922706; 20029944; 20032816; 20131310; 20136364; 20200426; 20237496; 20391138; 20391338; 20437850; 20461808; 20485444; 20549140; 20577141; 20628086; 20634891; 20661821; 20819778; 20847076; 20970553; 21072184; 21139048; 21513434; 21800051; 21890473; 21900206; 21963094; 21987572; 22178446; 22360420; 22505724; 22976281; 23000965; 23036584; 23077236; 23167362; 23576398; 23824909; 24250222,,,,,,,,,,,,,,,OGG:3000002947,,,,,,,glutathione S-transferase mu 3 (brain),,,,,,,,,,,,,"Other designations: GST class-mu 3|S-(hydroxyalkyl)glutathione lyase M3|brain GST|brain type mu-glutathione S-transferase|glutathione S-alkyltransferase M3|glutathione S-aralkyltransferase M3|glutathione S-aryltransferase M3|glutathione S-transferase M3 (brain)|glutathione S-transferase Mu 3|glutathione S-transferase, Mu-3|hGSTM3-3",,GSTM3,,,,,,,,,,,,,,,,,,,,,,,2947,RP4-735C1.2,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,GSTM3,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000002940,GSTA3,,Other designations: GST class-alpha member 3|S-(hydroxyalkyl)glutathione lyase A3|glutathione S-alkyltransferase A3|glutathione S-aralkyltransferase A3|glutathione S-aryltransferase A3|glutathione S-transferase A3|glutathione S-transferase A3-3,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,GTA3|GSTA3-3,,,,,,,,,,,,6,,,,,,Vega:OTTHUMG00000014865|MIM:605449|HGNC:4628|Ensembl:ENSG00000174156|HPRD:07290,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,glutathione S-transferase alpha 3,,,6p12.1,,,,,,,,,,,,,,,,GO_0004364 (EC: ISS); GO_0005829 (EC: TAS); GO_0006749 (EC: ISS); GO_0006805 (EC: TAS); GO_0044281 (EC: TAS); GO_1901687 (EC: TAS),,,,,,,,,PMID: 8307579; 9480897; 11418619; 11872752; 12477932; 14574404; 15454730; 15489334; 15595823; 16876319; 17601350; 18426392; 18977241; 19343046; 20083122; 20200426; 20237496; 21832049; 23650189; 23824909,,,,,,,,,,,,,,,OGG:3000002940,,,,,,,glutathione S-transferase alpha 3,,,,,,,,,,,,,Other designations: GST class-alpha member 3|S-(hydroxyalkyl)glutathione lyase A3|glutathione S-alkyltransferase A3|glutathione S-aralkyltransferase A3|glutathione S-aryltransferase A3|glutathione S-transferase A3|glutathione S-transferase A3-3,,GSTA3,,,,,,,,,,,,,,,,,,,,,,,2940,RP1-214M20.2,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,GSTA3,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000544,fibril-associated collagen,fibril associated collagens with interrupted triple helix|FACIT collagen,associate with the surface of fibrils and modify their interactive properties.,false,,,http://purl.obolibrary.org/obo/IMR_0000541,,,,,,,,,,,,,,,,,,,,GO:0005593,,associate with the surface of fibrils and modify their interactive properties.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,fibril associated collagens with interrupted triple helix|FACIT collagen,,,,,IMR:0000544,,,,,,,,,,,,,,,,,,,,,,fibril-associated collagen,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0002798,S6K1,,,false,,,http://purl.obolibrary.org/obo/IMR_0001845,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0002798,,,,,,,,,,,,,,,,,,,,,,S6K1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100118,glycine,Glycine|Gly|Aminoacetic acid,,false,,,http://purl.obolibrary.org/obo/CHEBI_33709,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_25512,,,,IMR:0200057,Glycine|Gly|Aminoacetic acid,,,,,IMR:0100118,,,,,,,,,,,,,,,,,,,,,,glycine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0015893,drug transport,,"The directed movement of a drug, a substance used in the diagnosis, treatment or prevention of a disease, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.",false,,,http://purl.obolibrary.org/obo/GO_0006810,,,,,,,,,,,,,,,,,,,,,,"The directed movement of a drug, a substance used in the diagnosis, treatment or prevention of a disease, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0015893,,,,,,,,,,,,,,,,,,,,,,drug transport,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000010273,STUB1,,Other designations: CLL-associated antigen KW-8|E3 ubiquitin-protein ligase CHIP|STIP1 homology and U box-containing protein 1|antigen NY-CO-7|carboxy terminus of Hsp70-interacting protein|heat shock protein A binding protein 2 (c-terminal)|serologically defined colon cancer antigen 7,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CHIP|HSPABP2|SDCCAG7|UBOX1|NY-CO-7,,,,,,,,,,,,16,,,,,,HGNC:11427|MIM:607207|HPRD:06232|Ensembl:ENSG00000103266|Vega:OTTHUMG00000121140,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"STIP1 homology and U-box containing protein 1, E3 ubiquitin protein ligase",,,16p13.3,,,,,,,,,,,,,,,,"GO_0000151 (EC: IDA, PMID: 16275660); GO_0000209 (EC: IDA, PMID: 15781469); GO_0000209 (EC: IMP, PMID: 19713937); GO_0004842 (EC: IDA, PMID: 15466472); GO_0004842 (EC: IMP, PMID: 19713937); GO_0004842 (EC: TAS, PMID: 16307917); GO_0005515 (EC: IPI, PMID: 11146632); GO_0005634 (EC: IDA); GO_0005730 (EC: IDA, Qualifier: NOT); GO_0005737 (EC: IDA); GO_0005829 (EC: TAS); GO_0005886 (EC: IDA); GO_0006281 (EC: IEA); GO_0006511 (EC: IMP, PMID: 19713937); GO_0006515 (EC: IDA, PMID: 16831871); GO_0007179 (EC: TAS); GO_0019899 (EC: IPI, PMID: 16280320); GO_0019900 (EC: IPI, PMID: 17512523); GO_0030512 (EC: TAS); GO_0030544 (EC: IDA, PMID: 10330192); GO_0030579 (EC: IDA, PMID: 15781469); GO_0030674 (EC: TAS, PMID: 16307917); GO_0030911 (EC: IDA, PMID: 11146632); GO_0031371 (EC: TAS, PMID: 16307917); GO_0031398 (EC: IDA, PMID: 11146632); GO_0031625 (EC: IEA); GO_0031943 (EC: IDA, PMID: 11146632); GO_0032436 (EC: IDA, PMID: 11146632); GO_0034450 (EC: ISS); GO_0042405 (EC: IDA, PMID: 16831871); GO_0042803 (EC: ISS); GO_0043161 (EC: IDA, PMID: 15781469); GO_0045111 (EC: IDA); GO_0046332 (EC: IDA, PMID: 15781469); GO_0051604 (EC: TAS, PMID: 16307917); GO_0051787 (EC: IDA, PMID: 16831871); GO_0051865 (EC: IDA, PMID: 16307917); GO_0051879 (EC: IDA, PMID: 11146632); GO_0070534 (EC: IDA, PMID: 16307917); GO_0071218 (EC: IDA, PMID: 16831871); GO_0090035 (EC: IDA, PMID: 16831871)",,,,,,,,,PMID: 9610721; 10330192; 11146632; 11146634; 11157797; 11557750; 11676916; 11743028; 11805346; 12150907; 12200376; 12239347; 12477932; 12559985; 12574167; 12837759; 14532117; 14532270; 14612456; 14701756; 14962978; 15001357; 15046863; 15107424; 15189447; 15198682; 15215316; 15254225; 15302935; 15358145; 15447663; 15456869; 15466472; 15489334; 15525661; 15538384; 15611333; 15694383; 15708501; 15761032; 15761153; 15781469; 15911628; 15936278; 16037132; 16038411; 16111477; 16135753; 16169070; 16169850; 16207813; 16275660; 16280320; 16293251; 16307917; 16621797; 16682404; 16712791; 16714300; 16720573; 16725394; 16740632; 16809764; 16831871; 16895519; 16964243; 17081983; 17127076; 17157513; 17178836; 17209571; 17239458; 17304350; 17317785; 17324930; 17512523; 17545168; 17595347; 17666403; 17873020; 17875712; 17962192; 17963781; 18042044; 18094050; 18223694; 18292230; 18313385; 18388150; 18411298; 18436529; 18457437; 18485199; 18541707; 18655187; 18678647; 18718056; 18784277; 18818696; 18955503; 18988734; 19011619; 19056735; 19098309; 19103148; 19153604; 19165527; 19196961; 19198599; 19237536; 19240029; 19306926; 19362296; 19406989; 19465479; 19471022; 19478201; 19483080; 19524548; 19536328; 19648119; 19706771; 19713937; 19818709; 19875381; 19892702; 19913553; 19940151; 20029029; 20146531; 20151404; 20349136; 20413784; 20466727; 20588253; 20618441; 20661446; 20675402; 20677910; 20704274; 20724525; 20729196; 20811636; 20924358; 20943656; 20947504; 20947508; 20959453; 20974249; 20974815; 21044950; 21124777; 21139048; 21157430; 21209460; 21220432; 21268072; 21272160; 21293491; 21325980; 21358815; 21360678; 21454478; 21518764; 21549100; 21625540; 21652633; 21710689; 21767636; 21775628; 21793045; 21855799; 21860411; 21898230; 21911421; 21942715; 21988832; 21995445; 22038067; 22090276; 22101235; 22118674; 22128174; 22190034; 22190037; 22254155; 22271573; 22350907; 22350919; 22407479; 22427670; 22433856; 22492994; 22535373; 22543587; 22551455; 22670667; 22734001; 22824801; 22842904; 22863883; 22895543; 22939629; 23023377; 23109339; 23134341; 23237806; 23246967; 23256568; 23271055; 23322406; 23344957; 23410750; 23412384; 23431407; 23455922; 23482560; 23493285; 23554879; 23560854; 23602568; 23629654; 23679257; 23686137; 23729439; 23764847; 23865999; 23880665; 23904609; 23963841; 23973223; 23990462; 24023840; 24043303; 24250222; 24509416,,,,,,,,,,,,,,,OGG:3000010273,,,,,,,"STIP1 homology and U-box containing protein 1, E3 ubiquitin protein ligase",,,,,,,,,,,,,Other designations: CLL-associated antigen KW-8|E3 ubiquitin-protein ligase CHIP|STIP1 homology and U box-containing protein 1|antigen NY-CO-7|carboxy terminus of Hsp70-interacting protein|heat shock protein A binding protein 2 (c-terminal)|serologically defined colon cancer antigen 7,,STUB1,,,,,,,,,,,,,,,,,,,,,,,10273,LA16c-313D11.6,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,STUB1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0200154,L-Threonine,,,false,,,http://purl.obolibrary.org/obo/CHEBI_33709,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0200154,,,,,,,,,,,,,,,,,,,,,,L-Threonine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_64912,antimycobacterial drug,antimycobacterial drugs|antimycobacterial agent|antimycobacterial agents|antimycobacterium|antimycobacterials,"A drug used to treat or prevent infections caused by Mycobacteria, a genus of actinobacteria. Aerobic and nonmotile, members of the genus include the pathogens responsible for causing tuberculosis and leprosy.",false,,,http://purl.obolibrary.org/obo/CHEBI_36047,,,,,,,,,,,,,,,,,,,,,,"A drug used to treat or prevent infections caused by Mycobacteria, a genus of actinobacteria. Aerobic and nonmotile, members of the genus include the pathogens responsible for causing tuberculosis and leprosy.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,antimycobacterial drugs|antimycobacterial agent|antimycobacterial agents|antimycobacterium|antimycobacterials,,,,,,,,,,,,,,,,,,,,,CHEBI:64912,,,,antimycobacterial drug,,CHEBI:64912,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_175901,gemcitabine,"gemcitabina|gemcitabine|gemcitabinum|2',2'-Difluorodeoxycytidine|4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one|2'-Deoxy-2',2'-difluorocytidine|2'-deoxy-2',2'-difluorocytidine","A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:22763439|PMID:11510027|PMID:28608357|PMID:16905983|PMID:17987263|PMID:17296587|PMID:19399788|PMID:17941128|PMID:17602464|PMID:18186604|PMID:15542781|PMID:12917815|PMID:11122828|PMID:11221019|PMID:17296311|PMID:16317298|PMID:11374818|Beilstein:5382060|LINCS:LSM-5333|PMID:16807463|PMID:18348652|PMID:12722691|PMID:12798170|PMID:28594276|PMID:18789834|PMID:19839926|PMID:11142482|PMID:12761494|PMID:12115355|PMID:18773046|PMID:17347561|PMID:12057041|PMID:17639396|PMID:11901308|PMID:15131028|PMID:17939651|PMID:16584929|PMID:16143373|PMID:12743987|PMID:19879060|PMID:11356111|PMID:16080557|DrugBank:DB00441|PMID:16041610|PMID:12057157|PMID:17887663|PMID:12520460|Drug_Central:1283|Reaxys:5382060|PMID:11061612|PMID:16894289|PMID:17101674|PMID:16149285|PMID:11489002|PMID:11088063|PMID:18257544|PMID:11859947|PMID:11585734|PMID:14720338|PMID:14653877|PMID:28912244|PMID:11504793|PMID:19177022|PMID:12571808|PMID:18050344|PMID:11132538|PMID:14606642|PMID:12722678|PMID:18035967|PMID:12057046|PMID:15297392|PMID:11807603|PMID:17429628|PMID:16001951|PMID:16807461|PMID:15282439|PMID:18086345|PMID:16500746|CAS:95058-81-4|PMID:15744590|PMID:11034044|PMID:16555971|PMID:12142097|PMID:18166944|PMID:17460420|PMID:15637766|PMID:15160243|PMID:18981552|PMID:15221904|PMID:11595724|PMID:19034448|PMID:12954073|PMID:18819792,,"A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_47868|http://purl.obolibrary.org/obo/CHEBI_35705|http://purl.obolibrary.org/obo/CHEBI_35610|http://purl.obolibrary.org/obo/CHEBI_59517|http://purl.obolibrary.org/obo/CHEBI_35703|http://purl.obolibrary.org/obo/CHEBI_35221|http://purl.obolibrary.org/obo/CHEBI_74213|http://purl.obolibrary.org/obo/CHEBI_132992|http://purl.obolibrary.org/obo/CHEBI_36044|http://purl.obolibrary.org/obo/CHEBI_78298|http://purl.obolibrary.org/obo/CHEBI_50266,,,,,"2'-deoxy-2',2'-difluorocytidine",,"gemcitabina|gemcitabine|gemcitabinum|2',2'-Difluorodeoxycytidine|4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one|2'-Deoxy-2',2'-difluorocytidine",,,,,,,,,,,,,,,,,,,,,CHEBI:175901,,,,gemcitabine,,CHEBI:175901,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_23924,enzyme inhibitor,inhibiteur enzymatique|inhibidor enzimatico|inhibidores enzimaticos|inhibiteurs enzymatiques|enzyme inhibitors|enzyme inhibitor,A compound or agent that combines with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.,false,,,http://purl.obolibrary.org/obo/TXPO_0003711|http://purl.obolibrary.org/obo/CHEBI_35222|http://purl.obolibrary.org/obo/CHEBI_52206,,,,,,,,,,,,,,,,,,,,,,A compound or agent that combines with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,enzyme inhibitor,,inhibiteur enzymatique|inhibidor enzimatico|inhibidores enzimaticos|inhibiteurs enzymatiques|enzyme inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:23924,,,,enzyme inhibitor,,CHEBI:23924,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003881,CYP4A11 - arachidonic acid metabolic factor (human)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001859,,,,,,,,,,,,,,,,,,,"Cyp4a11 relates to cardiovascular abnormality (blood pressure, etc.).",NCBI-Human-GeneID:1579|PMID:16712844|PMID:30069903|PMID:18433732|PMID:21912424|PMID:12464261,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001579,,,http://purl.obolibrary.org/obo/TXPO_0003887,,,,,,,,,,TXPO:0003881,,,,,,,,,,,,,,,,,,,,,,CYP4A11 - arachidonic acid metabolic factor (human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003888,tumor progression inhibitor,,A role played by the entity which inhibits the tumor progression.,false,,,http://purl.obolibrary.org/obo/TXPO_0003230,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000280,,,,,,,,,,,,,,,A role played by the entity which inhibits the tumor progression.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003888,,,,,,,,,,,,,,,,,,,,,,tumor progression inhibitor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003882,negative regulation of arachidonic acid metabolic process,,"Negative regulation of arachidonic acid metabolic process is a subtype of negative regulation process: A process  that stops, prevents, or reduces the frequency, rate or extent of the arachidonic acid metabolism.",false,,,http://purl.obolibrary.org/obo/TXPO_0000369,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of arachidonic acid metabolic process is a subtype of negative regulation process: A process  that stops, prevents, or reduces the frequency, rate or extent of the arachidonic acid metabolism.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003882,,,,,,,,,,,,,,,,,,,,,,negative regulation of arachidonic acid metabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003884,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003880,tumor metastasis inducer,,A role played by the entity  which positively regulates the tumor metastasis.,false,,,http://purl.obolibrary.org/obo/TXPO_0003230,,,,,,,,,,,,,,,,,,,,,,A role played by the entity  which positively regulates the tumor metastasis.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003880,,,,,,,,,,,,,,,,,,,,,,tumor metastasis inducer,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003885,omega-hydroxylase P450 pathway,,The chemical reactions and pathways by which arachidonic acid is converted to other compounds initially by omega-hydroxylation.,false,,,http://purl.obolibrary.org/obo/TXPO_0003884,,,,,,,,,,,,,,,,,,,,,,The chemical reactions and pathways by which arachidonic acid is converted to other compounds initially by omega-hydroxylation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003885,,,,,,,,,,,,,,,,,,,,,,omega-hydroxylase P450 pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003887,fatty acid omega-hydroxylase activity,,,false,,,http://purl.obolibrary.org/obo/TXPO_0000519,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003887,,,,,,,,,,,,,,,,,,,,,,fatty acid omega-hydroxylase activity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003884,arachidonic acid metabolism,,"The chemical reactions and pathways involving arachidonic acid, a straight chain fatty acid with 20 carbon atoms and four double bonds per molecule. Arachidonic acid is the all-Z-(5,8,11,14)-isomer.",false,,,http://purl.obolibrary.org/obo/GO_0001676,,,,,,,,,,,,,,,,,,,,Wikipedia:Arachidonic_acid,,"The chemical reactions and pathways involving arachidonic acid, a straight chain fatty acid with 20 carbon atoms and four double bonds per molecule. Arachidonic acid is the all-Z-(5,8,11,14)-isomer.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003884,,,,,,,,,,,,,,,,,,,,,,arachidonic acid metabolism,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003886,negative regulation of arachidonic acid metabolic process [phospholipidosis],,"Negative regulation of arachidonic acid metabolic process is a subtype of negative regulation process: A process  that stops, prevents, or reduces the frequency, rate or extent of the arachidonic acid metabolism.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0003882,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of arachidonic acid metabolic process is a subtype of negative regulation process: A process  that stops, prevents, or reduces the frequency, rate or extent of the arachidonic acid metabolism.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003582|http://purl.obolibrary.org/obo/TXPO_0003881,,,,,,,,,,,,,,,,,TXPO:0003886,,,,,,,,,,,,,,,,,,,,,,negative regulation of arachidonic acid metabolic process [phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003884,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003883,hyperfunctioning of autophagy,,Hyperfunctioning of apoptotic process is a subtype of hyperfunctioning: A process that performs an excesssive autophagy.,false,,,http://purl.obolibrary.org/obo/TXPO_0000435,,,,,,,,,,,,,,,,,,,,,,Hyperfunctioning of apoptotic process is a subtype of hyperfunctioning: A process that performs an excesssive autophagy.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003883,,,,,,,,,,,,,,,,,,,,,,hyperfunctioning of autophagy,,,,,,http://purl.obolibrary.org/obo/GO_0006915,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003889,Hyperfunctioning of apoptotic process [Phospholipidosis (excessive defense) ],,"Hyperfunctioning of apoptotic process is a subtype of hyperfunctioning: A process that performs an excesssive apoptosis.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense) .",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0003883,,,,,,,,,,,,,,,,,,,,PMID:17090686,,"Hyperfunctioning of apoptotic process is a subtype of hyperfunctioning: A process that performs an excesssive apoptosis.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense) .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000836,,,,,,,,,,,TXPO:0003889,,,,,,,,,,,,,,,,,,,,,,Hyperfunctioning of apoptotic process [Phospholipidosis (excessive defense) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000426,p300/CBP,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001397|http://purl.obolibrary.org/obo/TXPO_0003717,,,,,,,,,,IMR:0000426,,,,,,,,,,,,,,,,,,,,,,p300/CBP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100002,cGMP phosphodiesterase,cGMP-specific phosphodiesterase|cyclic GMP phosphodiesterase|cGMP-specific PDE,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,EC:3.1.4.35|GO:0004116,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003672,,,,,cGMP-specific phosphodiesterase|cyclic GMP phosphodiesterase|cGMP-specific PDE,,,,,IMR:0100002,,,,,,,,,,,,,,,,,,,,,,cGMP phosphodiesterase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003508,lipidosis dependent chemical compound,,"Lipidosis dependent chemical compound is a subtype of toxic course dependent chemical entity.
This entity (drug) can participate in the course of lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001089,,,,,,,,,,,,,,,,,,,,,,"Lipidosis dependent chemical compound is a subtype of toxic course dependent chemical entity.
This entity (drug) can participate in the course of lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003508,,,,,,,,,,,,,,,,,,,,,,lipidosis dependent chemical compound,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003502,hepatocellular hypertrophy [Liver Pathological Findings],,"Hypertrophy [liver findings] is a type of finding observed in the liver.  An increase in size (volume) of hepatocytes is observed based on pathological morphology.
It is sometimes accompanied by an increase in the number of cells.",false,,,http://purl.obolibrary.org/obo/TXPO_0001507,,,,,,,,,,,,,,,,,,,,,,"Hypertrophy [liver findings] is a type of finding observed in the liver.  An increase in size (volume) of hepatocytes is observed based on pathological morphology.
It is sometimes accompanied by an increase in the number of cells.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003502,,,,,,,,,,,,,,,,,,,,,,hepatocellular hypertrophy [Liver Pathological Findings],,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000182,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003505,hepatic fibrosis [Liver Pathological Findings],,Hepatic fibrosis [Liver PathologicalFindings] is a type of finding observed in the liver. Lesions are observed as a proliferation of fibrous tissue in the liver based on pathological morphology.,false,,,http://purl.obolibrary.org/obo/TXPO_0001507,,,,,,,,,,,,,,,,,,,,FI-L0780,,Hepatic fibrosis [Liver PathologicalFindings] is a type of finding observed in the liver. Lesions are observed as a proliferation of fibrous tissue in the liver based on pathological morphology.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003505,,,,,,,,,,,,,,,,,,,,,,hepatic fibrosis [Liver Pathological Findings],,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003507,hypofunction of lipoprotein biosynthesis [Lipidosis],,"Hypofunction of lipoprotein biosynthesis is a subtype of hypofunction of protein synthesis: A process that performs a decreased or insufficient lipoprotein biosynthesis.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0003506,,,,,,,,,,,,,,,,,,,,,,"Hypofunction of lipoprotein biosynthesis is a subtype of hypofunction of protein synthesis: A process that performs a decreased or insufficient lipoprotein biosynthesis.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003484,,,,,,,,,,,TXPO:0003507,,,,,,,,,,,,,,,,,,,,,,hypofunction of lipoprotein biosynthesis [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003504,hyperplasia [Liver Pathological Findings],,Hyperplasia [ [Liver PathologicalFindings] is a type of finding observed in the liver. An increase in cell number is observed based on pathological morphology.,false,,,http://purl.obolibrary.org/obo/TXPO_0001507,,,,,,,,,,,,,,,,,,,,Open TG-Gates:FI-L0910,,Hyperplasia [ [Liver PathologicalFindings] is a type of finding observed in the liver. An increase in cell number is observed based on pathological morphology.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003504,,,,,,,,,,,,,,,,,,,,,,hyperplasia [Liver Pathological Findings],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003509,CCL4 [Lipidosis],,,false,,,http://purl.obolibrary.org/obo/CHEBI_27385|http://purl.obolibrary.org/obo/TXPO_0003508,,,,,,,,,,,,,,,,,,,,ISBN:0071769234,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003509,,,,,,,,,,,,,,,,,,,,,,CCL4 [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003506,hypofunction of lipoprotein biosynthesis,,Hypofunction of lipoprotein biosynthesis is a subtype of hypofunction of protein synthesis: A process that performs a decreased or insufficient lipoprotein biosynthesis.,false,,,http://purl.obolibrary.org/obo/TXPO_0001958,,,,,,,,,,,,,,,,,,,,,,Hypofunction of lipoprotein biosynthesis is a subtype of hypofunction of protein synthesis: A process that performs a decreased or insufficient lipoprotein biosynthesis.,,,http://purl.obolibrary.org/obo/GO_0042158,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003506,,,,,,,,,,,,,,,,,,,,,,hypofunction of lipoprotein biosynthesis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003503,cholestasis [Liver Pathological Findings],,"Cholestasis [liver findings] is a type of finding observed in the liver. A pathological findings caused by obstruction in intrahepatic or extrahepatic biliary system.
Bile thrombus appears in the intrahepatic bile duct, and in general, bile pigment is observed in hepatocytes and Kupffer cells.",false,,,http://purl.obolibrary.org/obo/TXPO_0001507,,,,,,,,,,,,,,,,,,,,Open TG-Gates:FI-L0360,,"Cholestasis [liver findings] is a type of finding observed in the liver. A pathological findings caused by obstruction in intrahepatic or extrahepatic biliary system.
Bile thrombus appears in the intrahepatic bile duct, and in general, bile pigment is observed in hepatocytes and Kupffer cells.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003503,,,,,,,,,,,,,,,,,,,,,,cholestasis [Liver Pathological Findings],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003501,eosinophilic granular degeneration [Liver Pathological Findings],,Eosinophilic granular degeneration [Liver PathologicalFindings]  is a type of finding observed in hepatocytes. Lesions are observed in the form that the cytoplasm presents eosinophilic granules based on pathological morphology.,false,,,http://purl.obolibrary.org/obo/TXPO_0001507,,,,,,,,,,,,,,,,,,,,FI-L510,,Eosinophilic granular degeneration [Liver PathologicalFindings]  is a type of finding observed in hepatocytes. Lesions are observed in the form that the cytoplasm presents eosinophilic granules based on pathological morphology.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003501,,,,,,,,,,,,,,,,,,,,,,eosinophilic granular degeneration [Liver Pathological Findings],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76895,EC 3.6.3.* (acid anhydride hydrolase catalysing transmembrane movement of substances) inhibitor,EC 3.6.3.* (acid anhydride hydrolase catalysing transmembrane movement of substances) inhibitors|EC 3.6.3.* inhibitor|acid anhydride hydrolase catalysing transmembrane movement of substances (EC 3.6.3.*) inhibitors|EC 3.6.3.* inhibitors|acid anhydride hydrolase catalysing transmembrane movement of substances (EC 3.6.3.*) inhibitor,An EC 3.6.* (hydrolases acting on acid anhydrides) inhibitor that interferes with the action of any such enzyme that catalyses transmembrane movement of substances (EC 3.6.3.*).,false,,,http://purl.obolibrary.org/obo/CHEBI_73216,,,,,,,,,,,,,,,,,,,,,,An EC 3.6.* (hydrolases acting on acid anhydrides) inhibitor that interferes with the action of any such enzyme that catalyses transmembrane movement of substances (EC 3.6.3.*).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,EC 3.6.3.* (acid anhydride hydrolase catalysing transmembrane movement of substances) inhibitors|EC 3.6.3.* inhibitor|acid anhydride hydrolase catalysing transmembrane movement of substances (EC 3.6.3.*) inhibitors|EC 3.6.3.* inhibitors|acid anhydride hydrolase catalysing transmembrane movement of substances (EC 3.6.3.*) inhibitor,,,,,,,,,,,,,,,,,,,,,CHEBI:76895,,,,EC 3.6.3.* (acid anhydride hydrolase catalysing transmembrane movement of substances) inhibitor,,CHEBI:76895,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/BFO_0000142,one-dimensional continuant fiat boundary,,,false,,,http://purl.obolibrary.org/obo/BFO_0000140,,,,,,,,,,,,,,,,,,,,,,,,,,,,a one-dimensional continuant fiat boundary is a continuous fiat line whose location is defined in relation to some material entity. (axiom label in BFO2 Reference: [032-001]),the median sulcus of your tongue|all geopolitical boundaries|the line separating the outer surface of the mucosa of the lower lip from the outer surface of the skin of the chin.|The Equator|all lines of latitude and longitude,,,,,,,,,,,(iff (OneDimensionalContinuantFiatBoundary a) (and (ContinuantFiatBoundary a) (exists (b) (and (OneDimensionalSpatialRegion b) (forall (t) (locatedInAt a b t)))))) // axiom label in BFO2 CLIF: [032-001],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BFO:0000142,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/bfo.owl,one-dimensional continuant fiat boundary,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_64946,anti-HIV agent,anti-AIDS agent|anti-AIDS agents|anti-HIV agents,An antiviral agent that destroys or inhibits the replication of the human immunodeficiency virus.,false,,,http://purl.obolibrary.org/obo/CHEBI_22587,,,,,,,,,,,,,,,,,,,,,,An antiviral agent that destroys or inhibits the replication of the human immunodeficiency virus.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,anti-AIDS agent|anti-AIDS agents|anti-HIV agents,,,,,,,,,,,,,,,,,,,,,CHEBI:64946,,,,anti-HIV agent,,CHEBI:64946,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100555,FGF-5,HBGF-5|Smag-82,,false,,,http://purl.obolibrary.org/obo/IMR_0000049,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,HBGF-5|Smag-82,,,,,IMR:0100555,,,,,,,,,,,,,,,,,,,,,,FGF-5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_3387,carbamazepine,"5H-Dibenz(b,f)azepine-5-carboxamide|5-Carbamyl-5H-dibenzo(b,f)azepine|Carnexiv|carbamazepine|5-Carbamoyl-5H-dibenzo(b,f)azepine|carbamazepina|5-carbamoyl-5H-dibenz[b,f]azepine|Carbamazepen|5-Carbamoyl-5H-dibenz(b,f)azepine|carbamazepinum|5H-dibenzo[b,f]azepine-5-carboxamide","A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:12475188|PMID:16437428|PMID:17027750|PMID:17873967|PMID:16380297|PMID:17949959|PMID:11891095|PMID:15165631|PMID:15683742|PMID:14160216|PMID:16245817|Beilstein:1246090|PMID:16394456|PMID:7602118|PMID:17028629|PMID:11240598|PMID:18656520|PMID:18969759|PMID:14572037|PMID:11888243|PMID:12749779|PMID:16616830|PMID:18652684|PMID:16538175|LINCS:LSM-3610|PMID:12228880|PMID:11071486|PMID:18637155|PMID:17582711|PMID:11129121|PMID:22322005|PMID:16033627|CAS:298-46-4|PMID:11475584|PMID:16562645|PMID:19473818|PMID:16150575|PMID:11595204|PMID:16990009|PMID:17207414|PMID:15557493|PMID:19921623|PMID:19741433|PMID:15739418|PMID:18163657|Drug_Central:489|PMID:12799799|PMID:27967303|PMID:14723323|PMID:12073283|PMID:14581052|PMID:14713026|Reaxys:1246090|PMID:10411478|PMID:12957643|PMID:15820347|PMID:15665743|PMID:18415623|PMID:19135617|PMID:15850602|DrugBank:DB00564,,"A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35477|http://purl.obolibrary.org/obo/CHEBI_35703|http://purl.obolibrary.org/obo/CHEBI_61115|http://purl.obolibrary.org/obo/CHEBI_52290|http://purl.obolibrary.org/obo/CHEBI_64370|http://purl.obolibrary.org/obo/CHEBI_35480|http://purl.obolibrary.org/obo/CHEBI_38633|http://purl.obolibrary.org/obo/CHEBI_88188|http://purl.obolibrary.org/obo/CHEBI_35623|http://purl.obolibrary.org/obo/CHEBI_78298|http://purl.obolibrary.org/obo/CHEBI_35481,,,,,"5H-dibenzo[b,f]azepine-5-carboxamide",,"5H-Dibenz(b,f)azepine-5-carboxamide|5-Carbamyl-5H-dibenzo(b,f)azepine|Carnexiv|carbamazepine|5-Carbamoyl-5H-dibenzo(b,f)azepine|carbamazepina|5-carbamoyl-5H-dibenz[b,f]azepine|Carbamazepen|5-Carbamoyl-5H-dibenz(b,f)azepine|carbamazepinum",,,,,,,,,,,,,,,,,,,,,CHEBI:3387,,,,carbamazepine,,CHEBI:3387,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004560,FOXO1 - activation state (canonical)[mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/TXPO_0005080,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:84482|NCBI-Human-GeneID:2308|NCBI-Mouse-GeneID:56458|PMID:23299992,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0002805,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0002354,,,,http://purl.obolibrary.org/obo/TXPO_0003947,,,,,,,,,,TXPO:0004560,,,,,,,,,,,,,,,,,,,,,,FOXO1 - activation state (canonical)[mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004567,clofibrate [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004455|http://purl.obolibrary.org/obo/CHEBI_3750,,,,,,,,,,,,,,,,,,,,PMID:9209711|PMID:22008536,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004567,,,,,,,Clofibrate is a fibric acid derivative used in the therapy of hypertriglyceridemia and dyslipidemia.  Clofibrate therapy is associated with mild and transient serum aminotransferase elevations and with rare instances of acute liver injury.,,,,,,,,,,,,,,,clofibrate [hepatocarcinogenesis],,,,,,,,,,,http://purl.obolibrary.org/obo/NCBITaxon_9989,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004564,Decreasing GADD45G level,,Decreasing GADD45G level is a subtype of decreasing quantity: A process that changes the amount of GADD45G level to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000396,,,,,,,,,,,,,,,,,,,,,,Decreasing GADD45G level is a subtype of decreasing quantity: A process that changes the amount of GADD45G level to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004565,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004564,,,,,,,,,,,,,,,,,,,,,,Decreasing GADD45G level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004565,GADD45G (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:10912|NCBI-Rat-GeneID:291005|NCBI-Mouse-GeneID:23882,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004565,,,,,,,,,,,,,,,,,,,,,,GADD45G (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004568,GADD45G (rat) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004565|http://purl.obolibrary.org/obo/TXPO_0005070,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:291005|PMID:22008536,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004568,,,,,,,,,,,,,,,,,,,,,,GADD45G (rat) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004562,FZD,frizzled class receptor,,false,,,http://purl.obolibrary.org/obo/TXPO_0004563,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,frizzled class receptor,,,,,TXPO:0004562,,,,,,,,,,,,,,,,,,,,,,FZD,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004561,Hypofunction of heme biosynthesis [mitochondrial disorder],,"Hypofunction of heme biosynthesis is a subtype of hypofunction of biosynthesis: A process that performs a decreased or insufficient heme biosynthesis.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0005053,,,,,,,,,,,,,,,,,,,,PMID:23299992,,"Hypofunction of heme biosynthesis is a subtype of hypofunction of biosynthesis: A process that performs a decreased or insufficient heme biosynthesis.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,http://purl.obolibrary.org/obo/GO_0006783,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004225,,,,,,,,,,,TXPO:0004561,,,,,,,,,,,,,,,,,,,,,,Hypofunction of heme biosynthesis [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004563,GPCR,G protein-coupled receptors,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,G protein-coupled receptors,,,,,TXPO:0004563,,,,,,,,,,,,,,,,,,,,,,GPCR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004569,Increasing GDF15 level,,Increasing GDF15 level is a subtype of increasing quantity: A process that changes the amount of GDF15 level to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing GDF15 level is a subtype of increasing quantity: A process that changes the amount of GDF15 level to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_1000164,,,,,,,,,,,,,,,,,,,TXPO:0004569,,,,,,,,,,,,,,,,,,,,,,Increasing GDF15 level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004566,Decreasing GADD45G level [hepatocarcinogenesis],,"Decreasing GADD45G level is a subtype of decreasing quantity: A process that changes the amount of GADD45G level to be lower.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004564,,,,,,,,,,,,,,,,,,,,PMID:22008536,,"Decreasing GADD45G level is a subtype of decreasing quantity: A process that changes the amount of GADD45G level to be lower.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004568,,,,,,http://purl.obolibrary.org/obo/TXPO_0004567|http://purl.obolibrary.org/obo/TXPO_0004448,,,,,,http://purl.obolibrary.org/obo/TXPO_0004392,,,,,,,,,,,TXPO:0004566,,,,,,,,,,,,,,,,,,,,,,Decreasing GADD45G level [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001579,phosphatidylcholine metabolism balance,,Phosphatidylcholine metabolism balance is a subtype of glycerophospholipid metabolism balance: A process that keeps a balance of phosphatidylcholine metabolism.,false,,,http://purl.obolibrary.org/obo/TXPO_0001576,,,,,,,,,,,,,,,,,,,,,,Phosphatidylcholine metabolism balance is a subtype of glycerophospholipid metabolism balance: A process that keeps a balance of phosphatidylcholine metabolism.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001579,,,,,,,,,,,,,,,,,,,,,,phosphatidylcholine metabolism balance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001574,short (value),,A length quality value  which is small.,false,,,http://purl.obolibrary.org/obo/TXPO_0000287,,,,,,,,,,,,,,,,,,,,,,A length quality value  which is small.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001574,,,,,,,,,,,,,,,,,,,,,,short (value),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001576,glycerophospholipid metabolism balance,,Glycerophospholipid metabolism balance is a subtype of phospholipid metabolism balance: A process that keeps a balance of glycerophospholipid metabolism.,false,,,http://purl.obolibrary.org/obo/TXPO_0001434,,,,,,,,,,,,,,,,,,,,,,Glycerophospholipid metabolism balance is a subtype of phospholipid metabolism balance: A process that keeps a balance of glycerophospholipid metabolism.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001576,,,,,,,,,,,,,,,,,,,,,,glycerophospholipid metabolism balance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001575,PERK-eIF2a-ATF4-CHOP signal integration system,,"PERK-eIF2a-ATF4 signal integration system signal integration system is a subtype of PERK pathway system.
This entity has sub-parts and has a goal of transmitting signals and a gene regulation via PERK, eIF2a, ATF4, and CHOP as a systemic context.",false,,,http://purl.obolibrary.org/obo/TXPO_0001533,,,,,,,,,,,,,,,,,,,,,,"PERK-eIF2a-ATF4 signal integration system signal integration system is a subtype of PERK pathway system.
This entity has sub-parts and has a goal of transmitting signals and a gene regulation via PERK, eIF2a, ATF4, and CHOP as a systemic context.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001429,,,,,,,,,,,,,,,,,,,,,,TXPO:0001575,,,,,,,,,,,,,,,,,,,,,,PERK-eIF2a-ATF4-CHOP signal integration system,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001571,PPARalpha inactivation,PPAR alpha inactivation|inactivating peroxisome proliferator-activated receptor alpha,PPARalpha inactivation is a subtype of inactivating: A process that changes the activity of the activating PPAR alpha ( (Peroxisome Proliferator Activated Receptor Alpha)) with a nuclear receptor role to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0001589,,,,,,,,,,,,,,,,,,,,,,PPARalpha inactivation is a subtype of inactivating: A process that changes the activity of the activating PPAR alpha ( (Peroxisome Proliferator Activated Receptor Alpha)) with a nuclear receptor role to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PPAR alpha inactivation|inactivating peroxisome proliferator-activated receptor alpha,,,,,TXPO:0001571,,,,,,,,,,,,,,,,,,,,,,PPARalpha inactivation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001578,heoatocyte growth,,"Heoatocyte growth is a subtype of cell growth: A process that The process in which a hepatocyte, the main structural component of the liver, increases in size.",false,,,http://purl.obolibrary.org/obo/GO_0016049,,,,,,,,,,,,,,,,,,,,,,"Heoatocyte growth is a subtype of cell growth: A process that The process in which a hepatocyte, the main structural component of the liver, increases in size.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001578,,,,,,,,,,,,,,,,,,,,,,heoatocyte growth,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001577,glycerophospholipid metabolism balance  [phospholipidosis - glycerophospholipid disorder],,"Glycerophospholipid metabolism balance is a subtype of phospholipid metabolism balance: A process that keeps a balance of glycerophospholipid metabolism.
This process is dependent on the glycerophospholipid disorder and can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0001576,,,,,,,,,,,,,,,,,,,,,,"Glycerophospholipid metabolism balance is a subtype of phospholipid metabolism balance: A process that keeps a balance of glycerophospholipid metabolism.
This process is dependent on the glycerophospholipid disorder and can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001577,,,,,,,,,,,,,,,,,,,,,,glycerophospholipid metabolism balance  [phospholipidosis - glycerophospholipid disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001570,hepatocyte cell division,,Hepatocyte cell division is a subtype of cell division: The process resulting in division and partitioning of components of a heoatocyte cell to form more cells.,false,,,http://purl.obolibrary.org/obo/GO_0051301,,,,,,,,,,,,,,,,,,,,,,Hepatocyte cell division is a subtype of cell division: The process resulting in division and partitioning of components of a heoatocyte cell to form more cells.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001570,,,,,,,,,,,,,,,,,,,,,,hepatocyte cell division,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001572,ethanoleamines,,,false,,,http://purl.obolibrary.org/obo/IMR_0001693,,,,,,,,,,,,,,,,,,,,CHEBI:23981|MeSH:D004983,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001572,,,,,,,,,,,,,,,,,,,,,,ethanoleamines,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001573,ethanoleamine,,,false,,,http://purl.obolibrary.org/obo/TXPO_0001572,,,,,,,,,,,,,,,,,,,,MeSH:D019856,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001573,,,,,,,,,,,,,,,,,,,,,,ethanoleamine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000380,STAT5b,signal transducer and activator of transcription 5b,,false,,,http://purl.obolibrary.org/obo/IMR_0100733,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,signal transducer and activator of transcription 5b,,,,,IMR:0000380,,,,,,,,,,,,,,,,,,,,,,STAT5b,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/BFO_0000027,object aggregate,,,false,,,http://purl.obolibrary.org/obo/BFO_0000040,,,,,,,,,,,,,,,,,,,,,,,"ISBN:978-3-938793-98-5pp124-158#Thomas Bittner and Barry Smith, 'A Theory of Granular Partitions', in K. Munn and B. Smith (eds.), Applied Ontology: An Introduction, Frankfurt/Lancaster: ontos, 2008, 125-158.",,,"An entity a is an object aggregate if and only if there is a mutually exhaustive and pairwise disjoint partition of a into objects|BFO 2 Reference: object aggregates may gain and lose parts while remaining numerically identical (one and the same individual) over time. This holds both for aggregates whose membership is determined naturally (the aggregate of cells in your body) and aggregates determined by fiat (a baseball team, a congressional committee).",,b is an object aggregate means: b is a material entity consisting exactly of a plurality of objects as member_parts at all times at which b exists. (axiom label in BFO2 Reference: [025-004]),"a collection of cells in a blood biobank.|the aggregate of blood cells in your body|defined through physical attachment: the aggregate of atoms in a lump of granite|the restaurants in Palo Alto|defined through physical containment: the aggregate of molecules of carbon dioxide in a sealed container|the nitrogen atoms in the atmosphere|a swarm of bees is an aggregate of members who are linked together through natural bonds|the aggregate of bearings in a constant velocity axle joint|your collection of Meissen ceramic plates.|an organization is an aggregate whose member parts have roles of specific types (for example in a jazz band, a chess club, a football team)|a symphony orchestra|defined via attributive delimitations such as: the patients in this hospital|defined by fiat: the aggregate of members of an organization",,,,,,,,,,,(forall (x) (if (ObjectAggregate x) (and (MaterialEntity x) (forall (t) (if (existsAt x t) (exists (y z) (and (Object y) (Object z) (memberPartOfAt y x t) (memberPartOfAt z x t) (not (= y z)))))) (not (exists (w t_1) (and (memberPartOfAt w x t_1) (not (Object w)))))))) // axiom label in BFO2 CLIF: [025-004],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BFO:0000027,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/bfo.owl,object aggregate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100563,FGF-13,FHF-2|Fibroblast growth factor homologous factor 2,,false,,,http://purl.obolibrary.org/obo/IMR_0000049,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FHF-2|Fibroblast growth factor homologous factor 2,,,,,IMR:0100563,,,,,,,,,,,,,,,,,,,,,,FGF-13,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000281,phospholipid accumulation in lysosome,,Phospholipid accumulation in lysosome is a subtype of phospholipid accumulation: A process that keeps phospholipid in the lysosome.,false,,,http://purl.obolibrary.org/obo/TXPO_0001244,,,,,,,,,,,,,,,,,,,,,,Phospholipid accumulation in lysosome is a subtype of phospholipid accumulation: A process that keeps phospholipid in the lysosome.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000281,,,,,,,,,,,,,,,,,,,,,,phospholipid accumulation in lysosome,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005764,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000289,meta attribute value,,,false,,,http://purl.obolibrary.org/obo/TXPO_0000278,,,,,,,,,,,,,,,,,,,,,,,YAMATO Ontology,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000289,,,,,,,,,,,,,,,,,,,,,,meta attribute value,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000280,tumor cell survial,,Tumor cell survial is a subtype of cell survival: A process that keeps the viability of a tumor cell.,false,,,http://purl.obolibrary.org/obo/NCIT_C16407,,,,,,,,,,,,,,,,,,,,,,Tumor cell survial is a subtype of cell survival: A process that keeps the viability of a tumor cell.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000280,,,,,,,,,,,,,,,,,,,,,,tumor cell survial,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000286,large (value),,A value which is greater than the normal or average.,false,,,http://purl.obolibrary.org/obo/TXPO_0000288,,,,,,,,,,,,,,,,,,,,,,A value which is greater than the normal or average.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000286,,,,,,,,,,,,,,,,,,,,,,large (value),,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000287,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000282,LPL (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24539|NCBI-Mouse-GeneID:16956|NCBI-Human-GeneID:4023|Ensembl:ENSG00000175445|MIM:609708|HGNC:6677,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000004023,,,http://purl.obolibrary.org/obo/PR_000009897,,,,,,,,,,TXPO:0000282,,,,,,,lipoprotein lipase,,,,,,,,,,,,,,,LPL (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000288,qualitative quantity,,"Although these are qualitative values, they are essentially quantitative because they are derived from the quantitative values by introducing threshold value, and hence the values are ordinal.",false,,,http://purl.obolibrary.org/obo/TXPO_0000278,,,,,,,,,,,,,,,,,,,,,,"Although these are qualitative values, they are essentially quantitative because they are derived from the quantitative values by introducing threshold value, and hence the values are ordinal.",YAMATO Ontology,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000288,,,,,,,,,,,,,,,,,,,,,,qualitative quantity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000287,small (value),,"A qualitative value which is lower than the threshold, normal or average.",false,,,http://purl.obolibrary.org/obo/TXPO_0000288,,,,,,,,,,,,,,,,,,,,,,"A qualitative value which is lower than the threshold, normal or average.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000287,,,,,,,,,,,,,,,,,,,,,,small (value),,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000286,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000284,Increaseing fatty acid synthesis substrate,,Increasing fatty acid synthesis substrate is a subtype of increasing quantity: A process that changes the production amount of the substrate of the fatty acid synthesis.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing fatty acid synthesis substrate is a subtype of increasing quantity: A process that changes the production amount of the substrate of the fatty acid synthesis.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000284,,,,,,,,,,,,,,,,,,,,,,Increaseing fatty acid synthesis substrate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000283,converting to acetyl CoA,,Converting to acetyl CoA is a subtype of metabolic process that transforms into acetyl CoA.,false,,,http://purl.obolibrary.org/obo/GO_0008152,,,,,,,,,,,,,,,,,,,,,,Converting to acetyl CoA is a subtype of metabolic process that transforms into acetyl CoA.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000283,,,,,,,,,,,,,,,,,,,,,,converting to acetyl CoA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000285,PERK signal transduction pathway,,A series of molecular signals mediated by PERK (PKR-like ER kinase).,false,,,http://purl.obolibrary.org/obo/TXPO_0000609,,,,,,,,,,,,,,,,,,,,,,A series of molecular signals mediated by PERK (PKR-like ER kinase).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000454|http://purl.obolibrary.org/obo/TXPO_0001837,,,,,,,,,,,,,,,,,,TXPO:0000285,,,,,,,,,,,,,,,,,,,,,,PERK signal transduction pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000924,PLA2G2E (human) positively regulator of immune response[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001135|http://purl.obolibrary.org/obo/TXPO_0000736,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:30814|PMID:24910243,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000283,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003572|http://purl.obolibrary.org/obo/TXPO_0003671,,,,,,,,,,TXPO:0000924,,,,,,,,,,,,,,,,,,,,,,PLA2G2E (human) positively regulator of immune response[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000928,positive regulation of apoptotic process [Phospholipidosis (excessive defense) ],,"Any process that activates or increases the frequency, rate or extent of cell death by apoptotic process.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense) .",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/GO_0043065,,,,,,,,,,,,,,,,,,,,PMID:17090686,,"Any process that activates or increases the frequency, rate or extent of cell death by apoptotic process.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense) .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000664|http://purl.obolibrary.org/obo/TXPO_0001547|http://purl.obolibrary.org/obo/TXPO_0001845,http://purl.obolibrary.org/obo/TXPO_0003602|http://purl.obolibrary.org/obo/TXPO_0003226|http://purl.obolibrary.org/obo/TXPO_0003225|http://purl.obolibrary.org/obo/TXPO_0001586|http://purl.obolibrary.org/obo/TXPO_0003380,,,,,,http://purl.obolibrary.org/obo/TXPO_0000927|http://purl.obolibrary.org/obo/TXPO_0004123,,,,,,,,,,,TXPO:0000928,,,,,,,,,,,,,,,,,,,,,,positive regulation of apoptotic process [Phospholipidosis (excessive defense) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000922,mild accumulation of abnormal proteins in ER,,Mild accumulation of abnormal proteins in ER is a subtype of accumulation of abnormal proteins in ER: A process that keeps abnormal protein(s) in the ER (endoplasmic reticulum) mildly.,false,,,http://purl.obolibrary.org/obo/TXPO_0002187,,,,,,,,,,,,,,,,,,,,,,Mild accumulation of abnormal proteins in ER is a subtype of accumulation of abnormal proteins in ER: A process that keeps abnormal protein(s) in the ER (endoplasmic reticulum) mildly.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000922,,,,,,,,,,,,,,,,,,,,,,mild accumulation of abnormal proteins in ER,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000921,increasing hepatocellular volume [Phospholipidosis (excessive defense)],,"Increasing hepatocellular volume is a changing process to change the volume of the hepatocyte to increase.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense).",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0000164,,,,,,,,,,,,,,,,,,,,,,"Increasing hepatocellular volume is a changing process to change the volume of the hepatocyte to increase.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002276,,,,,,,,,,,TXPO:0000921,,,,,,,,,,,,,,,,,,,,,,increasing hepatocellular volume [Phospholipidosis (excessive defense)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000927,cell death [Phospholipidosis (severe) ],,"Any biological process that results in permanent cessation of all vital functions of a cell. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/GO_0008219,,,,,,,,,,,,,,,,,,,,,,"Any biological process that results in permanent cessation of all vital functions of a cell. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003596|http://purl.obolibrary.org/obo/TXPO_0001285,,,,,,,,,,,TXPO:0000927,,,,,,,,,,,,,,,,,,,,,,cell death [Phospholipidosis (severe) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000925,hypofunction of phospholipid degradation [Phospholipidosis],,"Hypofunction of phospholipid degradation is a subtype of hypofunction of decomposing: A process that performs a decreased or insufficient phospholipid degradation.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001253|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Hypofunction of phospholipid degradation is a subtype of hypofunction of decomposing: A process that performs a decreased or insufficient phospholipid degradation.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002324,,,,,,,,,,,TXPO:0000925,,,,,,,,,,,,,,,,,,,,,,hypofunction of phospholipid degradation [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000923,increasing phospholipid [Phospholipidosis],,"Increasing phospholipid is a subtype of increasing quantity: A process that changes the amount of phospholipid to be larger.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001250|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Increasing phospholipid is a subtype of increasing quantity: A process that changes the amount of phospholipid to be larger.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000908,,,,,,,,,,,TXPO:0000923,,,,,,,,,,,,,,,,,,,,,,increasing phospholipid [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000920,phospholipid accumulation in lysosome [Phospholipidosis (severe) ],,"Phospholipid accumulation in lysosome is a subtype of phospholipid accumulation: A process that keeps phospholipid in the lysosome. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",false,,,http://purl.obolibrary.org/obo/TXPO_0000910,,,,,,,,,,,,,,,,,,,,,,"Phospholipid accumulation in lysosome is a subtype of phospholipid accumulation: A process that keeps phospholipid in the lysosome. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003525,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001489|http://purl.obolibrary.org/obo/TXPO_0001487|http://purl.obolibrary.org/obo/TXPO_0004148|http://purl.obolibrary.org/obo/TXPO_0004010|http://purl.obolibrary.org/obo/TXPO_0002220|http://purl.obolibrary.org/obo/TXPO_0000921|http://purl.obolibrary.org/obo/TXPO_0002094|http://purl.obolibrary.org/obo/TXPO_0002281|http://purl.obolibrary.org/obo/TXPO_0003877|http://purl.obolibrary.org/obo/TXPO_0004001|http://purl.obolibrary.org/obo/TXPO_0000334,,,,,,,,,,,TXPO:0000920,,,,,,,,,,,,,,,,,,,,,,phospholipid accumulation in lysosome [Phospholipidosis (severe) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000926,phagocytosis [Phospholipidosis],,"A vesicle-mediated transport process that results in the engulfment of external particulate material by phagocytes and their delivery to the lysosome. The particles are initially contained within phagocytic vacuoles (phagosomes), which then fuse with primary lysosomes to effect digestion of the particles.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/GO_0006909,,,,,,,,,,,,,,,,,,,,,,"A vesicle-mediated transport process that results in the engulfment of external particulate material by phagocytes and their delivery to the lysosome. The particles are initially contained within phagocytic vacuoles (phagosomes), which then fuse with primary lysosomes to effect digestion of the particles.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001298,,,,,,,,,,,,,,,,,,TXPO:0000926,,,,,,,,,,,,,,,,,,,,,,phagocytosis [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000929,sphingomyelin metabolism imbalance in nervous system [Niemann Pick Disease Type A],,"A process that becomes lacking a homeostastasis balance of the sphingomyelin metabolism in the nervous system.
This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type A.",false,,,http://purl.obolibrary.org/obo/TXPO_0001476,,,,,,,,,,,,,,,,,,,,,,"A process that becomes lacking a homeostastasis balance of the sphingomyelin metabolism in the nervous system.
This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type A.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001692,,,,,,,,,,,TXPO:0000929,,,,,,,,,,,,,,,,,,,,,,sphingomyelin metabolism imbalance in nervous system [Niemann Pick Disease Type A],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100077,glucagon,,"A pancreatic peptide hormone of about 29 amino acids secreted by PANCREATIC ALPHA CELLS. It has an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes.",false,,,http://purl.obolibrary.org/obo/IMR_0100076,,,,,,,,,,,,,,,,,,,,MeSH:D005934,,"A pancreatic peptide hormone of about 29 amino acids secreted by PANCREATIC ALPHA CELLS. It has an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100077,,,,,,,,,,,,,,,,,,,,,,glucagon,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0045088,regulation of innate immune response,,"Any process that modulates the frequency, rate or extent of the innate immune response, the organism's first line of defense against infection.",false,,,http://purl.obolibrary.org/obo/GO_0050776,,,,,,,,,,,,,,,,,,,,,,"Any process that modulates the frequency, rate or extent of the innate immune response, the organism's first line of defense against infection.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0045088,,,,,,,,,,,,,,,,,,,,,,regulation of innate immune response,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0045087,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0045087,innate immune response,,Innate immune responses are defense responses mediated by germline encoded components that directly recognize components of potential pathogens.,false,,,http://purl.obolibrary.org/obo/GO_0006955,,,,,,,,,,,,,,,,,,,,,,Innate immune responses are defense responses mediated by germline encoded components that directly recognize components of potential pathogens.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0045087,,,,,,,,,,,,,,,,,,,,,,innate immune response,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000283,PLA2 (mol),phospholipase A2,phosphatidylcholine + H2O = 1-acylglycerophosphocholine + a carboxylate.,false,,,http://purl.obolibrary.org/obo/TXPO_0000635,,,,,,,,,,,,,,,,,,,,EC:3.1.1.4|PMID:30077006|GO:0004623,,phosphatidylcholine + H2O = 1-acylglycerophosphocholine + a carboxylate.,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000283,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003671,,,,,phospholipase A2,,,,,IMR:0000283,,,,,,,,,,,,,,,,,,,,,,PLA2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002099,increasing drug metabolite [cell death],,"Increasing drug metabolite is a subtype of increasing quantity: A process that changes the amount of drug metabolites to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0001727|http://purl.obolibrary.org/obo/TXPO_0002364,,,,,,,,,,,,,,,,,,,,,,"Increasing drug metabolite is a subtype of increasing quantity: A process that changes the amount of drug metabolites to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002409,,,,,,,,,,,TXPO:0002099,,,,,,,,,,,,,,,,,,,,,,increasing drug metabolite [cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002092,malfunctioning  of phospholipid metabolism,,Malfunctioning  of phospholipid metabolism is a subtype of malfunctioning of controlling: A process that cannot perform a regulation of phospholipid metabolism appropriately or cannot realize it at all.,false,,,http://purl.obolibrary.org/obo/TXPO_0000532,,,,,,,,,,,,,,,,,,,,,,Malfunctioning  of phospholipid metabolism is a subtype of malfunctioning of controlling: A process that cannot perform a regulation of phospholipid metabolism appropriately or cannot realize it at all.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002092,,,,,,,,,,,,,,,,,,,,,,malfunctioning  of phospholipid metabolism,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002097,autolysis [Phospholipidosis (severe) ],,"Autolysis is a subtype of dissolving: The disintegration of a cell by rupture of the cell membrane by the action of their own enzymes. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0002235,,,,,,,,,,,,,,,,,,,,,,"Autolysis is a subtype of dissolving: The disintegration of a cell by rupture of the cell membrane by the action of their own enzymes. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000539,,,,,,,,,,,TXPO:0002097,,,,,,,,,,,,,,,,,,,,,,autolysis [Phospholipidosis (severe) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002093,GSTM1 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0002089,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24424|NCBI-Mouse-GeneID:14863|NCBI-Human-GeneID:2944,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002093,,,,,,,,,,,,,,,,,,,,,,GSTM1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002098,dysfunction of phospholipid degradation [Phospholipidosis (severe) ],,"Dysfunction of phospholipid degradation is a subtype of dysfunctioning: A process that performs an abnormal and incomplete phospholipid degradation severely. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",false,,,http://purl.obolibrary.org/obo/TXPO_0001448,,,,,,,,,,,,,,,,,,,,,,"Dysfunction of phospholipid degradation is a subtype of dysfunctioning: A process that performs an abnormal and incomplete phospholipid degradation severely. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001778,,,,,,,,,,,TXPO:0002098,,,,,,,,,,,,,,,,,,,,,,dysfunction of phospholipid degradation [Phospholipidosis (severe) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002091,malfunctioning of phospholipid metabolism [Phospholipidosis (mild)],,"Malfunctioning of phospholipid metabolism is a subtype of malfunctioning of controlling: A process that cannot perform a regulation of phospholipid metabolism appropriately or cannot realize it at all. The degree is mild.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (mild).",false,,,http://purl.obolibrary.org/obo/TXPO_0002092,,,,,,,,,,,,,,,,,,,,,,"Malfunctioning of phospholipid metabolism is a subtype of malfunctioning of controlling: A process that cannot perform a regulation of phospholipid metabolism appropriately or cannot realize it at all. The degree is mild.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (mild).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002091,,,,,,,,,,,,,,,,,,,,,,malfunctioning of phospholipid metabolism [Phospholipidosis (mild)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002095,lysosomal enzyme leakage [Phospholipidosis (severe) ],,"Lysosomal enzyme leakage is a subtype of leaking: A process that leaks the enzyme out from the lysosome. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0002096,,,,,,,,,,,,,,,,,,,,,,"Lysosomal enzyme leakage is a subtype of leaking: A process that leaks the enzyme out from the lysosome. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002097|http://purl.obolibrary.org/obo/TXPO_0001400,,,,,,,,,,,TXPO:0002095,,,,,,,,,,,,,,,,,,,,,,lysosomal enzyme leakage [Phospholipidosis (severe) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002096,lysosomal enzyme leakage,,Lysosomal enzyme leakage is a subtype of leaking: A process that leaks the enzyme out from the lysosome.,false,,,http://purl.obolibrary.org/obo/TXPO_0001699,,,,,,,,,,,,,,,,,,,,,,Lysosomal enzyme leakage is a subtype of leaking: A process that leaks the enzyme out from the lysosome.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002096,,,,,,,,,,,,,,,,,,,,,,lysosomal enzyme leakage,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005764,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002094,lysosome damage [Phospholipidosis (severe) ],,"Lysosome damage is a subtype of organelle damage.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",false,,,http://purl.obolibrary.org/obo/TXPO_0000059|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,PMID:23921551,,"Lysosome damage is a subtype of organelle damage.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000797|http://purl.obolibrary.org/obo/TXPO_0002095|http://purl.obolibrary.org/obo/TXPO_0002240,,,,,,,,,,,TXPO:0002094,,,,,,,,,,,,,,,,,,,,,,lysosome damage [Phospholipidosis (severe) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002090,SGPL1(human) [Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000014|http://purl.obolibrary.org/obo/TXPO_0001135,,,,,,,,,,,,,,,,,,,,http://omim.org/entry/603729|NCBI-HUman-GeneID:8879|PMID:2061324|PMID:17090686|PMID:20097939|PMID:26886371,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002090,,,,,,,,,,,,,,,,,,,,,,SGPL1(human) [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000896,40S ribosomal protein,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003687,,,,,,,,,,IMR:0000896,,,,,,,,,,,,,,,,,,,,,,40S ribosomal protein,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000080267,EDEM3,,"Other designations: ER degradation-enhancing -mannosidase-like protein 3|ER degradation-enhancing alpha-mannosidase-like 3|ER degradation-enhancing alpha-mannosidase-like protein 3|alpha-1,2-mannosidase EDEM3",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,C1orf22,,,,,,,,,,,,1,,,,,,MIM:610214|HPRD:10724|Vega:OTTHUMG00000035387|HGNC:16787|Ensembl:ENSG00000116406,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"ER degradation enhancer, mannosidase alpha-like 3",,,1q25,,,,,,,,,,,,,,,,GO_0004569 (EC: IEA); GO_0004571 (EC: IEA); GO_0005509 (EC: IEA); GO_0005788 (EC: IEA); GO_0005789 (EC: TAS); GO_0006457 (EC: TAS); GO_0006516 (EC: IEA); GO_0006986 (EC: IEA); GO_0018279 (EC: TAS); GO_0043161 (EC: IEA); GO_0043687 (EC: TAS); GO_0044267 (EC: TAS),,,,,,,,,PMID:8125298; 11318611; 12477932; 14702039; 15537790; 15579471; 16344560; 16431915; 16710414; 17499246; 18303019; 20360068; 21890473; 22190034; 22268729; 23251661,,,,,,,,,,,,,,,OGG:3000080267,,,,,,,"ER degradation enhancer, mannosidase alpha-like 3",,,,,,,,,,,,,"Other designations: ER degradation-enhancing -mannosidase-like protein 3|ER degradation-enhancing alpha-mannosidase-like 3|ER degradation-enhancing alpha-mannosidase-like protein 3|alpha-1,2-mannosidase EDEM3",,EDEM3,,,,,,,,,,,,,,,,,,,,,,,80267,,,,,,,,9606,,,,,,,,,,,,,,,,,,,EDEM3,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0004846,Twist1 signal transduction pathway,,A series of molecular signals mediated by twist1.,false,,,http://purl.obolibrary.org/obo/TXPO_0000609,,,,,,,,,,,,,,,,,,,,,,A series of molecular signals mediated by twist1.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004846,,,,,,,,,,,,,,,,,,,,,,Twist1 signal transduction pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004845,Negative regulation of adherens junction assembly [hepatocarcinogenesis],,"Negative regulation of adherens junction assembly is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of adherens junction assembly. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0003813,,,,,,,,,,,,,,,,,,,,PMID:17428255,,"Negative regulation of adherens junction assembly is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of adherens junction assembly. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004404|http://purl.obolibrary.org/obo/TXPO_0004479|http://purl.obolibrary.org/obo/TXPO_0004518,,,,,,,,,,,TXPO:0004845,,,,,,,"TSLC1 and DAL‐1 are components of the TSLC cascade, which participates in organizing the actin cytoskeleton and constructing stable cell‐to‐cell adhesion. It is thought that disturbances in the cell adhesion system are critical factors in the growth, invasion and metastasis of cancer cells.",,,,,,,,,,,,,,,Negative regulation of adherens junction assembly [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004849,TWIST1(canonical) [hepatocarcinogenesis],twist family bHLH transcription factor 1 [Hepatocarcinogenesis],,false,,,http://purl.obolibrary.org/obo/TXPO_0000837|http://purl.obolibrary.org/obo/TXPO_1000380,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:22160|NCBI-Human-GeneID:7291|NCBI-Rat-GeneID:85489|PMID:31781608,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,twist family bHLH transcription factor 1 [Hepatocarcinogenesis],,,,,TXPO:0004849,,,,,,,,,,,,,,,,,,,,,,TWIST1(canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004840,negative regulation of TSLC signaling,negative regulation of TSLC signalling cascade,"Any process that stops, prevents, or reduces the frequency, rate or extent of TSLC signaling, a series of reactions mediated by TSLC.",false,,,http://purl.obolibrary.org/obo/GO_0023057,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents, or reduces the frequency, rate or extent of TSLC signaling, a series of reactions mediated by TSLC.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,negative regulation of TSLC signalling cascade,,,,,TXPO:0004840,,,,,,,,,,,,,,,,,,,,,,negative regulation of TSLC signaling,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004838|http://purl.obolibrary.org/obo/TXPO_0004839,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004844,negative regulation of actin cytoskeleton organization [hepatocarcinogenesis],,"Negative regulation of actin cytoskeleton organization is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of actin cytoskeleton organization.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004903,,,,,,,,,,,,,,,,,,,,PMID:17428255,,"Negative regulation of actin cytoskeleton organization is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of actin cytoskeleton organization.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004404|http://purl.obolibrary.org/obo/TXPO_0004479,,,,,,,,,,,TXPO:0004844,,,,,,,,,,,,,,,,,,,,,,negative regulation of actin cytoskeleton organization [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0030036,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004848,Twist1 signaling (primitive),,Twist1 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the cytokine Twist1.,false,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,,,Twist1 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the cytokine Twist1.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_1000380,http://purl.obolibrary.org/obo/TXPO_0004846,,,,,,,,,,,,,,,,TXPO:0004848,,,,,,,,,,,,,,,,,,,,,,Twist1 signaling (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004842,CADM1 (rat) [hepatocarcinogenesis],TSLC1,,false,,,http://purl.obolibrary.org/obo/TXPO_0005069|http://purl.obolibrary.org/obo/TXPO_0005070,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:363058|PMID:17428255,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TSLC1,,,,,TXPO:0004842,,,,,,,,,,,,,,,,,,,,,,CADM1 (rat) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004847,Twist1 signaling (primitive) [hepatocarcinogenesis],,"Twist1 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by Twist1.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004848,,,,,,,,,,,,,,,,,,,,PMID:31781608,,"Twist1 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by Twist1.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004849,http://purl.obolibrary.org/obo/TXPO_0004846,,,,,,,,,,,,,,,,TXPO:0004847,,,,,,,,,,,,,,,,,,,,,,Twist1 signaling (primitive) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004841,negative regulation of TSLC signaling [hepatocarcinogenesis],negative regulation of TSLC signalling cascade,"Any process that stops, prevents, or reduces the frequency, rate or extent of TSLC signaling, a series of reactions mediated by TSLC.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004840,,,,,,,,,,,,,,,,,,,,PMID:17428255,,"Any process that stops, prevents, or reduces the frequency, rate or extent of TSLC signaling, a series of reactions mediated by TSLC.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004704|http://purl.obolibrary.org/obo/TXPO_0004842|http://purl.obolibrary.org/obo/TXPO_0004843,,,,,,http://purl.obolibrary.org/obo/TXPO_0004845|http://purl.obolibrary.org/obo/TXPO_0004844,,,,,,negative regulation of TSLC signalling cascade,,,,,TXPO:0004841,,,,,,,,,,,,,,,,,,,,,,negative regulation of TSLC signaling [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004838|http://purl.obolibrary.org/obo/TXPO_0004839,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004843,EPB41L3 (rat) [hepatocarcinogenesis],DAL-1|differentially expressed in adenocarcinoma of the lung 1,,false,,,http://purl.obolibrary.org/obo/TXPO_0005079|http://purl.obolibrary.org/obo/TXPO_0005070,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:116724|PMID:17428255,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,DAL-1|differentially expressed in adenocarcinoma of the lung 1,,,,,TXPO:0004843,,,,,,,,,,,,,,,,,,,,,,EPB41L3 (rat) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/BFO_0000026,one-dimensional spatial region,,,false,,,http://purl.obolibrary.org/obo/BFO_0000006,,,,,,,,,,,,,,,,,,,,,,,,,,,,A one-dimensional spatial region is a line or aggregate of lines stretching from one point in space to another. (axiom label in BFO2 Reference: [038-001]),an edge of a cube-shaped portion of space.,,,,,,,,,,,(forall (x) (if (OneDimensionalSpatialRegion x) (SpatialRegion x))) // axiom label in BFO2 CLIF: [038-001],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BFO:0000026,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/bfo.owl,one-dimensional spatial region,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001043,thiolester hydrolases,,,false,,,http://purl.obolibrary.org/obo/TXPO_0003663,,,,,,,,,,,,,,,,,,,,EC:3.1.2.-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001043,,,,,,,,,,,,,,,,,,,,,,thiolester hydrolases,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100758,Dvl-2,Dishevelled-2|DSH homolog 2,,false,,,http://purl.obolibrary.org/obo/IMR_0100755,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Dishevelled-2|DSH homolog 2,,,,,IMR:0100758,,,,,,,,,,,,,,,,,,,,,,Dvl-2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0000178,blood,whole blood|portion of blood|vertebrate blood,A fluid that is composed of blood plasma and erythrocytes.,false,,,http://purl.obolibrary.org/obo/UBERON_0000179,,,,,,,,,,,,,,,,,,,"This class excludes blood analogues, such as the insect analog of blood. See UBERON:0000179 haemolymphatic fluid.",http://en.wikipedia.org/wiki/Blood|http://purl.obolibrary.org/obo/NCIT_C12434|http://linkedlifedata.com/resource/umls/id/C0005767|OpenCyc:Mx4rvVjI8JwpEbGdrcN5Y29ycA|MIAA:0000315|AAO:0000046|MESH:D001769|MA:0000059|BTO:0000089|galen:Blood|GAID:965|EMAPA:16332|ZFA:0000007|ENVO:02000027|TAO:0000007|EHDAA2:0000176|UMLS:C0005767|XAO:0000124|CALOHA:TS-0079|EV:0100047|EHDAA:418|VHOG:0000224|EFO:0000296|FMA:9670,,A fluid that is composed of blood plasma and erythrocytes.,,,,,,,,"A complex mixture of cells suspended in a liquid matrix that delivers nutrients to cells and removes wastes. (Source: BioGlossary, www.Biology-Text.com)[TAO]|Highly specialized circulating tissue consisting of several types of cells suspended in a fluid medium known as plasma.[AAO]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0001969,,,,,,,,,,,,,portion of blood|vertebrate blood,,whole blood,"Recent findings strongly suggest that the molecular pathways involved in the development and function of blood cells are highly conserved among vertebrates and various invertebrates phyla. (...) There is now good reason to believe that, in vertebrates and invertebrates alike, blood cell lineages diverge from a common type of progenitor cell, the hemocytoblast.[well established][VHOG]",http://purl.obolibrary.org/obo/UBERON_0004535|http://purl.obolibrary.org/obo/UBERON_0002390,UBERON:0000178,http://purl.obolibrary.org/obo/UBERON_0004535|http://purl.obolibrary.org/obo/UBERON_0002390,,,https://github.com/tmeehan|https://github.com/cmungall,,,,,,,,,,,,,,,,,,blood,,,,,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0000170,pair of lungs,lungs pair|set of lungs|lungs|pulmones,The pair of anatomical structures comprised of a left lung and right lung.,false,,,http://purl.obolibrary.org/obo/UBERON_0034925,,,,,,,,,,,,,,,,,,,,OpenCyc:Mx4rvVjKy5wpEbGdrcN5Y29ycA|FMA:68877,,The pair of anatomical structures comprised of a left lung and right lung.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002167|http://purl.obolibrary.org/obo/UBERON_0002168,,,,,,,,,,,,,,,,,lungs pair|set of lungs|lungs|pulmones,,,,,UBERON:0000170,,,,,,,,,,,,,,,,,,,,,,pair of lungs,,,,,,,http://purl.obolibrary.org/obo/oae.owl|http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0000179,haemolymphatic fluid,blood or blood analog|circulating fluid,"Circulating fluid that is part of the hemolymphoid system. Blood, lymph, interstitial fluid or its analogs.",false,,,http://purl.obolibrary.org/obo/UBERON_0006314|http://purl.obolibrary.org/obo/UBERON_0000463,,,,,,,,,,,,,,,,,,,,CARO:0000081,,"Circulating fluid that is part of the hemolymphoid system. Blood, lymph, interstitial fluid or its analogs.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,blood or blood analog|circulating fluid,,http://purl.obolibrary.org/obo/UBERON_0002193,UBERON:0000179,http://purl.obolibrary.org/obo/UBERON_0002193,,,,,,,,,,,,,,,,,,,,,haemolymphatic fluid,,,,,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0000171,respiration organ,gas exchange organ|breathing organ|organ of apparatus respiratorius|organ of respiratory system|apparatus respiratorius organ|respiratory system organ|respiratory organ,"Organ that functions in gaseous exchange between an organism and its environment. In plants, microorganisms, and many small animals, air or water makes direct contact with the organism's cells or tissue fluids, and the processes of diffusion supply the organism with dioxygen (O2) and remove carbon dioxide (CO2). In larger animals the efficiency of gaseous exchange is improved by specialized respiratory organs, such as lungs and gills, which are ventilated by breathing mechanisms.",false,,,http://purl.obolibrary.org/obo/UBERON_0000062,,,,,,,,,,,,,,,,,,,,http://www.snomedbrowser.com/Codes/Details/272626006|EMAPA:17607|SPD:0000428|TGMA:0001247,,"Organ that functions in gaseous exchange between an organism and its environment. In plants, microorganisms, and many small animals, air or water makes direct contact with the organism's cells or tissue fluids, and the processes of diffusion supply the organism with dioxygen (O2) and remove carbon dioxide (CO2). In larger animals the efficiency of gaseous exchange is improved by specialized respiratory organs, such as lungs and gills, which are ventilated by breathing mechanisms.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,breathing organ|organ of apparatus respiratorius|organ of respiratory system|apparatus respiratorius organ|respiratory system organ|respiratory organ,,gas exchange organ,,http://purl.obolibrary.org/obo/UBERON_0001004,UBERON:0000171,http://purl.obolibrary.org/obo/UBERON_0001004,,,,,,,,,,,,,,,,,,,,,respiration organ,,,,,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_68494,apoptosis inhibitor,Type I cell-death inhibitor,Any substance that inhibits the process of apoptosis (programmed cell death) in multi-celled organisms.,false,,,http://purl.obolibrary.org/obo/TXPO_0000327,,,,,,,http://purl.obolibrary.org/obo/GO_0006915,,,,,,,,,,,,,,,Any substance that inhibits the process of apoptosis (programmed cell death) in multi-celled organisms.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Type I cell-death inhibitor,,,CHEBI:68494,,,,,,,,,,,,,,,,,,,,,,apoptosis inhibitor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_10112,zileuton,N-(1-Benzo(b)thien-2-ylethyl)-N-hydroxyurea|(+-)-1-(1-Benzo[b]thien-2-ylethyl)-1-hydroxyurea|Leutrol|Zyflo|N-[1-(benzo[b]thiophen-2-yl)ethyl]-N-hydroxyurea|zileutonum|zileuton|1-[1-(1-benzothien-2-yl)ethyl]-1-hydroxyurea|Zileuton,"A member of the class of 1-benzothiophenes that is 1-benzothiophene in which the hydrogen at position 2 is replaced by a 1-[carbamoyl(hydroxy)amino]ethyl group. A selective 5-lipoxygenase inhibitor, it inhibits the formation of leukotrienes LTB4, LTC4, LDT4, and LTE4. It is used for the management of chronic asthma.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:111406-87-2|LINCS:LSM-5084|DrugBank:DB00744|PMID:20204486|PMID:19645854|Drug_Central:2862|PMID:19309543|PMID:20436887,,"A member of the class of 1-benzothiophenes that is 1-benzothiophene in which the hydrogen at position 2 is replaced by a 1-[carbamoyl(hydroxy)amino]ethyl group. A selective 5-lipoxygenase inhibitor, it inhibits the formation of leukotrienes LTB4, LTC4, LDT4, and LTE4. It is used for the management of chronic asthma.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_64964|http://purl.obolibrary.org/obo/CHEBI_49159|http://purl.obolibrary.org/obo/CHEBI_35475|http://purl.obolibrary.org/obo/CHEBI_49167,,,,,1-[1-(1-benzothien-2-yl)ethyl]-1-hydroxyurea|Zileuton,,N-(1-Benzo(b)thien-2-ylethyl)-N-hydroxyurea|(+-)-1-(1-Benzo[b]thien-2-ylethyl)-1-hydroxyurea|Leutrol|Zyflo|N-[1-(benzo[b]thiophen-2-yl)ethyl]-N-hydroxyurea|zileutonum|zileuton,,,,,,,,,,,,,,,,,,,,,CHEBI:10112,,,,zileuton,,CHEBI:10112,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000079799,UGT2A3,,Other designations: UDP-glucuronosyltransferase 2A3|UDPGT 2A3,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,4,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"UDP glucuronosyltransferase 2 family, polypeptide A3",,,4q13.2,,,,,,,,,,,,,,,,"GO_0015020 (EC: IDA, PMID: 19858781); GO_0016021 (EC: IEA); GO_0052695 (EC: IDA, PMID: 19858781)",,,,,,,,,PMID: 8125298; 12477932; 12975309; 15342556; 18523138; 19858781; 20379614; 20819778,,,,,,,,,,,,,,,OGG:3000079799,,20140408,protein-coding,,,,"UDP glucuronosyltransferase 2 family, polypeptide A3",,,,,,,,,,,,,Other designations: UDP-glucuronosyltransferase 2A3|UDPGT 2A3,,UGT2A3,,,,,,,,,,,,,,,,,,,,,,,79799,UNQ2559/PRO6239,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,UGT2A3,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000873,p52,NFKB2|NF-kappaB2|p100,,false,,,http://purl.obolibrary.org/obo/IMR_0000382,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,NFKB2|NF-kappaB2|p100,,,,,IMR:0000873,,,,,,,,,,,,,,,,,,,,,,p52,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000033,HGF,scatter factor|hepatocyte growth factor,,false,,,http://purl.obolibrary.org/obo/TXPO_0001382,,,,,,,,,,,,,,,,,,,,GO:0005171,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002395|http://purl.obolibrary.org/obo/TXPO_0000624,,,,,scatter factor|hepatocyte growth factor,,,,,IMR:0000033,,,,,,,,,,,,,,,,,,,,,,HGF,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003653,tranquilizing drug,,"A traditional grouping of drugs said to have a soothing or calming effect on mood, thought or behaviour.",false,,,http://purl.obolibrary.org/obo/CHEBI_35488,,,,,,,,,,,,,,,,,,,,,,"A traditional grouping of drugs said to have a soothing or calming effect on mood, thought or behaviour.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003653,,,,,,,,,,,,,,,,,,,,,,tranquilizing drug,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003652,dysfunction of fatty acid degradation,,Dysfunction of fatty acid degradation is a subtype of dysfunctioning: A process that performs an abnormal and incomplete fatty acid degradation.,false,,,http://purl.obolibrary.org/obo/TXPO_0001741,,,,,,,,,,,,,,,,,,,,,,Dysfunction of fatty acid degradation is a subtype of dysfunctioning: A process that performs an abnormal and incomplete fatty acid degradation.,,,http://purl.obolibrary.org/obo/GO_0009395,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_16247,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003652,,,,,,,,,,,,,,,,,,,,,,dysfunction of fatty acid degradation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003654,glutathione synthesis regulating agent role,,A role played by the entity which regulates the glutathione synthesis.,false,,,http://purl.obolibrary.org/obo/TXPO_0004023,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006750,,,,,,,,,,,,,A role played by the entity which regulates the glutathione synthesis.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003654,,,,,,,,,,,,,,,,,,,,,,glutathione synthesis regulating agent role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003651,phospholipid metabolism balance [Phospholipidosis (adaptation2)],,"Phospholipid metabolism balance is a subtype of maintaining balance: A process that keeps a balance of phospholipid metabolism at small level.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense).",false,,,http://purl.obolibrary.org/obo/TXPO_0001434,,,,,,,,,,,,,,,,,,,,,,"Phospholipid metabolism balance is a subtype of maintaining balance: A process that keeps a balance of phospholipid metabolism at small level.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002228,,,,,,,,,TXPO:0003651,,,,,,,,,,,,,,,,,,,,,,phospholipid metabolism balance [Phospholipidosis (adaptation2)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003658,antipsychotic agent,neuroleptic|major tranquilizers,"Antipsychotic drugs are agents that control agitated psychotic behaviour, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect.",false,,,http://purl.obolibrary.org/obo/TXPO_0003653,,,,,,,,,,,,,,,,,,,,,,"Antipsychotic drugs are agents that control agitated psychotic behaviour, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,neuroleptic|major tranquilizers,,,TXPO:0003658,,,,,,,,,,,,,,,,,,,,,,antipsychotic agent,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003656,sodium channel,,A role played by the entity which enables the facilitated diffusion of a sodium ion (by an energy-independent process) involving passage through a transmembrane aqueous pore or channel without evidence for a carrier-mediated mechanism.|related molecular function GO:0005272,false,,,http://purl.obolibrary.org/obo/TXPO_0002803,,,,,,,,,,,,,,,,,,,,,,A role played by the entity which enables the facilitated diffusion of a sodium ion (by an energy-independent process) involving passage through a transmembrane aqueous pore or channel without evidence for a carrier-mediated mechanism.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003656,,,,,,,,,,,,,,,,,,,,related molecular function GO:0005272,,sodium channel,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003655,potassium channel,,A role played by the entity which enables the facilitated diffusion of a potassium ion (by an energy-independent process) involving passage through a transmembrane aqueous pore or channel without evidence for a carrier-mediated mechanism.|related molecular function GO:0005267,false,,,http://purl.obolibrary.org/obo/TXPO_0002803,,,,,,,,,,,,,,,,,,,,,,A role played by the entity which enables the facilitated diffusion of a potassium ion (by an energy-independent process) involving passage through a transmembrane aqueous pore or channel without evidence for a carrier-mediated mechanism.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003655,,,,,,,,,,,,,,,,,,,,related molecular function GO:0005267,,potassium channel,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003657,adaptor protein role,anchoring protein|docking protein|scaffold protein,"A role played by the entity that brings together two or more molecules through a selective, non-covalent, often stoichiometric interaction, permitting those molecules to function in a coordinated way.",false,,,http://purl.obolibrary.org/obo/TXPO_0000564,,,,,,,,,,,,,,,,,,,,IMR:0000333 (obsolete),,"A role played by the entity that brings together two or more molecules through a selective, non-covalent, often stoichiometric interaction, permitting those molecules to function in a coordinated way.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,anchoring protein|docking protein|scaffold protein,,,,TXPO:0003657,,,,,,,General term for proteins in intracellular signaling pathways that link different proteins in the pathway directly together.,,,,,,,,,,,,,,,adaptor protein role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003650,gene expression regulator role,,A role played by the entity which involves in regulating a gene expression process.,false,,,http://purl.obolibrary.org/obo/TXPO_0003230,,,,,,,,,,,,,,,,,,,,,,A role played by the entity which involves in regulating a gene expression process.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003650,,,,,,,,,,,,,,,,,,,,,,gene expression regulator role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003659,first generation antipsychotic,,Antipsychotic drugs which can have different modes of action but which tend to be more likely than second generation antipsychotics to cause extrapyramidal motor control disabilities such as body rigidity or Parkinson's disease-type movements; such body movements can become permanent even after treatment has ceased.,false,,,http://purl.obolibrary.org/obo/TXPO_0003658,,,,,,,,,,,,,,,,,,,,Wikipedia:Typical_antipsychotic,,Antipsychotic drugs which can have different modes of action but which tend to be more likely than second generation antipsychotics to cause extrapyramidal motor control disabilities such as body rigidity or Parkinson's disease-type movements; such body movements can become permanent even after treatment has ceased.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003659,,,,,,,,,,,,,,,,,,,,,,first generation antipsychotic,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0002385,muscle tissue,textus muscularis|muscular tissue|portion of muscle tissue,"Muscle tissue is a contractile tissue made up of actin and myosin fibers[GO].|Vertebrate muscle is categorized into three major muscle types defined by their structural and functional properties: skeletal, cardiac and smooth. In Dmel the counterparts are somatic, heart/cardiac and visceral. Here we take a cell type based approach.",false,,,http://purl.obolibrary.org/obo/UBERON_0000479,,,,,,,,,,,,,,,,,,,,http://www.snomedbrowser.com/Codes/Details/91727004|http://linkedlifedata.com/resource/umls/id/C2328219|http://purl.obolibrary.org/obo/NCIT_C12435|http://en.wikipedia.org/wiki/Muscle_tissue|galen:MuscleTissue|EHDAA2:0003122|MESH:D009132|FMA:9641|UMLS:C2328219|AEO:0000122|MA:0002437|CALOHA:TS-0642|AAO:0000306|EMAPA:32715,,Muscle tissue is a contractile tissue made up of actin and myosin fibers[GO].,,,,,,,,One of the four types of tissue in traditional classifications. Tissue that contains cells with contractile filaments that move past each other and change the size of the cell. Muscle tissue also is separated into three distinct categories.[AAO],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,textus muscularis|muscular tissue|portion of muscle tissue,,,,,UBERON:0002385,,,,,,,,,,,,,,,,,,,,"Vertebrate muscle is categorized into three major muscle types defined by their structural and functional properties: skeletal, cardiac and smooth. In Dmel the counterparts are somatic, heart/cardiac and visceral. Here we take a cell type based approach.",,muscle tissue,,,,,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0002384,connective tissue,Bindegewebe|portion of connective tissue|textus connectivus,Tissue with cells that deposit non-polarized extracellular matrix including connective tissue fibers and ground substance.,false,,,http://purl.obolibrary.org/obo/UBERON_0000479,,,,,,,,,,,,,,,,,,,,http://linkedlifedata.com/resource/umls/id/C0009780|http://purl.obolibrary.org/obo/NCIT_C12374|http://www.snomedbrowser.com/Codes/Details/361919005|OpenCyc:Mx4rv-aBgZwpEbGdrcN5Y29ycA|MIAA:0000301|MA:0000011|CALOHA:TS-2009|ZFA:0001632|galen:ConnectiveTissue|GAID:100|BTO:0000421|EMAPA:35251|FMA:9640|VSAO:0000017|EFO:0000952|MAT:0000301|XAO:0001017|UMLS:C0009780|AAO:0000098|MESH:D003238|TAO:0001641,,Tissue with cells that deposit non-polarized extracellular matrix including connective tissue fibers and ground substance.,,,,,,,,"Portion of tissue that consists of mesodermally derived cells and intercellular matrix comprised of protein fibers and carbohydrates, which supports, ensheathes and binds together other tissues.[TAO]|Tissue with cells that deposit non-polarized extracellular matrix including connective tissue fibers and ground substance.[VSAO]|One of the four types of tissue in traditional classifications. It is largely a category of exclusion rather than one with a precise definition, but there are certain characteristics shared by all or most tissues in this category, such as involvement in structure and support, derived from mesoderm, and characterized largely by the traits of non-living tissue.[AAO]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,portion of connective tissue|textus connectivus,,Bindegewebe,,,UBERON:0002384,,,,https://github.com/cmungall|https://github.com/wdahdul,,,,,,,,,,,,,,,,,,connective tissue,,,,,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000002908,NR3C1,,Other designations: glucocorticoid nuclear receptor variant 1|glucocorticoid receptor,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,GCCR|GR|GCR|GRL,,,,,,,,,,,,5,,,,,,MIM:138040|HGNC:7978|HPRD:00679|Vega:OTTHUMG00000129677|Ensembl:ENSG00000113580,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)",,,5q31.3,,,,,,,,,,,,,,,,"GO_0003700 (EC: IEA); GO_0004883 (EC: IEA); GO_0005496 (EC: IEA); GO_0005515 (EC: IPI, PMID: 10364267); GO_0005634 (EC: IDA); GO_0005654 (EC: TAS); GO_0005730 (EC: IDA, Qualifier: NOT); GO_0005737 (EC: IDA); GO_0005759 (EC: TAS, PMID: 10887960); GO_0005829 (EC: IEA); GO_0006111 (EC: IEA); GO_0006351 (EC: TAS, PMID: 10887960); GO_0006355 (EC: IDA, PMID: 19141540); GO_0006366 (EC: TAS, PMID: 8621628); GO_0006367 (EC: TAS); GO_0007165 (EC: TAS, PMID: 7769088); GO_0008211 (EC: IEA); GO_0008270 (EC: IEA); GO_0010467 (EC: TAS); GO_0016020 (EC: IEA); GO_0016568 (EC: IEA); GO_0030325 (EC: IEA); GO_0031946 (EC: IEA); GO_0043525 (EC: IEA); GO_0043565 (EC: IEA); GO_0046983 (EC: IEA); GO_0060603 (EC: IEA)",,,,,,,,,PMID: 1152650; 1469072; 1562545; 1612132; 1704018; 1707881; 1865905; 1958537; 2019585; 2026589; 2793174; 2867473; 3597702; 3841189; 6261922; 6266631; 6509026; 6621034; 7254211; 7264103; 7295795; 7491111; 7621901; 7659084; 7683692; 7724608; 7769088; 7796394; 7823959; 7873448; 7877627; 7887964; 8051160; 8089152; 8107808; 8125298; 8157642; 8223438; 8269959; 8288028; 8290595; 8316249; 8341706; 8349631; 8358712; 8358735; 8445027; 8449898; 8530516; 8621522; 8621628; 8645634; 8733011; 8800208; 8863343; 8878484; 8898375; 9038175; 9079630; 9089287; 9115274; 9128241; 9148915; 9150737; 9154805; 9162033; 9195923; 9199329; 9215863; 9261129; 9334248; 9334723; 9348235; 9353307; 9388192; 9426156; 9435432; 9482670; 9528750; 9584182; 9590696; 9603979; 9637764; 9649342; 9671457; 9703718; 9742105; 9817600; 9873044; 9874563; 9915858; 9920895; 9928932; 10066374; 10085091; 10187825; 10359081; 10364267; 10391209; 10430878; 10477749; 10480874; 10490647; 10508170; 10517667; 10518526; 10566686; 10567404; 10601862; 10639135; 10659697; 10688647; 10691735; 10713165; 10713182; 10731636; 10784585; 10848625; 10866662; 10887960; 10898924; 10902803; 10903152; 10903900; 10933727; 10958685; 10995388; 11005817; 11027313; 11080152; 11096094; 11101523; 11117529; 11119758; 11146632; 11152650; 11154266; 11158330; 11162542; 11229437; 11238589; 11250851; 11266503; 11279115; 11287026; 11344238; 11358809; 11358960; 11435610; 11463861; 11555652; 11562347; 11571596; 11589680; 11591700; 11673782; 11689055; 11701741; 11704662; 11708406; 11710540; 11711524; 11739747; 11751894; 11792840; 11812797; 11818365; 11873873; 11932321; 11971959; 11983486; 11996936; 12000743; 12011091; 12039077; 12039962; 12050230; 12093808; 12099703; 12114257; 12114309; 12118039; 12144530; 12145329; 12151000; 12193561; 12208951; 12225995; 12237016; 12237292; 12351458; 12351702; 12361945; 12379213; 12430185; 12444143; 12466272; 12477485; 12477932; 12487626; 12490527; 12552091; 12569182; 12581885; 12595526; 12612067; 12623935; 12634356; 12637494; 12642036; 12686538; 12711001; 12730237; 12738786; 12748280; 12754700; 12773562; 12773573; 12787894; 12805402; 12807506; 12810720; 12843156; 12864802; 12874288; 12902338; 12903052; 12917342; 12920235; 12933681; 12974633; 14521715; 14522952; 14616881; 14617768; 14634838; 14715855; 14733805; 14739255; 14749509; 14764763; 14764810; 14966297; 15016838; 15044598; 15062560; 15142377; 15159550; 15171715; 15212141; 15265776; 15265780; 15276593; 15289446; 15292341; 15372022; 15380361; 15459252; 15462611; 15489334; 15497438; 15501915; 15511603; 15521959; 15531761; 15545613; 15550679; 15557560; 15576061; 15576464; 15590693; 15591061; 15604093; 15611350; 15638722; 15657031; 15698551; 15713213; 15725353; 15746190; 15755863; 15761032; 15769988; 15770078; 15774500; 15784617; 15797250; 15826950; 15832179; 15862824; 15866175; 15870285; 15879558; 15895983; 15916966; 15919839; 15933212; 15941832; 15955845; 15956716; 16083972; 16087666; 16131566; 16134770; 16143103; 16150697; 16189295; 16192984; 16204701; 16216909; 16222046; 16236267; 16239257; 16263717; 16319314; 16362036; 16380507; 16387802; 16423881; 16429131; 16446173; 16450310; 16458268; 16469772; 16523501; 16580345; 16610949; 16610957; 16615046; 16619302; 16621324; 16624805; 16636127; 16638864; 16648810; 16676134; 16684836; 16725041; 16728546; 16740143; 16759008; 16762839; 16806572; 16806906; 16809634; 16849409; 16855182; 16888650; 16890204; 16895953; 16914312; 16971495; 16973758; 16980656; 17003263; 17043312; 17065567; 17070695; 17081986; 17116691; 17133261; 17167179; 17184882; 17185395; 17186943; 17236775; 17239375; 17242171; 17242172; 17291258; 17382897; 17387179; 17392827; 17395275; 17404046; 17407502; 17438138; 17442162; 17455211; 17460547; 17490654; 17496926; 17512111; 17517920; 17522428; 17532759; 17535992; 17540466; 17552871; 17556642; 17559307; 17563720; 17572486; 17592773; 17602195; 17633252; 17633260; 17635946; 17641689; 17681029; 17682054; 17703412; 17704997; 17716631; 17848410; 17853270; 17884810; 17937535; 17951535; 17952860; 17989362; 18028994; 18029348; 18047640; 18079322; 18086889; 18096310; 18156379; 18160712; 18165172; 18182467; 18194492; 18195193; 18219286; 18246526; 18248637; 18269582; 18286599; 18295813; 18331827; 18337589; 18343955; 18362306; 18385010; 18396779; 18398271; 18407829; 18408151; 18417736; 18468809; 18483179; 18502562; 18510611; 18511904; 18515658; 18536531; 18562626; 18583474; 18595687; 18636124; 18660489; 18663733; 18668364; 18728163; 18772142; 18789525; 18801933; 18812484; 18818748; 18822299; 18827003; 18830906; 18838498; 18838540; 18854398; 18945813; 18952539; 18958157; 18983327; 18996102; 19005987; 19007848; 19007849; 19008334; 19019335; 19051288; 19074285; 19086053; 19089807; 19095219; 19100874; 19133972; 19141540; 19146914; 19174530; 19177170; 19183974; 19188741; 19207316; 19222494; 19230884; 19234455; 19234457; 19241242; 19248771; 19258923; 19275580; 19275583; 19275585; 19282465; 19318444; 19322201; 19336230; 19336370; 19339282; 19365399; 19372434; 19373457; 19375647; 19413563; 19429432; 19435830; 19450127; 19450611; 19453261; 19458171; 19463884; 19466222; 19471022; 19484926; 19491387; 19527514; 19545546; 19548263; 19562035; 19564704; 19570036; 19578796; 19586900; 19595997; 19605973; 19621425; 19628874; 19633971; 19646928; 19673019; 19683543; 19691529; 19692572; 19723618; 19758697; 19778524; 19779205; 19782477; 19783104; 19797430; 19801529; 19805480; 19818358; 19841061; 19874574; 19875381; 19875955; 19913032; 19913121; 19940520; 19948975; 20012529; 20015838; 20015871; 20018896; 20032106; 20035271; 20036846; 20093418; 20124551; 20137628; 20140262; 20156337; 20156759; 20170710; 20195357; 20199670; 20211142; 20219685; 20308989; 20335448; 20347598; 20351714; 20371666; 20376328; 20398657; 20399565; 20403506; 20419394; 20438742; 20440229; 20446002; 20448266; 20450542; 20472303; 20484466; 20485444; 20488636; 20503287; 20543003; 20545708; 20547006; 20561560; 20584071; 20602615; 20619282; 20628086; 20634891; 20660302; 20661446; 20680430; 20697295; 20712049; 20716560; 20727199; 20731635; 20733583; 20734064; 20841450; 20843780; 20850457; 20855522; 20861124; 20885351; 21050724; 21078539; 21084380; 21093928; 21113676; 21127044; 21146942; 21147850; 21148795; 21164266; 21169818; 21190962; 21234764; 21354648; 21355091; 21419342; 21438141; 21438768; 21473041; 21474440; 21477816; 21489275; 21511880; 21521257; 21521940; 21527497; 21531081; 21633323; 21641918; 21646426; 21664385; 21693764; 21730049; 21742609; 21750107; 21760925; 21764460; 21788965; 21789663; 21803757; 21853119; 21868756; 21881570; 21883217; 21900206; 21912096; 21930780; 21945289; 21963094; 21971518; 21980503; 21984896; 21988832; 21995950; 22003412; 22008062; 22015776; 22018181; 22032841; 22048965; 22068557; 22083731; 22085474; 22088926; 22174376; 22177699; 22185489; 22205602; 22227972; 22295073; 22357529; 22366879; 22371499; 22425674; 22427805; 22441538; 22444201; 22457708; 22469783; 22487832; 22507373; 22516378; 22516993; 22533504; 22570980; 22576823; 22587663; 22587831; 22592921; 22698871; 22728713; 22771494; 22773829; 22781842; 22798432; 22801563; 22810058; 22812453; 22832351; 22846929; 22848740; 22851186; 22855579; 22863883; 22879541; 22922069; 23028665; 23033538; 23033539; 23046934; 23055001; 23055525; 23068076; 23072594; 23073785; 23123359; 23124618; 23125313; 23127816; 23132854; 23148886; 23151527; 23176645; 23178279; 23196783; 23204024; 23209664; 23212335; 23219223; 23222642; 23228967; 23239753; 23239757; 23290588; 23297131; 23307810; 23325854; 23329746; 23334186; 23355259; 23391271; 23392094; 23393177; 23426617; 23428870; 23435844; 23440419; 23449091; 23493285; 23506845; 23548248; 23566423; 23603102; 23778418; 23814048; 23820903; 23892712; 24097989; 24128430; 24186266; 24316275,,,,,,,,,,,,,,,OGG:3000002908,,,,,,,"nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)",,,,,,,,,,,,,Other designations: glucocorticoid nuclear receptor variant 1|glucocorticoid receptor,,NR3C1,,,,,,,,,,,,,,,,,,,,,,,2908,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,NR3C1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0004417,AKT signaling (primitive) [hepatocarcinogenesis],,"AKT signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal transmitted by the intracellular serine/threonine kinase protein kinase B (also called AKT).
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.|PMID:30690589",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0001494,,,,,,,,,,,,,,,,,,,,PMID:28493839|PMID:30710550|PMID:29679563|PMID:28706416|PMID:31781608|PMID:28584306,,"AKT signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal transmitted by the intracellular serine/threonine kinase protein kinase B (also called AKT).
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004403|http://purl.obolibrary.org/obo/TXPO_0004419|http://purl.obolibrary.org/obo/TXPO_0004418|http://purl.obolibrary.org/obo/TXPO_0004421|http://purl.obolibrary.org/obo/TXPO_0004422|http://purl.obolibrary.org/obo/TXPO_0004420|http://purl.obolibrary.org/obo/TXPO_0004396|http://purl.obolibrary.org/obo/TXPO_0004391,,,,,,,,,,,TXPO:0004417,,,,,,,,,,,,,,,,,,,,PMID:30690589,,AKT signaling (primitive) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004419,TOR signaling (primitive)　[hepatocarcinogenesis],,"TOR signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the TOR (Target of rapamycin) .
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004028,,,,,,,,,,,,,,,,,,,,PMID:28493839|PMID:30710550|PMID:31239782,,"TOR signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the TOR (Target of rapamycin) .
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004836,http://purl.obolibrary.org/obo/GO_0031929,,,,,http://purl.obolibrary.org/obo/TXPO_0004457|http://purl.obolibrary.org/obo/TXPO_0004603|http://purl.obolibrary.org/obo/TXPO_0004745|http://purl.obolibrary.org/obo/TXPO_0004464|http://purl.obolibrary.org/obo/TXPO_0004837|http://purl.obolibrary.org/obo/TXPO_0004392,,,,,,,,,,,TXPO:0004419,,,,,,,,,,,,,,,,,,,,,,TOR signaling (primitive)　[hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004415,OR3A4 (human) [hepatocarcinogenesis],olfactory receptor family 3 subfamily A member 4 pseudogene,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/OGG_3000390756,,,,,,,,,,,,,,,,,,,,PMID:30710550|NCBI-Human-GeneID:390756,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,olfactory receptor family 3 subfamily A member 4 pseudogene,,,,,TXPO:0004415,,,,,,,"Olfactory receptors interact with odorant molecules in the nose, to initiate a neuronal response that triggers the perception of a smell. The olfactory receptor proteins are members of a large family of G-protein-coupled receptors (GPCR) arising from single coding-exon genes. Olfactory receptors share a 7-transmembrane domain structure with many neurotransmitter and hormone receptors and are responsible for the recognition and G protein-mediated transduction of odorant signals. The olfactory receptor gene family is the largest in the genome. The nomenclature assigned to the olfactory receptor genes and proteins for this organism is independent of other organisms. This olfactory receptor gene is transcribed and contains an intact ORF, but it is predicted to be a pseudogene due to a poorly conserved 7-transmembrane domain structure.",,,,,,,,,,,,,,,OR3A4 (human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004414,AGGF1 signaling [hepatocarcinogenesis],,"AGGF1 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by AGGF1.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0005065,,,,,,,,,,,,,,,,,,,,PMID:30710550,,"AGGF1 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by AGGF1.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004412,http://purl.obolibrary.org/obo/TXPO_0004195,,,,,,http://purl.obolibrary.org/obo/TXPO_0004417,,,,,,,,,,,TXPO:0004414,,,,,,,,,,,,,,,,,,,,,,AGGF1 signaling [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004413,Increasing VEGF level [hepatocarcinogenesis],,"Increasing VEGF level is a subtype of increasing quantity: A process that changes the amount of VEGF level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004856,,,,,,,,,,,,,,,,,,,,PMID:25796501|PMID:29679563|PMID:29340079,,"Increasing VEGF level is a subtype of increasing quantity: A process that changes the amount of VEGF level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004858|http://purl.obolibrary.org/obo/TXPO_0004857,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004603,,,,,,,,,,,TXPO:0004413,,,,,,,,,,,,,,,,,,,,,,Increasing VEGF level [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004411,Increasing AGGF1 level,,Increasing AGGF1 level is a subtype of increasing quantity: A process that changes the amount of AGGF1 level to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing AGGF1 level is a subtype of increasing quantity: A process that changes the amount of AGGF1 level to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_1000502,,,,,,,,,,,,,,,,,,,TXPO:0004411,,,,,,,,,,,,,,,,,,,,,,Increasing AGGF1 level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004410,positive regulation of arachidonic acid metabolic process [hepatocarcinogenesis],,"Any process that activates or increases the frequency, rate or extent of arachidonic acid metabolic process.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004920,,,,,,,,,,,,,,,,,,,,PMID:30008815,,"Any process that activates or increases the frequency, rate or extent of arachidonic acid metabolic process.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004396,,,,,,,,,,,TXPO:0004410,,,,,,,,,,,,,,,,,,,,,,positive regulation of arachidonic acid metabolic process [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003884,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004412,Increasing AGGF1 level [hepatocarcinogenesis],,"Increasing AGGF1 level is a subtype of increasing quantity: A process that changes the amount of AGGF1 level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004411,,,,,,,,,,,,,,,,,,,,PMID:30710550|PMID:25796501|PMID:29340079,,"Increasing AGGF1 level is a subtype of increasing quantity: A process that changes the amount of AGGF1 level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004415,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004195,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004414|http://purl.obolibrary.org/obo/TXPO_0004413,,,,,,,,,,,TXPO:0004412,,,,,,,,,,,,,,,,,,,,,,Increasing AGGF1 level [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004416,negative regulation of AKT signaling [mitochondrial disorder],,"Any process that stops, prevents, or reduces the frequency, rate or extent of protein kinase B signaling, a series of reactions mediated by the intracellular serine/threonine kinase protein kinase B.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/GO_0051898|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:31649547,,"Any process that stops, prevents, or reduces the frequency, rate or extent of protein kinase B signaling, a series of reactions mediated by the intracellular serine/threonine kinase protein kinase B.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004379,,,,,,,,,,,TXPO:0004416,,,,,,,,,,,,,,,,,,,,,,negative regulation of AKT signaling [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004418,GSK3beta signal (primitive) [hepatocarcinogenesis],,"GSK3beta signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by GSK3beta.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004576,,,,,,,,,,,,,,,,,,,,PMID:29679563,,"GSK3beta signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by GSK3beta.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004577,,,,,,,,,,,TXPO:0004418,,,,,,,,,,,,,,,,,,,,,,GSK3beta signal (primitive) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000064782,AEN,,Other designations: apoptosis-enhancing nuclease|interferon stimulated exonuclease gene 20kDa-like 1|interferon-stimulated 20 kDa exonuclease-like 1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,pp12744|ISG20L1,,,,,,,,,,,,15,,,,,,HPRD:08573|Ensembl:ENSG00000181026|Vega:OTTHUMG00000148681|HGNC:25722|MIM:610177,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,apoptosis enhancing nuclease,,,15q26.1,,,,,,,,,,,,,,,,"GO_0003676 (EC: IEA); GO_0004527 (EC: IDA, PMID: 16171785); GO_0005634 (EC: IDA); GO_0005654 (EC: IDA, PMID: 16171785); GO_0005730 (EC: IDA); GO_0010212 (EC: IDA, PMID: 16171785); GO_0031965 (EC: IDA); GO_0042771 (EC: IDA, PMID: 18264133); GO_0090305 (EC: IDA, PMID: 16171785)",,,,,,,,,PMID: 12477932; 14702039; 16171785; 17207965; 18029348; 18264133; 18816836; 20429933; 21906983,,,,,,,,,,,,,,,OGG:3000064782,,,,,,,apoptosis enhancing nuclease,,,,,,,,,,,,,Other designations: apoptosis-enhancing nuclease|interferon stimulated exonuclease gene 20kDa-like 1|interferon-stimulated 20 kDa exonuclease-like 1,,AEN,,,,,,,,,,,,,,,,,,,,,,,64782,SBBI58,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,AEN,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000064787,EPS8L2,,Other designations: EPS8-like protein 2|EPS8-related protein 2|epidermal growth factor receptor kinase substrate 8-like protein 2|epidermal growth factor receptor pathway substrate 8-related protein 2,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,EPS8R2,,,,,,,,,,,,11,,,,,,HGNC:21296|Ensembl:ENSG00000177106|MIM:614988|Vega:OTTHUMG00000165165|HPRD:10940,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,EPS8-like 2,,,11p15.5,,,,,,,,,,,,,,,,"GO_0003779 (EC: IDA, PMID: 14565974); GO_0005089 (EC: IDA, Qualifier: contributes_to, PMID: 14565974); GO_0005737 (EC: IDA); GO_0005886 (EC: IDA); GO_0007266 (EC: IDA, PMID: 14565974); GO_0030676 (EC: IDA, Qualifier: contributes_to, PMID: 14565974); GO_0032314 (EC: IDA, PMID: 14565974); GO_0032319 (EC: IDA, PMID: 14565974); GO_0032587 (EC: IDA, PMID: 14565974); GO_0035023 (EC: IDA, PMID: 14565974); GO_0043234 (EC: IDA, PMID: 14565974); GO_0070062 (EC: IDA, PMID: 19056867); GO_1900029 (EC: IGI, PMID: 14565974)",,,,,,,,,PMID: 8125298; 12477932; 12620401; 14565974; 14702039; 15489334; 15498874; 16083285; 18029348; 19056867; 21832049; 21900206; 21988832,,,,,,,,,,,,,,,OGG:3000064787,,,,,,,EPS8-like 2,,,,,,,,,,,,,Other designations: EPS8-like protein 2|EPS8-related protein 2|epidermal growth factor receptor kinase substrate 8-like protein 2|epidermal growth factor receptor pathway substrate 8-related protein 2,,EPS8L2,,,,,,,,,,,,,,,,,,,,,,,64787,PP13181,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,EPS8L2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_59897,EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor,DNA nucleotidyltransferase (RNA-directed) inhibitors|EC 2.7.7.49 inhibitors|deoxynucleoside-triphosphate:DNA deoxynucleotidyltransferase (RNA-directed) inhibitor|RNA-dependent deoxyribonucleate nucleotidyltransferase inhibitor|RNA-directed DNA polymerase inhibitors|RNA-dependent DNA polymerase inhibitors|RT inhibitors|deoxynucleoside-triphosphate:DNA deoxynucleotidyltransferase (RNA-directed) inhibitors|RNA-directed DNA polymerase inhibitor|revertase inhibitors|telomerase inhibitors|RNA-directed DNA polymerase (EC 2.7.7.49) inhibitors|reverse transcriptase inhibitor|DNA nucleotidyltransferase (RNA-directed) inhibitor|telomerase inhibitor|reverse transcriptase inhibitors|RNA-instructed DNA polymerase inhibitors|RNA-instructed DNA polymerase inhibitor|RT inhibitor|RNA-dependent DNA polymerase inhibitor|EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitors|RNA revertase inhibitor|RNA-directed DNA polymerase (EC 2.7.7.49) inhibitor|revertase inhibitor|RNA revertase inhibitors|EC 2.7.7.49 inhibitor|RNA-dependent deoxyribonucleate nucleotidyltransferase inhibitors,"A DNA polymerase inhibitor that interferes with the activity of reverse transcriptase, EC 2.7.7.49, a viral DNA polymerase enzyme that retroviruses need in order to reproduce.",false,,,http://purl.obolibrary.org/obo/CHEBI_22587|http://purl.obolibrary.org/obo/CHEBI_38234,,,,,,,,,,,,,,,,,,,,,,"A DNA polymerase inhibitor that interferes with the activity of reverse transcriptase, EC 2.7.7.49, a viral DNA polymerase enzyme that retroviruses need in order to reproduce.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,DNA nucleotidyltransferase (RNA-directed) inhibitors|EC 2.7.7.49 inhibitors|deoxynucleoside-triphosphate:DNA deoxynucleotidyltransferase (RNA-directed) inhibitor|RNA-dependent deoxyribonucleate nucleotidyltransferase inhibitor|RNA-directed DNA polymerase inhibitors|RNA-dependent DNA polymerase inhibitors|RT inhibitors|deoxynucleoside-triphosphate:DNA deoxynucleotidyltransferase (RNA-directed) inhibitors|RNA-directed DNA polymerase inhibitor|revertase inhibitors|telomerase inhibitors|RNA-directed DNA polymerase (EC 2.7.7.49) inhibitors|reverse transcriptase inhibitor|DNA nucleotidyltransferase (RNA-directed) inhibitor|telomerase inhibitor|reverse transcriptase inhibitors|RNA-instructed DNA polymerase inhibitors|RNA-instructed DNA polymerase inhibitor|RT inhibitor|RNA-dependent DNA polymerase inhibitor|EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitors|RNA revertase inhibitor|RNA-directed DNA polymerase (EC 2.7.7.49) inhibitor|revertase inhibitor|RNA revertase inhibitors|EC 2.7.7.49 inhibitor|RNA-dependent deoxyribonucleate nucleotidyltransferase inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:59897,,,,EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor,,CHEBI:59897,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000072,COL4A2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1284|NCBI-Mouse-GeneID:12827|NCBI-Rat-GeneID:306628,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001284,,,,,,,,,,,,,TXPO:1000072,,,,,,,,,,,,,,,,,,,,,,COL4A2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000073,COX6B1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:110323|NCBI-Rat-GeneID:688869|NCBI-Human-GeneID:1340,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001340,,,,,,,,,,,,,TXPO:1000073,,,,,,,,,,,,,,,,,,,,,,COX6B1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000079,CYP2C19 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0001553,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1557,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001557,,,,,,,,,,,,,TXPO:1000079,,,,,,,,,,,,,,,,,,,,,,CYP2C19 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000070,CLU (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1191|NCBI-Mouse-GeneID:12759|NCBI-Rat-GeneID:24854,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001191,,,,,,,,,,,,,TXPO:1000070,,,,,,,,,,,,,,,,,,,,,,CLU (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000076,CRP (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:12944|NCBI-Rat-GeneID:25419|NCBI-Human-GeneID:1401,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001401,,,,,,,,,,,,,TXPO:1000076,,,,,,,,,,,,,,,,,,,,,,CRP (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000075,CRELD2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:79174|NCBI-Mouse-GeneID:76737|NCBI-Rat-GeneID:362978,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000079174,,,,,,,,,,,,,TXPO:1000075,,,,,,,,,,,,,,,,,,,,,,CRELD2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000074,CRBPH (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:1000074,,,,,,,,,,,,,,,,,,,,,,CRBPH (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000077,CXCR3 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:84475|NCBI-Human-GeneID:2833|NCBI-Mouse-GeneID:12766,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000002833,,,,,,,,,,,,,TXPO:1000077,,,,,,,,,,,,,,,,,,,,,,CXCR3 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000078,CYP2B6 (mol),,"Orthologs of the human CYP2B6 genes can be found in other species including rats, mice, and dogs, which are termed Cyp2b1, Cyp2b10, and CYP2B11, respectively",false,,,http://purl.obolibrary.org/obo/TXPO_0001553,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1555,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001555,,,,,,,,,,,,,TXPO:1000078,,,,,,,,,,,,,,,,,,,,"Orthologs of the human CYP2B6 genes can be found in other species including rats, mice, and dogs, which are termed Cyp2b1, Cyp2b10, and CYP2B11, respectively",,CYP2B6 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000071,CNOT6L (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:246175|NCBI-Mouse-GeneID:231464|NCBI-Rat-GeneID:360917,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000246175,,,,,,,,,,,,,TXPO:1000071,,,,,,,,,,,,,,,,,,,,,,CNOT6L (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000414,keeping quantity,,Keeping quantity is a subtype of changing amount: A process that maintains the magnitude of the object at a constant level .,false,,,http://purl.obolibrary.org/obo/TXPO_0000394,,,,,,,,,,,,,,,,,,,,,,Keeping quantity is a subtype of changing amount: A process that maintains the magnitude of the object at a constant level .,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000414,,,,,,,,,,,,,,,,,,,,,,keeping quantity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000416,negative regulation of formation of cytoplasmic translation initiation complex by eIF2a [ER stress],,"Negative regulation of formation of cytoplasmic translation initiation complex by eIF2a is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of formation of cytoplasmic translation initiation complex by eIF2a.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000068|http://purl.obolibrary.org/obo/TXPO_0003736,,,,,,,,,,,,,,,,,,,,PMID:9930704|PMID:23334697,,"Negative regulation of formation of cytoplasmic translation initiation complex by eIF2a is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of formation of cytoplasmic translation initiation complex by eIF2a.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002555,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000416,,,,,,,,,,,,,,,,,,,,,,negative regulation of formation of cytoplasmic translation initiation complex by eIF2a [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000415,changing quality,,Changing quality is a subtype of changing an operand: A process that changes the quality of the object.,false,,,http://purl.obolibrary.org/obo/TXPO_0000392,,,,,,,,,,,,,,,,,,,,,,Changing quality is a subtype of changing an operand: A process that changes the quality of the object.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000415,,,,,,,,,,,,,,,,,,,,,,changing quality,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000410,changing shape,,Changing shape is a subtype of changing structure: A process that changes the form of the operand.,false,,,http://purl.obolibrary.org/obo/TXPO_0002566,,,,,,,,,,,,,,,,,,,,,,Changing shape is a subtype of changing structure: A process that changes the form of the operand.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000410,,,,,,,,,,,,,,,,,,,,,,changing shape,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000412,changing membrane fluidity,,Changing membrane fluidity is a subtype of changing fluidity: A process that changes the fluidity of the membrane.,false,,,http://purl.obolibrary.org/obo/TXPO_0000337,,,,,,,,,,,,,,,,,,,,,,Changing membrane fluidity is a subtype of changing fluidity: A process that changes the fluidity of the membrane.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000412,,,,,,,,,,,,,,,,,,,,,,changing membrane fluidity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000895,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000413,positive regulation of protein refolding [ER stress],,"Any process that activates or increases the frequency, rate or extent of protein refolding.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/GO_1904592|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"Any process that activates or increases the frequency, rate or extent of protein refolding.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002716,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002175,,,,,,,,,,,TXPO:0000413,,,,,,,,,,,,,,,,,,,,,,positive regulation of protein refolding [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000411,liver X receptor activation,activating LXR alpha|LxR alpha activation,Liver X receptor activation is a subtype of activating nuclear receptor: A process that changes the activity of the activating  LXR ( liver X receptor) with a nuclear receptor role to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000158,,,,,,,,,,,,,,,,,,,,,,Liver X receptor activation is a subtype of activating nuclear receptor: A process that changes the activity of the activating  LXR ( liver X receptor) with a nuclear receptor role to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,activating LXR alpha|LxR alpha activation,,,,,TXPO:0000411,,,,,,,,,,,,,,,,,,,,,,liver X receptor activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000417,changing volume,,Changing volume is a subtype of changing quality: A process that changes the volume of the object.,false,,,http://purl.obolibrary.org/obo/TXPO_0000415,,,,,,,,,,,,,,,,,,,,,,Changing volume is a subtype of changing quality: A process that changes the volume of the object.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/BFO_0000040,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000417,,,,,,,,,,,,,,,,,,,,,,changing volume,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000418,homeostatic imbalance of number of smooth endoplasmic reticulum,,Homeostatic imbalance of number of smooth endoplasmic reticulum is a subtype of imbalance: A process that becomes lacking a homeostastasis balance of the proliferation and elimination of smooth endoplasmic reticulum.,false,,,http://purl.obolibrary.org/obo/TXPO_0000567,,,,,,,,,,,,,,,,,,,,,,Homeostatic imbalance of number of smooth endoplasmic reticulum is a subtype of imbalance: A process that becomes lacking a homeostastasis balance of the proliferation and elimination of smooth endoplasmic reticulum.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000418,,,,,,,,,,,,,,,,,,,,,,homeostatic imbalance of number of smooth endoplasmic reticulum,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76661,EC 2.3.* (acyltransferase) inhibitor,EC 2.3.* (acyltransferase) inhibitors|EC 2.3.* inhibitor|acyltransferase inhibitor|acyltransferase inhibitors|EC 2.3.* inhibitors,A transferase inhibitor that interferes with the action of an acyltransferase (EC 2.3.*.*).,false,,,http://purl.obolibrary.org/obo/CHEBI_71300,,,,,,,,,,,,,,,,,,,,,,A transferase inhibitor that interferes with the action of an acyltransferase (EC 2.3.*.*).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,EC 2.3.* (acyltransferase) inhibitors|EC 2.3.* inhibitor|acyltransferase inhibitor|acyltransferase inhibitors|EC 2.3.* inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:76661,,,,EC 2.3.* (acyltransferase) inhibitor,,CHEBI:76661,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001092,FLI1,,,false,,,http://purl.obolibrary.org/obo/IMR_0000397,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001092,,,,,,,,,,,,,,,,,,,,,,FLI1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000005350,PLN,,Other designations: cardiac phospholamban,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CMH18|CMD1P|PLB,,,,,,,,,,,,6,,,,,,HPRD:01395|Ensembl:ENSG00000198523|HGNC:9080|Vega:OTTHUMG00000015462|MIM:172405,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,phospholamban,,,6q22.1,,,,,,,,,,,,,,,,"GO_0002026 (EC: IC, PMID: 19708671); GO_0004857 (EC: ISS, PMID: 12032137); GO_0005246 (EC: IEA); GO_0005515 (EC: IPI, PMID: 15598648); GO_0005739 (EC: IDA); GO_0005783 (EC: ISS); GO_0006816 (EC: IEA); GO_0008015 (EC: NAS, PMID: 8406504); GO_0008016 (EC: IMP, PMID: 16432188); GO_0010043 (EC: IEA); GO_0010459 (EC: IMP, PMID: 16432188); GO_0010881 (EC: IEA); GO_0016020 (EC: IDA, PMID: 19708671); GO_0031966 (EC: IEA); GO_0031982 (EC: IEA); GO_0032780 (EC: IDA, PMID: 19708671); GO_0032780 (EC: ISS); GO_0033017 (EC: IEA); GO_0033574 (EC: IEA); GO_0042030 (EC: IDA, PMID: 19708671); GO_0042030 (EC: ISS); GO_0042802 (EC: ISS); GO_0043086 (EC: ISS, PMID: 12032137); GO_0048471 (EC: ISS); GO_0048738 (EC: IEA); GO_0051117 (EC: ISS, PMID: 12032137); GO_0051260 (EC: IEA); GO_0051480 (EC: IC, PMID: 19708671); GO_0051924 (EC: IDA); GO_0051924 (EC: ISS); GO_0051926 (EC: IDA, PMID: 19708671); GO_0055119 (EC: TAS); GO_0060314 (EC: IEA); GO_0086004 (EC: IC, PMID: 19708671); GO_0086023 (EC: IEA); GO_0086036 (EC: IC, PMID: 19708671); GO_0086092 (EC: IEA); GO_0090281 (EC: ISS, PMID: 12032137); GO_0090534 (EC: IDA, PMID: 19708671); GO_1901020 (EC: IDA, PMID: 19708671); GO_1901020 (EC: ISS); GO_1901877 (EC: IDA, PMID: 19708671); GO_1901877 (EC: ISS); GO_1901894 (EC: IDA); GO_1901895 (EC: IDA, PMID: 19708671); GO_1901897 (EC: IC, PMID: 19708671); GO_1902081 (EC: ISS)",,,,,,,,,PMID: 1828805; 3759968; 7586307; 7749920; 7779806; 8406504; 8862513; 9345259; 9468536; 9512019; 9845327; 10096878; 10198197; 10551848; 10809745; 11526231; 11854448; 12032137; 12080135; 12477932; 12480535; 12525698; 12610310; 12639993; 12692302; 12705874; 12804600; 14530977; 15342556; 15489334; 15598648; 15640069; 15736939; 16043693; 16235537; 16382369; 16432188; 16476846; 16829191; 17009399; 17010801; 17515962; 17655857; 17766390; 17905829; 18192322; 18241046; 18708665; 19139388; 19305408; 19305409; 19324307; 19584346; 19587794; 19638213; 19671701; 19708671; 19875404; 20301486; 20301725; 20474083; 20634894; 20639392; 21076409; 21108950; 21167350; 21282613; 21332051; 21576492; 21687864; 21988832; 22137083; 22155237; 22172806; 22247554; 22427649; 22820313; 23166209; 23308118; 23349452; 23871674,,,,,,,,,,,,,,,OGG:3000005350,,,,,,,phospholamban,,,,,,,,,,,,,Other designations: cardiac phospholamban,,PLN,,,,,,,,,,,,,,,,,,,,,,,5350,RP3-509L4.2,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,PLN,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000003177,SLC29A2,,"Other designations: 36 kDa nucleolar protein HNP36|delayed-early response protein 12|equilibrative NBMPR-insensitive nucleoside transporter|equilibrative nitrobenzylmercaptopurine riboside-insensitive nucleoside transporter|equilibrative nucleoside transporter 2|hydrophobic nucleolar protein, 36 kDa|hydrophobic nucleolar protein, 36kD|nucleoside transporter, ei-type|solute carrier family 29 (nucleoside transporters), member 2|solute carrier family 29 member 2",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,DER12|HNP36|ENT2,,,,,,,,,,,,11,,,,,,MIM:602110|Ensembl:ENSG00000174669|HPRD:03662|Vega:OTTHUMG00000169056|HGNC:11004,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"solute carrier family 29 (equilibrative nucleoside transporter), member 2",,,11q13,,,,,,,,,,,,,,,,"GO_0005337 (EC: IEA); GO_0005730 (EC: TAS, PMID: 7639753); GO_0005886 (EC: TAS); GO_0005887 (EC: TAS, PMID: 7639753); GO_0006139 (EC: TAS, PMID: 9396714); GO_0008283 (EC: TAS, PMID: 7639753); GO_0015858 (EC: IDA, PMID: 12527552); GO_0016323 (EC: IDA, PMID: 12527552); GO_0031965 (EC: IEA); GO_0055085 (EC: TAS); GO_1901642 (EC: TAS, PMID: 9396714)",,,,,,,,,PMID: 7639753; 9192854; 9396714; 9478986; 12006583; 12411296; 12477932; 12527552; 12590919; 12820662; 12838422; 14612157; 14702039; 15386342; 15489334; 15644498; 15649894; 16214850; 16924660; 17921321; 17926640; 18635603; 18703227; 18945750; 19105964; 19297449; 20392501; 21156465; 21822668; 21906983; 21926972; 21963094; 21987572; 23590299; 23639800,,,,,,,,,,,,,,,OGG:3000003177,,,,,,,"solute carrier family 29 (equilibrative nucleoside transporter), member 2",,,,,,,,,,,,,"Other designations: 36 kDa nucleolar protein HNP36|delayed-early response protein 12|equilibrative NBMPR-insensitive nucleoside transporter|equilibrative nitrobenzylmercaptopurine riboside-insensitive nucleoside transporter|equilibrative nucleoside transporter 2|hydrophobic nucleolar protein, 36 kDa|hydrophobic nucleolar protein, 36kD|nucleoside transporter, ei-type|solute carrier family 29 (nucleoside transporters), member 2|solute carrier family 29 member 2",,SLC29A2,,,,,,,,,,,,,,,,,,,,,,,3177,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,SLC29A2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000728,PLD1,phospholipase D1,,false,,,http://purl.obolibrary.org/obo/IMR_0000287,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,phospholipase D1,,,,,IMR:0000728,,,,,,,,,,,,,,,,,,,,,,PLD1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_50751,anti-estrogen,antioestrogenic agent|anti-estrogenic agent|antiestrogenic drug|anti-oestrogen|antiestrogenic agent|antiestrogen|antioestrogen|anti-oestrogenic agent|anti-estrogenic drug|antioestrogenic drug|anti-oestrogenic drug,"A drug which acts to reduce estrogenic activity in the body, either by reducing the amount of estrogen or by reducing the activity of whatever estrogen is present.",false,,,http://purl.obolibrary.org/obo/CHEBI_23888,,,,,,,,,,,,,,,,,,,,,,"A drug which acts to reduce estrogenic activity in the body, either by reducing the amount of estrogen or by reducing the activity of whatever estrogen is present.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,antioestrogenic agent|anti-estrogenic agent|antiestrogenic drug|anti-oestrogen|antiestrogenic agent|antiestrogen|antioestrogen|anti-oestrogenic agent|anti-estrogenic drug|antioestrogenic drug|anti-oestrogenic drug,,,,,,,,,,,,,,,,,,,,,CHEBI:50751,,,,anti-estrogen,,CHEBI:50751,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003330,LSS (human)[Phospholipidosis],Lanosterol Synthase [Phospholipidosis],,false,,,http://purl.obolibrary.org/obo/TXPO_0002668|http://purl.obolibrary.org/obo/TXPO_1000228,,,,,,,,,,,,,,,,,,,,http://omim.org/entry/600909|NCBI-Human-GeneID:4047|PMID:11421484|PMID:17186944,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000004047,,,,,,,,Lanosterol Synthase [Phospholipidosis],,,,,TXPO:0003330,,,,,,,,,,,,,,,,,,,,,,LSS (human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001442,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003333,NR0B2 (human)[Phospholipidosis],Nuclear Receptor Subfamily 0 Group B Member 2 [Phospholipidosis]|Shp1 [Phospholipidosis],,false,,,http://purl.obolibrary.org/obo/TXPO_0002668|http://purl.obolibrary.org/obo/OGG_3000008431,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:8431|PMID:25720568|PMID:23042943,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000008431,,,http://purl.obolibrary.org/obo/TXPO_0003224,,,,,Nuclear Receptor Subfamily 0 Group B Member 2 [Phospholipidosis]|Shp1 [Phospholipidosis],,,,,TXPO:0003333,,,,,,,,,,,,,,,,,,,,,,NR0B2 (human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001442,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003336,glucose transmembrane transporter,glucose permease,A role played by the entity which enables the transfer of the hexose monosaccharide glucose from one side of a membrane to the other.|related molecular function GO:0005355,false,,,http://purl.obolibrary.org/obo/TXPO_0003701,,,,,,,,,,,,,,,,,,,,,,A role played by the entity which enables the transfer of the hexose monosaccharide glucose from one side of a membrane to the other.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,glucose permease,,,TXPO:0003336,,,,,,,,,,,,,,,,,,,,related molecular function GO:0005355,,glucose transmembrane transporter,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003335,SLC2A3 (human)[Phospholipidosis],GLUT3  [Phospholipidosis]|Solute Carrier Family 2 Member 3 [Phospholipidosis],,false,,,http://purl.obolibrary.org/obo/TXPO_0002668|http://purl.obolibrary.org/obo/TXPO_1000342,,,,,,,,,,,,,,,,,,,,http://omim.org/entry/138170|http://www.ncbi.nlm.nih.gov/gene/6515|NCBI-Human-GeneID:6515|PMID:17567588|PMID:27302065,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000006515,,,http://purl.obolibrary.org/obo/TXPO_0003336,,,,,GLUT3  [Phospholipidosis]|Solute Carrier Family 2 Member 3 [Phospholipidosis],,,,,TXPO:0003335,,,,,,,,,,,,,,,,,,,,,,SLC2A3 (human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001442,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003334,TAGLN (human)[Phospholipidosis],Transgelin [Phospholipidosis（Sawada）],,false,,,http://purl.obolibrary.org/obo/TXPO_0002668|http://purl.obolibrary.org/obo/TXPO_1000369,,,,,,,,,,,,,,,,,,,,AKT and JNK Signaling Pathways Increase the Metastatic Potential of Colorectal Cancer Cells by Altering Transgelin Expression.|NCBI-Human-GeneID:6876|http://omim.org/entry/600818|PMID:26847345|PMID:25841305,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000006876,,,,,,,,Transgelin [Phospholipidosis（Sawada）],,,,,TXPO:0003334,,,,,,,"This gene encodes a shape change and transformation sensitive actin-binding protein which belongs to the calponin family. It is ubiquitously expressed in vascular and visceral smooth muscle, and is an early marker of smooth muscle differentiation. The encoded protein is thought to be involved in calcium-independent smooth muscle contraction. It acts as a tumor suppressor, and the loss of its expression is an early event in cell transformation and the development of some tumors, coinciding with cellular plasticity. The encoded protein has a domain architecture consisting of an N-terminal calponin homology (CH) domain and a C-terminal calponin-like (CLIK) domain. Mice with a knockout of the orthologous gene are viable and fertile but their vascular smooth muscle cells exhibit alterations in the distribution of the actin filament and changes in cytoskeletal organization. [provided by RefSeq, Aug 2017]",,,,,,,,,,,,,,,TAGLN (human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001442,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003337,FABP1 (human)[Phospholipidosis],Fatty Acid Binding Protein 1 [Phospholipidosis],"This gene encodes the fatty acid binding protein found in liver. Fatty acid binding proteins are a family of small, highly conserved, cytoplasmic proteins that bind long-chain fatty acids and other hydrophobic ligands. This protein and FABP6 (the ileal fatty acid binding protein) are also able to bind bile acids. It is thought that FABPs roles include fatty acid uptake, transport, and metabolism. [provided by RefSeq, Mar 2011]",false,,,http://purl.obolibrary.org/obo/TXPO_0002668|http://purl.obolibrary.org/obo/TXPO_1000137,,,,,,,,,,,,,,,,,,,,http://omim.org/entry/134650|NCBI-Human-GeneID:2168|http://www.ncbi.nlm.nih.gov/entrez/gene/2168|GO:0005543,,"This gene encodes the fatty acid binding protein found in liver. Fatty acid binding proteins are a family of small, highly conserved, cytoplasmic proteins that bind long-chain fatty acids and other hydrophobic ligands. This protein and FABP6 (the ileal fatty acid binding protein) are also able to bind bile acids. It is thought that FABPs roles include fatty acid uptake, transport, and metabolism. [provided by RefSeq, Mar 2011]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000002168,,,http://purl.obolibrary.org/obo/TXPO_0003338,,,,,Fatty Acid Binding Protein 1 [Phospholipidosis],,,,,TXPO:0003337,,,,,,,,,,,,,,,,,,,,,,FABP1 (human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001442,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003339,SERPINA3 (human)[Phospholipidosis],Alpha-1-Antichymotrypsin|Serpin Family A Member 3,"The protein encoded by this gene is a plasma protease inhibitor and member of the serine protease inhibitor class. Polymorphisms in this protein appear to be tissue specific and influence protease targeting. Variations in this protein's sequence have been implicated in Alzheimer's disease, and deficiency of this protein has been associated with liver disease. Mutations have been identified in patients with Parkinson disease and chronic obstructive pulmonary disease. [provided by RefSeq, Jul 2008]",false,,,http://purl.obolibrary.org/obo/TXPO_0002668|http://purl.obolibrary.org/obo/TXPO_1000336,,,,,,,,,,,,,,,,,,,,"NCBI-Human-GeneID:12|http://omim.org/entry/107280
Alpha-1-antichymotrypsin is a plasma protease inhibitor synthesized in the liver.|https://www.ncbi.nlm.nih.gov/gene/12",,"The protein encoded by this gene is a plasma protease inhibitor and member of the serine protease inhibitor class. Polymorphisms in this protein appear to be tissue specific and influence protease targeting. Variations in this protein's sequence have been implicated in Alzheimer's disease, and deficiency of this protein has been associated with liver disease. Mutations have been identified in patients with Parkinson disease and chronic obstructive pulmonary disease. [provided by RefSeq, Jul 2008]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000012,,,,,,,,Alpha-1-Antichymotrypsin|Serpin Family A Member 3,,,,,TXPO:0003339,,,,,,,,,,,,,,,,,,,,,,SERPINA3 (human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001442,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003332,cholesterol biosynthetic process [Phospholipidosis],,"Cholesterol biosynthetic process is a subtype of lipid biosynthetic process:  The chemical reaction resulting in the formation of cholesterol, cholest-5-en-3 beta-ol, the principal sterol of vertebrates and the precursor of many steroids, including bile acids and steroid hormones.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/GO_0006695,,,,,,,,,,,,,,,,,,,,,,"Cholesterol biosynthetic process is a subtype of lipid biosynthetic process:  The chemical reaction resulting in the formation of cholesterol, cholest-5-en-3 beta-ol, the principal sterol of vertebrates and the precursor of many steroids, including bile acids and steroid hormones.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003330,,,,,,,,,,,,,,,,,TXPO:0003332,,,,,,,"The chemical reaction resulting in the formation of cholesterol, cholest-5-en-3 beta-ol, the principal sterol of vertebrates and the precursor of many steroids, including bile acids and steroid hormones.",,,,,,,,,,,,,,,cholesterol biosynthetic process [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003331,cytokine receptor,,Combining role with a cytokine and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.|related molecular function GO:0004896,false,,,http://purl.obolibrary.org/obo/TXPO_0000057,,,,,,,,,,,,,,,,,,,,IMR:0000095 (obsolete),,Combining role with a cytokine and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003331,,,,,,,,,,,,,,,,,,,,related molecular function GO:0004896,,cytokine receptor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003338,long-chain fatty acid transporter,,A role played by the entity which transfers long-chain fatty acids from one side of a membrane to the other. A long-chain fatty acid is a fatty acid with a chain length between C13 and C22|related molecular function GO:0005324,false,,,http://purl.obolibrary.org/obo/TXPO_0003699,,,,,,,,,,,,,,,,,,,,EC:3.6.3.47|PMID:15249972,,A role played by the entity which transfers long-chain fatty acids from one side of a membrane to the other. A long-chain fatty acid is a fatty acid with a chain length between C13 and C22,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003338,,,,,,,,,,,,,,,,,,,,related molecular function GO:0005324,,long-chain fatty acid transporter,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0043066,negative regulation of apoptotic process,negative regulation of apoptosis|inhibition of apoptosis|pro-survival|down-regulation of apoptosis|downregulation of apoptosis|down regulation of apoptosis|anti-apoptosis,"Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptotic process.",false,,,http://purl.obolibrary.org/obo/GO_0042981,,,,,,,,,,,,,,,,,,,,GO:0043066,,"Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptotic process.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,down-regulation of apoptosis|downregulation of apoptosis|down regulation of apoptosis|anti-apoptosis,negative regulation of apoptosis|inhibition of apoptosis,pro-survival,,,GO:0043066,,,,,,,,,,,,,,,,,,,,,,negative regulation of apoptotic process,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006915,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0043065,positive regulation of apoptotic process,activation of apoptosis|pro-apoptosis|up-regulation of apoptosis|up regulation of apoptosis|upregulation of apoptosis|positive regulation of apoptotic process,"Any process that activates or increases the frequency, rate or extent of cell death by apoptotic process.",false,,,http://purl.obolibrary.org/obo/GO_0042981,,,,,,,,,,,,,,,,,,,,,,"Any process that activates or increases the frequency, rate or extent of cell death by apoptotic process.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,up-regulation of apoptosis|up regulation of apoptosis|upregulation of apoptosis|positive regulation of apoptotic process,activation of apoptosis,pro-apoptosis,,,GO:0043065,,,,,,,,,,,,,,,,,,,,,,positive regulation of apoptotic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006915,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000348235,SKA2,,"Other designations: family with sequence similarity 33, member A|spindle and KT (kinetochore) associated 2|spindle and kinetochore-associated protein 2",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,FAM33A,,,,,,,,,,,,17,,,,,,Vega:OTTHUMG00000179361|HPRD:13306|Ensembl:ENSG00000182628|HGNC:28006,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,spindle and kinetochore associated complex subunit 2,,,17q22,,,,,,,,,,,,,,,,"GO_0000278 (EC: TAS); GO_0000940 (EC: IDA, PMID: 17093495); GO_0005515 (EC: IPI, PMID: 17093495); GO_0005737 (EC: IDA); GO_0005829 (EC: TAS); GO_0005876 (EC: IDA, PMID: 17093495); GO_0007059 (EC: IMP, PMID: 19289083); GO_0007067 (EC: IMP, PMID: 19289083); GO_0008017 (EC: IDA, PMID: 19289083); GO_0031110 (EC: IDA, PMID: 19289083); GO_0051301 (EC: IMP, PMID: 17093495)",,,,,,,,,PMID: 12477932; 14702039; 15489334; 16344560; 17093495; 17207965; 18583474; 19156129; 19289083; 20470754; 21988832; 22371557; 22483620; 23666239,,,,,,,,,,,,,,,OGG:3000348235,,20140408,protein-coding,,,,spindle and kinetochore associated complex subunit 2,,,,,,,,,,,,,"Other designations: family with sequence similarity 33, member A|spindle and KT (kinetochore) associated 2|spindle and kinetochore-associated protein 2",,SKA2,,,,,,,,,,,,,,,,,,,,,,,348235,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,SKA2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0001019,"cAMP-specific 3',5'-cyclic phosphodiesterase 4D",,,false,,,http://purl.obolibrary.org/obo/IMR_0100700,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001019,,,,,,,,,,,,,,,,,,,,,,"cAMP-specific 3',5'-cyclic phosphodiesterase 4D",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000027286,SRPX2,,"Other designations: sushi repeat-containing protein SRPX2|sushi-repeat protein up-regulated in leukemia|sushi-repeat protein upregulated in leukemia|sushi-repeat-containing protein, X-linked 2",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,RESDX|PMGX|SRPUL|CBPS|BPP,,,,,,,,,,,,X,,,,,,Vega:OTTHUMG00000022003|HGNC:30668|Ensembl:ENSG00000102359|HPRD:06726|MIM:300642,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"sushi-repeat containing protein, X-linked 2",,,Xq21.33-q23,,,,,,,,,,,,,,,,"GO_0001525 (EC: IEA); GO_0005102 (EC: IPI, PMID: 18718938); GO_0005515 (EC: IPI, PMID: 18718938); GO_0005615 (EC: IDA); GO_0005737 (EC: IDA, PMID: 19065654); GO_0009986 (EC: ISS); GO_0016337 (EC: IDA, PMID: 19065654); GO_0030054 (EC: IEA); GO_0036458 (EC: IDA); GO_0042325 (EC: IDA, PMID: 19065654); GO_0042802 (EC: IDA); GO_0048870 (EC: IDA, PMID: 19065654); GO_0051965 (EC: IDA); GO_0060076 (EC: ISS); GO_0090050 (EC: ISS); GO_0097060 (EC: ISS)",,,,,,,,,PMID: 209648; 9864177; 11375929; 11822025; 12477932; 15342556; 15489334; 15772651; 16303743; 16344560; 16497722; 17942002; 18029348; 18718938; 19065654; 19667118; 20236627; 20858596; 22242148; 23115050; 23933820; 24179158,,,,,,,,,,,,,,,OGG:3000027286,,20140408,protein-coding,,,,"sushi-repeat containing protein, X-linked 2",,,,,,,,,,,,,"Other designations: sushi repeat-containing protein SRPX2|sushi-repeat protein up-regulated in leukemia|sushi-repeat protein upregulated in leukemia|sushi-repeat-containing protein, X-linked 2",,SRPX2,,,,,,,,,,,,,,,,,,,,,,,27286,RP11-524D16__A.1,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,SRPX2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000886,TFIIF,,,false,,,http://purl.obolibrary.org/obo/IMR_0000888,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003645,,,,,,,,,,IMR:0000886,,,,,,,,,,,,,,,,,,,,,,TFIIF,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000530,RPS29 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:6235|NCBI-Mouse-GeneID:20090|NCBI-Rat-GeneID:25348,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000006235,,,,,,,,,,,,,TXPO:1000530,,,,,,,,,,,,,,,,,,,,,,RPS29 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000533,SKA2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:66140|NCBI-Human-GeneID:348235|NCBI-Rat-GeneID:287598,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000348235,,,,,,,,,,,,,TXPO:1000533,,,,,,,,,,,,,,,,,,,,,,SKA2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000539,TMEM150C (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:441027|NCBI-Mouse-GeneID:231503|NCBI-Rat-GeneID:360916,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000441027,,,,,,,,,,,,,TXPO:1000539,,,,,,,,,,,,,,,,,,,,,,TMEM150C (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000536,SPTLC3 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:55304|NCBI-Mouse-GeneID:228677|NCBI-Rat-GeneID:296188,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000055304,,,,,,,,,,,,,TXPO:1000536,,,,,,,,,,,,,,,,,,,,,,SPTLC3 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000534,SLC38A4 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:55089|NCBI-Rat-GeneID:170573|NCBI-Mouse-GeneID:69354,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000055089,,,,,,,,,,,,,TXPO:1000534,,,,,,,,,,,,,,,,,,,,,,SLC38A4 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000537,SRPX2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:68792|NCBI-Human-GeneID:27286|NCBI-Rat-GeneID:317181,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000027286,,,,,,,,,,,,,TXPO:1000537,,,,,,,,,,,,,,,,,,,,,,SRPX2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000538,TMEM139 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:109218|NCBI-Human-GeneID:135932|NCBI-Rat-GeneID:680244,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000135932,,,,,,,,,,,,,TXPO:1000538,,,,,,,,,,,,,,,,,,,,,,TMEM139 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000531,SCAPER (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:244891|NCBI-Rat-GeneID:117521|NCBI-Human-GeneID:49855,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000049855,,,,,,,,,,,,,TXPO:1000531,,,,,,,,,,,,,,,,,,,,,,SCAPER (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000532,SEL1L (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:314352|NCBI-Mouse-GeneID:20338|NCBI-Human-GeneID:6400,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000006400,,,,,,,,,,,,,TXPO:1000532,,,,,,,,,,,,,,,,,,,,,,SEL1L (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000535,SLC3A1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:20532|NCBI-Rat-GeneID:29484|NCBI-Human-GeneID:6519,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000006519,,,,,,,,,,,,,TXPO:1000535,,,,,,,,,,,,,,,,,,,,,,SLC3A1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001674,RGS17,,,false,,,http://purl.obolibrary.org/obo/IMR_0000431,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001674,,,,,,,,,,,,,,,,,,,,,,RGS17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010558,40S ribosomal protein S3,40S small ribosomal protein 3,,false,,,http://purl.obolibrary.org/obo/IMR_0000896,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,40S small ribosomal protein 3,,,,,IMR:0010558,,,,,,,,,,,,,,,,,,,,,,40S ribosomal protein S3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000824,MafB,,,false,,,http://purl.obolibrary.org/obo/IMR_0000411,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000824,,,,,,,,,,,,,,,,,,,,,,MafB,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002316,dysfunction of phosphatidyl-L-serine degradation,,Dysfunction of phosphatidyl-L-serine degradation is a subtype of dysfunction of glycerophospholipid degradation: A process that performs an abnormal and incomplete phosphatidyl-L-serine degradation.,false,,,http://purl.obolibrary.org/obo/TXPO_0002310,,,,,,,,,,,,,,,,,,,,,,Dysfunction of phosphatidyl-L-serine degradation is a subtype of dysfunction of glycerophospholipid degradation: A process that performs an abnormal and incomplete phosphatidyl-L-serine degradation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002316,,,,,,,,,,,,,,,,,,,,,,dysfunction of phosphatidyl-L-serine degradation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002311,hyperfunction of increasing the amount of phenobarbital  (sustained) [Ground glass appearance],,"Hyperfunction of increasing the amount of phenobarbital is a process of performing an excessive function of increasing the amount of drugs. This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) .",false,,,http://purl.obolibrary.org/obo/TXPO_0001840,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of increasing the amount of phenobarbital is a process of performing an excessive function of increasing the amount of drugs. This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) .",,,http://purl.obolibrary.org/obo/TXPO_0001637,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003856,,,,,,,,,,,TXPO:0002311,,,,,,,,,,,,,,,,,,,,,,hyperfunction of increasing the amount of phenobarbital  (sustained) [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002312,dysfunction ofphosphatidylinositol degradation,,Dysfunction ofphosphatidylinositol degradation is a subtype of dysfunction of glycerophospholipid degradation: A process that performs an abnormal and incomplete phosphatidylinositol degradation.,false,,,http://purl.obolibrary.org/obo/TXPO_0002310,,,,,,,,,,,,,,,,,,,,,,Dysfunction ofphosphatidylinositol degradation is a subtype of dysfunction of glycerophospholipid degradation: A process that performs an abnormal and incomplete phosphatidylinositol degradation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002312,,,,,,,,,,,,,,,,,,,,,,dysfunction ofphosphatidylinositol degradation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002317,dysfunction of phosphatidic acid degradation,,Dysfunction of phosphatidic acid degradation is a subtype of dysfunction of glycerophospholipid degradation: A process that performs an abnormal and incomplete phosphatidic acid degradation.,false,,,http://purl.obolibrary.org/obo/TXPO_0002310,,,,,,,,,,,,,,,,,,,,,,Dysfunction of phosphatidic acid degradation is a subtype of dysfunction of glycerophospholipid degradation: A process that performs an abnormal and incomplete phosphatidic acid degradation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002317,,,,,,,,,,,,,,,,,,,,,,dysfunction of phosphatidic acid degradation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002314,dysfunction of phosphatidylglycerol degradation,,Dysfunction of phosphatidylglycerol degradation is a subtype of dysfunction of glycerophospholipid degradation: A process that performs an abnormal and incomplete phosphatidylglycerol degradation.,false,,,http://purl.obolibrary.org/obo/TXPO_0002310,,,,,,,,,,,,,,,,,,,,,,Dysfunction of phosphatidylglycerol degradation is a subtype of dysfunction of glycerophospholipid degradation: A process that performs an abnormal and incomplete phosphatidylglycerol degradation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002314,,,,,,,,,,,,,,,,,,,,,,dysfunction of phosphatidylglycerol degradation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002313,dysfunction of phosphatidylethanolamine degradation,,Dysfunction of phosphatidylethanolamine degradation is a subtype of dysfunction of glycerophospholipid degradation: A process that performs an abnormal and incomplete phosphatidylethanolamine degradation.,false,,,http://purl.obolibrary.org/obo/TXPO_0002310,,,,,,,,,,,,,,,,,,,,,,Dysfunction of phosphatidylethanolamine degradation is a subtype of dysfunction of glycerophospholipid degradation: A process that performs an abnormal and incomplete phosphatidylethanolamine degradation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001545,,,,,,,,,,,,,,,,,,TXPO:0002313,,,,,,,,,,,,,,,,,,,,,,dysfunction of phosphatidylethanolamine degradation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002310,dysfunction of glycerophospholipid degradation,,Dysfunction of glycerophospholipid degradation is a subtype of dysfunction of phospholipid degradation: A process that performs an abnormal and incomplete glycerophospholipid degradation.,false,,,http://purl.obolibrary.org/obo/TXPO_0001447,,,,,,,,,,,,,,,,,,,,,,Dysfunction of glycerophospholipid degradation is a subtype of dysfunction of phospholipid degradation: A process that performs an abnormal and incomplete glycerophospholipid degradation.,,,http://purl.obolibrary.org/obo/GO_0046475,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002310,,,,,,,,,,,,,,,,,,,,,,dysfunction of glycerophospholipid degradation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002319,carcinogenesis [Ground glass appearance],,"A pathologic process that involves the transformation of normal cells to a neoplastic state.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/NCIT_C18078|http://purl.obolibrary.org/obo/TXPO_0001728,,,,,,,,,,,,,,,,,,,,ISBN:0071769234,,"A pathologic process that involves the transformation of normal cells to a neoplastic state.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001030|http://purl.obolibrary.org/obo/TXPO_0001028|http://purl.obolibrary.org/obo/TXPO_0000597|http://purl.obolibrary.org/obo/TXPO_0001013,,,,,,,,,,,TXPO:0002319,,,,,,,,,,,,,,,,,,,,,,carcinogenesis [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107|http://purl.obolibrary.org/obo/NCBITaxon_9989,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002315,dysfunction of phosphatidylcholine degradation,,Dysfunction of phosphatidylcholine degradation is a subtype of dysfunction of glycerophospholipid degradation: A process that performs an abnormal and incomplete phosphatidylcholine degradation.,false,,,http://purl.obolibrary.org/obo/TXPO_0002310,,,,,,,,,,,,,,,,,,,,,,Dysfunction of phosphatidylcholine degradation is a subtype of dysfunction of glycerophospholipid degradation: A process that performs an abnormal and incomplete phosphatidylcholine degradation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002315,,,,,,,,,,,,,,,,,,,,,,dysfunction of phosphatidylcholine degradation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002318,hyperfunction of cell proliferation,,Hyperfunction of cell proliferation is a subtype of hyperfunction of increasing number: A process that performs an excessive cell proliferation.,false,,,http://purl.obolibrary.org/obo/TXPO_0000473,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of cell proliferation is a subtype of hyperfunction of increasing number: A process that performs an excessive cell proliferation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002318,,,,,,,,,,,,,,,,,,,,,,hyperfunction of cell proliferation,,,,,,http://purl.obolibrary.org/obo/GO_0008283,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002791,dissociation of NF-kappaB - IkappaB [NfKB pathway],,"Dissociation of NF-kappaB -I-kappaB is a subtype of detaching: A process that disaggregates a NF-kappaB-I-kappaB to NF-kappaB dimers and I-kappaB. In a resting state, NF-kappaB dimers are bound to I-kappaB proteins, sequestering NF-kappaB in the cytoplasm. Phosphorylation of I-kappaB targets I-kappaB for ubiquitination and proteasomal degradation, thus releasing the NF-kappaB dimers, which can translocate to the nucleus to bind DNA and regulate transcription.
This entity is a specific course-dependent process. This process can constitute the course of NfKB pathway.",false,,,http://purl.obolibrary.org/obo/TXPO_0002492,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IEV_0000215|PMID:15134788,,"Dissociation of NF-kappaB -I-kappaB is a subtype of detaching: A process that disaggregates a NF-kappaB-I-kappaB to NF-kappaB dimers and I-kappaB. In a resting state, NF-kappaB dimers are bound to I-kappaB proteins, sequestering NF-kappaB in the cytoplasm. Phosphorylation of I-kappaB targets I-kappaB for ubiquitination and proteasomal degradation, thus releasing the NF-kappaB dimers, which can translocate to the nucleus to bind DNA and regulate transcription.
This entity is a specific course-dependent process. This process can constitute the course of NfKB pathway.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002778|http://purl.obolibrary.org/obo/TXPO_0002777|http://purl.obolibrary.org/obo/TXPO_0002808,,,,,,,,,,,,,,,,,,TXPO:0002791,,,,,,,,,,,,,,,,,,,,,,dissociation of NF-kappaB - IkappaB [NfKB pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002797,PERK-eIF2a signaling [ER stress - inflammation],,"PERK-eIF2a signaling is a subtype of PERK signaling (integrated pathway): Sequence of linked reactions, which has PERK-eIF2a signaling and gene regulation pathway.
This pathway is dependent on the inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000701,,,,,,,,,,,,,,,,,,,,,,"PERK-eIF2a signaling is a subtype of PERK signaling (integrated pathway): Sequence of linked reactions, which has PERK-eIF2a signaling and gene regulation pathway.
This pathway is dependent on the inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002847|http://purl.obolibrary.org/obo/TXPO_0002849|http://purl.obolibrary.org/obo/TXPO_0002853,,,,,,,,,,,,,,,,,,TXPO:0002797,,,,,,,,,,,,,,,,,,,,,,PERK-eIF2a signaling [ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002790,Binding of NF-kappaB and I-kappaB in cytosol [NfKB pathway],Binding of NF-kappaB and I-kappaB in cytosol [NfkB pathway],"The selective interaction of a inhibitory-kappaB (I-kappaB/IKB) protein with NF-kappaB. In the resting state, NF-kappaB dimers are bound to I-kappaB proteins, sequestering NF-kappaB in the cytoplasm.
This entity is a specific course-dependent process. This process can constitute the course of NfKB pathway.",false,,,http://purl.obolibrary.org/obo/TXPO_0002786,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IEV_0000214|PMID:15134788,,"The selective interaction of a inhibitory-kappaB (I-kappaB/IKB) protein with NF-kappaB. In the resting state, NF-kappaB dimers are bound to I-kappaB proteins, sequestering NF-kappaB in the cytoplasm.
This entity is a specific course-dependent process. This process can constitute the course of NfKB pathway.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Binding of NF-kappaB and I-kappaB in cytosol [NfkB pathway],,,TXPO:0002790,,,,,,,,,,,,,,,,,,,,,,Binding of NF-kappaB and I-kappaB in cytosol [NfKB pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002793,PERK-NFkB pathway [ER stress - inflammation],,"PERK-NFkB pathway is a subtype of PERK signaling (integrated pathway): Sequence of linked reactions, which has PERK signaling and gene regulation pathway.
This pathway is dependent on the inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000067,,,,,,,,,,,,,,,,,,,,PMID:12773372,,"PERK-NFkB pathway is a subtype of PERK signaling (integrated pathway): Sequence of linked reactions, which has PERK signaling and gene regulation pathway.
This pathway is dependent on the inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002779|http://purl.obolibrary.org/obo/TXPO_0002785|http://purl.obolibrary.org/obo/TXPO_0002789|http://purl.obolibrary.org/obo/TXPO_0002783,,http://purl.obolibrary.org/obo/TXPO_0000285,,,,,,,,,,,,,,,,TXPO:0002793,,,,,,,,,,,,,,,,,,,,,,PERK-NFkB pathway [ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002795,IRE1-TRAF2-NFkB signal transduction pathway [ER stress - inflammation],,"IRE1-TRAF2-NFkB signal transduction pathway is a subtype of IRE1 signaling (integrated pathway): Sequence of linked reactions, which has IRE1-TRAF2 signaling and gene regulation by NF-kappaB. This pathway is dependent on the  inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002563,,,,,,,,,,,,,,,,,,,,PMID:25232821|PMID:12843613|PMID:20303879,,"IRE1-TRAF2-NFkB signal transduction pathway is a subtype of IRE1 signaling (integrated pathway): Sequence of linked reactions, which has IRE1-TRAF2 signaling and gene regulation by NF-kappaB. This pathway is dependent on the  inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002815|http://purl.obolibrary.org/obo/TXPO_0002813|http://purl.obolibrary.org/obo/TXPO_0002816|http://purl.obolibrary.org/obo/TXPO_0002817|http://purl.obolibrary.org/obo/TXPO_0002807,,http://purl.obolibrary.org/obo/GO_0007249|http://purl.obolibrary.org/obo/TXPO_0002879,,,,,,,,,,,,,,,,TXPO:0002795,,,,,,,,,,,,,,,,,,,,,,IRE1-TRAF2-NFkB signal transduction pathway [ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002796,ATF6-NFkB signal transduction pathway [ER stress - inflammation],,"ATF6-NFkB signal transduction pathway is a subtype of ATF6 signaling (integrated pathway): Sequence of linked reactions, which has ATF6 signaling and gene regulation by NF-kappaB.
This process is dependent on positive inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002548,,,,,,,,,,,,,,,,,,,,PMID:20303879,,"ATF6-NFkB signal transduction pathway is a subtype of ATF6 signaling (integrated pathway): Sequence of linked reactions, which has ATF6 signaling and gene regulation by NF-kappaB.
This process is dependent on positive inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002841|http://purl.obolibrary.org/obo/TXPO_0002840|http://purl.obolibrary.org/obo/TXPO_0002837|http://purl.obolibrary.org/obo/TXPO_0002838,,http://purl.obolibrary.org/obo/GO_0007249|http://purl.obolibrary.org/obo/TXPO_0002126,,,,,,,,,,,,,,,,TXPO:0002796,,,,,,,,,,,,,,,,,,,,,,ATF6-NFkB signal transduction pathway [ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002792,ABCC5 (canonical)[Glutathione depletion],MRP5 [Glutathione depletion],,false,,,http://purl.obolibrary.org/obo/TXPO_0002045|http://purl.obolibrary.org/obo/TXPO_0003018,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MRP5 [Glutathione depletion],,,,,TXPO:0002792,,,,,,,,,,,,,,,,,,,,,,ABCC5 (canonical)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002798,NF-kappaB activation [ER stress - inflammation],,"NF-kappaB activation is a subtype of transcription factor activation: A process that changes the activity of the NF-kappaB to be higher.
This process is dependent on the inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002782|http://purl.obolibrary.org/obo/TXPO_0003736,,,,,,,,,,,,,,,,,,,,,,"NF-kappaB activation is a subtype of transcription factor activation: A process that changes the activity of the NF-kappaB to be higher.
This process is dependent on the inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002814,,,,,,,,,,,TXPO:0002798,,,,,,,"CHOP Knock Down resulted in reduced cytokine-induced NF-κB activity and expression of key NF-κB target genes involved in apoptosis and inflammation, including iNOS, FAS, IRF-7, IL-15, CCL5 and CXCL10. This was due to decreased IκB degradation and p65 translocation to the nucleus",,,,,,,,,,,,,,,NF-kappaB activation [ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002794,PERK-eIF2a-NFkB pathway [ER stress - inflammation],,"PERK-eIF2a-NFkB pathway is a subtype of PERK-eIF2a signaling: Sequence of linked reactions, which has PERK-eIF2a signaling and gene regulation by NF-kappa B.
This pathway is dependent on the  inflammation  and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000701,,,,,,,,,,,,,,,,,,,,PMID:28860159|PMID:20303879|PMID:15542827,,"PERK-eIF2a-NFkB pathway is a subtype of PERK-eIF2a signaling: Sequence of linked reactions, which has PERK-eIF2a signaling and gene regulation by NF-kappa B.
This pathway is dependent on the  inflammation  and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002812|http://purl.obolibrary.org/obo/TXPO_0002814|http://purl.obolibrary.org/obo/TXPO_0002798|http://purl.obolibrary.org/obo/TXPO_0002853,,http://purl.obolibrary.org/obo/TXPO_0002797,,,,,,,,,,,,,,,,TXPO:0002794,,,,,,,,,,,,,,,,,,,,,,PERK-eIF2a-NFkB pathway [ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002799,decreasing I-kappaB production,,Decreasing I-kappaB production is a subtype of decreasing production quantity of protein: A process that changes the quantity of the Iinhibitor of kappa B (I-kappaB) to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0001830,,,,,,,,,,,,,,,,,,,,,,Decreasing I-kappaB production is a subtype of decreasing production quantity of protein: A process that changes the quantity of the Iinhibitor of kappa B (I-kappaB) to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002799,,,,,,,,,,,,,,,,,,,,,,decreasing I-kappaB production,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76697,EC 5.99.* (other isomerases) inhibitor,EC 5.99.* (miscellaneous isomerases) inhibitor|EC 5.99.* (miscellaneous isomerases) inhibitors|EC 5.99.* (other isomerase) inhibitors|EC 5.99.* inhibitors|EC 5.99.* (other isomerase) inhibitor|EC 5.99.* inhibitor|EC 5.99.* (other isomerases) inhibitors,An isomerase inhibitor that interferes with the action of any member of the group of 'other isomerases' (EC 5.99.*.*).,false,,,http://purl.obolibrary.org/obo/CHEBI_75596,,,,,,,,,,,,,,,,,,,,,,An isomerase inhibitor that interferes with the action of any member of the group of 'other isomerases' (EC 5.99.*.*).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,EC 5.99.* (miscellaneous isomerases) inhibitor|EC 5.99.* (miscellaneous isomerases) inhibitors|EC 5.99.* (other isomerase) inhibitors|EC 5.99.* inhibitors|EC 5.99.* (other isomerase) inhibitor|EC 5.99.* inhibitor|EC 5.99.* (other isomerases) inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:76697,,,,EC 5.99.* (other isomerases) inhibitor,,CHEBI:76697,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_50837,estrogen antagonist,oestrogen antagonist,A compound which inhibits or antagonises the biosynthesis or actions of estrogens.,false,,,http://purl.obolibrary.org/obo/CHEBI_49020,,,,,,,,,,,,,,,,,,,,,,A compound which inhibits or antagonises the biosynthesis or actions of estrogens.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,oestrogen antagonist,,,,,,,,,,,,,,,,,,,,,CHEBI:50837,,,,estrogen antagonist,,CHEBI:50837,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000287,PLK2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:20620|NCBI-Human-GeneID:10769|NCBI-Rat-GeneID:83722,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000010769,,,,,,,,,,,,,TXPO:1000287,,,,,,,,,,,,,,,,,,,,,,PLK2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000285,PLD4 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:104759|NCBI-Rat-GeneID:362792|NCBI-Human-GeneID:122618,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000122618,,,,,,,,,,,,,TXPO:1000285,,,,,,,,,,,,,,,,,,,,,,PLD4 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000282,PLA2G16 (mol),,,false,,,http://purl.obolibrary.org/obo/IMR_0000283,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:225845|NCBI-Rat-GeneID:24913,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000011145,,,,,,,,,,,,,TXPO:1000282,,,,,,,,,,,,,,,,,,,,,,PLA2G16 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000284,PLB1 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0001303,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:192259|NCBI-Mouse-GeneID:665270|NCBI-Human-GeneID:151056,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000151056,,,,,,,,,,,,,TXPO:1000284,,,,,,,,,,,,,,,,,,,,,,PLB1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000283,PLA2G5 (mol),,,false,,,http://purl.obolibrary.org/obo/IMR_0000283,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:29354|NCBI-Mouse-GeneID:18784|NCBI-Human-GeneID:5322,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000005322,,,,,,,,,,,,,TXPO:1000283,,,,,,,,,,,,,,,,,,,,,,PLA2G5 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000288,POU6F1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:116545|NCBI-Mouse-GeneID:19009|NCBI-Human-GeneID:5463,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000005463,,,,,,,,,,,,,TXPO:1000288,,,,,,,,,,,,,,,,,,,,,,POU6F1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000286,PLIN2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:11520|NCBI-Human-GeneID:123|NCBI-Rat-GeneID:298199,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000123,,,,,,,,,,,,,TXPO:1000286,,,,,,,,,,,,,,,,,,,,,,PLIN2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000281,PLA2G15 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0000772,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:23659|NCBI-Rat-GeneID:361401|NCBI-Mouse-GeneID:192654,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000023659,,,,,,,,,,,,,TXPO:1000281,,,,,,,,,,,,,,,,,,,,,,PLA2G15 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000280,PRRT2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:112476|NCBI-Rat-GeneID:361651|NCBI-Mouse-GeneID:69017,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000112476,,,,,,,,,,,,,TXPO:1000280,,,,,,,,,,,,,,,,,,,,,,PRRT2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000289,PPM1E (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:360593|NCBI-Human-GeneID:22843|NCBI-Mouse-GeneID:320472,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000022843,,,,,,,,,,,,,TXPO:1000289,,,,,,,,,,,,,,,,,,,,,,PPM1E (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0016579,protein deubiquitination,,The removal of one or more ubiquitin groups from a protein.,false,,,http://purl.obolibrary.org/obo/GO_0070646,,,,,,,,,,,,,,,,,,,,,,The removal of one or more ubiquitin groups from a protein.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0016579,,,,,,,,,,,,,,,,,,,,,,protein deubiquitination,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000005570,PKIB,,Other designations: PKI-beta|cAMP-dependent protein kinase inhibitor 2|cAMP-dependent protein kinase inhibitor beta,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,PRKACN2,,,,,,,,,,,,6,,,,,,Vega:OTTHUMG00000015488|HPRD:06075|HGNC:9018|MIM:606914|Ensembl:ENSG00000135549,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"protein kinase (cAMP-dependent, catalytic) inhibitor beta",,,6q22.31,,,,,,,,,,,,,,,,GO_0004862 (EC: IEA),,,,,,,,,PMID: 2052616; 7684369; 8889548; 10880337; 11978406; 12061725; 12477932; 12748276; 14574404; 15342556; 15489334; 19035091; 19460752; 19483721; 21906983; 21988832; 23224602; 24250222,,,,,,,,,,,,,,,OGG:3000005570,,20140408,protein-coding,,,,"protein kinase (cAMP-dependent, catalytic) inhibitor beta",,,,,,,,,,,,,Other designations: PKI-beta|cAMP-dependent protein kinase inhibitor 2|cAMP-dependent protein kinase inhibitor beta,,PKIB,,,,,,,,,,,,,,,,,,,,,,,5570,RP11-95G17.1,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,PKIB,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000005579,PRKCB,,"Other designations: PKC-B|protein kinase C beta type|protein kinase C, beta 1 polypeptide",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,PKCB|PRKCB1|PKC-beta|PRKCB2,,,,,,,,,,,,16,,,,,,HPRD:01499|MIM:176970|Vega:OTTHUMG00000131615|Ensembl:ENSG00000166501|HGNC:9395,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"protein kinase C, beta",,,16p11.2,,,,,,,,,,,,,,,,"GO_0003682 (EC: IDA); GO_0004674 (EC: TAS); GO_0004697 (EC: IEA); GO_0005080 (EC: IPI); GO_0005246 (EC: IEA); GO_0005515 (EC: IPI, PMID: 18162466); GO_0005524 (EC: IEA); GO_0005634 (EC: IDA); GO_0005737 (EC: IDA, PMID: 15632189); GO_0005829 (EC: TAS); GO_0005886 (EC: IDA, PMID: 15632189); GO_0005886 (EC: TAS); GO_0006351 (EC: IEA); GO_0006357 (EC: IMP); GO_0006468 (EC: TAS, PMID: 3755548); GO_0006816 (EC: IEA); GO_0006874 (EC: IEA); GO_0006915 (EC: IEA); GO_0007165 (EC: NAS, PMID: 3755548); GO_0007268 (EC: TAS); GO_0007596 (EC: TAS); GO_0008270 (EC: IEA); GO_0010829 (EC: ISS); GO_0030168 (EC: TAS); GO_0030374 (EC: IMP); GO_0030949 (EC: ISS); GO_0035403 (EC: IDA); GO_0035408 (EC: IDA); GO_0035556 (EC: IEA); GO_0042113 (EC: ISS); GO_0042393 (EC: IDA); GO_0042953 (EC: TAS, PMID: 18981301); GO_0043123 (EC: ISS); GO_0045766 (EC: ISS); GO_0046627 (EC: ISS); GO_0050681 (EC: IDA); GO_0050853 (EC: ISS); GO_0050861 (EC: ISS); GO_0051092 (EC: ISS); GO_0070062 (EC: IDA); GO_0071322 (EC: IEA)",,,,,,,,,PMID: 1321150; 1324914; 1400396; 1556124; 1611098; 1714454; 1832084; 1970444; 2139676; 2140056; 2182321; 2757032; 3259291; 3658678; 3666134; 3677994; 3755548; 7499337; 7588787; 7642615; 7693453; 7716516; 7850771; 7876252; 7876254; 7880442; 7961692; 8034666; 8034726; 8080473; 8089108; 8163551; 8206685; 8327493; 8473314; 8557118; 8599832; 8626698; 8627654; 8631738; 8662663; 8663071; 8694767; 8749392; 8824244; 8898866; 8899875; 8914829; 8940095; 8940188; 8964400; 9021343; 9030777; 9052983; 9151826; 9244383; 9296367; 9446795; 9475183; 9671211; 9677319; 9694886; 9765207; 9814702; 9815893; 9856494; 10194441; 10212259; 10417813; 10433554; 10446219; 10480917; 10490850; 10491200; 10493829; 10502411; 10531036; 10542228; 10641798; 10828076; 10843712; 10856305; 10862698; 10871288; 11003709; 11035810; 11044099; 11063746; 11078718; 11120522; 11120743; 11123317; 11141237; 11145703; 11154208; 11179083; 11278382; 11278415; 11283022; 11306676; 11325528; 11376011; 11502742; 11504923; 11598012; 11700305; 11744714; 11749387; 11765038; 11781100; 11805327; 11833470; 11884598; 11901153; 11919157; 11930178; 12023512; 12033257; 12054501; 12056906; 12070292; 12080070; 12093536; 12118249; 12134071; 12147342; 12149258; 12167592; 12356761; 12435880; 12456365; 12477932; 12482669; 12509514; 12519779; 12551925; 12569090; 12618484; 12665801; 12679936; 12682249; 12724308; 12730099; 12743109; 12765965; 12766174; 12874455; 12917261; 12950453; 12958364; 14527960; 14561740; 14594954; 14602581; 14623273; 14654844; 14654845; 14699138; 14702039; 15037605; 15067001; 15090600; 15188402; 15213298; 15252133; 15322124; 15327405; 15381704; 15384959; 15488737; 15489334; 15499829; 15546881; 15591231; 15611095; 15632189; 15647851; 15689238; 15716278; 15741241; 15880462; 15894802; 15917249; 16000408; 16027742; 16055064; 16080189; 16102725; 16111671; 16224561; 16236825; 16331690; 16356855; 16430878; 16472601; 16517978; 16567829; 16574992; 16574993; 16626305; 16673150; 16775601; 16831865; 16854530; 16930534; 16954220; 17003377; 17069764; 17115053; 17121852; 17133356; 17167344; 17192257; 17203073; 17227757; 17455194; 17545677; 17625596; 17632570; 17719638; 17846295; 17893151; 17926183; 17936705; 17950644; 17991733; 18067888; 18162466; 18162471; 18167130; 18172602; 18278479; 18292183; 18303026; 18317465; 18440851; 18472156; 18497307; 18541226; 18557705; 18577246; 18596232; 18632858; 18637128; 18692180; 18701509; 18714023; 18768137; 18937679; 18981301; 19091746; 19112601; 19168795; 19277684; 19295663; 19363595; 19573263; 19681907; 19693767; 19738201; 19887445; 19895572; 19907441; 19913121; 19920073; 19949911; 19966859; 20015121; 20098747; 20099025; 20141354; 20164467; 20179100; 20228790; 20336759; 20346360; 20379614; 20439192; 20442744; 20511681; 20522523; 20534587; 20618341; 20628086; 20736472; 20842205; 20846475; 21044950; 21134959; 21323641; 21467074; 21482705; 21525390; 21651489; 21817106; 21997316; 22016563; 22114277; 22114345; 22162761; 22197823; 22322241; 22446963; 22479367; 22547057; 22633971; 22670899; 22833470; 22930730; 22939624; 23042805; 23128233; 23204109; 23280626; 23328482; 23337848; 23439007; 23455922; 23458603; 23503679; 23562913; 23960082; 23963366,,,,,,,,,,,,,,,OGG:3000005579,,,,,,,"protein kinase C, beta",,,,,,,,,,,,,"Other designations: PKC-B|protein kinase C beta type|protein kinase C, beta 1 polypeptide",,PRKCB,,,,,,,,,,,,,,,,,,,,,,,5579,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,PRKCB,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0000549,Phosphorylation of eIF2-alpha by PERK,,Phosphorylation of eIF2-alpha by PERK is a subtype of eIF2a phosphorylation: A process that The process of introducing a phosphate group into eIF2a by PERK.,false,,,http://purl.obolibrary.org/obo/TXPO_0001899,,,,,,,,,,,,,,,,,,,,,,Phosphorylation of eIF2-alpha by PERK is a subtype of eIF2a phosphorylation: A process that The process of introducing a phosphate group into eIF2a by PERK.,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001792,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000549,,,,,,,,,,,,,,,,,,,,,,Phosphorylation of eIF2-alpha by PERK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000540,inflammatory cell  infiltration,,Inflammatory cell infiltration is a subtype of moving A to the inside of B: A process that moves the outside inflammatory cell to the inside in response to an inflammatory reaction.,false,,,http://purl.obolibrary.org/obo/TXPO_0002587,,,,,,,,,,,,,,,,,,,,,,Inflammatory cell infiltration is a subtype of moving A to the inside of B: A process that moves the outside inflammatory cell to the inside in response to an inflammatory reaction.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000540,,,,,,,,,,,,,,,,,,,,,,inflammatory cell  infiltration,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000542,abnormality of membrane [Oxidative stress],,"Abnormality of membrane is a subtype of changing abnormal cellular structure: A process that changes the membrane stucture abnormally.
This entity is a specific course-dependent process. This process can constitute the course of Oxidative stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001730|http://purl.obolibrary.org/obo/TXPO_0001755,,,,,,,,,,,,,,,,,,,,,,"Abnormality of membrane is a subtype of changing abnormal cellular structure: A process that changes the membrane stucture abnormally.
This entity is a specific course-dependent process. This process can constitute the course of Oxidative stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000546|http://purl.obolibrary.org/obo/TXPO_0000566,,,,,,,,,,,TXPO:0000542,,,,,,,,,,,,,,,,,,,,,,abnormality of membrane [Oxidative stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000547,SLC10A1 (canonical)[Cholestasis],Na/taurocholate cotransporting polypeptide [Cholestasis]|NTCP [Cholestasis],,false,,,http://purl.obolibrary.org/obo/TXPO_0000276|http://purl.obolibrary.org/obo/TXPO_1000338,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:6554|NCBI-Mouse-GeneID:20493|NCBI-Rat-GeneID:24777,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003704,,,,,Na/taurocholate cotransporting polypeptide [Cholestasis]|NTCP [Cholestasis],,,,,TXPO:0000547,,,,,,,"The sodium dependent uptake of bile salts is mediated by the NTCP (sodium/bile acid cotransporter; SLC10A1), which is expressed in a polar manner at the basolateral plasma membrane of hepatocytes.
NTCP has a preference for conjugated bile salts.",,,,,,,,,,,,,,,SLC10A1 (canonical)[Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000541,inflammatory cell infiltration [Cell death],,Inflammatory cell infiltration is a subtype of moving A to the inside of B: A process that that moves the outside inflammatory cell to the inside in response to an inflammatory reaction. This entity is a specific course-dependent process. This process can constitute the course of Cell death.,false,,,http://purl.obolibrary.org/obo/TXPO_0001727|http://purl.obolibrary.org/obo/TXPO_0000540,,,,,,,,,,,,,,,,,,,,,,Inflammatory cell infiltration is a subtype of moving A to the inside of B: A process that that moves the outside inflammatory cell to the inside in response to an inflammatory reaction. This entity is a specific course-dependent process. This process can constitute the course of Cell death.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002142,,,,,,,,,,,TXPO:0000541,,,,,,,,,,,,,,,,,,,,,,inflammatory cell infiltration [Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000544,changing area,,Changing area is a subtype of changing quality: A process that changes the area of the object.,false,,,http://purl.obolibrary.org/obo/TXPO_0000415,,,,,,,,,,,,,,,,,,,,,,Changing area is a subtype of changing quality: A process that changes the area of the object.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000544,,,,,,,,,,,,,,,,,,,,,,changing area,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000545,increasing cell volume [Cholestasis],cell swelling [cholestasis],"Increasing cell volume is a changing process to change the volume of the cell to increase.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.|Toxicant induced cholestasis is associated with cell swelling, cell death, and inflammation",false,,,http://purl.obolibrary.org/obo/TXPO_0000142|http://purl.obolibrary.org/obo/TXPO_0000034,,,,,,,,,,,,,,,,,,,,,,"Increasing cell volume is a changing process to change the volume of the cell to increase.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,cell swelling [cholestasis],,,TXPO:0000545,,,,,,,,,,,,,,,,,,,,"Toxicant induced cholestasis is associated with cell swelling, cell death, and inflammation",,increasing cell volume [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000543,lipoperoxidation [Oxidative stress],,"Lipoperoxidation is a subtype of lipid oxidation: The degradation of lipids caused by an oxidative attack from free radicals.
This entity is a specific course-dependent process. This process can constitute the course of Oxidative stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0003514|http://purl.obolibrary.org/obo/TXPO_0001730,,,,,,,,,,,,,,,,,,,,,,"Lipoperoxidation is a subtype of lipid oxidation: The degradation of lipids caused by an oxidative attack from free radicals.
This entity is a specific course-dependent process. This process can constitute the course of Oxidative stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000542|http://purl.obolibrary.org/obo/TXPO_0000042,,,,,,,,,,,TXPO:0000543,,,,,,,,,,,,,,,,,,,,,,lipoperoxidation [Oxidative stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000546,positive regulation of mitochondrial membrane permeability [Oxidative stress],,"Any process that increases the frequency, rate or extent of the passage or uptake of molecules by the mitochondrial membrane.
This entity is a specific course-dependent process. This process can constitute the course of Oxidative stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001730|http://purl.obolibrary.org/obo/GO_0035794,,,,,,,,,,,,,,,,,,,,,,"Any process that increases the frequency, rate or extent of the passage or uptake of molecules by the mitochondrial membrane.
This entity is a specific course-dependent process. This process can constitute the course of Oxidative stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000515,,,,,,,,,,,TXPO:0000546,,,,,,,,,,,,,,,,,,,,,,positive regulation of mitochondrial membrane permeability [Oxidative stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000548,negative regulation of cell cycle,,"Negative regulation of cell cycle is a subtype of negative regulation process:  Any process that stops, prevents or reduces the rate or extent of progression through the cell cycle.",false,,,http://purl.obolibrary.org/obo/TXPO_0000369,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of cell cycle is a subtype of negative regulation process:  Any process that stops, prevents or reduces the rate or extent of progression through the cell cycle.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000548,,,,,,,,,,,,,,,,,,,,,,negative regulation of cell cycle,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0007049,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100086,"placental hormone, peptide",,"Hormones produced by the placenta include CHORIONIC GONADOTROPIN, and PLACENTAL LACTOGEN. Not include steroid hormones ( ESTROGENS; PROGESTERONE).",false,,,http://purl.obolibrary.org/obo/IMR_0000966,,,,,,,,,,,,,,,,,,,,MeSH:D010926,,"Hormones produced by the placenta include CHORIONIC GONADOTROPIN, and PLACENTAL LACTOGEN. Not include steroid hormones ( ESTROGENS; PROGESTERONE).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_24621,,,,,,,,,,IMR:0100086,,,,,,,,,,,,,,,,,,,,,,"placental hormone, peptide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000000101,ADAM8,,Other designations: a disintegrin and metalloproteinase domain 8|cell surface antigen MS2|disintegrin and metalloproteinase domain-containing protein 8|human leukocyte differentiation antigen,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CD156a|MS2|CD156,,,,,,,,,,,,10,,,,,,HPRD:03777|Vega:OTTHUMG00000019309|MIM:602267|HGNC:215|Ensembl:ENSG00000151651,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,ADAM metallopeptidase domain 8,,,10q26.3,,,,,,,,,,,,,,,,"GO_0000902 (EC: ISS); GO_0001525 (EC: ISS); GO_0002102 (EC: IDA, PMID: 15220135); GO_0002523 (EC: ISS); GO_0002675 (EC: ISS); GO_0004222 (EC: IEA); GO_0005509 (EC: ISS); GO_0005515 (EC: IPI, PMID: 12777399); GO_0005737 (EC: IDA, PMID: 18397961); GO_0005886 (EC: IDA, PMID: 17548643); GO_0005886 (EC: TAS); GO_0005887 (EC: IDA, PMID: 18397961); GO_0006954 (EC: IDA, PMID: 17548643); GO_0008237 (EC: IDA, PMID: 12777399); GO_0008270 (EC: TAS, PMID: 18397961); GO_0009986 (EC: IDA, PMID: 17548643); GO_0010954 (EC: NAS, PMID: 17548643); GO_0016337 (EC: IEA); GO_0022407 (EC: IDA, PMID: 17548643); GO_0022617 (EC: TAS); GO_0030198 (EC: TAS); GO_0032010 (EC: IDA, PMID: 17548643); GO_0032127 (EC: IDA, PMID: 17548643); GO_0033089 (EC: ISS); GO_0035419 (EC: ISS); GO_0042581 (EC: IDA, PMID: 17548643); GO_0043524 (EC: ISS); GO_0043621 (EC: TAS, PMID: 12777399); GO_0045780 (EC: ISS); GO_0045785 (EC: ISS); GO_0048247 (EC: ISS); GO_0050714 (EC: IC, PMID: 17548643); GO_0050839 (EC: IPI, PMID: 12777399); GO_0051044 (EC: IDA, PMID: 15220135); GO_0051092 (EC: ISS); GO_0051897 (EC: ISS); GO_0070245 (EC: ISS); GO_0070820 (EC: IDA, PMID: 17548643); GO_0071065 (EC: IDA, Qualifier: colocalizes_with, PMID: 15220135); GO_0071133 (EC: ISS); GO_0071456 (EC: IDA, PMID: 18566576); GO_2000309 (EC: ISS); GO_2000391 (EC: IDA, PMID: 17548643); GO_2000415 (EC: ISS); GO_2000418 (EC: ISS)",,,,,,,,,PMID: 9126482; 10354553; 12135759; 12477932; 12777399; 15220135; 15574124; 15623614; 16344560; 16385451; 17339047; 17548643; 17979891; 18397961; 18566576; 18682798; 18691140; 18710625; 18811590; 19284887; 19397475; 19469654; 19575316; 19601829; 19714641; 19766586; 20453887; 20628624; 21077325; 21640993; 21679521; 21728902; 21983884; 22215309; 22229154; 22878099; 22941466; 22959284; 22965687; 23670189,,,,,,,,,,,,,,,OGG:3000000101,,,,,,,ADAM metallopeptidase domain 8,,,,,,,,,,,,,Other designations: a disintegrin and metalloproteinase domain 8|cell surface antigen MS2|disintegrin and metalloproteinase domain-containing protein 8|human leukocyte differentiation antigen,,ADAM8,,,,,,,,,,,,,,,,,,,,,,,101,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,ADAM8,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0002102,negative regulation of insulin receptor signaling pathway,,"Negative regulation of insulin receptor signaling pathway is a subtype of negative regulation of signaling:  Any process that stops, prevents, or reduces the frequency, rate or extent of insulin receptor signaling.",false,,,http://purl.obolibrary.org/obo/GO_0023057,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of insulin receptor signaling pathway is a subtype of negative regulation of signaling:  Any process that stops, prevents, or reduces the frequency, rate or extent of insulin receptor signaling.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002102,,,,,,,,,,,,,,,,,,,,,,negative regulation of insulin receptor signaling pathway,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000477|http://purl.obolibrary.org/obo/GO_0008286,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002104,GSTM2 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0002089,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:2946|NCBI-Mouse-GeneID:68312|NCBI-Rat-GeneID:81869,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002104,,,,,,,,,,,,,,,,,,,,,,GSTM2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002103,negative regulation of AKT signaling [ER stress],,"Any process that stops, prevents, or reduces the frequency, rate or extent of protein kinase B signaling, a series of reactions mediated by the intracellular serine/threonine kinase protein kinase B.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/GO_0051898|http://purl.obolibrary.org/obo/TXPO_0003736,,,,,,,,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3126329/|PMID:25966993,,"Any process that stops, prevents, or reduces the frequency, rate or extent of protein kinase B signaling, a series of reactions mediated by the intracellular serine/threonine kinase protein kinase B.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002168|http://purl.obolibrary.org/obo/TXPO_0000779,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002101,,,,,,,,,,,TXPO:0002103,,,,,,,,,,,,,,,,,,,,,,negative regulation of AKT signaling [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002109,BIP-PERK complex (canonical)[ER stress],,"Bip-PERK sensor complex is a subtype of molecular complex.
This entity has sub-parts of molecules, BIP/GRP78 and PERK which has role of stress sensor.
This entity is dependent on ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002108,,,,,,,,,,,,,,,,,,,,,,"Bip-PERK sensor complex is a subtype of molecular complex.
This entity has sub-parts of molecules, BIP/GRP78 and PERK which has role of stress sensor.
This entity is dependent on ER stress.",,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002619|http://purl.obolibrary.org/obo/TXPO_0001841,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002109,,,,,,,,,,,,,,,,,,,,,,BIP-PERK complex (canonical)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002107,molecular complex,,Molecular complex is a subtype of onject aggregates. This entity has sub-parts of molecules.,false,,,http://purl.obolibrary.org/obo/BFO_0000027,,,,,,,,,,,,,,,,,,,,,,Molecular complex is a subtype of onject aggregates. This entity has sub-parts of molecules.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002107,,,,,,,,,,,,,,,,,,,,,,molecular complex,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002105,AKT (canonical)[ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000871|http://purl.obolibrary.org/obo/IMR_0100844,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24185|NCBI-Mouse-GeneID:11651|NCBI-Human-GeneID:207,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002105,,,,,,,,,,,,,,,,,,,,,,AKT (canonical)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002106,unfolded protein,,"Unfolded protein is a subtype of substance with role.
This entity participates in a unfolded protein response and plays a unfolded protein role.",false,,,http://purl.obolibrary.org/obo/CHEBI_25367|http://purl.obolibrary.org/obo/GOCHE_50906,,,,,,,,,,,,,,,,,,,,,,"Unfolded protein is a subtype of substance with role.
This entity participates in a unfolded protein response and plays a unfolded protein role.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002106,,,,,,,,,,,,,,,,,,,,,,unfolded protein,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002100,negative regulation of apoptotic process [Eosinophilic granular degeneration],,"Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptotic process.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/TXPO_0001729|http://purl.obolibrary.org/obo/GO_0043066,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptotic process.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002100,,,,,,,,,,,,,,,,,,,,,,negative regulation of apoptotic process [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002108,BIP-STRESS sensor complex (canonical)[ER stress],,"Bip-stress sensor complex is a subtype of molecular complex.
This entity has sub-parts of molecules, BIP/GRP78 and other molecule which has role of stress sensor.
This entity is dependent on ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_1000047|http://purl.obolibrary.org/obo/TXPO_0000871|http://purl.obolibrary.org/obo/TXPO_0002405,,,,,,,,,,,,,,,,,,,,,,"Bip-stress sensor complex is a subtype of molecular complex.
This entity has sub-parts of molecules, BIP/GRP78 and other molecule which has role of stress sensor.
This entity is dependent on ER stress.",,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002385,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002108,,,,,,,,,,,,,,,,,,,,,,BIP-STRESS sensor complex (canonical)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002101,negative regulation of insulin receptor signaling pathway [ER stress],,"Negative regulation of insulin receptor signaling pathway is a subtype of negative regulation of signaling: Any process that stops, prevents, or reduces the frequency, rate or extent of insulin receptor signaling.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/TXPO_0002102,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of insulin receptor signaling pathway is a subtype of negative regulation of signaling: Any process that stops, prevents, or reduces the frequency, rate or extent of insulin receptor signaling.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000779,,,,,,,,,,,,,,,,,TXPO:0002101,,,,,,,,,,,,,,,,,,,,,,negative regulation of insulin receptor signaling pathway [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000993,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100765,Wnt-1,Int-1,,false,,,http://purl.obolibrary.org/obo/IMR_0000003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Int-1,,,,,IMR:0100765,,,,,,,,,,,,,,,,,,,,,,Wnt-1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_64370,glutamate transporter activator,excitatory amino-acid transporter activator|excitatory amino-acid transporter activators|glutamate transporter activators,A neurotransmitter transporter modulator that activates glutamate transporters.,false,,,http://purl.obolibrary.org/obo/CHEBI_64371,,,,,,,,,,,,,,,,,,,,,,A neurotransmitter transporter modulator that activates glutamate transporters.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,excitatory amino-acid transporter activator|excitatory amino-acid transporter activators|glutamate transporter activators,,,,,,,,,,,,,,,,,,,,,CHEBI:64370,,,,glutamate transporter activator,,CHEBI:64370,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003426,IL2 (canonical)[Phospholipidosis - inflammatory cytokine],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002288,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003041,,,,,,,,,,TXPO:0003426,,,,,,,,,,,,,,,,,,,,,,IL2 (canonical)[Phospholipidosis - inflammatory cytokine],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003429,IL2 (canonical)[Phospholipidosis - cell cycle progression promoting factor],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002288,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002269,,,,,,,,,,TXPO:0003429,,,,,,,,,,,,,,,,,,,,,,IL2 (canonical)[Phospholipidosis - cell cycle progression promoting factor],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003428,IL2 (canonical)[Phospholipidosis - tumor cell proliferation promoting factor],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002288,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002272,,,,,,,,,,TXPO:0003428,,,,,,,,,,,,,,,,,,,,,,IL2 (canonical)[Phospholipidosis - tumor cell proliferation promoting factor],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003422,EGFR signaling (primitive) [Phospholipidosis (excessive defense) - cell proliferation ],,"EGFR signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal transmitted by the EGFR (epidermal growth factor receptor) on the surface of a cell, starting with a ligand binding to a EGFR
This process is dependent on the  cell proliferation  and can constitute the course of Phospholipidosis (excessive defense) .",false,,,http://purl.obolibrary.org/obo/TXPO_0001493,,,,,,,,,,,,,,,,,,,,,,"EGFR signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal transmitted by the EGFR (epidermal growth factor receptor) on the surface of a cell, starting with a ligand binding to a EGFR
This process is dependent on the  cell proliferation  and can constitute the course of Phospholipidosis (excessive defense) .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001175|http://purl.obolibrary.org/obo/TXPO_0001137|http://purl.obolibrary.org/obo/TXPO_0001798,,,,,,http://purl.obolibrary.org/obo/TXPO_0003418,,,,,,,,,,,TXPO:0003422,,,,,,,,,,,,,,,,,,,,,,EGFR signaling (primitive) [Phospholipidosis (excessive defense) - cell proliferation ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003420,PI3K - tumor cell proliferation promoting factor (canonical)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001800,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000265,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002272,,,,,,,,,,TXPO:0003420,,,,,,,,,,,,,,,,,,,,,,PI3K - tumor cell proliferation promoting factor (canonical)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003423,EGFR signaling (primitive) [Phospholipidosis (excessive defense) - tumor cell proliferation ],,"EGFR signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal transmitted by the EGFR (epidermal growth factor receptor) on the surface of a cell, starting with a ligand binding to a EGFR
This process is dependent on the  tumor cell proliferation  and can constitute the course of Phospholipidosis (excessive defense) .",false,,,http://purl.obolibrary.org/obo/TXPO_0001493,,,,,,,,,,,,,,,,,,,,,,"EGFR signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal transmitted by the EGFR (epidermal growth factor receptor) on the surface of a cell, starting with a ligand binding to a EGFR
This process is dependent on the  tumor cell proliferation  and can constitute the course of Phospholipidosis (excessive defense) .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001175|http://purl.obolibrary.org/obo/TXPO_0001137|http://purl.obolibrary.org/obo/TXPO_0001798,,,,,,http://purl.obolibrary.org/obo/TXPO_0003421,,,,,,,,,,,TXPO:0003423,,,,,,,,,,,,,,,,,,,,,,EGFR signaling (primitive) [Phospholipidosis (excessive defense) - tumor cell proliferation ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003424,EGFR (canonical)[Phospholipidosis - cell proliferation factor],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001798,,,,,,,,,,,,,,,,,,,,"The protein encoded by this gene is a transmembrane glycoprotein that is a member of the protein kinase superfamily. This protein is a receptor for members of the epidermal growth factor family. EGFR is a cell surface protein that binds to epidermal growth factor. Binding of the protein to a ligand induces receptor dimerization and tyrosine autophosphorylation and leads to cell proliferation. Mutations in this gene are associated with lung cancer. [provided by RefSeq, Jun 2016]|https://www.ncbi.nlm.nih.gov/gene?cmd=retrieve&dopt=default&rn=1&list_uids=1956",,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000081,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002271,,,,,,,,,,TXPO:0003424,,,,,,,,,,,,,,,,,,,,,,EGFR (canonical)[Phospholipidosis - cell proliferation factor],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003421,phosphatidylinositol 3-kinase signaling (primitive) [Phospholipidosis (excessive defense) - tumor cell proliferation ],,"Phosphatidylinositol 3-kinase signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal transmitted by the phosphatidylinositol 3-kinase (PI3K).
This process is dependent on the  tumor cell proliferation  and can constitute the course of Phospholipidosis (excessive defense) .",false,,,http://purl.obolibrary.org/obo/TXPO_0001495,,,,,,,,,,,,,,,,,,,,,,"Phosphatidylinositol 3-kinase signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal transmitted by the phosphatidylinositol 3-kinase (PI3K).
This process is dependent on the  tumor cell proliferation  and can constitute the course of Phospholipidosis (excessive defense) .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001857|http://purl.obolibrary.org/obo/TXPO_0001175|http://purl.obolibrary.org/obo/TXPO_0003420|http://purl.obolibrary.org/obo/TXPO_0001137,,,,,,http://purl.obolibrary.org/obo/TXPO_0003416,,,,,,,,,,,TXPO:0003421,,,,,,,,,,,,,,,,,,,,,,phosphatidylinositol 3-kinase signaling (primitive) [Phospholipidosis (excessive defense) - tumor cell proliferation ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003425,EGFR (canonical)[Phospholipidosis - tumor cell proliferation factor],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001798,,,,,,,,,,,,,,,,,,,,"The protein encoded by this gene is a transmembrane glycoprotein that is a member of the protein kinase superfamily. This protein is a receptor for members of the epidermal growth factor family. EGFR is a cell surface protein that binds to epidermal growth factor. Binding of the protein to a ligand induces receptor dimerization and tyrosine autophosphorylation and leads to cell proliferation. Mutations in this gene are associated with lung cancer. [provided by RefSeq, Jun 2016]|https://www.ncbi.nlm.nih.gov/gene?cmd=retrieve&dopt=default&rn=1&list_uids=1956",,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000081,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002272,,,,,,,,,,TXPO:0003425,,,,,,,,,,,,,,,,,,,,,,EGFR (canonical)[Phospholipidosis - tumor cell proliferation factor],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003427,IL2 (canonical)[Phospholipidosis - apotosis inhibitor],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002288,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_68494,,,,,,,,,,TXPO:0003427,,,,,,,,,,,,,,,,,,,,,,IL2 (canonical)[Phospholipidosis - apotosis inhibitor],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000055629,PNRC2,,,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,1,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,proline-rich nuclear receptor coactivator 2,,,1p36.11,,,,,,,,,,,,,,,,"GO_0000184 (EC: IDA, PMID: 19150429); GO_0000932 (EC: IDA, PMID: 19150429); GO_0005515 (EC: IPI, PMID: 19150429); GO_0005634 (EC: IDA, PMID: 19150429); GO_0006351 (EC: IEA); GO_0006355 (EC: IEA); GO_0031087 (EC: TAS, PMID: 19150429)",,,,,,,,,PMID: 10894149; 11042152; 11574675; 12477932; 14651967; 14702039; 15489334; 15604093; 16169070; 16344560; 16710414; 19150429; 21900206; 21906983; 23085078; 23251661,,,,,,,,,,,,,,,OGG:3000055629,,,,,,,proline-rich nuclear receptor coactivator 2,,,,,,,,,,,,,,,PNRC2,,,,,,,,,,,,,,,,,,,,,,,55629,RP11-4M23.5,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,PNRC2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000079071,ELOVL6,,"Other designations: 3-keto acyl-CoA synthase ELOVL6|ELOVL FA elongase 6|ELOVL family member 6, elongation of long chain fatty acids (FEN1/Elo2, SUR4/Elo3-like, yeast)|elongation of very long chain fatty acids protein 6|fatty acid elongase 2|fatty acyl-CoA elongase|hELO2|long-chain fatty-acyl elongase|very-long-chain 3-oxoacyl-CoA synthase 6",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,LCE|FAE|FACE,,,,,,,,,,,,4,,,,,,HPRD:13269|Vega:OTTHUMG00000132547|Ensembl:ENSG00000170522|MIM:611546|HGNC:15829,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,ELOVL fatty acid elongase 6,,,4q25,,,,,,,,,,,,,,,,GO_0005515 (EC: IPI); GO_0005783 (EC: IDA); GO_0005789 (EC: TAS); GO_0016747 (EC: IEA); GO_0019367 (EC: IDA); GO_0019432 (EC: TAS); GO_0030176 (EC: IEA); GO_0035338 (EC: TAS); GO_0042759 (EC: IDA); GO_0044255 (EC: TAS); GO_0044281 (EC: TAS),,,,,,,,,PMID: 8889549; 8944226; 11567032; 12477932; 14702039; 15342556; 15489334; 15815621; 16344560; 18660489; 19259639; 20332099; 20732626; 20937905; 21544602; 21701577; 21906983; 22753171; 23251661,,,,,,,,,,,,,,,OGG:3000079071,,,,,,,ELOVL fatty acid elongase 6,,,,,,,,,,,,,"Other designations: 3-keto acyl-CoA synthase ELOVL6|ELOVL FA elongase 6|ELOVL family member 6, elongation of long chain fatty acids (FEN1/Elo2, SUR4/Elo3-like, yeast)|elongation of very long chain fatty acids protein 6|fatty acid elongase 2|fatty acyl-CoA elongase|hELO2|long-chain fatty-acyl elongase|very-long-chain 3-oxoacyl-CoA synthase 6",,ELOVL6,,,,,,,,,,,,,,,,,,,,,,,79071,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,ELOVL6,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0100155,alpha-endorphin,,,false,,,http://purl.obolibrary.org/obo/IMR_0100154,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100155,,,,,,,,,,,,,,,,,,,,,,alpha-endorphin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100733,STAT5,,,false,,,http://purl.obolibrary.org/obo/IMR_0000374,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100733,,,,,,,,,,,,,,,,,,,,,,STAT5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_31446,Cyclofenil,ondogyne|cyclofenyl|fertodur|cyclophenil|cyclophenyl|cyclopenil|Cyclofenil,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:2624-43-3|Drug_Central:753,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Cyclofenil,,ondogyne|cyclofenyl|fertodur|cyclophenil|cyclophenyl|cyclopenil,,,,,,,,,,,,,,,,,,,,,CHEBI:31446,,,,Cyclofenil,,CHEBI:31446,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000005599,MAPK8,,Other designations: JUN N-terminal kinase|MAP kinase 8|c-Jun N-terminal kinase 1|mitogen-activated protein kinase 8 isoform JNK1 alpha1|mitogen-activated protein kinase 8 isoform JNK1 beta2|stress-activated protein kinase 1|stress-activated protein kinase 1c,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,SAPK1c|PRKM8|JNK1A2|SAPK1|JNK21B1/2|JNK1|JNK|JNK-46,,,,,,,,,,,,10,,,,,,Vega:OTTHUMG00000018172|HPRD:03100|HGNC:6881|MIM:601158|Ensembl:ENSG00000107643,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,mitogen-activated protein kinase 8,,,10q11.22,,,,,,,,,,,,,,,,"GO_0001503 (EC: IEA); GO_0002224 (EC: TAS); GO_0002755 (EC: TAS); GO_0002756 (EC: TAS); GO_0004674 (EC: IDA, PMID: 14967141); GO_0004705 (EC: IDA); GO_0005515 (EC: IPI, PMID: 10393177); GO_0005524 (EC: IEA); GO_0005634 (EC: IDA); GO_0005654 (EC: TAS); GO_0005739 (EC: IEA); GO_0005829 (EC: TAS); GO_0006915 (EC: TAS); GO_0006950 (EC: TAS, PMID: 8137421); GO_0007254 (EC: IDA, PMID: 8654373); GO_0007254 (EC: TAS); GO_0007258 (EC: IDA, PMID: 14967141); GO_0009411 (EC: IDA, PMID: 14967141); GO_0010628 (EC: IMP); GO_0018105 (EC: IDA, PMID: 15850461); GO_0018107 (EC: IDA); GO_0018107 (EC: IMP); GO_0031063 (EC: IMP); GO_0032091 (EC: IDA); GO_0032880 (EC: IDA); GO_0034134 (EC: TAS); GO_0034138 (EC: TAS); GO_0034142 (EC: TAS); GO_0034146 (EC: TAS); GO_0034162 (EC: TAS); GO_0034166 (EC: TAS); GO_0035033 (EC: IMP); GO_0035666 (EC: TAS); GO_0038095 (EC: TAS); GO_0038123 (EC: TAS); GO_0038124 (EC: TAS); GO_0042826 (EC: IPI); GO_0043065 (EC: TAS); GO_0043066 (EC: IDA, PMID: 14967141); GO_0045087 (EC: TAS); GO_0046686 (EC: IEA); GO_0048011 (EC: TAS); GO_0051090 (EC: TAS); GO_0051403 (EC: TAS); GO_0071260 (EC: IEP, PMID: 19593445); GO_0090045 (EC: IMP); GO_0097190 (EC: TAS); GO_0097193 (EC: TAS); GO_1900740 (EC: TAS); GO_2000017 (EC: IEA); GO_2001235 (EC: IEA)",,,,,,,,,PMID: 1748630; 7535770; 7642542; 7737129; 7737130; 7839144; 8001819; 8137421; 8177321; 8224842; 8586671; 8621542; 8632909; 8654373; 8846788; 8917518; 9020136; 9030579; 9045910; 9129988; 9162092; 9195981; 9199329; 9199504; 9207092; 9211903; 9223324; 9235954; 9343414; 9374537; 9393873; 9396779; 9399639; 9403476; 9405400; 9405416; 9520479; 9575168; 9621077; 9661668; 9670954; 9692890; 9724739; 9732264; 9733513; 9774977; 9788880; 9808624; 9851932; 9872331; 9889198; 10187783; 10346818; 10357815; 10383391; 10391943; 10393177; 10394361; 10419510; 10446219; 10471813; 10490659; 10509564; 10521505; 10523642; 10551811; 10567572; 10585392; 10597297; 10601313; 10629060; 10713157; 10722755; 10747973; 10756100; 10797012; 10799874; 10856240; 10878576; 10912793; 10913135; 10962563; 11042694; 11057897; 11062067; 11108663; 11153078; 11238452; 11260070; 11278395; 11278789; 11278799; 11279118; 11279197; 11279232; 11283254; 11323415; 11350938; 11387337; 11408587; 11432831; 11448159; 11468147; 11479302; 11489891; 11504923; 11517249; 11525649; 11551945; 11566021; 11602244; 11606564; 11698270; 11700324; 11707464; 11749722; 11781324; 11788583; 11865055; 11912216; 11931768; 11944898; 11948398; 11971973; 11983683; 11988087; 12023963; 12039864; 12052834; 12058026; 12058028; 12079429; 12089333; 12095152; 12097334; 12121974; 12135322; 12138158; 12140754; 12143039; 12148599; 12167088; 12171600; 12185592; 12189133; 12206715; 12223491; 12225289; 12228228; 12239168; 12242293; 12296995; 12351658; 12351702; 12354774; 12359245; 12376548; 12391307; 12413764; 12417588; 12421945; 12477932; 12478662; 12514174; 12538493; 12576423; 12591950; 12592382; 12646240; 12646564; 12659851; 12689591; 12697749; 12707267; 12714584; 12734330; 12756254; 12763138; 12775419; 12787561; 12788955; 12804775; 12810082; 12818176; 12821118; 12847227; 12853963; 12857973; 12859962; 12874243; 12878610; 12902351; 12917434; 12958075; 12960231; 12963725; 13130464; 14500675; 14500727; 14504284; 14514687; 14517282; 14532003; 14551213; 14557276; 14561739; 14572659; 14597672; 14612408; 14633987; 14637155; 14688370; 14699155; 14701702; 14701799; 14702039; 14724588; 14729602; 14764673; 14766760; 14967141; 14981905; 15013949; 15169762; 15184502; 15225643; 15238629; 15246824; 15276183; 15299005; 15302935; 15326485; 15334056; 15345747; 15383283; 15456887; 15474087; 15483136; 15516492; 15527495; 15528994; 15538975; 15542843; 15569856; 15590691; 15603708; 15629131; 15637062; 15655348; 15657352; 15659383; 15665513; 15677475; 15688026; 15693750; 15696159; 15721744; 15722200; 15733859; 15749833; 15755722; 15769735; 15778365; 15778501; 15827086; 15850461; 15857981; 15860507; 15890690; 15958389; 15979846; 15981086; 15998799; 16007099; 16038800; 16086581; 16105650; 16153436; 16157600; 16166642; 16176806; 16243842; 16260419; 16260609; 16264271; 16282329; 16283431; 16291755; 16307741; 16321971; 16328781; 16339571; 16344560; 16381010; 16395283; 16407310; 16412424; 16434970; 16446428; 16465391; 16481105; 16533805; 16539678; 16549498; 16569638; 16581800; 16611996; 16636664; 16648634; 16687404; 16699726; 16740711; 16760468; 16794185; 16802349; 16810318; 16814421; 16815888; 16824735; 16895791; 16912864; 16927023; 16972261; 16983342; 17008315; 17023523; 17054907; 17074809; 17079291; 17145805; 17158878; 17178870; 17189706; 17192257; 17255354; 17296730; 17303384; 17317777; 17363973; 17453826; 17478078; 17481915; 17496921; 17541429; 17545598; 17568996; 17584736; 17603935; 17620321; 17626013; 17640761; 17652454; 17690186; 17693927; 17699782; 17702750; 17703233; 17704768; 17719653; 17785464; 17875713; 17883418; 17904874; 17908987; 17913539; 17933493; 17942603; 17967471; 17982228; 18003900; 18025271; 18036196; 18055217; 18082745; 18086557; 18087676; 18094581; 18160848; 18164704; 18181766; 18199680; 18212053; 18218857; 18219313; 18249102; 18253836; 18256527; 18276794; 18286207; 18288129; 18292600; 18293403; 18297686; 18316600; 18316603; 18325654; 18337589; 18344085; 18348163; 18356158; 18373696; 18387958; 18401423; 18405916; 18429822; 18439101; 18457359; 18495129; 18506470; 18524773; 18540881; 18541008; 18547751; 18570871; 18573678; 18594007; 18603327; 18620777; 18636174; 18651223; 18663379; 18667537; 18681908; 18682391; 18703151; 18713649; 18713996; 18718914; 18723442; 18757369; 18769111; 18782768; 18813780; 18815275; 18818208; 18845538; 18922473; 18936517; 18950845; 18957422; 18978303; 18979912; 18982452; 18989785; 18996088; 19033664; 19036714; 19037093; 19041150; 19052872; 19056926; 19060920; 19069644; 19071215; 19074436; 19097143; 19153595; 19154785; 19159663; 19166930; 19168796; 19194824; 19204086; 19206162; 19234442; 19245816; 19248119; 19270716; 19275580; 19286999; 19287189; 19319745; 19339050; 19351724; 19352384; 19418584; 19424800; 19454725; 19468799; 19478459; 19479051; 19523467; 19527717; 19567513; 19570911; 19574423; 19589256; 19593445; 19596001; 19604147; 19616043; 19620725; 19638579; 19651615; 19664626; 19667122; 19676104; 19686584; 19690982; 19693773; 19695707; 19723092; 19723627; 19748889; 19778898; 19782079; 19801633; 19802005; 19803394; 19806201; 19815509; 19822148; 19822666; 19859790; 19862774; 19864026; 19877043; 19893453; 19900593; 19901160; 19910486; 19913121; 19923798; 19937141; 19940138; 19940360; 19966288; 19995557; 19996270; 20018857; 20027304; 20051532; 20056178; 20056910; 20060003; 20069553; 20070836; 20070945; 20074375; 20086174; 20088952; 20102411; 20103647; 20116378; 20130137; 20133937; 20138424; 20139358; 20142324; 20145041; 20150185; 20156194; 20173753; 20194509; 20225236; 20336759; 20371626; 20380698; 20432452; 20450729; 20452983; 20457808; 20483637; 20483734; 20490718; 20495362; 20510162; 20511226; 20512919; 20512932; 20525557; 20551953; 20566643; 20573157; 20581839; 20622336; 20628086; 20632440; 20647313; 20648623; 20680486; 20717968; 20732415; 20735357; 20829350; 20870032; 20878914; 20919940; 20944115; 20960177; 21106355; 21122381; 21123173; 21134350; 21139048; 21145111; 21148294; 21148313; 21152872; 21156789; 21172010; 21172429; 21187925; 21191018; 21212517; 21223552; 21237154; 21362231; 21364631; 21364637; 21368226; 21378396; 21384452; 21439937; 21444723; 21454558; 21465527; 21483469; 21483669; 21504622; 21511059; 21524306; 21526344; 21629969; 21651489; 21660049; 21697181; 21719561; 21729547; 21752354; 21757743; 21764057; 21768777; 21775054; 21806545; 21817106; 21822690; 21832049; 21856198; 21863240; 21900206; 21906983; 21930785; 21931671; 21943220; 21948112; 21959987; 21964465; 21984578; 21988832; 22005259; 22014979; 22021110; 22087220; 22100391; 22110360; 22114267; 22154358; 22164242; 22171160; 22184250; 22283740; 22327296; 22351776; 22357202; 22363806; 22394200; 22433870; 22435755; 22446103; 22447977; 22450687; 22456510; 22493283; 22493490; 22505724; 22506718; 22509080; 22689214; 22729748; 22749438; 22763043; 22766602; 22844345; 22850273; 22870247; 22902540; 22920299; 23020677; 23051914; 23056263; 23077074; 23237571; 23258237; 23273084; 23290789; 23326144; 23359252; 23393199; 23416355; 23440494; 23580093; 23602568; 23603344; 23608488; 23608534; 23615449; 23662689; 23712703; 23715767; 23770673; 23861391; 23906792; 23916702; 24023291; 24055030; 24091673; 24184208; 24225136,,,,,,,,,,,,,,,OGG:3000005599,,,,,,,mitogen-activated protein kinase 8,,,,,,,,,,,,,Other designations: JUN N-terminal kinase|MAP kinase 8|c-Jun N-terminal kinase 1|mitogen-activated protein kinase 8 isoform JNK1 alpha1|mitogen-activated protein kinase 8 isoform JNK1 beta2|stress-activated protein kinase 1|stress-activated protein kinase 1c,,MAPK8,,,,,,,,,,,,,,,,,,,,,,,5599,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,MAPK8,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0002693,IGFBP-5,,,false,,,http://purl.obolibrary.org/obo/IMR_0002688,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0002693,,,,,,,,,,,,,,,,,,,,,,IGFBP-5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76907,EC 4.2.1.* (hydro-lyases) inhibitor,EC 4.2.1.* (hydro-lyase) inhibitors|EC 4.2.1.* inhibitors|EC 4.2.1.* inhibitor|EC 4.2.1.* (hydro-lyases) inhibitors|hydro-lyase (EC 4.2.1.*) inhibitor|EC 4.2.1.* (hydro-lyase) inhibitor|hydro-lyase (EC 4.2.1.*) inhibitors,An EC 4.2.* (C-O lyase) inhibitor that interferes with the action of any hydro-lyase (EC 4.2.1.*).,false,,,http://purl.obolibrary.org/obo/CHEBI_76712,,,,,,,,,,,,,,,,,,,,,,An EC 4.2.* (C-O lyase) inhibitor that interferes with the action of any hydro-lyase (EC 4.2.1.*).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,EC 4.2.1.* (hydro-lyase) inhibitors|EC 4.2.1.* inhibitors|EC 4.2.1.* inhibitor|EC 4.2.1.* (hydro-lyases) inhibitors|hydro-lyase (EC 4.2.1.*) inhibitor|EC 4.2.1.* (hydro-lyase) inhibitor|hydro-lyase (EC 4.2.1.*) inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:76907,,,,EC 4.2.1.* (hydro-lyases) inhibitor,,CHEBI:76907,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000003726,JUNB,,Other designations: activator protein 1|transcription factor jun-B,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,AP-1,,,,,,,,,,,,19,,,,,,MIM:165161|Vega:OTTHUMG00000180373|HGNC:6205|Ensembl:ENSG00000171223|HPRD:01303,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,jun B proto-oncogene,,,19p13.2,,,,,,,,,,,,,,,,"GO_0000785 (EC: TAS, PMID:2513129); GO_0000977 (EC: IEA); GO_0001570 (EC: IEA); GO_0001649 (EC: IEA); GO_0001829 (EC: IEA); GO_0003677 (EC: TAS, PMID:10764760); GO_0003690 (EC: IEA); GO_0003700 (EC: IEA); GO_0003713 (EC: TAS, PMID:2513129); GO_0003714 (EC: TAS, PMID:2513129); GO_0005515 (EC: IPI, PMID:16511568); GO_0005634 (EC: IDA); GO_0005654 (EC: TAS); GO_0005730 (EC: IDA, Qualifier: NOT); GO_0006351 (EC: TAS); GO_0006357 (EC: TAS, PMID:2513129); GO_0006367 (EC: TAS); GO_0007179 (EC: TAS); GO_0009416 (EC: IEA); GO_0009612 (EC: IEA); GO_0010467 (EC: TAS); GO_0030316 (EC: IEA); GO_0032570 (EC: IEA); GO_0032870 (EC: IEA); GO_0033687 (EC: IEA); GO_0034097 (EC: IEA); GO_0042493 (EC: IEA); GO_0043434 (EC: IEA); GO_0045597 (EC: IEA); GO_0045944 (EC: TAS); GO_0046697 (EC: IEA); GO_0051412 (EC: IEA); GO_0051591 (EC: IEA); GO_0051726 (EC: IEA); GO_0060136 (EC: IEA); GO_0060716 (EC: IEA); GO_0071277 (EC: IEA)",,,,,,,,,PMID:1406655; 1633872; 1899335; 2112242; 2513129; 8125298; 8432525; 8530030; 8570175; 8649827; 8654373; 8917518; 8945519; 8954125; 9128241; 9154808; 9405416; 9872330; 9889198; 10220381; 10764760; 10777209; 10903323; 11036094; 11053448; 11477071; 11726656; 12080089; 12145210; 12165517; 12371906; 12393503; 12477932; 12506033; 12522006; 12592382; 12907453; 12907627; 14499865; 14673171; 15025563; 15231748; 15240010; 15302935; 15308641; 15489334; 15507668; 15867431; 16189514; 16511568; 16552541; 16880520; 17081983; 17204476; 17306025; 17495958; 17510411; 17601350; 17681951; 17690253; 17965727; 18029348; 18042260; 18259752; 18391017; 18424718; 18628455; 18843287; 18977241; 19064921; 19151755; 19321746; 19409613; 19471022; 19666408; 19923172; 20006998; 20030915; 20056077; 20132737; 20195357; 20200942; 21225234; 21289643; 21326808; 21393445; 21423810; 21693764; 21822216; 21906983; 21937452; 21963094; 21988832; 22020339; 22082156; 22242598; 22252121; 22328780; 22710716; 23000965; 23297064; 23308222; 23661758; 23749999; 24136993; 24200694,,,,,,,,,,,,,,,OGG:3000003726,,,,,,,jun B proto-oncogene,,,,,,,,,,,,,Other designations: activator protein 1|transcription factor jun-B,,JUNB,,,,,,,,,,,,,,,,,,,,,,,3726,,,,,,,,9606,,,,,,,,,,,,,,,,,,,JUNB,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000003725,JUN,,Other designations: Jun activation domain binding protein|activator protein 1|enhancer-binding protein AP1|jun oncogene|p39|proto-oncogene c-Jun|transcription factor AP-1|v-jun avian sarcoma virus 17 oncogene homolog|v-jun sarcoma virus 17 oncogene homolog,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,AP1|c-Jun|AP-1,,,,,,,,,,,,1,,,,,,HPRD:01302|Vega:OTTHUMG00000008376|MIM:165160|Ensembl:ENSG00000177606|HGNC:6204,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,jun proto-oncogene,,,1p32-p31,,,,,,,,,,,,,,,,"GO_0000228 (EC: TAS, PMID:10918580); GO_0000980 (EC: IDA, PMID:19861239); GO_0001077 (EC: IEA); GO_0001102 (EC: IPI, PMID:19861239); GO_0001190 (EC: IC, PMID:19861239); GO_0001525 (EC: IEA); GO_0001774 (EC: IEA); GO_0001836 (EC: IEA); GO_0001889 (EC: IEA); GO_0001938 (EC: IEA); GO_0002224 (EC: TAS); GO_0002755 (EC: TAS); GO_0002756 (EC: TAS); GO_0003151 (EC: IEA); GO_0003677 (EC: TAS, PMID:2825349); GO_0003690 (EC: IEA); GO_0003700 (EC: IDA, PMID:9732876); GO_0003705 (EC: IC, PMID:19861239); GO_0003705 (EC: IDA, PMID:2833704); GO_0003713 (EC: IDA, PMID:2833704); GO_0005100 (EC: IDA, PMID:11804590); GO_0005515 (EC: IPI, PMID:10327051); GO_0005654 (EC: TAS); GO_0005667 (EC: IEA); GO_0005719 (EC: IDA, PMID:19861239); GO_0005829 (EC: IEA); GO_0007179 (EC: IDA, PMID:9732876); GO_0007184 (EC: IDA, PMID:9732876); GO_0007568 (EC: IEA); GO_0007612 (EC: IEA); GO_0007623 (EC: IEA); GO_0008134 (EC: IPI, PMID:16007074); GO_0008285 (EC: IEA); GO_0009314 (EC: IEA); GO_0009612 (EC: IEA); GO_0017053 (EC: IEA); GO_0030224 (EC: IEA); GO_0031103 (EC: IEA); GO_0031953 (EC: IEA); GO_0032321 (EC: IDA, PMID:11804590); GO_0032496 (EC: IEA); GO_0034097 (EC: IEA); GO_0034134 (EC: TAS); GO_0034138 (EC: TAS); GO_0034142 (EC: TAS); GO_0034146 (EC: TAS); GO_0034162 (EC: TAS); GO_0034166 (EC: TAS); GO_0035026 (EC: IEA); GO_0035497 (EC: IDA, PMID:19861239); GO_0035666 (EC: TAS); GO_0038095 (EC: TAS); GO_0038123 (EC: TAS); GO_0038124 (EC: TAS); GO_0042493 (EC: IEA); GO_0042542 (EC: IEA); GO_0043392 (EC: IDA, PMID:14645924); GO_0043524 (EC: IEA); GO_0043525 (EC: IEA); GO_0043922 (EC: IDA, PMID:2833704); GO_0043923 (EC: IDA, PMID:2833704); GO_0044212 (EC: IDA, PMID:14645924); GO_0044822 (EC: IDA); GO_0045087 (EC: TAS); GO_0045657 (EC: IEA); GO_0045740 (EC: IEA); GO_0045892 (EC: IDA, PMID:2833704); GO_0045893 (EC: IDA, PMID:2833704); GO_0045944 (EC: IC, PMID:19861239); GO_0045944 (EC: IDA, PMID:2833704); GO_0048146 (EC: IEA); GO_0048661 (EC: IEA); GO_0051090 (EC: TAS); GO_0051365 (EC: IEA); GO_0051403 (EC: TAS); GO_0051591 (EC: IEA); GO_0051726 (EC: IEA); GO_0051899 (EC: IEA); GO_0060395 (EC: IDA, PMID:9732876); GO_0070412 (EC: IPI, PMID:9732876); GO_0071277 (EC: IEA); GO_0071837 (EC: IEA)",,,,,,,,,PMID:1310896; 1448082; 1516134; 1631061; 1651323; 1827203; 1922387; 2138276; 2320002; 2825349; 2833704; 3194415; 7623830; 7642615; 7662174; 7666555; 7690421; 7738014; 7816143; 7823959; 7848298; 7957556; 8001819; 8027667; 8087846; 8108109; 8137421; 8224842; 8302594; 8380166; 8387155; 8397339; 8440710; 8464713; 8480425; 8557686; 8570175; 8586671; 8617242; 8621542; 8621941; 8622660; 8628277; 8649793; 8654373; 8662824; 8663380; 8663478; 8733011; 8763994; 8798722; 8816797; 8816798; 8837781; 8846788; 8945519; 8974016; 8985011; 9020136; 9030721; 9129988; 9154808; 9155018; 9160889; 9207092; 9211894; 9223324; 9235954; 9334186; 9346889; 9374537; 9405416; 9443941; 9445037; 9468519; 9488446; 9510247; 9545246; 9566900; 9575168; 9621077; 9628874; 9642216; 9659924; 9670954; 9671405; 9681824; 9685505; 9692890; 9732876; 9774977; 9786917; 9808624; 9837938; 9872330; 9973222; 10026157; 10027715; 10188588; 10196196; 10207054; 10220381; 10327051; 10330159; 10346818; 10357819; 10388555; 10393177; 10419510; 10421840; 10428834; 10478848; 10488148; 10490605; 10490649; 10497212; 10506225; 10509564; 10523647; 10567391; 10567404; 10581001; 10620019; 10637231; 10644332; 10747973; 10766246; 10777532; 10788439; 10799874; 10847592; 10878360; 10903323; 10903862; 10913197; 10918580; 10962563; 10973489; 11022789; 11053448; 11090181; 11108663; 11254713; 11260070; 11274169; 11278277; 11278395; 11278640; 11278891; 11287617; 11306568; 11316804; 11331419; 11331585; 11371641; 11397794; 11431474; 11432833; 11448159; 11477071; 11479302; 11551904; 11641401; 11689449; 11704680; 11708771; 11738026; 11739718; 11801649; 11804590; 11823437; 11867732; 11877416; 11891228; 11891317; 11903046; 11909859; 11912197; 11914583; 11948398; 11956220; 11980644; 11983170; 12034730; 12052834; 12052862; 12077347; 12080089; 12087103; 12089333; 12091339; 12119282; 12145210; 12165517; 12167088; 12183893; 12185592; 12186939; 12228228; 12324474; 12419228; 12419805; 12437352; 12441106; 12446585; 12477932; 12485413; 12547826; 12554755; 12592382; 12600818; 12615916; 12618758; 12628923; 12676957; 12682910; 12692226; 12697749; 12700665; 12775419; 12788955; 12796506; 12798298; 12799614; 12805554; 12815619; 12853483; 12875982; 12909593; 12949493; 12954631; 12963547; 12963725; 12963995; 13130464; 14500675; 14506227; 14511403; 14517282; 14522952; 14530285; 14532268; 14572659; 14612408; 14630807; 14633987; 14638681; 14645224; 14645924; 14652666; 14654548; 14667575; 14675752; 14701799; 14701856; 14739464; 14973137; 15001576; 15034932; 15044437; 15087451; 15158360; 15175153; 15191540; 15226448; 15240010; 15249231; 15258149; 15262961; 15271374; 15276183; 15299005; 15302867; 15302935; 15314183; 15314185; 15319445; 15333603; 15334056; 15351693; 15378002; 15383523; 15385474; 15469925; 15480426; 15489334; 15507668; 15514030; 15528994; 15530430; 15544846; 15546613; 15550679; 15579469; 15586248; 15590691; 15626733; 15642950; 15654976; 15674337; 15677475; 15688015; 15696159; 15701643; 15702969; 15706351; 15708845; 15718494; 15746191; 15749833; 15806162; 15840658; 15863510; 15867431; 15870692; 15894171; 15897893; 15922298; 15923621; 15923644; 15936718; 15941782; 15944151; 15958389; 15991283; 15994313; 15994960; 16001969; 16007074; 16007099; 16023595; 16023596; 16045761; 16049073; 16055710; 16123044; 16140218; 16157600; 16158054; 16166642; 16179804; 16199533; 16223572; 16236267; 16243842; 16253992; 16266514; 16285957; 16289409; 16291755; 16303762; 16328781; 16341687; 16343055; 16361535; 16380075; 16410250; 16434970; 16478997; 16511568; 16533805; 16549498; 16569633; 16569638; 16571680; 16582099; 16586042; 16611996; 16620772; 16676006; 16690925; 16702224; 16710414; 16714286; 16740711; 16786139; 16824735; 16844113; 16880509; 16887814; 16895791; 16901904; 16905771; 16911523; 16916642; 16928756; 16928824; 16951171; 16980310; 16980615; 16983342; 17009014; 17056544; 17074809; 17082780; 17085440; 17088247; 17097050; 17101801; 17110928; 17121851; 17130130; 17182846; 17189706; 17215518; 17235455; 17237388; 17237407; 17283040; 17283046; 17296604; 17314269; 17317669; 17363973; 17390236; 17401435; 17403042; 17438848; 17440114; 17466952; 17495958; 17506864; 17510314; 17538020; 17588603; 17592138; 17634427; 17636030; 17637753; 17639289; 17651785; 17652081; 17658605; 17672916; 17681951; 17702894; 17703412; 17704768; 17761353; 17804415; 17845581; 17875713; 17908424; 17914574; 17920329; 17940019; 17952113; 17968316; 17978573; 18003900; 18032824; 18062835; 18065414; 18073204; 18097055; 18165900; 18171671; 18172215; 18174157; 18180292; 18180316; 18192274; 18234454; 18239671; 18253836; 18262488; 18281687; 18302882; 18304423; 18316037; 18316603; 18322962; 18347071; 18351441; 18352974; 18384814; 18410487; 18414033; 18429822; 18435914; 18443042; 18443043; 18445313; 18448277; 18467434; 18485515; 18487146; 18494816; 18497564; 18515365; 18543249; 18570890; 18572021; 18597608; 18600430; 18617512; 18619508; 18621151; 18644981; 18646516; 18650425; 18653452; 18653705; 18664273; 18671972; 18692129; 18708361; 18716056; 18725194; 18757369; 18775869; 18805449; 18823944; 18838675; 18844221; 18845538; 18922473; 18923650; 18931081; 18936204; 18940179; 18950845; 18952102; 18957410; 18957422; 18985028; 18992165; 19015316; 19018257; 19020743; 19022561; 19028685; 19035162; 19064921; 19080373; 19105933; 19123467; 19131506; 19156129; 19164581; 19165171; 19166930; 19176525; 19193763; 19206162; 19215067; 19219074; 19231233; 19238531; 19249008; 19258923; 19270716; 19281909; 19306295; 19334540; 19343052; 19357699; 19358752; 19384981; 19433309; 19435822; 19471022; 19495976; 19499154; 19513521; 19527717; 19528235; 19531482; 19578717; 19591174; 19595408; 19616043; 19653276; 19654329; 19656241; 19701800; 19714312; 19723051; 19734233; 19734545; 19738058; 19758340; 19758438; 19782465; 19787273; 19794957; 19795388; 19806201; 19811296; 19818398; 19837979; 19841138; 19859790; 19860880; 19861239; 19874574; 19878434; 19885545; 19898747; 19910471; 19910486; 19913121; 19919900; 19921846; 19937141; 19937979; 19939924; 19944700; 19959471; 19965873; 20012528; 20042607; 20044606; 20051654; 20053993; 20074357; 20093361; 20093369; 20102411; 20133937; 20137127; 20170659; 20185758; 20193273; 20195357; 20198339; 20203690; 20222112; 20225236; 20227498; 20232342; 20304822; 20306472; 20331627; 20331972; 20331980; 20333648; 20353950; 20353996; 20371606; 20376080; 20395206; 20410304; 20430872; 20432452; 20448330; 20459032; 20479273; 20479762; 20482821; 20483790; 20503287; 20505831; 20507572; 20508969; 20510020; 20511396; 20519498; 20531301; 20543003; 20554528; 20557936; 20590529; 20607803; 20619956; 20628086; 20628624; 20665665; 20680410; 20683948; 20688351; 20697347; 20698984; 20732415; 20837772; 20852630; 20936779; 20939893; 20942798; 20943203; 20952681; 20955203; 20976196; 20977688; 21030269; 21034562; 21081043; 21081472; 21106530; 21106746; 21134350; 21139048; 21145111; 21148792; 21196933; 21212516; 21268080; 21289643; 21338584; 21349840; 21350237; 21357535; 21360282; 21364631; 21381700; 21393476; 21397653; 21410405; 21417953; 21439937; 21451046; 21454713; 21496208; 21511059; 21518489; 21526160; 21530485; 21555589; 21559334; 21565167; 21570970; 21607373; 21617575; 21617851; 21640141; 21647439; 21675959; 21685329; 21693764; 21697091; 21699750; 21703547; 21732343; 21739277; 21743958; 21745629; 21799768; 21801875; 21814482; 21822357; 21829441; 21835421; 21835891; 21860413; 21862593; 21872498; 21890473; 21895606; 21937452; 21972703; 21988832; 21989944; 22001392; 22002117; 22051934; 22077140; 22083952; 22092038; 22110360; 22119392; 22132731; 22139817; 22176144; 22189957; 22235337; 22239235; 22265050; 22266871; 22271085; 22271878; 22307329; 22327296; 22328508; 22331067; 22354960; 22384197; 22384232; 22394497; 22399296; 22417306; 22429882; 22438909; 22450687; 22484283; 22508041; 22512945; 22570239; 22597534; 22675553; 22685373; 22688014; 22719067; 22749179; 22771387; 22791811; 22797068; 22801218; 22843696; 22853846; 22860098; 22869147; 22879913; 22911824; 22926518; 22933572; 22966201; 22974165; 22981541; 22988241; 23027969; 23028371; 23041974; 23047699; 23135283; 23153494; 23163821; 23182717; 23223231; 23226410; 23236059; 23269699; 23300800; 23331079; 23339184; 23362975; 23382074; 23437118; 23454483; 23467542; 23523566; 23546882; 23562910; 23580428; 23583295; 23602568; 23608488; 23614275; 23615400; 23624934; 23625009; 23625206; 23661758; 23665382; 23669365; 23671702; 23678002; 23682787; 23686163; 23690655; 23720779; 23747343; 23749999; 23762330; 23770289; 23814048; 23818969; 23832539; 23844083; 23906792; 23929433; 23942796; 24027432; 24113186,,,,,,,,,,,,,,,OGG:3000003725,,,,,,,jun proto-oncogene,,,,,,,,,,,,,Other designations: Jun activation domain binding protein|activator protein 1|enhancer-binding protein AP1|jun oncogene|p39|proto-oncogene c-Jun|transcription factor AP-1|v-jun avian sarcoma virus 17 oncogene homolog|v-jun sarcoma virus 17 oncogene homolog,,JUN,,,,,,,,,,,,,,,,,,,,,,,3725,,,,,,,,9606,,,,,,,,,,,,,,,,,,,JUN,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000003727,JUND,,Other designations: JunD-FL isoform|activator protein 1|transcription factor jun-D,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,AP-1,,,,,,,,,,,,19,,,,,,HGNC:6206|Vega:OTTHUMG00000183355|HPRD:01304|Ensembl:ENSG00000130522|MIM:165162,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,jun D proto-oncogene,,,19p13.2,,,,,,,,,,,,,,,,"GO_0000785 (EC: TAS, PMID:1903194); GO_0002076 (EC: IEA); GO_0003690 (EC: IEA); GO_0003700 (EC: IEA); GO_0005515 (EC: IPI, PMID:17577209); GO_0005634 (EC: IDA); GO_0005730 (EC: IDA, Qualifier: NOT); GO_0006357 (EC: TAS, PMID:1903194); GO_0006366 (EC: IEA); GO_0007568 (EC: IEA); GO_0007623 (EC: IEA); GO_0009416 (EC: IEA); GO_0009612 (EC: IEA); GO_0014070 (EC: IEA); GO_0016922 (EC: IEA); GO_0032496 (EC: IEA); GO_0043234 (EC: IEA); GO_0043434 (EC: IEA); GO_0043565 (EC: IEA); GO_0044212 (EC: IDA, PMID:1903194); GO_0045669 (EC: IEA); GO_0045944 (EC: IEA); GO_0071277 (EC: IEA)",,,,,,,,,PMID:1899335; 1903194; 2112242; 7848298; 8125298; 8152431; 8432525; 8570175; 8654373; 8837781; 8889548; 8945519; 9154808; 9739985; 9872330; 9989505; 10220381; 10500243; 10523647; 10713367; 10934195; 10942775; 11221882; 11431474; 11477071; 11903046; 12032852; 12052834; 12052862; 12054733; 12080089; 12082101; 12105216; 12165517; 12193410; 12226747; 12477932; 12615916; 12727841; 14559791; 14676207; 15044019; 15302935; 15507668; 15563473; 15688015; 15706351; 15867431; 16007120; 16129800; 16264271; 16423552; 16651450; 17081983; 17204476; 17205062; 17495958; 17510411; 17577209; 17651017; 17681951; 18071306; 18078517; 18095154; 18321953; 18386285; 18443593; 18454173; 18562690; 18671972; 18952102; 19166930; 19211927; 19322201; 19470832; 19471022; 20195357; 21145461; 21315773; 21393445; 21473742; 21559334; 21693764; 21734453; 21906983; 21937452; 22327296; 22493372; 22696638; 23000965; 23289756; 23376981; 23382074; 23667531; 23942796; 24140207,,,,,,,,,,,,,,,OGG:3000003727,,,,,,,jun D proto-oncogene,,,,,,,,,,,,,Other designations: JunD-FL isoform|activator protein 1|transcription factor jun-D,,JUND,,,,,,,,,,,,,,,,,,,,,,,3727,,,,,,,,9606,,,,,,,,,,,,,,,,,,,JUND,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000815,FRA-1,,,false,,,http://purl.obolibrary.org/obo/IMR_0000415,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000815,,,,,,,,,,,,,,,,,,,,,,FRA-1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_35222,inhibitor,inhibidor|inhibiteur|inhibitors|inhibitor,A substance that diminishes the rate of a chemical reaction.,false,,,http://purl.obolibrary.org/obo/CHEBI_24432|http://purl.obolibrary.org/obo/BFO_0000023|http://purl.obolibrary.org/obo/TXPO_0003710,,,,,,,,,,,,,,,,,,,,,,A substance that diminishes the rate of a chemical reaction.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,inhibitor,,inhibidor|inhibiteur|inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:35222,,,,inhibitor,,CHEBI:35222,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_132992,radiosensitizing agent,radiosensitisers|radiosensitizer|radiosensitiser|radiosensitising agents|radiosensitising agent|radiosensitizing agents|radiosensitizers,A drug that makes increases the sensitivity of tumour cells to radiation therapy.,false,,,http://purl.obolibrary.org/obo/CHEBI_23888,,,,,,,,,,,,,,,,,,,,PMID:12520460,,A drug that makes increases the sensitivity of tumour cells to radiation therapy.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,radiosensitisers|radiosensitizer|radiosensitiser|radiosensitising agents|radiosensitising agent|radiosensitizing agents|radiosensitizers,,,,,,,,,,,,,,,,,,,,,CHEBI:132992,,,,radiosensitizing agent,,CHEBI:132992,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0009719,response to endogenous stimulus,,"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus arising within the organism.|Note that this term is in the subset of terms that should not be used for direct gene product annotation. Instead, select a child term or, if no appropriate child term exists, please request a new term. Direct annotations to this term may be amended during annotation QC.",false,,,http://purl.obolibrary.org/obo/GO_0050896,,,,,,,,,,,,,,,,,,,,,,"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus arising within the organism.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0009719,,,,,,,,,,,,,,,,,,,,"Note that this term is in the subset of terms that should not be used for direct gene product annotation. Instead, select a child term or, if no appropriate child term exists, please request a new term. Direct annotations to this term may be amended during annotation QC.",,response to endogenous stimulus,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000008856,NR1I2,nuclear receptor subfamily 1 group I member 2|orphan nuclear receptor PXR|PXR|rphan nuclear receptor PAR1|pregnane X receptor|pregnane X nuclear receptor variant 2,,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,nuclear receptor subfamily 1 group I member 2|orphan nuclear receptor PXR|PXR|rphan nuclear receptor PAR1|pregnane X receptor|pregnane X nuclear receptor variant 2,,,,,OGG:3000008856,,,,,,,,,,,,,,,,,,,,,,NR1I2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000008851,CDK5R1,,Other designations: CDK5 activator 1|TPKII regulatory subunit|cyclin-dependent kinase 5 activator 1|cyclin-dependent kinase 5 regulatory subunit 1|neuronal CDK5 activator|regulatory partner for CDK5 kinase|tau protein kinase II 23kDa subunit,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CDK5R|p35|p25|NCK5A|CDK5P35|p35nck5a|p23,,,,,,,,,,,,17,,,,,,Ensembl:ENSG00000176749|Vega:OTTHUMG00000132814|HPRD:04586|MIM:603460|HGNC:1775,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cyclin-dependent kinase 5, regulatory subunit 1 (p35)",,,17q11.2,,,,,,,,,,,,,,,,"GO_0000079 (EC: TAS, PMID: 7592934); GO_0001764 (EC: ISS); GO_0004672 (EC: TAS, PMID: 7592934); GO_0004693 (EC: IEA); GO_0005509 (EC: ISS); GO_0005515 (EC: IPI, PMID: 10721722); GO_0005634 (EC: ISS); GO_0005737 (EC: ISS); GO_0005829 (EC: TAS); GO_0005886 (EC: IEA); GO_0007158 (EC: ISS); GO_0007213 (EC: ISS); GO_0007411 (EC: ISS); GO_0007411 (EC: TAS); GO_0007413 (EC: ISS); GO_0007420 (EC: ISS); GO_0007420 (EC: NAS, PMID: 10915792); GO_0008283 (EC: TAS, PMID: 8090221); GO_0009790 (EC: ISS); GO_0014069 (EC: ISS); GO_0016020 (EC: ISS); GO_0016301 (EC: ISS); GO_0016533 (EC: IEA); GO_0016534 (EC: IEA); GO_0018105 (EC: IDA, PMID: 12832520); GO_0018107 (EC: IDA, PMID: 12832520); GO_0019901 (EC: IPI, PMID: 12832520); GO_0021549 (EC: IEA); GO_0021722 (EC: IEA); GO_0021766 (EC: IEA); GO_0021819 (EC: IEA); GO_0030182 (EC: ISS); GO_0030424 (EC: ISS); GO_0030425 (EC: ISS); GO_0030426 (EC: ISS); GO_0030517 (EC: IEA); GO_0031175 (EC: ISS); GO_0031594 (EC: ISS); GO_0032956 (EC: IEA); GO_0033136 (EC: IEA); GO_0035235 (EC: ISS); GO_0043025 (EC: ISS); GO_0043197 (EC: ISS); GO_0043292 (EC: ISS); GO_0043525 (EC: ISS); GO_0043539 (EC: IDA, PMID: 12832520); GO_0043539 (EC: ISS); GO_0045296 (EC: ISS); GO_0045664 (EC: NAS, PMID: 10721722); GO_0045892 (EC: IMP); GO_0046875 (EC: IEA); GO_0048013 (EC: ISS); GO_0048471 (EC: IDA, PMID: 12832520); GO_0061001 (EC: ISS); GO_0070507 (EC: IEA); GO_0090314 (EC: IEA)",,,,,,,,,PMID: 7556643; 7592934; 8090221; 9010203; 9038181; 9933594; 10604467; 10721722; 10753743; 10830966; 10915792; 11113134; 11168528; 11389014; 11583627; 11604394; 11741927; 11784720; 11882646; 12037672; 12084709; 12223541; 12226093; 12230554; 12477932; 12491158; 12688339; 12826674; 12832492; 12832520; 12859671; 14521924; 14702039; 14976144; 15013773; 15123618; 15175076; 15342635; 15489224; 15489334; 15492003; 15536496; 15689152; 15741232; 15917097; 16189514; 16407256; 16425041; 16678793; 17036052; 17060323; 17121855; 17207965; 17491008; 17493033; 17496813; 17591690; 17762160; 18053171; 18247371; 18325333; 18829967; 19081376; 19154537; 19638632; 19874574; 19913121; 19953087; 20097924; 20354813; 20518484; 20618441; 20628086; 21130530; 21220307; 21544067; 21625387; 21772061; 21832049; 22654103; 22964075; 23151508; 23455922; 23602568; 24085300,,,,,,,,,,,,,,,OGG:3000008851,,,,,,,"cyclin-dependent kinase 5, regulatory subunit 1 (p35)",,,,,,,,,,,,,Other designations: CDK5 activator 1|TPKII regulatory subunit|cyclin-dependent kinase 5 activator 1|cyclin-dependent kinase 5 regulatory subunit 1|neuronal CDK5 activator|regulatory partner for CDK5 kinase|tau protein kinase II 23kDa subunit,,CDK5R1,,,,,,,,,,,,,,,,,,,,,,,8851,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,CDK5R1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000051250,C6orf203,,Other designations: uncharacterized protein C6orf203,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,PRED31,,,,,,,,,,,,6,,,,,,Vega:OTTHUMG00000015307|HPRD:12873|HGNC:17971|Ensembl:ENSG00000130349,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,chromosome 6 open reading frame 203,,,6q21,,,,,,,,,,,,,,,,GO_0005739 (EC: IDA),,,,,,,,,PMID: 11042152; 11707072; 12107413; 12477932; 14574404; 14702039; 15489334; 16169070; 16344560; 20186120; 20877624; 21832049; 21988832; 24250222,,,,,,,,,,,,,,,OGG:3000051250,,,,,,,chromosome 6 open reading frame 203,,,,,,,,,,,,,Other designations: uncharacterized protein C6orf203,,C6orf203,,,,,,,,,,,,,,,,,,,,,,,51250,HSPC230,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,C6orf203,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000004001,LMNB1,,Other designations: lamin-B1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,LMN|ADLD|LMN2|LMNB,,,,,,,,,,,,5,,,,,,MIM:150340|Vega:OTTHUMG00000128969|HGNC:6637|HPRD:01036|Ensembl:ENSG00000113368,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,lamin B1,,,5q23.2,,,,,,,,,,,,,,,,GO_0005198 (EC: IEA); GO_0005635 (EC: TAS); GO_0005637 (EC: IEA); GO_0005638 (EC: IEA); GO_0005654 (EC: TAS); GO_0006915 (EC: TAS); GO_0006921 (EC: TAS); GO_0031965 (EC: IDA); GO_0043274 (EC: IEA),,,,,,,,,PMID: 1986862; 2023931; 2325650; 2406262; 2544227; 7557986; 7628545; 8034666; 8324822; 8838815; 8978814; 9128241; 9243284; 9305626; 9367621; 9436978; 9490046; 10679189; 10806082; 10960149; 11095689; 11331782; 11441066; 11691994; 11790298; 11792809; 11901153; 12135703; 12477932; 12490158; 12670476; 12898336; 14504265; 15161933; 15265697; 15284226; 15635413; 16083285; 16196087; 16216881; 16236267; 16283426; 16344560; 16365157; 16410549; 16543417; 17550303; 17620012; 18334554; 18524819; 19001169; 19141474; 19151023; 19198602; 19322201; 19348623; 19383719; 19454010; 19471022; 19522540; 19727227; 19738201; 19765186; 19961535; 20004208; 20085707; 20230530; 20360068; 20816241; 21139048; 21225301; 21346760; 21549307; 21890473; 21897860; 21906983; 21909802; 21963094; 21988832; 22053931; 22155925; 22178446; 22246186; 22265972; 22268729; 22412018; 22446626; 22496421; 22505724; 22623428; 22658654; 22751105; 22863883; 22939629; 23000965; 23261988; 23439683; 23475125; 23649844; 23681646; 23733478; 23798571; 23934658; 23964094; 24157836; 24163370; 24244333; 24457600,,,,,,,,,,,,,,,OGG:3000004001,,,,,,,lamin B1,,,,,,,,,,,,,Other designations: lamin-B1,,LMNB1,,,,,,,,,,,,,,,,,,,,,,,4001,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,LMNB1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/PATO_0001637,necessity of occurrent,,A quality of single process inhering in a bearer by virtue of whether the bearer is essential or indispensable.,false,,,http://purl.obolibrary.org/obo/BFO_0000019,,,,,,,,,,,,,,,,,,,,,,A quality of single process inhering in a bearer by virtue of whether the bearer is essential or indispensable.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0001637,,,,,,,,,,,,,,,,,,,,,,necessity of occurrent,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0001639,unnecessary (occurrent),,A necessity quality inhering in a process by virtue of the bearer's being non-essential or dispensable.,false,,,http://purl.obolibrary.org/obo/PATO_0001637,,,,,,,,,,,,,,,,,,,,,,A necessity quality inhering in a process by virtue of the bearer's being non-essential or dispensable.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0001639,,,,,,,,,,,,,,,,,,,,,,unnecessary (occurrent),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0001638,necessary (occurrent),,A necessity quality inhering in a process by virtue of the bearer's being essential or indispensable.,false,,,http://purl.obolibrary.org/obo/PATO_0001637,,,,,,,,,,,,,,,,,,,,,,A necessity quality inhering in a process by virtue of the bearer's being essential or indispensable.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0001638,,,,,,,,,,,,,,,,,,,,,,necessary (occurrent),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0001193,hepatic artery,arteria hepatica|arteria hepatica propria,An artery that supplies the liver.,false,,,http://purl.obolibrary.org/obo/UBERON_0001637|http://purl.obolibrary.org/obo/UBERON_0015796,,,,,,,,,,,,,,,,,,,currently defined in a generic fashion.,http://purl.obolibrary.org/obo/NCIT_C32729|http://www.snomedbrowser.com/Codes/Details/76015000|http://linkedlifedata.com/resource/umls/id/C0019145|MESH:D006499|FMA:14769|EMAPA:17859|GAID:496|MA:0001963|TAO:0005161|UMLS:C0019145|OpenCyc:Mx4rvzKtFpwpEbGdrcN5Y29ycA|http://en.wikipedia.org/wiki/Hepatic_artery_proper|BTO:0004307|galen:HepaticArtery|ZFA:0005161,,An artery that supplies the liver.,,,,,,,,Artery that supplies blood to the liver.[TAO],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,arteria hepatica propria,,arteria hepatica,,,UBERON:0001193,,,,,,,,,,,,,,,,,,,,,,hepatic artery,,,,http://upload.wikimedia.org/wikipedia/commons/4/4c/Common_and_proper_hepatic_artery.png,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,
http://purl.obolibrary.org/obo/IMR_0000435,Sos,son of sevenless,"Drosophila Son of Sevenless (SOS) is homologous to the yeast exchange factor for Ras, CDC25. Mammalian cells contain two closely related homologs of Drosophila SOS: SOS1 and SOS2. Biochemical studies have established that SOS indeed functions as a guanine nucleotide exchange factor for Ras.",false,,,http://purl.obolibrary.org/obo/IMR_0100440,,,,,,,,,,,,,,,,,,,,,,"Drosophila Son of Sevenless (SOS) is homologous to the yeast exchange factor for Ras, CDC25. Mammalian cells contain two closely related homologs of Drosophila SOS: SOS1 and SOS2. Biochemical studies have established that SOS indeed functions as a guanine nucleotide exchange factor for Ras.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,son of sevenless,,,,,IMR:0000435,,,,,,,,,,,,,,,,,,,,,,Sos,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003292,microvascular dysfunction,,Mcrovascular dysfunction is a subtype of organ malfunction: A process that does not perform microvascular function correctly  or not functioning at all.,false,,,http://purl.obolibrary.org/obo/TXPO_0002073,,,,,,,,,,,,,,,,,,,,,,Mcrovascular dysfunction is a subtype of organ malfunction: A process that does not perform microvascular function correctly  or not functioning at all.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003292,,,,,,,,,,,,,,,,,,,,,,microvascular dysfunction,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003290,increasing blood glucose level [diabetes coruse],hyperglycemia,"Increasing blood glucose level is a subtype of increasing concentration: A process that changes the blood glucose concentration in the blood to be higher.
This entity is a specific course-dependent process. This process can constitute the course of diabetes.",false,,,http://purl.obolibrary.org/obo/TXPO_0003342|http://purl.obolibrary.org/obo/TXPO_0001912,,,,,,,,,,,,,,,,,,,,,,"Increasing blood glucose level is a subtype of increasing concentration: A process that changes the blood glucose concentration in the blood to be higher.
This entity is a specific course-dependent process. This process can constitute the course of diabetes.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,hyperglycemia,,,,,TXPO:0003290,,,,,,,,,,,,,,,,,,,,,,increasing blood glucose level [diabetes coruse],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003296,regulation of cell cycle [Hypertrophy],,"Any process that modulates the rate or extent of progression through the cell cycle.
This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy.",false,,,http://purl.obolibrary.org/obo/TXPO_0003279|http://purl.obolibrary.org/obo/GO_0051726,,,,,,,,,,,,,,,,,,,,,,"Any process that modulates the rate or extent of progression through the cell cycle.
This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003298,,,,,,,,,,,TXPO:0003296,,,,,,,,,,,,,,,,,,,,,,regulation of cell cycle [Hypertrophy],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003294,narrowing of the retinal artery [Diabetic retinopathy],,"Narrowing of the retinal artery is a subtype of decreasing cross-sectional area: A process that changes the cross-sectional area of the retinal arteries to be smaller.
This entity is a specific course-dependent process. This process can constitute the course of Diabetic retinopathy.",false,,,http://purl.obolibrary.org/obo/TXPO_0003293|http://purl.obolibrary.org/obo/TXPO_0003342,,,,,,,,,,,,,,,,,,,,,,"Narrowing of the retinal artery is a subtype of decreasing cross-sectional area: A process that changes the cross-sectional area of the retinal arteries to be smaller.
This entity is a specific course-dependent process. This process can constitute the course of Diabetic retinopathy.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003317,,,,,,,,,,,TXPO:0003294,,,,,,,,,,,,,,,,,,,,,,narrowing of the retinal artery [Diabetic retinopathy],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003297,increasing hepatocellular volume [Hypertrophy],,"Increasing hepatocellular volume is a changing process to change the volume of the hepatocyte to increase.
This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy.",false,,,http://purl.obolibrary.org/obo/TXPO_0003279|http://purl.obolibrary.org/obo/TXPO_0000164,,,,,,,,,,,,,,,,,,,,,,"Increasing hepatocellular volume is a changing process to change the volume of the hepatocyte to increase.
This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003304|http://purl.obolibrary.org/obo/TXPO_0003314,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003271,,,,,,,,,,,TXPO:0003297,,,,,,,,,,,,,,,,,,,,,,increasing hepatocellular volume [Hypertrophy],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003293,narrowing of the retinal artery,,Narrowing of the retinal artery is a subtype of decreasing cross-sectional area: A process that changes the cross-sectional area of the retinal arteries to be smaller.,false,,,http://purl.obolibrary.org/obo/TXPO_0002648,,,,,,,,,,,,,,,,,,,,,,Narrowing of the retinal artery is a subtype of decreasing cross-sectional area: A process that changes the cross-sectional area of the retinal arteries to be smaller.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003293,,,,,,,,,,,,,,,,,,,,,,narrowing of the retinal artery,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003291,diabetic retinopathy course,,The totality of all processes through which a given diabetic retinopathy instance is realized.,false,,,http://purl.obolibrary.org/obo/TXPO_0002033,,,,,,,,,,,,,,,,,,,,,,The totality of all processes through which a given diabetic retinopathy instance is realized.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003294|http://purl.obolibrary.org/obo/TXPO_0003295|http://purl.obolibrary.org/obo/TXPO_0003340|http://purl.obolibrary.org/obo/TXPO_0003317,,,,,,,,,,,,,,,,,,TXPO:0003291,,,,,,,,,,,,,,,,,,,,,,diabetic retinopathy course,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003298,cell division [Hypertrophy],,"The process resulting in division and partitioning of components of a cell to form more cells.
This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy.",false,,,http://purl.obolibrary.org/obo/GO_0051301|http://purl.obolibrary.org/obo/TXPO_0003279,,,,,,,,,,,,,,,,,,,,,,"The process resulting in division and partitioning of components of a cell to form more cells.
This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003319,,,,,,,,,,,TXPO:0003298,,,,,,,,,,,,,,,,,,,,,,cell division [Hypertrophy],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003299,water accumulation [Hypertrophy],,"A process of liquid water accumulation in a particular location in an organism, tissue or cell.
This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy.",false,,,http://purl.obolibrary.org/obo/TXPO_0001216|http://purl.obolibrary.org/obo/TXPO_0003279,,,,,,,,,,,,,,,,,,,,,,"A process of liquid water accumulation in a particular location in an organism, tissue or cell.
This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003309|http://purl.obolibrary.org/obo/TXPO_0003316,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003297,,,,,,,,,,,TXPO:0003299,,,,,,,,,,,,,,,,,,,,,,water accumulation [Hypertrophy],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000182,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003295,retinal degeneration [Diabetic retinopathy],,"Retinal degeneration is a subtype of changing material: A process that degenerates retinal photoreceptors and pigmented epithelial cells.
This entity is a specific course-dependent process. This process can constitute the course of Diabetic retinopathy.",false,,,http://purl.obolibrary.org/obo/TXPO_0001470|http://purl.obolibrary.org/obo/TXPO_0003342,,,,,,,,,,,,,,,,,,,,,,"Retinal degeneration is a subtype of changing material: A process that degenerates retinal photoreceptors and pigmented epithelial cells.
This entity is a specific course-dependent process. This process can constitute the course of Diabetic retinopathy.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003295,,,,,,,,,,,,,,,,,,,,,,retinal degeneration [Diabetic retinopathy],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001097,transportin SR,,,false,,,http://purl.obolibrary.org/obo/IMR_0100010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001097,,,,,,,,,,,,,,,,,,,,,,transportin SR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000393,membrane phospholipid catabolic process,,Membrane phospholipid catabolic process is a subtype of lipid catabolic process: The chemical reactions resulting in the breakdown of membrane phopholipids,false,,,http://purl.obolibrary.org/obo/GO_0009395,,,,,,,,,,,,,,,,,,,,,,Membrane phospholipid catabolic process is a subtype of lipid catabolic process: The chemical reactions resulting in the breakdown of membrane phopholipids,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_16247,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000393,,,,,,,,,,,,,,,,,,,,,,membrane phospholipid catabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000895,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000390,converting signal to information [ER stress],,"Converting signal to information is a subtype of converting to information: A process that changes a signal to information.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000389|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"Converting signal to information is a subtype of converting to information: A process that changes a signal to information.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000390,,,,,,,,,,,,,,,,,,,,,,converting signal to information [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000395,increasing quantity,,Increasing quantity is a subtype of changing quantity: A process that changes the magnitude of the object to be larger.,false,,,http://purl.obolibrary.org/obo/TXPO_0000394,,,,,,,,,,,,,,,,,,,,,,Increasing quantity is a subtype of changing quantity: A process that changes the magnitude of the object to be larger.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000395,,,,,,,,,,,,,,,,,,,,,,increasing quantity,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0000470,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000397,decreasing production quantity of protein [ER stress],,"Decreasing production quantity of protein is a subtype of decreasing quantity: A process that changes the production quantity of the protein to be lower.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/TXPO_0001830,,,,,,,,,,,,,,,,,,,,,,"Decreasing production quantity of protein is a subtype of decreasing quantity: A process that changes the production quantity of the protein to be lower.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000397,,,,,,,,,,,,,,,,,,,,,,decreasing production quantity of protein [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000394,changing quantity,,Changing quantity is a subtype of changing attribute: A process that changes the amount of the object as an output.,false,,,http://purl.obolibrary.org/obo/TXPO_0000392,,,,,,,,,,,,,,,,,,,,,,Changing quantity is a subtype of changing attribute: A process that changes the amount of the object as an output.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000394,,,,,,,,,,,,,,,,,,,,,,changing quantity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000391,converting signal to information [Cell death],,"Converting signal to information is a subtype of converting to information: A process that changes a signal to information.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0000389|http://purl.obolibrary.org/obo/TXPO_0001727,,,,,,,,,,,,,,,,,,,,,,"Converting signal to information is a subtype of converting to information: A process that changes a signal to information.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000391,,,,,,,,,,,,,,,,,,,,,,converting signal to information [Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000396,decreasing quantity,,Decreasing quantity is a subtype of changing quantity: A process that changes the magnitude of the object to be smaller.,false,,,http://purl.obolibrary.org/obo/TXPO_0000394,,,,,,,,,,,,,,,,,,,,,,Decreasing quantity is a subtype of changing quantity: A process that changes the magnitude of the object to be smaller.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000396,,,,,,,,,,,,,,,,,,,,,,decreasing quantity,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002450,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000399,gene expression [Cell death],,"The process in which a gene's sequence is converted into a mature gene product or products (proteins or RNA). This includes the production of an RNA transcript as well as any processing to produce a mature RNA product or an mRNA or circRNA (for protein-coding genes) and the translation of that mRNA or circRNA into protein. Protein maturation is included when required to form an active form of a product from an inactive precursor form.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/GO_0010467,,,,,,,,,,,,,,,,,,,,,,"The process in which a gene's sequence is converted into a mature gene product or products (proteins or RNA). This includes the production of an RNA transcript as well as any processing to produce a mature RNA product or an mRNA or circRNA (for protein-coding genes) and the translation of that mRNA or circRNA into protein. Protein maturation is included when required to form an active form of a product from an inactive precursor form.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000399,,,,,,,,,,,,,,,,,,,,,,gene expression [Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000392,changing an operand,,Changing an operand is a subtype of changing: A process that makes one object different.,false,,,http://purl.obolibrary.org/obo/TXPO_0000387,,,,,,,,,,,,,,,,,,,,,,Changing an operand is a subtype of changing: A process that makes one object different.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000392,,,,,,,,,,,,,,,,,,,,,,changing an operand,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000398,hyperfunction of hypoxia resonsive gene expression,,Hyperfunction of hypoxia resonsive gene expression is a subtype of hyperfunction of gene expression: A process that performs an excesssive hypoxia resonsive gene expression.,false,,,http://purl.obolibrary.org/obo/TXPO_0002345,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of hypoxia resonsive gene expression is a subtype of hyperfunction of gene expression: A process that performs an excesssive hypoxia resonsive gene expression.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000398,,,,,,,,,,,,,,,,,,,,,,hyperfunction of hypoxia resonsive gene expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000161253,REM2,,Other designations: GTP-binding protein REM 2|Rad and Gem-related 2 (rat homolog)|rad and Gem-like GTP-binding protein 2,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,14,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,RAS (RAD and GEM)-like GTP binding 2,,,14q11.2,,,,,,,,,,,,,,,,GO_0003924 (EC: IEA); GO_0005525 (EC: IEA); GO_0005886 (EC: IEA); GO_0007264 (EC: IEA),,,,,,,,,PMID: 10727423; 11181995; 12477932; 14702039; 15489334; 15728182; 18056257; 20231315; 21044950; 21485012; 21980534; 22815963,,,,,,,,,,,,,,,OGG:3000161253,,,,,,,RAS (RAD and GEM)-like GTP binding 2,,,,,,,,,,,,,Other designations: GTP-binding protein REM 2|Rad and Gem-related 2 (rat homolog)|rad and Gem-like GTP-binding protein 2,,REM2,,,,,,,,,,,,,,,,,,,,,,,161253,hCG_41987,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,REM2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/GO_0030730,sequestering of triglyceride,retention of triacylglycerol|triacylglycerol sequestering|triglyceride storage|retention of triglyceride|triacylglycerol sequestration|triacylglycerol storage|sequestering of triacylglycerol,The process of binding or confining any triester of glycerol such that it is separated from other components of a biological system.,false,,,http://purl.obolibrary.org/obo/GO_0019915,,,,,,,,,,,,,,,,,,,,GO:0030730,,The process of binding or confining any triester of glycerol such that it is separated from other components of a biological system.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_17855,,,,,,,,,,,,,,,,,,retention of triacylglycerol|triacylglycerol sequestering|triglyceride storage|retention of triglyceride|triacylglycerol sequestration|triacylglycerol storage|sequestering of triacylglycerol,,,,,GO:0030730,,,,,,,,,,,,,,,,,,,,,,sequestering of triglyceride,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000822,MafG,,,false,,,http://purl.obolibrary.org/obo/IMR_0000411,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000822,,,,,,,,,,,,,,,,,,,,,,MafG,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0002423,hepatobiliary system,liver/biliary system|liver and biliary system|hepaticobiliary system,The part of the digestive system that contains the liver and the biliary system,false,,,http://purl.obolibrary.org/obo/UBERON_0011216,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C43612|http://linkedlifedata.com/resource/umls/id/C1711359|http://en.wikipedia.org/wiki/Hepatobiliary_system|AAO:0011056|XAO:0000132|EHDAA:2189|MAT:0000024|EMAPA:16840|EV:0100088|TAO:0000036|CALOHA:TS-1308|MA:0000324|EFO:0000800|ZFA:0000036|UMLS:C1711359|MIAA:0000024|VHOG:0000294|EHDAA2:0000998,,The part of the digestive system that contains the liver and the biliary system,,,,,,,,System responsible for the production and movement of bile[ZFIN:curator].,,,,,,,"The hepaticobiliary system is responsible for metabolic and catabolic processing of small molecules absorbed from the blood or gut, hormones and serum proteins, detoxification, storage of glycogen, triglycerides, metals and lipid soluble vitamins and excretion of bile. Included are the synthesis of albumin, blood coagulation factors, complement, and specific binding proteins. The parts are: liver, bile duct, gall bladder and hepatic duct [GO:0061008]",,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002294|http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,liver and biliary system|hepaticobiliary system,,liver/biliary system,,http://purl.obolibrary.org/obo/UBERON_0001007,UBERON:0002423,http://purl.obolibrary.org/obo/UBERON_0001007,,,,,,,,,,,,,,,,,,,,,hepatobiliary system,,,,,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000222,Syk,Spleen tyrosine kinase,,false,,,http://purl.obolibrary.org/obo/IMR_0000220,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Spleen tyrosine kinase,,,,,IMR:0000222,,,,,,,,,,,,,,,,,,,,,,Syk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_60832,tubulin modulator,tubulin modulators,Any substance that interacts with tubulin to inhibit or promote polymerisation of microtubules.,false,,,http://purl.obolibrary.org/obo/CHEBI_52210,,,,,,,,,,,,,,,,,,,,,,Any substance that interacts with tubulin to inhibit or promote polymerisation of microtubules.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,tubulin modulators,,,,,,,,,,,,,,,,,,,,,CHEBI:60832,,,,tubulin modulator,,CHEBI:60832,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000056648,EIF5A2,,Other designations: eIF-5A-2|eukaryotic initiation factor 5A|eukaryotic translation initiation factor 5A-2,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,EIF-5A2|eIF5AII,,,,,,,,,,,,3,,,,,,Ensembl:ENSG00000163577|Vega:OTTHUMG00000158958|HGNC:3301|MIM:605782|HPRD:10426,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,eukaryotic translation initiation factor 5A2,,,3q26.2,,,,,,,,,,,,,,,,"GO_0003746 (EC: IEA); GO_0005515 (EC: IPI, PMID:14622290); GO_0005643 (EC: IEA); GO_0005789 (EC: IEA); GO_0005829 (EC: TAS); GO_0006452 (EC: IEA); GO_0007283 (EC: NAS, PMID:11161802); GO_0008284 (EC: IGI, PMID:14622290); GO_0008612 (EC: TAS); GO_0010509 (EC: NAS, PMID:11161802); GO_0015031 (EC: IEA); GO_0043022 (EC: IEA); GO_0043687 (EC: TAS); GO_0044267 (EC: TAS); GO_0045901 (EC: IEA); GO_0045905 (EC: IEA); GO_0051028 (EC: IEA)",,,,,,,,,PMID:11161802; 11325856; 12477932; 14622290; 15205331; 15489334; 15635413; 16169419; 16189514; 16452303; 16519677; 16916647; 17876542; 17949776; 19054548; 19155439; 19298601; 20112425; 20434207; 20639865; 21139048; 21145461; 21319273; 21813470; 21890473; 21903422; 21906983; 21942715; 21963094; 21988832; 22053931; 22505724; 22927971; 23000965,,,,,,,,,,,,,,,OGG:3000056648,,,,,,,eukaryotic translation initiation factor 5A2,,,,,,,,,,,,,Other designations: eIF-5A-2|eukaryotic initiation factor 5A|eukaryotic translation initiation factor 5A-2,,EIF5A2,,,,,,,,,,,,,,,,,,,,,,,56648,,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF5A2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0100258,SLP-76 family,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003684,,,,,,,,,,IMR:0100258,,,,,,,,,,,,,,,,,,,,,,SLP-76 family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100150,angiotensin II,,,false,,,http://purl.obolibrary.org/obo/IMR_0100149,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100150,,,,,,,,,,,,,,,,,,,,,,angiotensin II,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0051276,chromosome organization,,"A process that is carried out at the cellular level that results in the assembly, arrangement of constituent parts, or disassembly of chromosomes, structures composed of a very long molecule of DNA and associated proteins that carries hereditary information. This term covers covalent modifications at the molecular level as well as spatial relationships among the major components of a chromosome.",false,,,http://purl.obolibrary.org/obo/TXPO_0002566,,,,,,,,,,,,,,,,,,,,,,"A process that is carried out at the cellular level that results in the assembly, arrangement of constituent parts, or disassembly of chromosomes, structures composed of a very long molecule of DNA and associated proteins that carries hereditary information. This term covers covalent modifications at the molecular level as well as spatial relationships among the major components of a chromosome.",,,,,chromosome organization,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0051276,,,,,,,,,,,,,,,,,,,,,,chromosome organization,,,,,,,http://purl.obolibrary.org/obo/go.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002250,fibrosis inhibitor,,Any substance that inhibits the process of fibrosis.,false,,,http://purl.obolibrary.org/obo/TXPO_0003230,,,,,,,,,,,,,,,,,,,,,,Any substance that inhibits the process of fibrosis.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002250,,,,,,,,,,,,,,,,,,,,,,fibrosis inhibitor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002255,positive regulation of phospholipid catabolic process [phopholipidosis - normal],,"Any process that increases the rate, frequency, or extent of phospholipid catabolism, the chemical reactions and pathways resulting in the breakdown of phospholipids, any lipid containing phosphoric acid as a mono- or diester.
This entity is a specific course-dependent process. This process can constitute the course of phospholipidosis.",false,,,http://purl.obolibrary.org/obo/GO_0060697|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Any process that increases the rate, frequency, or extent of phospholipid catabolism, the chemical reactions and pathways resulting in the breakdown of phospholipids, any lipid containing phosphoric acid as a mono- or diester.
This entity is a specific course-dependent process. This process can constitute the course of phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002257,,,,,,,,,,,,,,,,,,TXPO:0002255,,,,,,,,,,,,,,,,,,,,,,positive regulation of phospholipid catabolic process [phopholipidosis - normal],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002251,Gadd45a - fibrosis inhibitor (rat)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001158,,,,,,,,,,,,,,,,,,,,http://omim.org/entry/126335|PMID:26973416|PMID:10779360|PMID:10747892|PMID:24104470,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002250,,,,,,,,,,TXPO:0002251,,,,,,,,,,,,,,,,,,,,,,Gadd45a - fibrosis inhibitor (rat)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001850,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002259,keeping acidic environment in lysosome,,Keeping acidic environment in lysosome is a subtype of keeping quality: A process that maintains  the acidic environment within  the interior of the lysosomes.,false,,,http://purl.obolibrary.org/obo/TXPO_0000474,,,,,,,,,,,,,,,,,,,,,,Keeping acidic environment in lysosome is a subtype of keeping quality: A process that maintains  the acidic environment within  the interior of the lysosomes.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002259,,,,,,,,,,,,,,,,,,,,,,keeping acidic environment in lysosome,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005764,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002257,hyperfunction of phospholipase gene expression [Phospholipidosis],,"Hyperfunction of phospholipase gene expression is a subtype of hyperfunction of gene expression: A process that performs an excesssive phospholipase gene expression.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0002256,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of phospholipase gene expression is a subtype of hyperfunction of gene expression: A process that performs an excesssive phospholipase gene expression.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003384,,,,,,,,,,,TXPO:0002257,,,,,,,,,,,,,,,,,,,,,,hyperfunction of phospholipase gene expression [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002256,hyperfunction of phospholipase gene expression,,Hyperfunction of phospholipase gene expression is a subtype of hyperfunction of gene expression: A process that performs an excesssive phospholipase gene expression.,false,,,http://purl.obolibrary.org/obo/TXPO_0002345,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of phospholipase gene expression is a subtype of hyperfunction of gene expression: A process that performs an excesssive phospholipase gene expression.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002256,,,,,,,,,,,,,,,,,,,,,,hyperfunction of phospholipase gene expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002253,decreasing CAD in lysosomal membranes,,Decreasing CAD in lysosomal membranes is a subtype of decreasing quantity: A process that changes the quantity of the Cationic Amphiphilic Drugs (CAD) in lysosomal membranes to be smaller.,false,,,http://purl.obolibrary.org/obo/TXPO_0000396,,,,,,,,,,,,,,,,,,,,,,Decreasing CAD in lysosomal membranes is a subtype of decreasing quantity: A process that changes the quantity of the Cationic Amphiphilic Drugs (CAD) in lysosomal membranes to be smaller.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002253,,,,,,,,,,,,,,,,,,,,,,decreasing CAD in lysosomal membranes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002252,decreasing CAD in lysosomal membranes [Phospholipidosis],,"Decreasing CAD in lysosomal membranes is a subtype of decreasing quantity: A process that changes the quantity of the Cationic Amphiphilic Drugs (CAD) in lysosomal membranes to be smaller.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0002253,,,,,,,,,,,,,,,,,,,,,,"Decreasing CAD in lysosomal membranes is a subtype of decreasing quantity: A process that changes the quantity of the Cationic Amphiphilic Drugs (CAD) in lysosomal membranes to be smaller.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002252,,,,,,,,,,,,,,,,,,,,,,decreasing CAD in lysosomal membranes [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002254,glutathione synthetic gene expression [Glutathione depletion],,"glutathione synthetic gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature  gene product or products (proteins or RNA) involved in glutathione synthesis.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0002224|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"glutathione synthetic gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature  gene product or products (proteins or RNA) involved in glutathione synthesis.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002392,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000193|http://purl.obolibrary.org/obo/TXPO_0002453,,,,,,http://purl.obolibrary.org/obo/TXPO_0001933,,,,,,,,,,,TXPO:0002254,,,,,,,,,,,,,,,,,,,,,,glutathione synthetic gene expression [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002258,keeping acidic environment in lysosome [Phospholipidosis],,"Keeping acidic environment in lysosome is a subtype of keeping quality: A process that maintains the acidic environment within the interior of the lysosomes.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0002259,,,,,,,,,,,,,,,,,,,,,,"Keeping acidic environment in lysosome is a subtype of keeping quality: A process that maintains the acidic environment within the interior of the lysosomes.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002258,,,,,,,,,,,,,,,,,,,,,,keeping acidic environment in lysosome [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005764,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000821,MafF,,,false,,,http://purl.obolibrary.org/obo/IMR_0000411,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000821,,,,,,,,,,,,,,,,,,,,,,MafF,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0001115,left lobe of liver,liver left lobe|lobus hepaticus sinister|left liver lobe,The left lobe is smaller and more flattened than the right. It is situated in the epigastric and left hypochondriac regions. Its upper surface is slightly convex and is moulded on to the diaphragm; its under surface presents the gastric impression and omental tuberosity.,false,,,http://purl.obolibrary.org/obo/UBERON_0001113,,,,,,,,,,,,,,,,,,,,http://www.snomedbrowser.com/Codes/Details/362183003|FMA:13363|http://en.wikipedia.org/wiki/Left_lobe_of_liver,,The left lobe is smaller and more flattened than the right. It is situated in the epigastric and left hypochondriac regions. Its upper surface is slightly convex and is moulded on to the diaphragm; its under surface presents the gastric impression and omental tuberosity.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,liver left lobe|lobus hepaticus sinister|left liver lobe,,,,,UBERON:0001115,,,,,,,,,,,,,,,,,,,,,,left lobe of liver,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0001113,lobe of liver,liver lobe|hepatic lobe|lobus hepatis,"Traditional gross anatomy divided the liver into four lobes based on surface features. The falciform ligament is visible on the front (anterior side) of the liver. This divides the liver into a left anatomical lobe, and a right anatomical lobe.",false,,,http://purl.obolibrary.org/obo/BFO_0000024,,,,,,,,,,,,,,,,,,,,UMLS:C0447541|FMA:13361,,"Traditional gross anatomy divided the liver into four lobes based on surface features. The falciform ligament is visible on the front (anterior side) of the liver. This divides the liver into a left anatomical lobe, and a right anatomical lobe.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,liver lobe|hepatic lobe|lobus hepatis,,,,http://purl.obolibrary.org/obo/UBERON_0002107,UBERON:0001113,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,lobe of liver,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100367,G-alpha-olf,,,false,,,http://purl.obolibrary.org/obo/IMR_0000317,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100367,,,,,,,,,,,,,,,,,,,,,,G-alpha-olf,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004285,cytoskeletal protein production,,"cytoskeletal protein production is a subtype of protein production: A process that makes existent of cytoskeletal protein due to biosynthesis, secretion, or membrane trafficking, resulting in an increase in its levels.",false,,,http://purl.obolibrary.org/obo/TXPO_0000382,,,,,,,,,,,,,,,,,,,,,,"cytoskeletal protein production is a subtype of protein production: A process that makes existent of cytoskeletal protein due to biosynthesis, secretion, or membrane trafficking, resulting in an increase in its levels.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004285,,,,,,,,,,,,,,,,,,,,,,cytoskeletal protein production,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004280,hepatocarcinogenesis  [toxic course],,The totality of all processes through which hepatocarcinogenesis is realized.|under construction,false,,,http://purl.obolibrary.org/obo/TXPO_0000009,,,,,,,,,,,,,,,,,,,,,,The totality of all processes through which hepatocarcinogenesis is realized.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004764|http://purl.obolibrary.org/obo/TXPO_0004703|http://purl.obolibrary.org/obo/TXPO_0004689|http://purl.obolibrary.org/obo/TXPO_0004683|http://purl.obolibrary.org/obo/TXPO_0004681|http://purl.obolibrary.org/obo/TXPO_0004686|http://purl.obolibrary.org/obo/TXPO_0004536|http://purl.obolibrary.org/obo/TXPO_0004538|http://purl.obolibrary.org/obo/TXPO_0004487|http://purl.obolibrary.org/obo/TXPO_0004480|http://purl.obolibrary.org/obo/TXPO_0004483|http://purl.obolibrary.org/obo/TXPO_0004489|http://purl.obolibrary.org/obo/TXPO_0004949|http://purl.obolibrary.org/obo/TXPO_0004899|http://purl.obolibrary.org/obo/TXPO_0004459|http://purl.obolibrary.org/obo/TXPO_0004452|http://purl.obolibrary.org/obo/TXPO_0004453|http://purl.obolibrary.org/obo/TXPO_0004457|http://purl.obolibrary.org/obo/TXPO_0004585|http://purl.obolibrary.org/obo/TXPO_0004588|http://purl.obolibrary.org/obo/TXPO_0004586|http://purl.obolibrary.org/obo/TXPO_0004587|http://purl.obolibrary.org/obo/TXPO_0004582|http://purl.obolibrary.org/obo/TXPO_0004589|http://purl.obolibrary.org/obo/TXPO_0004404|http://purl.obolibrary.org/obo/TXPO_0004407|http://purl.obolibrary.org/obo/TXPO_0004409|http://purl.obolibrary.org/obo/TXPO_0004403|http://purl.obolibrary.org/obo/TXPO_0004402|http://purl.obolibrary.org/obo/TXPO_0004400|http://purl.obolibrary.org/obo/TXPO_0004728|http://purl.obolibrary.org/obo/TXPO_0004497|http://purl.obolibrary.org/obo/TXPO_0004491|http://purl.obolibrary.org/obo/TXPO_0004492|http://purl.obolibrary.org/obo/TXPO_0004479|http://purl.obolibrary.org/obo/TXPO_0004470|http://purl.obolibrary.org/obo/TXPO_0004477|http://purl.obolibrary.org/obo/TXPO_0004476|http://purl.obolibrary.org/obo/TXPO_0004309|http://purl.obolibrary.org/obo/TXPO_0004276|http://purl.obolibrary.org/obo/TXPO_0004609|http://purl.obolibrary.org/obo/TXPO_0004600|http://purl.obolibrary.org/obo/TXPO_0004603|http://purl.obolibrary.org/obo/TXPO_0004507|http://purl.obolibrary.org/obo/TXPO_0004506|http://purl.obolibrary.org/obo/TXPO_0004501|http://purl.obolibrary.org/obo/TXPO_0004508|http://purl.obolibrary.org/obo/TXPO_0004505|http://purl.obolibrary.org/obo/TXPO_0004735|http://purl.obolibrary.org/obo/TXPO_0004738|http://purl.obolibrary.org/obo/TXPO_0004731|http://purl.obolibrary.org/obo/TXPO_0005026|http://purl.obolibrary.org/obo/TXPO_0005022|http://purl.obolibrary.org/obo/TXPO_0004874|http://purl.obolibrary.org/obo/TXPO_0004753|http://purl.obolibrary.org/obo/TXPO_0004758|http://purl.obolibrary.org/obo/TXPO_0004759|http://purl.obolibrary.org/obo/TXPO_0004755|http://purl.obolibrary.org/obo/TXPO_0004757|http://purl.obolibrary.org/obo/TXPO_0004854|http://purl.obolibrary.org/obo/TXPO_0005005|http://purl.obolibrary.org/obo/TXPO_0004577|http://purl.obolibrary.org/obo/TXPO_0004579|http://purl.obolibrary.org/obo/TXPO_0004570|http://purl.obolibrary.org/obo/TXPO_0004574|http://purl.obolibrary.org/obo/TXPO_0004773|http://purl.obolibrary.org/obo/TXPO_0004776|http://purl.obolibrary.org/obo/TXPO_0004779|http://purl.obolibrary.org/obo/TXPO_0004673|http://purl.obolibrary.org/obo/TXPO_0004679|http://purl.obolibrary.org/obo/TXPO_0004745|http://purl.obolibrary.org/obo/TXPO_0004749|http://purl.obolibrary.org/obo/TXPO_0004803|http://purl.obolibrary.org/obo/TXPO_0004809|http://purl.obolibrary.org/obo/TXPO_0004800|http://purl.obolibrary.org/obo/TXPO_0004431|http://purl.obolibrary.org/obo/TXPO_0004438|http://purl.obolibrary.org/obo/TXPO_0004434|http://purl.obolibrary.org/obo/TXPO_0004432|http://purl.obolibrary.org/obo/TXPO_0004661|http://purl.obolibrary.org/obo/TXPO_0004669|http://purl.obolibrary.org/obo/TXPO_0004664|http://purl.obolibrary.org/obo/TXPO_0004566|http://purl.obolibrary.org/obo/TXPO_0004845|http://purl.obolibrary.org/obo/TXPO_0004844|http://purl.obolibrary.org/obo/TXPO_0004847|http://purl.obolibrary.org/obo/TXPO_0004841|http://purl.obolibrary.org/obo/TXPO_0004417|http://purl.obolibrary.org/obo/TXPO_0004419|http://purl.obolibrary.org/obo/TXPO_0004414|http://purl.obolibrary.org/obo/TXPO_0004413|http://purl.obolibrary.org/obo/TXPO_0004410|http://purl.obolibrary.org/obo/TXPO_0004412|http://purl.obolibrary.org/obo/TXPO_0004418|http://purl.obolibrary.org/obo/TXPO_0004289|http://purl.obolibrary.org/obo/TXPO_0004952|http://purl.obolibrary.org/obo/TXPO_0004919|http://purl.obolibrary.org/obo/TXPO_0005014|http://purl.obolibrary.org/obo/TXPO_0005010|http://purl.obolibrary.org/obo/TXPO_0005019|http://purl.obolibrary.org/obo/TXPO_0005017|http://purl.obolibrary.org/obo/TXPO_0004783|http://purl.obolibrary.org/obo/TXPO_0004787|http://purl.obolibrary.org/obo/TXPO_0004789|http://purl.obolibrary.org/obo/TXPO_0004311|http://purl.obolibrary.org/obo/TXPO_0004617|http://purl.obolibrary.org/obo/TXPO_0004616|http://purl.obolibrary.org/obo/TXPO_0004464|http://purl.obolibrary.org/obo/TXPO_0004468|http://purl.obolibrary.org/obo/TXPO_0004421|http://purl.obolibrary.org/obo/TXPO_0004429|http://purl.obolibrary.org/obo/TXPO_0004427|http://purl.obolibrary.org/obo/TXPO_0004422|http://purl.obolibrary.org/obo/TXPO_0004420|http://purl.obolibrary.org/obo/TXPO_0004426|http://purl.obolibrary.org/obo/TXPO_0004518|http://purl.obolibrary.org/obo/TXPO_0004514|http://purl.obolibrary.org/obo/TXPO_0004517|http://purl.obolibrary.org/obo/TXPO_0004512|http://purl.obolibrary.org/obo/TXPO_0004996|http://purl.obolibrary.org/obo/TXPO_0005036|http://purl.obolibrary.org/obo/TXPO_0005035|http://purl.obolibrary.org/obo/TXPO_0005038|http://purl.obolibrary.org/obo/TXPO_0005032|http://purl.obolibrary.org/obo/TXPO_0004883|http://purl.obolibrary.org/obo/TXPO_0004882|http://purl.obolibrary.org/obo/TXPO_0004881|http://purl.obolibrary.org/obo/TXPO_0004627|http://purl.obolibrary.org/obo/TXPO_0004625|http://purl.obolibrary.org/obo/TXPO_0004828|http://purl.obolibrary.org/obo/TXPO_0004825|http://purl.obolibrary.org/obo/TXPO_0004543|http://purl.obolibrary.org/obo/TXPO_0004541|http://purl.obolibrary.org/obo/TXPO_0004546|http://purl.obolibrary.org/obo/TXPO_0004542|http://purl.obolibrary.org/obo/TXPO_0004640|http://purl.obolibrary.org/obo/TXPO_0004646|http://purl.obolibrary.org/obo/TXPO_0004643|http://purl.obolibrary.org/obo/TXPO_0004837|http://purl.obolibrary.org/obo/TXPO_0004834|http://purl.obolibrary.org/obo/TXPO_0004791|http://purl.obolibrary.org/obo/TXPO_0004793|http://purl.obolibrary.org/obo/TXPO_0004794|http://purl.obolibrary.org/obo/TXPO_0004597|http://purl.obolibrary.org/obo/TXPO_0004591|http://purl.obolibrary.org/obo/TXPO_0004590|http://purl.obolibrary.org/obo/TXPO_0004595|http://purl.obolibrary.org/obo/TXPO_0004598|http://purl.obolibrary.org/obo/TXPO_0004596|http://purl.obolibrary.org/obo/TXPO_0004593|http://purl.obolibrary.org/obo/TXPO_0004592|http://purl.obolibrary.org/obo/TXPO_0004901|http://purl.obolibrary.org/obo/TXPO_0004908|http://purl.obolibrary.org/obo/TXPO_0004633|http://purl.obolibrary.org/obo/TXPO_0004634|http://purl.obolibrary.org/obo/TXPO_0004636|http://purl.obolibrary.org/obo/TXPO_0004630|http://purl.obolibrary.org/obo/TXPO_0004555|http://purl.obolibrary.org/obo/TXPO_0004557|http://purl.obolibrary.org/obo/TXPO_0005051|http://purl.obolibrary.org/obo/TXPO_0004447|http://purl.obolibrary.org/obo/TXPO_0004923|http://purl.obolibrary.org/obo/TXPO_0004929|http://purl.obolibrary.org/obo/TXPO_0004963|http://purl.obolibrary.org/obo/TXPO_0004818|http://purl.obolibrary.org/obo/TXPO_0004816|http://purl.obolibrary.org/obo/TXPO_0004299|http://purl.obolibrary.org/obo/TXPO_0004298|http://purl.obolibrary.org/obo/TXPO_0004522|http://purl.obolibrary.org/obo/TXPO_0004525|http://purl.obolibrary.org/obo/TXPO_0004526|http://purl.obolibrary.org/obo/TXPO_0004529|http://purl.obolibrary.org/obo/TXPO_0004693|http://purl.obolibrary.org/obo/TXPO_0004695|http://purl.obolibrary.org/obo/TXPO_0004698|http://purl.obolibrary.org/obo/TXPO_0004652|http://purl.obolibrary.org/obo/TXPO_0004650|http://purl.obolibrary.org/obo/TXPO_0004655|http://purl.obolibrary.org/obo/TXPO_0004659|http://purl.obolibrary.org/obo/TXPO_0004656|http://purl.obolibrary.org/obo/TXPO_0004396|http://purl.obolibrary.org/obo/TXPO_0004394|http://purl.obolibrary.org/obo/TXPO_0004391|http://purl.obolibrary.org/obo/TXPO_0004392|http://purl.obolibrary.org/obo/TXPO_0004395,,,,,,,,,,,,,,,,,,TXPO:0004280,,,,,,,,,,,,,,,,,,,,under construction,,hepatocarcinogenesis  [toxic course],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004283,Collagen production,,"Collagen production is a subtype of scleroprotein production: A process that makes existent of collagen due to biosynthesis, secretion, or membrane trafficking, resulting in an increase in its levels.",false,,,http://purl.obolibrary.org/obo/TXPO_0004282,,,,,,,,,,,,,,,,,,,,,,"Collagen production is a subtype of scleroprotein production: A process that makes existent of collagen due to biosynthesis, secretion, or membrane trafficking, resulting in an increase in its levels.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004283,,,,,,,,,,,,,,,,,,,,,,Collagen production,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004281,liver malfunction  [mitochondrial disorder],,"Liver malfunction is a subtype of organ malfunction: A process that does not perform liver function correctly or not functioning at all.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0002074|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:25339807|PMID:26571396|PMID:29222479,,"Liver malfunction is a subtype of organ malfunction: A process that does not perform liver function correctly or not functioning at all.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004281,,,,,,,,,,,,,,,,,,,,,,liver malfunction  [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004282,Scleroprotein production,,"Scleroprotein production is a subtype of protein production: A process that makes existent of scleroprotein due to biosynthesis, secretion, or membrane trafficking, resulting in an increase in its levels.",false,,,http://purl.obolibrary.org/obo/TXPO_0000382,,,,,,,,,,,,,,,,,,,,,,"Scleroprotein production is a subtype of protein production: A process that makes existent of scleroprotein due to biosynthesis, secretion, or membrane trafficking, resulting in an increase in its levels.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004282,,,,,,,,,,,,,,,,,,,,,,Scleroprotein production,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004287,ACTA2 production,,"ACTA2 production is a subtype of Actin production: A process that makes existent of ACTA2 due to biosynthesis, secretion, or membrane trafficking, resulting in an increase in its levels.",false,,,http://purl.obolibrary.org/obo/TXPO_0004286,,,,,,,,,,,,,,,,,,,,,,"ACTA2 production is a subtype of Actin production: A process that makes existent of ACTA2 due to biosynthesis, secretion, or membrane trafficking, resulting in an increase in its levels.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004287,,,,,,,,,,,,,,,,,,,,,,ACTA2 production,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004284,COL1A1 production,,"COL1A1 production is a subtype of collagen production: A process that makes existent of a ollagen due to biosynthesis, secretion, or membrane trafficking, resulting in an increase in its levels.",false,,,http://purl.obolibrary.org/obo/TXPO_0004283,,,,,,,,,,,,,,,,,,,,,,"COL1A1 production is a subtype of collagen production: A process that makes existent of a ollagen due to biosynthesis, secretion, or membrane trafficking, resulting in an increase in its levels.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004284,,,,,,,,,,,,,,,,,,,,,,COL1A1 production,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004288,chemokine (C-C motif) ligand 2 production,CCL2 production,"The appearance of chemokine (C-C motif) ligand 2 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.",false,,,http://purl.obolibrary.org/obo/GO_0032602,,,,,,,,,,,,,,,,,,,,,,"The appearance of chemokine (C-C motif) ligand 2 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CCL2 production,,,,,TXPO:0004288,,,,,,,,,,,,,,,,,,,,,,chemokine (C-C motif) ligand 2 production,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004286,actin production,,"Actin production is a subtype of cytoskeletal protein  production: A process that makes existent of actin due to biosynthesis, secretion, or membrane trafficking, resulting in an increase in its levels.",false,,,http://purl.obolibrary.org/obo/TXPO_0004285,,,,,,,,,,,,,,,,,,,,,,"Actin production is a subtype of cytoskeletal protein  production: A process that makes existent of actin due to biosynthesis, secretion, or membrane trafficking, resulting in an increase in its levels.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004286,,,,,,,,,,,,,,,,,,,,,,actin production,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004289,CCL2 production [Hepatocarcinogenesis],,"The appearance of chemokine (C-C motif) ligand 2 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004288,,,,,,,,,,,,,,,,,,,,PMID:30894684,,"The appearance of chemokine (C-C motif) ligand 2 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004291,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004299,,,,,,,,,,,TXPO:0004289,,,,,,,,,,,,,,,,,,,,,,CCL2 production [Hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003590,changing cell homeostasis [Phospholipidosis],,"Changing cell homeostasis is a subtype of changing balance: A process that changes the steady state of cell within an organ or an organism.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003551|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Changing cell homeostasis is a subtype of changing balance: A process that changes the steady state of cell within an organ or an organism.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003590,,,,,,,,,,,,,,,,,,,,,,changing cell homeostasis [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003592,increasing energy [Phospholipidosis(severe)],,"Increasing energy is a subtype of increasing quantity: A process that changes the amount of energy to be larger.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",false,,,http://purl.obolibrary.org/obo/TXPO_0000144|http://purl.obolibrary.org/obo/TXPO_0003593,,,,,,,,,,,,,,,,,,,,,,"Increasing energy is a subtype of increasing quantity: A process that changes the amount of energy to be larger.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004065,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003594,,,,,,,,,,,TXPO:0003592,,,,,,,,,,,,,,,,,,,,,,increasing energy [Phospholipidosis(severe)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003595,energy supply [Phospholipidosis],,"Energy supply is a subtype of providing process to perform a meta-function “to provide energy.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0004077|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Energy supply is a subtype of providing process to perform a meta-function “to provide energy.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004137,,,,,,,,,,,,,,,,,,TXPO:0003595,,,,,,,,,,,,,,,,,,,,,,energy supply [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003599,ceramide -phopholipid metabolite [Phospholipidosis - positive regulation of apoptosis],,,false,,,http://purl.obolibrary.org/obo/CHEBI_17761|http://purl.obolibrary.org/obo/TXPO_0001849,,,,,,,,,,,,,,,,,,,,PMID:29147025,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003600,,,,,,,,,,TXPO:0003599,,,,,,,,,,,,,,,,,,,,,,ceramide -phopholipid metabolite [Phospholipidosis - positive regulation of apoptosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003596,increasing number of dead cells in liver [Phosholipidosis],,"Increasing number of dead cells in liver is a subtype of cell proliferation: A process that becomes larger in the number of dead cells in the liver.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",false,,,http://purl.obolibrary.org/obo/TXPO_0000341|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Increasing number of dead cells in liver is a subtype of cell proliferation: A process that becomes larger in the number of dead cells in the liver.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003547|http://purl.obolibrary.org/obo/TXPO_0002276,,,,,,,,,,,TXPO:0003596,,,,,,,,,,,,,,,,,,,,,,increasing number of dead cells in liver [Phosholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003593,increasing energy [Phospholipidosis],,"Increasing energy is a subtype of increasing quantity: A process that changes the amount of energy to be larger.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000144|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Increasing energy is a subtype of increasing quantity: A process that changes the amount of energy to be larger.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003593,,,,,,,,,,,,,,,,,,,,,,increasing energy [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003594,energy supply [Phospholipidosis(severe)],,"Energy supply is a subtype of providing process to perform a meta-function “to provide energy.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",false,,,http://purl.obolibrary.org/obo/TXPO_0004077|http://purl.obolibrary.org/obo/TXPO_0003595,,,,,,,,,,,,,,,,,,,,,,"Energy supply is a subtype of providing process to perform a meta-function “to provide energy.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003592,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002245,,,,,,,,,,,TXPO:0003594,,,,,,,,,,,,,,,,,,,,,,energy supply [Phospholipidosis(severe)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003591,maintaining cell homeostasis [Phospholiipidosis],,"Any process involved in the maintenance of an internal steady state of cell within an organ or an organism.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003552|http://purl.obolibrary.org/obo/TXPO_0003590,,,,,,,,,,,,,,,,,,,,,,"Any process involved in the maintenance of an internal steady state of cell within an organ or an organism.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003591,,,,,,,,,,,,,,,,,,,,,,maintaining cell homeostasis [Phospholiipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003597,cell survival-cell death imbalance [Ground glass appearance],,"Cell survival-cell death imbalance is a subtype is a subtype of imbalance: A process that lacks a balance between cell death and cell survival within an organ or an organism.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0003546|http://purl.obolibrary.org/obo/TXPO_0001728,,,,,,,,,,,,,,,,,,,,,,"Cell survival-cell death imbalance is a subtype is a subtype of imbalance: A process that lacks a balance between cell death and cell survival within an organ or an organism.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003597,,,,,,,,,,,,,,,,,,,,,,cell survival-cell death imbalance [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003598,maintaining cell survival-cell death balance [ER stress],,"Cell survival-cell death imbalance is a subtype is a subtype of imbalance: A process that lacks a balance between cell death and cell survival within an organ or an organism.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0003546|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"Cell survival-cell death imbalance is a subtype is a subtype of imbalance: A process that lacks a balance between cell death and cell survival within an organ or an organism.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003598,,,,,,,,,,,,,,,,,,,,,,maintaining cell survival-cell death balance [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100289,Bid (mol),,,false,,,http://purl.obolibrary.org/obo/IMR_0100709,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100289,,,,,,,,,,,,,,,,,,,,,,Bid (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0000327,color brightness,,A color brightness which is relatively low.,false,,,http://purl.obolibrary.org/obo/PATO_0000016,,,,,,,,,,,,,,,,,,,,,,A color brightness which is relatively low.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0000327,,,,,,,,,,,,,,,,,,,,,,color brightness,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0000322,red (quality),,"A color hue with high wavelength of the long-wave end of the visible spectrum, evoked in the human observer by radiant energy with wavelengths of approximately 630 to 750 nanometers.",false,,,http://purl.obolibrary.org/obo/PATO_0000014,,,,,,,,,,,,,,,,,,,,,,"A color hue with high wavelength of the long-wave end of the visible spectrum, evoked in the human observer by radiant energy with wavelengths of approximately 630 to 750 nanometers.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0000322,,,,,,,,,,,,,,,,,,,,,,red (quality),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000056521,DNAJC12,,Other designations: J domain containing protein 1 (JDP1)|J domain protein 1|dnaJ homolog subfamily C member 12|j domain-containing protein 1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,JDP1,,,,,,,,,,,,10,,,,,,HGNC:28908|MIM:606060|Ensembl:ENSG00000108176|Vega:OTTHUMG00000018339|HPRD:06930,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"DnaJ (Hsp40) homolog, subfamily C, member 12",,,10q22.1,,,,,,,,,,,,,,,,,,,,,,,,,PMID:10760603; 12477932; 15164054; 15489334; 16385451; 16391838; 16712791; 17373700; 21832049; 22939629,,,,,,,,,,,,,,,OGG:3000056521,,,,,,,"DnaJ (Hsp40) homolog, subfamily C, member 12",,,,,,,,,,,,,Other designations: J domain containing protein 1 (JDP1)|J domain protein 1|dnaJ homolog subfamily C member 12|j domain-containing protein 1,,DNAJC12,,,,,,,,,,,,,,,,,,,,,,,56521,RP11-57G10.2,,,,,,,9606,,,,,,,,,,,,,,,,,,,DNAJC12,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_50745,progestogen,progestogens|gestagens|progestagens|gestagen|progestagen,A compound that interacts with progesterone receptors in target tissues to bring about effects similar to those of progesterone.,false,,,http://purl.obolibrary.org/obo/CHEBI_50112,,,,,,,,,,,,,,,,,,,,,,A compound that interacts with progesterone receptors in target tissues to bring about effects similar to those of progesterone.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,progestogens|gestagens|progestagens|gestagen|progestagen,,,,,,,,,,,,,,,,,,,,,CHEBI:50745,,,,progestogen,,CHEBI:50745,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003761,negative regulation of extracellular matrix disassembly [Fibrosis],,"Any process that decreases the rate, frequency or extent of extracellular matrix disassembly. Extracellular matrix disassembly is a process that results in the breakdown of the extracellular matrix.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003742|http://purl.obolibrary.org/obo/GO_0010716,,,,,,,,,,,,,,,,,,,,,,"Any process that decreases the rate, frequency or extent of extracellular matrix disassembly. Extracellular matrix disassembly is a process that results in the breakdown of the extracellular matrix.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002152|http://purl.obolibrary.org/obo/TXPO_0001721,,,,,,,,,,,,,,,,,,TXPO:0003761,,,,,,,,,,,,,,,,,,,,,,negative regulation of extracellular matrix disassembly [Fibrosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003760,LEAP2 (human)[Fibrosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000029|http://purl.obolibrary.org/obo/TXPO_1000221,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:497901|NCBI-Human-GeneID:116842|NCBI-Mouse-GeneID:259301|http://www.ncbi.nlm.nih.gov/gene/116842|PMID:27335344,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003760,,,,,,,"Liver Enriched Antimicrobial Peptide 2|This gene encodes a cysteine-rich cationic antimicrobial peptide that is expressed predominantly in the liver. The mature peptide has activity against gram-positive bacteria and yeasts. [provided by RefSeq, Sep 2014]",,,,,,,,,,,,,,,LEAP2 (human)[Fibrosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003765,toxic course based on ground glass appearance,,This course is categorized from the viewpoint of the findings of ground glass appearance.,false,,,http://purl.obolibrary.org/obo/TXPO_0000608|http://purl.obolibrary.org/obo/TXPO_0003763,,,,,,,,,,,,,,,,,,,,,,This course is categorized from the viewpoint of the findings of ground glass appearance.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003765,,,,,,,,,,,,,,,,,,,,,,toxic course based on ground glass appearance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003768,CCL2 (canonical)[Fibrosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000086|http://purl.obolibrary.org/obo/TXPO_0003750,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:20296|NCBI-Human-GeneID:6347|NCBI-Rat-GeneID:24770,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003768,,,,,,,,,,,,,,,,,,,,,,CCL2 (canonical)[Fibrosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003763,toxic course based on pathological findings,,This course is categorized from the viewpoint of pathological findings derived by inference.,false,,,http://purl.obolibrary.org/obo/TXPO_0000608,,,,,,,,,,,,,,,,,,,,,,This course is categorized from the viewpoint of pathological findings derived by inference.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003763,,,,,,,,,,,,,,,,,,,,,,toxic course based on pathological findings,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003769,acetaldehyde [Fibrosis],,,false,,,http://purl.obolibrary.org/obo/CHEBI_15343|http://purl.obolibrary.org/obo/TXPO_0003771,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003769,,,,,,,,,,,,,,,,,,,,,,acetaldehyde [Fibrosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003762,HMGA1 (human)[Fibrosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000029|http://purl.obolibrary.org/obo/TXPO_1000187,,,,,,,,,,,,,,,,,,,,http://www.ncbi.nlm.nih.gov/gene/3159|NCBI-Human-GeneID:3159|NCBI-Mouse-GeneID:15361|NCBI-Rat-GeneID:117062|PMID:27001612 |PMID:27855356,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003762,,,,,,,"https://omim.org/entry/600701|High Mobility Group AT-Hook 1|This gene encodes a chromatin-associated protein involved in the regulation of gene transcription, integration of retroviruses into chromosomes, and the metastatic progression of cancer cells. The encoded protein preferentially binds to the minor groove of AT-rich regions in double-stranded DNA. Multiple transcript variants encoding different isoforms have been found for this gene. Pseudogenes of this gene have been identified on multiple chromosomes. [provided by RefSeq, Jan 2016]",,,,,,,,,,,,,,,HMGA1 (human)[Fibrosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003767,ET-1 (canonical)[Fibrosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003750|http://purl.obolibrary.org/obo/TXPO_1000128,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24323|NCBI-Mouse-GeneID:13614|NCBI-Human-GeneID:1906,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003767,,,,,,,,,,,,,,,,,,,,,,ET-1 (canonical)[Fibrosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003764,toxic course based on the eosinogranular degeneration (finding),,This course is categorized from the viewpoint of the findings of eosinogranular degeneration.,false,,,http://purl.obolibrary.org/obo/TXPO_0000608|http://purl.obolibrary.org/obo/TXPO_0003763,,,,,,,,,,,,,,,,,,,,,,This course is categorized from the viewpoint of the findings of eosinogranular degeneration.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003764,,,,,,,,,,,,,,,,,,,,,,toxic course based on the eosinogranular degeneration (finding),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003766,CERB processing,,CERB processing is a subtype of protein processing: CREB maturation process achieved by the cleavage of a peptide bond or bonds within CREB protein.,false,,,http://purl.obolibrary.org/obo/GO_0016485,,,,,,,,,,,,,,,,,,,,,,CERB processing is a subtype of protein processing: CREB maturation process achieved by the cleavage of a peptide bond or bonds within CREB protein.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003766,,,,,,,,,,,,,,,,,,,,,,CERB processing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_16469,17β-Estradiol,,The 17beta-isomer of estradiol.,false,,,http://purl.obolibrary.org/obo/CHEBI_23965,,,,,,,,,,,,,,,,,,,,,,The 17beta-isomer of estradiol.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:16469,,,,,,,,,,,,,,,,,,,,,,17β-Estradiol,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000832,ATF-6 beta,activating transcription factor 6 beta,,false,,,http://purl.obolibrary.org/obo/TXPO_1000013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,activating transcription factor 6 beta,,,,,IMR:0000832,,,,,,,,,,,,,,,,,,,,,,ATF-6 beta,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0032060,bleb assembly,membrane blebbing|plasma membrane bleb assembly|cell blebbing,"The assembly of a bleb, a cell extension caused by localized decoupling of the cytoskeleton from the plasma membrane and characterized by rapid formation, rounded shape, and scarcity of organelles within the protrusion. Plasma membrane blebbing occurs during apoptosis and other cellular processes, including cell locomotion, cell division, and as a result of physical or chemical stresses.",false,,,http://purl.obolibrary.org/obo/GO_0071840,,,,,,,,,,,,,,,,,,,,http://en.wikipedia.org/wiki/Bleb_(cell_biology)|PMID:12083798|PMID:16624291,,"The assembly of a bleb, a cell extension caused by localized decoupling of the cytoskeleton from the plasma membrane and characterized by rapid formation, rounded shape, and scarcity of organelles within the protrusion. Plasma membrane blebbing occurs during apoptosis and other cellular processes, including cell locomotion, cell division, and as a result of physical or chemical stresses.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,plasma membrane bleb assembly|cell blebbing,,,,,GO:0032060,,,,,,,,,,,,,,,,membrane blebbing,,,,,,bleb assembly,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000206,ankyrin,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003689,,,,,,,,,,IMR:0000206,,,,,,,,,,,,,,,,,,,,,,ankyrin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000078,insulin receptor,IR|insulin receptor beta subunit|insulin receptor alpha subunit|CD220 antigen|insulin receptor precursor,,false,,,http://purl.obolibrary.org/obo/IMR_0000075,,,,,,,,,,,,,,,,,,,,GO:0005009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0010308|IMR:0011304|IMR:0011542,IR|insulin receptor beta subunit|insulin receptor alpha subunit|CD220 antigen|insulin receptor precursor,,,,,IMR:0000078,,,,,,,,,,,,,,,,,,,,,,insulin receptor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76779,EC 3.4.21.26 (prolyl oligopeptidase) inhibitor,EC 3.4.21.26 inhibitors|post-proline endopeptidase inhibitors|proline-specific endopeptidase inhibitor|endoprolylpeptidase inhibitor|EC 3.4.21.26 inhibitor|post-proline endopeptidase inhibitor|endoprolylpeptidase inhibitors|prolyl endopeptidase inhibitors|post-proline cleaving enzyme inhibitor|prolyl oligopeptidase (EC 3.4.21.26) inhibitor|proline-specific endopeptidase inhibitors|prolyl endopeptidase inhibitor|post-proline cleaving enzyme inhibitors|proline endopeptidase inhibitors|prolyl oligopeptidase inhibitor|EC 3.4.21.26 (prolyl oligopeptidase) inhibitors|proline endopeptidase inhibitor|prolyl oligopeptidase (EC 3.4.21.26) inhibitors,Any EC 3.4.21.* (serine endopeptidase) inhibitor that interferes with the action of prolyl oligopeptidase (EC 3.4.21.26).,false,,,http://purl.obolibrary.org/obo/CHEBI_5924,,,,,,,,,,,,,,,,,,,,,,Any EC 3.4.21.* (serine endopeptidase) inhibitor that interferes with the action of prolyl oligopeptidase (EC 3.4.21.26).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,EC 3.4.21.26 inhibitors|post-proline endopeptidase inhibitors|proline-specific endopeptidase inhibitor|endoprolylpeptidase inhibitor|EC 3.4.21.26 inhibitor|post-proline endopeptidase inhibitor|endoprolylpeptidase inhibitors|prolyl endopeptidase inhibitors|post-proline cleaving enzyme inhibitor|prolyl oligopeptidase (EC 3.4.21.26) inhibitor|proline-specific endopeptidase inhibitors|prolyl endopeptidase inhibitor|post-proline cleaving enzyme inhibitors|proline endopeptidase inhibitors|prolyl oligopeptidase inhibitor|EC 3.4.21.26 (prolyl oligopeptidase) inhibitors|proline endopeptidase inhibitor|prolyl oligopeptidase (EC 3.4.21.26) inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:76779,,,,EC 3.4.21.26 (prolyl oligopeptidase) inhibitor,,CHEBI:76779,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0000082,persistence,,A rhythm quality inhering in a bearer by virtue of the repetitiveness of bearer's rhythm.,false,,,http://purl.obolibrary.org/obo/PATO_0002323,,,,,,,,,,,,,,,,,,,,,,A rhythm quality inhering in a bearer by virtue of the repetitiveness of bearer's rhythm.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0000082,,,,,,,,,,,,,,,,,,,,,,persistence,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0000083,phase,,A quality that exists by virtue of being a particular point in the time of a cycle.,false,,,http://purl.obolibrary.org/obo/PATO_0002323,,,,,,,,,,,,,,,,,,,,,,A quality that exists by virtue of being a particular point in the time of a cycle.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0000083,,,,,,,,,,,,,,,,,,,,,,phase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000005463,POU6F1,,"Other designations: POU domain, class 6, transcription factor 1|brain-5|brain-specific homeobox/POU domain protein 5|brn-5|mPOU homeobox protein",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,BRN5|TCFB1|MPOU,,,,,,,,,,,,12,,,,,,HPRD:17883|HGNC:9224,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,POU class 6 homeobox 1,,,12q13.13,,,,,,,,,,,,,,,,"GO_0003700 (EC: IEA); GO_0005634 (EC: IEA); GO_0006351 (EC: IEA); GO_0007420 (EC: TAS, PMID: 7908264); GO_0007507 (EC: TAS, PMID: 7908264); GO_0007517 (EC: TAS, PMID: 7908264); GO_0043565 (EC: IEA)",,,,,,,,,PMID: 1408763; 7908264; 8102789; 8567814; 8889548; 12477932; 14702039; 15489334; 16344560; 18029348; 18323601; 18976975; 19450691; 19874398; 20134265,,,,,,,,,,,,,,,OGG:3000005463,,,,,,,POU class 6 homeobox 1,,,,,,,,,,,,,"Other designations: POU domain, class 6, transcription factor 1|brain-5|brain-specific homeobox/POU domain protein 5|brn-5|mPOU homeobox protein",,POU6F1,,,,,,,,,,,,,,,,,,,,,,,5463,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,POU6F1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000005465,PPARA,,"Other designations: PPAR-alpha|nuclear receptor subfamily 1 group C member 1|peroxisome proliferative activated receptor, alpha|peroxisome proliferator-activated nuclear receptor alpha variant 3",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,hPPAR|NR1C1|PPARalpha|PPAR,,,,,,,,,,,,22,,,,,,HPRD:01369|Ensembl:ENSG00000186951|HGNC:9232|Vega:OTTHUMG00000150443|MIM:170998,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,peroxisome proliferator-activated receptor alpha,,,22q13.31,,,,,,,,,,,,,,,,"GO_0000122 (EC: IDA, PMID: 12700342); GO_0001103 (EC: IPI, PMID: 19955185); GO_0001666 (EC: IEA); GO_0003677 (EC: TAS, PMID: 10860941); GO_0003700 (EC: IDA, PMID: 19955185); GO_0003700 (EC: ISS); GO_0003707 (EC: IDA, PMID: 19955185); GO_0004879 (EC: IDA, PMID: 12955147); GO_0005515 (EC: IPI, PMID: 11915042); GO_0005634 (EC: TAS, PMID: 16271724); GO_0005654 (EC: TAS); GO_0006367 (EC: TAS); GO_0006629 (EC: TAS, PMID: 7684926); GO_0006631 (EC: IEA); GO_0007507 (EC: IEA); GO_0008144 (EC: IDA, PMID: 12955147); GO_0008270 (EC: IEA); GO_0008289 (EC: IDA, PMID: 12955147); GO_0008544 (EC: IEA); GO_0010467 (EC: TAS); GO_0010745 (EC: IC, PMID: 12700342); GO_0010745 (EC: IDA, PMID: 19114110); GO_0010871 (EC: IDA, PMID: 12700342); GO_0010887 (EC: IDA, PMID: 19114110); GO_0010891 (EC: IDA, PMID: 12700342); GO_0015908 (EC: TAS, PMID: 16271724); GO_0019902 (EC: IEA); GO_0019904 (EC: IEA); GO_0030522 (EC: IDA, PMID: 12955147); GO_0031624 (EC: IPI, PMID: 19955185); GO_0032000 (EC: TAS, PMID: 16271724); GO_0032091 (EC: IEA); GO_0032099 (EC: ISS); GO_0032403 (EC: IEA); GO_0032868 (EC: IEA); GO_0035095 (EC: IEA); GO_0042060 (EC: IEA); GO_0042157 (EC: IEA); GO_0043565 (EC: ISS); GO_0044255 (EC: TAS); GO_0044281 (EC: TAS); GO_0045776 (EC: IEA); GO_0045820 (EC: IC, PMID: 19955185); GO_0045893 (EC: IDA, PMID: 12955147); GO_0045944 (EC: IDA, PMID: 19955185); GO_0046321 (EC: ISS); GO_0051525 (EC: IEA); GO_0070166 (EC: IEA); GO_0072363 (EC: IDA, PMID: 19955185); GO_0072366 (EC: IDA, PMID: 19955185); GO_0072369 (EC: IDA, PMID: 19955185); GO_0097371 (EC: IEA); GO_1901215 (EC: IEA); GO_2000678 (EC: IEA)",,,,,,,,,PMID: 7684926; 7981125; 8621574; 8910358; 8993548; 9113987; 9238002; 9407140; 9610365; 9626662; 9627117; 9653119; 9748221; 9792666; 9795230; 9915808; 10022764; 10187842; 10195690; 10336495; 10377439; 10403814; 10542237; 10591208; 10669761; 10681503; 10731636; 10786636; 10860941; 10862523; 10872826; 10903152; 11119019; 11226238; 11337467; 11375929; 11409711; 11466580; 11587644; 11668221; 11698662; 11733490; 11818483; 11840500; 11845213; 11852057; 11864924; 11891224; 11897617; 11897821; 11914252; 11915042; 11923467; 11934839; 11940516; 11980898; 11981036; 12006394; 12023905; 12039952; 12042669; 12048138; 12055195; 12118000; 12118038; 12161442; 12163133; 12189208; 12203367; 12208475; 12395215; 12408750; 12468272; 12477932; 12482853; 12544508; 12554753; 12562861; 12594295; 12594814; 12615366; 12655356; 12700342; 12709436; 12745064; 12810707; 12835617; 12847522; 12855749; 12897377; 12914524; 12932225; 12938026; 12955147; 12962497; 14515181; 14519597; 14523052; 14633846; 14641801; 14671555; 14677049; 14702039; 14730379; 14764586; 14999402; 15001458; 15001550; 15051727; 15067378; 15083308; 15111510; 15128052; 15131257; 15196699; 15199365; 15221005; 15231516; 15258199; 15309680; 15318936; 15456881; 15461802; 15497675; 15500444; 15521013; 15539630; 15549499; 15608561; 15615782; 15642120; 15677519; 15685545; 15699244; 15699916; 15735069; 15759454; 15797250; 15811118; 15870285; 15888456; 15935279; 15940190; 16042408; 16043164; 16162941; 16169070; 16189514; 16221474; 16226051; 16239970; 16271724; 16275545; 16285997; 16288935; 16288986; 16297361; 16309557; 16377806; 16416313; 16492688; 16506057; 16511589; 16554032; 16630553; 16637234; 16652134; 16763159; 16806233; 16822823; 16847426; 16875506; 16956579; 17001213; 17008383; 17084382; 17129741; 17150915; 17181634; 17184146; 17195188; 17200111; 17244467; 17272748; 17300045; 17317762; 17331954; 17342071; 17355223; 17356846; 17363697; 17363837; 17431031; 17436029; 17492134; 17608096; 17616429; 17646210; 17655842; 17700210; 17705849; 17850927; 17926914; 17951966; 17962186; 17963696; 17991667; 17998026; 18003597; 18004978; 18061194; 18172578; 18182682; 18184928; 18219093; 18245819; 18255343; 18268046; 18292238; 18313368; 18336366; 18388689; 18394939; 18398047; 18440986; 18518955; 18541586; 18549840; 18586686; 18652775; 18660489; 18680716; 18710415; 18713766; 18725353; 18726867; 18727927; 18786524; 18787507; 18797151; 18848838; 18853997; 18855529; 18955051; 18977277; 18981151; 18996102; 19070893; 19114110; 19115207; 19118026; 19119483; 19141539; 19157507; 19208777; 19217440; 19223982; 19254215; 19255064; 19263263; 19279199; 19357976; 19362162; 19367093; 19386311; 19420105; 19422369; 19422653; 19433068; 19451226; 19453261; 19458633; 19527689; 19560472; 19628794; 19653005; 19660836; 19681917; 19706994; 19710929; 19733654; 19748481; 19776627; 19780876; 19782026; 19789836; 19822141; 19823578; 19828088; 19878569; 19887568; 19913121; 19937854; 19948841; 19948975; 19955185; 20016041; 20044476; 20045185; 20070029; 20178979; 20214982; 20238044; 20346360; 20379614; 20384434; 20385772; 20399568; 20400503; 20414453; 20421589; 20426853; 20450745; 20452482; 20466884; 20485444; 20496064; 20602615; 20620111; 20628086; 20638986; 20647061; 20653996; 20656057; 20673868; 20679960; 20682687; 20800603; 20810571; 20811626; 20825652; 20838448; 20855565; 20862655; 21030426; 21125992; 21159535; 21245137; 21282101; 21291392; 21304969; 21326871; 21430558; 21443859; 21487230; 21540177; 21562928; 21785974; 21967852; 21988832; 21990353; 22040870; 22065208; 22068265; 22089192; 22092351; 22168458; 22205725; 22215653; 22266374; 22315317; 22336959; 22349506; 22378291; 22435679; 22479552; 22510778; 22547144; 22647601; 22649490; 22654113; 22685582; 22920733; 22932900; 22940187; 22944052; 22983821; 22989886; 23141142; 23144166; 23158661; 23160450; 23208589; 23262340; 23295386; 23329136; 23372804; 23455924; 23476056; 23502212; 23522297; 23567058; 23583468; 23645771; 23657974; 23666678; 23707408; 23711995; 23736812; 23811234; 23814018; 23821302; 23891824; 23919842; 23930676; 24140347; 24169559; 24309288,,,,,,,,,,,,,,,OGG:3000005465,,,,,,,peroxisome proliferator-activated receptor alpha,,,,,,,,,,,,,"Other designations: PPAR-alpha|nuclear receptor subfamily 1 group C member 1|peroxisome proliferative activated receptor, alpha|peroxisome proliferator-activated nuclear receptor alpha variant 3",,PPARA,,,,,,,,,,,,,,,,,,,,,,,5465,SC22CB-5E3.5,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,PPARA,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/BFO_0000030,object,,,false,,,http://purl.obolibrary.org/obo/BFO_0000040,,,,,,,,,,,,,,,,,,,,,,,,,,"BFO 2 Reference: an object is a maximal causally unified material entity|BFO 2 Reference: To say that b is causally unified means: b is a material entity which is such that its material parts are tied together in such a way that, in environments typical for entities of the type in question,if c, a continuant part of b that is in the interior of b at t, is larger than a certain threshold size (which will be determined differently from case to case, depending on factors such as porosity of external cover) and is moved in space to be at t at a location on the exterior of the spatial region that had been occupied by b at t, then either b’s other parts will be moved in coordinated fashion or b will be damaged (be affected, for example, by breakage or tearing) in the interval between t and t.causal changes in one part of b can have consequences for other parts of b without the mediation of any entity that lies on the exterior of b. Material entities with no proper material parts would satisfy these conditions trivially. Candidate examples of types of causal unity for material entities of more complex sorts are as follows (this is not intended to be an exhaustive list):CU1: Causal unity via physical coveringHere the parts in the interior of the unified entity are combined together causally through a common membrane or other physical covering\. The latter points outwards toward and may serve a protective function in relation to what lies on the exterior of the entity [13, 47|BFO 2 Reference: BFO rests on the presupposition that at multiple micro-, meso- and macroscopic scales reality exhibits certain stable, spatially separated or separable material units, combined or combinable into aggregates of various sorts (for example organisms into what are called ‘populations’). Such units play a central role in almost all domains of natural science from particle physics to cosmology. Many scientific laws govern the units in question, employing general terms (such as ‘molecule’ or ‘planet’) referring to the types and subtypes of units, and also to the types and subtypes of the processes through which such units develop and interact. The division of reality into such natural units is at the heart of biological science, as also is the fact that these units may form higher-level units (as cells form multicellular organisms) and that they may also form aggregates of units, for example as cells form portions of tissue and organs form families, herds, breeds, species, and so on. At the same time, the division of certain portions of reality into engineered units (manufactured artifacts) is the basis of modern industrial technology, which rests on the distributed mass production of engineered parts through division of labor and on their assembly into larger, compound units such as cars and laptops. The division of portions of reality into units is one starting point for the phenomenon of counting.|BFO 2 Reference: Each object is such that there are entities of which we can assert unproblematically that they lie in its interior, and other entities of which we can assert unproblematically that they lie in its exterior. This may not be so for entities lying at or near the boundary between the interior and exterior. This means that two objects – for example the two cells depicted in Figure 3 – may be such that there are material entities crossing their boundaries which belong determinately to neither cell. Something similar obtains in certain cases of conjoined twins (see below).|BFO 2 Reference: ‘objects’ are sometimes referred to as ‘grains’ [74",,b is an object means: b is a material entity which manifests causal unity of one or other of the types CUn listed above & is of a type (a material universal) instances of which are maximal relative to this criterion of causal unity. (axiom label in BFO2 Reference: [024-001]),atom|solid portions of matter|organism|organelle|grain of sand|molecule|cells and organisms|star|cell|planet|engineered artifacts,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BFO:0000030,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/bfo.owl,object,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0016485,protein processing,protein maturation by peptide bond cleavage,Any protein maturation process achieved by the cleavage of a peptide bond or bonds within a protein. Protein maturation is the process leading to the attainment of the full functional capacity of a protein.,false,,,http://purl.obolibrary.org/obo/GO_0006508,,,,,,,,,,,,,,,,,,,,,,Any protein maturation process achieved by the cleavage of a peptide bond or bonds within a protein. Protein maturation is the process leading to the attainment of the full functional capacity of a protein.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,protein maturation by peptide bond cleavage,,,,,GO:0016485,,,,,,,,,,,,,,,,,,,,,,protein processing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_60798,excitatory amino acid antagonist,excitatory amino acid receptor antagonist|EAA receptor antagonists|excitatory amino acid antagonists|EAA receptor antagonist|excitatory amino acid receptor antagonists,Any substance which inhibits the action of receptors for excitatory amino acids.,false,,,http://purl.obolibrary.org/obo/CHEBI_48706,,,,,,,,,,,,,,,,,,,,,,Any substance which inhibits the action of receptors for excitatory amino acids.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,excitatory amino acid receptor antagonist|EAA receptor antagonists|excitatory amino acid antagonists|EAA receptor antagonist|excitatory amino acid receptor antagonists,,,,,,,,,,,,,,,,,,,,,CHEBI:60798,,,,excitatory amino acid antagonist,,CHEBI:60798,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006695,cholesterol biosynthetic process,,"The chemical reaction resulting in the formation of cholesterol, cholest-5-en-3 beta-ol, the principal sterol of vertebrates and the precursor of many steroids, including bile acids and steroid hormones.",false,,,http://purl.obolibrary.org/obo/GO_0008610,,,,,,,,,,,,,,,,,,,,GO:0006695,,"The chemical reaction resulting in the formation of cholesterol, cholest-5-en-3 beta-ol, the principal sterol of vertebrates and the precursor of many steroids, including bile acids and steroid hormones.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0006695,,,,,,,,,,,,,,,,,,,,,,cholesterol biosynthetic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006699,bile acid biosynthetic process,,"The chemical reactions resulting in the formation of bile acids, any of a group of steroid carboxylic acids occurring in bile.",false,,,http://purl.obolibrary.org/obo/GO_0009058,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions resulting in the formation of bile acids, any of a group of steroid carboxylic acids occurring in bile.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000509,,,,,,,,,,,,,,,,,,,GO:0006699,,,,,,,,,,,,,,,,,,,,,,bile acid biosynthetic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100704,thrombin,Prothrombin,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000304,,,,,Prothrombin,,,,,IMR:0100704,,,,,,,,,,,,,,,,,,,,,,thrombin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001147,PKC gamma,,,false,,,http://purl.obolibrary.org/obo/IMR_0100486,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001147,,,,,,,,,,,,,,,,,,,,,,PKC gamma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001150,hyperfunction of alcohol metabolism [lipidosis],,"Hyperfunction of alcohol metabolism is a subtype of hyperfunctioning: A process that performs an excessive alcohol metabolism.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001272|http://purl.obolibrary.org/obo/TXPO_0001720,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of alcohol metabolism is a subtype of hyperfunctioning: A process that performs an excessive alcohol metabolism.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001132|http://purl.obolibrary.org/obo/TXPO_0001246,,,,,,,,,,,TXPO:0001150,,,,,,,,,,,,,,,,,,,,,,hyperfunction of alcohol metabolism [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001159,Cyp2b1 (rat)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001134|http://purl.obolibrary.org/obo/TXPO_1000101,,,,,,,,,,,,,,,,,,,,"Orthologs of the human CYP2B6 genes can be found in other species including rats, mice, and dogs, which are termed Cyp2b1, Cyp2b10, and CYP2B11, respectively|https://www.ncbi.nlm.nih.gov/gene/24300|NCBI-Rat-GeneID:24300|http://rgd.mcw.edu/rgdweb/report/gene/main.html?id=2466|PMID:18798224|PMID:27321734|PMID:11852103",,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001553,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002262,,,,,,,,,,TXPO:0001159,,,,,,,,,,,,,,,,,,,,,,Cyp2b1 (rat)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001153,positive regulation of lipid biosynthetic process [lipidosis],,"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of lipids.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/GO_0046889|http://purl.obolibrary.org/obo/TXPO_0001720,,,,,,,,,,,,,,,,,,,,,,"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of lipids.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001153,,,,,,,,,,,,,,,,,,,,,,positive regulation of lipid biosynthetic process [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001154,lipidosis (normal course),,Lipidosis (normal course) is a subtype of process sequences: The courses of processes through which lipid homeostasis balance is keeping.,false,,,http://purl.obolibrary.org/obo/TXPO_0001155,,,,,,,,,,,,,,,,,,,,,,Lipidosis (normal course) is a subtype of process sequences: The courses of processes through which lipid homeostasis balance is keeping.,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001170,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001170|http://purl.obolibrary.org/obo/TXPO_0001157|http://purl.obolibrary.org/obo/TXPO_0001168,,,,,,,,,,,,,,,,,,TXPO:0001154,,,,,,,,,,,,,,,,,,,,,,lipidosis (normal course),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001156,keeping lipid metaolism balance,,keeping lipid metabolism balance is a subtype of maintaining balance: A process that keeps a balance of lipid metabolism.,false,,,http://purl.obolibrary.org/obo/TXPO_0000682,,,,,,,,,,,,,,,,,,,,,,keeping lipid metabolism balance is a subtype of maintaining balance: A process that keeps a balance of lipid metabolism.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001156,,,,,,,,,,,,,,,,,,,,,,keeping lipid metaolism balance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001152,unsaturated fatty acid,,,false,,,http://purl.obolibrary.org/obo/TXPO_0000834,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001152,,,,,,,,,,,,,,,,,,,,,,unsaturated fatty acid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001158,Gadd45a (rat)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000174|http://purl.obolibrary.org/obo/TXPO_0001134,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:25112|http://omim.org/entry/126335|PMID:10779360|PMID:10747892|PMID:24104470|PMID:22150313|PMID:9827804,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002270,,,,,,,,,,TXPO:0001158,,,,,,,,,,,,,,,,,,,,,,Gadd45a (rat)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001489|http://purl.obolibrary.org/obo/TXPO_0001488|http://purl.obolibrary.org/obo/TXPO_0001547|http://purl.obolibrary.org/obo/TXPO_0001850,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001155,lipidosis (course),,Lipidosis is a subtype of process sequences: The courses of processes through which lipidosis is realized.,false,,,http://purl.obolibrary.org/obo/TXPO_0000009,,,,,,,,,,,,,,,,,,,,,,Lipidosis is a subtype of process sequences: The courses of processes through which lipidosis is realized.,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001160,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001160|http://purl.obolibrary.org/obo/TXPO_0001163,,,,,,,,,,,,,,,,,,TXPO:0001155,,,,,,,,,,,,,,,,,,,,,,lipidosis (course),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001151,Sgpl1 (rat)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000014|http://purl.obolibrary.org/obo/TXPO_0001134,,,,,,,,,,,,,,,,,,,,http://omim.org/entry/603729|NCBI-Rat-GeneID:286896|PMID:2061324|PMID:17090686|PMID:20097939|PMID:26886371,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001151,,,,,,,,,,,,,,,,,,,,,,Sgpl1 (rat)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001157,maintaining lipid metabolism balance [Lipidosis],,"maintaining lipid metabolism balance is a subtype of maintaining balance: A process that keeps a balance of lipid metabolism.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001156|http://purl.obolibrary.org/obo/TXPO_0001160,,,,,,,,,,,,,,,,,,,,,,"maintaining lipid metabolism balance is a subtype of maintaining balance: A process that keeps a balance of lipid metabolism.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001168,,http://purl.obolibrary.org/obo/TXPO_0002076,,,,,,,,,TXPO:0001157,,,,,,,,,,,,,,,,,,,,,,maintaining lipid metabolism balance [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000486,beta-actin,cytoplasmic actin,,false,,,http://purl.obolibrary.org/obo/IMR_0000190,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,cytoplasmic actin,,,,,IMR:0000486,,,,,,,,,,,,,,,,,,,,,,beta-actin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001215,Axin1,Axin,,false,,,http://purl.obolibrary.org/obo/IMR_0000432,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Axin,,,,,IMR:0001215,,,,,,,,,,,,,,,,,,,,,,Axin1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000123688,HYKK,,Other designations: 5-hydroxy-L-lysine kinase|5-hydroxylysine kinase|aminoglycoside phosphotransferase domain containing 1|aminoglycoside phosphotransferase domain-containing protein 1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,AGPHD1,,,,,,,,,,,,15,,,,,,HGNC:34403|MIM:614681|Ensembl:ENSG00000188266|HPRD:12515|Vega:OTTHUMG00000177204,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,hydroxylysine kinase,,,15q25.1,,,,,,,,,,,,,,,,GO_0005737 (EC: IEA); GO_0047992 (EC: IEA),,,,,,,,,PMID: 12477932; 16341674; 18385676; 18385738; 18780872; 19300482; 19654303; 19733931; 20548021; 20554942; 20587604; 21081471; 21685187; 21890473; 21963094; 22241472; 22701590; 22837378,,,,,,,,,,,,,,,OGG:3000123688,,,,,,,hydroxylysine kinase,,,,,,,,,,,,,Other designations: 5-hydroxy-L-lysine kinase|5-hydroxylysine kinase|aminoglycoside phosphotransferase domain containing 1|aminoglycoside phosphotransferase domain-containing protein 1,,HYKK,,,,,,,,,,,,,,,,,,,,,,,123688,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,HYKK,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_16618,"1-phosphatidyl-1D-myo-inositol 3,4,5-trisphosphate","1-phosphatidyl-1D-myo-inositol 3,4,5-trisphosphate|PIP3|PtsIns(3,4,5)P3|1-phosphatidyl-1D-myo-inositol 3,4,5-trisphosphate|1-O-(3-sn-phosphatidyl)-1D-myo-inositol 3,4,5-tris(dihydrogen phosphate)|Phosphatidylinositol-3,4,5-trisphosphate|1-Phosphatidyl-1D-myo-inositol 3,4,5-trisphosphate",,false,,,http://purl.obolibrary.org/obo/CHEBI_60169,,,,,,,,,,,,,,,,,,,,IMR:0001352,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"1-phosphatidyl-1D-myo-inositol 3,4,5-trisphosphate|1-O-(3-sn-phosphatidyl)-1D-myo-inositol 3,4,5-tris(dihydrogen phosphate)|Phosphatidylinositol-3,4,5-trisphosphate|1-Phosphatidyl-1D-myo-inositol 3,4,5-trisphosphate",,"1-phosphatidyl-1D-myo-inositol 3,4,5-trisphosphate|PIP3|PtsIns(3,4,5)P3",,,CHEBI:16618,,,,,,,,,,,,,,,,,,,,,,"1-phosphatidyl-1D-myo-inositol 3,4,5-trisphosphate",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0040007,growth,,"The increase in size or mass of an entire organism, a part of an organism or a cell.",false,,,http://purl.obolibrary.org/obo/TXPO_0000138,,,,,,,,,,,,,,,,,,,,,,"The increase in size or mass of an entire organism, a part of an organism or a cell.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0040007,,,,,,,,,,,,,,,,,,,,,,growth,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100368,G-alpha-i 1,,,false,,,http://purl.obolibrary.org/obo/IMR_0000319,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100368,,,,,,,,,,,,,,,,,,,,,,G-alpha-i 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000170,accumulation of compound in ER [ER stress],,"Accumulation of compound in ER is a subtype of accumulation of xenobiotics: A process that keeps compound in the ER (endoplasmic reticulum).
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/TXPO_0002212,,,,,,,,,,,,,,,,,,,,,,"Accumulation of compound in ER is a subtype of accumulation of xenobiotics: A process that keeps compound in the ER (endoplasmic reticulum).
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001962|http://purl.obolibrary.org/obo/TXPO_0001980,,,,,,http://purl.obolibrary.org/obo/TXPO_0002161|http://purl.obolibrary.org/obo/TXPO_0000037|http://purl.obolibrary.org/obo/TXPO_0001965,,,,,,,,,,,TXPO:0000170,,,,,,,,,,,,,,,,,,,,,,accumulation of compound in ER [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005783,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000174,peroxisome fatty acid beta oxidation gene expression [Eosinophilic granular degeneration],,"Peroxisome fatty acid beta oxidation gene expression is a subtype of gene expression: A process that The process in which a gene sequence is converted into a mature peroxisome fatty acid beta oxidation gene product or products (proteins or RNA) .
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/TXPO_0001729|http://purl.obolibrary.org/obo/TXPO_0000175,,,,,,,,,,,,,,,,,,,,,,"Peroxisome fatty acid beta oxidation gene expression is a subtype of gene expression: A process that The process in which a gene sequence is converted into a mature peroxisome fatty acid beta oxidation gene product or products (proteins or RNA) .
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000110,http://purl.obolibrary.org/obo/TXPO_0001046|http://purl.obolibrary.org/obo/TXPO_0001057|http://purl.obolibrary.org/obo/TXPO_0001069|http://purl.obolibrary.org/obo/TXPO_0000846,,,,,,http://purl.obolibrary.org/obo/TXPO_0000110|http://purl.obolibrary.org/obo/TXPO_0000176,,,,,,,,,,,TXPO:0000174,,,,,,,,,,,,,,,,,,,,,,peroxisome fatty acid beta oxidation gene expression [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000171,ligase,,A role played by the role which catalyse the joining of two molecules with concomitant hydrolysis of the diphosphate bond in ATP or a similar triphosphate.|related molecular function GO:0016874,false,,,http://purl.obolibrary.org/obo/TXPO_0003660,,,,,,,,,,,,,,,,,,,,EC:6.-.-.-,,A role played by the role which catalyse the joining of two molecules with concomitant hydrolysis of the diphosphate bond in ATP or a similar triphosphate.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000171,,,,,,,,,,,,,,,,,,,,related molecular function GO:0016874,,ligase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000177,hyperfunction of peroxisomal fatty acid beta-oxidation,,Hyperfunction of peroxisomal fatty acid beta-oxidation is a subtype of hyperfunction of fatty acid beta-oxidation: A process that performs an excessive peroxisomal fatty acid beta-oxidation.,false,,,http://purl.obolibrary.org/obo/TXPO_0000095,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of peroxisomal fatty acid beta-oxidation is a subtype of hyperfunction of fatty acid beta-oxidation: A process that performs an excessive peroxisomal fatty acid beta-oxidation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000177,,,,,,,,,,,,,,,,,,,,,,hyperfunction of peroxisomal fatty acid beta-oxidation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000175,peroxisome fatty acid beta oxidation gene expression,,Peroxisome fatty acid beta oxidation gene expression is a subtype of gene expression: A process that The process in which a gene sequence is converted into a mature peroxisome fatty acid beta oxidation gene product or products (proteins or RNA) .,false,,,http://purl.obolibrary.org/obo/GO_0010467,,,,,,,,,,,,,,,,,,,,,,Peroxisome fatty acid beta oxidation gene expression is a subtype of gene expression: A process that The process in which a gene sequence is converted into a mature peroxisome fatty acid beta oxidation gene product or products (proteins or RNA) .,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000175,,,,,,,,,,,,,,,,,,,,,,peroxisome fatty acid beta oxidation gene expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000176,hyperfunction of peroxisomal fatty acid beta-oxidation [Eosinophilic granular degeneration],,"Hyperfunction of peroxisomal fatty acid beta-oxidation is a subtype of hyperfunction of fatty acid beta-oxidation: A process that performs an excessive peroxisomal fatty acid beta-oxidation.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/TXPO_0001729|http://purl.obolibrary.org/obo/TXPO_0000177,,,,,,,,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2948931/,,"Hyperfunction of peroxisomal fatty acid beta-oxidation is a subtype of hyperfunction of fatty acid beta-oxidation: A process that performs an excessive peroxisomal fatty acid beta-oxidation.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001074|http://purl.obolibrary.org/obo/TXPO_0001061|http://purl.obolibrary.org/obo/TXPO_0001060|http://purl.obolibrary.org/obo/TXPO_0003246|http://purl.obolibrary.org/obo/TXPO_0003250,,,,,,http://purl.obolibrary.org/obo/TXPO_0002134,,,,,,,,,,,TXPO:0000176,,,,,,,,,,,,,,,,,,,,,,hyperfunction of peroxisomal fatty acid beta-oxidation [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005777,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000179,increasing demand for peroxisomal fatty acid beta oxidation [Eosinophilic granular degeneration],,"Increasing demand for peroxisomal fatty acid beta oxidation is a subtype of increasing functional demand: A process that changes the functional demand for peroxisomal fatty acid beta oxidation to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/TXPO_0000180|http://purl.obolibrary.org/obo/TXPO_0001729,,,,,,,,,,,,,,,,,,,,,,"Increasing demand for peroxisomal fatty acid beta oxidation is a subtype of increasing functional demand: A process that changes the functional demand for peroxisomal fatty acid beta oxidation to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002158,,,,,,,,,,,TXPO:0000179,,,,,,,,,,,,,,,,,,,,,,increasing demand for peroxisomal fatty acid beta oxidation [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005777,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000172,ultimate toxicant,,"A role played by a chemical substance that reacts with the endogenous target molecule or critically alters the biological environment, initiating structural/functional alternations that result in toxicity.",false,,,http://purl.obolibrary.org/obo/CHEBI_64909,,,,,,,,,,,,,,,,,,,,,,"A role played by a chemical substance that reacts with the endogenous target molecule or critically alters the biological environment, initiating structural/functional alternations that result in toxicity.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000172,,,,,,,,,,,,,,,,,,,,,,ultimate toxicant,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000173,drug metabolism phase I,,"Drug metabolism phase I is a subtype of drug metabolic process: A process that of biotransformation reactions involving hydrolysis, reduction, and oxidation or introduces a functional group (such as -OH, -NH2, -SH or -COOH) to increase in the water solubility of a xenobiotic.|Phase 1 of metabolism is concerned with functionalization, that is the introduction or exposure of functional groups on the chemical structure of a compound. This provides a 'handle' for phase 2 conjugating species with which to react with. Many xenobiotics are lipophilic and almost chemically inert (e.g. PAHs) so would not necessarily undergo a phase 2 reaction. Making them more chemically reactive would facilitate their excretion but also increases their chance of reacting with cellular macromolecules (e.g. proteins, DNA). There is a fine balance between producing a more reactive metabolite and conjugation reactions.
There are two groups of enzymes in phase 1 - oxidoreductases and hydrolases. Oxidoreductases introduce an oxygen atom into or remove electrons from their substrates. The major oxidoreductase enzyme system is called the P450 monooxygenases. Other systems include flavin-containing monooxygenases (FMO), cyclooxygenases (COX) and monoamine oxidases (MAO). Hydrolases hydrolyse esters, amides, epoxides and glucuronides.",false,,,http://purl.obolibrary.org/obo/GO_0017144,,,,,,,,,,,,,,,,,,,"Functionalization of exogenous substances to prepare them for conjugation in PHASE II DETOXIFICATION. Phase I enzymes include CYTOCHROME P450 enzymes and some OXIDOREDUCTASES. Excess induction of phase I over phase II detoxification leads to higher levels of FREE RADICALS that can induce CANCER and other cell damage. Induction or antagonism of phase I detoxication is the basis of a number of DRUG INTERACTIONS.
MeSH:D050216",Reactome: R-HSA-211945|http://purl.bioontology.org/ontology/MESH/D050216,,"Drug metabolism phase I is a subtype of drug metabolic process: A process that of biotransformation reactions involving hydrolysis, reduction, and oxidation or introduces a functional group (such as -OH, -NH2, -SH or -COOH) to increase in the water solubility of a xenobiotic.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000173,,,,,,,,,,,,,,,,,,,,"Phase 1 of metabolism is concerned with functionalization, that is the introduction or exposure of functional groups on the chemical structure of a compound. This provides a 'handle' for phase 2 conjugating species with which to react with. Many xenobiotics are lipophilic and almost chemically inert (e.g. PAHs) so would not necessarily undergo a phase 2 reaction. Making them more chemically reactive would facilitate their excretion but also increases their chance of reacting with cellular macromolecules (e.g. proteins, DNA). There is a fine balance between producing a more reactive metabolite and conjugation reactions.
There are two groups of enzymes in phase 1 - oxidoreductases and hydrolases. Oxidoreductases introduce an oxygen atom into or remove electrons from their substrates. The major oxidoreductase enzyme system is called the P450 monooxygenases. Other systems include flavin-containing monooxygenases (FMO), cyclooxygenases (COX) and monoamine oxidases (MAO). Hydrolases hydrolyse esters, amides, epoxides and glucuronides.",,drug metabolism phase I,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001625,Rab34,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001625,,,,,,,,,,,,,,,,,,,,,,Rab34,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100168,endothelin-2,ET-2,,false,,,http://purl.obolibrary.org/obo/IMR_0100166,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ET-2,,,,,IMR:0100168,,,,,,,,,,,,,,,,,,,,,,endothelin-2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100514,Smurf2,Ubiquitin--protein ligase SMURF2|hSMURF2|Smad-specific E3 ubiquitin ligase 2,,false,,,http://purl.obolibrary.org/obo/IMR_0100512,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ubiquitin--protein ligase SMURF2|hSMURF2|Smad-specific E3 ubiquitin ligase 2,,,,,IMR:0100514,,,,,,,,,,,,,,,,,,,,,,Smurf2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000031,VEGF (mol),VEGFA|vascular endothelial growth factor,,false,,,http://purl.obolibrary.org/obo/TXPO_0001382,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:22339|NCBI-Human-GeneID:7422|GO:0005172|NCBI-Rat-GeneID:83785,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002395|http://purl.obolibrary.org/obo/TXPO_0000624,,,,,VEGFA|vascular endothelial growth factor,,,,,IMR:0000031,,,,,,,,,,,,,,,,,,,,,,VEGF (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100664,Clb1,G2/mitotic-specific cyclin 1,,false,,,http://purl.obolibrary.org/obo/IMR_0100673,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,G2/mitotic-specific cyclin 1,,,,,IMR:0100664,,,,,,,,,,,,,,,,,,,,,,Clb1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0010743,regulation of macrophage derived foam cell differentiation,,"Any process that modulates the rate, frequency or extent of macrophage derived foam cell differentiation. Macrophage derived foam cell differentiation is the process in which a macrophage acquires the specialized features of a foam cell. A foam cell is a type of cell containing lipids in small vacuoles and typically seen in atherosclerotic lesions, as well as other conditions.",false,,,http://purl.obolibrary.org/obo/GO_0045595,,,,,,,,,,,,,,,,,,,,,,"Any process that modulates the rate, frequency or extent of macrophage derived foam cell differentiation. Macrophage derived foam cell differentiation is the process in which a macrophage acquires the specialized features of a foam cell. A foam cell is a type of cell containing lipids in small vacuoles and typically seen in atherosclerotic lesions, as well as other conditions.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0010743,,,,,,,,,,,,,,,,,,,,,,regulation of macrophage derived foam cell differentiation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0010745,negative regulation of macrophage derived foam cell differentiation,,"Any process that decreases the rate, frequency or extent of macrophage derived foam cell differentiation. Macrophage derived foam cell differentiation is the process in which a macrophage acquires the specialized features of a foam cell. A foam cell is a type of cell containing lipids in small vacuoles and typically seen in atherosclerotic lesions, as well as other conditions.",false,,,http://purl.obolibrary.org/obo/GO_0010743,,,,,,,,,,,,,,,,,,,,,,"Any process that decreases the rate, frequency or extent of macrophage derived foam cell differentiation. Macrophage derived foam cell differentiation is the process in which a macrophage acquires the specialized features of a foam cell. A foam cell is a type of cell containing lipids in small vacuoles and typically seen in atherosclerotic lesions, as well as other conditions.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0010745,,,,,,,,,,,,,,,,,,,,,,negative regulation of macrophage derived foam cell differentiation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0010742,macrophage derived foam cell differentiation,,"The process in which a monocyte acquires the specialized features of a foam cell. A foam cell is a type of cell containing lipids in small vacuoles and typically seen in atherosclerotic lesions, as well as other conditions.",false,,,http://purl.obolibrary.org/obo/GO_0090077,,,,,,,,,,,,,,,,,,,,,,"The process in which a monocyte acquires the specialized features of a foam cell. A foam cell is a type of cell containing lipids in small vacuoles and typically seen in atherosclerotic lesions, as well as other conditions.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0010742,,,,,,,,,,,,,,,,,,,,,,macrophage derived foam cell differentiation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0010744,positive regulation of macrophage derived foam cell differentiation,,"Any process that increases the rate, frequency or extent of macrophage derived foam cell differentiation. Macrophage derived foam cell differentiation is the process in which a macrophage acquires the specialized features of a foam cell. A foam cell is a type of cell containing lipids in small vacuoles and typically seen in atherosclerotic lesions, as well as other conditions.",false,,,http://purl.obolibrary.org/obo/GO_0010743,,,,,,,,,,,,,,,,,,,,,,"Any process that increases the rate, frequency or extent of macrophage derived foam cell differentiation. Macrophage derived foam cell differentiation is the process in which a macrophage acquires the specialized features of a foam cell. A foam cell is a type of cell containing lipids in small vacuoles and typically seen in atherosclerotic lesions, as well as other conditions.",,,http://purl.obolibrary.org/obo/GO_0010742,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0010744,,,,,,,,,,,,,,,,,,,,,,positive regulation of macrophage derived foam cell differentiation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000020,SCF,stem cell factor,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,related molecular function GO:0005173|OMIM: 184745|Wikipedia:Stem_cell_factor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000155|http://purl.obolibrary.org/obo/TXPO_0000622,,,,,stem cell factor,,,,,IMR:0000020,,,,,,,,,,,,,,,,,,,,,,SCF,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0061024,membrane organization,cellular membrane organisation,"A process which results in the assembly, arrangement of constituent parts, or disassembly of a membrane. A membrane is a double layer of lipid molecules that encloses all cells, and, in eukaryotes, many organelles; may be a single or double lipid bilayer; also includes associated proteins.",false,,,http://purl.obolibrary.org/obo/GO_0071840,,,,,,,,,,,,,,,,,,,,,,"A process which results in the assembly, arrangement of constituent parts, or disassembly of a membrane. A membrane is a double layer of lipid molecules that encloses all cells, and, in eukaryotes, many organelles; may be a single or double lipid bilayer; also includes associated proteins.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,cellular membrane organisation,,,,,GO:0061024,,,,,,,,,,,,,,,,,,,,,,membrane organization,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005886,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000010020,GNE,,Other designations: N-acylmannosamine kinase|UDP-GlcNAc-2-epimerase/ManAc kinase|UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase|UDP-N-acetylglucosamine-2-epimerase/N-acetylmannosamine kinase|bifunctional UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,Uae1|IBM2|DMRV|NM|GLCNE,,,,,,,,,,,,9,,,,,,Vega:OTTHUMG00000019899|HGNC:23657|MIM:603824|HPRD:04825|Ensembl:ENSG00000159921,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase,,,9p13.3,,,,,,,,,,,,,,,,"GO_0005524 (EC: IEA); GO_0005737 (EC: TAS, PMID: 9305888); GO_0005829 (EC: IEA); GO_0006045 (EC: IEA); GO_0006047 (EC: IEA); GO_0006054 (EC: TAS, PMID: 9305888); GO_0007155 (EC: TAS, PMID: 10334995); GO_0008761 (EC: IEA); GO_0009103 (EC: IEA); GO_0009384 (EC: IEA); GO_0016787 (EC: IEA); GO_0046380 (EC: IEA); GO_0046835 (EC: TAS, PMID: 9305888); GO_0046872 (EC: IEA)",,,,,,,,,PMID: 2443758; 2808337; 8439453; 8789455; 8889548; 9305887; 9305888; 10330343; 10334995; 10356312; 10431835; 11326336; 11528398; 11749051; 11916006; 12177386; 12325084; 12409274; 12473753; 12473769; 12473780; 12477932; 12497639; 12612874; 12743242; 12811782; 12913203; 12921793; 12927803; 14707127; 14972325; 15136692; 15146476; 15164053; 15342556; 15489334; 15670773; 15748884; 15833430; 15987957; 16810679; 16847058; 17118363; 17597614; 17698786; 17704511; 17718674; 18029348; 18373408; 18560563; 18653764; 18698493; 18815882; 19322201; 19841673; 19845164; 19917666; 20059379; 20175955; 20300792; 20301343; 20301439; 20346669; 21131200; 21139048; 21584309; 21708040; 21868336; 21906983; 21910480; 21963094; 22049060; 22196754; 22231866; 22343627; 22349865; 22507750; 22863883; 22883483; 23000965; 23238814; 23437777; 23549799; 24005727,,,,,,,,,,,,,,,OGG:3000010020,,,,,,,glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase,,,,,,,,,,,,,Other designations: N-acylmannosamine kinase|UDP-GlcNAc-2-epimerase/ManAc kinase|UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase|UDP-N-acetylglucosamine-2-epimerase/N-acetylmannosamine kinase|bifunctional UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase,,GNE,,,,,,,,,,,,,,,,,,,,,,,10020,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,GNE,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0000784,Arrb2 -inactivation (mouse)[Ground glass appearance],,"ARRB2, GSK3beta->CAR, Cyp2B6?",false,,,http://purl.obolibrary.org/obo/TXPO_0000777,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:409|PMID:30283336|PMID:26582201|PMID:24658455,,,,,,,,,,,,,,,arrestin beta 2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_68495,http://purl.obolibrary.org/obo/PATO_0002355,,,,,,,,,TXPO:0000784,,,,,,,,,,,,,,,,,,,,"ARRB2, GSK3beta->CAR, Cyp2B6?",,Arrb2 -inactivation (mouse)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000782,malfunction of mitochondrial function,,Malfunction of mitochondria is a subtype of malfunctioning process: A process that cannot perform a mitochondrial function appropriately or cannot realize it at all.,false,,,http://purl.obolibrary.org/obo/TXPO_0000434,,,,,,,,,,,,,,,,,,,,,,Malfunction of mitochondria is a subtype of malfunctioning process: A process that cannot perform a mitochondrial function appropriately or cannot realize it at all.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000782,,,,,,,,,,,,,,,,,,,,,,malfunction of mitochondrial function,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000787,tamoxifen [Lipidosis],,,false,,,http://purl.obolibrary.org/obo/CHEBI_41774|http://purl.obolibrary.org/obo/TXPO_0003508,,,,,,,,,,,,,,,,,,,,ISBN:0071769234,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000787,,,,,,,,,,,,,,,,,,,,,,tamoxifen [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000783,Dnajb9 (rat)[ER stress],ERDJ4,,false,,,http://purl.obolibrary.org/obo/TXPO_0000753|http://purl.obolibrary.org/obo/TXPO_1000114,,,,,,,,,,,,,,,,,,,,https://omim.org/entry/602634,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003997,,,,,ERDJ4,,,,,TXPO:0000783,,,,,,,,,,,,,,,,,,,,,,Dnajb9 (rat)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000780,ARRB2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:25388|NCBI-Mouse-GeneID:216869|NCBI-Human-GeneID:409|PMID:30283336,,,,,,,,,,,,,,,arrestin beta 2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000780,,,,,,,,,,,,,,,,,,,,,,ARRB2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000781,negative regulation of AKT signaling [Ground glass appearance],,"Any process that stops, prevents, or reduces the frequency, rate or extent of protein kinase B signaling, a series of reactions mediated by the intracellular serine/threonine kinase protein kinase B.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/GO_0051898|http://purl.obolibrary.org/obo/TXPO_0001728,,,,,,,,,,,,,,,,,,,,PMID:26582201,,"Any process that stops, prevents, or reduces the frequency, rate or extent of protein kinase B signaling, a series of reactions mediated by the intracellular serine/threonine kinase protein kinase B.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000777,,,,,,http://purl.obolibrary.org/obo/TXPO_0001026,,,,,,,,,,,TXPO:0000781,,,,,,,,,,,,,,,,,,,,,,negative regulation of AKT signaling [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000786,GPRC5B (human)[Ground glass appearance],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001009|http://purl.obolibrary.org/obo/TXPO_0000785,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:51704|NCBI-Rat-GeneID:293546|NCBI-Mouse-GeneID:64297|PMID:23169819|PMID:24412205|PMID:18832180,,,,,,,,,,,,,,,G protein-coupled receptor class C group 5 member B,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000786,,,,,,,,,,,,,,,,,,,,,,GPRC5B (human)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000795,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000789,increasing demand for drug metabolism,,Increasing demand for drug metabolism is a subtype of increasing functional demand: A process changes the functional demand for the for drug metabolism to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000633,,,,,,,,,,,,,,,,,,,,,,Increasing demand for drug metabolism is a subtype of increasing functional demand: A process changes the functional demand for the for drug metabolism to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000789,,,,,,,,,,,,,,,,,,,,,,increasing demand for drug metabolism,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000785,GPRC5B (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:51704|NCBI-Rat-GeneID:293546|NCBI-Mouse-GeneID:64297,,,,,,,,,,,,,,,G protein-coupled receptor class C group 5 member B,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000785,,,,,,,,,,,,,,,,,,,,,,GPRC5B (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000788,valproic acid [Lipidosis],,,false,,,http://purl.obolibrary.org/obo/CHEBI_39867,,,,,,,,,,,,,,,,,,,,ISBN:0071769234,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000788,,,,,,,,,,,,,,,,,,,,,,valproic acid [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000092,TGF-beta receptor,Transforming growth factor-beta receptor,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,GO:0005024,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002154,,,,,Transforming growth factor-beta receptor,,,,,IMR:0000092,,,,,,,,,,,,,,,,,,,,,,TGF-beta receptor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001645,RABL2A,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001645,,,,,,,,,,,,,,,,,,,,,,RABL2A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_135512,clometacin,mindolic acid|clometazin|clomethacin|clometacine|duperan,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:25803-14-9|Drug_Central:698,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,mindolic acid|clometazin|clomethacin|clometacine|duperan,,,,,,,,,,,,,,,,,,,,,CHEBI:135512,,,,clometacin,,CHEBI:135512,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000157,FcepsilonRI,,,false,,,http://purl.obolibrary.org/obo/IMR_0000156,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000157,,,,,,,,,,,,,,,,,,,,,,FcepsilonRI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0010888,negative regulation of lipid storage,,"Any process that decreases the rate, frequency or extent of lipid storage. Lipid storage is the accumulation and maintenance in cells or tissues of lipids, compounds soluble in organic solvents but insoluble or sparingly soluble in aqueous solvents. Lipid reserves can be accumulated during early developmental stages for mobilization and utilization at later stages of development.",false,,,http://purl.obolibrary.org/obo/TXPO_0000369,,,,,,,,,,,,,,,,,,,,,,"Any process that decreases the rate, frequency or extent of lipid storage. Lipid storage is the accumulation and maintenance in cells or tissues of lipids, compounds soluble in organic solvents but insoluble or sparingly soluble in aqueous solvents. Lipid reserves can be accumulated during early developmental stages for mobilization and utilization at later stages of development.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0010888,,,,,,,,,,,,,,,,,,,,,,negative regulation of lipid storage,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0019915,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76964,Penicillium metabolite,Penicillium metabolites,Any fungal metabolite produced during a metabolic reaction in Penicillium.,false,,,http://purl.obolibrary.org/obo/CHEBI_76946,,,,,,,,,,,,,,,,,,,,,,Any fungal metabolite produced during a metabolic reaction in Penicillium.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Penicillium metabolites,,,,,,,,,,,,,,,,,,,,,CHEBI:76964,,,,Penicillium metabolite,,CHEBI:76964,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_28877,1-hydroxyanthraquinone,"1-hydroxyanthracene-9,10-dione",,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:129-43-1,,,,,,,,,,,,,,C14H8O3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"1-hydroxyanthracene-9,10-dione",,,,,CHEBI:28877,,,,,,,,,,,,,,,,,,,,,,1-hydroxyanthraquinone,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Oc1cccc2C(=O)c3ccccc3C(=O)c12,,,,,
http://purl.obolibrary.org/obo/IMR_0002121,biogenic amine,,"A group of naturally occurring amines derived by enzymatic decarboxylation of the natural amino acids. Many have powerful physiological effects (e.g., histamine, serotonin, epinephrine, tyramine). Those derived from aromatic amino acids, and also their synthetic analogs (e.g., amphetamine), are of use in pharmacology.",false,,,http://purl.obolibrary.org/obo/IMR_0001693,,,,,,,,,,,,,,,,,,,,CHEBI:22879|MeSH:D001679,,"A group of naturally occurring amines derived by enzymatic decarboxylation of the natural amino acids. Many have powerful physiological effects (e.g., histamine, serotonin, epinephrine, tyramine). Those derived from aromatic amino acids, and also their synthetic analogs (e.g., amphetamine), are of use in pharmacology.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0002121,,,,,,,,,,,,,,,,,,,,,,biogenic amine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000005319,PLA2G1B,,Other designations: phosphatidylcholine 2-acylhydrolase 1B|phospholipase A2,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,PPLA2|PLA2A|PLA2,,,,,,,,,,,,12,,,,,,HGNC:9030|Vega:OTTHUMG00000169343|HPRD:01396|Ensembl:ENSG00000170890|MIM:172410,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"phospholipase A2, group IB (pancreas)",,,12q24.31,,,,,,,,,,,,,,,,"GO_0000187 (EC: ISS, PMID: 15528384); GO_0002446 (EC: ISS, PMID: 16005851); GO_0004623 (EC: IDA, PMID: 1918029); GO_0005102 (EC: IDA, PMID: 1918029); GO_0005102 (EC: IPI, PMID: 7721806); GO_0005509 (EC: IDA, PMID: 7060561); GO_0005576 (EC: TAS); GO_0005615 (EC: IDA, PMID: 7060561); GO_0006633 (EC: IDA, PMID: 1918029); GO_0006644 (EC: TAS); GO_0006654 (EC: TAS); GO_0007015 (EC: TAS, PMID: 9886417); GO_0007165 (EC: TAS, PMID: 9886417); GO_0009986 (EC: IDA, PMID: 1918029); GO_0010524 (EC: ISS, PMID: 15528384); GO_0015758 (EC: ISS, PMID: 1918029); GO_0019370 (EC: ISS, PMID: 16005851); GO_0030141 (EC: IEA); GO_0030593 (EC: ISS, PMID: 16005851); GO_0032052 (EC: ISS, PMID: 7060561); GO_0032431 (EC: TAS, PMID: 17981679); GO_0032637 (EC: ISS, PMID: 15528384); GO_0032869 (EC: ISS, PMID: 1918029); GO_0035556 (EC: ISS, PMID: 15528384); GO_0036148 (EC: TAS); GO_0036149 (EC: TAS); GO_0036150 (EC: TAS); GO_0036151 (EC: TAS); GO_0036152 (EC: TAS); GO_0044240 (EC: IDA, PMID: 7060561); GO_0044281 (EC: TAS); GO_0045740 (EC: IDA, PMID: 1918029); GO_0045944 (EC: ISS, PMID: 15528384); GO_0046470 (EC: IDA, PMID: 7060561); GO_0046474 (EC: TAS); GO_0047498 (EC: IDA, PMID: 7060561); GO_0048146 (EC: IC, PMID: 1918029); GO_0050482 (EC: TAS, PMID: 12423354); GO_0050714 (EC: TAS, PMID: 17981679); GO_0050778 (EC: ISS, PMID: 16005851); GO_0051092 (EC: ISS, PMID: 15528384)",,,,,,,,,PMID: 1918029; 2052621; 3028739; 6349696; 6477929; 7060561; 7584826; 7590434; 7721806; 8175726; 8300559; 8358438; 9188469; 9377118; 9745929; 9847074; 9848887; 9886417; 10509674; 10551547; 10735945; 10873103; 10905638; 10964913; 11025364; 11353443; 11510783; 11807183; 11851982; 12423354; 12477932; 12759552; 14557262; 14998370; 15220446; 15489334; 15528384; 15736947; 16005851; 16391564; 16392040; 16495221; 16541075; 16567514; 17065600; 17223797; 17434532; 17470210; 17488462; 17981679; 18212756; 18492292; 18636547; 19297324; 19913121; 20536387; 20628086; 21988832; 22528125; 22680611,,,,,,,,,,,,,,,OGG:3000005319,,,,,,,"phospholipase A2, group IB (pancreas)",,,,,,,,,,,,,Other designations: phosphatidylcholine 2-acylhydrolase 1B|phospholipase A2,,PLA2G1B,,,,,,,,,,,,,,,,,,,,,,,5319,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,PLA2G1B,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_5165,Fosphenytoin,fosphenytoin sodium|fosphenytoin sodium hydrate|cerebyx|Fosphenytoin,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:93390-81-9|Drug_Central:1247,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Fosphenytoin,,fosphenytoin sodium|fosphenytoin sodium hydrate|cerebyx,,,,,,,,,,,,,,,,,,,,,CHEBI:5165,,,,Fosphenytoin,,CHEBI:5165,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3100506742,CASP12,,Other designations: caspase 12 pseudogene 1|inactive caspase-12,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CASP-12|CASP12P1,,,,,,,,,,,,11,,,,,,MIM:608633|Ensembl:ENSG00000204403|Vega:OTTHUMG00000154965|HGNC:19004,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,caspase 12 (gene/pseudogene),,,11q22.3,,,,,,,,,,,,,,,,"GO_0004197 (EC: IBA); GO_0005737 (EC: IBA); GO_0030968 (EC: IEA); GO_0042981 (EC: IEA); GO_0050727 (EC: IBA, Qualifier: NOT); GO_0070059 (EC: IBA); GO_0072557 (EC: IBA, Qualifier: NOT); GO_0072559 (EC: IBA, Qualifier: NOT); GO_0097169 (EC: IBA, Qualifier: NOT); GO_0097194 (EC: IBA, Qualifier: NOT)",,,,,,,,,PMID:9038361; 11278723; 11329013; 11943137; 12054529; 12975309; 14532116; 15033764; 15129283; 16532395; 16917906; 17574210; 18329614; 18332441; 18710920; 18791174; 19447924; 19721713; 20031604; 20041182; 20299359; 20299368; 20423816; 20577092; 20646990; 21706251; 21872999,,,,,,,,,,,,,,,OGG:3100506742,,,,,,,caspase 12 (gene/pseudogene),,,,,,,,,,,,,Other designations: caspase 12 pseudogene 1|inactive caspase-12,,CASP12,,,,,,,,,,,,,,,,,,,,,,,100506742,UNQ9415,,,,,,,9606,,,,,,,,,,,,,,,,,,,CASP12,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000695,HRAS (mol),Ha-ras|c-H-ras|HRAS|H-Ras|Transforming protein p21/H-Ras-1,,false,,,http://purl.obolibrary.org/obo/IMR_0000290,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:15461|NCBI-Rat-GeneID:293621|NCBI-Human-GeneID:3265,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0011341,Ha-ras|c-H-ras|HRAS|H-Ras|Transforming protein p21/H-Ras-1,,,,,IMR:0000695,,,,,,,,,,,,,,,,,,,,,,HRAS (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0002777,AMPK beta subunit,,,false,,,http://purl.obolibrary.org/obo/TXPO_0003221,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003722,,,,,,,,,,IMR:0002777,,,,,,,,,,,,,,,,,,,,,,AMPK beta subunit,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0006841,central vein of liver,central vein|terminal hepatic venule|vena centralis (hepar)|terminal branch of hepatic vein,Vein that is central to a lobule in the liver.,false,,,http://purl.obolibrary.org/obo/UBERON_0001143,,,,,,,,,,,,,,,,,,,,,,Vein that is central to a lobule in the liver.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,terminal hepatic venule|vena centralis (hepar)|terminal branch of hepatic vein,,,,,UBERON:0006841,,,,,,,,,,,,,,,,central vein,,,,,,central vein of liver,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_135666,tasosartan,ANA-756|verdia|ANA756,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Drug_Central:3839|CAS:145733-36-4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ANA-756|verdia|ANA756,,,,,,,,,,,,,,,,,,,,,CHEBI:135666,,,,tasosartan,,CHEBI:135666,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000647,Integrin beta-7,,,false,,,http://purl.obolibrary.org/obo/IMR_0000174,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000647,,,,,,,,,,,,,,,,,,,,,,Integrin beta-7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0200183,L-Proline,,,false,,,http://purl.obolibrary.org/obo/CHEBI_33709,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0200183,,,,,,,,,,,,,,,,,,,,,,L-Proline,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100356,PAK1,,,false,,,http://purl.obolibrary.org/obo/IMR_0000238,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100356,,,,,,,,,,,,,,,,,,,,,,PAK1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000299,Rab,Ras genes from rat brain,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,IPR:003579,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003669,,,,,Ras genes from rat brain,,,,,IMR:0000299,,,,,,,,,,,,,,,,,,,,,,Rab,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/BFO_0000144,process profile,,b is a process_profile =Def. there is some process c such that b process_profile_of c (axiom label in BFO2 Reference: [093-002]),false,,,http://purl.obolibrary.org/obo/BFO_0000015,,,,,,,,,,,,,,,,,,,,,,b is a process_profile =Def. there is some process c such that b process_profile_of c (axiom label in BFO2 Reference: [093-002]),,,,,,"b process_profile_of c holds when b proper_occurrent_part_of c& there is some proper_occurrent_part d of c which has no parts in common with b & is mutually dependent on b& is such that b, c and d occupy the same temporal region (axiom label in BFO2 Reference: [094-005])","The simplest type of process profiles are what we shall call ‘quality process profiles’, which are the process profiles which serve as the foci of the sort of selective abstraction that is involved when measurements are made of changes in single qualities, as illustrated, for example, by process profiles of mass, temperature, aortic pressure, and so on.|On a somewhat higher level of complexity are what we shall call rate process profiles, which are the targets of selective abstraction focused not on determinate quality magnitudes plotted over time, but rather on certain ratios between these magnitudes and elapsed times. A speed process profile, for example, is represented by a graph plotting against time the ratio of distance covered per unit of time. Since rates may change, and since such changes, too, may have rates of change, we have to deal here with a hierarchy of process profile universals at successive levels|One important sub-family of rate process profiles is illustrated by the beat or frequency profiles of cyclical processes, illustrated by the 60 beats per minute beating process of John’s heart, or the 120 beats per minute drumming process involved in one of John’s performances in a rock band, and so on. Each such process includes what we shall call a beat process profile instance as part, a subtype of rate process profile in which the salient ratio is not distance covered but rather number of beat cycles per unit of time. Each beat process profile instance instantiates the determinable universal beat process profile. But it also instantiates multiple more specialized universals at lower levels of generality, selected from   rate process profilebeat process profileregular beat process profile3 bpm beat process profile4 bpm beat process profileirregular beat process profileincreasing beat process profileand so on.In the case of a regular beat process profile, a rate can be assigned in the simplest possible fashion by dividing the number of cycles by the length of the temporal region occupied by the beating process profile as a whole. Irregular process profiles of this sort, for example as identified in the clinic, or in the readings on an aircraft instrument panel, are often of diagnostic significance.",,,,,,,,,,,(forall (x y) (if (processProfileOf x y) (and (properContinuantPartOf x y) (exists (z t) (and (properOccurrentPartOf z y) (TemporalRegion t) (occupiesSpatioTemporalRegion x t) (occupiesSpatioTemporalRegion y t) (occupiesSpatioTemporalRegion z t) (not (exists (w) (and (occurrentPartOf w x) (occurrentPartOf w z))))))))) // axiom label in BFO2 CLIF: [094-005]|(iff (ProcessProfile a) (exists (b) (and (Process b) (processProfileOf a b)))) // axiom label in BFO2 CLIF: [093-002],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BFO:0000144,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/bfo.owl,process profile,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000026512,INTS6,,Other designations: DEAD box protein|DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 26|RNA helicase HDB|protein deleted in cancer 1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,DDX26A|HDB|Notchl2|DBI-1|DDX26|DICE1|INT6,,,,,,,,,,,,13,,,,,,HGNC:14879|MIM:604331|Ensembl:ENSG00000102786|HPRD:05063,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,integrator complex subunit 6,,,13q14.3,,,,,,,,,,,,,,,,"GO_0004888 (EC: TAS, PMID: 10467397); GO_0005515 (EC: IPI, PMID: 16239144); GO_0005634 (EC: IDA); GO_0005730 (EC: IDA, Qualifier: NOT); GO_0007165 (EC: TAS, PMID: 10467397); GO_0015629 (EC: IDA); GO_0016180 (EC: IDA, PMID: 16239144); GO_0032039 (EC: IDA, PMID: 16239144)",,,,,,,,,PMID: 10467397; 11939413; 12477932; 12527901; 14702039; 15057823; 15254679; 15489334; 16007164; 16239144; 16271964; 17310990; 18029348; 18854154; 20133760; 21906983; 21963094; 22360420; 23280823; 24250222; 24457600,,,,,,,,,,,,,,,OGG:3000026512,,,,,,,integrator complex subunit 6,,,,,,,,,,,,,Other designations: DEAD box protein|DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 26|RNA helicase HDB|protein deleted in cancer 1,,INTS6,,,,,,,,,,,,,,,,,,,,,,,26512,RP11-24B19.2,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,INTS6,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_5924,EC 3.4.21.* (serine endopeptidase) inhibitor,EC 3.4.21.* inhibitors|serine endopeptidase inhibitor|serine endopeptidase inhibitors|EC 3.4.21.* inhibitor|inhibitor of serine endopeptidase (EC 3.4.21.*)|EC 3.4.21.* (serine endopeptidase) inhibitors|inhibitor of serine endopeptidase (EC 3.4.21.*)s,Any EC 3.4.* (hydrolases acting on peptide bond) inhibitor that inhibits the activity of a serine endopeptidase (EC 3.4.21.*).,false,,,http://purl.obolibrary.org/obo/CHEBI_60258,,,,,,,,,,,,,,,,,,,,,,Any EC 3.4.* (hydrolases acting on peptide bond) inhibitor that inhibits the activity of a serine endopeptidase (EC 3.4.21.*).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,EC 3.4.21.* inhibitors|serine endopeptidase inhibitor|serine endopeptidase inhibitors|EC 3.4.21.* inhibitor|inhibitor of serine endopeptidase (EC 3.4.21.*)|EC 3.4.21.* (serine endopeptidase) inhibitors|inhibitor of serine endopeptidase (EC 3.4.21.*)s,,,,,,,,,,,,,,,,,,,,,CHEBI:5924,,,,EC 3.4.21.* (serine endopeptidase) inhibitor,,CHEBI:5924,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_68495,apoptosis inducer,Type I cell-death inducer|Type I programmed cell-death inducer|Type I programmed cell-death inducers|Type I cell-death inducers|apoptosis inducers,Any substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms.,false,,,http://purl.obolibrary.org/obo/TXPO_0000327|http://purl.obolibrary.org/obo/CHEBI_52206,,,,,,,,http://purl.obolibrary.org/obo/GO_0006915,,,,,,,,,,,,,,Any substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Type I cell-death inducer|Type I programmed cell-death inducer|Type I programmed cell-death inducers|Type I cell-death inducers|apoptosis inducers,,,,,,,,,,,,,,,,,,,,,CHEBI:68495,,,,apoptosis inducer,,CHEBI:68495,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_3023,benzbromarone,"Uroleap (TN)|2-ethyl-3-(3,5-dibrom-4-hydroxybenzoyl)benzofuran|3,5-dibromo-4-hydroxyphenyl-2-ethyl-3-benzofuranyl ketone|(3,5-dibromo-4-hydroxyphenyl)(2-ethyl-1-benzofuran-3-yl)methanone|Benzbromarone","1-Benzofuran substituted at C-2 and C-3 by an ethyl group and a 3,5-dibromo-4-hydroxybenzoyl group respectively. An inhibitor of CYP2C9, it is used as an anti-gout medication.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:27391386|CAS:3562-84-3|PMID:28131653|PMID:28166217|Drug_Central:318|PMID:26693855|PMID:28202260|PMID:18636784|Beilstein:273668|PMID:26792818|PMID:7661033|LINCS:LSM-2239,,"1-Benzofuran substituted at C-2 and C-3 by an ethyl group and a 3,5-dibromo-4-hydroxybenzoyl group respectively. An inhibitor of CYP2C9, it is used as an anti-gout medication.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35841,,,,,"(3,5-dibromo-4-hydroxyphenyl)(2-ethyl-1-benzofuran-3-yl)methanone|Benzbromarone",,"Uroleap (TN)|2-ethyl-3-(3,5-dibrom-4-hydroxybenzoyl)benzofuran|3,5-dibromo-4-hydroxyphenyl-2-ethyl-3-benzofuranyl ketone",,,,,,,,,,,,,,,,,,,,,CHEBI:3023,,,,benzbromarone,,CHEBI:3023,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0000990,reproductive system,reproductive tract|genitalia|Geschlechtsorgan|organa genitalia|genital system|systemata genitalia|animal reproductive system|genital tract|reproductive tissue,Anatomical system that has as its parts the organs concerned with reproduction.,false,,,http://purl.obolibrary.org/obo/UBERON_0000467,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C12841|http://linkedlifedata.com/resource/umls/id/C1261210|http://en.wikipedia.org/wiki/Reproductive_system|http://www.snomedbrowser.com/Codes/Details/278875001|TAO:0000632|MA:0000326|EHDAA:5923|CALOHA:TS-1318|EFO:0000809|FMA:7160|BTO:0000081|MIAA:0000305|HAO:0000895|XAO:0000142|EV:0100100|EMAPA:17381|BILA:0000103|FBbt:00004857|UMLS:C1261210|AAO:0010258|OpenCyc:Mx4rvVja4ZwpEbGdrcN5Y29ycA|EHDAA2:0001603|HAO:0000374|GAID:363|VHOG:0000182|WBbt:0005747|ZFA:0000632,,Anatomical system that has as its parts the organs concerned with reproduction.,,,,consider splitting genitalia from reproductive system,,,,Anatomical system which consists of organs and tissues associated with sexual reproduction of the organism.[AAO],,,http://purl.obolibrary.org/obo/FMA_75572,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,reproductive tract|genitalia|Geschlechtsorgan|organa genitalia|genital system|systemata genitalia|animal reproductive system|genital tract|reproductive tissue,"Arguably, one of the most important aspects of urbilaterian organogenesis would have been gonadogenesis, since Urbilateria must have successfully generated gametes and developed a strategy for extrusion and fertilization, in order to be the ancestor of all living Bilateria.[well established][VHOG]",,UBERON:0000990,,,,,,,,,,,,,,,,,,,,,,reproductive system,,,,http://upload.wikimedia.org/wikipedia/commons/5/52/Penis.svg,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000066002,CYP4F12,,"Other designations: CYPIVF12|cytochrome P450 4F12|cytochrome P450, subfamily IVF, polypeptide 12",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,F22329_1,,,,,,,,,,,,19,,,,,,HGNC:18857|Ensembl:ENSG00000186204|HPRD:07102|Vega:OTTHUMG00000164477|MIM:611485,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 4, subfamily F, polypeptide 12",,,19p13.1,,,,,,,,,,,,,,,,GO_0000038 (EC: ISS); GO_0001676 (EC: ISS); GO_0003091 (EC: ISS); GO_0003095 (EC: ISS); GO_0005506 (EC: IEA); GO_0005737 (EC: ISS); GO_0005789 (EC: TAS); GO_0006805 (EC: TAS); GO_0008392 (EC: ISS); GO_0016021 (EC: IEA); GO_0016324 (EC: ISS); GO_0017144 (EC: ISS); GO_0018685 (EC: ISS); GO_0019369 (EC: ISS); GO_0019373 (EC: ISS); GO_0020037 (EC: IEA); GO_0030195 (EC: ISS); GO_0036101 (EC: ISS); GO_0042360 (EC: ISS); GO_0042371 (EC: ISS); GO_0043231 (EC: ISS); GO_0044281 (EC: TAS); GO_0047057 (EC: ISS); GO_0050051 (EC: ISS); GO_0055078 (EC: ISS); GO_0055114 (EC: ISS); GO_0070330 (EC: IEA),,,,,,,,,PMID:1116264; 9068972; 11162607; 11162645; 12477932; 12975309; 14702039; 15128046; 15548388; 16112640; 16303743; 16344560; 18065749; 21906983; 21988832,,,,,,,,,,,,,,,OGG:3000066002,,,,,,,"cytochrome P450, family 4, subfamily F, polypeptide 12",,,,,,,,,,,,,"Other designations: CYPIVF12|cytochrome P450 4F12|cytochrome P450, subfamily IVF, polypeptide 12",,CYP4F12,,,,,,,,,,,,,,,,,,,,,,,66002,UNQ568/PRO1129,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP4F12,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/BFO_0000019,quality,,,false,,,http://purl.obolibrary.org/obo/BFO_0000020,,,,,,,,,,,,,,,,,,,,YAMATO:property,,,,,,,,"a quality is a specifically dependent continuant that, in contrast to roles and dispositions, does not require any further process in order to be realized. (axiom label in BFO2 Reference: [055-001])",the mass of this piece of gold.|the shape of your nostril|the color of a tomato|the ambient temperature of this portion of air|the shape of your nose|the length of the circumference of your waist,,,,,,,,,,,(forall (x) (if (Quality x) (SpecificallyDependentContinuant x))) // axiom label in BFO2 CLIF: [055-001]|(forall (x) (if (exists (t) (and (existsAt x t) (Quality x))) (forall (t_1) (if (existsAt x t_1) (Quality x))))) // axiom label in BFO2 CLIF: [105-001],"If an entity is a quality at any time that it exists, then it is a quality at every time that it exists. (axiom label in BFO2 Reference: [105-001])",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BFO:0000019,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/bfo.owl,quality,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_38213,Methapyrilene hydrochloride,"N,N-dimethyl-N'-pyridin-2-yl-N'-[(thiophen-2-yl)methyl]ethane-1,2-diamine hydrochloride",A hydrochloride that is the monohydrochloride salt of methapyrilene.,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,DrugBank:DB04819|CAS:135-23-9,,A hydrochloride that is the monohydrochloride salt of methapyrilene.,,,,,,,,,,,,C14H20ClN3S|C14H19N3S.ClH,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35717|http://purl.obolibrary.org/obo/CHEBI_50857,,,,,"N,N-dimethyl-N'-pyridin-2-yl-N'-[(thiophen-2-yl)methyl]ethane-1,2-diamine hydrochloride",,,,,CHEBI:38213,,,,,,,,,,,,,,,,,,,,,,Methapyrilene hydrochloride,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Cl.CN(C)CCN(Cc1cccs1)c1ccccn1,,,,,
http://purl.obolibrary.org/obo/CHEBI_76737,EC 1.10.* (oxidoreductase acting on diphenols and related substances as donors) inhibitor,EC 1.10.* inhibitors|EC 1.10.* (oxidoreductases acting on diphenols and related substances as donors) inhibitor|inhibitor of an oxidoreductase acting on diphenols and related substances as donor|inhibitors of an oxidoreductase acting on diphenols and related substances as donors|inhibitors of an oxidoreductase acting on diphenols and related substances as donor|EC 1.10.* inhibitor|inhibitors of an oxidoreductase acting on diphenols and related substances as donor (EC 1.10.*)|EC 1.10.* (oxidoreductase acting on diphenols and related substances as donors) inhibitors|inhibitor of an oxidoreductase acting on diphenols and related substances as donor (EC 1.10.*)|EC 1.10.* (oxidoreductases acting on diphenols and related substances as donors) inhibitors|inhibitor of an oxidoreductase acting on diphenols and related substances as donors,An oxidoreductase inhibitor which interferes with the action of an oxidoreductase acting on diphenols and related substances as donors (EC 1.10.*.*).,false,,,http://purl.obolibrary.org/obo/CHEBI_76725,,,,,,,,,,,,,,,,,,,,,,An oxidoreductase inhibitor which interferes with the action of an oxidoreductase acting on diphenols and related substances as donors (EC 1.10.*.*).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,EC 1.10.* inhibitors|EC 1.10.* (oxidoreductases acting on diphenols and related substances as donors) inhibitor|inhibitor of an oxidoreductase acting on diphenols and related substances as donor|inhibitors of an oxidoreductase acting on diphenols and related substances as donors|inhibitors of an oxidoreductase acting on diphenols and related substances as donor|EC 1.10.* inhibitor|inhibitors of an oxidoreductase acting on diphenols and related substances as donor (EC 1.10.*)|EC 1.10.* (oxidoreductase acting on diphenols and related substances as donors) inhibitors|inhibitor of an oxidoreductase acting on diphenols and related substances as donor (EC 1.10.*)|EC 1.10.* (oxidoreductases acting on diphenols and related substances as donors) inhibitors|inhibitor of an oxidoreductase acting on diphenols and related substances as donors,,,,,,,,,,,,,,,,,,,,,CHEBI:76737,,,,EC 1.10.* (oxidoreductase acting on diphenols and related substances as donors) inhibitor,,CHEBI:76737,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_35660,HIV protease inhibitor,HIV protease inhibitors,"An inhibitor of HIV protease, an enzyme required for production of proteins needed for viral assembly.",false,,,http://purl.obolibrary.org/obo/CHEBI_37670|http://purl.obolibrary.org/obo/CHEBI_64946|http://purl.obolibrary.org/obo/CHEBI_36044,,,,,,,,,,,,,,,,,,,,Wikipedia:Protease_inhibitor_(pharmacology),,"An inhibitor of HIV protease, an enzyme required for production of proteins needed for viral assembly.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,HIV protease inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:35660,,,,HIV protease inhibitor,,CHEBI:35660,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001130,neurocan,,,false,,,http://purl.obolibrary.org/obo/IMR_0001126,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001130,,,,,,,,,,,,,,,,,,,,,,neurocan,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_39548,atorvastatin,"atorvastatinum|atorvastatin|atorvastatina|(R-(R*,R*))-2-(4-Fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid|atorvastatine|7-[2-(4-FLUORO-PHENYL)-5-ISOPROPYL-3-PHENYL-4-PHENYLCARBAMOYL-PYRROL-1-YL]-3,5-DIHYDROXY-HEPTANOIC ACID|Atorlip|(3R,5R)-7-[3-(anilinocarbonyl)-5-(4-fluorophenyl)-4-phenyl-2-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid|Atorvastatin","A dihydroxy monocarboxylic acid that is a member of the drug class known as statins, used primarily for lowering blood cholesterol and for preventing cardiovascular diseases.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Reaxys:8373630|Beilstein:8373630|LINCS:LSM-5771|PMID:15012735|PMID:18720283|Drug_Central:257|DrugBank:DB01076|CAS:134523-00-5|PMID:11693468,,"A dihydroxy monocarboxylic acid that is a member of the drug class known as statins, used primarily for lowering blood cholesterol and for preventing cardiovascular diseases.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35703|http://purl.obolibrary.org/obo/CHEBI_78298,,,,,"(3R,5R)-7-[3-(anilinocarbonyl)-5-(4-fluorophenyl)-4-phenyl-2-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid|Atorvastatin",,"atorvastatinum|atorvastatin|atorvastatina|(R-(R*,R*))-2-(4-Fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid|atorvastatine|7-[2-(4-FLUORO-PHENYL)-5-ISOPROPYL-3-PHENYL-4-PHENYLCARBAMOYL-PYRROL-1-YL]-3,5-DIHYDROXY-HEPTANOIC ACID|Atorlip",,,,,,,,,,,,,,,,,,,,,CHEBI:39548,,,,atorvastatin,,CHEBI:39548,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000055729,ATF7IP,,Other designations: ATF-interacting protein|ATF7-interacting protein|ATFa-associated modulator|MBD1-containing chromatin-associated factor 1|activating transcription factor 7-interacting protein 1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,AM|ATF-IP|p621|MCAF1|MCAF,,,,,,,,,,,,12,,,,,,MIM:613644|Ensembl:ENSG00000171681|Vega:OTTHUMG00000168656|HPRD:09811|HGNC:20092,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,activating transcription factor 7 interacting protein,,,12p13.1,,,,,,,,,,,,,,,,"GO_0000122 (EC: IEA); GO_0003714 (EC: IEA); GO_0005515 (EC: IPI, PMID:12665582); GO_0005634 (EC: IDA, PMID:12665582); GO_0005667 (EC: IEA); GO_0006306 (EC: IDA, PMID:12665582); GO_0006351 (EC: IEA); GO_0016032 (EC: IEA); GO_0016887 (EC: IEA); GO_0045892 (EC: IDA, PMID:12665582); GO_0045893 (EC: IDA, PMID:12665582); GO_0045898 (EC: IDA, PMID:12665582)",,,,,,,,,PMID:10777215; 10976766; 12477932; 12659632; 12665582; 12812986; 14536086; 14702039; 15231748; 15489334; 15691849; 16314315; 16344560; 16757475; 17081983; 18029348; 18842587; 19106100; 19394292; 19471022; 20543847; 20549333; 20936779; 21139048; 21693764; 21890473; 21906983; 21963094; 21987572; 21988832; 22939629; 23000965; 23359319; 23666240; 23935871; 24250222,,,,,,,,,,,,,,,OGG:3000055729,,,,,,,activating transcription factor 7 interacting protein,,,,,,,,,,,,,Other designations: ATF-interacting protein|ATF7-interacting protein|ATFa-associated modulator|MBD1-containing chromatin-associated factor 1|activating transcription factor 7-interacting protein 1,,ATF7IP,,,,,,,,,,,,,,,,,,,,,,,55729,,,,,,,,9606,,,,,,,,,,,,,,,,,,,ATF7IP,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0004952,negative regulation of connexin signaling [hepatocarcinogenesis],,"Any process that stops, prevents, or reduces the frequency, rate or extent of connexin signaling, a series of reactions mediated by connexin.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0004496|http://purl.obolibrary.org/obo/TXPO_0002340,,,,,,,,,,,,,,,,,,,,PMID:12717835,,"Any process that stops, prevents, or reduces the frequency, rate or extent of connexin signaling, a series of reactions mediated by connexin.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004953|http://purl.obolibrary.org/obo/TXPO_0004950,,,,,,http://purl.obolibrary.org/obo/TXPO_0004538,,,,,,,,,,,TXPO:0004952,,,,,,,,,,,,,,,,,,,,,,negative regulation of connexin signaling [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004494|http://purl.obolibrary.org/obo/TXPO_0004495,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004953,GJA1 (human) [hepatocarcinogenesis],CX43,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_0005087,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:2697|PMID:12717835,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CX43,,,,,TXPO:0004953,,,,,,,,,,,,,,,,,,,,,,GJA1 (human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004954,Increasing cholesterol level,,Increasing cholesterol level is a subtype of increasing quantity: A process that changes the amount of cholesterol level to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0001062,,,,,,,,,,,,,,,,,,,,,,Increasing cholesterol level is a subtype of increasing quantity: A process that changes the amount of cholesterol level to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004954,,,,,,,,,,,,,,,,,,,,,,Increasing cholesterol level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004950,GJB1 (human) [hepatocarcinogenesis],CX32,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_0005088,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:2705|PMID:30947731|PMID:12717835,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CX32,,,,,TXPO:0004950,,,,,,,,,,,,,,,,,,,,,,GJB1 (human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004958,drug resistance,,drug resistance (process) is a subtype of decreasing sensitivity: A process that changes the sensitivity to the drug to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000157,,,,,,,,,,,,,,,,,,,,,,drug resistance (process) is a subtype of decreasing sensitivity: A process that changes the sensitivity to the drug to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004958,,,,,,,,,,,,,,,,,,,,,,drug resistance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004956,Increasing triol level [mitochondrial disorder],,"Increasing triol level is a subtype of increasing quantity: A process that changes the amount of triol level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0004968,,,,,,,,,,,,,,,,,,,,PMID:31623280,,"Increasing triol level is a subtype of increasing quantity: A process that changes the amount of triol level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001992|http://purl.obolibrary.org/obo/TXPO_0000869,,,,,,,,,,,TXPO:0004956,,,,,,,,,,,,,,,,,,,,,,Increasing triol level [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004955,Increasing cholesterol level [mitochondrial disorder],,"Increasing cholesterol level is a subtype of increasing quantity: A process that changes the amount of cholesterol level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0004954,,,,,,,,,,,,,,,,,,,,PMID:31623280,,"Increasing cholesterol level is a subtype of increasing quantity: A process that changes the amount of cholesterol level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004956,,,,,,,,,,,TXPO:0004955,,,,,,,,,,,,,,,,,,,,,,Increasing cholesterol level [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004951,Src (human) [hepatocarcinogenesis],c-Src|p60-Src,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/IMR_0100575,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:6714|NCBI-Mouse-GeneID:20779|NCBI-Rat-GeneID:83805|PMID:30947731,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,c-Src|p60-Src,,,,,TXPO:0004951,,,,,,,,,,,,,,,,,,,,,,Src (human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004959,diacylglycerol acumulation,,"diacylglycerol accumulation is a subtype of accumulation of substances in a biological object: A process that keeps diacylglycerol in an organism, tissue, organelle, or cell.",false,,,http://purl.obolibrary.org/obo/GO_0019915,,,,,,,,,,,,,,,,,,,,,,"diacylglycerol accumulation is a subtype of accumulation of substances in a biological object: A process that keeps diacylglycerol in an organism, tissue, organelle, or cell.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0100027,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004959,,,,,,,,,,,,,,,,,,,,,,diacylglycerol acumulation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004957,cisplatin resistance,,cisplatin resistance (process) is a subtype of decreasing sensitivity: A process that changes the sensitivity to cisplatin to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0004958,,,,,,,,,,,,,,,,,,,,,,cisplatin resistance (process) is a subtype of decreasing sensitivity: A process that changes the sensitivity to cisplatin to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004957,,,,,,,,,,,,,,,,,,,,,,cisplatin resistance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001635,Rab40B,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001635,,,,,,,,,,,,,,,,,,,,,,Rab40B,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0011159,eIF4H,Williams-Beuren syndrome chromosome region 1 protein|eIF-4H|eukaryotic translation initiation factor 4H,,false,,,http://purl.obolibrary.org/obo/IMR_0010016,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Williams-Beuren syndrome chromosome region 1 protein|eIF-4H|eukaryotic translation initiation factor 4H,,,,,IMR:0011159,,,,,,,,,,,,,,,,,,,,,,eIF4H,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000005991,RFX3,,Other designations: DNA binding protein RFX3|transcription factor RFX3,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,9,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"regulatory factor X, 3 (influences HLA class II expression)",,,9p24.2,,,,,,,,,,,,,,,,"GO_0000790 (EC: IDA); GO_0003677 (EC: TAS, PMID: 8600444); GO_0003700 (EC: NAS, PMID: 8600444); GO_0003705 (EC: TAS, PMID: 8289803); GO_0005515 (EC: IPI); GO_0005634 (EC: IC, PMID: 12411430); GO_0005667 (EC: IC); GO_0006355 (EC: ISS); GO_0006366 (EC: TAS, PMID: 8289803); GO_0031018 (EC: ISS); GO_0042384 (EC: ISS); GO_0044212 (EC: IDA); GO_0045892 (EC: IDA, PMID: 12411430); GO_0045893 (EC: IDA); GO_0045944 (EC: ISS); GO_0048469 (EC: ISS); GO_0050796 (EC: ISS); GO_0060285 (EC: ISS); GO_0060287 (EC: ISS); GO_0072560 (EC: IEA); GO_2000078 (EC: ISS)",,,,,,,,,PMID: 8289803; 8600444; 8889548; 10330134; 11682486; 12411430; 12477932; 14702039; 15024578; 15164053; 15489334; 16189514; 16344560; 19671664; 20211142; 21532573; 22415835; 23822649; 24058526,,,,,,,,,,,,,,,OGG:3000005991,,,,,,,"regulatory factor X, 3 (influences HLA class II expression)",,,,,,,,,,,,,Other designations: DNA binding protein RFX3|transcription factor RFX3,,RFX3,,,,,,,,,,,,,,,,,,,,,,,5991,RP11-32F11.1,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,RFX3,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0200453,L-Serine,,,false,,,http://purl.obolibrary.org/obo/CHEBI_33709,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0200453,,,,,,,,,,,,,,,,,,,,,,L-Serine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003347,FABP5 (canonical)[Phospholipidosis],FATTY ACID-BINDING PROTEIN 5,,false,,,http://purl.obolibrary.org/obo/TXPO_1000153|http://purl.obolibrary.org/obo/TXPO_0003213,,,,,,,,,,,,,,,,,,,GO:0005504	fatty acid binding|Triglyceride catabolism,http://omim.org/entry/605168|NCBI-Mouse-GeneID:16592|http://www.ncbi.nlm.nih.gov/gene/2171|NCBI-Rat-GeneID:140868|NCBI-Human-GeneID:2171|PMID:28219080|PMID:19307565|PMID:28374947,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FATTY ACID-BINDING PROTEIN 5,,,,,TXPO:0003347,,,,,,,,,,,,,,,,,,,,,,FABP5 (canonical)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003349,S1P[Phospholipidosis - tumor proliferation],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001849|http://purl.obolibrary.org/obo/CHEBI_37550,,,,,,,,,,,,,,,,,,,,PMID:29147025,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002272,,,,,,,,,,TXPO:0003349,,,,,,,,,,,,,,,,,,,,,,S1P[Phospholipidosis - tumor proliferation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003345,CAD [Phospholipidosis],,Substance with substance with cationic amphiphilic drug role is a subtype of substance with role. This entity is participating in a phospholipidosis and playing a cationic amphiphilic drug role.,false,,,http://purl.obolibrary.org/obo/TXPO_0003353|http://purl.obolibrary.org/obo/TXPO_0001849,,,,,,,,,,,,,,,,,,,,PMID:9061852,,Substance with substance with cationic amphiphilic drug role is a subtype of substance with role. This entity is participating in a phospholipidosis and playing a cationic amphiphilic drug role.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001426,,,,,,,,,,TXPO:0003345,,,,,,,,,,,,,,,,,,,,,,CAD [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003342,Diabetes dependent process [diabetes course],,Diabetes dependent process is a subtype of disease course dependent process: A process that can constitute the course of diabetes.,false,,,http://purl.obolibrary.org/obo/TXPO_0000808,,,,,,,,,,,,,,,,,,,,,,Diabetes dependent process is a subtype of disease course dependent process: A process that can constitute the course of diabetes.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003342,,,,,,,,,,,,,,,,,,,,,,Diabetes dependent process [diabetes course],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003341,EGR1 (human)[ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000793|http://purl.obolibrary.org/obo/IMR_0000403,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:13653|http://omim.org/entry/128990|NCBI-Human-GeneID:1958|NCBI-Rat-GeneID:24330|http://www.ncbi.nlm.nih.gov/gene/1958|PMID:25122760|PMID:25737480|PMID:29607419|PMID:16344600|PMID:24619556|PMID:15752369,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,,,,,,TXPO:0003341,,,,,,,,,,,,,,,,,,,,,,EGR1 (human)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003346,FADS2 (canonical)[Phospholipidosis],Fatty Acid Desaturase 2 Delta-6 Fatty Acid Desaturase [Phospholipidosis]|Delta-6 Fatty Acid Desaturase [Phospholipidosis],,false,,,http://purl.obolibrary.org/obo/TXPO_0003213|http://purl.obolibrary.org/obo/TXPO_0000321,,,,,,,,,,,,,,,,,,,Linoleic acid (LA) metabolism，Fatty acid metabolism,http://omim.org/entry/606149|NCBI-Rat-GeneID:83512|http://www.ncbi.nlm.nih.gov/gene/9415|PMID:19875987,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003348,,,,,Fatty Acid Desaturase 2 Delta-6 Fatty Acid Desaturase [Phospholipidosis]|Delta-6 Fatty Acid Desaturase [Phospholipidosis],,,,,TXPO:0003346,,,,,,,"The protein encoded by this gene is a member of the fatty acid desaturase (FADS) gene family. Desaturase enzymes regulate unsaturation of fatty acids through the introduction of double bonds between defined carbons of the fatty acyl chain. FADS family members are considered fusion products composed of an N-terminal cytochrome b5-like domain and a C-terminal multiple membrane-spanning desaturase portion, both of which are characterized by conserved histidine motifs. This gene is clustered with family members at 11q12-q13.1; this cluster is thought to have arisen evolutionarily from gene duplication based on its similar exon/intron organization. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Jul 2013]",,,,,,,,,,,,,,,FADS2 (canonical)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003343,binding to DNA by electrophiles,,Process of binding by which electrophiles interact with DNA (deoxyribonucleic acid).,false,,,http://purl.obolibrary.org/obo/GO_0005488,,,,,,,,,,,,,,,,,,,,,,Process of binding by which electrophiles interact with DNA (deoxyribonucleic acid).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003343,,,,,,,,,,,,,,,,,,,,,,binding to DNA by electrophiles,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003340,increasing blood glucose level [Diabetic retinopathy],,"Increasing blood glucose lebvel is a subtype of increasing concentration: A process that changes the blood glucose concentration in the blood to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Diabetic retinopathy.",false,,,http://purl.obolibrary.org/obo/TXPO_0003290,,,,,,,,,,,,,,,,,,,,,,"Increasing blood glucose lebvel is a subtype of increasing concentration: A process that changes the blood glucose concentration in the blood to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Diabetic retinopathy.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003294,,,,,,,,,,,TXPO:0003340,,,,,,,,,,,,,,,,,,,,,,increasing blood glucose level [Diabetic retinopathy],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003344,binding to DNA by electrophiles [cell death],,"Process of binding by which electrophiles interact with DNA (deoxyribonucleic acid).
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0001727|http://purl.obolibrary.org/obo/TXPO_0003343,,,,,,,,,,,,,,,,,,,,,,"Process of binding by which electrophiles interact with DNA (deoxyribonucleic acid).
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000773,,,,,,,,,,,TXPO:0003344,,,,,,,,,,,,,,,,,,,,,,binding to DNA by electrophiles [cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003348,linoleoyl-CoA desaturase role,,Catalysis role of the reaction: linoleoyl-CoA + reduced acceptor + O2 = gamma-linolenoyl-CoA + acceptor + 2 H2O.|related molecular function GO:0016213,false,,,http://purl.obolibrary.org/obo/TXPO_0003328,,,,,,,,,,,,,,,,,,,,PMID:7212717|EC:1.14.19.3,,Catalysis role of the reaction: linoleoyl-CoA + reduced acceptor + O2 = gamma-linolenoyl-CoA + acceptor + 2 H2O.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003348,,,,,,,,,,,,,,,,,,,,related molecular function GO:0016213,,linoleoyl-CoA desaturase role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100082,hypothalamic hormone,,"Hormones isolated from the hypothalamus which exercise control over other organs, primarily the pituitary gland. Well-known members include certain pituitary hormone-releasing hormones and pituitary hormone release inhibiting hormones. Vasopressin and oxytocin which are found in the posterior pituitary may also be secreted by the hypothalamus but are not grouped here ( PITUITARY HORMONES, POSTERIOR).",false,,,http://purl.obolibrary.org/obo/IMR_0000966,,,,,,,,,,,,,,,,,,,,MeSH:D007028,,"Hormones isolated from the hypothalamus which exercise control over other organs, primarily the pituitary gland. Well-known members include certain pituitary hormone-releasing hormones and pituitary hormone release inhibiting hormones. Vasopressin and oxytocin which are found in the posterior pituitary may also be secreted by the hypothalamus but are not grouped here ( PITUITARY HORMONES, POSTERIOR).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_24621,,,,,,,,,,IMR:0100082,,,,,,,,,,,,,,,,,,,,,,hypothalamic hormone,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100714,Notch 1 (mol),Notch1|Notch-1,,false,,,http://purl.obolibrary.org/obo/IMR_0100712,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:4851|NCBI-Rat-GeneID:25496|NCBI-Mouse-GeneID:18128,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Notch1|Notch-1,,,,,IMR:0100714,,,,,,,,,,,,,,,,,,,,,,Notch 1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100660,Mdm2 (mol),Hdm2|Ubiquitin-protein ligase E3 Mdm2|Double minute 2 protein|Oncoprotein Mdm2|Ubiquitin-protein ligase E3 Mdm2 (EC 6.3.2.-) (p53-binding protein Mdm2) (Oncoprotein Mdm2) (Double minute 2 protein) (Hdm2)|p53-binding protein Mdm2,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000266,,,,IMR:0010776,Hdm2|Ubiquitin-protein ligase E3 Mdm2|Double minute 2 protein|Oncoprotein Mdm2|Ubiquitin-protein ligase E3 Mdm2 (EC 6.3.2.-) (p53-binding protein Mdm2) (Oncoprotein Mdm2) (Double minute 2 protein) (Hdm2)|p53-binding protein Mdm2,,,,,IMR:0100660,,,,,,,,,,,,,,,,,,,,,,Mdm2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0035397,helper T cell enhancement of adaptive immune response,,Positive regulation of an adaptive immune response mediated via cytokine production by helper T cell.,false,,,http://purl.obolibrary.org/obo/GO_0002250,,,,,,,,,,,,,,,,,,,,,,Positive regulation of an adaptive immune response mediated via cytokine production by helper T cell.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0035397,,,,,,,,,,,,,,,,,,,,,,helper T cell enhancement of adaptive immune response,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010560,"40S ribosomal protein S4, X isoform",SCR10|Single copy abundant mRNA protein|40S small ribosomal protein 4,,false,,,http://purl.obolibrary.org/obo/IMR_0000896,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,SCR10|Single copy abundant mRNA protein|40S small ribosomal protein 4,,,,,IMR:0010560,,,,,,,,,,,,,,,,,,,,,,"40S ribosomal protein S4, X isoform",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001031,group V phospholipase A2,,,false,,,http://purl.obolibrary.org/obo/IMR_0000283,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001031,,,,,,,,,,,,,,,,,,,,,,group V phospholipase A2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000170,R-cadherin,Retinal-cadherin|cadherin-4,,false,,,http://purl.obolibrary.org/obo/IMR_0000167,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Retinal-cadherin|cadherin-4,,,,,IMR:0000170,,,,,,,,,,,,,,,,,,,,,,R-cadherin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100757,Dvl-1,DSH homolog 1|Dishevelled-1,,false,,,http://purl.obolibrary.org/obo/IMR_0100755,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,DSH homolog 1|Dishevelled-1,,,,,IMR:0100757,,,,,,,,,,,,,,,,,,,,,,Dvl-1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0007219,Notch signaling pathway,,"A series of molecular signals initiated by the binding of an extracellular ligand to the receptor Notch on the surface of a target cell, and ending with regulation of a downstream cellular process, e.g. transcription.",false,,,http://purl.obolibrary.org/obo/TXPO_0000609,,,,,,,,,,,,,,,,,,,,,,"A series of molecular signals initiated by the binding of an extracellular ligand to the receptor Notch on the surface of a target cell, and ending with regulation of a downstream cellular process, e.g. transcription.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0007219,,,,,,,,,,,,,,,,,,,,,,Notch signaling pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_25805,oxygen atom,oxygen,,false,,,http://purl.obolibrary.org/obo/CHEBI_33250,,,,,,,,,,,,,,,,,,,,Inchikey:QVGXLLKOCUKJST-UHFFFAOYSA-N,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,oxygen,,,,,CHEBI:25805,,,,,,,,,,,,,,,,,,,,,,oxygen atom,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000506,canalicular bile acid transmembrane transporter,,A role played by the entity which transfers directed movement of bile acid and bile salts out of a hepatocyte and into the bile canaliculus.  Bile canaliculi are the thin tubes formed by hepatocyte membranes.|related molecular function GO:0015126,false,,,http://purl.obolibrary.org/obo/TXPO_0003703,,,,,,,,,,,,,,,,,,,,,,A role played by the entity which transfers directed movement of bile acid and bile salts out of a hepatocyte and into the bile canaliculus.  Bile canaliculi are the thin tubes formed by hepatocyte membranes.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000506,,,,,,,"Bile acids are any of a group of steroid carboxylic acids occurring in bile, where they are present as the sodium salts of their amides with glycine or taurine.",,,,,,,,,,,,,related molecular function GO:0015126,,canalicular bile acid transmembrane transporter,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000507,activation of thioredoxin pathway,,Activation of thioredoxin pathway is a subtype of activating: A process that changes the activity of the thioredoxin pathway to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000401,,,,,,,,,,,,,,,,,,,,,,Activation of thioredoxin pathway is a subtype of activating: A process that changes the activity of the thioredoxin pathway to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000507,,,,,,,,,,,,,,,,,,,,,,activation of thioredoxin pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000503,hyperfunction of alcohol metabolism [Fibrosis],,"Hyperfunction of alcohol metabolism is a subtype of hyperfunctioning: A process that performs an excessive alcohol metabolism.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003742|http://purl.obolibrary.org/obo/TXPO_0001272,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of alcohol metabolism is a subtype of hyperfunctioning: A process that performs an excessive alcohol metabolism.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001408|http://purl.obolibrary.org/obo/TXPO_0001288,,,,,,,,,,,TXPO:0000503,,,,,,,,,,,,,,,,,,,,,,hyperfunction of alcohol metabolism [Fibrosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000502,CASPASE (canonical)[ER stress],,,false,,,http://purl.obolibrary.org/obo/IMR_0000305|http://purl.obolibrary.org/obo/TXPO_0000871|http://purl.obolibrary.org/obo/TXPO_1000414,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000305,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000502,,,,,,,,,,,,,,,,,,,,,,CASPASE (canonical)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000508,decreasing amount of abnormal protein,,Decreasing amount of abnormal protein is a subtype of decreasing quantity: A process that changes the quantity of the abnormal protein to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000396,,,,,,,,,,,,,,,,,,,,,,Decreasing amount of abnormal protein is a subtype of decreasing quantity: A process that changes the quantity of the abnormal protein to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000508,,,,,,,,,,,,,,,,,,,,,,decreasing amount of abnormal protein,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000504,malfunctioning of regulation of gene expression,,Malfunctioning of regulation of gene expression is a subtype of malfunctioning of controlling: A process that cannot perform a regulation of gene expression appropriately or cannot realize it at all.,false,,,http://purl.obolibrary.org/obo/TXPO_0000532,,,,,,,,,,,,,,,,,,,,,,Malfunctioning of regulation of gene expression is a subtype of malfunctioning of controlling: A process that cannot perform a regulation of gene expression appropriately or cannot realize it at all.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000504,,,,,,,,,,,,,,,,,,,,,,malfunctioning of regulation of gene expression,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0010468,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000500,chloroquine [Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000418|http://purl.obolibrary.org/obo/TXPO_0001849,,,,,,,,,,,,,,,,,,,,PMID:16979167|PMID:9061852|PMID:24563379,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000500,,,,,,,,,,,,,,,,,,,,,,chloroquine [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000501,glutathione depletion [toxic course],,The totality of all processes through which glutathione depletion is realized.,false,,,http://purl.obolibrary.org/obo/TXPO_0000009,,,,,,,,,,,,,,,,,,,,PMID:23856494|PMID:24287781|PMID:16500922|PMID:22995213,,The totality of all processes through which glutathione depletion is realized.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001182|http://purl.obolibrary.org/obo/TXPO_0001183|http://purl.obolibrary.org/obo/TXPO_0001184|http://purl.obolibrary.org/obo/TXPO_0001181|http://purl.obolibrary.org/obo/TXPO_0001185|http://purl.obolibrary.org/obo/TXPO_0001180|http://purl.obolibrary.org/obo/TXPO_0001187|http://purl.obolibrary.org/obo/TXPO_0000655|http://purl.obolibrary.org/obo/TXPO_0002371|http://purl.obolibrary.org/obo/TXPO_0002370|http://purl.obolibrary.org/obo/TXPO_0002379|http://purl.obolibrary.org/obo/TXPO_0002375|http://purl.obolibrary.org/obo/TXPO_0002376|http://purl.obolibrary.org/obo/TXPO_0002373|http://purl.obolibrary.org/obo/TXPO_0002372|http://purl.obolibrary.org/obo/TXPO_0002613|http://purl.obolibrary.org/obo/TXPO_0001920|http://purl.obolibrary.org/obo/TXPO_0003168|http://purl.obolibrary.org/obo/TXPO_0003288|http://purl.obolibrary.org/obo/TXPO_0002734|http://purl.obolibrary.org/obo/TXPO_0002733|http://purl.obolibrary.org/obo/TXPO_0001200|http://purl.obolibrary.org/obo/TXPO_0001204|http://purl.obolibrary.org/obo/TXPO_0001203|http://purl.obolibrary.org/obo/TXPO_0001205|http://purl.obolibrary.org/obo/TXPO_0001206|http://purl.obolibrary.org/obo/TXPO_0001201|http://purl.obolibrary.org/obo/TXPO_0001202|http://purl.obolibrary.org/obo/TXPO_0001207|http://purl.obolibrary.org/obo/TXPO_0001944|http://purl.obolibrary.org/obo/TXPO_0003175|http://purl.obolibrary.org/obo/TXPO_0003177|http://purl.obolibrary.org/obo/TXPO_0003173|http://purl.obolibrary.org/obo/TXPO_0003178|http://purl.obolibrary.org/obo/TXPO_0003174|http://purl.obolibrary.org/obo/TXPO_0001179|http://purl.obolibrary.org/obo/TXPO_0001178|http://purl.obolibrary.org/obo/TXPO_0000904|http://purl.obolibrary.org/obo/TXPO_0001933|http://purl.obolibrary.org/obo/TXPO_0001191|http://purl.obolibrary.org/obo/TXPO_0001197|http://purl.obolibrary.org/obo/TXPO_0001196|http://purl.obolibrary.org/obo/TXPO_0001198|http://purl.obolibrary.org/obo/TXPO_0001194|http://purl.obolibrary.org/obo/TXPO_0001193|http://purl.obolibrary.org/obo/TXPO_0001192|http://purl.obolibrary.org/obo/TXPO_0001190|http://purl.obolibrary.org/obo/TXPO_0001199|http://purl.obolibrary.org/obo/TXPO_0002254|http://purl.obolibrary.org/obo/TXPO_0003208|http://purl.obolibrary.org/obo/TXPO_0003209|http://purl.obolibrary.org/obo/TXPO_0002430|http://purl.obolibrary.org/obo/TXPO_0002363|http://purl.obolibrary.org/obo/TXPO_0002367|http://purl.obolibrary.org/obo/TXPO_0002366|http://purl.obolibrary.org/obo/TXPO_0002369|http://purl.obolibrary.org/obo/TXPO_0002368|http://purl.obolibrary.org/obo/TXPO_0002404|http://purl.obolibrary.org/obo/TXPO_0002407|http://purl.obolibrary.org/obo/TXPO_0000675|http://purl.obolibrary.org/obo/TXPO_0002759|http://purl.obolibrary.org/obo/TXPO_0001149|http://purl.obolibrary.org/obo/TXPO_0003183|http://purl.obolibrary.org/obo/TXPO_0003186|http://purl.obolibrary.org/obo/TXPO_0003185|http://purl.obolibrary.org/obo/TXPO_0003189|http://purl.obolibrary.org/obo/TXPO_0003180|http://purl.obolibrary.org/obo/TXPO_0000844|http://purl.obolibrary.org/obo/TXPO_0002711,,,,,,,,,,,,,,,,,,TXPO:0000501,,,,,,,,,,,,,,,,,,,,,,glutathione depletion [toxic course],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000509,bile acid,,"Any member of a group of steroid carboxylic acids occuring in bile, where they are present as the sodium salts of their amides with glycine or taurine.",false,,,http://purl.obolibrary.org/obo/CHEBI_35341,,bile acids|Gallensaeure|Bile salt,,,,,,,,,,,,,,,,,,ISBN:0123878179|http://purl.obolibrary.org/obo/CHEBI_3098,,"Any member of a group of steroid carboxylic acids occuring in bile, where they are present as the sodium salts of their amides with glycine or taurine.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000509,,,,,,,,,,,,,,,,,,,,,,bile acid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000505,dissociation of BIP complex [ER stress],,"Dissociation of Bip complex is a subtype of detaching: A process that disaggregates a Bip complex into Bip and other molecule(s).
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000872,,,,,,,,,,,,,,,,,,,,PMID:10854322|PMID:23334697,,"Dissociation of Bip complex is a subtype of detaching: A process that disaggregates a Bip complex into Bip and other molecule(s).
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002106,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002385,,,,,,,,,,,,,,,,,,,TXPO:0000505,,,,,,,,,,,,,,,,,,,,,,dissociation of BIP complex [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005789,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0200342,L-Ornithine,,,false,,,http://purl.obolibrary.org/obo/CHEBI_33709,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0200342,,,,,,,,,,,,,,,,,,,,,,L-Ornithine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000012,IL-3,interleukin-3,,false,,,http://purl.obolibrary.org/obo/IMR_0000007,,,,,,,,,,,,,,,,,,,,GO:0005135,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000622,,,,,interleukin-3,,,,,IMR:0000012,,,,,,,,,,,,,,,,,,,,,,IL-3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000004318,MMP9,,"Other designations: 92 kDa gelatinase|92 kDa type IV collagenase|macrophage gelatinase|matrix metalloproteinase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase)|matrix metalloproteinase-9|type V collagenase",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,MANDP2|GELB|CLG4B|MMP-9,,,,,,,,,,,,20,,,,,,Ensembl:ENSG00000100985|Vega:OTTHUMG00000033044|HPRD:00387|HGNC:7176|MIM:120361,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase)",,,20q11.2-q13.1,,,,,,,,,,,,,,,,"GO_0001501 (EC: IEA); GO_0001503 (EC: IEA); GO_0004222 (EC: IDA, PMID: 16192646); GO_0005515 (EC: IPI, PMID: 16512877); GO_0005518 (EC: TAS, PMID: 2251898); GO_0005576 (EC: TAS); GO_0005578 (EC: IEA); GO_0005615 (EC: IDA, PMID: 2251898); GO_0006508 (EC: IDA, PMID: 2551898); GO_0007566 (EC: IEA); GO_0008270 (EC: TAS, PMID: 2251898); GO_0022617 (EC: TAS); GO_0030198 (EC: TAS); GO_0030225 (EC: TAS, PMID: 2251898); GO_0030574 (EC: TAS); GO_0042802 (EC: IPI); GO_0043065 (EC: IEA); GO_0050900 (EC: IEA); GO_0051549 (EC: IMP, PMID: 17704059)",,,,,,,,,PMID: 1281792; 1371271; 1400481; 1645657; 1653055; 1653238; 1851724; 1932376; 2158484; 2251898; 2551898; 7669817; 7694569; 7762981; 7896811; 8012988; 8216228; 8426746; 8568270; 8691515; 8978762; 9261109; 9268487; 9344465; 9360944; 9378998; 9578462; 9590175; 9789069; 9878537; 10095777; 10339412; 10389762; 10419448; 10580107; 10598806; 10636480; 10642956; 10644727; 10652271; 10706134; 10796887; 10859319; 10900205; 10988146; 11023497; 11081634; 11134254; 11168762; 11179305; 11279011; 11410119; 11468147; 11486009; 11546917; 11557670; 11576356; 11606713; 11675412; 11688724; 11708786; 11742492; 11756567; 11780052; 11781819; 11813159; 11827795; 11827968; 11830485; 11833938; 11839588; 11839746; 11854622; 11875051; 11876767; 11890521; 11916008; 11920503; 11920505; 11935310; 11940298; 11956628; 11958288; 11971760; 11978564; 11986939; 11994547; 11999552; 12004062; 12029498; 12034345; 12050187; 12051944; 12054499; 12062817; 12063180; 12077439; 12081477; 12082590; 12082592; 12084167; 12103254; 12105194; 12126625; 12127674; 12183836; 12193399; 12205736; 12208863; 12219015; 12231534; 12235127; 12235151; 12356580; 12372334; 12376362; 12398893; 12414663; 12431239; 12431981; 12437116; 12443715; 12444074; 12452001; 12464265; 12471459; 12477932; 12479097; 12479099; 12559990; 12569569; 12586837; 12587534; 12589095; 12606037; 12612199; 12615834; 12626459; 12642591; 12651627; 12663332; 12668489; 12671895; 12704537; 12712078; 12717622; 12717827; 12724312; 12727228; 12728308; 12745093; 12750540; 12753719; 12769333; 12789238; 12791318; 12810681; 12811828; 12824186; 12830465; 12847101; 12850503; 12861851; 12865405; 12866035; 12874388; 12879005; 12880418; 12914776; 12921631; 12947332; 12949792; 12950257; 12952836; 12958623; 12960156; 12960961; 12967855; 12970724; 14500349; 14520690; 14550288; 14550924; 14551878; 14561155; 14581136; 14605329; 14607966; 14624478; 14633819; 14644158; 14661062; 14661256; 14675172; 14676438; 14681642; 14687896; 14697951; 14705229; 14719079; 14744773; 14766231; 14767860; 14963289; 14973177; 14981939; 14982353; 14983226; 14990702; 15009705; 15015767; 15022328; 15033492; 15034761; 15064242; 15067014; 15070833; 15075244; 15084374; 15085249; 15094060; 15105396; 15118287; 15122332; 15123665; 15131051; 15132991; 15146197; 15165255; 15169910; 15191941; 15201662; 15204835; 15212936; 15214991; 15223247; 15239215; 15241180; 15247301; 15248826; 15254682; 15256791; 15265790; 15271946; 15277439; 15288392; 15311942; 15313474; 15316122; 15327032; 15328199; 15356679; 15363817; 15363818; 15384859; 15385524; 15449075; 15465610; 15489334; 15498369; 15522165; 15528190; 15531749; 15531921; 15536155; 15541021; 15556929; 15557756; 15565457; 15569994; 15583828; 15585220; 15604254; 15609121; 15609318; 15628723; 15642145; 15652414; 15672417; 15691353; 15748780; 15754326; 15754388; 15760647; 15760679; 15797648; 15800029; 15809093; 15820246; 15823277; 15824107; 15824527; 15826319; 15831558; 15834245; 15848174; 15855236; 15863510; 15866216; 15885317; 15888067; 15896974; 15904490; 15924675; 15935515; 15944607; 15947272; 15949868; 15952124; 15955221; 15956726; 15998676; 16005367; 16023005; 16026590; 16042227; 16054858; 16061701; 16061852; 16061858; 16080811; 16082623; 16083752; 16086239; 16097959; 16100452; 16102725; 16114056; 16126934; 16133529; 16135959; 16140265; 16155381; 16158251; 16159601; 16166639; 16168399; 16177394; 16179285; 16191301; 16192641; 16192646; 16202218; 16213873; 16237750; 16246065; 16248458; 16248506; 16260653; 16267613; 16272296; 16278009; 16280123; 16288746; 16291395; 16301860; 16313894; 16331612; 16338908; 16339461; 16356191; 16359987; 16372907; 16395864; 16405530; 16413616; 16426593; 16429190; 16432074; 16455621; 16456793; 16463672; 16467043; 16469801; 16476613; 16512877; 16514055; 16516857; 16528670; 16551853; 16574900; 16585124; 16596205; 16615041; 16615109; 16619037; 16631427; 16638593; 16643654; 16652230; 16670311; 16672230; 16674956; 16676616; 16678588; 16690896; 16700817; 16709939; 16718267; 16720051; 16722933; 16732316; 16733654; 16736997; 16739355; 16754484; 16772717; 16778129; 16780738; 16786122; 16803520; 16829143; 16830792; 16840178; 16840734; 16850107; 16864898; 16880228; 16884727; 16888026; 16894529; 16897078; 16914095; 16917093; 16919028; 16921111; 16926552; 16940985; 16945027; 16952784; 16954500; 16961137; 16980554; 16984917; 16987162; 16990034; 16990429; 17008230; 17011110; 17018612; 17020973; 17024375; 17029196; 17030690; 17033924; 17045024; 17049831; 17052690; 17065436; 17071711; 17076610; 17077165; 17077200; 17089188; 17091328; 17109104; 17110919; 17116693; 17126384; 17129456; 17134708; 17137622; 17137715; 17151782; 17161405; 17161406; 17163537; 17174275; 17175378; 17176047; 17178858; 17182940; 17186550; 17200207; 17205957; 17208328; 17214970; 17221318; 17222798; 17223007; 17224907; 17226791; 17237723; 17243139; 17261792; 17275003; 17275949; 17278189; 17289174; 17298441; 17299841; 17310847; 17311279; 17311292; 17320450; 17320799; 17332331; 17334233; 17346338; 17350093; 17357517; 17364896; 17367869; 17383306; 17384080; 17389601; 17394006; 17397984; 17407789; 17418871; 17437609; 17448043; 17448220; 17465457; 17473191; 17475671; 17485071; 17486447; 17487763; 17488482; 17489740; 17493172; 17493236; 17493602; 17498910; 17502998; 17505560; 17531242; 17540340; 17541305; 17546628; 17559070; 17559909; 17562263; 17564313; 17572184; 17572495; 17572998; 17574455; 17575075; 17581602; 17581988; 17582780; 17589947; 17597813; 17599356; 17599818; 17601679; 17607721; 17611666; 17617834; 17624083; 17624726; 17640671; 17643435; 17650671; 17655938; 17657740; 17660250; 17669467; 17671679; 17678975; 17698228; 17702963; 17704059; 17706116; 17706812; 17718386; 17721627; 17725804; 17729419; 17760717; 17761309; 17761425; 17763331; 17768685; 17786346; 17868665; 17879021; 17884772; 17888430; 17888724; 17889183; 17890452; 17892998; 17893005; 17901377; 17912241; 17914564; 17916907; 17917789; 17920311; 17922642; 17923814; 17928006; 17937912; 17949555; 17950725; 17964292; 17964826; 17972522; 17981679; 17986062; 17991734; 18000233; 18006768; 18006877; 18025061; 18028894; 18030366; 18035073; 18042068; 18045645; 18048360; 18048771; 18049028; 18050191; 18052707; 18061419; 18062964; 18063832; 18067861; 18069634; 18070420; 18070596; 18076359; 18077379; 18081721; 18091353; 18093986; 18095095; 18155162; 18155181; 18164995; 18166633; 18167127; 18173548; 18174366; 18177474; 18177875; 18187184; 18194081; 18194466; 18194849; 18214299; 18214300; 18215420; 18217401; 18222174; 18227728; 18234959; 18236174; 18237197; 18259971; 18276934; 18283635; 18288638; 18291374; 18292822; 18295959; 18296264; 18298353; 18302674; 18303200; 18307173; 18309649; 18323498; 18326820; 18332090; 18334147; 18336852; 18337444; 18342317; 18345028; 18347934; 18355442; 18356846; 18357389; 18359769; 18362300; 18368597; 18376229; 18378414; 18390930; 18391843; 18395263; 18397859; 18398039; 18401426; 18408070; 18410405; 18414015; 18414048; 18425389; 18426080; 18428024; 18437914; 18438343; 18444803; 18451168; 18451255; 18452312; 18455130; 18457660; 18468407; 18474748; 18477480; 18479418; 18480385; 18483282; 18483307; 18496568; 18506186; 18512818; 18513509; 18539681; 18548114; 18552608; 18552985; 18554282; 18554596; 18559505; 18563800; 18571010; 18575776; 18587729; 18596065; 18597705; 18609045; 18616513; 18617520; 18618693; 18619044; 18619594; 18632241; 18634035; 18636124; 18641922; 18644862; 18651887; 18652766; 18653544; 18660489; 18663625; 18665441; 18670324; 18674955; 18680431; 18683733; 18683786; 18700005; 18704317; 18706098; 18710428; 18712166; 18713734; 18713744; 18716555; 18719998; 18722610; 18763261; 18773430; 18782525; 18790699; 18797400; 18801463; 18801483; 18802702; 18809380; 18813792; 18818437; 18818748; 18821062; 18829111; 18835014; 18835540; 18835646; 18835949; 18835982; 18843978; 18849127; 18850474; 18852494; 18930181; 18937938; 18942717; 18945772; 18946196; 18948614; 18951331; 18952609; 18953959; 18954444; 18971037; 18976975; 18980523; 18997840; 19005290; 19010864; 19019335; 19019525; 19020728; 19020757; 19022565; 19064570; 19074885; 19093256; 19094228; 19100442; 19105397; 19109975; 19110045; 19130490; 19132754; 19134356; 19141347; 19141395; 19141401; 19144335; 19147749; 19148478; 19148494; 19150151; 19150878; 19150882; 19159011; 19165813; 19176371; 19180518; 19187648; 19188843; 19191857; 19197071; 19199380; 19208844; 19218340; 19219072; 19236750; 19242924; 19243899; 19248107; 19249761; 19264454; 19269113; 19270179; 19270357; 19274436; 19279308; 19283512; 19287189; 19298660; 19303106; 19306108; 19317417; 19317840; 19330734; 19331685; 19331801; 19334035; 19336370; 19337556; 19357773; 19358835; 19376817; 19381161; 19383343; 19385051; 19387352; 19388348; 19388358; 19389382; 19391484; 19395987; 19420105; 19435423; 19438845; 19444758; 19447587; 19448396; 19450561; 19453261; 19454280; 19455469; 19461556; 19464975; 19465902; 19466389; 19473053; 19475568; 19477063; 19480010; 19484688; 19484988; 19494703; 19501047; 19504098; 19507017; 19507256; 19513513; 19523650; 19524176; 19525292; 19526105; 19527514; 19528914; 19529860; 19536654; 19541004; 19541314; 19541433; 19543729; 19548069; 19551542; 19564415; 19574670; 19575173; 19575331; 19576586; 19578796; 19581416; 19582779; 19594729; 19596921; 19597352; 19602039; 19604544; 19608737; 19614693; 19615667; 19617223; 19625121; 19628284; 19629003; 19631393; 19633731; 19640333; 19641039; 19643940; 19657395; 19658178; 19661147; 19662350; 19664242; 19665460; 19668117; 19668239; 19672558; 19674198; 19681038; 19690403; 19693769; 19700239; 19716817; 19723042; 19723139; 19724058; 19724860; 19728856; 19731200; 19734590; 19748093; 19748669; 19751716; 19755933; 19762163; 19783786; 19789190; 19796534; 19799610; 19804834; 19814619; 19834535; 19836620; 19843640; 19857655; 19875168; 19880617; 19885578; 19885589; 19887608; 19887890; 19889076; 19889214; 19903304; 19903858; 19906411; 19909726; 19913121; 19915485; 19921474; 19927649; 19933216; 19933377; 19933990; 19940022; 19944559; 19946014; 19946898; 19956847; 19958602; 19995403; 19996286; 20001295; 20003765; 20009356; 20020446; 20021816; 20021931; 20021962; 20030715; 20030941; 20031158; 20035078; 20041335; 20043135; 20051489; 20051814; 20060752; 20066900; 20070253; 20070483; 20078883; 20082877; 20087345; 20091096; 20097566; 20100617; 20102205; 20110172; 20110530; 20111696; 20120864; 20128385; 20129576; 20133364; 20139322; 20144500; 20149706; 20159608; 20160036; 20160424; 20164037; 20181264; 20184534; 20184870; 20193458; 20195229; 20197064; 20207476; 20211062; 20211065; 20211160; 20214668; 20215707; 20219012; 20222942; 20226090; 20302034; 20305284; 20305574; 20333651; 20333791; 20338991; 20346360; 20352300; 20354277; 20356362; 20359813; 20360147; 20363273; 20364320; 20364697; 20372784; 20373132; 20375027; 20381197; 20388776; 20392358; 20392988; 20395963; 20413683; 20416216; 20417130; 20421725; 20425121; 20427044; 20431850; 20432471; 20443834; 20450704; 20452482; 20453000; 20453486; 20455995; 20458747; 20467172; 20471697; 20473759; 20482566; 20484597; 20485444; 20501425; 20514432; 20514437; 20514473; 20521099; 20529372; 20529817; 20533294; 20534121; 20534943; 20538124; 20541269; 20545111; 20549300; 20550708; 20554312; 20556397; 20563853; 20571492; 20574775; 20575100; 20578262; 20584616; 20587546; 20590473; 20596661; 20600798; 20605480; 20609440; 20616161; 20616708; 20621951; 20627731; 20628086; 20628624; 20631454; 20631638; 20636397; 20638438; 20639647; 20646231; 20646600; 20650312; 20652360; 20652762; 20654099; 20654108; 20654122; 20662554; 20672350; 20673868; 20674181; 20699364; 20704821; 20707923; 20707992; 20725135; 20725776; 20725790; 20732728; 20800577; 20800911; 20802378; 20808730; 20812964; 20813982; 20818082; 20824409; 20825973; 20827608; 20837483; 20838751; 20842516; 20843706; 20853162; 20857147; 20864363; 20872564; 20878580; 20889295; 20923324; 20936527; 20936699; 20937775; 20942234; 20948207; 20957628; 20960272; 20964870; 20970160; 20971661; 20971732; 20977848; 21034616; 21039753; 21041986; 21044610; 21047774; 21048031; 21081040; 21086628; 21089052; 21089054; 21094936; 21103065; 21106094; 21108787; 21116502; 21120482; 21128246; 21135557; 21136273; 21143201; 21146069; 21147512; 21148633; 21150136; 21151179; 21159039; 21159820; 21162890; 21165404; 21170498; 21170718; 21174909; 21187089; 21190541; 21194909; 21195432; 21205837; 21208653; 21212676; 21222132; 21227015; 21229878; 21231907; 21232745; 21238444; 21244504; 21249198; 21254649; 21261731; 21265099; 21274725; 21277149; 21277671; 21279695; 21283828; 21288887; 21305678; 21321391; 21336947; 21349701; 21354279; 21355964; 21367627; 21371122; 21376533; 21389674; 21391238; 21391788; 21393869; 21401309; 21424088; 21425178; 21425912; 21427648; 21428178; 21429222; 21430243; 21437624; 21437990; 21439274; 21442180; 21454378; 21454822; 21455563; 21455583; 21455597; 21461577; 21461859; 21462131; 21463121; 21473134; 21481333; 21485219; 21491088; 21496113; 21503582; 21503589; 21505993; 21506705; 21515251; 21516345; 21519142; 21525012; 21535601; 21541352; 21541674; 21550738; 21553521; 21557297; 21559401; 21559835; 21565179; 21567393; 21574189; 21577212; 21600177; 21601305; 21612954; 21616098; 21620482; 21620625; 21620672; 21621856; 21624249; 21641584; 21652634; 21655354; 21663729; 21664966; 21667159; 21672616; 21676452; 21678108; 21681346; 21687932; 21707819; 21707906; 21710351; 21710717; 21717058; 21718298; 21721010; 21723775; 21726963; 21733941; 21735328; 21737808; 21740772; 21742938; 21750188; 21752154; 21760532; 21760911; 21762266; 21763143; 21764478; 21764480; 21777517; 21781516; 21791204; 21802713; 21813510; 21814723; 21819758; 21824169; 21833719; 21839130; 21840940; 21842128; 21844877; 21855630; 21857898; 21857935; 21860087; 21861843; 21867689; 21872914; 21873432; 21881840; 21882477; 21889192; 21900582; 21913037; 21915713; 21922298; 21923032; 21928345; 21933581; 21933988; 21936677; 21940962; 21946941; 21956669; 21957576; 21958210; 21959615; 21963461; 21963570; 21963718; 21965756; 21969093; 21975935; 21983728; 21989104; 21993004; 21993452; 22005258; 22009750; 22020222; 22027013; 22030137; 22041445; 22052126; 22053594; 22086927; 22092736; 22094096; 22094285; 22107133; 22112973; 22113040; 22116092; 22117411; 22118839; 22121096; 22126484; 22132194; 22138288; 22139647; 22142952; 22151540; 22167195; 22178867; 22194464; 22197032; 22197408; 22200256; 22200563; 22200661; 22200690; 22204652; 22206665; 22210296; 22213073; 22215147; 22220395; 22220905; 22227305; 22228328; 22229442; 22232962; 22234512; 22237453; 22237587; 22241750; 22244537; 22252121; 22253805; 22259987; 22270366; 22272343; 22275073; 22278305; 22280559; 22288519; 22289521; 22289522; 22289852; 22291969; 22303700; 22304569; 22305865; 22309286; 22309692; 22321809; 22327326; 22336124; 22343748; 22391064; 22392094; 22394598; 22395516; 22395947; 22402435; 22402936; 22406112; 22406264; 22407864; 22410369; 22428754; 22433859; 22433968; 22439866; 22446321; 22448134; 22455335; 22459050; 22461694; 22465218; 22465234; 22472880; 22490156; 22490851; 22496335; 22513045; 22514348; 22516898; 22527933; 22528837; 22531699; 22532131; 22534634; 22541398; 22542663; 22547904; 22550024; 22573202; 22581515; 22582506; 22582975; 22591361; 22591362; 22608171; 22613329; 22619232; 22640376; 22640735; 22645431; 22646815; 22658256; 22664146; 22667130; 22674412; 22675930; 22677171; 22684547; 22684781; 22692967; 22694915; 22695075; 22697069; 22706255; 22710862; 22727497; 22729913; 22730324; 22738689; 22740037; 22740332; 22752570; 22773464; 22782080; 22796276; 22806308; 22808470; 22809399; 22810092; 22819245; 22821546; 22829602; 22832979; 22847199; 22848630; 22860023; 22863720; 22865631; 22866313; 22868188; 22878890; 22879913; 22880464; 22883193; 22883281; 22883459; 22884843; 22887854; 22888638; 22890115; 22906271; 22907074; 22914468; 22922035; 22923171; 22931588; 22936257; 22938481; 22942228; 22950839; 22954486; 22955446; 22957785; 22960198; 22964525; 22967049; 22969161; 22974233; 22977287; 22984561; 22985578; 22990627; 22994087; 23010359; 23011799; 23016931; 23018543; 23019342; 23031673; 23054355; 23064462; 23071279; 23076139; 23085464; 23091417; 23100088; 23104504; 23107277; 23107342; 23110201; 23114726; 23122824; 23123160; 23128233; 23134156; 23136157; 23146278; 23150684; 23151854; 23170789; 23175213; 23176145; 23179648; 23182966; 23183822; 23190621; 23201304; 23213753; 23221126; 23229548; 23232575; 23238437; 23240894; 23249715; 23252412; 23257253; 23257658; 23258534; 23263825; 23264211; 23269605; 23271730; 23273944; 23288142; 23292863; 23295196; 23303633; 23306155; 23307113; 23313298; 23317273; 23320481; 23326131; 23328249; 23341882; 23343958; 23349885; 23350235; 23353996; 23356642; 23372434; 23373240; 23375032; 23377317; 23387490; 23387827; 23388475; 23390835; 23401127; 23401274; 23409137; 23441116; 23454149; 23456480; 23476138; 23490413; 23504993; 23509357; 23510467; 23510472; 23516489; 23525277; 23525523; 23526143; 23536722; 23544610; 23547785; 23550278; 23554968; 23555986; 23557756; 23559867; 23566884; 23570558; 23575435; 23580092; 23601700; 23606791; 23615401; 23617547; 23637955; 23639553; 23650722; 23657566; 23660954; 23661254; 23663265; 23673111; 23679245; 23681803; 23696797; 23696833; 23697266; 23708302; 23715826; 23725476; 23742776; 23762835; 23768069; 23770289; 23770367; 23792205; 23793312; 23794948; 23801886; 23805466; 23807209; 23807291; 23814095; 23819814; 23824974; 23825535; 23829879; 23847438; 23870474; 23886165; 23897811; 23901237; 23908067; 23922934; 23936495; 23987197; 23991961; 23993112; 24025248; 24039251; 24065232; 24067484; 24072693; 24075964; 24099107; 24099425; 24122234; 24136650; 24141084; 24174628; 24210229; 24291031; 24297171; 24326842; 24330623; 24335416; 24344010; 24344026; 24374173; 24479343; 24479348,,,,,,,,,,,,,,,OGG:3000004318,,,,,,,"matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase)",,,,,,,,,,,,,"Other designations: 92 kDa gelatinase|92 kDa type IV collagenase|macrophage gelatinase|matrix metalloproteinase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase)|matrix metalloproteinase-9|type V collagenase",,MMP9,,,,,,,,,,,,,,,,,,,,,,,4318,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,MMP9,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000004313,MMP2,,Other designations: 72 kDa gelatinase|72 kDa type IV collagenase|MMP-2|collagenase type IV-A|gelatinase A|matrix metalloproteinase-2|matrix metalloproteinase-II|neutrophil gelatinase,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CLG4|MMP-II|MONA|TBE-1|CLG4A,,,,,,,,,,,,16,,,,,,Vega:OTTHUMG00000133202|Ensembl:ENSG00000087245|MIM:120360|HGNC:7166|HPRD:00386,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase)",,,16q13-q21,,,,,,,,,,,,,,,,"GO_0001525 (EC: IEA); GO_0001666 (EC: IEA); GO_0001955 (EC: IEA); GO_0001957 (EC: IEA); GO_0004222 (EC: IEA); GO_0004252 (EC: TAS); GO_0005515 (EC: IPI); GO_0005576 (EC: TAS); GO_0005578 (EC: IEA); GO_0005615 (EC: IDA, PMID: 18492766); GO_0005634 (EC: IEA); GO_0005739 (EC: IEA); GO_0005886 (EC: IEA); GO_0006508 (EC: TAS, PMID: 2834383); GO_0007566 (EC: IEA); GO_0008270 (EC: IEA); GO_0022617 (EC: TAS); GO_0030017 (EC: IEA); GO_0030198 (EC: TAS); GO_0030574 (EC: TAS); GO_0044267 (EC: TAS); GO_0060325 (EC: IEA); GO_0060346 (EC: IEA); GO_0071230 (EC: IEA)",,,,,,,,,PMID: 1460022; 1846313; 1851724; 2071140; 2158484; 2162831; 2834383; 7523391; 7583664; 7683678; 7694569; 7782289; 7935812; 7947821; 7998967; 8549817; 8663297; 8663332; 8692946; 8862926; 9119036; 9148753; 9182583; 9343394; 9344465; 9438380; 9640131; 9699154; 9737711; 9853262; 9933646; 10196161; 10356396; 10419448; 10551873; 10652000; 10652271; 10900205; 10947989; 10986281; 10991943; 11114309; 11134507; 11168762; 11179305; 11220743; 11368514; 11382769; 11420387; 11431697; 11485914; 11571304; 11598182; 11728453; 11748988; 11756567; 11762702; 11782389; 11790786; 11792711; 11824472; 11833938; 11839588; 11844598; 11854622; 11889208; 11895494; 11918086; 11920503; 11928808; 11928813; 11929863; 11935310; 11948127; 11956628; 11961384; 12007723; 12023034; 12029498; 12032297; 12034345; 12039803; 12077518; 12085233; 12087091; 12103254; 12115722; 12122099; 12147229; 12147339; 12149192; 12193399; 12194986; 12198653; 12225805; 12235151; 12371906; 12372458; 12374789; 12376362; 12393408; 12393872; 12431239; 12438229; 12439941; 12451991; 12470034; 12471459; 12473650; 12475252; 12477932; 12479097; 12486137; 12522578; 12559990; 12569569; 12586836; 12587534; 12589095; 12601782; 12602913; 12614934; 12615834; 12632066; 12632084; 12642591; 12651627; 12657623; 12676736; 12684625; 12753080; 12764090; 12810672; 12832446; 12845641; 12861074; 12873995; 12878157; 12879005; 12880418; 12914776; 12939660; 12952836; 12967855; 12970394; 12970724; 14500349; 14519487; 14520690; 14580155; 14583471; 14604886; 14614057; 14644155; 14644777; 14661256; 14666611; 14679018; 14694003; 14697951; 14710472; 14713104; 14732714; 14744781; 14766248; 14871985; 14973177; 14981939; 14982725; 14983226; 14990702; 14990972; 14996438; 15004438; 15009703; 15015767; 15051038; 15056834; 15067014; 15102849; 15146192; 15165255; 15201662; 15241180; 15248212; 15248826; 15250832; 15254682; 15255544; 15265790; 15271946; 15277330; 15280384; 15280448; 15317806; 15317818; 15351863; 15375490; 15381707; 15449075; 15475447; 15485653; 15489233; 15489334; 15492291; 15522165; 15541021; 15557756; 15567754; 15569994; 15604254; 15609121; 15609318; 15609323; 15616792; 15621117; 15632190; 15637056; 15651999; 15665288; 15665394; 15672417; 15691365; 15731163; 15743799; 15754118; 15756447; 15820246; 15831360; 15841469; 15866216; 15878967; 15885317; 15904490; 15911696; 15929171; 15944607; 15949313; 15955221; 15955448; 15955449; 15983226; 15998676; 15998788; 16005367; 16018746; 16023005; 16023011; 16042227; 16082623; 16083752; 16097959; 16134528; 16142392; 16142692; 16146757; 16158251; 16168111; 16188099; 16188574; 16213873; 16260653; 16275157; 16306050; 16308106; 16313894; 16338908; 16339461; 16341461; 16344560; 16356191; 16359987; 16361361; 16364202; 16379022; 16407830; 16413616; 16414983; 16424893; 16425263; 16438723; 16453304; 16456793; 16458924; 16476613; 16510149; 16551362; 16575904; 16585124; 16615109; 16647062; 16718267; 16718824; 16722933; 16728425; 16739355; 16755991; 16772717; 16776850; 16778129; 16803520; 16829143; 16840178; 16884384; 16888681; 16891619; 16894529; 16897078; 16919028; 16940985; 16961137; 16967187; 16987162; 17000679; 17008230; 17012225; 17029196; 17033924; 17065436; 17067460; 17070879; 17071711; 17081126; 17088079; 17088321; 17089188; 17099140; 17109104; 17151781; 17175151; 17177839; 17178858; 17181997; 17182940; 17188706; 17189319; 17203213; 17203468; 17205957; 17208328; 17217338; 17226791; 17236757; 17237723; 17243139; 17258390; 17265493; 17289174; 17299802; 17299841; 17314270; 17320450; 17326127; 17335808; 17350093; 17357514; 17363400; 17364896; 17367869; 17374529; 17377415; 17383306; 17384031; 17409012; 17429393; 17435175; 17437609; 17448043; 17473191; 17486447; 17487426; 17488654; 17493172; 17493602; 17516913; 17540340; 17541305; 17545513; 17546628; 17559909; 17563705; 17564313; 17570740; 17589947; 17593815; 17607721; 17611666; 17613170; 17616173; 17623663; 17624083; 17624726; 17638886; 17640671; 17650671; 17653824; 17660250; 17661346; 17666398; 17671679; 17678975; 17680282; 17699594; 17706116; 17706812; 17718386; 17725804; 17786346; 17845054; 17851253; 17876296; 17879021; 17886098; 17893005; 17893430; 17901377; 17908800; 17923814; 17943549; 17949555; 17950725; 17958893; 17962725; 17972522; 17981679; 17986062; 18000234; 18025061; 18029348; 18031543; 18035073; 18035727; 18038907; 18042068; 18045645; 18049448; 18052707; 18062285; 18063683; 18069632; 18070420; 18081721; 18088350; 18091353; 18093986; 18155181; 18160708; 18166633; 18172354; 18177474; 18177649; 18182154; 18185989; 18187184; 18194849; 18205826; 18208802; 18210196; 18214299; 18217401; 18220784; 18236174; 18251742; 18253117; 18256065; 18265895; 18283635; 18288638; 18288718; 18291374; 18292822; 18292932; 18295959; 18298353; 18308831; 18314110; 18329693; 18330957; 18332090; 18332634; 18337444; 18340378; 18359774; 18366007; 18378414; 18398039; 18400453; 18424416; 18425389; 18426670; 18431027; 18438431; 18444803; 18455130; 18462748; 18468407; 18469019; 18472160; 18473733; 18477480; 18483282; 18492766; 18496568; 18498066; 18506186; 18543216; 18552985; 18560213; 18575776; 18579756; 18580857; 18593949; 18597705; 18611410; 18618693; 18627313; 18636124; 18641922; 18644390; 18644862; 18651826; 18652765; 18653973; 18663625; 18664479; 18665467; 18670324; 18683733; 18692810; 18701818; 18707587; 18711060; 18712166; 18713744; 18714566; 18757369; 18773430; 18782525; 18784838; 18802398; 18802702; 18805052; 18814268; 18818748; 18829111; 18829229; 18835646; 18852494; 18937938; 18940384; 18946196; 18950008; 18971037; 18971427; 18974156; 19007982; 19019335; 19020757; 19022775; 19088110; 19088827; 19094228; 19100442; 19101987; 19105397; 19109975; 19116140; 19117773; 19121849; 19122458; 19124506; 19132754; 19134348; 19141395; 19159011; 19165813; 19176371; 19188819; 19189315; 19191857; 19196101; 19199380; 19212830; 19221481; 19223381; 19236750; 19241124; 19243899; 19248107; 19249761; 19266599; 19274436; 19281093; 19286653; 19287959; 19288452; 19295411; 19303106; 19324884; 19330734; 19331801; 19332048; 19337556; 19338750; 19345347; 19358835; 19360430; 19386107; 19391484; 19395678; 19426551; 19438747; 19445018; 19448672; 19449375; 19454611; 19455469; 19459623; 19460733; 19464975; 19465902; 19466389; 19469865; 19477063; 19484988; 19507256; 19515587; 19523650; 19523958; 19525975; 19527514; 19528914; 19529860; 19546837; 19551542; 19551856; 19560452; 19562509; 19574670; 19575173; 19577357; 19578796; 19580633; 19581306; 19594729; 19610062; 19615732; 19617223; 19617714; 19625121; 19637058; 19643940; 19653001; 19671357; 19682073; 19687355; 19698156; 19700865; 19709349; 19716817; 19723042; 19723139; 19724860; 19724922; 19731823; 19760465; 19780834; 19786072; 19787626; 19789190; 19814619; 19816602; 19820359; 19821096; 19853299; 19861308; 19874467; 19875168; 19875755; 19885578; 19887570; 19889076; 19901964; 19903768; 19903858; 19913121; 19921476; 19930715; 19939245; 19954064; 19956847; 19995403; 19995435; 19997654; 20003765; 20021962; 20021964; 20031158; 20044778; 20064641; 20071690; 20082877; 20091096; 20100617; 20110530; 20113256; 20129576; 20133364; 20138860; 20140262; 20145123; 20160036; 20175118; 20195229; 20207476; 20211062; 20211065; 20216978; 20219012; 20222942; 20230421; 20233617; 20305284; 20333791; 20346360; 20353950; 20360147; 20364697; 20372784; 20375027; 20381119; 20382120; 20394501; 20404912; 20416077; 20432471; 20435584; 20450704; 20452482; 20453000; 20453486; 20455995; 20473759; 20482566; 20484597; 20485444; 20501419; 20501425; 20510080; 20514432; 20514437; 20514447; 20529817; 20541540; 20563853; 20565774; 20576603; 20586027; 20587546; 20590473; 20600798; 20616161; 20616708; 20625418; 20625691; 20628086; 20628624; 20634891; 20646497; 20646600; 20652762; 20654108; 20654122; 20672350; 20673868; 20685029; 20717917; 20724289; 20725135; 20730428; 20730561; 20808730; 20811691; 20843706; 20845079; 20855151; 20864363; 20887714; 20889295; 20921293; 20932173; 20936527; 20936699; 20937816; 20948207; 20963502; 20970160; 20977637; 21041295; 21041693; 21045016; 21048031; 21053100; 21086628; 21103065; 21104439; 21104440; 21116502; 21142815; 21145461; 21147512; 21148629; 21151391; 21165404; 21174062; 21174909; 21193558; 21205070; 21206012; 21212676; 21228795; 21229878; 21248144; 21261731; 21264536; 21265099; 21276823; 21277149; 21307882; 21316839; 21331614; 21334717; 21336947; 21343160; 21344498; 21349701; 21359202; 21378341; 21393869; 21397857; 21401309; 21418186; 21421877; 21427648; 21432777; 21437624; 21453685; 21454822; 21461859; 21463121; 21471148; 21478099; 21483125; 21489023; 21503582; 21515251; 21516345; 21524920; 21526499; 21531813; 21541352; 21541674; 21565179; 21569377; 21574189; 21575462; 21576412; 21590355; 21611838; 21612407; 21620625; 21620672; 21624249; 21624510; 21627988; 21630198; 21637818; 21641389; 21656154; 21661398; 21667117; 21681346; 21687932; 21694463; 21705840; 21707819; 21712445; 21721010; 21722821; 21723775; 21734530; 21735328; 21745270; 21750404; 21756063; 21760911; 21764444; 21777461; 21782323; 21784671; 21794897; 21813640; 21820153; 21839835; 21842128; 21857898; 21858102; 21858104; 21880183; 21889192; 21901248; 21908153; 21909361; 21924036; 21928345; 21938405; 21956669; 21957576; 21958210; 21965295; 21968416; 21969874; 21989104; 21993452; 22006368; 22010139; 22020421; 22024074; 22030137; 22072145; 22082680; 22094096; 22110735; 22117411; 22169692; 22199296; 22200256; 22200661; 22200690; 22200710; 22204652; 22212960; 22227305; 22237453; 22252755; 22286800; 22288519; 22289521; 22291969; 22302011; 22303700; 22309692; 22323339; 22327101; 22327326; 22336124; 22342364; 22349830; 22374248; 22391064; 22396544; 22402435; 22406112; 22428754; 22448134; 22451655; 22455335; 22460086; 22472880; 22490679; 22490851; 22493443; 22509276; 22513045; 22513785; 22515887; 22519916; 22522455; 22527932; 22527933; 22531681; 22532131; 22534113; 22534634; 22546345; 22550139; 22551568; 22577146; 22580443; 22590832; 22591362; 22618590; 22634718; 22642972; 22646815; 22651889; 22652796; 22659470; 22669775; 22672240; 22684547; 22694915; 22707264; 22727191; 22783577; 22785600; 22820140; 22835601; 22836342; 22846578; 22848537; 22863019; 22865631; 22876575; 22883193; 22883459; 22898815; 22901190; 22931588; 22936257; 22938472; 22951829; 22959677; 22960198; 22964525; 22968857; 22985025; 23005037; 23006733; 23013132; 23038275; 23043936; 23057632; 23059760; 23064462; 23093058; 23096596; 23098370; 23100088; 23107277; 23107342; 23114726; 23134156; 23136827; 23146278; 23158991; 23164104; 23166329; 23171686; 23184003; 23201304; 23205572; 23220260; 23232575; 23242659; 23254288; 23257253; 23261429; 23264224; 23271497; 23271813; 23273944; 23280016; 23292837; 23306155; 23313298; 23320481; 23333895; 23343958; 23349885; 23357697; 23364396; 23375518; 23378725; 23381805; 23384723; 23387827; 23388341; 23388475; 23390835; 23395821; 23412981; 23424616; 23428182; 23440286; 23465389; 23494562; 23498792; 23510467; 23510472; 23516489; 23544610; 23557756; 23559867; 23566884; 23577575; 23588386; 23613407; 23623988; 23637955; 23650722; 23651923; 23660954; 23661021; 23661254; 23663265; 23673111; 23676485; 23685894; 23696025; 23696797; 23705892; 23716178; 23725476; 23736018; 23737137; 23763335; 23766685; 23768069; 23773714; 23791966; 23793312; 23796708; 23807209; 23814095; 23814098; 23817219; 23819399; 23832737; 23847438; 23852912; 23855590; 23870474; 23886165; 23897811; 23915070; 23915071; 23922934; 23936390; 24037915; 24047437; 24062440; 24067484; 24122234; 24164447; 24297171; 24335416; 24344010; 24374173; 24479343; 24479348,,,,,,,,,,,,,,,OGG:3000004313,,,,,,,"matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase)",,,,,,,,,,,,,Other designations: 72 kDa gelatinase|72 kDa type IV collagenase|MMP-2|collagenase type IV-A|gelatinase A|matrix metalloproteinase-2|matrix metalloproteinase-II|neutrophil gelatinase,,MMP2,,,,,,,,,,,,,,,,,,,,,,,4313,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,MMP2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0003127,SLCO1A2 (canonical)[Cholestasis],Solute Carrier Organic Anion Transporter Family Member 1A2 [Cholestasis]|SLC21A3 [Cholestasis]|OATP-1 [Cholestasis]|OATP-A [Cholestasis]|OATP1A2 [Cholestasis],,false,,,http://purl.obolibrary.org/obo/TXPO_0000272,,,,,,,,,,,,,,,,,,,,PMID:7557095|PMID:25924632,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Solute Carrier Organic Anion Transporter Family Member 1A2 [Cholestasis]|SLC21A3 [Cholestasis]|OATP-1 [Cholestasis]|OATP-A [Cholestasis]|OATP1A2 [Cholestasis],,,,,TXPO:0003127,,,,,,,"This gene encodes a sodium-independent transporter which mediates cellular uptake of organic ions in the liver. Its substrates include bile acids, bromosulphophthalein, and some steroidal compounds. The protein is a member of the SLC21A family of solute carriers. Alternative splicing of this gene results in multiple transcript variants. [provided by RefSeq, Dec 2008]",,,,,,,,,,,,,,,SLCO1A2 (canonical)[Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003125,LRH1 (canonical)[Cholestasis],CYP7A Promoter-Binding Factor [Cholestasis]|NR5A2 [Cholestasis],,false,,,http://purl.obolibrary.org/obo/TXPO_0000276|http://purl.obolibrary.org/obo/TXPO_1000227,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:60349|NCBI-Human-GeneID:2494|NCBI-Mouse-GeneID:26424|http://omim.org/entry/604453,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CYP7A Promoter-Binding Factor [Cholestasis]|NR5A2 [Cholestasis],,,,,TXPO:0003125,,,,,,,"Bile acids repress the transcription of cytochrome P450 7A1 (CYP7A1), which catalyzes the rate-limiting step in bile acid biosynthesis.
FXR induces expression of SHP-1, a member of the nuclear receptor family that lacks a DNA-binding domain.
SHP-1 represses expression of CYP7A1 by inhibiting the activity of liver receptor homolog 1 (LRH-1).",,,,,,,,,,,,,,,LRH1 (canonical)[Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003121,GR (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367|http://purl.obolibrary.org/obo/TXPO_0001509,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:14815|NCBI-Human-GeneID:2908|NCBI-Rat-GeneID:24413|http://omim.org/entry/138040,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000002908,,,http://purl.obolibrary.org/obo/TXPO_0003224,,,,,,,,,,TXPO:0003121,,,,,,,,,,,,,,,,,,,,,,GR (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003126,negative regularuion of bile acid and bile salt transport,,"Negative regularuion of bile acid and bile salt transport is a subtype of negative regulation of transport:  Any process that stops, prevents, or reduces the frequency, rate or extent of a bile acid and bile salts transport .",false,,,http://purl.obolibrary.org/obo/TXPO_0002682,,,,,,,,,,,,,,,,,,,,,,"Negative regularuion of bile acid and bile salt transport is a subtype of negative regulation of transport:  Any process that stops, prevents, or reduces the frequency, rate or extent of a bile acid and bile salts transport .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003126,,,,,,,,,,,,,,,,,,,,,,negative regularuion of bile acid and bile salt transport,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003123,BAK activation [Cell death],,"BAK activation is a subtype of molecular activation: A process that changes the activity of the BAK1 (BCL2 Antagonist/Killer 1), BCL-2 family, to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0001727|http://purl.obolibrary.org/obo/TXPO_0003106,,,,,,,,,,,,,,,,,,,,,,"BAK activation is a subtype of molecular activation: A process that changes the activity of the BAK1 (BCL2 Antagonist/Killer 1), BCL-2 family, to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003123,,,,,,,,,,,,,,,,,,,,,,BAK activation [Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003129,contraction,,Contraction is a subtype of generating motion: A process that generates the directed movement in which the object decreases in volume.,false,,,http://purl.obolibrary.org/obo/TXPO_0000765,,,,,,,,,,,,,,,,,,,,,,Contraction is a subtype of generating motion: A process that generates the directed movement in which the object decreases in volume.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003129,,,,,,,,,,,,,,,,,,,,,,contraction,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003128,phosphorus atom,phosphorus,,false,,,http://purl.obolibrary.org/obo/CHEBI_33250,,,,,,,,,,,,,,,,,,,,Inchikey:OAICVXFJPJFONN-UHFFFAOYSA-N|CAS:7723-14-0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,phosphorus,,,,,TXPO:0003128,,,,,,,,,,,,,,,,,,,,,,phosphorus atom,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003124,import substances into hepatocyte vascular side (sinusoidal side) membrane,,Import substances into hepatocyte vascular side (sinusoidal side) membrane is a subtype of transport: A process of the directed movement of substances into hepatocyte vascular side (sinusoidal side) membrane.,false,,,http://purl.obolibrary.org/obo/GO_0006810,,,,,,,,,,,,,,,,,,,,,,Import substances into hepatocyte vascular side (sinusoidal side) membrane is a subtype of transport: A process of the directed movement of substances into hepatocyte vascular side (sinusoidal side) membrane.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003124,,,,,,,,,,,,,,,,,,,,,,import substances into hepatocyte vascular side (sinusoidal side) membrane,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003120,PXR (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367|http://purl.obolibrary.org/obo/TXPO_0001509,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:84385|NCBI-Human-GeneID:8856|NCBI-Mouse-GeneID:18171,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000008856,,,http://purl.obolibrary.org/obo/TXPO_0003224,,,,,,,,,,TXPO:0003120,,,,,,,,,,,,,,,,,,,,,,PXR (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003122,back-flow,,Back-flow is a subtype of changing direction: A process that changes the flow to the opposite direction.,false,,,http://purl.obolibrary.org/obo/TXPO_0000022,,,,,,,,,,,,,,,,,,,,,,Back-flow is a subtype of changing direction: A process that changes the flow to the opposite direction.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003122,,,,,,,,,,,,,,,,,,,,,,back-flow,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001133,phospholipidosis dependent chemical entity,,"Phospholipidosis dependent chemical entity is a subtype of toxic course dependent chemical entity.
This entity can participate in the course of phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001731,,,,,,,,,,,,,,,,,,,,,,"Phospholipidosis dependent chemical entity is a subtype of toxic course dependent chemical entity.
This entity can participate in the course of phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001133,,,,,,,,,,,,,,,,,,,,,,phospholipidosis dependent chemical entity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001136,SLC44A2 (human)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000344|http://purl.obolibrary.org/obo/TXPO_0001135,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:57153|http://omim.org/entry/606106|http://www.genecards.org/cgi-bin/carddisp.pl?gene=SLC44A2&keywords=Slc44a2|Reactome:R-HSA-444451|PMID:20410607,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000057153,,,http://purl.obolibrary.org/obo/TXPO_0001307,,,,,,,,,,TXPO:0001136,,,,,,,,,,,,,,,,,,,,,,SLC44A2 (human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001137,GAB1 (human)[Phospholipidosis],GRB2-associated binding protein 1 [Phospholipidosis],A conserved inositol phospholipid binding site within the pleckstrin homology domain of the Gab1 docking protein is required for epithelial morphogenesis. (PMID:10531383),false,,,http://purl.obolibrary.org/obo/IMR_0001410|http://purl.obolibrary.org/obo/TXPO_0001135,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:2549|PMID:12069817|PMID:12414665|PMID:20555359,,A conserved inositol phospholipid binding site within the pleckstrin homology domain of the Gab1 docking protein is required for epithelial morphogenesis. (PMID:10531383),,,,,,,,,http://purl.obolibrary.org/obo/IMR_0001409,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000002549,,,http://purl.obolibrary.org/obo/TXPO_0002271,,,,,GRB2-associated binding protein 1 [Phospholipidosis],,,,,TXPO:0001137,,,,,,,,,,,,,,,,,,,,,,GAB1 (human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001491|http://purl.obolibrary.org/obo/TXPO_0001490,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001139,cellular senescence inhibitor,,A role played by the entity which negative regulates the cellular senescence.,false,,,http://purl.obolibrary.org/obo/TXPO_0001082,,,,,,,,,,,,,,,,,,,,,,A role played by the entity which negative regulates the cellular senescence.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001139,,,,,,,,,,,,,,,,,,,,,,cellular senescence inhibitor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001131,acetyl CoA increase [lipidosis],,"Increasing acetyl CoA is a subtype of increasing quantity: A process that changes the amount of acetyl CoA to be larger.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0000088,,,,,,,,,,,,,,,,,,,,,,"Increasing acetyl CoA is a subtype of increasing quantity: A process that changes the amount of acetyl CoA to be larger.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001739,,,,,,,,,,,TXPO:0001131,,,,,,,,,,,,,,,,,,,,,,acetyl CoA increase [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001132,Increasing production amount of acetaldehyde [lipidosis],,"Increasing production amount of acetaldehyde is a subtype of increasing quantity: A process that changes the production amount of acetaldehyde to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0001409,,,,,,,,,,,,,,,,,,,,PMID:17854140,,"Increasing production amount of acetaldehyde is a subtype of increasing quantity: A process that changes the production amount of acetaldehyde to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001130|http://purl.obolibrary.org/obo/TXPO_0002357,,,,,,,,,,,TXPO:0001132,,,,,,,,,,,,,,,,,,,,,,Increasing production amount of acetaldehyde [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001135,phospholipidosis dependent molecule (human in vitro),,"Phospholipidosis dependent molecule is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of Phospholipidosis as a gene product.
Gene profile:Human/in vitro/Hepatocyte/",false,,,http://purl.obolibrary.org/obo/TXPO_0001133,,,,,,,,,,,,,,,,,,,,,,"Phospholipidosis dependent molecule is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of Phospholipidosis as a gene product.
Gene profile:Human/in vitro/Hepatocyte/",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001135,,,,,,,,,,,,,,,,,,,,,,phospholipidosis dependent molecule (human in vitro),,,,,,,,,,,http://purl.obolibrary.org/obo/NCBITaxon_9606,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001138,PLB1 (human)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000284|http://purl.obolibrary.org/obo/TXPO_0001135,,,,,,,,,,,,,,,,,,,,http://omim.org/entry/610179|NCBI-Human-GeneID:151056|PMID:24520335,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000151056,,,http://purl.obolibrary.org/obo/TXPO_0003671,,,,,,,,,,TXPO:0001138,,,,,,,,,,,,,,,,,,,,,,PLB1 (human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001130,malfunctioning of TCA cycle [lipidosis],,"Malfunctioning of TCA cycle is a subtype of malfunctioning of metabolism: A process that cannot perform a tricarboxylic acid cycle appropriately or cannot realize it at all.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0001269,,,,,,,,,,,,,,,,,,,,,,"Malfunctioning of TCA cycle is a subtype of malfunctioning of metabolism: A process that cannot perform a tricarboxylic acid cycle appropriately or cannot realize it at all.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001749|http://purl.obolibrary.org/obo/TXPO_0001748|http://purl.obolibrary.org/obo/TXPO_0001131,,,,,,,,,,,TXPO:0001130,,,,,,,,,,,,,,,,,,,,,,malfunctioning of TCA cycle [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001134,phospholipidosis dependent molecule (rat),,"Phospholipidosis dependent molecule is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of phospholipidosis as a gene product.
Gene profile:Rat/Liver/",false,,,http://purl.obolibrary.org/obo/TXPO_0001133,,,,,,,,,,,,,,,,,,,,,,"Phospholipidosis dependent molecule is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of phospholipidosis as a gene product.
Gene profile:Rat/Liver/",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001134,,,,,,,,,,,,,,,,,,,,,,phospholipidosis dependent molecule (rat),,,,,,,,,,,http://purl.obolibrary.org/obo/NCBITaxon_10114,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_38809,ryanodine receptor modulator,RyR modulator,,false,,,http://purl.obolibrary.org/obo/CHEBI_38808,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,RyR modulator,,,CHEBI:38809,,,,,,,,,,,,,,,,,,,,,,ryanodine receptor modulator,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001607,Rab23,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001607,,,,,,,,,,,,,,,,,,,,,,Rab23,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100149,angiotensin,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,MeSH:D000809,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_25512,,,,,,,,,,IMR:0100149,,,,,,,,,,,,,,,,,,,,,,angiotensin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0005575,cellular_component,,"The part of a cell or its extracellular environment in which a gene product is located. A gene product may be located in one or more parts of a cell and its location may be as specific as a particular macromolecular complex, that is, a stable, persistent association of macromolecules that function together.",false,,,http://purl.obolibrary.org/obo/UBERON_0001062|http://purl.obolibrary.org/obo/GO_0005575,,,,,,,,,,,,,,,,,,,,,,"The part of a cell or its extracellular environment in which a gene product is located. A gene product may be located in one or more parts of a cell and its location may be as specific as a particular macromolecular complex, that is, a stable, persistent association of macromolecules that function together.",,,,,cellular component,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0005575,,,,,,,,,,,,,,,,,,,,,,cellular_component,,,,,,,http://purl.obolibrary.org/obo/go.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0005576,extracellular region,extracellular,"The space external to the outermost structure of a cell. For cells without external protective or external encapsulating structures this refers to space outside of the plasma membrane. This term covers the host cell environment outside an intracellular parasite.|Note that this term is intended to annotate gene products that are not attached to the cell surface. For gene products from multicellular organisms which are secreted from a cell but retained within the organism (i.e. released into the interstitial fluid or blood), consider the cellular component term 'extracellular space ; GO:0005615'.",false,,,http://purl.obolibrary.org/obo/GO_0044464,,,,,,,,,,,,,,,,,,,,Wikipedia:Extracellular,,The space external to the outermost structure of a cell. For cells without external protective or external encapsulating structures this refers to space outside of the plasma membrane. This term covers the host cell environment outside an intracellular parasite.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,extracellular,,,,,GO:0005576,,,,,,,,,,,,,,,,,,,,"Note that this term is intended to annotate gene products that are not attached to the cell surface. For gene products from multicellular organisms which are secreted from a cell but retained within the organism (i.e. released into the interstitial fluid or blood), consider the cellular component term 'extracellular space ; GO:0005615'.",,extracellular region,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004919,tumor cell survial [hepatocarcinogenesis],,"Tumor cell survial is a subtype of cell survival: A process that keeps the viability of a tumor cell.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0000280,,,,,,,,,,,,,,,,,,,,PMID:29227529|PMID:31507621|PMID:22576474,,"Tumor cell survial is a subtype of cell survival: A process that keeps the viability of a tumor cell.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004919,,,,,,,,,,,,,,,,,,,,,,tumor cell survial [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004913,CYP3A4(canonical) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000082|http://purl.obolibrary.org/obo/TXPO_0005063,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1576|PMID:24078988|PMID:29301315|PMID:19590965,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004913,,,,,,,,,,,,,,,,,,,,,,CYP3A4(canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004912,CYP2A6 (canonical) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0005063|http://purl.obolibrary.org/obo/TXPO_0005077,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1548|PMID:29301315,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001548,,,,,,,,,,,,,TXPO:0004912,,,,,,,,,,,,,,,,,,,,,,CYP2A6 (canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004911,CYP2A13 (canonical) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0005063|http://purl.obolibrary.org/obo/TXPO_0005076,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1553|PMID:29301315,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001553,,,,,,,,,,,,,TXPO:0004911,,,,,,,,,,,,,,,,,,,,,,CYP2A13 (canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004917,BCL2 (canonical) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000041|http://purl.obolibrary.org/obo/TXPO_0005063,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24224|NCBI-Mouse-GeneID:12043|NCBI-Human-GeneID:596|PMID:31781608,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000596,,,,,,,,,,,,,TXPO:0004917,,,,,,,,,,,,,,,,,,,,,,BCL2 (canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004915,CYP3A7 (canonical) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0005063|http://purl.obolibrary.org/obo/TXPO_0005078,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1551|PMID:24078988,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001551,,,,,,,,,,,,,TXPO:0004915,,,,,,,,,,,,,,,,,,,,,,CYP3A7 (canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004910,CYP1A2(canonical) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003633|http://purl.obolibrary.org/obo/TXPO_0005063,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24297|NCBI-Human-GeneID:1544|NCBI-Mouse-GeneID:13077|PMID:24078988|PMID:29301315|PMID:19590965,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001544,,,,,,,,,,,,,TXPO:0004910,,,,,,,,,,,,,,,,,,,,,,CYP1A2(canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004914,CYP3A5(canonical) [hepatocarcinogenesis],"cytochrome P450, family 3, subfamily A, polypeptide 5 [Hepatocarcinogenesis]",,false,,,http://purl.obolibrary.org/obo/TXPO_1000083|http://purl.obolibrary.org/obo/TXPO_0005063,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1577|PMID:24078988,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"cytochrome P450, family 3, subfamily A, polypeptide 5 [Hepatocarcinogenesis]",,,,,TXPO:0004914,,,,,,,,,,,,,,,,,,,,,,CYP3A5(canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004916,Cyp1A1 (canonical) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0005063|http://purl.obolibrary.org/obo/TXPO_1000100,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1543|NCBI-Rat-GeneID:24296|NCBI-Mouse-GeneID:13076|PMID:29301315,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001543,,,,,,,,,,,,,TXPO:0004916,,,,,,,,,,,,,,,,,,,,,,Cyp1A1 (canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004918,CCND1 (canonical) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000088|http://purl.obolibrary.org/obo/TXPO_0005063,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:58919|NCBI-Human-GeneID:595|NCBI-Mouse-GeneID:12443|PMID:31781608,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000595,,,,,,,,,,,,,TXPO:0004918,,,,,,,,,,,,,,,,,,,,,,CCND1 (canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100451,MEKK3,MAPK/ERK kinase kinase 3|MEK kinase 3,,false,,,http://purl.obolibrary.org/obo/IMR_0000234,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MAPK/ERK kinase kinase 3|MEK kinase 3,,,,,IMR:0100451,,,,,,,,,,,,,,,,,,,,,,MEKK3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_65001,EC 3.1.1.3 (triacylglycerol lipase) inhibitor,glycerol-ester hydrolase inhibitors|steapsin inhibitor|pancreatic lipase inhibitor|lipase inhibitors|Tweenase inhibitors|cacordase inhibitors|hepatic lipase inhibitor|hepatic lipase inhibitors|Tween hydrolase inhibitor|salt-resistant post-heparin lipase inhibitor|lipazin inhibitors|glycerol ester hydrolase inhibitor|post-heparin plasma protamine-resistant lipase inhibitor|triacylglycerol lipase inhibitors|glycerol ester hydrolase inhibitors|hepatic monoacylglycerol acyltransferase inhibitor|GEH inhibitor|liver lipase inhibitor|glycerol-ester hydrolase inhibitor|EC 3.1.1.3 (triacylglycerol lipase) inhibitors|tributyrase inhibitors|Tweenesterase inhibitor|tributyrin esterase inhibitor|EC 3.1.1.3 inhibitors|Tweenase inhibitor|PPL inhibitor|steapsin inhibitors|tween-hydrolyzing esterase inhibitors|post-heparin plasma protamine-resistant lipase inhibitors|triacylglycerol ester hydrolase inhibitor|cacordase inhibitor|butyrinase inhibitors|Tween hydrolase inhibitors|triolein hydrolase inhibitors|triacetinase inhibitor|triglyceride hydrolase inhibitors|lipazin inhibitor|capalase L inhibitor|pancreatic lipase inhibitors|tributyrinase inhibitors|tributyrase inhibitor|heparin releasable hepatic lipase inhibitors|triglyceridase inhibitor|triacylglycerol lipase inhibitor|triolein hydrolase inhibitor|tributyrin esterase inhibitors|triacetinase inhibitors|GEH inhibitors|heparin releasable hepatic lipase inhibitor|pancreatic triacylglycerol lipase inhibitors|capalase L inhibitors|tributyrinase inhibitor|tween-hydrolysing esterase inhibitor|triacylglycerol lipase (EC 3.1.1.3) inhibitor|triacylglycerol lipase (EC 3.1.1.3) inhibitors|triglyceridase inhibitors|EC 3.1.1.3 inhibitor|butyrinase inhibitor|Tweenesterase inhibitors|pancreatic triacylglycerol lipase inhibitor|triacylglycerol ester hydrolase inhibitors|hepatic monoacylglycerol acyltransferase inhibitors|liver lipase inhibitors|salt-resistant post-heparin lipase inhibitors|triglyceride hydrolase inhibitor|triglyceride lipase inhibitor|lipase inhibitor|PPL inhibitors|triglyceride lipase inhibitors,Any EC 3.1.1.* (carboxylic ester hydrolase) inhibitor that inhibits the action of triacylglycerol lipase (EC 3.1.1.3).,false,,,http://purl.obolibrary.org/obo/CHEBI_76773,,,,,,,,,,,,,,,,,,,,,,Any EC 3.1.1.* (carboxylic ester hydrolase) inhibitor that inhibits the action of triacylglycerol lipase (EC 3.1.1.3).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,glycerol-ester hydrolase inhibitors|steapsin inhibitor|pancreatic lipase inhibitor|lipase inhibitors|Tweenase inhibitors|cacordase inhibitors|hepatic lipase inhibitor|hepatic lipase inhibitors|Tween hydrolase inhibitor|salt-resistant post-heparin lipase inhibitor|lipazin inhibitors|glycerol ester hydrolase inhibitor|post-heparin plasma protamine-resistant lipase inhibitor|triacylglycerol lipase inhibitors|glycerol ester hydrolase inhibitors|hepatic monoacylglycerol acyltransferase inhibitor|GEH inhibitor|liver lipase inhibitor|glycerol-ester hydrolase inhibitor|EC 3.1.1.3 (triacylglycerol lipase) inhibitors|tributyrase inhibitors|Tweenesterase inhibitor|tributyrin esterase inhibitor|EC 3.1.1.3 inhibitors|Tweenase inhibitor|PPL inhibitor|steapsin inhibitors|tween-hydrolyzing esterase inhibitors|post-heparin plasma protamine-resistant lipase inhibitors|triacylglycerol ester hydrolase inhibitor|cacordase inhibitor|butyrinase inhibitors|Tween hydrolase inhibitors|triolein hydrolase inhibitors|triacetinase inhibitor|triglyceride hydrolase inhibitors|lipazin inhibitor|capalase L inhibitor|pancreatic lipase inhibitors|tributyrinase inhibitors|tributyrase inhibitor|heparin releasable hepatic lipase inhibitors|triglyceridase inhibitor|triacylglycerol lipase inhibitor|triolein hydrolase inhibitor|tributyrin esterase inhibitors|triacetinase inhibitors|GEH inhibitors|heparin releasable hepatic lipase inhibitor|pancreatic triacylglycerol lipase inhibitors|capalase L inhibitors|tributyrinase inhibitor|tween-hydrolysing esterase inhibitor|triacylglycerol lipase (EC 3.1.1.3) inhibitor|triacylglycerol lipase (EC 3.1.1.3) inhibitors|triglyceridase inhibitors|EC 3.1.1.3 inhibitor|butyrinase inhibitor|Tweenesterase inhibitors|pancreatic triacylglycerol lipase inhibitor|triacylglycerol ester hydrolase inhibitors|hepatic monoacylglycerol acyltransferase inhibitors|liver lipase inhibitors|salt-resistant post-heparin lipase inhibitors|triglyceride hydrolase inhibitor|triglyceride lipase inhibitor|lipase inhibitor|PPL inhibitors|triglyceride lipase inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:65001,,,,EC 3.1.1.3 (triacylglycerol lipase) inhibitor,,CHEBI:65001,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000230,mos,c-mos,,false,,,http://purl.obolibrary.org/obo/IMR_0000229,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,c-mos,,,,,IMR:0000230,,,,,,,,,,,,,,,,,,,,,,mos,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000404,EGR2,Krox20|pAT591,,false,,,http://purl.obolibrary.org/obo/IMR_0000402,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Krox20|pAT591,,,,,IMR:0000404,,,,,,,,,,,,,,,,,,,,,,EGR2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000109,IL-3 receptor,interleukin-3 receptor,,false,,,http://purl.obolibrary.org/obo/IMR_0000096,,,,,,,,,,,,,,,,,,,,GO:0004912,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,interleukin-3 receptor,,,,,IMR:0000109,,,,,,,,,,,,,,,,,,,,,,IL-3 receptor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004370,hypofunction of anti-oxidative stress[mitochondrial disorder],,"Hypofunction of anti-oxidative stress is a subtype of hypofunctioning: A process that performs a decreased or insufficient anti-oxidative stress function.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0004066|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:23299992,,"Hypofunction of anti-oxidative stress is a subtype of hypofunctioning: A process that performs a decreased or insufficient anti-oxidative stress function.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004373,,,,,,,,,,,TXPO:0004370,,,,,,,,,,,,,,,,,,,,,,hypofunction of anti-oxidative stress[mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004379,Malfunctioning of insulin signaling [mitochondrial disorder],,"Malfunctioning of insulin signaling is a subtype of malfunctioning process: A process that cannot perform insulin signaling [biological] appropriately or cannot realize it at all.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0001125,,,,,,,,,,,,,,,,,,,,PMID:31623280|PMID:31649547,,"Malfunctioning of insulin signaling is a subtype of malfunctioning process: A process that cannot perform insulin signaling [biological] appropriately or cannot realize it at all.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004347,,,,,,,,,,,TXPO:0004379,,,,,,,,,,,,,,,,,,,,,,Malfunctioning of insulin signaling [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004377,Increasing HMGB1 level [mitochondrial disorder],,"Increasing HMGB1 level is a subtype of increasing quantity: A process that changes the amount of HMGB1 level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0004618,,,,,,,,,,,,,,,,,,,,PMID:31623280,,"Increasing HMGB1 level is a subtype of increasing quantity: A process that changes the amount of HMGB1 level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004619,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001992|http://purl.obolibrary.org/obo/TXPO_0004342,,,,,,,,,,,TXPO:0004377,,,,,,,,,,,,,,,,,,,,,,Increasing HMGB1 level [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004373,increasing demand for response to oxidative stress [mitochondrial disorder],,"Increasing demand for response to oxidative stress is a subtype of increasing the demand for response to stress: A process that changes the functional demand for the response to the oxidative stress to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0000102|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:31623280|PMID:25339807|PMID:23299992|PMID:26571396,,"Increasing demand for response to oxidative stress is a subtype of increasing the demand for response to stress: A process that changes the functional demand for the response to the oxidative stress to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001991|http://purl.obolibrary.org/obo/TXPO_0004272|http://purl.obolibrary.org/obo/TXPO_0004349|http://purl.obolibrary.org/obo/TXPO_0004348|http://purl.obolibrary.org/obo/TXPO_0004390|http://purl.obolibrary.org/obo/TXPO_0004121,,,,,,,,,,,TXPO:0004373,,,,,,,,,,,,,,,,,,,,,,increasing demand for response to oxidative stress [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004372,lipid biosynthetic process [mitochondrial disorder],lipogenesis,"The chemical reactions and pathways resulting in the formation of lipids, compounds soluble in an organic solvent but not, or sparingly, in an aqueous solvent.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/GO_0008610|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:31623280|PMID:26571396,,"The chemical reactions and pathways resulting in the formation of lipids, compounds soluble in an organic solvent but not, or sparingly, in an aqueous solvent.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0005039,,,,,,lipogenesis,,,,,TXPO:0004372,,,,,,,,,,,,,,,,,,,,,,lipid biosynthetic process [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004378,TLR4 signaling [mitochondrial disorder],,"TLR4 signaling is a subtype of TLR signaling [biological]: Any series of molecular signals generated as a consequence of binding to toll-like receptor 4.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0004829,,,,,,,,,,,,,,,,,,,,PMID:31623280,,"TLR4 signaling is a subtype of TLR signaling [biological]: Any series of molecular signals generated as a consequence of binding to toll-like receptor 4.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004831,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0034142,,,,,http://purl.obolibrary.org/obo/TXPO_0004830,,,,,,,,,,,TXPO:0004378,,,,,,,,,,,,,,,,,,,,,,TLR4 signaling [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004376,cell cycle arrest [mitochondrial disorder],,"A regulatory process that halts progression through the cell cycle during one of the normal phases (G1, S, G2, M).
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/GO_0007050,,,,,,,,,,,,,,,,,,,,PMID:24746669,,"A regulatory process that halts progression through the cell cycle during one of the normal phases (G1, S, G2, M).
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004376,,,,,,,,,,,,,,,,,,,,,,cell cycle arrest [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004375,Negative regulation of mitochondrial respiratory chain complex I subunit phosphorylation [mitochondrial disorder],,"Negative regulation of mitochondrial respiratory chain complex I subunit phosphorylation is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of mitochondrial respiratory chain complex I subunit phosphorylation.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0004993,,,,,,,,,,,,,,,,,,,,PMID:24746669,,"Negative regulation of mitochondrial respiratory chain complex I subunit phosphorylation is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of mitochondrial respiratory chain complex I subunit phosphorylation.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004125,,,,,,,,,,,TXPO:0004375,,,,,,,,,,,,,,,,,,,,,,Negative regulation of mitochondrial respiratory chain complex I subunit phosphorylation [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004995,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004371,gluconeogenesis [mitochondrial disorder],glucose biosynthesis|glucose biosynthetic process,"The formation of glucose from noncarbohydrate precursors, such as pyruvate, amino acids and glycerol.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/GO_0016051|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:26571396|Reactome:R-HSA-70263,,"The formation of glucose from noncarbohydrate precursors, such as pyruvate, amino acids and glycerol.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_17234,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0005034,,,,,,glucose biosynthesis|glucose biosynthetic process,,,,,TXPO:0004371,,,,,,,,,,,,,,,,,,,,,,gluconeogenesis [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004374,ketone body biosynthetic process [mitochondrial disorder],ketogenesis,"ketone body biosynthetic process is a subtype of generating: A process that synthesizes ketone body resulting in having output (s).
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/GO_0046951,,,,,,,,,,,,,,,,,,,,PMID:23299992,,"ketone body biosynthetic process is a subtype of generating: A process that synthesizes ketone body resulting in having output (s).
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_73693,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004946,,,,,,ketogenesis,,,,,TXPO:0004374,,,,,,,,,,,,,,,,,,,,,,ketone body biosynthetic process [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001015,RNA splicing [Ground glass appearance],,"RNA splicing is a subtype of removing: The process of removing sections of the primary RNA transcript to remove sequences not present in the mature form of the RNA and joining the remaining sections to form the mature form of the RNA.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/GO_0008380,,,,,,,,,,,,,,,,,,,,,,"RNA splicing is a subtype of removing: The process of removing sections of the primary RNA transcript to remove sequences not present in the mature form of the RNA and joining the remaining sections to form the mature form of the RNA.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001015,,,,,,,,,,,,,,,,,,,,,,RNA splicing [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001013,tumorigenesis [Ground glass appearance],,"A pathologic process that involves the transformation of normal cells to a neoplastic state and resulting in polyclonal or monoclonal neoplastic cell proliferation.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.|Phenobarbital does not increase the liver tumors in humans.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/NCIT_C18121,,,,,,,,,,,,,,,,,,,,PMID:15492232,,"A pathologic process that involves the transformation of normal cells to a neoplastic state and resulting in polyclonal or monoclonal neoplastic cell proliferation.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001030|http://purl.obolibrary.org/obo/TXPO_0001028|http://purl.obolibrary.org/obo/TXPO_0002319,http://purl.obolibrary.org/obo/TXPO_0000986|http://purl.obolibrary.org/obo/TXPO_0001019,,,,,,,,,,,,,,,,,TXPO:0001013,,,,,,,,,,,,,,,,,,,,Phenobarbital does not increase the liver tumors in humans.,,tumorigenesis [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107|http://purl.obolibrary.org/obo/NCBITaxon_9989,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001010,PPARalpha activation (moderate) [Eosinophilic granular degeneration],,"PPARalpha activation is a subtype of activating nuclear receptor: A process that changes the activity of the activating PPAR alpha (Peroxisome Proliferator Activated Receptor Alpha) with a nuclear receptor role to be higher. The degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/TXPO_0001005,,,,,,,,,,,,,,,,,,,,PMID:20414453|https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2948931/|PMID:20101262,,"PPARalpha activation is a subtype of activating nuclear receptor: A process that changes the activity of the activating PPAR alpha (Peroxisome Proliferator Activated Receptor Alpha) with a nuclear receptor role to be higher. The degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000122|http://purl.obolibrary.org/obo/TXPO_0000121|http://purl.obolibrary.org/obo/TXPO_0001328,,,,,,http://purl.obolibrary.org/obo/TXPO_0000149|http://purl.obolibrary.org/obo/TXPO_0001023|http://purl.obolibrary.org/obo/TXPO_0002047|http://purl.obolibrary.org/obo/TXPO_0000118,,,,,,,,,,,TXPO:0001010,,,,,,,,,,,,,,,,,,,,,,PPARalpha activation (moderate) [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001018,negative regulation of autophagy [Ground glass appearance],,"Any process that stops, prevents, or reduces the frequency, rate or extent of autophagy. Autophagy is the process in which cells digest parts of their own cytoplasm.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/GO_0010507|http://purl.obolibrary.org/obo/TXPO_0001728,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents, or reduces the frequency, rate or extent of autophagy. Autophagy is the process in which cells digest parts of their own cytoplasm.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001018,,,,,,,,,,,,,,,,,,,,,,negative regulation of autophagy [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001011,hypofunction of carbohydrate transport [Ground glass appearance],,"Hypofunction of carbohydrate transport is a subtype of hypofunction of transport: A process that performs a decreased or insufficient carbohydrate transport.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0002048|http://purl.obolibrary.org/obo/TXPO_0001728,,,,,,,,,,,,,,,,,,,,,,"Hypofunction of carbohydrate transport is a subtype of hypofunction of transport: A process that performs a decreased or insufficient carbohydrate transport.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,http://purl.obolibrary.org/obo/TXPO_0000932,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002319,,,,,,,,,,,TXPO:0001011,,,,,,,,,,,,,,,,,,,,,,hypofunction of carbohydrate transport [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001017,GOT1 (canonical)[lipidosis],glutamic-oxaloacetic transaminase 1|AST1 [lipidosis],,false,,,http://purl.obolibrary.org/obo/TXPO_0003516|http://purl.obolibrary.org/obo/TXPO_0001014,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:2805|NCBI-Mouse-GeneID:14718|NCBI-Rat-GeneID:24401,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001021,,,,,glutamic-oxaloacetic transaminase 1|AST1 [lipidosis],,,,,TXPO:0001017,,,,,,,,,,,,,,,,,,,,,,GOT1 (canonical)[lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001012,PPARalpha activation (mild) [Eosinophilic granular degeneration],,"PPARalpha activation is a subtype of activating nuclear receptor: A process that changes the activity of the activating PPAR alpha (Peroxisome Proliferator Activated Receptor Alpha) with a nuclear receptor role to be higher. The degree is mild.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/TXPO_0001005,,,,,,,,,,,,,,,,,,,,PMID:20414453|https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2948931/|PMID:20101262,,"PPARalpha activation is a subtype of activating nuclear receptor: A process that changes the activity of the activating PPAR alpha (Peroxisome Proliferator Activated Receptor Alpha) with a nuclear receptor role to be higher. The degree is mild.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000122|http://purl.obolibrary.org/obo/TXPO_0000121|http://purl.obolibrary.org/obo/TXPO_0001328,,,,,,http://purl.obolibrary.org/obo/TXPO_0000149|http://purl.obolibrary.org/obo/TXPO_0002047|http://purl.obolibrary.org/obo/TXPO_0000118|http://purl.obolibrary.org/obo/TXPO_0001016,,,,,,,,,,,TXPO:0001012,,,,,,,,,,,,,,,,,,,,,,PPARalpha activation (mild) [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001016,peroxisomal proliferation in hepatocyte (mild) [Eosinophilic granular degeneration],,"Peroxisomal proliferation in hepatocyte is a subtype of hepatocyte organelle proliferation: A process that becomes larger in the number of peroxisome in hepatocyte(s). The degree is mild.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/TXPO_0000105,,,,,,,,,,,,,,,,,,,,,,"Peroxisomal proliferation in hepatocyte is a subtype of hepatocyte organelle proliferation: A process that becomes larger in the number of peroxisome in hepatocyte(s). The degree is mild.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003535,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001045,,,,,,http://purl.obolibrary.org/obo/TXPO_0002027,,,,,,,,,,,TXPO:0001016,,,,,,,"Humanized mice (ie, PPARalpha-null mice transfected with human PPAR alpha) also fail to respond with hepatocellular and peroxisomal proliferation to fibrates, indicating that the human receptor cannot signal for proliferation.|Humans do not respond with hepatocellular and peroxisomal proliferation to fibrates and express PPARalpha at low levels and often in nonfunctional forms.

Casarett & Doull's Toxicology: The Basic Science of Poisons, Eighth Edition",,,,,,,,,,,,,,,peroxisomal proliferation in hepatocyte (mild) [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCBITaxon_9989,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001014,GOT1 (mol),AST1|glutamic-oxaloacetic transaminase 1,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:2805|NCBI-Mouse-GeneID:14718|NCBI-Rat-GeneID:24401,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001021,,,,,AST1|glutamic-oxaloacetic transaminase 1,,,,,TXPO:0001014,,,,,,,,,,,,,,,,,,,,,,GOT1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001019,DDB2 (canonical)[Ground glass appearance],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001007|http://purl.obolibrary.org/obo/TXPO_0000472,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:107986|NCBI-Rat-GeneID:100362121|NCBI-Human-GeneID:1643|PMID:22334663|PMID:30297359|PMID:19428948,,,,,,,,,,,,,,,Damage Specific DNA Binding Protein 2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001561,,,,,,,,,,TXPO:0001019,,,,,,,,,,,,,,,,,,,,,,DDB2 (canonical)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000866,A-Myb,,,false,,,http://purl.obolibrary.org/obo/IMR_0000868,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000866,,,,,,,,,,,,,,,,,,,,,,A-Myb,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0001434,skeletal system,set of all bones and joints|Skelettsystem|skeleton system,"Anatomical system that is a multi-element, multi-tissue anatomical cluster that consists of the skeleton and the articular system.",false,,,http://purl.obolibrary.org/obo/UBERON_0011216,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C12788|http://linkedlifedata.com/resource/umls/id/C0037253|https://github.com/obophenotype/uberon/wiki/The-skeletal-system|XAO:0003060|FMA:23881|UMLS:C0037253|OpenCyc:Mx4rvVi1rpwpEbGdrcN5Y29ycA|AAO:0000566|EFO:0000806|ZFA:0000434|EMAPA:35773|TAO:0000434|VSAO:0000027|MA:0000018|BTO:0001486|CALOHA:TS-1320|EHDAA2:0003168|VHOG:0001254,,"Anatomical system that is a multi-element, multi-tissue anatomical cluster that consists of the skeleton and the articular system.",,,,,,,,"System that provides physical support to the organism.[AAO]|Anatomical system that is a multi-element, multi-tissue anatomical cluster that consists of the skeleton and the articular system.[VSAO]|Anatomical system consisting of multiple elements and tissues that provides physical support.[TAO]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0004288|http://purl.obolibrary.org/obo/UBERON_0004770,,,,,,,,,,,,,skeleton system,set of all bones and joints,Skelettsystem,"By taking a holistic approach, integration of the evidence from molecular and developmental features of model organisms, the phylogenetic distribution in the 'new animal phylogeny' and the earliest fossilized remains of mineralized animal skeletons suggests independent origins of the skeleton at the phylum level.[debated][VHOG]",http://purl.obolibrary.org/obo/UBERON_0002204,UBERON:0001434,http://purl.obolibrary.org/obo/UBERON_0002204,,,,,,,,,,,,,,,,,,,,,skeletal system,,,,,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005106,NDUFA12 inactivation [mitochondrial disorder],,"NDUFA12 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the NDUFA12 (NADH:ubiquinone oxidoreductase core subunit A12) to be lower.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0004706|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:24746669,,"NDUFA12 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the NDUFA12 (NADH:ubiquinone oxidoreductase core subunit A12) to be lower.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0005105,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004375,,,,,,,,,,,TXPO:0005106,,,,,,,,,,,,,,,,,,,,,,NDUFA12 inactivation [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005107,NDUFB6 (human) [mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004709,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:4712,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005107,,,,,,,,,,,,,,,,,,,,,,NDUFB6 (human) [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005102,MSH6 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:2956|NCBI-Rat-GeneID:100360342|NCBI-Mouse-GeneID:17688,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005102,,,,,,,,,,,,,,,,,,,,,,MSH6 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005103,MTAP (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:298227|NCBI-Human-GeneID:4507|NCBI-Mouse-GeneID:66902,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005103,,,,,,,,,,,,,,,,,,,,,,MTAP (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005109,NDUFB6 inactivation [mitochondrial disorder],,"NDUFB6 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the NDUFB6 (NADH:ubiquinone oxidoreductase core subunit B6) to be lower.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0004708|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:24746669,,"NDUFB6 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the NDUFB6 (NADH:ubiquinone oxidoreductase core subunit B6) to be lower.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0005108,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004375,,,,,,,,,,,TXPO:0005109,,,,,,,,,,,,,,,,,,,,,,NDUFB6 inactivation [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005101,MSH6 (canonical) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0005102|http://purl.obolibrary.org/obo/TXPO_0005063,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:2956|NCBI-Rat-GeneID:100360342|NCBI-Mouse-GeneID:17688,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005101,,,,,,,,,,,,,,,,,,,,,,MSH6 (canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005105,NDUFA12 - inactive form (human)[mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003603|http://purl.obolibrary.org/obo/TXPO_0005104,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:55967|PMID:24746669,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0002355,,,,,,,,,,,,,,TXPO:0005105,,,,,,,,,,,,,,,,,,,,,,NDUFA12 - inactive form (human)[mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005104,NDUFA12 (human) [mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004707,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:55967,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005104,,,,,,,,,,,,,,,,,,,,,,NDUFA12 (human) [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005100,MSH2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:81709|NCBI-Mouse-GeneID:17685|NCBI-Human-GeneID:4436,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005100,,,,,,,,,,,,,,,,,,,,,,MSH2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005108,NDUFB6 - inactive form (human)[mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003603|http://purl.obolibrary.org/obo/TXPO_0005107,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:4712|PMID:24746669,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0002355,,,,,,,,,,,,,,TXPO:0005108,,,,,,,,,,,,,,,,,,,,,,NDUFB6 - inactive form (human)[mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/NCIT_C15958,in vitro assay,,"A laboratory test or analysis of the biological activity of a substance performed by studying its effect in an experimental situation outside the organism, e.g. in the test tube rather than in living systems.",false,,,http://purl.obolibrary.org/obo/OBI_0000070,,,,,,,,,,,,,,,,,,,,,,"A laboratory test or analysis of the biological activity of a substance performed by studying its effect in an experimental situation outside the organism, e.g. in the test tube rather than in living systems.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,NCIT:C15958,,,,,,,,,,,,,,,,,,,,,,in vitro assay,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100393,IRS-1,insulin receptor substrate-1|IRS1,,false,,,http://purl.obolibrary.org/obo/IMR_0000351,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0011340|IMR:0010311|IMR:0011552,insulin receptor substrate-1|IRS1,,,,,IMR:0100393,,,,,,,,,,,,,,,,,,,,,,IRS-1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001953,RhoA,,,false,,,http://purl.obolibrary.org/obo/IMR_0000296,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001953,,,,,,,,,,,,,,,,,,,,,,RhoA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000171,VE-cadherin,Vascular endothelial-cadherin|cadherin-5,,false,,,http://purl.obolibrary.org/obo/IMR_0000167,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Vascular endothelial-cadherin|cadherin-5,,,,,IMR:0000171,,,,,,,,,,,,,,,,,,,,,,VE-cadherin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001247,increasing lysosomal pH,,Increasing lysosomal pH is a subtype of changing pH: A process that changes the pH in lysosome to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0001520,,,,,,,,,,,,,,,,,,,,,,Increasing lysosomal pH is a subtype of changing pH: A process that changes the pH in lysosome to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001247,,,,,,,,,,,,,,,,,,,,,,increasing lysosomal pH,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001245,increasing blood glucose level [ER stress],,"Increasing blood glucose lebvel is a subtype of increasing concentration: A process that changes the blood glucose concentration in the blood to be higher.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/TXPO_0001912,,,,,,,,,,,,,,,,,,,,PMID:22883813,,"Increasing blood glucose lebvel is a subtype of increasing concentration: A process that changes the blood glucose concentration in the blood to be higher.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001245,,,,,,,,,,,,,,,,,,,,,,increasing blood glucose level [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001248,increasing demand for phospholipid degradation,,Increasing demand for phospholipid degradation is a subtype of increasing functional demand: A process that changes the functional demand for the phospholipid degradation to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000633,,,,,,,,,,,,,,,,,,,,,,Increasing demand for phospholipid degradation is a subtype of increasing functional demand: A process that changes the functional demand for the phospholipid degradation to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001248,,,,,,,,,,,,,,,,,,,,,,increasing demand for phospholipid degradation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001242,compound accumulation in lysosome,,Compound accumulation in lysosome is a subtype of accumulation of xenobiotics: A process that keeps compound in the lysosome.,false,,,http://purl.obolibrary.org/obo/TXPO_0000169,,,,,,,,,,,,,,,,,,,,,,Compound accumulation in lysosome is a subtype of accumulation of xenobiotics: A process that keeps compound in the lysosome.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001242,,,,,,,,,,,,,,,,,,,,,,compound accumulation in lysosome,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001243,phospholipid homeostasis imbalance,,Phospholipid homeostasis imbalance is a subtype of lipid homeostasis imbalance: A process that becomes lacking a phospholipid homeostastasis balance.|phospholipid homeostasis imbalance,false,,,http://purl.obolibrary.org/obo/TXPO_0003488,,,,,,,,,,,,,,,,,,,,,,Phospholipid homeostasis imbalance is a subtype of lipid homeostasis imbalance: A process that becomes lacking a phospholipid homeostastasis balance.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002308,,,,,,,,,,,,,,,,,,TXPO:0001243,,,,,,,,,,,,,,,,,,,,phospholipid homeostasis imbalance,,phospholipid homeostasis imbalance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001241,CAD accumulation in lysosome [Phospholipidosis (mild)],,"CAD accumulation in lysosome is a subtype of compound accumulation in lysosome: A process that keeps CAD (Cationic Amphiphilic Drugs) in the lysosome.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (mild).",false,,,http://purl.obolibrary.org/obo/TXPO_0003367,,,,,,,,,,,,,,,,,,,,,,"CAD accumulation in lysosome is a subtype of compound accumulation in lysosome: A process that keeps CAD (Cationic Amphiphilic Drugs) in the lysosome.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (mild).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001403,,,,,,,,,,,TXPO:0001241,,,,,,,,,,,,,,,,,,,,,,CAD accumulation in lysosome [Phospholipidosis (mild)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001240,CAD accumulation in lysosome,,CAD accumulation in lysosome is a subtype of compound accumulation in lysosome: A process that keeps CAD (Cationic Amphiphilic Drug) in the lysosome.,false,,,http://purl.obolibrary.org/obo/TXPO_0001242,,,,,,,,,,,,,,,,,,,,,,CAD accumulation in lysosome is a subtype of compound accumulation in lysosome: A process that keeps CAD (Cationic Amphiphilic Drug) in the lysosome.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001240,,,,,,,,,,,,,,,,,,,,,,CAD accumulation in lysosome,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001244,phospholipid accumulation,,"Phospholipid accumulation is a subtype of accumulation of substances in a biological object: A process that keeps phospholipid in an organism, tissue, organelle, or cell.",false,,,http://purl.obolibrary.org/obo/GO_0019915,,,,,,,,,,,,,,,,,,,,,,"Phospholipid accumulation is a subtype of accumulation of substances in a biological object: A process that keeps phospholipid in an organism, tissue, organelle, or cell.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_16247,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001244,,,,,,,,,,,,,,,,,,,,,,phospholipid accumulation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001246,hyperfunction of reduction of NAD(+) to NADH [Lipidosis],,"Hyperfunction of reduction of NAD(+) to NADH is a subtype of hyperfunction of reduction: A process that performs an excesssive reduction of NAD(+) to NADH.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001302|http://purl.obolibrary.org/obo/TXPO_0001720,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of reduction of NAD(+) to NADH is a subtype of hyperfunction of reduction: A process that performs an excesssive reduction of NAD(+) to NADH.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001118,,,,,,,,,,,TXPO:0001246,,,,,,,,,,,,,,,,,,,,,,hyperfunction of reduction of NAD(+) to NADH [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001249,undigested membrane material accumulation,,Undigested membrane material accumulation is a subtype of accumulation of substances in a biological object: A process that keeps undigested membrane material.,false,,,http://purl.obolibrary.org/obo/TXPO_0000247,,,,,,,,,,,,,,,,,,,,,,Undigested membrane material accumulation is a subtype of accumulation of substances in a biological object: A process that keeps undigested membrane material.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001249,,,,,,,,,,,,,,,,,,,,,,undigested membrane material accumulation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000052,insulin,insulin fragments|insulin A chain|Humulin|Insulin precursor|insulin B chain,"A protein hormone secreted by beta cells of the pancreas. Insulin plays a major role in the regulation of glucose metabolism, generally promoting the cellular utilization of glucose. It is also an important regulator of protein and lipid metabolism. Insulin is used as a drug to control insulin-dependent diabetes mellitus.",false,,,http://purl.obolibrary.org/obo/IMR_0002835,,,,,,,,,,,,,,,,,,,,GO:0016088|MeSH:D007328,,"A protein hormone secreted by beta cells of the pancreas. Insulin plays a major role in the regulation of glucose metabolism, generally promoting the cellular utilization of glucose. It is also an important regulator of protein and lipid metabolism. Insulin is used as a drug to control insulin-dependent diabetes mellitus.",,,,,,,,,http://purl.obolibrary.org/obo/IMR_0002835,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0010309|IMR:0011543|IMR:0011922,insulin fragments|insulin A chain|Humulin|Insulin precursor|insulin B chain,,,,,IMR:0000052,,,,,,,,,,,,,,,,,,,,,,insulin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_73240,NF-kappaB inhibitor,NF-kappaB inhibitors|nuclear factor kappa-light-chain-enhancer of activated B cells inhibitor|nuclear factor kappa-light-chain-enhancer of activated B cells inhibitors,"An inhibitor of NF-kappaB (nuclear factor kappa-light-chain-enhancer of activated B cells), a protein complex involved in the transcription of DNA.",false,,,http://purl.obolibrary.org/obo/TXPO_0003711|http://purl.obolibrary.org/obo/CHEBI_35222,,,,,,,,,,,,,,,,,,,,,,"An inhibitor of NF-kappaB (nuclear factor kappa-light-chain-enhancer of activated B cells), a protein complex involved in the transcription of DNA.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,NF-kappaB inhibitors|nuclear factor kappa-light-chain-enhancer of activated B cells inhibitor|nuclear factor kappa-light-chain-enhancer of activated B cells inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:73240,,,,NF-kappaB inhibitor,,CHEBI:73240,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0002072,decreased affinity,,An affinity which is relatively low.,false,,,http://purl.obolibrary.org/obo/PATO_0002070,,,,,,,,,,,,,,,,,,,,,,An affinity which is relatively low.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0002072,,,,,,,,,,,,,,,,,,,,,,decreased affinity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0002070,affinity,,A molecular quality that arises from the molecular attraction exerted between two atoms or compounds.,false,,,http://purl.obolibrary.org/obo/BFO_0000019,,,,,,,,,,,,,,,,,,,,,,A molecular quality that arises from the molecular attraction exerted between two atoms or compounds.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0002070,,,,,,,,,,,,,,,,,,,,,,affinity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002283,lipase,,Catalysis role of the hydrolysis of a lipid or phospholipid.|related molecular function: GO:0016298,false,,,http://purl.obolibrary.org/obo/TXPO_0003663,,,,,,,,,,,,,,,,,,,,EC:3.1.1,,Catalysis role of the hydrolysis of a lipid or phospholipid.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002283,,,,,,,,,,,,,,,,,,,,related molecular function: GO:0016298,,lipase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002288,IL2 (canonical)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003213|http://purl.obolibrary.org/obo/TXPO_1000201,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:16183|NCBI-Rat-GeneID:116562|NCBI-Human-GeneID:3558,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000007,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003041,,,,,,,,,,TXPO:0002288,,,,,,,,,,,,,,,,,,,,,,IL2 (canonical)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002280,AKT - apotosis inhibitor (canonical)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001799,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000250,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_68494,,,,,,,,,,TXPO:0002280,,,,,,,,,,,,,,,,,,,,,,AKT - apotosis inhibitor (canonical)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002282,converting type,,"Converting type is a subtype of changing an operand: A process that changes the type, kind, or class  of the operand.",false,,,http://purl.obolibrary.org/obo/TXPO_0000392,,,,,,,,,,,,,,,,,,,,,,"Converting type is a subtype of changing an operand: A process that changes the type, kind, or class  of the operand.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002282,,,,,,,,,,,,,,,,,,,,,,converting type,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002284,immune responsor role,,A role played by an entity that responds to immunity.,false,,,http://purl.obolibrary.org/obo/TXPO_0003230,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006955,,,,,,,,,,,,,A role played by an entity that responds to immunity.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002284,,,,,,,,,,,,,,,,,,,,,,immune responsor role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002285,glutathione depletion dependent gene [mouse],,"Glutathione depletion dependent gene is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of glutathione depletion as a gene product.
Gene profile:Mice",false,,,http://purl.obolibrary.org/obo/TXPO_0001915,,,,,,,,,,,,,,,,,,,,,,"Glutathione depletion dependent gene is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of glutathione depletion as a gene product.
Gene profile:Mice",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002285,,,,,,,,,,,,,,,,,,,,,,glutathione depletion dependent gene [mouse],,,,,,,,,,,http://purl.obolibrary.org/obo/NCBITaxon_10090,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002281,carcinogenesis [Phospholipidosis (excessive defense)],,"A pathologic process that involves the transformation of normal cells to a neoplastic state.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense).",false,,,http://purl.obolibrary.org/obo/NCIT_C18078|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"A pathologic process that involves the transformation of normal cells to a neoplastic state.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002276|http://purl.obolibrary.org/obo/TXPO_0001491|http://purl.obolibrary.org/obo/TXPO_0002245,,,,,,,,,,,TXPO:0002281,,,,,,,,,,,,,,,,,,,,,,carcinogenesis [Phospholipidosis (excessive defense)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002289,inhibitor of immune response,,A role played by the entity which inhibits the process of infmammatory response.,false,,,http://purl.obolibrary.org/obo/TXPO_0003726,,,,,,,,,,,,,,,,,,,,,,A role played by the entity which inhibits the process of infmammatory response.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002289,,,,,,,,,,,,,,,,,,,,,,inhibitor of immune response,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002286,cytokine production inducer,,A role played by the entity that ipositive regulates the cytokine production.,false,,,http://purl.obolibrary.org/obo/TXPO_0003230,,,,,,,,http://purl.obolibrary.org/obo/GO_0001816,,,,,,,,,,,,,,A role played by the entity that ipositive regulates the cytokine production.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002286,,,,,,,,,,,,,,,,,,,,,,cytokine production inducer,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002287,IL-2 production inducer,,A role played by the entity that ipositive regulates the IL-2 production.,false,,,http://purl.obolibrary.org/obo/TXPO_0002286,,,,,,,,http://purl.obolibrary.org/obo/GO_0032623,,,,,,,,,,,,,,A role played by the entity that ipositive regulates the IL-2 production.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002287,,,,,,,,,,,,,,,,,,,,,,IL-2 production inducer,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000774,ryanodine receptor,RyR,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002628|http://purl.obolibrary.org/obo/TXPO_0003161,,,,,RyR,,,,,IMR:0000774,,,,,,,,,,,,,,,,,,,,,,ryanodine receptor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_50790,EC 1.14.14.14 (aromatase) inhibitor,oestrogen synthase inhibitors|oestrogen synthase inhibitor|oestrogen synthetase inhibitor|aromatase inhibitors|EC 1.14.14.14 inhibitor|estrogen synthetase inhibitor|EC 1.14.14.14 (aromatase) inhibitors|aromatase (EC 1.14.14.14) inhibitors|oestrogen synthetase inhibitors|estrogen synthase inhibitor|EC 1.14.14.14 inhibitors|estrogen synthetase inhibitors|aromatase inhibitor|estrogen synthase inhibitors|aromatase (EC 1.14.14.14) inhibitor,"An EC 1.14.14.* (oxidoreductase acting on paired donors, incorporating of 1 atom of oxygen, with reduced flavin or flavoprotein as one donor) inhibitor which interferes with the action of aromatase (EC 1.14.14.14) and so reduces production of estrogenic steroid hormones.",false,,,http://purl.obolibrary.org/obo/CHEBI_76838,,,,,,,,,,,,,,,,,,,,,,"An EC 1.14.14.* (oxidoreductase acting on paired donors, incorporating of 1 atom of oxygen, with reduced flavin or flavoprotein as one donor) inhibitor which interferes with the action of aromatase (EC 1.14.14.14) and so reduces production of estrogenic steroid hormones.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,oestrogen synthase inhibitors|oestrogen synthase inhibitor|oestrogen synthetase inhibitor|aromatase inhibitors|EC 1.14.14.14 inhibitor|estrogen synthetase inhibitor|EC 1.14.14.14 (aromatase) inhibitors|aromatase (EC 1.14.14.14) inhibitors|oestrogen synthetase inhibitors|estrogen synthase inhibitor|EC 1.14.14.14 inhibitors|estrogen synthetase inhibitors|aromatase inhibitor|estrogen synthase inhibitors|aromatase (EC 1.14.14.14) inhibitor,,,,,,,,,,,,,,,,,,,,,CHEBI:50790,,,,EC 1.14.14.14 (aromatase) inhibitor,,CHEBI:50790,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000433,GEF,guanine nucleotide exchange factor,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,GO:0005085,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003722,,,,,guanine nucleotide exchange factor,,,,,IMR:0000433,,,,,,,,,,,,,,,,,,,,,,GEF,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000002729,GCLC,,,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,,,,,,,Vega:OTTHUMG00000160220|HPRD:06032|MIM:606857|Ensembl:ENSG00000001084|HGNC:4311,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"GO_0000096 (EC: TAS); GO_0000287 (EC: IDA, PMID: 24639); GO_0004357 (EC: IDA, PMID: 11972604); GO_0004357 (EC: IMP, PMID: 16183645); GO_0005524 (EC: IEA); GO_0005737 (EC: IBA); GO_0005829 (EC: TAS); GO_0006534 (EC: IDA, PMID: 2294991); GO_0006536 (EC: IDA, PMID: 12663448); GO_0006750 (EC: IDA, PMID: 10395918); GO_0006750 (EC: IEA); GO_0006750 (EC: IMP, PMID: 12663448); GO_0006750 (EC: TAS); GO_0006805 (EC: TAS); GO_0006979 (EC: IDA, PMID: 10395918); GO_0008637 (EC: IEA); GO_0009408 (EC: IDA, PMID: 8104187); GO_0009725 (EC: IDA, PMID: 8104187); GO_0016595 (EC: IDA, PMID: 9841880); GO_0017109 (EC: IEA); ... (Note: Only 20 GO IDs shown. See more from web page source or RDF output.)""",,,,,,,,,PMID: 24639; 1350904; 2294991; 5058793; 7726839; 7789189; 8104187; 8825659; 8995480; 9675072; 9841880; 10395918; 10439045; 10515893; 10733484; 11820781; 11844594; 11972604; 12070177; 12477932; 12500194; 12598062; 12663448; 14574404; 14676828; 14702039; 15451055; 15485876; 15489334; 16183645; 16322067; 16403949; 16491484; 16599007; 16690975; 16766924; 17109620; 17207022; 17333241; 17344309; 17479437; 17601350; 17643973; 17921251; 17961430; 18035085; 18066575; 18276794; 18420959; 18549827;,,,,,,,,,,,,,,,OGG:3000002729,,,,,,,glutamate-cysteine ligase catalytic subunit,,,,,,,,,,,,,,,GCLC,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2729,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0043227,membrane-bounded organelle,,"Organized structure of distinctive morphology and function, bounded by a single or double lipid bilayer membrane. Includes the nucleus, mitochondria, plastids, vacuoles, and vesicles. Excludes the plasma membrane.",false,,,http://purl.obolibrary.org/obo/GO_0043226,,,,,,,,,,,,,,,,,,,,,,"Organized structure of distinctive morphology and function, bounded by a single or double lipid bilayer membrane. Includes the nucleus, mitochondria, plastids, vacuoles, and vesicles. Excludes the plasma membrane.",,,,,membrane-bounded organelle,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0043227,,,,,,,,,,,,,,,,,,,,,,membrane-bounded organelle,,,,,,,http://purl.obolibrary.org/obo/go.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0043226,organelle,,"Organized structure of distinctive morphology and function. Includes the nucleus, mitochondria, plastids, vacuoles, vesicles, ribosomes and the cytoskeleton, and prokaryotic structures such as anammoxosomes and pirellulosomes. Excludes the plasma membrane.",false,,,http://purl.obolibrary.org/obo/GO_0005575,,,,,,,,,,,,,,,,,,,,Wikipedia:Organelle|NIF_Subcellular:sao1539965131,,"Organized structure of distinctive morphology and function. Includes the nucleus, mitochondria, plastids, vacuoles, vesicles, ribosomes and the cytoskeleton, and prokaryotic structures such as anammoxosomes and pirellulosomes. Excludes the plasma membrane.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0043226,,,,,,,,,,,,,,,,,,,,,,organelle,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100124,tyramine,Tyramine|2-(p-Hydroxyphenyl)ethylamine,,false,,,http://purl.obolibrary.org/obo/IMR_0002121,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_25512,,,,IMR:0200018,Tyramine|2-(p-Hydroxyphenyl)ethylamine,,,,,IMR:0100124,,,,,,,,,,,,,,,,,,,,,,tyramine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100564,FGF-14,FHF-4|Fibroblast growth factor homologous factor 4,,false,,,http://purl.obolibrary.org/obo/IMR_0000049,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FHF-4|Fibroblast growth factor homologous factor 4,,,,,IMR:0100564,,,,,,,,,,,,,,,,,,,,,,FGF-14,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000000443,ASPA,,Other designations: ACY-2|aminoacylase 2|aminoacylase-2,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,ACY2|ASP,,,,,,,,,,,,17,,,,,,MIM:608034|HPRD:02033|HGNC:756,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,aspartoacylase,,,17p13.3,,,,,,,,,,,,,,,,"GO_0004046 (EC: TAS, PMID: 8252036); GO_0005634 (EC: IEA); GO_0005737 (EC: IDA); GO_0006533 (EC: TAS, PMID: 8252036); GO_0016788 (EC: IEA); GO_0019807 (EC: IEA); GO_0022010 (EC: IEA); GO_0046872 (EC: IEA); GO_0048714 (EC: IEA)",,,,,,,,,PMID: 27051; 3116332; 7599639; 7668285; 8023850; 8088831; 8252036; 8659549; 9407392; 10564886; 10837925; 10909858; 12205125; 12477932; 12638939; 12706335; 14699612; 15489334; 16189514; 16437572; 16669630; 16935940; 17027983; 17194761; 17391648; 18029348; 18264947; 18293939; 20201926; 20301412; 22019069; 22219087; 22468686; 22750302; 22878930; 23049088,,,,,,,,,,,,,,,OGG:3000000443,,20140408,protein-coding,,,,aspartoacylase,,,,,,,,,,,,,Other designations: ACY-2|aminoacylase 2|aminoacylase-2,,ASPA,,,,,,,,,,,,,,,,,,,,,,,443,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,ASPA,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0003043,inflammatory cytokine gene expression via ATF4 [ER stress - inflammation],,"Inflammatory cytokine gene expression via ATF4 is a subtype of gene expression: The process in which a gene sequence is converted into a mature inflammatory cytokine gene product or products (proteins or RNA) via ATF4.
This process is dependent on the inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002266|http://purl.obolibrary.org/obo/TXPO_0003736,,,,,,,,,,,,,,,,,,,,,,"Inflammatory cytokine gene expression via ATF4 is a subtype of gene expression: The process in which a gene sequence is converted into a mature inflammatory cytokine gene product or products (proteins or RNA) via ATF4.
This process is dependent on the inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003036,,http://purl.obolibrary.org/obo/TXPO_0002624,,,,,http://purl.obolibrary.org/obo/TXPO_0002766,,,,,,,,,,,TXPO:0003043,,,,,,,,,,,,,,,,,,,,,,inflammatory cytokine gene expression via ATF4 [ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003042,type II diabetes course,,The totality of all processes through which a typeII instance is realized.,false,,,http://purl.obolibrary.org/obo/TXPO_0002033,,,,,,,,,,,,,,,,,,,,,,The totality of all processes through which a typeII instance is realized.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003576|http://purl.obolibrary.org/obo/TXPO_0002443|http://purl.obolibrary.org/obo/TXPO_0003581,,,,,,,,,,,,,,,,,,TXPO:0003042,,,,,,,,,,,,,,,,,,,,,,type II diabetes course,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003049,GRP94 - chaperone (canonical)[proteinrefolding [persist]],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002410,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003997,,,,,,,,,,TXPO:0003049,,,,,,,,,,,,,,,,,,,,,,GRP94 - chaperone (canonical)[proteinrefolding [persist]],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003047,ATF6 -APR transcriptional factor (canonical)[ER stress - inflammation -APR],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003046,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000825,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,,,,,,TXPO:0003047,,,,,,,,,,,,,,,,,,,,,,ATF6 -APR transcriptional factor (canonical)[ER stress - inflammation -APR],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003046,ATF6 - transcriptional factor (canonical)[ER stress - inflammation],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002468,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000825,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,,,,,,TXPO:0003046,,,,,,,,,,,,,,,,,,,,,,ATF6 - transcriptional factor (canonical)[ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003045,APR gene expression by ATF6 [ER stress - inflammation - ATF6-ARP],,"APR gene expression by ATF6. is a subtype of Gene expression by transcriptional regulator: The process in which the sequence of APR is converted into a mature gene product or products (proteins or RNA) by ATF6.
This process is dependent on the ATF6-ARP mediated inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0003736|http://purl.obolibrary.org/obo/TXPO_0002521,,,,,,,,,,,,,,,,,,,,PMID:23334697|PMID:16469704,,"APR gene expression by ATF6. is a subtype of Gene expression by transcriptional regulator: The process in which the sequence of APR is converted into a mature gene product or products (proteins or RNA) by ATF6.
This process is dependent on the ATF6-ARP mediated inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003047,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003070|http://purl.obolibrary.org/obo/TXPO_0003087|http://purl.obolibrary.org/obo/TXPO_0003048,,http://purl.obolibrary.org/obo/TXPO_0003085,,,,,,,,,,,,,,,,,TXPO:0003045,,,,,,,,,,,,,,,,,,,,,,APR gene expression by ATF6 [ER stress - inflammation - ATF6-ARP],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003041,inflammatory substance role,,A role played by the entity that has inflammatory effects.,false,,,http://purl.obolibrary.org/obo/CHEBI_52209,,,,,,,,,,,,,,,,,,,,,,A role played by the entity that has inflammatory effects.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003041,,,,,,,,,,,,,,,,,,,,,,inflammatory substance role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003040,NLRP1 - inflammatory substance (canonical)[ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003039,,,,,,,,,,,,,,,,,,,NLRP1 is a inflammasome component,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003041,,,,,,,,,,TXPO:0003040,,,,,,,,,,,,,,,,,,,,,,NLRP1 - inflammatory substance (canonical)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003044,ATF6-CREBPH-APR pathway [ER stress - inflammation],,"ATF6-CREBPH-APR pathway is a subtype of ATF6 signaling (integrated pathway): Sequence of linked reactions, which has ATF6 signaling and gene regulation pathway.
This process is dependent on positive inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002548,,,,,,,,,,,,,,,,,,,,,,"ATF6-CREBPH-APR pathway is a subtype of ATF6 signaling (integrated pathway): Sequence of linked reactions, which has ATF6 signaling and gene regulation pathway.
This process is dependent on positive inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003072|http://purl.obolibrary.org/obo/TXPO_0003081|http://purl.obolibrary.org/obo/TXPO_0003045,,http://purl.obolibrary.org/obo/TXPO_0002126|http://purl.obolibrary.org/obo/TXPO_0003084,,,,,,,,,,,,,,,,TXPO:0003044,,,,,,,,,,,,,,,,,,,,,,ATF6-CREBPH-APR pathway [ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003048,APR gene (canonical)[ER stress],Acute Phase Response molecule [ER stress],,false,,,http://purl.obolibrary.org/obo/TXPO_0000871|http://purl.obolibrary.org/obo/TXPO_1000008,,,,,,,,,,,,,,,,,,,,PMID:23317820|PMID:16469704,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Acute Phase Response molecule [ER stress],,,,,TXPO:0003048,,,,,,,,,,,,,,,,,,,,,,APR gene (canonical)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76852,EC 1.2.1.* (oxidoreductase acting on donor aldehyde/oxo group with NAD(+) or NADP(+) as acceptor) inhibitor,EC 1.2.1.* inhibitors|EC 1.2.1.* (oxidoreductase acting on donor aldehyde/oxo group with NAD(+) or NADP(+) as acceptor) inhibitors|oxidoreductase acting on donor aldehyde/oxo group with NAD(+) or NADP(+) as acceptor (EC 1.2.1.*) inhibitors|oxidoreductase acting on donor aldehyde/oxo group with NAD(+) or NADP(+) as acceptor (EC 1.2.1.*) inhibitor|EC 1.2.1.* inhibitor,An EC 1.2.* (oxidoreductase acting on donor aldehyde/oxo group) inhibitor that interferes with the action of any such enzyme using NAD(+) or NADP(+) as acceptor (EC 1.2.1.*).,false,,,http://purl.obolibrary.org/obo/CHEBI_76727,,,,,,,,,,,,,,,,,,,,,,An EC 1.2.* (oxidoreductase acting on donor aldehyde/oxo group) inhibitor that interferes with the action of any such enzyme using NAD(+) or NADP(+) as acceptor (EC 1.2.1.*).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,EC 1.2.1.* inhibitors|EC 1.2.1.* (oxidoreductase acting on donor aldehyde/oxo group with NAD(+) or NADP(+) as acceptor) inhibitors|oxidoreductase acting on donor aldehyde/oxo group with NAD(+) or NADP(+) as acceptor (EC 1.2.1.*) inhibitors|oxidoreductase acting on donor aldehyde/oxo group with NAD(+) or NADP(+) as acceptor (EC 1.2.1.*) inhibitor|EC 1.2.1.* inhibitor,,,,,,,,,,,,,,,,,,,,,CHEBI:76852,,,,EC 1.2.1.* (oxidoreductase acting on donor aldehyde/oxo group with NAD(+) or NADP(+) as acceptor) inhibitor,,CHEBI:76852,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0019835,cytolysis,,The rupture of cell membranes and the loss of cytoplasm.,false,,,http://purl.obolibrary.org/obo/TXPO_0000437,,,,,,,,,,,,,,,,,,,,Wikipedia:Cytolysis,,The rupture of cell membranes and the loss of cytoplasm.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0019835,,,,,,,,,,,,,,,,,,,,,,cytolysis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000000,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_1901797,negative regulation of p53 signaling,downregulation of signal transduction by p53 class mediator,"Any process that stops, prevents or reduces the frequency, rate or extent of signal transduction by p53 class mediator.",false,,,http://purl.obolibrary.org/obo/GO_0023057,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents or reduces the frequency, rate or extent of signal transduction by p53 class mediator.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,downregulation of signal transduction by p53 class mediator,,,,,GO:1901797,,,,,,,,,,,,,,,,,,,,,,negative regulation of p53 signaling,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000001|http://purl.obolibrary.org/obo/GO_0007173,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_1901799,negative regulation of proteasomal protein catabolic process,,"Any process that stops, prevents or reduces the frequency, rate or extent of proteasomal protein catabolic process.",false,,,http://purl.obolibrary.org/obo/GO_0042177,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents or reduces the frequency, rate or extent of proteasomal protein catabolic process.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:1901799,,,,,,,,,,,,,,,,,,,,,,negative regulation of proteasomal protein catabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0010498,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001330,decreasing cholesterol concentration in blood,,Decreasing cholesterol concentration in blood is a subtype of decreasing concentration: A process that changes the concentration of the cholesterol in the blood to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000671,,,,,,,,,,,,,,,,,,,,,,Decreasing cholesterol concentration in blood is a subtype of decreasing concentration: A process that changes the concentration of the cholesterol in the blood to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001330,,,,,,,,,,,,,,,,,,,,,,decreasing cholesterol concentration in blood,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001337,increasing creatinine concentration,,Increasing creatinine concentration is a subtype of increasing concentration: A process that changes the creatinine concentration to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000352,,,,,,,,,,,,,,,,,,,,,,Increasing creatinine concentration is a subtype of increasing concentration: A process that changes the creatinine concentration to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001337,,,,,,,,,,,,,,,,,,,,,,increasing creatinine concentration,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001331,hypofunction of albumin biosynthesis,,Hypofunction of albumin biosynthesis is a subtype of hypofunction of biosynthesis: A process that performs a decreased or insufficient albumin biosynthesis.,false,,,http://purl.obolibrary.org/obo/TXPO_0001910,,,,,,,,,,,,,,,,,,,,,,Hypofunction of albumin biosynthesis is a subtype of hypofunction of biosynthesis: A process that performs a decreased or insufficient albumin biosynthesis.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001332,,,,,,,,,,,TXPO:0001331,,,,,,,,,,,,,,,,,,,,,,hypofunction of albumin biosynthesis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001338,renin-angiotensin activation,,"Renin-angiotensin activation is a subtype of activating: A process that changes the activity of the renin-angiotensin system, which regulates blood pressure and fluid balance,  to be higher.",false,,,http://purl.obolibrary.org/obo/TXPO_0000401,,,,,,,,,,,,,,,,,,,,,,"Renin-angiotensin activation is a subtype of activating: A process that changes the activity of the renin-angiotensin system, which regulates blood pressure and fluid balance,  to be higher.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001338,,,,,,,,,,,,,,,,,,,,,,renin-angiotensin activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001336,decreasing renal blood flow,,Decreasing renal blood flow is a subtype of decreasing flow: A process that changes the amount of renal flow to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000359,,,,,,,,,,,,,,,,,,,,,,Decreasing renal blood flow is a subtype of decreasing flow: A process that changes the amount of renal flow to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001336,,,,,,,,,,,,,,,,,,,,,,decreasing renal blood flow,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001332,decreasing albumin concentration in blood,,Decreasing albumin concentration in blood is a subtype of decreasing concentration: A process that changes the concentration of the albumin in the blood to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000671,,,,,,,,,,,,,,,,,,,,,,Decreasing albumin concentration in blood is a subtype of decreasing concentration: A process that changes the concentration of the albumin in the blood to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001333,,,,,,,,,,,TXPO:0001332,,,,,,,,,,,,,,,,,,,,,,decreasing albumin concentration in blood,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001333,decreasing blood osmotic pressure.,,Decreasing blood osmotic pressure. is a subtype of decreasing osmotic pressure.: A process that changes the osmotic pressure to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0003307,,,,,,,,,,,,,,,,,,,,,,Decreasing blood osmotic pressure. is a subtype of decreasing osmotic pressure.: A process that changes the osmotic pressure to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001380,,,,,,,,,,,TXPO:0001333,,,,,,,,,,,,,,,,,,,,,,decreasing blood osmotic pressure.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001339,low-density lipoprotein,Wikipedia:Low-density_lipoprotein|LDL,"A class of lipoproteins of small size (18-25 nm) and low density (1.019-1.063 g/ml) particles with a core composed mainly of cholesterol esters and smaller amounts of triglycerides. The surface monolayer consists mostly of phospholipids, a single copy of apolipoprotein B-100, and free cholesterol molecules. The main function of LDL is to transport cholesterol and cholesterol esters from the liver. Excessive levels are associated with cardiovascular disease.",false,,,http://purl.obolibrary.org/obo/CHEBI_6495,,,,,,,,,,,,,,,,,,,,,,"A class of lipoproteins of small size (18-25 nm) and low density (1.019-1.063 g/ml) particles with a core composed mainly of cholesterol esters and smaller amounts of triglycerides. The surface monolayer consists mostly of phospholipids, a single copy of apolipoprotein B-100, and free cholesterol molecules. The main function of LDL is to transport cholesterol and cholesterol esters from the liver. Excessive levels are associated with cardiovascular disease.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Wikipedia:Low-density_lipoprotein|LDL,,,TXPO:0001339,,,,,,,,,,,,,,,,,,,,,,low-density lipoprotein,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001334,movement attribute,,An attribute inhering in a bearer by virtue of the bearer's participation in movement.,false,,,http://purl.obolibrary.org/obo/TXPO_0000305,,,,,,,,,,,,,,,,,,,,,,An attribute inhering in a bearer by virtue of the bearer's participation in movement.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001334,,,,,,,,,,,,,,,,,,,,,,movement attribute,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001335,decreasing amount of circulating blood,,Decreasing amount of circulating blood is a subtype of decreasing blood flow: A process that changes the amount of circulating blood to be smaller.,false,,,http://purl.obolibrary.org/obo/TXPO_0000359,,,,,,,,,,,,,,,,,,,,,,Decreasing amount of circulating blood is a subtype of decreasing blood flow: A process that changes the amount of circulating blood to be smaller.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001336,,,,,,,,,,,TXPO:0001335,,,,,,,,,,,,,,,,,,,,,,decreasing amount of circulating blood,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001293,sphingophopholipid metabolism imbalance,,Sphingophopholipid metabolism imbalance is a subtype of phospholipid metabolism imbalance: A process that becomes lacking a homeostastasis balance of sphingophopholipid metabolism.,false,,,http://purl.obolibrary.org/obo/TXPO_0002308,,,,,,,,,,,,,,,,,,,,,,Sphingophopholipid metabolism imbalance is a subtype of phospholipid metabolism imbalance: A process that becomes lacking a homeostastasis balance of sphingophopholipid metabolism.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001293,,,,,,,,,,,,,,,,,,,,,,sphingophopholipid metabolism imbalance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001299,network attribute,,An attribute that inheres in a bearer by virtue of network,false,,,http://purl.obolibrary.org/obo/TXPO_0000305,,,,,,,,,,,,,,,,,,,,,,An attribute that inheres in a bearer by virtue of network,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001299,,,,,,,,,,,,,,,,,,,,,,network attribute,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001290,hyperfunction of sphingophospholipid synthesis gene expression,,Hyperfunction of sphingophospholipid synthesis gene expression is a subtype of hyperfunction of phospholipid synthesis gene expression: A process that performs an excesssive sphingophospholipid synthetic gene expression.,false,,,http://purl.obolibrary.org/obo/TXPO_0001726,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of sphingophospholipid synthesis gene expression is a subtype of hyperfunction of phospholipid synthesis gene expression: A process that performs an excesssive sphingophospholipid synthetic gene expression.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001290,,,,,,,,,,,,,,,,,,,,,,hyperfunction of sphingophospholipid synthesis gene expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001296,increasing number of damaged lysosomes,,increasing number of damaged lysosomes is a subtype of increasing number : A process that becomes larger in the number of damaged lysosomes.,false,,,http://purl.obolibrary.org/obo/TXPO_0000093,,,,,,,,,,,,,,,,,,,,,,increasing number of damaged lysosomes is a subtype of increasing number : A process that becomes larger in the number of damaged lysosomes.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001296,,,,,,,,,,,,,,,,,,,,,,increasing number of damaged lysosomes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000000,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001295,glycerophospholipid metabolism imbalance,,Glycerophospholipid metabolism imbalance  is a subtype of phospholipid metabolism imbalance: A process that becomes lacking a homeostastasis balance of glycerophospholipid metabolism.,false,,,http://purl.obolibrary.org/obo/TXPO_0002308,,,,,,,,,,,,,,,,,,,,,,Glycerophospholipid metabolism imbalance  is a subtype of phospholipid metabolism imbalance: A process that becomes lacking a homeostastasis balance of glycerophospholipid metabolism.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001295,,,,,,,,,,,,,,,,,,,,,,glycerophospholipid metabolism imbalance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001291,phosphosphingolipid biosynthesis,sphingophospholipid biosynthesis|phosphosphingolipid formation|sphingophospholipid anabolism|phosphosphingolipid anabolism|phosphosphingolipid synthesis|sphingophospholipid formation,The chemical reactions and pathways resulting in the formation of phosphosphingolipids.,false,,,http://purl.obolibrary.org/obo/GO_0008654,,,,,,,,,,,,,,,,,,,,,,The chemical reactions and pathways resulting in the formation of phosphosphingolipids.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35786,,,,,,,,,,,,,,sphingophospholipid biosynthesis|phosphosphingolipid formation|sphingophospholipid anabolism|phosphosphingolipid anabolism|phosphosphingolipid synthesis|sphingophospholipid formation,,,,,TXPO:0001291,,,,,,,,,,,,,,,,,,,,,,phosphosphingolipid biosynthesis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001298,autophagy [Phospholipidosis],,"The cellular catabolic process in which cells digest parts of their own cytoplasm; allows for both recycling of macromolecular constituents under conditions of cellular stress and remodeling the intracellular structure for cell differentiation
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/GO_0006914,,,,,,,,,,,,,,,,,,,,,,"The cellular catabolic process in which cells digest parts of their own cytoplasm; allows for both recycling of macromolecular constituents under conditions of cellular stress and remodeling the intracellular structure for cell differentiation
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001298,,,,,,,,,,,,,,,,,,,,,,autophagy [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001292,increasing NAD/NAD+ ratio,,Increasing NAD/NAD+ ratio is a subtype of increasing ratio: A process that changes the ratio of NAD to NAD+ to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000352,,,,,,,,,,,,,,,,,,,,,,Increasing NAD/NAD+ ratio is a subtype of increasing ratio: A process that changes the ratio of NAD to NAD+ to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001292,,,,,,,,,,,,,,,,,,,,,,increasing NAD/NAD+ ratio,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001297,hypofunction of maintaining lysosome homeostasis,,Hypofunction of maintaining lysosome homeostasis is a subtype of hypofunctioning: A process that performs a decreased or insufficient maintaining lysosome homeostasis.,false,,,http://purl.obolibrary.org/obo/TXPO_0000436,,,,,,,,,,,,,,,,,,,,,,Hypofunction of maintaining lysosome homeostasis is a subtype of hypofunctioning: A process that performs a decreased or insufficient maintaining lysosome homeostasis.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001297,,,,,,,,,,,,,,,,,,,,,,hypofunction of maintaining lysosome homeostasis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005764,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001294,negative regulation of lysophagy [Phospholipidosis (severe)],,"Any process that stops, prevents, or reduces the frequency, rate or extent of lysophagy.
This entity is a specific course-dependent process. This process can constitute the course of phospholipidosis (severe).",false,,,http://purl.obolibrary.org/obo/TXPO_0001258|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents, or reduces the frequency, rate or extent of lysophagy.
This entity is a specific course-dependent process. This process can constitute the course of phospholipidosis (severe).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004113,,,,,,,,,,,TXPO:0001294,,,,,,,,,,,,,,,,,,,,,,negative regulation of lysophagy [Phospholipidosis (severe)],,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0062093,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000009939,RBM8A,,Other designations: BOV-1|RNA binding motif protein 8B|RNA-binding motif protein 8A|RNA-binding protein 8A|RNA-binding protein Y14|binder of OVCA1-1|ribonucleoprotein RBM8|ribonucleoprotein RBM8A,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,MDS014|ZNRP|BOV-1B|RBM8|BOV-1C|DEL1q21.1|TAR|C1DELq21.1|ZRNP1|BOV-1A|RBM8B|Y14,,,,,,,,,,,,1,,,,,,HPRD:05609|Ensembl:ENSG00000131795|Vega:OTTHUMG00000013736|HGNC:9905|MIM:605313,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,RNA binding motif protein 8A,,,1q21.1,,,,,,,,,,,,,,,,"GO_0000166 (EC: IEA); GO_0000184 (EC: IMP, PMID: 16209946); GO_0000184 (EC: TAS); GO_0000381 (EC: IMP); GO_0000398 (EC: IC, PMID: 11991638); GO_0000398 (EC: TAS); GO_0003723 (EC: NAS, PMID: 11013075); GO_0003729 (EC: NAS, PMID: 11030346); GO_0005515 (EC: IPI, PMID: 10662555); GO_0005634 (EC: IDA); GO_0005634 (EC: NAS, PMID: 11013075); GO_0005654 (EC: TAS); GO_0005730 (EC: IDA, Qualifier: NOT); GO_0005737 (EC: NAS, PMID: 11030346); GO_0005829 (EC: TAS); GO_0006366 (EC: TAS); GO_0006369 (EC: TAS); GO_0006406 (EC: TAS); GO_0006417 (EC: IEA); GO_0008380 (EC: TAS); GO_0010467 (EC: TAS); GO_0016070 (EC: TAS); GO_0016071 (EC: TAS); GO_0016607 (EC: IEA); GO_0031124 (EC: TAS); GO_0035145 (EC: IDA, PMID: 16601204); GO_0044822 (EC: IDA); GO_0071013 (EC: IDA, PMID: 11991638)",,,,,,,,,PMID: 9222511; 9933612; 10662555; 11004516; 11013075; 11030346; 11042152; 11118221; 11447110; 11546873; 11546874; 11696323; 11707068; 11707413; 11991638; 12054603; 12093754; 12226669; 12477932; 12718880; 12730685; 12781131; 12944400; 14625303; 14730019; 15302935; 15489334; 15635413; 16083285; 16100109; 16159877; 16170325; 16189514; 16209946; 16303743; 16344560; 16452507; 16501559; 16601204; 16931718; 16964243; 17081983; 17456004; 18026120; 18029348; 18243119; 18503751; 19254694; 19410547; 19417104; 19471022; 19615732; 20098747; 20301781; 20371770; 21139048; 21145460; 21209085; 21832049; 22355610; 22365833; 22366785; 22939629; 22944692; 23084401; 23115303; 23602568; 23817415; 23940030; 23970407; 24244333; 24457600,,,,,,,,,,,,,,,OGG:3000009939,,,,,,,RNA binding motif protein 8A,,,,,,,,,,,,,Other designations: BOV-1|RNA binding motif protein 8B|RNA-binding motif protein 8A|RNA-binding protein 8A|RNA-binding protein Y14|binder of OVCA1-1|ribonucleoprotein RBM8|ribonucleoprotein RBM8A,,RBM8A,,,,,,,,,,,,,,,,,,,,,,,9939,HSPC114,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,RBM8A,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000153,BCR,B cell receptor|B-cell antigen receptor|BCR complex|B cell receptor complex,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,GO:0019815,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,B cell receptor|B-cell antigen receptor|BCR complex|B cell receptor complex,,,,,IMR:0000153,,,,,,,,,,,,,,,,,,,,,,BCR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006656,phosphatidylcholine biosynthetic process,phosphatidylcholine biosynthesis|phosphatidylcholine formation|phosphatidylcholine anabolism|phosphatidylcholine synthesis,"The chemical reactions and pathways resulting in the formation of phosphatidylcholines, any of a class of glycerophospholipids in which the phosphatidyl group is esterified to the hydroxyl group of choline.",false,,,http://purl.obolibrary.org/obo/GO_0046470|http://purl.obolibrary.org/obo/GO_0046474,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways resulting in the formation of phosphatidylcholines, any of a class of glycerophospholipids in which the phosphatidyl group is esterified to the hydroxyl group of choline.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_64482,,,,,,,,,,,,,,phosphatidylcholine biosynthesis|phosphatidylcholine formation|phosphatidylcholine anabolism|phosphatidylcholine synthesis,,,,,GO:0006656,,,,,,,,,,,,,,,,,,,,,,phosphatidylcholine biosynthetic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006654,phosphatidic acid biosynthetic process,phosphatidic acid formation|phosphatidic acid synthesis|phosphatidic acid biosynthesis|phosphatidic acid anabolism,"The chemical reactions and pathways resulting in the formation of phosphatidic acid, any derivative of glycerol phosphate in which both the remaining hydroxyl groups of the glycerol moiety are esterified with fatty acids.",false,,,http://purl.obolibrary.org/obo/GO_0046473|http://purl.obolibrary.org/obo/GO_0046474,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways resulting in the formation of phosphatidic acid, any derivative of glycerol phosphate in which both the remaining hydroxyl groups of the glycerol moiety are esterified with fatty acids.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_16337,,,,,,,,,,,,,,phosphatidic acid formation|phosphatidic acid synthesis|phosphatidic acid biosynthesis|phosphatidic acid anabolism,,,,,GO:0006654,,,,,,,,,,,,,,,,,,,,,,phosphatidic acid biosynthetic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006659,phosphatidylserine biosynthetic process,phosphatidylserine synthesis|phosphatidylserine formation|phosphatidylserine biosyntheis|phosphatidylserine biosynthesis|phosphatidylserine anabolism,"The chemical reactions and pathways resulting in the formation of phosphatidylserines, any of a class of glycerophospholipids in which the phosphatidyl group is esterified to the hydroxyl group of L-serine.",false,,,http://purl.obolibrary.org/obo/GO_0046474|http://purl.obolibrary.org/obo/GO_0006658,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways resulting in the formation of phosphatidylserines, any of a class of glycerophospholipids in which the phosphatidyl group is esterified to the hydroxyl group of L-serine.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_18303,,,,,,,,,,,,,,phosphatidylserine synthesis|phosphatidylserine formation|phosphatidylserine biosyntheis|phosphatidylserine biosynthesis|phosphatidylserine anabolism,,,,,GO:0006659,,,,,,,,,,,,,,,,,biological_process,,,,,phosphatidylserine biosynthetic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006650,glycerophospholipid metabolic process,alpha-glycerophosphate pathway|phosphoglyceride metabolism|glycerophospholipid metabolism|phosphoglyceride metabolic process,"The chemical reactions and pathways involving glycerophospholipids, any derivative of glycerophosphate that contains at least one O-acyl, O-alkyl, or O-alkenyl group attached to the glycerol residue.",false,,,http://purl.obolibrary.org/obo/GO_0006644,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways involving glycerophospholipids, any derivative of glycerophosphate that contains at least one O-acyl, O-alkyl, or O-alkenyl group attached to the glycerol residue.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_37739,,,,,,,,,,,,phosphoglyceride metabolism|glycerophospholipid metabolism|phosphoglyceride metabolic process,,alpha-glycerophosphate pathway,,,GO:0006650,,,,,,,,,,,,,,,,,,,,,,glycerophospholipid metabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006655,phosphatidylglycerol biosynthetic process,phosphatidylglycerol anabolism|phosphatidylglycerol formation|phosphatidylglycerol biosynthesis|phosphatidylglycerol synthesis,"The chemical reactions and pathways resulting in the formation of phosphatidylglycerols, any of a class of phospholipids in which the phosphatidyl group is esterified to the hydroxyl group of glycerol.",false,,,http://purl.obolibrary.org/obo/GO_0046471|http://purl.obolibrary.org/obo/GO_0046474,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways resulting in the formation of phosphatidylglycerols, any of a class of phospholipids in which the phosphatidyl group is esterified to the hydroxyl group of glycerol.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_17517,,,,,,,,,,,,,,phosphatidylglycerol anabolism|phosphatidylglycerol formation|phosphatidylglycerol biosynthesis|phosphatidylglycerol synthesis,,,,,GO:0006655,,,,,,,,,,,,,,,,,,,,,,phosphatidylglycerol biosynthetic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006658,phosphatidylserine metabolic process,phosphatidylserine metabolism,"The chemical reactions and pathways involving phosphatidylserines, any of a class of glycerophospholipids in which the phosphatidyl group is esterified to the hydroxyl group of L-serine. They are important constituents of cell membranes.",false,,,http://purl.obolibrary.org/obo/GO_0006650,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways involving phosphatidylserines, any of a class of glycerophospholipids in which the phosphatidyl group is esterified to the hydroxyl group of L-serine. They are important constituents of cell membranes.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_18303,,,,,,,,,,,,phosphatidylserine metabolism,,,,,GO:0006658,,,,,,,,,,,,,,,,,biological_process,,,,,phosphatidylserine metabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000256,fatty acid strorage,,Fatty acid strorage is a subtype of accumulation of substances in a biological object: A process that keeps fatty acid in a biological object.,false,,,http://purl.obolibrary.org/obo/GO_0019915,,,,,,,,,,,,,,,,,,,,,,Fatty acid strorage is a subtype of accumulation of substances in a biological object: A process that keeps fatty acid in a biological object.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000834,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000256,,,,,,,,,,,,,,,,,,,,,,fatty acid strorage,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000252,mitochondrial dysfunction [Cell death],,"Mitochondrial dysfunction is a subtype of dysfunctioning: A process that performs an abnormal and incomplete mitochondrial function.
This entity is a specific course-dependent process. This process can constitute the course of cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0001727|http://purl.obolibrary.org/obo/TXPO_0002361,,,,,,,,,,,,,,,,,,,,,,"Mitochondrial dysfunction is a subtype of dysfunctioning: A process that performs an abnormal and incomplete mitochondrial function.
This entity is a specific course-dependent process. This process can constitute the course of cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000346,,,,,,,,,,,TXPO:0000252,,,,,,,,,,,,,,,,,,,,,,mitochondrial dysfunction [Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000254,vitamine accumulation,,Vitamine accumulation is a subtype of accumulation of substances in a biological object: A process that keeps vitamin in a biological object.,false,,,http://purl.obolibrary.org/obo/TXPO_0000247,,,,,,,,,,,,,,,,,,,,,,Vitamine accumulation is a subtype of accumulation of substances in a biological object: A process that keeps vitamin in a biological object.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0001656,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000254,,,,,,,,,,,,,,,,,,,,,,vitamine accumulation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000257,substance with stress sensor role,,"Substance with stress sensor role is a subtype of substance with role.
This entity is participating in a stress response and playing a stress sensor role.|This entity is inferred from Description Logic.",false,,,http://purl.obolibrary.org/obo/CHEBI_24431|http://purl.obolibrary.org/obo/GOCHE_50906,,,,,,,,,,,,,,,,,,,,,,"Substance with stress sensor role is a subtype of substance with role.
This entity is participating in a stress response and playing a stress sensor role.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000257,,,,,,,,,,,,,,,,,,,,This entity is inferred from Description Logic.,,substance with stress sensor role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000250,accumulation of abnormal proteins in ER [ER stress (severe) ],,"Accumulation of abnormal proteins in ER is a subtype of accumulation of abnormal proteins: A process that keeps abnormal protein(s) in the ER (endoplasmic reticulum). And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of ER stress (severe) .",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/TXPO_0003528,,,,,,,,,,,,,,,,,,,,,,"Accumulation of abnormal proteins in ER is a subtype of accumulation of abnormal proteins: A process that keeps abnormal protein(s) in the ER (endoplasmic reticulum). And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of ER stress (severe) .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000752|http://purl.obolibrary.org/obo/TXPO_0002114|http://purl.obolibrary.org/obo/TXPO_0002505,,,,,,,,,,,TXPO:0000250,,,,,,,,,,,,,,,,,,,,,,accumulation of abnormal proteins in ER [ER stress (severe) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000253,increasing size of liver,hepatomegaly,Increasing size of liver is a subtype of increasing size: A process that changes the size of the liver to be larger.,false,,,http://purl.obolibrary.org/obo/TXPO_0000138,,,,,,,,,,,,,,,,,,,,,,Increasing size of liver is a subtype of increasing size: A process that changes the size of the liver to be larger.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,hepatomegaly,,,,TXPO:0000253,,,,,,,,,,,,,,,,,,,,,,increasing size of liver,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000251,accumulation of abnormal proteins,,Accumulation of abnormal proteins is a subtype of protein accumulation: A process that keeps abnormal protein(s) in a biological object.,false,,,http://purl.obolibrary.org/obo/TXPO_0000248,,,,,,,,,,,,,,,,,,,,,,Accumulation of abnormal proteins is a subtype of protein accumulation: A process that keeps abnormal protein(s) in a biological object.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000251,,,,,,,,,,,,,,,,,,,,,,accumulation of abnormal proteins,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000258,melanin deposition,,"Melanin deposition is a subtype of accumulation of pigments: The aggregation of melanin in a particular location in an organism, tissue or cell.",false,,,http://purl.obolibrary.org/obo/GO_0043473,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/MPATH_44,,"Melanin deposition is a subtype of accumulation of pigments: The aggregation of melanin in a particular location in an organism, tissue or cell.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003821,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000258,,,,,,,,,,,,,,,,,,,,,,melanin deposition,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000255,accumulation of protein aggregates,,Accumulation of protein aggregates is a subtype of protein accumulation: A process that keeps protein aggregates in a biological object.|Protein aggretates are often  insoluble and tend to sequester Fe 2+ ions.  Fe 2+ helps to produce ROS.,false,,,http://purl.obolibrary.org/obo/TXPO_0000248,,,,,,,,,,,,,,,,,,,,,,Accumulation of protein aggregates is a subtype of protein accumulation: A process that keeps protein aggregates in a biological object.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000255,,,,,,,,,,,,,,,,,,,,Protein aggretates are often  insoluble and tend to sequester Fe 2+ ions.  Fe 2+ helps to produce ROS.,,accumulation of protein aggregates,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000259,lipofuscin deposition,,"Lipofuscin deposition is a subtype of accumulation of pigments: The aggregation of lipofuscin in a particular location in an organism, tissue or cell.",false,,,http://purl.obolibrary.org/obo/GO_0043473,,,,,,,,,,,,,,,,,,,,,,"Lipofuscin deposition is a subtype of accumulation of pigments: The aggregation of lipofuscin in a particular location in an organism, tissue or cell.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003820,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000259,,,,,,,,,,,,,,,,,,,,,,lipofuscin deposition,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_48406,EC 2.1.1.6 (catechol O-methyltransferase) inhibitor,COMT inhibitors|EC 2.1.1.6 inhibitors|catechol O-methyltransferase (EC 2.1.1.6) inhibitors|catechol O-methyltransferase inhibitors|catechol methyltransferase inhibitor|COMT inhibitor|S-adenosyl-L-methionine:catechol O-methyltransferase inhibitors|EC 2.1.1.6 inhibitor|catechol O-methyltransferase (EC 2.1.1.6) inhibitor|catechol O-methyltransferase inhibitor|catecholamine O-methyltransferase inhibitors|catechol methyltransferase inhibitors|EC 2.1.1.6 (catechol O-methyltransferase) inhibitors|S-adenosyl-L-methionine:catechol O-methyltransferase inhibitor|catecholamine O-methyltransferase inhibitor,An EC 2.1.1.* (methyltransferase) inhibitor that interferes with the action of catechol O-methyltransferase (EC 2.1.1.6).,false,,,http://purl.obolibrary.org/obo/CHEBI_76871,,,,,,,,,,,,,,,,,,,,,,An EC 2.1.1.* (methyltransferase) inhibitor that interferes with the action of catechol O-methyltransferase (EC 2.1.1.6).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COMT inhibitors|EC 2.1.1.6 inhibitors|catechol O-methyltransferase (EC 2.1.1.6) inhibitors|catechol O-methyltransferase inhibitors|catechol methyltransferase inhibitor|COMT inhibitor|S-adenosyl-L-methionine:catechol O-methyltransferase inhibitors|EC 2.1.1.6 inhibitor|catechol O-methyltransferase (EC 2.1.1.6) inhibitor|catechol O-methyltransferase inhibitor|catecholamine O-methyltransferase inhibitors|catechol methyltransferase inhibitors|EC 2.1.1.6 (catechol O-methyltransferase) inhibitors|S-adenosyl-L-methionine:catechol O-methyltransferase inhibitor|catecholamine O-methyltransferase inhibitor,,,,,,,,,,,,,,,,,,,,,CHEBI:48406,,,,EC 2.1.1.6 (catechol O-methyltransferase) inhibitor,,CHEBI:48406,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_3732,clarithromycin,clarithromycin|6-O-methylerythromycin|clarithromycine|clarithromycinum|6-O-methylerythromycin A|CLA|clarithromycina|CLARITHROMYCIN|O(6)-methylerythromycin|Clarithromycin,"The 6-O-methyl ether of erythromycin A, clarithromycin is a macrolide antibiotic used in the treatment of respiratory-tract, skin and soft-tissue infections. It is also used to eradicate Helicobacter pylori in the treatment of peptic ulcer disease. It prevents bacteria from growing by interfering with their protein synthesis.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Reaxys:3581974|PMID:16387493|Drug_Central:668|Beilstein:3581974|DrugBank:DB01211|CAS:81103-11-9|LINCS:LSM-5606|LIPID_MAPS_instance:LMPK04000014,,"The 6-O-methyl ether of erythromycin A, clarithromycin is a macrolide antibiotic used in the treatment of respiratory-tract, skin and soft-tissue infections. It is also used to eradicate Helicobacter pylori in the treatment of peptic ulcer disease. It prevents bacteria from growing by interfering with their protein synthesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35703|http://purl.obolibrary.org/obo/CHEBI_48001|http://purl.obolibrary.org/obo/CHEBI_36047|http://purl.obolibrary.org/obo/CHEBI_78298,,,,,CLARITHROMYCIN|O(6)-methylerythromycin|Clarithromycin,,clarithromycin|6-O-methylerythromycin|clarithromycine|clarithromycinum|6-O-methylerythromycin A|CLA|clarithromycina,,,,,,,,,,,,,,,,,,,,,CHEBI:3732,,,,clarithromycin,,CHEBI:3732,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000176,alpha-catenin,,,false,,,http://purl.obolibrary.org/obo/TXPO_0003158,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003688,,,,,,,,,,IMR:0000176,,,,,,,,,,,,,,,,,,,,,,alpha-catenin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001041,group IVC phospholipase A2,,,false,,,http://purl.obolibrary.org/obo/IMR_0000283,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001041,,,,,,,,,,,,,,,,,,,,,,group IVC phospholipase A2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010544,40S ribosomal protein S19,40S small ribosomal protein 19,,false,,,http://purl.obolibrary.org/obo/IMR_0000896,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,40S small ribosomal protein 19,,,,,IMR:0010544,,,,,,,,,,,,,,,,,,,,,,40S ribosomal protein S19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_48561,dopaminergic antagonist,dopamine receptor antagonist|dopamine blocker|dopamine antagonist|dopaminergic antagonists,"A drug that binds to but does not activate dopamine receptors, thereby blocking the actions of dopamine or exogenous agonists.",false,,,http://purl.obolibrary.org/obo/CHEBI_48560,,,,,,,,,,,,,,,,,,,,,,"A drug that binds to but does not activate dopamine receptors, thereby blocking the actions of dopamine or exogenous agonists.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,dopamine receptor antagonist|dopamine blocker|dopamine antagonist|dopaminergic antagonists,,,,,,,,,,,,,,,,,,,,,CHEBI:48561,,,,dopaminergic antagonist,,CHEBI:48561,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000049,cleavage of ATF6-alpha by S1P [ER stress],,"Cleavage of ATF6-alpha by S1P is a subtype of proteolysis: A process in which ATF6-alpha is cleaved by endopeptidase S1P( MBTPS1).
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0003736|http://purl.obolibrary.org/obo/TXPO_0000048,,,,,,,,,,,,,,,,,,,,PMID:15299016|Reactome:R-HSA-381135|PMID:10564271|http://purl.obolibrary.org/obo/HINO_0008875|PMID:11163209,,"Cleavage of ATF6-alpha by S1P is a subtype of proteolysis: A process in which ATF6-alpha is cleaved by endopeptidase S1P( MBTPS1).
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000349,,,,,,,,,,,TXPO:0000049,,,,,,,,,,,,,,,,,,,,,,cleavage of ATF6-alpha by S1P [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000044,ATF6 (golgi apparatus) (canonical)[ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000879,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000044,,,,,,,,,,,,,,,,,,,,,,ATF6 (golgi apparatus) (canonical)[ER stress],,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005794,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000048,cleavage of ATF6-alpha by S1P,,Cleavage of ATF6-alpha by S1P is a subtype of proteolysis: A process  in which ATF6-alpha is cleaved by  endopeptidase S1P( MBTPS1).,false,,,http://purl.obolibrary.org/obo/TXPO_0000333,,,,,,,,,,,,,,,,,,,,,,Cleavage of ATF6-alpha by S1P is a subtype of proteolysis: A process  in which ATF6-alpha is cleaved by  endopeptidase S1P( MBTPS1).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000831,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000048,,,,,,,,,,,,,,,,,,,,,,cleavage of ATF6-alpha by S1P,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000041,inreasing blood ALP concentration [Cholestasis],inreasing blood ALP concentration [cholestasis],"Inreasing blood ALP concentration is a subtype of increasing concentration: A process that changes the bilirubin concentration in the blood to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001346|http://purl.obolibrary.org/obo/TXPO_0000034,,,,,,,,,,,,,,,,,,,,,,"Inreasing blood ALP concentration is a subtype of increasing concentration: A process that changes the bilirubin concentration in the blood to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,inreasing blood ALP concentration [cholestasis],,,,,TXPO:0000041,,,,,,,,,,,,,,,,,,,,,,inreasing blood ALP concentration [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000045,hypofunction of bile acid and bile salt transport,,Hypofunction of bile acid and bile salt transport is a subtype of hypofunction of transport: A process that performs a decreased or insufficient bile acid and bile salt transport.,false,,,http://purl.obolibrary.org/obo/TXPO_0001911,,,,,,,,,,,,,,,,,,,,,,Hypofunction of bile acid and bile salt transport is a subtype of hypofunction of transport: A process that performs a decreased or insufficient bile acid and bile salt transport.,,,http://purl.obolibrary.org/obo/GO_0015721,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000045,,,,,,,,,,,,,,,,,,,,,,hypofunction of bile acid and bile salt transport,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000047,NRF2 (canonical)[ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000871|http://purl.obolibrary.org/obo/TXPO_0002527,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:18024|NCBI-Rat-GeneID:83619|NCBI-Human-GeneID:4780|PMID:25203443,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000047,,,,,,,,,,,,,,,,,,,,,,NRF2 (canonical)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000042,mitochondrial dysfunction [Oxidative stress],,"Mitochondrial dysfunction is a subtype of dysfunctioning: A process that performs an abnormal and incomplete mitochondrial function.
This entity is a specific course-dependent process. This process can constitute the course of Oxidative stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001730|http://purl.obolibrary.org/obo/TXPO_0002361,,,,,,,,,,,,,,,,,,,,,,"Mitochondrial dysfunction is a subtype of dysfunctioning: A process that performs an abnormal and incomplete mitochondrial function.
This entity is a specific course-dependent process. This process can constitute the course of Oxidative stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000605,,,,,,,,,,,TXPO:0000042,,,,,,,,,,,,,,,,,,,,,,mitochondrial dysfunction [Oxidative stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000040,increasing weight,,Increasing weight is a subtype of changing weight: A process that changes the weight of the object to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000589,,,,,,,,,,,,,,,,,,,,,,Increasing weight is a subtype of changing weight: A process that changes the weight of the object to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000093|http://purl.obolibrary.org/obo/TXPO_0000139,,,,,,,,,,,,,,,,,,TXPO:0000040,,,,,,,,,,,,,,,,,,,,,,increasing weight,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000046,cleavage of ATF6-alpha by S2P,,Cleavage of ATF6-alpha by S2P is a subtype of proteolysis: A process  n which ATF6-alpha is cleaved by  endopeptidase S2P( MBTPS2). Site-2 cleavage comes after site-1 cleavage.,false,,,http://purl.obolibrary.org/obo/TXPO_0000333,,,,,,,,,,,,,,,,,,,,,,Cleavage of ATF6-alpha by S2P is a subtype of proteolysis: A process  n which ATF6-alpha is cleaved by  endopeptidase S2P( MBTPS2). Site-2 cleavage comes after site-1 cleavage.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000831,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000046,,,,,,,,,,,,,,,,,,,,,,cleavage of ATF6-alpha by S2P,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000128553,TSHZ2,,Other designations: cell growth-inhibiting protein 7|ovarian cancer-related protein 10-2|serologically defined colon cancer antigen 33 like|teashirt family zinc finger 2|teashirt homolog 2|zinc finger protein 218,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,OVC10-2|ZABC2|C20orf17|ZNF218|TSH2,,,,,,,,,,,,20,,,,,,MIM:614118|Vega:OTTHUMG00000033058|HPRD:10730|Ensembl:ENSG00000182463|HGNC:13010,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,teashirt zinc finger homeobox 2,,,20q13.2,,,,,,,,,,,,,,,,GO_0003700 (EC: IEA); GO_0005634 (EC: IEA); GO_0006351 (EC: IEA); GO_0007275 (EC: IEA); GO_0043565 (EC: IEA); GO_0046872 (EC: IEA),,,,,,,,,PMID: 9671742; 11181995; 11780052; 12477932; 14702039; 15561718; 16344560; 19343227; 19745106; 19862010; 19913121; 20379614; 20628086; 21423795,,,,,,,,,,,,,,,OGG:3000128553,,,,,,,teashirt zinc finger homeobox 2,,,,,,,,,,,,,Other designations: cell growth-inhibiting protein 7|ovarian cancer-related protein 10-2|serologically defined colon cancer antigen 33 like|teashirt family zinc finger 2|teashirt homolog 2|zinc finger protein 218,,TSHZ2,,,,,,,,,,,,,,,,,,,,,,,128553,RP5-823G15.3,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,TSHZ2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_50185,fatty acid synthesis inhibitor,,Any pathway inhibitor that inhibits the synthesis of fatty acids.,false,,,http://purl.obolibrary.org/obo/TXPO_0003648,,,,,,,http://purl.obolibrary.org/obo/GO_0006633,,,,,,,,,,,,,,,Any pathway inhibitor that inhibits the synthesis of fatty acids.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:50185,,,,,,,,,,,,,,,,,,,,,,fatty acid synthesis inhibitor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003812,SREBP1C (canonical)[Lipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003516|http://purl.obolibrary.org/obo/TXPO_0003966,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:78968|NCBI-Human-GeneID:6720|NCBI-Mouse-GeneID:20787|PMID:20817607|PMID:21286345|PMID:10962028,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,,,,,,TXPO:0003812,,,,,,,,,,,,,,,,,,,,,,SREBP1C (canonical)[Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003816,stress signal role,,A role played by the entity to transmit the stress to be detected.,false,,,http://purl.obolibrary.org/obo/TXPO_0003814,,,,,,,,,,,,,,,,,,,,,,A role played by the entity to transmit the stress to be detected.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003816,,,,,,,,,,,,,,,,,,,,,,stress signal role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003815,molecular assembly,,"Molecular assembly is a subtype of assembling: The aggregation, arrangement and bonding together of molecules.",false,,,http://purl.obolibrary.org/obo/TXPO_0000468,,,,,,,,,,,,,,,,,,,,,,"Molecular assembly is a subtype of assembling: The aggregation, arrangement and bonding together of molecules.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_23367,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003815,,,,,,,,,,,,,,,,,,,,,,molecular assembly,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0001629,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003819,tunicamycin - lipidosis inducer [ER stress],,,false,,,http://purl.obolibrary.org/obo/CHEBI_29699|http://purl.obolibrary.org/obo/TXPO_0003012,,,,,,,,,,,,,,,,,,,,Open TG-Gates compound_id:00A02|PMID:26977301,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003822,,,,,,,,,,TXPO:0003819,,,,,,,,,,,,,,,,,,,,,,tunicamycin - lipidosis inducer [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003814,signal role,,A role played by the entity to transmit something to be detected.,false,,,http://purl.obolibrary.org/obo/TXPO_0001393,,,,,,,,,,,,,,,,,,,,,,A role played by the entity to transmit something to be detected.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003814,,,,,,,,,,,,,,,,,,,,,,signal role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003811,increaing in fatty acid inflow into hepatocyte [NAFLD],,"Increaing in fatty acid inflow into hepatocyte is a subtype of increasing quantity: A process that changes the fatty acid inflow into the hepatocyte to be larger.
This entity is a specific course-dependent process. This process can constitute the course of NAFLD.",false,,,http://purl.obolibrary.org/obo/TXPO_0000892,,,,,,,,,,,,,,,,,,,,,,"Increaing in fatty acid inflow into hepatocyte is a subtype of increasing quantity: A process that changes the fatty acid inflow into the hepatocyte to be larger.
This entity is a specific course-dependent process. This process can constitute the course of NAFLD.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003494,,,,,,,,,,,TXPO:0003811,,,,,,,,,,,,,,,,,,,,,,increaing in fatty acid inflow into hepatocyte [NAFLD],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003810,increase in lipid inflow into hepatocyte [NAFLD],,"Increase in lipid inflow into hepatocyte is a subtype of increasing quantity: A process that changes the lipid inflow into the hepatocyte to be larger.
This entity is a specific course-dependent process. This process can constitute the course of NAFLD.",false,,,http://purl.obolibrary.org/obo/TXPO_0003494,,,,,,,,,,,,,,,,,,,,,,"Increase in lipid inflow into hepatocyte is a subtype of increasing quantity: A process that changes the lipid inflow into the hepatocyte to be larger.
This entity is a specific course-dependent process. This process can constitute the course of NAFLD.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003811,,,,,,,,,,,,,,,,,,TXPO:0003810,,,,,,,,,,,,,,,,,,,,,,increase in lipid inflow into hepatocyte [NAFLD],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003818,tunicamycin - apoptosis inducer [ER stress],,,false,,,http://purl.obolibrary.org/obo/CHEBI_29699|http://purl.obolibrary.org/obo/TXPO_0003012,,,,,,,,,,,,,,,,,,,,Open TG-Gates compound_id:00A02|PMID:26977301,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_68495,,,,,,,,,,TXPO:0003818,,,,,,,,,,,,,,,,,,,,,,tunicamycin - apoptosis inducer [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003817,ITGB3 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:3690|NCBI-Rat-GeneID:29302|NCBI-Mouse-GeneID:16416,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000003690,,,,,,,,,,,,,TXPO:0003817,,,,,,,,,,,,,,,,,,,,,,ITGB3 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003813,negative regulation of adherens junction assembly,,"Negative regulation of adherens junction assembly is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of adherens junction assembly.",false,,,http://purl.obolibrary.org/obo/TXPO_0000369,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of adherens junction assembly is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of adherens junction assembly.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003813,,,,,,,,,,,,,,,,,,,,,,negative regulation of adherens junction assembly,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0034333,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0010324,membrane invagination,,The infolding of a membrane.,false,,,http://purl.obolibrary.org/obo/TXPO_0002587,,,,,,,,,,,,,,,,,,,,,,The infolding of a membrane.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0010324,,,,,,,,,,,,,,,,,,,,,,membrane invagination,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_35488,central nervous system depressant,CNS depressants|central nervous system depressants,A loosely defined group of drugs that tend to reduce the activity of the central nervous system.,false,,,http://purl.obolibrary.org/obo/CHEBI_35470,,,,,,,,,,,,,,,,,,,,,,A loosely defined group of drugs that tend to reduce the activity of the central nervous system.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CNS depressants|central nervous system depressants,,,,,,,,,,,,,,,,,,,,,CHEBI:35488,,,,central nervous system depressant,,CHEBI:35488,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002674,decreasing bile flow [Cholestasis],,"Decreasing bile flow is a subtype of decreasing flow: A process that changes the amount of bile flow to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000034|http://purl.obolibrary.org/obo/TXPO_0002673,,,,,,,,,,,,,,,,,,,,,,"Decreasing bile flow is a subtype of decreasing flow: A process that changes the amount of bile flow to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002674,,,,,,,,,,,,,,,,,,,,,,decreasing bile flow [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002679,acumulation of bile pigment in hepatocyte [Cholestasis],,"Acumulation of bile pigment in hepatocyte is a subtype of bile pigment deposition: The aggregation of bile pigmentin a particular location in a hepatocyte.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003150|http://purl.obolibrary.org/obo/TXPO_0000034,,,,,,,,,,,,,,,,,,,,,,"Acumulation of bile pigment in hepatocyte is a subtype of bile pigment deposition: The aggregation of bile pigmentin a particular location in a hepatocyte.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002679,,,,,,,,,,,,,,,,,,,,,,acumulation of bile pigment in hepatocyte [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002672,decreasing flow,,Decreasing flow is a subtype of decreasing quantity: A process that changes the amount of flow to be lower.|Decreasing flow is a deacreasing process to decrease the magnitude of the flow.,false,,,http://purl.obolibrary.org/obo/TXPO_0000396,,,,,,,,,,,,,,,,,,,,,,Decreasing flow is a subtype of decreasing quantity: A process that changes the amount of flow to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002672,,,,,,,,,,,,,,,,,,,,Decreasing flow is a deacreasing process to decrease the magnitude of the flow.,,decreasing flow,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002673,decreasing bile flow,,Decreasing bile flow is a subtype of decreasing flow: A process that changes the amount of bile flow to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0002672,,,,,,,,,,,,,,,,,,,,,,Decreasing bile flow is a subtype of decreasing flow: A process that changes the amount of bile flow to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002673,,,,,,,,,,,,,,,,,,,,,,decreasing bile flow,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002677,GRP78 - chaperone (canonical)[ER stress - proteinrefolding (sustained)],Heat Shock Protein Family A (Hsp70) Member 5|MIF2|BIP|HEL-S-89n|HSPA5,,false,,,http://purl.obolibrary.org/obo/TXPO_0002385,,,,,,,,,,,,,,,,,,,,PMID:18653895|PMID:8020977|PMID:12110171,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003997,,,,,Heat Shock Protein Family A (Hsp70) Member 5|MIF2|BIP|HEL-S-89n|HSPA5,,,,,TXPO:0002677,,,,,,,,,,,,,,,,,,,,,,GRP78 - chaperone (canonical)[ER stress - proteinrefolding (sustained)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002675,enterohepatic circulation [Cholestasis],,"Enterohepatic circulation is a subtype of changing between operands: Bile salts secreted by the liver pass into the intestine, are absorbed in large part by the ileum, and return to the liver by way of the portal vein.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000034|http://purl.obolibrary.org/obo/TXPO_0001979,,,,,,,,,,,,,,,,,,,,,,"Enterohepatic circulation is a subtype of changing between operands: Bile salts secreted by the liver pass into the intestine, are absorbed in large part by the ileum, and return to the liver by way of the portal vein.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002675,,,,,,,"Bile salts (>90%) are absorbed along the small intestine and transported back by the portal blood to the liver.
They are taken up into hepatocytes and re-secreted into the canaliculi.
This round trip of bile salts between the intestine and the liver is termed enterohepatic circulation.",,,,,,,,,,,,,,,enterohepatic circulation [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002670,inflammatory response [Cholestasis],,"Inflammatory response is a subtype of changing material: The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000192|http://purl.obolibrary.org/obo/TXPO_0000034,,,,,,,,,,,,,,,,,,,,,,"Inflammatory response is a subtype of changing material: The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000639,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003154|http://purl.obolibrary.org/obo/TXPO_0003211,,,,,,,,,,,TXPO:0002670,,,,,,,,,,,,,,,,,,,,,,inflammatory response [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002676,increasing bile concentration in blood [Cholestasis],,"Increasing bile concentration in blood is a subtype of increasing concentration: A process that changes the concentration of the bile in the blood to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000034|http://purl.obolibrary.org/obo/TXPO_0002715,,,,,,,,,,,,,,,,,,,,,,"Increasing bile concentration in blood is a subtype of increasing concentration: A process that changes the concentration of the bile in the blood to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002676,,,,,,,,,,,,,,,,,,,,,,increasing bile concentration in blood [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002671,type I diabetes course,,The totality of all processes through which a given type I diabetes instance is realized.,false,,,http://purl.obolibrary.org/obo/TXPO_0002033,,,,,,,,,,,,,,,,,,,,,,The totality of all processes through which a given type I diabetes instance is realized.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003577|http://purl.obolibrary.org/obo/TXPO_0002435|http://purl.obolibrary.org/obo/TXPO_0002437,,,,,,,,,,,,,,,,,,TXPO:0002671,,,,,,,,,,,,,,,,,,,,,,type I diabetes course,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002678,acumulation of bile pigment in bile canaliculus [Cholestasis],,"Acumulation of bile pigment in bile canaliculus is a subtype of bile pigment deposition: The aggregation of bile pigmentin a particular location in a bile canaliculus.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000034|http://purl.obolibrary.org/obo/TXPO_0001906,,,,,,,,,,,,,,,,,,,,,,"Acumulation of bile pigment in bile canaliculus is a subtype of bile pigment deposition: The aggregation of bile pigmentin a particular location in a bile canaliculus.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002678,,,,,,,,,,,,,,,,,,,,,,acumulation of bile pigment in bile canaliculus [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100566,FGF-16,,,false,,,http://purl.obolibrary.org/obo/IMR_0000049,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100566,,,,,,,,,,,,,,,,,,,,,,FGF-16,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000316,G-alpha,"G-protein, alpha subunit|Guanine nucleotide-binding protein, alpha subunit",,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,EC:3.6.5.1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003668,,,,,"G-protein, alpha subunit|Guanine nucleotide-binding protein, alpha subunit",,,,,IMR:0000316,,,,,,,,,,,,,,,,,,,,,,G-alpha,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001847,changing balance,,Changing balance is a subtype of changing relationship between operands: A process that changes the balance between operands.,false,,,http://purl.obolibrary.org/obo/TXPO_0000261,,,,,,,,,,,,,,,,,,,,,,Changing balance is a subtype of changing relationship between operands: A process that changes the balance between operands.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001847,,,,,,,,,,,,,,,,,,,,,,changing balance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001844,lipid accumulation in hepatocyte [Phospholipidosis(severe)],,"Lipid accumulation in hepatocyte is a subtype of lipid strorage in hepatocyte: A process that keeps lipids in hepatocytes.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0001645,,,,,,,,,,,,,,,,,,,,,,"Lipid accumulation in hepatocyte is a subtype of lipid strorage in hepatocyte: A process that keeps lipids in hepatocytes.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001698,,,,,,,,,,,TXPO:0001844,,,,,,,,,,,,,,,,,,,,,,lipid accumulation in hepatocyte [Phospholipidosis(severe)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001846,malfunctioning of mitochondrial ATP synthesis coupled electron transpor,,Malfunctioning of mitochondrial ATP synthesis coupled electron transpor is a subtype of malfunctioning process: A process that cannot perform a respiratory electron transport chain appropriately or cannot realize it at all.,false,,,http://purl.obolibrary.org/obo/TXPO_0000434,,,,,,,,,,,,,,,,,,,,,,Malfunctioning of mitochondrial ATP synthesis coupled electron transpor is a subtype of malfunctioning process: A process that cannot perform a respiratory electron transport chain appropriately or cannot realize it at all.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001846,,,,,,,,,,,,,,,,,,,,,,malfunctioning of mitochondrial ATP synthesis coupled electron transpor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001840,hyperfunction of increasing the amount of phenobarbital  [Ground glass appearance],,"Hyperfunction of increasing the amount of phenobarbital is a process of performing an excessive function of increasing the amount of drugs.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001827,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of increasing the amount of phenobarbital is a process of performing an excessive function of increasing the amount of drugs.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,http://purl.obolibrary.org/obo/TXPO_0001637,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003860,,,,,,,,,,,TXPO:0001840,,,,,,,,,,,,,,,,,,,,,,hyperfunction of increasing the amount of phenobarbital  [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001845,S1P inactivation [Phospholipidosis],,S1P inactivation is a subtype of molecular inactivation: A process that  changes the activity of the S1P (Sphingosine-1-phosphate) to be lower. This entity is a specific course-dependent process. This process can constitute the course of phospholipidosis.,false,,,http://purl.obolibrary.org/obo/TXPO_0001706|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,S1P inactivation is a subtype of molecular inactivation: A process that  changes the activity of the S1P (Sphingosine-1-phosphate) to be lower. This entity is a specific course-dependent process. This process can constitute the course of phospholipidosis.,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001586,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001609,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000928,,,,,,,,,,,TXPO:0001845,,,,,,,,,,,,,,,,,,,,,,S1P inactivation [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001848,chemical compound accumulation in liver [Ground glass appearance (moderate) ],,"Compound accumulation in liver is a subtype of accumulation of xenobiotics: A process that keeps compound in the liver. And the degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (moderate) .",false,,,http://purl.obolibrary.org/obo/TXPO_0002068,,,,,,,,,,,,,,,,,,,,,,"Compound accumulation in liver is a subtype of accumulation of xenobiotics: A process that keeps compound in the liver. And the degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (moderate) .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001848,,,,,,,,,,,,,,,,,,,,,,chemical compound accumulation in liver [Ground glass appearance (moderate) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001843,drug metabolism imbalance[Ground glass appearance (moderate) ],,"Drug metabolism imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance of drug metabolism. And the degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (moderate) .",false,,,http://purl.obolibrary.org/obo/TXPO_0001665,,,,,,,,,,,,,,,,,,,,,,"Drug metabolism imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance of drug metabolism. And the degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (moderate) .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001848,,,,,,,,,,,TXPO:0001843,,,,,,,,,,,,,,,,,,,,,,drug metabolism imbalance[Ground glass appearance (moderate) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001849,phospholipidosis dependent chemical compound,,"Phospholipidosis dependent chemical compound is a subtype of toxic course dependent chemical entity.
This entity (drug) can participate in the course of phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001133,,,,,,,,,,,,,,,,,,,,,,"Phospholipidosis dependent chemical compound is a subtype of toxic course dependent chemical entity.
This entity (drug) can participate in the course of phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001849,,,,,,,,,,,,,,,,,,,,,,phospholipidosis dependent chemical compound,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001841,PERK - signal sensor (canonical)[Perk signalling system],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000878,http://purl.obolibrary.org/obo/TXPO_0001837,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UniProt_Q9NZJ5|http://www.uniprot.org/entry/Q9NZJ5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000882,,,,,,,,,,TXPO:0001841,,,,,,,,,,,,,,,,,,,,,,PERK - signal sensor (canonical)[Perk signalling system],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001842,increasing the amount of phenobarbital  [Ground glass appearance],,"Increasing the amount of phenobarbital  is a subtype of increasing amount of drugs.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001637,,,,,,,,,,,,,,,,,,,,,,"Increasing the amount of phenobarbital  is a subtype of increasing amount of drugs.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001842,,,,,,,,,,,,,,,,,,,,,,increasing the amount of phenobarbital  [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0030225,macrophage differentiation,macrophage cell differentiation,The process in which a relatively unspecialized monocyte acquires the specialized features of a macrophage.,false,,,http://purl.obolibrary.org/obo/GO_0002521,,,,,,,,,,,,,,,,,,,,,,The process in which a relatively unspecialized monocyte acquires the specialized features of a macrophage.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,macrophage cell differentiation,,,,,GO:0030225,,,,,,,,,,,,,,,,,,,,,,macrophage differentiation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000827,ATF-2 (mol),activating transcription factor 2,,false,,,http://purl.obolibrary.org/obo/IMR_0000825,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,activating transcription factor 2,,,,,IMR:0000827,,,,,,,,,,,,,,,,,,,,,,ATF-2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000009669,EIF5B,,Other designations: eIF-5B|translation initiation factor IF-2|translation initiation factor IF2,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,IF2,,,,,,,,,,,,2,,,,,,HGNC:30793|MIM:606086|Vega:OTTHUMG00000153242|Ensembl:ENSG00000158417|HPRD:07304,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,eukaryotic translation initiation factor 5B,,,2q11.2,,,,,,,,,,,,,,,,"GO_0003743 (EC: IDA, PMID:10432305); GO_0003743 (EC: NAS, PMID:10200264); GO_0003924 (EC: IEA); GO_0005515 (EC: IPI, PMID:12569173); GO_0005525 (EC: IEA); GO_0005829 (EC: TAS); GO_0006412 (EC: TAS); GO_0006413 (EC: TAS); GO_0006446 (EC: IDA, PMID:10432305); GO_0006446 (EC: NAS, PMID:10200264); GO_0010467 (EC: TAS); GO_0044267 (EC: TAS); GO_0044822 (EC: IDA)",,,,,,,,,PMID:8621719; 9872452; 10200264; 10432305; 11699879; 12477932; 12514125; 12569173; 14702039; 15302935; 16097034; 16964243; 17081983; 17161026; 17361185; 17568775; 18572216; 19135240; 19738201; 20195357; 20211142; 20562859; 21139048; 21145461; 21151833; 21697471; 21890473; 21907836; 21926972; 21963094; 22108332; 22113938; 22586326; 22678362; 22863883; 22939629; 22990118; 23000965; 24250222,,,,,,,,,,,,,,,OGG:3000009669,,,,,,,eukaryotic translation initiation factor 5B,,,,,,,,,,,,,Other designations: eIF-5B|translation initiation factor IF-2|translation initiation factor IF2,,EIF5B,,,,,,,,,,,,,,,,,,,,,,,9669,,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF5B,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0003693,intermediate filament protein,,The role played by the molecule that contributes to the structural integrity of the intermediate filaments.|related cellular component GO:0005882,false,,,http://purl.obolibrary.org/obo/TXPO_0003694,,,,,,,,,,,,,,,,,,,,IMR:0000496 (obsolete),,The role played by the molecule that contributes to the structural integrity of the intermediate filaments.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003693,,,,,,,,,,,,,,,,,,,,related cellular component GO:0005882,,intermediate filament protein,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003695,extracellular matrix structural constituent,ECM protein,The role of a molecule that contributes to the structural integrity of the extracellular matrix.|related molecular function GO:0005201,false,,,http://purl.obolibrary.org/obo/TXPO_0003691,,,,,,,,,,,,,,,,,,,,IMR:0000540 (obsolete),,The role of a molecule that contributes to the structural integrity of the extracellular matrix.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ECM protein,,,,TXPO:0003695,,,,,,,,,,,,,,,,,,,,related molecular function GO:0005201,,extracellular matrix structural constituent,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003694,cytoskeletal fiber protein,,The role played by the molecule that contributes to the structural integrity of cytoskeletal fibers.|related cellular component GO:0099513,false,,,http://purl.obolibrary.org/obo/TXPO_0003691,,,,,,,,,,,,,,,,,,,,,,The role played by the molecule that contributes to the structural integrity of cytoskeletal fibers.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003694,,,,,,,,,,,,,,,,,,,,related cellular component GO:0099513,,cytoskeletal fiber protein,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003690,motor protein,molecular motor,"A role played by the entity that catalyses the generation of force resulting either in movement along a microfilament or microtubule, or in torque resulting in membrane scission, coupled to the hydrolysis of a nucleoside triphosphate.|related molecular function GO:0003774",false,,,http://purl.obolibrary.org/obo/TXPO_0003689,,,,,,,,,,,,,,,,,,,,IMR:0000518 (obsolete),,"A role played by the entity that catalyses the generation of force resulting either in movement along a microfilament or microtubule, or in torque resulting in membrane scission, coupled to the hydrolysis of a nucleoside triphosphate.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003690,,,,,,,,,,,,,,,,molecular motor,,,,related molecular function GO:0003774,,motor protein,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003699,lipid transportor,,"A role played by the entity which enables the directed movement of lipids into, out of or within a cell, or between cells.|related molecular function GO:0005319",false,,,http://purl.obolibrary.org/obo/TXPO_0003638,,,,,,,,,,,,,,,,,,,,,,"A role played by the entity which enables the directed movement of lipids into, out of or within a cell, or between cells.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003699,,,,,,,,,,,,,,,,,,,,related molecular function GO:0005319,,lipid transportor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003691,structural molecule,,The role of a molecule that contributes to the structural integrity of a complex or its assembly within or outside a cell.,false,,,http://purl.obolibrary.org/obo/TXPO_0003731,,,,,,,,,,,,,,,,,,,,related molecular function GO:0005198|IMR:0000950 (obsolete),,The role of a molecule that contributes to the structural integrity of a complex or its assembly within or outside a cell.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003691,,,,,,,,,,,,,,,,,,,,,,structural molecule,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003698,transmembrane transporter,,"A role played by the entity which enables the transfer of a substance, usually a specific substance or a group of related substances, from one side of a membrane to the other.|related molecular function GO:0022857",false,,,http://purl.obolibrary.org/obo/TXPO_0003638,,,,,,,,,,,,,,,,,,,,,,"A role played by the entity which enables the transfer of a substance, usually a specific substance or a group of related substances, from one side of a membrane to the other.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003698,,,,,,,,,,,,,,,,,,,,related molecular function GO:0022857,,transmembrane transporter,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003692,microfilament protein,actin filament protein,The role played by the molecule that contributes to the structural integrity of an microfilament (actin filament). Actin filaments are a major component of the contractile apparatus of skeletal muscle and the microfilaments of the cytoskeleton of eukaryotic cells|related cellular component GO:0005884,false,,,http://purl.obolibrary.org/obo/TXPO_0003694,,,,,,,,,,,,,,,,,,,,,,The role played by the molecule that contributes to the structural integrity of an microfilament (actin filament). Actin filaments are a major component of the contractile apparatus of skeletal muscle and the microfilaments of the cytoskeleton of eukaryotic cells,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,actin filament protein,,,,,TXPO:0003692,,,,,,,,,,,,,,,,,,,,related cellular component GO:0005884,,microfilament protein,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003696,water channel,,A role played by the entity of transport systems. This type enable facilitated diffusion of water (by an energy-independent process) by passage through a transmembrane aqueous pore or channel without evidence for a carrier-mediated mechanism.|relate molecular function GO:0015250,false,,,http://purl.obolibrary.org/obo/TXPO_0003639,,,,,,,,,,,,,,,,,,,,IMR:0000656 (obsolete),,A role played by the entity of transport systems. This type enable facilitated diffusion of water (by an energy-independent process) by passage through a transmembrane aqueous pore or channel without evidence for a carrier-mediated mechanism.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003696,,,,,,,,,,,,,,,,,,,,relate molecular function GO:0015250,,water channel,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003697,amino acid transmembrane transporter,,A role played by the entity which enables the transfer of amino acids from one side of a membrane to the other. Amino acids are organic molecules that contain an amino group and a carboxyl group.|related molecular function GO:0015171,false,,,http://purl.obolibrary.org/obo/TXPO_0003698,,,,,,,,,,,,,,,,,,,,IMR:0000929 (obsolete),,A role played by the entity which enables the transfer of amino acids from one side of a membrane to the other. Amino acids are organic molecules that contain an amino group and a carboxyl group.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003697,,,,,,,,,,,,,,,,,,,,related molecular function GO:0015171,,amino acid transmembrane transporter,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76863,"EC 1.5.1.* (oxidoreductase acting on donor CH-NH group, NAD(+) or NADP(+) as acceptor) inhibitor","EC 1.5.1.* inhibitors|oxidoreductase acting on donor CH-NH group, NAD(+) or NADP(+) as acceptor (EC 1.5.1.*) inhibitors|EC 1.5.1.* inhibitor|EC 1.5.1.* (oxidoreductase acting on donor CH-NH group, NAD(+) or NADP(+) as acceptor) inhibitors|oxidoreductase acting on donor CH-NH group, NAD(+) or NADP(+) as acceptor (EC 1.5.1.*) inhibitor",An EC 1.5.* (oxidoreductase acting on donor CH-NH group) inhibitor that interferes with the action of any such enzyme using NAD(+) or NADP(+) as acceptor (EC 1.5.1.*).,false,,,http://purl.obolibrary.org/obo/CHEBI_76731,,,,,,,,,,,,,,,,,,,,,,An EC 1.5.* (oxidoreductase acting on donor CH-NH group) inhibitor that interferes with the action of any such enzyme using NAD(+) or NADP(+) as acceptor (EC 1.5.1.*).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"EC 1.5.1.* inhibitors|oxidoreductase acting on donor CH-NH group, NAD(+) or NADP(+) as acceptor (EC 1.5.1.*) inhibitors|EC 1.5.1.* inhibitor|EC 1.5.1.* (oxidoreductase acting on donor CH-NH group, NAD(+) or NADP(+) as acceptor) inhibitors|oxidoreductase acting on donor CH-NH group, NAD(+) or NADP(+) as acceptor (EC 1.5.1.*) inhibitor",,,,,,,,,,,,,,,,,,,,,CHEBI:76863,,,,"EC 1.5.1.* (oxidoreductase acting on donor CH-NH group, NAD(+) or NADP(+) as acceptor) inhibitor",,CHEBI:76863,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000054905,CYP2W1,,Other designations: CYPIIW1|cytochrome P450 2W1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,7,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 2, subfamily W, polypeptide 1",,,7p22.3,,,,,,,,,,,,,,,,GO_0004497 (EC: IEA); GO_0005506 (EC: IEA); GO_0005789 (EC: TAS); GO_0006805 (EC: TAS); GO_0016705 (EC: IEA); GO_0020037 (EC: IEA); GO_0044281 (EC: TAS),,,,,,,,,PMID:12477932; 15128046; 15489334; 16426568; 16677611; 17979506; 17998294; 20602611; 20805301; 21988832; 22591743; 22631658; 22993331; 23897914,,,,,,,,,,,,,,,OGG:3000054905,,,,,,,"cytochrome P450, family 2, subfamily W, polypeptide 1",,,,,,,,,,,,,Other designations: CYPIIW1|cytochrome P450 2W1,,CYP2W1,,,,,,,,,,,,,,,,,,,,,,,54905,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP2W1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/GO_0019395,fatty acid oxidation,,"The removal of one or more electrons from a fatty acid, with or without the concomitant removal of a proton or protons, by reaction with an electron-accepting substance, by addition of oxygen or by removal of hydrogen.",false,,,http://purl.obolibrary.org/obo/GO_0034440,,,,,,,,,,,,,,,,,,,,,,"The removal of one or more electrons from a fatty acid, with or without the concomitant removal of a proton or protons, by reaction with an electron-accepting substance, by addition of oxygen or by removal of hydrogen.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0019395,,,,,,,,,,,,,,,,,,,,,,fatty acid oxidation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_24848,inositol,,,false,,,http://purl.obolibrary.org/obo/CHEBI_18059,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:24848,,,,,,,,,,,,,,,,,,,,,,inositol,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002308,phospholipid metabolism imbalance,,Phospholipid metabolism imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance of phospholipid metabolism.,false,,,http://purl.obolibrary.org/obo/TXPO_0000567,,,,,,,,,,,,,,,,,,,,,,Phospholipid metabolism imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance of phospholipid metabolism.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002308,,,,,,,,,,,,,,,,,,,,,,phospholipid metabolism imbalance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002301,increasing demand for response to mitochondrial oxidative stress,,Increasing demand for response to mitochondrial oxidative stress is a subtype of increasing demand for response to oxidative stress: A process that changes the functional demand for the response to the mitochondrial oxidative stress to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000102,,,,,,,,,,,,,,,,,,,,,,Increasing demand for response to mitochondrial oxidative stress is a subtype of increasing demand for response to oxidative stress: A process that changes the functional demand for the response to the mitochondrial oxidative stress to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002301,,,,,,,,,,,,,,,,,,,,,,increasing demand for response to mitochondrial oxidative stress,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000047,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002307,triglyceride lipase,triacylglycerol acylhydrolase activity|tributyrin esterase activity|tributyrinase activity|triacylglycerol ester hydrolase activity|cacordase activity|triacylglycerol lipase activity|glycerol-ester hydrolase activity|glycerol ester hydrolase activity,Catalysis role of the reaction: triacylglycerol + H2O = diacylglycerol + a carboxylate.|related molecular finction GO:0004806,false,,,http://purl.obolibrary.org/obo/TXPO_0002283,,,,,,,,,,,,,,,,,,,,,,Catalysis role of the reaction: triacylglycerol + H2O = diacylglycerol + a carboxylate.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,triacylglycerol acylhydrolase activity|tributyrin esterase activity|tributyrinase activity|triacylglycerol ester hydrolase activity|cacordase activity|triacylglycerol lipase activity|glycerol-ester hydrolase activity|glycerol ester hydrolase activity,,,,,TXPO:0002307,,,,,,,,,,,,,,,,,,,,related molecular finction GO:0004806,,triglyceride lipase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002305,decreasing excretion quantity of the bile acid,,Decreasing excretion quantity of bile acid is a subtype of decreasing quantity: A process that changes the excretion quantity of of bile acids to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000396,,,,,,,,,,,,,,,,,,,,,,Decreasing excretion quantity of bile acid is a subtype of decreasing quantity: A process that changes the excretion quantity of of bile acids to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002305,,,,,,,,,,,,,,,,,,,,,,decreasing excretion quantity of the bile acid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002303,hyperfunction of biological repair function,,Hyperfunction of biological repair function is a subtype of hyperfunctioning: A process that performs an excessive biological repair function.,false,,,http://purl.obolibrary.org/obo/TXPO_0000435,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of biological repair function is a subtype of hyperfunctioning: A process that performs an excessive biological repair function.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002303,,,,,,,,,,,,,,,,,,,,,,hyperfunction of biological repair function,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002302,Glutathione conjugation (supply) - function demand imbalance,,Glutathione conjugation (supply) - function demand imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance between glutathione conjugation supply and demand.,false,,,http://purl.obolibrary.org/obo/TXPO_0000567,,,,,,,,,,,,,,,,,,,,,,Glutathione conjugation (supply) - function demand imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance between glutathione conjugation supply and demand.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002302,,,,,,,,,,,,,,,,,,,,,,Glutathione conjugation (supply) - function demand imbalance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002306,lysophosphatidic acid acyltransferase,LPAAT,Catalysis of the transfer of acyl groups from an acyl-CoA to lysophosphatidic acid to form phosphatidic acid.|related molecular function GO:0042171,false,,,http://purl.obolibrary.org/obo/TXPO_0000606,,,,,,,,,,,,,,,,,,,,"Lysophosphatidic acid (LPA) acyltransferase (LPAAT), also known as 1-acyl sn-glycerol-3-phosphate acyltransferase (1-AGPAT) (EC 2.3.1.51), catalyzes the conversion of LPA to phosphatidic acid (PA).|EC:2.3.1.51",,Catalysis of the transfer of acyl groups from an acyl-CoA to lysophosphatidic acid to form phosphatidic acid.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,LPAAT,,,,,TXPO:0002306,,,,,,,,,,,,,,,,,,,,related molecular function GO:0042171,,lysophosphatidic acid acyltransferase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002300,GCLM (canonical)[Glutathione depletion],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002045|http://purl.obolibrary.org/obo/TXPO_0002331,,,,,,,,,,,,,,,,,,,,PMID:23856494,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002394,,,,,,,,,,TXPO:0002300,,,,,,,,,,,,,,,,,,,,,,GCLM (canonical)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002304,hypofunction of xenobiotics conjugate excretion,,Hypofunction of xenobiotics conjugate excretion is a subtype of hypofunction of liver's excretion: A process that performs a decreased or insufficient xenobiotics conjugate excretion.,false,,,http://purl.obolibrary.org/obo/TXPO_0001342,,,,,,,,,,,,,,,,,,,,,,Hypofunction of xenobiotics conjugate excretion is a subtype of hypofunction of liver's excretion: A process that performs a decreased or insufficient xenobiotics conjugate excretion.,,,http://purl.obolibrary.org/obo/TXPO_0000631,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002304,,,,,,,,,,,,,,,,,,,,,,hypofunction of xenobiotics conjugate excretion,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002309,constitutive androstane receptor activation by phenobarbital [Ground glass appearance],activating CAR [Ground glass degeneration]|CAR activating [Ground glass ]|activating constitutive androstane receptor [Ground glass appearance],"Constitutive androstane receptor activation by phenobarbital is a subtype of activating nuclear receptor: A process that changes the activity of the activating CAR ( constitutive androstane receptor) with a nuclear receptor role to be higher by phenobarbital.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0000935,,,,,,,,,,,,,,,,,,,,PMID:12130690,,"Constitutive androstane receptor activation by phenobarbital is a subtype of activating nuclear receptor: A process that changes the activity of the activating CAR ( constitutive androstane receptor) with a nuclear receptor role to be higher by phenobarbital.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001524,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003858|http://purl.obolibrary.org/obo/TXPO_0003258,,,,,,activating CAR [Ground glass degeneration]|CAR activating [Ground glass ]|activating constitutive androstane receptor [Ground glass appearance],,,,,TXPO:0002309,,,,,,,,,,,,,,,,,,,,,,constitutive androstane receptor activation by phenobarbital [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000416,JUN (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,IPR:002112,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,,,,,,IMR:0000416,,,,,,,,,,,,,,,,,,,,,,JUN (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000057761,TRIB3,,Other designations: TRB-3|neuronal cell death inducible putative kinase|neuronal cell death-inducible putative kinase|p65-interacting inhibitor of NF-kappa-B|p65-interacting inhibitor of NF-kappaB|tribbles homolog 3,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,TRB3|SINK|NIPK|SKIP3|C20orf97,,,,,,,,,,,,20,,,,,,Vega:OTTHUMG00000031627|MIM:607898|HGNC:16228|HPRD:09836|Ensembl:ENSG00000101255,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,tribbles pseudokinase 3,,,20p13-p12.2,,,,,,,,,,,,,,,,"GO_0003714 (EC: ISS); GO_0004860 (EC: IEA); GO_0005515 (EC: IPI, PMID: 12743605); GO_0005524 (EC: IEA); GO_0005634 (EC: IDA); GO_0005634 (EC: ISS); GO_0005730 (EC: IDA, Qualifier: NOT); GO_0005829 (EC: TAS); GO_0005886 (EC: TAS); GO_0006351 (EC: IEA); GO_0006468 (EC: IEA); GO_0006469 (EC: IDA, PMID: 12791994); GO_0007173 (EC: TAS); GO_0008286 (EC: TAS); GO_0008543 (EC: TAS); GO_0010827 (EC: ISS, PMID: 12791994); GO_0016301 (EC: IDA, Qualifier: NOT, PMID: 12743605); GO_0019901 (EC: IPI, PMID: 12791994); GO_0019901 (EC: ISS); GO_0031625 (EC: ISS, PMID: 16794074); GO_0032092 (EC: ISS, PMID: 16794074); GO_0032869 (EC: ISS, PMID: 12791994); GO_0034976 (EC: IDA, PMID: 15775988); GO_0038095 (EC: TAS); GO_0043405 (EC: IDA, PMID: 15299019); GO_0044255 (EC: TAS); GO_0044281 (EC: TAS); GO_0045087 (EC: TAS); GO_0045599 (EC: ISS, PMID: 17576771); GO_0045717 (EC: ISS, PMID: 16794074); GO_0045892 (EC: IMP, PMID: 15775988); GO_0048011 (EC: TAS); GO_0048015 (EC: TAS); GO_0051443 (EC: ISS, PMID: 16794074); GO_0055106 (EC: ISS); GO_0070059 (EC: IDA, PMID: 15775988)",,,,,,,,,PMID: 8125298; 11780052; 12477932; 12736262; 12743605; 12791994; 13679039; 14702039; 15299019; 15489334; 15775988; 15781252; 16123373; 16129579; 16147992; 16169070; 16715410; 16794074; 16887816; 16966378; 17112672; 17369260; 17576771; 17576816; 17707795; 17872950; 18029348; 18187772; 18276110; 18408768; 18436806; 18660489; 18984671; 19139803; 19180501; 19291425; 19389115; 19389818; 19505541; 19904274; 19913121; 20064487; 20139130; 20393693; 20461355; 20592469; 20606298; 20628086; 20693163; 21130836; 21203563; 21220698; 21435438; 21492415; 21572435; 21704407; 21832049; 21864376; 21896644; 21935927; 22274752; 22577090; 22912727; 22977230; 23185332; 23319603; 23349842; 23455924; 23550039; 23632994; 23695665,,,,,,,,,,,,,,,OGG:3000057761,,,,,,,tribbles pseudokinase 3,,,,,,,,,,,,,Other designations: TRB-3|neuronal cell death inducible putative kinase|neuronal cell death-inducible putative kinase|p65-interacting inhibitor of NF-kappa-B|p65-interacting inhibitor of NF-kappaB|tribbles homolog 3,,TRIB3,,,,,,,,,,,,,,,,,,,,,,,57761,RP5-1103G7.7,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,TRIB3,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/UBERON_0000945,stomach,stomach chamber|anterior intestine|Ventricular|gaster|ventriculus|mesenteron,"An expanded region of the vertebrate alimentary tract that serves as a food storage compartment and digestive organ. A stomach is lined, in whole or in part by a glandular epithelium.|UBERON ontology restricts this to the vertebrate specific structure - see the grouping class 'food storage organ' for analogous structures in other species. Teleosts: Zebrafish is functionally stomach-less, but may retain ontogenic footprint. Although the precise shape and size of the stomach varies widely among different vertebrates, the relative positions of the oesophageal and duodenal openings remain relatively constant. As a result, the organ always curves somewhat to the left before curving back to meet the pyloric sphincter. However, lampreys, hagfishes, chimaeras, lungfishes, and some teleost fish have no stomach at all, with the oesophagus opening directly into the intestine. The gastric lining is usually divided into two regions, an anterior portion lined by fundic glands, and a posterior with pyloric glands. Cardiac glands are unique to mammals, and even then are absent in a number of species. The distributions of these glands vary between species, and do not always correspond with the same regions as in man. Furthermore, in many non-human mammals, a portion of the stomach anterior to the cardiac glands is lined with epithelium essentially identical to that of the oesophagus. Ruminants, in particular, have a complex stomach, the first three chambers of which are all lined with oesophageal mucosa",false,,,http://purl.obolibrary.org/obo/UBERON_0013765,,,,,,,,,,,,,,,,,,,,http://en.wikipedia.org/wiki/Stomach|http://www.snomedbrowser.com/Codes/Details/181246003|http://linkedlifedata.com/resource/umls/id/C0038351|http://purl.obolibrary.org/obo/NCIT_C12391|MA:0000353|EFO:0000837|EV:0100070|GAID:293|AAO:0000579|BTO:0001307|TAO:0002121|UMLS:C0038351|VHOG:0000408|ANISEED:1235297|MAT:0000051|XAO:0000128|EHDAA2:0001915|galen:Stomach|CALOHA:TS-0980|MESH:A03.492.766|FMA:7148|OpenCyc:Mx4rvVjlqpwpEbGdrcN5Y29ycA|EMAPA:17021|MIAA:0000051|EHDAA:2993,,"An expanded region of the vertebrate alimentary tract that serves as a food storage compartment and digestive organ. A stomach is lined, in whole or in part by a glandular epithelium.",,,,,,,,Portion of alimentary canal with increased circular and longitudinal smooth muscle. Bounded posteriorly by the pyloric sphincter. Mucosal lining has increased folding.[AAO],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,stomach chamber,anterior intestine|Ventricular|gaster|ventriculus|mesenteron,"It appears that the stomach has an ancient origin. The stomach first appears in the fish lineage. The prevertebrate chordates do not have a true stomach, whereas the cartilaginous and bony fish do. Although most fish do have a true stomach, some fish species appear to have lost the stomach secondarily. The remaining vertebrate lineages do have a true stomach (at least in the adult animal), although there is great variation in the size and shape of the stomach.[well established][VHOG]",http://purl.obolibrary.org/obo/UBERON_0001007,UBERON:0000945,http://purl.obolibrary.org/obo/UBERON_0001007,,,,,,,,,,,,,,,,,,,"UBERON ontology restricts this to the vertebrate specific structure - see the grouping class 'food storage organ' for analogous structures in other species. Teleosts: Zebrafish is functionally stomach-less, but may retain ontogenic footprint. Although the precise shape and size of the stomach varies widely among different vertebrates, the relative positions of the oesophageal and duodenal openings remain relatively constant. As a result, the organ always curves somewhat to the left before curving back to meet the pyloric sphincter. However, lampreys, hagfishes, chimaeras, lungfishes, and some teleost fish have no stomach at all, with the oesophagus opening directly into the intestine. The gastric lining is usually divided into two regions, an anterior portion lined by fundic glands, and a posterior with pyloric glands. Cardiac glands are unique to mammals, and even then are absent in a number of species. The distributions of these glands vary between species, and do not always correspond with the same regions as in man. Furthermore, in many non-human mammals, a portion of the stomach anterior to the cardiac glands is lined with epithelium essentially identical to that of the oesophagus. Ruminants, in particular, have a complex stomach, the first three chambers of which are all lined with oesophageal mucosa",,stomach,,,,http://upload.wikimedia.org/wikipedia/commons/e/e0/Stomach_diagram.svg,,,http://purl.obolibrary.org/obo/oae.owl|http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0000949,endocrine system,systema endocrinum|endocrine system|endocrine glandular system,Anatomical system that consists of the glands and parts of glands that produce endocrine secretions and help to integrate and control bodily metabolic activity.,false,,,http://purl.obolibrary.org/obo/UBERON_0000467,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002368,,,,http://purl.obolibrary.org/obo/NCIT_C12705|http://linkedlifedata.com/resource/umls/id/C0014136|http://en.wikipedia.org/wiki/Endocrine_system|http://www.snomedbrowser.com/Codes/Details/278876000|MESH:D004703|FMA:9668|EHDAA2:0002224|MA:0000012|ZFA:0001158|GAID:439|AAO:0010279|EMAPA:35306|TAO:0001158|XAO:0000158|FBbt:00005068|UMLS:C0014136|CALOHA:TS-1301|VHOG:0000098|EV:0100128|EFO:0002969,,Anatomical system that consists of the glands and parts of glands that produce endocrine secretions and help to integrate and control bodily metabolic activity.,,,,,,,,Anatomical system containing glands which regulates bodily functions though the secretion of hormones.[AAO],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,systema endocrinum|endocrine system|endocrine glandular system,,,"Multicellular organisms have complex endocrine systems, allowing responses to environmental stimuli, regulation of development, reproduction, and homeostasis. Nuclear receptors (NRs), a metazoan-specific family of ligand-activated transcription factors, play central roles in endocrine responses, as intermediates between signaling molecules and target genes. The NR family includes ligand-bound and orphan receptors, that is, receptors with no known ligand or for which there is no ligand Pocket. Understanding NR evolution has been further improved by comparison of several completed genomes, particularly those of deuterostomes and ecdysozoans. In contrast, evolution of NR ligands is still much debated. One hypothesis proposes that several independent gains and losses of ligand-binding ability in NRs occurred in protostomes and deuterostomes. A second hypothesis, pertaining to the NR3 subfamily (vertebrate steroid hormone receptors and estrogen related receptor), proposes that before the divergence of protostomes and deuterostomes, there was an ancestral steroid receptor (AncSR) that was ligand-activated and that orphan receptors secondarily lost the ability to bind a ligand. (...) Our analysis reveals that steroidogenesis has been independently elaborated in the 3 main bilaterian lineages (...).[well established][VHOG]",,UBERON:0000949,,,,,,,,,,,,,,,,,,,,,,endocrine system,,,,,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0000948,heart,,"A myogenic muscular circulatory organ found in the vertebrate cardiovascular system composed of chambers of cardiac muscle. It is the primary circulatory organ. [database_cross_reference: http://orcid.org/0000-0002-6601-2165][database_cross_reference: http://en.wikipedia.org/wiki/Heart]|Taxon notes:"" the ascidian tube-like heart lacks chambers....The ascidian heart is formed after metamorphosis as a simple tube-like structure with a single-layered myoepithelium that is continuous with a single-layered pericar- dial wall. It lacks chambers and endocardium.... The innovation of the chambered heart was a key event in vertebrate evolution, because the chambered heart generates one-way blood flow with high pressure, a critical requirement for the efficient blood supply of large-body vertebrates... all extant vertebrates have hearts with two or more chambers (Moorman and Christoffels 2003)"" http://dx.doi.org/10.1101/gad.1485706",false,,,http://purl.obolibrary.org/obo/UBERON_0000062,,,,,,,,,,,,,,,,,,,,UMLS:C0018787|EFO:0000815|FMA:7088|BTO:0000562|MESH:D006321|NCIT:C12727|EHDAA:420|C0018787,,A myogenic muscular circulatory organ found in the vertebrate cardiovascular system composed of chambers of cardiac muscle. It is the primary circulatory organ. [database_cross_reference: http://orcid.org/0000-0002-6601-2165][database_cross_reference: http://en.wikipedia.org/wiki/Heart],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0004535,UBERON:0000948,http://purl.obolibrary.org/obo/UBERON_0004535,,,,,,,,,,,,,,,,,,,"Taxon notes:"" the ascidian tube-like heart lacks chambers....The ascidian heart is formed after metamorphosis as a simple tube-like structure with a single-layered myoepithelium that is continuous with a single-layered pericar- dial wall. It lacks chambers and endocardium.... The innovation of the chambered heart was a key event in vertebrate evolution, because the chambered heart generates one-way blood flow with high pressure, a critical requirement for the efficient blood supply of large-body vertebrates... all extant vertebrates have hearts with two or more chambers (Moorman and Christoffels 2003)"" http://dx.doi.org/10.1101/gad.1485706",,heart,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100313,Smad5,,,false,,,http://purl.obolibrary.org/obo/IMR_0100507,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100313,,,,,,,,,,,,,,,,,,,,,,Smad5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100202,importin alpha,karyopherin alpha,,false,,,http://purl.obolibrary.org/obo/IMR_0100010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,karyopherin alpha,,,,,IMR:0100202,,,,,,,,,,,,,,,,,,,,,,importin alpha,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003412,negative regulation of phospholipid hydrolysis [Phospholipidosis (mild)],,"A process that stops, prevents, or reduces the frequency, rate or extent of phospholipid hydrolysis mildly.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (mild).",false,,,http://purl.obolibrary.org/obo/TXPO_0003448,,,,,,,,,,,,,,,,,,,,,,"A process that stops, prevents, or reduces the frequency, rate or extent of phospholipid hydrolysis mildly.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (mild).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001403,,,,,,,,,,,TXPO:0003412,,,,,,,,,,,,,,,,,,,,,,negative regulation of phospholipid hydrolysis [Phospholipidosis (mild)],,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003410,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003411,phospholipid hydrolysis,,Phospholipid hydrolysis is a subtype of hydrolysis: A chemical reaction that uses water to break down a phospholipid.,false,,,http://purl.obolibrary.org/obo/NCIT_C16702,,,,,,,,,,,,,,,,,,,,,,Phospholipid hydrolysis is a subtype of hydrolysis: A chemical reaction that uses water to break down a phospholipid.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_16247,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003411,,,,,,,,,,,,,,,,,,,,,,phospholipid hydrolysis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003417,AKT - tumor cell proliferation promoting factor (canonical)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001799,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000250,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002272,,,,,,,,,,TXPO:0003417,,,,,,,,,,,,,,,,,,,,,,AKT - tumor cell proliferation promoting factor (canonical)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003418,phosphatidylinositol 3-kinase signaling (primitive) [Phospholipidosis (excessive defense) - cell proliferation ],,"Phosphatidylinositol 3-kinase signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal transmitted by the phosphatidylinositol 3-kinase (PI3K).
This process is dependent on the  cell proliferation  and can constitute the course of Phospholipidosis (excessive defense) .",false,,,http://purl.obolibrary.org/obo/TXPO_0001495,,,,,,,,,,,,,,,,,,,,,,"Phosphatidylinositol 3-kinase signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal transmitted by the phosphatidylinositol 3-kinase (PI3K).
This process is dependent on the  cell proliferation  and can constitute the course of Phospholipidosis (excessive defense) .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001857|http://purl.obolibrary.org/obo/TXPO_0001175|http://purl.obolibrary.org/obo/TXPO_0001137|http://purl.obolibrary.org/obo/TXPO_0003419,,,,,,http://purl.obolibrary.org/obo/TXPO_0001796,,,,,,,,,,,TXPO:0003418,,,,,,,,,,,,,,,,,,,,,,phosphatidylinositol 3-kinase signaling (primitive) [Phospholipidosis (excessive defense) - cell proliferation ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003414,negative regulation of phospholipase-mediated phospholipid degradation by CAD [Phospholipidosis],,"Negative regulation of phospholipase-mediated phospholipid degradation by CAD is a subtype of negative regulation of phospholipid degradation: A process that stops, prevents, or reduces the frequency, rate or extent of phospholipase-mediated phospholipid deradation regulated by CAD.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003446|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of phospholipase-mediated phospholipid degradation by CAD is a subtype of negative regulation of phospholipid degradation: A process that stops, prevents, or reduces the frequency, rate or extent of phospholipase-mediated phospholipid deradation regulated by CAD.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003227|http://purl.obolibrary.org/obo/TXPO_0003228|http://purl.obolibrary.org/obo/TXPO_0000319,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000905,,,,,,,,,,,TXPO:0003414,,,,,,,,,,,,,,,,,,,,,,negative regulation of phospholipase-mediated phospholipid degradation by CAD [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003413,negative regulation of phospholipid hydrolysis,,"Negative regulation of phospholipid degradation is a subtype of negative regulation of phospholipid hydrolysis: A process that stops, prevents, or reduces the frequency, rate or extent of phospholipid hydrolysis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001256,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of phospholipid degradation is a subtype of negative regulation of phospholipid hydrolysis: A process that stops, prevents, or reduces the frequency, rate or extent of phospholipid hydrolysis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003413,,,,,,,,,,,,,,,,,,,,,,negative regulation of phospholipid hydrolysis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003410,phospholipid hydrolysis [Phospholipidosis],,"Phospholipid hydrolysis is a subtype of hydrolysis: A chemical reaction that uses water to break down a phospholipid.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.|phospholipase activity
http://purl.obolibrary.org/obo/GO_0004620",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0003411,,,,,,,,,,,,,,,,,,,,,,"Phospholipid hydrolysis is a subtype of hydrolysis: A chemical reaction that uses water to break down a phospholipid.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003410,,,,,,,,,,,,,,,,,,,,"phospholipase activity
http://purl.obolibrary.org/obo/GO_0004620",,phospholipid hydrolysis [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003415,AKT signaling (primitive) [phospholipidosis (excessive defense) - cell proliferation ],,"AKT signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal transmitted by the intracellular serine/threonine kinase protein kinase B (also called AKT).
This process is dependent on the  cell proliferation  and can constitute the course of Phospholipidosis (excessive defense) .",false,,,http://purl.obolibrary.org/obo/TXPO_0001796,,,,,,,,,,,,,,,,,,,,,,"AKT signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal transmitted by the intracellular serine/threonine kinase protein kinase B (also called AKT).
This process is dependent on the  cell proliferation  and can constitute the course of Phospholipidosis (excessive defense) .",,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001495,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003229|http://purl.obolibrary.org/obo/TXPO_0001857|http://purl.obolibrary.org/obo/TXPO_0001175|http://purl.obolibrary.org/obo/TXPO_0001137,,,,,,,,,,,,,,,,,TXPO:0003415,,,,,,,,,,,,,,,,,,,,,,AKT signaling (primitive) [phospholipidosis (excessive defense) - cell proliferation ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003416,AKT signaling (primitive) [Phospholipidosis (excessive defense) - tumor cell proliferation ],,"AKT signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal transmitted by the intracellular serine/threonine kinase protein kinase B (also called AKT).
This process is dependent on the  tumor cell proliferation  and can constitute the course of Phospholipidosis (excessive defense) .",false,,,http://purl.obolibrary.org/obo/TXPO_0001796,,,,,,,,,,,,,,,,,,,,,,"AKT signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal transmitted by the intracellular serine/threonine kinase protein kinase B (also called AKT).
This process is dependent on the  tumor cell proliferation  and can constitute the course of Phospholipidosis (excessive defense) .",,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001495,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003559|http://purl.obolibrary.org/obo/TXPO_0004106|http://purl.obolibrary.org/obo/TXPO_0001857|http://purl.obolibrary.org/obo/TXPO_0001175|http://purl.obolibrary.org/obo/TXPO_0001137|http://purl.obolibrary.org/obo/TXPO_0003417,,,,,,http://purl.obolibrary.org/obo/TXPO_0001491,,,,,,,,,,,TXPO:0003416,,,,,,,,,,,,,,,,,,,,,,AKT signaling (primitive) [Phospholipidosis (excessive defense) - tumor cell proliferation ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003419,PI3K - cell proliferation promoting factor (canonical)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001800,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000265,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002271,,,,,,,,,,TXPO:0003419,,,,,,,,,,,,,,,,,,,,,,PI3K - cell proliferation promoting factor (canonical)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100614,cyclin D,,,false,,,http://purl.obolibrary.org/obo/IMR_0100670,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100614,,,,,,,,,,,,,,,,,,,,,,cyclin D,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000007832,BTG2,,Other designations: B-cell translocation gene 2|NGF-inducible anti-proliferative protein PC3|nerve growth factor-inducible anti-proliferative|pheochromacytoma cell-3|protein BTG2,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,PC3|TIS21,,,,,,,,,,,,1,,,,,,MIM:601597|Ensembl:ENSG00000159388|HGNC:1131|Vega:OTTHUMG00000035834|HPRD:03357,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"BTG family, member 2",,,1q32,,,,,,,,,,,,,,,,"GO_0001077 (EC: IEA); GO_0005515 (EC: IPI, PMID: 11136725); GO_0006281 (EC: TAS, PMID: 8944033); GO_0006479 (EC: IEA); GO_0006974 (EC: IDA, PMID: 8944033); GO_0008285 (EC: IMP); GO_0008306 (EC: IEA); GO_0009612 (EC: IEA); GO_0009952 (EC: IEA); GO_0014070 (EC: IEA); GO_0017148 (EC: IDA); GO_0021542 (EC: IEA); GO_0021954 (EC: IEA); GO_0031175 (EC: IMP, PMID: 18773938); GO_0035914 (EC: IEA); GO_0043434 (EC: IEA); GO_0043524 (EC: IEA); GO_0051602 (EC: IEA); GO_0060213 (EC: IDA, PMID: 18337750); GO_0070062 (EC: IDA, PMID: 19056867); GO_2000178 (EC: IEA)",,,,,,,,,PMID: 1713584; 8663146; 8891336; 8944033; 9712883; 9828097; 10200315; 10341341; 10617598; 10669755; 11136725; 11237868; 11267995; 11377414; 11429045; 11470758; 11814693; 11856371; 11930152; 11989967; 12135500; 12360398; 12477932; 12771185; 15056715; 15378000; 15489334; 15542835; 15741235; 15788397; 16418486; 16710414; 16782888; 16997058; 17353931; 17371797; 18029348; 18196550; 18288394; 18337750; 18393292; 18773938; 18840609; 18854154; 18974182; 19056867; 19117054; 19203451; 19468252; 19546886; 19615363; 19728149; 20020054; 20398657; 20553615; 20569234; 21120602; 21172304; 21173166; 22266859; 22392501; 22493435; 22562501; 22614007; 22975506; 23089312; 23299537; 23857284; 23907596; 24047462; 24308156; 24440351,,,,,,,,,,,,,,,OGG:3000007832,,,,,,,"BTG family, member 2",,,,,,,,,,,,,Other designations: B-cell translocation gene 2|NGF-inducible anti-proliferative protein PC3|nerve growth factor-inducible anti-proliferative|pheochromacytoma cell-3|protein BTG2,,BTG2,,,,,,,,,,,,,,,,,,,,,,,7832,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,BTG2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0100198,MSH,Intermedin|Melanotropin,Peptide hormones secreted by the intermediate lobe of the pituitary that stimulate melanin release and dispersal. Melanocyte-stimulating hormones are also found in the brain where they are presumed to play a signaling role.,false,,,http://purl.obolibrary.org/obo/IMR_0100084,,,,,,,,,,,,,,,,,,,,MeSH:D009074,,Peptide hormones secreted by the intermediate lobe of the pituitary that stimulate melanin release and dispersal. Melanocyte-stimulating hormones are also found in the brain where they are presumed to play a signaling role.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Intermedin|Melanotropin,,,,,IMR:0100198,,,,,,,,,,,,,,,,,,,,,,MSH,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_22984,calcium atom,Ca|calcium,,false,,,http://purl.obolibrary.org/obo/CHEBI_33250,,,,,,,,,,,,,,,,,,,,DrugBank:DB01373|CAS:7440-70-2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,calcium,,Ca,,,CHEBI:22984,,,,,,,,,,,,,,,,,,,,,,calcium atom,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0005788,endoplasmic reticulum lumen,endoplasmic reticulum cisterna|ER lumen|ER cisterna,The volume enclosed by the membranes of the endoplasmic reticulum.,false,,,http://purl.obolibrary.org/obo/GO_0043233,,,,,,,,,,,,,,,,,,,,,,The volume enclosed by the membranes of the endoplasmic reticulum.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,endoplasmic reticulum cisterna|ER lumen|ER cisterna,,,,,GO:0005788,,,,,,,,,,,,,,,,,,,,,,endoplasmic reticulum lumen,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0005789,endoplasmic reticulum membrane,ER membrane,The lipid bilayer surrounding the endoplasmic reticulum.,false,,,http://purl.obolibrary.org/obo/GO_0031090,,,,,,,,,,,,,,,,,,,,,,The lipid bilayer surrounding the endoplasmic reticulum.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ER membrane,,,,,GO:0005789,,,,,,,,,,,,,,,,,,,,,,endoplasmic reticulum membrane,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0005783,endoplasmic reticulum,ER,"The irregular network of unit membranes, visible only by electron microscopy, that occurs in the cytoplasm of many eukaryotic cells. The membranes form a complex meshwork of tubular channels, which are often expanded into slitlike cavities called cisternae. The ER takes two forms, rough (or granular), with ribosomes adhering to the outer surface, and smooth (with no ribosomes attached).",false,,,http://purl.obolibrary.org/obo/GO_0043227,http://purl.obolibrary.org/obo/GO_0008610|http://purl.obolibrary.org/obo/GO_0016042|http://purl.obolibrary.org/obo/GO_0051208|http://purl.obolibrary.org/obo/TXPO_0000173|http://purl.obolibrary.org/obo/TXPO_0000820,,,,,,,,,,,,,,,,,,,Wikipedia:Endoplasmic_reticulum|ISBN:0815332181|NIF_Subcellular:sao1036339110,,"The irregular network of unit membranes, visible only by electron microscopy, that occurs in the cytoplasm of many eukaryotic cells. The membranes form a complex meshwork of tubular channels, which are often expanded into slitlike cavities called cisternae. The ER takes two forms, rough (or granular), with ribosomes adhering to the outer surface, and smooth (with no ribosomes attached).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005788|http://purl.obolibrary.org/obo/GO_0005789,,,,,,,,,,,,,ER,,,,http://purl.obolibrary.org/obo/GO_0005622,GO:0005783,http://purl.obolibrary.org/obo/GO_0005622,,,,,,,,,,,,,,,,,,,,,endoplasmic reticulum,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005015,malfunctioning of centrosome duplication,,Malfunctioning of centrosome duplication is a subtype of malfunctioning process: A process that cannot perform centrosome duplication appropriately or cannot realize it at all.,false,,,http://purl.obolibrary.org/obo/TXPO_0000434,,,,,,,,,,,,,,,,,,,,,,Malfunctioning of centrosome duplication is a subtype of malfunctioning process: A process that cannot perform centrosome duplication appropriately or cannot realize it at all.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005015,,,,,,,,,,,,,,,,,,,,,,malfunctioning of centrosome duplication,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005014,tumor malignancy alteration [hepatocarcinogenesis],,"Tumor malignancy alteration is a subtype of changing quality of tumor: A process that changes the quality of the tumors to progress, invade surrounding tissues or metastasize.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0005040|http://purl.obolibrary.org/obo/TXPO_0002340,,,,,,,,,,,,,,,,,,,,PMID:28584306,,"Tumor malignancy alteration is a subtype of changing quality of tumor: A process that changes the quality of the tumors to progress, invade surrounding tissues or metastasize.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004404|http://purl.obolibrary.org/obo/TXPO_0004479,,,,,,,,,,,,,,,,,,TXPO:0005014,,,,,,,,,,,,,,,,,,,,,,tumor malignancy alteration [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005013,increasing leptin level [mitochondrial disorder],,"Increasing leptin level is a subtype of increasing quantity: A process that changes the amount of glucagon level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0005012,,,,,,,,,,,,,,,,,,,,PMID:23299992,,"Increasing leptin level is a subtype of increasing quantity: A process that changes the amount of glucagon level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002041,,,,,,,,,,,TXPO:0005013,,,,,,,,,,,,,,,,,,,,,,increasing leptin level [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005010,lipoperoxidation [hepatocarcinogenesis],,"Lipoperoxidation is a subtype of lipid oxidation: The degradation of lipids caused by an oxidative attack from free radicals.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0003514,,,,,,,,,,,,,,,,,,,,PMID:11359698|PMID:28932315,,"Lipoperoxidation is a subtype of lipid oxidation: The degradation of lipids caused by an oxidative attack from free radicals.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004502,,http://purl.obolibrary.org/obo/TXPO_0004704|http://purl.obolibrary.org/obo/TXPO_0004516,,,,,,http://purl.obolibrary.org/obo/TXPO_0004392,,,,,,,,,,,TXPO:0005010,,,,,,,,,,,,,,,,,,,,,,lipoperoxidation [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005011,redox change,,Any process that results in a change in state of redox.,false,,,http://purl.obolibrary.org/obo/TXPO_0001984,,,,,,,,,,,,,,,,,,,,,,Any process that results in a change in state of redox.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005011,,,,,,,,,,,,,,,,,,,,,,redox change,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005012,increasing leptin level,,Increasing leptin level is a subtype of increasing quantity: A process that changes the amount of leptin level to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing leptin level is a subtype of increasing quantity: A process that changes the amount of leptin level to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005012,,,,,,,,,,,,,,,,,,,,,,increasing leptin level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005019,hypofunction of immune response to tumor cell [hepatocarcinogenesis],,"Hypofunction of immune response to tumor cell is a subtype of hypofunctioning: A process that performs a decreased or insufficient immune response to tumor cell.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0005028,,,,,,,,,,,,,,,,,,,,PMID:31507621,,"Hypofunction of immune response to tumor cell is a subtype of hypofunctioning: A process that performs a decreased or insufficient immune response to tumor cell.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,http://purl.obolibrary.org/obo/GO_0002418,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004919,,,,,,,,,,,TXPO:0005019,,,,,,,,,,,,,,,,,,,,,,hypofunction of immune response to tumor cell [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005017,hypoxia [hepatocarcinogenesis],,"reduced oxygenation of body tissues resulting in the decreased pressure of this component of body gases; commonly due to hypoxemia
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.|PMID:31781608",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/MP_0005039,,,,,,,,,,,,,,,,,,,,PMID:28493839|PMID:28584306,,"reduced oxygenation of body tissues resulting in the decreased pressure of this component of body gases; commonly due to hypoxemia
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004753|http://purl.obolibrary.org/obo/TXPO_0004854|http://purl.obolibrary.org/obo/TXPO_0004825|http://purl.obolibrary.org/obo/TXPO_0004640|http://purl.obolibrary.org/obo/TXPO_0004837|http://purl.obolibrary.org/obo/TXPO_0004557,,,,,,,,,,,TXPO:0005017,,,,,,,,,,,,,,,,,,,,PMID:31781608,,hypoxia [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005018,dysregulation of immune balance,immune imbalance,Dysregulation of immune balance is a subtype of malfunctioning of controlling: A process that cannot perform a regulation of immune balance appropriately or cannot realize it at all.,false,,,http://purl.obolibrary.org/obo/TXPO_0000532,,,,,,,,,,,,,,,,,,,,,,Dysregulation of immune balance is a subtype of malfunctioning of controlling: A process that cannot perform a regulation of immune balance appropriately or cannot realize it at all.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,immune imbalance,,,,,TXPO:0005018,,,,,,,,,,,,,,,,,,,,,,dysregulation of immune balance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005016,HIF1A(canonical) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004613|http://purl.obolibrary.org/obo/TXPO_0005063,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:3091|NCBI-Mouse-GeneID:15251|NCBI-Rat-GeneID:29560|PMID:28493839|PMID:31781608,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005016,,,,,,,,,,,,,,,,,,,,,,HIF1A(canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_40279,allopurinol,"4-HPP|4-Hydroxy-1H-pyrazolo(3,4-d)pyrimidine|1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidin-4-one|4'-Hydroxypyrazolol(3,4-d)pyrimidine|1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidine-4-one|Zyloprim (TN)|Allopurinolum|4-Hydroxy-3,4-pyrazolopyrimidine|4-Hydroxypyrazolo(3,4-d)pyrimidine|4H-Pyrazolo(3,4-d)pyrimidin-4-one|1H-Pyrazolo(3,4-d)pyrimidin-4-ol|Alopurinol|4-Hydroxypyrazolyl(3,4-d)pyrimidine|AL-100|4-Hydroxypyrazolopyrimidine|Allopurinol|1H-pyrazolo[3,4-d]pyrimidin-4-ol",A bicyclic structure comprising a pyrazole ring fused to a hydroxy-substituted pyrimidine ring.,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:24591375|Beilstein:608611|PMID:7602118|Drug_Central:124|DrugBank:DB00437|PMID:16650385|PMID:11333159|CAS:315-30-0|PMID:24395556|Reaxys:608611|PMID:24590210|LINCS:LSM-5919,,A bicyclic structure comprising a pyrazole ring fused to a hydroxy-substituted pyrimidine ring.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35634|http://purl.obolibrary.org/obo/CHEBI_35845|http://purl.obolibrary.org/obo/CHEBI_35221|http://purl.obolibrary.org/obo/CHEBI_48578,,,,,"Allopurinol|1H-pyrazolo[3,4-d]pyrimidin-4-ol",,"4-HPP|4-Hydroxy-1H-pyrazolo(3,4-d)pyrimidine|1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidin-4-one|4'-Hydroxypyrazolol(3,4-d)pyrimidine|1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidine-4-one|Zyloprim (TN)|Allopurinolum|4-Hydroxy-3,4-pyrazolopyrimidine|4-Hydroxypyrazolo(3,4-d)pyrimidine|4H-Pyrazolo(3,4-d)pyrimidin-4-one|1H-Pyrazolo(3,4-d)pyrimidin-4-ol|Alopurinol|4-Hydroxypyrazolyl(3,4-d)pyrimidine|AL-100|4-Hydroxypyrazolopyrimidine",,,,,,,,,,,,,,,,,,,,,CHEBI:40279,,,,allopurinol,,CHEBI:40279,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000826,ATF-1 (mol),activating transcription factor 1,,false,,,http://purl.obolibrary.org/obo/IMR_0000825,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,activating transcription factor 1,,,,,IMR:0000826,,,,,,,,,,,,,,,,,,,,,,ATF-1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001818,hypofunction of nervous system functioning [Niemann Pick Disease Type A],,"Hypofunction of nervous system functioning is a subtype of hypofunctioning: A process that performs a decreased or insufficient nervous system functioning.
This entity is a specific course-dependent process. This process can constitute the course of Niemann-Pick Disease Type A.",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0001819,,,,,,,,,,,,,,,,,,,,,,"Hypofunction of nervous system functioning is a subtype of hypofunctioning: A process that performs a decreased or insufficient nervous system functioning.
This entity is a specific course-dependent process. This process can constitute the course of Niemann-Pick Disease Type A.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001818,,,,,,,,,,,,,,,,,,,,,,hypofunction of nervous system functioning [Niemann Pick Disease Type A],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001819,hypofunction of nervous system functioning,,Hypofunction of nervous system functioning is a subtype of hypofunctioning: A process that performs a decreased or insufficient nervous system functioning.,false,,,http://purl.obolibrary.org/obo/TXPO_0000436,,,,,,,,,,,,,,,,,,,,,,Hypofunction of nervous system functioning is a subtype of hypofunctioning: A process that performs a decreased or insufficient nervous system functioning.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001819,,,,,,,,,,,,,,,,,,,,,,hypofunction of nervous system functioning,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001815,severe sphingomyelin accumulation in lysosome [Niemann Pick Disease Type A],,"Sphingomyelin accumulation in lysosome is a subtype of sphingophospholipid accumulation in lysosome: A process that keeps sphingomyelin in the lysosome.
This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type A.",false,,,http://purl.obolibrary.org/obo/TXPO_0001807,,,,,,,,,,,,,,,,,,,,,,"Sphingomyelin accumulation in lysosome is a subtype of sphingophospholipid accumulation in lysosome: A process that keeps sphingomyelin in the lysosome.
This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type A.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001692,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001481|http://purl.obolibrary.org/obo/TXPO_0001817,,,,,,,,,,,TXPO:0001815,,,,,,,,,,,,,,,,,,,,,,severe sphingomyelin accumulation in lysosome [Niemann Pick Disease Type A],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001817,splenohepatomegaly [Niemann Pick Disease Type A],,"A size change process in which the size of liver and spleen is increasing.
This entity is a specific course-dependent process. This process can constitute the course of Niemann-Pick Disease Type A.",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0001812,,,,,,,,,,,,,,,,,,,,,,"A size change process in which the size of liver and spleen is increasing.
This entity is a specific course-dependent process. This process can constitute the course of Niemann-Pick Disease Type A.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001817,,,,,,,,,,,,,,,,,,,,,,splenohepatomegaly [Niemann Pick Disease Type A],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001816,sphingomyelin metabolism imbalance [Niemann Pick Disease Type B],,"A process that becomes lacking a homeostastasis balance of the sphingomyelin metabolism.
This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type B.",false,,,http://purl.obolibrary.org/obo/TXPO_0001476,,,,,,,,,,,,,,,,,,,,,,"A process that becomes lacking a homeostastasis balance of the sphingomyelin metabolism.
This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type B.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001809,,,,,,,,,,,TXPO:0001816,,,,,,,,,,,,,,,,,,,,,,sphingomyelin metabolism imbalance [Niemann Pick Disease Type B],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001810,malfunction of mitochondria [ER stress],,"Malfunction of mitochondria is a subtype of malfunctioning process: A process that cannot perform a mitochondrial function appropriately or cannot realize it at all.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/TXPO_0000782,,,,,,,,,,,,,,,,,,,,,,"Malfunction of mitochondria is a subtype of malfunctioning process: A process that cannot perform a mitochondrial function appropriately or cannot realize it at all.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002209|http://purl.obolibrary.org/obo/TXPO_0002171,,,,,,,,,,,TXPO:0001810,,,,,,,,,,,,,,,,,,,,,,malfunction of mitochondria [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001814,pulmonary infection [Niemann Pick Disease Type B],,"Pulmonary infection is a subtype of pathogen colonization: A process that makes pathogen such as microorganism (bacteria, virus, mycoplasma, etc.) present in the lung to increase the number.
This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type B.",false,,,http://purl.obolibrary.org/obo/TXPO_0001478,,,,,,,,,,,,,,,,,,,,,,"Pulmonary infection is a subtype of pathogen colonization: A process that makes pathogen such as microorganism (bacteria, virus, mycoplasma, etc.) present in the lung to increase the number.
This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type B.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001814,,,,,,,,,,,,,,,,,,,,,,pulmonary infection [Niemann Pick Disease Type B],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001812,splenohepatomegaly,icreasing size of liver and spleen,A size change process in which the size of liver and spleen is increasing.,false,,,http://purl.obolibrary.org/obo/TXPO_0000138,,,,,,,,,,,,,,,,,,,,,,A size change process in which the size of liver and spleen is increasing.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,icreasing size of liver and spleen,,,,,TXPO:0001812,,,,,,,,,,,,,,,,,,,,,,splenohepatomegaly,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001813,JNK (canonical)[ER stress],,,false,,,http://purl.obolibrary.org/obo/IMR_0000225|http://purl.obolibrary.org/obo/TXPO_1000216|http://purl.obolibrary.org/obo/TXPO_0000871,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:5599|NCBI-Mouse-GeneID:26419|NCBI-Rat-GeneID:116554,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001813,,,,,,,,,,,,,,,,,,,,,,JNK (canonical)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001811,splenohepatomegaly [Niemann Pick Disease Type B],,"A size change process in which the size of liver and spleen is increasing.
This entity is a specific course-dependent process. This process can constitute the course of Niemann-Pick Disease Type B.",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0001812,,,,,,,,,,,,,,,,,,,,,,"A size change process in which the size of liver and spleen is increasing.
This entity is a specific course-dependent process. This process can constitute the course of Niemann-Pick Disease Type B.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001811,,,,,,,,,,,,,,,,,,,,,,splenohepatomegaly [Niemann Pick Disease Type B],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000819,JUND (mol),,,false,,,http://purl.obolibrary.org/obo/IMR_0000416,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000819,,,,,,,,,,,,,,,,,,,,,,JUND (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0002515,nonclassical MHC class I molecule,MHC class Ib molecule,"The MHC class Ib family members include HLA-E, HLA-F, HLA-G and HFE (HLA-H) in humans and gene products from the H2-M, H2-Q and H2-T regions in mice.",false,,,http://purl.obolibrary.org/obo/IMR_0000142,,,,,,,,,,,,,,,,,,,,,,"The MHC class Ib family members include HLA-E, HLA-F, HLA-G and HFE (HLA-H) in humans and gene products from the H2-M, H2-Q and H2-T regions in mice.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MHC class Ib molecule,,,,,IMR:0002515,,,,,,,,,,,,,,,,,,,,,,nonclassical MHC class I molecule,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000741,Gads,Grb2-related adaptor downstream of Shc,Gads is a member of the family of SH2 and SH3 domain containing adaptor proteins that is expressed specifically in hematopoietic cells and functions in the coordination of tyrosine kinase mediated signal transduction. Gads is a unique member of the Grb2 adaptor family.,false,,,http://purl.obolibrary.org/obo/IMR_0000339,,,,,,,,,,,,,,,,,,,,,,Gads is a member of the family of SH2 and SH3 domain containing adaptor proteins that is expressed specifically in hematopoietic cells and functions in the coordination of tyrosine kinase mediated signal transduction. Gads is a unique member of the Grb2 adaptor family.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Grb2-related adaptor downstream of Shc,,,,,IMR:0000741,,,,,,,,,,,,,,,,,,,,,,Gads,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010472,60S ribosomal protein L22,Epstein-Barr virus small RNA associated protein|EAP|Heparin binding protein HBp15|EBER associated protein,,false,,,http://purl.obolibrary.org/obo/IMR_0000897,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Epstein-Barr virus small RNA associated protein|EAP|Heparin binding protein HBp15|EBER associated protein,,,,,IMR:0010472,,,,,,,,,,,,,,,,,,,,,,60S ribosomal protein L22,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001103,importin 11,,,false,,,http://purl.obolibrary.org/obo/IMR_0100010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001103,,,,,,,,,,,,,,,,,,,,,,importin 11,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000462,TRAF family,TNF receptor associated factor family,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003657,,,,,TNF receptor associated factor family,,,,,IMR:0000462,,,,,,,,,,,,,,,,,,,,,,TRAF family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003200,FAS (canonical)[apotosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003195|http://purl.obolibrary.org/obo/TXPO_1000139,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:355|NCBI-Mouse-GeneID:14102|NCBI-Rat-GeneID:246097,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003200,,,,,,,,,,,,,,,,,,,,,,FAS (canonical)[apotosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003206,TRAF3 (canonical)[apotosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003195|http://purl.obolibrary.org/obo/IMR_0100424,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:22031|NCBI-Rat-GeneID:362788|NCBI-Human-GeneID:7187,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003206,,,,,,,,,,,,,,,,,,,,,,TRAF3 (canonical)[apotosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003204,CASP8 (canonical)[apotosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000058|http://purl.obolibrary.org/obo/TXPO_0003195,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:12370|NCBI-Human-GeneID:841|NCBI-Rat-GeneID:64044,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003204,,,,,,,,,,,,,,,,,,,,,,CASP8 (canonical)[apotosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003202,TP53 (canonical)[apotosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003195|http://purl.obolibrary.org/obo/IMR_0100659,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24842|NCBI-Human-GeneID:7157,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003202,,,,,,,,,,,,,,,,,,,,,,TP53 (canonical)[apotosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003201,TNF (canonical)[apotosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000374|http://purl.obolibrary.org/obo/TXPO_0003195,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:21926|NCBI-Rat-GeneID:24835|NCBI-Human-GeneID:7124,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003201,,,,,,,,,,,,,,,,,,,,,,TNF (canonical)[apotosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003205,CASPASE-3 (canonical)[apotosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003195|http://purl.obolibrary.org/obo/TXPO_0001145,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:12367|NCBI-Rat-GeneID:25402|NCBI-Human-GeneID:836,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003205,,,,,,,,,,,,,,,,,,,,,,CASPASE-3 (canonical)[apotosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003208,inflammatory cytokine gene expression [Glutathione depletion],,"Inflammatory cytokine gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature inflammatory cytokine gene product or products (proteins or RNA).
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0002266|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Inflammatory cytokine gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature inflammatory cytokine gene product or products (proteins or RNA).
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003208,,,,,,,,,,,,,,,,,,,,,,inflammatory cytokine gene expression [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003209,tumorigenesis [Glutathione depletion],,"A pathologic process that involves the transformation of normal cells to a neoplastic state and resulting in polyclonal or monoclonal neoplastic cell proliferation.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/NCIT_C18121|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,PMID:29558368,,"A pathologic process that involves the transformation of normal cells to a neoplastic state and resulting in polyclonal or monoclonal neoplastic cell proliferation.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000847,,,,,,,,,,,,,,,,,TXPO:0003209,,,,,,,,,,,,,,,,,,,,,,tumorigenesis [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003203,TRADD (canonical)[apotosis],,,false,,,http://purl.obolibrary.org/obo/IMR_0100464|http://purl.obolibrary.org/obo/TXPO_0003195,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:8717|NCBI-Rat-GeneID:246756|NCBI-Mouse-GeneID:71609,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003203,,,,,,,,,,,,,,,,,,,,,,TRADD (canonical)[apotosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003207,negative regulation of inflammatory response [Eosinophilic granular degeneration],,"Negative regulation of inflammatory response is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of inflammatory response.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/TXPO_0001729|http://purl.obolibrary.org/obo/TXPO_0002243,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of inflammatory response is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of inflammatory response.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000136,,,,,,,,,,,TXPO:0003207,,,,,,,,,,,,,,,,,,,,,,negative regulation of inflammatory response [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001504,Rap1,,,false,,,http://purl.obolibrary.org/obo/IMR_0000294,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001504,,,,,,,,,,,,,,,,,,,,,,Rap1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000630,Integrin alpha-8,,,false,,,http://purl.obolibrary.org/obo/IMR_0000173,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000630,,,,,,,,,,,,,,,,,,,,,,Integrin alpha-8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76790,EC 2.4.2.* (pentosyltransferase) inhibitor,EC 2.4.2.* (pentosyltransferase) inhibitors|EC 2.4.2.* inhibitors|pentosyltransferase inhibitors|pentosyltransferase inhibitor|EC 2.4.2.* inhibitor|pentosyltransferase (EC 2.4.2.*) inhibitors|pentosyltransferase (EC 2.4.2.*) inhibitor,An EC 2.4.* (glycosyltransferase) inhibitor that interferes with the action of any pentosyltransferase (EC 2.4.2.*).,false,,,http://purl.obolibrary.org/obo/CHEBI_76662,,,,,,,,,,,,,,,,,,,,,,An EC 2.4.* (glycosyltransferase) inhibitor that interferes with the action of any pentosyltransferase (EC 2.4.2.*).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,EC 2.4.2.* (pentosyltransferase) inhibitors|EC 2.4.2.* inhibitors|pentosyltransferase inhibitors|pentosyltransferase inhibitor|EC 2.4.2.* inhibitor|pentosyltransferase (EC 2.4.2.*) inhibitors|pentosyltransferase (EC 2.4.2.*) inhibitor,,,,,,,,,,,,,,,,,,,,,CHEBI:76790,,,,EC 2.4.2.* (pentosyltransferase) inhibitor,,CHEBI:76790,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000029103,DNAJC15,,"Other designations: DNAJ domain-containing|DnaJ (Hsp40) homolog, subfamily D, member 1|cell growth-inhibiting gene 22 protein|dnaJ homolog subfamily C member 15|methylation-controlled J protein",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,HSD18|DNAJD1|MCJ,,,,,,,,,,,,13,,,,,,Vega:OTTHUMG00000016813|MIM:615339|Ensembl:ENSG00000120675|HGNC:20325|HPRD:13238,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"DnaJ (Hsp40) homolog, subfamily C, member 15",,,13q14.1,,,,,,,,,,,,,,,,GO_0005743 (EC: IEA); GO_0015031 (EC: IEA); GO_0016021 (EC: IEA),,,,,,,,,PMID:11358853; 12477932; 14729589; 15057823; 15489334; 16049974; 17283040; 18029348; 18324624; 19322201; 19734545; 20877624; 23263864,,,,,,,,,,,,,,,OGG:3000029103,,,,,,,"DnaJ (Hsp40) homolog, subfamily C, member 15",,,,,,,,,,,,,"Other designations: DNAJ domain-containing|DnaJ (Hsp40) homolog, subfamily D, member 1|cell growth-inhibiting gene 22 protein|dnaJ homolog subfamily C member 15|methylation-controlled J protein",,DNAJC15,,,,,,,,,,,,,,,,,,,,,,,29103,GIG22,,,,,,,9606,,,,,,,,,,,,,,,,,,,DNAJC15,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0100488,IRAK,Interleukin-1 receptor-associated kinase|IL-1 receptor-associated kinase|Pelle-like protein kinase,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001966,,,,,Interleukin-1 receptor-associated kinase|IL-1 receptor-associated kinase|Pelle-like protein kinase,,,,,IMR:0100488,,,,,,,,,,,,,,,,,,,,,,IRAK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010563,40S ribosomal protein S7,40S small ribosomal protein 7,,false,,,http://purl.obolibrary.org/obo/IMR_0000896,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,40S small ribosomal protein 7,,,,,IMR:0010563,,,,,,,,,,,,,,,,,,,,,,40S ribosomal protein S7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100094,corticotropin-releasing hormone,Corticotropin-releasing factor|CRH,,false,,,http://purl.obolibrary.org/obo/IMR_0100093,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Corticotropin-releasing factor|CRH,,,,,IMR:0100094,,,,,,,,,,,,,,,,,,,,,,corticotropin-releasing hormone,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000864,14-3-3 tau/theta,,,false,,,http://purl.obolibrary.org/obo/IMR_0000456,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000864,,,,,,,,,,,,,,,,,,,,,,14-3-3 tau/theta,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_233869,4-(phenylazo)aniline,4-Aminoazobenzene|AAB|4-phenyldiazenylaniline|4-[(E)-phenyldiazenyl]aniline,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:60-09-3|Wikipedia:Aniline_Yellow,,,,,,,,,,,,,,C12H11N3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4-Aminoazobenzene|AAB|4-phenyldiazenylaniline|4-[(E)-phenyldiazenyl]aniline,,,,,CHEBI:233869,,,,,,,,,,,,,,,,,,,,,,4-(phenylazo)aniline,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,C1=CC=C(C=C1)N=NC2=CC=C(C=C2)N,,,,,
http://purl.obolibrary.org/obo/IMR_0001556,Rab3A,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001556,,,,,,,,,,,,,,,,,,,,,,Rab3A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0004111,anatomical conduit,ostium|ostia,"Any tube, opening or passage that connects two distinct anatomical spaces.",false,,,http://purl.obolibrary.org/obo/UBERON_0000061,,,,,,,,,,,,,,,,,,,,,,"Any tube, opening or passage that connects two distinct anatomical spaces.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0013686,,,,,,,,,,,,,,,ostium|ostia,,,UBERON:0004111,,,,,,,,,,,,,,,,,,,,,,anatomical conduit,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100364,Cbl-3,Cbl-c,,false,,,http://purl.obolibrary.org/obo/IMR_0000356,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Cbl-c,,,,,IMR:0100364,,,,,,,,,,,,,,,,,,,,,,Cbl-3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100219,TAO1,,,false,,,http://purl.obolibrary.org/obo/IMR_0000229,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100219,,,,,,,,,,,,,,,,,,,,,,TAO1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000003638,INSIG1,,Other designations: INSIG-1 membrane protein|insulin-induced gene 1 protein,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CL-6|CL6,,,,,,,,,,,,7,,,,,,HGNC:6083|HPRD:03633|Ensembl:ENSG00000186480|Vega:OTTHUMG00000151330|MIM:602055,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,insulin induced gene 1,,,7q36,,,,,,,,,,,,,,,,"GO_0005515 (EC: IPI, PMID: 12202038); GO_0005783 (EC: IDA, PMID: 12202038); GO_0005789 (EC: TAS); GO_0006641 (EC: IEA); GO_0006695 (EC: IEA); GO_0008152 (EC: TAS, PMID: 9268630); GO_0008283 (EC: TAS, PMID: 9268630); GO_0010894 (EC: IEA); GO_0032933 (EC: IDA, PMID: 12242332); GO_0032937 (EC: IDA, PMID: 15899885); GO_0042472 (EC: IEA); GO_0042474 (EC: IEA); GO_0044281 (EC: TAS); GO_0045599 (EC: IEA); GO_0045717 (EC: IEA); GO_0060021 (EC: IEA); GO_0060363 (EC: IEA); GO_1901303 (EC: IMP, PMID: 15899885)",,,,,,,,,PMID: 9268630; 12115587; 12202038; 12242332; 12242342; 12477932; 12482938; 12535518; 12690205; 12842885; 12869692; 12963821; 14660594; 14702039; 15085196; 15247248; 15304479; 15489334; 15782218; 15899885; 16168377; 16344560; 16399501; 16549805; 16606821; 17043353; 17106696; 18187584; 18195716; 18660489; 18835813; 18989534; 19322201; 19458199; 19617589; 19638338; 19740467; 19815544; 19913121; 19965593; 20068067; 20444954; 20458442; 20628086; 20877301; 21081644; 21343306; 21906983; 21963094; 22143767; 22505724; 22648509; 23223569; 24371122,,,,,,,,,,,,,,,OGG:3000003638,,,,,,,insulin induced gene 1,,,,,,,,,,,,,Other designations: INSIG-1 membrane protein|insulin-induced gene 1 protein,,INSIG1,,,,,,,,,,,,,,,,,,,,,,,3638,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,INSIG1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0002928,JNK - kinase (canonical)[ER stress - apotosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001813,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002928,,,,,,,,,,,,,,,,,,,,,,JNK - kinase (canonical)[ER stress - apotosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002927,JNK - kinase (canonical)[ER stress - inflammation],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001813,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002927,,,,,,,,,,,,,,,,,,,,,,JNK - kinase (canonical)[ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002929,JNK - signalling factor (canonical)[ER stress - apotosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001813,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001898,,,,,,,,,,TXPO:0002929,,,,,,,,,,,,,,,,,,,,,,JNK - signalling factor (canonical)[ER stress - apotosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002922,co-chaperone,,A role played by the entity that assists chaperon and ensures correct protein folding.,false,,,http://purl.obolibrary.org/obo/TXPO_0003732,,,,,,,,,,,,,,,,,,,,,,A role played by the entity that assists chaperon and ensures correct protein folding.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002922,,,,,,,,,,,,,,,,,,,,,,co-chaperone,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002921,HYOU1  (canonical)[ER stress],grp170 [ER stress],,false,,,http://purl.obolibrary.org/obo/TXPO_1000191|http://purl.obolibrary.org/obo/TXPO_0000871,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:10525|R-HSA-1791066.1|NCBI-Rat-GeneID:192235|https://omim.org/entry/601746|NCBI-Mouse-GeneID:12282|PMID:10037731|PMID:10837345,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,grp170 [ER stress],,,,,TXPO:0002921,,,,,,,,,,,,,,,,,,,,,,HYOU1  (canonical)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002920,HYOU1 - chaperone (canonical)[ER stress - Refolding],GRP170 - chaperone [ER stress - Refolding],,false,,,http://purl.obolibrary.org/obo/TXPO_0002921,,,,,,,,,,,,,,,,,,,,R-HSA-1791066.1|https://omim.org/entry/601746|PMID:20942857|PMID:14674765|PMID:10837345,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002922,,,,,GRP170 - chaperone [ER stress - Refolding],,,,,TXPO:0002920,,,,,,,,,,,,,,,,,,,,,,HYOU1 - chaperone (canonical)[ER stress - Refolding],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002923,XBP1 - transcriptional regulator (canonical)[ER stress - Refolding],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001968,http://purl.obolibrary.org/obo/TXPO_0002919,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002923,,,,,,,,,,,,,,,,,,,,,,XBP1 - transcriptional regulator (canonical)[ER stress - Refolding],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002924,ATF6 activation [ER stress - inflammation],,"ATF6 activation is a subtype of molecular activation: A process that changes the activity of the ATF6 (Activating Transcription Factor 6) to be higher.
This process is dependent on the inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000710|http://purl.obolibrary.org/obo/TXPO_0003736,,,,,,,,,,,,,,,,,,,,,,"ATF6 activation is a subtype of molecular activation: A process that changes the activity of the ATF6 (Activating Transcription Factor 6) to be higher.
This process is dependent on the inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002902,,,,,,,,,,,,,,,,,,,TXPO:0002924,,,,,,,,,,,,,,,,,,,,,,ATF6 activation [ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002925,positive regulation of gene expression via JNK signaling [ER stress],,"Positive regulation of gene expression via JNK signaling is a subtype of positive regulation of gene expression: A process that that activates or increases the frequency, rate or extent of gene expression via JNK signaling.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0003116|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"Positive regulation of gene expression via JNK signaling is a subtype of positive regulation of gene expression: A process that that activates or increases the frequency, rate or extent of gene expression via JNK signaling.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001813,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002925,,,,,,,,,,,,,,,,,,,,,,positive regulation of gene expression via JNK signaling [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002926,receiving abnormal protein signal by IRE1 [ER stress - apoptosis],,"Receiving abnormal protein signal by IRE1 is a subtype of receiving signal: A process that recognizes another object and changes into an abnormal protein (e.g., misfolded protein, etc.) signal by IRE1.
This process is dependent on the apoptosis and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002604|http://purl.obolibrary.org/obo/TXPO_0003736,,,,,,,,,,,,,,,,,,,,,,"Receiving abnormal protein signal by IRE1 is a subtype of receiving signal: A process that recognizes another object and changes into an abnormal protein (e.g., misfolded protein, etc.) signal by IRE1.
This process is dependent on the apoptosis and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000906,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002953,,,,,,,,,,,TXPO:0002926,,,,,,,,,,,,,,,,,,,,,,receiving abnormal protein signal by IRE1 [ER stress - apoptosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010561,40S ribosomal protein S5,40S small ribosomal protein 5,,false,,,http://purl.obolibrary.org/obo/IMR_0000896,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,40S small ribosomal protein 5,,,,,IMR:0010561,,,,,,,,,,,,,,,,,,,,,,40S ribosomal protein S5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003562,G1/S transition of mitotic cell cycle,,A role played by the entity that positively regulates the process ofof G1/S transition of mitotic cell cycle role.,false,,,http://purl.obolibrary.org/obo/TXPO_0003564,,,,,,,,http://purl.obolibrary.org/obo/GO_0044843,http://purl.obolibrary.org/obo/GO_0044843,,,,,,,,,,,,,A role played by the entity that positively regulates the process ofof G1/S transition of mitotic cell cycle role.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003562,,,,,,,,,,,,,,,,,,,,,,G1/S transition of mitotic cell cycle,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003561,G-Protein Coupled Receptor,GPCR,Combining role with an extracellular signal and transmitting the signal across the membrane by activating an associated G-protein; promotes the exchange of GDP for GTP on the alpha subunit of a heterotrimeric G-protein complex.|related molecular function GO:0004930,false,,,http://purl.obolibrary.org/obo/TXPO_0000057,,,,,,,,,,,,,,,,,,,,Wikipedia:GPCR|IMR:0000137 (obsolete),,Combining role with an extracellular signal and transmitting the signal across the membrane by activating an associated G-protein; promotes the exchange of GDP for GTP on the alpha subunit of a heterotrimeric G-protein complex.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GPCR,,,,,TXPO:0003561,,,,,,,,,,,,,,,,,,,,related molecular function GO:0004930,,G-Protein Coupled Receptor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003565,forming  a complex of CAD and phospholipid (mild),,"Forming a complex of CAD and phospholipid is a subtype of forming a complex of drugs and biological substance: A process that forms a complex consisiting phospholipids and  CAD (Cationic Amphiphilic Drug) in the lysosomal membrane, which causes structural change of the membrane. The degree is mild.",false,,,http://purl.obolibrary.org/obo/TXPO_0003364,,,,,,,,,,,,,,,,,,,,,,"Forming a complex of CAD and phospholipid is a subtype of forming a complex of drugs and biological substance: A process that forms a complex consisiting phospholipids and  CAD (Cationic Amphiphilic Drug) in the lysosomal membrane, which causes structural change of the membrane. The degree is mild.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003565,,,,,,,,,,,,,,,,,,,,,,forming  a complex of CAD and phospholipid (mild),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003567,forming  a complex of CAD and phospholipid (severe),,"Forming a complex of CAD and phospholipid is a subtype of forming a complex of drugs and biological substance: A process that forms a complex consisiting phospholipids and  CAD (Cationic Amphiphilic Drug) in the lysosomal membrane, which causes structural change of the membrane. The degree is severe.",false,,,http://purl.obolibrary.org/obo/TXPO_0003364,,,,,,,,,,,,,,,,,,,,,,"Forming a complex of CAD and phospholipid is a subtype of forming a complex of drugs and biological substance: A process that forms a complex consisiting phospholipids and  CAD (Cationic Amphiphilic Drug) in the lysosomal membrane, which causes structural change of the membrane. The degree is severe.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003567,,,,,,,,,,,,,,,,,,,,,,forming  a complex of CAD and phospholipid (severe),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003568,cell death [Mitochondrial disorder],,"Any biological process that results in permanent cessation of all vital functions of a cell.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder].",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/GO_0008219,,,,,,,,,,,,,,,,,,,,PMID:31623280,,"Any biological process that results in permanent cessation of all vital functions of a cell.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder].",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003568,,,,,,,,,,,,,,,,,,,,,,cell death [Mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003563,increased affinity,,An affinity which is relatively high.,false,,,http://purl.obolibrary.org/obo/PATO_0002070,,,,,,,,,,,,,,,,,,,,,,An affinity which is relatively high.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003563,,,,,,,,,,,,,,,,,,,,,,increased affinity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003560,KCNMA1 (predicted)(human)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001135|http://purl.obolibrary.org/obo/TXPO_0003839,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:3778,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000003778,,,,,,,,,,,,,TXPO:0003560,,,,,,,,,,,,,,,,,,,,,,KCNMA1 (predicted)(human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003566,forming  a complex of CAD and phospholipid (moderate),,"Forming a complex of CAD and phospholipid is a subtype of forming a complex of drugs and biological substance: A process that forms a complex consisiting phospholipids and  CAD (Cationic Amphiphilic Drug) in the lysosomal membrane, which causes structural change of the membrane. The degree is moderate.",false,,,http://purl.obolibrary.org/obo/TXPO_0003364,,,,,,,,,,,,,,,,,,,,,,"Forming a complex of CAD and phospholipid is a subtype of forming a complex of drugs and biological substance: A process that forms a complex consisiting phospholipids and  CAD (Cationic Amphiphilic Drug) in the lysosomal membrane, which causes structural change of the membrane. The degree is moderate.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003566,,,,,,,,,,,,,,,,,,,,,,forming  a complex of CAD and phospholipid (moderate),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003569,glutathione depletion [Mitochondrial disorder],,"Glutathione depletion is a subtype of depleting: A process that lessens markedly in the amount of glutathione.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0000483|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:25339807,,"Glutathione depletion is a subtype of depleting: A process that lessens markedly in the amount of glutathione.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001990|http://purl.obolibrary.org/obo/TXPO_0004370,,,,,,,,,,,TXPO:0003569,,,,,,,,,,,,,,,,,,,,,,glutathione depletion [Mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003564,positive regulator of cell cycle phase transition role,,A role played by the entity that positively regulates the process of cell cycle phase transition.,false,,,http://purl.obolibrary.org/obo/TXPO_0003230,,,,,,,,http://purl.obolibrary.org/obo/GO_0044770,http://purl.obolibrary.org/obo/GO_0044770,,,,,,,,,,,,,A role played by the entity that positively regulates the process of cell cycle phase transition.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003564,,,,,,,,,,,,,,,,,,,,,,positive regulator of cell cycle phase transition role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0007049,cell cycle,,"The progression of biochemical and morphological phases and events that occur in a cell during successive cell replication or nuclear replication events. Canonically, the cell cycle comprises the replication and segregation of genetic material followed by the division of the cell, but in endocycles or syncytial cells nuclear replication or nuclear division may not be followed by cell division.",false,,,http://purl.obolibrary.org/obo/TXPO_0000425,,,,,,,,,,,,,,,,,,,,,,"The progression of biochemical and morphological phases and events that occur in a cell during successive cell replication or nuclear replication events. Canonically, the cell cycle comprises the replication and segregation of genetic material followed by the division of the cell, but in endocycles or syncytial cells nuclear replication or nuclear division may not be followed by cell division.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0007049,,,,,,,,,,,,,,,,,,,,,,cell cycle,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0007041,lysosomal transport,,"The directed movement of substances into, out of or within a lysosome.",false,,,http://purl.obolibrary.org/obo/GO_0006810,,,,,,,,,,,,,,,,,,,,,,"The directed movement of substances into, out of or within a lysosome.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0007041,,,,,,,,,,,,,,,,,,,,,,lysosomal transport,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001093,ERM,ETV5,,false,,,http://purl.obolibrary.org/obo/IMR_0000397,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ETV5,,,,,IMR:0001093,,,,,,,,,,,,,,,,,,,,,,ERM,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000271,SHIP,Src homology-2 domain-containing inositol 5'-phosphatase,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Src homology-2 domain-containing inositol 5'-phosphatase,,,,,IMR:0000271,,,,,,,,,,,,,,,,,,,,,,SHIP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0050900,leukocyte migration,leucocyte migration|leukocyte trafficking|immune cell trafficking|leucocyte trafficking|immune cell migration,The movement of a leukocyte within or between different tissues and organs of the body.,false,,,http://purl.obolibrary.org/obo/GO_0016477,,,,,,,,,,,,,,,,,,,,,,The movement of a leukocyte within or between different tissues and organs of the body.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,leucocyte migration|leukocyte trafficking|immune cell trafficking|leucocyte trafficking|immune cell migration,,,,,GO:0050900,,,,,,,,,,,,,,,,,,,,,,leukocyte migration,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001784,organic anion import into hepatocyte vascular side (sinusoidal side) membrane [cholestasis] [Cholestasis],,"The sodium-dependent movement of the organic anion into hepatocyte vascular side (sinusoidal side) membrane.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001783,,,,,,,,,,,,,,,,,,,,,,"The sodium-dependent movement of the organic anion into hepatocyte vascular side (sinusoidal side) membrane.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000547,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001784,,,,,,,"Uptake of bile salts from sinusoidal blood into hepatocyte is predominantly sodium dependent, whichi is mediated by the NTCP (sodium/bile acid cotransporter; SLC10A1)  in a polar manner at the basolateral plasma membrane of hepatocytes",,,,,,,,,,,,,,,organic anion import into hepatocyte vascular side (sinusoidal side) membrane [cholestasis] [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001785,sphingomyelin phosphodiesterase,sphingomyelinase,Catalysis role of the reaction: H(2)O + sphingomyelin = ceramide + choline phosphate + H(+).,false,,,http://purl.obolibrary.org/obo/TXPO_0003672,,,,,,,,,,,,,,,,,,,,http://www.genome.ad.jp/dbget-bin/www_bget?enzyme+3.1.4.12|http://www.brenda-enzymes.org/ontology.php?ontology_id=1&f[id][value]=GO:0004767&f[id][type]=2&id_go=GO:0004767|EC 3.1.4.12,,Catalysis role of the reaction: H(2)O + sphingomyelin = ceramide + choline phosphate + H(+).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sphingomyelinase,,,,,TXPO:0001785,,,,,,,,,,,,,,,,,,,,,,sphingomyelin phosphodiesterase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001780,toxicological balance H=H (maintining homeostasis at higher level),,"In the imbalance model, the basic units are as follows:
1) a functioning process (supply) for biological defense and maintaining homeostasis;
2) a functional demand process (demand) as toxic activity;
3) balance/imbalance between toxic activity and defense processes; and
4) outcome from organelles, cells, or tissues to the organ exhibiting toxicity manifestations.

This entity is a compound state that inculdes step 1 to 4.
The defense performance level and the functional demand level are high, as a result, keeping the balance. This state reflects the adaptation in the body.",false,,,http://purl.obolibrary.org/obo/TXPO_0003992,,,,,,,,,,,,,,,,,,,,,,"In the imbalance model, the basic units are as follows:
1) a functioning process (supply) for biological defense and maintaining homeostasis;
2) a functional demand process (demand) as toxic activity;
3) balance/imbalance between toxic activity and defense processes; and
4) outcome from organelles, cells, or tissues to the organ exhibiting toxicity manifestations.

This entity is a compound state that inculdes step 1 to 4.
The defense performance level and the functional demand level are high, as a result, keeping the balance. This state reflects the adaptation in the body.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001734,,,,,,,,,,,,,,,,,,TXPO:0001780,,,,,,,,,,,,,,,,,,,,,,toxicological balance H=H (maintining homeostasis at higher level),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001788,negative regulation of sphingomyelin catabolic process [sphingomyelin disorder ],,"Negative regulation of sphingomyelin catabolic process is a subtype of negative regulation of sphingophopholipid degradation: Any process that stops, prevents, or reduces the frequency, rate or extent of the sphingomyelin catabolic process.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (sphingomyelin disorder).",false,,,http://purl.obolibrary.org/obo/TXPO_0000905|http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0001680,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of sphingomyelin catabolic process is a subtype of negative regulation of sphingophopholipid degradation: Any process that stops, prevents, or reduces the frequency, rate or extent of the sphingomyelin catabolic process.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (sphingomyelin disorder).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000318,,,,,,http://purl.obolibrary.org/obo/TXPO_0004162,,,,,,,,,,,TXPO:0001788,,,,,,,,,,,,,,,,,,,,,,negative regulation of sphingomyelin catabolic process [sphingomyelin disorder ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001782,phospholipid metabolism balance [Phospholipidosis (adaptation)],,"Phospholipid metabolism balance is a subtype of maintaining balance: A process that keeps a balance of phospholipid metabolism.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense).",false,,,http://purl.obolibrary.org/obo/TXPO_0001434,,,,,,,,,,,,,,,,,,,,,,"Phospholipid metabolism balance is a subtype of maintaining balance: A process that keeps a balance of phospholipid metabolism.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001780,,,,,,,,,TXPO:0001782,,,,,,,,,,,,,,,,,,,,,,phospholipid metabolism balance [Phospholipidosis (adaptation)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001787,negative regulation of enzyme activation,,"Negative regulation of enzyme activation is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of enzyme activation.",false,,,http://purl.obolibrary.org/obo/TXPO_0000369,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of enzyme activation is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of enzyme activation.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001787,,,,,,,,,,,,,,,,,,,,,,negative regulation of enzyme activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001786,lipidosis marker gene,,"Lipidosis marker is  predicted by SVM, which is possible to participate in the course of lipidosis as a gene product.
Predicted gene profile:Human/in vitro/Hepatocyte/",false,,,http://purl.obolibrary.org/obo/TXPO_0001090,,,,,,,,,,,,,,,,,,,,,,"Lipidosis marker is  predicted by SVM, which is possible to participate in the course of lipidosis as a gene product.
Predicted gene profile:Human/in vitro/Hepatocyte/",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001786,,,,,,,,,,,,,,,,,,,,,,lipidosis marker gene,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001783,importing anion into hepatocyte vascular side (sinusoidal side) membrane [cholestasis] [Cholestasis],,"The directed movement of the organic anion into hepatocyte vascular side (sinusoidal side) membrane during cholestasis.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001759,,,,,,,,,,,,,,,,,,,,,,"The directed movement of the organic anion into hepatocyte vascular side (sinusoidal side) membrane during cholestasis.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001783,,,,,,,Uptake of bile salts from sinusoidal blood into hepatocyte is predominantly sodium dependent,,,,,,,,,,,,,,,importing anion into hepatocyte vascular side (sinusoidal side) membrane [cholestasis] [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001789,SPON2(human)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001135|http://purl.obolibrary.org/obo/TXPO_0003834,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:10417|PMID:30318967|https://omim.org/entry/605918|PMID:29440144,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000010417,,,,,,,,,,,,,TXPO:0001789,,,,,,,,,,,,,,,,,,,,,,SPON2(human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001781,toxicological imbalance H<VH,,"In the imbalance model, the basic units are as follows:
1) a functioning process (supply) for biological defense and maintaining homeostasis;
2) a functional demand process (demand) as toxic activity;
3) balance/imbalance between toxic activity and defense processes; and
4) outcome from organelles, cells, or tissues to the organ exhibiting toxicity manifestations.

This entity  is a compound state that inculdes step 1 to 4.
The defense performance level is higher (H) than daily life; however, the functional demand level is Very high(VH), which leads to the imbalance and leads to toxicity manifestation.",false,,,http://purl.obolibrary.org/obo/TXPO_0001779,,,,,,,,,,,,,,,,,,,,,,"In the imbalance model, the basic units are as follows:
1) a functioning process (supply) for biological defense and maintaining homeostasis;
2) a functional demand process (demand) as toxic activity;
3) balance/imbalance between toxic activity and defense processes; and
4) outcome from organelles, cells, or tissues to the organ exhibiting toxicity manifestations.

This entity  is a compound state that inculdes step 1 to 4.
The defense performance level is higher (H) than daily life; however, the functional demand level is Very high(VH), which leads to the imbalance and leads to toxicity manifestation.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001735,,,,,,,,,,,,,,,,,,TXPO:0001781,,,,,,,,,,,,,,,,,,,,,,toxicological imbalance H<VH,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001474,DOCK6,,,false,,,http://purl.obolibrary.org/obo/IMR_0001469,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001474,,,,,,,,,,,,,,,,,,,,,,DOCK6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002001,negative regulation of mitochondrial gene expression,,"Negative regulation of mitochondrial gene expression is a subtype of negative regulation of gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of mitochondrial gene expression.",false,,,http://purl.obolibrary.org/obo/GO_0010629,,,,,,,,,,,,,,,,,,,,negative regulation of mitochondrial gene expression|PMID:28285835,,"Negative regulation of mitochondrial gene expression is a subtype of negative regulation of gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of mitochondrial gene expression.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002001,,,,,,,The process in which a mitochondrial gene's sequence is converted into a mature gene product or products (proteins or RNA). This includes the production of an RNA transcript as well as any processing to produce a mature RNA product or an mRNA or circRNA (for protein-coding genes) and the translation of that mRNA or circRNA into protein. Protein maturation is included when required to form an active form of a product from an inactive precursor form.,,,,,,,,,,,,,,,negative regulation of mitochondrial gene expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002003,Acot1 (rat)[Uncoupling],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002014|http://purl.obolibrary.org/obo/TXPO_0002018,,,,,,,,,,,,,,,,,,,,http://omim.org/entry/614313|NCBI-Rat-GeneID:50559|NCBI-Human-GeneID:641371|NCBI-Mouse-GeneID:26897|PMID:26519955|PMID:22465940|PMID:28511854|PMID:28607105,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002003,,,,,,,,,,,,,,,,,,,,,,Acot1 (rat)[Uncoupling],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002002,protein serine/threonine/tyrosine kinase,ATP:protein phosphotransferase (Ser/Thr- and Tyr-phosphorylating),Catalysis role of the reactions: ATP + a protein serine = ADP + protein serine phosphate; ATP + a protein threonine = ADP + protein threonine phosphate; and ATP + a protein tyrosine = ADP + protein tyrosine phosphate.|related molecular function GO:0004712,false,,,http://purl.obolibrary.org/obo/TXPO_0001865,,,,,,,,,,,,,,,,,,,,EC:2.7.12.1,,Catalysis role of the reactions: ATP + a protein serine = ADP + protein serine phosphate; ATP + a protein threonine = ADP + protein threonine phosphate; and ATP + a protein tyrosine = ADP + protein tyrosine phosphate.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ATP:protein phosphotransferase (Ser/Thr- and Tyr-phosphorylating),,,,,TXPO:0002002,,,,,,,,,,,,,,,,,,,,related molecular function GO:0004712,,protein serine/threonine/tyrosine kinase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002005,hypofunction of mitochondrial fatty acid beta-oxidation [Mitochondrial disorder],,"Hypofunction of mitochondrial fatty acid beta-oxidation is a subtype of hypofunction of fatty acid beta-oxidation: A process that performs a decreased or insufficient fatty acid beta-oxidation.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0002112,,,,,,,,,,,,,,,,,,,"Mitochondria are responsible for beta oxidation of fatty acids.Inhibition of mitochondrial beta -oxidationleads to hepatic steatosis and/or hepatotoxicity.

DRUG INDUCED LIVER DISEASE CHAPTER 5,
3rd Ed.
Editors: Neil Kaplowitz Laurie DeLev
Hardcover ISBN: 9780123878175",PMID:31623280|PMID:21145849|PMID:31649547,,"Hypofunction of mitochondrial fatty acid beta-oxidation is a subtype of hypofunction of fatty acid beta-oxidation: A process that performs a decreased or insufficient fatty acid beta-oxidation.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004332|http://purl.obolibrary.org/obo/TXPO_0004335|http://purl.obolibrary.org/obo/TXPO_0004330|http://purl.obolibrary.org/obo/TXPO_0004339|http://purl.obolibrary.org/obo/TXPO_0004364|http://purl.obolibrary.org/obo/TXPO_0004361|http://purl.obolibrary.org/obo/TXPO_0004362|http://purl.obolibrary.org/obo/TXPO_0004363|http://purl.obolibrary.org/obo/TXPO_0004358|http://purl.obolibrary.org/obo/TXPO_0004353|http://purl.obolibrary.org/obo/TXPO_0004352,,,,,,http://purl.obolibrary.org/obo/TXPO_0001990|http://purl.obolibrary.org/obo/TXPO_0002040|http://purl.obolibrary.org/obo/TXPO_0002004|http://purl.obolibrary.org/obo/TXPO_0002230,,,,,,,,,,,TXPO:0002005,,,,,,,,,,,,,,,,,,,,,,hypofunction of mitochondrial fatty acid beta-oxidation [Mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002007,hypofunction of fatty acid degradation,,Hypofunction of fatty acid degradation is a subtype of hypofunction of lipid degradation: A process that performs a decreased or insufficient fatty acid degradation.,false,,,http://purl.obolibrary.org/obo/TXPO_0002006,,,,,,,,,,,,,,,,,,,,,,Hypofunction of fatty acid degradation is a subtype of hypofunction of lipid degradation: A process that performs a decreased or insufficient fatty acid degradation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000834,,,,,http://purl.obolibrary.org/obo/TXPO_0002147,,,,,,,,,,,,,,,,,,TXPO:0002007,,,,,,,,,,,,,,,,,,,,,,hypofunction of fatty acid degradation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002009,changing iron ion concentration [Mitochondrial disorder],,"Changing iron ion concentration is a subtype of changing concentration: A process that changes the iron (Fe) concentration in the blood to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0002343|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,,,"Changing iron ion concentration is a subtype of changing concentration: A process that changes the iron (Fe) concentration in the blood to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002009,,,,,,,,,,,,,,,,,,,,,,changing iron ion concentration [Mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002008,hypofunction of fatty acid beta-oxidation,,Hypofunction of fatty acid beta-oxidation is a subtype of hypofunction of fatty acid oxidation: A process that performs a decreased or insufficient fatty acid beta-oxidation.,false,,,http://purl.obolibrary.org/obo/TXPO_0002147|http://purl.obolibrary.org/obo/TXPO_0002007,,,,,,,,,,,,,,,,,,,,,,Hypofunction of fatty acid beta-oxidation is a subtype of hypofunction of fatty acid oxidation: A process that performs a decreased or insufficient fatty acid beta-oxidation.,,,http://purl.obolibrary.org/obo/GO_0006635,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002008,,,,,,,,,,,,,,,,,,,,,,hypofunction of fatty acid beta-oxidation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002000,GCLC inactivation,,GCLC inactivation is a subtype of molecular inactivation: A process that  changes the activity of the GCLC to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000021,,,,,,,,,,,,,,,,,,,,,,GCLC inactivation is a subtype of molecular inactivation: A process that  changes the activity of the GCLC to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002000,,,,,,,,,,,,,,,,,,,,,,GCLC inactivation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002006,hypofunction of lipid degradation,,Hypofunction of lipid degradation is a subtype of hypofunction of decomposing: A process that performs a decreased or insufficient lipid degradation.,false,,,http://purl.obolibrary.org/obo/TXPO_0000940,,,,,,,,,,,,,,,,,,,,,,Hypofunction of lipid degradation is a subtype of hypofunction of decomposing: A process that performs a decreased or insufficient lipid degradation.,,,http://purl.obolibrary.org/obo/GO_0006629,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002006,,,,,,,,,,,,,,,,,,,,,,hypofunction of lipid degradation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002004,lipid storage in liver [Mitochondrial disorder],,"Lipid storage in liver is a subtype of lipid storage: The accumulation and maintenance in cells or tissues of lipids in the liver.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001276|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:31623280|PMID:23299992|PMID:29222479,,"Lipid storage in liver is a subtype of lipid storage: The accumulation and maintenance in cells or tissues of lipids in the liver.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004360|http://purl.obolibrary.org/obo/TXPO_0004359,,,,,,,,,,,TXPO:0002004,,,,,,,,,,,,,,,,,,,,,,lipid storage in liver [Mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000002551,GABPA,,Other designations: GA binding protein transcription factor alpha subunit 60kDa|GA-binding protein alpha chain|GABP subunit alpha|human nuclear respiratory factor-2 subunit alpha|nuclear respiratory factor 2 alpha subunit|nuclear respiratory factor 2 subunit alpha|transcription factor E4TF1-60,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,NRF2|NFT2|E4TF1A|E4TF1-60|NRF2A|RCH04A07,,,,,,,,,,,,21,,,,,,HGNC:4071|Vega:OTTHUMG00000078443|Ensembl:ENSG00000154727|MIM:600609|HPRD:11793,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"GA binding protein transcription factor, alpha subunit 60kDa",,,21q21.3,,,,,,,,,,,,,,,,"GO_0000122 (EC: IEA); GO_0000790 (EC: IDA); GO_0000978 (EC: IDA); GO_0001228 (EC: IDA); GO_0001701 (EC: IEA); GO_0003677 (EC: TAS, PMID: 8441384); GO_0003682 (EC: IEA); GO_0003700 (EC: TAS, PMID: 7590737); GO_0003713 (EC: TAS, PMID: 8441384); GO_0005515 (EC: IPI, PMID: 10675337); GO_0005634 (EC: IDA); GO_0005730 (EC: IDA, Qualifier: NOT); GO_0006366 (EC: TAS, PMID: 8441384); GO_0030154 (EC: IBA); GO_0044212 (EC: IDA, PMID: 9857059); GO_0045653 (EC: IEA); GO_0045944 (EC: IDA); GO_0046982 (EC: IDA, PMID: 9857059)",,,,,,,,,PMID: 7590737; 7737900; 7799916; 8125298; 8441384; 8543189; 8889548; 9016666; 9461436; 9792629; 9857059; 9990060; 10585419; 10660899; 10675337; 10830953; 11237613; 11953439; 12107413; 12477932; 15361867; 15928042; 16574658; 16581781; 16712791; 17161026; 17304221; 17357964; 17439941; 18020712; 18029348; 18378679; 18660489; 18852034; 19116932; 19187944; 19324871; 19409485; 19424503; 19471022; 19687146; 19951946; 20028934; 20127517; 21624509; 21693764; 21774808; 21832049; 21890473; 21906983; 21988832; 22480519; 22505724; 22749526; 22863883; 22939629; 23000965; 23099293; 23284628; 23684612; 23856623; 24076158,,,,,,,,,,,,,,,OGG:3000002551,,,,,,,"GA binding protein transcription factor, alpha subunit 60kDa",,,,,,,,,,,,,Other designations: GA binding protein transcription factor alpha subunit 60kDa|GA-binding protein alpha chain|GABP subunit alpha|human nuclear respiratory factor-2 subunit alpha|nuclear respiratory factor 2 alpha subunit|nuclear respiratory factor 2 subunit alpha|transcription factor E4TF1-60,,GABPA,,,,,,,,,,,,,,,,,,,,,,,2551,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,GABPA,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/PATO_0002242,velocity quality,,A physical quality inhering in a bearer by virtue of the bearer's rate of change of the position.,false,,,http://purl.obolibrary.org/obo/PATO_0001906|http://purl.obolibrary.org/obo/TXPO_0001525,,,,,,,,,,,,,,,,,,,,,,A physical quality inhering in a bearer by virtue of the bearer's rate of change of the position.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0002242,,,,,,,,,,,,,,,,,,,,,,velocity quality,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000363,cytokeratin 12,,,false,,,http://purl.obolibrary.org/obo/IMR_0000035,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000363,,,,,,,,,,,,,,,,,,,,,,cytokeratin 12,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000084263,HSDL2,,"Other designations: hydroxysteroid dehydrogenase-like protein 2|short chain dehydrogenase/reductase family 13C, member 1",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,C9orf99|SDR13C1,,,,,,,,,,,,9,,,,,,Vega:OTTHUMG00000020504|Ensembl:ENSG00000119471|HPRD:13679|HGNC:18572,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,hydroxysteroid dehydrogenase like 2,,,9q32,,,,,,,,,,,,,,,,"GO_0003674 (EC: ND); GO_0005739 (EC: IEA); GO_0005777 (EC: IDA, PMID: 19703561); GO_0008150 (EC: ND); GO_0016491 (EC: IEA); GO_0032934 (EC: IEA)",,,,,,,,,PMID: 8125298; 12477932; 12834046; 14702039; 16344560; 16501878; 18369455; 19027726; 19703561; 20583170; 20877624; 21139048; 21890473; 22002062; 22082156; 22268729; 23455922; 23798571; 24244333; 24250222,,,,,,,,,,,,,,,OGG:3000084263,,,,,,,hydroxysteroid dehydrogenase like 2,,,,,,,,,,,,,"Other designations: hydroxysteroid dehydrogenase-like protein 2|short chain dehydrogenase/reductase family 13C, member 1",,HSDL2,,,,,,,,,,,,,,,,,,,,,,,84263,RP11-32M23.1,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,HSDL2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_44032,indinavir,"(1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-Pentonamide|2-benzyl-5-[(2S)-2-(tert-butylcarbamoyl)-4-(pyridin-3-ylmethyl)piperazin-1-yl]-2,3,5-trideoxy-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-D-erythro-pentonamide|(2S)-1-[(2S,4R)-4-benzyl-2-hydroxy-5-{[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino}-5-oxopentyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide|Indinavir",,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,LINCS:LSM-5471|CAS:150378-17-9|DrugBank:DB00224|Drug_Central:1437,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35660,,,,,"2-benzyl-5-[(2S)-2-(tert-butylcarbamoyl)-4-(pyridin-3-ylmethyl)piperazin-1-yl]-2,3,5-trideoxy-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-D-erythro-pentonamide|(2S)-1-[(2S,4R)-4-benzyl-2-hydroxy-5-{[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino}-5-oxopentyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide|Indinavir",,"(1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-Pentonamide",,,,,,,,,,,,,,,,,,,,,CHEBI:44032,,,,indinavir,,CHEBI:44032,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0030198,extracellular matrix organization,,"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of structures in the space external to the outermost structure of a cell. For cells without external protective or external encapsulating structures this refers to space outside of the plasma membrane, and also covers the host cell environment outside an intracellular parasite.",false,,,http://purl.obolibrary.org/obo/TXPO_0000468,,,,,,,,,,,,,,,,,,,,,,"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of structures in the space external to the outermost structure of a cell. For cells without external protective or external encapsulating structures this refers to space outside of the plasma membrane, and also covers the host cell environment outside an intracellular parasite.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0030198,,,,,,,,,,,,,,,,,,,,,,extracellular matrix organization,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000227,ERK1/2,p42/p44 MAP kinase|p42/p44 MAPK|MAPK/ERK|ERK|Extracellular signal-regulated kinase,"ERK1 and ERK2 are isoforms of the 'classical' MAPK. Both ERK1 and ERK2 (referred to as ERK1/2) are activated by MAP/ERK kinase 1 (MEK1) and MEK2 (referred to as MEK1/2). MEK1/2 phosphorylates threonine and tyrosine residues in the Thr-Glu-Tyr (TEY) sequence of ERK1/2. Activated ERK1/2 phosphorylates many substrates including transcription factors, such as Elk1 and c-Myc, and protein kinases, such as ribosomal S6 kinase (RSK).",false,,,http://purl.obolibrary.org/obo/IMR_0000224,,,,,,,,,,,,,,,,,,,,IPR:008349,,"ERK1 and ERK2 are isoforms of the 'classical' MAPK. Both ERK1 and ERK2 (referred to as ERK1/2) are activated by MAP/ERK kinase 1 (MEK1) and MEK2 (referred to as MEK1/2). MEK1/2 phosphorylates threonine and tyrosine residues in the Thr-Glu-Tyr (TEY) sequence of ERK1/2. Activated ERK1/2 phosphorylates many substrates including transcription factors, such as Elk1 and c-Myc, and protein kinases, such as ribosomal S6 kinase (RSK).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p42/p44 MAP kinase|p42/p44 MAPK|MAPK/ERK|ERK|Extracellular signal-regulated kinase,,,,,IMR:0000227,,,,,,,,,,,,,,,,,,,,,,ERK1/2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002522,CAD accumulation in lysosome [Phospholipidosis (latent)],,"CAD accumulation in lysosome is a subtype of compound accumulation in lysosome: A process that keeps CAD (Cationic Amphiphilic Drugs) in the lysosome.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (latent).",false,,,http://purl.obolibrary.org/obo/TXPO_0003367,,,,,,,,,,,,,,,,,,,,,,"CAD accumulation in lysosome is a subtype of compound accumulation in lysosome: A process that keeps CAD (Cationic Amphiphilic Drugs) in the lysosome.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (latent).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001908,,,,,,,,,,,TXPO:0002522,,,,,,,,,,,,,,,,,,,,,,CAD accumulation in lysosome [Phospholipidosis (latent)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002529,aggregated protein production- degradation imbalance [ER stress],,"Aggregated protein production- degradation imbalance is a subtype of imbalance: A process that lacks a balance between aggregated protein production and degradation.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002530|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"Aggregated protein production- degradation imbalance is a subtype of imbalance: A process that lacks a balance between aggregated protein production and degradation.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002532,,,,,,,,,,,TXPO:0002529,,,,,,,,,,,,,,,,,,,,,,aggregated protein production- degradation imbalance [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002521,The process in which a gene's sequence is converted into a mature gene product or products (proteins or RNA) by ATF6.,gene expression by ATF6,The process in which a gene's sequence is converted into a mature gene product or products (proteins or RNA) by ATF6. is a subtype of Gene expression by transcriptional regulator: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) by ATF6.,false,,,http://purl.obolibrary.org/obo/TXPO_0000375,,,,,,,,,,,,,,,,,,,,,,The process in which a gene's sequence is converted into a mature gene product or products (proteins or RNA) by ATF6. is a subtype of Gene expression by transcriptional regulator: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) by ATF6.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,gene expression by ATF6,,,,,TXPO:0002521,,,,,,,,,,,,,,,,,,,,,,The process in which a gene's sequence is converted into a mature gene product or products (proteins or RNA) by ATF6.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002528,endoplasmic reticulum stress [toxic course],ER stress [toxic course],The totality of all processes through which endoplasmic reticulum (ER) stress is realized.,false,,,http://purl.obolibrary.org/obo/TXPO_0000009,,,,,,,,,,,,,,,,,,,,PMID:26977301|PMID:17765679|PMID:23334697|PMID:22883813|MeSH:D059865|PMID:23022383,,The totality of all processes through which endoplasmic reticulum (ER) stress is realized.,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002175,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003490|http://purl.obolibrary.org/obo/TXPO_0002539|http://purl.obolibrary.org/obo/TXPO_0002533|http://purl.obolibrary.org/obo/TXPO_0002532|http://purl.obolibrary.org/obo/TXPO_0002534|http://purl.obolibrary.org/obo/TXPO_0002535|http://purl.obolibrary.org/obo/TXPO_0002746|http://purl.obolibrary.org/obo/TXPO_0002460|http://purl.obolibrary.org/obo/TXPO_0000752|http://purl.obolibrary.org/obo/TXPO_0000758|http://purl.obolibrary.org/obo/TXPO_0002161|http://purl.obolibrary.org/obo/TXPO_0002200|http://purl.obolibrary.org/obo/TXPO_0002209|http://purl.obolibrary.org/obo/TXPO_0002204|http://purl.obolibrary.org/obo/TXPO_0002207|http://purl.obolibrary.org/obo/TXPO_0002201|http://purl.obolibrary.org/obo/TXPO_0000386|http://purl.obolibrary.org/obo/TXPO_0000831|http://purl.obolibrary.org/obo/TXPO_0000206|http://purl.obolibrary.org/obo/TXPO_0000204|http://purl.obolibrary.org/obo/TXPO_0000342|http://purl.obolibrary.org/obo/TXPO_0000760|http://purl.obolibrary.org/obo/TXPO_0000767|http://purl.obolibrary.org/obo/TXPO_0000214|http://purl.obolibrary.org/obo/TXPO_0003270|http://purl.obolibrary.org/obo/TXPO_0003276|http://purl.obolibrary.org/obo/TXPO_0002458|http://purl.obolibrary.org/obo/TXPO_0001977|http://purl.obolibrary.org/obo/TXPO_0000513|http://purl.obolibrary.org/obo/TXPO_0001965|http://purl.obolibrary.org/obo/TXPO_0000413|http://purl.obolibrary.org/obo/TXPO_0003598|http://purl.obolibrary.org/obo/TXPO_0000170|http://purl.obolibrary.org/obo/TXPO_0000250|http://purl.obolibrary.org/obo/TXPO_0001810|http://purl.obolibrary.org/obo/TXPO_0002529|http://purl.obolibrary.org/obo/TXPO_0002470|http://purl.obolibrary.org/obo/TXPO_0002479|http://purl.obolibrary.org/obo/TXPO_0002194|http://purl.obolibrary.org/obo/TXPO_0002199|http://purl.obolibrary.org/obo/TXPO_0002197|http://purl.obolibrary.org/obo/TXPO_0002191|http://purl.obolibrary.org/obo/TXPO_0002116|http://purl.obolibrary.org/obo/TXPO_0002114|http://purl.obolibrary.org/obo/TXPO_0002544|http://purl.obolibrary.org/obo/TXPO_0002505|http://purl.obolibrary.org/obo/TXPO_0002503|http://purl.obolibrary.org/obo/TXPO_0002502|http://purl.obolibrary.org/obo/TXPO_0002175|http://purl.obolibrary.org/obo/TXPO_0002171|http://purl.obolibrary.org/obo/TXPO_0002172|http://purl.obolibrary.org/obo/TXPO_0000722|http://purl.obolibrary.org/obo/TXPO_0003008|http://purl.obolibrary.org/obo/TXPO_0000817|http://purl.obolibrary.org/obo/TXPO_0002751|http://purl.obolibrary.org/obo/TXPO_0000569|http://purl.obolibrary.org/obo/TXPO_0001455|http://purl.obolibrary.org/obo/TXPO_0002188,,,,,,,,,,,,,ER stress [toxic course],,,,,TXPO:0002528,,,,,,,"The ER stress is a cellular response that occurs after sustained pertubation of ER protein synthesis, folding, and export machinery. Tis is likely to be induced by oxidative or covalent modification of ER proteins, which leads to misfolding of proteins.",,,,,,,,,,,,,,,endoplasmic reticulum stress [toxic course],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002526,NRf2 gene expression regulation system,,"NRF2 gene expression regulation system is a subtype of pathway system.
This entity has sub-parts and has a goal of regulating gene expressions by NRF2 as a systemic context.",false,,,http://purl.obolibrary.org/obo/TXPO_0000887,,,,,,,,,,,,,,,,,,,,,,"NRF2 gene expression regulation system is a subtype of pathway system.
This entity has sub-parts and has a goal of regulating gene expressions by NRF2 as a systemic context.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002526,,,,,,,,,,,,,,,,,,,,,,NRf2 gene expression regulation system,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002520,ATF6 gene regulation pathway,,ATF6 gene regulation pathway is a subtype of gene regulation pathway: Sequence of reactions to regulate genes by ATF6.,false,,,http://purl.obolibrary.org/obo/TXPO_0001902,,,,,,,,,,,,,,,,,,,,https://www.wikipathways.org/index.php/Pathway:WP2655|Reactome ID: 381183,,ATF6 gene regulation pathway is a subtype of gene regulation pathway: Sequence of reactions to regulate genes by ATF6.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002521,,,,,,,,,,,,,,,,,,TXPO:0002520,,,,,,,,,,,,,,,,,,,,,,ATF6 gene regulation pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002527,NRF2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:18024|NCBI-Rat-GeneID:83619|NCBI-Human-GeneID:4780,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000004780,,,http://purl.obolibrary.org/obo/TXPO_0003645,,,,,,,,,,TXPO:0002527,,,,,,,,,,,,,,,,,,,,,,NRF2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OBI_0302867,predicted data item,,A data item that was generated on the basis of a calculation or logical reasoning,false,,,http://purl.obolibrary.org/obo/TXPO_0000614,,,,,,,,,,,,,,,,,,,,,,A data item that was generated on the basis of a calculation or logical reasoning,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,OBI:0302867,,,,,,,,,,,,,,,,,,,,,,predicted data item,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_50924,sorafenib,sorafenibum|4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide|N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea|sorafenib|4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide,"A member of the class of phenylureas that is urea in which one of the nitrogens is substituted by a 4-chloro-3-trifluorophenyl group while the other is substituted by a phenyl group which, in turn, is substituted at the para position by a [2-(methylcarbamoyl)pyridin-4-yl]oxy group.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:284461-73-0|LINCS:LSM-1008|DrugBank:DB00398|Drug_Central:2459,,"A member of the class of phenylureas that is urea in which one of the nitrogens is substituted by a 4-chloro-3-trifluorophenyl group while the other is substituted by a phenyl group which, in turn, is substituted at the para position by a [2-(methylcarbamoyl)pyridin-4-yl]oxy group.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35610|http://purl.obolibrary.org/obo/CHEBI_50925|http://purl.obolibrary.org/obo/CHEBI_38637|http://purl.obolibrary.org/obo/CHEBI_36044|http://purl.obolibrary.org/obo/CHEBI_48422,,,,,4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide,,sorafenibum|4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide|N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea|sorafenib,,,,,,,,,,,,,,,,,,,,,CHEBI:50924,,,,sorafenib,,CHEBI:50924,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000187,paxillin,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000188|http://purl.obolibrary.org/obo/TXPO_0003657,,,,,,,,,,IMR:0000187,,,,,,,,,,,,,,,,,,,,,,paxillin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_16761,AMP,Adenosine 5'-monophosphate,A purine ribonucleoside 5'-diphosphate having adenine as the nucleobase.,false,,,http://purl.obolibrary.org/obo/CHEBI_36976,,,,,,,,,,,,,,,,,,,,CAS:20398-34-9|A purine ribonucleoside 5'-diphosphate having adenine as the nucleobase.,,A purine ribonucleoside 5'-diphosphate having adenine as the nucleobase.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Adenosine 5'-monophosphate,,,,,CHEBI:16761,,,,,,,,,,,,,,,,,,,,,,AMP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0008625,extrinsic apoptotic signaling pathway via death domain receptors,,"A series of molecular signals in which a signal is conveyed from the cell surface to trigger the apoptotic death of a cell. The pathway starts with a ligand binding to a death domain receptor on the cell surface, and ends when the execution phase of apoptosis is triggered.",false,,,http://purl.obolibrary.org/obo/TXPO_0000611,,,,,,,,,,,,,,,,,,,,"PMID:21525013|https://reactome.org/PathwayBrowser/#/R-HSA-140534&PATH=R-HSA-5357801,R-HSA-109581,R-HSA-5357769",,"A series of molecular signals in which a signal is conveyed from the cell surface to trigger the apoptotic death of a cell. The pathway starts with a ligand binding to a death domain receptor on the cell surface, and ends when the execution phase of apoptosis is triggered.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0008625,,,,,,,,,,,,,,,,,,,,,,extrinsic apoptotic signaling pathway via death domain receptors,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000005366,PMAIP1,,Other designations: PMA-induced protein 1|adult T cell leukemia-derived PMA-responsive|immediate-early-response protein APR|protein Noxa,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,NOXA|APR,,,,,,,,,,,,18,,,,,,Ensembl:ENSG00000141682|MIM:604959|HPRD:12002|Vega:OTTHUMG00000132765|HGNC:9108,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,phorbol-12-myristate-13-acetate-induced protein 1,,,18q21.32,,,,,,,,,,,,,,,,"GO_0001836 (EC: IEA); GO_0005515 (EC: IPI, PMID: 15705586); GO_0005634 (EC: IDA, PMID: 12879012); GO_0005739 (EC: IDA, PMID: 14500711); GO_0005741 (EC: TAS); GO_0005829 (EC: IDA, PMID: 15705586); GO_0005829 (EC: TAS); GO_0006915 (EC: IMP, PMID: 17599062); GO_0006915 (EC: TAS); GO_0006919 (EC: IEA); GO_0009411 (EC: IEA); GO_0010165 (EC: IEA); GO_0010498 (EC: IDA, PMID: 15901672); GO_0010907 (EC: IDA); GO_0010917 (EC: ISS, PMID: 14699081); GO_0032461 (EC: IDA, PMID: 17024184); GO_0042149 (EC: IMP); GO_0042771 (EC: IEA); GO_0043029 (EC: ISS); GO_0043065 (EC: IDA); GO_0043065 (EC: IMP, PMID: 17289999); GO_0043280 (EC: IDA, PMID: 14699081); GO_0043331 (EC: IDA, PMID: 15705586); GO_0043517 (EC: IMP, PMID: 15102863); GO_0043525 (EC: IEA); GO_0046902 (EC: IDA, PMID: 14500711); GO_0048147 (EC: IEA); GO_0051607 (EC: IDA, PMID: 15705586); GO_0071456 (EC: IEP, PMID: 14699081); GO_0072332 (EC: IMP, PMID: 15102863); GO_0072593 (EC: IDA, PMID: 14699081); GO_0090200 (EC: IDA, PMID: 14500711); GO_0090200 (EC: IMP, PMID: 15705586); GO_0097193 (EC: IDA, PMID: 14500711); GO_0097193 (EC: TAS); GO_1900740 (EC: TAS); GO_1902043 (EC: IDA, PMID: 15705586); GO_2001244 (EC: IDA); GO_2001244 (EC: TAS)",,,,,,,,,PMID: 2398525; 10807576; 11181995; 12477932; 12879012; 14500711; 14699081; 15102863; 15299072; 15489334; 15572378; 15694340; 15705586; 15856024; 15901672; 16169070; 16697956; 16782027; 16888645; 16928686; 17024184; 17038534; 17216584; 17227835; 17289999; 17599062; 18192275; 18231856; 18354037; 18398749; 18408751; 18630524; 18708163; 18784742; 19050264; 19148187; 19164757; 19269851; 19298224; 19322201; 19372561; 19452318; 19515722; 19540835; 19815839; 20051518; 20085765; 20156337; 20223826; 20393480; 20639865; 20694148; 20802529; 20935673; 21048031; 21113147; 21139048; 21139584; 21145489; 21153863; 21353614; 21454712; 21516346; 21518486; 21613222; 21628457; 21698224; 21890473; 21900206; 21906983; 21907705; 21911456; 22053931; 22216287; 22219388; 22245094; 22361683; 22430213; 22446329; 22548841; 22590594; 22615771; 22718761; 23000965; 23014529; 23300762; 23302226; 23341456; 23429261; 23499448; 23669352; 23684722; 23770605; 23798675,,,,,,,,,,,,,,,OGG:3000005366,,20140408,protein-coding,,,,phorbol-12-myristate-13-acetate-induced protein 1,,,,,,,,,,,,,Other designations: PMA-induced protein 1|adult T cell leukemia-derived PMA-responsive|immediate-early-response protein APR|protein Noxa,,PMAIP1,,,,,,,,,,,,,,,,,,,,,,,5366,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,PMAIP1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_51451,endothelin receptor antagonist,ERA,A hormone antagonist that blocks endothelin receptors.,false,,,http://purl.obolibrary.org/obo/CHEBI_49020,,,,,,,,,,,,,,,,,,,,,,A hormone antagonist that blocks endothelin receptors.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ERA,,,,,,,,,,,,,,,,,,,,,CHEBI:51451,,,,endothelin receptor antagonist,,CHEBI:51451,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001592,Rab12,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001592,,,,,,,,,,,,,,,,,,,,,,Rab12,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100745,TCF-1,TCF7|Transcription factor 7|T-cell-specific transcription factor 1|T-cell factor 1|TCF-1,,false,,,http://purl.obolibrary.org/obo/IMR_0000418,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TCF7|Transcription factor 7|T-cell-specific transcription factor 1|T-cell factor 1|TCF-1,,,,,IMR:0100745,,,,,,,,,,,,,,,,,,,,,,TCF-1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0000970,permeability,,A structural quality inhering in a bearer by virtue of the bearer's disposition to being permeated or pervaded by a gas or liquid (as by osmosis or diffusion).,false,,,http://purl.obolibrary.org/obo/TXPO_0003744|http://purl.obolibrary.org/obo/BFO_0000019,,,,,,,,,,,,,,,,,,,,,,A structural quality inhering in a bearer by virtue of the bearer's disposition to being permeated or pervaded by a gas or liquid (as by osmosis or diffusion).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0000970,,,,,,,,,,,,,,,,,,,,,,permeability,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_39123,calcium cation,,,false,,,http://purl.obolibrary.org/obo/CHEBI_39124,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:39123,,,,,,,,,,,,,,,,,,,,,,calcium cation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100627,cyclin K,,,false,,,http://purl.obolibrary.org/obo/IMR_0100606,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100627,,,,,,,,,,,,,,,,,,,,,,cyclin K,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/NCIT_C1029,Buthionine sulfoximine,BSO,"A synthetic amino acid. Buthionine sulfoximine irreversibly inhibits gamma-glutamylcysteine synthase, thereby depleting cells of glutathione, a metabolite that plays a critical role in protecting cells against oxidative stress, and resulting in free radical-induced apoptosis. Elevated glutathione levels are associated with tumor cell resistance to alkylating agents and platinum compounds. By depleting cells of glutathione, this agent may enhance the in vitro and in vivo cytotoxicities of various chemotherapeutic agents in drug-resistant tumors. Buthionine sulfoximine may also exhibit antiangiogenesis activity. (NCI04)",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,,,"A synthetic amino acid. Buthionine sulfoximine irreversibly inhibits gamma-glutamylcysteine synthase, thereby depleting cells of glutathione, a metabolite that plays a critical role in protecting cells against oxidative stress, and resulting in free radical-induced apoptosis. Elevated glutathione levels are associated with tumor cell resistance to alkylating agents and platinum compounds. By depleting cells of glutathione, this agent may enhance the in vitro and in vivo cytotoxicities of various chemotherapeutic agents in drug-resistant tumors. Buthionine sulfoximine may also exhibit antiangiogenesis activity. (NCI04)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BSO,,,NCIT:C1029,,,,,,,,,,,,,,,,,,,,,,Buthionine sulfoximine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_2100009606,ncRNA gene of Homo sapiens,,A gene of Homo sapiens that has a ncRNA gene disposition,false,,,http://purl.obolibrary.org/obo/OGG_2110009606,,,,,,,,,,,,,,,,,,,,,,A gene of Homo sapiens that has a ncRNA gene disposition,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,OGG:2100009606,,,,,,,,,,,,,,,,,,,,,,ncRNA gene of Homo sapiens,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9606,,,,,,,,,,,,,,,,,,,,,"Bin Zhao, Oliver He"
http://purl.obolibrary.org/obo/UBERON_0000160,intestine,,"Segment of the alimentary canal extending from the stomach to the anus and, in humans and other mammals, consists of two segments, the small intestine and the large intestine",false,,,http://purl.obolibrary.org/obo/UBERON_0013765,,,,,,,,,,,,,,,,,,,,,,"Segment of the alimentary canal extending from the stomach to the anus and, in humans and other mammals, consists of two segments, the small intestine and the large intestine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0001007,UBERON:0000160,http://purl.obolibrary.org/obo/UBERON_0001007,,,,,,,,,,,,,,,,,,,,,intestine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_64355,posaconazole,"Schering 56592|SCH56592|posaconazole|Noxafil|Sch 56592|2,5-anhydro-1,3,4-trideoxy-2-(2,4-difluorophenyl)-4-({4-[4-(4-{1-[(2S,3S)-2-hydroxypentan-3-yl]-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl}phenyl)piperazin-1-yl]phenoxy}methyl)-1-(1H-1,2,4-triazol-1-yl)-D-threo-pentitol",An N-arylpiperazine that consists of piperazine carrying two 4-substituted phenyl groups at positions 1 and 4. A triazole antifungal drug.,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:22303909|PMID:22427614|PMID:22286158|PMID:22215361|PMID:21967490|DrugBank:DB01263|PMID:21762211|PMID:22380765|PMID:22324990|PMID:22330929|PMID:22215487|PMID:22290952|PMID:22176629|Reaxys:8379448|PMID:22391464|Drug_Central:3483|CAS:171228-49-2|PMID:22391534|PMID:22058198,,An N-arylpiperazine that consists of piperazine carrying two 4-substituted phenyl groups at positions 1 and 4. A triazole antifungal drug.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_36335,,,,,"2,5-anhydro-1,3,4-trideoxy-2-(2,4-difluorophenyl)-4-({4-[4-(4-{1-[(2S,3S)-2-hydroxypentan-3-yl]-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl}phenyl)piperazin-1-yl]phenoxy}methyl)-1-(1H-1,2,4-triazol-1-yl)-D-threo-pentitol",,Schering 56592|SCH56592|posaconazole|Noxafil|Sch 56592,,,,,,,,,,,,,,,,,,,,,CHEBI:64355,,,,posaconazole,,CHEBI:64355,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100347,RasGRF1,,,false,,,http://purl.obolibrary.org/obo/IMR_0000440,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100347,,,,,,,,,,,,,,,,,,,,,,RasGRF1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004785,PTPRD inactivation,,PTPRD inactivation is a subtype of molecular inactivation: A process that  changes the activity of the PTPRD (protein tyrosine phosphatase receptor type D) to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000021,,,,,,,,,,,,,,,,,,,,,,PTPRD inactivation is a subtype of molecular inactivation: A process that  changes the activity of the PTPRD (protein tyrosine phosphatase receptor type D) to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004785,,,,,,,,,,,,,,,,,,,,,,PTPRD inactivation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004781,Increasing PROX1 level,,Increasing PROX1 level is a subtype of increasing quantity: A process that changes the amount of PROX1 level to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing PROX1 level is a subtype of increasing quantity: A process that changes the amount of PROX1 level to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004782,,,,,,,,,,,,,,,,,,,TXPO:0004781,,,,,,,,,,,,,,,,,,,,,,Increasing PROX1 level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004786,PTPRD - inactive form (predicted)(human) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004186|http://purl.obolibrary.org/obo/TXPO_0004185,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:5789|PMID:25796501|PMID:25831062,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657|http://purl.obolibrary.org/obo/PATO_0002355,,,,,,,,,,,,,,TXPO:0004786,,,,,,,,,,,,,,,,,,,,,,PTPRD - inactive form (predicted)(human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004783,Increasing PROX1 level [hepatocarcinogenesis],,"Increasing PROX1 level is a subtype of increasing quantity: A process that changes the amount of PROX1 level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004781,,,,,,,,,,,,,,,,,,,,PMID:28646551,,"Increasing PROX1 level is a subtype of increasing quantity: A process that changes the amount of PROX1 level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004784,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004298,,,,,,,,,,,TXPO:0004783,,,,,,,,,,,,,,,,,,,,,,Increasing PROX1 level [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004787,STAT3 activation [hepatocarcinogenesis],,"STAT3 activation is a subtype of molecular activation: A process that changes the activity of the STAT3 to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004326,,,,,,,,,,,,,,,,,,,,PMID:28159835,,"STAT3 activation is a subtype of molecular activation: A process that changes the activity of the STAT3 to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004758|http://purl.obolibrary.org/obo/TXPO_0004595|http://purl.obolibrary.org/obo/TXPO_0004392,,,,,,,,,,,TXPO:0004787,,,,,,,,,,,,,,,,,,,,,,STAT3 activation [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004788,PTPRD gene promoter methylation,,The covalent transfer of a methyl group to PTPRD gene promoter.,false,,,http://purl.obolibrary.org/obo/GO_0006306,,,,,,,,,,,,,,,,,,,,,,The covalent transfer of a methyl group to PTPRD gene promoter.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004788,,,,,,,,,,,,,,,,,,,,,,PTPRD gene promoter methylation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004789,PTPRD gene promoter methylation [hepatocarcinogenesis],,"The covalent transfer of a methyl group to PTPRD gene promoter.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004788,,,,,,,,,,,,,,,,,,,,PMID:25831062,,"The covalent transfer of a methyl group to PTPRD gene promoter.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004186,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004693,,,,,,,,,,,TXPO:0004789,,,,,,,,,,,,,,,,,,,,,,PTPRD gene promoter methylation [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004780,PROM1 (human) [hepatocarcinogenesis],CD133,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_0004778,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:8842|PMID:28584306,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CD133,,,,,TXPO:0004780,,,,,,,,,,,,,,,,,,,,,,PROM1 (human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004782,PROX1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:19130|NCBI-Rat-GeneID:305066|NCBI-Human-GeneID:5629,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004782,,,,,,,,,,,,,,,,,,,,,,PROX1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004784,PROX1 (human) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_0004782,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:5629|PMID:28646551,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004784,,,,,,,,,,,,,,,,,,,,,,PROX1 (human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000406942,MIR150,,,false,,,http://purl.obolibrary.org/obo/OGG_2100009606,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:406942,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,OGG:3000406942,,,,,,,,,,,,,,,,,,,,,,MIR150,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9606,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002299,creatine kinase,,Catalysis role of the reaction: ATP + creatine = N-phosphocreatine + ADP + 2 H(+).|related molecular function GO:0004111,false,,,http://purl.obolibrary.org/obo/TXPO_0001515,,,,,,,,,,,,,,,,,,,,IMR:0002602 (obsolete)|EC:2.7.3.2,,Catalysis role of the reaction: ATP + creatine = N-phosphocreatine + ADP + 2 H(+).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002299,,,,,,,"In both mammals and birds, the creatine kinase (CK) family consists of four types of genes: cytosolic brain type (B-CK); cytosolic muscle type (M-CK); mitochondrial ubiquitous, acidic type (Mia-CK); and mitochondrial sarcomeric, basic type (Mib-CK).",,,,,,,,,,,,,related molecular function GO:0004111,,creatine kinase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002296,di-22:6-BMP [Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001849|http://purl.obolibrary.org/obo/CHEBI_60815,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_60815,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002296,,,,,,,,,,,,,,,,,,,,,,di-22:6-BMP [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002295,hypofunction of phospholipase gene expression,"decreasing function of phospholipase transcription, DNA-templated","Hypofunction of phospholipase gene expression is a subtype of hypofunction of transcription, DNA-templated: A process that performs a decreased or insufficient phospholipase gene expression.",false,,,http://purl.obolibrary.org/obo/TXPO_0002356,,,,,,,,,,,,,,,,,,,,,,"Hypofunction of phospholipase gene expression is a subtype of hypofunction of transcription, DNA-templated: A process that performs a decreased or insufficient phospholipase gene expression.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"decreasing function of phospholipase transcription, DNA-templated",,,,,TXPO:0002295,,,,,,,,,,,,,,,,,,,,,,hypofunction of phospholipase gene expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002291,Gstm3 (mouse)[Glutathione depletion],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000180|http://purl.obolibrary.org/obo/TXPO_0002285,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:14864|PMID:22496397|PMID:25202346,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002291,,,,,,,,,,,,,,,,,,,,,,Gstm3 (mouse)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002290,PLA2G5 - anntiinflammation factor (human)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001142,,,,,,,,,,,,,,,,,,,,http://omim.org/entry/601192|PMID:14998370|PMID:25716287|PMID:24910243,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000283,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002289,,,,,,,,,,TXPO:0002290,,,,,,,,,,,,,,,,,,,,,,PLA2G5 - anntiinflammation factor (human)[Phospholipidosis],,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000136,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002298,JNK (canonical)[Glutathione depletion],,,false,,,http://purl.obolibrary.org/obo/IMR_0000225|http://purl.obolibrary.org/obo/TXPO_1000216|http://purl.obolibrary.org/obo/TXPO_0002045,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:5599|NCBI-Mouse-GeneID:26419|NCBI-Rat-GeneID:116554,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002298,,,,,,,,,,,,,,,,,,,,,,JNK (canonical)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002297,negative regulation of endocytosis [Phospholipidosis (severe) ],,"Any process that stops, prevents, or reduces the frequency, rate or extent of endocytosis. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/GO_0045806,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents, or reduces the frequency, rate or extent of endocytosis. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000911|http://purl.obolibrary.org/obo/TXPO_0000717,,,,,,,,,,,TXPO:0002297,,,,,,,,,,,,,,,,,,,,,,negative regulation of endocytosis [Phospholipidosis (severe) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002293,phospholipid metabolism balance [Phospholipidosis (latent) ],,"Phospholipid metabolism balance is a subtype of maintaining balance: A process that keeps a balance of phospholipid metabolism.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (latent).",false,,,http://purl.obolibrary.org/obo/TXPO_0001434|http://purl.obolibrary.org/obo/TXPO_0000946,,,,,,,,,,,,,,,,,,,,,,"Phospholipid metabolism balance is a subtype of maintaining balance: A process that keeps a balance of phospholipid metabolism.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (latent).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002273,,http://purl.obolibrary.org/obo/TXPO_0002076,,,,,,,,,TXPO:0002293,,,,,,,,,,,,,,,,,,,,,,phospholipid metabolism balance [Phospholipidosis (latent) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002294,NFKB1 (canonical)[Phospholipidosis],,"This gene encodes a 105 kD protein which can undergo cotranslational processing by the 26S proteasome to produce a 50 kD protein. The 105 kD protein is a Rel protein-specific transcription inhibitor and the 50 kD protein is a DNA binding subunit of the NF-kappa-B (NFKB) protein complex. NFKB is a transcription regulator that is activated by various intra- and extra-cellular stimuli such as cytokines, oxidant-free radicals, ultraviolet irradiation, and bacterial or viral products. Activated NFKB translocates into the nucleus and stimulates the expression of genes involved in a wide variety of biological functions. Inappropriate activation of NFKB has been associated with a number of inflammatory diseases while persistent inhibition of NFKB leads to inappropriate immune cell development or delayed cell growth. Alternative splicing results in multiple transcript variants encoding different isoforms, at least one of which is proteolytically processed. [provided by RefSeq, Feb 2016]",false,,,http://purl.obolibrary.org/obo/TXPO_0003213|http://purl.obolibrary.org/obo/TXPO_1000251,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:81736|NCBI-Mouse-GeneID:18033|NCBI-Human-GeneID:4790|https://omim.org/entry/164011|PMID:20457564,,"This gene encodes a 105 kD protein which can undergo cotranslational processing by the 26S proteasome to produce a 50 kD protein. The 105 kD protein is a Rel protein-specific transcription inhibitor and the 50 kD protein is a DNA binding subunit of the NF-kappa-B (NFKB) protein complex. NFKB is a transcription regulator that is activated by various intra- and extra-cellular stimuli such as cytokines, oxidant-free radicals, ultraviolet irradiation, and bacterial or viral products. Activated NFKB translocates into the nucleus and stimulates the expression of genes involved in a wide variety of biological functions. Inappropriate activation of NFKB has been associated with a number of inflammatory diseases while persistent inhibition of NFKB leads to inappropriate immune cell development or delayed cell growth. Alternative splicing results in multiple transcript variants encoding different isoforms, at least one of which is proteolytically processed. [provided by RefSeq, Feb 2016]",,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000382,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,,,,,,TXPO:0002294,,,,,,,,,,,,,,,,,,,,,,NFKB1 (canonical)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002292,protein tyrosine kinase,PTK,Catalysis of the reaction: ATP + a protein tyrosine = ADP + protein tyrosine phosphate.|related molecular function GO:0004713,false,,,http://purl.obolibrary.org/obo/TXPO_0001865,,,,,,,,,,,,,,,,,,,,,,Catalysis of the reaction: ATP + a protein tyrosine = ADP + protein tyrosine phosphate.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PTK,,,,,TXPO:0002292,,,,,,,,,,,,,,,,,,,,related molecular function GO:0004713,,protein tyrosine kinase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004310,decreasing mtDNA level,,Decreasing mtDNA level is a subtype of decreasing quantity: A process that changes the amount of mtDNA level to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000396,,,,,,,,,,,,,,,,,,,,,,Decreasing mtDNA level is a subtype of decreasing quantity: A process that changes the amount of mtDNA level to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004310,,,,,,,,,,,,,,,,,,,,,,decreasing mtDNA level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004319,IL-6(human)[mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003603|http://purl.obolibrary.org/obo/IMR_0000010,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:3569|PMID:25181692|PMID:31623280,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003724,,,,,,,,,,TXPO:0004319,,,,,,,,,,,,,,,,,,,,,,IL-6(human)[mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004311,mitochondrial fission [hepatocarcinogenesis],,"The division of a mitochondrion within a cell to form two or more separate mitochondrial compartments.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/GO_0000266|http://purl.obolibrary.org/obo/TXPO_0002340,,,,,,,,,,,,,,,,,,,,PMID:30894684,,"The division of a mitochondrion within a cell to form two or more separate mitochondrial compartments.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004233,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004309,,,,,,,,,,,TXPO:0004311,,,,,,,,,,,,,,,,,,,,,,mitochondrial fission [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004317,radicals [mitochondrial disorder],free radical,A molecular entity possessing an unpaired electron.,false,,,http://purl.obolibrary.org/obo/TXPO_0004312|http://purl.obolibrary.org/obo/CHEBI_26519,,,,,,,,,,,,,,,,,,,,,,A molecular entity possessing an unpaired electron.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,free radical,,,,,TXPO:0004317,,,,,,,,,,,,,,,,,,,,,,radicals [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004315,neutrophil migration,,The orderly movement of a neutrophil from one site to another.,false,,,http://purl.obolibrary.org/obo/GO_0050900,,,,,,,,,,,,,,,,,,,,,,The orderly movement of a neutrophil from one site to another.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004315,,,,,,,,,,,,,,,,,,,,,,neutrophil migration,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004316,CCL4 [mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/CHEBI_27385|http://purl.obolibrary.org/obo/TXPO_0004312,,,,,,,,,,,,,,,,,,,,PMID:29222479,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003572|http://purl.obolibrary.org/obo/TXPO_0002250|http://purl.obolibrary.org/obo/TXPO_0004314,,,,,,,,,,TXPO:0004316,,,,,,,,,,,,,,,,,,,,,,CCL4 [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004312,mitochondria disorder dependent chemical compound,,"mitochondrial disorder dependent chemical compound is a subtype of toxic course dependent chemical entity.
This entity (drug) can participate in the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0002012,,,,,,,,,,,,,,,,,,,,,,"mitochondrial disorder dependent chemical compound is a subtype of toxic course dependent chemical entity.
This entity (drug) can participate in the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004312,,,,,,,,,,,,,,,,,,,,,,mitochondria disorder dependent chemical compound,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004318,STAT3(human)[mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003603|http://purl.obolibrary.org/obo/IMR_0000377,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:|PMID:25181692,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003724,,,,,,,,,,TXPO:0004318,,,,,,,,,,,,,,,,,,,,,,STAT3(human)[mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004314,respiratory chain inhibitor role,,A role played by the entity which negative regulates the respiratory chain.,false,,,http://purl.obolibrary.org/obo/TXPO_0004023,,,,,,,,,,,,,,,,,,,,,,A role played by the entity which negative regulates the respiratory chain.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004314,,,,,,,,,,,,,,,,,,,,,,respiratory chain inhibitor role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004313,monocyte migration,,The orderly movement of a monocyte from one site to another.,false,,,http://purl.obolibrary.org/obo/GO_0050900,,,,,,,,,,,,,,,,,,,,,,The orderly movement of a monocyte from one site to another.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004313,,,,,,,,,,,,,,,,,,,,,,monocyte migration,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003320,FNDC4 (human)[Phospholipidosis],FRCP1 [Phospholipidosis]|Fibronectin Type III Domain Containing 4 [Phospholipidosis],,false,,,http://purl.obolibrary.org/obo/TXPO_1000150|http://purl.obolibrary.org/obo/TXPO_0002668,,,,,,,,,,,,,,,,,,,,"FNDC4 acts as an anti-inflammatory factor on macrophages and improves colitis in mice.
Analysis of binding of FNDC4 to different immune cell types reveals strong and specific binding to macrophages and monocytes. FNDC4 treatment of bone marrow-derived macrophages in vitro results in reduced phagocytosis, increased cell survival and reduced proinflammatory chemokine expression. Hence, treatment with FNDC4 results in a state of dampened macrophage activity, while enhancing their survival.|NCBI-Human-GeneID:64838|http://www.ncbi.nlm.nih.gov/gene/64838|http://omim.org/entry/611905|PMID:27066907",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000064838,,,,,,,,FRCP1 [Phospholipidosis]|Fibronectin Type III Domain Containing 4 [Phospholipidosis],,,,,TXPO:0003320,,,,,,,,,,,,,,,,,,,,,,FNDC4 (human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001442,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003326,fatty acid elongase,,Catalysis of the reaction: fatty acid (C-16 or longer) + 2-C = fatty acid (C-16 or longer + 2-C).|related molecular function GO:0009922,false,,,http://purl.obolibrary.org/obo/IMR_0010252,,,,,,,,,,,,,,,,,,,,,,Catalysis of the reaction: fatty acid (C-16 or longer) + 2-C = fatty acid (C-16 or longer + 2-C).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003326,,,,,,,,,,,,,,,,,,,,related molecular function GO:0009922,,fatty acid elongase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003324,AP1S1 (human)[Phospholipidosis],Adaptor Protein Complex AP-1 Subunit Sigma-1A [Phospholipidosis (Sawada)],"The protein encoded by this gene is part of the clathrin coat assembly complex which links clathrin to receptors in coated vesicles. These vesicles are involved in endocytosis and Golgi processing. This protein, as well as beta-prime-adaptin, gamma-adaptin, and the medium (mu) chain AP47, form the AP-1 assembly protein complex located at the Golgi vesicle. [provided by RefSeq, Jul 2008]",false,,,http://purl.obolibrary.org/obo/TXPO_0002668|http://purl.obolibrary.org/obo/TXPO_1000004,,,,,,,,,,,,,,,,,,,,"Clathrin-coated vesicles that form on the trans-Golgi network (TGN)1 concentrate newly synthesized lysosomal hydrolases for transport from the Golgi system to the endosome compartment.
The endosomes then deliver the hydrolases to the lysosome

The formation of clathrin coats depends on the recruitment of the Golgi-specific adaptor protein complex AP-1 onto the cytosolic face of the TGN.|NCBI-Human-GeneID:1174|http://www.ncbi.nlm.nih.gov/gene/1174|PMID:10069802|PMID:9733768|PMID:11031247",,"The protein encoded by this gene is part of the clathrin coat assembly complex which links clathrin to receptors in coated vesicles. These vesicles are involved in endocytosis and Golgi processing. This protein, as well as beta-prime-adaptin, gamma-adaptin, and the medium (mu) chain AP47, form the AP-1 assembly protein complex located at the Golgi vesicle. [provided by RefSeq, Jul 2008]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001174,,,http://purl.obolibrary.org/obo/TXPO_0003638,,,,,Adaptor Protein Complex AP-1 Subunit Sigma-1A [Phospholipidosis (Sawada)],,,,,TXPO:0003324,,,,,,,,,,,,,,,,,,,,,,AP1S1 (human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001442,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003327,SCD (human)[Phospholipidosis],Stearoyl-CoA Desaturase [Phospholipidosis],,false,,,http://purl.obolibrary.org/obo/TXPO_0002668|http://purl.obolibrary.org/obo/TXPO_0000587,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:6319|PMID:4382040|PMID:21045174|PMID:26519296|PMID:19850634,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000006319,,,http://purl.obolibrary.org/obo/TXPO_0003329,,,,,Stearoyl-CoA Desaturase [Phospholipidosis],,,,,TXPO:0003327,,,,,,,,,,,,,,,,,,,,,,SCD (human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001442,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003323,GDPD1 (human)[Phospholipidosis],GDE4 [Phospholipidosis]|MGC4171 [Phospholipidosis],,false,,,http://purl.obolibrary.org/obo/TXPO_0002668|http://purl.obolibrary.org/obo/TXPO_1000165,,,,,,,,,,,,,,,,,,,,http://www.ncbi.nlm.nih.gov/gene/284161|NCBI-Human-GeneID:284161|http://omim.org/entry/616317,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000284161,,,http://purl.obolibrary.org/obo/TXPO_0003672,,,,,GDE4 [Phospholipidosis]|MGC4171 [Phospholipidosis],,,,,TXPO:0003323,,,,,,,,,,,,,,,,,,,,,,GDPD1 (human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001442,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003325,ELOVL6 (human)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002668|http://purl.obolibrary.org/obo/TXPO_0000372|http://purl.obolibrary.org/obo/TXPO_1000125,,,,,,,,,,,,,,,,,,,,http://www.ncbi.nlm.nih.gov/gene/79071|http://omim.org/entry/611546|NCBI-Human-GeneID:79071|PMID:27467521|PMID:17906635,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000079071,,,http://purl.obolibrary.org/obo/TXPO_0003326,,,,,,,,,,TXPO:0003325,,,,,,,"The birth rate of Elovl6 knockout mice was lower, and the surviving mice were smaller in size and had reduced body weight.
Crucial role of a long-chain fatty acid elongase, Elovl6, in obesity-induced insulin resistance.
Secondary regulation of PPARa activity could be a part of SREBP-1c/Elovl6 regulation of lipogenesis.",,,,,,,,,,,,,,,ELOVL6 (human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001442,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003328,acyl-coA desaturase,,Catalysis role of the reaction: acyl-CoA + reduced acceptor + O2 = desaturated-acyl-CoA + acceptor + 2 H2O|related molecular function GO:0016215,false,,,http://purl.obolibrary.org/obo/TXPO_0000519,,,,,,,,,,,,,,,,,,,,EC:1.14.19,,Catalysis role of the reaction: acyl-CoA + reduced acceptor + O2 = desaturated-acyl-CoA + acceptor + 2 H2O,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003328,,,,,,,,,,,,,,,,,,,,related molecular function GO:0016215,,acyl-coA desaturase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003321,ceramidase,,Catalysis role of the reaction: N-acylsphingosine + H2O = a fatty acid + sphingosine.,false,,,http://purl.obolibrary.org/obo/TXPO_0003663,,,,,,,,,,,,,,,,,,,,,,Catalysis role of the reaction: N-acylsphingosine + H2O = a fatty acid + sphingosine.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003321,,,,,,,,,,,,,,,,,,,,,,ceramidase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003322,SMPDL3A (human)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002668|http://purl.obolibrary.org/obo/TXPO_1000348,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:10924|http://omim.org/entry/610728|https://www.ncbi.nlm.nih.gov/gene/10924|PMID:28414139,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000010924,,,,,,,,,,,,,TXPO:0003322,,,,,,,,,,,,,,,,,,,,,,SMPDL3A (human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001442,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003329,stearoyl-CoA 9-desaturase,,Catalysis role of the reaction: stearoyl-CoA + 2 ferrocytochrome b5 + O2 + 2 H+ = oleoyl-CoA + 2 ferricytochrome b5 + H2O.|related molecular function GO:0004768,false,,,http://purl.obolibrary.org/obo/TXPO_0003328,,,,,,,,,,,,,,,,,,,,EC:1.14.19.1,,Catalysis role of the reaction: stearoyl-CoA + 2 ferrocytochrome b5 + O2 + 2 H+ = oleoyl-CoA + 2 ferricytochrome b5 + H2O.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003329,,,,,,,,,,,,,,,,,,,,related molecular function GO:0004768,,stearoyl-CoA 9-desaturase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000467,cytokeratin 23,,,false,,,http://purl.obolibrary.org/obo/IMR_0000035,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000467,,,,,,,,,,,,,,,,,,,,,,cytokeratin 23,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100601,CDK5(mol),Cell division protein kinase 5|Tau protein kinase II catalytic subunit|TPKII catalytic subunit|Serine/threonine protein kinase PSSALRE|CRK6,,false,,,http://purl.obolibrary.org/obo/TXPO_0003241,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Cell division protein kinase 5|Tau protein kinase II catalytic subunit|TPKII catalytic subunit|Serine/threonine protein kinase PSSALRE|CRK6,,,,,IMR:0100601,,,,,,,,,,,,,,,,,,,,,,CDK5(mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000009829,DNAJC6,,"Other designations: DnaJ (Hsp40) homolog, subfamily B, member 6|auxilin|putative tyrosine-protein phosphatase auxilin",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,DJC6|PARK19,,,,,,,,,,,,1,,,,,,Ensembl:ENSG00000116675|MIM:608375|HPRD:16326|Vega:OTTHUMG00000009066|HGNC:15469,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"DnaJ (Hsp40) homolog, subfamily C, member 6",,,1p31.3,,,,,,,,,,,,,,,,GO_0004725 (EC: IEA); GO_0005829 (EC: TAS); GO_0006892 (EC: TAS); GO_0017124 (EC: IEA); GO_0061024 (EC: TAS),,,,,,,,,PMID:8524399; 9455477; 9455484; 11031247; 11147971; 11252894; 11470803; 12477932; 12732633; 15342556; 15489334; 15502813; 16710414; 18489706; 19165527; 19851296; 20198315; 22216198; 22365833; 22563501; 22647716; 23211418,,,,,,,,,,,,,,,OGG:3000009829,,,,,,,"DnaJ (Hsp40) homolog, subfamily C, member 6",,,,,,,,,,,,,"Other designations: DnaJ (Hsp40) homolog, subfamily B, member 6|auxilin|putative tyrosine-protein phosphatase auxilin",,DNAJC6,,,,,,,,,,,,,,,,,,,,,,,9829,,,,,,,,9606,,,,,,,,,,,,,,,,,,,DNAJC6,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/PATO_0001462,membrane potential,,A quality inhering in a cell's plasma membrane by virtue of the electrical potential difference across it.,false,,,http://purl.obolibrary.org/obo/PATO_0001464,,,,,,,,,,,,,,,,,,,,,,A quality inhering in a cell's plasma membrane by virtue of the electrical potential difference across it.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0001462,,,,,,,,,,,,,,,,,,,,,,membrane potential,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000895,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0001464,electric potential,,"A quality that is equal to the potential energy per unit charge associated with a static (time-invariant) electric field, also called the electrostatic potential.",false,,,http://purl.obolibrary.org/obo/BFO_0000019|http://purl.obolibrary.org/obo/TXPO_0002420,,,,,,,,,,,,,,,,,,,,,,"A quality that is equal to the potential energy per unit charge associated with a static (time-invariant) electric field, also called the electrostatic potential.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0001464,,,,,,,,,,,,,,,,,,,,,,electric potential,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002435,pancreatic beta cell damage [Type I Diabetes mellitus],,"Pancreatic beta cell damage is a subtype of cellular damage: A process that injuries the structure of the pancreatic beta cell as the direct or indirect result of an external force.
This entity is a specific course-dependent process. This process can constitute the course of Type I Diabetes mellitus.",false,,,http://purl.obolibrary.org/obo/TXPO_0003342|http://purl.obolibrary.org/obo/TXPO_0002182,,,,,,,,,,,,,,,,,,,,,,"Pancreatic beta cell damage is a subtype of cellular damage: A process that injuries the structure of the pancreatic beta cell as the direct or indirect result of an external force.
This entity is a specific course-dependent process. This process can constitute the course of Type I Diabetes mellitus.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002437,,,,,,,,,,,TXPO:0002435,,,,,,,,,,,,,,,,,,,,,,pancreatic beta cell damage [Type I Diabetes mellitus],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002439,decreasing blood glucose level in blood,,Decreasing blood glucose level in blood is a subtype of decreasing concentration: A process that changes the blood glucose concentration in the blood to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000671,,,,,,,,,,,,,,,,,,,,,,Decreasing blood glucose level in blood is a subtype of decreasing concentration: A process that changes the blood glucose concentration in the blood to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002439,,,,,,,,,,,,,,,,,,,,,,decreasing blood glucose level in blood,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002434,proteasome-mediated NRF2 degradation [Glutathione depletion],,"The chemical reaction resulting in the breakdown of NRF2, which is mediated by the proteasome.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0002432|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"The chemical reaction resulting in the breakdown of NRF2, which is mediated by the proteasome.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002434,,,,,,,,,,,,,,,,,,,,,,proteasome-mediated NRF2 degradation [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002433,gene expression by ATF4,,Gene expression by ATF4 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) by ATF4.,false,,,http://purl.obolibrary.org/obo/TXPO_0000375,,,,,,,,,,,,,,,,,,,,,,Gene expression by ATF4 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) by ATF4.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002433,,,,,,,,,,,,,,,,,,,,,,gene expression by ATF4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002436,dysfunction of dysfunction of insulin secretion,,Dysfunction of dysfunction of insulin secretion is a subtype of dysfunctioning: A process that performs an abnormal and incomplete insulin secretion.,false,,,http://purl.obolibrary.org/obo/TXPO_0000438,,,,,,,,,,,,,,,,,,,,,,Dysfunction of dysfunction of insulin secretion is a subtype of dysfunctioning: A process that performs an abnormal and incomplete insulin secretion.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002436,,,,,,,,,,,,,,,,,,,,,,dysfunction of dysfunction of insulin secretion,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002431,autophagy dependent Keap1 catabolic process  [Glutathione depletion],,"The cellular catabolic process in which cells digest parts of their own cytoplasm; allows for both recycling of macromolecular constituents under conditions of cellular stress and remodeling the intracellular structure for cell differentiation
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0002445|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,PMID:20173742,,"The cellular catabolic process in which cells digest parts of their own cytoplasm; allows for both recycling of macromolecular constituents under conditions of cellular stress and remodeling the intracellular structure for cell differentiation
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002431,,,,,,,,,,,,,,,,,,,,,,autophagy dependent Keap1 catabolic process  [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002430,negative regulation of inflammatory response [Glutathione depletion],,"Negative regulation of inflammatory response is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of inflammatory response.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0002243|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of inflammatory response is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of inflammatory response.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002430,,,,,,,,,,,,,,,,,,,,,,negative regulation of inflammatory response [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002438,changing concentration,,Changing concentration is a subtype of changing quality: A process that changes the concentration of the object.,false,,,http://purl.obolibrary.org/obo/TXPO_0000415,,,,,,,,,,,,,,,,,,,,,,Changing concentration is a subtype of changing quality: A process that changes the concentration of the object.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002438,,,,,,,,,,,,,,,,,,,,,,changing concentration,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0001159,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002432,proteasome-mediated ubiquitin-dependent NRF2 catabolic process,,"The chemical reaction resulting in the breakdown of NRF2, which is mediated by the proteasome.",false,,,http://purl.obolibrary.org/obo/GO_0043161,,,,,,,,,,,,,,,,,,,,,,"The chemical reaction resulting in the breakdown of NRF2, which is mediated by the proteasome.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002432,,,,,,,,,,,,,,,,,,,,,,proteasome-mediated ubiquitin-dependent NRF2 catabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002437,dysfunction of insulin secretion [Type I Diabetes mellitus],,"Dysfunction of insulin secretion is a subtype of dysfunctioning: A process that performs an abnormal and incomplete insulin secretion.
This entity is a specific course-dependent process. This process can constitute the course of Type I Diabetes mellitus.",false,,,http://purl.obolibrary.org/obo/TXPO_0003342|http://purl.obolibrary.org/obo/TXPO_0002436,,,,,,,,,,,,,,,,,,,,,,"Dysfunction of insulin secretion is a subtype of dysfunctioning: A process that performs an abnormal and incomplete insulin secretion.
This entity is a specific course-dependent process. This process can constitute the course of Type I Diabetes mellitus.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000169,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003577,,,,,,,,,,,TXPO:0002437,,,,,,,,,,,,,,,,,,,,,,dysfunction of insulin secretion [Type I Diabetes mellitus],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0002807,FOXO4,,,false,,,http://purl.obolibrary.org/obo/IMR_0002804,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0002807,,,,,,,,,,,,,,,,,,,,,,FOXO4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010556,40S ribosomal protein S30,40S small ribosomal protein 30,,false,,,http://purl.obolibrary.org/obo/IMR_0000896,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,40S small ribosomal protein 30,,,,,IMR:0010556,,,,,,,,,,,,,,,,,,,,,,40S ribosomal protein S30,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100115,noradrenalin,"L-Noradrenaline|Norepinephrine|4-[(1R)-2-Amino-1-hydroxyethyl]-1,2-benzenediol|LEVOPHED (TN)|Arterenol",,false,,,http://purl.obolibrary.org/obo/IMR_0001694,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_25512,,,,IMR:0200116,"L-Noradrenaline|Norepinephrine|4-[(1R)-2-Amino-1-hydroxyethyl]-1,2-benzenediol|LEVOPHED (TN)|Arterenol",,,,,IMR:0100115,,,,,,,,,,,,,,,,,,,,,,noradrenalin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_75771,mouse metabolite,Mus musculus metabolite|mouse metabolites|Mus musculus metabolites,Any mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).,false,,,http://purl.obolibrary.org/obo/CHEBI_75768,,,,,,,,,,,,,,,,,,,,,,Any mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Mus musculus metabolite|mouse metabolites|Mus musculus metabolites,,,,,,,,,,,,,,,,,,,,,CHEBI:75771,,,,mouse metabolite,,CHEBI:75771,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000813,c-FOS,,,false,,,http://purl.obolibrary.org/obo/IMR_0000415,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000813,,,,,,,,,,,,,,,,,,,,,,c-FOS,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CL_0000775,neutrophil,neutrophilic leucocyte|neutrophilic leukocyte|neutrophil leucocyte|neutrophil leukocyte|neutrocyte,"Any of the immature or mature forms of a granular leukocyte that in its mature form has a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes.",false,,,http://purl.obolibrary.org/obo/CL_0000094,,,,,,,,,,,,,,,,,,,,BTO:0000130|FMA:62860|CALOHA:TS-0688,,"Any of the immature or mature forms of a granular leukocyte that in its mature form has a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,neutrophilic leucocyte|neutrophilic leukocyte|neutrophil leucocyte|neutrophil leukocyte|neutrocyte,,,,,CL:0000775,,,,,,,,,,,,,,,,,,,,,,neutrophil,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CL_0000771,eosinophil,,"Any of the immature or mature forms of a granular leukocyte with a nucleus that usually has two lobes connected by one or more slender threads of chromatin, and cytoplasm containing coarse, round granules that are uniform in size and which can be stained by the dye eosin. Eosinophils are CD9-positive, CD191-positive, and CD193-positive.",false,,,http://purl.obolibrary.org/obo/CL_0000094,,,,,,,,,,,,,,,,,,,,,,"Any of the immature or mature forms of a granular leukocyte with a nucleus that usually has two lobes connected by one or more slender threads of chromatin, and cytoplasm containing coarse, round granules that are uniform in size and which can be stained by the dye eosin. Eosinophils are CD9-positive, CD191-positive, and CD193-positive.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CL:0000771,,,,,,,,,,,,,,,,,,,,,,eosinophil,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_24870,ion,,A molecular entity having a net electric charge.,false,,,http://purl.obolibrary.org/obo/CHEBI_23367,,,,,,,,,,,,,,,,,,,,,,A molecular entity having a net electric charge.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:24870,,,,,,,,,,,,,,,,,,,,,,ion,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_68509,glutathione depleting agent,glutathione depletion agent role,A compound which causes a reduction in the levels of glutathione in cells.,false,,,http://purl.obolibrary.org/obo/TXPO_0000638|http://purl.obolibrary.org/obo/TXPO_0002037,,,,,,,,,,,,,,,,,,,,,,A compound which causes a reduction in the levels of glutathione in cells.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,glutathione depletion agent role,,,,,CHEBI:68509,,,,,,,,,,,,,,,,,,,,,,glutathione depleting agent,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100744,LEF-1,TCF1-alpha|T cell-specific transcription factor 1-alpha,,false,,,http://purl.obolibrary.org/obo/IMR_0000418,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TCF1-alpha|T cell-specific transcription factor 1-alpha,,,,,IMR:0100744,,,,,,,,,,,,,,,,,,,,,,LEF-1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000431,RGS,regulator of G protein signaling,"RGS proteins act as negative regulators of G protein dependent signaling, at least in part, because they stimulate hydrolysis of the GTP bound to activated G alpha subunits.",false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,GO:0016299,,"RGS proteins act as negative regulators of G protein dependent signaling, at least in part, because they stimulate hydrolysis of the GTP bound to activated G alpha subunits.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003722,,,,,regulator of G protein signaling,,,,,IMR:0000431,,,,,,,,,,,,,,,,,,,,,,RGS,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000162,cytokeratin 5,,,false,,,http://purl.obolibrary.org/obo/IMR_0000050,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000162,,,,,,,,,,,,,,,,,,,,,,cytokeratin 5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0038110,interleukin-2-mediated signaling pathway,IL-2-mediated signaling pathway,"A series of molecular signals initiated by the binding of interleukin-2 to a receptor on the surface of a cell, and ending with regulation of a downstream cellular process, e.g. transcription.",false,,,http://purl.obolibrary.org/obo/TXPO_0000609,,,,,,,,,,,,,,,,,,,,,,"A series of molecular signals initiated by the binding of interleukin-2 to a receptor on the surface of a cell, and ending with regulation of a downstream cellular process, e.g. transcription.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IL-2-mediated signaling pathway,,,,,GO:0038110,,,,,,,,,,,,,,,,,,,,,,interleukin-2-mediated signaling pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0032606,type I interferon production,,"The appearance of type I interferon due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels. Type I interferons include the interferon-alpha, beta, delta, episilon, zeta, kappa, tau, and omega gene families.",false,,,http://purl.obolibrary.org/obo/GO_0001816,,,,,,,,,,,,,,,,,,,,,,"The appearance of type I interferon due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels. Type I interferons include the interferon-alpha, beta, delta, episilon, zeta, kappa, tau, and omega gene families.",,,,,type I interferon production,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0032606,,,,,,,,,,,,,,,,,,,,,,type I interferon production,,,,,,,http://purl.obolibrary.org/obo/go.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0032602,chemokine production,,"The appearance of a chemokine due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.",false,,,http://purl.obolibrary.org/obo/GO_0001816,,,,,,,,,,,,,,,,,,,,,,"The appearance of a chemokine due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.",,,,,chemokine production,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0032602,,,,,,,,,,,,,,,,,,,,,,chemokine production,,,,,,,http://purl.obolibrary.org/obo/go.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0032609,interferon-gamma production,,"The appearance of interferon-gamma due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels. Interferon-gamma is also known as type II interferon.",false,,,http://purl.obolibrary.org/obo/GO_0001816,,,,,,,,,,,,,,,,,,,,,,"The appearance of interferon-gamma due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels. Interferon-gamma is also known as type II interferon.",,,,,interferon-gamma production,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0032609,,,,,,,,,,,,,,,,,,,,,,interferon-gamma production,,,,,,,http://purl.obolibrary.org/obo/go.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003967,lipid synthesis positive regulator role,,A role played by the entity which positively regulates the formation of lipids.,false,,,http://purl.obolibrary.org/obo/TXPO_0002196,,,,,,,,,,,,,,,,,,,,,,A role played by the entity which positively regulates the formation of lipids.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003967,,,,,,,,,,,,,,,,,,,,,,lipid synthesis positive regulator role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003960,decreasing cholesterol [Ground glass appearance],,"Decreasing cholesterol is a subtype of decreasing lipid: A process that changes the amount of cholesterol to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/TXPO_0003963,,,,,,,,,,,,,,,,,,,,ISBN:0071769234,,"Decreasing cholesterol is a subtype of decreasing lipid: A process that changes the amount of cholesterol to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003960,,,,,,,,,,,,,,,,,,,,,,decreasing cholesterol [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003962,decreasing hepatic triglyceride,,Decreasing hepatic triglyceride is a subtype of decreasing lipid: A process that changes the quantity of the hepatic triglyceride in lysosomal membranes to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000396,,,,,,,,,,,,,,,,,,,,,,Decreasing hepatic triglyceride is a subtype of decreasing lipid: A process that changes the quantity of the hepatic triglyceride in lysosomal membranes to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003962,,,,,,,,,,,,,,,,,,,,,,decreasing hepatic triglyceride,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003963,decreasing cholesterol,,Decreasing cholesterol is a subtype of decreasing lipid: A process that changes the amount of cholesterol to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000644,,,,,,,,,,,,,,,,,,,,,,Decreasing cholesterol is a subtype of decreasing lipid: A process that changes the amount of cholesterol to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003963,,,,,,,,,,,,,,,,,,,,,,decreasing cholesterol,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003961,decreasing hepatic triglyceride [Ground glass appearance],,"Decreasing hepatic triglyceride is a subtype of decreasing lipid: A process that changes the quantity of the hepatic triglyceride to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/TXPO_0003962,,,,,,,,,,,,,,,,,,,,ISBN:0071769234,,"Decreasing hepatic triglyceride is a subtype of decreasing lipid: A process that changes the quantity of the hepatic triglyceride to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003961,,,,,,,,,,,,,,,,,,,,,,decreasing hepatic triglyceride [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003965,SREBP1 - inactive form (canonical)[Ground glass appearance],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003964,,,,,,,,,,,,,,,,,,,,ISBN:0071769234,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0002355,,,,,,,,,TXPO:0003965,,,,,,,,,,,,,,,,,,,,,,SREBP1 - inactive form (canonical)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003966,SREBF1 (mol),http://omim.org/entry/184756|Sterol Regulatory Element Binding Transcription Factor 1|SREBP1,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:78968|NCBI-Human-GeneID:6720|NCBI-Mouse-GeneID:20787,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://omim.org/entry/184756|Sterol Regulatory Element Binding Transcription Factor 1|SREBP1,,,,,TXPO:0003966,,,,,,,,,,,,,,,,,,,,,,SREBF1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003969,hyperfunction of mitochondrial fatty acid beta-oxidation [Ground glass appearance],,"Hyperfunction of mitochondrial fatty acid beta-oxidation is a subtype of hyperfunction of fatty acid beta-oxidation: A process that performs an excessive mitochondrial fatty acid beta-oxidation.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0002344|http://purl.obolibrary.org/obo/TXPO_0001728,,,,,,,,,,,,,,,,,,,,ISBN:0071769234,,"Hyperfunction of mitochondrial fatty acid beta-oxidation is a subtype of hyperfunction of fatty acid beta-oxidation: A process that performs an excessive mitochondrial fatty acid beta-oxidation.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003976|http://purl.obolibrary.org/obo/TXPO_0003972,,,,,,,,,,,,,,,,,TXPO:0003969,,,,,,,,,,,,,,,,,,,,,,hyperfunction of mitochondrial fatty acid beta-oxidation [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003964,SREBP1 (canonical)[Ground glass appearance],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000472|http://purl.obolibrary.org/obo/TXPO_0003966,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:78968|NCBI-Human-GeneID:6720|NCBI-Mouse-GeneID:20787,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003967|http://purl.obolibrary.org/obo/TXPO_0003968,,,,,,,,,,TXPO:0003964,,,,,,,,,,,,,,,,,,,,,,SREBP1 (canonical)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003968,cholesterol synthesis positive regulator role,,A role played by the entity which positively regulates the formation of cholesterol.,false,,,http://purl.obolibrary.org/obo/TXPO_0003967,,,,,,,,,,,,,,,,,,,,,,A role played by the entity which positively regulates the formation of cholesterol.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003968,,,,,,,,,,,,,,,,,,,,,,cholesterol synthesis positive regulator role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_77748,EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor,MDR protein inhibitor|PDR protein inhibitor|multidrug-resistance protein inhibitors|ATP phosphohydrolase (xenobiotic-exporting) inhibitors|P-glycoprotein inhibitors|ATP phosphohydrolase (steroid-exporting) inhibitor|P-glycoprotein inhibitor|multidrug-resistance protein inhibitor|xenobiotic-transporting ATPase inhibitor|xenobiotic-transporting ATPase inhibitors|pleiotropic-drug-resistance protein inhibitors|EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitors|ATP phosphohydrolase (steroid-exporting) inhibitors|EC 3.6.3.44 inhibitor|pleiotropic-drug-resistance protein inhibitor|PDR protein inhibitors|MDR protein inhibitors|ATP phosphohydrolase (xenobiotic-exporting) inhibitor|steroid-transporting ATPase inhibitor|xenobiotic-transporting ATPase (EC 3.6.3.44) inhibitors|EC 3.6.3.44 inhibitors|steroid-transporting ATPase inhibitors|xenobiotic-transporting ATPase (EC 3.6.3.44) inhibitor,An EC 3.6.3.* (acid anhydride hydrolase catalysing transmembrane movement of substances) inhibitor that interferes with the action of xenobiotic-transporting ATPase (EC 3.6.3.44).,false,,,http://purl.obolibrary.org/obo/CHEBI_76895,,,,,,,,,,,,,,,,,,,,,,An EC 3.6.3.* (acid anhydride hydrolase catalysing transmembrane movement of substances) inhibitor that interferes with the action of xenobiotic-transporting ATPase (EC 3.6.3.44).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MDR protein inhibitor|PDR protein inhibitor|multidrug-resistance protein inhibitors|ATP phosphohydrolase (xenobiotic-exporting) inhibitors|P-glycoprotein inhibitors|ATP phosphohydrolase (steroid-exporting) inhibitor|P-glycoprotein inhibitor|multidrug-resistance protein inhibitor|xenobiotic-transporting ATPase inhibitor|xenobiotic-transporting ATPase inhibitors|pleiotropic-drug-resistance protein inhibitors|EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitors|ATP phosphohydrolase (steroid-exporting) inhibitors|EC 3.6.3.44 inhibitor|pleiotropic-drug-resistance protein inhibitor|PDR protein inhibitors|MDR protein inhibitors|ATP phosphohydrolase (xenobiotic-exporting) inhibitor|steroid-transporting ATPase inhibitor|xenobiotic-transporting ATPase (EC 3.6.3.44) inhibitors|EC 3.6.3.44 inhibitors|steroid-transporting ATPase inhibitors|xenobiotic-transporting ATPase (EC 3.6.3.44) inhibitor,,,,,,,,,,,,,,,,,,,,,CHEBI:77748,,,,EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor,,CHEBI:77748,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001522,sequestering of triglyceride in hepatocyte,,"sequestering of triglyceride in hepatocyte is a subtype of lipid strorage in hepatocyte: A process that keeps triglycerides in hepatocytes.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/GO_0030730,,,,,,,,,,,,,,,,,,,,,,"sequestering of triglyceride in hepatocyte is a subtype of lipid strorage in hepatocyte: A process that keeps triglycerides in hepatocytes.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001522,,,,,,,,,,,,,,,,,,,,,,sequestering of triglyceride in hepatocyte,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001524,phenobarbital [Ground glass appearance],,,false,,,http://purl.obolibrary.org/obo/CHEBI_8069|http://purl.obolibrary.org/obo/TXPO_0000560,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001524,,,,,,,,,,,,,,,,,,,,,,phenobarbital [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001526,natural killer cell,,A lymphocyte that can spontaneously kill a variety of target cells without prior antigenic activation via germline encoded activation receptors and also regulate immune responses via cytokine release and direct contact with other cells.|lymphocyte and (capable of some natural killer cell mediated immunity) and (capable of some regulation of immune response) and (lacks_plasma_membrane_part some CD19 molecule) and (lacks_plasma_membrane_part some CD3 epsilon) and (lacks_plasma_membrane_part some membrane-spanning 4-domains subfamily A member 1) and (lacks_plasma_membrane_part some CD14 molecule),false,,,http://purl.obolibrary.org/obo/CL_0000542,,,,,,,,,,,,,,,,,,,,,,A lymphocyte that can spontaneously kill a variety of target cells without prior antigenic activation via germline encoded activation receptors and also regulate immune responses via cytokine release and direct contact with other cells.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001526,,,,,,,,,,,,,,,,,,,,lymphocyte and (capable of some natural killer cell mediated immunity) and (capable of some regulation of immune response) and (lacks_plasma_membrane_part some CD19 molecule) and (lacks_plasma_membrane_part some CD3 epsilon) and (lacks_plasma_membrane_part some membrane-spanning 4-domains subfamily A member 1) and (lacks_plasma_membrane_part some CD14 molecule),,natural killer cell,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001525,velocity attribute,,A physical attribute inhering in a bearer by virtue of the bearer's rate of change of the position,false,,,http://purl.obolibrary.org/obo/TXPO_0001334,,,,,,,,,,,,,,,,,,,,,,A physical attribute inhering in a bearer by virtue of the bearer's rate of change of the position,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001525,,,,,,,,,,,,,,,,,,,,,,velocity attribute,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001529,PERK signal integration system,,"PERK signal integration system is a subtype of pathway system.
This entity has sub-parts and has a goal of transmitting signals and a gene regulation via PERK as a systemic context.",false,,,http://purl.obolibrary.org/obo/TXPO_0001513,,,,,,,,,,,,,,,,,,,,,,"PERK signal integration system is a subtype of pathway system.
This entity has sub-parts and has a goal of transmitting signals and a gene regulation via PERK as a systemic context.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001696|http://purl.obolibrary.org/obo/TXPO_0000887,,,,,,,,,,,,,,,,,,,,,,TXPO:0001529,,,,,,,,,,,,,,,,,,,,,,PERK signal integration system,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001528,IRE1 (mol),ERN1,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:498013|NCBI-Mouse-GeneID:78943|NCBI-Human-GeneID:2081,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000002081,,,http://purl.obolibrary.org/obo/TXPO_0001966,,,,,ERN1,,,,,TXPO:0001528,,,,,,,,,,,,,,,,,,,,,,IRE1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001521,sequestering of triglyceride in hepatocyte (moderate) [lipidosis],,"sequestering of triglyceride (moderate) is a subtype of lipid strorage in hepatocyte: A process that keeps triglycerides in hepatocytes. And the degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001522,,,,,,,,,,,,,,,,,,,,,,"sequestering of triglyceride (moderate) is a subtype of lipid strorage in hepatocyte: A process that keeps triglycerides in hepatocytes. And the degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001521,,,,,,,,,,,,,,,,,,,,,,sequestering of triglyceride in hepatocyte (moderate) [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001523,regulation of innate immune response [Phospholipidosis],,"Any process that modulates the frequency, rate or extent of the innate immune response, the organism's first line of defense against infection.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/GO_0045088,,,,,,,,,,,,,,,,,,,,,,"Any process that modulates the frequency, rate or extent of the innate immune response, the organism's first line of defense against infection.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001523,,,,,,,,,,,,,,,,,,,,,,regulation of innate immune response [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001527,JNK activation by IRE1,,JNK activation by IRE1 is a subtype of JNK activation: A process that changes the activity of the JNK to be higher by IRE1.,false,,,http://purl.obolibrary.org/obo/TXPO_0002828,,,,,,,,,,,,,,,,,,,,,,JNK activation by IRE1 is a subtype of JNK activation: A process that changes the activity of the JNK to be higher by IRE1.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001527,,,,,,,,,,,,,,,,,,,,,,JNK activation by IRE1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001520,changing pH,,"Changing pH is a subtype of changing quality: A process that changes the pH of the object,  which denotes the acidity of a solution in terms of activity of hydrogen ions (H+).",false,,,http://purl.obolibrary.org/obo/TXPO_0000415,,,,,,,,,,,,,,,,,,,,,,"Changing pH is a subtype of changing quality: A process that changes the pH of the object,  which denotes the acidity of a solution in terms of activity of hydrogen ions (H+).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001520,,,,,,,,,,,,,,,,,,,,,,changing pH,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003859,hyperfunction of decreasing the amount of drugs [Ground glass appearance],,"Hyperfunction of decreasing the amount of drugs is a subtype of hyperfunction of decreasing: A process that performs an excesssive decreasing the amount of drugs.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/TXPO_0001834,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of decreasing the amount of drugs is a subtype of hyperfunction of decreasing: A process that performs an excesssive decreasing the amount of drugs.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000443,,,,,,,,,,,,,,,,,,TXPO:0003859,,,,,,,,,,,,,,,,,,,,,,hyperfunction of decreasing the amount of drugs [Ground glass appearance],,,,,,http://purl.obolibrary.org/obo/TXPO_0001647,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003852,necrosis [Ground glass appearance],,"A type of cell death that is morphologically characterized by an increasingly translucent cytoplasm, swelling of organelles, minor ultrastructural modifications of the nucleus (specifically, dilatation of the nuclear membrane and condensation of chromatin into small, irregular, circumscribed patches) and increased cell volume (oncosis), culminating in the disruption of the plasma membrane and subsequent loss of intracellular contents. Necrotic cells do not fragment into discrete corpses as their apoptotic counterparts do. Moreover, their nuclei remain intact and can aggregate and accumulate in necrotic tissues.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/GO_0070265,,,,,,,,,,,,,,,,,,,,,,"A type of cell death that is morphologically characterized by an increasingly translucent cytoplasm, swelling of organelles, minor ultrastructural modifications of the nucleus (specifically, dilatation of the nuclear membrane and condensation of chromatin into small, irregular, circumscribed patches) and increased cell volume (oncosis), culminating in the disruption of the plasma membrane and subsequent loss of intracellular contents. Necrotic cells do not fragment into discrete corpses as their apoptotic counterparts do. Moreover, their nuclei remain intact and can aggregate and accumulate in necrotic tissues.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001031|http://purl.obolibrary.org/obo/TXPO_0001582,,,,,,,,,,,TXPO:0003852,,,,,,,,,,,,,,,,,,,,,,necrosis [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003857,ground glass appearance with Cytochrome P450 activation [toxic course],,"The totality of all processes through which ground glass appearance is realized.
This toxic course  has processes of CYP activation.",false,,,http://purl.obolibrary.org/obo/TXPO_0001432,,,,,,,,,,,,,,,,,,,,,,"The totality of all processes through which ground glass appearance is realized.
This toxic course  has processes of CYP activation.",,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001621,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001621|http://purl.obolibrary.org/obo/TXPO_0003901|http://purl.obolibrary.org/obo/TXPO_0003902|http://purl.obolibrary.org/obo/TXPO_0000982|http://purl.obolibrary.org/obo/TXPO_0000981|http://purl.obolibrary.org/obo/TXPO_0001026|http://purl.obolibrary.org/obo/TXPO_0000781|http://purl.obolibrary.org/obo/TXPO_0000948,,,,,,,,,,,,,,,,,,TXPO:0003857,,,,,,,,,,,,,,,,,,,,,,ground glass appearance with Cytochrome P450 activation [toxic course],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003856,phenobarbital metabolism imbalance  [Ground glass appearance (severe) - tumorigenesis],,"Phenobarbital metabolism imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance of the phenobarbital metabolism. And the degree is severe.
This process is dependent on the tumorigenesis and can constitute the course of Ground glass appearance (severe).",false,,,http://purl.obolibrary.org/obo/TXPO_0003860,,,,,,,,,,,,,,,,,,,,,,"Phenobarbital metabolism imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance of the phenobarbital metabolism. And the degree is severe.
This process is dependent on the tumorigenesis and can constitute the course of Ground glass appearance (severe).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001675,,,,,,,,,,,TXPO:0003856,,,,,,,,,,,,,,,,,,,,,,phenobarbital metabolism imbalance  [Ground glass appearance (severe) - tumorigenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003855,nuclear receptor activation [Ground glass appearance],nuclear receptor activating [Ground glass ]|activating nuclear receptor [Ground glass appearance],"Nuclear receptor activation is a subtype of activation of transcription factor: A process that changes the activity of the molecule with a nuclear receptor role to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0000158|http://purl.obolibrary.org/obo/TXPO_0001728,,,,,,,,,,,,,,,,,,,,,,"Nuclear receptor activation is a subtype of activation of transcription factor: A process that changes the activity of the molecule with a nuclear receptor role to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000937,,,,,,nuclear receptor activating [Ground glass ]|activating nuclear receptor [Ground glass appearance],,,,,TXPO:0003855,,,,,,,,,,,,,,,,,,,,,,nuclear receptor activation [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003853,glycogen catabolic process (sustained) [Ground glass appearance],,"The chemical reactions and pathways resulting in the breakdown of glycogen, a polydisperse, highly branched glucan composed of chains of D-glucose residues. This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) .",false,,,http://purl.obolibrary.org/obo/TXPO_0000958,,,,,,,,,,,,,,,,,,,,PMID:24878338,,"The chemical reactions and pathways resulting in the breakdown of glycogen, a polydisperse, highly branched glucan composed of chains of D-glucose residues. This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) .",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001797,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003853,,,,,,,,,,,,,,,,,,,,,,glycogen catabolic process (sustained) [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003858,hyperfunction of cytochrome p450 gene expression by phenobarbital [Ground glass appearance],,"Hyperfunction of cytochrome p450 gene expression by phenobarbital is a subtype of hyperfunction of drug metabolizing enzyme gene expression: A process that performs an excesssive gene expression of cytochrome p450 by phenobarbital.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0000937|http://purl.obolibrary.org/obo/TXPO_0002051,,,,,,,,,,,,,,,,,,,,PMID:28546505,,"Hyperfunction of cytochrome p450 gene expression by phenobarbital is a subtype of hyperfunction of drug metabolizing enzyme gene expression: A process that performs an excesssive gene expression of cytochrome p450 by phenobarbital.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001524,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003907|http://purl.obolibrary.org/obo/TXPO_0003909|http://purl.obolibrary.org/obo/TXPO_0003908|http://purl.obolibrary.org/obo/TXPO_0000990|http://purl.obolibrary.org/obo/TXPO_0000979,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003864,,,,,,,,,,,TXPO:0003858,,,,,,,CAR activator phenobarbital can induce CYP2B10 and CYP3A11 in wild type and PXR knock-out mouse.,,,,,,,,,,,,,,,hyperfunction of cytochrome p450 gene expression by phenobarbital [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003851,mitochondrial dysfunction [Ground glass appearance],,"Mitochondrial dysfunction is a subtype of dysfunctioning: A process that performs an abnormal and incomplete mitochondrial function.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/TXPO_0002361,,,,,,,,,,,,,,,,,,,,PMID:17090686,,"Mitochondrial dysfunction is a subtype of dysfunctioning: A process that performs an abnormal and incomplete mitochondrial function.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003852,,,,,,,,,,,TXPO:0003851,,,,,,,,,,,,,,,,,,,,,,mitochondrial dysfunction [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003854,making existence of drug,,"Making existence of drug is a subtype of making existence of xenobiotics: A process that makes a drug to be present in in a cell, organelle, or an organism.",false,,,http://purl.obolibrary.org/obo/TXPO_0001851,,,,,,,,,,,,,,,,,,,,,,"Making existence of drug is a subtype of making existence of xenobiotics: A process that makes a drug to be present in in a cell, organelle, or an organism.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003854,,,,,,,,,,,,,,,,,,,,,,making existence of drug,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003850,reactive oxygen species biosynthetic process (sustained) [Ground glass appearance],,"The chemical reaction resulting in the formation of reactive oxygen species, any molecules or ions formed by the incomplete one-electron reduction of oxygen. This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) .",false,,,http://purl.obolibrary.org/obo/GO_1903409|http://purl.obolibrary.org/obo/TXPO_0000948,,,,,,,,,,,,,,,,,,,,,,"The chemical reaction resulting in the formation of reactive oxygen species, any molecules or ions formed by the incomplete one-electron reduction of oxygen. This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003851,,,,,,,,,,,TXPO:0003850,,,,,,,,,,,,,,,,,,,,,,reactive oxygen species biosynthetic process (sustained) [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000010611,PDLIM5,,Other designations: PDZ and LIM domain protein 5|enigma homolog|enigma-like LIM domain protein|enigma-like PDZ and LIM domains protein,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,ENH|LIM|ENH1,,,,,,,,,,,,4,,,,,,Ensembl:ENSG00000163110|MIM:605904|HGNC:17468|Vega:OTTHUMG00000130973|HPRD:05799,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,PDZ and LIM domain 5,,,4q22,,,,,,,,,,,,,,,,GO_0003779 (EC: ISS); GO_0005080 (EC: ISS); GO_0005829 (EC: ISS); GO_0008270 (EC: IEA); GO_0014069 (EC: ISS); GO_0015629 (EC: IDA); GO_0016020 (EC: ISS); GO_0030054 (EC: IEA); GO_0042805 (EC: ISS); GO_0043005 (EC: IEA); GO_0045211 (EC: IEA); GO_0051963 (EC: ISS); GO_0061001 (EC: ISS),,,,,,,,,PMID: 7698749; 8889548; 8940095; 10429367; 10737800; 10833443; 11076863; 11230166; 11256614; 12477932; 12665800; 14743183; 15334068; 15342556; 15346770; 15362566; 15489334; 15489336; 15555569; 16044170; 16189514; 16213469; 16344560; 16381901; 16549780; 16595163; 16713569; 17081983; 17287082; 18021463; 18197271; 18296710; 18456508; 18496208; 18496210; 19328558; 19448850; 19596686; 19636345; 19738201; 19767753; 20564319; 20878950; 21139048; 21266195; 21890473; 21906983; 22118674; 22589738; 22741436; 22863883; 22939629; 23031404; 24457600,,,,,,,,,,,,,,,OGG:3000010611,,,,,,,PDZ and LIM domain 5,,,,,,,,,,,,,Other designations: PDZ and LIM domain protein 5|enigma homolog|enigma-like LIM domain protein|enigma-like PDZ and LIM domains protein,,PDLIM5,,,,,,,,,,,,,,,,,,,,,,,10611,L9,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,PDLIM5,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0004612,HIF1A activation,,HIF1A activation is a subtype of molecular activation: A process that  changes the activity of the HIF1A (hypoxia inducible factor 1 subunit alpha) to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000023,,,,,,,,,,,,,,,,,,,,,,HIF1A activation is a subtype of molecular activation: A process that  changes the activity of the HIF1A (hypoxia inducible factor 1 subunit alpha) to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004612,,,,,,,,,,,,,,,,,,,,,,HIF1A activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004615,Increasing HILPDA level,,Increasing HILPDA level is a subtype of increasing quantity: A process that changes the amount of HILPDA level to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing HILPDA level is a subtype of increasing quantity: A process that changes the amount of HILPDA level to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_1000518,,,,,,,,,,,,,,,,,,,TXPO:0004615,,,,,,,,,,,,,,,,,,,,,,Increasing HILPDA level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004617,Increasing iron uptake level [hepatocarcinogenesis],,"Increasing iron uptake level is a subtype of increasing quantity: A process that changes the iron uptake level to be larger.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0005052,,,,,,,,,,,,,,,,,,,,PMID:25796501,,"Increasing iron uptake level is a subtype of increasing quantity: A process that changes the iron uptake level to be larger.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004661,,,,,,,,,,,TXPO:0004617,,,,,,,,,,,,,,,,,,,,,,Increasing iron uptake level [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004610,HHIP - inactive form (human) [hepatocarcinogenesis],hedgehog interacting protein [hepatocarcinogenesis],,false,,,http://purl.obolibrary.org/obo/TXPO_0005089,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:64399|PMID:29507645,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0002355,,,,,,,,,hedgehog interacting protein [hepatocarcinogenesis],,,,,TXPO:0004610,,,,,,,,,,,,,,,,,,,,,,HHIP - inactive form (human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004619,HMGB1 (canonical) [mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003603|http://purl.obolibrary.org/obo/TXPO_0000849,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:3146|NCBI-Mouse-GeneID:15289|PMID:31623280,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004619,,,,,,,,,,,,,,,,,,,,,,HMGB1 (canonical) [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004611,trimeric UHRF1 repression complex (human) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_0004850,,,,,,,,,,,,,,,,,,,,PMID:29507645,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004203|http://purl.obolibrary.org/obo/TXPO_0004851|http://purl.obolibrary.org/obo/TXPO_0004852,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,,,,,,TXPO:0004611,,,,,,,,,,,,,,,,,,,,,,trimeric UHRF1 repression complex (human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004616,Increasing HILPDA level [hepatocarcinogenesis],HIG2,"Increasing HILPDA level is a subtype of increasing quantity: A process that changes the amount of HILPDA level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004615,,,,,,,,,,,,,,,,,,,,PMID:25796501,,"Increasing HILPDA level is a subtype of increasing quantity: A process that changes the amount of HILPDA level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004194,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004404|http://purl.obolibrary.org/obo/TXPO_0004479|http://purl.obolibrary.org/obo/TXPO_0004617|http://purl.obolibrary.org/obo/TXPO_0004518|http://purl.obolibrary.org/obo/TXPO_0004396,,,,,,HIG2,,,,,TXPO:0004616,,,,,,,,,,,,,,,,,,,,,,Increasing HILPDA level [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004613,HIF1A (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:3091|NCBI-Mouse-GeneID:15251|NCBI-Rat-GeneID:29560,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004613,,,,,,,,,,,,,,,,,,,,,,HIF1A (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004618,Increasing HMGB1 level,,Increasing HMGB1 level is a subtype of increasing quantity: A process that changes the amount of HMGB1 level to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing HMGB1 level is a subtype of increasing quantity: A process that changes the amount of HMGB1 level to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000849,,,,,,,,,,,,,,,,,,,TXPO:0004618,,,,,,,,,,,,,,,,,,,,,,Increasing HMGB1 level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004614,HIF1A - activation state (canonical)[mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003603|http://purl.obolibrary.org/obo/TXPO_0005090,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:3091|NCBI-Mouse-GeneID:15251|NCBI-Rat-GeneID:29560|PMID:25339807|PMID:23299992,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0002354,,,,,,,,,,,,,,TXPO:0004614,,,,,,,,,,,,,,,,,,,,,,HIF1A - activation state (canonical)[mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100389,IFN delta,Interferon delta,,false,,,http://purl.obolibrary.org/obo/IMR_0000028,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Interferon delta,,,,,IMR:0100389,,,,,,,,,,,,,,,,,,,,,,IFN delta,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0005980,glycogen catabolic process,glycogenolysis|glycogen catabolism|glycogen breakdown|glycogen degradation,"The chemical reactions and pathways resulting in the breakdown of glycogen, a polydisperse, highly branched glucan composed of chains of D-glucose residues.",false,,,http://purl.obolibrary.org/obo/GO_0016052,,,,,,,,,,,,,,,,,,,,Reactome:REACT_1008,,"The chemical reactions and pathways resulting in the breakdown of glycogen, a polydisperse, highly branched glucan composed of chains of D-glucose residues.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_28087,,,,,,,,,,,,,,,,,,glycogenolysis|glycogen catabolism|glycogen breakdown|glycogen degradation,,,,,GO:0005980,,,,,,,,,,,,,,,,,,,,,,glycogen catabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001368,Gli3,,,false,,,http://purl.obolibrary.org/obo/IMR_0001372,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001368,,,,,,,,,,,,,,,,,,,,,,Gli3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003365,forming a complex of CAD and phospholipid [Phospholipidosis (severe) ],,"Forming a complex of CAD and phospholipid is a subtype of forming a complex of drugs and biological substance: A process that forms a complex consisiting phospholipids and CAD (Cationic Amphiphilic Drugs cationic amphiphile drug) in the lysosomal membrane, which causes structural change of the membrane. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",false,,,http://purl.obolibrary.org/obo/TXPO_0003567,,,,,,,,,,,,,,,,,,,,,,"Forming a complex of CAD and phospholipid is a subtype of forming a complex of drugs and biological substance: A process that forms a complex consisiting phospholipids and CAD (Cationic Amphiphilic Drugs cationic amphiphile drug) in the lysosomal membrane, which causes structural change of the membrane. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001560,,,,,,http://purl.obolibrary.org/obo/TXPO_0000010|http://purl.obolibrary.org/obo/TXPO_0001262,,,,,,,,,,,TXPO:0003365,,,,,,,,,,,,,,,,,,,,,,forming a complex of CAD and phospholipid [Phospholipidosis (severe) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003367,CAD accumulation in lysosome [Phospholipidosis],,"CAD accumulation in lysosome is a subtype of compound accumulation in lysosome: A process that keeps CAD (Cationic Amphiphilic Drug) in the lysosome.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0001240,,,,,,,,,,,,,,,,,,,,,,"CAD accumulation in lysosome is a subtype of compound accumulation in lysosome: A process that keeps CAD (Cationic Amphiphilic Drug) in the lysosome.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001560|http://purl.obolibrary.org/obo/TXPO_0000499|http://purl.obolibrary.org/obo/TXPO_0000317|http://purl.obolibrary.org/obo/TXPO_0000313,,,,,,http://purl.obolibrary.org/obo/TXPO_0001551|http://purl.obolibrary.org/obo/TXPO_0003414,,,,,,,,,,,TXPO:0003367,,,,,,,,,,,,,,,,,,,,,,CAD accumulation in lysosome [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005764,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003363,forming a complex of CAD and phospholipid [Phospholipidosis],,"Forming a complex of CAD and phospholipid is a subtype of forming a complex of drugs and biological substance: A process that forms a complex consisiting phospholipids and CAD (Cationic Amphiphilic Drug) in the lysosomal membrane, which causes structural change of the membrane.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0003364,,,,,,,,,,,,,,,,,,,,,,"Forming a complex of CAD and phospholipid is a subtype of forming a complex of drugs and biological substance: A process that forms a complex consisiting phospholipids and CAD (Cationic Amphiphilic Drug) in the lysosomal membrane, which causes structural change of the membrane.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001560,,,,,,,,,,,,,,,,,TXPO:0003363,,,,,,,,,,,,,,,,,,,,,,forming a complex of CAD and phospholipid [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003361,dysfunction of fatty acid degradation [Lipidosis],,"Dysfunction of fatty acid degradation is a subtype of hypofunctioning: A process that performs a decreased or insufficient lipid degradation.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001036|http://purl.obolibrary.org/obo/TXPO_0001720,,,,,,,,,,,,,,,,,,,,,,"Dysfunction of fatty acid degradation is a subtype of hypofunctioning: A process that performs a decreased or insufficient lipid degradation.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001539|http://purl.obolibrary.org/obo/TXPO_0001126,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001044,,,,,,,,,,,TXPO:0003361,,,,,,,,,,,,,,,,,,,,,,dysfunction of fatty acid degradation [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000182,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003366,hypofunction of phospholipid export from lysosome [Phospholipidosis (moderate) ],,"Hypofunction of phospholipid export from lysosome is a subtype of hypofunction of export: A process that performs a decreased or insufficient phospholipid export from lysosome. And the degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (moderate).",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0001261,,,,,,,,,,,,,,,,,,,,,,"Hypofunction of phospholipid export from lysosome is a subtype of hypofunction of export: A process that performs a decreased or insufficient phospholipid export from lysosome. And the degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (moderate).",,,http://purl.obolibrary.org/obo/TXPO_0000200,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003370,,,,,,,,,,,TXPO:0003366,,,,,,,,,,,,,,,,,,,,,,hypofunction of phospholipid export from lysosome [Phospholipidosis (moderate) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003368,CAD insertion into phospholipase binding site to lysosomal inner membrane [Phospholipidosis (moderate) ],,"CAD insertion into phospholipase binding site to lysosomal inner membrane is a subtype of binding: A process that CAD inserts and replaces the phospholipase binding site in the lysosomal inner membrane. And the degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (moderate).",false,,,http://purl.obolibrary.org/obo/TXPO_0001399,,,,,,,,,,,,,,,,,,,,PMID:22960355,,"CAD insertion into phospholipase binding site to lysosomal inner membrane is a subtype of binding: A process that CAD inserts and replaces the phospholipase binding site in the lysosomal inner membrane. And the degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (moderate).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001560,,,,,,http://purl.obolibrary.org/obo/TXPO_0003443,,,,,,,,,,,TXPO:0003368,,,,,,,,,,,,,,,,,,,,,,CAD insertion into phospholipase binding site to lysosomal inner membrane [Phospholipidosis (moderate) ],,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003404,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003362,CAD insertion into phospholipase binding site to lysosomal inner membrane [Phospholipidosis (mild)],,"CAD insertion into phospholipase binding site to lysosomal inner membrane is a subtype of binding: A process that CAD inserts and replaces the phospholipase binding site in the lysosomal inner membrane.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (mild).",false,,,http://purl.obolibrary.org/obo/TXPO_0001399,,,,,,,,,,,,,,,,,,,,PMID:22960355,,"CAD insertion into phospholipase binding site to lysosomal inner membrane is a subtype of binding: A process that CAD inserts and replaces the phospholipase binding site in the lysosomal inner membrane.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (mild).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001560,,,,,,http://purl.obolibrary.org/obo/TXPO_0003412,,,,,,,,,,,TXPO:0003362,,,,,,,,,,,,,,,,,,,,,,CAD insertion into phospholipase binding site to lysosomal inner membrane [Phospholipidosis (mild)],,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003404,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003364,forming a complex of CAD and phospholipid,,"Forming a complex of CAD (Cationic Amphiphilic Drugs) and phospholipid is a subtype of forming a complex of drugs and biological substance: A process that forms a complex consisiting phospholipids and  CAD in the lysosomal membrane, which causes structural change of the membrane.|CAD decreases phospholipid release for cell membrane repair from lysosome.",false,,,http://purl.obolibrary.org/obo/TXPO_0001254,,,,,,,,,,,,,,,,,,,,,,"Forming a complex of CAD (Cationic Amphiphilic Drugs) and phospholipid is a subtype of forming a complex of drugs and biological substance: A process that forms a complex consisiting phospholipids and  CAD in the lysosomal membrane, which causes structural change of the membrane.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_16247,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003364,,,,,,,,,,,,,,,,,,,,CAD decreases phospholipid release for cell membrane repair from lysosome.,,forming a complex of CAD and phospholipid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003369,phospholipidosis (moderate),,The totality of all processes through which the phospholipidosis is realized. The severity is moderate.,false,,,http://purl.obolibrary.org/obo/TXPO_0002215,,,,,,,,,,,,,,,,,,,,PMID:16979167|PMID:22960355|PMID:15342952,,The totality of all processes through which the phospholipidosis is realized. The severity is moderate.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001761|http://purl.obolibrary.org/obo/TXPO_0001700|http://purl.obolibrary.org/obo/TXPO_0001702|http://purl.obolibrary.org/obo/TXPO_0001704|http://purl.obolibrary.org/obo/TXPO_0003454|http://purl.obolibrary.org/obo/TXPO_0003372|http://purl.obolibrary.org/obo/TXPO_0003370|http://purl.obolibrary.org/obo/TXPO_0003371|http://purl.obolibrary.org/obo/TXPO_0003282|http://purl.obolibrary.org/obo/TXPO_0003366|http://purl.obolibrary.org/obo/TXPO_0001822|http://purl.obolibrary.org/obo/TXPO_0002086|http://purl.obolibrary.org/obo/TXPO_0002214,,,,,,,,,,,,,,,,,,TXPO:0003369,,,,,,,,,,,,,,,,,,,,,,phospholipidosis (moderate),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0002058,FGFR4,fibroblast growth factor receptor 4,,false,,,http://purl.obolibrary.org/obo/IMR_0000080,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,fibroblast growth factor receptor 4,,,,,IMR:0002058,,,,,,,,,,,,,,,,,,,,,,FGFR4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000007494,XBP1,,Other designations: X-box-binding protein 1|tax-responsive element-binding protein 5,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,XBP-1|TREB5|XBP2,,,,,,,,,,,,22,,,,,,MIM:194355|Ensembl:ENSG00000100219|HPRD:01908|Vega:OTTHUMG00000151094|HGNC:12801,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,X-box binding protein 1,,,22q12.1|22q12,,,,,,,,,,,,,,,,"GO_0003677 (EC: TAS, PMID: 1718857); GO_0003700 (EC: IEA); GO_0005634 (EC: IDA); GO_0005654 (EC: TAS); GO_0006366 (EC: IEA); GO_0006955 (EC: TAS, PMID: 1718857); GO_0006987 (EC: TAS); GO_0030968 (EC: TAS); GO_0031017 (EC: IEA); GO_0042493 (EC: IEA); GO_0043565 (EC: IEA); GO_0044267 (EC: TAS); GO_0051602 (EC: IEA); GO_0060096 (EC: IEA); GO_0060691 (EC: IEA); GO_0071236 (EC: IEA); GO_1900103 (EC: IMP, PMID: 16645094)",,,,,,,,,PMID: 1718857; 1903538; 2196176; 2321018; 8349596; 8657566; 9563853; 10591208; 10652269; 11076863; 11256614; 11779464; 11813207; 12067985; 12477932; 12586069; 12713871; 12805554; 12949534; 12954762; 14576841; 14634507; 14702039; 15063770; 15149721; 15184063; 15298659; 15331160; 15351732; 15380296; 15461802; 15489334; 15489336; 15598891; 15882996; 15892135; 15927087; 15936534; 16002735; 16009131; 16154272; 16342282; 16381901; 16461360; 16645094; 16958950; 17026957; 17034899; 17092596; 17418411; 17442311; 17660348; 17884689; 17898050; 17906960; 17928342; 17932454; 18082745; 18191223; 18192112; 18386815; 18417469; 18552212; 18583979; 18635891; 18676680; 18775308; 18840095; 18840627; 19009018; 19122331; 19154631; 19170196; 19176362; 19237300; 19265690; 19321437; 19380033; 19389935; 19403667; 19412428; 19416856; 19420237; 19435892; 19470730; 19471022; 19530237; 19543371; 19564049; 19622636; 19625176; 19669932; 19692168; 19722195; 19735688; 19751410; 19941857; 19958799; 20013084; 20170659; 20211142; 20368688; 20421453; 20688044; 20955178; 20980528; 21050047; 21061914; 21085187; 21129256; 21129257; 21138464; 21138840; 21233347; 21385877; 21423203; 21660045; 21693764; 21858728; 21906983; 21924241; 21963094; 22002058; 22370484; 22427205; 22445760; 22469468; 22505724; 22644804; 22669460; 22679299; 22787145; 22925926; 22960999; 23184933; 23277279; 23335490; 23421912; 23447676; 23470653; 23510626; 23560553; 23661758; 23737521; 24027308; 24029229; 24165480,,,,,,,,,,,,,,,OGG:3000007494,,,,,,,X-box binding protein 1,,,,,,,,,,,,,Other designations: X-box-binding protein 1|tax-responsive element-binding protein 5,,XBP1,,,,,,,,,,,,,,,,,,,,,,,7494,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,XBP1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0100248,ZAK,MRK|MLK7|MLTK|zipper sterile alpha motif kinase,,false,,,http://purl.obolibrary.org/obo/IMR_0000239,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MRK|MLK7|MLTK|zipper sterile alpha motif kinase,,,,,IMR:0100248,,,,,,,,,,,,,,,,,,,,,,ZAK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000001544,CYP1A2,,"Other designations: CYPIA2|P450 form 4|aryl hydrocarbon hydroxylase|cytochrome P(3)450|cytochrome P450 1A2|cytochrome P450 4|cytochrome P450, subfamily I (aromatic compound-inducible), polypeptide 2|cytochrome P450-P3|dioxin-inducible P3-450|flavoprotein-linked monooxygenase|microsomal monooxygenase|xenobiotic monooxygenase",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,P3-450|P450(PA)|CP12,,,,,,,,,,,,15,,,,,,Vega:OTTHUMG00000172901|MIM:124060|Ensembl:ENSG00000140505|HPRD:00489|HGNC:2596,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 1, subfamily A, polypeptide 2",,,15q24.1,,,,,,,,,,,,,,,,"GO_0004497 (EC: IDA, PMID:15327587); GO_0005506 (EC: IEA); GO_0005789 (EC: TAS); GO_0006706 (EC: IMP, PMID:18356043); GO_0006778 (EC: IEA); GO_0006805 (EC: TAS); GO_0009055 (EC: TAS, PMID:2813353); GO_0009403 (EC: IDA, PMID:11511187); GO_0009791 (EC: IEA); GO_0009820 (EC: IDA, PMID:11511187); GO_0010468 (EC: IEA); GO_0016098 (EC: IDA, PMID:16401082); GO_0016491 (EC: IDA, PMID:16401082); GO_0016712 (EC: IMP, PMID:2813353); GO_0017144 (EC: IDA, PMID:15327587); GO_0018894 (EC: IEA); GO_0019369 (EC: TAS); GO_0019373 (EC: TAS); GO_0019899 (EC: IPI, PMID:15680923); GO_0020037 (EC: IDA, PMID:17311915); GO_0030324 (EC: IEA); GO_0032259 (EC: TAS); GO_0032355 (EC: IEA); GO_0032451 (EC: IDA, PMID:2813353); GO_0032496 (EC: IEA); GO_0032787 (EC: IDA, PMID:19651758); GO_0034875 (EC: IDA, PMID:18619574); GO_0042737 (EC: IMP, PMID:18356043); GO_0042738 (EC: IDA, PMID:18619574); GO_0043231 (EC: IDA, PMID:2813353); GO_0044281 (EC: TAS); GO_0045333 (EC: IEA); GO_0046483 (EC: IDA, PMID:15327587); GO_0050665 (EC: IEA); GO_0055114 (EC: IDA, PMID:16401082); GO_0070330 (EC: IEA); GO_0070989 (EC: IDA, PMID:18619574); GO_0071276 (EC: IEA); GO_0071615 (EC: IDA, PMID:19029318); GO_0097267 (EC: TAS)",,,,,,,,,PMID:2575218; 2813353; 3000715; 3462722; 3517618; 3681487; 3755823; 8095225; 8287062; 8553685; 8573198; 8694864; 9398194; 9598815; 9797707; 9884316; 9890157; 10463577; 10493258; 10791558; 11153915; 11186132; 11207026; 11275366; 11393588; 11470995; 11496364; 11501059; 11507974; 11511187; 11749050; 11763009; 11782366; 11791895; 11817502; 11943609; 12067576; 12147246; 12181774; 12419832; 12445029; 12445035; 12477932; 12484238; 12534642; 12566081; 12569554; 12618594; 12630986; 12663508; 12692107; 12732846; 12790158; 12851801; 12900870; 12920202; 12925300; 12943470; 14563787; 14640293; 14648207; 14695651; 14714565; 14723376; 14976127; 15039299; 15110095; 15128046; 15241822; 15299091; 15319333; 15327587; 15349722; 15363478; 15382051; 15387446; 15466009; 15469410; 15489334; 15505641; 15519301; 15564895; 15643613; 15680923; 15734958; 15763632; 15770072; 15774926; 15849225; 15890241; 15901993; 15941966; 15949157; 15987714; 15996939; 16006997; 16048566; 16103451; 16130011; 16153396; 16157215; 16172230; 16188490; 16204462; 16307269; 16324277; 16385402; 16401082; 16402077; 16402549; 16406813; 16426572; 16471212; 16495781; 16505155; 16522833; 16538170; 16538176; 16609368; 16636061; 16740387; 16772608; 16775389; 16782969; 16800822; 16864595; 16882880; 16933202; 16969362; 16985026; 16985250; 17065585; 17164366; 17178267; 17191090; 17259654; 17295924; 17311915; 17345072; 17363580; 17370067; 17372239; 17418993; 17429315; 17477782; 17498780; 17503978; 17507615; 17507624; 17509724; 17564586; 17603224; 17603900; 17611010; 17615053; 17616786; 17627011; 17635176; 17688403; 17695473; 17823232; 17823234; 17852022; 17900275; 18052847; 18075470; 18077912; 18159984; 18180754; 18187423; 18200441; 18223460; 18231117; 18268115; 18318428; 18356043; 18389617; 18398030; 18455494; 18466106; 18490497; 18493746; 18496682; 18497059; 18499698; 18510611; 18544563; 18551037; 18569587; 18619574; 18628519; 18632753; 18690546; 18703023; 18751408; 18759349; 18784359; 18798002; 18801337; 18813311; 18825963; 18840375; 18850169; 18936436; 18941913; 18990750; 18992148; 18996102; 19000940; 19026171; 19029318; 19095219; 19106084; 19219744; 19229255; 19273964; 19274061; 19276377; 19285097; 19290787; 19307236; 19332078; 19336370; 19338043; 19339270; 19343046; 19356113; 19414633; 19415745; 19424794; 19430483; 19442564; 19450128; 19451835; 19452301; 19453261; 19479063; 19507017; 19534587; 19569730; 19571439; 19574343; 19575027; 19576320; 19583676; 19593158; 19593168; 19605743; 19636338; 19643819; 19651758; 19666078; 19682433; 19692168; 19751749; 19776291; 19789190; 19806921; 19822571; 19823875; 19843669; 19860743; 19913121; 19926050; 19956635; 19961320; 20029944; 20043572; 20047124; 20054636; 20080081; 20118554; 20125119; 20131310; 20136364; 20147896; 20163457; 20173083; 20175915; 20213484; 20214802; 20218903; 20304699; 20375710; 20381444; 20389299; 20390257; 20403997; 20437850; 20453000; 20505544; 20529763; 20559687; 20583967; 20602612; 20602615; 20628086; 20634197; 20634891; 20641098; 20652353; 20656072; 20663043; 20691427; 20701904; 20734064; 20797314; 20806393; 20829355; 20853468; 20881513; 20930417; 20933493; 20957336; 20970553; 21071160; 21072184; 21081473; 21086794; 21148426; 21210738; 21262253; 21281405; 21329464; 21357676; 21480221; 21490707; 21505853; 21598960; 21825116; 21876539; 21929532; 21977969; 22072123; 22086975; 22141270; 22228482; 22246422; 22258279; 22336631; 22426036; 22448362; 22466345; 22492992; 22628494; 22648710; 22673010; 22749033; 22785257; 22854411; 22855999; 22948892; 22949628; 23081704; 23128882; 23133610; 23138776; 23157985; 23167834; 23278694; 23292087; 23353840; 23492908; 23492909; 23601795; 23603339; 23628800; 23859573,,,,,,,,,,,,,,,OGG:3000001544,,,,,,,"cytochrome P450, family 1, subfamily A, polypeptide 2",,,,,,,,,,,,,"Other designations: CYPIA2|P450 form 4|aryl hydrocarbon hydroxylase|cytochrome P(3)450|cytochrome P450 1A2|cytochrome P450 4|cytochrome P450, subfamily I (aromatic compound-inducible), polypeptide 2|cytochrome P450-P3|dioxin-inducible P3-450|flavoprotein-linked monooxygenase|microsomal monooxygenase|xenobiotic monooxygenase",,CYP1A2,,,,,,,,,,,,,,,,,,,,,,,1544,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP1A2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001548,CYP2A6,,"Other designations: 1,4-cineole 2-exo-monooxygenase|coumarin 7-hydroxylase|cytochrome P450 2A6|cytochrome P450 IIA3|cytochrome P450(I)|cytochrome P450, subfamily IIA (phenobarbital-inducible), polypeptide 6|flavoprotein-linked monooxygenase|xenobiotic monooxygenase",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,P450PB|CYPIIA6|CPA6|CYP2A|P450C2A|CYP2A3,,,,,,,,,,,,19,,,,,,HPRD:00420|Ensembl:ENSG00000255974|Vega:OTTHUMG00000182713|HGNC:2610|MIM:122720,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 2, subfamily A, polypeptide 6",,,19q13.2,,,,,,,,,,,,,,,,"GO_0005506 (EC: IEA); GO_0005789 (EC: TAS); GO_0005881 (EC: IDA); GO_0006805 (EC: TAS); GO_0008202 (EC: IMP, PMID:18356043); GO_0008389 (EC: IDA, PMID:16086027); GO_0009804 (EC: IDA, PMID:19651758); GO_0016712 (EC: IEA); GO_0017144 (EC: IDA, PMID:19651758); GO_0017144 (EC: IMP, PMID:18356043); GO_0019899 (EC: IPI, PMID:15680923); GO_0020037 (EC: IDA, PMID:16086027); GO_0042738 (EC: IDA, PMID:15680923); GO_0044281 (EC: TAS); GO_0046226 (EC: IDA, PMID:19029318)",,,,,,,,,PMID:1889415; 1944238; 2322567; 2726448; 2748347; 3856261; 4011450; 7581481; 7668294; 7864805; 8587134; 9409631; 9827545; 9890157; 10544257; 10781881; 11054771; 11207029; 11237731; 11241319; 11259349; 11278503; 11434509; 11684323; 11725533; 11805739; 11927498; 11927840; 11960911; 11960914; 12115524; 12162851; 12164325; 12172220; 12223434; 12325023; 12406643; 12419832; 12445030; 12477932; 12708602; 12721789; 12749606; 12844137; 12883749; 14568264; 14583682; 14981342; 15039299; 15128046; 15203795; 15225612; 15308589; 15327835; 15370155; 15454735; 15469410; 15475735; 15489334; 15534625; 15564629; 15592323; 15618701; 15660270; 15665333; 15671201; 15680923; 15861035; 15861044; 15900015; 15940289; 15993850; 16006997; 16041240; 16048566; 16086027; 16126166; 16176798; 16207711; 16272956; 16344560; 16372023; 16377082; 16378601; 16402086; 16402128; 16452582; 16470306; 16636685; 16720336; 16758265; 16857725; 16891249; 16952495; 17015050; 17036930; 17112802; 17130279; 17156750; 17207267; 17220563; 17259654; 17267622; 17454707; 17522595; 17540336; 17549345; 17646279; 17683511; 17916905; 17927692; 17934923; 17979512; 18004205; 18188752; 18212800; 18216723; 18356043; 18360915; 18380793; 18425152; 18510611; 18666753; 18698229; 18715882; 18936436; 18941913; 18976031; 18979093; 19012698; 19029318; 19040121; 19082995; 19104915; 19225447; 19251454; 19279561; 19290787; 19300303; 19303722; 19339270; 19343046; 19361454; 19365400; 19371316; 19387893; 19406142; 19415821; 19454817; 19479063; 19533856; 19537956; 19604090; 19643819; 19651758; 19659438; 19702528; 19703308; 19751749; 19779319; 19789190; 19845430; 19921195; 19956635; 20012030; 20061389; 20089352; 20136358; 20139165; 20155256; 20173083; 20177288; 20336063; 20418888; 20418890; 20437850; 20438369; 20506136; 20596643; 20647221; 20656072; 20701904; 20717551; 20719908; 20734048; 20734064; 20860463; 20887713; 21205058; 21265876; 21326246; 21410749; 21418183; 21473878; 21521021; 21685187; 21745589; 21747048; 21765098; 21791872; 21964962; 22073590; 22080838; 22160797; 22217675; 22271297; 22322240; 22342802; 22465937; 22497566; 22498344; 22547082; 22614024; 22696418; 22706231; 22847926; 22854688; 22890016; 23049750; 23178447; 23203414; 23292114; 23371292; 23462429; 23471717; 23528144; 23585826; 23649654; 23733493; 23813797,,,,,,,,,,,,,,,OGG:3000001548,,,,,,,"cytochrome P450, family 2, subfamily A, polypeptide 6",,,,,,,,,,,,,"Other designations: 1,4-cineole 2-exo-monooxygenase|coumarin 7-hydroxylase|cytochrome P450 2A6|cytochrome P450 IIA3|cytochrome P450(I)|cytochrome P450, subfamily IIA (phenobarbital-inducible), polypeptide 6|flavoprotein-linked monooxygenase|xenobiotic monooxygenase",,CYP2A6,,,,,,,,,,,,,,,,,,,,,,,1548,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP2A6,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001543,CYP1A1,,"Other designations: CYPIA1|aryl hydrocarbon hydroxylase|cytochrome P1-450, dioxin-inducible|cytochrome P450 1A1|cytochrome P450 form 6|cytochrome P450, subfamily I (aromatic compound-inducible), polypeptide 1|cytochrome P450-C|cytochrome P450-P1|flavoprotein-linked monooxygenase|xenobiotic monooxygenase",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,AHH|P450DX|CYP1|CP11|P450-C|P1-450|AHRR,,,,,,,,,,,,15,,,,,,HPRD:00148|HGNC:2595|MIM:108330|Vega:OTTHUMG00000142812|Ensembl:ENSG00000140465,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 1, subfamily A, polypeptide 1",,,15q24.1,,,,,,,,,,,,,,,,"GO_0001666 (EC: IEA); GO_0005506 (EC: IEA); GO_0005739 (EC: IEA); GO_0005789 (EC: TAS); GO_0006778 (EC: IEA); GO_0006805 (EC: TAS); GO_0007568 (EC: IEA); GO_0008283 (EC: IEA); GO_0008395 (EC: IEA); GO_0009308 (EC: IEA); GO_0009611 (EC: IEA); GO_0009615 (EC: IEA); GO_0009624 (EC: IEA); GO_0009635 (EC: IEA); GO_0009792 (EC: IEA); GO_0009804 (EC: IEA); GO_0009812 (EC: IEA); GO_0010041 (EC: IEA); GO_0014070 (EC: IEA); GO_0016491 (EC: IDA, PMID:19219744); GO_0016679 (EC: IEA); GO_0016711 (EC: IEA); GO_0017143 (EC: IEA); GO_0017144 (EC: IDA, PMID:19219744); GO_0019341 (EC: IEA); GO_0019369 (EC: TAS); GO_0019373 (EC: TAS); GO_0019825 (EC: TAS, PMID:1691986); GO_0019899 (EC: IEA); GO_0020037 (EC: IEA); GO_0032094 (EC: IEA); GO_0032451 (EC: IEA); GO_0032496 (EC: IEA); GO_0033189 (EC: IEA); GO_0042359 (EC: IC, PMID:15546903); GO_0042493 (EC: IEA); GO_0042904 (EC: IEA); GO_0043010 (EC: IEA); GO_0044255 (EC: TAS); GO_0044281 (EC: TAS); GO_0046677 (EC: IEA); GO_0046685 (EC: IEA); GO_0048565 (EC: IEA); GO_0050665 (EC: IEA); GO_0055093 (EC: IEA); GO_0055114 (EC: IDA, PMID:19219744); GO_0060137 (EC: IEA); GO_0070330 (EC: IEA); GO_0070365 (EC: IEA); GO_0070576 (EC: IDA, PMID:15546903); GO_0097267 (EC: TAS); GO_1900087 (EC: IEA)",,,,,,,,,PMID:1691986; 1722803; 1761516; 2989797; 3000715; 3019683; 3714481; 3838385; 4000952; 6102994; 8095225; 8125298; 8313840; 8442765; 8548778; 8895751; 9500998; 9890157; 10493257; 10612842; 10739168; 11037802; 11037803; 11045797; 11052546; 11124296; 11159735; 11162685; 11172643; 11191882; 11207026; 11236859; 11246217; 11259393; 11275366; 11279306; 11291049; 11295132; 11295847; 11325850; 11330960; 11389067; 11393538; 11396202; 11406420; 11406608; 11408349; 11408954; 11410321; 11418090; 11422615; 11434510; 11436564; 11459424; 11470760; 11470992; 11470996; 11471167; 11484167; 11485833; 11487538; 11488937; 11500195; 11501853; 11503278; 11507974; 11511301; 11520401; 11525595; 11535253; 11551408; 11564581; 11641039; 11675150; 11675474; 11689007; 11698341; 11719088; 11751440; 11752233; 11779261; 11792676; 11793160; 11798822; 11833070; 11854392; 11859435; 11860825; 11860900; 11872636; 11895912; 11934439; 11952781; 11955671; 11967624; 11996959; 12018173; 12030651; 12034316; 12036913; 12063626; 12071517; 12100112; 12110344; 12139735; 12144816; 12147246; 12163326; 12170467; 12171760; 12175533; 12183419; 12189551; 12210502; 12210751; 12237110; 12269988; 12297440; 12351530; 12354067; 12365037; 12378791; 12397416; 12419832; 12435115; 12464257; 12468438; 12477932; 12484238; 12490585; 12496044; 12527337; 12548461; 12569554; 12574216; 12579334; 12590982; 12594823; 12602902; 12620480; 12631667; 12646505; 12670526; 12680328; 12690010; 12713578; 12718576; 12729704; 12732844; 12738724; 12746631; 12748560; 12760253; 12767509; 12767526; 12771031; 12772461; 12777964; 12824892; 12827651; 12845676; 12846365; 12854128; 12879168; 12880680; 12883749; 12903034; 12919721; 12925969; 12934333; 12949934; 14510941; 14534704; 14560034; 14582397; 14602139; 14602525; 14611903; 14634838; 14639127; 14646291; 14656945; 14665706; 14675315; 14687717; 14693745; 14695173; 14719475; 14724908; 14734460; 14758730; 14991750; 15013696; 15037607; 15039299; 15052670; 15059326; 15061915; 15064998; 15069692; 15088300; 15093273; 15111988; 15124938; 15127181; 15127559; 15128046; 15136237; 15152552; 15176217; 15177667; 15180167; 15184245; 15185560; 15194533; 15195126; 15206494; 15215328; 15217514; 15241822; 15279831; 15298956; 15298960; 15299091; 15319333; 15327835; 15333250; 15333597; 15341023; 15352038; 15355699; 15363546; 15375499; 15376230; 15381379; 15382051; 15382273; 15386428; 15459023; 15469410; 15478298; 15489334; 15491310; 15496536; 15521013; 15526353; 15528152; 15546903; 15547760; 15552037; 15579657; 15583370; 15591802; 15596250; 15605089; 15618738; 15640066; 15642161; 15643613; 15646021; 15647817; 15648054; 15653213; 15671210; 15712341; 15725614; 15731166; 15734083; 15734958; 15756908; 15764294; 15765281; 15769360; 15774541; 15774926; 15801491; 15849806; 15856430; 15861041; 15867368; 15870154; 15914211; 15914277; 15920291; 15928955; 15931768; 15938845; 15941966; 15952134; 15953982; 15981231; 15986113; 15991278; 16009381; 16012082; 16037119; 16043197; 16051642; 16084889; 16099114; 16103451; 16130011; 16142442; 16153604; 16202920; 16227674; 16228113; 16235998; 16254684; 16260521; 16270381; 16273625; 16284375; 16284498; 16318816; 16319265; 16337337; 16357593; 16357600; 16360200; 16367916; 16393248; 16402077; 16402549; 16403567; 16407087; 16414014; 16416283; 16424825; 16426572; 16466991; 16471212; 16481407; 16484137; 16488179; 16492926; 16493615; 16505155; 16527884; 16580705; 16598069; 16599372; 16608396; 16609368; 16614107; 16614120; 16620591; 16625286; 16638864; 16676594; 16697254; 16721740; 16763966; 16767678; 16771603; 16788090; 16792888; 16803538; 16807674; 16823842; 16834659; 16835796; 16837240; 16864595; 16882880; 16914185; 16926176; 16947004; 16949388; 16956909; 16971197; 16977255; 16985026; 16985033; 16985250; 16998606; 17022435; 17035385; 17053541; 17063266; 17078101; 17081983; 17083362; 17113562; 17118447; 17119063; 17158763; 17160265; 17160896; 17164366; 17167268; 17171211; 17174438; 17191090; 17192049; 17220347; 17307802; 17307803; 17311112; 17316563; 17361553; 17363580; 17367411; 17372239; 17372243; 17372252; 17403528; 17408703; 17412371; 17427032; 17428572; 17429172; 17429315; 17449539; 17461521; 17477782; 17479406; 17496311; 17498780; 17507624; 17512722; 17512776; 17526865; 17531965; 17548691; 17549424; 17566695; 17577786; 17588204; 17589376; 17590289; 17603290; 17610937; 17611777; 17620151; 17623765; 17630984; 17640999; 17642299; 17646057; 17651397; 17695473; 17706398; 17711714; 17717632; 17728147; 17786624; 17823232; 17852022; 17873299; 17896209; 17900751; 17908297; 17919073; 17919675; 17959138; 17980001; 17980933; 17981384; 17982751; 17996038; 18061941; 18065768; 18070799; 18074679; 18078203; 18082227; 18090121; 18159984; 18180754; 18200441; 18203021; 18203634; 18224491; 18241825; 18247309; 18261353; 18268125; 18285692; 18287863; 18287869; 18304461; 18317771; 18318428; 18320229; 18339256; 18351133; 18389617; 18409146; 18409147; 18414197; 18415690; 18415801; 18437510; 18447907; 18449058; 18463401; 18493746; 18495522; 18496222; 18497059; 18507050; 18507060; 18510611; 18550589; 18569591; 18577398; 18589596; 18590468; 18593984; 18601742; 18618215; 18628428; 18632753; 18636124; 18642288; 18676680; 18691756; 18698632; 18700132; 18706519; 18763031; 18767181; 18768509; 18774560; 18779756; 18784359; 18798002; 18800292; 18818748; 18819424; 18824009; 18849443; 18936436; 18941913; 18979064; 18980759; 18990008; 18990750; 18992263; 19009239; 19012698; 19013013; 19019335; 19022366; 19024313; 19031960; 19064581; 19070657; 19074885; 19110417; 19126602; 19127255; 19138996; 19143007; 19147266; 19160101; 19170196; 19174490; 19178087; 19219744; 19222528; 19229255; 19246429; 19252926; 19264525; 19267064; 19276377; 19285097; 19287966; 19290787; 19303595; 19307236; 19317600; 19336370; 19338043; 19339270; 19343046; 19346634; 19351467; 19356113; 19387820; 19412423; 19414505; 19415745; 19424633; 19424794; 19427967; 19430483; 19443378; 19452301; 19453261; 19456854; 19469619; 19472123; 19479063; 19505920; 19507017; 19507064; 19521675; 19526463; 19527514; 19537956; 19538838; 19561157; 19563927; 19574343; 19575027; 19576320; 19582785; 19598235; 19608585; 19625176; 19627379; 19630952; 19632247; 19639480; 19643819; 19650794; 19666078; 19679043; 19682433; 19692168; 19718946; 19750329; 19751749; 19776291; 19786002; 19789190; 19789301; 19797843; 19799358; 19822571; 19826048; 19827888; 19860743; 19863350; 19892789; 19899130; 19903800; 19913121; 19947517; 19948975; 19954068; 19954069; 19963114; 19963139; 19995559; 20009880; 20012094; 20027111; 20029944; 20032816; 20035380; 20047124; 20052535; 20054510; 20080081; 20088379; 20088394; 20094781; 20095411; 20131310; 20136364; 20177288; 20193595; 20214802; 20226777; 20297661; 20345875; 20373852; 20375710; 20377136; 20381444; 20428802; 20437850; 20453000; 20462615; 20491576; 20511665; 20529763; 20534171; 20544687; 20554493; 20559649; 20579990; 20584197; 20596254; 20602615; 20628086; 20628863; 20634197; 20634891; 20638923; 20644561; 20661821; 20664892; 20700368; 20701904; 20704749; 20723587; 20734064; 20734807; 20804547; 20817259; 20845989; 20846153; 20850372; 20855412; 20878561; 20878621; 20883830; 20884258; 20886582; 20887941; 20937634; 20957336; 20962519; 20965504; 20970553; 21081473; 21086258; 21130723; 21211368; 21246002; 21254355; 21254556; 21262253; 21270613; 21304969; 21329749; 21357676; 21385088; 21402622; 21418988; 21438753; 21490707; 21508386; 21545198; 21545219; 21586621; 21590276; 21709011; 21710246; 21718208; 21775774; 21848428; 21859547; 21869479; 21870186; 21876539; 21909115; 21977969; 22000673; 22018952; 22025136; 22086975; 22088806; 22109568; 22154617; 22183307; 22213191; 22217397; 22236719; 22273851; 22277800; 22292665; 22294106; 22296350; 22297691; 22304463; 22311486; 22312901; 22359202; 22365406; 22374940; 22384629; 22392998; 22395499; 22422552; 22442665; 22448487; 22470100; 22579698; 22594779; 22611936; 22660220; 22664944; 22707145; 22733497; 22752755; 22754477; 22782580; 22837390; 22846179; 22847262; 22854411; 22855999; 22876118; 22893352; 22901117; 22909097; 22918668; 22948778; 22949628; 22951721; 22952673; 22964275; 22994769; 22997752; 23000097; 23013535; 23033491; 23046808; 23055196; 23056546; 23065259; 23065291; 23098461; 23111888; 23124075; 23152866; 23174221; 23178447; 23229202; 23259321; 23288144; 23293967; 23350368; 23353840; 23369756; 23381648; 23411129; 23419638; 23424205; 23471717; 23475304; 23492908; 23508959; 23528250; 23548414; 23619522; 23661361; 23707957; 23785672; 23816456; 23832578; 23840148; 23842721; 23860774; 23870476; 23886179; 23918309; 24091107; 24316127; 24355420,,,,,,,,,,,,,,,OGG:3000001543,,,,,,,"cytochrome P450, family 1, subfamily A, polypeptide 1",,,,,,,,,,,,,"Other designations: CYPIA1|aryl hydrocarbon hydroxylase|cytochrome P1-450, dioxin-inducible|cytochrome P450 1A1|cytochrome P450 form 6|cytochrome P450, subfamily I (aromatic compound-inducible), polypeptide 1|cytochrome P450-C|cytochrome P450-P1|flavoprotein-linked monooxygenase|xenobiotic monooxygenase",,CYP1A1,,,,,,,,,,,,,,,,,,,,,,,1543,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP1A1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001545,CYP1B1,,"Other designations: aryl hydrocarbon hydroxylase|cytochrome P450 1B1|cytochrome P450, subfamily I (dioxin-inducible), polypeptide 1 (glaucoma 3, primary infantile)|flavoprotein-linked monooxygenase|microsomal monooxygenase|xenobiotic monooxygenase",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,GLC3A|CP1B|P4501B1|CYPIB1,,,,,,,,,,,,2,,,,,,HGNC:2597|Ensembl:ENSG00000138061|MIM:601771|HPRD:03464|Vega:OTTHUMG00000100970,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 1, subfamily B, polypeptide 1",,,2p22.2,,,,,,,,,,,,,,,,"GO_0001525 (EC: IEA); GO_0004497 (EC: TAS, PMID:9097971); GO_0005506 (EC: IEA); GO_0005789 (EC: TAS); GO_0006725 (EC: IEA); GO_0006805 (EC: IDA); GO_0006805 (EC: TAS); GO_0007601 (EC: TAS, PMID:9097971); GO_0008202 (EC: IDA); GO_0009404 (EC: IEA); GO_0009636 (EC: IEA); GO_0016125 (EC: TAS); GO_0016712 (EC: IDA, PMID:10871058); GO_0019369 (EC: TAS); GO_0019373 (EC: TAS); GO_0019825 (EC: TAS, PMID:9097971); GO_0020037 (EC: IDA); GO_0020037 (EC: TAS, PMID:9097971); GO_0043542 (EC: IEA); GO_0044281 (EC: TAS); GO_0055114 (EC: TAS, PMID:9097971); GO_0061298 (EC: IEA); GO_0070330 (EC: IEA); GO_0071603 (EC: IEA); GO_0097267 (EC: TAS)",,,,,,,,,PMID:1925598; 8175734; 8910454; 9097971; 9463332; 9497261; 9823305; 9890157; 10227395; 10614688; 10871058; 11221602; 11303589; 11389067; 11403040; 11452143; 11555828; 11558822; 11749050; 11774072; 11854439; 11955671; 12010864; 12183407; 12200121; 12372064; 12385014; 12415427; 12419832; 12477932; 12520071; 12525557; 12567107; 12598442; 12602902; 12618873; 12692107; 12718576; 12770747; 12807732; 12837283; 12844487; 12873984; 14507861; 14520706; 14562027; 14634838; 14656940; 14729846; 14734460; 14744739; 14961553; 15041720; 15072827; 15075793; 15102677; 15122594; 15128046; 15177664; 15199113; 15255109; 15255550; 15285606; 15297370; 15299091; 15333708; 15342454; 15342556; 15342693; 15382051; 15386537; 15475877; 15489334; 15596250; 15636228; 15654505; 15723004; 15733270; 15734954; 15734958; 15774541; 15777990; 15808404; 15861043; 15896461; 15905203; 15941966; 15958554; 15987428; 16006997; 16051642; 16103451; 16115918; 16172228; 16172230; 16202920; 16207128; 16260521; 16284375; 16319265; 16319821; 16344560; 16384942; 16490498; 16569655; 16598069; 16638984; 16688110; 16716118; 16730930; 16735991; 16735994; 16766147; 16808847; 16847423; 16850246; 16862072; 16864595; 16896040; 16949388; 16963504; 16977255; 16978616; 16985026; 16985250; 17035385; 17053044; 17063266; 17077994; 17157584; 17164573; 17174438; 17187946; 17200336; 17220347; 17224759; 17224914; 17301257; 17311112; 17321191; 17353931; 17363580; 17372239; 17372243; 17403528; 17429315; 17449539; 17449559; 17458695; 17496311; 17498780; 17507616; 17507624; 17548691; 17562158; 17563717; 17575219; 17588204; 17589376; 17591938; 17603900; 17615053; 17627011; 17642299; 17687619; 17704407; 17718864; 17893647; 17914928; 17919675; 17922187; 17925548; 17980933; 18055790; 18059014; 18067928; 18070520; 18187806; 18227148; 18258609; 18268125; 18318428; 18347981; 18385784; 18414103; 18415014; 18425393; 18470941; 18483560; 18486761; 18497059; 18510611; 18537981; 18544568; 18569579; 18569591; 18573508; 18575334; 18616618; 18622259; 18628428; 18632753; 18676680; 18763031; 18779756; 18784359; 18794456; 18820009; 18829176; 18841557; 18852424; 18922394; 18936436; 18977467; 18980759; 18989382; 18990750; 18992148; 19015200; 19031960; 19064581; 19074885; 19083124; 19094228; 19096718; 19116217; 19126602; 19127255; 19138946; 19138996; 19170196; 19174490; 19179758; 19195637; 19199255; 19208203; 19214745; 19229255; 19234632; 19247456; 19274671; 19287966; 19290787; 19293312; 19324859; 19331196; 19338043; 19343046; 19349377; 19357154; 19383894; 19414505; 19415745; 19424633; 19424794; 19443378; 19453261; 19479063; 19505920; 19514368; 19528825; 19536304; 19574343; 19575027; 19582785; 19597567; 19598235; 19622003; 19625176; 19630952; 19643970; 19666078; 19668563; 19668597; 19690133; 19692168; 19730035; 19736056; 19744731; 19751749; 19754948; 19776291; 19789190; 19789301; 19793111; 19820397; 19822571; 19857456; 19860743; 19895167; 19898482; 19908239; 19913121; 19956635; 19963139; 19995559; 20027111; 20029944; 20033481; 20037207; 20051892; 20054638; 20057908; 20088394; 20131310; 20137445; 20151268; 20184498; 20198857; 20198978; 20212917; 20214802; 20301314; 20357201; 20375710; 20391138; 20395011; 20403997; 20453000; 20461808; 20462226; 20492382; 20505544; 20529763; 20559649; 20568895; 20628086; 20632082; 20634197; 20634891; 20660114; 20664688; 20678202; 20683028; 20701755; 20734064; 20830506; 20845989; 20875115; 20878130; 20884258; 20887769; 21072184; 21081473; 21081970; 21139974; 21147782; 21168818; 21191305; 21303932; 21306220; 21409489; 21438753; 21458313; 21596299; 21600657; 21614911; 21655360; 21674184; 21683070; 21707071; 21742528; 21850185; 21854771; 21890473; 21963094; 21987572; 22004014; 22011756; 22114726; 22128238; 22138065; 22177211; 22190224; 22232929; 22272893; 22296381; 22327650; 22374940; 22459615; 22466345; 22504876; 22509109; 22594779; 22840970; 22859684; 22878448; 22942166; 23028769; 23032576; 23087145; 23215915; 23218183; 23218701; 23283740; 23325794; 23350153; 23350368; 23353840; 23370603; 23757320; 23785672; 23794133; 23861929; 23922489; 24227805,,,,,,,,,,,,,,,OGG:3000001545,,,,,,,"cytochrome P450, family 1, subfamily B, polypeptide 1",,,,,,,,,,,,,"Other designations: aryl hydrocarbon hydroxylase|cytochrome P450 1B1|cytochrome P450, subfamily I (dioxin-inducible), polypeptide 1 (glaucoma 3, primary infantile)|flavoprotein-linked monooxygenase|microsomal monooxygenase|xenobiotic monooxygenase",,CYP1B1,,,,,,,,,,,,,,,,,,,,,,,1545,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP1B1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001549,CYP2A7,,"Other designations: cytochrome P450 2A7|cytochrome P450 IIA4|cytochrome P450, subfamily IIA (phenobarbital-inducible), polypeptide 7|cytochrome P450IIA4",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CPA7|CYP2A|CPAD|CYPIIA7|P450-IIA4,,,,,,,,,,,,19,,,,,,MIM:608054|HGNC:2611|Vega:OTTHUMG00000182715|Ensembl:ENSG00000198077|HPRD:07453,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 2, subfamily A, polypeptide 7",,,19q13.2,,,,,,,,,,,,,,,,"GO_0005506 (EC: IEA); GO_0005789 (EC: IEA); GO_0019825 (EC: TAS, PMID:7864805); GO_0020037 (EC: IEA); GO_0070330 (EC: IEA)",,,,,,,,,PMID:2322567; 7668294; 7864805; 8043031; 8587134; 9890157; 10353262; 10493259; 11960914; 12325023; 12477932; 15128046; 16636685; 22890016,,,,,,,,,,,,,,,OGG:3000001549,,,,,,,"cytochrome P450, family 2, subfamily A, polypeptide 7",,,,,,,,,,,,,"Other designations: cytochrome P450 2A7|cytochrome P450 IIA4|cytochrome P450, subfamily IIA (phenobarbital-inducible), polypeptide 7|cytochrome P450IIA4",,CYP2A7,,,,,,,,,,,,,,,,,,,,,,,1549,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP2A7,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/GO_0050896,response to stimulus,,"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus. The process begins with detection of the stimulus and ends with a change in state or activity or the cell or organism.",false,,,http://purl.obolibrary.org/obo/TXPO_0001984,,,,,,,,,,,,,,,,,,,,,,"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus. The process begins with detection of the stimulus and ends with a change in state or activity or the cell or organism.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0050896,,,,,,,,,,,,,,,,,,,,,,response to stimulus,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100076,pancreatic hormone,,Peptide hormones secreted into the blood by cells in the ISLETS OF LANGERHANS of the pancreas. The alpha cells secrete glucagon; the beta cells secrete insulin; the delta cells secrete somatostatin; and the PP cells secrete pancreatic polypeptide.,false,,,http://purl.obolibrary.org/obo/IMR_0000966,,,,,,,,,,,,,,,,,,,,MeSH:D010187,,Peptide hormones secreted into the blood by cells in the ISLETS OF LANGERHANS of the pancreas. The alpha cells secrete glucagon; the beta cells secrete insulin; the delta cells secrete somatostatin; and the PP cells secrete pancreatic polypeptide.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_24621,,,,,,,,,,IMR:0100076,,,,,,,,,,,,,,,,,,,,,,pancreatic hormone,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003875,constitutive androstane receptor activation by phenobarbital (moderate) [Ground glass appearance ],continued CAR activation [Ground glass appearance]|CAR activating [sustained] [Ground glass ],"Constitutive androstane receptor activation by phenobarbital is a subtype of activating nuclear receptor: A process that changes the activity of the activating CAR ( constitutive androstane receptor) with a nuclear receptor role to be higher by phenobarbital.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (moderate) .",false,,,http://purl.obolibrary.org/obo/TXPO_0002309,,,,,,,,,,,,,,,,,,,,,,"Constitutive androstane receptor activation by phenobarbital is a subtype of activating nuclear receptor: A process that changes the activity of the activating CAR ( constitutive androstane receptor) with a nuclear receptor role to be higher by phenobarbital.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (moderate) .",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001524,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003874,,,,,,continued CAR activation [Ground glass appearance]|CAR activating [sustained] [Ground glass ],,,,,TXPO:0003875,,,,,,,,,,,,,,,,,,,,,,constitutive androstane receptor activation by phenobarbital (moderate) [Ground glass appearance ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003871,hyperfunction of decreasing the amount of phenobarbital [Ground glass appearance (moderate) ],,"Hyperfunction of decreasing the amount of phenobarbital is a subtype of hyperfunction of decreasing: A process that performs an excesssive decreasing the amount of the phenobarbital. And the degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (moderate) .",false,,,http://purl.obolibrary.org/obo/TXPO_0001654,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of decreasing the amount of phenobarbital is a subtype of hyperfunction of decreasing: A process that performs an excesssive decreasing the amount of the phenobarbital. And the degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (moderate) .",,,http://purl.obolibrary.org/obo/TXPO_0001647,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003873|http://purl.obolibrary.org/obo/TXPO_0003872,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003869,,,,,,,,,,,TXPO:0003871,,,,,,,,,,,,,,,,,,,,,,hyperfunction of decreasing the amount of phenobarbital [Ground glass appearance (moderate) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003876,hyperfunction of moving phenobarbital to the inside of liver [Ground glass appearance (moderate) ],,"A process that performs an excesssive moving the phenobarbital to the inside of liver. And the degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (moderate) .",false,,,http://purl.obolibrary.org/obo/TXPO_0002719,,,,,,,,,,,,,,,,,,,,,,"A process that performs an excesssive moving the phenobarbital to the inside of liver. And the degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (moderate) .",,,http://purl.obolibrary.org/obo/TXPO_0001719,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003868,,,,,,,,,,,TXPO:0003876,,,,,,,,,,,,,,,,,,,,,,hyperfunction of moving phenobarbital to the inside of liver [Ground glass appearance (moderate) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003870,phenobarbital accumulation in liver [Ground glass appearance (moderate) ],,"Phenobarbital accumulation in liver is a subtype of compound accumulation in liver: A process that keeps phenobarbital in the liver. And the degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (moderate) .",false,,,http://purl.obolibrary.org/obo/TXPO_0000934,,,,,,,,,,,,,,,,,,,,,,"Phenobarbital accumulation in liver is a subtype of compound accumulation in liver: A process that keeps phenobarbital in the liver. And the degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (moderate) .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003870,,,,,,,,,,,,,,,,,,,,,,phenobarbital accumulation in liver [Ground glass appearance (moderate) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003879,CTSB- tumor cell metastasis factor (human)[Phospholipidosis  - tumor metasitasis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003941,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1508|PMID:27398911|PMID:1837142|PMID:11016923|PMID:1637335|PMID:10876156|PMID:1540143,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001508,,,http://purl.obolibrary.org/obo/TXPO_0003880,,,,,,,,,,TXPO:0003879,,,,,,,,,,,,,,,,,,,,,,CTSB- tumor cell metastasis factor (human)[Phospholipidosis  - tumor metasitasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003878,CTSB- autophagy inducing factor (human)[Phospholipidosis - autophagy indution],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003941,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1508|PMID:27398911,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001508,,,http://purl.obolibrary.org/obo/TXPO_0000487,,,,,,,,,,TXPO:0003878,,,,,,,,,,,,,,,,,,,,,,CTSB- autophagy inducing factor (human)[Phospholipidosis - autophagy indution],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003877,positive regulation of autophagy [Phospholipidosis],,"Any process that activates, maintains or increases the rate of autophagy. Autophagy is the process in which cells digest parts of their own cytoplasm.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis",false,,,http://purl.obolibrary.org/obo/GO_0010508|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,PMID:27398911,,"Any process that activates, maintains or increases the rate of autophagy. Autophagy is the process in which cells digest parts of their own cytoplasm.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003788|http://purl.obolibrary.org/obo/TXPO_0003878|http://purl.obolibrary.org/obo/TXPO_0004000,,,,,,http://purl.obolibrary.org/obo/TXPO_0001497|http://purl.obolibrary.org/obo/TXPO_0003889,,,,,,,,,,,TXPO:0003877,,,,,,,,,,,,,,,,,,,,,,positive regulation of autophagy [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003874,hyperfunction of cytochrome p450 gene expression  by phenobarbital  [Ground glass appearance (moderate) ],,"Hyperfunction of cytochrome p450 gene expression is a subtype of hyperfunction of drug metabolizing enzyme gene expression: A process that performs an excesssive gene expression of cytochrome p450. And the degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (moderate) .",false,,,http://purl.obolibrary.org/obo/TXPO_0003858|http://purl.obolibrary.org/obo/TXPO_0002051,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of cytochrome p450 gene expression is a subtype of hyperfunction of drug metabolizing enzyme gene expression: A process that performs an excesssive gene expression of cytochrome p450. And the degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (moderate) .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003875,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003873,,,,,,,,,,,TXPO:0003874,,,,,,,,,,,,,,,,,,,,,,hyperfunction of cytochrome p450 gene expression  by phenobarbital  [Ground glass appearance (moderate) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003873,hyperfunction of phenobarbital metabolism phase I by Cytochrome P450 [Ground glass appearance (moderate) ],,"Hyperfunction of phenobarbital metabolism phase I by Cytochrome P450 is a subtype of hyperfunction of drug metabolism phase I: A process that performs an excesssive phenobarbital metabolism phase I by Cytochrome P450. And the degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (moderate) .",false,,,http://purl.obolibrary.org/obo/TXPO_0003864,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of phenobarbital metabolism phase I by Cytochrome P450 is a subtype of hyperfunction of drug metabolism phase I: A process that performs an excesssive phenobarbital metabolism phase I by Cytochrome P450. And the degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (moderate) .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003875|http://purl.obolibrary.org/obo/TXPO_0003874,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003872,,,,,,,,,,,TXPO:0003873,,,,,,,,,,,,,,,,,,,,,,hyperfunction of phenobarbital metabolism phase I by Cytochrome P450 [Ground glass appearance (moderate) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003872,hyperfunction of glucuronic acid conjugation for phenobarbital intermediate metabolite [Ground glass appearance (moderate) ],,"Hyperfunction of glucuronic acid conjugation is a subtype of hyperfunction of drug metabolism phase II: A process that performs an excessive glucuronic acid conjugation. And the degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (moderate) .",false,,,http://purl.obolibrary.org/obo/TXPO_0001663|http://purl.obolibrary.org/obo/TXPO_0001227,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of glucuronic acid conjugation is a subtype of hyperfunction of drug metabolism phase II: A process that performs an excessive glucuronic acid conjugation. And the degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (moderate) .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000992,,,,,,,,,,,,,,,,,TXPO:0003872,,,,,,,,,,,,,,,,,,,,,,hyperfunction of glucuronic acid conjugation for phenobarbital intermediate metabolite [Ground glass appearance (moderate) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001022,"cGMP-specific 3',5'-cyclic phosphodiesterase",CGB-PDE|cGMP-binding cGMP-specific phosphodiesterase,,false,,,http://purl.obolibrary.org/obo/IMR_0100002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CGB-PDE|cGMP-binding cGMP-specific phosphodiesterase,,,,,IMR:0001022,,,,,,,,,,,,,,,,,,,,,,"cGMP-specific 3',5'-cyclic phosphodiesterase",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001469,DOCK,,Superfamily members of DOCK180 possess the DHR-2 domain and bind to and exchange GDP for GTP on either Rac or Cdc42.,false,,,http://purl.obolibrary.org/obo/IMR_0001954,,,,,,,,,,,,,,,,,,,,,,Superfamily members of DOCK180 possess the DHR-2 domain and bind to and exchange GDP for GTP on either Rac or Cdc42.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001469,,,,,,,,,,,,,,,,,,,,,,DOCK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_35480,analgesic,,"An agent capable of relieving pain without the loss of consciousness or without producing anaesthesia. In addition, analgesic is a role played by a compound which is exhibited by a capability to cause a reduction of pain symptoms.",false,,,http://purl.obolibrary.org/obo/CHEBI_52210|http://purl.obolibrary.org/obo/CHEBI_23888,,,,,,,,,,,,,,,,,,,,,,"An agent capable of relieving pain without the loss of consciousness or without producing anaesthesia. In addition, analgesic is a role played by a compound which is exhibited by a capability to cause a reduction of pain symptoms.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:35480,,,,analgesic,,CHEBI:35480,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002470,accumulation of abnormal proteins in ER [ER stress (moderate) ],,"Accumulation of abnormal proteins in ER is a subtype of accumulation of abnormal proteins: A process that keeps abnormal protein(s) in the ER (endoplasmic reticulum). And the degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of ER stress (moderate).",false,,,http://purl.obolibrary.org/obo/TXPO_0000194,,,,,,,,,,,,,,,,,,,,,,"Accumulation of abnormal proteins in ER is a subtype of accumulation of abnormal proteins: A process that keeps abnormal protein(s) in the ER (endoplasmic reticulum). And the degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of ER stress (moderate).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002479,,,,,,,,,,,TXPO:0002470,,,,,,,,,,,,,,,,,,,,,,accumulation of abnormal proteins in ER [ER stress (moderate) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005783,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002471,increasing demand for protein degradation,,Increasing demand for protein degradation is a subtype of increasing functional demand: A process that is subjected to increasing load of protein degradation.,false,,,http://purl.obolibrary.org/obo/TXPO_0000633,,,,,,,,,,,,,,,,,,,,,,Increasing demand for protein degradation is a subtype of increasing functional demand: A process that is subjected to increasing load of protein degradation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002471,,,,,,,,,,,,,,,,,,,,,,increasing demand for protein degradation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002477,protein degradation insufficiency [ER stress],,"Protein degradation insufficiency is a subtype of malfunctioning process: A process that lacks performing the function of protein degradation required.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/TXPO_0002476,,,,,,,,,,,,,,,,,,,,,,"Protein degradation insufficiency is a subtype of malfunctioning process: A process that lacks performing the function of protein degradation required.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002479,,,,,,,,,,,TXPO:0002477,,,,,,,,,,,,,,,,,,,,,,protein degradation insufficiency [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005737,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002472,increasing demand for abnormal protein degradation,,Increasing demand for abnormal protein degradation is a subtype of increasing demand of protein degradation: A process is subjected to increasing load of abnormal protein degradation.,false,,,http://purl.obolibrary.org/obo/TXPO_0002471,,,,,,,,,,,,,,,,,,,,,,Increasing demand for abnormal protein degradation is a subtype of increasing demand of protein degradation: A process is subjected to increasing load of abnormal protein degradation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002472,,,,,,,,,,,,,,,,,,,,,,increasing demand for abnormal protein degradation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002474,protein refolding insufficiency,,Protein refolding insufficiency is a subtype of malfunctioning process: A process that lacks performing the function of protein refolding required.,false,,,http://purl.obolibrary.org/obo/TXPO_0000482,,,,,,,,,,,,,,,,,,,,,,Protein refolding insufficiency is a subtype of malfunctioning process: A process that lacks performing the function of protein refolding required.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002474,,,,,,,,,,,,,,,,,,,,,,protein refolding insufficiency,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002478,abnormal protein production- degradation imbalance,,Abnormal protein production- degradation imbalance is a subtype of imbalance: A process that lacks a balance between abnormal protein production and degradation.,false,,,http://purl.obolibrary.org/obo/TXPO_0000567,,,,,,,,,,,,,,,,,,,,,,Abnormal protein production- degradation imbalance is a subtype of imbalance: A process that lacks a balance between abnormal protein production and degradation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002478,,,,,,,,,,,,,,,,,,,,,,abnormal protein production- degradation imbalance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002473,increasing demand for abnormal protein degradation [ER stress],,"Increasing demand for abnormal protein degradation is a subtype of increasing demand of protein degradation: A process is subjected to increasing load of abnormal protein degradation.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/TXPO_0002472,,,,,,,,,,,,,,,,,,,,,,"Increasing demand for abnormal protein degradation is a subtype of increasing demand of protein degradation: A process is subjected to increasing load of abnormal protein degradation.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002479,,,,,,,,,,,TXPO:0002473,,,,,,,,,,,,,,,,,,,,,,increasing demand for abnormal protein degradation [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002479,abnormal protein production- degradation imbalance [ER stress],,"Abnormal protein production- degradation imbalance is a subtype of imbalance: A process that lacks a balance between abnormal protein production and degradation.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/TXPO_0002478,,,,,,,,,,,,,,,,,,,,,,"Abnormal protein production- degradation imbalance is a subtype of imbalance: A process that lacks a balance between abnormal protein production and degradation.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000250,,,,,,,,,,,TXPO:0002479,,,,,,,,,,,,,,,,,,,,,,abnormal protein production- degradation imbalance [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002475,protein refolding insufficiency (sustained) [ER stress],,"Protein refolding insufficiency is a subtype of malfunctioning process: A process that lacks performing the function of protein refolding required. This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of ER stress (sustained) .",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/TXPO_0002177,,,,,,,,,,,,,,,,,,,,,,"Protein refolding insufficiency is a subtype of malfunctioning process: A process that lacks performing the function of protein refolding required. This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of ER stress (sustained) .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002460,,,,,,,,,,,TXPO:0002475,,,,,,,,,,,,,,,,,,,,,,protein refolding insufficiency (sustained) [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005783,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002476,protein degradation insufficiency,,Protein degradation insufficiency is a subtype of malfunctioning process: A process that lacks performing the function of protein degradation required.,false,,,http://purl.obolibrary.org/obo/TXPO_0000482,,,,,,,,,,,,,,,,,,,,,,Protein degradation insufficiency is a subtype of malfunctioning process: A process that lacks performing the function of protein degradation required.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002476,,,,,,,,,,,,,,,,,,,,,,protein degradation insufficiency,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006928,cell motility,cell locomotion|movement of a cell|cell movement,Any process involved in the controlled self-propelled movement of a cell that results in translocation of the cell from one place to another.,false,,,http://purl.obolibrary.org/obo/GO_0040011,,,,,,,,,,,,,,,,,,,,,,Any process involved in the controlled self-propelled movement of a cell that results in translocation of the cell from one place to another.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000000,,,,,,,,,,,,cell locomotion|movement of a cell|cell movement,,,,,GO:0006928,,,,,,,,,,,,,,,,,,,,,,cell motility,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004460,CDK1 inactivation,,CDK1 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the CDK1 (cyclin dependent kinase 1) to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000021,,,,,,,,,,,,,,,,,,,,,,CDK1 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the CDK1 (cyclin dependent kinase 1) to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004460,,,,,,,,,,,,,,,,,,,,,,CDK1 inactivation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004464,Increasing CDK2 level [hepatocarcinogenesis],,"Increasing CDK2 level is a subtype of increasing quantity: A process that changes the amount of CDK2 level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004463,,,,,,,,,,,,,,,,,,,,PMID:31239782,,"Increasing CDK2 level is a subtype of increasing quantity: A process that changes the amount of CDK2 level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004465,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004459,,,,,,,,,,,TXPO:0004464,,,,,,,,,,,,,,,,,,,,,,Increasing CDK2 level [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004461,CDK1 inactivation [mitochondrial disorder],,"CDK1 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the CDK1 (cyclin dependent kinase 1) to be lower.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0004460,,,,,,,,,,,,,,,,,,,,PMID:24746669,,"CDK1 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the CDK1 (cyclin dependent kinase 1) to be lower.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004462,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004375,,,,,,,,,,,TXPO:0004461,,,,,,,,,,,,,,,,,,,,,,CDK1 inactivation [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004466,CDT1 inactivation,,CDT1 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the CDT1 (chromatin licensing and DNA replication factor 1) to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000021,,,,,,,,,,,,,,,,,,,,,,CDT1 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the CDT1 (chromatin licensing and DNA replication factor 1) to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004466,,,,,,,,,,,,,,,,,,,,,,CDT1 inactivation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004463,Increasing CDK2 level,,Increasing CDK2 level is a subtype of increasing quantity: A process that changes the amount of CDK2 level to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing CDK2 level is a subtype of increasing quantity: A process that changes the amount of CDK2 level to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0100598,,,,,,,,,,,,,,,,,,,TXPO:0004463,,,,,,,,,,,,,,,,,,,,,,Increasing CDK2 level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004468,CDT1 inactivation [hepatocarcinogenesis],,"CDT1 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the CDT1 (chromatin licensing and DNA replication factor 1) to be lower.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004466,,,,,,,,,,,,,,,,,,,,PMID:25797246,,"CDT1 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the CDT1 (chromatin licensing and DNA replication factor 1) to be lower.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004469,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004470,,,,,,,,,,,TXPO:0004468,,,,,,,,,,,,,,,,,,,,,,CDT1 inactivation [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004465,CDK2 (human) [hepatocarcinogenesis],Cdk2|cyclin-dependent kinase 2|p33 protein kinase|Cell division protein kinase 2|Cell division protein kinase 2 (EC 2.7.1.-)(p33 protein kinase)(CDK2),,false,,,http://purl.obolibrary.org/obo/IMR_0100598|http://purl.obolibrary.org/obo/TXPO_0004185,,,,,,,,,,,,,,,,,,,,PMID:31239782,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0010671,Cdk2|cyclin-dependent kinase 2|p33 protein kinase|Cell division protein kinase 2|Cell division protein kinase 2 (EC 2.7.1.-)(p33 protein kinase)(CDK2),,,,,TXPO:0004465,,,,,,,,,,,,,,,,,,,,,,CDK2 (human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004467,CDT1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:67177|NCBI-Human-GeneID:81620|NCBI-Rat-GeneID:292071,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004467,,,,,,,,,,,,,,,,,,,,,,CDT1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004469,CDT1 - inactive form (human) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0005075,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:81620|PMID:25797246,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0002355,,,,,,,,,,,,,,TXPO:0004469,,,,,,,,,,,,,,,,,,,,,,CDT1 - inactive form (human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004462,CDK1 - inactive form (predicted) (human) [mitochondrial damage],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003603|http://purl.obolibrary.org/obo/TXPO_0003611,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:983|PMID:24746669,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657|http://purl.obolibrary.org/obo/PATO_0002355,http://purl.obolibrary.org/obo/OGG_3000000983,,,,,,,,,,,,,TXPO:0004462,,,,,,,,,,,,,,,,,,,,,,CDK1 - inactive form (predicted) (human) [mitochondrial damage],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000056603,CYP26B1,,"Other designations: cytochrome P450 26B1|cytochrome P450 retinoic acid-inactivating 2|cytochrome P450 retinoid metabolizing protein|cytochrome P450, subfamily XXVIB, polypeptide 1|retinoic acid-metabolizing cytochrome",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,P450RAI2|RHFCA|CYP26A2|P450RAI-2,,,,,,,,,,,,2,,,,,,HGNC:20581|MIM:605207|HPRD:05550|Vega:OTTHUMG00000129756|Ensembl:ENSG00000003137,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 26, subfamily B, polypeptide 1",,,2p13.2,,,,,,,,,,,,,,,,"GO_0001709 (EC: ISS); GO_0001972 (EC: IDA, PMID:10823918); GO_0005506 (EC: IEA); GO_0005789 (EC: TAS); GO_0006766 (EC: TAS); GO_0006805 (EC: TAS); GO_0007140 (EC: ISS); GO_0007283 (EC: ISS); GO_0008401 (EC: IDA, PMID:10823918); GO_0009954 (EC: ISS); GO_0010628 (EC: IEA); GO_0020037 (EC: NAS, PMID:10823918); GO_0030326 (EC: ISS); GO_0034653 (EC: IDA, PMID:10823918); GO_0043587 (EC: IEA); GO_0044281 (EC: TAS); GO_0048384 (EC: IEA); GO_0048387 (EC: TAS, PMID:14532297); GO_0055114 (EC: IDA, PMID:10823918); GO_0060349 (EC: IMP); GO_0071300 (EC: IEA); GO_2001037 (EC: IEA)",,,,,,,,,PMID:10545224; 10823918; 11744378; 12101034; 12477932; 14532297; 15128046; 15489334; 15815621; 16574820; 16933217; 19322201; 19703508; 19884280; 19953087; 20375987; 20606468; 21482329; 21641851; 21945024; 22019272; 22020119; 22415012; 22666329; 22899867; 22965740; 22985482; 23298258; 23303528; 23320086; 23409080; 23554885; 23587162; 23837398,,,,,,,,,,,,,,,OGG:3000056603,,,,,,,"cytochrome P450, family 26, subfamily B, polypeptide 1",,,,,,,,,,,,,"Other designations: cytochrome P450 26B1|cytochrome P450 retinoic acid-inactivating 2|cytochrome P450 retinoid metabolizing protein|cytochrome P450, subfamily XXVIB, polypeptide 1|retinoic acid-metabolizing cytochrome",,CYP26B1,,,,,,,,,,,,,,,,,,,,,,,56603,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP26B1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000056605,ERO1LB,,Other designations: ERO1-L-beta|ERO1-like protein beta|endoplasmic oxidoreductin-1-like protein B|endoplasmic reticulum oxidoreductin-1-like protein B|oxidoreductin-1-L-beta,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,1,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,ERO1-like beta (S. cerevisiae),,,1q42.2-q43,,,,,,,,,,,,,,,,"GO_0003756 (EC: IEA); GO_0005515 (EC: IPI); GO_0005783 (EC: TAS, PMID: 10818100); GO_0005789 (EC: IEA); GO_0006457 (EC: TAS, PMID: 10818100); GO_0016491 (EC: NAS, PMID: 10818100); GO_0016671 (EC: IEA); GO_0051082 (EC: NAS, PMID: 10818100)",,,,,,,,,PMID: 10818100; 11707400; 11847130; 12477932; 12752442; 14702039; 15161913; 15489334; 16012172; 16263699; 16677073; 16822866; 17207965; 18395550; 18996753; 19730683; 20379614; 20802462; 21091435; 21139048; 22268729; 22990118,,,,,,,,,,,,,,,OGG:3000056605,,,,,,,ERO1-like beta (S. cerevisiae),,,,,,,,,,,,,Other designations: ERO1-L-beta|ERO1-like protein beta|endoplasmic oxidoreductin-1-like protein B|endoplasmic reticulum oxidoreductin-1-like protein B|oxidoreductin-1-L-beta,,ERO1LB,,,,,,,,,,,,,,,,,,,,,,,56605,RP5-985L19.2,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,ERO1LB,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0011142,eIF3i,"TRIP-1|eIF-3 beta|TGF-beta receptor interacting protein 1|Eukaryotic translation initiation factor 3 39 kDa subunit|eIF3 p39|eukaryotic translation initiation factor 3 subunit 2|Translation initiation factor eIF3, p39 subunit|eIF3 p36|Suppressor of uncontrolled mitosis 1",,false,,,http://purl.obolibrary.org/obo/IMR_0000916,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"TRIP-1|eIF-3 beta|TGF-beta receptor interacting protein 1|Eukaryotic translation initiation factor 3 39 kDa subunit|eIF3 p39|eukaryotic translation initiation factor 3 subunit 2|Translation initiation factor eIF3, p39 subunit|eIF3 p36|Suppressor of uncontrolled mitosis 1",,,,,IMR:0011142,,,,,,,,,,,,,,,,,,,,,,eIF3i,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000005,SHH (mol),Sonic hedgehog|HHG-1,,false,,,http://purl.obolibrary.org/obo/IMR_0000004,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:20423|NCBI-Rat-GeneID:29499|NCBI-Human-GeneID:6469,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Sonic hedgehog|HHG-1,,,,,IMR:0000005,,,,,,,,,,,,,,,,,,,,,,SHH (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004425,negative regulation of APC signaling,,"Any process that stops, prevents, or reduces the frequency, rate or extent of APC signaling, a series of reactions mediated by APC.",false,,,http://purl.obolibrary.org/obo/GO_0023057,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents, or reduces the frequency, rate or extent of APC signaling, a series of reactions mediated by APC.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004425,,,,,,,,,,,,,,,,,,,,,,negative regulation of APC signaling,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004424|http://purl.obolibrary.org/obo/TXPO_0004423,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004424,APC signaling (primitive),,APC signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by APC.,false,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,,,APC signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by APC.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004423,,,,,,,,,,,,,,,,TXPO:0004424,,,,,,,,,,,,,,,,,,,,,,APC signaling (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004421,Metalloprotease activation [hepatocarcinogenesis],,"Metalloprotease activation is a subtype of activating: A process that changes the activity of the metalloprotease to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0005001,,,,,,,,,,,,,,,,,,,,PMID:28706416,,"Metalloprotease activation is a subtype of activating: A process that changes the activity of the metalloprotease to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0005002|http://purl.obolibrary.org/obo/TXPO_0005003,,,,,http://purl.obolibrary.org/obo/TXPO_0004695,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004404|http://purl.obolibrary.org/obo/TXPO_0004479,,,,,,,,,,,TXPO:0004421,,,,,,,,,,,,,,,,,,,,,,Metalloprotease activation [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004429,ATF4 inactivation [hepatocarcinogenesis],,"ATF4 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the ATF4 (activating transcription factor 4) to be lower.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004428,,,,,,,,,,,,,,,,,,,,PMID:23284992,,"ATF4 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the ATF4 (activating transcription factor 4) to be lower.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004430,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004431,,,,,,,,,,,TXPO:0004429,,,,,,,,,,,,,,,,,,,,,,ATF4 inactivation [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004423,APC signal transduction pathway,,A series of molecular signals mediated by APC (Activated protein C).,false,,,http://purl.obolibrary.org/obo/TXPO_0000609,,,,,,,,,,,,,,,,,,,,,,A series of molecular signals mediated by APC (Activated protein C).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004423,,,,,,,,,,,,,,,,,,,,,,APC signal transduction pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004427,negative regulation of EPCR signaling [hepatocarcinogenesis],,"Any process that stops, prevents, or reduces the frequency, rate or extent of EPCR signaling, a series of reactions mediated by EPCR.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0004532|http://purl.obolibrary.org/obo/TXPO_0002340,,,,,,,,,,,,,,,,,,,,PMID:30690589,,"Any process that stops, prevents, or reduces the frequency, rate or extent of EPCR signaling, a series of reactions mediated by EPCR.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004533,,,,,,http://purl.obolibrary.org/obo/TXPO_0004417,,,,,,,,,,,TXPO:0004427,,,,,,,,,,,,,,,,,,,,,,negative regulation of EPCR signaling [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004531|http://purl.obolibrary.org/obo/TXPO_0004530,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004422,epithelial to mesenchymal transition [hepatocarcinogenesis],,"A transition where an epithelial cell loses apical/basolateral polarity, severs intercellular adhesive junctions, degrades basement membrane components and becomes a migratory mesenchymal cell.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/GO_0001837,,,,,,,,,,,,,,,,,,,,PMID:28493839|PMID:29358721|PMID:29787164|PMID:26017875|PMID:28706416|PMID:30008815|PMID:31781608|PMID:28060737|PMID:28584306,,"A transition where an epithelial cell loses apical/basolateral polarity, severs intercellular adhesive junctions, degrades basement membrane components and becomes a migratory mesenchymal cell.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004872,,,,,,http://purl.obolibrary.org/obo/TXPO_0004899|http://purl.obolibrary.org/obo/TXPO_0004404|http://purl.obolibrary.org/obo/TXPO_0004479|http://purl.obolibrary.org/obo/TXPO_0005014,,,,,,,,,,,TXPO:0004422,,,,,,,,,,,,,,,,,,,,,,epithelial to mesenchymal transition [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004428,ATF4 inactivation,,ATF4 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the ATF4 (activating transcription factor 4) to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000021,,,,,,,,,,,,,,,,,,,,,,ATF4 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the ATF4 (activating transcription factor 4) to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004428,,,,,,,,,,,,,,,,,,,,,,ATF4 inactivation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004420,p38 signaling (primitive) [hepatocarcinogenesis],,"p38 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the p38 (a Mitogen-Activated Protein Kinase).
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0004303|http://purl.obolibrary.org/obo/TXPO_0002340,,,,,,,,,,,,,,,,,,,,PMID:29358721|PMID:30690589,,"p38 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the p38 (a Mitogen-Activated Protein Kinase).
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004403|http://purl.obolibrary.org/obo/TXPO_0004298,,,,,,,,,,,TXPO:0004420,,,,,,,,,,,,,,,,,,,,,,p38 signaling (primitive) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004426,negative regulation of APC signaling [hepatocarcinogenesis],,"Any process that stops, prevents, or reduces the frequency, rate or extent of APC signaling, a series of reactions mediated by APC.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004425,,,,,,,,,,,,,,,,,,,,PMID:30690589,,"Any process that stops, prevents, or reduces the frequency, rate or extent of APC signaling, a series of reactions mediated by APC.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004427,,,,,,,,,,,TXPO:0004426,,,,,,,,,,,,,,,,,,,,,,negative regulation of APC signaling [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004424|http://purl.obolibrary.org/obo/TXPO_0004423,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000238,PAK,,,false,,,http://purl.obolibrary.org/obo/IMR_0000252|http://purl.obolibrary.org/obo/IMR_0000229,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000238,,,,,,,,,,,,,,,,,,,,,,PAK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_1903597,negative regulation of gap junction assembly,,"Any process that stops, prevents or reduces the frequency, rate or extent of gap junction assembly.",false,,,http://purl.obolibrary.org/obo/GO_1901889,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents or reduces the frequency, rate or extent of gap junction assembly.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:1903597,,,,,,,,,,,,,,,,,,,,,,negative regulation of gap junction assembly,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0016264,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76726,EC 1.1.* (oxidoreductase acting on donor CH-OH group) inhibitor,EC 1.1.* inhibitors|inhibitor of oxidoreductase acting on CH-OH group of donor|oxidoreductase acting on donor CH-OH group inhibitor|EC 1.1.* (oxidoreductase acting on donor CH-OH group) inhibitors|inhibitors of oxidoreductase acting on CH-OH group of donors|oxidoreductase acting on donor CH-OH group (EC 1.1.*) inhibitors|inhibitor of oxidoreductase acting on CH-OH group of donors|oxidoreductase acting on donor CH-OH group inhibitors|EC 1.1.* inhibitor|oxidoreductase acting on donor CH-OH group (EC 1.1.*) inhibitor|inhibitors of oxidoreductase acting on CH-OH group of donor,An oxidoreductase inhibitor which interferes with the action of an oxidoreductase acting on the CH-OH group of donors (EC 1.1.*.*).,false,,,http://purl.obolibrary.org/obo/CHEBI_76725,,,,,,,,,,,,,,,,,,,,,,An oxidoreductase inhibitor which interferes with the action of an oxidoreductase acting on the CH-OH group of donors (EC 1.1.*.*).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,EC 1.1.* inhibitors|inhibitor of oxidoreductase acting on CH-OH group of donor|oxidoreductase acting on donor CH-OH group inhibitor|EC 1.1.* (oxidoreductase acting on donor CH-OH group) inhibitors|inhibitors of oxidoreductase acting on CH-OH group of donors|oxidoreductase acting on donor CH-OH group (EC 1.1.*) inhibitors|inhibitor of oxidoreductase acting on CH-OH group of donors|oxidoreductase acting on donor CH-OH group inhibitors|EC 1.1.* inhibitor|oxidoreductase acting on donor CH-OH group (EC 1.1.*) inhibitor|inhibitors of oxidoreductase acting on CH-OH group of donor,,,,,,,,,,,,,,,,,,,,,CHEBI:76726,,,,EC 1.1.* (oxidoreductase acting on donor CH-OH group) inhibitor,,CHEBI:76726,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000852,increasing blood ALT concentration,increasing blood GPT concentration,Increasing ALT concentration in blood is a subtype of increasing concentration: A process that changes the alanine aminotransferase (ALT) concentration  to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000352,,,,,,,,,,,,,,,,,,,,http://purl.bioontology.org/ontology/MEDDRA/10001845,,Increasing ALT concentration in blood is a subtype of increasing concentration: A process that changes the alanine aminotransferase (ALT) concentration  to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,increasing blood GPT concentration,,,,,TXPO:0000852,,,,,,,,,,,,,,,,,,,,,,increasing blood ALT concentration,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000855,NRF2 -antioxidant (canonical)[Glutathione depletion],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002392,http://purl.obolibrary.org/obo/TXPO_0000656,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:83619|NCBI-Human-GeneID:4780,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_22586|http://purl.obolibrary.org/obo/TXPO_0003645,,,,,,,,,,TXPO:0000855,,,,,,,,,,,,,,,,,,,,,,NRF2 -antioxidant (canonical)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000853,Jund (rat)[Cell death],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000839|http://purl.obolibrary.org/obo/IMR_0000819,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24518,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000853,,,,,,,,,,,,,,,,,,,,,,Jund (rat)[Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000850,NRF2 -inflammasone activator (canonical)[Glutathione depletion],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002392|http://purl.obolibrary.org/obo/TXPO_0002045,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:18024|NCBI-Rat-GeneID:83619|NCBI-Human-GeneID:4780,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000851,,,,,,,,,,TXPO:0000850,,,,,,,,,,,,,,,,,,,,,,NRF2 -inflammasone activator (canonical)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000854,core process (value),,This entity is a role in which a process plays an essential role in the course of toxicity manifestation.,false,,,http://purl.obolibrary.org/obo/TXPO_0002178,,,,,,,,,,,,,,,,,,,,,,This entity is a role in which a process plays an essential role in the course of toxicity manifestation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000854,,,,,,,,,,,,,,,,,,,,,,core process (value),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000851,inflammasome activator,,A role played by the entity which positive regulates the inflammasone activity.,false,,,http://purl.obolibrary.org/obo/TXPO_0003714,,,,,,,,,,,,,,,,,,,,,,A role played by the entity which positive regulates the inflammasone activity.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000851,,,,,,,,,,,,,,,,,,,,,,inflammasome activator,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000858,gamma-glutamyltransferase.,EC 2.3.2.2|gamma-GTP,"Catalysis of the reaction: (5-L-glutamyl)-peptide + an amino acid = peptide + 5-L-glutamyl-amino acid.|The mammlian enzyme is part of the cell antioxidant defense mechanism. It initiates extracellular glutathione (GSH) breakdown, provides cells with a local cysteine supply and contributes to maintain intracelular GSH levels. The protein also has EC 3.4.19.13 (glutathione hydrolase) activity [3-4]. The enzyme consists of two chains that are created by the proteolytic cleavage of a single precursor polypeptide. The N-terminal L-threonine of the C-terminal subunit functions as the active site for both the cleavage and the hydrolysis reactions",false,,,http://purl.obolibrary.org/obo/TXPO_0001385,,,,,,,,,,,,,,,,,,,,,,Catalysis of the reaction: (5-L-glutamyl)-peptide + an amino acid = peptide + 5-L-glutamyl-amino acid.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,EC 2.3.2.2|gamma-GTP,,,,,TXPO:0000858,,,,,,,,,,,,,,,,,,,,"The mammlian enzyme is part of the cell antioxidant defense mechanism. It initiates extracellular glutathione (GSH) breakdown, provides cells with a local cysteine supply and contributes to maintain intracelular GSH levels. The protein also has EC 3.4.19.13 (glutathione hydrolase) activity [3-4]. The enzyme consists of two chains that are created by the proteolytic cleavage of a single precursor polypeptide. The N-terminal L-threonine of the C-terminal subunit functions as the active site for both the cleavage and the hydrolysis reactions",,gamma-glutamyltransferase.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000857,GGT1 (canonical)[lipidosis],gamma-glutamyltransferase 1,,false,,,http://purl.obolibrary.org/obo/TXPO_0003516|http://purl.obolibrary.org/obo/TXPO_0000856,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:14598|NCBI-Rat-GeneID:116568|NCBI-Human-GeneID:2678,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000858,,,,,gamma-glutamyltransferase 1,,,,,TXPO:0000857,,,,,,,,,,,,,,,,,,,,,,GGT1 (canonical)[lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000859,increasing γ-glutamyltransferase concentration in blood [Lipidosis],,"Increasing γ-glutamyltransferase concentration in blood is a subtype of increasing concentration: A process that changes the γ-glutamyltransferase (GGT) concentration  to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001347|http://purl.obolibrary.org/obo/TXPO_0001720,,,,,,,,,,,,,,,,,,,,,,"Increasing γ-glutamyltransferase concentration in blood is a subtype of increasing concentration: A process that changes the γ-glutamyltransferase (GGT) concentration  to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000857,,,,,,,,,,,,,,,,,,,TXPO:0000859,,,,,,,,,,,,,,,,,,,,,,increasing γ-glutamyltransferase concentration in blood [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000856,GGT1 (mol),gamma-glutamyltransferase 1,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:14598|NCBI-Rat-GeneID:116568|NCBI-Human-GeneID:2678,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000858,,,,,gamma-glutamyltransferase 1,,,,,TXPO:0000856,,,,,,,,,,,,,,,,,,,,,,GGT1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0044770,cell cycle phase transition,cell cycle transition,The cell cycle process by which a cell commits to entering the next cell cycle phase.,false,,,http://purl.obolibrary.org/obo/TXPO_0000425,,,,,,,,,,,,,,,,,,,,,,The cell cycle process by which a cell commits to entering the next cell cycle phase.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,cell cycle transition,,,,,GO:0044770,,,,,,,,,,,,,,,,,,,,,,cell cycle phase transition,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000009709,HERPUD1,,Other designations: MMS-inducible|homocysteine-inducible endoplasmic reticulum stress-inducible ubiquitin-like domain member 1 protein|homocysteine-responsive endoplasmic reticulum-resident ubiquitin-like domain member 1 protein|methyl methanesulfonate (MMF)-inducible fragment protein 1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,Mif1|HERP|SUP,,,,,,,,,,,,16,,,,,,Ensembl:ENSG00000051108|HPRD:07456|HGNC:13744|Vega:OTTHUMG00000133276|MIM:608070,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain member 1",,,16q13,,,,,,,,,,,,,,,,"GO_0003674 (EC: ND); GO_0005789 (EC: IDA, PMID: 10922362); GO_0005789 (EC: TAS); GO_0006511 (EC: IEA); GO_0006874 (EC: IEA); GO_0006986 (EC: IEP, PMID: 10708769); GO_0006987 (EC: TAS); GO_0016021 (EC: IEA); GO_0030968 (EC: TAS); GO_0031396 (EC: IEA); GO_0032092 (EC: IEA); GO_0043154 (EC: IEA); GO_0044267 (EC: TAS)",,,,,,,,,PMID: 7584026; 8125298; 8619474; 9110174; 10708769; 10922362; 11112790; 11799129; 12153396; 12370023; 12477932; 14550564; 15489334; 16169070; 16189514; 16289116; 16344560; 16713569; 16940180; 17020760; 17310145; 17420289; 18042451; 18307982; 18656546; 19251110; 19447887; 19788048; 20031564; 20054003; 20147634; 20604806; 20694148; 20838585; 20936779; 21139048; 21149444; 21832049; 21900206; 21906983; 21963094; 21965653; 23372434; 23505323; 23867461; 24120520,,,,,,,,,,,,,,,OGG:3000009709,,,,,,,"homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain member 1",,,,,,,,,,,,,Other designations: MMS-inducible|homocysteine-inducible endoplasmic reticulum stress-inducible ubiquitin-like domain member 1 protein|homocysteine-responsive endoplasmic reticulum-resident ubiquitin-like domain member 1 protein|methyl methanesulfonate (MMF)-inducible fragment protein 1,,HERPUD1,,,,,,,,,,,,,,,,,,,,,,,9709,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,HERPUD1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_33290,food role,,Any material that can be ingested by an organism.,false,,,http://purl.obolibrary.org/obo/CHEBI_24432,,,,,,,,,,,,,,,,,,,,,,Any material that can be ingested by an organism.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:33290,,,,,,,,,,,,,,,,,,,,,,food role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100848,PKA type I beta regulatory subunit,cAMP-dependent protein kinase type I-beta regulatory chain,,false,,,http://purl.obolibrary.org/obo/IMR_0100702,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,cAMP-dependent protein kinase type I-beta regulatory chain,,,,,IMR:0100848,,,,,,,,,,,,,,,,,,,,,,PKA type I beta regulatory subunit,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001560,Rab3C,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001560,,,,,,,,,,,,,,,,,,,,,,Rab3C,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_48279,serotonergic antagonist,5-hydroxytryptamine antagonists|5-HT antagonists|antiserotonergic agents|serotonin blockaders|serotonin antagonists,"Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or serotonergic agonists.",false,,,http://purl.obolibrary.org/obo/CHEBI_48278,,,,,,,,,,,,,,,,,,,,,,"Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or serotonergic agonists.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5-hydroxytryptamine antagonists|5-HT antagonists|antiserotonergic agents|serotonin blockaders|serotonin antagonists,,,,,,,,,,,,,,,,,,,,,CHEBI:48279,,,,serotonergic antagonist,,CHEBI:48279,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000002335,FN1,,Other designations: cold-insoluble globulin|fibronectin|migration-stimulating factor,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,LETS|FNZ|GFND|FINC|FN|CIG|GFND2|MSF|ED-B,,,,,,,,,,,,2,,,,,,Vega:OTTHUMG00000133054|HPRD:00626|MIM:135600|Ensembl:ENSG00000115414|HGNC:3778,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,fibronectin 1,,,2q34,,,,,,,,,,,,,,,,"GO_0001525 (EC: IEA); GO_0002020 (EC: IPI); GO_0002576 (EC: TAS); GO_0005178 (EC: IDA, PMID: 19738201); GO_0005515 (EC: IPI, PMID: 10627046); GO_0005518 (EC: NAS, PMID: 3024962); GO_0005576 (EC: NAS, PMID: 14718574); GO_0005576 (EC: TAS); GO_0005577 (EC: IDA, PMID: 3997886); GO_0005604 (EC: IEA); GO_0005615 (EC: IDA); GO_0005793 (EC: IDA, PMID: 15308636); GO_0006953 (EC: IEA); GO_0007044 (EC: IEA); GO_0007155 (EC: NAS, PMID: 1423622); GO_0007161 (EC: IEA); GO_0007596 (EC: TAS); GO_0008201 (EC: NAS, PMID: 10075919); GO_0008360 (EC: IEA); GO_0009611 (EC: NAS, PMID: 7989369); GO_0016324 (EC: IEA); GO_0016504 (EC: IEA); GO_0018149 (EC: IDA, PMID: 3997886); GO_0022617 (EC: TAS); GO_0030168 (EC: TAS); GO_0030198 (EC: TAS); GO_0031012 (EC: IDA, PMID: 16157329); GO_0031012 (EC: IDA, Qualifier: colocalizes_with); GO_0031012 (EC: ISS, Qualifier: colocalizes_with); GO_0031093 (EC: TAS); GO_0034446 (EC: IDA, PMID: 16236823); GO_0050900 (EC: TAS); GO_0070062 (EC: IDA, PMID: 19056867); GO_0072562 (EC: IDA)",,,,,,,,,PMID: 444675; 1311202; 1372909; 1400330; 1409674; 1423622; 1468447; 1532572; 1632457; 1694173; 1730778; 1875953; 1959621; 2012601; 2138612; 2229073; 2414772; 2531657; 2745554; 2822387; 2867902; 2989004; 2992573; 2992939; 3003095; 3021206; 3024962; 3031656; 3375063; 3478690; 3593230; 3770189; 3770201; 3900070; 3943369; 3988746; 3997552; 3997886; 4019516; 6092370; 6200322; 6304699; 6462919; 6630202; 6688418; 6693419; 6981115; 7050098; 7493623; 7499434; 7500359; 7519849; 7559467; 7583666; 7690138; 7963647; 7989369; 8063866; 8120056; 8120888; 8168508; 8173552; 8308892; 8360181; 8449034; 8468356; 8548820; 8599839; 8663002; 8756760; 8798654; 8905624; 8952048; 8997243; 8997639; 9016396; 9117345; 9169408; 9211865; 9334230; 9339851; 9361795; 9443108; 9501082; 9514732; 9626063; 9636140; 9651579; 9733622; 9751722; 9837825; 10075919; 10196121; 10451539; 10464263; 10470078; 10470109; 10627046; 10647176; 10706716; 10772816; 10783396; 10823831; 10848816; 11010812; 11023498; 11024059; 11134254; 11149921; 11157741; 11180285; 11276204; 11285119; 11285216; 11311202; 11342427; 11344214; 11419941; 11423128; 11423542; 11493006; 11500098; 11605051; 11686302; 11737888; 11751853; 11752017; 11768240; 11773026; 11775745; 11795204; 11801638; 11801679; 11829448; 11832485; 11847210; 11864705; 11867580; 11867643; 11891225; 11928812; 11937267; 11956183; 11960984; 11981027; 11997396; 12034705; 12069579; 12091360; 12100475; 12105189; 12119020; 12119179; 12127832; 12127836; 12149247; 12180907; 12225805; 12225811; 12270980; 12388756; 12401883; 12468382; 12477932; 12486316; 12497612; 12527107; 12535082; 12538453; 12538576; 12621118; 12631068; 12736686; 12761244; 12802498; 12810082; 12902636; 12917446; 14558920; 14602715; 14645245; 14662883; 14695199; 14702039; 14709558; 14718574; 14737076; 14760718; 15060148; 15161923; 15165854; 15174051; 15213410; 15231748; 15247227; 15265957; 15308636; 15331608; 15331737; 15384859; 15456495; 15456743; 15467744; 15485890; 15609325; 15645125; 15652337; 15699160; 15717924; 15721303; 15799029; 15806100; 15835821; 15855153; 15890670; 15912204; 15961545; 16005629; 16055535; 16083879; 16091757; 16106752; 16150826; 16157329; 16159961; 16236823; 16277979; 16322219; 16335952; 16336961; 16375583; 16378831; 16463680; 16495290; 16498633; 16581250; 16621928; 16757476; 16839338; 16928957; 16933105; 16978691; 16982604; 16984808; 16986166; 17003032; 17015452; 17027088; 17081983; 17136547; 17187346; 17266699; 17273763; 17416372; 17425334; 17459242; 17468934; 17490871; 17512904; 17526550; 17554369; 17596138; 17636193; 17704536; 17879163; 17929131; 17949711; 18006840; 18042364; 18064631; 18083324; 18268355; 18276110; 18313373; 18323857; 18332212; 18334936; 18340378; 18343220; 18348696; 18451110; 18451144; 18474427; 18499669; 18577581; 18624398; 18633626; 18690341; 18713862; 18716775; 18776591; 18801363; 18810851; 18824166; 18829569; 18957516; 18958156; 19020673; 19031824; 19037100; 19056867; 19094228; 19160003; 19161998; 19212764; 19224684; 19251642; 19342448; 19345424; 19391127; 19404402; 19417080; 19460753; 19471022; 19541353; 19542224; 19553700; 19564406; 19581300; 19616291; 19617627; 19701604; 19701759; 19730683; 19738201; 19760097; 19821053; 19834535; 19847669; 19880379; 19893244; 19893454; 19903114; 19913121; 19914350; 19935699; 20007695; 20012564; 20029029; 20043904; 20097172; 20097751; 20145126; 20161770; 20201928; 20210243; 20232238; 20357207; 20359090; 20364278; 20403349; 20419094; 20452482; 20463177; 20470202; 20484935; 20489157; 20495339; 20505078; 20506163; 20530259; 20552237; 20600851; 20628086; 20628340; 20628624; 20638438; 20643357; 20670094; 20671107; 20672308; 20672350; 20673868; 20686611; 20708078; 20725648; 20811396; 20814177; 20819642; 20851879; 20860816; 20939933; 21036168; 21036738; 21078624; 21098633; 21131589; 21138686; 21139048; 21148425; 21150319; 21160032; 21178109; 21190414; 21224775; 21311138; 21325030; 21330459; 21347378; 21429937; 21472136; 21508391; 21573010; 21630266; 21691075; 21768108; 21824169; 21840989; 21861843; 21876142; 21890473; 21924268; 21942715; 21961600; 21969082; 21980357; 21988832; 22009740; 22048274; 22219202; 22241990; 22319020; 22339947; 22351755; 22378065; 22496919; 22514602; 22523280; 22531343; 22586326; 22641031; 22674303; 22699679; 22705941; 22716248; 22782528; 22837202; 22848537; 22896658; 22918248; 22919069; 22936677; 23029023; 23056244; 23098431; 23116545; 23142796; 23170788; 23201264; 23201304; 23217101; 23238252; 23251222; 23288153; 23315067; 23341464; 23485472; 23509360; 23593224; 23612019; 23622001; 23643164; 23653350; 23653354; 23684510; 23740248; 23750785; 23763354; 23765377; 23791940; 23811340; 23872359; 23884219; 23908593; 23921871; 24030464; 24070235,,,,,,,,,,,,,,,OGG:3000002335,,,,,,,fibronectin 1,,,,,,,,,,,,,Other designations: cold-insoluble globulin|fibronectin|migration-stimulating factor,,FN1,,,,,,,,,,,,,,,,,,,,,,,2335,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,FN1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000002339,FNTA,,Other designations: FTase-alpha|GGTase-I-alpha|farnesyl-protein transferase alpha-subunit|protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha|protein prenyltransferase alpha subunit repeat containing 2|ras proteins prenyltransferase subunit alpha|type I protein geranyl-geranyltransferase alpha subunit,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,PTAR2|FPTA|PGGT1A,,,,,,,,,,,,8,,,,,,Ensembl:ENSG00000168522|Vega:OTTHUMG00000165279|MIM:134635|HGNC:3782|HPRD:00607,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"farnesyltransferase, CAAX box, alpha",,,8p11,,,,,,,,,,,,,,,,"GO_0004660 (EC: IDA, PMID: 16893176); GO_0004660 (EC: IDA, Qualifier: contributes_to, PMID: 19228685); GO_0004661 (EC: IDA, PMID: 16893176); GO_0004662 (EC: IEA); GO_0005515 (EC: IPI, PMID: 11687658); GO_0005737 (EC: TAS, PMID: 8599089); GO_0005829 (EC: TAS); GO_0005875 (EC: IDA, PMID: 19228685); GO_0005953 (EC: IDA, PMID: 16893176); GO_0005965 (EC: IDA, PMID: 16893176); GO_0006915 (EC: TAS); GO_0006921 (EC: TAS); GO_0007179 (EC: TAS, PMID: 8599089); GO_0007603 (EC: TAS); GO_0008017 (EC: IDA, PMID: 19228685); GO_0016056 (EC: TAS); GO_0018343 (EC: IDA, PMID: 16893176); GO_0018344 (EC: IDA, PMID: 16893176); GO_0022400 (EC: TAS); GO_0043014 (EC: IDA, PMID: 19228685); GO_0090044 (EC: IDA, PMID: 19228685); GO_0090045 (EC: IDA, PMID: 19228685)",,,,,,,,,PMID: 1400319; 2217184; 7713879; 8106351; 8175923; 8276393; 8419339; 8494894; 8530343; 8599089; 8830800; 8889548; 8910345; 10676968; 10747914; 10852915; 11313965; 11598000; 11687658; 12036349; 12374986; 12477932; 12825937; 14702039; 15170324; 15451670; 15489334; 16893176; 17192483; 17353931; 18187620; 18406652; 18654987; 19228685; 19841875; 20403997; 21139048; 21906983; 21988832; 22160308; 22863883; 23602568,,,,,,,,,,,,,,,OGG:3000002339,,,,,,,"farnesyltransferase, CAAX box, alpha",,,,,,,,,,,,,Other designations: FTase-alpha|GGTase-I-alpha|farnesyl-protein transferase alpha-subunit|protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha|protein prenyltransferase alpha subunit repeat containing 2|ras proteins prenyltransferase subunit alpha|type I protein geranyl-geranyltransferase alpha subunit,,FNTA,,,,,,,,,,,,,,,,,,,,,,,2339,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,FNTA,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0001581,Rab9A,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001581,,,,,,,,,,,,,,,,,,,,,,Rab9A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001669,RGS11,,,false,,,http://purl.obolibrary.org/obo/IMR_0000431,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001669,,,,,,,,,,,,,,,,,,,,,,RGS11,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_2825,aristolochic acid,"8-methoxy-6-nitrophenanthro[3,4-d][1,3]dioxole-5-carboxylic acid","A monocarboxylic acid that is phenanthrene-1-carboxylic acid that is substituted by a methylenedioxy group at the 3,4 positions, by a methoxy group at position 8, and by a nitro group at position 10. It is the most abundant of the aristolochic acids and is found in almost all Aristolochia (birthworts or pipevines) species. It has been tried in a number of treatments for inflammatory disorders, mainly in Chinese and folk medicine. However, there is concern over their use as aristolochic acid is both carcinogenic and nephrotoxic.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:313-67-7,,"A monocarboxylic acid that is phenanthrene-1-carboxylic acid that is substituted by a methylenedioxy group at the 3,4 positions, by a methoxy group at position 8, and by a nitro group at position 10. It is the most abundant of the aristolochic acids and is found in almost all Aristolochia (birthworts or pipevines) species. It has been tried in a number of treatments for inflammatory disorders, mainly in Chinese and folk medicine. However, there is concern over their use as aristolochic acid is both carcinogenic and nephrotoxic.",,,,,,,,,,,,C17H11NO7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"8-methoxy-6-nitrophenanthro[3,4-d][1,3]dioxole-5-carboxylic acid",,,,,CHEBI:2825,,,,,,,,,,,,,,,,,,,,,,aristolochic acid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COc1cccc2c1cc([N+]([O-])=O)c1c(cc3OCOc3c21)C(O)=O,,,,,
http://purl.obolibrary.org/obo/IMR_0000308,signaling (initiator) caspase,,,false,,,http://purl.obolibrary.org/obo/IMR_0000305,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000308,,,,,,,,,,,,,,,,,,,,,,signaling (initiator) caspase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000080,FGFR family,fibroblast growth factor receptor,"The vertebrate Fgfr gene family consists of four highly related genes, Fgfr1-4.",false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,GO:0005007,,"The vertebrate Fgfr gene family consists of four highly related genes, Fgfr1-4.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000823,,,,,fibroblast growth factor receptor,,,,,IMR:0000080,,,,,,,,,,,,,,,,,,,,,,FGFR family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100721,Delta-like3,DLL3,,false,,,http://purl.obolibrary.org/obo/IMR_0100718,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,DLL3,,,,,IMR:0100721,,,,,,,,,,,,,,,,,,,,,,Delta-like3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010470,60S ribosomal protein L18a,Q02543,,false,,,http://purl.obolibrary.org/obo/IMR_0000897,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Q02543,,,,,IMR:0010470,,,,,,,,,,,,,,,,,,,,,,60S ribosomal protein L18a,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000625,Integrin alpha-3,,,false,,,http://purl.obolibrary.org/obo/IMR_0000173,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000625,,,,,,,,,,,,,,,,,,,,,,Integrin alpha-3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001096,transportin 1,karyopherin beta2|importin beta2,,false,,,http://purl.obolibrary.org/obo/IMR_0100010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,karyopherin beta2|importin beta2,,,,,IMR:0001096,,,,,,,,,,,,,,,,,,,,,,transportin 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001412,Gab3,Grb2-associated binder 3,,false,,,http://purl.obolibrary.org/obo/IMR_0001409,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Grb2-associated binder 3,,,,,IMR:0001412,,,,,,,,,,,,,,,,,,,,,,Gab3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000055856,ACOT13,,Other designations: acyl-coenzyme A thioesterase 13|hypothalamus protein HT012|thioesterase superfamily member 2,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,PNAS-27|THEM2,,,,,,,,,,,,6,,,,,,MIM:615652|HGNC:20999|Ensembl:ENSG00000112304|HPRD:07158|Vega:OTTHUMG00000014359,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,acyl-CoA thioesterase 13,,,6p22.3,,,,,,,,,,,,,,,,"GO_0005739 (EC: IEA); GO_0008152 (EC: IDA, PMID:16934754); GO_0047617 (EC: IDA, PMID:16934754); GO_0051289 (EC: IPI, PMID:16934754)",,,,,,,,,PMID:8889548; 10931946; 12477932; 14574404; 14702039; 15489334; 16344560; 16934754; 17045243; 17704541; 18095154; 18624398; 19170545; 19405909; 19738201; 20877624; 21139048; 21319273; 22262880; 22939629; 23954868; 24250222,,,,,,,,,,,,,,,OGG:3000055856,,,,,,,acyl-CoA thioesterase 13,,,,,,,,,,,,,Other designations: acyl-coenzyme A thioesterase 13|hypothalamus protein HT012|thioesterase superfamily member 2,,ACOT13,,,,,,,,,,,,,,,,,,,,,,,55856,HT012,,,,,,,9606,,,,,,,,,,,,,,,,,,,ACOT13,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_27594,carbon atom,carbon,,false,,,http://purl.obolibrary.org/obo/CHEBI_33250,,,,,,,,,,,,,,,,,,,,Inchikey:OKTJSMMVPCPJKN-UHFFFAOYSA-N|CAS:7440-44-0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,carbon,,,,,CHEBI:27594,,,,,,,,,,,,,,,,,,,,,,carbon atom,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100058,MSH-releasing hormone,MSHRH,,false,,,http://purl.obolibrary.org/obo/IMR_0100093,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MSHRH,,,,,IMR:0100058,,,,,,,,,,,,,,,,,,,,,,MSH-releasing hormone,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001468,DOCK180,DOCK1,,false,,,http://purl.obolibrary.org/obo/IMR_0001469,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,DOCK1,,,,,IMR:0001468,,,,,,,,,,,,,,,,,,,,,,DOCK180,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000224,MAPK,mitogen-activated protein kinase|MAP kinase,"Mammals express at least four distinctly regulated groups of MAPKs, ERK-1/2, JNK/SAPK, p38 and ERK5. MAPKs are activated by dual phosphorylation on both tyrosine and threonine residues of a conserved TXY motif.",false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,IPR:003527|GO:0004707,,"Mammals express at least four distinctly regulated groups of MAPKs, ERK-1/2, JNK/SAPK, p38 and ERK5. MAPKs are activated by dual phosphorylation on both tyrosine and threonine residues of a conserved TXY motif.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001966,,,,,mitogen-activated protein kinase|MAP kinase,,,,,IMR:0000224,,,,,,,,,,,,,,,,,,,,,,MAPK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100114,adrenalin,"(R)-(-)-Epinephrine|L-Adrenaline|(R)-(-)-Epirenamine|(R)-(-)-Adnephrine|4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol|(R)-(-)-Adrenaline",,false,,,http://purl.obolibrary.org/obo/IMR_0001694,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_25512,,,,IMR:0200335,"(R)-(-)-Epinephrine|L-Adrenaline|(R)-(-)-Epirenamine|(R)-(-)-Adnephrine|4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol|(R)-(-)-Adrenaline",,,,,IMR:0100114,,,,,,,,,,,,,,,,,,,,,,adrenalin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_35717,sedative,sedative drug|hypnotics and sedatives|hypnotics|sedatives|sedatives and hypnotics,A central nervous system depressant used to induce drowsiness or sleep or to reduce psychological excitement or anxiety.,false,,,http://purl.obolibrary.org/obo/CHEBI_35488,,,,,,,,,,,,,,,,,,,,,,A central nervous system depressant used to induce drowsiness or sleep or to reduce psychological excitement or anxiety.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sedative drug|hypnotics and sedatives|hypnotics|sedatives|sedatives and hypnotics,,,,,,,,,,,,,,,,,,,,,CHEBI:35717,,,,sedative,,CHEBI:35717,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0015722,canalicular bile acid transport,,"Enables the transfer of bile acid from one side of a hepatocyte plasma membrane into a bile canaliculus. Bile canaliculi are the thin tubes formed by hepatocyte membranes. Bile acids are any of a group of steroid carboxylic acids occurring in bile, where they are present as the sodium salts of their amides with glycine or taurine.",false,,,http://purl.obolibrary.org/obo/GO_0015721,,,,,,,,,,,,,,,,,,,,,,"Enables the transfer of bile acid from one side of a hepatocyte plasma membrane into a bile canaliculus. Bile canaliculi are the thin tubes formed by hepatocyte membranes. Bile acids are any of a group of steroid carboxylic acids occurring in bile, where they are present as the sodium salts of their amides with glycine or taurine.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0015722,,,,,,,,,,,,,,,,,,,,,,canalicular bile acid transport,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0015721,bile acid and bile salt transport,bile acid transport,"The directed movement of bile acid and bile salts into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.",false,,,http://purl.obolibrary.org/obo/GO_0006810,,,,,,,,,,,,,,,,,,,,,,"The directed movement of bile acid and bile salts into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,bile acid transport,,,,GO:0015721,,,,,,,,,,,,,,,,,,,,,,bile acid and bile salt transport,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_25710,organophosphorus compound,,"An organophosphorus compound is formally a compound containing at least one carbon-phosphorus bond, but the term is often extended to include esters and thioesters.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,,,"An organophosphorus compound is formally a compound containing at least one carbon-phosphorus bond, but the term is often extended to include esters and thioesters.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:25710,,,,,,,,,,,,,,,,,,,,,,organophosphorus compound,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002693,bile acid and bile salt transport  to hepatocyte,,Bile acid and bile salt transport  to hepatocyte is a subtype of bile acid and bile salt transport: A process that transports bile acid and bile salts within a hepatocyte by means of some agent such as a transporter or pore.,false,,,http://purl.obolibrary.org/obo/GO_0015721,,,,,,,,,,,,,,,,,,,,,,Bile acid and bile salt transport  to hepatocyte is a subtype of bile acid and bile salt transport: A process that transports bile acid and bile salts within a hepatocyte by means of some agent such as a transporter or pore.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000182,,,,,,,,TXPO:0002693,,,,,,,,,,,,,,,,,,,,,,bile acid and bile salt transport  to hepatocyte,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002699,EDEM (canonical)[ER stress],,"Extracts misfolded glycoproteins, but not glycoproteins undergoing productive folding, from the calnexin cycle. It is directly involved in endoplasmic reticulum-associated degradation (ERAD) and targets misfolded glycoproteins for degradation in an N-glycan-independent manner, probably by forming a complex with SEL1L. It has low mannosidase activity, catalyzing mannose trimming from Man8GlcNAc2 to Man7GlcNAc2.",false,,,http://purl.obolibrary.org/obo/TXPO_0000298|http://purl.obolibrary.org/obo/TXPO_0000871,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:192193|http://omim.org/entry/607673|NCBI-Rat-GeneID:297504|NCBI-Human-GeneID:9695|PMID:18653895|PMID:11375934|PMID:12610306,,"Extracts misfolded glycoproteins, but not glycoproteins undergoing productive folding, from the calnexin cycle. It is directly involved in endoplasmic reticulum-associated degradation (ERAD) and targets misfolded glycoproteins for degradation in an N-glycan-independent manner, probably by forming a complex with SEL1L. It has low mannosidase activity, catalyzing mannose trimming from Man8GlcNAc2 to Man7GlcNAc2.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003663,,,,,,,,,,TXPO:0002699,,,,,,,,,,,,,,,,,,,,,,EDEM (canonical)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002697,glibenclamide [Cholestasis],,,false,,,http://purl.obolibrary.org/obo/CHEBI_5441|http://purl.obolibrary.org/obo/TXPO_0000749,,,,,,,,,,,,,,,,,,,,CASRN:10238-21-8|InChIKeyZ:NNLBTZKUZBEKO-UHFFFAOYSA-N|Wikipedia:Glyburide|DrugBank:DB01016|An urea that has formula C23H28ClN3O5S.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001866,,,,,,,,,,TXPO:0002697,,,,,,,"rifampicin, cyclosporine A, rifamycin SV, bosentan, troglitazone, erythromycin estolate, and glibenclamide inhibit Bsep in rats|OATP transporters are a critical factor controlling the uptake of glibenclamide by the liver. GLB is a substrate for OATP2B1 and OATP1B1, which are expressed at the sinusoidal membrane of hepatocytes.",,,,,,,,,,,,,,,glibenclamide [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002690,XBP1 activation by IRE1 [ER stress],,"XBP1 activation by IRE1 is a subtype of activation of transcription factor: A process that changes the activity of XBP1 (X-Box Binding Protein 1) to be higher by IRE1.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.|The XBP1 gene is transcribed to yield mRNA, the mRNA is spliced to yield Xbp(s) mRNA, and the mRNA is translated to yield protein.",false,,,http://purl.obolibrary.org/obo/TXPO_0003736|http://purl.obolibrary.org/obo/TXPO_0002592,,,,,,,,,,,,,,,,,,,,Reactome:R-HSA-1791121.3,,"XBP1 activation by IRE1 is a subtype of activation of transcription factor: A process that changes the activity of XBP1 (X-Box Binding Protein 1) to be higher by IRE1.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000726,,,,http://purl.obolibrary.org/obo/TXPO_0001968,,,,,,,,,,,,,,,,,TXPO:0002690,,,,,,,,,,,,,,,,,,,,"The XBP1 gene is transcribed to yield mRNA, the mRNA is spliced to yield Xbp(s) mRNA, and the mRNA is translated to yield protein.",,XBP1 activation by IRE1 [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002698,importing substance into hepatocyte vascular side (sinusoidal side) membrane by OATP [Cholestasis],,"The directed movement of drugs into hepatocyte vascular side (sinusoidal side) membrane by OATP.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001759,,,,,,,,,,,,,,,,,,,,,,"The directed movement of drugs into hepatocyte vascular side (sinusoidal side) membrane by OATP.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000272,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002697,,,,,,http://purl.obolibrary.org/obo/TXPO_0002702,,,,,,,,,,,,,,,,,TXPO:0002698,,,,,,,,,,,,,,,,,,,,,,importing substance into hepatocyte vascular side (sinusoidal side) membrane by OATP [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002694,ABC transporter,ATP-binding cassette Transporter,"A family of transmembrane proteins that usually function as dimers to hydrolyze ATP, which permits them to transport a wide variety of substrates across cellular membranes. These proteins consist of two distinct domains, a transmembrane domain and a nucleotide-binding domain. ATP binding is required for both dimerization and transporter activity.",false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C17750,,"A family of transmembrane proteins that usually function as dimers to hydrolyze ATP, which permits them to transport a wide variety of substrates across cellular membranes. These proteins consist of two distinct domains, a transmembrane domain and a nucleotide-binding domain. ATP binding is required for both dimerization and transporter activity.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ATP-binding cassette Transporter,,,,,TXPO:0002694,,,,,,,,,,,,,,,,,,,,,,ABC transporter,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002695,contraction of bile canaliculus,,Contraction of bile canaliculus is a subtype of contraction: A process that generates the directed movement in which the bile canaliculus decreases in volume.,false,,,http://purl.obolibrary.org/obo/TXPO_0003129,,,,,,,,,,,,,,,,,,,,PMID:2040644|PMID:7015506,,Contraction of bile canaliculus is a subtype of contraction: A process that generates the directed movement in which the bile canaliculus decreases in volume.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002695,,,,,,,,,,,,,,,,,,,,,,contraction of bile canaliculus,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002692,bile secretion to bile canaliculus,,Bile secretion to bile canaliculus is a subtype of bile secretion: A process that of the release from one side of a hepatocyte plasma membrane to a bile canaliculus. Bile canaliculi are the thin tubes formed by hepatocyte membranes.,false,,,http://purl.obolibrary.org/obo/TXPO_0002683,,,,,,,,,,,,,,,,,,,,,,Bile secretion to bile canaliculus is a subtype of bile secretion: A process that of the release from one side of a hepatocyte plasma membrane to a bile canaliculus. Bile canaliculi are the thin tubes formed by hepatocyte membranes.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002692,,,,,,,,,,,,,,,,,,,,,,bile secretion to bile canaliculus,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002691,ATF6 signaling (primitive) [ER stress - ERAD],,"ATF6 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the ATF6 (activating transcription factor 6). ATF6 generally plays a endoplasmic reticulum membrane stress sensor role.
This process is dependent on ERAD and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000719,,,,,,,,,,,,,,,,,,,,,,"ATF6 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the ATF6 (activating transcription factor 6). ATF6 generally plays a endoplasmic reticulum membrane stress sensor role.
This process is dependent on ERAD and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002901,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002918,,,,,,,,,,,,,,,,,,TXPO:0002691,,,,,,,,,,,,,,,,,,,,,,ATF6 signaling (primitive) [ER stress - ERAD],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002696,ERAD related gene expression byXBP1s [ER stress],,"ERAD related gene expression by XBP1s is a subtype of gene expression: The process in which a gene sequence is converted into a mature ER-associated degradation (ERAD) gene product or products (proteins or RNA) by XBP1s.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/TXPO_0000727,,,,,,,,,,,,,,,,,,,,,,"ERAD related gene expression by XBP1s is a subtype of gene expression: The process in which a gene sequence is converted into a mature ER-associated degradation (ERAD) gene product or products (proteins or RNA) by XBP1s.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002605,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002700,,,http://purl.obolibrary.org/obo/TXPO_0002610,,,,,,,,,,,,,,,,TXPO:0002696,,,,,,,,,,,,,,,,,,,,,,ERAD related gene expression byXBP1s [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0200307,L-Tryptophan,,,false,,,http://purl.obolibrary.org/obo/CHEBI_33709,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0200307,,,,,,,,,,,,,,,,,,,,,,L-Tryptophan,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004349,Hypofunction of sequestering of calcium ion in ER [mitochondrial disorder],,"Hypofunction of sequestering of calcium ion in ER is a subtype of hypofunctioning: A process that performs a decreased or insufficient sequestering of calcium ion in ER.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder..",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0002192,,,,,,,,,,,,,,,,,,,,PMID:31623280,,"Hypofunction of sequestering of calcium ion in ER is a subtype of hypofunctioning: A process that performs a decreased or insufficient sequestering of calcium ion in ER.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder..",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001990|http://purl.obolibrary.org/obo/TXPO_0001992,,,,,,,,,,,TXPO:0004349,,,,,,,,,,,,,,,,,,,,,,Hypofunction of sequestering of calcium ion in ER [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005783,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004347,Insulin resistance (process) [mitochondrial disorder],,"Insulin resistance (process) is a subtype of decreasing sensitivity: A process that changes the sensitivity to the circulating insulin to be lower.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0002189,,,,,,,,,,,,,,,,,,,,PMID:31623280|PMID:31649547,,"Insulin resistance (process) is a subtype of decreasing sensitivity: A process that changes the sensitivity to the circulating insulin to be lower.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002004,,,,,,,,,,,TXPO:0004347,,,,,,,,,,,,,,,,,,,,,,Insulin resistance (process) [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004340,increasing demand for response to ER stress [mitochondrial disorder],,"Increasing demand for response to ER stress is a subtype of increasing the demand for response to stress: A process that changes the functional demand for the response to the endoplasmic reticulum (ER) stress to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0000362,,,,,,,,,,,,,,,,,,,,PMID:31623280,,"Increasing demand for response to ER stress is a subtype of increasing the demand for response to stress: A process that changes the functional demand for the response to the endoplasmic reticulum (ER) stress to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004218,,,,,,,,,,,TXPO:0004340,,,,,,,,,,,,,,,,,,,,,,increasing demand for response to ER stress [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004341,cardiolipin peroxidation [mitochondrial disorder],,"cardiolipin peroxidation is a subtype of phospholipid oxidation:  The degradation of cardiolipin caused by an oxidative attack from free radicals.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.|PMID:25339807",false,,,http://purl.obolibrary.org/obo/TXPO_0004931|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,,,"cardiolipin peroxidation is a subtype of phospholipid oxidation:  The degradation of cardiolipin caused by an oxidative attack from free radicals.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_28494,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001991|http://purl.obolibrary.org/obo/TXPO_0000869|http://purl.obolibrary.org/obo/TXPO_0004436|http://purl.obolibrary.org/obo/TXPO_0004263,,,,,,,,,,,TXPO:0004341,,,,,,,,,,,,,,,,,,,,PMID:25339807,,cardiolipin peroxidation [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004343,cellular membrane lipoperoxidation [mitochondrial disorder],,"Cellular membrane lipoperoxidation is a subtype of lipoperoxidation: A process that the degradation of lipids of cellular membrane caused by an oxidative attack from free radicals.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0003513|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:25339807,,"Cellular membrane lipoperoxidation is a subtype of lipoperoxidation: A process that the degradation of lipids of cellular membrane caused by an oxidative attack from free radicals.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004343,,,,,,,,,,,,,,,,,,,,,,cellular membrane lipoperoxidation [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004342,necrosis [mitochondrial disorder],,"A type of cell death that is morphologically characterized by an increasingly translucent cytoplasm, swelling of organelles, minor ultrastructural modifications of the nucleus (specifically, dilatation of the nuclear membrane and condensation of chromatin into small, irregular, circumscribed patches) and increased cell volume (oncosis), culminating in the disruption of the plasma membrane and subsequent loss of intracellular contents. Necrotic cells do not fragment into discrete corpses as their apoptotic counterparts do. Moreover, their nuclei remain intact and can aggregate and accumulate in necrotic tissues.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/GO_0070265,,,,,,,,,,,,,,,,,,,,PMID:31623280|PMID:25339807,,"A type of cell death that is morphologically characterized by an increasingly translucent cytoplasm, swelling of organelles, minor ultrastructural modifications of the nucleus (specifically, dilatation of the nuclear membrane and condensation of chromatin into small, irregular, circumscribed patches) and increased cell volume (oncosis), culminating in the disruption of the plasma membrane and subsequent loss of intracellular contents. Necrotic cells do not fragment into discrete corpses as their apoptotic counterparts do. Moreover, their nuclei remain intact and can aggregate and accumulate in necrotic tissues.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003568,,,,,,,,,,,TXPO:0004342,,,,,,,,,,,,,,,,,,,,,,necrosis [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004344,hepatic stellate cell activation [mitochondrial disorder],,"A change in the morphology or behavior of a hepatic stellate cell resulting from exposure to a cytokine, chemokine, hormone, cellular ligand or soluble factor.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/GO_0035733|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:25339807,,"A change in the morphology or behavior of a hepatic stellate cell resulting from exposure to a cytokine, chemokine, hormone, cellular ligand or soluble factor.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004279,,,,,,,,,,,TXPO:0004344,,,,,,,,,,,,,,,,,,,,,,hepatic stellate cell activation [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004345,mitochondrial membrane morphology changes [mitochondrial disorder],,"mitochondrial membrane morphology changes is a subtype of mitochondria morphology changes: A process that changes the morphology of the mitochondrial membrane.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0004998,,,,,,,,,,,,,,,,,,,,,,"mitochondrial membrane morphology changes is a subtype of mitochondria morphology changes: A process that changes the morphology of the mitochondrial membrane.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004345,,,,,,,,,,,,,,,,,,,,,,mitochondrial membrane morphology changes [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004348,Calcium ion homeostasis imbalance [mitochondrial disorder],,"Calcium ion homeostasis imbalance is a subtype of chemical homeostasis imbalance: A process that becomes lacking a calcium ion homeostastasis balance.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001765|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:31623280,,"Calcium ion homeostasis imbalance is a subtype of chemical homeostasis imbalance: A process that becomes lacking a calcium ion homeostastasis balance.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004348,,,,,,,,,,,,,,,,,,,,,,Calcium ion homeostasis imbalance [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004346,IL-1beta production [mitochondrial disorder],,"The appearance of interleukin-1 beta due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/GO_0032611,,,,,,,,,,,,,,,,,,,,PMID:31623280,,"The appearance of interleukin-1 beta due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004648,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004271,,,,,,,,,,,TXPO:0004346,,,,,,,,,,,,,,,,,,,,,,IL-1beta production [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000867,B-Myb,,,false,,,http://purl.obolibrary.org/obo/IMR_0000868,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000867,,,,,,,,,,,,,,,,,,,,,,B-Myb,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100221,ASK2,MAPKKK6,,false,,,http://purl.obolibrary.org/obo/IMR_0000229,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MAPKKK6,,,,,IMR:0100221,,,,,,,,,,,,,,,,,,,,,,ASK2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000034,NGF family,neurotrophin|nerve growth factor family,,false,,,http://purl.obolibrary.org/obo/TXPO_0001382,,,,,,,,,,,,,,,,,,,,GO:0005165,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002395|http://purl.obolibrary.org/obo/TXPO_0000624,,,,,neurotrophin|nerve growth factor family,,,,,IMR:0000034,,,,,,,,,,,,,,,,,,,,,,NGF family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002194,hypofunction of sequestering of calcium ion [ER stress],,"Hypofunction of sequestering of calcium ion is a subtype of hypofunctioning: A process that performs a decreased or insufficient sequestering of calcium ion.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/TXPO_0002192,,,,,,,,,,,,,,,,,,,,PMID:27694578,,"Hypofunction of sequestering of calcium ion is a subtype of hypofunctioning: A process that performs a decreased or insufficient sequestering of calcium ion.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001810,,,,,,,,,,,TXPO:0002194,,,,,,,,,,,,,,,,,,,,,,hypofunction of sequestering of calcium ion [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005783,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002196,lipid synthesis regulator role,,A role played by the entity which regulates the formation of lipids.,false,,,http://purl.obolibrary.org/obo/TXPO_0002358,,,,,,,,,http://purl.obolibrary.org/obo/GO_0008610,,,,,,,,,,,,,A role played by the entity which regulates the formation of lipids.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002196,,,,,,,,,,,,,,,,,,,,,,lipid synthesis regulator role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002199,malfunctioning of cellular membrane [ER stress],,"Malfunctioning of cellular membrane is a subtype of malfunctioning process: A process that cannot perform a cellular membrane function appropriately or cannot realize it at all.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/TXPO_0002198,,,,,,,,,,,,,,,,,,,,,,"Malfunctioning of cellular membrane is a subtype of malfunctioning process: A process that cannot perform a cellular membrane function appropriately or cannot realize it at all.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002200,,,,,,,,,,,TXPO:0002199,,,,,,,,,,,,,,,,,,,,,,malfunctioning of cellular membrane [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002198,malfunctioning of cellular membrane,,Malfunctioning of cellular membrane is a subtype of malfunctioning process: A process that cannot perform a cellular membrane function appropriately or cannot realize it at all.,false,,,http://purl.obolibrary.org/obo/TXPO_0000434,,,,,,,,,,,,,,,,,,,,,,Malfunctioning of cellular membrane is a subtype of malfunctioning process: A process that cannot perform a cellular membrane function appropriately or cannot realize it at all.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002198,,,,,,,,,,,,,,,,,,,,,,malfunctioning of cellular membrane,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000895,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002197,malfunction of lipid biosynthesis [ER stress],,"Malfunction of lipid biosynthesis is a subtype of malfunctioning: A process that cannot perform  the lipid biosynthesis function appropriately or cannot realize it at all.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/TXPO_0003268,,,,,,,,,,,,,,,,,,,,,,"Malfunction of lipid biosynthesis is a subtype of malfunctioning: A process that cannot perform  the lipid biosynthesis function appropriately or cannot realize it at all.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002199,,,,,,,,,,,TXPO:0002197,,,,,,,,,,,,,,,,,,,,,,malfunction of lipid biosynthesis [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005783,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002192,hypofunction of sequestering of calcium ion,,Hypofunction of sequestering of calcium ion is a subtype of hypofunctioning: A process that performs a decreased or insufficient sequestering of calcium ion.,false,,,http://purl.obolibrary.org/obo/TXPO_0000436,,,,,,,,,,,,,,,,,,,,,,Hypofunction of sequestering of calcium ion is a subtype of hypofunctioning: A process that performs a decreased or insufficient sequestering of calcium ion.,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005783,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002192,,,,,,,,,,,,,,,,,,,,,,hypofunction of sequestering of calcium ion,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005783,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002191,hypofunction of drug metabolism [ER stress],,"Hypofunction of drug metabolism is a subtype of hypofunction of metabolism: A process that performs a decreased or insufficient drug metabolism.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/TXPO_0002190,,,,,,,,,,,,,,,,,,,,,,"Hypofunction of drug metabolism is a subtype of hypofunction of metabolism: A process that performs a decreased or insufficient drug metabolism.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002191,,,,,,,,,,,,,,,,,,,,,,hypofunction of drug metabolism [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002190,hypofunction of drug metabolism,,Hypofunction of drug metabolism is a subtype of hypofunction of metabolism: A process that performs a decreased or insufficient drug metabolism.,false,,,http://purl.obolibrary.org/obo/TXPO_0002354,,,,,,,,,,,,,,,,,,,,,,Hypofunction of drug metabolism is a subtype of hypofunction of metabolism: A process that performs a decreased or insufficient drug metabolism.,,,http://purl.obolibrary.org/obo/GO_0017144,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002190,,,,,,,,,,,,,,,,,,,,,,hypofunction of drug metabolism,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002193,adaptive response,,A role played by a process to maintain homeostasis and to ptotect the toxic insult.,false,,,http://purl.obolibrary.org/obo/TXPO_0002178,,,,,,,,,,,,,,,,,,,,,,A role played by a process to maintain homeostasis and to ptotect the toxic insult.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002193,,,,,,,,,,,,,,,,,,,,,,adaptive response,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002195,hypofunction of lipid biosynthesis,,Hypofunction of lipid biosynthesis is a subtype of hypofunction of biosynthesis: A process that performs a decreased or insufficient lipid biosynthesis.,false,,,http://purl.obolibrary.org/obo/TXPO_0001910,,,,,,,,,,,,,,,,,,,,,,Hypofunction of lipid biosynthesis is a subtype of hypofunction of biosynthesis: A process that performs a decreased or insufficient lipid biosynthesis.,,,http://purl.obolibrary.org/obo/GO_0008610,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002195,,,,,,,,,,,,,,,,,,,,,,hypofunction of lipid biosynthesis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0200448,L-Glutamine,,,false,,,http://purl.obolibrary.org/obo/CHEBI_33709,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0200448,,,,,,,,,,,,,,,,,,,,,,L-Glutamine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_17263,estrone,,An estrogen that has formula C18H22O2.,false,,,http://purl.obolibrary.org/obo/CHEBI_35341,,,,,,,,,,,,,,,,,,,,ATC:G03CC04|DrugBank:DB00655|ATC:G03CA07|CASRN:53-16-7|InChIKey:DNXHEGUUPJUMQT-CBZIJGRNSA-N,,An estrogen that has formula C18H22O2.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:17263,,,,,,,,,,,,,,,,,,,,,,estrone,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000054951,COMMD8,,Other designations: COMM domain-containing protein 8,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,4,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,COMM domain containing 8,,,4p12,,,,,,,,,,,,,,,,"GO_0005515 (EC: IPI, PMID: 15799966)",,,,,,,,,PMID: 12477932; 14702039; 15489334; 15799966; 16169070; 17207965; 20379614; 21139048; 21890473; 21900206; 22939629; 23000965; 23563313; 24250222,,,,,,,,,,,,,,,OGG:3000054951,,,,,,,COMM domain containing 8,,,,,,,,,,,,,Other designations: COMM domain-containing protein 8,,COMMD8,,,,,,,,,,,,,,,,,,,,,,,54951,MDS022,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,COMMD8,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/GO_0007253,cytoplasmic sequestering of NF-kappaB,,"The selective interaction of the transcription factor NF-kappaB with specific molecules in the cytoplasm, thereby inhibiting its translocation into the nucleus.",false,,,http://purl.obolibrary.org/obo/TXPO_0000433,,,,,,,,,,,,,,,,,,,,,,"The selective interaction of the transcription factor NF-kappaB with specific molecules in the cytoplasm, thereby inhibiting its translocation into the nucleus.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0007253,,,,,,,,,,,,,,,,,,,,,,cytoplasmic sequestering of NF-kappaB,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100037,mineralocorticoid,,,false,,,http://purl.obolibrary.org/obo/IMR_0100033,,,,,,,,,,,,,,,,,,,,CHEBI:25354,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100037,,,,,,,,,,,,,,,,,,,,,,mineralocorticoid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76710,EC 4.* (lyase) inhibitor,lyase (EC 4.*) inhibitorS|lyase (EC 4.*) inhibitor|lyase inhibitors|EC 4.* inhibitors|EC 4.* inhibitor|EC 4.*.*.* inhibitor|lyase inhibitor|EC 4.* (lyase) inhibitors|EC 4.*.*.* inhibitors,"An enzyme inhibitor which interferes with the action of a lyase (EC 4.*.*.*). Lyases are enzymes cleaving C-C, C-O, C-N and other bonds by other means than by hydrolysis or oxidation.",false,,,http://purl.obolibrary.org/obo/CHEBI_23924,,,,,,,,,,,,,,,,,,,,,,"An enzyme inhibitor which interferes with the action of a lyase (EC 4.*.*.*). Lyases are enzymes cleaving C-C, C-O, C-N and other bonds by other means than by hydrolysis or oxidation.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,lyase (EC 4.*) inhibitorS|lyase (EC 4.*) inhibitor|lyase inhibitors|EC 4.* inhibitors|EC 4.* inhibitor|EC 4.*.*.* inhibitor|lyase inhibitor|EC 4.* (lyase) inhibitors|EC 4.*.*.* inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:76710,,,,EC 4.* (lyase) inhibitor,,CHEBI:76710,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001216,Axin2,Axil|Axin-like protein|conductin,,false,,,http://purl.obolibrary.org/obo/IMR_0000432,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Axil|Axin-like protein|conductin,,,,,IMR:0001216,,,,,,,,,,,,,,,,,,,,,,Axin2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001595,Rab14,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001595,,,,,,,,,,,,,,,,,,,,,,Rab14,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OBI_0000093,patient role,,a role which inheres in a person and is realized by the process of being under the care of a physician or health care provider,false,,,http://purl.obolibrary.org/obo/CHEBI_52209,,,,,,,,,,,,,,,,,,,"CDISC definition:  patient. Person under a physician's care for a particular disease or condition. NOTE: A subject in a clinical trial is not necessarily a patient, but a patient in a clinical trial is a subject. See also subject, trial subject, healthy volunteer. Often used interchangeably",,,a role which inheres in a person and is realized by the process of being under the care of a physician or health care provider,"OBI, CDISC",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,OBI:0000093,,,,,,,,,,,,,,,,,,,,,,patient role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_38633,sodium channel blocker,Na channel blocker|sodium channel blockers,An agent that inhibits sodium influx through cell membranes.,false,,,http://purl.obolibrary.org/obo/CHEBI_39000,,,,,,,,,,,,,,,,,,,,,,An agent that inhibits sodium influx through cell membranes.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Na channel blocker|sodium channel blockers,,,,,,,,,,,,,,,,,,,,,CHEBI:38633,,,,sodium channel blocker,,CHEBI:38633,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0051258,protein polymerization,,"The process of creating protein polymers, compounds composed of a large number of component monomers; polymeric proteins may be made up of different or identical monomers. Polymerization occurs by the addition of extra monomers to an existing poly- or oligomeric protein.",false,,,http://purl.obolibrary.org/obo/GO_0006461,,,,,,,,,,,,,,,,,,,,,,"The process of creating protein polymers, compounds composed of a large number of component monomers; polymeric proteins may be made up of different or identical monomers. Polymerization occurs by the addition of extra monomers to an existing poly- or oligomeric protein.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0051258,,,,,,,,,,,,,,,,,,,,,,protein polymerization,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100612,cyclin B2,G2/mitotic-specific cyclin B2|CGB2,,false,,,http://purl.obolibrary.org/obo/IMR_0100610,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0010766|IMR:0011593,G2/mitotic-specific cyclin B2|CGB2,,,,,IMR:0100612,,,,,,,,,,,,,,,,,,,,,,cyclin B2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000301,Arf/Sar,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003669,,,,,,,,,,IMR:0000301,,,,,,,,,,,,,,,,,,,,,,Arf/Sar,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_68563,P2Y12 receptor antagonist,purinergic receptor subtype P2Y12 antagonist|ADP receptor subtype P2Y12 antagonists|purinergic receptor subtype P2Y12 antagonists|P2Y12 receptor antagonists|ADP receptor subtype P2Y12 antagonist,An antagonist at the P2Y12 receptor,false,,,http://purl.obolibrary.org/obo/CHEBI_91079,,,,,,,,,,,,,,,,,,,,,,An antagonist at the P2Y12 receptor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,purinergic receptor subtype P2Y12 antagonist|ADP receptor subtype P2Y12 antagonists|purinergic receptor subtype P2Y12 antagonists|P2Y12 receptor antagonists|ADP receptor subtype P2Y12 antagonist,,,,,,,,,,,,,,,,,,,,,CHEBI:68563,,,,P2Y12 receptor antagonist,,CHEBI:68563,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000054943,DNAJC28,,Other designations: dnaJ homolog subfamily C member 28,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,C21orf78|C21orf55,,,,,,,,,,,,21,,,,,,HPRD:10752|Vega:OTTHUMG00000065531|Ensembl:ENSG00000177692|HGNC:1297,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"DnaJ (Hsp40) homolog, subfamily C, member 28",,,21q22.11,,,,,,,,,,,,,,,,,,,,,,,,,PMID:8125298; 10830953; 12036298; 12477932; 14702039; 15489334; 16344560; 21900206; 21906983; 24250222,,,,,,,,,,,,,,,OGG:3000054943,,,,,,,"DnaJ (Hsp40) homolog, subfamily C, member 28",,,,,,,,,,,,,Other designations: dnaJ homolog subfamily C member 28,,DNAJC28,,,,,,,,,,,,,,,,,,,,,,,54943,,,,,,,,9606,,,,,,,,,,,,,,,,,,,DNAJC28,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000002247,FGF2,,Other designations: basic fibroblast growth factor bFGF|fibroblast growth factor 2|heparin-binding growth factor 2|prostatropin,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,BFGF|HBGF-2|FGF-2|FGFB,,,,,,,,,,,,4,,,,,,MIM:134920|HGNC:3676|Ensembl:ENSG00000138685|Vega:OTTHUMG00000039506|HPRD:00622,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,fibroblast growth factor 2 (basic),,,4q26,,,,,,,,,,,,,,,,"GO_0000186 (EC: IEA); GO_0000187 (EC: TAS, PMID: 9712850); GO_0000189 (EC: IEA); GO_0001658 (EC: IDA, PMID: 12631064); GO_0001759 (EC: IEA); GO_0001938 (EC: IMP, PMID: 18059339); GO_0002042 (EC: IDA, PMID: 18059339); GO_0002042 (EC: IGI, PMID: 19351956); GO_0005104 (EC: IPI, PMID: 10830168); GO_0005125 (EC: IDA, PMID: 18059339); GO_0005515 (EC: IPI, PMID: 10490103); GO_0005576 (EC: TAS); GO_0005615 (EC: IEA); GO_0005634 (EC: IEA); GO_0005829 (EC: IEA); GO_0006661 (EC: IDA); GO_0006700 (EC: IEA); GO_0006935 (EC: TAS, PMID: 10848592); GO_0007165 (EC: NAS, PMID: 9712850); GO_0007173 (EC: TAS); GO_0007265 (EC: TAS, PMID: 10848592); GO_0007399 (EC: TAS, PMID: 9576942); GO_0008083 (EC: IDA, PMID: 18059339); GO_0008201 (EC: IEA); GO_0008284 (EC: IGI, PMID: 8663044); GO_0008285 (EC: IEA); GO_0008286 (EC: TAS); GO_0008543 (EC: IDA, PMID: 17500071); GO_0008543 (EC: IGI, PMID: 8663044); GO_0008543 (EC: IPI, PMID: 10830168); GO_0008543 (EC: TAS); GO_0009887 (EC: TAS, PMID: 10903182); GO_0010001 (EC: IEA); GO_0010764 (EC: IDA, PMID: 19577615); GO_0010863 (EC: IDA); GO_0017134 (EC: IEA); GO_0021762 (EC: IEA); GO_0021940 (EC: IEA); GO_0030198 (EC: TAS); GO_0030214 (EC: IDA, PMID: 19577615); GO_0030308 (EC: IEA); GO_0030324 (EC: IEA); GO_0030374 (EC: IDA, PMID: 17500071); GO_0032958 (EC: IDA); GO_0038095 (EC: TAS); GO_0042056 (EC: IDA, PMID: 18059339); GO_0042060 (EC: TAS); GO_0042660 (EC: IDA, PMID: 18635606); GO_0043536 (EC: IDA, PMID: 18555217); GO_0043537 (EC: IDA, PMID: 18555217); GO_0043552 (EC: IDA); GO_0045087 (EC: TAS); GO_0045669 (EC: IEA); GO_0045765 (EC: TAS); GO_0045766 (EC: IDA); GO_0045892 (EC: IEA); GO_0045893 (EC: IDA, PMID: 17500071); GO_0045944 (EC: IDA, PMID: 18059339); GO_0046668 (EC: IEA); GO_0048011 (EC: TAS); GO_0048015 (EC: TAS); GO_0048598 (EC: TAS); GO_0048678 (EC: IEA); GO_0048864 (EC: IEA); GO_0050918 (EC: IDA, PMID: 18059339); GO_0051209 (EC: IDA); GO_0051726 (EC: IEA); GO_0051781 (EC: IEA); GO_0060045 (EC: IDA, PMID: 9553078); GO_0060128 (EC: IEA); GO_0060129 (EC: IEA); GO_0060548 (EC: IDA, PMID: 12631064); GO_0060591 (EC: IDA, PMID: 17167778); GO_0060644 (EC: IEA); GO_0061045 (EC: IDA, PMID: 19577615); GO_0070374 (EC: IDA, PMID: 17167778)",,,,,,,,,PMID: 1417798; 1697263; 1702556; 1707542; 1769963; 1785797; 1849658; 1885605; 2265560; 2320377; 2435284; 2435575; 2538817; 2726761; 3472745; 3579930; 3732516; 3780670; 3964259; 7532176; 7691311; 7735329; 7935812; 7999082; 8344959; 8530375; 8622701; 8663044; 8885834; 9139660; 9266968; 9342064; 9553078; 9558385; 9576942; 9712850; 9826564; 9858574; 9925931; 10358027; 10397733; 10438928; 10490103; 10574949; 10579907; 10652299; 10830168; 10848592; 10903182; 10950949; 11030354; 11053263; 11066092; 11075807; 11141237; 11276432; 11294897; 11390973; 11418238; 11509569; 11598182; 11708770; 11716516; 11742492; 11796824; 11815602; 11847221; 11864711; 11891198; 11891801; 11928807; 11940567; 11960370; 11964307; 11976347; 11985797; 11986954; 11999550; 12000311; 12006402; 12008951; 12020352; 12032827; 12054499; 12057924; 12080186; 12087465; 12145206; 12168799; 12172783; 12209593; 12235165; 12369790; 12393937; 12403780; 12428103; 12477932; 12478660; 12496364; 12509902; 12517814; 12538477; 12545206; 12571252; 12574959; 12590983; 12607599; 12623787; 12631064; 12631070; 12651930; 12659634; 12660731; 12676798; 12682649; 12717444; 12727994; 12746216; 12755687; 12799459; 12815619; 12823444; 12857600; 12857733; 12871330; 12871334; 12872165; 13680247; 14523006; 14630795; 14669345; 14672345; 14680499; 14699503; 14706681; 15033176; 15096041; 15117822; 15120936; 15146197; 15166228; 15199049; 15208265; 15243127; 15247002; 15247275; 15249224; 15293454; 15297314; 15302993; 15316024; 15342556; 15464234; 15481452; 15496150; 15525641; 15573376; 15603823; 15610530; 15631865; 15680705; 15689238; 15695515; 15703886; 15713745; 15725477; 15726914; 15731686; 15737206; 15756443; 15769511; 15769981; 15780951; 15809086; 15817123; 15825079; 15875316; 15875782; 15879597; 15906377; 15924676; 15942693; 15947088; 15985216; 15996482; 16020751; 16077964; 16077988; 16080018; 16095497; 16103882; 16135988; 16160009; 16210019; 16222707; 16227592; 16257968; 16278388; 16304044; 16320338; 16436505; 16463783; 16490198; 16495214; 16521228; 16597610; 16597617; 16631837; 16638370; 16685268; 16709186; 16723715; 16739027; 16769728; 16807244; 16816927; 16820871; 16822883; 16840552; 16867222; 16876430; 16905765; 16949906; 16982797; 16996573; 17133345; 17157157; 17166351; 17167778; 17169545; 17204151; 17217840; 17234579; 17285972; 17298206; 17381064; 17466952; 17478553; 17487982; 17497037; 17500071; 17503459; 17505261; 17522998; 17532297; 17537644; 17537668; 17543283; 17556598; 17562265; 17578349; 17605857; 17637743; 17651425; 17653045; 17676480; 17699594; 17706726; 17724016; 17726742; 17762899; 17825301; 17929017; 17942638; 17949478; 17968311; 17968943; 17981115; 17996481; 17997184; 18006148; 18025790; 18031768; 18036796; 18042549; 18051571; 18052595; 18055262; 18059339; 18088275; 18093228; 18094712; 18164591; 18164704; 18171671; 18179408; 18187129; 18253936; 18258238; 18279437; 18281281; 18298475; 18329368; 18332228; 18347025; 18364383; 18419755; 18420995; 18438927; 18452581; 18476630; 18481005; 18511454; 18519946; 18549879; 18555217; 18570917; 18592007; 18635606; 18639416; 18680389; 18698254; 18705695; 18773427; 18783914; 18802039; 18803285; 18819464; 18829480; 18930044; 18974971; 18979395; 19056764; 19059221; 19061884; 19086919; 19096229; 19096867; 19100714; 19107653; 19147956; 19160106; 19196427; 19197140; 19217457; 19235591; 19245795; 19279131; 19287993; 19301256; 19308772; 19318994; 19319189; 19351956; 19386985; 19423540; 19453261; 19456219; 19477940; 19478386; 19489096; 19495899; 19533745; 19541589; 19556344; 19577615; 19586755; 19587357; 19608737; 19614919; 19617559; 19631775; 19631914; 19651147; 19670348; 19696444; 19710942; 19713533; 19781633; 19802384; 19822079; 19828453; 19885553; 19890880; 19892399; 19913121; 19919531; 19930868; 19933269; 19950605; 19952401; 20001221; 20016498; 20053757; 20056600; 20116383; 20122687; 20127022; 20128380; 20150555; 20197313; 20202860; 20206949; 20224347; 20230531; 20335309; 20339243; 20362567; 20363749; 20371606; 20406964; 20438785; 20452482; 20504760; 20504870; 20514456; 20526813; 20571834; 20628086; 20628269; 20628624; 20634891; 20641033; 20644561; 20645833; 20646480; 20672350; 20673868; 20681019; 20713592; 20817637; 20819778; 20850693; 20857427; 20886037; 20926602; 20945415; 21029699; 21037114; 21041608; 21041986; 21048031; 21139048; 21161264; 21209880; 21224050; 21266348; 21350328; 21381082; 21382096; 21460777; 21471211; 21501244; 21506108; 21506113; 21515689; 21528671; 21539890; 21572099; 21678127; 21695795; 21699503; 21720547; 21733164; 21761458; 21766497; 21771176; 21830216; 21832283; 21835001; 21855631; 21894939; 21919032; 21923031; 21942441; 21996542; 21997191; 21998584; 22009965; 22016523; 22102278; 22125837; 22158871; 22174424; 22193058; 22228819; 22233184; 22237711; 22260074; 22267482; 22335910; 22393273; 22493287; 22506349; 22508498; 22542539; 22546563; 22577248; 22599586; 22680042; 22730382; 22732006; 22804708; 22836867; 22895562; 22927437; 22932066; 22962037; 22967508; 23053181; 23071632; 23086340; 23122986; 23154434; 23236888; 23239497; 23243019; 23264596; 23265436; 23290762; 23322705; 23331079; 23335070; 23352645; 23385422; 23435034; 23448571; 23457216; 23485603; 23620752; 23630597; 23677479; 23861152; 23869761; 23998120; 24014875; 24063890; 24089521; 24216509,,,,,,,,,,,,,,,OGG:3000002247,,,,,,,fibroblast growth factor 2 (basic),,,,,,,,,,,,,Other designations: basic fibroblast growth factor bFGF|fibroblast growth factor 2|heparin-binding growth factor 2|prostatropin,,FGF2,,,,,,,,,,,,,,,,,,,,,,,2247,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,FGF2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/HP_0000969,edema,Fluid retention|Hydrops|Oedema|Water retention|Dropsy,"An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body.",false,,,http://purl.obolibrary.org/obo/HP_0000118,,,,,,,,,,,,,,,,,,,,,,"An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Fluid retention|Hydrops|Oedema|Water retention|Dropsy,,,,,HP:0000969,,,,,,,,,,,,,,,,,,,,,,edema,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0200492,L-Leucine,,,false,,,http://purl.obolibrary.org/obo/CHEBI_33709,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0200492,,,,,,,,,,,,,,,,,,,,,,L-Leucine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100703,PKA catalytic subunit,cAMP-dependent protein kinase catalytic subunit,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,GO:0004691,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001966,,,,,cAMP-dependent protein kinase catalytic subunit,,,,,IMR:0100703,,,,,,,,,,,,,,,,,,,,,,PKA catalytic subunit,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0046676,negative regulation of insulin secretion,,"Any process that stops, prevents, or reduces the frequency, rate or extent of the release of insulin.",false,,,http://purl.obolibrary.org/obo/TXPO_0000369,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents, or reduces the frequency, rate or extent of the release of insulin.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0046676,,,,,,,,,,,,,,,,,,,,,,negative regulation of insulin secretion,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0030073,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0098869,cellular oxidant detoxification,,Any process carried out at the cellular level that reduces or removes the toxicity superoxide radicals or hydrogen peroxide.,false,,,http://purl.obolibrary.org/obo/GO_1990748,,,,,,,,,,,,,,,,,,,,,,Any process carried out at the cellular level that reduces or removes the toxicity superoxide radicals or hydrogen peroxide.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0098869,,,,,,,,,,,,,,,,,,,,,,cellular oxidant detoxification,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000029089,UBE2T,,Other designations: HSPC150 protein similar to ubiquitin-conjugating enzyme|cell proliferation-inducing gene 50 protein|ubiquitin carrier protein T|ubiquitin conjugating enzyme|ubiquitin-conjugating enzyme E2 T|ubiquitin-protein ligase T,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,PIG50,,,,,,,,,,,,1,,,,,,Ensembl:ENSG00000077152|HGNC:25009|MIM:610538|HPRD:13704|Vega:OTTHUMG00000041392,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,ubiquitin-conjugating enzyme E2T (putative),,,1q32.1,,,,,,,,,,,,,,,,"GO_0003682 (EC: IDA, PMID: 17938197); GO_0004842 (EC: IDA, PMID: 16916645); GO_0005524 (EC: IEA); GO_0005634 (EC: TAS, PMID: 17938197); GO_0005654 (EC: TAS); GO_0006281 (EC: IMP, PMID: 16916645); GO_0006281 (EC: TAS); GO_0006513 (EC: IDA, PMID: 16916645); GO_0006974 (EC: IMP, PMID: 16916645); GO_0031625 (EC: IPI, PMID: 16916645); GO_0035519 (EC: IDA); GO_0044314 (EC: IDA); GO_0051865 (EC: IDA, PMID: 16916645); GO_0070534 (EC: IDA); GO_0070936 (EC: IDA); GO_0070979 (EC: IDA); GO_0085020 (EC: IDA)",,,,,,,,,PMID: 10931946; 11042152; 12477932; 12938929; 14702039; 15489334; 16196087; 16710414; 16916645; 17203973; 17938197; 18029348; 18667844; 18781797; 19111657; 19471022; 19549727; 19589784; 19690564; 19887602; 20639865; 21139048; 21693764; 21722982; 21775430; 21890473; 21906983; 21963094; 22053931; 22287633; 22505724; 22939629; 23000965; 23535733; 23936387; 24250222; 24389026,,,,,,,,,,,,,,,OGG:3000029089,,20140408,protein-coding,,,,ubiquitin-conjugating enzyme E2T (putative),,,,,,,,,,,,,Other designations: HSPC150 protein similar to ubiquitin-conjugating enzyme|cell proliferation-inducing gene 50 protein|ubiquitin carrier protein T|ubiquitin conjugating enzyme|ubiquitin-conjugating enzyme E2 T|ubiquitin-protein ligase T,,UBE2T,,,,,,,,,,,,,,,,,,,,,,,29089,HSPC150,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,UBE2T,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0100145,insulin-like growth factor II,IGF-II,,false,,,http://purl.obolibrary.org/obo/IMR_0002835|http://purl.obolibrary.org/obo/IMR_0100143,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IGF-II,,,,,IMR:0100145,,,,,,,,,,,,,,,,,,,,,,insulin-like growth factor II,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100701,PTEN,"phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase",,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,EC:3.1.3.67,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase",,,,,IMR:0100701,,,,,,,,,,,,,,,,,,,,,,PTEN,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_65259,GABA antagonist,gamma-aminobutyric acid receptor antagonists|gamma-aminobutyric acid receptor antagonist|GABA antagonists,A compound that inhibits the action of gamma-aminobutyric acid.,false,,,http://purl.obolibrary.org/obo/CHEBI_51374|http://purl.obolibrary.org/obo/CHEBI_48706,,,,,,,,,,,,,,,,,,,,,,A compound that inhibits the action of gamma-aminobutyric acid.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,gamma-aminobutyric acid receptor antagonists|gamma-aminobutyric acid receptor antagonist|GABA antagonists,,,,,,,,,,,,,,,,,,,,,CHEBI:65259,,,,GABA antagonist,,CHEBI:65259,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000077,LTK,leukocyte tyrosine kinase,,false,,,http://purl.obolibrary.org/obo/IMR_0000075,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,leukocyte tyrosine kinase,,,,,IMR:0000077,,,,,,,,,,,,,,,,,,,,,,LTK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002634,MRP2 (canonical)[Cholestasis],ABCC2 [Cholestasis],,false,,,http://purl.obolibrary.org/obo/TXPO_0001506,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ABCC2 [Cholestasis],,,,,TXPO:0002634,,,,,,,,,,,,,,,,,,,,,,MRP2 (canonical)[Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002637,drug export from the hepatocyte to to bile tube [Cholestasis],,"Drug export from the hepatocyte to to bile tube is a subtype of compound excretion: A process that excretes the drug from the hepatocyte to the bile tube.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003153|http://purl.obolibrary.org/obo/TXPO_0000034,,,,,,,,,,,,,,,,,,,,,,"Drug export from the hepatocyte to to bile tube is a subtype of compound excretion: A process that excretes the drug from the hepatocyte to the bile tube.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002636|http://purl.obolibrary.org/obo/TXPO_0002635,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002637,,,,,,,"Export into the canaliculus is mediated by MDR1 .
MDR1 is also expressed at many oegan boundaries.",,,,,,,,,,,,,,,drug export from the hepatocyte to to bile tube [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002632,oranic anion export (from heptocyte menbrane to canaliculus) [cholestasis],,"A release process of organic anions from one side of a membrane of hepatocyte to the other side of canaliculus.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003609|http://purl.obolibrary.org/obo/TXPO_0000034,,,,,,,,,,,,,,,,,,,,,,"A release process of organic anions from one side of a membrane of hepatocyte to the other side of canaliculus.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002634|http://purl.obolibrary.org/obo/TXPO_0002635,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002632,,,,,,,"Biliary organic anions other than bile salts are mainly conjugates of bilirubin and GSH.

Drug metabolites excreted into bile are also organic anions, which are transported by the two ABC transporters, MRP2 (canalicular multi specific organic anion transport 1/multi drug resistance-associated protein 2, ABCC2) and ABCG2 (ABCG2).|Conjugates of glutathione, glucuronide, and sulfate are exported by multidrug resistance-associated protein2 (MRP2).",,,,,,,,,,,,,,,oranic anion export (from heptocyte menbrane to canaliculus) [cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002630,bile secretion (from heptocyte menbrane to canaliculus) [cholestasis],,"A release process of the bile from one side of a membrane of hepatocyte to the other side of canaliculus druing the cholestasis.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.|Bile circulation (whole body):
From the blood vessel side (sinusoidal side) -> hepatocyte ttransport -> bile secretion/excretion from the bile duct side membrane to the capillary bile duct, then to the bile duct, duodenum, intestinal hepatic circulation.

Hepatocytes have polarity and have transporters in the membranes on the side of the sinusoidal side and the bile duct.
Sinusoid side:
OATP family (OATP 1 B 1, OATP 1 B 3): organic anion
NTCP: Na dependent uptake
MRP 3, 4: Excretion of organic anion from inside the liver into sinusoids

Bile duct membrane side:
BSEP (ABCG 11): (amino acid conjugation) excretion of bile acid into the bile canaliculi
MRP 2: Excretion of organic anions such as sulfate conjugated bile acid, glucuronic acid conjugated bile acid, conjugated bilirubin
MDR1: cation excretion
MDR 3: phospholipid excretion
ABCG 5 / ABCG 8: cholesterol excretion",false,,,http://purl.obolibrary.org/obo/TXPO_0000034|http://purl.obolibrary.org/obo/TXPO_0002692,,,,,,,,,,,,,,,,,,,,,,"A release process of the bile from one side of a membrane of hepatocyte to the other side of canaliculus druing the cholestasis.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002630,,,,,,,"Export into the canaliculus is mediated by the BSEP (bile salt export pump, ABCB11) .",,,,,,,,,,,,,"Bile circulation (whole body):
From the blood vessel side (sinusoidal side) -> hepatocyte ttransport -> bile secretion/excretion from the bile duct side membrane to the capillary bile duct, then to the bile duct, duodenum, intestinal hepatic circulation.

Hepatocytes have polarity and have transporters in the membranes on the side of the sinusoidal side and the bile duct.
Sinusoid side:
OATP family (OATP 1 B 1, OATP 1 B 3): organic anion
NTCP: Na dependent uptake
MRP 3, 4: Excretion of organic anion from inside the liver into sinusoids

Bile duct membrane side:
BSEP (ABCG 11): (amino acid conjugation) excretion of bile acid into the bile canaliculi
MRP 2: Excretion of organic anions such as sulfate conjugated bile acid, glucuronic acid conjugated bile acid, conjugated bilirubin
MDR1: cation excretion
MDR 3: phospholipid excretion
ABCG 5 / ABCG 8: cholesterol excretion",,bile secretion (from heptocyte menbrane to canaliculus) [cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002639,importing substance into hepatocyte vascular side (sinusoidal side) membrane [cholestasis] [Cholestasis],,"The directed movement of drugs into hepatocyte vascular side (sinusoidal side) membrane.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001759,,,,,,,,,,,,,,,,,,,,,,"The directed movement of drugs into hepatocyte vascular side (sinusoidal side) membrane.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002640|http://purl.obolibrary.org/obo/TXPO_0002642,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002639,,,,,,,,,,,,,,,,,,,,,,importing substance into hepatocyte vascular side (sinusoidal side) membrane [cholestasis] [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002636,MDR1 (canonical)[Cholestasis],P-glycoprotein [Cholestasis]|ABCB1 [Cholestasis],,false,,,http://purl.obolibrary.org/obo/TXPO_0001506,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,P-glycoprotein [Cholestasis]|ABCB1 [Cholestasis],,,,,TXPO:0002636,,,,,,,,,,,,,,,,,,,,,,MDR1 (canonical)[Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002633,Translocation of NF-kappaB [ER stress],,"NF-kappaB transport into nucleus is a subtype of nuclear transport: A process that of the directed movement of NF-kappaB from the cytoplasm to the nucleus.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002779|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"NF-kappaB transport into nucleus is a subtype of nuclear transport: A process that of the directed movement of NF-kappaB from the cytoplasm to the nucleus.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002768,,,,,,,,,,,,,,,,,,,TXPO:0002633,,,,,,,,,,,,,,,,,,,,,,Translocation of NF-kappaB [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002635,ABCG2 (canonical)[Cholestasis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001506,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002635,,,,,,,,,,,,,,,,,,,,,,ABCG2 (canonical)[Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002631,ABCB4 (canonical)[Cholestasis],MRP4 [Cholestasis],,false,,,http://purl.obolibrary.org/obo/TXPO_0001506,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MRP4 [Cholestasis],,,,,TXPO:0002631,,,,,,,,,,,,,,,,,,,,,,ABCB4 (canonical)[Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002638,expcretion of drug metabolite from hepatocyte to bile tube [cholestasis],,"Expcretion of drug metabolite from hepatocyte to bile tube is a subtype of excretion of compound: A process that excretes the drug metabolite from the hepatocyte to to the bile tube.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003152|http://purl.obolibrary.org/obo/TXPO_0000034,,,,,,,,,,,,,,,,,,,,,,"Expcretion of drug metabolite from hepatocyte to bile tube is a subtype of excretion of compound: A process that excretes the drug metabolite from the hepatocyte to to the bile tube.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002634,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002638,,,,,,,"Export into the canaliculus is mediated by MDR1 .
MDR1 is also expressed at many organ boundaries.",,,,,,,,,,,,,,,expcretion of drug metabolite from hepatocyte to bile tube [cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_29191,hydroxyl,,,false,,,http://purl.obolibrary.org/obo/TXPO_0000201,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,HO,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:29191,,,,,,,,,,,,,,,,,,,,,,hydroxyl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,[O][H],,,,,
http://purl.obolibrary.org/obo/GO_0018377,protein myristoylation,,The covalent attachment of a myristoyl group to a protein.,false,,,http://purl.obolibrary.org/obo/GO_0006497,,,,,,,,,,,,,,,,,,,,,,The covalent attachment of a myristoyl group to a protein.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0018377,,,,,,,,,,,,,,,,,,,,,,protein myristoylation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0001850,scarred (quality),,A structural quality inhering in a bearer by virtue of the bearer's being fibrous tissue that replaces normal tissue destroyed by injury or disease.,false,,,http://purl.obolibrary.org/obo/PATO_0000141,,,,,,,,,,,,,,,,,,,,,,A structural quality inhering in a bearer by virtue of the bearer's being fibrous tissue that replaces normal tissue destroyed by injury or disease.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0001850,,,,,,,,,,,,,,,,,,,,,,scarred (quality),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000009159,PCSK7,,Other designations: lymphoma proprotein convertase|prohormone convertase 7|prohormone convertase PC7|proprotein convertase 7|proprotein convertase 8|proprotein convertase PC7|subtilisin/kexin-like protease PC7,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,PC8|SPC7|PC7|LPC,,,,,,,,,,,,11,,,,,,HGNC:8748|MIM:604872|HPRD:05339,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,proprotein convertase subtilisin/kexin type 7,,,11q23-q24,,,,,,,,,,,,,,,,"GO_0004252 (EC: IBA); GO_0016486 (EC: NAS, PMID: 9341152); GO_0030173 (EC: IDA, PMID: 9341152)",,,,,,,,,PMID: 7819324; 8125298; 8564950; 8615762; 8940009; 8995623; 9094426; 9341152; 9521771; 9820811; 10037747; 10050053; 10362256; 10409610; 10452538; 10715106; 10964928; 11051545; 11063880; 11104692; 11380615; 11723118; 12071862; 12084516; 12354117; 12477932; 14702039; 17242158; 18343183; 19322201; 20164418; 21075846; 21149283; 21209099; 21805236; 21805237; 21943158; 22294700; 22679642; 23390091; 23686857; 23775089,,,,,,,,,,,,,,,OGG:3000009159,,,,,,,proprotein convertase subtilisin/kexin type 7,,,,,,,,,,,,,Other designations: lymphoma proprotein convertase|prohormone convertase 7|prohormone convertase PC7|proprotein convertase 7|proprotein convertase 8|proprotein convertase PC7|subtilisin/kexin-like protease PC7,,PCSK7,,,,,,,,,,,,,,,,,,,,,,,9159,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,PCSK7,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000151126,ZNF385B,,Other designations: zinc finger protein 533,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,ZNF533,,,,,,,,,,,,2,,,,,,HPRD:15823|Vega:OTTHUMG00000154559|Ensembl:ENSG00000144331|HGNC:26332|MIM:612344,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,zinc finger protein 385B,,,2q31.2-q31.3,,,,,,,,,,,,,,,,GO_0002039 (EC: IPI); GO_0003676 (EC: IEA); GO_0005634 (EC: IDA); GO_0008270 (EC: IEA); GO_0072332 (EC: IDA),,,,,,,,,PMID: 12477932; 14702039; 15489334; 16344560; 19240061; 19401682; 20379614; 20849254; 21658281; 22945289; 23029477; 24457600,,,,,,,,,,,,,,,OGG:3000151126,,,,,,,zinc finger protein 385B,,,,,,,,,,,,,Other designations: zinc finger protein 533,,ZNF385B,,,,,,,,,,,,,,,,,,,,,,,151126,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,ZNF385B,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000669,PAK2,,,false,,,http://purl.obolibrary.org/obo/IMR_0000238,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000669,,,,,,,,,,,,,,,,,,,,,,PAK2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000053354,PANK1,,Other designations: pantothenic acid kinase 1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,PANK,,,,,,,,,,,,10,,,,,,HPRD:07549|MIM:606160|HGNC:8598|Ensembl:ENSG00000152782,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,pantothenate kinase 1,,,10q23.31,,,,,,,,,,,,,,,,GO_0004594 (EC: IEA); GO_0005524 (EC: IEA); GO_0005634 (EC: IEA); GO_0005829 (EC: TAS); GO_0006766 (EC: TAS); GO_0006767 (EC: TAS); GO_0009108 (EC: TAS); GO_0015937 (EC: IEA); GO_0015939 (EC: TAS); GO_0030118 (EC: IEA); GO_0044281 (EC: TAS); GO_0055037 (EC: IEA); GO_0071944 (EC: IEA),,,,,,,,,PMID: 2981478; 11479594; 11809413; 12379284; 12477932; 14523052; 15161933; 15164054; 15489334; 16385451; 17631502; 18029348; 18187620; 19060910; 19322201; 20379614; 20833636; 22912811; 23343762,,,,,,,,,,,,,,,OGG:3000053354,,,,,,,pantothenate kinase 1,,,,,,,,,,,,,Other designations: pantothenic acid kinase 1,,PANK1,,,,,,,,,,,,,,,,,,,,,,,53354,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,PANK1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_50114,estrogen,,"A hormone that stimulates or controls the development and maintenance of female sex characteristics in mammals by binding to oestrogen receptors. The oestrogens are named for their importance in the oestrous cycle. The oestrogens that occur naturally in the body, notably estrone, estradiol, estriol, and estetrol are steroids. Other compounds with oestrogenic activity are produced by plants (phytoestrogens) and fungi (mycoestrogens); synthetic compounds with oestrogenic activity are known as xenoestrogens.",false,,,http://purl.obolibrary.org/obo/CHEBI_50112,,,,,,,,,,,,,,,,,,,,Wikipedia:Estrogen,,"A hormone that stimulates or controls the development and maintenance of female sex characteristics in mammals by binding to oestrogen receptors. The oestrogens are named for their importance in the oestrous cycle. The oestrogens that occur naturally in the body, notably estrone, estradiol, estriol, and estetrol are steroids. Other compounds with oestrogenic activity are produced by plants (phytoestrogens) and fungi (mycoestrogens); synthetic compounds with oestrogenic activity are known as xenoestrogens.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:50114,,,,,,,,,,,,,,,,,,,,,,estrogen,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100548,CaM-kinase II,Ca2+/calmodulin-dependent protein kinase II|CaMKII,,false,,,http://purl.obolibrary.org/obo/IMR_0100543,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ca2+/calmodulin-dependent protein kinase II|CaMKII,,,,,IMR:0100548,,,,,,,,,,,,,,,,,,,,,,CaM-kinase II,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000113,IL-9 receptor,interleukin-9 receptor,,false,,,http://purl.obolibrary.org/obo/IMR_0000096,,,,,,,,,,,,,,,,,,,,GO:0004919,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,interleukin-9 receptor,,,,,IMR:0000113,,,,,,,,,,,,,,,,,,,,,,IL-9 receptor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100138,kallidin,,,false,,,http://purl.obolibrary.org/obo/IMR_0100165,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100138,,,,,,,,,,,,,,,,,,,,,,kallidin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001404,CBP,CREB-binding protein,,false,,,http://purl.obolibrary.org/obo/IMR_0000426,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CREB-binding protein,,,,,IMR:0001404,,,,,,,,,,,,,,,,,,,,,,CBP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000001565,CYP2D6,,"Other designations: cytochrome P450 2D6|cytochrome P450, family 2, subfamily D, polypeptide 7 pseudogene 2|cytochrome P450, family 2, subfamily D, polypeptide 8 pseudogene 2|cytochrome P450, subfamily II (debrisoquine, sparteine, etc., -metabolising), polypeptide 7 pseudogene 2|cytochrome P450, subfamily IID (debrisoquine, sparteine, etc., -metabolising), polypeptide 8 pseudogene 2|cytochrome P450, subfamily IID (debrisoquine, sparteine, etc., -metabolizing), polypeptide 6|cytochrome P450, subfamily IID (debrisoquine, sparteine, etc., -metabolizing)-like 1|cytochrome P450-DB1|debrisoquine 4-hydroxylase|flavoprotein-linked monooxygenase|microsomal monooxygenase|xenobiotic monooxygenase",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CYPIID6|P450-DB1|CYP2D7P2|CYP2D7BP|CYP2D|P450DB1|P450C2D|CYP2D7AP|CPD6|CYP2DL1|CYP2D8P2,,,,,,,,,,,,22,,,,,,HPRD:00487|Ensembl:ENSG00000100197|Vega:OTTHUMG00000150918|MIM:124030|HGNC:2625,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 2, subfamily D, polypeptide 6",,,22q13.1,,,,,,,,,,,,,,,,"GO_0004497 (EC: IDA, PMID:15327587); GO_0005506 (EC: IEA); GO_0005739 (EC: IDA, PMID:19438707); GO_0005783 (EC: TAS, PMID:19438707); GO_0005789 (EC: TAS); GO_0006805 (EC: TAS, PMID:19438707); GO_0008144 (EC: IDA, PMID:19448135); GO_0008202 (EC: IMP, PMID:18356043); GO_0009804 (EC: IDA, PMID:19438707); GO_0009820 (EC: IDA, PMID:19651758); GO_0009822 (EC: IDA, PMID:15039299); GO_0016098 (EC: IDA, PMID:16401082); GO_0016491 (EC: IDA, PMID:15039299); GO_0017144 (EC: IDA, PMID:19219744); GO_0017144 (EC: IMP, PMID:18356043); GO_0020037 (EC: IDA, PMID:16352597); GO_0033076 (EC: IDA, PMID:19448135); GO_0042737 (EC: IDA, PMID:15039299); GO_0044281 (EC: TAS); GO_0046483 (EC: IDA, PMID:15327587); GO_0051100 (EC: IDA, PMID:19448135); GO_0055114 (EC: IDA, PMID:16401082); GO_0070330 (EC: IEA); GO_0070989 (EC: IDA, PMID:15039299); GO_0090350 (EC: IDA, PMID:19448135)",,,,,,,,,PMID:1673290; 1844820; 1978251; 1978565; 2211621; 2466049; 2574001; 3123997; 3410476; 7845481; 7868129; 7903454; 7927337; 7951238; 8287064; 8449513; 8530011; 8634695; 8655150; 8971426; 9241659; 9264312; 9890157; 10064570; 10233205; 10493260; 10675100; 11037800; 11037802; 11055624; 11097351; 11097352; 11147929; 11204351; 11207030; 11207032; 11214775; 11266079; 11285084; 11291049; 11294012; 11295783; 11303596; 11372584; 11376189; 11422605; 11422615; 11442888; 11470994; 11477317; 11505218; 11505219; 11520401; 11549206; 11560558; 11668217; 11682257; 11702057; 11735606; 11741249; 11750286; 11751440; 11753271; 11753272; 11763000; 11778144; 11791895; 11809184; 11816009; 11829201; 11895912; 11901361; 11927839; 11940091; 12006905; 12063626; 12065557; 12077255; 12089164; 12106691; 12107620; 12142727; 12152006; 12171760; 12171978; 12172215; 12172336; 12175908; 12177686; 12187002; 12191703; 12206675; 12207635; 12210290; 12360109; 12386645; 12386646; 12392820; 12404686; 12419832; 12421483; 12422998; 12426523; 12438554; 12439227; 12446689; 12459840; 12468438; 12477932; 12486288; 12490310; 12503836; 12536989; 12548461; 12569554; 12579870; 12589966; 12610741; 12616663; 12622923; 12629505; 12651805; 12657030; 12691769; 12728976; 12734765; 12743673; 12748560; 12756206; 12756210; 12766554; 12782969; 12784098; 12861292; 12879168; 12879776; 12883230; 12893130; 12900870; 12900872; 12911679; 12915955; 12919180; 12942225; 12950145; 12960748; 12963435; 13680033; 14499311; 14499440; 14514498; 14515061; 14520122; 14557687; 14571354; 14602525; 14624403; 14635107; 14639062; 14640293; 14652703; 14653957; 14658041; 14716707; 14726620; 14726986; 14748763; 14985156; 14991823; 15005635; 15039299; 15048614; 15051713; 15061826; 15068562; 15090156; 15108188; 15115913; 15116051; 15118351; 15128046; 15149890; 15177309; 15205367; 15237854; 15256524; 15260906; 15289790; 15313161; 15319333; 15327587; 15330195; 15349705; 15349706; 15382273; 15461802; 15469410; 15469888; 15470329; 15484318; 15489334; 15499201; 15538128; 15584944; 15588859; 15590749; 15592325; 15618665; 15625333; 15632378; 15646732; 15648054; 15651900; 15669884; 15680923; 15690482; 15691505; 15708542; 15726636; 15729081; 15731591; 15764408; 15768052; 15769360; 15770075; 15774926; 15813658; 15817819; 15820320; 15843230; 15855722; 15861039; 15914211; 15932952; 15952058; 15970126; 15987423; 16006997; 16024198; 16025294; 16037945; 16048566; 16079496; 16130179; 16141609; 16160620; 16162505; 16189709; 16198657; 16205777; 16220080; 16236141; 16239355; 16249913; 16272752; 16283274; 16294366; 16315032; 16337409; 16352597; 16361630; 16401082; 16415111; 16423440; 16459354; 16466686; 16476126; 16478753; 16490169; 16493615; 16534507; 16537246; 16544144; 16550211; 16551910; 16584388; 16595916; 16611538; 16633140; 16633141; 16638736; 16638864; 16642541; 16679388; 16712791; 16716118; 16771603; 16775389; 16778723; 16812949; 16815318; 16819548; 16833023; 16835697; 16845507; 16849011; 16855473; 16858124; 16864175; 16880622; 16924387; 16960721; 17038884; 17089107; 17102541; 17113562; 17115111; 17178267; 17186005; 17194620; 17224713; 17225875; 17234366; 17241532; 17242628; 17244352; 17250723; 17259947; 17270484; 17289397; 17297618; 17301689; 17304721; 17311358; 17324244; 17325735; 17329852; 17361124; 17374963; 17392730; 17418993; 17431033; 17442289; 17449559; 17450472; 17454842; 17460029; 17470523; 17479406; 17503978; 17517247; 17530572; 17536768; 17541883; 17547692; 17554527; 17568504; 17570739; 17573783; 17581325; 17609736; 17610534; 17624022; 17635181; 17635183; 17667795; 17667959; 17697394; 17700359; 17701031; 17713466; 17714084; 17715206; 17725248; 17761971; 17764479; 17803873; 17828532; 17882159; 17908053; 17909762; 17921051; 17947222; 17957765; 17965519; 17965522; 17966194; 17971818; 17992535; 18024866; 18034624; 18048313; 18061941; 18070221; 18075468; 18086475; 18165569; 18167502; 18183034; 18197300; 18202841; 18204346; 18211048; 18214456; 18214849; 18223460; 18231117; 18240905; 18258609; 18261353; 18280655; 18287869; 18294285; 18300942; 18304900; 18317231; 18327668; 18346175; 18346782; 18356043; 18372530; 18382661; 18384443; 18401578; 18407954; 18414197; 18423013; 18425152; 18425996; 18429752; 18433425; 18445827; 18474629; 18474679; 18480698; 18520596; 18520597; 18543297; 18545991; 18547414; 18551040; 18553077; 18583979; 18597648; 18618215; 18625943; 18632250; 18641553; 18648788; 18663559; 18666237; 18676680; 18681789; 18690546; 18698000; 18708991; 18713907; 18719619; 18725510; 18728242; 18754843; 18784265; 18784654; 18794098; 18794105; 18797858; 18818748; 18827765; 18834373; 18840375; 18927241; 18958918; 18978520; 18979093; 18996102; 19000552; 19000940; 19001559; 19019335; 19024387; 19025845; 19032724; 19033450; 19037197; 19047159; 19071885; 19082882; 19094446; 19095219; 19142106; 19151603; 19153830; 19156902; 19162321; 19164093; 19169185; 19170196; 19189210; 19189212; 19192051; 19194367; 19219744; 19219857; 19225771; 19242697; 19284319; 19290787; 19296901; 19303860; 19308365; 19320528; 19330589; 19336370; 19343046; 19350405; 19356055; 19357842; 19364831; 19365402; 19374513; 19387424; 19387994; 19395173; 19405050; 19421167; 19429471; 19437119; 19438707; 19444434; 19448135; 19470220; 19474452; 19512959; 19521114; 19523031; 19527514; 19537956; 19575027; 19593158; 19593168; 19593180; 19593802; 19596663; 19597703; 19604081; 19604084; 19604091; 19625176; 19636337; 19651758; 19652678; 19656108; 19660006; 19692168; 19694742; 19702490; 19710640; 19710642; 19715474; 19719813; 19738170; 19761369; 19781968; 19797609; 19809024; 19823875; 19833260; 19840783; 19866496; 19887477; 19891553; 19892789; 19902987; 19907421; 19910717; 19937844; 19940985; 19946748; 19947517; 19953095; 19954080; 19954746; 19956635; 19995332; 19997080; 20007670; 20009880; 20031551; 20041956; 20075642; 20081063; 20118554; 20124171; 20133509; 20136364; 20137387; 20147896; 20173083; 20174590; 20185366; 20195825; 20201714; 20205348; 20206139; 20225176; 20297661; 20305604; 20309015; 20332423; 20335142; 20350136; 20364044; 20368706; 20373852; 20375710; 20385997; 20421845; 20430047; 20432045; 20435235; 20454926; 20456744; 20459744; 20461808; 20467479; 20473659; 20489028; 20492431; 20515869; 20520586; 20530222; 20531370; 20547595; 20563569; 20565970; 20574415; 20588073; 20590587; 20590588; 20597905; 20599499; 20602615; 20628863; 20634891; 20643254; 20656020; 20656072; 20679960; 20684753; 20686235; 20700584; 20701904; 20727252; 20731819; 20799519; 20809362; 20814331; 20827267; 20828547; 20846929; 20849243; 20851451; 20857895; 20859244; 20863179; 20877299; 20877302; 20878561; 20881950; 20925579; 20970553; 21063774; 21071160; 21072184; 21108610; 21135868; 21140323; 21173786; 21241245; 21248727; 21321564; 21391885; 21430657; 21433154; 21437611; 21449914; 21456632; 21485696; 21486104; 21518482; 21527579; 21543662; 21589866; 21596874; 21599570; 21605066; 21631295; 21677335; 21728792; 21743374; 21749835; 21787170; 21797939; 21803659; 21821735; 21823108; 21826689; 21835244; 21840870; 21860550; 21861665; 21880792; 21907728; 21913948; 21918425; 21956465; 21958961; 21971440; 21989258; 22039821; 22092298; 22109568; 22141351; 22159753; 22180068; 22180372; 22198443; 22216145; 22245658; 22277677; 22281720; 22301406; 22303032; 22308038; 22324840; 22355045; 22398969; 22399238; 22428763; 22459173; 22497725; 22531512; 22623212; 22623266; 22661184; 22688624; 22700965; 22735900; 22775532; 22777153; 22803153; 22905959; 22913530; 22929407; 22948856; 22986607; 22994728; 23167378; 23207012; 23212934; 23213055; 23258538; 23277250; 23280482; 23289191; 23292115; 23350374; 23357843; 23394389; 23469064; 23471717; 23503455; 23552177; 23555934; 23558964; 23570465; 23609392; 23644254; 23664723; 23686417; 23691026; 23700791; 23712329; 23733622; 23734807; 23737191; 23781139; 23803265; 23809878; 23842856; 23851570; 23855716; 23870808; 23872830; 23893861,,,,,,,,,,,,,,,OGG:3000001565,,,,,,,"cytochrome P450, family 2, subfamily D, polypeptide 6",,,,,,,,,,,,,"Other designations: cytochrome P450 2D6|cytochrome P450, family 2, subfamily D, polypeptide 7 pseudogene 2|cytochrome P450, family 2, subfamily D, polypeptide 8 pseudogene 2|cytochrome P450, subfamily II (debrisoquine, sparteine, etc., -metabolising), polypeptide 7 pseudogene 2|cytochrome P450, subfamily IID (debrisoquine, sparteine, etc., -metabolising), polypeptide 8 pseudogene 2|cytochrome P450, subfamily IID (debrisoquine, sparteine, etc., -metabolizing), polypeptide 6|cytochrome P450, subfamily IID (debrisoquine, sparteine, etc., -metabolizing)-like 1|cytochrome P450-DB1|debrisoquine 4-hydroxylase|flavoprotein-linked monooxygenase|microsomal monooxygenase|xenobiotic monooxygenase",,CYP2D6,,,,,,,,,,,,,,,,,,,,,,,1565,RP4-669P10.2,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP2D6,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001562,CYP2C18,,"Other designations: (S)-mephenytoin hydroxylase associated cytochrome P450|CYPIIC18|cytochrome P450 2C18|cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 17|cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 18|cytochrome P450-6B/29C|flavoprotein-linked monooxygenase|microsomal monooxygenase|unspecific monooxygenase",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CPCI|CYP2C|P450-6B/29C|CYP2C17|P450IIC17,,,,,,,,,,,,10,,,,,,HGNC:2620|HPRD:03085|MIM:601131|Vega:OTTHUMG00000018796|Ensembl:ENSG00000108242,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 2, subfamily C, polypeptide 18",,,10q24,,,,,,,,,,,,,,,,"GO_0004497 (EC: TAS, PMID:8110777); GO_0005506 (EC: IEA); GO_0005789 (EC: TAS); GO_0006805 (EC: TAS); GO_0019825 (EC: TAS, PMID:8110777); GO_0020037 (EC: IEA); GO_0044281 (EC: TAS); GO_0070330 (EC: IEA)",,,,,,,,,PMID:1306110; 1896026; 2009263; 7704034; 8095407; 8110777; 8125298; 8333835; 9028867; 9154796; 9797707; 9890157; 10487415; 10704292; 10768437; 11093772; 12378636; 12477932; 12694732; 15128046; 15164054; 15302935; 15319333; 15489334; 16359177; 16385451; 17048007; 17207965; 19038035; 19074885; 19204726; 19290787; 19578179; 19706858; 19751749; 19958090; 20045989; 20453000; 20529763; 21163940; 21798861; 21988832; 23755828,,,,,,,,,,,,,,,OGG:3000001562,,,,,,,"cytochrome P450, family 2, subfamily C, polypeptide 18",,,,,,,,,,,,,"Other designations: (S)-mephenytoin hydroxylase associated cytochrome P450|CYPIIC18|cytochrome P450 2C18|cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 17|cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 18|cytochrome P450-6B/29C|flavoprotein-linked monooxygenase|microsomal monooxygenase|unspecific monooxygenase",,CYP2C18,,,,,,,,,,,,,,,,,,,,,,,1562,RP11-466J14.4,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP2C18,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_38215,calcium channel blocker,calcium channel blockers|calcium channel antagonists|calcium channel antagonist,One of a class of drugs that acts by selective inhibition of calcium influx through cell membranes or on the release and binding of calcium in intracellular pools.,false,,,http://purl.obolibrary.org/obo/CHEBI_38808,,,,,,,,,,,,,,,,,,,,,,One of a class of drugs that acts by selective inhibition of calcium influx through cell membranes or on the release and binding of calcium in intracellular pools.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,calcium channel blockers|calcium channel antagonists|calcium channel antagonist,,,,,,,,,,,,,,,,,,,,,CHEBI:38215,,,,calcium channel blocker,,CHEBI:38215,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0000048,hardness,,"A physical quality inhering in a bearer by virtue of the bearer's resistance to pressure, being broken, or pierced",false,,,http://purl.obolibrary.org/obo/TXPO_0003729|http://purl.obolibrary.org/obo/BFO_0000019,,,,,,,,,,,,,,,,,,,,,,"A physical quality inhering in a bearer by virtue of the bearer's resistance to pressure, being broken, or pierced",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0000048,,,,,,,,,,,,,,,,,,,,,,hardness,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000405,EGR3,,,false,,,http://purl.obolibrary.org/obo/IMR_0000402,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000405,,,,,,,,,,,,,,,,,,,,,,EGR3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100769,Wnt-3a,,,false,,,http://purl.obolibrary.org/obo/IMR_0000003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100769,,,,,,,,,,,,,,,,,,,,,,Wnt-3a,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010446,60S ribosomal protein L26-like 1,Q9UNX3,,false,,,http://purl.obolibrary.org/obo/IMR_0000897,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Q9UNX3,,,,,IMR:0010446,,,,,,,,,,,,,,,,,,,,,,60S ribosomal protein L26-like 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100422,TRAF1,TNF receptor associated factor 1,,false,,,http://purl.obolibrary.org/obo/IMR_0000462,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TNF receptor associated factor 1,,,,,IMR:0100422,,,,,,,,,,,,,,,,,,,,,,TRAF1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100424,TRAF3 (mol),TNF receptor associated factor 3,,false,,,http://purl.obolibrary.org/obo/IMR_0000462,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TNF receptor associated factor 3,,,,,IMR:0100424,,,,,,,,,,,,,,,,,,,,,,TRAF3 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0051049,regulation of transport (biology),,"Any process that modulates the frequency, rate or extent of the directed movement of substances (such as macromolecules, small molecules, ions) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.",false,,,http://purl.obolibrary.org/obo/TXPO_0003636,,,,,,,,,,,,,,,,,,,,,,"Any process that modulates the frequency, rate or extent of the directed movement of substances (such as macromolecules, small molecules, ions) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0051049,,,,,,,,,,,,,,,,,,,,,,regulation of transport (biology),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006810,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0002718,IL-27,interleukin-27,,false,,,http://purl.obolibrary.org/obo/IMR_0000007,,,,,,,,,,,,,,,,,,,,GO:0045523,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000622,,,,,interleukin-27,,,,,IMR:0002718,,,,,,,,,,,,,,,,,,,,,,IL-27,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010515,Heterogeneous nuclear ribonucleoprotein K,ROK|CSBP|TUNP|Transformation upregulated nuclear protein|hnRNP K|DC-stretch binding protein,,false,,,http://purl.obolibrary.org/obo/IMR_0010024,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ROK|CSBP|TUNP|Transformation upregulated nuclear protein|hnRNP K|DC-stretch binding protein,,,,,IMR:0010515,,,,,,,,,,,,,,,,,,,,,,Heterogeneous nuclear ribonucleoprotein K,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/BFO_0000146,two-dimensional continuant fiat boundary,,,false,,,http://purl.obolibrary.org/obo/BFO_0000140,,,,,,,,,,,,,,,,,,,,,,,,,,,,a two-dimensional continuant fiat boundary (surface) is a self-connected fiat surface whose location is defined in relation to some material entity. (axiom label in BFO2 Reference: [033-001]),,,,,,,,,,,,(iff (TwoDimensionalContinuantFiatBoundary a) (and (ContinuantFiatBoundary a) (exists (b) (and (TwoDimensionalSpatialRegion b) (forall (t) (locatedInAt a b t)))))) // axiom label in BFO2 CLIF: [033-001],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BFO:0000146,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/bfo.owl,two-dimensional continuant fiat boundary,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000390756,OR3A4,,,false,,,http://purl.obolibrary.org/obo/OGG_2100009606,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:390756,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,OGG:3000390756,,,,,,,olfactory receptor family 3 subfamily A member 4 pseudogene,,,,,,,,,,,,,,,OR3A4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100665,Clb2,G2/mitotic-specific cyclin 2,,false,,,http://purl.obolibrary.org/obo/IMR_0100673,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,G2/mitotic-specific cyclin 2,,,,,IMR:0100665,,,,,,,,,,,,,,,,,,,,,,Clb2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001201,TRAIL-R1,TRAIL-R1|DR4|death receptor 4|TNF-related apoptosis-inducing ligand receptor 1|TRAIL receptor-1,,false,,,http://purl.obolibrary.org/obo/IMR_0000056,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TRAIL-R1|DR4|death receptor 4|TNF-related apoptosis-inducing ligand receptor 1|TRAIL receptor-1,,,,,IMR:0001201,,,,,,,,,,,,,,,,,,,,,,TRAIL-R1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100131,angiotensin I,angiotensin|Hypertensin,,false,,,http://purl.obolibrary.org/obo/IMR_0100149,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,angiotensin|Hypertensin,,,,,IMR:0100131,,,,,,,,,,,,,,,,,,,,,,angiotensin I,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0002090,immunoglobulin,antibody|Ig,"Antibody molecule (immunoglobulin) consists of four polypeptides chains, two identical light (L) chains and two identical heavy (H) chains.
In mammals, there are five classes of antibodies, IgA, IgD, IgE, IgG, and IgM.",false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,GO:0003823,,"Antibody molecule (immunoglobulin) consists of four polypeptides chains, two identical light (L) chains and two identical heavy (H) chains.
In mammals, there are five classes of antibodies, IgA, IgD, IgE, IgG, and IgM.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,antibody|Ig,,,,,IMR:0002090,,,,,,,,,,,,,,,,,,,,,,immunoglobulin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_137736,anxiogenic,panicogenic|Wikipedia:Anxiogenic,Any psychotropic drug that induces anxiety or panic.,false,,,http://purl.obolibrary.org/obo/CHEBI_35471,,,,,,,,,,,,,,,,,,,,,,Any psychotropic drug that induces anxiety or panic.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,panicogenic|Wikipedia:Anxiogenic,,,CHEBI:137736,,,,,,,,,,,,,,,,,,,,,,anxiogenic,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000256,Ndufaf4 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:29078|NCBI-Mouse-GeneID:68493|NCBI-Rat-GeneID:362495,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000029078,,,,,,,,,,,,,TXPO:1000256,,,,,,,,,,,,,,,,,,,,,,Ndufaf4 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000253,NME1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:18102|NCBI-Rat-GeneID:191575|NCBI-Human-GeneID:4830,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000004830,,,,,,,,,,,,,TXPO:1000253,,,,,,,,,,,,,,,,,,,,,,NME1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000252,NLRP1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:22861,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:1000252,,,,,,,,,,,,,,,,,,,,,,NLRP1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000251,NFKB1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:81736|NCBI-Mouse-GeneID:18033|NCBI-Human-GeneID:4790,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000004790,,,,,,,,,,,,,TXPO:1000251,,,,,,,,,,,,,,,,,,,,,,NFKB1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000258,NfkB (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:1000258,,,,,,,,,,,,,,,,,,,,,,NfkB (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000250,NEFL (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:18039|NCBI-Rat-GeneID:83613|NCBI-Human-GeneID:4747,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000004747,,,,,,,,,,,,,TXPO:1000250,,,,,,,,,,,,,,,,,,,,,,NEFL (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000259,Nfkbiz (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:304005|NCBI-Mouse-GeneID:80859|NCBI-Human-GeneID:64332,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000064332,,,,,,,,,,,,,TXPO:1000259,,,,,,,,,,,,,,,,,,,,,,Nfkbiz (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000254,NUCB2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:59295|NCBI-Mouse-GeneID:53322|NCBI-Human-GeneID:4925,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000004925,,,,,,,,,,,,,TXPO:1000254,,,,,,,,,,,,,,,,,,,,,,NUCB2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000255,NUDT4 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:71207|NCBI-Rat-GeneID:94267|NCBI-Human-GeneID:11163,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000011163,,,,,,,,,,,,,TXPO:1000255,,,,,,,,,,,,,,,,,,,,,,NUDT4 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_75763,eukaryotic metabolite,eukaryotic metabolites,"Any  metabolite produced during a metabolic reaction in eukaryotes, the taxon that include members of the fungi, plantae and animalia kingdoms.",false,,,http://purl.obolibrary.org/obo/CHEBI_25212,,,,,,,,,,,,,,,,,,,,,,"Any  metabolite produced during a metabolic reaction in eukaryotes, the taxon that include members of the fungi, plantae and animalia kingdoms.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,eukaryotic metabolites,,,,,,,,,,,,,,,,,,,,,CHEBI:75763,,,,eukaryotic metabolite,,CHEBI:75763,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0016311,dephosphorylation,,The process of removing one or more phosphoric (ester or anhydride) residues from a molecule.,false,,,http://purl.obolibrary.org/obo/GO_0006793,,,,,,,,,,,,,,,,,,,,,,The process of removing one or more phosphoric (ester or anhydride) residues from a molecule.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0016311,,,,,,,,,,,,,,,,,,,,,,dephosphorylation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0016310,phosphorylation,,"The process of introducing a phosphate group into a molecule, usually with the formation of a phosphoric ester, a phosphoric anhydride or a phosphoric amide.",false,,,http://purl.obolibrary.org/obo/GO_0006793,,,,,,,,,,,,,,,,,,,,EC:2.7.-.-|Wikipedia:Phosphorylation,,"The process of introducing a phosphate group into a molecule, usually with the formation of a phosphoric ester, a phosphoric anhydride or a phosphoric amide.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0016310,,,,,,,,,,,,,,,,,,,,,,phosphorylation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100363,Cbl-b,,,false,,,http://purl.obolibrary.org/obo/IMR_0000356,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100363,,,,,,,,,,,,,,,,,,,,,,Cbl-b,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0055091,maintaining phospholipid homeostasis,,Any process involved in the maintenance of an internal steady state of phospholipid within an organism or cell.,false,,,http://purl.obolibrary.org/obo/GO_0042592,,,,,,,,,,,,,,,,,,,,,,Any process involved in the maintenance of an internal steady state of phospholipid within an organism or cell.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0055091,,,,,,,,,,,,,,,,,,,,,,maintaining phospholipid homeostasis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000148,FLCN (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:216805|NCBI-Rat-GeneID:303185|NCBI-Human-GeneID:201163,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000201163,,,,,,,,,,,,,TXPO:1000148,,,,,,,,,,,,,,,,,,,,,,FLCN (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000145,FGF21 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:170580|NCBI-Mouse-GeneID:56636|NCBI-Human-GeneID:26291,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000026291,,,,,,,,,,,,,TXPO:1000145,,,,,,,,,,,,,,,,,,,,,,FGF21 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000140,FASLG (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:25385|NCBI-Human-GeneID:356,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000356,,,,,,,,,,,,,TXPO:1000140,,,,,,,,,,,,,,,,,,,,,,FASLG (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000142,FGF18 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:29369|NCBI-Mouse-GeneID:14172|NCBI-Human-GeneID:8817,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000008817,,,,,,,,,,,,,TXPO:1000142,,,,,,,,,,,,,,,,,,,,,,FGF18 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000149,FN1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:2335|NCBI-Mouse-GeneID:14268|NCBI-Rat-GeneID:25661,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000002335,,,,,,,,,,,,,TXPO:1000149,,,,,,,,,,,,,,,,,,,,,,FN1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000141,FGF14 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:63851|NCBI-Human-GeneID:2259|NCBI-Mouse-GeneID:14169,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000002259,,,,,,,,,,,,,TXPO:1000141,,,,,,,,,,,,,,,,,,,,,,FGF14 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000144,FGF2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:14173|NCBI-Rat-GeneID:54250|NCBI-Human-GeneID:2247,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000002247,,,,,,,,,,,,,TXPO:1000144,,,,,,,,,,,,,,,,,,,,,,FGF2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000143,FGF19 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:9965|NCBI-Rat-GeneID:170582,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000009965,,,,,,,,,,,,,TXPO:1000143,,,,,,,,,,,,,,,,,,,,,,FGF19 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000147,FHIT (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:60398|NCBI-Mouse-GeneID:14198|NCBI-Human-GeneID:2272,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000002272,,,,,,,,,,,,,TXPO:1000147,,,,,,,,,,,,,,,,,,,,,,FHIT (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000146,FHAD1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:329977|NCBI-Rat-GeneID:500577|NCBI-Human-GeneID:114827,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000114827,,,,,,,,,,,,,TXPO:1000146,,,,,,,,,,,,,,,,,,,,,,FHAD1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_63629,tizanidine,"tizanidinum|5-Chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiadiazole|tizanidine|tizanidina|Tizanidine|5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-2,1,3-benzothiadiazol-4-amine","2,1,3-Benzothiadiazole substituted at C-4 by a Delta(1)-imidazolin-2-ylamino group and at C-4 by a chloro group.  It is an agonist at alpha2-adrenergic receptor sites.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Beilstein:618691|PMID:22223284|CAS:51322-75-9|DrugBank:DB00697|PMID:22196407|Drug_Central:2683|PMID:21982341|Reaxys:618691|PMID:21733633|PMID:21317414|LINCS:LSM-5242,,"2,1,3-Benzothiadiazole substituted at C-4 by a Delta(1)-imidazolin-2-ylamino group and at C-4 by a chloro group.  It is an agonist at alpha2-adrenergic receptor sites.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_51371|http://purl.obolibrary.org/obo/CHEBI_35569,,,,,"Tizanidine|5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-2,1,3-benzothiadiazol-4-amine",,"tizanidinum|5-Chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiadiazole|tizanidine|tizanidina",,,,,,,,,,,,,,,,,,,,,CHEBI:63629,,,,tizanidine,,CHEBI:63629,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010447,40S ribosomal protein S27a,40S small ribosomal protein 27A,,false,,,http://purl.obolibrary.org/obo/IMR_0000896,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,40S small ribosomal protein 27A,,,,,IMR:0010447,,,,,,,,,,,,,,,,,,,,,,40S ribosomal protein S27a,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100302,caspase-1,,,false,,,http://purl.obolibrary.org/obo/IMR_0000305,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:25166|NCBI-Human-GeneID:834,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100302,,,,,,,,,,,,,,,,,,,,,,caspase-1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0032905,transforming growth factor beta1 production,,"The appearance of transforming growth factor-beta1 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.",false,,,http://purl.obolibrary.org/obo/GO_0001816,,,,,,,,,,,,,,,,,,,,,,"The appearance of transforming growth factor-beta1 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.",,,,,transforming growth factor beta1 production,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0032905,,,,,,,,,,,,,,,,,,,,,,transforming growth factor beta1 production,,,,,,,http://purl.obolibrary.org/obo/go.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001648,caveolin-2,Cav-2,,false,,,http://purl.obolibrary.org/obo/IMR_0000515,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Cav-2,,,,,IMR:0001648,,,,,,,,,,,,,,,,,,,,,,caveolin-2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_35223,catalyst,,A substance that increases the rate of a reaction without modifying the overall standard Gibbs energy change in the reaction.,false,,,http://purl.obolibrary.org/obo/CHEBI_51086,,,,,,,,,,,,,,,,,,,,,,A substance that increases the rate of a reaction without modifying the overall standard Gibbs energy change in the reaction.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:35223,,,,,,,,,,,,,,,,,,,,,,catalyst,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000582,ischemia [Cell death],,"Ischemia is a changing process to lack enough to blood supply.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0001727|http://purl.obolibrary.org/obo/TXPO_0000580,,,,,,,,,,,,,,,,,,,,,,"Ischemia is a changing process to lack enough to blood supply.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000645,,,,,,http://purl.obolibrary.org/obo/TXPO_0000226,,,,,,,,,,,TXPO:0000582,,,,,,,,,,,,,,,,,,,,,,ischemia [Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000580,ischemia,,Ischemia is a changing process to lack enough to blood supply.,false,,,http://purl.obolibrary.org/obo/TXPO_0000482,,,,,,,,,,,,,,,,,,,,,,Ischemia is a changing process to lack enough to blood supply.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000580,,,,,,,,,,,,,,,,,,,,,,ischemia,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000583,ATF6 (ATF6-alpha) activates chaperone genes,,ATF6 (ATF6-alpha) activates chaperone genes is a subtype of molecular activation: A process that changes the activity of the molecule  with chaperone role to be higher by ATF6.,false,,,http://purl.obolibrary.org/obo/TXPO_0000023,,,,,,,,,,,,,,,,,,,,,,ATF6 (ATF6-alpha) activates chaperone genes is a subtype of molecular activation: A process that changes the activity of the molecule  with chaperone role to be higher by ATF6.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000583,,,,,,,,,,,,,,,,,,,,,,ATF6 (ATF6-alpha) activates chaperone genes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000586,PERK activation [PERK pathway],,"PERK activation is a subtype of Molecular activation: A process that changes the activity of PERK to be higher.
This entity is a specific course-dependent process. This process can constitute the course of PERK pathway.",false,,,http://purl.obolibrary.org/obo/TXPO_0000357,,,,,,,,,,,,,,,,,,,,,,"PERK activation is a subtype of Molecular activation: A process that changes the activity of PERK to be higher.
This entity is a specific course-dependent process. This process can constitute the course of PERK pathway.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001852,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000712|http://purl.obolibrary.org/obo/TXPO_0000742,,,,,,,,,,,,,,,,,,,,,TXPO:0000586,,,,,,,,,,,,,,,,,,,,,,PERK activation [PERK pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000581,ANGPTL4 (human)[Cell death],,"This gene encodes a glycosylated, secreted protein containing a C-terminal fibrinogen domain. The encoded protein is induced by peroxisome proliferation activators and functions as a serum hormone that regulates glucose homeostasis, lipid metabolism, and insulin sensitivity. This protein can also act as an apoptosis survival factor for vascular endothelial cells and can prevent metastasis by inhibiting vascular growth and tumor cell invasion. The C-terminal domain may be proteolytically-cleaved from the full-length secreted protein. Decreased expression of this gene has been associated with type 2 diabetes. Alternative splicing results in multiple transcript variants. This gene was previously referred to as ANGPTL2 but has been renamed ANGPTL4. [provided by RefSeq, Sep 2013]",false,,,http://purl.obolibrary.org/obo/TXPO_1000002|http://purl.obolibrary.org/obo/TXPO_0000840,,,,,,,,,,,,,,,,,,,,http://omim.org/entry/605910|NCBI-Human-GeneID:51129|PMID:10698685|PMID:27460411,,"This gene encodes a glycosylated, secreted protein containing a C-terminal fibrinogen domain. The encoded protein is induced by peroxisome proliferation activators and functions as a serum hormone that regulates glucose homeostasis, lipid metabolism, and insulin sensitivity. This protein can also act as an apoptosis survival factor for vascular endothelial cells and can prevent metastasis by inhibiting vascular growth and tumor cell invasion. The C-terminal domain may be proteolytically-cleaved from the full-length secreted protein. Decreased expression of this gene has been associated with type 2 diabetes. Alternative splicing results in multiple transcript variants. This gene was previously referred to as ANGPTL2 but has been renamed ANGPTL4. [provided by RefSeq, Sep 2013]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000051129,,,,,,,,,,,,,TXPO:0000581,,,,,,,,,,,,,,,,,,,,,,ANGPTL4 (human)[Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000585,regulation of gene expression by TNF-alpha,,"Regulation of gene expression by TNF-alpha is a subtype of molecular activation: Any process that modulates the frequency, rate or extent of gene expression by TNFalpha.",false,,,http://purl.obolibrary.org/obo/GO_0010468,,,,,,,,,,,,,,,,,,,,,,"Regulation of gene expression by TNF-alpha is a subtype of molecular activation: Any process that modulates the frequency, rate or extent of gene expression by TNFalpha.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000585,,,,,,,,,,,,,,,,,,,,,,regulation of gene expression by TNF-alpha,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000589,changing weight,,Changing weight is a subtype of changing quality: A process that changes the weight of the object.,false,,,http://purl.obolibrary.org/obo/TXPO_0000415,,,,,,,,,,,,,,,,,,,,,,Changing weight is a subtype of changing quality: A process that changes the weight of the object.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000589,,,,,,,,,,,,,,,,,,,,,,changing weight,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000588,change in H+ ion concentrations,,Change in H+ ion concentrations is a subtype of changing concentration: A process that changes the hydrogen ion (H+) concentration in the blood.,false,,,http://purl.obolibrary.org/obo/TXPO_0002438,,,,,,,,,,,,,,,,,,,,,,Change in H+ ion concentrations is a subtype of changing concentration: A process that changes the hydrogen ion (H+) concentration in the blood.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000588,,,,,,,,,,,,,,,,,,,,,,change in H+ ion concentrations,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000587,SCD (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:6319,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000006319,,,http://purl.obolibrary.org/obo/TXPO_0003329,,,,,,,,,,TXPO:0000587,,,,,,,,,,,,,,,,,,,,,,SCD (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000584,regulation of Cxcl2 expression by TNF-alpha,,"Regulation of Cxcl2 expression by TNF-alpha is a subtype of regulation of gene expression by TNF-alpha: A process that Any process that modulates the frequency, rate or extent of Cxcl2 expression by TNFalpha.|CXCL1 is one of the members of chemokines, which are small heparin-binding proteins that generally direct the movement of circulating leukocytes to sites of inflammation or injury.

TNF-α stimulates CXCL1 release from human ECs through JNK-mediated CXCL1 mRNA expression and p38 MAPK- and PI-3K-mediated CXCL1 secretory processes.",false,,,http://purl.obolibrary.org/obo/TXPO_0000585,,,,,,,,,,,,,,,,,,,"TNFalpha->JNK->AP-1->CXCL1 mRNA expression
TNFalpha->p38MAPK->PI3K->AKT->CXCL1 release from the cell membrane",PMID:24487964,,"Regulation of Cxcl2 expression by TNF-alpha is a subtype of regulation of gene expression by TNF-alpha: A process that Any process that modulates the frequency, rate or extent of Cxcl2 expression by TNFalpha.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000584,,,,,,,,,,,,,,,,,,,,"CXCL1 is one of the members of chemokines, which are small heparin-binding proteins that generally direct the movement of circulating leukocytes to sites of inflammation or injury.

TNF-α stimulates CXCL1 release from human ECs through JNK-mediated CXCL1 mRNA expression and p38 MAPK- and PI-3K-mediated CXCL1 secretory processes.",,regulation of Cxcl2 expression by TNF-alpha,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010281,GLUT2,"Solute carrier family 2, facilitated glucose transporter, member 2|GTR2|Glucose transporter type 2, liver",,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003336,,,,,"Solute carrier family 2, facilitated glucose transporter, member 2|GTR2|Glucose transporter type 2, liver",,,,,IMR:0010281,,,,,,,,,,,,,,,,,,,,,,GLUT2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000584,IFN alpha-21,,,false,,,http://purl.obolibrary.org/obo/IMR_0100386,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000584,,,,,,,,,,,,,,,,,,,,,,IFN alpha-21,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000005241,PGR,,Other designations: nuclear receptor subfamily 3 group C member 3,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,PR|NR3C3,,,,,,,,,,,,11,,,,,,Vega:OTTHUMG00000167531|MIM:607311|Ensembl:ENSG00000082175|HGNC:8910|HPRD:07077,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,progesterone receptor,,,11q22-q23,,,,,,,,,,,,,,,,"GO_0001542 (EC: IEA); GO_0002070 (EC: IEA); GO_0003677 (EC: TAS, PMID: 3551956); GO_0003707 (EC: IEA); GO_0004879 (EC: IEA); GO_0005102 (EC: IPI, PMID: 12771131); GO_0005496 (EC: IEA); GO_0005515 (EC: IPI, PMID: 12011095); GO_0005654 (EC: TAS); GO_0005741 (EC: IEA); GO_0006367 (EC: TAS); GO_0007165 (EC: TAS, PMID: 1557371); GO_0007267 (EC: TAS, PMID: 1557371); GO_0008270 (EC: IEA); GO_0010467 (EC: TAS); GO_0010629 (EC: IEP); GO_0019899 (EC: IPI, PMID: 12039952); GO_0043565 (EC: IEA); GO_0050678 (EC: IEA); GO_0050847 (EC: IEA); GO_0060748 (EC: IEA)",,,,,,,,,PMID: 1557371; 2328727; 2736623; 3551956; 6849751; 7481822; 7983041; 7989520; 8626413; 8671234; 9115274; 9223281; 9305541; 9598870; 9620806; 9671457; 9710597; 9891052; 10338464; 10480874; 10655479; 10684807; 10722692; 10750018; 10757795; 10819762; 10840043; 10903152; 11110801; 11117526; 11117529; 11323389; 11326686; 11545730; 11668223; 11668524; 11677150; 11689696; 11717311; 11821088; 11918216; 11948021; 12009358; 12010857; 12011095; 12021276; 12021930; 12038703; 12039952; 12048256; 12088866; 12090595; 12101239; 12113882; 12114521; 12149147; 12174912; 12218173; 12297552; 12402980; 12414909; 12446585; 12466272; 12511607; 12517594; 12529333; 12538866; 12554765; 12554776; 12556966; 12574227; 12579263; 12594000; 12612073; 12644308; 12650698; 12650714; 12672823; 12673676; 12699057; 12748280; 12759236; 12771131; 12861133; 12874288; 12899921; 12917342; 12943706; 14500352; 14519645; 14551264; 14557830; 14586360; 14617569; 14634838; 14667966; 14667967; 14684847; 14764828; 14769635; 14978266; 15001645; 15019994; 15036714; 15084343; 15084345; 15102680; 15171716; 15184270; 15219637; 15272913; 15272917; 15282304; 15282324; 15308690; 15330195; 15381922; 15509639; 15535845; 15555905; 15562029; 15563544; 15572421; 15579801; 15598772; 15601848; 15607534; 15613410; 15632380; 15654614; 15694343; 15694360; 15698546; 15718480; 15728178; 15743833; 15797250; 15798179; 15807882; 15863956; 15866121; 15937332; 15996107; 16109739; 16126772; 16168103; 16244490; 16323958; 16331541; 16339279; 16339776; 16352595; 16360811; 16384861; 16439457; 16477637; 16478993; 16481409; 16484338; 16524927; 16537702; 16614108; 16646051; 16647340; 16728408; 16740656; 16759928; 16762974; 16772530; 16799708; 16901007; 16920727; 16973758; 16985250; 16999816; 17006756; 17018785; 17021053; 17081988; 17224149; 17259978; 17277083; 17291258; 17293450; 17316413; 17347654; 17413977; 17484509; 17512111; 17522428; 17592773; 17599361; 17609436; 17609999; 17646097; 17717077; 17727850; 17785366; 17805208; 17845055; 17847935; 17885486; 17896177; 17914494; 17919323; 17950525; 17951080; 17958742; 17965625; 17992477; 18029348; 18042733; 18048499; 18096667; 18184269; 18189290; 18197009; 18202149; 18215457; 18219286; 18249378; 18276950; 18281038; 18313072; 18316616; 18321550; 18375150; 18378698; 18384825; 18386458; 18391223; 18392676; 18394649; 18421469; 18481002; 18483177; 18483761; 18508999; 18510611; 18511503; 18557990; 18617611; 18628428; 18629635; 18631401; 18636124; 18645713; 18665217; 18668363; 18676680; 18681990; 18683043; 18686353; 18691687; 18722616; 18776045; 18798271; 18801410; 18818748; 18819936; 18835831; 18850387; 18980792; 19019335; 19031960; 19056530; 19061285; 19064572; 19093516; 19094228; 19095059; 19106225; 19124506; 19147544; 19147702; 19152063; 19154258; 19170196; 19175383; 19196877; 19205874; 19205877; 19208263; 19208313; 19211567; 19217090; 19220894; 19258476; 19267271; 19284643; 19296948; 19299443; 19309393; 19330259; 19336370; 19339282; 19357364; 19367380; 19372234; 19382201; 19383545; 19389812; 19415745; 19419938; 19423537; 19423654; 19436038; 19458022; 19462450; 19476621; 19497994; 19499404; 19527514; 19551860; 19555469; 19574343; 19574486; 19604497; 19609353; 19625176; 19636371; 19657752; 19673915; 19676041; 19692168; 19696694; 19701771; 19706513; 19715581; 19720911; 19739075; 19762712; 19782484; 19809499; 19820388; 19835506; 19838027; 19846565; 19852793; 19887485; 19913121; 19940123; 19940364; 19952285; 19952937; 19961842; 19996313; 20000807; 20019164; 20026682; 20063045; 20076999; 20082859; 20082875; 20087430; 20087433; 20090851; 20096719; 20097334; 20123965; 20124487; 20140262; 20148360; 20167054; 20228224; 20299092; 20305341; 20308044; 20308837; 20335148; 20337826; 20374701; 20379614; 20381444; 20392877; 20400074; 20404095; 20436503; 20453000; 20467438; 20484415; 20547493; 20550710; 20557310; 20586553; 20592363; 20628086; 20634197; 20646629; 20661446; 20690804; 20713855; 20716560; 20719308; 20734064; 20814185; 20829392; 20844986; 20861224; 20872186; 20873988; 20890067; 20920367; 20946440; 20956022; 20959426; 20960162; 20962507; 21029696; 21062926; 21085752; 21086036; 21093858; 21095220; 21119048; 21141441; 21145845; 21148628; 21152100; 21152841; 21184272; 21184768; 21243274; 21269613; 21271213; 21273440; 21340479; 21397694; 21422407; 21432776; 21437249; 21444077; 21447625; 21459801; 21464042; 21491087; 21518957; 21531767; 21544804; 21600232; 21619605; 21655654; 21700456; 21730049; 21736840; 21749714; 21751163; 21762477; 21764500; 21815951; 21816898; 21840784; 21840910; 21877015; 21901395; 21980607; 22004841; 22022496; 22047608; 22057681; 22092403; 22093824; 22102068; 22105149; 22107784; 22119825; 22199306; 22201220; 22203942; 22217299; 22281037; 22329840; 22369759; 22394363; 22396492; 22414972; 22419721; 22466340; 22492871; 22496908; 22509838; 22529366; 22535964; 22545144; 22564243; 22580007; 22590818; 22613790; 22633539; 22697792; 22722322; 22727345; 22808109; 22891251; 22972951; 23018797; 23022996; 23029355; 23060300; 23177737; 23199240; 23209664; 23222299; 23307470; 23349706; 23397283; 23474171; 23485561; 23490124; 23506845; 23558572; 23570281; 23574718; 23603247; 23666965; 23668054; 23687977; 23699411; 23723333; 23764995; 23810009; 23812730; 23818346; 23818347; 23818363; 23859042; 23873108; 23880761; 23881388; 23907837; 23995840; 24036907; 24269135; 24302725,,,,,,,,,,,,,,,OGG:3000005241,,,,,,,progesterone receptor,,,,,,,,,,,,,Other designations: nuclear receptor subfamily 3 group C member 3,,PGR,,,,,,,,,,,,,,,,,,,,,,,5241,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,PGR,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_49005,deferasirox,"ICL 670A|deferasiroxum|deferasirox|Exjade|ICL 670|4-[3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acid","A member of the class of triazoles, deferasirox is 1,2,4-triazole substituted by a 4-carboxyphenyl group at position 1 and by 2-hydroxyphenyl groups at positions 3 and 5. An orally active iron chelator, it is used to manage chronic iron overload in patients receiving long-term blood transfusions.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,DrugBank:DB01609|Beilstein:8442898|Reaxys:8442898|Drug_Central:3128|CAS:201530-41-8,,"A member of the class of triazoles, deferasirox is 1,2,4-triazole substituted by a 4-carboxyphenyl group at position 1 and by 2-hydroxyphenyl groups at positions 3 and 5. An orally active iron chelator, it is used to manage chronic iron overload in patients receiving long-term blood transfusions.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_38157,,,,,"4-[3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acid",,ICL 670A|deferasiroxum|deferasirox|Exjade|ICL 670,,,,,,,,,,,,,,,,,,,,,CHEBI:49005,,,,deferasirox,,CHEBI:49005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000002195,FAT1,,Other designations: FAT tumor suppressor 1|FAT tumor suppressor homolog 1|cadherin ME5|cadherin family member 7|cadherin-related family member 8|cadherin-related tumor suppressor homolog|protein fat homolog|protocadherin Fat 1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CDHR8|FAT|CDHF7|hFat1|ME5,,,,,,,,,,,,4,,,,,,HPRD:02986|HGNC:3595|MIM:600976|Vega:OTTHUMG00000160320|Ensembl:ENSG00000083857,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,FAT atypical cadherin 1,,,4q35,,,,,,,,,,,,,,,,"GO_0005509 (EC: IEA); GO_0005515 (EC: IPI, PMID: 16979624); GO_0005634 (EC: IDA, PMID: 15922730); GO_0005886 (EC: IDA, PMID: 15922730); GO_0005887 (EC: TAS, PMID: 8586420); GO_0005911 (EC: IDA, PMID: 15148305); GO_0007015 (EC: ISS); GO_0007155 (EC: TAS, PMID: 8586420); GO_0007156 (EC: IEA); GO_0007163 (EC: ISS); GO_0007267 (EC: TAS, PMID: 8586420); GO_0009653 (EC: TAS, PMID: 8586420); GO_0016337 (EC: ISS); GO_0016477 (EC: ISS); GO_0030027 (EC: IEA); GO_0030175 (EC: IEA); GO_0048471 (EC: IDA, PMID: 15922730); GO_0070062 (EC: IDA, PMID: 19056867)",,,,,,,,,PMID: 8586420; 8889548; 9182820; 9199196; 10737800; 12477932; 15146197; 15148305; 15342556; 15744052; 15922730; 16402135; 16979624; 17081983; 17325662; 17500054; 17895925; 17938632; 19033385; 19056867; 19126244; 19131340; 19328558; 19893579; 21139048; 21552555; 21617878; 21680732; 21890473; 21906983; 21963094; 22116550; 22194967; 22347407; 22505724; 22959770; 22986533; 23314748; 23354438; 23438482; 23785297,,,,,,,,,,,,,,,OGG:3000002195,,,,,,,FAT atypical cadherin 1,,,,,,,,,,,,,Other designations: FAT tumor suppressor 1|FAT tumor suppressor homolog 1|cadherin ME5|cadherin family member 7|cadherin-related family member 8|cadherin-related tumor suppressor homolog|protein fat homolog|protocadherin Fat 1,,FAT1,,,,,,,,,,,,,,,,,,,,,,,2195,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,FAT1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/UBERON_0000483,epithelium,portion of epithelium|epithelial tissue,"Portion of tissue, that consists of one or more layers of epithelial cells connected to each other by cell junctions and which is underlain by a basal lamina. Examples: simple squamous epithelium, glandular cuboidal epithelium, transitional epithelium, myoepithelium[CARO].",false,,,http://purl.obolibrary.org/obo/UBERON_0000479,,,,,,,,,,,,,,,,,,,,http://linkedlifedata.com/resource/umls/id/C0014609|http://purl.obolibrary.org/obo/NCIT_C12710|http://en.wikipedia.org/wiki/Epithelium|http://www.snomedbrowser.com/Codes/Details/31610004|EHDAA2:0003066|MESH:D004848|FBbt:00007005|FMA:9639|AAO:0010055|BTO:0000416|UMLS:C0014609|AEO:0000066|GAID:402|AAO:0000144|HAO:0000066|EMAPA:32738|BILA:0000066|CALOHA:TS-0288|MA:0003060|VHOG:0000387|CARO:0000066|ZFA:0001486|TAO:0001486|XAO:0003045,,"Portion of tissue, that consists of one or more layers of epithelial cells connected to each other by cell junctions and which is underlain by a basal lamina. Examples: simple squamous epithelium, glandular cuboidal epithelium, transitional epithelium, myoepithelium[CARO].",,,,,epithelium,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,portion of epithelium|epithelial tissue,,,"The two basic types of metazoan tissue are epithelial and connective. The simplest metazoans, and developmental stages of many primitive invertebrates, consist solely of these two layers. Thus, epithelial and connective tissues may be the primary (original) tissues of metazoans, and both are important in the functional organization of animals.[well established][VHOG]",,UBERON:0000483,,,,,,,,,,,,,,,,,,,,,,epithelium,,,,http://upload.wikimedia.org/wikipedia/commons/c/c3/Tkanka_nablonkowa.png,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000010053,AP1M2,,Other designations: AP-1 complex subunit mu-2|AP-mu chain family member mu1B|HA1 47 kDa subunit 2|adaptor protein complex AP-1 mu-2 subunit|adaptor protein complex AP-1 subunit mu-2|adaptor-related protein complex 1 mu-2 subunit|adaptor-related protein complex 1 subunit mu-2|clathrin assembly protein complex 1 medium chain 2|clathrin assembly protein complex 1 mu-2 medium chain 2|clathrin coat assembly protein AP47 2|clathrin coat associated protein AP47 2|clathrin-associated adaptor medium chain mu2|golgi adaptor AP-1 47 kDa protein|golgi adaptor HA1/AP1 adaptin mu-2 subunit|mu-adaptin 2|mu1B-adaptin,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,AP1-mu2|MU-1B|HSMU1B|mu2|MU1B,,,,,,,,,,,,19,,,,,,Ensembl:ENSG00000129354|HGNC:558|HPRD:06296|Vega:OTTHUMG00000180584|MIM:607309,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"adaptor-related protein complex 1, mu 2 subunit",,,19p13.2,,,,,,,,,,,,,,,,"GO_0000139 (EC: TAS); GO_0005765 (EC: TAS); GO_0005829 (EC: TAS); GO_0006605 (EC: TAS, PMID: 10338135); GO_0006892 (EC: TAS); GO_0006903 (EC: TAS, PMID: 10338135); GO_0016032 (EC: TAS); GO_0019886 (EC: TAS); GO_0030131 (EC: IEA); GO_0030659 (EC: TAS); GO_0030665 (EC: IEA); GO_0032588 (EC: TAS); GO_0050690 (EC: TAS); GO_0061024 (EC: TAS)",,,,,,,,,PMID: 7569928; 8125298; 8810314; 9714795; 9794796; 9882340; 10338135; 10535737; 10640811; 10887964; 11031247; 11157985; 11222723; 11252894; 11573956; 11694590; 12010461; 12086608; 12134076; 12477932; 14702039; 15182197; 15489334; 15569716; 16189514; 16343431; 16574660; 17145811; 17207965; 17220478; 17261850; 17381423; 18356317; 21048031; 21139048; 21163940; 21762802; 21890473; 21906983; 23000965; 23956138,,,,,,,,,,,,,,,OGG:3000010053,,,,,,,"adaptor-related protein complex 1, mu 2 subunit",,,,,,,,,,,,,Other designations: AP-1 complex subunit mu-2|AP-mu chain family member mu1B|HA1 47 kDa subunit 2|adaptor protein complex AP-1 mu-2 subunit|adaptor protein complex AP-1 subunit mu-2|adaptor-related protein complex 1 mu-2 subunit|adaptor-related protein complex 1 subunit mu-2|clathrin assembly protein complex 1 medium chain 2|clathrin assembly protein complex 1 mu-2 medium chain 2|clathrin coat assembly protein AP47 2|clathrin coat associated protein AP47 2|clathrin-associated adaptor medium chain mu2|golgi adaptor AP-1 47 kDa protein|golgi adaptor HA1/AP1 adaptin mu-2 subunit|mu-adaptin 2|mu1B-adaptin,,AP1M2,,,,,,,,,,,,,,,,,,,,,,,10053,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,AP1M2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_35443,anthelminthic drug,anthelmintics|antihelmintico|vermifuge|anthelmintic|antihelminth|anthelminthics|anthelminthic,Substance intended to kill parasitic worms (helminths).,false,,,http://purl.obolibrary.org/obo/CHEBI_35442,,,,,,,,,,,,,,,,,,,,,,Substance intended to kill parasitic worms (helminths).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,anthelminthic,,anthelmintics|antihelmintico|vermifuge|anthelmintic|antihelminth|anthelminthics,,,,,,,,,,,,,,,,,,,,,CHEBI:35443,,,,anthelminthic drug,,CHEBI:35443,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0030970,"retrograde protein transport, ER to cytosol","retrograde protein transport, endoplasmic reticulum to cytosol|protein retrotranslocation, ER to cytosol",The directed movement of unfolded or misfolded proteins from the endoplasmic reticulum to the cytosol through the translocon.,false,,,http://purl.obolibrary.org/obo/TXPO_0000111,,,,,,,,,,,,,,,,,,,,PMID:11994744,,The directed movement of unfolded or misfolded proteins from the endoplasmic reticulum to the cytosol through the translocon.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005829,http://purl.obolibrary.org/obo/GO_0005783,,"retrograde protein transport, endoplasmic reticulum to cytosol|protein retrotranslocation, ER to cytosol",,,,,GO:0030970,,,,,,,,,,,,,,,,,,,,,,"retrograde protein transport, ER to cytosol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000008667,EIF3H,,"Other designations: eIF-3-gamma|eIF3 p40 subunit|eukaryotic translation initiation factor 3 subunit 3|eukaryotic translation initiation factor 3 subunit H|eukaryotic translation initiation factor 3, subunit 2 (beta, 36kD)|eukaryotic translation initiation factor 3, subunit 3 (gamma, 40kD)|eukaryotic translation initiation factor 3, subunit 3 gamma, 40kDa",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,eIF3-p40|eIF3-gamma|EIF3S3,,,,,,,,,,,,8,,,,,,HGNC:3273|HPRD:04885|MIM:603912,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"eukaryotic translation initiation factor 3, subunit H",,,8q24.11,,,,,,,,,,,,,,,,"GO_0001731 (EC: IEA); GO_0003743 (EC: IC, Qualifier: contributes_to, PMID:17322308); GO_0003743 (EC: IDA, Qualifier: contributes_to, PMID:17581632); GO_0005515 (EC: IPI, PMID:12812986); GO_0005829 (EC: TAS); GO_0005852 (EC: IDA, PMID:17322308); GO_0006412 (EC: TAS); GO_0006413 (EC: IC, PMID:17322308); GO_0006413 (EC: IDA, PMID:17581632); GO_0006413 (EC: TAS); GO_0006446 (EC: TAS, PMID:9341143); GO_0010467 (EC: TAS); GO_0016282 (EC: IEA); GO_0033290 (EC: IEA); GO_0044267 (EC: TAS); GO_0044822 (EC: IDA); GO_0070062 (EC: IDA, PMID:19056867)",,,,,,,,,PMID:8125298; 8995409; 8995410; 9341143; 9822659; 11733359; 12477932; 12588972; 12812986; 14519125; 14578863; 14702039; 14997205; 15489334; 16159877; 16189514; 16196087; 16226712; 16263121; 16286006; 16344560; 16652384; 17043677; 17081983; 17322308; 17353931; 17361185; 17403899; 17581632; 18029348; 18187620; 18372905; 18544531; 18599441; 18628297; 19056867; 19060904; 19204574; 19615732; 20016921; 20020773; 20360068; 20437058; 20508642; 20659471; 20862326; 21139048; 21319273; 21761138; 21890473; 21906983; 21963094; 22108332; 22190034; 22505724; 22863883; 22939629; 22969067; 22990118; 23000965; 23184937; 23398456; 23402259; 23455922; 23463506; 24163370,,,,,,,,,,,,,,,OGG:3000008667,,,,,,,"eukaryotic translation initiation factor 3, subunit H",,,,,,,,,,,,,"Other designations: eIF-3-gamma|eIF3 p40 subunit|eukaryotic translation initiation factor 3 subunit 3|eukaryotic translation initiation factor 3 subunit H|eukaryotic translation initiation factor 3, subunit 2 (beta, 36kD)|eukaryotic translation initiation factor 3, subunit 3 (gamma, 40kD)|eukaryotic translation initiation factor 3, subunit 3 gamma, 40kDa",,EIF3H,,,,,,,,,,,,,,,,,,,,,,,8667,,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF3H,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000008664,EIF3D,,"Other designations: eIF-3-zeta|eIF3 p66|eukaryotic translation initiation factor 3 subunit 7|eukaryotic translation initiation factor 3 subunit D|eukaryotic translation initiation factor 3, subunit 7 zeta, 66/67kDa|translation initiation factor eIF3 p66 subunit",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,eIF3-zeta|EIF3S7|eIF3-p66,,,,,,,,,,,,22,,,,,,MIM:603915|HGNC:3278|Ensembl:ENSG00000100353|HPRD:04888|Vega:OTTHUMG00000150599,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"eukaryotic translation initiation factor 3, subunit D",,,22q13.1,,,,,,,,,,,,,,,,"GO_0001731 (EC: IEA); GO_0001732 (EC: IEA); GO_0003743 (EC: IC, Qualifier: contributes_to, PMID:17322308); GO_0003743 (EC: IDA, Qualifier: contributes_to, PMID:17581632); GO_0005515 (EC: IPI, PMID:11369516); GO_0005829 (EC: TAS); GO_0005852 (EC: IDA, PMID:17322308); GO_0006412 (EC: TAS); GO_0006413 (EC: IC, PMID:17322308); GO_0006413 (EC: IDA, PMID:17581632); GO_0006413 (EC: TAS); GO_0006446 (EC: IEA); GO_0010467 (EC: TAS); GO_0016282 (EC: IEA); GO_0033290 (EC: IEA); GO_0044267 (EC: TAS); GO_0044822 (EC: IDA)",,,,,,,,,PMID:8995409; 8995410; 9341143; 9822659; 10591208; 11331597; 11369516; 11590142; 12477932; 12588972; 14519125; 15047060; 15461802; 15489334; 15592455; 17322308; 17353931; 17361185; 17403899; 17474147; 17581632; 18571626; 18599441; 18628297; 19615732; 19738201; 20171186; 20360068; 20890303; 21139048; 21145461; 21890473; 21900206; 21906983; 21963094; 22145905; 22190034; 22505724; 22586326; 22863883; 22939629; 22944692; 23000965; 23455922; 24092755; 24457600,,,,,,,,,,,,,,,OGG:3000008664,,,,,,,"eukaryotic translation initiation factor 3, subunit D",,,,,,,,,,,,,"Other designations: eIF-3-zeta|eIF3 p66|eukaryotic translation initiation factor 3 subunit 7|eukaryotic translation initiation factor 3 subunit D|eukaryotic translation initiation factor 3, subunit 7 zeta, 66/67kDa|translation initiation factor eIF3 p66 subunit",,EIF3D,,,,,,,,,,,,,,,,,,,,,,,8664,RP5-1119A7.12-003,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF3D,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000008668,EIF3I,,"Other designations: TGF-beta receptor-interacting protein 1|TGFbeta receptor-interacting protein 1|eIF-3-beta|eIF3 p36|eukaryotic translation initiation factor 3 subunit 2|eukaryotic translation initiation factor 3 subunit I|eukaryotic translation initiation factor 3, subunit 2 (beta, 36kD)|eukaryotic translation initiation factor 3, subunit 2 beta, 36kDa|predicted protein of HQ2242",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,TRIP-1|PRO2242|eIF3-p36|TRIP1|EIF3S2|eIF3-beta,,,,,,,,,,,,1,,,,,,HGNC:3272|Vega:OTTHUMG00000007364|Ensembl:ENSG00000084623|MIM:603911|HPRD:04884,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"eukaryotic translation initiation factor 3, subunit I",,,1p34.1,,,,,,,,,,,,,,,,"GO_0001731 (EC: IEA); GO_0003743 (EC: IC, Qualifier: contributes_to, PMID:17322308); GO_0003743 (EC: IDA, PMID:17581632); GO_0005515 (EC: IPI, PMID:14688252); GO_0005829 (EC: TAS); GO_0005852 (EC: IDA, PMID:17322308); GO_0006412 (EC: TAS); GO_0006413 (EC: IC, PMID:17322308); GO_0006413 (EC: IDA, PMID:17581632); GO_0006413 (EC: TAS); GO_0006446 (EC: IEA); GO_0010467 (EC: TAS); GO_0016282 (EC: IEA); GO_0033290 (EC: IEA); GO_0044267 (EC: TAS); GO_0070062 (EC: IDA)",,,,,,,,,PMID:7566156; 7566158; 8125298; 8995409; 8995410; 9368056; 9599024; 9813058; 9822659; 10706629; 11781097; 12477932; 12588972; 14519125; 14688252; 15047060; 15231747; 15489334; 15592455; 15604093; 16159877; 16196087; 16236267; 16341674; 16541103; 16929481; 17314511; 17322308; 17353931; 17361185; 17403899; 17581632; 17620599; 18599441; 18624398; 18628297; 18781797; 19059401; 19329541; 19615732; 19738201; 20020773; 20360068; 20508642; 20972266; 21139048; 21145461; 21319273; 21378021; 21890473; 21906983; 21963094; 21987572; 22022972; 22053931; 22145905; 22174317; 22190034; 22505724; 22586326; 22623428; 22863883; 22939629; 22990118; 23000965; 23349634; 23398456; 23402259; 23455922; 23463506; 23602568; 24163370; 24457600,,,,,,,,,,,,,,,OGG:3000008668,,,,,,,"eukaryotic translation initiation factor 3, subunit I",,,,,,,,,,,,,"Other designations: TGF-beta receptor-interacting protein 1|TGFbeta receptor-interacting protein 1|eIF-3-beta|eIF3 p36|eukaryotic translation initiation factor 3 subunit 2|eukaryotic translation initiation factor 3 subunit I|eukaryotic translation initiation factor 3, subunit 2 (beta, 36kD)|eukaryotic translation initiation factor 3, subunit 2 beta, 36kDa|predicted protein of HQ2242",,EIF3I,,,,,,,,,,,,,,,,,,,,,,,8668,RP4-675E8.1,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF3I,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000008662,EIF3B,,"Other designations: eIF-3-eta|eIF3 p110|eIF3 p116|eukaryotic translation initiation factor 3 subunit 9|eukaryotic translation initiation factor 3 subunit B|eukaryotic translation initiation factor 3, subunit 9 (eta, 116kD)|eukaryotic translation initiation factor 3, subunit 9 eta, 116kDa|hPrt1|prt1 homolog",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,EIF3-P110|EIF3-P116|PRT1|EIF3S9|EIF3-ETA,,,,,,,,,,,,7,,,,,,Vega:OTTHUMG00000022839|HPRD:06795|Ensembl:ENSG00000106263|MIM:603917|HGNC:3280,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"eukaryotic translation initiation factor 3, subunit B",,,7p22.3,,,,,,,,,,,,,,,,"GO_0000166 (EC: IEA); GO_0001731 (EC: IEA); GO_0003743 (EC: IC, Qualifier: contributes_to, PMID:17322308); GO_0003743 (EC: IDA, PMID:8995410); GO_0003743 (EC: IDA, Qualifier: contributes_to, PMID:17581632); GO_0005515 (EC: IPI, PMID:11169732); GO_0005829 (EC: TAS); GO_0005852 (EC: IDA, PMID:17322308); GO_0006412 (EC: TAS); GO_0006413 (EC: IC, PMID:17322308); GO_0006413 (EC: IDA, PMID:17581632); GO_0006413 (EC: TAS); GO_0006446 (EC: IDA, PMID:8995410); GO_0010467 (EC: TAS); GO_0016282 (EC: IEA); GO_0031369 (EC: IEA); GO_0032947 (EC: TAS, PMID:17322308); GO_0033290 (EC: IEA); GO_0044267 (EC: TAS); GO_0070062 (EC: IDA)",,,,,,,,,PMID:7693677; 8889548; 8995409; 8995410; 9388245; 9822659; 9847074; 11169732; 11331597; 12477932; 12588972; 12690205; 14519125; 14688252; 14702039; 15047060; 15302935; 15489334; 15592455; 15946946; 16159877; 16196087; 16286006; 16541103; 17053147; 17081983; 17190833; 17322308; 17403899; 17581632; 18423202; 18457437; 18599441; 18628297; 18781797; 19245811; 19454010; 19615732; 19738201; 20020773; 20060839; 20360068; 20508642; 20862284; 20972266; 21045808; 21081666; 21139048; 21890473; 21906983; 21963094; 21987572; 22145905; 22190034; 22234522; 22268729; 22505724; 22623428; 22863883; 22939629; 22990118; 23000965; 23184937; 23398456; 23455922; 23463506; 23575475; 24457600,,,,,,,,,,,,,,,OGG:3000008662,,,,,,,"eukaryotic translation initiation factor 3, subunit B",,,,,,,,,,,,,"Other designations: eIF-3-eta|eIF3 p110|eIF3 p116|eukaryotic translation initiation factor 3 subunit 9|eukaryotic translation initiation factor 3 subunit B|eukaryotic translation initiation factor 3, subunit 9 (eta, 116kD)|eukaryotic translation initiation factor 3, subunit 9 eta, 116kDa|hPrt1|prt1 homolog",,EIF3B,,,,,,,,,,,,,,,,,,,,,,,8662,,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF3B,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000008663,EIF3C,,"Other designations: cell migration-inducing protein 17|eIF3 p110|eukaryotic translation initiation factor 3 subunit 8|eukaryotic translation initiation factor 3 subunit C|eukaryotic translation initiation factor 3, subunit 8 (110kD)|eukaryotic translation initiation factor 3, subunit 8, 110kDa",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,EIF3CL|eIF3-p110|EIF3S8,,,,,,,,,,,,16,,,,,,Vega:OTTHUMG00000099443|MIM:603916|HPRD:04889|HGNC:3279|Ensembl:ENSG00000184110,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"eukaryotic translation initiation factor 3, subunit C",,,16p11.2,,,,,,,,,,,,,,,,"GO_0001731 (EC: IEA); GO_0003743 (EC: IC, Qualifier: contributes_to, PMID:17322308); GO_0003743 (EC: IDA, Qualifier: contributes_to, PMID:17581632); GO_0005515 (EC: IPI, PMID:18628297); GO_0005829 (EC: TAS); GO_0005852 (EC: IDA, PMID:17322308); GO_0006412 (EC: TAS); GO_0006413 (EC: IC, PMID:17322308); GO_0006413 (EC: IDA, PMID:17581632); GO_0006413 (EC: TAS); GO_0006446 (EC: IEA); GO_0010467 (EC: TAS); GO_0016282 (EC: IEA); GO_0031369 (EC: IEA); GO_0033290 (EC: IEA); GO_0044267 (EC: TAS); GO_0044822 (EC: IDA)",,,,,,,,,PMID:8995409; 8995410; 9822659; 10493829; 10504338; 12477932; 12514125; 12588972; 14519125; 14702039; 15047060; 15146197; 15231748; 15302935; 15489334; 15840729; 15946946; 16083285; 16097034; 16169070; 16196087; 16286006; 16341674; 16964243; 17081983; 17322308; 17361185; 17403899; 17581632; 18599441; 18628297; 18781797; 19245811; 19615732; 19850743; 19915574; 20020773; 20360068; 20508642; 20972266; 21081666; 21102463; 21145461; 21209461; 21319273; 21890473; 21900206; 21906983; 21963094; 21987572; 22016036; 22145905; 22190034; 22505724; 22863883; 22939629; 23000965; 23128233; 23455922; 23463506; 23733421; 23862649; 24092755; 24515614,,,,,,,,,,,,,,,OGG:3000008663,,,,,,,"eukaryotic translation initiation factor 3, subunit C",,,,,,,,,,,,,"Other designations: cell migration-inducing protein 17|eIF3 p110|eukaryotic translation initiation factor 3 subunit 8|eukaryotic translation initiation factor 3 subunit C|eukaryotic translation initiation factor 3, subunit 8 (110kD)|eukaryotic translation initiation factor 3, subunit 8, 110kDa",,EIF3C,,,,,,,,,,,,,,,,,,,,,,,8663,,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF3C,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000008665,EIF3F,,"Other designations: deubiquitinating enzyme eIF3f|eIF-3-epsilon|eIF3-epsilon|eukaryotic translation initiation factor 3 subunit F|eukaryotic translation initiation factor 3, subunit 5 (epsilon, 47kD)|eukaryotic translation initiation factor 3, subunit 5 epsilon, 47kDa",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,EIF3S5|eIF3-p47,,,,,,,,,,,,11,,,,,,MIM:603914|HGNC:3275|HPRD:04887|Ensembl:ENSG00000175390,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"eukaryotic translation initiation factor 3, subunit F",,,11p15.4,,,,,,,,,,,,,,,,"GO_0001731 (EC: IEA); GO_0003743 (EC: IC, Qualifier: contributes_to, PMID:17322308); GO_0003743 (EC: IDA, Qualifier: contributes_to, PMID:17581632); GO_0003743 (EC: TAS, PMID:9341143); GO_0004843 (EC: IDA); GO_0005515 (EC: IPI, PMID:18354498); GO_0005829 (EC: TAS); GO_0005852 (EC: IDA, PMID:17322308); GO_0005852 (EC: TAS, PMID:9341143); GO_0006412 (EC: TAS); GO_0006413 (EC: IC, PMID:17322308); GO_0006413 (EC: IDA, PMID:17581632); GO_0006413 (EC: TAS); GO_0006446 (EC: IEA); GO_0010467 (EC: TAS); GO_0016282 (EC: IEA); GO_0016579 (EC: IDA); GO_0033290 (EC: IEA); GO_0044267 (EC: TAS)",,,,,,,,,PMID:8995409; 8995410; 9341143; 9822659; 12446680; 12477932; 12588972; 14519125; 14702039; 15231748; 15489334; 15862967; 16159877; 16169070; 16189514; 16196087; 16286006; 16537434; 16541103; 16712791; 17207965; 17322308; 17353931; 17361185; 17403899; 17581632; 17918192; 18354498; 18381585; 18599441; 18628297; 18724935; 19073596; 19237569; 19245811; 19454010; 19615732; 19738201; 19854136; 20360068; 20800221; 21081666; 21124883; 21139048; 21832049; 21963094; 22145905; 22190034; 22268729; 22457825; 22505724; 22797925; 22863883; 22939629; 23275563; 23463506; 24457600,,,,,,,,,,,,,,,OGG:3000008665,,,,,,,"eukaryotic translation initiation factor 3, subunit F",,,,,,,,,,,,,"Other designations: deubiquitinating enzyme eIF3f|eIF-3-epsilon|eIF3-epsilon|eukaryotic translation initiation factor 3 subunit F|eukaryotic translation initiation factor 3, subunit 5 (epsilon, 47kD)|eukaryotic translation initiation factor 3, subunit 5 epsilon, 47kDa",,EIF3F,,,,,,,,,,,,,,,,,,,,,,,8665,,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF3F,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000008666,EIF3G,,"Other designations: eIF-3 RNA-binding subunit|eIF-3-delta|eIF3 p42|eIF3 p44|eukaryotic translation initiation factor 3 RNA-binding subunit|eukaryotic translation initiation factor 3 subunit 4|eukaryotic translation initiation factor 3 subunit G|eukaryotic translation initiation factor 3 subunit p42|eukaryotic translation initiation factor 3, subunit 4 (delta, 44kD)|eukaryotic translation initiation factor 3, subunit 4 delta, 44kDa",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,eIF3-p44|EIF3S4|eIF3-delta|EIF3-P42,,,,,,,,,,,,19,,,,,,MIM:603913|Ensembl:ENSG00000130811|Vega:OTTHUMG00000180396|HGNC:3274|HPRD:04886,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"eukaryotic translation initiation factor 3, subunit G",,,19p13.2,,,,,,,,,,,,,,,,"GO_0000166 (EC: IEA); GO_0001731 (EC: IEA); GO_0003743 (EC: IC, Qualifier: contributes_to, PMID:17322308); GO_0003743 (EC: IDA, Qualifier: contributes_to, PMID:17581632); GO_0005515 (EC: IPI, PMID:14688252); GO_0005634 (EC: IEA); GO_0005829 (EC: TAS); GO_0005852 (EC: IDA, PMID:17322308); GO_0006412 (EC: TAS); GO_0006413 (EC: IC, PMID:17322308); GO_0006413 (EC: IDA, PMID:17581632); GO_0006413 (EC: TAS); GO_0006446 (EC: IEA); GO_0010467 (EC: TAS); GO_0016282 (EC: IEA); GO_0033290 (EC: IEA); GO_0044267 (EC: TAS); GO_0044822 (EC: IDA); GO_0048471 (EC: IEA)",,,,,,,,,PMID:8889549; 8995409; 8995410; 9341143; 9822659; 9973622; 10887144; 12477932; 12588972; 14519125; 14688252; 15231747; 15302935; 15489334; 16243297; 17094969; 17322308; 17353931; 17361185; 17403899; 17581632; 18599441; 18628297; 19471022; 19615732; 20360068; 20406461; 21044950; 21139048; 21145461; 21832049; 21890473; 21900206; 21906983; 22190034; 22493286; 22863883; 22939629; 23398456; 23402259; 23463506; 24080033,,,,,,,,,,,,,,,OGG:3000008666,,,,,,,"eukaryotic translation initiation factor 3, subunit G",,,,,,,,,,,,,"Other designations: eIF-3 RNA-binding subunit|eIF-3-delta|eIF3 p42|eIF3 p44|eukaryotic translation initiation factor 3 RNA-binding subunit|eukaryotic translation initiation factor 3 subunit 4|eukaryotic translation initiation factor 3 subunit G|eukaryotic translation initiation factor 3 subunit p42|eukaryotic translation initiation factor 3, subunit 4 (delta, 44kD)|eukaryotic translation initiation factor 3, subunit 4 delta, 44kDa",,EIF3G,,,,,,,,,,,,,,,,,,,,,,,8666,,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF3G,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000008661,EIF3A,,"Other designations: EIF3, p180 subunit|centrosomin homolog|cytoplasmic protein p167|eIF-3-theta|eIF3 p167|eIF3 p180|eIF3 p185|eukaryotic translation initiation factor 3 subunit 10|eukaryotic translation initiation factor 3 subunit A|eukaryotic translation initiation factor 3, subunit 10 (theta, 150/170kD)|eukaryotic translation initiation factor 3, subunit 10 (theta, 170kD)|eukaryotic translation initiation factor 3, subunit 10 theta, 150/170kDa|eukaryotic translation initiation factor 3, subunit 10, 170kD",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,EIF3|p185|eIF3-p170|eIF3-theta|p180|EIF3S10|P167|TIF32,,,,,,,,,,,,10,,,,,,HPRD:03618|HGNC:3271|Vega:OTTHUMG00000019144|Ensembl:ENSG00000107581|MIM:602039,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"eukaryotic translation initiation factor 3, subunit A",,,10q26,,,,,,,,,,,,,,,,"GO_0001731 (EC: IEA); GO_0001732 (EC: IDA, PMID:17581632); GO_0003743 (EC: IC, Qualifier: contributes_to, PMID:17322308); GO_0003743 (EC: IDA, Qualifier: contributes_to, PMID:17581632); GO_0005198 (EC: NAS, PMID:9150439); GO_0005515 (EC: IPI, PMID:11169732); GO_0005634 (EC: IDA); GO_0005730 (EC: IDA); GO_0005737 (EC: IDA); GO_0005737 (EC: NAS, PMID:9150439); GO_0005829 (EC: TAS); GO_0005852 (EC: IDA, PMID:17322308); GO_0006412 (EC: TAS); GO_0006413 (EC: IC, PMID:17322308); GO_0006413 (EC: TAS); GO_0006446 (EC: IEA); GO_0010467 (EC: TAS); GO_0016282 (EC: IEA); GO_0033290 (EC: IEA); GO_0044267 (EC: TAS); GO_0044822 (EC: IDA)",,,,,,,,,PMID:2110361; 8590280; 8816444; 8995409; 8995410; 9054404; 9150439; 9341143; 9418880; 9790534; 9804427; 9822659; 9925932; 10444591; 10611228; 11102443; 11169732; 11384103; 11590142; 12124384; 12477932; 12588972; 12812986; 12878157; 12904573; 14519125; 15946946; 16385451; 16497727; 16541103; 16582619; 16829125; 17322308; 17353931; 17361185; 17381544; 17403899; 17581632; 18000879; 18029348; 18354498; 18423202; 18502210; 18568671; 18599441; 18628297; 18725400; 18781797; 19245811; 19327350; 19454010; 19615732; 19738201; 20020773; 20056645; 20068067; 20360068; 20399188; 20562859; 20647036; 20818067; 20936779; 21078624; 21139048; 21319273; 21610145; 21625209; 21890473; 21906983; 21963094; 22022972; 22053931; 22108332; 22145905; 22190034; 22268729; 22505724; 22623428; 22634302; 22863883; 22939629; 22952844; 23000965; 23127338; 23184937; 23393223; 23437357; 23455922; 23463506; 23530232; 23623729; 23766293; 23862649; 23921387; 24457600; 24515614,,,,,,,,,,,,,,,OGG:3000008661,,,,,,,"eukaryotic translation initiation factor 3, subunit A",,,,,,,,,,,,,"Other designations: EIF3, p180 subunit|centrosomin homolog|cytoplasmic protein p167|eIF-3-theta|eIF3 p167|eIF3 p180|eIF3 p185|eukaryotic translation initiation factor 3 subunit 10|eukaryotic translation initiation factor 3 subunit A|eukaryotic translation initiation factor 3, subunit 10 (theta, 150/170kD)|eukaryotic translation initiation factor 3, subunit 10 (theta, 170kD)|eukaryotic translation initiation factor 3, subunit 10 theta, 150/170kDa|eukaryotic translation initiation factor 3, subunit 10, 170kD",,EIF3A,,,,,,,,,,,,,,,,,,,,,,,8661,,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF3A,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000008669,EIF3J,,"Other designations: eukaryotic translation initiation factor 3 subunit J|eukaryotic translation initiation factor 3, subunit 1 (alpha, 35kD)",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,eIF3-p35|EIF3S1|eIF3-alpha,,,,,,,,,,,,15,,,,,,HPRD:04883|Ensembl:ENSG00000104131|Vega:OTTHUMG00000131158|MIM:603910|HGNC:3270,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"eukaryotic translation initiation factor 3, subunit J",,,15q21.1,,,,,,,,,,,,,,,,"GO_0001731 (EC: IEA); GO_0003743 (EC: IC, Qualifier: contributes_to, PMID:17322308); GO_0005515 (EC: IPI, PMID:14688252); GO_0005829 (EC: TAS); GO_0005852 (EC: IDA, PMID:17322308); GO_0006412 (EC: TAS); GO_0006413 (EC: IC, PMID:17322308); GO_0006413 (EC: TAS); GO_0006446 (EC: IEA); GO_0010467 (EC: TAS); GO_0016282 (EC: IEA); GO_0033290 (EC: IEA); GO_0044267 (EC: TAS)",,,,,,,,,PMID:9822659; 10672017; 11560931; 12477932; 14519125; 14688252; 14702039; 15146197; 15489334; 15703437; 15946946; 16169070; 16766523; 16964243; 17081983; 17190833; 17322308; 17403899; 17588516; 18599441; 18628297; 18658124; 19471022; 19615732; 20060839; 20360068; 21139048; 21890473; 22025682; 22113938; 22190034; 22804784; 22863883; 23000965; 23455922; 24163370,,,,,,,,,,,,,,,OGG:3000008669,,,,,,,"eukaryotic translation initiation factor 3, subunit J",,,,,,,,,,,,,"Other designations: eukaryotic translation initiation factor 3 subunit J|eukaryotic translation initiation factor 3, subunit 1 (alpha, 35kD)",,EIF3J,,,,,,,,,,,,,,,,,,,,,,,8669,PRO0391,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF3J,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0010557,40S ribosomal protein S3a,40S small ribosomal protein 3A,,false,,,http://purl.obolibrary.org/obo/IMR_0000896,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,40S small ribosomal protein 3A,,,,,IMR:0010557,,,,,,,,,,,,,,,,,,,,,,40S ribosomal protein S3a,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0000061,anatomical structure,biological structure|connected biological structure,Material anatomical entity that is a single connected structure with inherent 3D shape generated by coordinated expression of the organism's own genome.,false,,,http://purl.obolibrary.org/obo/UBERON_0001062,,,,,,,,,,,,,,,,,,,,http://www.snomedbrowser.com/Codes/Details/362889002|http://dbpedia.org/ontology/AnatomicalStructure|ZFA:0000037|TAO:0000037|BILA:0000003|AEO:0000003|FBbt:00007001|AAO:0010825|HAO:0000003|EMAPA:0|GAID:781|VHOG:0001759|CARO:0000003|EHDAA2:0003003|XAO:0003000|TGMA:0001823|FMA:67135|WBbt:0000100|MA:0003000|MESH:D000825,,Material anatomical entity that is a single connected structure with inherent 3D shape generated by coordinated expression of the organism's own genome.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,biological structure|connected biological structure,,,,,UBERON:0000061,,,,,,,,,,,,,,,,,,,,,,anatomical structure,,,,,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0000064,organ part,regional part of organ|cardinal organ part,A multicellular structure that is a part of an organ.,false,,,http://purl.obolibrary.org/obo/UBERON_0000061,,,,,,,,,,,,,,,,,,,"currently defined in a very broad sense, may be replaced by more specific classes in the future",http://www.snomedbrowser.com/Codes/Details/91717005|http://www.snomedbrowser.com/Codes/Details/113343008|http://uri.neuinfo.org/nif/nifstd/birnlex_16|EFO:0000635|AAO:0011124|FMA:82472,,A multicellular structure that is a part of an organ.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,cardinal organ part,,regional part of organ,,http://purl.obolibrary.org/obo/UBERON_0000062,UBERON:0000064,http://purl.obolibrary.org/obo/UBERON_0000062,,,,,,,,,,,,,,,,,,,,,organ part,,,,,,,http://purl.obolibrary.org/obo/oae.owl|http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0000062,organ,element|anatomical unit|body organ,Anatomical structure that performs a specific function or group of functions [WP].,false,,,http://purl.obolibrary.org/obo/UBERON_0000061,,,,,,,,,,,,,,,,,,,,http://www.snomedbrowser.com/Codes/Details/272625005|http://uri.neuinfo.org/nif/nifstd/birnlex_4|http://en.wikipedia.org/wiki/Organ_(anatomy)|http://linkedlifedata.com/resource/umls/id/C0178784|http://purl.obolibrary.org/obo/NCIT_C13018|WBbt:0003760|OpenCyc:Mx4rv5XMb5wpEbGdrcN5Y29ycA|EFO:0000634|ENVO:01000162|MA:0003001|EMAPA:35949|CARO:0020004|OpenCyc:Mx4rwP3iWpwpEbGdrcN5Y29ycA|FMA:67498|UMLS:C0178784,,Anatomical structure that performs a specific function or group of functions [WP].,,,,,,,,"Organs are commonly observed as visibly distinct structures, but may also exist as loosely associated clusters of cells that work together to perform a specific function or functions.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,element|anatomical unit|body organ,,http://purl.obolibrary.org/obo/UBERON_0000467,UBERON:0000062,http://purl.obolibrary.org/obo/UBERON_0000467,,,,,,,,,,,,,,,,,,,,,organ,,,,,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000196463,PLBD2,,Other designations: 76 kDa protein|LAMA-like protein 2|PLB homolog 2|lamina ancestor homolog 2|mannose-6-phosphate protein associated protein p76|phospholipase B domain-containing protein 2|phospholipase B-like 2 32 kDa form|phospholipase B-like 2 45 kDa form|putative phospholipase B-like 2,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,P76,,,,,,,,,,,,12,,,,,,Ensembl:ENSG00000151176|HGNC:27283|Vega:OTTHUMG00000169567|HPRD:14116,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,phospholipase B domain containing 2,,,12q24.13,,,,,,,,,,,,,,,,GO_0016042 (EC: IEA); GO_0016787 (EC: IEA); GO_0043202 (EC: IEA),,,,,,,,,PMID: 12477932; 15146197; 15193148; 17105447; 21906983; 21963094; 22268729; 22939629,,,,,,,,,,,,,,,OGG:3000196463,,,,,,,phospholipase B domain containing 2,,,,,,,,,,,,,Other designations: 76 kDa protein|LAMA-like protein 2|PLB homolog 2|lamina ancestor homolog 2|mannose-6-phosphate protein associated protein p76|phospholipase B domain-containing protein 2|phospholipase B-like 2 32 kDa form|phospholipase B-like 2 45 kDa form|putative phospholipase B-like 2,,PLBD2,,,,,,,,,,,,,,,,,,,,,,,196463,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,PLBD2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0002808,FOXO6,,,false,,,http://purl.obolibrary.org/obo/IMR_0002804,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0002808,,,,,,,,,,,,,,,,,,,,,,FOXO6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000335,Crk,CT-10 regulator of kinase|Proto-oncogene C-crk,Alternative splicing of the mammal crk gene yields two translation products designated the 28-kDa Crk-I and the 42-kDa Crk-II protein.,false,,,http://purl.obolibrary.org/obo/IMR_0000745,,,,,,,,,,,,,,,,,,,,,,Alternative splicing of the mammal crk gene yields two translation products designated the 28-kDa Crk-I and the 42-kDa Crk-II protein.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CT-10 regulator of kinase|Proto-oncogene C-crk,,,,,IMR:0000335,,,,,,,,,,,,,,,,,,,,,,Crk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000045,GDNF,Glial cell line-derived neurotrophic factor,,false,,,http://purl.obolibrary.org/obo/TXPO_0001382,,,,,,,,,,,,,,,,,,,,GO:0005160,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002395|http://purl.obolibrary.org/obo/TXPO_0000624,,,,,Glial cell line-derived neurotrophic factor,,,,,IMR:0000045,,,,,,,,,,,,,,,,,,,,,,GDNF,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002363,cell survival [Glutathione depletion],,"Cell survial is a subtype of keeong quantity: A process that keeps the viability of a cell.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/NCIT_C16407|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Cell survial is a subtype of keeong quantity: A process that keeps the viability of a cell.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000661,,,,,,,,,,,,,,,,,TXPO:0002363,,,,,,,,,,,,,,,,,,,,,,cell survival [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002367,activation of thioredoxin pathway [Glutathione depletion],,"Activation of thioredoxin pathway is a subtype of activating: A process that changes the activity of the thioredoxin pathway to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0000507|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,PMID:20463017,,"Activation of thioredoxin pathway is a subtype of activating: A process that changes the activity of the thioredoxin pathway to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001930,,,,,,http://purl.obolibrary.org/obo/TXPO_0002368,,,,,,,,,,,TXPO:0002367,,,,,,,,,,,,,,,,,,,,,,activation of thioredoxin pathway [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002364,increasing drug metabolite,,Increasing drug metabolite is a subtype of increasing quantity: A process that changes the amount of drug metabolites to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing drug metabolite is a subtype of increasing quantity: A process that changes the amount of drug metabolites to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002364,,,,,,,,,,,,,,,,,,,,,,increasing drug metabolite,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002361,mitochondrial dysfunction,,Mitochondrial dysfunction is a subtype of dysfunctioning: A process that performs an abnormal and incomplete mitochondrial function.,false,,,http://purl.obolibrary.org/obo/TXPO_0000438,,,,,,,,,,,,,,,,,,,,,,Mitochondrial dysfunction is a subtype of dysfunctioning: A process that performs an abnormal and incomplete mitochondrial function.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002361,,,,,,,,,,,,,,,,,,,,,,mitochondrial dysfunction,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002366,dissociation of Nrf2-Keap1 complex [Glutathione depletion],,"Dissociation of Nrf2-Keap1 complex is a subtype of detaching: A process that disaggregates  a Nrf2-Keap1 complexe into Nrf2 and Keap1.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0002737|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Dissociation of Nrf2-Keap1 complex is a subtype of detaching: A process that disaggregates  a Nrf2-Keap1 complexe into Nrf2 and Keap1.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002216,,,,,,,,,,,TXPO:0002366,,,,,,,,,,,,,,,,,,,,,,dissociation of Nrf2-Keap1 complex [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002362,phospholipid biosynthetic positive regulator role,,A role played by the entity  which positively regulates the formation of phospholipids.,false,,,http://purl.obolibrary.org/obo/TXPO_0003647,,,,,,,,http://purl.obolibrary.org/obo/GO_0008654,,,,,,,,,,,,,,A role played by the entity  which positively regulates the formation of phospholipids.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002362,,,,,,,,,,,,,,,,,,,,,,phospholipid biosynthetic positive regulator role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002360,hyperfunction of defensive function,,Hyperfunction of defensive function is a subtype of hyperfunctioning: A process that performs an excessive defensive function.,false,,,http://purl.obolibrary.org/obo/TXPO_0000435,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of defensive function is a subtype of hyperfunctioning: A process that performs an excessive defensive function.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002360,,,,,,,,,,,,,,,,,,,,,,hyperfunction of defensive function,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002365,GCLC (mol),Glutamate-Cysteine Ligase Catalytic Subunit,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:29739|NCBI-Mouse-GeneID:14630|NCBI-Human-GeneID:2730,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000002729,,,,,,,,Glutamate-Cysteine Ligase Catalytic Subunit,,,,,TXPO:0002365,,,,,,,,,,,,,,,,,,,,,,GCLC (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002369,p53 signaling (primitive) [Glutathione depletion],,"P53 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by p53.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0000001|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"P53 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by p53.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001935|http://purl.obolibrary.org/obo/TXPO_0001932,,,,,,http://purl.obolibrary.org/obo/TXPO_0002370|http://purl.obolibrary.org/obo/TXPO_0002376,,,,,,,,,,,TXPO:0002369,,,,,,,,,,,,,,,,,,,,,,p53 signaling (primitive) [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002368,hyperfunction of anti-oxidative stress [Glutathione depletion],,"Hyperfunction of anti-oxidative stress is a subtype of hyperfunctioning: A process that performs an excesssive response to oxidative stress.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0002063|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of anti-oxidative stress is a subtype of hyperfunctioning: A process that performs an excesssive response to oxidative stress.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001938|http://purl.obolibrary.org/obo/TXPO_0001936|http://purl.obolibrary.org/obo/TXPO_0001930|http://purl.obolibrary.org/obo/TXPO_0001934,,,,,,http://purl.obolibrary.org/obo/TXPO_0003177,,,,,,,,,,,TXPO:0002368,,,,,,,,,,,,,,,,,,,,,,hyperfunction of anti-oxidative stress [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000487,alpha-cardiac actin,cardiac muscle actin,,false,,,http://purl.obolibrary.org/obo/IMR_0000490,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,cardiac muscle actin,,,,,IMR:0000487,,,,,,,,,,,,,,,,,,,,,,alpha-cardiac actin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001527,RalA,,,false,,,http://purl.obolibrary.org/obo/IMR_0000293,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001527,,,,,,,,,,,,,,,,,,,,,,RalA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0002804,FOXO family,,"FOXO proteins are conserved from worm to human. To date, only one FOXO species has been identified in invertebrates (called dauer formation-16 in Caenorhabditis elegans and dFOXO in Drosophila). In mammals, four subfamily members have been identified: FOXO1 (previously known as FKHR), FOXO3 (previously known as FKHRL1), FOXO4 (previously known as AFX) and FOXO6.",false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,"FOXO proteins are conserved from worm to human. To date, only one FOXO species has been identified in invertebrates (called dauer formation-16 in Caenorhabditis elegans and dFOXO in Drosophila). In mammals, four subfamily members have been identified: FOXO1 (previously known as FKHR), FOXO3 (previously known as FKHRL1), FOXO4 (previously known as AFX) and FOXO6.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,,,,,,IMR:0002804,,,,,,,,,,,,,,,,,,,,,,FOXO family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0002956,beta-arrestin 1,,,false,,,http://purl.obolibrary.org/obo/IMR_0000520,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0002956,,,,,,,,,,,,,,,,,,,,,,beta-arrestin 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0002346,gamma lipotropin,gamma-LPH,,false,,,http://purl.obolibrary.org/obo/IMR_0100197,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,gamma-LPH,,,,,IMR:0002346,,,,,,,,,,,,,,,,,,,,,,gamma lipotropin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000856,NF-ATc2,,,false,,,http://purl.obolibrary.org/obo/IMR_0000421,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000856,,,,,,,,,,,,,,,,,,,,,,NF-ATc2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001567,Rab5A,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001567,,,,,,,,,,,,,,,,,,,,,,Rab5A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_35472,anti-inflammatory drug,anti-inflammatory drugs|antiinflammatory drug|antiinflammatory agent|antiinflammatory drugs,A substance that reduces or suppresses inflammation.,false,,,http://purl.obolibrary.org/obo/CHEBI_23888,,,,,,,,,,,,,,,,,,,,,,A substance that reduces or suppresses inflammation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,anti-inflammatory drugs|antiinflammatory drug|antiinflammatory agent|antiinflammatory drugs,,,,,,,,,,,,,,,,,,,,,CHEBI:35472,,,,anti-inflammatory drug,,CHEBI:35472,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006355,"regulation of transcription, DNA-templated","regulation of cellular transcription, DNA-dependent","Any process that modulates the frequency, rate or extent of cellular DNA-templated transcription.",false,,,http://purl.obolibrary.org/obo/TXPO_0000113,,,,,,,,,,,,,,,,,,,,,,"Any process that modulates the frequency, rate or extent of cellular DNA-templated transcription.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"regulation of cellular transcription, DNA-dependent",,,,,GO:0006355,,,,,,,,,,,,,,,,,,,,,,"regulation of transcription, DNA-templated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006351,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006351,"transcription, DNA-templated","DNA-dependent transcription|cellular transcription, DNA-dependent",The cellular synthesis of RNA on a template of DNA.,false,,,http://purl.obolibrary.org/obo/GO_0010467,,,,,,,,,,,,,,,,,,,,GO:0006351|http://purl.obolibrary.org/obo/IEV_0000183,,The cellular synthesis of RNA on a template of DNA.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"DNA-dependent transcription|cellular transcription, DNA-dependent",,,,,GO:0006351,,,,,,,,,,,,,,,,,,,,,,"transcription, DNA-templated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0007179,transforming growth factor beta receptor signaling pathway,TGF-beta receptor signaling pathway,"A series of molecular signals initiated by the binding of an extracellular ligand to a transforming growth factor beta receptor on the surface of a target cell, and ending with regulation of a downstream cellular process, e.g. transcription.",false,,,http://purl.obolibrary.org/obo/TXPO_0000609,,,,,,,,,,,,,,,,,,,,,,"A series of molecular signals initiated by the binding of an extracellular ligand to a transforming growth factor beta receptor on the surface of a target cell, and ending with regulation of a downstream cellular process, e.g. transcription.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TGF-beta receptor signaling pathway,,,,,GO:0007179,,,,,,,,,,,,,,,,,,,,,,transforming growth factor beta receptor signaling pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0007173,epidermal growth factor receptor signaling pathway,EGFR signaling pathway|EGF receptor signaling pathway,"A series of molecular signals initiated by binding of a ligand to the tyrosine kinase receptor EGFR (ERBB1) on the surface of a cell. The pathway ends with regulation of a downstream cellular process, e.g. transcription.",false,,,http://purl.obolibrary.org/obo/TXPO_0000609,,,,,,,,,,,,,,,,,,,,,,"A series of molecular signals initiated by binding of a ligand to the tyrosine kinase receptor EGFR (ERBB1) on the surface of a cell. The pathway ends with regulation of a downstream cellular process, e.g. transcription.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,EGFR signaling pathway|EGF receptor signaling pathway,,,,,GO:0007173,,,,,,,,,,,,,,,,,,,,,,epidermal growth factor receptor signaling pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/BFO_0000011,spatiotemporal region,,,false,,,http://purl.obolibrary.org/obo/BFO_0000003,,,,,,,,,,,,,,,,,,,,,,,,,,,,A spatiotemporal region is an occurrent entity that is part of spacetime. (axiom label in BFO2 Reference: [095-001]),the spatiotemporal region occupied by the development of a cancer tumor|the spatiotemporal region occupied by a human life|the spatiotemporal region occupied by a process of cellular meiosis.,,,,,,,,,,,(forall (r) (if (SpatioTemporalRegion r) (occupiesSpatioTemporalRegion r r))) // axiom label in BFO2 CLIF: [107-002]|(forall (x t) (if (SpatioTemporalRegion x) (exists (y) (and (SpatialRegion y) (spatiallyProjectsOntoAt x y t))))) // axiom label in BFO2 CLIF: [099-001]|(forall (x y) (if (and (SpatioTemporalRegion x) (occurrentPartOf y x)) (SpatioTemporalRegion y))) // axiom label in BFO2 CLIF: [096-001]|(forall (x) (if (SpatioTemporalRegion x) (exists (y) (and (TemporalRegion y) (temporallyProjectsOnto x y))))) // axiom label in BFO2 CLIF: [098-001]|(forall (x) (if (SpatioTemporalRegion x) (Occurrent x))) // axiom label in BFO2 CLIF: [095-001],All parts of spatiotemporal regions are spatiotemporal regions. (axiom label in BFO2 Reference: [096-001])|Every spatiotemporal region s is such that s occupies_spatiotemporal_region s. (axiom label in BFO2 Reference: [107-002])|Each spatiotemporal region projects_onto some temporal region. (axiom label in BFO2 Reference: [098-001])|Every spatiotemporal region occupies_spatiotemporal_region itself.|Each spatiotemporal region at any time t projects_onto some spatial region at t. (axiom label in BFO2 Reference: [099-001]),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BFO:0000011,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/bfo.owl,spatiotemporal region,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100844,Akt1 (mol),RAC-alpha serine/threonine protein kinase|protein kinase B alpha|RAC-PK-alpha|C-AKT|PKB alpha,,false,,,http://purl.obolibrary.org/obo/IMR_0000250,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,RAC-alpha serine/threonine protein kinase|protein kinase B alpha|RAC-PK-alpha|C-AKT|PKB alpha,,,,,IMR:0100844,,,,,,,,,,,,,,,,,,,,,,Akt1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0015796,liver blood vessel,,,false,,,http://purl.obolibrary.org/obo/UBERON_0001981,,,,,,,,,,,,,,,,,,,A blood vessel that is part of a liver.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,UBERON:0015796,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,liver blood vessel,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0002093,IgE,immunoglobulin E,,false,,,http://purl.obolibrary.org/obo/IMR_0002090,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,immunoglobulin E,,,,,IMR:0002093,,,,,,,,,,,,,,,,,,,,,,IgE,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001959,hypofunction of forming disulfide bond [ER stress],,"Hypofunction of forming disulfide bond is a subtype of hypofunctioning: A process that performs a decreased or insufficient forming disulfide bond.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/TXPO_0001957,,,,,,,,,,,,,,,,,,,,,,"Hypofunction of forming disulfide bond is a subtype of hypofunctioning: A process that performs a decreased or insufficient forming disulfide bond.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000790,,,,,,http://purl.obolibrary.org/obo/TXPO_0000734,,,,,,,,,,,TXPO:0001959,,,,,,,,,,,,,,,,,,,,,,hypofunction of forming disulfide bond [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001951,GCLC - inactivated state (canonical)[Glutathione depletion],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000193,,,,,,,,,,,,,,,,,,,,PMID:23856494,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0002355,,,,http://purl.obolibrary.org/obo/TXPO_0002394,,,,,,,,,,TXPO:0001951,,,,,,,,,,,,,,,,,,,,,,GCLC - inactivated state (canonical)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001957,hypofunction of forming disulfide bond,,Hypofunction of forming disulfide bond is a subtype of hypofunctioning: A process that performs a decreased or insufficient forming disulfide bond.,false,,,http://purl.obolibrary.org/obo/TXPO_0000436,,,,,,,,,,,,,,,,,,,,,,Hypofunction of forming disulfide bond is a subtype of hypofunctioning: A process that performs a decreased or insufficient forming disulfide bond.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001957,,,,,,,,,,,,,,,,,,,,,,hypofunction of forming disulfide bond,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001955,GCLC inactivation [Glutathione depletion],,"GCLC inactivation is a subtype of is a subtype of molecular inactivation: A process that changes the activity of the GCLC to be lower.
This entity is a specific course-dependent process. This process can constitute the course of glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0002000|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"GCLC inactivation is a subtype of is a subtype of molecular inactivation: A process that changes the activity of the GCLC to be lower.
This entity is a specific course-dependent process. This process can constitute the course of glutathione depletion.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001942,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001951,,,,,,http://purl.obolibrary.org/obo/TXPO_0001944,,,,,,,,,,,TXPO:0001955,,,,,,,,,,,,,,,,,,,,,,GCLC inactivation [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001952,Gpx2 (rat)[Glutathione depletion],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001927|http://purl.obolibrary.org/obo/TXPO_1000178,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:29326,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001952,,,,,,,,,,,,,,,,,,,,,,Gpx2 (rat)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001953,Trib3 (rat)[Glutathione depletion],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001927|http://purl.obolibrary.org/obo/TXPO_1000378,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:246273|PMID:20621112,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001953,,,,,,,,,,,,,,,,,,,,,,Trib3 (rat)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001950,Pdk4 (rat)[Glutathione depletion],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001927|http://purl.obolibrary.org/obo/TXPO_1000298,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:89813|PMID:25264247,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001950,,,,,,,,,,,,,,,,,,,,,,Pdk4 (rat)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001954,Gstm3 (rat)[Glutathione depletion],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001927|http://purl.obolibrary.org/obo/TXPO_1000180,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:108348148|PMID:25202346,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001954,,,,,,,,,,,,,,,,,,,,,,Gstm3 (rat)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001958,hypofunction of protein synthesis,,Hypofunction of protein synthesis is a subtype of hypofunction of biosynthesis: A process that performs a decreased or insufficient protein synthesis.,false,,,http://purl.obolibrary.org/obo/TXPO_0001910,,,,,,,,,,,,,,,,,,,,,,Hypofunction of protein synthesis is a subtype of hypofunction of biosynthesis: A process that performs a decreased or insufficient protein synthesis.,,,http://purl.obolibrary.org/obo/TXPO_0000382,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001957,,,,,,,,,,,,,,,,,,TXPO:0001958,,,,,,,,,,,,,,,,,,,,,,hypofunction of protein synthesis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001956,changing protein structure [ER stress],,"Changing protein structure is a subtype of changing structure: A process that changes the stucture of the protein.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000660|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"Changing protein structure is a subtype of changing structure: A process that changes the stucture of the protein.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001965,,,,,,,,,,,,,,,,,,TXPO:0001956,,,,,,,,,,,,,,,,,,,,,,changing protein structure [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000089978,DPH6,,Other designations: ATP binding domain 4|ATP-binding domain-containing protein 4|DPH6 homolog|diphthamide synthase|diphthamide synthetase|diphthine--ammonia ligase|protein DPH6 homolog,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,ATPBD4,,,,,,,,,,,,15,,,,,,HGNC:30543|Vega:OTTHUMG00000129759|Ensembl:ENSG00000134146|HPRD:14443,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,diphthamine biosynthesis 6,,,15q14,,,,,,,,,,,,,,,,GO_0005524 (EC: IEA); GO_0017178 (EC: TAS); GO_0017183 (EC: IEA); GO_0017183 (EC: TAS),,,,,,,,,PMID: 12477932; 14702039; 15489334; 16344560; 19913121; 20379614; 20628086; 20732626; 21890473; 21906983; 21963094; 22505724; 23169644; 23468660; 23776197; 24045676; 24250222,,,,,,,,,,,,,,,OGG:3000089978,,,,,,,diphthamine biosynthesis 6,,,,,,,,,,,,,Other designations: ATP binding domain 4|ATP-binding domain-containing protein 4|DPH6 homolog|diphthamide synthase|diphthamide synthetase|diphthine--ammonia ligase|protein DPH6 homolog,,DPH6,,,,,,,,,,,,,,,,,,,,,,,89978,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,DPH6,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0100504,Smad2/3,,"Smads 2 and 3 serve principally as substrates for the TGFbeta, activin, and Nodal receptors.",false,,,http://purl.obolibrary.org/obo/IMR_0000371,,,,,,,,,,,,,,,,,,,,,,"Smads 2 and 3 serve principally as substrates for the TGFbeta, activin, and Nodal receptors.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100504,,,,,,,,,,,,,,,,,,,,,,Smad2/3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76760,EC 3.1.* (ester hydrolase) inhibitor,ester hydrolase (EC 3.1.*) inhibitor|ester hydrolase (EC 3.1.*) inhibitors|EC 3.1.* (ester hydrolase) inhibitors|ester hydrolase inhibitor|ester hydrolase inhibitors|EC 3.1.* inhibitors|EC 3.1.* inhibitor,A hydrolase inhibitor that interferes with the action of any ester hydrolase (EC 3.1.*.*).,false,,,http://purl.obolibrary.org/obo/CHEBI_76759,,,,,,,,,,,,,,,,,,,,,,A hydrolase inhibitor that interferes with the action of any ester hydrolase (EC 3.1.*.*).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ester hydrolase (EC 3.1.*) inhibitor|ester hydrolase (EC 3.1.*) inhibitors|EC 3.1.* (ester hydrolase) inhibitors|ester hydrolase inhibitor|ester hydrolase inhibitors|EC 3.1.* inhibitors|EC 3.1.* inhibitor,,,,,,,,,,,,,,,,,,,,,CHEBI:76760,,,,EC 3.1.* (ester hydrolase) inhibitor,,CHEBI:76760,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000036,Ankrd37 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:654824|NCBI-Rat-GeneID:361149|NCBI-Human-GeneID:353322,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000353322,,,,,,,,,,,,,TXPO:1000036,,,,,,,,,,,,,,,,,,,,,,Ankrd37 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000037,Arfgap3 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:503165|NCBI-Mouse-GeneID:66251|NCBI-Human-GeneID:26286,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000026286,,,,,,,,,,,,,TXPO:1000037,,,,,,,,,,,,,,,,,,,,,,Arfgap3 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000034,Alas1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:211|NCBI-Rat-GeneID:65155|NCBI-Mouse-GeneID:11655,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000211,,,,,,,,,,,,,TXPO:1000034,,,,,,,,,,,,,,,,,,,,,,Alas1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000039,Atr (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:545|NCBI-Mouse-GeneID:245000|NCBI-Rat-GeneID:685055,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000545,,,,,,,,,,,,,TXPO:1000039,,,,,,,,,,,,,,,,,,,,,,Atr (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000031,Aig1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:66253|NCBI-Rat-GeneID:292486|NCBI-Human-GeneID:51390,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000051390,,,,,,,,,,,,,TXPO:1000031,,,,,,,,,,,,,,,,,,,,,,Aig1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000033,Akr7a3 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:26760|NCBI-Human-GeneID:22977,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000022977,,,,,,,,,,,,,TXPO:1000033,,,,,,,,,,,,,,,,,,,,,,Akr7a3 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000032,Aimp2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:231872|NCBI-Human-GeneID:7965|NCBI-Rat-GeneID:288480,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000007965,,,,,,,,,,,,,TXPO:1000032,,,,,,,,,,,,,,,,,,,,,,Aimp2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000035,ALDH1A1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24188|NCBI-Human-GeneID:216|NCBI-Mouse-GeneID:11668,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000216,,,,,,,,,,,,,TXPO:1000035,,,,,,,,,,,,,,,,,,,,,,ALDH1A1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000038,Ataxn10 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:1000038,,,,,,,,,,,,,,,,,,,,,,Ataxn10 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000030,Ahr (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:25690|NCBI-Mouse-GeneID:11622|NCBI-Human-GeneID:196,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000196,,,,,,,,,,,,,TXPO:1000030,,,,,,,,,,,,,,,,,,,,,,Ahr (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0200051,Prostaglandin F2,,,false,,,http://purl.obolibrary.org/obo/IMR_0100019,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0200051,,,,,,,,,,,,,,,,,,,,,,Prostaglandin F2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100270,Arf GAP,Arf GTPase-activating protein,,false,,,http://purl.obolibrary.org/obo/IMR_0000442,,,,,,,,,,,,,,,,,,,,GO:0008060,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Arf GTPase-activating protein,,,,,IMR:0100270,,,,,,,,,,,,,,,,,,,,,,Arf GAP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0000069,normality (quality),,A quality inhering in a bearer by virtue of the whether the bearer differs from normal or average.,false,,,http://purl.obolibrary.org/obo/BFO_0000019,,,,,,,,,,,,,,,,,,,,,,A quality inhering in a bearer by virtue of the whether the bearer differs from normal or average.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0000069,,,,,,,,,,,,,,,,,,,,,,normality (quality),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0000068,qualitative property,,,false,,,http://purl.obolibrary.org/obo/BFO_0000019,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0000068,,,,,,,,,,,,,,,,,,,,,,qualitative property,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0000060,spatial pattern,,A spatial quality inhering in a bearer by virtue of the bearer's exhibiting repetition of placement of its parts.,false,,,http://purl.obolibrary.org/obo/BFO_0000019,,,,,,,,,,,,,,,,,,,,,,A spatial quality inhering in a bearer by virtue of the bearer's exhibiting repetition of placement of its parts.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0000060,,,,,,,,,,,,,,,,,,,,,,spatial pattern,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0042098,T cell proliferation,T-lymphocyte proliferation|T-cell proliferation|T lymphocyte proliferation,The expansion of a T cell population by cell division. Follows T cell activation.,false,,,http://purl.obolibrary.org/obo/GO_0046651,,,,,,,,,,,,,,,,,,,,,,The expansion of a T cell population by cell division. Follows T cell activation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,T-lymphocyte proliferation|T-cell proliferation|T lymphocyte proliferation,,,,,GO:0042098,,,,,,,,,,,,,,,,,,,,,,T cell proliferation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_37890,alpha-adrenergic antagonist,alpha-adrenergic blockers|alpha-adrenergic blocker|alpha-adrenoceptor antagonists|alpha-adrenergic receptor blockaders|alpha-adrenergic antagonists,"An agent that binds to but does not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous alpha-adrenergic agonists. alpha-Adrenergic antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma.",false,,,http://purl.obolibrary.org/obo/CHEBI_37887|http://purl.obolibrary.org/obo/CHEBI_48539,,,,,,,,,,,,,,,,,,,,,,"An agent that binds to but does not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous alpha-adrenergic agonists. alpha-Adrenergic antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,alpha-adrenergic blockers|alpha-adrenergic blocker|alpha-adrenoceptor antagonists|alpha-adrenergic receptor blockaders|alpha-adrenergic antagonists,,,,,,,,,,,,,,,,,,,,,CHEBI:37890,,,,alpha-adrenergic antagonist,,CHEBI:37890,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001202,TRAIL-R2,TRAIL-R2|death receptor 5|DR5|KILLER|TRICK2|TRAIL receptor-2,,false,,,http://purl.obolibrary.org/obo/IMR_0000056,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TRAIL-R2|death receptor 5|DR5|KILLER|TRICK2|TRAIL receptor-2,,,,,IMR:0001202,,,,,,,,,,,,,,,,,,,,,,TRAIL-R2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_2376,acarbose,"Precose|acarbosum|acarbose|acarbosa|Glucobay|4,6-dideoxy-4-{[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino}-alpha-D-glucopyranosyl-(1->4)-alpha-D-glucopyranosyl-(1->4)-D-glucopyranose|Acarbose","A tetrasaccharide derivative consisting of a dideoxy-4-{[4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl C7 cyclitol moiety [called valienol (or valienamine)] linked via nitrogen to isomaltotriose.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Drug_Central:39|PMID:8893066|PMID:9805641|PMID:11937512|CAS:56180-94-0|PMID:18248270|DrugBank:DB00284|LINCS:LSM-4345|PMID:25044702,,"A tetrasaccharide derivative consisting of a dideoxy-4-{[4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl C7 cyclitol moiety [called valienol (or valienamine)] linked via nitrogen to isomaltotriose.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_50627|http://purl.obolibrary.org/obo/CHEBI_35526|http://purl.obolibrary.org/obo/CHEBI_67239,,,,,"4,6-dideoxy-4-{[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino}-alpha-D-glucopyranosyl-(1->4)-alpha-D-glucopyranosyl-(1->4)-D-glucopyranose|Acarbose",,Precose|acarbosum|acarbose|acarbosa|Glucobay,,,,,,,,,,,,,,,,,,,,,CHEBI:2376,,,,acarbose,,CHEBI:2376,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000243,IKK complex,I-kappaB kinase complex,,false,,,http://purl.obolibrary.org/obo/TXPO_0002107,,,,,,,,,,,,,,,,,,,,GO:0008385,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001966,,,,,I-kappaB kinase complex,,,,,IMR:0000243,,,,,,,,,,,,,,,,,,,,,,IKK complex,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0002799,S6K2,,,false,,,http://purl.obolibrary.org/obo/IMR_0001845,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0002799,,,,,,,,,,,,,,,,,,,,,,S6K2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_35475,non-steroidal anti-inflammatory drug,non-steroidal anti-inflammatory agent|non-steroidal anti-inflammatory drugs|NSAIDs|NSAID,"An anti-inflammatory drug that is not a steroid. In addition to anti-inflammatory actions, non-steroidal anti-inflammatory drugs have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins.",false,,,http://purl.obolibrary.org/obo/CHEBI_35472|http://purl.obolibrary.org/obo/CHEBI_35842,,,,,,,,,,,,,,,,,,,,Wikipedia:Non-steroidal_anti-inflammatory_drug,,"An anti-inflammatory drug that is not a steroid. In addition to anti-inflammatory actions, non-steroidal anti-inflammatory drugs have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,non-steroidal anti-inflammatory agent|non-steroidal anti-inflammatory drugs|NSAIDs|NSAID,,,,,,,,,,,,,,,,,,,,,CHEBI:35475,,,,non-steroidal anti-inflammatory drug,,CHEBI:35475,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0003065,GDF-6,Growth/differentiation factor 6|cartilage-derived morphogenetic protein-2|Bone morphogenetic protein-13|BMP-13|CDMP-2,,false,,,http://purl.obolibrary.org/obo/IMR_0003085,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Growth/differentiation factor 6|cartilage-derived morphogenetic protein-2|Bone morphogenetic protein-13|BMP-13|CDMP-2,,,,,IMR:0003065,,,,,,,,,,,,,,,,,,,,,,GDF-6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001846,RSK1,p90RSK1|90 kDa ribosomal S6 kinase1,,false,,,http://purl.obolibrary.org/obo/IMR_0000248,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p90RSK1|90 kDa ribosomal S6 kinase1,,,,,IMR:0001846,,,,,,,,,,,,,,,,,,,,,,RSK1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0002094,IgG,immunoglobulin G,,false,,,http://purl.obolibrary.org/obo/IMR_0002090,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,immunoglobulin G,,,,,IMR:0002094,,,,,,,,,,,,,,,,,,,,,,IgG,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_4909,etodolac,"ETODOLIC ACID|1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-ylacetic acid|1,3,4,9-tetrahydro-1,8-diethylpyrano(3,4-b)indole-1-acetic acid|etodolaco|(1,8-Diethyl-1,3,4,9-tetrahydro-pyrano[3,4-b]indol-1-yl)-acetic acid|etodolacum|1,8-diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acid|(+-)-1,8-diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acid|etodolac|(1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl)acetic acid|ETODOLAC","A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl moiety. A preferential inhibitor of cyclo-oxygenase 2 and non-steroidal anti-inflammatory, it is used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain. Administered as the racemate, only the (S)-enantiomer is active.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:28166217|PMID:2970548|CAS:41340-25-4|DrugBank:DB00749|Drug_Central:1103|PMID:2527995|PMID:15369391|LINCS:LSM-1781,,"A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl moiety. A preferential inhibitor of cyclo-oxygenase 2 and non-steroidal anti-inflammatory, it is used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain. Administered as the racemate, only the (S)-enantiomer is active.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35493|http://purl.obolibrary.org/obo/CHEBI_50629|http://purl.obolibrary.org/obo/CHEBI_35475|http://purl.obolibrary.org/obo/CHEBI_35481,,,,,"(1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl)acetic acid|ETODOLAC",,"ETODOLIC ACID|1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-ylacetic acid|1,3,4,9-tetrahydro-1,8-diethylpyrano(3,4-b)indole-1-acetic acid|etodolaco|(1,8-Diethyl-1,3,4,9-tetrahydro-pyrano[3,4-b]indol-1-yl)-acetic acid|etodolacum|1,8-diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acid|(+-)-1,8-diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acid|etodolac",,,,,,,,,,,,,,,,,,,,,CHEBI:4909,,,,etodolac,,CHEBI:4909,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000051726,DNAJB11,,Other designations: APOBEC1-binding protein 2|DnaJ protein 9|ER-associated DNAJ protein 3|ER-associated Hsp40 co-chaperone|ER-resident protein ERdj3|PWP1-interacting protein 4|dnaJ homolog subfamily B member 11|endoplasmic reticulum DNA J domain-containing protein 3,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,Dj-9|ERj3p|ERdj3|ERj3|DJ9|ABBP-2|ABBP2|UNQ537|PRO1080|EDJ,,,,,,,,,,,,3,,,,,,HPRD:07485|MIM:611341|HGNC:14889|Ensembl:ENSG00000090520,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"DnaJ (Hsp40) homolog, subfamily B, member 11",,,3q27.3,,,,,,,,,,,,,,,,"GO_0005515 (EC: IPI, PMID:18923428); GO_0005634 (EC: IEA); GO_0005783 (EC: IDA); GO_0005783 (EC: TAS, PMID:16130169); GO_0005788 (EC: TAS); GO_0006457 (EC: IEA); GO_0006987 (EC: TAS); GO_0016556 (EC: IEA); GO_0030968 (EC: TAS); GO_0044267 (EC: TAS); GO_0051082 (EC: IEA)",,,,,,,,,PMID:10827079; 11147971; 11584023; 12475965; 12477932; 12975309; 14702039; 15195998; 15489334; 15525676; 15544163; 16130169; 16169070; 16236267; 16303743; 17353931; 17976514; 18029348; 18303054; 18624398; 18923428; 19167051; 19322201; 19748898; 19913121; 20335166; 20418907; 20628086; 20811636; 21081666; 21139048; 21145461; 21150319; 21182205; 21673190; 21844235; 21890473; 21900206; 21906983; 21963094; 22190034; 22268729; 22678362; 22863883; 22939629; 22990118; 23097496; 23349634; 23378021; 23455922; 23752268; 23798571,,,,,,,,,,,,,,,OGG:3000051726,,,,,,,"DnaJ (Hsp40) homolog, subfamily B, member 11",,,,,,,,,,,,,Other designations: APOBEC1-binding protein 2|DnaJ protein 9|ER-associated DNAJ protein 3|ER-associated Hsp40 co-chaperone|ER-resident protein ERdj3|PWP1-interacting protein 4|dnaJ homolog subfamily B member 11|endoplasmic reticulum DNA J domain-containing protein 3,,DNAJB11,,,,,,,,,,,,,,,,,,,,,,,51726,PSEC0121,,,,,,,9606,,,,,,,,,,,,,,,,,,,DNAJB11,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000051302,CYP39A1,,"Other designations: 24-hydroxycholesterol 7-alpha-hydroxylase|cytochrome P450, subfamily XXXIX (oxysterol 7 alpha-hydroxylase), polypeptide 1",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,6,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 39, subfamily A, polypeptide 1",,,6p21.1-p11.2,,,,,,,,,,,,,,,,"GO_0005506 (EC: IEA); GO_0005789 (EC: TAS); GO_0006699 (EC: IDA, PMID:10748047); GO_0006699 (EC: TAS); GO_0006707 (EC: IEA); GO_0006805 (EC: TAS); GO_0007586 (EC: TAS, PMID:10748047); GO_0008206 (EC: TAS); GO_0008387 (EC: IEA); GO_0008396 (EC: IDA, PMID:10748047); GO_0016125 (EC: TAS); GO_0020037 (EC: IEA); GO_0030573 (EC: IEA); GO_0033782 (EC: IEA); GO_0043231 (EC: TAS, PMID:10748047); GO_0044281 (EC: TAS)",,,,,,,,,PMID:10748047; 11329013; 12477932; 15128046; 15489334; 19553612; 20453000; 21988832,,,,,,,,,,,,,,,OGG:3000051302,,,,,,,"cytochrome P450, family 39, subfamily A, polypeptide 1",,,,,,,,,,,,,"Other designations: 24-hydroxycholesterol 7-alpha-hydroxylase|cytochrome P450, subfamily XXXIX (oxysterol 7 alpha-hydroxylase), polypeptide 1",,CYP39A1,,,,,,,,,,,,,,,,,,,,,,,51302,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP39A1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/GO_0046338,phosphatidylethanolamine catabolic process,phosphatidylethanolamine catabolism|phosphatidylethanolamine degradation|phosphatidylethanolamine breakdown,"The chemical reactions and pathways resulting in the breakdown of phosphatidylethanolamine, any of a class of glycerophospholipids in which a phosphatidyl group is esterified to the hydroxyl group of ethanolamine.",false,,,http://purl.obolibrary.org/obo/GO_0046475,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways resulting in the breakdown of phosphatidylethanolamine, any of a class of glycerophospholipids in which a phosphatidyl group is esterified to the hydroxyl group of ethanolamine.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_16038,,,,,,,,,,,,,,,,,,phosphatidylethanolamine catabolism|phosphatidylethanolamine degradation|phosphatidylethanolamine breakdown,,,,,GO:0046338,,,,,,,,,,,,,,,,,biological_process,,,,,phosphatidylethanolamine catabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_50748,antipsoriatic,antipsoriatic drug|antipsoriatic agent,A drug used to treat psoriasis.,false,,,http://purl.obolibrary.org/obo/CHEBI_50177,,,,,,,,,,,,,,,,,,,,,,A drug used to treat psoriasis.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,antipsoriatic drug|antipsoriatic agent,,,,,,,,,,,,,,,,,,,,,CHEBI:50748,,,,antipsoriatic,,CHEBI:50748,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001432,BMP-8a,OP-2|BMP8a|Bone morphogenetic protein 8a,,false,,,http://purl.obolibrary.org/obo/IMR_0003084,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,OP-2|BMP8a|Bone morphogenetic protein 8a,,,,,IMR:0001432,,,,,,,,,,,,,,,,,,,,,,BMP-8a,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000600,IL-17 receptor,interleukin-17 receptor,,false,,,http://purl.obolibrary.org/obo/IMR_0000096,,,,,,,,,,,,,,,,,,,,GO:0030368,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,interleukin-17 receptor,,,,,IMR:0000600,,,,,,,,,,,,,,,,,,,,,,IL-17 receptor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_63628,tipranavir,"3'-((1R)-1-((6R)-5,6-Dihydro-4-hydroxy-2-oxo-6-phenethyl-6-propyl-2H-pyran-3-yl)propyl)-5-(trifluoromethyl)-2-pyridinesulfonanilide|tipranavir|N-(3-{(1R)-1-[(6R)-4-hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-5,6-dihydro-2H-pyran-3-yl]propyl}phenyl)-5-(trifluoromethyl)pyridine-2-sulfonamide",A pyridine-2-sulfonamide substituted at C-5 by a trifluoromethyl group and at the sulfonamide nitrogen by a dihydropyrone-containing m-tolyl substituent. It is an HIV-1 protease inhibitor.,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:22096044|PMID:22258921|PMID:22007990|PMID:21825300|PMID:25017682|PMID:17620375|CAS:174484-41-4|PMID:21576452|PMID:21571982|PMID:21871444|Reaxys:7698323|PMID:21041916|DrugBank:DB00932|PMID:20368406,,A pyridine-2-sulfonamide substituted at C-5 by a trifluoromethyl group and at the sulfonamide nitrogen by a dihydropyrone-containing m-tolyl substituent. It is an HIV-1 protease inhibitor.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35660|http://purl.obolibrary.org/obo/CHEBI_36044,,,,,"N-(3-{(1R)-1-[(6R)-4-hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-5,6-dihydro-2H-pyran-3-yl]propyl}phenyl)-5-(trifluoromethyl)pyridine-2-sulfonamide",,"3'-((1R)-1-((6R)-5,6-Dihydro-4-hydroxy-2-oxo-6-phenethyl-6-propyl-2H-pyran-3-yl)propyl)-5-(trifluoromethyl)-2-pyridinesulfonanilide|tipranavir",,,,,,,,,,,,,,,,,,,,,CHEBI:63628,,,,tipranavir,,CHEBI:63628,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001136,brevican,,,false,,,http://purl.obolibrary.org/obo/IMR_0001126,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001136,,,,,,,,,,,,,,,,,,,,,,brevican,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001109,RanBP17,,,false,,,http://purl.obolibrary.org/obo/IMR_0001091,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001109,,,,,,,,,,,,,,,,,,,,,,RanBP17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001210,Noxa,,,false,,,http://purl.obolibrary.org/obo/IMR_0100709,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001210,,,,,,,,,,,,,,,,,,,,,,Noxa,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_23092,chemosterilant,chemosterilants,A substance intended to sterilize any organism.,false,,,http://purl.obolibrary.org/obo/CHEBI_25944,,,,,,,,,,,,,,,,,,,,,,A substance intended to sterilize any organism.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,chemosterilants,,,,,,,,,,,,,,,,,,,,,CHEBI:23092,,,,chemosterilant,,CHEBI:23092,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000459,cytokeratin 19,,,false,,,http://purl.obolibrary.org/obo/IMR_0000035,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000459,,,,,,,,,,,,,,,,,,,,,,cytokeratin 19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000001174,AP1S1,,"Other designations: AP-1 complex subunit sigma-1A|HA1 19 kDa subunit|adapter-related protein complex 1 sigma-1A subunit|adapter-related protein complex 1 subunit sigma-1A|adaptor protein complex AP-1 subunit sigma-1A|clathrin assembly protein complex 1 sigma-1A small chain|clathrin coat assembly protein AP19|clathrin-associated/assembly/adaptor protein, small 1 (19kD)|erythrokeratodermia variabilis 3 (Kamouraska type)|golgi adaptor HA1/AP1 adaptin sigma-1A subunit|sigma1A subunit of AP-1 clathrin adaptor complex|sigma1A-adaptin",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,AP19|SIGMA1A|EKV3|WUGSC:H_DJ0747G18.2|CLAPS1|MEDNIK,,,,,,,,,,,,7,,,,,,MIM:603531|Vega:OTTHUMG00000157103|HGNC:559|Ensembl:ENSG00000106367|HPRD:04635,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"adaptor-related protein complex 1, sigma 1 subunit",,,7q22.1,,,,,,,,,,,,,,,,"GO_0000139 (EC: TAS); GO_0005765 (EC: TAS); GO_0005829 (EC: TAS); GO_0005905 (EC: IEA); GO_0006886 (EC: IEA); GO_0006892 (EC: TAS); GO_0006898 (EC: TAS, PMID: 9733768); GO_0008565 (EC: IEA); GO_0009615 (EC: IEP, PMID: 16548883); GO_0016032 (EC: TAS); GO_0019886 (EC: TAS); GO_0030121 (EC: TAS, PMID: 9733768); GO_0030659 (EC: TAS); GO_0032588 (EC: TAS); GO_0050690 (EC: TAS); GO_0061024 (EC: TAS)",,,,,,,,,PMID: 2040623; 7593184; 9653655; 9733768; 9736718; 9811606; 9811611; 9847074; 9882340; 10535737; 10747088; 10966473; 11031247; 11222723; 11252894; 11463741; 11694590; 11707398; 12215646; 12477932; 12486136; 12836198; 12853948; 15469849; 15489334; 15569716; 15681409; 16253302; 16548883; 17353931; 18336259; 18781797; 19057675; 19149577; 19895210; 20594957; 21139048; 21762802; 21906983; 21963094; 21987572; 22103831; 22939629; 23000965; 23423674; 23956138; 24250222,,,,,,,,,,,,,,,OGG:3000001174,,,,,,,"adaptor-related protein complex 1, sigma 1 subunit",,,,,,,,,,,,,"Other designations: AP-1 complex subunit sigma-1A|HA1 19 kDa subunit|adapter-related protein complex 1 sigma-1A subunit|adapter-related protein complex 1 subunit sigma-1A|adaptor protein complex AP-1 subunit sigma-1A|clathrin assembly protein complex 1 sigma-1A small chain|clathrin coat assembly protein AP19|clathrin-associated/assembly/adaptor protein, small 1 (19kD)|erythrokeratodermia variabilis 3 (Kamouraska type)|golgi adaptor HA1/AP1 adaptin sigma-1A subunit|sigma1A subunit of AP-1 clathrin adaptor complex|sigma1A-adaptin",,AP1S1,,,,,,,,,,,,,,,,,,,,,,,1174,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,AP1S1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0100300,caspase-8,,,false,,,http://purl.obolibrary.org/obo/IMR_0000308,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100300,,,,,,,,,,,,,,,,,,,,,,caspase-8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000254,G-protein coupled receptor kinase,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001966,,,,,,,,,,IMR:0000254,,,,,,,,,,,,,,,,,,,,,,G-protein coupled receptor kinase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000080331,DNAJC5,,Other designations: cysteine string protein alpha|dnaJ homolog subfamily C member 5,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CSP|CLN4B|CLN4|DNAJC5A|NCL,,,,,,,,,,,,20,,,,,,MIM:611203|Vega:OTTHUMG00000033007|Ensembl:ENSG00000101152|HGNC:16235|HPRD:08539,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"DnaJ (Hsp40) homolog, subfamily C, member 5",,,20q13.33,,,,,,,,,,,,,,,,"GO_0001948 (EC: IEA); GO_0005739 (EC: IDA); GO_0005765 (EC: IDA, PMID:17897319); GO_0005886 (EC: IDA); GO_0005886 (EC: TAS); GO_0007268 (EC: TAS); GO_0007269 (EC: TAS); GO_0008021 (EC: IEA); GO_0008219 (EC: IEA); GO_0042470 (EC: IEA); GO_0043008 (EC: IEA); GO_0043524 (EC: IEA); GO_0061202 (EC: TAS)",,,,,,,,,PMID:2663281; 3284607; 8764987; 10194413; 11214971; 11604405; 11780052; 12039948; 12477932; 14570907; 14702039; 14997482; 15489334; 15610015; 15972823; 16469739; 16751776; 17897319; 18029348; 18314541; 18596047; 19098309; 20301601; 20453918; 21139048; 21674799; 21820099; 21890473; 21906983; 21963094; 21987572; 22073189; 22235333; 22902780; 22939629; 22978711; 23000965; 23535732; 24250222,,,,,,,,,,,,,,,OGG:3000080331,,,,,,,"DnaJ (Hsp40) homolog, subfamily C, member 5",,,,,,,,,,,,,Other designations: cysteine string protein alpha|dnaJ homolog subfamily C member 5,,DNAJC5,,,,,,,,,,,,,,,,,,,,,,,80331,,,,,,,,9606,,,,,,,,,,,,,,,,,,,DNAJC5,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0100768,Wnt-3,,,false,,,http://purl.obolibrary.org/obo/IMR_0000003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100768,,,,,,,,,,,,,,,,,,,,,,Wnt-3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001478,DOCK10,,,false,,,http://purl.obolibrary.org/obo/IMR_0001469,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001478,,,,,,,,,,,,,,,,,,,,,,DOCK10,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000005372,PMM1,,"Other designations: PMM 1|PMMH-22|brain glucose-1,6-bisphosphatase",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,Sec53,,,,,,,,,,,,22,,,,,,MIM:601786|HGNC:9114|Vega:OTTHUMG00000150972|Ensembl:ENSG00000100417|HPRD:03473,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,phosphomannomutase 1,,,22q13.2,,,,,,,,,,,,,,,,"GO_0004615 (EC: IDA, PMID: 16540464); GO_0005829 (EC: TAS); GO_0006013 (EC: IDA, PMID: 16540464); GO_0006488 (EC: TAS); GO_0009298 (EC: IEA); GO_0009298 (EC: TAS); GO_0018279 (EC: TAS); GO_0019307 (EC: IEA); GO_0043025 (EC: IEA); GO_0043687 (EC: TAS); GO_0044267 (EC: TAS); GO_0046872 (EC: IEA)",,,,,,,,,PMID: 9070917; 9119384; 9271215; 9376685; 9603909; 10085245; 10591208; 12477932; 12789572; 14702039; 15461802; 15489334; 16189514; 16540464; 17054774; 17186415; 18591914; 18854154; 18927083; 21078624; 21139048; 21890473; 21906983; 21988832; 23000965,,,,,,,,,,,,,,,OGG:3000005372,,,,,,,phosphomannomutase 1,,,,,,,,,,,,,"Other designations: PMM 1|PMMH-22|brain glucose-1,6-bisphosphatase",,PMM1,,,,,,,,,,,,,,,,,,,,,,,5372,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,PMM1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000581,IFN alpha-14,,,false,,,http://purl.obolibrary.org/obo/IMR_0100386,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000581,,,,,,,,,,,,,,,,,,,,,,IFN alpha-14,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010512,Heterogeneous nuclear ribonucleoprotein G,"hnRNP G|Glycoprotein p43|RNA binding motif protein, X chromosome|ROG",,false,,,http://purl.obolibrary.org/obo/IMR_0010024,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"hnRNP G|Glycoprotein p43|RNA binding motif protein, X chromosome|ROG",,,,,IMR:0010512,,,,,,,,,,,,,,,,,,,,,,Heterogeneous nuclear ribonucleoprotein G,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004518,Tumor cell proliferation [Hepatocarcinogenesis],,"Tumor cell proliferation is a subtype of cell proliferation: A process of the multiplication or reproduction of tumor cells, resulting in the rapid expansion of a tumor cell population.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0000339,,,,,,,,,,,,,,,,,,,,PMID:30205391|PMID:29335519|PMID:17428255|PMID:28036048|PMID:27093553|PMID:25649430|PMID:28706416,,"Tumor cell proliferation is a subtype of cell proliferation: A process of the multiplication or reproduction of tumor cells, resulting in the rapid expansion of a tumor cell population.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004930,,,,,,,,,,,,,,,,,TXPO:0004518,,,,,,,,,,,,,,,,,,,,,,Tumor cell proliferation [Hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004510,MSH2 - inactive form (canonical)[hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0005063|http://purl.obolibrary.org/obo/TXPO_0005099,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:81709|NCBI-Mouse-GeneID:17685|NCBI-Human-GeneID:4436|PMID:31781608,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0002355,,,,,,,,,,,,,,TXPO:0004510,,,,,,,,,,,,,,,,,,,,,,MSH2 - inactive form (canonical)[hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004514,Hyperfunction of DNA biosynthesis [hepatocarcinogenesis],,"Hyperfunction of DNA biosynthesis is a subtype of hyperfunction of biosynthesis: A process that performs an excessive DNA biosynthesis.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004515,,,,,,,,,,,,,,,,,,,,PMID:8106389,,"Hyperfunction of DNA biosynthesis is a subtype of hyperfunction of biosynthesis: A process that performs an excessive DNA biosynthesis.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004516,,,,,,,,,,,,,,,,,TXPO:0004514,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of DNA biosynthesis [hepatocarcinogenesis],,,,,,http://purl.obolibrary.org/obo/GO_0071897,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004517,DNA replication [hepatocarcinogenesis],,"The cellular metabolic process in which a cell duplicates one or more molecules of DNA. DNA replication begins when specific sequences, known as origins of replication, are recognized and bound by initiation proteins, and ends when the original DNA molecule has been completely duplicated and the copies topologically separated. The unit of replication usually corresponds to the genome of the cell, an organelle, or a virus. The template for replication can either be an existing DNA molecule or RNA.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/GO_0006260,,,,,,,,,,,,,,,,,,,,PMID:29270806|PMID:30166860,,"The cellular metabolic process in which a cell duplicates one or more molecules of DNA. DNA replication begins when specific sequences, known as origins of replication, are recognized and bound by initiation proteins, and ends when the original DNA molecule has been completely duplicated and the copies topologically separated. The unit of replication usually corresponds to the genome of the cell, an organelle, or a virus. The template for replication can either be an existing DNA molecule or RNA.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004519,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004518,,,,,,,,,,,TXPO:0004517,,,,,,,,,,,,,,,,,,,,,,DNA replication [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000304,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004511,MSH6 - inactive form (canonical) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0005101|http://purl.obolibrary.org/obo/TXPO_0005063,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:2956|NCBI-Rat-GeneID:100360342|NCBI-Mouse-GeneID:17688|PMID:31781608,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0002355,,,,,,,,,,,,,,TXPO:0004511,,,,,,,,,,,,,,,,,,,,,,MSH6 - inactive form (canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004512,induction of genomic instability [hepatocarcinogenesis],,"Any process that results in induction of genomic instability.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0004947|http://purl.obolibrary.org/obo/TXPO_0002340,,,,,,,,,,,,,,,,,,,,PMID:18245951|PMID:31781608,,"Any process that results in induction of genomic instability.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004392,,,,,,,,,,,TXPO:0004512,,,,,,,,,,,,,,,,,,,,,,induction of genomic instability [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004516,fumonisin B1 [hepatocarcinogenesis],"(2R,2'R)-2,2'-{[(5R,6R,7S,9S,11R,16R,18S,19S)-19-amino-11,16,18-trihydroxy-5,9-dimethylicosane-6,7-diyl]bis[oxy(2-oxoethane-2,1-diyl)]}dibutanedioic acid","A diester that results from the condensation of the 1-carboxy groups of two molecules of propane-1,2,3-tricarboxylic acid with hydroxy groups at positions 14 and 15 of (2S,3S,5R,10R,12S,14S,15R,16R)-2-amino-12,16-dimethylicosane-3,5,10,14,15-pentol.",false,,,http://purl.obolibrary.org/obo/TXPO_0004455|http://purl.obolibrary.org/obo/CHEBI_38221,,,,,,,,,,,,,,,,,,,,PMID:11359698|PMID:8106389|CAS:116355-83-0,,"A diester that results from the condensation of the 1-carboxy groups of two molecules of propane-1,2,3-tricarboxylic acid with hydroxy groups at positions 14 and 15 of (2S,3S,5R,10R,12S,14S,15R,16R)-2-amino-12,16-dimethylicosane-3,5,10,14,15-pentol.",,,,,,,,,,,,C34H59NO15,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"(2R,2'R)-2,2'-{[(5R,6R,7S,9S,11R,16R,18S,19S)-19-amino-11,16,18-trihydroxy-5,9-dimethylicosane-6,7-diyl]bis[oxy(2-oxoethane-2,1-diyl)]}dibutanedioic acid",,,,,TXPO:0004516,,,,,,,,,,,,,,,,,,,,,,fumonisin B1 [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CCCC[C@H]([C@H]([C@H](C[C@H](C[C@@H](CCCC[C@H](C[C@@H]([C@H](C)N)O)O)O)C)OC(C[C@@H](CC(=O)O)C(=O)O)=O)OC(=O)C[C@@H](CC(O)=O)C(=O)O)C,,,,,
http://purl.obolibrary.org/obo/TXPO_0004515,Hyperfunction of DNA biosynthesis,,Hyperfunction of DNA biosynthesis is a subtype of hyperfunction of biosynthesis: A process that performs an excessive DNA biosynthesis.,false,,,http://purl.obolibrary.org/obo/TXPO_0002346,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of DNA biosynthesis is a subtype of hyperfunction of biosynthesis: A process that performs an excessive DNA biosynthesis.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004515,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of DNA biosynthesis,,,,,,http://purl.obolibrary.org/obo/GO_0071897,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004513,2-acetamidofluorene [hepatocarcinogenesis],2-AAF|2-Acetylaminofluorene|N-(9H-fluoren-2-yl)acetamide,"The parent of the class of 2-acetamidofluorenes, being an ortho-fused polycyclic arene that consists of 9H-fluorene bearing an acetamido substituent at position 2. It is a carcinogenic and mutagenic derivative of fluorene.",false,,,http://purl.obolibrary.org/obo/TXPO_0004455|http://purl.obolibrary.org/obo/CHEBI_17356,,,,,,,,,,,,,,,,,,,,PMID:28932315|PMID:22584684|CAS:53-96-3|Wikipedia:2-Acetylaminofluorene,,"The parent of the class of 2-acetamidofluorenes, being an ortho-fused polycyclic arene that consists of 9H-fluorene bearing an acetamido substituent at position 2. It is a carcinogenic and mutagenic derivative of fluorene.",,,,,,,,,,,,C15H13NO,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,N-(9H-fluoren-2-yl)acetamide,,2-AAF|2-Acetylaminofluorene,,,TXPO:0004513,,,,,,,,,,,,,,,,,,,,,,2-acetamidofluorene [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,C(=O)(NC=1C=C2C(C=3C(C2)=CC=CC3)=CC1)C,,,,,
http://purl.obolibrary.org/obo/TXPO_0004519,FEN1 (human) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_1000515,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:2237,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000002237,,,,,,,,,,,,,TXPO:0004519,,,,,,,,,,,,,,,,,,,,,,FEN1 (human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0000639,degenerate (quality),,A structural quality inhering in a bearer whose structure deteriorates or is lost over time due to an active pathological process.,false,,,http://purl.obolibrary.org/obo/PATO_0002037,,,,,,,,,,,,,,,,,,,,,,A structural quality inhering in a bearer whose structure deteriorates or is lost over time due to an active pathological process.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0000639,,,,,,,,,,,,,,,,,,,,,,degenerate (quality),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0003014,Kif3A,,,false,,,http://purl.obolibrary.org/obo/IMR_0100193,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0003014,,,,,,,,,,,,,,,,,,,,,,Kif3A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100776,Wnt-8a,Wnt-8d,,false,,,http://purl.obolibrary.org/obo/IMR_0000003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Wnt-8d,,,,,IMR:0100776,,,,,,,,,,,,,,,,,,,,,,Wnt-8a,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0060290,Transdifferentiation,,The conversion of a differentiated cell of one fate into a differentiated cell of another fate without first undergoing cell division or reversion to a more primitive or stem cell-like fate.,false,,,http://purl.obolibrary.org/obo/GO_0030154,,,,,,,,,,,,,,,,,,,,Wikipedia:Transdifferentiation,,The conversion of a differentiated cell of one fate into a differentiated cell of another fate without first undergoing cell division or reversion to a more primitive or stem cell-like fate.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0060290,,,,,,,,,,,,,,,,,,,,,,Transdifferentiation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000057153,SLC44A2,,"Other designations: choline transporter-like protein 2|solute carrier family 44, member 2",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CTL2|PP1292,,,,,,,,,,,,19,,,,,,HPRD:16198|Ensembl:ENSG00000129353|MIM:606106|Vega:OTTHUMG00000180585|HGNC:17292,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"solute carrier family 44 (choline transporter), member 2",,,19p13.1,,,,,,,,,,,,,,,,"GO_0004871 (EC: IMP, PMID: 12761501); GO_0005765 (EC: IDA, PMID: 17897319); GO_0005886 (EC: TAS); GO_0006644 (EC: TAS); GO_0006656 (EC: TAS); GO_0007165 (EC: IMP, PMID: 12761501); GO_0015220 (EC: TAS, PMID: 10677542); GO_0015871 (EC: TAS, PMID: 10677542); GO_0016021 (EC: TAS, PMID: 10677542); GO_0043123 (EC: IMP, PMID: 12761501); GO_0044281 (EC: TAS); GO_0046474 (EC: TAS); GO_0055085 (EC: TAS); GO_0070062 (EC: IDA, PMID: 19056867)",,,,,,,,,PMID: 8619474; 9110174; 10677542; 12477932; 12761501; 14702039; 14973250; 15489334; 15715662; 16303743; 16344560; 17897319; 17926100; 18029348; 19056867; 20037594; 20040764; 20410607; 20665236; 21048031; 21564101; 21906983; 22040064; 22211383; 22414054; 23398146; 24250222,,,,,,,,,,,,,,,OGG:3000057153,,,,,,,"solute carrier family 44 (choline transporter), member 2",,,,,,,,,,,,,"Other designations: choline transporter-like protein 2|solute carrier family 44, member 2",,SLC44A2,,,,,,,,,,,,,,,,,,,,,,,57153,PSEC0210,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,SLC44A2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_50122,rosiglitazone,"LINCS:LSM-1949|5-(4-{2-[methyl(pyridin-2-yl)amino]ethoxy}benzyl)-1,3-thiazolidine-2,4-dione",,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Wikipedia:Rosiglitazone|CAS:122320-73-4|DrugBank:DB00412,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"LINCS:LSM-1949|5-(4-{2-[methyl(pyridin-2-yl)amino]ethoxy}benzyl)-1,3-thiazolidine-2,4-dione",,,,,CHEBI:50122,,,,,,,,,,,,,,,,,,,,,,rosiglitazone,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,,,,,
http://purl.obolibrary.org/obo/GO_0034976,response to endoplasmic reticulum stress,ER stress response|cellular response to endoplasmic reticulum stress|response to ER stress,"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stress acting at the endoplasmic reticulum. ER stress usually results from the accumulation of unfolded or misfolded proteins in the ER lumen.",false,,,http://purl.obolibrary.org/obo/GO_0006950,,,,,,,,,,,,,,,,,,,,,,"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stress acting at the endoplasmic reticulum. ER stress usually results from the accumulation of unfolded or misfolded proteins in the ER lumen.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ER stress response|cellular response to endoplasmic reticulum stress|response to ER stress,,,,,GO:0034976,,,,,,,,,,,,,,,,,,,,,,response to endoplasmic reticulum stress,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_36711,phosphoethanolamine,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25710,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:36711,,,,,,,,,,,,,,,,,,,,,,phosphoethanolamine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000260293,CYP4X1,,Other designations: cytochrome P450 4X1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CYPIVX1,,,,,,,,,,,,1,,,,,,Ensembl:ENSG00000186377|HPRD:13110|Vega:OTTHUMG00000008017|MIM:614999|HGNC:20244,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 4, subfamily X, polypeptide 1",,,1p33|1,,,,,,,,,,,,,,,,GO_0005506 (EC: IEA); GO_0005789 (EC: IEA); GO_0016021 (EC: IEA); GO_0020037 (EC: IEA); GO_0070330 (EC: IEA),,,,,,,,,PMID:12176035; 12477932; 12975309; 14702039; 15128046; 15489334; 15797250; 21890473,,,,,,,,,,,,,,,OGG:3000260293,,,,,,,"cytochrome P450, family 4, subfamily X, polypeptide 1",,,,,,,,,,,,,Other designations: cytochrome P450 4X1,,CYP4X1,,,,,,,,,,,,,,,,,,,,,,,260293,RP11-184J23.1,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP4X1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_421707,abacavir,"{(1S-cis)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl}methanol|abacavir|ABC|{(1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl}methanol|Abacavir","A 2,6-diaminopurine that is (1S)-cyclopent-2-en-1-ylmethanol in which the pro-R hydrogen at the 4-position is substituted by a 2-amino-6-(cyclopropylamino)-9H-purin-9-yl group. A nucleoside analogue reverse transcriptase inhibitor (NRTI) with antiretroviral activity against HIV, it is used (particularly as the sulfate) with other antiretrovirals in combination therapy of HIV infection.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:11806176|PMID:15887959|PMID:18029175|PMID:11678376|PMID:16458506|PMID:25017682|Drug_Central:34|PMID:16759112|PMID:12781181|PMID:26024233|PMID:17172311|PMID:25674793|PMID:24751900|PMID:17870541|PMID:16539393|PMID:18549801|Reaxys:7493116|Beilstein:7493116|CAS:136470-78-5|DrugBank:DB01048,,"A 2,6-diaminopurine that is (1S)-cyclopent-2-en-1-ylmethanol in which the pro-R hydrogen at the 4-position is substituted by a 2-amino-6-(cyclopropylamino)-9H-purin-9-yl group. A nucleoside analogue reverse transcriptase inhibitor (NRTI) with antiretroviral activity against HIV, it is used (particularly as the sulfate) with other antiretrovirals in combination therapy of HIV infection.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_53756|http://purl.obolibrary.org/obo/CHEBI_88188|http://purl.obolibrary.org/obo/CHEBI_36044,,,,,"{(1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl}methanol|Abacavir",,{(1S-cis)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl}methanol|abacavir|ABC,,,,,,,,,,,,,,,,,,,,,CHEBI:421707,,,,abacavir,,CHEBI:421707,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001613,Rab27B,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001613,,,,,,,,,,,,,,,,,,,,,,Rab27B,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001023,"High-affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A",,,false,,,http://purl.obolibrary.org/obo/IMR_0100002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001023,,,,,,,,,,,,,,,,,,,,,,"High-affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000021,TNF superfamily,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,IPR:006052|GO:0005164,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000622,,,,,,,,,,IMR:0000021,,,,,,,,,,,,,,,,,,,,,,TNF superfamily,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_24621,hormone,endocrine|hormones,"Originally referring to an endogenous compound that is formed in specialized organ or group of cells and carried to another organ or group of cells, in the same organism, upon which it has a specific regulatory function, the term is now commonly used to include non-endogenous, semi-synthetic and fully synthetic analogues of such compounds.|substance with hormone role:
http://purl.bioontology.org/ontology/STY/T125",false,,,http://purl.obolibrary.org/obo/CHEBI_48705|http://purl.obolibrary.org/obo/CHEBI_33280,,,,,,,,,,,,,,,,,,,,GO:0005180,,"Originally referring to an endogenous compound that is formed in specialized organ or group of cells and carried to another organ or group of cells, in the same organism, upon which it has a specific regulatory function, the term is now commonly used to include non-endogenous, semi-synthetic and fully synthetic analogues of such compounds.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,endocrine|hormones,,,,,,,,,,,,,,,,,,,,,CHEBI:24621,,"substance with hormone role:
http://purl.bioontology.org/ontology/STY/T125",,hormone,,CHEBI:24621,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000022826,DNAJC8,,Other designations: dnaJ homolog subfamily C member 8|splicing protein spf31,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,SPF31|HSPC331,,,,,,,,,,,,1,,,,,,HPRD:13236|Vega:OTTHUMG00000003538|HGNC:15470|Ensembl:ENSG00000126698,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"DnaJ (Hsp40) homolog, subfamily C, member 8",,,1p35.3,,,,,,,,,,,,,,,,GO_0000398 (EC: TAS); GO_0005654 (EC: TAS); GO_0008380 (EC: TAS); GO_0010467 (EC: TAS),,,,,,,,,PMID:11147971; 11790298; 12226669; 12234937; 12477932; 15489334; 15635413; 16159877; 16344560; 16710414; 17332742; 18850631; 19471022; 20098747; 20360068; 20379614; 21139048; 21693764; 21832049; 21890473; 22863883; 22939629; 22944692; 23602568; 23940030; 24163370,,,,,,,,,,,,,,,OGG:3000022826,,,,,,,"DnaJ (Hsp40) homolog, subfamily C, member 8",,,,,,,,,,,,,Other designations: dnaJ homolog subfamily C member 8|splicing protein spf31,,DNAJC8,,,,,,,,,,,,,,,,,,,,,,,22826,HSPC315,,,,,,,9606,,,,,,,,,,,,,,,,,,,DNAJC8,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000715,PLCbeta2,phospholipase C beta 2,,false,,,http://purl.obolibrary.org/obo/IMR_0000286,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,phospholipase C beta 2,,,,,IMR:0000715,,,,,,,,,,,,,,,,,,,,,,PLCbeta2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_35674,antihypertensive agent,antihypertensive drug|antihypertensive|antihypertensive agents|antihypertensive drugs,Any drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.,false,,,http://purl.obolibrary.org/obo/CHEBI_35554,,,,,,,,,,,,,,,,,,,,,,Any drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,antihypertensive drug|antihypertensive|antihypertensive agents|antihypertensive drugs,,,,,,,,,,,,,,,,,,,,,CHEBI:35674,,,,antihypertensive agent,,CHEBI:35674,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_25212,metabolite,secondary metabolites|metabolites|primary metabolites|metabolite,Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.,false,,,http://purl.obolibrary.org/obo/CHEBI_52206,,,,,,,,,,,,,,,,,,,,,,Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,metabolite,,secondary metabolites|metabolites|primary metabolites,,,,,,,,,,,,,,,,,,,,,CHEBI:25212,,,,metabolite,,CHEBI:25212,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100206,Ran GAP,Ran GTPase-activating protein,,false,,,http://purl.obolibrary.org/obo/IMR_0000442,,,,,,,,,,,,,,,,,,,,GO:0005098,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ran GTPase-activating protein,,,,,IMR:0100206,,,,,,,,,,,,,,,,,,,,,,Ran GAP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000004763,NF1,,Other designations: neurofibromatosis-related protein NF-1|neurofibromin,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,VRNF|NFNS|WSS,,,,,,,,,,,,17,,,,,,Vega:OTTHUMG00000132871|HPRD:01203|Ensembl:ENSG00000196712|HGNC:7765|MIM:613113,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,neurofibromin 1,,,17q11.2,,,,,,,,,,,,,,,,"GO_0000165 (EC: ISS); GO_0001649 (EC: ISS); GO_0001656 (EC: ISS); GO_0001666 (EC: ISS); GO_0001889 (EC: ISS); GO_0001937 (EC: IMP, PMID: 16648142); GO_0001938 (EC: IEA); GO_0001952 (EC: ISS); GO_0001953 (EC: IEA); GO_0005099 (EC: IDA, PMID: 1568247); GO_0005515 (EC: IPI, PMID: 11356864); GO_0005634 (EC: ISS, PMID: 1550670); GO_0005737 (EC: IBA); GO_0005737 (EC: ISS, PMID: 1550670); GO_0006469 (EC: ISS); GO_0007154 (EC: ISS); GO_0007265 (EC: ISS); GO_0007406 (EC: ISS); GO_0007420 (EC: ISS); GO_0007422 (EC: ISS); GO_0007507 (EC: ISS); GO_0007519 (EC: IEA); GO_0008429 (EC: IDA, PMID: 17187824); GO_0008542 (EC: ISS); GO_0008625 (EC: IEA); GO_0014044 (EC: ISS); GO_0014065 (EC: ISS); GO_0016525 (EC: IEA); GO_0021510 (EC: ISS); GO_0021897 (EC: ISS); GO_0021915 (EC: IEA); GO_0021987 (EC: ISS); GO_0022011 (EC: ISS); GO_0030036 (EC: ISS); GO_0030198 (EC: ISS); GO_0030199 (EC: ISS); GO_0030325 (EC: ISS); GO_0030336 (EC: IMP, PMID: 16648142); GO_0030424 (EC: IDA, PMID: 1550670); GO_0030425 (EC: IDA, PMID: 1550670); GO_0031210 (EC: IDA, PMID: 17187824); GO_0031235 (EC: IBA); GO_0032228 (EC: IEA); GO_0032318 (EC: IMP, PMID: 1570015); GO_0032320 (EC: IDA, PMID: 2121371); GO_0032320 (EC: IMP, PMID: 16648142); GO_0032320 (EC: ISS); GO_0035021 (EC: IEA); GO_0042060 (EC: ISS); GO_0042992 (EC: ISS); GO_0043065 (EC: ISS); GO_0043407 (EC: ISS); GO_0043409 (EC: IMP, PMID: 16648142); GO_0043409 (EC: ISS); GO_0043473 (EC: ISS); GO_0043525 (EC: ISS); GO_0043535 (EC: IMP, PMID: 17404841); GO_0045124 (EC: ISS); GO_0045671 (EC: IEA); GO_0045685 (EC: ISS); GO_0045762 (EC: ISS); GO_0045765 (EC: IMP, PMID: 17404841); GO_0046580 (EC: IBA); GO_0046929 (EC: IEA); GO_0048147 (EC: ISS); GO_0048169 (EC: IEA); GO_0048485 (EC: ISS); GO_0048593 (EC: ISS); GO_0048712 (EC: IEA); GO_0048715 (EC: ISS); GO_0048745 (EC: ISS); GO_0048844 (EC: ISS); GO_0048853 (EC: ISS); GO_0050890 (EC: IMP, PMID: 17299016); GO_1902043 (EC: IEA); GO_2001241 (EC: IEA)",,,,,,,,,PMID: 1302608; 1329097; 1339276; 1457041; 1550670; 1568247; 1570015; 1662505; 1715669; 1719426; 1745350; 1757093; 1783401; 1923522; 1937470; 2114220; 2116237; 2121370; 2121371; 2125369; 2134734; 2491776; 7519874; 7570581; 7633431; 7633452; 7649559; 7686513; 7774960; 7874161; 7903661; 7904209; 7959746; 7981679; 7981724; 8069310; 8081387; 8176268; 8317503; 8417346; 8544190; 8602361; 8619474; 8628317; 8664912; 8807336; 8825042; 8825634; 8834249; 8836031; 8931693; 9002664; 9003501; 9101300; 9110174; 9150739; 9298829; 9300663; 9529361; 9639526; 9668168; 9706718; 10220149; 10336779; 10553997; 10607834; 10625171; 10712197; 10721668; 10862698; 11140831; 11258625; 11356864; 11704931; 11727199; 11727265; 11735023; 11748857; 11751683; 11754043; 11857752; 11896214; 11896613; 11934389; 12073021; 12077339; 12095621; 12152785; 12191989; 12199909; 12368469; 12387455; 12438263; 12477932; 12483293; 12522551; 12552569; 12566521; 12660952; 12707950; 12730209; 12746402; 12807981; 12872266; 12963615; 13679444; 13680360; 14647436; 14722914; 14988005; 15096131; 15146197; 15146469; 15233998; 15302935; 15342556; 15371411; 15389774; 15520408; 15523626; 15523642; 15583390; 15627836; 15735964; 15767669; 15944227; 15988004; 15999204; 16005615; 16081245; 16083285; 16116616; 16138909; 16169856; 16199547; 16344560; 16374483; 16380919; 16405917; 16467218; 16470740; 16479075; 16565220; 16644864; 16648142; 16741618; 16773574; 16813595; 16830335; 16835260; 16835897; 16908010; 16914719; 16944271; 16944272; 17036045; 17053831; 17096025; 17102080; 17160901; 17187824; 17200120; 17216419; 17295913; 17299016; 17353900; 17404841; 17426081; 17514731; 17563086; 17581973; 17668375; 17726231; 17876295; 17880527; 17914445; 17960768; 17999360; 18021924; 18055911; 18086893; 18172006; 18183042; 18212816; 18214791; 18215124; 18218617; 18316778; 18331998; 18407053; 18484666; 18485440; 18503770; 18511569; 18546366; 18592002; 18802710; 18948576; 19041782; 19048115; 19061981; 19120036; 19142971; 19144660; 19215943; 19220708; 19221814; 19238080; 19291764; 19292874; 19351817; 19417008; 19449407; 19601812; 19650418; 19718661; 19773259; 19845691; 19913121; 19940123; 20002172; 20006588; 20015894; 20052761; 20082856; 20124472; 20129251; 20160012; 20160346; 20164853; 20301288; 20358387; 20379614; 20422842; 20428205; 20435627; 20442305; 20503322; 20505189; 20513137; 20543202; 20571392; 20587590; 20602485; 20624961; 20628086; 20655465; 20680410; 20687928; 20725927; 20927530; 21048031; 21089070; 21139048; 21142935; 21157378; 21199919; 21236316; 21244408; 21278392; 21280148; 21283084; 21337692; 21365283; 21478499; 21551249; 21674567; 21728811; 21732117; 21782795; 21890473; 21903422; 21931722; 21963094; 22015770; 22096509; 22105171; 22108604; 22125493; 22190464; 22207399; 22240541; 22241097; 22250039; 22293200; 22294457; 22354384; 22399775; 22412049; 22488919; 22573716; 22581253; 22585738; 22586326; 22700876; 22751498; 22807134; 22837079; 22925204; 22945628; 22962301; 22965642; 22965773; 23000965; 23010473; 23047742; 23077663; 23082153; 23135915; 23145129; 23165953; 23171796; 23222849; 23244495; 23288408; 23292448; 23312374; 23335975; 23437333; 23455922; 23460398; 23481210; 23528211; 23583712; 23624750; 23668869; 23906300; 23947441; 24249802; 24250222; 24255178,,,,,,,,,,,,,,,OGG:3000004763,,,,,,,neurofibromin 1,,,,,,,,,,,,,Other designations: neurofibromatosis-related protein NF-1|neurofibromin,,NF1,,,,,,,,,,,,,,,,,,,,,,,4763,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,NF1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000452,BAK,,,false,,,http://purl.obolibrary.org/obo/IMR_0100708,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000452,,,,,,,,,,,,,,,,,,,,,,BAK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001126,chondroitin sulfate proteoglycan,chondroitin sulfate proteoglycan,,false,,,http://purl.obolibrary.org/obo/IMR_0000552,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,chondroitin sulfate proteoglycan,,,,,IMR:0001126,,,,,,,,,,,,,,,,,,,,,,chondroitin sulfate proteoglycan,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000438,cytohesin,,,false,,,http://purl.obolibrary.org/obo/IMR_0000433,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000438,,,,,,,,,,,,,,,,,,,,,,cytohesin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000008637,EIF4EBP3,,Other designations: eIF4E-binding protein 3|eukaryotic initiation factor 4E-binding protein 3|eukaryotic translation initiation factor 4E-binding protein 3,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,4E-BP3|4EBP3,,,,,,,,,,,,5,,,,,,Ensembl:ENSG00000243056|MIM:603483|HGNC:3290|Vega:OTTHUMG00000129498|HPRD:09149,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,eukaryotic translation initiation factor 4E binding protein 3,,,5q31.3,,,,,,,,,,,,,,,,"GO_0005515 (EC: IPI, PMID:15153109); GO_0008190 (EC: IEA); GO_0016281 (EC: NAS, PMID:9593750); GO_0030371 (EC: NAS, PMID:9593750); GO_0045947 (EC: NAS, PMID:9593750)",,,,,,,,,PMID:9593750; 11865047; 12477932; 12482586; 14507920; 14557257; 15153109; 15489334; 16189514; 16271312; 17316564; 19615732; 20621385; 21088106; 21145461; 22684010,,,,,,,,,,,,,,,OGG:3000008637,,,,,,,eukaryotic translation initiation factor 4E binding protein 3,,,,,,,,,,,,,Other designations: eIF4E-binding protein 3|eukaryotic initiation factor 4E-binding protein 3|eukaryotic translation initiation factor 4E-binding protein 3,,EIF4EBP3,,,,,,,,,,,,,,,,,,,,,,,8637,,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF4EBP3,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0003642,Niemann–Pick disease dependent process [diabetes course],,Niemann–Pick disease dependent process is a subtype of disease course dependent process: A process that can constitute the course of Niemann–Pick disease.,false,,,http://purl.obolibrary.org/obo/TXPO_0000808,,,,,,,,,,,,,,,,,,,,,,Niemann–Pick disease dependent process is a subtype of disease course dependent process: A process that can constitute the course of Niemann–Pick disease.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003642,,,,,,,,,,,,,,,,,,,,,,Niemann–Pick disease dependent process [diabetes course],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003647,phospholipid metabolic regulator role,,A role played by the entity which regulates the formation of phospholipids.,false,,,http://purl.obolibrary.org/obo/TXPO_0002358,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006644,,,,,,,,,,,,,A role played by the entity which regulates the formation of phospholipids.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003647,,,,,,,,,,,,,,,,,,,,,,phospholipid metabolic regulator role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003646,acute phase  responses by cytokines,,"An early local inflammatory reaction to insult or injury that consists of fever, an increase in inflammatory humoral factors, and an increased synthesis by hepatocytes of a number of proteins or glycoproteins usually found in the plasma.",false,,,http://purl.obolibrary.org/obo/GO_0006955,,,,,,,,,,,,,,,,,,,,http://purl.bioontology.org/ontology/MESH/D000210|http://purl.bioontology.org/ontology/MEDDRA/10048998,,"An early local inflammatory reaction to insult or injury that consists of fever, an increase in inflammatory humoral factors, and an increased synthesis by hepatocytes of a number of proteins or glycoproteins usually found in the plasma.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003646,,,,,,,,,,,,,,,,,,,,,,acute phase  responses by cytokines,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003649,STAT1 (canonical)[Fibrosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003750|http://purl.obolibrary.org/obo/IMR_0000375,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:20846|NCBI-Human-GeneID:6772|NCBI-Rat-GeneID:25124,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003649,,,,,,,,,,,,,,,,,,,,,,STAT1 (canonical)[Fibrosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003644,transcription elongation regulation factor,transcriptional elongation factor,A role played by the entity that regulates transcriptional elongation by enabling the transition from transcription initiation to elongation or by altering the elongation properties of the enzyme during the elongation phase of transcription.|related molecular function GO:0003711,false,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,,,,,,,,,,,,,,,,,,A role played by the entity that regulates transcriptional elongation by enabling the transition from transcription initiation to elongation or by altering the elongation properties of the enzyme during the elongation phase of transcription.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,transcriptional elongation factor,,,,,TXPO:0003644,,,,,,,,,,,,,,,,,,,,related molecular function GO:0003711,,transcription elongation regulation factor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003643,NFKB (canonical)[Fibrosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003750|http://purl.obolibrary.org/obo/TXPO_1000258,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003643,,,,,,,,,,,,,,,,,,,,,,NFKB (canonical)[Fibrosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003640,phosphholipid binding by phospholipase,,Phosphholipid binding by phospholipase is a subtype of phospholipid binding: Interacting selectively and non-covalently with phospholipids byphospholipases.,false,,,http://purl.obolibrary.org/obo/GO_0005543,,,,,,,,,,,,,,,,,,,,,,Phosphholipid binding by phospholipase is a subtype of phospholipid binding: Interacting selectively and non-covalently with phospholipids byphospholipases.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003640,,,,,,,,,,,,,,,,,,,,,,phosphholipid binding by phospholipase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003645,transcription factor,,A role played by the entity to initiate or regulate transcription.|This term is sometimes used for both gene regulatory proteins as well as the general transcription factors.,false,,,http://purl.obolibrary.org/obo/TXPO_0003715,,,,,,,,,,,,,,,,,,,,IMR:0000368 (obsolete),,A role played by the entity to initiate or regulate transcription.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003645,,,,,,,,,,,,,,,,,,,,This term is sometimes used for both gene regulatory proteins as well as the general transcription factors.,,transcription factor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003641,protein dimerization,,"Protein dimerization is a subtype of protein polymerization: The formation of a protein dimer, a macromolecular structure consists of two noncovalently associated identical or nonidentical subunits.",false,,,http://purl.obolibrary.org/obo/GO_0051258,,,,,,,,,,,,,,,,,,,,,,"Protein dimerization is a subtype of protein polymerization: The formation of a protein dimer, a macromolecular structure consists of two noncovalently associated identical or nonidentical subunits.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003641,,,,,,,,,,,,,,,,,,,,,,protein dimerization,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003648,fatty accid metabolic regulator role,,A role played by the entity which regulates fatty acid metabolic process.,false,,,http://purl.obolibrary.org/obo/TXPO_0004023,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006631,,,,,,,,,,,,,A role played by the entity which regulates fatty acid metabolic process.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003648,,,,,,,,,,,,,,,,,,,,,,fatty accid metabolic regulator role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0044839,cell cycle G2/M phase transition,,The cell cycle process by which a cell in G2 phase commits to M phase.,false,,,http://purl.obolibrary.org/obo/GO_0044770,,,,,,,,,,,,,,,,,,,,,,The cell cycle process by which a cell in G2 phase commits to M phase.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0044839,,,,,,,,,,,,,,,,,,,,,,cell cycle G2/M phase transition,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0044838,cell quiescence,,"A specialized resting state that cells enter in response to cues from the cell's environment. Quiescence is characterized by the absence of cell growth and division, by a reprogramming of global gene expression, and by changes characteristic of the organism and specific cell type. Depending on external conditions, quiescence may persist until cell death or cells may resume cell growth and division. In some cell types or under certain conditions, cellular metabolism may proceed.",false,,,http://purl.obolibrary.org/obo/GO_0022403,,,,,,,,,,,,,,,,,,,,,,"A specialized resting state that cells enter in response to cues from the cell's environment. Quiescence is characterized by the absence of cell growth and division, by a reprogramming of global gene expression, and by changes characteristic of the organism and specific cell type. Depending on external conditions, quiescence may persist until cell death or cells may resume cell growth and division. In some cell types or under certain conditions, cellular metabolism may proceed.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0044838,,,,,,,,,,,,,,,,,,,,,,cell quiescence,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0032640,tumor necrosis factor production,,"The appearance of tumor necrosis factor due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.",false,,,http://purl.obolibrary.org/obo/GO_0071706,,TNF alpha production,,,,,,,,,,,,,,,,,,,,"The appearance of tumor necrosis factor due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.",,,,,tumor necrosis factor production,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0032640,,,,,,,,,,,,,,,,,,,,,,tumor necrosis factor production,,,,,,,http://purl.obolibrary.org/obo/go.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0000025,composition,,A single physical entity inhering in an bearer by virtue of the bearer's quantities or relative ratios of subparts,false,,,http://purl.obolibrary.org/obo/PATO_0000141,,,,,,,,,,,,,,,,,,,,,,A single physical entity inhering in an bearer by virtue of the bearer's quantities or relative ratios of subparts,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0000025,,,,,,,,,,,,,,,,,,,,,,composition,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002408,PLA2G5 (human)(canonical)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003213|http://purl.obolibrary.org/obo/TXPO_1000283,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:5322,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000283,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000005322,,,http://purl.obolibrary.org/obo/TXPO_0002289|http://purl.obolibrary.org/obo/TXPO_0003671,,,,,,,,,,TXPO:0002408,,,,,,,,,,,,,,,,,,,,,,PLA2G5 (human)(canonical)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0034638,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000795,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002405,BIP-stress sensor complex,,"BIP-stress sensor complex is a subtype of molecular complex.
This entity has sub-parts of molecules, BIP/GRP78 and other molecule which has role of stress sensor.",false,,,http://purl.obolibrary.org/obo/TXPO_0002107,,,,,,,,,,,,,,,,,,,,,,"BIP-stress sensor complex is a subtype of molecular complex.
This entity has sub-parts of molecules, BIP/GRP78 and other molecule which has role of stress sensor.",,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002385,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002405,,,,,,,,,,,,,,,,,,,,,,BIP-stress sensor complex,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002402,reduced glutathione biosynthetic promoting agent,,A role played by the entity  which positively regulates the reduced glutathione biosynthetic process,false,,,http://purl.obolibrary.org/obo/TXPO_0002400,,,,,,,,,,,,,,,,,,,,,,A role played by the entity  which positively regulates the reduced glutathione biosynthetic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002402,,,,,,,,,,,,,,,,,,,,,,reduced glutathione biosynthetic promoting agent,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002404,Keap1 inactivation [Glutathione depletion],,"Keap1 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the Keap1 to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0000889|http://purl.obolibrary.org/obo/TXPO_0002380,,,,,,,,,,,,,,,,,,,,,,"Keap1 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the Keap1 to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002407,,,http://purl.obolibrary.org/obo/TXPO_0002431,http://purl.obolibrary.org/obo/TXPO_0001172,,,,,,http://purl.obolibrary.org/obo/TXPO_0002216,,,,,,,,,,,TXPO:0002404,,,,,,,,,,,,,,,,,,,,,,Keap1 inactivation [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002403,release of cytochrome c from mitochondria [Cell death],,"The process that results in the movement of cytochrome c from the mitochondrial intermembrane space into the cytosol, which is part of the apoptotic signaling pathway and leads to caspase activation.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/GO_0001836|http://purl.obolibrary.org/obo/TXPO_0001727,,,,,,,,,,,,,,,,,,,,,,"The process that results in the movement of cytochrome c from the mitochondrial intermembrane space into the cytosol, which is part of the apoptotic signaling pathway and leads to caspase activation.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003737,,,,,,,,,,,TXPO:0002403,,,,,,,,,,,,,,,,,,,,,,release of cytochrome c from mitochondria [Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002400,glutathione biosynthetic promoting agent,,A role played by the entity  which positively regulates the glutathione biosynthetic process.,false,,,http://purl.obolibrary.org/obo/TXPO_0003654,,,,,,,,http://purl.obolibrary.org/obo/GO_0006750,,,,,,,,,,,,,,A role played by the entity  which positively regulates the glutathione biosynthetic process.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002400,,,,,,,,,,,,,,,,,,,,,,glutathione biosynthetic promoting agent,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002401,second messenger,,"A role played by small molecule that is formed in or released into the cytosol in response to an extracellular signal and helps to relay the signal to the interior of the cell. Examples include cAMP, IP3, and Ca++.",false,,,http://purl.obolibrary.org/obo/CHEBI_33280,,,,,,,,,,,,,,,,,,,,,,"A role played by small molecule that is formed in or released into the cytosol in response to an extracellular signal and helps to relay the signal to the interior of the cell. Examples include cAMP, IP3, and Ca++.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002401,,,,,,,,,,,,,,,,,,,,,,second messenger,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002407,Keap1 modification by electrophiles [Glutathione depletion],,"Keap1 modification by electrophiles is a subtype of oxidation by electrophiles.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0002377|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Keap1 modification by electrophiles is a subtype of oxidation by electrophiles.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000974,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002404,,,,,,,,,,,TXPO:0002407,,,,,,,,,,,,,,,,,,,,,,Keap1 modification by electrophiles [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002406,cell death modulator role,,A role played by the entity which regulates the process of cell death.,false,,,http://purl.obolibrary.org/obo/TXPO_0003230,,,,,,,,,http://purl.obolibrary.org/obo/GO_0008219,,,,,,,,,,,,,A role played by the entity which regulates the process of cell death.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002406,,,,,,,,,,,,,,,,,,,,,,cell death modulator role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002409,electrophiles formation [cell death],,"Electrophiles formation is a subtype of biosynthetic process: A process that that generates electrophiles. Electrophile is a reagent that forms a bond to its reaction partner (the nucleophile) by accepting both bonding electrons from that reaction partner.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0001727|http://purl.obolibrary.org/obo/TXPO_0000212,,,,,,,,,,,,,,,,,,,,,,"Electrophiles formation is a subtype of biosynthetic process: A process that that generates electrophiles. Electrophile is a reagent that forms a bond to its reaction partner (the nucleophile) by accepting both bonding electrons from that reaction partner.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003344,,,,,,,,,,,TXPO:0002409,,,,,,,"A number of xenobiotics exert a toxic effect theough their metabolites.
Electrophiles are molecules that contain an electron-deficient atom with a partial or full positive charge that can react by sharing electron pairs with electron rich atoms in nucleophiles.
Electrophilic toxicants generally are detoxificated by conjugation of with the nucleophile, glutathione.
This reaction can be facilitated by glutathione S-trasferases.",,,,,,,,,,,,,,,electrophiles formation [cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_26519,radical,free radical,A molecular entity possessing an unpaired electron.,false,,,http://purl.obolibrary.org/obo/CHEBI_23367,,,,,,,,,,,,,,,,,,,,,,A molecular entity possessing an unpaired electron.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,free radical,,,,,CHEBI:26519,,,,,,,,,,,,,,,,,,,,,,radical,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0009062,fatty acid catabolic process,fatty acid degradation|fatty acid catabolism,"The chemical reactions and pathways resulting in the breakdown of a fatty acid, any of the aliphatic monocarboxylic acids that can be liberated by hydrolysis from naturally occurring fats and oils. Fatty acids are predominantly straight-chain acids of 4 to 24 carbon atoms, which may be saturated or unsaturated; branched fatty acids and hydroxy fatty acids also occur, and very long chain acids of over 30 carbons are found in waxes.",false,,,http://purl.obolibrary.org/obo/GO_0016042,,,,,,,,,,,,,,,,,,,,Wikipedia:Fatty_acid_degradation,,"The chemical reactions and pathways resulting in the breakdown of a fatty acid, any of the aliphatic monocarboxylic acids that can be liberated by hydrolysis from naturally occurring fats and oils. Fatty acids are predominantly straight-chain acids of 4 to 24 carbon atoms, which may be saturated or unsaturated; branched fatty acids and hydroxy fatty acids also occur, and very long chain acids of over 30 carbons are found in waxes.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000834,,,,,http://purl.obolibrary.org/obo/GO_0019395,,,,,,,,,,,,,fatty acid degradation|fatty acid catabolism,,,,,GO:0009062,,,,,,,,,,,,,,,,,,,,,,fatty acid catabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000387,IRF-1,interferon regulatory factor-1,,false,,,http://purl.obolibrary.org/obo/IMR_0000386,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,interferon regulatory factor-1,,,,,IMR:0000387,,,,,,,,,,,,,,,,,,,,,,IRF-1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001536,time attribute,,An attribute in which events occur in sequence.,false,,,http://purl.obolibrary.org/obo/TXPO_0000305,,,,,,,,,,,,,,,,,,,,,,An attribute in which events occur in sequence.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001536,,,,,,,,,,,,,,,,,,,,,,time attribute,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001530,JNK activation by IRE1 [ER stress],,"JNK activation by IRE1 is a subtype of JNK activation: A process that changes the activity of the JNK to be higher by IRE1.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001527,,,,,,,,,,,,,,,,,,,,,,"JNK activation by IRE1 is a subtype of JNK activation: A process that changes the activity of the JNK to be higher by IRE1.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002601,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001813,,,,,,,,,,,,,,,,,,,TXPO:0001530,,,,,,,,,,,,,,,,,,,,,,JNK activation by IRE1 [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001533,PERK-eIF2a-ATF4 signal integration system,,"PERK-eIF2a-ATF4 signal integration system is a subtype of PERK pathway system.
This entity has sub-parts and has a goal of transmitting signals and a gene regulation via PERK, eIF2a, and ATF4 as a systemic context.",false,,,http://purl.obolibrary.org/obo/TXPO_0001529,,,,,,,,,,,,,,,,,,,,,,"PERK-eIF2a-ATF4 signal integration system is a subtype of PERK pathway system.
This entity has sub-parts and has a goal of transmitting signals and a gene regulation via PERK, eIF2a, and ATF4 as a systemic context.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001211|http://purl.obolibrary.org/obo/TXPO_0001414,,,,,,,,,,,,,,,,,,,,,,TXPO:0001533,,,,,,,,,,,,,,,,,,,,,,PERK-eIF2a-ATF4 signal integration system,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001535,Niemann–Pick disease type C,,The totality of all processes through which the Niemann–Pick disease type C is realized. This causal process is heredity.|under construction,false,,,http://purl.obolibrary.org/obo/TXPO_0003587|http://purl.obolibrary.org/obo/TXPO_0000888,,,,,,,,,,,,,,,,,,,,PMID:18953351|https://omim.org/entry/257220|https://omim.org/entry/607623|https://ghr.nlm.nih.gov/condition/niemann-pick-disease#genes|PMID:21502308|https://omim.org/entry/607625|PMID:9211850,,The totality of all processes through which the Niemann–Pick disease type C is realized. This causal process is heredity.,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001538,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001557|http://purl.obolibrary.org/obo/TXPO_0001556|http://purl.obolibrary.org/obo/TXPO_0001177|http://purl.obolibrary.org/obo/TXPO_0001538,,,,,,,,,,,,,,,,,,TXPO:0001535,,,,,,,,,,,,,,,,,,,,under construction,,Niemann–Pick disease type C,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/DOID_0070114|http://purl.obolibrary.org/obo/DOID_0070113,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001531,trannscriptional repressor,,"A role that represses the rate, timing and/or magnitude of transcription of genetic information.",false,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,,,,,,,,,,,,,,,,,,"A role that represses the rate, timing and/or magnitude of transcription of genetic information.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001531,,,,,,,,,,,,,,,,,,,,,,trannscriptional repressor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001537,lysosomal cholesterol storage,,Lysosomal cholesterol storage is a subtype of cholesterol storage: A process that keeps cholesterol in the lysosome.,false,,,http://purl.obolibrary.org/obo/GO_0010878,,,,,,,,,,,,,,,,,,,,,,Lysosomal cholesterol storage is a subtype of cholesterol storage: A process that keeps cholesterol in the lysosome.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001537,,,,,,,,,,,,,,,,,,,,,,lysosomal cholesterol storage,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001538,lysosomal cholesterol storage [Niemann Pick Disease Type C],,"Lysosomal cholesterol storage is a subtype of cholesterol storage: A process that keeps cholesterol in the lysosome.
This entity is a specific course-dependent process. This process can constitute the course of Niemann-Pick Disease Type C.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0001537,,,,,,,,,,,,,,,,,,,,,,"Lysosomal cholesterol storage is a subtype of cholesterol storage: A process that keeps cholesterol in the lysosome.
This entity is a specific course-dependent process. This process can constitute the course of Niemann-Pick Disease Type C.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001538,,,,,,,,,,,,,,,,,,,,,,lysosomal cholesterol storage [Niemann Pick Disease Type C],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001532,AP1M2 (human)[Phospholipidosis],Adaptor Related Protein Complex 1 Mu 2 Subunit [Phospholipidosis],Subunit of clathrin-associated adaptor protein complex 1 that plays a role in protein sorting in the trans-Golgi network (TGN) and endosomes. The AP complexes mediate the recruitment of clathrin to membranes and the recognition of sorting signals within the cytosolic tails of transmembrane cargo molecules.,false,,,http://purl.obolibrary.org/obo/TXPO_1000003|http://purl.obolibrary.org/obo/TXPO_0001135,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:10053|PMID:12914695|http://omim.org/entry/607309|PMID:17261850|PMID:2335054,,Subunit of clathrin-associated adaptor protein complex 1 that plays a role in protein sorting in the trans-Golgi network (TGN) and endosomes. The AP complexes mediate the recruitment of clathrin to membranes and the recognition of sorting signals within the cytosolic tails of transmembrane cargo molecules.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000010053,,,http://purl.obolibrary.org/obo/TXPO_0003638,,,,,Adaptor Related Protein Complex 1 Mu 2 Subunit [Phospholipidosis],,,,,TXPO:0001532,,,,,,,,,,,,,,,,,,,,,,AP1M2 (human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001539,Dysfunction of mitochondrial fatty acid beta-oxidation (severe) [Lipidosis],,"Dysfunction of mitochondrial fatty acid beta-oxidation (severe) is a subtype of hypofunction of fatty acid beta-oxidation: A process that performs a decreased or insufficient fatty acid beta-oxidation severely.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000901,,,,,,,,,,,,,,,,,,,,,,"Dysfunction of mitochondrial fatty acid beta-oxidation (severe) is a subtype of hypofunction of fatty acid beta-oxidation: A process that performs a decreased or insufficient fatty acid beta-oxidation severely.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003361,,,,,,,,,,,TXPO:0001539,,,,,,,,,,,,,,,,,,,,,,Dysfunction of mitochondrial fatty acid beta-oxidation (severe) [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001534,sorting cargo transport signal,,Sorting cargo transport signal is a subtype of extractng: A process that obtains a necessary cargo transport signal.,false,,,http://purl.obolibrary.org/obo/TXPO_0002578,,,,,,,,,,,,,,,,,,,,PMID:12914695,,Sorting cargo transport signal is a subtype of extractng: A process that obtains a necessary cargo transport signal.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001534,,,,,,,,,,,,,,,,,,,,,,sorting cargo transport signal,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0040029,"regulation of gene expression, epigenetic",,"Any process that modulates the frequency, rate or extent of gene expression; the process is mitotically or meiotically heritable, or is stably self-propagated in the cytoplasm of a resting cell, and does not entail a change in DNA sequence.",false,,,http://purl.obolibrary.org/obo/GO_0010468,,,,,,,,,,,,,,,,,,,,,,"Any process that modulates the frequency, rate or extent of gene expression; the process is mitotically or meiotically heritable, or is stably self-propagated in the cytoplasm of a resting cell, and does not entail a change in DNA sequence.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0040029,,,,,,,,,,,,,,,,,,,,,,"regulation of gene expression, epigenetic",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0002091,IgA,immunoglobulin A,,false,,,http://purl.obolibrary.org/obo/IMR_0002090,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,immunoglobulin A,,,,,IMR:0002091,,,,,,,,,,,,,,,,,,,,,,IgA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100668,Clb5,S-phase entry cyclin 5,,false,,,http://purl.obolibrary.org/obo/IMR_0100672,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,S-phase entry cyclin 5,,,,,IMR:0100668,,,,,,,,,,,,,,,,,,,,,,Clb5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0046777,protein autophosphorylation,,"The phosphorylation by a protein of one or more of its own amino acid residues (cis-autophosphorylation), or residues on an identical protein (trans-autophosphorylation).",false,,,http://purl.obolibrary.org/obo/GO_0016310,,,,,,,,,,,,,,,,,,,,,,"The phosphorylation by a protein of one or more of its own amino acid residues (cis-autophosphorylation), or residues on an identical protein (trans-autophosphorylation).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0046777,,,,,,,,,,,,,,,,,,,,,,protein autophosphorylation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0200253,Prostaglandin H2,,,false,,,http://purl.obolibrary.org/obo/IMR_0100019,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0200253,,,,,,,,,,,,,,,,,,,,,,Prostaglandin H2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000249,PKA,cAMP-dependent protein kinase|protein kinase A,PKA is comprised of two types of subunits. Two catalytic (C) subunits bind to a regulatory (R) subunit dimer to form an inactive holoenzyme complex. Binding of cAMP to the regulatory subunit causes the catalytic subunit to be unleashed.,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,GO:0004691|GO:0005952,,PKA is comprised of two types of subunits. Two catalytic (C) subunits bind to a regulatory (R) subunit dimer to form an inactive holoenzyme complex. Binding of cAMP to the regulatory subunit causes the catalytic subunit to be unleashed.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001966,,,,,cAMP-dependent protein kinase|protein kinase A,,,,,IMR:0000249,,,,,,,,,,,,,,,,,,,,,,PKA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000026,LT alpha,lymphotoxin|TNF beta|lymphotoxin alpha,,false,,,http://purl.obolibrary.org/obo/IMR_0000021,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,lymphotoxin|TNF beta|lymphotoxin alpha,,,,,IMR:0000026,,,,,,,,,,,,,,,,,,,,,,LT alpha,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0010900,negative regulation of phosphatidylcholine catabolic process,,"Any process that decreases the rate, frequency or extent of phosphatidylcholine catabolism. Phosphatidylcholine catabolic processes are the chemical reactions and pathways resulting in the breakdown of phosphatidylcholines, any of a class of glycerophospholipids in which the phosphatidyl group is esterified to the hydroxyl group of choline.",false,,,http://purl.obolibrary.org/obo/TXPO_0001304,,,,,,,,,,,,,,,,,,,,,,"Any process that decreases the rate, frequency or extent of phosphatidylcholine catabolism. Phosphatidylcholine catabolic processes are the chemical reactions and pathways resulting in the breakdown of phosphatidylcholines, any of a class of glycerophospholipids in which the phosphatidyl group is esterified to the hydroxyl group of choline.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0010900,,,,,,,,,,,,,,,,,,,,,,negative regulation of phosphatidylcholine catabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006517,protein deglycosylation,,The removal of sugar residues from a glycosylated protein.,false,,,http://purl.obolibrary.org/obo/GO_0036211,,,,,,,,,,,,,,,,,,,,,,The removal of sugar residues from a glycosylated protein.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0006517,,,,,,,,,,,,,,,,,,,,,,protein deglycosylation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000136,IFNR type II,Interferon-gamma receptor|IFNGR,,false,,,http://purl.obolibrary.org/obo/IMR_0000134,,,,,,,,,,,,,,,,,,,,GO:0004906,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Interferon-gamma receptor|IFNGR,,,,,IMR:0000136,,,,,,,,,,,,,,,,,,,,,,IFNR type II,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004995,mitochondrial respiratory chain complex I subunit phosphorylation,,,false,,,http://purl.obolibrary.org/obo/GO_0016310,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004329,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004995,,,,,,,,,,,,,,,,,,,,,,mitochondrial respiratory chain complex I subunit phosphorylation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004990,Increase in mitochondrial calcium level [mitochondrial disorder],,Increase in mitochondrial calcium level is a subtype of increase in calcium level: A process that changes the calcium ion concentration within a mitochondria to be higher. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.,false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0004989,,,,,,,,,,,,,,,,,,,,PMID:25339807,,Increase in mitochondrial calcium level is a subtype of increase in calcium level: A process that changes the calcium ion concentration within a mitochondria to be higher. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001991,,,,,,,,,,,TXPO:0004990,,,,,,,,,,,,,,,,,,,,,,Increase in mitochondrial calcium level [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004994,negative regulation of phosphorylation,,"Negative regulation of phosphorylation is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of phosphorylation.",false,,,http://purl.obolibrary.org/obo/TXPO_0000369,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of phosphorylation is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of phosphorylation.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004994,,,,,,,,,,,,,,,,,,,,,,negative regulation of phosphorylation,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0016310,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004992,mitochondrial cholesterol storage [mitochondrial disorder],,"Mitochondrial cholesterol storage is a subtype of cholesterol storage: A process that keeps cholesterol in the mitochondria.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0004991,,,,,,,,,,,,,,,,,,,,PMID:31623280|PMID:25339807|PMID:23299992,,"Mitochondrial cholesterol storage is a subtype of cholesterol storage: A process that keeps cholesterol in the mitochondria.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004351|http://purl.obolibrary.org/obo/TXPO_0004549|http://purl.obolibrary.org/obo/TXPO_0004833|http://purl.obolibrary.org/obo/TXPO_0004927|http://purl.obolibrary.org/obo/TXPO_0004249|http://purl.obolibrary.org/obo/TXPO_0004985,,,,,,,,,,,TXPO:0004992,,,,,,,,,,,,,,,,,,,,,,mitochondrial cholesterol storage [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004993,Negative regulation of mitochondrial respiratory chain complex I subunit phosphorylation,,"Negative regulation of mitochondrial respiratory chain complex I subunit phosphorylation is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of mitochondrial respiratory chain complex I subunit phosphorylation.",false,,,http://purl.obolibrary.org/obo/TXPO_0004994,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of mitochondrial respiratory chain complex I subunit phosphorylation is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of mitochondrial respiratory chain complex I subunit phosphorylation.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004993,,,,,,,,,,,,,,,,,,,,,,Negative regulation of mitochondrial respiratory chain complex I subunit phosphorylation,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004995,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004991,mitochondrial cholesterol storage,,Mitochondrial cholesterol storage is a subtype of cholesterol storage: A process that keeps cholesterol in the mitochondria.,false,,,http://purl.obolibrary.org/obo/GO_0010878,,,,,,,,,,,,,,,,,,,,,,Mitochondrial cholesterol storage is a subtype of cholesterol storage: A process that keeps cholesterol in the mitochondria.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004991,,,,,,,,,,,,,,,,,,,,,,mitochondrial cholesterol storage,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004999,Increasing mitochondrial membrane potential,,Increasing mitochondrial membrane potential is a subtype of increasing membrane potential: A process that changes the electrical potential of a mitochondrial membrane to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0005000,,,,,,,,,,,,,,,,,,,,,,Increasing mitochondrial membrane potential is a subtype of increasing membrane potential: A process that changes the electrical potential of a mitochondrial membrane to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004999,,,,,,,,,,,,,,,,,,,,,,Increasing mitochondrial membrane potential,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004997,dysregulation of mitochondrion organization,,Dysregulation of mitochondrion organization is a subtype of malfunctioning of controlling: A process that cannot perform a regulation of mitochondrion organization appropriately or cannot realize it at all.,false,,,http://purl.obolibrary.org/obo/TXPO_0000532,,,,,,,,,,,,,,,,,,,,,,Dysregulation of mitochondrion organization is a subtype of malfunctioning of controlling: A process that cannot perform a regulation of mitochondrion organization appropriately or cannot realize it at all.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004997,,,,,,,,,,,,,,,,,,,,,,dysregulation of mitochondrion organization,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004998,mitochondrial membrane morphology changes,,mitochondrial membrane morphology changes is a subtype of mitochondria morphology changes: A process that changes the morphology of the mitochondrial membrane.,false,,,http://purl.obolibrary.org/obo/TXPO_0004888,,,,,,,,,,,,,,,,,,,,,,mitochondrial membrane morphology changes is a subtype of mitochondria morphology changes: A process that changes the morphology of the mitochondrial membrane.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004998,,,,,,,,,,,,,,,,,,,,,,mitochondrial membrane morphology changes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004996,mitochondrial dysfunction [hepatocarcinogenesis],,"Mitochondrial dysfunction is a subtype of dysfunctioning: A process that performs an abnormal and incomplete mitochondrial function.
This entity is a specific course-dependent process. This process can constitute the hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0002361,,,,,,,,,,,,,,,,,,,,PMID:31623280,,"Mitochondrial dysfunction is a subtype of dysfunctioning: A process that performs an abnormal and incomplete mitochondrial function.
This entity is a specific course-dependent process. This process can constitute the hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004541|http://purl.obolibrary.org/obo/TXPO_0004794,,,,,,,,,,,TXPO:0004996,,,,,,,,,,,,,,,,,,,,,,mitochondrial dysfunction [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_36796,duloxetine,N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propan-1-amine|N-methyl-3-(naphthalen-1-yloxy)-3-(2-thienyl)propan-1-amine,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Beilstein:8842375|PMID:20825390|CAS:116539-58-3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_76779,,,,,N-methyl-3-(naphthalen-1-yloxy)-3-(2-thienyl)propan-1-amine,,N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propan-1-amine,,,,,,,,,,,,,,,,,,,,,CHEBI:36796,,,,duloxetine,,CHEBI:36796,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000016,Abhd1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:313917|NCBI-Mouse-GeneID:57742|NCBI-Human-GeneID:84696,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000084696,,,,,,,,,,,,,TXPO:1000016,,,,,,,,,,,,,,,,,,,,,,Abhd1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000018,Acbd6 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:72482|NCBI-Rat-GeneID:289125|NCBI-Human-GeneID:84320,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000084320,,,,,,,,,,,,,TXPO:1000018,,,,,,,,,,,,,,,,,,,,,,Acbd6 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000011,ATF3 (mol),activating transcription factor 3,,false,,,http://purl.obolibrary.org/obo/IMR_0000825,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:25389|NCBI-Human-GeneID:467|NCBI-Mouse-GeneID:11910,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000467,,,,,,,,activating transcription factor 3,,,,,TXPO:1000011,,,,,,,,,,,,,,,,,,,,,,ATF3 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000014,ATP-binding cassette (ABC) transporter superfamily,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:1000014,,,,,,,,,,,,,,,,,,,,,,ATP-binding cassette (ABC) transporter superfamily,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000012,ATF4 (mol),activating transcription factor 4,,false,,,http://purl.obolibrary.org/obo/IMR_0000825,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:468|NCBI-Rat-GeneID:79255|NCBI-Mouse-GeneID:11911,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000468,,,,,,,,activating transcription factor 4,,,,,TXPO:1000012,,,,,,,,,,,,,,,,,,,,,,ATF4 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000013,ATF6 (mol),,,false,,,http://purl.obolibrary.org/obo/IMR_0000825,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:304962|NCBI-Mouse-GeneID:226641|NCBI-Human-GeneID:22926,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000022926,,,,,,,,,,,,,TXPO:1000013,,,,,,,,,,,,,,,,,,,,,,ATF6 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000010,DBF4 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:10926|NCBI-Rat-GeneID:312046|NCBI-Mouse-GeneID:27214,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000010926,,,,,,,,,,,,,TXPO:1000010,,,,,,,,,,,,,,,,,,,,,,DBF4 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000017,Acaa1a (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24157|NCBI-Human-GeneID:30|NCBI-Mouse-GeneID:113868,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:1000017,,,,,,,,,,,,,,,,,,,,,,Acaa1a (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000015,Abc1b1  (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:1000015,,,,,,,,,,,,,,,,,,,,,,Abc1b1  (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000019,Acer2 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0001148,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:230379|NCBI-Rat-GeneID:313339|NCBI-Human-GeneID:340485,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000340485,,,,,,,,,,,,,TXPO:1000019,,,,,,,,,,,,,,,,,,,,,,Acer2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005065,AGGF1 signal (primitive),,AGGF1 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by AGGF1.,false,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,,,AGGF1 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by AGGF1.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_1000502,http://purl.obolibrary.org/obo/TXPO_0005064,,,,,,,,,,,,,,,,TXPO:0005065,,,,,,,,,,,,,,,,,,,,,,AGGF1 signal (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005067,ATF4(human) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_1000012,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:468,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000825,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000468,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,,,,,,TXPO:0005067,,,,,,,,,,,,,,,,,,,,,,ATF4(human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005063,liver cancer dependent molecule (canonical),,"Liver cancer dependent molecule is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of Liver cancer as a gene product.
Gene profile:canonical/in vitro/Hepatocyte/",false,,,http://purl.obolibrary.org/obo/TXPO_0000837,,,,,,,,,,,,,,,,,,,,,,"Liver cancer dependent molecule is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of Liver cancer as a gene product.
Gene profile:canonical/in vitro/Hepatocyte/",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005063,,,,,,,,,,,,,,,,,,,,,,liver cancer dependent molecule (canonical),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005066,AMPK(canonical) [mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003221|http://purl.obolibrary.org/obo/TXPO_0004293,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:105787|NCBI-Human-GeneID:5562|NCBI-Rat-GeneID:65248,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003221,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005066,,,,,,,,,,,,,,,,,,,,,,AMPK(canonical) [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005061,Hypofunction of 17β-Estradiol metabolic process,,Hypofunction of 17β-Estradiol metabolic process is a subtype of hypofunction of metabolism: A process that performs a decreased or insufficient 17β-Estradiol metabolic process.,false,,,http://purl.obolibrary.org/obo/TXPO_0001375,,,,,,,,,,,,,,,,,,,,,,Hypofunction of 17β-Estradiol metabolic process is a subtype of hypofunction of metabolism: A process that performs a decreased or insufficient 17β-Estradiol metabolic process.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005061,,,,,,,,,,,,,,,,,,,,,,Hypofunction of 17β-Estradiol metabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005064,AGGF1 signal transduction pathway,,A series of molecular signals mediated by AGGF1 (angiogenic factor with G-patch and FHA domains 1).,false,,,http://purl.obolibrary.org/obo/TXPO_0000609,,,,,,,,,,,,,,,,,,,,,,A series of molecular signals mediated by AGGF1 (angiogenic factor with G-patch and FHA domains 1).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005064,,,,,,,,,,,,,,,,,,,,,,AGGF1 signal transduction pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005068,BECN1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:56208|NCBI-Human-GeneID:8678|NCBI-Rat-GeneID:114558,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005068,,,,,,,,,,,,,,,,,,,,,,BECN1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005060,"1,2-dichloropropane [hepatocarcinogenesis]",,A chloroalkane that is propane in which a hydrogen from each of two adjacent carbons has been replaced by chlorines.,false,,,http://purl.obolibrary.org/obo/CHEBI_142468|http://purl.obolibrary.org/obo/TXPO_0004455,,,,,,,,,,,,,,,,,,,,PMID:12748687,,A chloroalkane that is propane in which a hydrogen from each of two adjacent carbons has been replaced by chlorines.,,,,,,,,,,,,C3H6Cl2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005060,,,,,,,,,,,,,,,,,,,,,,"1,2-dichloropropane [hepatocarcinogenesis]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CC(CCl)Cl,,,,,
http://purl.obolibrary.org/obo/TXPO_0005069,CADM1 (mol),TSLC1,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:363058|NCBI-Mouse-GeneID:54725|NCBI-Human-GeneID:23705,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TSLC1,,,,,TXPO:0005069,,,,,,,,,,,,,,,,,,,,,,CADM1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005062,1-hydroxyanthraquinone,"1-hydroxyanthracene-9,10-dione",,false,,,http://purl.obolibrary.org/obo/TXPO_0004455|http://purl.obolibrary.org/obo/CHEBI_28877,,,,,,,,,,,,,,,,,,,,PMID:2335008|CAS:129-43-1,,,,,,,,,,,,,,C14H8O3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"1-hydroxyanthracene-9,10-dione",,,,,TXPO:0005062,,,,,,,,,,,,,,,,,,,,,,1-hydroxyanthraquinone,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Oc1cccc2C(=O)c3ccccc3C(=O)c12,,,,,
http://purl.obolibrary.org/obo/CHEBI_65191,second generation antipsychotic,second generation antipsychotic agent|atypical antipsychotic drug|second generation antipsychotic drug|atypical antipsychotic|second generation antipsychotic drugs|second generation antipsychotic agents|atypical antipsychotic agent|atypical antipsychotic agents|atypical antipsychotic drugs|second generation antipsychotics|atypical antipsychotics,Antipsychotic drugs which can have different modes of action but which tend to be less likely than first generation antipsychotics to cause extrapyramidal motor control disabilities such as body rigidity or Parkinson's disease-type movements.,false,,,http://purl.obolibrary.org/obo/TXPO_0003658|http://purl.obolibrary.org/obo/CHEBI_35476,,,,,,,,,,,,,,,,,,,,Antipsychotic drugs which can have different modes of action but which tend to be less likely than first generation antipsychotics to cause extrapyramidal motor control disabilities such as body rigidity or Parkinson's disease-type movements.,,Antipsychotic drugs which can have different modes of action but which tend to be less likely than first generation antipsychotics to cause extrapyramidal motor control disabilities such as body rigidity or Parkinson's disease-type movements.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,second generation antipsychotic agent|atypical antipsychotic drug|second generation antipsychotic drug|atypical antipsychotic|second generation antipsychotic drugs|second generation antipsychotic agents|atypical antipsychotic agent|atypical antipsychotic agents|atypical antipsychotic drugs|second generation antipsychotics|atypical antipsychotics,,,,,,,,,,,,,,,,,,,,,CHEBI:65191,,,,second generation antipsychotic,,CHEBI:65191,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0002951,Arrow/LRP5/LRP6,,"Arrow/Lrp5/Lrp6 is a subfamily of the LDL receptor (LDLR) family. Arrow, and also its counterparts LRP5 and LRP6 in mammals and in frogs, appears to function as a coreceptor for Wnt together with the seven-transmembrane receptor Frizzled (frz) in forming the Wnt receptor signaling complex.",false,,,http://purl.obolibrary.org/obo/IMR_0000974,,,,,,,,,,,,,,,,,,,,,,"Arrow/Lrp5/Lrp6 is a subfamily of the LDL receptor (LDLR) family. Arrow, and also its counterparts LRP5 and LRP6 in mammals and in frogs, appears to function as a coreceptor for Wnt together with the seven-transmembrane receptor Frizzled (frz) in forming the Wnt receptor signaling complex.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0002951,,,,,,,,,,,,,,,,,,,,,,Arrow/LRP5/LRP6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002769,NFKB (canonical)[ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000871|http://purl.obolibrary.org/obo/TXPO_1000258,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000382,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,,,,,,TXPO:0002769,,,,,,,,,,,,,,,,,,,,,,NFKB (canonical)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002768,NFKB - transcriptional regulator (canonical)[ER stress - inflammation],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002769,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,,,,,,TXPO:0002768,,,,,,,,,,,,,,,,,,,,,,NFKB - transcriptional regulator (canonical)[ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002762,regulation of translation by eIF2a [ER stress - translation attenuation],,"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of proteins by the translation of mRNA or circRNA by eIF2A in the course of ER stress.
This process is dependent on the translation attenuation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/TXPO_0003736|http://purl.obolibrary.org/obo/TXPO_0002755,,,,,,,,,,,,,,,,,,,,,,"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of proteins by the translation of mRNA or circRNA by eIF2A in the course of ER stress.
This process is dependent on the translation attenuation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001275,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000416,,,,,,,,,,,,,,,,,,TXPO:0002762,,,,,,,,,,,,,,,,,,,,,,regulation of translation by eIF2a [ER stress - translation attenuation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002763,gene expression by NRF2,,Gene expression by NRF2 is a subtype of Gene expression by transcriptional regulator: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) by NRF2.,false,,,http://purl.obolibrary.org/obo/TXPO_0000375,,,,,,,,,,,,,,,,,,,,,,Gene expression by NRF2 is a subtype of Gene expression by transcriptional regulator: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) by NRF2.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002763,,,,,,,,,,,,,,,,,,,,,,gene expression by NRF2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002765,gene expression by NRF2 [ER stress],,"Gene expression by NRF2 is a subtype of Gene expression by transcriptional regulator: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) by NRF2.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002764,,,,,,,,,,,,,,,,,,,,,,"Gene expression by NRF2 is a subtype of Gene expression by transcriptional regulator: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) by NRF2.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002765,,,,,,,,,,,,,,,,,,,,,,gene expression by NRF2 [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002761,IRE1 signaling to XBP1 [ER stress - refolding],,"A process in which a signal to XBP1 is transduced by the IRE1.
This process is dependent on the refolding and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002571,,,,,,,,,,,,,,,,,,,,,,"A process in which a signal to XBP1 is transduced by the IRE1.
This process is dependent on the refolding and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002686|http://purl.obolibrary.org/obo/TXPO_0002689,,,,,,,,,,,,,,,,,,TXPO:0002761,,,,,,,,,,,,,,,,,,,,,,IRE1 signaling to XBP1 [ER stress - refolding],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002760,refolding promoting gene expression by XBP1s [ER stress],,"Refolding promoting gene expression by XBP1s is a subtype of gene expression: The process in which a gene sequence is converted into a mature refolding inducing gene product or products (proteins or RNA) by XbP1s .
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0003736|http://purl.obolibrary.org/obo/TXPO_0002716,,,,,,,,,,,,,,,,,,,,,,"Refolding promoting gene expression by XBP1s is a subtype of gene expression: The process in which a gene sequence is converted into a mature refolding inducing gene product or products (proteins or RNA) by XbP1s .
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002957|http://purl.obolibrary.org/obo/TXPO_0002919|http://purl.obolibrary.org/obo/TXPO_0000721,,http://purl.obolibrary.org/obo/TXPO_0002609,,,,,,,,,,,,,,,,TXPO:0002760,,,,,,,,,,,,,,,,,,,,,,refolding promoting gene expression by XBP1s [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002764,gene expression by NRF2 [PERK - NRF2 pathway],,"Gene expression by NRF2 is a subtype of Gene expression by transcriptional regulator: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) by NRF2.
This entity is a specific course-dependent process. This process can constitute the course of PERK - NRF2 pathway.",false,,,http://purl.obolibrary.org/obo/TXPO_0002763,,,,,,,,,,,,,,,,,,,,,,"Gene expression by NRF2 is a subtype of Gene expression by transcriptional regulator: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) by NRF2.
This entity is a specific course-dependent process. This process can constitute the course of PERK - NRF2 pathway.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002764,,,,,,,,,,,,,,,,,,,,,,gene expression by NRF2 [PERK - NRF2 pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002766,inflammatory cytokine gene expression [ER stress],,"Inflammatory cytokine gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature inflammatory cytokine gene product or products (proteins or RNA).
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002266|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,PMID:20303879,,"Inflammatory cytokine gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature inflammatory cytokine gene product or products (proteins or RNA).
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002811|http://purl.obolibrary.org/obo/TXPO_0002843|http://purl.obolibrary.org/obo/TXPO_0003043|http://purl.obolibrary.org/obo/TXPO_0002805|http://purl.obolibrary.org/obo/TXPO_0002830|http://purl.obolibrary.org/obo/TXPO_0002829,,http://purl.obolibrary.org/obo/TXPO_0002624|http://purl.obolibrary.org/obo/TXPO_0002599|http://purl.obolibrary.org/obo/TXPO_0002795|http://purl.obolibrary.org/obo/TXPO_0002796|http://purl.obolibrary.org/obo/TXPO_0002794|http://purl.obolibrary.org/obo/TXPO_0002836,,,,,http://purl.obolibrary.org/obo/TXPO_0000760,,,,,,,,,,,TXPO:0002766,,,,,,,,,,,,,,,,,,,,,,inflammatory cytokine gene expression [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002767,"gene expression by CHOP (DDIT3, GADD153) [ER stress - apoptosis]",,"Gene expression by CHOP (DDIT3, GADD153) is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) by CHOP (DDIT3, GADD153).
This process is dependent on the apoptosis and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001874,,,,,,,,,,,,,,,,,,,,PMID:26977301,,"Gene expression by CHOP (DDIT3, GADD153) is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) by CHOP (DDIT3, GADD153).
This process is dependent on the apoptosis and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000791|http://purl.obolibrary.org/obo/TXPO_0002167|http://purl.obolibrary.org/obo/TXPO_0002915,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002916,,,,,,,,,,,TXPO:0002767,,,,,,,,,,,,,,,,,,,,,,"gene expression by CHOP (DDIT3, GADD153) [ER stress - apoptosis]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000739,hepatocyte cell division [Hypertrophy],,"Hepatocyte cell division is a subtype of cell division: The process resulting in division and partitioning of components of a heoatocyte cell to form more cells.
This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy.",false,,,http://purl.obolibrary.org/obo/TXPO_0003279|http://purl.obolibrary.org/obo/TXPO_0001570,,,,,,,,,,,,,,,,,,,,,,"Hepatocyte cell division is a subtype of cell division: The process resulting in division and partitioning of components of a heoatocyte cell to form more cells.
This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001422,,,,,,,,,,,TXPO:0000739,,,,,,,,,,,,,,,,,,,,,,hepatocyte cell division [Hypertrophy],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000737,Hykk (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:235386|NCBI-Rat-GeneID:300723|NCBI-Human-GeneID:123688,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000123688,,,http://purl.obolibrary.org/obo/TXPO_0001548,,,,,,,,,,TXPO:0000737,,,,,,,,,,,,,,,,,,,,,,Hykk (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000731,hypofunction of endosome to lysosome transport of low-density lipoprotein particle,decreasing endosome to lysosome transport of LDL,Hypofunction of endosome to lysosome transport of low-density lipoprotein particle is a subtype of hypofunction of cholesterol transport: A process that performs a decreased or insufficient endosome to lysosome transport of low-density lipoprotein particle.,false,,,http://purl.obolibrary.org/obo/TXPO_0000714,,,,,,,,,,,,,,,,,,,,,,Hypofunction of endosome to lysosome transport of low-density lipoprotein particle is a subtype of hypofunction of cholesterol transport: A process that performs a decreased or insufficient endosome to lysosome transport of low-density lipoprotein particle.,,,http://purl.obolibrary.org/obo/GO_0090117,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,decreasing endosome to lysosome transport of LDL,,,,,TXPO:0000731,,,,,,,,,,,,,,,,,,,,,,hypofunction of endosome to lysosome transport of low-density lipoprotein particle,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000736,PLA2G2E (mol),,,false,,,http://purl.obolibrary.org/obo/IMR_0001035,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:30814,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000736,,,,,,,,,,,,,,,,,,,,,,PLA2G2E (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000730,IRE1 activation [ER stress],,"IRE1 activation is a subtype of molecular activation: A process that changes the activity of the IRE1 to be higher.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/TXPO_0003736|http://purl.obolibrary.org/obo/TXPO_0002591,,,,,,,,,,,,,,,,,,,,,,"IRE1 activation is a subtype of molecular activation: A process that changes the activity of the IRE1 to be higher.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002598|http://purl.obolibrary.org/obo/TXPO_0002596,,,,,,,,,,,,,,,,,,,,,TXPO:0000730,,,,,,,,,,,,,,,,,,,,,,IRE1 activation [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000733,starvation [ER stress],,"Starvation is a subtype of depleting: A process that lessens markedly in quantity of the nourishment.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/TXPO_0000673,,,,,,,,,,,,,,,,,,,,,,"Starvation is a subtype of depleting: A process that lessens markedly in quantity of the nourishment.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000733,,,,,,,,,,,,,,,,,,,,,,starvation [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000732,ischemia [ER stress],,"Ischemia is a changing process to lack enough to blood supply.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/TXPO_0000580,,,,,,,,,,,,,,,,,,,,,,"Ischemia is a changing process to lack enough to blood supply.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000732,,,,,,,,,,,,,,,,,,,,,,ischemia [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000734,increasing demand for response to ER stress [ER stress],,"Increasing demand for response to ER stress is a subtype of increasing the demand for response to stress: A process that changes the functional demand for the response to the edoplasmic reticulum (ER) stress to be higher.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/TXPO_0000362,,,,,,,,,,,,,,,,,,,,,,"Increasing demand for response to ER stress is a subtype of increasing the demand for response to stress: A process that changes the functional demand for the response to the edoplasmic reticulum (ER) stress to be higher.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000734,,,,,,,,,,,,,,,,,,,,,,increasing demand for response to ER stress [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000738,Lgpat2,,,false,,,http://purl.obolibrary.org/obo/TXPO_0000740,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000738,,,,,,,,,,,,,,,,,,,,,,Lgpat2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000735,response to endoplasmic reticulum stress [ER stress],,"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stress acting at the endoplasmic reticulum. ER stress usually results from the accumulation of unfolded or misfolded proteins in the ER lumen.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/GO_0034976,,,,,,,,,,,,,,,,,,,,,,"Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stress acting at the endoplasmic reticulum. ER stress usually results from the accumulation of unfolded or misfolded proteins in the ER lumen.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000735,,,,,,,,,,,,,,,,,,,,,,response to endoplasmic reticulum stress [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002111,BIP-IRE1 complex (canonical)[ER stress],,"BIP-IRE1 complex is a subtype of molecular complex.
This entity has sub-parts of molecules, BIP/GRP78 and IRE1 which has role of stress sensor.
This entity is dependent on ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002108,,,,,,,,,,,,,,,,,,,,,,"BIP-IRE1 complex is a subtype of molecular complex.
This entity has sub-parts of molecules, BIP/GRP78 and IRE1 which has role of stress sensor.
This entity is dependent on ER stress.",,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002621,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002111,,,,,,,,,,,,,,,,,,,,,,BIP-IRE1 complex (canonical)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002110,BIP-ATF6 complex (canonical)[ER stress],,"BIP-ATF6 complex is a subtype of molecular complex.
This entity has sub-parts of molecules, BIP/GRP78 and ATF6 which has role of stress sensor.
This entity is dependent on ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002108,,,,,,,,,,,,,,,,,,,,,,"BIP-ATF6 complex is a subtype of molecular complex.
This entity has sub-parts of molecules, BIP/GRP78 and ATF6 which has role of stress sensor.
This entity is dependent on ER stress.",,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002622,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000879,,,,,,,,,,,,,,,,,,TXPO:0002110,,,,,,,,,,,,,,,,,,,,,,BIP-ATF6 complex (canonical)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002119,PERK - signaling factor (canonical)[Perk-eIF2a signalling system],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001852,http://purl.obolibrary.org/obo/TXPO_0000062,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UniProt_Q9NZJ5|http://www.uniprot.org/entry/Q9NZJ5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001898,,,,,,,,,,TXPO:0002119,,,,,,,,,,,,,,,,,,,,,,PERK - signaling factor (canonical)[Perk-eIF2a signalling system],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002117,forming disulfide bond [ER stress],,"Forming disulfide bond is a subtype of binding: The interaction between molecules with interchain disulfide bonds.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/TXPO_0002118,,,,,,,,,,,,,,,,,,,,PMID:23198585|PMID:21091435|PMID:23637286,,"Forming disulfide bond is a subtype of binding: The interaction between molecules with interchain disulfide bonds.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002771,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000805|http://purl.obolibrary.org/obo/TXPO_0002497,,,,,,,,,,,,,,,,,TXPO:0002117,,,,,,,,,,,,,,,,,,,,,,forming disulfide bond [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002115,Bip-unfolded protein complex,,"Bip-unfolded protein is a subtype of a molecular complex.
This entity has sub-parts of molecules: BIP/GRP78, and an unfolded protein.",false,,,http://purl.obolibrary.org/obo/TXPO_0002107,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/HINO_0017506|https://identifiers.org/reactome:R-HSA-381062,,"Bip-unfolded protein is a subtype of a molecular complex.
This entity has sub-parts of molecules: BIP/GRP78, and an unfolded protein.",,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000132|http://purl.obolibrary.org/obo/TXPO_0002385,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002115,,,,,,,,,,,,,,,,,,,,,,Bip-unfolded protein complex,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002113,glutathione depletion [ER stress],,"Glutathione depletion is a subtype of depleting: A process that lessens markedly in the amount of glutathione.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000483|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,PMID:25931127,,"Glutathione depletion is a subtype of depleting: A process that lessens markedly in the amount of glutathione.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000807,,,,,,http://purl.obolibrary.org/obo/TXPO_0002116,,,,,,,,,,,TXPO:0002113,,,,,,,,,,,,,,,,,,,,,,glutathione depletion [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002118,forming disulfide bond,,Forming disulfide bond is a subtype of binding: The interaction between molecules with  interchain disulfide bonds.,false,,,http://purl.obolibrary.org/obo/GO_0005488,,,,,,,,,,,,,,,,,,,,,,Forming disulfide bond is a subtype of binding: The interaction between molecules with  interchain disulfide bonds.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002118,,,,,,,"In chemistry, a disulfide refers to a functional group with the structure R−S−S−R′. The linkage is also called an SS-bond or sometimes a disulfide bridge and is usually derived by the coupling of two thiol groups.

Occurrence in proteins
Disulfide bonds play an important role in the folding and stability of some proteins, usually proteins secreted to the extracellular medium. Since most cellular compartments are reducing environments, in general, disulfide bonds are unstable in the cytosol, with some exceptions as noted below, unless a sulfhydryl oxidase is present.

Disulfide bonds in proteins are formed between the thiol groups of cysteine residues by the process of oxidative folding. The other sulfur-containing amino acid, methionine, cannot form disulfide bonds. A disulfide bond is typically denoted by hyphenating the abbreviations for cysteine, e.g., when referring to ribonuclease A the ""Cys26–Cys84 disulfide bond"", or the ""26–84 disulfide bond"", or most simply as ""C26–C84""　where the disulfide bond is understood and does not need to be mentioned. The prototype of a protein disulfide bond is the two-amino-acid peptide cystine, which is composed of two cysteine amino acids joined by a disulfide bond (shown in Figure 3 in its unionized form). The structure of a disulfide bond can be described by its χss dihedral angle between the Cβ−Sγ−Sγ−Cβ atoms, which is usually close to ±90°.",,,,,,,,,,,,,,,forming disulfide bond,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002116,cell cycle arrest [ER stress],,"A regulatory process that halts progression through the cell cycle during one of the normal phases (G1, S, G2, M).
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/GO_0007050,,,,,,,,,,,,,,,,,,,,PMID:25931127,,"A regulatory process that halts progression through the cell cycle during one of the normal phases (G1, S, G2, M).
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002990,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002114,,,,,,,,,,,TXPO:0002116,,,,,,,,,,,,,,,,,,,,,,cell cycle arrest [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002114,positive regulation of apoptotic process [ER stress],,"Any process that activates or increases the frequency, rate or extent of cell death by apoptotic process.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/GO_0043065,,,,,,,,,,,,,,,,,,,,PMID:26977301,,"Any process that activates or increases the frequency, rate or extent of cell death by apoptotic process.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002916,http://purl.obolibrary.org/obo/TXPO_0003818,,,,,,http://purl.obolibrary.org/obo/TXPO_0000513,,,,,,,,,,,TXPO:0002114,,,,,,,,,,,,,,,,,,,,,,positive regulation of apoptotic process [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002112,hypofunction of mitochondrial fatty acid beta-oxidation,,Hypofunction of mitochondrial fatty acid beta-oxidation is a subtype of hypofunction of fatty acid beta-oxidation: A process that performs a decreased or insufficient mitochondrial fatty acid beta-oxidation.,false,,,http://purl.obolibrary.org/obo/TXPO_0002008,,,,,,,,,,,,,,,,,,,,,,Hypofunction of mitochondrial fatty acid beta-oxidation is a subtype of hypofunction of fatty acid beta-oxidation: A process that performs a decreased or insufficient mitochondrial fatty acid beta-oxidation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002112,,,,,,,,,,,,,,,,,,,,,,hypofunction of mitochondrial fatty acid beta-oxidation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_132742,lysophosphatidic acid,LPA,A member of the class of lysophosphatidic acids obtained by hydrolytic removal of one of the two acyl groups of any phosphatidic acid. A 'closed' class.,false,,,http://purl.obolibrary.org/obo/CHEBI_32957,,,,,,,,,,,,,,,,,,,,"PMID:7768880
Lysophosphatidic acid, a multifunctional phospholipid messenger.

Lysophosphatidic acid (LPA1(1); 1-acyl-glycerol-3-phosphate),is the simplest of all glycerophospholipids. While LPA has long been known as a precursor of phospholipid biosynthesis in both eukaryotic and prokaryotic cells, only recently has LPA emerged as an intercellular signaling molecule that is rapidly produced and released by activated cells, notably platelets, to influence target cells by acting on a specific cell-surface receptor.

The list of biological responses to LPA is quite diverse, ranging from induction of cell proliferation to stimulation of neurite retraction.

The mitogenic activities of LPA have been best studied in fibroblasts. As with peptide growth factors, induction of DNA synthesis by LPA requires its long term presence in the medium

LPA, but not peptide growth factors, can mimic serum in inducing invasion of carcinoma and hepatoma cells into monolayers of mesothelial cells. The underlying mechanism is not clear but may well involve both increased cell adhesion and enhanced cell motility.

Many mitogens activate the p85/p110 phosphatidylinositol (PI) 3-kinase in their target cells and so does LPA. LPA-induced PI 3-kinase activity has been found in 3T3 cells (Ref. 44; but see ref. 45 for conflicting data) and in megakaryoblastic cells. Whatever its precise link to the LPA receptor and physiological function, PI 3-kinase does not seem to be essential for mitogenic signaling, since microinjection of a neutralizing antibody does not affect LPA-induced DNA synthesis.|PMID:20118541

Lysophosphatidic acid (LPA) is a lipid mediator that is known to exhibit chemotactic activity toward a variety of cancer cells. However, its effect on the immune system has not been studied extensively. Another lipid mediator, sphingosine-1-phosphate (S1P), has been shown to influence lymphocyte recirculation by regulating lymphocyte egress from lymphoid organs. In this study, we found that LPA inhibits spontaneous migration of mouse splenic lymphocytes through a chemorepulsive effect. We also demonstrated that LPA inhibits chemokine CCL21-induced lymphocyte migration. This inhibitory effect on CCL21-induced migration was observed for both T and B cells. The involvement of a receptor, LPA(1), LPA(2) or LPA(3), in the inhibition of the CCL21-induced migration was confirmed with a synthetic agonist, oleyl thiophosphate. Considering that the signaling by CCL21 through cognate receptor CCR7 contributes to lymphocyte homing and dendritic cell trafficking to lymph nodes, LPA may play a role as a key regulator of these processes. The inhibitory effect of LPA is in remarkable contrast to the effect of S1P receptor signaling, which is known to potentiate lymphocyte chemotaxis involving CCR7.|MeSH:C032881",,A member of the class of lysophosphatidic acids obtained by hydrolytic removal of one of the two acyl groups of any phosphatidic acid. A 'closed' class.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003686|http://purl.obolibrary.org/obo/TXPO_0002401,,,,,LPA,,,,,CHEBI:132742,,,,,,,,,,,,,,,,,,,,,,lysophosphatidic acid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000009965,FGF19,,Other designations: FGF-19,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,11,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,fibroblast growth factor 19,,,11q13.1,,,,,,,,,,,,,,,,"GO_0001755 (EC: IEA); GO_0005104 (EC: IPI, PMID: 10525310); GO_0005515 (EC: IPI, PMID: 18829467); GO_0005576 (EC: TAS); GO_0007173 (EC: TAS); GO_0007399 (EC: TAS, PMID: 9931477); GO_0007507 (EC: IEA); GO_0008083 (EC: IEA); GO_0008284 (EC: IGI, PMID: 18187602); GO_0008286 (EC: TAS); GO_0008543 (EC: IGI, PMID: 18187602); GO_0008543 (EC: IPI, PMID: 10525310); GO_0008543 (EC: TAS); GO_0038095 (EC: TAS); GO_0045087 (EC: TAS); GO_0046326 (EC: IDA, PMID: 17623664); GO_0046330 (EC: IDA, PMID: 12815072); GO_0048011 (EC: TAS); GO_0048015 (EC: TAS); GO_0070374 (EC: IDA, PMID: 17623664); GO_0070858 (EC: IDA, PMID: 12815072)",,,,,,,,,PMID: 9931477; 10525310; 10579907; 10652257; 11110663; 11294897; 11956156; 12057932; 12477932; 12792807; 12815072; 12975309; 14730967; 14976145; 15199049; 15340161; 15489334; 16597617; 17000708; 17339340; 17599042; 17623664; 17711860; 18187602; 18559909; 18829467; 19185005; 19233843; 19237543; 19681655; 20013647; 20018895; 20093562; 20453838; 20691689; 21397858; 21436455; 21437243; 21574752; 21653700; 21691104; 21747170; 21953282; 22166511; 22267484; 22396169; 22442730; 22561792; 23038264; 23064887; 23205607; 23329754; 23456506; 23940810; 24321096,,,,,,,,,,,,,,,OGG:3000009965,,,,,,,fibroblast growth factor 19,,,,,,,,,,,,,Other designations: FGF-19,,FGF19,,,,,,,,,,,,,,,,,,,,,,,9965,UNQ334/PRO533,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,FGF19,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000573,IFN alpha-2,,,false,,,http://purl.obolibrary.org/obo/IMR_0100386,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000573,,,,,,,,,,,,,,,,,,,,,,IFN alpha-2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003464,intestine congestion [hepatic blood circulatory disorder],,"Intestine congestion is a subtype of hyperfunctioning of accumulation: A process that performs an excessive accumulation of blood in the intestine.
This entity is a specific course-dependent process. This process can constitute the course of hepatic blood circulatory disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0003618|http://purl.obolibrary.org/obo/TXPO_0003465,,,,,,,,,,,,,,,,,,,,,,"Intestine congestion is a subtype of hyperfunctioning of accumulation: A process that performs an excessive accumulation of blood in the intestine.
This entity is a specific course-dependent process. This process can constitute the course of hepatic blood circulatory disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003464,,,,,,,,,,,,,,,,,,,,,,intestine congestion [hepatic blood circulatory disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003460,hepatic lymph leakage [hepatic blood circulatory disorder],,"Hepatic lymph leakage is a subtype of leaking: A process that leaks lymph out from the liver lymphatic vessel.
This entity is a specific course-dependent process. This process can constitute the course of hepatic blood circulatory disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0003618|http://purl.obolibrary.org/obo/TXPO_0001368,,,,,,,,,,,,,,,,,,,,,,"Hepatic lymph leakage is a subtype of leaking: A process that leaks lymph out from the liver lymphatic vessel.
This entity is a specific course-dependent process. This process can constitute the course of hepatic blood circulatory disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003461,,,,,,,,,,,TXPO:0003460,,,,,,,,,,,,,,,,,,,,,,hepatic lymph leakage [hepatic blood circulatory disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003462,inzreasing size of the spleen [hepatic blood circulatory disorder],,"Inzreasing size of the spleen is a subtype of increasing size: A process that changes the size of the of the spleen to be larger.
This entity is a specific course-dependent process. This process can constitute the course of hepatic blood circulatory disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001360,,,,,,,,,,,,,,,,,,,,,,"Inzreasing size of the spleen is a subtype of increasing size: A process that changes the size of the of the spleen to be larger.
This entity is a specific course-dependent process. This process can constitute the course of hepatic blood circulatory disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003616,,,,,,,,,,,TXPO:0003462,,,,,,,,,,,,,,,,,,,,,,inzreasing size of the spleen [hepatic blood circulatory disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003461,ascites (process) [hepatic blood circulatory disorder],,"Ascites (process) is a subtype of accumulation of fluids: A process that keeps fluid in the peritoneal cavity.
This entity is a specific course-dependent process. This process can constitute the course of hepatic blood circulatory disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0003618|http://purl.obolibrary.org/obo/TXPO_0001369,,,,,,,,,,,,,,,,,,,,,,"Ascites (process) is a subtype of accumulation of fluids: A process that keeps fluid in the peritoneal cavity.
This entity is a specific course-dependent process. This process can constitute the course of hepatic blood circulatory disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003461,,,,,,,,,,,,,,,,,,,,,,ascites (process) [hepatic blood circulatory disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003468,sphingomyelinase gene mutation [Niemann Pick Disease Type A],,"Sphingomyelinase gene mutation is a subtype of phopholipase gene mutation: A process that changes the sequence of a sphingomyelinase gene.
This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type A.",false,,,http://purl.obolibrary.org/obo/TXPO_0001446,,,,,,,,,,,,,,,,,,,,,,"Sphingomyelinase gene mutation is a subtype of phopholipase gene mutation: A process that changes the sequence of a sphingomyelinase gene.
This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type A.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003470,,,,,,http://purl.obolibrary.org/obo/TXPO_0003474,,,,,,,,,,,TXPO:0003468,,,,,,,,,,,,,,,,,,,,,,sphingomyelinase gene mutation [Niemann Pick Disease Type A],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003465,intestine congestion,,Intestine congestion is a subtype of hyperfunctioning of accumulation: A process that performs an excessive accumulation of blood in the intestine.,false,,,http://purl.obolibrary.org/obo/TXPO_0000916,,,,,,,,,,,,,,,,,,,,,,Intestine congestion is a subtype of hyperfunctioning of accumulation: A process that performs an excessive accumulation of blood in the intestine.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003465,,,,,,,,,,,,,,,,,,,,,,intestine congestion,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0000160,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003467,varicosity of veins formation [hepatic blood circulatory disorder],,"Varicosity of veins formation is a subtype of biological structure formation: A process that have a varicosity of veins.
This entity is a specific course-dependent process. This process can constitute the course of hepatic blood circulatory disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001364,,,,,,,,,,,,,,,,,,,,,,"Varicosity of veins formation is a subtype of biological structure formation: A process that have a varicosity of veins.
This entity is a specific course-dependent process. This process can constitute the course of hepatic blood circulatory disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003467,,,,,,,,,,,,,,,,,,,,,,varicosity of veins formation [hepatic blood circulatory disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003466,bypass formation [hepatic blood circulatory disorder],,"Bypass formation is a subtype of biological structure formation: A process that constructs an alternate passage of a bodily substancepassage carrying blood.
This entity is a specific course-dependent process. This process can constitute the course of hepatic blood circulatory disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0003618|http://purl.obolibrary.org/obo/TXPO_0001363,,,,,,,,,,,,,,,,,,,,,,"Bypass formation is a subtype of biological structure formation: A process that constructs an alternate passage of a bodily substancepassage carrying blood.
This entity is a specific course-dependent process. This process can constitute the course of hepatic blood circulatory disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003467,,,,,,,,,,,TXPO:0003466,,,,,,,,,,,,,,,,,,,,,,bypass formation [hepatic blood circulatory disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003463,stomach congestion [hepatic blood circulatory disorder],,"Stomach congestion is a subtype of hyperfunctioning of accumulation: A process that performs an excessive accumulation of blood in the stomach.
This entity is a specific course-dependent process. This process can constitute the course of hepatic blood circulatory disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0003618|http://purl.obolibrary.org/obo/TXPO_0001365,,,,,,,,,,,,,,,,,,,,,,"Stomach congestion is a subtype of hyperfunctioning of accumulation: A process that performs an excessive accumulation of blood in the stomach.
This entity is a specific course-dependent process. This process can constitute the course of hepatic blood circulatory disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003463,,,,,,,,,,,,,,,,,,,,,,stomach congestion [hepatic blood circulatory disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003469,SMPD1 (canonical)[Niemann Pick Disease Type A -B],Sphingomyelin Phosphodiesterase 1 [Niemann Pick Disease Type A -B],,false,,,http://purl.obolibrary.org/obo/TXPO_0001464,,,,,,,,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/gene/6609,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003671,,,,,Sphingomyelin Phosphodiesterase 1 [Niemann Pick Disease Type A -B],,,,,TXPO:0003469,,,,,,,,,,,,,,,,,,,,,,SMPD1 (canonical)[Niemann Pick Disease Type A -B],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0001024,power,,A physical quality inhering in a bearer by virtue of the bearer's rate of doing work.,false,,,http://purl.obolibrary.org/obo/BFO_0000019|http://purl.obolibrary.org/obo/TXPO_0003521,,,,,,,,,,,,,,,,,,,,,,A physical quality inhering in a bearer by virtue of the bearer's rate of doing work.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0001024,,,,,,,,,,,,,,,,,,,,,,power,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0001025,pressure,,A physical quality that inheres in a bearer by virtue of the bearer's amount of force per unit area it exerts.,false,,,http://purl.obolibrary.org/obo/TXPO_0002418|http://purl.obolibrary.org/obo/BFO_0000019,,,,,,,,,,,,,,,,,,,,,,A physical quality that inheres in a bearer by virtue of the bearer's amount of force per unit area it exerts.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0001025,,,,,,,,,,,,,,,,,,,,,,pressure,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000055192,DNAJC17,,Other designations: dnaJ homolog subfamily C member 17,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,15,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"DnaJ (Hsp40) homolog, subfamily C, member 17",,,15q15.1,,,,,,,,,,,,,,,,GO_0000166 (EC: IEA); GO_0003723 (EC: IEA),,,,,,,,,PMID:12477932; 14702039; 15489334; 16344560; 17081983; 19913121; 20628086; 21139048; 21890473,,,,,,,,,,,,,,,OGG:3000055192,,,,,,,"DnaJ (Hsp40) homolog, subfamily C, member 17",,,,,,,,,,,,,Other designations: dnaJ homolog subfamily C member 17,,DNAJC17,,,,,,,,,,,,,,,,,,,,,,,55192,,,,,,,,9606,,,,,,,,,,,,,,,,,,,DNAJC17,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000055190,NUDT11,,"Other designations: DIPP-3-beta|DIPP3-beta|diadenosine 5',5'''-P1,P6-hexaphosphate hydrolase 3-beta|diadenosine hexaphosphate hydrolase (AMP-forming)|diphosphoinositol polyphosphate phosphohydrolase 3, beta|diphosphoinositol polyphosphate phosphohydrolase 3-beta|hAps1|nucleoside diphosphate-linked moiety X motif 11|nudix motif 11",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,ASP1|DIPP3b|DIPP3beta|hDIPP3beta|APS1,,,,,,,,,,,,X,,,,,,HGNC:18011|Ensembl:ENSG00000196368|Vega:OTTHUMG00000021531|MIM:300528|HPRD:06667,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,nudix (nucleoside diphosphate linked moiety X)-type motif 11,,,Xp11.22,,,,,,,,,,,,,,,,GO_0005622 (EC: IDA); GO_0005829 (EC: TAS); GO_0008486 (EC: ISS); GO_0043647 (EC: TAS); GO_0044281 (EC: TAS); GO_0046872 (EC: IEA); GO_0052840 (EC: IEA); GO_0052843 (EC: IEA); GO_0052844 (EC: IEA); GO_0052845 (EC: IEA); GO_0052846 (EC: IEA); GO_0052847 (EC: IEA); GO_0052848 (EC: IEA),,,,,,,,,PMID: 11076863; 11256614; 12105228; 12121577; 12370170; 12477932; 14702039; 15345747; 15489334; 15489336; 15772651; 16381901; 18264097; 18264098; 18854154; 19902474; 21071540; 21139048; 22730461,,,,,,,,,,,,,,,OGG:3000055190,,,,,,,nudix (nucleoside diphosphate linked moiety X)-type motif 11,,,,,,,,,,,,,"Other designations: DIPP-3-beta|DIPP3-beta|diadenosine 5',5'''-P1,P6-hexaphosphate hydrolase 3-beta|diadenosine hexaphosphate hydrolase (AMP-forming)|diphosphoinositol polyphosphate phosphohydrolase 3, beta|diphosphoinositol polyphosphate phosphohydrolase 3-beta|hAps1|nucleoside diphosphate-linked moiety X motif 11|nudix motif 11",,NUDT11,,,,,,,,,,,,,,,,,,,,,,,55190,RP11-348F1.5,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,NUDT11,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0001824,phospholipid accumulation in lysosome [Phospholipidosis (mild)],,"Phospholipid accumulation in lysosome is a subtype of phospholipid accumulation: A process that keeps phospholipid in the lysosome.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (mild).",false,,,http://purl.obolibrary.org/obo/TXPO_0000910,,,,,,,,,,,,,,,,,,,,,,"Phospholipid accumulation in lysosome is a subtype of phospholipid accumulation: A process that keeps phospholipid in the lysosome.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (mild).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001824,,,,,,,,,,,,,,,,,,,,,,phospholipid accumulation in lysosome [Phospholipidosis (mild)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001826,receiving abnormal protein signal by PERK [ER stress - refolding],,"Receiving abnormal protein signal by PERK is a subtype of receiving signal: A process that recognizes another object and changes into an abnormal protein (e.g., misfolded protein, etc.) signal by PERK.
This process is dependent on the refolding and can constitute the course of ER stress via protein refolding.",false,,,http://purl.obolibrary.org/obo/TXPO_0002741|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"Receiving abnormal protein signal by PERK is a subtype of receiving signal: A process that recognizes another object and changes into an abnormal protein (e.g., misfolded protein, etc.) signal by PERK.
This process is dependent on the refolding and can constitute the course of ER stress via protein refolding.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002994,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000463,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002412,,,,,,,,,,,TXPO:0001826,,,,,,,,,,,,,,,,,,,,,,receiving abnormal protein signal by PERK [ER stress - refolding],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001821,signal transduction system dependent molecule,,"Signaling transduction system dependent molecule is a subtype of system dependeny functional molecule.
This entity is dependent on a signal transduction system for functioning.",false,,,http://purl.obolibrary.org/obo/TXPO_0001820,,,,,,,,,,,,,,,,,,,,,,"Signaling transduction system dependent molecule is a subtype of system dependeny functional molecule.
This entity is dependent on a signal transduction system for functioning.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001821,,,,,,,,,,,,,,,,,,,,,,signal transduction system dependent molecule,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001827,hyperfunction of increasing the amount of drug [Ground glass appearance],,"Hyperfunction of increasing the amount of drug is a subtype of hyperfunction of increasing: A process that performs an excessive increase in the amount of drug.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/TXPO_0001825,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of increasing the amount of drug is a subtype of hyperfunction of increasing: A process that performs an excessive increase in the amount of drug.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,http://purl.obolibrary.org/obo/TXPO_0001637,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001665,,,,,,,,,,,TXPO:0001827,,,,,,,,,,,,,,,,,,,,,,hyperfunction of increasing the amount of drug [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001820,system dependent functional molecule,,"System dependent functional molecule is asubtype of chemical entity.
This entity is dependent on a system for functioning.",false,,,http://purl.obolibrary.org/obo/CHEBI_24431,,,,,,,,,,,,,,,,,,,,,,"System dependent functional molecule is asubtype of chemical entity.
This entity is dependent on a system for functioning.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001820,,,,,,,,,,,,,,,,,,,,,,system dependent functional molecule,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001822,lipid accumulation in hepatocyte [Phospholipidosis(moderate)],,"Lipid accumulation in hepatocyte is a subtype of lipid strorage in hepatocyte: A process that keeps lipids in hepatocytes.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (moderate).",false,,,http://purl.obolibrary.org/obo/TXPO_0001645,,,,,,,,,,,,,,,,,,,,,,"Lipid accumulation in hepatocyte is a subtype of lipid strorage in hepatocyte: A process that keeps lipids in hepatocytes.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (moderate).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001700,,,,,,,,,,,TXPO:0001822,,,,,,,,,,,,,,,,,,,,,,lipid accumulation in hepatocyte [Phospholipidosis(moderate)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001823,sphingomyelin metabolism imbalance [Phospholipidosis - sphingomyelin disorder],,"A process that becomes lacking a homeostastasis balance of the sphingomyelin metabolism.
This process is dependent on the sphingomyelin disorder and can constitute the course of sphingomyelin disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0004163,,,,,,,,,,,,,,,,,,,,,,"A process that becomes lacking a homeostastasis balance of the sphingomyelin metabolism.
This process is dependent on the sphingomyelin disorder and can constitute the course of sphingomyelin disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003381,,,,,,,,,,,TXPO:0001823,,,,,,,,,,,,,,,,,,,,,,sphingomyelin metabolism imbalance [Phospholipidosis - sphingomyelin disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001828,receptor molecule [signal transduction system],,"Receptor molecule is a subtype of signaling dependent molecule.
This entity is dependent on a signal transduction system and can participate in signaling process.",false,,,http://purl.obolibrary.org/obo/TXPO_0001821,,,,,,,,,,,,,,,,,,,,,,"Receptor molecule is a subtype of signaling dependent molecule.
This entity is dependent on a signal transduction system and can participate in signaling process.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002463,,,,,,,,,,TXPO:0001828,,,,,,,,,,,,,,,,,,,,,,receptor molecule [signal transduction system],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002174,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001829,hypofunction of ceramide degradation,,Hypofunction of ceramide degradation is a subtype of hypofunction of lipid degradation: A process that performs a decreased or insufficient ceramide degradation.,false,,,http://purl.obolibrary.org/obo/TXPO_0002006,,,,,,,,,,,,,,,,,,,,,,Hypofunction of ceramide degradation is a subtype of hypofunction of lipid degradation: A process that performs a decreased or insufficient ceramide degradation.,,,http://purl.obolibrary.org/obo/GO_0046514,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001829,,,,,,,,,,,,,,,,,,,,,,hypofunction of ceramide degradation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001825,hyperfunction of increasing the amount of drug,,Hyperfunction of increasing the amount of drug is a subtype of hyperfunction of increasing: A process that performs an excessive increase in the amount of drug.,false,,,http://purl.obolibrary.org/obo/TXPO_0001724,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of increasing the amount of drug is a subtype of hyperfunction of increasing: A process that performs an excessive increase in the amount of drug.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001825,,,,,,,,,,,,,,,,,,,,,,hyperfunction of increasing the amount of drug,,,,,,http://purl.obolibrary.org/obo/TXPO_0001635,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000218,Fak,Focal adhesion kinase,,false,,,http://purl.obolibrary.org/obo/IMR_0000217,,,,,,,,,,,,,,,,,,,,GO:0004717,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Focal adhesion kinase,,,,,IMR:0000218,,,,,,,,,,,,,,,,,,,,,,Fak,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010463,60S ribosomal protein L12,P30050,,false,,,http://purl.obolibrary.org/obo/IMR_0000897,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,P30050,,,,,IMR:0010463,,,,,,,,,,,,,,,,,,,,,,60S ribosomal protein L12,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001113,importin 9,,,false,,,http://purl.obolibrary.org/obo/IMR_0100010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001113,,,,,,,,,,,,,,,,,,,,,,importin 9,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_35942,neurotransmitter agent,neurotransmitter agents,"A substance used for its pharmacological action on any aspect of neurotransmitter systems. Neurotransmitter agents include agonists, antagonists, degradation inhibitors, uptake inhibitors, depleters, precursors, and modulators of receptor function.",false,,,http://purl.obolibrary.org/obo/CHEBI_52210|http://purl.obolibrary.org/obo/CHEBI_23888,,,,,,,,,,,,,,,,,,,,,,"A substance used for its pharmacological action on any aspect of neurotransmitter systems. Neurotransmitter agents include agonists, antagonists, degradation inhibitors, uptake inhibitors, depleters, precursors, and modulators of receptor function.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,neurotransmitter agents,,,,,,,,,,,,,,,,,,,,,CHEBI:35942,,,,neurotransmitter agent,,CHEBI:35942,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000087,Dnajb9 apoptosis inhibitor (rat)[ER stress],ERDJ4,,false,,,http://purl.obolibrary.org/obo/TXPO_0000753|http://purl.obolibrary.org/obo/TXPO_1000114,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24908|https://omim.org/entry/602634,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_68494,,,,,ERDJ4,,,,,TXPO:0000087,,,,,,,,,,,,,,,,,,,,,,Dnajb9 apoptosis inhibitor (rat)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000080,tumor progression marker role,,A role played by the entity that shows an expression change according to the degree of tumor progression.,false,,,http://purl.obolibrary.org/obo/TXPO_0001225,,,,,,,,,,,,,,,,,,,,,,A role played by the entity that shows an expression change according to the degree of tumor progression.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000080,,,,,,,,,,,,,,,,,,,,,,tumor progression marker role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000081,clomipramine_CAD [Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/CHEBI_47780|http://purl.obolibrary.org/obo/TXPO_0001849,,,,,,,,,,,,,,,,,,,,PMID:24003057,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001426,,,,,,,,,,TXPO:0000081,,,,,,,,,,,,,,,,,,,,,,clomipramine_CAD [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000088,increasing acetyl CoA,,Increasing acetyl CoA is a subtype of increasing quantity: A process that changes the amount of acetyl CoA to be larger.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing acetyl CoA is a subtype of increasing quantity: A process that changes the amount of acetyl CoA to be larger.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000088,,,,,,,,,,,,,,,,,,,,,,increasing acetyl CoA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000082,bile acid transport inhibitor role,,A role played by the entity which inhibits bile acid transport process.,false,,,http://purl.obolibrary.org/obo/TXPO_0000056,,,,,,,http://purl.obolibrary.org/obo/GO_0015721,,,,,,,,,,,,,,,A role played by the entity which inhibits bile acid transport process.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000082,,,,,,,,,,,,,,,,,,,,,,bile acid transport inhibitor role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000086,hypofunction of transmembrane transport [Cholestasis],,"Hypofunction of transmembrane transport is a subtype of hypofunction of transport: A process that performs a decreased or insufficient transmembrane transport.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000034|http://purl.obolibrary.org/obo/TXPO_0000085,,,,,,,,,,,,,,,,,,,,,,"Hypofunction of transmembrane transport is a subtype of hypofunction of transport: A process that performs a decreased or insufficient transmembrane transport.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,http://purl.obolibrary.org/obo/GO_0006810,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000086,,,,,,,,,,,,,,,,,,,,,,hypofunction of transmembrane transport [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000085,hypofunction of transmembrane transport,,Hypofunction of transmembrane transport is a subtype of hypofunction of transport: A process that performs a decreased or insufficient transmembrane transport.,false,,,http://purl.obolibrary.org/obo/TXPO_0001911,,,,,,,,,,,,,,,,,,,,,,Hypofunction of transmembrane transport is a subtype of hypofunction of transport: A process that performs a decreased or insufficient transmembrane transport.,,,http://purl.obolibrary.org/obo/GO_0006810,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000085,,,,,,,,,,,,,,,,,,,,,,hypofunction of transmembrane transport,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000084,changing membrane fluidity [Cholestasis],,"Changing membrane fluidity is a subtype of changing fluidity: A process that changes the fluidity of the membrane.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000034|http://purl.obolibrary.org/obo/TXPO_0000412,,,,,,,,,,,,,,,,,,,,,,"Changing membrane fluidity is a subtype of changing fluidity: A process that changes the fluidity of the membrane.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000084,,,,,,,,,,,,,,,,,,,,,,changing membrane fluidity [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000089,apoptotic process [Cholestasis],,"A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000034|http://purl.obolibrary.org/obo/GO_0006915,,,,,,,,,,,,,,,,,,,,,,"A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003312,,,,,,,,,,,TXPO:0000089,,,,,,,,,,,,,,,,,,,,,,apoptotic process [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000083,bile pigment deposition,,"Bile pigment deposition is a subtype of accumulation of pigments: The aggregation of bile pigmentin a particular location in an organism, tissue or cell.",false,,,http://purl.obolibrary.org/obo/GO_0043473,,,,,,,,,,,,,,,,,,,,,,"Bile pigment deposition is a subtype of accumulation of pigments: The aggregation of bile pigmentin a particular location in an organism, tissue or cell.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000083,,,,,,,,,,,,,,,,,,,,,,bile pigment deposition,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_132972,farnesoid X receptor agonist,bile acid receptor agonist|BAR agonist|FXR agonist,An agonist that binds to and activates farnesoid X receptors,false,,,http://purl.obolibrary.org/obo/CHEBI_48705,,,,,,,,,,,,,,,,,,,,Wikipedia:Farnesoid_X_receptor,,An agonist that binds to and activates farnesoid X receptors,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,bile acid receptor agonist|BAR agonist|FXR agonist,,,CHEBI:132972,,,,,,,,,,,,,,,,,,,,,,farnesoid X receptor agonist,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000388,TUBB4A (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:10382|NCBI-Mouse-GeneID:22153|NCBI-Rat-GeneID:29213,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000010382,,,,,,,,,,,,,TXPO:1000388,,,,,,,,,,,,,,,,,,,,,,TUBB4A (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000385,Tomm20 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:266601|NCBI-Human-GeneID:9804|NCBI-Mouse-GeneID:67952,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000009804,,,,,,,,,,,,,TXPO:1000385,,,,,,,,,,,,,,,,,,,,,,Tomm20 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000384,Tnfrsf21 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:94185|NCBI-Human-GeneID:27242|NCBI-Rat-GeneID:316256,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000027242,,,,,,,,,,,,,TXPO:1000384,,,,,,,,,,,,,,,,,,,,,,Tnfrsf21 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000387,Tsc22d3 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:14605|NCBI-Human-GeneID:1831|NCBI-Rat-GeneID:83514,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001831,,,,,,,,,,,,,TXPO:1000387,,,,,,,,,,,,,,,,,,,,,,Tsc22d3 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000381,Taf9 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:108143|NCBI-Human-GeneID:6880|NCBI-Rat-GeneID:373541,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000006880,,,,,,,,,,,,,TXPO:1000381,,,,,,,,,,,,,,,,,,,,,,Taf9 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000380,TWIST1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:22160|NCBI-Human-GeneID:7291|NCBI-Rat-GeneID:85489,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000007291,,,,,,,,,,,,,TXPO:1000380,,,,,,,,,,,,,,,,,,,,,,TWIST1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000383,Tnfrsf12a (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:27279|NCBI-Human-GeneID:51330|NCBI-Rat-GeneID:302965,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000051330,,,,,,,,,,,,,TXPO:1000383,,,,,,,,,,,,,,,,,,,,,,Tnfrsf12a (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000386,Tor1aip2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:240832|NCBI-Rat-GeneID:304881|NCBI-Human-GeneID:163590,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000163590,,,,,,,,,,,,,TXPO:1000386,,,,,,,,,,,,,,,,,,,,,,Tor1aip2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000389,Txnrd1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:7296|NCBI-Rat-GeneID:58819|NCBI-Mouse-GeneID:50493,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000007296,,,,,,,,,,,,,TXPO:1000389,,,,,,,,,,,,,,,,,,,,,,Txnrd1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_9588,ticlopidine,"ticlopidina|ticlopidine|ticlopidinum|5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine","A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Reaxys:1216802|PMID:19180126|LINCS:LSM-1986|Drug_Central:2657|CAS:55142-85-3|DrugBank:DB00208,,"A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_50249|http://purl.obolibrary.org/obo/CHEBI_50248|http://purl.obolibrary.org/obo/CHEBI_50427|http://purl.obolibrary.org/obo/CHEBI_68563|http://purl.obolibrary.org/obo/CHEBI_48676,,,,,"5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine",,ticlopidina|ticlopidine|ticlopidinum,,,,,,,,,,,,,,,,,,,,,CHEBI:9588,,,,ticlopidine,,CHEBI:9588,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100196,alpha-MSH,,A 13-amino acid peptide derived from the ANTERIOR PITUITARY GLAND in man and from the pars intermedia in lower vertebrates. Its amino acid sequence is identical to the first 13 amino acids of ACTH. It influences the formation of deposition of MELANIN in the body.,false,,,http://purl.obolibrary.org/obo/IMR_0100198,,,,,,,,,,,,,,,,,,,,MeSH:D000521,,A 13-amino acid peptide derived from the ANTERIOR PITUITARY GLAND in man and from the pars intermedia in lower vertebrates. Its amino acid sequence is identical to the first 13 amino acids of ACTH. It influences the formation of deposition of MELANIN in the body.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100196,,,,,,,,,,,,,,,,,,,,,,alpha-MSH,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_7864,oxymetholone,"17alpha-methyl-2-hydroxymethylene-17-hydroxy-5alpha-androstan-3-one|Pardroyd|Nastenon|2-hydroxymethylene-17alpha-methyl-17beta-hydroxy-5alpha-androstan-3-one|oxymetholone|2-hydroxymethylene-17alpha-methyl-5alpha-androstan-17beta-ol-3-one|Anapolon|17beta-hydroxy-2-(hydroxymethylene)-17-methyl-5alpha-androstan-3-one|oximetolona|4,5alpha-dihydro-2-hydroxymethylene-17alpha-methyltestosterone|Adroyd|2-hydroxymethylene-17alpha-methyldihydrotestosterone|Synasteron|Anadrol-50|Protanabol|oxymetholonum|Plenastril|(5alpha,17beta)-17-hydroxy-2-(hydroxymethylidene)-17-methylandrostan-3-one|17beta-hydroxy-2-(hydroxymethylidene)-17-methyl-5alpha-androstan-3-one","A 3-oxo-5alpha- steroid that is 4,5alpha-dihydrotestosterone which is substituted by a hydroxymethylidene group at position 2 and by a methyl group at the 17alpha position. A synthetic androgen, it was mainly used for the treatment of anaemias until being replaced by treatments with fewer side effects.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:21860526|PMID:11440282|PMID:11071398|CAS:434-07-1|Reaxys:2623806|PMID:1125426,,"A 3-oxo-5alpha- steroid that is 4,5alpha-dihydrotestosterone which is substituted by a hydroxymethylidene group at position 2 and by a methyl group at the 17alpha position. A synthetic androgen, it was mainly used for the treatment of anaemias until being replaced by treatments with fewer side effects.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_36413|http://purl.obolibrary.org/obo/CHEBI_50113,,,,,17beta-hydroxy-2-(hydroxymethylidene)-17-methyl-5alpha-androstan-3-one,,"17alpha-methyl-2-hydroxymethylene-17-hydroxy-5alpha-androstan-3-one|Pardroyd|Nastenon|2-hydroxymethylene-17alpha-methyl-17beta-hydroxy-5alpha-androstan-3-one|oxymetholone|2-hydroxymethylene-17alpha-methyl-5alpha-androstan-17beta-ol-3-one|Anapolon|17beta-hydroxy-2-(hydroxymethylene)-17-methyl-5alpha-androstan-3-one|oximetolona|4,5alpha-dihydro-2-hydroxymethylene-17alpha-methyltestosterone|Adroyd|2-hydroxymethylene-17alpha-methyldihydrotestosterone|Synasteron|Anadrol-50|Protanabol|oxymetholonum|Plenastril|(5alpha,17beta)-17-hydroxy-2-(hydroxymethylidene)-17-methylandrostan-3-one",,,,,,,,,,,,,,,,,,,,,CHEBI:7864,,,,oxymetholone,,CHEBI:7864,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010551,40S ribosomal protein S26,40S small ribosomal protein 26,,false,,,http://purl.obolibrary.org/obo/IMR_0000896,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,40S small ribosomal protein 26,,,,,IMR:0010551,,,,,,,,,,,,,,,,,,,,,,40S ribosomal protein S26,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010493,60S ribosomal protein L41,HG12,,false,,,http://purl.obolibrary.org/obo/IMR_0000897,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,HG12,,,,,IMR:0010493,,,,,,,,,,,,,,,,,,,,,,60S ribosomal protein L41,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002056,negative regulation of glutathione conjugation,,"Any process that stops, prevents, or reduces the frequency, rate or extent of glutathione conjugation process.",false,,,http://purl.obolibrary.org/obo/TXPO_0000369,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents, or reduces the frequency, rate or extent of glutathione conjugation process.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002056,,,,,,,,,,,,,,,,,,,,,,negative regulation of glutathione conjugation,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003991,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002058,hyperfunction of reduction,,Hyperfunction of reduction is a subtype of hyperfunctioning: A process that performs an excesssive reduction.,false,,,http://purl.obolibrary.org/obo/TXPO_0000435,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of reduction is a subtype of hyperfunctioning: A process that performs an excesssive reduction.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002058,,,,,,,,,,,,,,,,,,,,,,hyperfunction of reduction,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002052,hyperfunction of electron transport from NADH to cytochrome P450,,Hyperfunction of electron transport from NADH to cytochrome P450 is a subtype of hyperfunction of transport: A process that performs an excesssive electron transport from NADH to cytochrome P450.,false,,,http://purl.obolibrary.org/obo/TXPO_0002351,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of electron transport from NADH to cytochrome P450 is a subtype of hyperfunction of transport: A process that performs an excesssive electron transport from NADH to cytochrome P450.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002052,,,,,,,,,,,,,,,,,,,,,,hyperfunction of electron transport from NADH to cytochrome P450,,,,,,http://purl.obolibrary.org/obo/GO_0022900,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002057,negative regulation of cell proliferation inhibitor expression,,"Negative regulation of cell proliferation inhibitor expression is a subtype of negative regulation of gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of cell proliferation inhibitor expression.",false,,,http://purl.obolibrary.org/obo/GO_0010629,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of cell proliferation inhibitor expression is a subtype of negative regulation of gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of cell proliferation inhibitor expression.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002057,,,,,,,,,,,,,,,,,,,,,,negative regulation of cell proliferation inhibitor expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002053,dioxins and dioxin-like compounds accumulation in liver,,Dioxins and dioxin-like compounds accumulation in liver is a subtype of compound accumulation in liver: A process that keeps dioxins and dioxin-like compoundsin the liver.,false,,,http://purl.obolibrary.org/obo/TXPO_0001694,,,,,,,,,,,,,,,,,,,,,,Dioxins and dioxin-like compounds accumulation in liver is a subtype of compound accumulation in liver: A process that keeps dioxins and dioxin-like compoundsin the liver.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002053,,,,,,,,,,,,,,,,,,,,,,dioxins and dioxin-like compounds accumulation in liver,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002054,negative regulation of heat generation,inhibition of heat generation|downregulation of heat generation|down-regulation of heat generation|down regulation of heat generation,"Negative regulation of heat generation is a subtype of negative regulation process:  Any process that stops, prevents, or reduces the rate or extent of heat generation.",false,,,http://purl.obolibrary.org/obo/TXPO_0000369,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of heat generation is a subtype of negative regulation process:  Any process that stops, prevents, or reduces the rate or extent of heat generation.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,downregulation of heat generation|down-regulation of heat generation|down regulation of heat generation,inhibition of heat generation,,,,TXPO:0002054,,,,,,,,,,,,,,,,,,,,,,negative regulation of heat generation,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0031649,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002050,decreasing glycogen level,glycogen depletion,Decreasing glycogen level is a subtype of decreasing quantity: A process that changes the amount of glycogen level to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000396,,,,,,,,,,,,,,,,,,,,MPATH:50,,Decreasing glycogen level is a subtype of decreasing quantity: A process that changes the amount of glycogen level to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,glycogen depletion,,,TXPO:0002050,,,,,,,,,,,,,,,,,,,,,,decreasing glycogen level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002055,mitotic G2/M transition checkpoint,,Mitotic G2/M transition checkpoint is a subtype of negative regulation of G2/M transition of mitotic cell cycle:  A cell cycle checkpoint that detects and negatively regulates progression from G2 to M phase as part of a mitotic cell cycle.,false,,,http://purl.obolibrary.org/obo/TXPO_0000370,,,,,,,,,,,,,,,,,,,,,,Mitotic G2/M transition checkpoint is a subtype of negative regulation of G2/M transition of mitotic cell cycle:  A cell cycle checkpoint that detects and negatively regulates progression from G2 to M phase as part of a mitotic cell cycle.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002055,,,,,,,,,,,,,,,,,,,,,,mitotic G2/M transition checkpoint,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002059,decreasing negative regulator of G1/S transition,,Decreasing negative regulator of G1/S transition is a subtype of decreasing quantity: A process that chanes the quantity of the object with a negative regulator of G1/S role to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000396,,,,,,,,,,,,,,,,,,,,,,Decreasing negative regulator of G1/S transition is a subtype of decreasing quantity: A process that chanes the quantity of the object with a negative regulator of G1/S role to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002059,,,,,,,,,,,,,,,,,,,,,,decreasing negative regulator of G1/S transition,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002051,hyperfunction of Cyp gene expression,,Hyperfunction of Cyp gene expression is a subtype of hyperfunction of drug metabolizing enzyme gene expression: A process that performs an excesssive gene expression of cytochrome p450.,false,,,http://purl.obolibrary.org/obo/TXPO_0002332,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of Cyp gene expression is a subtype of hyperfunction of drug metabolizing enzyme gene expression: A process that performs an excesssive gene expression of cytochrome p450.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002051,,,,,,,,,,,,,,,,,,,,,,hyperfunction of Cyp gene expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000437,arresting function,,Arresting function is a subtype of malfunctioning process: A process that arrests the progress of function execution.,false,,,http://purl.obolibrary.org/obo/TXPO_0000434,,,,,,,,,,,,,,,,,,,,,,Arresting function is a subtype of malfunctioning process: A process that arrests the progress of function execution.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000437,,,,,,,,,,,,,,,,,,,,,,arresting function,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000439,loss of function (process),,Loss of function (process) is a subtype of malfunctioning process: A process that results in no longer having a function or the process that gradually loses it.,false,,,http://purl.obolibrary.org/obo/TXPO_0000434,,,,,,,,,,,,,,,,,,,,,,Loss of function (process) is a subtype of malfunctioning process: A process that results in no longer having a function or the process that gradually loses it.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000439,,,,,,,,,,,,,,,,,,,,,,loss of function (process),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000434,malfunctioning process,,Malfunctioning process is a subtype of function-related process: A process that cannot perform a function appropriately or cannot realize it at all.,false,,,http://purl.obolibrary.org/obo/TXPO_0000145,,,,,,,,,,,,,,,,,,,,,,Malfunctioning process is a subtype of function-related process: A process that cannot perform a function appropriately or cannot realize it at all.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000434,,,,,,,,,,,,,,,,,,,,,,malfunctioning process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000433,keeping position,,Keeping position is a subtype of moving: A process that maintains in the fixed position.,false,,,http://purl.obolibrary.org/obo/TXPO_0000429,,,,,,,,,,,,,,,,,,,,,,Keeping position is a subtype of moving: A process that maintains in the fixed position.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000433,,,,,,,,,,,,,,,,,,,,,,keeping position,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000431,lowering,,Lowering is a subtype of moving: A process that changes the location of the operand from a higher to a lower place or position.,false,,,http://purl.obolibrary.org/obo/TXPO_0000429,,,,,,,,,,,,,,,,,,,,,,Lowering is a subtype of moving: A process that changes the location of the operand from a higher to a lower place or position.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000431,,,,,,,,,,,,,,,,,,,,,,lowering,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000432,moving fluid,,Moving fluid is a subtype of moving: A process that changes the location of the liquid.,false,,,http://purl.obolibrary.org/obo/TXPO_0000429,,,,,,,,,,,,,,,,,,,,,,Moving fluid is a subtype of moving: A process that changes the location of the liquid.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000432,,,,,,,,,,,,,,,,,,,,,,moving fluid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000438,dysfunctioning,,Dysfunctioning is a subtype of malfunctioning process: A process that performs an abnormal and incomplete functioning.,false,,,http://purl.obolibrary.org/obo/TXPO_0000436,,,,,,,,,,,,,,,,,,,,,,Dysfunctioning is a subtype of malfunctioning process: A process that performs an abnormal and incomplete functioning.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000438,,,,,,,,,,,,,,,,,,,,,,dysfunctioning,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000430,elevating,,Elevating is a subtype of moving: A process that changes the location of the operand from a lower to a higher place or position.,false,,,http://purl.obolibrary.org/obo/TXPO_0000429,,,,,,,,,,,,,,,,,,,,,,Elevating is a subtype of moving: A process that changes the location of the operand from a lower to a higher place or position.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000430,,,,,,,,,,,,,,,,,,,,,,elevating,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000435,hyperfunctioning,,Hyperfunctioning is a subtype of malfunctioning process: A process that performs an excessive function.,false,,,http://purl.obolibrary.org/obo/TXPO_0000434,,,,,,,,,,,,,,,,,,,,,,Hyperfunctioning is a subtype of malfunctioning process: A process that performs an excessive function.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000435,,,,,,,,,,,,,,,,,,,,,,hyperfunctioning,,,,,,http://purl.obolibrary.org/obo/TXPO_0000271,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000436,hypofunctioning,decreasing function,Hypofunctioning is a subtype of malfunctioning process: A process that performs a decreased or insufficient functioning.,false,,,http://purl.obolibrary.org/obo/TXPO_0000434,,,,,,,,,,,,,,,,,,,,,,Hypofunctioning is a subtype of malfunctioning process: A process that performs a decreased or insufficient functioning.,,,http://purl.obolibrary.org/obo/BFO_0000015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,decreasing function,,,,,TXPO:0000436,,,,,,,,,,,,,,,,,,,,,,hypofunctioning,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0011157,eIF4GI,P220|eIF-4G|eukaryotic translation initiation factor 4 gamma 1|eIF-4G1|eIF-4-gamma 1,,false,,,http://purl.obolibrary.org/obo/IMR_0000910,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,P220|eIF-4G|eukaryotic translation initiation factor 4 gamma 1|eIF-4G1|eIF-4-gamma 1,,,,,IMR:0011157,,,,,,,,,,,,,,,,,,,,,,eIF4GI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001086,importin alpha3,importin alpha Q2|importin alpha4|karyopherin alpha3|KPNA3,,false,,,http://purl.obolibrary.org/obo/IMR_0100202,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,importin alpha Q2|importin alpha4|karyopherin alpha3|KPNA3,,,,,IMR:0001086,,,,,,,,,,,,,,,,,,,,,,importin alpha3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_27902,tetracycline,"(4S,4aS,5aS,6S,12aS)-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide",A broad-spectrum polyketide antibiotic produced by the Streptomyces genus of actinobacteria.,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:60-54-8|DrugBank:DB00759|Wikipedia:Tetracycline,,A broad-spectrum polyketide antibiotic produced by the Streptomyces genus of actinobacteria.,,,,,,,,,,,,C22H24N2O8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_33281,,,,,"(4S,4aS,5aS,6S,12aS)-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide",,,,,CHEBI:27902,,,,,,,,,,,,,,,,,,,,,,tetracycline,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,[H][C@@]12C[C@@]3([H])C(C(=O)c4c(O)cccc4[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C,,,,,
http://purl.obolibrary.org/obo/CHEBI_10023,voriconazole,"(R-(R*,S*))-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol|(alphaR,betaS)-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol|voriconazolum|Vfend|voriconazol|VCZ|voriconazole|(2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol|voriconazole","A triazole-based antifungal agent used for the treatment of esophageal candidiasis, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp. It is an inhibitor of cytochrome P450 2C9 (CYP2C9) and CYP3A4.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:23392902|PMID:24102553|PMID:23766489|Drug_Central:2846|CAS:137234-62-9|Beilstein:7694998|DrugBank:DB00582|PMID:23527908|PMID:22718362|LINCS:LSM-5244|PMID:12940129,,"A triazole-based antifungal agent used for the treatment of esophageal candidiasis, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp. It is an inhibitor of cytochrome P450 2C9 (CYP2C9) and CYP3A4.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_50183,,,,,"(2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol|voriconazole",,"(R-(R*,S*))-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol|(alphaR,betaS)-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol|voriconazolum|Vfend|voriconazol|VCZ|voriconazole",,,,,,,,,,,,,,,,,,,,,CHEBI:10023,,,,voriconazole,,CHEBI:10023,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0034197,triglyceride transport,triacylglycerol transport,"The directed movement of triglyceride into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Triglycerides are important components of plant oils, animal fats and animal plasma lipoproteins.",false,,,http://purl.obolibrary.org/obo/GO_0006869,,,,,,,,,,,,,,,,,,,,,,"The directed movement of triglyceride into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Triglycerides are important components of plant oils, animal fats and animal plasma lipoproteins.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,triacylglycerol transport,,,,,GO:0034197,,,,,,,,,,,,,,,,,,,,,,triglyceride transport,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002804,Translocation of NF-kappaB [ER stress - inflammation],,"NF-kappaB transport into nucleus is a subtype of nuclear transport: A process that of the directed movement of NF-kappaB from the cytoplasm to the nucleus.
This process is dependent on the inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002633,,,,,,,,,,,,,,,,,,,,,,"NF-kappaB transport into nucleus is a subtype of nuclear transport: A process that of the directed movement of NF-kappaB from the cytoplasm to the nucleus.
This process is dependent on the inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002768,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002805,,,,,,,,,,,TXPO:0002804,,,,,,,,,,,,,,,,,,,,,,Translocation of NF-kappaB [ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002800,decreasing I-kappaB production [ER stress - inflammation -Perk-eIF2a-NfkB],,"Decreasing I-kappaB production is a subtype of decreasing production quantity of protein: A process that changes the quantity of the Iinhibitor of kappa B (I-kappaB) to be lower.
This process is dependent on the Perk-eIF2a-NfkB pathway mediated inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002799,,,,,,,,,,,,,,,,,,,,PMID:25232821|PMID:22249202,,"Decreasing I-kappaB production is a subtype of decreasing production quantity of protein: A process that changes the quantity of the Iinhibitor of kappa B (I-kappaB) to be lower.
This process is dependent on the Perk-eIF2a-NfkB pathway mediated inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002800,,,,,,,,,,,,,,,,,,,,,,decreasing I-kappaB production [ER stress - inflammation -Perk-eIF2a-NfkB],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002803,cation channel,,A role played by the entity which enables the energy-independent passage of cations across a lipid bilayer down a concentration gradient.,false,,,http://purl.obolibrary.org/obo/TXPO_0000328,,,,,,,,,,,,,,,,,,,,related molecular function GO:0005261,,A role played by the entity which enables the energy-independent passage of cations across a lipid bilayer down a concentration gradient.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002803,,,,,,,,,,,,,,,,,,,,,,cation channel,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002809,ubiquitination of IkB [ER stress - inflammation - IRE1-NfKB pathway],,"Ubiquitination of IkB is a subtype of protein ubiquitination: The process in which one or more ubiquitin groups are added to IkB.
This process is dependent on the IRE1-NfkB pathway mediated inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002727,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/HINO_0017767|PMID:12464174,,"Ubiquitination of IkB is a subtype of protein ubiquitination: The process in which one or more ubiquitin groups are added to IkB.
This process is dependent on the IRE1-NfkB pathway mediated inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002810,,,,,,,,,,,TXPO:0002809,,,,,,,,,,,,,,,,,,,,,,ubiquitination of IkB [ER stress - inflammation - IRE1-NfKB pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002801,I-kappaB -NfkB inhibitor [ER stress - inflammation],inhibitor of NF-kappaB [ER stress - inflammation],,false,,,http://purl.obolibrary.org/obo/TXPO_0002802,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000464,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_73240,,,,,inhibitor of NF-kappaB [ER stress - inflammation],,,,,TXPO:0002801,,,,,,,,,,,,,,,,,,,,,,I-kappaB -NfkB inhibitor [ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002807,NF-kappaB activation [ER stress - inflammation - IRE1-TRAF2-IkB-NfkB pathway],,"NF-kappaB activation is a subtype of transcription factor activation: A process that changes the activity of the NF-kappaB to be higher.
This process is dependent on the IRE1-TRAF2-IkB-NfkB pathway mediated inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002782|http://purl.obolibrary.org/obo/TXPO_0003736,,,,,,,,,,,,,,,,,,,,,,"NF-kappaB activation is a subtype of transcription factor activation: A process that changes the activity of the NF-kappaB to be higher.
This process is dependent on the IRE1-TRAF2-IkB-NfkB pathway mediated inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002791,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002815,,,,,,,,,,,TXPO:0002807,,,,,,,,,,,,,,,,,,,,,,NF-kappaB activation [ER stress - inflammation - IRE1-TRAF2-IkB-NfkB pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002808,I-kappaB phosphorylation [ER stress - inflammation - IRE1-NfkB pathway],,"I-kappaB phosphorylation is a subtype of phosphorylation: The process of introducing a phosphate group into an inhibitor of kappa B (I-kappaB) protein. Phosphorylation of I-kappaB targets I-kappaB for ubiquitination and proteasomal degradation, thus releasing bound NF-kappaB dimers, which can translocate to the nucleus to bind DNA and regulate transcription.
This process is dependent on the IRE1-NfkB pathway mediated inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002495,,,,,,,,,,,,,,,,,,,,PMID:12464174|PMID:21772278|GO:0007252|PMID:15134788,,"I-kappaB phosphorylation is a subtype of phosphorylation: The process of introducing a phosphate group into an inhibitor of kappa B (I-kappaB) protein. Phosphorylation of I-kappaB targets I-kappaB for ubiquitination and proteasomal degradation, thus releasing bound NF-kappaB dimers, which can translocate to the nucleus to bind DNA and regulate transcription.
This process is dependent on the IRE1-NfkB pathway mediated inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002777,,,,,,,,,,,TXPO:0002808,,,,,,,,,,,,,,,,,,,,,,I-kappaB phosphorylation [ER stress - inflammation - IRE1-NfkB pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002802,IKB,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000464,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003720,,,,,,,,,,TXPO:0002802,,,,,,,,,,,,,,,,,,,,,,IKB,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002805,inflammatory cytokine gene expression by NF-kappa B via PERK [ER stress - inflammation],,"Inflammatory gene expression by NF-kappa B via PERK is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) related to the inflammation by NF-kappa B via PERK.
This process is dependent on the inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002266|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"Inflammatory gene expression by NF-kappa B via PERK is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) related to the inflammation by NF-kappa B via PERK.
This process is dependent on the inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002794,,,,,http://purl.obolibrary.org/obo/TXPO_0002766,,,,,,,,,,,TXPO:0002805,,,,,,,,,,,,,,,,,,,,,,inflammatory cytokine gene expression by NF-kappa B via PERK [ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002806,inflammatory cytokine gene expression via JNK [ER stress - inflammation],,"Inflammatory cytokine gene expression via JNK is a subtype of gene expression: The process in which a gene sequence is converted into a mature inflammatory cytokine gene product or products (proteins or RNA) via JNK pathway.
This process is dependent on the inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002266|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"Inflammatory cytokine gene expression via JNK is a subtype of gene expression: The process in which a gene sequence is converted into a mature inflammatory cytokine gene product or products (proteins or RNA) via JNK pathway.
This process is dependent on the inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002888|http://purl.obolibrary.org/obo/TXPO_0002835|http://purl.obolibrary.org/obo/TXPO_0002833|http://purl.obolibrary.org/obo/TXPO_0002829|http://purl.obolibrary.org/obo/TXPO_0002827|http://purl.obolibrary.org/obo/TXPO_0002823,,http://purl.obolibrary.org/obo/TXPO_0002599,,,,,,,,,,,,,,,,TXPO:0002806,,,,,,,,,,,,,,,,,,,,,,inflammatory cytokine gene expression via JNK [ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100842,SOCS-6,"Suppressor of cytokine signaling 6|NAP-4|Nck-associated protein 4|Nck, Ash and phospholipase C gamma-binding protein",,false,,,http://purl.obolibrary.org/obo/IMR_0000460,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Suppressor of cytokine signaling 6|NAP-4|Nck-associated protein 4|Nck, Ash and phospholipase C gamma-binding protein",,,,,IMR:0100842,,,,,,,,,,,,,,,,,,,,,,SOCS-6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000123876,ACSM2A,,"Other designations: Homolog of rat kidney-specific (KS)|acyl-coenzyme A synthetase ACSM2A, mitochondrial|butyrate--CoA ligase 2A|butyryl-coenzyme A synthetase 2A|middle-chain acyl-CoA synthetase 2A",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,ACSM2|A-923A4.1,,,,,,,,,,,,16,,,,,,MIM:614358|Vega:OTTHUMG00000177401|HGNC:32017|HPRD:17292|Ensembl:ENSG00000183747,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,acyl-CoA synthetase medium-chain family member 2A,,,16p12.3,,,,,,,,,,,,,,,,"GO_0005524 (EC: IEA); GO_0005739 (EC: NAS, PMID: 19634011); GO_0005759 (EC: IEA); GO_0006631 (EC: IEA); GO_0036112 (EC: IDA, PMID: 19345228); GO_0042593 (EC: NAS, PMID: 16521160); GO_0046872 (EC: IEA); GO_0047760 (EC: IDA, PMID: 19345228); GO_0070328 (EC: NAS, PMID: 16521160)",,,,,,,,,PMID: 10493829; 12477932; 14702039; 16344560; 16521160; 19345228; 19634011; 20877624,,,,,,,,,,,,,,,OGG:3000123876,,20140408,protein-coding,,,,acyl-CoA synthetase medium-chain family member 2A,,,,,,,,,,,,,"Other designations: Homolog of rat kidney-specific (KS)|acyl-coenzyme A synthetase ACSM2A, mitochondrial|butyrate--CoA ligase 2A|butyryl-coenzyme A synthetase 2A|middle-chain acyl-CoA synthetase 2A",,ACSM2A,,,,,,,,,,,,,,,,,,,,,,,123876,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,ACSM2A,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_45979,thiabendazole,"MK 360|2-(thiazol-4-yl)benzimidazole|Equizole|4-(2-benzimidazolyl)thiazole|2-(1,3-thiazol-4-yl)benzimidazole|Mintezol|Thibenzole|TBZ|Tiabendazole|2-(1,3-THIAZOL-4-YL)-1H-BENZIMIDAZOLE|2-(4-thiazolyl)-1H-benzimidazole|2-(1,3-thiazol-4-yl)-1H-benzimidazole|Thiabendazole","A member of the class of benzimidazoles carrying a 1,3-thiazol-4-yl substituent at position 2. A mainly post-harvest fungicide used to control a wide range of diseases including Aspergillus, Botrytis, Cladosporium and Fusarium.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Pesticides:thiabendazole|PMID:11226373|Drug_Central:2621|PMID:13900465|PMID:23790859|Beilstein:611403|PMID:9009055|DrugBank:DB00730|CAS:148-79-8|LINCS:LSM-3741|Reaxys:611403,,"A member of the class of benzimidazoles carrying a 1,3-thiazol-4-yl substituent at position 2. A mainly post-harvest fungicide used to control a wide range of diseases including Aspergillus, Botrytis, Cladosporium and Fusarium.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_86328|http://purl.obolibrary.org/obo/CHEBI_35444,,,,,"2-(1,3-thiazol-4-yl)-1H-benzimidazole|Thiabendazole",,"MK 360|2-(thiazol-4-yl)benzimidazole|Equizole|4-(2-benzimidazolyl)thiazole|2-(1,3-thiazol-4-yl)benzimidazole|Mintezol|Thibenzole|TBZ|Tiabendazole|2-(1,3-THIAZOL-4-YL)-1H-BENZIMIDAZOLE|2-(4-thiazolyl)-1H-benzimidazole",,,,,,,,,,,,,,,,,,,,,CHEBI:45979,,,,thiabendazole,,CHEBI:45979,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100567,FGF-17,,,false,,,http://purl.obolibrary.org/obo/IMR_0000049,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100567,,,,,,,,,,,,,,,,,,,,,,FGF-17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_47519,ketoconazole,"(+-)-cis-1-acetyl-4-(p-((2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazine|Fungoral|Panfungol|ketoconazole|Fungarest|Ketoderm|Nizoral|cis-1-acetyl-4-(4-((2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazine|Ketoisdin|ketoconazol|Xolegel|ketoconazolum|rac-1-acetyl-4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine","A racemate consisting of equimolar amounts of (2R,4S)- and (2S,4R)-ketoconazole.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Open TG-Gates compound_id=00047|CAS:65277-42-1|Gmelin:1713206|Beilstein:4303081|DrugBank:DB01026,,"A racemate consisting of equimolar amounts of (2R,4S)- and (2S,4R)-ketoconazole.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"rac-1-acetyl-4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine",,"(+-)-cis-1-acetyl-4-(p-((2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazine|Fungoral|Panfungol|ketoconazole|Fungarest|Ketoderm|Nizoral|cis-1-acetyl-4-(4-((2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazine|Ketoisdin|ketoconazol|Xolegel|ketoconazolum",,,,,,,,,,,,,,,,,,,,,CHEBI:47519,,,,ketoconazole,,CHEBI:47519,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_50777,etonogestrel,etonogestrelum|3-Oxodesogestrel|etonogestrel|Implanon|3-Ketodesogestrel|17alpha-ethynyl-17beta-hydroxy-11-methylidene-18a-homo-estr-4-en-3-one,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Beilstein:4237530|Drug_Central:1110|CAS:54048-10-1|DrugBank:DB00294,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_59826|http://purl.obolibrary.org/obo/CHEBI_49323|http://purl.obolibrary.org/obo/CHEBI_49324,,,,,17alpha-ethynyl-17beta-hydroxy-11-methylidene-18a-homo-estr-4-en-3-one,,etonogestrelum|3-Oxodesogestrel|etonogestrel|Implanon|3-Ketodesogestrel,,,,,,,,,,,,,,,,,,,,,CHEBI:50777,,,,etonogestrel,,CHEBI:50777,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005036,nodule formation [hepatocarcinogenesis],,"The process in which the anatomical structures of the nodule are generated and organized.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000612|http://purl.obolibrary.org/obo/TXPO_0002340,,,,,,,,,,,,,,,,,,,,PMID:20101231,,"The process in which the anatomical structures of the nodule are generated and organized.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004392,,,,,,,,,,,TXPO:0005036,,,,,,,,,,,,,,,,,,,,,,nodule formation [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005034,increasing blood glucose level [mitochondrial disorder],hyperglycemia,"Increasing blood glucose level is a subtype of increasing concentration: A process that changes the blood glucose concentration in the blood to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0001912,,,,,,,,,,,,,,,,,,,,PMID:26571396,,"Increasing blood glucose level is a subtype of increasing concentration: A process that changes the blood glucose concentration in the blood to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,hyperglycemia,,,,,TXPO:0005034,,,,,,,,,,,,,,,,,,,,,,increasing blood glucose level [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005033,malfunctioning of  cytokinesis,,Malfunctioning of cytokinesis is a subtype of malfunctioning process: A process that cannot perform cytokinesis appropriately or cannot realize it at all.,false,,,http://purl.obolibrary.org/obo/TXPO_0000434,,,,,,,,,,,,,,,,,,,,,,Malfunctioning of cytokinesis is a subtype of malfunctioning process: A process that cannot perform cytokinesis appropriately or cannot realize it at all.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005033,,,,,,,,,,,,,,,,,,,,,,malfunctioning of  cytokinesis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005031,release of inflammatory DAMPs [mitochondrial disorder],,"The process that results in the movement of inflammatory DAMPs from the  mitochondria.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0005139|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:31623280,,"The process that results in the movement of inflammatory DAMPs from the  mitochondria.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004271|http://purl.obolibrary.org/obo/TXPO_0004340|http://purl.obolibrary.org/obo/TXPO_0004253,,,,,,,,,,,TXPO:0005031,,,,,,,,,,,,,,,,,,,,,,release of inflammatory DAMPs [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005035,cellular damage [hepatocarcinogenesis],,"Cellular damage is a subtype of damaging: A process that injuries the structure of the cell as the direct or indirect result of an external force.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0000225,,,,,,,,,,,,,,,,,,,,PMID:31623280,,"Cellular damage is a subtype of damaging: A process that injuries the structure of the cell as the direct or indirect result of an external force.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004818|http://purl.obolibrary.org/obo/TXPO_0004392,,,,,,,,,,,TXPO:0005035,,,,,,,,,,,,,,,,,,,,,,cellular damage [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005039,increasing lipid concentration [mitochondrial disorder],hyperlipidemia,"Increasing lipid concentration in blood is a subtype of increasing concentration: A process that changes the lipid concentration in  the blood to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0005043|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:26571396,,"Increasing lipid concentration in blood is a subtype of increasing concentration: A process that changes the lipid concentration in  the blood to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,hyperlipidemia,,,,,TXPO:0005039,,,,,,,,,,,,,,,,,,,,,,increasing lipid concentration [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005038,Increasing lipid [hepatocarcinogenesis],,"Increasing lipid  is a subtype of increasing quantity: A process that changes the amount of lipid to be larger.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0001062,,,,,,,,,,,,,,,,,,,,PMID:25607821,,"Increasing lipid  is a subtype of increasing quantity: A process that changes the amount of lipid to be larger.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004803,,,,,,,,,,,TXPO:0005038,,,,,,,,,,,,,,,,,,,,,,Increasing lipid [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005030,increasing damaged mitochondria,,Increasing damaged mitochondria is a subtype of decreasing quantity: A process that changes the amount of damaged mitochondria to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing damaged mitochondria is a subtype of decreasing quantity: A process that changes the amount of damaged mitochondria to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005030,,,,,,,,,,,,,,,,,,,,,,increasing damaged mitochondria,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005032,negative regulation of ROS formation [hepatocarcinogenesis],negative regulation of reactive oxygen species biosynthetic process,"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of ROS.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/GO_1903427|http://purl.obolibrary.org/obo/TXPO_0002340,,,,,,,,,,,,,,,,,,,,PMID:25797246,,"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of ROS.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004431,,,,,,negative regulation of reactive oxygen species biosynthetic process,,,,,TXPO:0005032,,,,,,,,,,,,,,,,,,,,,,negative regulation of ROS formation [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_1903409,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005037,hepatocyte regeneration,,Hepatocyte regeneration is a subtype of changing material: The regrowth of lost or destroyed hepatocytes.,false,,,http://purl.obolibrary.org/obo/GO_0042246,,,,,,,,,,,,,,,,,,,,,,Hepatocyte regeneration is a subtype of changing material: The regrowth of lost or destroyed hepatocytes.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005037,,,,,,,,,,,,,,,,,,,,,,hepatocyte regeneration,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_62434,EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor,Eyk inhibitor|KIA0641 inhibitor|NEP inhibitor|EGFR inhibitor|receptor protein-tyrosine kinase (EC 2.7.10.1) inhibitors|anaplastic lymphoma kinase inhibitors|ACH inhibitor|AATK inhibitor|PTK7 inhibitor|EC 2.7.10.1 inhibitor|nork inhibitor|PDGFR inhibitor|LTK inhibitor|Cek10 inhibitor|Kin15 inhibitor|FGFR2 inhibitor|DAlk inhibitor|CAK inhibitor|NTRK2 inhibitor|PTK inhibitor|Kin16 inhibitor|SKY inhibitor|EPHA8 inhibitor|DDR2 inhibitor|AATYK inhibitor|JTK12 inhibitor|MTC1 inhibitor|ROR1 inhibitor|HGFR inhibitor|VEGFR2 inhibitor|EC 2.7.10.1 inhibitors|Ehk2 inhibitor|Bek inhibitor|MEN2A/B inhibitor|EphB5 inhibitor|Vik inhibitor|FLT1 inhibitor|KIAA1079 inhibitor|novel oncogene with kinase-domain inhibitor|STK inhibitor|receptor protein-tyrosine kinase inhibitor|Ehk3 inhibitor|MERTK inhibitor|MER inhibitor|Cek2 inhibitor|Mlk2 inhibitor|TIF inhibitor|FLT2 inhibitor|EPH inhibitor|FLK2 inhibitor|ERBB1 inhibitor|ATP:[protein]-L-tyrosine O-phosphotransferase (receptor-type) inhibitor|HEP inhibitor|anaplastic lymphoma kinase inhibitor|TYRO3 inhibitor|Kil inhibitor|CFD1 inhibitor|HTK inhibitor|CCK4 inhibitor|DTK inhibitor|SEA inhibitor|PHB6 inhibitor|NET inhibitor|FLT4 inhibitor|Drosophila Eph kinase inhibitor|Sfr inhibitor|TRK inhibitor|ALK inhibitors|FMS inhibitor|Fv2 inhibitor|VEGFR1 inhibitor|CDw135 inhibitor|Mlk1 inhibitor|ROS1 inhibitor|UFO inhibitor|INSR inhibitor|insulin receptor protein-tyrosine kinase inhibitor|Mdk1 inhibitor|TYK1 inhibitor|NGL inhibitor|NYK inhibitor|EPHA1 inhibitor|KIAA1459 inhibitor|RSE inhibitor|Yrk inhibitor|KGFR inhibitor|STK1 inhibitor|TRKB inhibitor|Cek5 inhibitor|Cek6 inhibitor|Sek2 inhibitor|ERBB3 inhibitor|RON inhibitor|Neu inhibitor|EPHT2 inhibitor|ERK inhibitor|MCF3 inhibitor|EPHA6 inhibitor|FLT3 inhibitor|HER4 inhibitor|Sek3 inhibitor|TIE1 inhibitor|TRKA inhibitor|TIE inhibitor|CKIT inhibitor|YK1 inhibitor|PCL inhibitor|Mrk inhibitor|EPHB1 inhibitor|FLK1 inhibitor|ROR2 inhibitor|Tyro11 inhibitor|RTK inhibitor|ERBB4 inhibitor|receptor protein tyrosine kinase inhibitor|KIT inhibitor|IGF1R inhibitor|TRKC inhibitor|Dek inhibitor|EPHX inhibitor|ARK inhibitor|RYK inhibitor|CD135 inhibitor|N-SAM inhibitor|EDDR1 inhibitor|NTRKR3 inhibitor|TIE2 inhibitor|JTK14 inhibitor|Cek7 inhibitor|NTRK1 inhibitor|KLG inhibitor|EPHB3 inhibitor|HEK11 inhibitor|EPHB4 inhibitor|Tyro5 inhibitor|neurite outgrowth regulating kinase inhibitor|KDR inhibitor|FGFR4 inhibitor|JWS inhibitor|Nsk2 inhibitor|HER3 inhibitor|DKFZp434C1418 inhibitor|Tyro6 inhibitor|ERBB inhibitor|Bfgfr inhibitor|MUSK inhibitor|Elk inhibitor|Sek4 inhibitor|HEK5 inhibitor|MEhk1 inhibitor|PDGFRA inhibitor|FGFR3 inhibitor|BRT inhibitor|Cek3 inhibitor|NTRKR1 inhibitor|EPHB2 inhibitor|Nuk inhibitor|CD115 inhibitor|NOK inhibitor|AXL inhibitor|ALK inhibitor|INSRR inhibitor|CSF1R inhibitor|Mdk5 inhibitor|PDGFRB inhibitor|TRKE inhibitor|ephrin-B3 receptor tyrosine kinase inhibitor|EPHA2 inhibitor|EPHT3 inhibitor|HEK2 inhibitor|AATYK3 inhibitor|Myk1 inhibitor|receptor protein-tyrosine kinase inhibitors|Bsk inhibitor|AATYK2 inhibitor|HSCR1 inhibitor|ECK inhibitor|NTRK3 inhibitor|EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitors|Ebk inhibitor|IR inhibitor|VEGFR3 inhibitor|JTK13 inhibitor|Mep inhibitor|HEK3 inhibitor|PTK3 inhibitor|MST1R inhibitor|NTRK4 inhibitor|C-FMS inhibitor|ATP:[protein]-L-tyrosine O-phosphotransferase (receptor-type) inhibitors|HEK6 inhibitor|Cek11 inhibitor|IRR inhibitor|TYRO10 inhibitor|ERBB2 inhibitor|K-SAM inhibitor|DDR1 inhibitor|FLG inhibitor|EPHT inhibitor|FGFR1 inhibitor|DRT inhibitor|TEK inhibitor|EPHA7 inhibitor|Mdk2 inhibitor|Eek inhibitor|receptor protein-tyrosine kinase (EC 2.7.10.1) inhibitor|NTRKR2 inhibitor|HER2 inhibitor|Cek1 inhibitor|HBGFR inhibitor|TYRO7 inhibitor|TKT inhibitor|RET inhibitor,An EC 2.7.10.* (protein-tyrosine kinase) inhibitor that interferes with the action of receptor protein-tyrosine kinase (EC 2.7.10.1).,false,,,http://purl.obolibrary.org/obo/CHEBI_38637|http://purl.obolibrary.org/obo/CHEBI_76817,,,,,,,,,,,,,,,,,,,,,,An EC 2.7.10.* (protein-tyrosine kinase) inhibitor that interferes with the action of receptor protein-tyrosine kinase (EC 2.7.10.1).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Eyk inhibitor|KIA0641 inhibitor|NEP inhibitor|EGFR inhibitor|receptor protein-tyrosine kinase (EC 2.7.10.1) inhibitors|anaplastic lymphoma kinase inhibitors|ACH inhibitor|AATK inhibitor|PTK7 inhibitor|EC 2.7.10.1 inhibitor|nork inhibitor|PDGFR inhibitor|LTK inhibitor|Cek10 inhibitor|Kin15 inhibitor|FGFR2 inhibitor|DAlk inhibitor|CAK inhibitor|NTRK2 inhibitor|PTK inhibitor|Kin16 inhibitor|SKY inhibitor|EPHA8 inhibitor|DDR2 inhibitor|AATYK inhibitor|JTK12 inhibitor|MTC1 inhibitor|ROR1 inhibitor|HGFR inhibitor|VEGFR2 inhibitor|EC 2.7.10.1 inhibitors|Ehk2 inhibitor|Bek inhibitor|MEN2A/B inhibitor|EphB5 inhibitor|Vik inhibitor|FLT1 inhibitor|KIAA1079 inhibitor|novel oncogene with kinase-domain inhibitor|STK inhibitor|receptor protein-tyrosine kinase inhibitor|Ehk3 inhibitor|MERTK inhibitor|MER inhibitor|Cek2 inhibitor|Mlk2 inhibitor|TIF inhibitor|FLT2 inhibitor|EPH inhibitor|FLK2 inhibitor|ERBB1 inhibitor|ATP:[protein]-L-tyrosine O-phosphotransferase (receptor-type) inhibitor|HEP inhibitor|anaplastic lymphoma kinase inhibitor|TYRO3 inhibitor|Kil inhibitor|CFD1 inhibitor|HTK inhibitor|CCK4 inhibitor|DTK inhibitor|SEA inhibitor|PHB6 inhibitor|NET inhibitor|FLT4 inhibitor|Drosophila Eph kinase inhibitor|Sfr inhibitor|TRK inhibitor|ALK inhibitors|FMS inhibitor|Fv2 inhibitor|VEGFR1 inhibitor|CDw135 inhibitor|Mlk1 inhibitor|ROS1 inhibitor|UFO inhibitor|INSR inhibitor|insulin receptor protein-tyrosine kinase inhibitor|Mdk1 inhibitor|TYK1 inhibitor|NGL inhibitor|NYK inhibitor|EPHA1 inhibitor|KIAA1459 inhibitor|RSE inhibitor|Yrk inhibitor|KGFR inhibitor|STK1 inhibitor|TRKB inhibitor|Cek5 inhibitor|Cek6 inhibitor|Sek2 inhibitor|ERBB3 inhibitor|RON inhibitor|Neu inhibitor|EPHT2 inhibitor|ERK inhibitor|MCF3 inhibitor|EPHA6 inhibitor|FLT3 inhibitor|HER4 inhibitor|Sek3 inhibitor|TIE1 inhibitor|TRKA inhibitor|TIE inhibitor|CKIT inhibitor|YK1 inhibitor|PCL inhibitor|Mrk inhibitor|EPHB1 inhibitor|FLK1 inhibitor|ROR2 inhibitor|Tyro11 inhibitor|RTK inhibitor|ERBB4 inhibitor|receptor protein tyrosine kinase inhibitor|KIT inhibitor|IGF1R inhibitor|TRKC inhibitor|Dek inhibitor|EPHX inhibitor|ARK inhibitor|RYK inhibitor|CD135 inhibitor|N-SAM inhibitor|EDDR1 inhibitor|NTRKR3 inhibitor|TIE2 inhibitor|JTK14 inhibitor|Cek7 inhibitor|NTRK1 inhibitor|KLG inhibitor|EPHB3 inhibitor|HEK11 inhibitor|EPHB4 inhibitor|Tyro5 inhibitor|neurite outgrowth regulating kinase inhibitor|KDR inhibitor|FGFR4 inhibitor|JWS inhibitor|Nsk2 inhibitor|HER3 inhibitor|DKFZp434C1418 inhibitor|Tyro6 inhibitor|ERBB inhibitor|Bfgfr inhibitor|MUSK inhibitor|Elk inhibitor|Sek4 inhibitor|HEK5 inhibitor|MEhk1 inhibitor|PDGFRA inhibitor|FGFR3 inhibitor|BRT inhibitor|Cek3 inhibitor|NTRKR1 inhibitor|EPHB2 inhibitor|Nuk inhibitor|CD115 inhibitor|NOK inhibitor|AXL inhibitor|ALK inhibitor|INSRR inhibitor|CSF1R inhibitor|Mdk5 inhibitor|PDGFRB inhibitor|TRKE inhibitor|ephrin-B3 receptor tyrosine kinase inhibitor|EPHA2 inhibitor|EPHT3 inhibitor|HEK2 inhibitor|AATYK3 inhibitor|Myk1 inhibitor|receptor protein-tyrosine kinase inhibitors|Bsk inhibitor|AATYK2 inhibitor|HSCR1 inhibitor|ECK inhibitor|NTRK3 inhibitor|EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitors|Ebk inhibitor|IR inhibitor|VEGFR3 inhibitor|JTK13 inhibitor|Mep inhibitor|HEK3 inhibitor|PTK3 inhibitor|MST1R inhibitor|NTRK4 inhibitor|C-FMS inhibitor|ATP:[protein]-L-tyrosine O-phosphotransferase (receptor-type) inhibitors|HEK6 inhibitor|Cek11 inhibitor|IRR inhibitor|TYRO10 inhibitor|ERBB2 inhibitor|K-SAM inhibitor|DDR1 inhibitor|FLG inhibitor|EPHT inhibitor|FGFR1 inhibitor|DRT inhibitor|TEK inhibitor|EPHA7 inhibitor|Mdk2 inhibitor|Eek inhibitor|receptor protein-tyrosine kinase (EC 2.7.10.1) inhibitor|NTRKR2 inhibitor|HER2 inhibitor|Cek1 inhibitor|HBGFR inhibitor|TYRO7 inhibitor|TKT inhibitor|RET inhibitor,,,,,,,,,,,,,,,,,,,,,CHEBI:62434,,,,EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor,,CHEBI:62434,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0006314,bodily fluid,fluid|body fluid,Liquid components of living organisms. includes fluids that are excreted or secreted from the body as well as body water that normally is not.,false,,,http://purl.obolibrary.org/obo/UBERON_0000463,,,,,,,,,,,,,,,,,,,,http://uri.neuinfo.org/nif/nifstd/birnlex_20|http://en.wikipedia.org/wiki/Body_fluid|FMA:280556|galen:BodyFluid|GAID:266|MESH:D001826,,Liquid components of living organisms. includes fluids that are excreted or secreted from the body as well as body water that normally is not.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,body fluid,,,,,UBERON:0006314,,,,,,,,,,,,,,,,fluid,,,,,,bodily fluid,,,,,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002423,hydrophobicity attribute,,A physical attribute inhering in a bearer by virtue the bearer's disposition to being water-repellent; tending to repel and not absorb water.,false,,,http://purl.obolibrary.org/obo/TXPO_0000305,,,,,,,,,,,,,,,,,,,,,,A physical attribute inhering in a bearer by virtue the bearer's disposition to being water-repellent; tending to repel and not absorb water.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002423,,,,,,,,,,,,,,,,,,,,,,hydrophobicity attribute,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002429,activation (attribute),activity (attribute),An attribute that inheres in a bearer in virtue of its realizing one of its functions.,false,,,http://purl.obolibrary.org/obo/TXPO_0000305,,,,,,,,,,,,,,,,,,,,,,An attribute that inheres in a bearer in virtue of its realizing one of its functions.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,activity (attribute),,,,,TXPO:0002429,,,,,,,,,,,,,,,,,,,,,,activation (attribute),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002424,age attribute,,A time attribute inhering in a bearer by virtue of how long the bearer has existed.,false,,,http://purl.obolibrary.org/obo/TXPO_0001536,,,,,,,,,,,,,,,,,,,,,,A time attribute inhering in a bearer by virtue of how long the bearer has existed.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002424,,,,,,,,,,,,,,,,,,,,,,age attribute,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002421,membrane potential attribute,,An attribute entity inhering in a cell's plasma membrane by virtue of the electrical potential difference across it.,false,,,http://purl.obolibrary.org/obo/TXPO_0002420,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0001462,,An attribute entity inhering in a cell's plasma membrane by virtue of the electrical potential difference across it.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002421,,,,,,,,,,,,,,,,,,,,,,membrane potential attribute,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002427,female value,,A biological sex value inhering in an individual or a population that only produces gametes that can be fertilised by male gametes.,false,,,http://purl.obolibrary.org/obo/TXPO_0002426,,,,,,,,,,,,,,,,,,,,,,A biological sex value inhering in an individual or a population that only produces gametes that can be fertilised by male gametes.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002427,,,,,,,,,,,,,,,,,,,,,,female value,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002422,hydrophilicity attribute,,A physical attribute inhering in a bearer by virtue the bearer's disposition to having an affinity for water; it is readily absorbing or dissolving in water.,false,,,http://purl.obolibrary.org/obo/TXPO_0000305,,,,,,,,,,,,,,,,,,,,,,A physical attribute inhering in a bearer by virtue the bearer's disposition to having an affinity for water; it is readily absorbing or dissolving in water.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002422,,,,,,,,,,,,,,,,,,,,,,hydrophilicity attribute,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002425,biological sex (attribute),,An organismal attribute inhering in a bearer by virtue of the bearer's ability to undergo sexual reproduction in order to differentiate the individuals or types involved.,false,,,http://purl.obolibrary.org/obo/TXPO_0000305,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0000047,,An organismal attribute inhering in a bearer by virtue of the bearer's ability to undergo sexual reproduction in order to differentiate the individuals or types involved.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002425,,,,,,,,,,,,,,,,,,,,,,biological sex (attribute),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002420,electric potential attribute,,"An attribute to the potential energy per unit charge associated with a static (time-invariant) electric field, also called the electrostatic potential.",false,,,http://purl.obolibrary.org/obo/TXPO_0000305,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0001464,,"An attribute to the potential energy per unit charge associated with a static (time-invariant) electric field, also called the electrostatic potential.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002420,,,,,,,,,,,,,,,,,,,,,,electric potential attribute,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002426,biological sex value,,,false,,,http://purl.obolibrary.org/obo/TXPO_0000277,,,,,,,,,,,,,,,,,,,,An organismal value of an attribute inhering in a bearer by virtue of the bearer's ability to undergo sexual reproduction in order to differentiate the individuals or types involved.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002426,,,,,,,,,,,,,,,,,,,,,,biological sex value,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002428,male value,,A biological sex attribute inhering in an individual or a population whose sex organs contain only male gametes.,false,,,http://purl.obolibrary.org/obo/TXPO_0002426,,,,,,,,,,,,,,,,,,,,,,A biological sex attribute inhering in an individual or a population whose sex organs contain only male gametes.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002428,,,,,,,,,,,,,,,,,,,,,,male value,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0044565,dendritic cell proliferation,,"The expansion of a dendritic cell population by cell division. A dendritic cell is a cell of hematopoietic origin, typically resident in particular tissues, specialized in the uptake, processing, and transport of antigens to lymph nodes for the purpose of stimulating an immune response via T cell activation.",false,,,http://purl.obolibrary.org/obo/GO_0046651,,,,,,,,,,,,,,,,,,,,,,"The expansion of a dendritic cell population by cell division. A dendritic cell is a cell of hematopoietic origin, typically resident in particular tissues, specialized in the uptake, processing, and transport of antigens to lymph nodes for the purpose of stimulating an immune response via T cell activation.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0044565,,,,,,,,,,,,,,,,,,,,,,dendritic cell proliferation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_31596,febuxostat,"febuxostat|febuxostatum|TEI-6720|2-(3-cyano-4-isobutoxyphenyl)-4-methyl-1,3-thiazole-5-carboxylic acid|TMX 67|Feburic|Goturic|TMX-67|Donifoxate|Goutex|Adenuric|Zurig|Uloric|TEI 6720|Febuday|2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid","A 1,3-thiazolemonocarboxylic acid that is 4-methyl-1,3-thiazole-5-carboxylic acid which is substituted by a 3-cyano-4-(2-methylpropoxy)phenyl group at position 2. It is an orally-active, potent, and selective xanthine oxidase inhibitor used for the treatment of chronic hyperuricaemia in patients with gout.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:31332638|PMID:31335677|PMID:31447893|PMID:31449565|PMID:31560952|PMID:25724536|CAS:144060-53-7|DrugBank:DB04854|PMID:31499267|Drug_Central:1137|PMID:31378626|LINCS:LSM-3064|PMID:30919894|PMID:30844048|PMID:31531831|PMID:31267805,,"A 1,3-thiazolemonocarboxylic acid that is 4-methyl-1,3-thiazole-5-carboxylic acid which is substituted by a 3-cyano-4-(2-methylpropoxy)phenyl group at position 2. It is an orally-active, potent, and selective xanthine oxidase inhibitor used for the treatment of chronic hyperuricaemia in patients with gout.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35634,,,,,"2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid",,"febuxostat|febuxostatum|TEI-6720|2-(3-cyano-4-isobutoxyphenyl)-4-methyl-1,3-thiazole-5-carboxylic acid|TMX 67|Feburic|Goturic|TMX-67|Donifoxate|Goutex|Adenuric|Zurig|Uloric|TEI 6720|Febuday",,,,,,,,,,,,,,,,,,,,,CHEBI:31596,,,,febuxostat,,CHEBI:31596,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000003604,TNFRSF9,,"Other designations: 4-1BB ligand receptor|CD137 antigen|T cell antigen ILA|T-cell antigen 4-1BB homolog|T-cell antigen ILA|homolog of mouse 4-1BB|induced by lymphocyte activation (ILA)|interleukin-activated receptor, homolog of mouse Ly63|receptor protein 4-1BB|tumor necrosis factor receptor superfamily member 9",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CDw137|ILA|CD137|4-1BB,,,,,,,,,,,,1,,,,,,HPRD:03767|HGNC:11924|MIM:602250,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"tumor necrosis factor receptor superfamily, member 9",,,1p36,,,,,,,,,,,,,,,,"GO_0004872 (EC: IEA); GO_0005615 (EC: IEA); GO_0005887 (EC: TAS, PMID: 8262389); GO_0006915 (EC: TAS, PMID: 8639902); GO_0008285 (EC: TAS, PMID: 8639902); GO_0009897 (EC: IEA); GO_0019955 (EC: IEA); GO_0070207 (EC: IEA); GO_2001180 (EC: IEA); GO_2001183 (EC: IEA)",,,,,,,,,PMID: 2784565; 7622190; 8088337; 8262389; 8639902; 9045669; 9207223; 9418902; 9464265; 9541583; 9607925; 10556203; 10604232; 11804328; 11828369; 11970964; 12009595; 12101260; 12356681; 12384425; 12477932; 12516549; 12645943; 13130507; 14716821; 15031666; 15301860; 15308117; 15340161; 15342556; 15353478; 15489334; 15618293; 15638367; 15941918; 16232366; 16596186; 16710414; 17309825; 17878391; 17878400; 18024793; 18276843; 18519814; 18645038; 18668547; 18768897; 18838252; 19211796; 19406689; 19573080; 19759901; 19773279; 19913121; 20008291; 20026323; 20190752; 20237496; 20347151; 20568250; 20616340; 20628086; 20643812; 21297633; 21396356; 21669186; 21670469; 21745658; 21747409; 21890473; 21963611; 22144129; 22204816; 22282196; 22326955; 22343053; 22343199; 22593548; 22797667; 22896640; 22901750; 23000965; 23128233; 23204227; 23437083; 23557259; 23560068; 23640752; 23690480; 23750604,,,,,,,,,,,,,,,OGG:3000003604,,,,,,,"tumor necrosis factor receptor superfamily, member 9",,,,,,,,,,,,,"Other designations: 4-1BB ligand receptor|CD137 antigen|T cell antigen ILA|T-cell antigen 4-1BB homolog|T-cell antigen ILA|homolog of mouse 4-1BB|induced by lymphocyte activation (ILA)|interleukin-activated receptor, homolog of mouse Ly63|receptor protein 4-1BB|tumor necrosis factor receptor superfamily member 9",,TNFRSF9,,,,,,,,,,,,,,,,,,,,,,,3604,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,TNFRSF9,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/GO_0052697,xenobiotic glucuronidation,,"The modification of a xenobiotic substance by the conjugation of glucuronic acid. The resultant glucuronosides are often much more water-soluble than the xenobiotic precursor, enabling efficient excretion.",false,,,http://purl.obolibrary.org/obo/GO_0019585,,,,,,,,,,,,,,,,,,,,,,"The modification of a xenobiotic substance by the conjugation of glucuronic acid. The resultant glucuronosides are often much more water-soluble than the xenobiotic precursor, enabling efficient excretion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0052697,,,,,,,,,,,,,,,,,,,,,,xenobiotic glucuronidation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_75768,mammalian metabolite,mammalian metabolites,Any animal metabolite produced during a metabolic reaction in mammals.,false,,,http://purl.obolibrary.org/obo/CHEBI_75767,,,,,,,,,,,,,,,,,,,,,,Any animal metabolite produced during a metabolic reaction in mammals.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,mammalian metabolites,,,,,,,,,,,,,,,,,,,,,CHEBI:75768,,,,mammalian metabolite,,CHEBI:75768,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100102,growth hormone (mol),somatotropin|GH,"A polypeptide that is secreted by the adenohypophysis ( PITUITARY GLAND, ANTERIOR). Growth hormone, also known as somatotropin, stimulates mitosis, cell differentiation and cell growth. Species-specific growth hormones have been synthesized.",false,,,http://purl.obolibrary.org/obo/IMR_0100096,,,,,,,,,,,,,,,,,,,,MeSH:D013006,,"A polypeptide that is secreted by the adenohypophysis ( PITUITARY GLAND, ANTERIOR). Growth hormone, also known as somatotropin, stimulates mitosis, cell differentiation and cell growth. Species-specific growth hormones have been synthesized.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,somatotropin|GH,,,,,IMR:0100102,,,,,,,,,,,,,,,,,,,,,,growth hormone (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001088,importin alpha6,KPNA5|karyopherin alpha5,,false,,,http://purl.obolibrary.org/obo/IMR_0100202,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,KPNA5|karyopherin alpha5,,,,,IMR:0001088,,,,,,,,,,,,,,,,,,,,,,importin alpha6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100840,SOCS-4,CIS-4|Cytokine-inducible SH2 protein 4|Suppressor of cytokine signaling 4,,false,,,http://purl.obolibrary.org/obo/IMR_0000460,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CIS-4|Cytokine-inducible SH2 protein 4|Suppressor of cytokine signaling 4,,,,,IMR:0100840,,,,,,,,,,,,,,,,,,,,,,SOCS-4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_88188,drug allergen,allergenic drug,Any drug which causes the onset of an allergic reaction.,false,,,http://purl.obolibrary.org/obo/CHEBI_23888|http://purl.obolibrary.org/obo/CHEBI_50904,,,,,,,,,,,,,,,,,,,,,,Any drug which causes the onset of an allergic reaction.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,allergenic drug,,,,,,,,,,,,,,,,,,,,,CHEBI:88188,,,,drug allergen,,CHEBI:88188,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0030163,protein catabolic process,protein degradation|protein catabolism|protein breakdown,"The chemical reactions and pathways resulting in the breakdown of a protein by the destruction of the native, active configuration, with or without the hydrolysis of peptide bonds.|This term refers to the breakdown of mature proteins. For cleavage events involved in generating a mature protein from a precursor, consider instead the term 'protein maturation ; GO:0051604' and its children.",false,,,http://purl.obolibrary.org/obo/GO_0009056,,,,,,,,,,,,,,,,,,,,Wikipedia:Protein_catabolism,,"The chemical reactions and pathways resulting in the breakdown of a protein by the destruction of the native, active configuration, with or without the hydrolysis of peptide bonds.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_36080,,,,,,,,,,,,,,,,,,protein degradation|protein catabolism|protein breakdown,,,,,GO:0030163,,,,,,,,,,,,,,,,,,,,"This term refers to the breakdown of mature proteins. For cleavage events involved in generating a mature protein from a precursor, consider instead the term 'protein maturation ; GO:0051604' and its children.",,protein catabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_36080,protein,,An amino acid chain that is produced de novo by ribosome-mediated translation of a genetically-encoded mRNA.,false,,,http://purl.obolibrary.org/obo/CHEBI_16670|http://purl.obolibrary.org/obo/CHEBI_33694,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PR_000000001,,An amino acid chain that is produced de novo by ribosome-mediated translation of a genetically-encoded mRNA.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:36080,,,,,,,,,,,,,,,,,,,,,,protein,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0070646,protein modification by small protein removal,,"A protein modification process in which one or more covalently attached groups of a small protein, such as ubiquitin or a ubiquitin-like protein, are removed from a target protein.",false,,,http://purl.obolibrary.org/obo/GO_0070647,,,,,,,,,,,,,,,,,,,,,,"A protein modification process in which one or more covalently attached groups of a small protein, such as ubiquitin or a ubiquitin-like protein, are removed from a target protein.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0070646,,,,,,,,,,,,,,,,,,,,,,protein modification by small protein removal,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0070647,protein modification by small protein conjugation or removal,,"A protein modification process in which one or more groups of a small protein, such as ubiquitin or a ubiquitin-like protein, are covalently attached to or removed from a target protein.",false,,,http://purl.obolibrary.org/obo/GO_0036211,,,,,,,,,,,,,,,,,,,,,,"A protein modification process in which one or more groups of a small protein, such as ubiquitin or a ubiquitin-like protein, are covalently attached to or removed from a target protein.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0070647,,,,,,,,,,,,,,,,,,,,,,protein modification by small protein conjugation or removal,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002541,optional contribution process,,"Optional contribution processis a subtype of meta-functioning and it represents optional contribution to functioning.
The “optional” means that the effect of fa is not mandatory to ft, that is, ft can be performed without the effect of fa.",false,,,http://purl.obolibrary.org/obo/TXPO_0000600,,,,,,,,,,,,,,,,,,,,,,"Optional contribution processis a subtype of meta-functioning and it represents optional contribution to functioning.
The “optional” means that the effect of fa is not mandatory to ft, that is, ft can be performed without the effect of fa.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002541,,,,,,,,,,,,,,,,,,,,,,optional contribution process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002547,negative regulation of increasing insulin resistance [ER stress],,"Negative regulation of increasing insulin resistance is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of insulin resistance.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002537|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of increasing insulin resistance is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of insulin resistance.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002547,,,,,,,,,,,,,,,,,,,,,,negative regulation of increasing insulin resistance [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002540,GRP78 - chaperone (canonical)[ER stress - refolding [early stage],BIP- chaperone [ER stress - refolding [early stage]|HSPA5- chaperone [ER stress - refolding [early stage]|MIF2- chaperone [ER stress - refolding [early stage]|Heat Shock Protein Family A (Hsp70) Member 5- chaperone [ER stress - refolding [early stage]|HEL-S-89n- chaperone [ER stress - refolding [early stage],,false,,,http://purl.obolibrary.org/obo/TXPO_0002385,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003997,,,,,BIP- chaperone [ER stress - refolding [early stage]|HSPA5- chaperone [ER stress - refolding [early stage]|MIF2- chaperone [ER stress - refolding [early stage]|Heat Shock Protein Family A (Hsp70) Member 5- chaperone [ER stress - refolding [early stage]|HEL-S-89n- chaperone [ER stress - refolding [early stage],,,,,TXPO:0002540,,,,,,,,,,,,,,,,,,,,,,GRP78 - chaperone (canonical)[ER stress - refolding [early stage],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002207,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002543,nuclear chromosome,,A chromosome that encodes the nuclear genome and is found in the nucleus of a eukaryotic cell during the cell cycle phases when the nucleus is intact.,false,,,http://purl.obolibrary.org/obo/GO_0005694,,,,,,,,,,,,,,,,,,,,,,A chromosome that encodes the nuclear genome and is found in the nucleus of a eukaryotic cell during the cell cycle phases when the nucleus is intact.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005634,TXPO:0002543,http://purl.obolibrary.org/obo/GO_0005634,,,,,,,,,,,,,,,,,,,,,nuclear chromosome,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002545,regulation of lipolytic gene expression,,"Regulation of lipolytic gene expression is a subtype of regulation of gene expression: A process that modulates the frequency, rate or extent of lipid degradation related gene expression.",false,,,http://purl.obolibrary.org/obo/GO_0010468,,,,,,,,,,,,,,,,,,,,,,"Regulation of lipolytic gene expression is a subtype of regulation of gene expression: A process that modulates the frequency, rate or extent of lipid degradation related gene expression.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002545,,,,,,,,,,,,,,,,,,,,,,regulation of lipolytic gene expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002542,enhancing,,"Enhancing is a type of functioning process of meta-function.
Both enhancing and improveing represents optional contribution to other function.
The “optional” means that the effect of fa is not mandatory to ft, that is, the target function can be performed without improving or enhancing.
The discrimination between improving and enhancing is made by whether augmentation of the output can be made without increase of the amount of the input energy or not.

For example, the “to make low pressure” of the condenser contributes to the efficiency of the “to generate torque” function without increment of input energy, so its functioning is “Improving”. On the other hand, the “to super-heat” function of the boiler optionally increases the amount of the input energy to make a contribution. Its meta-function is “Enhancing” .",false,,,http://purl.obolibrary.org/obo/TXPO_0002541,,,,,,,,,,,,,,,,,,,,,,"Enhancing is a type of functioning process of meta-function.
Both enhancing and improveing represents optional contribution to other function.
The “optional” means that the effect of fa is not mandatory to ft, that is, the target function can be performed without improving or enhancing.
The discrimination between improving and enhancing is made by whether augmentation of the output can be made without increase of the amount of the input energy or not.

For example, the “to make low pressure” of the condenser contributes to the efficiency of the “to generate torque” function without increment of input energy, so its functioning is “Improving”. On the other hand, the “to super-heat” function of the boiler optionally increases the amount of the input energy to make a contribution. Its meta-function is “Enhancing” .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002542,,,,,,,,,,,,,,,,,,,,,,enhancing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002544,protein quality control for unfolded proteins [ER stress],,"Protein quality control for misfolded or incompletely synthesized proteins is a subtype of keeping quality: A process that maintains the protein quality.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000213|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"Protein quality control for misfolded or incompletely synthesized proteins is a subtype of keeping quality: A process that maintains the protein quality.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002539|http://purl.obolibrary.org/obo/TXPO_0000214,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000569,,,,,,,,,,,TXPO:0002544,,,,,,,,,,,,,,,,,,,,,,protein quality control for unfolded proteins [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000000,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002546,refolding promoting gene expression by ATF6 [ER stress],,"Refolding promoting gene expression by ATF6 is a subtype of gene expression: The process in which a gene sequence is converted into a mature refolding inducing gene product or products (proteins or RNA) by ATF6 .
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0003736|http://purl.obolibrary.org/obo/TXPO_0002716,,,,,,,,,,,,,,,,,,,,,,"Refolding promoting gene expression by ATF6 is a subtype of gene expression: The process in which a gene sequence is converted into a mature refolding inducing gene product or products (proteins or RNA) by ATF6 .
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002550|http://purl.obolibrary.org/obo/TXPO_0002393|http://purl.obolibrary.org/obo/TXPO_0002447,,http://purl.obolibrary.org/obo/TXPO_0002549,,,,,,,,,,,,,,,,TXPO:0002546,,,,,,,,,,,,,,,,,,,,,,refolding promoting gene expression by ATF6 [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002548,ATF6 signaling (integrated pathway),,"ATF6 signaling (integrated pathway) is a subtype of integrated signaling pathway: Sequence of linked reactions, which has ATF6 signaling and gene regulation pathway.",false,,,http://purl.obolibrary.org/obo/TXPO_0000027,,,,,,,,,,,,,,,,,,,,,,"ATF6 signaling (integrated pathway) is a subtype of integrated signaling pathway: Sequence of linked reactions, which has ATF6 signaling and gene regulation pathway.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002554|http://purl.obolibrary.org/obo/TXPO_0000718|http://purl.obolibrary.org/obo/TXPO_0002521,,http://purl.obolibrary.org/obo/TXPO_0002126|http://purl.obolibrary.org/obo/TXPO_0002520,,,,,,,,,,,,,,,,TXPO:0002548,,,,,,,,,,,,,,,,,,,,,,ATF6 signaling (integrated pathway),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002549,ATF6 mediated chaperon gene producion pathway [ER stress -refolding],,"ATF6 mediated chaperon gene regulation pathway is a subtype of ATF6 signaling (integrated pathway): Sequence of linked reactions, which has ATF6 signaling and gene regulation pathway.
This process is dependent on the refolding and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002548,,,,,,,,,,,,,,,,,,,,,,"ATF6 mediated chaperon gene regulation pathway is a subtype of ATF6 signaling (integrated pathway): Sequence of linked reactions, which has ATF6 signaling and gene regulation pathway.
This process is dependent on the refolding and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002550|http://purl.obolibrary.org/obo/TXPO_0002393|http://purl.obolibrary.org/obo/TXPO_0002447,,http://purl.obolibrary.org/obo/TXPO_0002511,,,,,,,,,,,,,,,,TXPO:0002549,,,,,,,,,,,,,,,,,,,,,,ATF6 mediated chaperon gene producion pathway [ER stress -refolding],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_1902600,proton transmembrane transport,,The directed movement of a proton across a membrane.,false,,,http://purl.obolibrary.org/obo/GO_0006811,,,,,,,,,,,,,,,,,,,,,,The directed movement of a proton across a membrane.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:1902600,,,,,,,,,,,,,,,,,,,,,,proton transmembrane transport,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100353,Lck,P56-LCK|T cell-specific protein-tyrosine kinase|LSK,,false,,,http://purl.obolibrary.org/obo/IMR_0000211,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,P56-LCK|T cell-specific protein-tyrosine kinase|LSK,,,,,IMR:0100353,,,,,,,,,,,,,,,,,,,,,,Lck,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0031161,phosphatidylinositol catabolic process,PtdIns catabolism|phosphatidylinositol degradation|phosphatidylinositol breakdown|phosphatidylinositol catabolism|PtdIns catabolic process,"The chemical reactions and pathways resulting in the breakdown of phosphatidylinositol, any glycophospholipid with its sn-glycerol 3-phosphate residue is esterified to the 1-hydroxyl group of 1D-myo-inositol.",false,,,http://purl.obolibrary.org/obo/GO_0046488|http://purl.obolibrary.org/obo/GO_0046475,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways resulting in the breakdown of phosphatidylinositol, any glycophospholipid with its sn-glycerol 3-phosphate residue is esterified to the 1-hydroxyl group of 1D-myo-inositol.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_28874,,,,,,,,,,,,,,,,,,PtdIns catabolism|phosphatidylinositol degradation|phosphatidylinositol breakdown|phosphatidylinositol catabolism|PtdIns catabolic process,,,,,GO:0031161,,,,,,,,,,,,,,,,,,,,,,phosphatidylinositol catabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0002578,"inositol 1,4,5-trisphosphate 3-kinase B",IP3K-B,,false,,,http://purl.obolibrary.org/obo/IMR_0002576,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IP3K-B,,,,,IMR:0002578,,,,,,,,,,,,,,,,,,,,,,"inositol 1,4,5-trisphosphate 3-kinase B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001568,Rab5B,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001568,,,,,,,,,,,,,,,,,,,,,,Rab5B,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003806,overeating [NAFLD],,"Overeating is a subtype of increasing quantity: A process that changes the ingestion amount of food to be larger.
This entity is a specific course-dependent process. This process can constitute the course of NAFLD.",false,,,http://purl.obolibrary.org/obo/TXPO_0001541|http://purl.obolibrary.org/obo/TXPO_0001720,,,,,,,,,,,,,,,,,,,,,,"Overeating is a subtype of increasing quantity: A process that changes the ingestion amount of food to be larger.
This entity is a specific course-dependent process. This process can constitute the course of NAFLD.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003811|http://purl.obolibrary.org/obo/TXPO_0003810|http://purl.obolibrary.org/obo/TXPO_0003809,,,,,,,,,,,TXPO:0003806,,,,,,,,,,,,,,,,,,,,,,overeating [NAFLD],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003800,extracellular matrix production- degradation imbalance [Fibrosis],,"Extracellular matrix production- degradation imbalance is a subtype of imbalance: A process that lacks a balance between extracellular matrix production and degradation.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003742|http://purl.obolibrary.org/obo/TXPO_0003801,,,,,,,,,,,,,,,,,,,,,,"Extracellular matrix production- degradation imbalance is a subtype of imbalance: A process that lacks a balance between extracellular matrix production and degradation.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003802,,,,,,,,,,,TXPO:0003800,,,,,,,,,,,,,,,,,,,,,,extracellular matrix production- degradation imbalance [Fibrosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003804,hepatic fibrosis by NASH,,The totality of all processes through which hepatic fibrosis is realized by NASH.|under construction,false,,,http://purl.obolibrary.org/obo/TXPO_0002329,,,,,,,,,,,,,,,,,,,,,,The totality of all processes through which hepatic fibrosis is realized by NASH.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003804,,,,,,,,,,,,,,,,,,,,under construction,,hepatic fibrosis by NASH,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003807,increasing fatty acid synthesis substrate [lipidosis],,"Increasing fatty acid synthesis substrate is a subtype of increasing quantity: A process that changes the production amount of the substrate of the fatty acid synthesis.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0000284,,,,,,,,,,,,,,,,,,,,,,"Increasing fatty acid synthesis substrate is a subtype of increasing quantity: A process that changes the production amount of the substrate of the fatty acid synthesis.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003809|http://purl.obolibrary.org/obo/TXPO_0003808,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000890,,,,,,,,,,,TXPO:0003807,,,,,,,,,,,,,,,,,,,,,,increasing fatty acid synthesis substrate [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003805,CYP1A2(canonical) [Glutathione depletion],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003633|http://purl.obolibrary.org/obo/TXPO_0002045,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24297|NCBI-Human-GeneID:1544|NCBI-Mouse-GeneID:13077|PMID:21177773|PMID:19590965,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001544,,,,,,,,,,,,,TXPO:0003805,,,,,,,,,,,,,,,,,,,,,,CYP1A2(canonical) [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003801,extracellular matrix production- degradation imbalance,,Extracellular matrix production- degradation imbalance is a subtype of imbalance: A process that lacks a balance between extracellular matrix production and degradation.,false,,,http://purl.obolibrary.org/obo/TXPO_0000567,,,,,,,,,,,,,,,,,,,,,,Extracellular matrix production- degradation imbalance is a subtype of imbalance: A process that lacks a balance between extracellular matrix production and degradation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003801,,,,,,,,,,,,,,,,,,,,,,extracellular matrix production- degradation imbalance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003803,hepatic fibrosis by alcoholic liver injury,,The totality of all processes through which hepatic fibrosis is realized by alcoholic liver injury.|under construction,false,,,http://purl.obolibrary.org/obo/TXPO_0002329,,,,,,,,,,,,,,,,,,,,,,The totality of all processes through which hepatic fibrosis is realized by alcoholic liver injury.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001305|http://purl.obolibrary.org/obo/TXPO_0001310|http://purl.obolibrary.org/obo/TXPO_0001387|http://purl.obolibrary.org/obo/TXPO_0000503|http://purl.obolibrary.org/obo/TXPO_0001268|http://purl.obolibrary.org/obo/TXPO_0001289|http://purl.obolibrary.org/obo/TXPO_0001288,,,,,,,,,,,,,,,,,,TXPO:0003803,,,,,,,,,,,,,,,,,,,,under construction,,hepatic fibrosis by alcoholic liver injury,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003802,hepatic fibrosis [Fibrosis],,"Hepatic fibrosis is a subtype of fibrosis: A process that replaces liver tissues to fibrous connective tissues, usually as a consequence of inflammation or other injury.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003742|http://purl.obolibrary.org/obo/TXPO_0000816,,,,,,,,,,,,,,,,,,,,,,"Hepatic fibrosis is a subtype of fibrosis: A process that replaces liver tissues to fibrous connective tissues, usually as a consequence of inflammation or other injury.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003783,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003782,,,,,,,,,,,TXPO:0003802,,,,,,,,,,,,,,,,,,,,,,hepatic fibrosis [Fibrosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003809,increasing amount of carbohydrate [NAFLD],,"Increasing amount of carbohydrate is a subtype of increasing quantity: A process that changes the amount of carbohydrates to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis (NAFLD).",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0000267,,,,,,,,,,,,,,,,,,,,,,"Increasing amount of carbohydrate is a subtype of increasing quantity: A process that changes the amount of carbohydrates to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis (NAFLD).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003808,,,,,,,,,,,TXPO:0003809,,,,,,,,,,,,,,,,,,,,,,increasing amount of carbohydrate [NAFLD],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003808,converting to acetyl CoA [NAFLD],,"Converting to acetyl CoA is a subtype of metabolic process.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis (NAFLD).",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0000283,,,,,,,,,,,,,,,,,,,,,,"Converting to acetyl CoA is a subtype of metabolic process.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis (NAFLD).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003807,,,,,,,,,,,TXPO:0003808,,,,,,,,,,,,,,,,,,,,,,converting to acetyl CoA [NAFLD],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0001787,natural killer cell proliferation,,The expansion of a natural killer cell population by cell division.,false,,,http://purl.obolibrary.org/obo/GO_0046651,,,,,,,,,,,,,,,,,,,,,,The expansion of a natural killer cell population by cell division.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0001787,,,,,,,,,,,,,,,,,,,,,,natural killer cell proliferation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000696,NRAS (mol),N-Ras|Transforming protein N-Ras,,false,,,http://purl.obolibrary.org/obo/IMR_0000290,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:18176|NCBI-Rat-GeneID:24605|NCBI-Human-GeneID:4893,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0011343,N-Ras|Transforming protein N-Ras,,,,,IMR:0000696,,,,,,,,,,,,,,,,,,,,,,NRAS (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100390,IFN gamma,Interferon gamma,,false,,,http://purl.obolibrary.org/obo/IMR_0000029,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Interferon gamma,,,,,IMR:0100390,,,,,,,,,,,,,,,,,,,,,,IFN gamma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003837,FNIP2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:329679|NCBI-Human-GeneID:57600|NCBI-Rat-GeneID:310538,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000057600,,,,,,,,,,,,,TXPO:0003837,,,,,,,,,,,,,,,,,,,,,,FNIP2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003833,MMAA (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:109136|NCBI-Human-GeneID:166785|NCBI-Rat-GeneID:291939|PMID:15523652,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000166785,,,,,,,,,,,,,TXPO:0003833,,,,,,,,,,,,,,,,,,,,,,MMAA (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003838,PKIB (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:5570|NCBI-Mouse-GeneID:18768|NCBI-Rat-GeneID:24678|https://omim.org/entry/606914,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000005570,,,,,,,,,,,,,TXPO:0003838,,,,,,,,,,,,,,,,,,,,,,PKIB (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003830,inflammatory response [pyroptosis],,"Inflammatory response is a subtype of changing material: The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages.
This entity is a specific course-dependent process. This process can constitute the course of pyroptosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000192|http://purl.obolibrary.org/obo/TXPO_0001727,,,,,,,,,,,,,,,,,,,,,,"Inflammatory response is a subtype of changing material: The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages.
This entity is a specific course-dependent process. This process can constitute the course of pyroptosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003825|http://purl.obolibrary.org/obo/TXPO_0003827,http://purl.obolibrary.org/obo/TXPO_0003826|http://purl.obolibrary.org/obo/TXPO_0003828,,,,,,http://purl.obolibrary.org/obo/TXPO_0002144,,,,,,,,,,,TXPO:0003830,,,,,,,,,,,,,,,,,,,,,,inflammatory response [pyroptosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003835,RSAD2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:65190|NCBI-Human-GeneID:91543|NCBI-Mouse-GeneID:58185,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000091543,,,,,,,,,,,,,TXPO:0003835,,,,,,,,,,,,,,,,,,,,,,RSAD2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003836,CYP4A11 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1579|NCBI-Rat-GeneID:24306|https://omim.org/entry/601310,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001579,,,,,,,,,,,,,TXPO:0003836,,,,,,,,,,,,,,,,,,,,,,CYP4A11 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003839,KCNMA1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:16531|NCBI-Rat-GeneID:83731|NCBI-Human-GeneID:3778,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000003778,,,,,,,,,,,,,TXPO:0003839,,,,,,,,,,,,,,,,,,,,,,KCNMA1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003832,SULT1C2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:6819|NCBI-Rat-GeneID:171072|NCBI-Mouse-GeneID:69083,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000006819,,,,,,,,,,,,,TXPO:0003832,,,,,,,,,,,,,,,,,,,,,,SULT1C2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003834,SPON2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:100689|NCBI-Rat-GeneID:171569|NCBI-Human-GeneID:10417|https://omim.org/entry/605918,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000010417,,,,,,,,,,,,,TXPO:0003834,,,,,,,,,,,,,,,,,,,,,,SPON2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003831,inflammatory cell infiltration [pyroptosis],,Inflammatory cell infiltration is a subtype of moving A to the inside of B: A process that that moves the outside inflammatory cell to the inside in response to an inflammatory reaction. This entity is a specific course-dependent process. This process can constitute the course of pyroptosis.,false,,,http://purl.obolibrary.org/obo/TXPO_0001727|http://purl.obolibrary.org/obo/TXPO_0000540,,,,,,,,,,,,,,,,,,,,,,Inflammatory cell infiltration is a subtype of moving A to the inside of B: A process that that moves the outside inflammatory cell to the inside in response to an inflammatory reaction. This entity is a specific course-dependent process. This process can constitute the course of pyroptosis.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003830,,,,,,,,,,,TXPO:0003831,,,,,,,,,,,,,,,,,,,,,,inflammatory cell infiltration [pyroptosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100322,Tyk2,,,false,,,http://purl.obolibrary.org/obo/IMR_0000213,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100322,,,,,,,,,,,,,,,,,,,,,,Tyk2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002835,IRE1 signaling to TRAF2 [ER stress - inflammation - IRE1-TRAF2-ASK-JNK pathway],,"A process in which a signal to TRAF2 is transduced by the IRE1.
This process is dependent on the IRE1-TRAF2-ASK-JNK pathway mediated inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002594,,,,,,,,,,,,,,,,,,,,,,"A process in which a signal to TRAF2 is transduced by the IRE1.
This process is dependent on the IRE1-TRAF2-ASK-JNK pathway mediated inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002821|http://purl.obolibrary.org/obo/TXPO_0002823,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002827|http://purl.obolibrary.org/obo/TXPO_0002823,,,,,,,,,,,TXPO:0002835,,,,,,,,,,,,,,,,,,,,,,IRE1 signaling to TRAF2 [ER stress - inflammation - IRE1-TRAF2-ASK-JNK pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002839,PERK - stress sensor (canonical)[ER stress - translation attenuation],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000878,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000881,,,,,,,,,,TXPO:0002839,,,,,,,,,,,,,,,,,,,,,,PERK - stress sensor (canonical)[ER stress - translation attenuation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000123,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002832,XBP1 activation by IRE1 [ER stress - inflammation],,"XBP1 activation by IRE1 is a subtype of activation of transcription factor: A process that changes the activity of XBP1 (X-Box Binding Protein 1) to be higher by IRE1.
This process is dependent on the inflammation and can constitute the course of ER stress.|The XBP1 gene is transcribed to yield mRNA, the mRNA is spliced to yield Xbp(s) mRNA, and the mRNA is translated to yield protein.",false,,,http://purl.obolibrary.org/obo/TXPO_0002690,,,,,,,,,,,,,,,,,,,,"http://www.reactome.org/PathwayBrowser/#/R-HSA-381183&SEL=R-HSA-1791121&PATH=R-HSA-392499,R-HSA-381119,R-HSA-381033",,"XBP1 activation by IRE1 is a subtype of activation of transcription factor: A process that changes the activity of XBP1 (X-Box Binding Protein 1) to be higher by IRE1.
This process is dependent on the inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002773,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002830,,,,,,,,,,,TXPO:0002832,,,,,,,,,,,,,,,,,,,,"The XBP1 gene is transcribed to yield mRNA, the mRNA is spliced to yield Xbp(s) mRNA, and the mRNA is translated to yield protein.",,XBP1 activation by IRE1 [ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002834,IRE1 signaling to TRAF2 [ER stress - inflammation - IRE1-TRAF2-IKK-NfkB pathway],,"A process in which a signal to TRAF2 is transduced by the IRE1.
This process is dependent on the IRE1-TRAF2-IKK-NfkB pathway mediated inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002594,,,,,,,,,,,,,,,,,,,,,,"A process in which a signal to TRAF2 is transduced by the IRE1.
This process is dependent on the IRE1-TRAF2-IKK-NfkB pathway mediated inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002816,,,,,,,,,,,,,,,,,,TXPO:0002834,,,,,,,,,,,,,,,,,,,,,,IRE1 signaling to TRAF2 [ER stress - inflammation - IRE1-TRAF2-IKK-NfkB pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002837,Translocation of NF-kappaB from the Cytosol to the Nucleus [ER stress - inflammation - ATF6-NfkB pathway],,"Translocation of NF-kappaB from the Cytosol to the Nucleus is a subtype of nuclear transport: A process that of the directed movement of NF-kappaB from the cytoplasm to the nucleus.
This process is dependent on the ATF6-NfkB pathway mediated inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002633,,,,,,,,,,,,,,,,,,,,,,"Translocation of NF-kappaB from the Cytosol to the Nucleus is a subtype of nuclear transport: A process that of the directed movement of NF-kappaB from the cytoplasm to the nucleus.
This process is dependent on the ATF6-NfkB pathway mediated inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002768,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002805,,,,,,,,,,,TXPO:0002837,,,,,,,,,,,,,,,,,,,,,,Translocation of NF-kappaB from the Cytosol to the Nucleus [ER stress - inflammation - ATF6-NfkB pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002831,IRE1 signaling to XBP1 [ER stress - inflammation],,"A process in which a signal to XBP1 is transduced by the IRE1.
This process is dependent on the inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002571,,,,,,,,,,,,,,,,,,,,,,"A process in which a signal to XBP1 is transduced by the IRE1.
This process is dependent on the inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002688|http://purl.obolibrary.org/obo/TXPO_0002832,,,,,,,,,,,,,,,,,,TXPO:0002831,,,,,,,,,,,,,,,,,,,,,,IRE1 signaling to XBP1 [ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002836,IRE1-XBP1 mediated pathway [ER stress - inflammation],,"IRE1-XBP1 mediated pathway is a subtype of IRE1 signaling (integrated pathway): Sequence of linked reactions, which has IRE1 signaling and gene regulation by XBP1.
This process is dependent on inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002563,,,,,,,,,,,,,,,,,,,,,,"IRE1-XBP1 mediated pathway is a subtype of IRE1 signaling (integrated pathway): Sequence of linked reactions, which has IRE1 signaling and gene regulation by XBP1.
This process is dependent on inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002832|http://purl.obolibrary.org/obo/TXPO_0002831|http://purl.obolibrary.org/obo/TXPO_0002830,,http://purl.obolibrary.org/obo/TXPO_0002486|http://purl.obolibrary.org/obo/TXPO_0002155,,,,,,,,,,,,,,,,TXPO:0002836,,,,,,,,,,,,,,,,,,,,,,IRE1-XBP1 mediated pathway [ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002830,inflammatory cytokine gene expression by XBP1s [ER stress - inflammation],,"Inflammatory gene expression by XBP1s is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) related to the inflammation by XBP1s.
This process is dependent on the inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002266|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"Inflammatory gene expression by XBP1s is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) related to the inflammation by XBP1s.
This process is dependent on the inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002766,,,,,,,,,,,TXPO:0002830,,,,,,,,,,,,,,,,,,,,,,inflammatory cytokine gene expression by XBP1s [ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002838,ATF6 signaling (primitive) [ER stress - inflammation],,"ATF6 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the ATF6 (activating transcription factor 6). ATF6 generally plays a endoplasmic reticulum membrane stress sensor role.
This process is dependent on the inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000719,,,,,,,,,,,,,,,,,,,,,,"ATF6 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the ATF6 (activating transcription factor 6). ATF6 generally plays a endoplasmic reticulum membrane stress sensor role.
This process is dependent on the inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002902,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002924,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002841,,,,,,,,,,,TXPO:0002838,,,,,,,,,,,,,,,,,,,,,,ATF6 signaling (primitive) [ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002833,inflammatory cytokine gene expression by AP-1 [ER stress - inflammation],,"Inflammatory gene expression by AP-1 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) related to the inflammation by AP-1.
This process is dependent on the inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002266|http://purl.obolibrary.org/obo/TXPO_0003736,,,,,,,,,,,,,,,,,,,,PMID:22883813,,"Inflammatory gene expression by AP-1 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) related to the inflammation by AP-1.
This process is dependent on the inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002766,,,,,,,,,,,TXPO:0002833,,,,,,,,,,,,,,,,,,,,,,inflammatory cytokine gene expression by AP-1 [ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_4846,erythromycin estolate,,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,C40H71NO14.C12H26O4S,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_33281,,,,,,,,,,CHEBI:4846,,,,,,,,,,,,,,,,,,,,,,erythromycin estolate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CCCCCCCCCCCCOS(O)(=O)=O.CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2OC(=O)CC)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,,,,,
http://purl.obolibrary.org/obo/CHEBI_76971,Escherichia coli metabolite,E.coli metabolite|E.coli metabolites|Escherichia coli metabolites,Any bacterial metabolite produced during a metabolic reaction in Escherichia coli.,false,,,http://purl.obolibrary.org/obo/CHEBI_76969,,,,,,,,,,,,,,,,,,,,,,Any bacterial metabolite produced during a metabolic reaction in Escherichia coli.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,E.coli metabolite|E.coli metabolites|Escherichia coli metabolites,,,,,,,,,,,,,,,,,,,,,CHEBI:76971,,,,Escherichia coli metabolite,,CHEBI:76971,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000002081,ERN1,,Other designations: ER to nucleus signalling 1|endoplasmic reticulum-to-nucleus signaling 1|inositol-requiring 1|inositol-requiring enzyme 1|inositol-requiring protein 1|ire1-alpha|protein kinase/endoribonuclease|serine/threonine-protein kinase/endoribonuclease IRE1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,IRE1|IRE1P|IRE1a|hIRE1p,,,,,,,,,,,,17,,,,,,HPRD:04943|Vega:OTTHUMG00000178879|Ensembl:ENSG00000178607|MIM:604033|HGNC:3449,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,endoplasmic reticulum to nucleus signaling 1,,,17q24.2,,,,,,,,,,,,,,,,"GO_0000287 (EC: IDA, PMID: 9637683); GO_0004521 (EC: IDA, PMID: 11779465); GO_0004521 (EC: TAS); GO_0004674 (EC: IDA, PMID: 9637683); GO_0004674 (EC: TAS); GO_0005515 (EC: IPI, PMID: 11278723); GO_0005524 (EC: IDA, PMID: 9637683); GO_0005637 (EC: IEA); GO_0005739 (EC: IEA); GO_0005789 (EC: TAS); GO_0006351 (EC: IEA); GO_0006355 (EC: IEA); GO_0006468 (EC: IDA, PMID: 9637683); GO_0006987 (EC: IDA, PMID: 9637683); GO_0006987 (EC: TAS); GO_0007050 (EC: ISS); GO_0019899 (EC: IPI); GO_0030176 (EC: IDA, PMID: 9637683); GO_0030968 (EC: TAS); GO_0042802 (EC: IPI, PMID: 12637535); GO_0044267 (EC: TAS); GO_0046777 (EC: IEA); GO_0070055 (EC: IDA, PMID: 11779465); GO_0070059 (EC: IEA); GO_0090502 (EC: IDA, PMID: 11779465); GO_0090502 (EC: TAS); GO_1900103 (EC: IMP, PMID: 16645094)",,,,,,,,,PMID: 9637683; 10587643; 10650002; 10737800; 11175748; 11278723; 11779465; 11850408; 11897784; 12050113; 12446770; 12477932; 12637535; 12843613; 14702039; 15063770; 15234121; 16107700; 16344560; 16645094; 16680093; 17585877; 17638880; 17951406; 17991856; 18065414; 18242182; 18369366; 18840095; 19135427; 19913121; 20007910; 20013084; 20103773; 20379614; 20447464; 20625543; 20628086; 20702765; 20798350; 20819778; 20965234; 21118962; 21385877; 21482118; 21525936; 21680894; 21954231; 22194594; 22199355; 22219383; 22314839; 22315414; 22419015; 22446326; 22718352; 22787145; 22917505; 23001845; 23041190; 23042294; 23103912; 23110043; 23363253; 23575540; 23598528; 23602568; 23684307; 23748775; 23752693; 23942232; 23950715; 24330607,,,,,,,,,,,,,,,OGG:3000002081,,,,,,,endoplasmic reticulum to nucleus signaling 1,,,,,,,,,,,,,Other designations: ER to nucleus signalling 1|endoplasmic reticulum-to-nucleus signaling 1|inositol-requiring 1|inositol-requiring enzyme 1|inositol-requiring protein 1|ire1-alpha|protein kinase/endoribonuclease|serine/threonine-protein kinase/endoribonuclease IRE1,,ERN1,,,,,,,,,,,,,,,,,,,,,,,2081,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,ERN1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001062,CENPE,,"Other designations: Centromere autoantigen E (312kD)|centromere-associated protein E|kinesin family member 10|kinesin-related protein CENPE|protein phosphatase 1, regulatory subunit 61",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CENP-E|PPP1R61|KIF10,,,,,,,,,,,,4,,,,,,HGNC:1856|HPRD:00316|Ensembl:ENSG00000138778|Vega:OTTHUMG00000160980|MIM:117143,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"centromere protein E, 312kDa",,,4q24-q25,,,,,,,,,,,,,,,,"GO_0000089 (EC: TAS, PMID: 2022189); GO_0000278 (EC: TAS); GO_0000775 (EC: IDA, PMID: 11084331); GO_0000776 (EC: IDA, PMID: 11682612); GO_0000778 (EC: IEA); GO_0000779 (EC: IDA, PMID: 19465021); GO_0000940 (EC: TAS, Qualifier: colocalizes_with, PMID: 9763420); GO_0003777 (EC: IMP, PMID: 7889940); GO_0005515 (EC: IPI, PMID: 17535814); GO_0005524 (EC: IEA); GO_0005634 (EC: IMP, PMID: 9763420); GO_0005737 (EC: IDA); GO_0005819 (EC: IEA); GO_0005829 (EC: TAS); GO_0005871 (EC: IEA); GO_0005874 (EC: IDA, PMID: 7889940); GO_0007018 (EC: TAS); GO_0007079 (EC: TAS, PMID: 1406971); GO_0007080 (EC: TAS, PMID: 9363944); GO_0007275 (EC: IEA); GO_0007596 (EC: TAS); GO_0008017 (EC: IEA); GO_0008152 (EC: IMP, PMID: 7889940); GO_0015630 (EC: IDA); GO_0019886 (EC: TAS); GO_0043515 (EC: IDA, PMID: 9763420); GO_0045860 (EC: IMP, PMID: 12925705); GO_0051382 (EC: NAS, PMID: 9763420)",,,,,,,,,PMID: 1406971; 2022189; 7851898; 7889940; 9363944; 9391217; 9744883; 9763420; 9914370; 10477750; 10852915; 11084331; 11337467; 11682612; 12686615; 12925705; 12938929; 14684825; 15146197; 15159587; 15181147; 15236970; 15297875; 16144904; 16196087; 16565220; 16682006; 16926026; 17081983; 17268814; 17370265; 17535814; 18029348; 18342609; 18374647; 18460473; 19389623; 19465021; 19525938; 19553660; 19625775; 19723035; 19733075; 19779646; 20021663; 20085233; 20237434; 20332099; 20354862; 20360068; 20691903; 21139048; 21282530; 22110139; 22307330; 22637578; 22801780; 22974711; 23236152; 23314748; 23666240; 23955301,,,,,,,,,,,,,,,OGG:3000001062,,,,,,,"centromere protein E, 312kDa",,,,,,,,,,,,,"Other designations: Centromere autoantigen E (312kD)|centromere-associated protein E|kinesin family member 10|kinesin-related protein CENPE|protein phosphatase 1, regulatory subunit 61",,CENPE,,,,,,,,,,,,,,,,,,,,,,,1062,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,CENPE,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000229,MAPKKK,MAP kinase kinase kinase|MAPKK kinase|MKKK,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,GO:0004709,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001966,,,,,MAP kinase kinase kinase|MAPKK kinase|MKKK,,,,,IMR:0000229,,,,,,,,,,,,,,,,,,,,,,MAPKKK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006486,protein glycosylation,,"A protein modification process that results in the addition of a carbohydrate or carbohydrate derivative unit to a protein amino acid, e.g. the addition of glycan chains to proteins.",false,,,http://purl.obolibrary.org/obo/GO_0070085,,,,,,,,,,,,,,,,,,,,,,"A protein modification process that results in the addition of a carbohydrate or carbohydrate derivative unit to a protein amino acid, e.g. the addition of glycan chains to proteins.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0006486,,,,,,,,,,,,,,,,,,,,,,protein glycosylation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0030595,leukocyte chemotaxis,leucocyte chemotaxis|immune cell chemotaxis,The movement of a leukocyte in response to an external stimulus.,false,,,http://purl.obolibrary.org/obo/GO_0050900,,,,,,,,,,,,,,,,,,,,,,The movement of a leukocyte in response to an external stimulus.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,leucocyte chemotaxis|immune cell chemotaxis,,,,,GO:0030595,,,,,,,,,,,,,,,,,,,,,,leukocyte chemotaxis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_23367,molecular entity,,"Any constitutionally or isotopically distinct atom, molecule, ion, ion pair, radical, radical ion, complex, conformer etc., identifiable as a separately distinguishable entity.",false,,,http://purl.obolibrary.org/obo/CHEBI_24431,,,,,,,,,,,,,,,,,,,,,,"Any constitutionally or isotopically distinct atom, molecule, ion, ion pair, radical, radical ion, complex, conformer etc., identifiable as a separately distinguishable entity.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:23367,,,,,,,,,,,,,,,,,,,,,,molecular entity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004003,Alas1 (mouse) [Lipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001105|http://purl.obolibrary.org/obo/TXPO_1000034,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:11655|PMID:20018698|PMID:22070747,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000000211,,,,,,,,,,,,,TXPO:0004003,,,,,,,This gene encodes the mitochondrial enzyme which is catalyzes the rate-limiting step in heme (iron-protoporphyrin) biosynthesis.,,,,,,,,,,,,,,,Alas1 (mouse) [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004009,hypofunction of endocytic recycling,,Hypofunction of eidocytic recycling from ER to mitochondrial membrane is a subtype of hypofunction of transport: A process that performs a decreased or insufficient endocytic recycling.,false,,,http://purl.obolibrary.org/obo/TXPO_0001911,,,,,,,,,,,,,,,,,,,,,,Hypofunction of eidocytic recycling from ER to mitochondrial membrane is a subtype of hypofunction of transport: A process that performs a decreased or insufficient endocytic recycling.,,,http://purl.obolibrary.org/obo/GO_0032456,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004009,,,,,,,,,,,,,,,,,,,,,,hypofunction of endocytic recycling,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004008,tumor tissue,,Tumor tissue is a subtype of abnormal cellular tissue that consists of tumor cells .,false,,,http://purl.obolibrary.org/obo/TXPO_0004047,,,,,,,,,,,,,,,,,,,,,,Tumor tissue is a subtype of abnormal cellular tissue that consists of tumor cells .,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004008,,,,,,,,,,,,,,,,,,,,,,tumor tissue,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004002,recycling endosome dysfunction,,Recycling endosome dysfunction is a subtype of dysfunctioning: A process that performs an abnormal and incomplete recycling endosomal function. And the degree is severe.,false,,,http://purl.obolibrary.org/obo/TXPO_0000438,,,,,,,,,,,,,,,,,,,,,,Recycling endosome dysfunction is a subtype of dysfunctioning: A process that performs an abnormal and incomplete recycling endosomal function. And the degree is severe.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004002,,,,,,,,,,,,,,,,,,,,,,recycling endosome dysfunction,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005768,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004004,hyperfunction of heme biosynthesis,,Hyperfunction of phospholipid biosynthesis is a subtype of hyperfunction of biosynthesis: A process that performs an excessive heme biosynthesis.,false,,,http://purl.obolibrary.org/obo/TXPO_0002346,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of phospholipid biosynthesis is a subtype of hyperfunction of biosynthesis: A process that performs an excessive heme biosynthesis.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004004,,,,,,,,,,,,,,,,,,,,,,hyperfunction of heme biosynthesis,,,,,,http://purl.obolibrary.org/obo/GO_0006783,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004005,Pcca [Hepatocarcinogenesis],Propionyl-CoA Carboxylase Alpha Subunit [Hepatocarcinogenesis],,false,,,http://purl.obolibrary.org/obo/TXPO_0000837|http://purl.obolibrary.org/obo/TXPO_1000295,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:687008|NCBI-Human-GeneID:5095|http://omim.org/entry/232000|NCBI-Mouse-GeneID:110821|PMID:11461925|PMID:16918237|PMID:15464417,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Propionyl-CoA Carboxylase Alpha Subunit [Hepatocarcinogenesis],,,,,TXPO:0004005,,,,,,,,,,,,,,,,,,,,,,Pcca [Hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004001,recycling endososomal dysfunction [Phospholipidosis (severe) ],,"Recycling endosome dysfunction is a subtype of dysfunctioning: A process that performs an abnormal and incomplete recycling endosomal function. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0004002,,,,,,,,,,,,,,,,,,,,PMID:26574506|PMID:18216768|PMID:23625997,,"Recycling endosome dysfunction is a subtype of dysfunctioning: A process that performs an abnormal and incomplete recycling endosomal function. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004001,,,,,,,,,,,,,,,,,,,,,,recycling endososomal dysfunction [Phospholipidosis (severe) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004000,Ctsb- apoptosis inhibitor (mouse)[Phospholipidosis  - tumor metasitasis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003996,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:13030|PMID:27398911,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001508,,,http://purl.obolibrary.org/obo/TXPO_0000487,,,,,,,,,,TXPO:0004000,,,,,,,,,,,,,,,,,,,,,,Ctsb- apoptosis inhibitor (mouse)[Phospholipidosis  - tumor metasitasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004007,ADH1B(predicted)(human)[lipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001786|http://purl.obolibrary.org/obo/TXPO_0001092,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:125|PMID:29718361|PMID:26006114,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000000125,,,,,,,,,,,,,TXPO:0004007,,,,,,,This gene encodes the mitochondrial enzyme which is catalyzes the rate-limiting step in heme (iron-protoporphyrin) biosynthesis.,,,,,,,,,,,,,,,ADH1B(predicted)(human)[lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004006,PPARA lipid metabolism regulator (canonical)[Eosinophilic granular degeneration],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001328,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002358,,,,,,,,,,TXPO:0004006,,,,,,,,,,,,,,,,,,,,,,PPARA lipid metabolism regulator (canonical)[Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_35476,antipsychotic agent,neuroleptique|antipsychotics|major tranquilizing agents|antipsychotic agents|neuroleptic|major tranquilizers|antipsychotiques|antipsychotic drug|neuroleptiques|grosser Tranquilizer|neuroleptics|neuroleptic agents|antipsychotic drugs|Neuroleptikum,"Antipsychotic drugs are agents that control agitated psychotic behaviour, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect.",false,,,http://purl.obolibrary.org/obo/CHEBI_35473,,,,,,,,,,,,,,,,,,,,,,"Antipsychotic drugs are agents that control agitated psychotic behaviour, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,neuroleptique|antipsychotics|major tranquilizing agents|antipsychotic agents|neuroleptic|major tranquilizers|antipsychotiques|antipsychotic drug|neuroleptiques|grosser Tranquilizer|neuroleptics|neuroleptic agents|antipsychotic drugs|Neuroleptikum,,,,,,,,,,,,,,,,,,,,,CHEBI:35476,,,,antipsychotic agent,,CHEBI:35476,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000003778,KCNMA1,,"Other designations: BK channel alpha subunit|BKCA alpha subunit|calcium-activated potassium channel subunit alpha-1|calcium-activated potassium channel, subfamily M subunit alpha-1|hSlo|k(VCA)alpha|maxi-K channel HSLO|slo homolog|slowpoke homolog|stretch-activated Kca channel",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,BKTM|bA205K10.1|SLO-ALPHA|SAKCA|KCa1.1|SLO1|MaxiK|mSLO1|SLO,,,,,,,,,,,,10,,,,,,HPRD:15967|MIM:600150|HGNC:6284|Ensembl:ENSG00000156113|Vega:OTTHUMG00000018543,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"potassium large conductance calcium-activated channel, subfamily M, alpha member 1",,,10q22.3,,,,,,,,,,,,,,,,"GO_0001666 (EC: IDA, PMID: 15528406); GO_0003779 (EC: IDA, PMID: 15703204); GO_0005249 (EC: IDA, PMID: 11880513); GO_0005515 (EC: IPI, PMID: 10692449); GO_0005783 (EC: IEA); GO_0005886 (EC: TAS); GO_0005901 (EC: IDA, PMID: 15703204); GO_0006813 (EC: IDA, PMID: 11245614); GO_0006970 (EC: IDA, PMID: 10840032); GO_0007268 (EC: TAS); GO_0007596 (EC: TAS); GO_0007605 (EC: IEA); GO_0007628 (EC: IEA); GO_0008076 (EC: IDA, PMID: 7573516); GO_0009897 (EC: IEA); GO_0015269 (EC: IDA, PMID: 11245614); GO_0016021 (EC: IDA, PMID: 11880513); GO_0016324 (EC: IDA, PMID: 10840032); GO_0019228 (EC: IEA); GO_0030007 (EC: IDA, PMID: 11245614); GO_0032344 (EC: IEA); GO_0034465 (EC: IDA, PMID: 15528406); GO_0034465 (EC: IMP, PMID: 18180950); GO_0042391 (EC: IDA, PMID: 7877450); GO_0042491 (EC: IEA); GO_0043065 (EC: IMP, PMID: 11245614); GO_0043195 (EC: IEA); GO_0045211 (EC: IEA); GO_0045475 (EC: IEA); GO_0045794 (EC: IDA, PMID: 12388065); GO_0046541 (EC: IEA); GO_0046872 (EC: IEA); GO_0048469 (EC: IEA); GO_0050885 (EC: IEA); GO_0051260 (EC: IEA); GO_0051592 (EC: IDA, PMID: 12388065); GO_0060072 (EC: IDA, PMID: 7993625); GO_0060072 (EC: IMP, PMID: 15703204); GO_0060073 (EC: IDA, PMID: 11641143); GO_0060082 (EC: IEA); GO_0060083 (EC: IDA, PMID: 11641143); GO_0060087 (EC: IEA); GO_0071805 (EC: IBA); GO_0071805 (EC: IDA, PMID: 11880513)",,,,,,,,,PMID: 7573516; 7687074; 7877450; 7987297; 7993625; 8006036; 8612769; 8821792; 8962157; 9391153; 9829973; 10097176; 10489376; 10692449; 10758170; 10840032; 11245614; 11401860; 11604135; 11641143; 11832330; 11880485; 11880513; 11986367; 12009018; 12016222; 12161564; 12223479; 12388065; 12391293; 12434576; 12438308; 12477932; 12566537; 14522958; 14523450; 14584897; 14631046; 14702039; 14715246; 15164054; 15174051; 15194822; 15251455; 15280542; 15489334; 15528406; 15703204; 15849354; 15937479; 16042390; 16081418; 16100257; 16382103; 16385451; 16396928; 16790810; 16895996; 16951373; 17146446; 17150299; 17166942; 17468961; 17483867; 17521822; 17586600; 17591987; 17591990; 17706472; 17901123; 17989352; 18084004; 18162557; 18180950; 18227273; 18316727; 18345016; 18367663; 18385281; 18404672; 18414909; 18458941; 18480178; 18559348; 18719396; 18854754; 19052171; 19096717; 19118164; 19168436; 19204046; 19344525; 19430934; 19456106; 19482008; 19552602; 19617704; 19640305; 19718020; 19738431; 20012488; 20037152; 20051533; 20379614; 20400778; 20424473; 20427280; 20457834; 20479001; 20508092; 20574420; 20624858; 20630939; 20677014; 20808839; 20959415; 21072171; 21078868; 21301863; 21413024; 21613417; 21670298; 21708048; 21724437; 21757754; 22074915; 22140451; 22194818; 22331907; 22446331; 22474334; 22504420; 22538239; 22710124; 22896041; 22899999; 23232643; 23237801; 23255603; 23267835; 23626738; 23831469; 23992640; 24067659; 24457600,,,,,,,,,,,,,,,OGG:3000003778,,20140408,protein-coding,,,,"potassium large conductance calcium-activated channel, subfamily M, alpha member 1",,,,,,,,,,,,,"Other designations: BK channel alpha subunit|BKCA alpha subunit|calcium-activated potassium channel subunit alpha-1|calcium-activated potassium channel, subfamily M subunit alpha-1|hSlo|k(VCA)alpha|maxi-K channel HSLO|slo homolog|slowpoke homolog|stretch-activated Kca channel",,KCNMA1,,,,,,,,,,,,,,,,,,,,,,,3778,RP11-443A13.1,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,KCNMA1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_35816,leprostatic drug,leprostatic agent|leprostatic drugs|leprostatic,"A substance that suppresses Mycobacterium leprae, ameliorates the clinical manifestations of leprosy, and/or reduces the incidence and severity of leprous reactions.",false,,,http://purl.obolibrary.org/obo/CHEBI_64912,,,,,,,,,,,,,,,,,,,,,,"A substance that suppresses Mycobacterium leprae, ameliorates the clinical manifestations of leprosy, and/or reduces the incidence and severity of leprous reactions.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,leprostatic agent|leprostatic drugs|leprostatic,,,,,,,,,,,,,,,,,,,,,CHEBI:35816,,,,leprostatic drug,,CHEBI:35816,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000002619,GAS1,,Other designations: GAS-1|Growth arrest-specific gene-1|growth arrest-specific protein 1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,9,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,growth arrest-specific 1,,,9q21.3-q22,,,,,,,,,,,,,,,,"GO_0002053 (EC: IEA); GO_0005515 (EC: IPI); GO_0005886 (EC: IDA, PMID: 8127893); GO_0007050 (EC: IEA); GO_0007411 (EC: IEA); GO_0008589 (EC: ISS); GO_0010955 (EC: IMP); GO_0012501 (EC: IEA); GO_0016021 (EC: NAS, PMID: 8127893); GO_0021587 (EC: IEA); GO_0021904 (EC: IEA); GO_0030308 (EC: IEA); GO_0035924 (EC: IEP, PMID: 15070677); GO_0042473 (EC: IEA); GO_0042474 (EC: IEA); GO_0042476 (EC: IEA); GO_0042733 (EC: IEA); GO_0042981 (EC: ISS); GO_0043010 (EC: IEA); GO_0043066 (EC: IEA); GO_0045165 (EC: ISS); GO_0045879 (EC: IEA); GO_0045880 (EC: IEA); GO_0045930 (EC: IDA, PMID: 8127893); GO_0045930 (EC: IGI, PMID: 11356029); GO_0046658 (EC: ISS); GO_0048589 (EC: ISS); GO_0048592 (EC: IEA); GO_0048701 (EC: IEA); GO_0050679 (EC: IEA); GO_0050680 (EC: IEA); GO_0060021 (EC: IEA); GO_0060628 (EC: IMP); GO_2001240 (EC: IEA)",,,,,,,,,PMID: 1505026; 7956349; 8127893; 8307588; 8889548; 9466658; 10996315; 11356029; 11572986; 11846389; 11906213; 12477932; 15070677; 15103018; 16551639; 17726382; 18394855; 18981472; 19322201; 19460624; 19638344; 20050020; 20583177; 20628624; 21111449; 21357679; 21842183; 21890473; 21901158; 21971401; 22311470; 22846196; 23254899,,,,,,,,,,,,,,,OGG:3000002619,,,,,,,growth arrest-specific 1,,,,,,,,,,,,,Other designations: GAS-1|Growth arrest-specific gene-1|growth arrest-specific protein 1,,GAS1,,,,,,,,,,,,,,,,,,,,,,,2619,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,GAS1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_48550,EC 1.1.1.21 (aldehyde reductase) inhibitor,EC 1.1.1.21 inhibitor|aldose reductase inhibitors|aldehyde reductase (EC 1.1.1.21) inhibitor|NADPH-aldopentose reductase inhibitors|EC 1.1.1.21 inhibitors|ALR2 inhibitor|ALR2 inhibitors|polyol dehydrogenase (NADP(+)) inhibitor|EC 1.1.1.21 (aldehyde reductase) inhibitors|NADPH-aldopentose reductase inhibitor|NADPH-aldose reductase inhibitors|NADPH-aldose reductase inhibitor|alditol:NADP oxidoreductase inhibitors|alditol:NADP oxidoreductase inhibitor|aldehyde reductase inhibitor|polyol dehydrogenase (NADP(+)) inhibitors|aldehyde reductase (EC 1.1.1.21) inhibitors|aldehyde reductase inhibitors|alditol:NADP(+) 1-oxidoreductase inhibitor|alditol:NAD(P)(+) 1-oxidoreductase inhibitors|alditol:NAD(P)(+) 1-oxidoreductase inhibitor|alditol:NADP(+) 1-oxidoreductase inhibitors|aldose reductase inhibitor,"An EC 1.1.1.* (oxidoreductase acting on donor CH-OH group, NAD(+) or NADP(+) acceptor) inhibitor that interferes with the action of aldehyde reductase (EC 1.1.1.21).",false,,,http://purl.obolibrary.org/obo/CHEBI_76835,,,,,,,,,,,,,,,,,,,,,,"An EC 1.1.1.* (oxidoreductase acting on donor CH-OH group, NAD(+) or NADP(+) acceptor) inhibitor that interferes with the action of aldehyde reductase (EC 1.1.1.21).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,EC 1.1.1.21 inhibitor|aldose reductase inhibitors|aldehyde reductase (EC 1.1.1.21) inhibitor|NADPH-aldopentose reductase inhibitors|EC 1.1.1.21 inhibitors|ALR2 inhibitor|ALR2 inhibitors|polyol dehydrogenase (NADP(+)) inhibitor|EC 1.1.1.21 (aldehyde reductase) inhibitors|NADPH-aldopentose reductase inhibitor|NADPH-aldose reductase inhibitors|NADPH-aldose reductase inhibitor|alditol:NADP oxidoreductase inhibitors|alditol:NADP oxidoreductase inhibitor|aldehyde reductase inhibitor|polyol dehydrogenase (NADP(+)) inhibitors|aldehyde reductase (EC 1.1.1.21) inhibitors|aldehyde reductase inhibitors|alditol:NADP(+) 1-oxidoreductase inhibitor|alditol:NAD(P)(+) 1-oxidoreductase inhibitors|alditol:NAD(P)(+) 1-oxidoreductase inhibitor|alditol:NADP(+) 1-oxidoreductase inhibitors|aldose reductase inhibitor,,,,,,,,,,,,,,,,,,,,,CHEBI:48550,,,,EC 1.1.1.21 (aldehyde reductase) inhibitor,,CHEBI:48550,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002505,protein aggregation [ER stress],,"Protein aggregation is a subtype of molecular assembly: The aggregation, arrangement and bonding together of molecules.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.|Protein aggretates are often  insoluble and tend to sequester Fe 2+ ions.  Fe 2+ helps to produce ROS.",false,,,http://purl.obolibrary.org/obo/TXPO_0002661|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,accumulatiing protein aggregates,Protein aggregating [ER stress] is an assembling process to make proteins an aggregate in the course of ER stress.|protein aggregation [ER stress],,"Protein aggregation is a subtype of molecular assembly: The aggregation, arrangement and bonding together of molecules.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000204,,,,,,,,,,,TXPO:0002505,,,,,,,,,,,,,,,,,,,,Protein aggretates are often  insoluble and tend to sequester Fe 2+ ions.  Fe 2+ helps to produce ROS.,,protein aggregation [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002500,ABCC1 (mol),"ATP-Binding Cassette, Sub-Family C (CFTR/MRP), Member 1|MRP1|ATP Binding Cassette Subfamily C Member 1|Leukotriene C(4) Transporter|Multidrug Resistance-Associated Protein 1",,false,,,http://purl.obolibrary.org/obo/TXPO_0002694,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24565|NCBI-Mouse-GeneID:17250|NCBI-Human-GeneID:4363,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"ATP-Binding Cassette, Sub-Family C (CFTR/MRP), Member 1|MRP1|ATP Binding Cassette Subfamily C Member 1|Leukotriene C(4) Transporter|Multidrug Resistance-Associated Protein 1",,,,,TXPO:0002500,,,,,,,,,,,,,,,,,,,,,,ABCC1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002506,changing activity of eIF2a by PERK [ER stress - translation attenuation],,"A process that changes the activity of the eIF2a by PERK.
This process is dependent on the translation attenuation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002378,,,,,,,,,,,,,,,,,,,,,,"A process that changes the activity of the eIF2a by PERK.
This process is dependent on the translation attenuation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002507,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002762,,,,,,,,,,,TXPO:0002506,,,,,,,,,,,,,,,,,,,,,,changing activity of eIF2a by PERK [ER stress - translation attenuation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002504,hyperfunction of repeated protein unfolding [ER stress],,"Hyperfunction of repeated protein unfolding is a subtype of hyperfunctioning: A process that performs an excesssive protein unfolding.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/TXPO_0002718,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of repeated protein unfolding is a subtype of hyperfunctioning: A process that performs an excesssive protein unfolding.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000037|http://purl.obolibrary.org/obo/TXPO_0001965,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002469,,,,,,,,,,,TXPO:0002504,,,,,,,,,,,,,,,,,,,,,,hyperfunction of repeated protein unfolding [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005783,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002509,Phosphorylation of eIF2-alpha by PERK [ER stress - apoptosis],,"Phosphorylation of eIF2-alpha by PERK is a subtype of eIF2a phosphorylation: A process that The process of introducing a phosphate group into eIF2a by PERK.
This process is dependent on the apoptosis and can constitute the course of ER stress.|The C-terminal domain of PERK (EIF2AK3) has kinase activity when PERK homodimerizes. PERK kinase specifically phosphorylates Ser52 of eIF2-alpha, causing an arrest in translation. The result is that translation of ER-targeted proteins is halted on ribosomes in the vicinity of activated PERK. The general arrest of translation results in the loss of short-lived proteins such as Cyclin D1, causing an arrest of the cell cycle in G1.",false,,,http://purl.obolibrary.org/obo/TXPO_0000700,,,,,,,,,,,,,,,,,,,,Reactome:R-HSA-381111|PMID:9930704|PMID:23334697,,"Phosphorylation of eIF2-alpha by PERK is a subtype of eIF2a phosphorylation: A process that The process of introducing a phosphate group into eIF2a by PERK.
This process is dependent on the apoptosis and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002721,,,,,,,,,,,TXPO:0002509,,,,,,,,,,,,,,,,,,,,"The C-terminal domain of PERK (EIF2AK3) has kinase activity when PERK homodimerizes. PERK kinase specifically phosphorylates Ser52 of eIF2-alpha, causing an arrest in translation. The result is that translation of ER-targeted proteins is halted on ribosomes in the vicinity of activated PERK. The general arrest of translation results in the loss of short-lived proteins such as Cyclin D1, causing an arrest of the cell cycle in G1.",,Phosphorylation of eIF2-alpha by PERK [ER stress - apoptosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002503,accumulation of compound in ER [ER stress (severe) ],,"Accumulation of compound in ER is a subtype of accumulation of xenobiotics: A process that keeps compound in the ER (endoplasmic reticulum).
This entity is a specific course-dependent process. This process can constitute the course of ER stress (severe) .",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/TXPO_0002212,,,,,,,,,,,,,,,,,,,,,,"Accumulation of compound in ER is a subtype of accumulation of xenobiotics: A process that keeps compound in the ER (endoplasmic reticulum).
This entity is a specific course-dependent process. This process can constitute the course of ER stress (severe) .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001962|http://purl.obolibrary.org/obo/TXPO_0001980,,,,,,http://purl.obolibrary.org/obo/TXPO_0002502,,,,,,,,,,,TXPO:0002503,,,,,,,,,,,,,,,,,,,,,,accumulation of compound in ER [ER stress (severe) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005783,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002508,Phosphorylation of eIF2-alpha by PERK [ER stress - refolding],,"Phosphorylation of eIF2-alpha by PERK is a subtype of eIF2a phosphorylation: A process that The process of introducing a phosphate group into eIF2a by PERK.
This process is dependent on the refolding and can constitute the course of ER stress.|The C-terminal domain of PERK (EIF2AK3) has kinase activity when PERK homodimerizes. PERK kinase specifically phosphorylates Ser52 of eIF2-alpha, causing an arrest in translation. The result is that translation of ER-targeted proteins is halted on ribosomes in the vicinity of activated PERK. The general arrest of translation results in the loss of short-lived proteins such as Cyclin D1, causing an arrest of the cell cycle in G1.",false,,,http://purl.obolibrary.org/obo/TXPO_0000700,,,,,,,,,,,,,,,,,,,,Reactome:R-HSA-381111|PMID:9930704|PMID:23334697,,"Phosphorylation of eIF2-alpha by PERK is a subtype of eIF2a phosphorylation: A process that The process of introducing a phosphate group into eIF2a by PERK.
This process is dependent on the refolding and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000707,,,,,,,,,,,TXPO:0002508,,,,,,,,,,,,,,,,,,,,"The C-terminal domain of PERK (EIF2AK3) has kinase activity when PERK homodimerizes. PERK kinase specifically phosphorylates Ser52 of eIF2-alpha, causing an arrest in translation. The result is that translation of ER-targeted proteins is halted on ribosomes in the vicinity of activated PERK. The general arrest of translation results in the loss of short-lived proteins such as Cyclin D1, causing an arrest of the cell cycle in G1.",,Phosphorylation of eIF2-alpha by PERK [ER stress - refolding],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002501,Peroxisome Proliferator-Activated Receptor Alpha [lipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000159|http://purl.obolibrary.org/obo/TXPO_0003516,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:19013|NCBI-Rat-GeneID:25747|NCBI-Human-GeneID:5465,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002501,,,,,,,,,,,,,,,,,,,,,,Peroxisome Proliferator-Activated Receptor Alpha [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002507,Phosphorylation of eIF2-alpha by PERK [ER stress - translation attenuation],,"Phosphorylation of eIF2-alpha by PERK is a subtype of eIF2a phosphorylation: A process that The process of introducing a phosphate group into eIF2a by PERK.
This process is dependent on the translation attenuation and can constitute the course of ER stress.|The C-terminal domain of PERK (EIF2AK3) has kinase activity when PERK homodimerizes. PERK kinase specifically phosphorylates Ser52 of eIF2-alpha, causing an arrest in translation. The result is that translation of ER-targeted proteins is halted on ribosomes in the vicinity of activated PERK. The general arrest of translation results in the loss of short-lived proteins such as Cyclin D1, causing an arrest of the cell cycle in G1.",false,,,http://purl.obolibrary.org/obo/TXPO_0000700,,,,,,,,,,,,,,,,,,,,Reactome:R-HSA-381111|PMID:9930704|PMID:23334697,,"Phosphorylation of eIF2-alpha by PERK is a subtype of eIF2a phosphorylation: A process that The process of introducing a phosphate group into eIF2a by PERK.
This process is dependent on the translation attenuation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002988,,,,,,,,,,,TXPO:0002507,,,,,,,,,,,,,,,,,,,,"The C-terminal domain of PERK (EIF2AK3) has kinase activity when PERK homodimerizes. PERK kinase specifically phosphorylates Ser52 of eIF2-alpha, causing an arrest in translation. The result is that translation of ER-targeted proteins is halted on ribosomes in the vicinity of activated PERK. The general arrest of translation results in the loss of short-lived proteins such as Cyclin D1, causing an arrest of the cell cycle in G1.",,Phosphorylation of eIF2-alpha by PERK [ER stress - translation attenuation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002502,hyperfunction of protein unfolding (sustained) [ER stress],,"Hyperfunction of protein unfolding is a subtype of hyperfunctioning: A process that performs an excesssive protein unfolding. This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of ER stress (sustained) .",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/TXPO_0002718,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of protein unfolding is a subtype of hyperfunctioning: A process that performs an excesssive protein unfolding. This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of ER stress (sustained) .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000037|http://purl.obolibrary.org/obo/TXPO_0001965,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002460,,,,,,,,,,,TXPO:0002502,,,,,,,,,,,,,,,,,,,,,,hyperfunction of protein unfolding (sustained) [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005783,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0011143,eIF3g,"Translation initiation factor eIF3, p33 subunit|eIF-3 delta|eIF3 p33|Eukaryotic translation initiation factor 3 RNA-binding subunit|eIF-3 RNA-binding subunit|eukaryotic translation initiation factor 3 subunit 4|eIF3 p42|eIF3 p44",,false,,,http://purl.obolibrary.org/obo/IMR_0000916,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Translation initiation factor eIF3, p33 subunit|eIF-3 delta|eIF3 p33|Eukaryotic translation initiation factor 3 RNA-binding subunit|eIF-3 RNA-binding subunit|eukaryotic translation initiation factor 3 subunit 4|eIF3 p42|eIF3 p44",,,,,IMR:0011143,,,,,,,,,,,,,,,,,,,,,,eIF3g,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000314,apoptosis [liver tumor via ground glass appearance],,"A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died.
This entity is a specific course-dependent process. This process can constitute the course of liver tumor via ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001026|http://purl.obolibrary.org/obo/GO_0006915,,,,,,,,,,,,,,,,,,,,,,"A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died.
This entity is a specific course-dependent process. This process can constitute the course of liver tumor via ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001031,,,,,,,,,,,TXPO:0000314,,,,,,,,,,,,,,,,,,,,,,apoptosis [liver tumor via ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000319,tamoxifen phospholipase inhibitor[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/CHEBI_41774|http://purl.obolibrary.org/obo/TXPO_0001849,,,,,,,,,,,,,,,,,,,,PMID:24003057,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003220|http://purl.obolibrary.org/obo/TXPO_0001426,,,,,,,,,,TXPO:0000319,,,,,,,,,,,,,,,,,,,,,,tamoxifen phospholipase inhibitor[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000317,amiodarone_CAD [Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001849|http://purl.obolibrary.org/obo/CHEBI_2663,,,,,,,,,,,,,,,,,,,,PMID:15720040|PMID:22960355|PMID:9061852|PMID:28552552,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001426,,,,,,,,,,TXPO:0000317,,,,,,,,,,,,,,,,,,,,,,amiodarone_CAD [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000310,area (attribute),,A 2-D extent attribute inhering in a bearer by virtue of the bearer's two dimensional extent.,false,,,http://purl.obolibrary.org/obo/TXPO_0000305,,,,,,,,,,,,,,,,,,,,,,A 2-D extent attribute inhering in a bearer by virtue of the bearer's two dimensional extent.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000310,,,,,,,,,,,,,,,,,,,,,,area (attribute),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000313,tamoxifen [Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/CHEBI_41774|http://purl.obolibrary.org/obo/TXPO_0001849,,,,,,,,,,,,,,,,,,,,PMID:24003057,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001426,,,,,,,,,,TXPO:0000313,,,,,,,,,,,,,,,,,,,,,,tamoxifen [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000318,gentamicin_sphingomyelinase inhibitor [Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/CHEBI_17833|http://purl.obolibrary.org/obo/TXPO_0001849,,,,,,,,,,,,,,,,,,,,PMID:7159463|PMID:8091428,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_76811,,,,,,,,,,TXPO:0000318,,,,,,,,,,,,,,,,,,,,,,gentamicin_sphingomyelinase inhibitor [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000316,high brightness,,A color brightness which is relatively high.,false,,,http://purl.obolibrary.org/obo/PATO_0000016,,,,,,,,,,,,,,,,,,,,,,A color brightness which is relatively high.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000316,,,,,,,,,,,,,,,,,,,,,,high brightness,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000315,colorness (quality),,"A composite chromatic quality composed of hue, saturation and intensity parts.",false,,,http://purl.obolibrary.org/obo/PATO_0000068,,,,,,,,,,,,,,,,,,,,,,"A composite chromatic quality composed of hue, saturation and intensity parts.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000315,,,,,,,,,,,,,,,,,,,,,,colorness (quality),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000312,moving drug to the inside of liver,,Moving drug to the inside of liver is a subtype of moving A to the inside of B: A process that of the movement of drug into a liver.,false,,,http://purl.obolibrary.org/obo/TXPO_0002587,,,,,,,,,,,,,,,,,,,,,,Moving drug to the inside of liver is a subtype of moving A to the inside of B: A process that of the movement of drug into a liver.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000312,,,,,,,,,,,,,,,,,,,,,,moving drug to the inside of liver,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000311,color (attribute),,"Color as a kind is a generic quality. Red is a subclass of color and/or a value of color as discussed below, and being red is a property of things. The differentiation between red as a value of color and being red as a property is critical. In summary, there are three kinds of red.  It is unary rather than binary just like ordinary classes such as animal, car, etc",false,,,http://purl.obolibrary.org/obo/TXPO_0000305,,,,,,,,,,,,,,,,,,,,,,"Color as a kind is a generic quality. Red is a subclass of color and/or a value of color as discussed below, and being red is a property of things. The differentiation between red as a value of color and being red as a property is critical. In summary, there are three kinds of red.  It is unary rather than binary just like ordinary classes such as animal, car, etc",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000311,,,,,,,,,,,,,,,,,,,,,,color (attribute),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100201,vasopressin,VP|Antidiuretic hormone|ADH,"Octapeptide antidiuretic hormones released by the NEUROHYPOPHYSIS of all vertebrates (chemical composition varies with species). They control water metabolism and balance by regulating LUNG; GILLS; KIDNEY; etc., and water loss, and also contract smooth muscle. They may also be NEUROTRANSMITTERS.",false,,,http://purl.obolibrary.org/obo/IMR_0100103,,,,,,,,,,,,,,,,,,,,MeSH:D014667,,"Octapeptide antidiuretic hormones released by the NEUROHYPOPHYSIS of all vertebrates (chemical composition varies with species). They control water metabolism and balance by regulating LUNG; GILLS; KIDNEY; etc., and water loss, and also contract smooth muscle. They may also be NEUROTRANSMITTERS.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,VP|Antidiuretic hormone|ADH,,,,,IMR:0100201,,,,,,,,,,,,,,,,,,,,,,vasopressin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000002539,G6PD,,Other designations: glucose-6-phosphate 1-dehydrogenase,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,G6PD1,,,,,,,,,,,,X,,,,,,MIM:305900|Vega:OTTHUMG00000024237|HPRD:02377|HGNC:4057|Ensembl:ENSG00000160211,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,glucose-6-phosphate dehydrogenase,,,Xq28,,,,,,,,,,,,,,,,"GO_0001816 (EC: IMP, PMID: 17361089); GO_0004345 (EC: IDA, PMID: 15858258); GO_0004345 (EC: IMP, PMID: 2420826); GO_0005515 (EC: IPI); GO_0005536 (EC: IDA, PMID: 15858258); GO_0005536 (EC: IMP, PMID: 5643703); GO_0005634 (EC: IEA); GO_0005737 (EC: IDA); GO_0005829 (EC: IDA, PMID: 743300); GO_0005829 (EC: TAS); GO_0005975 (EC: TAS); GO_0006098 (EC: IDA, PMID: 2297768); GO_0006098 (EC: TAS); GO_0006629 (EC: TAS, PMID: 17361089); GO_0006695 (EC: IMP, PMID: 12027950); GO_0006739 (EC: IDA, PMID: 15858258); GO_0006740 (EC: IMP, PMID: 17516514); GO_0006749 (EC: IMP, PMID: 17516514); GO_0009051 (EC: IMP, PMID: 2420826); GO_0009898 (EC: IDA, PMID: 743300); GO_0010734 (EC: IMP, PMID: 17516514); GO_0014070 (EC: IEA); GO_0019322 (EC: IDA, PMID: 5643703); GO_0021762 (EC: IEP); GO_0032094 (EC: IEA); GO_0034599 (EC: IMP, PMID: 17516514); GO_0042803 (EC: IPI, PMID: 15858258); GO_0043249 (EC: IMP, PMID: 5643703); GO_0043523 (EC: IEA); GO_0044281 (EC: TAS); GO_0045471 (EC: IEA); GO_0046390 (EC: IMP, PMID: 2420826); GO_0050661 (EC: IDA, PMID: 15858258); GO_0051156 (EC: IDA, PMID: 15858258); GO_0051156 (EC: IMP, PMID: 5643703); GO_0055114 (EC: IMP, PMID: 2420826); GO_0070062 (EC: IDA, PMID: 19056867)",,,,,,,,,PMID: 743300; 1303180; 1303182; 1536798; 1611091; 1874446; 1889820; 1945893; 2297768; 2420826; 2428611; 2758468; 2836867; 2910917; 2912069; 3012556; 3126064; 3393536; 3446582; 3515319; 5643703; 5666113; 6696761; 7825590; 7857286; 7858267; 7959695; 8193373; 8356804; 8364584; 8466644; 8490627; 8533762; 8733135; 8826878; 9233561; 10087986; 10089300; 10627140; 10698963; 10745013; 11024211; 11042039; 11112389; 11237690; 11256614; 11440553; 11499668; 11793482; 11852882; 11857737; 11874436; 11876979; 11877026; 11920200; 12027950; 12130518; 12135480; 12378426; 12380870; 12439228; 12477932; 12497642; 12524354; 12588050; 12616531; 12641410; 12665801; 12680285; 12696079; 12737938; 12737940; 12737943; 12768444; 12850494; 12921788; 12972027; 14614139; 14757424; 14757426; 15223006; 15282679; 15307413; 15315792; 15330559; 15466166; 15476167; 15489334; 15506519; 15558953; 15592455; 15598086; 15622766; 15659240; 15718915; 15727905; 15748456; 15766741; 15772651; 15858258; 15864125; 15906717; 15906719; 15914531; 15951569; 15957246; 16020776; 16059744; 16088936; 16136268; 16137669; 16143877; 16155737; 16236267; 16255851; 16272653; 16331553; 16335966; 16356170; 16461316; 16483869; 16532971; 16569302; 16607506; 16637741; 16792831; 16859949; 16927025; 16934959; 16944148; 17007653; 17018380; 17077204; 17264545; 17361089; 17499234; 17516514; 17524386; 17557555; 17587269; 17611006; 17623298; 17637841; 17653668; 17660836; 17877203; 17959407; 18029348; 18043863; 18046504; 18056001; 18066402; 18086567; 18164966; 18173836; 18215251; 18226470; 18302154; 18376107; 18458302; 18493020; 18494377; 18558634; 18660489; 18677765; 18781797; 18985093; 19056867; 19219640; 19223928; 19224086; 19272180; 19317913; 19323016; 19336475; 19359662; 19419973; 19422023; 19465117; 19497363; 19589177; 19594365; 19632868; 19640310; 19738201; 19811411; 19858149; 19896395; 19913121; 19941843; 19996424; 20007901; 20017397; 20032314; 20113600; 20118060; 20200584; 20203002; 20236109; 20447239; 20459687; 20507315; 20514852; 20520804; 20528626; 20582980; 20602793; 20621077; 20628086; 20684792; 20713184; 20927393; 20949590; 21125776; 21139048; 21157431; 21180140; 21205543; 21302115; 21376116; 21376267; 21397531; 21507164; 21507207; 21549219; 21853274; 21890473; 21906983; 21963094; 21987572; 22012600; 22117603; 22139979; 22165289; 22307442; 22364808; 22431005; 22505724; 22537951; 22552160; 22768742; 22770933; 22848499; 22863883; 22906047; 22906837; 22939629; 22958163; 22963789; 23000965; 23023104; 23065279; 23146719; 23185302; 23233666; 23275194; 23389243; 23446634; 23631859; 23640907; 23696099; 23742107; 23824909,,,,,,,,,,,,,,,OGG:3000002539,,,,,,,glucose-6-phosphate dehydrogenase,,,,,,,,,,,,,Other designations: glucose-6-phosphate 1-dehydrogenase,,G6PD,,,,,,,,,,,,,,,,,,,,,,,2539,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,G6PD,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000002538,G6PC,,Other designations: G-6-Pase|G6Pase|G6Pase-alpha|glucose-6-phosphatase|glucose-6-phosphatase alpha,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,G6PT|G6PC1|GSD1|GSD1a,,,,,,,,,,,,17,,,,,,HPRD:01983|MIM:613742|HGNC:4056,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"glucose-6-phosphatase, catalytic subunit",,,17q21,,,,,,,,,,,,,,,,"GO_0004346 (EC: IDA, PMID: 10318794); GO_0005789 (EC: TAS); GO_0005975 (EC: TAS); GO_0005977 (EC: TAS, PMID: 8211187); GO_0005980 (EC: IEA); GO_0006094 (EC: IEA); GO_0006094 (EC: IMP, PMID: 8211187); GO_0006641 (EC: IEA); GO_0008202 (EC: IEA); GO_0008645 (EC: TAS); GO_0010468 (EC: IEA); GO_0015758 (EC: TAS); GO_0015760 (EC: IEA); GO_0016021 (EC: IDA, PMID: 10318794); GO_0016311 (EC: IDA, PMID: 10318794); GO_0016773 (EC: IEA); GO_0030176 (EC: TAS, PMID: 10318794); GO_0035264 (EC: IEA); GO_0042301 (EC: IMP, PMID: 12093795); GO_0042593 (EC: IMP, PMID: 8211187); GO_0042632 (EC: IEA); GO_0044281 (EC: TAS); GO_0046415 (EC: IEA); GO_0051156 (EC: IEA); GO_0055085 (EC: TAS)",,,,,,,,,PMID: 175958; 212064; 2172641; 2547044; 2986020; 7573034; 7623438; 7655466; 7668282; 7774924; 8182131; 8211187; 8612793; 8640227; 8733042; 9001800; 9332655; 9428641; 9675154; 9705299; 10023055; 10024523; 10026167; 10094563; 10318794; 10447271; 10452914; 10612834; 10748407; 10960498; 11672436; 11739393; 12093795; 12189168; 12373566; 12444104; 12477932; 12556524; 12560945; 13129915; 14718531; 14759518; 15316959; 15661744; 15696478; 15918042; 16892178; 16893891; 17354259; 18008183; 18449899; 18660489; 18805788; 18847435; 19082990; 19587243; 19832742; 20004937; 20301489; 20509832; 21109326; 21328436; 21733854; 21983240; 21988832; 23465595; 23755305,,,,,,,,,,,,,,,OGG:3000002538,,,,,,,"glucose-6-phosphatase, catalytic subunit",,,,,,,,,,,,,Other designations: G-6-Pase|G6Pase|G6Pase-alpha|glucose-6-phosphatase|glucose-6-phosphatase alpha,,G6PC,,,,,,,,,,,,,,,,,,,,,,,2538,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,G6PC,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_48540,beta-adrenergic drug,beta-adrenergic drugs,Any of the drugs that act on beta-adrenergic receptors.,false,,,http://purl.obolibrary.org/obo/CHEBI_37962,,,,,,,,,,,,,,,,,,,,,,Any of the drugs that act on beta-adrenergic receptors.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,beta-adrenergic drugs,,,,,,,,,,,,,,,,,,,,,CHEBI:48540,,,,beta-adrenergic drug,,CHEBI:48540,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100111,acetylcholine,O-Acetylcholine,,false,,,http://purl.obolibrary.org/obo/IMR_0002121,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_25512,,,,,O-Acetylcholine,,,,,IMR:0100111,,,,,,,,,,,,,,,,,,,,,,acetylcholine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001679,ground glass appearance with hypertrophy,,The totality of all processes through which ground glass appearance accompanied with hypertrophy is realized.,false,,,http://purl.obolibrary.org/obo/TXPO_0001432,,,,,,,,,,,,,,,,,,,,PMID:22723046|PMID:24180433,,The totality of all processes through which ground glass appearance accompanied with hypertrophy is realized.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000963|http://purl.obolibrary.org/obo/TXPO_0000969|http://purl.obolibrary.org/obo/TXPO_0000970|http://purl.obolibrary.org/obo/TXPO_0000972|http://purl.obolibrary.org/obo/TXPO_0000973,,,,,,,,,,,,,,,,,,TXPO:0001679,,,,,,,,,,,,,,,,,,,,,,ground glass appearance with hypertrophy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001672,sphingomyelin metabolism imbalance,,Sphingomyelin metabolism imbalance is a subtype of sphingophopholipid metabolism imbalance: A process that becomes lacking a homeostastasis balance of sphingomyelin metabolism.,false,,,http://purl.obolibrary.org/obo/TXPO_0001293,,,,,,,,,,,,,,,,,,,,,,Sphingomyelin metabolism imbalance is a subtype of sphingophopholipid metabolism imbalance: A process that becomes lacking a homeostastasis balance of sphingomyelin metabolism.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001672,,,,,,,,,,,,,,,,,,,,,,sphingomyelin metabolism imbalance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001670,increasing sphingomyelin material,,Increasing sphingomyelin material is a subtype of increasing sphingophopholipid material: A process that changes the amount of sphingomyelin material to be larger.,false,,,http://purl.obolibrary.org/obo/TXPO_0001669,,,,,,,,,,,,,,,,,,,,,,Increasing sphingomyelin material is a subtype of increasing sphingophopholipid material: A process that changes the amount of sphingomyelin material to be larger.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001670,,,,,,,,,,,,,,,,,,,,,,increasing sphingomyelin material,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001673,increase in fatty acid inflow into hepatocyte [Phpspholipidosis],,"Increase in fatty acid inflow into hepatocyte is a subtype of increasing quantity: A process that changes the fatty acid inflow into the hepatocyte to be larger.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003492|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Increase in fatty acid inflow into hepatocyte is a subtype of increasing quantity: A process that changes the fatty acid inflow into the hepatocyte to be larger.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001673,,,,,,,,,,,,,,,,,,,,,,increase in fatty acid inflow into hepatocyte [Phpspholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001674,hyperfunction of sphingomyelin synthetic gene expression,,Hyperfunction of sphingomyelin synthetic gene expression is a subtype of hyperfunction of sphingophospholipid synthesis gene expression: A process that performs an excesssive sphingomyelin synthetic gene expression.,false,,,http://purl.obolibrary.org/obo/TXPO_0001290,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of sphingomyelin synthetic gene expression is a subtype of hyperfunction of sphingophospholipid synthesis gene expression: A process that performs an excesssive sphingomyelin synthetic gene expression.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001674,,,,,,,,,,,,,,,,,,,,,,hyperfunction of sphingomyelin synthetic gene expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001675,phenobarbital accumulation in liver [Ground glass appearance (severe)],,"Phenobarbital accumulation in liver is a subtype of compound accumulation in liver: A process that keeps phenobarbital in the liver. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (severe).",false,,,http://purl.obolibrary.org/obo/TXPO_0000934,,,,,,,,,,,,,,,,,,,,,,"Phenobarbital accumulation in liver is a subtype of compound accumulation in liver: A process that keeps phenobarbital in the liver. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (severe).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001675,,,,,,,,,,,,,,,,,,,,,,phenobarbital accumulation in liver [Ground glass appearance (severe)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001677,smooth endoplasmic reticulum proliferation in hepatocyte (sustained) [Ground glass appearance],,"Smooth endoplasmic reticulum proliferation in hepatocyte is a subtype of endoplasmic reticulum proliferation in hepatocyte: A process that becomes larger in the number of smooth endoplasmic reticulum in hepatocyte(s). This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) .",false,,,http://purl.obolibrary.org/obo/TXPO_0003903|http://purl.obolibrary.org/obo/TXPO_0001230,,,,,,,,,,,,,,,,,,,,,,"Smooth endoplasmic reticulum proliferation in hepatocyte is a subtype of endoplasmic reticulum proliferation in hepatocyte: A process that becomes larger in the number of smooth endoplasmic reticulum in hepatocyte(s). This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003542,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003865|http://purl.obolibrary.org/obo/TXPO_0003845,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002320,,,,,,,,,,,TXPO:0001677,,,,,,,,,,,,,,,,,,,,,,smooth endoplasmic reticulum proliferation in hepatocyte (sustained) [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001678,negative regulation of sphingophopholipid degradation,,"Negative regulation of sphingophopholipid degradation is a subtype of negative regulation of phospholipid degradation: Any process that stops, prevents, or reduces the frequency, rate or extent of the sphingophospholipid catabolic process.",false,,,http://purl.obolibrary.org/obo/TXPO_0001256,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of sphingophopholipid degradation is a subtype of negative regulation of phospholipid degradation: Any process that stops, prevents, or reduces the frequency, rate or extent of the sphingophospholipid catabolic process.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001678,,,,,,,,,,,,,,,,,,,,,,negative regulation of sphingophopholipid degradation,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001465,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001671,increasing sphingomyelin material [Phospholipidosis - genetic- sphingomyelin disorder  ],,"Increasing sphingomyelin material is a subtype of increasing sphingophopholipid material: A process that changes the amount of sphingomyelin material to be larger.
This process is dependent on the  genetic and can constitute the course of Phospholipidosis (genetic).",false,,,http://purl.obolibrary.org/obo/TXPO_0001794,,,,,,,,,,,,,,,,,,,,,,"Increasing sphingomyelin material is a subtype of increasing sphingophopholipid material: A process that changes the amount of sphingomyelin material to be larger.
This process is dependent on the  genetic and can constitute the course of Phospholipidosis (genetic).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001671,,,,,,,,,,,,,,,,,,,,,,increasing sphingomyelin material [Phospholipidosis - genetic- sphingomyelin disorder  ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001676,hypofunction of sphingomyelin degradation,,Hypofunction of sphingomyelin degradation is a subtype of hypofunction of phosphosphingolipid degradation: A process that performs a decreased or insufficient sphingomyelin degradation.,false,,,http://purl.obolibrary.org/obo/TXPO_0001287,,,,,,,,,,,,,,,,,,,,,,Hypofunction of sphingomyelin degradation is a subtype of hypofunction of phosphosphingolipid degradation: A process that performs a decreased or insufficient sphingomyelin degradation.,,,http://purl.obolibrary.org/obo/GO_0006685,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_64583,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001676,,,,,,,,,,,,,,,,,,,,,,hypofunction of sphingomyelin degradation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000607,IL-8RB,interleukin-8 receptor B,,false,,,http://purl.obolibrary.org/obo/IMR_0000605,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,interleukin-8 receptor B,,,,,IMR:0000607,,,,,,,,,,,,,,,,,,,,,,IL-8RB,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000173,Integrin alpha,,,false,,,http://purl.obolibrary.org/obo/IMR_0000172,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000173,,,,,,,,,,,,,,,,,,,,,,Integrin alpha,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000834,C/EBP alpha,CCAAT/enhancer binding protein alpha,,false,,,http://purl.obolibrary.org/obo/IMR_0000422,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CCAAT/enhancer binding protein alpha,,,,,IMR:0000834,,,,,,,,,,,,,,,,,,,,,,C/EBP alpha,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100120,taurine,Taurine|2-aminoethanesulfonic acid,,false,,,http://purl.obolibrary.org/obo/CHEBI_33709,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_25512,,,,IMR:0200071,Taurine|2-aminoethanesulfonic acid,,,,,IMR:0100120,,,,,,,,,,,,,,,,,,,,,,taurine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002175,protein refolding (sustained) [ER stress],,"The process carried out by a cell that restores the biological activity of an unfolded or misfolded protein, using helper proteins such as chaperones. This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of ER stress (sustained) .",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/GO_0042026,,,,,,,,,,,,,,,,,,,,,,"The process carried out by a cell that restores the biological activity of an unfolded or misfolded protein, using helper proteins such as chaperones. This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of ER stress (sustained) .",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000801|http://purl.obolibrary.org/obo/TXPO_0002164|http://purl.obolibrary.org/obo/TXPO_0000783|http://purl.obolibrary.org/obo/TXPO_0002677|http://purl.obolibrary.org/obo/TXPO_0000828,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000561,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002460,,,,,,,,,,,TXPO:0002175,,,,,,,,,,,,,,,,,,,,,,protein refolding (sustained) [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005783,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002170,dysfunction of mitochondrial respiratory electron transport chain,,Dysfunction of mitochondrial respiratory electron transport chain is a subtype of dysfunctioning: A process that performs an abnormal and incomplete functioning of respiratory electron transport chain.,false,,,http://purl.obolibrary.org/obo/TXPO_0000438,,,,,,,,,,,,,,,,,,,,,,Dysfunction of mitochondrial respiratory electron transport chain is a subtype of dysfunctioning: A process that performs an abnormal and incomplete functioning of respiratory electron transport chain.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002170,,,,,,,,,,,,,,,,,,,,,,dysfunction of mitochondrial respiratory electron transport chain,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002177,protein refolding insufficiency [ER stress],,"Protein refolding insufficiency is a subtype of malfunctioning process: A process that lacks performing the function of protein refolding required.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/TXPO_0002474,,,,,,,,,,,,,,,,,,,,,,"Protein refolding insufficiency is a subtype of malfunctioning process: A process that lacks performing the function of protein refolding required.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002458,,,,,,,,,,,TXPO:0002177,,,,,,,,,,,,,,,,,,,,,,protein refolding insufficiency [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005783,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002173,cell proliferation [Eosinophilic granular degeneration],,"The multiplication or reproduction of cells, resulting in the rapid expansion of a cell population.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/TXPO_0001729|http://purl.obolibrary.org/obo/GO_0008283,,,,,,,,,,,,,,,,,,,,,,"The multiplication or reproduction of cells, resulting in the rapid expansion of a cell population.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001037,,,,,,,,,,,,,,,,,TXPO:0002173,,,,,,,,,,,,,,,,,,,,,,cell proliferation [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002174,receiving signal,,Receiving signal  is a subtype of receiving: A process that recognizes another object and changes into a signal.,false,,,http://purl.obolibrary.org/obo/TXPO_0000379,,,,,,,,,,,,,,,,,,,,,,Receiving signal  is a subtype of receiving: A process that recognizes another object and changes into a signal.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,TXPO:0002174,,,,,,,,,,,,,,,,,,,,,,receiving signal,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002176,Dissociation of IRE1:BIP Heterodimer [ER stress],,"Dissociation of IRE1:BIP heterodimer is a subtype of detaching: A process that disaggregates IRE-1-BIP heterodimers into BIP and IRE1.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0003736|http://purl.obolibrary.org/obo/TXPO_0000505,,,,,,,,,,,,,,,,,,,,PMID:10854322,,"Dissociation of IRE1:BIP heterodimer is a subtype of detaching: A process that disaggregates IRE-1-BIP heterodimers into BIP and IRE1.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002601,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000730,,,,,,,,,,,TXPO:0002176,,,,,,,,,,,,,,,,,,,,,,Dissociation of IRE1:BIP Heterodimer [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002178,toxicological role,,A role played by the entity within a toxicological context.,false,,,http://purl.obolibrary.org/obo/BFO_0000023,,,,,,,,,,,,,,,,,,,,,,A role played by the entity within a toxicological context.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002178,,,,,,,,,,,,,,,,,,,,,,toxicological role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002171,hypofunction of mitochondrial fatty acid beta-oxidation [ER stress],,"Hypofunction of mitochondrial fatty acid beta-oxidation is a subtype of hypofunction of fatty acid beta-oxidation: A process that performs a decreased or insufficient mitochondrial fatty acid beta-oxidation.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/TXPO_0002112,,,,,,,,,,,,,,,,,,,,,,"Hypofunction of mitochondrial fatty acid beta-oxidation is a subtype of hypofunction of fatty acid beta-oxidation: A process that performs a decreased or insufficient mitochondrial fatty acid beta-oxidation.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002172,,,,,,,,,,,TXPO:0002171,,,,,,,,,,,,,,,,,,,,,,hypofunction of mitochondrial fatty acid beta-oxidation [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002179,GSTK1 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0002089,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:373156|NCBI-Mouse-GeneID:76263|NCBI-Rat-GeneID:297029,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002179,,,,,,,,,,,,,,,,,,,,,,GSTK1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002172,lipid storage in liver [ER stress],,"Lipid storage in liver is a subtype of lipid storage: The accumulation and maintenance in cells or tissues of lipids in the liver.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001276|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,PMID:26977301|PMID:18556558|PMID:27325692,,"Lipid storage in liver is a subtype of lipid storage: The accumulation and maintenance in cells or tissues of lipids in the liver.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003819,,,,,,,,,,,,,,,,,TXPO:0002172,,,,,,,,,,,,,,,,,,,,,,lipid storage in liver [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000002937,GSS,,,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,glutathione synthetase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"GO_0000287 (EC: IDA, PMID: 10369661); GO_0004363 (EC: TAS); GO_0005524 (EC: IDA, PMID: 10369661); GO_0005829 (EC: TAS); GO_0006520 (EC: TAS, PMID: 8896573); GO_0006750 (EC: TAS); GO_0006805 (EC: TAS); GO_0006979 (EC: TAS, PMID: 465367); GO_0007399 (EC: TAS, PMID: 8896573); GO_0007568 (EC: IEA); GO_0016594 (EC: IEA); GO_0031667 (EC: IEA); GO_0034612 (EC: IEA); GO_0042803 (EC: IDA, PMID: 10369661); GO_0043200 (EC: IEA); GO_0043295 (EC: IDA, PMID: 10369661); GO_0044281 (EC: TAS); GO_0046686 (EC: IEA); GO_0070062 (EC: IDA, PMID: 19056867); GO_1901687 (EC: TAS)",,,,,,,,,PMID: 465367; 1518371; 6112263; 6137189; 7646467; 8825653; 8896573; 9215686; 9501919; 10369661; 10450861; 10652368; 10861239; 11167850; 11780052; 12477932; 12638941; 14990577; 15173170; 15489334; 15890065; 17206463; 17234469; 17503480; 17601350; 18977241; 19056867; 19111905; 19672693; 19913121; 20200426; 20413906; 20439344; 20485444; 20628086; 20800579; 20802163; 21044950; 21105962; 21139048; 21683691; 21771585; 21890473; 21906983; 21963094; 21988832; 22505724; 22863883; 22939629; 23000965; 24030972; 24250222,,,,,,,,,,,,,,,OGG:3000002937,,,,,,,,,,,,,,,,,,,,,,GSS,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2729,,,,,,,,,,,,,,,,,,,GSS,,
http://purl.obolibrary.org/obo/CHEBI_17361,CMP,,A cytidine 5'-phosphate that has formula C9H14N3O8P.,false,,,http://purl.obolibrary.org/obo/TXPO_0002623,,,,,,,,,,,,,,,,,,,,,,A cytidine 5'-phosphate that has formula C9H14N3O8P.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:17361,,,,,,,,,,,,,,,,,,,,,,CMP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_67114,ryanodine receptor agonist,RyR agonists|RyR activator,"A ryanodine receptor modulator which activates the receptor. Ryanodine receptors (RyRs) act as selective ion channels, modulating the release of calcium. Activating the receptors causes the release of calcium, so depleting internal calcium and ultimately preventing further muscle contraction.",false,,,http://purl.obolibrary.org/obo/CHEBI_38809,,,,,,,,,,,,,,,,,,,,Wikipedia:Ryanodine_receptor,,"A ryanodine receptor modulator which activates the receptor. Ryanodine receptors (RyRs) act as selective ion channels, modulating the release of calcium. Activating the receptors causes the release of calcium, so depleting internal calcium and ultimately preventing further muscle contraction.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,RyR agonists|RyR activator,,,CHEBI:67114,,,,,,,,,,,,,,,,,,,,,,ryanodine receptor agonist,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100711,40S ribosomal protein S6,40S small ribosomal protein 6|40S ribosomal subunit protein S6,,false,,,http://purl.obolibrary.org/obo/IMR_0000896,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0010562,40S small ribosomal protein 6|40S ribosomal subunit protein S6,,,,,IMR:0100711,,,,,,,,,,,,,,,,,,,,,,40S ribosomal protein S6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000533,cell repair,,Cell repair is a subtype of repairing: A process that restores the cell after damage.,false,,,http://purl.obolibrary.org/obo/TXPO_0000535,,,,,,,,,,,,,,,,,,,,,,Cell repair is a subtype of repairing: A process that restores the cell after damage.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000620,,,,,,,,,,,,,,,,,,TXPO:0000533,,,,,,,,,,,,,,,,,,,,,,cell repair,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000537,extracellular matrix excess deposition,,"Extracellular matrix excess deposition is a subtype of accumulation of substances in a biological object: A process that puts extracellular matrix down in an organism, tissue, organelle, or cell.",false,,,http://purl.obolibrary.org/obo/TXPO_0000247,,,,,,,,,,,,,,,,,,,,,,"Extracellular matrix excess deposition is a subtype of accumulation of substances in a biological object: A process that puts extracellular matrix down in an organism, tissue, organelle, or cell.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0031012,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000219,,,,,,,,,,,TXPO:0000537,,,,,,,,,,,,,,,,,,,,,,extracellular matrix excess deposition,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000539,necrosis [Phospholipidosis],,"A type of cell death that is morphologically characterized by an increasingly translucent cytoplasm, swelling of organelles, minor ultrastructural modifications of the nucleus (specifically, dilatation of the nuclear membrane and condensation of chromatin into small, irregular, circumscribed patches) and increased cell volume (oncosis), culminating in the disruption of the plasma membrane and subsequent loss of intracellular contents. Necrotic cells do not fragment into discrete corpses as their apoptotic counterparts do. Moreover, their nuclei remain intact and can aggregate and accumulate in necrotic tissues.
This entity is a specific course-dependent process. This process can constitute the course of Phosphoipidosis(severe).",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/GO_0070265,,,,,,,,,,,,,,,,,,,,PMID:18955971,,"A type of cell death that is morphologically characterized by an increasingly translucent cytoplasm, swelling of organelles, minor ultrastructural modifications of the nucleus (specifically, dilatation of the nuclear membrane and condensation of chromatin into small, irregular, circumscribed patches) and increased cell volume (oncosis), culminating in the disruption of the plasma membrane and subsequent loss of intracellular contents. Necrotic cells do not fragment into discrete corpses as their apoptotic counterparts do. Moreover, their nuclei remain intact and can aggregate and accumulate in necrotic tissues.
This entity is a specific course-dependent process. This process can constitute the course of Phosphoipidosis(severe).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000927|http://purl.obolibrary.org/obo/TXPO_0000555,,,,,,,,,,,TXPO:0000539,,,,,,,,,,,,,,,,,,,,,,necrosis [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000534,cell repair [Cell death],,"Cell repair is a subtype of repairing: A process that restores the cell after damage.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0001727|http://purl.obolibrary.org/obo/TXPO_0000533,,,,,,,,,,,,,,,,,,,,,,"Cell repair is a subtype of repairing: A process that restores the cell after damage.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000534,,,,,,,,,,,,,,,,,,,,,,cell repair [Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000538,process on structural viewpoint,,,false,,,http://purl.obolibrary.org/obo/TXPO_0000420,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000538,,,,,,,,,,,,,,,,,,,,,,process on structural viewpoint,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000535,repairing,,Repairing is a subtype of changing an operand: A process that restores the object after damage.,false,,,http://purl.obolibrary.org/obo/TXPO_0000392,,,,,,,,,,,,,,,,,,,,,,Repairing is a subtype of changing an operand: A process that restores the object after damage.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000619,,,,,,,,,,,,,,,,,,TXPO:0000535,,,,,,,,,,,,,,,,,,,,,,repairing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000536,JNK signaling (primitive) [Oxidative stress],,"JNK signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the JNK (a stress-activated protein kinase (SAPK) ).
This entity is a specific course-dependent process. This process can constitute the course of Oxidative stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000769|http://purl.obolibrary.org/obo/TXPO_0001730,,,,,,,,,,,,,,,,,,,,,,"JNK signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the JNK (a stress-activated protein kinase (SAPK) ).
This entity is a specific course-dependent process. This process can constitute the course of Oxidative stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001186,,,,,,,,,,,TXPO:0000536,,,,,,,,,,,,,,,,,,,,,,JNK signaling (primitive) [Oxidative stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000532,malfunctioning of controlling,,Malfunctioning of controlling is a subtype of malfunctioning process: A process that cannot perform a controlling function appropriately or cannot realize it at all.,false,,,http://purl.obolibrary.org/obo/TXPO_0000434,,,,,,,,,,,,,,,,,,,,,,Malfunctioning of controlling is a subtype of malfunctioning process: A process that cannot perform a controlling function appropriately or cannot realize it at all.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000532,,,,,,,,,,,,,,,,,,,,,,malfunctioning of controlling,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0031532,actin cytoskeleton reorganization,actin cytoskeleton remodeling,A process that is carried out at the cellular level which results in dynamic structural changes to the arrangement of constituent parts of cytoskeletal structures comprising actin filaments and their associated proteins.,false,,,http://purl.obolibrary.org/obo/GO_0030036,,,,,,,,,,,,,,,,,,,,,,A process that is carried out at the cellular level which results in dynamic structural changes to the arrangement of constituent parts of cytoskeletal structures comprising actin filaments and their associated proteins.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,actin cytoskeleton remodeling,,,,,GO:0031532,,,,,,,,,,,,,,,,,,,,,,actin cytoskeleton reorganization,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100027,diacylglycerol,DG|DAG|diacylglyceride|Diglyceride,,false,,,http://purl.obolibrary.org/obo/CHEBI_35741,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002401,,,,,DG|DAG|diacylglyceride|Diglyceride,,,,,IMR:0100027,,,,,,,,,,,,,,,,,,,,,,diacylglycerol,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000963,LRP4,LDL receptor-related protein 4|low density lipoprotein receptor-related protein 4,,false,,,http://purl.obolibrary.org/obo/IMR_0100798,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,LDL receptor-related protein 4|low density lipoprotein receptor-related protein 4,,,,,IMR:0000963,,,,,,,,,,,,,,,,,,,,,,LRP4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000251,PKG,cGMP-dependent protein kinase,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,GO:0004692,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001966,,,,,cGMP-dependent protein kinase,,,,,IMR:0000251,,,,,,,,,,,,,,,,,,,,,,PKG,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000201,IL2 (mol),,,false,,,http://purl.obolibrary.org/obo/IMR_0000007,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:16183|NCBI-Rat-GeneID:116562|NCBI-Human-GeneID:3558,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000003558,,,,,,,,,,,,,TXPO:1000201,,,,,,,,,,,,,,,,,,,,,,IL2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000207,Ier3 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:294235|NCBI-Mouse-GeneID:15937|NCBI-Human-GeneID:8870,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000008870,,,,,,,,,,,,,TXPO:1000207,,,,,,,,,,,,,,,,,,,,,,Ier3 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000200,IL-1b (mol),,,false,,,http://purl.obolibrary.org/obo/IMR_0000007,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:3553|NCBI-Rat-GeneID:24494|NCBI-Mouse-GeneID:16176,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000003553,,,,,,,,,,,,,TXPO:1000200,,,,,,,,,,,,,,,,,,,,,,IL-1b (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000205,INTS6 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:18130|NCBI-Human-GeneID:26512|NCBI-Rat-GeneID:361057,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000026512,,,,,,,,,,,,,TXPO:1000205,,,,,,,,,,,,,,,,,,,,,,INTS6 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000203,INHBE (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:83711|NCBI-Human-GeneID:83729|NCBI-Mouse-GeneID:16326,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000083729,,,,,,,,,,,,,TXPO:1000203,,,,,,,,,,,,,,,,,,,,,,INHBE (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000202,IL2RB (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:16185|NCBI-Human-GeneID:3560|NCBI-Rat-GeneID:25746,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000003560,,,,,,,,,,,,,TXPO:1000202,,,,,,,,,,,,,,,,,,,,,,IL2RB (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000204,INSC (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:293166|NCBI-Mouse-GeneID:233752|NCBI-Human-GeneID:387755,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000387755,,,,,,,,,,,,,TXPO:1000204,,,,,,,,,,,,,,,,,,,,,,INSC (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000206,ITGB1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:3688|NCBI-Rat-GeneID:24511|NCBI-Mouse-GeneID:16412,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000003688,,,,,,,,,,,,,TXPO:1000206,,,,,,,,,,,,,,,,,,,,,,ITGB1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000208,IGFBP1 (mol),,,false,,,http://purl.obolibrary.org/obo/IMR_0002688,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:25685|NCBI-Human-GeneID:3484|NCBI-Mouse-GeneID:16006|http://purl.obolibrary.org/obo/IMR_0002689,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000003484,,,,,,,,,,,,,TXPO:1000208,,,,,,,,,,,,,,,,,,,,,,IGFBP1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000209,Ing4 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:28019|NCBI-Human-GeneID:51147|NCBI-Rat-GeneID:297597,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000051147,,,,,,,,,,,,,TXPO:1000209,,,,,,,,,,,,,,,,,,,,,,Ing4 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76898,EC 1.14.14.1 (unspecific monooxygenase) inhibitor,"flavoprotein-linked monooxygenase inhibitors|unspecific monooxygenase inhibitors|microsomal monooxygenase inhibitors|flavoprotein monooxygenase inhibitor|substrate,reduced-flavoprotein:oxygen oxidoreductase (RH-hydroxylating or -epoxidising) inhibitor|aryl-4-monooxygenase inhibitor|microsomal P-450 inhibitors|microsomal monooxygenase inhibitor|flavoprotein-linked monooxygenase inhibitor|EC 1.14.14.1 (unspecific monooxygenase) inhibitors|unspecific monooxygenase (EC 1.14.14.1) inhibitors|EC 1.14.14.1 inhibitors|xenobiotic monooxygenase inhibitors|aryl-4-monooxygenase inhibitors|xenobiotic monooxygenase inhibitor|unspecific monooxygenase inhibitor|microsomal P-450 inhibitor|flavoprotein monooxygenase inhibitors|unspecific monooxygenase (EC 1.14.14.1) inhibitor|aryl hydrocarbon hydroxylase inhibitors|aryl hydrocarbon hydroxylase inhibitor|EC 1.14.14.1 inhibitor|substrate,reduced-flavoprotein:oxygen oxidoreductase (RH-hydroxylating or -epoxidising) inhibitors","An EC 1.14.14.* (oxidoreductase acting on paired donors, incorporating of 1 atom of oxygen, with reduced flavin or flavoprotein as one donor) inhibitor that interferes with the action of an unspecified monooxygenase (EC 1.14.14.1).",false,,,http://purl.obolibrary.org/obo/CHEBI_76838,,,,,,,,,,,,,,,,,,,,,,"An EC 1.14.14.* (oxidoreductase acting on paired donors, incorporating of 1 atom of oxygen, with reduced flavin or flavoprotein as one donor) inhibitor that interferes with the action of an unspecified monooxygenase (EC 1.14.14.1).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"flavoprotein-linked monooxygenase inhibitors|unspecific monooxygenase inhibitors|microsomal monooxygenase inhibitors|flavoprotein monooxygenase inhibitor|substrate,reduced-flavoprotein:oxygen oxidoreductase (RH-hydroxylating or -epoxidising) inhibitor|aryl-4-monooxygenase inhibitor|microsomal P-450 inhibitors|microsomal monooxygenase inhibitor|flavoprotein-linked monooxygenase inhibitor|EC 1.14.14.1 (unspecific monooxygenase) inhibitors|unspecific monooxygenase (EC 1.14.14.1) inhibitors|EC 1.14.14.1 inhibitors|xenobiotic monooxygenase inhibitors|aryl-4-monooxygenase inhibitors|xenobiotic monooxygenase inhibitor|unspecific monooxygenase inhibitor|microsomal P-450 inhibitor|flavoprotein monooxygenase inhibitors|unspecific monooxygenase (EC 1.14.14.1) inhibitor|aryl hydrocarbon hydroxylase inhibitors|aryl hydrocarbon hydroxylase inhibitor|EC 1.14.14.1 inhibitor|substrate,reduced-flavoprotein:oxygen oxidoreductase (RH-hydroxylating or -epoxidising) inhibitors",,,,,,,,,,,,,,,,,,,,,CHEBI:76898,,,,EC 1.14.14.1 (unspecific monooxygenase) inhibitor,,CHEBI:76898,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_17747,bis(2-ethylhexyl) phthalate,Diethylhexylphthalate|DEHP,"A phthalate ester that is the bis(2-ethylhexyl) ester of benzene-1,2-dicarboxylic acid.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:117-81-7,,"A phthalate ester that is the bis(2-ethylhexyl) ester of benzene-1,2-dicarboxylic acid.",,,,,,,,,,,,C24H38O4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Diethylhexylphthalate|DEHP,,,,,CHEBI:17747,,,,,,,,,,,,,,,,,,,,,,bis(2-ethylhexyl) phthalate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CCCCC(CC)COC(=O)c1ccccc1C(=O)OCC(CC)CCCC,,,,,
http://purl.obolibrary.org/obo/OGG_3000009517,SPTLC2,,"Other designations: LCB 2|SPT 2|long chain base biosynthesis protein 2a|serine palmitoyltransferase 2|serine palmitoyltransferase, subunit II|serine-palmitoyl-CoA transferase 2",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,LCB2|LCB2A|SPT2|NSAN1C|HSN1C|hLCB2a,,,,,,,,,,,,14,,,,,,Vega:OTTHUMG00000171540|HPRD:05755|HGNC:11278|Ensembl:ENSG00000100596|MIM:605713,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"serine palmitoyltransferase, long chain base subunit 2",,,14q24.3,,,,,,,,,,,,,,,,"GO_0004758 (EC: IDA, PMID: 19416851); GO_0005739 (EC: IEA); GO_0005789 (EC: TAS); GO_0006665 (EC: TAS); GO_0006686 (EC: IEA); GO_0016021 (EC: IEA); GO_0017059 (EC: IDA, PMID: 19416851); GO_0030148 (EC: TAS, PMID: 19416851); GO_0030170 (EC: IEA); GO_0044281 (EC: TAS); GO_0046511 (EC: IEA); GO_0046512 (EC: IEA); GO_0046513 (EC: IEA)",,,,,,,,,PMID: 7506601; 8889549; 8921873; 9363775; 9628581; 10722674; 10737800; 12207934; 12445191; 12477932; 12508121; 15489334; 16147992; 17081983; 17194770; 17331073; 19416851; 20877624; 20920666; 21139048; 21890473; 21906983; 23658386,,,,,,,,,,,,,,,OGG:3000009517,,,,,,,"serine palmitoyltransferase, long chain base subunit 2",,,,,,,,,,,,,"Other designations: LCB 2|SPT 2|long chain base biosynthesis protein 2a|serine palmitoyltransferase 2|serine palmitoyltransferase, subunit II|serine-palmitoyl-CoA transferase 2",,SPTLC2,,,,,,,,,,,,,,,,,,,,,,,9517,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,SPTLC2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000009518,GDF15,,Other designations: NRG-1|NSAID (nonsteroidal anti-inflammatory drug)-activated protein 1|NSAID-activated gene 1 protein|NSAID-regulated gene 1 protein|PTGF-beta|growth/differentiation factor 15|macrophage inhibitory cytokine 1|placental TGF-beta|placental bone morphogenetic protein|prostate differentiation factor,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,MIC1|PLAB|MIC-1|NAG-1|GDF-15|PTGFB|PDF,,,,,,,,,,,,19,,,,,,HGNC:30142|Ensembl:ENSG00000130513|MIM:605312|Vega:OTTHUMG00000183360|HPRD:05608,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,growth differentiation factor 15,,,19p13.11,,,,,,,,,,,,,,,,"GO_0005125 (EC: IEA); GO_0005576 (EC: TAS, PMID: 9326641); GO_0005615 (EC: IEA); GO_0007165 (EC: TAS, PMID: 9326641); GO_0007179 (EC: TAS, PMID: 9348093); GO_0007267 (EC: TAS, PMID: 9326641); GO_0008083 (EC: IEA)",,,,,,,,,PMID: 8125298; 9326641; 9348093; 9375789; 9426002; 9593718; 10524241; 10777512; 10811612; 11102463; 11134143; 11141057; 11259636; 11278594; 11445565; 11895857; 11994274; 12011055; 12082608; 12090982; 12139236; 12477932; 12514175; 12624183; 12855642; 12894347; 12900512; 12941831; 14575402; 14662774; 14726168; 15073115; 15316060; 15342369; 15670751; 15677629; 15757899; 15900300; 16154591; 16286461; 16388506; 16397141; 16484622; 16699947; 16741990; 16775185; 17050687; 17192395; 17328047; 17548705; 17637746; 17721544; 17908975; 17909264; 17982462; 18029348; 18264720; 18359786; 18398830; 18550273; 18624398; 18657084; 18676680; 18754039; 18801729; 18824595; 19047680; 19060904; 19074584; 19100681; 19125423; 19133249; 19152406; 19168526; 19170196; 19302795; 19341722; 19357976; 19375854; 19401523; 19470878; 19505289; 19505919; 19515791; 19521960; 19625176; 19692168; 19695766; 19913121; 19946339; 20024638; 20031597; 20067113; 20104227; 20130018; 20160200; 20167682; 20193126; 20215826; 20237496; 20357380; 20385121; 20431030; 20534737; 20576287; 20628086; 20800603; 20854422; 20855664; 20860541; 20884666; 20937742; 20966402; 20975101; 21097678; 21245963; 21312063; 21336029; 21437897; 21475976; 21487066; 21503121; 21504622; 21535154; 21548946; 21586550; 21616994; 21645023; 21773947; 21803025; 21809352; 21865063; 21881845; 21906983; 22023041; 22064648; 22144502; 22160844; 22180562; 22231869; 22301101; 22341306; 22365732; 22384099; 22484283; 22505696; 22511768; 22723347; 22815297; 22872134; 22975449; 23071585; 23146921; 23154866; 23262134; 23328263; 23335088; 23468844; 23503457; 23799024; 23836903; 23850849; 23996089; 24136234; 24345755,,,,,,,,,,,,,,,OGG:3000009518,,,,,,,growth differentiation factor 15,,,,,,,,,,,,,Other designations: NRG-1|NSAID (nonsteroidal anti-inflammatory drug)-activated protein 1|NSAID-activated gene 1 protein|NSAID-regulated gene 1 protein|PTGF-beta|growth/differentiation factor 15|macrophage inhibitory cytokine 1|placental TGF-beta|placental bone morphogenetic protein|prostate differentiation factor,,GDF15,,,,,,,,,,,,,,,,,,,,,,,9518,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,GDF15,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000180,N-CAM,neuronal cell adhesion molecule,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003688,,,,,neuronal cell adhesion molecule,,,,,IMR:0000180,,,,,,,,,,,,,,,,,,,,,,N-CAM,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010554,40S ribosomal protein S29,40S small ribosomal protein 29,,false,,,http://purl.obolibrary.org/obo/IMR_0000896,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,40S small ribosomal protein 29,,,,,IMR:0010554,,,,,,,,,,,,,,,,,,,,,,40S ribosomal protein S29,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100582,syndecan-3,N-syndecan|SYND3|Neuroglycan,,false,,,http://purl.obolibrary.org/obo/IMR_0100579,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,N-syndecan|SYND3|Neuroglycan,,,,,IMR:0100582,,,,,,,,,,,,,,,,,,,,,,syndecan-3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_2504,aflatoxin B1,"(6aR,9aS)-4-methoxy-2,3,6a,9a-tetrahydrocyclopenta[c]furo[3',2':4,5]furo[2,3-h]chromene-1,11-dione","An aflatoxin having a tetrahydrocyclopenta[c]furo[3',2':4,5]furo[2,3-h]chromene skeleton with oxygen functionality at positions 1, 4 and 11.",false,,,http://purl.obolibrary.org/obo/CHEBI_22271,,,,,,,,,,,,,,,,,,,,CAS:1162-65-8,,"An aflatoxin having a tetrahydrocyclopenta[c]furo[3',2':4,5]furo[2,3-h]chromene skeleton with oxygen functionality at positions 1, 4 and 11.",,,,,,,,,,,,C17H12O6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"(6aR,9aS)-4-methoxy-2,3,6a,9a-tetrahydrocyclopenta[c]furo[3',2':4,5]furo[2,3-h]chromene-1,11-dione",,,,,CHEBI:2504,,,,,,,,,,,,,,,,,,,,,,aflatoxin B1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,[H][C@]12OC=C[C@@]1([H])c1c(O2)cc(OC)c2c3CCC(=O)c3c(=O)oc12,,,,,
http://purl.obolibrary.org/obo/IMR_0000097,IL-2 receptor,interleukin-2 receptor,,false,,,http://purl.obolibrary.org/obo/IMR_0000096,,,,,,,,,,,,,,,,,,,,GO:0004911,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,interleukin-2 receptor,,,,,IMR:0000097,,,,,,,,,,,,,,,,,,,,,,IL-2 receptor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0031210,phosphatidylcholine binding,,"Interacting selectively and non-covalently with phosphatidylcholine, a class of glycophospholipids in which a phosphatidyl group is esterified to the hydroxyl group of choline.",false,,,http://purl.obolibrary.org/obo/GO_0005543,,,,,,,,,,,,,,,,,,,,GO:0031210,,"Interacting selectively and non-covalently with phosphatidylcholine, a class of glycophospholipids in which a phosphatidyl group is esterified to the hydroxyl group of choline.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0031210,,,,,,,,,,,,,,,,,,,,,,phosphatidylcholine binding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000120,IL-1 receptor,interleukin-1 receptor,,false,,,http://purl.obolibrary.org/obo/IMR_0000096,,,,,,,,,,,,,,,,,,,,GO:0004908,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,interleukin-1 receptor,,,,,IMR:0000120,,,,,,,,,,,,,,,,,,,,,,IL-1 receptor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000009871,SEC24D,,"Other designations: SEC24 family, member D|SEC24 related gene family, member D|SEC24-related protein D|protein transport protein Sec24D",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,4,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,SEC24 family member D,,,4q26,,,,,,,,,,,,,,,,"GO_0000139 (EC: IEA); GO_0002474 (EC: TAS); GO_0003674 (EC: ND); GO_0005789 (EC: TAS); GO_0005829 (EC: TAS); GO_0006886 (EC: IEA); GO_0006888 (EC: NAS, PMID: 10329445); GO_0006888 (EC: TAS); GO_0008270 (EC: IEA); GO_0012507 (EC: TAS); GO_0018279 (EC: TAS); GO_0019886 (EC: TAS); GO_0030127 (EC: NAS, PMID: 10329445); GO_0043687 (EC: TAS); GO_0044267 (EC: TAS); GO_0044281 (EC: TAS); GO_0048208 (EC: TAS); GO_0048471 (EC: IEA); GO_0061024 (EC: TAS)",,,,,,,,,PMID: 9872452; 10075675; 10329445; 11031247; 11252894; 12477932; 14702039; 15231748; 15580264; 16189514; 16344560; 17210573; 20332099; 20379614; 20889976; 21890473; 21906983; 22404651; 22863883; 22939629; 24250222,,,,,,,,,,,,,,,OGG:3000009871,,,,,,,SEC24 family member D,,,,,,,,,,,,,"Other designations: SEC24 family, member D|SEC24 related gene family, member D|SEC24-related protein D|protein transport protein Sec24D",,SEC24D,,,,,,,,,,,,,,,,,,,,,,,9871,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,SEC24D,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0100814,CKI-delta,"CKId|Casein kinase I, delta isoform",,false,,,http://purl.obolibrary.org/obo/IMR_0100809,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"CKId|Casein kinase I, delta isoform",,,,,IMR:0100814,,,,,,,,,,,,,,,,,,,,,,CKI-delta,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0005791,rough endoplasmic reticulum,rough ER|RER,"The rough (or granular) endoplasmic reticulum (ER) has ribosomes adhering to the outer surface; the ribosomes are the site of translation of the mRNA for those proteins which are either to be retained within the cisternae (ER-resident proteins), the proteins of the lysosomes, or the proteins destined for export from the cell. Glycoproteins undergo their initial glycosylation within the cisternae.",false,,,http://purl.obolibrary.org/obo/GO_0005783,,,,,,,,,,,,,,,,,,,,Wikipedia:Endoplasmic_reticulum#Rough_endoplasmic_reticulum|NIF_Subcellular:sao1881364067;,,"The rough (or granular) endoplasmic reticulum (ER) has ribosomes adhering to the outer surface; the ribosomes are the site of translation of the mRNA for those proteins which are either to be retained within the cisternae (ER-resident proteins), the proteins of the lysosomes, or the proteins destined for export from the cell. Glycoproteins undergo their initial glycosylation within the cisternae.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,rough ER|RER,,,,,GO:0005791,,,,,,,,,,,,,,,,,,,,,,rough endoplasmic reticulum,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0005790,smooth endoplasmic reticulum,,"The smooth endoplasmic reticulum (smooth ER or SER) has no ribosomes attached to it. The smooth ER is the recipient of the proteins synthesized in the rough ER. Those proteins to be exported are passed to the Golgi complex, the resident proteins are returned to the rough ER and the lysosomal proteins after phosphorylation of their mannose residues are passed to the lysosomes. Glycosylation of the glycoproteins also continues. The smooth ER is the site of synthesis of lipids, including the phospholipids. The membranes of the smooth ER also contain enzymes that catalyze a series of reactions to detoxify both lipid-soluble drugs and harmful products of metabolism. Large quantities of certain compounds such as phenobarbital cause an increase in the amount of the smooth ER.|The hepatocyte is a cell with an abundant smooth ER.",false,,,http://purl.obolibrary.org/obo/GO_0005783,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0042158|http://purl.obolibrary.org/obo/TXPO_0000173,,,ISBN:0815332181|NIF_Subcellular:sao710427438|Wikipedia:Endoplasmic_reticulum#Smooth_endoplasmic_reticulum,,"The smooth endoplasmic reticulum (smooth ER or SER) has no ribosomes attached to it. The smooth ER is the recipient of the proteins synthesized in the rough ER. Those proteins to be exported are passed to the Golgi complex, the resident proteins are returned to the rough ER and the lysosomal proteins after phosphorylation of their mannose residues are passed to the lysosomes. Glycosylation of the glycoproteins also continues. The smooth ER is the site of synthesis of lipids, including the phospholipids. The membranes of the smooth ER also contain enzymes that catalyze a series of reactions to detoxify both lipid-soluble drugs and harmful products of metabolism. Large quantities of certain compounds such as phenobarbital cause an increase in the amount of the smooth ER.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0005790,,,,,,,,,,,,,,,,,,,,The hepatocyte is a cell with an abundant smooth ER.,,smooth endoplasmic reticulum,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0005794,golgi apparatus,Golgi complex,"A compound membranous cytoplasmic organelle of eukaryotic cells, consisting of flattened, ribosome-free vesicles arranged in a more or less regular stack. The Golgi apparatus differs from the endoplasmic reticulum in often having slightly thicker membranes, appearing in sections as a characteristic shallow semicircle so that the convex side (cis or entry face) abuts the endoplasmic reticulum, secretory vesicles emerging from the concave side (trans or exit face). In vertebrate cells there is usually one such organelle, while in invertebrates and plants, where they are known usually as dictyosomes, there may be several scattered in the cytoplasm. The Golgi apparatus processes proteins produced on the ribosomes of the rough endoplasmic reticulum; such processing includes modification of the core oligosaccharides of glycoproteins, and the sorting and packaging of proteins for transport to a variety of cellular locations. Three different regions of the Golgi are now recognized both in terms of structure and function: cis, in the vicinity of the cis face, trans, in the vicinity of the trans face, and medial, lying between the cis and trans regions.|Note that the Golgi apparatus can be located in various places in the cytoplasm. In plants and lower animal cells, the Golgi apparatus exists as many copies of discrete stacks dispersed throughout the cytoplasm, while the Golgi apparatus of interphase mammalian cells is a juxtanuclear, often pericentriolar reticulum, where the discrete Golgi stacks are stitched together to form a compact and interconnected ribbon, sometimes called the Golgi ribbon.",false,,,http://purl.obolibrary.org/obo/GO_0043227,,,,,,,,,,,,,,,,,,,,Wikipedia:Golgi_apparatus|NIF_Subcellular:sao451912436,,"A compound membranous cytoplasmic organelle of eukaryotic cells, consisting of flattened, ribosome-free vesicles arranged in a more or less regular stack. The Golgi apparatus differs from the endoplasmic reticulum in often having slightly thicker membranes, appearing in sections as a characteristic shallow semicircle so that the convex side (cis or entry face) abuts the endoplasmic reticulum, secretory vesicles emerging from the concave side (trans or exit face). In vertebrate cells there is usually one such organelle, while in invertebrates and plants, where they are known usually as dictyosomes, there may be several scattered in the cytoplasm. The Golgi apparatus processes proteins produced on the ribosomes of the rough endoplasmic reticulum; such processing includes modification of the core oligosaccharides of glycoproteins, and the sorting and packaging of proteins for transport to a variety of cellular locations. Three different regions of the Golgi are now recognized both in terms of structure and function: cis, in the vicinity of the cis face, trans, in the vicinity of the trans face, and medial, lying between the cis and trans regions.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005796,,,,,,,,,,,,,Golgi complex,,,,http://purl.obolibrary.org/obo/GO_0005737,GO:0005794,http://purl.obolibrary.org/obo/GO_0005737,,,,,,,,,,,,,,,,,,,"Note that the Golgi apparatus can be located in various places in the cytoplasm. In plants and lower animal cells, the Golgi apparatus exists as many copies of discrete stacks dispersed throughout the cytoplasm, while the Golgi apparatus of interphase mammalian cells is a juxtanuclear, often pericentriolar reticulum, where the discrete Golgi stacks are stitched together to form a compact and interconnected ribbon, sometimes called the Golgi ribbon.",,golgi apparatus,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0005796,Golgi lumen,,"The volume enclosed by the membranes of any cisterna or subcompartment of the Golgi apparatus, including the cis- and trans-Golgi networks.",false,,,http://purl.obolibrary.org/obo/GO_0043233,,,,,,,,,,,,,,,,,,,,,,"The volume enclosed by the membranes of any cisterna or subcompartment of the Golgi apparatus, including the cis- and trans-Golgi networks.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0005796,,,,,,,,,,,,,,,,,,,,,,Golgi lumen,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000007099,TLR4,,Other designations: hToll|homolog of Drosophila toll,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,TLR-4|ARMD10|CD284|TOLL,,,,,,,,,,,,9,,,,,,Vega:OTTHUMG00000021046|MIM:603030|HGNC:11850|Ensembl:ENSG00000136869|HPRD:04325,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,toll-like receptor 4,,,9q33.1,,,,,,,,,,,,,,,,"GO_0000187 (EC: ISS); GO_0001530 (EC: IMP, PMID: 16514062); GO_0001530 (EC: NAS, PMID: 10835634); GO_0001875 (EC: IDA, PMID: 19252480); GO_0002224 (EC: TAS); GO_0002322 (EC: IEA); GO_0002537 (EC: IEA); GO_0002755 (EC: TAS); GO_0002756 (EC: TAS); GO_0004872 (EC: TAS, PMID: 10426995); GO_0004888 (EC: NAS, PMID: 11970998); GO_0005515 (EC: IPI, PMID: 11441107); GO_0005737 (EC: IDA, PMID: 19740627); GO_0005886 (EC: IDA, PMID: 19740627); GO_0005886 (EC: TAS); GO_0005887 (EC: IDA, PMID: 15027902); GO_0006955 (EC: TAS, PMID: 10426995); GO_0007249 (EC: TAS); GO_0007252 (EC: IDA, PMID: 19740627); GO_0009897 (EC: IDA, PMID: 16514062); GO_0010008 (EC: TAS); GO_0010572 (EC: ISS, PMID: 16514062); GO_0016046 (EC: NAS, PMID: 11254600); GO_0030890 (EC: IEA); GO_0031663 (EC: IDA, Qualifier: NOT, PMID: 10880523); GO_0031663 (EC: IGI, PMID: 10880523); GO_0032496 (EC: IC, PMID: 16514062); GO_0032496 (EC: IDA, PMID: 12594207); GO_0032497 (EC: IDA, PMID: 19252480); GO_0032609 (EC: IEA); GO_0032689 (EC: ISS); GO_0032700 (EC: ISS); GO_0032707 (EC: ISS); GO_0032715 (EC: ISS); GO_0032720 (EC: ISS); GO_0032722 (EC: IDA, PMID: 19740627); GO_0032727 (EC: ISS); GO_0032728 (EC: ISS); GO_0032729 (EC: ISS); GO_0032732 (EC: ISS); GO_0032733 (EC: ISS); GO_0032735 (EC: ISS); GO_0032755 (EC: IDA, PMID: 19740627); GO_0032757 (EC: IDA, PMID: 19740627); GO_0032760 (EC: ISS); GO_0034134 (EC: TAS); GO_0034138 (EC: TAS); GO_0034142 (EC: TAS); GO_0035666 (EC: TAS); GO_0038123 (EC: TAS); GO_0038124 (EC: TAS); GO_0042088 (EC: NAS, PMID: 11970998); GO_0042116 (EC: IMP, PMID: 10835634); GO_0042346 (EC: IDA, PMID: 19740627); GO_0042535 (EC: IDA, PMID: 17951129); GO_0042742 (EC: TAS, PMID: 10426995); GO_0043123 (EC: IEA); GO_0045084 (EC: IDA, PMID: 15027902); GO_0045087 (EC: TAS, PMID: 15356140); GO_0045348 (EC: IEA); GO_0045359 (EC: IEA); GO_0045416 (EC: IDA, PMID: 17951129); GO_0045429 (EC: IEA); GO_0045671 (EC: NAS, PMID: 12133979); GO_0045944 (EC: ISS); GO_0046330 (EC: IEA); GO_0046696 (EC: IDA, PMID: 19252480); GO_0048471 (EC: IDA, PMID: 15027902); GO_0050729 (EC: IC, PMID: 19740627); GO_0050829 (EC: IC, PMID: 16514062); GO_0051092 (EC: IDA, PMID: 12594207); GO_0051770 (EC: ISS); GO_0060729 (EC: ISS); GO_0060907 (EC: IEA); GO_0070373 (EC: ISS); GO_0070374 (EC: IEA); GO_0070430 (EC: IEA); GO_0070434 (EC: IEA); GO_0071222 (EC: ISS); GO_0071223 (EC: IEA); GO_0071260 (EC: IEP, PMID: 19593445)",,,,,,,,,PMID: 9237759; 9435236; 9625770; 10359581; 10426995; 10465784; 10524757; 10734131; 10835634; 10880523; 10952994; 11081518; 11104518; 11254600; 11441107; 11466383; 11477091; 11490012; 11494169; 11514453; 11526399; 11529488; 11544529; 11561001; 11688988; 11706042; 11728442; 11743586; 11751856; 11782555; 11835533; 11836257; 11841848; 11842086; 11877429; 11893689; 11912201; 11923281; 11932926; 11932927; 11964313; 11970998; 11976338; 12045108; 12055604; 12089142; 12117914; 12124407; 12133979; 12165534; 12174084; 12193670; 12196527; 12270725; 12324469; 12324481; 12391239; 12397216; 12402214; 12404174; 12406828; 12411706; 12438323; 12444143; 12447442; 12477932; 12477953; 12495941; 12525572; 12552467; 12588460; 12591474; 12592402; 12594207; 12599057; 12622779; 12630564; 12646618; 12717385; 12724322; 12730365; 12734376; 12738639; 12742999; 12773175; 12773319; 12777373; 12782302; 12794153; 12796470; 12810071; 12832426; 12846053; 12855579; 12865424; 12874320; 12897738; 12923493; 12925853; 12941697; 12942028; 12957699; 12960171; 12964127; 14517278; 14519765; 14551607; 14556004; 14557267; 14563652; 14565959; 14578307; 14597728; 14600154; 14610481; 14625308; 14638766; 14651524; 14693986; 14699116; 14699155; 14706103; 14709406; 14715415; 14735148; 14738464; 14739370; 14764071; 14764599; 14987294; 15007351; 15016407; 15022344; 15027902; 15039334; 15041961; 15044215; 15069085; 15081257; 15087412; 15107846; 15132988; 15138173; 15143473; 15148609; 15155619; 15175334; 15175649; 15187145; 15190267; 15194649; 15207785; 15213237; 15225640; 15247281; 15258789; 15273551; 15276183; 15277575; 15292002; 15302104; 15305230; 15321997; 15337750; 15340161; 15341923; 15351720; 15356101; 15356140; 15356557; 15358455; 15367917; 15373967; 15385480; 15452251; 15456896; 15489631; 15509550; 15516360; 15520404; 15525557; 15528333; 15547160; 15557191; 15576653; 15591473; 15610077; 15614130; 15623538; 15632890; 15644417; 15647432; 15650037; 15655821; 15661045; 15665723; 15670831; 15691841; 15694388; 15695310; 15696495; 15699327; 15728517; 15752733; 15760452; 15760459; 15770725; 15778388; 15790341; 15796767; 15809303; 15829498; 15843568; 15845500; 15852007; 15863460; 15864121; 15866212; 15866876; 15875057; 15879290; 15882292; 15883205; 15905704; 15910421; 15910856; 15919371; 15927851; 15932772; 15953129; 15972671; 15973118; 16002719; 16006099; 16010583; 16019531; 16024789; 16044857; 16051275; 16085746; 16107886; 16135957; 16142747; 16146574; 16157088; 16157451; 16202743; 16213463; 16215326; 16219107; 16219455; 16239565; 16239841; 16246938; 16266379; 16266460; 16267105; 16270639; 16290232; 16301860; 16304445; 16338228; 16338476; 16343635; 16344560; 16357190; 16371473; 16385250; 16388712; 16393227; 16395111; 16397127; 16436969; 16437636; 16439361; 16441767; 16443229; 16461792; 16463649; 16467847; 16469362; 16487240; 16508260; 16514062; 16517732; 16523497; 16525349; 16552356; 16556150; 16567359; 16581829; 16585591; 16603631; 16606645; 16613760; 16629651; 16651628; 16706818; 16714144; 16717116; 16731773; 16738534; 16740140; 16751411; 16754682; 16754684; 16754725; 16779724; 16780707; 16785528; 16786156; 16802353; 16803995; 16818785; 16829202; 16830219; 16836908; 16837493; 16840031; 16843693; 16849487; 16878026; 16879054; 16879199; 16879239; 16888192; 16890863; 16907704; 16933467; 16936080; 16950283; 16954131; 16955390; 16961803; 16969132; 16971956; 16973891; 16982657; 16988837; 16990552; 17008589; 17015691; 17038528; 17044867; 17045043; 17055575; 17056597; 17057796; 17062130; 17083795; 17086894; 17096074; 17100621; 17100625; 17100974; 17101559; 17111814; 17121827; 17124436; 17130564; 17143969; 17151549; 17156435; 17157899; 17172927; 17179672; 17206636; 17220311; 17228323; 17229603; 17235555; 17237368; 17258210; 17258734; 17264400; 17292969; 17301271; 17301562; 17301819; 17304101; 17309585; 17309748; 17314284; 17314700; 17322885; 17324405; 17328955; 17332447; 17333217; 17344072; 17362744; 17381056; 17381401; 17384648; 17389503; 17389921; 17390084; 17395901; 17404865; 17414051; 17417801; 17431743; 17448042; 17449325; 17456342; 17462092; 17465679; 17476680; 17482427; 17493663; 17513785; 17524268; 17529905; 17530716; 17538633; 17545720; 17549384; 17555409; 17556642; 17559631; 17565323; 17579019; 17579031; 17587646; 17588655; 17592300; 17592301; 17595233; 17597463; 17599732; 17600225; 17623651; 17624583; 17625598; 17629003; 17652449; 17660297; 17675516; 17681703; 17699831; 17703412; 17707233; 17709420; 17709532; 17713436; 17718424; 17720800; 17724596; 17767165; 17803912; 17827066; 17849054; 17850411; 17854755; 17855767; 17855803; 17872459; 17877764; 17877801; 17878380; 17892476; 17908769; 17909078; 17914947; 17916356; 17921137; 17925445; 17927684; 17928056; 17934216; 17942642; 17947706; 17951129; 17956467; 17956942; 17962701; 17964520; 17964870; 17967488; 17977838; 17982277; 17992260; 17992634; 17996871; 17999935; 18000954; 18001295; 18008256; 18025155; 18029454; 18031543; 18034244; 18034897; 18040078; 18042837; 18044001; 18054497; 18056968; 18062119; 18062835; 18067993; 18070880; 18082569; 18084608; 18089358; 18092352; 18097881; 18172114; 18174680; 18178854; 18180278; 18180796; 18182917; 18192488; 18209079; 18209571; 18213697; 18221795; 18234118; 18234474; 18251133; 18252714; 18268386; 18275280; 18286551; 18288881; 18292749; 18295348; 18297073; 18298826; 18299127; 18304834; 18306470; 18307517; 18312481; 18325643; 18326860; 18338763; 18344712; 18345485; 18348860; 18360565; 18368233; 18381796; 18382655; 18385087; 18394314; 18395849; 18403647; 18408113; 18415752; 18422738; 18424732; 18437214; 18452992; 18458086; 18462799; 18493210; 18495130; 18509450; 18517079; 18519568; 18522803; 18523439; 18541719; 18543224; 18544275; 18546014; 18549457; 18549840; 18559343; 18565796; 18586872; 18590761; 18596029; 18608206; 18618036; 18622013; 18622290; 18633131; 18634146; 18634786; 18641349; 18649875; 18650420; 18650783; 18666712; 18670786; 18680223; 18680520; 18686608; 18690351; 18698233; 18712040; 18714935; 18723631; 18725521; 18728522; 18755634; 18763053; 18763295; 18769358; 18771998; 18773284; 18775079; 18782768; 18785522; 18806258; 18809506; 18810425; 18818748; 18825409; 18826495; 18826950; 18832719; 18835634; 18845299; 18846558; 18849341; 18925411; 18927069; 18928988; 18930806; 18936436; 18942754; 18945182; 18946062; 18948841; 18950592; 18972554; 18975326; 18978678; 18983635; 18987746; 18996347; 19001446; 19006850; 19012493; 19015224; 19015258; 19017994; 19029192; 19033535; 19035500; 19035519; 19037967; 19046305; 19048480; 19050632; 19060757; 19061090; 19064998; 19067129; 19067670; 19085953; 19096003; 19106585; 19108989; 19109197; 19112167; 19118102; 19120486; 19124725; 19131814; 19134118; 19135114; 19140875; 19148143; 19148938; 19150884; 19159017; 19164128; 19181857; 19189651; 19191896; 19195606; 19200604; 19201903; 19215923; 19218437; 19238444; 19239434; 19247692; 19252480; 19254290; 19258923; 19264973; 19265114; 19265483; 19267370; 19275590; 19277200; 19280717; 19289835; 19295440; 19306954; 19317913; 19318560; 19321453; 19336370; 19336475; 19351596; 19368968; 19376887; 19380025; 19390489; 19395279; 19395541; 19398177; 19405031; 19407153; 19412184; 19412702; 19422935; 19423540; 19426173; 19430824; 19436306; 19445369; 19445990; 19447045; 19453261; 19455302; 19473079; 19483297; 19493410; 19494321; 19494325; 19496069; 19500628; 19502387; 19505919; 19509286; 19513622; 19522765; 19527514; 19528164; 19528814; 19531762; 19539691; 19541348; 19542021; 19543401; 19545686; 19546479; 19548630; 19554026; 19556306; 19556696; 19561617; 19564644; 19564704; 19566553; 19572373; 19573080; 19575238; 19578796; 19584052; 19586676; 19590686; 19592497; 19593445; 19596916; 19597734; 19614650; 19622038; 19627277; 19628747; 19631641; 19638314; 19643479; 19646345; 19646728; 19656901; 19660727; 19664207; 19691982; 19692168; 19706440; 19710105; 19723394; 19729601; 19730000; 19735472; 19737468; 19740627; 19741468; 19750015; 19754671; 19758312; 19760027; 19763595; 19764566; 19769961; 19771452; 19772581; 19773279; 19773677; 19779605; 19796532; 19796535; 19796680; 19809335; 19809507; 19810822; 19811440; 19816595; 19824106; 19826413; 19839752; 19840833; 19841637; 19844258; 19844589; 19846529; 19846881; 19847953; 19855253; 19858308; 19888805; 19891659; 19892918; 19902255; 19912257; 19913121; 19913922; 19915052; 19922963; 19924287; 19928913; 19929430; 19948740; 19948975; 19953283; 19956541; 19956717; 19960069; 20001205; 20002809; 20007708; 20007974; 20011079; 20011698; 20016852; 20018893; 20026833; 20026892; 20030948; 20037584; 20039305; 20047764; 20048342; 20056178; 20059631; 20063104; 20067961; 20067962; 20078877; 20079790; 20083228; 20085599; 20092898; 20093834; 20098705; 20105294; 20109750; 20120936; 20124101; 20125114; 20140262; 20145198; 20145615; 20146922; 20153491; 20164024; 20169003; 20170964; 20177675; 20179247; 20187300; 20194452; 20196781; 20197549; 20200442; 20201793; 20207250; 20212095; 20214986; 20222908; 20226000; 20227302; 20228668; 20228685; 20233331; 20237496; 20237756; 20299682; 20306049; 20307689; 20308035; 20331879; 20332463; 20348497; 20351099; 20357250; 20357716; 20360984; 20363151; 20364327; 20375613; 20379791; 20381257; 20384861; 20388081; 20399512; 20400193; 20400509; 20402671; 20403143; 20406964; 20412715; 20430725; 20438785; 20441696; 20442853; 20448286; 20452482; 20463618; 20472010; 20483368; 20485444; 20492496; 20496780; 20497256; 20503287; 20504212; 20504769; 20505764; 20506307; 20510162; 20518842; 20521908; 20525286; 20525894; 20556833; 20568250; 20575099; 20577092; 20587312; 20587548; 20595247; 20596538; 20596954; 20598754; 20604744; 20614721; 20616112; 20618976; 20620409; 20626741; 20628086; 20634913; 20636402; 20646321; 20646366; 20646633; 20660289; 20661259; 20664479; 20671584; 20673868; 20681284; 20685742; 20692469; 20702616; 20711192; 20711470; 20714796; 20717938; 20721625; 20725790; 20730440; 20736788; 20797905; 20799043; 20802145; 20805788; 20807077; 20818954; 20818961; 20819643; 20819670; 20819778; 20826579; 20835611; 20843333; 20848773; 20862798; 20865702; 20878353; 20880684; 20886065; 20887801; 20929567; 20933442; 20940109; 20945369; 20951669; 20952467; 20956019; 20964862; 20974832; 20977567; 20978888; 20979736; 20980751; 21033154; 21037101; 21037509; 21039068; 21042230; 21044745; 21046243; 21048031; 21050493; 21054580; 21054877; 21056683; 21059221; 21061265; 21063844; 21079743; 21081146; 21091668; 21092506; 21097451; 21099280; 21103885; 21125016; 21127066; 21129170; 21151974; 21152870; 21167252; 21168672; 21169414; 21175809; 21189260; 21191086; 21206505; 21211341; 21214494; 21220426; 21220427; 21220755; 21221801; 21236243; 21236709; 21238472; 21239179; 21246489; 21248470; 21253969; 21255012; 21262374; 21293887; 21298446; 21303685; 21306745; 21323660; 21329689; 21330606; 21356084; 21363926; 21377387; 21393102; 21398611; 21403649; 21406030; 21412052; 21417682; 21420934; 21424379; 21443084; 21455638; 21457584; 21460221; 21466684; 21468605; 21515468; 21518510; 21527067; 21538184; 21543336; 21553150; 21559380; 21563195; 21570715; 21571945; 21586524; 21602844; 21612766; 21616060; 21625017; 21628465; 21628510; 21632720; 21646346; 21649525; 21673343; 21677444; 21704385; 21704886; 21715681; 21721932; 21726670; 21729627; 21730023; 21730052; 21738462; 21752694; 21762706; 21768115; 21775336; 21776015; 21781537; 21782178; 21789185; 21789730; 21813858; 21820713; 21822168; 21827211; 21827576; 21829704; 21843566; 21852034; 21854645; 21864388; 21878171; 21883620; 21897371; 21897866; 21900253; 21902816; 21903422; 21905500; 21909400; 21911421; 21921986; 21923667; 21924074; 21924775; 21931695; 21942553; 21943186; 21949112; 21949133; 21950140; 21952248; 21968286; 21969092; 21976223; 21988832; 21990957; 21994256; 22005560; 22005564; 22011399; 22014880; 22015781; 22021706; 22022564; 22030478; 22032785; 22037282; 22046231; 22057691; 22067623; 22070100; 22085193; 22088250; 22092594; 22095710; 22100911; 22127462; 22127564; 22128242; 22131235; 22139835; 22145357; 22156348; 22166855; 22173288; 22174696; 22180778; 22194611; 22219617; 22221660; 22225630; 22229967; 22230402; 22238472; 22244044; 22251522; 22251849; 22265692; 22271762; 22272615; 22286521; 22288713; 22300618; 22302853; 22305616; 22308961; 22320262; 22330637; 22333167; 22348075; 22360682; 22372604; 22383676; 22384232; 22393779; 22396536; 22402138; 22427667; 22429552; 22433852; 22440522; 22441122; 22442690; 22447928; 22450324; 22451944; 22453525; 22461445; 22461698; 22466961; 22468087; 22474023; 22479513; 22485159; 22487528; 22499954; 22525209; 22533660; 22535679; 22537674; 22552381; 22555057; 22556042; 22560646; 22564191; 22571967; 22580394; 22582869; 22583829; 22593572; 22608210; 22613713; 22645142; 22648929; 22661708; 22662111; 22672741; 22679141; 22697069; 22699754; 22703024; 22717291; 22730532; 22733781; 22735756; 22749378; 22749779; 22753132; 22761186; 22763977; 22773901; 22775464; 22778396; 22792416; 22795952; 22807450; 22831837; 22851489; 22857799; 22870312; 22870324; 22872782; 22892989; 22906770; 22911652; 22915070; 22918682; 22927965; 22929539; 22938142; 22940059; 22948021; 22951730; 22952638; 22956123; 22962435; 22964479; 22964787; 22965987; 22970235; 22983353; 22984080; 22985132; 22987288; 22996386; 22999059; 23000519; 23021866; 23027874; 23028414; 23035361; 23053976; 23055527; 23059983; 23062767; 23065292; 23065466; 23071313; 23083518; 23084080; 23086127; 23086480; 23091345; 23093310; 23103560; 23106544; 23108090; 23121518; 23129427; 23141927; 23142582; 23163570; 23170831; 23170858; 23179584; 23179660; 23200752; 23200920; 23201091; 23209313; 23211828; 23212905; 23234648; 23239500; 23239925; 23239997; 23241898; 23251661; 23252918; 23259689; 23272070; 23275193; 23281696; 23285751; 23289411; 23289617; 23297396; 23311681; 23316065; 23318418; 23322736; 23338716; 23347362; 23355465; 23356143; 23365080; 23380629; 23398566; 23402610; 23407387; 23411097; 23414695; 23417037; 23417289; 23425749; 23436141; 23437218; 23437263; 23455503; 23455702; 23457721; 23460645; 23465595; 23467413; 23470644; 23497941; 23504385; 23510418; 23525077; 23554896; 23555011; 23565226; 23574398; 23589304; 23592020; 23592986; 23611610; 23612767; 23629657; 23633568; 23639307; 23651260; 23665674; 23671673; 23673286; 23677465; 23678609; 23680697; 23690937; 23691015; 23692033; 23727604; 23738004; 23747880; 23752129; 23755898; 23761639; 23766695; 23786414; 23798430; 23799413; 23802631; 23821954; 23828139; 23836485; 23853092; 23855294; 23864765; 23871732; 23879541; 23880187; 23888080; 23888605; 23908180; 23910802; 23921128; 23936050; 23936790; 23949880; 23962979; 23980810; 23985798; 24021278; 24030146; 24044965; 24068665; 24076166; 24080332; 24084649; 24106112; 24172224; 24178299; 24277938; 24298017; 24307174,,,,,,,,,,,,,,,OGG:3000007099,,,,,,,toll-like receptor 4,,,,,,,,,,,,,Other designations: hToll|homolog of Drosophila toll,,TLR4,,,,,,,,,,,,,,,,,,,,,,,7099,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,TLR4,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/UBERON_0001013,adipose tissue,,Portion of connective tissue composed of adipocytes enmeshed in areolar tissue,false,,,http://purl.obolibrary.org/obo/UBERON_0000479,,,,,,,,,,,,,,,,,,,,,,Portion of connective tissue composed of adipocytes enmeshed in areolar tissue,,,,,adipose tissue,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,UBERON:0001013,,,,,,,,,,,,,,,,,,,,,,adipose tissue,,,,,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0001017,central nervous system,cerebrospinal axis|neuraxis|CNS|systema nervosum centrale,The central nervous system is the core nervous system that serves an integrating and coordinating function. In vertebrates it consists of the neural tube derivatives: the brain and spinal cord. In invertebrates it includes central ganglia plus nerve cord.,false,,,http://purl.obolibrary.org/obo/UBERON_0011216,,,,,,,,,,,,,,,,,,,,http://braininfo.rprc.washington.edu/centraldirectory.aspx?ID=854|http://linkedlifedata.com/resource/umls/id/C0927232|http://purl.obolibrary.org/obo/NCIT_C12438|http://www.snomedbrowser.com/Codes/Details/278199004|http://en.wikipedia.org/wiki/Central_nervous_system|http://uri.neuinfo.org/nif/nifstd/birnlex_1099|EV:0100163|XAO:0000215|CALOHA:TS-0150|MESH:D002490|TAO:0000012|MAT:0000457|BILA:0000080|EFO:0000908|ZFA:0000012|OpenCyc:Mx4rvzYt3pwpEbGdrcN5Y29ycA|FMA:55675|FBbt:00005094|EMAPA:16754|BAMS:CNS|GAID:570|EMAPA:16470|MA:0000167|AAO:0000090|VHOG:0000293|BTO:0000227|UMLS:C0927232|EHDAA2:0000225|EHDAA:828,,The central nervous system is the core nervous system that serves an integrating and coordinating function. In vertebrates it consists of the neural tube derivatives: the brain and spinal cord. In invertebrates it includes central ganglia plus nerve cord.,,,,,,,,"The central nervous system (CNS) is the part of the nervous system which includes the brain, spinal cord, and nerve cell layer of the retina (CUMBO).|The brain and spinal cord. Kimmel et al, 1995.[TAO]|Part of the nervous system which includes the brain and spinal cord.[AAO]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CNS|systema nervosum centrale,cerebrospinal axis,neuraxis,"(...) at some stage of its development, every chordate exhibits five uniquely derived characters or synapomorphies of the group: (...) (4) a single, tubular nerve cord that is located dorsal to the notochord (...) (reference 1); The neural tube is destined to differentiate into the brain and spinal cord (the central nervous system) (reference 2); Taken together, our data make a very strong case that the complex molecular mediolateral architecture of the developing trunk CNS (central nervous system), as shared between Platynereis and vertebrates, was already present in their last common ancestor, Urbilateria. The concept of bilaterian nervous system centralization implies that neuron types concentrate on one side of the trunk, as is the case in vertebrates and many invertebrates including Platynereis, where they segregate and become spatially organized (as opposed to a diffuse nerve net). Our data reveal that a large part of the spatial organization of the annelid and vertebrate CNS was already present in their last common ancestor, which implies that Urbilateria had already possessed a CNS (reference 3).[well established][VHOG]",http://purl.obolibrary.org/obo/UBERON_0001016,UBERON:0001017,http://purl.obolibrary.org/obo/UBERON_0001016,,,,,,,,,,,,,,,,,,,,,central nervous system,,,,,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0001016,nervous system,nerve net|systema nervosum|neurological system,"The nervous system is an organ system containing predominantly neuron and glial cells. In bilaterally symmetrical organism, it is arranged in a network of tree-like structures connected to a central body. The main functions of the nervous system are to regulate and control body functions, and to receive sensory input, process this information, and generate behavior [CUMBO].",false,,,http://purl.obolibrary.org/obo/UBERON_0000467,,,,,,,,,,,,,,,,,,,,http://www.snomedbrowser.com/Codes/Details/278196006|http://purl.obolibrary.org/obo/NCIT_C12755|http://en.wikipedia.org/wiki/Nervous_system|http://linkedlifedata.com/resource/umls/id/C0027763|http://braininfo.rprc.washington.edu/centraldirectory.aspx?ID=3236|http://uri.neuinfo.org/nif/nifstd/birnlex_844|AAO:0000324|EV:0100162|ZFA:0000396|UMLS:C0027763|BTO:0001484|EMAPA:16469|EFO:0000802|MAT:0000026|VHOG:0000402|MIAA:0000026|EHDAA:826|XAO:0000177|CALOHA:TS-1313|TAO:0000396|GAID:466|FBbt:00005093|FMA:7157|OpenCyc:Mx4rvViT_pwpEbGdrcN5Y29ycA|EHDAA2:0001246|MA:0000016|MESH:D009420|WBbt:0005735|BILA:0000079,,"The nervous system is an organ system containing predominantly neuron and glial cells. In bilaterally symmetrical organism, it is arranged in a network of tree-like structures connected to a central body. The main functions of the nervous system are to regulate and control body functions, and to receive sensory input, process this information, and generate behavior [CUMBO].",,,,,,,,"Anatomical system consisting of nerve bodies and nerve fibers which regulate the response of the body to external and internal stimuli.[AAO]|A regulatory system of the body that consists of neurons and neuroglial cells. The nervous system is divided into two parts, the central nervous system (CNS) and the peripheral nervous system (PNS). (Source: BioGlossary, www.Biology-Text.com)[TAO]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,neurological system,nerve net,systema nervosum,Nervous systems evolved in the ancestor of Eumetazoa.[well established][VHOG],,UBERON:0001016,,,,,,,,,,,,,,,,,,,,,,nervous system,,,,http://upload.wikimedia.org/wikipedia/commons/b/b2/TE-Nervous_system_diagram.svg|http://upload.wikimedia.org/wikipedia/commons/b/ba/Nervous_system_diagram.png,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0036041,long-chain fatty acid binding,,Interacting selectively and non-covalently with a long-chain fatty acid. A long-chain fatty acid is a fatty acid with a chain length between C13 and C22.,false,,,http://purl.obolibrary.org/obo/GO_0005504,,,,,,,,,,,,,,,,,,,,,,Interacting selectively and non-covalently with a long-chain fatty acid. A long-chain fatty acid is a fatty acid with a chain length between C13 and C22.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0036041,,,,,,,,,,,,,,,,,,,,,,long-chain fatty acid binding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0036042,long-chain fatty acyl-CoA binding,,Interacting selectively and non-covalently with a long-chain fatty acyl-CoA. A long-chain fatty acyl-CoA is any derivative of coenzyme A in which the sulfhydryl group is in a thioester linkage with a long-chain fatty-acyl group. Long-chain fatty-acyl-CoAs have chain lengths of C13 or more.,false,,,http://purl.obolibrary.org/obo/GO_0000062,,,,,,,,,,,,,,,,,,,,,,Interacting selectively and non-covalently with a long-chain fatty acyl-CoA. A long-chain fatty acyl-CoA is any derivative of coenzyme A in which the sulfhydryl group is in a thioester linkage with a long-chain fatty-acyl group. Long-chain fatty-acyl-CoAs have chain lengths of C13 or more.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_33184,,,,,,,,,,,,,,,,,,,,,,,GO:0036042,,,,,,,,,,,,,,,,,,,,,,long-chain fatty acyl-CoA binding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001361,spleen hyperfunction,,Spleen hyperfunction is a subtype of hyperfunctioning: A process that performs an excessive spleen function.,false,,,http://purl.obolibrary.org/obo/TXPO_0000435,,,,,,,,,,,,,,,,,,,,,,Spleen hyperfunction is a subtype of hyperfunctioning: A process that performs an excessive spleen function.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001479|http://purl.obolibrary.org/obo/TXPO_0001362,,,,,,,,,,,TXPO:0001361,,,,,,,,,,,,,,,,,,,,,,spleen hyperfunction,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001360,inzreasing size of the spleen,splenomegaly,Inzreasing size of the spleen is a subtype of increasing size: A process that changes the size of the of the spleen to be larger.,false,,,http://purl.obolibrary.org/obo/TXPO_0000138,,,,,,,,,,,,,,,,,,,,,,Inzreasing size of the spleen is a subtype of increasing size: A process that changes the size of the of the spleen to be larger.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,splenomegaly,,,,,TXPO:0001360,,,,,,,,,,,,,,,,,,,,,,inzreasing size of the spleen,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001364,varicosity of veins formation,,Varicosity of veins formation is a subtype of biological structure formation: A process that have a varicosity of veins.,false,,,http://purl.obolibrary.org/obo/TXPO_0000134,,,,,,,,,,,,,,,,,,,,PMID:18453484,,Varicosity of veins formation is a subtype of biological structure formation: A process that have a varicosity of veins.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001364,,,,,,,,,,,,,,,,,,,,,,varicosity of veins formation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001365,stomach congestion,,Stomach congestion is a subtype of hyperfunctioning of accumulation: A process that performs an excessive accumulation of blood in the stomach.,false,,,http://purl.obolibrary.org/obo/TXPO_0000916,,,,,,,,,,,,,,,,,,,,,,Stomach congestion is a subtype of hyperfunctioning of accumulation: A process that performs an excessive accumulation of blood in the stomach.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001365,,,,,,,,,,,,,,,,,,,,,,stomach congestion,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0000945,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001367,hyperfunction of hepatic lymph production,,Hyperfunction of hepatic lymph production is a subtype of hyperfunction of biosynthesis: A process that performs an excessive  hepatic lymph production.,false,,,http://purl.obolibrary.org/obo/TXPO_0002346,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of hepatic lymph production is a subtype of hyperfunction of biosynthesis: A process that performs an excessive  hepatic lymph production.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001368,,,,,,,,,,,TXPO:0001367,,,,,,,,,,,,,,,,,,,,,,hyperfunction of hepatic lymph production,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001362,decreasing hemoglobin concentration in blood,,Decreasing hemoglobin concentration in blood is a subtype of decreasing concentration: A process that changes the concentration of the hemoglobin in the blood to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000671,,,,,,,,,,,,,,,,,,,,,,Decreasing hemoglobin concentration in blood is a subtype of decreasing concentration: A process that changes the concentration of the hemoglobin in the blood to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001362,,,,,,,,,,,,,,,,,,,,,,decreasing hemoglobin concentration in blood,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001363,bypass formation,,Bypass formation is a subtype of biological structure formation: A process that constructs an alternate passage of a bodily substancepassage carrying blood.,false,,,http://purl.obolibrary.org/obo/TXPO_0000134,,,,,,,,,,,,,,,,,,,,,,Bypass formation is a subtype of biological structure formation: A process that constructs an alternate passage of a bodily substancepassage carrying blood.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001363,,,,,,,,,,,,,,,,,,,,,,bypass formation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001366,increasing hepatic venous pressure,,Increasing hepatic venous pressure is a subtype of increasing pressure: A process that changes the hpatic venous pressure to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0001689,,,,,,,,,,,,,,,,,,,,,,Increasing hepatic venous pressure is a subtype of increasing pressure: A process that changes the hpatic venous pressure to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001366,,,,,,,,,,,,,,,,,,,,,,increasing hepatic venous pressure,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001368,hepatic lymph leakage,,Hepatic lymph leakage is a subtype of leaking: A process that leaks lymph out from the liver lymphatic vessel.,false,,,http://purl.obolibrary.org/obo/TXPO_0001699,,,,,,,,,,,,,,,,,,,,,,Hepatic lymph leakage is a subtype of leaking: A process that leaks lymph out from the liver lymphatic vessel.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001368,,,,,,,,,,,,,,,,,,,,,,hepatic lymph leakage,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001369,ascites (process),,Ascites (process) is a subtype of accumulation of fluids: A process that keeps fluid in the peritoneal cavity.,false,,,http://purl.obolibrary.org/obo/TXPO_0001216,,,,,,,,,,,,,,,,,,,,,,Ascites (process) is a subtype of accumulation of fluids: A process that keeps fluid in the peritoneal cavity.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001369,,,,,,,,,,,,,,,,,,,,,,ascites (process),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000688,p38gamma,SAPK-3|ERK6,,false,,,http://purl.obolibrary.org/obo/IMR_0000226,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,SAPK-3|ERK6,,,,,IMR:0000688,,,,,,,,,,,,,,,,,,,,,,p38gamma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0002408,watery,,Having the consistency of water.,false,,,http://purl.obolibrary.org/obo/PATO_0000025,,,,,,,,,,,,,,,,,,,,,,Having the consistency of water.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0002408,,,,,,,,,,,,,,,,,,,,,,watery,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002322,negative regulation of apoptotic process (sustained) [Ground glass appearance],,"Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptotic process. This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) .",false,,,http://purl.obolibrary.org/obo/TXPO_0000965|http://purl.obolibrary.org/obo/GO_0043066,,,,,,,,,,,,,,,,,,,,PMID:2379175|PMID:28356313|ISBN:0071769234,,"Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptotic process. This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) .",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004102,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001073|http://purl.obolibrary.org/obo/TXPO_0000976|http://purl.obolibrary.org/obo/TXPO_0000975|http://purl.obolibrary.org/obo/TXPO_0000784,,,,,,http://purl.obolibrary.org/obo/TXPO_0003904|http://purl.obolibrary.org/obo/TXPO_0000597|http://purl.obolibrary.org/obo/TXPO_0002320,,,,,,,,,,,TXPO:0002322,,,,,,,,,,,,,,,,,,,,,,negative regulation of apoptotic process (sustained) [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002323,negative regulation of autophagy (sustained) [Ground glass appearance],,"Any process that stops, prevents, or reduces the frequency, rate or extent of autophagy. Autophagy is the process in which cells digest parts of their own cytoplasm. This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) .",false,,,http://purl.obolibrary.org/obo/GO_0010507|http://purl.obolibrary.org/obo/TXPO_0001018,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents, or reduces the frequency, rate or extent of autophagy. Autophagy is the process in which cells digest parts of their own cytoplasm. This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001677,,,,,,,,,,,TXPO:0002323,,,,,,,,,,,,,,,,,,,,,,negative regulation of autophagy (sustained) [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002327,toxicological imbalance VL(defense),,"In the imbalance model, the basic units are as follows:
1) a functioning process (supply) for biological defense and maintaining homeostasis;
2) a functional demand process (demand) as toxic activity;
3) balance/imbalance between toxic activity and defense processes; and
4) outcome from organelles, cells, or tissues to the organ exhibiting toxicity manifestations.

This entity  is a compound state that inculdes step 1 to 4.
The defense performance level is  very low (L) than the moderate (M) in normal condition. Threfore even if the functional demand level is Moderatelevel (M) in the daily life in the helathy person, which leads to the imbalance and leads to toxicity manifestation.",false,,,http://purl.obolibrary.org/obo/TXPO_0003992,,,,,,,,,,,,,,,,,,,,,,"In the imbalance model, the basic units are as follows:
1) a functioning process (supply) for biological defense and maintaining homeostasis;
2) a functional demand process (demand) as toxic activity;
3) balance/imbalance between toxic activity and defense processes; and
4) outcome from organelles, cells, or tissues to the organ exhibiting toxicity manifestations.

This entity  is a compound state that inculdes step 1 to 4.
The defense performance level is  very low (L) than the moderate (M) in normal condition. Threfore even if the functional demand level is Moderatelevel (M) in the daily life in the helathy person, which leads to the imbalance and leads to toxicity manifestation.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001735,,,,,,,,,,,,,,,,,,TXPO:0002327,,,,,,,,,,,,,,,,,,,,,,toxicological imbalance VL(defense),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002329,hepatic fibrosis [toxic course],,The totality of all processes through which hepatic fibrosis is realized.|under construction,false,,,http://purl.obolibrary.org/obo/TXPO_0000009,,,,,,,,,,,,,,,,,,,,PMID:15690074|PMID:24966597|PMID:30002817|PMID:21497738|PMID:25869468|PMID:29391303,,The totality of all processes through which hepatic fibrosis is realized.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003782|http://purl.obolibrary.org/obo/TXPO_0003783|http://purl.obolibrary.org/obo/TXPO_0003781|http://purl.obolibrary.org/obo/TXPO_0003746|http://purl.obolibrary.org/obo/TXPO_0003743|http://purl.obolibrary.org/obo/TXPO_0003745|http://purl.obolibrary.org/obo/TXPO_0002152|http://purl.obolibrary.org/obo/TXPO_0001721|http://purl.obolibrary.org/obo/TXPO_0003755|http://purl.obolibrary.org/obo/TXPO_0003759|http://purl.obolibrary.org/obo/TXPO_0003757|http://purl.obolibrary.org/obo/TXPO_0003779|http://purl.obolibrary.org/obo/TXPO_0000224|http://purl.obolibrary.org/obo/TXPO_0003761|http://purl.obolibrary.org/obo/TXPO_0003800|http://purl.obolibrary.org/obo/TXPO_0003802,,,,,,,,,,,,,,,,,,TXPO:0002329,,,,,,,,,,,,,,,,,,,,under construction,,hepatic fibrosis [toxic course],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002320,hepatocyte proliferation (sustained) [Ground glass appearance],,"A process that results in an increase in hepatic cell number by cell division, often leading to an increase in the size of an liver. This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) .",false,,,http://purl.obolibrary.org/obo/TXPO_0000970,,,,,,,,,,,,,,,,,,,,ISBN:0071769234,,"A process that results in an increase in hepatic cell number by cell division, often leading to an increase in the size of an liver. This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000597|http://purl.obolibrary.org/obo/TXPO_0002319,,,,,,,,,,,TXPO:0002320,,,,,,,,,,,,,,,,,,,,,,hepatocyte proliferation (sustained) [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002321,hyperfunction of hepatocyte proliferation,,"Hyperfunction of hepatocyte proliferation is a subtype of hyperfunction of cell proliferation: The multiplication or reproduction of hepatocytes, resulting in the expansion of a cell population. Hepatocytes form the main structural component of the liver. They are specialized epithelial cells that are organized into interconnected plates called lobules.",false,,,http://purl.obolibrary.org/obo/TXPO_0002318,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of hepatocyte proliferation is a subtype of hyperfunction of cell proliferation: The multiplication or reproduction of hepatocytes, resulting in the expansion of a cell population. Hepatocytes form the main structural component of the liver. They are specialized epithelial cells that are organized into interconnected plates called lobules.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002321,,,,,,,,,,,,,,,,,,,,,,hyperfunction of hepatocyte proliferation,,,,,,http://purl.obolibrary.org/obo/GO_0072574,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002326,increasing demand for NAPQI metabolism,,Increasing demand for NAPQI metabolism is a subtype of increasing functional demand: A process changes the functional demand for the for NAPQI metabolism to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000789,,,,,,,,,,,,,,,,,,,,,,Increasing demand for NAPQI metabolism is a subtype of increasing functional demand: A process changes the functional demand for the for NAPQI metabolism to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002326,,,,,,,,,,,,,,,,,,,,,,increasing demand for NAPQI metabolism,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002324,phospholipid metabolism imbalance [Phospholipidosis],,"Phospholipid metabolism imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance of phospholipid metabolism.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002308|http://purl.obolibrary.org/obo/TXPO_0000946,,,,,,,,,,,,,,,,,,,,,,"Phospholipid metabolism imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance of phospholipid metabolism.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,http://purl.obolibrary.org/obo/TXPO_0001435,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000910,,http://purl.obolibrary.org/obo/TXPO_0003992,,,,,,,,,TXPO:0002324,,,,,,,,,,,,,,,,,,,,,,phospholipid metabolism imbalance [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002328,very low level,,The level of degree is very low.,false,,,http://purl.obolibrary.org/obo/TXPO_0004208,,,,,,,,,,,,,,,,,,,,,,The level of degree is very low.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002328,,,,,,,,,,,,,,,,,,,,,,very low level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002325,accumulation of drug in hepatocyte,,Accumulation of drug in hepatocyte is a subtype of accumulation of xenobiotics: A process that keeps compound in the hepatocyte.,false,,,http://purl.obolibrary.org/obo/TXPO_0000169,,,,,,,,,,,,,,,,,,,,,,Accumulation of drug in hepatocyte is a subtype of accumulation of xenobiotics: A process that keeps compound in the hepatocyte.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002325,,,,,,,,,,,,,,,,,,,,,,accumulation of drug in hepatocyte,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000010382,TUBB4A,,"Other designations: dystonia 4, torsion (autosomal dominant)|tubulin beta-4 chain|tubulin beta-4A chain|tubulin, beta, 5",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,TUBB5|beta-5|DYT4|TUBB4,,,,,,,,,,,,19,,,,,,HGNC:20774|Ensembl:ENSG00000104833|HPRD:04045|Vega:OTTHUMG00000181829|MIM:602662,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"tubulin, beta 4A class IVa",,,19p13.3,,,,,,,,,,,,,,,,GO_0000086 (EC: TAS); GO_0000278 (EC: TAS); GO_0003924 (EC: IEA); GO_0005200 (EC: IEA); GO_0005515 (EC: IPI); GO_0005525 (EC: IEA); GO_0005829 (EC: TAS); GO_0005874 (EC: IDA); GO_0005929 (EC: IEA); GO_0006457 (EC: TAS); GO_0007017 (EC: IEA); GO_0033269 (EC: IEA); GO_0043025 (EC: IEA); GO_0043209 (EC: IEA); GO_0044267 (EC: TAS); GO_0051084 (EC: TAS); GO_0051258 (EC: IEA),,,,,,,,,PMID: 3782288; 6462917; 6865944; 7790358; 8432555; 8619814; 8653701; 10908577; 11076968; 11120798; 12221128; 12477932; 12486001; 12840015; 12852856; 14702039; 15121898; 15188402; 15324660; 15331610; 15489334; 15691386; 15698476; 16196087; 16303743; 16462731; 16526095; 16565220; 16944923; 17360745; 17620599; 17627938; 18029348; 18553364; 18613978; 18781797; 19167051; 19299461; 19773279; 20171186; 20195357; 20473970; 20639865; 20972266; 21110914; 21139048; 21145461; 21151833; 21525035; 21839816; 21890473; 21906983; 21956287; 21963094; 21987572; 22174317; 22266860; 22268729; 22505724; 22586326; 22797925; 22863883; 23000965; 23142642; 23190606; 23246001; 23349634; 23424103; 23455922; 23463506; 23503679; 23582646; 23595291; 23703321; 23956138,,,,,,,,,,,,,,,OGG:3000010382,,,,,,,"tubulin, beta 4A class IVa",,,,,,,,,,,,,"Other designations: dystonia 4, torsion (autosomal dominant)|tubulin beta-4 chain|tubulin beta-4A chain|tubulin, beta, 5",,TUBB4A,,,,,,,,,,,,,,,,,,,,,,,10382,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,TUBB4A,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_35841,uricosuric drug,uricosuric drugs|uricosuric agent,"A gout suppressant that acts directly on the renal tubule to increase the excretion of uric acid, thus reducing its concentrations in plasma.",false,,,http://purl.obolibrary.org/obo/CHEBI_35845|http://purl.obolibrary.org/obo/CHEBI_35846,,,,,,,,,,,,,,,,,,,,,,"A gout suppressant that acts directly on the renal tubule to increase the excretion of uric acid, thus reducing its concentrations in plasma.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,uricosuric drugs|uricosuric agent,,,,,,,,,,,,,,,,,,,,,CHEBI:35841,,,,uricosuric drug,,CHEBI:35841,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_36044,antiviral drug,anti-virus drug|anti-viral drug|antiviral drugs,A substance used in the prophylaxis or therapy of virus diseases.,false,,,http://purl.obolibrary.org/obo/CHEBI_33281|http://purl.obolibrary.org/obo/CHEBI_36043|http://purl.obolibrary.org/obo/CHEBI_22587,,,,,,,,,,,,,,,,,,,,,,A substance used in the prophylaxis or therapy of virus diseases.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,anti-virus drug|anti-viral drug|antiviral drugs,,,,,,,,,,,,,,,,,,,,,CHEBI:36044,,,,antiviral drug,,CHEBI:36044,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002572,CAD insertion into phospholipase binding site to lysosomal inner membrane [Phospholipidosis (latent)],,"CAD insertion into phospholipase binding site to lysosomal inner membrane is a subtype of binding: A process that CAD inserts and replaces the phospholipase binding site in the lysosomal inner membrane.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (latent).",false,,,http://purl.obolibrary.org/obo/TXPO_0001399,,,,,,,,,,,,,,,,,,,,PMID:22960355,,"CAD insertion into phospholipase binding site to lysosomal inner membrane is a subtype of binding: A process that CAD inserts and replaces the phospholipase binding site in the lysosomal inner membrane.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (latent).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001560,,,,,,http://purl.obolibrary.org/obo/TXPO_0003578,,,,,,,,,,,TXPO:0002572,,,,,,,,,,,,,,,,,,,,,,CAD insertion into phospholipase binding site to lysosomal inner membrane [Phospholipidosis (latent)],,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003404,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002576,splitting,,Splitting is a subtype of separating: A process that divides the whole object into the same kinds of parts. A + A+ A,false,,,http://purl.obolibrary.org/obo/TXPO_0000333,,,,,,,,,,,,,,,,,,,,,,Splitting is a subtype of separating: A process that divides the whole object into the same kinds of parts. A + A+ A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002576,,,,,,,,,,,,,,,,,,,,,,splitting,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002577,taking,,Taking is a subtype of separating: A process that separates and chooses an object .,false,,,http://purl.obolibrary.org/obo/TXPO_0000333,,,,,,,,,,,,,,,,,,,,,,Taking is a subtype of separating: A process that separates and chooses an object .,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002577,,,,,,,,,,,,,,,,,,,,,,taking,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002574,composing,,Composing is a subtype of assembling: A process that  makes the different constituents into a connected whole.,false,,,http://purl.obolibrary.org/obo/TXPO_0000468,,,,,,,,,,,,,,,,,,,,,,Composing is a subtype of assembling: A process that  makes the different constituents into a connected whole.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002574,,,,,,,,,,,,,,,,,,,,,,composing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002570,dissolving,,Dissolving is a subtype of assembling: A process that creates a solvent-solute relationship between components.,false,,,http://purl.obolibrary.org/obo/TXPO_0000468,,,,,,,,,,,,,,,,,,,,,,Dissolving is a subtype of assembling: A process that creates a solvent-solute relationship between components.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002570,,,,,,,,,,,,,,,,,,,,,,dissolving,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002573,mixing,,"Mixing is a subtype of assembling: A process that combines two or more substances to a single element, and they cannot be distinguished.",false,,,http://purl.obolibrary.org/obo/TXPO_0000468,,,,,,,,,,,,,,,,,,,,,,"Mixing is a subtype of assembling: A process that combines two or more substances to a single element, and they cannot be distinguished.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002573,,,,,,,,,,,,,,,,,,,,,,mixing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002579,FNIP2 (predicted)(human)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001135|http://purl.obolibrary.org/obo/TXPO_0003837,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:57600,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000057600,,,,,,,,,,,,,TXPO:0002579,,,,,,,,,,,,,,,,,,,,,,FNIP2 (predicted)(human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002578,extracting,,Extracting is a subtype of taking: A process that obtains a necessary component from the whole object,false,,,http://purl.obolibrary.org/obo/TXPO_0002577,,,,,,,,,,,,,,,,,,,異種成分の１つに注目して取り出すこと,,,Extracting is a subtype of taking: A process that obtains a necessary component from the whole object,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002578,,,,,,,,,,,,,,,,,,,,,,extracting,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002575,gathering,,Gathering is a subtype of assembling: A process that groups components of the same type.,false,,,http://purl.obolibrary.org/obo/TXPO_0000468,,,,,,,,,,,,,,,,,,,,,,Gathering is a subtype of assembling: A process that groups components of the same type.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002575,,,,,,,,,,,,,,,,,,,,,,gathering,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002571,IRE1 signaling (primitive) [ER stress],,"IRE1 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the IRE1 (Inositol-requiring transmembrane kinase/endonuclease). IRE1 generally plays a endoplasmic reticulum membrane stress sensor role.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0003736|http://purl.obolibrary.org/obo/TXPO_0000720,,,,,,,,,,,,,,,,,,,,,,"IRE1 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the IRE1 (Inositol-requiring transmembrane kinase/endonuclease). IRE1 generally plays a endoplasmic reticulum membrane stress sensor role.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002591,,,,,,,,,,,,,,,,,,TXPO:0002571,,,,,,,,,,,,,,,,,,,,,,IRE1 signaling (primitive) [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0200274,L-Phenylalanine,,,false,,,http://purl.obolibrary.org/obo/CHEBI_33709,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0200274,,,,,,,,,,,,,,,,,,,,,,L-Phenylalanine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_18179,phosphoinositide,,Any phosphatidylinositol that is phosphorylated at one or more of the hydroxy groups of inositol.,false,,,http://purl.obolibrary.org/obo/CHEBI_28874,,,,,,,,,,,,,,,,,,,,,,Any phosphatidylinositol that is phosphorylated at one or more of the hydroxy groups of inositol.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:18179,,,,,,,,,,,,,,,,,,,,,,phosphoinositide,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001123,type VIII collagen,,,false,,,http://purl.obolibrary.org/obo/IMR_0001118,,,,,,,,,,,,,,,,,,,,GO:0005591,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001123,,,,,,,,,,,,,,,,,,,,,,type VIII collagen,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000650,LFA-1,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003688,,,,,,,,,,IMR:0000650,,,,,,,,,,,,,,,,,,,,,,LFA-1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001667,RGS9,,,false,,,http://purl.obolibrary.org/obo/IMR_0000431,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001667,,,,,,,,,,,,,,,,,,,,,,RGS9,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004712,NDUFV1 inactivation,,NDUFV1 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the NDUFV1 (NADH:ubiquinone oxidoreductase core subunit V1) to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000021,,,,,,,,,,,,,,,,,,,,,,NDUFV1 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the NDUFV1 (NADH:ubiquinone oxidoreductase core subunit V1) to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004712,,,,,,,,,,,,,,,,,,,,,,NDUFV1 inactivation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004716,Increasing production quantity of NO,,Increasing production quantity of NO is a subtype of increasing quantity: A process that changes the production amount of nitric oxide (NO) to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing production quantity of NO is a subtype of increasing quantity: A process that changes the production amount of nitric oxide (NO) to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004716,,,,,,,,,,,,,,,,,,,,,,Increasing production quantity of NO,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004713,NDUFV1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:17995|NCBI-Human-GeneID:4723|NCBI-Rat-GeneID:293655,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004713,,,,,,,,,,,,,,,,,,,,,,NDUFV1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004719,NRF2 inactivation,,NRF2 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the NRF2 (nuclear factor 2) to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000021,,,,,,,,,,,,,,,,,,,,,,NRF2 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the NRF2 (nuclear factor 2) to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004719,,,,,,,,,,,,,,,,,,,,,,NRF2 inactivation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004718,increasing production quantity of RNS  [mitochondrial disorder],,"Increasing production quantity of RNS  is a subtype of increasing quantity: A process that changes the production amount of reactive nitrogen species (RNS) to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0000365,,,,,,,,,,,,,,,,,,,,PMID:23299992,,"Increasing production quantity of RNS  is a subtype of increasing quantity: A process that changes the production amount of reactive nitrogen species (RNS) to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000933|http://purl.obolibrary.org/obo/TXPO_0004121,,,,,,,,,,,TXPO:0004718,,,,,,,,,,,,,,,,,,,,,,increasing production quantity of RNS  [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004710,NDUFS2 inactivaiton,,NDUFS2 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the NDUFS2 (NADH:ubiquinone oxidoreductase core subunit S2) to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000021,,,,,,,,,,,,,,,,,,,,,,NDUFS2 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the NDUFS2 (NADH:ubiquinone oxidoreductase core subunit S2) to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004710,,,,,,,,,,,,,,,,,,,,,,NDUFS2 inactivaiton,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004715,NDUFV3 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:78330|NCBI-Rat-GeneID:64539|NCBI-Human-GeneID:4731,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004715,,,,,,,,,,,,,,,,,,,,,,NDUFV3 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004711,NDUFS2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:289218|NCBI-Human-GeneID:4720|NCBI-Mouse-GeneID:226646,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004711,,,,,,,,,,,,,,,,,,,,,,NDUFS2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004714,NDUFV3 inactivation,,NDUFV3 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the NDUFV3 (NADH:ubiquinone oxidoreductase core subunit V3) to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000021,,,,,,,,,,,,,,,,,,,,,,NDUFV3 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the NDUFV3 (NADH:ubiquinone oxidoreductase core subunit V3) to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004714,,,,,,,,,,,,,,,,,,,,,,NDUFV3 inactivation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004717,Increasing production quantity of NO [mitochondrial disorder],,"Increasing production quantity of NO is a subtype of increasing quantity: A process that changes the production amount of nitric oxide (NO) to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0004716,,,,,,,,,,,,,,,,,,,,PMID:25339807|PMID:23299992,,"Increasing production quantity of NO is a subtype of increasing quantity: A process that changes the production amount of nitric oxide (NO) to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000869|http://purl.obolibrary.org/obo/TXPO_0004718,,,,,,,,,,,TXPO:0004717,,,,,,,,,,,,,,,,,,,,,,Increasing production quantity of NO [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001871,ADAM10,a disintegrin and metalloproteinase 10,,false,,,http://purl.obolibrary.org/obo/IMR_0001865,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,a disintegrin and metalloproteinase 10,,,,,IMR:0001871,,,,,,,,,,,,,,,,,,,,,,ADAM10,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000010209,EIF1,,Other designations: protein translation factor SUI1 homolog|sui1iso1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,A121|ISO1|EIF1A|SUI1|EIF-1,,,,,,,,,,,,17,,,,,,HGNC:3249|HPRD:15449,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,eukaryotic translation initiation factor 1,,,17q21.2,,,,,,,,,,,,,,,,"GO_0003743 (EC: NAS, PMID:10347211); GO_0005737 (EC: TAS, PMID:10347211); GO_0006446 (EC: TAS, PMID:10347211); GO_0006950 (EC: NAS, PMID:10347211); GO_0008135 (EC: TAS, PMID:10347211); GO_0009048 (EC: IEA); GO_0044822 (EC: IDA)",,,,,,,,,PMID:7904817; 8889549; 10208429; 10228174; 10347211; 10754390; 11073994; 12477932; 15489334; 15592455; 16169070; 20921384; 21139048; 21832049; 21890473; 21900206; 21906983; 21963094; 22053931; 22505724; 22813744; 22939629; 23000965; 23293029; 24250222,,,,,,,,,,,,,,,OGG:3000010209,,,,,,,eukaryotic translation initiation factor 1,,,,,,,,,,,,,Other designations: protein translation factor SUI1 homolog|sui1iso1,,EIF1,,,,,,,,,,,,,,,,,,,,,,,10209,,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/GO_0030073,insulin secretion,,"The regulated release of proinsulin from secretory granules accompanied by cleavage of proinsulin to form mature insulin. In vertebrates, insulin is secreted from B granules in the B cells of the vertebrate pancreas and from insulin-producing cells in insects.",false,,,http://purl.obolibrary.org/obo/TXPO_0002588,,,,,,,,,,,,,,,,,,,,,,"The regulated release of proinsulin from secretory granules accompanied by cleavage of proinsulin to form mature insulin. In vertebrates, insulin is secreted from B granules in the B cells of the vertebrate pancreas and from insulin-producing cells in insects.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000052,,,,,,,,,,,,,,,,,,,GO:0030073,,,,,,,,,,,,,,,,,,,,,,insulin secretion,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/BFO_0000141,immaterial entity,,,false,,,http://purl.obolibrary.org/obo/BFO_0000004,,,,,,,,,,,,,,,,,,,,,,,,,,"BFO 2 Reference: Immaterial entities are divided into two subgroups:boundaries and sites, which bound, or are demarcated in relation, to material entities, and which can thus change location, shape and size and as their material hosts move or change shape or size (for example: your nasal passage; the hold of a ship; the boundary of Wales (which moves with the rotation of the Earth) [38, 7, 10",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BFO:0000141,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/bfo.owl,immaterial entity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001464,TLR9 (mol),Toll-like receptor 9,,false,,,http://purl.obolibrary.org/obo/IMR_0000124,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:81897|NCBI-Human-GeneID:54106|NCBI-Rat-GeneID:338457,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Toll-like receptor 9,,,,,IMR:0001464,,,,,,,,,,,,,,,,,,,,,,TLR9 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000055632,G2E3,,Other designations: G2/M phase-specific E3 ubiquitin-protein ligase|G2/M-phase specific E3 ubiquitin ligase|PHD finger protein 7B,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,PHF7B|KIAA1333,,,,,,,,,,,,14,,,,,,HGNC:20338|HPRD:13851|Vega:OTTHUMG00000140204|Ensembl:ENSG00000092140|MIM:611299,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,G2/M-phase specific E3 ubiquitin protein ligase,,,14q12,,,,,,,,,,,,,,,,GO_0000209 (EC: IEA); GO_0001824 (EC: IEA); GO_0004842 (EC: IEA); GO_0005730 (EC: IEA); GO_0005737 (EC: IEA); GO_0006915 (EC: IEA); GO_0008270 (EC: IEA); GO_2001243 (EC: IEA),,,,,,,,,PMID: 8125298; 10718198; 11483598; 12477932; 14667819; 14702039; 15489334; 16189514; 16344560; 17239372; 18029348; 18511420; 21139048; 21890473; 22939624; 23000965,,,,,,,,,,,,,,,OGG:3000055632,,,,,,,G2/M-phase specific E3 ubiquitin protein ligase,,,,,,,,,,,,,Other designations: G2/M phase-specific E3 ubiquitin-protein ligase|G2/M-phase specific E3 ubiquitin ligase|PHD finger protein 7B,,G2E3,,,,,,,,,,,,,,,,,,,,,,,55632,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,G2E3,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/UBERON_0001970,bile,gall|fel,"vital aqueous secretion of the liver that is formed by hepatocytes and modified down stream by absorptive and secretory properties of the bile duct epithelium.|In many species, bile is stored in the gallbladder and upon eating is discharged into the duodenum.",false,,,http://purl.obolibrary.org/obo/UBERON_0006314,,,,,,,,,,,,,,,,,,,,http://linkedlifedata.com/resource/umls/id/C0005388|http://purl.obolibrary.org/obo/NCIT_C13192|http://en.wikipedia.org/wiki/Bile|CALOHA:TS-1172|MA:0002513|GAID:1157|MESH:D001646|galen:Bile|UMLS:C0005388|FMA:62971|BTO:0000121|ENVO:02000023,,vital aqueous secretion of the liver that is formed by hepatocytes and modified down stream by absorptive and secretory properties of the bile duct epithelium.,,,,,bile,,,,,,,,,,"major excretory route for potentially harmful exogenous lipophilic substances|many hormones and pheromones are excreted in bile, and contribute to growth and development of the intestine in some species and provide attractants for the weaning of non-human vertebrates|protects the organism from enteric infections by excreting immune globulin A (IgA), inflammatory cytokines, and stimulating the innate immune system in the intestine|bile salts function to emulsify dietary fats and facilitate their intestinal absorption|elimination of cholesterol|aids the process of digestion of lipids in the small intestine",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,gall|fel,,,UBERON:0001970,,,,,,,,,,,,,,,,,,,,"In many species, bile is stored in the gallbladder and upon eating is discharged into the duodenum.",,bile,,,,,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003244,Ppara - cell cycle regulator (mouse)[Eosinophilic granular degeneration],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003243,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:19013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002247,,,,,,,,,,TXPO:0003244,,,,,,,,,,,,,,,,,,,,,,Ppara - cell cycle regulator (mouse)[Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003248,Acox1 (mouse)[Eosinophilic granular degeneration],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000027|http://purl.obolibrary.org/obo/TXPO_0000648,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:11430|PMID:19710929,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000051,,,,,,,,,,,,,TXPO:0003248,,,,,,,,,,,,,,,,,,,,,,Acox1 (mouse)[Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003240,Cdk4 (mol),Cell division protein kinase 4 (EC 2.7.1.- ) (Cyclin-dependent kinase 4) (PSK-J3) (CDK4)|CRK3|Cell division protein kinase 4,,false,,,http://purl.obolibrary.org/obo/TXPO_0003241,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:94201|NCBI-Human-GeneID:1019|NCBI-Mouse-GeneID:12567|OMIM:123829,,,,,,,,,,,,,,,cyclin dependent kinase 4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Cell division protein kinase 4 (EC 2.7.1.- ) (Cyclin-dependent kinase 4) (PSK-J3) (CDK4)|CRK3|Cell division protein kinase 4,,,,,TXPO:0003240,,,,,,,,,,,,,,,,,,,,,,Cdk4 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003243,Ppara (mouse)[Eosinophilic granular degeneration],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000648|http://purl.obolibrary.org/obo/TXPO_0000159,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:19013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003243,,,,,,,,,,,,,,,,,,,,,,Ppara (mouse)[Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003242,Cdk4(mouse)[Eosinophilic granular degeneration],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000648|http://purl.obolibrary.org/obo/TXPO_0003240,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:12567|OMIM:123829,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003242,,,,,,,,,,,,,,,,,,,,,,Cdk4(mouse)[Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003245,Myc (mouse)[Eosinophilic granular degeneration],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000648|http://purl.obolibrary.org/obo/IMR_0000383,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:17869,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000383,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003245,,,,,,,,,,,,,,,,,,,,,,Myc (mouse)[Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003241,CDK (family),Cyclin-dependent kinase,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,GO:0004693,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001966,,,,,Cyclin-dependent kinase,,,,,TXPO:0003241,,,,,,,,,,,,,,,,,,,,,,CDK (family),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003249,ACOX1 (human)[Eosinophilic granular degeneration],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001034|http://purl.obolibrary.org/obo/TXPO_1000027,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:11430|PMID:19710929,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000051,,,,,,,,,,,,,TXPO:0003249,,,,,,,,,,,,,,,,,,,,,,ACOX1 (human)[Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003247,Acaa1a (mouse)[Eosinophilic granular degeneration],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000648|http://purl.obolibrary.org/obo/TXPO_1000017,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:113868|PMID:19710929,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003247,,,,,,,,,,,,,,,,,,,,,,Acaa1a (mouse)[Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003246,ACAA1A (human)[Eosinophilic granular degeneration],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001034|http://purl.obolibrary.org/obo/TXPO_1000017,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:30|PMID:19710929,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003246,,,,,,,,,,,,,,,,,,,,,,ACAA1A (human)[Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0002954,LRP5/LRP6,,"Lrp5 and Lrp6 are highly homologous, and are widely co-expressed during embryogenesis and in adult tissues. An orthologue in Drosophila melanogaster is known as arrow, a gene that functions in the canonical Wnt signaling pathway.",false,,,http://purl.obolibrary.org/obo/IMR_0002951,,,,,,,,,,,,,,,,,,,,,,"Lrp5 and Lrp6 are highly homologous, and are widely co-expressed during embryogenesis and in adult tissues. An orthologue in Drosophila melanogaster is known as arrow, a gene that functions in the canonical Wnt signaling pathway.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0002954,,,,,,,,,,,,,,,,,,,,,,LRP5/LRP6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000912,eIF4F subunit,,,false,,,http://purl.obolibrary.org/obo/IMR_0010016,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000912,,,,,,,,,,,,,,,,,,,,,,eIF4F subunit,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001547,Rab1A,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001547,,,,,,,,,,,,,,,,,,,,,,Rab1A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_61015,nephrotoxin,nephrotoxins,A poison that interferes with the function of the kidneys.,false,,,http://purl.obolibrary.org/obo/CHEBI_64909,,,,,,,,,,,,,,,,,,,,,,A poison that interferes with the function of the kidneys.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,nephrotoxins,,,,,,,,,,,,,,,,,,,,,CHEBI:61015,,,,nephrotoxin,,CHEBI:61015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001912,increasing blood glucose level,hyperglycemia (process),Increasing blood glucose lebvel is a subtype of increasing concentration: A process that changes the blood glucose concentration in the blood to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000352,,,,,,,,,,,,,,,,,,,,,,Increasing blood glucose lebvel is a subtype of increasing concentration: A process that changes the blood glucose concentration in the blood to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,hyperglycemia (process),,,,,TXPO:0001912,,,,,,,,,,,,,,,,,,,,,,increasing blood glucose level,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/HP_0003074,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001919,HISTH1H2BG  (predicted)(human)[Glutathione depletion],,predicted gene  by Support Vector Machine (SVM) using human primary hepatocyte,false,,,http://purl.obolibrary.org/obo/TXPO_1000194|http://purl.obolibrary.org/obo/TXPO_0001916,,,,,,,,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/gene/680403|NCBI-Human-GeneID:8339|PMID:21130743,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000008339,,,,,,,,,,,,,TXPO:0001919,,,,,,,,,,,,,,,,,,,,predicted gene  by Support Vector Machine (SVM) using human primary hepatocyte,,HISTH1H2BG  (predicted)(human)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001917,G6PD  (predicted)(human)[Glutathione depletion],,predicted gene  by Support Vector Machine (SVM) using human primary hepatocyte,false,,,http://purl.obolibrary.org/obo/TXPO_1000158|http://purl.obolibrary.org/obo/TXPO_0001916,,,,,,,,,,,,,,,,,,,,http://omim.org/entry/305900|NCBI-Human-GeneID:2539|PMID:24287781,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000002539,,,http://purl.obolibrary.org/obo/TXPO_0002402,,,,,,,,,,TXPO:0001917,,,,,,,,,,,,,,,,,,,,predicted gene  by Support Vector Machine (SVM) using human primary hepatocyte,,G6PD  (predicted)(human)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001910,hypofunction of biosynthesis,,Hypofunction of biosynthesis is a subtype of hypofunctioning: A process that performs a decreased or insufficient biosynthesis.,false,,,http://purl.obolibrary.org/obo/TXPO_0000436,,,,,,,,,,,,,,,,,,,,,,Hypofunction of biosynthesis is a subtype of hypofunctioning: A process that performs a decreased or insufficient biosynthesis.,,,http://purl.obolibrary.org/obo/GO_0009058,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001910,,,,,,,,,,,,,,,,,,,,,,hypofunction of biosynthesis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001916,glutathione depletion dependent molecule (human in vitro),,"Glutathione depletion dependent molecule is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of glutathione depletion as a gene product.
Gene profile:Human/in vitro/Hepatocyte/",false,,,http://purl.obolibrary.org/obo/TXPO_0001915,,,,,,,,,,,,,,,,,,,,,,"Glutathione depletion dependent molecule is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of glutathione depletion as a gene product.
Gene profile:Human/in vitro/Hepatocyte/",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001916,,,,,,,,,,,,,,,,,,,,,,glutathione depletion dependent molecule (human in vitro),,,,,,,,,,,http://purl.obolibrary.org/obo/NCBITaxon_9606,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001911,hypofunction of transport,,Hypofunction of transport is a subtype of hypofunctioning: A process that performs a decreased or insufficient transport.,false,,,http://purl.obolibrary.org/obo/TXPO_0000436,,,,,,,,,,,,,,,,,,,,,,Hypofunction of transport is a subtype of hypofunctioning: A process that performs a decreased or insufficient transport.,,,http://purl.obolibrary.org/obo/TXPO_0000442,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001911,,,,,,,,,,,,,,,,,,,,,,hypofunction of transport,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001918,BLHA15  (predicted)(human)[Glutathione depletion],MIST1 (predicted) [Glutathione depletion],predicted gene  by Support Vector Machine (SVM) using human primary hepatocyte,false,,,http://purl.obolibrary.org/obo/TXPO_1000045|http://purl.obolibrary.org/obo/TXPO_0001916,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:168620|PMID:26456005|PMID:9073453|PMID:27644325,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000168620,,,,,,,,MIST1 (predicted) [Glutathione depletion],,,,,TXPO:0001918,,,,,,,,,,,,,,,,,,,,predicted gene  by Support Vector Machine (SVM) using human primary hepatocyte,,BLHA15  (predicted)(human)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001915,glutathione depletion dependent chemical entity,,"Glutathione depletion dependent chemical entity is a subtype of toxic course dependent chemical entity.
This entity can participate in the course of glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0001731,,,,,,,,,,,,,,,,,,,,,,"Glutathione depletion dependent chemical entity is a subtype of toxic course dependent chemical entity.
This entity can participate in the course of glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001915,,,,,,,,,,,,,,,,,,,,,,glutathione depletion dependent chemical entity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001913,decresing pressure,,Decresing pressure is a subtype of changing pressure: A process that changes the pressure of the object to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000475,,,,,,,,,,,,,,,,,,,,,,Decresing pressure is a subtype of changing pressure: A process that changes the pressure of the object to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001913,,,,,,,,,,,,,,,,,,,,,,decresing pressure,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0001575,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001914,increasing BUN concentration,,Increasing BUN concentration is a subtype of increasing concentration: A process that changes the Blood Urea Nitrogen (BUN) concentration  to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000352,,,,,,,,,,,,,,,,,,,,,,Increasing BUN concentration is a subtype of increasing concentration: A process that changes the Blood Urea Nitrogen (BUN) concentration  to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001914,,,,,,,,,,,,,,,,,,,,,,increasing BUN concentration,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004889,TP53(human) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/IMR_0100659,,,,,,,,,,,,,,,,,,,,PMID:22576474|NCBI-Human-GeneID:7157,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004889,,,,,,,,,,,,,,,,,,,,,,TP53(human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004883,Malfunctioning of cytokinesis [hepatocarcinogenesis],,"Malfunctioning of cytokinesis is a subtype of malfunctioning process: A process that cannot perform cytokinesis appropriately or cannot realize it at all.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0005033,,,,,,,,,,,,,,,,,,,,PMID:18245951,,"Malfunctioning of cytokinesis is a subtype of malfunctioning process: A process that cannot perform cytokinesis appropriately or cannot realize it at all.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004392,,,,,,,,,,,TXPO:0004883,,,,,,,,,,,,,,,,,,,,,,Malfunctioning of cytokinesis [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004886,Decreasing miR-150 level,,Decreasing miR-150 level is a subtype of decreasing quantity: A process that changes the amount of miR-150 level to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000396,,,,,,,,,,,,,,,,,,,,,,Decreasing miR-150 level is a subtype of decreasing quantity: A process that changes the amount of miR-150 level to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000406942,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004886,,,,,,,,,,,,,,,,,,,,,,Decreasing miR-150 level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004885,NOS2 (canonical) [mitochondrial disorder],nitric oxide synthase 2,,false,,,http://purl.obolibrary.org/obo/TXPO_0005119|http://purl.obolibrary.org/obo/TXPO_0004293,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:18126|NCBI-Human-GeneID:4843|NCBI-Rat-GeneID:24599,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,nitric oxide synthase 2,,,,,TXPO:0004885,,,,,,,,,,,,,,,,,,,,,,NOS2 (canonical) [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004880,cytoplasmic sequestering of cyclin A,,"The selective interaction of the cyclin A with specific molecules in the cytoplasm, thereby inhibiting its translocation into the nucleus.",false,,,http://purl.obolibrary.org/obo/TXPO_0000433,,,,,,,,,,,,,,,,,,,,,,"The selective interaction of the cyclin A with specific molecules in the cytoplasm, thereby inhibiting its translocation into the nucleus.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004880,,,,,,,,,,,,,,,,,,,,,,cytoplasmic sequestering of cyclin A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004882,Malfunctioning of centrosome duplication [hepatocarcinogenesis],,"Malfunctioning of centrosome duplication is a subtype of malfunctioning process: A process that cannot perform centrosome duplication appropriately or cannot realize it at all.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0005015,,,,,,,,,,,,,,,,,,,,PMID:18245951,,"Malfunctioning of centrosome duplication is a subtype of malfunctioning process: A process that cannot perform centrosome duplication appropriately or cannot realize it at all.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004392,,,,,,,,,,,TXPO:0004882,,,,,,,,,,,,,,,,,,,,,,Malfunctioning of centrosome duplication [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004887,MIR150 (human) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/OGG_3000406942,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:406942|PMID:25796501,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004887,,,,,,,,,,,,,,,,,,,,,,MIR150 (human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9606,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004881,cytoplasmic sequestering of cyclin A [hepatocarcinogenesis],,"The selective interaction of the cyclin A with specific molecules in the cytoplasm, thereby inhibiting its translocation into the nucleus.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004880,,,,,,,,,,,,,,,,,,,,PMID:18245951,,"The selective interaction of the cyclin A with specific molecules in the cytoplasm, thereby inhibiting its translocation into the nucleus.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004187,,,,,,http://purl.obolibrary.org/obo/TXPO_0004512|http://purl.obolibrary.org/obo/TXPO_0004883|http://purl.obolibrary.org/obo/TXPO_0004882|http://purl.obolibrary.org/obo/TXPO_0004633|http://purl.obolibrary.org/obo/TXPO_0004392,,,,,,,,,,,TXPO:0004881,,,,,,,,,,,,,,,,,,,,,,cytoplasmic sequestering of cyclin A [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004888,mitochondria morphology change,,mitochondria morphology changes is a subtype of changing shape: A process that changes the morphology of the mitochondria.,false,,,http://purl.obolibrary.org/obo/TXPO_0000410,,,,,,,,,,,,,,,,,,,,,,mitochondria morphology changes is a subtype of changing shape: A process that changes the morphology of the mitochondria.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004888,,,,,,,,,,,,,,,,,,,,,,mitochondria morphology change,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004884,inducible nitric oxide synthase production,,"iNOS production is a subtype of protein production: A process that makes existent of iNOS ( inducible nitric oxide synthase) due to biosynthesis, secretion, or membrane trafficking, resulting in an increase in its levels.",false,,,http://purl.obolibrary.org/obo/TXPO_0005048,,,,,,,,,,,,,,,,,,,,,,"iNOS production is a subtype of protein production: A process that makes existent of iNOS ( inducible nitric oxide synthase) due to biosynthesis, secretion, or membrane trafficking, resulting in an increase in its levels.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004884,,,,,,,,,,,,,,,,,,,,,,inducible nitric oxide synthase production,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0030908,protein splicing,,The post-translational removal of peptide sequences from within a protein sequence.,false,,,http://purl.obolibrary.org/obo/GO_0016485,,,,,,,,,,,,,,,,,,,,,,The post-translational removal of peptide sequences from within a protein sequence.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0030908,,,,,,,,,,,,,,,,,,,,,,protein splicing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100385,p57KIP2,cyclin-dependent kinase inhibitor p57,,false,,,http://purl.obolibrary.org/obo/IMR_0000446,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,cyclin-dependent kinase inhibitor p57,,,,,IMR:0100385,,,,,,,,,,,,,,,,,,,,,,p57KIP2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002088,hypofunction of phospholipid degradation [Phospholipidosis (mild)],,"Hypofunction of phospholipid degradation is a subtype of hypofunction of decomposing: A process that performs a decreased or insufficient phospholipid degradation.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (mild).",false,,,http://purl.obolibrary.org/obo/TXPO_0000925,,,,,,,,,,,,,,,,,,,,,,"Hypofunction of phospholipid degradation is a subtype of hypofunction of decomposing: A process that performs a decreased or insufficient phospholipid degradation.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (mild).",,,http://purl.obolibrary.org/obo/TXPO_0001406,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000775|http://purl.obolibrary.org/obo/TXPO_0001804,,,,,,http://purl.obolibrary.org/obo/TXPO_0001777,,,,,,,,,,,TXPO:0002088,,,,,,,,,,,,,,,,,,,,,,hypofunction of phospholipid degradation [Phospholipidosis (mild)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002086,increasing lysosomal pH [Phospholipidosis (moderate) ],,"Increasing lysosomal pH is a subtype of changing pH: A process that changes the pH in lysosome to be higher. And the degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (moderate).",false,,,http://purl.obolibrary.org/obo/TXPO_0001247,,,,,,,,,,,,,,,,,,,,,,"Increasing lysosomal pH is a subtype of changing pH: A process that changes the pH in lysosome to be higher. And the degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (moderate).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003372|http://purl.obolibrary.org/obo/TXPO_0003370,,,,,,,,,,,TXPO:0002086,,,,,,,,,,,,,,,,,,,,,,increasing lysosomal pH [Phospholipidosis (moderate) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002085,decreasing phospholipid [Phospholipidosis],,"Decreasing phospholipid is a subtype of decreasing lipid: A process that changes the quantity of the phospholipid to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0002084,,,,,,,,,,,,,,,,,,,,,,"Decreasing phospholipid is a subtype of decreasing lipid: A process that changes the quantity of the phospholipid to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001485|http://purl.obolibrary.org/obo/TXPO_0003354|http://purl.obolibrary.org/obo/TXPO_0000200|http://purl.obolibrary.org/obo/TXPO_0003384|http://purl.obolibrary.org/obo/TXPO_0002255|http://purl.obolibrary.org/obo/TXPO_0002258|http://purl.obolibrary.org/obo/TXPO_0003395|http://purl.obolibrary.org/obo/TXPO_0003390|http://purl.obolibrary.org/obo/TXPO_0001406,,,,,,,,,,,,,,,,,,TXPO:0002085,,,,,,,,,,,,,,,,,,,,,,decreasing phospholipid [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002084,decreasing phospholipid,,Decreasing phospholipid is a subtype of decreasing lipid: A process that changes the quantity of the phospholipid to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000644,,,,,,,,,,,,,,,,,,,,,,Decreasing phospholipid is a subtype of decreasing lipid: A process that changes the quantity of the phospholipid to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002084,,,,,,,,,,,,,,,,,,,,,,decreasing phospholipid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002081,decreasing functional demand,,Decreasing functional demand is a subtype of decreasing demand: A process that changes the functional demand to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0002080,,,,,,,,,,,,,,,,,,,,,,Decreasing functional demand is a subtype of decreasing demand: A process that changes the functional demand to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002081,,,,,,,,,,,,,,,,,,,,,,decreasing functional demand,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002087,negative regulation of phospholipid degradation [Phospholipidosis (mild)],,"A process that stops, prevents, or reduces the frequency, rate or extent of phospholipid degradation. And the degree is mild.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (mild).",false,,,http://purl.obolibrary.org/obo/TXPO_0000905,,,,,,,,,,,,,,,,,,,,,,"A process that stops, prevents, or reduces the frequency, rate or extent of phospholipid degradation. And the degree is mild.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (mild).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001403,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002088,,,,,,,,,,,TXPO:0002087,,,,,,,,,,,,,,,,,,,,,,negative regulation of phospholipid degradation [Phospholipidosis (mild)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002082,decreasing demand for phospholipid degradation,,Decreasing demand for phospholipid degradation is a subtype of decreasing functional demand: A process that changes the functional demand for the phospholipid degradation to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0002081,,,,,,,,,,,,,,,,,,,,,,Decreasing demand for phospholipid degradation is a subtype of decreasing functional demand: A process that changes the functional demand for the phospholipid degradation to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002082,,,,,,,,,,,,,,,,,,,,,,decreasing demand for phospholipid degradation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002083,increasing phospholipid metabolite [Phospholipidosis (excessive defense)],,"ceramide accumulation is a subtype of accumulation of substances in a biological object: A process that keeps ceramide in an organism, tissue, organelle, or cell.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense).",false,,,http://purl.obolibrary.org/obo/TXPO_0004143|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"ceramide accumulation is a subtype of accumulation of substances in a biological object: A process that keeps ceramide in an organism, tissue, organelle, or cell.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002083,,,,,,,,,,,,,,,,,,,,,,increasing phospholipid metabolite [Phospholipidosis (excessive defense)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002080,decreasing demand,,Decreasing demand is a subtype of decreasing quantity: A process that changes the quantity demanded to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000396,,,,,,,,,,,,,,,,,,,,,,Decreasing demand is a subtype of decreasing quantity: A process that changes the quantity demanded to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002080,,,,,,,,,,,,,,,,,,,,,,decreasing demand,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002089,glutathione transferase family,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002089,,,,,,,,,,,,,,,,,,,,,,glutathione transferase family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_4953,exemestane,"6-methyleneandrosta-1,4-diene-3,17-dione|exemestane|exemestanum|exemestano|Exemestane|6-methylideneandrosta-1,4-diene-3,17-dione","A 17-oxo steroid that is androsta-1,4-diene-3,17-dione in which the hydrogens at position 6 are replaced by a double bond to a methylene group. A selective inhibitor of the aromatase (oestrogen synthase) system, it is used in the treatment of advanced breast cancer.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:107868-30-4|Reaxys:6609645|PMID:10882163|Drug_Central:1122|DrugBank:DB00990,,"A 17-oxo steroid that is androsta-1,4-diene-3,17-dione in which the hydrogens at position 6 are replaced by a double bond to a methylene group. A selective inhibitor of the aromatase (oestrogen synthase) system, it is used in the treatment of advanced breast cancer.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35610|http://purl.obolibrary.org/obo/CHEBI_35703|http://purl.obolibrary.org/obo/CHEBI_50790|http://purl.obolibrary.org/obo/CHEBI_78298,,,,,"Exemestane|6-methylideneandrosta-1,4-diene-3,17-dione",,"6-methyleneandrosta-1,4-diene-3,17-dione|exemestane|exemestanum|exemestano",,,,,,,,,,,,,,,,,,,,,CHEBI:4953,,,,exemestane,,CHEBI:4953,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000018,GM-CSF,granulocyte-macrophage colony-stimulating factor,relate molecular function GO:0005129,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,OMIM: 138960,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000622,,,,,granulocyte-macrophage colony-stimulating factor,,,,,IMR:0000018,,,,,,,,,,,,,,,,,,,,relate molecular function GO:0005129,,GM-CSF,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_32499,amineptine,"amineptinum|Survector|Amineptin|amineptine|amineptino|7-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylamino)heptanoic acid","A carbocyclic fatty acid that is 5-aminoheptanoic acid in which one of the hydrogens attached to the nitrogen is replaced by a 10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-yl group. A tricyclic antidepressant, it was never approved in the US and was withdrawn from the French market in 1999 due to concerns over abuse, dependence and severe acne.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:2141246|Drug_Central:161|PMID:9347390|PMID:2131927|PMID:2698268|DrugBank:DB04836|CAS:57574-09-1|PMID:7609861|Beilstein:2170218|Reaxys:2170218|Wikipedia:Amineptine,,"A carbocyclic fatty acid that is 5-aminoheptanoic acid in which one of the hydrogens attached to the nitrogen is replaced by a 10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-yl group. A tricyclic antidepressant, it was never approved in the US and was withdrawn from the French market in 1999 due to concerns over abuse, dependence and severe acne.",,,,,,,,,,,,C22H27NO2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_51039|http://purl.obolibrary.org/obo/CHEBI_35469,,,,,"7-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylamino)heptanoic acid",,amineptinum|Survector|Amineptin|amineptine|amineptino,,,,,,,,,,,,,,,,,,,,,CHEBI:32499,,,,amineptine,,CHEBI:32499,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,OC(=O)CCCCCCNC1c2ccccc2CCc2ccccc12,,,,,
http://purl.obolibrary.org/obo/CHEBI_37550,sphingosine-1-phosphate,S1P,A phosphosphingolipid that consists of sphingosine having a phospho group attached at position 1,false,,,http://purl.obolibrary.org/obo/CHEBI_35786,,,,,,,,,,,,,,,,,,,,IMR:0100179,,A phosphosphingolipid that consists of sphingosine having a phospho group attached at position 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003686|http://purl.obolibrary.org/obo/TXPO_0002401,,,,,S1P,,,,,CHEBI:37550,,,,,,,"Sphingolipid mediators, such as sphingosine 1-phosphate (S1P), ceramide, and sphingosine are derived by the enzymatic breakdown of sphingomyelin, an abundant membrane phospholipid. S1P is an evolutionarily conserved bioactive lipid mediator with potent effects on multiple organ systems.",,,,,,,,,,,,,,,sphingosine-1-phosphate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000009188,DDX21,,Other designations: DEAD (Asp-Glu-Ala-Asp) box polypeptide 21|DEAD box protein 21|DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 21|Gu protein|RH II/Gu|RNA helicase II/Gu alpha|gu-alpha|nucleolar RNA helicase 2|nucleolar RNA helicase Gu|nucleolar RNA helicase II,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,RH-II/GuA|GUA|GURDB|RH-II/GU,,,,,,,,,,,,10,,,,,,MIM:606357|Ensembl:ENSG00000165732|HGNC:2744|Vega:OTTHUMG00000018366|HPRD:05895,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,DEAD (Asp-Glu-Ala-Asp) box helicase 21,,,10q21,,,,,,,,,,,,,,,,"GO_0003725 (EC: IEA); GO_0004004 (EC: TAS, PMID: 8614622); GO_0005524 (EC: IEA); GO_0005634 (EC: IDA); GO_0005730 (EC: IDA); GO_0006200 (EC: TAS, PMID: 8614622); GO_0009615 (EC: IEA); GO_0043330 (EC: IEA); GO_0044822 (EC: IDA)",,,,,,,,,PMID: 8614622; 9177271; 10860663; 11237763; 11790298; 11823437; 11891046; 12477932; 12777385; 14559904; 15164054; 15302935; 15367657; 15489334; 15635413; 15840729; 15848144; 16045751; 16159877; 16385451; 16565220; 17081983; 17353931; 18029348; 18180292; 18781797; 19394292; 19454010; 19596686; 19710015; 19738201; 20020773; 20360068; 20431927; 20462248; 20800221; 20873769; 21044950; 21139048; 21145461; 21149631; 21182205; 21252943; 21319273; 21385873; 21726808; 21890473; 21907836; 22108332; 22113938; 22174317; 22178446; 22268729; 22446626; 22586326; 22623428; 22751105; 22939629; 22952844; 23000965; 23145133; 23151878; 23184937; 23277564; 23398456; 23419719; 23455922; 23503679; 23602568; 24457600,,,,,,,,,,,,,,,OGG:3000009188,,,,,,,DEAD (Asp-Glu-Ala-Asp) box helicase 21,,,,,,,,,,,,,Other designations: DEAD (Asp-Glu-Ala-Asp) box polypeptide 21|DEAD box protein 21|DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 21|Gu protein|RH II/Gu|RNA helicase II/Gu alpha|gu-alpha|nucleolar RNA helicase 2|nucleolar RNA helicase Gu|nucleolar RNA helicase II,,DDX21,,,,,,,,,,,,,,,,,,,,,,,9188,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,DDX21,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000375,STAT1 (mol),signal transducer and activator of transcription 1,There are two STAT1 isoforms (STAT1alpha and STAT1beta) produced by alternative splicing of a single mRNA.,false,,,http://purl.obolibrary.org/obo/IMR_0000374,,,,,,,,,,,,,,,,,,,,,,There are two STAT1 isoforms (STAT1alpha and STAT1beta) produced by alternative splicing of a single mRNA.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,signal transducer and activator of transcription 1,,,,,IMR:0000375,,,,,,,,,,,,,,,,,,,,,,STAT1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001659,negative regulation of phosphatidylinositol degradation,,"Negative regulation of phosphatidylinositol degradation is a subtype of Negative regulation of glycerophospholipid degradation: A process that stops, prevents, or reduces the frequency, rate or extent of phosphatidylinositol degradation.",false,,,http://purl.obolibrary.org/obo/TXPO_0001304,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of phosphatidylinositol degradation is a subtype of Negative regulation of glycerophospholipid degradation: A process that stops, prevents, or reduces the frequency, rate or extent of phosphatidylinositol degradation.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001659,,,,,,,,,,,,,,,,,,,,,,negative regulation of phosphatidylinositol degradation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001655,hyperfunction of phosphatidylinositol synthetic gene expression,,Hyperfunction of phosphatidylinositol synthetic gene expression is a subtype of hyperfunction of glycerophospholipid synthesis gene expression: A process that performs an excesssive phosphatidylinositol synthetic gene expression.,false,,,http://purl.obolibrary.org/obo/TXPO_0001264,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of phosphatidylinositol synthetic gene expression is a subtype of hyperfunction of glycerophospholipid synthesis gene expression: A process that performs an excesssive phosphatidylinositol synthetic gene expression.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001655,,,,,,,,,,,,,,,,,,,,,,hyperfunction of phosphatidylinositol synthetic gene expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001656,chemical homeostasis imbalance,,Chemical homeostasis imbalance is a subtype of homeostasis imbalance: A process that becomes lacking a chemical homeostastasis balance.,false,,,http://purl.obolibrary.org/obo/TXPO_0000568,,,,,,,,,,,,,,,,,,,,,,Chemical homeostasis imbalance is a subtype of homeostasis imbalance: A process that becomes lacking a chemical homeostastasis balance.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001656,,,,,,,,,,,,,,,,,,,,,,chemical homeostasis imbalance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001653,increasing phosphatidylinositol material,,Increasing phosphatidylinositol material is a subtype of increasing glycerophospholipid material: A process that changes the amount of phosphatidylinositol material to be larger.,false,,,http://purl.obolibrary.org/obo/TXPO_0001317,,,,,,,,,,,,,,,,,,,,,,Increasing phosphatidylinositol material is a subtype of increasing glycerophospholipid material: A process that changes the amount of phosphatidylinositol material to be larger.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001653,,,,,,,,,,,,,,,,,,,,,,increasing phosphatidylinositol material,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001658,changing balance of drug metabolism,,Changing balance of drug metabolism is a subtype of changing balance: A process that that changes the balance between break down and the continued presence of the drug.,false,,,http://purl.obolibrary.org/obo/TXPO_0001847,,,,,,,,,,,,,,,,,,,,,,Changing balance of drug metabolism is a subtype of changing balance: A process that that changes the balance between break down and the continued presence of the drug.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001658,,,,,,,,,,,,,,,,,,,,,,changing balance of drug metabolism,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001651,cell rupture,,Cell rupture is the tearing apart of a cell.,false,,,http://purl.obolibrary.org/obo/TXPO_0000462,,,,,,,,,,,,,,,,,,,,,,Cell rupture is the tearing apart of a cell.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001651,,,,,,,,,,,,,,,,,,,,,,cell rupture,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001652,AMPK (canonical)[lipidosis],,PRKAA1,false,,,http://purl.obolibrary.org/obo/TXPO_0003221|http://purl.obolibrary.org/obo/TXPO_0003516,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:105787|NCBI-Human-GeneID:5562|NCBI-Rat-GeneID:65248,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003221,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001682,,,,,,,,,,TXPO:0001652,,,,,,,"The protein encoded by this gene belongs to the ser/thr protein kinase family. It is the catalytic subunit of the 5'-prime-AMP-activated protein kinase (AMPK). AMPK is a cellular energy sensor conserved in all eukaryotic cells. The kinase activity of AMPK is activated by the stimuli that increase the cellular AMP/ATP ratio. AMPK regulates the activities of a number of key metabolic enzymes through phosphorylation. It protects cells from stresses that cause ATP depletion by switching off ATP-consuming biosynthetic pathways. Alternatively spliced transcript variants encoding distinct isoforms have been observed. [provided by RefSeq, Jul 2008]",,,,,,,,,,,,,PRKAA1,,AMPK (canonical)[lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001650,negative regulation of phosphatidylserine  degradation,,"Negative regulation of phosphatidylserine  degradation is a subtype of Negative regulation of glycerophospholipid degradation: A process that stops, prevents, or reduces the frequency, rate or extent of phosphatidylserine  degradation.",false,,,http://purl.obolibrary.org/obo/TXPO_0001304,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of phosphatidylserine  degradation is a subtype of Negative regulation of glycerophospholipid degradation: A process that stops, prevents, or reduces the frequency, rate or extent of phosphatidylserine  degradation.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001650,,,,,,,,,,,,,,,,,,,,,,negative regulation of phosphatidylserine  degradation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001657,hypofunction of phosphatidylinositol degradation,,Hypofunction of phosphatidylinositol degradation is a subtype of hypofunction of glycerophospholipid degradation: A process that performs a decreased or insufficient phosphatidylinositol degradation.,false,,,http://purl.obolibrary.org/obo/TXPO_0001418,,,,,,,,,,,,,,,,,,,,,,Hypofunction of phosphatidylinositol degradation is a subtype of hypofunction of glycerophospholipid degradation: A process that performs a decreased or insufficient phosphatidylinositol degradation.,,,http://purl.obolibrary.org/obo/GO_0031161,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_28874,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001657,,,,,,,,,,,,,,,,,,,,,,hypofunction of phosphatidylinositol degradation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001654,hyperfunction of decreasing the amount of phenobarbital [Ground glass appearance],,"Hyperfunction of decreasing the amount of phenobarbital is a subtype of hyperfunction of decreasing: A process that performs an excesssive decreasing the amount of the phenobarbital.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0003861,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of decreasing the amount of phenobarbital is a subtype of hyperfunction of decreasing: A process that performs an excesssive decreasing the amount of the phenobarbital.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001654,,,,,,,,,,,,,,,,,,,,,,hyperfunction of decreasing the amount of phenobarbital [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0034142,TLR4 signaling pathway,toll-like receptor 4 signaling pathway,Any series of molecular signals generated as a consequence of binding to toll-like receptor 4.,false,,,http://purl.obolibrary.org/obo/GO_0002224,,,,,,,,,,,,,,,,,,,,,,Any series of molecular signals generated as a consequence of binding to toll-like receptor 4.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,toll-like receptor 4 signaling pathway,,,,,GO:0034142,,,,,,,,,,,,,,,,,,,,,,TLR4 signaling pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000009451,EIF2AK3,,Other designations: PRKR-like endoplasmic reticulum kinase|eukaryotic translation initiation factor 2 alpha kinase 3|hsPEK|pancreatic EIF2-alpha kinase,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,PEK|PERK|WRS,,,,,,,,,,,,2,,,,,,Ensembl:ENSG00000172071|HPRD:04942|Vega:OTTHUMG00000155046|MIM:604032|HGNC:3255,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,eukaryotic translation initiation factor 2-alpha kinase 3,,,2p12,,,,,,,,,,,,,,,,"GO_0001501 (EC: ISS); GO_0001503 (EC: IMP, PMID:12086964); GO_0002063 (EC: ISS); GO_0004672 (EC: TAS, PMID:10026192); GO_0004674 (EC: ISS); GO_0004674 (EC: TAS); GO_0004694 (EC: IDA, PMID:10026192); GO_0004694 (EC: IMP, PMID:12086964); GO_0005515 (EC: IPI, PMID:11907036); GO_0005524 (EC: IEA); GO_0005737 (EC: ISS); GO_0005783 (EC: IC, PMID:11907036); GO_0005783 (EC: ISS); GO_0005783 (EC: TAS, PMID:12086964); GO_0005789 (EC: ISS); GO_0005789 (EC: NAS, PMID:11907036); GO_0005789 (EC: TAS); GO_0006412 (EC: IEA); GO_0006468 (EC: ISS); GO_0006919 (EC: ISS); GO_0006983 (EC: IDA, PMID:10677345); GO_0006987 (EC: TAS); GO_0007029 (EC: ISS); GO_0007595 (EC: IEA); GO_0009967 (EC: IEA); GO_0016021 (EC: IEA); GO_0017148 (EC: TAS, PMID:12086964); GO_0019217 (EC: IEA); GO_0019722 (EC: ISS); GO_0019899 (EC: IPI); GO_0019903 (EC: IPI); GO_0030073 (EC: ISS); GO_0030282 (EC: ISS); GO_0030968 (EC: IDA, PMID:10677345); GO_0030968 (EC: TAS, PMID:19816510); GO_0031018 (EC: IMP, PMID:12086964); GO_0031642 (EC: ISS); GO_0032057 (EC: TAS, PMID:10677345); GO_0032092 (EC: IEA); GO_0032933 (EC: IEA); GO_0034976 (EC: IMP, PMID:19061639); GO_0042802 (EC: IPI, PMID:11907036); GO_0044267 (EC: TAS); GO_0045444 (EC: IEA); GO_0046777 (EC: IDA, PMID:10026192); GO_0046777 (EC: IMP, PMID:12086964); GO_0048009 (EC: ISS); GO_0051260 (EC: IMP, PMID:11907036); GO_0070059 (EC: IEA)",,,,,,,,,PMID:1677563; 8099443; 9819435; 10026192; 10542257; 10575235; 10677345; 10848580; 10932183; 11555640; 11907036; 12014989; 12086964; 12370288; 12446770; 12446838; 12477932; 12610133; 14517290; 15146197; 15220213; 15234121; 15483661; 15489334; 15650164; 16147992; 16148948; 16288713; 16344560; 16720581; 17229688; 17785458; 17823375; 18063576; 18216498; 18426796; 18451152; 18664456; 18787411; 19009018; 19029953; 19061639; 19586904; 19816510; 19837917; 19913121; 20072656; 20103619; 20202148; 20348950; 20371724; 20379614; 20457808; 20463975; 20628086; 20709135; 20800603; 20881960; 21385877; 21419175; 21464971; 21518408; 21648287; 21685912; 21709020; 22028037; 22072062; 22169477; 22246806; 22253692; 22354021; 22446326; 22795130; 22813743; 22915762; 22917505; 22956602; 23103912; 23110043; 23116876; 23160380; 23471998; 23585173; 23592989; 23759358; 24103755; 24114838; 24457600,,,,,,,,,,,,,,,OGG:3000009451,,,,,,,eukaryotic translation initiation factor 2-alpha kinase 3,,,,,,,,,,,,,Other designations: PRKR-like endoplasmic reticulum kinase|eukaryotic translation initiation factor 2 alpha kinase 3|hsPEK|pancreatic EIF2-alpha kinase,,EIF2AK3,,,,,,,,,,,,,,,,,,,,,,,9451,,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF2AK3,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/GO_0006260,DNA replication,,"The cellular metabolic process in which a cell duplicates one or more molecules of DNA. DNA replication begins when specific sequences, known as origins of replication, are recognized and bound by initiation proteins, and ends when the original DNA molecule has been completely duplicated and the copies topologically separated. The unit of replication usually corresponds to the genome of the cell, an organelle, or a virus. The template for replication can either be an existing DNA molecule or RNA.",false,,,http://purl.obolibrary.org/obo/TXPO_0000093,,,,,,,,,,,,,,,,,,,,,,"The cellular metabolic process in which a cell duplicates one or more molecules of DNA. DNA replication begins when specific sequences, known as origins of replication, are recognized and bound by initiation proteins, and ends when the original DNA molecule has been completely duplicated and the copies topologically separated. The unit of replication usually corresponds to the genome of the cell, an organelle, or a virus. The template for replication can either be an existing DNA molecule or RNA.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0006260,,,,,,,,,,,,,,,,,,,,,,DNA replication,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000304,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_1903788,positive regulation of glutathione biosynthetic process,positive regulation of glutathione biosynthesis|positive regulation of glutathione synthesis|up regulation of glutathione biosynthesis|positive regulation of glutathione formation|up regulation of glutathione anabolism|positive regulation of glutathione anabolism,"Any process that activates or increases the frequency, rate or extent of glutathione biosynthetic process.",false,,,http://purl.obolibrary.org/obo/TXPO_0001223,,,,,,,,,,,,,,,,,,,,,,"Any process that activates or increases the frequency, rate or extent of glutathione biosynthetic process.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,positive regulation of glutathione biosynthesis|positive regulation of glutathione synthesis|up regulation of glutathione biosynthesis|positive regulation of glutathione formation|up regulation of glutathione anabolism|positive regulation of glutathione anabolism,,,,,GO:1903788,,,,,,,,,,,,,,,,,,,,,,positive regulation of glutathione biosynthetic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006750,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000001647,GADD45A,,Other designations: DDIT-1|DNA damage-inducible transcript 1 protein|DNA damage-inducible transcript-1|DNA-damage-inducible transcript 1|growth arrest and DNA damage-inducible protein GADD45 alpha|growth arrest and DNA-damage-inducible 45 alpha,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,GADD45|DDIT1,,,,,,,,,,,,1,,,,,,Ensembl:ENSG00000116717|HPRD:00528|HGNC:4095|Vega:OTTHUMG00000009374|MIM:126335,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"growth arrest and DNA-damage-inducible, alpha",,,1p31.2,,,,,,,,,,,,,,,,"GO_0000079 (EC: TAS, PMID: 10747892); GO_0000185 (EC: IDA, PMID: 9827804); GO_0001047 (EC: IEA); GO_0005515 (EC: IPI, PMID: 12716909); GO_0005634 (EC: IDA); GO_0005737 (EC: IDA, PMID: 9827804); GO_0006281 (EC: TAS, PMID: 7973727); GO_0006469 (EC: IEA); GO_0006915 (EC: TAS, PMID: 10828065); GO_0007050 (EC: IEA); GO_0007098 (EC: IEA); GO_0042770 (EC: IMP); GO_0043065 (EC: IDA, PMID: 9827804); GO_0046330 (EC: IDA, PMID: 9827804); GO_0071260 (EC: IEP, PMID: 19593445); GO_0071479 (EC: IMP); GO_1900745 (EC: IDA, PMID: 9827804); GO_2000379 (EC: IMP)",,,,,,,,,PMID: 1990262; 7478510; 7478594; 7784094; 7798274; 7973727; 8226988; 9178907; 9705499; 9827804; 10022855; 10362260; 10747892; 10828065; 10872826; 10912791; 10973963; 11076863; 11256614; 11498536; 11777930; 11893252; 12124778; 12168790; 12171872; 12477932; 12483522; 12716909; 12748288; 14506229; 14517299; 14586402; 14635187; 14647444; 15203190; 15328371; 15353598; 15489334; 15489336; 15616591; 15623356; 15642443; 15644315; 15650754; 15735726; 15736438; 15899854; 16157202; 16169070; 16189514; 16353139; 16381901; 16421274; 16772293; 16827157; 16951143; 16997058; 17140287; 17178890; 17230496; 17436581; 17474084; 17599061; 17616671; 17703175; 18243530; 18296737; 18350249; 18369439; 18413758; 18472964; 18480060; 18611122; 18760377; 18950845; 19048389; 19052873; 19064572; 19128509; 19190346; 19298651; 19452502; 19459735; 19536092; 19550118; 19593445; 19596022; 19728081; 19789190; 20012529; 20131288; 20444249; 20460379; 20639865; 20652500; 20932473; 21048031; 21120602; 21139048; 21211282; 21368893; 21739277; 21813510; 21890473; 21900206; 21906983; 21931671; 21963094; 21986581; 21988832; 22135303; 22313682; 22430142; 22521726; 22718299; 22825327; 22970179; 23000965; 23071284; 23114628; 23158659; 23187294; 23227140; 23478041; 23485469; 23563151; 23603344; 23616123; 23706118; 24104470; 24104471; 24104476,,,,,,,,,,,,,,,OGG:3000001647,,,,,,,"growth arrest and DNA-damage-inducible, alpha",,,,,,,,,,,,,Other designations: DDIT-1|DNA damage-inducible transcript 1 protein|DNA damage-inducible transcript-1|DNA-damage-inducible transcript 1|growth arrest and DNA damage-inducible protein GADD45 alpha|growth arrest and DNA-damage-inducible 45 alpha,,GADD45A,,,,,,,,,,,,,,,,,,,,,,,1647,RP5-975D15.1,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,GADD45A,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001649,DDIT3,GAD153|CHOP10|CHOP-10|CEBPZ|CHOP,Other designations: C/EBP zeta|CCAAT/enhancer-binding protein homologous protein|DDIT-3|DNA damage-inducible transcript 3 protein|c/EBP-homologous protein 10|growth arrest and DNA damage-inducible protein GADD153,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1649|HGNC:2726|HPRD:00529|MIM:126337|Ensembl:ENSG00000175197,,Other designations: C/EBP zeta|CCAAT/enhancer-binding protein homologous protein|DDIT-3|DNA damage-inducible transcript 3 protein|c/EBP-homologous protein 10|growth arrest and DNA damage-inducible protein GADD153,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001649,,,,,,,,GAD153|CHOP10|CHOP-10|CEBPZ|CHOP,,,,,OGG:3000001649,,,,,,,DNA-damage-inducible transcript 3,,,,,,,,,,,,,,,DDIT3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,DDIT3,,
http://purl.obolibrary.org/obo/CHEBI_35623,anticonvulsant,Antikonvulsivum|Antikonvulsiva|anti-convulsant|Antiepileptikum|anticonvulsants|anticonvulsive agents|anti-convulsive agents|antiepileptics|Antiepileptika|antiepileptique|anticonvulsive agent|anti-convulsive agent|antiepileptiques|antiepileptic|anti-convulsants,A drug used to prevent seizures or reduce their severity.,false,,,http://purl.obolibrary.org/obo/CHEBI_35488,,,,,,,,,,,,,,,,,,,,,,A drug used to prevent seizures or reduce their severity.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Antikonvulsivum|Antikonvulsiva|anti-convulsant|Antiepileptikum|anticonvulsants|anticonvulsive agents|anti-convulsive agents|antiepileptics|Antiepileptika|antiepileptique|anticonvulsive agent|anti-convulsive agent|antiepileptiques|antiepileptic|anti-convulsants,,,,,,,,,,,,,,,,,,,,,CHEBI:35623,,,,anticonvulsant,,CHEBI:35623,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000086,TR,thyroid hormone receptor|c-erbA,,false,,,http://purl.obolibrary.org/obo/TXPO_0001509,,,,,,,,,,,,,,,,,,,,GO:0004887,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003224,,,,,thyroid hormone receptor|c-erbA,,,,,IMR:0000086,,,,,,,,,,,,,,,,,,,,,,TR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000248,RSK,MAPK-activated protein kinase-1|90 kDa ribosomal S6 kinase|p90rsk|MAPKAP-K1|MAPKAP kinase-1,"A family of 90 kDa ribosomal S6 kinases (RSK; also known as p90rsk or MAPK-activated protein kinase-1, MAPKAP-K1). The RSK family of kinases includes three isoforms: RSK1, RSK2 and RSK3 that are encoded by distinct genes and show 75-80% amino acid identity. RSK proteins is regulated by the ERK kinase pathway.",false,,,http://purl.obolibrary.org/obo/IMR_0100271|http://purl.obolibrary.org/obo/IMR_0001844,,,,,,,,,,,,,,,,,,,,GO:0004711,,"A family of 90 kDa ribosomal S6 kinases (RSK; also known as p90rsk or MAPK-activated protein kinase-1, MAPKAP-K1). The RSK family of kinases includes three isoforms: RSK1, RSK2 and RSK3 that are encoded by distinct genes and show 75-80% amino acid identity. RSK proteins is regulated by the ERK kinase pathway.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MAPK-activated protein kinase-1|90 kDa ribosomal S6 kinase|p90rsk|MAPKAP-K1|MAPKAP kinase-1,,,,,IMR:0000248,,,,,,,,,,,,,,,,,,,,,,RSK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000700,Phosphorylation of eIF2-alpha by PERK [ER stress],,"Phosphorylation of eIF2-alpha by PERK is a subtype of eIF2a phosphorylation: A process that The process of introducing a phosphate group into eIF2a by PERK.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.|The C-terminal domain of PERK (EIF2AK3) has kinase activity when PERK homodimerizes. PERK kinase specifically phosphorylates Ser52 of eIF2-alpha, causing an arrest in translation. The result is that translation of ER-targeted proteins is halted on ribosomes in the vicinity of activated PERK. The general arrest of translation results in the loss of short-lived proteins such as Cyclin D1, causing an arrest of the cell cycle in G1.",false,,,http://purl.obolibrary.org/obo/TXPO_0003736|http://purl.obolibrary.org/obo/TXPO_0000549,,,,,,,,,,,,,,,,,,,,Reactome:R-HSA-381111|PMID:9930704|PMID:23334697,,"Phosphorylation of eIF2-alpha by PERK is a subtype of eIF2a phosphorylation: A process that The process of introducing a phosphate group into eIF2a by PERK.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000878,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001275,,,,http://purl.obolibrary.org/obo/TXPO_0000829,,,,,,,,,,,,,,,,,,,TXPO:0000700,,,,,,,,,,,,,,,,,,,,"The C-terminal domain of PERK (EIF2AK3) has kinase activity when PERK homodimerizes. PERK kinase specifically phosphorylates Ser52 of eIF2-alpha, causing an arrest in translation. The result is that translation of ER-targeted proteins is halted on ribosomes in the vicinity of activated PERK. The general arrest of translation results in the loss of short-lived proteins such as Cyclin D1, causing an arrest of the cell cycle in G1.",,Phosphorylation of eIF2-alpha by PERK [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000705,IGFBP1 activation,,IGFBP1 activation is a subtype of molecular activation: A process that  changes the activity of the IGFBP1 (Insulin Like Growth Factor Binding Protein 1) to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000023,,,,,,,,,,,,,,,,,,,,,,IGFBP1 activation is a subtype of molecular activation: A process that  changes the activity of the IGFBP1 (Insulin Like Growth Factor Binding Protein 1) to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000705,,,,,,,,,,,,,,,,,,,,,,IGFBP1 activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000704,expression of CCL2,,"Expression of CCL2 is a subtype of inflammatory cytokine gene expression: A process that convert a CCL2 (C-C Motif Chemokine Ligand 2) gene's sequenes into a mature gene prduct(s), i.e., (m)RNA, or protein.|The CCL2 gene is transcribed to yield mRNA and the mRNA is translated to yield protein.",false,,,http://purl.obolibrary.org/obo/TXPO_0002266,,,,,,,,,,,,,,,,,,,,"http://www.reactome.org/PathwayBrowser/#/R-HSA-380994&SEL=R-HSA-1791056&PATH=R-HSA-392499,R-HSA-381119,R-HSA-381042",,"Expression of CCL2 is a subtype of inflammatory cytokine gene expression: A process that convert a CCL2 (C-C Motif Chemokine Ligand 2) gene's sequenes into a mature gene prduct(s), i.e., (m)RNA, or protein.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000704,,,,,,,,,,,,,,,,,,,,The CCL2 gene is transcribed to yield mRNA and the mRNA is translated to yield protein.,,expression of CCL2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000702,PLA2G1B(canonical)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003555|http://purl.obolibrary.org/obo/TXPO_0003213,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:5319|NCBI-Mouse-GeneID:18778|NCBI-Rat-GeneID:29526|PMID:15528384|PMID:16005851,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000283,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003671,,,,,,,,,,TXPO:0000702,,,,,,,,,,,,,,,,,,,,,,PLA2G1B(canonical)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000701,PERK-eIF2a signaling (integrated pathway),,"PERK-eIF2a signaling (integrated pathway) is a subtype of PERK signaling (integrated pathway): Sequence of linked reactions, which has PERK-eIF2a signaling and gene regulation pathway.",false,,,http://purl.obolibrary.org/obo/TXPO_0000067,,,,,,,,,,,,,,,,,,,,,,"PERK-eIF2a signaling (integrated pathway) is a subtype of PERK signaling (integrated pathway): Sequence of linked reactions, which has PERK-eIF2a signaling and gene regulation pathway.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000062|http://purl.obolibrary.org/obo/TXPO_0002755|http://purl.obolibrary.org/obo/TXPO_0001837|http://purl.obolibrary.org/obo/TXPO_0000696,,http://purl.obolibrary.org/obo/TXPO_0000285|http://purl.obolibrary.org/obo/TXPO_0002754,,,,,,,,,,,,,,,,TXPO:0000701,,,,,,,,,,,,,,,,,,,,,,PERK-eIF2a signaling (integrated pathway),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000703,"Expression of CHOP (DDIT3, GADD153)",,"Expression of CHOP (DDIT3, GADD153) is a subtype of gene expression: The process in which a gene sequence is converted into a mature  CHOP (DDIT3, GADD153) gene product or products (proteins or RNA).",false,,,http://purl.obolibrary.org/obo/GO_0010467,,,,,,,,,,,,,,,,,,,,"http://www.reactome.org/PathwayBrowser/#/R-HSA-380994&SEL=R-HSA-1791107&PATH=R-HSA-392499,R-HSA-381119,R-HSA-381042",,"Expression of CHOP (DDIT3, GADD153) is a subtype of gene expression: The process in which a gene sequence is converted into a mature  CHOP (DDIT3, GADD153) gene product or products (proteins or RNA).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000703,,,,,,,,,,,,,,,,,,,,,,"Expression of CHOP (DDIT3, GADD153)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000706,ATF4 gene expression by eIF2a,,"ATF4 gene expression by eIF2a is a subtype of gene expression: The process in which a gene sequence is converted into a mature ATF4 gene product or products (proteins or RNA) by eIF2a.|Phosphorylation of eIF2-alpha causes increased translation of ATF4 mRNA. In mouse the mRNA of ATF4 contains 2 upstream ORFs (uORFs) (Vattem and Wek 2004). The second uORF overlaps the ORF encoding ATF4 and thus prevents translation of ATF4. When eIF2-alpha is phosphorylated, translation of the uORFs is suppressed and translation of the ORF encoding ATF4 is increased.",false,,,http://purl.obolibrary.org/obo/GO_0010467,,,,,,,,,,,,,,,,,,,,http://www.reactome.org/PathwayBrowser/#/R-HSA-381119&SEL=R-HSA-381128&PATH=R-HSA-392499,,ATF4 gene expression by eIF2a is a subtype of gene expression: The process in which a gene sequence is converted into a mature ATF4 gene product or products (proteins or RNA) by eIF2a.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000706,,,,,,,,,,,,,,,,,,,,"Phosphorylation of eIF2-alpha causes increased translation of ATF4 mRNA. In mouse the mRNA of ATF4 contains 2 upstream ORFs (uORFs) (Vattem and Wek 2004). The second uORF overlaps the ORF encoding ATF4 and thus prevents translation of ATF4. When eIF2-alpha is phosphorylated, translation of the uORFs is suppressed and translation of the ORF encoding ATF4 is increased.",,ATF4 gene expression by eIF2a,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000707,ATF4 gene expression by eIF2a [ER stress],,"ATF4 gene expression by eIF2a is a subtype of gene expression: The process in which a gene sequence is converted into a mature ATF4 gene product or products (proteins or RNA) by eIF2a.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0003736|http://purl.obolibrary.org/obo/TXPO_0000706,,,,,,,,,,,,,,,,,,,,PMID:23334697|http://www.ncbi.nlm.nih.gov/pubmed/18426796|Reactome:R-HSA-381128,,"ATF4 gene expression by eIF2a is a subtype of gene expression: The process in which a gene sequence is converted into a mature ATF4 gene product or products (proteins or RNA) by eIF2a.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000829,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001907,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000698,,,,,,,,,,,TXPO:0000707,,,,,,,,,,,,,,,,,,,,,,ATF4 gene expression by eIF2a [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000709,expression of CCL2 [ER stress],,"Expression of CCL2 is a subtype of inflammatory cytokine gene expression: A process that convert a CCL2 (C-C Motif Chemokine Ligand 2) gene's sequenes into a mature gene prduct(s), i.e., (m)RNA, or protein.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0003736|http://purl.obolibrary.org/obo/TXPO_0000704,,,,,,,,,,,,,,,,,,,,,,"Expression of CCL2 is a subtype of inflammatory cytokine gene expression: A process that convert a CCL2 (C-C Motif Chemokine Ligand 2) gene's sequenes into a mature gene prduct(s), i.e., (m)RNA, or protein.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002766,,,,,,,,,,,TXPO:0000709,,,,,,,,,,,,,,,,,,,,,,expression of CCL2 [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000708,IGFBP1 activation [ER stress],,"IGFBP1 activation is a subtype of molecular activation: A process that changes the activity of the IGFBP1 (Insulin Like Growth Factor Binding Protein 1) to be higher.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0003736|http://purl.obolibrary.org/obo/TXPO_0000705,,,,,,,,,,,,,,,,,,,,PMID:16687408,,"IGFBP1 activation is a subtype of molecular activation: A process that changes the activity of the IGFBP1 (Insulin Like Growth Factor Binding Protein 1) to be higher.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001907,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000776,,,,,,,,,,,,,,,,,TXPO:0000708,,,,,,,,,,,,,,,,,,,,,,IGFBP1 activation [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100104,oxytocin,Pitocin|OXT|oxtocin|Ocytocin,A nonapeptide posterior pituitary hormone that causes UTERINE CONTRACTIONS and stimulates MILK EJECTION.,false,,,http://purl.obolibrary.org/obo/IMR_0100103,,,,,,,,,,,,,,,,,,,,MeSH:D010121,,A nonapeptide posterior pituitary hormone that causes UTERINE CONTRACTIONS and stimulates MILK EJECTION.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Pitocin|OXT|oxtocin|Ocytocin,,,,,IMR:0100104,,,,,,,,,,,,,,,,,,,,,,oxytocin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100709,BH3 subfamily,Bik family,,false,,,http://purl.obolibrary.org/obo/IMR_0100707,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Bik family,,,,,IMR:0100709,,,,,,,,,,,,,,,,,,,,,,BH3 subfamily,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004626,HULC (human) [hepatocarcinogenesis],hepatocellular carcinoma up-regulated long non-coding RNA,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_0004623,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:728655|PMID:30008815|PMID:25592151,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,hepatocellular carcinoma up-regulated long non-coding RNA,,,,,TXPO:0004626,,,,,,,,,,,,,,,,,,,,,,HULC (human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004627,Increasing PPARA level [hepatocarcinogenesis],,"Increasing PPARA level is a subtype of increasing quantity: A process that changes the amount of PPARA level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0004765|http://purl.obolibrary.org/obo/TXPO_0002340,,,,,,,,,,,,,,,,,,,,PMID:30008815|PMID:25592151,,"Increasing PPARA level is a subtype of increasing quantity: A process that changes the amount of PPARA level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004766|http://purl.obolibrary.org/obo/TXPO_0004767,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004400,,,,,,,,,,,TXPO:0004627,,,,,,,,,,,,,,,,,,,,,,Increasing PPARA level [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004621,HNF4A (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:3172|NCBI-Mouse-GeneID:15378|NCBI-Rat-GeneID:25735,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004621,,,,,,,,,,,,,,,,,,,,,,HNF4A (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004625,Increasing HULC level [hepatocarcinogenesis],,Increasing HULC level is a subtype of increasing quantity: A process that changes the amount of HULC level to be higher. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.,false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004624,,,,,,,,,,,,,,,,,,,,PMID:30008815|PMID:25592151,,Increasing HULC level is a subtype of increasing quantity: A process that changes the amount of HULC level to be higher. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004626,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004627,,,,,,,,,,,TXPO:0004625,,,,,,,,,,,,,,,,,,,,,,Increasing HULC level [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004629,Hedgehog signaling (primitive),,Hedgehog signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by Hedgehog.,false,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,,,Hedgehog signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by Hedgehog.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004628,,,,,,,,,,,,,,,,TXPO:0004629,,,,,,,,,,,,,,,,,,,,,,Hedgehog signaling (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004628,Hedgehog signal transduction pathway,,A series of molecular signals mediated by Hedgehog (HH).,false,,,http://purl.obolibrary.org/obo/TXPO_0000609,,,,,,,,,,,,,,,,,,,,,,A series of molecular signals mediated by Hedgehog (HH).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004628,,,,,,,,,,,,,,,,,,,,,,Hedgehog signal transduction pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004623,HULC,hepatocellular carcinoma up-regulated long non-coding RNA,,false,,,http://purl.obolibrary.org/obo/OGG_2100009606,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:728655,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,hepatocellular carcinoma up-regulated long non-coding RNA,,,,,TXPO:0004623,,,,,,,,,,,,,,,,,,,,,,HULC,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004624,Increasing HULC level,,Increasing HULC level is a subtype of increasing quantity: A process that changes the amount of HULC level to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing HULC level is a subtype of increasing quantity: A process that changes the amount of HULC level to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004623,,,,,,,,,,,,,,,,,,,TXPO:0004624,,,,,,,,,,,,,,,,,,,,,,Increasing HULC level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004622,HNF4A - inactive form (canonical) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0005063|http://purl.obolibrary.org/obo/TXPO_0005091,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:3172|NCBI-Mouse-GeneID:15378|NCBI-Rat-GeneID:25735|PMID:30008815,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0002355,,,,,,,,,,,,,,TXPO:0004622,,,,,,,,,,,,,,,,,,,,,,HNF4A - inactive form (canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004620,HNF4A inactivation,,HNF4A inactivation is a subtype of molecular inactivation: A process that  changes the activity of the HNF4A (hepatocyte nuclear factor 4 alpha) to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000021,,,,,,,,,,,,,,,,,,,,,,HNF4A inactivation is a subtype of molecular inactivation: A process that  changes the activity of the HNF4A (hepatocyte nuclear factor 4 alpha) to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004620,,,,,,,,,,,,,,,,,,,,,,HNF4A inactivation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_135814,benziodarone,cardivix|dilafurane,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Drug_Central:321|CAS:68-90-6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,cardivix|dilafurane,,,,,,,,,,,,,,,,,,,,,CHEBI:135814,,,,benziodarone,,CHEBI:135814,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0011133,eIF2-alpha,"translation initiation factor 2, subunit 1|Eukaryotic translation initiation factor 2 subunit 1|translation initiation factor 2 alpha subunit|Eukaryotic translation initiation factor 2 alpha subunit|EIF- 2alpha|EIF-2A|eIF-2-alpha",,false,,,http://purl.obolibrary.org/obo/IMR_0000913,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0011979,"translation initiation factor 2, subunit 1|Eukaryotic translation initiation factor 2 subunit 1|translation initiation factor 2 alpha subunit|Eukaryotic translation initiation factor 2 alpha subunit|EIF- 2alpha|EIF-2A|eIF-2-alpha",,,,,IMR:0011133,,,,,,,,,,,,,,,,,,,,,,eIF2-alpha,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000003558,IL2,,Other designations: T cell growth factor|aldesleukin|interleukin-2|involved in regulation of T-cell clonal expansion,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,TCGF|lymphokine|IL-2,,,,,,,,,,,,4,,,,,,MIM:147680|HGNC:6001|HPRD:00979,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,interleukin 2,,,4q26-q27,,,,,,,,,,,,,,,,"GO_0001933 (EC: IEA); GO_0002903 (EC: IDA, PMID:9184696); GO_0005125 (EC: IDA, PMID:10072077); GO_0005134 (EC: IDA, PMID:8262055); GO_0005134 (EC: TAS, PMID:3925347); GO_0005576 (EC: TAS); GO_0005615 (EC: TAS, PMID:6608729); GO_0006955 (EC: TAS, PMID:2342538); GO_0007155 (EC: TAS, PMID:10929056); GO_0007204 (EC: IEA); GO_0007205 (EC: IEA); GO_0007267 (EC: TAS, PMID:8476561); GO_0008083 (EC: TAS, PMID:8476561); GO_0008284 (EC: TAS, PMID:8476561); GO_0019209 (EC: TAS, PMID:8476561); GO_0030101 (EC: TAS, PMID:8476561); GO_0030217 (EC: TAS, PMID:8476561); GO_0030246 (EC: IEA); GO_0030307 (EC: TAS, PMID:8476561); GO_0030890 (EC: IDA, PMID:9184696); GO_0031851 (EC: IEA); GO_0032729 (EC: IEA); GO_0032740 (EC: IDA, PMID:16482511); GO_0034105 (EC: IC, PMID:16482511); GO_0042104 (EC: IDA, PMID:10072077); GO_0042523 (EC: IDA, PMID:19088061); GO_0043066 (EC: TAS, PMID:8476561); GO_0043208 (EC: IEA); GO_0045591 (EC: IEA); GO_0045822 (EC: IEA); GO_0045944 (EC: IEA); GO_0046013 (EC: IEA); GO_0048304 (EC: IEA); GO_0050672 (EC: IEA); GO_0050728 (EC: IEA); GO_0050729 (EC: IC, PMID:16482511); GO_0051024 (EC: IEA); GO_0060999 (EC: IEA); GO_0097192 (EC: IEA)",,,,,,,,,PMID:1316918; 1346976; 1394441; 1396583; 1510960; 1527859; 1631562; 1830926; 1832084; 1888898; 1905933; 1993646; 2052609; 2109157; 2303462; 2315327; 2342538; 2552026; 2793860; 2842093; 3260003; 3262520; 3264184; 3265909; 3491296; 3500515; 3877307; 3925347; 6201860; 6306584; 6312994; 6318318; 6321163; 6324170; 6330695; 6333684; 6403867; 6608729; 7523014; 7529123; 7589092; 7591871; 7642615; 7695626; 7697734; 7722480; 7734194; 7957556; 7963560; 7983746; 7999066; 8049354; 8095514; 8102828; 8118889; 8183373; 8207793; 8262055; 8402910; 8476561; 8493579; 8598486; 8626603; 8706326; 8757311; 8765022; 8769094; 8824916; 9007200; 9045614; 9045910; 9065434; 9184696; 9187267; 9209269; 9226175; 9311917; 9334723; 9516115; 9517986; 9534962; 9712080; 9811677; 10072077; 10196292; 10201969; 10207088; 10393966; 10570282; 10618429; 10662798; 10825200; 10929056; 10985305; 11035066; 11093171; 11114167; 11254713; 11261789; 11315919; 11350667; 11354638; 11385624; 11418623; 11525806; 11544437; 11689614; 11714800; 11743717; 11826762; 11841848; 11911478; 11914641; 11940709; 11981437; 12055219; 12072494; 12089714; 12105273; 12121273; 12144536; 12162871; 12171778; 12176041; 12193716; 12200381; 12354082; 12354383; 12358847; 12392859; 12393431; 12409183; 12456594; 12464620; 12477932; 12480696; 12486027; 12504009; 12536241; 12542496; 12557940; 12582206; 12604780; 12605694; 12610796; 12633940; 12646760; 12687247; 12717025; 12727482; 12727483; 12759392; 12808095; 12816983; 12826155; 12826231; 12851716; 12864971; 12884288; 12944981; 12960316; 14499500; 14522096; 14566095; 14607923; 14607929; 14675394; 14680494; 14687725; 14688528; 14707112; 14715519; 14722108; 14975604; 15001467; 15005726; 15057902; 15100259; 15104679; 15120188; 15152368; 15170937; 15175153; 15187164; 15191519; 15238074; 15247007; 15259063; 15271977; 15339934; 15347678; 15353479; 15361128; 15458467; 15489334; 15514847; 15539078; 15562014; 15563472; 15638726; 15654770; 15676209; 15686714; 15710467; 15728489; 15733644; 15749888; 15814282; 15841182; 15841456; 15895884; 15904474; 15910743; 15951664; 15964333; 15976176; 16060678; 16091861; 16100774; 16125242; 16132828; 16148026; 16164695; 16169852; 16293250; 16293754; 16323127; 16333313; 16354571; 16361891; 16389181; 16393999; 16477002; 16478922; 16482511; 16518704; 16567828; 16573560; 16584887; 16606671; 16621991; 16678358; 16690518; 16783532; 16805135; 16824159; 16864905; 16864906; 16885196; 16889932; 16920920; 16938461; 16961803; 16966412; 16984280; 17002904; 17052299; 17077180; 17097050; 17110377; 17115417; 17142786; 17152005; 17175263; 17177332; 17203290; 17207965; 17215524; 17222831; 17237447; 17257312; 17327408; 17332243; 17336597; 17337059; 17355643; 17396252; 17439892; 17444587; 17457216; 17460561; 17537734; 17541281; 17558408; 17571248; 17604883; 17627763; 17651815; 17703412; 17714919; 17715020; 17728221; 17761346; 17889143; 17900510; 17913045; 17949552; 17956522; 17981641; 17981806; 17985312; 17994425; 18021367; 18021981; 18023521; 18073500; 18077789; 18095604; 18097023; 18165865; 18174230; 18192685; 18207244; 18209044; 18239807; 18271063; 18275276; 18299274; 18309287; 18311140; 18324310; 18331736; 18348982; 18418394; 18423386; 18430737; 18481948; 18496418; 18522869; 18539368; 18543227; 18566561; 18570590; 18574615; 18576303; 18593762; 18614637; 18624934; 18628433; 18632425; 18633131; 18650128; 18663124; 18670216; 18676680; 18676770; 18714042; 18755820; 18761558; 18768844; 18769450; 18773331; 18776133; 18780166; 18780949; 18794598; 18805825; 18818748; 18932275; 18942754; 18972297; 18991615; 19013323; 19019335; 19058298; 19058987; 19073967; 19088061; 19099187; 19105930; 19117745; 19126646; 19135418; 19141488; 19170196; 19200845; 19201773; 19234188; 19250279; 19258923; 19275586; 19279357; 19284443; 19302705; 19332120; 19339796; 19351491; 19364969; 19375249; 19404967; 19406689; 19408823; 19414780; 19427348; 19430480; 19450160; 19453859; 19470040; 19471255; 19494280; 19495883; 19497711; 19502081; 19505916; 19522766; 19523143; 19527514; 19543959; 19573080; 19594368; 19625176; 19638314; 19648290; 19675167; 19683555; 19692168; 19693089; 19693092; 19707465; 19710466; 19718824; 19733878; 19773279; 19773451; 19787624; 19832038; 19860911; 19889958; 19892918; 19913121; 19925666; 19938203; 19951419; 19965651; 20012528; 20027321; 20049409; 20060205; 20072139; 20082482; 20100932; 20112382; 20129796; 20145925; 20177758; 20179739; 20182632; 20184734; 20190192; 20190752; 20193755; 20203524; 20213229; 20219786; 20221423; 20222161; 20225066; 20227890; 20233754; 20236616; 20331378; 20378664; 20418110; 20424473; 20438365; 20444755; 20452482; 20453000; 20453842; 20465575; 20484443; 20485444; 20498205; 20503287; 20535218; 20542085; 20544350; 20553587; 20557936; 20561440; 20562654; 20568250; 20594918; 20595916; 20596022; 20599261; 20603050; 20626741; 20628086; 20671116; 20673868; 20679529; 20716621; 20802378; 20811626; 20814620; 20839488; 20870937; 20880293; 20883322; 20926141; 20942272; 20960273; 20962850; 21035858; 21037099; 21061265; 21072155; 21085635; 21086908; 21112091; 21162873; 21167738; 21176845; 21179414; 21198755; 21258967; 21269573; 21282039; 21288140; 21292764; 21297633; 21304239; 21317396; 21372257; 21375519; 21383498; 21394196; 21423578; 21425124; 21425313; 21482826; 21531896; 21532597; 21620040; 21640045; 21642596; 21648020; 21685912; 21688385; 21711552; 21819478; 21829393; 21839273; 21876034; 21889323; 21890374; 21905023; 21905024; 21925225; 21976679; 21978000; 21984699; 22036096; 22040441; 22062588; 22077623; 22111667; 22112982; 22174157; 22242968; 22246628; 22281835; 22313865; 22337875; 22434682; 22461703; 22467658; 22472080; 22474330; 22479496; 22504653; 22524835; 22554193; 22585398; 22609631; 22623329; 22634617; 22645657; 22732586; 22736314; 22791129; 22797138; 22819245; 22891215; 22905203; 22910795; 22932225; 22984628; 23009887; 23019580; 23058031; 23103669; 23104097; 23128233; 23129528; 23172754; 23185455; 23192659; 23217119; 23265966; 23272100; 23278180; 23303246; 23317891; 23319613; 23328843; 23349093; 23380740; 23414538; 23418630; 23451206; 23487197; 23541403; 23586039; 23640893; 23645042; 23665382; 23676143; 23677467; 23724099; 23806696; 23817571; 23857000; 24019486; 24098138,,,,,,,,,,,,,,,OGG:3000003558,,,,,,,interleukin 2,,,,,,,,,,,,,Other designations: T cell growth factor|aldesleukin|interleukin-2|involved in regulation of T-cell clonal expansion,,IL2,,,,,,,,,,,,,,,,,,,,,,,3558,,,,,,,,9606,,,,,,,,,,,,,,,,,,,IL2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000003551,IKBKB,,Other designations: I-kappa-B kinase 2|I-kappa-B-kinase beta|IKK-B|inhibitor of nuclear factor kappa-B kinase subunit beta|nuclear factor NF-kappa-B inhibitor kinase beta,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,IKKB|IKK2|NFKBIKB|IKK-beta|IMD15,,,,,,,,,,,,8,,,,,,HGNC:5960|HPRD:04462|Vega:OTTHUMG00000164092|Ensembl:ENSG00000104365|MIM:603258,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta",,,8p11.2,,,,,,,,,,,,,,,,"GO_0001782 (EC: IEA); GO_0002224 (EC: TAS); GO_0002755 (EC: TAS); GO_0002756 (EC: TAS); GO_0004672 (EC: IDA); GO_0004674 (EC: TAS); GO_0005515 (EC: IPI, PMID:10521409); GO_0005524 (EC: IEA); GO_0005634 (EC: IEA); GO_0005737 (EC: IDA); GO_0005829 (EC: TAS); GO_0006468 (EC: IDA); GO_0006468 (EC: NAS, PMID:9346484); GO_0006954 (EC: TAS, PMID:18626576); GO_0007249 (EC: TAS, PMID:18626576); GO_0007252 (EC: TAS, PMID:18626576); GO_0008384 (EC: TAS, PMID:18626576); GO_0008385 (EC: TAS, PMID:18626576); GO_0009615 (EC: TAS, PMID:18626576); GO_0009898 (EC: ISS); GO_0010765 (EC: IEA); GO_0019901 (EC: IPI, PMID:12492477); GO_0032481 (EC: TAS); GO_0034134 (EC: TAS); GO_0034138 (EC: TAS); GO_0034142 (EC: TAS); GO_0034146 (EC: TAS); GO_0034162 (EC: TAS); GO_0034166 (EC: TAS); GO_0035631 (EC: ISS); GO_0035666 (EC: TAS); GO_0035872 (EC: TAS); GO_0038095 (EC: TAS); GO_0038123 (EC: TAS); GO_0038124 (EC: TAS); GO_0042501 (EC: IDA); GO_0042803 (EC: IDA); GO_0043066 (EC: TAS); GO_0043123 (EC: TAS); GO_0045087 (EC: TAS, PMID:18626576); GO_0045121 (EC: IEA); GO_0045893 (EC: NAS, PMID:9346484); GO_0045944 (EC: IDA); GO_0046982 (EC: IDA); GO_0048011 (EC: TAS); GO_0050852 (EC: TAS); GO_0051092 (EC: IDA, PMID:15790681); GO_0051092 (EC: TAS, PMID:18626576); GO_0070423 (EC: TAS); GO_0071356 (EC: IDA); GO_2001259 (EC: IEA)",,,,,,,,,PMID:8601309; 8657102; 9214631; 9252186; 9346241; 9346484; 9346485; 9520446; 9632806; 9689078; 9721103; 9744859; 9751059; 9751060; 9763654; 9813230; 9819420; 9878263; 9891086; 9914500; 10022904; 10195894; 10356400; 10469655; 10485711; 10497169; 10521409; 10713178; 10722755; 10723127; 10733566; 10755617; 10779355; 10783893; 10807933; 10848580; 10962033; 10968790; 10980203; 11002417; 11057907; 11080499; 11096118; 11113112; 11120819; 11158290; 11278268; 11359906; 11429546; 11460167; 11527961; 11585904; 11594795; 11606564; 11777949; 11815618; 11821416; 11830587; 11839743; 11864612; 11945026; 11954826; 11959143; 11971985; 11976329; 12054687; 12070292; 12133833; 12210728; 12244103; 12351658; 12393548; 12411322; 12459277; 12477932; 12482991; 12486103; 12486112; 12492477; 12547194; 12589056; 12612076; 12637324; 12645577; 12657630; 12707358; 12709429; 12842894; 12890679; 12943667; 14514672; 14560022; 14585846; 14585847; 14585990; 14597638; 14625285; 14654787; 14702039; 14715628; 14743216; 14990741; 15084260; 15125834; 15128824; 15140882; 15184390; 15217951; 15218148; 15226300; 15254232; 15276183; 15319427; 15383283; 15389287; 15456791; 15489227; 15489334; 15492226; 15494311; 15564333; 15601829; 15749833; 15761153; 15790681; 15802604; 15808510; 15837793; 15856005; 15856023; 15880043; 15951441; 16024783; 16046471; 16051665; 16082226; 16123045; 16126728; 16135815; 16177806; 16207722; 16267042; 16280329; 16286467; 16291755; 16319058; 16344560; 16365431; 16393995; 16424386; 16497931; 16547522; 16583354; 16603398; 16611882; 16728640; 16840786; 16906147; 16920630; 16938294; 16966325; 16982623; 16989899; 16997282; 16998237; 17000764; 17016640; 17047224; 17079871; 17114296; 17145747; 17182689; 17213322; 17237423; 17244613; 17287217; 17363905; 17363973; 17419715; 17446166; 17466952; 17568778; 17616684; 17684021; 17693255; 17703412; 17891179; 17939994; 17947699; 17962807; 17977820; 17997719; 18029348; 18037881; 18163512; 18180283; 18207244; 18260825; 18266324; 18266467; 18308615; 18316610; 18362886; 18408758; 18411264; 18434448; 18456659; 18490760; 18571841; 18583959; 18600306; 18626576; 18636537; 18657515; 18692471; 18949366; 18952604; 18957422; 18981174; 18990758; 19050262; 19104039; 19109741; 19141566; 19150425; 19196987; 19202066; 19243472; 19258923; 19270264; 19365808; 19422324; 19453261; 19488402; 19526344; 19573080; 19591457; 19594441; 19656241; 19675099; 19716809; 19728335; 19730683; 19773279; 19786027; 19815509; 19818716; 19820708; 19850743; 20005846; 20007573; 20026656; 20051109; 20056178; 20068038; 20098747; 20145131; 20152798; 20164171; 20167598; 20176108; 20331378; 20347815; 20368414; 20371626; 20410276; 20421348; 20434986; 20448038; 20448286; 20449947; 20465575; 20503287; 20529849; 20568250; 20600852; 20614026; 20627395; 20657549; 20693425; 20797629; 20803413; 20856938; 20925653; 20932476; 20933503; 20977779; 21029719; 21048031; 21139048; 21204785; 21220427; 21248029; 21317297; 21331078; 21344388; 21390216; 21399639; 21474709; 21482671; 21575199; 21606193; 21606198; 21670849; 21703539; 21724995; 21784860; 21798539; 21803029; 21810613; 21811235; 21903422; 21911292; 21985298; 21987722; 21988832; 21993219; 22022389; 22099304; 22262057; 22331067; 22511786; 22605335; 22637744; 22766331; 22824620; 22848663; 22863883; 22891964; 22955948; 22990857; 23007157; 23016877; 23017601; 23032264; 23069812; 23090968; 23108365; 23123196; 23178494; 23349803; 23386606; 23453969; 23589370; 23636414; 23732909; 23743204; 23776175; 23776406; 23792959; 23817200; 23872070; 23974204; 23986494; 24127568; 24240172; 24266532; 24369075,,,,,,,,,,,,,,,OGG:3000003551,,,,,,,"inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta",,,,,,,,,,,,,Other designations: I-kappa-B kinase 2|I-kappa-B-kinase beta|IKK-B|inhibitor of nuclear factor kappa-B kinase subunit beta|nuclear factor NF-kappa-B inhibitor kinase beta,,IKBKB,,,,,,,,,,,,,,,,,,,,,,,3551,,,,,,,,9606,,,,,,,,,,,,,,,,,,,IKBKB,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000003552,IL1A,,Other designations: IL-1 alpha|hematopoietin-1|interleukin-1 alpha|preinterleukin 1 alpha|pro-interleukin-1-alpha,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,IL1-ALPHA|IL1F1|IL1|IL-1A,,,,,,,,,,,,2,,,,,,HGNC:5991|MIM:147760|HPRD:00988,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"interleukin 1, alpha",,,2q14,,,,,,,,,,,,,,,,"GO_0001660 (EC: IEA); GO_0005125 (EC: IMP, PMID: 2989698); GO_0005149 (EC: IEA); GO_0005507 (EC: IDA, PMID: 12746488); GO_0005515 (EC: IPI, PMID: 12746488); GO_0005576 (EC: TAS); GO_0005615 (EC: IDA, PMID: 12746488); GO_0005615 (EC: IMP, PMID: 3493774); GO_0005829 (EC: IDA, PMID: 12746488); GO_0006915 (EC: TAS, PMID: 1924307); GO_0006954 (EC: TAS, PMID: 6209582); GO_0006955 (EC: IEA); GO_0008283 (EC: TAS, PMID: 6209582); GO_0008285 (EC: IDA, PMID: 3493774); GO_0010575 (EC: ISS); GO_0019221 (EC: IMP, PMID: 2989698); GO_0034605 (EC: IDA, PMID: 12746488); GO_0035234 (EC: IEA); GO_0045086 (EC: IMP, PMID: 2989698); GO_0045766 (EC: ISS); GO_0045840 (EC: IMP, PMID: 2989698); GO_0045944 (EC: IEA); GO_0046688 (EC: IDA, PMID: 12746488); GO_0050715 (EC: IDA, PMID: 1739124); GO_0051781 (EC: IEA); GO_0097192 (EC: IEA); GO_2001240 (EC: TAS, PMID: 10748004)",,,,,,,,,PMID: 1548758; 1584804; 1675504; 1739124; 1905933; 1924307; 1993354; 2346741; 2536171; 2635664; 2783369; 2946959; 2989698; 2994016; 3281727; 3485152; 3486405; 3493774; 6209582; 7494249; 7499244; 7511078; 7526541; 7561697; 7566121; 7695626; 7706435; 7815507; 7818827; 7857652; 7878046; 8188271; 8346241; 8370968; 8436814; 8458986; 8621446; 8764000; 8892361; 8938574; 9108403; 9169134; 9185130; 9225992; 9658081; 9820540; 10441334; 10512743; 10625660; 10744718; 10748004; 10854325; 10860666; 10861041; 10953177; 10998424; 11065142; 11079552; 11093146; 11138328; 11145356; 11145836; 11233912; 11241561; 11264025; 11278614; 11350500; 11350506; 11423389; 11427627; 11436125; 11448121; 11453239; 11466363; 11554782; 11574262; 11640949; 11669478; 11703512; 11737511; 11774556; 11774564; 11777547; 11784248; 11790645; 11840488; 11858158; 11895290; 11895546; 11911995; 11921766; 11930657; 11940570; 11956022; 11991668; 11991722; 12028539; 12034804; 12037600; 12047332; 12051868; 12052540; 12052541; 12070246; 12082592; 12089333; 12100571; 12101079; 12102486; 12115161; 12115182; 12140751; 12149413; 12161036; 12164325; 12195069; 12209090; 12210881; 12212456; 12218254; 12220547; 12242547; 12362317; 12370389; 12390476; 12404162; 12425801; 12445219; 12445604; 12453471; 12477932; 12519748; 12528118; 12528119; 12530978; 12558814; 12558933; 12562360; 12598547; 12613995; 12622850; 12626603; 12631337; 12641660; 12651617; 12667716; 12673844; 12702109; 12710950; 12714264; 12729191; 12730545; 12737276; 12742380; 12746420; 12746488; 12749050; 12752101; 12752325; 12759172; 12782964; 12794386; 12801479; 12824054; 12869004; 12874528; 12890860; 12899665; 12901853; 12913118; 12928052; 12928381; 12930304; 12930389; 12931024; 12946945; 12947160; 12974682; 13679381; 14514232; 14533660; 14566095; 14584862; 14612453; 14633625; 14634838; 14639688; 14644395; 14656692; 14664464; 14672899; 14673470; 14674121; 14688369; 14693849; 14705223; 14735144; 14974822; 14983027; 14984963; 14986816; 14997019; 15007345; 15009111; 15036245; 15039285; 15050696; 15068111; 15082121; 15117956; 15130917; 15170937; 15190266; 15201366; 15219382; 15220553; 15238767; 15248873; 15270852; 15308963; 15338333; 15341923; 15351436; 15361128; 15377701; 15381245; 15465625; 15468358; 15476179; 15481145; 15489227; 15489334; 15514971; 15551344; 15561982; 15562658; 15562910; 15563458; 15566952; 15581980; 15587751; 15592292; 15633328; 15638425; 15679580; 15679582; 15694997; 15723707; 15726267; 15727567; 15732864; 15733644; 15737206; 15745939; 15777329; 15797878; 15830637; 15836820; 15854776; 15931231; 15951664; 15954918; 15974847; 15986200; 16021081; 16030091; 16046471; 16078996; 16100774; 16101131; 16106254; 16115908; 16155691; 16159520; 16160188; 16206345; 16226351; 16230423; 16246569; 16268484; 16291395; 16304445; 16317381; 16318580; 16361815; 16369899; 16375755; 16378839; 16384981; 16389181; 16403098; 16410064; 16410066; 16411061; 16428739; 16433908; 16464738; 16478776; 16504015; 16508980; 16510430; 16517748; 16546408; 16564702; 16564703; 16567828; 16573560; 16619041; 16636934; 16684536; 16702372; 16708852; 16719905; 16720107; 16733901; 16788102; 16792821; 16814297; 16842617; 16856121; 16879223; 16885196; 16888077; 16900886; 16905534; 16907768; 16911569; 16918024; 16930778; 16931944; 16934308; 16938461; 16945028; 16961803; 16965524; 16965825; 16971486; 16978691; 17002905; 17012236; 17034724; 17083033; 17138334; 17140155; 17141301; 17149369; 17179726; 17197697; 17205326; 17214636; 17244613; 17257312; 17290104; 17293495; 17309781; 17331078; 17335370; 17335371; 17335373; 17348886; 17353161; 17355643; 17360358; 17369174; 17371964; 17378887; 17388919; 17391495; 17436000; 17440718; 17444587; 17444864; 17448042; 17449468; 17458495; 17460270; 17471097; 17473736; 17477815; 17492470; 17500214; 17507369; 17532232; 17541168; 17549071; 17573384; 17575917; 17584583; 17596594; 17610660; 17621543; 17622713; 17627763; 17638785; 17703412; 17711477; 17716546; 17717316; 17823082; 17889143; 17907045; 17919610; 17926179; 17932347; 17941080; 17948066; 17949817; 17954336; 17960403; 17964974; 17978470; 17986158; 17997719; 18024394; 18038187; 18052703; 18063673; 18085494; 18086816; 18157711; 18158110; 18166103; 18199150; 18211631; 18271063; 18278133; 18284424; 18288454; 18292602; 18306451; 18315433; 18321309; 18322311; 18329368; 18336824; 18361934; 18393655; 18395750; 18416755; 18416756; 18441098; 18469698; 18484169; 18484691; 18496214; 18498295; 18510611; 18576312; 18583979; 18587204; 18607773; 18615092; 18615110; 18624935; 18628242; 18628526; 18631256; 18632425; 18633131; 18666137; 18673406; 18676404; 18676680; 18676870; 18702109; 18708672; 18709454; 18714935; 18716798; 18717723; 18723088; 18760325; 18763028; 18773331; 18787502; 18815552; 18818748; 18821666; 18832862; 18834321; 18838388; 18941541; 18952231; 18971305; 18974840; 18974842; 18976975; 19012493; 19013788; 19019335; 19026558; 19028820; 19035492; 19042953; 19046297; 19053923; 19066720; 19074885; 19076825; 19086955; 19088500; 19099590; 19110536; 19117745; 19131662; 19141488; 19141860; 19155622; 19158434; 19170196; 19180518; 19180798; 19184295; 19188531; 19191034; 19194673; 19204921; 19225544; 19240061; 19247692; 19247983; 19258923; 19263529; 19267917; 19279357; 19280228; 19290009; 19294239; 19307598; 19332120; 19336370; 19336475; 19348329; 19408823; 19431193; 19435817; 19453261; 19470040; 19479237; 19497711; 19505916; 19527514; 19546559; 19559392; 19563289; 19573080; 19594368; 19625176; 19648252; 19658300; 19661089; 19671938; 19680808; 19683555; 19684156; 19692168; 19701653; 19702713; 19708438; 19729601; 19733643; 19738620; 19742166; 19764937; 19773279; 19773451; 19775068; 19786079; 19789190; 19792847; 19805069; 19811432; 19820020; 19844779; 19860911; 19884766; 19889475; 19892918; 19913121; 19917630; 19926874; 19934104; 19948975; 20005085; 20011938; 20027454; 20056178; 20059417; 20059631; 20065999; 20070880; 20080142; 20113359; 20113413; 20116409; 20127018; 20131253; 20140262; 20141484; 20157068; 20169140; 20173430; 20178882; 20182449; 20192980; 20196868; 20200332; 20207250; 20213229; 20217044; 20220089; 20227257; 20237496; 20299682; 20335539; 20347268; 20353565; 20371868; 20400062; 20413850; 20418110; 20427258; 20445556; 20452482; 20453000; 20459687; 20472930; 20490394; 20490891; 20495422; 20503287; 20534741; 20536507; 20536609; 20551628; 20561568; 20565898; 20568250; 20574532; 20594066; 20595916; 20602615; 20603037; 20603050; 20619343; 20628086; 20630038; 20673868; 20677014; 20725607; 20800603; 20811626; 20844546; 20847078; 20848459; 20889944; 20934174; 20940514; 20942594; 20959405; 20961668; 21035110; 21037510; 21048327; 21054222; 21070631; 21086908; 21107309; 21133705; 21154765; 21196890; 21205020; 21235388; 21270123; 21279638; 21311438; 21336718; 21385326; 21393239; 21394384; 21449691; 21509504; 21518761; 21620624; 21621860; 21682548; 21712624; 21768915; 21795706; 21816944; 21847358; 21871094; 21968104; 22083707; 22092925; 22124068; 22143786; 22151432; 22153345; 22177239; 22197408; 22211888; 22216303; 22234841; 22282663; 22285242; 22312160; 22344672; 22348697; 22364598; 22417897; 22513697; 22582837; 22633328; 22675954; 22678894; 22732089; 22795294; 22805136; 22868802; 22879895; 22894561; 22949675; 23018032; 23052182; 23076369; 23100272; 23159404; 23203659; 23216199; 23241110; 23271701; 23289806; 23322030; 23349093; 23395675; 23454256; 23509928; 23527710; 23542780; 23554905; 23592003; 23639700; 23645090; 23723976; 23747396; 23846687; 23900673; 23927441; 24060296; 24062309; 24103372; 24146121; 24265545; 24273934; 24275344; 24313836,,,,,,,,,,,,,,,OGG:3000003552,,,,,,,"interleukin 1, alpha",,,,,,,,,,,,,Other designations: IL-1 alpha|hematopoietin-1|interleukin-1 alpha|preinterleukin 1 alpha|pro-interleukin-1-alpha,,IL1A,,,,,,,,,,,,,,,,,,,,,,,3552,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,IL1A,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000003553,IL1B,,Other designations: IL-1 beta|catabolin|interleukin-1 beta|preinterleukin 1 beta|pro-interleukin-1-beta,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,IL1-BETA|IL-1|IL1F2,,,,,,,,,,,,2,,,,,,MIM:147720|HGNC:5992|Vega:OTTHUMG00000131344|HPRD:00985|Ensembl:ENSG00000125538,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"interleukin 1, beta",,,2q14,,,,,,,,,,,,,,,,"GO_0000165 (EC: IMP); GO_0000187 (EC: IDA, PMID: 10748004); GO_0001660 (EC: IEA); GO_0001934 (EC: IDA, PMID: 10748004); GO_0001934 (EC: NAS, PMID: 16477012); GO_0002711 (EC: IC, PMID: 1919436); GO_0005125 (EC: IDA, PMID: 1919436); GO_0005125 (EC: IMP, PMID: 2989698); GO_0005149 (EC: NAS, PMID: 1919436); GO_0005576 (EC: IDA); GO_0005576 (EC: NAS, PMID: 1919436); GO_0005576 (EC: TAS); GO_0005615 (EC: IDA, PMID: 12483741); GO_0005615 (EC: IMP, PMID: 3493774); GO_0005829 (EC: TAS); GO_0006915 (EC: TAS, PMID: 9218611); GO_0006954 (EC: IDA, PMID: 10748004); GO_0006954 (EC: NAS, PMID: 1919436); GO_0006955 (EC: IEA); GO_0007165 (EC: TAS, PMID: 10786823); GO_0007267 (EC: TAS, PMID: 2989698); GO_0007566 (EC: TAS, PMID: 16720713); GO_0008285 (EC: IDA, PMID: 3493774); GO_0009743 (EC: IEA); GO_0010575 (EC: IDA, PMID: 12958148); GO_0010575 (EC: ISS); GO_0010829 (EC: ISS, PMID: 16865359); GO_0014805 (EC: NAS, PMID: 16477012); GO_0019221 (EC: IDA, PMID: 10748004); GO_0019904 (EC: IPI, PMID: 16575408); GO_0030141 (EC: IEA); GO_0030213 (EC: IDA, PMID: 15100360); GO_0030593 (EC: IEA); GO_0030730 (EC: IDA, PMID: 19032770); GO_0030949 (EC: IC, PMID: 12958148); GO_0031622 (EC: ISS); GO_0031663 (EC: IDA); GO_0032308 (EC: ISS); GO_0032611 (EC: IEA); GO_0032725 (EC: IDA); GO_0032729 (EC: IDA); GO_0032755 (EC: TAS, PMID: 16865359); GO_0032757 (EC: IDA, PMID: 19524870); GO_0033129 (EC: NAS); GO_0033198 (EC: IEA); GO_0034116 (EC: IDA, PMID: 15100360); GO_0034116 (EC: NAS, PMID: 19281832); GO_0035066 (EC: NAS); GO_0035234 (EC: IEA); GO_0035505 (EC: IDA, PMID: 18390750); GO_0035690 (EC: IDA, PMID: 19158679); GO_0042102 (EC: IDA, PMID: 1919436); GO_0042346 (EC: IDA, PMID: 18390750); GO_0043122 (EC: IDA, PMID: 10748004); GO_0043123 (EC: IEA); GO_0043407 (EC: ISS, PMID: 16865359); GO_0043491 (EC: IMP); GO_0045080 (EC: IEA); GO_0045086 (EC: IMP, PMID: 2989698); GO_0045410 (EC: IEA); GO_0045429 (EC: IDA, PMID: 8383325); GO_0045766 (EC: ISS); GO_0045833 (EC: ISS, PMID: 16865359); GO_0045840 (EC: IMP, PMID: 2989698); GO_0045893 (EC: IDA, PMID: 15100360); GO_0045944 (EC: IEA); GO_0046330 (EC: IEA); GO_0046627 (EC: ISS, PMID: 16865359); GO_0046827 (EC: NAS, PMID: 19281832); GO_0050796 (EC: IDA, PMID: 8383325); GO_0050995 (EC: IDA, PMID: 19032770); GO_0050996 (EC: ISS, PMID: 16865359); GO_0051044 (EC: IDA, PMID: 18373975); GO_0051091 (EC: IDA, PMID: 10748004); GO_0051092 (EC: IDA, PMID: 10383454); GO_0051781 (EC: IEA); GO_0060355 (EC: NAS, PMID: 19281832); GO_0060559 (EC: IDA, PMID: 16720713); GO_0070164 (EC: ISS, PMID: 16865359); GO_0070487 (EC: IDA, PMID: 15100360); GO_0071260 (EC: IEP, PMID: 19593445); GO_0071310 (EC: IDA, PMID: 19158679); GO_0071407 (EC: IDA); GO_0071639 (EC: IDA, PMID: 19524870); GO_0097192 (EC: IEA); GO_2001240 (EC: IDA, PMID: 10748004)",,,,,,,,,PMID: 1548758; 1753956; 1835838; 1837236; 1905933; 1907279; 1918997; 1919001; 1919436; 1993354; 2001363; 2137098; 2372550; 2466831; 2536171; 2585509; 2602367; 2635664; 2898301; 2946959; 2954882; 2989698; 3259176; 3264123; 3281727; 3490654; 3493774; 6083565; 6209582; 7494249; 7511078; 7526541; 7561697; 7642516; 7706435; 7797510; 7815507; 7818827; 7878046; 7981229; 8188271; 8383325; 8432529; 8537091; 8663297; 8764000; 8852605; 8869030; 8892361; 8939574; 9062193; 9108403; 9169134; 9185130; 9218611; 9225992; 9230816; 9288832; 9378998; 9658081; 9714181; 9820540; 10339575; 10358063; 10383454; 10438928; 10512743; 10625660; 10744718; 10746728; 10748004; 10756100; 10779559; 10786823; 10854325; 10860666; 10964543; 11023482; 11051551; 11057907; 11076651; 11079552; 11083263; 11093146; 11127488; 11138328; 11145836; 11171832; 11211945; 11226333; 11233912; 11238007; 11241561; 11260714; 11264025; 11278614; 11350500; 11350506; 11380940; 11422336; 11423389; 11427627; 11448121; 11466363; 11476790; 11481169; 11498264; 11500085; 11506478; 11527622; 11531943; 11574262; 11578018; 11579484; 11600466; 11606496; 11640949; 11641511; 11665666; 11669478; 11686217; 11686480; 11703512; 11704656; 11737511; 11751881; 11751921; 11756575; 11762793; 11770040; 11774564; 11777965; 11784248; 11790645; 11801594; 11806247; 11838837; 11840488; 11847219; 11849463; 11851889; 11853544; 11857060; 11858158; 11858187; 11868623; 11876744; 11895290; 11896542; 11898000; 11920321; 11921766; 11930657; 11950481; 11955925; 11958432; 11981835; 11991722; 12009575; 12021045; 12028539; 12031914; 12034804; 12038885; 12039524; 12042033; 12044341; 12050157; 12050395; 12052540; 12052541; 12067976; 12070246; 12077278; 12082592; 12089333; 12093792; 12095061; 12100571; 12101072; 12102486; 12105837; 12114904; 12115161; 12115182; 12117921; 12117953; 12117969; 12121221; 12121679; 12133437; 12133438; 12133467; 12140751; 12149413; 12161036; 12161099; 12163271; 12164325; 12165808; 12184914; 12191486; 12193665; 12195069; 12210881; 12212456; 12215823; 12220547; 12231216; 12235117; 12239970; 12297725; 12356774; 12362317; 12370389; 12377625; 12385002; 12390476; 12391274; 12418458; 12431777; 12433284; 12441323; 12445219; 12445604; 12454835; 12468823; 12472674; 12475255; 12477932; 12482999; 12483741; 12493411; 12500190; 12519748; 12525884; 12529421; 12530978; 12533683; 12551827; 12558933; 12562360; 12568735; 12572877; 12574335; 12578333; 12593203; 12593899; 12595908; 12598547; 12606524; 12606591; 12615834; 12622850; 12626603; 12631070; 12637574; 12637896; 12651071; 12651617; 12667023; 12667656; 12668157; 12673844; 12694213; 12699881; 12700687; 12702109; 12705485; 12714264; 12718576; 12718598; 12718604; 12722027; 12725322; 12726991; 12727794; 12729191; 12730545; 12730860; 12743452; 12744771; 12746420; 12746914; 12749050; 12751042; 12752101; 12756345; 12761889; 12775358; 12788304; 12790892; 12795791; 12801479; 12801886; 12802423; 12807444; 12824054; 12828754; 12837173; 12842905; 12854083; 12860389; 12869004; 12874528; 12881225; 12890860; 12891537; 12899665; 12901853; 12913327; 12928052; 12930389; 12945076; 12958148; 12958619; 12965265; 12970400; 12974682; 13129651; 13679820; 14510824; 14512722; 14514232; 14515062; 14521725; 14522096; 14523823; 14527933; 14533660; 14563376; 14566095; 14566840; 14582815; 14584052; 14584862; 14585879; 14617515; 14632761; 14633943; 14634838; 14638340; 14644395; 14656692; 14657427; 14661113; 14662866; 14664464; 14669220; 14672899; 14673470; 14675093; 14675394; 14681913; 14691340; 14723749; 14735144; 14746807; 14750640; 14758530; 14760799; 14764742; 14961572; 14966463; 14966591; 14974822; 14982742; 14984963; 14985387; 14986816; 14990538; 14997019; 15003925; 15009068; 15014040; 15017629; 15019285; 15020601; 15036245; 15036607; 15039285; 15063762; 15068111; 15070815; 15073122; 15077300; 15082121; 15088297; 15100360; 15115662; 15127646; 15141093; 15146435; 15146559; 15159477; 15162833; 15170937; 15172100; 15175940; 15184943; 15187102; 15188375; 15188516; 15190266; 15191916; 15192144; 15194470; 15201366; 15208668; 15212826; 15220553; 15222686; 15223609; 15233701; 15235132; 15236174; 15236409; 15240151; 15247172; 15248873; 15257081; 15257727; 15265021; 15266130; 15270852; 15273551; 15279067; 15286433; 15288392; 15288631; 15289894; 15292002; 15297440; 15300588; 15300650; 15306845; 15308667; 15308963; 15318095; 15325407; 15329330; 15336915; 15338333; 15339690; 15341921; 15341923; 15347683; 15351436; 15361128; 15363219; 15372364; 15373762; 15377701; 15379752; 15380900; 15381182; 15382119; 15388258; 15458430; 15464974; 15470475; 15472991; 15476179; 15481145; 15485792; 15488638; 15489334; 15496610; 15509550; 15518810; 15520404; 15529348; 15539626; 15539764; 15540224; 15550384; 15551344; 15560757; 15561713; 15561982; 15562658; 15562761; 15566952; 15579481; 15581980; 15583831; 15592292; 15597152; 15602586; 15610073; 15633328; 15638726; 15641051; 15644653; 15658613; 15663946; 15665553; 15672946; 15679582; 15688413; 15694997; 15704154; 15710472; 15723199; 15723707; 15726267; 15727567; 15732864; 15733644; 15748898; 15755725; 15766560; 15777329; 15787640; 15797878; 15800325; 15803022; 15809210; 15810887; 15816458; 15817483; 15830637; 15833737; 15834859; 15836820; 15851404; 15866604; 15878285; 15880353; 15884119; 15885804; 15891809; 15895884; 15900570; 15900573; 15910501; 15914210; 15916853; 15917409; 15925866; 15927855; 15931231; 15950779; 15951664; 15954918; 15956727; 15966908; 15967798; 15974847; 15979578; 15986200; 16002736; 16019233; 16021081; 16025481; 16026589; 16030091; 16036505; 16038043; 16043936; 16046471; 16053468; 16078996; 16087165; 16088107; 16095699; 16095910; 16096333; 16098232; 16100774; 16106254; 16114018; 16115908; 16120761; 16126303; 16128937; 16131798; 16133074; 16133447; 16137184; 16143884; 16146780; 16155691; 16159520; 16160188; 16164697; 16172101; 16174285; 16181755; 16202743; 16206345; 16207716; 16211343; 16216268; 16217062; 16226351; 16249450; 16251478; 16253969; 16257277; 16260731; 16263000; 16268484; 16284099; 16284368; 16297587; 16304445; 16310170; 16319982; 16323614; 16324093; 16338121; 16358261; 16359550; 16361815; 16362385; 16362796; 16369899; 16375755; 16380201; 16380445; 16388753; 16389181; 16403098; 16405550; 16411061; 16424284; 16425360; 16425433; 16436009; 16439360; 16454826; 16455661; 16456796; 16464738; 16464741; 16469330; 16469798; 16477012; 16487028; 16505590; 16508980; 16510430; 16520888; 16521194; 16533337; 16538639; 16539678; 16540751; 16541711; 16546408; 16549749; 16550552; 16573560; 16574427; 16575408; 16579840; 16596202; 16601113; 16617094; 16618781; 16627678; 16634865; 16635219; 16635751; 16636119; 16637265; 16638698; 16675485; 16675961; 16684958; 16698387; 16699452; 16702372; 16708852; 16713284; 16720713; 16764597; 16766392; 16769128; 16775170; 16777324; 16780720; 16785446; 16792821; 16795034; 16798739; 16814297; 16815316; 16817913; 16820326; 16820919; 16824064; 16840032; 16842617; 16856121; 16858645; 16860880; 16864901; 16864906; 16865359; 16870193; 16883066; 16883068; 16886894; 16900886; 16905295; 16907768; 16911569; 16918024; 16930778; 16931944; 16938461; 16942951; 16945028; 16955392; 16961803; 16965825; 16973269; 16984283; 16985030; 16998242; 17002905; 17003486; 17003844; 17006606; 17006981; 17015745; 17015748; 17023519; 17026971; 17034724; 17035400; 17036048; 17052682; 17054771; 17054948; 17068065; 17069782; 17075828; 17077296; 17082635; 17083033; 17096351; 17103073; 17107380; 17114844; 17115419; 17126080; 17126449; 17132473; 17138334; 17140155; 17141301; 17142509; 17169726; 17177339; 17182583; 17189320; 17196954; 17201881; 17207379; 17213232; 17222831; 17235630; 17241868; 17257312; 17258699; 17265786; 17283089; 17284226; 17287896; 17295876; 17295877; 17297261; 17304101; 17307204; 17307379; 17309751; 17314118; 17324969; 17334075; 17335370; 17335371; 17335817; 17338374; 17341683; 17348213; 17348886; 17353049; 17353161; 17355643; 17356794; 17359523; 17360530; 17361014; 17365860; 17369174; 17380888; 17385677; 17388919; 17413037; 17420005; 17426109; 17431094; 17435158; 17444587; 17444864; 17446060; 17448042; 17453104; 17453826; 17454884; 17458053; 17458495; 17460270; 17463301; 17466952; 17471097; 17477779; 17477815; 17483707; 17492470; 17500214; 17510951; 17511783; 17518659; 17532232; 17535900; 17541951; 17548806; 17562931; 17563722; 17573384; 17575917; 17584583; 17586708; 17586709; 17587593; 17592300; 17593860; 17596594; 17596959; 17597660; 17600714; 17601350; 17607547; 17608808; 17610660; 17611197; 17611547; 17611673; 17618436; 17622713; 17627086; 17627763; 17634253; 17638785; 17640324; 17640966; 17645476; 17645589; 17656565; 17676277; 17678915; 17678975; 17681786; 17681918; 17685194; 17686006; 17703412; 17711477; 17716546; 17724799; 17763205; 17763411; 17827818; 17845308; 17846855; 17850436; 17854273; 17854800; 17867984; 17877801; 17889143; 17890880; 17895302; 17900510; 17901998; 17903994; 17907045; 17907163; 17908769; 17920311; 17926179; 17954336; 17960403; 17963170; 17964974; 17978470; 17981284; 17982107; 17986158; 17988588; 17988804; 18024394; 18038187; 18040764; 18042638; 18047563; 18048494; 18052703; 18052726; 18060744; 18062835; 18063307; 18063379; 18063673; 18065201; 18069935; 18078615; 18078818; 18080321; 18086767; 18088554; 18090474; 18092345; 18154955; 18156442; 18157816; 18163503; 18164040; 18164995; 18165865; 18173740; 18174250; 18186699; 18199150; 18216863; 18224250; 18225559; 18235016; 18239554; 18240282; 18262272; 18271063; 18273643; 18274637; 18278133; 18281687; 18281914; 18286207; 18288454; 18289837; 18291094; 18297103; 18299273; 18310311; 18311798; 18314303; 18315433; 18321309; 18322311; 18327798; 18332090; 18332211; 18333945; 18335579; 18336824; 18344712; 18346907; 18354254; 18361937; 18364273; 18366487; 18369665; 18373975; 18380966; 18384390; 18385937; 18389618; 18390750; 18392912; 18392953; 18396210; 18396211; 18416755; 18416756; 18418395; 18433382; 18441098; 18446054; 18453587; 18454664; 18465425; 18468936; 18469698; 18471873; 18472001; 18484169; 18484691; 18495419; 18496214; 18498041; 18502475; 18502965; 18510611; 18515365; 18523012; 18541658; 18545091; 18565646; 18566416; 18568448; 18568476; 18573495; 18576312; 18579366; 18579691; 18583979; 18587204; 18597398; 18603357; 18607773; 18609140; 18617366; 18628242; 18631256; 18632424; 18632425; 18633131; 18647218; 18656550; 18660489; 18664147; 18664535; 18665932; 18666137; 18668392; 18673406; 18675847; 18676680; 18676870; 18684932; 18685129; 18688641; 18694861; 18702109; 18708672; 18710415; 18714022; 18714935; 18715339; 18715757; 18715885; 18716798; 18717723; 18723088; 18725521; 18728048; 18728809; 18757527; 18761558; 18763028; 18772363; 18773331; 18779738; 18781863; 18787502; 18789941; 18794066; 18799084; 18805021; 18807132; 18815552; 18818748; 18819899; 18821666; 18826654; 18830724; 18832862; 18838388; 18849440; 18926055; 18930197; 18936436; 18940468; 18941541; 18942754; 18949424; 18949619; 18950863; 18951205; 18952062; 18953879; 18962899; 18974840; 18974842; 18977241; 18980523; 18985541; 18987561; 18997828; 19004046; 19009622; 19012493; 19013323; 19013689; 19013788; 19016479; 19019335; 19026124; 19028820; 19030199; 19031173; 19031816; 19032770; 19035492; 19042953; 19043479; 19046297; 19052845; 19053923; 19060367; 19060757; 19066720; 19074885; 19075290; 19076825; 19086955; 19089489; 19091595; 19092239; 19096964; 19097143; 19102413; 19104081; 19107653; 19112497; 19116903; 19125864; 19127818; 19131662; 19131814; 19132772; 19135625; 19141058; 19141488; 19141860; 19142372; 19148546; 19151976; 19156204; 19158679; 19164476; 19166933; 19166966; 19168721; 19170196; 19180500; 19180518; 19180798; 19184295; 19188531; 19188907; 19191798; 19194673; 19218098; 19218687; 19220961; 19222370; 19228941; 19232515; 19236331; 19238444; 19240794; 19244371; 19247692; 19248089; 19248102; 19249142; 19251436; 19258923; 19263529; 19265174; 19267370; 19267917; 19272346; 19272615; 19272692; 19274529; 19278365; 19279357; 19280228; 19281832; 19289123; 19290009; 19292049; 19295440; 19307598; 19309436; 19317746; 19322201; 19325908; 19328242; 19332120; 19333723; 19334424; 19336370; 19336475; 19336858; 19338208; 19347053; 19349390; 19367581; 19375306; 19381066; 19392835; 19398847; 19399323; 19405833; 19408823; 19418669; 19419456; 19420105; 19426391; 19427781; 19428986; 19431193; 19444759; 19448967; 19453261; 19455469; 19461122; 19470040; 19473116; 19473152; 19474090; 19479237; 19488045; 19489682; 19492240; 19494323; 19495883; 19497711; 19497848; 19503839; 19505916; 19506726; 19508602; 19513556; 19524870; 19527514; 19527699; 19544559; 19546559; 19548631; 19550417; 19551451; 19556613; 19559392; 19561107; 19563289; 19573080; 19574724; 19578796; 19592498; 19593445; 19594368; 19603010; 19604093; 19607807; 19614627; 19618316; 19625176; 19629761; 19638314; 19643686; 19644155; 19657406; 19664671; 19666082; 19671674; 19671938; 19680808; 19683555; 19684156; 19692168; 19692203; 19697035; 19698128; 19701245; 19701653; 19702713; 19706826; 19708438; 19710156; 19711225; 19714579; 19714631; 19720214; 19729601; 19733643; 19733878; 19734419; 19734969; 19735272; 19737897; 19742166; 19757173; 19760027; 19764937; 19773279; 19773451; 19775068; 19786079; 19789190; 19792847; 19793334; 19801958; 19804405; 19811432; 19811434; 19815156; 19817957; 19818512; 19820020; 19825518; 19833722; 19840475; 19844779; 19846277; 19852794; 19854014; 19854106; 19857272; 19857655; 19857676; 19860911; 19861615; 19876593; 19880327; 19889076; 19892918; 19900820; 19904240; 19904560; 19909950; 19913121; 19918044; 19930406; 19933216; 19934104; 19940477; 19948975; 19953002; 19956635; 19966052; 19996595; 20005085; 20008285; 20011938; 20012528; 20012999; 20016407; 20018936; 20027291; 20027321; 20027454; 20035239; 20036421; 20038579; 20038581; 20041150; 20042686; 20044070; 20051644; 20056178; 20056442; 20059417; 20059418; 20059579; 20060205; 20067853; 20069553; 20070312; 20070836; 20070880; 20080142; 20081319; 20087638; 20103767; 20106900; 20113359; 20113413; 20116278; 20116409; 20124101; 20131253; 20138641; 20140262; 20141484; 20141541; 20156727; 20157068; 20160043; 20175886; 20178882; 20188863; 20192980; 20193596; 20194723; 20196868; 20200422; 20206549; 20207250; 20213229; 20217044; 20227257; 20229266; 20237151; 20237496; 20301318; 20306665; 20332462; 20334849; 20334922; 20335539; 20336759; 20347268; 20349753; 20353565; 20363151; 20364673; 20369436; 20372910; 20376628; 20378615; 20378664; 20380698; 20385987; 20388088; 20399210; 20399384; 20399512; 20400062; 20405297; 20413850; 20417488; 20418110; 20427258; 20431935; 20437198; 20445104; 20447254; 20452482; 20453000; 20463618; 20467172; 20468064; 20470442; 20472558; 20472930; 20473875; 20478455; 20482626; 20483667; 20484443; 20484876; 20485444; 20486195; 20490394; 20490891; 20495003; 20495422; 20503287; 20509889; 20517696; 20518842; 20522558; 20528961; 20529668; 20534741; 20535924; 20536507; 20536609; 20551628; 20561568; 20564140; 20565774; 20565898; 20568250; 20574123; 20574532; 20581747; 20585978; 20587610; 20588114; 20594066; 20595916; 20596075; 20602615; 20603037; 20603050; 20603871; 20620944; 20625956; 20626741; 20628086; 20628624; 20631624; 20639647; 20644561; 20650788; 20659236; 20671275; 20673868; 20685652; 20690185; 20696775; 20697295; 20698171; 20702406; 20702408; 20711808; 20724540; 20729213; 20731121; 20799933; 20802483; 20811626; 20812962; 20841404; 20848209; 20848459; 20848793; 20865400; 20880267; 20887233; 20889944; 20890567; 20929277; 20934174; 20934730; 20935210; 20936699; 20940514; 20942272; 20942594; 20959405; 20961668; 20962853; 20963558; 20965572; 20975573; 20979650; 20979861; 21035110; 21037509; 21037510; 21041296; 21048223; 21048327; 21054222; 21054877; 21057224; 21061265; 21078560; 21086908; 21088871; 21107607; 21133705; 21138659; 21166654; 21173731; 21178846; 21181166; 21181220; 21199393; 21211511; 21217200; 21228685; 21235388; 21239716; 21243433; 21246243; 21251078; 21265111; 21266527; 21276216; 21288573; 21307135; 21311438; 21323660; 21366387; 21368235; 21380730; 21385549; 21385879; 21394384; 21400614; 21403867; 21411094; 21418526; 21419289; 21421008; 21424904; 21427492; 21430222; 21431944; 21433061; 21445336; 21449691; 21465264; 21484857; 21486440; 21496483; 21509504; 21523343; 21535449; 21571945; 21572958; 21585612; 21604462; 21611201; 21614008; 21621860; 21623995; 21628463; 21637346; 21653279; 21659536; 21659743; 21664353; 21671260; 21682548; 21687998; 21688665; 21697093; 21700772; 21708940; 21712624; 21717421; 21726461; 21728024; 21731057; 21732076; 21762124; 21762900; 21768915; 21771656; 21776298; 21784976; 21804018; 21811191; 21819478; 21832049; 21837414; 21840356; 21843369; 21854541; 21862584; 21866808; 21871094; 21878338; 21878622; 21898353; 21914069; 21923858; 21935932; 21940680; 21948112; 21949132; 21962386; 21968104; 21978003; 21988351; 21992747; 21994456; 22003203; 22010855; 22019906; 22021895; 22023756; 22027397; 22059992; 22064385; 22065068; 22068351; 22071871; 22072054; 22073249; 22073367; 22092925; 22095718; 22101739; 22103356; 22108531; 22124068; 22125454; 22126705; 22128229; 22154780; 22155307; 22160471; 22172512; 22173128; 22178859; 22183425; 22195044; 22227487; 22251538; 22266275; 22267217; 22275254; 22280559; 22285242; 22286731; 22311026; 22312160; 22340390; 22341060; 22344672; 22348697; 22349547; 22371121; 22382666; 22384041; 22384091; 22386525; 22389405; 22395218; 22414649; 22417897; 22425603; 22425785; 22449968; 22455686; 22455954; 22466287; 22467534; 22481167; 22487523; 22493010; 22498095; 22503230; 22513786; 22537218; 22540426; 22545750; 22547706; 22568934; 22569251; 22580886; 22596214; 22621205; 22621214; 22629474; 22629855; 22649552; 22673037; 22708826; 22710193; 22714811; 22727020; 22738689; 22739237; 22750393; 22759516; 22763042; 22763186; 22764136; 22768033; 22791816; 22795101; 22795647; 22796164; 22796220; 22796605; 22804923; 22805115; 22808497; 22811570; 22815289; 22818022; 22818222; 22822059; 22829602; 22829643; 22869038; 22878044; 22884582; 22884587; 22894561; 22898394; 22902304; 22904187; 22909148; 22911481; 22923190; 22937208; 22946471; 22947907; 22951596; 22955577; 22960943; 22995155; 22997256; 23006543; 23009887; 23013363; 23018032; 23020284; 23029154; 23052182; 23062767; 23065753; 23079713; 23105097; 23110185; 23169178; 23181791; 23184659; 23192617; 23195019; 23195574; 23199001; 23208827; 23209292; 23209411; 23209664; 23209696; 23210983; 23215648; 23215728; 23216199; 23217179; 23220433; 23226210; 23226468; 23229544; 23233369; 23237500; 23239492; 23241110; 23264411; 23269671; 23276701; 23313749; 23315075; 23317890; 23322904; 23323013; 23328087; 23328930; 23331079; 23349093; 23375040; 23383347; 23386602; 23391392; 23406266; 23417678; 23421536; 23425136; 23437386; 23452206; 23457635; 23459183; 23460134; 23460908; 23472661; 23484124; 23500159; 23508571; 23509682; 23531221; 23536554; 23546865; 23554905; 23555186; 23564444; 23571448; 23592003; 23592910; 23592922; 23610862; 23630220; 23633957; 23643268; 23650922; 23651237; 23654353; 23656735; 23657597; 23659674; 23660804; 23666803; 23680697; 23689297; 23702978; 23704929; 23717664; 23723976; 23726808; 23728092; 23737648; 23740952; 23747396; 23762029; 23773024; 23784458; 23793845; 23821953; 23822621; 23839215; 23840644; 23841472; 23884315; 23884363; 23892591; 23911403; 23927441; 23935506; 23936458; 23963575; 24022484; 24025329; 24035972; 24046015; 24078775; 24081990; 24146121; 24186874; 24265545; 24275344; 24313836; 24314919; 24338609; 24552038; 24611340,,,,,,,,,,,,,,,OGG:3000003553,,,,,,,"interleukin 1, beta",,,,,,,,,,,,,Other designations: IL-1 beta|catabolin|interleukin-1 beta|preinterleukin 1 beta|pro-interleukin-1-beta,,IL1B,,,,,,,,,,,,,,,,,,,,,,,3553,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,IL1B,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_49637,hydrogen atom,Inchikey:YZCKVEUIGOORGS-UHFFFAOYSA-N|hydrogen,,false,,,http://purl.obolibrary.org/obo/CHEBI_33250,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Inchikey:YZCKVEUIGOORGS-UHFFFAOYSA-N|hydrogen,,,,,CHEBI:49637,,,,,,,,,,,,,,,,,,,,,,hydrogen atom,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000639,Integrin alpha-V,,,false,,,http://purl.obolibrary.org/obo/IMR_0000173,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000639,,,,,,,,,,,,,,,,,,,,,,Integrin alpha-V,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000150759,LINC00342,,,false,,,http://purl.obolibrary.org/obo/OGG_2100009606,,NCRNA00342,,,,,,,,,,,,2,,,,,,HGNC:42470,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,long intergenic non-protein coding RNA 342,,,2q11.2,,,,,,,,,,,,,,,,,,,,,,,,,PMID: 12477932; 14702039,,,,,,,,,,,,,,,OGG:3000150759,,,,,,,long intergenic non-protein coding RNA 342,,,,,,,,,,,,,,,LINC00342,,,,,,,,,,,,,,,,,,,,,,,150759,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,LINC00342,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0001698,glycoside,,"Any compound that contains a constituent sugar, in which the hydroxyl group attached to the first carbon is substituted by an alcoholic, phenolic, or other group. They are named specifically for the sugar contained, such as glucoside (glucose), pentoside (pentose), fructoside (fructose), etc. Upon hydrolysis, a sugar and nonsugar component (aglycone) are formed. (From Dorland, 28th ed; From Miall's Dictionary of Chemistry, 5th ed)",false,,,http://purl.obolibrary.org/obo/CHEBI_16646,,,,,,,,,,,,,,,,,,,,,,"Any compound that contains a constituent sugar, in which the hydroxyl group attached to the first carbon is substituted by an alcoholic, phenolic, or other group. They are named specifically for the sugar contained, such as glucoside (glucose), pentoside (pentose), fructoside (fructose), etc. Upon hydrolysis, a sugar and nonsugar component (aglycone) are formed. (From Dorland, 28th ed; From Miall's Dictionary of Chemistry, 5th ed)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001698,,,,,,,,,,,,,,,,,,,,,,glycoside,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_18059,lipid,,"'Lipids' is a loosely defined term for substances of biological origin that are soluble in nonpolar solvents. They consist of saponifiable lipids, such as glycerides (fats and oils) and phospholipids, as well as nonsaponifiable lipids, principally steroids.|Organic molecule that is insoluble in water but tends to dissolve in nonpolar organic solvent.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,,,"'Lipids' is a loosely defined term for substances of biological origin that are soluble in nonpolar solvents. They consist of saponifiable lipids, such as glycerides (fats and oils) and phospholipids, as well as nonsaponifiable lipids, principally steroids.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:18059,,,,,,,,,,,,,,,,,,,,Organic molecule that is insoluble in water but tends to dissolve in nonpolar organic solvent.,,lipid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004820,Hypofunction of TFAM gene expression,,"Hypofunction of TFAM gene expression is a subtype of hypofunction of transcription, DNA-templated: A process that performs a decreased or insufficient TFAM gene expression.",false,,,http://purl.obolibrary.org/obo/TXPO_0002356,,,,,,,,,,,,,,,,,,,,,,"Hypofunction of TFAM gene expression is a subtype of hypofunction of transcription, DNA-templated: A process that performs a decreased or insufficient TFAM gene expression.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004820,,,,,,,,,,,,,,,,,,,,,,Hypofunction of TFAM gene expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004826,TGFA (canonical) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0005135|http://purl.obolibrary.org/obo/TXPO_0005063,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24827|NCBI-Mouse-GeneID:21802|NCBI-Human-GeneID:7039|PMID:28493839,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004826,,,,,,,,,,,,,,,,,,,,,,TGFA (canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004824,TGF-alpha signaling (primitive),,TGF-alpha signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by TGF-alpha.,false,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,,,TGF-alpha signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by TGF-alpha.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004823,,,,,,,,,,,,,,,,TXPO:0004824,,,,,,,,,,,,,,,,,,,,,,TGF-alpha signaling (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004827,TGFB1(canonical) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000371|http://purl.obolibrary.org/obo/IMR_0000042|http://purl.obolibrary.org/obo/TXPO_0005063,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:|PMID:11359698|NCBI-Mouse-GeneID:|NCBI-Rat-GeneID:,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000041,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004827,,,,,,,,,,,,,,,,,,,,,,TGFB1(canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004822,TFAM (canonical) [mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/TXPO_0005134|http://purl.obolibrary.org/obo/TXPO_0004293,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:83474|NCBI-Human-GeneID:7019|NCBI-Mouse-GeneID:21780|PMID:31623280,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004822,,,,,,,,,,,,,,,,,,,,,,TFAM (canonical) [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004823,TGF-alpha signal transduction pathway,,A series of molecular signals mediated by TGF-alpha (transforming growth factor alpha).,false,,,http://purl.obolibrary.org/obo/TXPO_0000609,,,,,,,,,,,,,,,,,,,,,,A series of molecular signals mediated by TGF-alpha (transforming growth factor alpha).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004823,,,,,,,,,,,,,,,,,,,,,,TGF-alpha signal transduction pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004828,regulatory T cell migration [hepatocarcinogenesis],,"The orderly movement of a regulatory T cell from one site to another.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0005020,,,,,,,,,,,,,,,,,,,,PMID:31507621,,"The orderly movement of a regulatory T cell from one site to another.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0005019,,,,,,,,,,,TXPO:0004828,,,,,,,,,,,,,,,,,,,,,,regulatory T cell migration [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004829,TLR4 signaling (primitive),,TLR4 signaling (primitive) is a subtype of TLR signaling [biological]: Any series of molecular signals generated as a consequence of binding to toll-like receptor 4.,false,,,http://purl.obolibrary.org/obo/TXPO_0004301,,,,,,,,,,,,,,,,,,,,,,TLR4 signaling (primitive) is a subtype of TLR signaling [biological]: Any series of molecular signals generated as a consequence of binding to toll-like receptor 4.,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0001440,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0034142,,,,,,,,,,,,,,,,TXPO:0004829,,,,,,,,,,,,,,,,,,,,,,TLR4 signaling (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004825,TGF-alpha signaling (primitive) [hepatocarcinogenesis],,"TGF-alpha signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by TGF-alpha.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004824,,,,,,,,,,,,,,,,,,,,PMID:28493839,,"TGF-alpha signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by TGF-alpha.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004826,http://purl.obolibrary.org/obo/TXPO_0004823,,,,,http://purl.obolibrary.org/obo/TXPO_0004526,,,,,,,,,,,TXPO:0004825,,,,,,,,,,,,,,,,,,,,,,TGF-alpha signaling (primitive) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004821,Hypofunction of TFAM gene expression [mitochondrial disorder],,"Hypofunction of TFAM gene expression is a subtype of hypofunction of transcription, DNA-templated: A process that performs a decreased or insufficient TFAM gene expression.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0004820,,,,,,,,,,,,,,,,,,,,PMID:31623280,,"Hypofunction of TFAM gene expression is a subtype of hypofunction of transcription, DNA-templated: A process that performs a decreased or insufficient TFAM gene expression.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004822,,,,,,http://purl.obolibrary.org/obo/TXPO_0000933,,,,,,,,,,,TXPO:0004821,,,,,,,,,,,,,,,,,,,,,,Hypofunction of TFAM gene expression [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006813,potassium ion transport,,"The directed movement of potassium ions (K+) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.",false,,,http://purl.obolibrary.org/obo/GO_0006811,,,,,,,,,,,,,,,,,,,,,,"The directed movement of potassium ions (K+) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0006813,,,,,,,,,,,,,,,,,,,,,,potassium ion transport,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006811,ion transport,,"The directed movement of charged atoms or small charged molecules into, out of, within or between cells.",false,,,http://purl.obolibrary.org/obo/TXPO_0000111|http://purl.obolibrary.org/obo/GO_0006810,,,,,,,,,,,,,,,,,,,,,,"The directed movement of charged atoms or small charged molecules into, out of, within or between cells.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0006811,,,,,,,,,,,,,,,,,,,,,,ion transport,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006810,transport,,"The directed movement of substances (such as macromolecules, small molecules, ions) or cellular components (such as complexes and organelles) into, out of or within a cell, or between cells, or within a multicellular organism by means of some agent such as a transporter, pore or motor protein.",false,,,http://purl.obolibrary.org/obo/TXPO_0000442,,,,,,,,,,,,,,,,,,,,,,"The directed movement of substances (such as macromolecules, small molecules, ions) or cellular components (such as complexes and organelles) into, out of or within a cell, or between cells, or within a multicellular organism by means of some agent such as a transporter, pore or motor protein.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0006810,,,,,,,,,,,,,,,,,,,,,,transport,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_4877,ethambutol,"S,S-Ethambutol|etambutol|(+)-S,S-ethambutol|(+)-ethambutol|EMB|(2S,7S)-2,7-diethyl-3,6-diazaoctane-1,8-diol|ethambutol|ethambutolum|(S,S)-ethambutol|(+)-2,2'-(ethylenediimino)di-1-butanol|(+)-N,N'-bis(1-(hydroxymethyl)propyl)ethylenediamine|Ethambutol|(2S,2'S)-2,2'-(ethane-1,2-diyldiimino)dibutan-1-ol","An ethylenediamine derivative that is ethane-1,2-diamine in which one hydrogen attached to each of the nitrogens is sutstituted by a 1-hydroxybutan-2-yl group (S,S-configuration). It is a bacteriostatic antimycobacterial drug, effective against Mycobacterium tuberculosis and some other mycobacteria. It is used (as the dihydrochloride salt) in combination with other antituberculous drugs in the treatment of pulmonary and extrapulmonary tuberculosis; resistant strains of M. tuberculosis are readily produced if ethambutol is used alone.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:10891117|PMID:19524332|PMID:17888665|Beilstein:6312870|PMID:14695841|PMID:3934384|Drug_Central:1073|PMID:14698152|CAS:74-55-5|PMID:17331717|PMID:12182855|PMID:16870429|PMID:19648006|PMID:10649975|DrugBank:DB00330|Reaxys:6312870|PMID:15225698|PMID:17210775|PMID:10966749|PMID:17276683|PMID:17851083|PMID:16759086|PMID:17562368|PMID:17239593|PMID:16005211|PMID:17315960,,"An ethylenediamine derivative that is ethane-1,2-diamine in which one hydrogen attached to each of the nitrogens is sutstituted by a 1-hydroxybutan-2-yl group (S,S-configuration). It is a bacteriostatic antimycobacterial drug, effective against Mycobacterium tuberculosis and some other mycobacteria. It is used (as the dihydrochloride salt) in combination with other antituberculous drugs in the treatment of pulmonary and extrapulmonary tuberculosis; resistant strains of M. tuberculosis are readily produced if ethambutol is used alone.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35703|http://purl.obolibrary.org/obo/CHEBI_33231|http://purl.obolibrary.org/obo/CHEBI_78298,,,,,"Ethambutol|(2S,2'S)-2,2'-(ethane-1,2-diyldiimino)dibutan-1-ol",,"S,S-Ethambutol|etambutol|(+)-S,S-ethambutol|(+)-ethambutol|EMB|(2S,7S)-2,7-diethyl-3,6-diazaoctane-1,8-diol|ethambutol|ethambutolum|(S,S)-ethambutol|(+)-2,2'-(ethylenediimino)di-1-butanol|(+)-N,N'-bis(1-(hydroxymethyl)propyl)ethylenediamine",,,,,,,,,,,,,,,,,,,,,CHEBI:4877,,,,ethambutol,,CHEBI:4877,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100071,vasoactive intestinal peptide,VIP,"A highly basic, 28 amino acid neuropeptide released from intestinal mucosa. It has a wide range of biological actions affecting the cardiovascular, gastrointestinal, and respiratory systems and is neuroprotective. It binds special receptors ( RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE).",false,,,http://purl.obolibrary.org/obo/IMR_0100072,,,,,,,,,,,,,,,,,,,,MeSH:D014660,,"A highly basic, 28 amino acid neuropeptide released from intestinal mucosa. It has a wide range of biological actions affecting the cardiovascular, gastrointestinal, and respiratory systems and is neuroprotective. It binds special receptors ( RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,VIP,,,,,IMR:0100071,,,,,,,,,,,,,,,,,,,,,,vasoactive intestinal peptide,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000406926,MIR135A2,,,false,,,http://purl.obolibrary.org/obo/OGG_2100009606,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:406926,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,OGG:3000406926,,,,,,,,,,,,,,,,,,,,,,MIR135A2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9606,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000406925,MIR135A1,,,false,,,http://purl.obolibrary.org/obo/OGG_2100009606,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:406925,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,OGG:3000406925,,,,,,,,,,,,,,,,,,,,,,MIR135A1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9606,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004543,increasing demand for response to oxidative stress [hepatocarcinogenesis],,"Increasing demand for response to oxidative stress is a subtype of increasing the demand for response to stress: A process that changes the functional demand for the response to the oxidative stress to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0000102,,,,,,,,,,,,,,,,,,,,PMID:11359698|PMID:31623280|PMID:30704071,,"Increasing demand for response to oxidative stress is a subtype of increasing the demand for response to stress: A process that changes the functional demand for the response to the oxidative stress to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004516,,,,,,http://purl.obolibrary.org/obo/TXPO_0004505|http://purl.obolibrary.org/obo/TXPO_0005035,,,,,,,,,,,TXPO:0004543,,,,,,,,,,,,,,,,,,,,,,increasing demand for response to oxidative stress [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004549,FAS signaling [mitochondrial disorder],,"FAS signaling is a subtype of signaling [biological]: A process that in which a signal is transmitted by FAS.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0004548,,,,,,,,,,,,,,,,,,,,PMID:31623280,,"FAS signaling is a subtype of signaling [biological]: A process that in which a signal is transmitted by FAS.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004017,http://purl.obolibrary.org/obo/GO_0036337,,,,,http://purl.obolibrary.org/obo/TXPO_0004271|http://purl.obolibrary.org/obo/TXPO_0002004,,,,,,,,,,,TXPO:0004549,,,,,,,,,,,,,,,,,,,,,,FAS signaling [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004547,PTK2 (canonical) [hepatocarcinogenesis],FAK,,false,,,http://purl.obolibrary.org/obo/TXPO_0005130|http://purl.obolibrary.org/obo/TXPO_0005063,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:5747|NCBI-Rat-GeneID:25614|NCBI-Mouse-GeneID:14083|PMID:28706416,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FAK,,,,,TXPO:0004547,,,,,,,,,,,,,,,,,,,,,,PTK2 (canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004541,increasing demand for response to ER stress [hepatocarcinogenesis],,"Increasing demand for response to ER stress is a subtype of increasing the demand for response to stress: A process that changes the functional demand for the response to the endoplasmic reticulum (ER) stress to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0000362,,,,,,,,,,,,,,,,,,,,PMID:31623280|PMID:30704071,,"Increasing demand for response to ER stress is a subtype of increasing the demand for response to stress: A process that changes the functional demand for the response to the endoplasmic reticulum (ER) stress to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004403|http://purl.obolibrary.org/obo/TXPO_0004543|http://purl.obolibrary.org/obo/TXPO_0004542|http://purl.obolibrary.org/obo/TXPO_0004392,,,,,,,,,,,TXPO:0004541,,,,,,,,,,,,,,,,,,,,,,increasing demand for response to ER stress [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004548,FAS signaling (primitive),,FAS signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by FAS.,false,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,,,FAS signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by FAS.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0036337,,,,,,,,,,,,,,,,TXPO:0004548,,,,,,,,,,,,,,,,,,,,,,FAS signaling (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004544,FAK signal transduction pathway,,A series of molecular signals mediated by FAK (focal adhesion kinase).,false,,,http://purl.obolibrary.org/obo/TXPO_0000609,,,,,,,,,,,,,,,,,,,,,,A series of molecular signals mediated by FAK (focal adhesion kinase).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004544,,,,,,,,,,,,,,,,,,,,,,FAK signal transduction pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004546,FAK signaling (primitive) [hepatocarcinogenesis],,"FAK signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by FAK.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004545,,,,,,,,,,,,,,,,,,,,PMID:28706416,,"FAK signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by FAK.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004547,http://purl.obolibrary.org/obo/TXPO_0004544,,,,,http://purl.obolibrary.org/obo/TXPO_0004417,,,,,,,,,,,TXPO:0004546,,,,,,,,,,,,,,,,,,,,,,FAK signaling (primitive) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004545,FAK signaling (primitive),,FAK signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by FAK.,false,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,,,FAK signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by FAK.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004544,,,,,,,,,,,,,,,,TXPO:0004545,,,,,,,,,,,,,,,,,,,,,,FAK signaling (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004540,Grp78 signal transduction pathway,,A series of molecular signals mediated by Grp78 (Glucose-regulated protein 78).,false,,,http://purl.obolibrary.org/obo/TXPO_0000609,,,,,,,,,,,,,,,,,,,,,,A series of molecular signals mediated by Grp78 (Glucose-regulated protein 78).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004540,,,,,,,,,,,,,,,,,,,,,,Grp78 signal transduction pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004542,inflammatory response [hepatocarcinogenesis],,"Inflammatory response is a subtype of changing material: The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000192|http://purl.obolibrary.org/obo/TXPO_0002340,,,,,,,,,,,,,,,,,,,,PMID:31439937|PMID:30704071,,"Inflammatory response is a subtype of changing material: The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004392,,,,,,,,,,,TXPO:0004542,,,,,,,,,,,,,,,,,,,,,,inflammatory response [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0002394,bile duct,hepatic duct|gall duct|biliary duct|bile tube,"Any of the ducts that form the biliary tree, carrying bile from the liver to the small intestine.",false,,,http://purl.obolibrary.org/obo/UBERON_0000058|http://purl.obolibrary.org/obo/UBERON_0000025,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0001970,,,,,,,,,"Any of the ducts that form the biliary tree, carrying bile from the liver to the small intestine.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,hepatic duct|gall duct|biliary duct|bile tube,,http://purl.obolibrary.org/obo/UBERON_0001007,UBERON:0002394,http://purl.obolibrary.org/obo/UBERON_0001007,,,,,,,,,,,,,,,,,,,,,bile duct,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0002390,hematopoietic system,hematolymphoid system|hematological system|haematopoietic system|Blutbildungssystem|hemopoietic system|haemopoietic system|organa haemopoietica|haematological system,"Anatomical system that is involved in the production of hematopoietic cells.|In humans this is primarily the bone marrow, spleen, tonsils, and lymph nodes",false,,,http://purl.obolibrary.org/obo/UBERON_0000467,,,,,,,,,,,,,,,,,,,,http://www.snomedbrowser.com/Codes/Details/362587009|http://linkedlifedata.com/resource/umls/id/C0018957|http://en.wikipedia.org/wiki/Haematopoiesis|http://purl.obolibrary.org/obo/NCIT_C12909|EMAPA:35402|ZFA:0005023|TAO:0005023|EFO:0000798|EV:0100045|VHOG:0001624|MA:0002434|XAO:0000122|UMLS:C0018957|CALOHA:TS-0449|MESH:D006413|MAT:0000022|FMA:9667|MIAA:0000022|BTO:0000570|AAO:0011002|GAID:1008,,Anatomical system that is involved in the production of hematopoietic cells.,,,,,,,,Anatomical system that consists of the blood and blood forming tissues.[AAO],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,haemopoietic system|organa haemopoietica|haematological system,,hematolymphoid system|hematological system|haematopoietic system|Blutbildungssystem|hemopoietic system,Zebrafish developmental hematopoiesis shows close correspondence to the development of the mammalian hematopoietic system and is regulated by conserved molecular pathways.[well established][VHOG],http://purl.obolibrary.org/obo/UBERON_0002193,UBERON:0002390,http://purl.obolibrary.org/obo/UBERON_0002193,,,,,,,,,,,,,,,,,,,"In humans this is primarily the bone marrow, spleen, tonsils, and lymph nodes",,hematopoietic system,,,,,,,http://purl.obolibrary.org/obo/oae.owl|http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004642,IFN alpha inactivation,,IFN alpha inactivation is a subtype of molecular inactivation: A process that  changes the activity of the IFN alpha (interferon alpha) to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000021,,,,,,,,,,,,,,,,,,,,,,IFN alpha inactivation is a subtype of molecular inactivation: A process that  changes the activity of the IFN alpha (interferon alpha) to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004642,,,,,,,,,,,,,,,,,,,,,,IFN alpha inactivation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004640,YAP signaling (primitive) [hepatocarcinogenesis],,"YAP signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by YAP.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0004868|http://purl.obolibrary.org/obo/TXPO_0002340,,,,,,,,,,,,,,,,,,,,PMID:28493839|PMID:30700007,,"YAP signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by YAP.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004869,http://purl.obolibrary.org/obo/TXPO_0004867,,,,,http://purl.obolibrary.org/obo/TXPO_0004816|http://purl.obolibrary.org/obo/TXPO_0004529,,,,,,,,,,,TXPO:0004640,,,,,,,,,,,,,,,,,,,,,,YAP signaling (primitive) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004645,IGFBP3 (mol),insulin like growth factor binding protein 3,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:3486|NCBI-Rat-GeneID:24484|NCBI-Mouse-GeneID:16009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,insulin like growth factor binding protein 3,,,,,TXPO:0004645,,,,,,,,,,,,,,,,,,,,,,IGFBP3 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004647,IGFBP3 - inactive form (human) [hepatocarcinogenesis],insulin like growth factor binding protein 3,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_0005095,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:3486|PMID:29507645,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0002355,,,,,,,,,insulin like growth factor binding protein 3,,,,,TXPO:0004647,,,,,,,,,,,,,,,,,,,,,,IGFBP3 - inactive form (human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004648,IL-1B(canonical) [mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000200|http://purl.obolibrary.org/obo/TXPO_0004293,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:3553|NCBI-Rat-GeneID:24494|NCBI-Mouse-GeneID:16176|PMID:31623280,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003041,,,,,,,,,,TXPO:0004648,,,,,,,,,,,,,,,,,,,,,,IL-1B(canonical) [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004641,UHRF1 production,,UHRF1 production is a subtype of protein production: A process that makes existent of a UHRF1 protein due to biosynthesis or secretion resulting in an increase in its levels.,false,,,http://purl.obolibrary.org/obo/TXPO_0000382,,,,,,,,,,,,,,,,,,,,,,UHRF1 production is a subtype of protein production: A process that makes existent of a UHRF1 protein due to biosynthesis or secretion resulting in an increase in its levels.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_1000547,,,,,,,,,,,,,,,,,,,TXPO:0004641,,,,,,,,,,,,,,,,,,,,,,UHRF1 production,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004646,IGFBP3 inactivation [hepatocarcinogenesis],,"IGFBP3 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the IGFBP3 (insulin-like growth factor binding protein 3) to be lower.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004644,,,,,,,,,,,,,,,,,,,,PMID:29507645,,"IGFBP3 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the IGFBP3 (insulin-like growth factor binding protein 3) to be lower.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004611,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004647,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004392,,,,,,,,,,,TXPO:0004646,,,,,,,,,,,,,,,,,,,,,,IGFBP3 inactivation [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004643,IFN alpha inactivation [hepatocarcinogenesis],,"IFN alpha inactivation is a subtype of molecular inactivation: A process that  changes the activity of the IFN alpha (interferon alpha) to be lower.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004642,,,,,,,,,,,,,,,,,,,,PMID:29358721,,"IFN alpha inactivation is a subtype of molecular inactivation: A process that  changes the activity of the IFN alpha (interferon alpha) to be lower.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004525,,,,,,,,,,,TXPO:0004643,,,,,,,,,,,,,,,,,,,,,,IFN alpha inactivation [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004649,IL-6 inactivation,,IL-6 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the IL-6 (interleukin 6) to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000021,,,,,,,,,,,,,,,,,,,,,,IL-6 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the IL-6 (interleukin 6) to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004649,,,,,,,,,,,,,,,,,,,,,,IL-6 inactivation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004644,IGFBP3 inactivation,,IGFBP3 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the IGFBP3 (insulin-like growth factor-binding protein 3) to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000021,,,,,,,,,,,,,,,,,,,,,,IGFBP3 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the IGFBP3 (insulin-like growth factor-binding protein 3) to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004644,,,,,,,,,,,,,,,,,,,,,,IGFBP3 inactivation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000675,negative regulation of glycolytic process [Glutathione depletion],,"Any process that stops, prevents, or reduces the frequency, rate or extent of glycolysis.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0000889|http://purl.obolibrary.org/obo/GO_0045820,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents, or reduces the frequency, rate or extent of glycolysis.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000663|http://purl.obolibrary.org/obo/TXPO_0001919,,,,,,http://purl.obolibrary.org/obo/TXPO_0002379,,,,,,,,,,,TXPO:0000675,,,,,,,,,,,,,,,,,,,,,,negative regulation of glycolytic process [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000679,toxicological imbalance VH<  (excess biodefense function),,"In the imbalance model, the basic units are as follows:
1) a functioning process (supply) for biological defense and maintaining homeostasis;
2) a functional demand process (demand) as toxic activity;
3) balance/imbalance between toxic activity and defense processes; and
4) outcome from organelles, cells, or tissues to the organ exhibiting toxicity manifestations.

This entity is a compound state that includes step 1 to 4, and the defense performance level is very higher (VH) than usual which leads to imbalance and toxicity manifestations.",false,,,http://purl.obolibrary.org/obo/TXPO_0003992,,,,,,,,,,,,,,,,,,,,,,"In the imbalance model, the basic units are as follows:
1) a functioning process (supply) for biological defense and maintaining homeostasis;
2) a functional demand process (demand) as toxic activity;
3) balance/imbalance between toxic activity and defense processes; and
4) outcome from organelles, cells, or tissues to the organ exhibiting toxicity manifestations.

This entity is a compound state that includes step 1 to 4, and the defense performance level is very higher (VH) than usual which leads to imbalance and toxicity manifestations.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001735,,,,,,,,,,,,,,,,,,TXPO:0000679,,,,,,,,,,,,,,,,,,,,,,toxicological imbalance VH<  (excess biodefense function),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000674,PERK autophosphorylation [ER stress],,"PERK autophosphorylation is a subtype of protein autophosphorylation: The phosphorylation by PERK of one or more of its own amino acid residues (cis-autophosphorylation), or residues on PERK (trans-autophosphorylation).
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0003736|http://purl.obolibrary.org/obo/TXPO_0000742,,,,,,,,,,,,,,,,,,,,,,"PERK autophosphorylation is a subtype of protein autophosphorylation: The phosphorylation by PERK of one or more of its own amino acid residues (cis-autophosphorylation), or residues on PERK (trans-autophosphorylation).
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000878,,,,,,,,,,,,,,,,,TXPO:0000674,,,,,,,,,,,,,,,,,,,,,,PERK autophosphorylation [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000670,ethanol [Lipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003508,,,,,,,,,,,,,,,,,,,,ISBN:0071769234,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000670,,,,,,,,,,,,,,,,,,,,,,ethanol [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000677,oxidative stress [toxic course],,The totality of all processes through which oxidative stress is realized.|Generation of free radicals or depletion of free radical scavengers and other antioxidant defences such as glutathione -> generation of reactive oxyen metabolites ->damaging effects on cell,false,,,http://purl.obolibrary.org/obo/TXPO_0000009,,,,,,,,,,,,,,,,,,,,,,The totality of all processes through which oxidative stress is realized.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000605|http://purl.obolibrary.org/obo/TXPO_0000515|http://purl.obolibrary.org/obo/TXPO_0000542|http://purl.obolibrary.org/obo/TXPO_0000543|http://purl.obolibrary.org/obo/TXPO_0000546|http://purl.obolibrary.org/obo/TXPO_0000042|http://purl.obolibrary.org/obo/TXPO_0000455|http://purl.obolibrary.org/obo/TXPO_0000815|http://purl.obolibrary.org/obo/TXPO_0000814|http://purl.obolibrary.org/obo/TXPO_0002333|http://purl.obolibrary.org/obo/TXPO_0000467|http://purl.obolibrary.org/obo/TXPO_0000461|http://purl.obolibrary.org/obo/TXPO_0000566,,,,,,,,,,,,,,,,,,TXPO:0000677,,,,,,,,,,,,,,,,,,,,Generation of free radicals or depletion of free radical scavengers and other antioxidant defences such as glutathione -> generation of reactive oxyen metabolites ->damaging effects on cell,,oxidative stress [toxic course],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000673,starvation,,Starvation is a subtype of depleting: A process that lessens markedly in quantity of the nourishment.,false,,,http://purl.obolibrary.org/obo/TXPO_0000602,,,,,,,,,,,,,,,,,,,,http://purl.bioontology.org/ontology/MESH/D013217,,Starvation is a subtype of depleting: A process that lessens markedly in quantity of the nourishment.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000673,,,,,,,,,,,,,,,,,,,,,,starvation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000676,fructose-1-phosphate aldolase,,Catalysis of the reaction: D-fructose-1-phosphate = dihydroxyacetone phosphate + D-glyceraldehyde.,false,,,http://purl.obolibrary.org/obo/TXPO_0000804,,,,,,,,,,,,,,,,,,,,,,Catalysis of the reaction: D-fructose-1-phosphate = dihydroxyacetone phosphate + D-glyceraldehyde.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000676,,,,,,,,,,,,,,,,,,,,,,fructose-1-phosphate aldolase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000672,gene expression by estrogen receptor,,,false,,,http://purl.obolibrary.org/obo/TXPO_0000375,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000672,,,,,,,,,,,,,,,,,,,,,,gene expression by estrogen receptor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000671,decreasing concentration,,Decreasing concentration is a subtype of changing concentration: A process that changes the concentration of the object to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0002438,,,,,,,,,,,,,,,,,,,,,,Decreasing concentration is a subtype of changing concentration: A process that changes the concentration of the object to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000671,,,,,,,,,,,,,,,,,,,,,,decreasing concentration,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0001163,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000678,necrosis (course),,Necrosis (course) is a subtype of cell death (course). The totality of all processes through which necrosis is realized.|under construction,false,,,http://purl.obolibrary.org/obo/TXPO_0000323,,,,,,,,,,,,,,,,,,,,PMID:18846107|PMID:20823910,,Necrosis (course) is a subtype of cell death (course). The totality of all processes through which necrosis is realized.,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002387,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001449|http://purl.obolibrary.org/obo/TXPO_0002142|http://purl.obolibrary.org/obo/TXPO_0002390|http://purl.obolibrary.org/obo/TXPO_0000527|http://purl.obolibrary.org/obo/TXPO_0000346|http://purl.obolibrary.org/obo/TXPO_0000030|http://purl.obolibrary.org/obo/TXPO_0000486|http://purl.obolibrary.org/obo/TXPO_0002129|http://purl.obolibrary.org/obo/TXPO_0000355|http://purl.obolibrary.org/obo/TXPO_0000773|http://purl.obolibrary.org/obo/TXPO_0000226|http://purl.obolibrary.org/obo/TXPO_0002099|http://purl.obolibrary.org/obo/TXPO_0000541|http://purl.obolibrary.org/obo/TXPO_0003344|http://purl.obolibrary.org/obo/TXPO_0000582|http://purl.obolibrary.org/obo/TXPO_0002409|http://purl.obolibrary.org/obo/TXPO_0002381|http://purl.obolibrary.org/obo/TXPO_0002387|http://purl.obolibrary.org/obo/TXPO_0002389,,,,,,,,,,,,,,,,,,TXPO:0000678,,,,,,,"Necrosis is a type of cell death that is morphologically characterized by an increasingly translucent cytoplasm, swelling of organelles, minor ultrastructural modifications of the nucleus (specifically, dilatation of the nuclear membrane and condensation of chromatin into small, irregular, circumscribed patches) and increased cell volume (oncosis), culminating in the disruption of the plasma membrane and subsequent loss of intracellular contents. necrotic cells do not fragment into discrete corpses as their apoptotic counterparts do. moreover, their nuclei remain intact and can aggregate and accumulate in necrotic tissues.",,,,,,,,,,,,,under construction,,necrosis (course),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000483,alpha-actinin 2,,,false,,,http://purl.obolibrary.org/obo/IMR_0000189,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000483,,,,,,,,,,,,,,,,,,,,,,alpha-actinin 2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000317649,EIF4E3,,Other designations: eukaryotic translation initiation factor 4E type 3,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,eIF4E-3|eIF-4E3,,,,,,,,,,,,3,,,,,,Ensembl:ENSG00000163412|MIM:609896|HPRD:10687|HGNC:31837,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,eukaryotic translation initiation factor 4E family member 3,,,3p14,,,,,,,,,,,,,,,,GO_0003743 (EC: IEA); GO_0005829 (EC: TAS); GO_0005845 (EC: ISS); GO_0006417 (EC: IEA); GO_0019221 (EC: TAS),,,,,,,,,PMID:12477932; 15153109; 16344560; 19322201; 20434207; 23431134; 23587918,,,,,,,,,,,,,,,OGG:3000317649,,,,,,,eukaryotic translation initiation factor 4E family member 3,,,,,,,,,,,,,Other designations: eukaryotic translation initiation factor 4E type 3,,EIF4E3,,,,,,,,,,,,,,,,,,,,,,,317649,,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF4E3,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/GO_0051726,regulation of cell cycle,regulation of progression through cell cycle|modulation of cell cycle progression|cell cycle regulation|control of cell cycle progression|regulation of cell cycle progression|cell cycle modulation,Any process that modulates the rate or extent of progression through the cell cycle.,false,,,http://purl.obolibrary.org/obo/TXPO_0000113,,,,,,,,,,,,,,,,,,,,,,Any process that modulates the rate or extent of progression through the cell cycle.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,regulation of progression through cell cycle|modulation of cell cycle progression|cell cycle regulation|control of cell cycle progression|regulation of cell cycle progression|cell cycle modulation,,,,,GO:0051726,,,,,,,,,,,,,,,,,,,,,,regulation of cell cycle,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0007049,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100050,gastric inhibitory polypeptide,GIP,A gastrointestinal peptide hormone of about 43-amino acids.,false,,,http://purl.obolibrary.org/obo/IMR_0100072,,,,,,,,,,,,,,,,,,,,MeSH:D005749,,A gastrointestinal peptide hormone of about 43-amino acids.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GIP,,,,,IMR:0100050,,,,,,,,,,,,,,,,,,,,,,gastric inhibitory polypeptide,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100394,IRS-2,insulin receptor substrate-2|IRS2,,false,,,http://purl.obolibrary.org/obo/IMR_0000351,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0010312|IMR:0011553,insulin receptor substrate-2|IRS2,,,,,IMR:0100394,,,,,,,,,,,,,,,,,,,,,,IRS-2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_39027,very-low-density lipoprotein,very-low-density lipoproteins|VLDL,"A class of lipoproteins of large size (30-80 nm), very low density (0.93-1.006 g/ml) particles with a core composed mainly of triglycerides and a surface monolayer of phospholipids and cholesterol into which are imbedded the apolipoproteins B, E, and C. VLDL facilitate the transport of endogenously made triglycerides to extrahepatic tissues.",false,,,http://purl.obolibrary.org/obo/CHEBI_6495,,,,,,,,,,,,,,,,,,,,,,"A class of lipoproteins of large size (30-80 nm), very low density (0.93-1.006 g/ml) particles with a core composed mainly of triglycerides and a surface monolayer of phospholipids and cholesterol into which are imbedded the apolipoproteins B, E, and C. VLDL facilitate the transport of endogenously made triglycerides to extrahepatic tissues.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,very-low-density lipoproteins|VLDL,,,CHEBI:39027,,,,,,,,,,,,,,,,,,,,,,very-low-density lipoprotein,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000063934,ZNF667,,Other designations: myocardial ischemic preconditioning upregulated 1 ortholog,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,MIPU1,,,,,,,,,,,,19,,,,,,MIM:611024|HPRD:08592|Ensembl:ENSG00000198046|HGNC:28854|Vega:OTTHUMG00000181941,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,zinc finger protein 667,,,19q13.43,,,,,,,,,,,,,,,,GO_0003677 (EC: IEA); GO_0005634 (EC: IEA); GO_0006351 (EC: IEA); GO_0006355 (EC: IEA); GO_0046872 (EC: IEA),,,,,,,,,PMID: 12477932; 14702039; 15489334; 16344560; 17397802; 20379614; 21139048; 21900206; 23080069; 24250222,,,,,,,,,,,,,,,OGG:3000063934,,,,,,,zinc finger protein 667,,,,,,,,,,,,,Other designations: myocardial ischemic preconditioning upregulated 1 ortholog,,ZNF667,,,,,,,,,,,,,,,,,,,,,,,63934,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,ZNF667,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000005447,POR,,Other designations: NADPH--cytochrome P450 reductase|NADPH-dependent cytochrome P450 reductase,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,P450R|CPR|CYPOR,,,,,,,,,,,,7,,,,,,Vega:OTTHUMG00000130413|HGNC:9208|HPRD:00485|Ensembl:ENSG00000127948|MIM:124015,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,P450 (cytochrome) oxidoreductase,,,7q11.2,,,,,,,,,,,,,,,,"GO_0003420 (EC: IEA); GO_0003958 (EC: IDA, PMID: 19448135); GO_0003958 (EC: TAS, PMID: 10048323); GO_0004128 (EC: IEA); GO_0005506 (EC: IEA); GO_0005515 (EC: IPI); GO_0005739 (EC: IEA); GO_0005789 (EC: IEA); GO_0007584 (EC: IEA); GO_0008941 (EC: IEA); GO_0009055 (EC: IEA); GO_0009437 (EC: IEA); GO_0009812 (EC: IEA); GO_0010181 (EC: IEA); GO_0016787 (EC: IEA); GO_0018393 (EC: IEA); GO_0019395 (EC: IEA); GO_0019899 (EC: IEA); GO_0032332 (EC: IEA); GO_0032770 (EC: IDA, PMID: 19448135); GO_0042493 (EC: IEA); GO_0043066 (EC: IEA); GO_0043154 (EC: IEA); GO_0043231 (EC: IDA, PMID: 9618440); GO_0043602 (EC: IEA); GO_0045542 (EC: IEA); GO_0045880 (EC: IEA); GO_0046210 (EC: IEA); GO_0047726 (EC: IEA); GO_0050660 (EC: IEA); GO_0050661 (EC: IEA); GO_0055114 (EC: IDA, PMID: 19448135); GO_0055114 (EC: TAS, PMID: 10048323); GO_0060192 (EC: IEA); GO_0070988 (EC: IEA); GO_0071372 (EC: IEA); GO_0071375 (EC: IEA); GO_0090031 (EC: IEA); GO_0090346 (EC: IDA, PMID: 19448135)",,,,,,,,,PMID: 1550342; 2513880; 2516426; 7703255; 8460938; 8615895; 8812989; 9335117; 9398194; 9618440; 9642268; 9787138; 9847074; 9888582; 10048323; 10448278; 10990198; 11035953; 11118675; 11123926; 11181502; 11329262; 11329263; 11350900; 11716457; 11926825; 11971899; 12477932; 12626517; 12688675; 12725870; 12782579; 12787027; 12901793; 14758361; 14999778; 15220035; 15264278; 15342556; 15483095; 15489334; 15666840; 15680923; 15793702; 16169070; 16344560; 16434211; 16445284; 16467261; 16520232; 16574318; 16998238; 17018578; 17440066; 17505056; 17580970; 17595315; 17635179; 17827787; 17881660; 18216718; 18230729; 18259105; 18397975; 18551037; 18559916; 18630181; 18681889; 18781797; 19161969; 19258400; 19374516; 19448135; 19598235; 19744540; 19805543; 19837910; 19858215; 19884324; 19913121; 20096935; 20301592; 20628086; 20697309; 20722625; 20732302; 20844025; 20849814; 20879989; 20940534; 21070833; 21081644; 21084761; 21139048; 21164260; 21252943; 21265736; 21393444; 21655236; 21726529; 21741353; 21762695; 21770725; 21843508; 21890473; 21900206; 21900384; 21963094; 21973081; 21988832; 22162478; 22177374; 22462747; 22545110; 22547083; 22797925; 23000965; 23353702; 23911089; 24196959,,,,,,,,,,,,,,,OGG:3000005447,,,,,,,P450 (cytochrome) oxidoreductase,,,,,,,,,,,,,Other designations: NADPH--cytochrome P450 reductase|NADPH-dependent cytochrome P450 reductase,,POR,,,,,,,,,,,,,,,,,,,,,,,5447,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,POR,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/GO_0033108,mitochondrial respiratory chain complex assembly,,"The aggregation, arrangement and bonding together of a set of components to form a mitochondrial respiratory chain complex.",false,,,http://purl.obolibrary.org/obo/GO_0065003,,,,,,,,,,,,,,,,,,,,,,"The aggregation, arrangement and bonding together of a set of components to form a mitochondrial respiratory chain complex.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0007005,GO:0033108,http://purl.obolibrary.org/obo/GO_0007005,,,,,,,,,,,,,,,,,,,,,mitochondrial respiratory chain complex assembly,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000414061,DNAJB3,,Other designations: dnaJ homolog subfamily B member 3,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,HCG3,,,,,,,,,,,,2,,,,,,HGNC:32397|HPRD:13638,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"DnaJ (Hsp40) homolog, subfamily B, member 3",,,2q37,,,,,,,,,,,,,,,,,,,,,,,,,PMID:12477932; 15891074; 16189514; 17207965; 21890473; 21906983; 21963094; 23000965; 23824909,,,,,,,,,,,,,,,OGG:3000414061,,,,,,,"DnaJ (Hsp40) homolog, subfamily B, member 3",,,,,,,,,,,,,Other designations: dnaJ homolog subfamily B member 3,,DNAJB3,,,,,,,,,,,,,,,,,,,,,,,414061,,,,,,,,9606,,,,,,,,,,,,,,,,,,,DNAJB3,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/GO_0006402,mRNA catabolic process,,"The chemical reactions and pathways resulting in the breakdown of mRNA, messenger RNA, which is responsible for carrying the coded genetic 'message', transcribed from DNA, to sites of protein assembly at the ribosomes.",false,,,http://purl.obolibrary.org/obo/GO_0009056,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways resulting in the breakdown of mRNA, messenger RNA, which is responsible for carrying the coded genetic 'message', transcribed from DNA, to sites of protein assembly at the ribosomes.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0006402,,,,,,,,,,,,,,,,,,,,,,mRNA catabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_63589,etravirine,"etravirine|4-({6-amino-5-bromo-2-[(4-cyanophenyl)amino]pyrimidin-4-yl}oxy)-3,5-dimethylbenzonitrile","An aminopyrimidine that consists of 2,6-diaminopyrimidine bearing a bromo substituent at position 5, a 4-cyano-2,6-dimethylphenoxy substituent at position 4 and having a 4-cyanophenyl substituent attached to the 2-amino group. NNRTI of HIV-1, binds directly to RT and blocks RNA-dependent and DNA-dependent DNA polymerase activities",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:21637112|PMID:21189339|PMID:21600016|PMID:21881478|PMID:21557669|PMID:25017682|CAS:269055-15-4|PMID:22089378|Reaxys:8945855|PMID:21173188|DrugBank:DB06414|PMID:21464253|PMID:21142266|PMID:22190606|PMID:21114458|PMID:21383098|PMID:22011983,,"An aminopyrimidine that consists of 2,6-diaminopyrimidine bearing a bromo substituent at position 5, a 4-cyano-2,6-dimethylphenoxy substituent at position 4 and having a 4-cyanophenyl substituent attached to the 2-amino group. NNRTI of HIV-1, binds directly to RT and blocks RNA-dependent and DNA-dependent DNA polymerase activities",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_53756|http://purl.obolibrary.org/obo/CHEBI_22587,,,,,"4-({6-amino-5-bromo-2-[(4-cyanophenyl)amino]pyrimidin-4-yl}oxy)-3,5-dimethylbenzonitrile",,etravirine,,,,,,,,,,,,,,,,,,,,,CHEBI:63589,,,,etravirine,,CHEBI:63589,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002721,ATF4 gene expression by eIF2a [ER stress - apoptosis],,"ATF4 gene expression by eIF2a is a subtype of gene expression: The process in which a gene sequence is converted into a mature ATF4 gene product or products (proteins or RNA) by eIF2a.
This process is dependent on the apoptosis and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000707,,,,,,,,,,,,,,,,,,,,PMID:23334697|http://www.ncbi.nlm.nih.gov/pubmed/18426796|Reactome:R-HSA-381128,,"ATF4 gene expression by eIF2a is a subtype of gene expression: The process in which a gene sequence is converted into a mature ATF4 gene product or products (proteins or RNA) by eIF2a.
This process is dependent on the apoptosis and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000829,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002558,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002966|http://purl.obolibrary.org/obo/TXPO_0002722,,,,,,,,,,,TXPO:0002721,,,,,,,,,,,,,,,,,,,,,,ATF4 gene expression by eIF2a [ER stress - apoptosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002728,PERK - signaling factor (canonical)[ER stress - apotosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002119,http://purl.obolibrary.org/obo/TXPO_0002440,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UniProt_Q9NZJ5|http://www.uniprot.org/entry/Q9NZJ5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002728,,,,,,,,,,,,,,,,,,,,,,PERK - signaling factor (canonical)[ER stress - apotosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002720,rosiglitazone [Cholestasis],,,false,,,http://purl.obolibrary.org/obo/CHEBI_50122|http://purl.obolibrary.org/obo/TXPO_0000749,,,,,,,,,,,,,,,,,,,,Wikipedia:Rosiglitazone|InChIKey:YASAKCUCGLMORW-UHFFFAOYSA-N|ATC:A10BG02|DrugBank:DB00412,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002720,,,,,,,,,,,,,,,,,,,,,,rosiglitazone [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002724,CAR (canonical)[Cholestasis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000276|http://purl.obolibrary.org/obo/TXPO_0003862,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,,,,,,TXPO:0002724,,,,,,,"Genes encoding for organic anion uptake (NTCP, OATPs), canalicular export (BSEP, MRP2) and alternative basolateral export (MRP3, MRP4) in liver are regulated by hepatocyte nuclear factors (HNF1, 3, 4) and nuclear (orphan) receptors (e.g., FXR, PXR, CAR, RAR, LRH-1, SHP, GR). Bile acids, proinflammatory cytokines, hormones and drugs mediate causative and adaptive transporter changes at a transcriptional level by interacting with these nuclear factors and receptors.",,,,,,,,,,,,,,,CAR (canonical)[Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002726,PXR (canonical)[Cholestasis],NR1I2 [Cholestasis],,false,,,http://purl.obolibrary.org/obo/TXPO_0000276|http://purl.obolibrary.org/obo/OGG_3000008856|http://purl.obolibrary.org/obo/TXPO_0003120,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:84385|NCBI-Human-GeneID:8856|NCBI-Mouse-GeneID:18171|http://omim.org/entry/603065,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,NR1I2 [Cholestasis],,,,,TXPO:0002726,,,,,,,,,,,,,,,,,,,,,,PXR (canonical)[Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002722,Chop expression by ATF4 [ER stress] [ER stress - apoptosis],,"Chop expession by ATF4 is a subtype of gene expression by transcriptional factor: The process in which a sequence of the Chop is converted into a mature gene product or products (proteins or RNA) by ATF4.
This process is dependent on the apoptosis and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000698,,,,,,,,,,,,,,,,,,,,PMID:26977301,,"Chop expession by ATF4 is a subtype of gene expression by transcriptional factor: The process in which a sequence of the Chop is converted into a mature gene product or products (proteins or RNA) by ATF4.
This process is dependent on the apoptosis and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002558,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002915,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002767,,,,,,,,,,,TXPO:0002722,,,,,,,,,,,,,,,,,,,,,,Chop expression by ATF4 [ER stress] [ER stress - apoptosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002727,ubiquitination of IkB,,Ubiquitination of IkB is a subtype of protein ubiquitination: The process in which one or more ubiquitin groups are added to IkB.,false,,,http://purl.obolibrary.org/obo/TXPO_0004096,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/HINO_0017767|PMID:12464174,,Ubiquitination of IkB is a subtype of protein ubiquitination: The process in which one or more ubiquitin groups are added to IkB.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002727,,,,,,,,,,,,,,,,,,,,,,ubiquitination of IkB,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002723,SHP1 (canonical)[Cholestasis],PTPN6 [cholestasis],"Nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis.
SHP-1 represses expression of CYP7A1 by inhibiting the activity of liver receptor homolog 1 (LRH-1), an orphan nuclear receptor known to regulate CYP7A1 expression.",false,,,http://purl.obolibrary.org/obo/TXPO_0000276|http://purl.obolibrary.org/obo/TXPO_1000358,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:15170|NCBI-Human-GeneID:5777|NCBI-Rat-GeneID:116689,,"Nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis.
SHP-1 represses expression of CYP7A1 by inhibiting the activity of liver receptor homolog 1 (LRH-1), an orphan nuclear receptor known to regulate CYP7A1 expression.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PTPN6 [cholestasis],,,,,TXPO:0002723,,,,,,,,,,,,,,,,,,,,,,SHP1 (canonical)[Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002725,GR (canonical)[Cholestasis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000276|http://purl.obolibrary.org/obo/TXPO_0003121,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:14815|NCBI-Human-GeneID:2908|NCBI-Rat-GeneID:24413,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002725,,,,,,,,,,,,,,,,,,,,,,GR (canonical)[Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002729,PERK - signaling factor (canonical)[ER stress - Refolding],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002119,http://purl.obolibrary.org/obo/TXPO_0002412,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UniProt_Q9NZJ5|http://www.uniprot.org/entry/Q9NZJ5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002729,,,,,,,,,,,,,,,,,,,,,,PERK - signaling factor (canonical)[ER stress - Refolding],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0002411,Uev1A,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000018,,,,,,,,,,IMR:0002411,,,,,,,,,,,,,,,,,,,,,,Uev1A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_35341,steroid,steroids,"Any of naturally occurring compounds and synthetic analogues, based on the cyclopenta[a]phenanthrene carbon skeleton, partially or completely hydrogenated; there are usually methyl groups at C-10 and C-13, and often an alkyl group at C-17. By extension, one or more bond scissions, ring expansions and/or ring contractions of the skeleton may have occurred. Natural steroids are derived biogenetically from triterpenoids.",false,,,http://purl.obolibrary.org/obo/CHEBI_18059,,,,,,,,,,,,,,,,,,,,SMILES: C12C(C3C(C(CC3)*)(C)CC1)CCC4C2(CCCC4)C,,"Any of naturally occurring compounds and synthetic analogues, based on the cyclopenta[a]phenanthrene carbon skeleton, partially or completely hydrogenated; there are usually methyl groups at C-10 and C-13, and often an alkyl group at C-17. By extension, one or more bond scissions, ring expansions and/or ring contractions of the skeleton may have occurred. Natural steroids are derived biogenetically from triterpenoids.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,steroids,,,,,CHEBI:35341,,,,,,,,,,,,,,,,,,,,,,steroid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000552891,DNAJC25-GNG10,,Other designations: DNAJC25-GNG10 protein|DNAJC25-GNG10 readthrough transcript,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,9,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,DNAJC25-GNG10 readthrough,,,9q31.3,,,,,,,,,,,,,,,,,,,,,,,,,PMID:8889548; 12477932; 14702039; 15164053; 15489334; 20967262,,,,,,,,,,,,,,,OGG:3000552891,,,,,,,DNAJC25-GNG10 readthrough,,,,,,,,,,,,,Other designations: DNAJC25-GNG10 protein|DNAJC25-GNG10 readthrough transcript,,DNAJC25-GNG10,,,,,,,,,,,,,,,,,,,,,,,552891,,,,,,,,9606,,,,,,,,,,,,,,,,,,,DNAJC25-GNG10,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0100222,MEKK1,MEK kinase 1|MAPK/ERK kinase kinase 1,,false,,,http://purl.obolibrary.org/obo/IMR_0000234,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MEK kinase 1|MAPK/ERK kinase kinase 1,,,,,IMR:0100222,,,,,,,,,,,,,,,,,,,,,,MEKK1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0004122,genitourinary system,Urogenitalsystem|UG tract|genito-urinary system|genitourinary tract|urogenital tract|GU tract|urogenital system,Anatomical system that has as its parts the organs concerned with the production and excretion of urine and those concerned with reproduction.,false,,,http://purl.obolibrary.org/obo/UBERON_0000467,,,,,,,,,,,,,,,,,,,,http://www.snomedbrowser.com/Codes/Details/278861008|http://purl.obolibrary.org/obo/NCIT_C12810|http://linkedlifedata.com/resource/umls/id/C0042066|BILA:0000122|MESH:D014566|XAO:0000140|galen:GenitoUrinarySystem|VHOG:0000286|BTO:0003091|AAO:0000624|EV:0100094|OpenCyc:Mx4rQRpVMgAKEdyHxgDggVfs8g|EHDAA:1013|UMLS:C0042066|EMAPA:16367|EFO:0003864|FMA:280610|GAID:362,,Anatomical system that has as its parts the organs concerned with the production and excretion of urine and those concerned with reproduction.,,,,,,,,Anatomical system that has as its parts the organs concerned with the production and excretion of urine and those concerned with reproduction.[AAO],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0000990|http://purl.obolibrary.org/obo/UBERON_0001008,,,,,,,,,,,,,urogenital system,,Urogenitalsystem|UG tract|genito-urinary system|genitourinary tract|urogenital tract|GU tract,"Kidneys and gonads (of vertebrates) develop from adjacent tissues, and after the excretory or urinary ducts have developed, the reproductive system usually taps into them or their derivatives.[well established][VHOG]",,UBERON:0004122,,,,,,,,,,,,,,,,,,,,,,genitourinary system,,,,,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100440,RasGEF,Ras guanine nucleotide exchange factor,,false,,,http://purl.obolibrary.org/obo/IMR_0000433,,,,,,,,,,,,,,,,,,,,GO:0005088,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ras guanine nucleotide exchange factor,,,,,IMR:0100440,,,,,,,,,,,,,,,,,,,,,,RasGEF,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0055114,oxidation-reduction process,oxidation reduction|oxidoreductase process,"A metabolic process that results in the removal or addition of one or more electrons to or from a substance, with or without the concomitant removal or addition of a proton or protons.",false,,,http://purl.obolibrary.org/obo/GO_0008152,,,,,,,,,,,,,,,,,,,,,,"A metabolic process that results in the removal or addition of one or more electrons to or from a substance, with or without the concomitant removal or addition of a proton or protons.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,oxidation reduction|oxidoreductase process,,,,,GO:0055114,,,,,,,,,,,,,,,,,,,,,,oxidation-reduction process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000611,IL-11 receptor,,,false,,,http://purl.obolibrary.org/obo/IMR_0000096,,,,,,,,,,,,,,,,,,,,GO:0004921,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000611,,,,,,,,,,,,,,,,,,,,,,IL-11 receptor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/DOID_0070114,Niemann-Pick disease type C2,NPC2,A Niemann-Pick disease that has_material_basis_in an autosomal recessive mutation of NPC2 on chromosome 14q24.3.,false,,,http://purl.obolibrary.org/obo/DOID_14504,,,,,,,,,,,,,,,,,,,,OMIM:607625|ICD10CM:E75.2,,A Niemann-Pick disease that has_material_basis_in an autosomal recessive mutation of NPC2 on chromosome 14q24.3.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,NPC2,,,,,DOID:0070114,,,,,,,,,,,,,,,,,,,,,,Niemann-Pick disease type C2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/DOID_0070111,Niemann-Pick disease type A,,A Niemann-Pick disease characterized by onset in infancy and involvement of neurological tissues that has_material_basis_in an autosomal recessive mutation of SMPD1 on chromosome 11p15.4.,false,,,http://purl.obolibrary.org/obo/DOID_14504,,,,,,,,,,,,,,,,,,,,OMIM:257200|ICD10CM:E75.2,,A Niemann-Pick disease characterized by onset in infancy and involvement of neurological tissues that has_material_basis_in an autosomal recessive mutation of SMPD1 on chromosome 11p15.4.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,DOID:0070111,,,,,,,,,,,,,,,,,,,,,,Niemann-Pick disease type A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/DOID_0070112,Niemann-Pick disease type B,,A Niemann-Pick disease characterized by visceral involvement only and survival into adulthood that has_material_basis_in an autosomal recessive mutation of SMPD1 on chromosome 11p15.4.,false,,,http://purl.obolibrary.org/obo/DOID_14504,,,,,,,,,,,,,,,,,,,,OMIM:607616|ICD10CM:E75.2,,A Niemann-Pick disease characterized by visceral involvement only and survival into adulthood that has_material_basis_in an autosomal recessive mutation of SMPD1 on chromosome 11p15.4.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,DOID:0070112,,,,,,,,,,,,,,,,,,,,,,Niemann-Pick disease type B,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/DOID_0070113,Niemann-Pick disease type C1,NPC1,A Niemann-Pick disease that has_material_basis_in an autosomal recessive mutation of NPC1 on chromosome 18q11.2.,false,,,http://purl.obolibrary.org/obo/DOID_14504,,,,,,,,,,,,,,,,,,,,ICD10CM:E75.2|OMIM:257220,,A Niemann-Pick disease that has_material_basis_in an autosomal recessive mutation of NPC1 on chromosome 18q11.2.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,NPC1,,,,,DOID:0070113,,,,,,,,,,,,,,,,,,,,,,Niemann-Pick disease type C1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000406,EGR4,NGFI-C|pAT133,,false,,,http://purl.obolibrary.org/obo/IMR_0000402,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,NGFI-C|pAT133,,,,,IMR:0000406,,,,,,,,,,,,,,,,,,,,,,EGR4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_0000000002,gene,,A gene is a material entity that represents the entire DNA sequence required for synthesis of a functional protein or RNA molecule.,false,,,http://purl.obolibrary.org/obo/BFO_0000040|http://purl.obolibrary.org/obo/CHEBI_33696,,,,,,,,,,,,,,,,,,,,,,A gene is a material entity that represents the entire DNA sequence required for synthesis of a functional protein or RNA molecule.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,OGG:0000000002,,,,,,,"Physical and functional unit of heredity, which carries information from one generation to the next. In molecular terms, it is the entire DNA sequence including exons, introns, and noncoding transcription-control regions necessary for production of a functional protein or RNA.",,,,,,,,,,,,,,,gene,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_50177,dermatologic drug,dermatological agent|dermatologic drugs|dermatologic agent,A drug used to treat or prevent skin disorders or for the routine care of skin.,false,,,http://purl.obolibrary.org/obo/CHEBI_23888,,,,,,,,,,,,,,,,,,,,,,A drug used to treat or prevent skin disorders or for the routine care of skin.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,dermatological agent|dermatologic drugs|dermatologic agent,,,,,,,,,,,,,,,,,,,,,CHEBI:50177,,,,dermatologic drug,,CHEBI:50177,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000517,GPHN (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:268566|NCBI-Rat-GeneID:64845|NCBI-Human-GeneID:10243,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000010243,,,,,,,,,,,,,TXPO:1000517,,,,,,,,,,,,,,,,,,,,,,GPHN (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000511,CYP1A1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1543|NCBI-Rat-GeneID:24296|NCBI-Mouse-GeneID:13076,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001543,,,,,,,,,,,,,TXPO:1000511,,,,,,,,,,,,,,,,,,,,,,CYP1A1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000512,CYP1A2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24297|NCBI-Human-GeneID:1544|NCBI-Mouse-GeneID:13077,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001544,,,,,,,,,,,,,TXPO:1000512,,,,,,,,,,,,,,,,,,,,,,CYP1A2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000514,DPYD (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:81656|NCBI-Human-GeneID:1806|NCBI-Mouse-GeneID:99586,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001806,,,,,,,,,,,,,TXPO:1000514,,,,,,,,,,,,,,,,,,,,,,DPYD (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000513,DHFR (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24312|NCBI-Human-GeneID:1719|NCBI-Mouse-GeneID:13361,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001719,,,,,,,,,,,,,TXPO:1000513,,,,,,,,,,,,,,,,,,,,,,DHFR (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000519,HMMR (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:25460|NCBI-Mouse-GeneID:15366|NCBI-Human-GeneID:3161,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000003161,,,,,,,,,,,,,TXPO:1000519,,,,,,,,,,,,,,,,,,,,,,HMMR (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000516,GFRA1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:2674|NCBI-Rat-GeneID:25454|NCBI-Mouse-GeneID:14585,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000002674,,,,,,,,,,,,,TXPO:1000516,,,,,,,,,,,,,,,,,,,,,,GFRA1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000510,CXCL8 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:3576,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:1000510,,,,,,,,,,,,,,,,,,,,,,CXCL8 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000518,HILPDA (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:29923|NCBI-Rat-GeneID:100361568|NCBI-Mouse-GeneID:69573,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000029923,,,,,,,,,,,,,TXPO:1000518,,,,,,,,,,,,,,,,,,,,,,HILPDA (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000515,FEN1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:2237|NCBI-Mouse-GeneID:14156|NCBI-Rat-GeneID:84490,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000002237,,,,,,,,,,,,,TXPO:1000515,,,,,,,,,,,,,,,,,,,,,,FEN1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0071897,DNA biosynthetic process,DNA synthesis|DNA formation|DNA anabolism|DNA biosynthesis,"The cellular DNA metabolic process resulting in the formation of DNA, deoxyribonucleic acid, one of the two main types of nucleic acid, consisting of a long unbranched macromolecule formed from one or two strands of linked deoxyribonucleotides, the 3'-phosphate group of each constituent deoxyribonucleotide being joined in 3',5'-phosphodiester linkage to the 5'-hydroxyl group of the deoxyribose moiety of the next one.",false,,,http://purl.obolibrary.org/obo/GO_0009058,,,,,,,,,,,,,,,,,,,,,,"The cellular DNA metabolic process resulting in the formation of DNA, deoxyribonucleic acid, one of the two main types of nucleic acid, consisting of a long unbranched macromolecule formed from one or two strands of linked deoxyribonucleotides, the 3'-phosphate group of each constituent deoxyribonucleotide being joined in 3',5'-phosphodiester linkage to the 5'-hydroxyl group of the deoxyribose moiety of the next one.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_16991,,,,,,,,,,,,,,DNA synthesis|DNA formation|DNA anabolism|DNA biosynthesis,,,,,GO:0071897,,,,,,,,,,,,,,,,,,,,,,DNA biosynthetic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000722,attenuation of translation [ER stress],,"Translational attenuation is a regulatory mechanism analogous to ribosome-mediated transcriptional attenuation. the system requires the presence of a short orf, called a leader peptide, encoded in the mrna upstream of the ribosome-binding site and start codon of the gene whose translation is to be regulated. certain conditions, such as presence of the antibiotic tetracycline in bacteria or amino acid starvation, may cause slowing or stalling of the ribosome translating the leader peptide. the stalled ribosome masks a region of the mrna and affects which of two alternative mrna folded structures will form, therefore controlling whether or not a ribosome will bind and initiate translation of the downstream gene. translational attenuation is analogous to ribosome-mediated transcriptional attenuation, in which mrna remodeling caused by ribosome stalling regulates transcriptional termination rather than translational initiation.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/GO_0009386|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,PMID:9930704|PMID:23334697,,"Translational attenuation is a regulatory mechanism analogous to ribosome-mediated transcriptional attenuation. the system requires the presence of a short orf, called a leader peptide, encoded in the mrna upstream of the ribosome-binding site and start codon of the gene whose translation is to be regulated. certain conditions, such as presence of the antibiotic tetracycline in bacteria or amino acid starvation, may cause slowing or stalling of the ribosome translating the leader peptide. the stalled ribosome masks a region of the mrna and affects which of two alternative mrna folded structures will form, therefore controlling whether or not a ribosome will bind and initiate translation of the downstream gene. translational attenuation is analogous to ribosome-mediated transcriptional attenuation, in which mrna remodeling caused by ribosome stalling regulates transcriptional termination rather than translational initiation.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000061|http://purl.obolibrary.org/obo/TXPO_0000123|http://purl.obolibrary.org/obo/TXPO_0002762,,http://purl.obolibrary.org/obo/TXPO_0002157,,,,,,,,,,,,,,,,TXPO:0000722,,,,,,,,,,,,,,,,,,,,,,attenuation of translation [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000725,XBP1 splicing,,XBP1 splicing is a subtype of removing: The process of removing sections of the XBP1 RNA transcript to remove sequences.,false,,,http://purl.obolibrary.org/obo/GO_0008380,,,,,,,,,,,,,,,,,,,,,,XBP1 splicing is a subtype of removing: The process of removing sections of the XBP1 RNA transcript to remove sequences.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000725,,,,,,,,,,,,,,,,,,,,,,XBP1 splicing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000728,ERAD related gene expression [ER stress],,"ERAD related gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature ER-associated degradation (ERAD) gene product or products (proteins or RNA).
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/TXPO_0000727,,,,,,,,,,,,,,,,,,,,,,"ERAD related gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature ER-associated degradation (ERAD) gene product or products (proteins or RNA).
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002709|http://purl.obolibrary.org/obo/TXPO_0002696|http://purl.obolibrary.org/obo/TXPO_0002710,,http://purl.obolibrary.org/obo/TXPO_0002610,,,,,,,,,,,,,,,,TXPO:0000728,,,,,,,,,,,,,,,,,,,,,,ERAD related gene expression [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000724,SLCO1B1 (canonical)[Cholestasis],OATP1B1|OATP-C|OATP2|SLC21A6,,false,,,http://purl.obolibrary.org/obo/TXPO_0000272,,,,,,,,,,,,,,,,,,,,http://omim.org/entry/604843,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C107150,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,OATP1B1|OATP-C|OATP2|SLC21A6,,,,,TXPO:0000724,,,,,,,"The sodium-independent portion of bile salt uptake is mediated by OATPs (organic anion transporting polypeptides). OATP1B1 (SLCO1B1), OATP1B3 (SLCO1B3), and OATP2B1 (SLCO2B1) are expressed at the basolateral plasma membrane of hepatocytes, although OATP2B1 appears not to be a bile Salt transporter.",,,,,,,,,,,,,,,SLCO1B1 (canonical)[Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000721,IRE1 signaling (primitive) [ER stress - refolding],,"IRE1 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the IRE1 (Inositol-requiring transmembrane kinase/endonuclease). IRE1 generally plays a endoplasmic reticulum membrane stress sensor role.
This process is dependent on the refolding and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0003736|http://purl.obolibrary.org/obo/TXPO_0002571,,,,,,,,,,,,,,,,,,,,,,"IRE1 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the IRE1 (Inositol-requiring transmembrane kinase/endonuclease). IRE1 generally plays a endoplasmic reticulum membrane stress sensor role.
This process is dependent on the refolding and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000721,,,,,,,,,,,,,,,,,,TXPO:0000721,,,,,,,,,,,,,,,,,,,,,,IRE1 signaling (primitive) [ER stress - refolding],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000726,XBP1 splicing [ER stress],,"XBP1 splicing is a subtype of removing: The process of removing sections of the XBP1 RNA transcript to remove sequences.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0003736|http://purl.obolibrary.org/obo/TXPO_0000725,,,,,,,,,,,,,,,,,,,,,,"XBP1 splicing is a subtype of removing: The process of removing sections of the XBP1 RNA transcript to remove sequences.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000726,,,,,,,,,,,,,,,,,,,,,,XBP1 splicing [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000723,XBP1 activation,,XBP1 activation is a subtype of activation of transcription factor: A process that changes the activity of XBP1 (X-Box Binding Protein 1) to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000124,,,,,,,,,,,,,,,,,,,,,,XBP1 activation is a subtype of activation of transcription factor: A process that changes the activity of XBP1 (X-Box Binding Protein 1) to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001968,,,,,,,,,,,,,,,,,TXPO:0000723,,,,,,,,,,,,,,,,,,,,,,XBP1 activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000727,ERAD related gene expression,,ERAD related gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature ER-associated degradation (ERAD)  gene product or products (proteins or RNA).,false,,,http://purl.obolibrary.org/obo/GO_0010467,,,,,,,,,,,,,,,,,,,,,,ERAD related gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature ER-associated degradation (ERAD)  gene product or products (proteins or RNA).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000727,,,,,,,,,,,,,,,,,,,,,,ERAD related gene expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000729,IRE1 activation,,IRE1 activation is a subtype of molecular activation: A process that changes the activity of the IRE1 to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000023,,,,,,,,,,,,,,,,,,,,,,IRE1 activation is a subtype of molecular activation: A process that changes the activity of the IRE1 to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000729,,,,,,,,,,,,,,,,,,,,,,IRE1 activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000720,IRE1 signaling (primitive),,IRE1 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the IRE1 (Inositol-requiring transmembrane kinase/endonuclease). IRE1 generally plays a endoplasmic reticulum membrane stress sensor  role.,false,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,,,IRE1 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the IRE1 (Inositol-requiring transmembrane kinase/endonuclease). IRE1 generally plays a endoplasmic reticulum membrane stress sensor  role.,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002601,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002155,,,,,,,,,,,,,,,,TXPO:0000720,,,,,,,,,,,,,,,,,,,,,,IRE1 signaling (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000004193,MDM2,,"Other designations: E3 ubiquitin-protein ligase Mdm2|Mdm2, p53 E3 ubiquitin protein ligase homolog|Mdm2, transformed 3T3 cell double minute 2, p53 binding protein|double minute 2, human homolog of; p53-binding protein|oncoprotein Mdm2",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,HDMX|ACTFS|hdm2,,,,,,,,,,,,12,,,,,,HGNC:6973|MIM:164785|Ensembl:ENSG00000135679|HPRD:01272|Vega:OTTHUMG00000142827,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"MDM2 oncogene, E3 ubiquitin protein ligase",,,12q14.3-q15,,,,,,,,,,,,,,,,"GO_0000122 (EC: IDA, PMID: 9271120); GO_0002039 (EC: IPI, PMID: 15053879); GO_0004842 (EC: IDA, PMID: 9450543); GO_0004842 (EC: IMP, PMID: 19372219); GO_0005515 (EC: IPI, PMID: 10196247); GO_0005634 (EC: IDA, PMID: 10360174); GO_0005634 (EC: IMP); GO_0005654 (EC: IDA, PMID: 10707090); GO_0005654 (EC: TAS); GO_0005730 (EC: IDA, PMID: 10707090); GO_0005737 (EC: IMP); GO_0005829 (EC: TAS); GO_0005886 (EC: TAS); GO_0006461 (EC: IDA, PMID: 10608892); GO_0006977 (EC: IMP); GO_0006977 (EC: TAS); GO_0007089 (EC: IEA); GO_0007173 (EC: TAS); GO_0007268 (EC: TAS); GO_0008270 (EC: IDA, PMID: 10722742); GO_0008284 (EC: TAS, PMID: 7791904); GO_0008543 (EC: TAS); GO_0009743 (EC: IEA); GO_0010039 (EC: IEA); GO_0010628 (EC: IEA); GO_0010955 (EC: IEA); GO_0016032 (EC: IEA); GO_0016567 (EC: IDA, PMID: 15878855); GO_0016604 (EC: IDA, Qualifier: colocalizes_with, PMID: 10360174); GO_0018205 (EC: IMP, PMID: 19372219); GO_0019899 (EC: IPI, PMID: 15577914); GO_0030666 (EC: TAS); GO_0031625 (EC: IPI, PMID: 18382127); GO_0031648 (EC: IDA, PMID: 10360174); GO_0032026 (EC: IEA); GO_0032436 (EC: IDA, PMID: 11278372); GO_0034504 (EC: IDA, PMID: 10360174); GO_0038095 (EC: TAS); GO_0042176 (EC: IDA, PMID: 9153395); GO_0042220 (EC: IEA); GO_0042493 (EC: IEA); GO_0042787 (EC: IDA, PMID: 11278372); GO_0042802 (EC: IPI, PMID: 17159902); GO_0042975 (EC: IEA); GO_0043066 (EC: IEA); GO_0043154 (EC: IEA); GO_0043234 (EC: IDA, PMID: 9529249); GO_0043278 (EC: IEA); GO_0043518 (EC: IDA, PMID: 10360174); GO_0045087 (EC: TAS); GO_0045184 (EC: IDA, PMID: 10360174); GO_0045202 (EC: IEA); GO_0045472 (EC: IEA); GO_0045892 (EC: IDA, PMID: 9271120); GO_0045931 (EC: IMP, PMID: 17290220); GO_0046677 (EC: IEP); GO_0046827 (EC: IEA); GO_0048011 (EC: TAS); GO_0048015 (EC: TAS); GO_0070301 (EC: IEA); GO_0071157 (EC: IDA, PMID: 9529249); GO_0071229 (EC: IEA); GO_0071236 (EC: IEA); GO_0071301 (EC: IEA); GO_0071312 (EC: IEA); GO_0071375 (EC: IEA); GO_0071391 (EC: IEA); GO_0071456 (EC: IEP); GO_0071494 (EC: IEA); GO_0097110 (EC: IEA)",,,,,,,,,PMID: 1535557; 1614537; 7590734; 7606365; 7651818; 7686617; 7689721; 7791904; 7935455; 8058315; 8064888; 8219216; 8705862; 8875929; 9070662; 9131587; 9153395; 9153396; 9223638; 9270029; 9271120; 9278461; 9363941; 9388200; 9450543; 9485008; 9529248; 9529249; 9619834; 9632782; 9653180; 9671804; 9724636; 9809062; 9840926; 10074928; 10078201; 10188733; 10196247; 10207051; 10218570; 10360174; 10435614; 10469568; 10523842; 10561590; 10562557; 10597303; 10608892; 10611322; 10640274; 10681559; 10707090; 10713175; 10721693; 10722742; 10723139; 10737800; 10766163; 10781812; 10801444; 10822382; 10827196; 10871849; 10906133; 10949923; 10982879; 11046142; 11057904; 11070080; 11073989; 11087894; 11107050; 11172000; 11178989; 11223036; 11278372; 11306511; 11307150; 11331603; 11336244; 11351297; 11384992; 11397945; 11486026; 11494046; 11504915; 11562347; 11588219; 11590071; 11597128; 11606419; 11709713; 11714701; 11715018; 11718560; 11744695; 11764099; 11779693; 11839563; 11839577; 11859876; 11867628; 11877395; 11894120; 11923280; 11925449; 11927554; 11939408; 11953423; 11953887; 11956627; 11960368; 11960904; 11964305; 11983168; 12032546; 12052755; 12068014; 12080472; 12082526; 12082592; 12085228; 12110584; 12138177; 12145204; 12150820; 12167711; 12208736; 12231395; 12232053; 12297306; 12370303; 12372616; 12381304; 12393902; 12393906; 12414343; 12421820; 12426395; 12450795; 12477932; 12483531; 12488444; 12507556; 12538596; 12552135; 12556559; 12565795; 12582152; 12582232; 12582944; 12606552; 12620409; 12640129; 12646252; 12661905; 12687276; 12730202; 12740913; 12750288; 12759344; 12771937; 12782320; 12821780; 12842086; 12860999; 12867035; 12874296; 12883554; 12897156; 12915590; 12917636; 12926050; 12927808; 12944468; 12963717; 14499615; 14507915; 14507994; 14522887; 14559824; 14565663; 14578343; 14580339; 14587869; 14596917; 14610316; 14612427; 14614050; 14633995; 14654951; 14671306; 14720195; 14723816; 14729628; 14730303; 14731389; 14741215; 14756544; 14757843; 14761977; 14769800; 15001356; 15001357; 15013777; 15024078; 15024701; 15029243; 15044952; 15053879; 15053880; 15064742; 15144954; 15154850; 15192123; 15195100; 15210108; 15218947; 15225550; 15242646; 15273720; 15280377; 15308643; 15313915; 15314155; 15314173; 15314174; 15315825; 15321712; 15337531; 15355988; 15364927; 15375804; 15448710; 15485814; 15492852; 15525514; 15527798; 15546622; 15548678; 15550242; 15558054; 15577914; 15577944; 15604276; 15622743; 15632057; 15640443; 15644444; 15688025; 15714438; 15720184; 15720185; 15720186; 15720187; 15723837; 15733365; 15734740; 15734743; 15735750; 15742432; 15771712; 15782125; 15788536; 15807633; 15824742; 15832769; 15843377; 15848166; 15862297; 15866118; 15867431; 15876864; 15876874; 15878855; 15902285; 15908423; 15916963; 15933712; 15943041; 15950904; 15953616; 15963787; 15975924; 15985438; 16009130; 16023600; 16027727; 16055726; 16082221; 16107876; 16142358; 16152608; 16159876; 16163388; 16167062; 16170383; 16173922; 16202543; 16203772; 16212962; 16219768; 16227609; 16230424; 16239061; 16246554; 16258005; 16258514; 16287156; 16288830; 16314418; 16331255; 16337594; 16338389; 16343421; 16374512; 16394138; 16402859; 16432196; 16434608; 16439685; 16474402; 16478747; 16479015; 16496380; 16510145; 16563154; 16579792; 16621805; 16624812; 16624822; 16636310; 16675470; 16678796; 16696307; 16714300; 16737965; 16738062; 16751805; 16803902; 16815295; 16818855; 16825430; 16825434; 16845383; 16861890; 16866370; 16870621; 16876289; 16877339; 16883576; 16892553; 16896050; 16905769; 16914573; 16934800; 16943424; 16965791; 16980297; 16980628; 16983111; 16984978; 17003841; 17006543; 17013834; 17015431; 17018602; 17018606; 17056014; 17060450; 17080308; 17094469; 17096342; 17110379; 17110929; 17116689; 17120309; 17123590; 17139261; 17159902; 17170710; 17170761; 17171684; 17188136; 17214373; 17226766; 17237821; 17242401; 17290220; 17297477; 17301054; 17302414; 17310983; 17318220; 17327702; 17339337; 17347673; 17349959; 17353187; 17354236; 17359998; 17360557; 17371838; 17373842; 17380154; 17387621; 17426254; 17460193; 17468107; 17470788; 17473193; 17488676; 17498302; 17500067; 17513604; 17525743; 17527046; 17536310; 17537232; 17538168; 17545525; 17545546; 17545634; 17546054; 17553029; 17568997; 17576019; 17592964; 17616658; 17616682; 17620186; 17627285; 17634539; 17638920; 17640893; 17671677; 17671841; 17680991; 17684018; 17684142; 17697133; 17698841; 17717065; 17719241; 17721920; 17827408; 17846171; 17848574; 17875722; 17879958; 17895748; 17904523; 17909018; 17909070; 17914240; 17936559; 17938575; 17942278; 17957785; 17974989; 17981213; 17984062; 17989425; 18023538; 18026875; 18080767; 18086778; 18086887; 18096571; 18172499; 18199551; 18199985; 18204439; 18206965; 18214854; 18219319; 18234963; 18234968; 18235222; 18262501; 18264029; 18269578; 18281248; 18292944; 18309296; 18311135; 18313915; 18314481; 18317451; 18332046; 18332867; 18332869; 18348658; 18355939; 18356162; 18359851; 18381604; 18382127; 18390844; 18398041; 18418067; 18423915; 18426907; 18426989; 18433484; 18433491; 18451149; 18459109; 18462472; 18467333; 18467716; 18471438; 18480108; 18487080; 18499675; 18500263; 18504050; 18508789; 18519749; 18519798; 18520179; 18541670; 18544533; 18547962; 18548093; 18548200; 18558393; 18559624; 18560357; 18566590; 18568525; 18572327; 18575717; 18577987; 18582208; 18583933; 18604177; 18607552; 18612801; 18618574; 18632619; 18638452; 18644346; 18646312; 18665269; 18676680; 18706692; 18711402; 18723444; 18725577; 18754770; 18779328; 18781178; 18799058; 18804411; 18809412; 18813780; 18814047; 18815136; 18826207; 18828900; 18835771; 18836421; 18922973; 18948082; 18950845; 18951086; 18953830; 18976073; 19015526; 19015838; 19020940; 19029147; 19029954; 19032150; 19033382; 19046423; 19062713; 19064572; 19074170; 19075013; 19081178; 19082401; 19094228; 19098288; 19098711; 19106616; 19116388; 19124015; 19124506; 19128510; 19132120; 19144119; 19144715; 19150978; 19160491; 19165858; 19166840; 19166854; 19170196; 19176998; 19188367; 19193430; 19204927; 19217357; 19219073; 19226467; 19233569; 19234109; 19237173; 19237606; 19240029; 19244339; 19246469; 19247369; 19249676; 19255450; 19264476; 19273224; 19286999; 19287195; 19302219; 19303885; 19305137; 19318491; 19318567; 19321440; 19339270; 19344876; 19346994; 19357310; 19363159; 19369353; 19372219; 19379464; 19383811; 19411066; 19423162; 19432880; 19433585; 19448627; 19451596; 19454362; 19455066; 19468865; 19470478; 19470936; 19477214; 19483087; 19488782; 19492228; 19505873; 19507240; 19509552; 19521721; 19523862; 19524506; 19526525; 19541625; 19541936; 19542078; 19560254; 19560264; 19573080; 19573916; 19580521; 19590512; 19590949; 19594747; 19596022; 19597489; 19617712; 19619542; 19625176; 19631207; 19639206; 19648117; 19649205; 19656744; 19657064; 19671680; 19679062; 19683495; 19690564; 19690970; 19692168; 19696166; 19707196; 19751436; 19752772; 19756449; 19759023; 19764997; 19772793; 19773279; 19773383; 19779722; 19784069; 19789190; 19798103; 19799083; 19808967; 19811804; 19816404; 19821490; 19833129; 19837266; 19837670; 19838211; 19842060; 19861417; 19861461; 19874399; 19879840; 19934289; 19938200; 19941079; 19941302; 19941740; 19945467; 19946469; 19954744; 19955655; 19965871; 20019189; 20021639; 20025780; 20080680; 20081368; 20086099; 20089965; 20096447; 20110711; 20124408; 20145180; 20153724; 20172729; 20173098; 20190571; 20195357; 20196171; 20200430; 20204299; 20219101; 20232390; 20232446; 20234175; 20306673; 20308078; 20308654; 20333547; 20358297; 20370686; 20372076; 20380574; 20385133; 20388212; 20395212; 20398418; 20431480; 20438709; 20447891; 20453000; 20453884; 20473904; 20479273; 20484049; 20491880; 20503107; 20520810; 20528739; 20535124; 20538323; 20540933; 20542919; 20547751; 20554519; 20571051; 20577896; 20582981; 20583115; 20587610; 20588255; 20591429; 20591651; 20592017; 20598683; 20601938; 20622329; 20639885; 20644561; 20657550; 20659896; 20664183; 20680659; 20694676; 20705607; 20708156; 20713054; 20713061; 20724842; 20733054; 20736372; 20803550; 20813000; 20816748; 20822933; 20832750; 20849851; 20849854; 20855462; 20856200; 20858735; 20871633; 20874444; 20875869; 20881839; 20922573; 20930521; 20935493; 20948295; 20951946; 20972445; 20972456; 20979563; 21034743; 21047201; 21048031; 21051533; 21051655; 21057548; 21060154; 21071676; 21080085; 21081495; 21081496; 21084285; 21084564; 21088494; 21092204; 21093410; 21097889; 21098709; 21113617; 21132010; 21133853; 21149449; 21157430; 21170087; 21183956; 21191186; 21204735; 21209460; 21211512; 21229604; 21261729; 21268124; 21285945; 21290342; 21295542; 21305319; 21316347; 21316605; 21317463; 21317535; 21317707; 21317885; 21333377; 21336260; 21338495; 21339197; 21386656; 21389118; 21399665; 21402876; 21404460; 21444629; 21451571; 21454483; 21455220; 21460101; 21466165; 21477265; 21478269; 21479369; 21503588; 21504894; 21525355; 21530075; 21539745; 21547352; 21561866; 21565629; 21572037; 21602883; 21624367; 21647873; 21656578; 21665242; 21667122; 21685937; 21706156; 21725357; 21725850; 21726810; 21743494; 21750659; 21756282; 21761395; 21768776; 21770737; 21785463; 21804542; 21814224; 21822304; 21833626; 21844567; 21852383; 21862876; 21867960; 21877955; 21887275; 21890473; 21896991; 21900752; 21903592; 21906983; 21925390; 21925707; 21930127; 21933600; 21957016; 21963094; 21965653; 21982800; 21986495; 21986500; 21988832; 21990374; 22004076; 22004425; 22032989; 22038760; 22047081; 22056306; 22081073; 22083959; 22085928; 22095636; 22103682; 22104152; 22108807; 22120712; 22124327; 22128911; 22134502; 22137485; 22157679; 22173032; 22180099; 22180176; 22187011; 22195963; 22197810; 22205265; 22244827; 22245141; 22264786; 22266832; 22266850; 22266868; 22285926; 22290440; 22292622; 22301280; 22301498; 22301501; 22310835; 22318725; 22330136; 22331460; 22333590; 22336889; 22336942; 22337874; 22343716; 22349818; 22350919; 22379189; 22383580; 22391559; 22397410; 22410433; 22411991; 22413855; 22444248; 22467100; 22472959; 22487680; 22487911; 22493164; 22505724; 22510592; 22525275; 22558411; 22563815; 22566641; 22575647; 22586610; 22591662; 22593196; 22609775; 22634534; 22659184; 22668018; 22672907; 22685613; 22699518; 22701761; 22705356; 22710720; 22716509; 22729912; 22733537; 22737255; 22744426; 22773013; 22777350; 22787160; 22797925; 22807444; 22819825; 22825724; 22825850; 22842367; 22843172; 22844496; 22869143; 22892142; 22902369; 22902907; 22907703; 22912717; 22914606; 22914926; 22916154; 22916255; 22938470; 22939400; 22940738; 22976441; 22989009; 23028042; 23039052; 23039163; 23044487; 23045280; 23060298; 23089923; 23092970; 23096687; 23113306; 23132866; 23134341; 23139272; 23145162; 23147543; 23150668; 23159155; 23167335; 23167337; 23169665; 23201157; 23210739; 23218882; 23238568; 23244604; 23246961; 23252402; 23259295; 23260144; 23261415; 23292895; 23303139; 23318437; 23324352; 23347235; 23352573; 23356517; 23359199; 23383041; 23383273; 23391506; 23393136; 23405218; 23416275; 23423487; 23425231; 23437037; 23438693; 23451111; 23483203; 23506010; 23506213; 23529275; 23563151; 23564787; 23572512; 23609977; 23624782; 23652204; 23661019; 23671280; 23677067; 23679294; 23728348; 23745682; 23747528; 23749209; 23776060; 23776465; 23777425; 23786219; 23802716; 23826318; 23826411; 23837945; 23845465; 23870475; 23871895; 23874713; 23912932; 23933584; 23934659; 23946421; 23979978; 23982177; 23994832; 24003224; 24018792; 24027430; 24061453; 24143256; 24163099; 24167073; 24174547; 24240108; 24314634; 24325471; 24361594; 24413081; 24413661,,,,,,,,,,,,,,,OGG:3000004193,,,,,,,"MDM2 oncogene, E3 ubiquitin protein ligase",,,,,,,,,,,,,"Other designations: E3 ubiquitin-protein ligase Mdm2|Mdm2, p53 E3 ubiquitin protein ligase homolog|Mdm2, transformed 3T3 cell double minute 2, p53 binding protein|double minute 2, human homolog of; p53-binding protein|oncoprotein Mdm2",,MDM2,,,,,,,,,,,,,,,,,,,,,,,4193,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,MDM2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000004199,ME1,,"Other designations: Malic enzyme, cytoplasmic|NADP-ME|NADP-dependent malic enzyme|malate dehydrogenase|malic enzyme 1, soluble|pyruvic-malic carboxylase",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,HUMNDME|MES,,,,,,,,,,,,6,,,,,,MIM:154250|HPRD:01102|HGNC:6983|Vega:OTTHUMG00000015111|Ensembl:ENSG00000065833,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"malic enzyme 1, NADP(+)-dependent, cytosolic",,,6q12,,,,,,,,,,,,,,,,"GO_0004470 (EC: IDA, PMID: 7622060); GO_0004471 (EC: IEA); GO_0004473 (EC: IDA, PMID: 8187880); GO_0004473 (EC: ISS); GO_0005739 (EC: IEA); GO_0005829 (EC: ISS); GO_0005829 (EC: TAS); GO_0005975 (EC: NAS, PMID: 8187880); GO_0006108 (EC: IDA, PMID: 7622060); GO_0006741 (EC: TAS, PMID: 8187880); GO_0008948 (EC: IEA); GO_0009055 (EC: TAS, PMID: 7622060); GO_0009725 (EC: ISS); GO_0009743 (EC: TAS, PMID: 8187880); GO_0030145 (EC: IDA, PMID: 7622060); GO_0043531 (EC: TAS, PMID: 7622060); GO_0044255 (EC: TAS); GO_0044281 (EC: TAS); GO_0050661 (EC: TAS, PMID: 7622060); GO_0051262 (EC: IEA); GO_0051287 (EC: TAS, PMID: 7622060)",,,,,,,,,PMID: 1088824; 2015102; 3169368; 4689040; 7496989; 7622060; 7757881; 8125298; 8187880; 8804575; 9174159; 11085912; 11352855; 11358520; 12121650; 12477932; 14574404; 15489334; 16344560; 16757477; 18029348; 18660489; 19293334; 19416979; 19464998; 20877624; 21139048; 21555518; 21890473; 21906983; 21963094; 22456781; 22863883; 23114090; 23284632; 23334421,,,,,,,,,,,,,,,OGG:3000004199,,,,,,,"malic enzyme 1, NADP(+)-dependent, cytosolic",,,,,,,,,,,,,"Other designations: Malic enzyme, cytoplasmic|NADP-ME|NADP-dependent malic enzyme|malate dehydrogenase|malic enzyme 1, soluble|pyruvic-malic carboxylase",,ME1,,,,,,,,,,,,,,,,,,,,,,,4199,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,ME1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_25555,nitrogen atom,N,,false,,,http://purl.obolibrary.org/obo/CHEBI_33250,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,N,,,,,CHEBI:25555,,,,,,,,,,,,,,,,,,,,,,nitrogen atom,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000000285,ANGPT2,,Other designations: ANG-2|Tie2-ligand|angiopoietin-2|angiopoietin-2B|angiopoietin-2a,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,ANG2|AGPT2,,,,,,,,,,,,8,,,,,,Ensembl:ENSG00000091879|Vega:OTTHUMG00000090365|HPRD:03563|MIM:601922|HGNC:485,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,angiopoietin 2,,,8p23.1,,,,,,,,,,,,,,,,"GO_0001525 (EC: IEA); GO_0001666 (EC: IEA); GO_0005102 (EC: TAS, PMID:10766762); GO_0005515 (EC: IPI); GO_0005576 (EC: TAS); GO_0005615 (EC: IDA, PMID:9660821); GO_0005634 (EC: IEA); GO_0005886 (EC: IEA); GO_0007165 (EC: TAS, PMID:10766762); GO_0007281 (EC: IEA); GO_0007596 (EC: TAS); GO_0009314 (EC: IEA); GO_0009612 (EC: IEA); GO_0009749 (EC: IEA); GO_0010812 (EC: IEA); GO_0014070 (EC: IEA); GO_0014823 (EC: IEA); GO_0016525 (EC: IEA); GO_0030971 (EC: IPI, PMID:19922791); GO_0031100 (EC: IEA); GO_0042995 (EC: IEA); GO_0043537 (EC: IDA, PMID:9660821); GO_0045766 (EC: IEA); GO_0046872 (EC: IEA); GO_0048014 (EC: IDA, PMID:19922791); GO_0050900 (EC: TAS); GO_0050928 (EC: IDA, PMID:9660821); GO_0060135 (EC: IEA); GO_0071363 (EC: IEA); GO_0072012 (EC: ISS)",,,,,,,,,PMID:8125298; 9204896; 9545648; 9660821; 9723709; 9927494; 10051567; 10343124; 10514510; 10766762; 10964717; 11447223; 11578860; 11856872; 11861279; 12138242; 12176040; 12213874; 12427764; 12477932; 12612904; 12717391; 12810677; 12861074; 14507641; 14556828; 14568550; 14702352; 14726409; 14767538; 14768007; 14976056; 14991531; 15002056; 15003510; 15094228; 15112366; 15127326; 15161644; 15198927; 15213103; 15284088; 15284220; 15375511; 15489334; 15498854; 15542434; 15562207; 15642468; 15694966; 15734895; 15743799; 15769741; 15823283; 15893672; 16009172; 16020388; 16129411; 16182107; 16229183; 16242072; 16290311; 16338068; 16344560; 16417407; 16424009; 16458662; 16465407; 16525658; 16538528; 16614513; 16629644; 16690881; 16714355; 16723371; 16790091; 16803467; 16830384; 16877277; 16956819; 16978237; 16978614; 17003480; 17030814; 17141400; 17167981; 17200776; 17258205; 17287278; 17322632; 17341311; 17361220; 17395886; 17409768; 17505039; 17513791; 17558601; 17601353; 17630849; 17673702; 17704802; 17724803; 17785951; 17828495; 17904634; 17928052; 17931370; 17943167; 18006475; 18092380; 18182823; 18269030; 18310225; 18382887; 18483397; 18516587; 18541195; 18564921; 18568888; 18644593; 18664247; 18675456; 18720385; 18727515; 18791490; 18807212; 18952457; 18957536; 18991494; 18996102; 19010534; 19018553; 19082594; 19086654; 19102939; 19112163; 19164323; 19223473; 19226440; 19228739; 19271210; 19300530; 19339208; 19341361; 19351722; 19403561; 19435449; 19438587; 19476937; 19478794; 19499513; 19502452; 19539650; 19543148; 19551369; 19567053; 19616847; 19728062; 19815705; 19875484; 19913849; 19922791; 19954476; 20067780; 20068079; 20072144; 20088942; 20099495; 20179005; 20208992; 20213583; 20348331; 20359117; 20379614; 20382847; 20452482; 20482750; 20501615; 20519501; 20562294; 20583134; 20599737; 20629092; 20670479; 20673868; 20696814; 20806109; 20863203; 21042788; 21081932; 21119365; 21131273; 21143700; 21149250; 21163858; 21168819; 21179479; 21248670; 21257790; 21269615; 21300047; 21337734; 21368233; 21380565; 21400522; 21439064; 21450636; 21565611; 21575447; 21576085; 21603628; 21643812; 21672190; 21680733; 21685330; 21750433; 21762624; 21778249; 21809353; 21849906; 21851472; 21858121; 21884204; 21884468; 21900206; 21948244; 21956768; 21963094; 22000910; 22015631; 22095586; 22142364; 22182412; 22229541; 22279570; 22289349; 22311497; 22327175; 22342979; 22449617; 22483377; 22585576; 22640261; 22642477; 22659681; 22728324; 22730375; 22750392; 22770562; 22777681; 22949515; 22989097; 22995870; 23024612; 23099117; 23123737; 23149917; 23174599; 23190105; 23190218; 23232696; 23284823; 23302768; 23305976; 23409162; 23419030; 23421785; 23467610; 23503679; 23536671; 23587231; 23649549; 23652985; 23758184; 23785018; 23803577; 23826161; 23835996; 23899926; 24106271; 24355874; 24373251; 24421076,,,,,,,,,,,,,,,OGG:3000000285,,,,,,,angiopoietin 2,,,,,,,,,,,,,Other designations: ANG-2|Tie2-ligand|angiopoietin-2|angiopoietin-2B|angiopoietin-2a,,ANGPT2,,,,,,,,,,,,,,,,,,,,,,,285,,,,,,,,9606,,,,,,,,,,,,,,,,,,,ANGPT2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000000284,ANGPT1,,Other designations: ANG-1|angiopoietin-1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,AGP1|AGPT|ANG1,,,,,,,,,,,,8,,,,,,MIM:601667|HPRD:03392|Ensembl:ENSG00000154188|Vega:OTTHUMG00000164812|HGNC:484,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,angiopoietin 1,,,8q23.1,,,,,,,,,,,,,,,,"GO_0001701 (EC: IEA); GO_0001936 (EC: IDA, Qualifier: NOT, PMID:8980223); GO_0002040 (EC: IDA, PMID:10218485); GO_0002092 (EC: IDA, PMID:19424712); GO_0005576 (EC: TAS); GO_0005615 (EC: IDA, PMID:10218485); GO_0005886 (EC: IDA, PMID:19424712); GO_0005902 (EC: IDA, PMID:19424712); GO_0007162 (EC: IDA, PMID:19674970); GO_0007171 (EC: IDA, PMID:19424712); GO_0007596 (EC: TAS); GO_0010595 (EC: IDA, PMID:12958144); GO_0014068 (EC: IEA); GO_0014842 (EC: IDA, PMID:19733541); GO_0030097 (EC: IEA); GO_0030154 (EC: IEA); GO_0030210 (EC: IDA, PMID:19297368); GO_0030971 (EC: IPI, PMID:19922791); GO_0031398 (EC: IDA, PMID:19689429); GO_0031589 (EC: IEA); GO_0033138 (EC: IEA); GO_0034394 (EC: IDA, PMID:19615361); GO_0043066 (EC: IDA, PMID:10218485); GO_0043116 (EC: IDA, PMID:14978158); GO_0043524 (EC: IEA); GO_0043536 (EC: IDA, PMID:9660821); GO_0045121 (EC: IDA, PMID:19615361); GO_0045785 (EC: IEA); GO_0048014 (EC: IDA, PMID:19689429); GO_0050731 (EC: IDA, PMID:15851516); GO_0050900 (EC: TAS); GO_0050918 (EC: IDA, PMID:9660821); GO_0051897 (EC: IDA, PMID:18425120); GO_0070062 (EC: IDA, PMID:19199708); GO_0070374 (EC: IDA, PMID:18425120); GO_0072012 (EC: ISS); GO_2000352 (EC: IDA, PMID:19674970)",,,,,,,,,PMID:7584026; 7584028; 7642106; 8980223; 8980224; 9204896; 9525952; 9545648; 9560344; 9660821; 9723709; 10051567; 10218485; 10343124; 10514510; 10706866; 10766762; 10854239; 10944458; 11165944; 11729102; 11776343; 11827452; 11856872; 11870550; 11891175; 11967990; 12138242; 12168954; 12213874; 12239588; 12243755; 12402160; 12427764; 12477932; 12612904; 12649156; 12717391; 12810673; 12816861; 12890486; 12958144; 12958167; 14561809; 14597243; 14665640; 14672554; 14715662; 14749497; 14978158; 14991531; 15001532; 15019820; 15094228; 15161644; 15198927; 15213103; 15242771; 15284220; 15381091; 15453096; 15498854; 15542434; 15562207; 15692086; 15694363; 15746084; 15769741; 15781448; 15823283; 15851516; 15892598; 16000309; 16020388; 16049136; 16229183; 16354591; 16547766; 16614513; 16645159; 16690881; 16723371; 16803467; 16830384; 16917117; 16956819; 17039426; 17168735; 17322632; 17341311; 17466926; 17525262; 17558601; 17562701; 17603084; 17637706; 17724803; 17728252; 17785951; 17803352; 17943167; 18035072; 18080866; 18092380; 18199826; 18269030; 18310225; 18326231; 18330951; 18382887; 18425120; 18664247; 18675456; 18807212; 18823985; 18991494; 18996102; 19010534; 19028450; 19082480; 19082594; 19086654; 19127216; 19148554; 19199708; 19223473; 19297368; 19300530; 19301945; 19322669; 19339077; 19351722; 19424712; 19460752; 19476937; 19478794; 19487284; 19543148; 19567053; 19615361; 19674970; 19689429; 19733541; 19815705; 19875484; 19916173; 19919521; 19922791; 19954476; 20036815; 20056911; 20072144; 20098680; 20099495; 20185425; 20208992; 20346360; 20378606; 20471887; 20554518; 20602615; 20629092; 20696814; 20863203; 21042788; 21140268; 21168819; 21179479; 21212269; 21273558; 21300047; 21380565; 21400522; 21660578; 21672190; 21710361; 21778249; 21849906; 21858121; 21878936; 21884468; 21885850; 21905000; 21905955; 21906428; 21948244; 21963094; 22000910; 22015631; 22033412; 22095586; 22143796; 22205728; 22229541; 22235284; 22334788; 22391155; 22449617; 22483377; 22496856; 22583143; 22642477; 22867989; 22901561; 22949515; 23024612; 23099117; 23123737; 23190105; 23232696; 23288163; 23302768; 23382691; 23504320; 23592718; 23652985; 23686433; 23770419; 23785018; 23835996; 23840065; 24010773,,,,,,,,,,,,,,,OGG:3000000284,,,,,,,angiopoietin 1,,,,,,,,,,,,,Other designations: ANG-1|angiopoietin-1,,ANGPT1,,,,,,,,,,,,,,,,,,,,,,,284,,,,,,,,9606,,,,,,,,,,,,,,,,,,,ANGPT1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000000283,ANG,,Other designations: RNase 5|angiogenin|epididymis luminal protein 168|ribonuclease 5|ribonuclease A A1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,ALS9|HEL168|RNASE4|RNASE5|RAA1,,,,,,,,,,,,14,,,,,,MIM:105850|HGNC:483|Vega:OTTHUMG00000029576|HPRD:00105|Ensembl:ENSG00000214274,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"angiogenin, ribonuclease, RNase A family, 5",,,14q11.1-q11.2,,,,,,,,,,,,,,,,"GO_0001525 (EC: IDA, PMID: 8448182); GO_0001525 (EC: IMP, PMID: 17125737); GO_0001525 (EC: TAS, PMID: 16567967); GO_0001541 (EC: NAS, PMID: 12770725); GO_0001556 (EC: NAS, PMID: 11438326); GO_0001666 (EC: IDA, PMID: 10999833); GO_0001666 (EC: NAS, PMID: 15776477); GO_0001890 (EC: NAS, PMID: 11984825); GO_0001938 (EC: IDA, PMID: 9122172); GO_0003677 (EC: IC, PMID: 10649442); GO_0003779 (EC: IDA, PMID: 11782452); GO_0004519 (EC: TAS, PMID: 10103013); GO_0004540 (EC: IDA, PMID: 2424496); GO_0005102 (EC: IDA, PMID: 9122172); GO_0005507 (EC: IDA, PMID: 9245697); GO_0005515 (EC: IPI, PMID: 10413501); GO_0005605 (EC: IDA, PMID: 15166501); GO_0005615 (EC: IDA, PMID: 16461950); GO_0005634 (EC: IDA, PMID: 10649442); GO_0005730 (EC: ISS); GO_0006651 (EC: IDA, PMID: 2457905); GO_0007154 (EC: NAS, PMID: 10103013); GO_0007202 (EC: IMP, PMID: 2457905); GO_0008201 (EC: IDA, PMID: 10103013); GO_0008219 (EC: IEA); GO_0009303 (EC: IMP, PMID: 15735021); GO_0009725 (EC: IDA, PMID: 10999833); GO_0016477 (EC: IMP, PMID: 17125737); GO_0016892 (EC: IEA); GO_0017148 (EC: IEA); GO_0019843 (EC: TAS, PMID: 2457905); GO_0030041 (EC: ISS); GO_0030426 (EC: ISS); GO_0032148 (EC: IMP, PMID: 17125737); GO_0032311 (EC: IPI, PMID: 3470787); GO_0032431 (EC: IMP, PMID: 2646638); GO_0042277 (EC: IDA, PMID: 11782452); GO_0042327 (EC: IDA, PMID: 17125737); GO_0042592 (EC: NAS, PMID: 15166501); GO_0043025 (EC: ISS); GO_0048662 (EC: IDA, PMID: 10103013); GO_0050714 (EC: IDA, PMID: 2646638); GO_0050714 (EC: ISS); GO_0090305 (EC: TAS, PMID: 10103013); GO_0090501 (EC: IDA, PMID: 2424496)",,,,,,,,,PMID: 1400510; 1978563; 2276743; 2424496; 2440105; 2457905; 2479414; 2646638; 2730651; 2742853; 2866794; 2866795; 3470787; 3619929; 3663649; 7679494; 7945327; 8127865; 8159679; 8448182; 9122172; 9245697; 9311977; 9461294; 9707554; 9918722; 10103013; 10413501; 10648935; 10649442; 10999833; 11374889; 11438326; 11468363; 11751393; 11752456; 11782452; 11847008; 11851402; 11919285; 11984825; 12168899; 12209593; 12477932; 12515546; 12705339; 12770725; 12842050; 14593238; 14671622; 14756559; 15064314; 15067362; 15128420; 15166501; 15182336; 15236995; 15489334; 15557516; 15558023; 15735021; 15737636; 15776477; 15979542; 16169070; 16322296; 16461950; 16490744; 16567967; 16712791; 16937522; 17113198; 17125737; 17207965; 17462671; 17703939; 17886298; 17900154; 17991437; 18087731; 18636464; 18808740; 18852347; 18936943; 18955785; 19158252; 19160530; 19253715; 19262607; 19287993; 19332886; 19363631; 19423182; 19625371; 19631914; 20045391; 20105109; 20137109; 20174961; 20301623; 20452482; 20472325; 20484129; 20577002; 20629092; 20673868; 20838751; 20923443; 20952631; 20955379; 21085671; 21091473; 21103661; 21154263; 21209106; 21364907; 21375772; 21439815; 21528671; 21539846; 21621297; 21711968; 21778318; 21800332; 21808991; 21919032; 21988832; 22148849; 22190368; 22194915; 22266868; 22292798; 22292843; 22372545; 22384259; 22438557; 22449478; 22526325; 22633874; 22694909; 22940420; 23229115; 23231972; 23351638; 23379493; 23409128; 23665167; 23989187; 24122807; 24337645,,,,,,,,,,,,,,,OGG:3000000283,,,,,,,"angiogenin, ribonuclease, RNase A family, 5",,,,,,,,,,,,,Other designations: RNase 5|angiogenin|epididymis luminal protein 168|ribonuclease 5|ribonuclease A A1,,ANG,,,,,,,,,,,,,,,,,,,,,,,283,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,ANG,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0003679,protein tyrosine phosphatase,[phosphotyrosine]protein phosphatase|PPT-phosphatase|phosphotyrosylprotein phosphatase|PTPase|tyrosine O-phosphate phosphatase|protein-tyrosine-phosphate phosphohydrolase|phosphoprotein phosphatase (phosphotyrosine)|phosphotyrosine protein phosphatase|tyrosylprotein phosphatase|phosphotyrosine histone phosphatase|phosphotyrosine phosphatase,Catalysis of the reaction: protein tyrosine phosphate + H2O = protein tyrosine + phosphate.|related molecular function GO:0004725,false,,,http://purl.obolibrary.org/obo/TXPO_0003675,,,,,,,,,,,,,,,,,,,,EC:3.1.3.48,,Catalysis of the reaction: protein tyrosine phosphate + H2O = protein tyrosine + phosphate.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,[phosphotyrosine]protein phosphatase|PPT-phosphatase|phosphotyrosylprotein phosphatase|PTPase|tyrosine O-phosphate phosphatase|protein-tyrosine-phosphate phosphohydrolase|phosphoprotein phosphatase (phosphotyrosine)|phosphotyrosine protein phosphatase|tyrosylprotein phosphatase|phosphotyrosine histone phosphatase|phosphotyrosine phosphatase,,,,,TXPO:0003679,,,,,,,,,,,,,,,,,,,,related molecular function GO:0004725,,protein tyrosine phosphatase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003676,protein serine/threonine phosphatase,serine/threonine specific protein phosphatase,"Catalysis role of the reaction: protein serine phosphate + H2O = protein serine + phosphate, and protein threonine phosphate + H2O = protein threonine + phosphate.|related molecular function GO:0004722",false,,,http://purl.obolibrary.org/obo/TXPO_0003675,,,,,,,,,,,,,,,,,,,,IMR:0000277 (obsolete)|EC:3.1.3.16,,"Catalysis role of the reaction: protein serine phosphate + H2O = protein serine + phosphate, and protein threonine phosphate + H2O = protein threonine + phosphate.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,serine/threonine specific protein phosphatase,,,,,TXPO:0003676,,,,,,,,,,,,,,,,,,,,related molecular function GO:0004722,,protein serine/threonine phosphatase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003675,phosphoprotein phosphatase,protein phosphatase-2A|phosphoprotein phosphohydrolase|protein phosphatase,"Catalysis role of the reaction: a phosphoprotein + H2O = a protein + phosphate. Together with protein kinases, these enzymes control the state of phosphorylation of cell proteins and thereby provide an important mechanism for regulating cellular activity.|related molecular function GO:0004721",false,,,http://purl.obolibrary.org/obo/TXPO_0003673,,,,,,,,,,,,,,,,,,,,IMR:0000272 (obsolete),,"Catalysis role of the reaction: a phosphoprotein + H2O = a protein + phosphate. Together with protein kinases, these enzymes control the state of phosphorylation of cell proteins and thereby provide an important mechanism for regulating cellular activity.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,phosphoprotein phosphohydrolase|protein phosphatase,protein phosphatase-2A,,,,TXPO:0003675,,,,,,,,,,,,,,,,,,,,related molecular function GO:0004721,,phosphoprotein phosphatase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003671,phospholipase,,"related molecular fuction :
GO:0004620",false,,,http://purl.obolibrary.org/obo/TXPO_0002283,,,,,,,,,,,,,,,,,,,,Catalysis role of the hydrolysis of a glycerophospholipid.|IMR:0000281 (obsolete)|EC:3.1.1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003671,,,,,,,,,,TXPO:0003671,,,,,,,,,,,,,,,,,,,,"related molecular fuction :
GO:0004620",,phospholipase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003677,protein serine/threonine/tyrosine phosphatase,,Catalysis role of the reactions: protein serine + H2O = protein serine + phosphate; protein threonine phosphate + H2O = protein threonine + phosphate; and protein tyrosine phosphate + H2O = protein tyrosine + phosphate.|Note that this term applies only to free amino acids.,false,,,http://purl.obolibrary.org/obo/TXPO_0003675,,,,,,,,,,,,,,,,,,,,related molecular function GO:0008138|IMR:0100208 (obsolete),,Catalysis role of the reactions: protein serine + H2O = protein serine + phosphate; protein threonine phosphate + H2O = protein threonine + phosphate; and protein tyrosine phosphate + H2O = protein tyrosine + phosphate.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003677,,,,,,,,,,,,,,,,,,,,Note that this term applies only to free amino acids.,,protein serine/threonine/tyrosine phosphatase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003674,glucose-6-phosphatase,D-glucose-6-phosphate phosphohydrolase activity|G6Pase|G-6-Pase|glucose 6-phosphate phosphatase activity,Catalysis role of the reaction: D-glucopyranose 6-phosphate + H2O = D-glucose + phosphate. D-glucopyranose is also known as D-glucose 6-phosphate.,false,,,http://purl.obolibrary.org/obo/TXPO_0003673,,,,,,,,,,,,,,,,,,,,EC:3.1.3.9|IMR:0010260 (obsolete),,Catalysis role of the reaction: D-glucopyranose 6-phosphate + H2O = D-glucose + phosphate. D-glucopyranose is also known as D-glucose 6-phosphate.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,D-glucose-6-phosphate phosphohydrolase activity|G6Pase|G-6-Pase|glucose 6-phosphate phosphatase activity,,,,,TXPO:0003674,,,,,,,,,,,,,,,,,,,,,,glucose-6-phosphatase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003673,phosphatase,NPPase activity|phosphoric monoester hydrolase activity,"Catalysis of the hydrolysis of phosphoric monoesters, releasing inorganic phosphate.|related molecular function GO:0016791",false,,,http://purl.obolibrary.org/obo/TXPO_0003663,,,,,,,,,,,,,,,,,,,,EC:3.1.3.41|EC:3.1.3.|IMR:0000517 (obsolete),,"Catalysis of the hydrolysis of phosphoric monoesters, releasing inorganic phosphate.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,phosphoric monoester hydrolase activity,NPPase activity,,,,TXPO:0003673,,,,,,,,,,,,,,,,,,,,related molecular function GO:0016791,,phosphatase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003670,histone deacetylase,HDAC,"Catalysis role of the reaction: histone N6-acetyl-L-lysine + H2O = histone L-lysine + acetate. This reaction represents the removal of an acetyl group from a histone, a class of proteins complexed to DNA in chromatin and chromosomes.",false,,,http://purl.obolibrary.org/obo/TXPO_0003663,,,,,,,,,,,,,,,,,,,,"related molecule fuction
GO:0004407|IMR:0001166 (obsolete)",,"Catalysis role of the reaction: histone N6-acetyl-L-lysine + H2O = histone L-lysine + acetate. This reaction represents the removal of an acetyl group from a histone, a class of proteins complexed to DNA in chromatin and chromosomes.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,HDAC,,,,,TXPO:0003670,,,,,,,,,,,,,,,,,,,,,,histone deacetylase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003678,compound accumulation in lysosome [Phospholipidosis (latent)],,"Compound accumulation in lysosome is a subtype of accumulation of xenobiotics: A process that keeps compound in the lysosome.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (latent).",false,,,http://purl.obolibrary.org/obo/TXPO_0000930,,,,,,,,,,,,,,,,,,,,,,"Compound accumulation in lysosome is a subtype of accumulation of xenobiotics: A process that keeps compound in the lysosome.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (latent).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002522,http://purl.obolibrary.org/obo/TXPO_0001560|http://purl.obolibrary.org/obo/TXPO_0001566|http://purl.obolibrary.org/obo/TXPO_0001425|http://purl.obolibrary.org/obo/TXPO_0000081,,,,,,http://purl.obolibrary.org/obo/TXPO_0004933,,,,,,,,,,,TXPO:0003678,,,,,,,,,,,,,,,,,,,,,,compound accumulation in lysosome [Phospholipidosis (latent)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003672,phosphoric diester hydrolase,phosphodiesterase|PDE,Catalysis role of the hydrolysis of a phosphodiester to give a phosphomonoester and a free hydroxyl group.|related molecular function GO:0008081,false,,,http://purl.obolibrary.org/obo/TXPO_0003663,,,,,,,,,,,,,,,,,,,,EC:3.1.4.-,,Catalysis role of the hydrolysis of a phosphodiester to give a phosphomonoester and a free hydroxyl group.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PDE,phosphodiesterase,,,,TXPO:0003672,,,,,,,,,,,,,,,,,,,,related molecular function GO:0008081,,phosphoric diester hydrolase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CL_0000097,mast cell,,"A cell that is found in almost all tissues containing numerous basophilic granules and capable of releasing large amounts of histamine and heparin upon activation. Progenitors leave bone marrow and mature in connective and mucosal tissue. Mature mast cells are found in all tissues, except the bloodstream. Their phenotype is CD117-high, CD123-negative, CD193-positive, CD200R3-positive, and FceRI-high. Stem-cell factor (KIT-ligand; SCF) is the main controlling signal of their survival and development.",false,,,http://purl.obolibrary.org/obo/CL_0000738,,,,,,,,,,,,,,,,,,,,FMA:66784|BTO:0000830,,"A cell that is found in almost all tissues containing numerous basophilic granules and capable of releasing large amounts of histamine and heparin upon activation. Progenitors leave bone marrow and mature in connective and mucosal tissue. Mature mast cells are found in all tissues, except the bloodstream. Their phenotype is CD117-high, CD123-negative, CD193-positive, CD200R3-positive, and FceRI-high. Stem-cell factor (KIT-ligand; SCF) is the main controlling signal of their survival and development.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CL:0000097,,,,,,,,,,,,,,,,,,,,,,mast cell,,,,,,,http://purl.obolibrary.org/obo/cl.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CL_0000091,Kupffer cell,,"A tissue-resident macrophage of the reticuloendothelial system found on the luminal surface of the hepatic sinusoids involved in erythrocyte clearance. Markers include F4/80+, CD11b-low, CD68-positive, sialoadhesin-positive, CD163/SRCR-positive. Irregular, with long processes including lamellipodia extending into the sinusoid lumen, have flattened nucleus with cytoplasm containing characteristic invaginations of the plasma membrane (vermiform bodies); lie within the sinusoid lumen attached to the endothelial surface; derived from the bone marrow, form a major part of the body's mononuclear phagocyte system. Markers: Mouse: F4/80+, CD11b-low, CD68+, sialoadhesin+, CD163/SRCR+; role or process: immune, antigen-presentation, clearance of senescent erythrocytes, iron metabolism. Kupffer cells are also reportedly C3aR-positive, CD14-low, CD54-positive, CD88-positive, and CD284-positive. They are also capable of producing IL-1, IL-6, TNF-alpha, nitric oxide, PGD2, PGE2, PGF2alpha, and TXA2.",false,,,http://purl.obolibrary.org/obo/CL_0000864,,,,,,,,,,,,,,,,,,,,,,"A tissue-resident macrophage of the reticuloendothelial system found on the luminal surface of the hepatic sinusoids involved in erythrocyte clearance. Markers include F4/80+, CD11b-low, CD68-positive, sialoadhesin-positive, CD163/SRCR-positive. Irregular, with long processes including lamellipodia extending into the sinusoid lumen, have flattened nucleus with cytoplasm containing characteristic invaginations of the plasma membrane (vermiform bodies); lie within the sinusoid lumen attached to the endothelial surface; derived from the bone marrow, form a major part of the body's mononuclear phagocyte system. Markers: Mouse: F4/80+, CD11b-low, CD68+, sialoadhesin+, CD163/SRCR+; role or process: immune, antigen-presentation, clearance of senescent erythrocytes, iron metabolism. Kupffer cells are also reportedly C3aR-positive, CD14-low, CD54-positive, CD88-positive, and CD284-positive. They are also capable of producing IL-1, IL-6, TNF-alpha, nitric oxide, PGD2, PGE2, PGF2alpha, and TXA2.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CL:0000091,,,,,,,,,,,,,,,,,,,,,,Kupffer cell,,,,,,,http://purl.obolibrary.org/obo/cl.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CL_0000094,granulocyte,,A leukocyte with abundant granules in the cytoplasm.,false,,,http://purl.obolibrary.org/obo/CL_0000988,,,,,,,,,,,,,,,,,,,,,,A leukocyte with abundant granules in the cytoplasm.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CL:0000094,,,,,,,,,,,,,,,,,,,,,,granulocyte,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004832,TNF signaling (primitive),,TNF signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by TNF.,false,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,,,TNF signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by TNF.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0033209,,,,,,,,,,,,,,,,TXPO:0004832,,,,,,,,,,,,,,,,,,,,,,TNF signaling (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004838,TSLC signal transduction pathway,TSLC signaling cascade|TSLC signaling pathway,A series of molecular signals mediated by TSLC (Tumor suppressor in lung cancer-1) proteins.,false,,,http://purl.obolibrary.org/obo/TXPO_0000609,,,,,,,,,,,,,,,,,,,,,,A series of molecular signals mediated by TSLC (Tumor suppressor in lung cancer-1) proteins.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TSLC signaling cascade|TSLC signaling pathway,,,,,TXPO:0004838,,,,,,,,,,,,,,,,,,,,,,TSLC signal transduction pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004836,MTOR (canonical) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004020|http://purl.obolibrary.org/obo/TXPO_0005063,,,,,,,,,,,,,,,,,,,,PMID:28493839|https://omim.org/entry/601231|NCBI-Mouse-GeneID:56717|NCBI-Rat-GeneID:56718|NCBI-Human-GeneID:2475,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004836,,,,,,,,,,,,,,,,,,,,,,MTOR (canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004830,cytolysis [mitochondrial disorder],,"The rupture of cell membranes and the loss of cytoplasm.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/GO_0019835,,,,,,,,,,,,,,,,,,,,PMID:31623280|Wikipedia:Cytolysis,,"The rupture of cell membranes and the loss of cytoplasm.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001992|http://purl.obolibrary.org/obo/TXPO_0004342,,,,,,,,,,,TXPO:0004830,,,,,,,,,,,,,,,,,,,,,,cytolysis [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000000,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004831,TLR4 (canonical) [mitochondrial disorder],Toll-like receptor 4,,false,,,http://purl.obolibrary.org/obo/IMR_0001440|http://purl.obolibrary.org/obo/TXPO_0004293,,,,,,,,,,,,,,,,,,,,TLR4 (mol)＠ミトコンドリア障害|NCBI-Rat-GeneID:29260|PMID:31623280|NCBI-Human-GeneID:7099|NCBI-Mouse-GeneID:21898,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Toll-like receptor 4,,,,,TXPO:0004831,,,,,,,,,,,,,,,,,,,,,,TLR4 (canonical) [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004837,response to hypoxia [hepatocarcinogenesis],,"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating lowered oxygen tension. Hypoxia, defined as a decline in O2 levels below normoxic levels of 20.8 - 20.95%, results in metabolic adaptation at both the cellular and organismal level.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/GO_0001666|http://purl.obolibrary.org/obo/TXPO_0002340,,,,,,,,,,,,,,,,,,,,PMID:28493839|PMID:31781608,,"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating lowered oxygen tension. Hypoxia, defined as a decline in O2 levels below normoxic levels of 20.8 - 20.95%, results in metabolic adaptation at both the cellular and organismal level.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0005016,,,,,,http://purl.obolibrary.org/obo/TXPO_0004847|http://purl.obolibrary.org/obo/TXPO_0004598|http://purl.obolibrary.org/obo/TXPO_0004630|http://purl.obolibrary.org/obo/TXPO_0004557,,,,,,,,,,,TXPO:0004837,,,,,,,,,,,,,,,,,,,,,,response to hypoxia [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004833,TNF signaling [mitochondrial disorder],,"TNF signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by TNF.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0004832,,,,,,,,,,,,,,,,,,,,PMID:31623280,,"TNF signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by TNF.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004381,http://purl.obolibrary.org/obo/GO_0033209,,,,,http://purl.obolibrary.org/obo/TXPO_0004271|http://purl.obolibrary.org/obo/TXPO_0002004|http://purl.obolibrary.org/obo/TXPO_0004397,,,,,,,,,,,TXPO:0004833,,,,,,,,,,,,,,,,,,,,,,TNF signaling [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004835,TNFΑ(canonical) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000374|http://purl.obolibrary.org/obo/TXPO_0005063,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:21926|NCBI-Rat-GeneID:24835|NCBI-Human-GeneID:7124|PMID:31623280,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004835,,,,,,,,,,,,,,,,,,,,,,TNFΑ(canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004839,TSLC signaling (primitive),,TSLC signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the TSLC (Tumor suppressor in lung cancer-1) .,false,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,,,TSLC signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the TSLC (Tumor suppressor in lung cancer-1) .,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004838,,,,,,,,,,,,,,,,TXPO:0004839,,,,,,,,,,,,,,,,,,,,,,TSLC signaling (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004834,TNF signaling (primitive) [hepatocarcinogenesis],,"TNF signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by TNF.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004832,,,,,,,,,,,,,,,,,,,,PMID:31623280,,"TNF signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by TNF.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004835,http://purl.obolibrary.org/obo/GO_0033209,,,,,http://purl.obolibrary.org/obo/TXPO_0004661,,,,,,,,,,,TXPO:0004834,,,,,,,,,,,,,,,,,,,,,,TNF signaling (primitive) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004261,mitochondria fission [Mitochondrial disorder],,"The division of a mitochondrion within a cell to form two or more separate mitochondrial compartments.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/GO_0000266|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:30894684|PMID:28789970,,"The division of a mitochondrion within a cell to form two or more separate mitochondrial compartments.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001992|http://purl.obolibrary.org/obo/TXPO_0002230|http://purl.obolibrary.org/obo/TXPO_0004259,,,,,,,,,,,TXPO:0004261,,,,,,,,,,,,,,,,,,,,,,mitochondria fission [Mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004264,metabolic dysfunction of precursor metabolites and energy generation [mitochondrial disorder],,Energy metabolic dysfunction is a subtype of Metabolic dysfunctioning: A process that performs an abnormal and incomplete energy metabolic function. This entity is a specific course-dependent process. This process can constitute the Mitochondrial disorder.,false,,,http://purl.obolibrary.org/obo/TXPO_0004305|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:31623280|PMID:29335519|PMID:23299992|PMID:24746669|PMID:29222479,,Energy metabolic dysfunction is a subtype of Metabolic dysfunctioning: A process that performs an abnormal and incomplete energy metabolic function. This entity is a specific course-dependent process. This process can constitute the Mitochondrial disorder.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001029|http://purl.obolibrary.org/obo/TXPO_0001992|http://purl.obolibrary.org/obo/TXPO_0004246,,,,,,,,,,,TXPO:0004264,,,,,,,,,,,,,,,,,,,,,,metabolic dysfunction of precursor metabolites and energy generation [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004263,release of cytochrome c from mitochondria [mitochondrial disorder],,"The process that results in the movement of cytochrome c from the mitochondrial intermembrane space into the cytosol, which is part of the apoptotic signaling pathway and leads to caspase activation.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/GO_0001836|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:25339807|PMID:23299992|PMID:28789970,,"The process that results in the movement of cytochrome c from the mitochondrial intermembrane space into the cytosol, which is part of the apoptotic signaling pathway and leads to caspase activation.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001992|http://purl.obolibrary.org/obo/TXPO_0000869,,,,,,,,,,,TXPO:0004263,,,,,,,,,,,,,,,,,,,,,,release of cytochrome c from mitochondria [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004260,decreasing mtDNA level [mitochondrial disorder],,"Decreasing mtDNA level is a subtype of decreasing quantity: A process that changes the amount of glycogen level to be lower.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0004310,,,,,,,,,,,,,,,,,,,,PMID:25339807|PMID:30250064|PMID:21145849,,"Decreasing mtDNA level is a subtype of decreasing quantity: A process that changes the amount of glycogen level to be lower.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004335|http://purl.obolibrary.org/obo/TXPO_0004331|http://purl.obolibrary.org/obo/TXPO_0004337|http://purl.obolibrary.org/obo/TXPO_0004365|http://purl.obolibrary.org/obo/TXPO_0004389|http://purl.obolibrary.org/obo/TXPO_0004386|http://purl.obolibrary.org/obo/TXPO_0004387|http://purl.obolibrary.org/obo/TXPO_0004388,,,,,,http://purl.obolibrary.org/obo/TXPO_0000933|http://purl.obolibrary.org/obo/TXPO_0000869|http://purl.obolibrary.org/obo/TXPO_0004281|http://purl.obolibrary.org/obo/TXPO_0002005|http://purl.obolibrary.org/obo/TXPO_0002004,,,,,,,,,,,TXPO:0004260,,,,,,,,,,,,,,,,,,,,,,decreasing mtDNA level [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004265,Negative regulation of respiratory complex IV proteins synthesis [mitochondrial disorder],,"Any process that stops, prevents, or reduces the frequency, rate or extent of mitochondrial respiratory chain complex IV assembly.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0004217|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:29222479,,"Any process that stops, prevents, or reduces the frequency, rate or extent of mitochondrial respiratory chain complex IV assembly.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004316,,,,,,http://purl.obolibrary.org/obo/TXPO_0004125,,,,,,,,,,,TXPO:0004265,,,,,,,,,,,,,,,,,,,,,,Negative regulation of respiratory complex IV proteins synthesis [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004268,neutrophil migration [mitochondrial disorder],,"The orderly movement of a neutrophil from one site to another.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0004315,,,,,,,,,,,,,,,,,,,,PMID:29222479,,"The orderly movement of a neutrophil from one site to another.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004279|http://purl.obolibrary.org/obo/TXPO_0004271,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,TXPO:0004268,,,,,,,,,,,,,,,,,,,,,,neutrophil migration [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004267,increasing uptake amount of mitochondrial calcium ion [Mitochondrial disorder],,"Increasing uptake amount of mitochondrial calcium ion is a subtype of increasing quantity: A process that changes the uptake amount of mitochondrial calcium ion to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0002229,,,,,,,,,,,,,,,,,,,,,,"Increasing uptake amount of mitochondrial calcium ion is a subtype of increasing quantity: A process that changes the uptake amount of mitochondrial calcium ion to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001993,,,,,,,,,,,TXPO:0004267,,,,,,,,,,,,,,,,,,,,,,increasing uptake amount of mitochondrial calcium ion [Mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004266,monocyte migration [mitochondrial disorder],,"The orderly movement of a monocyte from one site to another.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0004313,,,,,,,,,,,,,,,,,,,,PMID:29222479,,"The orderly movement of a monocyte from one site to another.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004279|http://purl.obolibrary.org/obo/TXPO_0004271,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,TXPO:0004266,,,,,,,,,,,,,,,,,,,,,,monocyte migration [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004262,mitochondrial DNA catabolic process [mitochondrial disorder],,The chemical reactions and pathways resulting in the breakdown of mitochondrial DNA. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.,false,,,http://purl.obolibrary.org/obo/GO_0032043|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:29222479,,The chemical reactions and pathways resulting in the breakdown of mitochondrial DNA. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004262,,,,,,,,,,,,,,,,,,,,,,mitochondrial DNA catabolic process [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004269,cytokine production involved in inflammatory response [mitochondrial disorder],,"The synthesis or release of a cytokine following a inflammatory stimulus as part of an inflammatory response, resulting in an increase in its intracellular or extracellular levels.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/GO_0002534,,,,,,,,,,,,,,,,,,,,PMID:31623280|PMID:25339807|PMID:29222479,,"The synthesis or release of a cytokine following a inflammatory stimulus as part of an inflammatory response, resulting in an increase in its intracellular or extracellular levels.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004271,,,,,,,,,,,TXPO:0004269,,,,,,,,,,,,,,,,,,,,,,cytokine production involved in inflammatory response [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000235,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000054541,DDIT4,,Other designations: DNA damage-inducible transcript 4 protein|HIF-1 responsive protein RTP801|protein regulated in development and DNA damage response 1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,REDD1|REDD-1|Dig2,,,,,,,,,,,,10,,,,,,Vega:OTTHUMG00000183961|HGNC:24944|Ensembl:ENSG00000168209|HPRD:09662|MIM:607729,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,DNA-damage-inducible transcript 4,,,10q22.1,,,,,,,,,,,,,,,,"GO_0001666 (EC: IDA); GO_0001764 (EC: ISS); GO_0005622 (EC: IDA); GO_0005737 (EC: IDA, PMID: 12453409); GO_0005739 (EC: IEA); GO_0005829 (EC: IEA); GO_0007420 (EC: ISS); GO_0008283 (EC: ISS); GO_0010801 (EC: ISS); GO_0030182 (EC: ISS); GO_0032007 (EC: IMP); GO_0033137 (EC: ISS); GO_0042771 (EC: ISS); GO_0043241 (EC: IEA); GO_0045820 (EC: IEA); GO_0048011 (EC: ISS); GO_0051607 (EC: IEA); GO_0071889 (EC: IEA); GO_0072593 (EC: IEA); GO_1901216 (EC: ISS); GO_1902532 (EC: ISS)",,,,,,,,,PMID: 11076863; 11230166; 11256614; 11884613; 12453409; 12477932; 14646594; 15146197; 15180327; 15489336; 15592522; 15632201; 15988001; 16169070; 16196087; 16258273; 16341674; 16381901; 16713569; 17005863; 17307335; 18029348; 18781797; 18796435; 18953439; 19114033; 19127203; 19210572; 19221489; 19557001; 19996311; 20166753; 20354178; 20374513; 20473305; 20639865; 20972266; 21123297; 21139048; 21258409; 21266827; 21414293; 21460850; 21540236; 21798997; 21890473; 21900206; 21906983; 21909097; 21963094; 21987572; 22053931; 22505724; 23000965; 23193052; 23528835,,,,,,,,,,,,,,,OGG:3000054541,,,,,,,DNA-damage-inducible transcript 4,,,,,,,,,,,,,Other designations: DNA damage-inducible transcript 4 protein|HIF-1 responsive protein RTP801|protein regulated in development and DNA damage response 1,,DDIT4,,,,,,,,,,,,,,,,,,,,,,,54541,RP11-442H21.1,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,DDIT4,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001891,ECH1,,"Other designations: delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial|delta3,5-delta2,4-dienoyl-CoA isomerase|dienoyl-CoA isomerase|enoyl Coenzyme A hydratase 1, peroxisomal|peroxisomal enoyl-CoA hydratase 1",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,HPXEL,,,,,,,,,,,,19,,,,,,HPRD:02825|MIM:600696|Vega:OTTHUMG00000182609|HGNC:3149|Ensembl:ENSG00000104823,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"enoyl CoA hydratase 1, peroxisomal",,,19q13.1,,,,,,,,,,,,,,,,"GO_0005102 (EC: IPI); GO_0005515 (EC: IPI, PMID: 15383276); GO_0005739 (EC: IEA); GO_0005777 (EC: NAS, PMID: 7558027); GO_0006635 (EC: IEA); GO_0016853 (EC: IEA); GO_0070062 (EC: IDA)",,,,,,,,,PMID: 7558027; 9417087; 12477932; 14500732; 15383276; 15489334; 16169070; 16482509; 16615866; 17081983; 17676665; 18029348; 20178365; 20186120; 20877624; 21081666; 21139048; 21565611; 21832049; 21890473; 21906983; 21988832; 22002062; 22939629; 24255178,,,,,,,,,,,,,,,OGG:3000001891,,,,,,,"enoyl CoA hydratase 1, peroxisomal",,,,,,,,,,,,,"Other designations: delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial|delta3,5-delta2,4-dienoyl-CoA isomerase|dienoyl-CoA isomerase|enoyl Coenzyme A hydratase 1, peroxisomal|peroxisomal enoyl-CoA hydratase 1",,ECH1,,,,,,,,,,,,,,,,,,,,,,,1891,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,ECH1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000350,SLP-76,SH2 domain-containing leukocyte protein of 76 kD,,false,,,http://purl.obolibrary.org/obo/IMR_0100258,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,SH2 domain-containing leukocyte protein of 76 kD,,,,,IMR:0000350,,,,,,,,,,,,,,,,,,,,,,SLP-76,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0070085,glycosylation,,The covalent attachment and further modification of carbohydrate residues to a substrate molecule.,false,,,http://purl.obolibrary.org/obo/GO_0008152,,,,,,,,,,,,,,,,,,,,,,The covalent attachment and further modification of carbohydrate residues to a substrate molecule.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0070085,,,,,,,,,,,,,,,,,,,,,,glycosylation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0032456,endocytic recycling,retrograde transport of endocytic vesicles,The directed movement of membrane-bounded vesicles from recycling endosomes back to the plasma membrane where they are recycled for further rounds of transport.,false,,,http://purl.obolibrary.org/obo/GO_0016197,,,,,,,,,,,,,,,,,,,,,,The directed movement of membrane-bounded vesicles from recycling endosomes back to the plasma membrane where they are recycled for further rounds of transport.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,retrograde transport of endocytic vesicles,,,GO:0032456,,,,,,,,,,,,,,,,,,,,,,endocytic recycling,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000029948,OSGIN1,,"Other designations: bone marrow stromal cell-derived growth inhibitor|ovary, kidney and liver protein 38|oxidative stress-induced growth inhibitor 1|pregnancy-induced growth inhibitor OKL38",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,BDGI|OKL38,,,,,,,,,,,,16,,,,,,HPRD:06412|HGNC:30093|MIM:607975|Ensembl:ENSG00000140961|Vega:OTTHUMG00000137640,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,oxidative stress induced growth inhibitor 1,,,16q23.3,,,,,,,,,,,,,,,,"GO_0005575 (EC: ND); GO_0007275 (EC: IEA); GO_0008083 (EC: IDA, PMID: 11459809); GO_0030154 (EC: IEA); GO_0030308 (EC: IDA, PMID: 11459809)",,,,,,,,,PMID: 8889548; 11459809; 12374686; 12477932; 14570898; 15489334; 15569677; 16924236; 17192422; 18499678; 18597759; 19578798; 19851296; 20198315; 20307321; 21737788; 21906983; 22912861,,,,,,,,,,,,,,,OGG:3000029948,,,,,,,oxidative stress induced growth inhibitor 1,,,,,,,,,,,,,"Other designations: bone marrow stromal cell-derived growth inhibitor|ovary, kidney and liver protein 38|oxidative stress-induced growth inhibitor 1|pregnancy-induced growth inhibitor OKL38",,OSGIN1,,,,,,,,,,,,,,,,,,,,,,,29948,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,OSGIN1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0010013,NELF,negative elongation factor,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003644,,,,,negative elongation factor,,,,,IMR:0010013,,,,,,,,,,,,,,,,,,,,,,NELF,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76878,EC 2.3.1.* (acyltransferase transferring other than amino-acyl group) inhibitor,EC 2.3.1.* inhibitors|EC 2.3.1.* (acyltransferase transferring other than amino-acyl group) inhibitors|EC 2.3.1.* inhibitor|acyltransferase transferring other than amino-acyl group EC 2.3.1.* inhibitors|acyltransferase transferring other than amino-acyl group EC 2.3.1.* inhibitor,An EC 2.3.* (acyltransferase) inhibitor that inhibits the action of any acyltransferase transferring groups other than amino-acyl groups (EC 2.3.1.*).,false,,,http://purl.obolibrary.org/obo/CHEBI_76661,,,,,,,,,,,,,,,,,,,,,,An EC 2.3.* (acyltransferase) inhibitor that inhibits the action of any acyltransferase transferring groups other than amino-acyl groups (EC 2.3.1.*).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,EC 2.3.1.* inhibitors|EC 2.3.1.* (acyltransferase transferring other than amino-acyl group) inhibitors|EC 2.3.1.* inhibitor|acyltransferase transferring other than amino-acyl group EC 2.3.1.* inhibitors|acyltransferase transferring other than amino-acyl group EC 2.3.1.* inhibitor,,,,,,,,,,,,,,,,,,,,,CHEBI:76878,,,,EC 2.3.1.* (acyltransferase transferring other than amino-acyl group) inhibitor,,CHEBI:76878,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100550,PDGF B-chain,,,false,,,http://purl.obolibrary.org/obo/IMR_0000032,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100550,,,,,,,,,,,,,,,,,,,,,,PDGF B-chain,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001020,"High-affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A",,,false,,,http://purl.obolibrary.org/obo/IMR_0100700,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001020,,,,,,,,,,,,,,,,,,,,,,"High-affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100166,endothelin,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,MeSH:D016232,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100166,,,,,,,"21-Amino-acid peptides produced by vascular endothelial cells and functioning as potent vasoconstrictors. The endothelin family consists of three members, ENDOTHELIN-1; ENDOTHELIN-2; and ENDOTHELIN-3. All three peptides contain 21 amino acids, but vary in amino acid composition. The three peptides produce vasoconstrictor and pressor responses in various parts of the body. However, the quantitative profiles of the pharmacological activities are considerably different among the three isopeptides.",,,,,,,,,,,,,,,endothelin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005126,PPARA(mouse) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000159|http://purl.obolibrary.org/obo/TXPO_0005072,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:19013,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005126,,,,,,,,,,,,,,,,,,,,,,PPARA(mouse) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005128,PROCR (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:10544|NCBI-Mouse-GeneID:19124|NCBI-Rat-GeneID:362248,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000084696,,,,,,,,,,,,,TXPO:0005128,,,,,,,,,,,,,,,,,,,,,,PROCR (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005122,PCK1 (human) [Hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_1000524,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:5105,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000005105,,,,,,,,,,,,,TXPO:0005122,,,,,,,,,,,,,,,,,,,,,,PCK1 (human) [Hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005121,ORC1 (human) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_0004730,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:4998,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005121,,,,,,,,,,,,,,,,,,,,,,ORC1 (human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005125,PPARA(canonical) [mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000159|http://purl.obolibrary.org/obo/TXPO_0004293,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:19013|NCBI-Rat-GeneID:25747|NCBI-Human-GeneID:5465|PMID:23299992,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005125,,,,,,,,,,,,,,,,,,,,,,PPARA(canonical) [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005123,PCK1 - inactive form (predicted)(human) [mitochondrial damage],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003603|http://purl.obolibrary.org/obo/TXPO_0004176,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:5105|PMID:29335519,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657|http://purl.obolibrary.org/obo/PATO_0002355,http://purl.obolibrary.org/obo/OGG_3000005105,,,,,,,,,,,,,TXPO:0005123,,,,,,,,,,,,,,,,,,,,,,PCK1 - inactive form (predicted)(human) [mitochondrial damage],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005124,PHB (human) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_0004748,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:5245|PMID:30523154,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005124,,,,,,,,,,,,,,,,,,,,,,PHB (human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005120,NRF2(canonical) [mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002527|http://purl.obolibrary.org/obo/TXPO_0004293,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:18024|NCBI-Rat-GeneID:83619|NCBI-Human-GeneID:4780,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005120,,,,,,,,,,,,,,,,,,,,,,NRF2(canonical) [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005127,PPARGC1A (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:19017|NCBI-Rat-GeneID:83516|NCBI-Human-GeneID:10891,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005127,,,,,,,,,,,,,,,,,,,,,,PPARGC1A (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005129,PROM1 - activation state (human)[hepatocarcinogenesis],CD133,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_0004780,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:8842,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CD133,,,,,TXPO:0005129,,,,,,,,,,,,,,,,,,,,,,PROM1 - activation state (human)[hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000588,IL-9,interleukin-9,,false,,,http://purl.obolibrary.org/obo/IMR_0000007,,,,,,,,,,,,,,,,,,,,GO:0005140,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000622,,,,,interleukin-9,,,,,IMR:0000588,,,,,,,,,,,,,,,,,,,,,,IL-9,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76835,"EC 1.1.1.* (oxidoreductase acting on donor CH-OH group, NAD(+) or NADP(+) acceptor) inhibitor","EC 1.1.1.* inhibitors|EC 1.1.1.* inhibitor|oxidoreductase acting on donor CH-OH group, NAD(+) or NADP(+) acceptor (EC 1.1.1.*) inhibitors|oxidoreductase acting on donor CH-OH group, NAD(+) or NADP(+) acceptor (EC 1.1.1.*) inhibitor|EC 1.1.1.* (oxidoreductase acting on donor CH-OH group, NAD(+) or NADP(+)acceptor) inhibitors",An EC 1.1.* (oxidoreductase acting on donor CH-OH group) inhibitor that uses NAD(+) or NADP(+) as acceptor (EC 1.1.1.*).,false,,,http://purl.obolibrary.org/obo/CHEBI_76726,,,,,,,,,,,,,,,,,,,,,,An EC 1.1.* (oxidoreductase acting on donor CH-OH group) inhibitor that uses NAD(+) or NADP(+) as acceptor (EC 1.1.1.*).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"EC 1.1.1.* inhibitors|EC 1.1.1.* inhibitor|oxidoreductase acting on donor CH-OH group, NAD(+) or NADP(+) acceptor (EC 1.1.1.*) inhibitors|oxidoreductase acting on donor CH-OH group, NAD(+) or NADP(+) acceptor (EC 1.1.1.*) inhibitor|EC 1.1.1.* (oxidoreductase acting on donor CH-OH group, NAD(+) or NADP(+)acceptor) inhibitors",,,,,,,,,,,,,,,,,,,,,CHEBI:76835,,,,"EC 1.1.1.* (oxidoreductase acting on donor CH-OH group, NAD(+) or NADP(+) acceptor) inhibitor",,CHEBI:76835,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0000117,size,,A morphology quality inhering in a bearer by virtue of the bearer's physical magnitude.,false,,,http://purl.obolibrary.org/obo/TXPO_0003683|http://purl.obolibrary.org/obo/BFO_0000019,,,,,,,,,,,,,,,,,,,,,,A morphology quality inhering in a bearer by virtue of the bearer's physical magnitude.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0000117,,,,,,,,,,,,,,,,,,,,,,size,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0000119,height,,A 1-D extent quality inhering in a bearer by virtue of the bearer's vertical dimension of extension.,false,,,http://purl.obolibrary.org/obo/PATO_0000117,,,,,,,,,,,,,,,,,,,,,,A 1-D extent quality inhering in a bearer by virtue of the bearer's vertical dimension of extension.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0000119,,,,,,,,,,,,,,,,,,,,,,height,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000285126,DNAJC5G,,Other designations: cysteine string protein-gamma|dnaJ homolog subfamily C member 5G|gamma cysteine string protein|gamma-CSP|gamma-cysteine string protein,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CSP-gamma,,,,,,,,,,,,2,,,,,,HGNC:24844|Vega:OTTHUMG00000097079|Ensembl:ENSG00000163793|HPRD:07108|MIM:613946,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"DnaJ (Hsp40) homolog, subfamily C, member 5 gamma",,,2p23.3,,,,,,,,,,,,,,,,GO_0016020 (EC: IEA),,,,,,,,,PMID:12477932; 14702039; 15489334,,,,,,,,,,,,,,,OGG:3000285126,,,,,,,"DnaJ (Hsp40) homolog, subfamily C, member 5 gamma",,,,,,,,,,,,,Other designations: cysteine string protein-gamma|dnaJ homolog subfamily C member 5G|gamma cysteine string protein|gamma-CSP|gamma-cysteine string protein,,DNAJC5G,,,,,,,,,,,,,,,,,,,,,,,285126,,,,,,,,9606,,,,,,,,,,,,,,,,,,,DNAJC5G,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0002232,increasing uptake amount of mitochondrial calcium ion [Phospholipidosis],,"Increasing uptake amount of mitochondrial calcium ion is a subtype of increasing quantity: A process that changes the uptake amount of mitochondrial calcium ion to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0002229,,,,,,,,,,,,,,,,,,,,,,"Increasing uptake amount of mitochondrial calcium ion is a subtype of increasing quantity: A process that changes the uptake amount of mitochondrial calcium ion to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003477,,,,,,http://purl.obolibrary.org/obo/TXPO_0002233,,,,,,,,,,,TXPO:0002232,,,,,,,,,,,,,,,,,,,,,,increasing uptake amount of mitochondrial calcium ion [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002239,negative regulation of apoptotic process [Phospholipidosis (excessive defense) ],,"Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptotic process.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense) .|Negative regulation of apoptotic process might be a defense process prevent the number of cells from decreasing too much.",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/GO_0043066,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptotic process.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense) .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003406|http://purl.obolibrary.org/obo/TXPO_0003890,http://purl.obolibrary.org/obo/TXPO_0003570|http://purl.obolibrary.org/obo/TXPO_0003788|http://purl.obolibrary.org/obo/TXPO_0003993|http://purl.obolibrary.org/obo/TXPO_0003998|http://purl.obolibrary.org/obo/TXPO_0002244,,,,,,http://purl.obolibrary.org/obo/TXPO_0002245,,,,,,,,,,,TXPO:0002239,,,,,,,,,,,,,,,,,,,,Negative regulation of apoptotic process might be a defense process prevent the number of cells from decreasing too much.,,negative regulation of apoptotic process [Phospholipidosis (excessive defense) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002230,hypofunction of ATP biosynthesis [Mitochondrial disorder],,"Hypofunction of ATP biosynthesis is a subtype of hypofunction of biosynthesis: A process that performs a decreased or insufficient ATP biosynthesis.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001722|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:31623280|PMID:29335519|PMID:30232152|PMID:30250064|PMID:24746669|PMID:31649547|PMID:28789970,,"Hypofunction of ATP biosynthesis is a subtype of hypofunction of biosynthesis: A process that performs a decreased or insufficient ATP biosynthesis.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004232,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000933|http://purl.obolibrary.org/obo/TXPO_0001988|http://purl.obolibrary.org/obo/TXPO_0004264,,,,,,,,,,,TXPO:0002230,,,,,,,,,,,,,,,,,,,,,,hypofunction of ATP biosynthesis [Mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002233,decreasing mitochondrial membrane potential [Phospholipidosis],,"Decreasing mitochondrial membrane potential is a subtype of decreasing membrane potential: A process that changes the electrical potential of a mitochondrial membrane to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001855|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Decreasing mitochondrial membrane potential is a subtype of decreasing membrane potential: A process that changes the electrical potential of a mitochondrial membrane to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000928|http://purl.obolibrary.org/obo/TXPO_0002234,,,,,,,,,,,TXPO:0002233,,,,,,,,,,,,,,,,,,,,,,decreasing mitochondrial membrane potential [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0031966,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002231,release of calcium ion from lysosome,,The directed movement of calcium from the lysosome.,false,,,http://purl.obolibrary.org/obo/TXPO_0002588,,,,,,,,,,,,,,,,,,,,,,The directed movement of calcium from the lysosome.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_39124,,,,,,,,,,,,,,,,,,,TXPO:0002231,,,,,,,,,,,,,,,,,,,,,,release of calcium ion from lysosome,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005764,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002235,autolysis,,Autolysis is a subtype of dissolving: The disintegration of a cell by rupture of the cell membrane by the action of their own enzymes.,false,,,http://purl.obolibrary.org/obo/TXPO_0002570,,,,,,,,,,,,,,,,,,,,MeSH:D001329,,Autolysis is a subtype of dissolving: The disintegration of a cell by rupture of the cell membrane by the action of their own enzymes.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002235,,,,,,,,,,,,,,,,,,,,,,autolysis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002238,stabilizing lysosomal membrane structure [Phospholipidosis],,"Stabilizing lysosomal membrane structure is a subtype of stabilizing membrane structure: A process that maintains the membrane structure in the lysosome.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0002237,,,,,,,,,,,,,,,,,,,,PMID:21281795,,"Stabilizing lysosomal membrane structure is a subtype of stabilizing membrane structure: A process that maintains the membrane structure in the lysosome.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002239,,,,,,,,,,,TXPO:0002238,,,,,,,,,,,,,,,,,,,,,,stabilizing lysosomal membrane structure [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002237,stabilizing lysosomal membrane structure,,Stabilizing lysosomal membrane structure is a subtype of stabilizing membrane structure: A process that maintains the membrane structure in the lysosome.,false,,,http://purl.obolibrary.org/obo/TXPO_0002236,,,,,,,,,,,,,,,,,,,,,,Stabilizing lysosomal membrane structure is a subtype of stabilizing membrane structure: A process that maintains the membrane structure in the lysosome.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002237,,,,,,,,,,,,,,,,,,,,,,stabilizing lysosomal membrane structure,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002236,stabilizing membrane structure,,Stabilizing membrane structure is a subtype of keeping structure: A process that maintains the membrane structure.,false,,,http://purl.obolibrary.org/obo/TXPO_0003733,,,,,,,,,,,,,,,,,,,,,,Stabilizing membrane structure is a subtype of keeping structure: A process that maintains the membrane structure.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002236,,,,,,,,,,,,,,,,,,,,,,stabilizing membrane structure,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002234,hypofunction of ATP biosynthesis [Phospholipidosis],,"Hypofunction of ATP biosynthesis is a subtype of hypofunction of biosynthesis: A process that performs a decreased or insufficient ATP biosynthesis.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001722|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Hypofunction of ATP biosynthesis is a subtype of hypofunction of biosynthesis: A process that performs a decreased or insufficient ATP biosynthesis.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000927,,,,,,,,,,,TXPO:0002234,,,,,,,,,,,,,,,,,,,,,,hypofunction of ATP biosynthesis [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003255,PEX5 (human)[Eosinophilic granular degeneration],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001034|http://purl.obolibrary.org/obo/TXPO_0003254,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:5830,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003255,,,,,,,,,,,,,,,,,,,,,,PEX5 (human)[Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003250,Ehhadh (mouse)[Eosinophilic granular degeneration],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000648|http://purl.obolibrary.org/obo/TXPO_1000131,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:74147|PMID:19710929,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003250,,,,,,,,,,,,,,,,,,,,,,Ehhadh (mouse)[Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003253,ATM (human)[Eosinophilic granular degeneration],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001034|http://purl.obolibrary.org/obo/TXPO_0003252,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:300711|NCBI-Human-GeneID:472|NCBI-Mouse-GeneID:11920,,,https://www.ncbi.nlm.nih.gov/gene/641371,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003253,,,,,,,,,,,,,,,,,,,,,,ATM (human)[Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003259,hyperfunction of bile acid transport,,Hyperfunction of bile acid transport  is a subtype of hyperfunction of transport: A process that performs an excesssive bile acid transport.,false,,,http://purl.obolibrary.org/obo/TXPO_0002351,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of bile acid transport  is a subtype of hyperfunction of transport: A process that performs an excesssive bile acid transport.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003259,,,,,,,,,,,,,,,,,,,,,,hyperfunction of bile acid transport,,,,,,http://purl.obolibrary.org/obo/GO_0015721,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003256,farnesoid X receptor inactivation,Farnesoid X Receptor inactivation|FXR inactivation,Farnesoid X receptor inactivation is a subtype of inactivating nuclear receptor: A process that changes the activity of the inactivating FxR (farnesoid X receptor) with a nuclear receptor role to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0001589,,,,,,,,,,,,,,,,,,,,,,Farnesoid X receptor inactivation is a subtype of inactivating nuclear receptor: A process that changes the activity of the inactivating FxR (farnesoid X receptor) with a nuclear receptor role to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Farnesoid X Receptor inactivation|FXR inactivation,,,,,TXPO:0003256,,,,,,,,,,,,,,,,,,,,,,farnesoid X receptor inactivation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003254,PEX5 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:19305|NCBI-Human-GeneID:5830|NCBI-Rat-GeneID:312703,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000008800,,,,,,,,,,,,,TXPO:0003254,,,,,,,,,,,,,,,,,,,,,,PEX5 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003252,ATM (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0001146,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:300711|NCBI-Human-GeneID:472|NCBI-Mouse-GeneID:11920,,,https://www.ncbi.nlm.nih.gov/gene/641371,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003252,,,,,,,,,,,,,,,,,,,,,,ATM (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003251,drug transporter,,A role played by the entity which enables the transfer of drugs.,false,,,http://purl.obolibrary.org/obo/TXPO_0003638,,,,,,,,,,,,,,,,,,,,,,A role played by the entity which enables the transfer of drugs.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003251,,,,,,,,,,,,,,,,,,,,,,drug transporter,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003257,hyperfunction of drug transporter gene expression,,Hyperfunction of drug transporter gene expression is a subtype of hyperfunction of gene expression: A process that performs an excesssive drug transporter gene expression.,false,,,http://purl.obolibrary.org/obo/TXPO_0002345,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of drug transporter gene expression is a subtype of hyperfunction of gene expression: A process that performs an excesssive drug transporter gene expression.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003257,,,,,,,,,,,,,,,,,,,,,,hyperfunction of drug transporter gene expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003258,hyperfunction of drug transporter gene expression [Ground glass appearance],,"Hyperfunction of drug transporter gene expression is a subtype of hyperfunction of gene expression: A process that performs an excesssive drug transporter gene expression.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/TXPO_0003257,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of drug transporter gene expression is a subtype of hyperfunction of gene expression: A process that performs an excesssive drug transporter gene expression.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001032|http://purl.obolibrary.org/obo/TXPO_0003263,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003260,,,,,,,,,,,TXPO:0003258,,,,,,,,,,,,,,,,,,,,,,hyperfunction of drug transporter gene expression [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100706,Bcl-2 subfamily,,,false,,,http://purl.obolibrary.org/obo/IMR_0100705,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100706,,,,,,,,,,,,,,,,,,,,,,Bcl-2 subfamily,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76725,EC 1.* (oxidoreductase) inhibitor,EC 1.* (oxidoreductase) inhibitors|oxidoreductase inhibitors|oxidoreductase inhibitor|oxidoreductase (EC 1.*) inhibitor|EC 1.* inhibitor|oxidoreductase (EC 1.*) inhibitors|EC 1.* inhibitors,An enzyme inhibitor which interferes with the action of an oxidoreductase (EC 1.*.*.*).,false,,,http://purl.obolibrary.org/obo/CHEBI_23924,,,,,,,,,,,,,,,,,,,,,,An enzyme inhibitor which interferes with the action of an oxidoreductase (EC 1.*.*.*).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,EC 1.* (oxidoreductase) inhibitors|oxidoreductase inhibitors|oxidoreductase inhibitor|oxidoreductase (EC 1.*) inhibitor|EC 1.* inhibitor|oxidoreductase (EC 1.*) inhibitors|EC 1.* inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:76725,,,,EC 1.* (oxidoreductase) inhibitor,,CHEBI:76725,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/BFO_0000040,material entity,,,false,,,http://purl.obolibrary.org/obo/BFO_0000004,,,,,,,,,,,,,,,,,,,,,,,,,,"BFO 2 Reference: Material entities (continuants) can preserve their identity even while gaining and losing material parts. Continuants are contrasted with occurrents, which unfold themselves in successive temporal parts or phases [60|BFO 2 Reference: ‘Matter’ is intended to encompass both mass and energy (we will address the ontological treatment of portions of energy in a later version of BFO). A portion of matter is anything that includes elementary particles among its proper or improper parts: quarks and leptons, including electrons, as the smallest particles thus far discovered; baryons (including protons and neutrons) at a higher level of granularity; atoms and molecules at still higher levels, forming the cells, organs, organisms and other material entities studied by biologists, the portions of rock studied by geologists, the fossils studied by paleontologists, and so on.Material entities are three-dimensional entities (entities extended in three spatial dimensions), as contrasted with the processes in which they participate, which are four-dimensional entities (entities extended also along the dimension of time).According to the FMA, material entities may have immaterial entities as parts – including the entities identified below as sites; for example the interior (or ‘lumen’) of your small intestine is a part of your body. BFO 2.0 embodies a decision to follow the FMA here.|BFO 2 Reference: Object, Fiat Object Part and Object Aggregate are not intended to be exhaustive of Material Entity. Users are invited to propose new subcategories of Material Entity.",,A material entity is an independent continuant that has some portion of matter as proper or improper continuant part. (axiom label in BFO2 Reference: [019-002]),an epidemic|a forest fire|a tornado|the undetached arm of a human being|a photon|a human being|a sea wave|a hurricane|a puff of smoke|an energy wave|an aggregate of human beings.|a flame,,,,,,,,,,,(forall (x) (if (MaterialEntity x) (IndependentContinuant x))) // axiom label in BFO2 CLIF: [019-002]|(forall (x) (if (and (Entity x) (exists (y t) (and (MaterialEntity y) (continuantPartOfAt y x t)))) (MaterialEntity x))) // axiom label in BFO2 CLIF: [020-002]|(forall (x) (if (and (Entity x) (exists (y t) (and (MaterialEntity y) (continuantPartOfAt x y t)))) (MaterialEntity x))) // axiom label in BFO2 CLIF: [021-002],Every entity which has a material entity as continuant part is a material entity. (axiom label in BFO2 Reference: [020-002])|every entity of which a material entity is continuant part is also a material entity. (axiom label in BFO2 Reference: [021-002]),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BFO:0000040,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/bfo.owl,material entity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000221,ZAP-70,,,false,,,http://purl.obolibrary.org/obo/IMR_0000220,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000221,,,,,,,,,,,,,,,,,,,,,,ZAP-70,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000605,IL-8 receptor,interleukin-8 receptor,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,GO:0004918,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000096,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003561,,,,,interleukin-8 receptor,,,,,IMR:0000605,,,,,,,,,,,,,,,,,,,,,,IL-8 receptor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000684,JNK2,p54 alpha SAPK,,false,,,http://purl.obolibrary.org/obo/IMR_0000225,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p54 alpha SAPK,,,,,IMR:0000684,,,,,,,,,,,,,,,,,,,,,,JNK2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010504,60S acidic ribosomal protein P2,P05387,,false,,,http://purl.obolibrary.org/obo/IMR_0000897,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,P05387,,,,,IMR:0010504,,,,,,,,,,,,,,,,,,,,,,60S acidic ribosomal protein P2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_37699,protein kinase inhibitor,protein kinase inhibitors,An EC 2.7.* (P-containing group transferase) inhibitor that interferes with the action of protein kinases.,false,,,http://purl.obolibrary.org/obo/CHEBI_76668,,,,,,,,,,,,,,,,,,,,,,An EC 2.7.* (P-containing group transferase) inhibitor that interferes with the action of protein kinases.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,protein kinase inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:37699,,,,protein kinase inhibitor,,CHEBI:37699,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100572,FGF-22,,,false,,,http://purl.obolibrary.org/obo/IMR_0000049,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100572,,,,,,,,,,,,,,,,,,,,,,FGF-22,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001110,RanBP6,,,false,,,http://purl.obolibrary.org/obo/IMR_0001091,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001110,,,,,,,,,,,,,,,,,,,,,,RanBP6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/NCBITaxon_9606,homo sapiens,human,,false,,,http://purl.obolibrary.org/obo/NCBITaxon_40674,,,,,,,,,,,,,,,,,,,,http://purl.bioontology.org/ontology/STY/T016,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,human,,,,,NCBITaxon:9606,,,,,,,,,,,,,,,,,,,,,,homo sapiens,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000687,increasing demand for response to ER stress (moderate),,Increasing demand for response to ER stress (moderate) is a subtype of increasing the demand for response to ER stress: A process that changes the functional demand for the response to the edoplasmic reticulum (ER) stress to be moderately higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000362,,,,,,,,,,,,,,,,,,,,,,Increasing demand for response to ER stress (moderate) is a subtype of increasing the demand for response to ER stress: A process that changes the functional demand for the response to the edoplasmic reticulum (ER) stress to be moderately higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000687,,,,,,,,,,,,,,,,,,,,,,increasing demand for response to ER stress (moderate),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000684,maintaining stress response balance,,Maintaining stress response balance is a subtype of maintaining balance: A process that keeps a balance between the stimulation (stress) and the response.,false,,,http://purl.obolibrary.org/obo/TXPO_0000682,,,,,,,,,,,,,,,,,,,,,,Maintaining stress response balance is a subtype of maintaining balance: A process that keeps a balance between the stimulation (stress) and the response.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000684,,,,,,,,,,,,,,,,,,,,,,maintaining stress response balance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000689,increasing demand for response to ER stress [ER stress (mild) ],,"Increasing demand for response to ER stress is a subtype of increasing the demand for response to stress: A process that changes the functional demand for the response to the edoplasmic reticulum (ER) stress to be higher.
This entity is a specific course-dependent process. This process can constitute the course of ER stress (mild).",false,,,http://purl.obolibrary.org/obo/TXPO_0000734,,,,,,,,,,,,,,,,,,,,,,"Increasing demand for response to ER stress is a subtype of increasing the demand for response to stress: A process that changes the functional demand for the response to the edoplasmic reticulum (ER) stress to be higher.
This entity is a specific course-dependent process. This process can constitute the course of ER stress (mild).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000689,,,,,,,,,,,,,,,,,,,,,,increasing demand for response to ER stress [ER stress (mild) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000681,scarring,,Scarring is a subtype of changing material: A process of keeping area replaced into fibrous tissue by injury.,false,,,http://purl.obolibrary.org/obo/TXPO_0000219,,,,,,,,,,,,,,,,,,,,,,Scarring is a subtype of changing material: A process of keeping area replaced into fibrous tissue by injury.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000681,,,,,,,,,,,,,,,,,,,,,,scarring,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0001850,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000682,maintaining balance,,Maintaining balance is a subtype of changing balance: A process that keeps the steady state between operands.,false,,,http://purl.obolibrary.org/obo/TXPO_0001847,,,,,,,,,,,,,,,,,,,,,,Maintaining balance is a subtype of changing balance: A process that keeps the steady state between operands.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000682,,,,,,,,,,,,,,,,,,,,,,maintaining balance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000680,toxicological imbalance M<H,,"In the imbalance model, the basic units are as follows:
1) a functioning process (supply) for biological defense and maintaining homeostasis;
2) a functional demand process (demand) as toxic activity;
3) balance/imbalance between toxic activity and defense processes; and
4) outcome from organelles, cells, or tissues to the organ exhibiting toxicity manifestations.

This entity  is a compound state that inculdes step 1 to 4.
The defense performance level is Moderate (M) in the normal coindition; however, the functional demand level is High (H), which leads to the imbalance.",false,,,http://purl.obolibrary.org/obo/TXPO_0003992,,,,,,,,,,,,,,,,,,,,,,"In the imbalance model, the basic units are as follows:
1) a functioning process (supply) for biological defense and maintaining homeostasis;
2) a functional demand process (demand) as toxic activity;
3) balance/imbalance between toxic activity and defense processes; and
4) outcome from organelles, cells, or tissues to the organ exhibiting toxicity manifestations.

This entity  is a compound state that inculdes step 1 to 4.
The defense performance level is Moderate (M) in the normal coindition; however, the functional demand level is High (H), which leads to the imbalance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000680,,,,,,,,,,,,,,,,,,,,,,toxicological imbalance M<H,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000688,increasing demand for response to ER stress (mild),,Increasing demand for response to ER stress (mild) is a subtype of increasing the demand for response to ER stress: A process that changes the functional demand for the response to the edoplasmic reticulum (ER) stress to be mildly higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000362,,,,,,,,,,,,,,,,,,,,,,Increasing demand for response to ER stress (mild) is a subtype of increasing the demand for response to ER stress: A process that changes the functional demand for the response to the edoplasmic reticulum (ER) stress to be mildly higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000688,,,,,,,,,,,,,,,,,,,,,,increasing demand for response to ER stress (mild),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000686,maintaining endoplasmic reticulum stress response balance [ER stress],,"Maintaining endoplasmic reticulum stress response balance is a subtype of maintaining stress response balance: A process that keeps a balance between the stimulation (stress) acting on the endoplasmic reticulum and the biological defence response.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/TXPO_0000685,,,,,,,,,,,,,,,,,,,,,,"Maintaining endoplasmic reticulum stress response balance is a subtype of maintaining stress response balance: A process that keeps a balance between the stimulation (stress) acting on the endoplasmic reticulum and the biological defence response.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000686,,,,,,,,,,,,,,,,,,,,,,maintaining endoplasmic reticulum stress response balance [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000685,maintaining endoplasmic reticulum stress response balance,,Maintaining endoplasmic reticulum stress response balance is a subtype of maintaining stress response balance: A process that keeps a balance between the stimulation (stress) acting on the endoplasmic reticulum and the biological defence response.,false,,,http://purl.obolibrary.org/obo/TXPO_0000684,,,,,,,,,,,,,,,,,,,,,,Maintaining endoplasmic reticulum stress response balance is a subtype of maintaining stress response balance: A process that keeps a balance between the stimulation (stress) acting on the endoplasmic reticulum and the biological defence response.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000685,,,,,,,,,,,,,,,,,,,,,,maintaining endoplasmic reticulum stress response balance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006996,organelle organization,organelle organisation,"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of an organelle within a cell. An organelle is an organized structure of distinctive morphology and function. Includes the nucleus, mitochondria, plastids, vacuoles, vesicles, ribosomes and the cytoskeleton.",false,,,http://purl.obolibrary.org/obo/GO_0071840,,,,,,,,,,,,,,,,,,,,,,"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of an organelle within a cell. An organelle is an organized structure of distinctive morphology and function. Includes the nucleus, mitochondria, plastids, vacuoles, vesicles, ribosomes and the cytoskeleton.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,organelle organisation,,,,,GO:0006996,,,,,,,,,,,,,,,,,,,,,,organelle organization,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000623,Integrin alpha-1,,,false,,,http://purl.obolibrary.org/obo/IMR_0000173,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000623,,,,,,,,,,,,,,,,,,,,,,Integrin alpha-1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_77102,EC 1.3.5.* (oxidoreductase acting on CH-CH of donor with a quinone or related compound as acceptor) inhibitor,oxidoreductase acting on CH-CH of donor with a quinone or related compound as acceptor (EC 1.3.5.*) inhibitor|inhibitor of oxidoreductase acting on CH-CH of donor with a quinone or related compound as acceptor|inhibitor of oxidoreductase acting on CH-CH of donor with a quinone or related compound as acceptor (EC 1.3.5.*)|inhibitors of oxidoreductase acting on CH-CH of donor with a quinone or related compound as acceptor (EC 1.3.5.*)|EC 1.3.5.* inhibitor|oxidoreductase acting on CH-CH of donor with a quinone or related compound as acceptor (EC 1.3.5.*) inhibitors|inhibitors of oxidoreductase acting on CH-CH of donor with a quinone or related compound as acceptor|EC 1.3.5.* (oxidoreductase acting on CH-CH of donor with a quinone or related compound as acceptor) inhibitors|EC 1.3.5.* inhibitors,An EC 1.3.* (oxidoreductase acting on donor CH-CH group) inhibitor that interferes with the action of any such enzyme using a quinone or related compound as acceptor (EC 1.3.5.*).,false,,,http://purl.obolibrary.org/obo/CHEBI_76729,,,,,,,,,,,,,,,,,,,,,,An EC 1.3.* (oxidoreductase acting on donor CH-CH group) inhibitor that interferes with the action of any such enzyme using a quinone or related compound as acceptor (EC 1.3.5.*).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,oxidoreductase acting on CH-CH of donor with a quinone or related compound as acceptor (EC 1.3.5.*) inhibitor|inhibitor of oxidoreductase acting on CH-CH of donor with a quinone or related compound as acceptor|inhibitor of oxidoreductase acting on CH-CH of donor with a quinone or related compound as acceptor (EC 1.3.5.*)|inhibitors of oxidoreductase acting on CH-CH of donor with a quinone or related compound as acceptor (EC 1.3.5.*)|EC 1.3.5.* inhibitor|oxidoreductase acting on CH-CH of donor with a quinone or related compound as acceptor (EC 1.3.5.*) inhibitors|inhibitors of oxidoreductase acting on CH-CH of donor with a quinone or related compound as acceptor|EC 1.3.5.* (oxidoreductase acting on CH-CH of donor with a quinone or related compound as acceptor) inhibitors|EC 1.3.5.* inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:77102,,,,EC 1.3.5.* (oxidoreductase acting on CH-CH of donor with a quinone or related compound as acceptor) inhibitor,,CHEBI:77102,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100486,cPKC,conventional PKC,"classical PKC isoforms (alpha, betaI, betaII and gamma) are regulated by calcium, diacylglycerol (DAG) and phospholipids.",false,,,http://purl.obolibrary.org/obo/IMR_0000245,,,,,,,,,,,,,,,,,,,,,,"classical PKC isoforms (alpha, betaI, betaII and gamma) are regulated by calcium, diacylglycerol (DAG) and phospholipids.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,conventional PKC,,,,,IMR:0100486,,,,,,,,,,,,,,,,,,,,,,cPKC,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000117,IL-15 receptor,interleukin-15 receptor,,false,,,http://purl.obolibrary.org/obo/IMR_0000096,,,,,,,,,,,,,,,,,,,,GO:0042010,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,interleukin-15 receptor,,,,,IMR:0000117,,,,,,,,,,,,,,,,,,,,,,IL-15 receptor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100321,JAK3,,,false,,,http://purl.obolibrary.org/obo/IMR_0000213,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100321,,,,,,,,,,,,,,,,,,,,,,JAK3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000153020,RASGEF1B,,Other designations: GPI gamma-4|GPI-gamma 4|ras-GEF domain-containing family member 1B,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,GPIG4,,,,,,,,,,,,4,,,,,,MIM:614532|HPRD:17955|HGNC:24881|Ensembl:ENSG00000138670|Vega:OTTHUMG00000160890,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"RasGEF domain family, member 1B",,,4q21.21,,,,,,,,,,,,,,,,"GO_0005088 (EC: IDA, PMID: 19645719); GO_0005769 (EC: IEA); GO_0005770 (EC: IEA); GO_0007264 (EC: IEA); GO_0030496 (EC: IEA); GO_0032318 (EC: IDA, PMID: 19645719)",,,,,,,,,PMID: 12477932; 12488504; 14702039; 18391951; 19645719; 22303795; 23377640,,,,,,,,,,,,,,,OGG:3000153020,,,,,,,"RasGEF domain family, member 1B",,,,,,,,,,,,,Other designations: GPI gamma-4|GPI-gamma 4|ras-GEF domain-containing family member 1B,,RASGEF1B,,,,,,,,,,,,,,,,,,,,,,,153020,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,RASGEF1B,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_76735,EC 1.8.* (oxidoreductase acting on sulfur group of donors) inhibitor,EC 1.8.* inhibitor|oxidoreductase acting on a sulfur group of donors (EC 1.8.*) inhibitors|EC 1.8.* inhibitors|EC 1.8.* (oxidoreductase acting on sulfur group of donors) inhibitors|oxidoreductase acting on a sulfur group of donors (EC 1.8.*) inhibitor,An oxidoreductase inhibitor which interferes with the action of an oxidoreductase of class EC 1.8.*.* (acting on a sulfur group of donors).,false,,,http://purl.obolibrary.org/obo/CHEBI_76725,,,,,,,,,,,,,,,,,,,,,,An oxidoreductase inhibitor which interferes with the action of an oxidoreductase of class EC 1.8.*.* (acting on a sulfur group of donors).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,EC 1.8.* inhibitor|oxidoreductase acting on a sulfur group of donors (EC 1.8.*) inhibitors|EC 1.8.* inhibitors|EC 1.8.* (oxidoreductase acting on sulfur group of donors) inhibitors|oxidoreductase acting on a sulfur group of donors (EC 1.8.*) inhibitor,,,,,,,,,,,,,,,,,,,,,CHEBI:76735,,,,EC 1.8.* (oxidoreductase acting on sulfur group of donors) inhibitor,,CHEBI:76735,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0070269,pyroptosis,,A caspase-1-dependent cell death subroutine that is associated with the generation of pyrogenic mediators such as IL-1beta and IL-18.,false,,,http://purl.obolibrary.org/obo/GO_0008219,,,,,,,,,,,,,,,,,,,,PMID:18846107|PMID: 21760595|PMID:21760595,,A caspase-1-dependent cell death subroutine that is associated with the generation of pyrogenic mediators such as IL-1beta and IL-18.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0070269,,,,,,,,,,,,,,,,,,,,,,pyroptosis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0070265,necrosis,cellular necrosis,"A type of cell death that is morphologically characterized by an increasingly translucent cytoplasm, swelling of organelles, minor ultrastructural modifications of the nucleus (specifically, dilatation of the nuclear membrane and condensation of chromatin into small, irregular, circumscribed patches) and increased cell volume (oncosis), culminating in the disruption of the plasma membrane and subsequent loss of intracellular contents. Necrotic cells do not fragment into discrete corpses as their apoptotic counterparts do. Moreover, their nuclei remain intact and can aggregate and accumulate in necrotic tissues.|Note that the word necrosis has been widely used in earlier literature to describe forms of cell death which are now known by more precise terms, such as apoptosis. Necrosis can occur in a regulated fashion, involving a precise sequence of signals; in this case, consider annotating to GO:0097300 'programmed necrotic cell death' or to its more specific child GO:0070266 'necroptotic process'.",false,,,http://purl.obolibrary.org/obo/GO_0008219,,,,,,,,,,,,,,,,,,,,,,"A type of cell death that is morphologically characterized by an increasingly translucent cytoplasm, swelling of organelles, minor ultrastructural modifications of the nucleus (specifically, dilatation of the nuclear membrane and condensation of chromatin into small, irregular, circumscribed patches) and increased cell volume (oncosis), culminating in the disruption of the plasma membrane and subsequent loss of intracellular contents. Necrotic cells do not fragment into discrete corpses as their apoptotic counterparts do. Moreover, their nuclei remain intact and can aggregate and accumulate in necrotic tissues.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,cellular necrosis,,,,,GO:0070265,,,,,,,,,,,,,,,,,,,,"Note that the word necrosis has been widely used in earlier literature to describe forms of cell death which are now known by more precise terms, such as apoptosis. Necrosis can occur in a regulated fashion, involving a precise sequence of signals; in this case, consider annotating to GO:0097300 'programmed necrotic cell death' or to its more specific child GO:0070266 'necroptotic process'.",,necrosis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_51061,hormone receptor modulator,hormone receptor modulators,"A drug that modulates the function of the endocrine glands, the biosynthesis of their secreted hormones, or the action of hormones upon their specific sites.",false,,,http://purl.obolibrary.org/obo/CHEBI_23888|http://purl.obolibrary.org/obo/CHEBI_90710,,,,,,,,,,,,,,,,,,,,,,"A drug that modulates the function of the endocrine glands, the biosynthesis of their secreted hormones, or the action of hormones upon their specific sites.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,hormone receptor modulators,,,,,,,,,,,,,,,,,,,,,CHEBI:51061,,,,hormone receptor modulator,,CHEBI:51061,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76712,EC 4.2.* (C-O lyase) inhibitor,C-O lyase inhibitors|C-O lyase (EC 4.2.*) inhibitor|C-O lyase inhibitor|EC 4.2.* inhibitor|EC 4.2.* inhibitors|C-O lyase (EC 4.2.*) inhibitors|EC 4.2.* (C-O lyase) inhibitors,A lyase inhibitor which inhibits the action of a C-O lyase (EC 4.2.*.*).,false,,,http://purl.obolibrary.org/obo/CHEBI_76710,,,,,,,,,,,,,,,,,,,,,,A lyase inhibitor which inhibits the action of a C-O lyase (EC 4.2.*.*).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,C-O lyase inhibitors|C-O lyase (EC 4.2.*) inhibitor|C-O lyase inhibitor|EC 4.2.* inhibitor|EC 4.2.* inhibitors|C-O lyase (EC 4.2.*) inhibitors|EC 4.2.* (C-O lyase) inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:76712,,,,EC 4.2.* (C-O lyase) inhibitor,,CHEBI:76712,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000833,ATF-7 (mol),ATF-a|activating transcription factor 7,,false,,,http://purl.obolibrary.org/obo/IMR_0000825,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ATF-a|activating transcription factor 7,,,,,IMR:0000833,,,,,,,,,,,,,,,,,,,,,,ATF-7 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000001842,ECM2,,Other designations: extracellular matrix protein 2|matrix glycoprotein SC1/ECM2,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,9,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"extracellular matrix protein 2, female organ and adipocyte specific",,,9q22.3,,,,,,,,,,,,,,,,"GO_0005178 (EC: TAS, PMID: 9790758); GO_0005578 (EC: TAS, PMID: 9790758); GO_0005614 (EC: IEA); GO_0007160 (EC: TAS, PMID: 9790758); GO_0008201 (EC: IEA); GO_0010811 (EC: IEA); GO_0030198 (EC: IEA); GO_0070052 (EC: IEA)",,,,,,,,,PMID: 8889548; 9345023; 9790758; 11076863; 11230166; 12477932; 15164053; 15489334; 15489336; 16381901,,,,,,,,,,,,,,,OGG:3000001842,,20140408,protein-coding,,,,"extracellular matrix protein 2, female organ and adipocyte specific",,,,,,,,,,,,,Other designations: extracellular matrix protein 2|matrix glycoprotein SC1/ECM2,,ECM2,,,,,,,,,,,,,,,,,,,,,,,1842,RP11-77D6.2,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,ECM2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_17517,phosphatidylglycerol,,A glycerophosphoglycerol that is glycerol in which the hydrogen of one of the primary hydroxy groups has been replaced by a phosphatidyl group.,false,,,http://purl.obolibrary.org/obo/CHEBI_24360,,,,,,,,,,,,,,,,,,,,,,A glycerophosphoglycerol that is glycerol in which the hydrogen of one of the primary hydroxy groups has been replaced by a phosphatidyl group.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:17517,,,,,,,,,,,,,,,,,,,,,,phosphatidylglycerol,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100211,gastrin,,A family of gastrointestinal peptide hormones that excite the secretion of GASTRIC JUICE. They may also occur in the central nervous system where they are presumed to be neurotransmitters.,false,,,http://purl.obolibrary.org/obo/IMR_0100072,,,,,,,,,,,,,,,,,,,,MeSH:D005755,,A family of gastrointestinal peptide hormones that excite the secretion of GASTRIC JUICE. They may also occur in the central nervous system where they are presumed to be neurotransmitters.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100211,,,,,,,,,,,,,,,,,,,,,,gastrin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0002721,TOR,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001966,,,,,,,,,,IMR:0002721,,,,,,,,,,,,,,,,,,,,,,TOR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0046651,lymphocyte proliferation,,The expansion of a lymphocyte population by cell division.,false,,,http://purl.obolibrary.org/obo/GO_0008283,,,,,,,,,,,,,,,,,,,,,,The expansion of a lymphocyte population by cell division.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0046651,,,,,,,,,,,,,,,,,,,,,,lymphocyte proliferation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006805,xenobiotic metabolic process,xenobiotic biotransformation,"The chemical reactions and physical changes involving a xenobiotic compound, a compound foreign to living organisms. Used of chemical compounds, e. g. a xenobiotic chemical, such as a pesticide. (Gene Ontology)|Xenobiotic biotransformation is metabolic conversion of xenobiotic chemicals to more hydrophilic (water-soluble) compounds.",false,,,http://purl.obolibrary.org/obo/GO_0008152,,,,,,,,,,,,,,,,,,,,ISBN:0071769234,,"The chemical reactions and physical changes involving a xenobiotic compound, a compound foreign to living organisms. Used of chemical compounds, e. g. a xenobiotic chemical, such as a pesticide. (Gene Ontology)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,xenobiotic biotransformation,,,,,GO:0006805,,,,,,,,,,,,,,,,,,,,Xenobiotic biotransformation is metabolic conversion of xenobiotic chemicals to more hydrophilic (water-soluble) compounds.,,xenobiotic metabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0001759,granular,,A composition quality inhering in a bearer by virtue of the bearer's containing granules.,false,,,http://purl.obolibrary.org/obo/PATO_0000025,,,,,,,,,,,,,,,,,,,,,,A composition quality inhering in a bearer by virtue of the bearer's containing granules.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0001759,,,,,,,,,,,,,,,,,,,,,,granular,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_791,17β-estradiol 17-glucosiduronic acid,Estradiol-17beta-glucuronide,A steroid glucosiduronic acid that consists of 17β-estradiol having a beta-glucuronyl residue attached at position 17 via a glycosidic linkage.,false,,,http://purl.obolibrary.org/obo/CHEBI_35341,,,,,,,,,,,,,,,,,,,,InChIKey:MTKNDAQYHASLID-QXYWQCSFSA-N|Nikkaji:J386.923G|http://purl.bioontology.org/ontology/MESH/C025483,,A steroid glucosiduronic acid that consists of 17β-estradiol having a beta-glucuronyl residue attached at position 17 via a glycosidic linkage.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Estradiol-17beta-glucuronide,,,,,CHEBI:791,,,,,,,,,,,,,,,,,,,,,,17β-estradiol 17-glucosiduronic acid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100024,cAMP,"Adenosine 3',5'-phosphate|Cyclic adenylic acid|3',5'-Cyclic AMP|Cyclic AMP",,false,,,http://purl.obolibrary.org/obo/IMR_0001355,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002401,,,,,"Adenosine 3',5'-phosphate|Cyclic adenylic acid|3',5'-Cyclic AMP|Cyclic AMP",,,,,IMR:0100024,,,,,,,,,,,,,,,,,,,,,,cAMP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_135774,ebrotidine,ebrodin|FI-3542|ulsanic,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:100981-43-9|Drug_Central:979,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ebrodin|FI-3542|ulsanic,,,,,,,,,,,,,,,,,,,,,CHEBI:135774,,,,ebrotidine,,CHEBI:135774,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001385,inositol phosphate,phosphoinositol,,false,,,http://purl.obolibrary.org/obo/TXPO_0001122,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,phosphoinositol,,,,,IMR:0001385,,,,,,,,,,,,,,,,,,,,,,inositol phosphate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0070498,IL-1 signal transduction pathway,IL-1-mediated signaling pathway|interleukin-1-mediated signaling pathway,"A series of molecular signals initiated by the binding of interleukin-1 to a receptor on the surface of a cell, and ending with regulation of a downstream cellular process, e.g. transcription.",false,,,http://purl.obolibrary.org/obo/TXPO_0000609,,,,,,,,,,,,,,,,,,,,,,"A series of molecular signals initiated by the binding of interleukin-1 to a receptor on the surface of a cell, and ending with regulation of a downstream cellular process, e.g. transcription.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IL-1-mediated signaling pathway|interleukin-1-mediated signaling pathway,,,,,GO:0070498,,,,,,,,,,,,,,,,,,,,,,IL-1 signal transduction pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004795,hypofunction of S-adenosylmethionine biosynthetic process,,hypofunction of S-adenosylmethionine biosynthetic process is a subtype of hypofunction of biosynthesis: A process that performs a decreased or insufficient S-adenosylmethionine biosynthetic process.,false,,,http://purl.obolibrary.org/obo/TXPO_0001910,,,,,,,,,,,,,,,,,,,,,,hypofunction of S-adenosylmethionine biosynthetic process is a subtype of hypofunction of biosynthesis: A process that performs a decreased or insufficient S-adenosylmethionine biosynthetic process.,,,http://purl.obolibrary.org/obo/GO_0006556,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004795,,,,,,,,,,,,,,,,,,,,,,hypofunction of S-adenosylmethionine biosynthetic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004792,Pvt1 (human) [hepatocarcinogenesis],Pvt1 oncogene,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/OGG_3000005820,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:5820|PMID:25796501,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Pvt1 oncogene,,,,,TXPO:0004792,,,,,,,"This gene represents a long non-coding RNA locus that has been identified as a candidate oncogene. Increased copy number and overexpression of this gene are associated with many types of cancers including breast and ovarian cancers, acute myeloid leukemia and Hodgkin lymphoma. Allelic variants of this gene are also associated with end-stage renal disease attributed to type 1 diabetes. Consistent with its association with various types of cancer, transcription of this gene is regulated by the tumor suppressor p53 through a canonical p53-binding site, and it has been implicated in regulating levels of the proto-oncogene MYC to promote tumorigenesis.",,,,,,,,,,,,,,,Pvt1 (human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004791,Increasing PVT1 level [hepatocarcinogenesis],,"Increasing PVT1 level is a subtype of increasing quantity: A process that changes the amount of PVT1 level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004790,,,,,,,,,,,,,,,,,,,,PMID:25796501,,"Increasing PVT1 level is a subtype of increasing quantity: A process that changes the amount of PVT1 level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004792,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004793,,,,,,,,,,,TXPO:0004791,,,,,,,,,,,,,,,,,,,,,,Increasing PVT1 level [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004793,Decreasing MIR150 level [hepatocarcinogenesis],,"Decreasing MIR150 level is a subtype of decreasing quantity: A process that changes the amount of miR-150 level to be lower.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004886,,,,,,,,,,,,,,,,,,,,PMID:25796501,,"Decreasing MIR150 level is a subtype of decreasing quantity: A process that changes the amount of miR-150 level to be lower.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004887,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004616,,,,,,,,,,,TXPO:0004793,,,,,,,,,,,,,,,,,,,,,,Decreasing MIR150 level [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004796,hypofunction of S-adenosylmethionine biosynthetic process [mitochondrial disorder],,"hypofunction of S-adenosylmethionine biosynthetic process is a subtype of hypofunction of biosynthesis: A process that performs a decreased or insufficient S-adenosylmethionine biosynthetic process.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0004795,,,,,,,,,,,,,,,,,,,,PMID:25339807,,"hypofunction of S-adenosylmethionine biosynthetic process is a subtype of hypofunction of biosynthesis: A process that performs a decreased or insufficient S-adenosylmethionine biosynthetic process.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,http://purl.obolibrary.org/obo/GO_0006556,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004797,,,,,,,,,,,TXPO:0004796,,,,,,,,,,,,,,,,,,,,,,hypofunction of S-adenosylmethionine biosynthetic process [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004797,decreasing glutathione level [mitochondrial disorder],,"Decreasing glutathione level is a subtype of decreasing quantity: A process that changes the amount of glutathione level to be lower.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0004943|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:25339807|PMID:23299992,,"Decreasing glutathione level is a subtype of decreasing quantity: A process that changes the amount of glutathione level to be lower.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004370|http://purl.obolibrary.org/obo/TXPO_0003569,,,,,,,,,,,TXPO:0004797,,,,,,,,,,,,,,,,,,,,,,decreasing glutathione level [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004790,Increasing PVT1 level,,Increasing PVT1 level is a subtype of increasing quantity: A process that changes the amount of PVT1 level to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing PVT1 level is a subtype of increasing quantity: A process that changes the amount of PVT1 level to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000005820,,,,,,,,,,,,,,,,,,,TXPO:0004790,,,,,,,,,,,,,,,,,,,,,,Increasing PVT1 level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004798,SFRP1 inactivation,,SFRP1 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the SFRP1 (secreted frizzled related protein 1) to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000021,,,,,,,,,,,,,,,,,,,,,,SFRP1 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the SFRP1 (secreted frizzled related protein 1) to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004798,,,,,,,,,,,,,,,,,,,,,,SFRP1 inactivation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004794,increasing production quantity of ROS [hepatocarcinogenesis],,"Increaseing production quantity of ROS is a subtype of increasing quantity: A process that changes the production amount of reactive oxygen species, any molecules or ions formed by the incomplete one-electron reduction of oxygen, to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0000364,,,,,,,,,,,,,,,,,,,,PMID:31623280|PMID:28932315,,"Increaseing production quantity of ROS is a subtype of increasing quantity: A process that changes the production amount of reactive oxygen species, any molecules or ions formed by the incomplete one-electron reduction of oxygen, to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004513,,,,,,http://purl.obolibrary.org/obo/TXPO_0004505,,,,,,,,,,,TXPO:0004794,,,,,,,,,,,,,,,,,,,,,,increasing production quantity of ROS [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004799,SFRP1 (mol),secreted frizzled related protein 1,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:6422|NCBI-Rat-GeneID:84402|NCBI-Mouse-GeneID:20377,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,secreted frizzled related protein 1,,,,,TXPO:0004799,,,,,,,,,,,,,,,,,,,,,,SFRP1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0018411,protein glucuronidation,glucronide conjugation,The modification of a protein by amino acid glucuronidation.,false,,,http://purl.obolibrary.org/obo/GO_0036211,,,,,,,,,,,,,,,,,,,,,,The modification of a protein by amino acid glucuronidation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,glucronide conjugation,,,GO:0018411,,,,,,,,,,,,,,,,,,,,,,protein glucuronidation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000007184,HSP90B1,,Other designations: 94 kDa glucose-regulated protein|endoplasmin|endothelial cell (HBMEC) glycoprotein|epididymis luminal protein 35|epididymis secretory sperm binding protein Li 125m|heat shock protein 90 kDa beta member 1|stress-inducible tumor rejection antigen gp96|tumor rejection antigen (gp96) 1|tumor rejection antigen 1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,TRA1|ECGP|GRP94|GP96|HEL-S-125m|HEL35,,,,,,,,,,,,12,,,,,,MIM:191175|HGNC:12028|Vega:OTTHUMG00000170118|HPRD:01860|Ensembl:ENSG00000166598,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"heat shock protein 90kDa beta (Grp94), member 1",,,12q24.2-q24.3,,,,,,,,,,,,,,,,"GO_0001666 (EC: IDA, PMID: 15620698); GO_0002224 (EC: TAS); GO_0003723 (EC: IDA, PMID: 11958450); GO_0005509 (EC: TAS, PMID: 10497210); GO_0005515 (EC: IPI, PMID: 11907036); GO_0005524 (EC: IEA); GO_0005576 (EC: TAS); GO_0005783 (EC: IDA); GO_0005783 (EC: TAS, PMID: 16130169); GO_0005788 (EC: IDA, PMID: 10497210); GO_0005788 (EC: TAS); GO_0005789 (EC: IDA, PMID: 10497210); GO_0005829 (EC: IDA, PMID: 9596688); GO_0005886 (EC: IEA); GO_0006457 (EC: IEA); GO_0006987 (EC: TAS); GO_0015031 (EC: NAS, PMID: 15845869); GO_0019903 (EC: IDA, PMID: 19000834); GO_0030433 (EC: IMP, PMID: 18264092); GO_0030496 (EC: IDA, PMID: 15166316); GO_0030968 (EC: TAS); GO_0031247 (EC: IDA, PMID: 19000834); GO_0042470 (EC: IEA); GO_0043066 (EC: IMP, PMID: 10497210); GO_0043066 (EC: TAS, PMID: 16130169); GO_0043666 (EC: IDA, PMID: 19000834); GO_0044267 (EC: TAS); GO_0045087 (EC: TAS); GO_0046790 (EC: IPI, PMID: 11958450); GO_0048471 (EC: IDA, PMID: 10497210); GO_0050750 (EC: IDA, PMID: 15082773); GO_0051082 (EC: IEA); GO_0051208 (EC: NAS, PMID: 15192333); GO_0070062 (EC: IDA, PMID: 19199708); GO_0071318 (EC: IDA, PMID: 19000834); GO_0071682 (EC: TAS)",,,,,,,,,PMID: 1512535; 1923827; 2377606; 2378869; 2546060; 2924290; 7523574; 7768954; 8460400; 8617772; 9006956; 9596688; 9694898; 10049727; 10497210; 10887119; 11557039; 11584270; 11726552; 11861214; 11907036; 11912201; 11958450; 12167617; 12397072; 12470827; 12471035; 12475965; 12477932; 12643545; 12654781; 12665801; 12754519; 14499622; 14500642; 15082718; 15082773; 15107540; 15166316; 15192333; 15257553; 15489334; 15576338; 15620698; 15637761; 15728573; 15845869; 15952740; 15962384; 16015374; 16130169; 16257961; 16263699; 16269234; 16288044; 16335966; 16497268; 16630554; 16754684; 17081065; 17082602; 17347446; 17431395; 17545519; 17558393; 17612505; 17726464; 17805476; 17936703; 18029348; 18155754; 18178560; 18190237; 18239673; 18264092; 18273841; 18331622; 18340425; 18411291; 18482745; 18554719; 18662321; 18781797; 18816836; 18941243; 19000834; 19135240; 19199708; 19212831; 19343720; 19578160; 19615732; 19697319; 19724918; 19752220; 19875450; 19895174; 19913121; 20000738; 20159978; 20176102; 20195357; 20232284; 20237496; 20300187; 20351288; 20352117; 20510162; 20562859; 20599762; 20628086; 20704820; 20721957; 20811636; 20839070; 20936779; 21081666; 21110914; 21139048; 21145461; 21208614; 21319273; 21343306; 21472681; 21559462; 21565611; 21637029; 21642380; 21708117; 21739154; 21774995; 21890473; 21900206; 21906983; 21963094; 21988832; 21992474; 21998592; 22079093; 22174317; 22178446; 22190034; 22245095; 22268729; 22270544; 22304920; 22363530; 22427667; 22532561; 22554506; 22653265; 22672426; 22724016; 22777994; 22863883; 22938940; 22939629; 23000965; 23035116; 23077236; 23097496; 23109341; 23182705; 23190606; 23208072; 23266770; 23349634; 23428871; 23431407; 23455922; 23503679; 23589305; 23703321; 23755898; 23798571; 23862649; 24244333; 24457600; 24511009,,,,,,,,,,,,,,,OGG:3000007184,,,,,,,"heat shock protein 90kDa beta (Grp94), member 1",,,,,,,,,,,,,Other designations: 94 kDa glucose-regulated protein|endoplasmin|endothelial cell (HBMEC) glycoprotein|epididymis luminal protein 35|epididymis secretory sperm binding protein Li 125m|heat shock protein 90 kDa beta member 1|stress-inducible tumor rejection antigen gp96|tumor rejection antigen (gp96) 1|tumor rejection antigen 1,,HSP90B1,,,,,,,,,,,,,,,,,,,,,,,7184,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,HSP90B1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000007186,TRAF2,,Other designations: E3 ubiquitin-protein ligase TRAF2|tumor necrosis factor type 2 receptor associated protein 3|tumor necrosis factor type 2 receptor-associated protein 3,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,TRAP3|MGC:45012|TRAP,,,,,,,,,,,,9,,,,,,Ensembl:ENSG00000127191|Vega:OTTHUMG00000020952|MIM:601895|HPRD:03538|HGNC:12032,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,TNF receptor-associated factor 2,,,9q34,,,,,,,,,,,,,,,,"GO_0002726 (EC: IMP, PMID: 15125833); GO_0004842 (EC: IDA, PMID: 15258597); GO_0004871 (EC: NAS, PMID: 8702708); GO_0005164 (EC: IPI, PMID: 11279055); GO_0005174 (EC: ISS); GO_0005515 (EC: IPI, PMID: 10514511); GO_0005737 (EC: IDA); GO_0005829 (EC: TAS); GO_0005938 (EC: IEA); GO_0006461 (EC: TAS, PMID: 8702708); GO_0006915 (EC: TAS); GO_0006919 (EC: TAS); GO_0007165 (EC: TAS, PMID: 8702708); GO_0007250 (EC: IMP, PMID: 15125833); GO_0008270 (EC: IEA); GO_0009898 (EC: ISS); GO_0019899 (EC: IPI, PMID: 16636664); GO_0019903 (EC: IPI, PMID: 15696169); GO_0030163 (EC: IEA); GO_0031435 (EC: IEA); GO_0031625 (EC: IPI, PMID: 11279055); GO_0031996 (EC: IPI, PMID: 11279055); GO_0032403 (EC: IEA); GO_0032743 (EC: IMP, PMID: 15125833); GO_0033209 (EC: IDA, PMID: 11907583); GO_0034351 (EC: IEA); GO_0035631 (EC: ISS); GO_0042802 (EC: IPI, PMID: 16189514); GO_0042981 (EC: IDA, PMID: 11907583); GO_0043507 (EC: IDA, PMID: 11907583); GO_0043623 (EC: ISS); GO_0045087 (EC: TAS); GO_0045121 (EC: IEA); GO_0046625 (EC: IDA); GO_0050870 (EC: IC, PMID: 15125833); GO_0051023 (EC: IEA); GO_0051091 (EC: IMP, PMID: 12296995); GO_0051092 (EC: IDA, PMID: 11279055); GO_0051092 (EC: IMP, PMID: 12296995); GO_0051291 (EC: IEA); GO_0051865 (EC: IDA); GO_0051865 (EC: TAS, PMID: 16378096); GO_0070207 (EC: IPI); GO_0070534 (EC: IDA, PMID: 15258597); GO_0090073 (EC: IMP, PMID: 11278723); GO_0097190 (EC: TAS); GO_2001238 (EC: IMP); GO_2001239 (EC: TAS)",,,,,,,,,PMID: 7639698; 7758105; 8069916; 8125298; 8548810; 8565075; 8612133; 8627180; 8643514; 8662842; 8692885; 8702708; 8710854; 8875942; 8943045; 8985011; 8999898; 9020361; 9104814; 9153189; 9162022; 9168896; 9208847; 9244310; 9275204; 9353251; 9384571; 9418902; 9461607; 9464265; 9488716; 9500555; 9582383; 9607925; 9685412; 9692890; 9705938; 9712898; 9718306; 9733516; 9774460; 9774977; 9794406; 9827693; 9852070; 9990007; 10025951; 10037686; 10075662; 10206649; 10339433; 10346818; 10352240; 10411888; 10477597; 10490605; 10514511; 10521462; 10523862; 10544141; 10581243; 10617615; 10650002; 10753917; 10759890; 10764746; 10809768; 10837247; 10880535; 10882101; 10892748; 10903733; 10911999; 10980203; 10990461; 11035039; 11057907; 11064452; 11112773; 11181075; 11278268; 11278723; 11279055; 11340079; 11359906; 11384837; 11435475; 11466612; 11479302; 11562359; 11607847; 11728344; 11777919; 11784851; 11798190; 11804591; 11805080; 11821416; 11882293; 11907088; 11907583; 11909853; 11932422; 11971184; 12005438; 12136106; 12169272; 12220533; 12296995; 12411322; 12411493; 12477932; 12529173; 12547194; 12571250; 12591926; 12637493; 12796506; 12842894; 12843613; 12867425; 12887920; 12917689; 12917690; 12917691; 14517219; 14557256; 14585990; 14633987; 14644197; 14702039; 14741690; 14743216; 14982987; 15084608; 15121867; 15125833; 15208311; 15258597; 15265700; 15308666; 15310755; 15327770; 15383523; 15485634; 15485837; 15489334; 15670770; 15670977; 15696169; 15707590; 15708970; 15743837; 15861135; 15941918; 15944293; 16009713; 16153868; 16189514; 16214042; 16227629; 16260598; 16263936; 16282325; 16291755; 16304992; 16311516; 16341674; 16378096; 16446357; 16603398; 16611992; 16636664; 16713569; 16876162; 16891304; 16936264; 17015619; 17314283; 17379600; 17384642; 17389591; 17544371; 17599408; 17626074; 17724081; 17851586; 17923499; 18022363; 18024283; 18029348; 18069092; 18230756; 18271526; 18292192; 18312353; 18362156; 18362886; 18671942; 18776134; 18787502; 18818748; 18827186; 18950704; 18981220; 18990758; 19019335; 19150425; 19151112; 19234489; 19243308; 19287455; 19336370; 19380743; 19453261; 19506082; 19527514; 19573080; 19584093; 19586614; 19667091; 19690440; 19773279; 19795416; 19810754; 19815509; 19815541; 19937093; 20005846; 20047764; 20056178; 20064526; 20133937; 20138174; 20184394; 20237496; 20333651; 20348096; 20368287; 20385093; 20447407; 20448643; 20449947; 20562859; 20568250; 20577214; 20585848; 20614026; 20628086; 20676093; 20732415; 20856938; 20949042; 20972266; 20974987; 21041452; 21041727; 21071692; 21078302; 21078624; 21119000; 21139048; 21229359; 21266470; 21282461; 21282507; 21289304; 21325409; 21331077; 21421854; 21620750; 21653699; 21793045; 21810480; 21864338; 21886773; 21890473; 21903422; 21906983; 21921033; 21963094; 21987572; 21988832; 22029577; 22078441; 22167321; 22170762; 22179575; 22184250; 22195745; 22212761; 22271254; 22343716; 22505724; 22525270; 22550173; 22585859; 22685297; 22711886; 22732732; 22792062; 22847298; 22863753; 23000965; 23007157; 23051914; 23088713; 23142077; 23160117; 23188828; 23301098; 23319823; 23357418; 23381138; 23405219; 23414308; 23453969; 23524849; 23543740; 23595117; 23608757; 23624947; 23638224; 23690480; 23743189; 23754945; 23775076; 23885119; 23890813; 23918987; 23972990; 24008839; 24434549; 24457600,,,,,,,,,,,,,,,OGG:3000007186,,,,,,,TNF receptor-associated factor 2,,,,,,,,,,,,,Other designations: E3 ubiquitin-protein ligase TRAF2|tumor necrosis factor type 2 receptor associated protein 3|tumor necrosis factor type 2 receptor-associated protein 3,,TRAF2,,,,,,,,,,,,,,,,,,,,,,,7186,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,TRAF2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000007187,TRAF3,,Other designations: CD40 associated protein 1|CD40 binding protein|CD40 receptor associated factor 1|LMP1-associated protein 1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CAP-1|CAP1|IIAE5|CD40bp|LAP1|CRAF1,,,,,,,,,,,,14,,,,,,HPRD:03539|MIM:601896|Ensembl:ENSG00000131323|Vega:OTTHUMG00000171902|HGNC:12033,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,TNF receptor-associated factor 3,,,14q32.32,,,,,,,,,,,,,,,,"GO_0001817 (EC: ISS); GO_0002224 (EC: ISS); GO_0002224 (EC: TAS); GO_0002756 (EC: TAS); GO_0004842 (EC: IEA); GO_0004871 (EC: TAS, PMID: 7530216); GO_0005515 (EC: IPI, PMID: 10791955); GO_0005739 (EC: IEA); GO_0005768 (EC: IEA); GO_0005829 (EC: TAS); GO_0006915 (EC: IEA); GO_0007165 (EC: TAS, PMID: 7530216); GO_0008270 (EC: IEA); GO_0009898 (EC: ISS); GO_0019901 (EC: IEA); GO_0030162 (EC: IMP); GO_0031625 (EC: IPI, PMID: 11279055); GO_0031996 (EC: IPI, PMID: 11279055); GO_0032088 (EC: IMP); GO_0032480 (EC: TAS); GO_0032648 (EC: ISS); GO_0033209 (EC: IMP); GO_0034138 (EC: TAS); GO_0034142 (EC: TAS); GO_0035631 (EC: ISS); GO_0035666 (EC: TAS); GO_0042981 (EC: IEA); GO_0045087 (EC: TAS); GO_0050688 (EC: ISS)",,,,,,,,,PMID: 7527023; 7530216; 7533327; 7859281; 8565075; 8612133; 8626767; 8662842; 8663299; 8710854; 9122217; 9162022; 9168896; 9275204; 9384571; 9388227; 9418902; 9464265; 9488716; 9550380; 9582383; 9718306; 9774460; 9774977; 9794406; 9852070; 9990007; 10025951; 10037686; 10199393; 10207006; 10352240; 10514511; 10523862; 10557073; 10635328; 10644711; 10764746; 10781837; 10791955; 10799510; 10809768; 10837247; 10862698; 10903733; 10984535; 11035039; 11098060; 11226259; 11261798; 11278268; 11279055; 11384837; 11435475; 11562359; 11607847; 11728344; 11950878; 12005438; 12089335; 12136149; 12169272; 12220533; 12270937; 12471121; 12477932; 12529173; 12571250; 12637493; 12860972; 14517219; 14572659; 14716302; 14743216; 14982987; 15084608; 15208311; 15280356; 15383523; 15485634; 15489334; 15514968; 15585864; 15708970; 15941918; 15944293; 16009714; 16260598; 16280329; 16306936; 16311516; 16429118; 16582590; 16858409; 17544371; 17586463; 17608743; 17626074; 17692805; 17823124; 17878343; 17991829; 18042799; 18275617; 18607851; 18614628; 19023125; 19074885; 19419966; 19667091; 19693093; 19893624; 19913121; 19937093; 19954665; 19996094; 20008286; 20056178; 20080758; 20097753; 20138174; 20161788; 20174559; 20185819; 20237496; 20348096; 20504251; 20585848; 20614026; 20628086; 20800603; 20832341; 21041452; 21041727; 21084666; 21139048; 21200404; 21228035; 21660053; 21703539; 21864338; 21885437; 21890473; 21903422; 21906983; 21963094; 21988832; 22011580; 22017431; 22022264; 22079989; 22330071; 22469134; 22709905; 22715070; 22792062; 22901541; 22908223; 22945920; 23303668; 23308279; 23329887; 23333941; 23334419; 23381138; 23524849; 23543740; 23612708; 23717208; 23962979; 23986588; 24260396,,,,,,,,,,,,,,,OGG:3000007187,,,,,,,TNF receptor-associated factor 3,,,,,,,,,,,,,Other designations: CD40 associated protein 1|CD40 binding protein|CD40 receptor associated factor 1|LMP1-associated protein 1,,TRAF3,,,,,,,,,,,,,,,,,,,,,,,7187,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,TRAF3,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/UBERON_0002365,exocrine gland,,"A gland that secretes products (excluding hormones and other chemical messengers) into ducts (duct glands) which lead directly into the external environment. Typical exocrine glands include sweat glands, salivary glands, mammary glands, stomach, liver, pancreas",false,,,http://purl.obolibrary.org/obo/UBERON_0002530,,,,,,,,,,,,,,,,,,,,NCIT:C12712|UMLS:C0015282|MESH:D005088|FMA:9596,,"A gland that secretes products (excluding hormones and other chemical messengers) into ducts (duct glands) which lead directly into the external environment. Typical exocrine glands include sweat glands, salivary glands, mammary glands, stomach, liver, pancreas",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002330,UBERON:0002365,http://purl.obolibrary.org/obo/UBERON_0002330,,,,,,,,,,,,,,,,,,,,,exocrine gland,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0002368,endocrine gland,,Endocrine glands are glands of the endocrine system that secrete their products directly into the circulatory system rather than through a duct.,false,,,http://purl.obolibrary.org/obo/UBERON_0002530,,,,,,,,,,,,,,,,,,,,UMLS:C0014133|NCIT:C1270|FMA:9602|MESH:D004702,,Endocrine glands are glands of the endocrine system that secrete their products directly into the circulatory system rather than through a duct.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0000949,UBERON:0002368,http://purl.obolibrary.org/obo/UBERON_0000949,,,,,,,,,,,,,,,,,,,,,endocrine gland,,,,http://upload.wikimedia.org/wikipedia/commons/d/da/Illu_endocrine_system.png,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76727,EC 1.2.* (oxidoreductase acting on donor aldehyde/oxo group) inhibitor,inhibitors of oxidoreductase acting on aldehyde/oxo group of donors|inhibitor of oxidoreductase acting on aldehyde/oxo group of donors|EC 1.2.* inhibitor|EC 1.2.* (oxidoreductase acting on donor aldehyde or oxo group) inhibitors|inhibitor of oxidoreductase acting on aldehyde/oxo group of donor|inhibitors of oxidoreductase acting on aldehyde or oxo group of donors|EC 1.2.* (oxidoreductase acting on donor aldehyde/oxo group) inhibitors|EC 1.2.* inhibitors|inhibitors of oxidoreductase acting on aldehyde/oxo group of donor|oxidoreductase acting on donor aldehyde/oxo group (EC 1.2.*) inhibitors|oxidoreductase acting on donor aldehyde/oxo group inhibitor|oxidoreductase acting on donor aldehyde or oxo group (EC 1.2.*) inhibitors|oxidoreductase acting on donor aldehyde or oxo group inhibitor|oxidoreductase acting on donor aldehyde/oxo group (EC 1.2.*) inhibitor|oxidoreductase acting on donor aldehyde or oxo group (EC 1.2.*) inhibitor|inhibitors of oxidoreductase acting on aldehyde or oxo group of donor|oxidoreductase acting on donor aldehyde or oxo group inhibitors|oxidoreductase acting on donor aldehyde/oxo group inhibitors|inhibitor of oxidoreductase acting on aldehyde or oxo group of donor|EC 1.2.* (oxidoreductase acting on donor aldehyde or oxo group) inhibitor|inhibitor of oxidoreductase acting on aldehyde or oxo group of donors,An oxidoreductase inhibitor which interferes with the action of an oxidoreductase acting on the aldehyde or oxo group of donors (EC 1.2.*.*).,false,,,http://purl.obolibrary.org/obo/CHEBI_76725,,,,,,,,,,,,,,,,,,,,,,An oxidoreductase inhibitor which interferes with the action of an oxidoreductase acting on the aldehyde or oxo group of donors (EC 1.2.*.*).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,inhibitors of oxidoreductase acting on aldehyde/oxo group of donors|inhibitor of oxidoreductase acting on aldehyde/oxo group of donors|EC 1.2.* inhibitor|EC 1.2.* (oxidoreductase acting on donor aldehyde or oxo group) inhibitors|inhibitor of oxidoreductase acting on aldehyde/oxo group of donor|inhibitors of oxidoreductase acting on aldehyde or oxo group of donors|EC 1.2.* (oxidoreductase acting on donor aldehyde/oxo group) inhibitors|EC 1.2.* inhibitors|inhibitors of oxidoreductase acting on aldehyde/oxo group of donor|oxidoreductase acting on donor aldehyde/oxo group (EC 1.2.*) inhibitors|oxidoreductase acting on donor aldehyde/oxo group inhibitor|oxidoreductase acting on donor aldehyde or oxo group (EC 1.2.*) inhibitors|oxidoreductase acting on donor aldehyde or oxo group inhibitor|oxidoreductase acting on donor aldehyde/oxo group (EC 1.2.*) inhibitor|oxidoreductase acting on donor aldehyde or oxo group (EC 1.2.*) inhibitor|inhibitors of oxidoreductase acting on aldehyde or oxo group of donor|oxidoreductase acting on donor aldehyde or oxo group inhibitors|oxidoreductase acting on donor aldehyde/oxo group inhibitors|inhibitor of oxidoreductase acting on aldehyde or oxo group of donor|EC 1.2.* (oxidoreductase acting on donor aldehyde or oxo group) inhibitor|inhibitor of oxidoreductase acting on aldehyde or oxo group of donors,,,,,,,,,,,,,,,,,,,,,CHEBI:76727,,,,EC 1.2.* (oxidoreductase acting on donor aldehyde/oxo group) inhibitor,,CHEBI:76727,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000197350,CASP16,,Other designations: putative caspase-14-like protein|putative caspase-16,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CASP14L,,,,,,,,,,,,16,,,,,,HGNC:27290,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"caspase 16, apoptosis-related cysteine peptidase (putative)",,,16p13.3,,,,,,,,,,,,,,,,GO_0004197 (EC: IBA); GO_0005737 (EC: IBA); GO_0008630 (EC: IBA); GO_0097192 (EC: IBA),,,,,,,,,PMID:9847080; 12477932; 14702039; 15489334; 15616553; 18281271,,,,,,,,,,,,,,,OGG:3000197350,,,,,,,"caspase 16, apoptosis-related cysteine peptidase (putative)",,,,,,,,,,,,,Other designations: putative caspase-14-like protein|putative caspase-16,,CASP16,,,,,,,,,,,,,,,,,,,,,,,197350,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CASP16,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/BFO_0000038,one-dimensional temporal region,,,false,,,http://purl.obolibrary.org/obo/BFO_0000008,,,,,,,,,,,,,,,,,,,,,,,,,,"BFO 2 Reference: A temporal interval is a special kind of one-dimensional temporal region, namely one that is self-connected (is without gaps or breaks).",,A one-dimensional temporal region is a temporal region that is extended. (axiom label in BFO2 Reference: [103-001]),the temporal region during which a process occurs.,,,,,,,,,,,(forall (x) (if (OneDimensionalTemporalRegion x) (TemporalRegion x))) // axiom label in BFO2 CLIF: [103-001],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BFO:0000038,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/bfo.owl,one-dimensional temporal region,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_71415,nitrofurantoin,"nitrofurantoina|nitrofurantoine|1-(5-Nitro-2-furfurylidenamino)hydantoin|nitrofurantoinum|N-(5-Nitrofurfurylidene)-1-aminohydantoin|5-Nitrofurantoin|1-((5-Nitrofurfurylidene)amino)hydantoin|1-(5-Nitro-2-furfurylideneamino)hydantoin|1-[(5-Nitrofurfurylidene)amino]hydantoin|nitrofurantoin|1-{[(5-nitro-2-furyl)methylene]amino}imidazolidine-2,4-dione","An imidazolidine-2,4-dione that is hydantoin substituted at position 1 by a [(5-nitro-2-furyl)methylene]amino group. An antibiotic that damages bacterial DNA.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:22535452|PMID:22240115|PMID:23114172|PMID:22552451|PMID:22857139|PMID:22508296|PMID:22252772|PMID:22977056|PMID:22332195|PMID:23113731|PMID:22722224|PMID:22836745|Drug_Central:1949|PMID:22923965|CAS:67-20-9|DrugBank:DB00698|PMID:22929632|PMID:22285235|PMID:22876623|PMID:22787489|PMID:22779302|PMID:22869929|PMID:21567157|PMID:23109011|PMID:23016316|PMID:22252808|Reaxys:8132135,,"An imidazolidine-2,4-dione that is hydantoin substituted at position 1 by a [(5-nitro-2-furyl)methylene]amino group. An antibiotic that damages bacterial DNA.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35441|http://purl.obolibrary.org/obo/CHEBI_50908|http://purl.obolibrary.org/obo/CHEBI_36047,,,,,"1-{[(5-nitro-2-furyl)methylene]amino}imidazolidine-2,4-dione",,nitrofurantoina|nitrofurantoine|1-(5-Nitro-2-furfurylidenamino)hydantoin|nitrofurantoinum|N-(5-Nitrofurfurylidene)-1-aminohydantoin|5-Nitrofurantoin|1-((5-Nitrofurfurylidene)amino)hydantoin|1-(5-Nitro-2-furfurylideneamino)hydantoin|1-[(5-Nitrofurfurylidene)amino]hydantoin|nitrofurantoin,,,,,,,,,,,,,,,,,,,,,CHEBI:71415,,,,nitrofurantoin,,CHEBI:71415,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002017,Acot1 (mouse)[Eosinophilic granular degeneration],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000648|http://purl.obolibrary.org/obo/TXPO_0002018,,,,,,,,,,,,,,,,,,,,http://omim.org/entry/614313|NCBI-Rat-GeneID:50559|NCBI-Human-GeneID:641371|NCBI-Mouse-GeneID:26897|PMID:21094633|PMID:17485727|PMID:28385385|PMID:23967086,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002017,,,,,,,,,,,,,,,,,,,,,,Acot1 (mouse)[Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002014,uncoupling dependent molecule (rat in vivo),,"Uncoupling dependent molecule is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of uncoupling of miochondrial damage as a gene product.
Gene profile:Rat/Liver/|under construction",false,,,http://purl.obolibrary.org/obo/TXPO_0000400,,,,,,,,,,,,,,,,,,,,,,"Uncoupling dependent molecule is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of uncoupling of miochondrial damage as a gene product.
Gene profile:Rat/Liver/",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002014,,,,,,,,,,,,,,,,,,,,under construction,,uncoupling dependent molecule (rat in vivo),,,,,,,,,,,http://purl.obolibrary.org/obo/NCBITaxon_10114,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002010,mitohagy [Mitochondrial disorder],,"Degradation of a mitochondrion by macroautophagy.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/GO_0000423,,,,,,,,,,,,,,,,,,,,PMID:22187934|PMID:27151080|PMID:22743996,,"Degradation of a mitochondrion by macroautophagy.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002010,,,,,,,,,,,,,,,,,,,,,,mitohagy [Mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002015,Ucp3 (rat)[Uncoupling],,"GENATLAS Biochemistry:
uncoupling protein of inner mitochondrial membrane 3,with two forms,long and short missing C terminal 37 residues,dissipating the proton electrochemical gradient by uncoupling fuel oxidation from ADP-ATP conversion,highly expressed in skeletal muscle during development,regulated by nutritional factors,possible mediator of adaptive thermogenesis,involved in the variation of energy metabolism and obesity,regulated by PPARA and PPARG in mice,and dysregulated in states of insulin resistance,increased expression in function of obesity and in type 2 diabetes (NIDDM) UCP3

UniProtKB/Swiss-Prot Function:
UCP are mitochondrial transporter proteins that create proton leaks across the inner mitochondrial membrane, thus uncoupling oxidative phosphorylation. As a result, energy is dissipated in the form of heat. May play a role in the modulation of tissue respiratory control. Participates in thermogenesis and energy balance. UCP3_HUMAN,P55916",false,,,http://purl.obolibrary.org/obo/TXPO_1000393|http://purl.obolibrary.org/obo/TXPO_0002014,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:22229|NCBI-Rat-GeneID:25708|NCBI-Human-GeneID:7352|https://omim.org/entry/602044|PMID:19710539,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002015,,,,,,,,,,,,,,,,,,,,"GENATLAS Biochemistry:
uncoupling protein of inner mitochondrial membrane 3,with two forms,long and short missing C terminal 37 residues,dissipating the proton electrochemical gradient by uncoupling fuel oxidation from ADP-ATP conversion,highly expressed in skeletal muscle during development,regulated by nutritional factors,possible mediator of adaptive thermogenesis,involved in the variation of energy metabolism and obesity,regulated by PPARA and PPARG in mice,and dysregulated in states of insulin resistance,increased expression in function of obesity and in type 2 diabetes (NIDDM) UCP3

UniProtKB/Swiss-Prot Function:
UCP are mitochondrial transporter proteins that create proton leaks across the inner mitochondrial membrane, thus uncoupling oxidative phosphorylation. As a result, energy is dissipated in the form of heat. May play a role in the modulation of tissue respiratory control. Participates in thermogenesis and energy balance. UCP3_HUMAN,P55916",,Ucp3 (rat)[Uncoupling],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002011,perhexiline - fatty acid oxidation inhibitor [lipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002013,,,,,,,,,,,,,,,,,,,,Wikipedia:Perhexiline|PMID:21145849|DrugBank:DB01074,,,,,,,,,,,,,,C19H35N,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_133190,,,,,,,,,,TXPO:0002011,,,,,,,,,,,,,,,,,,,,,,perhexiline - fatty acid oxidation inhibitor [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,C1CCC(CC1)C(CC1CCCCN1)C1CCCCC1,,,,,
http://purl.obolibrary.org/obo/TXPO_0002016,Acot12 (rat)[Uncoupling],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000021|http://purl.obolibrary.org/obo/TXPO_0002014,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:74156|NCBI-Human-GeneID:134526|NCBI-Rat-GeneID:170570,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002016,,,,,,,,,,,,,,,,,,,,,,Acot12 (rat)[Uncoupling],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002013,perhexiline [lipidosis],,,false,,,http://purl.obolibrary.org/obo/CHEBI_35553|http://purl.obolibrary.org/obo/TXPO_0003508,,,,,,,,,,,,,,,,,,,,Wikipedia:Perhexiline|DrugBank:DB01074,,,,,,,,,,,,,,C19H35N,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002013,,,,,,,,,,,,,,,,,,,,,,perhexiline [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,C1CCC(CC1)C(CC1CCCCN1)C1CCCCC1,,,,,
http://purl.obolibrary.org/obo/TXPO_0002019,tamoxifen -mitochondrial respiratory chain inhibitor [Lipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000787,,,,,,,,,,,,,,,,,,,,PMID:21145849|ISBN:0071769234,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_25355,,,,,,,,,,TXPO:0002019,,,,,,,,,,,,,,,,,,,,,,tamoxifen -mitochondrial respiratory chain inhibitor [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002012,mitochondrial damage dependent chemical entity,,"Mitochondrial damage dependent chemical entity is a subtype of toxic course dependent chemical entity.
This entity can participate in the course of mitochondrial damage.",false,,,http://purl.obolibrary.org/obo/TXPO_0001731,,,,,,,,,,,,,,,,,,,,,,"Mitochondrial damage dependent chemical entity is a subtype of toxic course dependent chemical entity.
This entity can participate in the course of mitochondrial damage.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002012,,,,,,,,,,,,,,,,,,,,,,mitochondrial damage dependent chemical entity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002018,Acot1 (mol),,ACOT1 (Acyl-CoA Thioesterase 1) is a Protein Coding gene. Diseases associated with ACOT1 include Human Immunodeficiency Virus Infectious Disease. Among its related pathways are Metabolism and Fatty acid elongation. GO annotations related to this gene include hydrolase activity and palmitoyl-CoA hydrolase activity. An important paralog of this gene is ACOT2.,false,,,http://purl.obolibrary.org/obo/TXPO_0001146,,,,,,,,,,,,,,,,,,,,http://omim.org/entry/614313|NCBI-Rat-GeneID:50559|NCBI-Human-GeneID:641371|NCBI-Mouse-GeneID:26897,,ACOT1 (Acyl-CoA Thioesterase 1) is a Protein Coding gene. Diseases associated with ACOT1 include Human Immunodeficiency Virus Infectious Disease. Among its related pathways are Metabolism and Fatty acid elongation. GO annotations related to this gene include hydrolase activity and palmitoyl-CoA hydrolase activity. An important paralog of this gene is ACOT2.,https://www.ncbi.nlm.nih.gov/gene/641371,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000641371,,,,,,,,,,,,,TXPO:0002018,,,,,,,,,,,,,,,,,,,,,,Acot1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003995,protooncogene role,,"A role played by the oncogene that is altered forms of normal cellular genes. Many proto-oncogenes are homologous to viral oncogenes and involved in the control of cell proliferation or differentiation. Mutations, amplifications or rearrangements of proto-oncogenes lead to upregulated or deregulated cell growth and allow them to function as oncogenes.|Normal cellular genes at a stage prior to carcinogenesis. The products of proto-oncogenes are important regulators of biological processes and appear to be involved in the events that serve to maintain the ordered procession through the cell cycle. Proto-oncogenes have names of the form c-onc.",false,,,http://purl.obolibrary.org/obo/CHEBI_52209,,,,,,,,,,,,,,,,,,,,http://purl.bioontology.org/ontology/MESH/D011519|http://purl.bioontology.org/ontology/SNOMEDCT/1496005,,"A role played by the oncogene that is altered forms of normal cellular genes. Many proto-oncogenes are homologous to viral oncogenes and involved in the control of cell proliferation or differentiation. Mutations, amplifications or rearrangements of proto-oncogenes lead to upregulated or deregulated cell growth and allow them to function as oncogenes.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003995,,,,,,,,,,,,,,,,,,,,Normal cellular genes at a stage prior to carcinogenesis. The products of proto-oncogenes are important regulators of biological processes and appear to be involved in the events that serve to maintain the ordered procession through the cell cycle. Proto-oncogenes have names of the form c-onc.,,protooncogene role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003999,Ctsb- tumor cell metastasis factor (human)[Phospholipidosis  - tumor metasitasis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003996,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:13030|PMID:3458210|PMID:27398911|PMID:1540143,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001508,,,http://purl.obolibrary.org/obo/TXPO_0003880,,,,,,,,,,TXPO:0003999,,,,,,,,,,,,,,,,,,,,,,Ctsb- tumor cell metastasis factor (human)[Phospholipidosis  - tumor metasitasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003996,Ctsb (mouse)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003278|http://purl.obolibrary.org/obo/TXPO_0003843,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:13030|PMID:27398911|PMID:1837142|PMID:11016923|PMID:1637335|PMID:10876156,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001508,,,,,,,,,,,,,TXPO:0003996,,,,,,,,,,,,,,,,,,,,,,Ctsb (mouse)[Phospholipidosis],,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005764,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003990,leukocyte infiltration,,Leukocyte infiltration is a subtype of inflammatory cell inflow: A process that that moves the outside leukocyte cell to the inside.,false,,,http://purl.obolibrary.org/obo/TXPO_0000540,,,,,,,,,,,,,,,,,,,,,,Leukocyte infiltration is a subtype of inflammatory cell inflow: A process that that moves the outside leukocyte cell to the inside.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003990,,,,,,,,,,,,,,,,,,,,,,leukocyte infiltration,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003992,toxicological imbalance,,"In the imbalance model, the basic units are as follows:
1) a functioning process (supply) for biological defense and maintaining homeostasis;
2) a functional demand process (demand) as toxic activity;
3) balance/imbalance between toxic activity and defense processes; and
4) outcome from organelles, cells, or tissues to the organ exhibiting toxicity manifestations.

This entity  is a compound state that inculdes step 1 to 4.",false,,,http://purl.obolibrary.org/obo/TXPO_0000270,,,,,,,,,,,,,,,,,,,,,,"In the imbalance model, the basic units are as follows:
1) a functioning process (supply) for biological defense and maintaining homeostasis;
2) a functional demand process (demand) as toxic activity;
3) balance/imbalance between toxic activity and defense processes; and
4) outcome from organelles, cells, or tissues to the organ exhibiting toxicity manifestations.

This entity  is a compound state that inculdes step 1 to 4.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003992,,,,,,,,,,,,,,,,,,,,,,toxicological imbalance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003991,glutathione conjugation,,"Glutathione conjugation is a detoxication reaction. Four types of activation reaction have been recognized: direct-acting compounds, conjugates that are activated through cysteine conjugate beta-lyase, conjugates that are activated through redox cycling and lastly conjugates that release the original reactive parent compound. The glutathione S-transferases have three connections with the formation of biactivated conjugatesto make them more soluble for excretion.",false,,,http://purl.obolibrary.org/obo/GO_0006749,,,,,,,,,,,,,,,,,,,,PMID:6339228|https://reactome.org/content/detail/R-HSA-156590,,"Glutathione conjugation is a detoxication reaction. Four types of activation reaction have been recognized: direct-acting compounds, conjugates that are activated through cysteine conjugate beta-lyase, conjugates that are activated through redox cycling and lastly conjugates that release the original reactive parent compound. The glutathione S-transferases have three connections with the formation of biactivated conjugatesto make them more soluble for excretion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003991,,,,,,,"Glutathione S-Transferases (GSTs; EC 2.5.1.18) are another major set of phase II conjugation enzymes. They can be found in the cytosol as well as being microsomal membrane-bound. Cytosolic GSTs are encoded by at least 5 gene families (alpha, mu, pi, theta and zeta GST) whereas membrane-bound enzymes are encoded by single genes. Soluble GSTs are homo- or hetero-dimeric enzymes (approximately 25KDa subunits) which can act on a wide range of endogenous and exogenous electrophiles. GSTs mediate conjugation using glutathione (GSH), a tripeptide synthesized from its precursor amino acids gamma-glutamate, cysteine and glycine. A generalized reaction isRX + GSH -> HX + GSRGlutathione conjugates are excreted in bile and converted to cysteine and mercapturic acid conjugates in the intestine and kidneys. GSH is the major, low molecular weight, non-protein thiol synthesized de novo in mammalian cells. As well as taking part in conjugation reactions, GSH also has antioxidant ability and can metabolize endogenous and exogenous compounds. The nucleophilic GSH attacks the electrophilic substrate forming a thioether bond between the cysteine residue of GSH and the electrophile. The result is generally a less reactive and more water-soluble conjugate that can be easily excreted. In some cases, GSTs can activate compounds to reactive species such as certain haloalkanes and haloalkenes. Substrates for GSTs include epoxides, alkenes and compounds with electrophilic carbon, sulfur or nitrogen centres. There are two types of conjugation reaction with glutathione: displacement reactions where glutathione displaces an electron-withdrawing group and addition reactions where glutathione is added to activated double bond structures or strained ring systems.",,,,,,,,,,,,,,,glutathione conjugation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003993,CTSB- apoptosis inhibitor (human)[Phospholipidosis  - tumor metasitasis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003941,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1508|PMID:27398911|PMID:10876156,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001508,,,http://purl.obolibrary.org/obo/CHEBI_68494,,,,,,,,,,TXPO:0003993,,,,,,,,,,,,,,,,,,,,,,CTSB- apoptosis inhibitor (human)[Phospholipidosis  - tumor metasitasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003998,Ctsb- apoptosis inhibitor (mouse)[Phospholipidosis  - apoptosis inhibitor],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003996,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:13030|PMID:27398911|PMID:1837142|PMID:1637335,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001508,,,http://purl.obolibrary.org/obo/CHEBI_68494,,,,,,,,,,TXPO:0003998,,,,,,,,,,,,,,,,,,,,,,Ctsb- apoptosis inhibitor (mouse)[Phospholipidosis  - apoptosis inhibitor],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003994,Pik3c2g [Hepatocarcinogenesis],Phosphatidylinositol-4-Phosphate 3-Kinase Catalytic Subunit Type 2 Gamma [Hepatocarcinogenesis],"Phosphoinositide (PI) 3-kinases have been shown to have critical roles in signaling pathways that regulate proliferation, oncogenic transformation, cell survival, cell migration, and intracellular protein trafficking.",false,,,http://purl.obolibrary.org/obo/TXPO_0000837|http://purl.obolibrary.org/obo/TXPO_1000303,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:18705|NCBI-Human-GeneID:5288|NCBI-Rat-GeneID:116720|PMID:9516481|PMID:9878262,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Phosphatidylinositol-4-Phosphate 3-Kinase Catalytic Subunit Type 2 Gamma [Hepatocarcinogenesis],,,,,TXPO:0003994,,,,,,,,,,,,,,,,,,,,"Phosphoinositide (PI) 3-kinases have been shown to have critical roles in signaling pathways that regulate proliferation, oncogenic transformation, cell survival, cell migration, and intracellular protein trafficking.",,Pik3c2g [Hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003997,chaperone role,,"A role of the cytoplasmic proteins that bind to nascent or unfolded polypeptides and ensure correct folding or transport. Chaperone proteins do not covalently bind to their targets and do not form part of the finished product. Heat-shock proteins are an important sub set of chaperones. Three major families are recognised, the chaperonins (groEL and hsp60), the hsp70 family and the hsp90 family. Outside these major families are other proteins with similar functions including nucleoplasmin, secB and T-cell receptor associated protein.",false,,,http://purl.obolibrary.org/obo/TXPO_0003712,,,,,,,,,,,,,,,,,,,,,,"A role of the cytoplasmic proteins that bind to nascent or unfolded polypeptides and ensure correct folding or transport. Chaperone proteins do not covalently bind to their targets and do not form part of the finished product. Heat-shock proteins are an important sub set of chaperones. Three major families are recognised, the chaperonins (groEL and hsp60), the hsp70 family and the hsp90 family. Outside these major families are other proteins with similar functions including nucleoplasmin, secB and T-cell receptor associated protein.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003997,,,,,,,,,,,,,,,,,,,,,,chaperone role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000023766,GABARAPL3,,,false,,,http://purl.obolibrary.org/obo/OGG_2070009606,,ATG8D,,,,,,,,,,,,15,,,,,,HGNC:4069,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"GABA(A) receptors associated protein like 3, pseudogene",,,15q26.1,,,,,,,,,,,,,,,,GO_0000421 (EC: IEA); GO_0005783 (EC: IEA); GO_0005794 (EC: IEA); GO_0005874 (EC: IEA); GO_0006914 (EC: IEA); GO_0031410 (EC: IEA); GO_0032590 (EC: IEA); GO_0032839 (EC: IEA); GO_0044297 (EC: IEA),,,,,,,,,PMID: 11414770; 22446963,,,,,,,,,,,,,,,OGG:3000023766,,,,,,,"GABA(A) receptors associated protein like 3, pseudogene",,,,,,,,,,,,,,,GABARAPL3,,,,,,,,,,,,,,,,,,,,,,,23766,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,GABARAPL3,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_39098,pyrethrins,,The active insecticidal constituents of Chrysanthemum cinerariifolium flowers.,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:8003-34-7,,The active insecticidal constituents of Chrysanthemum cinerariifolium flowers.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:39098,,,,,,,,,,,,,,,,,,,,,,pyrethrins,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100809,Casein kinase I,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,GO:0004681,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001966,,,,,,,,,,IMR:0100809,,,,,,,,,,,,,,,,,,,,,,Casein kinase I,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000005021,OXTR,,,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,OT-R,,,,,,,,,,,,3,,,,,,Ensembl:ENSG00000180914|MIM:167055|HPRD:01328|HGNC:8529|Vega:OTTHUMG00000090537,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,oxytocin receptor,,,3p25,,,,,,,,,,,,,,,,"GO_0001967 (EC: IEA); GO_0001975 (EC: IEA); GO_0004990 (EC: IEA); GO_0005000 (EC: IEA); GO_0005886 (EC: TAS); GO_0005887 (EC: TAS, PMID: 10858434); GO_0005902 (EC: IEA); GO_0005913 (EC: IEA); GO_0006936 (EC: TAS, PMID: 1313946); GO_0007166 (EC: TAS, PMID: 1313946); GO_0007204 (EC: IEA); GO_0007507 (EC: IEA); GO_0007565 (EC: IEA); GO_0007595 (EC: TAS, PMID: 1313946); GO_0007613 (EC: IEA); GO_0010701 (EC: IEA); GO_0016324 (EC: IEA); GO_0017046 (EC: IEA); GO_0021537 (EC: IEA); GO_0030431 (EC: IEA); GO_0032230 (EC: IEA); GO_0032355 (EC: IEA); GO_0032570 (EC: IEA); GO_0034059 (EC: IEA); GO_0034097 (EC: IEA); GO_0035176 (EC: IEA); GO_0042220 (EC: IEA); GO_0042493 (EC: IEA); GO_0042711 (EC: IEA); GO_0042713 (EC: IEA); GO_0042755 (EC: IEA); GO_0043434 (EC: IEA); GO_0045777 (EC: IEA); GO_0048565 (EC: IEA); GO_0051965 (EC: IEA); GO_0051968 (EC: IEA); GO_0060137 (EC: IEA); GO_0060206 (EC: IEA); GO_0060406 (EC: IEA); GO_0060455 (EC: IEA); GO_0070371 (EC: IEA); GO_0070474 (EC: IEA)",,,,,,,,,PMID: 1313946; 7607693; 7798245; 7921229; 8077313; 8593829; 8593830; 9283088; 9433921; 10027615; 10453463; 10698266; 10858434; 10910058; 11140838; 11279203; 11955056; 12126740; 12161007; 12166628; 12270111; 12477932; 12810550; 12843193; 12955084; 14664707; 14691010; 14749664; 15035619; 15044599; 15089975; 15089977; 15093695; 15452121; 15591449; 15705593; 15831296; 15992526; 16042376; 16333859; 16754659; 16888077; 16966388; 17148753; 17383819; 17492653; 17726073; 17728669; 17893705; 17939166; 17952758; 18082926; 18207134; 18312604; 19001515; 19015103; 19086053; 19126785; 19336370; 19347709; 19376182; 19423652; 19461999; 19515497; 19598235; 19777562; 19845972; 19934046; 19943975; 20094064; 20096818; 20097922; 20196918; 20303388; 20347913; 20400491; 20413116; 20436377; 20452482; 20488544; 20547007; 20547038; 20585395; 20647384; 20670427; 20673868; 20708845; 20711752; 20724662; 20832055; 20926803; 21090345; 21208749; 21561435; 21734268; 21876222; 21896752; 21906983; 21934640; 21963428; 21964067; 21984889; 22015110; 22064162; 22084107; 22123970; 22146101; 22212599; 22296985; 22336563; 22357335; 22372486; 22421562; 22457427; 22487732; 22510359; 22563705; 22763666; 22809402; 22882465; 22892716; 22986294; 22999795; 23040540; 23089921; 23219106; 23252931; 23284802; 23354128; 23355275; 23470776; 23637833; 23678036; 23684879; 23889750; 23915847; 24367110,,,,,,,,,,,,,,,OGG:3000005021,,20140408,protein-coding,,,,oxytocin receptor,,,,,,,,,,,,,,,OXTR,,,,,,,,,,,,,,,,,,,,,,,5021,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,OXTR,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0001553,Rab2B,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001553,,,,,,,,,,,,,,,,,,,,,,Rab2B,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0042981,regulation of apoptotic process,,Any process that modulates the occurrence or rate of cell death by apoptotic process.,false,,,http://purl.obolibrary.org/obo/TXPO_0000113,,,,,,,,,,,,,,,,,,,,Reactome:R-HSA-169911,,Any process that modulates the occurrence or rate of cell death by apoptotic process.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0042981,,,,,,,,,,,,,,,,,,,,,,regulation of apoptotic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006915,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000007376,NR1H2,,Other designations: LX receptor beta|liver X nuclear receptor beta|nuclear orphan receptor LXR-beta|nuclear receptor NER|oxysterols receptor LXR-beta|steroid hormone-nuclear receptor NER|ubiquitously-expressed nuclear receptor,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,RIP15|NER-I|LXRB|NER|LXR-b|UNR,,,,,,,,,,,,19,,,,,,HPRD:02660|HGNC:7965|Ensembl:ENSG00000131408|Vega:OTTHUMG00000183036|MIM:600380,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"nuclear receptor subfamily 1, group H, member 2",,,19q13.3,,,,,,,,,,,,,,,,"GO_0000122 (EC: IEA); GO_0001133 (EC: IEA); GO_0003677 (EC: TAS, PMID: 7926814); GO_0003707 (EC: IEA); GO_0004879 (EC: IEA); GO_0005515 (EC: IPI, PMID: 12393874); GO_0005634 (EC: IDA, PMID: 12393874); GO_0005654 (EC: TAS); GO_0005737 (EC: IDA, PMID: 12393874); GO_0006367 (EC: TAS); GO_0008270 (EC: IEA); GO_0010467 (EC: TAS); GO_0010745 (EC: IC, PMID: 17693624); GO_0010867 (EC: IMP, PMID: 17186944); GO_0010875 (EC: IMP, PMID: 17186944); GO_0010884 (EC: IEA); GO_0010887 (EC: IMP, PMID: 17693624); GO_0032270 (EC: IMP, PMID: 17186944); GO_0032369 (EC: IMP, PMID: 17693624); GO_0032376 (EC: IDA, PMID: 16141411); GO_0042632 (EC: IEA); GO_0043565 (EC: IEA); GO_0044255 (EC: IEA); GO_0045723 (EC: IMP, PMID: 17186944); GO_0045861 (EC: IEA); GO_0045892 (EC: IDA, PMID: 12393874); GO_0045944 (EC: IDA, PMID: 16141411); GO_0045944 (EC: IMP, PMID: 17186944); GO_0046965 (EC: IEA); GO_0048384 (EC: IEA); GO_0048550 (EC: IMP, PMID: 17693624); GO_0051006 (EC: IMP, PMID: 17186944); GO_0060336 (EC: NAS); GO_0090108 (EC: IEA); GO_0090187 (EC: IEA); GO_0090340 (EC: IEA); GO_2000188 (EC: ISS)",,,,,,,,,PMID: 7625741; 7760852; 7782080; 7926814; 7971966; 9874807; 10187832; 11158331; 11546778; 12040022; 12198243; 12393874; 12477932; 12663743; 12724417; 12736258; 12819202; 12957674; 14643652; 14699103; 14702039; 15489334; 15539633; 15548517; 15604093; 15774904; 16141411; 16189514; 16219912; 16298468; 16344560; 16354658; 16482468; 16524875; 16567856; 16904112; 16973760; 17045963; 17108812; 17110595; 17135302; 17186944; 17218271; 17391100; 17396233; 17405904; 17626048; 17693624; 17724434; 17766241; 17845217; 17900622; 17936707; 18026184; 18081155; 18182682; 18221307; 18372238; 18597895; 18636124; 18660489; 18782758; 18854425; 19060904; 19105208; 19242521; 19292929; 19303409; 19426978; 19436111; 19481530; 19796621; 19837721; 19913121; 19933273; 19948975; 20159957; 20176747; 20219900; 20364260; 20628086; 20655109; 20836841; 20855565; 20939869; 21042792; 21315073; 21331046; 21356276; 21507939; 21900206; 21937108; 21951066; 21988832; 22027013; 22029530; 22257474; 22367754; 22610535; 22723445; 22766509; 22939629; 22969086; 22990668; 23018104; 23223141; 23455924; 23838803; 23867501; 23987069; 24100084; 24398515,,,,,,,,,,,,,,,OGG:3000007376,,,,,,,"nuclear receptor subfamily 1, group H, member 2",,,,,,,,,,,,,Other designations: LX receptor beta|liver X nuclear receptor beta|nuclear orphan receptor LXR-beta|nuclear receptor NER|oxysterols receptor LXR-beta|steroid hormone-nuclear receptor NER|ubiquitously-expressed nuclear receptor,,NR1H2,,,,,,,,,,,,,,,,,,,,,,,7376,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,NR1H2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0003394,decreasing number of lysosomes [Phospholipidosis],,"Decreasing number of lysosomes is a subtype of decreasing number of objects: A process that becomes smaller in number of lysosomes.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0003393,,,,,,,,,,,,,,,,,,,,,,"Decreasing number of lysosomes is a subtype of decreasing number of objects: A process that becomes smaller in number of lysosomes.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001298,,,,,,,,,,,,,,,,,,TXPO:0003394,,,,,,,,,,,,,,,,,,,,,,decreasing number of lysosomes [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003392,hyperfunctioning of apoptotic process,,Hyperfunctioning of apoptotic process is a subtype of hyperfunctioning: A process that performs an excesssive apoptosis.,false,,,http://purl.obolibrary.org/obo/TXPO_0000435,,,,,,,,,,,,,,,,,,,,,,Hyperfunctioning of apoptotic process is a subtype of hyperfunctioning: A process that performs an excesssive apoptosis.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003392,,,,,,,,,,,,,,,,,,,,,,hyperfunctioning of apoptotic process,,,,,,http://purl.obolibrary.org/obo/GO_0006915,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003396,removing phospholipid by Kupffer cell or macrophage,,Removing phospholipid by Kupffer cell or macrophage is a subtype of removing: A process that takes a phospholipid from a cell by  Kupffer cells or macrophages .,false,,,http://purl.obolibrary.org/obo/TXPO_0000458,,,,,,,,,,,,,,,,,,,,,,Removing phospholipid by Kupffer cell or macrophage is a subtype of removing: A process that takes a phospholipid from a cell by  Kupffer cells or macrophages .,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000091|http://purl.obolibrary.org/obo/CL_0000235,,,,,,,,,,,,,,,,,TXPO:0003396,,,,,,,,,,,,,,,,,,,,,,removing phospholipid by Kupffer cell or macrophage,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003395,removing phospholipid by Kupffer cell or macrophage [Phospholipidosis],,"Removing phospholipid by Kupffer cell or macrophage is a subtype of removing: A process that takes a phospholipid from a cell by Kupffer cells or macrophages .
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (normal condition).",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0003396,,,,,,,,,,,,,,,,,,,,,,"Removing phospholipid by Kupffer cell or macrophage is a subtype of removing: A process that takes a phospholipid from a cell by Kupffer cells or macrophages .
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (normal condition).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003395,,,,,,,,,,,,,,,,,,,,,,removing phospholipid by Kupffer cell or macrophage [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003393,decreasing number of lysosomes,,Decreasing number of lysosomes is a subtype of decreasing number of objects: A process that becomes smaller in number of lysosomes.,false,,,http://purl.obolibrary.org/obo/TXPO_0000348,,,,,,,,,,,,,,,,,,,,,,Decreasing number of lysosomes is a subtype of decreasing number of objects: A process that becomes smaller in number of lysosomes.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003393,,,,,,,,,,,,,,,,,,,,,,decreasing number of lysosomes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003398,phospholipid synthesis gene expression,,Phospholipid synthesis gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature phospholipid synthesis gene product or products (proteins or RNA).,false,,,http://purl.obolibrary.org/obo/GO_0010467,,,,,,,,,,,,,,,,,,,,,,Phospholipid synthesis gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature phospholipid synthesis gene product or products (proteins or RNA).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003398,,,,,,,,,,,,,,,,,,,,,,phospholipid synthesis gene expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003391,apoptotic process [Phospholipidosis],,"A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/GO_0006915,,,,,,,,,,,,,,,,,,,,PMID:17090686,,"A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003391,,,,,,,,,,,,,,,,,,,,,,apoptotic process [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003397,phospholipid synthesis gene expression [Phospholipidosis],,"Phospholipid synthesis gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature phospholipid synthesis gene product or products (proteins or RNA).
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0003398,,,,,,,,,,,,,,,,,,,,,,"Phospholipid synthesis gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature phospholipid synthesis gene product or products (proteins or RNA).
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003387,,,,,,,,,,,TXPO:0003397,,,,,,,,,,,,,,,,,,,,,,phospholipid synthesis gene expression [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003390,decreasing number of cells [Phospholipidosis],,"Decreasing number of cells is a subtype of decreasing number of objects: A process that becomes smaller in number of cells.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000351|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Decreasing number of cells is a subtype of decreasing number of objects: A process that becomes smaller in number of cells.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003391,,,,,,,,,,,,,,,,,,TXPO:0003390,,,,,,,,,,,,,,,,,,,,,,decreasing number of cells [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000376,STAT2,signal transducer and activator of transcription 2,,false,,,http://purl.obolibrary.org/obo/IMR_0000374,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,signal transducer and activator of transcription 2,,,,,IMR:0000376,,,,,,,,,,,,,,,,,,,,,,STAT2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000311,Prmt5 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:364382|NCBI-Mouse-GeneID:27374|NCBI-Human-GeneID:10419,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000010419,,,,,,,,,,,,,TXPO:1000311,,,,,,,,,,,,,,,,,,,,,,Prmt5 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000319,RNF130 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:652955|NCBI-Mouse-GeneID:59044|NCBI-Human-GeneID:55819,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000055819,,,,,,,,,,,,,TXPO:1000319,,,,,,,,,,,,,,,,,,,,,,RNF130 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000314,RASGRP1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:10125|NCBI-Mouse-GeneID:19419|NCBI-Rat-GeneID:29434,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000010125,,,,,,,,,,,,,TXPO:1000314,,,,,,,,,,,,,,,,,,,,,,RASGRP1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000317,RECQL5 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:287834|NCBI-Human-GeneID:9400|NCBI-Mouse-GeneID:170472,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000009400,,,,,,,,,,,,,TXPO:1000317,,,,,,,,,,,,,,,,,,,,,,RECQL5 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000316,RBbp9 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:29459|NCBI-Mouse-GeneID:26450|NCBI-Human-GeneID:10741,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000010741,,,,,,,,,,,,,TXPO:1000316,,,,,,,,,,,,,,,,,,,,,,RBbp9 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000310,Prkcb (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:18751|NCBI-Human-GeneID:5579|NCBI-Rat-GeneID:25023,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000005579,,,,,,,,,,,,,TXPO:1000310,,,,,,,,,,,,,,,,,,,,,,Prkcb (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000313,Qprt (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:293504|NCBI-Human-GeneID:23475|NCBI-Mouse-GeneID:67375,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000023475,,,,,,,,,,,,,TXPO:1000313,,,,,,,,,,,,,,,,,,,,,,Qprt (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000318,RFX3 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:361746|NCBI-Human-GeneID:5991|NCBI-Mouse-GeneID:19726,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000005991,,,,,,,,,,,,,TXPO:1000318,,,,,,,,,,,,,,,,,,,,,,RFX3 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000315,RBL1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:680111|NCBI-Mouse-GeneID:19650|NCBI-Human-GeneID:5933,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000005933,,,,,,,,,,,,,TXPO:1000315,,,,,,,,,,,,,,,,,,,,,,RBL1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003003,PERK - signaling factor (canonical)[ER stress - cell cycle arrest],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002119,http://purl.obolibrary.org/obo/TXPO_0002991,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UniProt_Q9NZJ5|http://www.uniprot.org/entry/Q9NZJ5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003003,,,,,,,,,,,,,,,,,,,,,,PERK - signaling factor (canonical)[ER stress - cell cycle arrest],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003007,changing calcium ion concentration,,Changing calcium ion concentration is a subtype of changing concentration: A process that changes the calcium ion concentration in the blood.,false,,,http://purl.obolibrary.org/obo/TXPO_0002438,,,,,,,,,,,,,,,,,,,,,,Changing calcium ion concentration is a subtype of changing concentration: A process that changes the calcium ion concentration in the blood.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003007,,,,,,,,,,,,,,,,,,,,,,changing calcium ion concentration,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003009,changing calcium ion concentration in ER,,Changing calcium ion concentration in ER is a subtype of changing calcium ion concentration: A process that changes the calcium ion concentration in the endoplasmic reticulum (ER).,false,,,http://purl.obolibrary.org/obo/TXPO_0003007,,,,,,,,,,,,,,,,,,,,,,Changing calcium ion concentration in ER is a subtype of changing calcium ion concentration: A process that changes the calcium ion concentration in the endoplasmic reticulum (ER).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003009,,,,,,,,,,,,,,,,,,,,,,changing calcium ion concentration in ER,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003001,changing activity of eIF2a by PERK [ER stress - cell cycle arrest],,"A process that changes the activity of the eIF2a by PERK.
This process is dependent on the cell cycle arrest and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002378,,,,,,,,,,,,,,,,,,,,,,"A process that changes the activity of the eIF2a by PERK.
This process is dependent on the cell cycle arrest and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002507,,,,,,,,,,,,,,,,,,,,,TXPO:0003001,,,,,,,,,,,,,,,,,,,,,,changing activity of eIF2a by PERK [ER stress - cell cycle arrest],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003006,CCND1 (canonical)[ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000088|http://purl.obolibrary.org/obo/TXPO_0000871,,,,,,,,,,,,,,,,,,,,PMID:23334697|PMID:10411905,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0100614|http://purl.obolibrary.org/obo/IMR_0100615,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003562,,,,,,,,,,TXPO:0003006,,,,,,,,,,,,,,,,,,,,,,CCND1 (canonical)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003004,PERK dimerization [ER stress - cell cycle arrest],,"PERK dimerization is a subtype of protein dimerization: The formation of a PERK dimer, a macromolecular structure consists of two noncovalently associated identical or nonidentical subunits.
This entity is a specific course-dependent process. This process is dependent on the process of cell cycle arrest and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000713,,,,,,,,,,,,,,,,,,,,Reactome:R-HSA-381087|http://www.ncbi.nlm.nih.gov/pubmed/11907036,,"PERK dimerization is a subtype of protein dimerization: The formation of a PERK dimer, a macromolecular structure consists of two noncovalently associated identical or nonidentical subunits.
This entity is a specific course-dependent process. This process is dependent on the process of cell cycle arrest and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003005,,,,,,http://purl.obolibrary.org/obo/TXPO_0002997,,,,,,,,,,,TXPO:0003004,,,,,,,,,,,,,,,,,,,,,,PERK dimerization [ER stress - cell cycle arrest],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003002,PERK activation [ER stress - cell cycle arrest],,"PERK activation is a subtype of Molecular activation: A process that changes the activity of PERK to be higher.
This process is dependent on the cell cycle arrest and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000402,,,,,,,,,,,,,,,,,,,,,,"PERK activation is a subtype of Molecular activation: A process that changes the activity of PERK to be higher.
This process is dependent on the cell cycle arrest and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002997|http://purl.obolibrary.org/obo/TXPO_0003004,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002506,,,,,,,,,,,TXPO:0003002,,,,,,,,,,,,,,,,,,,,,,PERK activation [ER stress - cell cycle arrest],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003008,changing calcium ion concentration in ER [ER stress],,"Changing calcium ion concentration in ER is a subtype of changing calcium ion concentration: A process that changes the calcium ion concentration in the endoplasmic reticulum (ER).
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/TXPO_0003009,,,,,,,,,,,,,,,,,,,,PMID:23334697|PMID:16672378,,"Changing calcium ion concentration in ER is a subtype of changing calcium ion concentration: A process that changes the calcium ion concentration in the endoplasmic reticulum (ER).
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003015|http://purl.obolibrary.org/obo/TXPO_0003010|http://purl.obolibrary.org/obo/TXPO_0003011,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003014,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000513,,,,,,,,,,,TXPO:0003008,,,,,,,,,,,,,,,,,,,,,,changing calcium ion concentration in ER [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005783,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003005,PERK dimer (canonical)[ER stress - cell cycle arrest],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002880,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003005,,,,,,,,,,,,,,,,,,,,,,PERK dimer (canonical)[ER stress - cell cycle arrest],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003004,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003000,Phosphorylation of eIF2-alpha by PERK [ER stress - cell cycle arrest],,"Phosphorylation of eIF2-alpha by PERK is a subtype of eIF2a phosphorylation: A process that The process of introducing a phosphate group into eIF2a by PERK.
This process is dependent on the cell cycle arrest and can constitute the course of ER stress.|The C-terminal domain of PERK (EIF2AK3) has kinase activity when PERK homodimerizes. PERK kinase specifically phosphorylates Ser52 of eIF2-alpha, causing an arrest in translation. The result is that translation of ER-targeted proteins is halted on ribosomes in the vicinity of activated PERK. The general arrest of translation results in the loss of short-lived proteins such as Cyclin D1, causing an arrest of the cell cycle in G1.",false,,,http://purl.obolibrary.org/obo/TXPO_0000700,,,,,,,,,,,,,,,,,,,,Reactome:R-HSA-381111|PMID:9930704|PMID:23334697,,"Phosphorylation of eIF2-alpha by PERK is a subtype of eIF2a phosphorylation: A process that The process of introducing a phosphate group into eIF2a by PERK.
This process is dependent on the cell cycle arrest and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002989,,,,,,,,,,,TXPO:0003000,,,,,,,,,,,,,,,,,,,,"The C-terminal domain of PERK (EIF2AK3) has kinase activity when PERK homodimerizes. PERK kinase specifically phosphorylates Ser52 of eIF2-alpha, causing an arrest in translation. The result is that translation of ER-targeted proteins is halted on ribosomes in the vicinity of activated PERK. The general arrest of translation results in the loss of short-lived proteins such as Cyclin D1, causing an arrest of the cell cycle in G1.",,Phosphorylation of eIF2-alpha by PERK [ER stress - cell cycle arrest],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004597,PPARalpha activation [hepatocarcinogenesis],,"PPARalpha activation is a subtype of activating nuclear receptor: A process that changes the activity of the activating PPAR alpha ( (Peroxisome Proliferator Activated Receptor Alpha)) with a nuclear receptor role to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000013|http://purl.obolibrary.org/obo/TXPO_0002340,,,,,,,,,,,,,,,,,,,"Reactome

The set of genes regulated by PPAR-alpha is not fully known in humans, however many examples have been found in mice. Genes directly activated by PPAR-alpha contain peroxisome proliferator receptor elements (PPREs) in their promoters and include:
1) genes involved in fatty acid oxidation and ketogenesis (Acox1, Cyp4a, Acadm, Hmgcs2);
2) genes involved in fatty acid transport (Cd36, , Slc27a1, Fabp1, Cpt1a, Cpt2);
3) genes involved in producing fatty acids and very low density lipoproteins (Me1, Scd1);
4) genes encoding apolipoproteins (Apoa1, Apoa2, Apoa5);
5) genes involved in triglyceride clearance ( Angptl4);
6) genes involved in glycerol metabolism (Gpd1 in mouse);",PMID:18188449,,"PPARalpha activation is a subtype of activating nuclear receptor: A process that changes the activity of the activating PPAR alpha ( (Peroxisome Proliferator Activated Receptor Alpha)) with a nuclear receptor role to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004770,,http://purl.obolibrary.org/obo/TXPO_0004567,,,,,,http://purl.obolibrary.org/obo/TXPO_0004759|http://purl.obolibrary.org/obo/TXPO_0004392,,,,,,,,,,,TXPO:0004597,,,,,,,,,,,,,,,,,,,,,,PPARalpha activation [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004591,necrosis [hepatocarcinogenesis],,"A type of cell death that is morphologically characterized by an increasingly translucent cytoplasm, swelling of organelles, minor ultrastructural modifications of the nucleus (specifically, dilatation of the nuclear membrane and condensation of chromatin into small, irregular, circumscribed patches) and increased cell volume (oncosis), culminating in the disruption of the plasma membrane and subsequent loss of intracellular contents. Necrotic cells do not fragment into discrete corpses as their apoptotic counterparts do. Moreover, their nuclei remain intact and can aggregate and accumulate in necrotic tissues.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/GO_0070265,,,,,,,,,,,,,,,,,,,,PMID:31439937|PMID:22584684,,"A type of cell death that is morphologically characterized by an increasingly translucent cytoplasm, swelling of organelles, minor ultrastructural modifications of the nucleus (specifically, dilatation of the nuclear membrane and condensation of chromatin into small, irregular, circumscribed patches) and increased cell volume (oncosis), culminating in the disruption of the plasma membrane and subsequent loss of intracellular contents. Necrotic cells do not fragment into discrete corpses as their apoptotic counterparts do. Moreover, their nuclei remain intact and can aggregate and accumulate in necrotic tissues.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004969,,,,,,http://purl.obolibrary.org/obo/TXPO_0004507|http://purl.obolibrary.org/obo/TXPO_0004392,,,,,,,,,,,TXPO:0004591,,,,,,,,,,,,,,,,,,,,,,necrosis [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004590,telomerase reverse transcriptase gene mutation [hepatocarcinogenesis],,"Telomerase reverse transcriptase gene mutation is a subtype of changing an operand: A process that changes the nucleotide sequence of Telomerase reverse transcriptase gene randomly and permanently.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004966,,,,,,,,,,,,,,,,,,,,PMID:31439937,,"Telomerase reverse transcriptase gene mutation is a subtype of changing an operand: A process that changes the nucleotide sequence of Telomerase reverse transcriptase gene randomly and permanently.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004967,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004392,,,,,,,,,,,TXPO:0004590,,,,,,,,,,,,,,,,,,,,,,telomerase reverse transcriptase gene mutation [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004595,HCV infection [hepatocarcinogenesis],,"HCV infection is a subtype of pathogen colonization: A process that makes HCV present in the liver to increase the number.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004594,,,,,,,,,,,,,,,,,,,,PMID:29361730|PMID:28159835|PMID:31439937|PMID:26017875|PMID:18188449|PMID:31781608,,"HCV infection is a subtype of pathogen colonization: A process that makes HCV present in the liver to increase the number.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004453|http://purl.obolibrary.org/obo/TXPO_0004597|http://purl.obolibrary.org/obo/TXPO_0004596|http://purl.obolibrary.org/obo/TXPO_0004555|http://purl.obolibrary.org/obo/TXPO_0004557,,,,,,,,,,,TXPO:0004595,,,,,,,,,,,,,,,,,,,,,,HCV infection [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004598,HGFR signaling (primitive) [hepatocarcinogenesis],,"HGFR signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by HGFR.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004599,,,,,,,,,,,,,,,,,,,,PMID:31781608,,"HGFR signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by HGFR.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004600,http://purl.obolibrary.org/obo/TXPO_0004601|http://purl.obolibrary.org/obo/TXPO_0004602,http://purl.obolibrary.org/obo/GO_0048012,,,,,http://purl.obolibrary.org/obo/TXPO_0004404|http://purl.obolibrary.org/obo/TXPO_0004603|http://purl.obolibrary.org/obo/TXPO_0004518,,,,,,,,,,,TXPO:0004598,,,,,,,,,,,,,,,,,,,,,,HGFR signaling (primitive) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004596,Increasing MIR135A level [hepatocarcinogenesis],,"Increasing MIR135A level is a subtype of increasing quantity: A process that changes the amount of MIR135A level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004690,,,,,,,,,,,,,,,,,,,,PMID:28159835,,"Increasing MIR135A level is a subtype of increasing quantity: A process that changes the amount of MIR135A level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004691|http://purl.obolibrary.org/obo/TXPO_0004692,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004693,,,,,,,,,,,TXPO:0004596,,,,,,,,,,,,,,,,,,,,,,Increasing MIR135A level [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004594,HCV infection,,HCV infection is a subtype of pathogen colonization: A process that makes HCV present in the liver to increase the number.,false,,,http://purl.obolibrary.org/obo/TXPO_0002139,,,,,,,,,,,,,,,,,,,,,,HCV infection is a subtype of pathogen colonization: A process that makes HCV present in the liver to increase the number.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004594,,,,,,,,,,,,,,,,,,,,,,HCV infection,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004599,HGFR signal (primitive),,HGFR signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by HGFR.,false,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,,,HGFR signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by HGFR.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004604,http://purl.obolibrary.org/obo/GO_0048012,,,,,,,,,,,,,,,,TXPO:0004599,,,,,,,,,,,,,,,,,,,,,,HGFR signal (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004593,hepatocyte regeneration [hepatocarcinogenesis],,"Hepatocyte regeneration is a subtype of changing material: The regrowth of lost or destroyed hepatocytes.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0005037,,,,,,,,,,,,,,,,,,,,PMID:31439937|PMID:22584684,,"Hepatocyte regeneration is a subtype of changing material: The regrowth of lost or destroyed hepatocytes.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004969,,,,,,http://purl.obolibrary.org/obo/TXPO_0004507|http://purl.obolibrary.org/obo/TXPO_0004392,,,,,,,,,,,TXPO:0004593,,,,,,,,,,,,,,,,,,,,,,hepatocyte regeneration [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004592,dysregulation of immune balance [hepatocarcinogenesis],immune imbalance,"Dysregulation of immune balance is a subtype of malfunctioning of controlling: A process that cannot perform a regulation of immune balance appropriately or cannot realize it at all.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0005018,,,,,,,,,,,,,,,,,,,,PMID:31507621,,"Dysregulation of immune balance is a subtype of malfunctioning of controlling: A process that cannot perform a regulation of immune balance appropriately or cannot realize it at all.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0005019|http://purl.obolibrary.org/obo/TXPO_0004828,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004392,,,,,,immune imbalance,,,,,TXPO:0004592,,,,,,,,,,,,,,,,,,,,,,dysregulation of immune balance [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CL_0000988,hematopoietic cell,haemopoietic cell|haematopoietic cell|hemopoietic cell,A cell of a hematopoietic lineage.,false,,,http://purl.obolibrary.org/obo/CL_0000000,,,,,,,,,,,,,,,,,,,,BTO:0000574|FMA:83598|CALOHA:TS-2017|FMA:70366,,A cell of a hematopoietic lineage.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,haemopoietic cell|haematopoietic cell|hemopoietic cell,,,,,CL:0000988,,,,,,,,,,,,,,,,,,,,,,hematopoietic cell,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000916,eIF3 subunit,,,false,,,http://purl.obolibrary.org/obo/IMR_0010016,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000916,,,,,,,,,,,,,,,,,,,,,,eIF3 subunit,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_17677,CTP,cytidine 5'-(tetrahydrogen triphosphate),,false,,,http://purl.obolibrary.org/obo/TXPO_0002623,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,cytidine 5'-(tetrahydrogen triphosphate),,,,,CHEBI:17677,,,,,,,,,,,,,,,,,,,,,,CTP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0001052,rectum,,"the terminal portion of the intestinal tube, terminating with the anus",false,,,http://purl.obolibrary.org/obo/UBERON_0000160,,,,,,,,,,,,,,,,,,,,UMLS:C0034896|http://en.wikipedia.org/wiki/Rectum|NCIT:C12390|http://www.snomedbrowser.com/Codes/Details/181261002|FMA:14544,,"the terminal portion of the intestinal tube, terminating with the anus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0000059,UBERON:0001052,http://purl.obolibrary.org/obo/UBERON_0000059,,,,,,,,,,,,,,,,,,,,,rectum,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100212,pancreatic polypeptide,,"A 36-amino acid polypeptide secreted by the PANCREAS that has physiological regulatory functions. Plasma pancreatic polypeptide increases after ingestion of food, with age, and in disease states. A lack of pancreatic polypeptide in the ISLETS OF LANGERHANS has been associated with the OBESITY in rats and mice.",false,,,http://purl.obolibrary.org/obo/IMR_0100076,,,,,,,,,,,,,,,,,,,,MeSH:D010191,,"A 36-amino acid polypeptide secreted by the PANCREAS that has physiological regulatory functions. Plasma pancreatic polypeptide increases after ingestion of food, with age, and in disease states. A lack of pancreatic polypeptide in the ISLETS OF LANGERHANS has been associated with the OBESITY in rats and mice.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100212,,,,,,,,,,,,,,,,,,,,,,pancreatic polypeptide,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000469,cytokeratin 6,,,false,,,http://purl.obolibrary.org/obo/IMR_0000050,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000469,,,,,,,,,,,,,,,,,,,,,,cytokeratin 6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000687,p38beta,SAPK2b|p38-2,,false,,,http://purl.obolibrary.org/obo/IMR_0000226,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,SAPK2b|p38-2,,,,,IMR:0000687,,,,,,,,,,,,,,,,,,,,,,p38beta,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000455,increasing demand for response to oxidative stress [Oxidative stress],,"Increasing demand for response to oxidative stress is a subtype of increasing the demand for response to oxidative stress: A process that changes the functional demand for the response to the oxidative stress to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Oxidative stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001730|http://purl.obolibrary.org/obo/TXPO_0000102,,,,,,,,,,,,,,,,,,,,,,"Increasing demand for response to oxidative stress is a subtype of increasing the demand for response to oxidative stress: A process that changes the functional demand for the response to the oxidative stress to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Oxidative stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000461,,,,,,,,,,,TXPO:0000455,,,,,,,,,,,,,,,,,,,,,,increasing demand for response to oxidative stress [Oxidative stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000456,retrograde protein transport from ER to cytosol [ER stress],,"The directed movement of unfolded or misfolded proteins from the endoplasmic reticulum to the cytosol through the translocon.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/GO_0030970,,,,,,,,,,,,,,,,,,,,,,"The directed movement of unfolded or misfolded proteins from the endoplasmic reticulum to the cytosol through the translocon.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000516,,,,,,,,,,,TXPO:0000456,,,,,,,,,,,,,,,,,,,,,,retrograde protein transport from ER to cytosol [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000451,GRP78 - autophagy inducing factor (canonical)[ER stress - autophagy indution],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002385,,,,,,,,,,,,,,,,,,,,PMID:26481188,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000487,,,,,,,,,,TXPO:0000451,,,,,,,,,,,,,,,,,,,,,,GRP78 - autophagy inducing factor (canonical)[ER stress - autophagy indution],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000459,giving,,Giving is a subtype of sifting: A process that provides an object to a medium.,false,,,http://purl.obolibrary.org/obo/TXPO_0000441,,,,,,,,,,,,,,,,,,,,,,Giving is a subtype of sifting: A process that provides an object to a medium.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000459,,,,,,,,,,,,,,,,,,,,,,giving,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000450,NRF2 signaling (primitive) [ER stress],,"NRF2 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal transmitted by the NRF2.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/TXPO_0000449,,,,,,,,,,,,,,,,,,,,,,"NRF2 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal transmitted by the NRF2.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000047,,,,,,http://purl.obolibrary.org/obo/TXPO_0000376|http://purl.obolibrary.org/obo/TXPO_0000371,,,,,,,,,,,TXPO:0000450,,,,,,,,,,,,,,,,,,,,,,NRF2 signaling (primitive) [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000457,release of arachidonic acid from cell membrane,,The process that results in the movement of arachidonic acid from the cell membrane.,false,,,http://purl.obolibrary.org/obo/TXPO_0002588,,,,,,,,,,,,,,,,,,,,,,The process that results in the movement of arachidonic acid from the cell membrane.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000457,,,,,,,,,,,,,,,,,,,,,,release of arachidonic acid from cell membrane,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005886,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000454,PERK signaling (primitive) [PERK pathway],,"PERK signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the PERK. PERK generally plays a endoplasmic reticulum membrane stress sensor role.
This entity is a specific course-dependent process. This process can constitute the course of PERK pathway.",false,,,http://purl.obolibrary.org/obo/TXPO_0000274,,,,,,,,,,,,,,,,,,,,,,"PERK signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the PERK. PERK generally plays a endoplasmic reticulum membrane stress sensor role.
This entity is a specific course-dependent process. This process can constitute the course of PERK pathway.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001852,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000586|http://purl.obolibrary.org/obo/TXPO_0001861,,,,,,,,,,,,,,,,,,TXPO:0000454,,,,,,,,,,,,,,,,,,,,,,PERK signaling (primitive) [PERK pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000453,p53 signaling (primitive) [Cell death],,"P53 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by p53.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0000001|http://purl.obolibrary.org/obo/TXPO_0001727,,,,,,,,,,,,,,,,,,,,,,"P53 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by p53.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000650|http://purl.obolibrary.org/obo/TXPO_0000653|http://purl.obolibrary.org/obo/TXPO_0000640|http://purl.obolibrary.org/obo/TXPO_0000845|http://purl.obolibrary.org/obo/TXPO_0000843,,,,,,http://purl.obolibrary.org/obo/TXPO_0002135,,,,,,,,,,,TXPO:0000453,,,,,,,,,,,,,,,,,,,,,,p53 signaling (primitive) [Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000458,removing (from A),,Removing (from A) is a subtype of taking: A process that takes an unnecessary operand from a medium.,false,,,http://purl.obolibrary.org/obo/TXPO_0002577,,,,,,,,,,,,,,,,,,,,,,Removing (from A) is a subtype of taking: A process that takes an unnecessary operand from a medium.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000458,,,,,,,,,,,,,,,,,,,,,,removing (from A),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000452,p53 signaling (primitive) [ER stress],,"P53 signaling (primitive) isis a subtype of signaling [biological]: A process that in which a signal is transmitted by the p53.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000001|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"P53 signaling (primitive) isis a subtype of signaling [biological]: A process that in which a signal is transmitted by the p53.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000445,,,,,,,,,,,TXPO:0000452,,,,,,,,,,,,,,,,,,,,,,p53 signaling (primitive) [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000006554,SLC10A1,,"Other designations: Na(+)/bile acid cotransporter|Na(+)/taurocholate transport protein|Na/taurocholate cotransporting polypeptide|cell growth-inhibiting gene 29 protein|growth-inhibiting protein 29|sodium/bile acid cotransporter|sodium/taurocholate cotransporter|sodium/taurocholate cotransporting polypeptide|solute carrier family 10 (sodium/bile acid cotransporter family), member 1|solute carrier family 10 member 1",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,NTCP,,,,,,,,,,,,14,,,,,,HGNC:10905|MIM:182396|HPRD:01672,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"solute carrier family 10 (sodium/bile acid cotransporter), member 1",,,14q24.1,,,,,,,,,,,,,,,,"GO_0005886 (EC: TAS); GO_0005887 (EC: TAS, PMID: 8132774); GO_0006810 (EC: TAS, PMID: 8132774); GO_0008206 (EC: TAS); GO_0008508 (EC: IEA); GO_0015721 (EC: TAS); GO_0016323 (EC: IEA); GO_0044281 (EC: TAS)",,,,,,,,,PMID: 8132774; 11031103; 12044156; 12477932; 12663868; 14660639; 14701722; 15489334; 15604201; 15922475; 16027164; 16123152; 16541252; 17207965; 17635184; 18976975; 19343046; 19815625; 20031551; 20346360; 20424473; 20679960; 20857261; 21109590; 21341987; 21988832; 22029531; 22098322; 22744337; 23150796; 23815591; 23886862; 23930675; 24342612,,,,,,,,,,,,,,,OGG:3000006554,,,,,,,"solute carrier family 10 (sodium/bile acid cotransporter), member 1",,,,,,,,,,,,,"Other designations: Na(+)/bile acid cotransporter|Na(+)/taurocholate transport protein|Na/taurocholate cotransporting polypeptide|cell growth-inhibiting gene 29 protein|growth-inhibiting protein 29|sodium/bile acid cotransporter|sodium/taurocholate cotransporter|sodium/taurocholate cotransporting polypeptide|solute carrier family 10 (sodium/bile acid cotransporter family), member 1|solute carrier family 10 member 1",,SLC10A1,,,,,,,,,,,,,,,,,,,,,,,6554,GIG29,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,SLC10A1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_53559,topoisomerase IV inhibitor,topoisomerase IV inhibitors,"A topoisomerase inhibitor that inhibits DNA topoisomerase IV, which catalyses ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands.",false,,,http://purl.obolibrary.org/obo/CHEBI_70727,,,,,,,,,,,,,,,,,,,,,,"A topoisomerase inhibitor that inhibits DNA topoisomerase IV, which catalyses ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,topoisomerase IV inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:53559,,,,topoisomerase IV inhibitor,,CHEBI:53559,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000813,tumor cell survial [Glutathione depletion],,"Tumor cell survial is a subtype of keeong quantity: A process that keeps the viability of a tumor cell.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/NCIT_C16407|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Tumor cell survial is a subtype of keeong quantity: A process that keeps the viability of a tumor cell.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000663|http://purl.obolibrary.org/obo/TXPO_0000079,,,,,,,,,,,,,,,,,TXPO:0000813,,,,,,,,,,,,,,,,,,,,,,tumor cell survial [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000812,ER stress dependent moleule (mouse),,"ER stress dependent molecule is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of ER stress as a gene product.
Gene profile:Mouse//Liver/",false,,,http://purl.obolibrary.org/obo/TXPO_0000794,,,,,,,,,,,,,,,,,,,,,,"ER stress dependent molecule is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of ER stress as a gene product.
Gene profile:Mouse//Liver/",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000812,,,,,,,,,,,,,,,,,,,,,,ER stress dependent moleule (mouse),,,,,,,,,,,http://purl.obolibrary.org/obo/NCBITaxon_10090,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000817,hepatic fibrosis [ER stress],,"Hepatic fibrosis is a subtype of fibrosis: A process that replaces liver tissues to fibrous connective tissues, usually as a consequence of inflammation or other injury.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/TXPO_0000816,,,,,,,,,,,,,,,,,,,,,,"Hepatic fibrosis is a subtype of fibrosis: A process that replaces liver tissues to fibrous connective tissues, usually as a consequence of inflammation or other injury.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000206,,,,,,,,,,,TXPO:0000817,,,,,,,,,,,,,,,,,,,,,,hepatic fibrosis [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000815,Inflammatory response [Oxidative stress],,"Inflammatory response is a subtype of changing material: The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages.
This entity is a specific course-dependent process. This process can constitute the course of Oxidative stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000192|http://purl.obolibrary.org/obo/TXPO_0001730,,,,,,,,,,,,,,,,,,,,,,"Inflammatory response is a subtype of changing material: The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages.
This entity is a specific course-dependent process. This process can constitute the course of Oxidative stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000842,,,,,,,,,,,,,,,,,,TXPO:0000815,,,,,,,,,,,,,,,,,,,,,,Inflammatory response [Oxidative stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000816,hepatic fibrosis,,"Hepatic fibrosis is a subtype of fibrosis: A process that replaces liver tissues to fibrous connective tissues, usually as a consequence of inflammation or other injury.",false,,,http://purl.obolibrary.org/obo/TXPO_0000219,,,,,,,,,,,,,,,,,,,,,,"Hepatic fibrosis is a subtype of fibrosis: A process that replaces liver tissues to fibrous connective tissues, usually as a consequence of inflammation or other injury.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000816,,,,,,,,,,,,,,,,,,,,,,hepatic fibrosis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000811,SEC61B (human)[ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000793|http://purl.obolibrary.org/obo/TXPO_1000335,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:10952,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000010952,,,,,,,,,,,,,TXPO:0000811,,,,,,,,,,,,,,,,,,,,,,SEC61B (human)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000795,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000814,cell death [Oxidative stress],,"Any biological process that results in permanent cessation of all vital functions of a cell.
This entity is a specific course-dependent process. This process can constitute the course of Oxidative stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001730|http://purl.obolibrary.org/obo/GO_0008219,,,,,,,,,,,,,,,,,,,,,,"Any biological process that results in permanent cessation of all vital functions of a cell.
This entity is a specific course-dependent process. This process can constitute the course of Oxidative stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000815|http://purl.obolibrary.org/obo/TXPO_0002333,,,,,,,,,,,TXPO:0000814,,,,,,,,,,,,,,,,,,,,,,cell death [Oxidative stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000810,HERPUD1 (human)[ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000793|http://purl.obolibrary.org/obo/TXPO_1000184,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:9709|PMID:16289116,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000009709,,,,,,,,,,,,,TXPO:0000810,,,,,,,,,,,,,,,,,,,,,,HERPUD1 (human)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000818,protein production [ER stress],,"Protein production is a subtype of making existence: Aprocess that makes existent of a protein due to biosynthesis or secretion resulting in an increase in its levels.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000382|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"Protein production is a subtype of making existence: Aprocess that makes existent of a protein due to biosynthesis or secretion resulting in an increase in its levels.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000818,,,,,,,,,,,,,,,,,,,,,,protein production [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000022809,ATF5,,Other designations: cAMP-dependent transcription factor ATF-5|cyclic AMP-dependent transcription factor ATF-5|transcription factor ATFx,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,ATFX|HMFN0395,,,,,,,,,,,,19,,,,,,Ensembl:ENSG00000169136|Vega:OTTHUMG00000183065|HGNC:790|MIM:606398|HPRD:05906,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,activating transcription factor 5,,,19q13.3,,,,,,,,,,,,,,,,"GO_0003700 (EC: IEA); GO_0003714 (EC: TAS, PMID:10373550); GO_0005515 (EC: IPI, PMID:10373550); GO_0005634 (EC: IDA); GO_0005667 (EC: IEA); GO_0005730 (EC: IDA, Qualifier: NOT); GO_0005737 (EC: IDA); GO_0006351 (EC: IEA); GO_0006357 (EC: IEA); GO_0009791 (EC: IEA); GO_0021891 (EC: IEA); GO_0031072 (EC: IEA); GO_0035264 (EC: IEA); GO_0043066 (EC: IEA); GO_0043565 (EC: IEA); GO_0048712 (EC: IEA)",,,,,,,,,PMID:1371974; 8889548; 10373550; 11087824; 11278933; 12477932; 12812986; 14702039; 15221005; 15342556; 15358120; 15489334; 15890932; 16164412; 16170340; 16300731; 16344560; 17346882; 18029348; 18055463; 18195013; 18276110; 18332083; 18458088; 18701499; 18832568; 19167516; 19251251; 19285020; 19531563; 20379614; 20423929; 21212266; 21521685; 21791614; 21972289; 21988832; 22442021; 22528486; 23018213; 23275563; 23661758; 23876217; 24250222,,,,,,,,,,,,,,,OGG:3000022809,,,,,,,activating transcription factor 5,,,,,,,,,,,,,Other designations: cAMP-dependent transcription factor ATF-5|cyclic AMP-dependent transcription factor ATF-5|transcription factor ATFx,,ATF5,,,,,,,,,,,,,,,,,,,,,,,22809,,,,,,,,9606,,,,,,,,,,,,,,,,,,,ATF5,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OBI_0001866,secondary cultured cell,,A cultured cell that has been passaged or derives from a cell that has been passaged in culture.|A secondary cultured cell has been passaged in culture or is a descendant of such a cell that is derived through propagation in culture.,false,,,http://purl.obolibrary.org/obo/CL_0000010,,,,,,,,,,,,,,,,,,,,,,A cultured cell that has been passaged or derives from a cell that has been passaged in culture.,,,,"The term 'secondary cell culture' is generally used in biological texts/protocols to refer to any culture following an initial passage.  We include it here because there are often a number of passages between a primary culture and the establishment of a stable, homogenous cell line.  Such cultures are considered to be 'secondary cultures' but not 'cell lines' during this intermediate passaging/selection period between their derivation from a 'primary cell culture' and derivation into a 'cell line', which is a more specific type of secondary culture.",secondary cultured cell,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,OBI:0001866,,,,,,,,,,,,,,,,,,,,A secondary cultured cell has been passaged in culture or is a descendant of such a cell that is derived through propagation in culture.,,secondary cultured cell,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Person: Matthew Brush
http://purl.obolibrary.org/obo/CHEBI_3090,bicalutamide,"Bicusan|Casodex|Kalumid|Calutide|racemic bicalutamide|(RS)-bicalutamide|Cosudex|Ormandyl|Bicamide|Calumid|Bical|Calutol|bicalutamidum|Bicalox|ICI 176,334|bicalutamide|(+-)-bicalutamide|Binabic|Bicadex|ICI 176334|bicalutamida|(RS)-4'-cyano-alpha',alpha',alpha',-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono-m-toluidide|Bypro|ICI-176334|Bicatlon|rac-N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide",A racemate comprising of equal amounts of (R)-bicalutamide and (S)-bicalutamide. It is an oral non-steroidal antiandrogen used in the treatment of prostate cancer and hirsutism.,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:18062751|PMID:30784326|PMID:19194583|Beilstein:5364666|PMID:11915584|LINCS:LSM-1437|Drug_Central:367|PMID:12015321|DrugBank:DB01128|PMID:12421104|PMID:15509184|Reaxys:5364666|PMID:23527766|CAS:90357-06-5|PMID:12017896|PMID:12959312|PMID:17313204|PMID:31099426,,A racemate comprising of equal amounts of (R)-bicalutamide and (S)-bicalutamide. It is an oral non-steroidal antiandrogen used in the treatment of prostate cancer and hirsutism.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35610|http://purl.obolibrary.org/obo/CHEBI_35497|http://purl.obolibrary.org/obo/CHEBI_35703|http://purl.obolibrary.org/obo/CHEBI_78298,,,,,rac-N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide,,"Bicusan|Casodex|Kalumid|Calutide|racemic bicalutamide|(RS)-bicalutamide|Cosudex|Ormandyl|Bicamide|Calumid|Bical|Calutol|bicalutamidum|Bicalox|ICI 176,334|bicalutamide|(+-)-bicalutamide|Binabic|Bicadex|ICI 176334|bicalutamida|(RS)-4'-cyano-alpha',alpha',alpha',-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono-m-toluidide|Bypro|ICI-176334|Bicatlon",,,,,,,,,,,,,,,,,,,,,CHEBI:3090,,,,bicalutamide,,CHEBI:3090,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100707,pro-apoptotic Bcl-2 family,,,false,,,http://purl.obolibrary.org/obo/IMR_0000451,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100707,,,,,,,,,,,,,,,,,,,,,,pro-apoptotic Bcl-2 family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000226,p38,,,false,,,http://purl.obolibrary.org/obo/IMR_0000224,,,,,,,,,,,,,,,,,,,,IPR:008352,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000226,,,,,,,,,,,,,,,,,,,,,,p38,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/BFO_0000002,continuant,,,false,,,http://purl.obolibrary.org/obo/BFO_0000001,,,,,,,,,,,,,,,,,,,,,,,,,,"BFO 2 Reference: Continuant entities are entities which can be sliced to yield parts only along the spatial dimension, yielding for example the parts of your table which we call its legs, its top, its nails. ‘My desk stretches from the window to the door. It has spatial parts, and can be sliced (in space) in two. With respect to time, however, a thing is a continuant.’ [60, p. 240|Continuant doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. For example, in an expansion involving bringing in some of Ceuster's other portions of reality, questions are raised as to whether universals are continuants",,"A continuant is an entity that persists, endures, or continues to exist through time while maintaining its identity. (axiom label in BFO2 Reference: [008-002])",,,,,,,,,,,,(forall (x y) (if (and (Continuant x) (exists (t) (continuantPartOfAt y x t))) (Continuant y))) // axiom label in BFO2 CLIF: [009-002]|(forall (x y) (if (and (Continuant x) (exists (t) (hasContinuantPartOfAt y x t))) (Continuant y))) // axiom label in BFO2 CLIF: [126-001]|(forall (x) (if (Continuant x) (Entity x))) // axiom label in BFO2 CLIF: [008-002]|(forall (x) (if (Material Entity x) (exists (t) (and (TemporalRegion t) (existsAt x t))))) // axiom label in BFO2 CLIF: [011-002],"if b is a continuant and if, for some t, cis continuant_part of b at t, then c is a continuant. (axiom label in BFO2 Reference: [009-002])|if b is a material entity, then there is some temporal interval (referred to below as a one-dimensional temporal region) during which b exists. (axiom label in BFO2 Reference: [011-002])|if b is a continuant and if, for some t, c has_continuant_part b at t, then c is a continuant. (axiom label in BFO2 Reference: [126-001])",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BFO:0000002,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/bfo.owl,continuant,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0002717,IL-23 receptor,interleukin-23 receptor,,false,,,http://purl.obolibrary.org/obo/IMR_0000096,,,,,,,,,,,,,,,,,,,,GO:0042020,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,interleukin-23 receptor,,,,,IMR:0002717,,,,,,,,,,,,,,,,,,,,,,IL-23 receptor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000003084,NRG1,,"Other designations: MSTP131|glial growth factor|heregulin, alpha (45kD, ERBB2 p185-activator)|neu differentiation factor|neuregulin 1 type IV beta 1a|neuregulin 1 type IV beta 3|pro-NRG1|pro-neuregulin-1, membrane-bound isoform|sensory and motor neuron derived factor",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,GGF2|SMDF|HGL|MST131|HRG1|HRGA|HRG|GGF|NDF|ARIA,,,,,,,,,,,,8,,,,,,HGNC:7997|Vega:OTTHUMG00000163918|Ensembl:ENSG00000157168|HPRD:00802|MIM:142445,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,neuregulin 1,,,8p12,,,,,,,,,,,,,,,,"GO_0000165 (EC: IEA); GO_0000902 (EC: IEA); GO_0003161 (EC: IEA); GO_0003222 (EC: IDA, PMID: 17336907); GO_0003712 (EC: IDA, PMID: 15073182); GO_0005102 (EC: IPI, PMID: 7514177); GO_0005125 (EC: TAS, PMID: 10372964); GO_0005176 (EC: IEA); GO_0005515 (EC: IPI, PMID: 7592681); GO_0005576 (EC: NAS, PMID: 1348215); GO_0005576 (EC: TAS); GO_0005615 (EC: IDA, PMID: 11389077); GO_0005634 (EC: IEA); GO_0005737 (EC: IEA); GO_0005887 (EC: IEA); GO_0007154 (EC: TAS, PMID: 17432114); GO_0007169 (EC: IDA, PMID: 7514177); GO_0007171 (EC: IDA, PMID: 9553078); GO_0007171 (EC: NAS, PMID: 1348215); GO_0007173 (EC: TAS); GO_0007399 (EC: TAS, PMID: 17432114); GO_0007416 (EC: IEA); GO_0007422 (EC: IEA); GO_0007626 (EC: IEA); GO_0008083 (EC: IDA, PMID: 11389077); GO_0008083 (EC: NAS, PMID: 8096067); GO_0008283 (EC: IDA, PMID: 11389077); GO_0008543 (EC: TAS); GO_0009790 (EC: IEA); GO_0010667 (EC: IDA, PMID: 9553078); GO_0014032 (EC: TAS, PMID: 17432114); GO_0016020 (EC: NAS, PMID: 8096067); GO_0016324 (EC: IDA, PMID: 12646923); GO_0016477 (EC: IEA); GO_0021781 (EC: IEA); GO_0030296 (EC: IDA, PMID: 7556068); GO_0030297 (EC: IC, PMID: 9553078); GO_0030297 (EC: NAS, PMID: 1348215); GO_0030307 (EC: IDA, PMID: 9553078); GO_0030424 (EC: IEA); GO_0030879 (EC: TAS, PMID: 17432114); GO_0030971 (EC: NAS, PMID: 1348215); GO_0031594 (EC: IEA); GO_0038095 (EC: TAS); GO_0038127 (EC: IDA, PMID: 11389077); GO_0042060 (EC: IDA, PMID: 12646923); GO_0042060 (EC: TAS, PMID: 16412517); GO_0042177 (EC: IEA); GO_0043125 (EC: IDA, PMID: 7556068); GO_0043125 (EC: IPI, PMID: 11389077); GO_0043496 (EC: TAS, PMID: 16412517); GO_0043497 (EC: IDA, PMID: 10559227); GO_0043624 (EC: IGI, PMID: 15155732); GO_0045087 (EC: TAS); GO_0045213 (EC: IEA); GO_0045785 (EC: IDA, PMID: 7556068); GO_0045892 (EC: IDA, PMID: 15073182); GO_0046579 (EC: IEA); GO_0048011 (EC: TAS); GO_0048015 (EC: TAS); GO_0048663 (EC: IEA); GO_0051048 (EC: IDA, PMID: 10559227); GO_0051155 (EC: ISS); GO_0051897 (EC: IEA); GO_0055007 (EC: ISS); GO_0055012 (EC: IDA, PMID: 9553078); GO_0060045 (EC: IDA, PMID: 9553078); GO_0060379 (EC: IDA, PMID: 17336907); GO_0060956 (EC: IDA, PMID: 17336907); GO_0061098 (EC: IDA, PMID: 7556068); GO_2001240 (EC: IDA, PMID: 9553078)",,,,,,,,,PMID: 1348215; 1350381; 7509448; 7514177; 7556068; 7592681; 7689552; 7721889; 7730382; 7782315; 7876250; 7903175; 8062828; 8095334; 8096067; 8125298; 8325659; 8702572; 9168114; 9168115; 9333014; 9342050; 9553078; 9565587; 9685409; 10372964; 10523851; 10537356; 10559227; 10585499; 10597312; 11116142; 11389077; 11555649; 11896060; 12082616; 12145742; 12204892; 12471041; 12477932; 12478479; 12509456; 12528817; 12556556; 12600989; 12646923; 12768307; 12800145; 12808428; 12874607; 14569272; 14632199; 14647391; 14699424; 14702039; 14729827; 14966480; 15007393; 15073182; 15155732; 15159416; 15162166; 15197397; 15219675; 15248869; 15276238; 15303101; 15326116; 15466169; 15489334; 15494726; 15498868; 15527969; 15538186; 15545978; 15584912; 15609326; 15645137; 15703820; 15897877; 15939841; 16082692; 16155362; 16158055; 16189508; 16219117; 16219118; 16249994; 16287046; 16326006; 16344560; 16412517; 16428439; 16442083; 16446404; 16470843; 16483744; 16520822; 16526041; 16618933; 16638076; 16687441; 16690615; 16730337; 16767099; 16825199; 16867224; 16868568; 16891421; 16940976; 17033632; 17072305; 17214955; 17275115; 17300918; 17336907; 17336946; 17366345; 17405926; 17408693; 17432114; 17447867; 17499242; 17503451; 17519028; 17562386; 17565985; 17598910; 17602072; 17631867; 17652086; 17884806; 17901998; 17903296; 17925794; 17941827; 17962208; 18032396; 18159252; 18180429; 18193072; 18198266; 18234478; 18255317; 18282690; 18286587; 18291420; 18395550; 18455303; 18455369; 18466879; 18466881; 18470533; 18494263; 18494554; 18497096; 18516516; 18543275; 18571900; 18583979; 18584117; 18585932; 18606232; 18668031; 18704261; 18714568; 18728681; 18798975; 18799465; 18806920; 19054571; 19058791; 19086053; 19127563; 19148499; 19150438; 19156152; 19184335; 19196962; 19199244; 19229203; 19269083; 19306381; 19328558; 19339916; 19350564; 19367581; 19367584; 19394386; 19439994; 19448847; 19449332; 19497323; 19521112; 19545856; 19556605; 19569180; 19573260; 19575259; 19594860; 19597049; 19626024; 19644050; 19652122; 19659570; 19733651; 19736351; 19782967; 19797898; 19801490; 19802002; 19913121; 19913623; 19937977; 19965935; 19967439; 20036336; 20061032; 20102668; 20182055; 20215529; 20218976; 20227043; 20371257; 20374152; 20379614; 20427670; 20435087; 20472376; 20497232; 20520724; 20526724; 20580130; 20582876; 20625696; 20628086; 20638435; 20671236; 20682778; 20736300; 20800603; 20921115; 20926259; 20927045; 20978455; 21035784; 21041608; 21057508; 21127983; 21234898; 21239627; 21246584; 21247898; 21283760; 21368034; 21371516; 21437657; 21467033; 21512575; 21546767; 21555713; 21576249; 21653853; 21706185; 21716252; 21745728; 21792199; 21840482; 21858616; 21865659; 21965611; 22019858; 22027878; 22042562; 22052506; 22158511; 22183611; 22200588; 22209534; 22216327; 22226049; 22226548; 22249266; 22249457; 22267200; 22350758; 22377709; 22378022; 22378872; 22414959; 22425775; 22467496; 22494484; 22504067; 22520967; 22563075; 22574178; 22590542; 22613991; 22739235; 22790889; 22832904; 22886427; 22891299; 22944276; 22968213; 22974608; 22999558; 23032943; 23035098; 23104879; 23148218; 23213231; 23247143; 23253390; 23301017; 23308187; 23328545; 23360725; 23399902; 23400839; 23408906; 23468880; 23480537; 23489597; 23524320; 23572145; 23590603; 23625463; 23632455; 23739962; 23870195; 23934736; 23937725; 24097984; 24112719,,,,,,,,,,,,,,,OGG:3000003084,,,,,,,neuregulin 1,,,,,,,,,,,,,"Other designations: MSTP131|glial growth factor|heregulin, alpha (45kD, ERBB2 p185-activator)|neu differentiation factor|neuregulin 1 type IV beta 1a|neuregulin 1 type IV beta 3|pro-NRG1|pro-neuregulin-1, membrane-bound isoform|sensory and motor neuron derived factor",,NRG1,,,,,,,,,,,,,,,,,,,,,,,3084,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,NRG1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0003482,hyperfunction of glucose transport to liver [Lipidosis],,"Hyperfunction of glucose transport to liver is a subtype of hyperfunction of transport: A process that performs an excesssive glucose transport to liver.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0003481,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of glucose transport to liver is a subtype of hyperfunction of transport: A process that performs an excesssive glucose transport to liver.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000890,,,,,,,,,,,TXPO:0003482,,,,,,,,,,,,,,,,,,,,,,hyperfunction of glucose transport to liver [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003481,hyperfunction of glucose transport to liver,,Hyperfunction of glucose transport to liver is a subtype of hyperfunction of transport: A process that performs an excesssive glucose transport to liver.,false,,,http://purl.obolibrary.org/obo/TXPO_0002351,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of glucose transport to liver is a subtype of hyperfunction of transport: A process that performs an excesssive glucose transport to liver.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003481,,,,,,,,,,,,,,,,,,,,,,hyperfunction of glucose transport to liver,,,,,,http://purl.obolibrary.org/obo/GO_0008643,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003480,increasing hepatocellular volume [Lipidosis],,"Increasing hepatocellular volume is a changing process to change the volume of the hepatocyte to increase.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0000164,,,,,,,,,,,,,,,,,,,,,,"Increasing hepatocellular volume is a changing process to change the volume of the hepatocyte to increase.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003628,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003480,,,,,,,,,,,,,,,,,,,,,,increasing hepatocellular volume [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003485,HSP90B1 - apotosis repressor -vitro (human)[ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000802,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003485,,,,,,,,,,,,,,,,,,,,,,HSP90B1 - apotosis repressor -vitro (human)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000795,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003484,hypofunction of triglyceride transport from hepatocyte to extrahepatic [Lipidosis],,"Hypofunction of triglyceride transport from hepatocyte to extrahepatic is a subtype of hypofunction of transport: A process that performs a decreased or insufficient triglyceride transport from hepatocyte to extrahepatic.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0003483,,,,,,,,,,,,,,,,,,,,,,"Hypofunction of triglyceride transport from hepatocyte to extrahepatic is a subtype of hypofunction of transport: A process that performs a decreased or insufficient triglyceride transport from hepatocyte to extrahepatic.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,http://purl.obolibrary.org/obo/TXPO_0003487,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003491,,,,,,,,,,,TXPO:0003484,,,,,,,,,,,,,,,,,,,,,,hypofunction of triglyceride transport from hepatocyte to extrahepatic [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003488,lipid homeostasis imbalance,,Lipid homeostasis imbalance is a subtype of chemical homeostasis imbalance: A process that becomes lacking a lipid homeostastasis balance.|lipid homeostasis imbalance,false,,,http://purl.obolibrary.org/obo/TXPO_0001656,,,,,,,,,,,,,,,,,,,,,,Lipid homeostasis imbalance is a subtype of chemical homeostasis imbalance: A process that becomes lacking a lipid homeostastasis balance.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003488,,,,,,,,,,,,,,,,,,,,lipid homeostasis imbalance,,lipid homeostasis imbalance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003483,hypofunction of triglyceride transport from hepatocyte to extrahepatic,,Hypofunction of triglyceride transport from hepatocyte to extrahepatic is a subtype of hypofunction of transport: A process that performs a decreased or insufficient triglyceride transport from hepatocyte to extrahepatic.,false,,,http://purl.obolibrary.org/obo/TXPO_0001911,,,,,,,,,,,,,,,,,,,,,,Hypofunction of triglyceride transport from hepatocyte to extrahepatic is a subtype of hypofunction of transport: A process that performs a decreased or insufficient triglyceride transport from hepatocyte to extrahepatic.,,,http://purl.obolibrary.org/obo/TXPO_0003486,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003483,,,,,,,,,,,,,,,,,,,,,,hypofunction of triglyceride transport from hepatocyte to extrahepatic,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003487,triglyceride transport from hepatocyte to extrahepatic [Lipidosis],,"Triglyceride transport from hepatocyte to extrahepatic is a subtype of triglyceride transport: A process that of the transfer of a triglyceride from the hepatocyte to the exrrahepatic tissues.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0003486,,,,,,,,,,,,,,,,,,,,,,"Triglyceride transport from hepatocyte to extrahepatic is a subtype of triglyceride transport: A process that of the transfer of a triglyceride from the hepatocyte to the exrrahepatic tissues.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001371|http://purl.obolibrary.org/obo/TXPO_0001281,,,,,,,,,,,,,,,,,,TXPO:0003487,,,,,,,,,,,,,,,,,,,,,,triglyceride transport from hepatocyte to extrahepatic [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003489,GRP78 - apotosis repressor (canonical)[ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002385,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003489,,,,,,,,,,,,,,,,,,,,,,GRP78 - apotosis repressor (canonical)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003486,triglyceride transport from hepatocyte to extrahepatic,,Triglyceride transport from hepatocyte to extrahepatic is a subtype of triglyceride transport: A process that of the transfer of a triglyceride from the hepatocyte to the exrrahepatic tissues.,false,,,http://purl.obolibrary.org/obo/GO_0034197,,,,,,,,,,,,,,,,,,,,,,Triglyceride transport from hepatocyte to extrahepatic is a subtype of triglyceride transport: A process that of the transfer of a triglyceride from the hepatocyte to the exrrahepatic tissues.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000182,,,,,,,TXPO:0003486,,,,,,,,,,,,,,,,,,,,,,triglyceride transport from hepatocyte to extrahepatic,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001662,RGS4,,,false,,,http://purl.obolibrary.org/obo/IMR_0000431,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001662,,,,,,,,,,,,,,,,,,,,,,RGS4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100759,Dvl-3,DSH homolog 3|Dishevelled-3,,false,,,http://purl.obolibrary.org/obo/IMR_0100755,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,DSH homolog 3|Dishevelled-3,,,,,IMR:0100759,,,,,,,,,,,,,,,,,,,,,,Dvl-3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001605,Rab21,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001605,,,,,,,,,,,,,,,,,,,,,,Rab21,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000203228,C9orf72,,Other designations: protein C9orf72,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,FTDALS|ALSFTD,,,,,,,,,,,,9,,,,,,MIM:614260|HPRD:12975|Ensembl:ENSG00000147894|HGNC:28337|Vega:OTTHUMG00000019716,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,chromosome 9 open reading frame 72,,,9p21.2,,,,,,,,,,,,,,,,GO_0005515 (EC: IPI); GO_0005615 (EC: IDA); GO_0005634 (EC: IDA); GO_0005764 (EC: IDA); GO_0005768 (EC: IDA); GO_0005776 (EC: IDA); GO_0006897 (EC: IMP); GO_0006914 (EC: IMP); GO_0008219 (EC: IEA); GO_0017137 (EC: IDA),,,,,,,,,PMID: 11015796; 12477932; 12672552; 14702039; 15164053; 15489334; 16495328; 19322201; 19734901; 20301623; 20423481; 20562461; 20801717; 20801718; 21832049; 21890473; 21944778; 21944779; 22083254; 22181065; 22216764; 22228244; 22300873; 22300876; 22305801; 22343411; 22344582; 22366791; 22366792; 22366793; 22366794; 22366795; 22399792; 22399793; 22406228; 22410647; 22418734; 22426854; 22445326; 22459598; 22483864; 22487746; 22499346; 22502998; 22550220; 22564974; 22571983; 22650353; 22673113; 22678362; 22692064; 22702520; 22708871; 22721568; 22727276; 22732773; 22739338; 22742426; 22766072; 22766732; 22807188; 22815561; 22840558; 22843265; 22875086; 22875087; 22936364; 22959728; 22964910; 22964911; 22985429; 23012445; 23035801; 23036583; 23063644; 23084342; 23088937; 23100398; 23107433; 23111906; 23116878; 23117491; 23160421; 23254636; 23261768; 23264878; 23273600; 23284068; 23338682; 23352322; 23381195; 23393093; 23413259; 23421625; 23423380; 23434116; 23435409; 23437264; 23463871; 23473366; 23551834; 23555189; 23558488; 23587638; 23588422; 23588498; 23597494; 23602568; 23731538; 23771489; 23870417; 23894576; 24011653; 24027057; 24077574; 24081456; 24170860; 24185425; 24212388; 24248382; 24363131; 24549040; 24598541,,,,,,,,,,,,,,,OGG:3000203228,,,,,,,chromosome 9 open reading frame 72,,,,,,,,,,,,,Other designations: protein C9orf72,,C9orf72,,,,,,,,,,,,,,,,,,,,,,,203228,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,C9orf72,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0001666,RGS8,,,false,,,http://purl.obolibrary.org/obo/IMR_0000431,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001666,,,,,,,,,,,,,,,,,,,,,,RGS8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_51086,chemical role,,A role played by the molecular entity or part thereof within a chemical context.,false,,,http://purl.obolibrary.org/obo/BFO_0000023,,,,,,,,,,,,,,,,,,,,,,A role played by the molecular entity or part thereof within a chemical context.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:51086,,,,chemical role,,CHEBI:51086,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100095,gonadotropin-releasing hormone,GnRH|FSH-Releasing Hormone|LHRH|gonadorelin|gonadoliberin|LH-Releasing Hormone,A decapeptide hormone released by the hypothalamus. It stimulates the synthesis and secretion of both FOLLICLE STIMULATING HORMONE and luteinizing hormone (LH) from the pituitary gland.,false,,,http://purl.obolibrary.org/obo/IMR_0100093,,,,,,,,,,,,,,,,,,,,MeSH:D007987,,A decapeptide hormone released by the hypothalamus. It stimulates the synthesis and secretion of both FOLLICLE STIMULATING HORMONE and luteinizing hormone (LH) from the pituitary gland.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GnRH|FSH-Releasing Hormone|LHRH|gonadorelin|gonadoliberin|LH-Releasing Hormone,,,,,IMR:0100095,,,,,,,,,,,,,,,,,,,,,,gonadotropin-releasing hormone,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_42355,erythromycin A,,"An erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Wikipedia:Erythromycin|DrugBank:DB00199,,"An erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively.",,,,,,,,,,,,C37H67NO13,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_33281,,,,,,,,,,CHEBI:42355,,,,,,,,,,,,,,,,,,,,,,erythromycin A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,,,,,
http://purl.obolibrary.org/obo/CHEBI_36335,trypanocidal drug,antitrypanosomal agent|antitrypanosomal drug|trypanosomicidal agents|trypanocidal drugs|trypanocide|antitrypanosomal agents|antitrypanosomal drugs,A drug used to treat or prevent infections caused by protozoal organisms belonging to the suborder Trypanosomatida.,false,,,http://purl.obolibrary.org/obo/CHEBI_35820,,,,,,,,,,,,,,,,,,,,,,A drug used to treat or prevent infections caused by protozoal organisms belonging to the suborder Trypanosomatida.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,antitrypanosomal agent|antitrypanosomal drug|trypanosomicidal agents|trypanocidal drugs|trypanocide|antitrypanosomal agents|antitrypanosomal drugs,,,,,,,,,,,,,,,,,,,,,CHEBI:36335,,,,trypanocidal drug,,CHEBI:36335,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0000467,anatomical system,anatomical systems|system|organ system|connected anatomical system|body system,"Multicellular, connected anatomical structure that has multiple organs as parts and whose parts work together to achieve some shared function.",false,,,http://purl.obolibrary.org/obo/UBERON_0000061,,,,,,,,,,,,,,,,,,,,http://www.snomedbrowser.com/Codes/Details/278195005|http://linkedlifedata.com/resource/umls/id/C0460002|http://purl.obolibrary.org/obo/NCIT_C12919|http://purl.obolibrary.org/obo/EHDAA2_0001330|http://en.wikipedia.org/wiki/Organ_system|BILA:0000011|AEO:0000011|TGMA:0001831|TAO:0001439|FBbt:00004856|FMA:7149|EHDAA:392|WBbt:0005746|EMAPA:16103|EHDAA2:0003011|WBbt:0005763|UMLS:C0460002|galen:AnatomicalSystem|VHOG:0001725|AAO:0000007|CARO:0000011|HAO:0000011|MA:0000003|BSA:0000049|XAO:0003002|ZFA:0001439|EV:0100000|CALOHA:TS-2088|OpenCyc:Mx4rCWM0QCtDEdyAAADggVbxzQ,,"Multicellular, connected anatomical structure that has multiple organs as parts and whose parts work together to achieve some shared function.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0000062,,,,,,,,,,,,,organ system|connected anatomical system|body system,,anatomical systems,,,UBERON:0000467,,,,,,,,,,,,,,,,system,,,,,,anatomical system,,,,,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0000463,organism substance,body substance,"Material anatomical entity in a gaseous, liquid, semisolid or solid state; produced by anatomical structures or derived from inhaled and ingested substances that have been modified by anatomical structures as they pass through the body.",false,,,http://purl.obolibrary.org/obo/BFO_0000027,,,,,,,,,,,,,,,,,,,,,,"Material anatomical entity in a gaseous, liquid, semisolid or solid state; produced by anatomical structures or derived from inhaled and ingested substances that have been modified by anatomical structures as they pass through the body.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,body substance,,,,,UBERON:0000463,,,,,,,,,,,,,,,,,,,,,,organism substance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0000464,anatomical space,lumen space,"Non-material anatomical entity of three dimensions, that is generated by morphogenetic or other physiologic processes; is surrounded by one or more anatomical structures; contains one or more organism substances or anatomical structures.",false,,,http://purl.obolibrary.org/obo/UBERON_0001062,,,,,,,,,,,,,,,,,,,,,,"Non-material anatomical entity of three dimensions, that is generated by morphogenetic or other physiologic processes; is surrounded by one or more anatomical structures; contains one or more organism substances or anatomical structures.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,lumen space,,,,,UBERON:0000464,,,,,,,,,,,,,,,,,,,,,,anatomical space,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000010857,PGRMC1,,Other designations: membrane-associated progesterone receptor component 1|progesterone binding protein,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,MPR|HPR6.6,,,,,,,,,,,,X,,,,,,Ensembl:ENSG00000101856|HPRD:02338|MIM:300435|Vega:OTTHUMG00000022268|HGNC:16090,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,progesterone receptor membrane component 1,,,Xq22-q24,,,,,,,,,,,,,,,,GO_0005496 (EC: IEA); GO_0005515 (EC: IPI); GO_0005730 (EC: IDA); GO_0005783 (EC: IDA); GO_0005789 (EC: IEA); GO_0007411 (EC: IEA); GO_0016021 (EC: IEA); GO_0020037 (EC: IEA),,,,,,,,,PMID: 9705155; 11697142; 12477932; 12493773; 14523988; 15302935; 15489334; 15702432; 15782218; 15970648; 16234411; 16565220; 17081983; 17215244; 17276356; 17353931; 18029348; 18249431; 18319313; 18440126; 18479732; 18782852; 18818748; 18922159; 19019335; 19292867; 19417032; 19527514; 19797399; 20140262; 20164297; 20537145; 20538600; 21081644; 21109987; 21131300; 21139048; 21145461; 21148105; 21455559; 21825115; 21890473; 21900206; 21906983; 21918976; 22053931; 22190034; 22245528; 22492871; 22588913; 22939629; 23000965; 23116217; 23246001; 23455922; 23557589; 23798571,,,,,,,,,,,,,,,OGG:3000010857,,,,,,,progesterone receptor membrane component 1,,,,,,,,,,,,,Other designations: membrane-associated progesterone receptor component 1|progesterone binding protein,,PGRMC1,,,,,,,,,,,,,,,,,,,,,,,10857,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,PGRMC1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000010858,CYP46A1,,"Other designations: CH24H|cholesterol 24-hydroxylase|cytochrome P450 46A1|cytochrome P450, subfamily 46 (cholesterol 24-hydroxylase)",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CYP46|CP46,,,,,,,,,,,,14,,,,,,HGNC:2641|MIM:604087|Vega:OTTHUMG00000171510|HPRD:04970|Ensembl:ENSG00000036530,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 46, subfamily A, polypeptide 1",,,14q32.1,,,,,,,,,,,,,,,,"GO_0005506 (EC: IEA); GO_0005783 (EC: TAS, PMID:10377398); GO_0005789 (EC: TAS); GO_0006699 (EC: TAS); GO_0006707 (EC: IDA, PMID:18621681); GO_0006805 (EC: IDA); GO_0006805 (EC: TAS); GO_0007399 (EC: TAS, PMID:10377398); GO_0008206 (EC: TAS); GO_0008395 (EC: TAS, PMID:10377398); GO_0016021 (EC: IEA); GO_0016125 (EC: TAS); GO_0020037 (EC: IDA, PMID:18621681); GO_0033781 (EC: IDA, PMID:18621681); GO_0044281 (EC: TAS)",,,,,,,,,PMID:9717719; 10377398; 11111082; 11698143; 12123847; 12232784; 12477932; 12533083; 12533085; 14640697; 14702039; 15034781; 15106838; 15128046; 15165699; 15172102; 15286456; 15331159; 15450677; 15489334; 15936520; 15975088; 16013913; 16055229; 16157450; 16258842; 16734927; 16960449; 17335784; 17550732; 17854420; 18511756; 18621681; 18842294; 18976975; 19059217; 19161969; 19212968; 19286353; 19363267; 19553612; 19647891; 20193040; 20535486; 20667828; 20682755; 20693622; 21049985; 21386929; 21729100; 22185844; 22528464; 22977134; 23070465; 23167762; 23288837; 23604141,,,,,,,,,,,,,,,OGG:3000010858,,,,,,,"cytochrome P450, family 46, subfamily A, polypeptide 1",,,,,,,,,,,,,"Other designations: CH24H|cholesterol 24-hydroxylase|cytochrome P450 46A1|cytochrome P450, subfamily 46 (cholesterol 24-hydroxylase)",,CYP46A1,,,,,,,,,,,,,,,,,,,,,,,10858,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP46A1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000124,TLR,Toll-like receptor,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003441,,,,,Toll-like receptor,,,,,IMR:0000124,,,,,,,,,,,,,,,,,,,,,,TLR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000442,fibrate,,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:1000442,,,,,,,,,,,,,,,,,,,,,,fibrate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0011216,organ system subdivision,,A subdivision of an anatomical system.,false,,,http://purl.obolibrary.org/obo/UBERON_0000061,,,,,,,,,,,,,,,,,,,,http://www.snomedbrowser.com/Codes/Details/91690000|http://www.snomedbrowser.com/Codes/Details/91690000|FMA:67509|FBbt:00007330,,A subdivision of an anatomical system.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0000467,UBERON:0011216,http://purl.obolibrary.org/obo/UBERON_0000467,,,,,,,,,,,,,,,,,,,,,organ system subdivision,,,,,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_35554,cardiovascular drug,cardiovascular drugs|cardiovascular agent,"A drug that affects the rate or intensity of cardiac contraction, blood vessel diameter or blood volume.",false,,,http://purl.obolibrary.org/obo/CHEBI_23888,,,,,,,,,,,,,,,,,,,,,,"A drug that affects the rate or intensity of cardiac contraction, blood vessel diameter or blood volume.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,cardiovascular drugs|cardiovascular agent,,,,,,,,,,,,,,,,,,,,,CHEBI:35554,,,,cardiovascular drug,,CHEBI:35554,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001558,Rab3B,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001558,,,,,,,,,,,,,,,,,,,,,,Rab3B,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0046951,ketone body biosynthetic process,,ketone body biosynthetic process is a subtype of generating: A process that synthesizes ketone body resulting in having output (s).,false,,,http://purl.obolibrary.org/obo/TXPO_0000019,,,,,,,,,,,,,,,,,,,,,,ketone body biosynthetic process is a subtype of generating: A process that synthesizes ketone body resulting in having output (s).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_73693,,,,,,,,,,,,,,,,,,,GO:0046951,,,,,,,,,,,,,,,,,,,,,,ketone body biosynthetic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0031012,extracellular matrix,,"A structure lying external to one or more cells, which provides structural support for cells or tissues.",false,,,http://purl.obolibrary.org/obo/TXPO_0000065,,,,,,,,,,,,,,,,,,,,NCIT:C13232|MESH:D005109,,"A structure lying external to one or more cells, which provides structural support for cells or tissues.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0031012,,,,,,,,,,,,,,,,,,,,,,extracellular matrix,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0017129,triglyceride binding,,Interacting selectively and non-covalently with any triester of glycerol.,false,,,http://purl.obolibrary.org/obo/GO_0008289,,,,,,,,,,,,,,,,,,,,GO:0017129,,Interacting selectively and non-covalently with any triester of glycerol.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0017129,,,,,,,Interacting selectively and non-covalently with any triester of glycerol.,,,,,,,,,,,,,,,triglyceride binding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100308,caspase-14,,,false,,,http://purl.obolibrary.org/obo/IMR_0000305,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100308,,,,,,,,,,,,,,,,,,,,,,caspase-14,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000437,Dbl,,,false,,,http://purl.obolibrary.org/obo/IMR_0001954,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000437,,,,,,,,,,,,,,,,,,,,,,Dbl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_38161,chelator,chelators|Metal chelator|chelating agents|complexon|Chelating agent,"A ligand with two or more separate binding sites that can bind to a single metallic central atom, forming a chelate.",false,,,http://purl.obolibrary.org/obo/CHEBI_52214|http://purl.obolibrary.org/obo/CHEBI_51086,,,,,,,,,,,,,,,,,,,,,,"A ligand with two or more separate binding sites that can bind to a single metallic central atom, forming a chelate.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000624,,,,,,,chelators|Metal chelator|chelating agents|complexon|Chelating agent,,,,,,,,,,,,,,,,,,,,,CHEBI:38161,,,,chelator,,CHEBI:38161,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0002107,liver,jecur|iecur,"An exocrine gland which secretes bile and functions in metabolism of protein and carbohydrate and fat, synthesizes substances involved in the clotting of the blood, synthesizes vitamin A, detoxifies poisonous substances, stores glycogen, and breaks down worn-out erythrocytes.",false,,,http://purl.obolibrary.org/obo/UBERON_0013765,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0008152|http://purl.obolibrary.org/obo/TXPO_0002552|http://purl.obolibrary.org/obo/GO_0002384|http://purl.obolibrary.org/obo/GO_0005978|http://purl.obolibrary.org/obo/GO_0005977|http://purl.obolibrary.org/obo/GO_0032782|http://purl.obolibrary.org/obo/TXPO_0000173|http://purl.obolibrary.org/obo/GO_0005980,,,http://www.snomedbrowser.com/Codes/Details/181268008|http://linkedlifedata.com/resource/umls/id/C0023884|http://purl.obolibrary.org/obo/NCIT_C12392|http://en.wikipedia.org/wiki/Liver|VHOG:0000257|MIAA:0000097|GAID:288|EFO:0000887|BTO:0000759|MESH:D008099|OpenCyc:Mx4rvVimppwpEbGdrcN5Y29ycA|galen:Liver|EV:0100089|FMA:7197|MA:0000358|ZFA:0000123|TAO:0000123|UMLS:C0023884|XAO:0000133|EHDAA:2197|EHDAA2:0000997|EMAPA:16846|MAT:0000097|AAO:0010111|CALOHA:TS-0564,,"An exocrine gland which secretes bile and functions in metabolism of protein and carbohydrate and fat, synthesizes substances involved in the clotting of the blood, synthesizes vitamin A, detoxifies poisonous substances, stores glycogen, and breaks down worn-out erythrocytes.",,,,,,,,Organ which secretes bile and participates in formation of certain blood proteins.[AAO],,,,,,,"secretes bile and functions in metabolism of protein and carbohydrate and fat, synthesizes substances involved in the clotting of the blood, synthesizes vitamin A, detoxifies poisonous substances, stores glycogen, and breaks down worn-out erythrocytes[GO].",,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0001113,,,,,,,,,,,,,,,jecur|iecur,"All vertebrates possess a liver (reference 1); Later in craniate evolution, an anterior gill arch was transformed into jaws, and many new types of feeding subsequently evolved.(...) A liver evolved that, among its many functions, stores considerable energy as glycogen or lipid (reference 2).[well established][VHOG]",http://purl.obolibrary.org/obo/UBERON_0002423|http://purl.obolibrary.org/obo/UBERON_0000949|http://purl.obolibrary.org/obo/UBERON_0001007|http://purl.obolibrary.org/obo/UBERON_0002330,UBERON:0002107,http://purl.obolibrary.org/obo/UBERON_0002423|http://purl.obolibrary.org/obo/UBERON_0000949|http://purl.obolibrary.org/obo/UBERON_0001007|http://purl.obolibrary.org/obo/UBERON_0002330,,,,,,,,,,,,,,,,,,,,,liver,,,,http://upload.wikimedia.org/wikipedia/commons/6/64/Leber_Schaf.jpg,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"An organ sometimes referred to as a liver is found associated with the digestive tract of the primitive chordate Amphioxus. However, this is an enzyme secreting gland, not a metabolic organ, and it is unclear how truly homologous it is to the vertebrate liver. The zebrafish liver differs from the mammalian liver in that the hepatocytes are not clearly organized in cords or lobules and the typical portal triads are not apparent. In addition, the zebrafish liver does not have Kuppfer cells. Furthermore, a clear distinction can be made between the male and female liver in the adult zebrafish. The female hepatocytes are very basophilic (Figure 15c) as a result of the production of vitellogenin (Van der Ven et al. 2003).|The liver is found in all vertebrates, and is typically the largest visceral organ. Its form varies considerably in different species, and is largely determined by the shape and arrangement of the surrounding organs. Nonetheless, in most species it is divided into right and left lobes; exceptions to this general rule include snakes, where the shape of the body necessitates a simple cigar-like form. The internal structure of the liver is broadly similar in all vertebrates.",
http://purl.obolibrary.org/obo/UBERON_0002106,spleen,,the organ that functions to filter blood and to store red corpuscles and platelets,false,,,http://purl.obolibrary.org/obo/UBERON_0000062,,,,,,,,,,,,,,,,,,,,UMLS:C0037993|http://upload.wikimedia.org/wikipedia/commons/d/d6/Illu_spleen.jpg|http://en.wikipedia.org/wiki/Spleen,,the organ that functions to filter blood and to store red corpuscles and platelets,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002390,UBERON:0002106,http://purl.obolibrary.org/obo/UBERON_0002390,,,,,,,,,,,,,,,,,,,,,spleen,,,,http://www.snomedbrowser.com/Codes/Details/181279003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0002108,small intestine,anterior intestine|intestinum tenue|mid intestine|small intestine|small bowel,"Subdivision of digestive tract that connects the stomach to the large intestine and is where much of the digestion and absorption of food takes place (with the exception of ruminants). The mammalian small intestine is long and coiled and can be differentiated histologically into: duodenum, jejunem, ileum[WP,cjm,Kardong].",false,,,http://purl.obolibrary.org/obo/UBERON_0000160,,,,,,,,,,,,,,,,,,,,http://linkedlifedata.com/resource/umls/id/C0021852|http://www.snomedbrowser.com/Codes/Details/181250005|http://purl.obolibrary.org/obo/NCIT_C12386|http://en.wikipedia.org/wiki/Small_intestine|FMA:7200|BTO:0000651|CALOHA:TS-0942|AAO:0010397|EMAPA:32834|VHOG:0000055|galen:SmallIntestine|MIAA:0000047|OpenCyc:Mx4rvVjlIJwpEbGdrcN5Y29ycA|MAT:0000047|MESH:A03.492.411.620|TAO:0001323|EFO:0000841|GAID:313|XAO:0000130|EV:0100072|ZFA:0001323|UMLS:C0021852|MA:0000337,,"Subdivision of digestive tract that connects the stomach to the large intestine and is where much of the digestion and absorption of food takes place (with the exception of ruminants). The mammalian small intestine is long and coiled and can be differentiated histologically into: duodenum, jejunem, ileum[WP,cjm,Kardong].",,,,,,,,"The terminal region of the mid intestine is comprised of specialized enterocytes that appear to play a role in mucosal immunity. Wallace et al, 2005.[TAO]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,small intestine|small bowel,,anterior intestine|intestinum tenue|mid intestine,Intestinal surface area also is increased in amphibians and reptiles by internal folds and occasionally by a few villi. The intestine can be divided into a small intestine and a slightly wider large intestine.[well established][VHOG],http://purl.obolibrary.org/obo/UBERON_0000160,UBERON:0002108,http://purl.obolibrary.org/obo/UBERON_0000160,,,,,,,,,,,,,,,,,,,,,small intestine,,,,http://upload.wikimedia.org/wikipedia/commons/8/82/Stomach_colon_rectum_diagram.svg,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_51450,bosentan,"4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl) benzenesulfornamide|bosentanum|bosentan|p-tert-Butyl-N-(6-(2-hydroxyethoxy)-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl)benzenesulfonamide|4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl]benzenesulfonamide",,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Drug_Central:392|DrugBank:DB00559|ATC:C02KX01|Wikipedia:Bosentan|CAS:147536-97-8|LINCS:LSM-5825,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_51451|http://purl.obolibrary.org/obo/CHEBI_35674,,,,,"4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl]benzenesulfonamide",,"4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl) benzenesulfornamide|bosentanum|bosentan|p-tert-Butyl-N-(6-(2-hydroxyethoxy)-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl)benzenesulfonamide",,,,,,,,,,,,,,,,,,,,,CHEBI:51450,,,,bosentan,,CHEBI:51450,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(cc2)C(C)(C)C)nc(nc1OCCO)-c1ncccn1,,,,,
http://purl.obolibrary.org/obo/IMR_0100350,TCR alpha,T-cell receptor alpha,,false,,,http://purl.obolibrary.org/obo/IMR_0000151,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,T-cell receptor alpha,,,,,IMR:0100350,,,,,,,,,,,,,,,,,,,,,,TCR alpha,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100122,octopamine,p-hydroxyphenylethanolamine|1-(4-Hydroxyphenyl)-2-aminoethanol,,false,,,http://purl.obolibrary.org/obo/IMR_0002121,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_25512,,,,,p-hydroxyphenylethanolamine|1-(4-Hydroxyphenyl)-2-aminoethanol,,,,,IMR:0100122,,,,,,,,,,,,,,,,,,,,,,octopamine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_35442,antiparasitic agent,antiparasitic drugs|parasiticides|antiparasitics,A substance used to treat or prevent parasitic infections.,false,,,http://purl.obolibrary.org/obo/CHEBI_35441,,,,,,,,,,,,,,,,,,,,,,A substance used to treat or prevent parasitic infections.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,antiparasitic drugs|parasiticides|antiparasitics,,,,,,,,,,,,,,,,,,,,,CHEBI:35442,,,,antiparasitic agent,,CHEBI:35442,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010468,60S ribosomal protein L18,Q07020,,false,,,http://purl.obolibrary.org/obo/IMR_0000897,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Q07020,,,,,IMR:0010468,,,,,,,,,,,,,,,,,,,,,,60S ribosomal protein L18,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76158,ibufenac,Ibunac|ibufenacum|4-(2-Methylpropyl)benzeneacetic acid|(p-Isobutylphenyl)acetic acid|ibufenaco|4-Isobutylphenylacetic acid|Dytransin|ibufenac|(4-isobutylphenyl)acetic acid|[4-(2-methylpropyl)phenyl]acetic acid,"A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by a 4-isobutylphenyl group. Although it was shown to be effective in treatment of rheumatoid arthritis, the clinical use of ibufenac was discontinued due to hepatotoxic side-effects.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:5748163|PMID:21128314|CAS:1553-60-2|PMID:16456879|Reaxys:2046683|PMID:2585272|PMID:5657238|PMID:7587932|PMID:9061203|PMID:687781|PMID:5752436|PMID:5807207|PMID:3215965|PMID:1479559|Drug_Central:3293|PMID:5329891,,"A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by a 4-isobutylphenyl group. Although it was shown to be effective in treatment of rheumatoid arthritis, the clinical use of ibufenac was discontinued due to hepatotoxic side-effects.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35544|http://purl.obolibrary.org/obo/CHEBI_50908|http://purl.obolibrary.org/obo/CHEBI_35475|http://purl.obolibrary.org/obo/CHEBI_35481,,,,,(4-isobutylphenyl)acetic acid|[4-(2-methylpropyl)phenyl]acetic acid,,Ibunac|ibufenacum|4-(2-Methylpropyl)benzeneacetic acid|(p-Isobutylphenyl)acetic acid|ibufenaco|4-Isobutylphenylacetic acid|Dytransin|ibufenac,,,,,,,,,,,,,,,,,,,,,CHEBI:76158,,,,ibufenac,,CHEBI:76158,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0001008,renal system,renal/urinary system|renal or urinary system|systema urinaria|systema urinarium|renal system|urinary tract|excretory system|urinary system,"The renal system in an anatomical system that maintains fluid balance and contributes to electrolyte balance, acid/base balance, and disposal of nitrogenous waste products..|In humans, the renal system comprises a pair of kidneys, a pair of ureters, urinary bladder, urethra, sphincter muscle and associated blood vessels",false,,,http://purl.obolibrary.org/obo/UBERON_0000467|http://purl.obolibrary.org/obo/UBERON_0011216,,,,,,,,,,,,,,,,,,,,http://en.wikipedia.org/wiki/Excretory_system|galen:UrinaryTract|MESH:D014551|FMA:7159,,"The renal system in an anatomical system that maintains fluid balance and contributes to electrolyte balance, acid/base balance, and disposal of nitrogenous waste products..",,,,"In various sources such as Encyclopedia Britannica, the excretory and urinary systems are indeed the same system (see wikipedia talk page); we merge two BTO classes here",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,systema urinaria|systema urinarium|renal system|urinary tract|excretory system|urinary system,,renal/urinary system|renal or urinary system,"Evolution of vertebrate renal anatomy appears quite conservative when compared, for example, to evolution of respiratory and cardiovascular systems in vertebrates. Major anatomical changes in vertebrates kidneys separate those of birds and mammals from kidneys of lower vertebrates. General increase in animal size from fish to mammals is reflected by an increase in total number of nephrons per kidney, rather than by constant change in tubular dimensions.[well established][VHOG]",,UBERON:0001008,,,,,,,,,,,,,,,,,,,,"In humans, the renal system comprises a pair of kidneys, a pair of ureters, urinary bladder, urethra, sphincter muscle and associated blood vessels",,renal system,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0001009,circulatory system,systema cardiovasculare,"organ system that passes nutrients (such as amino acids and electrolytes), gases, hormones, blood cells, etc. to and from cells in the body to help fight diseases and help stabilize body temperature and pH to maintain homeostasis[WP].",false,,,http://purl.obolibrary.org/obo/UBERON_0000467,,,,,,,,,,,,,,,,,,,the cardiovascular system and the lymphatic system are parts of the circulatory system,http://en.wikipedia.org/wiki/Circulatory_system|CALOHA:TS-2103|OpenCyc:Mx4rvVjzG5wpEbGdrcN5Y29ycA|AAO:0000959|FBbt:00005057|VHOG:0001248,,"organ system that passes nutrients (such as amino acids and electrolytes), gases, hormones, blood cells, etc. to and from cells in the body to help fight diseases and help stabilize body temperature and pH to maintain homeostasis[WP].",,,,,,,,"Anatomical system of ion binding, a pumping mechanism, and an efficient vascular system; consisting of the blood, heart, and blood and lymph vessels, respectively.[AAO]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,systema cardiovasculare,"We should divest ourselves of the view that earlier vertebrate groups were 'on their way' to becoming mammals, as clearly they were not such visionaries. Neither were their systems 'imperfect' as earlier anatomists thought. Instead, their circulatory systems served them well to address the ecological demands arising from their lifestyles.[well established][VHOG]",,UBERON:0001009,,,,,,,,,,,,,,,,,,,,,,circulatory system,,,,http://upload.wikimedia.org/wikipedia/commons/2/29/Circulatory_System_en.svg,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0001007,digestive system,gut|alimentary tract|gastrointestinal system|alimentary system,"Anatomical system that has as its parts the organs devoted to the ingestion, digestion, and assimilation of food and the discharge of residual wastes.",false,,,http://purl.obolibrary.org/obo/UBERON_0000467,,,,,,,,,,,,,,,,,,,,http://www.snomedbrowser.com/Codes/Details/278859004|http://en.wikipedia.org/wiki/Digestive_system|AAO:0000129|EV:0100056|MIAA:0000018|FMA:7152|XAO:0000125|CALOHA:TS-1293|BILA:0000082|FBbt:00005055|BTO:0000058|ZFA:0000339|WBbt:0005748|MAT:0000018|MA:0002431|TAO:0000339|MESH:D004064|EFO:0000793|TADS:0000170|ncithesaurus:Digestive_System|galen:DigestiveSystem|GAID:278,,"Anatomical system that has as its parts the organs devoted to the ingestion, digestion, and assimilation of food and the discharge of residual wastes.",,,,,,,,"An anatomical system consisting of the alimentary canal and digestive glands responsible for intake, absorption, digestion and excretion of food.[AAO]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,gut|alimentary tract|gastrointestinal system|alimentary system,,,UBERON:0001007,,,,,,,,,,,,,,,,,,,,,,digestive system,,,,,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0001004,respiratory system,apparatus respiratorius|Atmungssystem|systema respiratorium|apparatus respiratorius|respiratory system,Functional system which consists of structures involved in respiration.,false,,,http://purl.obolibrary.org/obo/UBERON_0000467,,,,,,,,,,,,,,,,,,,,http://www.snomedbrowser.com/Codes/Details/278197002|http://en.wikipedia.org/wiki/Respiratory_system|http://linkedlifedata.com/resource/umls/id/C0035237|http://purl.obolibrary.org/obo/NCIT_C12779|ZFA:0000272|MA:0000327|MESH:D012137|TAO:0000272|CALOHA:TS-1319|MIAA:0000030|BTO:0000203|EMAPA:16727|MAT:0000030|FMA:7158|EHDAA2:0001604|EV:0100036|EFO:0000804|XAO:0000117|GAID:78|VHOG:0000202|OpenCyc:Mx4rvVjzFJwpEbGdrcN5Y29ycA|UMLS:C0035237|AAO:0000541|EHDAA:2203,,Functional system which consists of structures involved in respiration.,,,,,,,,The anatomical system in which the exchange of oxygen and carbon dioxide between the organism and its environment.[AAO],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,apparatus respiratorius|respiratory system,,apparatus respiratorius|Atmungssystem|systema respiratorium,There is no doubt that the primitive pattern of vertebrate air-breathing is the buccal pulse pump found in actinopterygian fishes.[well established][VHOG],,UBERON:0001004,,,,,,,,,,,,,,,,,,,,,,respiratory system,,,,http://upload.wikimedia.org/wikipedia/commons/5/5e/Respiratory_system_complete_en.svg,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_6067,isotretinoin,"isotretinoinum|13-RA|isotretinoina|isotretinoine|Neovitamin A acid|cis-RA|(7E,9E,11E,13Z)-retinoic acid|isotretinoin|13-cis-Vitamin A acid|Amnesteem|13-cis-retinoic acid|Claravis|Accutane|isotretinoino|(2Z,4E6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid","A retinoic acid that is all-trans-retinoic acid in which the double bond which is alpha,beta- to the carboxy group is isomerised to Z configuration. A synthetic retinoid, it is used for the treatment of severe cases of acne and other skin diseases.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Drug_Central:1508|PMID:9807973|LIPID_MAPS_instance:LMPR01090021|Beilstein:1885770|PMID:18788179|DrugBank:DB00982|PMID:15304471|PMID:23676507|PMID:18077132|PMID:20482692|Reaxys:1885770|CAS:4759-48-2|PMID:11606947|PMID:19568610|PMID:11866680,,"A retinoic acid that is all-trans-retinoic acid in which the double bond which is alpha,beta- to the carboxy group is isomerised to Z configuration. A synthetic retinoid, it is used for the treatment of severe cases of acne and other skin diseases.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_50905|http://purl.obolibrary.org/obo/CHEBI_35610|http://purl.obolibrary.org/obo/CHEBI_50176,,,,,"(2Z,4E6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid",,"isotretinoinum|13-RA|isotretinoina|isotretinoine|Neovitamin A acid|cis-RA|(7E,9E,11E,13Z)-retinoic acid|isotretinoin|13-cis-Vitamin A acid|Amnesteem|13-cis-retinoic acid|Claravis|Accutane|isotretinoino",,,,,,,,,,,,,,,,,,,,,CHEBI:6067,,,,isotretinoin,,CHEBI:6067,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_254496,"7,12-dimethyltetraphene","7,12-dimethylbenzo[a]anthracene|7,12-dimethylbenz(a)anthracene",A tetraphene having methyl substituents at the 7- and 12-positions. It is a potent carcinogen and is present in tobacco smoke.,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:57-97-6,,A tetraphene having methyl substituents at the 7- and 12-positions. It is a potent carcinogen and is present in tobacco smoke.,,,,,,,,,,,,C20H16,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"7,12-dimethylbenzo[a]anthracene|7,12-dimethylbenz(a)anthracene",,,,,CHEBI:254496,,,,,,,,,,,,,,,,,,,,,,"7,12-dimethyltetraphene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Cc1c2ccccc2c(C)c2c1ccc1ccccc21,,,,,
http://purl.obolibrary.org/obo/OGG_3000005890,RAD51B,,Other designations: DNA repair protein RAD51 homolog 2|RAD51 homolog B|RecA-like protein|recombination repair protein,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,REC2|RAD51L1|R51H2,,,,,,,,,,,,14,,,,,,HPRD:04255|Vega:OTTHUMG00000157530|Ensembl:ENSG00000182185|HGNC:9822|MIM:602948,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,RAD51 paralog B,,,14q23-q24.2,,,,,,,,,,,,,,,,"GO_0000400 (EC: IDA, Qualifier: contributes_to); GO_0000724 (EC: IMP); GO_0003677 (EC: TAS, PMID: 9512535); GO_0003690 (EC: IDA, PMID: 12441335); GO_0003697 (EC: IDA, PMID: 12441335); GO_0005515 (EC: IPI); GO_0005524 (EC: IEA); GO_0005634 (EC: TAS, PMID: 9512535); GO_0005654 (EC: TAS); GO_0005657 (EC: IDA); GO_0006200 (EC: IDA, PMID: 12441335); GO_0006281 (EC: TAS, PMID: 9512535); GO_0006310 (EC: TAS, PMID: 9512535); GO_0007131 (EC: TAS, PMID: 9441753); GO_0007596 (EC: TAS); GO_0008094 (EC: IDA, PMID: 12441335); GO_0010971 (EC: IMP); GO_0033063 (EC: IDA, PMID: 11751635)",,,,,,,,,PMID: 4595808; 6261043; 8889548; 9207106; 9441753; 9512535; 9788630; 9878257; 9892177; 10565301; 10938124; 11744692; 11751635; 11751636; 11842112; 11842113; 11978964; 12118380; 12427746; 12441335; 12477932; 12508121; 12649198; 12975363; 14595808; 14704354; 15065660; 15115758; 15489334; 15701685; 18270339; 19329439; 19330030; 19657362; 19714462; 19850743; 20095854; 20195514; 20237344; 20379614; 20496165; 20522537; 20610542; 20881960; 21368091; 21399635; 21533530; 21852249; 21965664; 22017238; 22139419; 22232737; 22454379; 23001122; 23108668; 23251661; 23455636; 23535729; 23535732; 23810717; 24022229,,,,,,,,,,,,,,,OGG:3000005890,,,,,,,RAD51 paralog B,,,,,,,,,,,,,Other designations: DNA repair protein RAD51 homolog 2|RAD51 homolog B|RecA-like protein|recombination repair protein,,RAD51B,,,,,,,,,,,,,,,,,,,,,,,5890,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,RAD51B,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0002692,IGFBP-4,,,false,,,http://purl.obolibrary.org/obo/IMR_0002688,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0002692,,,,,,,,,,,,,,,,,,,,,,IGFBP-4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000525,PIM3 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:64534|NCBI-Human-GeneID:415116|NCBI-Mouse-GeneID:223775,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000415116,,,,,,,,,,,,,TXPO:1000525,,,,,,,,,,,,,,,,,,,,,,PIM3 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000520,KIAA0101 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:9768,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000009768,,,,,,,,,,,,,TXPO:1000520,,,,,,,,,,,,,,,,,,,,,,KIAA0101 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000522,ORC6 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:23594|NCBI-Rat-GeneID:291927|NCBI-Mouse-GeneID:56452,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000023594,,,,,,,,,,,,,TXPO:1000522,,,,,,,,,,,,,,,,,,,,,,ORC6 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000527,PTPRD (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:5789|NCBI-Mouse-GeneID:19266|NCBI-Rat-GeneID:313278,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:1000527,,,,,,,,,,,,,,,,,,,,,,PTPRD (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000523,PBLD (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:64081|NCBI-Rat-GeneID:171564|NCBI-Mouse-GeneID:68371,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000064081,,,,,,,,,,,,,TXPO:1000523,,,,,,,,,,,,,,,,,,,,,,PBLD (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000529,RHNO1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:83695|NCBI-Mouse-GeneID:72440|NCBI-Rat-GeneID:297627,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000083695,,,,,,,,,,,,,TXPO:1000529,,,,,,,,,,,,,,,,,,,,,,RHNO1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000528,RAD51AP1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:10635|NCBI-Rat-GeneID:689055|NCBI-Mouse-GeneID:19362,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000010635,,,,,,,,,,,,,TXPO:1000528,,,,,,,,,,,,,,,,,,,,,,RAD51AP1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000521,NEAT1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:66961|NCBI-Human-GeneID:283131,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000283131,,,,,,,,,,,,,TXPO:1000521,,,,,,,,,,,,,,,,,,,,,,NEAT1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000524,PCK1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:5105|NCBI-Mouse-GeneID:18534|NCBI-Rat-GeneID:362282,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000005105,,,,,,,,,,,,,TXPO:1000524,,,,,,,,,,,,,,,,,,,,,,PCK1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000526,PMAIP1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:492821|NCBI-Mouse-GeneID:58801|NCBI-Human-GeneID:5366,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000005366,,,,,,,,,,,,,TXPO:1000526,,,,,,,,,,,,,,,,,,,,,,PMAIP1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100608,cyclin A1,CGA1|Cyclin A1,,false,,,http://purl.obolibrary.org/obo/IMR_0100607,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0011589|IMR:0010764,CGA1|Cyclin A1,,,,,IMR:0100608,,,,,,,,,,,,,,,,,,,,,,cyclin A1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_48676,fibrin modulating drug,fibrin modulating drugs|fibrin modulating agents|fibrin modulating agent,A drug that affects the function of fibrin in blood coagulation.,false,,,http://purl.obolibrary.org/obo/CHEBI_23888,,,,,,,,,,,,,,,,,,,,,,A drug that affects the function of fibrin in blood coagulation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,fibrin modulating drugs|fibrin modulating agents|fibrin modulating agent,,,,,,,,,,,,,,,,,,,,,CHEBI:48676,,,,fibrin modulating drug,,CHEBI:48676,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001602,Rab18,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001602,,,,,,,,,,,,,,,,,,,,,,Rab18,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0034329,cell junction assembly,,"A cellular process that results in the aggregation, arrangement and bonding together of a set of components to form a cell junction.",false,,,http://purl.obolibrary.org/obo/TXPO_0000468,,,,,,,,,,,,,,,,,,,,,,"A cellular process that results in the aggregation, arrangement and bonding together of a set of components to form a cell junction.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0034329,,,,,,,,,,,,,,,,,,,,,,cell junction assembly,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_38214,Monuron,"3-(4-chlorophenyl)-1,1-dimethylurea",A member of the class of phhenylureas that is urea in which one of the nitrogens is substituted by a p-chlorophenyl group while the other is substituted by two methyl groups.,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:150-68-5,,A member of the class of phhenylureas that is urea in which one of the nitrogens is substituted by a p-chlorophenyl group while the other is substituted by two methyl groups.,,,,,,,,,,,,C9H11ClN2O,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"3-(4-chlorophenyl)-1,1-dimethylurea",,,,,CHEBI:38214,,,,,,,,,,,,,,,,,,,,,,Monuron,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CN(C)C(=O)Nc1ccc(Cl)cc1,,,,,
http://purl.obolibrary.org/obo/OGG_3000001973,EIF4A1,,Other designations: ATP-dependent RNA helicase eIF4A-1|eukaryotic initiation factor 4A-I|eukaryotic initiation factor 4AI|eukaryotic translation initiation factor 4A,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,EIF4A|eIF4A-I|eIF-4A-I|EIF-4A|DDX2A,,,,,,,,,,,,17,,,,,,MIM:602641|Vega:OTTHUMG00000108149|HPRD:04030|Ensembl:ENSG00000161960|HGNC:3282,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,eukaryotic translation initiation factor 4A1,,,17p13,,,,,,,,,,,,,,,,"GO_0000288 (EC: TAS); GO_0000289 (EC: TAS); GO_0000339 (EC: TAS, PMID:3215517); GO_0003725 (EC: IDA); GO_0003729 (EC: TAS, PMID:3215517); GO_0003743 (EC: IEA); GO_0004386 (EC: TAS, PMID:3215517); GO_0005515 (EC: IPI, PMID:16166382); GO_0005524 (EC: IEA); GO_0005829 (EC: TAS); GO_0006412 (EC: TAS); GO_0006413 (EC: TAS); GO_0008026 (EC: IEA); GO_0008135 (EC: TAS, PMID:10880459); GO_0010467 (EC: TAS); GO_0016032 (EC: IEA); GO_0016070 (EC: TAS); GO_0016071 (EC: TAS); GO_0016281 (EC: TAS, PMID:9168945); GO_0019221 (EC: TAS); GO_0031100 (EC: IEA); GO_0044267 (EC: TAS); GO_0044822 (EC: IDA); GO_0070062 (EC: IDA)",,,,,,,,,PMID:3215517; 8449919; 8493113; 8619474; 9110174; 9168945; 9372926; 9418880; 9548260; 9790779; 10611228; 10644445; 10880459; 11073994; 11408474; 11903057; 12426392; 12477932; 12588972; 15082783; 15282546; 15489334; 16027165; 16159877; 16166382; 16169070; 16196087; 16541103; 16648488; 17053147; 17130132; 17284590; 17314511; 17353931; 17361185; 17643375; 18034160; 18296639; 18700728; 18719248; 18781797; 19135240; 19203580; 19661379; 19738201; 19805454; 20000738; 20080577; 20156963; 20360068; 20639865; 20927385; 20972266; 21081666; 21110914; 21139048; 21145461; 21182205; 21252943; 21319273; 21377182; 21427765; 21454508; 21800051; 21840318; 21853274; 21890473; 21900206; 21906983; 21963094; 21987572; 22053931; 22076380; 22118674; 22145905; 22268729; 22505724; 22586265; 22586326; 22589333; 22623428; 22689062; 22797925; 22939629; 22990118; 23000965; 23077236; 23402259; 23463506; 23747307; 23798571; 24113185; 24130170; 24248602,,,,,,,,,,,,,,,OGG:3000001973,,,,,,,eukaryotic translation initiation factor 4A1,,,,,,,,,,,,,Other designations: ATP-dependent RNA helicase eIF4A-1|eukaryotic initiation factor 4A-I|eukaryotic initiation factor 4AI|eukaryotic translation initiation factor 4A,,EIF4A1,,,,,,,,,,,,,,,,,,,,,,,1973,,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF4A1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001979,EIF4EBP2,,"Other designations: 4E-BP2|eIF4E-binding protein 2|eukaryotic translation initiation factor 4E-binding protein 2|phosphorylated, heat and acid stable regulated by insulin protein II",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,PHASII|4EBP2,,,,,,,,,,,,10,,,,,,MIM:602224|HPRD:03747|Ensembl:ENSG00000148730|Vega:OTTHUMG00000018409|HGNC:3289,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,eukaryotic translation initiation factor 4E binding protein 2,,,10q21-q22,,,,,,,,,,,,,,,,"GO_0005515 (EC: IPI, PMID:16271312); GO_0006412 (EC: TAS, PMID:7935836); GO_0008190 (EC: IEA); GO_0008286 (EC: IEA); GO_0019933 (EC: IEA); GO_0045947 (EC: IEA)",,,,,,,,,PMID:7651417; 7935836; 8939971; 8975712; 9344920; 9381973; 9465032; 9531283; 10092805; 11069026; 11847216; 11865047; 12151318; 12477932; 14507920; 14702039; 15153109; 15489334; 16271312; 16385451; 16751776; 16798736; 17316564; 18789325; 19244480; 19322201; 19913121; 20424163; 20628086; 20628624; 21661078; 23824909,,,,,,,,,,,,,,,OGG:3000001979,,,,,,,eukaryotic translation initiation factor 4E binding protein 2,,,,,,,,,,,,,"Other designations: 4E-BP2|eIF4E-binding protein 2|eukaryotic translation initiation factor 4E-binding protein 2|phosphorylated, heat and acid stable regulated by insulin protein II",,EIF4EBP2,,,,,,,,,,,,,,,,,,,,,,,1979,,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF4EBP2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001974,EIF4A2,,Other designations: ATP-dependent RNA helicase eIF4A-2|eukaryotic initiation factor 4A-II|eukaryotic translation initiation factor 4A,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,eIF4A-II|EIF4A|eIF-4A-II|BM-010|DDX2B|EIF4F,,,,,,,,,,,,3,,,,,,MIM:601102|Vega:OTTHUMG00000156564|Ensembl:ENSG00000156976|HGNC:3284|HPRD:03062,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,eukaryotic translation initiation factor 4A2,,,3q28,,,,,,,,,,,,,,,,"GO_0000288 (EC: TAS); GO_0000289 (EC: TAS); GO_0003743 (EC: IEA); GO_0004386 (EC: TAS, PMID:8521730); GO_0005524 (EC: IEA); GO_0005829 (EC: TAS); GO_0006412 (EC: TAS); GO_0006413 (EC: TAS); GO_0006446 (EC: TAS, PMID:8521730); GO_0008026 (EC: IEA); GO_0010467 (EC: TAS); GO_0016032 (EC: IEA); GO_0016070 (EC: TAS); GO_0016071 (EC: TAS); GO_0016281 (EC: TAS, PMID:8521730); GO_0019221 (EC: TAS); GO_0044267 (EC: TAS); GO_0044822 (EC: IDA)",,,,,,,,,PMID:8125298; 8449919; 8521730; 11172724; 11408474; 11922617; 12477932; 12588972; 15047060; 15489334; 15946665; 16014927; 16169070; 16567544; 17353931; 17643375; 18250159; 18593934; 18976975; 19034380; 19596686; 19615732; 20360068; 20639865; 20972266; 21110914; 21139048; 21427765; 21890473; 21900206; 21906983; 21963094; 21987572; 22053931; 22360420; 22505724; 22589333; 22759308; 22939629; 22944692; 22990118; 23000965; 23383273; 23463506; 23559250; 23824909,,,,,,,,,,,,,,,OGG:3000001974,,,,,,,eukaryotic translation initiation factor 4A2,,,,,,,,,,,,,Other designations: ATP-dependent RNA helicase eIF4A-2|eukaryotic initiation factor 4A-II|eukaryotic translation initiation factor 4A,,EIF4A2,,,,,,,,,,,,,,,,,,,,,,,1974,,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF4A2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001978,EIF4EBP1,,Other designations: eIF4E-binding protein 1|eukaryotic translation initiation factor 4E-binding protein 1|phosphorylated heat- and acid-stable protein regulated by insulin 1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,BP-1|4E-BP1|4EBP1|PHAS-I,,,,,,,,,,,,8,,,,,,HPRD:03746|Ensembl:ENSG00000187840|Vega:OTTHUMG00000164012|MIM:602223|HGNC:3288,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,eukaryotic translation initiation factor 4E binding protein 1,,,8p12,,,,,,,,,,,,,,,,"GO_0000082 (EC: IMP, PMID:14673156); GO_0002931 (EC: IEA); GO_0005515 (EC: IPI, PMID:10772338); GO_0005634 (EC: IDA); GO_0005730 (EC: IDA, Qualifier: NOT); GO_0005737 (EC: IDA); GO_0005829 (EC: TAS); GO_0006412 (EC: TAS); GO_0006413 (EC: TAS); GO_0008190 (EC: IEA); GO_0008286 (EC: TAS); GO_0010467 (EC: TAS); GO_0030324 (EC: IEA); GO_0030371 (EC: IDA); GO_0031333 (EC: IEA); GO_0031929 (EC: IDA, PMID:12150926); GO_0043234 (EC: IEA); GO_0044267 (EC: TAS); GO_0045471 (EC: IEA); GO_0045931 (EC: IMP, PMID:14673156); GO_0045947 (EC: IDA)",,,,,,,,,PMID:7651417; 7935836; 8083223; 8521827; 8816458; 8957083; 8975712; 9092573; 9344920; 9405468; 9465032; 9628874; 9806882; 10022874; 10092805; 10198256; 10364159; 10405182; 10608806; 10698949; 10713094; 10753870; 10772338; 10779345; 10942774; 10971657; 11069026; 11114166; 11146653; 11280764; 11438723; 11553333; 11605658; 11691836; 11777913; 11847216; 11865047; 11909977; 12071973; 12080086; 12105188; 12150925; 12150926; 12151318; 12271141; 12477932; 12588975; 12604610; 12618431; 12665511; 12665801; 12747827; 12759354; 12820960; 12912989; 14507920; 14673156; 15066126; 15094042; 15153109; 15178440; 15459249; 15467718; 15489334; 15542544; 15767663; 15809305; 15854902; 15927069; 16098202; 16098514; 16109716; 16169070; 16189514; 16242075; 16271312; 16648488; 16652388; 16715128; 16798736; 16824195; 16837165; 16873412; 16899564; 16983702; 17081983; 17114181; 17200342; 17254965; 17316564; 17353931; 17386266; 17502379; 17601486; 17604271; 17653084; 17693255; 17699757; 17724476; 18029348; 18051367; 18280804; 18337562; 18337751; 18384376; 18439897; 18442140; 18660489; 18668138; 18701920; 18708753; 18722121; 18810319; 18922789; 18957614; 19036825; 19107520; 19211763; 19244480; 19271249; 19336517; 19360336; 19367274; 19428047; 19429661; 19533653; 19541645; 19574449; 19603014; 19648884; 19834456; 19850923; 20090955; 20133758; 20304964; 20372058; 20532202; 20609351; 20621385; 20671708; 21046149; 21067588; 21071439; 21366462; 21460630; 21576371; 21661078; 21750861; 21784851; 21841310; 21900206; 21913890; 21914810; 21922152; 21964297; 22110663; 22142830; 22178476; 22184107; 22216185; 22248270; 22457629; 22493283; 22578813; 22586265; 22641346; 22652449; 22690797; 22918237; 22977662; 23082216; 23100465; 23175522; 23340172; 23451476; 23547259; 23640516; 23707523; 23814053; 24030155; 24211447; 24255178,,,,,,,,,,,,,,,OGG:3000001978,,,,,,,eukaryotic translation initiation factor 4E binding protein 1,,,,,,,,,,,,,Other designations: eIF4E-binding protein 1|eukaryotic translation initiation factor 4E-binding protein 1|phosphorylated heat- and acid-stable protein regulated by insulin 1,,EIF4EBP1,,,,,,,,,,,,,,,,,,,,,,,1978,,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF4EBP1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001975,EIF4B,,,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,PRO1843|EIF-4B,,,,,,,,,,,,12,,,,,,HPRD:04892|Vega:OTTHUMG00000169570|MIM:603928|Ensembl:ENSG00000063046|HGNC:3285,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,eukaryotic translation initiation factor 4B,,,12q13.13,,,,,,,,,,,,,,,,"GO_0000166 (EC: IEA); GO_0000288 (EC: TAS); GO_0000289 (EC: TAS); GO_0003723 (EC: TAS, PMID:2390971); GO_0003743 (EC: IEA); GO_0005515 (EC: IPI); GO_0005829 (EC: TAS); GO_0006412 (EC: TAS); GO_0006413 (EC: TAS); GO_0006446 (EC: TAS, PMID:2390971); GO_0008286 (EC: TAS); GO_0010467 (EC: TAS); GO_0016070 (EC: TAS); GO_0016071 (EC: TAS); GO_0016281 (EC: TAS, PMID:2390971); GO_0044267 (EC: TAS); GO_0044822 (EC: IDA)",,,,,,,,,PMID:2016328; 2390971; 6722878; 8125298; 8139536; 8182051; 8816444; 10585411; 10672017; 11274152; 12477932; 12489981; 12588972; 12885229; 14702039; 14968112; 15071500; 15078951; 15302935; 15314020; 15342556; 16281055; 16286006; 16763566; 17081983; 17361185; 17620599; 18719248; 19167051; 19322201; 19369421; 19542561; 19615732; 20360068; 20462248; 20562859; 21044950; 21139048; 21145461; 21427765; 21743057; 21840318; 21906983; 21987572; 21994950; 22113938; 22268729; 22863883; 22939629; 23000965; 23084401; 23184937; 23398456; 23749639; 23813671; 24244333; 24250222,,,,,,,,,,,,,,,OGG:3000001975,,,,,,,eukaryotic translation initiation factor 4B,,,,,,,,,,,,,,,EIF4B,,,,,,,,,,,,,,,,,,,,,,,1975,,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF4B,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001977,EIF4E,,Other designations: eIF-4E|eIF-4F 25 kDa subunit|eukaryotic translation initiation factor 4E-like 1|mRNA cap-binding protein,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CBP|AUTS19|EIF4EL1|EIF4E1|EIF4F,,,,,,,,,,,,4,,,,,,MIM:133440|HPRD:00591|HGNC:3287,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,eukaryotic translation initiation factor 4E,,,4q21-q25,,,,,,,,,,,,,,,,"GO_0000082 (EC: IMP, PMID:14673156); GO_0000288 (EC: TAS); GO_0000289 (EC: TAS); GO_0000339 (EC: TAS, PMID:3469651); GO_0000932 (EC: IDA); GO_0003743 (EC: IDA); GO_0003743 (EC: ISS); GO_0005515 (EC: IPI, PMID:10772338); GO_0005737 (EC: IDA); GO_0005829 (EC: TAS); GO_0005845 (EC: IDA, PMID:16271312); GO_0006406 (EC: TAS); GO_0006412 (EC: TAS); GO_0006413 (EC: TAS); GO_0006417 (EC: IDA); GO_0008286 (EC: TAS); GO_0010467 (EC: TAS); GO_0010494 (EC: IDA); GO_0016032 (EC: IEA); GO_0016070 (EC: TAS); GO_0016071 (EC: TAS); GO_0016281 (EC: IDA); GO_0016442 (EC: IDA); GO_0019221 (EC: TAS); GO_0030324 (EC: IEA); GO_0031370 (EC: IEA); GO_0033391 (EC: IEA); GO_0044267 (EC: TAS); GO_0044822 (EC: IDA); GO_0045931 (EC: IMP, PMID:14673156); GO_0070062 (EC: IDA)",,,,,,,,,PMID:1384058; 1672854; 1674733; 1736299; 1916814; 1993647; 2016328; 3112145; 3469651; 7590282; 7651417; 7665584; 7782323; 7935836; 8449919; 8505316; 8521827; 8662663; 8816458; 8939971; 9155017; 9330633; 9372926; 9418880; 9593750; 9607624; 9628874; 9873047; 9878069; 10022874; 10364159; 10394359; 10405182; 10600798; 10648556; 10698949; 10753870; 10772338; 10856257; 10870064; 10880459; 10910074; 11072066; 11154262; 11401917; 11408474; 11500381; 11553333; 11575918; 11605658; 11771728; 11847216; 11879179; 11959093; 12071973; 12089333; 12105188; 12138083; 12151318; 12167712; 12169454; 12186496; 12189553; 12239292; 12374671; 12477932; 12482586; 12554669; 12588972; 12588975; 12691746; 12775419; 12781867; 12897141; 12918105; 12975586; 14558943; 14645512; 14673156; 14732354; 14990584; 15094042; 15122903; 15153109; 15220445; 15247416; 15355912; 15361857; 15371741; 15375804; 15487973; 15489334; 15542544; 15767663; 15809305; 15840819; 15878868; 15897904; 15956551; 15961545; 16023599; 16112647; 16124648; 16242075; 16271312; 16281055; 16332685; 16341674; 16540463; 16541103; 16648488; 16699599; 16720573; 16739988; 16756390; 16798736; 16824195; 17010208; 17074885; 17203162; 17245113; 17254965; 17316564; 17353931; 17357517; 17524464; 17601486; 17631896; 17638893; 17667941; 17689990; 17724079; 17786246; 17855553; 18234281; 18250159; 18343217; 18479935; 18593934; 18614538; 18719964; 18789325; 18805096; 18957614; 19020722; 19060904; 19114552; 19122207; 19134194; 19188486; 19244480; 19261348; 19262567; 19289374; 19367274; 19383915; 19440045; 19483468; 19556253; 19560264; 19603014; 19615732; 19776122; 19850923; 19850929; 20053821; 20101233; 20224576; 20359850; 20360068; 20379614; 20421305; 20427534; 20434207; 20499137; 20537983; 20652449; 20655307; 20686366; 21047768; 21088106; 21139048; 21145089; 21159249; 21238947; 21320304; 21334199; 21389327; 21415224; 21661078; 21750861; 21832049; 21876152; 21883093; 21890473; 21913890; 21941146; 21963094; 21964297; 21987572; 21988832; 21995271; 22216185; 22397984; 22456335; 22457629; 22505724; 22509910; 22556409; 22586265; 22614784; 22623428; 22684010; 22748716; 22759308; 22797067; 22851180; 22863883; 22872150; 22902403; 22939629; 23000965; 23100465; 23277284; 23359369; 23410891; 23467026; 23471078; 23472659; 23547259; 23588929; 23665580; 23665581; 23667251; 23737503; 23831578; 23883783; 23901100; 24211447; 24250222,,,,,,,,,,,,,,,OGG:3000001977,,,,,,,eukaryotic translation initiation factor 4E,,,,,,,,,,,,,Other designations: eIF-4E|eIF-4F 25 kDa subunit|eukaryotic translation initiation factor 4E-like 1|mRNA cap-binding protein,,EIF4E,,,,,,,,,,,,,,,,,,,,,,,1977,,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF4E,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0001471,DOCK3,,,false,,,http://purl.obolibrary.org/obo/IMR_0001469,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001471,,,,,,,,,,,,,,,,,,,,,,DOCK3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100615,cyclin D1,G1/S-specific cyclin D1|PRAD1 oncogene|CGD1|BCL-1 oncogene,,false,,,http://purl.obolibrary.org/obo/IMR_0100614,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0010664|IMR:0011612,G1/S-specific cyclin D1|PRAD1 oncogene|CGD1|BCL-1 oncogene,,,,,IMR:0100615,,,,,,,,,,,,,,,,,,,,,,cyclin D1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0043277,apoptotic cell clearance,apoptotic cell removal,The recognition and removal of an apoptotic cell by a neighboring cell or by a phagocyte.,false,,,http://purl.obolibrary.org/obo/TXPO_0000458,,,,,,,,,,,,,,,,,,,,,,The recognition and removal of an apoptotic cell by a neighboring cell or by a phagocyte.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,apoptotic cell removal,,,,,GO:0043277,,,,,,,,,,,,,,,,,,,,,,apoptotic cell clearance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0043276,anoikis,,Apoptosis triggered by inadequate or inappropriate adherence to substrate e.g. after disruption of the interactions between normal epithelial cells and the extracellular matrix.,false,,,http://purl.obolibrary.org/obo/GO_0006915,,,,,,,,,,,,,,,,,,,,"Wikipedia:Anoikis|An adherent cell-restricted lethal cascade that is ignited by detachment from the matrix and that is characterized by (i) lack of beta1-integrin engagement, (ii) downregulation of EGFR expression, (iii) inhibition of extracellular-regulated kinase 1 (ERK1) signaling, and (iv) overexpression of the BCL-2 family member BIM.
 It should be noted that in most, if not all, instances, the cell death program ignited by anoikis is executed by the molecular machinery for intrinsic apoptosis.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3252826/",,Apoptosis triggered by inadequate or inappropriate adherence to substrate e.g. after disruption of the interactions between normal epithelial cells and the extracellular matrix.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0043276,,,,,,,,,,,,,,,,,,,,,,anoikis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000125,leptin receptor,OB-R,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003331,,,,,OB-R,,,,,IMR:0000125,,,,,,,,,,,,,,,,,,,,,,leptin receptor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001213,DLC1,dynein light chain 1|DLC8a|PIN|protein inhibitor of neuronal nitric oxide synthase,,false,,,http://purl.obolibrary.org/obo/IMR_0000200,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,dynein light chain 1|DLC8a|PIN|protein inhibitor of neuronal nitric oxide synthase,,,,,IMR:0001213,,,,,,,,,,,,,,,,,,,,,,DLC1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002216,NRF2 activation [Glutathione depletion],,"A process that changes the activity of the NRF2 to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0000889|http://purl.obolibrary.org/obo/TXPO_0001283,,,,,,,,,,,,,,,,,,,,,,"A process that changes the activity of the NRF2 to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002366,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000904|http://purl.obolibrary.org/obo/TXPO_0002254,,,,,,,,,,,TXPO:0002216,,,,,,,,,,,,,,,,,,,,,,NRF2 activation [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002215,phospholipidosis (toxic course),,The totality of all processes through which the phospholipidosis is realized.,false,,,http://purl.obolibrary.org/obo/TXPO_0003382,,,,,,,,,,,,,,,,,,,,http://purl.bioontology.org/ontology/MEDDRA/10074564|PMID:16979167|PMID:22960355|PMID:15342952,,The totality of all processes through which the phospholipidosis is realized.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001551|http://purl.obolibrary.org/obo/TXPO_0000910|http://purl.obolibrary.org/obo/TXPO_0000930|http://purl.obolibrary.org/obo/TXPO_0000907|http://purl.obolibrary.org/obo/TXPO_0000905|http://purl.obolibrary.org/obo/TXPO_0004117|http://purl.obolibrary.org/obo/TXPO_0000925|http://purl.obolibrary.org/obo/TXPO_0002324,,,,,,,,,,,,,,,,,,TXPO:0002215,,,,,,,,,,,,,,,,,,,,,,phospholipidosis (toxic course),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002213,Dissociation of PERK:BIP Heterodimer [ER stress],,"Dissociation of PERK:BIP heterodimer is a subtype of detaching: A process that disaggregates PERK-BIP heterodimers into BIP and PERK.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.|PERK (EIF2AK3) is a single-pass transmembrane protein located in the Endoplasmic Reticulum (ER) membrane. PERK has an N-terminal luminal domain and a C-terminal cytosolic domain. It is maintained in an inactive state by association of its luminal domain with BiP, a chaperone in the ER. Because BiP also binds unfolded proteins, BiP dissociates from PERK when unfolded proteins exceed chaperone activity in the ER.",false,,,http://purl.obolibrary.org/obo/TXPO_0003736|http://purl.obolibrary.org/obo/TXPO_0000505,,,,,,,,,,,,,,,,,,,,PMID:10854322|Reactome PathwayStep4038|http://www.reactome.org/PathwayBrowser/#/R-HSA-381119&SEL=R-HSA-381086&PATH=R-HSA-392499|PMID:11907036|Reactome:R-HSA-381086,,"Dissociation of PERK:BIP heterodimer is a subtype of detaching: A process that disaggregates PERK-BIP heterodimers into BIP and PERK.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003157|http://purl.obolibrary.org/obo/TXPO_0000878,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000713,,,,,,,,,,,TXPO:0002213,,,,,,,,,,,,,,,,,,,,"PERK (EIF2AK3) is a single-pass transmembrane protein located in the Endoplasmic Reticulum (ER) membrane. PERK has an N-terminal luminal domain and a C-terminal cytosolic domain. It is maintained in an inactive state by association of its luminal domain with BiP, a chaperone in the ER. Because BiP also binds unfolded proteins, BiP dissociates from PERK when unfolded proteins exceed chaperone activity in the ER.",,Dissociation of PERK:BIP Heterodimer [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002210,increasing demand for protein refolding [ER stress],,"Increasing demand for protein refolding is a subtype of increasing functional demand: A process that changes the functional demand for protein refolding to be higher.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/TXPO_0002211,,,,,,,,,,,,,,,,,,,,,,"Increasing demand for protein refolding is a subtype of increasing functional demand: A process that changes the functional demand for protein refolding to be higher.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002458,,,,,,,,,,,TXPO:0002210,,,,,,,,,,,,,,,,,,,,,,increasing demand for protein refolding [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005783,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002219,hypofunction of phospholipase gene expression [Phospholipidosis (severe) ],,"Hypofunction of phospholipase gene expression is a subtype of hypofunction of phospholipase gene expression: A process that performs a decreased or insufficient phospholipase gene expression. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0002295,,,,,,,,,,,,,,,,,,,,,,"Hypofunction of phospholipase gene expression is a subtype of hypofunction of phospholipase gene expression: A process that performs a decreased or insufficient phospholipase gene expression. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001448,,,,,,,,,,,TXPO:0002219,,,,,,,,,,,,,,,,,,,,,,hypofunction of phospholipase gene expression [Phospholipidosis (severe) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002211,increasing demand for protein refolding,,Increasing demand for protein refolding is a subtype of increasing functional demand: A process that changes the functional demand for protein refolding to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000633,,,,,,,,,,,,,,,,,,,,,,Increasing demand for protein refolding is a subtype of increasing functional demand: A process that changes the functional demand for protein refolding to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002211,,,,,,,,,,,,,,,,,,,,,,increasing demand for protein refolding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002212,accumulation of compound in ER,,Accumulation of compound in ER is a subtype of accumulation of xenobiotics: A process that keeps compound in the ER (endoplasmic reticulum).,false,,,http://purl.obolibrary.org/obo/TXPO_0000169,,,,,,,,,,,,,,,,,,,,,,Accumulation of compound in ER is a subtype of accumulation of xenobiotics: A process that keeps compound in the ER (endoplasmic reticulum).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_24431,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002212,,,,,,,,,,,,,,,,,,,,,,accumulation of compound in ER,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002217,negative regulation of phospholipid degradation [Phospholipidosis (severe) ],,"A process that stops, prevents, or reduces the frequency, rate or extent of phospholipid degradation severely. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",false,,,http://purl.obolibrary.org/obo/TXPO_0000905,,,,,,,,,,,,,,,,,,,,,,"A process that stops, prevents, or reduces the frequency, rate or extent of phospholipid degradation severely. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000497,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004032|http://purl.obolibrary.org/obo/TXPO_0002098,,,,,,,,,,,TXPO:0002217,,,,,,,,,,,,,,,,,,,,,,negative regulation of phospholipid degradation [Phospholipidosis (severe) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002214,CAD accumulation in lysosome [Phospholipidosis (moderate) ],,"CAD accumulation in lysosome is a subtype of compound accumulation in lysosome: A process that keeps CAD (Cationic Amphiphilic Drugs cationic amphiphile drug) in the lysosome. And the degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (moderate).",false,,,http://purl.obolibrary.org/obo/TXPO_0003367,,,,,,,,,,,,,,,,,,,,,,"CAD accumulation in lysosome is a subtype of compound accumulation in lysosome: A process that keeps CAD (Cationic Amphiphilic Drugs cationic amphiphile drug) in the lysosome. And the degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (moderate).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001560|http://purl.obolibrary.org/obo/TXPO_0000081,,,,,,http://purl.obolibrary.org/obo/TXPO_0003442|http://purl.obolibrary.org/obo/TXPO_0001260,,,,,,,,,,,TXPO:0002214,,,,,,,,,,,,,,,,,,,,,,CAD accumulation in lysosome [Phospholipidosis (moderate) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005764,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002218,negative regulation of phospholipase transcription,,"Negative regulation of phospholipase transcription is a subtype of negative regulation of transcription, DNA-templated: A process that stops, prevents, or reduces the frequency, rate or extent of phospholipase transcription.",false,,,http://purl.obolibrary.org/obo/GO_0045892,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of phospholipase transcription is a subtype of negative regulation of transcription, DNA-templated: A process that stops, prevents, or reduces the frequency, rate or extent of phospholipase transcription.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002218,,,,,,,,,,,,,,,,,,,,,,negative regulation of phospholipase transcription,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100850,PKA type II beta regulatory subunit,cAMP-dependent protein kinase type II-beta regulatory chain,,false,,,http://purl.obolibrary.org/obo/IMR_0100702,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,cAMP-dependent protein kinase type II-beta regulatory chain,,,,,IMR:0100850,,,,,,,,,,,,,,,,,,,,,,PKA type II beta regulatory subunit,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_2000009606,gene of Homo sapiens,,A gene of an organism of Homo sapiens,false,,,http://purl.obolibrary.org/obo/OGG_2000002759,,,,,,,,,,,,,,,,,,,,,,A gene of an organism of Homo sapiens,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,OGG:2000009606,,,,,,,,,,,,,,,,,,,,,,gene of Homo sapiens,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCBITaxon_9606,,,,,,,,,,,,,,,,,,,9606,,,,,,,,,,,,,,,,,,,,,"Yue Liu, Bin Zhao, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0003912,EGFR (canonical)[Ground glass appearance],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000472|http://purl.obolibrary.org/obo/IMR_0000081,,,,,,,,,,,,,,,,,,,,"NCBI-Rat-GeneID:24329|The protein encoded by this gene is a transmembrane glycoprotein that is a member of the protein kinase superfamily. This protein is a receptor for members of the epidermal growth factor family. EGFR is a cell surface protein that binds to epidermal growth factor. Binding of the protein to a ligand induces receptor dimerization and tyrosine autophosphorylation and leads to cell proliferation. Mutations in this gene are associated with lung cancer. [provided by RefSeq, Jun 2016]|NCBI-Human-GeneID:1956|NCBI-Mouse-GeneID:13649|https://www.ncbi.nlm.nih.gov/gene?cmd=retrieve&dopt=default&rn=1&list_uids=1956",,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000081,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003912,,,,,,,,,,,,,,,,,,,,,,EGFR (canonical)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003919,hypofunction of gluconeogenesis [Ground glass appearance],,"Hypofunction of gluconeogenesis is a subtype of hypofunction of biosynthesis: A process that performs a decreased or insufficient gluconeogenesis.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/TXPO_0003920,,,,,,,,,,,,,,,,,,,,,,"Hypofunction of gluconeogenesis is a subtype of hypofunction of biosynthesis: A process that performs a decreased or insufficient gluconeogenesis.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003926,,,,,,,,,,,TXPO:0003919,,,,,,,,,,,,,,,,,,,,,,hypofunction of gluconeogenesis [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003913,EGFR - inactivation (canonical)[Ground glass appearance],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003912,,,,,,,,,,,,,,,,,,,,"The protein encoded by this gene is a transmembrane glycoprotein that is a member of the protein kinase superfamily. This protein is a receptor for members of the epidermal growth factor family. EGFR is a cell surface protein that binds to epidermal growth factor. Binding of the protein to a ligand induces receptor dimerization and tyrosine autophosphorylation and leads to cell proliferation. Mutations in this gene are associated with lung cancer. [provided by RefSeq, Jun 2016]|https://www.ncbi.nlm.nih.gov/gene?cmd=retrieve&dopt=default&rn=1&list_uids=1956",,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000081,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0002355,,,,,,,,,,,,,,TXPO:0003913,,,,,,,,,,,,,,,,,,,,,,EGFR - inactivation (canonical)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003918,Translocation of CAR from the cytosol to the nucleus [Ground glass appearance],,"Translocation of CAR from the cytosol to the nucleus is a subtype of nuclear transport: A process that of the directed movement of CAR from the cytoplasm to the nucleus.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/TXPO_0003917,,,,,,,,,,,,,,,,,,,,,,"Translocation of CAR from the cytosol to the nucleus is a subtype of nuclear transport: A process that of the directed movement of CAR from the cytoplasm to the nucleus.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000967,,,,,,,,,,,TXPO:0003918,,,,,,,,,,,,,,,,,,,,,,Translocation of CAR from the cytosol to the nucleus [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003916,DAB2(mouse)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003278|http://purl.obolibrary.org/obo/TXPO_0003841,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:13132|PMID:25331956|PMID:23781020|PMID:11387212|PMID:27398911,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001601,,,,,,,,,,,,,TXPO:0003916,,,,,,,PMID:19000037,,,,,,,,,,,,,,,DAB2(mouse)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003915,ALAS1(predicted)(human)[lipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001786|http://purl.obolibrary.org/obo/TXPO_1000034,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:211|PMID:19710929,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000000211,,,,,,,,,,,,,TXPO:0003915,,,,,,,This gene encodes the mitochondrial enzyme which is catalyzes the rate-limiting step in heme (iron-protoporphyrin) biosynthesis.,,,,,,,,,,,,,,,ALAS1(predicted)(human)[lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003914,DAB2(human)[Phospholipidosis - apotosis inhibitor],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003900,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1601|PMID:25331956|PMID:23781020|PMID:11387212|PMID:27398911,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001601,,,http://purl.obolibrary.org/obo/CHEBI_68495,,,,,,,,,,TXPO:0003914,,,,,,,PMID:19000037,,,,,,,,,,,,,,,DAB2(human)[Phospholipidosis - apotosis inhibitor],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003911,EGFR pathway negative regulator role,,A role of the entity which negatively regulates the EGFR signaling pathway.,false,,,http://purl.obolibrary.org/obo/CHEBI_76932,,,,,,,,,,,,,,,,,,,,,,A role of the entity which negatively regulates the EGFR signaling pathway.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003911,,,,,,,,,,,,,,,,,,,,,,EGFR pathway negative regulator role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003910,CITCO [Ground glass appearance],"6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime [Ground glass appearance]",,false,,,http://purl.obolibrary.org/obo/TXPO_1000069|http://purl.obolibrary.org/obo/TXPO_0000560,,,,,,,,,,,,,,,,,,,,PMID:12611900,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime [Ground glass appearance]",,,,,TXPO:0003910,,,,,,,,,,,,,,,,,,,,,,CITCO [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003917,Translocation of CAR from the cytosol to the nucleus,,Translocation of CAR from the cytosol to the nucleus is a subtype of nuclear transport: A process that of the directed movement of CAR from the cytoplasm to the nucleus.,false,,,http://purl.obolibrary.org/obo/GO_0051169,,,,,,,,,,,,,,,,,,,,,,Translocation of CAR from the cytosol to the nucleus is a subtype of nuclear transport: A process that of the directed movement of CAR from the cytoplasm to the nucleus.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005634,http://purl.obolibrary.org/obo/GO_0005829,,,,,,,TXPO:0003917,,,,,,,,,,,,,,,,,,,,,,Translocation of CAR from the cytosol to the nucleus,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000001340,COX6B1,,Other designations: COX VIb-1|cytochrome c oxidase subunit 6B1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,COX6B|COXVIb1|COXG,,,,,,,,,,,,19,,,,,,HGNC:2280|Ensembl:ENSG00000126267|MIM:124089|HPRD:00493|Vega:OTTHUMG00000048112,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,cytochrome c oxidase subunit VIb polypeptide 1 (ubiquitous),,,19q13.1,,,,,,,,,,,,,,,,"GO_0004129 (EC: NAS, PMID: 2172092); GO_0005739 (EC: IDA); GO_0005743 (EC: TAS); GO_0005758 (EC: IEA); GO_0021762 (EC: IEP); GO_0022904 (EC: TAS); GO_0044237 (EC: TAS); GO_0044281 (EC: TAS); GO_1902600 (EC: NAS, PMID: 2172092)",,,,,,,,,PMID: 1647217; 1650756; 1651883; 2172092; 2537962; 7821789; 11943455; 12477932; 15057824; 15489334; 17353931; 17500595; 17516841; 18029348; 18499082; 19843159; 20877624; 21139048; 21890473; 21906983; 21963094; 22190034; 22419111; 22505724; 22939629; 23000965,,,,,,,,,,,,,,,OGG:3000001340,,,,,,,cytochrome c oxidase subunit VIb polypeptide 1 (ubiquitous),,,,,,,,,,,,,Other designations: COX VIb-1|cytochrome c oxidase subunit 6B1,,COX6B1,,,,,,,,,,,,,,,,,,,,,,,1340,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,COX6B1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_15422,ATP,adenosine triphosphate|adenosine 5'-triphosphate,An adenosine 5'-phosphate in which the 5'-phosphate is a triphosphate group. It is involved in the transportation of chemical energy during metabolic pathways.,false,,,http://purl.obolibrary.org/obo/CHEBI_36976,,,,,,,,,,,,,,,,,,,,CAS:56-65-5|DrugBank:DB00171,,An adenosine 5'-phosphate in which the 5'-phosphate is a triphosphate group. It is involved in the transportation of chemical energy during metabolic pathways.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_25512,,,,,adenosine triphosphate|adenosine 5'-triphosphate,,,,,CHEBI:15422,,,,,,,,,,,,,,,,,,,,,,ATP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0055085,transmembrane transport,membrane transport,"The process in which a solute is transported across a lipid bilayer, from one side of a membrane to the other.|Transmembrane transport requires transport of a solute across a lipid bilayer. Note that transport through the nuclear pore complex is not transmembrane because the nuclear membrane is a double membrane and is not traversed. For transport through the nuclear pore, consider instead the term 'nucleocytoplasmic transport ; GO:0006913' and its children. Note also that this term is not intended for use in annotating lateral movement within membranes.",false,,,http://purl.obolibrary.org/obo/GO_0006810,,,,,,,,,,,,,,,,,,,,,,"The process in which a solute is transported across a lipid bilayer, from one side of a membrane to the other.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,membrane transport,,,,,GO:0055085,,,,,,,,,,,,,,,,,,,,"Transmembrane transport requires transport of a solute across a lipid bilayer. Note that transport through the nuclear pore complex is not transmembrane because the nuclear membrane is a double membrane and is not traversed. For transport through the nuclear pore, consider instead the term 'nucleocytoplasmic transport ; GO:0006913' and its children. Note also that this term is not intended for use in annotating lateral movement within membranes.",,transmembrane transport,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000895,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000397,ets,E26 transformation-specific,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,IPR:000418,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,E26 transformation-specific,,,,,IMR:0000397,,,,,,,,,,,,,,,,,,,,,,ets,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000636,Integrin alpha-E,,,false,,,http://purl.obolibrary.org/obo/IMR_0000173,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000636,,,,,,,,,,,,,,,,,,,,,,Integrin alpha-E,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000827,negative regulation of phospholipase A2 mediated phospholipid degradation,,"Negative regulation of phospholipase A2 mediated phospholipid degradation is a subtype of negative regulation of phospholipid degradation: A process that stops, prevents, or reduces the frequency, rate or extent of phospholipase A2 mediated phospholipid degradation.",false,,,http://purl.obolibrary.org/obo/TXPO_0001256,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of phospholipase A2 mediated phospholipid degradation is a subtype of negative regulation of phospholipid degradation: A process that stops, prevents, or reduces the frequency, rate or extent of phospholipase A2 mediated phospholipid degradation.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000827,,,,,,,,,,,,,,,,,,,,,,negative regulation of phospholipase A2 mediated phospholipid degradation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000822,decreasing amount of xenobiotics,,Decreasing amount of xenobiotics is a subtype of decreasing quantity: A process that changes the quantity of xenobiotics  to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000396,,,,,,,,,,,,,,,,,,,,,,Decreasing amount of xenobiotics is a subtype of decreasing quantity: A process that changes the quantity of xenobiotics  to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006805,,,,,,,,,,,,,,,,,,TXPO:0000822,,,,,,,,,,,,,,,,,,,,,,decreasing amount of xenobiotics,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000828,HSP90B1 - chaperone -vitro (human)[ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000802,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000828,,,,,,,,,,,,,,,,,,,,,,HSP90B1 - chaperone -vitro (human)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000795,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000823,transmembrane receptor protein tyrosine kinase,transmembrane receptor tyrosine kinase,A role of combining with a signal and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity by catalysis of the reaction: ATP + a protein-L-tyrosine = ADP + a protein-L-tyrosine phosphate.|related molecular function GO:0004714,false,,,http://purl.obolibrary.org/obo/TXPO_0002292,,,,,,,,,,,,,,,,,,,,EC:2.7.10.1,,A role of combining with a signal and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity by catalysis of the reaction: ATP + a protein-L-tyrosine = ADP + a protein-L-tyrosine phosphate.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,transmembrane receptor tyrosine kinase,,,,,TXPO:0000823,,,,,,,,,,,,,,,,,,,,related molecular function GO:0004714,,transmembrane receptor protein tyrosine kinase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000821,lysosome homeostasis [Phospholipidosis],,"Lysosome homeostasis is a subtype of homeostatic process: A process that that preserves a lysosome in a stable functional or structural state.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000470|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Lysosome homeostasis is a subtype of homeostatic process: A process that that preserves a lysosome in a stable functional or structural state.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000821,,,,,,,,,,,,,,,,,,,,,,lysosome homeostasis [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000829,P-EIF2A (canonical)[ER stress],phosphorylated eIF2A [ER stress],,false,,,http://purl.obolibrary.org/obo/TXPO_0001275,,,,,,,,,,,,,,,,,,,,http://www.ncbi.nlm.nih.gov/gene/83939,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001909,,,,,phosphorylated eIF2A [ER stress],,,,,TXPO:0000829,,,,,,,,,,,,,,,,,,,,,,P-EIF2A (canonical)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000820,membrane protein production,,"Membrane protein production is a subtype of protein production: A process that makes existent of a membrane protein due to biosynthesis, secretion, or membrane trafficking, resulting in an increase in its levels.",false,,,http://purl.obolibrary.org/obo/TXPO_0000382,,,,,,,,,,,,,,,,,,,,,,"Membrane protein production is a subtype of protein production: A process that makes existent of a membrane protein due to biosynthesis, secretion, or membrane trafficking, resulting in an increase in its levels.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000820,,,,,,,,,,,,,,,,,,,,,,membrane protein production,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000824,IRE - stress sensor (canonical)[ER stress -Refolding],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002602,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000881,,,,,,,,,,TXPO:0000824,,,,,,,,,,,,,,,,,,,,,,IRE - stress sensor (canonical)[ER stress -Refolding],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002957,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000825,functional attribute,,A physical attribute inhering in a bearer by virtue of the bearer's function.,false,,,http://purl.obolibrary.org/obo/TXPO_0000305,,,,,,,,,,,,,,,,,,,,,,A physical attribute inhering in a bearer by virtue of the bearer's function.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000825,,,,,,,,,,,,,,,,,,,,,,functional attribute,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000379,STAT5a,signal transducer and activator of transcription 5a,,false,,,http://purl.obolibrary.org/obo/IMR_0100733,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,signal transducer and activator of transcription 5a,,,,,IMR:0000379,,,,,,,,,,,,,,,,,,,,,,STAT5a,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002752,dephosphorylation of eIF2a [ER stress],,"The process of removing one or more phosphoric (ester or anhydride) residues from the eIF2a.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0003736|http://purl.obolibrary.org/obo/GO_0016311,,,,,,,,,,,,,,,,,,,,,,"The process of removing one or more phosphoric (ester or anhydride) residues from the eIF2a.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002935,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002931,,,,http://purl.obolibrary.org/obo/TXPO_0002932,,,,,,,,,,,,,,,,,,,TXPO:0002752,,,,,,,,,,,,,,,,,,,,,,dephosphorylation of eIF2a [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002751,enabling translation [ER stress],,"Enabling translation is a subtype of enabling: A process that sets conditions for translation to work correctly.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.|This entity refers to the process of restarting translation.
During protein refolding, it is known that a translation attenuation is occurred temporarily to reduce the production of new proteins.",false,,,http://purl.obolibrary.org/obo/TXPO_0002617|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"Enabling translation is a subtype of enabling: A process that sets conditions for translation to work correctly.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002752|http://purl.obolibrary.org/obo/TXPO_0003054,,http://purl.obolibrary.org/obo/TXPO_0003058,,,,,http://purl.obolibrary.org/obo/TXPO_0002716,,,,,,,,,,,TXPO:0002751,,,,,,,,,,,,,,,,,,,,"This entity refers to the process of restarting translation.
During protein refolding, it is known that a translation attenuation is occurred temporarily to reduce the production of new proteins.",,enabling translation [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002758,degradation of I-kappaB,,Degradation of I-kappaB is a subtype of protein catabolic process: A process of the chemical reactions resulting in the breakdown of inhibitor of kappa B (I-kappaB) protein,false,,,http://purl.obolibrary.org/obo/GO_0030163,,,,,,,,,,,,,,,,,,,,,,Degradation of I-kappaB is a subtype of protein catabolic process: A process of the chemical reactions resulting in the breakdown of inhibitor of kappa B (I-kappaB) protein,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002758,,,,,,,,,,,,,,,,,,,,,,degradation of I-kappaB,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002757,positive regulation of uORF dependent gene expression [eIF2a [translation regulation],,"Positive regulation of uORF dependent gene expression is a subtype of positive regulation of gene expression: A process that modulates the frequency, rate or extent of uORF dependent gene expression.
This entity is a specific eIF2a translational system depedent.",false,,,http://purl.obolibrary.org/obo/TXPO_0002756,,,,,,,,,,,,,,,,,,,,,,"Positive regulation of uORF dependent gene expression is a subtype of positive regulation of gene expression: A process that modulates the frequency, rate or extent of uORF dependent gene expression.
This entity is a specific eIF2a translational system depedent.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002757,,,,,,,,,,,,,,,,,,,,,,positive regulation of uORF dependent gene expression [eIF2a [translation regulation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002759,Bile acid accumulation in hepatocyte [Glutathione depletion],,"Bile acid accumulation in hepatocyte is a subtype of accumulation of substances in a biological object: A process that keeps bile acid within the hepatocute in the liver (intrahepatic).
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0000889|http://purl.obolibrary.org/obo/TXPO_0000263,,,,,,,,,,,,,,,,,,,,,,"Bile acid accumulation in hepatocyte is a subtype of accumulation of substances in a biological object: A process that keeps bile acid within the hepatocute in the liver (intrahepatic).
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002734,,,,,,,,,,,TXPO:0002759,,,,,,,,,,,,,,,,,,,,,,Bile acid accumulation in hepatocyte [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002755,regulation of translation by eIF2a [ER stress],,"Regulation of translation by eIF2a is a subtype of regulation of translation: A process that modulates the frequency, rate or extent of eIF2 alpha mediated translation.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002874,,,,,,,,,,,,,,,,,,,,,,"Regulation of translation by eIF2a is a subtype of regulation of translation: A process that modulates the frequency, rate or extent of eIF2 alpha mediated translation.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001275,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002755,,,,,,,,,,,,,,,,,,,,,,regulation of translation by eIF2a [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002754,eIF2a gene regulation pathway,,eIF2a gene regulation pathway is a subtype of gene regulation pathway: Sequence of reactions to regulate translation of genes by eIF2a.,false,,,http://purl.obolibrary.org/obo/TXPO_0001902,,,,,,,,,,,,,,,,,,,,,,eIF2a gene regulation pathway is a subtype of gene regulation pathway: Sequence of reactions to regulate translation of genes by eIF2a.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002757|http://purl.obolibrary.org/obo/TXPO_0002755,,,,,,,,,,,,,,,,,,TXPO:0002754,,,,,,,,,,,,,,,,,,,,,,eIF2a gene regulation pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002750,PERK activation [ER stress - antioxidation],,"PERK activation is a subtype of Molecular activation: A process that changes the activity of PERK to be higher.
This process is dependent on the antioxidation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000402,,,,,,,,,,,,,,,,,,,,,,"PERK activation is a subtype of Molecular activation: A process that changes the activity of PERK to be higher.
This process is dependent on the antioxidation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002739,,,,,,,,,,,TXPO:0002750,,,,,,,,,,,,,,,,,,,,,,PERK activation [ER stress - antioxidation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002756,positive regulation of uORF dependent gene expression,,"Positive regulation of uORF dependent gene expression is a subtype of positive regulation of gene expression: A process that modulates the frequency, rate or extent of uORF dependent gene expression.",false,,,http://purl.obolibrary.org/obo/GO_0010628,,,,,,,,,,,,,,,,,,,,,,"Positive regulation of uORF dependent gene expression is a subtype of positive regulation of gene expression: A process that modulates the frequency, rate or extent of uORF dependent gene expression.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002756,,,,,,,,,,,,,,,,,,,,,,positive regulation of uORF dependent gene expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002753,gene expression patheway dependent molecule,,"Gene expression patheway dependent molecule is a subtype of system dependeny functional molecule.
This entity is dependent on a gene expresion system for functioning.",false,,,http://purl.obolibrary.org/obo/TXPO_0001820,,,,,,,,,,,,,,,,,,,,,,"Gene expression patheway dependent molecule is a subtype of system dependeny functional molecule.
This entity is dependent on a gene expresion system for functioning.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002753,,,,,,,,,,,,,,,,,,,,,,gene expression patheway dependent molecule,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001611,Rab26,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001611,,,,,,,,,,,,,,,,,,,,,,Rab26,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006629,lipid metabolic process,lipid metabolism,"The chemical reactions and pathways involving lipids, compounds soluble in an organic solvent but not, or sparingly, in an aqueous solvent. Includes fatty acids; neutral fats, other fatty-acid esters, and soaps; long-chain (fatty) alcohols and waxes; sphingoids and other long-chain bases; glycolipids, phospholipids and sphingolipids; and carotenes, polyprenols, sterols, terpenes and other isoprenoids.",false,,,http://purl.obolibrary.org/obo/GO_0008152,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways involving lipids, compounds soluble in an organic solvent but not, or sparingly, in an aqueous solvent. Includes fatty acids; neutral fats, other fatty-acid esters, and soaps; long-chain (fatty) alcohols and waxes; sphingoids and other long-chain bases; glycolipids, phospholipids and sphingolipids; and carotenes, polyprenols, sterols, terpenes and other isoprenoids.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0008610|http://purl.obolibrary.org/obo/GO_0016042,,,,,,,,,,,,,lipid metabolism,,,,,GO:0006629,,,,,,,,,,,,,,,,,,,,,,lipid metabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001021,"cAMP-specific 3',5'-cyclic phosphodiesterase 7B",,,false,,,http://purl.obolibrary.org/obo/IMR_0100700,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001021,,,,,,,,,,,,,,,,,,,,,,"cAMP-specific 3',5'-cyclic phosphodiesterase 7B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001577,Rab7,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001577,,,,,,,,,,,,,,,,,,,,,,Rab7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/BFO_0000031,generically dependent continuant,,b is a generically dependent continuant = Def. b is a continuant that g-depends_on one or more other entities. (axiom label in BFO2 Reference: [074-001]),false,,,http://purl.obolibrary.org/obo/BFO_0000002,,,,,,,,,,,,,,,,,,,,,,b is a generically dependent continuant = Def. b is a continuant that g-depends_on one or more other entities. (axiom label in BFO2 Reference: [074-001]),,,,,,,"the pdf file on your laptop, the pdf file that is a copy thereof on my laptop|the sequence of this protein molecule; the sequence that is a copy thereof in that protein molecule.|The entries in your database are patterns instantiated as quality instances in your hard drive. The database itself is an aggregate of such patterns. When you create the database you create a particular instance of the generically dependent continuant type database. Each entry in the database is an instance of the generically dependent continuant type IAO: information content entity.",,,,,,,,,,,(iff (GenericallyDependentContinuant a) (and (Continuant a) (exists (b t) (genericallyDependsOnAt a b t)))) // axiom label in BFO2 CLIF: [074-001],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BFO:0000031,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/bfo.owl,generically dependent continuant,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0011149,eIF3c,Nuclear transport protein NIP1|eIF3 p110|Eukaryotic translation initiation factor 3 93 kDa subunit|eIF3 p93|Eukaryotic translation initiation factor 3 subunit 8,,false,,,http://purl.obolibrary.org/obo/IMR_0000916,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Nuclear transport protein NIP1|eIF3 p110|Eukaryotic translation initiation factor 3 93 kDa subunit|eIF3 p93|Eukaryotic translation initiation factor 3 subunit 8,,,,,IMR:0011149,,,,,,,,,,,,,,,,,,,,,,eIF3c,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003029,GSK2606414 [ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000172|http://purl.obolibrary.org/obo/TXPO_0003012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000876,,,,,,,,,,TXPO:0003029,,,,,,,,,,,,,,,,,,,,,,GSK2606414 [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003028,STF-083010 [ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003012|http://purl.obolibrary.org/obo/TXPO_1000354,,,,,,,,,,,,,,,,,,,,PMID:29438776|PMID:30538632|PMID:29457838,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003028,,,,,,,,,,,,,,,,,,,,,,STF-083010 [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003022,PPARA - inactivated (canonical)[lipidosis],Peroxisome Proliferator-Activated Receptor Alpha - inactivated[lipidosis],,false,,,http://purl.obolibrary.org/obo/TXPO_0001632,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:19013|NCBI-Rat-GeneID:25747|NCBI-Human-GeneID:5465,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Peroxisome Proliferator-Activated Receptor Alpha - inactivated[lipidosis],,,,,TXPO:0003022,,,,,,,,,,,,,,,,,,,,,,PPARA - inactivated (canonical)[lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003026,intrinsic apotosis signaling (primitive),,"Intrinsic apoptosis signaling (primitive) is a subtype of signaling [biological]: A process in which an intracellular signal is conveyed to trigger the apoptotic death of a cell. The process starts with reception of an intracellular signal (e.g. DNA damage, endoplasmic reticulum stress, oxidative stress etc.).
This process is crucially regulated by permeabilization of the mitochondrial outer membrane (MOMP).
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0001727|http://purl.obolibrary.org/obo/TXPO_0003237,,,,,,,,,,,,,,,,,,,,Reactome:R-HSA-109606.3,,"Intrinsic apoptosis signaling (primitive) is a subtype of signaling [biological]: A process in which an intracellular signal is conveyed to trigger the apoptotic death of a cell. The process starts with reception of an intracellular signal (e.g. DNA damage, endoplasmic reticulum stress, oxidative stress etc.).
This process is crucially regulated by permeabilization of the mitochondrial outer membrane (MOMP).
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003111,,,,,http://purl.obolibrary.org/obo/TXPO_0003737,,,,,,,,,,,TXPO:0003026,,,,,,,,,,,,,,,,,,,,,,intrinsic apotosis signaling (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003025,sorafenib [ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003012|http://purl.obolibrary.org/obo/CHEBI_50924,,,,,,,,,,,,,,,,,,,,PMID:25501753|PMID:25901709|PMID:26546044,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003025,,,,,,,,,,,,,,,,,,,,,,sorafenib [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003024,atazanavir [ER stress],,,false,,,http://purl.obolibrary.org/obo/CHEBI_37924|http://purl.obolibrary.org/obo/TXPO_0003012,,,,,,,,,,,,,,,,,,,,PMID:23973637|PMID:18006837,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003024,,,,,,,,,,,,,,,,,,,,,,atazanavir [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003027,resveratrol [ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003012|http://purl.obolibrary.org/obo/CHEBI_27881,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003027,,,,,,,,,,,,,,,,,,,,,,resveratrol [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003020,MG-132 [ER stress],,,false,,,http://purl.obolibrary.org/obo/CHEBI_75142|http://purl.obolibrary.org/obo/TXPO_0003012,,,,,,,,,,,,,,,,,,,,PMID:19520899,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001147,,,,,,,,,,TXPO:0003020,,,,,,,,,,,,,,,,,,,,,,MG-132 [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003021,bortezomib [ER stress],,,false,,,http://purl.obolibrary.org/obo/CHEBI_52717|http://purl.obolibrary.org/obo/TXPO_0003012,,,,,,,,,,,,,,,,,,,,PMID: 28588081|Wikipedia:Bortezomib|PMID: 23877657|PMID:29980790,,,,,,,,,,,,,,C19H25BN4O4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003021,,,,,,,,,,,,,,,,,,,,,,bortezomib [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,,,,,
http://purl.obolibrary.org/obo/TXPO_0003023,nelfinavir  [ER stress],,,false,,,http://purl.obolibrary.org/obo/CHEBI_7496|http://purl.obolibrary.org/obo/TXPO_0003012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003023,,,,,,,,,,,,,,,,,,,,,,nelfinavir  [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_30737,trichloromethyl(.),,,false,,,http://purl.obolibrary.org/obo/CHEBI_26519,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CCl3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:30737,,,,,,,,,,,,,,,,,,,,,,trichloromethyl(.),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Cl[C](Cl)Cl,,,,,
http://purl.obolibrary.org/obo/IMR_0000343,Nck,NCK adaptor protein 1|IRS-4a-P|Nck alpha|Cytoplasmic protein NCK1|SH2/SH3 adaptor protein NCK-alpha,,false,,,http://purl.obolibrary.org/obo/IMR_0000342,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0011207,NCK adaptor protein 1|IRS-4a-P|Nck alpha|Cytoplasmic protein NCK1|SH2/SH3 adaptor protein NCK-alpha,,,,,IMR:0000343,,,,,,,,,,,,,,,,,,,,,,Nck,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0007033,vacuole organization,,"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a vacuole.",false,,,http://purl.obolibrary.org/obo/GO_0071840,,,,,,,,,,,,,,,,,,,,,,"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a vacuole.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0007033,,,,,,,,,,,,,,,,,,,,,,vacuole organization,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000009768,KIAA0101,,Other designations: HCV NS5A-transactivated protein 9|PCNA-associated factor|PCNA-associated factor of 15 kDa|hepatitis C virus NS5A-transactivated protein 9|overexpressed in anaplastic thyroid carcinoma 1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,OEATC1|OEATC-1|p15(PAF)|OEATC|NS5ATP9|p15/PAF|PAF|PAF15|p15PAF,,,,,,,,,,,,15,,,,,,Ensembl:ENSG00000166803|MIM:610696|Vega:OTTHUMG00000133017|HPRD:13778|HGNC:28961,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,KIAA0101,,,15q22.31,,,,,,,,,,,,,,,,GO_0003682 (EC: IDA); GO_0005515 (EC: IPI); GO_0005634 (EC: IDA); GO_0005737 (EC: IDA); GO_0006260 (EC: IDA); GO_0006974 (EC: IDA); GO_0009411 (EC: IDA); GO_0019985 (EC: IMP); GO_0048471 (EC: IDA); GO_0051297 (EC: IMP); GO_0051726 (EC: IMP),,,,,,,,,PMID: 7788527; 11313979; 12477932; 15334068; 15489334; 15789362; 16288740; 16646990; 17207965; 17213182; 17875765; 18068894; 18727915; 18781797; 19219066; 20118010; 20639865; 20972266; 21070969; 21139048; 21263028; 21628590; 21673012; 21689861; 21890473; 21906983; 21963094; 22053931; 22096502; 22505724; 22576474; 22863883; 22939629; 23000965; 23157749; 23209346; 23240630; 23593430; 23698777; 24055345; 24145239; 24197986,,,,,,,,,,,,,,,OGG:3000009768,,20140408,protein-coding,,,,KIAA0101,,,,,,,,,,,,,Other designations: HCV NS5A-transactivated protein 9|PCNA-associated factor|PCNA-associated factor of 15 kDa|hepatitis C virus NS5A-transactivated protein 9|overexpressed in anaplastic thyroid carcinoma 1,,KIAA0101,,,,,,,,,,,,,,,,,,,,,,,9768,L5,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,KIAA0101,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_64947,anti-HIV-1 agent,anti-LAV agent|anti-HTLV-III agent|anti-HTLV-III agents|anti-LAV agents|anti-HIV-1 agents,"An anti-HIV agent that destroys or inhibits the replication of HIV-1, the more infective and more virulent of the two types of HIV virus.",false,,,http://purl.obolibrary.org/obo/CHEBI_64946,,,,,,,,,,,,,,,,,,,,,,"An anti-HIV agent that destroys or inhibits the replication of HIV-1, the more infective and more virulent of the two types of HIV virus.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,anti-LAV agent|anti-HTLV-III agent|anti-HTLV-III agents|anti-LAV agents|anti-HIV-1 agents,,,,,,,,,,,,,,,,,,,,,CHEBI:64947,,,,anti-HIV-1 agent,,CHEBI:64947,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000010,IL-6 (mol),interleukin-6,,false,,,http://purl.obolibrary.org/obo/IMR_0000007,,,,,,,,,,,,,,,,,,,,GO:0005138,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000622,,,,,interleukin-6,,,,,IMR:0000010,,,,,,,,,,,,,,,,,,,,,,IL-6 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010252,fatty acid synthase,,A role played by the entity which catalyses the reaction: acetyl-CoA + n malonyl-CoA + 2n NADPH + 2n H+ = long-chain fatty acid + n+1 CoA + n CO2 + 2n NADP+.|related molecular function GO:0004312,false,,,http://purl.obolibrary.org/obo/TXPO_0001385,,,,,,,,,,,,,,,,,,,,EC:2.3.1.85,,A role played by the entity which catalyses the reaction: acetyl-CoA + n malonyl-CoA + 2n NADPH + 2n H+ = long-chain fatty acid + n+1 CoA + n CO2 + 2n NADP+.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0010252,,,,,,,,,,,,,,,,,,,,related molecular function GO:0004312,,fatty acid synthase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001029,"Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase gamma-subunit",GMP-PDE gamma,,false,,,http://purl.obolibrary.org/obo/IMR_0100002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GMP-PDE gamma,,,,,IMR:0001029,,,,,,,,,,,,,,,,,,,,,,"Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase gamma-subunit",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000011124,FAF1,,Other designations: FAS-associated factor 1|TNFRSF6-associated factor 1|UBX domain protein 3A|UBX domain-containing protein 12|UBX domain-containing protein 3A,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,UBXD12|hFAF1|HFAF1s|UBXN3A,,,,,,,,,,,,1,,,,,,HPRD:05124|Ensembl:ENSG00000185104|HGNC:3578|MIM:604460,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,Fas (TNFRSF6) associated factor 1,,,1p33,,,,,,,,,,,,,,,,"GO_0005515 (EC: IPI, PMID: 15688372); GO_0005634 (EC: IDA, PMID: 15596450); GO_0005635 (EC: IEA); GO_0005829 (EC: IDA, PMID: 15596450); GO_0006915 (EC: IEA); GO_0007253 (EC: IMP, PMID: 14600157); GO_0008219 (EC: IMP, PMID: 15743842); GO_0019887 (EC: NAS, PMID: 11713579); GO_0019901 (EC: IDA, PMID: 11713579); GO_0019904 (EC: IEA); GO_0030155 (EC: IEA); GO_0031072 (EC: IDA, PMID: 15596450); GO_0031265 (EC: NAS, PMID: 12702723); GO_0031334 (EC: IMP, PMID: 15688372); GO_0031625 (EC: IDA, PMID: 18775313); GO_0034098 (EC: IDA, PMID: 18775313); GO_0042176 (EC: IMP, PMID: 15743842); GO_0043065 (EC: NAS, PMID: 10462485); GO_0043130 (EC: IDA, PMID: 18775313); GO_0043161 (EC: NAS, PMID: 15743842); GO_0045859 (EC: NAS, PMID: 11713579); GO_0048471 (EC: IDA, PMID: 11713579); GO_0051059 (EC: IPI, PMID: 14600157); GO_1902043 (EC: IEA)",,,,,,,,,PMID: 8524870; 9740801; 10094392; 10462485; 10810093; 11243799; 11378439; 11527403; 11713579; 12087183; 12372427; 12477932; 12702723; 12832043; 12963981; 14600157; 14702039; 15207703; 15231748; 15489334; 15592455; 15596450; 15688372; 15743842; 16169070; 16807242; 17046979; 17684021; 17999750; 18573343; 18775313; 18790738; 19013454; 19174780; 19422935; 19471022; 19615732; 19722279; 19913121; 20057067; 20124726; 20195546; 20237496; 20379614; 20628086; 20639865; 20886065; 21076409; 21139048; 21282461; 21295280; 21411632; 21414298; 21645854; 21849551; 21890473; 21900206; 21906983; 21914798; 21963094; 21978668; 21987572; 22053931; 22064162; 22102026; 22350894; 22505724; 22730322; 22863883; 22876279; 22939629; 23000965; 23293021; 23314748; 23383273; 23720822,,,,,,,,,,,,,,,OGG:3000011124,,,,,,,Fas (TNFRSF6) associated factor 1,,,,,,,,,,,,,Other designations: FAS-associated factor 1|TNFRSF6-associated factor 1|UBX domain protein 3A|UBX domain-containing protein 12|UBX domain-containing protein 3A,,FAF1,,,,,,,,,,,,,,,,,,,,,,,11124,CGI-03,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,FAF1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_90710,receptor modulator,receptor modulators,"A drug that acts as an antagonist, agonist, reverse agonist, or in some other fashion when interacting with cellular receptors.",false,,,http://purl.obolibrary.org/obo/CHEBI_23888,,,,,,,,,,,,,,,,,,,,,,"A drug that acts as an antagonist, agonist, reverse agonist, or in some other fashion when interacting with cellular receptors.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,receptor modulators,,,,,,,,,,,,,,,,,,,,,CHEBI:90710,,,,receptor modulator,,CHEBI:90710,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100558,FGF-8,Fibroblast growth factor-8|AIGF|HBGF-8,,false,,,http://purl.obolibrary.org/obo/IMR_0000049,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Fibroblast growth factor-8|AIGF|HBGF-8,,,,,IMR:0100558,,,,,,,,,,,,,,,,,,,,,,FGF-8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100592,PI3-kinase p110 subunit alpha,"Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit, alpha isoform|Phosphatidylinositol 3-kinase catalytic subunit, alpha isoform (EC 2.7.1.137) (PI3-kinase p110 subunit alpha) (PtdIns-3-kinase p110) (PI3K)|PI3K|PtdIns-3-kinase p110",,false,,,http://purl.obolibrary.org/obo/IMR_0000267,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0010389,"Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit, alpha isoform|Phosphatidylinositol 3-kinase catalytic subunit, alpha isoform (EC 2.7.1.137) (PI3-kinase p110 subunit alpha) (PtdIns-3-kinase p110) (PI3K)|PI3K|PtdIns-3-kinase p110",,,,,IMR:0100592,,,,,,,,,,,,,,,,,,,,,,PI3-kinase p110 subunit alpha,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_16755,chenodeoxycholic acid,"7alpha-hydroxylithocholic acid|chenic acid|anthropodesoxycholic acid|Chenodiol|3alpha,7alpha-Dihydroxy-5beta-cholanic acid|CDCA|anthropodeoxycholic acid|Chenix|gallodesoxycholic acid|Chenodeoxycholic acid|3alpha,7alpha-dihydroxy-5beta-cholan-24-oic acid",A dihydroxy-5beta-cholanic acid that is (5beta)-cholan-24-oic acid substituted by hydroxy groups at positions 3 and 7 respectively.|A dihydroxy-5β-cholanic acid that is (5β)-cholan-24-oic acid substituted by hydroxy groups at positions 3 and 7 respectively.,false,,,http://purl.obolibrary.org/obo/CHEBI_50860|http://purl.obolibrary.org/obo/TXPO_0000509,,,,,,,,,,,,,,,,,,,,LINCS:LSM-5353|Drug_Central:4361|PMID:24448653|PMID:16037564|PMID:24464484|PMID:11530998|Beilstein:3219887|CAS:474-25-9|DrugBank:DB06777|Reaxys:3219887|LIPID_MAPS_instance:LMST04010032,,A dihydroxy-5beta-cholanic acid that is (5beta)-cholan-24-oic acid substituted by hydroxy groups at positions 3 and 7 respectively.|A dihydroxy-5β-cholanic acid that is (5β)-cholan-24-oic acid substituted by hydroxy groups at positions 3 and 7 respectively.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_77746|http://purl.obolibrary.org/obo/CHEBI_75771,,,,,"Chenodeoxycholic acid|3alpha,7alpha-dihydroxy-5beta-cholan-24-oic acid",,"7alpha-hydroxylithocholic acid|chenic acid|anthropodesoxycholic acid|Chenodiol|3alpha,7alpha-Dihydroxy-5beta-cholanic acid|CDCA|anthropodeoxycholic acid|Chenix|gallodesoxycholic acid",,,,,,,,,,InChIKey:RUDATBOHQWOJDD-BSWAIDMHSA-N,,,,,,,,,,,CHEBI:16755,,,,chenodeoxycholic acid,,CHEBI:16755,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000002206,MS4A2,,"Other designations: Fc fragment of IgE, high affinity I, receptor for; beta polypeptide|High affinity immunoglobulin epsilon receptor beta-subunit (FcERI) (IgE Fc receptor, beta-subunit) (Fc epsilon receptor I beta-chain)|high affinity IgE receptor beta subunit|high affinity immunoglobulin epsilon receptor subunit beta|igE Fc receptor subunit beta|immunoglobulin E receptor, high affinity, beta polypeptide",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,FCER1B|IGEL|MS4A1|FCERI|IGHER|APY|ATOPY|IGER,,,,,,,,,,,,11,,,,,,MIM:147138|HGNC:7316|HPRD:00915,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"membrane-spanning 4-domains, subfamily A, member 2",,,11q12-q13,,,,,,,,,,,,,,,,"GO_0005768 (EC: IEA); GO_0005886 (EC: TAS); GO_0005887 (EC: NAS, PMID: 1535625); GO_0006954 (EC: IEA); GO_0006955 (EC: IMP, PMID: 7920628); GO_0007202 (EC: IEA); GO_0007205 (EC: IEA); GO_0009897 (EC: IEA); GO_0019863 (EC: IEA); GO_0019901 (EC: IEA); GO_0032998 (EC: IEA); GO_0038095 (EC: TAS); GO_0042169 (EC: IEA); GO_0043306 (EC: IEA); GO_0045087 (EC: TAS); GO_0045121 (EC: IEA); GO_0050663 (EC: IEA); GO_0051219 (EC: IEA); GO_0051279 (EC: IEA)",,,,,,,,,PMID: 1386024; 1533242; 1535625; 2146219; 2448768; 7528770; 7612892; 7920628; 8071371; 8094113; 8188278; 8805698; 8817330; 8842731; 8968765; 8995445; 9169438; 9341761; 9379041; 11134951; 11142503; 11150000; 11245344; 11368631; 11447385; 11702205; 11758232; 12047428; 12082592; 12217393; 12393595; 12422339; 12477932; 12697656; 12753743; 12903039; 12919239; 14687477; 15087090; 15316148; 15453830; 15479187; 15489334; 15528387; 15953854; 16002993; 16344560; 16750991; 16839401; 16839402; 16867043; 17014622; 17088130; 17121586; 17178032; 17430357; 17686114; 17703412; 18269668; 18379861; 18534082; 18579528; 18691306; 18931892; 18949059; 18974840; 19028820; 19131662; 19218813; 19247692; 19258923; 19264973; 19288130; 19356729; 19416867; 19479237; 19514647; 19559392; 19796196; 19824886; 19862939; 19913121; 19948975; 20028371; 20085599; 20358027; 20395963; 20503287; 20536507; 20554927; 20628086; 20703737; 20716621; 21061265; 21832049; 22150093; 22845063; 23643722,,,,,,,,,,,,,,,OGG:3000002206,,,,,,,"membrane-spanning 4-domains, subfamily A, member 2",,,,,,,,,,,,,"Other designations: Fc fragment of IgE, high affinity I, receptor for; beta polypeptide|High affinity immunoglobulin epsilon receptor beta-subunit (FcERI) (IgE Fc receptor, beta-subunit) (Fc epsilon receptor I beta-chain)|high affinity IgE receptor beta subunit|high affinity immunoglobulin epsilon receptor subunit beta|igE Fc receptor subunit beta|immunoglobulin E receptor, high affinity, beta polypeptide",,MS4A2,,,,,,,,,,,,,,,,,,,,,,,2206,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,MS4A2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000250,Akt,protein kinase B|PKB|RAC serine/threonine protein kinase|RAC-PK,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001966,,,,,protein kinase B|PKB|RAC serine/threonine protein kinase|RAC-PK,,,,,IMR:0000250,,,,,,,,,,,,,,,,,,,,,,Akt,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100279,EGF (mol),epidermal growth factor,,false,,,http://purl.obolibrary.org/obo/IMR_0000047,,,,,,,,,,,,,,,,,,,,GO:0005154　epidermal growth factor receptor binding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,epidermal growth factor,,,,,IMR:0100279,,,,,,,,,,,,,,,,,,,,,,EGF (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0043543,protein acylation,,"The addition of an acyl group, any group or radical of the form RCO- where R is an organic group, to a protein amino acid.",false,,,http://purl.obolibrary.org/obo/GO_0036211,,,,,,,,,,,,,,,,,,,,,,"The addition of an acyl group, any group or radical of the form RCO- where R is an organic group, to a protein amino acid.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0043543,,,,,,,,,,,,,,,,,,,,,,protein acylation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0046514,ceramide catabolic process,ceramide breakedown|catabolosm|ceramide degradation,"The chemical reactions and pathways resulting in the breakdown of ceramides, any N-acetylated sphingoid.",false,,,http://purl.obolibrary.org/obo/TXPO_0000071,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways resulting in the breakdown of ceramides, any N-acetylated sphingoid.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_17761,,,,,,,,,,,,,,,,,,ceramide breakedown|catabolosm|ceramide degradation,,,,,GO:0046514,,,,,,,,,,,,,,,,,,,,,,ceramide catabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0046513,ceramide biosynthetic process,ceramide anabolism|ceramide biosynthesis|ceramide synthesis|ceramide formation,"The chemical reactions and pathways resulting in the formation of ceramides, any N-acylated sphingoid.",false,,,http://purl.obolibrary.org/obo/GO_0008610,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways resulting in the formation of ceramides, any N-acylated sphingoid.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ceramide anabolism|ceramide biosynthesis|ceramide synthesis|ceramide formation,,,,,GO:0046513,,,,,,,,,,,,,,,,,,,,,,ceramide biosynthetic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76866,EC 1.6.5.* (oxidoreductase acting on NADH or NADPH with a quinone or similar as acceptor) inhibitor,EC 1.6.5.* inhibitor|EC 1.6.5.* (oxidoreductase acting on NADH or NADPH with a quinone or similar as acceptor) inhibitors|oxidoreductase acting on NADH or NADPH with a quinone or similar as acceptor (EC 1.6.5.*) inhibitors|EC 1.6.5.* inhibitors|oxidoreductase acting on NADH or NADPH with a quinone or similar as acceptor (EC 1.6.5.*) inhibitor,An EC 1.6.* (oxidoreductase acting on NADH or NADPH) inhibitor that interferes with the action of any such enzyme using a quinone or similar as acceptor (EC 1.6.5.*).,false,,,http://purl.obolibrary.org/obo/CHEBI_76733,,,,,,,,,,,,,,,,,,,,,,An EC 1.6.* (oxidoreductase acting on NADH or NADPH) inhibitor that interferes with the action of any such enzyme using a quinone or similar as acceptor (EC 1.6.5.*).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,EC 1.6.5.* inhibitor|EC 1.6.5.* (oxidoreductase acting on NADH or NADPH with a quinone or similar as acceptor) inhibitors|oxidoreductase acting on NADH or NADPH with a quinone or similar as acceptor (EC 1.6.5.*) inhibitors|EC 1.6.5.* inhibitors|oxidoreductase acting on NADH or NADPH with a quinone or similar as acceptor (EC 1.6.5.*) inhibitor,,,,,,,,,,,,,,,,,,,,,CHEBI:76866,,,,EC 1.6.5.* (oxidoreductase acting on NADH or NADPH with a quinone or similar as acceptor) inhibitor,,CHEBI:76866,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_4868,estramustine,"estramustina|estramustinum|estramustine|17beta-Estradiol 3-(bis(2-chloroethyl)carbamate)|Estradiol 3-(N,N-bis(2-chloroethyl)carbamate)|(17beta)-17-hydroxyestra-1(10),2,4-trien-3-yl bis(2-chloroethyl)carbamate|Estramustine",A carbamate ester obtained by the formal condensation of the hydroxy group of 17beta-estradiol with the carboxy group of bis(2-chloroethyl)carbamic acid.,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:15762353|LIPID_MAPS_instance:LMST02010038|PMID:11131983|Beilstein:5637599|Drug_Central:1065|Reaxys:5637599|CAS:2998-57-4|PMID:7638085|DrugBank:DB01196,,A carbamate ester obtained by the formal condensation of the hydroxy group of 17beta-estradiol with the carboxy group of bis(2-chloroethyl)carbamic acid.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35610|http://purl.obolibrary.org/obo/CHEBI_22333|http://purl.obolibrary.org/obo/CHEBI_66987,,,,,"(17beta)-17-hydroxyestra-1(10),2,4-trien-3-yl bis(2-chloroethyl)carbamate|Estramustine",,"estramustina|estramustinum|estramustine|17beta-Estradiol 3-(bis(2-chloroethyl)carbamate)|Estradiol 3-(N,N-bis(2-chloroethyl)carbamate)",,,,,,,,,,,,,,,,,,,,,CHEBI:4868,,,,estramustine,,CHEBI:4868,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0200281,Prostaglandin I2,,,false,,,http://purl.obolibrary.org/obo/IMR_0100019,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0200281,,,,,,,,,,,,,,,,,,,,,,Prostaglandin I2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0009247,glycolipid biosynthetic process,glycolipid anabolism|glycolipid biosynthesis,"The chemical reactions and pathways resulting in the formation of glycolipid, a class of 1,2-di-O-acylglycerols joined at oxygen 3 by a glycosidic linkage to a carbohydrate part (usually a mono-, di- or tri-saccharide).",false,,,http://purl.obolibrary.org/obo/GO_0008610,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways resulting in the formation of glycolipid, a class of 1,2-di-O-acylglycerols joined at oxygen 3 by a glycosidic linkage to a carbohydrate part (usually a mono-, di- or tri-saccharide).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,glycolipid anabolism|glycolipid biosynthesis,,,,,GO:0009247,,,,,,,,,,,,,,,,,,,,,,glycolipid biosynthetic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002330,hypofunction of drug metabolism phase II,,Hypofunction of drug metabolism phase II is a subtype of hypofunction of drug metabolism: A process that performs a decreased or insufficient drug metabolism phase II.,false,,,http://purl.obolibrary.org/obo/TXPO_0002190,,,,,,,,,,,,,,,,,,,,,,Hypofunction of drug metabolism phase II is a subtype of hypofunction of drug metabolism: A process that performs a decreased or insufficient drug metabolism phase II.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002330,,,,,,,,,,,,,,,,,,,,,,hypofunction of drug metabolism phase II,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002335,hyperfunction of fatty acid biosynthesis,,Hyperfunction of fatty acid biosynthesis is a subtype of hyperfunction of biosynthesis: A process that performs an excessive fatty acid biosynthesis.,false,,,http://purl.obolibrary.org/obo/TXPO_0002346,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of fatty acid biosynthesis is a subtype of hyperfunction of biosynthesis: A process that performs an excessive fatty acid biosynthesis.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002335,,,,,,,,,,,,,,,,,,,,,,hyperfunction of fatty acid biosynthesis,,,,,,http://purl.obolibrary.org/obo/GO_0006633,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002334,cel cycle related gene expression,,Cel cycle related gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature cell cycle related gene product or products (proteins or RNA).,false,,,http://purl.obolibrary.org/obo/GO_0010467,,,,,,,,,,,,,,,,,,,,,,Cel cycle related gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature cell cycle related gene product or products (proteins or RNA).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002334,,,,,,,,,,,,,,,,,,,,,,cel cycle related gene expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002332,hyperfunction of drug metabolizing enzyme gene expression,,Hyperfunction of drug metabolizing enzyme gene expression is a subtype of hyperfunction of gene expression: A process that performs an excesssive drug metabolizing enzyme gene expression.,false,,,http://purl.obolibrary.org/obo/TXPO_0002345,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of drug metabolizing enzyme gene expression is a subtype of hyperfunction of gene expression: A process that performs an excesssive drug metabolizing enzyme gene expression.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002332,,,,,,,,,,,,,,,,,,,,,,hyperfunction of drug metabolizing enzyme gene expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002337,hyperfunction of lipid biosynthesis,,Hyperfunction of lipid biosynthesis is a subtype of hyperfunction of biosynthesis: A process that performs an excessive lipid biosynthesis.,false,,,http://purl.obolibrary.org/obo/TXPO_0002346,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of lipid biosynthesis is a subtype of hyperfunction of biosynthesis: A process that performs an excessive lipid biosynthesis.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002337,,,,,,,,,,,,,,,,,,,,,,hyperfunction of lipid biosynthesis,,,,,,http://purl.obolibrary.org/obo/GO_0008610,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002331,glutamate-cysteine ligase modifier subunit,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:14629|NCBI-Rat-GeneID:25283|NCBI-Human-GeneID:2729,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000002730,,,,,,,,,,,,,TXPO:0002331,,,,,,,,,,,,,,,,,,,,,,glutamate-cysteine ligase modifier subunit,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002333,increasing number of dead cells in liver [Oxidative stress],,"Increasing number of dead cells in liver is a subtype of cell proliferation: A process that becomes larger in the number of dead cells in the liver.
This entity is a specific course-dependent process. This process can constitute the course of Oxidative stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000341|http://purl.obolibrary.org/obo/TXPO_0001730,,,,,,,,,,,,,,,,,,,,,,"Increasing number of dead cells in liver is a subtype of cell proliferation: A process that becomes larger in the number of dead cells in the liver.
This entity is a specific course-dependent process. This process can constitute the course of Oxidative stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002333,,,,,,,,,,,,,,,,,,,,,,increasing number of dead cells in liver [Oxidative stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002339,lipid vacuole organization,,"Lipid vacuole organization is a subtype of vacuole organization: A process that s carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a lipid vacuole.",false,,,http://purl.obolibrary.org/obo/GO_0007033,,,,,,,,,,,,,,,,,,,,,,"Lipid vacuole organization is a subtype of vacuole organization: A process that s carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a lipid vacuole.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002339,,,,,,,,,,,,,,,,,,,,,,lipid vacuole organization,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002336,lipid metabolism imbalance,,Lipid metabolism imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance of lipid metabolism.,false,,,http://purl.obolibrary.org/obo/TXPO_0000567,,,,,,,,,,,,,,,,,,,,,,Lipid metabolism imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance of lipid metabolism.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002336,,,,,,,,,,,,,,,,,,,,,,lipid metabolism imbalance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002338,hyperfunction of lipid synthetic gene expression,,Hyperfunction of lipid synthetic gene expression is a subtype of hyperfunction of gene expression: A process that performs an excesssive lipid biosynthetic gene expression.,false,,,http://purl.obolibrary.org/obo/TXPO_0002345,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of lipid synthetic gene expression is a subtype of hyperfunction of gene expression: A process that performs an excesssive lipid biosynthetic gene expression.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002338,,,,,,,,,,,,,,,,,,,,,,hyperfunction of lipid synthetic gene expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001673,RGS16,,,false,,,http://purl.obolibrary.org/obo/IMR_0000431,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001673,,,,,,,,,,,,,,,,,,,,,,RGS16,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0000498,increased duration,,A duration quality of a process which is relatively high.,false,,,http://purl.obolibrary.org/obo/PATO_0001309,,,,,,,,,,,,,,,,,,,,,,A duration quality of a process which is relatively high.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0000498,,,,,,,,,,,,,,,,,,,,,,increased duration,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0000499,decreased duration,,A duration quality of a process which is relatively low.,false,,,http://purl.obolibrary.org/obo/PATO_0001309,,,,,,,,,,,,,,,,,,,,,,A duration quality of a process which is relatively low.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0000499,,,,,,,,,,,,,,,,,,,,,,decreased duration,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000005777,PTPN6,,Other designations: hematopoietic cell phosphatase|hematopoietic cell protein-tyrosine phosphatase|protein-tyrosine phosphatase 1C|protein-tyrosine phosphatase SHP-1|tyrosine-protein phosphatase non-receptor type 6,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,HCP|HPTP1C|SHP1|SHP-1|HCPH|SHP-1L|PTP-1C|SH-PTP1,,,,,,,,,,,,12,,,,,,MIM:176883|Ensembl:ENSG00000111679|HGNC:9658|Vega:OTTHUMG00000168518|HPRD:01475,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"protein tyrosine phosphatase, non-receptor type 6",,,12p13,,,,,,,,,,,,,,,,"GO_0001784 (EC: IEA); GO_0002924 (EC: IEA); GO_0004725 (EC: TAS); GO_0005001 (EC: IDA, PMID: 11266449); GO_0005515 (EC: IPI, PMID: 10206955); GO_0005634 (EC: IDA); GO_0005730 (EC: IDA); GO_0005737 (EC: IDA, PMID: 10940933); GO_0005829 (EC: TAS); GO_0006470 (EC: IDA, PMID: 11266449); GO_0006915 (EC: TAS, PMID: 10506221); GO_0007186 (EC: TAS, PMID: 7781604); GO_0007596 (EC: TAS); GO_0008283 (EC: IDA, PMID: 11266449); GO_0008284 (EC: IMP, PMID: 19749791); GO_0008285 (EC: NAS, PMID: 10497187); GO_0014068 (EC: IMP, PMID: 19838216); GO_0016020 (EC: TAS, PMID: 10506221); GO_0017124 (EC: IEA); GO_0018108 (EC: IDA, PMID: 18802077); GO_0019221 (EC: TAS); GO_0019901 (EC: IPI, PMID: 11266449); GO_0030154 (EC: IDA, PMID: 11266449); GO_0031295 (EC: TAS); GO_0042105 (EC: IEA); GO_0042130 (EC: IEA); GO_0042169 (EC: IEA); GO_0042267 (EC: IEA); GO_0043407 (EC: IEA); GO_0045577 (EC: IEA); GO_0050732 (EC: IMP, PMID: 19749791); GO_0050853 (EC: IEA); GO_0050860 (EC: IEA); GO_0050900 (EC: TAS); GO_0060333 (EC: TAS); GO_0060334 (EC: TAS); GO_0060337 (EC: TAS); GO_0060338 (EC: TAS); GO_0060397 (EC: TAS); GO_0070062 (EC: IDA, PMID: 19056867); GO_0070372 (EC: IDA, PMID: 11266449); GO_2000045 (EC: IMP, PMID: 19838216)",,,,,,,,,PMID: 1639416; 1652101; 1732748; 1736296; 7512963; 7518460; 7528577; 7539038; 7539106; 7618087; 7629131; 7665165; 7673163; 7684496; 7716523; 7781604; 7889566; 8114715; 8125298; 8246974; 8524272; 8541543; 8574854; 8627166; 8632004; 8638162; 8647855; 8692915; 8760799; 8780698; 8790380; 8943344; 8943354; 9029147; 9045636; 9064344; 9074930; 9148918; 9151699; 9162089; 9211920; 9244303; 9254654; 9261115; 9285411; 9285412; 9305905; 9368621; 9379041; 9405464; 9482905; 9485206; 9507021; 9520455; 9528781; 9531263; 9590210; 9632636; 9632768; 9712903; 9733788; 9740800; 9765283; 9774441; 9774457; 9788431; 9813145; 9842885; 9867848; 9890995; 9973385; 10072516; 10082557; 10206955; 10228003; 10229828; 10350061; 10457220; 10458769; 10488096; 10497187; 10506221; 10506573; 10521452; 10574931; 10585470; 10617656; 10640770; 10660565; 10660620; 10747947; 10764762; 10772872; 10790433; 10800945; 10835420; 10903717; 10903736; 10940933; 11001933; 11027300; 11042209; 11114375; 11160222; 11162587; 11171044; 11178971; 11266449; 11278955; 11294838; 11328818; 11337495; 11356834; 11414741; 11489943; 11511520; 11544253; 11551923; 11714803; 11723252; 11786908; 11812650; 11826756; 11858824; 11895767; 11907066; 11920268; 11964172; 11986327; 11987243; 12051764; 12130517; 12145285; 12145687; 12163025; 12176037; 12176909; 12196526; 12198247; 12361947; 12393607; 12438221; 12459556; 12468540; 12468645; 12477932; 12482860; 12571228; 12591278; 12646642; 12705885; 12734331; 12774026; 12791978; 12796776; 12832410; 12882840; 12917349; 14500659; 14551136; 14630083; 14662855; 14672952; 14691303; 14976049; 15070900; 15184070; 15187115; 15197735; 15269224; 15339845; 15456853; 15489334; 15549731; 15557341; 15574429; 15579525; 15588985; 15701718; 15746253; 15831474; 15870198; 16169070; 16326706; 16341674; 16344560; 16453023; 16482509; 16501054; 17046078; 17079228; 17142110; 17143285; 17218319; 17227821; 17239936; 17272397; 17404032; 17561098; 17579069; 18029348; 18086677; 18174230; 18209728; 18377662; 18441283; 18502033; 18543080; 18604210; 18729074; 18802077; 18948549; 18952289; 19056867; 19096001; 19104650; 19147543; 19166311; 19167335; 19204726; 19234487; 19379557; 19398961; 19542910; 19543515; 19551406; 19561639; 19591923; 19619438; 19749791; 19789387; 19838216; 19874234; 19950550; 20068065; 20117097; 20130595; 20196786; 20351292; 20398180; 20424160; 20687222; 20696858; 20840866; 21291405; 21357539; 21406173; 21465528; 21505184; 21505186; 21536801; 21604205; 21719561; 21799016; 21806449; 21818116; 21821701; 21890473; 21900501; 21906983; 21964525; 22043923; 22180308; 22210881; 22258937; 22371396; 22458809; 22458980; 22488585; 22505724; 22539788; 22589543; 22730659; 22738830; 22939629; 22960265; 23074279; 23391724; 23406209; 23766558; 23842094; 23979523,,,,,,,,,,,,,,,OGG:3000005777,,,,,,,"protein tyrosine phosphatase, non-receptor type 6",,,,,,,,,,,,,Other designations: hematopoietic cell phosphatase|hematopoietic cell protein-tyrosine phosphatase|protein-tyrosine phosphatase 1C|protein-tyrosine phosphatase SHP-1|tyrosine-protein phosphatase non-receptor type 6,,PTPN6,,,,,,,,,,,,,,,,,,,,,,,5777,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,PTPN6,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000005775,PTPN4,,Other designations: PTPase-MEG1|megakaryocyte phosphatase|megakaryocyte protein-tyrosine phosphatase|protein tyrosine phosphatase MEG1|protein-tyrosine phosphatase MEG1|tyrosine-protein phosphatase non-receptor type 4,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,PTPMEG1|PTPMEG|MEG,,,,,,,,,,,,2,,,,,,MIM:176878|HGNC:9656|HPRD:01471|Ensembl:ENSG00000088179|Vega:OTTHUMG00000131436,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"protein tyrosine phosphatase, non-receptor type 4 (megakaryocyte)",,,2q14.2,,,,,,,,,,,,,,,,"GO_0004726 (EC: IEA); GO_0005515 (EC: IPI, PMID: 16169070); GO_0005737 (EC: IDA, PMID: 10940933); GO_0005856 (EC: IEA); GO_0006470 (EC: TAS, PMID: 1648233); GO_0008092 (EC: IEA); GO_0009898 (EC: IDA, PMID: 10940933); GO_0035335 (EC: TAS, PMID: 1648233)",,,,,,,,,PMID: 1648233; 8910369; 8917530; 10748123; 10940933; 11054567; 12477932; 15489334; 16169070; 16226712; 17474147; 18614237; 21900206; 21988832; 23666597; 24250222,,,,,,,,,,,,,,,OGG:3000005775,,,,,,,"protein tyrosine phosphatase, non-receptor type 4 (megakaryocyte)",,,,,,,,,,,,,Other designations: PTPase-MEG1|megakaryocyte phosphatase|megakaryocyte protein-tyrosine phosphatase|protein tyrosine phosphatase MEG1|protein-tyrosine phosphatase MEG1|tyrosine-protein phosphatase non-receptor type 4,,PTPN4,,,,,,,,,,,,,,,,,,,,,,,5775,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,PTPN4,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0004900,tumor suppressor inactivation,,Tumor suppressor inactivation is a subtype of molecular inactivation: A process that  changes the activity of the tumor suppressor to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000021,,,,,,,,,,,,,,,,,,,,,,Tumor suppressor inactivation is a subtype of molecular inactivation: A process that  changes the activity of the tumor suppressor to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004900,,,,,,,,,,,,,,,,,,,,,,tumor suppressor inactivation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004904,acetyl-CoA biosynthetic process,,acetyl-CoA biosynthetic process is a subtype of generating: A process that synthesizes acetyl-CoA resulting in having output (s).,false,,,http://purl.obolibrary.org/obo/TXPO_0000019,,,,,,,,,,,,,,,,,,,,,,acetyl-CoA biosynthetic process is a subtype of generating: A process that synthesizes acetyl-CoA resulting in having output (s).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_73693,,,,,,,,,,,,,,,,,,,TXPO:0004904,,,,,,,,,,,,,,,,,,,,,,acetyl-CoA biosynthetic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004909,"aflatoxin B1 exo-8,9-epoxide [hepatocarcinogenesis]","6aS,7aS,8aR,8bR)-4-methoxy-2,3,6a,7a,8a,8b-hexahydrocyclopenta[c]oxireno[4',5']furo[3',2':4,5]furo[2,3-h]chromene-1,10-dione",,false,,,http://purl.obolibrary.org/obo/TXPO_0004455|http://purl.obolibrary.org/obo/CHEBI_30725,,,,,,,,,,,,,,,,,,,,PMID:24078988|PMID:31439937|CAS:42583-46-0|PMID:29301315|PMID:19590965,,,,,,,,,,,,,,C17H12O7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"6aS,7aS,8aR,8bR)-4-methoxy-2,3,6a,7a,8a,8b-hexahydrocyclopenta[c]oxireno[4',5']furo[3',2':4,5]furo[2,3-h]chromene-1,10-dione",,,,,TXPO:0004909,,,,,,,,,,,,,,,,,,,,,,"aflatoxin B1 exo-8,9-epoxide [hepatocarcinogenesis]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,[H][C@@]12Oc3cc(OC)c4c5CCC(=O)c5c(=O)oc4c3[C@]1([H])[C@@]1([H])O[C@@]1([H])O2,,,,,
http://purl.obolibrary.org/obo/TXPO_0004906,decreasing adiponectin level [mitochondrial disorder],,"Decreasing adiponectin level is a subtype of decreasing quantity: A process that changes the amount of adiponectin level to be lower.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0004905,,,,,,,,,,,,,,,,,,,,PMID:23299992,,"Decreasing adiponectin level is a subtype of decreasing quantity: A process that changes the amount of adiponectin level to be lower.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000869,,,,,,,,,,,TXPO:0004906,,,,,,,,,,,,,,,,,,,,,,decreasing adiponectin level [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004902,Tumor suppressor gene mutation,,Tumor suppressor gene mutation is a subtype of changing an operand: A process that changes the nucleotide sequence of Tumor suppressor gene randomly and permanently.,false,,,http://purl.obolibrary.org/obo/TXPO_0001985,,,,,,,,,,,,,,,,,,,,,,Tumor suppressor gene mutation is a subtype of changing an operand: A process that changes the nucleotide sequence of Tumor suppressor gene randomly and permanently.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004902,,,,,,,,,,,,,,,,,,,,,,Tumor suppressor gene mutation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004907,aflatoxin B1 [hepatocarcinogenesis],"(6aR,9aS)-4-methoxy-2,3,6a,9a-tetrahydrocyclopenta[c]furo[3',2':4,5]furo[2,3-h]chromene-1,11-dione","An aflatoxin having a tetrahydrocyclopenta[c]furo[3',2':4,5]furo[2,3-h]chromene skeleton with oxygen functionality at positions 1, 4 and 11.",false,,,http://purl.obolibrary.org/obo/TXPO_0004455|http://purl.obolibrary.org/obo/CHEBI_2504,,,,,,,,,,,,,,,,,,,,PMID:24078988|PMID:31439937|CAS:1162-65-8|PMID:21160980|PMID:19590965,,"An aflatoxin having a tetrahydrocyclopenta[c]furo[3',2':4,5]furo[2,3-h]chromene skeleton with oxygen functionality at positions 1, 4 and 11.",,,,,,,,,,,,C17H12O6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"(6aR,9aS)-4-methoxy-2,3,6a,9a-tetrahydrocyclopenta[c]furo[3',2':4,5]furo[2,3-h]chromene-1,11-dione",,,,,TXPO:0004907,,,,,,,,,,,,,,,,,,,,,,aflatoxin B1 [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,[H][C@]12OC=C[C@@]1([H])c1c(O2)cc(OC)c2c3CCC(=O)c3c(=O)oc12,,,,,
http://purl.obolibrary.org/obo/TXPO_0004905,decreasing adiponectin level,,Decreasing adiponectin level is a subtype of decreasing quantity: A process that changes the amount of adiponectin level to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000396,,,,,,,,,,,,,,,,,,,,,,Decreasing adiponectin level is a subtype of decreasing quantity: A process that changes the amount of adiponectin level to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004905,,,,,,,,,,,,,,,,,,,,,,decreasing adiponectin level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004903,negative regulation of actin cytoskeleton organization,,"Negative regulation of actin cytoskeleton organization is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of actin cytoskeleton organization.",false,,,http://purl.obolibrary.org/obo/TXPO_0000369,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of actin cytoskeleton organization is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of actin cytoskeleton organization.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004903,,,,,,,,,,,,,,,,,,,,,,negative regulation of actin cytoskeleton organization,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0030036,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004901,Tumor suppressor inactivation [hepatocarcinogenesis],,"Tumor suppressor inactivation is a subtype of molecular inactivation: A process that  changes the activity of the tumor suppressor to be lower.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004900,,,,,,,,,,,,,,,,,,,,,,"Tumor suppressor inactivation is a subtype of molecular inactivation: A process that  changes the activity of the tumor suppressor to be lower.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004683|http://purl.obolibrary.org/obo/TXPO_0004402|http://purl.obolibrary.org/obo/TXPO_0004507|http://purl.obolibrary.org/obo/TXPO_0004738|http://purl.obolibrary.org/obo/TXPO_0004749|http://purl.obolibrary.org/obo/TXPO_0004431|http://purl.obolibrary.org/obo/TXPO_0004841|http://purl.obolibrary.org/obo/TXPO_0004789|http://purl.obolibrary.org/obo/TXPO_0004693,,,,,,,,,,,,,,,,,,TXPO:0004901,,,,,,,,,,,,,,,,,,,,,,Tumor suppressor inactivation [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004908,aflatoxin metabolic process [hepatocarcinogenesis],aflatoxin metabolism,"The chemical reactions and pathways involving aflatoxin, a fungal metabolite found as a contaminant in moldy grains that induces liver cancer. Aflatoxin induces a G to T transversion at codon 249 of p53, leading to its inactivation. Aflatoxin is converted to a chemical carcinogen by P450.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/GO_0046222|http://purl.obolibrary.org/obo/TXPO_0002340,,,,,,,,,,,,,,,,,,,,PMID:24078988|PMID:31439937|PMID:29301315|PMID:19590965,,"The chemical reactions and pathways involving aflatoxin, a fungal metabolite found as a contaminant in moldy grains that induces liver cancer. Aflatoxin induces a G to T transversion at codon 249 of p53, leading to its inactivation. Aflatoxin is converted to a chemical carcinogen by P450.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004913|http://purl.obolibrary.org/obo/TXPO_0004912|http://purl.obolibrary.org/obo/TXPO_0004911|http://purl.obolibrary.org/obo/TXPO_0004915|http://purl.obolibrary.org/obo/TXPO_0004910|http://purl.obolibrary.org/obo/TXPO_0004914|http://purl.obolibrary.org/obo/TXPO_0004916,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004907,,,,http://purl.obolibrary.org/obo/TXPO_0004909,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004507,,,,,,aflatoxin metabolism,,,,,TXPO:0004908,,,,,,,,,,,,,,,,,,,,,,aflatoxin metabolic process [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001017,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B",,,false,,,http://purl.obolibrary.org/obo/IMR_0100700,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001017,,,,,,,,,,,,,,,,,,,,,,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000447,INK4 family,,,false,,,http://purl.obolibrary.org/obo/IMR_0000445,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000447,,,,,,,,,,,,,,,,,,,,,,INK4 family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100253,MLK4,,,false,,,http://purl.obolibrary.org/obo/IMR_0100249,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100253,,,,,,,,,,,,,,,,,,,,,,MLK4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000463,I-kappaB family,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003720,,,,,,,,,,IMR:0000463,,,,,,,,,,,,,,,,,,,,,,I-kappaB family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004631,IHH (canonical) [hepatocarcinogenesis],Indian hedgehog|HHG-2,,false,,,http://purl.obolibrary.org/obo/TXPO_0005063|http://purl.obolibrary.org/obo/IMR_0100739,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:16147|NCBI-Rat-GeneID:84399|NCBI-Human-GeneID:3549|PMID:28706416,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Indian hedgehog|HHG-2,,,,,TXPO:0004631,,,,,,,,,,,,,,,,,,,,,,IHH (canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004639,STK3 (canonical) [hepatocarcinogenesis],MST2,,false,,,http://purl.obolibrary.org/obo/TXPO_0005063|http://purl.obolibrary.org/obo/TXPO_0005094,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:56274|NCBI-Human-GeneID:6788|NCBI-Rat-GeneID:65189|PMID:30700007,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MST2,,,,,TXPO:0004639,,,,,,,,,,,,,,,,,,,,,,STK3 (canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004638,MST1 (canonical) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0005063|http://purl.obolibrary.org/obo/TXPO_0005093,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24566|NCBI-Human-GeneID:4485|NCBI-Mouse-GeneID:15235|PMID:30700007,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004638,,,,,,,,,,,,,,,,,,,,,,MST1 (canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004633,neoplastic cell transformation [hepatocarcinogenesis],,A changing process in which cells become to have neoplastic quality. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.,false,,,http://purl.obolibrary.org/obo/OMIT_0003800|http://purl.obolibrary.org/obo/TXPO_0002340,,,,,,,,,,,,,,,,,,,,PMID:22576474|PMID:18245951,,A changing process in which cells become to have neoplastic quality. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004392,,,,,,,,,,,TXPO:0004633,,,,,,,,,,,,,,,,,,,,,,neoplastic cell transformation [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004632,SHH (canonical) [hepatocarcinogenesis],Sonic hedgehog|HHG-1,,false,,,http://purl.obolibrary.org/obo/IMR_0000005|http://purl.obolibrary.org/obo/TXPO_0005063,,,,,,,,,,,,,,,,,,,,PMID:28706416|NCBI-Mouse-GeneID:20423|NCBI-Rat-GeneID:29499|NCBI-Human-GeneID:6469,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Sonic hedgehog|HHG-1,,,,,TXPO:0004632,,,,,,,,,,,,,,,,,,,,,,SHH (canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004637,Hippo signaling (primitive),,Hippo signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by Hippo.,false,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,,,Hippo signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by Hippo.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0005093|http://purl.obolibrary.org/obo/TXPO_0005094,http://purl.obolibrary.org/obo/TXPO_0004635,,,,,,,,,,,,,,,,TXPO:0004637,,,,,,,,,,,,,,,,,,,,,,Hippo signaling (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004634,glycolytic process [hepatocarcinogenesis],,"The chemical reactions and pathways resulting in the breakdown of a carbohydrate into pyruvate, with the concomitant production of a small amount of ATP and the reduction of NAD(P) to NAD(P)H. Glycolysis begins with the metabolism of a carbohydrate to generate products that can enter the pathway and ends with the production of pyruvate. Pyruvate may be converted to acetyl-coenzyme A, ethanol, lactate, or other small molecules.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/GO_0006096|http://purl.obolibrary.org/obo/TXPO_0002340,,,,,,,,,,,,,,,,,,,,PMID:28706416,,"The chemical reactions and pathways resulting in the breakdown of a carbohydrate into pyruvate, with the concomitant production of a small amount of ATP and the reduction of NAD(P) to NAD(P)H. Glycolysis begins with the metabolism of a carbohydrate to generate products that can enter the pathway and ends with the production of pyruvate. Pyruvate may be converted to acetyl-coenzyme A, ethanol, lactate, or other small molecules.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004518,,,,,,,,,,,TXPO:0004634,,,,,,,,,,,,,,,,,,,,,,glycolytic process [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004635,Hippo signal transduction pathway,,A series of molecular signals mediated by Hippo (Mst1 and Mst2 in mammals).,false,,,http://purl.obolibrary.org/obo/TXPO_0000609,,,,,,,,,,,,,,,,,,,,,,A series of molecular signals mediated by Hippo (Mst1 and Mst2 in mammals).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004635,,,,,,,,,,,,,,,,,,,,,,Hippo signal transduction pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004636,Hippo signaling (primitive) [hepatocarcinogenesis],,"Hippo signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by Hippo.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004637,,,,,,,,,,,,,,,,,,,,PMID:30700007,,"Hippo signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by Hippo.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004639|http://purl.obolibrary.org/obo/TXPO_0004638,http://purl.obolibrary.org/obo/TXPO_0004635,,,,,http://purl.obolibrary.org/obo/TXPO_0004640,,,,,,,,,,,TXPO:0004636,,,,,,,,,,,,,,,,,,,,,,Hippo signaling (primitive) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004630,Hedgehog signaling [hepatocarcinogenesis],,"Hedgehog signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by Hedgehog.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004629,,,,,,,,,,,,,,,,,,,,PMID:28706416|PMID:31781608,,"Hedgehog signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by Hedgehog.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004631|http://purl.obolibrary.org/obo/TXPO_0004632,http://purl.obolibrary.org/obo/TXPO_0004628,,,,,http://purl.obolibrary.org/obo/TXPO_0004422|http://purl.obolibrary.org/obo/TXPO_0004546|http://purl.obolibrary.org/obo/TXPO_0004633|http://purl.obolibrary.org/obo/TXPO_0004634,,,,,,,,,,,TXPO:0004630,,,,,,,,,,,,,,,,,,,,,,Hedgehog signaling [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003132,cyclosporineA [Cholestasis],,,false,,,http://purl.obolibrary.org/obo/CHEBI_4031|http://purl.obolibrary.org/obo/TXPO_0000749,,,,,,,,,,,,,,,,,,,,DrugBank:DB00091|InChIKey:PMATZTZNYRCHOR-CGLBZJNRSA-N,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001866,,,,,,,,,,TXPO:0003132,,,,,,,"Cyclosporine, an MDR1 substrate, can cause cholestatic liver injury through a number of different mechanisms:

i) Competitive inhibition of ATP dependent transporters,
ii) Iinhibition of intrahepatic vesicle transport and targeting of ATP dependent transporters to the canalicular membrane
and iii) Impairment of bile secretion partly by increasing canalicular membrane fluidity without affecting the expression of canalicular transporter.|cyclosporine reduces the expression of glutathione synthesizing enzymes and the canalicular glutathione efflux system, MRP2, leading to reduced bile salt-independent bile flow|rifampicin, cyclosporine A, rifamycin SV, bosentan, troglitazone, erythromycin estolate, and glibenclamide inhibit Bsep in rats",,,,,,,,,,,,,,,cyclosporineA [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003135,cholesterol biosynthetic process [Cholestasis],,"Cholesterol biosynthetic process is a subtype of lipid biosynthetic process:  The chemical reaction resulting in the formation of cholesterol, cholest-5-en-3 beta-ol, the principal sterol of vertebrates and the precursor of many steroids, including bile acids and steroid hormones.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000034|http://purl.obolibrary.org/obo/GO_0006695,,,,,,,,,,,,,,,,,,,,,,"Cholesterol biosynthetic process is a subtype of lipid biosynthetic process:  The chemical reaction resulting in the formation of cholesterol, cholest-5-en-3 beta-ol, the principal sterol of vertebrates and the precursor of many steroids, including bile acids and steroid hormones.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003135,,,,,,,,,,,,,,,,,,,,,,cholesterol biosynthetic process [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003137,increasing materials for bile formation [Cholestasis],,"Increasing materials for bile formation is a subtype of increasing quantity: A process that changes the amount of bile formation material to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003144|http://purl.obolibrary.org/obo/TXPO_0000034,,,,,,,,,,,,,,,,,,,,,,"Increasing materials for bile formation is a subtype of increasing quantity: A process that changes the amount of bile formation material to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003135,,,,,,,,,,,,,,,,,,TXPO:0003137,,,,,,,,,,,,,,,,,,,,,,increasing materials for bile formation [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003130,bile accumulation,,"Bile accumulation is a subtype of accumulation of substances in a biological object: A process that keeps bile within the liver (intrahepatic), or outside the liver (extrahepatic) in the bile duct system.",false,,,http://purl.obolibrary.org/obo/TXPO_0000247,,,,,,,,,,,,,,,,,,,,,,"Bile accumulation is a subtype of accumulation of substances in a biological object: A process that keeps bile within the liver (intrahepatic), or outside the liver (extrahepatic) in the bile duct system.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0001970,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003130,,,,,,,,,,,,,,,,,,,,,,bile accumulation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003133,vesicle-mediated transport [Cholestasis],,"A cellular transport process in which transported substances are moved in membrane-bounded vesicles; transported substances are enclosed in the vesicle lumen or located in the vesicle membrane.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/GO_0016192|http://purl.obolibrary.org/obo/TXPO_0000034,,,,,,,,,,,,,,,,,,,,,,"A cellular transport process in which transported substances are moved in membrane-bounded vesicles; transported substances are enclosed in the vesicle lumen or located in the vesicle membrane.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003133,,,,,,,,,,,,,,,,,,,,,,vesicle-mediated transport [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003131,erythromycin estolate [Cholestasis],,,false,,,http://purl.obolibrary.org/obo/CHEBI_4846|http://purl.obolibrary.org/obo/TXPO_0000749,,,,,,,,,,,,,,,,,,,,erythromycin estolate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001866,,,,,,,,,,TXPO:0003131,,,,,,,"rifampicin, cyclosporine A, rifamycin SV, bosentan, troglitazone, erythromycin estolate, and glibenclamide inhibit Bsep in rats|Erythromycin estolate, troglitazone, and bosentan resulted in a decrease in , bile excretion and in vitro biliary clearance of euterium-labeled sodium taurocholate",,,,,,,,,,,,,,,erythromycin estolate [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003136,increasing bile level [Cholestasis],,"Increasing bile level is a subtype of increasing quantity: A process that changes the amount of bile to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000034|http://purl.obolibrary.org/obo/TXPO_0002714,,,,,,,,,,,,,,,,,,,,,,"Increasing bile level is a subtype of increasing quantity: A process that changes the amount of bile to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003137,,,,,,,,,,,,,,,,,,TXPO:0003136,,,,,,,,,,,,,,,,,,,,,,increasing bile level [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003134,increasing glutathione [Cholestasis],,"Increasing glutathione is a subtype of increasing quantity: A process that changes the amount of glutathione to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003151|http://purl.obolibrary.org/obo/TXPO_0000034,,,,,,,,,,,,,,,,,,,,,,"Increasing glutathione is a subtype of increasing quantity: A process that changes the amount of glutathione to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003134,,,,,,,,,,,,,,,,,,,,,,increasing glutathione [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003138,regulation of transporter gene expression by cytokine,,Regulation of transporter gene expression by cytokine is a subtype of regulation of transporter gene expression: A process that changes the the gene expression level of the transporter by cytokines.,false,,,http://purl.obolibrary.org/obo/TXPO_0003139,,,,,,,,,,,,,,,,,,,,,,Regulation of transporter gene expression by cytokine is a subtype of regulation of transporter gene expression: A process that changes the the gene expression level of the transporter by cytokines.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003138,,,,,,,"IL-1beta, TNF-alpha or IL-6 alters human hepatic transporters expression.
Bile salt transporters as well as sinusoidal solute carrier transporters are usually repressed, whereas ATP-binding cassette drug efflux pumps remain unchanged or are either downregulated or upregulated.
They maight  alter drug pharmacokinetics, impairment of bile salt secretion and cholestasis caused by inflammation in humans.",,,,,,,,,,,,,,,regulation of transporter gene expression by cytokine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003139,regulation of transporter gene expression,,Regulation of transporter gene expression is a subtype of regulation of gene expression: A process that changes the the gene expression level of the transporter.,false,,,http://purl.obolibrary.org/obo/GO_0010468,,,,,,,,,,,,,,,,,,,,,,Regulation of transporter gene expression is a subtype of regulation of gene expression: A process that changes the the gene expression level of the transporter.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003139,,,,,,,,,,,,,,,,,,,,,,regulation of transporter gene expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100092,prolactin release-inhibiting hormone,PIH,,false,,,http://purl.obolibrary.org/obo/IMR_0100090,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PIH,,,,,IMR:0100092,,,,,,,,,,,,,,,,,,,,,,prolactin release-inhibiting hormone,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100044,triiodothyronine,"L-3,5,3'-Triiodothyronine|Liothyronine|T3 Thyroid Hormone|3,5,3'-Triiodo-L-thyronine|3,5,3'-Triiodothyronine|Triiodothyronine|3,3'5-Triiodo-L-thyronine",,false,,,http://purl.obolibrary.org/obo/CHEBI_33709|http://purl.obolibrary.org/obo/IMR_0100042,,,,,,,,,,,,,,,,,,,,MeSH:D014284,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"L-3,5,3'-Triiodothyronine|Liothyronine|T3 Thyroid Hormone|3,5,3'-Triiodo-L-thyronine|3,5,3'-Triiodothyronine|Triiodothyronine|3,3'5-Triiodo-L-thyronine",,,,,IMR:0100044,,,,,,,,,,,,,,,,,,,,,,triiodothyronine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100839,SOCS-3,STAT induced STAT inhibitor 3|Protein EF-10|Cytokine-inducible SH2 protein 3|CIS-3|Suppressor of cytokine signaling 3|SSI-3,,false,,,http://purl.obolibrary.org/obo/IMR_0000460,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,STAT induced STAT inhibitor 3|Protein EF-10|Cytokine-inducible SH2 protein 3|CIS-3|Suppressor of cytokine signaling 3|SSI-3,,,,,IMR:0100839,,,,,,,,,,,,,,,,,,,,,,SOCS-3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0072331,signal transduction by p53 class mediator,,A series of molecular signals transduced with the regulation of transcription of target genes by p53.,false,,,http://purl.obolibrary.org/obo/TXPO_0001902,,,,,,,,,,,,,,,,,,,,,,A series of molecular signals transduced with the regulation of transcription of target genes by p53.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000237,,,,,,,,,,,,,,,,,,GO:0072331,,,,,,,,,,,,,,,,,,,,,,signal transduction by p53 class mediator,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100625,cyclin H,MO15-associated protein|p34|p37|CYCH|Cyclin H,,false,,,http://purl.obolibrary.org/obo/IMR_0100606,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0010772|IMR:0011707,MO15-associated protein|p34|p37|CYCH|Cyclin H,,,,,IMR:0100625,,,,,,,,,,,,,,,,,,,,,,cyclin H,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_74440,epidermal growth factor receptor antagonist,EGFR inhibitor|epidermal growth factor receptor inhibitor|EGFR antagonoist|epidermal growth factor receptor inhibitors|EGFR antagonoists|EGFR inhibitors|epidermal growth factor receptor antagonists,An antagonist at the epidermal growth factor receptor.,false,,,http://purl.obolibrary.org/obo/CHEBI_48706|http://purl.obolibrary.org/obo/CHEBI_37699,,,,,,,,,,,,,,,,,,,,,,An antagonist at the epidermal growth factor receptor.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,EGFR inhibitor|epidermal growth factor receptor inhibitor|EGFR antagonoist|epidermal growth factor receptor inhibitors|EGFR antagonoists|EGFR inhibitors|epidermal growth factor receptor antagonists,,,,,,,,,,,,,,,,,,,,,CHEBI:74440,,,,epidermal growth factor receptor antagonist,,CHEBI:74440,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001211,Puma,bbc3,,false,,,http://purl.obolibrary.org/obo/IMR_0100709,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,bbc3,,,,,IMR:0001211,,,,,,,,,,,,,,,,,,,,,,Puma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003869,phenobarbital metabolism imbalance [Ground glass appearance (moderate) ],,"Phenobarbital metabolism imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance of the phenobarbital metabolism. And the degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (moderate) .",false,,,http://purl.obolibrary.org/obo/TXPO_0003860,,,,,,,,,,,,,,,,,,,,,,"Phenobarbital metabolism imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance of the phenobarbital metabolism. And the degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (moderate) .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003870,,,,,,,,,,,TXPO:0003869,,,,,,,,,,,,,,,,,,,,,,phenobarbital metabolism imbalance [Ground glass appearance (moderate) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003863,xenosensor,,A role played by the entity which receives xenobiotics (signal) and transmits operand(s).,false,,,http://purl.obolibrary.org/obo/TXPO_0000882,,,,,,,,,,,,,,,,,,,,,,A role played by the entity which receives xenobiotics (signal) and transmits operand(s).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003863,,,,,,,,,,,,,,,,,,,,,,xenosensor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003864,hyperfunction of phenobarbital metabolism phase I by Cytochrome P450 [Ground glass appearance],,"Hyperfunction of phenobarbital metabolism phase I by Cytochrome P450 is a subtype of hyperfunction of drug metabolism phase I: A process that performs an excesssive that performs an excesssive phenobarbital metabolism phase I by Cytochrome P450.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001621,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of phenobarbital metabolism phase I by Cytochrome P450 is a subtype of hyperfunction of drug metabolism phase I: A process that performs an excesssive that performs an excesssive phenobarbital metabolism phase I by Cytochrome P450.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002309|http://purl.obolibrary.org/obo/TXPO_0003858,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003903|http://purl.obolibrary.org/obo/TXPO_0001663,,,,,,,,,,,TXPO:0003864,,,,,,,,,,,,,,,,,,,,,,hyperfunction of phenobarbital metabolism phase I by Cytochrome P450 [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003866,phenobarbital induced  liver tumor via ground glass appearance,,"The totality of all processes through which ground glass appearance is realized.
This toxic course has a process of CYP activation by phenobarbital and manifests liver tumor.",false,,,http://purl.obolibrary.org/obo/TXPO_0001588,,,,,,,,,,,,,,,,,,,,PMID:22723046|PMID:24180433,,"The totality of all processes through which ground glass appearance is realized.
This toxic course has a process of CYP activation by phenobarbital and manifests liver tumor.",,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003844,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003979|http://purl.obolibrary.org/obo/TXPO_0000669|http://purl.obolibrary.org/obo/TXPO_0000962|http://purl.obolibrary.org/obo/TXPO_0001031|http://purl.obolibrary.org/obo/TXPO_0001033|http://purl.obolibrary.org/obo/TXPO_0001030|http://purl.obolibrary.org/obo/TXPO_0001028|http://purl.obolibrary.org/obo/TXPO_0000597|http://purl.obolibrary.org/obo/TXPO_0003796|http://purl.obolibrary.org/obo/TXPO_0001582|http://purl.obolibrary.org/obo/TXPO_0000977|http://purl.obolibrary.org/obo/TXPO_0000978|http://purl.obolibrary.org/obo/TXPO_0002319|http://purl.obolibrary.org/obo/TXPO_0003597|http://purl.obolibrary.org/obo/TXPO_0001013|http://purl.obolibrary.org/obo/TXPO_0003852|http://purl.obolibrary.org/obo/TXPO_0003856|http://purl.obolibrary.org/obo/TXPO_0003851|http://purl.obolibrary.org/obo/TXPO_0003850|http://purl.obolibrary.org/obo/TXPO_0000314|http://purl.obolibrary.org/obo/TXPO_0001675|http://purl.obolibrary.org/obo/TXPO_0001677|http://purl.obolibrary.org/obo/TXPO_0002322|http://purl.obolibrary.org/obo/TXPO_0002323|http://purl.obolibrary.org/obo/TXPO_0002320|http://purl.obolibrary.org/obo/TXPO_0003865|http://purl.obolibrary.org/obo/TXPO_0000954|http://purl.obolibrary.org/obo/TXPO_0000952|http://purl.obolibrary.org/obo/TXPO_0000959|http://purl.obolibrary.org/obo/TXPO_0000947|http://purl.obolibrary.org/obo/TXPO_0003848|http://purl.obolibrary.org/obo/TXPO_0003844|http://purl.obolibrary.org/obo/TXPO_0003845,,,,,,,,,,,,,,,,,,TXPO:0003866,,,,,,,,,,,,,,,,,,,,,,phenobarbital induced  liver tumor via ground glass appearance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003868,hyperfunction of increasing the amount of phenobarbital  [Ground glass appearance (moderate) ],,"Hyperfunction of increasing the amount of drug is a process of performing an excessive function of increasing the amount of drugs. And the degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (moderate) .",false,,,http://purl.obolibrary.org/obo/TXPO_0001840,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of increasing the amount of drug is a process of performing an excessive function of increasing the amount of drugs. And the degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (moderate) .",,,http://purl.obolibrary.org/obo/TXPO_0001637,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003869,,,,,,,,,,,TXPO:0003868,,,,,,,,,,,,,,,,,,,,,,hyperfunction of increasing the amount of phenobarbital  [Ground glass appearance (moderate) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003867,clonal expansion of preneoplastic cell,,Clonal expansion of preneoplastic cell is a subtype of clonal expansion: A process that becomes larger in the number of preneoplastic cells by cell division of a population of identical cells descended from a single progenitor.,false,,,http://purl.obolibrary.org/obo/NCIT_C20613,,,,,,,,,,,,,,,,,,,,,,Clonal expansion of preneoplastic cell is a subtype of clonal expansion: A process that becomes larger in the number of preneoplastic cells by cell division of a population of identical cells descended from a single progenitor.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003867,,,,,,,,,,,,,,,,,,,,,,clonal expansion of preneoplastic cell,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003865,regulation of generation of precursor metabolites and energy (sustained) [Ground glass appearance],,"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of precursor metabolites, substances from which energy is derived, and the processes involved in the liberation of energy from these substances. This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) .",false,,,http://purl.obolibrary.org/obo/TXPO_0003953,,,,,,,,,,,,,,,,,,,,,,"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of precursor metabolites, substances from which energy is derived, and the processes involved in the liberation of energy from these substances. This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003952|http://purl.obolibrary.org/obo/TXPO_0003925,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001677,,,,,,,,,,,TXPO:0003865,,,,,,,,,,,,,,,,,,,,,,regulation of generation of precursor metabolites and energy (sustained) [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003861,hyperfunction of decreasing the amount of drugs by Cytochrome P450 [Ground glass appearance],,"Hyperfunction of decreasing the amount of drugs is a process of performing an excessive function of decreasing the amount of drugs by Cytochrome P450.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0003859,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of decreasing the amount of drugs is a process of performing an excessive function of decreasing the amount of drugs by Cytochrome P450.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003861,,,,,,,,,,,,,,,,,,,,,,hyperfunction of decreasing the amount of drugs by Cytochrome P450 [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003862,CAR (mol),Constitutive Androstane Receptor|NR1I3,,false,,,http://purl.obolibrary.org/obo/TXPO_0001509,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:65035|NCBI-Human-GeneID:9970|NCBI-Mouse-GeneID:12355,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Constitutive Androstane Receptor|NR1I3,,,,,TXPO:0003862,,,,,,,,,,,,,,,,,,,,,,CAR (mol),,,,,,,,,,,,,,,,,,,,,,,9970,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003860,phenobarbital metabolism imbalance [Ground glass appearance],,"Phenobarbital metabolism imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance of the phenobarbital metabolism.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001665,,,,,,,,,,,,,,,,,,,,,,"Phenobarbital metabolism imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance of the phenobarbital metabolism.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000934,,,,,,,,,,,TXPO:0003860,,,,,,,,,,,,,,,,,,,,,,phenobarbital metabolism imbalance [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000058,FasR,Fas receptor|CD95|Apo-1,,false,,,http://purl.obolibrary.org/obo/IMR_0000056,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Fas receptor|CD95|Apo-1,,,,,IMR:0000058,,,,,,,,,,,,,,,,,,,,,,FasR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004094,Tyms [Hepatocarcinogenesis],thymidylate synthetase [Hepatocarcinogenesis],,false,,,http://purl.obolibrary.org/obo/TXPO_1000391|http://purl.obolibrary.org/obo/TXPO_0000837,,,,,,,,,,,,,,,,,,,,"NCBI-Mouse-GeneID:22171|NCBI-Human-GeneID:7298|http://omim.org/entry/188350|Thymidylate synthase catalyzes the methylation of deoxyuridylate to deoxythymidylate using 5,10-methylenetetrahydrofolate (methylene-THF) as a cofactor. This function maintains the dTMP (thymidine-5-prime monophosphate) pool critical for DNA replication and repair. The enzyme has been of interest as a target for cancer chemotherapeutic agents. It is considered to be the primary site of action for 5-fluorouracil, 5-fluoro-2-prime-deoxyuridine, and some folate analogs. Expression of this gene and that of a naturally occuring antisense transcript rTSalpha (GeneID:55556) vary inversely when cell-growth progresses from late-log to plateau phase. [provided by RefSeq, Jul 2008]
https://www.ncbi.nlm.nih.gov/gene/7298|NCBI-Rat-GeneID:29261",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,thymidylate synthetase [Hepatocarcinogenesis],,,,,TXPO:0004094,,,,,,,,,,,,,,,,,,,,,,Tyms [Hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004093,TWIST1 [Hepatocarcinogenesis],twist family bHLH transcription factor 1 [Hepatocarcinogenesis],,false,,,http://purl.obolibrary.org/obo/TXPO_0000837|http://purl.obolibrary.org/obo/TXPO_1000380,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:22160|NCBI-Human-GeneID:7291|NCBI-Rat-GeneID:85489|PMID:19345188|PMID:15210113|PMID:25653024,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,twist family bHLH transcription factor 1 [Hepatocarcinogenesis],,,,,TXPO:0004093,,,,,,,,,,,,,,,,,,,,,,TWIST1 [Hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004099,"negative regulation of mitochondrial electron transport, succinate to ubiquinone",,"Any process that stops, prevents or reduces the frequency, rate or extent of the transfer of electrons from succinate to ubiquinone.",false,,,http://purl.obolibrary.org/obo/TXPO_0002342,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents or reduces the frequency, rate or extent of the transfer of electrons from succinate to ubiquinone.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004099,,,,,,,,,,,,,,,,,,,,,,"negative regulation of mitochondrial electron transport, succinate to ubiquinone",,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006121,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004096,protein ubiquitination,protein ubiquitinylation|protein ubiquitylation,The process in which one or more ubiquitin groups are added to a protein.,false,,,http://purl.obolibrary.org/obo/TXPO_0004107,,,,,,,,,,,,,,,,,,,,,,The process in which one or more ubiquitin groups are added to a protein.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,protein ubiquitinylation|protein ubiquitylation,,,,,TXPO:0004096,,,,,,,,,,,,,,,,,,,,,,protein ubiquitination,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004097,genetic information carrier role,,genetic information carrier role is a subtype of role dependent on transmitting genetic information process,false,,,http://purl.obolibrary.org/obo/TXPO_0001393,,,,,,,,,,,,,,,,,,,,,,genetic information carrier role is a subtype of role dependent on transmitting genetic information process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004097,,,,,,,,,,,,,,,,,,,,,,genetic information carrier role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004095,MMAA (human)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001135|http://purl.obolibrary.org/obo/TXPO_0003833,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:166785|http://www.reactome.org/content/detail/R-HSA-3359475,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000166785,,,,,,,,,,,,,TXPO:0004095,,,,,,,,,,,,,,,,,,,,,,MMAA (human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004091,Sub1 [Hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000837|http://purl.obolibrary.org/obo/TXPO_1000368,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:20024|NCBI-Human-GeneID:10923|NCBI-Rat-GeneID:192269|PMID:25961912|PMID:8062391,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004091,,,,,,,,,,,,,,,,,,,,,,Sub1 [Hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004090,insulin(canonical)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003213|http://purl.obolibrary.org/obo/IMR_0000052,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004090,,,,,,,,,,,,,,,,,,,,,,insulin(canonical)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004092,Kcnma1(mouse)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003278|http://purl.obolibrary.org/obo/TXPO_0003839,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:16531|PMID:27800604|https://omim.org/entry/600150|https://reactome.org/PathwayBrowser/#/R-HSA-1296052,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000003778,,,,,,,,,,,,,TXPO:0004092,,,,,,,,,,,,,,,,,,,,,,Kcnma1(mouse)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004098,positive regulation of glutathione biosynthetic process [Glutathione depletion],,"Any process that activates or increases the frequency, rate or extent of glutathione biosynthetic process.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/GO_1903788|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Any process that activates or increases the frequency, rate or extent of glutathione biosynthetic process.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001938,,,,,,,,,,,,,,,,,TXPO:0004098,,,,,,,,,,,,,,,,,,,,,,positive regulation of glutathione biosynthetic process [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006750,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/NCBITaxon_10090,mus musculus,house mouse|mouse,,false,,,http://purl.obolibrary.org/obo/NCBITaxon_9989,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,house mouse|mouse,,,,,NCBITaxon:10090,,,,,,,,,,,,,,,,,,,,,,mus musculus,,,,,,,http://purl.obolibrary.org/obo/ncbitaxon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_50689,reproductive control drug,reproductive control drugs|reproductive control agent,A substance used either in the prevention or facilitation of pregnancy.,false,,,http://purl.obolibrary.org/obo/CHEBI_23888,,,,,,,,,,,,,,,,,,,,,,A substance used either in the prevention or facilitation of pregnancy.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,reproductive control drugs|reproductive control agent,,,,,,,,,,,,,,,,,,,,,CHEBI:50689,,,,reproductive control drug,,CHEBI:50689,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003053,DNAJC3 -cochaperone (canonical)[ER stress -Refolding [persist]],p58IPK [ER stress],,false,,,http://purl.obolibrary.org/obo/TXPO_0003052,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002922,,,,,p58IPK [ER stress],,,,,TXPO:0003053,,,,,,,,,,,,,,,,,,,,,,DNAJC3 -cochaperone (canonical)[ER stress -Refolding [persist]],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003059,PERK signaling to eIF2a [ER stress - translation],,"A process in which a signal to eIF2a is transduced by PERK.
This process is dependent on the translation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002449|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"A process in which a signal to eIF2a is transduced by PERK.
This process is dependent on the translation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003054,,,,,,,,,,,TXPO:0003059,,,,,,,,,,,,,,,,,,,,,,PERK signaling to eIF2a [ER stress - translation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003051,refolding promoting factor role,,Refolding promotor is a role played by any substance that promotes the process of refolding.,false,,,http://purl.obolibrary.org/obo/TXPO_0003230,,,,,,,,http://purl.obolibrary.org/obo/GO_0042026,,,,,,,,,,,,,,Refolding promotor is a role played by any substance that promotes the process of refolding.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003051,,,,,,,,,,,,,,,,,,,,,,refolding promoting factor role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Yuki Y. 2018.08.31
http://purl.obolibrary.org/obo/TXPO_0003054,ATF4 gene expression by eIF2a [ER stress - translation],,"ATF4 gene expression by eIF2a is a subtype of gene expression: The process in which a gene sequence is converted into a mature ATF4 gene product or products (proteins or RNA) by eIF2a.
This process is dependent on the retranslation process and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000707,,,,,,,,,,,,,,,,,,,,PMID:23334697|http://www.ncbi.nlm.nih.gov/pubmed/18426796|Reactome:R-HSA-381128,,"ATF4 gene expression by eIF2a is a subtype of gene expression: The process in which a gene sequence is converted into a mature ATF4 gene product or products (proteins or RNA) by eIF2a.
This process is dependent on the retranslation process and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003057,,,,,,,,,,,TXPO:0003054,,,,,,,,,,,,,,,,,,,,,,ATF4 gene expression by eIF2a [ER stress - translation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003050,XBP1 - transcriptional regulator (canonical)[ER stress - Refolding -ATF6 pathway],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001968,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003051,,,,,,,,,,TXPO:0003050,,,,,,,,,,,,,,,,,,,,,,XBP1 - transcriptional regulator (canonical)[ER stress - Refolding -ATF6 pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003057,GADD34 gene expression by ATF4 [ER stress],,"GADD34 gene expression by ATF4 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence of GADD34 is converted into a mature gene product or products (proteins or RNA) by ATF4.
This process is dependent on the retranslation process and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0003056,,,,,,,,,,,,,,,,,,,,PMID:27346803,,"GADD34 gene expression by ATF4 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence of GADD34 is converted into a mature gene product or products (proteins or RNA) by ATF4.
This process is dependent on the retranslation process and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003055,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002935,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002752,,,,,,,,,,,TXPO:0003057,,,,,,,,,,,,,,,,,,,,,,GADD34 gene expression by ATF4 [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003052,DNAJC3 (canonical)[ER stress],ERdj6 [ER stress]|p58IPK [ER stress],,false,,,http://purl.obolibrary.org/obo/TXPO_1000115|http://purl.obolibrary.org/obo/TXPO_0000871,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:100037258|NCBI-Rat-GeneID:63880|NCBI-Human-GeneID:5611|http://omim.org/entry/601184,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ERdj6 [ER stress]|p58IPK [ER stress],,,,,TXPO:0003052,,,,,,,,,,,,,,,,,,,,,,DNAJC3 (canonical)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003055,ATF4 - transcriptional regulator (canonical)[ER stress - translation],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001907,http://purl.obolibrary.org/obo/TXPO_0002966,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,,,,,,TXPO:0003055,,,,,,,,,,,,,,,,,,,,,,ATF4 - transcriptional regulator (canonical)[ER stress - translation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003058,PERK-ATF4-GADD34 signaling [ER stress - retranslation],,"PERK-eIF2a-ATF4 mediated pathway is a subtype of PERK-eIF2a signaling: Sequence of linked reactions, which has PERK-eIF2a signaling and GADD34 gene regulation by ATF4.
This pathway is dependent on the retranslation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002513,,,,,,,,,,,,,,,,,,,,,,"PERK-eIF2a-ATF4 mediated pathway is a subtype of PERK-eIF2a signaling: Sequence of linked reactions, which has PERK-eIF2a signaling and GADD34 gene regulation by ATF4.
This pathway is dependent on the retranslation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003059|http://purl.obolibrary.org/obo/TXPO_0003054|http://purl.obolibrary.org/obo/TXPO_0003057,,http://purl.obolibrary.org/obo/TXPO_0002483|http://purl.obolibrary.org/obo/TXPO_0000285,,,,,,,,,,,,,,,,TXPO:0003058,,,,,,,,,,,,,,,,,,,,,,PERK-ATF4-GADD34 signaling [ER stress - retranslation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003056,tranlation promotion gene expression by ATF4 [ER stress],,"Tranlation promotion gene expression by ATF4 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) related to the translation promotion by ATF4.
This process is dependent on the retranslation process and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000698,,,,,,,,,,,,,,,,,,,,PMID:27346803|PMID:11564868,,"Tranlation promotion gene expression by ATF4 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) related to the translation promotion by ATF4.
This process is dependent on the retranslation process and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003055,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002114,,,,,,,,,,,TXPO:0003056,,,,,,,,,,,,,,,,,,,,,,tranlation promotion gene expression by ATF4 [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OBI_1110012,occurrence of allergy,,The process of an allergic disease occurring in an organism.,false,,,http://purl.obolibrary.org/obo/OGMS_0000063,,,,,,,,,,,,,,,,,,,,,,The process of an allergic disease occurring in an organism.,IEDB,,,,occurrence of allergy,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IAO_0000123,,,,,,,,,,,,,,,,,,,,,,,,,,,,,OBI:1110012,,,,,,,,,,,,,,,,,,,,,,occurrence of allergy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IEDB
http://purl.obolibrary.org/obo/IMR_0000174,Integrin beta,,,false,,,http://purl.obolibrary.org/obo/IMR_0000172,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000174,,,,,,,,,,,,,,,,,,,,,,Integrin beta,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000009972,NUP153,,Other designations: 153 kDa nucleoporin|nuclear pore complex protein Nup153|nuclear pore complex protein hnup153|nucleoporin Nup153,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,N153|HNUP153,,,,,,,,,,,,6,,,,,,Vega:OTTHUMG00000014312|HGNC:8062|MIM:603948|Ensembl:ENSG00000124789|HPRD:04899,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,nucleoporin 153kDa,,,6p22.3,,,,,,,,,,,,,,,,"GO_0000278 (EC: TAS); GO_0003677 (EC: IEA); GO_0005215 (EC: TAS, PMID: 8110839); GO_0005487 (EC: IDA); GO_0005515 (EC: IPI, PMID: 11896061); GO_0005643 (EC: IDA, PMID: 12802065); GO_0005654 (EC: TAS); GO_0005730 (EC: IDA); GO_0005737 (EC: IDA); GO_0005975 (EC: TAS); GO_0007077 (EC: TAS); GO_0008270 (EC: IEA); GO_0008645 (EC: TAS); GO_0010827 (EC: TAS); GO_0015031 (EC: IEA); GO_0015758 (EC: TAS); GO_0016032 (EC: TAS); GO_0017056 (EC: IMP, PMID: 15229283); GO_0019221 (EC: TAS); GO_0031965 (EC: IDA); GO_0034399 (EC: IDA, PMID: 11839768); GO_0042405 (EC: IDA, PMID: 11839768); GO_0042802 (EC: IPI); GO_0043495 (EC: IMP, PMID: 12802065); GO_0044281 (EC: TAS); GO_0044615 (EC: IDA, PMID: 11839768); GO_0046718 (EC: IEA); GO_0046832 (EC: IDA); GO_0051028 (EC: IEA); GO_0051292 (EC: IMP, PMID: 12802065); GO_0055085 (EC: TAS); GO_0075732 (EC: IEA)",,,,,,,,,PMID: 7603572; 8110839; 9114010; 9275187; 9847314; 10069809; 10202161; 10601273; 10629106; 10668806; 10749866; 10891500; 11024021; 11073998; 11238447; 11266456; 11567018; 11574060; 11598013; 11777942; 11839768; 11896061; 12138183; 12163599; 12191473; 12192048; 12228227; 12477932; 12802065; 12894213; 12917407; 14578343; 14718558; 15229283; 15302935; 15522285; 15632149; 15659641; 16133350; 16344560; 16543150; 16964243; 17081983; 17255949; 17314511; 17426026; 17615301; 17916694; 18029348; 18068677; 18187620; 18391951; 18854154; 19158386; 19369352; 19454010; 19471022; 19596686; 19615732; 20126445; 20360068; 20561986; 20658144; 20936779; 21139048; 21145461; 21182205; 21318276; 21327100; 21327106; 21489275; 21555518; 21593146; 21693764; 21858095; 21890473; 21906983; 21963094; 21983083; 22075984; 22082286; 22110128; 22118420; 22174692; 22249246; 22412018; 22505724; 22510057; 22586326; 22939629; 23000965; 23007389; 23251661; 23523133; 23752268,,,,,,,,,,,,,,,OGG:3000009972,,,,,,,nucleoporin 153kDa,,,,,,,,,,,,,Other designations: 153 kDa nucleoporin|nuclear pore complex protein Nup153|nuclear pore complex protein hnup153|nucleoporin Nup153,,NUP153,,,,,,,,,,,,,,,,,,,,,,,9972,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,NUP153,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000009971,NR1H4,farnesoid X-activated receptor|bile acid receptor|retinoid X receptor-interacting protein 14|farnesol receptor HRR-1|RXR-interacting protein 14|farnesoid X nuclear receptor,,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,farnesoid X-activated receptor|bile acid receptor|retinoid X receptor-interacting protein 14|farnesol receptor HRR-1|RXR-interacting protein 14|farnesoid X nuclear receptor,,,,,OGG:3000009971,,,,,,,"nuclear receptor subfamily 1, group H, member 4",,,,,,,,,,,,,,,NR1H4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000009970,NR1I3,Nuclear Receptor Subfamily 1 Group I Member 3|MB67|Constitutive Activator Of Retinoid Response|Constitutive Androstane Receptor|CAR,,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,,,,,,,https://omim.org/entry/603881,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Nuclear Receptor Subfamily 1 Group I Member 3|MB67|Constitutive Activator Of Retinoid Response|Constitutive Androstane Receptor|CAR,,,,,OGG:3000009970,,,,,,,"This gene encodes a member of the nuclear receptor superfamily, and is a key regulator of xenobiotic and endobiotic metabolism. The protein binds to DNA as a monomer or a heterodimer with the retinoid X receptor and regulates the transcription of target genes involved in drug metabolism and bilirubin clearance, such as cytochrome P450 family members. Unlike most nuclear receptors, this transcriptional regulator is constitutively active in the absence of ligand but is regulated by both agonists and inverse agonists. Ligand binding results in translocation of this protein to the nucleus, where it activates or represses target gene transcription. These ligands include bilirubin, a variety of foreign compounds, steroid hormones, and prescription drugs. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]",,,,,,,,,,,,,,,NR1I3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000007352,UCP3,,Other designations: mitochondrial uncoupling protein 3|solute carrier family 25 member 9,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,SLC25A9,,,,,,,,,,,,11,,,,,,MIM:602044|Vega:OTTHUMG00000168109|Ensembl:ENSG00000175564|HGNC:12519|HPRD:03623,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"uncoupling protein 3 (mitochondrial, proton carrier)",,,11q13.4,,,,,,,,,,,,,,,,"GO_0000303 (EC: IEA); GO_0001666 (EC: IEA); GO_0005215 (EC: TAS, PMID: 9196039); GO_0005515 (EC: IPI); GO_0005739 (EC: TAS, PMID: 9180264); GO_0005743 (EC: TAS); GO_0006629 (EC: TAS, PMID: 10935638); GO_0006631 (EC: IEA); GO_0006839 (EC: IEA); GO_0007568 (EC: IEA); GO_0007584 (EC: IEA); GO_0007585 (EC: TAS, PMID: 9180264); GO_0009409 (EC: IEA); GO_0014823 (EC: IEA); GO_0015992 (EC: TAS); GO_0016021 (EC: IEA); GO_0017077 (EC: IEA); GO_0022904 (EC: TAS); GO_0032868 (EC: IEA); GO_0032870 (EC: IEA); GO_0044237 (EC: TAS); GO_0044281 (EC: TAS); GO_0051384 (EC: IEA)",,,,,,,,,PMID: 9180264; 9196039; 9305858; 9325252; 9480760; 9498661; 9769326; 10329378; 10620491; 10748196; 10772343; 10785390; 10935638; 10958796; 11126413; 11151767; 11238538; 11319649; 11683368; 11842047; 11875702; 11920154; 11994670; 12051710; 12075570; 12145158; 12145475; 12170470; 12217879; 12351640; 12395215; 12477932; 12612210; 12634927; 12670931; 12720538; 12734183; 12756473; 12824081; 12843208; 14671191; 14702039; 14708035; 15045692; 15120704; 15211595; 15346230; 15489334; 15496137; 15520825; 15564896; 15870396; 15910756; 15959859; 15978856; 16006788; 16046300; 16178820; 16215931; 16337086; 16344560; 16352674; 16373902; 16622580; 16631432; 16644712; 16741147; 16752430; 16966355; 17150099; 17351641; 17502873; 17512314; 17544366; 17571165; 17587402; 17676309; 17728536; 17786284; 17786291; 17870627; 18059082; 18167556; 18191161; 18223008; 18249216; 18305572; 18348082; 18426825; 18426866; 18484143; 18648851; 18660489; 18676680; 18755175; 18825612; 18924534; 18956255; 18996102; 19039313; 19056482; 19056576; 19073146; 19155787; 19170196; 19336475; 19369366; 19413708; 19468707; 19491387; 19578796; 19625176; 19653005; 19680556; 19692168; 19710539; 19753844; 19769793; 19876004; 19913121; 19913848; 19948975; 20031128; 20186155; 20416077; 20468064; 20538960; 20628086; 20679960; 20694293; 20734064; 20802238; 20877624; 21047682; 21074158; 21175267; 21336965; 21544083; 21613221; 21751002; 21775425; 21897112; 22241057; 22774401; 22811361; 23165529; 23266187; 23365654; 23412863; 23505621; 23521650; 23560041; 23639961; 24124336,,,,,,,,,,,,,,,OGG:3000007352,,,,,,,"uncoupling protein 3 (mitochondrial, proton carrier)",,,,,,,,,,,,,Other designations: mitochondrial uncoupling protein 3|solute carrier family 25 member 9,,UCP3,,,,,,,,,,,,,,,,,,,,,,,7352,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,UCP3,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000007357,UGCG,,Other designations: GLCT-1|UDP-glucose:N-acylsphingosine D-glucosyltransferase|ceramide glucosyltransferase|glucosylceramide synthase,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,GCS|GLCT1,,,,,,,,,,,,9,,,,,,HPRD:04190|HGNC:12524|MIM:602874,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,UDP-glucose ceramide glucosyltransferase,,,9q31,,,,,,,,,,,,,,,,"GO_0000139 (EC: TAS); GO_0006665 (EC: TAS); GO_0006679 (EC: TAS, PMID: 8643456); GO_0006687 (EC: TAS); GO_0006688 (EC: TAS, PMID: 8643456); GO_0008120 (EC: IEA); GO_0008544 (EC: TAS, PMID: 9545298); GO_0016020 (EC: TAS, PMID: 8643456); GO_0016021 (EC: IEA); GO_0044281 (EC: TAS)",,,,,,,,,PMID: 1533793; 8643456; 8901638; 9545298; 9605861; 10945987; 11335714; 11915344; 12477932; 12489486; 12873973; 14766899; 15263008; 15489334; 15661399; 15747776; 16500619; 17709137; 18155680; 18560890; 19693666; 20533270; 20540746; 20843709; 21278235; 21380926; 21558327; 21617856; 21756066; 21832049; 21890473; 22270805; 22936806; 23133636; 23555901; 24510559,,,,,,,,,,,,,,,OGG:3000007357,,,,,,,UDP-glucose ceramide glucosyltransferase,,,,,,,,,,,,,Other designations: GLCT-1|UDP-glucose:N-acylsphingosine D-glucosyltransferase|ceramide glucosyltransferase|glucosylceramide synthase,,UGCG,,,,,,,,,,,,,,,,,,,,,,,7357,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,UGCG,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0001131,perlecan,basement membrane heparan sulfate proteoglycan,,false,,,http://purl.obolibrary.org/obo/IMR_0001125,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,basement membrane heparan sulfate proteoglycan,,,,,IMR:0001131,,,,,,,,,,,,,,,,,,,,,,perlecan,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_50792,estrogen receptor antagonist,estrogen receptor antagonists,An antagonist at the estrogen receptor.,false,,,http://purl.obolibrary.org/obo/CHEBI_48706,,,,,,,,,,,,,,,,,,,,,,An antagonist at the estrogen receptor.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,estrogen receptor antagonists,,,,,,,,,,,,,,,,,,,,,CHEBI:50792,,,,estrogen receptor antagonist,,CHEBI:50792,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006066,alcohol metabolic process,alcohol metabolism,"The chemical reactions and pathways involving alcohols, any of a class of compounds containing one or more hydroxyl groups attached to a saturated carbon atom.",false,,,http://purl.obolibrary.org/obo/GO_0008152,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways involving alcohols, any of a class of compounds containing one or more hydroxyl groups attached to a saturated carbon atom.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,alcohol metabolism,,,,,GO:0006066,,,,,,,,,,,,,,,,,,,,,,alcohol metabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000008310,ACOX3,,"Other designations: BRCACox|acyl-Coenzyme A oxidase 3, pristanoyl|branched-chain acyl-CoA oxidase|peroxisomal acyl-coenzyme A oxidase 3|pristanoyl-CoA oxidase",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,4,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"acyl-CoA oxidase 3, pristanoyl",,,4p15.3,,,,,,,,,,,,,,,,"GO_0003995 (EC: IEA); GO_0005102 (EC: IPI); GO_0005739 (EC: IEA); GO_0005777 (EC: IDA, PMID:8993592); GO_0005782 (EC: TAS); GO_0016402 (EC: TAS); GO_0033540 (EC: IEA); GO_0033540 (EC: TAS); GO_0044255 (EC: TAS); GO_0044281 (EC: TAS); GO_0050660 (EC: IEA)",,,,,,,,,PMID:8125298; 8387517; 8993592; 9271077; 12477932; 15231748; 15489334; 15599942; 16344560; 16756494; 20178365; 20677014; 20877624; 21659360; 21906983; 22505724,,,,,,,,,,,,,,,OGG:3000008310,,,,,,,"acyl-CoA oxidase 3, pristanoyl",,,,,,,,,,,,,"Other designations: BRCACox|acyl-Coenzyme A oxidase 3, pristanoyl|branched-chain acyl-CoA oxidase|peroxisomal acyl-coenzyme A oxidase 3|pristanoyl-CoA oxidase",,ACOX3,,,,,,,,,,,,,,,,,,,,,,,8310,,,,,,,,9606,,,,,,,,,,,,,,,,,,,ACOX3,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0003626,cross-sectional area,,A 2-D extent attribute of the bearer which has been cut off to an axis.,false,,,http://purl.obolibrary.org/obo/TXPO_0000310,,,,,,,,,,,,,,,,,,,,,,A 2-D extent attribute of the bearer which has been cut off to an axis.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003626,,,,,,,,,,,,,,,,,,,,,,cross-sectional area,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003627,balooning [Liver Pathological Findings],,"Balooning [Liver PathologicalFindings] is a type of finding observed in the liver. On the basis of pathological morphology, the cytoplasm becomes enlarged like balloons accompanied by the vacuolation.",false,,,http://purl.obolibrary.org/obo/TXPO_0001507,,,,,,,,,,,,,,,,,,,,,,"Balooning [Liver PathologicalFindings] is a type of finding observed in the liver. On the basis of pathological morphology, the cytoplasm becomes enlarged like balloons accompanied by the vacuolation.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003627,,,,,,,,,,,,,,,,,,,,,,balooning [Liver Pathological Findings],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003620,inflammatory response [Lipidosis],,"Inflammatory response is a subtype of changing material: The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000192|http://purl.obolibrary.org/obo/TXPO_0001720,,,,,,,,,,,,,,,,,,,,PMID:25232821|https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2887297/|PMID:26609140|PMID:21038418|PMID:20303879|PMID:27814504|PMID:22883813|PMID:27346803|https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2887297/figure/F1/,,"Inflammatory response is a subtype of changing material: The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001744|http://purl.obolibrary.org/obo/TXPO_0000050|http://purl.obolibrary.org/obo/TXPO_0001878,http://purl.obolibrary.org/obo/TXPO_0001875|http://purl.obolibrary.org/obo/TXPO_0001901,,,,,,http://purl.obolibrary.org/obo/TXPO_0001890|http://purl.obolibrary.org/obo/TXPO_0003621,,,,,,,,,,,TXPO:0003620,,,,,,,,,,,,,,,,,,,,,,inflammatory response [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003625,decreased cross-sectional area,,An cross-sectional area which is relatively low.,false,,,http://purl.obolibrary.org/obo/PATO_0002058|http://purl.obolibrary.org/obo/TXPO_0003626,,,,,,,,,,,,,,,,,,,,,,An cross-sectional area which is relatively low.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003625,,,,,,,,,,,,,,,,,,,,,,decreased cross-sectional area,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003628,balooning [Liver Pathological Findings] [Lipidosis],,"Balooning [Liver PathologicalFindings] is a type of finding observed in the liver. On the basis of pathological morphology, the cytoplasm becomes enlarged like balloons accompanied by the vacuolation .
This finding is observable in the course of lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003627,,,,,,,,,,,,,,,,,,,,,,"Balooning [Liver PathologicalFindings] is a type of finding observed in the liver. On the basis of pathological morphology, the cytoplasm becomes enlarged like balloons accompanied by the vacuolation .
This finding is observable in the course of lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003628,,,,,,,,,,,,,,,,,,,,,,balooning [Liver Pathological Findings] [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000182,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003621,hepatic fibrosis [Lipidosis],,"Hepatic fibrosis is a subtype of fibrosis: A process that replaces liver tissues to fibrous connective tissues, usually as a consequence of inflammation or other injury.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0000816,,,,,,,,,,,,,,,,,,,,,,"Hepatic fibrosis is a subtype of fibrosis: A process that replaces liver tissues to fibrous connective tissues, usually as a consequence of inflammation or other injury.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003621,,,,,,,,,,,,,,,,,,,,,,hepatic fibrosis [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003623,lipid accumulation in hepatocyte,,Lipid accumulation  in hepatocyte is a subtype of lipid storage: A process that keeps lipids in hepatocytes.,false,,,http://purl.obolibrary.org/obo/GO_0019915,,,,,,,,,,,,,,,,,,,,,,Lipid accumulation  in hepatocyte is a subtype of lipid storage: A process that keeps lipids in hepatocytes.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_18059,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003623,,,,,,,,,,,,,,,,,,,,,,lipid accumulation in hepatocyte,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003624,lipid accumulation in hepatocyte (mild) [Lipidosis],lipid strorage in hepatocyte [Lipidosis (mild)],"Lipid accumulation in hepatocyte (mild) is a subtype of lipid strorage in hepatocyte: A process that keeps lipids in hepatocytes mildly.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001129,,,,,,,,,,,,,,,,,,,,,,"Lipid accumulation in hepatocyte (mild) is a subtype of lipid strorage in hepatocyte: A process that keeps lipids in hepatocytes mildly.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003538,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001519,,,,,,,,,,,,,lipid strorage in hepatocyte [Lipidosis (mild)],,,,,TXPO:0003624,,,,,,,,,,,,,,,,,,,,,,lipid accumulation in hepatocyte (mild) [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003629,hypofunction of peroxisomal fatty acid beta-oxidation,,Hypofunction of peroxisomal fatty acid beta-oxidation is a subtype of hypofunction of fatty acid beta-oxidation: A process that performs a decreased or insufficient fatty acid degradation.,false,,,http://purl.obolibrary.org/obo/TXPO_0002147|http://purl.obolibrary.org/obo/TXPO_0002007,,,,,,,,,,,,,,,,,,,,,,Hypofunction of peroxisomal fatty acid beta-oxidation is a subtype of hypofunction of fatty acid beta-oxidation: A process that performs a decreased or insufficient fatty acid degradation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003629,,,,,,,,,,,,,,,,,,,,,,hypofunction of peroxisomal fatty acid beta-oxidation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003622,inflammatory cell infiltration [Lipidosis],,Inflammatory cell infiltration is a subtype of moving A to the inside of B: A process that that moves the  outside inflammatory cell to the inside in response to an inflammatory reaction. This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.,false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0000540,,,,,,,,,,,,,,,,,,,,,,Inflammatory cell infiltration is a subtype of moving A to the inside of B: A process that that moves the  outside inflammatory cell to the inside in response to an inflammatory reaction. This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003620,,,,,,,,,,,TXPO:0003622,,,,,,,,,,,,,,,,,,,,,,inflammatory cell infiltration [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004972,fialuridine,2'-fluoro-5-iodoarauracil|FIAU,"Fialuridine, or 1-(2-deoxy-2-fluoro-1-D-arabinofuranosyl)-5-iodouracil (FIAU), is a nucleoside analogue that was investigated as a potential therapy for hepatitis B virus infection. (by Wikipedia)",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Wikipedia:Fialuridine|DrugBank:DB15427|CAS:69123-98-4,,"Fialuridine, or 1-(2-deoxy-2-fluoro-1-D-arabinofuranosyl)-5-iodouracil (FIAU), is a nucleoside analogue that was investigated as a potential therapy for hepatitis B virus infection. (by Wikipedia)",,,,,,,,,,,,C9H10FIN2O5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_36044,,,,,2'-fluoro-5-iodoarauracil|FIAU,,,,,TXPO:0004972,,,,,,,,,,,,,,,,,,,,,,fialuridine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,OC[C@H]1O[C@H]([C@@H](F)[C@@H]1O)N1C=C(I)C(=O)NC1=O,,,,,
http://purl.obolibrary.org/obo/TXPO_0004977,nagative regulation of mitophagy,,"Any process that activates or decreases the frequency, rate or extent of mitophagy.",false,,,http://purl.obolibrary.org/obo/GO_1901524,,,,,,,,,,,,,,,,,,,,,,"Any process that activates or decreases the frequency, rate or extent of mitophagy.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004977,,,,,,,,,,,,,,,,,,,,,,nagative regulation of mitophagy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0000423,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004975,Hypofunction of mitochondrial repair [mitochondrial disorder],,"Hypofunction of mitochondrial repair is a subtype of hypofunctioning: A process that performs a decreased or insufficient mitochondrial repair.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0004988,,,,,,,,,,,,,,,,,,,,PMID:31623280,,"Hypofunction of mitochondrial repair is a subtype of hypofunctioning: A process that performs a decreased or insufficient mitochondrial repair.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004975,,,,,,,,,,,,,,,,,,,,,,Hypofunction of mitochondrial repair [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004970,panadiplon,U-78875,Panadiplon (U-78875) is an anxiolytic drug with a novel chemical structure that is not closely related to other drugs of this type. (by Wikipedia),false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:124423-84-3|Wikipedia:Panadiplon,,Panadiplon (U-78875) is an anxiolytic drug with a novel chemical structure that is not closely related to other drugs of this type. (by Wikipedia),,,,,,,,,,,,C18H17N5O2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35474,,,,,U-78875,,,,,TXPO:0004970,,,,,,,,,,,,,,,,,,,,,,panadiplon,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004971,pyrethrins [hepatocarcinogenesis],,The active insecticidal constituents of Chrysanthemum cinerariifolium flowers.,false,,,http://purl.obolibrary.org/obo/TXPO_0004455|http://purl.obolibrary.org/obo/CHEBI_39098,,,,,,,,,,,,,,,,,,,,CAS:8003-34-7|PMID:19463055,,The active insecticidal constituents of Chrysanthemum cinerariifolium flowers.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004971,,,,,,,,,,,,,,,,,,,,,,pyrethrins [hepatocarcinogenesis],,,,,,,,,,,http://purl.obolibrary.org/obo/NCBITaxon_9989,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004973,Increasing fructose level,,Increasing fructose level is a subtype of increasing quantity: A process that changes the amount of fructose level to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing fructose level is a subtype of increasing quantity: A process that changes the amount of fructose level to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004973,,,,,,,,,,,,,,,,,,,,,,Increasing fructose level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004976,Increasing uric acid level [mitochondrial disorder],,"Increasing uric acid level is a subtype of increasing quantity: A process that changes the amount of uric acid level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0005027|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:31623280,,"Increasing uric acid level is a subtype of increasing quantity: A process that changes the amount of uric acid level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004373,,,,,,,,,,,TXPO:0004976,,,,,,,,,,,,,,,,,,,,,,Increasing uric acid level [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004974,Increasing fructose level [mitochondrial disorder],,"Increasing fructose level is a subtype of increasing quantity: A process that changes the amount of fructose level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0004973,,,,,,,,,,,,,,,,,,,,PMID:31623280,,"Increasing fructose level is a subtype of increasing quantity: A process that changes the amount of fructose level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001988|http://purl.obolibrary.org/obo/TXPO_0004373|http://purl.obolibrary.org/obo/TXPO_0004372|http://purl.obolibrary.org/obo/TXPO_0002005|http://purl.obolibrary.org/obo/TXPO_0004975|http://purl.obolibrary.org/obo/TXPO_0004976|http://purl.obolibrary.org/obo/TXPO_0004121,,,,,,,,,,,TXPO:0004974,,,,,,,,,,,,,,,,,,,,,,Increasing fructose level [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004978,macrophage migration [mitochondrial disorder],,"The orderly movement of a macrophage from one site to another.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/GO_1905517|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:31649547,,"The orderly movement of a macrophage from one site to another.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004249,,,,,,,,,,,TXPO:0004978,,,,,,,,,,,,,,,,,,,,,,macrophage migration [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004979,malondialdehyde [mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/CHEBI_566274|http://purl.obolibrary.org/obo/TXPO_0004312,,,,,,,,,,,,,,,,,,,,PMID:25339807,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004979,,,,,,,,,,,,,,,,,,,,,,malondialdehyde [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000025822,DNAJB5,,Other designations: dnaJ homolog subfamily B member 5|heat shock cognate 40|heat shock protein Hsp40-2|heat shock protein Hsp40-3|heat shock protein cognate 40,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,Hsc40,,,,,,,,,,,,9,,,,,,Vega:OTTHUMG00000019840|MIM:611328|HGNC:14887|Ensembl:ENSG00000137094,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"DnaJ (Hsp40) homolog, subfamily B, member 5",,,9p13.3,,,,,,,,,,,,,,,,"GO_0000122 (EC: IEA); GO_0005515 (EC: IPI); GO_0005634 (EC: IEA); GO_0005829 (EC: IEA); GO_0006457 (EC: IEA); GO_0006986 (EC: IEP, PMID:10570961); GO_0051082 (EC: IEA)",,,,,,,,,PMID:7566098; 10570961; 11147971; 12477932; 14702039; 15456869; 18457437; 18555775; 21078624; 21139048; 23000965,,,,,,,,,,,,,,,OGG:3000025822,,,,,,,"DnaJ (Hsp40) homolog, subfamily B, member 5",,,,,,,,,,,,,Other designations: dnaJ homolog subfamily B member 5|heat shock cognate 40|heat shock protein Hsp40-2|heat shock protein Hsp40-3|heat shock protein cognate 40,,DNAJB5,,,,,,,,,,,,,,,,,,,,,,,25822,RP11-392A14.5,,,,,,,9606,,,,,,,,,,,,,,,,,,,DNAJB5,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/UBERON_0002405,immune system,,"Anatomical system that protects the body from foreign substances, cells, and tissues by producing the immune response and that includes especially the thymus, spleen, lymphoid tissue, lymphocytes including the B cells and T cells, and antibodies.",false,,,http://purl.obolibrary.org/obo/UBERON_0000467,,,,,,,,,,,,,,,,,,,,http://linkedlifedata.com/resource/umls/id/C0020962|http://www.snomedbrowser.com/Codes/Details/362590003|http://purl.obolibrary.org/obo/NCIT_C12735|http://en.wikipedia.org/wiki/Immune_system|http://www.snomedbrowser.com/Codes/Details/362590003|BILA:0000104|TAO:0001159|MA:0002711|GAID:328|ZFA:0001159|MESH:D007107|NCIT:C12735|AAO:0011003|VHOG:0001247|FMA:9825|XAO:0003152|OpenCyc:Mx4rvWNkm5wpEbGdrcN5Y29ycA|UMLS:C0020962,,"Anatomical system that protects the body from foreign substances, cells, and tissues by producing the immune response and that includes especially the thymus, spleen, lymphoid tissue, lymphocytes including the B cells and T cells, and antibodies.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"The antibody-based immune system defined by the presence of the major histocompatibility complex (MHC), T cell receptor (TCR), B cell receptor (BCR) or recombination activating genes (RAGs) is known beginning from jawed fishes.[well established][VHOG]",,UBERON:0002405,,,,,,,,,,,,,,,,,,,,,,immune system,,,,,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000277,PDLIM5 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:64353|NCBI-Mouse-GeneID:56376|NCBI-Human-GeneID:10611,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000010611,,,,,,,,,,,,,TXPO:1000277,,,,,,,,,,,,,,,,,,,,,,PDLIM5 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000276,P4HB (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:18453|NCBI-Rat-GeneID:25506|NCBI-Human-GeneID:5034,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000005034,,,,,,,,,,,,,TXPO:1000276,,,,,,,,,,,,,,,,,,,,,,P4HB (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000271,OCT family (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:1000271,,,,,,,,,,,,,,,,,,,,,,OCT family (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000275,PDGF (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:1000275,,,,,,,,,,,,,,,,,,,,,,PDGF (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000270,OATPs family,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:1000270,,,,,,,,,,,,,,,,,,,,,,OATPs family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000279,PITX2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:18741|NCBI-Rat-GeneID:54284|NCBI-Human-GeneID:5308,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000005308,,,,,,,,,,,,,TXPO:1000279,,,,,,,,,,,,,,,,,,,,,,PITX2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000274,PCK2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:74551|NCBI-Rat-GeneID:361042|NCBI-Human-GeneID:5106,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000005106,,,,,,,,,,,,,TXPO:1000274,,,,,,,,,,,,,,,,,,,,,,PCK2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000278,PEX11a (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:85249|NCBI-Human-GeneID:8800|NCBI-Mouse-GeneID:18631,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000008800,,,,,,,,,,,,,TXPO:1000278,,,,,,,,,,,,,,,,,,,,,,PEX11a (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000272,Osgin1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:171493|NCBI-Mouse-GeneID:71839|NCBI-Human-GeneID:29948,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000029948,,,,,,,,,,,,,TXPO:1000272,,,,,,,,,,,,,,,,,,,,,,Osgin1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000273,PCDH9 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:306091|NCBI-Human-GeneID:5101|NCBI-Mouse-GeneID:211712,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000005101,,,,,,,,,,,,,TXPO:1000273,,,,,,,,,,,,,,,,,,,,,,PCDH9 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_33250,atom,,A chemical entity constituting the smallest component of an element having the chemical properties of the element.,false,,,http://purl.obolibrary.org/obo/CHEBI_24431,,,,,,,,,,,,,,,,,,,,,,A chemical entity constituting the smallest component of an element having the chemical properties of the element.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:33250,,,,,,,,,,,,,,,,,,,,,,atom,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000055571,CNOT11,,Other designations: CCR4-NOT transcription complex subunit 11|UPF0760 protein C2orf29,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,C2orf29,,,,,,,,,,,,2,,,,,,HGNC:25217|Ensembl:ENSG00000158435|Vega:OTTHUMG00000130686|HPRD:12812,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"CCR4-NOT transcription complex, subunit 11",,,2q11.2,,,,,,,,,,,,,,,,"GO_0000288 (EC: TAS); GO_0000289 (EC: TAS); GO_0003674 (EC: ND); GO_0005515 (EC: IPI); GO_0005634 (EC: IEA); GO_0005829 (EC: TAS); GO_0006351 (EC: IEA); GO_0006355 (EC: IEA); GO_0006417 (EC: IEA); GO_0008283 (EC: NAS, PMID: 10497265); GO_0010467 (EC: TAS); GO_0016070 (EC: TAS); GO_0016071 (EC: TAS); GO_0030014 (EC: IDA, PMID: 19558367); GO_0031047 (EC: IEA)",,,,,,,,,PMID: 10497265; 12477932; 14702039; 15489334; 15815621; 19322201; 19558367; 20360068; 21139048; 21890473; 21906983; 21963094; 22505724; 23232451; 23303381; 23602568; 24250222,,,,,,,,,,,,,,,OGG:3000055571,,,,,,,"CCR4-NOT transcription complex, subunit 11",,,,,,,,,,,,,Other designations: CCR4-NOT transcription complex subunit 11|UPF0760 protein C2orf29,,CNOT11,,,,,,,,,,,,,,,,,,,,,,,55571,C40,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,CNOT11,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0001475,DOCK7,,,false,,,http://purl.obolibrary.org/obo/IMR_0001469,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001475,,,,,,,,,,,,,,,,,,,,,,DOCK7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000064215,DNAJC1,,Other designations: DnaJ-like protein|dnaJ homolog subfamily C member 1|dnaJ protein homolog MTJ1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,DNAJL1|HTJ1|ERdj1|MTJ1,,,,,,,,,,,,10,,,,,,HPRD:09922|Ensembl:ENSG00000136770|MIM:611207|HGNC:20090|Vega:OTTHUMG00000017800,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"DnaJ (Hsp40) homolog, subfamily C, member 1",,,10p12.31,,,,,,,,,,,,,,,,"GO_0001671 (EC: TAS, PMID:14668352); GO_0003677 (EC: IEA); GO_0003682 (EC: IEA); GO_0005515 (EC: IPI, PMID:14668352); GO_0005783 (EC: ISS); GO_0005789 (EC: IEA); GO_0006417 (EC: IEA); GO_0006457 (EC: IEA); GO_0016021 (EC: IEA); GO_0031965 (EC: IEA); GO_0032781 (EC: TAS, PMID:14668352); GO_0045861 (EC: TAS, PMID:14668352); GO_0050708 (EC: IDA, PMID:14668352); GO_0051087 (EC: IEA)",,,,,,,,,PMID:10777498; 12477932; 14667819; 14668352; 14702039; 15164054; 15489334; 16271702; 16385451; 18029348; 22412018; 23535729; 23535730,,,,,,,,,,,,,,,OGG:3000064215,,,,,,,"DnaJ (Hsp40) homolog, subfamily C, member 1",,,,,,,,,,,,,Other designations: DnaJ-like protein|dnaJ homolog subfamily C member 1|dnaJ protein homolog MTJ1,,DNAJC1,,,,,,,,,,,,,,,,,,,,,,,64215,RP11-399C16.1,,,,,,,9606,,,,,,,,,,,,,,,,,,,DNAJC1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000051512,GTSE1,,Other designations: G2 and S phase-expressed protein 1|protein B99 homolog,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,B99,,,,,,,,,,,,22,,,,,,Ensembl:ENSG00000075218|HGNC:13698|Vega:OTTHUMG00000150486|HPRD:09593|MIM:607477,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,G-2 and S-phase expressed 1,,,22q13.2-q13.3,,,,,,,,,,,,,,,,"GO_0000085 (EC: NAS, PMID: 10974554); GO_0003674 (EC: ND); GO_0005515 (EC: IPI); GO_0005881 (EC: NAS, PMID: 10974554); GO_0006977 (EC: NAS, PMID: 10974554); GO_0007017 (EC: NAS, PMID: 10974554)",,,,,,,,,PMID: 8125298; 8889548; 10591208; 10974554; 10984615; 12477932; 12750368; 14702039; 14707141; 15146197; 15231747; 15302935; 15461802; 15489334; 15790807; 15998911; 16344560; 16964243; 19531213; 19615732; 19913121; 20018861; 20577264; 20628086; 20800603; 21139048; 21693764; 21890473; 22292647; 22990118; 23236459; 24250222,,,,,,,,,,,,,,,OGG:3000051512,,,,,,,G-2 and S-phase expressed 1,,,,,,,,,,,,,Other designations: G2 and S phase-expressed protein 1|protein B99 homolog,,GTSE1,,,,,,,,,,,,,,,,,,,,,,,51512,RP5-1163J1.2,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,GTSE1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0001509,Rap2B,,,false,,,http://purl.obolibrary.org/obo/IMR_0001507,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001509,,,,,,,,,,,,,,,,,,,,,,Rap2B,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000084696,ABHD1,,Other designations: abhydrolase domain-containing protein 1|lung alpha/beta hydrolase 1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,LABH1,,,,,,,,,,,,2,,,,,,HGNC:17553|Ensembl:ENSG00000143994|MIM:612195|Vega:OTTHUMG00000097072|HPRD:07468,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,abhydrolase domain containing 1,,,2p23.3,,,,,,,,,,,,,,,,"GO_0003674 (EC: ND); GO_0008150 (EC: ND); GO_0016021 (EC: NAS, PMID: 12735795); GO_0016787 (EC: IEA)",,,,,,,,,PMID: 11922611; 12477932; 12735795; 14702039; 15489334; 15815621,,,,,,,,,,,,,,,OGG:3000084696,,,,,,,abhydrolase domain containing 1,,,,,,,,,,,,,Other designations: abhydrolase domain-containing protein 1|lung alpha/beta hydrolase 1,,ABHD1,,,,,,,,,,,,,,,,,,,,,,,84696,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,ABHD1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0010553,40S ribosomal protein S28,40S small ribosomal protein 28,,false,,,http://purl.obolibrary.org/obo/IMR_0000896,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,40S small ribosomal protein 28,,,,,IMR:0010553,,,,,,,,,,,,,,,,,,,,,,40S ribosomal protein S28,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000004258,MGST2,,,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,GST2|MGST-II,,,,,,,,,,,,,,,,,,HGNC:7063|MIM:601733|Ensembl:ENSG00000085871|HPRD:03436,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,microsomal glutathione S-transferase 2,,,,,,,,,,,,,,,,,,,"GO_0004364 (EC: IDA, PMID: 8703034); GO_0004464 (EC: IDA, PMID: 8703034); GO_0004602 (EC: IBA); GO_0005635 (EC: IBA); GO_0005789 (EC: TAS); GO_0005886 (EC: IDA, PMID: 9092565); GO_0006750 (EC: IDA, PMID: 8703034); GO_0006805 (EC: TAS); GO_0008047 (EC: IEA); GO_0010243 (EC: IEA); GO_0016021 (EC: IEA); GO_0019370 (EC: IDA, PMID: 8703034); GO_0032496 (EC: IEA); GO_0043231 (EC: IDA, PMID: 8703034); GO_0044281 (EC: TAS); GO_0055114 (EC: IBA); GO_1901687 (EC: TAS)",,,,,,,,,PMID: 8703034; 8889549; 9092565; 9278457; 9302651; 10673221; 11322876; 12477932; 15489334; 16169070; 16344560; 16498398; 16773312; 19343046; 20379614; 23409838,,,,,,,,,,,,,,,OGG:3000004258,,,,,,,microsomal glutathione S-transferase 2,,,,,,,,,,,,,,,MGST2,,,,,,,,,,,,,,,,,,,,,,,4258,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000004257,MGST1,,,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,,,,,,,Ensembl:ENSG00000008394|HGNC:7061|HPRD:00705|MIM:138330|Vega:OTTHUMG00000168816,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,microsomal glutathione S-transferase 1,,,,,,,,,,,,,,,,,,,"GO_0004364 (EC: IDA); GO_0004602 (EC: IDA); GO_0005515 (EC: IPI); GO_0005634 (EC: IEA); GO_0005739 (EC: IDA); GO_0005741 (EC: IEA); GO_0005743 (EC: IEA); GO_0005778 (EC: ISS); GO_0005783 (EC: ISS); GO_0005789 (EC: TAS); GO_0006749 (EC: IEA); GO_0006805 (EC: TAS); GO_0010243 (EC: IEA); GO_0016021 (EC: ISS); GO_0032496 (EC: IEA); GO_0033327 (EC: IEA); GO_0042493 (EC: IEA); GO_0042803 (EC: IEA); GO_0043295 (EC: IEA); GO_0044281 (EC: TAS); ... (Note: Only 20 GO IDs shown. See more from web page source or RDF output.)""",,,,,,,,,PMID: 1544849; 2307478; 3372534; 7566098; 7663172; 8812420; 10095775; 10524215; 10673221; 10777602; 11034337; 11587073; 11752456; 12359356; 12477932; 12818425; 14726533; 15338373; 15489334; 16384981; 17483957; 17714764; 18781797; 19343046; 20195357; 20727966; 21139048; 21963094; 22589738; 23314968; 23805041,,,,,,,,,,,,,,,OGG:3000004257,,,,,,,microsomal glutathione S-transferase 1,,,,,,,,,,,,,,,MGST1,,,,,,,,,,,,,,,,,,,,,,,4257,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000004259,MGST3,,,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,,,,,,,Ensembl:ENSG00000143198|Vega:OTTHUMG00000034627|MIM:604564|HPRD:05192|HGNC:7064,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,microsomal glutathione S-transferase 3,,,,,,,,,,,,,,,,,,,"GO_0004364 (EC: IBA); GO_0004601 (EC: TAS, PMID: 9278457); GO_0004602 (EC: IBA); GO_0005635 (EC: IBA); GO_0005789 (EC: TAS); GO_0006629 (EC: TAS, PMID: 9278457); GO_0006805 (EC: TAS); GO_0007165 (EC: TAS, PMID: 9278457); GO_0016020 (EC: TAS, PMID: 9278457); GO_0016021 (EC: IEA); GO_0043231 (EC: TAS, PMID: 9278457); GO_0044281 (EC: TAS); GO_0055114 (EC: IBA); GO_0055114 (EC: TAS, PMID: 9278457); GO_1901687 (EC: TAS)",,,,,,,,,PMID: 8125298; 9278457; 10673221; 12477932; 12898215; 15489334; 16169070; 16710414; 17207965; 17719568; 18781797; 19064610; 19322201; 19343046; 19471022; 19536175; 20360068; 20379614; 21116278; 21139048; 21853274; 21890473; 21906983; 21963094; 22939629; 24250222,,,,,,,,,,,,,,,OGG:3000004259,,,,,,,microsomal glutathione S-transferase 3,,,,,,,,,,,,,,,MGST3,,,,,,,,,,,,,,,,,,,,,,,4259,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CL_0002320,connective tissue cell,,"A cell of the supporting or framework tissue of the body, arising chiefly from the embryonic mesoderm and including adipose tissue, cartilage, and bone.",false,,,http://purl.obolibrary.org/obo/CL_0000000,,,,,,,,,,,,,,,,,,,,FMA:63875|CALOHA:TS-2096,,"A cell of the supporting or framework tissue of the body, arising chiefly from the embryonic mesoderm and including adipose tissue, cartilage, and bone.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CL:0002320,,,,,,,,,,,,,,,,,,,,,,connective tissue cell,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000006235,RPS29,,Other designations: 40S ribosomal protein S29,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,S29,,,,,,,,,,,,14,,,,,,MIM:603633|Ensembl:ENSG00000213741|HPRD:04698|Vega:OTTHUMG00000140272|HGNC:10419,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,ribosomal protein S29,,,14q,,,,,,,,,,,,,,,,"GO_0000184 (EC: TAS); GO_0003735 (EC: IDA, PMID: 15883184); GO_0005737 (EC: IDA); GO_0005829 (EC: TAS); GO_0006412 (EC: IC, PMID: 15883184); GO_0006412 (EC: TAS); GO_0006413 (EC: TAS); GO_0006414 (EC: TAS); GO_0006415 (EC: TAS); GO_0006614 (EC: TAS); GO_0008270 (EC: IDA, PMID: 8781548); GO_0010467 (EC: TAS); GO_0015935 (EC: IDA, PMID: 15883184); GO_0016032 (EC: TAS); GO_0016070 (EC: TAS); GO_0016071 (EC: TAS); GO_0019058 (EC: TAS); GO_0019083 (EC: TAS); GO_0022627 (EC: IDA, PMID: 15883184); GO_0044267 (EC: TAS); GO_0070062 (EC: IDA)",,,,,,,,,PMID: 7772601; 8706699; 8722009; 8781548; 9582194; 10708601; 11751223; 11875025; 12477932; 12588972; 12625830; 15189156; 15489334; 15883184; 16196087; 17353931; 18029348; 21890473; 21906983; 21988832; 22589738; 22863883; 22939629; 23000965; 23455922; 23726511; 24250222,,,,,,,,,,,,,,,OGG:3000006235,,20140408,protein-coding,,,,ribosomal protein S29,,,,,,,,,,,,,Other designations: 40S ribosomal protein S29,,RPS29,,,,,,,,,,,,,,,,,,,,,,,6235,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,RPS29,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0001144,NG2,,,false,,,http://purl.obolibrary.org/obo/IMR_0001126,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001144,,,,,,,,,,,,,,,,,,,,,,NG2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100731,presenilin 1,S182 protein|PS-1,,false,,,http://purl.obolibrary.org/obo/IMR_0000560,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,S182 protein|PS-1,,,,,IMR:0100731,,,,,,,,,,,,,,,,,,,,,,presenilin 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100774,Wnt-7a,,,false,,,http://purl.obolibrary.org/obo/IMR_0000003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100774,,,,,,,,,,,,,,,,,,,,,,Wnt-7a,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001831,phosphatidylinositol accumulation in lysosome,,Phosphatidylinositol accumulation in lysosome is a subtype of glycerophospholipid accumulation in lysosome: A process that keeps phosphatidylinositol in the lysosome.,false,,,http://purl.obolibrary.org/obo/TXPO_0001697,,,,,,,,,,,,,,,,,,,,,,Phosphatidylinositol accumulation in lysosome is a subtype of glycerophospholipid accumulation in lysosome: A process that keeps phosphatidylinositol in the lysosome.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001831,,,,,,,,,,,,,,,,,,,,,,phosphatidylinositol accumulation in lysosome,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001830,decreasing production quantity of protein,,Decreasing production quantity of protein is a subtype of decreasing quantity: A process that changes the production quantity of the protein to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000396,,,,,,,,,,,,,,,,,,,,decreasing protein production,,Decreasing production quantity of protein is a subtype of decreasing quantity: A process that changes the production quantity of the protein to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001830,,,,,,,,,,,,,,,,,,,,,,decreasing production quantity of protein,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001835,Dissociation of PERK:BIP Heterodimer [ER stress - refolding],,"Dissociation of PERK:BIP heterodimer is a subtype of detaching: A process that disaggregates PERK-BIP heterodimers into BIP and PERK.
This process is dependent on the refolding and can constitute the course of ER stress.|PERK (EIF2AK3) is a single-pass transmembrane protein located in the Endoplasmic Reticulum (ER) membrane. PERK has an N-terminal luminal domain and a C-terminal cytosolic domain. It is maintained in an inactive state by association of its luminal domain with BiP, a chaperone in the ER. Because BiP also binds unfolded proteins, BiP dissociates from PERK when unfolded proteins exceed chaperone activity in the ER.",false,,,http://purl.obolibrary.org/obo/TXPO_0002213,,,,,,,,,,,,,,,,,,,,PMID:10854322|Reactome PathwayStep4038|PMID:11907036|Reactome:R-HSA-381086,,"Dissociation of PERK:BIP heterodimer is a subtype of detaching: A process that disaggregates PERK-BIP heterodimers into BIP and PERK.
This process is dependent on the refolding and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002109,,,,http://purl.obolibrary.org/obo/TXPO_0003157|http://purl.obolibrary.org/obo/TXPO_0002864,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002867,,,,,,,,,,,TXPO:0001835,,,,,,,,,,,,,,,,,,,,"PERK (EIF2AK3) is a single-pass transmembrane protein located in the Endoplasmic Reticulum (ER) membrane. PERK has an N-terminal luminal domain and a C-terminal cytosolic domain. It is maintained in an inactive state by association of its luminal domain with BiP, a chaperone in the ER. Because BiP also binds unfolded proteins, BiP dissociates from PERK when unfolded proteins exceed chaperone activity in the ER.",,Dissociation of PERK:BIP Heterodimer [ER stress - refolding],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001839,Dissociation of PERK:BIP Heterodimer [ER stress - apoptosis],,"Dissociation of PERK:BIP heterodimer is a subtype of detaching: A process that disaggregates PERK-BIP heterodimers into BIP and PERK.
This process is dependent on the apoptosis and can constitute the course of ER stress.|PERK (EIF2AK3) is a single-pass transmembrane protein located in the Endoplasmic Reticulum (ER) membrane. PERK has an N-terminal luminal domain and a C-terminal cytosolic domain. It is maintained in an inactive state by association of its luminal domain with BiP, a chaperone in the ER. Because BiP also binds unfolded proteins, BiP dissociates from PERK when unfolded proteins exceed chaperone activity in the ER.",false,,,http://purl.obolibrary.org/obo/TXPO_0002213,,,,,,,,,,,,,,,,,,,,PMID:10854322|Reactome PathwayStep4038|PMID:11907036|Reactome:R-HSA-381086,,"Dissociation of PERK:BIP heterodimer is a subtype of detaching: A process that disaggregates PERK-BIP heterodimers into BIP and PERK.
This process is dependent on the apoptosis and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003157|http://purl.obolibrary.org/obo/TXPO_0002845,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002866,,,,,,,,,,,TXPO:0001839,,,,,,,,,,,,,,,,,,,,"PERK (EIF2AK3) is a single-pass transmembrane protein located in the Endoplasmic Reticulum (ER) membrane. PERK has an N-terminal luminal domain and a C-terminal cytosolic domain. It is maintained in an inactive state by association of its luminal domain with BiP, a chaperone in the ER. Because BiP also binds unfolded proteins, BiP dissociates from PERK when unfolded proteins exceed chaperone activity in the ER.",,Dissociation of PERK:BIP Heterodimer [ER stress - apoptosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001833,signaling molecule [signal transduction system],,"Signaling molecule is a subtype of signaling dependent molecule.
This entity is dependent on a signal transduction system and can participate in signaling process.",false,,,http://purl.obolibrary.org/obo/TXPO_0001821,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,,"Signaling molecule is a subtype of signaling dependent molecule.
This entity is dependent on a signal transduction system and can participate in signaling process.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001898,,,,,,,,,,TXPO:0001833,,,,,,,,,,,,,,,,,,,,,,signaling molecule [signal transduction system],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001834,hyperfunction of decreasing the amount of drugs,,Hyperfunction of decreasing the amount of drugs is a subtype of hyperfunction of decreasing: A process that performs an excesssive decreasing the amount of drugs.,false,,,http://purl.obolibrary.org/obo/TXPO_0001832,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of decreasing the amount of drugs is a subtype of hyperfunction of decreasing: A process that performs an excesssive decreasing the amount of drugs.,,,http://purl.obolibrary.org/obo/TXPO_0001639,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001834,,,,,,,,,,,,,,,,,,,,,,hyperfunction of decreasing the amount of drugs,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001838,hyperfunction of hepatocyte proliferation [Ground glass appearance],,"Hyperfunction of hepatocyte proliferation is a subtype of hyperfunction of cell proliferation: The multiplication or reproduction of hepatocytes, resulting in the expansion of a cell population. Hepatocytes form the main structural component of the liver. They are specialized epithelial cells that are organized into interconnected plates called lobules.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/TXPO_0002321,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of hepatocyte proliferation is a subtype of hyperfunction of cell proliferation: The multiplication or reproduction of hepatocytes, resulting in the expansion of a cell population. Hepatocytes form the main structural component of the liver. They are specialized epithelial cells that are organized into interconnected plates called lobules.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001838,,,,,,,,,,,,,,,,,,,,,,hyperfunction of hepatocyte proliferation [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001832,hyperfunction of decreasing,,Hyperfunction of decreasing is a subtype of hyperfunctioning: A process that performs an excesssive decreasing amount or decreasing number of objects.,false,,,http://purl.obolibrary.org/obo/TXPO_0000435,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of decreasing is a subtype of hyperfunctioning: A process that performs an excesssive decreasing amount or decreasing number of objects.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001832,,,,,,,,,,,,,,,,,,,,,,hyperfunction of decreasing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001836,hyperfunction of decreasing the amount of drug  [Ground glass appearance (moderate) ],,"Hyperfunction of decreasing the amount of drug is a subtype of hyperfunction of decreasing: A process that performs an excesssive decreasing the amount of drugs. And the degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (moderate) .",false,,,http://purl.obolibrary.org/obo/TXPO_0003859,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of decreasing the amount of drug is a subtype of hyperfunction of decreasing: A process that performs an excesssive decreasing the amount of drugs. And the degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (moderate) .",,,http://purl.obolibrary.org/obo/TXPO_0001647,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001843,,,,,,,,,,,TXPO:0001836,,,,,,,,,,,,,,,,,,,,,,hyperfunction of decreasing the amount of drug  [Ground glass appearance (moderate) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001837,receiving signal in PERK signal transduction pathway [PERK pathway],,"Receiving signal in PERK signal transduction pathway is a subtype of receiving signal: A process that recognizes another object and changes into a signal in a PERK signal transduction pathway.
This entity is a specific course-dependent process. This process can constitute the course of PERK pathway.",false,,,http://purl.obolibrary.org/obo/TXPO_0002174,,,,,,,,,,,,,,,,,,,,,,"Receiving signal in PERK signal transduction pathway is a subtype of receiving signal: A process that recognizes another object and changes into a signal in a PERK signal transduction pathway.
This entity is a specific course-dependent process. This process can constitute the course of PERK pathway.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000454,,,,,,,,,,,TXPO:0001837,,,,,,,,,,,,,,,,,,,,,,receiving signal in PERK signal transduction pathway [PERK pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100599,CDK3(mol),Cell division protein kinase 3,,false,,,http://purl.obolibrary.org/obo/TXPO_0003241,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Cell division protein kinase 3,,,,,IMR:0100599,,,,,,,,,,,,,,,,,,,,,,CDK3(mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000323,G-alpha-q class,,,false,,,http://purl.obolibrary.org/obo/IMR_0000316,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000323,,,,,,,,,,,,,,,,,,,,,,G-alpha-q class,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76967,human xenobiotic metabolite,human xenobiotic metabolites,Any human metabolite produced by metabolism of a xenobiotic compound in humans.,false,,,http://purl.obolibrary.org/obo/CHEBI_76206|http://purl.obolibrary.org/obo/CHEBI_77746,,,,,,,,,,,,,,,,,,,,,,Any human metabolite produced by metabolism of a xenobiotic compound in humans.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,human xenobiotic metabolites,,,,,,,,,,,,,,,,,,,,,CHEBI:76967,,,,human xenobiotic metabolite,,CHEBI:76967,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_16749,1-phosphatidyl-1D-myo-inositol,1-O-(3-sn-phosphatidyl)-1D-myo-inositol,A phosphatidylinositol in which the inositol moiety is the 1D-myo isomer and the phosphatidyl group is located at its position 1.,false,,,http://purl.obolibrary.org/obo/CHEBI_28874,,,,,,,,,,,,,,,,,,,,PMID:28600633,,A phosphatidylinositol in which the inositol moiety is the 1D-myo isomer and the phosphatidyl group is located at its position 1.,,,,,,,,,,,,C11H17O13P,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1-O-(3-sn-phosphatidyl)-1D-myo-inositol,,,,,CHEBI:16749,,,,,,,,,,,,,,,,,,,,,,1-phosphatidyl-1D-myo-inositol,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,[C@@H]1([C@@H]([C@@H]([C@@H]([C@H]([C@@H]1O)O)O)O)OP(OC[C@@H](COC(*)=O)OC(=O)*)(=O)O)O,,,,,
http://purl.obolibrary.org/obo/UBERON_0004571,systemic arterial system,systemic arterial circulatory system,"The part of the arterial system which carries oxygenated blood away from the heart to the body, and returns deoxygenated blood back to the heart.",false,,,http://purl.obolibrary.org/obo/UBERON_0007798,,,,,,,,,,,,,,,,,,,,http://en.wikipedia.org/wiki/Systemic_circulation#Arteries|FMA:45623,,"The part of the arterial system which carries oxygenated blood away from the heart to the body, and returns deoxygenated blood back to the heart.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,systemic arterial circulatory system,,,,http://purl.obolibrary.org/obo/UBERON_0004572,UBERON:0004571,http://purl.obolibrary.org/obo/UBERON_0004572,,,,,,,,,,,,,,,,,,,,,systemic arterial system,,,,,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0004572,arterial system,,The part of the cardiovascular system consisting of all arteries.,false,,,http://purl.obolibrary.org/obo/UBERON_0007798,,,,,,,,,,,,,,,,,,,,http://www.snomedbrowser.com/Codes/Details/362030008|MA:0002719|EMAPA:16371|EHDAA2:0000143|EHDAA:396|BTO:0004690|VHOG:0000273|EMAPA:16201,,The part of the cardiovascular system consisting of all arteries.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0001637,,,,,,,,,,,,,,,,,,,,"The appearance of Chordata and subsequently the vertebrates is accompanied by a rapid structural diversification of this primitive linear heart: looping, unidirectional circulation, an enclosed vasculature, and the conduction system.[well established][VHOG]",http://purl.obolibrary.org/obo/UBERON_0004535,UBERON:0004572,http://purl.obolibrary.org/obo/UBERON_0004535,,,,,,,,,,,,,,,,,,,,,arterial system,,,,,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002650,intrahepatic cholestasis,,Impairment of the bile flow caused by obstruction within the liver.|under construction,false,,,http://purl.obolibrary.org/obo/TXPO_0001277,,,,,,,,,,,,,,,,,,,,,,Impairment of the bile flow caused by obstruction within the liver.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000066|http://purl.obolibrary.org/obo/TXPO_0003154|http://purl.obolibrary.org/obo/TXPO_0003147|http://purl.obolibrary.org/obo/TXPO_0002669|http://purl.obolibrary.org/obo/TXPO_0002666|http://purl.obolibrary.org/obo/TXPO_0002664|http://purl.obolibrary.org/obo/TXPO_0002662|http://purl.obolibrary.org/obo/TXPO_0002660|http://purl.obolibrary.org/obo/TXPO_0002663|http://purl.obolibrary.org/obo/TXPO_0001994|http://purl.obolibrary.org/obo/TXPO_0002649|http://purl.obolibrary.org/obo/TXPO_0002646|http://purl.obolibrary.org/obo/TXPO_0002641|http://purl.obolibrary.org/obo/TXPO_0002645|http://purl.obolibrary.org/obo/TXPO_0002644|http://purl.obolibrary.org/obo/TXPO_0002681|http://purl.obolibrary.org/obo/TXPO_0001759|http://purl.obolibrary.org/obo/TXPO_0000545|http://purl.obolibrary.org/obo/TXPO_0000041|http://purl.obolibrary.org/obo/TXPO_0002674|http://purl.obolibrary.org/obo/TXPO_0002679|http://purl.obolibrary.org/obo/TXPO_0002675|http://purl.obolibrary.org/obo/TXPO_0002670|http://purl.obolibrary.org/obo/TXPO_0002676|http://purl.obolibrary.org/obo/TXPO_0002678|http://purl.obolibrary.org/obo/TXPO_0002637|http://purl.obolibrary.org/obo/TXPO_0002630|http://purl.obolibrary.org/obo/TXPO_0002638|http://purl.obolibrary.org/obo/TXPO_0000086|http://purl.obolibrary.org/obo/TXPO_0000084|http://purl.obolibrary.org/obo/TXPO_0000089|http://purl.obolibrary.org/obo/TXPO_0003135|http://purl.obolibrary.org/obo/TXPO_0003137|http://purl.obolibrary.org/obo/TXPO_0003133|http://purl.obolibrary.org/obo/TXPO_0003136|http://purl.obolibrary.org/obo/TXPO_0003134|http://purl.obolibrary.org/obo/TXPO_0002659|http://purl.obolibrary.org/obo/TXPO_0002657|http://purl.obolibrary.org/obo/TXPO_0002658|http://purl.obolibrary.org/obo/TXPO_0002652|http://purl.obolibrary.org/obo/TXPO_0002654|http://purl.obolibrary.org/obo/TXPO_0000268|http://purl.obolibrary.org/obo/TXPO_0000264|http://purl.obolibrary.org/obo/TXPO_0000265,,,,,,,,,,,,,,,,,,TXPO:0002650,,,,,,,,,,,,,,,,,,,,under construction,,intrahepatic cholestasis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002659,regulation of bile acid and bile salt transport [Cholestasis],,"Regulation of bile acid and bile salt transport is a subtype of regulation of transport (biology): Any process that modulates the frequency, rate or extent of the directed movement of bile acid and bile salts .
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003637|http://purl.obolibrary.org/obo/TXPO_0000034,,,,,,,,,,,,,,,,,,,,,,"Regulation of bile acid and bile salt transport is a subtype of regulation of transport (biology): Any process that modulates the frequency, rate or extent of the directed movement of bile acid and bile salts .
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002659,,,,,,,,,,,,,,,,,,,,,,regulation of bile acid and bile salt transport [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002651,extrahepatic cholestasis,,Impairment of the bile flow caused by an obstruction in the portion of the bile duct system located outside of the liver.|under construction,false,,,http://purl.obolibrary.org/obo/TXPO_0001277,,,,,,,,,,,,,,,,,,,,,,Impairment of the bile flow caused by an obstruction in the portion of the bile duct system located outside of the liver.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002651,,,,,,,,,,,,,,,,,,,,under construction,,extrahepatic cholestasis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002656,changing topology,,Changing topology is a subtype of changing structure: A process that changes the setting of the subsets of a topological space.,false,,,http://purl.obolibrary.org/obo/TXPO_0002566,,,,,,,,,,,,,,,,,,,,,,Changing topology is a subtype of changing structure: A process that changes the setting of the subsets of a topological space.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002656,,,,,,,,,,,,,,,,,,,,,,changing topology,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002657,decreasing bile flow in bile canaliculus [Cholestasis],,"Decreasing bile flow in bile canaliculus is a subtype of decreasing bile flow: A process that changes the amount of bile flow in bile canaliculus to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002348|http://purl.obolibrary.org/obo/TXPO_0000034,,,,,,,,,,,,,,,,,,,,,,"Decreasing bile flow in bile canaliculus is a subtype of decreasing bile flow: A process that changes the amount of bile flow in bile canaliculus to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000350,,,,,,,,,,,TXPO:0002657,,,,,,,,,,,,,,,,,,,,,,decreasing bile flow in bile canaliculus [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002658,decreasing bile acid production level [Cholestasis],,"Decreasing bile acid production level is a subtype of decreasing quantity: A process that changes the production amount of bile acid to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003140|http://purl.obolibrary.org/obo/TXPO_0000034,,,,,,,,,,,,,,,,,,,,,,"Decreasing bile acid production level is a subtype of decreasing quantity: A process that changes the production amount of bile acid to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002658,,,,,,,,,,,,,,,,,,,,,,decreasing bile acid production level [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002653,bile transport (import-export) imbalance,,Bile transport (import-export) imbalance is a subtype of imbalance: A process that lacks a balance between bile import and export.,false,,,http://purl.obolibrary.org/obo/TXPO_0000567,,,,,,,,,,,,,,,,,,,,,,Bile transport (import-export) imbalance is a subtype of imbalance: A process that lacks a balance between bile import and export.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002653,,,,,,,,,,,,,,,,,,,,,,bile transport (import-export) imbalance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002655,biliary tract stenosis,,Biliary tract stenosis is a subtype of decreasing cross-sectional area: A process that changes the cross-sectional area of the biliary tract to be smaller.,false,,,http://purl.obolibrary.org/obo/TXPO_0002648,,,,,,,,,,,,,,,,,,,,,,Biliary tract stenosis is a subtype of decreasing cross-sectional area: A process that changes the cross-sectional area of the biliary tract to be smaller.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002655,,,,,,,,,,,,,,,,,,,,,,biliary tract stenosis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002652,binding to bile canaliculus membrane transporter by drug [Cholestasis],,"Binding to bile canaliculus membrane transporter by drug is a subtype of protein binding: Interacting process with the membrane transporter of bile canaliculus by the drug.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003117|http://purl.obolibrary.org/obo/TXPO_0000034,,,,,,,,,,,,,,,,,,,,,,"Binding to bile canaliculus membrane transporter by drug is a subtype of protein binding: Interacting process with the membrane transporter of bile canaliculus by the drug.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002652,,,,,,,,,,,,,,,,,,,,,,binding to bile canaliculus membrane transporter by drug [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002654,bile transport (import-export) imbalance [Cholestasis],,"Bile transport (import-export) imbalance is a subtype of imbalance: A process that lacks a balance between bile import and export.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000034|http://purl.obolibrary.org/obo/TXPO_0002653,,,,,,,,,,,,,,,,,,,,,,"Bile transport (import-export) imbalance is a subtype of imbalance: A process that lacks a balance between bile import and export.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002654,,,,,,,,,,,,,,,,,,,,,,bile transport (import-export) imbalance [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0001283,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000005933,RBL1,,Other designations: 107 kDa retinoblastoma-associated protein|cellular protein 107|retinoblastoma-like 1 (p107)|retinoblastoma-like protein 1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,p107|PRB1|CP107,,,,,,,,,,,,20,,,,,,Ensembl:ENSG00000080839|HPRD:00312|Vega:OTTHUMG00000032406|MIM:116957|HGNC:9893,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,retinoblastoma-like 1,,,20q11.2,,,,,,,,,,,,,,,,"GO_0000122 (EC: IEA); GO_0000278 (EC: TAS); GO_0005515 (EC: IPI, PMID: 1331501); GO_0005634 (EC: IDA); GO_0005654 (EC: TAS); GO_0005667 (EC: IEA); GO_0005730 (EC: IDA, Qualifier: NOT); GO_0006351 (EC: TAS); GO_0006367 (EC: TAS); GO_0007179 (EC: TAS); GO_0008134 (EC: IPI, PMID: 16360038); GO_0010467 (EC: TAS); GO_0016032 (EC: IEA); GO_0016568 (EC: IEA); GO_0043550 (EC: IDA, PMID: 16286473); GO_0045944 (EC: TAS); GO_0051726 (EC: IEA)",,,,,,,,,PMID: 1331501; 1532458; 1833063; 7565695; 7739537; 7760804; 7791762; 7892279; 7935440; 7958924; 7958925; 8076603; 8230483; 8319904; 8622916; 8643455; 8657117; 8798463; 8816797; 8832394; 9242374; 9372959; 9464541; 9472014; 9501179; 9566894; 9697699; 9710587; 9721205; 9724724; 9724731; 9747874; 9858615; 9891079; 9927208; 10022926; 10082561; 10330166; 10376528; 10490602; 10540350; 10766737; 10863094; 11034201; 11313936; 11521194; 11571651; 11573202; 11642725; 11780052; 11799066; 11884610; 12006580; 12096339; 12150994; 12434308; 12439743; 12450794; 12466551; 12477932; 12549820; 12588981; 12621062; 12947099; 14555653; 14666683; 14671316; 15467457; 15479636; 15489334; 15631990; 15716956; 15735762; 15750587; 15827088; 15939381; 16135806; 16189514; 16286473; 16360038; 16537896; 16600870; 16620772; 16712791; 16943418; 17255935; 17531812; 17563750; 17620012; 17671431; 18086563; 18418057; 18799622; 19279001; 19453261; 19738611; 20379614; 20453000; 20663872; 21139048; 21900206; 21903422; 21988832; 22094256; 22157815; 22303805; 22673945; 23455922; 23602568; 23853093,,,,,,,,,,,,,,,OGG:3000005933,,,,,,,retinoblastoma-like 1,,,,,,,,,,,,,Other designations: 107 kDa retinoblastoma-associated protein|cellular protein 107|retinoblastoma-like 1 (p107)|retinoblastoma-like protein 1,,RBL1,,,,,,,,,,,,,,,,,,,,,,,5933,RP11-382A12.1,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,RBL1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0100672,S-cyclin,,,false,,,http://purl.obolibrary.org/obo/IMR_0100606,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100672,,,,,,,,,,,,,,,,,,,,,,S-cyclin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000915,eIF2B subunit,,,false,,,http://purl.obolibrary.org/obo/IMR_0010016,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000915,,,,,,,,,,,,,,,,,,,,,,eIF2B subunit,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CL_0000084,T cell,,A type of lymphocyte whose defining characteristic is the expression of a T cell receptor complex.,false,,,http://purl.obolibrary.org/obo/CL_0000542,,,,,,,,,,,,,,,,,,,,,,A type of lymphocyte whose defining characteristic is the expression of a T cell receptor complex.,,,,,T cell,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CL:0000084,,,,,,,,,,,,,,,,,,,,,,T cell,,,,,,,http://purl.obolibrary.org/obo/cl.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010503,60S acidic ribosomal protein P1,P05386,,false,,,http://purl.obolibrary.org/obo/IMR_0000897,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,P05386,,,,,IMR:0010503,,,,,,,,,,,,,,,,,,,,,,60S acidic ribosomal protein P1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_135357,zimeldine,zimelidine dihydrochloride monohydrate|zimelidine HCl|zimelidine hydrochloride|cis-Zimelidine|zimelidine dihydrochloride hydrate|zimelidine dihydrochloride|zimeldine hydrochloride hydrate|zimelidine,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Drug_Central:2863|CAS:56775-88-3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,zimelidine dihydrochloride monohydrate|zimelidine HCl|zimelidine hydrochloride|cis-Zimelidine|zimelidine dihydrochloride hydrate|zimelidine dihydrochloride|zimeldine hydrochloride hydrate|zimelidine,,,,,,,,,,,,,,,,,,,,,CHEBI:135357,,,,zimeldine,,CHEBI:135357,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_135358,oxyphenisatine,veripaque|phenolisatin|oxyphenisatin,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:125-13-3|Drug_Central:2038,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,veripaque|phenolisatin|oxyphenisatin,,,,,,,,,,,,,,,,,,,,,CHEBI:135358,,,,oxyphenisatine,,CHEBI:135358,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010487,60S ribosomal protein L37,G1.16,,false,,,http://purl.obolibrary.org/obo/IMR_0000897,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,G1.16,,,,,IMR:0010487,,,,,,,,,,,,,,,,,,,,,,60S ribosomal protein L37,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100269,Rab GAP,Rab GTPase-activating protein,,false,,,http://purl.obolibrary.org/obo/IMR_0000442,,,,,,,,,,,,,,,,,,,,GO:0005097,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Rab GTPase-activating protein,,,,,IMR:0100269,,,,,,,,,,,,,,,,,,,,,,Rab GAP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003477,NRF2 (canonical)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003213|http://purl.obolibrary.org/obo/TXPO_0002527,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:18024|NCBI-Rat-GeneID:83619|NCBI-Human-GeneID:4780,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003477,,,,,,,,,,,,,,,,,,,,,,NRF2 (canonical)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003474,dysfunction of sphingomyelin degradation [Niemann Pick Disease Type A],,"Dysfunction of sphingomyelin degradation is a subtype of dysfunction of phosphosphingolipid degradation: A process that performs an abnormal and incomplete sphingomyelin degradation.
This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type A.",false,,,http://purl.obolibrary.org/obo/TXPO_0001475,,,,,,,,,,,,,,,,,,,,,,"Dysfunction of sphingomyelin degradation is a subtype of dysfunction of phosphosphingolipid degradation: A process that performs an abnormal and incomplete sphingomyelin degradation.
This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type A.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001472,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001482,,,,,,,,,,,TXPO:0003474,,,,,,,,,,,,,,,,,,,,,,dysfunction of sphingomyelin degradation [Niemann Pick Disease Type A],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003470,SMPD1 (canonical)[Niemann Pick Disease Type A],Sphingomyelin Phosphodiesterase 1 [Niemann Pick Disease Type A],,false,,,http://purl.obolibrary.org/obo/TXPO_0003469,,,,,,,,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/gene/6609,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003671,,,,,Sphingomyelin Phosphodiesterase 1 [Niemann Pick Disease Type A],,,,,TXPO:0003470,,,,,,,,,,,,,,,,,,,,,,SMPD1 (canonical)[Niemann Pick Disease Type A],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003478,positive regulation of autophagy [Lipidosis],,"Any process that activates, maintains or increases the rate of autophagy. Autophagy is the process in which cells digest parts of their own cytoplasm.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/GO_0010508|http://purl.obolibrary.org/obo/TXPO_0001720,,,,,,,,,,,,,,,,,,,,,,"Any process that activates, maintains or increases the rate of autophagy. Autophagy is the process in which cells digest parts of their own cytoplasm.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003478,,,,,,,,,,,,,,,,,,,,,,positive regulation of autophagy [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003475,dysfunction of sphingomyelin degradation  [Niemann Pick Disease Type B],,"Dysfunction of sphingomyelin degradation is a subtype of dysfunction of phosphosphingolipid degradation: A process that performs an abnormal and incomplete sphingomyelin degradation.
This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type B.",false,,,http://purl.obolibrary.org/obo/TXPO_0001475,,,,,,,,,,,,,,,,,,,,,,"Dysfunction of sphingomyelin degradation is a subtype of dysfunction of phosphosphingolipid degradation: A process that performs an abnormal and incomplete sphingomyelin degradation.
This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type B.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001816,,,,,,,,,,,TXPO:0003475,,,,,,,,,,,,,,,,,,,,,,dysfunction of sphingomyelin degradation  [Niemann Pick Disease Type B],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003473,sphingomyelinase gene mutation [Niemann Pick Disease Type B],,"Sphingomyelinase gene mutation is a subtype of phopholipase gene mutation: A process that changes the sequence of a sphingomyelinase gene.
This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type B.",false,,,http://purl.obolibrary.org/obo/TXPO_0001446,,,,,,,,,,,,,,,,,,,,,,"Sphingomyelinase gene mutation is a subtype of phopholipase gene mutation: A process that changes the sequence of a sphingomyelinase gene.
This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type B.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003472,,,,,,http://purl.obolibrary.org/obo/TXPO_0003475,,,,,,,,,,,TXPO:0003473,,,,,,,,,,,,,,,,,,,,,,sphingomyelinase gene mutation [Niemann Pick Disease Type B],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003472,SMPD1 (canonical)[Niemann Pick Disease Type B],Sphingomyelin Phosphodiesterase 1 [Niemann Pick Disease Type B],,false,,,http://purl.obolibrary.org/obo/TXPO_0003469,,,,,,,,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/gene/6609,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003671,,,,,Sphingomyelin Phosphodiesterase 1 [Niemann Pick Disease Type B],,,,,TXPO:0003472,,,,,,,,,,,,,,,,,,,,,,SMPD1 (canonical)[Niemann Pick Disease Type B],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003471,DNAJB9 - apotosis repressor -vitro (human)[ER stress],ERDJ4,,false,,,http://purl.obolibrary.org/obo/TXPO_0002165,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:4189|PMID:25146923|PMID:28452953,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_68494,,,,,ERDJ4,,,,,TXPO:0003471,,,,,,,,,,,,,,,,,,,,,,DNAJB9 - apotosis repressor -vitro (human)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000795,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003476,lipid accumulation in hepatocyte (severe) [Lipidosis],lipid storage in hepatocyte (severe) [Lipidosis],"Lipid accumulation in hepatocyte (severe) is a subtype of lipid strorage in hepatocyte: A process that keeps lipids in hepatocytes. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001129,,,,,,,,,,,,,,,,,,,,,,"Lipid accumulation in hepatocyte (severe) is a subtype of lipid strorage in hepatocyte: A process that keeps lipids in hepatocytes. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003541,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001232,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003495|http://purl.obolibrary.org/obo/TXPO_0003511|http://purl.obolibrary.org/obo/TXPO_0003512|http://purl.obolibrary.org/obo/TXPO_0003480|http://purl.obolibrary.org/obo/TXPO_0003622|http://purl.obolibrary.org/obo/TXPO_0003478|http://purl.obolibrary.org/obo/TXPO_0000897,,,,,,lipid storage in hepatocyte (severe) [Lipidosis],,,,,TXPO:0003476,,,,,,,,,,,,,,,,,,,,,,lipid accumulation in hepatocyte (severe) [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000010542,LAMTOR5,,Other designations: HBV X-interacting protein|HBx-interacting protein|hepatitis B virus x interacting protein|hepatitis B virus x-interacting protein (9.6kD)|late endosomal/lysosomal adaptor and MAPK and MTOR activator 5|ragulator complex protein LAMTOR5,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,HBXIP|XIP,,,,,,,,,,,,1,,,,,,MIM:608521|Vega:OTTHUMG00000011568|Ensembl:ENSG00000134248|HGNC:17955|HPRD:09773,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"late endosomal/lysosomal adaptor, MAPK and MTOR activator 5",,,1p13.3,,,,,,,,,,,,,,,,"GO_0005085 (EC: IDA, Qualifier: contributes_to); GO_0005515 (EC: IPI, PMID: 12773388); GO_0005764 (EC: IDA); GO_0005829 (EC: IDA, PMID: 12773388); GO_0008361 (EC: IMP); GO_0009615 (EC: TAS, PMID: 9499022); GO_0019079 (EC: IEA); GO_0032008 (EC: IMP); GO_0032947 (EC: IDA, Qualifier: contributes_to); GO_0043066 (EC: IDA, PMID: 12773388); GO_0043087 (EC: IDA); GO_0043154 (EC: IDA, PMID: 12773388); GO_0061462 (EC: IMP); GO_0071230 (EC: IMP); GO_0071986 (EC: IDA)",,,,,,,,,PMID: 9499022; 11788598; 11925594; 12477932; 12773388; 14578865; 14702039; 15489334; 15955450; 16055925; 16169070; 16176273; 17050029; 17303008; 17428866; 18029348; 18032378; 18158869; 18976975; 19885569; 20811532; 20877624; 21139048; 21343296; 21651858; 21706058; 21988832; 22209835; 22293503; 22740693; 22939629; 22980980; 23266610; 23291272; 23352642; 23494474; 23537647; 23667255,,,,,,,,,,,,,,,OGG:3000010542,,,,,,,"late endosomal/lysosomal adaptor, MAPK and MTOR activator 5",,,,,,,,,,,,,Other designations: HBV X-interacting protein|HBx-interacting protein|hepatitis B virus x interacting protein|hepatitis B virus x-interacting protein (9.6kD)|late endosomal/lysosomal adaptor and MAPK and MTOR activator 5|ragulator complex protein LAMTOR5,,LAMTOR5,,,,,,,,,,,,,,,,,,,,,,,10542,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,LAMTOR5,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000402,EGR family,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,,,,,,IMR:0000402,,,,,,,,,,,,,,,,,,,,,,EGR family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000465,changing distance,,Changing distance is a subtype of changing position: A process that changes the relative position between objects.,false,,,http://purl.obolibrary.org/obo/TXPO_0000464,,,,,,,,,,,,,,,,,,,,,,Changing distance is a subtype of changing position: A process that changes the relative position between objects.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000465,,,,,,,,,,,,,,,,,,,,,,changing distance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000468,assembling,,Assembling is a subtype of changing composition: A process that combines multiple components as one configuration.,false,,,http://purl.obolibrary.org/obo/TXPO_0002568,,,,,,,,,,,,,,,,,,,,,,Assembling is a subtype of changing composition: A process that combines multiple components as one configuration.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000468,,,,,,,,,,,,,,,,,,,,,,assembling,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000460,ER to Golgi transport,,ER to Golgi transport is a subtype of transport: A process of the directed movement of substances from the endoplasmic reticulum (ER) to the Golgi.,false,,,http://purl.obolibrary.org/obo/GO_0006810,,,,,,,,,,,,,,,,,,,,,,ER to Golgi transport is a subtype of transport: A process of the directed movement of substances from the endoplasmic reticulum (ER) to the Golgi.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000460,,,,,,,,,,,,,,,,,,,,,,ER to Golgi transport,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000464,changing position,,Changing position is a subtype of changing between operands: A process that that changes the relative position between objects.,false,,,http://purl.obolibrary.org/obo/TXPO_0000261,,,,,,,,,,,,,,,,,,,,,,Changing position is a subtype of changing between operands: A process that that changes the relative position between objects.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000464,,,,,,,,,,,,,,,,,,,,,,changing position,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000462,detaching,,Detaching is a subtype of separating: A process that disaggregates the whole object into  constituent components.,false,,,http://purl.obolibrary.org/obo/TXPO_0000333,,,,,,,,,,,,,,,,,,,,,,Detaching is a subtype of separating: A process that disaggregates the whole object into  constituent components.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000462,,,,,,,,,,,,,,,,,,,,,,detaching,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000463,Dissociation of PERK:BIP Heterodimer [ER stress translation attenuation],,"Dissociation of PERK:BIP heterodimer is a subtype of detaching: A process that disaggregates PERK-BIP heterodimers into BIP and PERK.
This process is dependent on the translation attenuation and can constitute the course of ER stress.|PERK (EIF2AK3) is a single-pass transmembrane protein located in the Endoplasmic Reticulum (ER) membrane. PERK has an N-terminal luminal domain and a C-terminal cytosolic domain. It is maintained in an inactive state by association of its luminal domain with BiP, a chaperone in the ER. Because BiP also binds unfolded proteins, BiP dissociates from PERK when unfolded proteins exceed chaperone activity in the ER.",false,,,http://purl.obolibrary.org/obo/TXPO_0002213,,,,,,,,,,,,,,,,,,,,PMID:10854322|PMID:11907036,,"Dissociation of PERK:BIP heterodimer is a subtype of detaching: A process that disaggregates PERK-BIP heterodimers into BIP and PERK.
This process is dependent on the translation attenuation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003157|http://purl.obolibrary.org/obo/TXPO_0002839,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000063,,,,,,,,,,,TXPO:0000463,,,,,,,,,,,,,,,,,,,,"PERK (EIF2AK3) is a single-pass transmembrane protein located in the Endoplasmic Reticulum (ER) membrane. PERK has an N-terminal luminal domain and a C-terminal cytosolic domain. It is maintained in an inactive state by association of its luminal domain with BiP, a chaperone in the ER. Because BiP also binds unfolded proteins, BiP dissociates from PERK when unfolded proteins exceed chaperone activity in the ER.",,Dissociation of PERK:BIP Heterodimer [ER stress translation attenuation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000467,increasing free radical [Oxidative stress],,"Increasing free radical is a subtype of increasing quantity: A process that changes the amount of free radicals to be larger.
This entity is a specific course-dependent process. This process can constitute the course of Oxidative stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001730|http://purl.obolibrary.org/obo/TXPO_0001790,,,,,,,,,,,,,,,,,,,,,,"Increasing free radical is a subtype of increasing quantity: A process that changes the amount of free radicals to be larger.
This entity is a specific course-dependent process. This process can constitute the course of Oxidative stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000543|http://purl.obolibrary.org/obo/TXPO_0000536,,,,,,,,,,,TXPO:0000467,,,,,,,,,,,,,,,,,,,,,,increasing free radical [Oxidative stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000461,oxidation-antioxidtion inbalance [Oxidative stress],,"Oxidation-antioxidtion inbalance is a subtype of imbalance: A process that lacks a balance between oxidation and anti-oxidation that inhibits oxidation.
This entity is a specific course-dependent process. This process can constitute the course of Oxidative stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002748|http://purl.obolibrary.org/obo/TXPO_0001730,,,,,,,,,,,,,,,,,,,,,,"Oxidation-antioxidtion inbalance is a subtype of imbalance: A process that lacks a balance between oxidation and anti-oxidation that inhibits oxidation.
This entity is a specific course-dependent process. This process can constitute the course of Oxidative stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000467,,,,,,,,,,,TXPO:0000461,,,,,,,,,,,,,,,,,,,,,,oxidation-antioxidtion inbalance [Oxidative stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000469,joining,,Joining is a subtype of combining: A process that makes bonds between the components.,false,,,http://purl.obolibrary.org/obo/TXPO_0002569,,,,,,,,,,,,,,,,,,,,,,Joining is a subtype of combining: A process that makes bonds between the components.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000469,,,,,,,,,,,,,,,,,,,,,,joining,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000466,increasing distance,,Increasing distance is a subtype of changing distance: A process that keeps object A away from object B.,false,,,http://purl.obolibrary.org/obo/TXPO_0000465,,,,,,,,,,,,,,,,,,,,,,Increasing distance is a subtype of changing distance: A process that keeps object A away from object B.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000466,,,,,,,,,,,,,,,,,,,,,,increasing distance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000003833,KIFC1,,Other designations: kinesin-like 2|kinesin-like protein 2|kinesin-like protein KIFC1|kinesin-related protein HSET,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,KNSL2|HSET,,,,,,,,,,,,6,,,,,,MIM:603763|Ensembl:ENSG00000237649|HGNC:6389|Vega:OTTHUMG00000031209,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,kinesin family member C1,,,6p21.3,,,,,,,,,,,,,,,,"GO_0000070 (EC: NAS, PMID: 8276466); GO_0003777 (EC: NAS, PMID: 8276466); GO_0005524 (EC: NAS, PMID: 8276466); GO_0005634 (EC: IEA); GO_0005769 (EC: IEA); GO_0005815 (EC: IEA); GO_0005819 (EC: IEA); GO_0005871 (EC: IEA); GO_0005874 (EC: IEA); GO_0007018 (EC: TAS); GO_0007596 (EC: TAS); GO_0008017 (EC: IEA); GO_0008152 (EC: NAS, PMID: 8276466)",,,,,,,,,PMID: 8276466; 10369922; 11416179; 12477932; 14574404; 15489334; 17081983; 17326138; 18082152; 19116309; 19190132; 19525938; 19679349; 19851445; 21139048; 21252943; 21832049; 21890473; 21963094; 22201025; 22946058; 23000965; 23318213; 24250222,,,,,,,,,,,,,,,OGG:3000003833,,,,,,,kinesin family member C1,,,,,,,,,,,,,Other designations: kinesin-like 2|kinesin-like protein 2|kinesin-like protein KIFC1|kinesin-related protein HSET,,KIFC1,,,,,,,,,,,,,,,,,,,,,,,3833,DAQB-126H3.5,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,KIFC1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/GO_0030217,T cell differentiation,T-lymphocyte differentiation|T lymphocyte differentiation|T-cell differentiation,The process in which a precursor cell type acquires characteristics of a more mature T-cell. A T cell is a type of lymphocyte whose definin characteristic is the expression of a T cell receptor complex.,false,,,http://purl.obolibrary.org/obo/GO_0030098,,,,,,,,,,,,,,,,,,,,,,The process in which a precursor cell type acquires characteristics of a more mature T-cell. A T cell is a type of lymphocyte whose definin characteristic is the expression of a T cell receptor complex.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,T-lymphocyte differentiation|T lymphocyte differentiation|T-cell differentiation,,,,,GO:0030217,,,,,,,,,,,,,,,,,,,,,,T cell differentiation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_35718,antifungal agent,antifungal drugs|antifungal drug|antifungal agents|antifungal|antifungals,An  antimicrobial agent that destroys fungi by suppressing their ability to grow or reproduce.,false,,,http://purl.obolibrary.org/obo/CHEBI_33281,,,,,,,,,,,,,,,,,,,,,,An  antimicrobial agent that destroys fungi by suppressing their ability to grow or reproduce.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,antifungal drugs|antifungal drug|antifungal agents|antifungal|antifungals,,,,,,,,,,,,,,,,,,,,,CHEBI:35718,,,,antifungal agent,,CHEBI:35718,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010012,nucleoside diphosphate kinase,Nm23|NDK|NME|NDP kinase,"Nucleoside diphoshate kinases (NDKs), an evolutionarily conserved family of proteins, synthesize nucleoside triphosphates from nucleoside diphosphates and ATP. To date, eight human NDK homologues have been identified.",false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,GO:0004550|EC:2.7.4.6,,"Nucleoside diphoshate kinases (NDKs), an evolutionarily conserved family of proteins, synthesize nucleoside triphosphates from nucleoside diphosphates and ATP. To date, eight human NDK homologues have been identified.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Nm23|NDK|NME|NDP kinase,,,,,IMR:0010012,,,,,,,,,,,,,,,,,,,,,,nucleoside diphosphate kinase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000970,LRP6,low density lipoprotein receptor-related protein 6|LDL receptor-related protein 6,,false,,,http://purl.obolibrary.org/obo/IMR_0002954|http://purl.obolibrary.org/obo/IMR_0100798,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,low density lipoprotein receptor-related protein 6|LDL receptor-related protein 6,,,,,IMR:0000970,,,,,,,,,,,,,,,,,,,,,,LRP6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000101,IL-5 receptor,interleukin-5 receptor,,false,,,http://purl.obolibrary.org/obo/IMR_0000096,,,,,,,,,,,,,,,,,,,,GO:0004914,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,interleukin-5 receptor,,,,,IMR:0000101,,,,,,,,,,,,,,,,,,,,,,IL-5 receptor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001235,carbohydrate storage in liver,,Carbohydrate storage in liver is a subtype of carbohydrate storage: The accumulation in hepatocytes of carbohydrates.,false,,,http://purl.obolibrary.org/obo/TXPO_0000169,,,,,,,,,,,,,,,,,,,,,,Carbohydrate storage in liver is a subtype of carbohydrate storage: The accumulation in hepatocytes of carbohydrates.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_16646,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001235,,,,,,,,,,,,,,,,,,,,,,carbohydrate storage in liver,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001232,sequestering of triglyceride (severe) [lipidosis],,"sequestering of triglyceride (severe) is a subtype of lipid strorage in hepatocyte: A process that keeps triglycerides in hepatocytes. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001522,,,,,,,,,,,,,,,,,,,,,,"sequestering of triglyceride (severe) is a subtype of lipid strorage in hepatocyte: A process that keeps triglycerides in hepatocytes. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001232,,,,,,,,,,,,,,,,,,,,,,sequestering of triglyceride (severe) [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001234,phenobarbital accumulation in liver,,Phenobarbital accumulation in liver is a subtype of compound accumulation in liver: A process that keeps phenobarbital in the liver.,false,,,http://purl.obolibrary.org/obo/TXPO_0001694,,,,,,,,,,,,,,,,,,,,,,Phenobarbital accumulation in liver is a subtype of compound accumulation in liver: A process that keeps phenobarbital in the liver.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001234,,,,,,,,,,,,,,,,,,,,,,phenobarbital accumulation in liver,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001237,hyperfunction of iron supply,,Hyperfunction of iron supply is a subtype of hyperfunctioning: A process that performs an excesssive iorn supply.,false,,,http://purl.obolibrary.org/obo/TXPO_0000435,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of iron supply is a subtype of hyperfunctioning: A process that performs an excesssive iorn supply.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001237,,,,,,,,,,,,,,,,,,,,,,hyperfunction of iron supply,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001238,citric acid,,,false,,,http://purl.obolibrary.org/obo/TXPO_0001222,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001238,,,,,,,,,,,,,,,,,,,,,,citric acid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001230,smooth endoplasmic reticulum proliferation in hepatocyte,increasing number of sER,Smooth endoplasmic reticulum proliferation in hepatocyte is a subtype of endoplasmic reticulum proliferation in hepatocyte: A process that becomes larger in the number of smooth endoplasmic reticulum in hepatocyte(s).,false,,,http://purl.obolibrary.org/obo/TXPO_0000091,,,,,,,,,,,,,,,,,,,,,,Smooth endoplasmic reticulum proliferation in hepatocyte is a subtype of endoplasmic reticulum proliferation in hepatocyte: A process that becomes larger in the number of smooth endoplasmic reticulum in hepatocyte(s).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,increasing number of sER,,,,,TXPO:0001230,,,,,,,,,,,,,,,,,,,,,,smooth endoplasmic reticulum proliferation in hepatocyte,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001239,lactic acid,,,false,,,http://purl.obolibrary.org/obo/TXPO_0001222,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001239,,,,,,,,,,,,,,,,,,,,,,lactic acid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001231,tumor cell invasion,,A moving process of a tumor cell from the outside to the inside of other organ.,false,,,http://purl.obolibrary.org/obo/TXPO_0002587,,,,,,,,,,,,,,,,,,,,,,A moving process of a tumor cell from the outside to the inside of other organ.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001231,,,,,,,,,,,,,,,,,,,,,,tumor cell invasion,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001233,glucose homeostasis imbalance,,Glucose homeostasis imbalance is a subtype of chemical homeostasis imbalance: A process that becomes lacking a glucose homeostastasis balance.,false,,,http://purl.obolibrary.org/obo/TXPO_0001656,,,,,,,,,,,,,,,,,,,,,,Glucose homeostasis imbalance is a subtype of chemical homeostasis imbalance: A process that becomes lacking a glucose homeostastasis balance.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001233,,,,,,,,,,,,,,,,,,,,,,glucose homeostasis imbalance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001236,hyperfunction of drug metabolism phase II,,Hyperfunction of drug metabolism phase II is a subtype of hyperfunction of drug metabolism: A process that performs an excessive drug metabolism phase II.,false,,,http://purl.obolibrary.org/obo/TXPO_0002347,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of drug metabolism phase II is a subtype of hyperfunction of drug metabolism: A process that performs an excessive drug metabolism phase II.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001236,,,,,,,,,,,,,,,,,,,,,,hyperfunction of drug metabolism phase II,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000080255,SLC35F5,,Other designations: HCV NS5A-transactivated protein 3|hepatitis C virus NS5A-transactivated protein 3|solute carrier family 35 member F5,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,2,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"solute carrier family 35, member F5",,,2q14.1,,,,,,,,,,,,,,,,GO_0006810 (EC: IEA); GO_0016021 (EC: IEA),,,,,,,,,PMID: 12477932; 12975309; 21139048; 21963094,,,,,,,,,,,,,,,OGG:3000080255,,,,,,,"solute carrier family 35, member F5",,,,,,,,,,,,,Other designations: HCV NS5A-transactivated protein 3|hepatitis C virus NS5A-transactivated protein 3|solute carrier family 35 member F5,,SLC35F5,,,,,,,,,,,,,,,,,,,,,,,80255,UNQ2545/PRO6097,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,SLC35F5,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0100195,corticotropin,Adrenocorticotropic hormone|ACTH,"An anterior pituitary hormone that stimulates the secretion of CORTICOSTEROIDS and induces growth of the ADRENAL CORTEX. It is a single-chain polypeptide of about 39 amino acids, the first 24 of which are identical in all species. This 24-amino acid segment is said to be responsible for the biological activity of the peptide while the remaining 15-amino acid segment is said to be necessary for any immunological specificity.",false,,,http://purl.obolibrary.org/obo/IMR_0100096,,,,,,,,,,,,,,,,,,,,MeSH:D000324,,"An anterior pituitary hormone that stimulates the secretion of CORTICOSTEROIDS and induces growth of the ADRENAL CORTEX. It is a single-chain polypeptide of about 39 amino acids, the first 24 of which are identical in all species. This 24-amino acid segment is said to be responsible for the biological activity of the peptide while the remaining 15-amino acid segment is said to be necessary for any immunological specificity.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Adrenocorticotropic hormone|ACTH,,,,,IMR:0100195,,,,,,,,,,,,,,,,,,,,,,corticotropin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0003084,BMP-5 subfamily,OP-1 group,"BMP-related proteins can be subdivided into several groups based on their structures and functions. BMP-5, BMP-6, BMP-7 (OP-1), BMP-8 (OP-2), and the Drosophila Gbb form one subgroup.",false,,,http://purl.obolibrary.org/obo/IMR_0000040,,,,,,,,,,,,,,,,,,,,,,"BMP-related proteins can be subdivided into several groups based on their structures and functions. BMP-5, BMP-6, BMP-7 (OP-1), BMP-8 (OP-2), and the Drosophila Gbb form one subgroup.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,OP-1 group,,,,,IMR:0003084,,,,,,,,,,,,,,,,,,,,,,BMP-5 subfamily,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_7573,nilutamide,"nilutamide|5,5-Dimethyl-3-(alpha,alpha,alpha-trifluoro-4-nitro-m-tolyl)hydantoin|Nilandron|nilutamida|nilutamidum|5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]imidazolidine-2,4-dione|Nilutamide","Nilutamide, sold under the brand names Nilandron and Anandron, is a nonsteroidal antiandrogen (NSAA) which is used in the treatment of prostate cancer. (by Wikipedia)",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,DrugBank:DB00665|LINCS:LSM-2513|Drug_Central:1933|Wikipedia:Nilutamide|CAS:63612-50-0|Beilstein:841906,,"Nilutamide, sold under the brand names Nilandron and Anandron, is a nonsteroidal antiandrogen (NSAA) which is used in the treatment of prostate cancer. (by Wikipedia)",,,,,,,,,,,,C12H10F3N3O4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35610|http://purl.obolibrary.org/obo/CHEBI_35497,,,,,"5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]imidazolidine-2,4-dione|Nilutamide",,"nilutamide|5,5-Dimethyl-3-(alpha,alpha,alpha-trifluoro-4-nitro-m-tolyl)hydantoin|Nilandron|nilutamida|nilutamidum",,,,,,,,,,,,,,,,,,,,,CHEBI:7573,,,,nilutamide,,CHEBI:7573,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CC1(C)NC(=O)N(C1=O)c1ccc(c(c1)C(F)(F)F)[N+]([O-])=O,,,,,
http://purl.obolibrary.org/obo/GOCHE_50906,substance with role,,"Substance with role is a subtype of object.
This entity is participating in a specific process and playing a role.|In YAMATO ontology theory, an entity (continuant) playing a role in a specific context is called a role holder.",false,,,http://purl.obolibrary.org/obo/BFO_0000030|http://purl.obolibrary.org/obo/BFO_0000040,,,,,,,,,,,,,,,,,,,,,,"Substance with role is a subtype of object.
This entity is participating in a specific process and playing a role.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/BFO_0000023,,,,,,,,,,GOCHE:50906,,,,,,,,,,,,,,,,,,,,"In YAMATO ontology theory, an entity (continuant) playing a role in a specific context is called a role holder.",,substance with role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CL_0000863,inflammatory macrophage,M1 macrophage,"An elicited macrophage that is recruited into the tissues in response to injury and infection as part of an inflammatory response, expresses high levels of pro-inflammatory cytokines, ROS and NO, and shows potent microbicidal activity.|Markers: Express: TNFa, IL1b, IL6, iNOS, NADPH-oxidase; produce: reactive oxygen species, nitric oxide; role or process: immune, inflammation (inflammatory response).",false,,,http://purl.obolibrary.org/obo/CL_0000235,,,,,,,,,,,,,,,,,,,,,,"An elicited macrophage that is recruited into the tissues in response to injury and infection as part of an inflammatory response, expresses high levels of pro-inflammatory cytokines, ROS and NO, and shows potent microbicidal activity.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M1 macrophage,,,,,CL:0000863,,,,,,,,,,,,,,,,,,,,"Markers: Express: TNFa, IL1b, IL6, iNOS, NADPH-oxidase; produce: reactive oxygen species, nitric oxide; role or process: immune, inflammation (inflammatory response).",,inflammatory macrophage,,,,,,,http://purl.obolibrary.org/obo/cl.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CL_0000864,tissue-resident macrophage,,"A macrophage constitutively resident in a particular tissue under non-inflammatory conditions, and capable of phagocytosing a variety of extracellular particulate material, including immune complexes, microorganisms, and dead cells.",false,,,http://purl.obolibrary.org/obo/CL_0000235,,,,,,,,,,,,,,,,,,,,,,"A macrophage constitutively resident in a particular tissue under non-inflammatory conditions, and capable of phagocytosing a variety of extracellular particulate material, including immune complexes, microorganisms, and dead cells.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CL:0000864,,,,,,,,,,,,,,,,,,,,,,tissue-resident macrophage,,,,,,,http://purl.obolibrary.org/obo/cl.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010024,Heterogeneous nuclear ribonucleoprotein,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0010024,,,,,,,,,,,,,,,,,,,,,,Heterogeneous nuclear ribonucleoprotein,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0002534,cytokine production involved in inflammatory response,,"The synthesis or release of a cytokine following a inflammatory stimulus as part of an inflammatory response, resulting in an increase in its intracellular or extracellular levels.",false,,,http://purl.obolibrary.org/obo/GO_0001816,,,,,,,,,,,,,,,,,,,,GO:0002534,,"The synthesis or release of a cytokine following a inflammatory stimulus as part of an inflammatory response, resulting in an increase in its intracellular or extracellular levels.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0002534,,,,,,,,,,,,,,,,,,,,,,cytokine production involved in inflammatory response,,,,,,,http://purl.obolibrary.org/obo/go.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000055735,DNAJC11,,Other designations: dnaJ homolog subfamily C member 11|novel DnaJ domain-containing protein,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,dJ126A5.1,,,,,,,,,,,,1,,,,,,MIM:614827|HGNC:25570|Ensembl:ENSG00000007923|Vega:OTTHUMG00000001443|HPRD:07112,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"DnaJ (Hsp40) homolog, subfamily C, member 11",,,1p36.31,,,,,,,,,,,,,,,,"GO_0005515 (EC: IPI, PMID:17500595); GO_0005743 (EC: IEA)",,,,,,,,,PMID:8619474; 9110174; 12477932; 12964007; 14702039; 15489334; 16710414; 17207965; 17222547; 17500595; 17624330; 19808946; 20877624; 21139048; 21890473; 21900206; 21906983; 21987572; 22114354; 22268729; 24255178,,,,,,,,,,,,,,,OGG:3000055735,,,,,,,"DnaJ (Hsp40) homolog, subfamily C, member 11",,,,,,,,,,,,,Other designations: dnaJ homolog subfamily C member 11|novel DnaJ domain-containing protein,,DNAJC11,,,,,,,,,,,,,,,,,,,,,,,55735,RP1-126A5.3,,,,,,,9606,,,,,,,,,,,,,,,,,,,DNAJC11,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_76830,EC 5.99.1.* (miscellaneous isomerase) inhibitor,EC 5.99.1.* (miscellaneous isomerase) inhibitors|EC 5.99.1.* inhibitors|EC 5.99.1.* inhibitor,An EC 5.99.* (other isomerases) inhibitor that interferes with the activity of any enzyme in the EC 5.99.1.* class.,false,,,http://purl.obolibrary.org/obo/CHEBI_76697,,,,,,,,,,,,,,,,,,,,,,An EC 5.99.* (other isomerases) inhibitor that interferes with the activity of any enzyme in the EC 5.99.1.* class.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,EC 5.99.1.* (miscellaneous isomerase) inhibitors|EC 5.99.1.* inhibitors|EC 5.99.1.* inhibitor,,,,,,,,,,,,,,,,,,,,,CHEBI:76830,,,,EC 5.99.1.* (miscellaneous isomerase) inhibitor,,CHEBI:76830,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000010005,ACOT8,,Other designations: HIV-Nef associated acyl-CoA thioesterase|acyl-coenzyme A thioesterase 8|choloyl-CoA hydrolase|choloyl-coenzyme A thioesterase|long-chain fatty-acyl-CoA hydrolase|palmitoyl-CoA hydrolase|peroxisomal acyl-CoA thioesterase 1|peroxisomal acyl-coenzyme A thioester hydrolase 1|peroxisomal long-chain acyl-CoA thioesterase 1|thioesterase II|thioesterase III,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,HNAACTE|PTE-2|PTE2|PTE-1|hACTE-III|hTE|PTE1,,,,,,,,,,,,20,,,,,,HPRD:06998|MIM:608123|HGNC:15919|Vega:OTTHUMG00000033045|Ensembl:ENSG00000101473,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,acyl-CoA thioesterase 8,,,20q13.12,,,,,,,,,,,,,,,,"GO_0005102 (EC: IPI); GO_0005515 (EC: IPI); GO_0005739 (EC: IEA); GO_0005782 (EC: IDA, PMID:10092594); GO_0005782 (EC: IMP, PMID:14709540); GO_0005782 (EC: TAS); GO_0006637 (EC: IDA, PMID:9299485); GO_0006699 (EC: TAS); GO_0008206 (EC: TAS); GO_0016032 (EC: IEA); GO_0016290 (EC: IDA, PMID:9299485); GO_0016559 (EC: IDA, PMID:15194431); GO_0033540 (EC: TAS); GO_0033559 (EC: TAS); GO_0033882 (EC: IEA); GO_0036109 (EC: TAS); GO_0043649 (EC: IDA, PMID:16141203); GO_0044255 (EC: TAS); GO_0044281 (EC: TAS); GO_0047617 (EC: IDA, PMID:10092594); GO_0052815 (EC: IDA, PMID:9299485)",,,,,,,,,PMID:9153233; 9299485; 10092594; 10799608; 10807905; 10944470; 11549316; 11755680; 11780052; 12477932; 14702039; 14709540; 15194431; 15489334; 16009940; 16103133; 16141203; 16335799; 16756494; 16940157; 17314511; 17624024; 20178365; 21139048; 21824805; 22002062; 22190034; 22810585; 23540296; 24457600,,,,,,,,,,,,,,,OGG:3000010005,,,,,,,acyl-CoA thioesterase 8,,,,,,,,,,,,,Other designations: HIV-Nef associated acyl-CoA thioesterase|acyl-coenzyme A thioesterase 8|choloyl-CoA hydrolase|choloyl-coenzyme A thioesterase|long-chain fatty-acyl-CoA hydrolase|palmitoyl-CoA hydrolase|peroxisomal acyl-CoA thioesterase 1|peroxisomal acyl-coenzyme A thioester hydrolase 1|peroxisomal long-chain acyl-CoA thioesterase 1|thioesterase II|thioesterase III,,ACOT8,,,,,,,,,,,,,,,,,,,,,,,10005,RP3-337O18.2,,,,,,,9606,,,,,,,,,,,,,,,,,,,ACOT8,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000729,PLD2,phospholipase D2,,false,,,http://purl.obolibrary.org/obo/IMR_0000287,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,phospholipase D2,,,,,IMR:0000729,,,,,,,,,,,,,,,,,,,,,,PLD2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000535,myelin protein,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003691,,,,,,,,,,IMR:0000535,,,,,,,,,,,,,,,,,,,,,,myelin protein,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_67199,AP-1 antagonist,,An antogonist that interferes with the action of activator protein 1 (AP-1).,false,,,http://purl.obolibrary.org/obo/CHEBI_48706,,,,,,,,,,,,,,,,,,,,,,An antogonist that interferes with the action of activator protein 1 (AP-1).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:67199,,,,,,,,,,,,,,,,,,,,,,AP-1 antagonist,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000043,TGF-beta2,transforming growth factor-beta 2,,false,,,http://purl.obolibrary.org/obo/IMR_0000041,,,,,,,,,,,,,,,,,,,,GO:0005160,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,transforming growth factor-beta 2,,,,,IMR:0000043,,,,,,,,,,,,,,,,,,,,,,TGF-beta2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010467,60S ribosomal protein L17,L23,,false,,,http://purl.obolibrary.org/obo/IMR_0000897,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,L23,,,,,IMR:0010467,,,,,,,,,,,,,,,,,,,,,,60S ribosomal protein L17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001808,CYP2C8 (human)[lipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001786|http://purl.obolibrary.org/obo/TXPO_0001791,,,,,,,,,,,,,,,,,,,,PMID:25160618|NCBI-Human-GeneID:1558|PMID:26467040,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001553,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000001558,,,http://purl.obolibrary.org/obo/TXPO_0002262,,,,,,,,,,TXPO:0001808,,,,,,,,,,,,,,,,,,,,,,CYP2C8 (human)[lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001804,PLA2 (canonical)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003213|http://purl.obolibrary.org/obo/IMR_0000283,,,,,,,,,,,,,,,,,,,,PMID:30077006,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000283,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003671,,,,,,,,,,TXPO:0001804,,,,,,,,,,,,,,,,,,,,,,PLA2 (canonical)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001801,P53 (canonical)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003213|http://purl.obolibrary.org/obo/IMR_0100659,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24842|NCBI-Human-GeneID:7157,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0100659,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000329,,,,,,,,,,TXPO:0001801,,,,,,,,,,,,,,,,,,,,,,P53 (canonical)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001802,BMP (canonical)[Phospholipidosis],LBPA [Phospholipidosis],,false,,,http://purl.obolibrary.org/obo/TXPO_0003213|http://purl.obolibrary.org/obo/CHEBI_60815,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,LBPA [Phospholipidosis],,,,,TXPO:0001802,,,,,,,,,,,,,,,,,,,,,,BMP (canonical)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001805,PLC (canonical)[Phospholipidosis],,"Catalysis of the reaction: a phospholipid + H2O = 1,2-diacylglycerol + a phosphatidate.",false,,,http://purl.obolibrary.org/obo/TXPO_0003213|http://purl.obolibrary.org/obo/IMR_0000284,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:313641|NCBI-Mouse-GeneID:15530|NCBI-Human-GeneID:3339,,"Catalysis of the reaction: a phospholipid + H2O = 1,2-diacylglycerol + a phosphatidate.",,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000284,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003671,,,,,,,,,,TXPO:0001805,,,,,,,,,,,,,,,,,,,,,,PLC (canonical)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001803,PLA1 (canonical)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003213|http://purl.obolibrary.org/obo/TXPO_0000120,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:25833|NCBI-Rat-GeneID:116544|NCBI-Mouse-GeneID:18988,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001803,,,,,,,,,,,,,,,,,,,,,,PLA1 (canonical)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001809,severe sphingomyelin accumulation in lysosome [Niemann Pick Disease Type B],,"Sphingomyelin accumulation in lysosome is a subtype of sphingophospholipid accumulation in lysosome: A process that keeps sphingomyelin in the lysosome.
This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type B.",false,,,http://purl.obolibrary.org/obo/TXPO_0001807,,,,,,,,,,,,,,,,,,,,,,"Sphingomyelin accumulation in lysosome is a subtype of sphingophospholipid accumulation in lysosome: A process that keeps sphingomyelin in the lysosome.
This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type B.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001480|http://purl.obolibrary.org/obo/TXPO_0001814|http://purl.obolibrary.org/obo/TXPO_0001811,,,,,,,,,,,TXPO:0001809,,,,,,,,,,,,,,,,,,,,,,severe sphingomyelin accumulation in lysosome [Niemann Pick Disease Type B],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001806,M6PR (canonical)[Phospholipidosis],mannose-6-phosphate receptor [Phospholipidosis],,false,,,http://purl.obolibrary.org/obo/TXPO_0003213|http://purl.obolibrary.org/obo/TXPO_1000240,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:4074|NCBI-Rat-GeneID:312689|NCBI-Mouse-GeneID:17113,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,mannose-6-phosphate receptor [Phospholipidosis],,,,,TXPO:0001806,,,,,,,,,,,,,,,,,,,,,,M6PR (canonical)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001807,severe sphingomyelin accumulation in lysosome [Niemann Pick Disease Type A/ B (severe)],,"Sphingomyelin accumulation in lysosome is a subtype of sphingophospholipid accumulation in lysosome: A process that keeps sphingomyelin in the lysosome.
This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type A/ B (severe).",false,,,http://purl.obolibrary.org/obo/TXPO_0001690,,,,,,,,,,,,,,,,,,,,,,"Sphingomyelin accumulation in lysosome is a subtype of sphingophospholipid accumulation in lysosome: A process that keeps sphingomyelin in the lysosome.
This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type A/ B (severe).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004147,,,,,,http://purl.obolibrary.org/obo/TXPO_0002263|http://purl.obolibrary.org/obo/TXPO_0001478|http://purl.obolibrary.org/obo/TXPO_0004146|http://purl.obolibrary.org/obo/TXPO_0002072|http://purl.obolibrary.org/obo/TXPO_0002071,,,,,,,,,,,TXPO:0001807,,,,,,,,,,,,,,,,,,,,,,severe sphingomyelin accumulation in lysosome [Niemann Pick Disease Type A/ B (severe)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001800,PI3K (canonical)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003223|http://purl.obolibrary.org/obo/TXPO_0003213,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:170911|NCBI-Mouse-GeneID:18706|NCBI-Human-GeneID:5290,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000265,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001800,,,,,,,,,,,,,,,,,,,,,,PI3K (canonical)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004551,increasing FGF21 level [mitochondrial disorder],,"Increasing FGF21 level is a subtype of increasing quantity: A process that changes the amount of FGF21 level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0004550,,,,,,,,,,,,,,,,,,,,PMID:23299992,,"Increasing FGF21 level is a subtype of increasing quantity: A process that changes the amount of FGF21 level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004552,,,,,,,,,,,,,,,,,,,TXPO:0004551,,,,,,,,,,,,,,,,,,,,,,increasing FGF21 level [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004553,FGF2 signal transduction pathway,,A series of molecular signals mediated by FGF2.,false,,,http://purl.obolibrary.org/obo/TXPO_0000609,,,,,,,,,,,,,,,,,,,,,,A series of molecular signals mediated by FGF2.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004553,,,,,,,,,,,,,,,,,,,,,,FGF2 signal transduction pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004554,FGF2 signal (primitive),,FGF2 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by FGF2.,false,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,,,FGF2 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by FGF2.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_1000144,http://purl.obolibrary.org/obo/TXPO_0004553,,,,,,,,,,,,,,,,TXPO:0004554,,,,,,,,,,,,,,,,,,,,,,FGF2 signal (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004556,FGF2 (canonical) [hepatocarcinogenesis],BFGF,,false,,,http://purl.obolibrary.org/obo/TXPO_1000144|http://purl.obolibrary.org/obo/TXPO_0005063,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:14173|NCBI-Rat-GeneID:54250|NCBI-Human-GeneID:2247|PMID:31781608,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000002247,,,,,,,,BFGF,,,,,TXPO:0004556,,,,,,,,,,,,,,,,,,,,,,FGF2 (canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004550,increasing FGF21 level,,Increasing FGF21 level is a subtype of increasing quantity: A process that changes the amount of FGF21 level to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing FGF21 level is a subtype of increasing quantity: A process that changes the amount of FGF21 level to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004550,,,,,,,,,,,,,,,,,,,,,,increasing FGF21 level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004552,FGF21(canonical) [mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000145|http://purl.obolibrary.org/obo/TXPO_0004293,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:26291|NCBI-Rat-GeneID:170580|PMID:23299992|NCBI-Mouse-GeneID:56636,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0100571,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000026291,,,,,,,,,,,,,TXPO:0004552,,,,,,,,,,,,,,,,,,,,,,FGF21(canonical) [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004555,FGF2 signaling (primitive) [hepatocarcinogenesis],,"FGF2 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by FGF2.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004554,,,,,,,,,,,,,,,,,,,,PMID:31781608,,"FGF2 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by FGF2.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004556,http://purl.obolibrary.org/obo/TXPO_0004553,,,,,http://purl.obolibrary.org/obo/TXPO_0004557,,,,,,,,,,,TXPO:0004555,,,,,,,,,,,,,,,,,,,,,,FGF2 signaling (primitive) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004558,FOXO1 activation,,FOXO1 activation is a subtype of molecular activation: A process that  changes the activity of the FOXO1 (forkhead box O1) to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000023,,,,,,,,,,,,,,,,,,,,,,FOXO1 activation is a subtype of molecular activation: A process that  changes the activity of the FOXO1 (forkhead box O1) to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004558,,,,,,,,,,,,,,,,,,,,,,FOXO1 activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004557,WNT signaling (primitive) [hepatocarcinogenesis],,"WNT signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by WNT.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0004860|http://purl.obolibrary.org/obo/TXPO_0002340,,,,,,,,,,,,,,,,,,,,PMID:29361730|PMID:29786110|PMID:28493839|PMID:26017875|PMID:31781608,,"WNT signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by WNT.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004866|http://purl.obolibrary.org/obo/TXPO_0004862|http://purl.obolibrary.org/obo/TXPO_0004863|http://purl.obolibrary.org/obo/TXPO_0004865|http://purl.obolibrary.org/obo/TXPO_0004861|http://purl.obolibrary.org/obo/TXPO_0004864|http://purl.obolibrary.org/obo/IMR_0000003,http://purl.obolibrary.org/obo/TXPO_0004859,,,,,http://purl.obolibrary.org/obo/TXPO_0004577,,,,,,,,,,,TXPO:0004557,,,,,,,,,,,,,,,,,,,,,,WNT signaling (primitive) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004559,FOXO1 activation [mitochondrial disorder],,"FOXO1 activation is a subtype of molecular activation: A process that  changes the activity of the FOXO1 (forkhead box O1) to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0004558,,,,,,,,,,,,,,,,,,,,PMID:23299992,,"FOXO1 activation is a subtype of molecular activation: A process that  changes the activity of the FOXO1 (forkhead box O1) to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004560,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004561|http://purl.obolibrary.org/obo/TXPO_0004390,,,,,,,,,,,TXPO:0004559,,,,,,,,,,,,,,,,,,,,,,FOXO1 activation [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000807,GADD45 gamma,CR6,,false,,,http://purl.obolibrary.org/obo/IMR_0000559,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CR6,,,,,IMR:0000807,,,,,,,,,,,,,,,,,,,,,,GADD45 gamma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_73044,lumiracoxib,COX 189|lumiracoxibum|COX-189|COX189|Prexige|2-((2-chloro-6-fluorophenyl)amino)-5-methylbenzeneacetic acid|lumiracoxib|{2-[(2-chloro-6-fluorophenyl)amino]-5-methylphenyl}acetic acid,"An amino acid that is phenylacetic acid which is substituted at position 2 by the nitrogen of 2-chloro-6-fluoroaniline and at position 5 by a methyl group. A highly selective cyclooxygenase 2 inhibitor, it was briefly used for the treatment of osteoarthritis, but was withdrawn due to concersns of hepatotoxicity.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:14965322|PMID:21688392|PMID:15311562|PMID:22732767|PMID:22621454|PMID:19800190|PMID:17380211|Drug_Central:1618|PMID:22142375|DrugBank:DB01283|PMID:22069133|Reaxys:9784107|PMID:15456339|CAS:220991-20-8,,"An amino acid that is phenylacetic acid which is substituted at position 2 by the nitrogen of 2-chloro-6-fluoroaniline and at position 5 by a methyl group. A highly selective cyclooxygenase 2 inhibitor, it was briefly used for the treatment of osteoarthritis, but was withdrawn due to concersns of hepatotoxicity.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_50629|http://purl.obolibrary.org/obo/CHEBI_35475,,,,,{2-[(2-chloro-6-fluorophenyl)amino]-5-methylphenyl}acetic acid,,COX 189|lumiracoxibum|COX-189|COX189|Prexige|2-((2-chloro-6-fluorophenyl)amino)-5-methylbenzeneacetic acid|lumiracoxib,,,,,,,,,,,,,,,,,,,,,CHEBI:73044,,,,lumiracoxib,,CHEBI:73044,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0030242,autophagy of peroxisome,,The process in which peroxisomes are delivered to the vacuole and degraded in response to changing nutrient conditions.,false,,,http://purl.obolibrary.org/obo/GO_0006914,,,,,,,,,,,,,,,,,,,,PMID:10547367|PMID:20083110,,The process in which peroxisomes are delivered to the vacuole and degraded in response to changing nutrient conditions.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005777,,,,,,,,,,,,,,,,,,,,,,,GO:0030242,,,,,,,,,,,,,,,,,,,,,,autophagy of peroxisome,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0000078,rhythm quality,,A quality of a single process inhering in a bearer by virtue of the bearer's movement or variation characterized by the regular recurrence or alternation of different quantities or conditions.,false,,,http://purl.obolibrary.org/obo/PATO_0002323,,,,,,,,,,,,,,,,,,,,,,A quality of a single process inhering in a bearer by virtue of the bearer's movement or variation characterized by the regular recurrence or alternation of different quantities or conditions.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0000078,,,,,,,,,,,,,,,,,,,,,,rhythm quality,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0000070,quantity (property),,The number of entities of this type that are part of the whole organism.,false,,,http://purl.obolibrary.org/obo/BFO_0000019,,,,,,,,,,,,,,,,,,,,,,The number of entities of this type that are part of the whole organism.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0000070,,,,,,,,,,,,,,,,,,,,,,quantity (property),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000554,laminin family,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003695,,,,,,,,,,IMR:0000554,,,,,,,,,,,,,,,,,,,,,,laminin family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100256,LZK,leucine zipper kinase|MAP3K13,,false,,,http://purl.obolibrary.org/obo/IMR_0100254,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,leucine zipper kinase|MAP3K13,,,,,IMR:0100256,,,,,,,,,,,,,,,,,,,,,,LZK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005117,NDUFV3 - inactive form (human)[mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003603|http://purl.obolibrary.org/obo/TXPO_0005116,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:4731|PMID:24746669,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0002355,,,,,,,,,,,,,,TXPO:0005117,,,,,,,,,,,,,,,,,,,,,,NDUFV3 - inactive form (human)[mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005111,NDUFS2 - inactive form (human)[mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003603|http://purl.obolibrary.org/obo/TXPO_0005110,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:4720|PMID:24746669,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0002355,,,,,,,,,,,,,,TXPO:0005111,,,,,,,,,,,,,,,,,,,,,,NDUFS2 - inactive form (human)[mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005118,NDUFV3 inactovation [mitochondrial disorder],,"NDUFV3 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the NDUFV3 (NADH:ubiquinone oxidoreductase core subunit V3) to be lower.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0004714,,,,,,,,,,,,,,,,,,,,PMID:24746669,,"NDUFV3 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the NDUFV3 (NADH:ubiquinone oxidoreductase core subunit V3) to be lower.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0005117,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004375,,,,,,,,,,,TXPO:0005118,,,,,,,,,,,,,,,,,,,,,,NDUFV3 inactovation [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005110,NDUFS2 (human) [mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004711,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:4720,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005110,,,,,,,,,,,,,,,,,,,,,,NDUFS2 (human) [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005115,NDUFV1 inactivation [mitochondrial disorder],,"NDUFV1 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the NDUFV1 (NADH:ubiquinone oxidoreductase core subunit V1) to be lower.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0004712,,,,,,,,,,,,,,,,,,,,PMID:24746669,,"NDUFV1 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the NDUFV1 (NADH:ubiquinone oxidoreductase core subunit V1) to be lower.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0005114,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004375,,,,,,,,,,,TXPO:0005115,,,,,,,,,,,,,,,,,,,,,,NDUFV1 inactivation [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005113,NDUFV1 (human) [mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004713,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:4723,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005113,,,,,,,,,,,,,,,,,,,,,,NDUFV1 (human) [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005116,NDUFV3 (human) [mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004715,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:4731,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005116,,,,,,,,,,,,,,,,,,,,,,NDUFV3 (human) [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005114,NDUFV1 - inactive form (human)[mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003603|http://purl.obolibrary.org/obo/TXPO_0005113,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:4723|PMID:24746669,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0002355,,,,,,,,,,,,,,TXPO:0005114,,,,,,,,,,,,,,,,,,,,,,NDUFV1 - inactive form (human)[mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005112,NDUFS2 inactivation [mitochondrial disorder],,"NDUFS2 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the NDUFS2 (NADH:ubiquinone oxidoreductase core subunit S2) to be lower.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0004710,,,,,,,,,,,,,,,,,,,,PMID:24746669,,"NDUFS2 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the NDUFS2 (NADH:ubiquinone oxidoreductase core subunit S2) to be lower.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0005111,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004375,,,,,,,,,,,TXPO:0005112,,,,,,,,,,,,,,,,,,,,,,NDUFS2 inactivation [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005119,NOS2 (mol),nitric oxide synthase 2,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:18126|NCBI-Human-GeneID:4843|NCBI-Rat-GeneID:24599,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,nitric oxide synthase 2,,,,,TXPO:0005119,,,,,,,,,,,,,,,,,,,,,,NOS2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000458,cytokeratin 18,,,false,,,http://purl.obolibrary.org/obo/IMR_0000035,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000458,,,,,,,,,,,,,,,,,,,,,,cytokeratin 18,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100670,G1-cyclin,,,false,,,http://purl.obolibrary.org/obo/IMR_0100606,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100670,,,,,,,,,,,,,,,,,,,,,,G1-cyclin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000113130,CDCA5,,Other designations: cell division cycle-associated protein 5|p35|sororin,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,SORORIN,,,,,,,,,,,,11,,,,,,Ensembl:ENSG00000146670|HGNC:14626|Vega:OTTHUMG00000150420|HPRD:13016|MIM:609374,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,cell division cycle associated 5,,,11q12.1,,,,,,,,,,,,,,,,"GO_0000082 (EC: IDA, PMID: 15837422); GO_0000278 (EC: TAS); GO_0000775 (EC: TAS); GO_0000790 (EC: ISS); GO_0003682 (EC: TAS, PMID: 15837422); GO_0005515 (EC: IPI); GO_0005634 (EC: IDA); GO_0005634 (EC: ISS); GO_0005654 (EC: TAS); GO_0005694 (EC: TAS); GO_0005730 (EC: IDA, Qualifier: NOT); GO_0005737 (EC: ISS); GO_0005829 (EC: TAS); GO_0005886 (EC: IDA); GO_0006302 (EC: IMP, PMID: 17349791); GO_0007064 (EC: IMP, PMID: 17349791); GO_0007067 (EC: IDA, PMID: 15837422); GO_0007076 (EC: IMP, PMID: 15837422); GO_0007080 (EC: IMP, PMID: 15837422); GO_0008278 (EC: IDA, Qualifier: colocalizes_with, PMID: 15837422); GO_0051329 (EC: ISS); GO_0071922 (EC: IMP, PMID: 17349791)",,,,,,,,,PMID: 11111111; 12188893; 12477932; 14702039; 15146197; 15489334; 15837422; 16169070; 16964243; 17081983; 17349791; 17361102; 18029348; 20360068; 20379614; 20551060; 21111234; 21115494; 21890473; 21987589; 21988832; 22833568; 22939629; 23455924,,,,,,,,,,,,,,,OGG:3000113130,,20140408,protein-coding,,,,cell division cycle associated 5,,,,,,,,,,,,,Other designations: cell division cycle-associated protein 5|p35|sororin,,CDCA5,,,,,,,,,,,,,,,,,,,,,,,113130,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,CDCA5,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0003069,GDF-7,BMP-12|Bone morphogenetic protein-12|Growth/differentiation factor 7,,false,,,http://purl.obolibrary.org/obo/IMR_0003085,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BMP-12|Bone morphogenetic protein-12|Growth/differentiation factor 7,,,,,IMR:0003069,,,,,,,,,,,,,,,,,,,,,,GDF-7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_36357,polyatomic entity,,Any molecular entity consisting of more than one atom.,false,,,http://purl.obolibrary.org/obo/CHEBI_23367,,,,,,,,,,,,,,,,,,,,,,Any molecular entity consisting of more than one atom.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:36357,,,,,,,,,,,,,,,,,,,,,,polyatomic entity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_50172,acitretin,"9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid","A retinoid that consists of 3,7-dimethylnona-2,4,6,8-tetraenoic acid having a 4-methoxy-2,3,6-trimethylphenyl group attached at position 9.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,LINCS:LSM-5713|Reaxys:15057225|CAS:54757-46-9,,"A retinoid that consists of 3,7-dimethylnona-2,4,6,8-tetraenoic acid having a 4-methoxy-2,3,6-trimethylphenyl group attached at position 9.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid",,,,,,,,,,,,,,,,,,,,,,,CHEBI:50172,,,,acitretin,,CHEBI:50172,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001127,chondroitin/dermatan sulfate proteoglycan,chondroitin/dermatan sulfate proteoglycan,,false,,,http://purl.obolibrary.org/obo/IMR_0000552,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,chondroitin/dermatan sulfate proteoglycan,,,,,IMR:0001127,,,,,,,,,,,,,,,,,,,,,,chondroitin/dermatan sulfate proteoglycan,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001132,versican,PG-M,,false,,,http://purl.obolibrary.org/obo/IMR_0001126,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PG-M,,,,,IMR:0001132,,,,,,,,,,,,,,,,,,,,,,versican,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001668,RGS10,,,false,,,http://purl.obolibrary.org/obo/IMR_0000431,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001668,,,,,,,,,,,,,,,,,,,,,,RGS10,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100106,chorionic gonadotropin,CG,"A gonadotropic glycoprotein hormone produced primarily by the PLACENTA. Similar to the pituitary LUTEINIZING HORMONE in structure and function, chorionic gonadotropin is involved in maintaining the CORPUS LUTEUM during pregnancy. CG consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is virtually identical to the three pituitary glycoprotein hormones (TSH, LH, and FSH), but the beta subunit is unique and confers its biological specificity.",false,,,http://purl.obolibrary.org/obo/IMR_0100087|http://purl.obolibrary.org/obo/IMR_0100086,,,,,,,,,,,,,,,,,,,,MeSH:D006063,,"A gonadotropic glycoprotein hormone produced primarily by the PLACENTA. Similar to the pituitary LUTEINIZING HORMONE in structure and function, chorionic gonadotropin is involved in maintaining the CORPUS LUTEUM during pregnancy. CG consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is virtually identical to the three pituitary glycoprotein hormones (TSH, LH, and FSH), but the beta subunit is unique and confers its biological specificity.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CG,,,,,IMR:0100106,,,,,,,,,,,,,,,,,,,,,,chorionic gonadotropin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_4659,disulfiram,"tetraethylthiuram disulphide|Antabuse|1,1'-dithiobis(N,N-diethylthioformamide)|tetraethylthiuram disulfide|Tetraethylthiuram disulfide|tetraethylthioperoxydicarbonic diamide|bis(diethylthiocarbamoyl) disulfide|N,N,N',N'-tetraethylthiuram disulfide|1,1',1'',1'''-[disulfanediylbis(carbonothioylnitrilo)]tetraethane|Disulfiram","An organic disulfide that results from the formal oxidative dimerisation of N,N-diethyldithiocarbamic acid. A multi-enzyme inhibitor that is used in alcohol aversion therapy and also exhibits anticancer properties.|An organic disulfide that results from the formal oxidative dimerisation of N,N-diethyldithiocarbamic acid.  A multi-enzyme inhibitor that is used in alcohol aversion therapy and also exhibits anticancer properties.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:14978246|CAS:97-77-8|PMID:18579431|PMID:26517513|PMID:8572926|PMID:10841824|Wikipedia:Disulfiram|PMID:17667894|PMID:25133664|PMID:25557293|PMID:25777347|PMID:16880974|PMID:21471244|PMID:26550292|PMID:16426571|PMID:11716515|PMID:24496638|PMID:25464072|PMID:19787200|LINCS:LSM-5467|PMID:19782464|PMID:19720750|PMID:11005259|PMID:26314552|PMID:8442800|DrugBank:DB00822|PMID:17079463|PMID:25445071|PMID:25476326|PMID:25657800|PMID:25495604|PMID:15325261|PMID:26239994|PMID:16661923|Drug_Central:928|PMID:26235918|PMID:16666414|Reaxys:1712560|PMID:26224731|PMID:17579916|PMID:15709459|PMID:26033731|PMID:25565438,,"An organic disulfide that results from the formal oxidative dimerisation of N,N-diethyldithiocarbamic acid. A multi-enzyme inhibitor that is used in alcohol aversion therapy and also exhibits anticancer properties.|An organic disulfide that results from the formal oxidative dimerisation of N,N-diethyldithiocarbamic acid.  A multi-enzyme inhibitor that is used in alcohol aversion therapy and also exhibits anticancer properties.",,,,,,,,,,,,C10H20N2S4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_24127|http://purl.obolibrary.org/obo/CHEBI_35610|http://purl.obolibrary.org/obo/CHEBI_37733|http://purl.obolibrary.org/obo/CHEBI_50276|http://purl.obolibrary.org/obo/CHEBI_68495|http://purl.obolibrary.org/obo/CHEBI_73240|http://purl.obolibrary.org/obo/CHEBI_35487|http://purl.obolibrary.org/obo/CHEBI_78444|http://purl.obolibrary.org/obo/CHEBI_48422,,,,,"1,1',1'',1'''-[disulfanediylbis(carbonothioylnitrilo)]tetraethane|Disulfiram",,"tetraethylthiuram disulphide|Antabuse|1,1'-dithiobis(N,N-diethylthioformamide)|tetraethylthiuram disulfide|Tetraethylthiuram disulfide|tetraethylthioperoxydicarbonic diamide|bis(diethylthiocarbamoyl) disulfide|N,N,N',N'-tetraethylthiuram disulfide",,,,,,,,,,,,,,,,,,,,,CHEBI:4659,,,,disulfiram,,CHEBI:4659,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,S(SC(N(CC)CC)=S)C(N(CC)CC)=S,,,,,
http://purl.obolibrary.org/obo/HP_0003074,Hyperglycemia,High blood glucose|High blood sugar,An increased concentration of glucose in the blood.,false,,,http://purl.obolibrary.org/obo/PATO_0001162,,,,,,,,,,,,,,,,,,,,,,An increased concentration of glucose in the blood.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,High blood glucose|High blood sugar,,,,,HP:0003074,,,,,,,,,,,,,,,,,,,,,,Hyperglycemia,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_33696,nucleic acid,,"A macromolecule made up of nucleotide units and hydrolysable into certain pyrimidine or purine bases (usually adenine, cytosine, guanine, thymine, uracil), D-ribose or 2-deoxy-D-ribose and phosphoric acid.",false,,,http://purl.obolibrary.org/obo/CHEBI_15986,,,,,,,,,,,,,,,,,,,,,,"A macromolecule made up of nucleotide units and hydrolysable into certain pyrimidine or purine bases (usually adenine, cytosine, guanine, thymine, uracil), D-ribose or 2-deoxy-D-ribose and phosphoric acid.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:33696,,,,,,,,,,,,,,,,,,,,,,nucleic acid,,,,,,,http://purl.obolibrary.org/obo/chebi.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100143,somatomedin,,"Somatomedin is a group of hormones that is produced, when stimulated by somatotropin (STH), to promote cell growth and division. In this way, they mediate the effect of somatotropin (also known as growth hormone).

They have similar biological effects to somatotropin.

Three forms include:

    * somatomedin A, which is another name for insulin-like growth factor 2
    * somatomedin B, which is derived from vitronectin
    * somatomedin C, which is another name for insulin-like growth factor 1",false,,,http://purl.obolibrary.org/obo/IMR_0000966,,,,,,,,,,,,,,,,,,,,MeSH:D013002,,"Somatomedin is a group of hormones that is produced, when stimulated by somatotropin (STH), to promote cell growth and division. In this way, they mediate the effect of somatotropin (also known as growth hormone).

They have similar biological effects to somatotropin.

Three forms include:

    * somatomedin A, which is another name for insulin-like growth factor 2
    * somatomedin B, which is derived from vitronectin
    * somatomedin C, which is another name for insulin-like growth factor 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_24621,,,,,,,,,,IMR:0100143,,,,,,,,,,,,,,,,,,,,,,somatomedin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000133746,JMY,,Other designations: WAS protein homology region 2 domain containing 1-like 3|junction-mediating and -regulatory protein|junction-mediating and regulatory protein,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,WHDC1L3,,,,,,,,,,,,5,,,,,,HGNC:28916|MIM:604279|HPRD:05045|Vega:OTTHUMG00000131301|Ensembl:ENSG00000152409,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"junction mediating and regulatory protein, p53 cofactor",,,5q14.1,,,,,,,,,,,,,,,,"GO_0003713 (EC: ISS); GO_0003779 (EC: IEA); GO_0005515 (EC: IPI, PMID: 10518217); GO_0005634 (EC: ISS); GO_0005737 (EC: IEA); GO_0005856 (EC: IEA); GO_0006281 (EC: IEA); GO_0006357 (EC: ISS); GO_0007050 (EC: ISS); GO_0031252 (EC: IDA, PMID: 19287377); GO_0034314 (EC: ISS); GO_0043065 (EC: ISS); GO_0051091 (EC: ISS); GO_0070060 (EC: ISS); GO_0070358 (EC: ISS); GO_0072332 (EC: IEA)",,,,,,,,,PMID: 8889548; 10518217; 12477932; 14702039; 15146197; 15706352; 16344560; 17170761; 18398821; 19287377; 19897726; 21625218; 21965285; 22262458; 23758122; 24250222,,,,,,,,,,,,,,,OGG:3000133746,,,,,,,"junction mediating and regulatory protein, p53 cofactor",,,,,,,,,,,,,Other designations: WAS protein homology region 2 domain containing 1-like 3|junction-mediating and -regulatory protein|junction-mediating and regulatory protein,,JMY,,,,,,,,,,,,,,,,,,,,,,,133746,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,JMY,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0100565,FGF-15,,,false,,,http://purl.obolibrary.org/obo/IMR_0000049,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100565,,,,,,,,,,,,,,,,,,,,,,FGF-15,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_72695,organic molecule,organic compound,Any molecule that consists of at least one carbon atom as part of the electrically neutral entity.,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,Any molecule that consists of at least one carbon atom as part of the electrically neutral entity.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,organic compound,,,,,CHEBI:72695,,,,,,,,,,,,,,,,,,,,,,organic molecule,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_67239,EC 3.2.1.20 (alpha-glucosidase) inhibitor,"alpha-glucoside hydrolase inhibitors|EC 3.2.1.20 inhibitors|alpha-glucosidase inhibitor|alpha-glucopyranosidase inhibitors|maltase-glucoamylase inhibitors|maltase-glucoamylase inhibitor|glucoinvertase inhibitors|maltase inhibitors|glucosidosucrase inhibitor|glucosidoinvertase inhibitors|alpha-1,4-glucosidase inhibitors|EC 3.2.1.20 inhibitor|alpha-glucoside hydrolase inhibitor|alpha-D-glucosidase inhibitor|alpha-glucosidase inhibitors|alpha-1,4-glucosidase inhibitor|alpha-glucosidase (EC 3.2.1.20) inhibitor|EC 3.2.1.20 (alpha-glucosidase) inhibitors|alpha-glucosidase (EC 3.2.1.20) inhibitors|alpha-glucopyranosidase inhibitor|glucosidoinvertase inhibitor|maltase inhibitor|glucosidosucrase inhibitors|alpha-D-glucosidase inhibitors|glucoinvertase inhibitor",An EC 3.2.1.* (glycosidase) inhibitor that interferes with the action of alpha-glucosidase (EC 3.2.1.20).,false,,,http://purl.obolibrary.org/obo/CHEBI_52424,,,,,,,,,,,,,,,,,,,,,,An EC 3.2.1.* (glycosidase) inhibitor that interferes with the action of alpha-glucosidase (EC 3.2.1.20).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"alpha-glucoside hydrolase inhibitors|EC 3.2.1.20 inhibitors|alpha-glucosidase inhibitor|alpha-glucopyranosidase inhibitors|maltase-glucoamylase inhibitors|maltase-glucoamylase inhibitor|glucoinvertase inhibitors|maltase inhibitors|glucosidosucrase inhibitor|glucosidoinvertase inhibitors|alpha-1,4-glucosidase inhibitors|EC 3.2.1.20 inhibitor|alpha-glucoside hydrolase inhibitor|alpha-D-glucosidase inhibitor|alpha-glucosidase inhibitors|alpha-1,4-glucosidase inhibitor|alpha-glucosidase (EC 3.2.1.20) inhibitor|EC 3.2.1.20 (alpha-glucosidase) inhibitors|alpha-glucosidase (EC 3.2.1.20) inhibitors|alpha-glucopyranosidase inhibitor|glucosidoinvertase inhibitor|maltase inhibitor|glucosidosucrase inhibitors|alpha-D-glucosidase inhibitors|glucoinvertase inhibitor",,,,,,,,,,,,,,,,,,,,,CHEBI:67239,,,,EC 3.2.1.20 (alpha-glucosidase) inhibitor,,CHEBI:67239,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000053,cytokeratin 1,,,false,,,http://purl.obolibrary.org/obo/IMR_0000050,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000053,,,,,,,,,,,,,,,,,,,,,,cytokeratin 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000004609,MYC,,Other designations: avian myelocytomatosis viral oncogene homolog|class E basic helix-loop-helix protein 39|myc proto-oncogene protein|myc-related translation/localization regulatory factor|proto-oncogene c-Myc|transcription factor p64|v-myc myelocytomatosis viral oncogene homolog,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,MYCC|bHLHe39|c-Myc|MRTL,,,,,,,,,,,,8,,,,,,HGNC:7553|MIM:190080|Ensembl:ENSG00000136997|Vega:OTTHUMG00000128475|HPRD:01818,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,v-myc avian myelocytomatosis viral oncogene homolog,,,8q24.21,,,,,,,,,,,,,,,,"GO_0000122 (EC: IDA, PMID: 9924025); GO_0000165 (EC: IMP, PMID: 17873522); GO_0001658 (EC: ISS); GO_0002053 (EC: ISS); GO_0003677 (EC: ISS); GO_0003677 (EC: TAS, PMID: 10597290); GO_0003700 (EC: IDA, PMID: 9924025); GO_0005515 (EC: IPI, PMID: 10597290); GO_0005634 (EC: IDA, PMID: 11793365); GO_0005654 (EC: IDA, PMID: 17558397); GO_0005654 (EC: TAS); GO_0005730 (EC: IDA, PMID: 17558397); GO_0005819 (EC: IEA); GO_0006112 (EC: NAS, PMID: 9924025); GO_0006338 (EC: IDA); GO_0006351 (EC: TAS); GO_0006367 (EC: TAS); GO_0006879 (EC: IDA, PMID: 9924025); GO_0006974 (EC: IDA, PMID: 17873522); GO_0007050 (EC: IDA, PMID: 10962037); GO_0007179 (EC: TAS); GO_0007219 (EC: TAS); GO_0008134 (EC: IPI, PMID: 15674325); GO_0008284 (EC: IDA, PMID: 15994933); GO_0010332 (EC: IDA, PMID: 19179467); GO_0010467 (EC: TAS); GO_0010468 (EC: IDA); GO_0015671 (EC: NAS, PMID: 9924025); GO_0032204 (EC: IMP, PMID: 17765874); GO_0032403 (EC: IDA, PMID: 18987311); GO_0032873 (EC: ISS); GO_0034644 (EC: IEP, PMID: 17873522); GO_0035690 (EC: IDA, PMID: 17873522); GO_0042493 (EC: IEP, PMID: 18291362); GO_0043066 (EC: ISS); GO_0043234 (EC: IDA, PMID: 17873522); GO_0043280 (EC: IDA, PMID: 19179467); GO_0044346 (EC: TAS, PMID: 10962037); GO_0045656 (EC: IMP, PMID: 9924025); GO_0045893 (EC: IDA, PMID: 10962037); GO_0045944 (EC: IMP, PMID: 9924025); GO_0045944 (EC: TAS); GO_0046983 (EC: IEA); GO_0048146 (EC: IDA, PMID: 18987311); GO_0048146 (EC: IMP, PMID: 15674325); GO_0048147 (EC: IDA, PMID: 10962037); GO_0050679 (EC: IDA, PMID: 18987311); GO_0051276 (EC: IDA, PMID: 10962037); GO_0051782 (EC: IDA, PMID: 10962037); GO_0060070 (EC: IDA); GO_0070491 (EC: IPI, PMID: 15674325); GO_0070848 (EC: TAS, PMID: 18987311); GO_0070888 (EC: IDA, PMID: 18818310); GO_0090096 (EC: ISS); GO_2000573 (EC: IMP, PMID: 9924025); GO_2001022 (EC: IDA, PMID: 19179467)",,,,,,,,,PMID: 1318011; 1559612; 1597196; 1651323; 1748630; 1914517; 2006410; 2430795; 2663470; 2834731; 3033665; 3243428; 3277717; 3540591; 3778453; 6298632; 6304538; 6304729; 6321164; 6324175; 6414718; 6419122; 6431612; 6547209; 6578511; 6714223; 7565735; 7642555; 7651436; 7729426; 7838535; 7892279; 7957875; 8076603; 8220424; 8224841; 8247524; 8266081; 8377829; 8386367; 8668343; 8755740; 9129988; 9155018; 9184233; 9187264; 9207092; 9308237; 9312026; 9315742; 9461566; 9528857; 9680483; 9689053; 9708738; 9788437; 9792694; 9797456; 9924025; 9927431; 10229200; 10319872; 10380878; 10421840; 10446203; 10465786; 10551811; 10593926; 10597290; 10611234; 10899308; 10918583; 10962037; 11046155; 11182042; 11208609; 11274368; 11282029; 11283613; 11306501; 11311202; 11431533; 11441001; 11443860; 11509179; 11511539; 11567024; 11585818; 11602341; 11673469; 11777933; 11793365; 11795828; 11804592; 11817538; 11839798; 11840336; 11844794; 11848444; 11848471; 11850082; 11861398; 11877042; 11877298; 11877389; 11891322; 11909963; 11916966; 11956070; 11960382; 11968011; 12027803; 12031912; 12032779; 12036888; 12049739; 12072203; 12077335; 12080043; 12082260; 12091391; 12130502; 12149248; 12149649; 12177005; 12196529; 12209953; 12213716; 12226097; 12237776; 12356725; 12360279; 12362975; 12379776; 12391307; 12394763; 12420224; 12435808; 12446731; 12452058; 12477932; 12490316; 12509468; 12529648; 12538578; 12545156; 12553908; 12562237; 12575534; 12584560; 12637327; 12637527; 12644583; 12646176; 12660246; 12673205; 12688321; 12706874; 12721301; 12729735; 12748187; 12769844; 12776177; 12776737; 12783888; 12808131; 12818373; 12821782; 12824159; 12824180; 12829833; 12842909; 12855588; 12857727; 12873812; 12909717; 12944920; 12963825; 12970749; 14532990; 14559996; 14563837; 14576301; 14612409; 14625288; 14645543; 14645547; 14663479; 14663583; 14672406; 14697225; 14724288; 14744757; 14749374; 14760071; 14769798; 14991929; 15048125; 15067010; 15071503; 15077166; 15083194; 15084259; 15098029; 15103331; 15108364; 15126105; 15150404; 15160911; 15190416; 15191563; 15192039; 15198123; 15199070; 15199147; 15210690; 15243561; 15282543; 15286700; 15287031; 15355849; 15358760; 15361884; 15457447; 15459488; 15468060; 15474507; 15489334; 15498494; 15502847; 15516975; 15522869; 15528212; 15542830; 15572685; 15580293; 15595642; 15601838; 15616584; 15616592; 15629428; 15645079; 15663936; 15674325; 15688026; 15697230; 15716988; 15723053; 15723054; 15735755; 15739117; 15743499; 15756435; 15763593; 15769738; 15780936; 15800668; 15808510; 15839202; 15856024; 15878876; 15910003; 15929079; 15937962; 15944709; 15965094; 15972952; 15986448; 15988031; 15991278; 15992821; 15994933; 16007143; 16023596; 16081735; 16085756; 16094360; 16107691; 16107734; 16116477; 16126174; 16139224; 16140957; 16167342; 16169462; 16172399; 16173081; 16174239; 16201965; 16205115; 16210249; 16247449; 16260605; 16269333; 16287840; 16293596; 16295419; 16308474; 16316993; 16328057; 16352593; 16367922; 16376880; 16378632; 16410719; 16410805; 16423995; 16423996; 16432227; 16455494; 16466700; 16478988; 16490593; 16494045; 16508012; 16537449; 16537801; 16541139; 16543245; 16552729; 16554306; 16572399; 16582589; 16596619; 16628215; 16631470; 16675879; 16682952; 16690525; 16705173; 16706751; 16724113; 16785237; 16788099; 16797278; 16809765; 16857742; 16874304; 16878156; 16940161; 16964280; 16984727; 16996503; 17001014; 17028906; 17046748; 17050536; 17070983; 17072308; 17081983; 17082179; 17082780; 17093053; 17114293; 17141659; 17145812; 17146437; 17146439; 17151361; 17157259; 17158641; 17159920; 17170079; 17219990; 17264126; 17268552; 17289033; 17297307; 17308053; 17310999; 17314511; 17353931; 17363738; 17401363; 17401366; 17404030; 17404512; 17418410; 17419941; 17419945; 17431415; 17444495; 17445886; 17452451; 17466258; 17466981; 17471507; 17482131; 17485441; 17486099; 17503467; 17525531; 17541401; 17558397; 17560940; 17567920; 17568564; 17573914; 17587243; 17597761; 17599065; 17606868; 17613764; 17616526; 17622571; 17632056; 17634226; 17643117; 17646408; 17656250; 17670825; 17698969; 17699159; 17700029; 17700062; 17704800; 17706770; 17726380; 17728244; 17765874; 17766436; 17784791; 17785433; 17785457; 17822678; 17873522; 17877160; 17881732; 17881904; 17885207; 17908964; 17913706; 17917571; 17927853; 17959148; 17967894; 17989722; 17993259; 18003922; 18024371; 18026954; 18059336; 18059365; 18060517; 18066065; 18084761; 18085637; 18089500; 18157115; 18190704; 18204787; 18206534; 18206725; 18216297; 18235046; 18240345; 18242516; 18247372; 18256156; 18256542; 18262050; 18271930; 18291362; 18292777; 18297523; 18308950; 18314492; 18320361; 18321953; 18323656; 18345030; 18348166; 18348176; 18349290; 18365874; 18369647; 18375382; 18381641; 18382371; 18393360; 18398700; 18408012; 18413597; 18422165; 18426604; 18426731; 18433872; 18451027; 18460403; 18483244; 18483343; 18490439; 18498136; 18535662; 18542060; 18544539; 18556416; 18559552; 18562319; 18566574; 18567993; 18586674; 18593994; 18597608; 18621930; 18623111; 18628098; 18628958; 18632605; 18642056; 18647998; 18676680; 18677108; 18679422; 18713946; 18714337; 18722373; 18752058; 18752503; 18754028; 18776924; 18780787; 18782427; 18794855; 18808065; 18809243; 18813796; 18813857; 18816594; 18818310; 18818322; 18838534; 18851746; 18852287; 18923429; 18932273; 18937283; 18950845; 18953412; 18985155; 18987311; 18987359; 19008924; 19017648; 19020659; 19020761; 19022255; 19022256; 19022773; 19033664; 19038003; 19061835; 19061838; 19084934; 19086036; 19087307; 19111069; 19118200; 19119907; 19126644; 19131971; 19134217; 19143767; 19147754; 19164469; 19170058; 19170196; 19174556; 19176757; 19179467; 19180571; 19202062; 19204574; 19211792; 19219026; 19259613; 19269368; 19270750; 19276364; 19287990; 19322201; 19330026; 19330811; 19331129; 19332536; 19336552; 19351506; 19358757; 19364925; 19379561; 19387923; 19395026; 19398483; 19407242; 19453846; 19454499; 19461583; 19470954; 19481339; 19497851; 19524285; 19535347; 19549807; 19549847; 19554081; 19560862; 19561607; 19562729; 19564413; 19568426; 19573080; 19574298; 19575869; 19578763; 19581307; 19586553; 19594747; 19596917; 19596922; 19597184; 19602047; 19623651; 19625176; 19633646; 19672269; 19673870; 19684017; 19690609; 19692168; 19696787; 19700410; 19704118; 19729955; 19730683; 19740707; 19748357; 19755676; 19766114; 19773279; 19786833; 19787269; 19815507; 19818711; 19821490; 19840458; 19843847; 19855079; 19857615; 19881537; 19895682; 19900447; 19908297; 19923826; 19934275; 19956635; 19966299; 19966300; 19996270; 20008140; 20008325; 20010808; 20010876; 20063409; 20065031; 20071475; 20086171; 20087644; 20113841; 20118770; 20133585; 20133671; 20143187; 20144848; 20170530; 20173740; 20190818; 20194507; 20195357; 20208519; 20212154; 20215511; 20221419; 20232342; 20233711; 20300622; 20308430; 20348956; 20359089; 20378577; 20379146; 20382893; 20383333; 20402410; 20416159; 20423888; 20426839; 20434984; 20440510; 20442643; 20453196; 20473309; 20487546; 20493879; 20498406; 20509972; 20515470; 20520840; 20551172; 20561405; 20562918; 20564213; 20573831; 20579853; 20596624; 20598117; 20607354; 20634801; 20643075; 20647308; 20659471; 20661666; 20662834; 20691906; 20697356; 20714214; 20716114; 20716118; 20737197; 20737421; 20820186; 20848231; 20852628; 20852632; 20873543; 20878079; 20890087; 20936779; 20946988; 20949568; 20950152; 20956327; 20962620; 20970423; 20972266; 20972438; 20974848; 20974860; 20981461; 21036740; 21039844; 21048031; 21054888; 21059853; 21059911; 21060841; 21073496; 21092188; 21098095; 21098324; 21113618; 21120662; 21129250; 21131959; 21135252; 21138684; 21148746; 21150319; 21173787; 21187426; 21217079; 21219856; 21242960; 21245140; 21262914; 21264535; 21284881; 21298377; 21302450; 21317922; 21324178; 21336720; 21346144; 21378543; 21383696; 21390222; 21394210; 21400515; 21405945; 21406394; 21406400; 21412688; 21419292; 21435462; 21441954; 21447796; 21460180; 21468039; 21478095; 21478429; 21497295; 21527520; 21533051; 21556123; 21557726; 21575199; 21610111; 21618595; 21620836; 21627565; 21628855; 21638011; 21640157; 21643008; 21646687; 21667531; 21668996; 21692100; 21693596; 21693764; 21708481; 21724525; 21741827; 21769863; 21774525; 21781227; 21783402; 21793975; 21795698; 21807902; 21808024; 21833088; 21835891; 21851818; 21856782; 21862873; 21876152; 21878679; 21882178; 21885567; 21890444; 21890473; 21903590; 21906983; 21908617; 21909081; 21913186; 21915097; 21941025; 21941367; 21949397; 21963094; 21969377; 21975934; 21986497; 21987572; 21988832; 21998677; 22002311; 22002575; 22005580; 22010341; 22011035; 22015605; 22016811; 22020439; 22022427; 22025562; 22037351; 22068108; 22081066; 22090452; 22094256; 22108803; 22120970; 22121953; 22128178; 22145969; 22155254; 22157079; 22158906; 22159222; 22168746; 22169291; 22172699; 22178210; 22184109; 22186139; 22205151; 22235332; 22245592; 22249265; 22253833; 22281794; 22285861; 22286234; 22307329; 22310977; 22314191; 22317895; 22326218; 22327960; 22328504; 22330139; 22333584; 22333947; 22364879; 22371483; 22383169; 22384171; 22393362; 22417306; 22429595; 22430491; 22448750; 22453922; 22456335; 22484426; 22484818; 22496461; 22505724; 22510570; 22535747; 22543587; 22545246; 22547830; 22573578; 22573825; 22578181; 22581054; 22614067; 22615405; 22623531; 22623730; 22661084; 22665062; 22665537; 22670178; 22706665; 22707729; 22710719; 22713676; 22733550; 22736142; 22739149; 22754359; 22768805; 22791812; 22801218; 22804688; 22814375; 22826122; 22826319; 22833560; 22842522; 22844532; 22851565; 22863009; 22880082; 22884659; 22887866; 22889122; 22897848; 22912356; 22941468; 22942279; 22945648; 22949148; 22957790; 22967991; 22976378; 22986535; 22992334; 22999547; 23000965; 23012230; 23012233; 23018644; 23024800; 23029531; 23042398; 23045412; 23053136; 23062488; 23071356; 23079660; 23079661; 23088399; 23089465; 23106691; 23108410; 23112173; 23113893; 23135913; 23143306; 23143645; 23145106; 23155275; 23175515; 23177619; 23178486; 23178487; 23237560; 23237807; 23239811; 23243310; 23249808; 23250739; 23266555; 23266556; 23269272; 23277542; 23291854; 23308051; 23318434; 23330001; 23335369; 23341364; 23355209; 23364919; 23380875; 23389829; 23424671; 23438603; 23449635; 23455924; 23466707; 23468463; 23504319; 23507140; 23509080; 23521519; 23530127; 23532756; 23535729; 23535730; 23538750; 23552692; 23555992; 23560086; 23560736; 23574779; 23576579; 23578955; 23583198; 23588620; 23588859; 23589839; 23601184; 23603171; 23603392; 23613397; 23649631; 23704919; 23714368; 23716601; 23720054; 23770341; 23775087; 23776131; 23791182; 23792459; 23797802; 23816886; 23817571; 23821202; 23860446; 23860775; 23861098; 23894778; 23901000; 23907459; 23908595; 23930820; 23939148; 23982173; 23994632; 24009228; 24036151; 24053468; 24063893; 24095110; 24140063; 24157866; 24169826; 24216476; 24249258; 24259667; 24272483; 24316975; 24333422,,,,,,,,,,,,,,,OGG:3000004609,,,,,,,v-myc avian myelocytomatosis viral oncogene homolog,,,,,,,,,,,,,Other designations: avian myelocytomatosis viral oncogene homolog|class E basic helix-loop-helix protein 39|myc proto-oncogene protein|myc-related translation/localization regulatory factor|proto-oncogene c-Myc|transcription factor p64|v-myc myelocytomatosis viral oncogene homolog,,MYC,,,,,,,,,,,,,,,,,,,,,,,4609,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,MYC,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000004605,MYBL2,,Other designations: myb-like protein 2|myb-related protein B|v-myb myeloblastosis viral oncogene homolog-like 2,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,BMYB|B-MYB,,,,,,,,,,,,20,,,,,,MIM:601415|HGNC:7548|HPRD:03247|Ensembl:ENSG00000101057|Vega:OTTHUMG00000033062,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,v-myb avian myeloblastosis viral oncogene homolog-like 2,,,20q13.1,,,,,,,,,,,,,,,,"GO_0000086 (EC: TAS); GO_0000278 (EC: TAS); GO_0003677 (EC: IEA); GO_0003682 (EC: IEA); GO_0003700 (EC: IEA); GO_0005515 (EC: IPI, PMID: 17159899); GO_0005634 (EC: IDA); GO_0005654 (EC: TAS); GO_0005730 (EC: IDA, Qualifier: NOT); GO_0006351 (EC: IEA); GO_0031523 (EC: IEA); GO_0051726 (EC: TAS); GO_0090307 (EC: IEA)",,,,,,,,,PMID: 1376749; 1717494; 1984793; 3060855; 7642110; 8062924; 8123011; 8125298; 8142646; 8314782; 8812502; 9012818; 9840932; 10095772; 10544265; 10593981; 10645009; 10656684; 10744766; 10766737; 10770937; 10871850; 11259168; 11264176; 11423988; 11522824; 11733503; 11780052; 11973331; 11997503; 12439743; 12475768; 12477932; 12645566; 12673206; 12748276; 12927788; 12947099; 14506250; 14769798; 15256398; 15302935; 15489334; 15618219; 16055500; 16476973; 16551698; 17081983; 17098733; 17159899; 17531812; 17563750; 17588787; 17671431; 18026132; 18548008; 18676680; 19016757; 19043454; 19170196; 19383908; 19471022; 19625176; 19692168; 19725879; 19821490; 20211142; 20360068; 20734103; 20857481; 20864510; 21148321; 21187425; 21304178; 21367750; 21419759; 21480327; 21693764; 21900206; 21988832; 22910183; 23032261; 23555285; 24199710,,,,,,,,,,,,,,,OGG:3000004605,,,,,,,v-myb avian myeloblastosis viral oncogene homolog-like 2,,,,,,,,,,,,,Other designations: myb-like protein 2|myb-related protein B|v-myb myeloblastosis viral oncogene homolog-like 2,,MYBL2,,,,,,,,,,,,,,,,,,,,,,,4605,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,MYBL2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000051141,INSIG2,,Other designations: INSIG-2|INSIG2 membrane protein|insulin induced protein 2|insulin-induced gene 2 protein,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,2,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,insulin induced gene 2,,,2q14.2,,,,,,,,,,,,,,,,"GO_0005515 (EC: IPI, PMID: 12242332); GO_0005789 (EC: TAS); GO_0006641 (EC: IEA); GO_0006695 (EC: IEA); GO_0008134 (EC: IEA); GO_0010894 (EC: IEA); GO_0032868 (EC: IEA); GO_0032933 (EC: IDA, PMID: 12242332); GO_0032937 (EC: IDA, PMID: 12242332); GO_0042472 (EC: IEA); GO_0042474 (EC: IEA); GO_0044281 (EC: TAS); GO_0045717 (EC: IEA); GO_0060021 (EC: IEA); GO_0060363 (EC: IEA); GO_0070542 (EC: IEA)",,,,,,,,,PMID: 12242332; 12477932; 12482938; 12624180; 12842885; 14702039; 16549805; 16606821; 16614226; 17137505; 17428920; 17465681; 17471297; 17489846; 18003761; 18070740; 18162505; 18195716; 18223638; 18239574; 18270535; 18319320; 18347269; 18398047; 18426866; 18464289; 18514965; 18570692; 18615239; 18660489; 18682847; 18839134; 18989534; 19105843; 19197259; 19197262; 19224890; 19263810; 19360016; 19399648; 19523229; 19617589; 19638338; 19740467; 19772594; 19815544; 19851442; 19913121; 19948975; 20007308; 20028541; 20045156; 20083228; 20092643; 20145255; 20373477; 20504252; 20538960; 20628086; 20645959; 20653998; 20712903; 20816152; 20816195; 20858904; 20877301; 20920244; 20955599; 21163096; 21443541; 21544599; 21978759; 22020349; 22143767; 22355322; 22504420; 22695173; 22968099; 24250222; 24371122,,,,,,,,,,,,,,,OGG:3000051141,,,,,,,insulin induced gene 2,,,,,,,,,,,,,Other designations: INSIG-2|INSIG2 membrane protein|insulin induced protein 2|insulin-induced gene 2 protein,,INSIG2,,,,,,,,,,,,,,,,,,,,,,,51141,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,INSIG2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000051147,ING4,,Other designations: brain my036 protein|candidate tumor suppressor p33 ING1 homolog|inhibitor of growth protein 4,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,p29ING4|my036,,,,,,,,,,,,12,,,,,,MIM:608524|HPRD:09774|Vega:OTTHUMG00000141274|Ensembl:ENSG00000111653|HGNC:19423,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"inhibitor of growth family, member 4",,,12p13.31,,,,,,,,,,,,,,,,"GO_0000123 (EC: IDA, PMID: 16387653); GO_0003713 (EC: IDA, PMID: 16387653); GO_0005515 (EC: IPI, PMID: 12750254); GO_0005634 (EC: IDA, PMID: 15029197); GO_0005654 (EC: TAS); GO_0006260 (EC: IDA, PMID: 16387653); GO_0006325 (EC: TAS); GO_0006473 (EC: IDA, PMID: 12750254); GO_0006915 (EC: IDA, PMID: 15251430); GO_0006978 (EC: IDA, PMID: 16387653); GO_0007050 (EC: IDA, PMID: 15251430); GO_0008270 (EC: IEA); GO_0008285 (EC: IDA, PMID: 12750254); GO_0035064 (EC: IDA, PMID: 16728974); GO_0043065 (EC: IDA, PMID: 16387653); GO_0043966 (EC: IDA, PMID: 16387653); GO_0043981 (EC: IDA, PMID: 16387653); GO_0043982 (EC: IDA, PMID: 16387653); GO_0043983 (EC: IDA, PMID: 16387653); GO_0043984 (EC: IDA, Qualifier: NOT, PMID: 16387653); GO_0045892 (EC: IDA, PMID: 15029197); GO_0045926 (EC: IDA, PMID: 12750254)",,,,,,,,,PMID: 8889548; 10931946; 12477932; 12750254; 15029197; 15251430; 15342556; 15489334; 15528276; 15882981; 15897452; 15935570; 16096374; 16387653; 16728974; 16916647; 16920330; 16973615; 17157298; 17325660; 17363573; 17517644; 17848618; 17954561; 18381289; 18394746; 18399550; 18775696; 18779315; 18789575; 19034511; 19250543; 19430401; 19571607; 19775294; 20053357; 20211142; 20381459; 20445261; 20501848; 20705953; 20707719; 20716169; 20953165; 21056991; 21177815; 21310648; 21315418; 21454715; 21626442; 21890473; 21971889; 21988832; 22078444; 22144582; 22228137; 22334692; 22436625; 22767438; 23055189; 23056468; 23181555; 23455924; 23603392; 23624912; 24130172; 24157826,,,,,,,,,,,,,,,OGG:3000051147,,,,,,,"inhibitor of growth family, member 4",,,,,,,,,,,,,Other designations: brain my036 protein|candidate tumor suppressor p33 ING1 homolog|inhibitor of growth protein 4,,ING4,,,,,,,,,,,,,,,,,,,,,,,51147,My036,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,ING4,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000836,C/EBP delta,CCAAT/enhancer binding protein delta,,false,,,http://purl.obolibrary.org/obo/IMR_0000422,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CCAAT/enhancer binding protein delta,,,,,IMR:0000836,,,,,,,,,,,,,,,,,,,,,,C/EBP delta,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_49201,anti-ulcer drug,anti-ulcer agent,One of various classes of drugs with different action mechanisms used to treat or ameliorate peptic ulcer or irritation of the gastrointestinal tract.,false,,,http://purl.obolibrary.org/obo/CHEBI_23888,,,,,,,,,,,,,,,,,,,,,,One of various classes of drugs with different action mechanisms used to treat or ameliorate peptic ulcer or irritation of the gastrointestinal tract.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,anti-ulcer agent,,,CHEBI:49201,,,,,,,,,,,,,,,,,,,,,,anti-ulcer drug,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000054431,DNAJC10,,"Other designations: ER-resident protein ERdj5|J-domain-containing protein disulfide isomerase-like protein|dnaJ homolog subfamily C member 10|endoplasmic reticulum DNA J domain-containing protein 5|macrothioredoxin|protein disulfide isomerase family A, member 19",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,MTHr|ERdj5|PDIA19|JPDI,,,,,,,,,,,,2,,,,,,HGNC:24637|HPRD:09722|MIM:607987,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"DnaJ (Hsp40) homolog, subfamily C, member 10",,,2q32.1,,,,,,,,,,,,,,,,"GO_0001671 (EC: ISS); GO_0001933 (EC: IDA, PMID:19122239); GO_0005515 (EC: IPI, PMID:19706418); GO_0005783 (EC: IDA, PMID:12411443); GO_0005788 (EC: IDA); GO_0006662 (EC: IEA); GO_0015035 (EC: IDA); GO_0015035 (EC: ISS); GO_0015036 (EC: ISS); GO_0016671 (EC: ISS); GO_0030433 (EC: IMP, PMID:18400946); GO_0030544 (EC: IPI); GO_0032781 (EC: ISS); GO_0034663 (EC: IDA, PMID:18400946); GO_0034975 (EC: IDA); GO_0034976 (EC: IDA, PMID:19122239); GO_0045454 (EC: IEA); GO_0051087 (EC: IDA, PMID:12411443); GO_0051117 (EC: IPI, PMID:12411443); GO_0051787 (EC: IDA, PMID:18400946); GO_0070059 (EC: IDA, PMID:19122239)",,,,,,,,,PMID:12411443; 12446677; 12477932; 12975309; 14587667; 14702039; 15489334; 15815621; 16189514; 16303743; 16344560; 17353921; 18400946; 18653895; 19122239; 19706418; 19815549; 20347046; 21139048; 21145461; 21266254; 21329881; 21632540; 21890473; 21906983; 22229892; 22354994; 22797925; 23192594; 23363602; 23455922; 23769672,,,,,,,,,,,,,,,OGG:3000054431,,,,,,,"DnaJ (Hsp40) homolog, subfamily C, member 10",,,,,,,,,,,,,"Other designations: ER-resident protein ERdj5|J-domain-containing protein disulfide isomerase-like protein|dnaJ homolog subfamily C member 10|endoplasmic reticulum DNA J domain-containing protein 5|macrothioredoxin|protein disulfide isomerase family A, member 19",,DNAJC10,,,,,,,,,,,,,,,,,,,,,,,54431,UNQ495/PRO1012,,,,,,,9606,,,,,,,,,,,,,,,,,,,DNAJC10,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0100798,LRP family,LDL receptor-related protein|low-density lipoprotein receptor-related protein|low density lipoprotein receptor-related protein,,false,,,http://purl.obolibrary.org/obo/IMR_0000974,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,LDL receptor-related protein|low-density lipoprotein receptor-related protein|low density lipoprotein receptor-related protein,,,,,IMR:0100798,,,,,,,,,,,,,,,,,,,,,,LRP family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003311,improving,,"Improving is a type of functioning process of meta-function.
Both enhancing and improveing represents optional contribution to other function.
The “optional” means that the effect of fa is not mandatory to ft, that is, the target function can be performed without improving or enhancing.
The discrimination between improving and enhancing is made by whether augmentation of the output can be made without increase of the amount of the input energy or not.

For example, the “to make low pressure” of the condenser contributes to the efficiency of the “to generate torque” function without increment of input energy, so its functioning is “Improving”. On the other hand, the “to super-heat” function of the boiler optionally increases the amount of the input energy to make a contribution. Its meta-function is “Enhancing” .",false,,,http://purl.obolibrary.org/obo/TXPO_0002541,,,,,,,,,,,,,,,,,,,,,,"Improving is a type of functioning process of meta-function.
Both enhancing and improveing represents optional contribution to other function.
The “optional” means that the effect of fa is not mandatory to ft, that is, the target function can be performed without improving or enhancing.
The discrimination between improving and enhancing is made by whether augmentation of the output can be made without increase of the amount of the input energy or not.

For example, the “to make low pressure” of the condenser contributes to the efficiency of the “to generate torque” function without increment of input energy, so its functioning is “Improving”. On the other hand, the “to super-heat” function of the boiler optionally increases the amount of the input energy to make a contribution. Its meta-function is “Enhancing” .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003311,,,,,,,,,,,,,,,,,,,,,,improving,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003315,decreasing retinal blood flow,,Decreasing retinal blood flow is a subtype of decreasing flow: A process that changes the amount of retinal flow to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000359,,,,,,,,,,,,,,,,,,,,,,Decreasing retinal blood flow is a subtype of decreasing flow: A process that changes the amount of retinal flow to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003315,,,,,,,,,,,,,,,,,,,,,,decreasing retinal blood flow,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003316,moving water to the inside of cell [Hypertrophy],,"Moving water to the inside of cell is a subtype of moving A to the inside of B: A process of the movement of water into a cell.
This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy.",false,,,http://purl.obolibrary.org/obo/TXPO_0003279|http://purl.obolibrary.org/obo/TXPO_0003318,,,,,,,,,,,,,,,,,,,,,,"Moving water to the inside of cell is a subtype of moving A to the inside of B: A process of the movement of water into a cell.
This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003299,,,,,,,,,,,TXPO:0003316,,,,,,,,,,,,,,,,,,,,,,moving water to the inside of cell [Hypertrophy],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000182,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003317,decreasing retinal blood flow [Diabetic retinopathy],,"Decreasing retinal blood flow is a subtype of decreasing flow: A process that changes the amount of retinal flow to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Diabetic retinopathy.",false,,,http://purl.obolibrary.org/obo/TXPO_0003342|http://purl.obolibrary.org/obo/TXPO_0003315,,,,,,,,,,,,,,,,,,,,,,"Decreasing retinal blood flow is a subtype of decreasing flow: A process that changes the amount of retinal flow to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Diabetic retinopathy.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003295,,,,,,,,,,,TXPO:0003317,,,,,,,,,,,,,,,,,,,,,,decreasing retinal blood flow [Diabetic retinopathy],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003313,accumulation of substance in hepatocyte,,Accumulation of substance in hepatocyte is a subtype of accumulation of substances in a biological object: A process that keeps substances in the hepatocyte.,false,,,http://purl.obolibrary.org/obo/TXPO_0000247,,,,,,,,,,,,,,,,,,,,,,Accumulation of substance in hepatocyte is a subtype of accumulation of substances in a biological object: A process that keeps substances in the hepatocyte.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003313,,,,,,,,,,,,,,,,,,,,,,accumulation of substance in hepatocyte,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000182,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003314,accumulation of substance in hepatocyte [Hypertrophy],,"Accumulation of substance in hepatocyte is a subtype of accumulation of substances in a biological object: A process that keeps substances in the hepatocyte.
This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy.",false,,,http://purl.obolibrary.org/obo/TXPO_0003279|http://purl.obolibrary.org/obo/TXPO_0003313,,,,,,,,,,,,,,,,,,,,,,"Accumulation of substance in hepatocyte is a subtype of accumulation of substances in a biological object: A process that keeps substances in the hepatocyte.
This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003299|http://purl.obolibrary.org/obo/TXPO_0003310|http://purl.obolibrary.org/obo/TXPO_0001266,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003297,,,,,,,,,,,TXPO:0003314,,,,,,,,,,,,,,,,,,,,,,accumulation of substance in hepatocyte [Hypertrophy],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003318,moving water to the inside of cell,,Moving water to the inside of cell is a subtype of moving A to the inside of B: A process of the movement of water into a cell.,false,,,http://purl.obolibrary.org/obo/TXPO_0002587,,,,,,,,,,,,,,,,,,,,,,Moving water to the inside of cell is a subtype of moving A to the inside of B: A process of the movement of water into a cell.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003318,,,,,,,,,,,,,,,,,,,,,,moving water to the inside of cell,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000000,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003310,lipid strorage in hepatocyte [Hypertrophy],,"Lipid strorage in hepatocyte is a subtype of lipid storage: A process that keeps lipids in hepatocytes.
This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy.",false,,,http://purl.obolibrary.org/obo/TXPO_0003279|http://purl.obolibrary.org/obo/TXPO_0003623,,,,,,,,,,,,,,,,,,,,,,"Lipid strorage in hepatocyte is a subtype of lipid storage: A process that keeps lipids in hepatocytes.
This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003297,,,,,,,,,,,TXPO:0003310,,,,,,,,,,,,,,,,,,,,,,lipid strorage in hepatocyte [Hypertrophy],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003312,increasing number of dead cells in liver [Cholestasis],,"Increasing number of dead cells in liver is a subtype of cell proliferation: A process that becomes larger in the number of dead cells in the liver.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000341|http://purl.obolibrary.org/obo/TXPO_0000034,,,,,,,,,,,,,,,,,,,,,,"Increasing number of dead cells in liver is a subtype of cell proliferation: A process that becomes larger in the number of dead cells in the liver.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003312,,,,,,,,,,,,,,,,,,,,,,increasing number of dead cells in liver [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003319,cell growth [Hypertrophy],,"The process in which a cell irreversibly increases in size over time by accretion and biosynthetic production of matter similar to that already present.
This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy.",false,,,http://purl.obolibrary.org/obo/GO_0016049|http://purl.obolibrary.org/obo/TXPO_0003279,,,,,,,,,,,,,,,,,,,,,,"The process in which a cell irreversibly increases in size over time by accretion and biosynthetic production of matter similar to that already present.
This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003297,,,,,,,,,,,TXPO:0003319,,,,,,,,,,,,,,,,,,,,,,cell growth [Hypertrophy],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_50864,insulin-sensitizing drug,,An agent which overcomes insulin resistance by activation of the peroxisome proliferator activated receptor gamma (PPAR-gamma).,false,,,http://purl.obolibrary.org/obo/CHEBI_48705,,,,,,,,,,,,,,,,,,,,,,An agent which overcomes insulin resistance by activation of the peroxisome proliferator activated receptor gamma (PPAR-gamma).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:50864,,,,,,,,,,,,,,,,,,,,,,insulin-sensitizing drug,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100800,LRP2,Glycoprotein 330|LDL-receptor-related protein 2|low density lipoprotein (LDL) receptor-related protein 2|gp330|Megalin,,false,,,http://purl.obolibrary.org/obo/IMR_0100798,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Glycoprotein 330|LDL-receptor-related protein 2|low density lipoprotein (LDL) receptor-related protein 2|gp330|Megalin,,,,,IMR:0100800,,,,,,,,,,,,,,,,,,,,,,LRP2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_64583,sphingomyelin,Ceramide phosphocholine,"Any of a class of phospholipids in which the amino group of a sphingoid base is in amide linkage with one of several fatty acids, while the terminal hydroxy group of the sphingoid base is esterified to phosphorylcholine.",false,,,http://purl.obolibrary.org/obo/CHEBI_35786,,,,,,,,,,,,,,,,,,,,,,"Any of a class of phospholipids in which the amino group of a sphingoid base is in amide linkage with one of several fatty acids, while the terminal hydroxy group of the sphingoid base is esterified to phosphorylcholine.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ceramide phosphocholine,,,,,CHEBI:64583,,,,,,,,,,,,,,,,,,,,,,sphingomyelin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_73693,ketone body,,"A carbonyl compound produced as a water-soluble byproduct when fatty acids are broken down for energy in the liver. There are three endogenous ketone bodies: acetone, acetoacetic acid, and (R)-3-hydroxybutyric acid; others may be produced as a result of the metabolism of synthetic triglycerides.",false,,,http://purl.obolibrary.org/obo/CHEBI_23899,,,,,,,,,,,,,,,,,,,,,,"A carbonyl compound produced as a water-soluble byproduct when fatty acids are broken down for energy in the liver. There are three endogenous ketone bodies: acetone, acetoacetic acid, and (R)-3-hydroxybutyric acid; others may be produced as a result of the metabolism of synthetic triglycerides.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:73693,,,,,,,,,,,,,,,,,,,,,,ketone body,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0045862,positive regulation of proteolysis,,"Any process that activates or increases the frequency, rate or extent of the hydrolysis of a peptide bond or bonds within a protein.",false,,,http://purl.obolibrary.org/obo/TXPO_0001223,,,,,,,,,,,,,,,,,,,,,,"Any process that activates or increases the frequency, rate or extent of the hydrolysis of a peptide bond or bonds within a protein.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0045862,,,,,,,,,,,,,,,,,,,,,,positive regulation of proteolysis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006508,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001147,proteasome inhibitor,,"A drug that blocks the action of proteasomes, cellular complexes that break down proteins.",false,,,http://purl.obolibrary.org/obo/TXPO_0003713,,,,,,,,,,,,,,,,,,,,,,"A drug that blocks the action of proteasomes, cellular complexes that break down proteins.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001147,,,,,,,,,,,,,,,,,,,,,,proteasome inhibitor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001142,PLA2G5 (human)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000283|http://purl.obolibrary.org/obo/TXPO_0001135,,,,,,,,,,,,,,,,,,,,http://omim.org/entry/601192|NCBI-Human-GeneID:5322|PMID:14998370|PMID:25716287|PMID:24910243,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000283,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000005322,,,http://purl.obolibrary.org/obo/TXPO_0002289|http://purl.obolibrary.org/obo/TXPO_0003671,,,,,,,,,,TXPO:0001142,,,,,,,,,,,,,,,,,,,,,,PLA2G5 (human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001140,FGF18 (human)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001135|http://purl.obolibrary.org/obo/TXPO_1000142,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:8817|PMID:21319186|PMID:24018557,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000008817,,,http://purl.obolibrary.org/obo/TXPO_0002272,,,,,,,,,,TXPO:0001140,,,,,,,,,,,,,,,,,,,,,,FGF18 (human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000836|http://purl.obolibrary.org/obo/TXPO_0001491|http://purl.obolibrary.org/obo/TXPO_0001490|http://purl.obolibrary.org/obo/TXPO_0000841,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000795,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001144,carboxylic acid,,,false,,,http://purl.obolibrary.org/obo/CHEBI_72695,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001144,,,,,,,,,,,,,,,,,,,,,,carboxylic acid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001149,negative regulation of apoptotic process [Glutathione depletion],,"Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptotic process.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/GO_0043066|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptotic process.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003209,,,,,,,,,,,TXPO:0001149,,,,,,,,,,,,,,,,,,,,,,negative regulation of apoptotic process [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001145,caspase-3,,,false,,,http://purl.obolibrary.org/obo/IMR_0000306,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001145,,,,,,,,,,,,,,,,,,,,,,caspase-3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001141,lipid biosynthetic process [Lipidosis],,"The chemical reactions and pathways resulting in the formation of lipids, compounds soluble in an organic solvent but not, or sparingly, in an aqueous solvent.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/GO_0008610|http://purl.obolibrary.org/obo/TXPO_0001720,,,,,,,,,,,,,,,,,,,,PMID:18556558,,"The chemical reactions and pathways resulting in the formation of lipids, compounds soluble in an organic solvent but not, or sparingly, in an aqueous solvent.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001157,,,,,,,,,,,TXPO:0001141,,,,,,,,,,,,,,,,,,,,,,lipid biosynthetic process [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001146,ACOT family,Acyl-CoA thioesterase,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Acyl-CoA thioesterase,,,TXPO:0001146,,,,,,,,,,,,,,,,,,,,,,ACOT family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001143,IL2RB (human)[Phospholipidosis],"interleukin 2 receptor, beta [Phospholipidosis]",,false,,,http://purl.obolibrary.org/obo/TXPO_0001135|http://purl.obolibrary.org/obo/TXPO_1000202,,,,,,,,,,,,,,,,,,,"IL2->IL2R->PI3K->Akt->Bcl2/c-myc->Cell cycle progression
IL2->IL2R->PI3K->Akt->Bcl2->anti-apoptosis",https://www.omim.org/entry/146710|NCBI-Human-GeneID:3560|PMID:10982827|PMID:9108028|PMID:12200137|PMID:10579998,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000096,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000003560,,,http://purl.obolibrary.org/obo/TXPO_0003331,,,,,"interleukin 2 receptor, beta [Phospholipidosis]",,,,,TXPO:0001143,,,,,,,,,,,,,,,,,,,,,,IL2RB (human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001488|http://purl.obolibrary.org/obo/TXPO_0000833,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001148,ACER,alkaline ceramidase,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,alkaline ceramidase,,,TXPO:0001148,,,,,,,,,,,,,,,,,,,,,,ACER,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0007050,cell cycle arrest,arrest of cell cycle progression|termination of cell cycle|cessation of cell cycle,"A regulatory process that halts progression through the cell cycle during one of the normal phases (G1, S, G2, M).",false,,,http://purl.obolibrary.org/obo/TXPO_0003798,,,,,,,,,,,,,,,,,,,,,,"A regulatory process that halts progression through the cell cycle during one of the normal phases (G1, S, G2, M).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,arrest of cell cycle progression|termination of cell cycle|cessation of cell cycle,,,,,GO:0007050,,,,,,,,,,,,,,,,,,,,,,cell cycle arrest,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0007049,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001128,keratan sulfate proteoglycan,,,false,,,http://purl.obolibrary.org/obo/IMR_0000552,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001128,,,,,,,,,,,,,,,,,,,,,,keratan sulfate proteoglycan,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76114,benoxaprofen,"benoxaprofeno|benoxaprofenum|2-(4-Chlorophenyl)-alpha-methyl-5-benzoxazoleacetic acid|(+-)-benoxaprofen|benoxaprofene|benoxaprofen|2-(4-chlorophenyl)-alpha-methyl-5-benzoxazoleacetic acid|Lilly 90459|2-(p-chlorophenyl)-alpha-methyl-5-benzoxazoleacetic acid|DL-benoxaprofen|(1)-2-(4-Chlorophenyl)benzoxazole-5-propionic acid|2-[2-(4-chlorophenyl)-1,3-benzoxazol-5-yl]propanoic acid","A monocarboxylic acid that is propionic acid substituted at position 2 by a 2-(4-chlorophenyl)-1,3-benzoxazol-5-yl group. It was used as a non-steroidal anti-inflammatory drug until 1982 when it was withdrawn from the market due to adverse side-effects including liver necrosis, photosensitivity, and carcinogenicity in animals.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:2413686|PMID:7084283|PMID:6645654|PMID:23250699|PMID:7044801|PMID:6526401|PMID:6813936|PMID:6993671|DrugBank:DB04812|PMID:21128314|Reaxys:1085080|CAS:51234-28-7|PMID:19439485|PMID:2947294|PMID:2833969|PMID:3981515|PMID:6993670|PMID:22514582|PMID:7084287|PMID:7221526|Drug_Central:311|PMID:7044799|PMID:19773537|PMID:6407402|PMID:6993669|PMID:6993672,,"A monocarboxylic acid that is propionic acid substituted at position 2 by a 2-(4-chlorophenyl)-1,3-benzoxazol-5-yl group. It was used as a non-steroidal anti-inflammatory drug until 1982 when it was withdrawn from the market due to adverse side-effects including liver necrosis, photosensitivity, and carcinogenicity in animals.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_64964|http://purl.obolibrary.org/obo/CHEBI_35493|http://purl.obolibrary.org/obo/CHEBI_64018|http://purl.obolibrary.org/obo/CHEBI_50908|http://purl.obolibrary.org/obo/CHEBI_35475|http://purl.obolibrary.org/obo/CHEBI_50748|http://purl.obolibrary.org/obo/CHEBI_61015|http://purl.obolibrary.org/obo/CHEBI_35481,,,,,"2-[2-(4-chlorophenyl)-1,3-benzoxazol-5-yl]propanoic acid",,benoxaprofeno|benoxaprofenum|2-(4-Chlorophenyl)-alpha-methyl-5-benzoxazoleacetic acid|(+-)-benoxaprofen|benoxaprofene|benoxaprofen|2-(4-chlorophenyl)-alpha-methyl-5-benzoxazoleacetic acid|Lilly 90459|2-(p-chlorophenyl)-alpha-methyl-5-benzoxazoleacetic acid|DL-benoxaprofen|(1)-2-(4-Chlorophenyl)benzoxazole-5-propionic acid,,,,,,,,,,,,,,,,,,,,,CHEBI:76114,,,,benoxaprofen,,CHEBI:76114,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004080,Nudt11 [Hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000265|http://purl.obolibrary.org/obo/TXPO_0000837,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:680248|NCBI-Human-GeneID:55190|NCBI-Mouse-GeneID:58242|PMID:22730461|PMID:12105228,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004080,,,,,,,,,,,,,,,,,,,,,,Nudt11 [Hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004089,Rnase1l2 [Hepatocarcinogenesis],"ribonuclease, RNase A family, 1-like 2 (pancreatic)",,false,,,http://purl.obolibrary.org/obo/TXPO_0000837|http://purl.obolibrary.org/obo/TXPO_1000328,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:305844,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"ribonuclease, RNase A family, 1-like 2 (pancreatic)",,,,,TXPO:0004089,,,,,,,,,,,,,,,,,,,,,,Rnase1l2 [Hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004087,KCNMA1(human)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001135|http://purl.obolibrary.org/obo/TXPO_0003839,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:3778|https://omim.org/entry/600150|PMID:18562499|https://reactome.org/PathwayBrowser/#/R-HSA-1296052|PMID:18998093,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000003778,,,,,,,,,,,,,TXPO:0004087,,,,,,,,,,,,,,,,,,,,,,KCNMA1(human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004081,"negative regulation of mitochondrial electron transport, ubiquinol to cytochrome c",,"Any process that stops, prevents or reduces the frequency, rate or extent of tmitochondrial electron transport, ubiquinol to cytochrome c",false,,,http://purl.obolibrary.org/obo/TXPO_0002342,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents or reduces the frequency, rate or extent of tmitochondrial electron transport, ubiquinol to cytochrome c",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004081,,,,,,,,,,,,,,,,,,,,,,"negative regulation of mitochondrial electron transport, ubiquinol to cytochrome c",,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006122,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004084,negative regulation of potassium ion transport [Phospholipidosis],,"Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of potassium ions (K+) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.",false,,,http://purl.obolibrary.org/obo/GO_0043267|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of potassium ions (K+) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003560|http://purl.obolibrary.org/obo/TXPO_0004087,,,,,,,,,,,,,,,,,TXPO:0004084,,,,,,,,,,,,,,,,,,,,,,negative regulation of potassium ion transport [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004085,positive regulation of macrophage derived foam cell differentiation [Phospholipidosis],,"Any process that increases the rate, frequency or extent of macrophage derived foam cell differentiation. Macrophage derived foam cell differentiation is the process in which a macrophage acquires the specialized features of a foam cell. A foam cell is a type of cell containing lipids in small vacuoles and typically seen in atherosclerotic lesions, as well as other conditions.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/GO_0010744,,,,,,,,,,,,,,,,,,,,,,"Any process that increases the rate, frequency or extent of macrophage derived foam cell differentiation. Macrophage derived foam cell differentiation is the process in which a macrophage acquires the specialized features of a foam cell. A foam cell is a type of cell containing lipids in small vacuoles and typically seen in atherosclerotic lesions, as well as other conditions.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000077|http://purl.obolibrary.org/obo/TXPO_0004086,,,,,,http://purl.obolibrary.org/obo/TXPO_0004154,,,,,,,,,,,TXPO:0004085,,,,,,,,,,,,,,,,,,,,,,positive regulation of macrophage derived foam cell differentiation [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004083,Pcsk7 [Hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000837|http://purl.obolibrary.org/obo/TXPO_1000296,,,,,,,,,,,,,,,,,,,,"http://omim.org/entry/604872|NCBI-Human-GeneID:9159|NCBI-Rat-GeneID:29606|NCBI-Mouse-GeneID:18554|Pro-protein convertase gene expression in human breast cancer. 
9185698 |PMID:12782675 |PMID:24556216",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004083,,,,,,,,,,,,,,,,,,,,,,Pcsk7 [Hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004086,ITGB3(human)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001135|http://purl.obolibrary.org/obo/TXPO_0003817,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:3690|PMID:15215180|PMID:8247041|PMID:15917997|PMID:22879933|PMID:22210111,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000003690,,,,,,,,,,,,,TXPO:0004086,,,,,,,,,,,,,,,,,,,,,,ITGB3(human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004088,malfunctioning of insulin signaling [Phospholipidosis],,"Malfunctioning of insulin signaling is a subtype of malfunctioning process: A process that cannot perform insulin signaling [biological] appropriately or cannot realize it at all.
This entity is a specific course-dependent process. This process can constitute the course of Phosphoipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0001125,,,,,,,,,,,,,,,,,,,,PMID:27800604|malfunctioning of insulin signaling [Phospholipidosis],,"Malfunctioning of insulin signaling is a subtype of malfunctioning process: A process that cannot perform insulin signaling [biological] appropriately or cannot realize it at all.
This entity is a specific course-dependent process. This process can constitute the course of Phosphoipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003560|http://purl.obolibrary.org/obo/TXPO_0004090|http://purl.obolibrary.org/obo/TXPO_0004092,,,,,,,,,,,,,,,,,TXPO:0004088,,,,,,,,,,,,,,,,,,,,,,malfunctioning of insulin signaling [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004082,negative regulation of cell death,,"Any process that decreases the rate or frequency of cell death. Cell death is the specific activation or halting of processes within a cell so that its vital functions markedly cease, rather than simply deteriorating gradually over time, which culminates in cell death.",false,,,http://purl.obolibrary.org/obo/GO_0010941,,,,,,,,,,,,,,,,,,,,,,"Any process that decreases the rate or frequency of cell death. Cell death is the specific activation or halting of processes within a cell so that its vital functions markedly cease, rather than simply deteriorating gradually over time, which culminates in cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004082,,,,,,,,,,,,,,,,,,,,,,negative regulation of cell death,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0008219,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000671,PAK4,,,false,,,http://purl.obolibrary.org/obo/IMR_0000238,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000671,,,,,,,,,,,,,,,,,,,,,,PAK4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000962,LRP3,low density lipoprotein receptor-related protein 3|LDL receptor-related protein 3,,false,,,http://purl.obolibrary.org/obo/IMR_0100798,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,low density lipoprotein receptor-related protein 3|LDL receptor-related protein 3,,,,,IMR:0000962,,,,,,,,,,,,,,,,,,,,,,LRP3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_73216,EC 3.6.* (hydrolases acting on acid anhydrides) inhibitor,EC 3.6 inhibitors|inhibitors of hydrolase acting on acid anhydride (EC 3.6.*)|EC 3.6.*.* inhibitors|acid anhydride hydrolase inhibitors|EC 3.6.*.* inhibitor|EC 3.6.* (hydrolases acting on acid anhydrides) inhibitors|EC 3.6.* inhibitor|acid anhydride hydrolase inhibitor|inhibitor of hydrolase acting on acid anhydride (EC 3.6.*)|EC 3.6.* inhibitors|EC 3.6 inhibitor,Any hydrolase inhibitor that interferes with the action of a hydrolase which acts on acid anhydrides (EC 3.6.*.*).,false,,,http://purl.obolibrary.org/obo/CHEBI_76759,,,,,,,,,,,,,,,,,,,,,,Any hydrolase inhibitor that interferes with the action of a hydrolase which acts on acid anhydrides (EC 3.6.*.*).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,EC 3.6 inhibitors|inhibitors of hydrolase acting on acid anhydride (EC 3.6.*)|EC 3.6.*.* inhibitors|acid anhydride hydrolase inhibitors|EC 3.6.*.* inhibitor|EC 3.6.* (hydrolases acting on acid anhydrides) inhibitors|EC 3.6.* inhibitor|acid anhydride hydrolase inhibitor|inhibitor of hydrolase acting on acid anhydride (EC 3.6.*)|EC 3.6.* inhibitors|EC 3.6 inhibitor,,,,,,,,,,,,,,,,,,,,,CHEBI:73216,,,,EC 3.6.* (hydrolases acting on acid anhydrides) inhibitor,,CHEBI:73216,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76668,EC 2.7.* (P-containing group transferase) inhibitor,EC 2.7.* (phosphorus-containing group transferase) inhibitors|phosphorus-containing group transferase (EC 2.7.*) inhibitors|EC 2.7.* (P-containing group transferase) inhibitors|EC 2.7.* (phosphorus-containing group transferase) inhibitor|phosphorus-containing group transferase inhibitor|phosphorus-containing group transferase inhibitors|EC 2.7.* inhibitors|EC 2.7.* inhibitor|phosphorus-containing group transferase (EC 2.7.*) inhibitor,A transferase inhibitor that inhibits the action of a phosphorus-containing group transferase (EC 2.7.*.*).,false,,,http://purl.obolibrary.org/obo/CHEBI_71300,,,,,,,,,,,,,,,,,,,,,,A transferase inhibitor that inhibits the action of a phosphorus-containing group transferase (EC 2.7.*.*).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,EC 2.7.* (phosphorus-containing group transferase) inhibitors|phosphorus-containing group transferase (EC 2.7.*) inhibitors|EC 2.7.* (P-containing group transferase) inhibitors|EC 2.7.* (phosphorus-containing group transferase) inhibitor|phosphorus-containing group transferase inhibitor|phosphorus-containing group transferase inhibitors|EC 2.7.* inhibitors|EC 2.7.* inhibitor|phosphorus-containing group transferase (EC 2.7.*) inhibitor,,,,,,,,,,,,,,,,,,,,,CHEBI:76668,,,,EC 2.7.* (P-containing group transferase) inhibitor,,CHEBI:76668,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003097,caspase-3 activation [ER stress],,"Caspase-3 activation is a subtype of caspase activation: A process that changes the activity of the caspase-3, intracellular cysteine endopeptidase family members, to be higher.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0003736|http://purl.obolibrary.org/obo/TXPO_0003098,,,,,,,,,,,,,,,,,,,,PMID:29335519,,"Caspase-3 activation is a subtype of caspase activation: A process that changes the activity of the caspase-3, intracellular cysteine endopeptidase family members, to be higher.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003097,,,,,,,,,,,,,,,,,,,,,,caspase-3 activation [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003096,caspase-9 activation [ER stress],,"Caspase-9 activation is a subtype of caspase activation: A process that changes the activity of the caspase-9, intracellular cysteine endopeptidase family members, to be higher.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0003736|http://purl.obolibrary.org/obo/TXPO_0003099,,,,,,,,,,,,,,,,,,,,,,"Caspase-9 activation is a subtype of caspase activation: A process that changes the activity of the caspase-9, intracellular cysteine endopeptidase family members, to be higher.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003097,,,,,,,,,,,TXPO:0003096,,,,,,,,,,,,,,,,,,,,,,caspase-9 activation [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003091,caspase 12 signaling (primitive) [ER stress - apoptosis],,"Caspase 12 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the caspase 12.
This process is dependent on the apoptosis and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0003736|http://purl.obolibrary.org/obo/TXPO_0000444,,,,,,,,,,,,,,,,,,,,,,"Caspase 12 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the caspase 12.
This process is dependent on the apoptosis and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003093,,,,,,,,,,,,,,,,,,TXPO:0003091,,,,,,,,,,,,,,,,,,,,,,caspase 12 signaling (primitive) [ER stress - apoptosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003092,caspase 4 signaling (primitive) [ER stress - apoptosis],,"Caspase 4 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the caspase 4.
This process is dependent on the apoptosis and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0003736|http://purl.obolibrary.org/obo/TXPO_0000444,,,,,,,,,,,,,,,,,,,ミトコンドリア(intrinsic)と独立のパスウェイ,,,"Caspase 4 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the caspase 4.
This process is dependent on the apoptosis and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003094,,,,,,,,,,,,,,,,,,TXPO:0003092,,,,,,,,,,,,,,,,,,,,,,caspase 4 signaling (primitive) [ER stress - apoptosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003094,caspase-4 activation [ER stress],,"Caspase-4 activation is a subtype of caspase activation: A process that changes the activity of the caspase-4, intracellular cysteine endopeptidase family members, to be higher.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0003101|http://purl.obolibrary.org/obo/TXPO_0003736,,,,,,,,,,,,,,,,,,,,,,"Caspase-4 activation is a subtype of caspase activation: A process that changes the activity of the caspase-4, intracellular cysteine endopeptidase family members, to be higher.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003096,,,,,,,,,,,TXPO:0003094,,,,,,,,,,,,,,,,,,,,,,caspase-4 activation [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003090,IRE1 dimer (canonical)[ER stress -RIDD],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002972,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003090,,,,,,,,,,,,,,,,,,,,,,IRE1 dimer (canonical)[ER stress -RIDD],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003089,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003095,caspase activation,,"Caspase activation is a subtype of molecular activation: A process that changes the activity of the caspase, intracellular cysteine endopeptidase family members, to be higher.",false,,,http://purl.obolibrary.org/obo/TXPO_0000023,,,,,,,,,,,,,,,,,,,,,,"Caspase activation is a subtype of molecular activation: A process that changes the activity of the caspase, intracellular cysteine endopeptidase family members, to be higher.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003095,,,,,,,,,,,,,,,,,,,,,,caspase activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003099,caspase-9 activation,,"Caspase-9 activation is a subtype of caspase activation: A process that changes the activity of the caspase-9, intracellular cysteine endopeptidase family members, to be higher.",false,,,http://purl.obolibrary.org/obo/TXPO_0003095,,,,,,,,,,,,,,,,,,,,,,"Caspase-9 activation is a subtype of caspase activation: A process that changes the activity of the caspase-9, intracellular cysteine endopeptidase family members, to be higher.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003099,,,,,,,,,,,,,,,,,,,,,,caspase-9 activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003093,caspase-12 activation [ER stress],,"Caspase-12 activation is a subtype of caspase activation: A process that changes the activity of the caspase-12, intracellular cysteine endopeptidase family members, to be higher.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0003100|http://purl.obolibrary.org/obo/TXPO_0003736,,,,,,,,,,,,,,,,,,,,PMID:11278723,,"Caspase-12 activation is a subtype of caspase activation: A process that changes the activity of the caspase-12, intracellular cysteine endopeptidase family members, to be higher.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003093,,,,,,,,,,,,,,,,,,,,,,caspase-12 activation [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003098,caspase-3 activation,,"Caspase-3 activation is a subtype of caspase activation: A process that changes the activity of the caspase-3, intracellular cysteine endopeptidase family members, to be higher.",false,,,http://purl.obolibrary.org/obo/TXPO_0003095,,,,,,,,,,,,,,,,,,,,,,"Caspase-3 activation is a subtype of caspase activation: A process that changes the activity of the caspase-3, intracellular cysteine endopeptidase family members, to be higher.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003098,,,,,,,,,,,,,,,,,,,,,,caspase-3 activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000685,JNK3,p54 beta SAPK,,false,,,http://purl.obolibrary.org/obo/IMR_0000225,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p54 beta SAPK,,,,,IMR:0000685,,,,,,,,,,,,,,,,,,,,,,JNK3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001095,Sap-1,Elk-4,,false,,,http://purl.obolibrary.org/obo/IMR_0000397,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Elk-4,,,,,IMR:0001095,,,,,,,,,,,,,,,,,,,,,,Sap-1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0043233,organelle lumen,,"The internal volume enclosed by the membranes of a particular organelle; includes the volume enclosed by a single organelle membrane, e.g. endoplasmic reticulum lumen, or the volume enclosed by the innermost of the two lipid bilayers of an organelle envelope, e.g. nuclear lumen.",false,,,http://purl.obolibrary.org/obo/UBERON_0000464,,,,,,,,,,,,,,,,,,,,,,"The internal volume enclosed by the membranes of a particular organelle; includes the volume enclosed by a single organelle membrane, e.g. endoplasmic reticulum lumen, or the volume enclosed by the innermost of the two lipid bilayers of an organelle envelope, e.g. nuclear lumen.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0043233,,,,,,,,,,,,,,,,,,,,,,organelle lumen,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_32246,Tolvaptan,OPC-41061|OPC 41061|jinarc|Tolvaptan,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Drug_Central:4110|CAS:150683-30-0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Tolvaptan,,OPC-41061|OPC 41061|jinarc,,,,,,,,,,,,,,,,,,,,,CHEBI:32246,,,,Tolvaptan,,CHEBI:32246,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_18303,phosphatidyl-L-serine,phosphatidylserine|Ptd-L-Ser,A class of aminophospholipids in which a phosphatidyl group is esterified to the hydroxy group of serine.,false,,,http://purl.obolibrary.org/obo/CHEBI_35766,,,,,,,,,,,,,,,,,,,,DrugBank:DB00144,,A class of aminophospholipids in which a phosphatidyl group is esterified to the hydroxy group of serine.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,phosphatidylserine|Ptd-L-Ser,,,,,CHEBI:18303,,,,,,,,,,,,,,,,,,,,,,phosphatidyl-L-serine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100408,BDNF,brain-derived neurotrophic factor,,false,,,http://purl.obolibrary.org/obo/IMR_0000034,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,brain-derived neurotrophic factor,,,,,IMR:0100408,,,,,,,,,,,,,,,,,,,,,,BDNF,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000629,Integrin alpha-7,,,false,,,http://purl.obolibrary.org/obo/IMR_0000173,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000629,,,,,,,,,,,,,,,,,,,,,,Integrin alpha-7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000029785,CYP2S1,,"Other designations: CYPIIS1|cytochrome P450 2S1|cytochrome P450 family member predicted from ESTs|cytochrome P540, subfamily IIS, polypeptide 1",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,19,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 2, subfamily S, polypeptide 1",,,19q13.1,,,,,,,,,,,,,,,,GO_0005506 (EC: IEA); GO_0005789 (EC: TAS); GO_0006805 (EC: TAS); GO_0020037 (EC: IEA); GO_0044281 (EC: TAS); GO_0070330 (EC: IEA),,,,,,,,,PMID:7566098; 11181079; 12477932; 12711469; 12721789; 12975309; 14702039; 15128046; 15450424; 15489334; 17277313; 17280660; 17495422; 17529885; 19343046; 19368491; 19713358; 21139048; 21319273; 21430234; 22039172; 22232929; 22863683; 23224081; 23648403,,,,,,,,,,,,,,,OGG:3000029785,,,,,,,"cytochrome P450, family 2, subfamily S, polypeptide 1",,,,,,,,,,,,,"Other designations: CYPIIS1|cytochrome P450 2S1|cytochrome P450 family member predicted from ESTs|cytochrome P540, subfamily IIS, polypeptide 1",,CYP2S1,,,,,,,,,,,,,,,,,,,,,,,29785,UNQ891/PRO1906,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP2S1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000738,ShcA,,,false,,,http://purl.obolibrary.org/obo/IMR_0000347,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0011555|IMR:0010596,,,,,,IMR:0000738,,,,,,,,,,,,,,,,,,,,,,ShcA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100854,IL-1 alpha,Interleukin-1 alpha,,false,,,http://purl.obolibrary.org/obo/IMR_0000011,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Interleukin-1 alpha,,,,,IMR:0100854,,,,,,,,,,,,,,,,,,,,,,IL-1 alpha,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_50691,abortifacient,abortifacient agents|abortifacient drug|abortifacient drugs|abortifacient agent|abortifacients,A chemical substance that interrupts pregnancy after implantation.,false,,,http://purl.obolibrary.org/obo/CHEBI_50689,,,,,,,,,,,,,,,,,,,,,,A chemical substance that interrupts pregnancy after implantation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,abortifacient agents|abortifacient drug|abortifacient drugs|abortifacient agent|abortifacients,,,,,,,,,,,,,,,,,,,,,CHEBI:50691,,,,abortifacient,,CHEBI:50691,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100298,caspase-7,,,false,,,http://purl.obolibrary.org/obo/IMR_0000306,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100298,,,,,,,,,,,,,,,,,,,,,,caspase-7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000325,increasing drug metabolite [Ground glass appearance],,"Increasing drug metabolite is a subtype of increasing quantity: A process that changes the amount of drug metabolites to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/TXPO_0002364,,,,,,,,,,,,,,,,,,,,,,"Increasing drug metabolite is a subtype of increasing quantity: A process that changes the amount of drug metabolites to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000325,,,,,,,,,,,,,,,,,,,,,,increasing drug metabolite [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000323,cell death (toxic course),,The totality of all processes through which cell death is realized.,false,,,http://purl.obolibrary.org/obo/TXPO_0000009,,,,,,,,,,,,,,,,,,,,PMID:18846107|https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3252826/|PMID:21760595,,The totality of all processes through which cell death is realized.,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000008,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003829|http://purl.obolibrary.org/obo/TXPO_0000008,,,,,,,,,,,,,,,,,,TXPO:0000323,,,,,,,,,,,,,,,,,,,,,,cell death (toxic course),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000326,pyroptosis (course),,Pyroptosis (course) is a subtype of cell death (course). The totality of all processes through which pyroptosis is realized.|under construction,false,,,http://purl.obolibrary.org/obo/TXPO_0000323,,,,,,,,,,,,,,,,,,,,PMID:18846107|https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3252826/|PMID:21760595,,Pyroptosis (course) is a subtype of cell death (course). The totality of all processes through which pyroptosis is realized.,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002144,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002144|http://purl.obolibrary.org/obo/TXPO_0002140|http://purl.obolibrary.org/obo/TXPO_0002141|http://purl.obolibrary.org/obo/TXPO_0003830|http://purl.obolibrary.org/obo/TXPO_0003831,,,,,,,,,,,,,,,,,,TXPO:0000326,,,,,,,Pyroptosis is related to a caspase-1-dependent cell death subroutine that is associated with the generation of pyrogenic mediators such as Il-1beta and Il-18.,,,,,,,,,,,,,under construction,,pyroptosis (course),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000321,FADs2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003348,,,,,,,,,,TXPO:0000321,,,,,,,,,,,,,,,,,,,,,,FADs2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000327,apoptosis regulator role,,Apoptosis modulator is a role played by any substance that regulates the process of apoptosis (programmed cell death) in multi-celled organisms.,false,,,http://purl.obolibrary.org/obo/TXPO_0003230,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006915,,,,,,,,,,,,,Apoptosis modulator is a role played by any substance that regulates the process of apoptosis (programmed cell death) in multi-celled organisms.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000327,,,,,,,,,,,,,,,,,,,,,,apoptosis regulator role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000329,inhibitor of tumor cell activity role,,A role played by the entity that ihibits the activity of tumor cells.,false,,,http://purl.obolibrary.org/obo/TXPO_0003725,,,,,,,,,,,,,,,,,,,,,,A role played by the entity that ihibits the activity of tumor cells.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000329,,,,,,,,,,,,,,,,,,,,,,inhibitor of tumor cell activity role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000324,apoptosis (course),,Apoptosis (course) is a subtype of cell death (course). The totality of all processes through which apoptosis is realized.|under construction,false,,,http://purl.obolibrary.org/obo/TXPO_0000323,,,,,,,,,,,,,,,,,,,,,,Apoptosis (course) is a subtype of cell death (course). The totality of all processes through which apoptosis is realized.,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000514,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000234|http://purl.obolibrary.org/obo/TXPO_0002390|http://purl.obolibrary.org/obo/TXPO_0002128|http://purl.obolibrary.org/obo/TXPO_0002125|http://purl.obolibrary.org/obo/TXPO_0000377|http://purl.obolibrary.org/obo/TXPO_0000374|http://purl.obolibrary.org/obo/TXPO_0000573|http://purl.obolibrary.org/obo/TXPO_0000574|http://purl.obolibrary.org/obo/TXPO_0003737|http://purl.obolibrary.org/obo/TXPO_0000514|http://purl.obolibrary.org/obo/TXPO_0002135|http://purl.obolibrary.org/obo/TXPO_0002137|http://purl.obolibrary.org/obo/TXPO_0000223|http://purl.obolibrary.org/obo/TXPO_0002403|http://purl.obolibrary.org/obo/TXPO_0000453|http://purl.obolibrary.org/obo/TXPO_0003026|http://purl.obolibrary.org/obo/TXPO_0000448|http://purl.obolibrary.org/obo/TXPO_0000446,,,,,,,,,,,,,,,,,,TXPO:0000324,,,,,,,,,,,,,,,,,,,,under construction,,apoptosis (course),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000322,myelin figureformation in lysosome,lamellar body formation in lysosome,Lamellar body formation in lysosome is a subtype of biological structure formation: A process that costructs lamellar body in lysosome.,false,,,http://purl.obolibrary.org/obo/TXPO_0000134,,,,,,,,,,,,,,,,,,,,,,Lamellar body formation in lysosome is a subtype of biological structure formation: A process that costructs lamellar body in lysosome.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,lamellar body formation in lysosome,,,,,TXPO:0000322,,,,,,,,,,,,,,,,,,,,,,myelin figureformation in lysosome,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005764,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000328,ion channel,,A role played by the entity which enables the facilitated diffusion of an ion (by an energy-independent process) by passage through a transmembrane aqueous pore or channel without evidence for a carrier-mediated mechanism. May be either selective (it enables passage of a specific ion only) or non-selective (it enables passage of two or more ions of same charge but different size).|related molecular function GO:0005216,false,,,http://purl.obolibrary.org/obo/TXPO_0003639,,,,,,,,,,,,,,,,,,,,,,A role played by the entity which enables the facilitated diffusion of an ion (by an energy-independent process) by passage through a transmembrane aqueous pore or channel without evidence for a carrier-mediated mechanism. May be either selective (it enables passage of a specific ion only) or non-selective (it enables passage of two or more ions of same charge but different size).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000328,,,,,,,,,,,,,,,,,,,,related molecular function GO:0005216,,ion channel,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000320,acute phase response role,,A role played by the entity which receives acute phase response signal and transmits operand(s).,false,,,http://purl.obolibrary.org/obo/TXPO_0003728,,,,,,,,,,,,,,,,,,,,,,A role played by the entity which receives acute phase response signal and transmits operand(s).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000320,,,,,,,,,,,,,,,,,,,,,,acute phase response role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000392,IRF-6,,,false,,,http://purl.obolibrary.org/obo/IMR_0000386,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000392,,,,,,,,,,,,,,,,,,,,,,IRF-6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000733,PLC gamma2,phospholipase C gamma 2,,false,,,http://purl.obolibrary.org/obo/IMR_0000285,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,phospholipase C gamma 2,,,,,IMR:0000733,,,,,,,,,,,,,,,,,,,,,,PLC gamma2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010513,Heterogeneous nuclear ribonucleoprotein H,ROH1|hnRNP H,,false,,,http://purl.obolibrary.org/obo/IMR_0010024,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ROH1|hnRNP H,,,,,IMR:0010513,,,,,,,,,,,,,,,,,,,,,,Heterogeneous nuclear ribonucleoprotein H,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000475,NF-M,,,false,,,http://purl.obolibrary.org/obo/IMR_0000203,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000475,,,,,,,,,,,,,,,,,,,,,,NF-M,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001209,DLC2,dynein light chain 2|DLC8b,,false,,,http://purl.obolibrary.org/obo/IMR_0000200,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,dynein light chain 2|DLC8b,,,,,IMR:0001209,,,,,,,,,,,,,,,,,,,,,,DLC2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_22587,antiviral agent,anti-viral agent|antiviral agents|anti-viral agents|antiviral|antivirals,A substance that destroys or inhibits replication of viruses.,false,,,http://purl.obolibrary.org/obo/CHEBI_33281,,,,,,,,,,,,,,,,,,,,,,A substance that destroys or inhibits replication of viruses.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,anti-viral agent|antiviral agents|anti-viral agents|antiviral|antivirals,,,,,,,,,,,,,,,,,,,,,CHEBI:22587,,,,antiviral agent,,CHEBI:22587,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000002863,GPR39,,Other designations: G-protein coupled receptor 39,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,2,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,G protein-coupled receptor 39,,,2q21-q22,,,,,,,,,,,,,,,,"GO_0004930 (EC: IEA); GO_0005886 (EC: TAS); GO_0005887 (EC: TAS, PMID: 9441746); GO_0007186 (EC: TAS, PMID: 9441746); GO_0046872 (EC: IEA)",,,,,,,,,PMID: 8889548; 9441746; 12477932; 14702039; 15383539; 15489334; 15815621; 16344560; 16959833; 17054911; 17488974; 17885920; 18180304; 18588883; 18815158; 19920139; 20379614; 20424473; 20522546; 21352519; 21900206; 22545109; 22879599; 23485550,,,,,,,,,,,,,,,OGG:3000002863,,,,,,,G protein-coupled receptor 39,,,,,,,,,,,,,Other designations: G-protein coupled receptor 39,,GPR39,,,,,,,,,,,,,,,,,,,,,,,2863,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,GPR39,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0001563,Rab3D,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001563,,,,,,,,,,,,,,,,,,,,,,Rab3D,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0002037,degeneration (quality),,A structural quality inhering in a bearer by virtue of the bearer exhibiting deterioration of its structure.,false,,,http://purl.obolibrary.org/obo/PATO_0000141,,,,,,,,,,,,,,,,,,,,,,A structural quality inhering in a bearer by virtue of the bearer exhibiting deterioration of its structure.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0002037,,,,,,,,,,,,,,,,,,,,,,degeneration (quality),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000818,JUNB (mol),,,false,,,http://purl.obolibrary.org/obo/IMR_0000416,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000818,,,,,,,,,,,,,,,,,,,,,,JUNB (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76869,"EC 1.8.1.* (oxidoreductase acting on sulfur group of donors, NAD(+) or NADP(+) as acceptor) inhibitor","oxidoreductase acting on sulfur group of donors, NAD(+) or NADP(+) as acceptor (EC 1.8.1.*) inhibitors|EC 1.8.1.* inhibitors|EC 1.8.1.* inhibitor|oxidoreductase acting on sulfur group of donors, NAD(+) or NADP(+) as acceptor (EC 1.8.1.*) inhibitor|EC 1.8.1.* (oxidoreductase acting on sulfur group of donors, NAD(+) or NADP(+) as acceptor) inhibitors",An EC 1.8.* (oxidoreductase acting on sulfur group of donors) inhibitor that interferes with the action of any such enzyme using NAD(+) or NADP(+) as acceptor (EC 1.8.1.*).,false,,,http://purl.obolibrary.org/obo/CHEBI_76735,,,,,,,,,,,,,,,,,,,,,,An EC 1.8.* (oxidoreductase acting on sulfur group of donors) inhibitor that interferes with the action of any such enzyme using NAD(+) or NADP(+) as acceptor (EC 1.8.1.*).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"oxidoreductase acting on sulfur group of donors, NAD(+) or NADP(+) as acceptor (EC 1.8.1.*) inhibitors|EC 1.8.1.* inhibitors|EC 1.8.1.* inhibitor|oxidoreductase acting on sulfur group of donors, NAD(+) or NADP(+) as acceptor (EC 1.8.1.*) inhibitor|EC 1.8.1.* (oxidoreductase acting on sulfur group of donors, NAD(+) or NADP(+) as acceptor) inhibitors",,,,,,,,,,,,,,,,,,,,,CHEBI:76869,,,,"EC 1.8.1.* (oxidoreductase acting on sulfur group of donors, NAD(+) or NADP(+) as acceptor) inhibitor",,CHEBI:76869,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000415,FOS family,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,IPR:000837,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,,,,,,IMR:0000415,,,,,,,,,,,,,,,,,,,,,,FOS family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005160,pralnacasan,,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005160,,,,,,,,,,,,,,,,,,,,,,pralnacasan,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005165,azacitidine,,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005165,,,,,,,,,,,,,,,,,,,,,,azacitidine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005168,fipexide,,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005168,,,,,,,,,,,,,,,,,,,,,,fipexide,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005163,pafuramidine,,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005163,,,,,,,,,,,,,,,,,,,,,,pafuramidine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005167,exifone,,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005167,,,,,,,,,,,,,,,,,,,,,,exifone,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005164,phenoxypropazine,,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005164,,,,,,,,,,,,,,,,,,,,,,phenoxypropazine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005166,cinchophen,,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005166,,,,,,,,,,,,,,,,,,,,,,cinchophen,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005161,triacetyldiphenolisatin,,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005161,,,,,,,,,,,,,,,,,,,,,,triacetyldiphenolisatin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005162,fiduxosin,,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005162,,,,,,,,,,,,,,,,,,,,,,fiduxosin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005169,isocarboxazid,,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005169,,,,,,,,,,,,,,,,,,,,,,isocarboxazid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005057,Increasing saturated fatty acid level [mitochondrial disorder],,"Increasing saturated fatty acid level is a subtype of increasing quantity: A process that changes the amount of saturated fatty acid level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0005056,,,,,,,,,,,,,,,,,,,,PMID:31623280,,"Increasing saturated fatty acid level is a subtype of increasing quantity: A process that changes the amount of saturated fatty acid level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0005058,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004225|http://purl.obolibrary.org/obo/TXPO_0001990|http://purl.obolibrary.org/obo/TXPO_0004271|http://purl.obolibrary.org/obo/TXPO_0000933|http://purl.obolibrary.org/obo/TXPO_0001988|http://purl.obolibrary.org/obo/TXPO_0004373|http://purl.obolibrary.org/obo/TXPO_0002004|http://purl.obolibrary.org/obo/TXPO_0004960|http://purl.obolibrary.org/obo/TXPO_0004964,,,,,,,,,,,TXPO:0005057,,,,,,,,,,,,,,,,,,,,,,Increasing saturated fatty acid level [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005050,iron metabolic dysfunction,,iron metabolic dysfunction is a subtype of Metabolic dysfunctioning: A process that performs an abnormal and incomplete energy metabolic function.,false,,,http://purl.obolibrary.org/obo/TXPO_0002131,,,,,,,,,,,,,,,,,,,,,,iron metabolic dysfunction is a subtype of Metabolic dysfunctioning: A process that performs an abnormal and incomplete energy metabolic function.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005050,,,,,,,,,,,,,,,,,,,,,,iron metabolic dysfunction,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005053,hypofunction of heme biosynthesis,,Hypofunction of heme biosynthesis is a subtype of hypofunction of biosynthesis: A process that performs a decreased or insufficient heme biosynthesis.,false,,,http://purl.obolibrary.org/obo/TXPO_0001910,,,,,,,,,,,,,,,,,,,,,,Hypofunction of heme biosynthesis is a subtype of hypofunction of biosynthesis: A process that performs a decreased or insufficient heme biosynthesis.,,,http://purl.obolibrary.org/obo/GO_0006783,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005053,,,,,,,,,,,,,,,,,,,,,,hypofunction of heme biosynthesis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005055,Increasing long-chain free fatty acid level [mitochondrial disorder],,"Increasing long-chain free fatty acid level is a subtype of increasing quantity: A process that changes the amount of long-chain free fatty acid level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0005054,,,,,,,,,,,,,,,,,,,,PMID:25339807,,"Increasing long-chain free fatty acid level is a subtype of increasing quantity: A process that changes the amount of long-chain free fatty acid level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001990,,,,,,,,,,,TXPO:0005055,,,,,,,,,,,,,,,,,,,,,,Increasing long-chain free fatty acid level [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005054,Increasing long-chain free fatty acid level,,Increasing long-chain free fatty acid level is a subtype of increasing quantity: A process that changes the amount of long-chain free fatty acid level to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing long-chain free fatty acid level is a subtype of increasing quantity: A process that changes the amount of long-chain free fatty acid level to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005054,,,,,,,,,,,,,,,,,,,,,,Increasing long-chain free fatty acid level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005052,Increasing iron uptake level,,Increasing iron uptake level is a subtype of increasing quantity: A process that changes the iron uptake level to be larger.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing iron uptake level is a subtype of increasing quantity: A process that changes the iron uptake level to be larger.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005052,,,,,,,,,,,,,,,,,,,,,,Increasing iron uptake level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005059,hypofunction of phospholipid degradation [Phospholipidosis(latent)],,"Hypofunction of phospholipid degradation is a subtype of hypofunction of decomposing: A process that performs a decreased or insufficient phospholipid degradation.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (latent).",false,,,http://purl.obolibrary.org/obo/TXPO_0000925,,,,,,,,,,,,,,,,,,,,,,"Hypofunction of phospholipid degradation is a subtype of hypofunction of decomposing: A process that performs a decreased or insufficient phospholipid degradation.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (latent).",,,http://purl.obolibrary.org/obo/TXPO_0001406,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000775|http://purl.obolibrary.org/obo/TXPO_0001804,,,,,,http://purl.obolibrary.org/obo/TXPO_0002293,,,,,,,,,,,TXPO:0005059,,,,,,,,,,,,,,,,,,,,,,hypofunction of phospholipid degradation [Phospholipidosis(latent)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005056,increasing saturated fatty acid level,,Increasing saturated fatty acid level is a subtype of increasing quantity: A process that changes the amount of saturated fatty acid level to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0001062,,,,,,,,,,,,,,,,,,,,,,Increasing saturated fatty acid level is a subtype of increasing quantity: A process that changes the amount of saturated fatty acid level to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005056,,,,,,,,,,,,,,,,,,,,,,increasing saturated fatty acid level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005051,iron metabolic dysfunction [hepatocarcinogenesis],,"iron metabolic dysfunction is a subtype of Metabolic dysfunctioning: A process that performs an abnormal and incomplete energy metabolic function.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0005050,,,,,,,,,,,,,,,,,,,,PMID:25796501,,"iron metabolic dysfunction is a subtype of Metabolic dysfunctioning: A process that performs an abnormal and incomplete energy metabolic function.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004661|http://purl.obolibrary.org/obo/TXPO_0004617,,,,,,,,,,,,,,,,,,TXPO:0005051,,,,,,,,,,,,,,,,,,,,,,iron metabolic dysfunction [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005058,saturated fatty acid [mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004312|http://purl.obolibrary.org/obo/CHEBI_26607,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005058,,,,,,,,,,,,,,,,,,,,,,saturated fatty acid [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001908,negative regulation of phospholipase-mediated phospholipid degradation by CAD [Phospholipidosis (latent)],,"Negative regulation of phospholipase-mediated phospholipid degradation by CAD is a subtype of negative regulation of phospholipid degradation: A process that stops, prevents, or reduces the frequency, rate or extent of phospholipase-mediated phospholipid deradation regulated by CAD.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (latent).",false,,,http://purl.obolibrary.org/obo/TXPO_0003414,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of phospholipase-mediated phospholipid degradation by CAD is a subtype of negative regulation of phospholipid degradation: A process that stops, prevents, or reduces the frequency, rate or extent of phospholipase-mediated phospholipid deradation regulated by CAD.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (latent).",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003227|http://purl.obolibrary.org/obo/TXPO_0003228|http://purl.obolibrary.org/obo/TXPO_0000319,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003578|http://purl.obolibrary.org/obo/TXPO_0002572,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004933,,,,,,,,,,,TXPO:0001908,,,,,,,,,,,,,,,,,,,,,,negative regulation of phospholipase-mediated phospholipid degradation by CAD [Phospholipidosis (latent)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001901,TNF alpha (canonical)[lipidosis],tumor necrosis factor alpha [lipidosis],,false,,,http://purl.obolibrary.org/obo/TXPO_0003516|http://purl.obolibrary.org/obo/TXPO_1000374,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:21926|NCBI-Rat-GeneID:24835|NCBI-Human-GeneID:7124,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,tumor necrosis factor alpha [lipidosis],,,,,TXPO:0001901,,,,,,,,,,,,,,,,,,,,,,TNF alpha (canonical)[lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001904,ATF6 activation,,ATF6 activation is a subtype of molecular activation: A process that changes the activity of the ATF6 (Activating Transcription Factor 6) to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000124,,,,,,,,,,,,,,,,,,,,PMID:12376530,,ATF6 activation is a subtype of molecular activation: A process that changes the activity of the ATF6 (Activating Transcription Factor 6) to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001904,,,,,,,,,,,,,,,,,,,,,,ATF6 activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001909,negative regulator role of translational initiation,,"A role played by the entity which stops, prevents, or reduces the frequency, rate or extent of translational initiation.|related process

GO:0036495 negative regulation of translation initiation in response to endoplasmic reticulum stress


GO:0010998: regulation of translational initiation by eIF2 alpha phosphorylation (Any process that modulates the frequency, rate or extent of translation initiation in response to stress by the phosphorylation of eIF2 alpha.)

GO:0036492 eiF2alpha phosphorylation in response to endoplasmic reticulum stress

inverse of
GO:0036497  eIF2alpha dephosphorylation in response to endoplasmic reticulum stress",false,,,http://purl.obolibrary.org/obo/TXPO_0002557,,,,,,,,,,,,,,,,,,,,,,"A role played by the entity which stops, prevents, or reduces the frequency, rate or extent of translational initiation.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001909,,,,,,,,,,,,,,,,,,,,"related process

GO:0036495 negative regulation of translation initiation in response to endoplasmic reticulum stress


GO:0010998: regulation of translational initiation by eIF2 alpha phosphorylation (Any process that modulates the frequency, rate or extent of translation initiation in response to stress by the phosphorylation of eIF2 alpha.)

GO:0036492 eiF2alpha phosphorylation in response to endoplasmic reticulum stress

inverse of
GO:0036497  eIF2alpha dephosphorylation in response to endoplasmic reticulum stress",,negative regulator role of translational initiation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001900,anion channel,,A role played by the entity which enables the energy-independent passage of anions across a lipid bilayer down a concentration gradient.|related molecular function GO:0005253,false,,,http://purl.obolibrary.org/obo/TXPO_0000328,,,,,,,,,,,,,,,,,,,,,,A role played by the entity which enables the energy-independent passage of anions across a lipid bilayer down a concentration gradient.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001900,,,,,,,,,,,,,,,,,,,,related molecular function GO:0005253,,anion channel,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001903,RSAD2(predicted)(human)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001135|http://purl.obolibrary.org/obo/TXPO_0003835,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:91543|https://omim.org/entry/607810|PMID:23758785,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000091543,,,,,,,,,,,,,TXPO:0001903,,,,,,,,,,,,,,,,,,,,,,RSAD2(predicted)(human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001902,gene regulation pathway,,Gene regulation pathway is a subtype of pathway: Sequence of reactions to regulate genes following signaling.,false,,,http://purl.obolibrary.org/obo/NCIT_C54214,,,,,,,,,,,,,,,,,,,,,,Gene regulation pathway is a subtype of pathway: Sequence of reactions to regulate genes following signaling.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000389|http://purl.obolibrary.org/obo/GO_0010468|http://purl.obolibrary.org/obo/GO_0010467,,,,,,,,,,,,,,,,,,TXPO:0001902,,,,,,,,,,,,,,,,,,,,,,gene regulation pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000027,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001906,acumulation of bile pigment in bile canaliculus,,Acumulation of bile pigment in bile canaliculus is a subtype of bile pigment deposition: The aggregation of bile pigmentin a particular location in a bile canaliculus.,false,,,http://purl.obolibrary.org/obo/TXPO_0000083,,,,,,,,,,,,,,,,,,,,,,Acumulation of bile pigment in bile canaliculus is a subtype of bile pigment deposition: The aggregation of bile pigmentin a particular location in a bile canaliculus.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001906,,,,,,,,,,,,,,,,,,,,,,acumulation of bile pigment in bile canaliculus,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0001283,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001905,ATF6 activation [ER stress - refolding],,"ATF6 activation is a subtype of molecular activation: A process that changes the activity of the ATF6 (Activating Transcription Factor 6) to be higher.
This process is dependent on the refolding and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000710|http://purl.obolibrary.org/obo/TXPO_0003736,,,,,,,,,,,,,,,,,,,,,,"ATF6 activation is a subtype of molecular activation: A process that changes the activity of the ATF6 (Activating Transcription Factor 6) to be higher.
This process is dependent on the refolding and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002901,http://purl.obolibrary.org/obo/TXPO_0002466|http://purl.obolibrary.org/obo/TXPO_0002467,,,,,,,,,,,,,,,,,,TXPO:0001905,,,,,,,,,,,,,,,,,,,,,,ATF6 activation [ER stress - refolding],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001907,ATF4 (canonical)[ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000871|http://purl.obolibrary.org/obo/TXPO_1000012,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:468|NCBI-Rat-GeneID:79255|NCBI-Mouse-GeneID:11911,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000825,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000468,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,,,,,,TXPO:0001907,,,,,,,,,,,,,,,,,,,,,,ATF4 (canonical)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100379,G-alpha-Y,,,false,,,http://purl.obolibrary.org/obo/IMR_0000323,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100379,,,,,,,,,,,,,,,,,,,,,,G-alpha-Y,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010543,40S ribosomal protein S18,40S small ribosomal protein 18|KE3|KE-3,,false,,,http://purl.obolibrary.org/obo/IMR_0000896,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,40S small ribosomal protein 18|KE3|KE-3,,,,,IMR:0010543,,,,,,,,,,,,,,,,,,,,,,40S ribosomal protein S18,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004444,Dysregulation of mitochondrion organization,,"Dysregulation of mitochondrion organization is a subtype of malfunctioning of controlling: A process that cannot perform a regulation of mitochondrion organization appropriately or cannot realize it at all.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0004997,,,,,,,,,,,,,,,,,,,,PMID:27151080,,"Dysregulation of mitochondrion organization is a subtype of malfunctioning of controlling: A process that cannot perform a regulation of mitochondrion organization appropriately or cannot realize it at all.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004350,,,,,,,,,,,TXPO:0004444,,,,,,,,,,,,,,,,,,,,,,Dysregulation of mitochondrion organization,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004442,positive regulation of autophagy [mitochondrial disorder],,"Any process that activates, maintains or increases the rate of autophagy. Autophagy is the process in which cells digest parts of their own cytoplasm.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/GO_0010508|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:27151080,,"Any process that activates, maintains or increases the rate of autophagy. Autophagy is the process in which cells digest parts of their own cytoplasm.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004928,,,,,,,,,,,TXPO:0004442,,,,,,,,,,,,,,,,,,,,,,positive regulation of autophagy [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004447,CAR activation [hepatocarcinogenesis],,"CAR activation is a subtype of molecular activation: A process that  changes the activity of the CAR (constitutive active/androstane receptor) to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004446,,,,,,,,,,,,,,,,,,,,PMID:23626729,,"CAR activation is a subtype of molecular activation: A process that  changes the activity of the CAR (constitutive active/androstane receptor) to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004450,,http://purl.obolibrary.org/obo/TXPO_0004449|http://purl.obolibrary.org/obo/TXPO_0004448,,,,,,http://purl.obolibrary.org/obo/TXPO_0004392,,,,,,,,,,,TXPO:0004447,,,,,,,,,,,,,,,,,,,,,,CAR activation [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004440,C9ORF72 inactivation [mitochondrial disorder],,"C9ORF72 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the C9ORF72 (C9orf72-SMCR8 complex subunit) to be lower.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0004439,,,,,,,,,,,,,,,,,,,,PMID:27151080,,"C9ORF72 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the C9ORF72 (C9orf72-SMCR8 complex subunit) to be lower.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004441,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004444|http://purl.obolibrary.org/obo/TXPO_0004442|http://purl.obolibrary.org/obo/TXPO_0004445|http://purl.obolibrary.org/obo/TXPO_0004443,,,,,,,,,,,TXPO:0004440,,,,,,,,,,,,,,,,,,,,,,C9ORF72 inactivation [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004441,C9orf72_inactivated (predicted)(human) [mitochondrial damage],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004171,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:203228|PMID:27151080,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657|http://purl.obolibrary.org/obo/PATO_0002355,http://purl.obolibrary.org/obo/OGG_3000203228,,,,,,,,,,,,,TXPO:0004441,,,,,,,,,,,,,,,,,,,,,,C9orf72_inactivated (predicted)(human) [mitochondrial damage],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004446,CAR activation,,CAR activation is a subtype of molecular activation: A process that  changes the activity of the CAR (constitutive active/androstane receptor) to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000023,,,,,,,,,,,,,,,,,,,,,,CAR activation is a subtype of molecular activation: A process that  changes the activity of the CAR (constitutive active/androstane receptor) to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004446,,,,,,,,,,,,,,,,,,,,,,CAR activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004445,Increasing mitochondrial membrane potential [mitochondrial disorder],,"Increasing mitochondrial membrane potential is a subtype of increasing membrane potential: A process that changes the electrical potential of a mitochondrial membrane to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0005000|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:27151080,,"Increasing mitochondrial membrane potential is a subtype of increasing membrane potential: A process that changes the electrical potential of a mitochondrial membrane to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001990,,,,,,,,,,,TXPO:0004445,,,,,,,,,,,,,,,,,,,,,,Increasing mitochondrial membrane potential [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004449,"1,4-bis[2-(3,5-dichloropyridyloxy)]benzene [hepatocarcinogenesis]",TCPOBOP,,false,,,http://purl.obolibrary.org/obo/TXPO_0004455|http://purl.obolibrary.org/obo/TXPO_0004819,,,,,,,,,,,,,,,,,,,,CAS:76150-91-9|PMID:25979168|PubChem CID:5382|PMID:23626729,,,,,,,,,,,,,,C16H8Cl4N2O2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TCPOBOP,,,,,TXPO:0004449,,,,,,,,,,,,,,,,,,,,,,"1,4-bis[2-(3,5-dichloropyridyloxy)]benzene [hepatocarcinogenesis]",,,,,,,,,,,http://purl.obolibrary.org/obo/NCBITaxon_9989,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,C1=CC(=CC=C1OC2=C(C=C(C=N2)Cl)Cl)OC3=C(C=C(C=N3)Cl)Cl,,,,,
http://purl.obolibrary.org/obo/TXPO_0004443,positive regulation of mitophagy [mitochondrial disorder],,"Any process that activates or increases the frequency, rate or extent of mitophagy.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/GO_1901526,,,,,,,,,,,,,,,,,,,,PMID:27151080,,"Any process that activates or increases the frequency, rate or extent of mitophagy.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002010,,,,,,,,,,,TXPO:0004443,,,,,,,,,,,,,,,,,,,,,,positive regulation of mitophagy [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0000423,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004448,phenobarbital [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004455|http://purl.obolibrary.org/obo/CHEBI_8069,,,,,,,,,,,,,,,,,,,,PMID:29270806|PMID:28932315|PMID:22584684|PMID:30141584|PMID:19463055|PMID:23626729|PMID:22008536,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004448,,,,,,,,,,,,,,,,,,,,,,phenobarbital [hepatocarcinogenesis],,,,,,,,,,,http://purl.obolibrary.org/obo/NCBITaxon_9989,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0042579,microbody,,"Cytoplasmic organelles, spherical or oval in shape, that are bounded by a single membrane and contain oxidative enzymes, especially those utilizing hydrogen peroxide (H2O2).",false,,,http://purl.obolibrary.org/obo/GO_0043227,,,,,,,,,,,,,,,,,,,,,,"Cytoplasmic organelles, spherical or oval in shape, that are bounded by a single membrane and contain oxidative enzymes, especially those utilizing hydrogen peroxide (H2O2).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0042579,,,,,,,,,,,,,,,,,,,,,,microbody,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000364,cytokeratin 13,,,false,,,http://purl.obolibrary.org/obo/IMR_0000035,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000364,,,,,,,,,,,,,,,,,,,,,,cytokeratin 13,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000344,Nck beta/Grb4,IRS-4b-P|SH2/SH3 adaptor protein NCK-beta|Cytoplasmic protein NCK2|NCK adaptor protein 2|Nck-2,,false,,,http://purl.obolibrary.org/obo/IMR_0000342,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0011208,IRS-4b-P|SH2/SH3 adaptor protein NCK-beta|Cytoplasmic protein NCK2|NCK adaptor protein 2|Nck-2,,,,,IMR:0000344,,,,,,,,,,,,,,,,,,,,,,Nck beta/Grb4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002244,Ang (mouse)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001517|http://purl.obolibrary.org/obo/TXPO_0003278,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:305843|http://omim.org/entry/105850|NCBI-Human-GeneID:283|PMID:25604905|PMID:10334936|PMID:15776477,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002261,,,,,,,,,,TXPO:0002244,,,,,,,,,,,,,,,,,,,,,,Ang (mouse)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OBI_0000070,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002249,Gadd45a - cell cycle arrest factor (rat)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001158,,,,,,,,,,,,,,,,,,,,http://omim.org/entry/126335|PMID:10779360|PMID:10747892|PMID:15353598|PMID:24104470|PMID:22150313,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002247,,,,,,,,,,TXPO:0002249,,,,,,,,,,,,,,,,,,,,,,Gadd45a - cell cycle arrest factor (rat)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001489|http://purl.obolibrary.org/obo/TXPO_0001547|http://purl.obolibrary.org/obo/TXPO_0001850,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002245,tumor growth [Phospholipidosis],,"Tumor growth is a subtype of cell growth: The process in which a tumor cell increases in size.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000766|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Tumor growth is a subtype of cell growth: The process in which a tumor cell increases in size.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003347|http://purl.obolibrary.org/obo/TXPO_0002244,,,,,,,,,,,,,,,,,TXPO:0002245,,,,,,,,,,,,,,,,,,,,,,tumor growth [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002247,cell cycle regulator role,,A role played by the entity which involves in regulating a cell cycle process.,false,,,http://purl.obolibrary.org/obo/TXPO_0003230,,,,,,,,,http://purl.obolibrary.org/obo/GO_0007049,,,,,,,,,,,,,A role played by the entity which involves in regulating a cell cycle process.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002247,,,,,,,,,,,,,,,,,,,,,,cell cycle regulator role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002240,release of calcium ion from lysosome [Phospholipidosis],,"The directed movement of calcium from the lysosome.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0002231,,,,,,,,,,,,,,,,,,,,PMID:27977664,,"The directed movement of calcium from the lysosome.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002227,,,,,,,,,,,TXPO:0002240,,,,,,,,,,,,,,,,,,,,,,release of calcium ion from lysosome [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002243,negative regulation of inflammatory response,,"Negative regulation of inflammatory response is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of inflammatory response.",false,,,http://purl.obolibrary.org/obo/TXPO_0000369,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of inflammatory response is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of inflammatory response.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002243,,,,,,,,,,,,,,,,,,,,,,negative regulation of inflammatory response,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000192,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002246,DNA repair role,,"A role played by  the entity involved in DNA repair processes including direct reversal, base excision repair, nucleotide excision repair, photoreactivation, bypass, double-strand break repair pathway, and mismatch repair pathway.",false,,,http://purl.obolibrary.org/obo/TXPO_0001316,,,,,,,,,,,,,,,,,,,,,,"A role played by  the entity involved in DNA repair processes including direct reversal, base excision repair, nucleotide excision repair, photoreactivation, bypass, double-strand break repair pathway, and mismatch repair pathway.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002246,,,,,,,,,,,,,,,,,,,,,,DNA repair role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006281,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002248,increasing phospholipid metabolite,,Increasing phospholipid metabolite is a subtype of increasing quantity: A process that changes the amount of phospholipid metabolites to be larger.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing phospholipid metabolite is a subtype of increasing quantity: A process that changes the amount of phospholipid metabolites to be larger.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002248,,,,,,,,,,,,,,,,,,,,,,increasing phospholipid metabolite,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002241,obesity [Phospholipidosis],,"Obesity is a subtype of increasing weight: A process that changes the body weight to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0001286,,,,,,,,,,,,,,,,,,,,,,"Obesity is a subtype of increasing weight: A process that changes the body weight to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004111|http://purl.obolibrary.org/obo/TXPO_0004088,http://purl.obolibrary.org/obo/TXPO_0001142,,,,,,http://purl.obolibrary.org/obo/TXPO_0004158|http://purl.obolibrary.org/obo/TXPO_0001822,,,,,,,,,,,TXPO:0002241,,,,,,,,,,,,,,,,,,,,,,obesity [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002242,negative regulation of inflammatory response [Phospholipidosis],,"Negative regulation of inflammatory response is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of inflammatory response.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0002243,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of inflammatory response is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of inflammatory response.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002290,,,,,,,,,,,,,,,,,TXPO:0002242,,,,,,,,,,,,,,,,,,,,,,negative regulation of inflammatory response [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000083729,INHBE,,Other designations: activin beta E|activin beta-E chain|inhibin beta E chain,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,12,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"inhibin, beta E",,,12q13.3,,,,,,,,,,,,,,,,GO_0005179 (EC: IEA); GO_0005576 (EC: IEA); GO_0008083 (EC: IEA); GO_0040007 (EC: IEA),,,,,,,,,PMID: 12242034; 12477932; 14702039; 15489334; 15717329; 16303743; 16426570; 18413775; 19322201; 20012305; 20033758; 20734064; 21092084; 23263486,,,,,,,,,,,,,,,OGG:3000083729,,,,,,,"inhibin, beta E",,,,,,,,,,,,,Other designations: activin beta E|activin beta-E chain|inhibin beta E chain,,INHBE,,,,,,,,,,,,,,,,,,,,,,,83729,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,INHBE,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_30879,alcohol,,"A compound in which a hydroxy group, -OH, is attached to a saturated carbon atom.",false,,,http://purl.obolibrary.org/obo/CHEBI_72695,,,,,,,,,,,,,,,,,,,,,,"A compound in which a hydroxy group, -OH, is attached to a saturated carbon atom.",,,,,,,,,,,,HOR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:30879,,,,,,,,,,,,,,,,,,,,,,alcohol,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,O[*],,,,,
http://purl.obolibrary.org/obo/GO_0006644,phospholipid metabolic process,phospholipid metabolism,"The chemical reactions and pathways involving phospholipids, any lipid containing phosphoric acid as a mono- or diester.",false,,,http://purl.obolibrary.org/obo/GO_0006629,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways involving phospholipids, any lipid containing phosphoric acid as a mono- or diester.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0009395|http://purl.obolibrary.org/obo/GO_0008654,,,,,,,,,,,,,phospholipid metabolism,,,,,GO:0006644,,,,,,,,,,,,,,,,,biological_process,,,,,phospholipid metabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006646,phosphatidylethanolamine biosynthetic process,phosphatidylethanolamine synthesis|phosphatidylethanolamine biosynthesis|phosphatidylethanolamine formation|phosphatidylethanolamine anabolism,"The chemical reactions and pathways resulting in the formation of phosphatidylethanolamine, any of a class of glycerophospholipids in which a phosphatidyl group is esterified to the hydroxyl group of ethanolamine.",false,,,http://purl.obolibrary.org/obo/GO_0046474,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways resulting in the formation of phosphatidylethanolamine, any of a class of glycerophospholipids in which a phosphatidyl group is esterified to the hydroxyl group of ethanolamine.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_16038,,,,,,,,,,,,,,phosphatidylethanolamine synthesis|phosphatidylethanolamine biosynthesis|phosphatidylethanolamine formation|phosphatidylethanolamine anabolism,,,,,GO:0006646,,,,,,,,,,,,,,,,,biological_process,,,,,phosphatidylethanolamine biosynthetic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006649,phospholipid transfer to membrane,,The transfer of a phospholipid from its site of synthesis to the plasma membrane.,false,,,http://purl.obolibrary.org/obo/GO_0015914,,,,,,,,,,,,,,,,,,,,,,The transfer of a phospholipid from its site of synthesis to the plasma membrane.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000895,,,,,,,,GO:0006649,,,,,,,,,,,,,,,,,,,,,,phospholipid transfer to membrane,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000005138,PDE2A,,"Other designations: cGMP-dependent 3',5'-cyclic phosphodiesterase|cGMP-stimulated phosphodiesterase 1|cGMP-stimulated phosphodiesterase 4|cyclic GMP-stimulated phosphodiesterase",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CGS-PDE|PDE2A1|PED2A4|cGSPDE,,,,,,,,,,,,11,,,,,,MIM:602658|HPRD:04041|Ensembl:ENSG00000186642|HGNC:8777|Vega:OTTHUMG00000102045,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"phosphodiesterase 2A, cGMP-stimulated",,,11q13.4,,,,,,,,,,,,,,,,"GO_0000122 (EC: IDA, PMID: 17329248); GO_0004112 (EC: IDA, PMID: 15938621); GO_0004118 (EC: IDA, PMID: 17329248); GO_0005262 (EC: TAS, PMID: 10375378); GO_0005515 (EC: IPI, PMID: 17329248); GO_0005634 (EC: IDA, PMID: 10375378); GO_0005737 (EC: IDA, PMID: 10375378); GO_0005759 (EC: ISS); GO_0005783 (EC: ISS); GO_0005794 (EC: ISS); GO_0005829 (EC: IDA, PMID: 17329248); GO_0005829 (EC: TAS); GO_0005886 (EC: IDA, PMID: 19252089); GO_0005886 (EC: IDA, Qualifier: colocalizes_with, PMID: 17329248); GO_0006198 (EC: IDA, PMID: 14687666); GO_0006198 (EC: IMP, PMID: 19252089); GO_0006626 (EC: ISS); GO_0007596 (EC: TAS); GO_0008144 (EC: IDA, PMID: 15938621); GO_0008144 (EC: IPI, PMID: 15938621); GO_0008152 (EC: IDA, PMID: 17329248); GO_0019933 (EC: IMP, PMID: 17704206); GO_0019934 (EC: IMP, PMID: 17704206); GO_0030224 (EC: IEP, PMID: 14687666); GO_0030424 (EC: IEA); GO_0030425 (EC: IEA); GO_0030552 (EC: IMP, PMID: 15938621); GO_0030553 (EC: IDA, PMID: 17329248); GO_0030553 (EC: IMP, PMID: 15938621); GO_0030818 (EC: ISS); GO_0030911 (EC: IPI, PMID: 17329248); GO_0033159 (EC: IDA, PMID: 17329248); GO_0035690 (EC: IEP, PMID: 14687666); GO_0035690 (EC: IMP, PMID: 15938621); GO_0036006 (EC: IDA, PMID: 14687666); GO_0042734 (EC: ISS); GO_0042803 (EC: IPI, PMID: 19828435); GO_0043116 (EC: IMP, PMID: 17704206); GO_0043117 (EC: IMP, PMID: 17704206); GO_0046069 (EC: IDA, PMID: 14687666); GO_0046872 (EC: IEA); GO_0048471 (EC: IDA, PMID: 10375378); GO_0050729 (EC: ISS); GO_0061028 (EC: ISS); GO_0070588 (EC: TAS, PMID: 10375378); GO_0071260 (EC: ISS); GO_0071321 (EC: IDA, PMID: 17704206); GO_0071560 (EC: IEP, PMID: 17704206); GO_0097011 (EC: IDA, PMID: 14687666)",,,,,,,,,PMID: 8557689; 9210593; 10375378; 11156964; 12038792; 12271124; 12477932; 14687666; 14702039; 15650061; 15938621; 16344560; 17329248; 17704206; 19252089; 19390057; 19506089; 19689430; 19828435; 19913121; 20351714; 20395239; 20628086; 21697861; 21724846; 21766240; 21987572; 22446963; 23381931; 23810893; 23899287,,,,,,,,,,,,,,,OGG:3000005138,,,,,,,"phosphodiesterase 2A, cGMP-stimulated",,,,,,,,,,,,,"Other designations: cGMP-dependent 3',5'-cyclic phosphodiesterase|cGMP-stimulated phosphodiesterase 1|cGMP-stimulated phosphodiesterase 4|cyclic GMP-stimulated phosphodiesterase",,PDE2A,,,,,,,,,,,,,,,,,,,,,,,5138,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,PDE2A,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/GO_0006417,regulation of translation,regulation of protein anabolism|regulation of protein formation|regulation of protein synthesis|regulation of protein biosynthesis,"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of proteins by the translation of mRNA or circRNA.",false,,,http://purl.obolibrary.org/obo/TXPO_0000113,,,,,,,,,,,,,,,,,,,,,,"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of proteins by the translation of mRNA or circRNA.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,regulation of protein anabolism|regulation of protein formation|regulation of protein synthesis|regulation of protein biosynthesis,,,,,GO:0006417,,,,,,,,,,,,,,,,,,,,,,regulation of translation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006412,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006412,translation,,"The cellular metabolic process in which a protein is formed, using the sequence of a mature mRNA or circRNA molecule to specify the sequence of amino acids in a polypeptide chain. Translation is mediated by the ribosome, and begins with the formation of a ternary complex between aminoacylated initiator methionine tRNA, GTP, and initiation factor 2, which subsequently associates with the small subunit of the ribosome and an mRNA or circRNA. Translation ends with the release of a polypeptide chain from the ribosome.",false,,,http://purl.obolibrary.org/obo/GO_0010467,,,,,,,,,,,,,,,,,,,,Wikipedia:Translation_(genetics),,"The cellular metabolic process in which a protein is formed, using the sequence of a mature mRNA or circRNA molecule to specify the sequence of amino acids in a polypeptide chain. Translation is mediated by the ribosome, and begins with the formation of a ternary complex between aminoacylated initiator methionine tRNA, GTP, and initiation factor 2, which subsequently associates with the small subunit of the ribosome and an mRNA or circRNA. Translation ends with the release of a polypeptide chain from the ribosome.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0006412,,,,,,,,,,,,,,,,,,,,,,translation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000435,calreticulin (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:64202|NCBI-Mouse-GeneID:716910|http://omim.org/entry/109091|NCBI-Human-GeneID:811,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:1000435,,,,,,,,,,,,,,,,,,,,,,calreticulin (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000431,TIMP family,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:1000431,,,,,,,,,,,,,,,,,,,,,,TIMP family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_48887,bile acid metabolite,,"Metabolites of bile acids, four-ringed steroid acids formed along the cholesterol degradation pathway.",false,,,http://purl.obolibrary.org/obo/CHEBI_25212,,,,,,,,,,,,,,,,,,,,,,"Metabolites of bile acids, four-ringed steroid acids formed along the cholesterol degradation pathway.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:48887,,,,,,,,,,,,,,,,,,,,,,bile acid metabolite,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000079094,CHAC1,,"Other designations: ChaC, cation transport regulator-like 1|blocks Notch protein|botch|cation transport regulator-like protein 1|gamma-GCT acting on glutathione homolog 1",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,15,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"ChaC, cation transport regulator homolog 1 (E. coli)",,,15q15.1,,,,,,,,,,,,,,,,"GO_0005112 (EC: ISS); GO_0005515 (EC: IPI, PMID: 16189514); GO_0005794 (EC: IEA); GO_0005802 (EC: ISS); GO_0005829 (EC: IDA, PMID: 19109178); GO_0006986 (EC: IEA); GO_0007219 (EC: IEA); GO_0010955 (EC: IMP); GO_0022008 (EC: ISS); GO_0045746 (EC: IMP); GO_0070059 (EC: IMP, PMID: 19109178)",,,,,,,,,PMID: 8889548; 12477932; 15489334; 16189514; 16341674; 19109178; 21890473; 21906983; 22108517; 22589738; 23000965; 23070364; 23342279,,,,,,,,,,,,,,,OGG:3000079094,,,,,,,"ChaC, cation transport regulator homolog 1 (E. coli)",,,,,,,,,,,,,"Other designations: ChaC, cation transport regulator-like 1|blocks Notch protein|botch|cation transport regulator-like protein 1|gamma-GCT acting on glutathione homolog 1",,CHAC1,,,,,,,,,,,,,,,,,,,,,,,79094,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,CHAC1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0001711,vinculin,,Involved in cell adhesion. May be involved in the attachment of the actin-based microfilaments to the plasma membrane.,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,Involved in cell adhesion. May be involved in the attachment of the actin-based microfilaments to the plasma membrane.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000188,,,,,,,,,,IMR:0001711,,,,,,,,,,,,,,,,,,,,,,vinculin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010490,60S ribosomal protein L3-like,Q92901,,false,,,http://purl.obolibrary.org/obo/IMR_0000897,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Q92901,,,,,IMR:0010490,,,,,,,,,,,,,,,,,,,,,,60S ribosomal protein L3-like,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100667,Clb4,G2/mitotic-specific cyclin 4,,false,,,http://purl.obolibrary.org/obo/IMR_0100673,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,G2/mitotic-specific cyclin 4,,,,,IMR:0100667,,,,,,,,,,,,,,,,,,,,,,Clb4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002565,changing protein fold,,Changing protein fold is a subtype of changing protein structure: A process that changes the folding stucture of the protein.,false,,,http://purl.obolibrary.org/obo/TXPO_0000660,,,,,,,,,,,,,,,,,,,,,,Changing protein fold is a subtype of changing protein structure: A process that changes the folding stucture of the protein.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002565,,,,,,,,,,,,,,,,,,,,,,changing protein fold,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002566,changing structure,,Changing structure is a subtype of changing an operand: A process that change sthe stucture of the operand.,false,,,http://purl.obolibrary.org/obo/TXPO_0000392,,,,,,,,,,,,,,,,,,,,,,Changing structure is a subtype of changing an operand: A process that change sthe stucture of the operand.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002566,,,,,,,,,,,,,,,,,,,,,,changing structure,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002560,ATF4 - transcriptional regulator (canonical)[ER stress - insulin resistance],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001907,,,,,,,,,,,,,,,,,,,仮　要調査,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,,,,,,TXPO:0002560,,,,,,,,,,,,,,,,,,,,,,ATF4 - transcriptional regulator (canonical)[ER stress - insulin resistance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002568,changing composition,,Changing composition is a subtype of changing between operands: A process that changes the relationship of the overall components.,false,,,http://purl.obolibrary.org/obo/TXPO_0000261,,,,,,,,,,,,,,,,,,,,,,Changing composition is a subtype of changing between operands: A process that changes the relationship of the overall components.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002568,,,,,,,,,,,,,,,,,,,,,,changing composition,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002569,combining,,Combining is a subtype of assembling: A process that merges different parts into one. Each element can be recognized after combination.,false,,,http://purl.obolibrary.org/obo/TXPO_0000468,,,,,,,,,,,,,,,,,,,,,,Combining is a subtype of assembling: A process that merges different parts into one. Each element can be recognized after combination.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002569,,,,,,,,,,,,,,,,,,,,,,combining,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002562,Trib3 gene expression by ATF4 [ER stress],,"Trib3 gene expression by ATF4 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence of Trib3 is converted into a mature gene product or products (proteins or RNA) related to the refolding by ATF4.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000698,,,,,,,,,,,,,,,,,,,,,,"Trib3 gene expression by ATF4 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence of Trib3 is converted into a mature gene product or products (proteins or RNA) related to the refolding by ATF4.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001907,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002168,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002201,,,,,,,,,,,TXPO:0002562,,,,,,,,,,,,,,,,,,,,,,Trib3 gene expression by ATF4 [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002567,converting to information,,Converting to information is a subtype of converting type: A process that changes a type of object to information.,false,,,http://purl.obolibrary.org/obo/TXPO_0002282,,,,,,,,,,,,,,,,,,,,,,Converting to information is a subtype of converting type: A process that changes a type of object to information.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002567,,,,,,,,,,,,,,,,,,,,,,converting to information,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002561,PERK-ATF4-TRIB3 signaling [ER stress - insulin resistance],,"PERK-eIF2a-ATF4 mediated pathway is a subtype of PERK-eIF2a signaling: Sequence of linked reactions, which has PERK-eIF2a signaling and TRIB3 gene regulation by ATF4.
This pathway is dependent on the insulin resistance and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002513,,,,,,,,,,,,,,,,,,,,,,"PERK-eIF2a-ATF4 mediated pathway is a subtype of PERK-eIF2a signaling: Sequence of linked reactions, which has PERK-eIF2a signaling and TRIB3 gene regulation by ATF4.
This pathway is dependent on the insulin resistance and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002562,,http://purl.obolibrary.org/obo/TXPO_0002483|http://purl.obolibrary.org/obo/TXPO_0000285,,,,,,,,,,,,,,,,TXPO:0002561,,,,,,,,,,,,,,,,,,,,,,PERK-ATF4-TRIB3 signaling [ER stress - insulin resistance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002563,IRE1 signaling (integrated pathway),,"IRE1 signaling (integrated pathway) is a subtype of integrated signaling pathway: Sequence of linked reactions, which has IRE1 signaling and gene regulation pathway.",false,,,http://purl.obolibrary.org/obo/TXPO_0000027,,,,,,,,,,,,,,,,,,,,,,"IRE1 signaling (integrated pathway) is a subtype of integrated signaling pathway: Sequence of linked reactions, which has IRE1 signaling and gene regulation pathway.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002604|http://purl.obolibrary.org/obo/GO_0010468|http://purl.obolibrary.org/obo/TXPO_0002593,,http://purl.obolibrary.org/obo/TXPO_0002155,,,,,,,,,,,,,,,,TXPO:0002563,,,,,,,,,,,,,,,,,,,,,,IRE1 signaling (integrated pathway),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002564,excretion of glutathione conjugates from hepatocyte [Glutathione depletion.],,"Excretion of glutathione conjugates from hepatocyte is a subtype of compound excretion: A process that excretes the glutathione conjugates from the hepatocyte.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0002551|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Excretion of glutathione conjugates from hepatocyte is a subtype of compound excretion: A process that excretes the glutathione conjugates from the hepatocyte.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002493,,,,,,,,,,,,,,,,,TXPO:0002564,,,,,,,,,,,,,,,,,,,,,,excretion of glutathione conjugates from hepatocyte [Glutathione depletion.],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100051,motilin,,"A peptide of about 22-amino acids isolated from the DUODENUM. At low pH it inhibits gastric motor activity, whereas at high pH it has a stimulating effect.",false,,,http://purl.obolibrary.org/obo/IMR_0100072,,,,,,,,,,,,,,,,,,,,MeSH:D009037,,"A peptide of about 22-amino acids isolated from the DUODENUM. At low pH it inhibits gastric motor activity, whereas at high pH it has a stimulating effect.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100051,,,,,,,,,,,,,,,,,,,,,,motilin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0002114,fatty,,A composition quality inhering in a bearer by virtue of the bearer's containing excess lipid.,false,,,http://purl.obolibrary.org/obo/PATO_0000025,,,,,,,,,,,,,,,,,,,,,,A composition quality inhering in a bearer by virtue of the bearer's containing excess lipid.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0002114,,,,,,,,,,,,,,,,,,,,,,fatty,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000007157,TP53,,Other designations: antigen NY-CO-13|cellular tumor antigen p53|mutant tumor protein 53|p53 tumor suppressor|phosphoprotein p53|transformation-related protein 53|tumor protein 53,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,BCC7|TRP53|P53|LFS1,,,,,,,,,,,,17,,,,,,HGNC:11998|HPRD:01859|Vega:OTTHUMG00000162125|MIM:191170|Ensembl:ENSG00000141510,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,tumor protein p53,,,17p13.1,,,,,,,,,,,,,,,,"GO_0000060 (EC: IEA); GO_0000122 (EC: IBA); GO_0000122 (EC: IDA, PMID: 15340061); GO_0000122 (EC: ISS, PMID: 19749791); GO_0000733 (EC: IDA, PMID: 8183576); GO_0000785 (EC: IBA); GO_0000790 (EC: IDA, PMID: 15710329); GO_0000979 (EC: IEA); GO_0001077 (EC: IEA); GO_0001085 (EC: IPI, PMID: 18549481); GO_0001228 (EC: IDA, PMID: 17146433); GO_0001701 (EC: IEA); GO_0001756 (EC: IEA); GO_0001836 (EC: IEA); GO_0002020 (EC: IPI, PMID: 11923872); GO_0002039 (EC: IBA); GO_0002309 (EC: IEA); GO_0002326 (EC: IEA); GO_0002360 (EC: IEA); GO_0002931 (EC: IEA); GO_0003677 (EC: IMP, PMID: 2144364); GO_0003682 (EC: IDA, PMID: 16322561); GO_0003684 (EC: IBA); GO_0003700 (EC: IDA, PMID: 18549481); GO_0005507 (EC: IDA, PMID: 7824276); GO_0005515 (EC: IPI, PMID: 10196247); GO_0005524 (EC: IDA, PMID: 8183576); GO_0005634 (EC: IDA); GO_0005654 (EC: IDA, PMID: 11080164); GO_0005654 (EC: TAS); GO_0005657 (EC: IBA); GO_0005669 (EC: IDA, Qualifier: colocalizes_with, PMID: 15053879); GO_0005730 (EC: IDA, PMID: 12080348); GO_0005737 (EC: IDA, PMID: 14744935); GO_0005739 (EC: IDA, PMID: 12667443); GO_0005759 (EC: IEA); GO_0005783 (EC: IEA); GO_0005829 (EC: IBA); GO_0005829 (EC: IDA, PMID: 14963330); GO_0006284 (EC: TAS, PMID: 15116721); GO_0006289 (EC: IMP, PMID: 7663514); GO_0006302 (EC: IEA); GO_0006355 (EC: IDA, PMID: 7587074); GO_0006461 (EC: IDA, PMID: 12915590); GO_0006915 (EC: TAS); GO_0006974 (EC: IDA, PMID: 14744935); GO_0006977 (EC: TAS); GO_0006978 (EC: IMP, PMID: 7958916); GO_0006983 (EC: IDA, PMID: 14744935); GO_0007050 (EC: IDA, PMID: 15149599); GO_0007050 (EC: IMP, PMID: 10962037); GO_0007179 (EC: IEA); GO_0007219 (EC: TAS); GO_0007265 (EC: IEP, PMID: 9054499); GO_0007275 (EC: IMP, PMID: 10065150); GO_0007369 (EC: IEA); GO_0007406 (EC: IEA); GO_0007417 (EC: IEA); GO_0007569 (EC: IMP, PMID: 12080348); GO_0007596 (EC: TAS); GO_0008104 (EC: IDA, PMID: 16507995); GO_0008134 (EC: IPI, PMID: 15053879); GO_0008156 (EC: IEA); GO_0008270 (EC: TAS, PMID: 10065153); GO_0008283 (EC: TAS, PMID: 10065150); GO_0008285 (EC: ISS); GO_0008340 (EC: ISS); GO_0009303 (EC: IEA); GO_0009651 (EC: IEA); GO_0010165 (EC: IBA); GO_0010332 (EC: IMP, PMID: 7958916); GO_0010666 (EC: IEA); GO_0016032 (EC: IEA); GO_0016363 (EC: IDA, PMID: 11080164); GO_0016604 (EC: IDA, Qualifier: colocalizes_with, PMID: 10360174); GO_0016605 (EC: IDA, PMID: 12006491); GO_0019899 (EC: IPI, PMID: 10666337); GO_0019901 (EC: IPI, PMID: 11546806); GO_0019903 (EC: IPI); GO_0030154 (EC: TAS, PMID: 10065150); GO_0030308 (EC: IMP, PMID: 8986812); GO_0030330 (EC: IDA, PMID: 15149599); GO_0030330 (EC: IMP); GO_0030512 (EC: IEA); GO_0030971 (EC: IPI); GO_0031065 (EC: IBA); GO_0031497 (EC: IDA, PMID: 16322561); GO_0031571 (EC: IMP, PMID: 7958916); GO_0031625 (EC: IPI, PMID: 10415337); GO_0032461 (EC: IDA, PMID: 12667443); GO_0033077 (EC: IEA); GO_0034103 (EC: IEA); GO_0034613 (EC: IDA, PMID: 15340061); GO_0034644 (EC: IBA); GO_0035033 (EC: IEA); GO_0035035 (EC: IPI, PMID: 10518217); GO_0035264 (EC: IEA); GO_0035690 (EC: IEP); GO_0042149 (EC: IDA, PMID: 14744935); GO_0042771 (EC: IDA, PMID: 14654789); GO_0042802 (EC: IPI, PMID: 16291740); GO_0042981 (EC: IDA, PMID: 14744935); GO_0043065 (EC: IDA, PMID: 12667443); GO_0043066 (EC: IDA, PMID: 16131611); GO_0043066 (EC: IEA); GO_0043234 (EC: IDA, PMID: 9529249); GO_0043525 (EC: IBA); GO_0044212 (EC: IDA, PMID: 15710329); GO_0045892 (EC: ISS, PMID: 19749791); GO_0045893 (EC: IDA, PMID: 16322561); GO_0045893 (EC: IMP); GO_0045944 (EC: IDA, PMID: 11672523); GO_0045944 (EC: IGI, PMID: 16061649); GO_0045944 (EC: IMP, PMID: 17146433); GO_0046677 (EC: IEP); GO_0046902 (EC: TAS, PMID: 15116721); GO_0046982 (EC: IPI, PMID: 10837489); GO_0047485 (EC: IPI, PMID: 11861836); GO_0048147 (EC: IMP, PMID: 10962037); GO_0048568 (EC: IEA); GO_0050731 (EC: ISS, PMID: 19749791); GO_0051087 (EC: IPI, PMID: 18086682); GO_0051097 (EC: TAS, PMID: 7663514); GO_0051262 (EC: TAS, PMID: 15116721); GO_0051402 (EC: IEA); GO_0051721 (EC: IPI, PMID: 17245430); GO_0070245 (EC: ISS); GO_0071158 (EC: IMP); GO_0071456 (EC: IEP); GO_0071479 (EC: IMP); GO_0071850 (EC: IEA); GO_0072332 (EC: IMP, PMID: 12172011); GO_0090200 (EC: IDA, PMID: 12667443); GO_0090343 (EC: IEA); GO_0090399 (EC: IMP, PMID: 19951988); GO_0090403 (EC: IMP, PMID: 19951988); GO_0097193 (EC: TAS, PMID: 16462759); GO_0097252 (EC: IDA, PMID: 7720704); GO_0097371 (EC: IEA); GO_1900740 (EC: TAS); GO_1901525 (EC: IEA); GO_1902108 (EC: IEA); GO_2000378 (EC: IEA); GO_2000379 (EC: IMP); GO_2001244 (EC: IMP, PMID: 14963330)",,,,,,,,,PMID: 1088347; 1303181; 1327751; 1349102; 1349175; 1394225; 1437144; 1454855; 1459726; 1465435; 1565143; 1565144; 1591732; 1600943; 1631137; 1631151; 1644930; 1647768; 1672732; 1673792; 1679237; 1683921; 1694291; 1699228; 1705009; 1737852; 1762941; 1848668; 1849234; 1868473; 1905840; 1915267; 1933902; 1939648; 1978757; 1999338; 2047879; 2141171; 2144364; 2156209; 2259385; 2263646; 2531845; 2839831; 2905688; 2946935; 2994241; 3001719; 3025664; 3456488; 3894933; 4006916; 6396087; 7587074; 7663514; 7682763; 7686617; 7720704; 7753047; 7761466; 7773777; 7777531; 7799929; 7809597; 7811761; 7818536; 7824276; 7853525; 7878469; 7887414; 7935417; 7935455; 7958916; 8013454; 8016121; 8023157; 8023159; 8028670; 8058315; 8090726; 8118819; 8125298; 8134127; 8183576; 8207805; 8221626; 8266092; 8316628; 8336944; 8361542; 8364550; 8380895; 8389468; 8401536; 8402617; 8423216; 8463313; 8513440; 8612585; 8617246; 8619474; 8623534; 8623910; 8632903; 8632915; 8639538; 8649785; 8668206; 8675009; 8729618; 8816502; 8825920; 8829627; 8829653; 8875926; 8875929; 8895579; 8921390; 8940078; 8943363; 8961277; 8986812; 9010216; 9054499; 9101296; 9110174; 9119221; 9129988; 9135004; 9143503; 9183006; 9194564; 9194565; 9215863; 9223638; 9226370; 9235949; 9278461; 9288740; 9288775; 9312058; 9312059; 9315650; 9321402; 9349507; 9363941; 9369221; 9372954; 9380510; 9393873; 9405613; 9419979; 9440695; 9444950; 9450901; 9472015; 9472029; 9482880; 9492043; 9514881; 9520163; 9529249; 9537326; 9556563; 9565608; 9569035; 9571186; 9582019; 9582267; 9620776; 9628871; 9653180; 9679063; 9685344; 9688277; 9724636; 9724739; 9732264; 9744860; 9765199; 9809062; 9811893; 9827557; 9837938; 9840937; 9843217; 9891054; 9891077; 9926942; 9935181; 10024883; 10065150; 10065153; 10078201; 10196247; 10198638; 10214938; 10347180; 10348343; 10358050; 10359315; 10360174; 10380882; 10415337; 10435622; 10468612; 10470151; 10477429; 10484981; 10518217; 10521394; 10544138; 10551785; 10557093; 10562557; 10597287; 10606744; 10608806; 10608892; 10629029; 10634809; 10640274; 10644693; 10644996; 10656684; 10656795; 10666337; 10673501; 10710310; 10713094; 10713716; 10721693; 10736619; 10744705; 10744722; 10747897; 10747903; 10749849; 10766163; 10777477; 10781812; 10788439; 10794522; 10822382; 10823891; 10825186; 10827196; 10837489; 10842192; 10848610; 10850547; 10853038; 10876243; 10882116; 10884347; 10891493; 10913176; 10913622; 10930427; 10942770; 10951572; 10958792; 10961991; 10962037; 11002423; 11002963; 11007800; 11023613; 11024482; 11025664; 11027293; 11045785; 11046142; 11050162; 11058590; 11070080; 11080152; 11080164; 11094089; 11097227; 11099047; 11106654; 11108663; 11118038; 11130248; 11146230; 11146555; 11152513; 11165394; 11172000; 11174479; 11175333; 11196199; 11223036; 11238924; 11239457; 11240705; 11245491; 11251186; 11251969; 11255264; 11258898; 11259085; 11278372; 11278647; 11283254; 11285227; 11293726; 11297531; 11311202; 11313951; 11327730; 11328884; 11340159; 11359905; 11360197; 11388671; 11399766; 11403041; 11409876; 11416144; 11420669; 11427532; 11429426; 11430832; 11447225; 11458982; 11459832; 11481490; 11483158; 11486030; 11500059; 11501650; 11504717; 11504770; 11507088; 11507974; 11511362; 11518545; 11519852; 11527429; 11528400; 11532197; 11535556; 11546806; 11551930; 11554448; 11554765; 11559355; 11562347; 11564578; 11566488; 11583632; 11593383; 11597128; 11597326; 11600572; 11602059; 11602639; 11668523; 11672523; 11682637; 11684014; 11687965; 11692157; 11704667; 11704853; 11706030; 11707401; 11707411; 11707426; 11708408; 11709713; 11710828; 11713287; 11718557; 11733360; 11737306; 11739724; 11740489; 11744990; 11746272; 11748221; 11748232; 11751390; 11751391; 11751402; 11751427; 11751853; 11753428; 11753641; 11755471; 11756653; 11763417; 11764099; 11776898; 11779500; 11779589; 11779855; 11780126; 11781842; 11782467; 11783017; 11783119; 11786482; 11788578; 11788906; 11792711; 11793443; 11793474; 11799106; 11804596; 11804609; 11804688; 11805092; 11805286; 11807792; 11809417; 11814547; 11815410; 11818510; 11818669; 11821948; 11828992; 11836677; 11838964; 11838966; 11839095; 11840332; 11842245; 11844595; 11844788; 11844800; 11844810; 11845987; 11852106; 11853669; 11854266; 11856771; 11857304; 11859067; 11859195; 11859970; 11861393; 11861400; 11861836; 11865061; 11867628; 11867732; 11872638; 11875057; 11875500; 11877378; 11877395; 11880381; 11881786; 11883440; 11883897; 11887018; 11888672; 11890931; 11892796; 11893247; 11893750; 11895857; 11896572; 11900485; 11900859; 11904448; 11907332; 11911244; 11914273; 11915341; 11917009; 11919562; 11920528; 11923280; 11923872; 11925430; 11925449; 11925591; 11927843; 11934017; 11935300; 11936585; 11940482; 11943780; 11948395; 11948396; 11948632; 11949842; 11949843; 11950834; 11953423; 11953436; 11953857; 11953859; 11956602; 11956638; 11957139; 11960374; 11960383; 11960904; 11960918; 11961303; 11964141; 11971958; 11971968; 11973333; 11978184; 11979459; 11980658; 11983168; 11983757; 11988847; 11992381; 11992547; 11992551; 11992552; 11996107; 11997498; 11999565; 12006491; 12007715; 12011055; 12011072; 12011430; 12014634; 12019159; 12032546; 12032659; 12032848; 12034444; 12034820; 12034830; 12036888; 12036913; 12036943; 12039466; 12045262; 12046064; 12046074; 12048243; 12049739; 12051912; 12060398; 12062821; 12064478; 12065086; 12068014; 12071291; 12071847; 12073053; 12077306; 12077343; 12080066; 12080348; 12082526; 12082529; 12082592; 12082608; 12082615; 12082636; 12084347; 12084746; 12085209; 12089322; 12091386; 12093899; 12096336; 12096338; 12099684; 12101184; 12101417; 12101418; 12105992; 12107116; 12110584; 12110597; 12112314; 12115545; 12119414; 12124396; 12127401; 12127695; 12135983; 12136132; 12136662; 12138177; 12138209; 12144687; 12144822; 12145207; 12145320; 12151395; 12154087; 12160929; 12161031; 12161427; 12162806; 12163498; 12164325; 12164929; 12165799; 12167711; 12167722; 12168882; 12168898; 12168936; 12169206; 12170762; 12171773; 12172011; 12172977; 12174591; 12174820; 12174901; 12174951; 12175902; 12186903; 12190289; 12194286; 12198151; 12203403; 12208736; 12209584; 12209590; 12209989; 12217802; 12221910; 12226108; 12232053; 12234998; 12235242; 12242109; 12242661; 12270344; 12324474; 12324477; 12351827; 12355087; 12365037; 12367518; 12368717; 12370303; 12370812; 12372430; 12372616; 12374798; 12376521; 12379483; 12379854; 12380307; 12381304; 12383858; 12384512; 12384701; 12386810; 12386819; 12388558; 12388812; 12392301; 12393814; 12393879; 12393902; 12397361; 12397362; 12403781; 12404120; 12411481; 12413700; 12419336; 12419825; 12420214; 12420220; 12421820; 12426395; 12427745; 12427754; 12429911; 12430182; 12432277; 12433927; 12434001; 12434121; 12434294; 12438652; 12439747; 12444079; 12445188; 12445252; 12445680; 12446718; 12446780; 12447653; 12451999; 12452037; 12452062; 12458344; 12459171; 12459315; 12459451; 12459463; 12459877; 12464630; 12467072; 12468914; 12470840; 12471108; 12471629; 12474051; 12477932; 12479364; 12479855; 12480939; 12482984; 12492368; 12492369; 12492370; 12494467; 12496062; 12496474; 12496479; 12496480; 12499093; 12501250; 12503212; 12505256; 12507430; 12507556; 12508351; 12509469; 12514174; 12514180; 12515622; 12518062; 12519780; 12524418; 12524540; 12526791; 12527466; 12527892; 12527938; 12529318; 12530090; 12532420; 12534345; 12534455; 12535653; 12538356; 12543796; 12548019; 12550754; 12552135; 12553064; 12556232; 12556559; 12562237; 12563316; 12565178; 12565873; 12567188; 12568865; 12569576; 12573582; 12574499; 12575207; 12575534; 12582031; 12584563; 12588988; 12591737; 12592393; 12600206; 12606552; 12606585; 12607595; 12607601; 12607604; 12609716; 12610779; 12612087; 12615706; 12615712; 12619118; 12620407; 12620801; 12628922; 12628923; 12634062; 12635827; 12637159; 12640129; 12642583; 12642697; 12642870; 12642871; 12646262; 12648751; 12654245; 12659830; 12660163; 12665570; 12667443; 12668287; 12669312; 12670525; 12670866; 12670900; 12673251; 12679912; 12684392; 12684648; 12687275; 12687276; 12690203; 12692266; 12694871; 12698195; 12698197; 12700230; 12702766; 12704785; 12706118; 12708345; 12712134; 12713809; 12716906; 12724314; 12725329; 12725330; 12725531; 12725534; 12727844; 12730672; 12731623; 12732139; 12734410; 12735900; 12738987; 12743423; 12743601; 12748190; 12749011; 12750254; 12750285; 12750368; 12750388; 12756247; 12756585; 12759240; 12759537; 12761448; 12766905; 12767266; 12768030; 12771886; 12772781; 12773566; 12779080; 12782403; 12782576; 12782597; 12788915; 12789271; 12789273; 12794118; 12794243; 12796380; 12800224; 12802680; 12804595; 12808109; 12809883; 12810724; 12811820; 12813031; 12818446; 12820330; 12820372; 12820398; 12821135; 12821780; 12821781; 12821945; 12823440; 12823592; 12824702; 12824925; 12826609; 12829999; 12830514; 12838617; 12839924; 12839966; 12840112; 12841598; 12841870; 12842086; 12851404; 12854888; 12857899; 12860918; 12867035; 12871978; 12872134; 12874009; 12874296; 12875622; 12875991; 12879009; 12883749; 12885235; 12888634; 12890487; 12890671; 12891704; 12893432; 12894226; 12897130; 12897156; 12898523; 12901798; 12901974; 12905527; 12907596; 12907646; 12909720; 12911720; 12915590; 12917199; 12917636; 12920132; 12921568; 12923319; 12926050; 12926080; 12926093; 12926120; 12926130; 12926152; 12931731; 12935924; 12939400; 12940438; 12942774; 12944468; 12947108; 12954772; 12955365; 12958068; 12959929; 12963547; 12969350; 12970887; 12972634; 13678722; 13679039; 13679996; 14499615; 14500353; 14500711; 14500729; 14504475; 14506283; 14507241; 14511408; 14513722; 14517211; 14517280; 14517281; 14519637; 14519663; 14523002; 14527689; 14529662; 14532990; 14534297; 14534696; 14534749; 14551300; 14555204; 14555661; 14557644; 14557665; 14558950; 14559824; 14560002; 14562055; 14566828; 14572637; 14576150; 14576823; 14577584; 14580323; 14581358; 14582705; 14583449; 14583450; 14583461; 14584049; 14586398; 14586402; 14592451; 14595650; 14607337; 14608092; 14610316; 14612290; 14612402; 14612423; 14612427; 14612499; 14612511; 14612513; 14612521; 14614455; 14617836; 14618087; 14623330; 14623878; 14627345; 14627987; 14628083; 14631373; 14634213; 14634508; 14636569; 14637168; 14640983; 14641293; 14644318; 14644340; 14645509; 14645574; 14645705; 14647426; 14647431; 14648233; 14654539; 14654549; 14654789; 14654903; 14654927; 14656244; 14660794; 14663467; 14669308; 14670539; 14671306; 14673037; 14675203; 14675665; 14676802; 14676844; 14678586; 14678961; 14680293; 14680497; 14682374; 14689061; 14690015; 14693272; 14699137; 14702041; 14704000; 14707141; 14710355; 14714296; 14716820; 14719105; 14719118; 14719475; 14722092; 14722922; 14724564; 14729628; 14730312; 14734461; 14735465; 14737103; 14740296; 14741214; 14741326; 14743210; 14744727; 14744758; 14744935; 14745598; 14749371; 14755251; 14756543; 14756544; 14757278; 14757832; 14759115; 14761400; 14764039; 14764457; 14960324; 14960327; 14961077; 14963330; 14964781; 14965474; 14966292; 14966293; 14967026; 14968111; 14976551; 14978302; 14981901; 14982997; 14986171; 14990579; 14991543; 14992692; 14993250; 14994997; 14995078; 14997055; 15001356; 15001357; 15004035; 15015569; 15016620; 15016801; 15017387; 15018706; 15023836; 15026322; 15029243; 15033690; 15033824; 15033825; 15033827; 15036661; 15036662; 15037740; 15039530; 15041222; 15041737; 15042092; 15044383; 15047823; 15050687; 15052934; 15052938; 15053879; 15058298; 15059885; 15060172; 15061204; 15064416; 15064706; 15064727; 15064730; 15064742; 15064747; 15067011; 15067062; 15069555; 15069711; 15073118; 15073170; 15077116; 15077166; 15077194; 15078178; 15081425; 15082766; 15087457; 15088070; 15094062; 15095978; 15099937; 15099969; 15102863; 15103385; 15104366; 15105048; 15111320; 15116093; 15116098; 15116721; 15120697; 15121773; 15123817; 15131018; 15131588; 15133049; 15136035; 15138483; 15140517; 15140942; 15142382; 15144954; 15145278; 15145527; 15145929; 15149157; 15149158; 15149599; 15149862; 15153330; 15155458; 15155568; 15158001; 15159397; 15161716; 15168247; 15170665; 15175154; 15177663; 15178678; 15183530; 15183535; 15183536; 15186775; 15187095; 15192123; 15195682; 15199132; 15199139; 15199150; 15201954; 15201971; 15201979; 15202001; 15208672; 15210108; 15216398; 15218947; 15220443; 15222050; 15225550; 15225611; 15226443; 15230885; 15231748; 15240512; 15242646; 15247280; 15254240; 15254760; 15256442; 15256449; 15257943; 15262986; 15263792; 15272143; 15273281; 15273725; 15273730; 15279793; 15280377; 15282313; 15284248; 15284293; 15284338; 15286711; 15291355; 15292938; 15295102; 15297421; 15297424; 15299072; 15302882; 15304330; 15308643; 15310147; 15310756; 15310764; 15313891; 15314173; 15314174; 15314287; 15320716; 15321712; 15324660; 15327968; 15331571; 15331608; 15334053; 15334064; 15334668; 15337531; 15337767; 15339933; 15340061; 15341441; 15342238; 15342377; 15350302; 15351976; 15353294; 15355915; 15355990; 15358177; 15358195; 15358233; 15358769; 15358771; 15359011; 15361841; 15364927; 15364958; 15365822; 15367600; 15367885; 15371422; 15371445; 15371598; 15373786; 15377670; 15378004; 15378026; 15381368; 15383276; 15386362; 15386430; 15388813; 15390294; 15448009; 15448010; 15450681; 15456759; 15456784; 15466207; 15467428; 15469934; 15469940; 15471885; 15472230; 15474092; 15485928; 15488761; 15489334; 15489903; 15492790; 15497017; 15498930; 15500550; 15509522; 15509555; 15509808; 15510160; 15523694; 15525514; 15525938; 15531928; 15532030; 15533911; 15534883; 15534934; 15536084; 15537749; 15538975; 15539839; 15539956; 15542844; 15545228; 15545268; 15548678; 15548685; 15548700; 15550400; 15554555; 15555357; 15557124; 15557758; 15558054; 15563462; 15564800; 15566643; 15569630; 15571721; 15573180; 15574328; 15574785; 15576338; 15577913; 15577914; 15577944; 15578720; 15580300; 15580302; 15580310; 15582998; 15583690; 15583825; 15592418; 15598783; 15601585; 15604276; 15604409; 15606307; 15607964; 15608028; 15608668; 15609309; 15609317; 15611070; 15611139; 15613472; 15616590; 15621215; 15623478; 15629713; 15632057; 15632067; 15632413; 15633234; 15634502; 15634909; 15638389; 15639342; 15642401; 15642743; 15644269; 15645452; 15647482; 15650224; 15651660; 15654624; 15657147; 15657348; 15657356; 15659406; 15659650; 15660129; 15661746; 15664194; 15670080; 15670751; 15671037; 15671551; 15674334; 15674341; 15674351; 15680394; 15683227; 15688025; 15688418; 15696860; 15701641; 15701968; 15701975; 15702478; 15703170; 15704837; 15705792; 15705871; 15707991; 15709766; 15710230; 15710329; 15710382; 15713654; 15713979; 15719270; 15720412; 15721419; 15723718; 15723837; 15731778; 15734290; 15734740; 15734961; 15735003; 15735006; 15735102; 15735750; 15735814; 15741235; 15748509; 15750621; 15752352; 15752772; 15753095; 15756275; 15756520; 15764300; 15764647; 15765147; 15770529; 15772596; 15774209; 15775976; 15777220; 15777783; 15778501; 15780936; 15780941; 15781620; 15782125; 15782130; 15790310; 15790808; 15791651; 15793143; 15795472; 15796908; 15798209; 15800978; 15802048; 15802278; 15806145; 15808506; 15811121; 15814626; 15816455; 15816541; 15819981; 15824059; 15824734; 15824742; 15830705; 15831478; 15832422; 15832769; 15833845; 15835821; 15837541; 15838728; 15839202; 15841715; 15843377; 15844595; 15844633; 15846069; 15846088; 15848166; 15848594; 15849742; 15850555; 15851479; 15851483; 15855171; 15856024; 15862297; 15865924; 15865925; 15865935; 15866118; 15867431; 15876864; 15878620; 15882069; 15882981; 15888975; 15896780; 15899386; 15900046; 15902285; 15902745; 15905198; 15905205; 15905603; 15906354; 15906362; 15907477; 15908423; 15911628; 15913547; 15916722; 15916963; 15916964; 15917304; 15917726; 15923428; 15923430; 15925988; 15927816; 15931224; 15933712; 15933740; 15937335; 15940268; 15941720; 15942083; 15942101; 15943041; 15943410; 15945132; 15950766; 15950904; 15950944; 15958551; 15958617; 15960923; 15960975; 15961390; 15963787; 15964625; 15964795; 15966238; 15967108; 15977174; 15979781; 15981097; 15981211; 15987456; 15989956; 15989967; 15991278; 15993272; 15993843; 15996546; 15998523; 15998635; 16003391; 16004824; 16005638; 16007146; 16007153; 16007163; 16007417; 16009130; 16009172; 16012716; 16014569; 16023600; 16024113; 16024788; 16024799; 16030116; 16033823; 16033918; 16037820; 16038035; 16039051; 16043423; 16045761; 16046401; 16051302; 16054204; 16055707; 16055726; 16061649; 16061860; 16077963; 16077965; 16080524; 16082197; 16082221; 16082224; 16082226; 16088313; 16091363; 16094360; 16094622; 16101161; 16103461; 16103882; 16105547; 16105905; 16107691; 16107692; 16107721; 16107876; 16109171; 16110022; 16111803; 16112647; 16121365; 16122737; 16122882; 16125276; 16125822; 16128105; 16129609; 16129685; 16131611; 16131817; 16140998; 16142332; 16142358; 16142387; 16144912; 16151013; 16151725; 16158057; 16159876; 16159878; 16161633; 16163384; 16168122; 16168468; 16169070; 16169726; 16170349; 16172235; 16172461; 16174251; 16177659; 16183105; 16186805; 16189514; 16199549; 16200870; 16202543; 16203738; 16203772; 16203773; 16204849; 16207712; 16211227; 16212876; 16212962; 16219768; 16226255; 16227609; 16227626; 16228292; 16229746; 16230356; 16230424; 16243804; 16243918; 16246554; 16246896; 16247442; 16248462; 16249378; 16251187; 16255765; 16255923; 16256294; 16258005; 16258285; 16260623; 16264229; 16264230; 16268414; 16270158; 16271069; 16272802; 16273189; 16273227; 16273238; 16273653; 16278683; 16283431; 16286925; 16287156; 16289503; 16289646; 16289694; 16291740; 16293623; 16293709; 16297369; 16299809; 16301995; 16302680; 16308474; 16313886; 16314399; 16314418; 16314517; 16318864; 16322227; 16322335; 16322561; 16325212; 16327987; 16328005; 16331344; 16331559; 16331566; 16337599; 16343421; 16343438; 16344056; 16344560; 16351648; 16352595; 16353134; 16354195; 16354677; 16354872; 16358373; 16360120; 16362795; 16364249; 16376338; 16376884; 16376985; 16377624; 16380082; 16380088; 16397624; 16398049; 16402859; 16407418; 16412606; 16415881; 16416221; 16418181; 16418264; 16418486; 16419081; 16430884; 16432196; 16432214; 16432227; 16434591; 16434604; 16436515; 16438982; 16440000; 16442531; 16442532; 16443602; 16446369; 16446403; 16447252; 16448675; 16448698; 16449651; 16449974; 16455050; 16455055; 16455125; 16458330; 16458891; 16458962; 16459017; 16461914; 16461916; 16462759; 16462765; 16463673; 16465622; 16469747; 16474133; 16474402; 16477330; 16479062; 16481301; 16482425; 16482544; 16485142; 16487937; 16488468; 16489069; 16489641; 16492679; 16492918; 16493710; 16494995; 16499995; 16501611; 16504179; 16506220; 16507123; 16507995; 16513254; 16516153; 16518869; 16521213; 16524972; 16525651; 16525665; 16525684; 16529749; 16530164; 16530191; 16531411; 16532027; 16533178; 16537920; 16541312; 16542834; 16543236; 16546135; 16547496; 16547498; 16548519; 16551852; 16552184; 16552814; 16554913; 16569330; 16569765; 16579792; 16581806; 16582589; 16582625; 16582880; 16595680; 16598767; 16600182; 16601678; 16601686; 16601753; 16601838; 16609366; 16611260; 16611888; 16611991; 16616141; 16616891; 16619038; 16619042; 16620772; 16620878; 16621805; 16624812; 16624822; 16625286; 16629527; 16631474; 16636310; 16636674; 16644204; 16646561; 16651519; 16652373; 16677609; 16678111; 16678112; 16681440; 16682429; 16682816; 16682957; 16684540; 16685387; 16686942; 16687402; 16690525; 16690937; 16691626; 16696307; 16697770; 16697957; 16698048; 16699611; 16704422; 16705155; 16705183; 16708390; 16713569; 16714289; 16717128; 16721749; 16721787; 16723121; 16728565; 16728594; 16729031; 16736613; 16737921; 16738336; 16739124; 16739339; 16740634; 16741250; 16741917; 16741955; 16741990; 16750013; 16751805; 16753148; 16754663; 16760300; 16760301; 16761419; 16773083; 16773719; 16777982; 16777989; 16777994; 16778101; 16778203; 16778209; 16782868; 16784539; 16785993; 16786124; 16786570; 16788846; 16793543; 16797751; 16798743; 16799632; 16799873; 16803902; 16808798; 16810312; 16810754; 16814250; 16815295; 16818665; 16818696; 16818855; 16820091; 16821145; 16825434; 16827139; 16827804; 16830793; 16835330; 16835507; 16839413; 16844765; 16845383; 16847267; 16847809; 16847810; 16855398; 16858402; 16860930; 16861890; 16864176; 16865671; 16867217; 16869745; 16870621; 16872365; 16875676; 16880779; 16888811; 16893887; 16894028; 16896365; 16897187; 16897432; 16905769; 16909101; 16909106; 16912209; 16912210; 16912213; 16912290; 16912307; 16916644; 16916716; 16917063; 16917513; 16918502; 16918534; 16919027; 16920112; 16924229; 16924240; 16928824; 16930536; 16930632; 16931761; 16936264; 16937443; 16941491; 16943578; 16948516; 16951143; 16951228; 16951253; 16951290; 16959223; 16959611; 16963839; 16964264; 16969087; 16969106; 16969499; 16972754; 16973168; 16980608; 16982033; 16983332; 16983338; 16983346; 16984108; 16984978; 16988471; 16988840; 16989164; 16990795; 16996204; 17000754; 17000756; 17001034; 17001315; 17007666; 17009393; 17010455; 17012228; 17012841; 17013801; 17014845; 17014852; 17018618; 17018785; 17028100; 17030796; 17041757; 17043663; 17050670; 17050675; 17050687; 17054774; 17054906; 17055453; 17056014; 17059853; 17060450; 17060456; 17060459; 17060721; 17062677; 17063386; 17064470; 17065008; 17065198; 17066464; 17069461; 17070499; 17072987; 17077087; 17077165; 17079356; 17080083; 17080554; 17082593; 17084966; 17085012; 17085447; 17091766; 17093398; 17094395; 17096342; 17096406; 17097318; 17098746; 17101792; 17102589; 17105820; 17106238; 17106255; 17106521; 17106522; 17107393; 17108107; 17108971; 17110336; 17110929; 17113101; 17113725; 17116689; 17118779; 17118968; 17119852; 17120592; 17121812; 17121821; 17130833; 17130838; 17131388; 17132229; 17135243; 17136003; 17139261; 17143016; 17145812; 17146433; 17149973; 17150106; 17151828; 17151932; 17157788; 17158854; 17158927; 17159902; 17161371; 17170702; 17170736; 17171684; 17172844; 17172861; 17172869; 17174923; 17177838; 17178878; 17180249; 17184779; 17186020; 17186536; 17188136; 17189186; 17189187; 17198188; 17198452; 17198740; 17200338; 17203247; 17208332; 17213797; 17214516; 17214517; 17214880; 17216584; 17221157; 17223878; 17224235; 17224908; 17227108; 17229476; 17230496; 17234448; 17234468; 17234915; 17236590; 17237848; 17242401; 17244920; 17245430; 17252199; 17254968; 17259658; 17264218; 17264673; 17268548; 17269744; 17270093; 17272277; 17274640; 17275163; 17276397; 17280505; 17284368; 17289842; 17289876; 17290218; 17291568; 17294448; 17297477; 17298945; 17301054; 17301252; 17301692; 17302414; 17306604; 17308083; 17309603; 17310253; 17310847; 17310850; 17310983; 17317670; 17317671; 17317953; 17318340; 17319790; 17326708; 17328050; 17332323; 17332328; 17332504; 17336302; 17339230; 17339337; 17341484; 17347673; 17349958; 17349959; 17350573; 17350822; 17351129; 17353187; 17353266; 17354237; 17354442; 17360176; 17360476; 17360541; 17361096; 17363555; 17364023; 17369602; 17369817; 17369843; 17371838; 17372198; 17374954; 17374967; 17380123; 17380154; 17383050; 17383977; 17387044; 17387280; 17387621; 17388661; 17390010; 17390041; 17390072; 17393088; 17395153; 17397394; 17397945; 17400331; 17400332; 17401423; 17401424; 17401425; 17401427; 17401428; 17401429; 17401430; 17401431; 17401432; 17403527; 17403783; 17404594; 17406354; 17406801; 17409195; 17409234; 17409384; 17409407; 17409824; 17409930; 17412337; 17417627; 17417775; 17419939; 17426439; 17426704; 17426708; 17427234; 17428325; 17429838; 17434128; 17436385; 17437012; 17438265; 17447881; 17449902; 17452332; 17452980; 17460193; 17460194; 17461446; 17465990; 17471233; 17474797; 17477370; 17478762; 17482142; 17487454; 17488272; 17488404; 17488735; 17488820; 17490723; 17490733; 17492690; 17494866; 17495352; 17497677; 17498291; 17499344; 17499812; 17500067; 17504383; 17504512; 17504517; 17505880; 17510313; 17511743; 17513604; 17513613; 17515610; 17516921; 17518987; 17523278; 17525743; 17530187; 17531965; 17533375; 17534149; 17535811; 17535973; 17536310; 17537232; 17538794; 17540598; 17540599; 17541742; 17544001; 17544403; 17545048; 17545525; 17545546; 17545619; 17545634; 17546054; 17546594; 17548471; 17549665; 17549699; 17554199; 17554370; 17555331; 17556661; 17557246; 17557566; 17562177; 17564309; 17564316; 17565818; 17565819; 17567589; 17567834; 17567906; 17568776; 17569660; 17573896; 17573955; 17574348; 17575133; 17575320; 17575952; 17576382; 17581420; 17581423; 17582679; 17584297; 17584785; 17586686; 17587242; 17591690; 17592964; 17593217; 17593335; 17595776; 17597242; 17598983; 17599045; 17599062; 17599613; 17599946; 17604627; 17606709; 17607506; 17609875; 17611691; 17612295; 17612495; 17613764; 17616526; 17616578; 17616658; 17616682; 17620186; 17620598; 17622940; 17624591; 17624602; 17627287; 17628545; 17630509; 17630510; 17630511; 17630856; 17631738; 17631895; 17634554; 17634560; 17636382; 17638885; 17638920; 17640893; 17641416; 17642181; 17646389; 17650224; 17651038; 17651710; 17652955; 17653608; 17653713; 17656095; 17656250; 17656254; 17659731; 17662641; 17663418; 17663506; 17665040; 17666403; 17666433; 17671118; 17671422; 17671694; 17671760; 17671841; 17676397; 17676485; 17678892; 17683073; 17683074; 17684018; 17684142; 17684496; 17688945; 17689819; 17690113; 17690688; 17692090; 17692879; 17693405; 17693666; 17694537; 17694957; 17695524; 17696741; 17698841; 17699158; 17699779; 17700029; 17700068; 17701148; 17701916; 17703463; 17704262; 17704809; 17704924; 17707234; 17709345; 17709397; 17709727; 17713095; 17716930; 17719241; 17719541; 17719542; 17721438; 17721920; 17724467; 17727479; 17728781; 17761206; 17762884; 17763087; 17767549; 17785079; 17785449; 17785557; 17786186; 17803295; 17804489; 17804819; 17805299; 17805549; 17823933; 17827154; 17828505; 17848143; 17848574; 17849423; 17849424; 17850928; 17854663; 17855337; 17855516; 17869221; 17875722; 17875924; 17878219; 17879942; 17879958; 17881637; 17886559; 17890905; 17891181; 17897950; 17897960; 17898049; 17900613; 17900801; 17905135; 17906639; 17907599; 17908790; 17908953; 17908957; 17908995; 17909016; 17909070; 17910948; 17912039; 17912449; 17912468; 17913397; 17914225; 17914240; 17914575; 17914590; 17916908; 17917588; 17918160; 17918207; 17919692; 17920683; 17925548; 17927872; 17931634; 17932356; 17932466; 17934643; 17935714; 17936556; 17936559; 17936560; 17936562; 17938176; 17938203; 17938582; 17939878; 17942278; 17942552; 17942889; 17949449; 17949684; 17952118; 17952123; 17954263; 17954561; 17957137; 17957141; 17957444; 17960397; 17962810; 17964266; 17965547; 17967874; 17968145; 17970074; 17970695; 17971485; 17972508; 17974918; 17974978; 17975013; 17975552; 17977211; 17977830; 17979566; 17980001; 17980096; 17981213; 17981542; 17982131; 17982487; 17982488; 17982625; 17982649; 17982662; 17983802; 17984062; 17984111; 17989721; 17990259; 17991895; 17996705; 17998337; 18000166; 18003626; 18003932; 18006764; 18006810; 18008140; 18019675; 18019682; 18021213; 18021719; 18022393; 18024870; 18025081; 18025460; 18026119; 18026140; 18026859; 18032786; 18035414; 18035504; 18036557; 18038118; 18038880; 18040854; 18041310; 18042465; 18042550; 18048390; 18049450; 18050226; 18056407; 18058229; 18058461; 18059320; 18059557; 18060030; 18061646; 18063429; 18065756; 18067229; 18067855; 18068527; 18071310; 18076421; 18080767; 18084613; 18084622; 18086682; 18087040; 18087215; 18088187; 18088404; 18089646; 18089732; 18089808; 18089819; 18091325; 18091326; 18092951; 18094375; 18094376; 18095132; 18097574; 18097575; 18158568; 18158619; 18159026; 18159160; 18159231; 18160400; 18160537; 18161363; 18161655; 18161662; 18162465; 18164407; 18165800; 18172257; 18172499; 18172861; 18174288; 18176677; 18176964; 18181044; 18184270; 18184456; 18187663; 18189286; 18191951; 18193166; 18197409; 18199527; 18199985; 18202704; 18205229; 18206965; 18208354; 18208803; 18211920; 18215142; 18215742; 18216278; 18219279; 18220274; 18221322; 18223210; 18223555; 18223681; 18223694; 18225585; 18226366; 18226502; 18230133; 18230179; 18230337; 18230339; 18234542; 18234963; 18234968; 18235223; 18235501; 18235502; 18238895; 18240345; 18242117; 18243116; 18246126; 18248785; 18249029; 18249187; 18250140; 18250150; 18251181; 18256523; 18256893; 18258596; 18258602; 18259947; 18260640; 18262501; 18264133; 18264135; 18265644; 18267949; 18268127; 18269649; 18270270; 18270339; 18271758; 18271927; 18272203; 18280004; 18280244; 18280645; 18281248; 18281511; 18282133; 18288414; 18289041; 18291097; 18291388; 18292944; 18294283; 18296270; 18296503; 18296650; 18296737; 18297513; 18299245; 18299254; 18303029; 18305112; 18306460; 18309296; 18310316; 18313840; 18313915; 18314181; 18314481; 18314620; 18314877; 18316600; 18317451; 18318116; 18322392; 18322661; 18323654; 18325917; 18327303; 18330257; 18330473; 18330889; 18331287; 18331779; 18332046; 18332869; 18334006; 18334838; 18334933; 18335551; 18336191; 18336951; 18337559; 18339852; 18342932; 18343205; 18343378; 18345033; 18347195; 18348141; 18348286; 18349850; 18353898; 18354501; 18355840; 18356162; 18357466; 18359760; 18359851; 18361427; 18363031; 18363968; 18365550; 18367096; 18367114; 18367825; 18369088; 18372207; 18372914; 18374497; 18374905; 18375498; 18376314; 18379354; 18381604; 18382127; 18383208; 18383819; 18385154; 18385383; 18386191; 18386458; 18390474; 18390844; 18391200; 18391982; 18391985; 18391986; 18393224; 18393238; 18397889; 18398703; 18400748; 18402691; 18402767; 18403641; 18409045; 18410249; 18413751; 18414054; 18415014; 18415123; 18418048; 18418052; 18418864; 18419600; 18420787; 18423915; 18424783; 18425350; 18425358; 18425359; 18425390; 18426907; 18426989; 18433491; 18434539; 18438339; 18439434; 18451145; 18451149; 18452430; 18452596; 18453682; 18453734; 18454140; 18454141; 18454316; 18455580; 18455581; 18458532; 18459109; 18462472; 18464525; 18465328; 18465329; 18465330; 18467159; 18467333; 18468835; 18469003; 18469517; 18471974; 18472002; 18472962; 18476631; 18477214; 18480060; 18481172; 18482988; 18483253; 18485870; 18487080; 18490454; 18493017; 18494939; 18495777; 18497562; 18498065; 18498133; 18499678; 18502749; 18504427; 18504456; 18505818; 18505846; 18505928; 18507052; 18509272; 18510673; 18510931; 18511570; 18511705; 18511948; 18512237; 18513854; 18516295; 18516322; 18518978; 18519039; 18519672; 18524770; 18528419; 18536020; 18540692; 18541673; 18547443; 18547741; 18547962; 18548093; 18549475; 18549481; 18552821; 18552833; 18555516; 18555592; 18555750; 18559494; 18559976; 18560357; 18561741; 18561747; 18567547; 18568671; 18569579; 18571704; 18572327; 18573881; 18574470; 18580072; 18583933; 18583979; 18585004; 18593932; 18593934; 18593981; 18594472; 18594537; 18595518; 18596741; 18600534; 18602353; 18602486; 18604737; 18606525; 18607537; 18607961; 18608210; 18609695; 18612219; 18612383; 18612801; 18614011; 18616513; 18616935; 18617062; 18618574; 18619950; 18621066; 18621913; 18622497; 18624398; 18625714; 18628487; 18628956; 18630481; 18631247; 18632130; 18635530; 18635961; 18638452; 18639375; 18639569; 18640142; 18640487; 18640791; 18641418; 18642075; 18644983; 18645275; 18646041; 18646516; 18647660; 18650397; 18651966; 18656471; 18656689; 18661100; 18662989; 18665932; 18666234; 18667022; 18669630; 18670315; 18676680; 18676755; 18677110; 18677113; 18681908; 18681909; 18682598; 18685109; 18688630; 18688713; 18689267; 18689542; 18691182; 18692035; 18695251; 18697203; 18700251; 18701437; 18701504; 18705766; 18706692; 18712678; 18713157; 18714189; 18714371; 18714402; 18714570; 18715257; 18715757; 18716061; 18717684; 18718914; 18719371; 18719376; 18719392; 18719612; 18724893; 18724895; 18725978; 18728663; 18752044; 18753141; 18756595; 18757082; 18757425; 18758183; 18758421; 18758819; 18762572; 18765292; 18765668; 18769132; 18775696; 18775730; 18775979; 18779317; 18779328; 18781154; 18781178; 18786442; 18787404; 18788631; 18789822; 18791921; 18792899; 18793611; 18794809; 18798277; 18798306; 18799058; 18802408; 18803266; 18803879; 18812169; 18813348; 18813780; 18813817; 18813857; 18814047; 18815136; 18818514; 18818522; 18818700; 18819919; 18820009; 18820708; 18821037; 18823025; 18823952; 18824006; 18829023; 18829268; 18829481; 18830263; 18831896; 18833288; 18833293; 18835622; 18838865; 18840612; 18840648; 18841476; 18842998; 18843043; 18843282; 18846217; 18850004; 18852884; 18853251; 18854777; 18856068; 18923929; 18924150; 18930016; 18930193; 18937320; 18948382; 18948956; 18949380; 18949386; 18949611; 18949740; 18949744; 18950845; 18951086; 18953830; 18954551; 18957720; 18959757; 18971636; 18972317; 18974396; 18974932; 18978339; 18978812; 18979157; 18983962; 18988302; 18988897; 18989156; 18989634; 18990008; 18990748; 18991686; 18992151; 18996371; 18996393; 18997816; 19001376; 19001415; 19001852; 19002614; 19003964; 19005564; 19010591; 19011621; 19011633; 19011642; 19015633; 19016757; 19018238; 19019173; 19020308; 19020536; 19020758; 19020764; 19020765; 19022222; 19023333; 19026164; 19026165; 19026650; 19027352; 19029147; 19029954; 19031258; 19033382; 19033390; 19033443; 19034233; 19034270; 19034345; 19034659; 19035176; 19035278; 19040285; 19043414; 19046423; 19046801; 19047144; 19048115; 19048399; 19048622; 19050681; 19052714; 19052872; 19054132; 19060337; 19060923; 19060927; 19061288; 19063876; 19064568; 19064572; 19064990; 19065343; 19065760; 19065769; 19067003; 19067849; 19071156; 19072763; 19074170; 19074876; 19074885; 19075013; 19076682; 19081178; 19082401; 19082441; 19082758; 19084918; 19084934; 19085961; 19086036; 19091459; 19091625; 19092295; 19094228; 19096301; 19096302; 19096907; 19097418; 19098008; 19098288; 19098711; 19100519; 19100681; 19102934; 19103203; 19106109; 19106603; 19106616; 19107228; 19115684; 19116388; 19117984; 19119599; 19121375; 19124506; 19125417; 19127094; 19129997; 19136058; 19137883; 19138991; 19141386; 19141397; 19141477; 19141643; 19144715; 19145674; 19146679; 19146777; 19147537; 19147582; 19148546; 19151620; 19151662; 19151705; 19151774; 19153082; 19153488; 19155088; 19157504; 19158830; 19158844; 19159630; 19160064; 19160092; 19160491; 19165225; 19165858; 19166313; 19166840; 19170058; 19170196; 19171829; 19178978; 19180570; 19182148; 19184427; 19187116; 19188449; 19190338; 19193430; 19195690; 19196987; 19197340; 19198855; 19199318; 19201468; 19201868; 19202062; 19203586; 19204208; 19204927; 19208263; 19208740; 19209008; 19210572; 19211769; 19212102; 19212643; 19212663; 19214186; 19214744; 19216023; 19217035; 19217357; 19217391; 19217709; 19218448; 19219073; 19219602; 19220000; 19220422; 19220630; 19221500; 19223463; 19223905; 19224462; 19224585; 19225112; 19225536; 19228762; 19229245; 19232460; 19234109; 19234438; 19234440; 19237173; 19237606; 19237633; 19238535; 19239324; 19242059; 19242126; 19243472; 19244234; 19244339; 19245247; 19245591; 19246003; 19246451; 19246647; 19247656; 19248224; 19248552; 19249676; 19252416; 19255450; 19258312; 19261598; 19261747; 19263877; 19264955; 19265193; 19265551; 19267881; 19267931; 19269198; 19270098; 19270646; 19273588; 19273598; 19273710; 19274075; 19275583; 19276375; 19276448; 19276551; 19277210; 19279387; 19286843; 19286999; 19287195; 19287463; 19287958; 19289498; 19291875; 19292788; 19293287; 19294769; 19295915; 19296337; 19297317; 19298746; 19302219; 19303885; 19305137; 19305147; 19305157; 19307610; 19309322; 19318089; 19318491; 19321440; 19330026; 19331830; 19332559; 19336552; 19336573; 19337030; 19339270; 19339276; 19339993; 19342895; 19343786; 19344876; 19345189; 19346874; 19346994; 19347028; 19347736; 19347737; 19348791; 19351493; 19351817; 19351845; 19357310; 19357867; 19357962; 19358278; 19358752; 19363521; 19364824; 19366810; 19366907; 19367277; 19367287; 19367569; 19367581; 19373781; 19375154; 19375220; 19376640; 19376776; 19377286; 19377293; 19377469; 19378321; 19380588; 19382257; 19383392; 19383811; 19384064; 19386249; 19389934; 19394062; 19398576; 19398950; 19403344; 19405127; 19410540; 19411067; 19411634; 19414295; 19414363; 19414370; 19416725; 19416861; 19419935; 19423162; 19423538; 19426493; 19427386; 19428372; 19428789; 19429664; 19430562; 19432615; 19432880; 19433585; 19434453; 19434633; 19434759; 19435786; 19435816; 19435914; 19437562; 19440053; 19443408; 19448592; 19448627; 19448667; 19448675; 19451550; 19451596; 19452712; 19458054; 19461506; 19465063; 19465901; 19467764; 19468865; 19470478; 19470788; 19471604; 19473449; 19473450; 19473992; 19479602; 19482343; 19483087; 19486858; 19487292; 19488782; 19491257; 19493415; 19494119; 19499352; 19500100; 19503094; 19505151; 19505873; 19505915; 19506726; 19507240; 19507255; 19509300; 19509332; 19513497; 19513503; 19513627; 19515076; 19515722; 19521340; 19521721; 19521985; 19523860; 19523975; 19525231; 19527492; 19536092; 19536131; 19536170; 19538885; 19540192; 19541822; 19541923; 19541936; 19542078; 19543244; 19543321; 19543839; 19543899; 19544111; 19548527; 19550118; 19550124; 19551350; 19551637; 19556538; 19556618; 19556892; 19558213; 19558368; 19558493; 19558663; 19560264; 19563416; 19565339; 19565930; 19567200; 19567674; 19571709; 19573080; 19574718; 19575869; 19576684; 19577853; 19578553; 19580479; 19580521; 19580641; 19581934; 19582475; 19583749; 19584398; 19585117; 19586936; 19588484; 19589272; 19590512; 19594747; 19596263; 19597154; 19597352; 19597886; 19602056; 19602465; 19602589; 19604078; 19605487; 19608020; 19608668; 19608766; 19609560; 19609950; 19615732; 19617345; 19619279; 19619542; 19619545; 19621295; 19622832; 19623649; 19625176; 19625214; 19626115; 19626602; 19628749; 19629483; 19629678; 19638413; 19638426; 19639181; 19639206; 19639960; 19640329; 19642109; 19642869; 19643719; 19643729; 19643813; 19643983; 19646415; 19648117; 19648965; 19649205; 19649206; 19650989; 19651615; 19654313; 19656744; 19657064; 19657586; 19657726; 19657731; 19657752; 19661141; 19662811; 19664338; 19664395; 19665069; 19665071; 19666408; 19667129; 19667193; 19667403; 19668210; 19669908; 19670804; 19671681; 19672255; 19672706; 19672874; 19676105; 19676140; 19680556; 19681600; 19682377; 19683495; 19684601; 19684617; 19687314; 19688691; 19690760; 19690970; 19692106; 19692168; 19693693; 19693773; 19694823; 19696742; 19700401; 19701195; 19704056; 19706164; 19706526; 19707196; 19713765; 19713960; 19714248; 19714488; 19714490; 19716362; 19718045; 19718052; 19718455; 19723039; 19723045; 19723057; 19723065; 19723092; 19723093; 19723643; 19724860; 19727814; 19730444; 19730774; 19731416; 19732026; 19737973; 19738459; 19739123; 19748360; 19748724; 19749791; 19750108; 19751190; 19756158; 19756449; 19759023; 19759556; 19760041; 19760750; 19764997; 19766185; 19766654; 19771536; 19772793; 19773259; 19773279; 19773383; 19774948; 19776115; 19777343; 19777616; 19777788; 19779722; 19783986; 19784069; 19784392; 19786090; 19786980; 19787241; 19787255; 19787260; 19787269; 19787626; 19789190; 19794270; 19794957; 19797274; 19798104; 19799083; 19799611; 19800042; 19800395; 19800766; 19801173; 19801972; 19802006; 19802016; 19805223; 19805293; 19806023; 19806450; 19810096; 19811448; 19815500; 19815839; 19816195; 19816404; 19817904; 19818772; 19819244; 19822419; 19825993; 19826048; 19826414; 19828042; 19828454; 19832838; 19833129; 19836055; 19837266; 19837670; 19840791; 19842060; 19843866; 19846554; 19847292; 19850740; 19851197; 19851199; 19853019; 19853299; 19854077; 19854137; 19855378; 19855428; 19855935; 19857493; 19861417; 19861461; 19861536; 19862414; 19862502; 19863319; 19866438; 19875755; 19876867; 19877175; 19880522; 19881536; 19884837; 19885580; 19885592; 19885596; 19885698; 19887449; 19887606; 19887612; 19888426; 19889971; 19890398; 19890662; 19897582; 19897726; 19898227; 19900105; 19901969; 19903800; 19903847; 19909015; 19910580; 19911701; 19913028; 19913121; 19914341; 19916559; 19917135; 19918261; 19922265; 19923826; 19927155; 19930417; 19931552; 19932175; 19933157; 19933326; 19934289; 19939245; 19940524; 19940548; 19941079; 19941080; 19941302; 19941740; 19944185; 19945467; 19946469; 19948725; 19948727; 19948747; 19950209; 19950226; 19950227; 19951988; 19952118; 19952400; 19952748; 19952937; 19954513; 19954744; 19955396; 19955567; 19956635; 19956882; 19960433; 19963114; 19965871; 19966853; 19995558; 19996201; 19996275; 19996278; 20003326; 20003329; 20005840; 20006376; 20007968; 20009884; 20010306; 20010526; 20012564; 20015931; 20017137; 20017945; 20018398; 20018721; 20019182; 20019189; 20019240; 20021639; 20021828; 20023260; 20025073; 20025780; 20025891; 20026061; 20032382; 20036665; 20036807; 20040103; 20040571; 20043073; 20044243; 20044778; 20048189; 20049641; 20053357; 20056613; 20060114; 20061391; 20062014; 20062083; 20064378; 20064835; 20066118; 20070253; 20071335; 20071787; 20072654; 20075077; 20075707; 20075864; 20077225; 20080206; 20080630; 20081368; 20081802; 20082263; 20082479; 20082848; 20082853; 20082880; 20085806; 20089604; 20092957; 20093361; 20096117; 20096447; 20097875; 20098441; 20099418; 20101205; 20101219; 20101229; 20103649; 20104224; 20106900; 20110284; 20110711; 20112543; 20113324; 20118229; 20118233; 20121258; 20122174; 20122687; 20123963; 20123995; 20124405; 20124455; 20124456; 20126473; 20126990; 20127014; 20127977; 20129645; 20130056; 20130515; 20131498; 20134482; 20135637; 20137853; 20140870; 20140875; 20142252; 20142599; 20145147; 20145180; 20146885; 20153329; 20157532; 20157537; 20159018; 20159469; 20160010; 20160358; 20160496; 20167600; 20169661; 20172729; 20173098; 20174603; 20174854; 20175992; 20177397; 20177704; 20178585; 20179198; 20181625; 20182602; 20182617; 20182618; 20186124; 20189840; 20190571; 20190799; 20190805; 20190809; 20190820; 20190821; 20193563; 20193843; 20193851; 20195357; 20195506; 20197393; 20197462; 20198299; 20198344; 20198350; 20198607; 20200430; 20200435; 20202977; 20203688; 20204287; 20204299; 20212049; 20213049; 20213747; 20219101; 20219685; 20220765; 20221446; 20223820; 20225330; 20226664; 20227041; 20227286; 20228093; 20228809; 20228833; 20229506; 20231315; 20232390; 20233581; 20233677; 20233728; 20234175; 20234365; 20235143; 20236666; 20299546; 20301425; 20301488; 20301891; 20305378; 20306157; 20306449; 20306497; 20307547; 20308539; 20308559; 20308654; 20309662; 20309933; 20309940; 20331441; 20332106; 20332115; 20333547; 20335021; 20336668; 20346139; 20349288; 20350215; 20351271; 20352431; 20353948; 20357201; 20360478; 20361939; 20362227; 20362235; 20362557; 20363151; 20363586; 20364130; 20364585; 20368352; 20369488; 20370686; 20371617; 20372076; 20372800; 20372852; 20378837; 20380571; 20383190; 20383576; 20385091; 20385133; 20386703; 20388212; 20388487; 20388565; 20389250; 20392698; 20393600; 20395210; 20395212; 20398418; 20400479; 20400976; 20403997; 20404322; 20406462; 20407015; 20408960; 20412452; 20414055; 20414934; 20414935; 20417304; 20417621; 20418953; 20419384; 20421238; 20421506; 20422012; 20423464; 20427142; 20428765; 20428774; 20429933; 20432164; 20434805; 20435362; 20436704; 20442586; 20443055; 20443084; 20444664; 20448056; 20449797; 20452352; 20452958; 20452981; 20453000; 20453538; 20453859; 20455025; 20457152; 20457898; 20459648; 20463968; 20464958; 20465947; 20466628; 20466633; 20466735; 20470425; 20470934; 20471942; 20472336; 20473327; 20479273; 20480729; 20482847; 20482849; 20484049; 20491778; 20491788; 20491880; 20496165; 20496166; 20497343; 20499310; 20499313; 20501846; 20501855; 20504317; 20504344; 20504346; 20504360; 20504876; 20505364; 20506484; 20506947; 20510020; 20511662; 20512074; 20512840; 20513428; 20514446; 20514470; 20514505; 20515613; 20515749; 20519945; 20520707; 20520810; 20522432; 20524403; 20525364; 20529827; 20532936; 20534591; 20535124; 20536385; 20538734; 20541486; 20542001; 20542099; 20542620; 20542919; 20543135; 20544687; 20544688; 20547751; 20549370; 20551268; 20552298; 20552631; 20562907; 20562916; 20563922; 20564066; 20564491; 20566882; 20570891; 20570896; 20571075; 20575032; 20576604; 20577264; 20577896; 20579853; 20581473; 20581802; 20586629; 20587334; 20587415; 20587610; 20588255; 20589130; 20589832; 20591580; 20592345; 20593220; 20593380; 20594067; 20595817; 20597837; 20598361; 20599664; 20600004; 20600834; 20606085; 20606252; 20606732; 20607720; 20610713; 20614030; 20614336; 20615891; 20618441; 20619728; 20619763; 20622899; 20628086; 20628269; 20628283; 20629008; 20629644; 20630574; 20632071; 20633551; 20634494; 20638924; 20639885; 20644561; 20649542; 20652953; 20656324; 20658010; 20660729; 20661218; 20661667; 20662002; 20662834; 20663147; 20663916; 20664182; 20664183; 20669023; 20670604; 20673369; 20673990; 20675383; 20680659; 20682393; 20685653; 20686359; 20686376; 20688913; 20689556; 20696760; 20697090; 20699639; 20701069; 20702468; 20702634; 20706634; 20708154; 20712900; 20713054; 20713061; 20713460; 20714883; 20716666; 20719955; 20724842; 20728566; 20729006; 20730711; 20731606; 20731661; 20732856; 20734458; 20738752; 20798688; 20802181; 20803550; 20804729; 20805372; 20805487; 20807096; 20807181; 20808790; 20809021; 20809023; 20810912; 20811532; 20811663; 20811699; 20811700; 20811722; 20811949; 20813662; 20815042; 20816748; 20817676; 20818423; 20823770; 20824703; 20826787; 20827430; 20832539; 20832750; 20833636; 20837656; 20840860; 20842446; 20846124; 20847049; 20849464; 20849851; 20851891; 20855462; 20857345; 20858413; 20858735; 20861261; 20861852; 20861914; 20862247; 20862745; 20862982; 20864041; 20864684; 20868604; 20869096; 20870288; 20870725; 20870738; 20871609; 20871633; 20875869; 20876941; 20878061; 20878064; 20880178; 20880848; 20881002; 20884963; 20885946; 20886596; 20890425; 20922573; 20923779; 20930521; 20932800; 20935061; 20935395; 20935493; 20935676; 20935678; 20936988; 20937277; 20937856; 20939739; 20940029; 20944651; 20945503; 20947454; 20947501; 20947805; 20947822; 20948295; 20949558; 20951946; 20952436; 20952507; 20952509; 20953816; 20954283; 20955243; 20959462; 20959480; 20962272; 20962589; 20963515; 20967502; 20972454; 20972456; 20972462; 20974249; 20978130; 20978925; 20979814; 20979905; 20981655; 21033219; 21038427; 21041409; 21041410; 21042017; 21042708; 21042724; 21042727; 21042751; 21042757; 21042759; 21043833; 21046311; 21047201; 21048031; 21050851; 21051533; 21052841; 21054790; 21056547; 21056685; 21057505; 21057547; 21058037; 21060032; 21060154; 21061181; 21061796; 21062982; 21063465; 21068437; 21070477; 21071137; 21071676; 21072204; 21072901; 21073496; 21075072; 21075307; 21078665; 21078964; 21079653; 21080063; 21080251; 21081126; 21081666; 21084285; 21084564; 21085986; 21086258; 21088492; 21088494; 21092204; 21094160; 21098709; 21103049; 21108607; 21108931; 21109929; 21111452; 21112961; 21113594; 21115003; 21115891; 21115940; 21115975; 21116760; 21118481; 21120662; 21123835; 21124037; 21127074; 21127431; 21129811; 21130767; 21131755; 21132010; 21133638; 21135152; 21135996; 21136228; 21138557; 21140221; 21142704; 21146147; 21146529; 21146884; 21146886; 21147777; 21148311; 21148320; 21149449; 21149740; 21150319; 21156242; 21156285; 21156789; 21159183; 21161088; 21170034; 21170087; 21173028; 21174181; 21177815; 21178072; 21178074; 21183956; 21184030; 21185067; 21187340; 21187651; 21191186; 21191746; 21192060; 21192816; 21192925; 21194832; 21199790; 21199873; 21203526; 21205967; 21208455; 21211512; 21212262; 21212465; 21212516; 21225432; 21232794; 21233845; 21233847; 21233848; 21240456; 21242962; 21242964; 21245319; 21247336; 21248071; 21248301; 21248371; 21249215; 21251329; 21252575; 21261729; 21263241; 21264535; 21266458; 21268072; 21274377; 21278235; 21283750; 21284603; 21285945; 21286777; 21288114; 21289082; 21291320; 21293058; 21293287; 21295542; 21296169; 21297583; 21298377; 21300779; 21305319; 21306611; 21307660; 21308745; 21316118; 21316347; 21317290; 21317535; 21317560; 21317885; 21319261; 21323870; 21323960; 21323968; 21324396; 21324654; 21325068; 21325273; 21325409; 21325804; 21325822; 21327897; 21331359; 21331782; 21332394; 21334198; 21334717; 21335959; 21336307; 21336310; 21338495; 21338602; 21339197; 21343334; 21343879; 21344396; 21345471; 21346315; 21346816; 21348641; 21348943; 21350561; 21354936; 21356337; 21357744; 21358596; 21361779; 21362334; 21364582; 21364923; 21365326; 21376265; 21376395; 21378543; 21383020; 21383696; 21383700; 21386967; 21386980; 21388911; 21388952; 21390126; 21394211; 21396347; 21396915; 21397192; 21397859; 21402054; 21402876; 21403619; 21404058; 21404460; 21411755; 21418001; 21418191; 21419318; 21423215; 21424069; 21426305; 21427767; 21429301; 21435003; 21435506; 21438026; 21441093; 21443127; 21445056; 21445348; 21448428; 21448430; 21450905; 21451571; 21454483; 21454520; 21454683; 21454715; 21455220; 21457718; 21457722; 21457773; 21460037; 21460101; 21460846; 21461655; 21461980; 21462189; 21463115; 21463657; 21464733; 21465263; 21465532; 21465572; 21466614; 21467160; 21468597; 21469425; 21470402; 21471221; 21471252; 21472523; 21473292; 21474069; 21475306; 21477265; 21478094; 21478095; 21478550; 21478871; 21478910; 21478913; 21479369; 21480340; 21482671; 21482821; 21483000; 21483755; 21484410; 21484931; 21487039; 21488187; 21489989; 21493295; 21501231; 21503581; 21503588; 21506732; 21511729; 21513535; 21513714; 21514041; 21514416; 21515331; 21516123; 21517233; 21518729; 21518799; 21519010; 21519792; 21520998; 21521785; 21524306; 21526487; 21527506; 21528083; 21528672; 21530075; 21531726; 21531789; 21532285; 21532626; 21535365; 21536413; 21537838; 21539745; 21539808; 21541195; 21546086; 21547408; 21547915; 21548882; 21552135; 21552211; 21552291; 21553245; 21554918; 21557216; 21559393; 21561095; 21561866; 21562767; 21563216; 21565625; 21565979; 21566457; 21569770; 21570119; 21572037; 21572399; 21573174; 21573788; 21576488; 21586550; 21586571; 21595775; 21596316; 21597459; 21598212; 21598312; 21599513; 21600917; 21601526; 21601984; 21604156; 21606339; 21606432; 21607615; 21607949; 21608063; 21608079; 21611785; 21612408; 21615965; 21617227; 21618350; 21619452; 21621504; 21622854; 21623257; 21624367; 21624951; 21624955; 21625211; 21630092; 21637297; 21642657; 21642658; 21642980; 21658391; 21659476; 21659514; 21660944; 21660965; 21664839; 21665145; 21665181; 21665183; 21665242; 21665306; 21667122; 21668571; 21668955; 21670725; 21670726; 21671008; 21672450; 21675959; 21677540; 21678496; 21680522; 21682651; 21683812; 21685937; 21687937; 21688173; 21690062; 21691232; 21693655; 21694464; 21699775; 21700777; 21703625; 21704149; 21706156; 21708241; 21712378; 21713341; 21716161; 21717430; 21718492; 21719749; 21720382; 21720999; 21725357; 21726628; 21729169; 21731648; 21735667; 21738398; 21740549; 21741128; 21741598; 21742769; 21742773; 21743494; 21745313; 21747090; 21747166; 21747195; 21748595; 21750655; 21750659; 21753697; 21756282; 21756780; 21760960; 21761334; 21761402; 21764706; 21764762; 21764855; 21765464; 21765469; 21765936; 21768375; 21773947; 21775823; 21777146; 21778786; 21779982; 21780975; 21784522; 21785463; 21786090; 21786572; 21790217; 21790244; 21791603; 21792176; 21795694; 21796446; 21799424; 21801448; 21801713; 21802012; 21804386; 21804388; 21805040; 21808882; 21808961; 21809390; 21809666; 21810023; 21811225; 21811412; 21814224; 21820150; 21821029; 21823831; 21829513; 21831006; 21831840; 21833626; 21837677; 21837762; 21838531; 21841506; 21842249; 21844794; 21845536; 21845541; 21845734; 21852235; 21852383; 21852537; 21853057; 21857907; 21857971; 21857991; 21858191; 21862591; 21862876; 21866459; 21866568; 21867493; 21868761; 21875573; 21875946; 21878502; 21878508; 21879253; 21880462; 21880715; 21887275; 21887328; 21888455; 21890444; 21892170; 21892957; 21893597; 21896753; 21896987; 21896994; 21900206; 21900401; 21900752; 21901162; 21903092; 21903246; 21903579; 21903592; 21903770; 21907236; 21907315; 21907923; 21910968; 21911363; 21911423; 21915115; 21920989; 21921327; 21925390; 21925707; 21930790; 21931130; 21932578; 21933600; 21933903; 21937259; 21941086; 21941372; 21942715; 21943018; 21946351; 21947322; 21947346; 21952639; 21952824; 21953469; 21954601; 21956468; 21956786; 21962518; 21965653; 21965721; 21968188; 21971103; 21972713; 21973212; 21976716; 21978692; 21979461; 21979585; 21979593; 21979946; 21982800; 21986495; 21986947; 21988832; 21990067; 22002313; 22005259; 22006292; 22006999; 22008105; 22009029; 22013048; 22013068; 22020975; 22022355; 22022528; 22024162; 22024481; 22024503; 22025681; 22027593; 22028325; 22028823; 22032898; 22032922; 22032989; 22033326; 22033922; 22034226; 22037227; 22039050; 22040408; 22045851; 22046250; 22046379; 22047081; 22052190; 22052239; 22052359; 22052649; 22052707; 22052810; 22055193; 22057359; 22057681; 22057999; 22065914; 22067611; 22068033; 22071692; 22074660; 22075712; 22075982; 22077486; 22077956; 22081070; 22081073; 22083959; 22084066; 22085928; 22090360; 22096025; 22099172; 22099309; 22099934; 22101337; 22101376; 22103682; 22104152; 22105316; 22105368; 22109999; 22110125; 22110706; 22110707; 22114072; 22115592; 22116280; 22117079; 22118929; 22120717; 22123926; 22124156; 22124327; 22126203; 22127205; 22128038; 22129893; 22133803; 22134354; 22134502; 22134635; 22135025; 22139380; 22143931; 22144470; 22145567; 22147694; 22150335; 22154617; 22156152; 22157679; 22159450; 22159712; 22159872; 22160829; 22162658; 22165746; 22169637; 22170163; 22170717; 22171325; 22171791; 22172840; 22172947; 22174378; 22174681; 22174788; 22174876; 22176582; 22178617; 22179964; 22180176; 22184063; 22184120; 22184967; 22186996; 22187033; 22189267; 22189680; 22190353; 22192357; 22193543; 22194206; 22194619; 22197541; 22197810; 22198213; 22198284; 22198295; 22199279; 22199295; 22200742; 22200788; 22203015; 22203497; 22210468; 22210716; 22212723; 22213398; 22214662; 22214764; 22216266; 22216294; 22217266; 22217299; 22220854; 22223137; 22227409; 22227579; 22230478; 22230750; 22231431; 22233820; 22234063; 22235305; 22236162; 22242180; 22243433; 22244827; 22245141; 22246403; 22249259; 22249977; 22252757; 22253229; 22254155; 22258307; 22261536; 22262171; 22262183; 22262409; 22263566; 22264786; 22265402; 22265415; 22266186; 22266309; 22266850; 22266861; 22266868; 22267390; 22267755; 22275381; 22276141; 22277327; 22280536; 22282309; 22283740; 22286760; 22287741; 22289634; 22290440; 22291954; 22292621; 22293932; 22294769; 22299208; 22301190; 22302483; 22303479; 22309998; 22311583; 22319594; 22323293; 22324744; 22330136; 22331460; 22331725; 22334068; 22334079; 22334668; 22335907; 22335944; 22336889; 22336942; 22340598; 22345153; 22348878; 22349816; 22353881; 22354696; 22354970; 22357201; 22357944; 22361354; 22361592; 22362889; 22365966; 22366412; 22367371; 22370482; 22372375; 22373952; 22374402; 22374670; 22374672; 22376288; 22378745; 22381680; 22383394; 22384858; 22389383; 22389451; 22389628; 22391559; 22391565; 22392074; 22393962; 22395445; 22395499; 22395505; 22395508; 22396072; 22396451; 22398042; 22399500; 22401965; 22405092; 22406215; 22410433; 22410801; 22411991; 22416758; 22417132; 22417303; 22420423; 22421154; 22421763; 22422199; 22425911; 22427364; 22427654; 22427690; 22428663; 22430213; 22431589; 22431922; 22433872; 22434242; 22440256; 22440942; 22441365; 22444248; 22446329; 22446679; 22448750; 22451655; 22459764; 22459898; 22466965; 22467874; 22469844; 22479585; 22480684; 22483988; 22484427; 22487818; 22493095; 22495821; 22496369; 22499945; 22502699; 22503977; 22505350; 22508983; 22509368; 22510504; 22510560; 22510592; 22511763; 22514277; 22514644; 22515118; 22516242; 22523600; 22524816; 22525470; 22532853; 22534503; 22534828; 22540896; 22545084; 22546833; 22547059; 22548738; 22549273; 22549949; 22551440; 22551548; 22552282; 22555846; 22556425; 22562509; 22563078; 22564437; 22570471; 22574148; 22575263; 22575647; 22576742; 22577164; 22578566; 22579650; 22580601; 22586326; 22588298; 22588717; 22591662; 22592924; 22593196; 22593484; 22595792; 22607092; 22607702; 22609107; 22609129; 22609775; 22611192; 22611237; 22613405; 22615843; 22616991; 22621920; 22622028; 22624712; 22627629; 22628410; 22628563; 22631671; 22634494; 22641095; 22641442; 22647703; 22648906; 22652532; 22652861; 22653586; 22653678; 22659184; 22660439; 22664917; 22666537; 22668018; 22669068; 22669776; 22672907; 22673192; 22673234; 22675167; 22675170; 22675488; 22678923; 22683204; 22683628; 22685613; 22688387; 22689594; 22692183; 22696478; 22698402; 22698404; 22699455; 22700878; 22700930; 22706378; 22707142; 22710110; 22711357; 22712299; 22712728; 22714709; 22715097; 22723347; 22726440; 22728651; 22729835; 22729911; 22729912; 22730327; 22732402; 22733133; 22736329; 22737255; 22744426; 22747700; 22759751; 22761580; 22761954; 22763759; 22765508; 22768103; 22768805; 22772468; 22773013; 22773829; 22773839; 22777350; 22777358; 22777360; 22780299; 22782351; 22784258; 22787160; 22787161; 22790665; 22791815; 22797063; 22797073; 22797925; 22800615; 22801382; 22801474; 22802528; 22802529; 22803606; 22806321; 22807444; 22810507; 22811390; 22819212; 22819825; 22820403; 22824800; 22825821; 22825850; 22829776; 22829934; 22836579; 22841759; 22842154; 22843046; 22843172; 22844323; 22845047; 22847613; 22848370; 22851211; 22855178; 22855598; 22856646; 22859066; 22859294; 22859938; 22861165; 22862424; 22863952; 22864287; 22868530; 22869143; 22869710; 22869713; 22870275; 22874878; 22880004; 22886512; 22886602; 22886769; 22893124; 22894933; 22895816; 22898080; 22899716; 22899882; 22901123; 22901126; 22901221; 22902550; 22904680; 22905155; 22905229; 22906635; 22907436; 22908277; 22911014; 22911296; 22911849; 22912861; 22914606; 22914926; 22915551; 22915647; 22918438; 22919278; 22922869; 22923510; 22927405; 22927443; 22929185; 22933333; 22933706; 22934707; 22939624; 22941060; 22945757; 22948151; 22952705; 22955915; 22962266; 22964580; 22965952; 22965953; 22972749; 22975381; 22982291; 22983008; 22983585; 22984579; 22985798; 22989750; 22990118; 22990386; 22990545; 22991139; 22993345; 22994752; 22995373; 22998186; 22999923; 23009112; 23011884; 23012405; 23013791; 23020228; 23025236; 23026641; 23027126; 23028042; 23028800; 23029043; 23029260; 23034174; 23038753; 23040663; 23042265; 23042398; 23043633; 23045280; 23047509; 23049793; 23049825; 23052192; 23053979; 23054019; 23056559; 23060298; 23063560; 23065429; 23068099; 23071787; 23072722; 23073555; 23077249; 23079576; 23089923; 23092908; 23092970; 23095338; 23096687; 23100276; 23102701; 23102841; 23106581; 23110309; 23112865; 23114628; 23115335; 23118962; 23121011; 23124483; 23124863; 23125046; 23128792; 23129176; 23131771; 23133524; 23133535; 23134341; 23135266; 23139272; 23146687; 23148227; 23149933; 23150668; 23158659; 23159155; 23162013; 23165746; 23166734; 23167333; 23167335; 23167364; 23167810; 23168175; 23168703; 23168708; 23169665; 23170979; 23172776; 23175693; 23177619; 23178494; 23178529; 23178973; 23184057; 23187810; 23188674; 23192640; 23197232; 23199549; 23200676; 23201157; 23206596; 23207172; 23207289; 23208500; 23210340; 23210739; 23213260; 23214297; 23219661; 23220852; 23222509; 23224600; 23224642; 23228226; 23232572; 23235459; 23242140; 23242655; 23243274; 23243311; 23244080; 23246487; 23246812; 23246961; 23253087; 23255126; 23255232; 23255396; 23255406; 23259501; 23261415; 23261448; 23261524; 23262097; 23263379; 23268317; 23268330; 23268708; 23268996; 23269546; 23269799; 23272046; 23273944; 23273978; 23284306; 23285001; 23287481; 23287532; 23289390; 23291854; 23291982; 23291986; 23292286; 23292895; 23293969; 23297687; 23299342; 23306062; 23306555; 23313511; 23315175; 23316052; 23317197; 23317213; 23317414; 23317892; 23318437; 23318444; 23319048; 23319609; 23319651; 23324352; 23324739; 23328582; 23329847; 23335286; 23341181; 23341460; 23343762; 23343766; 23344532; 23354312; 23354912; 23356234; 23356517; 23356739; 23358872; 23359201; 23359294; 23360829; 23360998; 23361940; 23363223; 23370271; 23374541; 23376231; 23378270; 23379189; 23380758; 23382381; 23382584; 23383273; 23384026; 23386643; 23387809; 23388101; 23388179; 23388826; 23392172; 23397771; 23398456; 23401182; 23401530; 23402884; 23403321; 23404110; 23404342; 23404471; 23409163; 23412343; 23412385; 23416147; 23416275; 23416979; 23417151; 23421999; 23422071; 23423487; 23423975; 23429506; 23431171; 23433851; 23435014; 23435420; 23435461; 23437037; 23442362; 23447676; 23449391; 23451161; 23452320; 23453606; 23455382; 23455922; 23456460; 23462994; 23468244; 23470568; 23471665; 23472201; 23478443; 23482364; 23483203; 23483263; 23487038; 23487462; 23492369; 23492773; 23497522; 23499753; 23504554; 23507139; 23510323; 23514281; 23515929; 23516071; 23516500; 23519249; 23519469; 23521708; 23522190; 23524907; 23525475; 23525797; 23528269; 23528315; 23534750; 23536279; 23536437; 23543742; 23545415; 23545901; 23547411; 23550211; 23555186; 23555710; 23558569; 23559007; 23559009; 23563200; 23564481; 23571142; 23571737; 23572512; 23572574; 23573956; 23574746; 23575399; 23576507; 23576563; 23578198; 23578831; 23580068; 23583237; 23583409; 23583620; 23583669; 23585871; 23586029; 23588418; 23589328; 23589839; 23595149; 23595658; 23596757; 23599430; 23602568; 23603558; 23604351; 23607988; 23608226; 23608884; 23609977; 23612020; 23612969; 23612976; 23613387; 23613399; 23613406; 23620080; 23620409; 23620777; 23624524; 23624687; 23624782; 23624843; 23626008; 23630584; 23632916; 23639512; 23640975; 23643883; 23649769; 23649806; 23649808; 23650532; 23650552; 23652204; 23653000; 23653187; 23657012; 23663243; 23665236; 23665932; 23667851; 23670029; 23670238; 23671280; 23676490; 23677994; 23678008; 23678541; 23683469; 23684722; 23686119; 23686257; 23687300; 23687381; 23702906; 23706820; 23706821; 23708675; 23715779; 23716179; 23717592; 23718721; 23720736; 23722592; 23727578; 23727990; 23728348; 23729685; 23733769; 23736031; 23739040; 23742673; 23743335; 23744327; 23745682; 23747015; 23747308; 23747528; 23748877; 23752197; 23759592; 23760493; 23762372; 23764844; 23772552; 23775119; 23775793; 23785149; 23785201; 23786219; 23786650; 23788249; 23790165; 23793604; 23794094; 23796514; 23796712; 23799027; 23799104; 23800173; 23800953; 23802716; 23804139; 23811687; 23812725; 23812727; 23817390; 23818345; 23818355; 23818364; 23826318; 23835407; 23835706; 23836507; 23837945; 23841076; 23844043; 23844254; 23845906; 23851436; 23852341; 23860773; 23863845; 23870121; 23870475; 23873310; 23878395; 23880211; 23880345; 23880760; 23881403; 23886144; 23894400; 23896410; 23907539; 23908595; 23908596; 23915071; 23916609; 23918540; 23933584; 23935506; 23936455; 23942113; 23946421; 23954287; 23954291; 23954467; 23959174; 23959540; 23960076; 23962557; 23965232; 23966169; 23966171; 23966406; 23966881; 23967302; 23971040; 23973262; 23973461; 23977882; 23981578; 23982177; 23990016; 23991992; 23994832; 24001612; 24003224; 24006363; 24006461; 24008423; 24012673; 24014029; 24022481; 24023291; 24023325; 24025248; 24026986; 24029231; 24032713; 24038938; 24042100; 24043769; 24044511; 24045667; 24046089; 24052075; 24053468; 24056649; 24061453; 24067370; 24067899; 24067978; 24074410; 24076372; 24078252; 24091621; 24099634; 24101517; 24113167; 24113472; 24120139; 24122997; 24129246; 24134839; 24143256; 24145651; 24163369; 24164297; 24183724; 24190973; 24200963; 24209622; 24219989; 24220032; 24231352; 24239288; 24240685; 24241536; 24248600; 24256616; 24272483; 24285725; 24289924; 24314634; 24316591; 24323028; 24344030; 24361594; 24379070; 24379358; 24403473; 24434386; 24449575; 24617039,,,,,,,,,,,,,,,OGG:3000007157,,,,,,,tumor protein p53,,,,,,,,,,,,,Other designations: antigen NY-CO-13|cellular tumor antigen p53|mutant tumor protein 53|p53 tumor suppressor|phosphoprotein p53|transformation-related protein 53|tumor protein 53,,TP53,,,,,,,,,,,,,,,,,,,,,,,7157,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,TP53,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000002549,GAB1,,Other designations: GRB2-associated binder 1|GRB2-associated-binding protein 1|growth factor receptor bound protein 2-associated protein 1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,4,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,GRB2-associated binding protein 1,,,4q31.21,,,,,,,,,,,,,,,,"GO_0004871 (EC: IEA); GO_0005070 (EC: TAS, PMID: 8596638); GO_0005515 (EC: IPI, PMID: 10978177); GO_0005829 (EC: TAS); GO_0006979 (EC: IEA); GO_0007173 (EC: TAS); GO_0007257 (EC: IEA); GO_0007507 (EC: IEA); GO_0008283 (EC: TAS, PMID: 8596638); GO_0008286 (EC: TAS); GO_0008543 (EC: TAS); GO_0008544 (EC: IEA); GO_0030334 (EC: IEA); GO_0038095 (EC: TAS); GO_0045087 (EC: TAS); GO_0048008 (EC: IEA); GO_0048011 (EC: TAS); GO_0048015 (EC: TAS); GO_0060711 (EC: IEA); GO_0070102 (EC: IEA)",,,,,,,,,PMID: 8596638; 9045692; 9242692; 9252406; 9356464; 9658397; 9804835; 9878555; 9890893; 9891995; 10022866; 10068651; 10455108; 10648629; 10734310; 10747014; 10753869; 10871282; 10913131; 10978177; 10995442; 11134009; 11278704; 11314042; 11323411; 11353842; 11360177; 11402314; 11432805; 11507676; 11606067; 11701952; 11707404; 11894096; 11896055; 11940581; 11960376; 12008033; 12065326; 12138161; 12176364; 12370245; 12477932; 12486104; 12522270; 12582165; 12748184; 12766170; 12773374; 12808090; 12819203; 12855672; 14560030; 14660651; 14665621; 14701753; 14702039; 14973141; 14982882; 15010462; 15351743; 15379552; 15489334; 15574420; 15665327; 15815621; 15940252; 15952937; 16344560; 16638574; 16687399; 16787925; 16849525; 17145761; 17178724; 17211494; 17625596; 18003605; 18192688; 18271526; 18577518; 19167335; 19233262; 19380743; 19665053; 19881549; 19913121; 20005866; 20237496; 20467438; 20602450; 20628086; 20677014; 20723025; 20936779; 21282639; 21706016; 21782801; 21804548; 22366451; 22536782; 22751113; 22851227; 22865653; 22883624; 22915589; 23334917; 23612964; 23824909,,,,,,,,,,,,,,,OGG:3000002549,,,,,,,GRB2-associated binding protein 1,,,,,,,,,,,,,Other designations: GRB2-associated binder 1|GRB2-associated-binding protein 1|growth factor receptor bound protein 2-associated protein 1,,GAB1,,,,,,,,,,,,,,,,,,,,,,,2549,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,GAB1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0003183,iron accumulation [Glutathione depletion],,"Iron accumulation is a subtype of accumulation of substances in a biological object: A process that keeps iron in an organism, tissue, organelle, or cell.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0003182|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,PMID:21373260|PMID:24200681,,"Iron accumulation is a subtype of accumulation of substances in a biological object: A process that keeps iron in an organism, tissue, organelle, or cell.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003173,,,,,,,,,,,TXPO:0003183,,,,,,,,,,,,,,,,,,,,,,iron accumulation [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003186,accumulation of ethanol in intestine [Glutathione depletion],,"Accumulation of ethanol in intestine is a subtype of accumulation of xenobiotics: A process that keeps ethanol in the intestine.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0003187|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Accumulation of ethanol in intestine is a subtype of accumulation of xenobiotics: A process that keeps ethanol in the intestine.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001180,,,,,,,,,,,TXPO:0003186,,,,,,,,,,,,,,,,,,,,,,accumulation of ethanol in intestine [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003184,kupffer cell activation,,"Kupffer cell activation is a subtype of macrophage activation: A change in morphology and behavior of a kupffer cell resulting from exposure to a cytokine, chemokine, cellular ligand, or soluble factor.",false,,,http://purl.obolibrary.org/obo/GO_0042116,,,,,,,,,,,,,,,,,,,,,,"Kupffer cell activation is a subtype of macrophage activation: A change in morphology and behavior of a kupffer cell resulting from exposure to a cytokine, chemokine, cellular ligand, or soluble factor.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003184,,,,,,,,,,,,,,,,,,,,,,kupffer cell activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003185,kupffer cell activation [Glutathione depletion],,"Kupffer cell activation is a subtype of macrophage activation: A change in morphology and behavior of a kupffer cell resulting from exposure to a cytokine, chemokine, cellular ligand, or soluble factor.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0003184|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,"Chronic ethanol exposure increases the gut permeability, resulting in translocation of gut endotoxin/LPS to liver. In liver, LPS leads to KCs activation via activating NOX and the TLR-4 pathway.
The activated KCs then produce a large amount of reactive oxygen species (ROS), pro-inflammatory cytokines, and chemokines, which finally lead to liver injury",,"Kupffer cell activation is a subtype of macrophage activation: A change in morphology and behavior of a kupffer cell resulting from exposure to a cytokine, chemokine, cellular ligand, or soluble factor.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003173,,,,,,,,,,,TXPO:0003185,,,,,,,,,,,,,,,,,,,,,,kupffer cell activation [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003188,LPS translocation from gut to liver,,LPS translocation from gut to liver is a subtype of transmitting: A process that of the directed movement of LPS from the gut to the liver.,false,,,http://purl.obolibrary.org/obo/GO_0006810,,,,,,,,,,,,,,,,,,,,"chronic ethanol-induced activation of KCs is attributed to gut-sourced LPS, which is a major component of outer membrane of Gram-negative bacteria and passes through the intestinal epithelial barrier.
Chronic ethanol exposure can increase translocation of LPS from gut to liver by enhancing the intestinal permeability and altering the gut microflora.",,LPS translocation from gut to liver is a subtype of transmitting: A process that of the directed movement of LPS from the gut to the liver.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,http://purl.obolibrary.org/obo/UBERON_0000160,,,,,,,TXPO:0003188,,,,,,,,,,,,,,,,,,,,,,LPS translocation from gut to liver,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003189,LPS translocation from gut to liver [Glutathione depletion],,"LPS translocation from gut to liver is a subtype of transmitting: A process that of the directed movement of LPS from the gut to the liver.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0003188|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,"chronic ethanol-induced activation of KCs is attributed to gut-sourced LPS, which is a major component of outer membrane of Gram-negative bacteria and passes through the intestinal epithelial barrier.
Chronic ethanol exposure can increase translocation of LPS from gut to liver by enhancing the intestinal permeability and altering the gut microflora.",,"LPS translocation from gut to liver is a subtype of transmitting: A process that of the directed movement of LPS from the gut to the liver.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003185,,,,,,,,,,,TXPO:0003189,,,,,,,,,,,,,,,,,,,,,,LPS translocation from gut to liver [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003181,ATP biosynthetic process [Glutathione depletion],,"The chemical reaction resulting in the formation of ATP, adenosine 5'-triphosphate, a universally important coenzyme and enzyme regulator.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/GO_0006754|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"The chemical reaction resulting in the formation of ATP, adenosine 5'-triphosphate, a universally important coenzyme and enzyme regulator.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003173,,,,,,,,,,,TXPO:0003181,,,,,,,,,,,,,,,,,,,,,,ATP biosynthetic process [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003182,iron accumulation,,"Iron accumulation is a subtype of accumulation of substances in a biological object: A process that keeps iron in an organism, tissue, organelle, or cell.",false,,,http://purl.obolibrary.org/obo/TXPO_0000247,,,,,,,,,,,,,,,,,,,,,,"Iron accumulation is a subtype of accumulation of substances in a biological object: A process that keeps iron in an organism, tissue, organelle, or cell.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_18248,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003182,,,,,,,,,,,,,,,,,,,,,,iron accumulation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003180,hyperfunction of peroxisomal fatty acid beta-oxidation [Glutathione depletion],,"Hyperfunction of peroxisomal fatty acid beta-oxidation is a subtype of hyperfunction of fatty acid beta-oxidation: A process that performs an excessive peroxisomal fatty acid beta-oxidation.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0000177|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of peroxisomal fatty acid beta-oxidation is a subtype of hyperfunction of fatty acid beta-oxidation: A process that performs an excessive peroxisomal fatty acid beta-oxidation.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003173,,,,,,,,,,,TXPO:0003180,,,,,,,,,,,,,,,,,,,,,,hyperfunction of peroxisomal fatty acid beta-oxidation [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005777,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003187,accumulation of ethanol in intestine,,Accumulation of ethanol in intestine is a subtype of accumulation of xenobiotics: A process that keeps ethanol in the intestine.,false,,,http://purl.obolibrary.org/obo/TXPO_0000169,,,,,,,,,,,,,,,,,,,,,,Accumulation of ethanol in intestine is a subtype of accumulation of xenobiotics: A process that keeps ethanol in the intestine.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_16236,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003187,,,,,,,,,,,,,,,,,,,,,,accumulation of ethanol in intestine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010278,Glutathione peroxidase,Glutathione peroxidase 1|Cellular glutathione peroxidase|GSHPx-1|GSHC|glutathione peroxidase monomer,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,EC:1.11.1.9,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Glutathione peroxidase 1|Cellular glutathione peroxidase|GSHPx-1|GSHC|glutathione peroxidase monomer,,,,,IMR:0010278,,,,,,,,,,,,,,,,,,,,,,Glutathione peroxidase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002061,antioxidant gene expression,,Antioxidant gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature antioxidant gene product or products (proteins or RNA).,false,,,http://purl.obolibrary.org/obo/GO_0010467,,,,,,,,,,,,,,,,,,,,,,Antioxidant gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature antioxidant gene product or products (proteins or RNA).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002061,,,,,,,,,,,,,,,,,,,,,,antioxidant gene expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002064,decreasing proton motive force,,Decreasing proton motive force is a subtype of decreasing force: A process that changes the force of proton generated by electrochemical proton gradient to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0002046,,,,,,,,,,,,,,,,,,,,,,Decreasing proton motive force is a subtype of decreasing force: A process that changes the force of proton generated by electrochemical proton gradient to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002064,,,,,,,,,,,,,,,,,,,,,,decreasing proton motive force,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002068,chemical compound accumulation in liver [Ground glass appearance],,"Compound accumulation in liver is a subtype of accumulation of xenobiotics: A process that keeps compound in the liver.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/TXPO_0001694,,,,,,,,,,,,,,,,,,,,,,"Compound accumulation in liver is a subtype of accumulation of xenobiotics: A process that keeps compound in the liver.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002068,,,,,,,,,,,,,,,,,,,,,,chemical compound accumulation in liver [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002069,dysfunction of phospholipid degradation [Phospholipidosis - genetic],,"Dysfunction of phospholipid degradation is a subtype of dysfunctioning: A process that performs an abnormal and incomplete phospholipid degradation.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (genetic).",false,,,http://purl.obolibrary.org/obo/TXPO_0001448|http://purl.obolibrary.org/obo/TXPO_0001447,,,,,,,,,,,,,,,,,,,,,,"Dysfunction of phospholipid degradation is a subtype of dysfunctioning: A process that performs an abnormal and incomplete phospholipid degradation.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (genetic).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001776,,,,,,,,,,,TXPO:0002069,,,,,,,,,,,,,,,,,,,,,,dysfunction of phospholipid degradation [Phospholipidosis - genetic],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002063,hyprerfunction of anti-oxidative stress,,Hyprerfunction of anti-oxidative stress is a subtype of hyperfunctioning: A process that performs an excesssive response to oxidative stress.,false,,,http://purl.obolibrary.org/obo/TXPO_0000435,,,,,,,,,,,,,,,,,,,,,,Hyprerfunction of anti-oxidative stress is a subtype of hyperfunctioning: A process that performs an excesssive response to oxidative stress.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002063,,,,,,,,,,,,,,,,,,,,,,hyprerfunction of anti-oxidative stress,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002062,LPL (canonical)[Eosinophilic granular degeneration],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000282|http://purl.obolibrary.org/obo/TXPO_0001280,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24539|NCBI-Mouse-GeneID:16956|NCBI-Human-GeneID:4023|https://en.wikipedia.org/wiki/Lipoprotein_lipase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002062,,,,,,,,,,,,,,,,,,,,,,LPL (canonical)[Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002066,CAR binding,constitutive androstane receptor binding,CAR binding is a subtype of binding: Interacting with CAR (constitutive androstane receptor) .,false,,,http://purl.obolibrary.org/obo/GO_0005488,,,,,,,,,,,,,,,,,,,,,,CAR binding is a subtype of binding: Interacting with CAR (constitutive androstane receptor) .,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,constitutive androstane receptor binding,,,,,TXPO:0002066,,,,,,,,,,,,,,,,,,,,,,CAR binding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002060,insufficient detoxification,,Insufficient detoxification is a subtype of making insufficient: A process that lacks in detoxification.,false,,,http://purl.obolibrary.org/obo/TXPO_0000482,,,,,,,,,,,,,,,,,,,,,,Insufficient detoxification is a subtype of making insufficient: A process that lacks in detoxification.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002060,,,,,,,,,,,,,,,,,,,,,,insufficient detoxification,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002065,coumarin [Glutathione depletion],,A chromenone having the keto group located at the 2-position.,false,,,http://purl.obolibrary.org/obo/TXPO_0001921|http://purl.obolibrary.org/obo/CHEBI_28794,,,,,,,,,,,,,,,,,,,,PMID:2922762,,A chromenone having the keto group located at the 2-position.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002065,,,,,,,,,,,,,,,,,,,,,,coumarin [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002067,GSTA4 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0002089,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:2941,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002067,,,,,,,,,,,,,,,,,,,,,,GSTA4 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_38147,cardiotonic drug,,A drug that has a strengthening effect on the heart or that can increase cardiac output.,false,,,http://purl.obolibrary.org/obo/CHEBI_35554,,,,,,,,,,,,,,,,,,,,,,A drug that has a strengthening effect on the heart or that can increase cardiac output.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:38147,,,,,,,,,,,,,,,,,,,,,,cardiotonic drug,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001035,group IIE secretory phospholipase A2,,,false,,,http://purl.obolibrary.org/obo/IMR_0000283,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001035,,,,,,,,,,,,,,,,,,,,,,group IIE secretory phospholipase A2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_35640,adrenergic uptake inhibitor,ARI|adrenergic reuptake inhibitor|NRI|adrenergic uptake inhibitors|NERI|norepinephrine reuptake inhibitors|norepinephrine reuptake inhibitor|adrenergic reuptake inhibitors,Adrenergic uptake inhibitors are drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin.,false,,,http://purl.obolibrary.org/obo/CHEBI_37962,,,,,,,,,,,,,,,,,,,,,,Adrenergic uptake inhibitors are drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ARI|adrenergic reuptake inhibitor|NRI|adrenergic uptake inhibitors|NERI|norepinephrine reuptake inhibitors|norepinephrine reuptake inhibitor|adrenergic reuptake inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:35640,,,,adrenergic uptake inhibitor,,CHEBI:35640,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_60258,EC 3.4.* (hydrolases acting on peptide bond) inhibitor,inhibitor of hydrolases acting on peptide bond (EC 3.4.*)|EC 3.4.* inhibitor|protease inhibitor|protease inhibitors|EC 3.4.* (peptidase) inhibitors|inhibitors of hydrolases acting on peptide bond (EC 3.4.*)|EC 3.4.* (peptidase) inhibitor|EC 3.4.* inhibitors|peptidase inhibitors|EC 3.4.* (hydrolase acting on peptide bond) inhibitor|EC 3.4.* (hydrolases acting on peptide bond) inhibitors|EC 3.4.* (hydrolase acting on peptide bonds) inhibitors,"A hydrolase inhibitor that interferes with the action of any hydrolase acting on peptide bonds (peptidase), EC 3.4.*.*).",false,,,http://purl.obolibrary.org/obo/CHEBI_76759,,,,,,,,,,,,,,,,,,,,,,"A hydrolase inhibitor that interferes with the action of any hydrolase acting on peptide bonds (peptidase), EC 3.4.*.*).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,inhibitor of hydrolases acting on peptide bond (EC 3.4.*)|EC 3.4.* inhibitor|protease inhibitor|protease inhibitors|EC 3.4.* (peptidase) inhibitors|inhibitors of hydrolases acting on peptide bond (EC 3.4.*)|EC 3.4.* (peptidase) inhibitor|EC 3.4.* inhibitors|peptidase inhibitors|EC 3.4.* (hydrolase acting on peptide bond) inhibitor|EC 3.4.* (hydrolases acting on peptide bond) inhibitors|EC 3.4.* (hydrolase acting on peptide bonds) inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:60258,,,,EC 3.4.* (hydrolases acting on peptide bond) inhibitor,,CHEBI:60258,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000007873,MANF,,"Other designations: arginine-rich, mutated in early stage tumors",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,ARMET|ARP,,,,,,,,,,,,3,,,,,,HPRD:03558|MIM:601916|HGNC:15461|Ensembl:ENSG00000145050|Vega:OTTHUMG00000156897,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,mesencephalic astrocyte-derived neurotrophic factor,,,3p21.1,,,,,,,,,,,,,,,,GO_0002014 (EC: IEA); GO_0003674 (EC: ND); GO_0005575 (EC: ND); GO_0005615 (EC: IEA); GO_0006986 (EC: IEA); GO_0008083 (EC: IEA); GO_0008150 (EC: ND); GO_0044822 (EC: IDA); GO_0048471 (EC: IEA),,,,,,,,,PMID: 8649854; 8971156; 9174057; 9230196; 10767373; 12477932; 12665801; 12794311; 14699964; 15146197; 15489334; 18561914; 18718866; 19258449; 19399876; 19641128; 20186704; 20685313; 21047780; 21139048; 21890473; 23000965; 23255601,,,,,,,,,,,,,,,OGG:3000007873,,,,,,,mesencephalic astrocyte-derived neurotrophic factor,,,,,,,,,,,,,"Other designations: arginine-rich, mutated in early stage tumors",,MANF,,,,,,,,,,,,,,,,,,,,,,,7873,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,MANF,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0011349,Elongin C protein,EloB|Transcription elongation factor B polypeptide 2|Elongin 18 kDa subunit|RNA polymerase II transcription factor SIII subunit B|SIII p18|Elongin B,,false,,,http://purl.obolibrary.org/obo/IMR_0010020,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,EloB|Transcription elongation factor B polypeptide 2|Elongin 18 kDa subunit|RNA polymerase II transcription factor SIII subunit B|SIII p18|Elongin B,,,,,IMR:0011349,,,,,,,,,,,,,,,,,,,,,,Elongin C protein,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000060,CCDC126 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:500117|NCBI-Mouse-GeneID:57895|NCBI-Human-GeneID:90693,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000090693,,,,,,,,,,,,,TXPO:1000060,,,,,,,,,,,,,,,,,,,,,,CCDC126 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000062,CD200 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24560|NCBI-Human-GeneID:4345|NCBI-Mouse-GeneID:17470,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000004345,,,,,,,,,,,,,TXPO:1000062,,,,,,,,,,,,,,,,,,,,,,CD200 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000064,CENPE (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1062|NCBI-Mouse-GeneID:229841|NCBI-Rat-GeneID:362044,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001062,,,,,,,,,,,,,TXPO:1000064,,,,,,,,,,,,,,,,,,,,,,CENPE (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000067,DDIT3 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:29467|NCBI-Mouse-GeneID:13198|NCBI-Human-GeneID:1649,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001649,,,,,,,,,,,,,TXPO:1000067,,,,,,,,,,,,,,,,,,,,,,DDIT3 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000065,CFLAR (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:12633|NCBI-Rat-GeneID:117279|NCBI-Human-GeneID:8837,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000008837,,,,,,,,,,,,,TXPO:1000065,,,,,,,,,,,,,,,,,,,,,,CFLAR (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000069,"6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime",CITCO,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CITCO,,,TXPO:1000069,,,,,,,,,,,,,,,,,,,,,,"6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000068,CHORDC1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:66917|NCBI-Rat-GeneID:315447|NCBI-Human-GeneID:26973,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000026973,,,,,,,,,,,,,TXPO:1000068,,,,,,,,,,,,,,,,,,,,,,CHORDC1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000063,CDK5R1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:8851|NCBI-Rat-GeneID:116671|NCBI-Mouse-GeneID:12569,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000008851,,,,,,,,,,,,,TXPO:1000063,,,,,,,,,,,,,,,,,,,,,,CDK5R1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000061,CCNB2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:363088|NCBI-Mouse-GeneID:12442|NCBI-Human-GeneID:9133,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000009133,,,,,,,,,,,,,TXPO:1000061,,,,,,,,,,,,,,,,,,,,,,CCNB2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000066,CHAC1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:79094|NCBI-Rat-GeneID:362196|NCBI-Mouse-GeneID:69065,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000079094,,,,,,,,,,,,,TXPO:1000066,,,,,,,,,,,,,,,,,,,,,,CHAC1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100630,cyclin T2,Cyclin T2,,false,,,http://purl.obolibrary.org/obo/IMR_0100628,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0010178,Cyclin T2,,,,,IMR:0100630,,,,,,,,,,,,,,,,,,,,,,cyclin T2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100780,Wnt-10a,,,false,,,http://purl.obolibrary.org/obo/IMR_0000003,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100780,,,,,,,,,,,,,,,,,,,,,,Wnt-10a,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_137209,glycerophosphonocholine,sn-glycero-3-phosphonocholine,,false,,,http://purl.obolibrary.org/obo/CHEBI_37739,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sn-glycero-3-phosphonocholine,,,,,CHEBI:137209,,,,,,,,,,,,,,,,,,,,,,glycerophosphonocholine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_6343,labetalol,labetalol|labetalolum|5-(1-Hydroxy-2-(1-methyl-3-phenylpropylamino)ethyl)salicylamide|3-Carboxamido-4-hydroxy-alpha-((1-methyl-3-phenylpropylamino)methyl)benzyl alcohol|kabetalol|2-hydroxy-5-{1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl}benzamide|Labetalol,A secondary amino compound formally derived from ammonia by replacing two of the hydrogens by 2-(3-carbamoyl-4-hydroxyphenyl)-2-hydroxyethyl and 4-phenylbutan-2-yl groups. It is an adrenergic antagonist used to treat high blood pressure.,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Reaxys:2948416|PMID:28166217|Drug_Central:1531|PMID:22300487|PMID:23055089|Beilstein:2948416|PMID:22528277|PMID:21908132|DrugBank:DB00598|LINCS:LSM-1282|CAS:36894-69-6,,A secondary amino compound formally derived from ammonia by replacing two of the hydrogens by 2-(3-carbamoyl-4-hydroxyphenyl)-2-hydroxyethyl and 4-phenylbutan-2-yl groups. It is an adrenergic antagonist used to treat high blood pressure.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_66991|http://purl.obolibrary.org/obo/CHEBI_37890|http://purl.obolibrary.org/obo/CHEBI_35674|http://purl.obolibrary.org/obo/CHEBI_35530,,,,,2-hydroxy-5-{1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl}benzamide|Labetalol,,labetalol|labetalolum|5-(1-Hydroxy-2-(1-methyl-3-phenylpropylamino)ethyl)salicylamide|3-Carboxamido-4-hydroxy-alpha-((1-methyl-3-phenylpropylamino)methyl)benzyl alcohol|kabetalol,,,,,,,,,,,,,,,,,,,,,CHEBI:6343,,,,labetalol,,CHEBI:6343,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/HINO_0016227,Activation and oligomerization of BAK protein,,,false,,,http://purl.obolibrary.org/obo/TXPO_0003222,,,,,,,,,,,,,,,,,,,,Reactome:R-HSA-114294.2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,HINO:0016227,,,,,,,tBID binds to its mitochondrial partner BAK to release cytochrome c.  Activated tBID results in an allosteric activation of BAK. This may induce its intramembranous oligomerization into a pore for cytochrome c efflux.,,,,,,,,,,,,,,,Activation and oligomerization of BAK protein,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/HINO_0016226,"Activation, translocation and oligomerization of BAX",,,false,,,http://purl.obolibrary.org/obo/TXPO_0003222,,,,,,,,,,,,,,,,,,,,Reactome:R-HSA-114294.2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,HINO:0016226,,,,,,,"As a result of binding to Bid, Bax oligomerizes and   integrates in the outer mitochondrial membrane that triggers cytochrome c release. Bax mitochondrial membrane insertion triggered by Bid may represent a key step in pathways leading to apoptosis (Eskes et al., 2000)",,,,,,,,,,,,,,,"Activation, translocation and oligomerization of BAX",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000079882,ZC3H14,,Other designations: mammalian suppressor of tau pathology-2|nuclear protein UKp68|renal carcinoma antigen NY-REN-37|zinc finger CCCH domain-containing protein 14,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,SUT2|MSUT-2|UKp68|NY-REN-37,,,,,,,,,,,,14,,,,,,MIM:613279|HGNC:20509|HPRD:13348|Vega:OTTHUMG00000170803|Ensembl:ENSG00000100722,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,zinc finger CCCH-type containing 14,,,14q31.3,,,,,,,,,,,,,,,,"GO_0005515 (EC: IPI, PMID: 19273536); GO_0005634 (EC: IDA); GO_0005730 (EC: IDA); GO_0005730 (EC: IDA, Qualifier: NOT); GO_0005737 (EC: IDA, PMID: 19303045); GO_0005737 (EC: IEA); GO_0016607 (EC: IEA); GO_0044822 (EC: IDA); GO_0046872 (EC: IEA)",,,,,,,,,PMID: 10508479; 12477932; 14702039; 16159877; 16189514; 16344560; 17630287; 18029348; 19273536; 19303045; 19471022; 20658987; 21139048; 21355046; 21734151; 21890473; 21906983; 22505724; 22586326; 22939629; 23000965; 24163370; 24250222; 24457600,,,,,,,,,,,,,,,OGG:3000079882,,,,,,,zinc finger CCCH-type containing 14,,,,,,,,,,,,,Other designations: mammalian suppressor of tau pathology-2|nuclear protein UKp68|renal carcinoma antigen NY-REN-37|zinc finger CCCH domain-containing protein 14,,ZC3H14,,,,,,,,,,,,,,,,,,,,,,,79882,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,ZC3H14,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0010510,Heterogeneous nuclear ribonucleoprotein D0,hnRNP D0|AU-rich element RNA-binding protein 1|ROD,,false,,,http://purl.obolibrary.org/obo/IMR_0010024,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,hnRNP D0|AU-rich element RNA-binding protein 1|ROD,,,,,IMR:0010510,,,,,,,,,,,,,,,,,,,,,,Heterogeneous nuclear ribonucleoprotein D0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100096,"pituitary hormone, anterior",,"Hormones secreted by the adenohypophysis ( PITUITARY GLAND, ANTERIOR).",false,,,http://purl.obolibrary.org/obo/IMR_0100084,,,,,,,,,,,,,,,,,,,,MeSH:D010908,,"Hormones secreted by the adenohypophysis ( PITUITARY GLAND, ANTERIOR).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100096,,,,,,,,,,,,,,,,,,,,,,"pituitary hormone, anterior",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0048878,chemical homeostasis,,Any biological process involved in the maintenance of an internal steady state of a chemical.,false,,,http://purl.obolibrary.org/obo/GO_0042592,,,,,,,,,,,,,,,,,,,,,,Any biological process involved in the maintenance of an internal steady state of a chemical.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0048878,,,,,,,,,,,,,,,,,,,,,,chemical homeostasis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_63726,neuroprotective agent,neuroprotective agents|neuroprotectant|neuroprotectants,Any compound that can be used for the treatment of neurodegenerative disorders.,false,,,http://purl.obolibrary.org/obo/CHEBI_50267,,,,,,,,,,,,,,,,,,,,,,Any compound that can be used for the treatment of neurodegenerative disorders.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,neuroprotective agents|neuroprotectant|neuroprotectants,,,,,,,,,,,,,,,,,,,,,CHEBI:63726,,,,neuroprotective agent,,CHEBI:63726,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_50912,cardiotoxic agent,,A role played by aan entity exihibiting itself through the ability to induce damage to the heart and cardiomyocytes.,false,,,http://purl.obolibrary.org/obo/TXPO_0000038,,,,,,,,,,,,,,,,,,,,,,A role played by aan entity exihibiting itself through the ability to induce damage to the heart and cardiomyocytes.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:50912,,,,,,,,,,,,,,,,,,,,,,cardiotoxic agent,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000219,Pyk2,prolin-rich tyrosine kinase 2|related adhesion focal tyrosine kinase|RAFTK|CADTK|cell adhesion kinase beta|Cak beta|calcium-dependent tyrosine kinase,,false,,,http://purl.obolibrary.org/obo/IMR_0000217,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,prolin-rich tyrosine kinase 2|related adhesion focal tyrosine kinase|RAFTK|CADTK|cell adhesion kinase beta|Cak beta|calcium-dependent tyrosine kinase,,,,,IMR:0000219,,,,,,,,,,,,,,,,,,,,,,Pyk2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0200501,L-Valine,,,false,,,http://purl.obolibrary.org/obo/CHEBI_33709,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0200501,,,,,,,,,,,,,,,,,,,,,,L-Valine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000093273,LEMD1,,Other designations: LEM domain protein 1|LEM domain-containing protein 1|cancer/testis antigen 50,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CT50|LEMP-1,,,,,,,,,,,,1,,,,,,HGNC:18725|HPRD:13983|Vega:OTTHUMG00000037201|Ensembl:ENSG00000186007|MIM:610480,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,LEM domain containing 1,,,1q32.1,,,,,,,,,,,,,,,,GO_0016021 (EC: IEA),,,,,,,,,PMID: 12477932; 15254688; 17207965; 20682177,,,,,,,,,,,,,,,OGG:3000093273,,,,,,,LEM domain containing 1,,,,,,,,,,,,,Other designations: LEM domain protein 1|LEM domain-containing protein 1|cancer/testis antigen 50,,LEMD1,,,,,,,,,,,,,,,,,,,,,,,93273,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,LEMD1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/NCBITaxon_7742,vertebrate,vertebrates|Vertebrata,,false,,,http://purl.obolibrary.org/obo/NCBITaxon_2759,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,vertebrates|Vertebrata,,,,,NCBITaxon:7742,,,,,,,,,,,,,,,,,,,,,,vertebrate,,,,,,,http://purl.obolibrary.org/obo/ncbitaxon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010547,40S ribosomal protein S21,40S small ribosomal protein 21,,false,,,http://purl.obolibrary.org/obo/IMR_0000896,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,40S small ribosomal protein 21,,,,,IMR:0010547,,,,,,,,,,,,,,,,,,,,,,40S ribosomal protein S21,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0200240,L-Tyrosine,,,false,,,http://purl.obolibrary.org/obo/CHEBI_33709,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0200240,,,,,,,,,,,,,,,,,,,,,,L-Tyrosine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000569,K-cadherin,cadherin-6|Kidney-cadherin,,false,,,http://purl.obolibrary.org/obo/IMR_0000167,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,cadherin-6|Kidney-cadherin,,,,,IMR:0000569,,,,,,,,,,,,,,,,,,,,,,K-cadherin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_31183,alclofenac,alclofenaco|alclofenacum|alclofenac|3-Chloro-4-(2-propenyloxy)benzeneacetic acid|(4-Allyloxy-3-chlorphenyl)essigsaeure|[4-(allyloxy)-3-chlorophenyl]acetic acid|[3-chloro-4-(prop-2-en-1-yloxy)phenyl]acetic acid,"An aromatic ether in which the ether oxygen links an allyl group to the 4-position of (3-chlorophenyl)acetic acid.A non-steroidal anti-inflammatory drug, it was withdrawn from the UK market in 1979 due to concerns with its association with vasculitis and rash.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:7853459|PMID:241601|PMID:21068|PMID:241602|PMID:241596|Drug_Central:107|PMID:6103793|PMID:6120697|PMID:6106453|PMID:6141199|PMID:241598|PMID:19205|PMID:24426|PMID:241595|PMID:241603|PMID:241600|PMID:509935|PMID:6109575|PMID:237493|CAS:22131-79-9|PMID:241597|PMID:236805|PMID:7905004|PMID:18796|PMID:241593|Reaxys:2116510|PMID:4279126,,"An aromatic ether in which the ether oxygen links an allyl group to the 4-position of (3-chlorophenyl)acetic acid.A non-steroidal anti-inflammatory drug, it was withdrawn from the UK market in 1979 due to concerns with its association with vasculitis and rash.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35475|http://purl.obolibrary.org/obo/CHEBI_88188|http://purl.obolibrary.org/obo/CHEBI_35481,,,,,[3-chloro-4-(prop-2-en-1-yloxy)phenyl]acetic acid,,alclofenaco|alclofenacum|alclofenac|3-Chloro-4-(2-propenyloxy)benzeneacetic acid|(4-Allyloxy-3-chlorphenyl)essigsaeure|[4-(allyloxy)-3-chlorophenyl]acetic acid,,,,,,,,,,,,,,,,,,,,,CHEBI:31183,,,,alclofenac,,CHEBI:31183,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000849,HMGB1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:3146|NCBI-Mouse-GeneID:15289,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000849,,,,,,,,,,,,,,,,,,,,,,HMGB1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000846,Acot5 (mouse)[Eosinophilic granular degeneration],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000648|http://purl.obolibrary.org/obo/TXPO_0000868,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:217698|PMID:16103133|PMID:28385385,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000846,,,,,,,,,,,,,,,,,,,,,,Acot5 (mouse)[Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000848,increasing demand for glutathione conjugation,,Increasing demand for glutathione conjugation is a subtype of increasing functional demand: A process changes the functional demand for the for glutathione conjugation to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000633,,,,,,,,,,,,,,,,,,,,,,Increasing demand for glutathione conjugation is a subtype of increasing functional demand: A process changes the functional demand for the for glutathione conjugation to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000848,,,,,,,,,,,,,,,,,,,,,,increasing demand for glutathione conjugation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000840,cell death dependent molecule (human in vitro),,"Cell death dependent molecule is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of cell death as a gene product.
Gene profile:Human/in vitro/Hepatocyte/",false,,,http://purl.obolibrary.org/obo/TXPO_0000838,,,,,,,,,,,,,,,,,,,,,,"Cell death dependent molecule is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of cell death as a gene product.
Gene profile:Human/in vitro/Hepatocyte/",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000840,,,,,,,,,,,,,,,,,,,,,,cell death dependent molecule (human in vitro),,,,,,,,,,,http://purl.obolibrary.org/obo/NCBITaxon_9606,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000842,inflammatory cytokine gene expression [Oxidative stress].,,"Inflammatory cytokine gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature inflammatory cytokine gene product or products (proteins or RNA).
This entity is a specific course-dependent process. This process can constitute the course of Oxidative stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002266|http://purl.obolibrary.org/obo/TXPO_0001730,,,,,,,,,,,,,,,,,,,,,,"Inflammatory cytokine gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature inflammatory cytokine gene product or products (proteins or RNA).
This entity is a specific course-dependent process. This process can constitute the course of Oxidative stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000842,,,,,,,,,,,,,,,,,,,,,,inflammatory cytokine gene expression [Oxidative stress].,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000841,increasing liver weight [Phospholipidosis (excessive defense)],,"Increasing liver weight is a subtype of increasing weight: A process that changes the weight of the liver to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense).",false,,,http://purl.obolibrary.org/obo/TXPO_0000054|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,PMID:9742123,,"Increasing liver weight is a subtype of increasing weight: A process that changes the weight of the liver to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001140,,,,,,,,,,,,,,,,,TXPO:0000841,,,,,,,,,,,,,,,,,,,,,,increasing liver weight [Phospholipidosis (excessive defense)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000844,inflammasome activation [Glutathione depletion],,"Inflammasome activation is a subtype of activating: A process that changes the activity of the inflammasome,  to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0001107|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,PMID:29558368|Reactome: R-HSA-844456.2,,"Inflammasome activation is a subtype of activating: A process that changes the activity of the inflammasome,  to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000850|http://purl.obolibrary.org/obo/TXPO_0000894,,,,,,http://purl.obolibrary.org/obo/TXPO_0003209,,,,,,,,,,,TXPO:0000844,,,,,,,,,,,,,,,,,,,,,,inflammasome activation [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000845,MDM2 (canonical)[Cell death],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003195|http://purl.obolibrary.org/obo/IMR_0100660,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:314856,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_68494,,,,,,,,,,TXPO:0000845,,,,,,,,,,,,,,,,,,,,,,MDM2 (canonical)[Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000843,TP53 (canonical)[Cell death],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003195|http://purl.obolibrary.org/obo/IMR_0100659,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24842,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000843,,,,,,,,,,,,,,,,,,,,,,TP53 (canonical)[Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000847,Hmgb1 (mouse)[Glutathione depletion],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002285|http://purl.obolibrary.org/obo/TXPO_0000849,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:15289,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000847,,,,,,,,,,,,,,,,,,,,,,Hmgb1 (mouse)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0000169,viability,,An organismal quality inhering in a bearer or a population by virtue of the bearer's disposition to survive and develop normally or the number of surviving individuals in a given population.,false,,,http://purl.obolibrary.org/obo/BFO_0000019,,,,,,,,,,,,,,,,,,,,,,An organismal quality inhering in a bearer or a population by virtue of the bearer's disposition to survive and develop normally or the number of surviving individuals in a given population.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0000169,,,,,,,,,,,,,,,,,,,,,,viability,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0000165,time quality,,A quality in which events occur in sequence.,false,,,http://purl.obolibrary.org/obo/BFO_0000019|http://purl.obolibrary.org/obo/TXPO_0001536,,,,,,,,,,,,,,,,,,,,,,A quality in which events occur in sequence.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0000165,,,,,,,,,,,,,,,,,,,,,,time quality,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000635,Integrin alpha-D,,,false,,,http://purl.obolibrary.org/obo/IMR_0000173,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000635,,,,,,,,,,,,,,,,,,,,,,Integrin alpha-D,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000010401,PIAS3,,"Other designations: E3 SUMO-protein ligase PIAS3|protein inhibitor of activated STAT protein 3|zinc finger, MIZ-type containing 5",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,ZMIZ5,,,,,,,,,,,,1,,,,,,HGNC:16861|HPRD:09068|MIM:605987|Ensembl:ENSG00000131788|Vega:OTTHUMG00000013750,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"protein inhibitor of activated STAT, 3",,,1q21,,,,,,,,,,,,,,,,"GO_0003676 (EC: IEA); GO_0005515 (EC: IPI, PMID: 11060035); GO_0005634 (EC: IEA); GO_0005737 (EC: IEA); GO_0006351 (EC: IEA); GO_0006355 (EC: IEA); GO_0008022 (EC: IPI, PMID: 14715251); GO_0008270 (EC: IEA); GO_0009725 (EC: IEA); GO_0010628 (EC: IEA); GO_0015459 (EC: IEA); GO_0016925 (EC: IEA); GO_0016925 (EC: ISS); GO_0019789 (EC: IEA); GO_0019899 (EC: IPI, PMID: 17087506); GO_0030425 (EC: IEA); GO_0033235 (EC: IDA, PMID: 17696781); GO_0045202 (EC: IEA); GO_0045838 (EC: IEA); GO_0047485 (EC: IEA)",,,,,,,,,PMID: 9388184; 9724754; 10319586; 11060035; 11071847; 11117529; 11390395; 11429412; 11477070; 11709556; 12208521; 12387893; 12477932; 12804609; 12869526; 14630083; 14691252; 14702039; 14715251; 15138572; 15140884; 15171715; 15231748; 15489334; 15907835; 16029420; 16098628; 16368885; 16455055; 16522640; 16524884; 16679534; 17032498; 17087506; 17533377; 17565989; 17696781; 17987106; 18037959; 18212042; 18408014; 18550668; 18681895; 19217413; 19308990; 19322201; 19471022; 19569236; 19760037; 19903771; 20159969; 20231901; 20351170; 20516148; 20935639; 20936779; 21288202; 21317457; 21497567; 21532337; 21693764; 21733403; 21900206; 21906983; 21963094; 21988832; 22321011; 22584572; 22649547; 23092970; 23322197; 23704280; 23959540,,,,,,,,,,,,,,,OGG:3000010401,,,,,,,"protein inhibitor of activated STAT, 3",,,,,,,,,,,,,"Other designations: E3 SUMO-protein ligase PIAS3|protein inhibitor of activated STAT protein 3|zinc finger, MIZ-type containing 5",,PIAS3,,,,,,,,,,,,,,,,,,,,,,,10401,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,PIAS3,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000010404,CPQ,,Other designations: Ser-Met dipeptidase|aminopeptidase|blood plasma glutamate carboxypeptidase|lysosomal dipeptidase,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,PGCP|LDP,,,,,,,,,,,,8,,,,,,Vega:OTTHUMG00000164690|HGNC:16910|HPRD:07140|Ensembl:ENSG00000104324,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,carboxypeptidase Q,,,8q22.2,,,,,,,,,,,,,,,,"GO_0004180 (EC: IEA); GO_0005615 (EC: IDA, PMID: 10206990); GO_0005737 (EC: IDA, PMID: 10206990); GO_0005764 (EC: ISS); GO_0005783 (EC: ISS); GO_0005794 (EC: ISS); GO_0006508 (EC: IDA, PMID: 10206990); GO_0006590 (EC: ISS); GO_0042246 (EC: ISS); GO_0042803 (EC: IDA, PMID: 12675526); GO_0043171 (EC: IDA, PMID: 10206990); GO_0046872 (EC: IEA); GO_0070573 (EC: IDA, PMID: 10206990)",,,,,,,,,PMID: 10206990; 12477932; 12591738; 12675526; 16303743; 16344560; 17214548; 20201926; 20379614; 20802479; 23725790; 23728906,,,,,,,,,,,,,,,OGG:3000010404,,,,,,,carboxypeptidase Q,,,,,,,,,,,,,Other designations: Ser-Met dipeptidase|aminopeptidase|blood plasma glutamate carboxypeptidase|lysosomal dipeptidase,,CPQ,,,,,,,,,,,,,,,,,,,,,,,10404,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,CPQ,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/GO_0006119,oxidative phosphorylation,respiratory-chain phosphorylation,"The phosphorylation of ADP to ATP that accompanies the oxidation of a metabolite through the operation of the respiratory chain. Oxidation of compounds establishes a proton gradient across the membrane, providing the energy for ATP synthesis.",false,,,http://purl.obolibrary.org/obo/GO_0016310,,,,,,,,,,,,,,,,,,,,,,"The phosphorylation of ADP to ATP that accompanies the oxidation of a metabolite through the operation of the respiratory chain. Oxidation of compounds establishes a proton gradient across the membrane, providing the energy for ATP synthesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,respiratory-chain phosphorylation,,,,,GO:0006119,,,,,,,,,,,,,,,,,,,,,,oxidative phosphorylation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000011080,DNAJB4,,Other designations: DnaJ-like heat shock protein 40|HSP40 homolog|dnaJ homolog subfamily B member 4|heat shock 40 kDa protein 1 homolog|heat shock protein 40 homolog|human liver DnaJ-like protein,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,DjB4|DNAJW|HLJ1,,,,,,,,,,,,1,,,,,,HPRD:07486|HGNC:14886|MIM:611327,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"DnaJ (Hsp40) homolog, subfamily B, member 4",,,1p31.1,,,,,,,,,,,,,,,,"GO_0005515 (EC: IPI); GO_0005634 (EC: IDA); GO_0005730 (EC: IDA, Qualifier: NOT); GO_0005737 (EC: IDA); GO_0005886 (EC: IDA); GO_0006457 (EC: IEA); GO_0006986 (EC: TAS, PMID:9546042); GO_0009408 (EC: TAS, PMID:9546042); GO_0051082 (EC: IEA)",,,,,,,,,PMID:9546042; 11147971; 11371506; 12477932; 15489334; 15592455; 15661747; 15782117; 16009940; 16542645; 16788156; 18029348; 18794131; 20145123; 20360068; 20615403; 21345358; 21906983; 21963094; 21988832; 22145905; 22863883; 22939629; 23000965; 23306212; 23824909; 24318877,,,,,,,,,,,,,,,OGG:3000011080,,,,,,,"DnaJ (Hsp40) homolog, subfamily B, member 4",,,,,,,,,,,,,Other designations: DnaJ-like heat shock protein 40|HSP40 homolog|dnaJ homolog subfamily B member 4|heat shock 40 kDa protein 1 homolog|heat shock protein 40 homolog|human liver DnaJ-like protein,,DNAJB4,,,,,,,,,,,,,,,,,,,,,,,11080,,,,,,,,9606,,,,,,,,,,,,,,,,,,,DNAJB4,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0010511,Heterogeneous nuclear ribonucleoprotein F,hnRNP F|ROF,,false,,,http://purl.obolibrary.org/obo/IMR_0010024,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,hnRNP F|ROF,,,,,IMR:0010511,,,,,,,,,,,,,,,,,,,,,,Heterogeneous nuclear ribonucleoprotein F,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001169,keeping amount of lipid in liver,,Keeping amount of lipid in liver is a subtype of keeping amount: A process that maintaining the amount of lipid in the liver.,false,,,http://purl.obolibrary.org/obo/TXPO_0000414,,,,,,,,,,,,,,,,,,,,,,Keeping amount of lipid in liver is a subtype of keeping amount: A process that maintaining the amount of lipid in the liver.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001169,,,,,,,,,,,,,,,,,,,,,,keeping amount of lipid in liver,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001160,changing balance of lipid metabolism [Lipidosis],,"Changing balance of lipid metabolism is a subtype of changing balance: A process that changes the balance between lipid anabolism and catabolism.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0001161,,,,,,,,,,,,,,,,,,,,,,"Changing balance of lipid metabolism is a subtype of changing balance: A process that changes the balance between lipid anabolism and catabolism.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001163,,,,,,,,,,,TXPO:0001160,,,,,,,,,,,,,,,,,,,,,,changing balance of lipid metabolism [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001165,ATP degradation,,ATP degradation is a subtype of catabolic process: A process of the chemical reactions resulting in the breakdown of  ATP: ATP + H2O = ADP + phosphate + 2 H+.,false,,,http://purl.obolibrary.org/obo/GO_0009056,,,,,,,,,,,,,,,,,,,,,,ATP degradation is a subtype of catabolic process: A process of the chemical reactions resulting in the breakdown of  ATP: ATP + H2O = ADP + phosphate + 2 H+.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_15422,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001165,,,,,,,,,,,,,,,,,,,,,,ATP degradation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001161,changing balance of lipid metabolism,,Changing balance of lipid metabolism is a subtype of changing balance: A process that changes the balance between lipid anabolism and catabolism.,false,,,http://purl.obolibrary.org/obo/TXPO_0001847,,,,,,,,,,,,,,,,,,,,,,Changing balance of lipid metabolism is a subtype of changing balance: A process that changes the balance between lipid anabolism and catabolism.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001161,,,,,,,,,,,,,,,,,,,,,,changing balance of lipid metabolism,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001164,maintaining lipid homeostasis,,Any process involved in the maintenance of an internal steady state of lipid within an organism or cell.,false,,,http://purl.obolibrary.org/obo/GO_0042592,,,,,,,,,,,,,,,,,,,,,,Any process involved in the maintenance of an internal steady state of lipid within an organism or cell.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001164,,,,,,,,,,,,,,,,,,,,,,maintaining lipid homeostasis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001163,changing lipid homeostasis [Lipidosis],,"Changing lipid homeostasis is a subtype of changing balance: A process that changes the steady state of lipid within an organism or cell.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0001162,,,,,,,,,,,,,,,,,,,,,,"Changing lipid homeostasis is a subtype of changing balance: A process that changes the steady state of lipid within an organism or cell.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001163,,,,,,,,,,,,,,,,,,,,,,changing lipid homeostasis [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001167,cholesterol transport gene mutation,,Cholesteroltransport gene mutation is a subtype of gene mutation: A process thatchanges the sequence of a cholesterol transport gene.,false,,,http://purl.obolibrary.org/obo/TXPO_0001985,,,,,,,,,,,,,,,,,,,,,,Cholesteroltransport gene mutation is a subtype of gene mutation: A process thatchanges the sequence of a cholesterol transport gene.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001167,,,,,,,,,,,,,,,,,,,,,,cholesterol transport gene mutation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001166,arachidonic acid,,,false,,,http://purl.obolibrary.org/obo/TXPO_0001152,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001166,,,,,,,,,,,,,,,,,,,,,,arachidonic acid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001168,maintaining lipid homeostasis [Lipidosis],,"Any process involved in the maintenance of an internal steady state of lipid within an organism or cell.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001164|http://purl.obolibrary.org/obo/TXPO_0001163,,,,,,,,,,,,,,,,,,,,,,"Any process involved in the maintenance of an internal steady state of lipid within an organism or cell.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001168,,,,,,,,,,,,,,,,,,,,,,maintaining lipid homeostasis [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001162,changing lipid homeostasis,,Changing lipid homeostasis is a subtype of changing balance: A process that changes the steady state of lipid within an organism or cell.,false,,,http://purl.obolibrary.org/obo/TXPO_0001847,,,,,,,,,,,,,,,,,,,,,,Changing lipid homeostasis is a subtype of changing balance: A process that changes the steady state of lipid within an organism or cell.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001162,,,,,,,,,,,,,,,,,,,,,,changing lipid homeostasis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0019538,protein metabolic process,protein metabolism,The chemical reactions and pathways involving a protein. Includes protein modification.,false,,,http://purl.obolibrary.org/obo/GO_0008152,,,,,,,,,,,,,,,,,,,,Wikipedia:Protein_metabolism,,The chemical reactions and pathways involving a protein. Includes protein modification.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000306|http://purl.obolibrary.org/obo/GO_0030163,http://purl.obolibrary.org/obo/CHEBI_36080,,,,,,,,,,,,protein metabolism,,,,,GO:0019538,,,,,,,,,,,,,,,,,,,,,,protein metabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100580,syndecan-1,CD138 antigen|SYND1,,false,,,http://purl.obolibrary.org/obo/IMR_0100579,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CD138 antigen|SYND1,,,,,IMR:0100580,,,,,,,,,,,,,,,,,,,,,,syndecan-1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_23357,cofactor,,An organic molecule or ion (usually a metal ion) that is required by an enzyme for its activity. It may be attached either loosely (coenzyme) or tightly (prosthetic group).,false,,,http://purl.obolibrary.org/obo/TXPO_0003732,,,,,,,,,,,,,,,,,,,,Wikipedia:Cofactor_(biochemistry),,An organic molecule or ion (usually a metal ion) that is required by an enzyme for its activity. It may be attached either loosely (coenzyme) or tightly (prosthetic group).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:23357,,,,,,,,,,,,,,,,,,,,,,cofactor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000353,BLNK/SLP-65,,,false,,,http://purl.obolibrary.org/obo/IMR_0100258,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000353,,,,,,,,,,,,,,,,,,,,,,BLNK/SLP-65,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000001982,EIF4G2,,Other designations: DAP-5|aging-associated protein 1|death-associated protein 5|eIF-4-gamma 2|eIF-4G 2|eIF4G 2|eukaryotic translation initiation factor 4 gamma 2|eukaryotic translation initiation factor 4G-like 1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,AAG1|P97|DAP5|NAT1,,,,,,,,,,,,11,,,,,,HGNC:3297|Vega:OTTHUMG00000165823|HPRD:09084|Ensembl:ENSG00000110321|MIM:602325,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"eukaryotic translation initiation factor 4 gamma, 2",,,11p15,,,,,,,,,,,,,,,,"GO_0003743 (EC: IDA, PMID:11943866); GO_0005515 (EC: IPI, PMID:16166382); GO_0005829 (EC: TAS); GO_0006446 (EC: IDA, PMID:11943866); GO_0007050 (EC: TAS, PMID:9032289); GO_0008135 (EC: IDA, PMID:16289705); GO_0008219 (EC: TAS, PMID:9032289); GO_0016281 (EC: IDA, PMID:11943866); GO_0019221 (EC: TAS); GO_0044822 (EC: IDA)",,,,,,,,,PMID:8125298; 9027506; 9032289; 9049310; 9372926; 9418880; 9878069; 10394359; 10611228; 11172724; 11175261; 11331597; 11511540; 11943866; 12477932; 12505164; 12665801; 12703993; 14507913; 14702039; 15016848; 15231748; 15302935; 15361857; 15489334; 15718103; 16166382; 16289705; 16344560; 16410684; 16751776; 16932749; 17195095; 17237356; 17353931; 18450493; 18491231; 18722383; 19615732; 19738201; 19769989; 20057060; 20467438; 20544972; 21139048; 21145461; 21890473; 21906983; 21963094; 21988832; 22505724; 22555068; 22623428; 22909319; 22939629; 23000965; 23318444,,,,,,,,,,,,,,,OGG:3000001982,,,,,,,"eukaryotic translation initiation factor 4 gamma, 2",,,,,,,,,,,,,Other designations: DAP-5|aging-associated protein 1|death-associated protein 5|eIF-4-gamma 2|eIF-4G 2|eIF4G 2|eukaryotic translation initiation factor 4 gamma 2|eukaryotic translation initiation factor 4G-like 1,,EIF4G2,,,,,,,,,,,,,,,,,,,,,,,1982,OK/SW-cl.75,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF4G2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001981,EIF4G1,,Other designations: EIF4-gamma|eIF-4-gamma 1|eucaryotic translation initiation factor 4G|eukaryotic translation initiation factor 4 gamma 1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,P220|EIF-4G1|EIF4GI|EIF4F|EIF4G|PARK18,,,,,,,,,,,,3,,,,,,HPRD:06774|MIM:600495|Vega:OTTHUMG00000156784|HGNC:3296|Ensembl:ENSG00000114867,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"eukaryotic translation initiation factor 4 gamma, 1",,,3q27.1,,,,,,,,,,,,,,,,"GO_0000184 (EC: TAS); GO_0000288 (EC: TAS); GO_0000289 (EC: TAS); GO_0003743 (EC: TAS, PMID:8961935); GO_0005515 (EC: IPI, PMID:10523622); GO_0005829 (EC: TAS); GO_0006412 (EC: TAS); GO_0006413 (EC: TAS); GO_0006446 (EC: IMP, PMID:19648179); GO_0006446 (EC: NAS, PMID:8961935); GO_0008135 (EC: TAS, PMID:10880459); GO_0008219 (EC: IEA); GO_0008286 (EC: TAS); GO_0010467 (EC: TAS); GO_0016032 (EC: IEA); GO_0016070 (EC: TAS); GO_0016071 (EC: TAS); GO_0016281 (EC: TAS, PMID:9857202); GO_0019221 (EC: TAS); GO_0044267 (EC: TAS); GO_0044822 (EC: IDA)",,,,,,,,,PMID:1429670; 7601469; 7651417; 7935836; 8396129; 8449919; 8521827; 8889548; 8961935; 9002667; 9139875; 9372926; 9418880; 9755181; 9857202; 9878069; 10205060; 10523622; 10600798; 10753870; 10859165; 10872469; 10880459; 10970864; 10996799; 11154262; 11331597; 11340157; 11408474; 11606767; 11821405; 11866104; 12052860; 12054647; 12054764; 12071973; 12086624; 12149653; 12239292; 12477932; 12505164; 12581158; 12682023; 12897141; 14592777; 14610163; 14701818; 14702039; 15047801; 15128869; 15153109; 15193258; 15220445; 15231748; 15234964; 15302935; 15314020; 15314025; 15361857; 15452223; 15592455; 15713657; 15743837; 15755734; 15885108; 15897904; 15961545; 16009940; 16010989; 16156639; 16169070; 16236269; 16281055; 16344560; 16412378; 16513844; 16541103; 16556936; 16648488; 16698552; 16720573; 16766523; 16964243; 16982693; 17053147; 17081983; 17130132; 17195095; 17266347; 17290396; 17353931; 17361185; 17601486; 18250159; 18296639; 18426977; 18508616; 18573886; 18593934; 18614538; 18631141; 18799579; 19114555; 19203580; 19525934; 19596686; 19615732; 19648179; 19716330; 19738201; 19769989; 19850929; 19956697; 20020773; 20028737; 20053821; 20360068; 20398343; 21139048; 21145461; 21182205; 21252943; 21377182; 21454508; 21576361; 21840318; 21890473; 21900206; 21906983; 21907011; 21964297; 21988832; 22108332; 22145905; 22178476; 22280895; 22431630; 22505724; 22509910; 22561553; 22586265; 22586326; 22623428; 22658323; 22707335; 22759308; 22772876; 22863883; 22909319; 22939629; 23000965; 23041282; 23092605; 23112151; 23124435; 23261770; 23263986; 23408866; 23409027; 23455922; 23490116; 23562511; 23617574; 23726718; 23805307; 23862649; 23901100; 24092755; 24248602; 24250222,,,,,,,,,,,,,,,OGG:3000001981,,,,,,,"eukaryotic translation initiation factor 4 gamma, 1",,,,,,,,,,,,,Other designations: EIF4-gamma|eIF-4-gamma 1|eucaryotic translation initiation factor 4G|eukaryotic translation initiation factor 4 gamma 1,,EIF4G1,,,,,,,,,,,,,,,,,,,,,,,1981,,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF4G1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001984,EIF5A,,Other designations: eIF-4D|eIF-5A-1|eIF-5A1|eukaryotic initiation factor 5A|eukaryotic translation initiation factor 5A-1|rev-binding factor,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,EIF-5A|EIF5A1|eIF5AI,,,,,,,,,,,,17,,,,,,Vega:OTTHUMG00000102197|MIM:600187|HGNC:3300|HPRD:02555|Ensembl:ENSG00000132507,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,eukaryotic translation initiation factor 5A,,,17p13-p12,,,,,,,,,,,,,,,,"GO_0003723 (EC: IDA, PMID:15303967); GO_0003746 (EC: ISS); GO_0005515 (EC: IPI, PMID:10381392); GO_0005634 (EC: IDA, PMID:12210765); GO_0005642 (EC: IDA, PMID:12210765); GO_0005643 (EC: IDA, PMID:10381392); GO_0005737 (EC: IDA, PMID:12210765); GO_0005789 (EC: IEA); GO_0005829 (EC: TAS); GO_0006406 (EC: IMP, PMID:9465063); GO_0006452 (EC: IEA); GO_0006611 (EC: IMP, PMID:8596953); GO_0006913 (EC: IDA, Qualifier: NOT, PMID:12210765); GO_0006913 (EC: IMP, PMID:10381392); GO_0006915 (EC: IDA, PMID:15371445); GO_0008284 (EC: IGI, PMID:14622290); GO_0008612 (EC: TAS); GO_0017070 (EC: IDA, PMID:9285100); GO_0043022 (EC: IEA); GO_0043687 (EC: TAS); GO_0044267 (EC: TAS); GO_0044822 (EC: IDA); GO_0045901 (EC: ISS); GO_0045905 (EC: IEA); GO_0047485 (EC: IPI, PMID:15371445)",,,,,,,,,PMID:1286667; 1850732; 1900436; 2492279; 3095320; 7545941; 7578077; 7622067; 7759117; 7929297; 7971969; 8125298; 8253832; 8596953; 9285095; 9285100; 9442029; 9465063; 10229683; 10381392; 10944119; 11161802; 11238447; 11742107; 11790298; 11870779; 12210765; 12477932; 12562768; 12687616; 12788913; 12894223; 14622290; 15231747; 15303967; 15371445; 15489334; 16354571; 16371467; 16452303; 16515720; 16519677; 16522190; 16712791; 16842744; 16916647; 16987817; 17008552; 17187778; 17213197; 17578650; 18067580; 18781797; 19149558; 19160416; 19322201; 19379712; 19471022; 19825182; 19998337; 20232312; 20360068; 20639865; 20830705; 20942800; 21139048; 21145461; 21224998; 21360055; 21565611; 21693764; 21778671; 21890473; 21906983; 21942715; 21963094; 22053931; 22304920; 22354994; 22505724; 22771473; 22863883; 22908221; 22927971; 22939629; 22944692; 23000965; 23132580; 23322277; 23383273; 23402259; 23539416; 23733422; 23862649; 24220243; 24250222; 24509416,,,,,,,,,,,,,,,OGG:3000001984,,,,,,,eukaryotic translation initiation factor 5A,,,,,,,,,,,,,Other designations: eIF-4D|eIF-5A-1|eIF-5A1|eukaryotic initiation factor 5A|eukaryotic translation initiation factor 5A-1|rev-binding factor,,EIF5A,,,,,,,,,,,,,,,,,,,,,,,1984,,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF5A,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001983,EIF5,,,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,EIF-5A|EIF-5,,,,,,,,,,,,14,,,,,,HPRD:03417|Ensembl:ENSG00000100664|MIM:601710|Vega:OTTHUMG00000171839|HGNC:3299,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,eukaryotic translation initiation factor 5,,,14q32.32,,,,,,,,,,,,,,,,"GO_0003743 (EC: NAS, PMID:8663286); GO_0003924 (EC: TAS, PMID:8663286); GO_0005525 (EC: IEA); GO_0005737 (EC: IDA); GO_0005829 (EC: NAS, PMID:8663286); GO_0005829 (EC: TAS); GO_0005886 (EC: IDA); GO_0006184 (EC: TAS, PMID:8663286); GO_0006412 (EC: TAS); GO_0006413 (EC: NAS, PMID:8663286); GO_0006413 (EC: TAS); GO_0006446 (EC: TAS, PMID:8663286); GO_0008135 (EC: TAS, PMID:8663286); GO_0010467 (EC: TAS); GO_0044267 (EC: TAS); GO_0044822 (EC: IDA)",,,,,,,,,PMID:8663286; 9395514; 9973622; 10805737; 10982835; 11092890; 11230166; 11331597; 11861906; 12477932; 12569173; 14702039; 15489334; 16227438; 16584190; 16781736; 17081983; 17207965; 18029348; 19738201; 19953087; 20562859; 21139048; 21832049; 21890473; 21906983; 21963094; 21988832; 22062548; 22412018; 22813744; 22863883; 22939629; 23222517; 23293029; 24319994,,,,,,,,,,,,,,,OGG:3000001983,,,,,,,eukaryotic translation initiation factor 5,,,,,,,,,,,,,,,EIF5,,,,,,,,,,,,,,,,,,,,,,,1983,,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF5,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0100376,G-alpha-14,,,false,,,http://purl.obolibrary.org/obo/IMR_0000323,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100376,,,,,,,,,,,,,,,,,,,,,,G-alpha-14,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006508,proteolysis,,"The hydrolysis of proteins into smaller polypeptides and/or amino acids by cleavage of their peptide bonds.|This term was intentionally placed under 'protein metabolic process ; GO:0019538' rather than 'protein catabolic process ; GO:0030163' to cover all processes centered on breaking peptide bonds, including those involved in protein processing.",false,,,http://purl.obolibrary.org/obo/TXPO_0000333,,,,,,,,,,,,,,,,,,,,Wikipedia:Proteolysis,,The hydrolysis of proteins into smaller polypeptides and/or amino acids by cleavage of their peptide bonds.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_36080,,,,,,,,,,,,,,,,,,,,,,,GO:0006508,,,,,,,,,,,,,,,,,,,,"This term was intentionally placed under 'protein metabolic process ; GO:0019538' rather than 'protein catabolic process ; GO:0030163' to cover all processes centered on breaking peptide bonds, including those involved in protein processing.",,proteolysis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002353,positive regulator role of feeding behavior,,"A role played by the entity that activates or increases the frequency, rate or extent of feeding behavior.",false,,,http://purl.obolibrary.org/obo/TXPO_0003230,,,,,,,,,,,,,,,,,,,,,,"A role played by the entity that activates or increases the frequency, rate or extent of feeding behavior.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002353,,,,,,,,,,,,,,,,,,,,,,positive regulator role of feeding behavior,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002355,hypofunction of removing,,Hypofunction of removing is a subtype of hypofunctioning: A process that performs a decreased or insufficient removing.,false,,,http://purl.obolibrary.org/obo/TXPO_0000436,,,,,,,,,,,,,,,,,,,,,,Hypofunction of removing is a subtype of hypofunctioning: A process that performs a decreased or insufficient removing.,,,http://purl.obolibrary.org/obo/TXPO_0000458,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002355,,,,,,,,,,,,,,,,,,,,,,hypofunction of removing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002357,PPARalpha inactivation [alcoholic fatty liver],,"PPARalpha inactivation is a subtype of inactivation: A process that changes the activity of the activating PPAR alpha (Peroxisome Proliferator Activated Receptor Alpha) with a nuclear receptor role to be lower.
This entity is a specific course-dependent process. This process can constitute the course of alcoholic fatty liver.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0001571,,,,,,,,,,,,,,,,,,,"Reactome

The set of genes regulated by PPAR-alpha is not fully known in humans, however many examples have been found in mice. Genes directly activated by PPAR-alpha contain peroxisome proliferator receptor elements (PPREs) in their promoters and include:
1) genes involved in fatty acid oxidation and ketogenesis (Acox1, Cyp4a, Acadm, Hmgcs2);
2) genes involved in fatty acid transport (Cd36, , Slc27a1, Fabp1, Cpt1a, Cpt2);
3) genes involved in producing fatty acids and very low density lipoproteins (Me1, Scd1);
4) genes encoding apolipoproteins (Apoa1, Apoa2, Apoa5);
5) genes involved in triglyceride clearance ( Angptl4);
6) genes involved in glycerol metabolism (Gpd1 in mouse);",PMID:17854140,,"PPARalpha inactivation is a subtype of inactivation: A process that changes the activity of the activating PPAR alpha (Peroxisome Proliferator Activated Receptor Alpha) with a nuclear receptor role to be lower.
This entity is a specific course-dependent process. This process can constitute the course of alcoholic fatty liver.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001634,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002501,,,,,,,,,,,,,,,,,TXPO:0002357,,,,,,,,,,,,,,,,,,,,,,PPARalpha inactivation [alcoholic fatty liver],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002359,hyperfunction of moving drug to the inside of liver,,Hyperfunction of moving drug to the inside of liver is a subtype of hyperfunction of moving A to the inside of B: A process that performs an excesssive moving drug to the inside of liver.,false,,,http://purl.obolibrary.org/obo/TXPO_0001681,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of moving drug to the inside of liver is a subtype of hyperfunction of moving A to the inside of B: A process that performs an excesssive moving drug to the inside of liver.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002359,,,,,,,,,,,,,,,,,,,,,,hyperfunction of moving drug to the inside of liver,,,,,,http://purl.obolibrary.org/obo/TXPO_0000312,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002352,hyperfunction of metabolism,,Hyperfunction of metabolism is a subtype of hyperfunctioning: A process that performs an excessive metabolism.,false,,,http://purl.obolibrary.org/obo/TXPO_0000435,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of metabolism is a subtype of hyperfunctioning: A process that performs an excessive metabolism.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002352,,,,,,,,,,,,,,,,,,,,,,hyperfunction of metabolism,,,,,,http://purl.obolibrary.org/obo/GO_0008152,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002354,hypofunction of metabolism,,Hypofunction of metabolism is a subtype of hypofunction of changing between operands: A process that performs a decreased or insufficient metabolism.,false,,,http://purl.obolibrary.org/obo/TXPO_0000436,,,,,,,,,,,,,,,,,,,,,,Hypofunction of metabolism is a subtype of hypofunction of changing between operands: A process that performs a decreased or insufficient metabolism.,,,http://purl.obolibrary.org/obo/GO_0008152,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002354,,,,,,,,,,,,,,,,,,,,,,hypofunction of metabolism,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002351,hyperfunction of transport,,Hyperfunction of transport is a subtype of hyperfunctioning: A process that performs an excesssive transport.,false,,,http://purl.obolibrary.org/obo/TXPO_0000435,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of transport is a subtype of hyperfunctioning: A process that performs an excesssive transport.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002351,,,,,,,,,,,,,,,,,,,,,,hyperfunction of transport,,,,,,http://purl.obolibrary.org/obo/GO_0006810,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002356,"hypofunction of transcription, DNA-templated","decreasing function of transcription, DNA-templated","Hypofunction of transcription, DNA-templated is a subtype of hypofunctioning: A process that hypofunction of transcription, DNA-templated",false,,,http://purl.obolibrary.org/obo/TXPO_0000436,,,,,,,,,,,,,,,,,,,,,,"Hypofunction of transcription, DNA-templated is a subtype of hypofunctioning: A process that hypofunction of transcription, DNA-templated",,,http://purl.obolibrary.org/obo/GO_0006351,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"decreasing function of transcription, DNA-templated",,,,,TXPO:0002356,,,,,,,,,,,,,,,,,,,,,,"hypofunction of transcription, DNA-templated",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002350,peroxisome proliferator,,A role played by the entity for peroxisome proliferation,false,,,http://purl.obolibrary.org/obo/TXPO_0000625,,,,,,,,,,,,,,,,,,,,,,A role played by the entity for peroxisome proliferation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002350,,,,,,,,,,,,,,,,,,,,,,peroxisome proliferator,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002358,lipid metabolic regulator role,,A role played by the entity which regulates lipid metabolic process.,false,,,http://purl.obolibrary.org/obo/TXPO_0004023,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006629,,,,,,,,,,,,,A role played by the entity which regulates lipid metabolic process.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002358,,,,,,,,,,,,,,,,,,,,,,lipid metabolic regulator role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100255,DLK family,zipper protein kinase|ZPK|MUK|MAP3K12|Leucine-zipper protein kinase|Dual leucine zipper bearing kinase|MAPK upstream kinase,,false,,,http://purl.obolibrary.org/obo/IMR_0100254,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,zipper protein kinase|ZPK|MUK|MAP3K12|Leucine-zipper protein kinase|Dual leucine zipper bearing kinase|MAPK upstream kinase,,,,,IMR:0100255,,,,,,,,,,,,,,,,,,,,,,DLK family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_35469,antidepressant,thymoleptics|antidepressant drugs|thymoanaleptics|antidepressants|thymoleptic drugs,Antidepressants are mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions.,false,,,http://purl.obolibrary.org/obo/CHEBI_35471,,,,,,,,,,,,,,,,,,,,,,Antidepressants are mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,thymoleptics|antidepressant drugs|thymoanaleptics|antidepressants|thymoleptic drugs,,,,,,,,,,,,,,,,,,,,,CHEBI:35469,,,,antidepressant,,CHEBI:35469,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0007028,cytoplasm organization,cytoplasm organisation,"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the cytoplasm. The cytoplasm is all of the contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures.",false,,,http://purl.obolibrary.org/obo/GO_0071840,,,,,,,,,,,,,,,,,,,,,,"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the cytoplasm. The cytoplasm is all of the contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,cytoplasm organisation,,,,,GO:0007028,,,,,,,,,,,,,,,,,,,,,,cytoplasm organization,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000017,G-CSF,granulocyte colony-stimulating factor,related molecular function GO:0005130,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000622,,,,,granulocyte colony-stimulating factor,,,,,IMR:0000017,,,,,,,,,,,,,,,,,,,,related molecular function GO:0005130,,G-CSF,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_34559,benzarone,2-Ethyl-3-(4-hydroxybenzoyl)benzofuran|benzaron|Benzarone,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Drug_Central:317|CAS:1477-19-6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Benzarone,,2-Ethyl-3-(4-hydroxybenzoyl)benzofuran|benzaron,,,,,,,,,,,,,,,,,,,,,CHEBI:34559,,,,benzarone,,CHEBI:34559,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100193,kinesin-like protein,,,false,,,http://purl.obolibrary.org/obo/IMR_0100192,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100193,,,,,,,,,,,,,,,,,,,,,,kinesin-like protein,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_77103,EC 1.3.5.2 [dihydroorotate dehydrogenase (quinone)] inhibitor,(S)-dihydroorotate:acceptor oxidoreductase inhibitors|DHODH inhibitor|dihydroorotate:ubiquinone oxidoreductase inhibitors|(S)-dihydroorotate:acceptor oxidoreductase inhibitor|EC 1.3.5.2 inhibitors|DHOD inhibitors|(S)-dihydroorotate:(acceptor) oxidoreductase inhibitors|DHOdehase inhibitors|EC 1.3.5.2 (dihydroorotate dehydrogenase (quinone)) inhibitors|DHOD inhibitor|EC 1.3.5.2 [dihydroorotate dehydrogenase (quinone)] inhibitors|EC 1.3.5.2 (dihydroorotate dehydrogenase (quinone)) inhibitor|(S)-dihydroorotate:(acceptor) oxidoreductase inhibitor|EC 1.3.5.2 inhibitor|(S)-dihydroorotate:quinone oxidoreductase inhibitors|DHODH inhibitors|(S)-dihydroorotate:quinone oxidoreductase inhibitor|dihydroorotate:ubiquinone oxidoreductase inhibitor|DHOdehase inhibitor,"An EC 1.3.5.* (oxidoreductase acting on CH-CH of donor with a quinone or related compound as acceptor) inhibitor that interferes with the action of dihydroorotate dehydrogenase (quinone), EC 1.3.5.2.",false,,,http://purl.obolibrary.org/obo/CHEBI_77102,,,,,,,,,,,,,,,,,,,,,,"An EC 1.3.5.* (oxidoreductase acting on CH-CH of donor with a quinone or related compound as acceptor) inhibitor that interferes with the action of dihydroorotate dehydrogenase (quinone), EC 1.3.5.2.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,(S)-dihydroorotate:acceptor oxidoreductase inhibitors|DHODH inhibitor|dihydroorotate:ubiquinone oxidoreductase inhibitors|(S)-dihydroorotate:acceptor oxidoreductase inhibitor|EC 1.3.5.2 inhibitors|DHOD inhibitors|(S)-dihydroorotate:(acceptor) oxidoreductase inhibitors|DHOdehase inhibitors|EC 1.3.5.2 (dihydroorotate dehydrogenase (quinone)) inhibitors|DHOD inhibitor|EC 1.3.5.2 [dihydroorotate dehydrogenase (quinone)] inhibitors|EC 1.3.5.2 (dihydroorotate dehydrogenase (quinone)) inhibitor|(S)-dihydroorotate:(acceptor) oxidoreductase inhibitor|EC 1.3.5.2 inhibitor|(S)-dihydroorotate:quinone oxidoreductase inhibitors|DHODH inhibitors|(S)-dihydroorotate:quinone oxidoreductase inhibitor|dihydroorotate:ubiquinone oxidoreductase inhibitor|DHOdehase inhibitor,,,,,,,,,,,,,,,,,,,,,CHEBI:77103,,,,EC 1.3.5.2 [dihydroorotate dehydrogenase (quinone)] inhibitor,,CHEBI:77103,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000522,Aquaporin,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003696,,,,,,,,,,IMR:0000522,,,,,,,,,,,,,,,,,,,,,,Aquaporin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_17855,triglyceride,Triacylglycerol,"Any glyceride resulting from the condensation of all three hydroxy groups of glycerol (propane-1,2,3-triol) with fatty acids.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:2474544,,"Any glyceride resulting from the condensation of all three hydroxy groups of glycerol (propane-1,2,3-triol) with fatty acids.",,,,,,,,,,,,C6H5O6R3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Triacylglycerol,,,,,CHEBI:17855,,,,,,,,,,,,,,,,,,,,,,triglyceride,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,[*]C(=O)OCC(COC([*])=O)OC([*])=O,,,,,
http://purl.obolibrary.org/obo/IMR_0000488,gamma-actin,,,false,,,http://purl.obolibrary.org/obo/IMR_0000190,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000488,,,,,,,,,,,,,,,,,,,,,,gamma-actin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000001374,CPT1A,,,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CPTI|CPT1-L|L-CPT1,,,,,,,,,,,,22,,,,,,MIM:600528|Vega:OTTHUMG00000167892|HPRD:02755|Ensembl:ENSG00000110090|HGNC:2328,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,carnitine palmitoyltransferase 1A (liver),,,11q13.2,,,,,,,,,,,,,,,,GO_0004095 (EC: IEA); GO_0005739 (EC: IDA); GO_0005741 (EC: TAS); GO_0006635 (EC: IEA); GO_0006853 (EC: TAS); GO_0016021 (EC: IEA); GO_0044255 (EC: TAS); GO_0044281 (EC: TAS),,,,,,,,,PMID: 7892212; 9070836; 9070950; 9691089; 10408760; 11001805; 11095714; 11257506; 11350182; 11441142; 12111367; 12189492; 12464674; 12477932; 14517221; 14711372; 15489334; 15647998; 15669684; 15846373; 16054041; 16246309; 16271724; 16344560; 16697732; 16806233; 17089095; 17445541; 17452323; 18029348; 18253084; 18385088; 18996102; 19181627; 19217814; 19460752; 19913121; 20124555; 20301700; 20562859; 20602615; 20628086; 20638986; 20691246; 20696606; 20843525; 20877624; 20937660; 21139048; 21252943,,,,,,,,,,,,,,,OGG:3000001374,,,,,,,carnitine palmitoyltransferase 1,,,,,,,,,,,,,,,CPT1A,,,,,,,,,,,,,,,,,,,,,,,1374,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,CPT1A,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001376,CPT2,,"Other designations: CPT II|carnitine O-palmitoyltransferase 2, mitochondrial|carnitine palmitoyltransferase II",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CPTASE|CPT1|IIAE4,,,,,,,,,,,,1,,,,,,Vega:OTTHUMG00000008942|HPRD:02802|MIM:600650|Ensembl:ENSG00000157184|HGNC:2330,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,carnitine palmitoyltransferase 2,,,1p32,,,,,,,,,,,,,,,,"GO_0004095 (EC: NAS, PMID: 1988962); GO_0005634 (EC: IDA); GO_0005730 (EC: IDA); GO_0005730 (EC: IDA, Qualifier: NOT); GO_0005739 (EC: IDA); GO_0005743 (EC: NAS, PMID: 1988962); GO_0005743 (EC: TAS); GO_0006635 (EC: IEA); GO_0006853 (EC: TAS); GO_0044255 (EC: TAS); GO_0044281 (EC: TAS)",,,,,,,,,PMID: 1528846; 1961767; 1988962; 2174799; 7711730; 7892212; 7896283; 8086471; 8125298; 8358442; 8499929; 8651281; 9600456; 9758712; 10090476; 10607472; 11001805; 11095714; 11257506; 11477613; 11855939; 11994355; 12408750; 12410208; 12477932; 12707442; 12971426; 14605500; 14615409; 15489334; 15622536; 15642848; 15647998; 15754283; 16054041; 16168441; 16670153; 16671104; 16710414; 16996287; 17179390; 17651973; 17709715; 17936304; 18024217; 18029348; 18306170; 18363739; 18550408; 18645163; 18996102; 19362304; 19762733; 19913121; 20186120; 20301431; 20370797; 20538056; 20602615; 20628086; 20810031; 20877624; 20934285; 20952238; 21277129; 21641254; 21697855; 21913903; 22493507; 23322164; 23475205; 23566841,,,,,,,,,,,,,,,OGG:3000001376,,,,,,,carnitine palmitoyltransferase 2,,,,,,,,,,,,,"Other designations: CPT II|carnitine O-palmitoyltransferase 2, mitochondrial|carnitine palmitoyltransferase II",,CPT2,,,,,,,,,,,,,,,,,,,,,,,1376,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,CPT2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_52217,pharmaceutical,pharmaceuticals|medicament|farmaco,Any substance introduced into a living organism with therapeutic or diagnostic purpose.,false,,,http://purl.obolibrary.org/obo/BFO_0000023,,,,,,,,,,,,,,,,,,,,,,Any substance introduced into a living organism with therapeutic or diagnostic purpose.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pharmaceuticals|medicament|farmaco,,,,,,,,,,,,,,,,,,,,,CHEBI:52217,,,,pharmaceutical,,CHEBI:52217,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000005734,PTGER4,,"Other designations: PGE receptor EP4 subtype|PGE receptor, EP4 subtype|PGE2 receptor EP4 subtype|prostaglandin E2 receptor EP4 subtype|prostanoid EP4 receptor",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,EP4R|EP4,,,,,,,,,,,,5,,,,,,MIM:601586|Vega:OTTHUMG00000094769|Ensembl:ENSG00000171522|HPRD:03350|HGNC:9596,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,prostaglandin E receptor 4 (subtype EP4),,,5p13.1,,,,,,,,,,,,,,,,"GO_0004957 (EC: IDA, PMID: 8163486); GO_0005515 (EC: IPI, PMID: 16424369); GO_0005886 (EC: TAS); GO_0006955 (EC: IEP, PMID: 8862514); GO_0007188 (EC: IDA, PMID: 8163486); GO_0007254 (EC: ISS); GO_0009612 (EC: IEP); GO_0016021 (EC: NAS, PMID: 8163486); GO_0030278 (EC: IEA); GO_0032496 (EC: IEA); GO_0033624 (EC: IDA); GO_0042093 (EC: ISS); GO_0050710 (EC: ISS); GO_0050715 (EC: ISS); GO_0050728 (EC: IDA, PMID: 16424369); GO_0050729 (EC: ISS); GO_0051492 (EC: ISS); GO_0060348 (EC: ISS); GO_0070371 (EC: ISS); GO_0071260 (EC: ISS); GO_2000420 (EC: IDA)",,,,,,,,,PMID: 7759114; 8078484; 8163486; 8250933; 8661119; 8855294; 8862514; 9214685; 10880739; 11093764; 11344234; 11423555; 11470276; 11597569; 11706038; 11782353; 11876748; 11948128; 11951086; 12036966; 12149218; 12215436; 12228765; 12477932; 12566441; 14517215; 14709160; 15100359; 15290741; 15347673; 15489334; 15528329; 15970595; 16020747; 16424369; 16428339; 16432186; 16574793; 16857763; 17046175; 17130837; 17290397; 17447842; 17496729; 17525067; 17611676; 17631291; 17684544; 17877755; 18005048; 18083712; 18086382; 18254372; 18270204; 18319253; 18516068; 18587394; 18797183; 18802112; 18829529; 19227010; 19273625; 19336370; 19407222; 19407341; 19444759; 19445930; 19453261; 19525953; 19558693; 19760754; 19879194; 19913121; 20014019; 20018632; 20086108; 20145136; 20222910; 20237496; 20353998; 20452482; 20484658; 20503412; 20549515; 20551148; 20561984; 20587336; 20628086; 20673868; 20846217; 20962850; 20970516; 21052031; 21071691; 21072187; 21081469; 21102463; 21111772; 21297633; 21365278; 21424266; 21589857; 21600299; 21681739; 21683675; 21723865; 21743469; 21832044; 21833088; 21890473; 22037551; 22080750; 22199300; 22276108; 22353936; 22362924; 22412388; 22570697; 22580611; 22695889; 22704539; 22706114; 22732652; 22924768; 22936669; 23090667; 23128233; 23242524; 23300802; 23337716; 23613969; 23619266; 23759445; 23817569,,,,,,,,,,,,,,,OGG:3000005734,,,,,,,prostaglandin E receptor 4 (subtype EP4),,,,,,,,,,,,,"Other designations: PGE receptor EP4 subtype|PGE receptor, EP4 subtype|PGE2 receptor EP4 subtype|prostaglandin E2 receptor EP4 subtype|prostanoid EP4 receptor",,PTGER4,,,,,,,,,,,,,,,,,,,,,,,5734,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,PTGER4,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/GO_0042059,negative regulation of epidermal growth factor receptor signaling pathway,negative regulation of EGF receptor signaling pathway|negative regulation of EGF receptor signalling pathway|negative regulation of epidermal growth factor receptor signaling pathway|down regulation of epidermal growth factor receptor signaling pathway|negative regulation of EGFR signaling pathway,"Any process that stops, prevents, or reduces the frequency, rate or extent of epidermal growth factor receptor signaling pathway activity.",false,,,http://purl.obolibrary.org/obo/GO_0023057,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents, or reduces the frequency, rate or extent of epidermal growth factor receptor signaling pathway activity.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,negative regulation of EGF receptor signaling pathway|negative regulation of EGF receptor signalling pathway|negative regulation of epidermal growth factor receptor signaling pathway|down regulation of epidermal growth factor receptor signaling pathway|negative regulation of EGFR signaling pathway,,,,,GO:0042059,,,,,,,,,,,,,,,,,,,,,,negative regulation of epidermal growth factor receptor signaling pathway,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001492|http://purl.obolibrary.org/obo/GO_0007173,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000008717,TRADD,,Other designations: TNFR1-associated death domain protein|tumor necrosis factor receptor type 1 associated death domain protein|tumor necrosis factor receptor type 1-associated DEATH domain protein|tumor necrosis factor receptor-1-associated protein,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,Hs.89862,,,,,,,,,,,,16,,,,,,MIM:603500|HGNC:12030|HPRD:04610,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,TNFRSF1A-associated via death domain,,,16q22,,,,,,,,,,,,,,,,"GO_0004871 (EC: IEA); GO_0005164 (EC: IEA); GO_0005515 (EC: IPI, PMID: 1040062); GO_0005634 (EC: IEA); GO_0005737 (EC: IDA, PMID: 11684708); GO_0005829 (EC: TAS); GO_0005856 (EC: IEA); GO_0006915 (EC: TAS); GO_0006919 (EC: TAS); GO_0007165 (EC: TAS, PMID: 7758105); GO_0008625 (EC: TAS, PMID: 8612133); GO_0019900 (EC: IPI, PMID: 8612133); GO_0031264 (EC: TAS, PMID: 18309324); GO_0032403 (EC: IEA); GO_0033209 (EC: TAS, PMID: 8612133); GO_0042802 (EC: IPI, PMID: 11684708); GO_0043065 (EC: TAS, PMID: 18309324); GO_0043123 (EC: IEP, PMID: 12761501); GO_0043235 (EC: IDA, PMID: 8612133); GO_0045121 (EC: IEA); GO_0051092 (EC: TAS, PMID: 18309324); GO_0051291 (EC: IEA); GO_0051798 (EC: IEA); GO_0060090 (EC: IPI, PMID: 8612133); GO_0070513 (EC: IPI, PMID: 8612133); GO_0097190 (EC: TAS); GO_0097191 (EC: IMP, PMID: 16611992); GO_0097191 (EC: TAS, PMID: 18309324); GO_2001239 (EC: TAS)",,,,,,,,,PMID: 1040062; 7758105; 8565075; 8612133; 8621670; 8681376; 8702708; 8934525; 8943045; 9020361; 9082980; 9356494; 9427646; 9430227; 9560245; 9714541; 9915703; 9916731; 9916988; 10187805; 10356400; 10400625; 10544141; 10848577; 10892748; 10911999; 10980203; 11032752; 11035039; 11112409; 11112773; 11181075; 11226577; 11435712; 11479302; 11684708; 11821416; 11934887; 12045187; 12107169; 12417987; 12446787; 12477932; 12576460; 12604596; 12665801; 12753742; 12761501; 12796506; 12887920; 12911633; 14585990; 14644197; 14660619; 14702039; 14743216; 15103018; 15247912; 15310755; 15485837; 15489334; 15707590; 15761471; 16006552; 16227624; 16344560; 16603398; 16611992; 17051333; 17235653; 17540176; 17702576; 17922260; 18174230; 18198944; 18309324; 18661484; 18776134; 18939944; 18990758; 19151112; 19176810; 19287455; 19336370; 19379743; 19453261; 19573080; 19773279; 19781631; 19815541; 19854717; 20005846; 20568250; 20628368; 21068102; 21421854; 21724995; 21906983; 22099304; 22170762; 22179575; 22297296; 22510408; 22561347; 23732909; 23908590; 23955153; 23982205; 24130170; 24250222; 24374337,,,,,,,,,,,,,,,OGG:3000008717,,,,,,,TNFRSF1A-associated via death domain,,,,,,,,,,,,,Other designations: TNFR1-associated death domain protein|tumor necrosis factor receptor type 1 associated death domain protein|tumor necrosis factor receptor type 1-associated DEATH domain protein|tumor necrosis factor receptor-1-associated protein,,TRADD,,,,,,,,,,,,,,,,,,,,,,,8717,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,TRADD,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_33521,metal atom,,,false,,,http://purl.obolibrary.org/obo/CHEBI_33250,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:33521,,,,,,,,,,,,,,,,,,,,,,metal atom,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001097,BAD (human)[Lipidosis],,,false,,,http://purl.obolibrary.org/obo/IMR_0100288|http://purl.obolibrary.org/obo/TXPO_0001090,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:572|NCBI-Rat-GeneID:64639|NCBI-Mouse-GeneID:12015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001097,,,,,,,,,,,,,,,,,,,,,,BAD (human)[Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001090,lipidosis dependent molecule (human in vitro),,"Lipidosis dependent molecule is a subtype of toxic course dependent chemical entity.
This molecule can participate in the course of lipidosis as a gene product.
Gene profile:Human/in vitro/Hepatocyte/",false,,,http://purl.obolibrary.org/obo/TXPO_0001089,,,,,,,,,,,,,,,,,,,,,,"Lipidosis dependent molecule is a subtype of toxic course dependent chemical entity.
This molecule can participate in the course of lipidosis as a gene product.
Gene profile:Human/in vitro/Hepatocyte/",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001090,,,,,,,,,,,,,,,,,,,,,,lipidosis dependent molecule (human in vitro),,,,,,,,,,,http://purl.obolibrary.org/obo/NCBITaxon_9606,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001098,OXTR (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:18430|NCBI-Human-GeneID:5021|NCBI-Rat-GeneID:25342,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000005021,,,,,,,,,,,,,TXPO:0001098,,,,,,,,,,,,,,,,,,,,,,OXTR (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001099,OXTR (human)[lipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001786|http://purl.obolibrary.org/obo/TXPO_0001098,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:5021|PMID:21980491|PMID:24389591,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000005021,,,,,,,,,,,,,TXPO:0001099,,,,,,,,,,,,,,,,,,,,,,OXTR (human)[lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001091,ADH1B (human)[lipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001090|http://purl.obolibrary.org/obo/TXPO_0001092,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:125|PMID:29718361|PMID:29063269|PMID:26006114,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000125,,,,,,,,,,,,,TXPO:0001091,,,,,,,This gene encodes the mitochondrial enzyme which is catalyzes the rate-limiting step in heme (iron-protoporphyrin) biosynthesis.,,,,,,,,,,,,,,,ADH1B (human)[lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001093,BID (human)[Lipidosis],,,false,,,http://purl.obolibrary.org/obo/IMR_0100289|http://purl.obolibrary.org/obo/TXPO_0001090,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:64625|NCBI-Mouse-GeneID:12122|NCBI-Human-GeneID:637,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001093,,,,,,,,,,,,,,,,,,,,,,BID (human)[Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001092,ADH1B (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0001094,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:125,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000125,,,,,,,,,,,,,TXPO:0001092,,,,,,,,,,,,,,,,,,,,,,ADH1B (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001094,ADH family,Alcohol dehydrogenase family|alcohol dehydrogenase (NAD),,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,EC 1.1.1.1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Alcohol dehydrogenase family|alcohol dehydrogenase (NAD),,,,,TXPO:0001094,,,,,,,,,,,,,,,,,,,,,,ADH family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001096,hypofunction of alcohol metabolism,,Hypofunction of alcohol metabolism is a subtype of hyperfunctioning: A process that performs a decreased or insufficient alcohol metabolism.,false,,,http://purl.obolibrary.org/obo/TXPO_0000436,,,,,,,,,,,,,,,,,,,,,,Hypofunction of alcohol metabolism is a subtype of hyperfunctioning: A process that performs a decreased or insufficient alcohol metabolism.,,,http://purl.obolibrary.org/obo/GO_0006066,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001096,,,,,,,,,,,,,,,,,,,,,,hypofunction of alcohol metabolism,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001095,hyporfunction of alcohol metabolism [Lipidosis],,"Hypofunction of alcohol metabolism is a subtype of hyperfunctioning: A process that performs a decreased or insufficient alcohol metabolism.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0001096,,,,,,,,,,,,,,,,,,,,PMID:29718361,,"Hypofunction of alcohol metabolism is a subtype of hyperfunctioning: A process that performs a decreased or insufficient alcohol metabolism.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004007|http://purl.obolibrary.org/obo/TXPO_0001091,,,,,,http://purl.obolibrary.org/obo/TXPO_0001739,,,,,,,,,,,TXPO:0001095,,,,,,,,,,,,,,,,,,,,,,hyporfunction of alcohol metabolism [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100705,anti-apoptotic Bcl-2 family,pro-survival Bcl-2 family,,false,,,http://purl.obolibrary.org/obo/IMR_0000451,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pro-survival Bcl-2 family,,,,,IMR:0100705,,,,,,,,,,,,,,,,,,,,,,anti-apoptotic Bcl-2 family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000568,homeostasis imbalance,,"Homeostasis imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance.
Imbalance of homeostasis in the body is a  lacking balance between performing amounts of defense (supply) and required amounts of protection (demand)  in the maintenance of an internal state.",false,,,http://purl.obolibrary.org/obo/TXPO_0000567,,,,,,,,,,,,,,,,,,,,,,"Homeostasis imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance.
Imbalance of homeostasis in the body is a  lacking balance between performing amounts of defense (supply) and required amounts of protection (demand)  in the maintenance of an internal state.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000568,,,,,,,,,,,,,,,,,,,,,,homeostasis imbalance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000561,HYOU1 - chaperone -vitro (human)[ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000800,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000561,,,,,,,,,,,,,,,,,,,,,,HYOU1 - chaperone -vitro (human)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000795,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000566,calcium ion homeostasis imbalance [Oxidative stress],,"Calcium ion homeostasis imbalance is a subtype of chemical homeostasis imbalance: A process that becomes lacking a calcium ion homeostastasis balance.
This entity is a specific course-dependent process. This process can constitute the course of Oxidative stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001765|http://purl.obolibrary.org/obo/TXPO_0001730,,,,,,,,,,,,,,,,,,,,,,"Calcium ion homeostasis imbalance is a subtype of chemical homeostasis imbalance: A process that becomes lacking a calcium ion homeostastasis balance.
This entity is a specific course-dependent process. This process can constitute the course of Oxidative stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000814,,,,,,,,,,,TXPO:0000566,,,,,,,,,,,,,,,,,,,,,,calcium ion homeostasis imbalance [Oxidative stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000560,ground glass appearance dependent chemical compound,,"Ground glass appearance dependent chemical compound is a subtype of toxic course dependent chemical entity.
This entity (drug) can participate in the course of ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0000984,,,,,,,,,,,,,,,,,,,,,,"Ground glass appearance dependent chemical compound is a subtype of toxic course dependent chemical entity.
This entity (drug) can participate in the course of ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000560,,,,,,,,,,,,,,,,,,,,,,ground glass appearance dependent chemical compound,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000563,G6PC (mol),Glucose-6-Phosphatase Catalytic Subunit|G6Pase|Glucose-6-Phosphatase Alpha,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:14377|NCBI-Human-GeneID:2538|OMIM:232200|RGD:2644|NCBI-Rat-GeneID:25634,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000002538,,,,,,,,Glucose-6-Phosphatase Catalytic Subunit|G6Pase|Glucose-6-Phosphatase Alpha,,,,,TXPO:0000563,,,,,,,,,,,,,,,,,,,,,,G6PC (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000562,phospholipase C inhibitor role,EC.3.1.4.3 (phospholipase C) inhibitor,"A role played by the entity that inhibits the catalysis of the reaction: a phospholipid + H2O = 1,2-diacylglycerol + a phosphatidate.",false,,,http://purl.obolibrary.org/obo/TXPO_0000559,,,,,,,,,,,,,,,,,,,,,,"A role played by the entity that inhibits the catalysis of the reaction: a phospholipid + H2O = 1,2-diacylglycerol + a phosphatidate.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,EC.3.1.4.3 (phospholipase C) inhibitor,,,TXPO:0000562,,,,,,,,,,,,,,,,,,,,,,phospholipase C inhibitor role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000567,imbalance,,Imbalance is a subtype of changing balance: A process that becomes lacking a correct balance between operands.,false,,,http://purl.obolibrary.org/obo/TXPO_0001847,,,,,,,,,,,,,,,,,,,,,,Imbalance is a subtype of changing balance: A process that becomes lacking a correct balance between operands.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000567,,,,,,,,,,,,,,,,,,,,,,imbalance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000565,peroxidase,oxyperoxidase,Catalysis role of the reaction: donor + hydrogen peroxide = oxidized donor + 2 H2O.|related molecular function GO:0004601,false,,,http://purl.obolibrary.org/obo/TXPO_0003660,,,,,,,,,,,,,,,,,,,,EC:1.11.1.7,,Catalysis role of the reaction: donor + hydrogen peroxide = oxidized donor + 2 H2O.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_22586,,,,,oxyperoxidase,,,,,TXPO:0000565,,,,,,,,,,,,,,,,,,,,related molecular function GO:0004601,,peroxidase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000569,endoplasmic reticulum stress response imbalance [ER stress],,"Endoplasmic reticulum stress response imbalance is a subtype of stress response imbalance: A process that lacks a balance between the stimulation (stress) acting on the endoplasmic reticulum and the biological defence response.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000571|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"Endoplasmic reticulum stress response imbalance is a subtype of stress response imbalance: A process that lacks a balance between the stimulation (stress) acting on the endoplasmic reticulum and the biological defence response.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002747|http://purl.obolibrary.org/obo/TXPO_0002460|http://purl.obolibrary.org/obo/TXPO_0002458|http://purl.obolibrary.org/obo/TXPO_0002479,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000752,,,,,,,,,,,TXPO:0000569,,,,,,,,,,,,,,,,,,,,,,endoplasmic reticulum stress response imbalance [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000564,signalling molecule role,signal molecule|signaling molecule,"A molecular messenger in which the molecule is specifically involved in transmitting information between cells. Such molecules are released from the cell sending the signal, cross over the gap between cells by diffusion, and interact with specific receptors in another cell, triggering a response in that cell by activating a series of enzyme controlled reactions which lead to changes inside the cell.",false,,,http://purl.obolibrary.org/obo/CHEBI_33280,,,,,,,,,,,,,,,,,,,,,,"A molecular messenger in which the molecule is specifically involved in transmitting information between cells. Such molecules are released from the cell sending the signal, cross over the gap between cells by diffusion, and interact with specific receptors in another cell, triggering a response in that cell by activating a series of enzyme controlled reactions which lead to changes inside the cell.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,signal molecule|signaling molecule,,,TXPO:0000564,,,,,,,,,,,,,,,,,,,,,,signalling molecule role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0001281,hepatic sinusoid,liver sinusoid|liver hepatic sinusoids|sinusoid of liver|liver sinusoidal blood vessel|vas capillare sinusoideum,Wide thin-walled blood vessels in the liver. In mammals they have neither veinous or arterial markers.,false,,,http://purl.obolibrary.org/obo/UBERON_0015796,,,,,,,,,,,,,,,,,,,,,,Wide thin-walled blood vessels in the liver. In mammals they have neither veinous or arterial markers.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,liver sinusoid|liver hepatic sinusoids|sinusoid of liver|liver sinusoidal blood vessel|vas capillare sinusoideum,,,,,UBERON:0001281,,,,,,,,,,,,,,,,,,,,,,hepatic sinusoid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0001283,bile canaliculus,,"An intercellular channel that takes up bile from hepatocytes, transporting it to the bile ducts.",false,,,http://purl.obolibrary.org/obo/UBERON_0000464,,,,,,,,,,,,,,,,,,,,,,"An intercellular channel that takes up bile from hepatocytes, transporting it to the bile ducts.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0001113|http://purl.obolibrary.org/obo/UBERON_0002394,UBERON:0001283,http://purl.obolibrary.org/obo/UBERON_0001113|http://purl.obolibrary.org/obo/UBERON_0002394,,,,,,bile canaliculus,,,,,,,,,,,,,,,bile canaliculus,,,,http://en.wikipedia.org/wiki/Bile_canaliculus,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000003182,HNRNPAB,,"Other designations: ABBP-1|APOBEC1-binding protein 1|apobec-1 binding protein 1|apolipoprotein B mRNA editing enzyme, catalytic polypeptide 1-binding protein 1|hnRNP A/B|hnRNP type A/B protein",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,ABBP1|HNRPAB,,,,,,,,,,,,5,,,,,,Ensembl:ENSG00000197451|HPRD:04067|HGNC:5034|Vega:OTTHUMG00000163452|MIM:602688,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,heterogeneous nuclear ribonucleoprotein A/B,,,5q35.3,,,,,,,,,,,,,,,,"GO_0000166 (EC: IEA); GO_0001837 (EC: ISS); GO_0003700 (EC: ISS, Qualifier: contributes_to); GO_0003723 (EC: TAS, PMID: 1717314); GO_0003729 (EC: TAS, PMID: 8999813); GO_0005634 (EC: ISS); GO_0005737 (EC: ISS); GO_0030529 (EC: IDA, PMID: 17289661); GO_0043565 (EC: ISS, Qualifier: contributes_to); GO_0044822 (EC: IDA); GO_0045893 (EC: ISS)",,,,,,,,,PMID: 1717314; 8125298; 8895530; 8999813; 11313474; 11790298; 11937625; 12388589; 12477932; 12692135; 14702039; 14704337; 14722087; 15324660; 15489334; 15782174; 16964243; 17289661; 17332742; 17353931; 17643375; 18029348; 18457437; 18850631; 19738201; 20000738; 20020773; 20085233; 20211142; 20360068; 21110914; 21139048; 21145461; 21182205; 21642987; 21853274; 21890473; 21906983; 21942715; 22053931; 22174317; 22178446; 22365833; 22505724; 22623428; 22751105; 22863883; 22939629; 23000965; 23077236; 23151878; 23184937; 23246001; 23398456; 23455922; 23500468; 24457600,,,,,,,,,,,,,,,OGG:3000003182,,,,,,,heterogeneous nuclear ribonucleoprotein A/B,,,,,,,,,,,,,"Other designations: ABBP-1|APOBEC1-binding protein 1|apobec-1 binding protein 1|apolipoprotein B mRNA editing enzyme, catalytic polypeptide 1-binding protein 1|hnRNP A/B|hnRNP type A/B protein",,HNRNPAB,,,,,,,,,,,,,,,,,,,,,,,3182,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,HNRNPAB,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_28757,fructose,,A ketohexose that is an isomer of glucose.,false,,,http://purl.obolibrary.org/obo/CHEBI_35381,,,,,,,,,,,,,,,,,,,,,,A ketohexose that is an isomer of glucose.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:28757,,,,,,,,,,,,,,,,,,,,,,fructose,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100430,NF-1,Neurofibromatosis-related protein NF-1|Neurofibromin,,false,,,http://purl.obolibrary.org/obo/IMR_0000443,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Neurofibromatosis-related protein NF-1|Neurofibromin,,,,,IMR:0100430,,,,,,,,,,,,,,,,,,,,,,NF-1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100276,epiregulin,EPR,,false,,,http://purl.obolibrary.org/obo/IMR_0000047,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,EPR,,,,,IMR:0100276,,,,,,,,,,,,,,,,,,,,,,epiregulin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100813,CKI-gamma 3,"Casein kinase I, gamma 3 isoform",,false,,,http://purl.obolibrary.org/obo/IMR_0100809,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Casein kinase I, gamma 3 isoform",,,,,IMR:0100813,,,,,,,,,,,,,,,,,,,,,,CKI-gamma 3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000485,alpha-actinin 4,,,false,,,http://purl.obolibrary.org/obo/IMR_0000189,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000485,,,,,,,,,,,,,,,,,,,,,,alpha-actinin 4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001646,RABL2B,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001646,,,,,,,,,,,,,,,,,,,,,,RABL2B,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0019585,glucuronate metabolic process,,"The chemical reactions and pathways involving glucuronate, any salt or ester of glucuronic acid, the uronic acid formally derived from glucose by oxidation of the hydroxymethylene group at C-6 to a carboxyl group.",false,,,http://purl.obolibrary.org/obo/GO_0008152,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways involving glucuronate, any salt or ester of glucuronic acid, the uronic acid formally derived from glucose by oxidation of the hydroxymethylene group at C-6 to a carboxyl group.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0019585,,,,,,,,,,,,,,,,,,,,,,glucuronate metabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001379,lipid degradation related gene expression [lipidosis],,"Lipid degradtion related gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature lipid degradation related gene product or products (proteins or RNA).
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0001381,,,,,,,,,,,,,,,,,,,,,,"Lipid degradtion related gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature lipid degradation related gene product or products (proteins or RNA).
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001220,,,,,,,,,,,TXPO:0001379,,,,,,,,,,,,,,,,,,,,,,lipid degradation related gene expression [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005634,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001370,NRF2 activation by PERK,,"NRF2 activation by PERK is a subtype of NRF2 activation: A process that changes the activity of NRF2 (Nuclear Factor, Erythroid 2 Like 2) to be higher by PERK.",false,,,http://purl.obolibrary.org/obo/TXPO_0001283,,,,,,,,,,,,,,,,,,,,,,"NRF2 activation by PERK is a subtype of NRF2 activation: A process that changes the activity of NRF2 (Nuclear Factor, Erythroid 2 Like 2) to be higher by PERK.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001370,,,,,,,,,,,,,,,,,,,,,,NRF2 activation by PERK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001378,hyperfunction of glutathione synthetic gene expression,,Hyperfunction of glutathione synthetic gene expression is a subtype of hyperfunction of gene expression: A process that performs an excesssive glutathione synthetic gene expression.,false,,,http://purl.obolibrary.org/obo/TXPO_0002345,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of glutathione synthetic gene expression is a subtype of hyperfunction of gene expression: A process that performs an excesssive glutathione synthetic gene expression.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001378,,,,,,,,,,,,,,,,,,,,,,hyperfunction of glutathione synthetic gene expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001372,increasing aldosterone concentration in blood,,Increasing aldosterone concentration in blood is a subtype of increasing concentration: A process that changes the aldosterone concentration in the blood to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000352,,,,,,,,,,,,,,,,,,,,,,Increasing aldosterone concentration in blood is a subtype of increasing concentration: A process that changes the aldosterone concentration in the blood to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001372,,,,,,,,,,,,,,,,,,,,,,increasing aldosterone concentration in blood,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001374,edema (process),,Edema is a subtype of accumulation of fluids: A process that keeps an excessive fluid in cells or intercellular tissues.,false,,,http://purl.obolibrary.org/obo/TXPO_0000488,,,,,,,,,,,,,,,,,,,,HP:0000969,,Edema is a subtype of accumulation of fluids: A process that keeps an excessive fluid in cells or intercellular tissues.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001374,,,,,,,,,,,,,,,,,,,,,,edema (process),,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/HP_0000969,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001376,hypofunction of estrogen degradation,,Hypofunction of estrogen degradation is a subtype of hypofunction of decomposing: A process that performs a decreased or insufficient estrogen degradation.,false,,,http://purl.obolibrary.org/obo/TXPO_0000940,,,,,,,,,,,,,,,,,,,,,,Hypofunction of estrogen degradation is a subtype of hypofunction of decomposing: A process that performs a decreased or insufficient estrogen degradation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001377,,,,,,,,,,,TXPO:0001376,,,,,,,,,,,,,,,,,,,,,,hypofunction of estrogen degradation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001371,VLDL release from hepatocyte [Lipidosis],,"The directed movement of VLDL, out of a hepatocyte.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001356|http://purl.obolibrary.org/obo/TXPO_0001720,,,,,,,,,,,,,,,,,,,,,,"The directed movement of VLDL, out of a hepatocyte.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001371,,,,,,,,,,,,,,,,,,,,,,VLDL release from hepatocyte [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001375,hypofunction of hormone metabolic process,,Hypofunction of hormone metabolic process is a subtype of hypofunction of metabolism: A process that performs a decreased or insufficient hormone metabolic process.,false,,,http://purl.obolibrary.org/obo/TXPO_0002354,,,,,,,,,,,,,,,,,,,,,,Hypofunction of hormone metabolic process is a subtype of hypofunction of metabolism: A process that performs a decreased or insufficient hormone metabolic process.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001375,,,,,,,,,,,,,,,,,,,,,,hypofunction of hormone metabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001373,nephrotoxic agent,nephrotoxicant,A role played by a chemical compound exihibiting itself through the ability to induce damage to the kidney in animals.,false,,,http://purl.obolibrary.org/obo/TXPO_0000038,,,,,,,,,,,,,,,,,,,,,,A role played by a chemical compound exihibiting itself through the ability to induce damage to the kidney in animals.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,nephrotoxicant,,,TXPO:0001373,,,,,,,,,,,,,,,,,,,,,,nephrotoxic agent,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001377,increasing estrogen concentration in blood,,Increasing estrogen concentration in blood is a subtype of increasing concentration: A process that changes the estrogen concentration in  the blood to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000352,,,,,,,,,,,,,,,,,,,,,,Increasing estrogen concentration in blood is a subtype of increasing concentration: A process that changes the estrogen concentration in  the blood to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001377,,,,,,,,,,,,,,,,,,,,,,increasing estrogen concentration in blood,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000000843,CASP10,,"Other designations: CASP-10|FADD-like ICE2|FAS-associated death domain protein interleukin-1B-converting enzyme 2|ICE-like apoptotic protease 4|apoptotic protease MCH-4|caspase 10, apoptosis-related cysteine protease|caspase-10|interleukin-1B-converting enzyme 2",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,ALPS2|FLICE2|MCH4,,,,,,,,,,,,2,,,,,,HPRD:03458|Vega:OTTHUMG00000132818|Ensembl:ENSG00000003400|MIM:601762|HGNC:1500,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"caspase 10, apoptosis-related cysteine peptidase",,,2q33-q34,,,,,,,,,,,,,,,,"GO_0004197 (EC: TAS, PMID:10412980); GO_0005515 (EC: IPI, PMID:12884866); GO_0005737 (EC: IBA); GO_0005829 (EC: TAS); GO_0005886 (EC: TAS); GO_0006915 (EC: IBA); GO_0006915 (EC: TAS); GO_0031265 (EC: IDA, PMID:11717445); GO_0031625 (EC: IPI, PMID:15069192); GO_0035877 (EC: IPI, PMID:11717445); GO_0042981 (EC: IEA); GO_0043123 (EC: IMP, PMID:12884866); GO_0043123 (EC: RCA, PMID:19641626); GO_0045087 (EC: TAS); GO_0097190 (EC: TAS); GO_0097199 (EC: IMP, PMID:11717445); GO_0097342 (EC: IDA)",,,,,,,,,PMID:170210; 1171445; 3031469; 8125298; 8521391; 8755496; 8962078; 9045686; 9153302; 9208847; 9228018; 9289491; 9325248; 9337844; 9792675; 10187817; 10412980; 10432301; 10716992; 10734073; 11002417; 11048727; 11098060; 11161814; 11395500; 11583996; 11717445; 11832478; 11973654; 12010812; 12037669; 12198154; 12388546; 12477932; 12527898; 12884866; 12887920; 14687710; 14688482; 14759258; 14761933; 15069192; 15280356; 15452117; 15500642; 15659383; 15735701; 15767684; 15772077; 16186808; 16251207; 16344560; 16446975; 16767158; 17071630; 17085968; 17159907; 17450141; 17479112; 17534194; 17623017; 17822854; 17999750; 18381704; 18563783; 18676680; 18716417; 18823309; 19074885; 19141860; 19166881; 19170196; 19219602; 19269008; 19380486; 19414860; 19423537; 19550122; 19604093; 19625176; 19641626; 19692168; 19773279; 19784808; 19826114; 19861680; 19900088; 19902255; 20025484; 20301287; 20402676; 20453000; 20467438; 20644561; 20661084; 20800603; 20802294; 20829884; 20855536; 20959405; 20978178; 21048031; 21139048; 21368896; 21454616; 21559821; 21911414; 21988832; 22683265; 22782902; 22843554; 22864571; 23212337; 23303631; 23541952; 23770605; 23921907,,,,,,,,,,,,,,,OGG:3000000843,,,,,,,"caspase 10, apoptosis-related cysteine peptidase",,,,,,,,,,,,,"Other designations: CASP-10|FADD-like ICE2|FAS-associated death domain protein interleukin-1B-converting enzyme 2|ICE-like apoptotic protease 4|apoptotic protease MCH-4|caspase 10, apoptosis-related cysteine protease|caspase-10|interleukin-1B-converting enzyme 2",,CASP10,,,,,,,,,,,,,,,,,,,,,,,843,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CASP10,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000000840,CASP7,,"Other designations: ICE-like apoptotic protease 3|apoptotic protease MCH-3|caspase 7, apoptosis-related cysteine protease|caspase-7",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CMH-1|ICE-LAP3|CASP-7|MCH3|LICE2,,,,,,,,,,,,10,,,,,,Ensembl:ENSG00000165806|Vega:OTTHUMG00000019076|HGNC:1508|MIM:601761|HPRD:03457,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"caspase 7, apoptosis-related cysteine peptidase",,,10q25,,,,,,,,,,,,,,,,"GO_0001836 (EC: IEA); GO_0004190 (EC: IEA); GO_0004197 (EC: IBA); GO_0004197 (EC: TAS); GO_0005515 (EC: IPI, PMID:11084335); GO_0005634 (EC: IDA, PMID:17167422); GO_0005654 (EC: TAS); GO_0005737 (EC: TAS, PMID:8576161); GO_0005829 (EC: IDA, PMID:17167422); GO_0005829 (EC: TAS); GO_0006508 (EC: IDA, PMID:12888622); GO_0006915 (EC: TAS); GO_0006921 (EC: TAS); GO_0007507 (EC: IEA); GO_0007568 (EC: IEA); GO_0008234 (EC: TAS, PMID:8567622); GO_0008635 (EC: TAS); GO_0009411 (EC: IEA); GO_0043525 (EC: IEA); GO_0097153 (EC: IEA); GO_0097193 (EC: TAS); GO_0097194 (EC: IBA)",,,,,,,,,PMID:1056466; 7983002; 8125298; 8521391; 8567622; 8576161; 8631895; 8755496; 8780721; 8812467; 8889548; 8962078; 9070923; 9219695; 9228018; 9230442; 9298992; 9323209; 9325343; 9337844; 9384571; 9525868; 9535906; 9593687; 9607320; 9671712; 9850056; 9875225; 9894612; 9922454; 9990034; 10069390; 10082581; 10103059; 10200531; 10318789; 10469173; 10564664; 10675528; 10731697; 10791974; 10862606; 10998058; 11016947; 11024045; 11058599; 11084335; 11170436; 11257230; 11257231; 11257232; 11278572; 11356849; 11359776; 11387340; 11399776; 11420704; 11423904; 11425872; 11448953; 11514563; 11535131; 11555640; 11752425; 11755217; 11802788; 11815631; 11829465; 11832478; 11859414; 11875078; 11904443; 11943137; 12107159; 12145703; 12181742; 12477932; 12586738; 12665508; 12804035; 12824163; 12888622; 12951057; 12970753; 14512414; 14583630; 14584591; 14623896; 14713958; 15033720; 15200957; 15254227; 15489334; 15500642; 15507451; 15511269; 15580265; 15650747; 15735701; 16123041; 16213496; 16339151; 16344560; 16385451; 16498457; 16918502; 17023557; 17094969; 17167422; 17283187; 17337451; 17504820; 17532763; 17697120; 17880920; 17978580; 18072206; 18086147; 18459962; 18521960; 18596415; 18708163; 18723680; 18785314; 19022247; 19052714; 19058873; 19141860; 19219602; 19241192; 19258326; 19269008; 19323650; 19414860; 19531679; 19573080; 19581639; 19604093; 19605487; 19617626; 19655253; 19655254; 19692467; 19698783; 19738422; 19759058; 19770576; 19773279; 19782763; 19826114; 19913121; 19996278; 20159985; 20379614; 20402676; 20404718; 20453000; 20468060; 20566630; 20567846; 20628086; 20661084; 20800603; 20819778; 20855536; 20950443; 20959405; 21044950; 21142842; 21157428; 21484410; 21555521; 21936563; 22184066; 22441531; 22451931; 22548721; 22561518; 22584050; 22863883; 22986525; 23000965; 23190606; 23383273; 23650375; 23765963; 23979166,,,,,,,,,,,,,,,OGG:3000000840,,,,,,,"caspase 7, apoptosis-related cysteine peptidase",,,,,,,,,,,,,"Other designations: ICE-like apoptotic protease 3|apoptotic protease MCH-3|caspase 7, apoptosis-related cysteine protease|caspase-7",,CASP7,,,,,,,,,,,,,,,,,,,,,,,840,RP11-211N11.6,,,,,,,9606,,,,,,,,,,,,,,,,,,,CASP7,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000000842,CASP9,,"Other designations: ICE-like apoptotic protease 6|apoptotic protease MCH-6|apoptotic protease activating factor 3|caspase-9|protein phosphatase 1, regulatory subunit 56",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,MCH6|APAF-3|ICE-LAP6|PPP1R56|APAF3,,,,,,,,,,,,1,,,,,,HGNC:1511|HPRD:03756|Vega:OTTHUMG00000002256|Ensembl:ENSG00000132906|MIM:602234,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"caspase 9, apoptosis-related cysteine peptidase",,,1p36.21,,,,,,,,,,,,,,,,"GO_0004197 (EC: IBA); GO_0005515 (EC: IPI, PMID:10206961); GO_0005634 (EC: IEA); GO_0005739 (EC: IEA); GO_0005829 (EC: IDA, PMID:17167422); GO_0005829 (EC: TAS); GO_0006915 (EC: TAS, PMID:8663294); GO_0006974 (EC: IDA, PMID:15657060); GO_0007173 (EC: TAS); GO_0007568 (EC: IEA); GO_0008047 (EC: TAS, PMID:9390557); GO_0008233 (EC: IDA); GO_0008543 (EC: TAS); GO_0008630 (EC: IMP, PMID:15657060); GO_0008635 (EC: TAS); GO_0017124 (EC: IDA, PMID:15657060); GO_0019901 (EC: IDA, PMID:15657060); GO_0030220 (EC: TAS, PMID:18309324); GO_0032025 (EC: IEA); GO_0032355 (EC: IEA); GO_0032496 (EC: IEA); GO_0034349 (EC: IEA); GO_0034644 (EC: IDA, PMID:15657060); GO_0038095 (EC: TAS); GO_0042770 (EC: IDA, PMID:15657060); GO_0042981 (EC: TAS); GO_0043065 (EC: TAS); GO_0043293 (EC: IDA); GO_0043525 (EC: IEA); GO_0045087 (EC: TAS); GO_0046677 (EC: IEA); GO_0048011 (EC: TAS); GO_0048015 (EC: TAS); GO_0071549 (EC: IEA); GO_0097193 (EC: TAS); GO_2001020 (EC: IMP, PMID:15657060)",,,,,,,,,PMID:1067155; 7983002; 8663294; 8900201; 8962078; 9323209; 9337844; 9390557; 9488720; 9539746; 9545235; 9651578; 9671712; 9812896; 9837928; 9878060; 9890966; 9922454; 9990849; 10070954; 10085063; 10187815; 10206961; 10329646; 10376594; 10384055; 10438581; 10469173; 10671558; 10708425; 11024045; 11069302; 11076957; 11084335; 11113115; 11230124; 11242052; 11248093; 11350957; 11387340; 11390657; 11393657; 11408476; 11423904; 11462036; 11514563; 11734640; 11801602; 11801603; 11803376; 11832478; 11870543; 11905052; 11919192; 11927604; 11948397; 12021264; 12055227; 12095993; 12096338; 12145703; 12147322; 12372609; 12393263; 12393884; 12404116; 12477932; 12566444; 12586738; 12620238; 12620239; 12637514; 12732844; 12749848; 12782307; 12792650; 12804035; 12914932; 12954616; 14512414; 14523016; 14566819; 14634335; 14684629; 14701803; 14747474; 14982875; 14991812; 14993223; 15200957; 15214043; 15220451; 15254227; 15262985; 15273730; 15280366; 15300255; 15473998; 15485395; 15485396; 15489334; 15500642; 15507451; 15578977; 15629764; 15657060; 15657349; 15674327; 15703181; 15725353; 15735701; 15749826; 15767427; 15811855; 15829969; 15935070; 16038259; 16120388; 16181301; 16242324; 16260615; 16287866; 16300929; 16322207; 16337360; 16339151; 16344560; 16480911; 16497673; 16505307; 16505493; 16511342; 16520893; 16687442; 16689829; 16701639; 16710414; 16716256; 16780893; 16895904; 16936772; 16979168; 17030903; 17071630; 17079734; 17140287; 17167422; 17179183; 17207965; 17285546; 17291493; 17299206; 17379327; 17409234; 17437405; 17466630; 17534194; 17626072; 17653867; 17893147; 17899380; 17967742; 18022362; 18054197; 18083711; 18086147; 18202770; 18297401; 18309324; 18381704; 18415681; 18632964; 18676680; 18723680; 18813792; 18814044; 18840411; 19013323; 19016842; 19052714; 19058789; 19074885; 19081073; 19141860; 19153467; 19159073; 19170196; 19183163; 19219602; 19238172; 19269008; 19275583; 19275584; 19275586; 19275587; 19359048; 19412632; 19414860; 19458171; 19465923; 19493480; 19550122; 19573080; 19625176; 19626422; 19655415; 19674438; 19692168; 19692467; 19698783; 19724860; 19741144; 19758996; 19770581; 19773279; 19789190; 19807657; 19826114; 19895210; 19906200; 19913121; 20012528; 20013803; 20022954; 20042134; 20060927; 20071584; 20227371; 20227384; 20340172; 20357690; 20379614; 20402676; 20404718; 20453000; 20490276; 20628086; 20644561; 20650551; 20661084; 20667824; 20800603; 20804486; 20855536; 20887385; 20959405; 20978129; 21045158; 21048031; 21091209; 21117896; 21142842; 21178828; 21266831; 21282934; 21284734; 21297999; 21382445; 21396853; 21461653; 21483669; 21538054; 21555338; 21565459; 21612408; 21622622; 21644232; 21659556; 21724551; 21757755; 21785112; 21827945; 21868008; 21869827; 21944661; 21957492; 21988832; 22086301; 22120515; 22191568; 22219640; 22306364; 22339913; 22552851; 22573662; 22616010; 22629415; 22679284; 22683311; 22926545; 22944165; 22974165; 22981751; 23038270; 23303631; 23383273; 23396972; 23424205; 23430060; 23443079; 23539542; 23566959; 23572523; 23615977; 23637769; 23645041; 23652278; 23678002; 23725396; 23867824; 24121507; 24161344; 24346702,,,,,,,,,,,,,,,OGG:3000000842,,,,,,,"caspase 9, apoptosis-related cysteine peptidase",,,,,,,,,,,,,"Other designations: ICE-like apoptotic protease 6|apoptotic protease MCH-6|apoptotic protease activating factor 3|caspase-9|protein phosphatase 1, regulatory subunit 56",,CASP9,,,,,,,,,,,,,,,,,,,,,,,842,RP11-265F14.3,,,,,,,9606,,,,,,,,,,,,,,,,,,,CASP9,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000000841,CASP8,,"Other designations: FADD-homologous ICE/CED-3-like protease|FADD-like ICE|ICE-like apoptotic protease 5|MACH-alpha-1/2/3 protein|MACH-beta-1/2/3/4 protein|MORT1-associated ced-3 homolog|apoptotic cysteine protease|apoptotic protease Mch-5|caspase 8, apoptosis-related cysteine protease|caspase-8",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,MCH5|MACH|Casp-8|FLICE|ALPS2B|CAP4,,,,,,,,,,,,2,,,,,,Ensembl:ENSG00000064012|Vega:OTTHUMG00000132821|HGNC:1509|MIM:601763|HPRD:03459,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"caspase 8, apoptosis-related cysteine peptidase",,,2q33-q34,,,,,,,,,,,,,,,,"GO_0001525 (EC: IEA); GO_0001841 (EC: IEA); GO_0002020 (EC: IPI); GO_0002224 (EC: TAS); GO_0002756 (EC: TAS); GO_0004197 (EC: IDA, PMID:19240112); GO_0004197 (EC: TAS); GO_0005164 (EC: IEA); GO_0005515 (EC: IPI, PMID:10442631); GO_0005634 (EC: IDA); GO_0005730 (EC: IDA, Qualifier: NOT); GO_0005737 (EC: IDA); GO_0005739 (EC: IDA); GO_0005741 (EC: TAS); GO_0005815 (EC: IDA); GO_0005829 (EC: IDA, PMID:17167422); GO_0005829 (EC: TAS); GO_0005856 (EC: TAS, PMID:10891503); GO_0006508 (EC: IDA, PMID:12888622); GO_0006915 (EC: IGI, PMID:17599062); GO_0006915 (EC: IMP); GO_0006915 (EC: TAS); GO_0006919 (EC: TAS); GO_0006921 (EC: TAS); GO_0007507 (EC: IEA); GO_0008233 (EC: IMP, PMID:17047155); GO_0008234 (EC: TAS, PMID:8681376); GO_0008625 (EC: IBA); GO_0009409 (EC: IEA); GO_0016032 (EC: IEA); GO_0030101 (EC: TAS, PMID:18309324); GO_0030225 (EC: TAS, PMID:18309324); GO_0030690 (EC: IEA); GO_0031264 (EC: IDA, PMID:11101870); GO_0031265 (EC: IDA, PMID:11717445); GO_0031625 (EC: IPI, PMID:15069192); GO_0032025 (EC: IEA); GO_0032355 (EC: IEA); GO_0032496 (EC: IEA); GO_0034138 (EC: TAS); GO_0034142 (EC: TAS); GO_0034612 (EC: IMP, PMID:10521396); GO_0035666 (EC: TAS); GO_0035872 (EC: TAS); GO_0035877 (EC: IPI, PMID:11717445); GO_0042110 (EC: TAS, PMID:18309324); GO_0042113 (EC: TAS, PMID:18309324); GO_0043005 (EC: IEA); GO_0043123 (EC: IEP, PMID:12761501); GO_0043123 (EC: IMP, PMID:12884866); GO_0043124 (EC: IMP, PMID:17047155); GO_0044297 (EC: IEA); GO_0045087 (EC: TAS); GO_0045121 (EC: IEA); GO_0045471 (EC: IEA); GO_0045651 (EC: IMP, PMID:17047155); GO_0045862 (EC: IDA, PMID:18387192); GO_0046677 (EC: IEA); GO_0051291 (EC: IEA); GO_0051603 (EC: IMP, PMID:10521396); GO_0060715 (EC: TAS, PMID:18309324); GO_0070243 (EC: IEA); GO_0070423 (EC: TAS); GO_0071260 (EC: IEP, PMID:19593445); GO_0071407 (EC: IEA); GO_0097153 (EC: IMP); GO_0097190 (EC: IMP, PMID:11101870); GO_0097190 (EC: TAS); GO_0097191 (EC: IDA); GO_0097193 (EC: TAS); GO_0097194 (EC: IMP); GO_0097199 (EC: IMP, PMID:11717445); GO_0097202 (EC: IDA, PMID:18387192); GO_0097284 (EC: IEA); GO_0097342 (EC: IDA); GO_1900740 (EC: TAS); GO_2001238 (EC: IEA); GO_2001239 (EC: TAS)",,,,,,,,,PMID:170210; 3031469; 7983002; 8521391; 8681376; 8681377; 8755496; 8962078; 9006941; 9027312; 9184224; 9208847; 9219695; 9228018; 9271594; 9289491; 9325248; 9326610; 9334338; 9337844; 9380701; 9535906; 9539746; 9560245; 9575181; 9624166; 9632733; 9721089; 9727491; 9727492; 9763668; 9774341; 9792675; 9804161; 9875225; 9878167; 9931493; 9971775; 9990034; 10069390; 10235259; 10329646; 10432301; 10435619; 10438581; 10442631; 10469173; 10493725; 10508784; 10521396; 10616217; 10708425; 10716992; 10734073; 10860845; 10891503; 10894160; 10911620; 10926122; 10964557; 11000244; 11002417; 11016947; 11048727; 11085743; 11098060; 11101867; 11101870; 11102441; 11161814; 11177389; 11181075; 11260720; 11264300; 11340079; 11387340; 11395500; 11406564; 11420686; 11423904; 11431480; 11437602; 11479289; 11514563; 11555640; 11583996; 11683038; 11684016; 11717445; 11733517; 11734564; 11735112; 11741396; 11741985; 11751056; 11751897; 11752160; 11772515; 11788820; 11832478; 11865194; 11877293; 11917123; 11933563; 11940602; 11965497; 11992615; 12010809; 12021264; 12037669; 12041673; 12052891; 12065591; 12095993; 12096338; 12097160; 12107159; 12107169; 12122017; 12131184; 12170765; 12189238; 12191471; 12196516; 12198154; 12215447; 12218097; 12220669; 12232792; 12353035; 12393901; 12404116; 12438416; 12477932; 12496481; 12496482; 12507932; 12527898; 12598529; 12620239; 12646168; 12668660; 12692130; 12700635; 12700660; 12702723; 12707329; 12721308; 12738800; 12748179; 12750393; 12750404; 12753742; 12754217; 12761501; 12765336; 12804595; 12841868; 12884866; 12887920; 12888622; 12911633; 12912912; 12960156; 13679856; 14522966; 14560027; 14584591; 14625033; 14644092; 14644197; 14684825; 14688019; 14701762; 14713958; 14759258; 14970175; 14982875; 14982947; 14991747; 14993214; 15015772; 15024054; 15034549; 15067048; 15069192; 15111130; 15142380; 15159409; 15205454; 15210716; 15254227; 15262979; 15280356; 15289853; 15369772; 15383280; 15388581; 15389560; 15390286; 15473998; 15476874; 15489334; 15492869; 15507451; 15507484; 15509781; 15531912; 15578977; 15592455; 15592525; 15601643; 15611097; 15637055; 15640164; 15645452; 15650242; 15659383; 15701651; 15717329; 15735701; 15735742; 15746428; 15760909; 15782135; 15815621; 15849201; 15906362; 15956881; 15976052; 16036110; 16135563; 16169070; 16179347; 16179941; 16183855; 16186808; 16193064; 16225956; 16227629; 16242324; 16251207; 16344560; 16374545; 16397500; 16436380; 16446372; 16478725; 16497673; 16528386; 16538383; 16541419; 16556893; 16607283; 16619028; 16633737; 16636047; 16722146; 16733806; 16762833; 16886176; 16920630; 16936772; 16938569; 16951203; 17018785; 17030903; 17047155; 17064406; 17071630; 17159907; 17167422; 17170703; 17182797; 17224200; 17272309; 17283187; 17290218; 17293864; 17314102; 17337451; 17378240; 17436592; 17442709; 17450141; 17488272; 17525260; 17532763; 17534194; 17545522; 17572490; 17585337; 17599062; 17616526; 17623017; 17626072; 17627287; 17653867; 17666167; 17684142; 17726263; 17891485; 17911615; 17932347; 17940865; 18029348; 18045865; 18054197; 18076022; 18086677; 18089778; 18089800; 18097748; 18158779; 18161513; 18216014; 18245485; 18305469; 18309324; 18324486; 18328427; 18343995; 18362937; 18381704; 18387192; 18398042; 18431743; 18455983; 18458084; 18473402; 18483392; 18485876; 18516683; 18563783; 18570872; 18596409; 18603835; 18617900; 18625728; 18632964; 18675369; 18676680; 18676836; 18684943; 18691973; 18716417; 18725521; 18728974; 18776134; 18796435; 18823309; 18823701; 18840411; 18974049; 19001123; 19013323; 19048023; 19048627; 19060883; 19074885; 19094228; 19111387; 19112091; 19115040; 19122169; 19124506; 19125371; 19141860; 19152111; 19160091; 19166881; 19170196; 19176810; 19203830; 19214542; 19214744; 19219602; 19239323; 19240112; 19258216; 19260109; 19269008; 19275584; 19275586; 19276244; 19289465; 19318553; 19343040; 19345995; 19372376; 19373245; 19412632; 19414860; 19427028; 19432816; 19453261; 19470771; 19492233; 19493480; 19521670; 19528225; 19531679; 19542541; 19543235; 19550122; 19573080; 19593445; 19597472; 19617217; 19625176; 19629679; 19644511; 19665028; 19684859; 19692168; 19692467; 19698994; 19710364; 19738422; 19770581; 19773279; 19773432; 19778795; 19795398; 19801665; 19807657; 19812265; 19826114; 19843670; 19852930; 19854135; 19902255; 19913121; 19923319; 19954364; 19996275; 20005201; 20012528; 20013803; 20033750; 20033885; 20044137; 20080300; 20085538; 20086182; 20087649; 20132554; 20143425; 20145138; 20150972; 20176653; 20198319; 20237344; 20301425; 20308068; 20353946; 20356928; 20363033; 20379197; 20398055; 20402676; 20403046; 20404718; 20443055; 20448643; 20453000; 20471133; 20502973; 20554749; 20564345; 20565257; 20572163; 20605201; 20606168; 20613771; 20616437; 20628086; 20644561; 20652397; 20661084; 20671745; 20677014; 20702410; 20724831; 20799830; 20800603; 20802294; 20804486; 20808443; 20811726; 20817393; 20819778; 20825417; 20829884; 20855536; 20870287; 20877624; 20937773; 20951133; 20959405; 20972266; 20978129; 20978178; 21048031; 21072056; 21104989; 21107701; 21135236; 21139048; 21153367; 21157428; 21166494; 21178828; 21183680; 21183955; 21248767; 21282461; 21328377; 21380726; 21396853; 21419663; 21426305; 21436691; 21444671; 21454681; 21458669; 21461653; 21483669; 21487429; 21524651; 21525013; 21538054; 21548803; 21554547; 21569377; 21576355; 21620750; 21628531; 21633787; 21667042; 21669575; 21697465; 21704196; 21714991; 21724551; 21737329; 21751259; 21785112; 21785459; 21801448; 21803845; 21816816; 21819468; 21822306; 21865223; 21868312; 21900206; 21906983; 21979465; 21983787; 21988832; 22010212; 22027693; 22037414; 22056502; 22094081; 22120515; 22160860; 22179575; 22211869; 22253841; 22266862; 22267217; 22274400; 22297296; 22322857; 22339913; 22357491; 22383778; 22408249; 22421964; 22508042; 22513478; 22528489; 22585859; 22588838; 22632162; 22644571; 22659694; 22672670; 22683265; 22683266; 22691345; 22801217; 22806078; 22815944; 22820578; 22843554; 22860893; 22864571; 22922291; 22949938; 22971934; 23071110; 23081800; 23096115; 23142077; 23185580; 23230268; 23244104; 23255602; 23289213; 23306557; 23313206; 23418437; 23434145; 23618862; 23659359; 23751956; 23770605; 23844036; 23921907; 23972990; 23982205; 24021263; 24121507; 24391214,,,,,,,,,,,,,,,OGG:3000000841,,,,,,,"caspase 8, apoptosis-related cysteine peptidase",,,,,,,,,,,,,"Other designations: FADD-homologous ICE/CED-3-like protease|FADD-like ICE|ICE-like apoptotic protease 5|MACH-alpha-1/2/3 protein|MACH-beta-1/2/3/4 protein|MORT1-associated ced-3 homolog|apoptotic cysteine protease|apoptotic protease Mch-5|caspase 8, apoptosis-related cysteine protease|caspase-8",,CASP8,,,,,,,,,,,,,,,,,,,,,,,841,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CASP8,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000000846,CASR,,Other designations: extracellular calcium-sensing receptor|parathyroid Ca(2+)-sensing receptor 1|parathyroid cell calcium-sensing receptor 1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,NSHPT|HHC|EIG8|PCAR1|GPRC2A|FIH|HYPOC1|HHC1|FHH|CAR,,,,,,,,,,,,3,,,,,,Vega:OTTHUMG00000159491|HPRD:03122|Ensembl:ENSG00000036828|HGNC:1514|MIM:601199,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,calcium-sensing receptor,,,3q13,,,,,,,,,,,,,,,,"GO_0001503 (EC: TAS, PMID: 7874174); GO_0004435 (EC: TAS, PMID: 7874174); GO_0004930 (EC: IEA); GO_0005513 (EC: TAS, PMID: 7759551); GO_0005515 (EC: IPI); GO_0005886 (EC: TAS); GO_0005887 (EC: TAS, PMID: 7759551); GO_0006874 (EC: TAS, PMID: 7874174); GO_0007186 (EC: TAS, PMID: 7759551); GO_0007635 (EC: TAS, PMID: 7759551); GO_0008152 (EC: TAS, PMID: 7874174); GO_0009653 (EC: TAS, PMID: 7916660); GO_0070509 (EC: IDA)",,,,,,,,,PMID: 7673400; 7677761; 7726161; 7759551; 7874174; 7916660; 8597637; 8613532; 8675635; 8702647; 8733126; 8756555; 9168937; 9217223; 9298824; 9677383; 9694886; 9722601; 9852126; 9920108; 9920407; 10405337; 10487661; 11013439; 11095989; 11108243; 11161843; 11248745; 11390379; 11390380; 11589681; 11668634; 11762699; 11863123; 11889154; 11889203; 11907035; 11979955; 11984699; 12018449; 12036954; 12040821; 12050233; 12052452; 12095982; 12150336; 12239240; 12241879; 12356761; 12399473; 12409307; 12459170; 12469911; 12477932; 12517779; 12544508; 12574201; 12605346; 12656660; 12700051; 12773131; 12783889; 12890593; 12899245; 12914574; 14508624; 14660633; 14713274; 14729680; 14976203; 14985373; 15201280; 15219850; 15472173; 15489334; 15501733; 15531522; 15551332; 15572418; 15579475; 15591042; 15598778; 15613438; 15637145; 15657061; 15684428; 15718278; 15781005; 15805541; 15837785; 15864123; 15879434; 15888439; 15960151; 16109841; 16117875; 16147994; 16218047; 16278666; 16472767; 16497624; 16509534; 16513638; 16596260; 16598859; 16616098; 16622736; 16642557; 16735501; 16738533; 16740430; 16754659; 16854379; 16938272; 17018660; 17046587; 17054460; 17062884; 17097611; 17110864; 17122384; 17124506; 17132283; 17138967; 17284438; 17309124; 17310098; 17320849; 17331389; 17332735; 17372216; 17374704; 17374709; 17426287; 17463182; 17473068; 17478419; 17482347; 17513419; 17537980; 17555508; 17591780; 17623778; 17698911; 17853337; 17932932; 17962359; 17974568; 17979873; 18065418; 18240029; 18296474; 18322048; 18328986; 18348986; 18393231; 18410554; 18443236; 18497443; 18525093; 18577758; 18621740; 18622738; 18676680; 18680227; 18703641; 18712808; 18751724; 18756473; 18796518; 18843020; 18852253; 18938753; 18980667; 19011996; 19035514; 19038444; 19058262; 19066294; 19073830; 19088423; 19133942; 19151705; 19157541; 19170196; 19179454; 19237714; 19257819; 19285978; 19328421; 19350667; 19389809; 19397786; 19423559; 19432691; 19453261; 19471101; 19474519; 19580466; 19621386; 19625176; 19640368; 19690432; 19692168; 19695239; 19706842; 19716891; 19789209; 19839774; 19887834; 19912241; 19913121; 19915295; 20034274; 20067903; 20130845; 20164288; 20237496; 20361938; 20364112; 20421307; 20424473; 20457124; 20558521; 20558539; 20595056; 20602573; 20628086; 20631026; 20634891; 20648625; 20654748; 20661308; 20668040; 20697181; 20705733; 20798521; 20826781; 20846291; 21048031; 21082232; 21084311; 21130730; 21183554; 21187282; 21209619; 21240254; 21317879; 21340433; 21369680; 21393549; 21414629; 21441391; 21532883; 21566074; 21645025; 21667241; 21843504; 21965686; 21966463; 22010828; 22024717; 22094462; 22107799; 22144504; 22158862; 22187299; 22192860; 22210744; 22278364; 22315359; 22403735; 22422767; 22424352; 22449852; 22577108; 22730443; 22789683; 22798347; 23009664; 23103379; 23108190; 23125333; 23169696; 23228129; 23247143; 23269116; 23271661; 23287098; 23300272; 23334987; 23372019; 23533647; 23552627; 23555732; 23569134; 23639611; 23674327; 23756480; 23764372; 23817301; 23856265; 23860708; 23864702; 23913941; 23917029; 23946278; 24068962; 24120622; 24238055; 24336654; 24455835,,,,,,,,,,,,,,,OGG:3000000846,,,,,,,calcium-sensing receptor,,,,,,,,,,,,,Other designations: extracellular calcium-sensing receptor|parathyroid Ca(2+)-sensing receptor 1|parathyroid cell calcium-sensing receptor 1,,CASR,,,,,,,,,,,,,,,,,,,,,,,846,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,CASR,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGMS_0000063,disease course,,The totality of all processes through which a given disease instance is realized.,false,,,http://purl.obolibrary.org/obo/TXPO_0000608,,,,,,,,,,,,,,,,,,,"replace 'OBI:occurrence of disease', need to add logical definition
The axioms of OBI occurence of disease:
Equivalent classes:
realizes some disease
Superclasses:
'has part' some 'pathologic process'
'has participant' some
    (organism
     and ('has role' some 'host of immune response role'))
biological_process
realizes some 'host of immune response role'",,,The totality of all processes through which a given disease instance is realized.,,,,,disease course,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000808,,,,,,,,,,,,,,,,,,OGMS:0000063,,,,,,,,,,,,,,,,,,,,,,disease course,,,,,,,http://purl.obolibrary.org/obo/ogms.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/DOID_4,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0090158,endoplasmic reticulum membrane organization,,"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts of an endoplasmic reticulum membrane.",false,,,http://purl.obolibrary.org/obo/GO_0061024,,,,,,,,,,,,,,,,,,,,,,"A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts of an endoplasmic reticulum membrane.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0090158,,,,,,,,,,,,,,,,,,,,,,endoplasmic reticulum membrane organization,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000002877,GPX2,,Other designations: gastrointestinal glutathione peroxidase|glutathione peroxidase 2|glutathione peroxidase-related protein 2,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,GSHPX-GI|GI-GPx|GPx-2|GSHPx-2|GPRP|GPRP-2|GPx-GI,,,,,,,,,,,,14,,,,,,Ensembl:ENSG00000176153|MIM:138319|Vega:OTTHUMG00000171677|HPRD:11818|HGNC:4554,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,glutathione peroxidase 2 (gastrointestinal),,,14q24.1,,,,,,,,,,,,,,,,"GO_0001659 (EC: IEA); GO_0002862 (EC: IEA); GO_0004602 (EC: TAS); GO_0005737 (EC: TAS, PMID: 8428933); GO_0005829 (EC: TAS); GO_0006979 (EC: IEA); GO_0009055 (EC: TAS, PMID: 8428933); GO_0009609 (EC: IEA); GO_0051702 (EC: IEA)",,,,,,,,,PMID: 2388849; 8125298; 8287691; 8428933; 8833155; 9501919; 10652368; 10806356; 11368344; 11373322; 11811519; 12477932; 12674495; 12751789; 15489334; 15910762; 15923610; 16446369; 16794261; 17277236; 17937616; 18029348; 18056462; 18479189; 18483336; 18676680; 19047153; 19161995; 19170196; 19573080; 19625176; 19692168; 19773279; 19884766; 19913121; 20200426; 20628086; 20813000; 21988832; 22683372; 22758632,,,,,,,,,,,,,,,OGG:3000002877,,,,,,,glutathione peroxidase 2 (gastrointestinal),,,,,,,,,,,,,Other designations: gastrointestinal glutathione peroxidase|glutathione peroxidase 2|glutathione peroxidase-related protein 2,,GPX2,,,,,,,,,,,,,,,,,,,,,,,2877,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,GPX2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0010489,60S ribosomal protein L39,,,false,,,http://purl.obolibrary.org/obo/IMR_0000897,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0010489,,,,,,,,,,,,,,,,,,,,,,60S ribosomal protein L39,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0005634,nucleus,cell nucleus,"A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent.",false,,,http://purl.obolibrary.org/obo/GO_0043227,,,,,,,,,,,,,,,,,,,,Wikipedia:Cell_nucleus|NIF_Subcellular:sao1702920020,,"A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0031965,,,,,,,,,,,,,cell nucleus,,,,http://purl.obolibrary.org/obo/GO_0005622,GO:0005634,http://purl.obolibrary.org/obo/GO_0005622,,,,,,,,,,,,,,,,,,,,,nucleus,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000004673,NAP1L1,,Other designations: HSP22-like protein interacting protein|NAP-1 related protein|NAP-1-related protein|hNRP,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,NAP1|NAP1L|NRP,,,,,,,,,,,,12,,,,,,HPRD:01248|MIM:164060|HGNC:7637|Vega:OTTHUMG00000169786|Ensembl:ENSG00000187109,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,nucleosome assembly protein 1-like 1,,,12q21.2,,,,,,,,,,,,,,,,"GO_0005515 (EC: IPI, PMID: 11940655); GO_0005634 (EC: IEA); GO_0006260 (EC: TAS, PMID: 8297347); GO_0006334 (EC: IEA); GO_0008284 (EC: TAS, PMID: 8297347); GO_0042470 (EC: IEA); GO_0044822 (EC: IDA)",,,,,,,,,PMID: 7821789; 8297347; 11073993; 11940655; 12477932; 12777385; 14702039; 14966293; 15308774; 15345747; 15489334; 16169070; 16196087; 16287874; 16565220; 16964243; 17081065; 17081983; 17339334; 17620599; 17725712; 18226242; 18781797; 18985028; 19322201; 19339032; 19471022; 19884766; 19888548; 20002496; 20195357; 20473970; 20639865; 20697350; 20972266; 21044950; 21110914; 21139048; 21145461; 21319273; 21333655; 21565611; 21890473; 21900206; 21906983; 21963094; 21988832; 22053931; 22134777; 22145905; 22174317; 22242598; 22505724; 22586326; 22810585; 22863883; 22939629; 23000965; 23251661; 23438482; 23455922; 23691099; 23824909,,,,,,,,,,,,,,,OGG:3000004673,,,,,,,nucleosome assembly protein 1-like 1,,,,,,,,,,,,,Other designations: HSP22-like protein interacting protein|NAP-1 related protein|NAP-1-related protein|hNRP,,NAP1L1,,,,,,,,,,,,,,,,,,,,,,,4673,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,NAP1L1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/PATO_0001447,calcified,,A composition quality inhering in an bearer by virtue of the bearer's being encrusted or impregnated with calcium carbonate (CHEBI:3311).,false,,,http://purl.obolibrary.org/obo/PATO_0000025,,,,,,,,,,,,,,,,,,,,,,A composition quality inhering in an bearer by virtue of the bearer's being encrusted or impregnated with calcium carbonate (CHEBI:3311).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0001447,,,,,,,,,,,,,,,,,,,,,,calcified,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/NCBITaxon_10114,rattus,rat|rats,,false,,,http://purl.obolibrary.org/obo/NCBITaxon_9989,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,rat|rats,,,,,NCBITaxon:10114,,,,,,,,,,,,,,,,,,,,,,rattus,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000953,UGT1A1 (canonical)[Ground glass appearance],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000472|http://purl.obolibrary.org/obo/TXPO_1000395,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24861|NCBI-Mouse-GeneID:394436|NCBI-Human-GeneID:54658|ISBN:0071769234,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000953,,,,,,,,,,,,,,,,,,,,,,UGT1A1 (canonical)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000954,regulation of cell cycle [Ground glass appearance],,"Any process that modulates the rate or extent of progression through the cell cycle.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/GO_0051726,,,,,,,,,,,,,,,,,,,,,,"Any process that modulates the rate or extent of progression through the cell cycle.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000669|http://purl.obolibrary.org/obo/TXPO_0000962|http://purl.obolibrary.org/obo/TXPO_0000959,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002319,,,,,,,,,,,TXPO:0000954,,,,,,,,,,,,,,,,,,,,,,regulation of cell cycle [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000955,negative regulation of cell junction assembly [Ground glass appearance],,"Negative regulation of cell junction assembly is a subtype of negative regulation process: Any process that stops, prevents or reduces the frequency, rate or extent of cell junction assembly.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/GO_1901889|http://purl.obolibrary.org/obo/TXPO_0001728,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of cell junction assembly is a subtype of negative regulation process: Any process that stops, prevents or reduces the frequency, rate or extent of cell junction assembly.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001524,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000955,,,,,,,,,,,,,,,,,,,,,,negative regulation of cell junction assembly [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000957,changing phospholipid homeostasis,,Changing phospholipid homeostasis is a subtype of changing balance: A process that changes the steady state of phospholipid within an organism or cell.,false,,,http://purl.obolibrary.org/obo/TXPO_0001847,,,,,,,,,,,,,,,,,,,,,,Changing phospholipid homeostasis is a subtype of changing balance: A process that changes the steady state of phospholipid within an organism or cell.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000957,,,,,,,,,,,,,,,,,,,,,,changing phospholipid homeostasis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000956,expcretion of drug metabolite from hepatocyte to bile tube [Ground glass appearance],,"Expcretion of drug metabolite from hepatocyte to bile tube is a subtype of excretion of compound: A process that excretes the drug metabolite from the hepatocyte to to the bile tube.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0003152|http://purl.obolibrary.org/obo/TXPO_0001728,,,,,,,,,,,,,,,,,,,,,,"Expcretion of drug metabolite from hepatocyte to bile tube is a subtype of excretion of compound: A process that excretes the drug metabolite from the hepatocyte to to the bile tube.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001032,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000956,,,,,,,,,,,,,,,,,,,,,,expcretion of drug metabolite from hepatocyte to bile tube [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000950,overeating [Phospholipidosis],,"Overeating is a subtype of increasing quantity: A process that changes the ingestion amount of food to be larger.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001541|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Overeating is a subtype of increasing quantity: A process that changes the ingestion amount of food to be larger.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004158,,,,,,,,,,,TXPO:0000950,,,,,,,,,,,,,,,,,,,,,,overeating [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000952,DNA damage [Ground glass appearance],,"Drug-, radiation-induced, or spontaneous injuries to DNA that introduce deviations from its normal double-helical conformation. These changes include structural distortions that interfere with replication and transcription, as well as point mutations that disrupt base pairs and exert damaging effects on future generations through changes in DNA sequence. If the damage is minor, it can often be repaired (DNA repair); extensive damage can induce apoptosis.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/NCIT_C16507,,,,,,,,,,,,,,,,,,,,,,"Drug-, radiation-induced, or spontaneous injuries to DNA that introduce deviations from its normal double-helical conformation. These changes include structural distortions that interfere with replication and transcription, as well as point mutations that disrupt base pairs and exert damaging effects on future generations through changes in DNA sequence. If the damage is minor, it can often be repaired (DNA repair); extensive damage can induce apoptosis.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000954,,,,,,,,,,,TXPO:0000952,,,,,,,,,,,,,,,,,,,,,,DNA damage [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000958,glycogen catabolic process [Ground glass appearance],,"The chemical reactions and pathways resulting in the breakdown of glycogen, a polydisperse, highly branched glucan composed of chains of D-glucose residues.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/GO_0005980,,,,,,,,,,,,,,,,,,,,PMID:24878338,,"The chemical reactions and pathways resulting in the breakdown of glycogen, a polydisperse, highly branched glucan composed of chains of D-glucose residues.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001797,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000958,,,,,,,,,,,,,,,,,,,,,,glycogen catabolic process [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000951,changing phospholipid homeostasis [Phospholipidosis],,"Changing phospholipid homeostasis is a subtype of changing balance: A process that changes the steady state of phospholipid within an organism or cell.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0000957,,,,,,,,,,,,,,,,,,,,,,"Changing phospholipid homeostasis is a subtype of changing balance: A process that changes the steady state of phospholipid within an organism or cell.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000951,,,,,,,,,,,,,,,,,,,,,,changing phospholipid homeostasis [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000959,decreasing negative regulator of G1/S transition [Ground glass appearance],,"Decreasing negative regulator of G1/S transition is a subtype of decreasing quantity: A process that chanes the quantity of the object with a negative regulator of G1/S role to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/TXPO_0002059,,,,,,,,,,,,,,,,,,,,,,"Decreasing negative regulator of G1/S transition is a subtype of decreasing quantity: A process that chanes the quantity of the object with a negative regulator of G1/S role to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000669,,,,,,,,,,,TXPO:0000959,,,,,,,,,,,,,,,,,,,,,,decreasing negative regulator of G1/S transition [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100292,Bfl-1,A1,,false,,,http://purl.obolibrary.org/obo/IMR_0100706,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,A1,,,,,IMR:0100292,,,,,,,,,,,,,,,,,,,,,,Bfl-1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0032611,IL-1 beta production,,"The appearance of interleukin-1 beta due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.",false,,,http://purl.obolibrary.org/obo/GO_0001816,,,,,,,,,,,,,,,,,,,,,,"The appearance of interleukin-1 beta due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000091,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0032611,,,,,,,,,,,,,,,,,,,,,,IL-1 beta production,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0032612,interleukin-1 production,,"The appearance of interleukin-1 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.",false,,,http://purl.obolibrary.org/obo/GO_0001816,,,,,,,,,,,,,,,,,,,,GO:0032612,,"The appearance of interleukin-1 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.",,,,,interleukin-1 production,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0032612,,,,,,,,,,,,,,,,,,,,,,interleukin-1 production,,,,,,,http://purl.obolibrary.org/obo/go.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0044281,small molecule metabolic process,,"Small molecules in GO include monosaccharides but exclude disaccharides and polysaccharides.|The chemical reactions and pathways involving small molecules, any low molecular weight, monomeric, non-encoded molecule.",false,,,http://purl.obolibrary.org/obo/GO_0008152,,,,,,,,,,,,,,,,,,,,,,Small molecules in GO include monosaccharides but exclude disaccharides and polysaccharides.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0044281,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways involving small molecules, any low molecular weight, monomeric, non-encoded molecule.",,small molecule metabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000000,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000161,PGR (mol),Progesterone Receptor,,false,,,http://purl.obolibrary.org/obo/TXPO_0001509,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003224,,,,,Progesterone Receptor,,,,,TXPO:0000161,,,,,,,,,,,,,,,,,,,,,,PGR (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000169,accumulation of xenobiotics,,"Accumulation of xenobiotics is a subtype of accumulation of substances in a biological object: A process that keeps xenobiotics in an organism, tissue, organelle, or cell.",false,,,http://purl.obolibrary.org/obo/TXPO_0000247,,,,,,,,,,,,,,,,,,,,,,"Accumulation of xenobiotics is a subtype of accumulation of substances in a biological object: A process that keeps xenobiotics in an organism, tissue, organelle, or cell.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000169,,,,,,,,,,,,,,,,,,,,,,accumulation of xenobiotics,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000168,having extra parts,,Having extra parts is a subtype of changing structure: A process that changes to have additional parts of the structure.,false,,,http://purl.obolibrary.org/obo/TXPO_0002566,,,,,,,,,,,,,,,,,,,,,,Having extra parts is a subtype of changing structure: A process that changes to have additional parts of the structure.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000168,,,,,,,,,,,,,,,,,,,,,,having extra parts,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000164,increasing hepatocellular volume,hepatocellular swelling|hepatocellular hypertrophy,Increasing hepatocellular volume is a subtype of increasing cell volume to change the volume of the hepatocyte to increase.,false,,,http://purl.obolibrary.org/obo/TXPO_0000142,,,,,,,,,,,,,,,,,,,,,,Increasing hepatocellular volume is a subtype of increasing cell volume to change the volume of the hepatocyte to increase.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000182,,,,,,,,,,,,,,,,,,,,hepatocellular swelling|hepatocellular hypertrophy,,,TXPO:0000164,,,,,,,,,,,,,,,,,,,,,,increasing hepatocellular volume,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000182,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000166,addition of foreign substance,,Addition of foreign substance is a subtype of assembling: A process that foreign substance to make an addition.,false,,,http://purl.obolibrary.org/obo/TXPO_0000468,,,,,,,,,,,,,,,,,,,,,,Addition of foreign substance is a subtype of assembling: A process that foreign substance to make an addition.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000166,,,,,,,,,,,,,,,,,,,,,,addition of foreign substance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000163,release of phospholipid from lysosome,,Release of phospholipid from lysosome is a subtype of moving A to the outside of B: A process that that moves phospholipids to the outside of the lysosome.,false,,,http://purl.obolibrary.org/obo/TXPO_0002588,,,,,,,,,,,,,,,,,,,,,,Release of phospholipid from lysosome is a subtype of moving A to the outside of B: A process that that moves phospholipids to the outside of the lysosome.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000163,,,,,,,,,,,,,,,,,,,,,,release of phospholipid from lysosome,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005764,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000162,PPARG,PPAR gamma|Peroxisome Proliferator-Activated Receptor Gamma,,false,,,http://purl.obolibrary.org/obo/IMR_0000089,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PPAR gamma|Peroxisome Proliferator-Activated Receptor Gamma,,,,,TXPO:0000162,,,,,,,,,,,,,,,,,,,,,,PPARG,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000165,increasing hepatocellular volume [Eosinophilic granular degeneration],,"Increasing hepatocellular volume is a changing process to change the volume of the hepatocyte to increase.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/TXPO_0001729|http://purl.obolibrary.org/obo/TXPO_0000164,,,,,,,,,,,,,,,,,,,,https://doi.org/10.1002/9780470744307.gat023,,"Increasing hepatocellular volume is a changing process to change the volume of the hepatocyte to increase.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000165,,,,,,,,,,,,,,,,,,,,,,increasing hepatocellular volume [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000160,AR,Androgen Receptor,,false,,,http://purl.obolibrary.org/obo/TXPO_0001509,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003224,,,,,Androgen Receptor,,,,,TXPO:0000160,,,,,,,,,,,,,,,,,,,,,,AR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000167,dysfunction of calcium transport,,Dysfunction of calcium transport is a subtype of dysfunctioning: A process that performs an abnormal and incomplete calcium transport.,false,,,http://purl.obolibrary.org/obo/TXPO_0000438,,,,,,,,,,,,,,,,,,,,,,Dysfunction of calcium transport is a subtype of dysfunctioning: A process that performs an abnormal and incomplete calcium transport.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000366,,,,,,,,,,,TXPO:0000167,,,,,,,,,,,,,,,,,,,,,,dysfunction of calcium transport,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0200488,L-Methionine,,,false,,,http://purl.obolibrary.org/obo/CHEBI_33709,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0200488,,,,,,,,,,,,,,,,,,,,,,L-Methionine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OBI_0000718,pathogen role,,pathogen role is a role which inheres in an organism and realized in the process of disease course in the organism bearing host role caused by the organism bearing pathogen role,false,,,http://purl.obolibrary.org/obo/CHEBI_52209,,,,,,,,,,,,,,,,,,,,,,pathogen role is a role which inheres in an organism and realized in the process of disease course in the organism bearing host role caused by the organism bearing pathogen role,OBI,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,OBI:0000718,,,,,,,,,,,,,,,,,,,,,,pathogen role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000590,IL-12,interleukin-12,,false,,,http://purl.obolibrary.org/obo/IMR_0000007,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000622,,,,,interleukin-12,,,,,IMR:0000590,,,,,,,,,,,,,,,,,,,,,,IL-12,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0002049,NDK7,,,false,,,http://purl.obolibrary.org/obo/IMR_0010012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0002049,,,,,,,,,,,,,,,,,,,,,,NDK7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_52206,biochemical role,,A biological role played by the molecular entity or part thereof within a biochemical context.,false,,,http://purl.obolibrary.org/obo/CHEBI_24432,,,,,,,,,,,,,,,,,,,,,,A biological role played by the molecular entity or part thereof within a biochemical context.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:52206,,,,biochemical role,,CHEBI:52206,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000297,Rac,,,false,,,http://purl.obolibrary.org/obo/IMR_0000295,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000297,,,,,,,,,,,,,,,,,,,,,,Rac,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/BFO_0000035,process boundary,,p is a process boundary =Def. p is a temporal part of a process & p has no proper temporal parts. (axiom label in BFO2 Reference: [084-001]),false,,,http://purl.obolibrary.org/obo/BFO_0000003,,,,,,,,,,,,,,,,,,,,,,p is a process boundary =Def. p is a temporal part of a process & p has no proper temporal parts. (axiom label in BFO2 Reference: [084-001]),,,,,,,the boundary between the 2nd and 3rd year of your life.,,,,,,,,,,,(forall (x) (if (ProcessBoundary x) (exists (y) (and (ZeroDimensionalTemporalRegion y) (occupiesTemporalRegion x y))))) // axiom label in BFO2 CLIF: [085-002]|(iff (ProcessBoundary a) (exists (p) (and (Process p) (temporalPartOf a p) (not (exists (b) (properTemporalPartOf b a)))))) // axiom label in BFO2 CLIF: [084-001],Every process boundary occupies_temporal_region a zero-dimensional temporal region. (axiom label in BFO2 Reference: [085-002]),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BFO:0000035,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/bfo.owl,process boundary,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100560,FGF-10,Keratinocyte growth factor 2,,false,,,http://purl.obolibrary.org/obo/IMR_0000049,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Keratinocyte growth factor 2,,,,,IMR:0100560,,,,,,,,,,,,,,,,,,,,,,FGF-10,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_46081,fluconazole,"fluconazole|fluconazolum|2,4-difluoro-alpha,alpha-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol|2-(2,4-DIFLUOROPHENYL)-1,3-DI(1H-1,2,4-TRIAZOL-1-YL)PROPAN-2-OL|Elazor|Triflucan|Biozole|fluconazol|Diflucan|fluconazole|2-(2,4-difluorophenyl)-1,3-bis-(1H-1,2,4-triazol-1-yl)propan-2-ol","A member of the class of  triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:16822276|PMID:23171950|Drug_Central:1187|DrugBank:DB00196|Reaxys:7311650|CAS:86386-73-4|Beilstein:4269710|PMID:11366931|LINCS:LSM-2106|PMID:23793863,,"A member of the class of  triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_50183|http://purl.obolibrary.org/obo/CHEBI_35703|http://purl.obolibrary.org/obo/CHEBI_78298,,,,,"fluconazole|2-(2,4-difluorophenyl)-1,3-bis-(1H-1,2,4-triazol-1-yl)propan-2-ol",,"fluconazole|fluconazolum|2,4-difluoro-alpha,alpha-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol|2-(2,4-DIFLUOROPHENYL)-1,3-DI(1H-1,2,4-TRIAZOL-1-YL)PROPAN-2-OL|Elazor|Triflucan|Biozole|fluconazol|Diflucan",,,,,,,,,,,,,,,,,,,,,CHEBI:46081,,,,fluconazole,,CHEBI:46081,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000083854,ANGPTL6,,Other designations: angiopoietin-like protein 6|angiopoietin-related growth factor|angiopoietin-related protein 5|angiopoietin-related protein 6,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,ARP5|AGF,,,,,,,,,,,,19,,,,,,HPRD:12453|Ensembl:ENSG00000130812|Vega:OTTHUMG00000180395|MIM:609336|HGNC:23140,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,angiopoietin-like 6,,,19p13.2,,,,,,,,,,,,,,,,GO_0001525 (EC: IEA); GO_0005576 (EC: IEA); GO_0030141 (EC: IEA); GO_0030154 (EC: IEA),,,,,,,,,PMID:12477932; 12871997; 12975309; 14764539; 15231747; 16335952; 16806062; 18464913; 19447061; 20673930; 21460784; 22406517; 23070965; 23400010; 24250222,,,,,,,,,,,,,,,OGG:3000083854,,,,,,,angiopoietin-like 6,,,,,,,,,,,,,Other designations: angiopoietin-like protein 6|angiopoietin-related growth factor|angiopoietin-related protein 5|angiopoietin-related protein 6,,ANGPTL6,,,,,,,,,,,,,,,,,,,,,,,83854,UNQ152/PRO178,,,,,,,9606,,,,,,,,,,,,,,,,,,,ANGPTL6,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0100373,G-alpha-t 1,transducin alpha-1,,false,,,http://purl.obolibrary.org/obo/IMR_0000321,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,transducin alpha-1,,,,,IMR:0100373,,,,,,,,,,,,,,,,,,,,,,G-alpha-t 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0036337,Fas signaling pathway,,"A series of molecular signals initiated by the binding of a ligand to the receptor Fas on the surface of the cell, and ending with regulation of a downstream cellular process, e.g. transcription. Fas is a death domain-containing member of the tumor necrosis factor receptor (TNFR) superfamily.",false,,,http://purl.obolibrary.org/obo/TXPO_0000609,,,,,,,,,,,,,,,,,,,,,,"A series of molecular signals initiated by the binding of a ligand to the receptor Fas on the surface of the cell, and ending with regulation of a downstream cellular process, e.g. transcription. Fas is a death domain-containing member of the tumor necrosis factor receptor (TNFR) superfamily.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0036337,,,,,,,,,,,,,,,,,,,,,,Fas signaling pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000551,type IV collagen,,,false,,,http://purl.obolibrary.org/obo/IMR_0001124,,,,,,,,,,,,,,,,,,,,GO:0005587,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000551,,,,,,,,,,,,,,,,,,,,,,type IV collagen,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0008210,estrogen metabolic process,,"The chemical reactions and pathways involving estrogens, C18 steroid hormones that can stimulate the development of female sexual characteristics. Also found in plants.",false,,,http://purl.obolibrary.org/obo/GO_0042445,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways involving estrogens, C18 steroid hormones that can stimulate the development of female sexual characteristics. Also found in plants.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0008210,,,,,,,,,,,,,,,,,,,,,,estrogen metabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0008219,cell death,,"Any biological process that results in permanent cessation of all vital functions of a cell. A cell should be considered dead when any one of the following molecular or morphological criteria is met: (1) the cell has lost the integrity of its plasma membrane; (2) the cell, including its nucleus, has undergone complete fragmentation into discrete bodies (frequently referred to as apoptotic bodies). The cell corpse (or its fragments) may be engulfed by an adjacent cell in vivo, but engulfment of whole cells should not be considered a strict criteria to define cell death as, under some circumstances, live engulfed cells can be released from phagosomes (see PMID:18045538).",false,,,http://purl.obolibrary.org/obo/TXPO_0000437,,,,,,,,,,,,,,,,,,,,,,"Any biological process that results in permanent cessation of all vital functions of a cell. A cell should be considered dead when any one of the following molecular or morphological criteria is met: (1) the cell has lost the integrity of its plasma membrane; (2) the cell, including its nucleus, has undergone complete fragmentation into discrete bodies (frequently referred to as apoptotic bodies). The cell corpse (or its fragments) may be engulfed by an adjacent cell in vivo, but engulfment of whole cells should not be considered a strict criteria to define cell death as, under some circumstances, live engulfed cells can be released from phagosomes (see PMID:18045538).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000000,,,,,,,,,,,,,,,,,,,,,,,GO:0008219,,,,,,,,,,,,,,,,,,,,,,cell death,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010500,60S ribosomal protein L8,,,false,,,http://purl.obolibrary.org/obo/IMR_0000897,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0010500,,,,,,,,,,,,,,,,,,,,,,60S ribosomal protein L8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000002237,FEN1,,Other designations: DNase IV|flap endonuclease 1|maturation factor 1|maturation factor-1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,MF1|RAD2|FEN-1,,,,,,,,,,,,11,,,,,,HPRD:02670|Vega:OTTHUMG00000168162|HGNC:3650|Ensembl:ENSG00000168496|MIM:600393,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,flap structure-specific endonuclease 1,,,11q12,,,,,,,,,,,,,,,,"GO_0000278 (EC: TAS); GO_0000287 (EC: IEA); GO_0000722 (EC: TAS); GO_0000723 (EC: TAS); GO_0000737 (EC: IDA, PMID: 18995831); GO_0000737 (EC: IMP, PMID: 11986308); GO_0000738 (EC: TAS, PMID: 8131753); GO_0003677 (EC: IMP, PMID: 11986308); GO_0003684 (EC: TAS, PMID: 8007985); GO_0003690 (EC: TAS, PMID: 8131753); GO_0004519 (EC: TAS, PMID: 8131753); GO_0004523 (EC: IDA, PMID: 7961795); GO_0004527 (EC: TAS, PMID: 9778254); GO_0005515 (EC: IPI, PMID: 11430825); GO_0005634 (EC: IDA); GO_0005654 (EC: TAS); GO_0005730 (EC: IDA); GO_0005739 (EC: IDA, PMID: 18995831); GO_0006260 (EC: NAS, PMID: 15504738); GO_0006271 (EC: TAS); GO_0006281 (EC: NAS, PMID: 15504738); GO_0006281 (EC: TAS); GO_0006284 (EC: TAS); GO_0006302 (EC: TAS, PMID: 8131753); GO_0007613 (EC: IEA); GO_0008309 (EC: TAS, PMID: 8131753); GO_0008409 (EC: IDA, PMID: 7961795); GO_0009650 (EC: TAS, PMID: 8007985); GO_0017108 (EC: IDA, PMID: 18995831); GO_0017108 (EC: IMP, PMID: 11986308); GO_0030145 (EC: IEA); GO_0032201 (EC: TAS); GO_0043137 (EC: IDA, PMID: 18995831); GO_0048015 (EC: NAS, PMID: 15504738); GO_0090305 (EC: IDA, PMID: 7961795); GO_0090305 (EC: TAS, PMID: 8131753); GO_0090502 (EC: IDA, PMID: 7961795)",,,,,,,,,PMID: 1477073; 7673186; 7774922; 7961795; 8007985; 8131753; 8621570; 8668533; 8876181; 9178907; 9214649; 9305916; 9445487; 9545252; 9705499; 9778254; 10460157; 10545607; 10559261; 10635332; 11260214; 11313979; 11430825; 11598021; 11601988; 11948189; 11986308; 12065902; 12171929; 12200445; 12356323; 12411510; 12427278; 12453426; 12477932; 12494477; 12515398; 12554738; 12683998; 12853968; 12856420; 12917330; 14562054; 14657243; 14688284; 14690413; 15037610; 15131255; 15146197; 15342556; 15489334; 15504738; 15556996; 15561706; 15576034; 15579905; 15592449; 15616578; 15635413; 15758026; 16133872; 16169070; 16216273; 16326861; 16543152; 16554811; 16582103; 16914748; 17115032; 17176113; 17488975; 18029348; 18097100; 18291413; 18394896; 18417526; 18443037; 18499658; 18541666; 18662981; 18669164; 18692475; 18781797; 18786645; 18995831; 19010819; 19068479; 19208620; 19218431; 19329428; 19471022; 19525235; 19595719; 19618370; 19674974; 19738201; 20019387; 20126648; 20226869; 20444887; 20496165; 20522537; 20551483; 20574454; 20643645; 20729856; 20802161; 20819778; 21044950; 21139048; 21252943; 21345332; 21454907; 21496641; 21829377; 21832049; 21890473; 21900206; 21906983; 21963094; 21987572; 22011247; 22072618; 22139419; 22145905; 22244820; 22505724; 22556262; 22586102; 22592530; 22606318; 22749529; 22751659; 22787431; 22863883; 22918592; 22939629; 22990118; 23000965; 23128233; 23184144; 23277564; 23362303; 23378610; 23382697; 23675412; 23975198; 24126913; 24515614,,,,,,,,,,,,,,,OGG:3000002237,,20140408,protein-coding,,,,flap structure-specific endonuclease 1,,,,,,,,,,,,,Other designations: DNase IV|flap endonuclease 1|maturation factor 1|maturation factor-1,,FEN1,,,,,,,,,,,,,,,,,,,,,,,2237,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,FEN1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0001578,Rab7L,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001578,,,,,,,,,,,,,,,,,,,,,,Rab7L,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000882,sensor,,A role played by the entity which receives a stimulus and transmits operand(s).,false,,,http://purl.obolibrary.org/obo/TXPO_0003728,,,,,,,,,,,,,,,,,,,,,,A role played by the entity which receives a stimulus and transmits operand(s).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000882,,,,,,,,,,,,,,,,,,,,,,sensor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000880,amiodarone [Lipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003508|http://purl.obolibrary.org/obo/CHEBI_2663,,,,,,,,,,,,,,,,,,,,ISBN:0071769234,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000880,,,,,,,,,,,,,,,,,,,,,,amiodarone [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000884,hyperfunction of dead cell phagocytosis by Kupffer cells (macrophages),,Hyperfunction of dead cell phagocytosis by Kupffer cells is a subtype of hyperfunctioning: A process that performs phagocytosis of dead cells by Kupffer cells or macrophages execessively.,false,,,http://purl.obolibrary.org/obo/TXPO_0002279,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of dead cell phagocytosis by Kupffer cells is a subtype of hyperfunctioning: A process that performs phagocytosis of dead cells by Kupffer cells or macrophages execessively.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000884,,,,,,,,,,,,,,,,,,,,,,hyperfunction of dead cell phagocytosis by Kupffer cells (macrophages),,,,,,http://purl.obolibrary.org/obo/TXPO_0000744,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000885,nucleocytoplasmic carrier,,A role of the entity which carries substances between the nucleus and the cytoplasm of a cell by moving along with the target protein.|relatd molecular function GO:0140142,false,,,http://purl.obolibrary.org/obo/TXPO_0003723,,,,,,,,,,,,,,,,,,,,IMR:0000653 (obsolete),,A role of the entity which carries substances between the nucleus and the cytoplasm of a cell by moving along with the target protein.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000885,,,,,,,,,,,,,,,,,,,,relatd molecular function GO:0140142,,nucleocytoplasmic carrier,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000881,stress sensor,,A role played by the entity which receives some stress and transmits operand(s).,false,,,http://purl.obolibrary.org/obo/TXPO_0000882,,,,,,,,,,,,,,,,,,,,,,A role played by the entity which receives some stress and transmits operand(s).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000881,,,,,,,,,,,,,,,,,,,,,,stress sensor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000883,negative regulation of immune response,,"negative regulation of immune response is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of the immune response.",false,,,http://purl.obolibrary.org/obo/TXPO_0000369,,,,,,,,,,,,,,,,,,,,,,"negative regulation of immune response is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of the immune response.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000883,,,,,,,,,,,,,,,,,,,,,,negative regulation of immune response,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006955,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000888,lipidosis [toxic course],fatty liver [toxic course],Lipidosis (toxic course) is a subtype of process sequences: The courses of processes through which lipidosis is realized via lipid homeostasis imbalance.,false,,,http://purl.obolibrary.org/obo/TXPO_0001155,,,,,,,,,,,,,,,,,,,,PMID:23262638|PMID:24954301|PMID:21145849|PMID:15254578|ISBN:0071769234|PMID:10962028,,Lipidosis (toxic course) is a subtype of process sequences: The courses of processes through which lipidosis is realized via lipid homeostasis imbalance.,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001129,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003494|http://purl.obolibrary.org/obo/TXPO_0003491|http://purl.obolibrary.org/obo/TXPO_0000901|http://purl.obolibrary.org/obo/TXPO_0003507|http://purl.obolibrary.org/obo/TXPO_0003484|http://purl.obolibrary.org/obo/TXPO_0001129|http://purl.obolibrary.org/obo/TXPO_0000893|http://purl.obolibrary.org/obo/TXPO_0000898|http://purl.obolibrary.org/obo/TXPO_0000892|http://purl.obolibrary.org/obo/TXPO_0000899|http://purl.obolibrary.org/obo/TXPO_0000891|http://purl.obolibrary.org/obo/TXPO_0000890,,,,,,,,,,,,,fatty liver [toxic course],,,,,TXPO:0000888,,,,,,,,,,,,,,,,,,,,,,lipidosis [toxic course],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000886,ER process,,,false,,,http://purl.obolibrary.org/obo/BFO_0000015|http://purl.obolibrary.org/obo/TXPO_0000538,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000886,,,,,,,,,,,,,,,,,,,,,,ER process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000887,gene expression regulation system,,"Gene expression regulation system is a subtype of pathway system.
This entity has sub-parts and has a goal of regulating gene expressions as a systemic context.",false,,,http://purl.obolibrary.org/obo/TXPO_0000603,,,,,,,,,,,,,,,,,,,,,,"Gene expression regulation system is a subtype of pathway system.
This entity has sub-parts and has a goal of regulating gene expressions as a systemic context.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000887,,,,,,,,,,,,,,,,,,,,,,gene expression regulation system,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000889,glutathione depletion dependent process,,Glutathione depletion dependent process is a subtype of toxic course dependent process: A process that can constitute the course of glutathione depletion .,false,,,http://purl.obolibrary.org/obo/TXPO_0001715,,,,,,,,,,,,,,,,,,,,,,Glutathione depletion dependent process is a subtype of toxic course dependent process: A process that can constitute the course of glutathione depletion .,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000889,,,,,,,,,,,,,,,,,,,,,,glutathione depletion dependent process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000337,changing fluidity,,Changing fluidity is a subtype of changing quality: A process that changes the fluidity of the object.,false,,,http://purl.obolibrary.org/obo/TXPO_0000415,,,,,,,,,,,,,,,,,,,,,,Changing fluidity is a subtype of changing quality: A process that changes the fluidity of the object.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000337,,,,,,,,,,,,,,,,,,,,,,changing fluidity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000339,tumor cell proliferation,,"Tumor cell proliferation is a subtype of cell proliferation: A process of the multiplication or reproduction of tumor cells, resulting in the rapid expansion of a tumor cell population.",false,,,http://purl.obolibrary.org/obo/GO_0008283,,,,,,,,,,,,,,,,,,,,,,"Tumor cell proliferation is a subtype of cell proliferation: A process of the multiplication or reproduction of tumor cells, resulting in the rapid expansion of a tumor cell population.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000339,,,,,,,,,,,,,,,,,,,,,,tumor cell proliferation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000333,separating,,Separating is a subtype of changing between operands: A process that divides the whole object into multiple components.|separating into multiple components,false,,,http://purl.obolibrary.org/obo/TXPO_0000261,,,,,,,,,,,,,,,,,,,,,,Separating is a subtype of changing between operands: A process that divides the whole object into multiple components.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000333,,,,,,,,,,,,,,,,,,,,separating into multiple components,,separating,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000332,genome,,"The totality of genetic information belonging to a cell or an organism; in particular, the DNA that carries this information.",false,,,http://purl.obolibrary.org/obo/GO_0005575,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_0000000001,,"The totality of genetic information belonging to a cell or an organism; in particular, the DNA that carries this information.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_0000000002,,,,,,,,,,,,,,,,,,TXPO:0000332,,,,,,,,,,,,,,,,,,,,,,genome,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000330,transcription regulator,,"A role that controls the rate, timing and/or magnitude of transcription of genetic information. The function of transcriptional regulators is to modulate gene expression at the transcription step so that they are expressed in the right cell at the right time and in the right amount throughout the life of the cell and the organism.|related molecular function GO:0140110",false,,,http://purl.obolibrary.org/obo/TXPO_0003230,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006351,,,,,,,,,,,IMR:0000369 (obsolete),,"A role that controls the rate, timing and/or magnitude of transcription of genetic information. The function of transcriptional regulators is to modulate gene expression at the transcription step so that they are expressed in the right cell at the right time and in the right amount throughout the life of the cell and the organism.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000330,,,,,,,,,,,,,,,,,,,,related molecular function GO:0140110,,transcription regulator,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000338,cell proliferation [Cell death],,"The multiplication or reproduction of cells, resulting in the rapid expansion of a cell population.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0001727|http://purl.obolibrary.org/obo/GO_0008283,,,,,,,,,,,,,,,,,,,,,,"The multiplication or reproduction of cells, resulting in the rapid expansion of a cell population.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000338,,,,,,,,,,,,,,,,,,,,,,cell proliferation [Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000335,ATF6 signaling (primitive),,ATF6 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the ATF6 (activating transcription factor 6). ATF6 generally plays a endoplasmic reticulum membrane stress sensor role.,false,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,,,ATF6 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the ATF6 (activating transcription factor 6). ATF6 generally plays a endoplasmic reticulum membrane stress sensor role.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002126,,,,,,,,,,,,,,,,TXPO:0000335,,,,,,,,,,,,,,,,,,,,,,ATF6 signaling (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000331,drug transmembrane transporter,,"A role played by the entity which enables the transfer of a drug from one side of a membrane to the other. A drug is any naturally occurring or synthetic substance, other than a nutrient, that, when administered or applied to an organism, affects the structure or functioning of the organism; in particular, any such substance used in the diagnosis, prevention, or treatment of disease.|related molecular function GO:0015238",false,,,http://purl.obolibrary.org/obo/TXPO_0003698,,,,,,,,,,,,,,,,,,,,,,"A role played by the entity which enables the transfer of a drug from one side of a membrane to the other. A drug is any naturally occurring or synthetic substance, other than a nutrient, that, when administered or applied to an organism, affects the structure or functioning of the organism; in particular, any such substance used in the diagnosis, prevention, or treatment of disease.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000331,,,,,,,,,,,,,,,,,,,,related molecular function GO:0015238,,drug transmembrane transporter,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000336,amino acid conjugatied bile acid  transport into bile canaliculus,,Amino acid conjugatied bile acid  transport into bile canaliculus is a subtype of canalicular bile acid transport: A process that enables the transfer of amino acid conjugated bile acid from one side of a hepatocyte plasma membrane into a bile canaliculus.,false,,,http://purl.obolibrary.org/obo/GO_0015722,,,,,,,,,,,,,,,,,,,,,,Amino acid conjugatied bile acid  transport into bile canaliculus is a subtype of canalicular bile acid transport: A process that enables the transfer of amino acid conjugated bile acid from one side of a hepatocyte plasma membrane into a bile canaliculus.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0001283,,,,,,,,TXPO:0000336,,,,,,,,,,,,,,,,,,,,,,amino acid conjugatied bile acid  transport into bile canaliculus,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000334,hyperfunction of Kupffer cell differentiation [Phospholipidosis (excessive defense)],,"Hyperfunction of Kupffer cell differentiation is a subtype of hyperfunction of cell differentiation: A process that performs an excesssive kupffer cell differentiation.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense).",false,,,http://purl.obolibrary.org/obo/TXPO_0000636,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of Kupffer cell differentiation is a subtype of hyperfunction of cell differentiation: A process that performs an excesssive kupffer cell differentiation.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003431,,,,,,,,,,,TXPO:0000334,,,,,,,,,,,,,,,,,,,,,,hyperfunction of Kupffer cell differentiation [Phospholipidosis (excessive defense)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000637,Integrin alpha-L,,,false,,,http://purl.obolibrary.org/obo/IMR_0000173,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000637,,,,,,,,,,,,,,,,,,,,,,Integrin alpha-L,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001405,p300,,,false,,,http://purl.obolibrary.org/obo/IMR_0000426,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001405,,,,,,,,,,,,,,,,,,,,,,p300,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001087,importin alpha4,KPNA4|importin alpha3|importin alpha Q1|Qip1|karyopherin alpha4,,false,,,http://purl.obolibrary.org/obo/IMR_0100202,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,KPNA4|importin alpha3|importin alpha Q1|Qip1|karyopherin alpha4,,,,,IMR:0001087,,,,,,,,,,,,,,,,,,,,,,importin alpha4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004922,aristolochic acid [hepatocarcinogenesis],"8-methoxy-6-nitrophenanthro[3,4-d][1,3]dioxole-5-carboxylic acid","A monocarboxylic acid that is phenanthrene-1-carboxylic acid that is substituted by a methylenedioxy group at the 3,4 positions, by a methoxy group at position 8, and by a nitro group at position 10. It is the most abundant of the aristolochic acids and is found in almost all Aristolochia (birthworts or pipevines) species. It has been tried in a number of treatments for inflammatory disorders, mainly in Chinese and folk medicine. However, there is concern over their use as aristolochic acid is both carcinogenic and nephrotoxic.",false,,,http://purl.obolibrary.org/obo/TXPO_0004455|http://purl.obolibrary.org/obo/CHEBI_2825,,,,,,,,,,,,,,,,,,,,PMID:31439937,,"A monocarboxylic acid that is phenanthrene-1-carboxylic acid that is substituted by a methylenedioxy group at the 3,4 positions, by a methoxy group at position 8, and by a nitro group at position 10. It is the most abundant of the aristolochic acids and is found in almost all Aristolochia (birthworts or pipevines) species. It has been tried in a number of treatments for inflammatory disorders, mainly in Chinese and folk medicine. However, there is concern over their use as aristolochic acid is both carcinogenic and nephrotoxic.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"8-methoxy-6-nitrophenanthro[3,4-d][1,3]dioxole-5-carboxylic acid",,,,,TXPO:0004922,,,,,,,,,,,,,,,,,,,,,,aristolochic acid [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004925,NLRP3 (canonical)[mitochondrial disorder]],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003516|http://purl.obolibrary.org/obo/TXPO_0001877,,,,,,,,,,,,,,,,,,,NLRP3 is a inflammasome component,NCBI-Rat-GeneID:287362|NCBI-Human-GeneID:114548|NCBI-Mouse-GeneID:216799|PMID:31623280,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004925,,,,,,,,,,,,,,,,,,,,,,NLRP3 (canonical)[mitochondrial disorder]],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004928,autophagy [mitochondrial disorder],,The cellular catabolic process in which cells digest parts of their own cytoplasm; allows for both recycling of macromolecular constituents under conditions of cellular stress and remodeling the intracellular structure for cell differentiation. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorders.,false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/GO_0006914,,,,,,,,,,,,,,,,,,,,PMID:27151080,,The cellular catabolic process in which cells digest parts of their own cytoplasm; allows for both recycling of macromolecular constituents under conditions of cellular stress and remodeling the intracellular structure for cell differentiation. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorders.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004928,,,,,,,,,,,,,,,,,,,,,,autophagy [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004923,alcohol intake [hepatocarcinogenesis],,"A moving process of alcohol from the outside to the inside of a body.
This entity is a specific course dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0001224,,,,,,,,,,,,,,,,,,,,PMID:31439937|PMID:28706416,,"A moving process of alcohol from the outside to the inside of a body.
This entity is a specific course dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004924,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004453|http://purl.obolibrary.org/obo/TXPO_0004506|http://purl.obolibrary.org/obo/TXPO_0004630,,,,,,,,,,,TXPO:0004923,,,,,,,,,,,,,,,,,,,,,,alcohol intake [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004926,hypofunction of oxysterol biosynthesis,,Hypofunction of oxysterol biosynthesis is a subtype of hypofunction of lipid biosynthesis: A process that performs a decreased or insufficient oxysterol biosynthesis.,false,,,http://purl.obolibrary.org/obo/TXPO_0002195,,,,,,,,,,,,,,,,,,,,,,Hypofunction of oxysterol biosynthesis is a subtype of hypofunction of lipid biosynthesis: A process that performs a decreased or insufficient oxysterol biosynthesis.,,,http://purl.obolibrary.org/obo/GO_0006695,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001330,,,,,,,,,,,TXPO:0004926,,,,,,,,,,,,,,,,,,,,,,hypofunction of oxysterol biosynthesis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004920,positive regulation of arachidonic acid metabolic process,,"Any process that activates or increases the frequency, rate or extent of arachidonic acid metabolic process.",false,,,http://purl.obolibrary.org/obo/TXPO_0001223,,,,,,,,,,,,,,,,,,,,,,"Any process that activates or increases the frequency, rate or extent of arachidonic acid metabolic process.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004920,,,,,,,,,,,,,,,,,,,,,,positive regulation of arachidonic acid metabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003884,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004921,Decreasing arachidonic acid level,,Decreasing arachidonic acid level is a subtype of decreasing quantity: A process that changes the amount of arachidonic acid level to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000396,,,,,,,,,,,,,,,,,,,,,,Decreasing arachidonic acid level is a subtype of decreasing quantity: A process that changes the amount of arachidonic acid level to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001166,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004921,,,,,,,,,,,,,,,,,,,,,,Decreasing arachidonic acid level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004924,alcohol [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004455|http://purl.obolibrary.org/obo/CHEBI_30879,,,,,,,,,,,,,,,,,,,,PMID:28932315,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004924,,,,,,,,,,,,,,,,,,,,,,alcohol [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004927,hypofunction of oxysterol biosynthesis [mitochondrial disorder],,"Hypofunction of oxysterol biosynthesis is a subtype of hypofunction of lipid biosynthesis: A process that performs a decreased or insufficient oxysterol biosynthesis.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0004926,,,,,,,,,,,,,,,,,,,,,,"Hypofunction of oxysterol biosynthesis is a subtype of hypofunction of lipid biosynthesis: A process that performs a decreased or insufficient oxysterol biosynthesis.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004927,,,,,,,,,,,,,,,,,,,,,,hypofunction of oxysterol biosynthesis [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004929,autophagy [hepatocarcinogenesis],,The cellular catabolic process in which cells digest parts of their own cytoplasm; allows for both recycling of macromolecular constituents under conditions of cellular stress and remodeling the intracellular structure for cell differentiation. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.,false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/GO_0006914,,,,,,,,,,,,,,,,,,,,PMID:25649430,,The cellular catabolic process in which cells digest parts of their own cytoplasm; allows for both recycling of macromolecular constituents under conditions of cellular stress and remodeling the intracellular structure for cell differentiation. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004930|http://purl.obolibrary.org/obo/TXPO_0004193,,,,,,http://purl.obolibrary.org/obo/TXPO_0004518,,,,,,,,,,,TXPO:0004929,,,,,,,,,,,,,,,,,,,,,,autophagy [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100702,PKA regulatory subunit,cAMP-dependent protein kinase regulatory chain,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,GO:0008603,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003722,,,,,cAMP-dependent protein kinase regulatory chain,,,,,IMR:0100702,,,,,,,,,,,,,,,,,,,,,,PKA regulatory subunit,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010494,60S ribosomal protein L36a,60S ribosomal protein L44,,false,,,http://purl.obolibrary.org/obo/IMR_0000897,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,60S ribosomal protein L44,,,,,IMR:0010494,,,,,,,,,,,,,,,,,,,,,,60S ribosomal protein L36a,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000627,removing damaged cell,,Removing damaged cell is a subtype of removing damaged object: A process that takes a damaged cell from an organism or tissue.,false,,,http://purl.obolibrary.org/obo/TXPO_0000619,,,,,,,,,,,,,,,,,,,,,,Removing damaged cell is a subtype of removing damaged object: A process that takes a damaged cell from an organism or tissue.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000627,,,,,,,,,,,,,,,,,,,,,,removing damaged cell,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000628,negative regulation of phopholipase C mediated phosphatidyliserine degradation,,"Negative regulation of phopholipase C mediated phosphatidyliserine degradation is a subtype of negative regulation of phosphatidylserine  degradation: A process that stops, prevents, or reduces the frequency, rate or extent of phopholipase C mediated phosphatidyliserine degradation.",false,,,http://purl.obolibrary.org/obo/TXPO_0001650,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of phopholipase C mediated phosphatidyliserine degradation is a subtype of negative regulation of phosphatidylserine  degradation: A process that stops, prevents, or reduces the frequency, rate or extent of phopholipase C mediated phosphatidyliserine degradation.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000628,,,,,,,,,,,,,,,,,,,,,,negative regulation of phopholipase C mediated phosphatidyliserine degradation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000629,negative regulation of phopholipase C mediated phosphatidylinositol degradation,,"Negative regulation of phopholipase C mediated phosphatidylinositol degradation is a subtype of negative regulation of phosphatidylinositol degradation: A process that stops, prevents, or reduces the frequency, rate or extent of phopholipase C mediated phosphatidylinositol degradation.",false,,,http://purl.obolibrary.org/obo/TXPO_0001659,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of phopholipase C mediated phosphatidylinositol degradation is a subtype of negative regulation of phosphatidylinositol degradation: A process that stops, prevents, or reduces the frequency, rate or extent of phopholipase C mediated phosphatidylinositol degradation.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000629,,,,,,,,,,,,,,,,,,,,,,negative regulation of phopholipase C mediated phosphatidylinositol degradation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000625,role related to increasing number,,A role played by the entity to increase number of operand(s),false,,,http://purl.obolibrary.org/obo/TXPO_0003712,,,,,,,,,,,,,,,,,,,,,,A role played by the entity to increase number of operand(s),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000625,,,,,,,,,,,,,,,,,,,,,,role related to increasing number,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000622,cytokine,,"A signaling role played by the entity such as protein, polypeptide, or glycoprotein that acts on neighboring cells to alter their behavior.|related molecular function GO:0005125",false,,,http://purl.obolibrary.org/obo/CHEBI_33280,,,,,,,,,,,,,,,,,,,,IMR:0000006 (obsolete),,"A signaling role played by the entity such as protein, polypeptide, or glycoprotein that acts on neighboring cells to alter their behavior.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000624,,,,,,,,,,TXPO:0000622,,,,,,,Extracellular signal protein or peptide that acts as a local mediator in cell-cell communication.,,,,,,,,,,,,,related molecular function GO:0005125,,cytokine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000620,removing damaged organelle,,Removing damaged organelle is a subtype of removing damaged object: A process that takes a damaged organelle from a cell.,false,,,http://purl.obolibrary.org/obo/TXPO_0000619,,,,,,,,,,,,,,,,,,,,,,Removing damaged organelle is a subtype of removing damaged object: A process that takes a damaged organelle from a cell.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000620,,,,,,,,,,,,,,,,,,,,,,removing damaged organelle,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000621,negative regulation of phospholipase C mediated phosphatidylcholine degradation,,"Negative regulation of phospholipase C mediated phosphatidylcholine degradation is a subtype of negative regulation of phosphatidylcholine catabolic process: A process that stops, prevents, or reduces the frequency, rate or extent of phospholipase C mediated phosphatidylcholine degradation.",false,,,http://purl.obolibrary.org/obo/GO_0010900,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of phospholipase C mediated phosphatidylcholine degradation is a subtype of negative regulation of phosphatidylcholine catabolic process: A process that stops, prevents, or reduces the frequency, rate or extent of phospholipase C mediated phosphatidylcholine degradation.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000621,,,,,,,,,,,,,,,,,,,,,,negative regulation of phospholipase C mediated phosphatidylcholine degradation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000623,regulator role of receiving,,A role of regulating receiving process of receptors such that the proportion of receptors in the active form is changed.|related molecular function GO:0030545,false,,,http://purl.obolibrary.org/obo/TXPO_0003230,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000379,,,,,,,,,,,,,A role of regulating receiving process of receptors such that the proportion of receptors in the active form is changed.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000623,,,,,,,,,,,,,,,,,,,,related molecular function GO:0030545,,regulator role of receiving,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000626,DNA replication factor role,,A role played by the entity to replicate DNA.,false,,,http://purl.obolibrary.org/obo/TXPO_0000625,,,,,,,,,,,,,,,,,,,,,,A role played by the entity to replicate DNA.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000626,,,,,,,,,,,,,,,,,,,,,,DNA replication factor role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006260,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000624,ligand,,"A role played by the entity that Interacts selectively and non-covalently with one or more specific sites on a receptor molecule, a macromolecule that undergoes combination with a hormone, neurotransmitter, drug or intracellular messenger to initiate a change in cell function.|related molecular function GO:0005102",false,,,http://purl.obolibrary.org/obo/TXPO_0000623,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_52214|Wikipedia:Ligand_(biochemistry)|IMR:0000002 (obsolete),,"A role played by the entity that Interacts selectively and non-covalently with one or more specific sites on a receptor molecule, a macromolecule that undergoes combination with a hormone, neurotransmitter, drug or intracellular messenger to initiate a change in cell function.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000624,,,,,,,Binding to a specific receptor protein and activating intracellular signaling cascades that alter the behavior of the cell.,,,,,,,,,,,,,related molecular function GO:0005102,,ligand,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001793,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000029028,ATAD2,,Other designations: AAA nuclear coregulator cancer-associated protein|ATPase family AAA domain-containing protein 2,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,PRO2000|CT137|ANCCA,,,,,,,,,,,,8,,,,,,Vega:OTTHUMG00000165090|HPRD:10678|Ensembl:ENSG00000156802|MIM:611941|HGNC:30123,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"ATPase family, AAA domain containing 2",,,8q24.13,,,,,,,,,,,,,,,,"GO_0005524 (EC: IEA); GO_0005634 (EC: IEA); GO_0006200 (EC: IDA, PMID: 17998543); GO_0006351 (EC: IEA); GO_0016887 (EC: IDA, PMID: 17998543); GO_0045893 (EC: IDA, PMID: 17998543); GO_0070062 (EC: IDA, PMID: 19056867)",,,,,,,,,PMID: 12477932; 14702039; 15302935; 15334068; 15342556; 15489334; 16712791; 17081983; 17998543; 18029348; 19056867; 19318566; 19471022; 19843847; 20374707; 20855524; 20864510; 21139048; 21252943; 21693764; 21890473; 21906983; 22178446; 22586326; 22771493; 22914773; 23000965; 23393560; 23752268,,,,,,,,,,,,,,,OGG:3000029028,,20140408,protein-coding,,,,"ATPase family, AAA domain containing 2",,,,,,,,,,,,,Other designations: AAA nuclear coregulator cancer-associated protein|ATPase family AAA domain-containing protein 2,,ATAD2,,,,,,,,,,,,,,,,,,,,,,,29028,L16,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,ATAD2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_63247,reducing agent,reducer|Wikipedia:Reducing_agent|reductant,The element or compound in a reduction-oxidation (redox) reaction that donates an electron to another species.,false,,,http://purl.obolibrary.org/obo/CHEBI_51086,,,,,,,,,,,,,,,,,,,,,,The element or compound in a reduction-oxidation (redox) reaction that donates an electron to another species.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,reducer|Wikipedia:Reducing_agent|reductant,,,CHEBI:63247,,,,,,,,,,,,,,,,,,,,,,reducing agent,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000641,Integrin beta-1,,,false,,,http://purl.obolibrary.org/obo/IMR_0000174,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000641,,,,,,,,,,,,,,,,,,,,,,Integrin beta-1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_367163,darunavir,"darunavir|darunavirum|(3R,3AS,6AR)-HEXAHYDROFURO[2,3-B]FURAN-3-YL(1S,2R)-3-[[(4-AMINOPHENYL)SULFONYL](ISOBUTYL)AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE|[(S)-3-[(4-Amino-benzenesulfonyl)-isobutyl-amino]-2-hydroxy-1-((R)-phenylmethyl)-propyl]-carbamic acid (3R,3aS,6aR)-(hexahydro-furo[2,3-b]furan-3-yl) ester|(3R,3aS,6aR)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate|{(1S,2R)-3-[(4-Amino-benzenesulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl}-carbamic acid (3R,3aS,6aR)-(hexahydro-furo[2,3-b]furan-3-yl) ester|TMC114|N-((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-benzylpropyl)((1S,2R,5R)-4,6-dioxabicyclo(3.3.0)oct-2-yloxy)carboxamide|(3R,3aS,6aR)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-neopentylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate|(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl N-((1S,2R)-1-benzyl-2-hydroxy-3-(N(1)-isobutylsulfanilamido)propyl)carbamate|(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl [(2S,3R)-4-{[(4-aminophenyl)sulfonyl](2-methylpropyl)amino}-3-hydroxy-1-phenylbutan-2-yl]carbamate|Darunavir","An N,N-disubstituted benzenesulfonamide bearing an unsubstituted amino group at the 4-position, used for the treatment of HIV infection. A second-generation HIV protease inhibitor, darunavir was designed to form robust interactions with the protease  enzyme from many strains of HIV, including those from treatment-experienced patients with multiple resistance mutations to other protease inhibitors.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Reaxys:7960555|PMID:25017682|DrugBank:DB01264|Drug_Central:4143|Beilstein:7960555|PMID:15771427|PMID:16480273|CAS:206361-99-1,,"An N,N-disubstituted benzenesulfonamide bearing an unsubstituted amino group at the 4-position, used for the treatment of HIV infection. A second-generation HIV protease inhibitor, darunavir was designed to form robust interactions with the protease  enzyme from many strains of HIV, including those from treatment-experienced patients with multiple resistance mutations to other protease inhibitors.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35660|http://purl.obolibrary.org/obo/CHEBI_36044,,,,,"(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl [(2S,3R)-4-{[(4-aminophenyl)sulfonyl](2-methylpropyl)amino}-3-hydroxy-1-phenylbutan-2-yl]carbamate|Darunavir",,"darunavir|darunavirum|(3R,3AS,6AR)-HEXAHYDROFURO[2,3-B]FURAN-3-YL(1S,2R)-3-[[(4-AMINOPHENYL)SULFONYL](ISOBUTYL)AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE|[(S)-3-[(4-Amino-benzenesulfonyl)-isobutyl-amino]-2-hydroxy-1-((R)-phenylmethyl)-propyl]-carbamic acid (3R,3aS,6aR)-(hexahydro-furo[2,3-b]furan-3-yl) ester|(3R,3aS,6aR)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate|{(1S,2R)-3-[(4-Amino-benzenesulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl}-carbamic acid (3R,3aS,6aR)-(hexahydro-furo[2,3-b]furan-3-yl) ester|TMC114|N-((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-benzylpropyl)((1S,2R,5R)-4,6-dioxabicyclo(3.3.0)oct-2-yloxy)carboxamide|(3R,3aS,6aR)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-neopentylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate|(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl N-((1S,2R)-1-benzyl-2-hydroxy-3-(N(1)-isobutylsulfanilamido)propyl)carbamate",,,,,,,,,,,,,,,,,,,,,CHEBI:367163,,,,darunavir,,CHEBI:367163,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000948,reactive oxygen species biosynthetic process [Ground glass appearance],,"The chemical reaction resulting in the formation of reactive oxygen species, any molecules or ions formed by the incomplete one-electron reduction of oxygen.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/GO_1903409,,,,,,,,,,,,,,,,,,,,,,"The chemical reaction resulting in the formation of reactive oxygen species, any molecules or ions formed by the incomplete one-electron reduction of oxygen.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000981,,,,,,,,,,,TXPO:0000948,,,,,,,,,,,,,,,,,,,,,,reactive oxygen species biosynthetic process [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000942,forming a complex with Cytochrome P450 [Ground glass appearance],,"Forming a complex with Cytochrome P450 is a subtype of protein complex assembly: The aggregation, arrangement and bonding together with Cyp (cytochrome P450) to form a complex.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001212|http://purl.obolibrary.org/obo/TXPO_0001728,,,,,,,,,,,,,,,,,,,,,,"Forming a complex with Cytochrome P450 is a subtype of protein complex assembly: The aggregation, arrangement and bonding together with Cyp (cytochrome P450) to form a complex.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000992,,,,,,,,,,,,,,,,,TXPO:0000942,,,,,,,,,,,,,,,,,,,,,,forming a complex with Cytochrome P450 [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000949,phospholipidosis via obese,,This process is totality of all processes through which the phospholipidosis is realized caused by obesity.  The severity is moderate.,false,,,http://purl.obolibrary.org/obo/TXPO_0003369,,,,,,,,,,,,,,,,,,,,,,This process is totality of all processes through which the phospholipidosis is realized caused by obesity.  The severity is moderate.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002241|http://purl.obolibrary.org/obo/TXPO_0000950|http://purl.obolibrary.org/obo/TXPO_0001645,,,,,,,,,,,,,,,,,,TXPO:0000949,,,,,,,,,,,,,,,,,,,,,,phospholipidosis via obese,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000944,AMPK (canonical)[Ground glass appearance],,PRKAA1,false,,,http://purl.obolibrary.org/obo/TXPO_0003221|http://purl.obolibrary.org/obo/TXPO_0000472,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:105787|NCBI-Human-GeneID:5562|NCBI-Rat-GeneID:65248,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003221,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0002354,,,,http://purl.obolibrary.org/obo/TXPO_0001682,,,,,,,,,,TXPO:0000944,,,,,,,"The protein encoded by this gene belongs to the ser/thr protein kinase family. It is the catalytic subunit of the 5'-prime-AMP-activated protein kinase (AMPK). AMPK is a cellular energy sensor conserved in all eukaryotic cells. The kinase activity of AMPK is activated by the stimuli that increase the cellular AMP/ATP ratio. AMPK regulates the activities of a number of key metabolic enzymes through phosphorylation. It protects cells from stresses that cause ATP depletion by switching off ATP-consuming biosynthetic pathways. Alternatively spliced transcript variants encoding distinct isoforms have been observed. [provided by RefSeq, Jul 2008]",,,,,,,,,,,,,PRKAA1,,AMPK (canonical)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000943,hyperfunction of drug metabolism phase II [Ground glass appearance],,"Hyperfunction of drug metabolism phase II is a subtype of hyperfunction of drug metabolism: A process that performs an excessive drug metabolism phase II.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/TXPO_0001236,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of drug metabolism phase II is a subtype of hyperfunction of drug metabolism: A process that performs an excessive drug metabolism phase II.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000443,,,,,,,,,,,TXPO:0000943,,,,,,,,,,,,,,,,,,,,,,hyperfunction of drug metabolism phase II [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000945,negative regulation of ATP consuming [Ground glass appearance],,"Negative regulation of ATP consuming is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of ATP consuming.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0003978|http://purl.obolibrary.org/obo/TXPO_0001728,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of ATP consuming is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of ATP consuming.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000945,,,,,,,,,,,,,,,,,,,,,,negative regulation of ATP consuming [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000947,increasing demand for response to oxidative stress [Ground glass appearance],,"Increasing demand for response to oxidative stress is a subtype of increasing the demand for response to stress: A process that changes the functional demand for the response to the oxidative stress to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/TXPO_0000102,,,,,,,,,,,,,,,,,,,,,,"Increasing demand for response to oxidative stress is a subtype of increasing the demand for response to stress: A process that changes the functional demand for the response to the oxidative stress to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002319,,,,,,,,,,,TXPO:0000947,,,,,,,,,,,,,,,,,,,,,,increasing demand for response to oxidative stress [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000941,hyperfunction of electron transport from NADH to cytochrome P450 [Ground glass appearance],,"Hyperfunction of electron transport from NADH to cytochrome P450 is a subtype of hyperfunction of transport: A process that performs an excesssive electron transport from NADH to cytochrome P450.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/TXPO_0002052,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of electron transport from NADH to cytochrome P450 is a subtype of hyperfunction of transport: A process that performs an excesssive electron transport from NADH to cytochrome P450.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000995,,,,,,http://purl.obolibrary.org/obo/TXPO_0001621,,,,,,,,,,,TXPO:0000941,,,,,,,,,,,,,,,,,,,,,,hyperfunction of electron transport from NADH to cytochrome P450 [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000940,hypofunction of decomposing,,Hypofunction of decomposing is a subtype of hypofunctioning: A process that performs a decreased or insufficient decomposing.,false,,,http://purl.obolibrary.org/obo/TXPO_0000436,,,,,,,,,,,,,,,,,,,,,,Hypofunction of decomposing is a subtype of hypofunctioning: A process that performs a decreased or insufficient decomposing.,,,http://purl.obolibrary.org/obo/TXPO_0000343,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000940,,,,,,,,,,,,,,,,,,,,,,hypofunction of decomposing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000946,changing balance of phospholipid metabolism [Phospholipidosis],,"Changing balance of phospholipid metabolism is a subtype of changing balance: A process that changes the balance between phospholipid anabolism and catabolism.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0001263,,,,,,,,,,,,,,,,,,,,,,"Changing balance of phospholipid metabolism is a subtype of changing balance: A process that changes the balance between phospholipid anabolism and catabolism.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000951,,,,,,,,,,,TXPO:0000946,,,,,,,,,,,,,,,,,,,,,,changing balance of phospholipid metabolism [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_85012,thrombopoietin receptor agonist,TPO receptor agonists|TPO receptor agonist|thrombopoietin receptor agonists,An agonist that selectively binds to and activates the thrombopoietin receptor [myeloproliferative leukemia protein or CD110 (Cluster of Differentiation 110)].,false,,,http://purl.obolibrary.org/obo/CHEBI_48705,,,,,,,,,,,,,,,,,,,,,,An agonist that selectively binds to and activates the thrombopoietin receptor [myeloproliferative leukemia protein or CD110 (Cluster of Differentiation 110)].,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TPO receptor agonists|TPO receptor agonist|thrombopoietin receptor agonists,,,,,,,,,,,,,,,,,,,,,CHEBI:85012,,,,thrombopoietin receptor agonist,,CHEBI:85012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/NCBITaxon_9989,rodentia,rodent,,false,,,http://purl.obolibrary.org/obo/NCBITaxon_40674,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,rodent,,,,,NCBITaxon:9989,,,,,,,,,,,,,,,,,,,,,,rodentia,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0002240,spinal cord,medulla spinalis|cerebro-cerebellar fissure|fissura cerebro-cerebellaris|spinal cord structure|fissura cerebrocerebellaris|SpC|cerebrocerebellar fissure|spinal medulla,"Part of the central nervous system located in the vertebral canal continuous with and caudal to the brain; demarcated from brain by plane of foramen magnum. It is composed of an inner core of gray matter in which nerve cells predominate, and an outer layer of white matter in which myelinated nerve fibers predominate, and surrounds the central canal. (CUMBO)",false,,,http://purl.obolibrary.org/obo/UBERON_0000062,,,,,,,,,,,,,,,,,,,,http://linkedlifedata.com/resource/umls/id/C0037925|http://braininfo.rprc.washington.edu/centraldirectory.aspx?ID=22|http://www.snomedbrowser.com/Codes/Details/180959008|http://en.wikipedia.org/wiki/Spinal_cord|http://uri.neuinfo.org/nif/nifstd/birnlex_1709|http://purl.obolibrary.org/obo/NCIT_C12464|BM:SpC|GAID:695|XAO:0000020|OpenCyc:Mx4rvVjjk5wpEbGdrcN5Y29ycA|UMLS:C0037925|BAMS:SP|EHDAA2:0001255|EMAPA:17577|MAT:0000183|DHBA:12890|CALOHA:TS-0953|BAMS:Spinal|MIAA:0000183|VHOG:0000601|FMA:7647|MA:0000216|EFO:0000110|TAO:0000075|MESH:D013116|http://braininfo.rprc.washington.edu/centraldirectory.aspx?ID=22|ZFA:0000075|DMBA:17651|EV:0100316|AAO:0010151|EHDAA:2863|BTO:0001279,,"Part of the central nervous system located in the vertebral canal continuous with and caudal to the brain; demarcated from brain by plane of foramen magnum. It is composed of an inner core of gray matter in which nerve cells predominate, and an outer layer of white matter in which myelinated nerve fibers predominate, and surrounds the central canal. (CUMBO)",,,,TODO - add superclass to unify with VNC?,,,,Part of the central nervous system which descends from the hindbrain within the vertebral column.[AAO],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,medulla spinalis|cerebro-cerebellar fissure|fissura cerebro-cerebellaris|spinal cord structure|fissura cerebrocerebellaris|SpC|cerebrocerebellar fissure|spinal medulla,"(...) at some stage of its development, every chordate exhibits five uniquely derived characters or synapomorphies of the group: (...) (4) a single, tubular nerve cord that is located dorsal to the notochord (...) (reference 1); The neural tube is destined to differentiate into the brain and spinal cord (the central nervous system) (reference 2).[well established][VHOG]",http://purl.obolibrary.org/obo/UBERON_0001017,UBERON:0002240,http://purl.obolibrary.org/obo/UBERON_0001017,,,,,,,,,,,,,,,,,,,,,spinal cord,,,,http://upload.wikimedia.org/wikipedia/commons/5/58/Spinal_cord_direv.svg,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100453,MEK2(MKK2),MAP kinase kinase 2|ERK activator kinase 2|MAPK/ERK kinase 2|MKK2|MEK2|MAPKK 2,,false,,,http://purl.obolibrary.org/obo/IMR_0000261,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MAP kinase kinase 2|ERK activator kinase 2|MAPK/ERK kinase 2|MKK2|MEK2|MAPKK 2,,,,,IMR:0100453,,,,,,,,,,,,,,,,,,,,,,MEK2(MKK2),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_114785,erlotinib,"erlotinib|[6,7-bis(2-methoxy-ethoxy)quinazoline-4-yl]-(3-ethynylphenyl)amine|erlotinibum|[6,7-bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine|N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine",A quinazoline compound having a (3-ethynylphenyl)amino group at the 4-position and two 2-methoxyethoxy groups at the 6- and 7-positions.,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,DrugBank:DB00530|PMID:16014882|PMID:30150014|PMID:12270171|PMID:30158288|PMID:29579331|PMID:16480284|CAS:183321-74-6|PMID:17889528|PMID:29448920|Reaxys:8798958|PMID:30071517|LINCS:LSM-1097|PMID:16014883|PMID:14684309|PMID:17983745|PMID:15711537|Drug_Central:1045|PMID:30039303|PMID:29687154,,A quinazoline compound having a (3-ethynylphenyl)amino group at the 4-position and two 2-methoxyethoxy groups at the 6- and 7-positions.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35610|http://purl.obolibrary.org/obo/CHEBI_37699|http://purl.obolibrary.org/obo/CHEBI_74440,,,,,"N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine",,"erlotinib|[6,7-bis(2-methoxy-ethoxy)quinazoline-4-yl]-(3-ethynylphenyl)amine|erlotinibum|[6,7-bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine",,,,,,,,,,,,,,,,,,,,,CHEBI:114785,,,,erlotinib,,CHEBI:114785,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0001134,skeletal muscle tissue,,Muscle tissue that consists primarily of skeletal muscle fibers.,false,,,http://purl.obolibrary.org/obo/UBERON_0000479,,,,,,,,,,,,,,,,,,,,,,Muscle tissue that consists primarily of skeletal muscle fibers.,,,,,skeletal muscle tissue,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,UBERON:0001134,,,,,,,,,,,,,,,,,,,,,,skeletal muscle tissue,,,,,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000338,Crk II,,,false,,,http://purl.obolibrary.org/obo/IMR_0000335,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000338,,,,,,,,,,,,,,,,,,,,,,Crk II,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0002577,"inositol 1,4,5-trisphosphate 3-kinase A",IP3K-A,,false,,,http://purl.obolibrary.org/obo/IMR_0002576,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IP3K-A,,,,,IMR:0002577,,,,,,,,,,,,,,,,,,,,,,"inositol 1,4,5-trisphosphate 3-kinase A",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_28077,rifampicin,,A member of the class of rifamycins that is a a semisynthetic antibiotic derived from Amycolatopsis rifamycinica (previously known as Amycolatopsis mediterranei and Streptomyces mediterranei),false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,DrugBank:DB01045|CASRN:13292-46-1|Wikipedia:Rifampicin,,A member of the class of rifamycins that is a a semisynthetic antibiotic derived from Amycolatopsis rifamycinica (previously known as Amycolatopsis mediterranei and Streptomyces mediterranei),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:28077,,,,,,,,,,,,,,,,,,,,,,rifampicin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(\C=N\N1CCN(C)CC1)c(O)c4c3C2=O,,,,,
http://purl.obolibrary.org/obo/IMR_0000597,IL-15,interleukin-15,,false,,,http://purl.obolibrary.org/obo/IMR_0000007,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000622,,,,,interleukin-15,,,,,IMR:0000597,,,,,,,,,,,,,,,,,,,,,,IL-15,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000001235,CCR6,,"Other designations: C-C chemokine receptor type 6|G protein-coupled receptor 29|G-protein coupled receptor 29|LARC receptor|chemokine (C-C) receptor 6|chemokine receptor-like 3|seven-transmembrane receptor, lymphocyte, 22",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,STRL22|CD196|CMKBR6|CKRL3|GPR29|CC-CKR-6|DCR2|CKR-L3|GPRCY4|BN-1|DRY6|CCR-6|C-C CKR-6,,,,,,,,,,,,6,,,,,,MIM:601835|Ensembl:ENSG00000112486|HPRD:03498|HGNC:1607|Vega:OTTHUMG00000016015,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,chemokine (C-C motif) receptor 6,,,6q27,,,,,,,,,,,,,,,,"GO_0002407 (EC: TAS, PMID:16621978); GO_0004872 (EC: TAS, PMID:9186513); GO_0004950 (EC: TAS, PMID:11001880); GO_0005886 (EC: TAS); GO_0005887 (EC: TAS, PMID:9186513); GO_0006928 (EC: TAS, PMID:9186513); GO_0006935 (EC: TAS, PMID:11001880); GO_0006955 (EC: TAS, PMID:9223454); GO_0006959 (EC: TAS, PMID:11001880); GO_0006968 (EC: TAS, PMID:10521347); GO_0007165 (EC: TAS, PMID:9186513); GO_0007204 (EC: TAS, PMID:9223454); GO_0016493 (EC: IEA); GO_0045087 (EC: TAS); GO_0070098 (EC: TAS, PMID:11001880)",,,,,,,,,PMID:2834384; 8125298; 8886020; 9070937; 9169459; 9186513; 9223454; 9294137; 9294138; 10521347; 11001880; 11164896; 11714836; 11751947; 11994436; 12067311; 12070001; 12081481; 12149255; 12193700; 12477932; 12514792; 12642342; 14574404; 15483227; 15489334; 15591779; 15701269; 15972662; 16095490; 16215992; 16344560; 16621978; 16622267; 16641550; 17075975; 17133360; 17171755; 17562763; 17615381; 18097022; 18218038; 18240029; 18465142; 18577758; 18587394; 18703490; 19233848; 19249008; 19305396; 19324905; 19423540; 19492413; 19539215; 19760754; 19811428; 20022113; 20023216; 20056178; 20068036; 20194631; 20220766; 20334681; 20379614; 20406964; 20438785; 20439195; 20453841; 20453842; 20459729; 20483750; 20511548; 20526339; 20526340; 20570966; 20634891; 20720211; 20872189; 21072187; 21092675; 21102463; 21228329; 21261017; 21300824; 21398606; 21624121; 21724701; 21763254; 21873313; 21912453; 21935436; 21937703; 21949768; 21984702; 22079021; 22092173; 22269120; 22490506; 22732549; 22796894; 22842622; 22859539; 22926920; 23128233; 23306142; 23599932; 23681234; 23758411; 23765988; 23790181; 23850713; 23935994; 23983073,,,,,,,,,,,,,,,OGG:3000001235,,,,,,,chemokine (C-C motif) receptor 6,,,,,,,,,,,,,"Other designations: C-C chemokine receptor type 6|G protein-coupled receptor 29|G-protein coupled receptor 29|LARC receptor|chemokine (C-C) receptor 6|chemokine receptor-like 3|seven-transmembrane receptor, lymphocyte, 22",,CCR6,,,,,,,,,,,,,,,,,,,,,,,1235,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CCR6,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001230,CCR1,,Other designations: C-C CKR-1|C-C chemokine receptor type 1|CC-CKR-1|CCR-1|LD78 receptor|MIP-1alpha-R|RANTES receptor|RANTES-R|macrophage inflammatory protein 1-alpha receptor,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CKR1|MIP1aR|CD191|CMKBR1|CKR-1|SCYAR1|HM145,,,,,,,,,,,,3,,,,,,Vega:OTTHUMG00000133451|HPRD:03101|MIM:601159|Ensembl:ENSG00000163823|HGNC:1602,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,chemokine (C-C motif) receptor 1,,,3p21,,,,,,,,,,,,,,,,"GO_0002407 (EC: TAS, PMID:16621978); GO_0004435 (EC: IDA, PMID:10734056); GO_0004950 (EC: IDA, PMID:10660125); GO_0005515 (EC: IPI, PMID:15001559); GO_0005886 (EC: IDA, PMID:10660125); GO_0005886 (EC: IMP, PMID:15001559); GO_0005886 (EC: TAS); GO_0005887 (EC: TAS, PMID:7505609); GO_0006816 (EC: IDA, PMID:10734056); GO_0006874 (EC: IDA, PMID:10734056); GO_0006887 (EC: IDA, PMID:10734056); GO_0006935 (EC: NAS, PMID:15474493); GO_0006954 (EC: IEA); GO_0006955 (EC: IDA, PMID:10734056); GO_0007155 (EC: TAS, PMID:10910894); GO_0007166 (EC: TAS, PMID:10770925); GO_0007187 (EC: TAS, PMID:7505609); GO_0007204 (EC: IDA, PMID:10734056); GO_0007267 (EC: IDA, PMID:10734056); GO_0008152 (EC: IDA, PMID:10734056); GO_0009611 (EC: TAS, PMID:7505609); GO_0009897 (EC: IDA, PMID:10706735); GO_0010629 (EC: IMP); GO_0016493 (EC: IDA, PMID:10734056); GO_0019221 (EC: NAS, PMID:15474493); GO_0019957 (EC: IPI, PMID:10660125); GO_0030502 (EC: IMP); GO_0035717 (EC: IPI, PMID:10660125); GO_0045672 (EC: IMP); GO_0051928 (EC: IDA, PMID:15764707); GO_0070098 (EC: IDA); GO_0070374 (EC: IMP); GO_0071791 (EC: IPI, PMID:10660125); GO_0090026 (EC: IDA, PMID:18587271)",,,,,,,,,PMID:2834384; 7505609; 7545673; 7594543; 7679328; 7683036; 8011297; 8530354; 8626727; 8631787; 8699119; 9115216; 9143512; 9289016; 9346309; 9558365; 9886417; 10094132; 10202040; 10583963; 10660125; 10702689; 10706735; 10734056; 10770925; 10910894; 11085751; 11110672; 11116158; 11449371; 11470772; 11804551; 11832479; 11920567; 12070001; 12085329; 12270118; 12477932; 12651617; 12763925; 12794150; 14530297; 14595653; 14637022; 14674010; 15001559; 15039444; 15053339; 15103513; 15265234; 15337751; 15474493; 15489334; 15548526; 15764707; 15927850; 15950672; 16182378; 16226254; 16323127; 16621978; 16837468; 16969502; 17135764; 17192849; 17298994; 17336272; 17389578; 17464174; 17558413; 17914560; 18178867; 18240029; 18311140; 18559339; 18577758; 18587271; 18972130; 19017998; 19423540; 19553544; 19603542; 19664396; 19687291; 19693089; 19913121; 20015385; 20056178; 20086017; 20154287; 20190752; 20406964; 20429924; 20438785; 20628086; 20634891; 20802378; 20921899; 21148810; 21942940; 22007486; 22104149; 22650026; 22727097; 22829007; 22842622; 23054685; 23125416; 23217400; 23219091; 23233369; 23276697; 23291587; 24056371,,,,,,,,,,,,,,,OGG:3000001230,,,,,,,chemokine (C-C motif) receptor 1,,,,,,,,,,,,,Other designations: C-C CKR-1|C-C chemokine receptor type 1|CC-CKR-1|CCR-1|LD78 receptor|MIP-1alpha-R|RANTES receptor|RANTES-R|macrophage inflammatory protein 1-alpha receptor,,CCR1,,,,,,,,,,,,,,,,,,,,,,,1230,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CCR1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001234,CCR5,,Other designations: C-C chemokine receptor type 5|C-C motif chemokine receptor 5 A159A|HIV-1 fusion coreceptor|chemokine receptor CCR5|chemr13,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,IDDM22|CC-CKR-5|CCR-5|CKR-5|CD195|CMKBR5|CKR5|CCCKR5,,,,,,,,,,,,3,,,,,,Vega:OTTHUMG00000133481|HPRD:03223|MIM:601373|Ensembl:ENSG00000160791|HGNC:1606,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,chemokine (C-C motif) receptor 5 (gene/pseudogene),,,3p21.31,,,,,,,,,,,,,,,,"GO_0000165 (EC: IEP, PMID:12032188); GO_0001974 (EC: IEA); GO_0002407 (EC: TAS, PMID:16621978); GO_0003779 (EC: IDA, PMID:12421915); GO_0004435 (EC: TAS, PMID:8663314); GO_0004950 (EC: TAS, PMID:10201901); GO_0005515 (EC: IPI, PMID:12421915); GO_0005737 (EC: TAS, PMID:10415069); GO_0005768 (EC: IDA, PMID:10679098); GO_0005886 (EC: TAS); GO_0005887 (EC: TAS, PMID:10393923); GO_0006816 (EC: IDA, PMID:8699119); GO_0006935 (EC: TAS, PMID:10741397); GO_0006954 (EC: IEA); GO_0006955 (EC: IEA); GO_0006968 (EC: TAS, PMID:10201901); GO_0007166 (EC: TAS, PMID:8639485); GO_0007186 (EC: IMP, PMID:19523456); GO_0007204 (EC: TAS, PMID:10201901); GO_0007267 (EC: IDA, PMID:10679098); GO_0009897 (EC: IDA, PMID:10679098); GO_0009986 (EC: IDA, PMID:10521508); GO_0014808 (EC: IDA, PMID:19523456); GO_0015026 (EC: TAS, PMID:10469138); GO_0016032 (EC: TAS); GO_0016493 (EC: IDA, PMID:11278962); GO_0016493 (EC: NAS, PMID:8639485); GO_0019722 (EC: IDA, PMID:10679098); GO_0019957 (EC: IPI, PMID:10679098); GO_0023052 (EC: IEP, PMID:12032188); GO_0030260 (EC: TAS); GO_0070098 (EC: IDA, PMID:11278962); GO_0070098 (EC: NAS, PMID:8639485); GO_0070098 (EC: TAS, PMID:10201901); GO_0070723 (EC: IMP, PMID:19523456); GO_0071222 (EC: IEP, PMID:10679098); GO_0071791 (EC: IPI, PMID:8699119); GO_0090026 (EC: IEA)",,,,,,,,,PMID:2183196; 2564392; 2569467; 2834384; 3346208; 3512269; 3960725; 8639485; 8649511; 8649512; 8663314; 8674119; 8699119; 8751444; 8756719; 8805353; 8898753; 8906795; 8906796; 8976200; 8995603; 9020356; 9031325; 9143512; 9184207; 9188565; 9207783; 9256481; 9261346; 9261451; 9289016; 9334377; 9343222; 9353123; 9359654; 9359702; 9362541; 9388201; 9399903; 9420225; 9420238; 9445013; 9446638; 9468473; 9525683; 9576751; 9576954; 9632396; 9636210; 9653051; 9653130; 9765440; 9870313; 9882290; 9882373; 9890944; 9971818; 10029247; 10037796; 10085131; 10089882; 10200301; 10201901; 10229873; 10339592; 10357469; 10364178; 10370370; 10384144; 10393923; 10393974; 10413516; 10415069; 10438703; 10438870; 10446313; 10449282; 10453044; 10465086; 10469138; 10477567; 10477718; 10482561; 10482572; 10487781; 10497246; 10505675; 10521508; 10527688; 10544150; 10555208; 10559284; 10562492; 10574939; 10585143; 10590105; 10590121; 10602038; 10602409; 10606089; 10623731; 10640778; 10644351; 10679098; 10702689; 10725362; 10738970; 10741397; 10751368; 10758170; 10775626; 10801487; 10807185; 10816381; 10820198; 10823934; 10826481; 10872839; 10877489; 10882583; 10888615; 10888639; 10917742; 10938094; 10961858; 10970739; 10985308; 11005830; 11023492; 11023526; 11024154; 11069996; 11072599; 11085751; 11086073; 11115360; 11116158; 11118070; 11125885; 11125899; 11134270; 11141322; 11153675; 11162839; 11175286; 11177400; 11181160; 11188946; 11196681; 11196706; 11238869; 11263244; 11264152; 11264346; 11264367; 11265761; 11274729; 11278567; 11278738; 11278962; 11290759; 11312658; 11313374; 11334429; 11335892; 11336643; 11342415; 11350939; 11354628; 11356952; 11356961; 11356967; 11369664; 11377705; 11385319; 11390601; 11393656; 11397808; 11398114; 11403814; 11413305; 11414813; 11427892; 11429110; 11447384; 11448957; 11449371; 11464139; 11468147; 11470772; 11477473; 11484163; 11485305; 11485615; 11489906; 11500196; 11504955; 11511825; 11517394; 11529558; 11543895; 11559423; 11591716; 11595595; 11596075; 11602715; 11679153; 11679916; 11689632; 11693435; 11694103; 11696224; 11698270; 11698699; 11700073; 11703822; 11709091; 11709782; 11711617; 11727771; 11729511; 11733580; 11734558; 11751947; 11752157; 11756347; 11781692; 11803051; 11809184; 11856781; 11859127; 11860793; 11860823; 11861850; 11861874; 11873082; 11876757; 11877445; 11878912; 11901272; 11920312; 11920324; 11937056; 11958683; 11964548; 11966764; 11966770; 11988632; 11994442; 11994538; 12001056; 12010355; 12023175; 12032188; 12032878; 12036855; 12055576; 12056598; 12065593; 12070001; 12082592; 12085329; 12091904; 12093918; 12131184; 12136242; 12140749; 12163044; 12163614; 12166499; 12169668; 12176010; 12183462; 12200385; 12201365; 12202222; 12215252; 12239139; 12271718; 12355376; 12356205; 12368322; 12377943; 12378793; 12403355; 12403770; 12408990; 12412204; 12413885; 12421915; 12426392; 12426393; 12426633; 12427015; 12429730; 12437612; 12445801; 12447757; 12451219; 12461425; 12462338; 12477875; 12477932; 12490404; 12496074; 12509908; 12514416; 12522035; 12531905; 12532229; 12551992; 12552446; 12555203; 12556692; 12557141; 12571248; 12571520; 12579509; 12584049; 12586555; 12587636; 12599073; 12610055; 12610158; 12612298; 12612937; 12619446; 12634405; 12651900; 12667818; 12680626; 12688247; 12689409; 12692222; 12726730; 12745546; 12751031; 12767984; 12788308; 12798016; 12815099; 12819030; 12829440; 12837756; 12846056; 12853745; 12857973; 12858455; 12865070; 12871111; 12873764; 12873765; 12874407; 12882661; 12884524; 12887913; 12887918; 12913933; 12915585; 12925765; 12960231; 12960247; 12963807; 12964123; 14501804; 14505910; 14517611; 14533004; 14533983; 14576050; 14581567; 14583186; 14597737; 14616291; 14624371; 14636691; 14637022; 14644028; 14645006; 14647058; 14672331; 14673528; 14674010; 14694113; 14697747; 14715575; 14716309; 14742283; 14963124; 14981141; 14982745; 14990703; 15000812; 15001559; 15004773; 15009175; 15016843; 15039132; 15047829; 15076247; 15080861; 15086346; 15086398; 15113926; 15117454; 15124759; 15125257; 15135805; 15140377; 15169555; 15180829; 15181567; 15192272; 15192276; 15215889; 15230854; 15236615; 15242539; 15251452; 15258189; 15279544; 15280786; 15288441; 15301862; 15302103; 15307921; 15308751; 15319853; 15321703; 15331395; 15354329; 15362666; 15385740; 15458467; 15465089; 15479838; 15488313; 15489334; 15500552; 15548261; 15557916; 15566517; 15575507; 15577536; 15585333; 15586413; 15588345; 15591779; 15592455; 15596839; 15602133; 15610230; 15629079; 15639953; 15650194; 15651660; 15708547; 15725749; 15737629; 15754978; 15757671; 15767435; 15767436; 15769362; 15787642; 15793360; 15793370; 15802968; 15807900; 15821335; 15851912; 15854903; 15856455; 15857992; 15863470; 15882964; 15885315; 15890935; 15902300; 15916792; 15932625; 15950936; 15958832; 15962231; 15964018; 15964389; 15972662; 15976369; 15980670; 15980693; 15981170; 15983047; 15985194; 15992849; 16015368; 16034118; 16055130; 16100775; 16118671; 16140745; 16144840; 16157597; 16161154; 16174786; 16179731; 16182378; 16196460; 16206074; 16233918; 16248677; 16249462; 16249700; 16261210; 16270124; 16284527; 16286055; 16300985; 16305685; 16312181; 16314800; 16323127; 16335661; 16344560; 16358723; 16375941; 16378977; 16395252; 16405836; 16418398; 16442182; 16461193; 16476734; 16476981; 16478397; 16480760; 16481131; 16485782; 16501811; 16512757; 16513874; 16524739; 16529059; 16541097; 16545485; 16547971; 16598837; 16614115; 16621960; 16621978; 16631222; 16633049; 16641997; 16672419; 16672549; 16702010; 16703416; 16721228; 16721558; 16764352; 16774544; 16775617; 16807236; 16817962; 16841089; 16847113; 16855620; 16865553; 16872485; 16879946; 16887960; 16888899; 16909455; 16916647; 16937446; 16943294; 16960780; 16963439; 16966601; 16999868; 16999983; 17030448; 17053144; 17053352; 17060059; 17063508; 17067435; 17079285; 17091019; 17094383; 17101151; 17101166; 17112859; 17121788; 17135764; 17145599; 17147503; 17148969; 17166523; 17169533; 17202224; 17207111; 17210123; 17214851; 17237417; 17240189; 17255952; 17257590; 17261788; 17273779; 17301575; 17305874; 17306322; 17328229; 17329448; 17331026; 17331851; 17346133; 17351762; 17355643; 17361671; 17383752; 17411375; 17413295; 17417600; 17426779; 17428349; 17442950; 17445875; 17460174; 17462514; 17465678; 17507467; 17507486; 17511851; 17522201; 17530006; 17560067; 17564248; 17565662; 17582634; 17585540; 17596666; 17604289; 17607321; 17620369; 17625759; 17627030; 17633563; 17640964; 17644519; 17645788; 17653092; 17671738; 17672867; 17675516; 17686153; 17691823; 17703412; 17713445; 17722977; 17786209; 17845302; 17855336; 17855654; 17884183; 17901336; 17909797; 17920529; 17929678; 17952079; 17963165; 17971448; 17971457; 17977968; 17984846; 17989610; 18036244; 18060801; 18076768; 18094161; 18096812; 18097239; 18160142; 18162443; 18179388; 18179389; 18182569; 18189189; 18191728; 18194353; 18195571; 18197127; 18203956; 18205260; 18205925; 18218038; 18230715; 18240029; 18242797; 18255039; 18295459; 18296630; 18311470; 18346864; 18353949; 18353956; 18361062; 18379014; 18386165; 18391751; 18405329; 18436884; 18453587; 18462992; 18468560; 18480458; 18480460; 18490657; 18498240; 18500445; 18511806; 18524826; 18543610; 18577758; 18588983; 18590744; 18611987; 18619974; 18623133; 18629619; 18632580; 18633131; 18648518; 18673537; 18676680; 18689270; 18691022; 18692212; 18706447; 18753930; 18763111; 18776933; 18781860; 18786994; 18814951; 18815295; 18820725; 18845960; 18846999; 18855658; 18923649; 18925934; 18928397; 18941536; 18949389; 18952441; 18972295; 18974840; 18977142; 18989363; 18991615; 19005677; 19017985; 19017998; 19018669; 19028820; 19032065; 19037908; 19050382; 19064579; 19064722; 19098363; 19116725; 19124913; 19129082; 19129457; 19131662; 19143484; 19149577; 19155524; 19170196; 19170639; 19172482; 19196047; 19200444; 19201454; 19212663; 19218218; 19225544; 19247692; 19250219; 19258923; 19260142; 19263529; 19289833; 19297481; 19321618; 19334035; 19339951; 19339953; 19357773; 19389855; 19402700; 19420105; 19433914; 19460331; 19474452; 19476483; 19479237; 19479371; 19506371; 19520154; 19523456; 19535121; 19538721; 19553544; 19559392; 19561149; 19578796; 19585516; 19603542; 19625176; 19625411; 19644155; 19644158; 19669591; 19679608; 19680536; 19692168; 19692476; 19692480; 19700905; 19706316; 19722264; 19729379; 19740335; 19744036; 19744740; 19769961; 19811270; 19811439; 19816596; 19841162; 19864932; 19874552; 19886839; 19894308; 19913121; 19917679; 19950235; 19956635; 19958843; 20018238; 20025530; 20025985; 20038229; 20050936; 20053336; 20068218; 20075058; 20087947; 20107582; 20130232; 20153665; 20169157; 20174557; 20182805; 20190752; 20203694; 20206716; 20220260; 20237496; 20331378; 20334567; 20364409; 20377425; 20378664; 20381825; 20411675; 20420684; 20442634; 20442662; 20453841; 20463745; 20465832; 20503287; 20507591; 20518834; 20530467; 20531015; 20536507; 20570309; 20594957; 20598754; 20603037; 20608170; 20628086; 20628649; 20682662; 20710056; 20729133; 20801883; 20811274; 20842205; 20855251; 20856130; 20861743; 20865789; 20875295; 20921899; 20923564; 20932773; 20969781; 21041313; 21068438; 21084992; 21091093; 21118814; 21132346; 21134114; 21148810; 21152581; 21155586; 21156032; 21188555; 21248683; 21258050; 21280323; 21284403; 21288812; 21288824; 21288827; 21295814; 21325401; 21330910; 21345957; 21349294; 21354457; 21356539; 21362450; 21381021; 21388649; 21396623; 21429204; 21454526; 21465943; 21473821; 21513481; 21525208; 21555814; 21569409; 21573951; 21592988; 21602126; 21634220; 21637819; 21647388; 21655330; 21663455; 21667221; 21671175; 21676905; 21680525; 21696586; 21703201; 21709449; 21715437; 21723943; 21731496; 21739422; 21741662; 21744265; 21760891; 21763489; 21775441; 21789236; 21814863; 21819370; 21820915; 21835796; 21846359; 21859712; 21860345; 21878623; 21886032; 21890375; 21926353; 21926633; 21944757; 21984373; 21984929; 21988832; 22011385; 22024519; 22026334; 22028271; 22044225; 22047989; 22050776; 22069466; 22079021; 22083068; 22085486; 22102307; 22103833; 22103834; 22157596; 22175768; 22218121; 22264071; 22265023; 22282138; 22285384; 22286874; 22292949; 22297516; 22313935; 22314435; 22325341; 22342838; 22348061; 22374185; 22380870; 22392992; 22403408; 22404213; 22416573; 22424737; 22479344; 22496149; 22496885; 22506069; 22537745; 22547820; 22554649; 22554651; 22583417; 22612293; 22637726; 22638733; 22657741; 22665517; 22701041; 22727097; 22728273; 22732432; 22787219; 22808111; 22811524; 22815758; 22818666; 22830600; 22852142; 22862553; 22875513; 22893032; 22908191; 22918850; 22924548; 22933279; 22954962; 22957026; 22957692; 22966075; 22988032; 22994752; 23041556; 23057571; 23077246; 23115275; 23152559; 23185351; 23217182; 23217400; 23235831; 23250822; 23289212; 23298254; 23312573; 23355876; 23454776; 23480650; 23490419; 23493400; 23515570; 23588722; 23594959; 23632061; 23632983; 23643185; 23691059; 23696662; 23753295; 23773920; 23852305; 23856897; 23880174; 23888779; 23903010; 23936229; 23954573; 24030490; 24078580; 24090135; 24128342; 24129241; 24405814,,,,,,,,,,,,,,,OGG:3000001234,,,,,,,chemokine (C-C motif) receptor 5 (gene/pseudogene),,,,,,,,,,,,,Other designations: C-C chemokine receptor type 5|C-C motif chemokine receptor 5 A159A|HIV-1 fusion coreceptor|chemokine receptor CCR5|chemr13,,CCR5,,,,,,,,,,,,,,,,,,,,,,,1234,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CCR5,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001237,CCR8,,Other designations: C-C chemokine receptor type 8|CC chemokine receptor 8|CC chemokine receptor CHEMR1|CC-chemokine receptor chemr1|chemokine (C-C) receptor 8|chemokine (C-C) receptor-like 2|chemokine receptor-like 1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CDw198|CC-CKR-8|CMKBRL2|CMKBR8|CKRL1|CY6|CCR-8|TER1|GPRCY6,,,,,,,,,,,,3,,,,,,Vega:OTTHUMG00000131290|Ensembl:ENSG00000179934|HGNC:1609|MIM:601834|HPRD:03497,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,chemokine (C-C motif) receptor 8,,,3p22,,,,,,,,,,,,,,,,"GO_0004950 (EC: TAS, PMID:9417093); GO_0005886 (EC: TAS); GO_0005887 (EC: TAS, PMID:8816377); GO_0006935 (EC: IEA); GO_0006955 (EC: IEA); GO_0007155 (EC: TAS, PMID:10910894); GO_0007186 (EC: TAS, PMID:8816377); GO_0007204 (EC: IEA); GO_0015026 (EC: TAS, PMID:9417093); GO_0016493 (EC: IEA); GO_0070098 (EC: TAS, PMID:9417093)",,,,,,,,,PMID:8816377; 8886020; 8977299; 9207005; 9211859; 9417093; 9469461; 9480837; 9521068; 9670926; 10469138; 10540332; 10888633; 10910894; 11007922; 11804551; 12163566; 12477932; 12525579; 12547701; 12551893; 12645948; 12832759; 12967681; 14576057; 15053339; 15489334; 15814739; 15992849; 16631222; 17023422; 17082609; 17558413; 17641040; 17693327; 18240029; 18577758; 19074885; 19423540; 20237496; 20406964; 20438785; 20455898; 21976223; 22479563; 22842622; 23043070; 23363815; 23999500,,,,,,,,,,,,,,,OGG:3000001237,,,,,,,chemokine (C-C motif) receptor 8,,,,,,,,,,,,,Other designations: C-C chemokine receptor type 8|CC chemokine receptor 8|CC chemokine receptor CHEMR1|CC-chemokine receptor chemr1|chemokine (C-C) receptor 8|chemokine (C-C) receptor-like 2|chemokine receptor-like 1,,CCR8,,,,,,,,,,,,,,,,,,,,,,,1237,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CCR8,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001236,CCR7,,Other designations: C-C CKR-7|C-C chemokine receptor type 7|CC chemokine receptor 7|CC-CKR-7|CCR-7|EBV-induced G protein-coupled receptor 1|EBV-induced G-protein coupled receptor 1|Epstein-Barr virus induced G-protein coupled receptor|Epstein-Barr virus induced gene 1|MIP-3 beta receptor|chemokine (C-C) receptor 7|epstein-Barr virus-induced G-protein coupled receptor 1|lymphocyte-specific G protein-coupled peptide receptor,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CDw197|BLR2|CMKBR7|CD197|EBI1,,,,,,,,,,,,17,,,,,,HPRD:02588|Ensembl:ENSG00000126353|Vega:OTTHUMG00000133375|MIM:600242|HGNC:1608,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,chemokine (C-C motif) receptor 7,,,17q12-q21.2,,,,,,,,,,,,,,,,"GO_0001768 (EC: IC, PMID:12729902); GO_0001954 (EC: IC, PMID:15569314); GO_0002407 (EC: IC, PMID:15778365); GO_0002408 (EC: IC, PMID:14592837); GO_0002606 (EC: ISS); GO_0002885 (EC: ISS); GO_0002922 (EC: ISS); GO_0004930 (EC: TAS, PMID:16621978); GO_0005622 (EC: IDA); GO_0005886 (EC: IDA); GO_0005886 (EC: TAS); GO_0006954 (EC: NAS, PMID:14592837); GO_0006955 (EC: IEA); GO_0007186 (EC: TAS, PMID:16621978); GO_0007204 (EC: TAS, PMID:9153236); GO_0009897 (EC: IEA); GO_0016021 (EC: IEA); GO_0016493 (EC: ISS); GO_0030838 (EC: IC, PMID:11242036); GO_0031274 (EC: IC, PMID:11242036); GO_0031529 (EC: IC, PMID:15569314); GO_0032496 (EC: IEA); GO_0032649 (EC: ISS); GO_0032735 (EC: ISS); GO_0032862 (EC: IC, PMID:15778365); GO_0034695 (EC: IC, PMID:14592837); GO_0035757 (EC: IPI, PMID:9507024); GO_0035758 (EC: IPI, PMID:9507024); GO_0038115 (EC: IDA, PMID:9507024); GO_0038116 (EC: IDA, PMID:9507024); GO_0038117 (EC: IDA, PMID:9507024); GO_0038121 (EC: IDA, PMID:9507024); GO_0043123 (EC: IC, PMID:15059845); GO_0043552 (EC: IC, PMID:15059845); GO_0045060 (EC: IEA); GO_0045785 (EC: IC, PMID:15569314); GO_0045860 (EC: IC, PMID:14592837); GO_0046330 (EC: IC, PMID:15778365); GO_0050706 (EC: ISS); GO_0050862 (EC: IEA); GO_0051209 (EC: IC, PMID:14592837); GO_0051491 (EC: IC, PMID:15569314); GO_0051897 (EC: IC, PMID:15059845); GO_0070098 (EC: ISS); GO_0070374 (EC: IC, PMID:12729902); GO_0071731 (EC: IC, PMID:16249377); GO_0072610 (EC: ISS); GO_0090023 (EC: IDA); GO_0097022 (EC: TAS, PMID:18379575); GO_0097029 (EC: ISS); GO_2000107 (EC: IC, PMID:15059845); GO_2000147 (EC: IC, PMID:15778365); GO_2000510 (EC: ISS); GO_2000522 (EC: ISS); GO_2000525 (EC: ISS); GO_2000526 (EC: ISS); GO_2000547 (EC: ISS)",,,,,,,,,PMID:2834384; 7488016; 7851893; 8383238; 8889548; 9153236; 9507024; 9585422; 9725259; 9743376; 10607681; 10706668; 10741397; 10861057; 11145663; 11242036; 11359797; 11507220; 11830455; 11861876; 11929789; 11970971; 12023337; 12070001; 12149218; 12477932; 12486098; 12642342; 12673677; 12729902; 12799021; 12851649; 14592837; 14990723; 15034011; 15040017; 15059845; 15073111; 15122702; 15247147; 15265234; 15284247; 15304089; 15489334; 15569314; 15674360; 15743472; 15753377; 15778365; 15867478; 15950936; 15972662; 16115904; 16223574; 16225771; 16249377; 16272303; 16278001; 16278374; 16278415; 16344560; 16494043; 16500130; 16621978; 16690519; 16786131; 16802356; 16857986; 16887149; 17006331; 17032700; 17178876; 17192395; 17431094; 17440035; 17587445; 17687340; 17890452; 18065728; 18166500; 18235009; 18240029; 18310327; 18319253; 18379575; 18437055; 18497951; 18544997; 18577758; 18623114; 18664492; 18696160; 18802075; 19068542; 19074885; 19087620; 19136936; 19196101; 19287948; 19423540; 19513547; 19536265; 19536742; 19540558; 19585516; 19615795; 19731977; 19749090; 19862774; 20029460; 20036791; 20056178; 20150960; 20237496; 20406964; 20438785; 20439195; 20651394; 20811680; 20855251; 20889506; 20889923; 21048031; 21071608; 21081040; 21092675; 21165563; 21165582; 21261017; 21347514; 21464944; 21548969; 21624121; 21680174; 21698152; 21731495; 21735098; 21739164; 21739671; 21953548; 22020953; 22043010; 22158872; 22163030; 22221265; 22251626; 22334704; 22350183; 22438908; 22498742; 22533989; 22619482; 22634622; 22659045; 22718198; 22797918; 22821963; 22842622; 22923218; 22990666; 23028633; 23290307; 23363813; 23449735; 23469143; 23498789; 23519840; 23747721; 23888080; 23922113; 24052640; 24136650; 24138884; 24311382,,,,,,,,,,,,,,,OGG:3000001236,,,,,,,chemokine (C-C motif) receptor 7,,,,,,,,,,,,,Other designations: C-C CKR-7|C-C chemokine receptor type 7|CC chemokine receptor 7|CC-CKR-7|CCR-7|EBV-induced G protein-coupled receptor 1|EBV-induced G-protein coupled receptor 1|Epstein-Barr virus induced G-protein coupled receptor|Epstein-Barr virus induced gene 1|MIP-3 beta receptor|chemokine (C-C) receptor 7|epstein-Barr virus-induced G-protein coupled receptor 1|lymphocyte-specific G protein-coupled peptide receptor,,CCR7,,,,,,,,,,,,,,,,,,,,,,,1236,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CCR7,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001233,CCR4,,Other designations: C-C CKR-4|C-C chemokine receptor type 4|CCR-4|chemokine (C-C) receptor 4,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CKR4|CD194|K5-5|CC-CKR-4|ChemR13|HGCN:14099|CMKBR4,,,,,,,,,,,,3,,,,,,HGNC:1605|HPRD:05324|MIM:604836,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,chemokine (C-C motif) receptor 4,,,3p24,,,,,,,,,,,,,,,,"GO_0001764 (EC: IEA); GO_0002507 (EC: IEA); GO_0004950 (EC: TAS, PMID:7642634); GO_0005886 (EC: TAS); GO_0005887 (EC: TAS, PMID:7642634); GO_0006935 (EC: IEA); GO_0006954 (EC: IEA); GO_0006955 (EC: IEA); GO_0007204 (EC: TAS, PMID:7642634); GO_0009314 (EC: IEA); GO_0009617 (EC: IEA); GO_0009897 (EC: IEA); GO_0016493 (EC: IEA); GO_0043025 (EC: IEA); GO_0046677 (EC: IEA); GO_0050927 (EC: IEA); GO_0070098 (EC: TAS, PMID:7642634)",,,,,,,,,PMID:7642634; 8573157; 8884276; 9169480; 9430724; 9743322; 9933589; 10036181; 10466728; 10754297; 11196669; 11861261; 12070001; 12270118; 12406880; 12429730; 12456591; 12477932; 12485447; 12778466; 14657875; 15187160; 15202833; 15328188; 15489334; 15569983; 15621800; 15857508; 15955100; 17071491; 17117949; 17546636; 18071306; 18240029; 18577758; 18782672; 19106589; 19239991; 19244125; 19261691; 19374191; 19423540; 19903885; 19913121; 19942450; 20148806; 20164417; 20190752; 20237293; 20237496; 20334681; 20364559; 20406964; 20412707; 20438785; 20628086; 20963786; 21443538; 21525208; 21739422; 22490506; 22842622; 23180648; 23644599; 23731651; 24127572,,,,,,,,,,,,,,,OGG:3000001233,,,,,,,chemokine (C-C motif) receptor 4,,,,,,,,,,,,,Other designations: C-C CKR-4|C-C chemokine receptor type 4|CCR-4|chemokine (C-C) receptor 4,,CCR4,,,,,,,,,,,,,,,,,,,,,,,1233,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CCR4,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001232,CCR3,,Other designations: C-C CKR-3|C-C chemokine receptor type 3|CC chemokine receptor 3|CCR-3|b-chemokine receptor|eosinophil CC chemokine receptor 3|eosinophil eotaxin receptor,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CC-CKR-3|CKR3|CMKBR3|CD193,,,,,,,,,,,,3,,,,,,HGNC:1604|HPRD:03167|MIM:601268|Ensembl:ENSG00000183625|Vega:OTTHUMG00000133484,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,chemokine (C-C motif) receptor 3,,,3p21.3,,,,,,,,,,,,,,,,"GO_0001938 (EC: IEA); GO_0004950 (EC: TAS, PMID:10415069); GO_0005515 (EC: IPI); GO_0005886 (EC: TAS); GO_0005887 (EC: TAS, PMID:9302298); GO_0006935 (EC: IEA); GO_0006954 (EC: IEA); GO_0006968 (EC: TAS, PMID:10713092); GO_0007155 (EC: TAS, PMID:10201960); GO_0007188 (EC: TAS, PMID:10201960); GO_0007204 (EC: TAS, PMID:9302298); GO_0016032 (EC: IEA); GO_0016493 (EC: IEA); GO_0045766 (EC: IMP, PMID:19525930); GO_0070098 (EC: TAS, PMID:10415069)",,,,,,,,,PMID:7594543; 7622448; 8609214; 8631813; 8631926; 8642344; 8674119; 8676064; 8884276; 9005985; 9024664; 9143512; 9182688; 9252350; 9289016; 9302298; 9346309; 9359702; 9419219; 9573273; 9636210; 9653051; 9712872; 9736741; 9765440; 9789057; 10094132; 10201960; 10415069; 10488147; 10514402; 10527858; 10590105; 10642580; 10666479; 10713092; 10877489; 10900353; 10975800; 11001881; 11085751; 11110785; 11115360; 11120849; 11149986; 11196669; 11307756; 11396683; 11449371; 11832479; 11920572; 11991282; 11994538; 12023397; 12079287; 12149192; 12218106; 12393570; 12397598; 12477932; 12654630; 12794150; 12884299; 12902471; 14581140; 14647058; 14702039; 14733956; 15053339; 15086398; 15194768; 15219825; 15476879; 15489334; 15507393; 15580493; 15607028; 15807893; 15857508; 15992849; 16081847; 16174786; 16470129; 16631222; 16712896; 16904155; 16920975; 17041228; 17135764; 17146638; 17672867; 17703412; 17845580; 17983872; 18240029; 18244953; 18311140; 18379861; 18577758; 18636124; 18676680; 18805825; 18974840; 19017998; 19028820; 19131662; 19170196; 19218218; 19247692; 19258923; 19414538; 19423540; 19525930; 19526283; 19542083; 19553323; 19559392; 19625176; 19692168; 19693089; 19714638; 19731977; 20022477; 20056178; 20144207; 20190752; 20220260; 20237496; 20306659; 20364559; 20380698; 20406964; 20438785; 20503287; 20505746; 20603037; 20647273; 20659406; 20726325; 20734064; 20921899; 20923436; 21041734; 21077277; 21143381; 21280323; 21406396; 21660963; 21735070; 21917937; 22086059; 22217447; 22702503; 22829007; 22842622; 23017229; 23054685; 23183094; 23251661; 23291587; 23566847; 23636060; 23643185; 23702389; 23742077; 23955446,,,,,,,,,,,,,,,OGG:3000001232,,,,,,,chemokine (C-C motif) receptor 3,,,,,,,,,,,,,Other designations: C-C CKR-3|C-C chemokine receptor type 3|CC chemokine receptor 3|CCR-3|b-chemokine receptor|eosinophil CC chemokine receptor 3|eosinophil eotaxin receptor,,CCR3,,,,,,,,,,,,,,,,,,,,,,,1232,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CCR3,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0001018,"cAMP-specific 3',5'-cyclic phosphodiesterase 4C",,,false,,,http://purl.obolibrary.org/obo/IMR_0100700,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001018,,,,,,,,,,,,,,,,,,,,,,"cAMP-specific 3',5'-cyclic phosphodiesterase 4C",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000115265,DDIT4L,,Other designations: DNA damage-inducible transcript 4-like protein|HIF-1 responsive protein RTP801-like|REDD-2|homolog of mouse SMHS1|protein regulated in development and DNA damage response 2|regulated in development and DNA damage response 2,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,REDD2|Rtp801L,,,,,,,,,,,,4,,,,,,MIM:607730|HPRD:09663|Ensembl:ENSG00000145358|Vega:OTTHUMG00000161019|HGNC:30555,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,DNA-damage-inducible transcript 4-like,,,4q24,,,,,,,,,,,,,,,,GO_0005737 (EC: ISS); GO_0009968 (EC: IEA),,,,,,,,,PMID: 12453409; 12477932; 14702039; 15308555; 15632201; 16189514; 16344560; 17207965; 19268525; 19491193; 19616115,,,,,,,,,,,,,,,OGG:3000115265,,,,,,,DNA-damage-inducible transcript 4-like,,,,,,,,,,,,,Other designations: DNA damage-inducible transcript 4-like protein|HIF-1 responsive protein RTP801-like|REDD-2|homolog of mouse SMHS1|protein regulated in development and DNA damage response 2|regulated in development and DNA damage response 2,,DDIT4L,,,,,,,,,,,,,,,,,,,,,,,115265,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,DDIT4L,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/PATO_0002323,temporal distribution quality,,A temporal distribution pattern of process occurrences within a regulation/reference process.,false,,,http://purl.obolibrary.org/obo/PATO_0001236,,,,,,,,,,,,,,,,,,,,,,A temporal distribution pattern of process occurrences within a regulation/reference process.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0002323,,,,,,,,,,,,,,,,,,,,,,temporal distribution quality,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100332,Survivin,,,false,,,http://purl.obolibrary.org/obo/IMR_0000454,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100332,,,,,,,,,,,,,,,,,,,,,,Survivin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000441027,TMEM150C,,,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,4,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,transmembrane protein 150C,,,4q21.22,,,,,,,,,,,,,,,,GO_0016021 (EC: IEA),,,,,,,,,PMID: 12477932; 14702039; 21906983,,,,,,,,,,,,,,,OGG:3000441027,,20140408,protein-coding,,,,transmembrane protein 150C,,,,,,,,,,,,,,,TMEM150C,,,,,,,,,,,,,,,,,,,,,,,441027,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,TMEM150C,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/GO_0071706,tumor necrosis factor superfamily cytokine production,,"The appearance of any member of the TNF superfamily due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.",false,,,http://purl.obolibrary.org/obo/GO_0001816,,,,,,,,,,,,,,,,,,,,,,"The appearance of any member of the TNF superfamily due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.",,,,,tumor necrosis factor superfamily cytokine production,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0071706,,,,,,,,,,,,,,,,,,,,,,tumor necrosis factor superfamily cytokine production,,,,,,,http://purl.obolibrary.org/obo/go.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000910,eIF4G,eukaryotic translation initiation factor 4G,Mammalian cells contain two isoforms of eIF4G (I&II). eIF4G is a subunit of the heterotrimeric eIF4F complex that binds to the cap structure at the 50 end of the mRNA.,false,,,http://purl.obolibrary.org/obo/IMR_0000912,,,,,,,,,,,,,,,,,,,,,,Mammalian cells contain two isoforms of eIF4G (I&II). eIF4G is a subunit of the heterotrimeric eIF4F complex that binds to the cap structure at the 50 end of the mRNA.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,eukaryotic translation initiation factor 4G,,,,,IMR:0000910,,,,,,,,,,,,,,,,,,,,,,eIF4G,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000618,ICAM-1,intercellular adhesion molecule 1,,false,,,http://purl.obolibrary.org/obo/IMR_0000178,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,intercellular adhesion molecule 1,,,,,IMR:0000618,,,,,,,,,,,,,,,,,,,,,,ICAM-1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_78298,environmental contaminant,environmental contaminants,Any minor or unwanted substance introduced into the environment that can have undesired effects.,false,,,http://purl.obolibrary.org/obo/CHEBI_51086,,,,,,,,,,,,,,,,,,,,,,Any minor or unwanted substance introduced into the environment that can have undesired effects.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,environmental contaminants,,,,,,,,,,,,,,,,,,,,,CHEBI:78298,,,,environmental contaminant,,CHEBI:78298,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_135829,alatrofloxacin,alatrofloxacin mesylate|alatrofloxacin mesilate,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:146961-76-4|Drug_Central:102,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,alatrofloxacin mesylate|alatrofloxacin mesilate,,,,,,,,,,,,,,,,,,,,,CHEBI:135829,,,,alatrofloxacin,,CHEBI:135829,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001121,ChREBP activation [lipidosis],,"ChREBP activation is a subtype of activating nuclear receptor: A process that changes the activity of the activating ChREBP to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000051|http://purl.obolibrary.org/obo/TXPO_0001720,,,,,,,,,,,,,,,,,,,,PMID:30642126,,"ChREBP activation is a subtype of activating nuclear receptor: A process that changes the activity of the activating ChREBP to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001123,,,,,,http://purl.obolibrary.org/obo/TXPO_0000899,,,,,,,,,,,TXPO:0001121,,,,,,,,,,,,,,,,,,,,,,ChREBP activation [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001124,CHREBP (mol),Carbohydrate-Responsive Element-Binding Protein [lipidosis]|MLXIPL,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:171078|NCBI-Human-GeneID:51085|NCBI-Mouse-GeneID:58805,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,Carbohydrate-Responsive Element-Binding Protein [lipidosis]|MLXIPL,,,,,TXPO:0001124,,,,,,,,,,,,,,,,,,,,,,CHREBP (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001123,CHREBP (canonical)[lipidosis],Carbohydrate-Responsive Element-Binding Protein [lipidosis]|MLXIPL,,false,,,http://purl.obolibrary.org/obo/TXPO_0003516|http://purl.obolibrary.org/obo/TXPO_0001124,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:171078|NCBI-Human-GeneID:51085|NCBI-Mouse-GeneID:58805,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,Carbohydrate-Responsive Element-Binding Protein [lipidosis]|MLXIPL,,,,,TXPO:0001123,,,,,,,,,,,,,,,,,,,,,,CHREBP (canonical)[lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001129,lipid strorage in hepatocyte [Lipidosis],lipid accumulation in hepatocyte [lipidosis],"Lipid accumulation in hepatocyte is a subtype of lipid strorage in hepatocyte: A process that keeps lipids in hepatocytes mildly.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0003623,,,,,,,,,,,,,,,,,,,,,,"Lipid accumulation in hepatocyte is a subtype of lipid strorage in hepatocyte: A process that keeps lipids in hepatocytes mildly.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003499,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001522,,,,,,,,,,,,,lipid accumulation in hepatocyte [lipidosis],,,,,TXPO:0001129,,,,,,,,,,,,,,,,,,,,,,lipid strorage in hepatocyte [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001127,non-alcoholic steatohepatitis (toxic course),NASH (toxic course),The totality of all processes through which non-alcoholic steatohepatitis (NASH) is realized.,false,,,http://purl.obolibrary.org/obo/TXPO_0003498,,,,,,,,,,,,,,,,,,,,,,The totality of all processes through which non-alcoholic steatohepatitis (NASH) is realized.,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003476,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003495|http://purl.obolibrary.org/obo/TXPO_0000809|http://purl.obolibrary.org/obo/TXPO_0001044|http://purl.obolibrary.org/obo/TXPO_0001115|http://purl.obolibrary.org/obo/TXPO_0001116|http://purl.obolibrary.org/obo/TXPO_0001117|http://purl.obolibrary.org/obo/TXPO_0001113|http://purl.obolibrary.org/obo/TXPO_0001038|http://purl.obolibrary.org/obo/TXPO_0001882|http://purl.obolibrary.org/obo/TXPO_0003512|http://purl.obolibrary.org/obo/TXPO_0003510|http://purl.obolibrary.org/obo/TXPO_0000050|http://purl.obolibrary.org/obo/TXPO_0003799|http://purl.obolibrary.org/obo/TXPO_0001856|http://purl.obolibrary.org/obo/TXPO_0001858|http://purl.obolibrary.org/obo/TXPO_0001083|http://purl.obolibrary.org/obo/TXPO_0001085|http://purl.obolibrary.org/obo/TXPO_0001086|http://purl.obolibrary.org/obo/TXPO_0003756|http://purl.obolibrary.org/obo/TXPO_0001894|http://purl.obolibrary.org/obo/TXPO_0001618|http://purl.obolibrary.org/obo/TXPO_0003507|http://purl.obolibrary.org/obo/TXPO_0003811|http://purl.obolibrary.org/obo/TXPO_0003810|http://purl.obolibrary.org/obo/TXPO_0003361|http://purl.obolibrary.org/obo/TXPO_0001539|http://purl.obolibrary.org/obo/TXPO_0003806|http://purl.obolibrary.org/obo/TXPO_0003807|http://purl.obolibrary.org/obo/TXPO_0003809|http://purl.obolibrary.org/obo/TXPO_0003808|http://purl.obolibrary.org/obo/TXPO_0003482|http://purl.obolibrary.org/obo/TXPO_0003480|http://purl.obolibrary.org/obo/TXPO_0003484|http://purl.obolibrary.org/obo/TXPO_0003620|http://purl.obolibrary.org/obo/TXPO_0003621|http://purl.obolibrary.org/obo/TXPO_0003622|http://purl.obolibrary.org/obo/TXPO_0003478|http://purl.obolibrary.org/obo/TXPO_0003476|http://purl.obolibrary.org/obo/TXPO_0001095|http://purl.obolibrary.org/obo/TXPO_0001121|http://purl.obolibrary.org/obo/TXPO_0001126|http://purl.obolibrary.org/obo/TXPO_0001864|http://purl.obolibrary.org/obo/TXPO_0004128|http://purl.obolibrary.org/obo/TXPO_0000898|http://purl.obolibrary.org/obo/TXPO_0000899|http://purl.obolibrary.org/obo/TXPO_0000891|http://purl.obolibrary.org/obo/TXPO_0000890,,,,,,,,,,,,,NASH (toxic course),,,,,TXPO:0001127,,,,,,,,,,,,,,,,,,,,,,non-alcoholic steatohepatitis (toxic course),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001126,dysfunction of peroxisomal fatty acid beta-oxidation [NASH],,"Dysfunction of peroxisomal fatty acid beta-oxidation is a subtype of hypofunction of fatty acid beta-oxidation: A process that performs a decreased or insufficient fatty acid degradation severely.
This entity is a specific course-dependent process. This process can constitute the course of NASH.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0003652|http://purl.obolibrary.org/obo/TXPO_0003629,,,,,,,,,,,,,,,,,,,,,,"Dysfunction of peroxisomal fatty acid beta-oxidation is a subtype of hypofunction of fatty acid beta-oxidation: A process that performs a decreased or insufficient fatty acid degradation severely.
This entity is a specific course-dependent process. This process can constitute the course of NASH.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003361,,,,,,,,,,,TXPO:0001126,,,,,,,,,,,,,,,,,,,,,,dysfunction of peroxisomal fatty acid beta-oxidation [NASH],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005777,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001125,malfunctioning of insulin signaling,,Malfunctioning of insulin signaling is a subtype of malfunctioning process: A process that cannot perform insulin signaling [biological] appropriately or cannot realize it at all.,false,,,http://purl.obolibrary.org/obo/TXPO_0001453,,,,,,,,,,,,,,,,,,,,,,Malfunctioning of insulin signaling is a subtype of malfunctioning process: A process that cannot perform insulin signaling [biological] appropriately or cannot realize it at all.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001125,,,,,,,,,,,,,,,,,,,,,,malfunctioning of insulin signaling,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001128,simple steatosis,,The totality of all processes through which simple steatosis is realized.,false,,,http://purl.obolibrary.org/obo/TXPO_0003498,,,,,,,,,,,,,,,,,,,,,,The totality of all processes through which simple steatosis is realized.,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003624,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001039|http://purl.obolibrary.org/obo/TXPO_0000919|http://purl.obolibrary.org/obo/TXPO_0000901|http://purl.obolibrary.org/obo/TXPO_0003507|http://purl.obolibrary.org/obo/TXPO_0003811|http://purl.obolibrary.org/obo/TXPO_0003810|http://purl.obolibrary.org/obo/TXPO_0003806|http://purl.obolibrary.org/obo/TXPO_0003807|http://purl.obolibrary.org/obo/TXPO_0003809|http://purl.obolibrary.org/obo/TXPO_0003808|http://purl.obolibrary.org/obo/TXPO_0003482|http://purl.obolibrary.org/obo/TXPO_0003484|http://purl.obolibrary.org/obo/TXPO_0003624|http://purl.obolibrary.org/obo/TXPO_0001121|http://purl.obolibrary.org/obo/TXPO_0000898|http://purl.obolibrary.org/obo/TXPO_0000899|http://purl.obolibrary.org/obo/TXPO_0000891|http://purl.obolibrary.org/obo/TXPO_0000890,,,,,,,,,,,,,,,,,,TXPO:0001128,,,,,,,,,,,,,,,,,,,,,,simple steatosis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001122,organophosphate,,,false,,,http://purl.obolibrary.org/obo/CHEBI_72695,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001122,,,,,,,,,,,,,,,,,,,,,,organophosphate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001120,LXRa (mol),Liver X Receptor Alpha|NR1H3,,false,,,http://purl.obolibrary.org/obo/TXPO_0001509,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:58852|NCBI-Mouse-GeneID:22259|NCBI-Human-GeneID:10062,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Liver X Receptor Alpha|NR1H3,,,,,TXPO:0001120,,,,,,,,,,,,,,,,,,,,,,LXRa (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001449,TLR1,Toll-like receptor 1,,false,,,http://purl.obolibrary.org/obo/IMR_0000124,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Toll-like receptor 1,,,,,IMR:0001449,,,,,,,,,,,,,,,,,,,,,,TLR1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001452,Bhmt (rat)[Phospholipidosis],Betaine--Homocysteine S-Methyltransferase,,false,,,http://purl.obolibrary.org/obo/TXPO_1000046|http://purl.obolibrary.org/obo/TXPO_0001134,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:81508|PMID:21349258|PMID:19635752,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Betaine--Homocysteine S-Methyltransferase,,,,,TXPO:0001452,,,,,,,,,,,,,,,,,,,,,,Bhmt (rat)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001456,changing membrane potential,,Changing membrane potential is a subtype of changing quality: A process that changes the electrical potential across a membrane.,false,,,http://purl.obolibrary.org/obo/TXPO_0000415,,,,,,,,,,,,,,,,,,,,,,Changing membrane potential is a subtype of changing quality: A process that changes the electrical potential across a membrane.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001456,,,,,,,,,,,,,,,,,,,,,,changing membrane potential,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001455,positive regulation of autophagy [ER stress],autophagy in response to ER stress,"Any process that activates, maintains or increases the rate of autophagy. Autophagy is the process in which cells digest parts of their own cytoplasm.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/GO_0010508|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,PMID:26481188,,"Any process that activates, maintains or increases the rate of autophagy. Autophagy is the process in which cells digest parts of their own cytoplasm.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000451,,,,,,http://purl.obolibrary.org/obo/TXPO_0003490|http://purl.obolibrary.org/obo/TXPO_0000204|http://purl.obolibrary.org/obo/TXPO_0000371,,,,,,autophagy in response to ER stress,,,,,TXPO:0001455,,,,,,,,,,,,,,,,,,,,,,positive regulation of autophagy [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001457,cholesterol efflux from hepatoyte [Lipidosis],,"A release process of the cholesterol from hepatocyte.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/GO_0033344|http://purl.obolibrary.org/obo/TXPO_0001720,,,,,,,,,,,,,,,,,,,,,,"A release process of the cholesterol from hepatocyte.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001428,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001457,,,,,,,,,,,,,,,,,,,,,,cholesterol efflux from hepatoyte [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001459,relative value,,A value in comparison to something else.,false,,,http://purl.obolibrary.org/obo/TXPO_0000288,,,,,,,,,,,,,,,,,,,,,,A value in comparison to something else.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001459,,,,,,,,,,,,,,,,,,,,,,relative value,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001454,malfunctioning of receptor function,,Malfunctioning of receptor function is a subtype of malfunctioning process: A process that cannot perform  a receiving function appropriately or cannot realize it at all.,false,,,http://purl.obolibrary.org/obo/TXPO_0000434,,,,,,,,,,,,,,,,,,,,,,Malfunctioning of receptor function is a subtype of malfunctioning process: A process that cannot perform  a receiving function appropriately or cannot realize it at all.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001454,,,,,,,,,,,,,,,,,,,,,,malfunctioning of receptor function,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000379,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001451,cholesterol transporter role,,"A role played by the entity which enables the directed movement of cholesterol into, out of or within a cell, or between cells.",false,,,http://purl.obolibrary.org/obo/TXPO_0003699,,,,,,,,,,,,,,,,,,,,,,"A role played by the entity which enables the directed movement of cholesterol into, out of or within a cell, or between cells.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001451,,,,,,,,,,,,,,,,,,,,,,cholesterol transporter role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001450,hypofunction of mitochondrial fatty acid beta-oxidation [Glutathione depletion],,"Hypofunction of mitochondrial fatty acid beta-oxidation is a subtype of hypofunction of fatty acid beta-oxidation: A process that performs a decreased or insufficient mitochondrial fatty acid beta-oxidation.
This entity is a specific course-dependent process. This process can constitute the course of glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0002112|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Hypofunction of mitochondrial fatty acid beta-oxidation is a subtype of hypofunction of fatty acid beta-oxidation: A process that performs a decreased or insufficient mitochondrial fatty acid beta-oxidation.
This entity is a specific course-dependent process. This process can constitute the course of glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001450,,,,,,,,,,,,,,,,,,,,,,hypofunction of mitochondrial fatty acid beta-oxidation [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001458,hypofunction of cholesterol export from hepatoyte [lipidosis],,"Hypofunction of cholesterol transport from hepatocyte is a subtype of hypofunction of transport: A process that performs a decreased or insufficient cholesterol transport from hepatocyte.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0003483,,,,,,,,,,,,,,,,,,,,,,"Hypofunction of cholesterol transport from hepatocyte is a subtype of hypofunction of transport: A process that performs a decreased or insufficient cholesterol transport from hepatocyte.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,http://purl.obolibrary.org/obo/TXPO_0001457,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003491,,,,,,,,,,,TXPO:0001458,,,,,,,,,,,,,,,,,,,,,,hypofunction of cholesterol export from hepatoyte [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001453,malfunctioning of  intracellular signal transduction,,Malfunctioning of  intracellular signal transduction is a subtype of malfunctioning process: A process that cannot perform signaling [biological] appropriately or cannot realize it at all.,false,,,http://purl.obolibrary.org/obo/TXPO_0000434,,,,,,,,,,,,,,,,,,,,,,Malfunctioning of  intracellular signal transduction is a subtype of malfunctioning process: A process that cannot perform signaling [biological] appropriately or cannot realize it at all.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001453,,,,,,,,,,,,,,,,,,,,,,malfunctioning of  intracellular signal transduction,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0000915,thickness,,A 1-D extent quality which is equal to the dimension through an object as opposed to its length or width.,false,,,http://purl.obolibrary.org/obo/PATO_0000117,,,,,,,,,,,,,,,,,,,,,,A 1-D extent quality which is equal to the dimension through an object as opposed to its length or width.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0000915,,,,,,,,,,,,,,,,,,,,,,thickness,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0000918,volume,,A 3-D extent quality inhering in a bearer by virtue of the bearer's amount of 3-dimensional space it occupies.,false,,,http://purl.obolibrary.org/obo/TXPO_0002416|http://purl.obolibrary.org/obo/PATO_0000117,,,,,,,,,,,,,,,,,,,,,,A 3-D extent quality inhering in a bearer by virtue of the bearer's amount of 3-dimensional space it occupies.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0000918,,,,,,,,,,,,,,,,,,,,,,volume,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0011139,eIF2B-epsilon,"Translation initiation factor eIF-2B epsilon subunit|eIF-2B GDP-GTP exchange factor, epsilon subunit|translation initiation factor 2B epsilon subunit|eIF-2B GDP-GTP exchange factor",,false,,,http://purl.obolibrary.org/obo/IMR_0000915,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Translation initiation factor eIF-2B epsilon subunit|eIF-2B GDP-GTP exchange factor, epsilon subunit|translation initiation factor 2B epsilon subunit|eIF-2B GDP-GTP exchange factor",,,,,IMR:0011139,,,,,,,,,,,,,,,,,,,,,,eIF2B-epsilon,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0002110,gall bladder,vesica biliaris|vesica fellea|gallbladder|gall bladder,"An organ that aids digestion and stores bile produced by the liver[WP].|Rats do not have a gallbladder, but produce bile. The bile flows directly from the liver through the (hepatic) bile duct into the small intestine (Hebel and Stromberg, 1988)",false,,,http://purl.obolibrary.org/obo/UBERON_0013765,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C12377|http://www.snomedbrowser.com/Codes/Details/181269000|http://en.wikipedia.org/wiki/Gallbladder|http://linkedlifedata.com/resource/umls/id/C0016976|MA:0000356|OpenCyc:Mx4rvVkGr5wpEbGdrcN5Y29ycA|MAT:0000072|ZFA:0000208|EMAPA:17202|CALOHA:TS-0394|EHDAA:8062|MESH:D005704|galen:Gallbladder|XAO:0000135|BTO:0000493|EHDAA2:0000699|EFO:0000853|EV:0100090|AAO:0010114|TAO:0000208|MIAA:0000072|VHOG:0000221|FMA:7202|UMLS:C0016976,,An organ that aids digestion and stores bile produced by the liver[WP].,,,,,,,,"Membranous muscular sac in which the bile from the liver remains stored until it is required. [Dorian_AF, Elsevier's_encyclopaedic_dictionary_of_medicine, Part_B:_Anatomy_(1988)_Amsterdam_etc.:_Elsevier][VHOG]|Organ attached to the liver which stores bile and empties into the duodenum via the bile duct as needed for digestion.[AAO]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,gallbladder|gall bladder,,vesica biliaris|vesica fellea,"The presence of a gallbladder appears to be a primitive trait. It is found in most fish and all adult reptiles and amphibians and has been well conserved in mammals, for the most part.[well established][VHOG]",http://purl.obolibrary.org/obo/UBERON_0002423,UBERON:0002110,http://purl.obolibrary.org/obo/UBERON_0002423,,,,,,,,,,,,,,,,,,,"Rats do not have a gallbladder, but produce bile. The bile flows directly from the liver through the (hepatic) bile duct into the small intestine (Hebel and Stromberg, 1988)",,gall bladder,,,,https://upload.wikimedia.org/wikipedia/commons/b/b1/GallbladderAnatomy-en.svg|http://upload.wikimedia.org/wikipedia/commons/f/f4/Abdomal_organs.svg,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0002113,kidney,reniculate kidney,A paired organ of the urinary tract which has the production of urine as its primary function.,false,,,http://purl.obolibrary.org/obo/UBERON_0000062,,,,,,,,,,,,,,,,,,,,http://en.wikipedia.org/wiki/Kidney|http://www.snomedbrowser.com/Codes/Details/181414000|http://linkedlifedata.com/resource/umls/id/C0022646|http://purl.obolibrary.org/obo/NCIT_C12415|GAID:423|AAO:0000250|BTO:0000671|FMA:7203|EV:0100096|EFO:0000929|MESH:D007668|galen:Kidney|MAT:0000119|OpenCyc:Mx4rvVjlYpwpEbGdrcN5Y29ycA|CALOHA:TS-0510|XAO:0003267|UMLS:C0022646|MA:0000368|MIAA:0000119|EMAPA:17373,,A paired organ of the urinary tract which has the production of urine as its primary function.,,,,,,,,One of either of a pair of structures lying on either side of the dorsal aorta in which fluid balance is regulated and waste is excreted out in the form of urine.[AAO],,,http://purl.obolibrary.org/obo/FMA_264815,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,reniculate kidney,,,,UBERON:0002113,,,,,,,,,,,,,,,,,,,,,,kidney,,,,,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76729,EC 1.3.* (oxidoreductase acting on donor CH-CH group) inhibitor,oxidoreductase acting on donor CH-CH group (EC 1.3.*) inhibitors|inhibitor of oxidoreductase acting on CH-CH group of donors|EC 1.3.* inhibitor|oxidoreductase acting on donor CH-CH group (EC 1.3.*) inhibitor|inhibitors of oxidoreductase acting on CH-CH group of donor|oxidoreductase acting on donor CH-CH group inhibitors|inhibitors of oxidoreductase acting on CH-CH group of donors|oxidoreductase acting on donor CH-CH group inhibitor|EC 1.3.* inhibitors|inhibitor of oxidoreductase acting on CH-CH group of donor|EC 1.3.* (oxidoreductase acting on donor CH-CH group) inhibitors,An oxidoreductase inhibitor which interferes with the action of an oxidoreductase acting on the CH-CH group of donors (EC 1.3.*.*).,false,,,http://purl.obolibrary.org/obo/CHEBI_76725,,,,,,,,,,,,,,,,,,,,,,An oxidoreductase inhibitor which interferes with the action of an oxidoreductase acting on the CH-CH group of donors (EC 1.3.*.*).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,oxidoreductase acting on donor CH-CH group (EC 1.3.*) inhibitors|inhibitor of oxidoreductase acting on CH-CH group of donors|EC 1.3.* inhibitor|oxidoreductase acting on donor CH-CH group (EC 1.3.*) inhibitor|inhibitors of oxidoreductase acting on CH-CH group of donor|oxidoreductase acting on donor CH-CH group inhibitors|inhibitors of oxidoreductase acting on CH-CH group of donors|oxidoreductase acting on donor CH-CH group inhibitor|EC 1.3.* inhibitors|inhibitor of oxidoreductase acting on CH-CH group of donor|EC 1.3.* (oxidoreductase acting on donor CH-CH group) inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:76729,,,,EC 1.3.* (oxidoreductase acting on donor CH-CH group) inhibitor,,CHEBI:76729,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_31257,bendazac,EINECS 243-569-2|bendazaco|Iwazac|bendazolic acid|BRN 0893958|bendazacum|UNII-G4AG71204O|bendazac|[(1-benzyl-1H-indazol-3-yl)oxy]acetic acid,"A monocarboxylic acid that is glycolic acid in which the hydrogen attached to the 2-hydroxy group is replaced by a 1-benzyl-1H-indazol-3-yl group. Although it has anti-inflammatory, antinecrotic, choleretic and antilipidaemic properties and has been used for the treatment of various inflammatory skin disorders, its principal effect is to inhibit the denaturation of proteins. Its lysine salt is used in the management of cataracts.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:1809299|PMID:3508133|PMID:2190795|Reaxys:893958|PMID:3176111|PMID:4389308|PMID:8736488|PMID:5746786|PMID:3817034|PMID:4099158|Drug_Central:303|CAS:20187-55-7|PMID:8483582,,"A monocarboxylic acid that is glycolic acid in which the hydrogen attached to the 2-hydroxy group is replaced by a 1-benzyl-1H-indazol-3-yl group. Although it has anti-inflammatory, antinecrotic, choleretic and antilipidaemic properties and has been used for the treatment of various inflammatory skin disorders, its principal effect is to inhibit the denaturation of proteins. Its lysine salt is used in the management of cataracts.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35475|http://purl.obolibrary.org/obo/CHEBI_48578,,,,,[(1-benzyl-1H-indazol-3-yl)oxy]acetic acid,,EINECS 243-569-2|bendazaco|Iwazac|bendazolic acid|BRN 0893958|bendazacum|UNII-G4AG71204O|bendazac,,,,,,,,,,,,,,,,,,,,,CHEBI:31257,,,,bendazac,,CHEBI:31257,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000393,IRF-7,,,false,,,http://purl.obolibrary.org/obo/IMR_0000386,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000393,,,,,,,,,,,,,,,,,,,,,,IRF-7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100216,ERK5,BMK1,"ERK5, also known as big MAP kinase 1 (BMK1), is twice the size of other MAPKs. The amino-terminal half contains the kinase domain, which is similar to that of ERK1/2 and has the TEY activation motif, whereas the carboxy-terminal half is unique. MEK5 phosphorylates and activates ERK5, and then the activated ERK5 phosphorylates substrates including myocyte enhancer factor 2 (MEF2).",false,,,http://purl.obolibrary.org/obo/IMR_0000224,,,,,,,,,,,,,,,,,,,,,,"ERK5, also known as big MAP kinase 1 (BMK1), is twice the size of other MAPKs. The amino-terminal half contains the kinase domain, which is similar to that of ERK1/2 and has the TEY activation motif, whereas the carboxy-terminal half is unique. MEK5 phosphorylates and activates ERK5, and then the activated ERK5 phosphorylates substrates including myocyte enhancer factor 2 (MEF2).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BMK1,,,,,IMR:0100216,,,,,,,,,,,,,,,,,,,,,,ERK5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0002355,inactive,,A quality of a physical object that is currently realizing none of its functions.,false,,,http://purl.obolibrary.org/obo/TXPO_0002429|http://purl.obolibrary.org/obo/PATO_0002353,,,,,,,,,,,,,,,,,,,,,,A quality of a physical object that is currently realizing none of its functions.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0002355,,,,,,,,,,,,,,,,,,,,,,inactive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0002354,active,,A quality of an physical object that is currently realizing one of its functions.,false,,,http://purl.obolibrary.org/obo/TXPO_0002429|http://purl.obolibrary.org/obo/PATO_0002353,,,,,,,,,,,,,,,,,,,,,,A quality of an physical object that is currently realizing one of its functions.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0002354,,,,,,,,,,,,,,,,,,,,,,active,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0002353,activation quality,,A quality that inheres in a bearer in virtue of its realizing one of its functions.,false,,,http://purl.obolibrary.org/obo/BFO_0000019|http://purl.obolibrary.org/obo/TXPO_0002429,,,,,,,,,,,,,,,,,,,,,,A quality that inheres in a bearer in virtue of its realizing one of its functions.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0002353,,,,,,,,,,,,,,,,,,,,,,activation quality,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000116842,LEAP2,,Other designations: liver-expressed antimicrobial peptide 2,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,LEAP-2,,,,,,,,,,,,5,,,,,,MIM:611373|HGNC:29571|HPRD:17269,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,liver expressed antimicrobial peptide 2,,,5q31.1,,,,,,,,,,,,,,,,GO_0005576 (EC: IEA); GO_0042742 (EC: IEA),,,,,,,,,PMID: 12477932; 12493837; 15489334; 19852990; 20038463; 20379614; 20845358,,,,,,,,,,,,,,,OGG:3000116842,,,,,,,liver expressed antimicrobial peptide 2,,,,,,,,,,,,,Other designations: liver-expressed antimicrobial peptide 2,,LEAP2,,,,,,,,,,,,,,,,,,,,,,,116842,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,LEAP2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0010449,60S ribosomal protein L37a,,,false,,,http://purl.obolibrary.org/obo/IMR_0000897,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0010449,,,,,,,,,,,,,,,,,,,,,,60S ribosomal protein L37a,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000003565,IL4,,Other designations: B cell growth factor 1|B_cell stimulatory factor 1|binetrakin|interleukin 4 variant 2|interleukin-4|lymphocyte stimulatory factor 1|pitrakinra,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,IL-4|BSF-1|BSF1|BCGF-1|BCGF1,,,,,,,,,,,,5,,,,,,Ensembl:ENSG00000113520|MIM:147780|Vega:OTTHUMG00000059724|HGNC:6014|HPRD:00989,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,interleukin 4,,,5q31.1,,,,,,,,,,,,,,,,"GO_0002227 (EC: IEA); GO_0002296 (EC: IEA); GO_0002674 (EC: IEA); GO_0002677 (EC: IEA); GO_0005125 (EC: IEA); GO_0005136 (EC: TAS, PMID: 11418631); GO_0005515 (EC: IPI, PMID: 10219247); GO_0005615 (EC: TAS, PMID: 11418631); GO_0006935 (EC: TAS, PMID: 10725748); GO_0006955 (EC: TAS, PMID: 3016727); GO_0006968 (EC: TAS, PMID: 10725748); GO_0007565 (EC: IEA); GO_0007584 (EC: IEA); GO_0008083 (EC: NAS, PMID: 11418631); GO_0008203 (EC: ISS, PMID: 11971948); GO_0009897 (EC: IEA); GO_0010155 (EC: IEA); GO_0014070 (EC: IEA); GO_0030183 (EC: TAS, PMID: 11418631); GO_0030890 (EC: ISS); GO_0031296 (EC: IEA); GO_0032733 (EC: IEA); GO_0032736 (EC: IDA, PMID: 19346497); GO_0034097 (EC: IEA); GO_0035745 (EC: IDA); GO_0042092 (EC: TAS, PMID: 11676128); GO_0042102 (EC: ISS); GO_0042104 (EC: IEA); GO_0042325 (EC: ISS); GO_0042493 (EC: IEA); GO_0042523 (EC: IEA); GO_0042832 (EC: IEA); GO_0043031 (EC: IEA); GO_0043066 (EC: ISS); GO_0045019 (EC: IEA); GO_0045064 (EC: IEA); GO_0045080 (EC: IEA); GO_0045189 (EC: TAS, PMID: 11967989); GO_0045191 (EC: TAS, PMID: 11418631); GO_0045348 (EC: ISS); GO_0045471 (EC: IEA); GO_0045582 (EC: IDA); GO_0045671 (EC: ISS); GO_0045892 (EC: IDA, PMID: 18579517); GO_0045893 (EC: IDA, PMID: 18579517); GO_0045944 (EC: ISS); GO_0048295 (EC: ISS); GO_0048304 (EC: ISS); GO_0050776 (EC: ISS); GO_0051091 (EC: IEA); GO_0071288 (EC: IEA); GO_0097028 (EC: IDA); GO_0097192 (EC: IEA); GO_2000320 (EC: IEA); GO_2001237 (EC: IEA)",,,,,,,,,PMID: 1197194; 1346976; 1400355; 1511746; 1567880; 1567881; 1569578; 1609277; 1932028; 1946344; 1993171; 2535858; 3016727; 3257560; 7523014; 7589092; 7664036; 7695626; 7806280; 7963560; 8151703; 8266078; 8516290; 8602263; 8603435; 8609418; 8764000; 9113989; 9130521; 9130652; 9334723; 9799097; 9856950; 10219247; 10438901; 10473513; 10623799; 10710213; 10714547; 10725748; 10753117; 10853974; 11023480; 11035134; 11122213; 11149986; 11167377; 11233912; 11258628; 11258696; 11294568; 11298547; 11315919; 11316066; 11316069; 11320251; 11350513; 11396683; 11418631; 11466338; 11496248; 11502824; 11528525; 11587989; 11676128; 11678851; 11704810; 11728464; 11777980; 11786020; 11811777; 11841848; 11842291; 11872954; 11877044; 11881490; 11886168; 11897522; 11897999; 11907068; 11920312; 11922633; 11930331; 11950517; 11953141; 11960309; 11967989; 11968047; 11971948; 11980568; 11994288; 12020266; 12030894; 12039414; 12063527; 12066847; 12072494; 12082592; 12089714; 12102661; 12105273; 12107748; 12115161; 12121273; 12124654; 12133437; 12144536; 12161424; 12162874; 12165514; 12207324; 12220533; 12358844; 12363051; 12366695; 12368275; 12402189; 12420205; 12426308; 12435565; 12441140; 12442007; 12470598; 12477932; 12479817; 12504082; 12508140; 12508786; 12509382; 12513914; 12515722; 12517954; 12525574; 12542496; 12552499; 12574355; 12578333; 12587822; 12595908; 12600829; 12613995; 12626590; 12660931; 12663328; 12667657; 12687213; 12687247; 12689929; 12694433; 12700447; 12715242; 12738651; 12748907; 12753568; 12813360; 12851716; 12877559; 12884288; 12897746; 12900808; 12902508; 12911786; 12940513; 12944981; 12973929; 14499500; 14503851; 14522096; 14523823; 14530362; 14551608; 14561191; 14568946; 14583474; 14610476; 14634065; 14634100; 14652008; 14654080; 14675394; 14681304; 14688371; 14692664; 14693849; 14697238; 14697936; 14725568; 14729510; 14746805; 14764715; 14767810; 14983029; 14986816; 15001290; 15004182; 15007352; 15013759; 15014952; 15021309; 15041089; 15042002; 15051937; 15057902; 15063762; 15084933; 15086621; 15087090; 15100288; 15122773; 15123681; 15128803; 15163899; 15166131; 15170937; 15177147; 15178889; 15187156; 15191519; 15210741; 15213252; 15215692; 15241348; 15274656; 15292002; 15297269; 15298559; 15322832; 15361128; 15367434; 15373917; 15474066; 15489334; 15501397; 15527169; 15528258; 15563083; 15570643; 15591113; 15592292; 15596681; 15627726; 15644127; 15660235; 15660293; 15661875; 15676220; 15678501; 15679809; 15687724; 15695802; 15713213; 15714203; 15723707; 15733644; 15755291; 15778356; 15811521; 15816837; 15825027; 15869882; 15883744; 15885323; 15900570; 15900573; 15904474; 15919378; 15932621; 15941525; 15951665; 15969687; 15970635; 16001979; 16002690; 16004996; 16034134; 16043936; 16044136; 16046318; 16053729; 16083175; 16083600; 16091861; 16100774; 16164695; 16166103; 16184405; 16190985; 16193177; 16195814; 16215326; 16230423; 16232344; 16249002; 16289646; 16301860; 16313303; 16313681; 16315031; 16334248; 16343431; 16375755; 16380445; 16387595; 16388492; 16403098; 16427155; 16429138; 16429733; 16449530; 16461126; 16466711; 16487180; 16492782; 16511411; 16520888; 16522370; 16544245; 16547227; 16547693; 16551465; 16573560; 16574063; 16596275; 16601843; 16640778; 16681592; 16690518; 16702372; 16707627; 16720107; 16722389; 16750991; 16750993; 16759385; 16810739; 16864907; 16867043; 16877367; 16914241; 16916659; 16929824; 16930576; 16931887; 16938461; 16950634; 16973957; 16987060; 17006724; 17014622; 17015714; 17015735; 17063753; 17097641; 17117487; 17121586; 17133536; 17141086; 17143971; 17148075; 17151125; 17151939; 17152005; 17159260; 17177148; 17203290; 17207024; 17208210; 17209513; 17213232; 17222831; 17237413; 17257312; 17284225; 17291854; 17295710; 17299718; 17303794; 17303923; 17309781; 17311314; 17327605; 17355643; 17369174; 17371990; 17379175; 17388919; 17389011; 17389870; 17405833; 17420820; 17428692; 17433443; 17444864; 17451413; 17454884; 17460561; 17523428; 17524861; 17530998; 17536219; 17540990; 17541280; 17548690; 17563406; 17566759; 17576577; 17623648; 17627763; 17631734; 17640324; 17640674; 17644317; 17653830; 17655693; 17656331; 17662651; 17678726; 17703412; 17714919; 17851828; 17855802; 17882904; 17889143; 17908769; 17914408; 17916404; 17916900; 17937745; 17938902; 17961771; 17968425; 18008330; 18031948; 18042256; 18056382; 18058260; 18064451; 18088017; 18156980; 18165865; 18174230; 18179754; 18179773; 18202702; 18204280; 18206261; 18210751; 18211631; 18230112; 18239807; 18243101; 18251702; 18263811; 18273035; 18273643; 18276105; 18286287; 18294957; 18295676; 18310157; 18322173; 18342537; 18351434; 18371377; 18385759; 18389618; 18394346; 18396027; 18403443; 18410779; 18418228; 18422436; 18425216; 18433468; 18439079; 18441098; 18448485; 18454680; 18455629; 18476609; 18485518; 18497474; 18522869; 18533937; 18538381; 18547691; 18558283; 18566561; 18568448; 18568476; 18574615; 18579517; 18593330; 18596736; 18597704; 18599603; 18610831; 18610832; 18614592; 18624944; 18625055; 18626468; 18628242; 18629290; 18632425; 18633131; 18635180; 18636124; 18641314; 18651887; 18662263; 18674658; 18676680; 18676870; 18682601; 18688110; 18694328; 18696265; 18708672; 18716132; 18776133; 18781131; 18818748; 18834248; 18924208; 18927306; 18931892; 18936436; 18941246; 18955794; 18971287; 18971305; 18974110; 18974840; 19008611; 19013323; 19019335; 19028820; 19050632; 19058298; 19058839; 19066394; 19074885; 19116009; 19117745; 19122650; 19126646; 19129082; 19131452; 19131662; 19141349; 19164348; 19168731; 19169254; 19170196; 19185507; 19190772; 19193442; 19200845; 19222422; 19247692; 19249119; 19251840; 19254294; 19258923; 19261373; 19262574; 19263529; 19264973; 19275586; 19279357; 19332120; 19332998; 19336370; 19346497; 19347053; 19351467; 19370405; 19372547; 19375306; 19382262; 19385959; 19408823; 19409508; 19419769; 19421745; 19426601; 19437232; 19470040; 19479237; 19495883; 19497039; 19505916; 19508433; 19515749; 19521787; 19527514; 19536153; 19541591; 19544559; 19544973; 19552791; 19555572; 19559392; 19566553; 19573080; 19575932; 19578876; 19586918; 19586939; 19594368; 19621989; 19625176; 19657367; 19682920; 19683555; 19692168; 19698128; 19699526; 19706316; 19707465; 19718656; 19718824; 19721012; 19726720; 19735490; 19753334; 19762488; 19772762; 19773279; 19773451; 19799628; 19804407; 19811408; 19817957; 19818512; 19835477; 19840389; 19845895; 19857574; 19860911; 19862939; 19878651; 19882211; 19892918; 19910025; 19913121; 19915002; 19933216; 19938203; 19948975; 19959237; 20003246; 20010912; 20012528; 20016407; 20027321; 20030788; 20039421; 20049266; 20053586; 20056178; 20059579; 20082482; 20093796; 20100010; 20112007; 20121760; 20128416; 20139223; 20140262; 20145925; 20147633; 20177758; 20184663; 20192866; 20213229; 20217044; 20219689; 20222161; 20237496; 20299965; 20304823; 20305143; 20332709; 20349326; 20349753; 20364398; 20367137; 20394509; 20395963; 20403914; 20406299; 20413987; 20416077; 20418110; 20424473; 20442634; 20444155; 20452482; 20453000; 20459687; 20485362; 20503287; 20506498; 20517665; 20524005; 20525402; 20530519; 20533927; 20536507; 20565368; 20568250; 20580039; 20603037; 20603050; 20618516; 20620947; 20628086; 20644561; 20673868; 20703737; 20711808; 20713631; 20716621; 20719954; 20723894; 20726231; 20736038; 20808855; 20811626; 20814620; 20839488; 20852371; 20859068; 20880001; 20921925; 20942272; 20970781; 20980261; 21048327; 21054877; 21061265; 21067483; 21071541; 21085635; 21086908; 21106245; 21106524; 21111725; 21127885; 21191414; 21195738; 21198753; 21211660; 21268015; 21270410; 21276216; 21323696; 21354455; 21460743; 21471214; 21478113; 21501388; 21611195; 21636115; 21640045; 21644211; 21645924; 21646796; 21658970; 21690322; 21713407; 21729106; 21749213; 21755390; 21771210; 21788379; 21799768; 21819409; 21846818; 21857939; 21890374; 21900165; 21913997; 21966389; 21989417; 22045834; 22053598; 22087298; 22092872; 22104567; 22142023; 22143036; 22156341; 22157213; 22170601; 22174091; 22214155; 22226971; 22227092; 22249152; 22358381; 22365405; 22366824; 22387551; 22406175; 22441356; 22484241; 22484276; 22512783; 22521249; 22528336; 22538865; 22574929; 22583827; 22594992; 22615205; 22652416; 22675249; 22705603; 22805022; 22805115; 22824342; 22875803; 22884982; 22892939; 22921153; 22942430; 22986179; 22992805; 22997428; 23070918; 23087426; 23107766; 23110190; 23124025; 23128233; 23185315; 23222300; 23234779; 23245479; 23259293; 23276701; 23306429; 23333893; 23334651; 23376457; 23394902; 23398789; 23454622; 23511027; 23527200; 23527710; 23559861; 23572437; 23576103; 23591975; 23644020; 23651591; 23654077; 23668806; 23685257; 23694808; 23756167; 23756192; 23766027; 23768103; 23797532; 23831512; 23844087; 23883285; 23913957; 23923066; 23924473; 23935100; 23936398; 23958647; 23964553; 23983153; 24406619; 24510574,,,,,,,,,,,,,,,OGG:3000003565,,,,,,,interleukin 4,,,,,,,,,,,,,Other designations: B cell growth factor 1|B_cell stimulatory factor 1|binetrakin|interleukin 4 variant 2|interleukin-4|lymphocyte stimulatory factor 1|pitrakinra,,IL4,,,,,,,,,,,,,,,,,,,,,,,3565,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,IL4,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000003560,IL2RB,,"Other designations: CD122 antigen|IL-2 receptor subunit beta|IL-2R subunit beta|IL-2RB|high affinity IL-2 receptor beta subunit|high affinity IL-2 receptor subunit beta|interleukin 15 receptor, beta|interleukin-2 receptor subunit beta|p75",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,P70-75|IL15RB|CD122,,,,,,,,,,,,22,,,,,,HPRD:00896|HGNC:6009|Ensembl:ENSG00000100385|MIM:146710|Vega:OTTHUMG00000150534,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"interleukin 2 receptor, beta",,,22q13.1,,,,,,,,,,,,,,,,"GO_0004911 (EC: IDA, PMID: 7736574); GO_0004911 (EC: TAS, Qualifier: contributes_to, PMID: 2467293); GO_0005886 (EC: TAS); GO_0005887 (EC: TAS, PMID: 8514792); GO_0006461 (EC: TAS, PMID: 2467293); GO_0007165 (EC: TAS, PMID: 2785715); GO_0009897 (EC: ISS); GO_0016032 (EC: IEA); GO_0019221 (EC: IDA, PMID: 7736574); GO_0019976 (EC: ISS); GO_0038110 (EC: IDA, PMID: 7736574); GO_0038110 (EC: TAS, PMID: 2467293); GO_0043066 (EC: IDA, PMID: 7736574)",,,,,,,,,PMID: 1394441; 1557373; 1639773; 1915291; 1973832; 2047859; 2303462; 2315327; 2333293; 2467293; 2785715; 2843775; 3925551; 7529123; 7600304; 7641685; 7693677; 7734194; 7736574; 7973658; 7973659; 8026467; 8041779; 8049354; 8294403; 8483935; 8493579; 8514792; 8648694; 8700888; 9176231; 9341758; 9520455; 9553136; 9637477; 9774657; 10214954; 10373548; 10514520; 10591208; 10602027; 10825200; 11035066; 11133764; 11238664; 11359922; 11463390; 11750878; 11856346; 11886175; 12133952; 12200137; 12230826; 12477932; 12676936; 12960323; 14680494; 15063762; 15191519; 15350462; 15461802; 15489334; 16084898; 16284400; 16293754; 16380905; 16477002; 17108990; 17115417; 17152005; 17703412; 18299274; 18445679; 18490721; 18589435; 18592269; 18715339; 18774388; 18791162; 18818748; 18829468; 19019335; 19240061; 19258923; 19471255; 19527514; 19602517; 19615332; 19773451; 19817957; 19822714; 19913121; 19923221; 20049410; 20140262; 20179739; 20219786; 20237496; 20379614; 20424473; 20495002; 20498205; 20503287; 20585888; 20628086; 20728947; 20811626; 20860503; 21345943; 21362618; 21653640; 21674833; 21829393; 21834013; 21839273; 21865161; 21984699; 22558434; 22573796; 23341462; 23418630; 23512675; 23628622; 23676143,,,,,,,,,,,,,,,OGG:3000003560,,,,,,,"interleukin 2 receptor, beta",,,,,,,,,,,,,"Other designations: CD122 antigen|IL-2 receptor subunit beta|IL-2R subunit beta|IL-2RB|high affinity IL-2 receptor beta subunit|high affinity IL-2 receptor subunit beta|interleukin 15 receptor, beta|interleukin-2 receptor subunit beta|p75",,IL2RB,,,,,,,,,,,,,,,,,,,,,,,3560,RP5-1170K4.6,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,IL2RB,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000003569,IL6,,"Other designations: B-cell differentiation factor|B-cell stimulatory factor 2|BSF-2|CDF|CTL differentiation factor|IFN-beta-2|hybridoma growth factor|interferon beta-2|interferon, beta 2|interleukin 6 (interferon, beta 2)|interleukin BSF-2|interleukin-6",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,IL-6|HSF|BSF2|IFNB2|HGF,,,,,,,,,,,,7,,,,,,HGNC:6018|Ensembl:ENSG00000136244|MIM:147620|HPRD:00970|Vega:OTTHUMG00000023178,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,interleukin 6,,,7p21,,,,,,,,,,,,,,,,"GO_0001781 (EC: IDA, PMID: 7595060); GO_0002384 (EC: IDA, PMID: 2444978); GO_0002384 (EC: TAS, PMID: 12832423); GO_0002446 (EC: IC, PMID: 16034137); GO_0002548 (EC: IC, PMID: 10510402); GO_0002675 (EC: IDA, PMID: 2444978); GO_0002690 (EC: IC, PMID: 16034137); GO_0005125 (EC: IDA, PMID: 3023045); GO_0005125 (EC: NAS, PMID: 10443688); GO_0005138 (EC: IPI, PMID: 12829785); GO_0005138 (EC: IPI, Qualifier: contributes_to, PMID: 12829785); GO_0005138 (EC: NAS, PMID: 1883960); GO_0005515 (EC: IPI, PMID: 11238858); GO_0005576 (EC: TAS); GO_0005615 (EC: IDA, PMID: 10443688); GO_0005896 (EC: IDA, PMID: 12829785); GO_0006469 (EC: IEA); GO_0006953 (EC: TAS, PMID: 12832423); GO_0006954 (EC: IDA, PMID: 10443688); GO_0006959 (EC: IC, PMID: 3491322); GO_0007568 (EC: IEA); GO_0008083 (EC: IDA, PMID: 12643274); GO_0008284 (EC: IDA, PMID: 2261637); GO_0008284 (EC: IMP, PMID: 18719127); GO_0008285 (EC: IEA); GO_0008360 (EC: IEA); GO_0009408 (EC: IEA); GO_0009409 (EC: IEA); GO_0009612 (EC: IEA); GO_0009897 (EC: IEA); GO_0010574 (EC: IDA, PMID: 8557680); GO_0010888 (EC: NAS, PMID: 16464856); GO_0016049 (EC: IEA); GO_0019221 (EC: IDA, PMID: 12643274); GO_0030168 (EC: TAS, PMID: 7831669); GO_0031000 (EC: IEA); GO_0031018 (EC: ISS, PMID: 18719127); GO_0031175 (EC: IMP, PMID: 3264880); GO_0031667 (EC: IEA); GO_0032494 (EC: IEP, PMID: 16034137); GO_0032496 (EC: IEA); GO_0032722 (EC: IDA, PMID: 10510402); GO_0032722 (EC: IMP, PMID: 16034137); GO_0032755 (EC: IDA, PMID: 10510402); GO_0032868 (EC: IEA); GO_0032966 (EC: IDA, PMID: 12419823); GO_0033138 (EC: IDA, PMID: 7508917); GO_0033160 (EC: IEA); GO_0042102 (EC: IDA, PMID: 3130269); GO_0042493 (EC: IEA); GO_0042517 (EC: IDA, PMID: 12643274); GO_0042832 (EC: IEA); GO_0043065 (EC: IDA, PMID: 9949178); GO_0043066 (EC: IDA, PMID: 7595060); GO_0043154 (EC: IEA); GO_0043200 (EC: IEA); GO_0043410 (EC: IDA, PMID: 12419823); GO_0045079 (EC: ISS); GO_0045188 (EC: IEA); GO_0045429 (EC: IEA); GO_0045454 (EC: IEA); GO_0045599 (EC: NAS, PMID: 16464856); GO_0045630 (EC: IEA); GO_0045666 (EC: IEA); GO_0045669 (EC: TAS, PMID: 12372336); GO_0045721 (EC: IEA); GO_0045727 (EC: IDA, PMID: 16732314); GO_0045740 (EC: IEA); GO_0045765 (EC: IC, PMID: 8557680); GO_0045893 (EC: IDA, PMID: 7749983); GO_0045944 (EC: IDA, PMID: 17324931); GO_0046427 (EC: IDA, PMID: 12419823); GO_0046677 (EC: IEA); GO_0046716 (EC: IEA); GO_0046849 (EC: IEA); GO_0046888 (EC: IEA); GO_0048635 (EC: IEA); GO_0048661 (EC: IDA, PMID: 10510402); GO_0050679 (EC: IEA); GO_0050710 (EC: IEA); GO_0050731 (EC: IDA, PMID: 7508917); GO_0050829 (EC: IEP, PMID: 16034137); GO_0050830 (EC: IEP, PMID: 16034137); GO_0050871 (EC: IDA, PMID: 3491322); GO_0051024 (EC: IDA, PMID: 3491322); GO_0051091 (EC: IDA, PMID: 7749983); GO_0051092 (EC: IDA, Qualifier: NOT, PMID: 12419823); GO_0051384 (EC: IDA, PMID: 10443688); GO_0051592 (EC: IEA); GO_0051602 (EC: IEA); GO_0051607 (EC: IDA, PMID: 3023045); GO_0051897 (EC: IEA); GO_0051971 (EC: IEA); GO_0060445 (EC: IEA); GO_0060664 (EC: IEA); GO_0070091 (EC: ISS, PMID: 18719127); GO_0070102 (EC: IDA, PMID: 12552091); GO_0070301 (EC: IDA, PMID: 19168699); GO_0070374 (EC: IEA); GO_0072540 (EC: ISS); GO_1901215 (EC: IEA); GO_2000366 (EC: IC, PMID: 17324931); GO_2000676 (EC: TAS, PMID: 18719127)",,,,,,,,,PMID: 1113021; 1291290; 1346976; 1610348; 1656094; 1883960; 1918997; 2037043; 2261637; 2444978; 2472117; 2610854; 2680567; 2788034; 2789513; 2829354; 2906047; 3023045; 3130269; 3264880; 3266463; 3279116; 3294161; 3320204; 3491322; 3500852; 3538015; 3758081; 7494249; 7508917; 7511078; 7511596; 7523444; 7526541; 7536422; 7553888; 7595060; 7656270; 7693046; 7704970; 7749983; 7803268; 7815507; 7831669; 7851440; 7986583; 8018916; 8086129; 8113688; 8179923; 8190832; 8206884; 8247028; 8510564; 8555185; 8557680; 8764000; 8806809; 8938574; 9094636; 9108403; 9118960; 9159484; 9169458; 9225992; 9378998; 9658081; 9671211; 9792375; 9927325; 9949178; 10358063; 10388525; 10415019; 10443688; 10510402; 10657672; 10671302; 10775602; 10777583; 10925276; 10964543; 11028446; 11040178; 11054276; 11072134; 11072751; 11116068; 11145851; 11167813; 11196676; 11196678; 11199329; 11204808; 11212160; 11224491; 11233912; 11238858; 11266856; 11266927; 11266928; 11267084; 11282548; 11312376; 11315919; 11316066; 11342474; 11354638; 11355017; 11371414; 11391238; 11397324; 11404167; 11448119; 11485024; 11500818; 11517385; 11520812; 11544427; 11544434; 11544437; 11557672; 11574109; 11640949; 11687509; 11689614; 11692078; 11703956; 11713964; 11716039; 11728144; 11733366; 11751408; 11758653; 11774563; 11777983; 11781191; 11788581; 11792588; 11794009; 11801594; 11818668; 11820460; 11847482; 11849463; 11853279; 11855786; 11858187; 11862386; 11884027; 11884029; 11884401; 11884403; 11889177; 11895465; 11902285; 11906646; 11914754; 11918227; 11919083; 11922913; 11949822; 11950481; 11950697; 11956023; 11959895; 11960393; 11961304; 11966578; 11981433; 11983287; 11984595; 11988246; 11988625; 11990931; 11992567; 12000745; 12012622; 12027404; 12031914; 12032172; 12036196; 12038454; 12047360; 12050565; 12051396; 12067898; 12070032; 12080442; 12082590; 12082592; 12086705; 12089333; 12089714; 12091348; 12095061; 12096924; 12096927; 12107724; 12110411; 12114287; 12117737; 12117921; 12117953; 12121679; 12133353; 12140751; 12149213; 12150965; 12151314; 12164325; 12165085; 12176919; 12183057; 12185451; 12187073; 12198224; 12200114; 12201209; 12202945; 12214260; 12215823; 12217290; 12218157; 12219016; 12220549; 12226829; 12232842; 12235153; 12239630; 12240899; 12297113; 12297725; 12352619; 12359225; 12359431; 12370346; 12370360; 12370503; 12371985; 12372336; 12382118; 12383455; 12391243; 12392859; 12393446; 12393542; 12393699; 12394188; 12396456; 12412787; 12413693; 12419823; 12430875; 12431817; 12445202; 12445803; 12451269; 12453469; 12468916; 12472176; 12477932; 12482836; 12483530; 12491092; 12493411; 12495721; 12507818; 12509497; 12517591; 12517814; 12519862; 12526950; 12540635; 12552091; 12553555; 12554901; 12558814; 12559950; 12560330; 12560873; 12571160; 12574335; 12574550; 12584029; 12585340; 12589429; 12590978; 12591385; 12592380; 12594059; 12595908; 12606524; 12615367; 12618859; 12626585; 12629515; 12633940; 12634650; 12637697; 12643274; 12647840; 12651071; 12653788; 12657090; 12660820; 12660878; 12663465; 12664314; 12668153; 12668157; 12681965; 12690205; 12694213; 12709682; 12713584; 12714254; 12714267; 12716337; 12719374; 12720537; 12727482; 12727794; 12727841; 12727948; 12727959; 12736743; 12737276; 12742994; 12743452; 12745542; 12746914; 12748876; 12754410; 12756345; 12757654; 12760309; 12768442; 12770686; 12771987; 12789531; 12790760; 12792728; 12794182; 12796383; 12799618; 12802423; 12810629; 12811627; 12815949; 12818128; 12819039; 12828754; 12829659; 12829785; 12830005; 12832117; 12832326; 12832423; 12839942; 12840146; 12843190; 12843357; 12846758; 12850808; 12853948; 12857677; 12857678; 12870175; 12871882; 12876073; 12883476; 12888915; 12897342; 12900415; 12901869; 12919773; 12923493; 12926107; 12928051; 12928784; 12932839; 12934185; 12937023; 12938195; 12940515; 12944981; 12945076; 12952969; 12958150; 12960275; 12960348; 12967650; 12969979; 12970232; 13678786; 14508181; 14508221; 14512079; 14514772; 14521945; 14522096; 14523169; 14523823; 14532843; 14557255; 14557477; 14557872; 14563376; 14566095; 14566255; 14568951; 14582815; 14585094; 14586325; 14604894; 14607690; 14625191; 14633738; 14634582; 14634584; 14643032; 14644408; 14654926; 14656692; 14657427; 14675394; 14676217; 14680981; 14684705; 14688371; 14691340; 14709647; 14711458; 14718574; 14733913; 14735187; 14739370; 14739540; 14748439; 14756669; 14872501; 14967376; 14969768; 14970177; 14981536; 14990346; 14997289; 15001458; 15005726; 15005841; 15015143; 15016829; 15019283; 15021309; 15025214; 15028733; 15030461; 15034082; 15036420; 15041164; 15041717; 15041721; 15044662; 15050298; 15051507; 15057902; 15070705; 15070960; 15072962; 15075299; 15083368; 15086488; 15100309; 15100312; 15104679; 15105457; 15118287; 15120188; 15120189; 15121272; 15135265; 15135368; 15152368; 15153787; 15154666; 15158360; 15166129; 15167972; 15170937; 15171792; 15172007; 15172469; 15180970; 15180973; 15189946; 15193488; 15193763; 15194285; 15194822; 15200452; 15203561; 15205588; 15207246; 15209388; 15212825; 15214940; 15220185; 15220553; 15223609; 15223612; 15230289; 15236771; 15256272; 15256287; 15265021; 15273081; 15273551; 15284113; 15288392; 15288631; 15292466; 15299003; 15303107; 15304054; 15304377; 15306845; 15308667; 15308783; 15308875; 15313471; 15319170; 15322060; 15331795; 15336915; 15341921; 15341923; 15342284; 15345683; 15351436; 15355555; 15361124; 15364891; 15369724; 15373762; 15373964; 15375172; 15375575; 15377473; 15380900; 15383370; 15448117; 15452323; 15458467; 15458685; 15462469; 15462470; 15466088; 15467541; 15469436; 15472205; 15481145; 15489334; 15494357; 15497456; 15501028; 15507390; 15516360; 15520404; 15531184; 15541252; 15543342; 15550378; 15552843; 15561952; 15562761; 15564333; 15566952; 15570310; 15581980; 15582581; 15591791; 15592292; 15596840; 15599305; 15603866; 15604420; 15608432; 15609131; 15609321; 15610507; 15610530; 15616014; 15619425; 15621151; 15622443; 15629668; 15630704; 15635591; 15638425; 15642878; 15644653; 15645209; 15661740; 15663746; 15663749; 15663966; 15664628; 15664789; 15665272; 15677734; 15686457; 15686588; 15688424; 15690532; 15694997; 15696921; 15710474; 15712220; 15718495; 15718915; 15723707; 15726267; 15733644; 15733973; 15737987; 15741245; 15745939; 15746456; 15754274; 15755291; 15756054; 15760495; 15763337; 15769552; 15780075; 15784411; 15784966; 15787640; 15790343; 15790728; 15793269; 15809210; 15814282; 15816827; 15820616; 15831279; 15831362; 15837947; 15841043; 15845864; 15846175; 15847080; 15847702; 15848524; 15854776; 15854959; 15857508; 15859365; 15863389; 15863613; 15883744; 15894122; 15894558; 15894559; 15895091; 15896304; 15896753; 15900570; 15901906; 15902127; 15904871; 15905620; 15905624; 15910501; 15914210; 15917161; 15917409; 15919456; 15919832; 15925543; 15935883; 15939070; 15940250; 15951664; 15952088; 15955385; 15965659; 15969253; 15979549; 15981030; 15985484; 15985687; 15986200; 15988318; 15989803; 15992611; 15993715; 16005243; 16006475; 16006970; 16008970; 16009564; 16009674; 16014026; 16029943; 16032529; 16034137; 16043358; 16043746; 16051899; 16095005; 16096323; 16098388; 16099893; 16100774; 16104959; 16107886; 16110031; 16115611; 16115908; 16115919; 16127269; 16135414; 16140413; 16147857; 16148087; 16149059; 16150725; 16160188; 16164695; 16169070; 16179573; 16181755; 16183136; 16183563; 16185356; 16198603; 16198606; 16202743; 16206161; 16207551; 16208404; 16229816; 16235772; 16243534; 16244501; 16260731; 16265697; 16269662; 16269960; 16273337; 16276011; 16278387; 16278864; 16284733; 16285960; 16287542; 16288983; 16293576; 16297587; 16299685; 16301860; 16304445; 16306329; 16310043; 16313297; 16313298; 16317381; 16318580; 16323614; 16323703; 16324758; 16338121; 16339311; 16340466; 16344268; 16361815; 16361891; 16372246; 16374139; 16375755; 16388753; 16389181; 16391840; 16395669; 16403098; 16403955; 16411061; 16413198; 16413199; 16418171; 16424284; 16426569; 16427731; 16428383; 16433832; 16442710; 16443741; 16444434; 16449530; 16464738; 16464741; 16464856; 16467451; 16469407; 16485780; 16487028; 16491351; 16493118; 16499908; 16507605; 16512757; 16516857; 16518703; 16518755; 16519772; 16524883; 16525568; 16538639; 16538877; 16539678; 16540406; 16540751; 16544245; 16547804; 16552338; 16564564; 16565838; 16567828; 16573560; 16583473; 16607077; 16611358; 16617919; 16618781; 16620830; 16635548; 16642549; 16644865; 16647016; 16647242; 16648144; 16676071; 16684268; 16690518; 16704689; 16708557; 16708852; 16720107; 16721634; 16722148; 16730575; 16731080; 16732314; 16741147; 16759385; 16760905; 16762155; 16764962; 16767656; 16769764; 16773437; 16775170; 16782174; 16787648; 16797905; 16802343; 16803517; 16803995; 16804071; 16820586; 16820919; 16824159; 16837641; 16840032; 16840657; 16842617; 16842669; 16845637; 16857895; 16858645; 16864901; 16864905; 16864906; 16864908; 16869943; 16870193; 16873708; 16879054; 16887796; 16912152; 16916659; 16919469; 16921112; 16926159; 16929824; 16930778; 16931134; 16937502; 16938116; 16938461; 16939660; 16952201; 16954375; 16959787; 16961803; 16962335; 16978071; 16984279; 16988060; 16988089; 16989825; 16997495; 16998242; 17002904; 17003362; 17003778; 17005410; 17012252; 17016617; 17023036; 17023074; 17024220; 17034727; 17046587; 17047337; 17052299; 17052682; 17055359; 17072955; 17076613; 17079331; 17083041; 17090647; 17092389; 17094271; 17097497; 17101288; 17103073; 17107380; 17109502; 17112887; 17113059; 17113632; 17115186; 17115419; 17115422; 17119059; 17122961; 17123852; 17125598; 17130180; 17132891; 17135599; 17138053; 17138064; 17139467; 17142509; 17145371; 17150965; 17151125; 17161613; 17177164; 17182550; 17182572; 17182950; 17187019; 17192276; 17192490; 17192581; 17194482; 17194638; 17196171; 17197385; 17198275; 17203290; 17207568; 17208210; 17209781; 17213200; 17220301; 17223976; 17241868; 17241887; 17257312; 17261502; 17272771; 17273664; 17286233; 17286759; 17298206; 17298885; 17306245; 17307204; 17309100; 17310346; 17322283; 17324931; 17331078; 17335789; 17336597; 17338374; 17346257; 17355643; 17360657; 17362351; 17362770; 17363400; 17369174; 17373677; 17373716; 17374439; 17376903; 17379849; 17380888; 17392554; 17409234; 17412556; 17416433; 17416766; 17420140; 17428355; 17431659; 17439892; 17441979; 17442294; 17444587; 17448042; 17450584; 17452560; 17454884; 17463301; 17465679; 17466952; 17471097; 17472849; 17475670; 17476620; 17483704; 17487763; 17490702; 17496310; 17497030; 17497035; 17498265; 17498309; 17505301; 17506774; 17508011; 17509454; 17511783; 17519976; 17526950; 17530721; 17531096; 17531241; 17532054; 17544514; 17544674; 17548183; 17560462; 17582674; 17584642; 17594514; 17596140; 17597660; 17607501; 17608808; 17610900; 17612762; 17616429; 17617741; 17621267; 17623760; 17627181; 17627763; 17629591; 17641729; 17645589; 17652155; 17653646; 17654453; 17656329; 17665434; 17667842; 17668881; 17671745; 17671746; 17672997; 17684217; 17684929; 17686006; 17689974; 17694420; 17700210; 17703412; 17704111; 17705048; 17706955; 17711410; 17712756; 17716608; 17716703; 17716775; 17716980; 17724799; 17785926; 17805558; 17823083; 17823310; 17823890; 17845205; 17845635; 17847004; 17848119; 17848619; 17850436; 17851087; 17851695; 17869127; 17869650; 17875573; 17875759; 17876341; 17878722; 17878753; 17880940; 17889143; 17889209; 17898129; 17900510; 17908769; 17911088; 17911113; 17916761; 17916900; 17931612; 17938902; 17944600; 17950274; 17952446; 17952840; 17953695; 17953698; 17953945; 17956865; 17959884; 17965799; 17972945; 17975158; 17975159; 17977694; 17979192; 17979974; 17982069; 17982709; 17984211; 17988266; 17988804; 17994165; 17996468; 17998015; 18001296; 18003888; 18007247; 18024284; 18025155; 18027847; 18039346; 18039467; 18041006; 18041648; 18047677; 18048771; 18055234; 18056971; 18060032; 18060036; 18060802; 18064337; 18065201; 18065760; 18069022; 18070438; 18075466; 18075483; 18082358; 18086782; 18086924; 18088482; 18088554; 18091322; 18091699; 18157711; 18158110; 18158121; 18159174; 18163209; 18164040; 18165865; 18172744; 18176176; 18181010; 18182917; 18190463; 18191407; 18192685; 18198221; 18199986; 18205904; 18209571; 18211631; 18215266; 18215484; 18215601; 18216863; 18226879; 18234565; 18235016; 18239554; 18239642; 18243142; 18249219; 18251163; 18256065; 18257935; 18260177; 18260266; 18260730; 18261959; 18262272; 18267353; 18269659; 18271063; 18271757; 18273643; 18274637; 18274638; 18276608; 18276775; 18279814; 18281810; 18283248; 18284424; 18285696; 18292749; 18297540; 18300111; 18305316; 18305954; 18307517; 18307986; 18310089; 18310311; 18311435; 18312445; 18314542; 18316168; 18320358; 18321738; 18332163; 18336388; 18336871; 18337305; 18341424; 18344399; 18344712; 18346864; 18348986; 18353715; 18356242; 18356846; 18359883; 18364273; 18366487; 18375611; 18378582; 18380561; 18388036; 18388249; 18391842; 18393231; 18395522; 18395775; 18397431; 18398743; 18399716; 18402776; 18406623; 18418640; 18419107; 18420533; 18421029; 18427208; 18434913; 18435790; 18436879; 18439079; 18441098; 18443271; 18446552; 18448485; 18449426; 18450743; 18451782; 18453602; 18456276; 18458677; 18461289; 18462799; 18467705; 18469018; 18469355; 18469698; 18474224; 18479302; 18483242; 18485152; 18486766; 18487018; 18495419; 18495462; 18496509; 18502475; 18502564; 18502691; 18502965; 18508793; 18515365; 18522869; 18522933; 18523031; 18523355; 18528653; 18535190; 18538149; 18543249; 18547996; 18551071; 18556001; 18558283; 18560870; 18562207; 18565757; 18566306; 18566561; 18571528; 18573122; 18576303; 18577878; 18580350; 18580852; 18584045; 18589089; 18593632; 18596918; 18597410; 18600325; 18607165; 18608123; 18615482; 18616920; 18617366; 18617512; 18617605; 18617614; 18617679; 18621420; 18624749; 18627438; 18628242; 18632424; 18632425; 18633131; 18637012; 18638042; 18640689; 18649055; 18660489; 18661238; 18662595; 18665050; 18665387; 18665932; 18668419; 18673406; 18676404; 18676738; 18676870; 18680515; 18684932; 18684968; 18685607; 18689272; 18689695; 18692934; 18693004; 18694328; 18702109; 18704713; 18708672; 18710929; 18715339; 18719127; 18719610; 18728048; 18752089; 18752567; 18753312; 18753723; 18757054; 18758806; 18758908; 18759290; 18763028; 18773331; 18774574; 18777460; 18778820; 18780208; 18781131; 18782771; 18784373; 18784616; 18787381; 18792065; 18794066; 18796448; 18799077; 18799095; 18799360; 18800145; 18804384; 18810365; 18815552; 18818748; 18821666; 18825409; 18826654; 18832862; 18834707; 18841030; 18842358; 18843772; 18848327; 18922529; 18924133; 18925325; 18927546; 18930197; 18930842; 18931595; 18937577; 18937599; 18942706; 18942752; 18945465; 18948841; 18951205; 18951869; 18971305; 18971377; 18974155; 18974840; 18974842; 18975235; 18976446; 18980999; 18988929; 18990769; 18991689; 18992148; 18992196; 18992263; 18996291; 18997828; 19005290; 19005292; 19008611; 19009499; 19009622; 19010373; 19010690; 19011039; 19012493; 19013323; 19017034; 19019335; 19019369; 19027008; 19028820; 19029268; 19029276; 19031817; 19032817; 19035456; 19039953; 19050632; 19055487; 19056105; 19056642; 19058987; 19060757; 19064572; 19066003; 19072030; 19074641; 19074885; 19076825; 19077731; 19081678; 19084430; 19085695; 19086263; 19086955; 19089489; 19094228; 19106168; 19107369; 19107725; 19111610; 19117239; 19117745; 19118119; 19120897; 19121950; 19124510; 19126646; 19127455; 19128984; 19129371; 19130178; 19131662; 19131814; 19136380; 19139198; 19140096; 19140875; 19141488; 19147545; 19147624; 19147919; 19156204; 19157552; 19158563; 19164257; 19168699; 19168721; 19169973; 19170075; 19171135; 19176759; 19185507; 19188531; 19189403; 19200845; 19201396; 19203086; 19208585; 19209241; 19218687; 19220961; 19223152; 19225544; 19225954; 19226262; 19228610; 19233564; 19234509; 19238444; 19240061; 19240160; 19240794; 19242540; 19244371; 19249525; 19249913; 19252766; 19252806; 19257990; 19258923; 19260868; 19263529; 19265263; 19267250; 19267370; 19267406; 19268915; 19272082; 19272152; 19272615; 19272692; 19275586; 19275588; 19277666; 19278477; 19280716; 19282863; 19288024; 19299182; 19300393; 19303205; 19307187; 19325234; 19327240; 19328242; 19332120; 19333684; 19336370; 19336475; 19337556; 19337832; 19338208; 19338485; 19342252; 19347053; 19349293; 19349390; 19351789; 19358670; 19359268; 19375766; 19375805; 19376162; 19376428; 19376889; 19377212; 19377912; 19380809; 19387461; 19390056; 19401270; 19401628; 19403348; 19404549; 19404917; 19406470; 19407822; 19408175; 19408823; 19414645; 19419945; 19420105; 19422646; 19435922; 19436686; 19439300; 19442892; 19445568; 19448905; 19450686; 19453261; 19459788; 19460731; 19460789; 19467703; 19470040; 19474090; 19479237; 19483720; 19484147; 19491251; 19491387; 19494710; 19495883; 19497039; 19497711; 19501493; 19502081; 19503017; 19505401; 19505916; 19505919; 19506792; 19508433; 19522649; 19522765; 19523152; 19526283; 19527514; 19527699; 19527938; 19542367; 19542902; 19543846; 19546559; 19548631; 19549135; 19550417; 19551157; 19552919; 19553556; 19554087; 19554506; 19555357; 19558856; 19559392; 19562463; 19565371; 19566553; 19567922; 19569017; 19570208; 19573080; 19578796; 19579695; 19581928; 19583994; 19585495; 19585572; 19590686; 19592000; 19594368; 19595462; 19596318; 19597488; 19604707; 19621989; 19622906; 19624695; 19626047; 19626399; 19635908; 19640729; 19644155; 19648274; 19650110; 19652645; 19658188; 19661010; 19665805; 19669729; 19670170; 19671870; 19672706; 19676135; 19680808; 19683555; 19687301; 19688109; 19690405; 19690422; 19692168; 19692203; 19698128; 19698145; 19701194; 19706022; 19706826; 19707465; 19710156; 19711225; 19715970; 19728052; 19729601; 19729797; 19733878; 19733948; 19734419; 19734969; 19736361; 19738620; 19741197; 19741199; 19744034; 19744138; 19747414; 19750100; 19751193; 19751561; 19751774; 19758168; 19760027; 19760348; 19761682; 19762082; 19773279; 19773451; 19775068; 19778488; 19783680; 19784814; 19789190; 19789511; 19790045; 19796538; 19802007; 19805069; 19805306; 19822443; 19825523; 19825524; 19828434; 19833146; 19833726; 19837795; 19844779; 19846277; 19847432; 19849941; 19850661; 19851831; 19853505; 19854106; 19857655; 19857676; 19858310; 19860911; 19862334; 19876004; 19877033; 19877052; 19877065; 19878271; 19878981; 19889475; 19890236; 19892918; 19897004; 19898853; 19902173; 19907660; 19909503; 19913121; 19914334; 19915052; 19919828; 19920796; 19926874; 19933216; 19934301; 19934771; 19935847; 19936367; 19936625; 19937696; 19938160; 19938957; 19940521; 19942621; 19945777; 19946956; 19948975; 19953100; 19956635; 19957198; 19965896; 19966016; 19996656; 20001857; 20005739; 20007708; 20012010; 20012528; 20012999; 20015663; 20016056; 20016208; 20030788; 20031642; 20032122; 20035059; 20043171; 20043205; 20044471; 20044998; 20047081; 20052801; 20056178; 20056442; 20059469; 20060205; 20061317; 20061995; 20074813; 20080841; 20082482; 20083555; 20083667; 20083961; 20084405; 20088988; 20091488; 20097948; 20100571; 20100935; 20101226; 20103767; 20106948; 20107186; 20113359; 20116278; 20118277; 20121167; 20124101; 20129796; 20132036; 20132164; 20132806; 20137666; 20138641; 20144192; 20145198; 20145925; 20148189; 20149313; 20156727; 20156756; 20157327; 20159251; 20160059; 20160446; 20161734; 20164544; 20171025; 20171114; 20171115; 20173430; 20175976; 20176930; 20178529; 20186139; 20187772; 20189706; 20190550; 20190679; 20195402; 20195952; 20200229; 20202139; 20206549; 20206550; 20207250; 20213229; 20217044; 20218918; 20222161; 20222971; 20227485; 20228669; 20229017; 20229266; 20237486; 20300619; 20302034; 20303780; 20303782; 20305143; 20306666; 20306684; 20331841; 20333461; 20340055; 20350647; 20352618; 20354000; 20355242; 20358354; 20361349; 20361391; 20368384; 20370995; 20375583; 20375612; 20380698; 20381257; 20383729; 20384434; 20385468; 20386787; 20388088; 20393813; 20396801; 20398511; 20399529; 20405297; 20417488; 20418110; 20419805; 20424554; 20430366; 20430640; 20431935; 20436380; 20437058; 20438838; 20441409; 20443669; 20443866; 20452482; 20453000; 20454933; 20456313; 20457835; 20459474; 20460375; 20463618; 20465571; 20465852; 20468060; 20468064; 20470305; 20473875; 20478455; 20482449; 20482813; 20483707; 20484443; 20484656; 20484876; 20485444; 20486195; 20490277; 20493832; 20502044; 20503287; 20506652; 20507572; 20511231; 20516073; 20523065; 20526368; 20535794; 20536507; 20536609; 20551628; 20562100; 20564140; 20565368; 20565774; 20565840; 20568250; 20570482; 20585578; 20587610; 20588103; 20592333; 20592377; 20593431; 20595152; 20598594; 20599261; 20602615; 20603037; 20603050; 20607798; 20608170; 20609172; 20617559; 20621720; 20622166; 20623261; 20626020; 20628086; 20628624; 20631726; 20632037; 20633553; 20637651; 20640364; 20640910; 20644561; 20650996; 20651278; 20653817; 20653818; 20655350; 20660911; 20661259; 20667498; 20673868; 20675757; 20681812; 20682687; 20685768; 20686866; 20687222; 20702406; 20709566; 20711808; 20715974; 20716621; 20718660; 20726000; 20730440; 20731043; 20731121; 20732366; 20733339; 20734064; 20736797; 20739337; 20800651; 20804645; 20811626; 20817073; 20819268; 20820764; 20827447; 20835611; 20836881; 20839488; 20843912; 20845058; 20847078; 20848459; 20848848; 20851233; 20855565; 20860222; 20860759; 20860764; 20864555; 20874851; 20877724; 20881337; 20883364; 20884746; 20887801; 20888901; 20889146; 20929576; 20930550; 20934730; 20937002; 20937006; 20937539; 20939703; 20942594; 20942931; 20951096; 20951370; 20951753; 20953574; 20953967; 20954977; 20960273; 20961463; 20964870; 20967696; 20970549; 20971801; 20973681; 20974296; 20978825; 21037509; 21037957; 21040233; 21040938; 21042834; 21044752; 21048114; 21048327; 21054880; 21055228; 21057561; 21059493; 21061265; 21067752; 21070631; 21072509; 21083649; 21086908; 21087078; 21090238; 21090240; 21091907; 21095135; 21104146; 21106853; 21112385; 21114131; 21116047; 21123547; 21127061; 21131162; 21131394; 21132384; 21147638; 21147639; 21147711; 21148399; 21148800; 21149504; 21153318; 21153418; 21153673; 21155043; 21157373; 21163075; 21166654; 21169033; 21173731; 21177727; 21178846; 21179199; 21179572; 21180882; 21181220; 21190512; 21190868; 21196492; 21196908; 21198209; 21199393; 21207764; 21209110; 21209948; 21211272; 21211286; 21220315; 21226932; 21228692; 21229891; 21233768; 21235536; 21238488; 21239715; 21241793; 21245598; 21245987; 21252539; 21253506; 21253618; 21255427; 21258401; 21277639; 21278254; 21278793; 21279994; 21282066; 21282107; 21282511; 21287288; 21292497; 21293887; 21294915; 21296109; 21298325; 21300046; 21307288; 21312239; 21314275; 21316985; 21320026; 21321193; 21321840; 21321954; 21323660; 21329460; 21333594; 21334078; 21334625; 21343371; 21350025; 21352255; 21353307; 21353594; 21353595; 21355310; 21357189; 21362045; 21376376; 21377916; 21382729; 21385538; 21388350; 21393356; 21407237; 21408055; 21410438; 21414799; 21419646; 21421628; 21421702; 21422077; 21424184; 21436461; 21442077; 21454528; 21455087; 21466366; 21468030; 21468565; 21474330; 21474332; 21474440; 21478032; 21481788; 21490101; 21490132; 21492332; 21493089; 21497830; 21498913; 21511827; 21512395; 21515913; 21518761; 21518763; 21520044; 21520052; 21526159; 21527852; 21530175; 21535154; 21535317; 21536090; 21540553; 21546767; 21547256; 21559372; 21562768; 21565862; 21586579; 21591973; 21592994; 21594636; 21595886; 21600698; 21611774; 21619709; 21619877; 21620438; 21621860; 21623995; 21626471; 21632260; 21639625; 21640816; 21645137; 21656745; 21658317; 21664423; 21668366; 21681687; 21684758; 21689404; 21697747; 21700657; 21702700; 21708999; 21709158; 21712995; 21714933; 21716327; 21729562; 21740541; 21752694; 21757719; 21757746; 21762913; 21767605; 21769475; 21771210; 21773651; 21776298; 21778161; 21795706; 21801267; 21802729; 21811961; 21811986; 21813290; 21833041; 21833517; 21843047; 21845403; 21845872; 21845926; 21851175; 21854184; 21858117; 21863560; 21870243; 21875833; 21876502; 21880216; 21881374; 21881585; 21886773; 21889771; 21898505; 21898706; 21898993; 21900165; 21902578; 21911244; 21912394; 21913828; 21919032; 21921047; 21923250; 21925926; 21929671; 21931651; 21933586; 21935443; 21938724; 21952248; 21953462; 21954831; 21957581; 21959016; 21961943; 21965736; 21966220; 21967801; 21976712; 21977994; 21982018; 21983734; 21984125; 21989726; 21995322; 21995333; 21996739; 22000300; 22004976; 22010855; 22012292; 22015309; 22015454; 22018243; 22019000; 22019436; 22021612; 22023383; 22024650; 22025890; 22027148; 22030312; 22030478; 22035595; 22046434; 22048241; 22052387; 22053612; 22055894; 22068677; 22068875; 22070971; 22072054; 22072539; 22075267; 22078452; 22082020; 22084439; 22105366; 22107760; 22113576; 22113815; 22115178; 22117975; 22119941; 22122521; 22132241; 22133543; 22135153; 22140472; 22150003; 22155094; 22156348; 22158046; 22159219; 22171160; 22171994; 22174866; 22180363; 22187702; 22192353; 22194466; 22196489; 22203929; 22203932; 22205395; 22209080; 22228719; 22229879; 22230324; 22234866; 22242132; 22243796; 22252554; 22261689; 22265273; 22272811; 22289556; 22296202; 22296277; 22301094; 22301607; 22303451; 22304944; 22306454; 22324945; 22330622; 22334615; 22337942; 22349830; 22350281; 22357713; 22362117; 22364742; 22365967; 22366404; 22367386; 22369948; 22382666; 22385075; 22386866; 22386961; 22387051; 22389450; 22403134; 22407921; 22410655; 22417709; 22417897; 22420891; 22421411; 22422499; 22425021; 22426116; 22426177; 22426431; 22427231; 22427564; 22427681; 22428468; 22431998; 22434029; 22436412; 22441019; 22445549; 22452603; 22452847; 22457277; 22457856; 22459738; 22462419; 22466975; 22468900; 22473756; 22475215; 22479352; 22481167; 22486303; 22491065; 22496403; 22496888; 22503230; 22507133; 22508062; 22513191; 22516897; 22521547; 22531363; 22531887; 22532634; 22532637; 22539302; 22552350; 22553973; 22554382; 22562290; 22563871; 22565057; 22569438; 22571276; 22575724; 22577092; 22579111; 22579472; 22580582; 22580886; 22583691; 22586157; 22592039; 22595649; 22615316; 22616715; 22617158; 22617683; 22634718; 22642105; 22644871; 22647735; 22648519; 22667128; 22672862; 22673037; 22677780; 22677919; 22681487; 22686131; 22687336; 22688021; 22692705; 22695063; 22696056; 22698992; 22701584; 22710869; 22711534; 22711691; 22714907; 22726456; 22728071; 22734797; 22739041; 22739042; 22740511; 22743617; 22752116; 22753384; 22761193; 22761857; 22763042; 22763101; 22769440; 22773460; 22782910; 22796263; 22808178; 22810465; 22814248; 22814515; 22818022; 22819248; 22819326; 22819759; 22836752; 22843654; 22843899; 22849850; 22867712; 22869038; 22872134; 22883217; 22883518; 22894740; 22895491; 22904305; 22906998; 22908985; 22921280; 22923190; 22923236; 22924939; 22927445; 22931953; 22948743; 22956742; 22964303; 22968454; 22976070; 22977256; 22977658; 22982189; 22983646; 22984080; 22984233; 22986484; 22990627; 23009764; 23013217; 23013513; 23018032; 23019398; 23022409; 23025692; 23027872; 23027890; 23034889; 23036532; 23038213; 23043537; 23044206; 23052480; 23052692; 23056300; 23058014; 23058031; 23062767; 23065424; 23071313; 23073774; 23078005; 23078984; 23086036; 23087143; 23088295; 23092922; 23097096; 23100065; 23116190; 23117246; 23118848; 23124416; 23124693; 23136553; 23136554; 23136556; 23142265; 23154434; 23158132; 23159256; 23159283; 23161179; 23166328; 23168096; 23168996; 23175672; 23177780; 23178494; 23180271; 23185547; 23190106; 23195133; 23197841; 23198942; 23204162; 23206733; 23207068; 23219526; 23224211; 23225885; 23227240; 23232337; 23233117; 23236659; 23242654; 23246692; 23250823; 23251686; 23255681; 23257175; 23262029; 23265967; 23269580; 23272057; 23276493; 23276701; 23281720; 23289913; 23298711; 23300019; 23303450; 23311694; 23320781; 23322593; 23322904; 23326472; 23332218; 23336844; 23344094; 23347173; 23348396; 23349093; 23349310; 23350010; 23357299; 23357300; 23363979; 23364322; 23369187; 23371411; 23375410; 23377045; 23378274; 23378460; 23380741; 23389820; 23392112; 23399848; 23408619; 23411129; 23415255; 23421536; 23423626; 23425215; 23428306; 23441314; 23444260; 23461479; 23461851; 23470607; 23470916; 23478175; 23480455; 23484124; 23487197; 23489698; 23490068; 23490413; 23498057; 23505291; 23506572; 23509207; 23510010; 23510983; 23517877; 23524623; 23525184; 23536722; 23538947; 23555579; 23555719; 23559389; 23561329; 23564454; 23564789; 23567762; 23569034; 23582441; 23582716; 23591770; 23593036; 23593346; 23601055; 23616277; 23617681; 23619188; 23622344; 23625043; 23630220; 23632023; 23633489; 23633491; 23637318; 23637926; 23638863; 23639700; 23648010; 23651237; 23654074; 23657600; 23658720; 23665320; 23666170; 23674845; 23701120; 23735697; 23737648; 23743311; 23746176; 23748363; 23756867; 23761639; 23762476; 23762858; 23766379; 23770252; 23774701; 23776669; 23777202; 23784949; 23785756; 23791019; 23792529; 23807226; 23815102; 23819403; 23821953; 23828679; 23832741; 23844163; 23884764; 23889749; 23893709; 23910616; 23913484; 23921153; 23928667; 23929842; 23933386; 23936495; 23953057; 23953866; 23954444; 23954871; 23968978; 23969696; 24032723; 24043651; 24044580; 24051035; 24077340; 24078775; 24114793; 24120137; 24136650; 24152848; 24186266; 24200066; 24243972; 24265545; 24294778; 24299316; 24308236; 24314919; 24340926; 24409674; 24434384; 24547612,,,,,,,,,,,,,,,OGG:3000003569,,,,,,,interleukin 6,,,,,,,,,,,,,"Other designations: B-cell differentiation factor|B-cell stimulatory factor 2|BSF-2|CDF|CTL differentiation factor|IFN-beta-2|hybridoma growth factor|interferon beta-2|interferon, beta 2|interleukin 6 (interferon, beta 2)|interleukin BSF-2|interleukin-6",,IL6,,,,,,,,,,,,,,,,,,,,,,,3569,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,IL6,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0005077,CYP2A6 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0001553,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1548,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001548,,,,,,,,,,,,,TXPO:0005077,,,,,,,,,,,,,,,,,,,,,,CYP2A6 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005079,EPB41L3 (mol),DAL-1|differentially expressed in adenocarcinoma of the lung 1,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:13823|NCBI-Rat-GeneID:116724|NCBI-Human-GeneID:23136,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,DAL-1|differentially expressed in adenocarcinoma of the lung 1,,,,,TXPO:0005079,,,,,,,,,,,,,,,,,,,,,,EPB41L3 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005078,CYP3A7 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0001554,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1551,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001551,,,,,,,,,,,,,TXPO:0005078,,,,,,,,,,,,,,,,,,,,,,CYP3A7 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005072,liver cancer dependent molecule (mouse in vitro),,"Liver cancer dependent molecule is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of Liver cancer as a gene product.
Gene profile:Mouse",false,,,http://purl.obolibrary.org/obo/TXPO_0000837,,,,,,,,,,,,,,,,,,,,,,"Liver cancer dependent molecule is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of Liver cancer as a gene product.
Gene profile:Mouse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005072,,,,,,,,,,,,,,,,,,,,,,liver cancer dependent molecule (mouse in vitro),,,,,,,,,,,http://purl.obolibrary.org/obo/NCBITaxon_10090,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005073,CDH1 (canonical) [hepatocarcinogenesis],E-cadherin,,false,,,http://purl.obolibrary.org/obo/TXPO_0005063|http://purl.obolibrary.org/obo/TXPO_0005074,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:83502|NCBI-Human-GeneID:999|NCBI-Mouse-GeneID:12550,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,E-cadherin,,,,,TXPO:0005073,,,,,,,,,,,,,,,,,,,,,,CDH1 (canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005075,CDT1 (human) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_0004467,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:81620,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005075,,,,,,,,,,,,,,,,,,,,,,CDT1 (human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005071,CAR (mouse) [hepatocarcinogenesis],Constitutive Androstane Receptor|NR1I3,,false,,,http://purl.obolibrary.org/obo/TXPO_0003862|http://purl.obolibrary.org/obo/TXPO_0005072,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:12355,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Constitutive Androstane Receptor|NR1I3,,,,,TXPO:0005071,,,,,,,,,,,,,,,,,,,,,,CAR (mouse) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005076,CYP2A13 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0001553,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1553,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001553,,,,,,,,,,,,,TXPO:0005076,,,,,,,,,,,,,,,,,,,,,,CYP2A13 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005070,liver cancer dependent molecule (rat),,"Liver cancer dependent molecule is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of Liver cancer as a gene product.
Gene profile:Mouse",false,,,http://purl.obolibrary.org/obo/TXPO_0000837,,,,,,,,,,,,,,,,,,,,,,"Liver cancer dependent molecule is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of Liver cancer as a gene product.
Gene profile:Mouse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005070,,,,,,,,,,,,,,,,,,,,,,liver cancer dependent molecule (rat),,,,,,,,,,,http://purl.obolibrary.org/obo/NCBITaxon_10114,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005074,CDH1 (mol),,,false,,,http://purl.obolibrary.org/obo/IMR_0000168,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:83502|NCBI-Human-GeneID:999|NCBI-Mouse-GeneID:12550,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005074,,,,,,,,,,,,,,,,,,,,,,CDH1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000690,increasing the demand for response to ER stress [ER stress] [ER stress (moderate) ],,"Increasing demand for response to ER stress is a subtype of increasing the demand for response to stress: A process that changes the functional demand for the response to the edoplasmic reticulum (ER) stress to be higher.
This entity is a specific course-dependent process. This process can constitute the course of ER stress (moderate).",false,,,http://purl.obolibrary.org/obo/TXPO_0000734,,,,,,,,,,,,,,,,,,,,,,"Increasing demand for response to ER stress is a subtype of increasing the demand for response to stress: A process that changes the functional demand for the response to the edoplasmic reticulum (ER) stress to be higher.
This entity is a specific course-dependent process. This process can constitute the course of ER stress (moderate).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000690,,,,,,,,,,,,,,,,,,,,,,increasing the demand for response to ER stress [ER stress] [ER stress (moderate) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000691,hypoxia [ER stress],,"reduced oxygenation of body tissues resulting in the decreased pressure of this component of body gases; commonly due to hypoxemia
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/MP_0005039,,,,,,,,,,,,,,,,,,,,,,"reduced oxygenation of body tissues resulting in the decreased pressure of this component of body gases; commonly due to hypoxemia
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000691,,,,,,,,,,,,,,,,,,,,,,hypoxia [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000696,changing activity of eIF2a by PERK [PERK - eIF2A pathway],,"A process that changes the activity of the eIF2a by PERK.
This entity is a specific course-dependent process. This process can constitute the course of PERK - eIF2A pathway.",false,,,http://purl.obolibrary.org/obo/TXPO_0001861,,,,,,,,,,,,,,,,,,,,,,"A process that changes the activity of the eIF2a by PERK.
This entity is a specific course-dependent process. This process can constitute the course of PERK - eIF2A pathway.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000549,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002755,,,,,,,,,,,TXPO:0000696,,,,,,,,,,,,,,,,,,,,,,changing activity of eIF2a by PERK [PERK - eIF2A pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000695,ER stress response gene expression via PERK [ER stress],,"ER stress response gene expression via PERK is a subtype of gene expression: The process in which a gene sequence is converted into a mature ER stress response gene product or products (proteins or RNA) by PERK.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001626|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"ER stress response gene expression via PERK is a subtype of gene expression: The process in which a gene sequence is converted into a mature ER stress response gene product or products (proteins or RNA) by PERK.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000695,,,,,,,,,,,,,,,,,,,,,,ER stress response gene expression via PERK [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000694,lysosomal cholesterol storage [Phospholipidosis],,"Lysosomal cholesterol storage is a subtype of cholesterol storage: A process that keeps cholesterol in the lysosome.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0001537,,,,,,,,,,,,,,,,,,,,,,"Lysosomal cholesterol storage is a subtype of cholesterol storage: A process that keeps cholesterol in the lysosome.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000694,,,,,,,,,,,,,,,,,,,,,,lysosomal cholesterol storage [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000698,gene expression by ATF4 [ER stress],,"Gene expression by ATF4 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) by ATF4.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.|ATF4 is a transcription factor and activates expression of IL-8, MCP1, IGFBP-1, CHOP, HERP1 and ATF3.",false,,,http://purl.obolibrary.org/obo/TXPO_0003736|http://purl.obolibrary.org/obo/TXPO_0002433,,,,,,,,,,,,,,,,,,,,PMID:23334697|R-HSA-380994,,"Gene expression by ATF4 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) by ATF4.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001907,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000698,,,,,,,,,,,,,,,,,,,,"ATF4 is a transcription factor and activates expression of IL-8, MCP1, IGFBP-1, CHOP, HERP1 and ATF3.",,gene expression by ATF4 [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000697,eIFF2a phophorylation [ER stress],,"EIF2a phosphorylation is a subtype of phosphorylation: The process of introducing a phosphate group into eIF2a.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001899|http://purl.obolibrary.org/obo/TXPO_0003736,,,,,,,,,,,,,,,,,,,,,,"EIF2a phosphorylation is a subtype of phosphorylation: The process of introducing a phosphate group into eIF2a.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000416|http://purl.obolibrary.org/obo/TXPO_0000707,,,,,,,,,,,TXPO:0000697,,,,,,,,,,,,,,,,,,,,,,eIFF2a phophorylation [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000692,lysosomal proliferation in hepatocyte,,Lysosomal proliferation in hepatocyte is a subtype of increasing number of organelle: A process that becomes larger in the number of lysosome in hepatocyte(s).,false,,,http://purl.obolibrary.org/obo/TXPO_0003303,,,,,,,,,,,,,,,,,,,,,,Lysosomal proliferation in hepatocyte is a subtype of increasing number of organelle: A process that becomes larger in the number of lysosome in hepatocyte(s).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000692,,,,,,,,,,,,,,,,,,,,,,lysosomal proliferation in hepatocyte,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000182,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000699,changing speed,,Changing velocity is a subtype of changing quality: A process that chnges the velocity of the object.,false,,,http://purl.obolibrary.org/obo/TXPO_0000415,,,,,,,,,,,,,,,,,,,,,,Changing velocity is a subtype of changing quality: A process that chnges the velocity of the object.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000699,,,,,,,,,,,,,,,,,,,,,,changing speed,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000693,glycolipid biosynthetic process [ER stress],,"The chemical reactions and pathways resulting in the formation of glycolipid, a class of 1,2-di-O-acylglycerols joined at oxygen 3 by a glycosidic linkage to a carbohydrate part (usually a mono-, di- or tri-saccharide).
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/GO_0009247,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways resulting in the formation of glycolipid, a class of 1,2-di-O-acylglycerols joined at oxygen 3 by a glycosidic linkage to a carbohydrate part (usually a mono-, di- or tri-saccharide).
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000693,,,,,,,,,,,,,,,,,,,,,,glycolipid biosynthetic process [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0002367,cytokine production involved in immune response,,"The appearance of a cytokine due to biosynthesis or secretion following a cellular stimulus contributing to an immune response, resulting in an increase in its intracellular or extracellular levels.",false,,,http://purl.obolibrary.org/obo/GO_0001816,,,,,,,,,,,,,,,,,,,,,,"The appearance of a cytokine due to biosynthesis or secretion following a cellular stimulus contributing to an immune response, resulting in an increase in its intracellular or extracellular levels.",,,,,cytokine production involved in immune response,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0002367,,,,,,,,,,,,,,,,,,,,,,cytokine production involved in immune response,,,,,,,http://purl.obolibrary.org/obo/go.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000011,IL-1 (mol),interleukin-1,,false,,,http://purl.obolibrary.org/obo/IMR_0000007,,,,,,,,,,,,,,,,,,,,GO:0005149,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000622,,,,,interleukin-1,,,,,IMR:0000011,,,,,,,,,,,,,,,,,,,,,,IL-1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000010965,ACOT2,,"Other designations: acyl-coenzyme A thioester hydrolase 2a|acyl-coenzyme A thioesterase 2, mitochondrial|long-chain acyl-CoA thioesterase 2|mitochondrial acyl-CoA thioesterase 1|peroxisomal long-chain acyl-coA thioesterase 2",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,ZAP128|CTE-IA|PTE2|MTE1|CTE1A|PTE2A,,,,,,,,,,,,14,,,,,,Vega:OTTHUMG00000171608|HPRD:10173|HGNC:18431|MIM:609972|Ensembl:ENSG00000119673,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,acyl-CoA thioesterase 2,,,14q24.3,,,,,,,,,,,,,,,,"GO_0000038 (EC: IDA, PMID:16940157); GO_0001676 (EC: IDA, PMID:16940157); GO_0005102 (EC: IPI); GO_0005739 (EC: IDA, PMID:16940157); GO_0006637 (EC: IDA, PMID:10944470); GO_0016290 (EC: IEA); GO_0047617 (EC: IDA, PMID:10944470)",,,,,,,,,PMID:7596406; 8125298; 10944470; 12477932; 12665801; 14702039; 15007068; 15489334; 16103133; 16940157; 17353931; 19497300; 20178365; 20379614; 20877624; 21139048; 21890473; 21963094; 21987572,,,,,,,,,,,,,,,OGG:3000010965,,,,,,,acyl-CoA thioesterase 2,,,,,,,,,,,,,"Other designations: acyl-coenzyme A thioester hydrolase 2a|acyl-coenzyme A thioesterase 2, mitochondrial|long-chain acyl-CoA thioesterase 2|mitochondrial acyl-CoA thioesterase 1|peroxisomal long-chain acyl-coA thioesterase 2",,ACOT2,,,,,,,,,,,,,,,,,,,,,,,10965,,,,,,,,9606,,,,,,,,,,,,,,,,,,,ACOT2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_35741,glycerolipid,,Any member of the group of lipids containing a common glycerol backbone to which at least one fatty acid-derived group is attached.,false,,,http://purl.obolibrary.org/obo/CHEBI_18059,,,,,,,,,,,,,,,,,,,,IMR:0001382,,Any member of the group of lipids containing a common glycerol backbone to which at least one fatty acid-derived group is attached.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:35741,,,,,,,,,,,,,,,,,,,,,,glycerolipid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100268,Rho GAP,Rho GTPase-activating protein,,false,,,http://purl.obolibrary.org/obo/IMR_0000442,,,,,,,,,,,,,,,,,,,,GO:0005100,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Rho GTPase-activating protein,,,,,IMR:0100268,,,,,,,,,,,,,,,,,,,,,,Rho GAP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000022843,PPM1E,,Other designations: ca(2+)/calmodulin-dependent protein kinase phosphatase N|caMKP-nucleus|nuclear calmodulin-dependent protein kinase phosphatase|partner of PIX 1|partner of PIX-alpha|partner of PIXA|protein phosphatase 1E|protein phosphatase 1E (PP2C domain containing),false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,PP2CH|POPX1|caMKN|CaMKP-N,,,,,,,,,,,,17,,,,,,HPRD:17888|HGNC:19322,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"protein phosphatase, Mg2+/Mn2+ dependent, 1E",,,17q22,,,,,,,,,,,,,,,,"GO_0004722 (EC: IDA); GO_0005515 (EC: IPI, PMID: 11864573); GO_0005634 (EC: IDA); GO_0005730 (EC: IDA); GO_0005739 (EC: IEA); GO_0006469 (EC: IDA, PMID: 11864573); GO_0035690 (EC: IDA); GO_0035970 (EC: IDA); GO_0043234 (EC: IDA, PMID: 11864573); GO_0046872 (EC: IEA); GO_0051496 (EC: IDA, PMID: 11864573)",,,,,,,,,PMID: 10470851; 11726284; 11864573; 12477932; 15496589; 15680915; 17043677; 17897624; 17903297; 18029348; 20801214; 23620142; 23666239,,,,,,,,,,,,,,,OGG:3000022843,,,,,,,"protein phosphatase, Mg2+/Mn2+ dependent, 1E",,,,,,,,,,,,,Other designations: ca(2+)/calmodulin-dependent protein kinase phosphatase N|caMKP-nucleus|nuclear calmodulin-dependent protein kinase phosphatase|partner of PIX 1|partner of PIX-alpha|partner of PIXA|protein phosphatase 1E|protein phosphatase 1E (PP2C domain containing),,PPM1E,,,,,,,,,,,,,,,,,,,,,,,22843,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,PPM1E,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000579,IFN alpha-9,,,false,,,http://purl.obolibrary.org/obo/IMR_0100386,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000579,,,,,,,,,,,,,,,,,,,,,,IFN alpha-9,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0051168,nuclear export,nucleus export|export from nucleus,The directed movement of substances out of the nucleus.,false,,,http://purl.obolibrary.org/obo/GO_0051169,,,,,,,,,,,,,,,,,,,,,,The directed movement of substances out of the nucleus.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005634,,nucleus export|export from nucleus,,,,,GO:0051168,,,,,,,,,,,,,,,,,,,,,,nuclear export,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0051169,nuclear transport,nucleus transport,"The directed movement of substances into, out of, or within the nucleus.",false,,,http://purl.obolibrary.org/obo/GO_0006810,,,,,,,,,,,,,,,,,,,,,,"The directed movement of substances into, out of, or within the nucleus.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,nucleus transport,,,,,GO:0051169,,,,,,,,,,,,,,,,,,,,,,nuclear transport,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005634,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100594,PI3-kinase p110 subunit delta,"PI3K|Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit, delta isoform|p110delta|PtdIns-3-kinase p110",,false,,,http://purl.obolibrary.org/obo/IMR_0000267,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"PI3K|Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit, delta isoform|p110delta|PtdIns-3-kinase p110",,,,,IMR:0100594,,,,,,,,,,,,,,,,,,,,,,PI3-kinase p110 subunit delta,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010536,40S ribosomal protein S11,40S small ribosomal protein 11,,false,,,http://purl.obolibrary.org/obo/IMR_0000896,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,40S small ribosomal protein 11,,,,,IMR:0010536,,,,,,,,,,,,,,,,,,,,,,40S ribosomal protein S11,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003525,vacuolation [Liver Pathological Findings][Phospholipidosis],,"Fatty change [Liver PathologicalFindings] is a type of finding observed in hepatocytes. Lesions are observed as lipid droplets consisting of neutral fat in the hepatocyte based on pathological morphology.
This finding is observable in the course of phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003524,,,,,,,,,,,,,,,,,,,,,,"Fatty change [Liver PathologicalFindings] is a type of finding observed in hepatocytes. Lesions are observed as lipid droplets consisting of neutral fat in the hepatocyte based on pathological morphology.
This finding is observable in the course of phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003525,,,,,,,"A metabolic disorder of neutral fat causes fatty change.
Lipid droplets consisting of large and small neutral fats (triglycerides) increase in the cytoplasm of hepatocytes.
In the case of large lipid droplets, the uneven distribution of nuclei is observed, but in the case of small loose droplets (microvesicular fatty change), uneven distribution of nuclei is not observed.
According to the distribution, it classifies into centrilobular, periportal, and diffuse type.",,,,,,,,,,,,,,,vacuolation [Liver Pathological Findings][Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005737,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003529,Sgpl1 (mouse)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000014|http://purl.obolibrary.org/obo/TXPO_0003278,,,,,,,,,,,,,,,,,,,,http://omim.org/entry/603729|NCBI-Mouse-GeneID:20397|PMID:2061324|PMID:17090686|PMID:20097939|PMID:26886371,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003529,,,,,,,,,,,,,,,,,,,,,,Sgpl1 (mouse)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003520,metabolic intermediate accumulation [Glutathione depletion],,"Metabolic intermediate accumulation is a subtype of accumulation of substances in a biological object: A process that keeps intermediate(s) of metabolism in an organism, tissue, organelle, or cell.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0000576|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,,,"Metabolic intermediate accumulation is a subtype of accumulation of substances in a biological object: A process that keeps intermediate(s) of metabolism in an organism, tissue, organelle, or cell.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001193,,,,,,,,,,,TXPO:0003520,,,,,,,,,,,,,,,,,,,,,,metabolic intermediate accumulation [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003526,myelin figure in lysosome [Phospholipidosis],,"myelin figure in lysosome [Liver Pathological Findings] is a type of finding observed in the liver. Based on pathological morphology, lesions are observed as myelin-like layered structures under electron microscopy.
This finding is observable in the course of phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001508,,,,,,,,,,,,,,,,,,,,,,"myelin figure in lysosome [Liver Pathological Findings] is a type of finding observed in the liver. Based on pathological morphology, lesions are observed as myelin-like layered structures under electron microscopy.
This finding is observable in the course of phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003526,,,,,,,"The presence of phospholipid inclusions are characterized by the presence of cytoplasmic vacuoles seen under the electron microscope as dense cytoplasmic myelin-like bodies showing a concentric lamellar structure with  a periodicity of 4-4.5 nm along with an amorphorous matrix within a single membrane-bound lysosomal space.

Histopathology of preclinical toxicity studies : interpretation and relevance in drug safety studies, Peter Greaves.
4th ed. Amsterdam ; Boston : Elsevier/AP, 2012.",,,,,,,,,,,,,,,myelin figure in lysosome [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005764,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003527,moderate accumulation of abnormal proteins in ER,,Moderate accumulation of abnormal proteins in ER is a subtype of accumulation of abnormal proteins in ER: A process that keeps abnormal protein(s) in the ER (endoplasmic reticulum) moderately.,false,,,http://purl.obolibrary.org/obo/TXPO_0002187,,,,,,,,,,,,,,,,,,,,,,Moderate accumulation of abnormal proteins in ER is a subtype of accumulation of abnormal proteins in ER: A process that keeps abnormal protein(s) in the ER (endoplasmic reticulum) moderately.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003527,,,,,,,,,,,,,,,,,,,,,,moderate accumulation of abnormal proteins in ER,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003528,severe accumulation of abnormal proteins in ER,,Severe accumulation of abnormal proteins in ER is a subtype of accumulation of abnormal proteins in ER: A process that keeps abnormal protein(s) in the ER (endoplasmic reticulum) severely.,false,,,http://purl.obolibrary.org/obo/TXPO_0002187,,,,,,,,,,,,,,,,,,,,,,Severe accumulation of abnormal proteins in ER is a subtype of accumulation of abnormal proteins in ER: A process that keeps abnormal protein(s) in the ER (endoplasmic reticulum) severely.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003528,,,,,,,,,,,,,,,,,,,,,,severe accumulation of abnormal proteins in ER,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003522,ground glass appearance [Liver Pathological Findings] [Ground glass appearance (course)],,"Ground glass appearance [Liver PathologicalFindings] is a type of finding observed in hepatocyte cytoplasm. Based on the pathological morphology, lesions are observed as a frosted-like change in whole or most of the hepatocytes.
This finding is observable in the course of ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0000060,,,,,,,,,,,,,,,,,,,,,,"Ground glass appearance [Liver PathologicalFindings] is a type of finding observed in hepatocyte cytoplasm. Based on the pathological morphology, lesions are observed as a frosted-like change in whole or most of the hepatocytes.
This finding is observable in the course of ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003522,,,,,,,,,,,,,,,,,,,,,,ground glass appearance [Liver Pathological Findings] [Ground glass appearance (course)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003523,eosinophilic granular degeneration [Liver Pathological Findings] [eosinogranular degeneration (course) ],,"Eosinophilic granular degeneration [Liver PathologicalFindings]  is a type of finding observed in hepatocytes. Lesions are observed in the form that the cytoplasm presents eosinophilic granules based on pathological morphology.
This finding is observable as a result of increasing peroxisome caused by PPAR.",false,,,http://purl.obolibrary.org/obo/TXPO_0003501,,,,,,,,,,,,,,,,,,,,,,"Eosinophilic granular degeneration [Liver PathologicalFindings]  is a type of finding observed in hepatocytes. Lesions are observed in the form that the cytoplasm presents eosinophilic granules based on pathological morphology.
This finding is observable as a result of increasing peroxisome caused by PPAR.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003523,,,,,,,,,,,,,,,,,,,,,,eosinophilic granular degeneration [Liver Pathological Findings] [eosinogranular degeneration (course) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003521,power (attribute),,A physical attribute inhering in a bearer by virtue of the bearer's rate of doing work.,false,,,http://purl.obolibrary.org/obo/TXPO_0000305,,,,,,,,,,,,,,,,,,,,,,A physical attribute inhering in a bearer by virtue of the bearer's rate of doing work.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003521,,,,,,,,,,,,,,,,,,,,,,power (attribute),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003524,fatty change [Liver Pathological Findings],steatosis [Liver PathologicalFindings]|vacuolation [Liver PathologicalFindings]|fatty degeneration [Liver PathologicalFindings],Fatty change [Liver PathologicalFindings] is a type of finding observed in hepatocytes. Lesions are observed as lipid droplets consisting of neutral fat in the hepatocyte based on pathological morphology.,false,,,http://purl.obolibrary.org/obo/TXPO_0001507,,,,,,,,,,,,,,,,,,,,Open TG-Gates:FI-L1580,,Fatty change [Liver PathologicalFindings] is a type of finding observed in hepatocytes. Lesions are observed as lipid droplets consisting of neutral fat in the hepatocyte based on pathological morphology.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,fatty degeneration [Liver PathologicalFindings],,steatosis [Liver PathologicalFindings]|vacuolation [Liver PathologicalFindings],,,TXPO:0003524,,,,,,,"A metabolic disorder of neutral fat causes fatty change.
Lipid droplets consisting of large and small neutral fats (triglycerides) increase in the cytoplasm of hepatocytes.
In the case of large lipid droplets, the uneven distribution of nuclei is observed, but in the case of small loose droplets (microvesicular fatty change), uneven distribution of nuclei is not observed.
According to the distribution, it classifies into centrilobular, periportal, and diffuse type.",,,,,,,,,,,,,,,fatty change [Liver Pathological Findings],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0072574,hepatocyte proliferation,hepatocellular hyperplasia,"The multiplication or reproduction of hepatocytes, resulting in the expansion of a cell population. Hepatocytes form the main structural component of the liver. They are specialized epithelial cells that are organized into interconnected plates called lobules.",false,,,http://purl.obolibrary.org/obo/GO_0008283,,,,,,,,,,,,,,,,,,,,,,"The multiplication or reproduction of hepatocytes, resulting in the expansion of a cell population. Hepatocytes form the main structural component of the liver. They are specialized epithelial cells that are organized into interconnected plates called lobules.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,hepatocellular hyperplasia,,,GO:0072574,,,,,,,,,,,,,,,,,,,,,,hepatocyte proliferation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010549,40S ribosomal protein S24,40S small ribosomal protein 24|S19,,false,,,http://purl.obolibrary.org/obo/IMR_0000896,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,40S small ribosomal protein 24|S19,,,,,IMR:0010549,,,,,,,,,,,,,,,,,,,,,,40S ribosomal protein S24,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000202052,DNAJC18,,Other designations: dnaJ homolog subfamily C member 18,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,5,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"DnaJ (Hsp40) homolog, subfamily C, member 18",,,5q31.2,,,,,,,,,,,,,,,,GO_0016021 (EC: IEA),,,,,,,,,PMID:8889548; 12477932; 14702039; 15489334; 16344560; 17207965; 18676680; 19170196; 19240791; 19625176; 19692168,,,,,,,,,,,,,,,OGG:3000202052,,,,,,,"DnaJ (Hsp40) homolog, subfamily C, member 18",,,,,,,,,,,,,Other designations: dnaJ homolog subfamily C member 18,,DNAJC18,,,,,,,,,,,,,,,,,,,,,,,202052,,,,,,,,9606,,,,,,,,,,,,,,,,,,,DNAJC18,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0010538,40S ribosomal protein S13,40S small ribosomal protein 13,,false,,,http://purl.obolibrary.org/obo/IMR_0000896,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,40S small ribosomal protein 13,,,,,IMR:0010538,,,,,,,,,,,,,,,,,,,,,,40S ribosomal protein S13,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000617,neuregulin-4,NRG-4,,false,,,http://purl.obolibrary.org/obo/IMR_0000048,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,NRG-4,,,,,IMR:0000617,,,,,,,,,,,,,,,,,,,,,,neuregulin-4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001406,phospholipid catabolic process [Phospholipidosis],phospholipid degradation,"The chemical reactions and pathways resulting in the breakdown of phospholipids, any lipid containing phosphoric acid as a mono- or diester.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/GO_0009395,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways resulting in the breakdown of phospholipids, any lipid containing phosphoric acid as a mono- or diester.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003404|http://purl.obolibrary.org/obo/TXPO_0003410,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001435,,,,,,phospholipid degradation,,,,,TXPO:0001406,,,,,,,,,,,,,,,,,,,,,,phospholipid catabolic process [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005764,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001409,increasing production amount of acetaldehyde,,Increasing production amount of acetaldehyde is a subtype of increasing quantity: A process that changes the production amount of acetaldehyde to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing production amount of acetaldehyde is a subtype of increasing quantity: A process that changes the production amount of acetaldehyde to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001409,,,,,,,,,,,,,,,,,,,,,,increasing production amount of acetaldehyde,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001401,ACC1 (canonical)[lipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003970|http://purl.obolibrary.org/obo/TXPO_0003516,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:31|NCBI-Mouse-GeneID:107476|NCBI-Rat-GeneID:60581|PMID:28290443,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003973,,,,,,,,,,TXPO:0001401,,,,,,,,,,,,,,,,,,,,,,ACC1 (canonical)[lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001400,increasing number of damaged lysosomes[Phospholipidosis (severe)],,"increasing number of damaged lysosomes is a subtype of increasing number : A process that becomes larger in the number of damaged lysosomes.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe) .",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0001296,,,,,,,,,,,,,,,,,,,,,,"increasing number of damaged lysosomes is a subtype of increasing number : A process that becomes larger in the number of damaged lysosomes.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe) .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001294,,,,,,,,,,,TXPO:0001400,,,,,,,,,,,,,,,,,,,,,,increasing number of damaged lysosomes[Phospholipidosis (severe)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000000,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001404,negative regulation of phospholipase binding to phospholipid by CAD,,"Negative regulation of phospholipase binding to phospholipid by CAD is a subtype of negative regulation of phospholipid binding: A process that stops, prevents, or reduces the frequency, rate or extent of phosphholipid binding by phospholipase.",false,,,http://purl.obolibrary.org/obo/TXPO_0001402,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of phospholipase binding to phospholipid by CAD is a subtype of negative regulation of phospholipid binding: A process that stops, prevents, or reduces the frequency, rate or extent of phosphholipid binding by phospholipase.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001404,,,,,,,,,,,,,,,,,,,,,,negative regulation of phospholipase binding to phospholipid by CAD,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001407,negative regulation of lipid transport from liver to peripheral tissue,,"Negative regulation of lipid transport from liver to peripheral tissue is a subtype of negative regulation of lipid transport: A process that stops, prevents, or reduces the frequency, rate or extent of lipid transport from liver to peripheral tissue.",false,,,http://purl.obolibrary.org/obo/TXPO_0001391,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of lipid transport from liver to peripheral tissue is a subtype of negative regulation of lipid transport: A process that stops, prevents, or reduces the frequency, rate or extent of lipid transport from liver to peripheral tissue.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001407,,,,,,,,,,,,,,,,,,,,,,negative regulation of lipid transport from liver to peripheral tissue,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001408,increasing production amount of acetaldehyde [Fibrosis],,"Increasing production amount of acetaldehyde is a subtype of increasing quantity: A process that changes the production amount of acetaldehyde to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003742|http://purl.obolibrary.org/obo/TXPO_0001409,,,,,,,,,,,,,,,,,,,,,,"Increasing production amount of acetaldehyde is a subtype of increasing quantity: A process that changes the production amount of acetaldehyde to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003779,,,,,,,,,,,TXPO:0001408,,,,,,,,,,,,,,,,,,,,,,increasing production amount of acetaldehyde [Fibrosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001403,negative regulation of phospholipase-mediated phospholipid degradation by CAD [Phospholipidosis (mild)],,"Negative regulation of phospholipase-mediated phospholipid degradation by CAD is a subtype of negative regulation of phospholipid degradation: A process that stops, prevents, or reduces the frequency, rate or extent of phospholipase-mediated phospholipid deradation regulated by CAD.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (mild).",false,,,http://purl.obolibrary.org/obo/TXPO_0003414,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of phospholipase-mediated phospholipid degradation by CAD is a subtype of negative regulation of phospholipid degradation: A process that stops, prevents, or reduces the frequency, rate or extent of phospholipase-mediated phospholipid deradation regulated by CAD.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (mild).",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003227|http://purl.obolibrary.org/obo/TXPO_0003228|http://purl.obolibrary.org/obo/TXPO_0000319,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003412|http://purl.obolibrary.org/obo/TXPO_0003362,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002087,,,,,,,,,,,TXPO:0001403,,,,,,,,,,,,,,,,,,,,,,negative regulation of phospholipase-mediated phospholipid degradation by CAD [Phospholipidosis (mild)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001402,negative regulation of phospholipid binding,,"Negative regulation of phospholipid binding is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of phospholipid binding.",false,,,http://purl.obolibrary.org/obo/TXPO_0000369,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of phospholipid binding is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of phospholipid binding.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001402,,,,,,,,,,,,,,,,,,,,,,negative regulation of phospholipid binding,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005543,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001405,Dgat1 (rat)[lipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001423|http://purl.obolibrary.org/obo/TXPO_0001088,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:13350|NCBI-Human-GeneID:8694|NCBI-Rat-GeneID:84497|PMID:16864897|PMID:15308631,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001405,,,,,,,,,,,,,,,,,,,,,,Dgat1 (rat)[lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489|http://purl.obolibrary.org/obo/NCIT_C15958,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_50694,minocycline,"minomycin|7-Dimethylamino-6-demethyl-6-deoxytetracycline|(4S,4AS,5AR,12AS)-4,7-BIS(DIMETHYLAMINO)-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2-CARBOXAMIDE|minocycline|minociclinum|minociclina|Minocycline|(4S,4aS,5aR,12aS)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide",A tetracycline analogue having a dimethylamino group at position 7 and lacking the methyl and hydroxy groups at position 5.,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:28709717|PMID:31719236|DrugBank:DB01017|PMID:31733348|Drug_Central:1813|PMID:31630007|Beilstein:3077644|Reaxys:3077644|CAS:10118-90-8|LIPID_MAPS_instance:LMPK07000002,,A tetracycline analogue having a dimethylamino group at position 7 and lacking the methyl and hydroxy groups at position 5.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_36047|http://purl.obolibrary.org/obo/CHEBI_76971,,,,,"Minocycline|(4S,4aS,5aR,12aS)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide",,"minomycin|7-Dimethylamino-6-demethyl-6-deoxytetracycline|(4S,4AS,5AR,12AS)-4,7-BIS(DIMETHYLAMINO)-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2-CARBOXAMIDE|minocycline|minociclinum|minociclina",,,,,,,,,,,,,,,,,,,,,CHEBI:50694,,,,minocycline,,CHEBI:50694,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001440,TLR4 (mol),Toll-like receptor 4,,false,,,http://purl.obolibrary.org/obo/IMR_0000124,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:29260|NCBI-Human-GeneID:7099|NCBI-Mouse-GeneID:21898,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Toll-like receptor 4,,,,,IMR:0001440,,,,,,,,,,,,,,,,,,,,,,TLR4 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_60169,phosphatidylinositol trisphosphate,,A derivative of phosphatidylinositol in which the inositol ring is phosphorylated at three unspecified positions.,false,,,http://purl.obolibrary.org/obo/CHEBI_28765,,,,,,,,,,,,,,,,,,,,,,A derivative of phosphatidylinositol in which the inositol ring is phosphorylated at three unspecified positions.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:60169,,,,,,,,,,,,,,,,,,,,,,phosphatidylinositol trisphosphate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0011136,eIF2B-alpha,"translation initiation factor 2B alpha subunit|eIF-2B GDP-GTP exchange factor, alpha subunit|eIF-2B GDP-GTP exchange factor|Translation initiation factor eIF-2B alpha subunit",,false,,,http://purl.obolibrary.org/obo/IMR_0000915,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"translation initiation factor 2B alpha subunit|eIF-2B GDP-GTP exchange factor, alpha subunit|eIF-2B GDP-GTP exchange factor|Translation initiation factor eIF-2B alpha subunit",,,,,IMR:0011136,,,,,,,,,,,,,,,,,,,,,,eIF2B-alpha,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001867,negative regulator role of transport,,"A role played by the entity which stops, prevents, or reduces the frequency, rate or extent of trasnport.",false,,,http://purl.obolibrary.org/obo/TXPO_0000036,,,,,,,http://purl.obolibrary.org/obo/GO_0006810,,,,,,,,,,,,,,,"A role played by the entity which stops, prevents, or reduces the frequency, rate or extent of trasnport.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001867,,,,,,,,,,,,,,,,,,,,,,negative regulator role of transport,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001865,protein kinase,,"Catalysis role of the phosphorylation of an amino acid residue in a protein, usually according to the reaction: a protein + ATP = a phosphoprotein + ADP.",false,,,http://purl.obolibrary.org/obo/TXPO_0001515,,,,,,,,,,,,,,,,,,,,rerlated molecular fuction GO:0004672,,"Catalysis role of the phosphorylation of an amino acid residue in a protein, usually according to the reaction: a protein + ATP = a phosphoprotein + ADP.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001865,,,,,,,,,,,,,,,,,,,,,,protein kinase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001864,release of DNA from mitochondria [lipidosis],,"The process that results in the movement of mitochondriall DNA from the  mitochondria.
This entity is a specific course-dependent process. This process can constitute the course of lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0001863,,,,,,,,,,,,,,,,,,,,PMID:30046112,,"The process that results in the movement of mitochondriall DNA from the  mitochondria.
This entity is a specific course-dependent process. This process can constitute the course of lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001102,,,,,,http://purl.obolibrary.org/obo/TXPO_0001744,,,,,,,,,,,TXPO:0001864,,,,,,,,,,,,,,,,,,,,,,release of DNA from mitochondria [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001866,inhibitor role of BSEP bile acid transport,,A role played by the entity which inhibits bile acid transport by BSEP.,false,,,http://purl.obolibrary.org/obo/TXPO_0000082,,,,,,,http://purl.obolibrary.org/obo/GO_0015721,,,,,,,,,,,,,,,A role played by the entity which inhibits bile acid transport by BSEP.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001866,,,,,,,,,,,,,,,,,,,,,,inhibitor role of BSEP bile acid transport,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001869,organic anion import into hepatocyte vascular side (sinusoidal side) membrane [Cholestasis],,"The sodium-independent movement of the organic anion into hepatocyte vascular side (sinusoidal side) membrane.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001783,,,,,,,,,,,,,,,,,,,,PMID:23907487,,"The sodium-independent movement of the organic anion into hepatocyte vascular side (sinusoidal side) membrane.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000272,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001869,,,,,,,"The sodium-independent portion of bile salt uptake is mediated by OATPs|Sodium-independent uptake of conjugated and unconjugated bile acids is performed by members of the organic anion-transporting polypeptides (OATPs).
OATPs also transport numerous drugs and hepatotoxicants.",,,,,,,,,,,,,,,organic anion import into hepatocyte vascular side (sinusoidal side) membrane [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001861,changing activity of target molecule by PERK [PERK pathway],,"A process that changes the activity of the target object by PERK.
This entity is a specific course-dependent process. This process can constitute the course of PERK pathway.",false,,,http://purl.obolibrary.org/obo/TXPO_0000020,,,,,,,,,,,,,,,,,,,,,,"A process that changes the activity of the target object by PERK.
This entity is a specific course-dependent process. This process can constitute the course of PERK pathway.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001861,,,,,,,,,,,,,,,,,,,,,,changing activity of target molecule by PERK [PERK pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001863,release of DNA from mitochondria,mtDNA stress,The process that results in the movement of mitochondriall DNA from the  mitochondria.,false,,,http://purl.obolibrary.org/obo/TXPO_0002588,,,,,,,,,,,,,,,,,,,,,,The process that results in the movement of mitochondriall DNA from the  mitochondria.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,mtDNA stress,,,TXPO:0001863,,,,,,,,,,,,,,,,,,,,,,release of DNA from mitochondria,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001860,hypofunction of PPARa regulated gene expression,,"Hypofunction of PPARa regulated gene expression is a subtype of Hypofunction of phospholipase gene expression is a subtype of hypofunction of transcription, DNA-templated: A process that performs a decreased or insufficient PPARa regulated gene expression.",false,,,http://purl.obolibrary.org/obo/TXPO_0002356,,,,,,,,,,,,,,,,,,,,,,"Hypofunction of PPARa regulated gene expression is a subtype of Hypofunction of phospholipase gene expression is a subtype of hypofunction of transcription, DNA-templated: A process that performs a decreased or insufficient PPARa regulated gene expression.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001860,,,,,,,,,,,,,,,,,,,,,,hypofunction of PPARa regulated gene expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000247,aPKC,atypical protein kinase C,atypical PKC isoforms (zeta and lambda/iota; PKC-lambda is the mouse ortholog of human PKC-iota) are insensitive to both calcium and DAG.,false,,,http://purl.obolibrary.org/obo/IMR_0000245,,,,,,,,,,,,,,,,,,,,GO:0004700,,atypical PKC isoforms (zeta and lambda/iota; PKC-lambda is the mouse ortholog of human PKC-iota) are insensitive to both calcium and DAG.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,atypical protein kinase C,,,,,IMR:0000247,,,,,,,,,,,,,,,,,,,,,,aPKC,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004246,negative regulation of cell cycle G2/M phase transition [mitochondrial disorder],,"Negative regulation of cell cycle G2/M phase transition is a subtype of negative regulation of cell cycle:  Any process that stops, prevents or reduces the frequency, rate or extent of cell cycle G2/M phase transition.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0000370|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:24746669,,"Negative regulation of cell cycle G2/M phase transition is a subtype of negative regulation of cell cycle:  Any process that stops, prevents or reduces the frequency, rate or extent of cell cycle G2/M phase transition.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004376,,,,,,,,,,,TXPO:0004246,,,,,,,,,,,,,,,,,,,,,,negative regulation of cell cycle G2/M phase transition [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004243,CCL2 production [mitochondrial disorder],,"The appearance of chemokine (C-C motif) ligand 2 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0004288,,,,,,,,,,,,,,,,,,,,PID:30894684,,"The appearance of chemokine (C-C motif) ligand 2 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003610,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004273|http://purl.obolibrary.org/obo/TXPO_0004274,,,,,,,,,,,TXPO:0004243,,,,,,,,,,,,,,,,,,,,,,CCL2 production [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004244,binding to DNA by free radicals,,Process of binding by which free radicals interact with DNA (deoxyribonucleic acid).,false,,,http://purl.obolibrary.org/obo/TXPO_0003343,,,,,,,,,,,,,,,,,,,,,,Process of binding by which free radicals interact with DNA (deoxyribonucleic acid).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004244,,,,,,,,,,,,,,,,,,,,,,binding to DNA by free radicals,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004245,COL1A1 production [mitochondrial disorder],,"COL1A1 production is a subtype of collagen production: A process that makes existent of a ollagen due to biosynthesis, secretion, or membrane trafficking, resulting in an increase in its levels.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0004284,,,,,,,,,,,,,,,,,,,,PMID:29222479,,"COL1A1 production is a subtype of collagen production: A process that makes existent of a ollagen due to biosynthesis, secretion, or membrane trafficking, resulting in an increase in its levels.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004221,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004307,,,,,,,,,,,TXPO:0004245,,,,,,,,,,,,,,,,,,,,,,COL1A1 production [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004248,GDF15 inactivation,,GDF15 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the GDF15 (Growth differentiation factor 15) to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000021,,,,,,,,,,,,,,,,,,,,,,GDF15 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the GDF15 (Growth differentiation factor 15) to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004248,,,,,,,,,,,,,,,,,,,,,,GDF15 inactivation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004240,cyclin B1-CDK1 complex inactivation,,cyclin B1-CDK1 complex inactivation is a subtype of molecular inactivation: A process that  changes the activity of the cyclin B1-CDK1 complex to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000021,,,,,,,,,,,,,,,,,,,,,,cyclin B1-CDK1 complex inactivation is a subtype of molecular inactivation: A process that  changes the activity of the cyclin B1-CDK1 complex to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004240,,,,,,,,,,,,,,,,,,,,,,cyclin B1-CDK1 complex inactivation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004242,ACTA2 production [mitochondrial disorder],,"ACTA2 production is a subtype of Actin production: A process that makes existent of ACTA2 due to biosynthesis, secretion, or membrane trafficking, resulting in an increase in its levels.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0004287,,,,,,,,,,,,,,,,,,,,PMID:29222479,,"ACTA2 production is a subtype of Actin production: A process that makes existent of ACTA2 due to biosynthesis, secretion, or membrane trafficking, resulting in an increase in its levels.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004219,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004279,,,,,,,,,,,TXPO:0004242,,,,,,,,,,,,,,,,,,,,,,ACTA2 production [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004247,GDF15 inactivation [mitochondrial disorder],,"GDF15 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the GDF15 (Growth differentiation factor 15) to be lower.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0004248,,,,,,,,,,,,,,,,,,,,PMID:29222479,,"GDF15 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the GDF15 (Growth differentiation factor 15) to be lower.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004223,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002004|http://purl.obolibrary.org/obo/TXPO_0004268|http://purl.obolibrary.org/obo/TXPO_0004266|http://purl.obolibrary.org/obo/TXPO_0004269|http://purl.obolibrary.org/obo/TXPO_0004245|http://purl.obolibrary.org/obo/TXPO_0004242|http://purl.obolibrary.org/obo/TXPO_0004249|http://purl.obolibrary.org/obo/TXPO_0004251|http://purl.obolibrary.org/obo/TXPO_0004252|http://purl.obolibrary.org/obo/TXPO_0004254|http://purl.obolibrary.org/obo/TXPO_0004256,,,,,,,,,,,TXPO:0004247,,,,,,,,,,,,,,,,,,,,,,GDF15 inactivation [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004241,cyclin B1-CDK1 complex inactivation [mitochondrial disorder],,"cyclin B1-CDK1 complex inactivation is a subtype of molecular inactivation: A process that  changes the activity of the cyclin B1-CDK1 complex to be lower.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0004240,,,,,,,,,,,,,,,,,,,,PMID:24746669,,"cyclin B1-CDK1 complex inactivation is a subtype of molecular inactivation: A process that  changes the activity of the cyclin B1-CDK1 complex to be lower.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004239,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004375,,,,,,,,,,,TXPO:0004241,,,,,,,,,,,,,,,,,,,,,,cyclin B1-CDK1 complex inactivation [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004249,JNK signaling (primitive) [mitochondrial disorder],,"JNK signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the JNK (a stress-activated protein kinase (SAPK) ).
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0000769|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:31623280|PMID:23299992|PMID:30898010|PMID:29222479|PMID:31649547,,"JNK signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the JNK (a stress-activated protein kinase (SAPK) ).
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004230,,,,,,http://purl.obolibrary.org/obo/TXPO_0001991|http://purl.obolibrary.org/obo/TXPO_0004279|http://purl.obolibrary.org/obo/TXPO_0004271|http://purl.obolibrary.org/obo/TXPO_0000869|http://purl.obolibrary.org/obo/TXPO_0004379|http://purl.obolibrary.org/obo/TXPO_0004377|http://purl.obolibrary.org/obo/TXPO_0004378,,,,,,,,,,,TXPO:0004249,,,,,,,,,,,,,,,,,,,,,,JNK signaling (primitive) [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_23018,EC 4.2.1.1 (carbonic anhydrase) inhibitor,carbonate dehydratase inhibitors|carbonic anhydrase inhibitors|carbonate anhydrase inhibitor|carbonic acid anhydrase inhibitors|carbonic anhydrase A inhibitors|anhydrase inhibitor|EC 4.2.1.1 (carbonic anhydrase) inhibitors|carbonic anhydrase A inhibitor|EC 4.2.1.1 inhibitors|carbonic anhydrase (EC 4.2.1.1) inhibitors|carbonate hydro-lyase (carbon-dioxide-forming) inhibitor|carbonic anhydrase (EC 4.2.1.1) inhibitor|carbonate anhydrase inhibitors|carbonate hydro-lyase (carbon-dioxide-forming) inhibitors|carbonate dehydratase inhibitor|carbonic anhydrase inhibitor|EC 4.2.1.1 inhibitor|anhydrase inhibitors|carbonic acid anhydrase inhibitor|carbonate hydro-lyase inhibitor|carbonate hydro-lyase inhibitors|carboxyanhydrase inhibitors|carboxyanhydrase inhibitor,An EC 4.2.1.* (hydro-lyases) inhibitor that interferes with the action of carbonic anhydrase (EC 4.2.1.1). Such compounds reduce the secretion of H(+) ions by the proximal kidney tubule.,false,,,http://purl.obolibrary.org/obo/CHEBI_76907,,,,,,,,,,,,,,,,,,,,,,An EC 4.2.1.* (hydro-lyases) inhibitor that interferes with the action of carbonic anhydrase (EC 4.2.1.1). Such compounds reduce the secretion of H(+) ions by the proximal kidney tubule.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,carbonate dehydratase inhibitors|carbonic anhydrase inhibitors|carbonate anhydrase inhibitor|carbonic acid anhydrase inhibitors|carbonic anhydrase A inhibitors|anhydrase inhibitor|EC 4.2.1.1 (carbonic anhydrase) inhibitors|carbonic anhydrase A inhibitor|EC 4.2.1.1 inhibitors|carbonic anhydrase (EC 4.2.1.1) inhibitors|carbonate hydro-lyase (carbon-dioxide-forming) inhibitor|carbonic anhydrase (EC 4.2.1.1) inhibitor|carbonate anhydrase inhibitors|carbonate hydro-lyase (carbon-dioxide-forming) inhibitors|carbonate dehydratase inhibitor|carbonic anhydrase inhibitor|EC 4.2.1.1 inhibitor|anhydrase inhibitors|carbonic acid anhydrase inhibitor|carbonate hydro-lyase inhibitor|carbonate hydro-lyase inhibitors|carboxyanhydrase inhibitors|carboxyanhydrase inhibitor,,,,,,,,,,,,,,,,,,,,,CHEBI:23018,,,,EC 4.2.1.1 (carbonic anhydrase) inhibitor,,CHEBI:23018,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76741,"EC 1.14.* (oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen) inhibitor","inhibitor of oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (EC 1.14.*)|oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen inhibitor|oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen (EC 1.14.*) inhibitors|EC 1.14.* (oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen) inhibitors|inhibitors of oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen (EC 1.14.*)|EC 1.14.* inhibitor|inhibitors of oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (EC 1.14.*)|inhibitor of oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen (EC 1.14.*)|oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen (EC 1.14.*) inhibitor|oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen inhibitors|EC 1.14.* inhibitors",An oxidoreductase inhibitor which interferes with the action of an oxidoreductase acting on hydrogen as donors (EC 1.14.*.*).,false,,,http://purl.obolibrary.org/obo/CHEBI_76725,,,,,,,,,,,,,,,,,,,,,,An oxidoreductase inhibitor which interferes with the action of an oxidoreductase acting on hydrogen as donors (EC 1.14.*.*).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"inhibitor of oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (EC 1.14.*)|oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen inhibitor|oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen (EC 1.14.*) inhibitors|EC 1.14.* (oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen) inhibitors|inhibitors of oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen (EC 1.14.*)|EC 1.14.* inhibitor|inhibitors of oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (EC 1.14.*)|inhibitor of oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen (EC 1.14.*)|oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen (EC 1.14.*) inhibitor|oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen inhibitors|EC 1.14.* inhibitors",,,,,,,,,,,,,,,,,,,,,CHEBI:76741,,,,"EC 1.14.* (oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen) inhibitor",,CHEBI:76741,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000003646,EIF3E,,"Other designations: eIF-3 p48|eukaryotic translation initiation factor 3 subunit 6|eukaryotic translation initiation factor 3 subunit E|eukaryotic translation initiation factor 3, subunit 6 (48kD)|eukaryotic translation initiation factor 3, subunit 6 48kDa|mammary tumor-associated protein INT6|murine mammary tumor integration site 6 (oncogene homolog)|viral integration site protein INT-6 homolog",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,EIF3S6|eIF3-p46|EIF3-P48|INT6,,,,,,,,,,,,8,,,,,,MIM:602210|Vega:OTTHUMG00000164858|HGNC:3277|HPRD:03734|Ensembl:ENSG00000104408,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"eukaryotic translation initiation factor 3, subunit E",,,8q22-q23,,,,,,,,,,,,,,,,"GO_0000184 (EC: IMP, PMID:17468741); GO_0000785 (EC: NAS, Qualifier: colocalizes_with, PMID:17468741); GO_0001731 (EC: IEA); GO_0003743 (EC: IC, PMID:9295280); GO_0003743 (EC: IC, Qualifier: contributes_to, PMID:17322308); GO_0003743 (EC: IDA, Qualifier: contributes_to, PMID:17581632); GO_0005515 (EC: IPI, PMID:10504338); GO_0005634 (EC: IDA); GO_0005654 (EC: NAS, PMID:17468741); GO_0005730 (EC: IDA, Qualifier: NOT); GO_0005737 (EC: IDA); GO_0005829 (EC: TAS); GO_0005852 (EC: IDA, PMID:17322308); GO_0005852 (EC: NAS, PMID:10504338); GO_0006412 (EC: TAS); GO_0006413 (EC: IC, PMID:17322308); GO_0006413 (EC: IDA, PMID:17581632); GO_0006413 (EC: TAS); GO_0006446 (EC: NAS, PMID:17468741); GO_0010467 (EC: TAS); GO_0016282 (EC: IEA); GO_0016605 (EC: IDA, Qualifier: colocalizes_with, PMID:10504338); GO_0033290 (EC: IEA); GO_0044267 (EC: TAS); GO_0044822 (EC: IDA); GO_0045947 (EC: NAS, PMID:10504338); GO_0047485 (EC: IPI, PMID:10504338); GO_0070062 (EC: IDA)",,,,,,,,,PMID:8688078; 8995409; 8995410; 9295280; 9403073; 9733766; 9822659; 10504338; 10644362; 11118224; 11121040; 11590142; 12220626; 12386384; 12435599; 12477932; 12553909; 12588972; 14519125; 14667819; 14702039; 15030549; 15231748; 15489334; 15558017; 15592455; 15862967; 15867213; 16045761; 16169070; 16189514; 16343815; 16766523; 17220478; 17310990; 17314511; 17322308; 17324924; 17353931; 17403899; 17468741; 17516841; 17581632; 17623298; 18029348; 18562274; 18599441; 18628297; 18781797; 19454010; 19471022; 19615732; 19738201; 20360068; 20434207; 20453879; 20462248; 20890303; 21139048; 21319273; 21693764; 21732829; 21890473; 21906983; 21963094; 21987572; 21988832; 22053931; 22190034; 22268729; 22505724; 22508697; 22532700; 22553336; 22586326; 22623428; 22797925; 22863883; 22907435; 22939629; 23000965; 23184937; 23402259; 23455922; 23463506; 23478175; 24092755; 24250222,,,,,,,,,,,,,,,OGG:3000003646,,,,,,,"eukaryotic translation initiation factor 3, subunit E",,,,,,,,,,,,,"Other designations: eIF-3 p48|eukaryotic translation initiation factor 3 subunit 6|eukaryotic translation initiation factor 3 subunit E|eukaryotic translation initiation factor 3, subunit 6 (48kD)|eukaryotic translation initiation factor 3, subunit 6 48kDa|mammary tumor-associated protein INT6|murine mammary tumor integration site 6 (oncogene homolog)|viral integration site protein INT-6 homolog",,EIF3E,,,,,,,,,,,,,,,,,,,,,,,3646,,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF3E,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0001670,RGS12,,,false,,,http://purl.obolibrary.org/obo/IMR_0000431,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001670,,,,,,,,,,,,,,,,,,,,,,RGS12,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0002330,exocrine system,exocrine glandular system,"Anatomical system that consists of the glands and parts of glands that produce exocrine secretions and help to integrate and control bodily metabolic activity. Exocrine glands are glands that secrete their products (hormones) into ducts (duct glands). They are the counterparts to endocrine glands, which secrete their products (hormones) directly into the bloodstream (ductless glands) or release hormones (paracrines) that affect only target cells nearby the release site. [Wikipedia].",false,,,http://purl.obolibrary.org/obo/UBERON_0000467,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002365,,,,http://linkedlifedata.com/resource/umls/id/C1516995|http://purl.obolibrary.org/obo/NCIT_C12957|http://en.wikipedia.org/wiki/Exocrine_gland|CALOHA:TS-2057|MA:0002411|EMAPA:35329|UMLS:C1516995|EHDAA2:0002225|FMA:85539|WikipediaCategory:Exocrine_system,,"Anatomical system that consists of the glands and parts of glands that produce exocrine secretions and help to integrate and control bodily metabolic activity. Exocrine glands are glands that secrete their products (hormones) into ducts (duct glands). They are the counterparts to endocrine glands, which secrete their products (hormones) directly into the bloodstream (ductless glands) or release hormones (paracrines) that affect only target cells nearby the release site. [Wikipedia].",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,exocrine glandular system,,,,,UBERON:0002330,,,,,,,,,,,,,,,,,,,,,,exocrine system,,,,,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003848,hyperfunction of glucuronic acid conjugation for phenobarbital intermediate metabolite (sustained) [Ground glass appearance],,"Hyperfunction of glucuronic acid conjugation is a subtype of hyperfunction of drug metabolism phase II: A process that performs an excessive glucuronic acid conjugation. This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) .",false,,,http://purl.obolibrary.org/obo/TXPO_0001663|http://purl.obolibrary.org/obo/TXPO_0001227,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of glucuronic acid conjugation is a subtype of hyperfunction of drug metabolism phase II: A process that performs an excessive glucuronic acid conjugation. This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000992,,,,,,,,,,,,,,,,,TXPO:0003848,,,,,,,,,,,,,,,,,,,,,,hyperfunction of glucuronic acid conjugation for phenobarbital intermediate metabolite (sustained) [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003847,hyperfunction of decreasing the amount of phenobarbital (sustained) [Ground glass appearance],,"Hyperfunction of decreasing the amount of phenobarbital is a subtype of hyperfunction of decreasing: A process that performs an excesssive decreasing the amount of the phenobarbital. This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) .",false,,,http://purl.obolibrary.org/obo/TXPO_0001654,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of decreasing the amount of phenobarbital is a subtype of hyperfunction of decreasing: A process that performs an excesssive decreasing the amount of the phenobarbital. This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) .",,,http://purl.obolibrary.org/obo/TXPO_0001647,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003848|http://purl.obolibrary.org/obo/TXPO_0003844,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003856,,,,,,,,,,,TXPO:0003847,,,,,,,,,,,,,,,,,,,,,,hyperfunction of decreasing the amount of phenobarbital (sustained) [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003843,CTSB  (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1508|NCBI-Rat-GeneID:64529|NCBI-Mouse-GeneID:13030,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001508,,,,,,,,,,,,,TXPO:0003843,,,,,,,,,,,,,,,,,,,,,,CTSB  (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003846,hyperfunction of drug metabolism phase I  (sustained) [Ground glass appearance],,"Hyperfunction of drug metabolism phase I is a subtype of hyperfunction of drug metabolism: A process that performs an excesssive drug metabolism phase I. This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) .",false,,,http://purl.obolibrary.org/obo/TXPO_0000938,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of drug metabolism phase I is a subtype of hyperfunction of drug metabolism: A process that performs an excesssive drug metabolism phase I. This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000991|http://purl.obolibrary.org/obo/TXPO_0000990,,,,,,http://purl.obolibrary.org/obo/TXPO_0000943,,,,,,,,,,,TXPO:0003846,,,,,,,,,,,,,,,,,,,,,,hyperfunction of drug metabolism phase I  (sustained) [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005790,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003842,NCR3LG1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:374383|NCBI-Rat-GeneID:691092|PMID:19528259|https://omim.org/entry/613714,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000374383,,,,,,,,,,,,,TXPO:0003842,,,,,,,,,,,,,,,,,,,,,,NCR3LG1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003840,ASPA (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:443|NCBI-Mouse-GeneID:11484|NCBI-Rat-GeneID:79251,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000443,,,,,,,,,,,,,TXPO:0003840,,,,,,,,,,,,,,,,,,,,,,ASPA (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003844,hyperfunction of phenobarbital metabolism phase I by Cytochrome P450 (sustained) [Ground glass appearance],,"Hyperfunction of phenobarbital metabolism phase I by Cytochrome P450 is a subtype of hyperfunction of drug metabolism phase I: A process that performs an excesssive phenobarbital metabolism phase I by Cytochrome P450. This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) .",false,,,http://purl.obolibrary.org/obo/TXPO_0003864,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of phenobarbital metabolism phase I by Cytochrome P450 is a subtype of hyperfunction of drug metabolism phase I: A process that performs an excesssive phenobarbital metabolism phase I by Cytochrome P450. This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001627|http://purl.obolibrary.org/obo/TXPO_0000967,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003850|http://purl.obolibrary.org/obo/TXPO_0001677|http://purl.obolibrary.org/obo/TXPO_0003848,,,,,,,,,,,TXPO:0003844,,,,,,,,,,,,,,,,,,,,,,hyperfunction of phenobarbital metabolism phase I by Cytochrome P450 (sustained) [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003841,DAB2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1601|NCBI-Mouse-GeneID:13132|NCBI-Rat-GeneID:79128,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001601,,,,,,,,,,,,,TXPO:0003841,,,,,,,,,,,,,,,,,,,,,,DAB2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003849,hyperfunction of drug metabolism phase II (sustained) [Ground glass appearance],,"Hyperfunction of drug metabolism phase II is a subtype of hyperfunction of drug metabolism: A process that performs an excessive drug metabolism phase II. This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) .",false,,,http://purl.obolibrary.org/obo/TXPO_0000943,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of drug metabolism phase II is a subtype of hyperfunction of drug metabolism: A process that performs an excessive drug metabolism phase II. This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003849,,,,,,,,,,,,,,,,,,,,,,hyperfunction of drug metabolism phase II (sustained) [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003845,smooth endoplasmic reticulum membrane organization (sustained) [Ground glass appearance],,"Smooth endoplasmic reticulum membrane organization is a subtype of endoplasmic reticulum membrane organization: A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts of a smooth endoplasmic reticulum membrane. This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) .",false,,,http://purl.obolibrary.org/obo/TXPO_0001615|http://purl.obolibrary.org/obo/TXPO_0001613,,,,,,,,,,,,,,,,,,,,,,"Smooth endoplasmic reticulum membrane organization is a subtype of endoplasmic reticulum membrane organization: A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts of a smooth endoplasmic reticulum membrane. This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001677,,,,,,,,,,,TXPO:0003845,,,,,,,,,,,,,,,,,,,,,,smooth endoplasmic reticulum membrane organization (sustained) [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_18154,polysaccharide,Polysaccharide|polysaccharides,A biomacromolecule consisting of large numbers of monosaccharide residues linked glycosidically. This term is commonly used only for those containing more than ten monosaccharide residues.,false,,,http://purl.obolibrary.org/obo/CHEBI_33694|http://purl.obolibrary.org/obo/CHEBI_16646,,,,,,,,,,,,,,,,,,,,,,A biomacromolecule consisting of large numbers of monosaccharide residues linked glycosidically. This term is commonly used only for those containing more than ten monosaccharide residues.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Polysaccharide|polysaccharides,,,,,CHEBI:18154,,,,,,,,,,,,,,,,,,,,,,polysaccharide,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_35842,antirheumatic drug,antirheumatic drugs|antirheumatic agent|anti-rheumatic drugs,A drug used to treat rheumatoid arthritis.,false,,,http://purl.obolibrary.org/obo/CHEBI_23888,,,,,,,,,,,,,,,,,,,,,,A drug used to treat rheumatoid arthritis.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,antirheumatic drugs|antirheumatic agent|anti-rheumatic drugs,,,,,,,,,,,,,,,,,,,,,CHEBI:35842,,,,antirheumatic drug,,CHEBI:35842,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CL_0000151,secretory cell,,A cell that specializes in controlled release of one or more substances.,false,,,http://purl.obolibrary.org/obo/CL_0000000,,,,,,,,,,,,,,,,,,,,FMA:86916|BTO:0003659,,A cell that specializes in controlled release of one or more substances.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CL:0000151,,,,,,,,,,,,,,,,,,,,,,secretory cell,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000007965,AIMP2,,Other designations: ARS-interacting multi-functional protein 2|aminoacyl tRNA synthase complex-interacting multifunctional protein 2|multisynthase complex auxiliary component p38|multisynthetase complex auxiliary component p38|protein JTV-1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,JTV1|P38|JTV-1,,,,,,,,,,,,7,,,,,,MIM:600859|Vega:OTTHUMG00000122077|HGNC:20609|HPRD:02915|Ensembl:ENSG00000106305,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,aminoacyl tRNA synthetase complex-interacting multifunctional protein 2,,,7p22,,,,,,,,,,,,,,,,"GO_0005515 (EC: IPI, PMID: 16189514); GO_0005634 (EC: IEA); GO_0005829 (EC: TAS); GO_0006418 (EC: TAS); GO_0006915 (EC: IEA); GO_0008285 (EC: IEA); GO_0010467 (EC: TAS); GO_0031398 (EC: IEA); GO_0060510 (EC: IEA)",,,,,,,,,PMID: 600859; 1651330; 8052601; 8078941; 8188258; 8449960; 8666379; 9278442; 9878398; 10913161; 11714285; 12477932; 12690205; 12729910; 12783850; 12819782; 12853948; 15479637; 15489334; 16049031; 16055448; 16125937; 16135753; 16189514; 16714300; 17512523; 18676680; 18695251; 18781797; 19060904; 19170196; 19584093; 19625176; 19692168; 19738201; 21044950; 21110914; 21139048; 21209200; 21483803; 21832049; 21890473; 21900206; 21988832; 22190034; 22285955; 22532625; 22562359; 22751010; 22863883; 22939629; 23000965; 23455922; 23815603; 23824909; 23974709; 24250222,,,,,,,,,,,,,,,OGG:3000007965,,,,,,,aminoacyl tRNA synthetase complex-interacting multifunctional protein 2,,,,,,,,,,,,,Other designations: ARS-interacting multi-functional protein 2|aminoacyl tRNA synthase complex-interacting multifunctional protein 2|multisynthase complex auxiliary component p38|multisynthetase complex auxiliary component p38|protein JTV-1,,AIMP2,,,,,,,,,,,,,,,,,,,,,,,7965,PRO0992,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,AIMP2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0100604,CDK8(mol),Protein kinase K35|Cell division protein kinase 8,,false,,,http://purl.obolibrary.org/obo/TXPO_0003241,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Protein kinase K35|Cell division protein kinase 8,,,,,IMR:0100604,,,,,,,,,,,,,,,,,,,,,,CDK8(mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000007804,LRP8,,Other designations: ApoE receptor 2|low-density lipoprotein receptor-related protein 8,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,APOER2|LRP-8|HSZ75190|MCI1,,,,,,,,,,,,1,,,,,,MIM:602600|HGNC:6700|HPRD:04002,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"low density lipoprotein receptor-related protein 8, apolipoprotein e receptor",,,1p34,,,,,,,,,,,,,,,,"GO_0000122 (EC: ISS); GO_0001523 (EC: TAS); GO_0004888 (EC: TAS, PMID: 8626535); GO_0005509 (EC: IEA); GO_0005515 (EC: IPI, PMID: 12950167); GO_0005576 (EC: IEA); GO_0005875 (EC: IEA); GO_0005886 (EC: TAS); GO_0005901 (EC: IDA, PMID: 11369809); GO_0006508 (EC: NAS, PMID: 11152697); GO_0006629 (EC: NAS, PMID: 11152697); GO_0006897 (EC: IDA, PMID: 8626535); GO_0006898 (EC: IDA, PMID: 8626535); GO_0007165 (EC: TAS, PMID: 10380922); GO_0007596 (EC: TAS); GO_0007603 (EC: TAS); GO_0008035 (EC: IEA); GO_0014069 (EC: IEA); GO_0016021 (EC: IC, PMID: 11152697); GO_0019221 (EC: NAS, PMID: 11152697); GO_0019894 (EC: IEA); GO_0021541 (EC: ISS); GO_0021819 (EC: IEA); GO_0030229 (EC: IDA, PMID: 8626535); GO_0030425 (EC: IEA); GO_0032793 (EC: ISS); GO_0034185 (EC: IC, PMID: 8626535); GO_0038025 (EC: ISS); GO_0038026 (EC: ISS); GO_0042493 (EC: IEA); GO_0043025 (EC: IEA); GO_0043235 (EC: IDA); GO_0050731 (EC: ISS); GO_0050804 (EC: ISS); GO_0061003 (EC: ISS); GO_0061098 (EC: ISS); GO_0071363 (EC: IEA); GO_0071397 (EC: IEA); GO_1900006 (EC: ISS)",,,,,,,,,PMID: 8626535; 9079678; 10218790; 10231386; 10380922; 10508213; 10571240; 10827173; 11152697; 11369809; 12167620; 12169628; 12399018; 12426372; 12477932; 12621059; 12670700; 12681505; 12807892; 12824284; 12871934; 12899622; 12950167; 14702039; 14732905; 15313836; 15459198; 15489334; 15950758; 16034672; 16332682; 16481437; 16642433; 16951405; 17470198; 17614163; 17847002; 18039658; 18089558; 18489431; 18592168; 19056482; 19116273; 19282863; 19439088; 19661487; 19720620; 19913121; 19948739; 20208369; 20331378; 20493228; 20628086; 21157031; 21316997; 21347244; 21554715; 21601501; 21906983; 21963094; 22109552; 22170052; 22404453; 22419519; 22589174; 22889673; 23192594; 23524007; 23739027,,,,,,,,,,,,,,,OGG:3000007804,,,,,,,"low density lipoprotein receptor-related protein 8, apolipoprotein e receptor",,,,,,,,,,,,,Other designations: ApoE receptor 2|low-density lipoprotein receptor-related protein 8,,LRP8,,,,,,,,,,,,,,,,,,,,,,,7804,RP5-1024G6.8,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,LRP8,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/GO_0031929,TOR signaling,target of rapamycin signaling pathway|TOR signaling cascade|TOR signaling pathway,"A series of molecular signals mediated by TOR (Target of rapamycin) proteins, members of the phosphoinositide (PI) 3-kinase related kinase (PIKK) family that act as serine/threonine kinases in response to nutrient availability or growth factors.",false,,,http://purl.obolibrary.org/obo/TXPO_0000609,,,,,,,,,,,,,,,,,,,,,,"A series of molecular signals mediated by TOR (Target of rapamycin) proteins, members of the phosphoinositide (PI) 3-kinase related kinase (PIKK) family that act as serine/threonine kinases in response to nutrient availability or growth factors.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,target of rapamycin signaling pathway|TOR signaling cascade|TOR signaling pathway,,,,,GO:0031929,,,,,,,,,,,,,,,,,,,,,,TOR signaling,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000164,cytokeratin 8,,,false,,,http://purl.obolibrary.org/obo/IMR_0000050,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000164,,,,,,,,,,,,,,,,,,,,,,cytokeratin 8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/BFO_0000145,relational quality,,"b is a relational quality = Def. for some independent continuants c, d and for some time t: b quality_of c at t & b quality_of d at t. (axiom label in BFO2 Reference: [057-001])",false,,,http://purl.obolibrary.org/obo/BFO_0000019,,,,,,,,,,,,,,,,,,,,,,"b is a relational quality = Def. for some independent continuants c, d and for some time t: b quality_of c at t & b quality_of d at t. (axiom label in BFO2 Reference: [057-001])",,,,,,,"a marriage bond, an instance of love, an obligation between one person and another.|John’s role of husband to Mary is dependent on Mary’s role of wife to John, and both are dependent on the object aggregate comprising John and Mary as member parts joined together through the relational quality of being married.",,,,,,,,,,,(iff (RelationalQuality a) (exists (b c t) (and (IndependentContinuant b) (IndependentContinuant c) (qualityOfAt a b t) (qualityOfAt a c t)))) // axiom label in BFO2 CLIF: [057-001],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BFO:0000145,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/bfo.owl,relational quality,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100070,gastrin-releasing peptide,GRP,"Neuropeptide and gut hormone that helps regulate GASTRIC ACID secretion and motor function. Once released from nerves in the antrum of the STOMACH, the neuropeptide stimulates release of GASTRIN from the GASTRIN-SECRETING CELLS.",false,,,http://purl.obolibrary.org/obo/IMR_0100072,,,,,,,,,,,,,,,,,,,,MeSH:D019886,,"Neuropeptide and gut hormone that helps regulate GASTRIC ACID secretion and motor function. Once released from nerves in the antrum of the STOMACH, the neuropeptide stimulates release of GASTRIN from the GASTRIN-SECRETING CELLS.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GRP,,,,,IMR:0100070,,,,,,,,,,,,,,,,,,,,,,gastrin-releasing peptide,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100427,TRAF6,TNF receptor associated factor 6,,false,,,http://purl.obolibrary.org/obo/IMR_0000462,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TNF receptor associated factor 6,,,,,IMR:0100427,,,,,,,,,,,,,,,,,,,,,,TRAF6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0000504,arrhythmic,,A rhythm quality inhering in a bearer by virtue of the bearer's lacking rhythm.,false,,,http://purl.obolibrary.org/obo/PATO_0000078,,,,,,,,,,,,,,,,,,,,,,A rhythm quality inhering in a bearer by virtue of the bearer's lacking rhythm.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0000504,,,,,,,,,,,,,,,,,,,,,,arrhythmic,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0000505,rhythmic,,A rhythm quality inhering in a bearer by virtue of the bearer's having rhythm.,false,,,http://purl.obolibrary.org/obo/PATO_0000078,,,,,,,,,,,,,,,,,,,,,,A rhythm quality inhering in a bearer by virtue of the bearer's having rhythm.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0000505,,,,,,,,,,,,,,,,,,,,,,rhythmic,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76969,bacterial metabolite,,Any prokaryotic metabolite produced during a metabolic reaction in bacteria.,false,,,http://purl.obolibrary.org/obo/CHEBI_75787,,,,,,,,,,,,,,,,,,,,,,Any prokaryotic metabolite produced during a metabolic reaction in bacteria.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:76969,,,,bacterial metabolite,,CHEBI:76969,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100838,SOCS-2,Cytokine-inducible SH2 protein 2|STAT induced STAT inhibitor 2|Suppressor of cytokine signaling 2|SSI-2|CIS-2,,false,,,http://purl.obolibrary.org/obo/IMR_0000460,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Cytokine-inducible SH2 protein 2|STAT induced STAT inhibitor 2|Suppressor of cytokine signaling 2|SSI-2|CIS-2,,,,,IMR:0100838,,,,,,,,,,,,,,,,,,,,,,SOCS-2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_50266,prodrug,Prodrugs,"A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug.",false,,,http://purl.obolibrary.org/obo/CHEBI_23888,,,,,,,,,,,,,,,,,,,,PMID:28334528|PMID:28259775|PMID:24329110|PMID:24709544|PMID:25269430|PMID:25795057|PMID:23998799|PMID:25620096|PMID:25157234|PMID:28319647|PMID:24628402|PMID:28215138|PMID:26028253|PMID:28070577|PMID:28329729|PMID:25391982|PMID:25591121|PMID:25144792|PMID:28219047|PMID:23993918|PMID:26184144,,"A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Prodrugs,,,,,,,,,,,,,,,,,,,,,CHEBI:50266,,,,prodrug,,CHEBI:50266,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CL_0000767,basophil,,"Any of the immature or mature forms of a granular leukocyte that in its mature form has an irregularly shaped, pale-staining nucleus that is partially constricted into two lobes, and with cytoplasm that contains coarse, bluish-black granules of variable size. Basophils contain vasoactive amines such as histamine and serotonin, which are released on appropriate stimulation. A basophil is CD123-positive, CD193-positive, CD203c-positive, and FceRIa-positive.",false,,,http://purl.obolibrary.org/obo/CL_0000094,,,,,,,,,,,,,,,,,,,,,,"Any of the immature or mature forms of a granular leukocyte that in its mature form has an irregularly shaped, pale-staining nucleus that is partially constricted into two lobes, and with cytoplasm that contains coarse, bluish-black granules of variable size. Basophils contain vasoactive amines such as histamine and serotonin, which are released on appropriate stimulation. A basophil is CD123-positive, CD193-positive, CD203c-positive, and FceRIa-positive.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CL:0000767,,,,,,,,,,,,,,,,,,,,,,basophil,,,,,,,http://purl.obolibrary.org/obo/cl.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000582,IFN alpha-16,,,false,,,http://purl.obolibrary.org/obo/IMR_0100386,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000582,,,,,,,,,,,,,,,,,,,,,,IFN alpha-16,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_47381,diclofenac,"diclofenac|[2-(2,6-dichloroanilino)phenyl]acetic acid|diclofenacum|diclofenamic acid|diclofenaco|2-((2,6-dichlorophenyl)amino)benzeneacetic acid|diclofenac acid|Diclofenac|2-[(2,6-dichlorophenyl)amino]benzeneacetic acid|{2-[(2,6-dichlorophenyl)amino]phenyl}acetic acid","A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Reaxys:2146636|PMID:11322639|PMID:23777257|Drug_Central:865|PMID:1502708|Wikipedia:Diclofenac|Beilstein:2146636|ATC:D11AX18|ATC:M02AA15|CAS:15307-86-5|PMID:27967303|LINCS:LSM-2160|ATC:M01AB05|PMID:7838674|ATC:S01BC03|DrugBank:DB00586,,"A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.",,,,,,,,,,,,C14H11Cl2NO2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35493|http://purl.obolibrary.org/obo/CHEBI_35544|http://purl.obolibrary.org/obo/CHEBI_35703|http://purl.obolibrary.org/obo/CHEBI_35475|http://purl.obolibrary.org/obo/CHEBI_88188|http://purl.obolibrary.org/obo/CHEBI_78298|http://purl.obolibrary.org/obo/CHEBI_35481,,,,,"Diclofenac|2-[(2,6-dichlorophenyl)amino]benzeneacetic acid|{2-[(2,6-dichlorophenyl)amino]phenyl}acetic acid",,"diclofenac|[2-(2,6-dichloroanilino)phenyl]acetic acid|diclofenacum|diclofenamic acid|diclofenaco|2-((2,6-dichlorophenyl)amino)benzeneacetic acid|diclofenac acid",,,,,,,,,,,,,,,,,,,,,CHEBI:47381,,,,diclofenac,,CHEBI:47381,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,C1(Cl)=CC=CC(=C1NC2=CC=CC=C2CC(=O)O)Cl,,,,,
http://purl.obolibrary.org/obo/IMR_0000220,ZAP-70/Syk,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001054,,,,,,,,,,IMR:0000220,,,,,,,,,,,,,,,,,,,,,,ZAP-70/Syk,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0050996,positive regulation of lipid catabolic process,,"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of lipids.",false,,,http://purl.obolibrary.org/obo/TXPO_0001223,,,,,,,,,,,,,,,,,,,,,,"Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of lipids.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0050996,,,,,,,,,,,,,,,,,,,,,,positive regulation of lipid catabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0016042,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_60815,lysobisphosphatidic acid,bis(monoacylglycerol) hydrogen phosphate|BMP|LBPA,A lysophosphatidic acid having the unusual property of a phosphodiester moiety linked to positions sn-1 and sn1' of glycerol; and two additional fatty acids esterified to the glycerol head group.,false,,,http://purl.obolibrary.org/obo/CHEBI_32957,,,,,,,,,,,,,,,,,,,,"BMP is a negatively charged phospholipid found almost exclusively in late endosomes/lysosomes.
BMP content is higher in alveolar macrophages (18% of total phospholipids) than in other cell types.

BMP is a structural isomer of phosphatidylglycerol (PG) and is synthesized through a series of acylation and deacylation steps involving a transacylase.
BMP its unusual sn-1;sn-1′ structural configuration (based on the phosphate-linked glycerol carbon), which is not observed in other phospholipids.
 This unusual configuration is thought to play a role in the resistance of BMP to many phospholipases, and its stability in late endosomes/lysosomes. BMP stimulates the degradation of glycosphingolipids in coordination with lipid binding proteins (saposins) in lysosomes.
PMID:25795792",,A lysophosphatidic acid having the unusual property of a phosphodiester moiety linked to positions sn-1 and sn1' of glycerol; and two additional fatty acids esterified to the glycerol head group.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BMP|LBPA,,bis(monoacylglycerol) hydrogen phosphate,,,CHEBI:60815,,,,,,,,,,,,,,,,,,,,,,lysobisphosphatidic acid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000001576,CYP3A4,,"Other designations: 1,8-cineole 2-exo-monooxygenase|P450-III, steroid inducible|albendazole monooxygenase|albendazole sulfoxidase|cytochrome P450 3A3|cytochrome P450 3A4|cytochrome P450 HLp|cytochrome P450 NF-25|cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 3|cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 4|cytochrome P450-PCN1|glucocorticoid-inducible P450|nifedipine oxidase|quinine 3-monooxygenase|taurochenodeoxycholate 6-alpha-hydroxylase",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CYPIIIA3|P450C3|CP33|P450PCN1|NF-25|CP34|CYP3A3|CYP3A|HLP|CYPIIIA4,,,,,,,,,,,,7,,,,,,HGNC:2637|MIM:124010|HPRD:00484,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 3, subfamily A, polypeptide 4",,,7q21.1,,,,,,,,,,,,,,,,"GO_0004497 (EC: IDA, PMID:15327587); GO_0004497 (EC: ISS); GO_0005496 (EC: IDA, PMID:15256616); GO_0005506 (EC: IDA, PMID:15256616); GO_0005737 (EC: IDA, PMID:18446064); GO_0005789 (EC: TAS); GO_0006629 (EC: TAS, PMID:2492107); GO_0006706 (EC: IMP, PMID:18356043); GO_0006805 (EC: TAS); GO_0008202 (EC: IMP, PMID:3259858); GO_0008209 (EC: TAS, PMID:19651758); GO_0008395 (EC: IMP, PMID:18356043); GO_0009822 (EC: IDA, PMID:15039299); GO_0016021 (EC: IEA); GO_0016098 (EC: IDA, PMID:16401082); GO_0016491 (EC: IDA, PMID:15039299); GO_0016712 (EC: IEA); GO_0017144 (EC: IDA, PMID:15327587); GO_0019825 (EC: TAS, PMID:2492107); GO_0019899 (EC: IPI, PMID:15680923); GO_0020037 (EC: IEA); GO_0030343 (EC: IDA, PMID:15546903); GO_0033780 (EC: IEA); GO_0034875 (EC: IDA, PMID:18619574); GO_0036378 (EC: IDA, PMID:15546903); GO_0042359 (EC: IC, PMID:15546903); GO_0042737 (EC: IDA, PMID:15039299); GO_0042737 (EC: IMP, PMID:18356043); GO_0042738 (EC: IDA, PMID:18619574); GO_0043231 (EC: TAS, PMID:3460094); GO_0044281 (EC: TAS); GO_0046483 (EC: IDA, PMID:15327587); GO_0047638 (EC: IEA); GO_0050591 (EC: IEA); GO_0050649 (EC: IMP, PMID:3259858); GO_0055114 (EC: IDA, PMID:16401082); GO_0070576 (EC: IDA, PMID:15546903); GO_0070989 (EC: IDA, PMID:15039299)",,,,,,,,,PMID:1391968; 2463251; 2492107; 3243766; 3259858; 3267210; 3460094; 3464943; 3898085; 8269949; 9088578; 9394023; 9456308; 9890157; 10222036; 10322772; 10668853; 10933049; 11051261; 11067821; 11137287; 11161840; 11181494; 11266076; 11470997; 11549683; 11714865; 11726664; 11745731; 11749050; 11782366; 11809184; 11875366; 11876753; 11890939; 11907494; 11940601; 11956645; 11991950; 12072427; 12107441; 12130689; 12142725; 12147248; 12151999; 12202670; 12419838; 12439220; 12446983; 12464248; 12477932; 12485945; 12493773; 12532467; 12569554; 12623762; 12644831; 12690205; 12692107; 12695546; 12732844; 12738724; 12747609; 12756206; 12756210; 12809821; 12867495; 12900870; 12900872; 12960109; 12966368; 12969965; 12975335; 14504207; 14515058; 14515059; 14580164; 14640293; 14643022; 14660173; 14681232; 14690448; 14693733; 14697480; 14742674; 15039299; 15114431; 15128046; 15256616; 15258162; 15260917; 15277015; 15307840; 15319333; 15327587; 15334674; 15365656; 15370963; 15379787; 15454728; 15459178; 15462611; 15469410; 15475069; 15496535; 15496639; 15523087; 15540736; 15546903; 15548719; 15592326; 15611481; 15618745; 15622315; 15634941; 15650881; 15680923; 15684873; 15698606; 15707415; 15708356; 15708542; 15713537; 15731117; 15770073; 15770075; 15778453; 15801936; 15817670; 15820320; 15882469; 15896485; 15900215; 15900284; 15901749; 15931768; 15932952; 15981231; 16004554; 16006997; 16059671; 16079101; 16103451; 16109480; 16130011; 16146556; 16172230; 16207150; 16243813; 16267764; 16299241; 16306861; 16314882; 16321621; 16324277; 16338276; 16344560; 16401082; 16414488; 16434211; 16467307; 16507515; 16538176; 16580902; 16608838; 16633141; 16645157; 16684709; 16711396; 16758258; 16765145; 16771603; 16842392; 16862439; 16890574; 16890579; 16906020; 16909599; 16924387; 16954191; 16981844; 16985250; 17007050; 17014074; 17015051; 17042920; 17047492; 17065585; 17083953; 17118447; 17119944; 17162468; 17178267; 17200113; 17220347; 17224914; 17270371; 17279585; 17296590; 17352764; 17357589; 17363580; 17364054; 17367411; 17372239; 17373732; 17392393; 17409981; 17418993; 17429319; 17433262; 17434921; 17460031; 17460547; 17465708; 17495874; 17495878; 17495880; 17498886; 17502835; 17526062; 17526937; 17545536; 17548528; 17548691; 17555301; 17582393; 17601520; 17605821; 17609736; 17615053; 17622974; 17624028; 17634410; 17635182; 17691855; 17697139; 17701008; 17704997; 17724065; 17764444; 17766366; 17827338; 17827444; 17854673; 17880367; 17900275; 17912464; 17918187; 17919092; 17919884; 17922881; 17925385; 17925548; 17952011; 17965521; 17974099; 17985934; 17992531; 18004209; 18004210; 18021343; 18028890; 18052847; 18058330; 18092806; 18097620; 18163429; 18192894; 18211048; 18217151; 18223457; 18231117; 18240903; 18258609; 18268015; 18294295; 18294936; 18309947; 18332045; 18348473; 18356043; 18364084; 18382661; 18385010; 18394438; 18408564; 18431572; 18433425; 18446064; 18496131; 18509327; 18518855; 18528690; 18551040; 18566991; 18569587; 18619574; 18632753; 18636247; 18669585; 18688081; 18704002; 18768784; 18781853; 18784074; 18794335; 18825162; 18854779; 18936436; 18957504; 18976975; 18978522; 18979093; 18981009; 18981011; 18989234; 18996102; 19005401; 19020497; 19027952; 19064572; 19070657; 19074750; 19076156; 19077426; 19103148; 19127255; 19143748; 19206087; 19214745; 19219744; 19225447; 19228205; 19228751; 19232333; 19239339; 19242060; 19258929; 19282874; 19332043; 19337788; 19339270; 19343046; 19343062; 19343327; 19349540; 19350405; 19356113; 19376514; 19395426; 19406954; 19414505; 19420105; 19424794; 19433561; 19451401; 19453261; 19460945; 19470925; 19474452; 19480557; 19505920; 19506580; 19538885; 19546880; 19560436; 19571438; 19574343; 19575027; 19576320; 19591893; 19626470; 19636001; 19651758; 19659438; 19667110; 19692168; 19696793; 19712670; 19727863; 19752211; 19761365; 19762492; 19773538; 19784640; 19797609; 19801957; 19802823; 19812066; 19823875; 19833260; 19842932; 19846565; 19865079; 19907160; 19913121; 19921206; 19926050; 19934400; 19934793; 19937844; 19956635; 19963139; 20007670; 20012430; 20017669; 20027111; 20031551; 20038391; 20068078; 20088394; 20118548; 20136364; 20147837; 20147896; 20171174; 20173083; 20212519; 20213484; 20214802; 20218903; 20235787; 20338069; 20350051; 20350136; 20354687; 20361990; 20386561; 20389299; 20395213; 20403997; 20437850; 20453000; 20459744; 20490798; 20505544; 20523106; 20526235; 20529763; 20530282; 20538049; 20538721; 20578904; 20583967; 20588308; 20602612; 20602615; 20604570; 20615193; 20617557; 20621111; 20625352; 20628086; 20630055; 20634197; 20642445; 20654748; 20656072; 20679960; 20682687; 20697309; 20715157; 20734064; 20809279; 20812728; 20833683; 20841961; 20847137; 20849814; 20861742; 20863320; 20879989; 20884258; 20931330; 20951982; 20959500; 20970553; 21047202; 21063236; 21071160; 21072155; 21072184; 21081028; 21081644; 21114969; 21169260; 21177853; 21186373; 21199372; 21207936; 21209460; 21223952; 21292004; 21342487; 21380731; 21402137; 21402692; 21412247; 21433154; 21471209; 21493872; 21513075; 21566342; 21605066; 21692828; 21750466; 21767526; 21798277; 21835977; 21838784; 21863748; 21886157; 21902501; 21902502; 21903774; 21916909; 21925256; 21940338; 21952236; 21963990; 21964586; 21988832; 21992114; 21996064; 21998292; 22050110; 22076448; 22094027; 22096084; 22101235; 22106171; 22108774; 22157006; 22194603; 22277676; 22292071; 22333269; 22369694; 22388796; 22472546; 22510778; 22517972; 22562045; 22617232; 22621802; 22645092; 22677141; 22696420; 22699155; 22728071; 22741198; 22763214; 22773874; 22885098; 22906825; 22945461; 22971138; 22985909; 22990330; 22993851; 23090875; 23107770; 23129512; 23143891; 23146479; 23160340; 23162896; 23179402; 23212742; 23217392; 23223499; 23252948; 23264496; 23277250; 23290512; 23295386; 23313934; 23320986; 23334403; 23361102; 23400261; 23436703; 23459029; 23469989; 23491640; 23510058; 23527115; 23530020; 23557865; 23574760; 23640974; 23665933; 23715232; 23732298; 23746300; 23780963; 23837477; 23965431; 23977680; 24256945; 24273886,,,,,,,,,,,,,,,OGG:3000001576,,,,,,,"cytochrome P450, family 3, subfamily A, polypeptide 4",,,,,,,,,,,,,"Other designations: 1,8-cineole 2-exo-monooxygenase|P450-III, steroid inducible|albendazole monooxygenase|albendazole sulfoxidase|cytochrome P450 3A3|cytochrome P450 3A4|cytochrome P450 HLp|cytochrome P450 NF-25|cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 3|cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 4|cytochrome P450-PCN1|glucocorticoid-inducible P450|nifedipine oxidase|quinine 3-monooxygenase|taurochenodeoxycholate 6-alpha-hydroxylase",,CYP3A4,,,,,,,,,,,,,,,,,,,,,,,1576,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP3A4,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001572,CYP2F1,,"Other designations: CYPIIF1|cytochrome P450 2F1|cytochrome P450, subfamily IIF, polypeptide 1|flavoprotein-linked monooxygenase|microsomal monooxygenase|xenobiotic monooxygenase",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,C2F1|CYP2F,,,,,,,,,,,,19,,,,,,HPRD:00490|HGNC:2632|Vega:OTTHUMG00000167412|Ensembl:ENSG00000197446|MIM:124070,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 2, subfamily F, polypeptide 1",,,19q13.2,,,,,,,,,,,,,,,,"GO_0004497 (EC: TAS, PMID:1974816); GO_0005506 (EC: IEA); GO_0005789 (EC: TAS); GO_0006805 (EC: TAS); GO_0009636 (EC: IEA); GO_0016712 (EC: IDA, PMID:10383923); GO_0018931 (EC: IDA, PMID:10383923); GO_0018979 (EC: IEA); GO_0019825 (EC: IEA); GO_0020037 (EC: IEA); GO_0043231 (EC: IDA, PMID:10383923); GO_0044281 (EC: TAS); GO_0070330 (EC: IEA)",,,,,,,,,PMID:1974816; 2045106; 8432525; 8587134; 8619884; 9539103; 10383923; 11827709; 12477932; 12598524; 15128046; 16883522; 17327131; 17943660; 19343046; 20198857; 22232929; 22397853,,,,,,,,,,,,,,,OGG:3000001572,,,,,,,"cytochrome P450, family 2, subfamily F, polypeptide 1",,,,,,,,,,,,,"Other designations: CYPIIF1|cytochrome P450 2F1|cytochrome P450, subfamily IIF, polypeptide 1|flavoprotein-linked monooxygenase|microsomal monooxygenase|xenobiotic monooxygenase",,CYP2F1,,,,,,,,,,,,,,,,,,,,,,,1572,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP2F1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001571,CYP2E1,,"Other designations: 4-nitrophenol 2-hydroxylase|CYPIIE1|cytochrome P450 2E1|cytochrome P450, subfamily IIE (ethanol-inducible), polypeptide 1|cytochrome P450-J|flavoprotein-linked monooxygenase|microsomal monooxygenase|xenobiotic monooxygenase",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,P450C2E|CYP2E|CPE1|P450-J,,,,,,,,,,,,10,,,,,,HPRD:11813|HGNC:2631|Ensembl:ENSG00000130649|Vega:OTTHUMG00000019322|MIM:124040,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 2, subfamily E, polypeptide 1",,,10q26.3,,,,,,,,,,,,,,,,"GO_0000139 (EC: IEA); GO_0004497 (EC: IDA, PMID:19651758); GO_0005506 (EC: IEA); GO_0005739 (EC: IEA); GO_0005789 (EC: TAS); GO_0006641 (EC: IEA); GO_0006805 (EC: TAS); GO_0008202 (EC: IMP, PMID:18356043); GO_0010193 (EC: IEA); GO_0010243 (EC: IEA); GO_0016098 (EC: IDA, PMID:16401082); GO_0016491 (EC: IDA, PMID:16401082); GO_0016709 (EC: TAS, PMID:18818195); GO_0016712 (EC: IEA); GO_0017144 (EC: IDA, PMID:19219744); GO_0017144 (EC: IMP, PMID:18356043); GO_0019825 (EC: TAS, PMID:3233219); GO_0019899 (EC: IPI, PMID:15680923); GO_0020037 (EC: IDA, PMID:18818195); GO_0031227 (EC: IEA); GO_0042493 (EC: IEA); GO_0044281 (EC: TAS); GO_0045471 (EC: IEA); GO_0046483 (EC: IDA, PMID:19651758); GO_0055114 (EC: IDA, PMID:16401082)",,,,,,,,,PMID:1719479; 1778977; 2587619; 3233219; 3675576; 3782137; 7529759; 7733943; 7773503; 8031147; 8307581; 8809087; 9058590; 9129165; 9398194; 9834965; 9890157; 9918138; 10620320; 10731522; 10741631; 11051375; 11104220; 11191882; 11198676; 11207032; 11236836; 11259352; 11263781; 11275366; 11305777; 11331106; 11377232; 11389775; 11406608; 11410713; 11422615; 11503278; 11520401; 11535247; 11535253; 11641039; 11675150; 11696658; 11697456; 11700262; 11701230; 11719088; 11746208; 11748356; 11751440; 11756225; 11766168; 11774269; 11776598; 11782477; 11798822; 11802217; 11815398; 11854903; 11869835; 11895912; 11907164; 11911601; 11960914; 11964928; 11966948; 12010862; 12047484; 12055050; 12063626; 12080432; 12115524; 12172927; 12198369; 12211622; 12351530; 12355548; 12365037; 12376502; 12376511; 12397416; 12403788; 12452057; 12454736; 12460800; 12469218; 12477932; 12490624; 12540498; 12548461; 12552594; 12554615; 12561466; 12563175; 12569554; 12579334; 12601351; 12668988; 12705718; 12707490; 12710951; 12718576; 12718671; 12721789; 12732844; 12738724; 12739102; 12759747; 12760253; 12767509; 12771559; 12774019; 12777398; 12777962; 12777965; 12813050; 12824748; 12824892; 12851035; 12860273; 12883487; 12883749; 12915519; 12939804; 12940444; 12960506; 14499622; 14500779; 14510941; 14527082; 14535982; 14578150; 14606109; 14634838; 14646291; 14661969; 14669323; 14681495; 14691069; 14695651; 14695664; 14696128; 14751678; 14757192; 14991750; 15036355; 15039299; 15061915; 15064998; 15066574; 15112335; 15125228; 15128046; 15138035; 15162526; 15177663; 15182482; 15215328; 15220553; 15226677; 15289170; 15318112; 15327835; 15349722; 15355699; 15370874; 15469410; 15491310; 15519646; 15532721; 15536330; 15632182; 15633127; 15640066; 15646021; 15660387; 15680923; 15712341; 15714076; 15734972; 15753073; 15763499; 15769360; 15774926; 15780023; 15793883; 15849806; 15899651; 15902904; 15914211; 15914277; 15928955; 15938845; 15952134; 15961886; 15968714; 15991278; 16006997; 16019049; 16039674; 16043197; 16052683; 16125881; 16126235; 16137184; 16142352; 16172237; 16235983; 16235992; 16253141; 16311924; 16324524; 16337880; 16365683; 16372174; 16380384; 16385451; 16393248; 16401082; 16424825; 16425414; 16440362; 16459354; 16470306; 16471212; 16484137; 16488179; 16497268; 16535827; 16551616; 16600530; 16634857; 16679316; 16720291; 16721740; 16758119; 16770646; 16834659; 16837478; 16841220; 16962935; 16985026; 16985032; 17007050; 17016589; 17022435; 17034788; 17059334; 17078101; 17118447; 17119198; 17119944; 17134659; 17146594; 17156750; 17176083; 17178637; 17219769; 17264406; 17284772; 17292341; 17331164; 17361553; 17367411; 17373732; 17380320; 17384900; 17427487; 17440116; 17442289; 17486761; 17498780; 17559142; 17564586; 17577619; 17584020; 17603900; 17611777; 17617119; 17627011; 17659824; 17695473; 17885617; 17916905; 17935737; 17950035; 17963298; 17996038; 18025800; 18028774; 18034693; 18056994; 18211048; 18218609; 18231117; 18258609; 18261353; 18304215; 18322963; 18327668; 18356043; 18369917; 18418580; 18420361; 18423013; 18446064; 18460770; 18466102; 18472009; 18473182; 18497573; 18507060; 18510611; 18544910; 18550589; 18569579; 18569587; 18569591; 18628434; 18636124; 18642288; 18645668; 18663376; 18676680; 18698632; 18713495; 18715838; 18726416; 18769766; 18773092; 18798002; 18798003; 18801337; 18818195; 18936436; 18990750; 18992148; 19012698; 19058336; 19064572; 19074885; 19096130; 19115622; 19124503; 19131562; 19157621; 19157724; 19170196; 19190172; 19219744; 19230487; 19250143; 19267064; 19288740; 19290787; 19334053; 19336370; 19339548; 19343046; 19351467; 19357030; 19381774; 19382518; 19390575; 19428381; 19442564; 19481674; 19484729; 19489076; 19492240; 19506726; 19521675; 19528831; 19537956; 19575027; 19625176; 19643819; 19651758; 19655364; 19686770; 19692168; 19706845; 19751749; 19761367; 19786980; 19789190; 19796841; 19805575; 19822571; 19826048; 19860798; 19874574; 19887496; 19891553; 19913121; 19927646; 19948975; 19956635; 19958676; 19963114; 19963139; 20026093; 20029944; 20031389; 20093049; 20095411; 20100563; 20100738; 20101753; 20102722; 20117323; 20131310; 20171022; 20173083; 20180013; 20195803; 20364586; 20392357; 20394984; 20401433; 20404016; 20406102; 20426969; 20437058; 20453000; 20463018; 20511665; 20529763; 20554493; 20556843; 20576306; 20598484; 20602615; 20628086; 20634891; 20637790; 20661821; 20663217; 20675267; 20692331; 20715111; 20819434; 20932821; 20939108; 20941486; 20957336; 20958328; 20969746; 21072184; 21076874; 21209460; 21228414; 21261721; 21265876; 21281483; 21295098; 21360299; 21385088; 21553050; 21557999; 21590276; 21705789; 21729529; 21745589; 21856753; 21869556; 21895718; 21988832; 22012226; 22077825; 22088806; 22109568; 22126492; 22155602; 22156006; 22222162; 22228187; 22230367; 22238121; 22249978; 22251540; 22335459; 22342293; 22384697; 22392284; 22436864; 22442693; 22485222; 22506592; 22589738; 22591346; 22606226; 22613106; 22614694; 22761909; 22788240; 22807108; 22815852; 22954124; 22957075; 22997752; 23007992; 23066397; 23077626; 23104821; 23124075; 23131254; 23139769; 23186213; 23193974; 23193996; 23244081; 23251661; 23335995; 23355335; 23363738; 23394127; 23404349; 23418369; 23454624; 23460870; 23471973; 23530020; 23534720; 23583009; 23595220; 23628324; 23632049; 23636797; 23660503; 23707663; 23875638; 23886179; 23934444; 24113184; 24333271,,,,,,,,,,,,,,,OGG:3000001571,,,,,,,"cytochrome P450, family 2, subfamily E, polypeptide 1",,,,,,,,,,,,,"Other designations: 4-nitrophenol 2-hydroxylase|CYPIIE1|cytochrome P450 2E1|cytochrome P450, subfamily IIE (ethanol-inducible), polypeptide 1|cytochrome P450-J|flavoprotein-linked monooxygenase|microsomal monooxygenase|xenobiotic monooxygenase",,CYP2E1,,,,,,,,,,,,,,,,,,,,,,,1571,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP2E1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001573,CYP2J2,,"Other designations: CYPIIJ2|arachidonic acid epoxygenase|cytochrome P450 2J2|cytochrome P450, subfamily IIJ (arachidonic acid epoxygenase) polypeptide 2|flavoprotein-linked monooxygenase|microsomal monooxygenase",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CPJ2,,,,,,,,,,,,1,,,,,,HPRD:03159|Ensembl:ENSG00000134716|HGNC:2634|Vega:OTTHUMG00000008991|MIM:601258,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 2, subfamily J, polypeptide 2",,,1p31.3-p31.2,,,,,,,,,,,,,,,,"GO_0005506 (EC: IEA); GO_0005789 (EC: TAS); GO_0006690 (EC: TAS, PMID:8631948); GO_0006805 (EC: TAS, PMID:11901223); GO_0008016 (EC: TAS, PMID:8631948); GO_0008392 (EC: IDA, PMID:11901223); GO_0008404 (EC: IDA, PMID:11901223); GO_0008405 (EC: IDA, PMID:11901223); GO_0019369 (EC: TAS); GO_0019373 (EC: IDA, PMID:11901223); GO_0019373 (EC: TAS); GO_0020037 (EC: IEA); GO_0043651 (EC: IDA, PMID:11901223); GO_0044281 (EC: TAS); GO_0070330 (EC: IEA); GO_0071614 (EC: IDA, PMID:11901223)",,,,,,,,,PMID:8631948; 8913342; 9048644; 9187259; 9570962; 10065373; 10405341; 10681399; 10828211; 11901223; 12386130; 12477932; 12737630; 14575523; 14702039; 15128046; 15256482; 15361551; 15466638; 15489334; 15861034; 15864120; 16008525; 16182271; 16202848; 16842392; 16957870; 17126841; 17162467; 17286575; 17327508; 17429317; 17470359; 17475630; 17638876; 17705402; 17979511; 18004755; 18216721; 18219097; 18303964; 18496133; 18675280; 18729130; 18769365; 19105833; 19290787; 19420105; 19448409; 19550113; 19576320; 19578796; 19615687; 19823578; 19851119; 19913121; 19923256; 20140850; 20173083; 20379614; 20480811; 20597138; 20628086; 21030485; 21059750; 21642892; 21988832; 22028915; 22232929; 22731644; 22761738; 23155181; 23647230; 23661295; 23684773; 23696562,,,,,,,,,,,,,,,OGG:3000001573,,,,,,,"cytochrome P450, family 2, subfamily J, polypeptide 2",,,,,,,,,,,,,"Other designations: CYPIIJ2|arachidonic acid epoxygenase|cytochrome P450 2J2|cytochrome P450, subfamily IIJ (arachidonic acid epoxygenase) polypeptide 2|flavoprotein-linked monooxygenase|microsomal monooxygenase",,CYP2J2,,,,,,,,,,,,,,,,,,,,,,,1573,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP2J2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001577,CYP3A5,,"Other designations: aryl hydrocarbon hydroxylase|cytochrome P450 3A5|cytochrome P450 HLp2|cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 5|cytochrome P450-PCN3|flavoprotein-linked monooxygenase|microsomal monooxygenase|xenobiotic monooxygenase",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,P450PCN3|CP35|PCN3|CYPIIIA5,,,,,,,,,,,,7,,,,,,Ensembl:ENSG00000106258|MIM:605325|HGNC:2638|HPRD:05617|Vega:OTTHUMG00000156724,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 3, subfamily A, polypeptide 5",,,7q21.1,,,,,,,,,,,,,,,,"GO_0004497 (EC: ISS); GO_0005506 (EC: IEA); GO_0005789 (EC: TAS); GO_0006805 (EC: TAS); GO_0008202 (EC: TAS, PMID:2732228); GO_0009822 (EC: IDA, PMID:15039299); GO_0016491 (EC: IDA, PMID:15039299); GO_0019825 (EC: TAS, PMID:2732228); GO_0020037 (EC: IEA); GO_0042737 (EC: IDA, PMID:15039299); GO_0043231 (EC: TAS, PMID:2732228); GO_0044281 (EC: TAS); GO_0070330 (EC: IEA); GO_0070989 (EC: IDA, PMID:15039299)",,,,,,,,,PMID:2732228; 2802615; 7750548; 7811260; 7883227; 7894497; 7895614; 8004129; 8125298; 8569713; 8619878; 8619884; 8694864; 8869826; 8877031; 8889549; 8946469; 9070608; 9364212; 9797707; 9890157; 10069460; 10403825; 11137287; 11266076; 11279519; 11502729; 11726664; 11740341; 11809184; 11836601; 12042671; 12202670; 12242601; 12324482; 12433824; 12439220; 12477932; 12690205; 12692107; 12694732; 12754175; 12756511; 12814460; 12822676; 12853948; 12893984; 12960109; 12966368; 12969965; 12975492; 14504207; 14515058; 14515059; 14647405; 14676821; 14702039; 14747421; 14961555; 15039299; 15114431; 15116055; 15128046; 15167702; 15226679; 15248218; 15252010; 15284534; 15289787; 15319333; 15385835; 15454734; 15469410; 15489334; 15502717; 15548719; 15592326; 15596297; 15596575; 15622315; 15632378; 15634941; 15698606; 15707415; 15708542; 15729180; 15801936; 15808586; 15814280; 15833928; 15876487; 15882469; 15900215; 15900284; 15919447; 15931768; 15952872; 15961978; 15978331; 15981231; 16004554; 16024008; 16086282; 16116487; 16141800; 16160620; 16168193; 16172230; 16188140; 16207150; 16243813; 16249748; 16253141; 16267764; 16272171; 16272955; 16299241; 16306861; 16314882; 16321621; 16338276; 16361630; 16421475; 16424824; 16442753; 16513443; 16584389; 16595916; 16612255; 16612333; 16614106; 16628701; 16638864; 16684709; 16765145; 16765147; 16769602; 16771603; 16772608; 16791115; 16815317; 16822233; 16827636; 16842392; 16847425; 16906018; 16906020; 17015051; 17032130; 17042920; 17047492; 17048977; 17049058; 17049128; 17162466; 17178265; 17178267; 17192506; 17192769; 17198275; 17224914; 17244352; 17264302; 17286792; 17296590; 17329995; 17339868; 17352764; 17358097; 17363580; 17372036; 17373732; 17377957; 17391324; 17395652; 17425754; 17430486; 17443134; 17450472; 17460031; 17495880; 17495881; 17502835; 17510208; 17517050; 17545536; 17554244; 17568575; 17582393; 17605821; 17615053; 17635176; 17635181; 17635182; 17691921; 17700595; 17701008; 17761709; 17827141; 17851225; 17875118; 17885626; 17900275; 17914095; 17922881; 17925548; 17941052; 17979504; 17979523; 17992026; 18021343; 18024866; 18028890; 18058330; 18192894; 18211618; 18212618; 18214455; 18221820; 18223457; 18240903; 18248681; 18294295; 18300941; 18306354; 18309947; 18315786; 18315894; 18319058; 18322448; 18334918; 18382661; 18385010; 18385991; 18394438; 18408564; 18414696; 18429967; 18443548; 18490434; 18496128; 18496131; 18502461; 18509327; 18509328; 18509645; 18518855; 18551040; 18566991; 18582803; 18587567; 18589174; 18597650; 18603015; 18628519; 18636247; 18641551; 18650247; 18688081; 18704002; 18708991; 18727922; 18752284; 18930278; 18936931; 18978522; 18979093; 18981009; 18989234; 18996102; 19005401; 19005461; 19010156; 19033450; 19034006; 19040121; 19064572; 19067682; 19074750; 19076156; 19106083; 19106084; 19114346; 19125240; 19139162; 19141860; 19205682; 19225447; 19228205; 19228751; 19229255; 19239339; 19258929; 19289993; 19290787; 19290795; 19332043; 19337788; 19343046; 19343327; 19349540; 19350405; 19376366; 19376514; 19384171; 19384264; 19414505; 19414633; 19424794; 19470925; 19474452; 19506580; 19516253; 19523815; 19538885; 19545678; 19546880; 19576320; 19584153; 19591893; 19593168; 19636001; 19644155; 19650988; 19659438; 19663817; 19667110; 19693007; 19696793; 19710077; 19730841; 19744012; 19761365; 19762492; 19801957; 19812606; 19817997; 19823770; 19842932; 19855314; 19865079; 19881258; 19904021; 19907160; 19913121; 19916993; 19925383; 19934793; 19946748; 20010459; 20017669; 20030680; 20031551; 20038391; 20040338; 20041908; 20118548; 20133509; 20136364; 20147896; 20160155; 20172323; 20173083; 20179710; 20207952; 20212519; 20214802; 20218903; 20231858; 20235787; 20332423; 20345875; 20354687; 20357698; 20368718; 20383212; 20389299; 20393454; 20395213; 20403997; 20415563; 20430047; 20453000; 20459744; 20479955; 20490798; 20514078; 20526235; 20529763; 20530282; 20565970; 20588203; 20596503; 20602615; 20615193; 20617557; 20621111; 20625352; 20628086; 20630055; 20662624; 20679960; 20696882; 20716514; 20720558; 20818295; 20833683; 20846929; 20860463; 20873239; 20881953; 20931330; 20959405; 20959500; 20970553; 20970601; 20970628; 20970643; 21039054; 21047202; 21072155; 21072184; 21076384; 21081028; 21094057; 21094796; 21094797; 21148251; 21153923; 21165655; 21173786; 21206424; 21209234; 21225912; 21237140; 21265876; 21380731; 21389905; 21418106; 21434577; 21436775; 21493872; 21513075; 21519338; 21544031; 21644845; 21677300; 21698374; 21711429; 21743379; 21770725; 21806386; 21814220; 21839244; 21851254; 21896346; 21916909; 21950641; 21988832; 22007612; 22022918; 22096084; 22210422; 22214815; 22277678; 22292071; 22304537; 22369694; 22511346; 22610055; 22645092; 22696420; 22704849; 22819265; 22875663; 22889968; 22923690; 22993851; 23023417; 23073208; 23107770; 23131698; 23143606; 23143891; 23146466; 23146479; 23149441; 23223499; 23320986; 23354298; 23364483; 23385102; 23432535; 23459029; 23491640; 23557865; 23584898; 23633119; 23700791; 23715232; 23723360; 23734777; 23780963; 23837476; 23845965; 23873120; 23984379,,,,,,,,,,,,,,,OGG:3000001577,,,,,,,"cytochrome P450, family 3, subfamily A, polypeptide 5",,,,,,,,,,,,,"Other designations: aryl hydrocarbon hydroxylase|cytochrome P450 3A5|cytochrome P450 HLp2|cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 5|cytochrome P450-PCN3|flavoprotein-linked monooxygenase|microsomal monooxygenase|xenobiotic monooxygenase",,CYP3A5,,,,,,,,,,,,,,,,,,,,,,,1577,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP3A5,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001579,CYP4A11,,"Other designations: 20-HETE synthase|20-hydroxyeicosatetraenoic acid synthase|CYPIVA11|P450HL-omega|alkane-1 monooxygenase|cytochrome P-450HK-omega|cytochrome P450 4A11|cytochrome P450, subfamily IVA, polypeptide 11|cytochrome P450HL-omega|fatty acid omega-hydroxylase|lauric acid omega-hydroxylase",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CYP4A2|CYP4AII|CP4Y,,,,,,,,,,,,1,,,,,,HPRD:03201|MIM:601310|Vega:OTTHUMG00000008020|HGNC:2642|Ensembl:ENSG00000187048,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 4, subfamily A, polypeptide 11",,,1p33,,,,,,,,,,,,,,,,"GO_0001676 (EC: IDA, PMID:18433732); GO_0003091 (EC: IEP, PMID:10660572); GO_0003095 (EC: IEP, PMID:10660572); GO_0005506 (EC: IEA); GO_0005737 (EC: IDA, PMID:10660572); GO_0005789 (EC: TAS); GO_0006631 (EC: TAS, PMID:7679927); GO_0006691 (EC: IDA, PMID:9799565); GO_0006805 (EC: TAS); GO_0008392 (EC: IDA, PMID:9618440); GO_0016324 (EC: IDA, PMID:10660572); GO_0018685 (EC: IDA, PMID:18433732); GO_0019369 (EC: IDA, PMID:10660572); GO_0019369 (EC: TAS); GO_0019373 (EC: IDA, PMID:9618440); GO_0020037 (EC: IEA); GO_0032305 (EC: IMP, PMID:18391101); GO_0036101 (EC: IDA, PMID:9799565); GO_0043231 (EC: IDA, PMID:10660572); GO_0044255 (EC: TAS); GO_0044281 (EC: TAS); GO_0050051 (EC: IDA, PMID:9799565); GO_0052869 (EC: IEA); GO_0055078 (EC: IEP, PMID:10660572); GO_0055114 (EC: IDA, PMID:18433732); GO_0097267 (EC: TAS)",,,,,,,,,PMID:1739747; 7679927; 7798189; 8274222; 8363569; 8914854; 9618440; 9799565; 10024026; 10660572; 10860550; 11139583; 11736898; 11821421; 12464261; 12464262; 12477932; 15028279; 15128046; 15319333; 15611369; 16144986; 16957555; 18227405; 18300855; 18385420; 18391101; 18433732; 18484194; 18574070; 18624398; 18660489; 18936345; 19343046; 19366684; 19615687; 19898482; 20130494; 21326303; 21617944; 21820496; 21873888; 21886157; 21912424; 22327816; 22804341; 23085321,,,,,,,,,,,,,,,OGG:3000001579,,,,,,,"cytochrome P450, family 4, subfamily A, polypeptide 11",,,,,,,,,,,,,"Other designations: 20-HETE synthase|20-hydroxyeicosatetraenoic acid synthase|CYPIVA11|P450HL-omega|alkane-1 monooxygenase|cytochrome P-450HK-omega|cytochrome P450 4A11|cytochrome P450, subfamily IVA, polypeptide 11|cytochrome P450HL-omega|fatty acid omega-hydroxylase|lauric acid omega-hydroxylase",,CYP4A11,,,,,,,,,,,,,,,,,,,,,,,1579,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP4A11,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0002958,Dlp/Dally,,,false,,,http://purl.obolibrary.org/obo/IMR_0001139,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0002958,,,,,,,,,,,,,,,,,,,,,,Dlp/Dally,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0008380,RNA splicing,,The process of removing sections of the primary RNA transcript to remove sequences not present in the mature form of the RNA and joining the remaining sections to form the mature form of the RNA.,false,,,http://purl.obolibrary.org/obo/TXPO_0000333,,,,,,,,,,,,,,,,,,,,,,The process of removing sections of the primary RNA transcript to remove sequences not present in the mature form of the RNA and joining the remaining sections to form the mature form of the RNA.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0008380,,,,,,,,,,,,,,,,,,,,,,RNA splicing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0002516,nonclassical MHC class II molecule,,"MHC class II-like proteins are produced from the class II region of the MHC, HLA-DM (DM) and HLA-DO (DO) (called H2-M, or H2-DM and H2-O in the mouse).",false,,,http://purl.obolibrary.org/obo/IMR_0000142,,,,,,,,,,,,,,,,,,,,,,"MHC class II-like proteins are produced from the class II region of the MHC, HLA-DM (DM) and HLA-DO (DO) (called H2-M, or H2-DM and H2-O in the mouse).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0002516,,,,,,,,,,,,,,,,,,,,,,nonclassical MHC class II molecule,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100157,enkephalin,,,false,,,http://purl.obolibrary.org/obo/IMR_0100153,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_25512,,,,,,,,,,IMR:0100157,,,,,,,,,,,,,,,,,,,,,,enkephalin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0200251,L-Alanine,,,false,,,http://purl.obolibrary.org/obo/CHEBI_33709,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0200251,,,,,,,,,,,,,,,,,,,,,,L-Alanine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0003026,alpha PIX,,,false,,,http://purl.obolibrary.org/obo/IMR_0001954,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0003026,,,,,,,,,,,,,,,,,,,,,,alpha PIX,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006913,nucleocytoplasmic transport,,The directed movement of molecules between the nucleus and the cytoplasm.,false,,,http://purl.obolibrary.org/obo/GO_0051169,,,,,,,,,,,,,,,,,,,,,,The directed movement of molecules between the nucleus and the cytoplasm.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0006913,,,,,,,,,,,,,,,,,,,,,,nucleocytoplasmic transport,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006914,autophagy,,The cellular catabolic process in which cells digest parts of their own cytoplasm; allows for both recycling of macromolecular constituents under conditions of cellular stress and remodeling the intracellular structure for cell differentiation,false,,,http://purl.obolibrary.org/obo/GO_0009056,,,,,,,,,,,,,,,,,,,,Wikipedia:Autophagy_(cellular),,The cellular catabolic process in which cells digest parts of their own cytoplasm; allows for both recycling of macromolecular constituents under conditions of cellular stress and remodeling the intracellular structure for cell differentiation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0006914,,,,,,,,,,,,,,,,,,,,,,autophagy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006915,apoptotic process,apoptotic cell death|programmed cell death by apoptosis|apoptotic programmed cell death,"A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died.",false,,,http://purl.obolibrary.org/obo/GO_0008219,,,,,,,,,,,,,,,,,,,,IEV:0000070 (obsolete)|Wikipedia:Apoptosis,,"A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000000,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,apoptotic cell death|programmed cell death by apoptosis|apoptotic programmed cell death,,,,,GO:0006915,,,,,,,,,,,,,,,,,,,,,,apoptotic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006910,"phagocytosis, recognition",recognition of phagocytosed substance by phagocytic cell,"The initial step in phagocytosis involving adhesion to bacteria, immune complexes and other particulate matter, or an apoptotic cell and based on recognition of factors such as bacterial cell wall components, opsonins like complement and antibody or protein receptors and lipids like phosphatidyl serine, and leading to intracellular signaling in the phagocytosing cell.|Note that cell surface molecules involved in the direct binding of bacteria may be also annotated to the molecular function term 'bacterial cell surface binding ; GO:0051635'. Note that cell surface molecules involved in the direct binding to opsonins such as complement components or antibodies may be also annotated to the term 'opsonin binding ; GO:0001846'.",false,,,http://purl.obolibrary.org/obo/TXPO_0000379,,,,,,,,,,,,,,,,,,,,,,"The initial step in phagocytosis involving adhesion to bacteria, immune complexes and other particulate matter, or an apoptotic cell and based on recognition of factors such as bacterial cell wall components, opsonins like complement and antibody or protein receptors and lipids like phosphatidyl serine, and leading to intracellular signaling in the phagocytosing cell.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,recognition of phagocytosed substance by phagocytic cell,,,,http://purl.obolibrary.org/obo/GO_0006909,GO:0006910,http://purl.obolibrary.org/obo/GO_0006909,,,,,,,,,,,,,,,,,,,Note that cell surface molecules involved in the direct binding of bacteria may be also annotated to the molecular function term 'bacterial cell surface binding ; GO:0051635'. Note that cell surface molecules involved in the direct binding to opsonins such as complement components or antibodies may be also annotated to the term 'opsonin binding ; GO:0001846'.,,"phagocytosis, recognition",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001796,AKT signaling (primitive) [Phospholipidosis (excessive defense) ],,"AKT signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal transmitted by the intracellular serine/threonine kinase protein kinase B (also called AKT).
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense) .",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0001494,,,,,,,,,,,,,,,,,,,,,,"AKT signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal transmitted by the intracellular serine/threonine kinase protein kinase B (also called AKT).
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense) .",,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001495,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003229|http://purl.obolibrary.org/obo/TXPO_0001857|http://purl.obolibrary.org/obo/TXPO_0001175|http://purl.obolibrary.org/obo/TXPO_0001137,,,,,,http://purl.obolibrary.org/obo/TXPO_0001490,,,,,,,,,,,TXPO:0001796,,,,,,,,,,,,,,,,,,,,,,AKT signaling (primitive) [Phospholipidosis (excessive defense) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001797,G6PC (canonical)[Ground glass appearance],Glucose-6-Phosphatase Catalytic Subunit [Ground glass appearance],,false,,,http://purl.obolibrary.org/obo/TXPO_0000472|http://purl.obolibrary.org/obo/TXPO_0000563,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:25634|NCBI-Human-GeneID:2538|NCBI-Mouse-GeneID:14377|G6PC [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003674,,,,,Glucose-6-Phosphatase Catalytic Subunit [Ground glass appearance],,,,,TXPO:0001797,,,,,,,,,,,,,,,,,,,,,,G6PC (canonical)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001794,increasing glycerophospholipid material [Phospholipidosis -  sphingophospholipid disorder],,"Increasing glycerophospholipid material is a subtype of increasing materials for lipid formation: A process that changes the amount of glycerophospholipid material to be larger.
This process is dependent on the sphingophospholipid disorder and can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001317,,,,,,,,,,,,,,,,,,,,,,"Increasing glycerophospholipid material is a subtype of increasing materials for lipid formation: A process that changes the amount of glycerophospholipid material to be larger.
This process is dependent on the sphingophospholipid disorder and can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001794,,,,,,,,,,,,,,,,,,,,,,increasing glycerophospholipid material [Phospholipidosis -  sphingophospholipid disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001795,phosphatidylinositol 3-kinase signaling (primitive),,Phosphatidylinositol 3-kinase signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal transmitted by the phosphatidylinositol 3-kinase (PI3K).,false,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,,,Phosphatidylinositol 3-kinase signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal transmitted by the phosphatidylinositol 3-kinase (PI3K).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002481,,,,,,,,,,,,,,,,TXPO:0001795,,,,,,,,,,,,,,,,,,,,,,phosphatidylinositol 3-kinase signaling (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001791,CYP2C8 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0001553,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1558,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001555,,,,,,,,,,,,,TXPO:0001791,,,,,,,,,,,,,,,,,,,,,,CYP2C8 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001792,PERK (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:13666|NCBI-Human-GeneID:9451|NCBI-Rat-GeneID:29702|http://www.uniprot.org/entry/Q9NZJ5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000009451,,,http://purl.obolibrary.org/obo/TXPO_0001966,,,,,,,,,,TXPO:0001792,,,,,,,"Metabolic-stress sensing protein kinase that phosphorylates the alpha subunit of eukaryotic translation initiation factor 2 (eIF-2-alpha/EIF2S1) on 'Ser-52' during the unfolded protein response (UPR) and in response to low amino acid availability. Converts phosphorylated eIF-2-alpha/EIF2S1 either in a global protein synthesis inhibitor, leading to a reduced overall utilization of amino acids, or to a translation initiation activator of specific mRNAs, such as the transcriptional activator ATF4, and hence allowing ATF4-mediated reprogramming of amino acid biosynthetic gene expression to alleviate nutrient depletion. Serves as a critical effector of unfolded protein response (UPR)-induced G1 growth arrest due to the loss of cyclin-D1 (CCND1). Involved in control of mitochondrial morphology and function.",,,,,,,,,,,,,,,PERK (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001798,EGFR (canonical)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/IMR_0000081|http://purl.obolibrary.org/obo/TXPO_0003213,,,,,,,,,,,,,,,,,,,,"NCBI-Rat-GeneID:24329|The protein encoded by this gene is a transmembrane glycoprotein that is a member of the protein kinase superfamily. This protein is a receptor for members of the epidermal growth factor family. EGFR is a cell surface protein that binds to epidermal growth factor. Binding of the protein to a ligand induces receptor dimerization and tyrosine autophosphorylation and leads to cell proliferation. Mutations in this gene are associated with lung cancer. [provided by RefSeq, Jun 2016]|NCBI-Human-GeneID:1956|NCBI-Mouse-GeneID:13649|https://www.ncbi.nlm.nih.gov/gene?cmd=retrieve&dopt=default&rn=1&list_uids=1956",,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001956,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002271,,,,,,,,,,TXPO:0001798,,,,,,,,,,,,,,,,,,,,,,EGFR (canonical)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001793,generating signal [Signaling pathway],,"Generating signal is a subtype of generating: A process that produces a signal as an output.
This entity is a specific course-dependent process. This process can constitute the course of Signaling pathway.",false,,,http://purl.obolibrary.org/obo/TXPO_0000011,,,,,,,,,,,,,,,,,,,,,,"Generating signal is a subtype of generating: A process that produces a signal as an output.
This entity is a specific course-dependent process. This process can constitute the course of Signaling pathway.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001793,,,,,,,,,,,,,,,,,,,,,,generating signal [Signaling pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001790,increasing free radical,,Increasing free radical is a subtype of increasing quantity: A process that changes the amount of free radicals to be larger.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing free radical is a subtype of increasing quantity: A process that changes the amount of free radicals to be larger.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001790,,,,,,,,,,,,,,,,,,,,,,increasing free radical,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001799,AKT (canonical)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003213|http://purl.obolibrary.org/obo/IMR_0100844,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24185|NCBI-Mouse-GeneID:11651|NCBI-Human-GeneID:207,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000250,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001799,,,,,,,,,,,,,,,,,,,,,,AKT (canonical)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GOCHE_22586,substance with antioxidant role,,"Substance with antioxidant role is a subtype of substance with role.
This entity is participating in a oxidative stress response and playing an antioxidant role.",false,,,http://purl.obolibrary.org/obo/CHEBI_24431|http://purl.obolibrary.org/obo/GOCHE_50906,,,,,,,,,,,,,,,,,,,,,,"Substance with antioxidant role is a subtype of substance with role.
This entity is participating in a oxidative stress response and playing an antioxidant role.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_22586,,,,,,,,,,GOCHE:22586,,,,,,,,,,,,,,,,,,,,,,substance with antioxidant role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_35530,beta-adrenergic antagonist,beta-adrenergic blocker|beta-blockers|beta-adrenergic blockers|beta-adrenergic antagonists|beta-adrenoceptor antagonists|beta-adrenergic receptor blockaders|beta-blocker,"An agent that binds to but does not activate beta-adrenergic receptors thereby blocking the actions of endogenous or exogenous beta-adrenergic agonists. beta-Adrenergic antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches and anxiety.",false,,,http://purl.obolibrary.org/obo/CHEBI_37887|http://purl.obolibrary.org/obo/CHEBI_48540,,,,,,,,,,,,,,,,,,,,,,"An agent that binds to but does not activate beta-adrenergic receptors thereby blocking the actions of endogenous or exogenous beta-adrenergic agonists. beta-Adrenergic antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches and anxiety.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,beta-adrenergic blocker|beta-blockers|beta-adrenergic blockers|beta-adrenergic antagonists|beta-adrenoceptor antagonists|beta-adrenergic receptor blockaders|beta-blocker,,,,,,,,,,,,,,,,,,,,,CHEBI:35530,,,,beta-adrenergic antagonist,,CHEBI:35530,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_63613,nevirapine,"Viramune|NEV|11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one|NVP|nevirapine|11-cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one|Nevirapine","A dipyridodiazepine that is  5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:28827836|PMID:28782122|PMID:1712395|PMID:28786740|CAS:129618-40-2|PMID:28835669|PMID:28819312|PMID:25017682|LINCS:LSM-5336|DrugBank:DB00238|Reaxys:4757598,,"A dipyridodiazepine that is  5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_53756|http://purl.obolibrary.org/obo/CHEBI_36044,,,,,"11-cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one|Nevirapine",,"Viramune|NEV|11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one|NVP|nevirapine",,,,,,,,,,,,,,,,,,,,,CHEBI:63613,,,,nevirapine,,CHEBI:63613,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100698,IP2,"myo-Inositol 1,4-bisphosphate|Inositol 1,4-bisphosphate|1D-myo-Inositol 1,4-bisphosphate|D-myo-Inositol 1,4-bisphosphate",,false,,,http://purl.obolibrary.org/obo/IMR_0001385,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002401,,,,IMR:0200368,"myo-Inositol 1,4-bisphosphate|Inositol 1,4-bisphosphate|1D-myo-Inositol 1,4-bisphosphate|D-myo-Inositol 1,4-bisphosphate",,,,,IMR:0100698,,,,,,,,,,,,,,,,,,,,,,IP2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_48578,radical scavenger,free radical scavenger|free-radical scavenger|free radical scavengers,"A role played by a substance that can react readily with, and thereby eliminate, radicals.",false,,,http://purl.obolibrary.org/obo/CHEBI_22586,,,,,,,,,,,,,,,,,,,,,,"A role played by a substance that can react readily with, and thereby eliminate, radicals.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,free radical scavenger|free-radical scavenger|free radical scavengers,,,,,,,,,,,,,,,,,,,,,CHEBI:48578,,,,radical scavenger,,CHEBI:48578,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_76764,EC 3.5.* (hydrolases acting on non-peptide C-N bonds) inhibitor,"EC 3.5.* inhibitors|EC 3.5.* (hydrolases acting on C-N bonds, other than peptide bonds) inhibitors|EC 3.5.* inhibitor|EC 3.5.* (hydrolase acting on non-peptide C-N bond) inhibitors|EC 3.5.* (hydrolases acting on C-N bonds, other than peptide bonds) inhibitor|EC 3.5.* (hydrolase acting on non-peptide C-N bond) inhibitor|EC 3.5.* (hydrolases acting on non-peptide C-N bonds) inhibitors","Any hydrolase inhibitor that interferes with the action of a hydrolase acting on C-N bonds, other than peptide bonds (EC 3.5.*.*).",false,,,http://purl.obolibrary.org/obo/CHEBI_76759,,,,,,,,,,,,,,,,,,,,,,"Any hydrolase inhibitor that interferes with the action of a hydrolase acting on C-N bonds, other than peptide bonds (EC 3.5.*.*).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"EC 3.5.* inhibitors|EC 3.5.* (hydrolases acting on C-N bonds, other than peptide bonds) inhibitors|EC 3.5.* inhibitor|EC 3.5.* (hydrolase acting on non-peptide C-N bond) inhibitors|EC 3.5.* (hydrolases acting on C-N bonds, other than peptide bonds) inhibitor|EC 3.5.* (hydrolase acting on non-peptide C-N bond) inhibitor|EC 3.5.* (hydrolases acting on non-peptide C-N bonds) inhibitors",,,,,,,,,,,,,,,,,,,,,CHEBI:76764,,,,EC 3.5.* (hydrolases acting on non-peptide C-N bonds) inhibitor,,CHEBI:76764,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001329,Hmox1 (rat)[Glutathione depletion],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001927|http://purl.obolibrary.org/obo/TXPO_1000196,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24451,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001329,,,,,,,,,,,,,,,,,,,,,,Hmox1 (rat)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000489,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001328,PPARA (canonical)[Eosinophilic granular degeneration],Peroxisome Proliferator-Activated Receptor Alpha [Eosinophilic granular degeneration],,false,,,http://purl.obolibrary.org/obo/TXPO_0000159|http://purl.obolibrary.org/obo/TXPO_0001280,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:19013|NCBI-Rat-GeneID:25747|NCBI-Human-GeneID:5465|PMID:25450203,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Peroxisome Proliferator-Activated Receptor Alpha [Eosinophilic granular degeneration],,,,,TXPO:0001328,,,,,,,,,,,,,,,,,,,,,,PPARA (canonical)[Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001325,hypofunction of lipid metabolism,,Hypofunction of lipid metabolism is a subtype of hypofunction of metabolism: A process that performs a decreased or insufficient lipid metabolism.,false,,,http://purl.obolibrary.org/obo/TXPO_0002354,,,,,,,,,,,,,,,,,,,,,,Hypofunction of lipid metabolism is a subtype of hypofunction of metabolism: A process that performs a decreased or insufficient lipid metabolism.,,,http://purl.obolibrary.org/obo/GO_0006629,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001327,,,,,,,,,,,,,,,,,,TXPO:0001325,,,,,,,,,,,,,,,,,,,,,,hypofunction of lipid metabolism,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001322,AP-1 activation [ER stress],,"AP-1 activation is a subtype of AP-1 activation: A process that changes the activity of the AP-1 to be higher by JNK.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001321,,,,,,,,,,,,,,,,,,,,,,"AP-1 activation is a subtype of AP-1 activation: A process that changes the activity of the AP-1 to be higher by JNK.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001322,,,,,,,,,,,,,,,,,,,,,,AP-1 activation [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001323,hypofunction of hepatic metabolism,,Hypofunction of hepatic metabolism is a subtype of hypofunction of metabolism: A process that performs a decreased or insufficient hepatic metabolism.,false,,,http://purl.obolibrary.org/obo/TXPO_0002354,,,,,,,,,,,,,,,,,,,,,,Hypofunction of hepatic metabolism is a subtype of hypofunction of metabolism: A process that performs a decreased or insufficient hepatic metabolism.,,,http://purl.obolibrary.org/obo/GO_0008152,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001323,,,,,,,,,,,,,,,,,,,,,,hypofunction of hepatic metabolism,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001320,choline transport [Phospholipidosis - phosphatidylcholine disorder],,"The directed movement of choline into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Choline (2-hydroxyethyltrimethylammonium) is an amino alcohol that occurs widely in living organisms as a constituent of certain types of phospholipids and in the neurotransmitter acetylcholine.
This process is dependent on the phosphatidylcholine disorder and can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/GO_0015871|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"The directed movement of choline into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Choline (2-hydroxyethyltrimethylammonium) is an amino alcohol that occurs widely in living organisms as a constituent of certain types of phospholipids and in the neurotransmitter acetylcholine.
This process is dependent on the phosphatidylcholine disorder and can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001136,,,,,,http://purl.obolibrary.org/obo/GO_0006656,,,,,,,,,,,TXPO:0001320,,,,,,,,,,,,,,,,,,,,,,choline transport [Phospholipidosis - phosphatidylcholine disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001327,hypofunction of cholesterol biosynthesis,,Hypofunction of cholesterol biosynthesis is a subtype of hypofunction of lipid biosynthesis: A process that performs a decreased or insufficient cholesterol biosynthesis.,false,,,http://purl.obolibrary.org/obo/TXPO_0002195,,,,,,,,,,,,,,,,,,,,,,Hypofunction of cholesterol biosynthesis is a subtype of hypofunction of lipid biosynthesis: A process that performs a decreased or insufficient cholesterol biosynthesis.,,,http://purl.obolibrary.org/obo/GO_0006695,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001330,,,,,,,,,,,TXPO:0001327,,,,,,,,,,,,,,,,,,,,,,hypofunction of cholesterol biosynthesis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001324,hypofunction of protein metabolism,,Hypofunction of protein metabolism is a subtype of hypofunction of metabolism: A process that performs a decreased or insufficient protein metabolism.,false,,,http://purl.obolibrary.org/obo/TXPO_0002354,,,,,,,,,,,,,,,,,,,,,,Hypofunction of protein metabolism is a subtype of hypofunction of metabolism: A process that performs a decreased or insufficient protein metabolism.,,,http://purl.obolibrary.org/obo/GO_0019538,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001331,,,,,,,,,,,,,,,,,,TXPO:0001324,,,,,,,,,,,,,,,,,,,,,,hypofunction of protein metabolism,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001321,AP-1 activation by JNK,,AP-1 activation is a subtype of AP-1 activation: A process that changes the activity of the AP-1 to be higher by JNK.,false,,,http://purl.obolibrary.org/obo/TXPO_0001313,,,,,,,,,,,,,,,,,,,,,,AP-1 activation is a subtype of AP-1 activation: A process that changes the activity of the AP-1 to be higher by JNK.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001321,,,,,,,,,,,,,,,,,,,,,,AP-1 activation by JNK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001326,hypofunction of carbohydrate metabolism,,Hypofunction of carbohydrate metabolism is a subtype of hypofunction of metabolism: A process that performs a decreased or insufficient carbohydrate metabolism.,false,,,http://purl.obolibrary.org/obo/TXPO_0002354,,,,,,,,,,,,,,,,,,,,,,Hypofunction of carbohydrate metabolism is a subtype of hypofunction of metabolism: A process that performs a decreased or insufficient carbohydrate metabolism.,,,http://purl.obolibrary.org/obo/GO_0005975,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001326,,,,,,,,,,,,,,,,,,,,,,hypofunction of carbohydrate metabolism,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100843,SOCS-7,Suppressor of cytokine signaling 7,,false,,,http://purl.obolibrary.org/obo/IMR_0000460,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Suppressor of cytokine signaling 7,,,,,IMR:0100843,,,,,,,,,,,,,,,,,,,,,,SOCS-7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000000123,PLIN2,,Other designations: adipophilin|adipose differentiation-related protein|perilipin-2,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,ADFP|ADRP,,,,,,,,,,,,9,,,,,,MIM:103195|Ensembl:ENSG00000147872|Vega:OTTHUMG00000019624|HPRD:00057|HGNC:248,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,perilipin 2,,,9p22.1,,,,,,,,,,,,,,,,"GO_0005576 (EC: TAS, PMID: 9003395); GO_0005634 (EC: IEA); GO_0005783 (EC: TAS, PMID: 9003395); GO_0005811 (EC: IDA, PMID: 14741744); GO_0005886 (EC: TAS); GO_0014070 (EC: IEA); GO_0015909 (EC: IEA); GO_0019915 (EC: IEA); GO_0042493 (EC: IEA); GO_0044255 (EC: TAS); GO_0044281 (EC: TAS)",,,,,,,,,PMID: 1518805; 7829101; 9003395; 9799447; 12114189; 12387890; 12477932; 12591929; 14671211; 14707038; 14741744; 15136565; 15146197; 15336557; 15489334; 15545278; 16230742; 16391323; 16489205; 16808905; 16884492; 16936283; 17200350; 17322100; 17446422; 17620659; 17927964; 18188946; 18393390; 18606814; 18624398; 18827892; 18832575; 19054096; 19169702; 19351497; 19460752; 19602560; 19638644; 19843633; 19851831; 20032580; 20118912; 20143336; 20504295; 20661576; 20887090; 21566511; 21828233; 21906983; 22238364; 22496505; 22667335; 22949030; 22952953; 23129790; 23603836; 23688400,,,,,,,,,,,,,,,OGG:3000000123,,,,,,,perilipin 2,,,,,,,,,,,,,Other designations: adipophilin|adipose differentiation-related protein|perilipin-2,,PLIN2,,,,,,,,,,,,,,,,,,,,,,,123,RP11-151J10.1,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,PLIN2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000000125,ADH1B,,"Other designations: ADH, beta subunit|alcohol dehydrogenase 1B|alcohol dehydrogenase 2 (class I), beta polypeptide|alcohol dehydrogenase subunit beta|aldehyde reductase|epididymis secretory protein Li 117",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,HEL-S-117|ADH2,,,,,,,,,,,,4,,,,,,HGNC:250|MIM:103720|HPRD:00065,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"alcohol dehydrogenase 1B (class I), beta polypeptide",,,4q23,,,,,,,,,,,,,,,,"GO_0004024 (EC: IDA, PMID: 9982); GO_0005829 (EC: TAS); GO_0006069 (EC: IDA, PMID: 2398055); GO_0006069 (EC: TAS); GO_0006805 (EC: TAS); GO_0008270 (EC: IDA, PMID: 9982); GO_0044281 (EC: TAS)",,,,,,,,,PMID: 9982; 1896463; 2169444; 2210383; 2295648; 2347582; 2398055; 2547609; 2679216; 2737681; 2935533; 2935875; 2986130; 3000832; 3006456; 3397059; 3619918; 6374651; 6391920; 8201622; 8663387; 8889548; 10424757; 10733556; 11051375; 11117576; 11238183; 11259352; 11274460; 11398342; 11410735; 11584144; 11696658; 11748356; 11781503; 11781511; 11966948; 12080432; 12081471; 12089173; 12153842; 12173598; 12189549; 12211622; 12213289; 12244546; 12351924; 12419833; 12452180; 12461493; 12477932; 12505800; 12517056; 12519453; 12545748; 12554615; 12658118; 12668919; 12710951; 12713190; 12777946; 12824748; 12884000; 12915514; 12915519; 14634838; 14693654; 14745297; 14768474; 15084894; 15162847; 15220553; 15318096; 15318112; 15327835; 15342556; 15456134; 15489334; 15511718; 15519646; 15534263; 15542751; 15597094; 15842823; 15863807; 15886702; 15902904; 15957670; 16006997; 16078602; 16086315; 16117582; 16127737; 16135443; 16163053; 16184481; 16235983; 16307179; 16309369; 16324524; 16332725; 16358724; 16385179; 16404797; 16423594; 16440362; 16520888; 16600530; 16608143; 16685648; 16702384; 16737450; 16758956; 16822169; 16930209; 16958672; 16970620; 17036331; 17071628; 17134659; 17134660; 17180580; 17185388; 17207821; 17250612; 17268812; 17279314; 17285601; 17289126; 17292341; 17293864; 17295732; 17421009; 17454860; 17471563; 17486761; 17489985; 17515815; 17517051; 17559546; 17618743; 17631643; 17762315; 17847010; 17850643; 17885622; 17923853; 17963305; 18033686; 18049455; 18056758; 18078815; 18216179; 18254707; 18266839; 18299763; 18322963; 18331377; 18336668; 18336671; 18382665; 18439068; 18500343; 18510611; 18516948; 18715275; 18761854; 18763293; 18773092; 18782342; 18784359; 18818748; 18936436; 18996923; 19019335; 19068087; 19094228; 19124091; 19124506; 19164089; 19185835; 19193628; 19250143; 19262484; 19298323; 19339270; 19343046; 19365573; 19403456; 19420105; 19449376; 19452585; 19469618; 19486361; 19527514; 19550411; 19618839; 19655364; 19667493; 19687126; 19698717; 19706845; 19751749; 19769429; 19799139; 19812523; 19826048; 19860798; 19861527; 19874574; 19887496; 19898482; 19913121; 19948975; 20010786; 20025435; 20031627; 20077761; 20101753; 20140262; 20171022; 20180859; 20205700; 20219057; 20336794; 20357489; 20401433; 20403997; 20437850; 20462248; 20477764; 20477767; 20494945; 20568895; 20598484; 20628086; 20634891; 20685249; 20700531; 20806441; 20833657; 21048924; 21133627; 21157980; 21166830; 21168396; 21284671; 21303386; 21351086; 21355870; 21378355; 21437268; 21497796; 21517275; 21576033; 21601984; 21635275; 21895720; 21917409; 21968928; 21988832; 22004471; 22048268; 22150722; 22231434; 22287615; 22292652; 22325912; 22363810; 22560290; 22674868; 22690706; 22703580; 22930414; 22931071; 22960999; 23149980; 23266708; 23285246; 23296215; 23414439; 23456092; 23468174; 23550892; 23615284; 23701534; 23743675; 23806636; 24217933,,,,,,,,,,,,,,,OGG:3000000125,,20140408,protein-coding,,,,"alcohol dehydrogenase 1B (class I), beta polypeptide",,,,,,,,,,,,,"Other designations: ADH, beta subunit|alcohol dehydrogenase 1B|alcohol dehydrogenase 2 (class I), beta polypeptide|alcohol dehydrogenase subunit beta|aldehyde reductase|epididymis secretory protein Li 117",,ADH1B,,,,,,,,,,,,,,,,,,,,,,,125,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,ADH1B,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CL_0000578,experimentally modified cell in vitro,,A cell in vitro that has undergone physical changes as a consequence of a deliberate and specific experimental procedure.,false,,,http://purl.obolibrary.org/obo/CL_0000000,,,,,,,,,,,,,,,,,,,,,,A cell in vitro that has undergone physical changes as a consequence of a deliberate and specific experimental procedure.,,,,,experimentally modified cell in vitro,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CL:0000578,,,,,,,,,,,,,,,,,,,,,,experimentally modified cell in vitro,,,,,,,http://purl.obolibrary.org/obo/cl.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CL_0000576,monocyte,,"Myeloid mononuclear recirculating leukocyte that can act as a precursor of tissue macrophages, osteoclasts and some populations of tissue dendritic cells.",false,,,http://purl.obolibrary.org/obo/CL_0000842,,,,,,,,,,,,,,,,,,,,FMA:62864|BTO:0000876,,"Myeloid mononuclear recirculating leukocyte that can act as a precursor of tissue macrophages, osteoclasts and some populations of tissue dendritic cells.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CL:0000576,,,,,,,,,,,,,,,,,,,,,,monocyte,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_35481,non-narcotic analgesic,,"A drug that has principally analgesic, antipyretic and anti-inflammatory actions. Non-narcotic analgesics do not bind to opioid receptors.",false,,,http://purl.obolibrary.org/obo/CHEBI_35480,,,,,,,,,,,,,,,,,,,,,,"A drug that has principally analgesic, antipyretic and anti-inflammatory actions. Non-narcotic analgesics do not bind to opioid receptors.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:35481,,,,non-narcotic analgesic,,CHEBI:35481,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000913,eIF2 subunit,,,false,,,http://purl.obolibrary.org/obo/IMR_0010016,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000913,,,,,,,,,,,,,,,,,,,,,,eIF2 subunit,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000001719,DHFR,,,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,DHFRP1|DYR,,,,,,,,,,,,5,,,,,,MIM:126060|Vega:OTTHUMG00000162529|HGNC:2861|Ensembl:ENSG00000228716|HPRD:00519,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,dihydrofolate reductase,,,5q11.2-q13.2,,,,,,,,,,,,,,,,,,,,,,,,,PMID: 1731871; 1935897; 2248959; 2592384; 2859520; 3185016; 3383852; 6235374; 6306253; 6323448; 6504041; 6687716; 6750132; 8527095; 8559246; 8976559; 9119086; 9374868; 10749676; 10898545; 11448909; 11779239; 11964483; 11996001; 12084458; 12096917; 12384595; 12477932; 12588981; 12612070; 12788094; 12812497; 14664697; 14679136; 14735580; 15039552; 15489334; 15755837; 15817466; 16116078; 16124424; 16196087; 16467096; 16735474; 16969375; 17237763; 17336564; 17413111; 17449906; 17486595; 17597297; 17683969; 17917571; 18045573; 18056255; 18093916; 18247058; 18451149; 18498051; 18636124; 18676680; 18682947; 18785313; 18799873; 18818748; 18988749; 19019335; 19022952; 19048631; 19055622; 19064572; 19064578; 19161160; 19170196; 19196009; 19336370; 19353223; 19360472; 19461557; 19471022; 19493349; 19527514; 19533788; 19536847; 19578876; 19625176; 19666584; 19683694; 19692168; 19706381; 19727391; 19776634; 19861437; 19898482; 19913121; 20031554; 20237949; 20347265; 20472929; 20544798; 20615890; 20628086; 20634891; 20639865; 20670920; 20737570; 20834190; 20948192; 21120433; 21310276; 21310277; 21857842; 21890473; 21906983; 21963094; 22005284; 22024482; 22324981; 22505724; 22797925; 22954684; 22994778; 23000965; 23053953; 23197646; 23421317; 23707606; 23726796; 23733948; 23838799; 24053334; 24077226,,,,,,,,,,,,,,,OGG:3000001719,,20140408,protein-coding,,,,dihydrofolate reductase,,,,,,,,,,,,,,,DHFR,,,,,,,,,,,,,,,,,,,,,,,1719,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,DHFR,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000064816,CYP3A43,,"Other designations: cytochrome P450 3A43|cytochrome P450, subfamily IIIA, polypeptide 43",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,7,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 3, subfamily A, polypeptide 43",,,7q21.1,,,,,,,,,,,,,,,,GO_0004497 (EC: ISS); GO_0005506 (EC: IEA); GO_0005789 (EC: TAS); GO_0006805 (EC: TAS); GO_0020037 (EC: IEA); GO_0044281 (EC: TAS); GO_0070330 (EC: IEA),,,,,,,,,PMID:9890157; 11137287; 11160876; 11243885; 11266076; 11726664; 12477932; 12853948; 14695544; 14759258; 15128046; 15548719; 15894682; 16314882; 16848237; 18566991; 19343046; 19789190; 20529763; 20715157; 21081028; 21533175,,,,,,,,,,,,,,,OGG:3000064816,,,,,,,"cytochrome P450, family 3, subfamily A, polypeptide 43",,,,,,,,,,,,,"Other designations: cytochrome P450 3A43|cytochrome P450, subfamily IIIA, polypeptide 43",,CYP3A43,,,,,,,,,,,,,,,,,,,,,,,64816,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP3A43,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0002851,XBP1 splicing [ER stress - refolding],,"XBP1 splicing is a subtype of removing: The process of removing sections of the XBP1 RNA transcript to remove sequences.
This process is dependent on the refolding process and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000726,,,,,,,,,,,,,,,,,,,,,,"XBP1 splicing is a subtype of removing: The process of removing sections of the XBP1 RNA transcript to remove sequences.
This process is dependent on the refolding process and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002851,,,,,,,,,,,,,,,,,,,,,,XBP1 splicing [ER stress - refolding],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002859,PERK - autophosphorylation kinase (canonical)[ER stress - inflammation],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000878,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002859,,,,,,,,,,,,,,,,,,,,,,PERK - autophosphorylation kinase (canonical)[ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002868,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002855,PERK dimerization [ER stress - inflammation],,"PERK dimerization is a subtype of protein dimerization: The formation of a PERK dimer, a macromolecular structure consists of two noncovalently associated identical or nonidentical subunits.
This process is dependent on the inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000713,,,,,,,,,,,,,,,,,,,,Reactome:R-HSA-381087|http://www.ncbi.nlm.nih.gov/pubmed/11907036,,"PERK dimerization is a subtype of protein dimerization: The formation of a PERK dimer, a macromolecular structure consists of two noncovalently associated identical or nonidentical subunits.
This process is dependent on the inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002882,,,,,,http://purl.obolibrary.org/obo/TXPO_0002868,,,,,,,,,,,TXPO:0002855,,,,,,,,,,,,,,,,,,,,,,PERK dimerization [ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002854,PERK activation [ER stress - inflammation],,"PERK activation is a subtype of Molecular activation: A process that changes the activity of PERK to be higher.
This process is dependent on the inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000402,,,,,,,,,,,,,,,,,,,,,,"PERK activation is a subtype of Molecular activation: A process that changes the activity of PERK to be higher.
This process is dependent on the inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002868|http://purl.obolibrary.org/obo/TXPO_0002855,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002852,,,,,,,,,,,TXPO:0002854,,,,,,,,,,,,,,,,,,,,,,PERK activation [ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002850,PERK - signaling factor (canonical)[ER stress - inflammation],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002119,http://purl.obolibrary.org/obo/TXPO_0000061,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UniProt_Q9NZJ5|http://www.uniprot.org/entry/Q9NZJ5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002850,,,,,,,,,,,,,,,,,,,,,,PERK - signaling factor (canonical)[ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002858,PERK - autophosphorylation kinase (canonical)[ER stress - translation attenuation],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000878,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002858,,,,,,,,,,,,,,,,,,,,,,PERK - autophosphorylation kinase (canonical)[ER stress - translation attenuation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000388,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002852,changing activity of eIF2a by PERK [ER stress - inflammation],,"A process that changes the activity of the eIF2a by PERK.
This process is dependent on the inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002378,,,,,,,,,,,,,,,,,,,,,,"A process that changes the activity of the eIF2a by PERK.
This process is dependent on the inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002510,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002853,,,,,,,,,,,TXPO:0002852,,,,,,,,,,,,,,,,,,,,,,changing activity of eIF2a by PERK [ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002856,PERK - kinase (canonical)[ER stress - inflammation],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000878,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002856,,,,,,,,,,,,,,,,,,,,,,PERK - kinase (canonical)[ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002510,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002857,PERK - kinase (canonical)[ER stress - translation attenuation],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000878,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002857,,,,,,,,,,,,,,,,,,,,,,PERK - kinase (canonical)[ER stress - translation attenuation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002507,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002853,attenuation of I-kappaB translation by eIF2a [ER stress - inflammation],,"Any process that stops, prevents, or reduces the frequency, rate or extent of I-Kappa B translation by eIF2a.
This process is dependent on the inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000722,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents, or reduces the frequency, rate or extent of I-Kappa B translation by eIF2a.
This process is dependent on the inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002896,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002988,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002798,,,,,,,,,,,TXPO:0002853,,,,,,,,,,,,,,,,,,,,,,attenuation of I-kappaB translation by eIF2a [ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000868,Myb family,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,,,,,,IMR:0000868,,,,,,,,,,,,,,,,,,,,,,Myb family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_22693,barbiturates,,"Members of the class of pyrimidones consisting of pyrimidine-2,4,6(1H,3H,5H)-trione (barbituric acid) and its derivatives. Largest group of the synthetic sedative/hypnotics, sharing a characteristic six-membered ring structure.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,,,"Members of the class of pyrimidones consisting of pyrimidine-2,4,6(1H,3H,5H)-trione (barbituric acid) and its derivatives. Largest group of the synthetic sedative/hypnotics, sharing a characteristic six-membered ring structure.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:22693,,,,,,,,,,,,,,,,,,,,,,barbiturates,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_59132,antigen,,,false,,,http://purl.obolibrary.org/obo/CHEBI_52209,,,,,,,,,,,,,,,,,,,,"Any substance that stimulates an immune response in the body, such as through antibody production or by presentation to a T-cell receptor after binding to a major histocompability complex (MHC).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:59132,,,,,,,,,,,,,,,,,,,,,,antigen,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CL_0000738,leukocyte,leucocyte|white blood cell,"An achromatic cell of the myeloid or lymphoid lineages capable of ameboid movement, found in blood or other tissue.",false,,,http://purl.obolibrary.org/obo/CL_0000988,,,,,,,,,,,,,,,,,,,,,,"An achromatic cell of the myeloid or lymphoid lineages capable of ameboid movement, found in blood or other tissue.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,leucocyte|white blood cell,,,,,CL:0000738,,,,,,,,,,,,,,,,,,,,,,leukocyte,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100307,caspase-12,,,false,,,http://purl.obolibrary.org/obo/IMR_0000305,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100307,,,,,,,,,,,,,,,,,,,,,,caspase-12,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000006347,CCL2,,"Other designations: C-C motif chemokine 2|monocyte chemoattractant protein 1|monocyte chemoattractant protein-1|monocyte chemotactic and activating factor|monocyte chemotactic protein 1|monocyte secretory protein JE|small inducible cytokine A2 (monocyte chemotactic protein 1, homologous to mouse Sig-je)|small inducible cytokine subfamily A (Cys-Cys), member 2|small-inducible cytokine A2",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,MCP1|SMC-CF|MCP-1|GDCF-2|HSMCR30|SCYA2|HC11|MCAF,,,,,,,,,,,,17,,,,,,MIM:158105|Ensembl:ENSG00000108691|HPRD:01149|HGNC:10618|Vega:OTTHUMG00000132887,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,chemokine (C-C motif) ligand 2,,,17q11.2-q12,,,,,,,,,,,,,,,,"GO_0000165 (EC: IMP); GO_0001525 (EC: TAS, PMID: 18334747); GO_0001666 (EC: IEA); GO_0001938 (EC: IEA); GO_0002548 (EC: IDA, PMID: 12207323); GO_0004672 (EC: TAS, PMID: 9973507); GO_0005102 (EC: TAS, PMID: 10542238); GO_0005576 (EC: IDA); GO_0005576 (EC: TAS); GO_0005615 (EC: IEA); GO_0005737 (EC: IEA); GO_0006468 (EC: TAS, PMID: 9670957); GO_0006874 (EC: IEA); GO_0006935 (EC: TAS, PMID: 10623817); GO_0006954 (EC: IDA); GO_0006959 (EC: TAS, PMID: 9548499); GO_0006987 (EC: TAS); GO_0007010 (EC: IDA, PMID: 10072545); GO_0007155 (EC: TAS, PMID: 10198043); GO_0007165 (EC: NAS, PMID: 10770925); GO_0007166 (EC: TAS, PMID: 9548499); GO_0007179 (EC: IEA); GO_0007186 (EC: TAS, PMID: 10542238); GO_0007187 (EC: TAS, PMID: 10770925); GO_0007259 (EC: TAS, PMID: 9670957); GO_0007568 (EC: IEA); GO_0008009 (EC: IEA); GO_0008201 (EC: IEA); GO_0008360 (EC: IDA, PMID: 10072545); GO_0009408 (EC: IEA); GO_0009612 (EC: IEA); GO_0009617 (EC: IEP, PMID: 16034137); GO_0009887 (EC: TAS, PMID: 9364936); GO_0010332 (EC: IEA); GO_0010574 (EC: IEA); GO_0010759 (EC: IEA); GO_0014823 (EC: IEA); GO_0016525 (EC: IEA); GO_0019079 (EC: TAS, PMID: 10985244); GO_0019221 (EC: IDA, PMID: 12207323); GO_0019725 (EC: TAS, PMID: 18334747); GO_0030593 (EC: IEA); GO_0030968 (EC: TAS); GO_0031100 (EC: IEA); GO_0031663 (EC: IDA); GO_0031727 (EC: ISS); GO_0031727 (EC: TAS, PMID: 18021937); GO_0032570 (EC: IEA); GO_0033552 (EC: IEA); GO_0034351 (EC: IDA, PMID: 12753088); GO_0035684 (EC: ISS); GO_0042493 (EC: IEA); GO_0043025 (EC: IEA); GO_0043200 (EC: IEA); GO_0043491 (EC: IMP); GO_0043524 (EC: IDA, PMID: 12753088); GO_0043615 (EC: IDA, PMID: 12271471); GO_0044267 (EC: TAS); GO_0044344 (EC: IEP, PMID: 9407497); GO_0045471 (EC: IEA); GO_0046677 (EC: IEA); GO_0048010 (EC: IEA); GO_0048246 (EC: IDA, PMID: 12207323); GO_0048247 (EC: IEA); GO_0050806 (EC: IEA); GO_0050870 (EC: ISS); GO_0051384 (EC: IEA); GO_0051770 (EC: ISS); GO_0060137 (EC: IEA); GO_0070098 (EC: IEA); GO_0071222 (EC: ISS); GO_0071346 (EC: IEP, PMID: 9407497); GO_0071346 (EC: ISS); GO_0071347 (EC: IEP, PMID: 9407497); GO_0071347 (EC: ISS); GO_0071356 (EC: IEP, PMID: 9407497); GO_0071356 (EC: ISS); GO_0071407 (EC: IDA); GO_0090265 (EC: IEA); GO_2000427 (EC: ISS); GO_2000502 (EC: IDA, PMID: 7545673)",,,,,,,,,PMID: 1661560; 1857712; 2004761; 2071154; 2322286; 2357211; 2465924; 2501656; 2513477; 2518726; 2648385; 2923622; 7545673; 7651403; 8051410; 8107690; 8195247; 8627182; 8631787; 8639605; 8642344; 8898111; 8989326; 9287323; 9364936; 9405404; 9407497; 9501225; 9548499; 9558113; 9670957; 9789057; 9792375; 9792674; 9837883; 9973507; 10068657; 10072545; 10198043; 10453044; 10477718; 10529171; 10542238; 10587439; 10623817; 10644332; 10706668; 10734104; 10751368; 10770925; 10918580; 10982368; 10985244; 11083865; 11145723; 11154208; 11313374; 11350939; 11500196; 11544456; 11750041; 11751881; 11776402; 11844145; 11878903; 11912219; 11929421; 11989790; 11999660; 12009356; 12022754; 12067898; 12078856; 12082252; 12089333; 12093796; 12117737; 12127997; 12149192; 12183528; 12186702; 12195705; 12204371; 12207323; 12234797; 12239249; 12271471; 12351486; 12358851; 12372466; 12374865; 12391099; 12391196; 12393171; 12397639; 12399623; 12408680; 12410798; 12413001; 12419245; 12443832; 12460032; 12462338; 12470469; 12473373; 12477932; 12485413; 12488502; 12505750; 12520153; 12520365; 12540965; 12632067; 12651071; 12665582; 12724308; 12753088; 12758167; 12787135; 12805068; 12826189; 12826377; 12846738; 12904997; 12944979; 12946945; 12957789; 12960255; 13679391; 14517168; 14517792; 14550782; 14571188; 14576080; 14597108; 14602575; 14620921; 14647058; 14651522; 14660607; 14687706; 14733721; 14767014; 15005768; 15016614; 15022320; 15033992; 15034225; 15041705; 15067078; 15077296; 15081318; 15082170; 15110609; 15115316; 15123743; 15135805; 15167690; 15188361; 15191525; 15191888; 15191916; 15194470; 15203564; 15226634; 15257681; 15280531; 15288699; 15296827; 15302103; 15308783; 15312962; 15349727; 15389752; 15466648; 15468376; 15481145; 15488313; 15489334; 15492853; 15529362; 15545821; 15579297; 15599324; 15602730; 15607028; 15611878; 15627719; 15630704; 15654958; 15677312; 15722361; 15740484; 15745922; 15780578; 15832427; 15848524; 15866653; 15880317; 15883814; 15900302; 15919935; 15976326; 15979992; 16003740; 16004967; 16009177; 16009638; 16020745; 16034137; 16050950; 16078996; 16095529; 16105652; 16116069; 16129702; 16160188; 16164699; 16195477; 16204411; 16206161; 16206198; 16213182; 16214031; 16230097; 16249002; 16278381; 16280328; 16280979; 16307829; 16309586; 16318581; 16351713; 16352737; 16356504; 16358960; 16359995; 16362156; 16397773; 16415174; 16427785; 16436595; 16439461; 16439481; 16439891; 16445900; 16474202; 16479072; 16504689; 16516290; 16518346; 16524739; 16597919; 16609683; 16631114; 16636247; 16636603; 16672419; 16697212; 16697654; 16697675; 16705739; 16712788; 16719905; 16730843; 16733654; 16741188; 16750572; 16751386; 16781696; 16795034; 16802342; 16804844; 16814297; 16825597; 16828028; 16835702; 16867220; 16872505; 16873204; 16903979; 16934270; 16939660; 16980310; 16988194; 16997300; 17008880; 17032917; 17046994; 17052731; 17062130; 17065190; 17082648; 17091019; 17098977; 17138827; 17169533; 17187019; 17202846; 17207568; 17218539; 17262819; 17280738; 17283105; 17284607; 17307163; 17322498; 17364892; 17376903; 17379849; 17384985; 17390372; 17395051; 17404035; 17407231; 17416748; 17417600; 17424890; 17426779; 17431224; 17458901; 17465499; 17485071; 17486299; 17490777; 17495598; 17522215; 17525255; 17530707; 17582674; 17596666; 17625600; 17694504; 17700210; 17703277; 17703412; 17704101; 17706208; 17707134; 17728497; 17763208; 17767550; 17804911; 17822317; 17884268; 17886678; 17917677; 17920586; 17922439; 17928143; 17934860; 17940904; 17943082; 17949278; 17968528; 17968796; 17975143; 17977907; 17982227; 18021937; 18022660; 18032547; 18040846; 18042260; 18055544; 18060801; 18061474; 18069114; 18069417; 18070228; 18074388; 18089573; 18093183; 18093816; 18158188; 18164957; 18172114; 18186797; 18190912; 18191726; 18203956; 18205260; 18208975; 18230355; 18242157; 18266131; 18266972; 18270300; 18271757; 18272603; 18274642; 18276775; 18284633; 18310503; 18314120; 18334747; 18347511; 18371304; 18373164; 18381789; 18395486; 18395775; 18402383; 18436581; 18439751; 18443042; 18458846; 18469140; 18495743; 18506929; 18508485; 18515987; 18521742; 18522702; 18525219; 18528529; 18570214; 18611860; 18615095; 18619701; 18623207; 18636124; 18637012; 18646053; 18651322; 18656701; 18660381; 18660489; 18665050; 18678243; 18684531; 18690522; 18702087; 18702954; 18710415; 18718072; 18758234; 18762729; 18784079; 18790652; 18804983; 18808740; 18818748; 18824549; 18829011; 18837094; 18855195; 18937353; 18940815; 18953909; 18954908; 18962899; 18976655; 18976766; 18977211; 18996102; 18996288; 19001328; 19002595; 19009499; 19014891; 19017462; 19019335; 19020833; 19032843; 19032844; 19032966; 19034671; 19048368; 19055601; 19072670; 19074885; 19092169; 19099590; 19099689; 19100389; 19115220; 19132243; 19136823; 19147409; 19148342; 19152916; 19154405; 19155472; 19156168; 19166999; 19167353; 19168721; 19170716; 19176388; 19185603; 19187096; 19211266; 19215923; 19218821; 19228389; 19233564; 19234509; 19242604; 19247692; 19247801; 19258635; 19258923; 19267279; 19277984; 19281798; 19287949; 19288202; 19298002; 19317061; 19327225; 19328242; 19332042; 19347053; 19357773; 19360344; 19361458; 19364494; 19371341; 19373627; 19376162; 19379593; 19392835; 19409809; 19411748; 19420105; 19423540; 19426980; 19439012; 19441883; 19441886; 19443842; 19446037; 19450143; 19458908; 19465691; 19479998; 19494437; 19496969; 19506371; 19524871; 19525388; 19525846; 19526283; 19527514; 19555664; 19558503; 19565503; 19573434; 19576791; 19587356; 19587833; 19625220; 19628738; 19632522; 19639050; 19641159; 19642141; 19642908; 19644155; 19646633; 19658300; 19664934; 19668598; 19706805; 19711822; 19720836; 19726280; 19729601; 19736361; 19755790; 19755933; 19760754; 19773451; 19777601; 19781192; 19781803; 19782713; 19819989; 19822078; 19828696; 19833726; 19844201; 19851831; 19864434; 19865101; 19866475; 19881959; 19885629; 19893256; 19902472; 19904283; 19906815; 19913121; 19923858; 19926874; 19929093; 19938194; 19941075; 19942750; 19948975; 19957783; 19995900; 20000039; 20004457; 20016208; 20029197; 20029451; 20031554; 20038977; 20040767; 20041183; 20056091; 20056178; 20087947; 20097750; 20100200; 20102417; 20111728; 20121167; 20125127; 20137666; 20138641; 20140679; 20177146; 20179890; 20187772; 20193755; 20196868; 20221866; 20228199; 20231199; 20237358; 20237496; 20299238; 20299783; 20339010; 20339966; 20349326; 20351714; 20364004; 20368224; 20370601; 20374368; 20389059; 20406462; 20406964; 20414371; 20416077; 20423879; 20430117; 20431065; 20432237; 20437404; 20438785; 20442634; 20446021; 20449800; 20449809; 20451256; 20452482; 20484496; 20485444; 20488574; 20497022; 20503287; 20504881; 20523065; 20526368; 20531015; 20540976; 20546673; 20563852; 20570966; 20573518; 20576301; 20602615; 20605053; 20607592; 20610178; 20617559; 20625355; 20628086; 20634732; 20637631; 20650649; 20673868; 20677014; 20681057; 20692455; 20725607; 20726788; 20737475; 20811626; 20818133; 20825374; 20859200; 20861640; 20880493; 20934684; 20947712; 20950459; 20960176; 20962626; 20965747; 21033620; 21037509; 21072187; 21073393; 21087336; 21097527; 21102463; 21107756; 21114970; 21134984; 21135144; 21148795; 21181544; 21183736; 21187454; 21190865; 21199725; 21220697; 21224075; 21247529; 21251883; 21264298; 21264360; 21327296; 21328336; 21354997; 21361908; 21368227; 21376205; 21383955; 21384169; 21385934; 21397653; 21401388; 21413027; 21423810; 21447688; 21450101; 21486440; 21486949; 21504590; 21527853; 21529268; 21529952; 21532752; 21551367; 21556333; 21569455; 21574823; 21610567; 21615418; 21620438; 21627744; 21654748; 21691937; 21701898; 21726903; 21734368; 21744268; 21760952; 21774078; 21787749; 21799302; 21851000; 21855541; 21858104; 21859809; 21868018; 21868706; 21883707; 21890375; 21898402; 21900689; 21906274; 21910857; 21920519; 21924076; 21930770; 21951843; 21951854; 21961038; 21975431; 21991356; 21992868; 22026334; 22037282; 22037980; 22059352; 22081934; 22117412; 22117820; 22125641; 22131127; 22132892; 22138288; 22142522; 22147846; 22152380; 22159219; 22183310; 22197827; 22203484; 22210436; 22226505; 22240432; 22265030; 22276574; 22288595; 22300682; 22301094; 22303443; 22319587; 22319627; 22321225; 22362506; 22377751; 22378888; 22381103; 22384203; 22396538; 22412388; 22420243; 22422499; 22425139; 22427564; 22448134; 22466290; 22472119; 22476561; 22484917; 22487967; 22490648; 22493691; 22541401; 22543850; 22554651; 22558273; 22612293; 22617682; 22619484; 22641100; 22664781; 22669976; 22691208; 22694757; 22697070; 22707193; 22711527; 22721162; 22729037; 22733495; 22739041; 22750227; 22752804; 22759858; 22762377; 22763298; 22766373; 22815949; 22823210; 22848642; 22857869; 22859936; 22861370; 22868806; 22927430; 22942263; 22961048; 22980664; 22981148; 22985557; 22989614; 22992722; 23007133; 23017229; 23037589; 23039889; 23069648; 23090289; 23128233; 23135705; 23143679; 23151275; 23154550; 23160182; 23161207; 23166687; 23180368; 23185481; 23185512; 23192155; 23206327; 23211090; 23224211; 23255244; 23274856; 23300810; 23303452; 23349788; 23350010; 23352833; 23375122; 23383162; 23402987; 23408426; 23416968; 23418647; 23429817; 23434371; 23454776; 23474119; 23490412; 23529020; 23542734; 23548612; 23549806; 23555755; 23557387; 23559389; 23583295; 23629827; 23657965; 23686489; 23704830; 23712703; 23762283; 23770363; 23782302; 23816715; 23831464; 23845726; 23886148; 23887394; 23890452; 23939977; 23954399; 23982944; 23999007; 24058270; 24077340; 24078580; 24260304; 24273921,,,,,,,,,,,,,,,OGG:3000006347,,,,,,,chemokine (C-C motif) ligand 2,,,,,,,,,,,,,"Other designations: C-C motif chemokine 2|monocyte chemoattractant protein 1|monocyte chemoattractant protein-1|monocyte chemotactic and activating factor|monocyte chemotactic protein 1|monocyte secretory protein JE|small inducible cytokine A2 (monocyte chemotactic protein 1, homologous to mouse Sig-je)|small inducible cytokine subfamily A (Cys-Cys), member 2|small-inducible cytokine A2",,CCL2,,,,,,,,,,,,,,,,,,,,,,,6347,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,CCL2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000006341,SCO1,,"Other designations: SCO cytochrome oxidase deficient homolog 1|protein SCO1 homolog, mitochondrial",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,SCOD1,,,,,,,,,,,,17,,,,,,HPRD:04705|Ensembl:ENSG00000133028|HGNC:10603|Vega:OTTHUMG00000130364|MIM:603644,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,SCO1 cytochrome c oxidase assembly protein,,,17p13.1,,,,,,,,,,,,,,,,"GO_0005507 (EC: IEA); GO_0005739 (EC: TAS, PMID: 9878253); GO_0005743 (EC: IEA); GO_0006091 (EC: TAS, PMID: 9878253); GO_0006825 (EC: IEA); GO_0006878 (EC: IEA); GO_0008535 (EC: IEA); GO_0030016 (EC: IDA)",,,,,,,,,PMID: 2543907; 2835635; 8619474; 8889548; 9110174; 9878253; 10218584; 10545952; 11013136; 11027508; 11579424; 12477932; 15229189; 15489334; 15659396; 16091356; 16344560; 16520371; 16735468; 17189203; 18458339; 19295170; 19336478; 19465909; 19913121; 20628086; 20864674; 20877624; 21139048; 21890473; 23345593; 24068947,,,,,,,,,,,,,,,OGG:3000006341,,,,,,,SCO1 cytochrome c oxidase assembly protein,,,,,,,,,,,,,"Other designations: SCO cytochrome oxidase deficient homolog 1|protein SCO1 homolog, mitochondrial",,SCO1,,,,,,,,,,,,,,,,,,,,,,,6341,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,SCO1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/GO_0070300,phosphatidic acid binding,,"Interacting selectively and non-covalently with phosphatidic acid, any of a class of glycerol phosphate in which both the remaining hydroxyl groups of the glycerol moiety are esterified with fatty acids.",false,,,http://purl.obolibrary.org/obo/GO_0005543,,,,,,,,,,,,,,,,,,,,GO:0070300,,"Interacting selectively and non-covalently with phosphatidic acid, any of a class of glycerol phosphate in which both the remaining hydroxyl groups of the glycerol moiety are esterified with fatty acids.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0070300,,,,,,,,,,,,,,,,,,,,,,phosphatidic acid binding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001676,RGS19,,,false,,,http://purl.obolibrary.org/obo/IMR_0000431,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001676,,,,,,,,,,,,,,,,,,,,,,RGS19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_52629,EC 3.1.26.13 (retroviral ribonuclease H) inhibitor,retroviral reverse transcriptase RNaseH inhibitor|retroviral ribonuclease H (EC 3.1.26.13) inhibitor|retroviral reverse transcriptase RNaseH inhibitors|EC 3.1.26.13 inhibitors|HIV RNase H inhibitor|RT/RNase H inhibitor|HIV RNase H inhibitors|EC 3.1.26.13 inhibitor|HIV-1 RNase H inhibitor|retroviral ribonuclease H (EC 3.1.26.13) inhibitors|EC 3.1.26.13 (retroviral ribonuclease H) inhibitors|HIV-1 ribonuclease H inhibitor|HIV-1 RNase H inhibitors|RT/RNase H inhibitors|retroviral ribonuclease H inhibitor|HIV-1 ribonuclease H inhibitors,"An inhibitor of ribonuclease H (EC 3.1.26.13), an enzyme required for specific hydrolysis of the RNA strand of an RNA/DNA hybrid.",false,,,http://purl.obolibrary.org/obo/CHEBI_76785|http://purl.obolibrary.org/obo/CHEBI_64947,,,,,,,,,,,,,,,,,,,,,,"An inhibitor of ribonuclease H (EC 3.1.26.13), an enzyme required for specific hydrolysis of the RNA strand of an RNA/DNA hybrid.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,retroviral reverse transcriptase RNaseH inhibitor|retroviral ribonuclease H (EC 3.1.26.13) inhibitor|retroviral reverse transcriptase RNaseH inhibitors|EC 3.1.26.13 inhibitors|HIV RNase H inhibitor|RT/RNase H inhibitor|HIV RNase H inhibitors|EC 3.1.26.13 inhibitor|HIV-1 RNase H inhibitor|retroviral ribonuclease H (EC 3.1.26.13) inhibitors|EC 3.1.26.13 (retroviral ribonuclease H) inhibitors|HIV-1 ribonuclease H inhibitor|HIV-1 RNase H inhibitors|RT/RNase H inhibitors|retroviral ribonuclease H inhibitor|HIV-1 ribonuclease H inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:52629,,,,EC 3.1.26.13 (retroviral ribonuclease H) inhibitor,,CHEBI:52629,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000471,cytokeratin 21,,,false,,,http://purl.obolibrary.org/obo/IMR_0000035,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000471,,,,,,,,,,,,,,,,,,,,,,cytokeratin 21,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_27881,resveratrol,"5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol","A stilbenol that is stilbene in which the phenyl groups are substituted at positions 3, 5, and 4' by hydroxy groups.",false,,,http://purl.obolibrary.org/obo/TXPO_0000591,,,,,,,,,,,,,,,,,,,,DrugBank:DB02709|LINCS:LSM-2557|CAS:501-36-0,,"A stilbenol that is stilbene in which the phenyl groups are substituted at positions 3, 5, and 4' by hydroxy groups.",,,,,,,,,,,,C14H12O3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_22586,,,,,"5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol",,,,,CHEBI:27881,,,,,,,,,,,,,,,,,,,,,,resveratrol,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,[H]C(=C([H])c1cc(O)cc(O)c1)c1ccc(O)cc1,,,,,
http://purl.obolibrary.org/obo/OGG_3000134218,DNAJC21,,Other designations: DnaJ homology subfamily A member 5|JJJ1 DnaJ domain protein homolog|dnaJ homolog subfamily A member 5|dnaJ homolog subfamily C member 21,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,DNAJA5|GS3|JJJ1,,,,,,,,,,,,5,,,,,,Ensembl:ENSG00000168724|Vega:OTTHUMG00000074103|HGNC:27030|HPRD:14056,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"DnaJ (Hsp40) homolog, subfamily C, member 21",,,5p13.2,,,,,,,,,,,,,,,,"GO_0003674 (EC: ND); GO_0005515 (EC: IPI, PMID:17500595); GO_0005840 (EC: NAS, PMID:16952052); GO_0006457 (EC: NAS, PMID:16952052); GO_0008270 (EC: IEA); GO_0044822 (EC: IDA)",,,,,,,,,PMID:12477932; 14702039; 15067379; 15489334; 16952052; 17081983; 17500595; 18654987; 20195357; 21139048; 21145461; 21890473; 22566498; 23000965; 24457600,,,,,,,,,,,,,,,OGG:3000134218,,,,,,,"DnaJ (Hsp40) homolog, subfamily C, member 21",,,,,,,,,,,,,Other designations: DnaJ homology subfamily A member 5|JJJ1 DnaJ domain protein homolog|dnaJ homolog subfamily A member 5|dnaJ homolog subfamily C member 21,,DNAJC21,,,,,,,,,,,,,,,,,,,,,,,134218,,,,,,,,9606,,,,,,,,,,,,,,,,,,,DNAJC21,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_50630,cyclooxygenase 1 inhibitor,cyclo-oxygenase 1 inhibitor|PTGS1 inhibitors|cyclooxygenase 1 inhibitors|prostaglandin-endoperoxide synthase 1 inhibitor|prostaglandin H2 synthase 1 inhibitor|COX-1 inhibitor|cyclooxygenase-1 inhibitor|cyclooxygenase-1 inhibitors|prostaglandin H2 synthase 1 inhibitors|prostaglandin G/H synthase 1 inhibitors|cyclo-oxygenase 1 inhibitors|PTGS1 inhibitor|prostaglandin-endoperoxide synthase 1 inhibitors|COX-1 inhibitors|prostaglandin G/H synthase 1 inhibitor,A cyclooxygenase inhibitor that interferes with the action of cyclooxygenase 1.,false,,,http://purl.obolibrary.org/obo/CHEBI_35544,,,,,,,,,,,,,,,,,,,,,,A cyclooxygenase inhibitor that interferes with the action of cyclooxygenase 1.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,cyclo-oxygenase 1 inhibitor|PTGS1 inhibitors|cyclooxygenase 1 inhibitors|prostaglandin-endoperoxide synthase 1 inhibitor|prostaglandin H2 synthase 1 inhibitor|COX-1 inhibitor|cyclooxygenase-1 inhibitor|cyclooxygenase-1 inhibitors|prostaglandin H2 synthase 1 inhibitors|prostaglandin G/H synthase 1 inhibitors|cyclo-oxygenase 1 inhibitors|PTGS1 inhibitor|prostaglandin-endoperoxide synthase 1 inhibitors|COX-1 inhibitors|prostaglandin G/H synthase 1 inhibitor,,,,,,,,,,,,,,,,,,,,,CHEBI:50630,,,,cyclooxygenase 1 inhibitor,,CHEBI:50630,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004984,Negative regulation of glutathione transport into mitochondria,,"Negative regulation of glutathione transport into mitochondria is a subtype of negative regulation of transport:  Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of glutathione into mitochondria by means of some agent such as a transporter or pore.",false,,,http://purl.obolibrary.org/obo/TXPO_0004944,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of glutathione transport into mitochondria is a subtype of negative regulation of transport:  Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of glutathione into mitochondria by means of some agent such as a transporter or pore.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004984,,,,,,,,,,,,,,,,,,,,,,Negative regulation of glutathione transport into mitochondria,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004983,glutathione transport from cytoplasm into mitochondria,,glutathione transport from cytoplasm into mitochondria is a subtype of glutathione transport: A process that exports the glutathione from cytoplasm into mitochondria.,false,,,http://purl.obolibrary.org/obo/GO_0034635,,,,,,,,,,,,,,,,,,,,PMID:23299992,,glutathione transport from cytoplasm into mitochondria is a subtype of glutathione transport: A process that exports the glutathione from cytoplasm into mitochondria.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005737,,,,,,,TXPO:0004983,,,,,,,,,,,,,,,,,,,,,,glutathione transport from cytoplasm into mitochondria,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004982,increasing mtDNA level,,Increasing mtDNA level is a subtype of decreasing quantity: A process that changes the amount of glycogen level to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing mtDNA level is a subtype of decreasing quantity: A process that changes the amount of glycogen level to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004982,,,,,,,,,,,,,,,,,,,,,,increasing mtDNA level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004987,long-chain fatty acid import into mitochondria [mitochondrial disorder],,"The directed movement of long-chain fatty acids into a mitochondria. A long-chain fatty acid is a fatty acid with a chain length between C13 and C22.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0004986,,,,,,,,,,,,,,,,,,,,PMID:23299992,,"The directed movement of long-chain fatty acids into a mitochondria. A long-chain fatty acid is a fatty acid with a chain length between C13 and C22.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004474,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002041,,,,,,,,,,,TXPO:0004987,,,,,,,,,,,,,,,,,,,,,,long-chain fatty acid import into mitochondria [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004986,long-chain fatty acid import into mitochondria,,The directed movement of long-chain fatty acids into a mitochondria. A long-chain fatty acid is a fatty acid with a chain length between C13 and C22.,false,,,http://purl.obolibrary.org/obo/GO_0015909,,,,,,,,,,,,,,,,,,,,,,The directed movement of long-chain fatty acids into a mitochondria. A long-chain fatty acid is a fatty acid with a chain length between C13 and C22.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004986,,,,,,,,,,,,,,,,,,,,,,long-chain fatty acid import into mitochondria,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004981,Disruption of ER-mitochondria contact sites [mitochondrial disorder],,"Disruption of ER-mitochondria contact sites is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of ER-mitochondria contact site.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0004980,,,,,,,,,,,,,,,,,,,,PMID:31623280,,"Disruption of ER-mitochondria contact sites is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of ER-mitochondria contact site.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004937,,,,,,,,,,,TXPO:0004981,,,,,,,,,,,,,,,,,,,,,,Disruption of ER-mitochondria contact sites [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004980,disruption of ER-mitochondria contact sites,,"Disruption of ER-mitochondria contact sites is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of ER-mitochondria contact site.",false,,,http://purl.obolibrary.org/obo/TXPO_0000369,,,,,,,,,,,,,,,,,,,,,,"Disruption of ER-mitochondria contact sites is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of ER-mitochondria contact site.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004980,,,,,,,,,,,,,,,,,,,,,,disruption of ER-mitochondria contact sites,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000192,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004988,Hypofunction of mitochondrial repair,,Hypofunction of mitochondrial repair is a subtype of hypofunctioning: A process that performs a decreased or insufficient mitochondrial repair.,false,,,http://purl.obolibrary.org/obo/TXPO_0000436,,,,,,,,,,,,,,,,,,,,,,Hypofunction of mitochondrial repair is a subtype of hypofunctioning: A process that performs a decreased or insufficient mitochondrial repair.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004988,,,,,,,,,,,,,,,,,,,,,,Hypofunction of mitochondrial repair,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004985,Negative regulation of glutathione transport into mitochondria [mitochondrial disorder],,"Negative regulation of glutathione transport into mitochondria is a subtype of negative regulation of transport:  Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of glutathione into mitochondria by means of some agent such as a transporter or pore.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0004984,,,,,,,,,,,,,,,,,,,,PMID:25339807|PMID:23299992,,"Negative regulation of glutathione transport into mitochondria is a subtype of negative regulation of transport:  Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of glutathione into mitochondria by means of some agent such as a transporter or pore.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004797,,,,,,,,,,,TXPO:0004985,,,,,,,,,,,,,,,,,,,,,,Negative regulation of glutathione transport into mitochondria [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004989,Increase in mitochondrial calcium level,,Increase in mitochondrial calcium level is a subtype of increase in calcium level: A process that changes the calcium ion concentration within a mitochondria to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000353,,,,,,,,,,,,,,,,,,,,,,Increase in mitochondrial calcium level is a subtype of increase in calcium level: A process that changes the calcium ion concentration within a mitochondria to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004989,,,,,,,,,,,,,,,,,,,,,,Increase in mitochondrial calcium level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010465,60S ribosomal protein L14,CAG-ISL 7,,false,,,http://purl.obolibrary.org/obo/IMR_0000897,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CAG-ISL 7,,,,,IMR:0010465,,,,,,,,,,,,,,,,,,,,,,60S ribosomal protein L14,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000011145,PLA2G16,,Other designations: Ca-independent phospholipase A1/2|H-rev 107 protein homolog|HRAS-like suppressor 1|HRAS-like suppressor 3|adipose-specific PLA2|adipose-specific phospholipase A2|group XVI phospholipase A1/A2|group XVI phospholipase A2|renal carcinoma antigen NY-REN-65,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,HREV107-1|H-REV107-1|HRSL3|HRASLS3|AdPLA|HREV107-3|HREV107,,,,,,,,,,,,11,,,,,,HGNC:17825|MIM:613867|HPRD:13671|Ensembl:ENSG00000176485,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"phospholipase A2, group XVI",,,11q12.3,,,,,,,,,,,,,,,,"GO_0004623 (EC: IDA); GO_0005515 (EC: IPI, PMID: 17374643); GO_0005575 (EC: ND); GO_0005783 (EC: IEA); GO_0005829 (EC: TAS); GO_0006644 (EC: IDA); GO_0006644 (EC: TAS); GO_0008970 (EC: IEA); GO_0016021 (EC: IEA); GO_0016042 (EC: IEA); GO_0036149 (EC: TAS); GO_0036150 (EC: TAS); GO_0036151 (EC: TAS); GO_0036152 (EC: TAS); GO_0044281 (EC: TAS); GO_0045786 (EC: IEA); GO_0046474 (EC: TAS); GO_0048471 (EC: IEA); GO_0052739 (EC: IEA); GO_0052740 (EC: IEA)",,,,,,,,,PMID: 9771974; 10508479; 11337467; 11526504; 11973642; 12054741; 12477932; 15489334; 16189514; 16713569; 17003497; 17374643; 18614531; 19136964; 19615464; 20501645; 21139048; 21890473; 21963094; 22605381; 22923616,,,,,,,,,,,,,,,OGG:3000011145,,,,,,,"phospholipase A2, group XVI",,,,,,,,,,,,,Other designations: Ca-independent phospholipase A1/2|H-rev 107 protein homolog|HRAS-like suppressor 1|HRAS-like suppressor 3|adipose-specific PLA2|adipose-specific phospholipase A2|group XVI phospholipase A1/A2|group XVI phospholipase A2|renal carcinoma antigen NY-REN-65,,PLA2G16,,,,,,,,,,,,,,,,,,,,,,,11145,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,PLA2G16,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/TXPO_0004960,diacylglycerol accumulation [mitochondrial disorder],,"diacylglycerol accumulation is a subtype of accumulation of substances in a biological object: A process that keeps diacylglycerol in an organism, tissue, organelle, or cell.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0004959,,,,,,,,,,,,,,,,,,,,PMID:31623280|PMID:31649547,,"diacylglycerol accumulation is a subtype of accumulation of substances in a biological object: A process that keeps diacylglycerol in an organism, tissue, organelle, or cell.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0100027,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004761,,,,,,,,,,,TXPO:0004960,,,,,,,,,,,,,,,,,,,,,,diacylglycerol accumulation [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004969,Methapyrilene hydrochloride [hepatocarcinogenesis],"N,N-dimethyl-N'-pyridin-2-yl-N'-[(thiophen-2-yl)methyl]ethane-1,2-diamine hydrochloride",A hydrochloride that is the monohydrochloride salt of methapyrilene.,false,,,http://purl.obolibrary.org/obo/TXPO_0004455|http://purl.obolibrary.org/obo/CHEBI_38213,,,,,,,,,,,,,,,,,,,,DrugBank:DB04819|CAS:135-23-9|PMID:22584684,,A hydrochloride that is the monohydrochloride salt of methapyrilene.,,,,,,,,,,,,C14H20ClN3S|C14H19N3S.ClH,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"N,N-dimethyl-N'-pyridin-2-yl-N'-[(thiophen-2-yl)methyl]ethane-1,2-diamine hydrochloride",,,,,TXPO:0004969,,,,,,,,,,,,,,,,,,,,,,Methapyrilene hydrochloride [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Cl.CN(C)CCN(Cc1cccs1)c1ccccn1,,,,,
http://purl.obolibrary.org/obo/TXPO_0004962,Negative regulation of sphingolipid metabolic process,,"Negative regulation of sphingolipid metabolic process is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of sphingolipid metabolic process.",false,,,http://purl.obolibrary.org/obo/TXPO_0000369,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of sphingolipid metabolic process is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of sphingolipid metabolic process.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004962,,,,,,,,,,,,,,,,,,,,,,Negative regulation of sphingolipid metabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006665,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004964,ceramide accumulation [mitochondrial disorder],,"ceramide accumulation is a subtype of accumulation of substances in a biological object: A process that keeps ceramide in an organism, tissue, organelle, or cell.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0004143|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:31623280|PMID:31649547,,"ceramide accumulation is a subtype of accumulation of substances in a biological object: A process that keeps ceramide in an organism, tissue, organelle, or cell.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004761,,,,,,,,,,,TXPO:0004964,,,,,,,,,,,,,,,,,,,,,,ceramide accumulation [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004961,styrene oxide [hepatocarcinogenesis],"styrene-7,8-oxide|2-phenyloxirane",An epoxide that is oxirane in which one of the hydrogens has been replaced by a phenyl group.,false,,,http://purl.obolibrary.org/obo/TXPO_0004455|http://purl.obolibrary.org/obo/CHEBI_17907,,,,,,,,,,,,,,,,,,,,CAS:96-09-3|Wikipedia:Styrene_oxide|PMID:21724974,,An epoxide that is oxirane in which one of the hydrogens has been replaced by a phenyl group.,,,,,,,,,,,,C8H8O,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2-phenyloxirane,,"styrene-7,8-oxide",,,TXPO:0004961,,,,,,,,,,,,,,,,,,,,,,styrene oxide [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,C1OC1c1ccccc1,,,,,
http://purl.obolibrary.org/obo/TXPO_0004968,Increasing triol level,,Increasing triol level is a subtype of increasing quantity: A process that changes the amount of triol level to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing triol level is a subtype of increasing quantity: A process that changes the amount of triol level to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004968,,,,,,,,,,,,,,,,,,,,,,Increasing triol level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004966,Telomerase reverse transcriptase gene mutation,,Telomerase reverse transcriptase gene mutation is a subtype of changing an operand: A process that changes the nucleotide sequence of Telomerase reverse transcriptase gene randomly and permanently.,false,,,http://purl.obolibrary.org/obo/TXPO_0001985,,,,,,,,,,,,,,,,,,,,,,Telomerase reverse transcriptase gene mutation is a subtype of changing an operand: A process that changes the nucleotide sequence of Telomerase reverse transcriptase gene randomly and permanently.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004966,,,,,,,,,,,,,,,,,,,,,,Telomerase reverse transcriptase gene mutation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004967,TERT (canonical) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0005133|http://purl.obolibrary.org/obo/TXPO_0005063,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:21752|NCBI-Human-GeneID:7015|NCBI-Rat-GeneID:301965|PMID:31439937,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004967,,,,,,,,,,,,,,,,,,,,,,TERT (canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004963,Negative regulation of sphingolipid metabolic process [hepatocarcinogenesis],,"Negative regulation of sphingolipid metabolic process is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of sphingolipid metabolic process.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004962,,,,,,,,,,,,,,,,,,,,PMID:11359698|PMID:8106389,,"Negative regulation of sphingolipid metabolic process is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of sphingolipid metabolic process.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004516,,,,,,http://purl.obolibrary.org/obo/TXPO_0004403|http://purl.obolibrary.org/obo/TXPO_0004396,,,,,,,,,,,TXPO:0004963,,,,,,,,,,,,,,,,,,,,,,Negative regulation of sphingolipid metabolic process [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006665,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004965,sorafenib resistance (process),,sorafenib resistance (process) is a subtype of decreasing sensitivity: A process that changes the sensitivity to sorafenib to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0004958,,,,,,,,,,,,,,,,,,,,,,sorafenib resistance (process) is a subtype of decreasing sensitivity: A process that changes the sensitivity to sorafenib to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004965,,,,,,,,,,,,,,,,,,,,,,sorafenib resistance (process),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000015,TPO,thrombopoietin,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,Wikipedia:Thrombopoietin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000155,,,,,thrombopoietin,,,,,IMR:0000015,,,,,,,,,,,,,,,,,,,,,,TPO,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100218,ASK1,MEKK 5|MAPK/ERK kinase kinase 5|apoptosis inducing kinase1|Apoptosis signal-regulating kinase 1|MAPKKK5|MEK kinase 5,,false,,,http://purl.obolibrary.org/obo/IMR_0000229,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MEKK 5|MAPK/ERK kinase kinase 5|apoptosis inducing kinase1|Apoptosis signal-regulating kinase 1|MAPKKK5|MEK kinase 5,,,,,IMR:0100218,,,,,,,,,,,,,,,,,,,,,,ASK1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000005322,PLA2G5,,Other designations: Ca2+-dependent phospholipase A2|calcium-dependent phospholipase A2|phosphatidylcholine 2-acylhydrolase 5,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,FRFB|hVPLA(2)|PLA2-10|GV-PLA2,,,,,,,,,,,,1,,,,,,HPRD:03117|MIM:601192|HGNC:9038,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"phospholipase A2, group V",,,1p36-p34,,,,,,,,,,,,,,,,GO_0005509 (EC: IEA); GO_0005576 (EC: TAS); GO_0005794 (EC: IEA); GO_0005886 (EC: IEA); GO_0006644 (EC: TAS); GO_0006654 (EC: TAS); GO_0006663 (EC: IEA); GO_0008201 (EC: IEA); GO_0009986 (EC: IEA); GO_0016042 (EC: IEA); GO_0019370 (EC: IEA); GO_0034097 (EC: IEA); GO_0036148 (EC: TAS); GO_0036149 (EC: TAS); GO_0036150 (EC: TAS); GO_0036151 (EC: TAS); GO_0036152 (EC: TAS); GO_0044281 (EC: TAS); GO_0046474 (EC: TAS); GO_0047498 (EC: IEA); GO_0048471 (EC: IEA); GO_0050482 (EC: IEA); GO_0051591 (EC: IEA),,,,,,,,,PMID: 8300559; 8838795; 8889548; 9377118; 9745929; 9767110; 10531350; 10751642; 10839997; 10873151; 11080676; 11522612; 11741884; 12124392; 12423354; 12477932; 12796497; 12963740; 14702039; 15259375; 15377291; 15489334; 16040605; 16115226; 16146426; 16476735; 16601231; 16710414; 16785555; 16794232; 17545304; 19913121; 20083228; 20448053; 20628086; 22041135; 22137173; 23650617,,,,,,,,,,,,,,,OGG:3000005322,,,,,,,"phospholipase A2, group V",,,,,,,,,,,,,Other designations: Ca2+-dependent phospholipase A2|calcium-dependent phospholipase A2|phosphatidylcholine 2-acylhydrolase 5,,PLA2G5,,,,,,,,,,,,,,,,,,,,,,,5322,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,PLA2G5,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0100010,importin,,,false,,,http://purl.obolibrary.org/obo/IMR_0001091,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100010,,,,,,,,,,,,,,,,,,,,,,importin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_18320,"1,4-dithiothreitol",,"The threo-diastereomer of 1,4-dimercaptobutane-2,3-diol.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,DrugBank:DB04447|CAS:3483-12-3|LINCS:LSM-36870,,"The threo-diastereomer of 1,4-dimercaptobutane-2,3-diol.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_38161,,,,,,,,,,CHEBI:18320,,,,,,,,,,,,,,,,,,,,,,"1,4-dithiothreitol",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000002171,FABP5,,"Other designations: epidermal-type fatty acid-binding protein|fatty acid-binding protein, epidermal|psoriasis-associated fatty acid-binding protein homolog",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,KFABP|E-FABP|EFABP|PAFABP|PA-FABP,,,,,,,,,,,,8,,,,,,Ensembl:ENSG00000164687|HGNC:3560|HPRD:05524|Vega:OTTHUMG00000134313|MIM:605168,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,fatty acid binding protein 5 (psoriasis-associated),,,8q21.13,,,,,,,,,,,,,,,,"GO_0005215 (EC: IEA); GO_0005504 (EC: IEA); GO_0005515 (EC: IPI, PMID: 12839573); GO_0005737 (EC: TAS, PMID: 16130169); GO_0006006 (EC: IEA); GO_0006629 (EC: TAS, PMID: 8092987); GO_0006656 (EC: IEA); GO_0008289 (EC: TAS, PMID: 1512466); GO_0008544 (EC: TAS, PMID: 1512466); GO_0009611 (EC: IEA); GO_0015758 (EC: IEA); GO_0070062 (EC: IDA)",,,,,,,,,PMID: 1286667; 1512466; 8092987; 8125298; 8427590; 8726632; 8947466; 9285630; 9438903; 10191275; 10331666; 10493790; 11113456; 12049637; 12477932; 12665801; 12839573; 15146197; 15335354; 15489334; 15592455; 16130169; 16759896; 16806233; 17353931; 17428383; 18360704; 18729184; 19156129; 19337991; 19339807; 19434059; 19554614; 19861119; 20040021; 20057506; 20424164; 20452069; 20563994; 20833513; 21139048; 21288588; 21356353; 21492859; 21890473; 21906983; 22010213; 22505724; 22761399; 22825302; 23000965; 23039948; 23327868; 23528210; 23535730; 23722546; 24457600,,,,,,,,,,,,,,,OGG:3000002171,,,,,,,fatty acid binding protein 5 (psoriasis-associated),,,,,,,,,,,,,"Other designations: epidermal-type fatty acid-binding protein|fatty acid-binding protein, epidermal|psoriasis-associated fatty acid-binding protein homolog",,FABP5,,,,,,,,,,,,,,,,,,,,,,,2171,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,FABP5,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/GO_0006793,phosphorus metabolic process,,"The chemical reactions and pathways involving the nonmetallic element phosphorus or compounds that contain phosphorus, usually in the form of a phosphate group (PO4).",false,,,http://purl.obolibrary.org/obo/GO_0008152,,,,,,,,,,,,,,,,,,,,phosphorus metabolic process,,"The chemical reactions and pathways involving the nonmetallic element phosphorus or compounds that contain phosphorus, usually in the form of a phosphate group (PO4).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0006793,,,,,,,,,,,,,,,,,,,,,,phosphorus metabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_35487,EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor,EC 1.2.1.3 inhibitor|m-methylbenzaldehyde dehydrogenase inhibitor|NAD-linked aldehyde dehydrogenase inhibitor|NAD-aldehyde dehydrogenase inhibitors|aldehyde dehydrogenase (NAD(+)) inhibitor|NAD-aldehyde dehydrogenase inhibitor|aldehyde dehydrogenase (NAD) inhibitor|aldehyde dehydrogenase (NAD(+)) (EC 1.2.1.3) inhibitors|EC 1.2.1.3 (aldehyde dehydrogenase (NAD(+))) inhibitor|m-methylbenzaldehyde dehydrogenase inhibitors|aldehyde dehydrogenase (NAD(+)) inhibitors|NAD-dependent 4-hydroxynonenal dehydrogenase inhibitor|CoA-independent aldehyde dehydrogenase inhibitor|EC 1.2.1.3 (aldehyde dehydrogenase (NAD(+))) inhibitors|aldehyde dehydrogenase (NAD(+)) (EC 1.2.1.3) inhibitor|CoA-independent aldehyde dehydrogenase inhibitors|EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitors|NAD-dependent aldehyde dehydrogenase inhibitor|NAD-dependent 4-hydroxynonenal dehydrogenase inhibitors|NAD-linked aldehyde dehydrogenase inhibitors|aldehyde dehydrogenase (NAD) inhibitors|NAD-dependent aldehyde dehydrogenase inhibitors|EC 1.2.1.3 inhibitors|propionaldehyde dehydrogenase inhibitor|aldehyde dehydrogenase inhibitor|aldehyde dehydrogenase inhibitors|propionaldehyde dehydrogenase inhibitors,"An EC 1.2.1.* (oxidoreductase acting on donor aldehyde/oxo group with NAD(+) or NADP(+) as acceptor) inhibitor that interferes with the action of aldehyde dehydrogenase (NAD(+)), EC 1.2.1.3.",false,,,http://purl.obolibrary.org/obo/CHEBI_76852,,,,,,,,,,,,,,,,,,,,,,"An EC 1.2.1.* (oxidoreductase acting on donor aldehyde/oxo group with NAD(+) or NADP(+) as acceptor) inhibitor that interferes with the action of aldehyde dehydrogenase (NAD(+)), EC 1.2.1.3.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,EC 1.2.1.3 inhibitor|m-methylbenzaldehyde dehydrogenase inhibitor|NAD-linked aldehyde dehydrogenase inhibitor|NAD-aldehyde dehydrogenase inhibitors|aldehyde dehydrogenase (NAD(+)) inhibitor|NAD-aldehyde dehydrogenase inhibitor|aldehyde dehydrogenase (NAD) inhibitor|aldehyde dehydrogenase (NAD(+)) (EC 1.2.1.3) inhibitors|EC 1.2.1.3 (aldehyde dehydrogenase (NAD(+))) inhibitor|m-methylbenzaldehyde dehydrogenase inhibitors|aldehyde dehydrogenase (NAD(+)) inhibitors|NAD-dependent 4-hydroxynonenal dehydrogenase inhibitor|CoA-independent aldehyde dehydrogenase inhibitor|EC 1.2.1.3 (aldehyde dehydrogenase (NAD(+))) inhibitors|aldehyde dehydrogenase (NAD(+)) (EC 1.2.1.3) inhibitor|CoA-independent aldehyde dehydrogenase inhibitors|EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitors|NAD-dependent aldehyde dehydrogenase inhibitor|NAD-dependent 4-hydroxynonenal dehydrogenase inhibitors|NAD-linked aldehyde dehydrogenase inhibitors|aldehyde dehydrogenase (NAD) inhibitors|NAD-dependent aldehyde dehydrogenase inhibitors|EC 1.2.1.3 inhibitors|propionaldehyde dehydrogenase inhibitor|aldehyde dehydrogenase inhibitor|aldehyde dehydrogenase inhibitors|propionaldehyde dehydrogenase inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:35487,,,,EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor,,CHEBI:35487,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000009415,FADS2,,Other designations: delta(6) desaturase|delta(6) fatty acid desaturase|delta-6 desaturase|delta-6 fatty acid desaturase|delta-6-desaturase|linoleoyl-CoA desaturase (delta-6-desaturase)-like 2,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,D6D|SLL0262|TU13|LLCDL2|FADSD6|DES6,,,,,,,,,,,,11,,,,,,HPRD:05854|Vega:OTTHUMG00000163794|HGNC:3575|Ensembl:ENSG00000134824|MIM:606149,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,fatty acid desaturase 2,,,11q12.2,,,,,,,,,,,,,,,,"GO_0004768 (EC: IEA); GO_0005506 (EC: IEA); GO_0005789 (EC: TAS); GO_0005887 (EC: TAS, PMID: 9867867); GO_0006636 (EC: IEA); GO_0016020 (EC: TAS, PMID: 9867867); GO_0020037 (EC: IEA); GO_0033559 (EC: TAS); GO_0036109 (EC: TAS); GO_0043651 (EC: TAS); GO_0044281 (EC: TAS)",,,,,,,,,PMID: 9445487; 9867867; 10860662; 12147235; 12477932; 12562861; 12713571; 12851727; 12951357; 14702039; 16196087; 16303743; 16344560; 16670158; 16713569; 16893529; 16908951; 17284757; 17852835; 17984066; 18320251; 18479586; 18626191; 18842780; 18936223; 18937842; 19060906; 19060910; 19060911; 19144731; 19148276; 19352218; 19546342; 19776639; 19809313; 19875987; 19913121; 19948371; 20045144; 20335541; 20339536; 20364269; 20379614; 20395685; 20427696; 20484448; 20562440; 20565855; 20615514; 20628086; 20644632; 20686565; 20691134; 20694148; 20714348; 20948998; 20972250; 20980488; 21040914; 21106917; 21139048; 21414826; 21560298; 21605700; 21629299; 21733300; 21793953; 21818279; 21829377; 21890473; 21917437; 21980057; 21987572; 22001757; 22140540; 22194195; 22286219; 22359512; 22505724; 22619218; 22629455; 22748975; 22877655; 22916037; 22960237; 23000965; 23128233; 23160180; 23211517; 23221573; 23362303; 23378610; 23414387; 23464991; 23555103; 23667444; 23737301; 23844124,,,,,,,,,,,,,,,OGG:3000009415,,,,,,,fatty acid desaturase 2,,,,,,,,,,,,,Other designations: delta(6) desaturase|delta(6) fatty acid desaturase|delta-6 desaturase|delta-6 fatty acid desaturase|delta-6-desaturase|linoleoyl-CoA desaturase (delta-6-desaturase)-like 2,,FADS2,,,,,,,,,,,,,,,,,,,,,,,9415,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,FADS2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000007076,TIMP1,,Other designations: TIMP-1|collagenase inhibitor|erythroid potentiating activity|erythroid-potentiating activity|fibroblast collagenase inhibitor|metalloproteinase inhibitor 1|tissue inhibitor of metalloproteinases 1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CLGI|TIMP|EPO|EPA|HCI,,,,,,,,,,,,X,,,,,,Ensembl:ENSG00000102265|MIM:305370|Vega:OTTHUMG00000021447|HGNC:11820|HPRD:02371,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,TIMP metallopeptidase inhibitor 1,,,Xp11.3-p11.23,,,,,,,,,,,,,,,,"GO_0002020 (EC: IEA); GO_0002576 (EC: TAS); GO_0005515 (EC: IPI, PMID: 16917503); GO_0005576 (EC: NAS, PMID: 1653055); GO_0005576 (EC: TAS); GO_0005604 (EC: IEA); GO_0007568 (EC: IEA); GO_0007596 (EC: TAS); GO_0008191 (EC: IDA, PMID: 12714508); GO_0008284 (EC: TAS, PMID: 3839290); GO_0010951 (EC: IDA, PMID: 12714508); GO_0022617 (EC: TAS); GO_0030168 (EC: TAS); GO_0030198 (EC: TAS); GO_0031093 (EC: TAS); GO_0034097 (EC: IEA); GO_0043066 (EC: IEA); GO_0043249 (EC: IEA); GO_0043434 (EC: IEA); GO_0046872 (EC: IEA); GO_0051045 (EC: IDA, PMID: 12714508); GO_1901164 (EC: IMP)",,,,,,,,,PMID: 1420137; 1653055; 1730286; 2163605; 2171551; 2251898; 2921031; 3010309; 3460333; 3688834; 3839290; 3903517; 7507419; 8757599; 9063449; 9286280; 9288970; 9778693; 10071915; 10233411; 10441576; 10623524; 11279011; 11598182; 11606052; 11705862; 11762702; 11796725; 11876751; 11935340; 11940298; 12032189; 12034345; 12063180; 12081564; 12082592; 12147251; 12150976; 12218659; 12376362; 12406369; 12452001; 12475252; 12477932; 12479097; 12496489; 12538453; 12612199; 12614934; 12620441; 12626459; 12634064; 12651627; 12704667; 12714508; 12717827; 12771930; 12791318; 12834347; 12846741; 12861139; 12869573; 12873541; 12904305; 12921631; 12951656; 12970724; 14517716; 14605322; 14622947; 14630798; 14648584; 14652000; 14661256; 14669348; 14688084; 14710472; 14734567; 14871825; 14962256; 14973177; 14983226; 15028476; 15051730; 15073104; 15161657; 15225209; 15248826; 15277439; 15287862; 15313474; 15340161; 15363817; 15363818; 15465038; 15479729; 15485866; 15489334; 15494493; 15515157; 15516987; 15530852; 15557756; 15616792; 15754326; 15754388; 15797648; 15818737; 15841325; 15867221; 15888067; 15890357; 15896974; 15944607; 16005367; 16019435; 16042227; 16061701; 16100012; 16103240; 16107690; 16169070; 16188099; 16191301; 16219294; 16248458; 16263699; 16269968; 16280123; 16288711; 16289162; 16303743; 16335952; 16372907; 16407831; 16410344; 16474379; 16496359; 16555295; 16615041; 16631927; 16740002; 16754484; 16767366; 16772717; 16786122; 16840178; 16864898; 16877361; 16880228; 16917503; 16931892; 16935611; 16940985; 16960901; 16996520; 17008230; 17009408; 17012236; 17045024; 17050530; 17071711; 17072372; 17114213; 17136882; 17162914; 17182940; 17192464; 17202148; 17205957; 17209789; 17222415; 17226791; 17299802; 17301822; 17340613; 17350093; 17380436; 17409012; 17456311; 17478562; 17489740; 17493602; 17543340; 17549663; 17564313; 17572998; 17589947; 17634538; 17660250; 17703334; 17726014; 17763191; 17786346; 17878270; 17893005; 17899257; 17920311; 17928006; 17998244; 18025061; 18034264; 18042068; 18049028; 18063811; 18159069; 18214300; 18217401; 18236174; 18273688; 18291374; 18292822; 18298349; 18385523; 18391843; 18395263; 18474748; 18477480; 18487063; 18502033; 18630499; 18634035; 18636124; 18645261; 18683786; 18692810; 18704317; 18787947; 18850474; 18854176; 18945772; 18984437; 19012952; 19019896; 19020757; 19036126; 19134356; 19141395; 19246282; 19288452; 19331801; 19336475; 19358835; 19383295; 19383343; 19383344; 19387352; 19390929; 19430729; 19464975; 19506087; 19513566; 19524176; 19551542; 19560452; 19596921; 19608737; 19609944; 19629003; 19637058; 19653096; 19717938; 19723139; 19723899; 19728856; 19747478; 19758569; 19766963; 19781774; 19796534; 19814619; 19863693; 19875168; 19887890; 19889076; 19904223; 19911067; 19913121; 19927649; 20021931; 20030715; 20039537; 20041335; 20051489; 20095885; 20111696; 20164040; 20193458; 20215736; 20298300; 20305574; 20361393; 20371206; 20388222; 20423842; 20450704; 20452482; 20459644; 20484597; 20514432; 20533294; 20545111; 20545310; 20556397; 20584750; 20587546; 20595097; 20616161; 20628086; 20628624; 20646231; 20654099; 20655547; 20673868; 20685094; 20707923; 20798956; 20838751; 20853162; 20854182; 20889295; 20921293; 21041986; 21086628; 21094936; 21115936; 21128246; 21139048; 21163810; 21165404; 21167221; 21211402; 21283828; 21427648; 21437624; 21437772; 21454617; 21463121; 21487066; 21506705; 21524282; 21535601; 21547130; 21586274; 21684102; 21709637; 21720458; 21731773; 21745383; 21763297; 21786179; 21858035; 21860087; 21881840; 21882477; 21903858; 21906983; 21928345; 21946941; 21963094; 21963718; 21969093; 21987572; 21993004; 21995626; 22016393; 22020222; 22051851; 22110238; 22122951; 22139647; 22177802; 22199358; 22200256; 22200690; 22200710; 22204652; 22223664; 22257687; 22268729; 22286923; 22289852; 22291969; 22305865; 22364921; 22397869; 22402936; 22427646; 22457727; 22465225; 22516898; 22532131; 22544540; 22547904; 22558080; 22645431; 22667130; 22671570; 22706255; 22712305; 22718114; 22739984; 22788708; 22820628; 22859303; 22883459; 22901654; 22906271; 22957045; 22965799; 22971139; 22975753; 22985578; 23000965; 23016931; 23043898; 23057632; 23060593; 23064462; 23107442; 23122949; 23158994; 23175213; 23179318; 23223421; 23318123; 23388475; 23407481; 23412981; 23457635; 23509357; 23522389; 23525523; 23548070; 23555182; 23557756; 23563628; 23583449; 23592002; 23650722; 23660069; 23673111; 23763354; 23768069; 23815085; 23817219; 23834019; 23881388; 23893334; 23967215; 23993112; 24039251; 24174628; 24330623; 24479343,,,,,,,,,,,,,,,OGG:3000007076,,,,,,,TIMP metallopeptidase inhibitor 1,,,,,,,,,,,,,Other designations: TIMP-1|collagenase inhibitor|erythroid potentiating activity|erythroid-potentiating activity|fibroblast collagenase inhibitor|metalloproteinase inhibitor 1|tissue inhibitor of metalloproteinases 1,,TIMP1,,,,,,,,,,,,,,,,,,,,,,,7076,RP1-230G1.3,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,TIMP1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000006876,TAGLN,,Other designations: 22 kDa actin-binding protein|SM22-alpha|smooth muscle protein 22-alpha|transgelin variant 2,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,TAGLN1|SM22|SMCC|WS3-10,,,,,,,,,,,,11,,,,,,HPRD:02891|HGNC:11553|Ensembl:ENSG00000149591|Vega:OTTHUMG00000167067|MIM:600818,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,transgelin,,,11q23.2,,,,,,,,,,,,,,,,"GO_0003779 (EC: IEA); GO_0005515 (EC: IPI); GO_0005737 (EC: IEA); GO_0007517 (EC: TAS, PMID: 9615232); GO_0030855 (EC: IDA)",,,,,,,,,PMID: 1520290; 1872880; 7788527; 8117285; 8125298; 9242426; 9276683; 9384215; 9615232; 11053353; 11773051; 12200029; 12477932; 12521938; 15489334; 16009940; 17082327; 17305610; 17353931; 17629319; 18245174; 18291675; 18378184; 18446369; 19011151; 19188659; 19329940; 19724680; 19796641; 19848416; 19913121; 20012321; 20066125; 20098441; 20336793; 20379614; 20540360; 20628086; 20705054; 20707403; 21044950; 21051832; 21092460; 21139048; 21677441; 21763649; 21943158; 22245152; 22257561; 22365974; 22939629; 23138394; 23174934; 23331552; 23538046; 23824909,,,,,,,,,,,,,,,OGG:3000006876,,,,,,,transgelin,,,,,,,,,,,,,Other designations: 22 kDa actin-binding protein|SM22-alpha|smooth muscle protein 22-alpha|transgelin variant 2,,TAGLN,,,,,,,,,,,,,,,,,,,,,,,6876,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,TAGLN,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000011163,NUDT4,,"Other designations: DIPP-2|diadenosine 5',5'''-P1,P6-hexaphosphate hydrolase 2|diphosphoinositol polyphosphate phosphohydrolase 2|diphosphoinositol polyphosphate phosphohydrolase type 2",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,DIPP2alpha|DIPP2beta|DIPP2,,,,,,,,,,,,12,,,,,,HGNC:8051|HPRD:14850|MIM:609229|Ensembl:ENSG00000173598|Vega:OTTHUMG00000170155,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,nudix (nucleoside diphosphate linked moiety X)-type motif 4,,,12q21,,,,,,,,,,,,,,,,"GO_0005622 (EC: TAS, PMID: 10777568); GO_0005829 (EC: TAS); GO_0008486 (EC: IDA, PMID: 10777568); GO_0009187 (EC: TAS, PMID: 10777568); GO_0019722 (EC: TAS, PMID: 10777568); GO_0019935 (EC: TAS, PMID: 10777568); GO_0030515 (EC: ISS); GO_0035556 (EC: NAS, PMID: 10777568); GO_0043647 (EC: TAS); GO_0044281 (EC: TAS); GO_0046831 (EC: TAS, PMID: 10777568); GO_0046872 (EC: IEA); GO_0046907 (EC: TAS, PMID: 10777568); GO_0050072 (EC: ISS, Qualifier: NOT); GO_0052840 (EC: TAS); GO_0052843 (EC: IEA); GO_0052844 (EC: IEA); GO_0052845 (EC: IEA); GO_0052846 (EC: IEA); GO_0052847 (EC: IEA); GO_0052848 (EC: IEA)",,,,,,,,,PMID: 8125298; 9455484; 10777568; 11376937; 12121577; 12370170; 12477932; 15252450; 15489334; 18976975,,,,,,,,,,,,,,,OGG:3000011163,,,,,,,nudix (nucleoside diphosphate linked moiety X)-type motif 4,,,,,,,,,,,,,"Other designations: DIPP-2|diadenosine 5',5'''-P1,P6-hexaphosphate hydrolase 2|diphosphoinositol polyphosphate phosphohydrolase 2|diphosphoinositol polyphosphate phosphohydrolase type 2",,NUDT4,,,,,,,,,,,,,,,,,,,,,,,11163,HDCMB47P,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,NUDT4,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000011164,NUDT5,,Other designations: 8-oxo-dGDP phosphatase|ADP-sugar pyrophosphatase,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,YSA1|YSA1H|YSAH1|hYSAH1,,,,,,,,,,,,10,,,,,,MIM:609230|Ensembl:ENSG00000165609|HPRD:14851|HGNC:8052,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,nudix (nucleoside diphosphate linked moiety X)-type motif 5,,,10p14,,,,,,,,,,,,,,,,"GO_0000287 (EC: IDA, PMID: 18462755); GO_0005622 (EC: NAS, PMID: 10567213); GO_0005829 (EC: TAS); GO_0009117 (EC: NAS, PMID: 10567213); GO_0009191 (EC: IDA, PMID: 18462755); GO_0017110 (EC: IEA); GO_0019144 (EC: IDA, PMID: 10567213); GO_0019303 (EC: NAS, PMID: 10567213); GO_0030515 (EC: ISS); GO_0034656 (EC: TAS); GO_0044281 (EC: TAS); GO_0047631 (EC: EXP); GO_0050072 (EC: ISS, Qualifier: NOT); GO_0055086 (EC: TAS); GO_0070062 (EC: IDA, PMID: 19056867)",,,,,,,,,PMID: 10373642; 10567213; 10722730; 11042152; 12477932; 12717453; 15489334; 15592455; 16002790; 16169070; 16716086; 17052728; 17261271; 18462755; 19056867; 19699693; 20144704; 20176146; 20360068; 21139048; 21389046; 21768126; 21890473; 21900206; 21906983; 21963094; 22200976; 22351996; 22505724; 22863883; 22939629; 23000965; 23184937,,,,,,,,,,,,,,,OGG:3000011164,,,,,,,nudix (nucleoside diphosphate linked moiety X)-type motif 5,,,,,,,,,,,,,Other designations: 8-oxo-dGDP phosphatase|ADP-sugar pyrophosphatase,,NUDT5,,,,,,,,,,,,,,,,,,,,,,,11164,HSPC115,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,NUDT5,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_44445,nimesulide,4'-nitro-2'-phenoxymethanesulfonanilide|4-NITRO-2-PHENOXYMETHANESULFONANILIDE|Nimesulide|N-(4-nitro-2-phenoxyphenyl)methanesulfonamide,An aromatic ether having phenyl and 2-methylsulfonamido-5-nitrophenyl as the two aryl groups.,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:51803-78-2|Reaxys:2421175|PMID:18426087|Drug_Central:1935|LINCS:LSM-3718|DrugBank:DB04743|Beilstein:2421175,,An aromatic ether having phenyl and 2-methylsulfonamido-5-nitrophenyl as the two aryl groups.,,,,,,,,,,,,C13H12N2O5S,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_50629|http://purl.obolibrary.org/obo/CHEBI_35475,,,,,Nimesulide|N-(4-nitro-2-phenoxyphenyl)methanesulfonamide,,4'-nitro-2'-phenoxymethanesulfonanilide|4-NITRO-2-PHENOXYMETHANESULFONANILIDE,,,,,,,,,,,,,,,,,,,,,CHEBI:44445,,,,nimesulide,,CHEBI:44445,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CS(=O)(=O)Nc1ccc(cc1Oc1ccccc1)[N+]([O-])=O,,,,,
http://purl.obolibrary.org/obo/TXPO_0004817,TAZ (canonical) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0005063|http://purl.obolibrary.org/obo/TXPO_0004815,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:363521|NCBI-Mouse-GeneID:66826|NCBI-Human-GeneID:6901|PMID:30700007,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004817,,,,,,,,,,,,,,,,,,,,,,TAZ (canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004815,TAZ (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:363521|NCBI-Mouse-GeneID:66826|NCBI-Human-GeneID:6901,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004815,,,,,,,,,,,,,,,,,,,,,,TAZ (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004812,SNAI1 (human) [hepatocarcinogenesis],Snail,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_0005132,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:6615|PMID:29358721|PMID:28584306,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Snail,,,,,TXPO:0004812,,,,,,,,,,,,,,,,,,,,,,SNAI1 (human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004813,TAZ signal transduction pathway,,A series of molecular signals mediated by TAZ (tafazzin).,false,,,http://purl.obolibrary.org/obo/TXPO_0000609,,,,,,,,,,,,,,,,,,,,,,A series of molecular signals mediated by TAZ (tafazzin).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004813,,,,,,,,,,,,,,,,,,,,,,TAZ signal transduction pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004811,Snail1 signal transduction pathway,,A series of molecular signals mediated by Snail1 (snail family transcriptional repressor 1).,false,,,http://purl.obolibrary.org/obo/TXPO_0000609,,,,,,,,,,,,,,,,,,,,,,A series of molecular signals mediated by Snail1 (snail family transcriptional repressor 1).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004811,,,,,,,,,,,,,,,,,,,,,,Snail1 signal transduction pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004810,Snail1 signaling (primitive),,Snail1 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the Snail1 (snail family transcriptional repressor 1) .,false,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,,,Snail1 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the Snail1 (snail family transcriptional repressor 1) .,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004811,,,,,,,,,,,,,,,,TXPO:0004810,,,,,,,,,,,,,,,,,,,,,,Snail1 signaling (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004818,Hepatic fibrosis [hepatocarcinogenesis],,"Hepatic fibrosis is a subtype of fibrosis: A process that replaces liver tissues to fibrous connective tissues, usually as a consequence of inflammation or other injury.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0000816,,,,,,,,,,,,,,,,,,,,PMID:30700007|PMID:26017875,,"Hepatic fibrosis is a subtype of fibrosis: A process that replaces liver tissues to fibrous connective tissues, usually as a consequence of inflammation or other injury.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004392,,,,,,,,,,,TXPO:0004818,,,,,,,,,,,,,,,,,,,,,,Hepatic fibrosis [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004816,TAZ signaling (primitive) [hepatocarcinogenesis],,"TAZ signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by TAZ.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004814,,,,,,,,,,,,,,,,,,,,PMID:30700007,,"TAZ signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by TAZ.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004817,http://purl.obolibrary.org/obo/TXPO_0004813,,,,,http://purl.obolibrary.org/obo/TXPO_0004404|http://purl.obolibrary.org/obo/TXPO_0004403|http://purl.obolibrary.org/obo/TXPO_0004603|http://purl.obolibrary.org/obo/TXPO_0004818|http://purl.obolibrary.org/obo/TXPO_0004396,,,,,,,,,,,TXPO:0004816,,,,,,,,,,,,,,,,,,,,,,TAZ signaling (primitive) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004814,TAZ signaling (primitive),,TAZ signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by TAZ.,false,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,,,TAZ signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by TAZ.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004815,http://purl.obolibrary.org/obo/TXPO_0004813,,,,,,,,,,,,,,,,TXPO:0004814,,,,,,,,,,,,,,,,,,,,,,TAZ signaling (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004819,"1,4-bis[2-(3,5-dichloropyridyloxy)]benzene",TCPOBOP,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:76150-91-9|PubChem CID:5382,,,,,,,,,,,,,,C16H8Cl4N2O2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TCPOBOP,,,,,TXPO:0004819,,,,,,,,,,,,,,,,,,,,,,"1,4-bis[2-(3,5-dichloropyridyloxy)]benzene",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,C1=CC(=CC=C1OC2=C(C=C(C=N2)Cl)Cl)OC3=C(C=C(C=N3)Cl)Cl,,,,,
http://purl.obolibrary.org/obo/IMR_0100536,GCK,germinal center kinase,,false,,,http://purl.obolibrary.org/obo/IMR_0100535,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,germinal center kinase,,,,,IMR:0100536,,,,,,,,,,,,,,,,,,,,,,GCK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000268,bile acid biosynthetic process [Cholestasis],,"Bile acid biosynthetic process is a subtype of biosynthetic process:  The chemical reactions resulting in the formation of bile acids, any of a group of steroid carboxylic acids occurring in bile.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000034|http://purl.obolibrary.org/obo/GO_0006699,,,,,,,,,,,,,,,,,,,,,,"Bile acid biosynthetic process is a subtype of biosynthetic process:  The chemical reactions resulting in the formation of bile acids, any of a group of steroid carboxylic acids occurring in bile.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000268,,,,,,,,,,,,,,,,,,,,,,bile acid biosynthetic process [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000264,bile acid accumulation in hepatocyte [Cholestasis],,"Bile acid accumulation in hepatocyte is a subtype of accumulation of substances in a biological object: A process that keeps bile acid within the hepatocute in the liver (intrahepatic).
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000034|http://purl.obolibrary.org/obo/TXPO_0000263,,,,,,,,,,,,,,,,,,,,,,"Bile acid accumulation in hepatocyte is a subtype of accumulation of substances in a biological object: A process that keeps bile acid within the hepatocute in the liver (intrahepatic).
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000265,,,,,,,,,,,TXPO:0000264,,,,,,,,,,,,,,,,,,,,,,bile acid accumulation in hepatocyte [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000269,bile acid  transport to hepatocyte,,Bile acid  transport to hepatocyte is a subtype of bile acid and bile salt transport: A process that transports bile acid within a hepatocyte by means of some agent such as a transporter or pore.,false,,,http://purl.obolibrary.org/obo/GO_0015721,,,,,,,,,,,,,,,,,,,,PMID:9806540,,Bile acid  transport to hepatocyte is a subtype of bile acid and bile salt transport: A process that transports bile acid within a hepatocyte by means of some agent such as a transporter or pore.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000182,,,,,,,,TXPO:0000269,,,,,,,,,,,,,,,,,,,,,,bile acid  transport to hepatocyte,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000263,bile acid accumulation in hepatocyte,,"Bile acid strorage is a subtype of accumulation of substances in a biological object: A process that keeps bile acid within the liver (intrahepatic), or outside the liver (extrahepatic) in the bile duct system.",false,,,http://purl.obolibrary.org/obo/TXPO_0003130,,,,,,,,,,,,,,,,,,,,,,"Bile acid strorage is a subtype of accumulation of substances in a biological object: A process that keeps bile acid within the liver (intrahepatic), or outside the liver (extrahepatic) in the bile duct system.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000263,,,,,,,,,,,,,,,,,,,,,,bile acid accumulation in hepatocyte,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000182,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000261,changing relationship between operands,,Changing relationship between operands is a subtype of changing: A process that changing the relationship between multiple objects.,false,,,http://purl.obolibrary.org/obo/TXPO_0000387,,,,,,,,,,,,,,,,,,,,,,Changing relationship between operands is a subtype of changing: A process that changing the relationship between multiple objects.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000261,,,,,,,,,,,,,,,,,,,,,,changing relationship between operands,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000260,substance with apoptosis inducer role,,Substance with apoptosis inducer role is a subtype of substance with role. This entity is participating in a positive regulation of apoptosis process and playing an apoptosis inducer role.|This entity is inferred from Description Logic.,false,,,http://purl.obolibrary.org/obo/CHEBI_24431|http://purl.obolibrary.org/obo/GOCHE_50906,,,,,,,,,,,,,,,,,,,,,,Substance with apoptosis inducer role is a subtype of substance with role. This entity is participating in a positive regulation of apoptosis process and playing an apoptosis inducer role.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000260,,,,,,,,,,,,,,,,,,,,This entity is inferred from Description Logic.,,substance with apoptosis inducer role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000262,ATP depletion [toxic course],,The totality of all processes through which ATP depltion is realized.,false,,,http://purl.obolibrary.org/obo/TXPO_0000009,,,,,,,,,,,,,,,,,,,,,,The totality of all processes through which ATP depltion is realized.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000207|http://purl.obolibrary.org/obo/TXPO_0000485|http://purl.obolibrary.org/obo/TXPO_0000218|http://purl.obolibrary.org/obo/TXPO_0000354|http://purl.obolibrary.org/obo/TXPO_0000366|http://purl.obolibrary.org/obo/TXPO_0000367|http://purl.obolibrary.org/obo/TXPO_0000368|http://purl.obolibrary.org/obo/TXPO_0000167,,,,,,,,,,,,,,,,,,TXPO:0000262,,,,,,,,,,,,,,,,,,,,,,ATP depletion [toxic course],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000267,increasing amount of carbohydrate,,Increasing amount of carbohydrate is a subtype of increasing quantity: A process that changes the amount of carbohydrates to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing amount of carbohydrate is a subtype of increasing quantity: A process that changes the amount of carbohydrates to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000267,,,,,,,,,,,,,,,,,,,,,,increasing amount of carbohydrate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000265,increasing hepatocellular volume [Cholestasis],,"Increasing hepatocellular volume is a changing process to change the volume of the hepatocyte to increase.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000034|http://purl.obolibrary.org/obo/TXPO_0000164,,,,,,,,,,,,,,,,,,,,,,"Increasing hepatocellular volume is a changing process to change the volume of the hepatocyte to increase.
This entity is a specific course-dependent process. This process can constitute the course of Cholestasis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000265,,,,,,,,,,,,,,,,,,,,,,increasing hepatocellular volume [Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000266,ubiquitin ligase,,"A role played by the entity that catalyses the transfer of ubiquitin to a substrate protein via the reaction X-ubiquitin + S -> X + S-ubiquitin, where X is either an E2 or E3 enzyme, the X-ubiquitin linkage is a thioester bond, and the S-ubiquitin linkage is an amide bond: an isopeptide bond between the C-terminal glycine of ubiquitin and the epsilon-amino group of lysine residues in the substrate or, in the linear extension of ubiquitin chains, a peptide bond the between the C-terminal glycine and N-terminal methionine of ubiquitin residues.",false,,,http://purl.obolibrary.org/obo/TXPO_0000171,,,,,,,,,,,,,,,,,,,,GO:0004842,,"A role played by the entity that catalyses the transfer of ubiquitin to a substrate protein via the reaction X-ubiquitin + S -> X + S-ubiquitin, where X is either an E2 or E3 enzyme, the X-ubiquitin linkage is a thioester bond, and the S-ubiquitin linkage is an amide bond: an isopeptide bond between the C-terminal glycine of ubiquitin and the epsilon-amino group of lysine residues in the substrate or, in the linear extension of ubiquitin chains, a peptide bond the between the C-terminal glycine and N-terminal methionine of ubiquitin residues.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000266,,,,,,,,,,,,,,,,,,,,,,ubiquitin ligase,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000357,Grb7,Growth factor receptor-bound protein 7,,false,,,http://purl.obolibrary.org/obo/IMR_0100382,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Growth factor receptor-bound protein 7,,,,,IMR:0000357,,,,,,,,,,,,,,,,,,,,,,Grb7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000574,IFN alpha-4,,,false,,,http://purl.obolibrary.org/obo/IMR_0100386,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000574,,,,,,,,,,,,,,,,,,,,,,IFN alpha-4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002381,abnormality of membrane (severe) [Cell death],,"Abnormality of membrane is a subtype of changing abnormal cellular structure: A process that changes the membrane stucture abnormally.
The degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0001727|http://purl.obolibrary.org/obo/TXPO_0001755,,,,,,,,,,,,,,,,,,,,,,"Abnormality of membrane is a subtype of changing abnormal cellular structure: A process that changes the membrane stucture abnormally.
The degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002387,,,,,,,,,,,TXPO:0002381,,,,,,,,,,,,,,,,,,,,,,abnormality of membrane (severe) [Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002382,TP53 - cell cycle regulation factor (canonical)[Cell death],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000843,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002247,,,,,,,,,,TXPO:0002382,,,,,,,,,,,,,,,,,,,,,,TP53 - cell cycle regulation factor (canonical)[Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002387,necrosis [Cell death],,"A type of cell death that is morphologically characterized by an increasingly translucent cytoplasm, swelling of organelles, minor ultrastructural modifications of the nucleus (specifically, dilatation of the nuclear membrane and condensation of chromatin into small, irregular, circumscribed patches) and increased cell volume (oncosis), culminating in the disruption of the plasma membrane and subsequent loss of intracellular contents. Necrotic cells do not fragment into discrete corpses as their apoptotic counterparts do. Moreover, their nuclei remain intact and can aggregate and accumulate in necrotic tissues.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0000008|http://purl.obolibrary.org/obo/GO_0070265,,,,,,,,,,,,,,,,,,,,,,"A type of cell death that is morphologically characterized by an increasingly translucent cytoplasm, swelling of organelles, minor ultrastructural modifications of the nucleus (specifically, dilatation of the nuclear membrane and condensation of chromatin into small, irregular, circumscribed patches) and increased cell volume (oncosis), culminating in the disruption of the plasma membrane and subsequent loss of intracellular contents. Necrotic cells do not fragment into discrete corpses as their apoptotic counterparts do. Moreover, their nuclei remain intact and can aggregate and accumulate in necrotic tissues.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002389,,,,,,,,,,,TXPO:0002387,,,,,,,,,,,,,,,,,,,,,,necrosis [Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002384,chaperon production [ER stress],,"Chaperon production is a subtype of protein production: A process that makes existent of a protein with a chaperon role due to biosynthesis or secretion resulting in an increase in its levels.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000384|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,Generating a chparon protein is a generating process to make a protein as an output in the course of ER stress.,,"Chaperon production is a subtype of protein production: A process that makes existent of a protein with a chaperon role due to biosynthesis or secretion resulting in an increase in its levels.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000801|http://purl.obolibrary.org/obo/TXPO_0002164|http://purl.obolibrary.org/obo/TXPO_0000783|http://purl.obolibrary.org/obo/TXPO_0002677|http://purl.obolibrary.org/obo/TXPO_0000828|http://purl.obolibrary.org/obo/TXPO_0000561,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002716,,,,,,,,,,,TXPO:0002384,,,,,,,,,,,,,,,,,,,,,,chaperon production [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002386,OCT1 (canonical)[Cholestasis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002647,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C21204,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002386,,,,,,,FXR inhibits OCT1 via SHP1,,,,,,,,,,,,,,,OCT1 (canonical)[Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002385,GRP78 (canonical)[ER stress],HSPA5 [ER stress]|HEL-S-89n [ER stress]|BIP [ER stress]|Heat Shock Protein Family A (Hsp70) Member 5 [ER stress]|MIF2 [ER stress],,false,,,http://purl.obolibrary.org/obo/TXPO_0001002|http://purl.obolibrary.org/obo/TXPO_0000871,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:3309|NCBI-Mouse-GeneID:14828|NCBI-Rat-GeneID:25617|PMID:8020977|PMID:12110171,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003997,,,,,HSPA5 [ER stress]|HEL-S-89n [ER stress]|BIP [ER stress]|Heat Shock Protein Family A (Hsp70) Member 5 [ER stress]|MIF2 [ER stress],,,,,TXPO:0002385,,,,,,,,,,,,,,,,,,,,,,GRP78 (canonical)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002383,eosinogranular degeneration dependent chemical compound,,"Eosinogranular degeneration dependent chemical compound is a subtype of toxic course dependent chemical entity.
This entity (drug) can participate in the course of eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/TXPO_0000835,,,,,,,,,,,,,,,,,,,,,,"Eosinogranular degeneration dependent chemical compound is a subtype of toxic course dependent chemical entity.
This entity (drug) can participate in the course of eosinogranular degeneration.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002383,,,,,,,,,,,,,,,,,,,,,,eosinogranular degeneration dependent chemical compound,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002389,increasing cell volume [Necrosis],cell swelling [Necrosis],"Increasing cell volume is a changing process to change the volume of the cell to increase.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0000142|http://purl.obolibrary.org/obo/TXPO_0001727,,,,,,,,,,,,,,,,,,,,,,"Increasing cell volume is a changing process to change the volume of the cell to increase.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001449,,,,,,,,cell swelling [Necrosis],,,TXPO:0002389,,,,,,,,,,,,,,,,,,,,,,increasing cell volume [Necrosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002388,apoptotic DNA fragmentation [Apoptosis],,"The cleavage of DNA during apoptosis, which usually occurs in two stages: cleavage into fragments of about 50 kbp followed by cleavage between nucleosomes to yield 200 bp fragments.
This entity is a specific course-dependent process. This process can constitute the course of Apoptosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001727|http://purl.obolibrary.org/obo/GO_0006309,,,,,,,,,,,,,,,,,,,,REACT:1213.3,,"The cleavage of DNA during apoptosis, which usually occurs in two stages: cleavage into fragments of about 50 kbp followed by cleavage between nucleosomes to yield 200 bp fragments.
This entity is a specific course-dependent process. This process can constitute the course of Apoptosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002388,,,,,,,,,,,,,,,,,,,,,,apoptotic DNA fragmentation [Apoptosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002380,Keap1 inactivation,,Keap1 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the Keap1 to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000021,,,,,,,,,,,,,,,,,,,,,,Keap1 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the Keap1 to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002380,,,,,,,,,,,,,,,,,,,,,,Keap1 inactivation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0200113,L-Asparagine,,,false,,,http://purl.obolibrary.org/obo/CHEBI_33709,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0200113,,,,,,,,,,,,,,,,,,,,,,L-Asparagine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_140921,Hedgehog signaling pathway inhibitor,Hedgehog signaling pathway inhibitors|Hedgehog pathway inhibitor|Hedgehog pathway inhibitors,Any pathway inhibitor that inhibits the Hedgehog signalling pathway.,false,,,http://purl.obolibrary.org/obo/CHEBI_76932,,,,,,,,,,,,,,,,,,,,,,Any pathway inhibitor that inhibits the Hedgehog signalling pathway.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hedgehog signaling pathway inhibitors|Hedgehog pathway inhibitor|Hedgehog pathway inhibitors,,,,,,,,,,,,,,,,,,,,,CHEBI:140921,,,,Hedgehog signaling pathway inhibitor,,CHEBI:140921,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000274,SHP family,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000274,,,,,,,,,,,,,,,,,,,,,,SHP family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0042592,homeostatic process,,Any biological process involved in the maintenance of an internal steady state.,false,,,http://purl.obolibrary.org/obo/TXPO_0000682,,,,,,,,,,,,,,,,,,,,,,Any biological process involved in the maintenance of an internal steady state.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0042592,,,,,,,,,,,,,,,,,,,,,,homeostatic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100319,JAK1,,,false,,,http://purl.obolibrary.org/obo/IMR_0000213,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100319,,,,,,,,,,,,,,,,,,,,,,JAK1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GOCHE_52214,substance with ligand role,,"Substance with ligand role is a subtype of substance with role.
This entity is participating in signaling and playing a ligand role.|This entity is inferred from Description Logic.",false,,,http://purl.obolibrary.org/obo/CHEBI_24431|http://purl.obolibrary.org/obo/GOCHE_50906,,,,,,,,,,,,,,,,,,,,,,"Substance with ligand role is a subtype of substance with role.
This entity is participating in signaling and playing a ligand role.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GOCHE:52214,,,,,,,,,,,,,,,,,,,,This entity is inferred from Description Logic.,,substance with ligand role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000011010,GLIPR1,,"Other designations: GLI pathogenesis-related 1 (glioma)|gliPR 1|glioma pathogenesis-related protein 1|protein RTVP-1|related to testis-specific, vespid, and pathogenesis proteins 1|testes-specific vespid and pathogenesis protein 1",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,RTVP1|GLIPR|CRISP7,,,,,,,,,,,,12,,,,,,HPRD:04071|HGNC:17001|MIM:602692,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,GLI pathogenesis-related 1,,,12q21.2,,,,,,,,,,,,,,,,GO_0005576 (EC: IEA); GO_0005886 (EC: TAS); GO_0016021 (EC: IEA); GO_0044255 (EC: TAS); GO_0044281 (EC: TAS),,,,,,,,,PMID: 7607567; 8973356; 9482873; 11971968; 12477932; 14702039; 14871827; 15489334; 16712791; 16714093; 17207965; 17825796; 18030365; 18199537; 19483285; 19913121; 20356381; 20628086; 21045302; 21777672; 21922325; 21931216; 22025562; 23333597; 23714687,,,,,,,,,,,,,,,OGG:3000011010,,,,,,,GLI pathogenesis-related 1,,,,,,,,,,,,,"Other designations: GLI pathogenesis-related 1 (glioma)|gliPR 1|glioma pathogenesis-related protein 1|protein RTVP-1|related to testis-specific, vespid, and pathogenesis proteins 1|testes-specific vespid and pathogenesis protein 1",,GLIPR1,,,,,,,,,,,,,,,,,,,,,,,11010,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,GLIPR1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000011016,ATF7,,Other designations: cyclic AMP-dependent transcription factor ATF-7|transcription factor ATF-A,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,ATFA,,,,,,,,,,,,12,,,,,,HPRD:06968|HGNC:792|Vega:OTTHUMG00000169776|Ensembl:ENSG00000170653|MIM:606371,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,activating transcription factor 7,,,12q13,,,,,,,,,,,,,,,,"GO_0003700 (EC: IEA); GO_0005515 (EC: IPI, PMID:10376527); GO_0005634 (EC: NAS, PMID:8288576); GO_0005654 (EC: IEA); GO_0005737 (EC: IEA); GO_0006351 (EC: IEA); GO_0006355 (EC: IDA, PMID:8288576); GO_0008134 (EC: IDA, PMID:10376527); GO_0016032 (EC: IEA); GO_0034399 (EC: IDA, PMID:17264123); GO_0043565 (EC: IEA); GO_0046872 (EC: IEA); GO_0051019 (EC: IDA, PMID:10376527)",,,,,,,,,PMID:1694576; 7769693; 8288576; 8649858; 8889548; 8939888; 10376527; 10698518; 11278933; 11566021; 12477932; 12805554; 14643450; 15342556; 15735663; 15867431; 16147992; 16344560; 17081983; 17264123; 18029348; 18671972; 18950637; 19471022; 20189936; 20195357; 21693764; 21858082; 21890473; 21998595; 22242598; 22939629; 23000965; 23426901; 23793025,,,,,,,,,,,,,,,OGG:3000011016,,,,,,,activating transcription factor 7,,,,,,,,,,,,,Other designations: cyclic AMP-dependent transcription factor ATF-7|transcription factor ATF-A,,ATF7,,,,,,,,,,,,,,,,,,,,,,,11016,,,,,,,,9606,,,,,,,,,,,,,,,,,,,ATF7,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000011014,KDELR2,,Other designations: (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 2|ER lumen protein retaining receptor 2|ERD-2-like protein|ERD2-like protein 1|KDEL endoplasmic reticulum protein retention receptor 2|KDEL receptor 2,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,ERD2.2|ELP-1,,,,,,,,,,,,7,,,,,,HGNC:6305|Ensembl:ENSG00000136240|HPRD:06598|MIM:609024|Vega:OTTHUMG00000023103,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 2,,,7p22.1,,,,,,,,,,,,,,,,"GO_0005046 (EC: TAS, PMID: 1316805); GO_0005783 (EC: TAS, PMID: 1316805); GO_0005789 (EC: IEA); GO_0005794 (EC: TAS, PMID: 1316805); GO_0005801 (EC: IEA); GO_0006621 (EC: IEA); GO_0006886 (EC: TAS, PMID: 1325562); GO_0016021 (EC: IEA); GO_0016192 (EC: IEA)",,,,,,,,,PMID: 1316805; 1325562; 9118249; 11752456; 12071860; 12477932; 12690205; 12853948; 14702039; 15489334; 16344560; 17353931; 19322201; 21139048; 21890473; 24250222,,,,,,,,,,,,,,,OGG:3000011014,,,,,,,KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 2,,,,,,,,,,,,,Other designations: (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 2|ER lumen protein retaining receptor 2|ERD-2-like protein|ERD2-like protein 1|KDEL endoplasmic reticulum protein retention receptor 2|KDEL receptor 2,,KDELR2,,,,,,,,,,,,,,,,,,,,,,,11014,tcag7.840,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,KDELR2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000199,kinesin,,,false,,,http://purl.obolibrary.org/obo/IMR_0100192,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000199,,,,,,,,,,,,,,,,,,,,,,kinesin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000008892,EIF2B2,,Other designations: S20I15|S20III15|eIF-2B GDP-GTP exchange factor subunit beta|translation initiation factor eIF-2B subunit beta,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,EIF2B|EIF-2Bbeta,,,,,,,,,,,,14,,,,,,HGNC:3258|Vega:OTTHUMG00000171764|Ensembl:ENSG00000119718|MIM:606454|HPRD:05923,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"eukaryotic translation initiation factor 2B, subunit 2 beta, 39kDa",,,14q24.3,,,,,,,,,,,,,,,,"GO_0001541 (EC: IMP, PMID:15507143); GO_0003743 (EC: IDA, Qualifier: contributes_to, PMID:16289705); GO_0005085 (EC: IDA, Qualifier: contributes_to, PMID:11323413); GO_0005085 (EC: IMP, Qualifier: contributes_to, PMID:15054402); GO_0005515 (EC: IPI, PMID:15060152); GO_0005524 (EC: IDA, PMID:11323413); GO_0005525 (EC: IDA, PMID:11323413); GO_0005737 (EC: IDA, PMID:11323413); GO_0005829 (EC: TAS); GO_0005851 (EC: IDA, PMID:11323413); GO_0006412 (EC: TAS); GO_0006413 (EC: IDA, PMID:16289705); GO_0006413 (EC: TAS); GO_0006446 (EC: IBA); GO_0006446 (EC: TAS, PMID:15060152); GO_0007417 (EC: IMP, PMID:15776425); GO_0009408 (EC: ISS); GO_0009408 (EC: TAS, PMID:12499492); GO_0009749 (EC: ISS); GO_0010467 (EC: TAS); GO_0014003 (EC: IMP, PMID:15217090); GO_0019509 (EC: IBA, Qualifier: NOT); GO_0042552 (EC: IMP, PMID:14566705); GO_0043087 (EC: IDA, PMID:11323413); GO_0043087 (EC: IMP, PMID:15054402); GO_0043434 (EC: ISS); GO_0044267 (EC: TAS); GO_0046523 (EC: IBA, Qualifier: NOT); GO_0051716 (EC: IDA, PMID:8626696)",,,,,,,,,PMID:7596406; 8619474; 8626696; 8887689; 9110174; 9446619; 10805739; 10858531; 11323413; 11704758; 11959995; 12477932; 12499492; 12508121; 12707859; 14566705; 14993275; 15054402; 15060152; 15217090; 15489334; 15507143; 15776425; 16169070; 16225457; 16289705; 17878805; 18029348; 18263758; 18632786; 19913121; 20301435; 20434207; 20628086; 20734064; 21139048; 21795329; 21832049; 21890473; 21988832; 22053931; 22285377; 22729508; 22863883; 22939629; 23000965; 23956138,,,,,,,,,,,,,,,OGG:3000008892,,,,,,,"eukaryotic translation initiation factor 2B, subunit 2 beta, 39kDa",,,,,,,,,,,,,Other designations: S20I15|S20III15|eIF-2B GDP-GTP exchange factor subunit beta|translation initiation factor eIF-2B subunit beta,,EIF2B2,,,,,,,,,,,,,,,,,,,,,,,8892,,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF2B2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000008894,EIF2S2,,"Other designations: eukaryotic translation initiation factor 2 subunit 2|eukaryotic translation initiation factor 2 subunit beta|protein phosphatase 1, regulatory subunit 67",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,EIF2|eIF-2-beta|EIF2B|EIF2beta|PPP1R67,,,,,,,,,,,,20,,,,,,HGNC:3266|Vega:OTTHUMG00000032287|MIM:603908|Ensembl:ENSG00000125977|HPRD:04882,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"eukaryotic translation initiation factor 2, subunit 2 beta, 38kDa",,,20q11.2,,,,,,,,,,,,,,,,"GO_0001701 (EC: IEA); GO_0002176 (EC: IEA); GO_0003723 (EC: TAS, PMID:3044606); GO_0003743 (EC: IDA, PMID:16289705); GO_0005515 (EC: IPI, PMID:16288713); GO_0005829 (EC: TAS); GO_0005850 (EC: TAS, PMID:3044606); GO_0006412 (EC: TAS); GO_0006413 (EC: TAS); GO_0008135 (EC: TAS, PMID:10805737); GO_0008584 (EC: IEA); GO_0010467 (EC: TAS); GO_0044267 (EC: TAS); GO_0044822 (EC: IDA); GO_0046872 (EC: IEA)",,,,,,,,,PMID:1104615; 3044606; 8024572; 9079663; 9395514; 9442054; 9446619; 9933616; 10620360; 10648795; 10805737; 10805739; 11092890; 11739746; 11780052; 11959995; 12477932; 12588972; 12901717; 15489334; 15635413; 16169070; 16288713; 16289705; 16932749; 17081983; 18423202; 18639529; 18781797; 18850631; 20000738; 20434207; 20972266; 21139048; 21145461; 21832049; 21890473; 21906983; 21907836; 22113938; 22174317; 22678362; 22813744; 22863883; 22939629; 22976474; 22990118; 23000965; 23455922; 24250222; 24457600,,,,,,,,,,,,,,,OGG:3000008894,,,,,,,"eukaryotic translation initiation factor 2, subunit 2 beta, 38kDa",,,,,,,,,,,,,"Other designations: eukaryotic translation initiation factor 2 subunit 2|eukaryotic translation initiation factor 2 subunit beta|protein phosphatase 1, regulatory subunit 67",,EIF2S2,,,,,,,,,,,,,,,,,,,,,,,8894,,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF2S2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000008890,EIF2B4,,Other designations: eIF-2B GDP-GTP exchange factor subunit delta|eukaryotic translation initiation factor 2B subunit 4 delta|translation initiation factor eIF-2B subunit delta|translation initiation factor eIF-2b delta subunit,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,EIF2B|EIF-2B|EIF2Bdelta,,,,,,,,,,,,2,,,,,,Vega:OTTHUMG00000151927|MIM:606687|HGNC:3260|Ensembl:ENSG00000115211|HPRD:09459,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"eukaryotic translation initiation factor 2B, subunit 4 delta, 67kDa",,,2p23.3,,,,,,,,,,,,,,,,"GO_0001541 (EC: IMP, PMID:15507143); GO_0003743 (EC: IDA, Qualifier: contributes_to, PMID:16289705); GO_0005085 (EC: IDA, Qualifier: contributes_to, PMID:11323413); GO_0005085 (EC: IMP, Qualifier: contributes_to, PMID:15054402); GO_0005515 (EC: IPI, PMID:15060152); GO_0005737 (EC: IDA, PMID:11323413); GO_0005829 (EC: TAS); GO_0005851 (EC: IDA, PMID:11323413); GO_0006412 (EC: TAS); GO_0006413 (EC: IDA, PMID:16289705); GO_0006413 (EC: TAS); GO_0006417 (EC: NAS, PMID:12556349); GO_0006446 (EC: IBA); GO_0009408 (EC: ISS); GO_0009408 (EC: TAS, PMID:12499492); GO_0009749 (EC: ISS); GO_0010467 (EC: TAS); GO_0014003 (EC: IMP, PMID:15217090); GO_0019509 (EC: IBA, Qualifier: NOT); GO_0031369 (EC: ISS); GO_0032057 (EC: ISS); GO_0042552 (EC: IMP, PMID:14566705); GO_0043087 (EC: IDA, PMID:11323413); GO_0043087 (EC: IMP, PMID:15054402); GO_0043434 (EC: ISS); GO_0044267 (EC: TAS); GO_0045947 (EC: IBA); GO_0046523 (EC: IBA, Qualifier: NOT); GO_0051716 (EC: IDA, PMID:8626696)",,,,,,,,,PMID:7982969; 8626696; 8887689; 8929216; 9446619; 10805739; 10858531; 10931946; 11323413; 11835386; 12477932; 12499492; 12556349; 12707859; 14566705; 15054402; 15060152; 15217090; 15489334; 15507143; 16288713; 16289705; 18005052; 18061208; 18160716; 18263758; 18330844; 18539998; 18632786; 19158808; 19460752; 20016818; 20301435; 20434207; 20532202; 20709751; 20734064; 21139048; 21503715; 21890473; 21906983; 22505724; 22737209; 22939629; 23000965; 23382691,,,,,,,,,,,,,,,OGG:3000008890,,,,,,,"eukaryotic translation initiation factor 2B, subunit 4 delta, 67kDa",,,,,,,,,,,,,Other designations: eIF-2B GDP-GTP exchange factor subunit delta|eukaryotic translation initiation factor 2B subunit 4 delta|translation initiation factor eIF-2B subunit delta|translation initiation factor eIF-2b delta subunit,,EIF2B4,,,,,,,,,,,,,,,,,,,,,,,8890,,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF2B4,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000008891,EIF2B3,,Other designations: eIF-2B GDP-GTP exchange factor subunit gamma|translation initiation factor eIF-2B subunit gamma,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,EIF2Bgamma|EIF-2B,,,,,,,,,,,,1,,,,,,HGNC:3259|HPRD:09379|Ensembl:ENSG00000070785|MIM:606273|Vega:OTTHUMG00000008585,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"eukaryotic translation initiation factor 2B, subunit 3 gamma, 58kDa",,,1p34.1,,,,,,,,,,,,,,,,"GO_0003743 (EC: IDA, Qualifier: contributes_to, PMID:10900014); GO_0005085 (EC: IDA, Qualifier: contributes_to, PMID:11323413); GO_0005085 (EC: IMP, Qualifier: contributes_to, PMID:15054402); GO_0005515 (EC: IPI, PMID:15060152); GO_0005737 (EC: IDA, PMID:11323413); GO_0005829 (EC: TAS); GO_0005851 (EC: IDA, PMID:11323413); GO_0006412 (EC: TAS); GO_0006413 (EC: IDA, PMID:10900014); GO_0006413 (EC: TAS); GO_0008135 (EC: IDA, Qualifier: contributes_to, PMID:10900014); GO_0009408 (EC: ISS); GO_0009408 (EC: TAS, PMID:12499492); GO_0009749 (EC: ISS); GO_0010467 (EC: TAS); GO_0014003 (EC: IMP, PMID:15217090); GO_0016779 (EC: IEA); GO_0032057 (EC: ISS); GO_0043087 (EC: IDA, PMID:11323413); GO_0043087 (EC: IMP, PMID:15054402); GO_0043434 (EC: ISS); GO_0044267 (EC: TAS); GO_0051716 (EC: IDA, PMID:8626696)",,,,,,,,,PMID:8626696; 8889549; 10737800; 10805739; 10858531; 10900014; 11076863; 11230166; 11323413; 11835386; 12477932; 12499492; 12707859; 14702039; 15054402; 15060152; 15217090; 15489334; 15489336; 16169070; 16288713; 16289705; 16344560; 16381901; 16710414; 17353931; 18263758; 18632786; 20301435; 20379614; 21139048; 21484434; 21890473; 21906983; 21963094; 21987572; 22268729; 22312164; 22863883; 22939629; 23000965; 23956138,,,,,,,,,,,,,,,OGG:3000008891,,,,,,,"eukaryotic translation initiation factor 2B, subunit 3 gamma, 58kDa",,,,,,,,,,,,,Other designations: eIF-2B GDP-GTP exchange factor subunit gamma|translation initiation factor eIF-2B subunit gamma,,EIF2B3,,,,,,,,,,,,,,,,,,,,,,,8891,RP5-882O7.2,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF2B3,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000008893,EIF2B5,,Other designations: eIF-2B GDP-GTP exchange factor subunit epsilon|translation initiation factor eIF-2B subunit epsilon,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CACH|LVWM|EIF2Bepsilon|EIF-2B|CLE,,,,,,,,,,,,3,,,,,,Vega:OTTHUMG00000156840|HPRD:04898|Ensembl:ENSG00000145191|HGNC:3261|MIM:603945,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"eukaryotic translation initiation factor 2B, subunit 5 epsilon, 82kDa",,,3q27.1,,,,,,,,,,,,,,,,"GO_0001541 (EC: IMP, PMID:15507143); GO_0003743 (EC: IDA, Qualifier: contributes_to, PMID:16289705); GO_0003743 (EC: NAS, PMID:8688466); GO_0005085 (EC: IDA, Qualifier: contributes_to, PMID:11323413); GO_0005085 (EC: IMP, PMID:15054402); GO_0005085 (EC: ISS); GO_0005515 (EC: IPI, PMID:15060152); GO_0005634 (EC: ISS); GO_0005737 (EC: IDA, PMID:11323413); GO_0005829 (EC: TAS); GO_0005851 (EC: IDA, PMID:11323413); GO_0006412 (EC: TAS); GO_0006413 (EC: IDA, PMID:16289705); GO_0006413 (EC: TAS); GO_0009408 (EC: IMP, PMID:15723074); GO_0009408 (EC: ISS); GO_0009408 (EC: TAS, PMID:12499492); GO_0009749 (EC: ISS); GO_0010467 (EC: TAS); GO_0014002 (EC: IMP, PMID:15723074); GO_0014003 (EC: IMP, PMID:15217090); GO_0031369 (EC: ISS); GO_0032057 (EC: ISS); GO_0034976 (EC: IMP, PMID:16041584); GO_0035690 (EC: IDA, PMID:8626696); GO_0042552 (EC: IMP, PMID:14566705); GO_0043087 (EC: IDA, PMID:11323413); GO_0043087 (EC: IMP, PMID:15054402); GO_0043087 (EC: ISS); GO_0043434 (EC: ISS); GO_0044267 (EC: TAS); GO_0045948 (EC: ISS); GO_0048708 (EC: IMP, PMID:15723074)",,,,,,,,,PMID:8626696; 8688466; 9446619; 9468292; 10441579; 10805739; 10858531; 11323413; 11500362; 11704758; 12133000; 12325082; 12477932; 12499492; 12707859; 14566705; 14572143; 14702039; 14993275; 15054402; 15060152; 15217090; 15302935; 15489334; 15507143; 15723074; 16041584; 16097034; 16289705; 16730941; 17081983; 17353931; 17439913; 17646634; 18263758; 18294360; 18562513; 18565837; 18632786; 18854154; 19913121; 20301435; 20628086; 20734064; 20975056; 21204011; 21307862; 21503715; 21832049; 21890473; 21906983; 22472876; 22939629; 23956138,,,,,,,,,,,,,,,OGG:3000008893,,,,,,,"eukaryotic translation initiation factor 2B, subunit 5 epsilon, 82kDa",,,,,,,,,,,,,Other designations: eIF-2B GDP-GTP exchange factor subunit epsilon|translation initiation factor eIF-2B subunit epsilon,,EIF2B5,,,,,,,,,,,,,,,,,,,,,,,8893,,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF2B5,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0001664,RGS6,,,false,,,http://purl.obolibrary.org/obo/IMR_0000431,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001664,,,,,,,,,,,,,,,,,,,,,,RGS6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002183,abnormal protein production,,Abnormal protein production is a subtype of protein production: A process that makes existent of an abnormal protein due to biosynthesis or secretion resulting in an increase in its levels.,false,,,http://purl.obolibrary.org/obo/TXPO_0000382,,,,,,,,,,,,,,,,,,,,,,Abnormal protein production is a subtype of protein production: A process that makes existent of an abnormal protein due to biosynthesis or secretion resulting in an increase in its levels.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002183,,,,,,,,,,,,,,,,,,,,,,abnormal protein production,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002182,pancreatic beta cell damage,,Pancreatic beta cell damage is a subtype of cellular damage: A process that injuries the structure of the pancreatic beta cell as the direct or indirect result of an external force.,false,,,http://purl.obolibrary.org/obo/TXPO_0000225,,,,,,,,,,,,,,,,,,,,,,Pancreatic beta cell damage is a subtype of cellular damage: A process that injuries the structure of the pancreatic beta cell as the direct or indirect result of an external force.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002182,,,,,,,,,,,,,,,,,,,,,,pancreatic beta cell damage,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002184,protein glycosylation inhibitor role,,"A role played by the entity which inhibits or decreases the frequency, rate or extent of the glycosylation of one or more amino acid residues within a protein.|related process: GO:0060051",false,,,http://purl.obolibrary.org/obo/TXPO_0003230,,,,,,,,,,,,,,,,,,,,,,"A role played by the entity which inhibits or decreases the frequency, rate or extent of the glycosylation of one or more amino acid residues within a protein.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002184,,,,,,,,,,,,,,,,,,,,related process: GO:0060051,,protein glycosylation inhibitor role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002181,GSTT1 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0002089,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:2952,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002181,,,,,,,,,,,,,,,,,,,,,,GSTT1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002188,hypofunction of carbohydrate metabolism [ER stress],,"Hypofunction of carbohydrate metabolism is a subtype of hypofunction of metabolism: A process that performs a decreased or insufficient carbohydrate metabolism.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/TXPO_0001326,,,,,,,,,,,,,,,,,,,,,,"Hypofunction of carbohydrate metabolism is a subtype of hypofunction of metabolism: A process that performs a decreased or insufficient carbohydrate metabolism.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002201,,,,,,,,,,,TXPO:0002188,,,,,,,,,,,,,,,,,,,,,,hypofunction of carbohydrate metabolism [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002186,GSTT2B (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0002089,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:653689,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002186,,,,,,,,,,,,,,,,,,,,,,GSTT2B (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002187,accumulation of abnormal proteins in ER,,Accumulation of abnormal proteins in ER is a subtype of accumulation of abnormal proteins: A process that keeps abnormal protein(s) in the ER (endoplasmic reticulum).,false,,,http://purl.obolibrary.org/obo/TXPO_0000251,,,,,,,,,,,,,,,,,,,,,,Accumulation of abnormal proteins in ER is a subtype of accumulation of abnormal proteins: A process that keeps abnormal protein(s) in the ER (endoplasmic reticulum).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002187,,,,,,,,,,,,,,,,,,,,,,accumulation of abnormal proteins in ER,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002180,GSTP1 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0002089,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:14870|NCBI-Rat-GeneID:24426|NCBI-Human-GeneID:2950,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002180,,,,,,,,,,,,,,,,,,,,,,GSTP1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002189,insulin resistance (process),decreasing isulin sensitivity,Insulin resistance (process) is a subtype of decreasing sensitivity: A process that changes the sensitivity to the circulating insulin to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000157,,,,,,,,,,,,,,,,,,,,"see quality :
http://purl.obolibrary.org/obo/HP_0000855",,Insulin resistance (process) is a subtype of decreasing sensitivity: A process that changes the sensitivity to the circulating insulin to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,decreasing isulin sensitivity,,,,,TXPO:0002189,,,,,,,,,,,,,,,,,,,,,,insulin resistance (process),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002185,GSTT2 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0002089,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:14872|NCBI-Human-GeneID:2953|NCBI-Rat-GeneID:29487,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002185,,,,,,,,,,,,,,,,,,,,,,GSTT2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100100,luteinizing hormone,lutropin|LH,"A major gonadotropin secreted by the adenohypophysis ( PITUITARY GLAND, ANTERIOR). Follicle-stimulating hormone stimulates GAMETOGENESIS and the supporting cells such as the ovarian GRANULOSA CELLS, the testicular SERTOLI CELLS, and LEYDIG CELLS. FSH consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the three pituitary glycoprotein hormones (TSH, LH, and FSH), but the beta subunit is unique and confers its biological specificity.",false,,,http://purl.obolibrary.org/obo/IMR_0100098,,,,,,,,,,,,,,,,,,,,MeSH:D005640,,"A major gonadotropin secreted by the adenohypophysis ( PITUITARY GLAND, ANTERIOR). Follicle-stimulating hormone stimulates GAMETOGENESIS and the supporting cells such as the ovarian GRANULOSA CELLS, the testicular SERTOLI CELLS, and LEYDIG CELLS. FSH consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the three pituitary glycoprotein hormones (TSH, LH, and FSH), but the beta subunit is unique and confers its biological specificity.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,lutropin|LH,,,,,IMR:0100100,,,,,,,,,,,,,,,,,,,,,,luteinizing hormone,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000903,eIF2B,eukaryotic initiation factor 2B,"heteropentamer of alpha, beta, gamma, delta, epsilon subunits. guanine nucleotide exchange factor (GEF) activity of eIF2B is necessary to recycle eIF2:GTP to eIF2:GTP.",false,,,http://purl.obolibrary.org/obo/IMR_0010016,,,,,,,,,,,,,,,,,,,,,,"heteropentamer of alpha, beta, gamma, delta, epsilon subunits. guanine nucleotide exchange factor (GEF) activity of eIF2B is necessary to recycle eIF2:GTP to eIF2:GTP.",,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000433,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,eukaryotic initiation factor 2B,,,,,IMR:0000903,,,,,,,,,,,,,,,,,,,,,,eIF2B,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0051055,negative regulation of lipid biosynthetic process,downregulation of lipid biosynthetic process|down-regulation of lipid biosynthetic process|negative regulation of lipid anabolism|negative regulation of lipid biosynthesis|negative regulation of lipid formation|down regulation of lipid biosynthetic process,"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of lipids.",false,,,http://purl.obolibrary.org/obo/TXPO_0000369,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of lipids.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,downregulation of lipid biosynthetic process|down-regulation of lipid biosynthetic process|negative regulation of lipid anabolism|negative regulation of lipid biosynthesis|negative regulation of lipid formation|down regulation of lipid biosynthetic process,,,,,GO:0051055,,,,,,,,,,,,,,,,,,,,,,negative regulation of lipid biosynthetic process,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0008610,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_38234,DNA polymerase inhibitor,,Any inhibitor of a DNA polymerase.,false,,,http://purl.obolibrary.org/obo/CHEBI_76815,,,,,,,,,,,,,,,,,,,,,,Any inhibitor of a DNA polymerase.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:38234,,,,DNA polymerase inhibitor,,CHEBI:38234,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100328,NAIP,neuronal apoptosis inhibitory protein,,false,,,http://purl.obolibrary.org/obo/IMR_0000454,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,neuronal apoptosis inhibitory protein,,,,,IMR:0100328,,,,,,,,,,,,,,,,,,,,,,NAIP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100557,FGF-7,HBGF-7|KGF|Fibroblast growth factor-7,,false,,,http://purl.obolibrary.org/obo/IMR_0000049,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,HBGF-7|KGF|Fibroblast growth factor-7,,,,,IMR:0100557,,,,,,,,,,,,,,,,,,,,,,FGF-7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_1902957,"negative regulation of mitochondrial electron transport, NADH to ubiquinone",,"Any process that stops, prevents or reduces the frequency, rate or extent of mitochondrial electron transport, NADH to ubiquinone.",false,,,http://purl.obolibrary.org/obo/TXPO_0002342,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents or reduces the frequency, rate or extent of mitochondrial electron transport, NADH to ubiquinone.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:1902957,,,,,,,,,,,,,,,,,,,,,,"negative regulation of mitochondrial electron transport, NADH to ubiquinone",,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006120,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000742,PERK autophosphorylation,,"PERK autophosphorylation is a subtype of protein autophosphorylation: The phosphorylation by PERK of one or more of its own amino acid residues (cis-autophosphorylation), or residues on PERK (trans-autophosphorylation).",false,,,http://purl.obolibrary.org/obo/GO_0046777,,,,,,,,,,,,,,,,,,,,,,"PERK autophosphorylation is a subtype of protein autophosphorylation: The phosphorylation by PERK of one or more of its own amino acid residues (cis-autophosphorylation), or residues on PERK (trans-autophosphorylation).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000742,,,,,,,,,,,,,,,,,,,,,,PERK autophosphorylation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000743,SLCO1B3 (canonical)[Cholestasis],OATP1B3,,false,,,http://purl.obolibrary.org/obo/TXPO_0000272,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C107150,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,OATP1B3,,,,,TXPO:0000743,,,,,,,"The sodium-independent portion of bile salt uptake is mediated by OATPs (organic anion transporting polypeptides). OATP1B1 (SLCO1B1), OATP1B3 (SLCO1B3), and OATP2B1 (SLCO2B1) are expressed at the basolateral plasma membrane of hepatocytes, although OATP2B1 appears not to be a bile Salt transporter.",,,,,,,,,,,,,,,SLCO1B3 (canonical)[Cholestasis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000740,Lgpat,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002306,,,,,,,,,,TXPO:0000740,,,,,,,,,,,,,,,,,,,,,,Lgpat,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000745,increasing number of stress responses [ER stress],,"Increasing number of stress responses is a subtype of increasing number of actions: A process that becomes larger in the number of stress responses.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000216|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"Increasing number of stress responses is a subtype of increasing number of actions: A process that becomes larger in the number of stress responses.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000752,,,,,,,,,,,TXPO:0000745,,,,,,,,,,,,,,,,,,,,,,increasing number of stress responses [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000744,Removing dead cell by Kupffer cell or macrophage,,Removing phospholipid by Kupffer cell or macrophage is a subtype of removing: A process that takes dead cells from a cell by  Kupffer cells or macrophages .,false,,,http://purl.obolibrary.org/obo/TXPO_0000458,,,,,,,,,,,,,,,,,,,,,,Removing phospholipid by Kupffer cell or macrophage is a subtype of removing: A process that takes dead cells from a cell by  Kupffer cells or macrophages .,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000744,,,,,,,,,,,,,,,,,,,,,,Removing dead cell by Kupffer cell or macrophage,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000747,increasing demand for protein quality control,,Increasing demand for protein quality control is a subtype of increasing functional demand: A process that changes the functional demand for the protein quality control to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000633,,,,,,,,,,,,,,,,,,,,,,Increasing demand for protein quality control is a subtype of increasing functional demand: A process that changes the functional demand for the protein quality control to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000747,,,,,,,,,,,,,,,,,,,,,,increasing demand for protein quality control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000741,supplying (from stored substance(s)),,Supplying from stored substance(s) is a subtype of making existence: A process that supplies (the stored) objects to the output.|A process of  supplying the operand from the stored substances,false,,,http://purl.obolibrary.org/obo/TXPO_0000380,,,,,,,,,,,,,,,,,,,,,,Supplying from stored substance(s) is a subtype of making existence: A process that supplies (the stored) objects to the output.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000741,,,,,,,,,,,,,,,,,,,,A process of  supplying the operand from the stored substances,,supplying (from stored substance(s)),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000746,moving drug to hepatocyte [Eosinophilic granular degeneration],,"Moving drug to the inside of liver is a subtype of moving A to the inside of B: A process that of the movement of drug into hepatocytes.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",false,,,http://purl.obolibrary.org/obo/TXPO_0001729|http://purl.obolibrary.org/obo/TXPO_0001684,,,,,,,,,,,,,,,,,,,,,,"Moving drug to the inside of liver is a subtype of moving A to the inside of B: A process that of the movement of drug into hepatocytes.
This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000122|http://purl.obolibrary.org/obo/TXPO_0000121,,,,,,http://purl.obolibrary.org/obo/TXPO_0001005,,,,,,,,,,,TXPO:0000746,,,,,,,,,,,,,,,,,,,,,,moving drug to hepatocyte [Eosinophilic granular degeneration],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000748,increasing demand for protein quality control [ER stress],,"Increasing demand for protein quality control is a subtype of increasing functional demand: A process that changes the functional demand for the protein quality control to be higher.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/TXPO_0000747,,,,,,,,,,,,,,,,,,,,,,"Increasing demand for protein quality control is a subtype of increasing functional demand: A process that changes the functional demand for the protein quality control to be higher.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000748,,,,,,,,,,,,,,,,,,,,,,increasing demand for protein quality control [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000749,cholestasis dependent chemical compound,,"Cholestasis dependent chemical compound is a subtype of toxic course dependent chemical entity.
This entity (drug) can participate in the course of cholestasis.|under construction",false,,,http://purl.obolibrary.org/obo/TXPO_0000273,,,,,,,,,,,,,,,,,,,,,,"Cholestasis dependent chemical compound is a subtype of toxic course dependent chemical entity.
This entity (drug) can participate in the course of cholestasis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000749,,,,,,,,,,,,,,,,,,,,under construction,,cholestasis dependent chemical compound,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0000587,decreased size,small|tiny|reduced|hyposia,A size quality which is relatively low.,false,,,http://purl.obolibrary.org/obo/PATO_0000117,,,,,,,,,,,,,,,,,,,,,,A size quality which is relatively low.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,small|tiny|reduced|hyposia,,,PATO:0000587,,,,,,,,,,,,,,,,,,,,,,decreased size,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0000584,hypertrophic,hypertrophy,"An increased size quality inhering in a bearer by virtue of the bearer's exhibiting enlargement of a cell or constituent group of cells (for example, organ).",false,,,http://purl.obolibrary.org/obo/PATO_0000595,,,,,,,,,,,,,,,,,,,,http://purl.bioontology.org/ontology/SNOMEDCT/56246009|MeSH:D006984,,"An increased size quality inhering in a bearer by virtue of the bearer's exhibiting enlargement of a cell or constituent group of cells (for example, organ).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,hypertrophy,,,,PATO:0000584,,,,,,,,,,,,,,,,,,,,,,hypertrophic,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0000586,increased size,big|great|enlarged|expanded|large,A size quality which is relatively high.,false,,,http://purl.obolibrary.org/obo/TXPO_0003683|http://purl.obolibrary.org/obo/PATO_0000117,,,,,,,,,,,,,,,,,,,,,,A size quality which is relatively high.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,big|great|enlarged|expanded|large,,,PATO:0000586,,,,,,,,,,,,,,,,,,,,,,increased size,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000417,BCL-6,,"BCL-6 belongs to a subset of transcription factors which all have a similar structure composed of an amino-terminal 'POZ' domain and several zinc finger modules at the carboxy-terminus. BCL-6 is highly conserved among vertebrate species. BCL-6 homologues have been identified from human, mouse, frog, and chicken species.",false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,"BCL-6 belongs to a subset of transcription factors which all have a similar structure composed of an amino-terminal 'POZ' domain and several zinc finger modules at the carboxy-terminus. BCL-6 is highly conserved among vertebrate species. BCL-6 homologues have been identified from human, mouse, frog, and chicken species.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,,,,,,IMR:0000417,,,,,,,,,,,,,,,,,,,,,,BCL-6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_38940,sunitinib,"sunitinibum|Sutent|sunitinib|SU-11248|Sunitinib|N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide",,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:17962201|PMID:24403097|Drug_Central:2544|PMID:16845442|CAS:557795-19-4|PMID:24521256|PMID:19830602|DrugBank:DB01268|PMID:24402960|PMID:12531805|PMID:21792888|PMID:16916320|PMID:20406969|PMID:18971320|PMID:24188025|PMID:17327610|PMID:24393200,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35610|http://purl.obolibrary.org/obo/CHEBI_50846|http://purl.obolibrary.org/obo/CHEBI_65207|http://purl.obolibrary.org/obo/CHEBI_62434|http://purl.obolibrary.org/obo/CHEBI_63726|http://purl.obolibrary.org/obo/CHEBI_48422,,,,,"Sunitinib|N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide",,sunitinibum|Sutent|sunitinib|SU-11248,,,,,,,,,,,,,,,,,,,,,CHEBI:38940,,,,sunitinib,,CHEBI:38940,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001634,Rab40A,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001634,,,,,,,,,,,,,,,,,,,,,,Rab40A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0002410,UBE2N,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000018,,,,,,,,,,IMR:0002410,,,,,,,,,,,,,,,,,,,,,,UBE2N,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001663,RGS5,,,false,,,http://purl.obolibrary.org/obo/IMR_0000431,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001663,,,,,,,,,,,,,,,,,,,,,,RGS5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000341,Grap,Grb2-related adaptor protein,,false,,,http://purl.obolibrary.org/obo/IMR_0000339,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Grb2-related adaptor protein,,,,,IMR:0000341,,,,,,,,,,,,,,,,,,,,,,Grap,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000009420,CYP7B1,,"Other designations: 25-hydroxycholesterol 7-alpha-hydroxylase|cytochrome P450 7B1|cytochrome P450, subfamily VIIB (oxysterol 7 alpha-hydroxylase), polypeptide 1|oxysterol 7-alpha-hydroxylase|oxysterol 7alpha-hydroxylase",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CBAS3|CP7B|SPG5A,,,,,,,,,,,,8,,,,,,Ensembl:ENSG00000172817|HPRD:04753|Vega:OTTHUMG00000164387|HGNC:2652|MIM:603711,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 7, subfamily B, polypeptide 1",,,8q21.3,,,,,,,,,,,,,,,,GO_0005506 (EC: IEA); GO_0005789 (EC: TAS); GO_0006699 (EC: IEA); GO_0006699 (EC: TAS); GO_0006805 (EC: TAS); GO_0008203 (EC: IEA); GO_0008206 (EC: TAS); GO_0008219 (EC: IEA); GO_0008396 (EC: IEA); GO_0016125 (EC: TAS); GO_0020037 (EC: IEA); GO_0033147 (EC: IEA); GO_0033783 (EC: IEA); GO_0044281 (EC: TAS); GO_0050679 (EC: IEA); GO_0060740 (EC: IEA),,,,,,,,,PMID:7987300; 9559267; 9802883; 10588945; 12477932; 12721789; 14521990; 15003524; 15007371; 15128046; 15181079; 15698543; 15751070; 16630558; 17467270; 17680536; 18055760; 18252231; 18331353; 18676680; 18790053; 18855023; 19170196; 19187859; 19343046; 19363635; 19439420; 19625176; 19687010; 19692168; 19732851; 19913121; 20628086; 21214876; 21452256; 21541746; 21567895; 21890473; 22174851; 23180418; 23393555; 23400010,,,,,,,,,,,,,,,OGG:3000009420,,,,,,,"cytochrome P450, family 7, subfamily B, polypeptide 1",,,,,,,,,,,,,"Other designations: 25-hydroxycholesterol 7-alpha-hydroxylase|cytochrome P450 7B1|cytochrome P450, subfamily VIIB (oxysterol 7 alpha-hydroxylase), polypeptide 1|oxysterol 7-alpha-hydroxylase|oxysterol 7alpha-hydroxylase",,CYP7B1,,,,,,,,,,,,,,,,,,,,,,,9420,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP7B1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_38221,fumonisin B1,"(2R,2'R)-2,2'-{[(5R,6R,7S,9S,11R,16R,18S,19S)-19-amino-11,16,18-trihydroxy-5,9-dimethylicosane-6,7-diyl]bis[oxy(2-oxoethane-2,1-diyl)]}dibutanedioic acid","A diester that results from the condensation of the 1-carboxy groups of two molecules of propane-1,2,3-tricarboxylic acid with hydroxy groups at positions 14 and 15 of (2S,3S,5R,10R,12S,14S,15R,16R)-2-amino-12,16-dimethylicosane-3,5,10,14,15-pentol.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:116355-83-0,,"A diester that results from the condensation of the 1-carboxy groups of two molecules of propane-1,2,3-tricarboxylic acid with hydroxy groups at positions 14 and 15 of (2S,3S,5R,10R,12S,14S,15R,16R)-2-amino-12,16-dimethylicosane-3,5,10,14,15-pentol.",,,,,,,,,,,,C34H59NO15,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"(2R,2'R)-2,2'-{[(5R,6R,7S,9S,11R,16R,18S,19S)-19-amino-11,16,18-trihydroxy-5,9-dimethylicosane-6,7-diyl]bis[oxy(2-oxoethane-2,1-diyl)]}dibutanedioic acid",,,,,CHEBI:38221,,,,,,,,,,,,,,,,,,,,,,fumonisin B1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CCCC[C@H]([C@H]([C@H](C[C@H](C[C@@H](CCCC[C@H](C[C@@H]([C@H](C)N)O)O)O)C)OC(C[C@@H](CC(=O)O)C(=O)O)=O)OC(=O)C[C@@H](CC(O)=O)C(=O)O)C,,,,,
http://purl.obolibrary.org/obo/OGG_3000000229,ALDOB,,"Other designations: aldolase 2|aldolase B, fructose-bisphosphatase|fructose-bisphosphate aldolase B|liver-type aldolase",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,ALDO2|ALDB,,,,,,,,,,,,9,,,,,,HGNC:417|Ensembl:ENSG00000136872|Vega:OTTHUMG00000020378|MIM:612724|HPRD:01972,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"aldolase B, fructose-bisphosphate",,,9q21.3-q22.2,,,,,,,,,,,,,,,,"GO_0004332 (EC: EXP); GO_0004332 (EC: IDA, PMID: 10625657); GO_0005515 (EC: IPI, PMID: 18000879); GO_0005815 (EC: IDA, PMID: 18000879); GO_0005829 (EC: TAS); GO_0005975 (EC: TAS); GO_0006000 (EC: IMP, PMID: 3383242); GO_0006001 (EC: TAS); GO_0006006 (EC: TAS); GO_0006094 (EC: TAS); GO_0006096 (EC: IDA, PMID: 10625657); GO_0006096 (EC: IEA); GO_0006096 (EC: TAS); GO_0006116 (EC: IDA, PMID: 17576770); GO_0008092 (EC: IDA, PMID: 9244396); GO_0030388 (EC: IDA, PMID: 10625657); GO_0032781 (EC: IGI, PMID: 17576770); GO_0034451 (EC: IDA, PMID: 18000879); GO_0042802 (EC: IPI, PMID: 10625657); GO_0044281 (EC: TAS); GO_0051117 (EC: IDA, PMID: 17576770); GO_0070061 (EC: IMP, PMID: 10625657); GO_0070072 (EC: IGI, PMID: 17576770)",,,,,,,,,PMID: 1967768; 2336380; 2410860; 2649152; 2830249; 3000275; 3016456; 3383242; 6548561; 6585824; 6689266; 7717389; 8162030; 8299883; 8535439; 9244396; 10024431; 10625657; 10970798; 11241348; 11399750; 11679716; 11752456; 12205126; 12417303; 12464284; 12477932; 14966907; 15063762; 15532022; 15880727; 16406649; 17292585; 17457694; 17576770; 17955389; 18000879; 18029348; 18541450; 18700007; 19817957; 20033295; 20162364; 20848650; 20882353; 21166391; 21832049; 21890473; 21963094; 21987572; 21988832; 22001757; 22505724; 22911800,,,,,,,,,,,,,,,OGG:3000000229,,20140408,protein-coding,,,,"aldolase B, fructose-bisphosphate",,,,,,,,,,,,,"Other designations: aldolase 2|aldolase B, fructose-bisphosphatase|fructose-bisphosphate aldolase B|liver-type aldolase",,ALDOB,,,,,,,,,,,,,,,,,,,,,,,229,RP11-490D19.1,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,ALDOB,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000010243,GPHN,,,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,GPH|GEPH|GPHRYN|MOCODC|HKPX1,,,,,,,,,,,,14,,,,,,HPRD:04893|HGNC:15465|Ensembl:ENSG00000171723|Vega:OTTHUMG00000029785|MIM:603930,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,gephyrin,,,14q23.3,,,,,,,,,,,,,,,,GO_0005524 (EC: IEA); GO_0005737 (EC: IEA); GO_0005856 (EC: IEA); GO_0005886 (EC: TAS); GO_0006766 (EC: TAS); GO_0006767 (EC: TAS); GO_0006777 (EC: IEA); GO_0007529 (EC: IEA); GO_0016740 (EC: TAS); GO_0030054 (EC: IEA); GO_0032324 (EC: TAS); GO_0044281 (EC: TAS); GO_0045211 (EC: IEA); GO_0046872 (EC: IEA); GO_0061598 (EC: IEA); GO_0061599 (EC: IEA),,,,,,,,,PMID: 1319186; 1657993; 7546736; 9473484; 9990024; 10037506; 10325225; 10607391; 10718198; 10839351; 10900017; 10947798; 11095995; 11418245; 11554796; 11727829; 12097491; 12477932; 12535948; 12684523; 12754701; 12967995; 14622920; 14751928; 14760703; 15489334; 16964243; 17293395; 17347650; 18315564; 18334916; 18403029; 19615732; 19874574; 19913121; 20206270; 20301437; 20360068; 20379614; 20468064; 20622020; 20628086; 21071388; 21094642; 21139048; 21404332; 21726808; 21829170; 21988832; 22270318; 22778260; 22863883; 23077067; 23290196; 23393157; 23408424; 24128675; 24297911,,,,,,,,,,,,,,,OGG:3000010243,,20140408,protein-coding,,,,gephyrin,,,,,,,,,,,,,,,GPHN,,,,,,,,,,,,,,,,,,,,,,,10243,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,GPHN,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000191,myosin,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000188|http://purl.obolibrary.org/obo/TXPO_0003690,,,,,,,,,,IMR:0000191,,,,,,,,,,,,,,,,,,,,,,myosin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002494,NF-kappaB transport into nucleus,,NF-kappaB transport into nucleus is a subtype of nuclear transport: A process that of the directed movement of NF-kappaB from the cytoplasm to the nucleus.,false,,,http://purl.obolibrary.org/obo/GO_0051169,,,,,,,,,,,,,,,,,,,,,,NF-kappaB transport into nucleus is a subtype of nuclear transport: A process that of the directed movement of NF-kappaB from the cytoplasm to the nucleus.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005634,,,,,,,,TXPO:0002494,,,,,,,,,,,,,,,,,,,,,,NF-kappaB transport into nucleus,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002491,glutathione export from hepatocyte [Glutathione depletion],,"glutathione export from hepatocyte is a subtype of glutathione transport: A process that exports the glutathione from the hepatocyte.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0002488|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,ISBN:0071769234|PMID:18786560,,"glutathione export from hepatocyte is a subtype of glutathione transport: A process that exports the glutathione from the hepatocyte.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002512|http://purl.obolibrary.org/obo/TXPO_0002787|http://purl.obolibrary.org/obo/TXPO_0002493,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002491,,,,,,,,,,,,,,,,,,,,,,glutathione export from hepatocyte [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002496,ABCC2 (mol),"ATP Binding Cassette Subfamily C Member 2|Multidrug Resistance-Associated Protein 2|ATP-Binding Cassette, Sub-Family C (CFTR/MRP), Member 2|MRP2|Canalicular Multispecific Organic Anion Transporter 1",,false,,,http://purl.obolibrary.org/obo/TXPO_0002694,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1244|NCBI-Rat-GeneID:25303|NCBI-Mouse-GeneID:12780,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"ATP Binding Cassette Subfamily C Member 2|Multidrug Resistance-Associated Protein 2|ATP-Binding Cassette, Sub-Family C (CFTR/MRP), Member 2|MRP2|Canalicular Multispecific Organic Anion Transporter 1",,,,,TXPO:0002496,,,,,,,,,,,,,,,,,,,,,,ABCC2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002498,IGFBP1 gene expression by ATF4 [ER stress],,"IGFBP1 gene expression by ATF4 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature IGFBP1 product or products (proteins or RNA) by ATF4.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002967,,,,,,,,,,,,,,,,,,,,,,"IGFBP1 gene expression by ATF4 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature IGFBP1 product or products (proteins or RNA) by ATF4.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002560,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002547,,,,,,,,,,,TXPO:0002498,,,,,,,,,,,,,,,,,,,,,,IGFBP1 gene expression by ATF4 [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002495,I-kappaB phosphorylation,,"The process of introducing a phosphate group into an inhibitor of kappa B (I-kappaB) protein. Phosphorylation of I-kappaB targets I-kappaB for ubiquitination and proteasomal degradation, thus releasing bound NF-kappaB dimers, which can translocate to the nucleus to bind DNA and regulate transcription. PMID:21772278",false,,,http://purl.obolibrary.org/obo/GO_0016310,,,,,,,,,,,,,,,,,,,,GO:0007252,,"The process of introducing a phosphate group into an inhibitor of kappa B (I-kappaB) protein. Phosphorylation of I-kappaB targets I-kappaB for ubiquitination and proteasomal degradation, thus releasing bound NF-kappaB dimers, which can translocate to the nucleus to bind DNA and regulate transcription. PMID:21772278",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002495,,,,,,,,,,,,,,,,,,,,,,I-kappaB phosphorylation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002499,abnormal protein production [ER stress],,"Abnormal protein production is a subtype of protein production: A process that makes existent of an abnormal protein due to biosynthesis or secretion resulting in an increase in its levels.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001717|http://purl.obolibrary.org/obo/TXPO_0002183,,,,,,,,,,,,,,,,,,,,,,"Abnormal protein production is a subtype of protein production: A process that makes existent of an abnormal protein due to biosynthesis or secretion resulting in an increase in its levels.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002499,,,,,,,,,,,,,,,,,,,,,,abnormal protein production [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002497,ERO1 (canonical)[ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000871|http://purl.obolibrary.org/obo/TXPO_1000135,,,,,,,,,,,,,,,,,,,,https://doi.org/10.1271/kagakutoseibutsu.50.484,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002497,,,,,,,,,,,,,,,,,,,,,,ERO1 (canonical)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002493,MRP2 (canonical)[Glutathione depletion],ABCC2 [Glutathione depletion],,false,,,http://purl.obolibrary.org/obo/TXPO_0002045|http://purl.obolibrary.org/obo/TXPO_0002496,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ABCC2 [Glutathione depletion],,,,,TXPO:0002493,,,,,,,,,,,,,,,,,,,,,,MRP2 (canonical)[Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002492,dissociation of NF-kappaB-I-kappaB,,"Dissociation of NF-kappaB -I-kappaB is a subtype of detaching: A process that disaggregates a NF-kappaB-I-kappaB to NF-kappaB dimers and I-kappaB. In a resting state, NF-kappaB dimers are bound to I-kappaB proteins, sequestering NF-kappaB in the cytoplasm. Phosphorylation of I-kappaB targets I-kappaB for ubiquitination and proteasomal degradation, thus releasing the NF-kappaB dimers, which can translocate to the nucleus to bind DNA and regulate transcription.",false,,,http://purl.obolibrary.org/obo/TXPO_0000462,,,,,,,,,,,,,,,,,,,,"GO:0008588|The release of NF-kappaB from specific molecules in the cytoplasm to which it was bound, thereby allowing its translocation into the nucleus.",,"Dissociation of NF-kappaB -I-kappaB is a subtype of detaching: A process that disaggregates a NF-kappaB-I-kappaB to NF-kappaB dimers and I-kappaB. In a resting state, NF-kappaB dimers are bound to I-kappaB proteins, sequestering NF-kappaB in the cytoplasm. Phosphorylation of I-kappaB targets I-kappaB for ubiquitination and proteasomal degradation, thus releasing the NF-kappaB dimers, which can translocate to the nucleus to bind DNA and regulate transcription.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002492,,,,,,,,,,,,,,,,,,,,,,dissociation of NF-kappaB-I-kappaB,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002490,NRF2 signaling pathway,nuclear factor erythroid 2 like 2 signaling pathway,"NRF2 signaling (integrated pathway) is a subtype of integrated signaling pathway: Sequence of linked reactions, which has NRF2 signaling and gene regulation pathway.",false,,,http://purl.obolibrary.org/obo/TXPO_0000027,,,,,,,,,,,,,,,,,,,,,,"NRF2 signaling (integrated pathway) is a subtype of integrated signaling pathway: Sequence of linked reactions, which has NRF2 signaling and gene regulation pathway.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002763,,,,,,,,,,,,,nuclear factor erythroid 2 like 2 signaling pathway,,,,,TXPO:0002490,,,,,,,,,,,,,,,,,,,,,,NRF2 signaling pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100484,PKC theta,protein kinase C theta,,false,,,http://purl.obolibrary.org/obo/IMR_0000246,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,protein kinase C theta,,,,,IMR:0100484,,,,,,,,,,,,,,,,,,,,,,PKC theta,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_39000,sodium channel modulator,sodium channel modulators,,false,,,http://purl.obolibrary.org/obo/CHEBI_38632,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sodium channel modulators,,,,,,,,,,,,,,,,,,,,,CHEBI:39000,,,,sodium channel modulator,,CHEBI:39000,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000193,troponin,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000188,,,,,,,,,,IMR:0000193,,,,,,,,,,,,,,,,,,,,,,troponin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_23995,N-ethyl-N-nitrosourea,1-ethyl-1-nitrosourea,A member of the class of N-nitrosoureas that is urea in which one of the nitrogens is substituted by ethyl and nitroso groups.,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:759-73-9|Wikipedia:ENU,,A member of the class of N-nitrosoureas that is urea in which one of the nitrogens is substituted by ethyl and nitroso groups.,,,,,,,,,,,,C3H7N3O2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1-ethyl-1-nitrosourea,,,,,CHEBI:23995,,,,,,,,,,,,,,,,,,,,,,N-ethyl-N-nitrosourea,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CCN(N=O)C(N)=O,,,,,
http://purl.obolibrary.org/obo/CHEBI_30725,"aflatoxin B1 exo-8,9-epoxide","6aS,7aS,8aR,8bR)-4-methoxy-2,3,6a,7a,8a,8b-hexahydrocyclopenta[c]oxireno[4',5']furo[3',2':4,5]furo[2,3-h]chromene-1,10-dione",,false,,,http://purl.obolibrary.org/obo/CHEBI_22271,,,,,,,,,,,,,,,,,,,,CAS:42583-46-0,,,,,,,,,,,,,,C17H12O7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"6aS,7aS,8aR,8bR)-4-methoxy-2,3,6a,7a,8a,8b-hexahydrocyclopenta[c]oxireno[4',5']furo[3',2':4,5]furo[2,3-h]chromene-1,10-dione",,,,,CHEBI:30725,,,,,,,,,,,,,,,,,,,,,,"aflatoxin B1 exo-8,9-epoxide",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,[H][C@@]12Oc3cc(OC)c4c5CCC(=O)c5c(=O)oc4c3[C@]1([H])[C@@]1([H])O[C@@]1([H])O2,,,,,
http://purl.obolibrary.org/obo/IMR_0000211,Src family,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,MeSH:D019061,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001054,,,,,,,,,,IMR:0000211,,,,,,,,,,,,,,,,,,,,,,Src family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_7953,pemoline,"Myamin|Dantromin|Hyton|2-Amino-5-phenyl-4(5H)-oxazolone|Betanamin|pemolinum|Nitan|phenylpseudohydantoin|5-phenyl-2-imino-4-oxooxazolidine|5-phenylisohydantion|Deltamine|pheniminooxazolidinone|5-phenyl-2-imino-4-oxazolidinone|2-imino-4-keto-5-phenyltetrahydrooxazole|2-imino-5-phenyl-4-oxazolidinone|Cylert|pemoline|Azoxodon|Notair|phenylisohydantoin|pemolina|2-amino-5-phenyl-1,3-oxazol-4(5H)-one","A member of the class of 1,3-oxazoles that is 1,3-oxazol-4(5H)-one which is substituted by an amino group at position 2 and by a phenyl group at position 5. A central nervous system stimulant, it was used to treat hyperactivity disorders in children, but withdrawn from use following reports of serious hepatotoxicity.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:641739|LINCS:LSM-5159|Drug_Central:2075|PMID:772696|PMID:2210262|PMID:4021028|PMID:11216184|PMID:2388127|PMID:2303976|CAS:2152-34-3|DrugBank:DB01230|Reaxys:151559,,"A member of the class of 1,3-oxazoles that is 1,3-oxazol-4(5H)-one which is substituted by an amino group at position 2 and by a phenyl group at position 5. A central nervous system stimulant, it was used to treat hyperactivity disorders in children, but withdrawn from use following reports of serious hepatotoxicity.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35337,,,,,"2-amino-5-phenyl-1,3-oxazol-4(5H)-one",,Myamin|Dantromin|Hyton|2-Amino-5-phenyl-4(5H)-oxazolone|Betanamin|pemolinum|Nitan|phenylpseudohydantoin|5-phenyl-2-imino-4-oxooxazolidine|5-phenylisohydantion|Deltamine|pheniminooxazolidinone|5-phenyl-2-imino-4-oxazolidinone|2-imino-4-keto-5-phenyltetrahydrooxazole|2-imino-5-phenyl-4-oxazolidinone|Cylert|pemoline|Azoxodon|Notair|phenylisohydantoin|pemolina,,,,,,,,,,,,,,,,,,,,,CHEBI:7953,,,,pemoline,,CHEBI:7953,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0002204,musculoskeletal system,musculo-skeletal system,Anatomical system that consists of the muscular and skeletal systems.,false,,,http://purl.obolibrary.org/obo/UBERON_0000467,,,,,,,,,,,,,,,,,,,,http://en.wikipedia.org/wiki/Musculoskeletal_system|http://www.snomedbrowser.com/Codes/Details/278858007|http://purl.obolibrary.org/obo/NCIT_C12754|http://linkedlifedata.com/resource/umls/id/C0026860|XAO:0000168|EMAPA:32714|VSAO:0000031|GAID:98|AAO:0010546|MA:0002418|UMLS:C0026860|VHOG:0001275|FMA:7482|MESH:D009141|CALOHA:TS-1311|EV:0100139|OpenCyc:Mx4rQRpVNgAKEdyHxgDggVfs8g,,Anatomical system that consists of the muscular and skeletal systems.,,,,,,,,Anatomical system that provides locomotion and physical support to the organism.[AAO],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0001434,,,,,,,,,,,,,musculo-skeletal system,,,"There are more than 50,000 extant vertebrate species, representing over 500 million years of evolution. During that time, the vertebrate musculoskeletal systems have adapted to aquatic, terrestrial, fossorial, and arboreal lifestyles, while simultaneously retaining functionally integrated axial and appendicular skeletal systems.[well established][VHOG]",,UBERON:0002204,,,,https://github.com/cmungall,,,,,,,,,,,,,,,,,,musculoskeletal system,,,,,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010499,60S ribosomal protein L7,P18124,,false,,,http://purl.obolibrary.org/obo/IMR_0000897,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,P18124,,,,,IMR:0010499,,,,,,,,,,,,,,,,,,,,,,60S ribosomal protein L7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000372,Co-Smad,common Smad|common-mediator Smad|common-partner Smad|co-mediator Smad|Smad4,"Co-Smad forms hetero-oligomers with R-Smads, which in turn translocate into the nucleus and regulate transcriptional responses.
Only Smad4 has been identified as a common-mediator Smad in vertebrates. A Smad4 homologue has been identified in Drosophila (Medea) and C. elegans (Sma-4).",false,,,http://purl.obolibrary.org/obo/IMR_0000370,,,,,,,,,,,,,,,,,,,,,,"Co-Smad forms hetero-oligomers with R-Smads, which in turn translocate into the nucleus and regulate transcriptional responses.
Only Smad4 has been identified as a common-mediator Smad in vertebrates. A Smad4 homologue has been identified in Drosophila (Medea) and C. elegans (Sma-4).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,common Smad|common-mediator Smad|common-partner Smad|co-mediator Smad|Smad4,,,,,IMR:0000372,,,,,,,,,,,,,,,,,,,,,,Co-Smad,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001458,TLR7,Toll-like receptor 7,,false,,,http://purl.obolibrary.org/obo/IMR_0000124,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Toll-like receptor 7,,,,,IMR:0001458,,,,,,,,,,,,,,,,,,,,,,TLR7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0034553,mitochondrial respiratory chain complex II assembly,,"The aggregation, arrangement and bonding together of a set of components to form respiratory chain complex II, in the mitochondrial inner membrane.",false,,,http://purl.obolibrary.org/obo/GO_0033108,,,,,,,,,,,,,,,,,,,,,,"The aggregation, arrangement and bonding together of a set of components to form respiratory chain complex II, in the mitochondrial inner membrane.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0034553,,,,,,,,,,,,,,,,,,,,,,mitochondrial respiratory chain complex II assembly,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0034551,mitochondrial respiratory chain complex III assembly,mitochondrial cytochrome bc(1) complex assembly,"The aggregation, arrangement and bonding together of a set of components to form the cytochrome bc(1) complex (also known as ubiquinol-cytochrome c reductase), in the mitochondrial inner membrane.",false,,,http://purl.obolibrary.org/obo/GO_0033108,,,,,,,,,,,,,,,,,,,,,,"The aggregation, arrangement and bonding together of a set of components to form the cytochrome bc(1) complex (also known as ubiquinol-cytochrome c reductase), in the mitochondrial inner membrane.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,mitochondrial cytochrome bc(1) complex assembly,,,,,GO:0034551,,,,,,,,,,,,,,,,,,,,,,mitochondrial respiratory chain complex III assembly,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002826,JNK activation [JNK pathway],,"JNK activation is a subtype of molecular activation: A process that changes the activity of the JNK to be higher.
This entity is a specific course-dependent process. This process can constitute the course of JNK pathway.",false,,,http://purl.obolibrary.org/obo/TXPO_0002828,,,,,,,,,,,,,,,,,,,,,,"JNK activation is a subtype of molecular activation: A process that changes the activity of the JNK to be higher.
This entity is a specific course-dependent process. This process can constitute the course of JNK pathway.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002826,,,,,,,,,,,,,,,,,,,,,,JNK activation [JNK pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002821,TRAF2 activation by IRE1 [ER stress - inflammation - IRE1-TRAF2-ASK-JNK pathway],,"TRAF2 activation by IRE1 is a subtype of molecular activation: A process that changes the activity of the TARF2 to be higher by IRE1.
This process is dependent on the  IRE1-TRAF2-ASK-JNK pathway mediated inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002820,,,,,,,,,,,,,,,,,,,,PMID:25232821,,"TRAF2 activation by IRE1 is a subtype of molecular activation: A process that changes the activity of the TARF2 to be higher by IRE1.
This process is dependent on the  IRE1-TRAF2-ASK-JNK pathway mediated inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002894,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002822,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002823,,,,,,,,,,,TXPO:0002821,,,,,,,,,,,,,,,,,,,,,,TRAF2 activation by IRE1 [ER stress - inflammation - IRE1-TRAF2-ASK-JNK pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002824,ASK activation [IRE-TRAF2-ASK-JNK pathway],,"ASK activation is a subtype of molecular activation: A process that changes the activity of one of the ASK (apoptosis signal-regulating kinase) family to be higher.
This entity is a specific course-dependent process. This process can constitute the course of IRE-TRAF2-ASK-JNK pathway.",false,,,http://purl.obolibrary.org/obo/TXPO_0002825,,,,,,,,,,,,,,,,,,,,,,"ASK activation is a subtype of molecular activation: A process that changes the activity of one of the ASK (apoptosis signal-regulating kinase) family to be higher.
This entity is a specific course-dependent process. This process can constitute the course of IRE-TRAF2-ASK-JNK pathway.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002826,,,,,,,,,,,TXPO:0002824,,,,,,,,,,,,,,,,,,,,,,ASK activation [IRE-TRAF2-ASK-JNK pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002825,ASK activation,,ASK activation is a subtype of molecular activation: A process that changes the activity of one of the ASK （apoptosis signal-regulating kinase) family to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000023,,,,,,,,,,,,,,,,,,,,,,ASK activation is a subtype of molecular activation: A process that changes the activity of one of the ASK （apoptosis signal-regulating kinase) family to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002825,,,,,,,,,,,,,,,,,,,,,,ASK activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002829,AP-1 activation by JNK [ER stress - inflammation - IRE1-TRAF2-ASK-JNK pathway],,"AP-1 activation is a subtype of AP-1 activation: A process that changes the activity of the AP-1 to be higher by JNK.
This process is dependent on the IRE1-TRAF2-ASK-JNK pathway mediated inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001321,,,,,,,,,,,,,,,,,,,,,,"AP-1 activation is a subtype of AP-1 activation: A process that changes the activity of the AP-1 to be higher by JNK.
This process is dependent on the IRE1-TRAF2-ASK-JNK pathway mediated inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002833,,,,,,,,,,,TXPO:0002829,,,,,,,,,,,,,,,,,,,,,,AP-1 activation by JNK [ER stress - inflammation - IRE1-TRAF2-ASK-JNK pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002820,TRAF2 activation by IRE1 [ER stress],,"TRAF2 activation by IRE1 is a subtype of molecular activation: A process that changes the activity of the TARF2 to be higher by IRE1.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002872,,,,,,,,,,,,,,,,,,,,PMID:25232821,,"TRAF2 activation by IRE1 is a subtype of molecular activation: A process that changes the activity of the TARF2 to be higher by IRE1.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002819,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002817,,,,,,,,,,,TXPO:0002820,,,,,,,,,,,,,,,,,,,,,,TRAF2 activation by IRE1 [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002828,JNK activation,,JNK activation is a subtype of molecular activation: A process that changes the activity of the JNK to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000023,,,,,,,,,,,,,,,,,,,,,,JNK activation is a subtype of molecular activation: A process that changes the activity of the JNK to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002828,,,,,,,,,,,,,,,,,,,,,,JNK activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002827,JNK activation [ER stress - inflammation - IRE1-TRAF2-ASK-JNK pathway],,"JNK activation is a subtype of molecular activation: A process that changes the activity of the JNK to be higher.
This process is dependent on the  IRE1-TRAF2-ASK-JNK pathway mediated inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0003736|http://purl.obolibrary.org/obo/TXPO_0002828,,,,,,,,,,,,,,,,,,,,PMID:25232821,,"JNK activation is a subtype of molecular activation: A process that changes the activity of the JNK to be higher.
This process is dependent on the  IRE1-TRAF2-ASK-JNK pathway mediated inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002829,,,,,,,,,,,TXPO:0002827,,,,,,,,,,,,,,,,,,,,,,JNK activation [ER stress - inflammation - IRE1-TRAF2-ASK-JNK pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002822,TRAF2 -IRE1 adaptor protein (canonical)[ER stress - inflammation -IRE1-JNK],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002818,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000462,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003657,,,,,,,,,,TXPO:0002822,,,,,,,,,,,,,,,,,,,,,,TRAF2 -IRE1 adaptor protein (canonical)[ER stress - inflammation -IRE1-JNK],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002823,ASK activation [ER stress - inflammation],,"ASK activation is a subtype of molecular activation: A process that changes the activity of one of the ASK (apoptosis signal-regulating kinase) family to be higher.
This process is dependent on the inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002824,,,,,,,,,,,,,,,,,,,,PMID:25232821|PMID:12843613,,"ASK activation is a subtype of molecular activation: A process that changes the activity of one of the ASK (apoptosis signal-regulating kinase) family to be higher.
This process is dependent on the inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002822,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002827,,,,,,,,,,,TXPO:0002823,,,,,,,,,,,,,,,,,,,,,,ASK activation [ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000000578,BAK1,,Other designations: BCL2-like 7 protein|apoptosis regulator BAK|bcl-2 homologous antagonist/killer|bcl-2-like protein 7|bcl2-L-7|pro-apoptotic protein BAK,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,BAK|BCL2L7|BAK-LIKE|CDN1,,,,,,,,,,,,6,,,,,,Vega:OTTHUMG00000014530|HPRD:02744|HGNC:949|MIM:600516|Ensembl:ENSG00000030110,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,BCL2-antagonist/killer 1,,,6p21.3,,,,,,,,,,,,,,,,"GO_0001782 (EC: IEA); GO_0001783 (EC: IEA); GO_0001836 (EC: IDA, PMID: 16199525); GO_0001836 (EC: IGI); GO_0001974 (EC: IEA); GO_0002262 (EC: IEA); GO_0002352 (EC: IEA); GO_0005515 (EC: IPI, PMID: 10381623); GO_0005739 (EC: IDA, PMID: 9843949); GO_0005741 (EC: IBA); GO_0005741 (EC: TAS); GO_0005783 (EC: IEA); GO_0005829 (EC: IEA); GO_0006915 (EC: TAS); GO_0007420 (EC: IEA); GO_0007568 (EC: IEA); GO_0008053 (EC: IEA); GO_0008283 (EC: IEA); GO_0008285 (EC: IEA); GO_0008630 (EC: IBA); GO_0008635 (EC: IEA); GO_0009620 (EC: IEA); GO_0010046 (EC: IEA); GO_0010225 (EC: IEA); GO_0010248 (EC: IDA, PMID: 9843949); GO_0010332 (EC: IEA); GO_0010524 (EC: IEA); GO_0010629 (EC: IEA); GO_0014070 (EC: IEA); GO_0031018 (EC: IEA); GO_0031072 (EC: IEA); GO_0031100 (EC: IEA); GO_0031307 (EC: ISS); GO_0032469 (EC: TAS, PMID: 18309324); GO_0032471 (EC: IEA); GO_0033137 (EC: IEA); GO_0034644 (EC: IMP, PMID: 15901672); GO_0034644 (EC: ISS); GO_0035108 (EC: IEA); GO_0042493 (EC: IEA); GO_0042542 (EC: IEA); GO_0042802 (EC: IPI, PMID: 15901672); GO_0042803 (EC: IBA); GO_0043065 (EC: IMP, PMID: 17289999); GO_0043496 (EC: IDA, PMID: 9111042); GO_0043497 (EC: IDA, PMID: 9111042); GO_0044346 (EC: IEA); GO_0045471 (EC: IEA); GO_0045862 (EC: IDA, PMID: 18387192); GO_0046872 (EC: IEA); GO_0046902 (EC: IDA); GO_0046930 (EC: IDA, PMID: 9843949); GO_0046982 (EC: IPI, PMID: 10837489); GO_0048597 (EC: IEA); GO_0051087 (EC: IEA); GO_0051400 (EC: IEA); GO_0051726 (EC: IEA); GO_0051881 (EC: IDA, PMID: 9843949); GO_0060068 (EC: IEA); GO_0070059 (EC: IEA); GO_0070242 (EC: IEA); GO_0071260 (EC: IEP, PMID: 19593445); GO_0090200 (EC: IEA); GO_0097190 (EC: IMP, PMID: 15901672); GO_0097192 (EC: IBA); GO_0097193 (EC: TAS); GO_0097202 (EC: IDA, PMID: 18387192); GO_1900103 (EC: IMP, PMID: 16645094); GO_1901030 (EC: TAS); GO_1902262 (EC: IEA)",,,,,,,,,PMID: 7715729; 7715730; 7715731; 8521816; 8887627; 9020082; 9111042; 9463381; 9573342; 9843949; 9878060; 10085290; 10365962; 10381623; 10381646; 10579309; 10639121; 10837489; 10950869; 11175750; 11206074; 11326099; 11571294; 11728179; 11795669; 11867266; 11908704; 11929871; 11932420; 11940658; 11964315; 12070120; 12137781; 12176904; 12297281; 12454021; 12477932; 12624108; 12624178; 12721291; 12808108; 12847083; 12881569; 14574404; 14596824; 14647456; 14702039; 14980220; 15003505; 15077116; 15124764; 15159409; 15194786; 15248898; 15292519; 15322047; 15351796; 15467752; 15478112; 15489334; 15637055; 15638360; 15638362; 15757910; 15846303; 15846589; 15901672; 16172118; 16199525; 16341674; 16376985; 16410245; 16436379; 16439990; 16529740; 16645094; 16712791; 16794010; 16847458; 16874066; 16978419; 16988840; 17015472; 17074758; 17188240; 17227835; 17235284; 17289999; 17353931; 17513609; 17686864; 17698840; 17699158; 17724463; 17879944; 17880809; 17927446; 17991745; 18056640; 18178565; 18251703; 18299329; 18309324; 18349538; 18362892; 18387192; 18413764; 18471982; 18472157; 18524770; 18593893; 18636124; 18665919; 18676680; 18715924; 18927073; 19041633; 19056676; 19060904; 19074885; 19135534; 19148187; 19168699; 19170196; 19255499; 19282307; 19343496; 19351886; 19381065; 19463775; 19481066; 19483681; 19514060; 19587033; 19593445; 19625176; 19692168; 19820697; 19875445; 19898928; 19913121; 19955184; 20034877; 20139978; 20308427; 20428767; 20453000; 20460378; 20503275; 20561923; 20618440; 20628086; 20629644; 20836993; 20855536; 20877624; 20930068; 20959805; 20978950; 21036904; 21041309; 21148306; 21158936; 21159883; 21196599; 21233848; 21613222; 21617256; 21656147; 21658363; 21712378; 21726118; 21727192; 21852253; 21900206; 21988832; 22024133; 22056880; 22065578; 22072546; 22139419; 22188816; 22253918; 22257632; 22297299; 22354970; 22378505; 22423221; 22440942; 22479585; 22493436; 22504646; 22515821; 22526391; 22686245; 22700719; 22719244; 22939629; 23140172; 23189150; 23192964; 23217248; 23229512; 23242420; 23251661; 23263863; 23283967; 23303126; 23389372; 23404709; 23480852; 23604079; 23666239; 23666240; 23770605; 23798675; 23928699; 23954442; 23954445; 23966164; 24026423; 24074954; 24097825; 24100034; 24265320,,,,,,,,,,,,,,,OGG:3000000578,,,,,,,BCL2-antagonist/killer 1,,,,,,,,,,,,,Other designations: BCL2-like 7 protein|apoptosis regulator BAK|bcl-2 homologous antagonist/killer|bcl-2-like protein 7|bcl2-L-7|pro-apoptotic protein BAK,,BAK1,,,,,,,,,,,,,,,,,,,,,,,578,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,BAK1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000000572,BAD,,Other designations: BCL-X/BCL-2 binding protein|BCL2-antagonist of cell death protein|BCL2-binding component 6|BCL2-binding protein|bcl-2-binding component 6|bcl-2-like protein 8|bcl-XL/Bcl-2-associated death promoter|bcl2 antagonist of cell death|bcl2-L-8,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,BCL2L8|BBC2,,,,,,,,,,,,11,,,,,,Vega:OTTHUMG00000134302|Ensembl:ENSG00000002330|HGNC:936|HPRD:04409|MIM:603167,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,BCL2-associated agonist of cell death,,,11q13.1,,,,,,,,,,,,,,,,"GO_0001836 (EC: IEA); GO_0005515 (EC: IPI, PMID: 10949025); GO_0005543 (EC: IMP); GO_0005739 (EC: IDA); GO_0005741 (EC: IDA); GO_0005741 (EC: TAS); GO_0005829 (EC: IDA); GO_0005829 (EC: TAS); GO_0006007 (EC: IEA); GO_0006915 (EC: IDA, PMID: 19667065); GO_0006915 (EC: TAS, PMID: 7834748); GO_0006919 (EC: ISS); GO_0007173 (EC: TAS); GO_0008289 (EC: IDA, PMID: 19667065); GO_0008543 (EC: TAS); GO_0008625 (EC: IEA); GO_0008630 (EC: IEA); GO_0008656 (EC: IDA, PMID: 18402937); GO_0009749 (EC: IEA); GO_0010508 (EC: TAS, PMID: 18309324); GO_0010918 (EC: ISS); GO_0019050 (EC: IEA); GO_0019221 (EC: IEA); GO_0019901 (EC: IPI, PMID: 17270021); GO_0030346 (EC: IEA); GO_0032024 (EC: ISS); GO_0032355 (EC: IEA); GO_0032570 (EC: IEA); GO_0033133 (EC: ISS); GO_0033574 (EC: IEA); GO_0034201 (EC: IEA); GO_0035774 (EC: IEA); GO_0038095 (EC: TAS); GO_0042493 (EC: IEA); GO_0042542 (EC: IEA); GO_0042593 (EC: ISS); GO_0043065 (EC: IDA, PMID: 9388232); GO_0043065 (EC: IMP, PMID: 17289999); GO_0043065 (EC: TAS); GO_0043200 (EC: IEA); GO_0043280 (EC: IDA, PMID: 18402937); GO_0043422 (EC: IEA); GO_0044342 (EC: ISS); GO_0045087 (EC: TAS); GO_0045471 (EC: IEA); GO_0045579 (EC: IEA); GO_0045582 (EC: IEA); GO_0045862 (EC: IDA, PMID: 18387192); GO_0046031 (EC: ISS); GO_0046034 (EC: ISS); GO_0046902 (EC: IMP); GO_0046931 (EC: IDA, PMID: 19667065); GO_0046982 (EC: IEA); GO_0048011 (EC: TAS); GO_0048015 (EC: TAS); GO_0050679 (EC: IMP, PMID: 19593445); GO_0051384 (EC: IEA); GO_0051592 (EC: IEA); GO_0060139 (EC: IEA); GO_0060154 (EC: IEA); GO_0071247 (EC: IEA); GO_0071260 (EC: IEP, PMID: 19593445); GO_0071316 (EC: IDA, PMID: 18676776); GO_0071396 (EC: IEA); GO_0071456 (EC: IEP); GO_0090200 (EC: IMP, PMID: 17289999); GO_0097190 (EC: TAS); GO_0097191 (EC: IMP, PMID: 18852119); GO_0097192 (EC: IEA); GO_0097193 (EC: IMP, PMID: 18676776); GO_0097193 (EC: TAS); GO_0097202 (EC: IDA, PMID: 18387192); GO_1900740 (EC: TAS); GO_1901216 (EC: IEA); GO_2000078 (EC: ISS); GO_2001244 (EC: TAS)",,,,,,,,,PMID: 7834748; 8929531; 8929532; 9130713; 9305851; 9369453; 9381178; 9388232; 9389483; 9463381; 9651683; 9824152; 9878060; 9973195; 10195903; 10381646; 10407019; 10521512; 10558990; 10579309; 10611223; 10620799; 10811615; 10837486; 10837489; 10880354; 10949025; 10949026; 11077446; 11206074; 11278245; 11410287; 11483855; 11494146; 11500364; 11544290; 11583631; 11689886; 11697890; 11717309; 11739707; 11742726; 11781193; 11839683; 11878929; 11908866; 11994280; 12084714; 12087097; 12115603; 12137781; 12239175; 12376548; 12477932; 12657644; 12754297; 12787561; 12842996; 12897128; 12931191; 12954615; 12965220; 14702039; 14767529; 14967141; 15033904; 15078178; 15131699; 15183529; 15226424; 15231831; 15280438; 15489334; 15574335; 15694340; 15705582; 15721256; 15731037; 15751984; 15767261; 15784622; 15849194; 15901741; 15978696; 15990872; 15998799; 16148027; 16189514; 16297499; 16403219; 16413544; 16445909; 16484005; 16603546; 16697956; 16710454; 16728406; 16767165; 16785131; 16843435; 16847055; 16908594; 16932738; 16949642; 16978419; 17011751; 17110373; 17270021; 17274640; 17287851; 17289999; 17393317; 17404594; 17420275; 17438366; 17446862; 17457084; 17474147; 17499381; 17541305; 17544220; 17557568; 17670745; 17696955; 17696989; 17900801; 17927446; 17979178; 18006502; 18029348; 18165867; 18246127; 18276761; 18309324; 18387192; 18391004; 18402774; 18402937; 18420586; 18449891; 18508762; 18508827; 18568448; 18593990; 18628207; 18636124; 18651163; 18651222; 18676776; 18775810; 18798227; 18832722; 18852119; 18973553; 19168699; 19171933; 19508210; 19587239; 19593445; 19624871; 19641507; 19667065; 19679565; 19730683; 19773546; 19882362; 19895838; 19913121; 20012528; 20043968; 20339252; 20596645; 20618440; 20628086; 20647330; 20691103; 20700721; 20810912; 20855536; 20877624; 20936779; 21076048; 21081150; 21187157; 21302807; 21317286; 21419810; 21444773; 21674599; 21849418; 21900206; 21918885; 21988832; 22011203; 22057915; 22096607; 22172950; 22214866; 22423221; 22464442; 22805310; 22837380; 23135712; 23383273; 23547889; 24255178,,,,,,,,,,,,,,,OGG:3000000572,,,,,,,BCL2-associated agonist of cell death,,,,,,,,,,,,,Other designations: BCL-X/BCL-2 binding protein|BCL2-antagonist of cell death protein|BCL2-binding component 6|BCL2-binding protein|bcl-2-binding component 6|bcl-2-like protein 8|bcl-XL/Bcl-2-associated death promoter|bcl2 antagonist of cell death|bcl2-L-8,,BAD,,,,,,,,,,,,,,,,,,,,,,,572,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,BAD,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000159,FcgammaRIII,Low affinity immunoglobulin gamma FC region receptor III,,false,,,http://purl.obolibrary.org/obo/IMR_0000156,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Low affinity immunoglobulin gamma FC region receptor III,,,,,IMR:0000159,,,,,,,,,,,,,,,,,,,,,,FcgammaRIII,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000284541,CYP4A22,,Other designations: CYPIVA22|cytochrome P450 4A22|cytochrome P450 4A22K|fatty acid omega-hydroxylase|lauric acid omega-hydroxylase,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,1,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 4, subfamily A, polypeptide 22",,,1p33,,,,,,,,,,,,,,,,GO_0005506 (EC: IEA); GO_0005789 (EC: IEA); GO_0018685 (EC: IEA); GO_0020037 (EC: IEA); GO_0052869 (EC: IEA),,,,,,,,,PMID:10860550; 12464262; 12477932; 15128046; 15611369; 20079672; 21820496,,,,,,,,,,,,,,,OGG:3000284541,,,,,,,"cytochrome P450, family 4, subfamily A, polypeptide 22",,,,,,,,,,,,,Other designations: CYPIVA22|cytochrome P450 4A22|cytochrome P450 4A22K|fatty acid omega-hydroxylase|lauric acid omega-hydroxylase,,CYP4A22,,,,,,,,,,,,,,,,,,,,,,,284541,RP1-18D14.1,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP4A22,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_49324,female contraceptive drug,female contraceptive drugs|female contraceptive agent,A chemical substance or agent with contraceptive activity in females.,false,,,http://purl.obolibrary.org/obo/CHEBI_49323,,,,,,,,,,,,,,,,,,,,,,A chemical substance or agent with contraceptive activity in females.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,female contraceptive drugs|female contraceptive agent,,,,,,,,,,,,,,,,,,,,,CHEBI:49324,,,,female contraceptive drug,,CHEBI:49324,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005091,HNF4A (canonical) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0005063|http://purl.obolibrary.org/obo/TXPO_0004621,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:3172|NCBI-Mouse-GeneID:15378|NCBI-Rat-GeneID:25735,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005091,,,,,,,,,,,,,,,,,,,,,,HNF4A (canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005098,MET (mol),HGFR,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24553|NCBI-Mouse-GeneID:17295|NCBI-Human-GeneID:4233,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,HGFR,,,,,TXPO:0005098,,,,,,,,,,,,,,,,,,,,,,MET (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005093,MST1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24566|NCBI-Human-GeneID:4485|NCBI-Mouse-GeneID:15235,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005093,,,,,,,,,,,,,,,,,,,,,,MST1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005097,KIAA0101 tv2 (predicted)(human) [hepatocarcinogenesis],KIAA0101 transcript variant 2,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_0004193,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:9768,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000009768,,,,,,,,KIAA0101 transcript variant 2,,,,,TXPO:0005097,,,,,,,,,,,,,,,,,,,,,,KIAA0101 tv2 (predicted)(human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005090,HIF1A(canonical) [mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004613|http://purl.obolibrary.org/obo/TXPO_0004293,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:3091|NCBI-Mouse-GeneID:15251|NCBI-Rat-GeneID:29560,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005090,,,,,,,,,,,,,,,,,,,,,,HIF1A(canonical) [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005094,STK3 (mol),MST2,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:56274|NCBI-Human-GeneID:6788|NCBI-Rat-GeneID:65189,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MST2,,,,,TXPO:0005094,,,,,,,,,,,,,,,,,,,,,,STK3 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005096,KDR (mol),VEGFR2,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:25589|NCBI-Human-GeneID:3791|NCBI-Mouse-GeneID:16542,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,VEGFR2,,,,,TXPO:0005096,,,,,,,,,,,,,,,,,,,,,,KDR (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005092,HOTAIR (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:100503872|NCBI-Human-GeneID:100124700,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005092,,,,,,,,,,,,,,,,,,,,,,HOTAIR (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005095,IGFBP3 (human) [hepatocarcinogenesis],insulin like growth factor binding protein 3,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_0004645,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:3486,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,insulin like growth factor binding protein 3,,,,,TXPO:0005095,,,,,,,,,,,,,,,,,,,,,,IGFBP3 (human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005099,MSH2 (canonical) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0005100|http://purl.obolibrary.org/obo/TXPO_0005063,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:81709|NCBI-Mouse-GeneID:17685|NCBI-Human-GeneID:4436,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005099,,,,,,,,,,,,,,,,,,,,,,MSH2 (canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000004051,CYP4F3,,"Other designations: CYPIVF3|cytochrome P-450|cytochrome P450 4F3|cytochrome P450, subfamily IVF, polypeptide 3 (leukotriene B4 omega hydroxylase)|cytochrome P450-LTB-omega|leukotriene B4 omega hydroxylase|leukotriene-B(4) 20-monooxygenase 2|leukotriene-B(4) omega-hydroxylase 2|leukotriene-B4 20-monooxygenase",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CYP4F|LTB4H|CPF3,,,,,,,,,,,,19,,,,,,MIM:601270|HPRD:03169|Ensembl:ENSG00000186529|HGNC:2646|Vega:OTTHUMG00000182374,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cytochrome P450, family 4, subfamily F, polypeptide 3",,,19p13.2,,,,,,,,,,,,,,,,"GO_0004497 (EC: TAS, PMID:8486631); GO_0005506 (EC: IEA); GO_0005789 (EC: TAS); GO_0006690 (EC: TAS); GO_0006691 (EC: TAS); GO_0006805 (EC: TAS); GO_0016021 (EC: IEA); GO_0019369 (EC: TAS); GO_0020037 (EC: IEA); GO_0044281 (EC: TAS); GO_0050051 (EC: IEA); GO_0052871 (EC: IEA)",,,,,,,,,PMID:8026587; 8486631; 9068972; 9539102; 10409674; 11461919; 12477932; 12709424; 14715252; 15128046; 16344560; 16380383; 17980168; 18065749; 18566475; 18577768; 19138970; 19343046; 20047521; 20237496; 21666788; 21906983; 22706230,,,,,,,,,,,,,,,OGG:3000004051,,,,,,,"cytochrome P450, family 4, subfamily F, polypeptide 3",,,,,,,,,,,,,"Other designations: CYPIVF3|cytochrome P-450|cytochrome P450 4F3|cytochrome P450, subfamily IVF, polypeptide 3 (leukotriene B4 omega hydroxylase)|cytochrome P450-LTB-omega|leukotriene B4 omega hydroxylase|leukotriene-B(4) 20-monooxygenase 2|leukotriene-B(4) omega-hydroxylase 2|leukotriene-B4 20-monooxygenase",,CYP4F3,,,,,,,,,,,,,,,,,,,,,,,4051,,,,,,,,9606,,,,,,,,,,,,,,,,,,,CYP4F3,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0010464,60S ribosomal protein L13,Breast basic conserved protein 1,,false,,,http://purl.obolibrary.org/obo/IMR_0000897,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Breast basic conserved protein 1,,,,,IMR:0010464,,,,,,,,,,,,,,,,,,,,,,60S ribosomal protein L13,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000387755,INSC,,Other designations: inscuteable spindle orientation adaptor protein|protein inscuteable homolog,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,11,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,inscuteable homolog (Drosophila),,,11p15.2,,,,,,,,,,,,,,,,GO_0000132 (EC: IEA); GO_0005737 (EC: IEA); GO_0007399 (EC: IEA); GO_0045177 (EC: IEA); GO_0060487 (EC: IEA),,,,,,,,,PMID: 12469229; 12477932; 16458856; 20065032; 20379614; 22074847; 22219177; 22889411; 22977735; 23251661; 23667675,,,,,,,,,,,,,,,OGG:3000387755,,,,,,,inscuteable homolog (Drosophila),,,,,,,,,,,,,Other designations: inscuteable spindle orientation adaptor protein|protein inscuteable homolog,,INSC,,,,,,,,,,,,,,,,,,,,,,,387755,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,INSC,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_2060009606,protein-coding gene of Homo sapiens,,A gene of Homo sapiens that has a protein-coding gene disposition,false,,,http://purl.obolibrary.org/obo/OGG_2000009606,,,,,,,,,,,,,,,,,,,,,,A gene of Homo sapiens that has a protein-coding gene disposition,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,OGG:2060009606,,,,,,,,,,,,,,,,,,,,,,protein-coding gene of Homo sapiens,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9606,,,,,,,,,,,,,,,,,,,,,"Bin Zhao, Oliver He"
http://purl.obolibrary.org/obo/IMR_0001042,group IIC secretory phospholipase A2,,,false,,,http://purl.obolibrary.org/obo/IMR_0000283,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001042,,,,,,,,,,,,,,,,,,,,,,group IIC secretory phospholipase A2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000642,Integrin beta-2,,,false,,,http://purl.obolibrary.org/obo/IMR_0000174,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000642,,,,,,,,,,,,,,,,,,,,,,Integrin beta-2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100351,TCR beta,T-cell receptor beta,,false,,,http://purl.obolibrary.org/obo/IMR_0000151,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,T-cell receptor beta,,,,,IMR:0100351,,,,,,,,,,,,,,,,,,,,,,TCR beta,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001789,"beta-1,3-glucan","(1 --> 3)-beta-D-glucan|(1,3)-beta-D-glucan|(1-->3)-beta-D-glucan|(1->3)-beta-D-glucan|beta-1,3-D-glucan",component of fungal cell walls.,false,,,http://purl.obolibrary.org/obo/CHEBI_18154,,,,,,,,,,,,,,,,,,,,MeSH:C033363,,component of fungal cell walls.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"(1 --> 3)-beta-D-glucan|(1,3)-beta-D-glucan|(1-->3)-beta-D-glucan|(1->3)-beta-D-glucan|beta-1,3-D-glucan",,,,,IMR:0001789,,,,,,,,,,,,,,,,,,,,,,"beta-1,3-glucan",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_78444,EC 3.1.1.1 (carboxylesterase) inhibitor,nonspecific carboxylesterase inhibitors|carboxylic acid esterase inhibitors|carboxyl ester hydrolase inhibitor|butyrate esterase inhibitors|vitamin A esterase inhibitors|propionyl esterase inhibitor|serine esterase inhibitor|triacetin esterase inhibitors|procaine esterase inhibitor|carboxylic acid esterase inhibitor|esterase B inhibitor|esterase A inhibitors|carboxylic-ester hydrolase inhibitor|Beta-esterase inhibitors|carboxyl ester hydrolase inhibitors|nonspecific carboxylesterase inhibitor|propionyl esterase inhibitors|ali-esterase inhibitor|triacetin esterase inhibitor|esterase A inhibitor|butyryl esterase inhibitors|esterase D inhibitor|Beta-esterase inhibitor|cocaine esterase inhibitors|cocaine esterase inhibitor|vitamin A esterase inhibitor|carboxylic-ester hydrolase inhibitors|methylbutyrase inhibitors|butyrate esterase inhibitor|methylbutyrase inhibitor|serine esterase inhibitors|carboxylic esterase inhibitors|carboxylate esterase inhibitor|esterase B inhibitors|carboxylesterase inhibitor|EC 3.1.1.1 (carboxylesterase) inhibitors|procaine esterase inhibitors|carboxylic esterase inhibitor|Alpha-carboxylesterase inhibitor|monobutyrase inhibitors|Alpha-carboxylesterase inhibitors|butyryl esterase inhibitor|methylbutyrate esterase inhibitor|ali-esterase inhibitors|carboxylesterase inhibitors|carboxylate esterase inhibitors|esterase D inhibitors|methylbutyrate esterase inhibitors|monobutyrase inhibitor,Any EC 3.1.1.* (carboxylic ester hydrolase) inhibitor that inhibits the action of carboxylesterase (EC 3.1.1.1 ).,false,,,http://purl.obolibrary.org/obo/CHEBI_76773,,,,,,,,,,,,,,,,,,,,,,Any EC 3.1.1.* (carboxylic ester hydrolase) inhibitor that inhibits the action of carboxylesterase (EC 3.1.1.1 ).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,nonspecific carboxylesterase inhibitors|carboxylic acid esterase inhibitors|carboxyl ester hydrolase inhibitor|butyrate esterase inhibitors|vitamin A esterase inhibitors|propionyl esterase inhibitor|serine esterase inhibitor|triacetin esterase inhibitors|procaine esterase inhibitor|carboxylic acid esterase inhibitor|esterase B inhibitor|esterase A inhibitors|carboxylic-ester hydrolase inhibitor|Beta-esterase inhibitors|carboxyl ester hydrolase inhibitors|nonspecific carboxylesterase inhibitor|propionyl esterase inhibitors|ali-esterase inhibitor|triacetin esterase inhibitor|esterase A inhibitor|butyryl esterase inhibitors|esterase D inhibitor|Beta-esterase inhibitor|cocaine esterase inhibitors|cocaine esterase inhibitor|vitamin A esterase inhibitor|carboxylic-ester hydrolase inhibitors|methylbutyrase inhibitors|butyrate esterase inhibitor|methylbutyrase inhibitor|serine esterase inhibitors|carboxylic esterase inhibitors|carboxylate esterase inhibitor|esterase B inhibitors|carboxylesterase inhibitor|EC 3.1.1.1 (carboxylesterase) inhibitors|procaine esterase inhibitors|carboxylic esterase inhibitor|Alpha-carboxylesterase inhibitor|monobutyrase inhibitors|Alpha-carboxylesterase inhibitors|butyryl esterase inhibitor|methylbutyrate esterase inhibitor|ali-esterase inhibitors|carboxylesterase inhibitors|carboxylate esterase inhibitors|esterase D inhibitors|methylbutyrate esterase inhibitors|monobutyrase inhibitor,,,,,,,,,,,,,,,,,,,,,CHEBI:78444,,,,EC 3.1.1.1 (carboxylesterase) inhibitor,,CHEBI:78444,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000004189,DNAJB9,,Other designations: ER-resident protein ERdj4|dnaJ homolog subfamily B member 9|endoplasmic reticulum DNA J domain-containing protein 4|endoplasmic reticulum DnaJ homolog 4|microvascular endothelial differentiation gene 1 protein,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,MDG-1|ERdj4|MST049|MDG1|MSTP049,,,,,,,,,,,,7,,,,,,Ensembl:ENSG00000128590|HGNC:6968|HPRD:07047|Vega:OTTHUMG00000154866|MIM:602634,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"DnaJ (Hsp40) homolog, subfamily B, member 9",,,7q31|14q24.2-q24.3,,,,,,,,,,,,,,,,"GO_0005515 (EC: IPI, PMID:19815549); GO_0005730 (EC: ISS); GO_0005737 (EC: ISS); GO_0005783 (EC: IDA); GO_0005788 (EC: IEA); GO_0005789 (EC: TAS); GO_0006987 (EC: TAS); GO_0030433 (EC: IMP, PMID:18400946); GO_0030968 (EC: TAS); GO_0044267 (EC: TAS); GO_0051787 (EC: IDA, PMID:18400946); GO_0070062 (EC: IDA, PMID:19199708)",,,,,,,,,PMID:9533036; 11042152; 11147971; 11230166; 11256614; 11525638; 11836248; 12356756; 12477932; 12581160; 12690205; 12975309; 14516790; 14559994; 14702039; 15456888; 15489334; 15882996; 16169070; 16205636; 16344560; 17132139; 17936241; 18400946; 18431251; 19123479; 19199708; 19322201; 19815549; 20054003; 20335527; 20554776; 20682791; 21906983; 21988832; 22006218; 24250222,,,,,,,,,,,,,,,OGG:3000004189,,,,,,,"DnaJ (Hsp40) homolog, subfamily B, member 9",,,,,,,,,,,,,Other designations: ER-resident protein ERdj4|dnaJ homolog subfamily B member 9|endoplasmic reticulum DNA J domain-containing protein 4|endoplasmic reticulum DnaJ homolog 4|microvascular endothelial differentiation gene 1 protein,,DNAJB9,,,,,,,,,,,,,,,,,,,,,,,4189,UNQ743/PRO1471,,,,,,,9606,,,,,,,,,,,,,,,,,,,DNAJB9,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0100349,RasGRP,,,false,,,http://purl.obolibrary.org/obo/IMR_0100440,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100349,,,,,,,,,,,,,,,,,,,,,,RasGRP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0043335,protein unfolding,,"The process of assisting in the disassembly of non-covalent linkages in a protein or protein aggregate, often where the proteins are in a non-functional or denatured state.",false,,,http://purl.obolibrary.org/obo/TXPO_0002565,,,,,,,,,,,,,,,,,,,chaperone-mediated protein transport involved in chaperone-mediated autophagy subClassOf : has_part some protein unfolding,,,"The process of assisting in the disassembly of non-covalent linkages in a protein or protein aggregate, often where the proteins are in a non-functional or denatured state.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0043335,,,,,,,,,,,,,,,,,,,,,,protein unfolding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003034,HSP90B1 - chaperone (canonical)[ER stress -Refolding [persist]],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001960,,,,,,,,,,,,,,,,,,,,PMID:23334697,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003997,,,,,,,,,,TXPO:0003034,,,,,,,,,,,,,,,,,,,,,,HSP90B1 - chaperone (canonical)[ER stress -Refolding [persist]],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003036,inflammatory gene expression by ATF4 [ER stress],,"Inflammatiory gene expression by ATF4 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) related to the induction of inflammation by ATF4.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000698,,,,,,,,,,,,,,,,,,,,PMID:28860159|PMID:26086088|PMID:27346803,,"Inflammatiory gene expression by ATF4 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) related to the induction of inflammation by ATF4.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002559,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003040|http://purl.obolibrary.org/obo/TXPO_0003038,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003043,,,,,,,,,,,TXPO:0003036,,,,,,,,,,,,,,,,,,,,,,inflammatory gene expression by ATF4 [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003030,receiving abnormal protein signal by ATF6 [ER stress - apoptosis],,"Receiving abnormal protein signal by ATF6 is a subtype of receiving signal: A process that recognizes another object and changes into an abnormal protein (e.g., misfolded protein, etc.) signal by ATF6.
This process is dependent on the apoptosis and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002554|http://purl.obolibrary.org/obo/TXPO_0003736,,,,,,,,,,,,,,,,,,,,,,"Receiving abnormal protein signal by ATF6 is a subtype of receiving signal: A process that recognizes another object and changes into an abnormal protein (e.g., misfolded protein, etc.) signal by ATF6.
This process is dependent on the apoptosis and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003032,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003031,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002909,,,,,,,,,,,TXPO:0003030,,,,,,,,,,,,,,,,,,,,,,receiving abnormal protein signal by ATF6 [ER stress - apoptosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003033,proapoptic gene regulation pathway by ATF6  [ER stress],,Proapoptic gene regulation pathway by ATF6 is a subtype of ATF6 gene regulation pathway: Sequence of reactions to regulate genes which have a proapoptosis inducer role by ATF6. This process can constitute the course of ER stress.,false,,,http://purl.obolibrary.org/obo/TXPO_0002520,,,,,,,,,,,,,,,,,,,,,,Proapoptic gene regulation pathway by ATF6 is a subtype of ATF6 gene regulation pathway: Sequence of reactions to regulate genes which have a proapoptosis inducer role by ATF6. This process can constitute the course of ER stress.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002912,,,,,,,,,,,,,,,,,,TXPO:0003033,,,,,,,,,,,,,,,,,,,,,,proapoptic gene regulation pathway by ATF6  [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003031,Dissociation of ATF6-alpha:BIP Complex [ER stress - apoptosis],,"Dissociation of ATF6:BIP heterodimer is a subtype of detaching: A process that disaggregates ATF6-BIP heterodimers into BIP and ATF6.
This process is dependent on the apoptosis and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002903,,,,,,,,,,,,,,,,,,,,,,"Dissociation of ATF6:BIP heterodimer is a subtype of detaching: A process that disaggregates ATF6-BIP heterodimers into BIP and ATF6.
This process is dependent on the apoptosis and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003032,,,,,,,,,,,,,,,,,,,TXPO:0003031,,,,,,,,,,,,,,,,,,,,,,Dissociation of ATF6-alpha:BIP Complex [ER stress - apoptosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003032,ATF6 - stress sensor (canonical)[ER stress - apotosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000879,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000825,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000881,,,,,,,,,,TXPO:0003032,,,,,,,,,,,,,,,,,,,,,,ATF6 - stress sensor (canonical)[ER stress - apotosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003030,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003038,IL-6 - inflammatory cytokine (canonical)[ER stress - inflammation -ATF4 pathway],,,false,,,http://purl.obolibrary.org/obo/TXPO_0003037,,,,,,,,,,,,,,,,,,,,PMID:23990363,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003041,,,,,,,,,,TXPO:0003038,,,,,,,,,,,,,,,,,,,,,,IL-6 - inflammatory cytokine (canonical)[ER stress - inflammation -ATF4 pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003039,NLRP1 (canonical)[ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000871|http://purl.obolibrary.org/obo/TXPO_1000252,,,,,,,,,,,,,,,,,,,NLRP1 is a inflammasome component,NCBI-Human-GeneID:22861|PMID:27662089|PMID:25879280|PMID:22634126,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003039,,,,,,,,,,,,,,,,,,,,,,NLRP1 (canonical)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003037,IL-6 (canonical)[ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000871|http://purl.obolibrary.org/obo/IMR_0000010,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:3569|NCBI-Mouse-GeneID:16193|NCBI-Rat-GeneID:24498,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003037,,,,,,,,,,,,,,,,,,,,,,IL-6 (canonical)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003035,ATF4 gene expression by eIF2a [ER stress - inflammation],,"ATF4 gene expression by eIF2a is a subtype of gene expression: The process in which a gene sequence is converted into a mature ATF4 gene product or products (proteins or RNA) by eIF2a.
This process is dependent on the inflammation and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000707,,,,,,,,,,,,,,,,,,,,http://www.ncbi.nlm.nih.gov/pubmed/18426796|Reactome:R-HSA-381128,,"ATF4 gene expression by eIF2a is a subtype of gene expression: The process in which a gene sequence is converted into a mature ATF4 gene product or products (proteins or RNA) by eIF2a.
This process is dependent on the inflammation and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000829,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002559,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003036,,,,,,,,,,,TXPO:0003035,,,,,,,,,,,,,,,,,,,,,,ATF4 gene expression by eIF2a [ER stress - inflammation],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_49167,anti-asthmatic drug,anti-asthmatic agents|anti-asthmatic drugs|anti-asthmatic agent,A drug used to treat asthma.,false,,,http://purl.obolibrary.org/obo/CHEBI_65023|http://purl.obolibrary.org/obo/CHEBI_23888,,,,,,,,,,,,,,,,,,,,,,A drug used to treat asthma.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,anti-asthmatic agents|anti-asthmatic drugs|anti-asthmatic agent,,,,,,,,,,,,,,,,,,,,,CHEBI:49167,,,,anti-asthmatic drug,,CHEBI:49167,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005156,raltegravir potassium,,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005156,,,,,,,,,,,,,,,,,,,,,,raltegravir potassium,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005157,dronedarone hydrochloride,,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005157,,,,,,,,,,,,,,,,,,,,,,dronedarone hydrochloride,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005153,entecavir,,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005153,,,,,,,,,,,,,,,,,,,,,,entecavir,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005155,ticrynafen,,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005155,,,,,,,,,,,,,,,,,,,,,,ticrynafen,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005151,cyclosporine,,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005151,,,,,,,,,,,,,,,,,,,,,,cyclosporine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005158,divalproex sodium,,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005158,,,,,,,,,,,,,,,,,,,,,,divalproex sodium,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005154,nilotinib hydrochloride monohydrate,,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005154,,,,,,,,,,,,,,,,,,,,,,nilotinib hydrochloride monohydrate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005150,niacin,,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005150,,,,,,,,,,,,,,,,,,,,,,niacin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005152,aminosalicylic acid,,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005152,,,,,,,,,,,,,,,,,,,,,,aminosalicylic acid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005159,aplaviroc,,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005159,,,,,,,,,,,,,,,,,,,,,,aplaviroc,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000572,IFN alpha-1,,,false,,,http://purl.obolibrary.org/obo/IMR_0100386,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000572,,,,,,,,,,,,,,,,,,,,,,IFN alpha-1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0042116,macrophage activation,macrophage polarization,"A change in morphology and behavior of a macrophage resulting from exposure to a cytokine, chemokine, cellular ligand, or soluble factor.",false,,,http://purl.obolibrary.org/obo/GO_0045321,,,,,,,,,,,,,,,,,,,,,,"A change in morphology and behavior of a macrophage resulting from exposure to a cytokine, chemokine, cellular ligand, or soluble factor.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,macrophage polarization,,,,,GO:0042116,,,,,,,,,,,,,,,,,,,,,,macrophage activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0042110,T cell activation,,"The change in morphology and behavior of a mature or immature T cell resulting from exposure to a mitogen, cytokine, chemokine, cellular ligand, or an antigen for which it is specific.",false,,,http://purl.obolibrary.org/obo/GO_0046649,,,,,,,,,,,,,,,,,,,,,,"The change in morphology and behavior of a mature or immature T cell resulting from exposure to a mitogen, cytokine, chemokine, cellular ligand, or an antigen for which it is specific.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0042110,,,,,,,,,,,,,,,,,,,,,,T cell activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000006747,SSR3,,Other designations: SSR gamma|SSR-gamma|TRAP-complex gamma subunit|TRAP-gamma|signal sequence receptor subunit gamma|translocon-associated protein gamma subunit|translocon-associated protein subunit gamma,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,TRAPG,,,,,,,,,,,,3,,,,,,HPRD:16206|MIM:606213|HGNC:11325|Ensembl:ENSG00000114850|Vega:OTTHUMG00000158632,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"signal sequence receptor, gamma (translocon-associated protein gamma)",,,3q25.31,,,,,,,,,,,,,,,,GO_0005784 (EC: IEA); GO_0006412 (EC: TAS); GO_0006614 (EC: TAS); GO_0010467 (EC: TAS); GO_0030176 (EC: IEA); GO_0044267 (EC: TAS),,,,,,,,,PMID: 7916687; 9631292; 10471800; 12477932; 14667819; 15489334; 16344560; 17081983; 17353931; 18781797; 18976975; 19615732; 21139048; 21906983; 21963094; 22632162; 22939629; 23000965; 23660295,,,,,,,,,,,,,,,OGG:3000006747,,,,,,,"signal sequence receptor, gamma (translocon-associated protein gamma)",,,,,,,,,,,,,Other designations: SSR gamma|SSR-gamma|TRAP-complex gamma subunit|TRAP-gamma|signal sequence receptor subunit gamma|translocon-associated protein gamma subunit|translocon-associated protein subunit gamma,,SSR3,,,,,,,,,,,,,,,,,,,,,,,6747,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,SSR3,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000006742,SSBP1,,"Other designations: PWP1-interacting protein 17|single-stranded DNA-binding protein, mitochondrial",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,SOSS-B1|Mt-SSB|SSBP|mtSSB,,,,,,,,,,,,7,,,,,,HGNC:11317|HPRD:02703|Ensembl:ENSG00000106028|MIM:600439|Vega:OTTHUMG00000157572,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"single-stranded DNA binding protein 1, mitochondrial",,,7q34,,,,,,,,,,,,,,,,"GO_0003682 (EC: IDA, PMID: 18063578); GO_0003697 (EC: IEA); GO_0005515 (EC: IPI); GO_0005739 (EC: IDA); GO_0006260 (EC: IEA); GO_0042645 (EC: IDA, PMID: 18063578); GO_0044822 (EC: IDA); GO_0051096 (EC: IDA, PMID: 12975372); GO_0070062 (EC: IDA); GO_0070584 (EC: IEA)",,,,,,,,,PMID: 7789991; 8482537; 9033597; 9452467; 10827171; 11556757; 11964388; 12381786; 12464025; 12477932; 12479417; 12690205; 12853948; 12975372; 15161933; 15342556; 15489334; 15710247; 16407974; 16428295; 18029348; 18063578; 18305033; 18457437; 19066201; 19167051; 19605351; 19683501; 19738201; 19759019; 19786724; 20000738; 20028516; 20100872; 20186120; 20360068; 20434493; 20639865; 20843780; 20877624; 20972266; 21139048; 21145461; 21150319; 21242961; 21319273; 21360678; 21890473; 21906983; 21953457; 22153281; 22190034; 22242598; 22354994; 22505724; 22939629; 23000965; 23042605; 23184057; 23246001; 23290262; 23398456; 23438482; 23568457; 24244333,,,,,,,,,,,,,,,OGG:3000006742,,,,,,,"single-stranded DNA binding protein 1, mitochondrial",,,,,,,,,,,,,"Other designations: PWP1-interacting protein 17|single-stranded DNA-binding protein, mitochondrial",,SSBP1,,,,,,,,,,,,,,,,,,,,,,,6742,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,SSBP1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000213,JAK,Janus kinase,"Janus kinases (Jaks) are non-receptor tyrosine kinases. In mammals, the family has four members, Jak1, Jak2, Jak3 and Tyrosine kinase 2 (Tyk2). In Drosophila there is only one Jak kinase, Hopscotch (Hop).",false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,GO:0004718,,"Janus kinases (Jaks) are non-receptor tyrosine kinases. In mammals, the family has four members, Jak1, Jak2, Jak3 and Tyrosine kinase 2 (Tyk2). In Drosophila there is only one Jak kinase, Hopscotch (Hop).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001054,,,,,Janus kinase,,,,,IMR:0000213,,,,,,,,,,,,,,,,,,,,,,JAK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_22563,anion,,A monoatomic or polyatomic species having one or more elementary charges of the electron.,false,,,http://purl.obolibrary.org/obo/CHEBI_24870,,,,,,,,,,,,,,,,,,,,,,A monoatomic or polyatomic species having one or more elementary charges of the electron.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:22563,,,,,,,,,,,,,,,,,,,,,,anion,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000594,IL-1RII : IL-1R AcP,,,false,,,http://purl.obolibrary.org/obo/IMR_0000120,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000594,,,,,,,,,,,,,,,,,,,,,,IL-1RII : IL-1R AcP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010508,Heterogeneous nuclear ribonucleoprotein A3,D10S102|ROA3|hnRNP A3,,false,,,http://purl.obolibrary.org/obo/IMR_0010024,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,D10S102|ROA3|hnRNP A3,,,,,IMR:0010508,,,,,,,,,,,,,,,,,,,,,,Heterogeneous nuclear ribonucleoprotein A3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_16393,sphingosine,Sphingenine|Sphingoid,A sphing-4-enine in which the double bond is trans.,false,,,http://purl.obolibrary.org/obo/CHEBI_26739,,,,,,,,,,,,,,,,,,,,IMR:0100178,,A sphing-4-enine in which the double bond is trans.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002401,,,,,Sphingenine|Sphingoid,,,,,CHEBI:16393,,,,,,,,,,,,,,,,,,,,,,sphingosine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000321,G-alpha-t,transducin alpha,,false,,,http://purl.obolibrary.org/obo/IMR_0000318,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,transducin alpha,,,,,IMR:0000321,,,,,,,,,,,,,,,,,,,,,,G-alpha-t,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004290,ACTA2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:11475|NCBI-Rat-GeneID:81633|NCBI-Human-GeneID:59,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000006347,,,,,,,,,,,,,TXPO:0004290,,,,,,,,,,,,,,,,,,,,,,ACTA2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004295,carbon tetrachloride metabolic process [mitochondrial disorder],,"The chemical reactions and pathways involving carbon tetrachloride, a toxic, carcinogenic compound which is used as a general solvent in industrial degreasing operations. It is also used as grain fumigant and a chemical intermediate in the production of refrigerants. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0004294,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0018885|PMID:29222479,,"The chemical reactions and pathways involving carbon tetrachloride, a toxic, carcinogenic compound which is used as a general solvent in industrial degreasing operations. It is also used as grain fumigant and a chemical intermediate in the production of refrigerants. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004229,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004317,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004258,,,,,,,,,,,TXPO:0004295,,,,,,,,,,,,,,,,,,,,,,carbon tetrachloride metabolic process [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004299,TLR9 signaling [hepatocarcinogenesis],,TLR9 signaling is a subtype of signaling [biological]: Any series of molecular signals generated as a consequence of binding to toll-like receptor 9. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.,false,,,http://purl.obolibrary.org/obo/TXPO_0004300|http://purl.obolibrary.org/obo/TXPO_0002340,,,,,,,,,,,,,,,,,,,,PMID:30894684,,TLR9 signaling is a subtype of signaling [biological]: Any series of molecular signals generated as a consequence of binding to toll-like receptor 9. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004236,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0034162,,,,,http://purl.obolibrary.org/obo/TXPO_0004298,,,,,,,,,,,TXPO:0004299,,,,,,,,,,,,,,,,,,,,,,TLR9 signaling [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004297,NEAT1 inactivation,,NEAT1 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the NEAT1 (nuclear paraspeckle assembly transcript 1) to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000021,,,,,,,,,,,,,,,,,,,,,,NEAT1 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the NEAT1 (nuclear paraspeckle assembly transcript 1) to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004297,,,,,,,,,,,,,,,,,,,,,,NEAT1 inactivation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004294,carbon tetrachloride metabolic process,,"The chemical reactions and pathways involving carbon tetrachloride, a toxic, carcinogenic compound which is used as a general solvent in industrial degreasing operations. It is also used as grain fumigant and a chemical intermediate in the production of refrigerants.",false,,,http://purl.obolibrary.org/obo/GO_0006805,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0018885,,"The chemical reactions and pathways involving carbon tetrachloride, a toxic, carcinogenic compound which is used as a general solvent in industrial degreasing operations. It is also used as grain fumigant and a chemical intermediate in the production of refrigerants.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004294,,,,,,,,,,,,,,,,,,,,,,carbon tetrachloride metabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004296,DNA sensor,,A role played by the entity which receives DNA and transmits operand(s).,false,,,http://purl.obolibrary.org/obo/TXPO_0000882,,,,,,,,,,,,,,,,,,,,,,A role played by the entity which receives DNA and transmits operand(s).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004296,,,,,,,,,,,,,,,,,,,,,,DNA sensor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004298,NfkB signaling (primitive) [hepatocarcinogenesis],,"NfkB signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transduced with the regulation of transcription of target genes by NF-kappaB.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0000761,,,,,,,,,,,,,,,,,,,,PMID:30523154|PMID:29358721|PMID:30894684|PMID:28646551|PMID:31781608,,"NfkB signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transduced with the regulation of transcription of target genes by NF-kappaB.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000382,,,,,,http://purl.obolibrary.org/obo/TXPO_0004276|http://purl.obolibrary.org/obo/TXPO_0004396|http://purl.obolibrary.org/obo/TXPO_0004394|http://purl.obolibrary.org/obo/TXPO_0004395,,,,,,,,,,,TXPO:0004298,,,,,,,,,,,,,,,,,,,,,,NfkB signaling (primitive) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004293,mitochondrial damage dependent molecule (canonical),,"Mitochondrial damage dependent molecule is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of Mitochondrial damage as a gene product.
Gene profile:caonical that described in textbooks or articles.",false,,,http://purl.obolibrary.org/obo/TXPO_0002012,,,,,,,,,,,,,,,,,,,,,,"Mitochondrial damage dependent molecule is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of Mitochondrial damage as a gene product.
Gene profile:caonical that described in textbooks or articles.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004293,,,,,,,,,,,,,,,,,,,,,,mitochondrial damage dependent molecule (canonical),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004291,CCL2(human)[hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_1000086,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:6347|PMID:30894684,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000006347,,,,,,,,,,,,,TXPO:0004291,,,,,,,,,,,,,,,,,,,,,,CCL2(human)[hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004292,p38(canonical) [mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/IMR_0000226|http://purl.obolibrary.org/obo/TXPO_0004293,,,,,,,,,,,,,,,,,,,,PMID:29222479,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004292,,,,,,,,,,,,,,,,,,,,,,p38(canonical) [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000001026,CDKN1A,,Other designations: CDK-interacting protein 1|CDK-interaction protein 1|DNA synthesis inhibitor|cyclin-dependent kinase inhibitor 1|melanoma differentiation associated protein 6|wild-type p53-activated fragment 1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CDKN1|MDA-6|p21CIP1|P21|CAP20|CIP1|WAF1|SDI1,,,,,,,,,,,,6,,,,,,Vega:OTTHUMG00000014603|HGNC:1784|HPRD:00298|Ensembl:ENSG00000124762|MIM:116899,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"cyclin-dependent kinase inhibitor 1A (p21, Cip1)",,,6p21.2,,,,,,,,,,,,,,,,"GO_0000079 (EC: TAS, PMID: 8242751); GO_0000082 (EC: IDA, PMID: 10208428); GO_0000082 (EC: TAS); GO_0000086 (EC: IMP, PMID: 17553787); GO_0000278 (EC: TAS); GO_0000307 (EC: IDA, PMID: 17420273); GO_0004861 (EC: TAS, PMID: 7958916); GO_0005515 (EC: IPI, PMID: 15232106); GO_0005634 (EC: IDA); GO_0005654 (EC: TAS); GO_0005730 (EC: IDA, Qualifier: NOT); GO_0005829 (EC: TAS); GO_0006468 (EC: IDA, PMID: 9106657); GO_0006974 (EC: IMP); GO_0006977 (EC: IDA, PMID: 15149599); GO_0006977 (EC: TAS); GO_0007050 (EC: IDA, PMID: 15149599); GO_0007050 (EC: IMP, PMID: 17553787); GO_0007173 (EC: TAS); GO_0007265 (EC: IEP, PMID: 9054499); GO_0008285 (EC: IDA, PMID: 10208428); GO_0008285 (EC: IMP, PMID: 17553787); GO_0008543 (EC: TAS); GO_0009411 (EC: IEA); GO_0009636 (EC: IEA); GO_0010243 (EC: IEA); GO_0010629 (EC: IEA); GO_0019912 (EC: IDA, PMID: 9106657); GO_0030308 (EC: IDA, PMID: 10208428); GO_0030332 (EC: IEA); GO_0030890 (EC: IEA); GO_0031100 (EC: IEA); GO_0031668 (EC: IMP, PMID: 17553787); GO_0032403 (EC: IEA); GO_0033158 (EC: IEA); GO_0038095 (EC: TAS); GO_0042326 (EC: IDA, PMID: 10208428); GO_0042493 (EC: IEA); GO_0042771 (EC: IEA); GO_0043066 (EC: IEA); GO_0043068 (EC: IEA); GO_0043231 (EC: IDA); GO_0045087 (EC: TAS); GO_0045736 (EC: IEA); GO_0045860 (EC: IDA, PMID: 9106657); GO_0046685 (EC: IEA); GO_0046872 (EC: IEA); GO_0048011 (EC: TAS); GO_0048015 (EC: TAS); GO_0048146 (EC: IMP, PMID: 17420273); GO_0051412 (EC: IEA); GO_0055093 (EC: IEA); GO_0070557 (EC: IDA, PMID: 18794347); GO_0071479 (EC: IMP); GO_0071850 (EC: IEA); GO_0090398 (EC: IMP, PMID: 15149599); GO_0090400 (EC: TAS); GO_0097193 (EC: TAS, PMID: 9660939); GO_2000278 (EC: IEA); GO_2000379 (EC: IMP)",,,,,,,,,PMID: 7478582; 7478594; 7655464; 7698009; 7753561; 7780738; 7911228; 7958916; 8084608; 8101826; 8125163; 8242751; 8242752; 8259214; 8560263; 8622677; 8641969; 8647134; 8657154; 8662825; 8700517; 8756624; 8807325; 8861913; 8861969; 8891332; 8999999; 9054499; 9106657; 9178907; 9190208; 9218599; 9372966; 9380407; 9396813; 9464540; 9465025; 9467962; 9472014; 9515786; 9545252; 9546435; 9632134; 9658399; 9660939; 9705499; 9716181; 9716736; 9736735; 9798959; 9799125; 9811456; 9822382; 9837900; 9840927; 9840943; 9858585; 9858587; 10022118; 10022926; 10208428; 10323868; 10337545; 10455148; 10486249; 10529385; 10581175; 10679299; 10692450; 10698951; 10710306; 10753973; 10764767; 10828884; 10837373; 10848585; 10858286; 10873631; 10874474; 10878006; 10891505; 10912791; 10918595; 10973963; 11022036; 11076863; 11084299; 11132966; 11175348; 11179504; 11231585; 11254741; 11255227; 11302688; 11313979; 11343236; 11350925; 11389691; 11463845; 11477082; 11498536; 11559705; 11642719; 11684722; 11695244; 11700040; 11733969; 11741909; 11748297; 11751405; 11751903; 11756412; 11762751; 11781193; 11809712; 11815410; 11842244; 11860939; 11872638; 11877274; 11877298; 11877436; 11882322; 11893252; 11896572; 11908736; 11911463; 11931757; 11943869; 11953864; 11956602; 11968052; 11989975; 12015083; 12025230; 12036888; 12046058; 12052868; 12054510; 12054572; 12054658; 12055678; 12058028; 12111504; 12123335; 12138103; 12145325; 12151346; 12151347; 12151395; 12168821; 12204872; 12205674; 12354776; 12359245; 12361598; 12370305; 12379120; 12383116; 12384701; 12388558; 12392301; 12393707; 12396717; 12400017; 12407107; 12412576; 12417334; 12417722; 12429910; 12431783; 12431987; 12434183; 12441075; 12457968; 12459877; 12474524; 12477932; 12485998; 12513833; 12517948; 12519780; 12522211; 12527941; 12531694; 12545156; 12573582; 12599217; 12612054; 12642873; 12644083; 12651158; 12665570; 12665584; 12680256; 12681289; 12690110; 12698196; 12699883; 12705898; 12706118; 12716906; 12727210; 12727815; 12748190; 12771291; 12781424; 12782595; 12800980; 12809883; 12810668; 12820963; 12825853; 12839982; 12841870; 12847090; 12853982; 12855666; 12867429; 12884030; 12885947; 12890637; 12897156; 12930830; 12930846; 12931225; 12936910; 12947099; 12949733; 12963997; 12964161; 12970742; 13678583; 14504476; 14572899; 14574404; 14580260; 14592451; 14597617; 14607331; 14607337; 14628083; 14633995; 14637149; 14642618; 14647439; 14677632; 14702288; 14712207; 14715257; 14719078; 14726710; 14738489; 14744793; 14751560; 14759525; 14761977; 14762439; 14764039; 14981901; 15001356; 15003515; 15014036; 15016552; 15024057; 15033443; 15036662; 15059516; 15060836; 15069711; 15081425; 15082782; 15084259; 15094066; 15107488; 15111320; 15122333; 15142382; 15149599; 15161699; 15169570; 15171713; 15173090; 15179054; 15181148; 15184045; 15184659; 15190207; 15201954; 15201979; 15226418; 15232106; 15240512; 15251435; 15286705; 15291355; 15297421; 15302882; 15309711; 15317660; 15321712; 15340083; 15342418; 15347670; 15367606; 15371422; 15371446; 15378017; 15386430; 15389598; 15456784; 15474507; 15475071; 15489334; 15489336; 15492264; 15497017; 15509808; 15510615; 15528212; 15546622; 15555546; 15557281; 15574338; 15576034; 15580267; 15582998; 15592362; 15598783; 15606307; 15609309; 15616584; 15623356; 15645120; 15647383; 15660129; 15664193; 15665589; 15665816; 15671036; 15674334; 15674341; 15690394; 15694358; 15694838; 15695403; 15708847; 15709169; 15710329; 15716956; 15735102; 15736438; 15738655; 15743033; 15743834; 15746092; 15750619; 15752352; 15753078; 15756520; 15763542; 15764647; 15765097; 15767448; 15776189; 15780936; 15780937; 15798220; 15807891; 15817070; 15819981; 15839202; 15840769; 15856024; 15866118; 15878916; 15880444; 15880942; 15890360; 15893728; 15905168; 15936816; 15942645; 15944261; 15960923; 15964852; 15964998; 15965232; 15972853; 15975933; 15989967; 16009130; 16012716; 16014176; 16054204; 16078010; 16080520; 16081043; 16082198; 16082224; 16091736; 16111738; 16122475; 16135801; 16142303; 16142340; 16149052; 16150942; 16169070; 16182613; 16189514; 16191374; 16199872; 16200730; 16214366; 16226712; 16243918; 16248979; 16254341; 16256947; 16262255; 16276353; 16280359; 16283431; 16287849; 16288006; 16289646; 16343435; 16344056; 16344560; 16364249; 16381901; 16394138; 16432835; 16434701; 16464125; 16474839; 16479163; 16480585; 16507767; 16510448; 16514663; 16533812; 16551699; 16554660; 16580634; 16581770; 16616141; 16678112; 16705171; 16712793; 16718778; 16723699; 16735508; 16765349; 16775840; 16777994; 16782892; 16803887; 16804724; 16804901; 16818630; 16831599; 16835890; 16837471; 16867219; 16951143; 16952553; 16953367; 16964243; 16982699; 17008550; 17014852; 17016640; 17050675; 17054950; 17055654; 17059853; 17062672; 17072949; 17074759; 17079232; 17079872; 17080297; 17080554; 17108107; 17109628; 17115032; 17130157; 17158927; 17172426; 17172832; 17188136; 17203174; 17214516; 17239344; 17273559; 17283049; 17284535; 17286201; 17292858; 17293600; 17293864; 17294043; 17300726; 17303651; 17317670; 17325029; 17337084; 17339230; 17351341; 17371838; 17373842; 17388661; 17409409; 17420273; 17431791; 17438369; 17443496; 17448597; 17460193; 17460194; 17465503; 17477906; 17498252; 17502456; 17513615; 17517622; 17536310; 17553787; 17556661; 17560543; 17585201; 17588519; 17592292; 17595776; 17606716; 17611661; 17616661; 17617120; 17619016; 17627285; 17634558; 17638911; 17641414; 17656367; 17662641; 17671089; 17671689; 17671727; 17679094; 17682292; 17684142; 17686574; 17692879; 17700068; 17721438; 17804869; 17855660; 17873065; 17885207; 17894409; 17911387; 17920036; 17925548; 17937105; 17941827; 17952758; 17972508; 18004740; 18024214; 18025091; 18035504; 18046503; 18049450; 18057010; 18067855; 18071305; 18086887; 18097575; 18156402; 18162471; 18162533; 18166158; 18172194; 18174230; 18174243; 18181833; 18202757; 18203777; 18205772; 18212054; 18215742; 18226366; 18230337; 18243530; 18251939; 18263614; 18278446; 18281511; 18281541; 18292944; 18298387; 18316600; 18334933; 18339845; 18348176; 18353898; 18358634; 18361427; 18374497; 18385383; 18385759; 18386236; 18400748; 18413741; 18427550; 18441278; 18451802; 18456456; 18458079; 18459109; 18463164; 18498065; 18507837; 18508827; 18509005; 18546941; 18559599; 18562088; 18563330; 18583941; 18593937; 18619950; 18632985; 18644983; 18655775; 18664350; 18694622; 18698027; 18703516; 18710616; 18713757; 18719376; 18765563; 18766473; 18782865; 18788572; 18790797; 18791688; 18794347; 18794348; 18798266; 18806827; 18818310; 18823025; 18829543; 18842998; 18850004; 18850315; 18852884; 18923142; 18941111; 18948188; 18949380; 18950845; 18979138; 18981726; 19001415; 19002614; 19033664; 19041685; 19058005; 19064572; 19091404; 19096232; 19102934; 19106607; 19122196; 19124506; 19125693; 19129183; 19134409; 19141585; 19159630; 19161984; 19176223; 19176530; 19177004; 19211566; 19211842; 19221506; 19223555; 19224585; 19237173; 19243472; 19249676; 19258477; 19262578; 19263441; 19269967; 19273588; 19275888; 19276188; 19276356; 19305381; 19321391; 19322021; 19322654; 19329556; 19330811; 19332548; 19339270; 19356250; 19364816; 19367277; 19383287; 19384944; 19407849; 19409758; 19435914; 19452712; 19453261; 19458054; 19465901; 19465904; 19481339; 19487575; 19491257; 19491398; 19502805; 19505915; 19513497; 19528229; 19536092; 19536131; 19538940; 19541625; 19550124; 19557639; 19560419; 19572978; 19578553; 19581932; 19609363; 19626602; 19628749; 19629483; 19635457; 19638413; 19643983; 19657064; 19657726; 19664338; 19667069; 19668373; 19670700; 19672706; 19686092; 19686743; 19692168; 19693773; 19704162; 19713748; 19723065; 19723093; 19723627; 19730150; 19732026; 19738611; 19750108; 19773351; 19789190; 19795398; 19798054; 19802676; 19818775; 19819988; 19820361; 19822666; 19840446; 19855935; 19860623; 19895794; 19910837; 19913121; 19914103; 19921577; 19923826; 19931389; 19935879; 19950226; 19955391; 19956635; 19956888; 19958256; 20006705; 20012529; 20018861; 20025780; 20039273; 20054616; 20062013; 20062063; 20067556; 20071335; 20079711; 20084294; 20086099; 20101223; 20102411; 20112071; 20126416; 20127253; 20139077; 20144199; 20154723; 20160708; 20164022; 20169278; 20179200; 20190802; 20190813; 20190815; 20193371; 20203690; 20204299; 20204303; 20211058; 20219912; 20301197; 20302655; 20303835; 20308078; 20331843; 20347598; 20349127; 20350217; 20351180; 20357201; 20363991; 20369488; 20370687; 20383190; 20388787; 20419447; 20428774; 20433229; 20444901; 20452353; 20453000; 20458559; 20466633; 20495378; 20504375; 20508865; 20510020; 20510146; 20524403; 20544840; 20583115; 20587660; 20598695; 20600642; 20605778; 20606006; 20622899; 20628086; 20644561; 20668328; 20701798; 20702488; 20732856; 20803550; 20813048; 20814747; 20818156; 20844987; 20858736; 20878079; 20890119; 20954283; 20955243; 20966541; 20979563; 21040707; 21046779; 21048031; 21054888; 21076409; 21087528; 21088000; 21098705; 21115898; 21124069; 21127431; 21139048; 21148311; 21165952; 21242961; 21245169; 21262772; 21288367; 21292770; 21308745; 21311948; 21325273; 21325288; 21325480; 21336720; 21342417; 21358637; 21368573; 21383005; 21402054; 21415438; 21415862; 21417953; 21419318; 21430453; 21437722; 21439247; 21443127; 21460037; 21475302; 21478095; 21511729; 21515331; 21526487; 21532626; 21546904; 21552210; 21554918; 21559393; 21561680; 21565979; 21567397; 21575583; 21608063; 21616632; 21628527; 21637851; 21637966; 21642427; 21652709; 21666704; 21677879; 21685936; 21704589; 21709715; 21725088; 21726628; 21729169; 21768776; 21769863; 21780161; 21791360; 21804532; 21820300; 21832049; 21858171; 21870644; 21875573; 21877955; 21887277; 21890473; 21900206; 21903579; 21906983; 21907315; 21918011; 21933447; 21933903; 21938741; 21956786; 21963094; 21976111; 21988832; 22001409; 22002313; 22009857; 22032898; 22101335; 22110135; 22117196; 22135025; 22147197; 22160829; 22172947; 22173494; 22190353; 22199295; 22206000; 22211246; 22214381; 22216119; 22217266; 22227369; 22244827; 22249270; 22262409; 22266309; 22277651; 22291954; 22296117; 22311974; 22320961; 22321971; 22371483; 22383522; 22392074; 22401965; 22427654; 22428663; 22446964; 22449259; 22469187; 22490020; 22503977; 22510560; 22511267; 22511763; 22514271; 22521293; 22547059; 22547681; 22555846; 22615960; 22634755; 22650359; 22662213; 22673765; 22675167; 22683204; 22684370; 22698403; 22711822; 22713239; 22732402; 22735451; 22751124; 22771799; 22797886; 22814028; 22814742; 22820403; 22828875; 22858377; 22859066; 22869584; 22956625; 22964432; 22980580; 22988851; 22995373; 22997714; 23000965; 23007394; 23007395; 23013131; 23026136; 23034899; 23037503; 23066038; 23085750; 23085987; 23128396; 23133524; 23146670; 23153928; 23158659; 23159636; 23160381; 23167335; 23167427; 23169665; 23178572; 23184467; 23187802; 23208500; 23210340; 23211592; 23213251; 23215027; 23219618; 23224600; 23231583; 23236067; 23238566; 23253087; 23255119; 23261596; 23261678; 23271730; 23275116; 23292332; 23306062; 23306186; 23318451; 23324739; 23329847; 23333058; 23349794; 23349842; 23359201; 23375502; 23376845; 23382584; 23383273; 23388456; 23399735; 23449391; 23455922; 23457546; 23458879; 23463857; 23536437; 23555284; 23577194; 23582783; 23590292; 23601845; 23602568; 23603558; 23618860; 23639631; 23645206; 23652278; 23665236; 23684928; 23715767; 23737759; 23745637; 23759594; 23780339; 23807750; 23832541; 23832542; 23856463; 23928864; 23949224; 24027428; 24074410; 24076166; 24082141; 24119401; 24123000; 24134839; 24217248; 24225749; 24244542; 24277930; 24291038; 24379070,,,,,,,,,,,,,,,OGG:3000001026,,,,,,,"cyclin-dependent kinase inhibitor 1A (p21, Cip1)",,,,,,,,,,,,,Other designations: CDK-interacting protein 1|CDK-interaction protein 1|DNA synthesis inhibitor|cyclin-dependent kinase inhibitor 1|melanoma differentiation associated protein 6|wild-type p53-activated fragment 1,,CDKN1A,,,,,,,,,,,,,,,,,,,,,,,1026,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,CDKN1A,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0001510,Rap2C,,,false,,,http://purl.obolibrary.org/obo/IMR_0001507,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001510,,,,,,,,,,,,,,,,,,,,,,Rap2C,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006520,cellular amino acid metabolic process,amino acid and derivative metabolism|cellular amino acid metabolism|cellular amino acid and derivative metabolic process|amino acid metabolic process,"The chemical reactions and pathways involving amino acids, carboxylic acids containing one or more amino groups, as carried out by individual cells.",false,,,http://purl.obolibrary.org/obo/GO_0044281,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways involving amino acids, carboxylic acids containing one or more amino groups, as carried out by individual cells.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_33709,,,,,,,,,,,,amino acid and derivative metabolism|cellular amino acid metabolism|cellular amino acid and derivative metabolic process|amino acid metabolic process,,,,,GO:0006520,,,,,,,,,,,,,,,,,,,,,,cellular amino acid metabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000000,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGMS_0000014,clinical finding,,"A representation that is either the output of a clinical history taking or a physical examination or an image finding, or some combination thereof.",false,,,http://purl.obolibrary.org/obo/TXPO_0001503,,,,,,,,,,,,,,,,,,,,,,"A representation that is either the output of a clinical history taking or a physical examination or an image finding, or some combination thereof.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,OGMS:0000014,,,,,,,,,,,,,,,,,,,,,,clinical finding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000377,STAT3 (mol),signal transducer and activator of transcription 3,,false,,,http://purl.obolibrary.org/obo/IMR_0000374,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,signal transducer and activator of transcription 3,,,,,IMR:0000377,,,,,,,,,,,,,,,,,,,,,,STAT3 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004255,alcohol intake [mitochondrial disorder],,"A moving process of alcohol from the outside to the inside of a body.
This entity is a specific course dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001224|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:25339807|PMID:29222479,,"A moving process of alcohol from the outside to the inside of a body.
This entity is a specific course dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004384,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004225|http://purl.obolibrary.org/obo/TXPO_0002004|http://purl.obolibrary.org/obo/TXPO_0004383|http://purl.obolibrary.org/obo/TXPO_0004121,,,,,,,,,,,TXPO:0004255,,,,,,,,,,,,,,,,,,,,,,alcohol intake [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004251,NfkB signaling (primitive) [Mitochondrial disorder],,"NfkB signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transduced with the regulation of transcription of target genes by NF-kappaB.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0000761|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:31623280|PMID:30894684|PMID:29222479,,"NfkB signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transduced with the regulation of transcription of target genes by NF-kappaB.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000382,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004279|http://purl.obolibrary.org/obo/TXPO_0004273|http://purl.obolibrary.org/obo/TXPO_0004271|http://purl.obolibrary.org/obo/TXPO_0004243,,,,,,,,,,,TXPO:0004251,,,,,,,,,,,,,,,,,,,,,,NfkB signaling (primitive) [Mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004252,p38 signaling (primitive) [mitochondrial disorder],,"p38 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the p38 (a Mitogen-Activated Protein Kinase).
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0004303|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:29222479,,"p38 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the p38 (a Mitogen-Activated Protein Kinase).
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004292,,,,,,http://purl.obolibrary.org/obo/TXPO_0004279|http://purl.obolibrary.org/obo/TXPO_0004271,,,,,,,,,,,TXPO:0004252,,,,,,,,,,,,,,,,,,,,,,p38 signaling (primitive) [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004250,NEAT1 inactivation [mitochondrial disorder],,"NEAT1 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the NEAT1 (nuclear paraspeckle assembly transcript 1) to be lower.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0004297,,,,,,,,,,,,,,,,,,,,PMID:30250064,,"NEAT1 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the NEAT1 (nuclear paraspeckle assembly transcript 1) to be lower.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004234,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004260|http://purl.obolibrary.org/obo/TXPO_0002230|http://purl.obolibrary.org/obo/TXPO_0004125,,,,,,,,,,,TXPO:0004250,,,,,,,,,,,,,,,,,,,,,,NEAT1 inactivation [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004257,binding to mtDNA by radicals [mitochondrial disorder]],,"Process of binding by which radicals interact with mtDNA (mitochondrial deoxyribonucleic acid).
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0004308|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:29222479,,"Process of binding by which radicals interact with mtDNA (mitochondrial deoxyribonucleic acid).
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004262,,,,,,,,,,,TXPO:0004257,,,,,,,,,,,,,,,,,,,,,,binding to mtDNA by radicals [mitochondrial disorder]],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004254,tumor necrosis factor production [mitochondrial disorder],,"The appearance of tumor necrosis factor due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/GO_0032640,,,,,,,,,,,,,,,,,,,,PMID:31623280|PMID:25339807|PMID:23299992|PMID:29222479,,"The appearance of tumor necrosis factor due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004381,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004225|http://purl.obolibrary.org/obo/TXPO_0004271|http://purl.obolibrary.org/obo/TXPO_0004350|http://purl.obolibrary.org/obo/TXPO_0001879|http://purl.obolibrary.org/obo/TXPO_0004383|http://purl.obolibrary.org/obo/TXPO_0004382|http://purl.obolibrary.org/obo/TXPO_0004121,,,,,,,,,,,TXPO:0004254,,,,,,,,,,,,,,,,,,,,,,tumor necrosis factor production [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004258,increasing free radical [mitochondrial disorder],,"Increasing free radical is a subtype of increasing quantity: A process that changes the amount of free radicals to be larger.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0001790,,,,,,,,,,,,,,,,,,,,PMID:29222479,,"Increasing free radical is a subtype of increasing quantity: A process that changes the amount of free radicals to be larger.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004278|http://purl.obolibrary.org/obo/TXPO_0004257,,,,,,,,,,,TXPO:0004258,,,,,,,,,,,,,,,,,,,,,,increasing free radical [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004259,release of DNA from mitochondria [mitochondria disorder],,"The process that results in the movement of mitochondriall DNA from the  mitochondria.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0001863,,,,,,,,,,,,,,,,,,,,PMID:30894684,,"The process that results in the movement of mitochondriall DNA from the  mitochondria.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004218|http://purl.obolibrary.org/obo/TXPO_0004253,,,,,,,,,,,TXPO:0004259,,,,,,,,,,,,,,,,,,,,,,release of DNA from mitochondria [mitochondria disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004253,TLR9 signaling [Mitochondrial disorder],,TLR9 signaling is a subtype of signaling [biological]: Any series of molecular signals generated as a consequence of binding to toll-like receptor 9. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.,false,,,http://purl.obolibrary.org/obo/TXPO_0004300|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:31623280|PMID:30894684,,TLR9 signaling is a subtype of signaling [biological]: Any series of molecular signals generated as a consequence of binding to toll-like receptor 9. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004235,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0034162,,,,,http://purl.obolibrary.org/obo/TXPO_0004251|http://purl.obolibrary.org/obo/TXPO_0004380,,,,,,,,,,,TXPO:0004253,,,,,,,,,,,,,,,,,,,,,,TLR9 signaling [Mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004256,interleukin-6 production [mitochondrial disorder],,"The appearance of interleukin-6 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0004304|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:31623280|PMID:23299992,,"The appearance of interleukin-6 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004224|http://purl.obolibrary.org/obo/TXPO_0004385,,,,,,,,,,,,,,,,,,,TXPO:0004256,,,,,,,,,,,,,,,,,,,,,,interleukin-6 production [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001586,Rab10,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001586,,,,,,,,,,,,,,,,,,,,,,Rab10,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000096,Cpq (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:54381|NCBI-Human-GeneID:10404|NCBI-Rat-GeneID:58952,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000010404,,,,,,,,,,,,,TXPO:1000096,,,,,,,,,,,,,,,,,,,,,,Cpq (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000090,Cdc34 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:216150|NCBI-Rat-GeneID:299602|NCBI-Human-GeneID:997,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000997,,,,,,,,,,,,,TXPO:1000090,,,,,,,,,,,,,,,,,,,,,,Cdc34 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000095,Commd8 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:27784|NCBI-Rat-GeneID:289603|NCBI-Human-GeneID:54951,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000054951,,,,,,,,,,,,,TXPO:1000095,,,,,,,,,,,,,,,,,,,,,,Commd8 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000093,Cnot11 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:52846|NCBI-Human-GeneID:55571|NCBI-Rat-GeneID:363221,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000055571,,,,,,,,,,,,,TXPO:1000093,,,,,,,,,,,,,,,,,,,,,,Cnot11 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000097,Cpt1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:25757|NCBI-Mouse-GeneID:12894|NCBI-Human-GeneID:1374,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001374,,,http://purl.obolibrary.org/obo/TXPO_0001967,,,,,,,,,,TXPO:1000097,,,,,,,,,,,,,,,,,,,,,,Cpt1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000092,Cenpw (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:689399|NCBI-Human-GeneID:387103|NCBI-Mouse-GeneID:66311,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000387103,,,,,,,,,,,,,TXPO:1000092,,,,,,,,,,,,,,,,,,,,,,Cenpw (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000091,Cdkn1a (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1026|NCBI-Rat-GeneID:114851|NCBI-Mouse-GeneID:12575,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001026,,,,,,,,,,,,,TXPO:1000091,,,,,,,,,,,,,,,,,,,,,,Cdkn1a (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000094,Ctnnb1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:84353|NCBI-Mouse-GeneID:12387|NCBI-Human-GeneID:1499,,,,,,,,,,,,,,,catenin beta 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:1000094,,,,,,,,,,,,,,,,,,,,,,Ctnnb1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000098,Cpt2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:12896|NCBI-Rat-GeneID:25413|NCBI-Human-GeneID:1376,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001376,,,,,,,,,,,,,TXPO:1000098,,,,,,,,,,,,,,,,,,,,,,Cpt2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001265,lipid storage in liver [Fibrosis],,"Lipid storage in liver is a subtype of lipid storage: The accumulation and maintenance in cells or tissues of lipids in the liver.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003742|http://purl.obolibrary.org/obo/TXPO_0001276,,,,,,,,,,,,,,,,,,,,,,"Lipid storage in liver is a subtype of lipid storage: The accumulation and maintenance in cells or tissues of lipids in the liver.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001265,,,,,,,,,,,,,,,,,,,,,,lipid storage in liver [Fibrosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001261,hypofunction of phospholipid export from lysosome,,Hypofunction of phospholipid export from lysosome is a subtype of hypofunction of export: A process that performs a decreased or insufficient phospholipid export from lysosome.,false,,,http://purl.obolibrary.org/obo/TXPO_0001911,,,,,,,,,,,,,,,,,,,,,,Hypofunction of phospholipid export from lysosome is a subtype of hypofunction of export: A process that performs a decreased or insufficient phospholipid export from lysosome.,,,http://purl.obolibrary.org/obo/TXPO_0003388,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001261,,,,,,,,,,,,,,,,,,,,,,hypofunction of phospholipid export from lysosome,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005764,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001260,forming a complex of CAD and phospholipid [Phospholipidosis (moderate) ],,"Forming a complex of CAD and phospholipid is a subtype of forming a complex of drugs and biological substance: A process that forms a complex consisiting phospholipids and CAD (Cationic Amphiphilic Drugs cationic amphiphile drug) in the lysosomal membrane, which causes structural change of the membrane. The degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (moderate).",false,,,http://purl.obolibrary.org/obo/TXPO_0003566,,,,,,,,,,,,,,,,,,,,,,"Forming a complex of CAD and phospholipid is a subtype of forming a complex of drugs and biological substance: A process that forms a complex consisiting phospholipids and CAD (Cationic Amphiphilic Drugs cationic amphiphile drug) in the lysosomal membrane, which causes structural change of the membrane. The degree is moderate.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (moderate).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001560,,,,,,http://purl.obolibrary.org/obo/TXPO_0003366,,,,,,,,,,,TXPO:0001260,,,,,,,,,,,,,,,,,,,,,,forming a complex of CAD and phospholipid [Phospholipidosis (moderate) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001262,hypofunction of phospholipid export from lysosome [Phospholipidosis (severe) ],,Hypofunction of phospholipid export from lysosome is a subtype of hypofunction of export: A process that performs a decreased or insufficient phospholipid export from lysosome. And the degree is severe. This process can constitute the course of Phospholipidosis (severe).,false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0001261,,,,,,,,,,,,,,,,,,,,,,Hypofunction of phospholipid export from lysosome is a subtype of hypofunction of export: A process that performs a decreased or insufficient phospholipid export from lysosome. And the degree is severe. This process can constitute the course of Phospholipidosis (severe).,,,http://purl.obolibrary.org/obo/TXPO_0000200,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003435,,,,,,,,,,,TXPO:0001262,,,,,,,,,,,,,,,,,,,,,,hypofunction of phospholipid export from lysosome [Phospholipidosis (severe) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001264,hyperfunction of glycerophospholipid synthesis gene expression,,Hyperfunction of glycerophospholipid synthesis gene expression is a subtype of hyperfunction of phospholipid synthesis gene expression: A process that performs an excesssive glycerophospholipid synthestic gene expression.,false,,,http://purl.obolibrary.org/obo/TXPO_0001726,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of glycerophospholipid synthesis gene expression is a subtype of hyperfunction of phospholipid synthesis gene expression: A process that performs an excesssive glycerophospholipid synthestic gene expression.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001264,,,,,,,,,,,,,,,,,,,,,,hyperfunction of glycerophospholipid synthesis gene expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001266,carbohydrate storage in liver [Hypertrophy],,"Carbohydrate storage in liver is a subtype of carbohydrate storage: The accumulation in hepatocytes of carbohydrates.
This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy.",false,,,http://purl.obolibrary.org/obo/TXPO_0003279|http://purl.obolibrary.org/obo/TXPO_0001235,,,,,,,,,,,,,,,,,,,,,,"Carbohydrate storage in liver is a subtype of carbohydrate storage: The accumulation in hepatocytes of carbohydrates.
This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003297,,,,,,,,,,,TXPO:0001266,,,,,,,,,,,,,,,,,,,,,,carbohydrate storage in liver [Hypertrophy],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001269,malfunctioning of TCA cycle,,Malfunctioning of TCA cycle is a subtype of malfunctioning of metabolism: A process that cannot perform a tricarboxylic acid cycle appropriately or cannot realize it at all.,false,,,http://purl.obolibrary.org/obo/TXPO_0002130,,,,,,,,,,,,,,,,,,,,,,Malfunctioning of TCA cycle is a subtype of malfunctioning of metabolism: A process that cannot perform a tricarboxylic acid cycle appropriately or cannot realize it at all.,,,http://purl.obolibrary.org/obo/GO_0006099,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001269,,,,,,,,,,,,,,,,,,,,,,malfunctioning of TCA cycle,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001263,changing balance of phospholipid metabolism,,Changing balance of phospholipid metabolism is a subtype of changing balance: A process that changes the balance between phospholipid anabolism and catabolism.,false,,,http://purl.obolibrary.org/obo/TXPO_0001847,,,,,,,,,,,,,,,,,,,,,,Changing balance of phospholipid metabolism is a subtype of changing balance: A process that changes the balance between phospholipid anabolism and catabolism.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001263,,,,,,,,,,,,,,,,,,,,,,changing balance of phospholipid metabolism,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001268,malfunctioning of TCA cycle [Fibrosis],,"Malfunctioning of TCA cycle is a subtype of malfunctioning of metabolism: A process that cannot perform a tricarboxylic acid cycle appropriately or cannot realize it at all.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003742|http://purl.obolibrary.org/obo/TXPO_0001269,,,,,,,,,,,,,,,,,,,,,,"Malfunctioning of TCA cycle is a subtype of malfunctioning of metabolism: A process that cannot perform a tricarboxylic acid cycle appropriately or cannot realize it at all.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001305,,,,,,,,,,,TXPO:0001268,,,,,,,,,,,,,,,,,,,,,,malfunctioning of TCA cycle [Fibrosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001267,moving lipid to the hepatocyte [lipidosis],,"Moving lipid to the hepatocyte is a subtype of moving A to the inside of B: A process of the movement of lipid into a hepatocyte.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001270|http://purl.obolibrary.org/obo/TXPO_0001720,,,,,,,,,,,,,,,,,,,,,,"Moving lipid to the hepatocyte is a subtype of moving A to the inside of B: A process of the movement of lipid into a hepatocyte.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001049,,,,,,,,,,,,,,,,,,TXPO:0001267,,,,,,,,,,,,,,,,,,,,,,moving lipid to the hepatocyte [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100602,CDK6(mol),Cell division protein kinase 6 (EC 2.7.1.-)(Serine/threonine-protein kinase) (PLSTIRE)(CDK6)|Serine/threonine protein kinase PLSTIRE|Cdk6|CRK2|Cell division protein kinase 6,,false,,,http://purl.obolibrary.org/obo/TXPO_0003241,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0010667,Cell division protein kinase 6 (EC 2.7.1.-)(Serine/threonine-protein kinase) (PLSTIRE)(CDK6)|Serine/threonine protein kinase PLSTIRE|Cdk6|CRK2|Cell division protein kinase 6,,,,,IMR:0100602,,,,,,,,,,,,,,,,,,,,,,CDK6(mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_134728,mebanazine,mebanazine hydrochloride|mebanazine monosulfate|mebanazine sulfate|mebanazine monohydrochloride|mebanazine monooxalate|ICI-31397|actomol|mebanazine oxalate,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:65-64-5|Drug_Central:4865,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,mebanazine hydrochloride|mebanazine monosulfate|mebanazine sulfate|mebanazine monohydrochloride|mebanazine monooxalate|ICI-31397|actomol|mebanazine oxalate,,,,,,,,,,,,,,,,,,,,,CHEBI:134728,,,,mebanazine,,CHEBI:134728,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000259,MAPKK,MAP kinase kinase|MAPK kinase,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,GO:0004708,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002002,,,,,MAP kinase kinase|MAPK kinase,,,,,IMR:0000259,,,,,,,,,,,,,,,,,,,,,,MAPKK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004383,inducible nitric oxide synthase production [mitochondrial disorder],,"iNOS production is a subtype of protein production: A process that makes existent of iNOS ( inducible nitric oxide synthase) due to biosynthesis, secretion, or membrane trafficking, resulting in an increase in its levels.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0004884,,,,,,,,,,,,,,,,,,,,PMID:25339807|PMID:23299992,,"iNOS production is a subtype of protein production: A process that makes existent of iNOS ( inducible nitric oxide synthase) due to biosynthesis, secretion, or membrane trafficking, resulting in an increase in its levels.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004885,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004718|http://purl.obolibrary.org/obo/TXPO_0004717,,,,,,,,,,,TXPO:0004383,,,,,,,,,,,,,,,,,,,,,,inducible nitric oxide synthase production [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004389,fialuridine [mitochondrial disorder],FIAU,,false,,,http://purl.obolibrary.org/obo/TXPO_0004312|http://purl.obolibrary.org/obo/TXPO_0004972,,,,,,,,,,,,,,,,,,,,Wikipedia:Fialuridine|PMID:21145849,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,FIAU,,,,,TXPO:0004389,,,,,,,,,,,,,,,,,,,,,,fialuridine [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004384,alcohol [mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004312|http://purl.obolibrary.org/obo/CHEBI_30879,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,HOR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004384,,,,,,,,,,,,,,,,,,,,,,alcohol [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,O[*],,,,,
http://purl.obolibrary.org/obo/TXPO_0004381,TNFΑ (canonical)[mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000374|http://purl.obolibrary.org/obo/TXPO_0004293,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:21926|NCBI-Rat-GeneID:24835|NCBI-Human-GeneID:7124,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004381,,,,,,,,,,,,,,,,,,,,,,TNFΑ (canonical)[mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004386,didanosine [mitochondrial disorder],ddI,,false,,,http://purl.obolibrary.org/obo/CHEBI_490877|http://purl.obolibrary.org/obo/TXPO_0004312,,,,,,,,,,,,,,,,,,,,PMID:21145849|Wikipedia:Didanosine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ddI,,,,,TXPO:0004386,,,,,,,,,,,,,,,,,,,,,,didanosine [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004385,IL-6(canonical) [mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/IMR_0000010|http://purl.obolibrary.org/obo/TXPO_0004293,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:3569|NCBI-Mouse-GeneID:16193|NCBI-Rat-GeneID:24498|PMID:23299992,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004385,,,,,,,,,,,,,,,,,,,,,,IL-6(canonical) [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004387,zidovudine [mitochondrial disorder],AZT,,false,,,http://purl.obolibrary.org/obo/CHEBI_10110|http://purl.obolibrary.org/obo/TXPO_0004312,,,,,,,,,,,,,,,,,,,,PMID:21145849|Wikipedia:Zidovudine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,AZT,,,,,TXPO:0004387,,,,,,,,,,,,,,,,,,,,,,zidovudine [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004388,stavudine [mitochondrial disorder],,,false,,,http://purl.obolibrary.org/obo/CHEBI_63581|http://purl.obolibrary.org/obo/TXPO_0004312,,,,,,,,,,,,,,,,,,,,PMID:21145849|Wikipedia:Stavudine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004388,,,,,,,,,,,,,,,,,,,,,,stavudine [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004382,HIF1A activation [mitochondrial disorder],,"HIF1A activation is a subtype of molecular activation: A process that  changes the activity of the HIF1A (hypoxia inducible factor 1 subunit alpha) to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0004612,,,,,,,,,,,,,,,,,,,,PMID:25339807|PMID:23299992,,"HIF1A activation is a subtype of molecular activation: A process that  changes the activity of the HIF1A (hypoxia inducible factor 1 subunit alpha) to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004614,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000869,,,,,,,,,,,TXPO:0004382,,,,,,,,,,,,,,,,,,,,,,HIF1A activation [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004380,inflammasome activation [mitochondrial disorder],,"Inflammasome activation is a subtype of activating: A process that changes the activity of the inflammasome to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001107|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:31623280|Reactome: R-HSA-844456.2,,"Inflammasome activation is a subtype of activating: A process that changes the activity of the inflammasome to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004925,,,,,,http://purl.obolibrary.org/obo/TXPO_0004271,,,,,,,,,,,TXPO:0004380,,,,,,,,,,,,,,,,,,,,,,inflammasome activation [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006109,regulation of carbohydrate metabolic process,regulation of carbohydrate metabolism,"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving carbohydrates.",false,,,http://purl.obolibrary.org/obo/GO_0019222,,,,,,,,,,,,,,,,,,,,,,"Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving carbohydrates.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,regulation of carbohydrate metabolism,,,,,GO:0006109,,,,,,,,,,,,,,,,,,,,,,regulation of carbohydrate metabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005975,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010016,eIF,eukaryotic initiation factor,Translation initiation in eukaryotes is an intricate process requiring at least 11 eukaryotic initiation factors (eIFs).,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,Translation initiation in eukaryotes is an intricate process requiring at least 11 eukaryotic initiation factors (eIFs).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003685,,,,,eukaryotic initiation factor,,,,,IMR:0010016,,,,,,,,,,,,,,,,,,,,,,eIF,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001372,Ci/Gli,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,,,,,,IMR:0001372,,,,,,,,,,,,,,,,,,,,,,Ci/Gli,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000391,IRF-5,,,false,,,http://purl.obolibrary.org/obo/IMR_0000386,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000391,,,,,,,,,,,,,,,,,,,,,,IRF-5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003921,AMPK activation [Ground glass appearance],,"AMPK activation is a subtype of molecular activation: A process that changes the activity of the AMPK (AMP-activated protein kinase) to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/TXPO_0000405,,,,,,,,,,,,,,,,,,,,PMID:25500869|ISBN:0071769234|PMID:22815988,,"AMPK activation is a subtype of molecular activation: A process that changes the activity of the AMPK (AMP-activated protein kinase) to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003922,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000944,,,,http://purl.obolibrary.org/obo/TXPO_0003948,,,,,,,,,,,,,,,,,,,TXPO:0003921,,,,,,,"AMPK is sensitive to energy charge, which is activated by an increase in the ratio of AMP/ATP.",,,,,,,,,,,,,,,AMPK activation [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003924,FOXO1 - inactive form (canonical)[Ground glass appearance],,,false,,,http://purl.obolibrary.org/obo/IMR_0002805|http://purl.obolibrary.org/obo/TXPO_0003923,,,,,,,,,,,,,,,,,,,,ISBN:0071769234,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0002805,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0002355,,,,,,,,,,,,,,TXPO:0003924,,,,,,,,,,,,,,,,,,,,,,FOXO1 - inactive form (canonical)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003923,FOXO1 (canonical)[Ground glass appearance],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000472|http://purl.obolibrary.org/obo/IMR_0002805,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:84482|NCBI-Human-GeneID:2308|NCBI-Mouse-GeneID:56458|ISBN:0071769234,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0002805,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003947,,,,,,,,,,TXPO:0003923,,,,,,,,,,,,,,,,,,,,,,FOXO1 (canonical)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003920,hypofunction of gluconeogenesis,,Hypofunction of gluconeogenesis is a subtype of hypofunction of biosynthesis: A process that performs a decreased or insufficient gluconeogenesis.,false,,,http://purl.obolibrary.org/obo/TXPO_0001910,,,,,,,,,,,,,,,,,,,,,,Hypofunction of gluconeogenesis is a subtype of hypofunction of biosynthesis: A process that performs a decreased or insufficient gluconeogenesis.,,,http://purl.obolibrary.org/obo/GO_0006094,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003920,,,,,,,,,,,,,,,,,,,,,,hypofunction of gluconeogenesis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003929,gluconeogenesis inhibitor role,,A role played by the entity which inhibits gluconeogenesis.,false,,,http://purl.obolibrary.org/obo/TXPO_0003949,,,,,,,http://purl.obolibrary.org/obo/GO_0006094,,,,,,,,,,,,,,,A role played by the entity which inhibits gluconeogenesis.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003929,,,,,,,,,,,,,,,,,,,,,,gluconeogenesis inhibitor role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003926,negative regulation of gluconeogenesis [Ground glass appearance],,"Any process that stops, prevents, or reduces the frequency, rate or extent of gluconeogenesis.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001728|http://purl.obolibrary.org/obo/GO_0045721,,,,,,,,,,,,,,,,,,,,ISBN:0071769234,,"Any process that stops, prevents, or reduces the frequency, rate or extent of gluconeogenesis.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003923,,,,http://purl.obolibrary.org/obo/TXPO_0003924,http://purl.obolibrary.org/obo/TXPO_0003936|http://purl.obolibrary.org/obo/TXPO_0003942|http://purl.obolibrary.org/obo/TXPO_0003919,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003954|http://purl.obolibrary.org/obo/TXPO_0000977,,,,,,,,,,,TXPO:0003926,,,,,,,,,,,,,,,,,,,,,,negative regulation of gluconeogenesis [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003922,phenobarbital - gluconeogenic inhibitor [Ground glass appearance],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001524,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003929,,,,,,,,,,TXPO:0003922,,,,,,,,,,,,,,,,,,,,,,phenobarbital - gluconeogenic inhibitor [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003925,negative regulation of ATP consuming via CAR activation (sustained) [Ground glass appearance],,"Any process that stops, prevents, or reduces the frequency, rate or extent of an ATP consuming process in the course of the ground glass degeneration via Constitutive Androstane Receptor (CAR). This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) .",false,,,http://purl.obolibrary.org/obo/TXPO_0003954,,,,,,,,,,,,,,,,,,,,PMID:22460906,,"Any process that stops, prevents, or reduces the frequency, rate or extent of an ATP consuming process in the course of the ground glass degeneration via Constitutive Androstane Receptor (CAR). This process persists for a certain period or over a long period.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) .",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003932,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003952|http://purl.obolibrary.org/obo/TXPO_0001028,,,,,,,,,,,TXPO:0003925,,,,,,,,,,,,,,,,,,,,,,negative regulation of ATP consuming via CAR activation (sustained) [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003927,GLUCOSE-6- phosphatase - gluconeogenic (canonical)[Ground glass appearance],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001797,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003928,,,,,,,,,,TXPO:0003927,,,,,,,,,,,,,,,,,,,,,,GLUCOSE-6- phosphatase - gluconeogenic (canonical)[Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003928,gluconeogenic factor,,A role played by the entity involved in gluconeogenesis.,false,,,http://purl.obolibrary.org/obo/TXPO_0003712,,,,,,,,,,,,,,,,,,,,,,A role played by the entity involved in gluconeogenesis.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003928,,,,,,,,,,,,,,,,,,,,,,gluconeogenic factor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_23965,estradiol,,"A 3-hydroxy steroid that is estra-1,3,5(10)-triene substituted by hydroxy groups at positions 3 and 17.",false,,,http://purl.obolibrary.org/obo/CHEBI_35341,,,,,,,,,,,,,,,,,,,,Wikipedia:Estradiol,,"A 3-hydroxy steroid that is estra-1,3,5(10)-triene substituted by hydroxy groups at positions 3 and 17.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:23965,,,,,,,InChIKey=VOXZDWNPVJITMN-WKUFJEKOSA-N,,,,,,,,,,,,,,,estradiol,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000253935,ANGPTL5,,Other designations: angiopoietin-like protein 5|angiopoietin-related protein 5,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,11,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,angiopoietin-like 5,,,11q22.1,,,,,,,,,,,,,,,,GO_0005576 (EC: IEA),,,,,,,,,PMID:12477932; 12624729; 12975309; 15489334; 21559522,,,,,,,,,,,,,,,OGG:3000253935,,,,,,,angiopoietin-like 5,,,,,,,,,,,,,Other designations: angiopoietin-like protein 5|angiopoietin-related protein 5,,ANGPTL5,,,,,,,,,,,,,,,,,,,,,,,253935,UNQ5795/PRO19600,,,,,,,9606,,,,,,,,,,,,,,,,,,,ANGPTL5,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000001831,TSC22D3,,"Other designations: DSIP-immunoreactive leucine zipper protein|DSIP-immunoreactive peptide|TSC-22 related protein|TSC-22-like protein|TSC-22-related protein|TSC22 domain family protein 3|delta sleep inducing peptide, immunoreactor|delta sleep-inducing peptide immunoreactor|glucocorticoid-induced leucine zipper protein",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,GILZ|TSC-22R|DIP|hDIP|DSIPI,,,,,,,,,,,,X,,,,,,HGNC:3051|Ensembl:ENSG00000157514|HPRD:04266|Vega:OTTHUMG00000022168|MIM:300506,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"TSC22 domain family, member 3",,,Xq22.3,,,,,,,,,,,,,,,,"GO_0000122 (EC: IEA); GO_0003700 (EC: IEA); GO_0005634 (EC: IEA); GO_0005829 (EC: TAS); GO_0006355 (EC: TAS, PMID: 8982256); GO_0006970 (EC: IEA); GO_0007589 (EC: IEA); GO_0034220 (EC: TAS); GO_0043426 (EC: IEA); GO_0048642 (EC: IEA); GO_0055085 (EC: TAS); GO_0070236 (EC: IEA)",,,,,,,,,PMID: 8619474; 8982256; 9110174; 11230166; 11313722; 11397794; 11468175; 11688842; 12391160; 12393603; 12477932; 12671681; 14702039; 15031210; 15489334; 15705665; 16189514; 16196087; 16216878; 17356131; 17956870; 18468809; 18499442; 19260870; 19322201; 19380724; 19814803; 19875485; 20018851; 20124407; 20671745; 20947508; 20970683; 21512757; 21556028; 21726808; 21750716; 21804606; 21906983; 21988832; 22137507; 22539300; 22832853; 23440419; 23494955; 23573276; 23650723; 23729444,,,,,,,,,,,,,,,OGG:3000001831,,,,,,,"TSC22 domain family, member 3",,,,,,,,,,,,,"Other designations: DSIP-immunoreactive leucine zipper protein|DSIP-immunoreactive peptide|TSC-22 related protein|TSC-22-like protein|TSC-22-related protein|TSC22 domain family protein 3|delta sleep inducing peptide, immunoreactor|delta sleep-inducing peptide immunoreactor|glucocorticoid-induced leucine zipper protein",,TSC22D3,,,,,,,,,,,,,,,,,,,,,,,1831,RP13-364K23.1,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,TSC22D3,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0001094,Elk-1,,,false,,,http://purl.obolibrary.org/obo/IMR_0000397,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001094,,,,,,,,,,,,,,,,,,,,,,Elk-1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000550,cause,,,false,,,http://purl.obolibrary.org/obo/TXPO_0000553,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000550,,,,,,,,,,,,,,,,,,,,,,cause,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000557,transport signal sorting of NPC1 / NPC2,,Sorting transport signal of NPC1 / NPC2 is a subtype of extractng: A process that obtains a necessary NPC1/NPC2 transport signal.,false,,,http://purl.obolibrary.org/obo/TXPO_0001534,,,,,,,,,,,,,,,,,,,,,,Sorting transport signal of NPC1 / NPC2 is a subtype of extractng: A process that obtains a necessary NPC1/NPC2 transport signal.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000557,,,,,,,,,,,,,,,,,,,,,,transport signal sorting of NPC1 / NPC2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000551,result,,,false,,,http://purl.obolibrary.org/obo/TXPO_0000554,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000551,,,,,,,,,,,,,,,,,,,,,,result,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000556,negative regulation of phospholipase C mediated phospholipid degradation,,"Negative regulation of phospholipase C mediated phospholipid degradation is a subtype of negative regulation of phospholipid degradation: A process that stops, prevents, or reduces the frequency, rate or extent of phospholipase C mediated phospholipid degradation.",false,,,http://purl.obolibrary.org/obo/TXPO_0001256,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of phospholipase C mediated phospholipid degradation is a subtype of negative regulation of phospholipid degradation: A process that stops, prevents, or reduces the frequency, rate or extent of phospholipase C mediated phospholipid degradation.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000556,,,,,,,,,,,,,,,,,,,,,,negative regulation of phospholipase C mediated phospholipid degradation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000554,downstream,,,false,,,http://purl.obolibrary.org/obo/TXPO_0001299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000554,,,,,,,,,,,,,,,,,,,,,,downstream,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000553,upstream,,,false,,,http://purl.obolibrary.org/obo/TXPO_0001299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000553,,,,,,,,,,,,,,,,,,,,,,upstream,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000555,leaking content from cell [Phospholipidosis],,"Leaking content from cell is a subtype of leaking: A process that leaks contents from the cell.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000526|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Leaking content from cell is a subtype of leaking: A process that leaks contents from the cell.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004113,,,,,,,,,,,TXPO:0000555,,,,,,,,,,,,,,,,,,,,,,leaking content from cell [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000558,positive regulation of macrophage derived foam cell differentiation [Phospholipidosis (severe)],,"Any process that increases the rate, frequency or extent of macrophage derived foam cell differentiation. Macrophage derived foam cell differentiation is the process in which a macrophage acquires the specialized features of a foam cell.  The degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0004085,,,,,,,,,,,,,,,,,,,,,,"Any process that increases the rate, frequency or extent of macrophage derived foam cell differentiation. Macrophage derived foam cell differentiation is the process in which a macrophage acquires the specialized features of a foam cell.  The degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000077|http://purl.obolibrary.org/obo/TXPO_0004086,,,,,,http://purl.obolibrary.org/obo/TXPO_0004154,,,,,,,,,,,TXPO:0000558,,,,,,,,,,,,,,,,,,,,,,positive regulation of macrophage derived foam cell differentiation [Phospholipidosis (severe)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000559,phospholipase inhibitor role,,A role played by the entity that inhibits the catalysis of the hydrolysis of a phospholipid.,false,,,http://purl.obolibrary.org/obo/CHEBI_76759,,,,,,,,,,,,,,,,,,,,,,A role played by the entity that inhibits the catalysis of the hydrolysis of a phospholipid.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000559,,,,,,,,,,,,,,,,,,,,,,phospholipase inhibitor role,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000552,changing length,,Changing length is a subtype of changing quality: A process that changes the length of the object.,false,,,http://purl.obolibrary.org/obo/TXPO_0000415,,,,,,,,,,,,,,,,,,,,,,Changing length is a subtype of changing quality: A process that changes the length of the object.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000552,,,,,,,,,,,,,,,,,,,,,,changing length,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0000425,pexophagy,,The selective autophagy process in which a peroxisome is degraded by macroautophagy.,false,,,http://purl.obolibrary.org/obo/GO_0030242,,,,,,,,,,,,,,,,,,,,,,The selective autophagy process in which a peroxisome is degraded by macroautophagy.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005777,,,,,,,,,,,,,,,,,,,,,,,GO:0000425,,,,,,,,,,,,,,,,,,,,,,pexophagy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0000422,autophagy of mitochondrion,mitochondrion autophagy|Wikipedia:Mitophagy,The autophagic process in which mitochondria are delivered to the vacuole and degraded in response to changing cellular conditions.,false,,,http://purl.obolibrary.org/obo/GO_0006914,,,,,,,,,,,,,,,,,,,,,,The autophagic process in which mitochondria are delivered to the vacuole and degraded in response to changing cellular conditions.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,,,,,,,,,,,mitochondrion autophagy|Wikipedia:Mitophagy,,,,,GO:0000422,,,,,,,,,,,,,,,,,,,,,,autophagy of mitochondrion,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0000423,mitohagy,,Degradation of a mitochondrion by macroautophagy.,false,,,http://purl.obolibrary.org/obo/GO_0000422,,,,,,,,,,,,,,,,,,,,PMID:22406072,,Degradation of a mitochondrion by macroautophagy.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,,,,,,,,,,,,,,,,GO:0000423,,,,,,,,,,,,,,,,,,,,,,mitohagy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_50514,vasoconstrictor agent,,Drug used to cause constriction of the blood vessels.,false,,,http://purl.obolibrary.org/obo/CHEBI_35554,,,,,,,,,,,,,,,,,,,,,,Drug used to cause constriction of the blood vessels.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:50514,,,,,,,,,,,,,,,,,,,,,,vasoconstrictor agent,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000009648,GCC2,,"Other designations: 185 kDa Golgi coiled-coil protein|CLL-associated antigen KW-11|CTCL tumor antigen se1-1|GCC protein, 185-kD|GRIP and coiled-coil domain-containing protein 2|Golgi coiled-coil protein GCC185|Ran-binding protein 2-like 4|renal carcinoma antigen NY-REN-53",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,GCC185|REN53|RANBP2L4,,,,,,,,,,,,2,,,,,,Vega:OTTHUMG00000153214|HGNC:23218|MIM:612711|HPRD:11001|Ensembl:ENSG00000135968,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,GRIP and coiled-coil domain containing 2,,,2q12.3,,,,,,,,,,,,,,,,"GO_0000042 (EC: IEA); GO_0005515 (EC: IPI, PMID: 16885419); GO_0005634 (EC: IDA); GO_0005737 (EC: IDA); GO_0005794 (EC: IDA); GO_0005802 (EC: IDA, PMID: 16885419); GO_0006622 (EC: IMP, PMID: 16885419); GO_0016020 (EC: IEA); GO_0031023 (EC: IMP, PMID: 17543864); GO_0034067 (EC: IMP, PMID: 16885419); GO_0034453 (EC: IMP, PMID: 17543864); GO_0034499 (EC: IMP, PMID: 16885419); GO_0042147 (EC: IMP, PMID: 17488291); GO_0042802 (EC: IPI, PMID: 18243103); GO_0043001 (EC: IMP, Qualifier: NOT, PMID: 16885419); GO_0070861 (EC: IMP, PMID: 17488291); GO_0071955 (EC: IMP, PMID: 17488291); GO_0090161 (EC: IMP, PMID: 16885419)",,,,,,,,,PMID: 8889548; 9205841; 10508479; 11149944; 12200376; 12446665; 12477932; 12972563; 14702039; 15489334; 15522892; 15654769; 15815621; 16344560; 16885419; 16964243; 17488291; 17543864; 18029348; 18243103; 18946081; 19013454; 19615732; 19703403; 21139048; 21875948; 21890473; 22159419; 22939629; 23000965,,,,,,,,,,,,,,,OGG:3000009648,,,,,,,GRIP and coiled-coil domain containing 2,,,,,,,,,,,,,"Other designations: 185 kDa Golgi coiled-coil protein|CLL-associated antigen KW-11|CTCL tumor antigen se1-1|GCC protein, 185-kD|GRIP and coiled-coil domain-containing protein 2|Golgi coiled-coil protein GCC185|Ran-binding protein 2-like 4|renal carcinoma antigen NY-REN-53",,GCC2,,,,,,,,,,,,,,,,,,,,,,,9648,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,GCC2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000009641,IKBKE,,Other designations: I-kappa-B kinase epsilon|IKK-epsilon|IKK-related kinase epsilon|inducible I kappa-B kinase|inducible IkappaB kinase|inhibitor of nuclear factor kappa-B kinase subunit epsilon,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,IKK-i|IKK-E|IKKE|IKKI,,,,,,,,,,,,1,,,,,,HPRD:05442|MIM:605048|Vega:OTTHUMG00000036346|HGNC:14552|Ensembl:ENSG00000143466,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase epsilon",,,1q32.1,,,,,,,,,,,,,,,,"GO_0002224 (EC: TAS); GO_0002756 (EC: TAS); GO_0004704 (EC: IDA, PMID:10882136); GO_0005515 (EC: IPI, PMID:14743216); GO_0005524 (EC: IEA); GO_0005634 (EC: IDA); GO_0005730 (EC: IDA, Qualifier: NOT); GO_0005737 (EC: IDA); GO_0005829 (EC: TAS); GO_0006468 (EC: IDA, PMID:10882136); GO_0006955 (EC: NAS, PMID:10421793); GO_0008384 (EC: IEA); GO_0008630 (EC: IMP); GO_0010008 (EC: TAS); GO_0016605 (EC: IDA); GO_0032480 (EC: TAS); GO_0034138 (EC: TAS); GO_0034142 (EC: TAS); GO_0035666 (EC: TAS); GO_0038061 (EC: IDA, PMID:10882136); GO_0043123 (EC: IEP, PMID:12761501); GO_0045087 (EC: TAS)",,,,,,,,,PMID:8590280; 8889548; 9914500; 10421793; 10759890; 10882136; 11470787; 11839743; 11902829; 11959143; 12133833; 12477932; 12676577; 12692549; 12736252; 12761501; 14560022; 14702039; 14743216; 15276183; 15367631; 15489227; 15489334; 15550384; 15556946; 15661910; 15695821; 15767399; 15879144; 15939554; 16177806; 16281057; 16299251; 16344560; 16380379; 16393995; 16710414; 16731946; 16840782; 16888014; 16914100; 17003035; 17327220; 17328045; 17353931; 17468758; 17568778; 17574021; 17599067; 17823124; 18029348; 18353649; 18434448; 18636086; 18636090; 19153231; 19380491; 19481526; 19497997; 19786281; 19820708; 19913121; 19940156; 20188669; 20449947; 20581830; 20588308; 20628086; 20634891; 21171089; 21179067; 21200404; 21212807; 21221132; 21271611; 21464307; 21685032; 21718646; 21885437; 21903422; 21906983; 21908616; 21987572; 22065572; 22072751; 22079989; 22266464; 22330135; 22505724; 22531926; 22532683; 22552702; 22787218; 22851696; 22939624; 22942254; 23007157; 23096996; 23157677; 23308279; 23365428; 23453969; 23478265; 23535865; 23691078; 23816933; 23873932; 23950712,,,,,,,,,,,,,,,OGG:3000009641,,,,,,,"inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase epsilon",,,,,,,,,,,,,Other designations: I-kappa-B kinase epsilon|IKK-epsilon|IKK-related kinase epsilon|inducible I kappa-B kinase|inducible IkappaB kinase|inhibitor of nuclear factor kappa-B kinase subunit epsilon,,IKBKE,,,,,,,,,,,,,,,,,,,,,,,9641,RP11-534L20.1,,,,,,,9606,,,,,,,,,,,,,,,,,,,IKBKE,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000023317,DNAJC13,,Other designations: DnaJ domain-containing protein RME-8|RME-8|dnaJ homolog subfamily C member 13|required for receptor-mediated endocytosis 8,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,RME8,,,,,,,,,,,,3,,,,,,HGNC:30343|MIM:614334|Vega:OTTHUMG00000159674|HPRD:10915|Ensembl:ENSG00000138246,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"DnaJ (Hsp40) homolog, subfamily C, member 13",,,3q22.1,,,,,,,,,,,,,,,,"GO_0005765 (EC: IDA, PMID:17897319); GO_0070062 (EC: IDA, PMID:19056867)",,,,,,,,,PMID:9734811; 12438707; 12477932; 14702039; 15051737; 15302935; 15489334; 15538384; 15840729; 16179350; 17897319; 18256511; 18307993; 19056867; 19874558; 21139048; 21145461; 21674799; 21900206; 21906983; 21963094; 22507240; 23402259; 24250222,,,,,,,,,,,,,,,OGG:3000023317,,,,,,,"DnaJ (Hsp40) homolog, subfamily C, member 13",,,,,,,,,,,,,Other designations: DnaJ domain-containing protein RME-8|RME-8|dnaJ homolog subfamily C member 13|required for receptor-mediated endocytosis 8,,DNAJC13,,,,,,,,,,,,,,,,,,,,,,,23317,,,,,,,,9606,,,,,,,,,,,,,,,,,,,DNAJC13,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000005872,RAB13,,Other designations: RAS-associated protein RAB13|cell growth-inhibiting gene 4 protein|growth-inhibiting gene 4 protein|ras-related protein Rab-13,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,,,,,,,,,,,,,1,,,,,,,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"RAB13, member RAS oncogene family",,,1q21.2,,,,,,,,,,,,,,,,"GO_0003924 (EC: EXP); GO_0005515 (EC: IPI, PMID: 16525024); GO_0005525 (EC: IDA); GO_0005737 (EC: IDA); GO_0005794 (EC: IDA, Qualifier: NOT, PMID: 18779367); GO_0005802 (EC: IDA, PMID: 18779367); GO_0005886 (EC: IDA); GO_0005923 (EC: IDA, PMID: 12058051); GO_0006184 (EC: EXP); GO_0007264 (EC: IEA); GO_0010737 (EC: IMP, PMID: 15096524); GO_0015031 (EC: IEA); GO_0016197 (EC: IMP, PMID: 18779367); GO_0016328 (EC: IDA, PMID: 12058051); GO_0030027 (EC: ISS); GO_0030139 (EC: IDA, PMID: 15528189); GO_0030658 (EC: IEA); GO_0030659 (EC: TAS); GO_0030866 (EC: ISS); GO_0031175 (EC: IMP); GO_0031410 (EC: IDA, PMID: 8294494); GO_0032456 (EC: IMP, PMID: 15528189); GO_0032593 (EC: ISS); GO_0032869 (EC: ISS); GO_0034236 (EC: IEA); GO_0035767 (EC: ISS); GO_0043005 (EC: IDA); GO_0044795 (EC: ISS); GO_0055037 (EC: IDA, PMID: 18779367); GO_0055038 (EC: IEA); GO_0061024 (EC: TAS); GO_0070062 (EC: IDA, PMID: 19056867); GO_0070830 (EC: IMP, PMID: 12058051); GO_0090002 (EC: IMP, PMID: 15096524); GO_0097368 (EC: ISS)",,,,,,,,,PMID: 8294494; 8375503; 9605854; 9712853; 9918381; 11076863; 12058051; 12477932; 14702039; 15096524; 15146197; 15489334; 15489336; 15528189; 15761153; 16381901; 16525024; 16710414; 16923123; 17891173; 18029348; 18779367; 19056867; 19273188; 19885626; 20360680; 21139048; 21890473; 21906983; 22178446; 22562557; 23000965; 23246001,,,,,,,,,,,,,,,OGG:3000005872,,,,,,,"RAB13, member RAS oncogene family",,,,,,,,,,,,,Other designations: RAS-associated protein RAB13|cell growth-inhibiting gene 4 protein|growth-inhibiting gene 4 protein|ras-related protein Rab-13,,RAB13,,,,,,,,,,,,,,,,,,,,,,,5872,GIG4,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,RAB13,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0011414,NDKA,,,false,,,http://purl.obolibrary.org/obo/IMR_0010012,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0011414,,,,,,,,,,,,,,,,,,,,,,NDKA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000421,NF-AT,Nuclear factor of activated T-cells,"NFAT proteins are a family of transcription factors (NFATC1~C4) whose activation is controlled by calcineurin, a Ca2+-dependent phosphatase.",false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,"NFAT proteins are a family of transcription factors (NFATC1~C4) whose activation is controlled by calcineurin, a Ca2+-dependent phosphatase.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,Nuclear factor of activated T-cells,,,,,IMR:0000421,,,,,,,,,,,,,,,,,,,,,,NF-AT,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100739,IHH (mol),Indian hedgehog|HHG-2,,false,,,http://purl.obolibrary.org/obo/IMR_0000004,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:16147|NCBI-Rat-GeneID:84399|NCBI-Human-GeneID:3549,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Indian hedgehog|HHG-2,,,,,IMR:0100739,,,,,,,,,,,,,,,,,,,,,,IHH (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000318,G-alpha-i class,,,false,,,http://purl.obolibrary.org/obo/IMR_0000316,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000318,,,,,,,,,,,,,,,,,,,,,,G-alpha-i class,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100108,"thymic factor, circulating",Thymulin,,false,,,http://purl.obolibrary.org/obo/IMR_0100089,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Thymulin,,,,,IMR:0100108,,,,,,,,,,,,,,,,,,,,,,"thymic factor, circulating",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000106,Cyp3a11 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0001554,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:13112,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:1000106,,,,,,,,,,,,,,,,,,,,,,Cyp3a11 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000104,Cyp2d3 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0001553,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24303,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:1000104,,,,,,,,,,,,,,,,,,,,,,Cyp2d3 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000107,Cyp4a1 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0001555,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:50549,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:1000107,,,,,,,,,,,,,,,,,,,,,,Cyp4a1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000101,Cyp2b1 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0001553,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24300,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:1000101,,,,,,,,,,,,,,,,,,,,,,Cyp2b1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000105,Cyp2d4 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0001553,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:171522,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:1000105,,,,,,,,,,,,,,,,,,,,,,Cyp2d4 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000102,Cyp2b10 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0001553,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:13088,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:1000102,,,,,,,,,,,,,,,,,,,,,,Cyp2b10 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000108,Cyp4a3 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0001555,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:298423,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:1000108,,,,,,,,,,,,,,,,,,,,,,Cyp4a3 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000100,Cyp1A1 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0001552,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1543|NCBI-Rat-GeneID:24296|NCBI-Mouse-GeneID:13076,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001543,,,,,,,,,,,,,TXPO:1000100,,,,,,,,,,,,,,,,,,,,,,Cyp1A1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000103,Cyp2c6v1 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0001553,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:293989,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:1000103,,,,,,,,,,,,,,,,,,,,,,Cyp2c6v1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000109,Cyp4f4 (mol),,,false,,,http://purl.obolibrary.org/obo/TXPO_0001555,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:286904,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:1000109,,,,,,,,,,,,,,,,,,,,,,Cyp4f4 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005173,suloctidil,,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005173,,,,,,,,,,,,,,,,,,,,,,suloctidil,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005174,fenclozic acid,,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005174,,,,,,,,,,,,,,,,,,,,,,fenclozic acid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005178,mepazine,,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005178,,,,,,,,,,,,,,,,,,,,,,mepazine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005176,xenazoic acid,,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005176,,,,,,,,,,,,,,,,,,,,,,xenazoic acid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005171,nialamide,,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005171,,,,,,,,,,,,,,,,,,,,,,nialamide,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005179,alaproclate,,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005179,,,,,,,,,,,,,,,,,,,,,,alaproclate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005170,moxisylyte,,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005170,,,,,,,,,,,,,,,,,,,,,,moxisylyte,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005172,pentostatin,,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005172,,,,,,,,,,,,,,,,,,,,,,pentostatin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005175,tetrabamate,,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005175,,,,,,,,,,,,,,,,,,,,,,tetrabamate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0005177,falnidamol,,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0005177,,,,,,,,,,,,,,,,,,,,,,falnidamol,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001289,increasing NAD/NAD+ ratio [Fibrosis],,"Increasing NAD/NAD+ ratio is a subtype of increasing ratio: A process that changes the ratio of NAD to NAD+ to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003742|http://purl.obolibrary.org/obo/TXPO_0001292,,,,,,,,,,,,,,,,,,,,,,"Increasing NAD/NAD+ ratio is a subtype of increasing ratio: A process that changes the ratio of NAD to NAD+ to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001268,,,,,,,,,,,TXPO:0001289,,,,,,,,,,,,,,,,,,,,,,increasing NAD/NAD+ ratio [Fibrosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001283,NRF2 activation,,"NRF2 activation is a subtype of activation of transcription factor: A process that changes the activity of NRF2 (Nuclear Factor, Erythroid 2 Like 2) to be higher.",false,,,http://purl.obolibrary.org/obo/TXPO_0000124,,,,,,,,,,,,,,,,,,,,,,"NRF2 activation is a subtype of activation of transcription factor: A process that changes the activity of NRF2 (Nuclear Factor, Erythroid 2 Like 2) to be higher.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001283,,,,,,,,,,,,,,,,,,,,,,NRF2 activation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001280,eosinogranular degeneration dependent molecule (canonical),,"Eosinogranular degeneration dependent molecule is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of eosinogranular degeneration as a gene product.
Gene profile:caonical that described in textbooks or articles.",false,,,http://purl.obolibrary.org/obo/TXPO_0000835,,,,,,,,,,,,,,,,,,,,,,"Eosinogranular degeneration dependent molecule is a subtype of toxic course dependent chemical entity.
This gene can participate in the course of eosinogranular degeneration as a gene product.
Gene profile:caonical that described in textbooks or articles.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001280,,,,,,,,,,,,,,,,,,,,,,eosinogranular degeneration dependent molecule (canonical),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001286,obesity,,Obesity is a subtype of increasing weight: A process that changes the body weight  to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000040,,,,,,,,,,,,,,,,,,,,,,Obesity is a subtype of increasing weight: A process that changes the body weight  to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001286,,,,,,,,,,,,,,,,,,,,,,obesity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001285,liver dysfunction [Phospholipidosis (severe) ],,"Liver dysfunction is a subtype of dysfunctioning: A process that performs an abnormal and incomplete liver function. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",false,,,http://purl.obolibrary.org/obo/TXPO_0000203|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,,,"Liver dysfunction is a subtype of dysfunctioning: A process that performs an abnormal and incomplete liver function. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001285,,,,,,,,,,,,,,,,,,,,,,liver dysfunction [Phospholipidosis (severe) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001281,VLDL formation [lipidosis],,"The non-covalent aggregation and arrangement of proteins and lipids in the liver to form a very-low-density lipoprotein particle.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/GO_0034379|http://purl.obolibrary.org/obo/TXPO_0001720,,,,,,,,,,,,,,,,,,,,,,"The non-covalent aggregation and arrangement of proteins and lipids in the liver to form a very-low-density lipoprotein particle.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001351,,http://purl.obolibrary.org/obo/TXPO_0001405,,,,,,http://purl.obolibrary.org/obo/TXPO_0001371,,,,,,,,,,,TXPO:0001281,,,,,,,,,,,,,,,,,,,,,,VLDL formation [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001287,hypofunction of phosphosphingolipid degradation,,Hypofunction of phosphosphingolipid degradation is a subtype of hypofunction of phospholipid degradation: A process that performs a decreased or insufficient phosphosphingolipid degradation.,false,,,http://purl.obolibrary.org/obo/TXPO_0001253,,,,,,,,,,,,,,,,,,,,,,Hypofunction of phosphosphingolipid degradation is a subtype of hypofunction of phospholipid degradation: A process that performs a decreased or insufficient phosphosphingolipid degradation.,,,http://purl.obolibrary.org/obo/TXPO_0001465,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35786,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001287,,,,,,,,,,,,,,,,,,,,,,hypofunction of phosphosphingolipid degradation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001282,CASPASE-2 (canonical)[ER stress],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000502,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001282,,,,,,,,,,,,,,,,,,,,,,CASPASE-2 (canonical)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001284,CD36 activation [lipidosis],,"CD36 activation is a subtype of molecular activation: A process that changes the activity of the CD36 to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001309|http://purl.obolibrary.org/obo/TXPO_0001720,,,,,,,,,,,,,,,,,,,,PMID:17728375|PMID:18242221,,"CD36 activation is a subtype of molecular activation: A process that changes the activity of the CD36 to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001319,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001500,,,,,,,,,,,TXPO:0001284,,,,,,,,,,,,,,,,,,,,,,CD36 activation [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001288,hyperfunction of reduction of NAD(+) to NADH [Fibrosis],,"Hyperfunction of reduction of NAD(+) to NADH is a subtype of hyperfunction of reduction: A process that performs an excesssive reduction of NAD(+) to NADH.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001302|http://purl.obolibrary.org/obo/TXPO_0003742,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of reduction of NAD(+) to NADH is a subtype of hyperfunction of reduction: A process that performs an excesssive reduction of NAD(+) to NADH.
This entity is a specific course-dependent process. This process can constitute the course of Fibrosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001289,,,,,,,,,,,TXPO:0001288,,,,,,,,,,,,,,,,,,,,,,hyperfunction of reduction of NAD(+) to NADH [Fibrosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100851,PKA alpha catalytic subunit,"PKA C-alpha|cAMP-dependent protein kinase, alpha-catalytic subunit",,false,,,http://purl.obolibrary.org/obo/IMR_0100703,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"PKA C-alpha|cAMP-dependent protein kinase, alpha-catalytic subunit",,,,,IMR:0100851,,,,,,,,,,,,,,,,,,,,,,PKA alpha catalytic subunit,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0042026,protein refolding,,"The process carried out by a cell that restores the biological activity of an unfolded or misfolded protein, using helper proteins such as chaperones.",false,,,http://purl.obolibrary.org/obo/GO_0006457,,,,,,,,,,,,,,,,,,,,PMID:23637286,,"The process carried out by a cell that restores the biological activity of an unfolded or misfolded protein, using helper proteins such as chaperones.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0042026,,,,,,,,,,,,,,,,,,,,,,protein refolding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/NCIT_C19151,metastasis,,The spread or migration of cancer cells from one part of the body (the organ in which it first appeared) to another. The secondary tumor contains cells that are like those in the original (primary) tumor.,false,,,http://purl.obolibrary.org/obo/GO_0016477,,,,,,,,,,,,,,,,,,,,,,The spread or migration of cancer cells from one part of the body (the organ in which it first appeared) to another. The secondary tumor contains cells that are like those in the original (primary) tumor.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,NCIT:C19151,,,,,,,,,,,,,,,,,,,,,,metastasis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_9753,troglitazone,"Romglizone|5-(4-(6-Hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl)thiazolidine-2,4-dione|(+-)-all-rac-5-(p-((6-Hydroxy-2,5,7,8-tetramethyl-2-chromanyl)methoxy)benzyl)-2,4-thiazolidinedione|Rezulin (TN)|troglitazona|troglitazonum|troglitazone|Troglitazone|5-{4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2-yl)methoxy]benzyl}-1,3-thiazolidine-2,4-dione","A chromane that has formula C24H27NO5S.|Troglitazone is an antidiabetic and anti-inflammatory drug, and a member of the drug class of the thiazolidinediones. It was prescribed for people with diabetes mellitus type 2. (by Wikipedia)",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Drug_Central:2767|CAS:97322-87-7|DrugBank:DB00197|Beilstein:4338399|LINCS:LSM-4890|ATC:A10BG01,,"A chromane that has formula C24H27NO5S.|Troglitazone is an antidiabetic and anti-inflammatory drug, and a member of the drug class of the thiazolidinediones. It was prescribed for people with diabetes mellitus type 2. (by Wikipedia)",,,,,,,,,,,,C24H27NO5S,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_50249|http://purl.obolibrary.org/obo/CHEBI_35610|http://purl.obolibrary.org/obo/CHEBI_22586|http://purl.obolibrary.org/obo/CHEBI_35526|http://purl.obolibrary.org/obo/CHEBI_50427|http://purl.obolibrary.org/obo/CHEBI_35620|http://purl.obolibrary.org/obo/CHEBI_35623,,,,,"Troglitazone|5-{4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2-yl)methoxy]benzyl}-1,3-thiazolidine-2,4-dione",,"Romglizone|5-(4-(6-Hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl)thiazolidine-2,4-dione|(+-)-all-rac-5-(p-((6-Hydroxy-2,5,7,8-tetramethyl-2-chromanyl)methoxy)benzyl)-2,4-thiazolidinedione|Rezulin (TN)|troglitazona|troglitazonum|troglitazone",,,,,,,,,,Wikipedia:Troglitazone,,,,,,,,,,,CHEBI:9753,,,,troglitazone,,CHEBI:9753,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Cc1c(C)c2OC(C)(CCc2c(C)c1O)COc1ccc(CC2SC(=O)NC2=O)cc1,,,,,
http://purl.obolibrary.org/obo/CHEBI_48422,angiogenesis inhibitor,angiostatic agents|anti-angiogenic agent|angiogenesis antagonist,An agent and endogenous substances that antagonize or inhibit the development of new blood vessels.,false,,,http://purl.obolibrary.org/obo/CHEBI_23888,,,,,,,,,,,,,,,,,,,,,,An agent and endogenous substances that antagonize or inhibit the development of new blood vessels.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,angiostatic agents|anti-angiogenic agent|angiogenesis antagonist,,,,,,,,,,,,,,,,,,,,,CHEBI:48422,,,,angiogenesis inhibitor,,CHEBI:48422,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_52208,biophysical role,,,false,,,http://purl.obolibrary.org/obo/CHEBI_24432,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:52208,,,,biophysical role,,CHEBI:52208,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000388,IRF-2,interferon regulatory factor-2,,false,,,http://purl.obolibrary.org/obo/IMR_0000386,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,interferon regulatory factor-2,,,,,IMR:0000388,,,,,,,,,,,,,,,,,,,,,,IRF-2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000094,TGF-beta receptor type II,Transforming growth factor-beta receptor type II,,false,,,http://purl.obolibrary.org/obo/IMR_0000092,,,,,,,,,,,,,,,,,,,,GO:0005026,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Transforming growth factor-beta receptor type II,,,,,IMR:0000094,,,,,,,,,,,,,,,,,,,,,,TGF-beta receptor type II,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010519,Heterogenous nuclear ribonucleoprotein U,SAF-A|Scaffold attachment factor A|ROU|hnRNP U,,false,,,http://purl.obolibrary.org/obo/IMR_0010024,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,SAF-A|Scaffold attachment factor A|ROU|hnRNP U,,,,,IMR:0010519,,,,,,,,,,,,,,,,,,,,,,Heterogenous nuclear ribonucleoprotein U,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004520,Increasing DNMT1 level,,Increasing DNMT1 level is a subtype of increasing quantity: A process that changes the amount of DNMT1 level to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing DNMT1 level is a subtype of increasing quantity: A process that changes the amount of DNMT1 level to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004521,,,,,,,,,,,,,,,,,,,TXPO:0004520,,,,,,,,,,,,,,,,,,,,,,Increasing DNMT1 level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004522,Increasing DNMT1 level [hepatocarcinogenesis],,"Increasing DNMT1 level is a subtype of increasing quantity: A process that changes the amount of DNMT1 level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004520,,,,,,,,,,,,,,,,,,,,PMID:30141584,,"Increasing DNMT1 level is a subtype of increasing quantity: A process that changes the amount of DNMT1 level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004523,,http://purl.obolibrary.org/obo/TXPO_0004448,,,,,,,,,,,,,,,,,TXPO:0004522,,,,,,,,,,,,,,,,,,,,,,Increasing DNMT1 level [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004525,Increasing DPYD level [hepatocarcinogenesis],,"Increasing DPYD level is a subtype of increasing quantity: A process that changes the amount of DPYD level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004524,,,,,,,,,,,,,,,,,,,,PMID:29358721,,"Increasing DPYD level is a subtype of increasing quantity: A process that changes the amount of DPYD level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004192,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004404|http://purl.obolibrary.org/obo/TXPO_0004479|http://purl.obolibrary.org/obo/TXPO_0004420,,,,,,,,,,,TXPO:0004525,,,,,,,,,,,,,,,,,,,,,,Increasing DPYD level [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004526,EGFR signaling (primitive) [hepatocarcinogenesis],,"EGFR signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by EGFR.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0001492,,,,,,,,,,,,,,,,,,,,PMID:28493839|PMID:30947731,,"EGFR signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by EGFR.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004528|http://purl.obolibrary.org/obo/TXPO_0004527,http://purl.obolibrary.org/obo/GO_0007173,,,,,http://purl.obolibrary.org/obo/TXPO_0004529|http://purl.obolibrary.org/obo/TXPO_0004396,,,,,,,,,,,TXPO:0004526,,,,,,,,,,,,,,,,,,,,,,EGFR signaling (primitive) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004524,Increasing DPYD level,,Increasing DPYD level is a subtype of increasing quantity: A process that changes the amount of DPYD level to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing DPYD level is a subtype of increasing quantity: A process that changes the amount of DPYD level to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_1000514,,,,,,,,,,,,,,,,,,,TXPO:0004524,,,,,,,,,,,,,,,,,,,,,,Increasing DPYD level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004528,EGFR(human) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/IMR_0000081,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1956|PMID:30947731,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000081,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004528,,,,,,,,,,,,,,,,,,,,,,EGFR(human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004527,EGFR(canonical) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/IMR_0000081|http://purl.obolibrary.org/obo/TXPO_0005063,,,,,,,,,,,,,,,,,,,,"NCBI-Rat-GeneID:24329|The protein encoded by this gene is a transmembrane glycoprotein that is a member of the protein kinase superfamily. This protein is a receptor for members of the epidermal growth factor family. EGFR is a cell surface protein that binds to epidermal growth factor. Binding of the protein to a ligand induces receptor dimerization and tyrosine autophosphorylation and leads to cell proliferation. Mutations in this gene are associated with lung cancer. [provided by RefSeq, Jun 2016]|NCBI-Human-GeneID:1956|NCBI-Mouse-GeneID:13649|PMID:28493839",,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000081,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004527,,,,,,,,,,,,,,,,,,,,,,EGFR(canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004521,DNMT1 (mol),DNA methyltransferase 1,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:13433|NCBI-Rat-GeneID:84350|NCBI-Human-GeneID:1786,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,DNA methyltransferase 1,,,,,TXPO:0004521,,,,,,,,,,,,,,,,,,,,,,DNMT1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004523,DNMT1 (rat) [hepatocarcinogenesis],DNA methyltransferase 1,,false,,,http://purl.obolibrary.org/obo/TXPO_0005070|http://purl.obolibrary.org/obo/TXPO_0004521,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:84350|PMID:30141584,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,DNA methyltransferase 1,,,,,TXPO:0004523,,,,,,,,,,,,,,,,,,,,,,DNMT1 (rat) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004529,sorafenib resistance (process)  [hepatocarcinogenesis],,"sorafenib resistance (process) is a subtype of decreasing sensitivity: A process that changes the sensitivity to sorafenib to be lower.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004965,,,,,,,,,,,,,,,,,,,,PMID:28493839,,"sorafenib resistance (process) is a subtype of decreasing sensitivity: A process that changes the sensitivity to sorafenib to be lower.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004518,,,,,,,,,,,TXPO:0004529,,,,,,,,,,,,,,,,,,,,,,sorafenib resistance (process)  [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100747,TCF-4,HMG box transcription factor 4|hTCF-4|mTCF-4|T-cell-specific transcription factor 4|TCF7L2|TCF-4,,false,,,http://purl.obolibrary.org/obo/IMR_0000418,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,HMG box transcription factor 4|hTCF-4|mTCF-4|T-cell-specific transcription factor 4|TCF7L2|TCF-4,,,,,IMR:0100747,,,,,,,,,,,,,,,,,,,,,,TCF-4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100125,histamine,Histamine|1H-Imidazole-4-ethanamine|2-(4-Imidazolyl)ethylamine,,false,,,http://purl.obolibrary.org/obo/IMR_0002121,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_25512,,,,IMR:0200295,Histamine|1H-Imidazole-4-ethanamine|2-(4-Imidazolyl)ethylamine,,,,,IMR:0100125,,,,,,,,,,,,,,,,,,,,,,histamine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0000955,brain,the brain|encephalon|suprasegmental levels of nervous system|suprasegmental structures|synganglion,"The brain is the center of the nervous system in all vertebrate, and most invertebrate, animals. Some primitive animals such as jellyfish and starfish have a decentralized nervous system without a brain, while sponges lack any nervous system at all. In vertebrates, the brain is located in the head, protected by the skull and close to the primary sensory apparatus of vision, hearing, balance, taste, and smell[WP].",false,,,http://purl.obolibrary.org/obo/UBERON_0000062,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCIT_C12439|http://uri.neuinfo.org/nif/nifstd/birnlex_796|http://linkedlifedata.com/resource/umls/id/C0006104|http://www.snomedbrowser.com/Codes/Details/258335003|http://braininfo.rprc.washington.edu/centraldirectory.aspx?ID=21|http://en.wikipedia.org/wiki/Brain|http://linkedlifedata.com/resource/umls/id/C1269537|GAID:571|ABA:Brain|DHBA:10155|galen:Brain|BAMS:Br|MA:0000168|http://braininfo.rprc.washington.edu/centraldirectory.aspx?ID=21|XAO:0000010|EHDAA:6485|PBA:3999|UMLS:C0006104|CALOHA:TS-0095|ZFA:0000008|FMA:50801|OpenCyc:Mx4rvVjT65wpEbGdrcN5Y29ycA|FBbt:00005095|AAO:0010478|EHDAA:2641|EHDAA2:0000183|MAT:0000098|MIAA:0000098|EMAPA:16894|BAMS:Brain|TAO:0000008|BTO:0000142|UMLS:C1269537|VHOG:0000157|BILA:0000135|HBA:4005|MESH:D001921|EFO:0000302|EV:0100164,,"The brain is the center of the nervous system in all vertebrate, and most invertebrate, animals. Some primitive animals such as jellyfish and starfish have a decentralized nervous system without a brain, while sponges lack any nervous system at all. In vertebrates, the brain is located in the head, protected by the skull and close to the primary sensory apparatus of vision, hearing, balance, taste, and smell[WP].",,,,"requires review for applicability to invertebrate structures, e.g. synganglion",brain,,,"Part of the central nervous system situated within the cranium and composed of both nerve cell bodies and nerve fibers.[AAO]|Cavitated compound organ which is comprised of gray and white matter and surrounds the cerebral ventricular system.[TAO]|The part of the central nervous system contained within the cranium, comprising the forebrain, midbrain, hindbrain, and metencephalon. It is derived from the anterior part of the embryonic neural tube (or the encephalon). Does not include retina. (CUMBO)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,the brain|encephalon|suprasegmental levels of nervous system|suprasegmental structures|synganglion,"(...) at some stage of its development, every chordate exhibits five uniquely derived characters or synapomorphies of the group: (...) (4) a single, tubular nerve cord that is located dorsal to the notochord (...) (reference 1); The neural tube is destined to differentiate into the brain and spinal cord (the central nervous system) (reference 2).[well established][VHOG]",http://purl.obolibrary.org/obo/UBERON_0001017,UBERON:0000955,http://purl.obolibrary.org/obo/UBERON_0001017,,,https://github.com/cmungall,,,,,,,,,,,,,,,,,,brain,,,,,,,http://purl.obolibrary.org/obo/oae.owl|http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000717,PLCbeta4,phospholipase C beta 4,,false,,,http://purl.obolibrary.org/obo/IMR_0000286,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,phospholipase C beta 4,,,,,IMR:0000717,,,,,,,,,,,,,,,,,,,,,,PLCbeta4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000121,Dnajc7 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:303536|NCBI-Human-GeneID:7266|NCBI-Mouse-GeneID:56354,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000007266,,,,,,,,,,,,,TXPO:1000121,,,,,,,,,,,,,,,,,,,,,,Dnajc7 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000125,ELOVL6 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:170439|NCBI-Rat-GeneID:171402|NCBI-Human-GeneID:79071,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000079071,,,,,,,,,,,,,TXPO:1000125,,,,,,,,,,,,,,,,,,,,,,ELOVL6 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000123,EIF4BP1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:319118,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000319118,,,,,,,,,,,,,TXPO:1000123,,,,,,,,,,,,,,,,,,,,,,EIF4BP1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000127,DNAJC10 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:54431|NCBI-Mouse-GeneID:66861|NCBI-Rat-GeneID:295690,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000054431,,,,,,,,,,,,,TXPO:1000127,,,,,,,,,,,,,,,,,,,,,,DNAJC10 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000120,Ddx6 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:13209|NCBI-Rat-GeneID:500988|NCBI-Human-GeneID:1656,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001656,,,,,,,,,,,,,TXPO:1000120,,,,,,,,,,,,,,,,,,,,,,Ddx6 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000124,ELAVL4 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1996|NCBI-Rat-GeneID:432358|NCBI-Mouse-GeneID:15572,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001996,,,,,,,,,,,,,TXPO:1000124,,,,,,,,,,,,,,,,,,,,,,ELAVL4 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000126,ERO1LB (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:67475,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000056605,,,,,,,,,,,,,TXPO:1000126,,,,,,,,,,,,,,,,,,,,,,ERO1LB (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000129,Ech1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:64526|NCBI-Human-GeneID:1891|NCBI-Mouse-GeneID:51798,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001891,,,,,,,,,,,,,TXPO:1000129,,,,,,,,,,,,,,,,,,,,,,Ech1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000128,ET-1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24323|NCBI-Mouse-GeneID:13614|NCBI-Human-GeneID:1906,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001906,,,,,,,,,,,,,TXPO:1000128,,,,,,,,,,,,,,,,,,,,,,ET-1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000006519,SLC3A1,,"Other designations: B(0,+)-type amino acid transport protein|SLC3A1 variant B|SLC3A1 variant C|SLC3A1 variant D|SLC3A1 variant E|SLC3A1 variant F|SLC3A1 variant G|amino acid transporter 1|neutral and basic amino acid transport protein rBAT|solute carrier family 3 (cystine, dibasic and neutral amino acid transporters), member 1|solute carrier family 3 (cystine, dibasic and neutral amino acid transporters, activator of cystine, dibasic and neutral amino acid transport), member 1|solute carrier family 3 member 1",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CSNU1|RBAT|ATR1|D2H|NBAT,,,,,,,,,,,,2,,,,,,MIM:104614|HPRD:00090|HGNC:11025,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"solute carrier family 3 (amino acid transporter heavy chain), member 1",,,2p16.3,,,,,,,,,,,,,,,,"GO_0003333 (EC: TAS, PMID: 10799513); GO_0003824 (EC: IEA); GO_0005515 (EC: IPI, PMID: 12167606); GO_0005743 (EC: IEA); GO_0005774 (EC: IEA); GO_0005886 (EC: TAS); GO_0005887 (EC: IEA); GO_0005975 (EC: IEA); GO_0006520 (EC: TAS, PMID: 8054986); GO_0006811 (EC: TAS); GO_0006865 (EC: TAS); GO_0015171 (EC: TAS, PMID: 10799513); GO_0015174 (EC: TAS, PMID: 8054986); GO_0015184 (EC: TAS, PMID: 8054986); GO_0015802 (EC: TAS, PMID: 8054986); GO_0015811 (EC: TAS, PMID: 8054986); GO_0016020 (EC: TAS, PMID: 8054986); GO_0031526 (EC: IDA, PMID: 12167606); GO_0043169 (EC: IEA); GO_0046982 (EC: IEA); GO_0055085 (EC: TAS); GO_0070062 (EC: IDA, PMID: 19056867)",,,,,,,,,PMID: 7539209; 7568194; 7573036; 7575432; 7686906; 7789946; 8054986; 8125298; 8486766; 8663184; 9186880; 10574970; 10588648; 10799513; 11318953; 11458794; 11748844; 12060600; 12167606; 12234283; 12239244; 12372889; 12477932; 12820697; 14531788; 14561219; 14702039; 14991253; 15489334; 15635077; 15691362; 15815621; 15818800; 15818801; 15818802; 15913950; 16138908; 16358225; 17010017; 18195088; 18234729; 18332091; 18752446; 18778962; 19056867; 19782624; 20146678; 20800603; 21255007; 22796000; 23794250,,,,,,,,,,,,,,,OGG:3000006519,,20140408,protein-coding,,,,"solute carrier family 3 (amino acid transporter heavy chain), member 1",,,,,,,,,,,,,"Other designations: B(0,+)-type amino acid transport protein|SLC3A1 variant B|SLC3A1 variant C|SLC3A1 variant D|SLC3A1 variant E|SLC3A1 variant F|SLC3A1 variant G|amino acid transporter 1|neutral and basic amino acid transport protein rBAT|solute carrier family 3 (cystine, dibasic and neutral amino acid transporters), member 1|solute carrier family 3 (cystine, dibasic and neutral amino acid transporters, activator of cystine, dibasic and neutral amino acid transport), member 1|solute carrier family 3 member 1",,SLC3A1,,,,,,,,,,,,,,,,,,,,,,,6519,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,SLC3A1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000006515,SLC2A3,,"Other designations: GLUT-3|glucose transporter type 3, brain|solute carrier family 2, facilitated glucose transporter member 3",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,GLUT3,,,,,,,,,,,,12,,,,,,HPRD:00686|MIM:138170|Vega:OTTHUMG00000133685|HGNC:11007|Ensembl:ENSG00000059804,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"solute carrier family 2 (facilitated glucose transporter), member 3",,,12p13.3,,,,,,,,,,,,,,,,GO_0005355 (EC: IEA); GO_0005886 (EC: TAS); GO_0005975 (EC: TAS); GO_0006766 (EC: TAS); GO_0006767 (EC: TAS); GO_0008645 (EC: TAS); GO_0015758 (EC: TAS); GO_0016021 (EC: IEA); GO_0019852 (EC: TAS); GO_0044281 (EC: TAS); GO_0055085 (EC: TAS); GO_0070062 (EC: IDA),,,,,,,,,PMID: 1417839; 1695905; 3170580; 7502272; 8457197; 9253355; 9477959; 10086067; 11991658; 12064911; 12112827; 12397394; 12477932; 12554125; 12583599; 14757434; 15123239; 15489334; 16049004; 16125330; 16136514; 16169070; 16303743; 17442736; 17559076; 17611657; 17920708; 18029348; 18172662; 18299470; 18401196; 18764953; 18802725; 18976975; 19261894; 19322201; 19536037; 19554504; 19659459; 19681047; 19782666; 19786962; 20308990; 20424473; 20428049; 20468064; 20599725; 20870738; 21890473; 21920790; 21963094; 21987572; 22000473; 22069254; 22113212; 22234467; 22265971; 22270867; 22645302; 22663547; 22706202; 22876317; 22901689; 22901702; 23341039; 23343953; 23720776; 23995067,,,,,,,,,,,,,,,OGG:3000006515,,,,,,,"solute carrier family 2 (facilitated glucose transporter), member 3",,,,,,,,,,,,,"Other designations: GLUT-3|glucose transporter type 3, brain|solute carrier family 2, facilitated glucose transporter member 3",,SLC2A3,,,,,,,,,,,,,,,,,,,,,,,6515,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,SLC2A3,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000046,Nodal family,,,false,,,http://purl.obolibrary.org/obo/IMR_0000036,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000046,,,,,,,,,,,,,,,,,,,,,,Nodal family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000120526,DNAJC24,,"Other designations: 1700030A21Rik|CSL-type zinc finger-containing protein 3|DPH4 homolog (JJJ3, S. cerevisiae)|DPH4, JJJ3 homolog|diphthamide biosynthesis protein 4|dnaJ homolog subfamily C member 24|zinc finger, CSL domain containing 3|zinc finger, CSL-type containing 3",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,JJJ3|DPH4|ZCSL3,,,,,,,,,,,,11,,,,,,HGNC:26979|HPRD:15705|MIM:611072,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"DnaJ (Hsp40) homolog, subfamily C, member 24",,,11p13,,,,,,,,,,,,,,,,GO_0001671 (EC: IDA); GO_0005737 (EC: IEA); GO_0005856 (EC: IEA); GO_0008198 (EC: IDA); GO_0008270 (EC: IDA); GO_0017183 (EC: IEA); GO_0032781 (EC: IDA); GO_0055114 (EC: IEA); GO_0061077 (EC: TAS),,,,,,,,,PMID:12477932; 14702039; 15485916; 15489334; 22367199; 22509046,,,,,,,,,,,,,,,OGG:3000120526,,,,,,,"DnaJ (Hsp40) homolog, subfamily C, member 24",,,,,,,,,,,,,"Other designations: 1700030A21Rik|CSL-type zinc finger-containing protein 3|DPH4 homolog (JJJ3, S. cerevisiae)|DPH4, JJJ3 homolog|diphthamide biosynthesis protein 4|dnaJ homolog subfamily C member 24|zinc finger, CSL domain containing 3|zinc finger, CSL-type containing 3",,DNAJC24,,,,,,,,,,,,,,,,,,,,,,,120526,AC108456.1,,,,,,,9606,,,,,,,,,,,,,,,,,,,DNAJC24,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000673,PAK7,PAK5,,false,,,http://purl.obolibrary.org/obo/IMR_0000238,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PAK5,,,,,IMR:0000673,,,,,,,,,,,,,,,,,,,,,,PAK7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_25355,mitochondrial respiratory-chain inhibitor,mitochondrial electron transport chain inhibitors,A role played by the entity  that inhibits the mitochondrial respiratory-chain.,false,,,http://purl.obolibrary.org/obo/CHEBI_38497,,,,,,,,,,,,,,,,,,,,,,A role played by the entity  that inhibits the mitochondrial respiratory-chain.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,mitochondrial electron transport chain inhibitors,,,CHEBI:25355,,,,,,,,,,,,,,,,,,,,,,mitochondrial respiratory-chain inhibitor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_35473,tranquilizing drug,ataractics|tranquillizing agents|tranquilizing drugs|tranquilising drug|tranquillising agent,"A traditional grouping of drugs said to have a soothing or calming effect on mood, thought or behaviour.",false,,,http://purl.obolibrary.org/obo/CHEBI_35471|http://purl.obolibrary.org/obo/CHEBI_35488,,,,,,,,,,,,,,,,,,,,,,"A traditional grouping of drugs said to have a soothing or calming effect on mood, thought or behaviour.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ataractics|tranquillizing agents|tranquilizing drugs|tranquilising drug|tranquillising agent,,,,,,,,,,,,,,,,,,,,,CHEBI:35473,,,,tranquilizing drug,,CHEBI:35473,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0002688,IGFBP,insulin-like growth factor-binding protein|IGF-binding protein,"IGFBPs are a family of secreted proteins that bind IGF with high affinities that are equal to or greater than those of the IGF-IR. Six distinct IGFBPs, designated as IGFBP-1 to -6, have been isolated and characterized from human and a variety of vertebrate species.",false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,"IGFBPs are a family of secreted proteins that bind IGF with high affinities that are equal to or greater than those of the IGF-IR. Six distinct IGFBPs, designated as IGFBP-1 to -6, have been isolated and characterized from human and a variety of vertebrate species.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003720,,,,,insulin-like growth factor-binding protein|IGF-binding protein,,,,,IMR:0002688,,,,,,,,,,,,,,,,,,,,,,IGFBP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0040011,locomotion,,Self-propelled movement of a cell or organism from one location to another.,false,,,http://purl.obolibrary.org/obo/TXPO_0000765,,,,,,,,,,,,,,,,,,,,,,Self-propelled movement of a cell or organism from one location to another.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0040011,,,,,,,,,,,,,,,,,,,,,,locomotion,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000003161,HMMR,,Other designations: hyaluronan mediated motility receptor|intracellular hyaluronic acid-binding protein|receptor for hyaluronan-mediated motility,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CD168|RHAMM|IHABP,,,,,,,,,,,,5,,,,,,HPRD:02963|HGNC:5012|Vega:OTTHUMG00000130381|MIM:600936|Ensembl:ENSG00000072571,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,hyaluronan-mediated motility receptor (RHAMM),,,5q34,,,,,,,,,,,,,,,,GO_0005540 (EC: IEA); GO_0005737 (EC: IEA); GO_0005886 (EC: TAS); GO_0005975 (EC: TAS); GO_0009986 (EC: IEA); GO_0030203 (EC: TAS); GO_0030212 (EC: TAS); GO_0030214 (EC: TAS); GO_0044281 (EC: TAS),,,,,,,,,PMID: 1602151; 7541721; 7683315; 8595891; 8890751; 9601098; 10216086; 10547355; 10882722; 11403955; 11433424; 11448954; 11716065; 12225794; 12477932; 12712331; 12808028; 12939665; 15705883; 15809329; 16112646; 16344560; 16565220; 17157168; 17392272; 17395888; 17872502; 17922014; 17978170; 18174258; 18354082; 18425326; 18559599; 18971636; 19001852; 19011633; 19064580; 19092852; 19148505; 19212667; 19424574; 19580345; 19724689; 19826009; 19857547; 20301425; 20309963; 20360068; 20619784; 20849445; 20956971; 21139048; 21274712; 21435222; 21903422; 21914806; 22095138; 22110403; 22371883; 22532518; 22610405; 23166824; 23328114; 23382057; 23455922; 24250222; 24367099,,,,,,,,,,,,,,,OGG:3000003161,,20140408,protein-coding,,,,hyaluronan-mediated motility receptor (RHAMM),,,,,,,,,,,,,Other designations: hyaluronan mediated motility receptor|intracellular hyaluronic acid-binding protein|receptor for hyaluronan-mediated motility,,HMMR,,,,,,,,,,,,,,,,,,,,,,,3161,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,HMMR,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000003162,HMOX1,,"Other designations: heat shock protein, 32-kD|heme oxygenase 1",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,HSP32|HMOX1D|bK286B10|HO-1,,,,,,,,,,,,22,,,,,,Ensembl:ENSG00000100292|MIM:141250|Vega:OTTHUMG00000150960|HPRD:00782|HGNC:5013,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,heme oxygenase (decycling) 1,,,22q13.1,,,,,,,,,,,,,,,,"GO_0001525 (EC: TAS, PMID: 12239590); GO_0001935 (EC: TAS, PMID: 12239590); GO_0002246 (EC: IMP, PMID: 9884342); GO_0002686 (EC: TAS, PMID: 14525760); GO_0004392 (EC: IDA, PMID: 17915953); GO_0004392 (EC: IMP, PMID: 19556236); GO_0004630 (EC: IEA); GO_0004871 (EC: IMP, PMID: 12761501); GO_0005615 (EC: TAS, PMID: 18307065); GO_0005634 (EC: ISS); GO_0005730 (EC: IEA); GO_0005783 (EC: IDA, PMID: 19556236); GO_0005783 (EC: ISS); GO_0005789 (EC: TAS); GO_0005829 (EC: IEA); GO_0005901 (EC: IEA); GO_0006778 (EC: TAS); GO_0006788 (EC: IDA, PMID: 17915953); GO_0006879 (EC: TAS); GO_0006979 (EC: IMP, PMID: 9884342); GO_0007264 (EC: IEA); GO_0007588 (EC: IC, PMID: 17915953); GO_0008217 (EC: IEA); GO_0008219 (EC: ISS); GO_0008630 (EC: IEA); GO_0010656 (EC: IEA); GO_0014806 (EC: TAS, PMID: 18289072); GO_0016020 (EC: TAS, PMID: 3345742); GO_0019899 (EC: ISS, PMID: 15516695); GO_0020037 (EC: IDA, PMID: 17915953); GO_0031670 (EC: IEA); GO_0032764 (EC: IEA); GO_0034101 (EC: IMP, PMID: 9884342); GO_0034383 (EC: TAS, PMID: 9884342); GO_0035094 (EC: IDA, PMID: 18205746); GO_0035556 (EC: TAS, PMID: 17652371); GO_0042167 (EC: IDA, PMID: 17915953); GO_0042167 (EC: TAS); GO_0042542 (EC: ISS); GO_0042803 (EC: IDA, PMID: 19556236); GO_0043123 (EC: IMP, PMID: 12761501); GO_0043305 (EC: IEA); GO_0043392 (EC: IEA); GO_0043433 (EC: IEA); GO_0043524 (EC: IEA); GO_0043619 (EC: ISS); GO_0043627 (EC: IEA); GO_0044281 (EC: TAS); GO_0045080 (EC: TAS, PMID: 17652371); GO_0045765 (EC: TAS, PMID: 17652371); GO_0045766 (EC: IEA); GO_0045909 (EC: IC, PMID: 17915953); GO_0046872 (EC: IEA); GO_0048661 (EC: IDA, PMID: 17600318); GO_0048662 (EC: IDA, PMID: 17600318); GO_0051090 (EC: ISS); GO_0051260 (EC: IDA, PMID: 19556236); GO_0055072 (EC: IDA, PMID: 17915953); GO_0055072 (EC: IMP, PMID: 9884342); GO_0055085 (EC: TAS); GO_0071243 (EC: IEA); GO_0071276 (EC: IEA); GO_0071456 (EC: IEP, PMID: 12511571); GO_1902042 (EC: IMP, PMID: 18202225)",,,,,,,,,PMID: 2537723; 2911585; 3345742; 7778849; 8034330; 8146161; 8650873; 9884342; 9890653; 10082382; 10467099; 10591208; 10631150; 10952020; 11385506; 11718398; 11727267; 11786534; 11820797; 11829463; 11849436; 11986386; 12086318; 12091240; 12099373; 12117910; 12118938; 12130498; 12133007; 12136229; 12151344; 12153964; 12182912; 12202863; 12207883; 12222997; 12239590; 12376298; 12376363; 12376366; 12377749; 12379283; 12396617; 12397597; 12431619; 12433915; 12469218; 12477932; 12480749; 12493432; 12500973; 12511571; 12566526; 12579334; 12585963; 12626517; 12649161; 12679469; 12690112; 12709566; 12709568; 12709569; 12709590; 12709592; 12716475; 12730098; 12736395; 12761501; 12777398; 12783778; 12805077; 12810075; 12832044; 12842469; 12865654; 12872043; 12891549; 12909459; 12927812; 12927819; 12933701; 12941774; 12947311; 12969148; 13678532; 14521259; 14523007; 14525760; 14529548; 14587309; 14615405; 14635185; 14647439; 14660632; 14683741; 14691581; 14715242; 14726403; 14733911; 14981149; 14988408; 14992466; 15004156; 15024026; 15028349; 15049686; 15064108; 15084931; 15140586; 15161530; 15166181; 15184199; 15233805; 15284058; 15285018; 15297453; 15316927; 15319861; 15336443; 15337692; 15342556; 15365571; 15451051; 15461802; 15465821; 15470195; 15474356; 15516695; 15519649; 15522396; 15525643; 15544924; 15547665; 15581622; 15611319; 15618017; 15629867; 15652505; 15661856; 15688187; 15690204; 15741166; 15763346; 15797262; 15797755; 15805230; 15817713; 15833736; 15834587; 15849554; 15875813; 15878918; 15885363; 15897578; 15899048; 15964514; 16020495; 16100019; 16117883; 16123320; 16154535; 16181102; 16189191; 16210136; 16232329; 16234431; 16249618; 16271489; 16309585; 16309586; 16309588; 16313248; 16319139; 16374439; 16387424; 16399210; 16455537; 16462769; 16474202; 16485041; 16495813; 16530877; 16540907; 16545694; 16582079; 16596642; 16609364; 16620829; 16697692; 16712795; 16724942; 16771696; 16772700; 16783602; 16804400; 16840713; 16849502; 16882737; 16887359; 16923960; 16945925; 16950787; 16951197; 16971418; 16999951; 17003650; 17018578; 17018862; 17020887; 17064313; 17065227; 17079780; 17081983; 17095719; 17203192; 17204476; 17211576; 17216339; 17219054; 17229906; 17244614; 17254481; 17277740; 17295091; 17389623; 17391133; 17400606; 17413033; 17452746; 17467999; 17511591; 17520317; 17526019; 17526500; 17531161; 17541213; 17558910; 17567933; 17600318; 17601350; 17603281; 17620093; 17652371; 17657593; 17667816; 17721824; 17726138; 17823375; 17853070; 17873285; 17883332; 17886034; 17896171; 17915953; 17919491; 17919492; 17927807; 17953374; 17964723; 17971338; 17991645; 18007994; 18042465; 18045827; 18048809; 18050210; 18077487; 18093274; 18174022; 18195184; 18200441; 18201862; 18202225; 18205746; 18216050; 18234118; 18261117; 18272347; 18274635; 18275848; 18289072; 18307065; 18312299; 18332044; 18344023; 18381758; 18390757; 18404535; 18443197; 18459998; 18460015; 18461097; 18483307; 18502573; 18508827; 18515325; 18524839; 18544348; 18550526; 18560362; 18566988; 18576916; 18582925; 18586007; 18587252; 18596041; 18597895; 18620357; 18640487; 18651163; 18665050; 18689604; 18692581; 18757839; 18769149; 18774956; 18786476; 18787101; 18799519; 18804049; 18811919; 18841019; 18845641; 18923065; 18930811; 18957281; 18975324; 18977241; 18981090; 18983509; 19056482; 19120903; 19122175; 19129475; 19133325; 19165391; 19194559; 19236506; 19238116; 19243019; 19243105; 19246912; 19250338; 19255063; 19255829; 19282863; 19289500; 19303319; 19322201; 19325051; 19336475; 19360326; 19371606; 19389234; 19399816; 19422386; 19428335; 19445907; 19457084; 19457866; 19475336; 19484149; 19487598; 19508729; 19522732; 19526221; 19526463; 19536150; 19548360; 19556236; 19578796; 19586801; 19587144; 19590927; 19604147; 19625608; 19669099; 19676145; 19696228; 19777608; 19785642; 19797297; 19808663; 19808972; 19822148; 19850937; 19853072; 19874887; 19879747; 19884647; 19886851; 19895178; 19903700; 19903769; 19910578; 19913121; 19924377; 19925812; 19965783; 20013271; 20020468; 20021945; 20039940; 20049130; 20064636; 20110814; 20121710; 20127796; 20155807; 20170613; 20175935; 20188821; 20190330; 20193368; 20194081; 20223113; 20229611; 20232486; 20299368; 20345481; 20345975; 20346360; 20351094; 20386498; 20395442; 20404253; 20416077; 20430037; 20446774; 20482362; 20485444; 20504881; 20508205; 20509889; 20518850; 20526373; 20580464; 20585394; 20587610; 20597111; 20599261; 20628086; 20633528; 20667089; 20682519; 20689807; 20705711; 20706680; 20708634; 20733275; 20796278; 20811623; 20832528; 20838751; 20846452; 20868356; 20869265; 20934533; 20938987; 21037234; 21044950; 21079975; 21080099; 21081499; 21091076; 21102410; 21113640; 21136273; 21144518; 21148661; 21157922; 21172416; 21174817; 21191307; 21198350; 21206978; 21211285; 21216973; 21233593; 21236443; 21275653; 21296438; 21307400; 21321939; 21354100; 21366594; 21389316; 21412259; 21425334; 21426408; 21454555; 21495030; 21497776; 21502755; 21506927; 21518986; 21525764; 21531452; 21545264; 21552291; 21555518; 21556890; 21576421; 21598088; 21620964; 21646819; 21647550; 21725851; 21729576; 21737788; 21741353; 21742584; 21756955; 21765894; 21781496; 21808062; 21827279; 21833623; 21861350; 21868703; 21889036; 21898994; 21902835; 21906983; 21911884; 21911919; 21945498; 21963094; 21982894; 21987660; 21988832; 21992109; 22048453; 22078849; 22088544; 22095074; 22123460; 22137262; 22138245; 22142473; 22147556; 22155307; 22158875; 22200625; 22203790; 22212955; 22264017; 22271370; 22276118; 22290142; 22302482; 22323644; 22330859; 22338608; 22418244; 22427825; 22438807; 22461696; 22490514; 22503972; 22541814; 22542718; 22545110; 22549002; 22559824; 22573121; 22578468; 22578957; 22579918; 22580187; 22583702; 22587389; 22594519; 22613607; 22630328; 22666428; 22670665; 22682876; 22689053; 22698995; 22750196; 22776971; 22842631; 22843690; 22849380; 22875919; 22879597; 22881289; 22901690; 22939811; 22945906; 22959128; 22966170; 22989377; 23010497; 23046979; 23051580; 23052192; 23055342; 23074199; 23087099; 23090292; 23092328; 23103292; 23114386; 23123430; 23139759; 23150184; 23158494; 23221079; 23226098; 23238643; 23251661; 23255485; 23288142; 23293173; 23324179; 23345623; 23403148; 23403272; 23406266; 23406650; 23412940; 23423194; 23430116; 23437133; 23454680; 23521418; 23526997; 23536693; 23569422; 23571756; 23580430; 23583371; 23602216; 23606537; 23615401; 23617628; 23660665; 23665328; 23671274; 23714423; 23720344; 23725037; 23737527; 23792437; 23840483; 24038461; 24053646; 24109237; 24211270; 24239896,,,,,,,,,,,,,,,OGG:3000003162,,,,,,,heme oxygenase (decycling) 1,,,,,,,,,,,,,"Other designations: heat shock protein, 32-kD|heme oxygenase 1",,HMOX1,,,,,,,,,,,,,,,,,,,,,,,3162,CTA-286B10.6,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,HMOX1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0001665,RGS7,,,false,,,http://purl.obolibrary.org/obo/IMR_0000431,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001665,,,,,,,,,,,,,,,,,,,,,,RGS7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000096,interleukin receptor,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,GO:0004907,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003331,,,,,,,,,,IMR:0000096,,,,,,,,,,,,,,,,,,,,,,interleukin receptor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004691,MIR135A1 (human) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/OGG_3000406925,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:406925|PMID:25796501,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004691,,,,,,,,,,,,,,,,,,,,,,MIR135A1 (human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9606,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004692,MIR135A2 (human) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/OGG_3000406926,,,,,,,,,,,,,,,,,,,,PMID:28159835|NCBI-Human-GeneID:406926,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004692,,,,,,,,,,,,,,,,,,,,,,MIR135A2 (human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9606,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004690,Increasing MIR135A level,,Increasing MIR135A level is a subtype of increasing quantity: A process that changes the amount of MIR135A level to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing MIR135A level is a subtype of increasing quantity: A process that changes the amount of MIR135A level to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004690,,,,,,,,,,,,,,,,,,,,,,Increasing MIR135A level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004693,PTPRD inactivation [hepatocarcinogenesis],,"PTPRD inactivation is a subtype of molecular inactivation: A process that  changes the activity of the PTPRD (protein tyrosine phosphatase receptor type D) to be lower.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004785,,,,,,,,,,,,,,,,,,,,PMID:28159835|PMID:25831062,,"PTPRD inactivation is a subtype of molecular inactivation: A process that  changes the activity of the PTPRD (protein tyrosine phosphatase receptor type D) to be lower.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004786,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004787,,,,,,,,,,,TXPO:0004693,,,,,,,,,,,,,,,,,,,,,,PTPRD inactivation [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004695,MMP7 signaling (primitive) [hepatocarcinogenesis],,"MMP7 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by MMP7.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004696,,,,,,,,,,,,,,,,,,,,PMID:29679563,,"MMP7 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by MMP7.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004404,,,,,,,,,,,TXPO:0004695,,,,,,,,,,,,,,,,,,,,,,MMP7 signaling (primitive) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004696,MMP7 signal (primitive),,MMP7 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by MMP7.,false,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,,,MMP7 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by MMP7.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004694,,,,,,,,,,,,,,,,TXPO:0004696,,,,,,,,,,,,,,,,,,,,,,MMP7 signal (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004694,MMP7 signal transduction pathway,,A series of molecular signals mediated by MMP7 (matrix metallopeptidase 7).,false,,,http://purl.obolibrary.org/obo/TXPO_0000609,,,,,,,,,,,,,,,,,,,,,,A series of molecular signals mediated by MMP7 (matrix metallopeptidase 7).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004694,,,,,,,,,,,,,,,,,,,,,,MMP7 signal transduction pathway,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004697,Increasing MYC level,,Increasing MYC level is a subtype of increasing quantity: A process that changes the amount of MYC level to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing MYC level is a subtype of increasing quantity: A process that changes the amount of MYC level to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000383,,,,,,,,,,,,,,,,,,,TXPO:0004697,,,,,,,,,,,,,,,,,,,,,,Increasing MYC level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004699,Myc(mouse) [hepatocarcinogenesis],c-Myc,,false,,,http://purl.obolibrary.org/obo/IMR_0000383|http://purl.obolibrary.org/obo/TXPO_0005072,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:17869|PMID:10774822,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,c-Myc,,,,,TXPO:0004699,,,,,,,,,,,,,,,,,,,,,,Myc(mouse) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004698,Increasing MYC level [hepatocarcinogenesis],,"Increasing MYC level is a subtype of increasing quantity: A process that changes the amount of MYC level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004697,,,,,,,,,,,,,,,,,,,,PMID:11359698|PMID:10774822|PMID:30141584,,"Increasing MYC level is a subtype of increasing quantity: A process that changes the amount of MYC level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004701|http://purl.obolibrary.org/obo/TXPO_0004700|http://purl.obolibrary.org/obo/TXPO_0004699,,http://purl.obolibrary.org/obo/TXPO_0004516,,,,,,http://purl.obolibrary.org/obo/TXPO_0004392,,,,,,,,,,,TXPO:0004698,,,,,,,,,,,,,,,,,,,,,,Increasing MYC level [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004051,C1orf162 [Hepatocarcinogenesis],Chromosome 1 Open Reading Frame 162,,false,,,http://purl.obolibrary.org/obo/TXPO_1000052|http://purl.obolibrary.org/obo/TXPO_0000837,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:128346,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Chromosome 1 Open Reading Frame 162,,,,,TXPO:0004051,,,,,,,,,,,,,,,,,,,,,,C1orf162 [Hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004057,Ccng1 [Hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000089|http://purl.obolibrary.org/obo/TXPO_0000837,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:900|NCBI-Rat-GeneID:25405|NCBI-Mouse-GeneID:12450|PMID:22835824|PMID:12015958,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004057,,,,,,,,,,,,,,,,,,,,,,Ccng1 [Hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004055,Caspase-3 [Hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0000837|http://purl.obolibrary.org/obo/TXPO_0001145,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:12367|NCBI-Rat-GeneID:25402|NCBI-Human-GeneID:836,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004055,,,,,,,,,,,,,,,,,,,,,,Caspase-3 [Hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004052,HMGCS2(human)[Phospholipidosis],,"HMGCS2 transcription is heavily regulated by FOXA2, mTOR, PPARα, and FGF21.",false,,,http://purl.obolibrary.org/obo/TXPO_1000189|http://purl.obolibrary.org/obo/TXPO_0001135,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:3158|PMID:28888048|PMID:27816970|PMID:21502324,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000003158,,,,,,,,,,,,,TXPO:0004052,,,,,,,,,,,,,,,,,,,,"HMGCS2 transcription is heavily regulated by FOXA2, mTOR, PPARα, and FGF21.",,HMGCS2(human)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004059,Cdkn1a [Hepatocarcinogenesis],p21/waf1 [Hepatocarcinogenesis],,false,,,http://purl.obolibrary.org/obo/TXPO_0000837|http://purl.obolibrary.org/obo/TXPO_1000091,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1026|NCBI-Rat-GeneID:114851|NCBI-Mouse-GeneID:12575|PMID:17239344|PMID:24626178|PMID:24092862|PMID:26238857,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p21/waf1 [Hepatocarcinogenesis],,,,,TXPO:0004059,,,,,,,,,,,,,,,,,,,,,,Cdkn1a [Hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004050,HMGCS2 (predicted)[Phospholipidosis],,,false,,,http://purl.obolibrary.org/obo/TXPO_1000189|http://purl.obolibrary.org/obo/TXPO_0001135,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:3158,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000003158,,,,,,,,,,,,,TXPO:0004050,,,,,,,,,,,,,,,,,,,,,,HMGCS2 (predicted)[Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004054,CARMIL3 [Hepatocarcinogenesis],capping protein regulator and myosin 1 linker 3|LRRC16B,,false,,,http://purl.obolibrary.org/obo/TXPO_1000057|http://purl.obolibrary.org/obo/TXPO_0000837,,,,,,,,,,,,,,,,,,,,PMID:26578515|PMID:21102520,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,capping protein regulator and myosin 1 linker 3|LRRC16B,,,,,TXPO:0004054,,,,,,,,,,,,,,,,,,,,,,CARMIL3 [Hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004056,CCNB2 [Hepatocarcinogenesis],cyclin B2,,false,,,http://purl.obolibrary.org/obo/TXPO_0000837|http://purl.obolibrary.org/obo/TXPO_1000061,,,,,,,,,,,,,,,,,,,"Cyclin B2 and p53 control proper timing of centrosome separation.
PMID:9539739

A centrosomal route for cancer genome instability.
Cyclin B2 is now shown to control a pathway - involving the centrosomal kinases aurora A and Plk1 and the tumour suppressor p53 - the alteration of which causes defective centrosome separation, aneuploidy and tumour development. 
PMID:24875738",NCBI-Rat-GeneID:363088|NCBI-Mouse-GeneID:12442|NCBI-Human-GeneID:9133|PMID:9926943|PMID:24875738|PMID:17533373|PMID:9539739|PMID:24324638|PMID:20660152,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,cyclin B2,,,,,TXPO:0004056,,,,,,,,,,,,,,,,,,,,,,CCNB2 [Hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004058,CENPE [Hepatocarcinogenesis],,The CENPE gene encodes a large kinetochore-associated kinesin-like motor protein required for spindle microtubule capture and attachment at the kinetochore during cell division,false,,,http://purl.obolibrary.org/obo/TXPO_0000837|http://purl.obolibrary.org/obo/TXPO_1000064,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1062|NCBI-Mouse-GeneID:229841|NCBI-Rat-GeneID:362044|PMID:20021663,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004058,,,,,,,,,,,,,,,,,,,,The CENPE gene encodes a large kinetochore-associated kinesin-like motor protein required for spindle microtubule capture and attachment at the kinetochore during cell division,,CENPE [Hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004053,PPARalpha activation [Phospholipidosis],,"PPARalpha activation is a subtype of activating nuclear receptor: A process that changes the activity of the activating PPAR alpha ( (Peroxisome Proliferator Activated Receptor Alpha)) with a nuclear receptor role to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000013|http://purl.obolibrary.org/obo/TXPO_0001716,,,,,,,,,,,,,,,,,,,,PMID:27816970,,"PPARalpha activation is a subtype of activating nuclear receptor: A process that changes the activity of the activating PPAR alpha ( (Peroxisome Proliferator Activated Receptor Alpha)) with a nuclear receptor role to be higher.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004061|http://purl.obolibrary.org/obo/TXPO_0004052|http://purl.obolibrary.org/obo/TXPO_0004050,,,,,,http://purl.obolibrary.org/obo/TXPO_0001497,,,,,,,,,,,TXPO:0004053,,,,,,,,,,,,,,,,,,,,,,PPARalpha activation [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_39025,high-density lipoprotein,HDL,"A class of lipoproteins of small size (4-13 nm) and dense (greater than 1.063 g/ml) particles. They are synthesized in the liver without a lipid core, accumulate cholesterol esters from peripheral tissues and transport them to the liver for re-utilization or elimination from the body (the reverse cholesterol transport).",false,,,http://purl.obolibrary.org/obo/CHEBI_6495,,,,,,,,,,,,,,,,,,,,,,"A class of lipoproteins of small size (4-13 nm) and dense (greater than 1.063 g/ml) particles. They are synthesized in the liver without a lipid core, accumulate cholesterol esters from peripheral tissues and transport them to the liver for re-utilization or elimination from the body (the reverse cholesterol transport).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,HDL,,,CHEBI:39025,,,,,,,,,,,,,,,,,,,,,,high-density lipoprotein,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0013765,digestive system element,digestive organ|digestive system organ,"Any of the organs or elements that are part of the digestive system. Examples: tongue, esophagus, spleen, crop, lunge feeding organ, tooth elements.",false,,,http://purl.obolibrary.org/obo/UBERON_0000062,,,,,,,,,,,,,,,,,,,,http://www.snomedbrowser.com/Codes/Details/272627002,,"Any of the organs or elements that are part of the digestive system. Examples: tongue, esophagus, spleen, crop, lunge feeding organ, tooth elements.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,digestive organ|digestive system organ,,,,http://purl.obolibrary.org/obo/UBERON_0001007,UBERON:0013765,http://purl.obolibrary.org/obo/UBERON_0001007,,,,,,,,,,,,,,,,,,,,,digestive system element,,,,,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0045820,negative regulation of glycolytic process,down-regulation of glycolysis|downregulation of glycolysis|down regulation of glycolysis,"Any process that stops, prevents, or reduces the frequency, rate or extent of glycolysis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000115,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents, or reduces the frequency, rate or extent of glycolysis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,down-regulation of glycolysis|downregulation of glycolysis|down regulation of glycolysis,,,,,GO:0045820,,,,,,,,,,,,,,,,,,,,,,negative regulation of glycolytic process,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006096,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000068,PDGF receptor,platelet derived growth factor receptor,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,GO:0005017,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000823,,,,,platelet derived growth factor receptor,,,,,IMR:0000068,,,,,,,,,,,,,,,,,,,,,,PDGF receptor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_17356,2-acetamidofluorene,2-AAF|2-Acetylaminofluorene|N-(9H-fluoren-2-yl)acetamide,"The parent of the class of 2-acetamidofluorenes, being an ortho-fused polycyclic arene that consists of 9H-fluorene bearing an acetamido substituent at position 2. It is a carcinogenic and mutagenic derivative of fluorene.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,CAS:53-96-3|Wikipedia:2-Acetylaminofluorene,,"The parent of the class of 2-acetamidofluorenes, being an ortho-fused polycyclic arene that consists of 9H-fluorene bearing an acetamido substituent at position 2. It is a carcinogenic and mutagenic derivative of fluorene.",,,,,,,,,,,,C15H13NO,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,N-(9H-fluoren-2-yl)acetamide,,2-AAF|2-Acetylaminofluorene,,,CHEBI:17356,,,,,,,,,,,,,,,,,,,,,,2-acetamidofluorene,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,C(=O)(NC=1C=C2C(C=3C(C2)=CC=CC3)=CC1)C,,,,,
http://purl.obolibrary.org/obo/CHEBI_38068,antimalarial,antimalarials,A drug used in the treatment of malaria. Antimalarials are usually classified on the basis of their action against Plasmodia at different stages in their life cycle in the human.,false,,,http://purl.obolibrary.org/obo/CHEBI_64915,,,,,,,,,,,,,,,,,,,,,,A drug used in the treatment of malaria. Antimalarials are usually classified on the basis of their action against Plasmodia at different stages in their life cycle in the human.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,antimalarials,,,,,,,,,,,,,,,,,,,,,CHEBI:38068,,,,antimalarial,,CHEBI:38068,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000615,neuregulin-2,NRG-2,,false,,,http://purl.obolibrary.org/obo/IMR_0000048,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,NRG-2,,,,,IMR:0000615,,,,,,,,,,,,,,,,,,,,,,neuregulin-2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000008,IL-2,TCGF|Interleukin-2,,false,,,http://purl.obolibrary.org/obo/IMR_0000007,,,,,,,,,,,,,,,,,,,,GO:0005134,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000622,,,,,TCGF|Interleukin-2,,,,,IMR:0000008,,,,,,,,,,,,,,,,,,,,,,IL-2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004652,KIAA0101 inactivation [hepatocarcinogenesis],,"KIAA0101 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the KIAA0101 (PCLAF, PCNA clamp associated factor) to be lower.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004677,,,,,,,,,,,,,,,,,,,,PMID:29227529,,"KIAA0101 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the KIAA0101 (PCLAF, PCNA clamp associated factor) to be lower.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004678,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004679|http://purl.obolibrary.org/obo/TXPO_0004650,,,,,,,,,,,TXPO:0004652,,,,,,,,,,,,,,,,,,,,,,KIAA0101 inactivation [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004650,IL-6 inactivation [hepatocarcinogenesis],,"IL-6 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the IL-6 (interleukin 6) to be lower.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004649,,,,,,,,,,,,,,,,,,,,PMID:29227529,,"IL-6 inactivation is a subtype of molecular inactivation: A process that  changes the activity of the IL-6 (interleukin 6) to be lower.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004651,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004652,,,,,,,,,,,TXPO:0004650,,,,,,,,,,,,,,,,,,,,,,IL-6 inactivation [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004655,JAK signaling (primitive) [hepatocarcinogenesis],,"JAK signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the JAK (Janus kinase) .
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004667,,,,,,,,,,,,,,,,,,,,PMID:28584306,,"JAK signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the JAK (Janus kinase) .
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004587,,,,,,,,,,,TXPO:0004655,,,,,,,,,,,,,,,,,,,,,,JAK signaling (primitive) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004657,IL1 signaling (primitive),,IL1 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the cytokine IL1.,false,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,,,IL1 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the cytokine IL1.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0070498,,,,,,,,,,,,,,,,TXPO:0004657,,,,,,,,,,,,,,,,,,,,,,IL1 signaling (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004658,IL-1B(canonical) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0005063|http://purl.obolibrary.org/obo/TXPO_1000200,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:3553|NCBI-Rat-GeneID:24494|NCBI-Mouse-GeneID:16176|PMID:31781608,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003041,,,,,,,,,,TXPO:0004658,,,,,,,,,,,,,,,,,,,,,,IL-1B(canonical) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004651,IL-6 - inactive form (human)[hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_0004654,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:3569|PMID:29227529,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0002355,,,,http://purl.obolibrary.org/obo/TXPO_0003724,,,,,,,,,,TXPO:0004651,,,,,,,,,,,,,,,,,,,,,,IL-6 - inactive form (human)[hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004659,IL-6 signaling [hepatocarcinogenesis],,IL-6 signaling is a subtype of signaling [biological]: Any series of molecular signals generated as a consequence of binding to Interleukin 6. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.,false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004327,,,,,,,,,,,,,,,,,,,,PMID:25181692|PMID:31623280|PMID:31781608,,IL-6 signaling is a subtype of signaling [biological]: Any series of molecular signals generated as a consequence of binding to Interleukin 6. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004660,http://purl.obolibrary.org/obo/GO_0070102,,,,,http://purl.obolibrary.org/obo/TXPO_0004276|http://purl.obolibrary.org/obo/TXPO_0004661,,,,,,,,,,,TXPO:0004659,,,,,,,,,,,,,,,,,,,,,,IL-6 signaling [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004656,IL1 signaling (primitive) [hepatocarcinogenesis],,"IL1 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the cytokine IL1.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004657,,,,,,,,,,,,,,,,,,,,PMID:31781608,,"IL1 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the cytokine IL1.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004658,http://purl.obolibrary.org/obo/GO_0070498,,,,,http://purl.obolibrary.org/obo/TXPO_0004479|http://purl.obolibrary.org/obo/TXPO_0004276,,,,,,,,,,,TXPO:0004656,,,,,,,,,,,,,,,,,,,,,,IL1 signaling (primitive) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004653,Increasing IL-6 level,,Increasing IL-6 level is a subtype of increasing quantity: A process that changes the amount of IL-6 level to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing IL-6 level is a subtype of increasing quantity: A process that changes the amount of IL-6 level to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004654,,,,,,,,,,,,,,,,,,,TXPO:0004653,,,,,,,,,,,,,,,,,,,,,,Increasing IL-6 level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004654,IL-6(human)[hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/IMR_0000010,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:3569,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003724,,,,,,,,,,TXPO:0004654,,,,,,,,,,,,,,,,,,,,,,IL-6(human)[hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_16412,liposaccharide,LPS,Liposaccharide natural compounds consisting of a trisaccharide repeating unit (two heptose units and octulosonic acid) with oligosaccharide side chains and 3-hydroxytetradecanoic acid units (they are a major constituent of the cell walls of Gram-negative bacteria).|Lipopolysaccharide (LPS) is a glycosylated lipid on the outer surface of Gram-negative bacteria acts as immunostimulants.,false,,,http://purl.obolibrary.org/obo/CHEBI_18059|http://purl.obolibrary.org/obo/CHEBI_18154,,,,,,,,,,,,,,,,,,,,,,Liposaccharide natural compounds consisting of a trisaccharide repeating unit (two heptose units and octulosonic acid) with oligosaccharide side chains and 3-hydroxytetradecanoic acid units (they are a major constituent of the cell walls of Gram-negative bacteria).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,LPS,,,,,CHEBI:16412,,,,,,,,,,,,,,,,,,,,Lipopolysaccharide (LPS) is a glycosylated lipid on the outer surface of Gram-negative bacteria acts as immunostimulants.,,liposaccharide,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0098800,inner mitochondrial membrane protein complex,,Any protein complex that is part of the inner mitochondrial membrane.,false,,,http://purl.obolibrary.org/obo/TXPO_0002107,,,,,,,,,,,,,,,,,,,,,,Any protein complex that is part of the inner mitochondrial membrane.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0098800,,,,,,,,,,,,,,,,,,,,,,inner mitochondrial membrane protein complex,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001593,Rab13 (mol),,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001593,,,,,,,,,,,,,,,,,,,,,,Rab13 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0003085,GDF-5 subfamily,,"BMP-related proteins can be subdivided into several groups based on their structures and functions. GDF-5 (CDMP- 1), GDF-6 (CDMP-2 or BMP-13), and GDF-7 (BMP-12) form one sugroup.",false,,,http://purl.obolibrary.org/obo/IMR_0000040,,,,,,,,,,,,,,,,,,,,,,"BMP-related proteins can be subdivided into several groups based on their structures and functions. GDF-5 (CDMP- 1), GDF-6 (CDMP-2 or BMP-13), and GDF-7 (BMP-12) form one sugroup.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0003085,,,,,,,,,,,,,,,,,,,,,,GDF-5 subfamily,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000449,NRF2 signaling (primitive),,NRF2 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal transmitted by the NRF2.,false,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,,,NRF2 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal transmitted by the NRF2.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002490,,,,,http://purl.obolibrary.org/obo/NCIT_C16407|http://purl.obolibrary.org/obo/GO_0043066,,,,,,,,,,,TXPO:0000449,,,,,,,,,,,,,,,,,,,,,,NRF2 signaling (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000443,hyperfunction of drug metabolism [Ground glass appearance],,"Hyperfunction of drug metabolism is a subtype of hyperfunctioning of metabolism: A process that performs an excessive drug metabolism.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0002347|http://purl.obolibrary.org/obo/TXPO_0001728,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of drug metabolism is a subtype of hyperfunctioning of metabolism: A process that performs an excessive drug metabolism.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000938|http://purl.obolibrary.org/obo/TXPO_0000943,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001665,,,,,,,,,,,TXPO:0000443,,,,,,,,,,,,,,,,,,,,,,hyperfunction of drug metabolism [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000445,caspase signaling (primitive) [ER stress],,"Caspase signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the caspase.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0003736|http://purl.obolibrary.org/obo/TXPO_0000444,,,,,,,,,,,,,,,,,,,,,,"Caspase signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the caspase.
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000513,,,,,,,,,,,TXPO:0000445,,,,,,,,,,,,,,,,,,,,,,caspase signaling (primitive) [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000442,transmitting,,Transmitting is a subtype of sifting: A process to send out an operand from a medium A to a medium B.,false,,,http://purl.obolibrary.org/obo/TXPO_0000441,,,,,,,,,,,,,,,,,,,,,,Transmitting is a subtype of sifting: A process to send out an operand from a medium A to a medium B.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000442,,,,,,,,,,,,,,,,,,,,,,transmitting,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000447,extrinsic (Death Domain) signaling (primitive),,Death Domain sgnaling (primitive) is a subtype of signaling [biological]: A process in which a signal is transmitted from the cell membrane receptor starting with a ligand. The death domain at the cytoplsmic tail of the receptor binds the other death domain of the docking protein to form a death-inducing signaling complex (DISC).,false,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,ISBN:0123878179,,Death Domain sgnaling (primitive) is a subtype of signaling [biological]: A process in which a signal is transmitted from the cell membrane receptor starting with a ligand. The death domain at the cytoplsmic tail of the receptor binds the other death domain of the docking protein to form a death-inducing signaling complex (DISC).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000611,,,,,,,,,,,,,,,,TXPO:0000447,,,,,,,"This signal triggers the assembly of intracellular proteins to form a death including signaling complex (DISC), which includes a specific intiator procaspase (procaspase-8, 10). These initiator procasapases cleave and converts effector procaspases (i.e., caspase-3, 6, 7)  to activate.  Then, these effector caspases cleave target proteins, which leads to execute apoptosis.",,,,,,,,,,,,,,,extrinsic (Death Domain) signaling (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000441,sifting,,Sifting is a subtype of changing between operands: A process to move an operand from one medium to another medium.|Changing medium from medium A to medium B.,false,,,http://purl.obolibrary.org/obo/TXPO_0000261,,,,,,,,,,,,,,,,,,,,,,Sifting is a subtype of changing between operands: A process to move an operand from one medium to another medium.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000441,,,,,,,,,,,,,,,,,,,,Changing medium from medium A to medium B.,,sifting,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000444,caspase signaling (primitive),,Caspase signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the caspase.,false,,,http://purl.obolibrary.org/obo/GO_0023052,,,,,,,,,,,,,,,,,,,,,,Caspase signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the caspase.,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/IMR_0000305,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002482,,,,,,,,,,,,,,,,TXPO:0000444,,,,,,,,,,,,,,,,,,,,,,caspase signaling (primitive),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000448,extrinsic (Death domain) signaling (primitive) [Cell death],,"Death Domain signaling (primitive) is a subtype of signaling [biological]: A process in which a signal is transmitted from the cell membrane receptor starting with a ligand. The death domain at the cytoplsmic tail of the receptor binds the other death domain of the docking protein to form a death-inducing signaling complex (DISC).
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0001727|http://purl.obolibrary.org/obo/TXPO_0000447,,,,,,,,,,,,,,,,,,,,,,"Death Domain signaling (primitive) is a subtype of signaling [biological]: A process in which a signal is transmitted from the cell membrane receptor starting with a ligand. The death domain at the cytoplsmic tail of the receptor binds the other death domain of the docking protein to form a death-inducing signaling complex (DISC).
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000653,http://purl.obolibrary.org/obo/TXPO_0003061,,,,,http://purl.obolibrary.org/obo/TXPO_0000514,,,,,,,,,,,TXPO:0000448,,,,,,,,,,,,,,,,,,,,,,extrinsic (Death domain) signaling (primitive) [Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000446,caspase signaling (primitive) [Cell death],,"Caspase signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the caspase.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",false,,,http://purl.obolibrary.org/obo/TXPO_0001727|http://purl.obolibrary.org/obo/TXPO_0000444,,,,,,,,,,,,,,,,,,,,,,"Caspase signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the caspase.
This entity is a specific course-dependent process. This process can constitute the course of Cell death.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000653,,,,,,http://purl.obolibrary.org/obo/TXPO_0000514,,,,,,,,,,,TXPO:0000446,,,,,,,,,,,,,,,,,,,,,,caspase signaling (primitive) [Cell death],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000440,negative regulation of phospholipase C mediated phosphatidylinositol degradation,,"Negative regulation of phospholipase C mediated phosphatidylinositol is a subtype of negative regulation of phospholipase C mediated phospholipid degradation: A process that stops, prevents, or reduces the frequency, rate or extent of phospholipase C mediated phosphatidylinositol degradation.",false,,,http://purl.obolibrary.org/obo/TXPO_0001659,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of phospholipase C mediated phosphatidylinositol is a subtype of negative regulation of phospholipase C mediated phospholipid degradation: A process that stops, prevents, or reduces the frequency, rate or extent of phospholipase C mediated phosphatidylinositol degradation.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000440,,,,,,,,,,,,,,,,,,,,,,negative regulation of phospholipase C mediated phosphatidylinositol degradation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100042,thyroid hormone (substance),,,false,,,http://purl.obolibrary.org/obo/IMR_0000966,,,,,,,,,,,,,,,,,,,,MeSH:D013963,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100042,,,,,,,,,,,,,,,,,,,,,,thyroid hormone (substance),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001502,Rac2,,,false,,,http://purl.obolibrary.org/obo/IMR_0000297,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001502,,,,,,,,,,,,,,,,,,,,,,Rac2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/UBERON_0002416,integumental system,integumentum commune|dermal system|surface|external covering of organism|body surface|organism surface|integumentary system,"Connected anatomical system that forms a barrier between an animal and its environment. In vertebrates, the integumental system consists of the epidermis, dermis plus associated glands and adnexa such as hair and scales. In invertebrates, the integumental system may include cuticle.",false,,,http://purl.obolibrary.org/obo/UBERON_0000467,,,,,,,,,,,,,,,,,,,,http://en.wikipedia.org/wiki/Integumentary_system|http://www.snomedbrowser.com/Codes/Details/361692004|http://linkedlifedata.com/resource/umls/id/C0037267|http://purl.obolibrary.org/obo/NCIT_C12907|EV:0100151|AEO:0000154|EHDAA2:0000836|TADS:0000108|EHDAA2_RETIRED:0003154|HAO:0000421|MA:0000014|UMLS:C0037267|FMA:72979|CALOHA:TS-1299|VHOG:0000403|XAO:0000176|EFO:0000807|FBbt:00004969|CARO:0002001|BILA:0000118|galen:Surface|EMAPA:17524|EHDAA:6520|MIAA:0000033|MAT:0000033|MESH:D034582,,"Connected anatomical system that forms a barrier between an animal and its environment. In vertebrates, the integumental system consists of the epidermis, dermis plus associated glands and adnexa such as hair and scales. In invertebrates, the integumental system may include cuticle.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,UBERON:0007029,integumentary system,,integumentum commune|dermal system|surface|external covering of organism|body surface|organism surface,(...) the integument of many tetrapods is reinforced by a morphologically and structurally diverse assemblage of skeletal elements. These elements are widely understood to be derivatives of the once all-encompassing dermal skeleton of stem-gnathostomes (...).[well established][VHOG],,UBERON:0002416,,,,https://github.com/cmungall|https://github.com/tfhayamizu,,,,,,,,,,,,,,,,,,integumental system,,,,,,,http://purl.obolibrary.org/obo/uberon.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/BFO_0000020,specifically dependent continuant,,b is a specifically dependent continuant = Def. b is a continuant & there is some independent continuant c which is not a spatial region and which is such that b s-depends_on c at every time t during the course of b’s existence. (axiom label in BFO2 Reference: [050-003]),false,,,http://purl.obolibrary.org/obo/BFO_0000002,,,,,,,,,,,,,,,,,,,,,,b is a specifically dependent continuant = Def. b is a continuant & there is some independent continuant c which is not a spatial region and which is such that b s-depends_on c at every time t during the course of b’s existence. (axiom label in BFO2 Reference: [050-003]),,,,"Specifically dependent continuant doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. We're not sure what else will develop here, but for example there are questions such as what are promises, obligation, etc.",,,"the pink color of a medium rare piece of grilled filet mignon at its center|the shape of this hole.|the disposition of this fish to decay|the mutual dependence of proton donors and acceptors in chemical reactions [79|the role of being a doctor|Reciprocal specifically dependent continuants: the function of this key to open this lock and the mutually dependent disposition of this lock: to be opened by this key|the smell of this portion of mozzarella|the mutual dependence of the role predator and the role prey as played by two organisms in a given interaction|the function of this heart: to pump blood|of one-sided specifically dependent continuants: the mass of this tomato|of relational dependent continuants (multiple bearers): John’s love for Mary, the ownership relation between John and this statue, the relation of authority between John and his subordinates.",,,,,,,,,,,(iff (SpecificallyDependentContinuant a) (and (Continuant a) (forall (t) (if (existsAt a t) (exists (b) (and (IndependentContinuant b) (not (SpatialRegion b)) (specificallyDependsOnAt a b t))))))) // axiom label in BFO2 CLIF: [050-003],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BFO:0000020,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/bfo.owl,specifically dependent continuant,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004396,negative regulation of apoptotic process [hepatocarcinogenesis],,"Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptotic process.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/GO_0043066,,,,,,,,,,,,,,,,,,,,PMID:29270806|PMID:25797246|PMID:28493839|PMID:29335519|PMID:30700007|PMID:22576474|PMID:30947731|PMID:31781608|PMID:23284992,,"Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptotic process.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004764,http://purl.obolibrary.org/obo/TXPO_0004917|http://purl.obolibrary.org/obo/TXPO_0004918,,,,,,http://purl.obolibrary.org/obo/TXPO_0004919,,,,,,,,,,,TXPO:0004396,,,,,,,,,,,,,,,,,,,,,,negative regulation of apoptotic process [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004394,chemokine (C-X-C motif) ligand 8 production [hepatocarcinogenesis],CXCL8 production,"The appearance of chemokine (C-X-C motif) ligand 8 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0004478|http://purl.obolibrary.org/obo/TXPO_0002340,,,,,,,,,,,,,,,,,,,,PMID:30523154|PMID:29679563,,"The appearance of chemokine (C-X-C motif) ligand 8 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004198,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004404|http://purl.obolibrary.org/obo/TXPO_0004479|http://purl.obolibrary.org/obo/TXPO_0004438|http://purl.obolibrary.org/obo/TXPO_0004413,,,,,,CXCL8 production,,,,,TXPO:0004394,,,,,,,,,,,,,,,,,,,,,,chemokine (C-X-C motif) ligand 8 production [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004390,Hypofunction of PPARGC1A gene expression [mitochondrial disorder],,"Hypofunction of PPARGC1A gene expression is a subtype of hypofunction of transcription, DNA-templated: A process that performs a decreased or insufficient PPARGC1A gene expression.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0004768|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:31623280|PMID:23299992,,"Hypofunction of PPARGC1A gene expression is a subtype of hypofunction of transcription, DNA-templated: A process that performs a decreased or insufficient PPARGC1A gene expression.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004769,,,,,,http://purl.obolibrary.org/obo/TXPO_0004225,,,,,,,,,,,TXPO:0004390,,,,,,,,,,,,,,,,,,,,,,Hypofunction of PPARGC1A gene expression [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004391,Increasing IL-6 level [hepatocarcinogenesis],,"Increasing IL-6 level is a subtype of increasing quantity: A process that changes the amount of IL-6 level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004653,,,,,,,,,,,,,,,,,,,,PMID:25181692|PMID:28584306,,"Increasing IL-6 level is a subtype of increasing quantity: A process that changes the amount of IL-6 level to be higher.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004654,,http://purl.obolibrary.org/obo/NCIT_C116387,,,,,,http://purl.obolibrary.org/obo/TXPO_0004655,,,,,,,,,,,TXPO:0004391,,,,,,,,,,,,,,,,,,,,,,Increasing IL-6 level [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004393,increasing production amount of reactive aldehyde [mitochondrial disorder],,"Increasing production amount of reactive aldehyde is a subtype of increasing quantity: A process that changes the production amount of reactive aldehyde to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0005023|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:25339807|PMID:23299992,,"Increasing production amount of reactive aldehyde is a subtype of increasing quantity: A process that changes the production amount of reactive aldehyde to be higher.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0005025|http://purl.obolibrary.org/obo/TXPO_0005024|http://purl.obolibrary.org/obo/TXPO_0004979,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000869,,,,,,,,,,,TXPO:0004393,,,,,,,,,,,,,,,,,,,,,,increasing production amount of reactive aldehyde [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004392,tumorigenesis [hepatocarcinogenesis],,"A pathologic process that involves the transformation of normal cells to a neoplastic state and resulting in polyclonal or monoclonal neoplastic cell proliferation.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/NCIT_C18121,,,,,,,,,,,,,,,,,,,,PMID:28159835|PMID:31439937|PMID:1596892|PMID:28932315|PMID:31507621|PMID:30710550|PMID:22584684|PMID:12748687|PMID:20101231|PMID:22576474|PMID:26017875|PMID:31239782|PMID:15511635|PMID:30894684|PMID:18245951|PMID:9884324|PMID:23626729|PMID:25607821|PMID:21724974|PMID:2335008|PMID:30704071,,"A pathologic process that involves the transformation of normal cells to a neoplastic state and resulting in polyclonal or monoclonal neoplastic cell proliferation.
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004704|http://purl.obolibrary.org/obo/TXPO_0004948|http://purl.obolibrary.org/obo/TXPO_0005138|http://purl.obolibrary.org/obo/TXPO_0004934|http://purl.obolibrary.org/obo/TXPO_0005008|http://purl.obolibrary.org/obo/TXPO_0004513|http://purl.obolibrary.org/obo/TXPO_0005060|http://purl.obolibrary.org/obo/TXPO_0005062|http://purl.obolibrary.org/obo/TXPO_0004907|http://purl.obolibrary.org/obo/TXPO_0004971|http://purl.obolibrary.org/obo/TXPO_0004448|http://purl.obolibrary.org/obo/TXPO_0004922|http://purl.obolibrary.org/obo/TXPO_0004924|http://purl.obolibrary.org/obo/TXPO_0004961,,,,,,,,,,,,,,,,,TXPO:0004392,,,,,,,,,,,,,,,,,,,,,,tumorigenesis [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/UBERON_0002107,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004399,ACSL1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:25288|NCBI-Human-GeneID:2180|NCBI-Mouse-GeneID:14081,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004399,,,,,,,,,,,,,,,,,,,,,,ACSL1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004397,Iron accumulation [mitochondrial disorder],,"Iron accumulation is a subtype of accumulation of substances in a biological object: A process that keeps iron in an organism, tissue, organelle, or cell.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0003182,,,,,,,,,,,,,,,,,,,,PMID:31623280,,"Iron accumulation is a subtype of accumulation of substances in a biological object: A process that keeps iron in an organism, tissue, organelle, or cell.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_18248,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004373,,,,,,,,,,,TXPO:0004397,,,,,,,,,,,,,,,,,,,,,,Iron accumulation [mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004395,Snail1 signaling [hepatocarcinogenesis],,"Snail1 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the Snail1 (snail family transcriptional repressor 1) .
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002340|http://purl.obolibrary.org/obo/TXPO_0004810,,,,,,,,,,,,,,,,,,,,PMID:29358721|PMID:28584306,,"Snail1 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the Snail1 (snail family transcriptional repressor 1) .
This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004812,,,,,,http://purl.obolibrary.org/obo/TXPO_0004779|http://purl.obolibrary.org/obo/TXPO_0004422|http://purl.obolibrary.org/obo/TXPO_0004392,,,,,,,,,,,TXPO:0004395,,,,,,,,,,,,,,,,,,,,,,Snail1 signaling [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004398,Increasing ACSL1 level,,Increasing ACSL1 level is a subtype of increasing quantity: A process that changes the amount of ACSL1 level to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing ACSL1 level is a subtype of increasing quantity: A process that changes the amount of ACSL1 level to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004399,,,,,,,,,,,,,,,,,,,TXPO:0004398,,,,,,,,,,,,,,,,,,,,,,Increasing ACSL1 level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000065992,DDRGK1,,Other designations: DDRGK domain-containing protein 1|Dashurin|UFM1-binding protein 1 containing a PCI domain,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,UFBP1|dJ1187M17.3|C20orf116,,,,,,,,,,,,20,,,,,,HPRD:12741|HGNC:16110|Ensembl:ENSG00000198171|Vega:OTTHUMG00000031732,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,DDRGK domain containing 1,,,20p13,,,,,,,,,,,,,,,,GO_0005515 (EC: IPI); GO_0005783 (EC: IDA),,,,,,,,,PMID: 11780052; 12477932; 15489334; 17207965; 17353931; 20018847; 20036718; 20228063; 20637204; 21139048; 21494687; 21659334; 21832049; 21890473; 22939629; 23675531; 24250222,,,,,,,,,,,,,,,OGG:3000065992,,,,,,,DDRGK domain containing 1,,,,,,,,,,,,,Other designations: DDRGK domain-containing protein 1|Dashurin|UFM1-binding protein 1 containing a PCI domain,,DDRGK1,,,,,,,,,,,,,,,,,,,,,,,65992,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,DDRGK1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000029923,HILPDA,,Other designations: hypoxia inducible gene 2|hypoxia-inducible gene 2 protein|hypoxia-inducible lipid droplet-associated protein|hypoxia-inducible protein 2,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,C7orf68|HIG-2|HIG2,,,,,,,,,,,,7,,,,,,HGNC:28859|Vega:OTTHUMG00000157712|HPRD:17105|Ensembl:ENSG00000135245,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,hypoxia inducible lipid droplet-associated,,,7q32.1,,,,,,,,,,,,,,,,"GO_0001819 (EC: IDA); GO_0005102 (EC: IPI, PMID: 15930302); GO_0005515 (EC: IPI, PMID: 15930302); GO_0005615 (EC: IDA, PMID: 15930302); GO_0005811 (EC: IDA); GO_0006950 (EC: NAS, PMID: 10690527); GO_0008284 (EC: IDA, PMID: 15930302); GO_0009986 (EC: IDA, PMID: 15930302); GO_0010884 (EC: IDA); GO_0016021 (EC: IEA); GO_0030141 (EC: IDA, PMID: 15930302); GO_0035425 (EC: IDA, PMID: 15930302)",,,,,,,,,PMID: 8125298; 10690527; 12477932; 12690205; 15489334; 15642117; 15930302; 18550099; 20134266; 20624928; 21124928; 21614900; 21906983; 23916472; 24250222,,,,,,,,,,,,,,,OGG:3000029923,,20140408,protein-coding,,,,hypoxia inducible lipid droplet-associated,,,,,,,,,,,,,Other designations: hypoxia inducible gene 2|hypoxia-inducible gene 2 protein|hypoxia-inducible lipid droplet-associated protein|hypoxia-inducible protein 2,,HILPDA,,,,,,,,,,,,,,,,,,,,,,,29923,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,HILPDA,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0100274,amphiregulin,SDGF|AR,,false,,,http://purl.obolibrary.org/obo/IMR_0000047,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,SDGF|AR,,,,,IMR:0100274,,,,,,,,,,,,,,,,,,,,,,amphiregulin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_9727,Trimethadione,tridione|trimetadione|trimetin|Tridione (TN)|Trimethadione,,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,LINCS:LSM-5345|Drug_Central:2751|CAS:127-48-0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Trimethadione,,tridione|trimetadione|trimetin|Tridione (TN),,,,,,,,,,,,,,,,,,,,,CHEBI:9727,,,,Trimethadione,,CHEBI:9727,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001847,RSK2,p90RSK2|90 kDa ribosomal S6 kinase2,,false,,,http://purl.obolibrary.org/obo/IMR_0000248,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p90RSK2|90 kDa ribosomal S6 kinase2,,,,,IMR:0001847,,,,,,,,,,,,,,,,,,,,,,RSK2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001142,K-glypican,,,false,,,http://purl.obolibrary.org/obo/IMR_0001139,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001142,,,,,,,,,,,,,,,,,,,,,,K-glypican,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100636,CAK,CDK-activating kinase,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001966,,,,,CDK-activating kinase,,,,,IMR:0100636,,,,,,,,,,,,,,,,,,,,,,CAK,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010546,40S ribosomal protein S20,40S small ribosomal protein 20,,false,,,http://purl.obolibrary.org/obo/IMR_0000896,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,40S small ribosomal protein 20,,,,,IMR:0010546,,,,,,,,,,,,,,,,,,,,,,40S ribosomal protein S20,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001124,basement membrane collagen,,,false,,,http://purl.obolibrary.org/obo/IMR_0000541,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001124,,,,,,,,,,,,,,,,,,,,,,basement membrane collagen,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_45783,imatinib,alpha-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-toluidide|4-(4-METHYL-PIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-PHENYL]-BENZAMIDE|STI 571|imatinib|4-[(4-methylpiperazin-1-yl)methyl]-N-{4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl}benzamide,"A benzamide obtained by formal condensation of the carboxy group of 4-[(4-methylpiperazin-1-yl)methyl]benzoic acid with the primary aromatic amino group of 4-methyl-N(3)-[4-(pyridin-3-yl)pyrimidin-2-yl]benzene-1,3-diamine. Used (as its mesylate salt) for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:19527930|PMID:23394269|PMID:18407734|PMID:15794712|DrugBank:DB00619|PMID:15966213|PMID:18376233|PMID:19182535|PMID:19097599|PMID:19853594|PMID:19749465|Beilstein:7671333|PMID:16826359|PMID:18216472|PMID:17410337|PMID:18780518|Drug_Central:1423|PMID:18337118|PMID:17457302|PMID:19920908|PMID:19415889|PMID:18420270|PMID:19810774|PMID:18548219|PMID:18344535|CAS:152459-95-5|PMID:23536338|PMID:18623899|PMID:19591692|PMID:15170967|PMID:23183914|PMID:14715630|PMID:15073101|PMID:23313020|PMID:19693287|PMID:19242505|PMID:17717205|PMID:23480638|PMID:19052981|PMID:23574742|PMID:23503753|LINCS:LSM-1023|Reaxys:7671333|PMID:16122278|PMID:19020005|PMID:14660054|PMID:23580311|PMID:23587588|PMID:18423008|PMID:18809244|PMID:18193246|PMID:16983347|PMID:22891806|PMID:23075630|PMID:19077095|PMID:17190842|PMID:15722647,,"A benzamide obtained by formal condensation of the carboxy group of 4-[(4-methylpiperazin-1-yl)methyl]benzoic acid with the primary aromatic amino group of 4-methyl-N(3)-[4-(pyridin-3-yl)pyrimidin-2-yl]benzene-1,3-diamine. Used (as its mesylate salt) for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35610|http://purl.obolibrary.org/obo/CHEBI_38637|http://purl.obolibrary.org/obo/CHEBI_68495,,,,,4-[(4-methylpiperazin-1-yl)methyl]-N-{4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl}benzamide,,alpha-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-toluidide|4-(4-METHYL-PIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-PHENYL]-BENZAMIDE|STI 571|imatinib,,,,,,,,,,,,,,,,,,,,,CHEBI:45783,,,,imatinib,,CHEBI:45783,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100540,p62,Sequestosome 1,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Sequestosome 1,,,,,IMR:0100540,,,,,,,,,,,,,,,,,,,,,,p62,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_46195,paracetamol,APAP|Acetaminophen|N-(4-hydroxyphenyl)acetamide,A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.,false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Wikipedia:Paracetamol|Wikipedia:Acetaminophen|CAS:103-90-2|DrugBank:DB00316,,A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.,,,,,,,,,,,,C8H9NO2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35475,,,,,N-(4-hydroxyphenyl)acetamide,,APAP|Acetaminophen,,,CHEBI:46195,,,,,,,,,,,,,,,,,,,,,,paracetamol,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CC(=O)Nc1ccc(O)cc1,,,,,
http://purl.obolibrary.org/obo/TXPO_1000133,Eif4a1 (mol),,,false,,,http://purl.obolibrary.org/obo/IMR_0010016,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:13681|NCBI-Human-GeneID:1973|NCBI-Rat-GeneID:287436,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001973,,,,,,,,,,,,,TXPO:1000133,,,,,,,,,,,,,,,,,,,,,,Eif4a1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000138,FAF1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:11124|NCBI-Mouse-GeneID:14084|NCBI-Rat-GeneID:140657,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000011124,,,,,,,,,,,,,TXPO:1000138,,,,,,,,,,,,,,,,,,,,,,FAF1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000137,FABP1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:24360|NCBI-Human-GeneID:2168|NCBI-Mouse-GeneID:14080,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000002168,,,,,,,,,,,,,TXPO:1000137,,,,,,,,,,,,,,,,,,,,,,FABP1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000136,Etnk2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:55224|NCBI-Rat-GeneID:360843|NCBI-Mouse-GeneID:214253,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000055224,,,,,,,,,,,,,TXPO:1000136,,,,,,,,,,,,,,,,,,,,,,Etnk2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000132,Eif2s1 (mol),,,false,,,http://purl.obolibrary.org/obo/IMR_0010016,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:54318|NCBI-Human-GeneID:1965|NCBI-Mouse-GeneID:13665,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001965,,,,,,,,,,,,,TXPO:1000132,,,,,,,,,,,,,,,,,,,,,,Eif2s1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000134,Eps8l2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:64787|NCBI-Mouse-GeneID:98845|NCBI-Rat-GeneID:361674,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000064787,,,,,,,,,,,,,TXPO:1000134,,,,,,,,,,,,,,,,,,,,,,Eps8l2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000131,Ehhadh (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:171142|NCBI-Human-GeneID:1962|NCBI-Mouse-GeneID:74147,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000001962,,,,,,,,,,,,,TXPO:1000131,,,,,,,,,,,,,,,,,,,,,,Ehhadh (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000135,Ero1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:1000135,,,,,,,,,,,,,,,,,,,,,,Ero1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000139,FAS (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:355|NCBI-Mouse-GeneID:14102|NCBI-Rat-GeneID:246097,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000000355,,,,,,,,,,,,,TXPO:1000139,,,,,,,,,,,,,,,,,,,,,,FAS (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_16480,nitric oxide,,"A nitrogen oxide which is a free radical, each molecule of which consists of one nitrogen and one oxygen atom.",false,,,http://purl.obolibrary.org/obo/CHEBI_26519,,,,,,,,,,,,,,,,,,,,,,"A nitrogen oxide which is a free radical, each molecule of which consists of one nitrogen and one oxygen atom.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:16480,,,,,,,,,,,,,,,,,,,,,,nitric oxide,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000735,COX-2 (mol),prostaglandin endoperoxide synthase 2|cyclooxygenase 2,,false,,,http://purl.obolibrary.org/obo/IMR_0000331,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:19225|NCBI-Human-GeneID:5743|NCBI-Rat-GeneID:29527,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,prostaglandin endoperoxide synthase 2|cyclooxygenase 2,,,,,IMR:0000735,,,,,,,,,,,,,,,,,,,,,,COX-2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000286,PLCbeta,phospholipase C beta,,false,,,http://purl.obolibrary.org/obo/IMR_0000284,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,phospholipase C beta,,,,,IMR:0000286,,,,,,,,,,,,,,,,,,,,,,PLCbeta,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000200,dynein,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000186|http://purl.obolibrary.org/obo/TXPO_0003690,,,,,,,,,,IMR:0000200,,,,,,,,,,,,,,,,,,,,,,dynein,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_45980,tacrine,"1,2,3,4-tetrahydroacridin-9-amine","A member of the class of acridines that is 1,2,3,4-tetrahydroacridine substituted by an amino group at position 9. It is used in the treatment of Alzheimer's disease.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,DrugBank:DB00382|CAS:321-64-2|Wikipedia:Tacrine,,"A member of the class of acridines that is 1,2,3,4-tetrahydroacridine substituted by an amino group at position 9. It is used in the treatment of Alzheimer's disease.",,,,,,,,,,,,C13H14N2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_38462,,,,,"1,2,3,4-tetrahydroacridin-9-amine",,,,,CHEBI:45980,,,,,,,,,,,,,,,,,,,,,,tacrine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Nc1c2CCCCc2nc2ccccc12,,,,,
http://purl.obolibrary.org/obo/IMR_0001661,RGS3,,,false,,,http://purl.obolibrary.org/obo/IMR_0000431,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001661,,,,,,,,,,,,,,,,,,,,,,RGS3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000027335,EIF3K,,"Other designations: eIF-3 p25|eIF-3 p28|eukaryotic translation initiation factor 3 subunit 12|eukaryotic translation initiation factor 3 subunit K|eukaryotic translation initiation factor 3, subunit 12|muscle specific|muscle-specific gene M9 protein",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,EIF3S12|MSTP001|PLAC24|M9|HSPC029|EIF3-p28|PTD001|PRO1474|PLAC-24,,,,,,,,,,,,19,,,,,,HGNC:24656|MIM:609596|HPRD:11740|Ensembl:ENSG00000178982|Vega:OTTHUMG00000180865,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"eukaryotic translation initiation factor 3, subunit K",,,19q13.2,,,,,,,,,,,,,,,,"GO_0001731 (EC: IEA); GO_0003743 (EC: IC, Qualifier: contributes_to, PMID:17322308); GO_0003743 (EC: IDA, Qualifier: contributes_to, PMID:17581632); GO_0005515 (EC: IPI); GO_0005634 (EC: IEA); GO_0005829 (EC: TAS); GO_0005852 (EC: IDA, PMID:17322308); GO_0006412 (EC: TAS); GO_0006413 (EC: IC, PMID:17322308); GO_0006413 (EC: IDA, PMID:17581632); GO_0006413 (EC: TAS); GO_0006446 (EC: IEA); GO_0010467 (EC: TAS); GO_0016282 (EC: IEA); GO_0033290 (EC: IEA); GO_0043022 (EC: IEA); GO_0044267 (EC: TAS)",,,,,,,,,PMID:11042152; 12006665; 12477932; 12588972; 14519125; 15180986; 15327989; 15489334; 16189514; 17081983; 17207965; 17322308; 17353931; 17403899; 17581632; 18029348; 18577580; 18599441; 18628297; 19471022; 19615732; 19738201; 20360068; 21139048; 21693764; 21890473; 21906983; 21963094; 21987572; 21988832; 22053931; 22190034; 22505724; 22623428; 22678362; 22779921; 22863883; 22939629; 23000965; 23349634; 23463506; 24036361; 24250222,,,,,,,,,,,,,,,OGG:3000027335,,,,,,,"eukaryotic translation initiation factor 3, subunit K",,,,,,,,,,,,,"Other designations: eIF-3 p25|eIF-3 p28|eukaryotic translation initiation factor 3 subunit 12|eukaryotic translation initiation factor 3 subunit K|eukaryotic translation initiation factor 3, subunit 12|muscle specific|muscle-specific gene M9 protein",,EIF3K,,,,,,,,,,,,,,,,,,,,,,,27335,ARG134,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF3K,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000975,LRP1B,LDL receptor-related protein 1B,,false,,,http://purl.obolibrary.org/obo/IMR_0100798,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,LDL receptor-related protein 1B,,,,,IMR:0000975,,,,,,,,,,,,,,,,,,,,,,LRP1B,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100423,TRAF2 (mol),TNF receptor associated factor 2,,false,,,http://purl.obolibrary.org/obo/IMR_0000462,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TNF receptor associated factor 2,,,,,IMR:0100423,,,,,,,,,,,,,,,,,,,,,,TRAF2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0042246,tissue regeneration,,Tissue regeneration is a subtype of changing material: The regrowth of lost or destroyed tissues.,false,,,http://purl.obolibrary.org/obo/TXPO_0002590,,,,,,,,,,,,,,,,,,,,,,Tissue regeneration is a subtype of changing material: The regrowth of lost or destroyed tissues.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0042246,,,,,,,,,,,,,,,,,,,,,,tissue regeneration,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0042245,RNA repair,,Any process that results in the repair of damaged RNA.,false,,,http://purl.obolibrary.org/obo/TXPO_0000535,,,,,,,,,,,,,,,,,,,,,,Any process that results in the repair of damaged RNA.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0042245,,,,,,,,,,,,,,,,,,,,,,RNA repair,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0016264,gap junction assembly,,"Assembly of gap junctions, which are found in most animal tissues, and serve as direct connections between the cytoplasms of adjacent cells. They provide open channels through the plasma membrane, allowing ions and small molecules (less than approximately a thousand daltons) to diffuse freely between neighboring cells, but preventing the passage of proteins and nucleic acids.",false,,,http://purl.obolibrary.org/obo/GO_0034329,,,,,,,,,,,,,,,,,,,,Reactome:REACT_9509,,"Assembly of gap junctions, which are found in most animal tissues, and serve as direct connections between the cytoplasms of adjacent cells. They provide open channels through the plasma membrane, allowing ions and small molecules (less than approximately a thousand daltons) to diffuse freely between neighboring cells, but preventing the passage of proteins and nucleic acids.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0016264,,,,,,,,,,,,,,,,,,,,,,gap junction assembly,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000029,IFN type II,type II Interferon,,false,,,http://purl.obolibrary.org/obo/IMR_0000027,,,,,,,,,,,,,,,,,,,,GO:0005133,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,type II Interferon,,,,,IMR:0000029,,,,,,,,,,,,,,,,,,,,,,IFN type II,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000403,EGR1 (mol),Zif268|pAT225|NGFI-A|TIS8|Krox24,,false,,,http://purl.obolibrary.org/obo/IMR_0000402,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Zif268|pAT225|NGFI-A|TIS8|Krox24,,,,,IMR:0000403,,,,,,,,,,,,,,,,,,,,,,EGR1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0045738,negative regulation of DNA repair,,"Negative regulation of DNA repair is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of DNA repair.",false,,,http://purl.obolibrary.org/obo/TXPO_0000369,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of DNA repair is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of DNA repair.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0045738,,,,,,,,,,,,,,,,,,,,,,negative regulation of DNA repair,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006281,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000057216,VANGL2,,"Other designations: loop-tail protein 1 homolog|loop-tail-associated protein|strabismus 1|van Gogh-like protein 2|vang-like 2 (van gogh, Drosophila)|vang-like protein 2",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,LPP1|LTAP|STBM|STBM1|STB1,,,,,,,,,,,,1,,,,,,Ensembl:ENSG00000162738|Vega:OTTHUMG00000033122|HPRD:02758|MIM:600533|HGNC:15511,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,VANGL planar cell polarity protein 2,,,1q22-q23,,,,,,,,,,,,,,,,GO_0001736 (EC: ISS); GO_0001843 (EC: ISS); GO_0001942 (EC: IEA); GO_0001947 (EC: ISS); GO_0003149 (EC: IEA); GO_0003150 (EC: IEA); GO_0003402 (EC: IEA); GO_0005886 (EC: TAS); GO_0005911 (EC: ISS); GO_0007266 (EC: IEA); GO_0009952 (EC: IEA); GO_0016021 (EC: IEA); GO_0016323 (EC: IEA); GO_0016324 (EC: ISS); GO_0016328 (EC: ISS); GO_0022007 (EC: IEA); GO_0032835 (EC: IEA); GO_0032956 (EC: IEA); GO_0035019 (EC: IEA); GO_0035058 (EC: ISS); GO_0035787 (EC: ISS); GO_0036342 (EC: IEA); GO_0042060 (EC: IEA); GO_0043507 (EC: IEA); GO_0045176 (EC: ISS); GO_0045197 (EC: IEA); GO_0048103 (EC: IEA); GO_0048105 (EC: IEA); GO_0048546 (EC: IEA); GO_0060028 (EC: IEA); GO_0060122 (EC: IEA); GO_0060187 (EC: IEA); GO_0060488 (EC: IEA); GO_0060489 (EC: IEA); GO_0060490 (EC: IEA); GO_0060993 (EC: IEA); GO_0090103 (EC: IEA); GO_0090177 (EC: IEA); GO_0090179 (EC: IEA),,,,,,,,,PMID: 10574462; 11431695; 12477932; 12490194; 15195140; 15489334; 16710414; 18034999; 18849982; 19577357; 19734545; 20223754; 20558380; 20738329; 21139048; 21142127; 23579212,,,,,,,,,,,,,,,OGG:3000057216,,,,,,,VANGL planar cell polarity protein 2,,,,,,,,,,,,,"Other designations: loop-tail protein 1 homolog|loop-tail-associated protein|strabismus 1|van Gogh-like protein 2|vang-like 2 (van gogh, Drosophila)|vang-like protein 2",,VANGL2,,,,,,,,,,,,,,,,,,,,,,,57216,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,VANGL2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000646,Integrin beta-6,,,false,,,http://purl.obolibrary.org/obo/IMR_0000174,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000646,,,,,,,,,,,,,,,,,,,,,,Integrin beta-6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006635,fatty acid beta-oxidation,,"A fatty acid oxidation process that results in the complete oxidation of a long-chain fatty acid. Fatty acid beta-oxidation begins with the addition of coenzyme A to a fatty acid, and occurs by successive cycles of reactions during each of which the fatty acid is shortened by a two-carbon fragment removed as acetyl coenzyme A; the cycle continues until only two or three carbons remain (as acetyl-CoA or propionyl-CoA respectively).",false,,,http://purl.obolibrary.org/obo/GO_0019395,,,,,,,,,,,,,,,,,,,,,,"A fatty acid oxidation process that results in the complete oxidation of a long-chain fatty acid. Fatty acid beta-oxidation begins with the addition of coenzyme A to a fatty acid, and occurs by successive cycles of reactions during each of which the fatty acid is shortened by a two-carbon fragment removed as acetyl coenzyme A; the cycle continues until only two or three carbons remain (as acetyl-CoA or propionyl-CoA respectively).",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0006635,,,,,,,,,,,,,,,,,,,,,,fatty acid beta-oxidation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006633,fatty acid biosynthetic process,fatty acid anabolism|fatty acid formation|fatty acid synthesis|fatty acid biosynthesis,"The chemical reactions and pathways resulting in the formation of a fatty acid, any of the aliphatic monocarboxylic acids that can be liberated by hydrolysis from naturally occurring fats and oils. Fatty acids are predominantly straight-chain acids of 4 to 24 carbon atoms, which may be saturated or unsaturated; branched fatty acids and hydroxy fatty acids also occur, and very long chain acids of over 30 carbons are found in waxes.",false,,,http://purl.obolibrary.org/obo/GO_0008610,,,,,,,,,,,,,,,,,,,,MetaCyc:PWY-4381|Wikipedia:Fatty_acid_synthesis,,"The chemical reactions and pathways resulting in the formation of a fatty acid, any of the aliphatic monocarboxylic acids that can be liberated by hydrolysis from naturally occurring fats and oils. Fatty acids are predominantly straight-chain acids of 4 to 24 carbon atoms, which may be saturated or unsaturated; branched fatty acids and hydroxy fatty acids also occur, and very long chain acids of over 30 carbons are found in waxes.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,fatty acid anabolism|fatty acid formation|fatty acid synthesis|fatty acid biosynthesis,,,,,GO:0006633,,,,,,,,,,,,,,,,,,,,,,fatty acid biosynthetic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006631,fatty acid metabolic process,fatty acid metabolism,"The chemical reactions and pathways involving fatty acids, aliphatic monocarboxylic acids liberated from naturally occurring fats and oils by hydrolysis.",false,,,http://purl.obolibrary.org/obo/GO_0006629,,,,,,,,,,,,,,,,,,,,Wikipedia:Fatty_acid_metabolism,,"The chemical reactions and pathways involving fatty acids, aliphatic monocarboxylic acids liberated from naturally occurring fats and oils by hydrolysis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0009062|http://purl.obolibrary.org/obo/GO_0006633,,,,,,,,,,,,,fatty acid metabolism,,,,,GO:0006631,,,,,,,,,,,,,,,,,,,,,,fatty acid metabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0002002,increased number (quality),,A number quality which is relatively many.,false,,,http://purl.obolibrary.org/obo/TXPO_0000304|http://purl.obolibrary.org/obo/TXPO_0003753,,,,,,,,,,,,,,,,,,,,,,A number quality which is relatively many.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0002002,,,,,,,,,,,,,,,,,,,,,,increased number (quality),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000291,KRAS (mol),K-Ras|Ki-ras,,false,,,http://purl.obolibrary.org/obo/IMR_0000290,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:3845|NCBI-Rat-GeneID:24525|NCBI-Mouse-GeneID:16653,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,K-Ras|Ki-ras,,,,,IMR:0000291,,,,,,,,,,,,,,,,,,,,,,KRAS (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000009,IL-5,interleukin-5,,false,,,http://purl.obolibrary.org/obo/IMR_0000007,,,,,,,,,,,,,,,,,,,,GO:0005137,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000622,,,,,interleukin-5,,,,,IMR:0000009,,,,,,,,,,,,,,,,,,,,,,IL-5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006556,S-adenosylmethionine biosynthetic process,,"The chemical reactions and pathways resulting in the formation of S-adenosylmethionine, S-(5'-adenosyl)-L-methionine, an important intermediate in one-carbon metabolism.",false,,,http://purl.obolibrary.org/obo/GO_0009058,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways resulting in the formation of S-adenosylmethionine, S-(5'-adenosyl)-L-methionine, an important intermediate in one-carbon metabolism.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0006556,,,,,,,,,,,,,,,,,,,,,,S-adenosylmethionine biosynthetic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006555,methionine metabolic process,methionine metabolism,"The chemical reactions and pathways involving methionine (2-amino-4-(methylthio)butanoic acid), a sulfur-containing, essential amino acid found in peptide linkage in proteins.",false,,,http://purl.obolibrary.org/obo/GO_0008152,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways involving methionine (2-amino-4-(methylthio)butanoic acid), a sulfur-containing, essential amino acid found in peptide linkage in proteins.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001165,,,,,,,,,,,,,methionine metabolism,,,,,GO:0006555,,,,,,,,,,,,,,,,,,,,,,methionine metabolic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_26607,saturated fatty acid,,Any fatty acid containing no carbon to carbon multiple bonds. Known to produce adverse biological effects when ingested to excess.,false,,,http://purl.obolibrary.org/obo/CHEBI_18059,,,,,,,,,,,,,,,,,,,,,,Any fatty acid containing no carbon to carbon multiple bonds. Known to produce adverse biological effects when ingested to excess.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:26607,,,,,,,,,,,,,,,,,,,,,,saturated fatty acid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_74518,anti-obesity agent,anti-obesity agents|anti-obestic agents|anti-obestic agent,Any substance which is used to reduce or control weight.,false,,,http://purl.obolibrary.org/obo/CHEBI_52210,,,,,,,,,,,,,,,,,,,,,,Any substance which is used to reduce or control weight.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,anti-obesity agents|anti-obestic agents|anti-obestic agent,,,,,,,,,,,,,,,,,,,,,CHEBI:74518,,,,anti-obesity agent,,CHEBI:74518,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_50857,anti-allergic agent,anti-allergic drug,A drug used to treat allergic reactions.,false,,,http://purl.obolibrary.org/obo/CHEBI_23888,,,,,,,,,,,,,,,,,,,,,,A drug used to treat allergic reactions.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,anti-allergic drug,,,CHEBI:50857,,,,,,,,,,,,,,,,,,,,,,anti-allergic agent,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_2663,amiodarone,"2-Butyl-3-benzofuranyl 4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl ketone|2-Butyl-3-(3,5-diiodo-4-(2-diethylaminoethoxy)benzoyl)benzofuran|amiodarona|2-n-Butyl-3',5'-diiodo-4'-N-diethylaminoethoxy-3-benzoylbenzofuran|amiodaronum|Amiodarone|(2-butyl-1-benzofuran-3-yl){4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl}methanone","A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a  cardiovascular drug used for the treatment of cardiac dysrhythmias.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:16479044|PMID:10188629|LINCS:LSM-2379|Beilstein:1271711|DrugBank:DB01118|Open TG-Gates compound_id=00033|CAS:1951-25-3|PMID:18368867|ChemicalBook:CB5310616|Drug_Central:176,,"A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a  cardiovascular drug used for the treatment of cardiac dysrhythmias.",,,,,,,,,,,,C25H29I2NO3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0001886|http://purl.obolibrary.org/obo/PATO_0001884,,,,http://purl.obolibrary.org/obo/CHEBI_35554,,,,,"Amiodarone|(2-butyl-1-benzofuran-3-yl){4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl}methanone",,"2-Butyl-3-benzofuranyl 4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl ketone|2-Butyl-3-(3,5-diiodo-4-(2-diethylaminoethoxy)benzoyl)benzofuran|amiodarona|2-n-Butyl-3',5'-diiodo-4'-N-diethylaminoethoxy-3-benzoylbenzofuran|amiodaronum",,,,,,,,,,,,,,,,,,,,,CHEBI:2663,,,,amiodarone,,CHEBI:2663,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1,,,,,
http://purl.obolibrary.org/obo/CHEBI_2666,amitriptyline,"3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N,N-dimethylpropan-1-amine","An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(dimethylamino)propylidene group at position 5.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,Patent:WO2011089289|Wikipedia:Amitriptyline|MeSH:D000639|CAS:50-48-6|LINCS:LSM-3190|DrugBank:DB00321,,"An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(dimethylamino)propylidene group at position 5.",,,,,,,,,,,,C20H23N,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N,N-dimethylpropan-1-amine",,,,,CHEBI:2666,,,,,,,,,,,,,,,,,,,,,,amitriptyline,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CN(C)CCC=C1c2ccccc2CCc2ccccc12,,,,,
http://purl.obolibrary.org/obo/IMR_0000267,PI3-kinase p110 subunit,Phosphatidylinositol 3-kinase p110 catalytic subunit,,false,,,http://purl.obolibrary.org/obo/TXPO_0003223,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Phosphatidylinositol 3-kinase p110 catalytic subunit,,,,,IMR:0000267,,,,,,,,,,,,,,,,,,,,,,PI3-kinase p110 subunit,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002715,increasing bile concentration in blood,,Increasing bile concentration in blood is a subtype of increasing concentration: A process that changes the concentration of the bile in the blood to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000352,,,,,,,,,,,,,,,,,,,,,,Increasing bile concentration in blood is a subtype of increasing concentration: A process that changes the concentration of the bile in the blood to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002715,,,,,,,,,,,,,,,,,,,,,,increasing bile concentration in blood,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002716,refolding promoting gene expression [ER stress],,"Refolding promoting gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature refolding inducing gene product or products (proteins or RNA) .
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0001300|http://purl.obolibrary.org/obo/TXPO_0001717,,,,,,,,,,,,,,,,,,,,,,"Refolding promoting gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature refolding inducing gene product or products (proteins or RNA) .
This entity is a specific course-dependent process. This process can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002760|http://purl.obolibrary.org/obo/TXPO_0002546|http://purl.obolibrary.org/obo/TXPO_0002384,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000413,,,,,,,,,,,TXPO:0002716,,,,,,,,,,,,,,,,,,,,,,refolding promoting gene expression [ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002713,bile tube occlusion,,Bile tube occlusion is a subtype of occlusion: Obstruction or a closure of bile tube.,false,,,http://purl.obolibrary.org/obo/NCIT_C50678,,,,,,,,,,,,,,,,,,,,,,Bile tube occlusion is a subtype of occlusion: Obstruction or a closure of bile tube.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002713,,,,,,,,,,,,,,,,,,,,,,bile tube occlusion,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002711,hyperfunction of glutathione export from hepatocyte [Glutathione depletion],,"Hyperfunction of glutathione export from hepatocyte  is a subtype of hyperfunction of transport: A process that performs an excesssive export of the glutathione from the hepatocyte.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",false,,,http://purl.obolibrary.org/obo/TXPO_0002708|http://purl.obolibrary.org/obo/TXPO_0000889,,,,,,,,,,,,,,,,,,,,PMID:18786560|ISBN:0071769234,,"Hyperfunction of glutathione export from hepatocyte  is a subtype of hyperfunction of transport: A process that performs an excesssive export of the glutathione from the hepatocyte.
This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002512|http://purl.obolibrary.org/obo/TXPO_0002493,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002733,,,,,,,,,,,TXPO:0002711,,,,,,,,,,,,,,,,,,,,,,hyperfunction of glutathione export from hepatocyte [Glutathione depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002714,increasing bile level,,Increasing bile level is a subtype of increasing quantity: A process that changes the amount of bile to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000395,,,,,,,,,,,,,,,,,,,,,,Increasing bile level is a subtype of increasing quantity: A process that changes the amount of bile to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002714,,,,,,,,,,,,,,,,,,,,,,increasing bile level,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002712,regulator of OATP bile acid transport,,A role played by the entity which regulatess OATP bile acid transport process.,false,,,http://purl.obolibrary.org/obo/TXPO_0000056,,,,,,,,,,,,,,,,,,,,,,A role played by the entity which regulatess OATP bile acid transport process.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002712,,,,,,,,,,,,,,,,,,,,,,regulator of OATP bile acid transport,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002717,increasing vomume of bile canaliculus,,Increasing vomume of bile canaliculus is a subtype of increasing volume: A process that changes the volume of the bile canaliculus to be higher.,false,,,http://purl.obolibrary.org/obo/TXPO_0000139,,,,,,,,,,,,,,,,,,,,,,Increasing vomume of bile canaliculus is a subtype of increasing volume: A process that changes the volume of the bile canaliculus to be higher.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002717,,,,,,,,,,,,,,,,,,,,,,increasing vomume of bile canaliculus,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002710,receiving abnormal protein signal by IRE1 [ER stress - ERAD],,"Receiving abnormal protein signal by IRE1 is a subtype of receiving signal: A process that recognizes another object and changes into an abnormal protein (e.g., misfolded protein, etc.) signal by IRE1.
This process is dependent on the ERAD and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002604|http://purl.obolibrary.org/obo/TXPO_0003736,,,,,,,,,,,,,,,,,,,,,,"Receiving abnormal protein signal by IRE1 is a subtype of receiving signal: A process that recognizes another object and changes into an abnormal protein (e.g., misfolded protein, etc.) signal by IRE1.
This process is dependent on the ERAD and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000875,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002709,,,,,,,,,,,TXPO:0002710,,,,,,,,,,,,,,,,,,,,,,receiving abnormal protein signal by IRE1 [ER stress - ERAD],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002718,hyperfunction of protein unfolding,,Hyperfunction of protein unfolding is a subtype of hyperfunctioning: A process that performs an excesssive protein unfolding.,false,,,http://purl.obolibrary.org/obo/TXPO_0000435,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of protein unfolding is a subtype of hyperfunctioning: A process that performs an excesssive protein unfolding.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002718,,,,,,,,,,,,,,,,,,,,,,hyperfunction of protein unfolding,,,,,,http://purl.obolibrary.org/obo/GO_0042026,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002719,hyperfunction of moving phenobarbital to the inside of liver [Ground glass appearance],,"A process that performs an excesssive moving phenobarbital to the inside of liver.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0002600,,,,,,,,,,,,,,,,,,,,,,"A process that performs an excesssive moving phenobarbital to the inside of liver.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,http://purl.obolibrary.org/obo/TXPO_0001719,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001840,,,,,,,,,,,TXPO:0002719,,,,,,,,,,,,,,,,,,,,,,hyperfunction of moving phenobarbital to the inside of liver [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0006379,mRNA cleavage,,Any process in which a pre-mRNA or mRNA molecule is cleaved at specific sites or in a regulated manner.,false,,,http://purl.obolibrary.org/obo/TXPO_0000333,,,,,,,,,,,,,,,,,,,,,,Any process in which a pre-mRNA or mRNA molecule is cleaved at specific sites or in a regulated manner.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0006379,,,,,,,,,,,,,,,,,,,,,,mRNA cleavage,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0000386,hard,,A hardness quality of being rigid and resistant to pressure.,false,,,http://purl.obolibrary.org/obo/TXPO_0003729|http://purl.obolibrary.org/obo/PATO_0000048,,,,,,,,,,,,,,,,,,,,,,A hardness quality of being rigid and resistant to pressure.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0000386,,,,,,,,,,,,,,,,,,,,,,hard,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0000389,acute,,"A quality of a process inhering in a bearer by virtue of the bearer's having a sudden onset, sharp rise, and short course.",false,,,http://purl.obolibrary.org/obo/PATO_0001309,,,,,,,,,,,,,,,,,,,,,,"A quality of a process inhering in a bearer by virtue of the bearer's having a sudden onset, sharp rise, and short course.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0000389,,,,,,,,,,,,,,,,,,,,,,acute,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/PATO_0000387,soft,,A hardness quality of giving little resistance to pressure.,false,,,http://purl.obolibrary.org/obo/TXPO_0003729|http://purl.obolibrary.org/obo/PATO_0000048,,,,,,,,,,,,,,,,,,,,,,A hardness quality of giving little resistance to pressure.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PATO:0000387,,,,,,,,,,,,,,,,,,,,,,soft,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000628,Integrin alpha-6,,,false,,,http://purl.obolibrary.org/obo/IMR_0000173,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000628,,,,,,,,,,,,,,,,,,,,,,Integrin alpha-6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0002055,FGFR1,fibroblast growth factor receptor 1,,false,,,http://purl.obolibrary.org/obo/IMR_0000080,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,fibroblast growth factor receptor 1,,,,,IMR:0002055,,,,,,,,,,,,,,,,,,,,,,FGFR1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000245,Mgll (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:23945|NCBI-Rat-GeneID:29254|NCBI-Human-GeneID:11343,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000011343,,,,,,,,,,,,,TXPO:1000245,,,,,,,,,,,,,,,,,,,,,,Mgll (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000246,Mybl2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:296344|NCBI-Human-GeneID:4605|NCBI-Mouse-GeneID:17865,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000004605,,,,,,,,,,,,,TXPO:1000246,,,,,,,,,,,,,,,,,,,,,,Mybl2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000240,M6PR (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:4074|NCBI-Rat-GeneID:312689|NCBI-Mouse-GeneID:17113,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000010857,,,,,,,,,,,,,TXPO:1000240,,,,,,,,,,,,,,,,,,,,,,M6PR (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000242,MUC3 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:687030|NCBI-Mouse-GeneID:666339,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3100133790,,,,,,,,,,,,,TXPO:1000242,,,,,,,,,,,,,,,,,,,,,,MUC3 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000241,MS4A2 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:25316|NCBI-Human-GeneID:2206|NCBI-Mouse-GeneID:14126,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000002206,,,,,,,,,,,,,TXPO:1000241,,,,,,,,,,,,,,,,,,,,,,MS4A2 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000243,MYCN (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Mouse-GeneID:18109|NCBI-Rat-GeneID:298894|NCBI-Human-GeneID:4613,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000004613,,,,,,,,,,,,,TXPO:1000243,,,,,,,,,,,,,,,,,,,,,,MYCN (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000244,Me1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:4199|NCBI-Rat-GeneID:24552|NCBI-Mouse-GeneID:17436,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000004199,,,,,,,,,,,,,TXPO:1000244,,,,,,,,,,,,,,,,,,,,,,Me1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000248,NAP1L1 (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:89825|NCBI-Mouse-GeneID:53605|NCBI-Human-GeneID:4673,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000004673,,,,,,,,,,,,,TXPO:1000248,,,,,,,,,,,,,,,,,,,,,,NAP1L1 (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_1000249,NBAS (mol),,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:51594|NCBI-Rat-GeneID:690073|NCBI-Mouse-GeneID:71169,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/OGG_3000051594,,,,,,,,,,,,,TXPO:1000249,,,,,,,,,,,,,,,,,,,,,,NBAS (mol),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002977,IRE1 autophosphorylation [ER stress - ERAD],,"IRE1 autophosphorylation is a subtype of protein autophosphorylation: The phosphorylation by IRE1 of one or more of its own amino acid residues (cis-autophosphorylation), or residues on IRE1 (trans-autophosphorylation).
This process is dependent on the ERAD and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0003736|http://purl.obolibrary.org/obo/TXPO_0002598,,,,,,,,,,,,,,,,,,,,,,"IRE1 autophosphorylation is a subtype of protein autophosphorylation: The phosphorylation by IRE1 of one or more of its own amino acid residues (cis-autophosphorylation), or residues on IRE1 (trans-autophosphorylation).
This process is dependent on the ERAD and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002979,,,,,,,,,,,,,,,,,TXPO:0002977,,,,,,,,,,,,,,,,,,,,,,IRE1 autophosphorylation [ER stress - ERAD],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002970,ATF4 - transcriptional regulator (canonical)[ER stress - dyslipidemia],,,false,,,http://purl.obolibrary.org/obo/TXPO_0001907,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000330,,,,,,,,,,TXPO:0002970,,,,,,,,,,,,,,,,,,,,,,ATF4 - transcriptional regulator (canonical)[ER stress - dyslipidemia],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002974,IRE1 dimer (canonical)[ER stress -ERAD],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002972,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002974,,,,,,,,,,,,,,,,,,,,,,IRE1 dimer (canonical)[ER stress -ERAD],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002971,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002976,IRE1 autophosphorylation [ER stress - refolding],,"IRE1 autophosphorylation is a subtype of protein autophosphorylation: The phosphorylation by IRE1 of one or more of its own amino acid residues (cis-autophosphorylation), or residues on IRE1 (trans-autophosphorylation).
This process is dependent on the refolding and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0003736|http://purl.obolibrary.org/obo/TXPO_0002598,,,,,,,,,,,,,,,,,,,,,,"IRE1 autophosphorylation is a subtype of protein autophosphorylation: The phosphorylation by IRE1 of one or more of its own amino acid residues (cis-autophosphorylation), or residues on IRE1 (trans-autophosphorylation).
This process is dependent on the refolding and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002978,,,,,,,,,,,,,,,,,TXPO:0002976,,,,,,,,,,,,,,,,,,,,,,IRE1 autophosphorylation [ER stress - refolding],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002971,IRE1 dimerization [ER stress - refolding],,"IRE1 dimerization is a subtype of protein dimerization: The formation of a IRE1 dimer, a macromolecular structure consists of two noncovalently associated identical or nonidentical subunits.
This process is dependent on the refolding and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002596,,,,,,,,,,,,,,,,,,,,PMID:23236464|PMID:11897784|Reactome:R-HSA-381109,,"IRE1 dimerization is a subtype of protein dimerization: The formation of a IRE1 dimer, a macromolecular structure consists of two noncovalently associated identical or nonidentical subunits.
This process is dependent on the refolding and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002973,,,,,,http://purl.obolibrary.org/obo/TXPO_0002976,,,,,,,,,,,TXPO:0002971,,,,,,,,,,,,,,,,,,,,,,IRE1 dimerization [ER stress - refolding],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002975,IRE1 dimerization [ER stress - ERAD],,"IRE1 dimerization is a subtype of protein dimerization: The formation of a IRE1 dimer, a macromolecular structure consists of two noncovalently associated identical or nonidentical subunits.
This entity is a specific course-dependent process. This process is dependent on ERAD and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002596,,,,,,,,,,,,,,,,,,,,PMID:23236464|PMID:11897784|Reactome:R-HSA-381109,,"IRE1 dimerization is a subtype of protein dimerization: The formation of a IRE1 dimer, a macromolecular structure consists of two noncovalently associated identical or nonidentical subunits.
This entity is a specific course-dependent process. This process is dependent on ERAD and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002974,,,,,,http://purl.obolibrary.org/obo/TXPO_0002977,,,,,,,,,,,TXPO:0002975,,,,,,,,,,,,,,,,,,,,,,IRE1 dimerization [ER stress - ERAD],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002972,IRE1 dimer (canonical)[ER stress],ERN1 dimer [ER stress],,false,,,http://purl.obolibrary.org/obo/TXPO_0000871|http://purl.obolibrary.org/obo/TXPO_0001528,,,,,,,,,,,,,,,,,,,,NCBI-Rat-GeneID:498013|NCBI-Mouse-GeneID:78943|NCBI-Human-GeneID:2081|http://omim.org/entry/604032,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ERN1 dimer [ER stress],,,,,TXPO:0002972,,,,,,,,,,,,,,,,,,,,,,IRE1 dimer (canonical)[ER stress],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002596,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002979,IRE1 - autophosphorylation kinase (canonical)[ER stress -ERAD],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002601,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002979,,,,,,,,,,,,,,,,,,,,,,IRE1 - autophosphorylation kinase (canonical)[ER stress -ERAD],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002975,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002973,IRE1 dimer (canonical)[ER stress - Refolding],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002972,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002973,,,,,,,,,,,,,,,,,,,,,,IRE1 dimer (canonical)[ER stress - Refolding],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002971,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002978,IRE1 - autophosphorylation kinase (canonical)[ER stress - Refolding],,,false,,,http://purl.obolibrary.org/obo/TXPO_0002601,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002978,,,,,,,,,,,,,,,,,,,,,,IRE1 - autophosphorylation kinase (canonical)[ER stress - Refolding],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002971,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001036,group IIF secretory phospholipase A2,,,false,,,http://purl.obolibrary.org/obo/IMR_0000283,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001036,,,,,,,,,,,,,,,,,,,,,,group IIF secretory phospholipase A2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001642,phosphatidic acid metabolism imbalance,,Phosphatidic acid metabolism imbalance is a subtype of glycerophospholipid metabolism imbalance : A process that becomes lacking a homeostastasis balance of phosphatidic acid metabolism.,false,,,http://purl.obolibrary.org/obo/TXPO_0001295,,,,,,,,,,,,,,,,,,,,,,Phosphatidic acid metabolism imbalance is a subtype of glycerophospholipid metabolism imbalance : A process that becomes lacking a homeostastasis balance of phosphatidic acid metabolism.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001642,,,,,,,,,,,,,,,,,,,,,,phosphatidic acid metabolism imbalance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001648,hypofunction of phosphatidylserine  degradation,,Hypofunction of phosphatidylserine  degradation is a subtype of hypofunction of glycerophospholipid degradation: A process that performs a decreased or insufficient phosphatidylcholine degradation.,false,,,http://purl.obolibrary.org/obo/TXPO_0001418,,,,,,,,,,,,,,,,,,,,,,Hypofunction of phosphatidylserine  degradation is a subtype of hypofunction of glycerophospholipid degradation: A process that performs a decreased or insufficient phosphatidylcholine degradation.,,,http://purl.obolibrary.org/obo/GO_0006660,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_18303,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001648,,,,,,,,,,,,,,,,,,,,,,hypofunction of phosphatidylserine  degradation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001645,lipid accumulation in hepatocyte [Phospholipidosis],,"Lipid accumulation in hepatocyte is a subtype of lipid strorage in hepatocyte: A process that keeps lipids in hepatocytes mildly.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0003623,,,,,,,,,,,,,,,,,,,,,,"Lipid accumulation in hepatocyte is a subtype of lipid strorage in hepatocyte: A process that keeps lipids in hepatocytes mildly.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001645,,,,,,,,,,,,,,,,,,,,,,lipid accumulation in hepatocyte [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001640,phosphatidylserine metabolism imbalance,,Phosphatidylserine metabolism imbalance is a subtype of glycerophospholipid metabolism imbalance : A process that becomes lacking a homeostastasis balance of phosphatidylserine metabolism.,false,,,http://purl.obolibrary.org/obo/TXPO_0001295,,,,,,,,,,,,,,,,,,,,,,Phosphatidylserine metabolism imbalance is a subtype of glycerophospholipid metabolism imbalance : A process that becomes lacking a homeostastasis balance of phosphatidylserine metabolism.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001640,,,,,,,,,,,,,,,,,,,,,,phosphatidylserine metabolism imbalance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001641,removing myelin figure by Kupffer cell or macrophage,,Removing myelin figure by Kupffer cell or macrophage is a subtype of removing: A process that takes myelin figure from a cell by  Kupffer cells or macrophages.,false,,,http://purl.obolibrary.org/obo/TXPO_0000458,,,,,,,,,,,,,,,,,,,,,,Removing myelin figure by Kupffer cell or macrophage is a subtype of removing: A process that takes myelin figure from a cell by  Kupffer cells or macrophages.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000091|http://purl.obolibrary.org/obo/CL_0000235,,,,,,,,,,,,,,,,,TXPO:0001641,,,,,,,,,,,,,,,,,,,,,,removing myelin figure by Kupffer cell or macrophage,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001643,removing myelin figure by Kupffer cell or macrophage [Phospholipidosis],,Removing myelin figure by Kupffer cell or macrophage is a subtype of removing: A process that takes myelin figure from a cell by  Kupffer cells or macrophages. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.,false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0001641,,,,,,,,,,,,,,,,,,,,,,Removing myelin figure by Kupffer cell or macrophage is a subtype of removing: A process that takes myelin figure from a cell by  Kupffer cells or macrophages. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000558,,,,,,,,,,,TXPO:0001643,,,,,,,,,,,,,,,,,,,,,,removing myelin figure by Kupffer cell or macrophage [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001647,decreasing amount of drug [Ground glass appearance],,"Decreasing amount of drug is a subtype of decreasing amount of xenobiotics: A process that changes the quantity of the drug to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",false,,,http://purl.obolibrary.org/obo/TXPO_0001639|http://purl.obolibrary.org/obo/TXPO_0001728,,,,,,,,,,,,,,,,,,,,,,"Decreasing amount of drug is a subtype of decreasing amount of xenobiotics: A process that changes the quantity of the drug to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001584,,,,,,,,,,,,,,,,,,TXPO:0001647,,,,,,,,,,,,,,,,,,,,,,decreasing amount of drug [Ground glass appearance],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001646,hyperfunction of Phosphatidylserine synthesis gene expression,,Hyperfunction of Phosphatidylserine synthesis gene expression is a subtype of hyperfunction of glycerophospholipid synthesis gene expression: A process that performs an excesssive phosphatidylserine synthetic gene expression.,false,,,http://purl.obolibrary.org/obo/TXPO_0001264,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of Phosphatidylserine synthesis gene expression is a subtype of hyperfunction of glycerophospholipid synthesis gene expression: A process that performs an excesssive phosphatidylserine synthetic gene expression.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001646,,,,,,,,,,,,,,,,,,,,,,hyperfunction of Phosphatidylserine synthesis gene expression,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001644,phosphatidylinositol metabolism imbalance,,Phosphatidylinositol metabolism imbalance is a subtype of glycerophospholipid metabolism imbalance : A process that becomes lacking a homeostastasis balance of phosphatidylinositol metabolism.,false,,,http://purl.obolibrary.org/obo/TXPO_0001295,,,,,,,,,,,,,,,,,,,,,,Phosphatidylinositol metabolism imbalance is a subtype of glycerophospholipid metabolism imbalance : A process that becomes lacking a homeostastasis balance of phosphatidylinositol metabolism.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001644,,,,,,,,,,,,,,,,,,,,,,phosphatidylinositol metabolism imbalance,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0001649,keeping amount of drug,,Keeping amount of drug is a subtype of keeping amount: A process that maintains the amount of the drug at a constant level .,false,,,http://purl.obolibrary.org/obo/TXPO_0000414,,,,,,,,,,,,,,,,,,,,,,Keeping amount of drug is a subtype of keeping amount: A process that maintains the amount of the drug at a constant level .,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0001649,,,,,,,,,,,,,,,,,,,,,,keeping amount of drug,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0010477,60S ribosomal protein L28,P46779,,false,,,http://purl.obolibrary.org/obo/IMR_0000897,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,P46779,,,,,IMR:0010477,,,,,,,,,,,,,,,,,,,,,,60S ribosomal protein L28,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000601,IL-18,interleukin-18,,false,,,http://purl.obolibrary.org/obo/IMR_0000007,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000622,,,,,interleukin-18,,,,,IMR:0000601,,,,,,,,,,,,,,,,,,,,,,IL-18,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0200290,L-Dopa,,,false,,,http://purl.obolibrary.org/obo/CHEBI_33709,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0200290,,,,,,,,,,,,,,,,,,,,,,L-Dopa,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000246175,CNOT6L,,Other designations: CCR4-NOT transcription complex subunit 6-like|carbon catabolite repressor protein 4 homolog B,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CCR4b,,,,,,,,,,,,4,,,,,,Ensembl:ENSG00000138767|HGNC:18042|Vega:OTTHUMG00000160832|HPRD:10841,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"CCR4-NOT transcription complex, subunit 6-like",,,4q13.3,,,,,,,,,,,,,,,,"GO_0000288 (EC: TAS); GO_0000289 (EC: TAS); GO_0004535 (EC: TAS); GO_0005515 (EC: IPI, PMID: 17452450); GO_0005634 (EC: IDA); GO_0005737 (EC: IDA); GO_0005829 (EC: TAS); GO_0006351 (EC: IEA); GO_0006355 (EC: IEA); GO_0006417 (EC: IEA); GO_0008284 (EC: IMP); GO_0010467 (EC: TAS); GO_0010606 (EC: IMP); GO_0016070 (EC: TAS); GO_0016071 (EC: TAS); GO_0030014 (EC: IDA, PMID: 19558367); GO_0031047 (EC: IEA); GO_0046872 (EC: IEA); GO_0061157 (EC: IEA); GO_0090503 (EC: TAS)",,,,,,,,,PMID: 14702039; 16344560; 17353931; 17452450; 18377426; 19558367; 20211142; 20360068; 20379614; 20628353; 20818722; 21233283; 23591815,,,,,,,,,,,,,,,OGG:3000246175,,,,,,,"CCR4-NOT transcription complex, subunit 6-like",,,,,,,,,,,,,Other designations: CCR4-NOT transcription complex subunit 6-like|carbon catabolite repressor protein 4 homolog B,,CNOT6L,,,,,,,,,,,,,,,,,,,,,,,246175,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,CNOT6L,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0001204,Apaf-1,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000327,,,,,,,,,,IMR:0001204,,,,,,,,,,,,,,,,,,,,,,Apaf-1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004127,increasing acetyl CoA [Mitochondrial disorder],,"Increasing acetyl CoA is a subtype of increasing quantity: A process that changes the amount of acetyl CoA to be larger.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder].",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0000088,,,,,,,,,,,,,,,,,,,,PMID:23299992,,"Increasing acetyl CoA is a subtype of increasing quantity: A process that changes the amount of acetyl CoA to be larger.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder].",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004374|http://purl.obolibrary.org/obo/TXPO_0002005,,,,,,,,,,,TXPO:0004127,,,,,,,,,,,,,,,,,,,,,,increasing acetyl CoA [Mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004123,positive regulation of tumor cell death [Phospholipidosis],,"Any process that increases the rate or frequency of tumor cell death.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0004122,,,,,,,,,,,,,,,,,,,,,,"Any process that increases the rate or frequency of tumor cell death.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001395,,,,,,,,,,,,,,,,,TXPO:0004123,,,,,,,,,,,,,,,,,,,,,,positive regulation of tumor cell death [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004129,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004120,"negative regulation of mitochondrial electron transport, ubiquinol to cytochrome c [Mitochondrial disorder]",,"Any process that stops, prevents or reduces the frequency, rate or extent of tmitochondrial electron transport, ubiquinol to cytochrome c.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0004081,,,,,,,,,,,,,,,,,,,,,,"Any process that stops, prevents or reduces the frequency, rate or extent of tmitochondrial electron transport, ubiquinol to cytochrome c.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004120,,,,,,,,,,,,,,,,,,,,,,"negative regulation of mitochondrial electron transport, ubiquinol to cytochrome c [Mitochondrial disorder]",,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006122,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004126,malfunctioning of TCA cycle [Mitochondrial disorder],,"Malfunctioning of TCA cycle is a subtype of malfunctioning of metabolism: A process that cannot perform a tricarboxylic acid cycle appropriately or cannot realize it at all.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0001269,,,,,,,,,,,,,,,,,,,,PMID:29335519|PMID:26571396,,"Malfunctioning of TCA cycle is a subtype of malfunctioning of metabolism: A process that cannot perform a tricarboxylic acid cycle appropriately or cannot realize it at all.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004271|http://purl.obolibrary.org/obo/TXPO_0001989|http://purl.obolibrary.org/obo/TXPO_0004373|http://purl.obolibrary.org/obo/TXPO_0004372|http://purl.obolibrary.org/obo/TXPO_0004371|http://purl.obolibrary.org/obo/TXPO_0004127|http://purl.obolibrary.org/obo/TXPO_0004125,,,,,,,,,,,TXPO:0004126,,,,,,,,,,,,,,,,,,,,,,malfunctioning of TCA cycle [Mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004124,negative regulation of heat generation [Mitochondrial disorder],inhibition of heat generation [Mitochondrial disorder]|downregulation of heat generation [Mitochondrial disorder]|down-regulation of heat generation [Mitochondrial disorder]|down regulation of heat generation [Mitochondrial disorder],"Negative regulation of heat generation is a subtype of negative regulation process:  Any process that stops, prevents, or reduces the rate or extent of heat generation.
This process can constitute the course of Mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001987|http://purl.obolibrary.org/obo/TXPO_0002054,,,,,,,,,,,,,,,,,,,,,,"Negative regulation of heat generation is a subtype of negative regulation process:  Any process that stops, prevents, or reduces the rate or extent of heat generation.
This process can constitute the course of Mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,downregulation of heat generation [Mitochondrial disorder]|down-regulation of heat generation [Mitochondrial disorder]|down regulation of heat generation [Mitochondrial disorder],inhibition of heat generation [Mitochondrial disorder],,,,TXPO:0004124,,,,,,,,,,,,,,,,,,,,,,negative regulation of heat generation [Mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0031649,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004121,DNA damage [Mitochondrial disorder],,"Drug-, radiation-induced, or spontaneous injuries to DNA that introduce deviations from its normal double-helical conformation. These changes include structural distortions that interfere with replication and transcription, as well as point mutations that disrupt base pairs and exert damaging effects on future generations through changes in DNA sequence. If the damage is minor, it can often be repaired (DNA repair); extensive damage can induce apoptosis.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/NCIT_C16507|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:31623280|PMID:21145849|PMID:23299992|PMID:29222479,,"Drug-, radiation-induced, or spontaneous injuries to DNA that introduce deviations from its normal double-helical conformation. These changes include structural distortions that interfere with replication and transcription, as well as point mutations that disrupt base pairs and exert damaging effects on future generations through changes in DNA sequence. If the damage is minor, it can often be repaired (DNA repair); extensive damage can induce apoptosis.
This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004331|http://purl.obolibrary.org/obo/TXPO_0004337,,,,,,http://purl.obolibrary.org/obo/TXPO_0004218|http://purl.obolibrary.org/obo/TXPO_0001990|http://purl.obolibrary.org/obo/TXPO_0000869|http://purl.obolibrary.org/obo/TXPO_0003568,,,,,,,,,,,TXPO:0004121,,,,,,,,,,,,,,,,,,,,,,DNA damage [Mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004128,increasing volume of mitochondria [lipidosis],,"Increasing volume of mitochondria is a changing process to change the volume of the mitochondria to increase.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0000143|http://purl.obolibrary.org/obo/TXPO_0001720,,,,,,,,,,,,,,,,,,,,,,"Increasing volume of mitochondria is a changing process to change the volume of the mitochondria to increase.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005739,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004128,,,,,,,,,,,,,,,,,,,,,,increasing volume of mitochondria [lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004129,tumor cell death,,Any biological process that results in permanent cessation of tumor cells.,false,,,http://purl.obolibrary.org/obo/GO_0008219,,,,,,,,,,,,,,,,,,,,,,Any biological process that results in permanent cessation of tumor cells.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004129,,,,,,,,,,,,,,,,,,,,,,tumor cell death,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004122,positive regulation of tumor cell death,,Any process that increases the rate or frequency of tumor cell death.,false,,,http://purl.obolibrary.org/obo/TXPO_0004079,,,,,,,,,,,,,,,,,,,,,,Any process that increases the rate or frequency of tumor cell death.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0004122,,,,,,,,,,,,,,,,,,,,,,positive regulation of tumor cell death,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0008219,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004125,negative regulation of oxidative phosphorylation [Mitochondrial disorder],,"Negative regulation of oxidative phosphorylation is a subtype of negative regulation process: Any process that stops, prevents or reduces the frequency, rate or extent of the oxidative phosphorylation.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",false,,,http://purl.obolibrary.org/obo/TXPO_0001771|http://purl.obolibrary.org/obo/TXPO_0001987,,,,,,,,,,,,,,,,,,,,PMID:30250064|PMID:23299992|PMID:24746669|PMID:29222479|PMID:31649547,,"Negative regulation of oxidative phosphorylation is a subtype of negative regulation process: Any process that stops, prevents or reduces the frequency, rate or extent of the oxidative phosphorylation.
This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0004135,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000075|http://purl.obolibrary.org/obo/TXPO_0002005|http://purl.obolibrary.org/obo/TXPO_0002230,,,,,,,,,,,TXPO:0004125,,,,,,,,,,,,,,,,,,,,,,negative regulation of oxidative phosphorylation [Mitochondrial disorder],,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0006119,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000004925,NUCB2,,Other designations: DNA-binding protein NEFA|epididymis secretory protein Li 109|gastric cancer antigen Zg4|nesfatin-1|nucleobindin-2|nucleobinding 2|prepronefastin|prepronesfatin,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,NEFA|HEL-S-109,,,,,,,,,,,,11,,,,,,HPRD:09726|HGNC:8044|Ensembl:ENSG00000070081|Vega:OTTHUMG00000166050|MIM:608020,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,nucleobindin 2,,,11p15.1,,,,,,,,,,,,,,,,"GO_0003677 (EC: IEA); GO_0005509 (EC: IEA); GO_0005515 (EC: IPI); GO_0005615 (EC: TAS, PMID: 7811391); GO_0005640 (EC: IEA); GO_0005783 (EC: IEA); GO_0005793 (EC: IDA, PMID: 15308636); GO_0005794 (EC: IDA); GO_0005829 (EC: TAS, PMID: 7811391); GO_0005886 (EC: TAS, PMID: 7811391); GO_0070062 (EC: IDA, PMID: 19199708)",,,,,,,,,PMID: 7811391; 9639681; 10381334; 10915798; 11749975; 12087473; 12477932; 12909641; 14702039; 15308636; 15604093; 16344560; 16407280; 18029348; 18154733; 19199708; 19262995; 19351608; 19913121; 20030931; 20032201; 20427481; 20427483; 20625762; 20628086; 20813143; 20881960; 20937336; 21139048; 21145461; 21252251; 21459029; 21554911; 21653697; 21803054; 21890473; 21988594; 21988832; 22020667; 22036920; 22108805; 22203468; 22225987; 22270345; 22334726; 22367584; 22863883; 22950627; 23141462; 23155701; 23178145; 23266808; 23269222; 23346951; 23515787; 23613885; 23739643; 23764403; 23768444,,,,,,,,,,,,,,,OGG:3000004925,,,,,,,nucleobindin 2,,,,,,,,,,,,,Other designations: DNA-binding protein NEFA|epididymis secretory protein Li 109|gastric cancer antigen Zg4|nesfatin-1|nucleobindin-2|nucleobinding 2|prepronefastin|prepronesfatin,,NUCB2,,,,,,,,,,,,,,,,,,,,,,,4925,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,NUCB2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/GO_0008654,phospholipid biosynthetic process,phospholipid biosynthesis|phospholipid formation|phospholipid synthesis|phospholipid anabolism,"The chemical reactions and pathways resulting in the formation of phospholipids, any lipid containing phosphoric acid as a mono- or diester.",false,,,http://purl.obolibrary.org/obo/GO_0008610,,,,,,,,,,,,,,,,,,,,,,"The chemical reactions and pathways resulting in the formation of phospholipids, any lipid containing phosphoric acid as a mono- or diester.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_16247,,,,,,,,,,,,,,phospholipid biosynthesis|phospholipid formation|phospholipid synthesis|phospholipid anabolism,,,,,GO:0008654,,,,,,,,,,,,,,,,,,,,,,phospholipid biosynthetic process,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100554,FGF-4,HST-1|HST|K-fibroblast growth factor|Transforming protein KS3|HBGF-4|Heparin secretory transforming protein|KFGF,,false,,,http://purl.obolibrary.org/obo/IMR_0000049,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,HST-1|HST|K-fibroblast growth factor|Transforming protein KS3|HBGF-4|Heparin secretory transforming protein|KFGF,,,,,IMR:0100554,,,,,,,,,,,,,,,,,,,,,,FGF-4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_48407,antiparkinson drug,antiparkinson agent,A drug used in the treatment of Parkinson's disease.,false,,,http://purl.obolibrary.org/obo/CHEBI_66956|http://purl.obolibrary.org/obo/CHEBI_23888,,,,,,,,,,,,,,,,,,,,Wikipedia:Antiparkinson,,A drug used in the treatment of Parkinson's disease.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,antiparkinson agent,,,,,,,,,,,,,,,,,,,,,CHEBI:48407,,,,antiparkinson drug,,CHEBI:48407,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100169,endothelin-3,ET-3,,false,,,http://purl.obolibrary.org/obo/IMR_0100166,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ET-3,,,,,IMR:0100169,,,,,,,,,,,,,,,,,,,,,,endothelin-3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000156,FcR,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000156,,,,,,,,,,,,,,,,,,,,,,FcR,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/GO_0001732,formation of cytoplasmic translation initiation complex,,"Joining of the large subunit, with release of IF2/eIF2 and IF3/eIF3. This leaves the functional ribosome at the AUG, with the methionyl/formyl-methionyl-tRNA positioned at the P site.",false,,,http://purl.obolibrary.org/obo/GO_0006461,,,,,,,,,,,,,,,,,,,,,,"Joining of the large subunit, with release of IF2/eIF2 and IF3/eIF3. This leaves the functional ribosome at the AUG, with the methionyl/formyl-methionyl-tRNA positioned at the P site.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GO:0001732,,,,,,,,,,,,,,,,,,,,,,formation of cytoplasmic translation initiation complex,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000317,G-alpha-s class,,,false,,,http://purl.obolibrary.org/obo/IMR_0000316,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000317,,,,,,,,,,,,,,,,,,,,,,G-alpha-s class,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000897,lipid storage in liver [Lipidosis],,"Lipid storage in liver is a subtype of lipid storage: The accumulation and maintenance in cells or tissues of lipids in the liver.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001276|http://purl.obolibrary.org/obo/TXPO_0001720,,,,,,,,,,,,,,,,,,,,ISBN:0071769234,,"Lipid storage in liver is a subtype of lipid storage: The accumulation and maintenance in cells or tissues of lipids in the liver.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000897,,,,,,,,,,,,,,,,,,,,,,lipid storage in liver [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000893,lipid metabolism imbalance [Lipidosis],,"Lipid metabolism imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance of lipid metabolism.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0002336|http://purl.obolibrary.org/obo/TXPO_0001160,,,,,,,,,,,,,,,,,,,,,,"Lipid metabolism imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance of lipid metabolism.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003491,,,,,,,,,,,TXPO:0000893,,,,,,,,,,,,,,,,,,,,,,lipid metabolism imbalance [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000894,CASP1 (predicted)(human)[Glutathone depletion],,predicted gene  by Support Vector Machine (SVM) using human primary hepatocyte,false,,,http://purl.obolibrary.org/obo/IMR_0100302|http://purl.obolibrary.org/obo/TXPO_0001916,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:834|PMID:20303873|PMID:29558368|PMID:28102119|PMID:9558119|PMID:24146141|PMID:10854226,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000000834,,,,,,,,,,,,,TXPO:0000894,,,,,,,,,,,,,,,,,,,,predicted gene  by Support Vector Machine (SVM) using human primary hepatocyte,,CASP1 (predicted)(human)[Glutathone depletion],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000898,hyperfunction of lipid biosynthesis [Lipidosis],,"Hyperfunction of lipid biosynthesis is a subtype of hyperfunction of biosynthesis: A process that performs an excessive lipid biosynthesis.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0002337,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of lipid biosynthesis is a subtype of hyperfunction of biosynthesis: A process that performs an excessive lipid biosynthesis.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000890,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000893,,,,,,,,,,,TXPO:0000898,,,,,,,,,,,,,,,,,,,,,,hyperfunction of lipid biosynthesis [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000895,biological membrane,,A sheet or layer to separate or connect between biological structures.,false,,,http://purl.obolibrary.org/obo/GO_0005575,,,,,,,,,,,,,,,,,,,,Wikipedia:Biological_membrane,,A sheet or layer to separate or connect between biological structures.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000895,,,,,,,,,,,,,,,,,,,,,,biological membrane,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000892,increaing in fatty acid inflow into hepatocyte [Lipidosis],,"Increaing in fatty acid inflow into hepatocyte is a subtype of increasing quantity: A process that changes the fatty acid inflow into the hepatocyte to be larger.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0003492|http://purl.obolibrary.org/obo/TXPO_0001720,,,,,,,,,,,,,,,,,,,,,,"Increaing in fatty acid inflow into hepatocyte is a subtype of increasing quantity: A process that changes the fatty acid inflow into the hepatocyte to be larger.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003494,,,,,,,,,,,TXPO:0000892,,,,,,,,,,,,,,,,,,,,,,increaing in fatty acid inflow into hepatocyte [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000899,hyperfunction of lipid synthetic gene expression [Lipidosis],,"Hyperfunction of lipid synthetic gene expression is a subtype of hyperfunction of gene expression: A process that performs an excesssive lipid biosynthetic gene expression.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0002338,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of lipid synthetic gene expression is a subtype of hyperfunction of gene expression: A process that performs an excesssive lipid biosynthetic gene expression.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001108|http://purl.obolibrary.org/obo/TXPO_0003812,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001301|http://purl.obolibrary.org/obo/TXPO_0001394|http://purl.obolibrary.org/obo/TXPO_0001401,,,,,,http://purl.obolibrary.org/obo/TXPO_0000898|http://purl.obolibrary.org/obo/TXPO_0000890,,,,,,,,,,,TXPO:0000899,,,,,,,,,,,,,,,,,,,,,,hyperfunction of lipid synthetic gene expression [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000891,hypofunction of lipid degradation [Lipidosis],,"Hypofunction of lipid degradation is a subtype of hypofunction of decomposing: A process that performs a decreased or insufficient lipid degradation.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0002006,,,,,,,,,,,,,,,,,,,,,,"Hypofunction of lipid degradation is a subtype of hypofunction of decomposing: A process that performs a decreased or insufficient lipid degradation.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001036,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000893,,,,,,,,,,,TXPO:0000891,,,,,,,,,,,,,,,,,,,,,,hypofunction of lipid degradation [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000896,Deacreasing flow rate,,Deacreasing flow velocity is a subtype of changing flow: A process that changes the velocity of the object to be slower.,false,,,http://purl.obolibrary.org/obo/TXPO_0000711,,,,,,,,,,,,,,,,,,,,,,Deacreasing flow velocity is a subtype of changing flow: A process that changes the velocity of the object to be slower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0000896,,,,,,,,,,,,,,,,,,,,,,Deacreasing flow rate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0000890,hyperfunction of fatty acid biosynthesis [Lipidosis],,"Hyperfunction of fatty acid biosynthesis is a subtype of hyperfunction of biosynthesis: A process that performs an excessive fatty acid biosynthesis.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001720|http://purl.obolibrary.org/obo/TXPO_0002335,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of fatty acid biosynthesis is a subtype of hyperfunction of biosynthesis: A process that performs an excessive fatty acid biosynthesis.
This entity is a specific course-dependent process. This process can constitute the course of Lipidosis.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003812,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000898,,,,,,,,,,,TXPO:0000890,,,,,,,,,,,,,,,,,,,,,,hyperfunction of fatty acid biosynthesis [Lipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004193,KIAA0101 (predicted)(human) [hepatocarcinogenesis],NS5ATP9|PCLAF,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_1000520,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:9768|PMID:25649430,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000009768,,,,,,,,NS5ATP9|PCLAF,,,,,TXPO:0004193,,,,,,,,,,,,,,,,,,,,,,KIAA0101 (predicted)(human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004198,CXCL8 (predicted)(human) [hepatocarcinogenesis],IL-8,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_1000510,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:3576|PMID:30523154|PMID:29679563,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,,,,,,,,,IL-8,,,,,TXPO:0004198,,,,,,,,,,,,,,,,,,,,,,CXCL8 (predicted)(human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004192,DPYD (predicted)(human) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_1000514,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:1806|PMID:29358721,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000001806,,,,,,,,,,,,,TXPO:0004192,,,,,,,,,,,,,,,,,,,,,,DPYD (predicted)(human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004190,ACSM2B (predicted)(human) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_1000501,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:348158,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000348158,,,,,,,,,,,,,TXPO:0004190,,,,,,,,,,,,,,,,,,,,,,ACSM2B (predicted)(human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004194,HILPDA (predicted)(human) [hepatocarcinogenesis],HIG2,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_1000518,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:29923|PMID:25796501,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000029923,,,,,,,,HIG2,,,,,TXPO:0004194,,,,,,,,,,,,,,,,,,,,,,HILPDA (predicted)(human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004195,AGGF1 (predicted)(human) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_1000502,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:55109|PMID:30710550|PMID:25796501,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000055109,,,,,,,,,,,,,TXPO:0004195,,,,,,,,,,,,,,,,,,,,,,AGGF1 (predicted)(human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004197,RPS29 (predicted)(human) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_1000530,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:6235,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000006235,,,,,,,,,,,,,TXPO:0004197,,,,,,,,,,,,,,,,,,,,,,RPS29 (predicted)(human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004191,SPTLC3 (predicted)(human) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_1000536,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:55304,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000055304,,,,,,,,,,,,,TXPO:0004191,,,,,,,,,,,,,,,,,,,,,,SPTLC3 (predicted)(human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004196,CLMN (predicted)(human) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_1000508,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:79789,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000079789,,,,,,,,,,,,,TXPO:0004196,,,,,,,,,,,,,,,,,,,,,,CLMN (predicted)(human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0004199,ZNF385B (predicted)(human) [hepatocarcinogenesis],,,false,,,http://purl.obolibrary.org/obo/TXPO_0004185|http://purl.obolibrary.org/obo/TXPO_1000406,,,,,,,,,,,,,,,,,,,,NCBI-Human-GeneID:151126,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000657,http://purl.obolibrary.org/obo/OGG_3000151126,,,,,,,,,,,,,TXPO:0004199,,,,,,,,,,,,,,,,,,,,,,ZNF385B (predicted)(human) [hepatocarcinogenesis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000005610,EIF2AK2,,"Other designations: P1/eIF-2A protein kinase|double stranded RNA activated protein kinase|eIF-2A protein kinase 2|interferon-induced, double-stranded RNA-activated protein kinase|interferon-inducible elF2alpha kinase|p68 kinase|protein kinase, interferon-inducible double stranded RNA dependent|tyrosine-protein kinase EIF2AK2",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,PRKR|PKR|EIF2AK1,,,,,,,,,,,,2,,,,,,MIM:176871|HPRD:01468|Ensembl:ENSG00000055332|HGNC:9437,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,eukaryotic translation initiation factor 2-alpha kinase 2,,,2p22-p21,,,,,,,,,,,,,,,,"GO_0000186 (EC: IMP, PMID:15229216); GO_0001819 (EC: ISS); GO_0003725 (EC: IDA); GO_0004672 (EC: IDA, PMID:12882984); GO_0004672 (EC: IMP); GO_0004674 (EC: TAS, PMID:1695551); GO_0004694 (EC: TAS, PMID:10866685); GO_0004715 (EC: IEA); GO_0005515 (EC: IPI, PMID:10390359); GO_0005524 (EC: IEA); GO_0005634 (EC: IEA); GO_0005737 (EC: IDA, PMID:15121867); GO_0005829 (EC: TAS); GO_0006351 (EC: IEA); GO_0006412 (EC: IEA); GO_0006468 (EC: IDA, PMID:19189853); GO_0008285 (EC: TAS, PMID:1351683); GO_0008601 (EC: TAS, PMID:10866685); GO_0009615 (EC: IMP, PMID:19189853); GO_0017148 (EC: IDA, PMID:12882984); GO_0017148 (EC: IMP, PMID:19189853); GO_0019048 (EC: TAS); GO_0019054 (EC: TAS); GO_0019058 (EC: TAS); GO_0030683 (EC: TAS); GO_0030968 (EC: IEA); GO_0032722 (EC: ISS); GO_0032874 (EC: ISS); GO_0033689 (EC: IMP, PMID:16216244); GO_0035455 (EC: IDA, PMID:19840259); GO_0044822 (EC: IDA); GO_0045071 (EC: IMP, PMID:19189853); GO_0045087 (EC: IEA); GO_0046777 (EC: IDA); GO_0046777 (EC: IMP, PMID:16216244); GO_0048471 (EC: IDA, PMID:15121867); GO_0051092 (EC: IDA, PMID:15121867); GO_0051607 (EC: IEA); GO_1900225 (EC: ISS); GO_1901224 (EC: ISS); GO_1901532 (EC: ISS); GO_1902033 (EC: ISS); GO_1902036 (EC: ISS)",,,,,,,,,PMID:1351683; 1373553; 1373554; 1677563; 1695551; 1708818; 2180064; 7491766; 7568151; 7686883; 7686884; 7738010; 7757816; 8099444; 8576172; 8601309; 8812437; 8887659; 8889548; 8921913; 9079663; 9135145; 9143277; 9214631; 9447982; 9528799; 9687506; 9721103; 9726442; 9735304; 9736623; 9781815; 9819435; 10320367; 10330179; 10348343; 10390359; 10400669; 10400814; 10542257; 10557102; 10620360; 10648614; 10684936; 10723127; 10747897; 10848580; 10866685; 10884347; 11123929; 11152499; 11238927; 11278865; 11337501; 11350938; 11438532; 11438536; 11438540; 11447118; 11468270; 11526399; 11555640; 11773402; 11836380; 11921349; 11985496; 11991642; 12051728; 12055262; 12060652; 12138106; 12231563; 12349906; 12368306; 12368348; 12396729; 12397061; 12447867; 12473108; 12477932; 12483527; 12539042; 12609980; 12665801; 12679338; 12882984; 12944978; 13678666; 14638359; 14698665; 14765129; 14961569; 15121867; 15122791; 15207627; 15229216; 15299030; 15489334; 15535414; 15596837; 15607693; 15625311; 15635413; 15737233; 15815621; 15880455; 15907845; 16009940; 16156900; 16216244; 16271080; 16288713; 16339759; 16373505; 16446363; 16466763; 16580685; 16785445; 16861340; 16861808; 16924232; 16954686; 16957780; 16989899; 17202131; 17284445; 17290288; 17307214; 17318221; 17353931; 17420072; 17451862; 17522227; 17541283; 17596833; 17597457; 17612505; 17686861; 17716668; 17785458; 17851256; 17928244; 17928446; 17959656; 17975119; 17977969; 18023289; 18048689; 18063576; 18087277; 18362360; 18426922; 18496558; 18599499; 18684815; 18684960; 18728014; 18835251; 18927075; 18936160; 18957415; 18976633; 18991615; 19004947; 19023099; 19028691; 19106640; 19109397; 19151623; 19189853; 19210572; 19229320; 19259124; 19322201; 19349624; 19353519; 19364808; 19416861; 19434718; 19445956; 19507191; 19515768; 19605474; 19605483; 19642004; 19651874; 19710021; 19733181; 19744687; 19776135; 19812373; 19840259; 19846517; 19846675; 20006836; 20006840; 20171114; 20181660; 20309637; 20331378; 20353946; 20395957; 20447405; 20485506; 20587610; 20588308; 20628624; 20685959; 20930042; 21029237; 21048031; 21072047; 21123378; 21123651; 21139048; 21145461; 21294215; 21338484; 21377708; 21385567; 21464971; 21468538; 21504114; 21526770; 21698289; 21710204; 21715487; 21790829; 21846836; 21882225; 21890473; 21903422; 21906983; 21907836; 22022264; 22102852; 22174754; 22190034; 22278235; 22281122; 22306812; 22381929; 22473766; 22647704; 22787234; 22801494; 22894766; 22896602; 22912486; 22939624; 22939629; 22948139; 22986343; 23064357; 23084476; 23115276; 23115300; 23148689; 23151878; 23221979; 23229543; 23302873; 23314571; 23320095; 23370317; 23372823; 23399035; 23455922; 23527187; 23682076; 23706307; 23853588; 24089560; 24163370; 24334130,,,,,,,,,,,,,,,OGG:3000005610,,,,,,,eukaryotic translation initiation factor 2-alpha kinase 2,,,,,,,,,,,,,"Other designations: P1/eIF-2A protein kinase|double stranded RNA activated protein kinase|eIF-2A protein kinase 2|interferon-induced, double-stranded RNA-activated protein kinase|interferon-inducible elF2alpha kinase|p68 kinase|protein kinase, interferon-inducible double stranded RNA dependent|tyrosine-protein kinase EIF2AK2",,EIF2AK2,,,,,,,,,,,,,,,,,,,,,,,5610,,,,,,,,9606,,,,,,,,,,,,,,,,,,,EIF2AK2,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_3000005611,DNAJC3,,"Other designations: ER-resident protein ERdj6|dnaJ homolog subfamily C member 3|endoplasmic reticulum DNA J domain-containing protein 6|endoplasmic reticulum DnaJ protein 6|interferon-induced, double-stranded RNA-activated protein kinase inhibitor|protein kinase inhibitor of 58 kDa|protein kinase inhibitor p58|protein-kinase, interferon-inducible double stranded RNA dependent inhibitor",false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,P58|HP58|PRKRI|ERdj6|P58IPK,,,,,,,,,,,,13,,,,,,Ensembl:ENSG00000102580|MIM:601184|HGNC:9439|HPRD:03114|Vega:OTTHUMG00000017227,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"DnaJ (Hsp40) homolog, subfamily C, member 3",,,13q32.1,,,,,,,,,,,,,,,,"GO_0004860 (EC: TAS, PMID:7511204); GO_0005737 (EC: TAS, PMID:8666242); GO_0005788 (EC: TAS); GO_0006469 (EC: TAS, PMID:7511204); GO_0006987 (EC: TAS); GO_0030968 (EC: TAS); GO_0031205 (EC: IEA); GO_0044267 (EC: TAS); GO_0051087 (EC: IEA); GO_0051603 (EC: IEA); GO_0051607 (EC: IEA); GO_0051787 (EC: IEA); GO_0070062 (EC: IDA, PMID:19199708)",,,,,,,,,PMID:7511204; 8576172; 8666242; 8824806; 8824808; 9447982; 9920933; 11116152; 11147971; 11526399; 11939789; 11991713; 12034040; 12446838; 12477932; 12601012; 15057823; 15489334; 18568130; 19199708; 20237496; 20554776; 21139048; 21799829; 21906983; 21963094; 22064321; 22190034; 24250222,,,,,,,,,,,,,,,OGG:3000005611,,,,,,,"DnaJ (Hsp40) homolog, subfamily C, member 3",,,,,,,,,,,,,"Other designations: ER-resident protein ERdj6|dnaJ homolog subfamily C member 3|endoplasmic reticulum DNA J domain-containing protein 6|endoplasmic reticulum DnaJ protein 6|interferon-induced, double-stranded RNA-activated protein kinase inhibitor|protein kinase inhibitor of 58 kDa|protein kinase inhibitor p58|protein-kinase, interferon-inducible double stranded RNA dependent inhibitor",,DNAJC3,,,,,,,,,,,,,,,,,,,,,,,5611,,,,,,,,9606,,,,,,,,,,,,,,,,,,,DNAJC3,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/CHEBI_16646,carbohydrate,,"Any member of the class of organooxygen compounds that is a polyhydroxy-aldehyde or -ketone or a lactol resulting from their intramolecular condensation (monosaccharides); substances derived from these by reduction of the carbonyl group (alditols), by oxidation of one or more hydroxy groups to afford the corresponding aldehydes, ketones, or carboxylic acids, or by replacement of one or more hydroxy group(s) by a hydrogen atom; and polymeric products arising by intermolecular acetal formation between two or more such molecules (disaccharides, polysaccharides and oligosaccharides). Carbohydrates contain only carbon, hydrogen and oxygen atoms; prior to any oxidation or reduction, most have the empirical formula Cm(H2O)n. Compounds obtained from carbohydrates by substitution, etc., are known as carbohydrate derivatives and may contain other elements. Cyclitols are generally not regarded as carbohydrates.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,,,"Any member of the class of organooxygen compounds that is a polyhydroxy-aldehyde or -ketone or a lactol resulting from their intramolecular condensation (monosaccharides); substances derived from these by reduction of the carbonyl group (alditols), by oxidation of one or more hydroxy groups to afford the corresponding aldehydes, ketones, or carboxylic acids, or by replacement of one or more hydroxy group(s) by a hydrogen atom; and polymeric products arising by intermolecular acetal formation between two or more such molecules (disaccharides, polysaccharides and oligosaccharides). Carbohydrates contain only carbon, hydrogen and oxygen atoms; prior to any oxidation or reduction, most have the empirical formula Cm(H2O)n. Compounds obtained from carbohydrates by substitution, etc., are known as carbohydrate derivatives and may contain other elements. Cyclitols are generally not regarded as carbohydrates.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CHEBI:16646,,,,,,,,,,,,,,,,,,,,,,carbohydrate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000075,insulin receptor family,,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000823,,,,,,,,,,IMR:0000075,,,,,,,,,,,,,,,,,,,,,,insulin receptor family,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_6402,leflunomide,"Arava|leflunomida|leflunomide|5-Methyl-N-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamide|alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide|leflunomidum|5-Methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide|Leflunomide|5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide","A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.",false,,,http://purl.obolibrary.org/obo/CHEBI_50860,,,,,,,,,,,,,,,,,,,,PMID:15385935|CAS:75706-12-6|PMID:16778342|PMID:11391470|PMID:19715969|DrugBank:DB01097|PMID:16202258|PMID:19190124|PMID:18663553|PMID:9777697|Drug_Central:1552|PMID:18173611|PMID:15537652|PMID:11067959|PMID:17366662|PMID:11718154|PMID:15789891|PMID:15489872|PMID:15188371|PMID:15652966|PMID:11475244|PMID:11053058|PMID:19344337|Reaxys:4323174|PMID:11333342|Beilstein:4323174|PMID:10890256|PMID:16645972|LINCS:LSM-3771|PMID:11043056|PMID:15127974|PMID:17604599|PMID:11994686|PMID:9075844|PMID:16769661|PMID:14622739|PMID:16284916|PMID:10515382|PMID:15127968|PMID:18034546|PMID:15030575|PMID:11522581|PMID:17646975|PMID:11876141|PMID:12017890|PMID:16638062|PMID:15934905|PMID:18688040|PMID:15899055|PMID:12074690|PMID:8610393|PMID:10702725|PMID:18413415|PMID:11707749|PMID:7496341|PMID:19751817|PMID:15214907|PMID:16106593|PMID:19581389|PMID:15665760|PMID:12833393|PMID:19770782|PMID:19169882|PMID:9123314|PMID:16638420|PMID:16142756|PMID:9625011|PMID:17854740|PMID:11884931|PMID:16688677|PMID:11271257|PMID:11340750|PMID:7676489|PMID:18496682,,"A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CHEBI_35705|http://purl.obolibrary.org/obo/CHEBI_37153|http://purl.obolibrary.org/obo/CHEBI_35610|http://purl.obolibrary.org/obo/CHEBI_38637|http://purl.obolibrary.org/obo/CHEBI_68542|http://purl.obolibrary.org/obo/CHEBI_68543|http://purl.obolibrary.org/obo/CHEBI_50908|http://purl.obolibrary.org/obo/CHEBI_35475|http://purl.obolibrary.org/obo/CHEBI_35442|http://purl.obolibrary.org/obo/CHEBI_50266,,,,,"Leflunomide|5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide",,"Arava|leflunomida|leflunomide|5-Methyl-N-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamide|alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide|leflunomidum|5-Methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide",,,,,,,,,,,,,,,,,,,,,CHEBI:6402,,,,leflunomide,,CHEBI:6402,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003434,hyperfunction of Kupffer cell differentiation,,Hyperfunction of Kupffer cell differentiation is a subtype of hyperfunction of cell differentiation: A process that performs an excesssive kupffer cell differentiation.,false,,,http://purl.obolibrary.org/obo/TXPO_0003433,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of Kupffer cell differentiation is a subtype of hyperfunction of cell differentiation: A process that performs an excesssive kupffer cell differentiation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003434,,,,,,,,,,,,,,,,,,,,,,hyperfunction of Kupffer cell differentiation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003432,hyperfunction of phospholipid phagocytosis by Kupffer cells,,Hyperfunction of phospholipid phagocytosis by Kupffer cells  is a subtype of hyperfunctioning: A process that performs an excessive phospholipid phagocytosis by Kupffer cells.,false,,,http://purl.obolibrary.org/obo/TXPO_0001483,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of phospholipid phagocytosis by Kupffer cells  is a subtype of hyperfunctioning: A process that performs an excessive phospholipid phagocytosis by Kupffer cells.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003432,,,,,,,,,,,,,,,,,,,,,,hyperfunction of phospholipid phagocytosis by Kupffer cells,,,,,,http://purl.obolibrary.org/obo/TXPO_0003396,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003438,decreasing lysosomal membrane permeability,,Decreasing lysosomal membrane permeability is a subtype of decreasing membrane permeability: A process that changes the permeability of the lysosomal membrane to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0003439,,,,,,,,,,,,,,,,,,,,,,Decreasing lysosomal membrane permeability is a subtype of decreasing membrane permeability: A process that changes the permeability of the lysosomal membrane to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003438,,,,,,,,,,,,,,,,,,,,,,decreasing lysosomal membrane permeability,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003437,in vitro (human) 8hr,,,false,,,http://purl.obolibrary.org/obo/TXPO_0000795,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003437,,,,,,,,,,,,,,,,,,,,,,in vitro (human) 8hr,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003431,hyperfunction of phospholipid phagocytosis by Kupffer cells [Phospholipidosis (excessive defense)],,"Hyperfunction of phospholipid phagocytosis by Kupffer cells is a subtype of hyperfunctioning: A process that performs an excessive phospholipid phagocytosis by Kupffer cells.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense).",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0003432,,,,,,,,,,,,,,,,,,,,,,"Hyperfunction of phospholipid phagocytosis by Kupffer cells is a subtype of hyperfunctioning: A process that performs an excessive phospholipid phagocytosis by Kupffer cells.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense).",,,http://purl.obolibrary.org/obo/TXPO_0003395,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/CL_0000091|http://purl.obolibrary.org/obo/CL_0000235,,,,,,http://purl.obolibrary.org/obo/TXPO_0000558,,,,,,,,,,,TXPO:0003431,,,,,,,,,,,,,,,,,,,,,,hyperfunction of phospholipid phagocytosis by Kupffer cells [Phospholipidosis (excessive defense)],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003430,kupffer cell differentiation,,Kupffer cell differentiation is a subtype of macrophage differentiation: The process that acquires the specialized features of a kupffer cell.,false,,,http://purl.obolibrary.org/obo/GO_0030225,,,,,,,,,,,,,,,,,,,,,,Kupffer cell differentiation is a subtype of macrophage differentiation: The process that acquires the specialized features of a kupffer cell.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003430,,,,,,,The process in which a relatively unspecialized monocyte acquires the specialized features of a Kupffer cell.,,,,,,,,,,,,,,,kupffer cell differentiation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003435,phospholipid homeostasis imbalance [Phospholipidosis (severe) ],,"Phospholipid homeostasis imbalance is a subtype of lipid homeostasis imbalance: A process that becomes lacking a phospholipid homeostastasis balance. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",false,,,http://purl.obolibrary.org/obo/TXPO_0000907,,,,,,,,,,,,,,,,,,,,,,"Phospholipid homeostasis imbalance is a subtype of lipid homeostasis imbalance: A process that becomes lacking a phospholipid homeostastasis balance. And the degree is severe.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe).",,,http://purl.obolibrary.org/obo/TXPO_0001683,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001778,,,,,,,http://purl.obolibrary.org/obo/TXPO_0000920,,,,,,,,,,,TXPO:0003435,,,,,,,,,,,,,,,,,,,,,,phospholipid homeostasis imbalance [Phospholipidosis (severe) ],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003436,decreasing lysosomal membrane permeability [Phospholipidosis],,"Decreasing lysosomal membrane permeability is a subtype of decreasing membrane permeability: A process that changes the permeability of the lysosomal membrane to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",false,,,http://purl.obolibrary.org/obo/TXPO_0001716|http://purl.obolibrary.org/obo/TXPO_0003438,,,,,,,,,,,,,,,,,,,,,,"Decreasing lysosomal membrane permeability is a subtype of decreasing membrane permeability: A process that changes the permeability of the lysosomal membrane to be lower.
This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002239,,,,,,,,,,,TXPO:0003436,,,,,,,,,,,,,,,,,,,,,,decreasing lysosomal membrane permeability [Phospholipidosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/GO_0005765,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003433,hyperfunction of cell differentiation,,Hyperfunction of cell differentiation is a subtype of hyperfunctioning: A process that performs an excesssive cell differentiation.,false,,,http://purl.obolibrary.org/obo/TXPO_0000435,,,,,,,,,,,,,,,,,,,,,,Hyperfunction of cell differentiation is a subtype of hyperfunctioning: A process that performs an excesssive cell differentiation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003433,,,,,,,,,,,,,,,,,,,,,,hyperfunction of cell differentiation,,,,,,http://purl.obolibrary.org/obo/GO_0030154,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0003439,decreasing membrane permeability,,Decreasing membrane permeability is a subtype of changing permeability: A process that changes the permeability of the membrane to be lower.,false,,,http://purl.obolibrary.org/obo/TXPO_0002704,,,,,,,,,,,,,,,,,,,,,,Decreasing membrane permeability is a subtype of changing permeability: A process that changes the permeability of the membrane to be lower.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0003439,,,,,,,,,,,,,,,,,,,,,,decreasing membrane permeability,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100553,FGF-3,INT-2|Fibroblast growth factor-3|HBGF-3,,false,,,http://purl.obolibrary.org/obo/IMR_0000049,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,INT-2|Fibroblast growth factor-3|HBGF-3,,,,,IMR:0100553,,,,,,,,,,,,,,,,,,,,,,FGF-3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000632,Integrin alpha-10,,,false,,,http://purl.obolibrary.org/obo/IMR_0000173,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000632,,,,,,,,,,,,,,,,,,,,,,Integrin alpha-10,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_38503,EC 1.6.5.3 [NADH:ubiquinone reductase (H(+)-translocating)] inhibitor,complex I (electron transport chain) inhibitors|NADH:ubiquinone reductase (H(+)-translocating) inhibitor|dihydronicotinamide adenine dinucleotide-coenzyme Q reductase inhibitor|NADH coenzyme Q1 reductase inhibitors|complex I (NADH:Q1 oxidoreductase) inhibitors|NADH dehydrogenase (ubiquinone) inhibitor|coenzyme Q reductase|NADH-CoQ reductase inhibitors|complex I (mitochondrial electron transport) inhibitors|EC 1.6.5.3 [NADH:ubiquinone reductase (H(+)-translocating)] inhibitors|ubiquinone reductase inhibitor|type 1 dehydrogenase inhibitor|NADH-CoQ reductase inhibitor|NADH-ubiquinone-1 reductase inhibitors|NADH-CoQ oxidoreductase inhibitors|reduced nicotinamide adenine dinucleotide-coenzyme Q reductase inhibitors|NADH:ubiquinone oxidoreductase inhibitors|NADH:ubiquinone oxidoreductase complex inhibitor|NADH:ubiquinone reductase inhibitor|DPNH-ubiquinone reductase inhibitor|mitochondrial electron transport complex 1 inhibitor|NADH:ubiquinone reductase (H+-translocating) inhibitor|NADH-Q6 oxidoreductase inhibitor|NADH-ubiquinone-1 reductase inhibitor|electron transfer complex I inhibitor|NADH:ubiquinone reductase (H(+)-translocating) inhibitors|NADH-coenzyme Q reductase inhibitors|type 1 dehydrogenase inhibitors|NADH-ubiquinone oxidoreductase inhibitors|mitochondrial electron transport complex I inhibitors|EC 1.6.5.3 inhibitors|NADH-coenzyme Q oxidoreductase inhibitors|NADH2 dehydrogenase (ubiquinone) inhibitor|NADH-ubiquinone reductase inhibitors|EC 1.6.5.3 (NADH:ubiquinone reductase (H(+)-translocating)) inhibitors|DPNH-coenzyme Q reductase inhibitor|NADH-coenzyme Q reductase inhibitor|reduced nicotinamide adenine dinucleotide-coenzyme Q reductase inhibitor|NADH dehydrogenase (ubiquinone) inhibitors|NADH coenzyme Q1 reductase inhibitor|mitochondrial electron transport complex I inhibitor|NADH:ubiquinone oxidoreductase inhibitor|EC 1.6.5.3 inhibitor|NADH-CoQ oxidoreductase inhibitor|electron transfer complex I inhibitors|EC 1.6.5.3 (NADH:ubiquinone reductase (H(+)-translocating)) inhibitor|ubiquinone reductase inhibitors|NADH-ubiquinone oxidoreductase inhibitor|NADH-ubiquinone reductase inhibitor|complex 1 dehydrogenase inhibitor,"A respiratory-chain inhibitor that interferes with the action of the the enzyme NADH:ubiquinone reductase (H(+)-translocating), EC 1.6.5.3.",false,,,http://purl.obolibrary.org/obo/CHEBI_38497|http://purl.obolibrary.org/obo/CHEBI_76866,,,,,,,,,,,,,,,,,,,,,,"A respiratory-chain inhibitor that interferes with the action of the the enzyme NADH:ubiquinone reductase (H(+)-translocating), EC 1.6.5.3.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,complex I (electron transport chain) inhibitors|NADH:ubiquinone reductase (H(+)-translocating) inhibitor|dihydronicotinamide adenine dinucleotide-coenzyme Q reductase inhibitor|NADH coenzyme Q1 reductase inhibitors|complex I (NADH:Q1 oxidoreductase) inhibitors|NADH dehydrogenase (ubiquinone) inhibitor|coenzyme Q reductase|NADH-CoQ reductase inhibitors|complex I (mitochondrial electron transport) inhibitors|EC 1.6.5.3 [NADH:ubiquinone reductase (H(+)-translocating)] inhibitors|ubiquinone reductase inhibitor|type 1 dehydrogenase inhibitor|NADH-CoQ reductase inhibitor|NADH-ubiquinone-1 reductase inhibitors|NADH-CoQ oxidoreductase inhibitors|reduced nicotinamide adenine dinucleotide-coenzyme Q reductase inhibitors|NADH:ubiquinone oxidoreductase inhibitors|NADH:ubiquinone oxidoreductase complex inhibitor|NADH:ubiquinone reductase inhibitor|DPNH-ubiquinone reductase inhibitor|mitochondrial electron transport complex 1 inhibitor|NADH:ubiquinone reductase (H+-translocating) inhibitor|NADH-Q6 oxidoreductase inhibitor|NADH-ubiquinone-1 reductase inhibitor|electron transfer complex I inhibitor|NADH:ubiquinone reductase (H(+)-translocating) inhibitors|NADH-coenzyme Q reductase inhibitors|type 1 dehydrogenase inhibitors|NADH-ubiquinone oxidoreductase inhibitors|mitochondrial electron transport complex I inhibitors|EC 1.6.5.3 inhibitors|NADH-coenzyme Q oxidoreductase inhibitors|NADH2 dehydrogenase (ubiquinone) inhibitor|NADH-ubiquinone reductase inhibitors|EC 1.6.5.3 (NADH:ubiquinone reductase (H(+)-translocating)) inhibitors|DPNH-coenzyme Q reductase inhibitor|NADH-coenzyme Q reductase inhibitor|reduced nicotinamide adenine dinucleotide-coenzyme Q reductase inhibitor|NADH dehydrogenase (ubiquinone) inhibitors|NADH coenzyme Q1 reductase inhibitor|mitochondrial electron transport complex I inhibitor|NADH:ubiquinone oxidoreductase inhibitor|EC 1.6.5.3 inhibitor|NADH-CoQ oxidoreductase inhibitor|electron transfer complex I inhibitors|EC 1.6.5.3 (NADH:ubiquinone reductase (H(+)-translocating)) inhibitor|ubiquinone reductase inhibitors|NADH-ubiquinone oxidoreductase inhibitor|NADH-ubiquinone reductase inhibitor|complex 1 dehydrogenase inhibitor,,,,,,,,,,,,,,,,,,,,,CHEBI:38503,,,,EC 1.6.5.3 [NADH:ubiquinone reductase (H(+)-translocating)] inhibitor,,CHEBI:38503,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000009891,NUAK1,,Other designations: AMP-activated protein kinase family member 5|AMPK-related protein kinase 5|NUAK family SNF1-like kinase 1|omphalocele kinase 1,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,ARK5,,,,,,,,,,,,12,,,,,,Vega:OTTHUMG00000169763|HPRD:12171|HGNC:14311|Ensembl:ENSG00000074590|MIM:608130,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,"NUAK family, SNF1-like kinase, 1",,,12q23.3,,,,,,,,,,,,,,,,"GO_0002039 (EC: IPI); GO_0004674 (EC: IDA, PMID: 19927127); GO_0005515 (EC: IPI, PMID: 19927127); GO_0005524 (EC: IEA); GO_0005634 (EC: IDA); GO_0005730 (EC: IDA); GO_0005737 (EC: IDA); GO_0006974 (EC: IEA); GO_0007155 (EC: IEA); GO_0015630 (EC: IDA); GO_0030155 (EC: IDA); GO_0035507 (EC: IDA); GO_0042127 (EC: TAS); GO_0046872 (EC: IEA); GO_2000772 (EC: IDA, PMID: 19927127)",,,,,,,,,PMID: 9628581; 12409306; 12477932; 13679856; 14702039; 14976552; 15060171; 15273717; 15354411; 16044163; 16306228; 16488889; 17353931; 18254724; 19322201; 19927127; 20354225; 20602751; 20978832; 21317932; 21750233; 21832049; 22105900; 22460906; 23063350; 23080069; 23215946; 23419831; 23516026; 23934065; 23940030,,,,,,,,,,,,,,,OGG:3000009891,,,,,,,"NUAK family, SNF1-like kinase, 1",,,,,,,,,,,,,Other designations: AMP-activated protein kinase family member 5|AMPK-related protein kinase 5|NUAK family SNF1-like kinase 1|omphalocele kinase 1,,NUAK1,,,,,,,,,,,,,,,,,,,,,,,9891,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,NUAK1,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0010565,40S ribosomal protein S9,40S small ribosomal protein 9,,false,,,http://purl.obolibrary.org/obo/IMR_0000896,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,40S small ribosomal protein 9,,,,,IMR:0010565,,,,,,,,,,,,,,,,,,,,,,40S ribosomal protein S9,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_83612,hepatic steatosis inducing agent,hepatic steatosis inducing drugs,Any  hepatotoxic agent capable of inducing liver  steatosis or fatty liver disease.,false,,,http://purl.obolibrary.org/obo/CHEBI_50908,,,,,,,,,,,,,,,,,,,,,,Any  hepatotoxic agent capable of inducing liver  steatosis or fatty liver disease.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,hepatic steatosis inducing drugs,,,CHEBI:83612,,,,,,,,,,,,,,,,,,,,,,hepatic steatosis inducing agent,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000006794,STK11,,Other designations: liver kinase B1|polarization-related protein LKB1|renal carcinoma antigen NY-REN-19|serine/threonine-protein kinase 11|serine/threonine-protein kinase LKB1|serine/threonine-protein kinase STK11,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,PJS|LKB1|hLKB1,,,,,,,,,,,,19,,,,,,HGNC:11389|Vega:OTTHUMG00000180118|MIM:602216|Ensembl:ENSG00000118046|HPRD:03740,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,serine/threonine kinase 11,,,19p13.3,,,,,,,,,,,,,,,,"GO_0000287 (EC: IDA, PMID: 12805220); GO_0001558 (EC: ISS); GO_0001894 (EC: IEA); GO_0001944 (EC: ISS); GO_0002039 (EC: IDA, PMID: 11430832); GO_0004674 (EC: IDA, PMID: 11430832); GO_0004674 (EC: TAS); GO_0005515 (EC: IPI, PMID: 12595760); GO_0005524 (EC: IDA, PMID: 12805220); GO_0005634 (EC: IDA); GO_0005737 (EC: IDA, PMID: 11430832); GO_0005739 (EC: IDA, PMID: 11430832); GO_0005829 (EC: ISS); GO_0005829 (EC: TAS); GO_0006112 (EC: TAS); GO_0006468 (EC: IDA, PMID: 12805220); GO_0006914 (EC: IEA); GO_0006974 (EC: IEA); GO_0007050 (EC: IDA, PMID: 12805220); GO_0007050 (EC: TAS); GO_0007286 (EC: IEA); GO_0007409 (EC: IEA); GO_0008285 (EC: IMP, PMID: 17216128); GO_0008286 (EC: TAS); GO_0010212 (EC: ISS); GO_0016020 (EC: ISS); GO_0030010 (EC: ISS); GO_0030111 (EC: IEA); GO_0030275 (EC: IEA); GO_0030295 (EC: IDA, PMID: 19892943); GO_0030308 (EC: ISS); GO_0030511 (EC: IMP, PMID: 18311138); GO_0032147 (EC: IDA, PMID: 18854309); GO_0032147 (EC: IEA); GO_0032403 (EC: IEA); GO_0033762 (EC: IEA); GO_0033993 (EC: IEA); GO_0036398 (EC: IEA); GO_0036399 (EC: IEA); GO_0042304 (EC: TAS); GO_0042593 (EC: ISS); GO_0043276 (EC: IMP, PMID: 19622832); GO_0044281 (EC: TAS); GO_0045059 (EC: IEA); GO_0045722 (EC: IEA); GO_0046777 (EC: IDA, PMID: 11430832); GO_0050731 (EC: IEA); GO_0050772 (EC: IEA); GO_0050852 (EC: IEA); GO_0051291 (EC: IEA); GO_0051645 (EC: IEA); GO_0051896 (EC: IEA); GO_0060070 (EC: IEA); GO_0060770 (EC: IEA); GO_0070062 (EC: IDA, PMID: 19056867); GO_0072332 (EC: IDA, PMID: 11430832)",,,,,,,,,PMID: 8889548; 8988175; 9425897; 9428765; 9537235; 9760200; 9837816; 10208439; 10362809; 10408777; 10508479; 10642499; 10642527; 11297520; 11430832; 11445556; 11668633; 11733352; 11741830; 11853558; 12097271; 12218179; 12234250; 12477932; 12489981; 12533684; 12552571; 12595760; 12753905; 12805220; 12847291; 12879020; 12912948; 14511394; 14511408; 14517247; 14517248; 14668798; 14676191; 14702039; 14976552; 14985505; 15077168; 15121768; 15183188; 15188174; 15231735; 15287029; 15292028; 15331174; 15485651; 15489334; 15561763; 15607222; 15608654; 15617552; 15731909; 15733851; 15774015; 15800014; 15987703; 16054041; 16169070; 16287113; 16311241; 16396636; 16407220; 16407837; 16540748; 16580634; 16582077; 16648371; 16822578; 16882735; 16912160; 16927138; 16953221; 17010524; 17026623; 17098823; 17108107; 17114342; 17212587; 17216128; 17234589; 17244606; 17319781; 17344591; 17384680; 17573348; 17575127; 17599048; 17637250; 17641416; 17676035; 17711506; 17766436; 17884763; 17921699; 17928927; 17950019; 18000088; 18029348; 18199157; 18245474; 18256292; 18303014; 18311138; 18321849; 18403917; 18483235; 18495044; 18594528; 18600394; 18676680; 18681789; 18687677; 18794113; 18854309; 18854318; 19029933; 19056867; 19068194; 19145097; 19165201; 19170196; 19177591; 19204826; 19229701; 19250387; 19287990; 19340305; 19351817; 19369417; 19386264; 19407487; 19414597; 19463221; 19507030; 19513107; 19520843; 19584313; 19615099; 19615732; 19622832; 19625176; 19692168; 19724060; 19727776; 19892943; 19908348; 20010869; 20018878; 20020146; 20057966; 20082862; 20193846; 20207041; 20227367; 20301443; 20354225; 20357370; 20368287; 20368693; 20400510; 20418665; 20423848; 20424326; 20428811; 20435009; 20452353; 20489196; 20497868; 20559149; 20562859; 20623358; 20668229; 20682687; 20686846; 20722467; 20818976; 20864035; 20881644; 20939895; 20956321; 20974850; 21048031; 21102257; 21118512; 21150337; 21191146; 21191700; 21192934; 21241696; 21396365; 21450399; 21532627; 21572398; 21706049; 21816872; 21832049; 21860411; 21876548; 21994947; 22005930; 22118009; 22168747; 22226967; 22265968; 22270359; 22384927; 22412893; 22457270; 22460425; 22487816; 22543132; 22575644; 22635025; 22775437; 22814264; 22848740; 22928647; 22939624; 22942091; 22983157; 22986809; 22988252; 23027127; 23044421; 23074285; 23086944; 23207623; 23322200; 23367447; 23393134; 23399955; 23415580; 23430953; 23451056; 23526220; 23572524; 23592276; 23612973; 23637231; 23645358; 23648482; 23679304; 23706335; 23788249; 23810581; 23861764; 23878245; 23892522; 24074562; 24154639; 24285539; 24362629,,,,,,,,,,,,,,,OGG:3000006794,,,,,,,serine/threonine kinase 11,,,,,,,,,,,,,Other designations: liver kinase B1|polarization-related protein LKB1|renal carcinoma antigen NY-REN-19|serine/threonine-protein kinase 11|serine/threonine-protein kinase LKB1|serine/threonine-protein kinase STK11,,STK11,,,,,,,,,,,,,,,,,,,,,,,6794,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,STK11,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/OGG_2000002759,gene of Eukaryota,,A gene of an organism of Eukaryota,false,,,http://purl.obolibrary.org/obo/OGG_0000000002,,,,,,,,,,,,,,,,,,,,,,A gene of an organism of Eukaryota,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,OGG:2000002759,,,,,,,,,,,,,,,,,,,,,,gene of Eukaryota,,,,,,,,,,,,http://purl.obolibrary.org/obo/NCBITaxon_2759,,,,,,,,,,,,,,,,,,,2759,,,,,,,,,,,,,,,,,,,,,"Yue Liu, Bin Zhao, Oliver He"
http://purl.obolibrary.org/obo/CL_0000235,macrophage,,"A mononuclear phagocyte present in variety of tissues, typically differentiated from monocytes, capable of phagocytosing a variety of extracellular particulate material, including immune complexes, microorganisms, and dead cells.|Morphology: Diameter 30_M-80 _M, abundant cytoplasm, low N/C ratio, eccentric nucleus. Irregular shape with pseudopods, highly adhesive. Contain vacuoles and phagosomes, may contain azurophilic granules; markers: Mouse &amp; Human: CD68, in most cases CD11b. Mouse: in most cases F4/80+; role or process: immune, antigen presentation, &amp; tissue remodelling; lineage: hematopoietic, myeloid.",false,,,http://purl.obolibrary.org/obo/CL_0000234,,,,,,,,,,,,,,,,,,,,,,"A mononuclear phagocyte present in variety of tissues, typically differentiated from monocytes, capable of phagocytosing a variety of extracellular particulate material, including immune complexes, microorganisms, and dead cells.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CL:0000235,,,,,,,,,,,,,,,,,,,,"Morphology: Diameter 30_M-80 _M, abundant cytoplasm, low N/C ratio, eccentric nucleus. Irregular shape with pseudopods, highly adhesive. Contain vacuoles and phagosomes, may contain azurophilic granules; markers: Mouse &amp; Human: CD68, in most cases CD11b. Mouse: in most cases F4/80+; role or process: immune, antigen presentation, &amp; tissue remodelling; lineage: hematopoietic, myeloid.",,macrophage,,,,,,,http://purl.obolibrary.org/obo/cl.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CL_0000232,erythrocyte,,"A red blood cell. In mammals, mature erythrocytes are biconcave disks containing hemoglobin whose function is to transport oxygen.",false,,,http://purl.obolibrary.org/obo/CL_0000988,,,,,,,,,,,,,,,,,,,,,,"A red blood cell. In mammals, mature erythrocytes are biconcave disks containing hemoglobin whose function is to transport oxygen.",,,,,erythrocyte,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CL:0000232,,,,,,,,,,,,,,,,,,,,,,erythrocyte,,,,,,,http://purl.obolibrary.org/obo/cl.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CL_0000234,phagocyte,,Any cell capable of ingesting particulate matter via phagocytosis.,false,,,http://purl.obolibrary.org/obo/CL_0000000,,,,,,,,,,,,,,,,,,,,,,Any cell capable of ingesting particulate matter via phagocytosis.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CL:0000234,,,,,,,,,,,,,,,,,,,,,,phagocyte,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CL_0000233,platelet,,"A non-nucleated disk-shaped cell formed by extrusion from megakaryocytes, found in the blood of all mammals, and mainly involved in blood coagulation.|Platelets are reportedly CCR1-positive, CCR2-negative, CCR3-positive, CCR4-positive, CCR5-negative, CCR6-negative, CCR7-negative, CCR8-negative, CCR9-negative, CCR10-negative, CD16-positive, CD23-positive, CD32-positive, CD40-positive, CD41-positive CD42-positive, CD61-positive, CD62P-positive, CD64-positive, CD89-positive, CD102-positive, CD147-positive (activated platelets), CD154-positive (activated platelets), CD162-positive, CD209, CD282-positive, CD284-positive, CD289-positive, CD181-negative, CD182-negative, CD183-negative, CD184-positive, CLEC2-positive, GPVI-positive, JAMC-positive, PAR1-positive, PAR2-negative, PAR3-positive, PAR4-positive, TSP1-positive, and TXA2R-positive. Platelets can reportedly produce CCL2, CCL3, CCL5, CCL7, CCL17, CD40L, CXCL1, CXCL4, CXCL4L1, CXCL5, CXCL7, CXCL8, CXCL12, EGF, factor V, factor VII, factor XI, factor XIII, bFGF, histamine, IGF-1, IL-1beta, PAI-1, PDGF, plasminogen, protein S, serotonin, TGF-beta, TFPI, VEGF, and vWF. A non-nucleated disk-shaped cell formed by extrusion from megakaryocytes, found in the blood of all mammals, and mainly involved in blood coagulation.",false,,,http://purl.obolibrary.org/obo/CL_0000151,,,,,,,,,,,,,,,,,,,,,,"A non-nucleated disk-shaped cell formed by extrusion from megakaryocytes, found in the blood of all mammals, and mainly involved in blood coagulation.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CL:0000233,,,,,,,,,,,,,,,,,,,,"Platelets are reportedly CCR1-positive, CCR2-negative, CCR3-positive, CCR4-positive, CCR5-negative, CCR6-negative, CCR7-negative, CCR8-negative, CCR9-negative, CCR10-negative, CD16-positive, CD23-positive, CD32-positive, CD40-positive, CD41-positive CD42-positive, CD61-positive, CD62P-positive, CD64-positive, CD89-positive, CD102-positive, CD147-positive (activated platelets), CD154-positive (activated platelets), CD162-positive, CD209, CD282-positive, CD284-positive, CD289-positive, CD181-negative, CD182-negative, CD183-negative, CD184-positive, CLEC2-positive, GPVI-positive, JAMC-positive, PAR1-positive, PAR2-negative, PAR3-positive, PAR4-positive, TSP1-positive, and TXA2R-positive. Platelets can reportedly produce CCL2, CCL3, CCL5, CCL7, CCL17, CD40L, CXCL1, CXCL4, CXCL4L1, CXCL5, CXCL7, CXCL8, CXCL12, EGF, factor V, factor VII, factor XI, factor XIII, bFGF, histamine, IGF-1, IL-1beta, PAI-1, PDGF, plasminogen, protein S, serotonin, TGF-beta, TFPI, VEGF, and vWF. A non-nucleated disk-shaped cell formed by extrusion from megakaryocytes, found in the blood of all mammals, and mainly involved in blood coagulation.",,platelet,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CL_0000236,B cell,,"A lymphocyte of B lineage with the phenotype CD19-positive, CD20-positive, and capable of B cell mediated immunity.",false,,,http://purl.obolibrary.org/obo/CL_0000542,,,,,,,,,,,,,,,,,,,,,,"A lymphocyte of B lineage with the phenotype CD19-positive, CD20-positive, and capable of B cell mediated immunity.",,,,,B cell,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CL:0000236,,,,,,,,,,,,,,,,,,,,,,B cell,,,,,,,http://purl.obolibrary.org/obo/cl.owl,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002877,IRE1 pathway [ER stress - ERAD],,"A series of molecular signals mediated by the endoplasmic reticulum stress sensor IRE1 (Inositol-requiring transmembrane kinase/endonuclease).
This process is dependent on the inflammation that can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002487,,,,,,,,,,,,,,,,,,,,,,"A series of molecular signals mediated by the endoplasmic reticulum stress sensor IRE1 (Inositol-requiring transmembrane kinase/endonuclease).
This process is dependent on the inflammation that can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002709|http://purl.obolibrary.org/obo/GO_0010468|http://purl.obolibrary.org/obo/TXPO_0002710,,http://purl.obolibrary.org/obo/TXPO_0002155,,,,,,,,,,,,,,,,TXPO:0002877,,,,,,,,,,,,,,,,,,,,,,IRE1 pathway [ER stress - ERAD],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002872,TRAF2 activation by IRE1,,TRAF2 activation by IRE1 is a subtype of molecular activation: A process that changes the activity of the TARF2 to be higher by IRE1.,false,,,http://purl.obolibrary.org/obo/TXPO_0000023|http://purl.obolibrary.org/obo/TXPO_0003736,,,,,,,,,,,,,,,,,,,,PMID:25232821,,TRAF2 activation by IRE1 is a subtype of molecular activation: A process that changes the activity of the TARF2 to be higher by IRE1.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002819,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002817,,,,,,,,,,,TXPO:0002872,,,,,,,,,,,,,,,,,,,,,,TRAF2 activation by IRE1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002876,IRE1 pathway [ER stress - inflammation - IRE1-XBP1 pathway],,"A series of molecular signals mediated by the endoplasmic reticulum stress sensor IRE1 (Inositol-requiring transmembrane kinase/endonuclease).
This process is dependent on the inflammation via IRE1-XBP1 pathway that can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002487,,,,,,,,,,,,,,,,,,,,,,"A series of molecular signals mediated by the endoplasmic reticulum stress sensor IRE1 (Inositol-requiring transmembrane kinase/endonuclease).
This process is dependent on the inflammation via IRE1-XBP1 pathway that can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002895|http://purl.obolibrary.org/obo/GO_0010468|http://purl.obolibrary.org/obo/TXPO_0002831,,http://purl.obolibrary.org/obo/TXPO_0002155,,,,,,,,,,,,,,,,TXPO:0002876,,,,,,,,,,,,,,,,,,,,,,IRE1 pathway [ER stress - inflammation - IRE1-XBP1 pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002871,XBP1 splicing [ER stress - ERAD],,"XBP1 splicing is a subtype of removing: The process of removing sections of the XBP1 RNA transcript to remove sequences.
This entity is a specific course-dependent process. This process is dependent on the ERAD process and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000726,,,,,,,,,,,,,,,,,,,,,,"XBP1 splicing is a subtype of removing: The process of removing sections of the XBP1 RNA transcript to remove sequences.
This entity is a specific course-dependent process. This process is dependent on the ERAD process and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001968,,,,,,,,,,,,,,,,,TXPO:0002871,,,,,,,,,,,,,,,,,,,,,,XBP1 splicing [ER stress - ERAD],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002873,chronic,,A duration quality of a process inhering in a bearer by virtue of the bearer's having slow progressive course of indefinite duration.,false,,,http://purl.obolibrary.org/obo/PATO_0001309,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/PATO_0001863,,A duration quality of a process inhering in a bearer by virtue of the bearer's having slow progressive course of indefinite duration.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002873,,,,,,,,,,,,,,,,,,,,,,chronic,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002870,PERK autophosphorylation [ER stress - refolding],,"PERK autophosphorylation is a subtype of protein autophosphorylation: The phosphorylation by PERK of one or more of its own amino acid residues (cis-autophosphorylation), or residues on PERK (trans-autophosphorylation).
This process is dependent on the refolding and can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0000674,,,,,,,,,,,,,,,,,,,,,,"PERK autophosphorylation is a subtype of protein autophosphorylation: The phosphorylation by PERK of one or more of its own amino acid residues (cis-autophosphorylation), or residues on PERK (trans-autophosphorylation).
This process is dependent on the refolding and can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002861,,,,,,,,,,,,,,,,,TXPO:0002870,,,,,,,,,,,,,,,,,,,,,,PERK autophosphorylation [ER stress - refolding],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002879,IRE1 pathway [ER stress - inflammation - IRE1-NfkB pathway],,"A series of molecular signals mediated by the endoplasmic reticulum stress sensor IRE1 (Inositol-requiring transmembrane kinase/endonuclease).
This process is dependent on the inflammation via IRE1-NfkB pathway that can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002487,,,,,,,,,,,,,,,,,,,,,,"A series of molecular signals mediated by the endoplasmic reticulum stress sensor IRE1 (Inositol-requiring transmembrane kinase/endonuclease).
This process is dependent on the inflammation via IRE1-NfkB pathway that can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002889|http://purl.obolibrary.org/obo/GO_0010468|http://purl.obolibrary.org/obo/TXPO_0002834,,http://purl.obolibrary.org/obo/TXPO_0002155,,,,,,,,,,,,,,,,TXPO:0002879,,,,,,,,,,,,,,,,,,,,,,IRE1 pathway [ER stress - inflammation - IRE1-NfkB pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002878,IRE1 pathway [ER stress - inflammation - IRE1-JNK pathway],,"A series of molecular signals mediated by the endoplasmic reticulum stress sensor IRE1 (Inositol-requiring transmembrane kinase/endonuclease).
This process is dependent on the inflammation via IRE1-JNK pathway that can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002487,,,,,,,,,,,,,,,,,,,,,,"A series of molecular signals mediated by the endoplasmic reticulum stress sensor IRE1 (Inositol-requiring transmembrane kinase/endonuclease).
This process is dependent on the inflammation via IRE1-JNK pathway that can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002888|http://purl.obolibrary.org/obo/GO_0010468|http://purl.obolibrary.org/obo/TXPO_0002835,,http://purl.obolibrary.org/obo/TXPO_0002155,,,,,,,,,,,,,,,,TXPO:0002878,,,,,,,,,,,,,,,,,,,,,,IRE1 pathway [ER stress - inflammation - IRE1-JNK pathway],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002875,IRE1 pathway [ER stress - apoptosis],,"A series of molecular signals mediated by the endoplasmic reticulum stress sensor IRE1 (Inositol-requiring transmembrane kinase/endonuclease).
This process is dependent on the apoptosis that can constitute the course of ER stress.",false,,,http://purl.obolibrary.org/obo/TXPO_0002487,,,,,,,,,,,,,,,,,,,,,,"A series of molecular signals mediated by the endoplasmic reticulum stress sensor IRE1 (Inositol-requiring transmembrane kinase/endonuclease).
This process is dependent on the apoptosis that can constitute the course of ER stress.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0002953|http://purl.obolibrary.org/obo/GO_0010468|http://purl.obolibrary.org/obo/TXPO_0002926,,http://purl.obolibrary.org/obo/TXPO_0002155,,,,,,,,,,,,,,,,TXPO:0002875,,,,,,,,,,,,,,,,,,,,,,IRE1 pathway [ER stress - apoptosis],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/TXPO_0002874,regulation of translation by eIF2a,,"Regulation of translation by eIF2a is a subtype of regulation of translation: A process that modulates the frequency, rate or extent of eIF2 alpha mediated translation.",false,,,http://purl.obolibrary.org/obo/GO_0006417,,,,,,,,,,,,,,,,,,,,,,"Regulation of translation by eIF2a is a subtype of regulation of translation: A process that modulates the frequency, rate or extent of eIF2 alpha mediated translation.",,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0001275,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TXPO:0002874,,,,,,,,,,,,,,,,,,,,,,regulation of translation by eIF2a,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3000000581,BAX,,Other designations: BCL2-associated X protein omega|BCL2-associated X protein transcript variant delta2|apoptosis regulator BAX|bcl-2-like protein 4|bcl2-L-4,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,BCL2L4,,,,,,,,,,,,19,,,,,,Ensembl:ENSG00000087088|Vega:OTTHUMG00000160476|MIM:600040|HPRD:02498|HGNC:959,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,BCL2-associated X protein,,,19q13.3-q13.4,,,,,,,,,,,,,,,,"GO_0001101 (EC: IEA); GO_0001541 (EC: IEA); GO_0001764 (EC: IEA); GO_0001777 (EC: IEA); GO_0001782 (EC: IEA); GO_0001783 (EC: IDA, PMID: 15214043); GO_0001822 (EC: IEA); GO_0001836 (EC: IDA, PMID: 16199525); GO_0001844 (EC: IEA); GO_0001974 (EC: IEA); GO_0002262 (EC: IEA); GO_0002352 (EC: IEA); GO_0002358 (EC: IEA); GO_0002904 (EC: IEA); GO_0005515 (EC: IPI, PMID: 10753914); GO_0005634 (EC: IMP, PMID: 15102863); GO_0005739 (EC: IDA, PMID: 11912183); GO_0005741 (EC: IBA); GO_0005741 (EC: TAS); GO_0005757 (EC: IDA, PMID: 9843949); GO_0005783 (EC: IDA, PMID: 16424160); GO_0005789 (EC: IDA, PMID: 16424160); GO_0005829 (EC: IDA, PMID: 11912183); GO_0005829 (EC: TAS); GO_0006687 (EC: IEA); GO_0006808 (EC: IEA); GO_0006915 (EC: NAS, PMID: 9920818); GO_0006915 (EC: TAS); GO_0006919 (EC: IDA, PMID: 11912183); GO_0006919 (EC: IMP, PMID: 11350920); GO_0006927 (EC: IMP, PMID: 10739008); GO_0007281 (EC: IEA); GO_0008053 (EC: IDA, PMID: 14769861); GO_0008289 (EC: IDA, PMID: 14522999); GO_0008625 (EC: IC, PMID: 16199525); GO_0008630 (EC: IBA); GO_0008635 (EC: IDA, PMID: 15214043); GO_0008637 (EC: IDA, PMID: 9843949); GO_0009566 (EC: IEA); GO_0009636 (EC: IDA, PMID: 16307838); GO_0009651 (EC: IEA); GO_0010248 (EC: IDA, PMID: 9843949); GO_0010332 (EC: IEA); GO_0015267 (EC: IDA, PMID: 9219694); GO_0016032 (EC: IEA); GO_0021854 (EC: IEA); GO_0021987 (EC: IEA); GO_0030264 (EC: IEA); GO_0032091 (EC: IDA, PMID: 9388232); GO_0032461 (EC: IDA, PMID: 19805544); GO_0032469 (EC: TAS, PMID: 18309324); GO_0032471 (EC: IEA); GO_0032976 (EC: IDA, PMID: 9843949); GO_0033137 (EC: IEA); GO_0033599 (EC: IEA); GO_0034644 (EC: IEA); GO_0035234 (EC: IEA); GO_0042475 (EC: IEA); GO_0042802 (EC: IPI, PMID: 10620504); GO_0042803 (EC: IDA, PMID: 16608847); GO_0042803 (EC: IPI, PMID: 9111042); GO_0043065 (EC: IMP, PMID: 17289999); GO_0043496 (EC: IDA, PMID: 9111042); GO_0043497 (EC: IPI, PMID: 9111042); GO_0043524 (EC: IEA); GO_0043525 (EC: IDA, PMID: 15637643); GO_0043653 (EC: IDA, PMID: 12499352); GO_0045136 (EC: IEA); GO_0046666 (EC: IEA); GO_0046930 (EC: IDA, PMID: 9219694); GO_0046982 (EC: IPI, PMID: 9111042); GO_0048087 (EC: IEA); GO_0048147 (EC: IEA); GO_0048515 (EC: IEA); GO_0048597 (EC: IEA); GO_0048678 (EC: IEA); GO_0048873 (EC: IEA); GO_0051259 (EC: IDA, PMID: 19074440); GO_0051260 (EC: IDA, PMID: 14522999); GO_0051281 (EC: IEA); GO_0051402 (EC: IEA); GO_0051434 (EC: IDA); GO_0051434 (EC: IPI, PMID: 15705586); GO_0051726 (EC: IEA); GO_0051881 (EC: IDA, PMID: 9843949); GO_0060011 (EC: IEA); GO_0060041 (EC: IEA); GO_0060058 (EC: IEA); GO_0060068 (EC: IEA); GO_0070059 (EC: IMP, PMID: 16645094); GO_0070062 (EC: IDA); GO_0070242 (EC: IEA); GO_0071310 (EC: IEA); GO_0072332 (EC: IEA); GO_0090200 (EC: IDA, PMID: 14963330); GO_0097136 (EC: IDA); GO_0097144 (EC: IDA, PMID: 19767770); GO_0097190 (EC: IDA, PMID: 16424160); GO_0097191 (EC: IDA, PMID: 15214043); GO_0097192 (EC: IBA); GO_0097193 (EC: IDA, PMID: 16462759); GO_0097193 (EC: TAS); GO_0097296 (EC: IEA); GO_1900103 (EC: IMP, PMID: 16645094); GO_1901030 (EC: TAS); GO_1902262 (EC: IEA); GO_1902263 (EC: IEA); GO_1902512 (EC: IMP, PMID: 11350920); GO_1990009 (EC: IMP, PMID: 10702418); GO_1990117 (EC: IDA, PMID: 15214043); GO_2001234 (EC: IEA); GO_2001241 (EC: IEA); GO_2001244 (EC: IMP, PMID: 14963330)",,,,,,,,,PMID: 7566098; 7607685; 7834749; 8358790; 8521816; 8580080; 8760290; 8889548; 8961277; 9020077; 9027312; 9111042; 9130713; 9153240; 9219694; 9372935; 9388232; 9449720; 9463381; 9531611; 9565621; 9742125; 9748162; 9824152; 9843949; 9920818; 9988273; 10200447; 10365962; 10381646; 10437917; 10620504; 10620603; 10620799; 10629050; 10702418; 10716992; 10739008; 10753914; 10772918; 10837489; 10854321; 10908576; 10942389; 11060313; 11106734; 11136736; 11161816; 11175251; 11175336; 11251969; 11259440; 11278245; 11283018; 11350920; 11437653; 11571294; 11574543; 11602639; 11642719; 11742726; 11759059; 11759062; 11782443; 11787859; 11839668; 11839683; 11842081; 11850803; 11850816; 11852106; 11867266; 11869962; 11875499; 11894116; 11899739; 11909872; 11911971; 11912124; 11912183; 11922616; 11929871; 11932420; 11943780; 11949842; 11992551; 11994280; 11997495; 12023951; 12025227; 12032841; 12036888; 12058280; 12070030; 12070120; 12082629; 12137781; 12151395; 12161031; 12165421; 12169275; 12176904; 12189556; 12193163; 12214154; 12215338; 12215842; 12270344; 12359369; 12388688; 12389125; 12393866; 12393884; 12408758; 12419244; 12426317; 12439925; 12445631; 12454021; 12477729; 12477932; 12481899; 12490315; 12496485; 12499352; 12510156; 12575534; 12579342; 12583439; 12592374; 12606781; 12732850; 12737446; 12743423; 12749011; 12767928; 12782632; 12808108; 12816867; 12837286; 12839682; 12853473; 12901880; 12907654; 12917444; 12963997; 12970744; 14522999; 14550297; 14559989; 14596892; 14606101; 14612448; 14612938; 14628086; 14631373; 14634023; 14647416; 14647455; 14661970; 14681224; 14698203; 14704000; 14714449; 14716828; 14719078; 14730312; 14752512; 14766748; 14767525; 14769861; 14963330; 14971737; 14980220; 15024076; 15033690; 15037603; 15073604; 15077116; 15096513; 15102863; 15131699; 15148411; 15149158; 15158440; 15214043; 15231068; 15254227; 15258908; 15262986; 15292938; 15298965; 15302859; 15304079; 15314639; 15322047; 15351796; 15375594; 15375604; 15383280; 15388581; 15459197; 15467752; 15484294; 15489334; 15516208; 15555592; 15574335; 15607964; 15613549; 15637055; 15637643; 15638363; 15642728; 15655830; 15657356; 15688029; 15694358; 15705586; 15710329; 15735127; 15735709; 15743033; 15743760; 15757910; 15764647; 15767261; 15770735; 15773546; 15782132; 15806163; 15830715; 15832769; 15843890; 15846375; 15889622; 15893728; 15901672; 15949439; 15962362; 16009130; 16010425; 16085058; 16113678; 16132718; 16139338; 16148027; 16151013; 16172114; 16172118; 16186627; 16199525; 16215676; 16229013; 16235026; 16246184; 16307023; 16307838; 16344548; 16380996; 16410245; 16424160; 16436379; 16443387; 16462759; 16472763; 16479009; 16485142; 16518869; 16538501; 16552754; 16568093; 16572399; 16575548; 16603637; 16608847; 16611260; 16642033; 16645094; 16709574; 16810067; 16830365; 16832704; 16855163; 16874066; 16946732; 16949642; 16987815; 17007374; 17015472; 17015762; 17052454; 17067385; 17074758; 17084966; 17091766; 17097560; 17107772; 17118768; 17140287; 17171827; 17203183; 17203211; 17213822; 17235284; 17274640; 17289842; 17289999; 17335847; 17346710; 17388661; 17390059; 17395004; 17404017; 17426704; 17438366; 17438390; 17486058; 17494694; 17496930; 17499214; 17509221; 17513609; 17519046; 17525161; 17534116; 17535899; 17556360; 17562177; 17575222; 17626754; 17634542; 17635522; 17635912; 17643375; 17666167; 17668322; 17676485; 17686764; 17693666; 17803695; 17823127; 17855051; 17880809; 17897954; 17900801; 17905238; 17911107; 17912641; 17927446; 17927572; 17978676; 17981213; 17990907; 17993285; 17996028; 17997990; 18006502; 18006817; 18006836; 18019411; 18023359; 18029348; 18034190; 18054155; 18059532; 18074738; 18089567; 18158779; 18160666; 18177350; 18178565; 18193434; 18195012; 18211414; 18214681; 18223689; 18240345; 18251703; 18258596; 18259190; 18259191; 18282575; 18299320; 18299329; 18307410; 18309324; 18331646; 18344566; 18362350; 18362892; 18375382; 18390829; 18395515; 18415681; 18415689; 18445700; 18449500; 18453545; 18454316; 18462830; 18472156; 18472157; 18474606; 18481805; 18494554; 18508723; 18511705; 18534994; 18546202; 18563851; 18568448; 18590739; 18590778; 18594472; 18636124; 18642056; 18644472; 18651163; 18651223; 18664350; 18665919; 18670882; 18676372; 18676680; 18692524; 18695676; 18705408; 18705844; 18718060; 18719392; 18727869; 18772168; 18793611; 18812638; 18813857; 18814044; 18818203; 18818304; 18835031; 18840646; 18925695; 18928586; 18928588; 18936968; 18941118; 18948948; 18973553; 18974096; 18979557; 19031258; 19035131; 19054058; 19056676; 19062087; 19074440; 19074885; 19101510; 19118032; 19125733; 19141860; 19148187; 19150424; 19157504; 19170196; 19177010; 19196429; 19221769; 19228953; 19237173; 19247369; 19265193; 19266703; 19278624; 19319745; 19336552; 19351510; 19360919; 19363595; 19376889; 19380879; 19429011; 19439449; 19439472; 19453261; 19463775; 19475409; 19481066; 19494020; 19541585; 19564333; 19573080; 19587033; 19625176; 19629483; 19636580; 19655415; 19657228; 19660860; 19680558; 19692168; 19692349; 19700502; 19723045; 19729672; 19737817; 19745831; 19767770; 19773279; 19801665; 19805544; 19809877; 19812265; 19846939; 19875445; 19880508; 19888426; 19895710; 19898928; 19913121; 19931389; 19937732; 19938958; 19955813; 19956635; 19968986; 20015862; 20034877; 20045442; 20075864; 20101465; 20114030; 20130137; 20140092; 20180421; 20200776; 20300062; 20308427; 20333643; 20340172; 20346360; 20360684; 20382739; 20404718; 20416158; 20423844; 20431057; 20453000; 20485298; 20490654; 20503275; 20561923; 20565851; 20584903; 20627094; 20628086; 20644561; 20652449; 20683843; 20683914; 20723294; 20723427; 20728382; 20732674; 20803149; 20819778; 20822926; 20850011; 20855536; 20877624; 20929130; 20929131; 20942963; 20959405; 20960177; 20966963; 21029589; 21041309; 21042904; 21048031; 21060336; 21067292; 21069436; 21070973; 21090097; 21104343; 21115898; 21122152; 21123558; 21138867; 21139048; 21148306; 21156403; 21159883; 21173168; 21196320; 21199865; 21223758; 21245196; 21289292; 21367852; 21414921; 21458670; 21483469; 21506333; 21521785; 21530645; 21565982; 21567405; 21597469; 21606679; 21642427; 21642428; 21674599; 21695182; 21706237; 21712378; 21717192; 21725926; 21729540; 21746927; 21751259; 21752397; 21778226; 21785112; 21810274; 21819468; 21847364; 21852238; 21861179; 21862870; 21883444; 21887277; 21890473; 21903925; 21906983; 21907236; 21936009; 21947543; 21949851; 21952639; 21953454; 21978892; 22014978; 22015607; 22037145; 22052011; 22053931; 22056880; 22065578; 22067154; 22072718; 22109662; 22141411; 22159712; 22189282; 22198199; 22201672; 22246181; 22262057; 22277657; 22278385; 22292626; 22297694; 22309278; 22366766; 22418443; 22440942; 22442678; 22479585; 22484496; 22524261; 22526391; 22544745; 22552851; 22560721; 22570867; 22590594; 22629415; 22645134; 22668011; 22675938; 22685558; 22707322; 22710714; 22719244; 22729748; 22732402; 22736223; 22745744; 22748563; 22761420; 22785534; 22852863; 22860893; 22892098; 22906710; 22910913; 22926545; 22949938; 22995373; 23000965; 23038985; 23049480; 23064052; 23088735; 23140172; 23151078; 23151600; 23170075; 23213219; 23220614; 23245210; 23283967; 23289213; 23291169; 23295106; 23297497; 23324193; 23329846; 23334076; 23383273; 23389372; 23392123; 23421021; 23421973; 23442864; 23479508; 23479509; 23487455; 23543151; 23553948; 23562578; 23658815; 23682076; 23744079; 23777485; 23788040; 23824909; 23900080; 23900644; 23907458; 23907941; 23908591; 23966164; 24055994; 24074954; 24100034; 24113173; 24161344; 24200861; 24379070,,,,,,,,,,,,,,,OGG:3000000581,,,,,,,BCL2-associated X protein,,,,,,,,,,,,,Other designations: BCL2-associated X protein omega|BCL2-associated X protein transcript variant delta2|apoptosis regulator BAX|bcl-2-like protein 4|bcl2-L-4,,BAX,,,,,,,,,,,,,,,,,,,,,,,581,,,,Official from a nomenclature committee,,,,9606,,,,,,,,,,,,,,,,,,,BAX,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0000362,cytokeratin 10,,,false,,,http://purl.obolibrary.org/obo/IMR_0000035,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0000362,,,,,,,,,,,,,,,,,,,,,,cytokeratin 10,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0001627,Rab36,,,false,,,http://purl.obolibrary.org/obo/IMR_0000299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0001627,,,,,,,,,,,,,,,,,,,,,,Rab36,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/CHEBI_16038,phosphatidylethanolamine,PtdEtn,A class of glycerophospholipids in which a phosphatidyl group is esterified to the hydroxy group of ethanolamine.,false,,,http://purl.obolibrary.org/obo/CHEBI_36314,,,,,,,,,,,,,,,,,,,,DrugBank:DB04327,,A class of glycerophospholipids in which a phosphatidyl group is esterified to the hydroxy group of ethanolamine.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PtdEtn,,,,,CHEBI:16038,,,,,,,,,,,,,,,,,,,,,,phosphatidylethanolamine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0100607,cyclin A,,,false,,,http://purl.obolibrary.org/obo/IMR_0100672,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IMR:0100607,,,,,,,,,,,,,,,,,,,,,,cyclin A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/IMR_0000205,APC,Adenomatous Polyposis Coli Protein,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003689|http://purl.obolibrary.org/obo/TXPO_0003721,,,,,Adenomatous Polyposis Coli Protein,,,,,IMR:0000205,,,,,,,,,,,,,,,,,,,,,,APC,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
http://purl.obolibrary.org/obo/OGG_3100861540,CYP3A7-CYP3AP1,,,false,,,http://purl.obolibrary.org/obo/OGG_2060009606,,CYP3A7-3AP1|CYP3A7.1L,,,,,,,,,,,,7,,,,,,-,,,WEB: http://www.ncbi.nlm.nih.gov/gene,,,,,,,,,,,,,,,7q,,,,,,,,,,,,,,,,,,,,,,,,,PMID:9847074; 11137287; 12853948; 15937338,,,,,,,,,,,,,,,OGG:3100861540,,,,,,,CYP3A7-CYP3AP1 readthrough,,,,,,,,,,,,,,,CYP3A7-CYP3AP1,,,,,,,,,,,,,,,,,,,,,,,100861540,,,,,,,,9606,,,,,,,,,,,,,,,,,,,,,"Bin Zhao, Yue Liu, Oliver He"
http://purl.obolibrary.org/obo/IMR_0010628,TFIIS protein,Transcription elongation factor A protein 1|Transcription elongation factor A protein 1 (Transcription elongation factor S-II protein 1) (Transcription elongation factor TFIIS.o)|Transcription elongation factor S-II protein 1|Transcription elongation factor TFIIS.o,,false,,,http://purl.obolibrary.org/obo/CHEBI_25367,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://purl.obolibrary.org/obo/TXPO_0003644,,,,,Transcription elongation factor A protein 1|Transcription elongation factor A protein 1 (Transcription elongation factor S-II protein 1) (Transcription elongation factor TFIIS.o)|Transcription elongation factor S-II protein 1|Transcription elongation factor TFIIS.o,,,,,IMR:0010628,,,,,,,,,,,,,,,,,,,,,,TFIIS protein,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
